id|nct_id|intervention_type|name|description
41267466|NCT00004493|DRUG|sodium dichloroacetate|
41092740|NCT00147654|DRUG|Tolterodine ER 4 mg QD|
40919431|NCT01499368|DRUG|Lafutidine|Lafutidine 20mg/day
41092741|NCT00147654|DRUG|Tamsulosin 0.4 mg QD|
41267467|NCT01349647|BIOLOGICAL|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
41267468|NCT01349647|BIOLOGICAL|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|"Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16."
40919432|NCT01499368|DRUG|Famotidine|Famotidine 40mg/day
40919433|NCT01499368|DRUG|Omeprazole|Omeprazole 20mg/day
41267469|NCT01745757|DRUG|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
41267470|NCT01745757|DRUG|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
40919434|NCT00842907|DRUG|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
41267471|NCT03352245|BEHAVIORAL|Prescribed Activity|Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)
41267472|NCT04805086|BIOLOGICAL|MON002|Autologous monocytes
41267473|NCT04553107|BEHAVIORAL|Deprescribing Intervention|An individualized deprescribing intervention will be created by a pharmacist working with a patient to identify harmful, costly, and unnecessary medications to be reduced. The intervention will include a plan and monitoring for up to 3 months to reduce medication use.
40919435|NCT00842907|DRUG|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
40919436|NCT04052178|DEVICE|rTMS active and sham|Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
40919437|NCT04052178|DEVICE|PES active and sham|Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
41092742|NCT05975996|DRUG|Cyclophosphamide added to standard immunosuppressive therapy with herombopag|Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. The moderate-dose cyclophosphamide (20mg/kg) will be administered on days 29-30 and days 43-44.
41092743|NCT04071522|OTHER|no intervention|no intervention
41092744|NCT00009685|DRUG|VRC4302|
41092745|NCT06610357|OTHER|Group 1|42 diparetic children with cerebral palsy were included in the study. The Modified Ashworth Scale (MAS), the Children's Functional Independence Measure (WeeFIM)-Mobility section and the Gross Motor Function Measure-88 (GMFM-88) were applied before and after SDR surgery.
40919438|NCT04052178|DIETARY_SUPPLEMENT|Capsaicin active and placebo|Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.
41092746|NCT04500743|DRUG|Dienogest|Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF
41267474|NCT04553107|BEHAVIORAL|Usual Care|The usual care arm will receive the current standard of care, which includes medication reconciliation by a clinic nurse at the time of their appointment. Nurses review all medications and answer medication-related questions, and refer medication questions to the healthcare provider for further discussion when necessary.
40919439|NCT05473650|DIAGNOSTIC_TEST|CBC.with with differential Peripheral smear|determine spectrum of hematological disorders in childern with pancytopenia
40919440|NCT00947440|DRUG|ABT-072|See arm description for more information
40919441|NCT04176653|DRUG|SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo|IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
40919442|NCT03168958|DRUG|Methadone|Methadone will be provided at induction of anesthesia
41092747|NCT04500743|DRUG|leuprorelin acetate|Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)
41092748|NCT04103047|OTHER|SAD|The patients who have an SAD inserted as part of their normal Anaesthetic plan will be consented prior to their Anaesthetic and then have a questionnaire to fill out post operatively.
41092749|NCT04660435|DIAGNOSTIC_TEST|Thymidine kinase activity|DiviTum® assay determines the enzymatic activity of TK in serum samples
40919443|NCT03168958|DRUG|Saline|Saline will be administered at induction of anesthesia
40919444|NCT04614402|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
40919445|NCT04614402|DEVICE|Edwards PASCAL Precision Transcatheter Valve Repair System|The Edwards PASCAL Precision Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
40919446|NCT02621840|BEHAVIORAL|Mandatory On-Site Pre-Admission Testing|
40919447|NCT04136119|OTHER|questionnaire|survey exploring practice of vitamin and micronutrient supplementation
40919448|NCT03664349|DEVICE|SuperEar9000|Handheld hearing amplifier, not FDA regulated.
41092750|NCT06420167|DRUG|Dapagliflozin|10mg orally once daily
41092751|NCT03463811|DIAGNOSTIC_TEST|Lactate concentration in vaginal fluid|Lactate concentration in vaginal fluid
41267475|NCT00546364|DRUG|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m\^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
41267476|NCT00546364|DRUG|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
41267477|NCT00546364|DRUG|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m\^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
40919449|NCT06069440|OTHER|Swimming Fatigue Task|Swim freestyle at a steady, controlled pace until mechanical failure (i.e., inability to maintain the predetermined speed) is reached.
40919450|NCT00910299|DRUG|Prasugrel|One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
41092752|NCT03382743|DRUG|Endocervical Lidocaine spray|5 sprays of endocervical Lidocaine spray (10%) is used 3 minutes before office hysteroscopy
41092753|NCT00920374|BIOLOGICAL|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
41092754|NCT01730417|DRUG|no carrier added metaiodobenzylguanidine|Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
41092755|NCT01627236|DRUG|methylprednisolone|methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
41092756|NCT02788656|DEVICE|Implantable Hemodynamic Monitor|The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.
41267478|NCT02344225|DRUG|Caffeine citrate|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
41267479|NCT02344225|DRUG|Ibuprofen|Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
41267480|NCT02344225|DRUG|Ketorolac|Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
41267481|NCT01728779|DRUG|Nelfinavir|Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.
41267482|NCT01728779|RADIATION|Stereotactic Body Radiation (SBRT)|15 Gy dose (per lesion site) of SBRT will be administered
41267483|NCT05750992|PROCEDURE|surgical TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
41267484|NCT05750992|PROCEDURE|US guided TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
41267485|NCT00792298|DRUG|Suvorexant|oral tablet taken before bedtime
41267486|NCT00792298|DRUG|Dose-matched Placebo to Suvorexant|Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
41267487|NCT00008190|BIOLOGICAL|aldesleukin|
41092757|NCT02788656|DRUG|Angiotensin-Converting Enzyme Inhibitor|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
41267488|NCT00008190|BIOLOGICAL|filgrastim|
41267489|NCT00008190|DRUG|busulfan|
40919451|NCT00910299|DRUG|Clopidogrel|75 mg oral daily maintenance dose up to 6 months.
40919452|NCT03847441|DRUG|Calcipotriol|Calcipotriol ointment (0.005%)
40919453|NCT03847441|DEVICE|Narrow Band UVB|NB-UVB (311nm) phototherapy
40919454|NCT03847441|DIAGNOSTIC_TEST|vitamin D3 level|vitamin D3 (ng/ml)
40919455|NCT04109885|DRUG|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
40919456|NCT04109885|DRUG|prochlorperazine and diphenhydramine.(Standard Treatment)|Intravenous administration of prochlorperazine and diphenhydramine.
41267490|NCT00008190|DRUG|cyclophosphamide|
41267491|NCT00008190|DRUG|etoposide|
41267492|NCT00008190|DRUG|melphalan|
41267493|NCT00008190|PROCEDURE|peripheral blood stem cell transplantation|
41267494|NCT05133830|DRUG|Obeticholic acid|OCA will be administered
41267495|NCT05133830|DRUG|Linerixibat|Linerixibat will be administered
41267496|NCT04274296|DEVICE|Activation of Advisory|Advisory is activated which will show if driving pressure is greater or equal 15
41267497|NCT00214461|BIOLOGICAL|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
41267498|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
41267499|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
40919457|NCT02908542|GENETIC|genetic analysis with massively parallel sequencing|
40919458|NCT02560506|DEVICE|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
40919459|NCT01429337|DRUG|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).
40919460|NCT01429337|DRUG|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.
41267500|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
41267501|NCT03419858|BEHAVIORAL|Mindfulness Meditation|A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice mindfulness meditation.
41267502|NCT03419858|BEHAVIORAL|Placebo Meditation|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
41267503|NCT03419858|BEHAVIORAL|Slow-Breathing|Study volunteers practiced lowering their breathing rate, across four, 20 minute training sessions, in response to a fluctuating light with the guidance of a trained facilitator.
41267504|NCT03419858|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.
41092758|NCT02788656|DRUG|Angiotensin II Type 1 Receptor Blocker|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients
41092759|NCT02788656|DRUG|sacubitril/valsartan|Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker
41267505|NCT03419858|OTHER|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.
40919461|NCT05197660|PROCEDURE|surgical procedures|number of hospital stays
40919462|NCT04607668|DRUG|Trilaciclib|Trilaciclib or placebo
41267506|NCT00935389|DRUG|tripterygium glycosides|The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
41442344|NCT00110604|BEHAVIORAL|folic acid (0.8 mg)|
40919463|NCT04607668|DRUG|Placebo|dextrose 5% in water or normal saline (sodium chloride solution 0.9%)
40919464|NCT03165604|OTHER|standard information|The participates will be given a standard information regarding the water drink before physical activity
40919465|NCT03165604|OTHER|positive information|"The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity"
40919466|NCT03034603|DIETARY_SUPPLEMENT|Nutri-jelly with PEITC|Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
41092760|NCT05092932|OTHER|Normal Foot Force|LoadSol Insoles will be inserted into the participants shoes. The device measures the pressure distribution on the bottom of the foot. Participants will then be asked to walk normally, use crutches, use a walker, and use a wheeled knee scooter. The pressure placed throughout the foot will be analyzed and compared under different conditions. This testing will take approximately 10 minutes.
41092761|NCT04308616|OTHER|Blood samples|Blood samples
41092762|NCT01096056|BIOLOGICAL|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
41267507|NCT02282787|DRUG|DEXMEDETOMIDINE|Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
41267508|NCT00705978|DRUG|Pancreatin|Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
40919467|NCT03034603|DIETARY_SUPPLEMENT|Nutri-jelly|Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
41452959|NCT00012818|BEHAVIORAL|educational program|
40919468|NCT02438475|DEVICE|Mynx Vascular Closure System|MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
40919469|NCT02438475|OTHER|Manual Compression|manual pressure applied to your groin for approximately 5-10 minutes
40919470|NCT02135003|OTHER|patient-selected care buddy|Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
40919471|NCT05414357|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging at rest and in activation with attentional task|"Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:~* Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2).~* Biological and physiological measurements~* Spatial memory task~* Cognitive battery~* Questionnaires (sleep, quality of life)"
40919472|NCT00514748|PROCEDURE|DIEP|flap survival, operation time, flap complications, donor site morbidity.
41267509|NCT00705978|DRUG|Placebo|placebo
41092763|NCT01096056|BIOLOGICAL|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
40919473|NCT00514748|PROCEDURE|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
40919474|NCT02717832|DRUG|hyperinsulinemic-euglycemic clamp|
40919475|NCT01643772|DRUG|Oxycodone hydrochloride|The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
40919476|NCT02754700|OTHER|Neuromuscular Training|Standardized, comprehensive neuromuscular training
40919477|NCT02754700|OTHER|Hip Focused ROBUST Training|Biofeedback training focused on the hip extensors
40919478|NCT02754700|OTHER|Knee Focused ROBUST Training|Biofeedback training focused on knee abduction
41092764|NCT01096056|BIOLOGICAL|Fluarix|Intramuscular administration, 1 dose
41092765|NCT02452229|OTHER|Review of the Literature for Human Herpes Virus infections|"Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.~PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used."
41092766|NCT01720719|DRUG|atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
41092767|NCT01720719|DRUG|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
41092768|NCT06443047|DEVICE|TTS suturing system|The use of TTS suturing system could allow a quick, complete endoscopic closure of colonic post-ESD defects, providing relevant clinical and medico-economic benefits.
41133191|NCT04373291|BIOLOGICAL|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
41267510|NCT06005584|DEVICE|Spinal Cord Stimulation - High Frequency SCS|"High Frequency-SCS consists of delivering electrical stimulation at frequencies equal to or greater than 1kHz.~This intervention will last up to 6 weeks."
41267511|NCT06005584|DEVICE|Spinal Cord Stimulation - Burst SCS|"Burst SCS consists of closely spaced, high frequency stimuli delivered to the spinal cord.~This intervention will last up to 6 weeks."
41267512|NCT06005584|DEVICE|Spinal Cord Stimulation - Sham SCS|This intervention will last up to 6 weeks.
41267513|NCT01666223|DRUG|Colesevelam|Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
41267514|NCT01666223|DRUG|Chenodeoxycholic Acid|1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
41267515|NCT01666223|OTHER|saline|100 ml saline
41267516|NCT01666223|DRUG|Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg|Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
40919479|NCT01233232|DRUG|Placebo|Oral dose bid
40919480|NCT01233232|DRUG|AZD5069 50mg|Oral dose bid
40919481|NCT01233232|DRUG|AZD5069 80mg|Oral dose bid
40919482|NCT02642224|BEHAVIORAL|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
40919483|NCT06327724|DRUG|Belimumab|Start of new treatment due to active disease
40919484|NCT02384798|OTHER|noninvasive ventilatory support|noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
40919485|NCT02384798|OTHER|interval training|interval training
40919486|NCT00744302|DRUG|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
41267517|NCT06091644|DEVICE|AirAngel® 3D printed videolaryngoscope|This is a mannequin study that aims to compare a videolaryngoscope produced with 3D printing with a Storz videolaryngoscope and a Macintosh direct laryngoscope in the hands of inexperienced users in terms of ease of use, glottic imaging and intubation success.
41092769|NCT02022462|BEHAVIORAL|Health Navigation|"Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention."
41267518|NCT01496157|DRUG|18F-DCFBC|A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.
41092770|NCT03992638|PROCEDURE|leucocyte and platelet-rich fibrin (L-PRF) in combination with CAF|Completing root coverage by coronally advanced flap technique in combination with L-PRF.
41092771|NCT03992638|PROCEDURE|CAF|Completing root coverage by coronally advanced flap technique alone
41092772|NCT02232763|DRUG|Losartan|12 weeks of losartan or placebo with crossover to the other
41267519|NCT01812902|PROCEDURE|Radical Prostatectomy|
41267520|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
41267521|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
41267522|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
41092773|NCT02232763|DRUG|Placebo|12 weeks of losartan or placebo with crossover to the other
41267523|NCT04310644|OTHER|No intervention planned, but all patients get our standart treatment|Patients are selected from clinical Routine and get our standart Treatment based on their disease
41267524|NCT00938730|DRUG|YM150|oral
41267525|NCT00938730|DRUG|Warfarin|oral
40919487|NCT00266786|DRUG|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
40919488|NCT00266786|DRUG|Intranasal Placebo|Intranasal Placebo
40919489|NCT00382642|DRUG|Ondansetron + Cognitive Behavioral Therapy|13 week outpatient trial
40919490|NCT00382642|DRUG|Placebo + Cognitive Behavioral Therapy|13 week outpatient trial
40919491|NCT02133703|BEHAVIORAL|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
40919492|NCT02133703|BEHAVIORAL|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
40919493|NCT02133703|BEHAVIORAL|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
40919494|NCT02133703|BEHAVIORAL|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
40919495|NCT02133703|BEHAVIORAL|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
41267526|NCT01405092|DEVICE|use of continuous renal replacement machine for renal replacement|usual care with volume removal during continuous renal replacement therapy
41267527|NCT01405092|DEVICE|use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal|blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
40919496|NCT04015375|DRUG|Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
40919497|NCT04015375|DRUG|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical gel
40919498|NCT04015375|OTHER|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
40919499|NCT01912313|PROCEDURE|Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy|
40947733|NCT04087304|BEHAVIORAL|Risk Status Optimization|Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.
41267528|NCT01755663|DRUG|Ivabradine and Metoprolol|
41267529|NCT01630525|OTHER|Neuropsychological assessment|Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).
41267530|NCT01630525|OTHER|ophthalmologic checkup|Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).
41092774|NCT00672256|BEHAVIORAL|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
41092775|NCT05391802|DEVICE|Transcatheter mitral valve repair|Transcatheter mitral valve repair (TMVr) is a minimally invasive procedure. Doctors place a thin tube (calleda catheter) into a large vein to reach your heart. A clip is then placed onto the center of your mitral valve. The valve continues to open and close, allowing blood to flow through while reducing MR.
41267531|NCT01630525|OTHER|Automated non-invasive oculometry|Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).
41267532|NCT01749384|BIOLOGICAL|Bevacizumab|Given IV
41267533|NCT01749384|OTHER|Laboratory Biomarker Analysis|Correlative studies
41267534|NCT01749384|OTHER|Pharmacological Study|Correlative studies
40919500|NCT03020940|DRUG|Cefuroxime Axetil Dispersible Tablets|"Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults"
40919501|NCT04308200|OTHER|CO-OP approach|"There are 3 stages in the CO-OP approach. Stage I, the Preparation Stage, is primarily concerned with establishing the goal. Before the first interview, the child was contacted, the family and the child were informed, and it was checked whether they met the prerequisites. At this stage, 3 targets were selected and the basic performance level was determined. Stage II, the Acquisition Stage, is essentially the plan and do stage, in which the work of using strategies to acquire skills is done. This stage originally comprised 10 sessions. At this stage, the first session enabling principles were implemented and the global strategy goal-plan-do-check was introduced. The family attended this process with observation. Parents / caregivers were encouraged to make observations to generalize strategies. Stage III, the Verificatíon stage usually consists of only one session in which control is performed; the progress made was revised as learned strategies."
41267535|NCT01749384|DRUG|Tivantinib|Given PO
40919502|NCT04308200|OTHER|NDT|All participations received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. Although the treatment activities varied for each CP participant, the overall goals (improved smoothness and efficiency of movement), which included improved trunk, hip, knee and ankle control, were the same for all CP participants. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity, weight-shifting and postural reactions.
40919503|NCT06434987|PROCEDURE|Retrograde Inferior Vena Cava Perfusion|Retrograde inferior vena cava (RIVP) involves perfusing oxygenated blood into the inferior vena cava, which then flows towards the viscera, abdominal organs and lower extremities. By maintaining perfusion to these regions during cardiopulmonary bypass (CPB) and induced hypothermia, Retrograde inferior vena cava (RIVP) helps mitigate the risk of ischemic injury to the abdominal organs. Following the initiation of total cardiopulmonary bypass, the body temperature will be gradually lowered to achieve deep-moderate hypothermia ( 24-38°C). This procedure will involve the combination of selective antegrade cerebral perfusion and retrograde inferior vena cava perfusion. Antegrade perfusion will be maintained at a flow rate of 5-7mL/min/kg, while retrograde perfusion will be regulated to sustain the required pumm pressure and blood flow.
40919504|NCT06434987|PROCEDURE|Antegrade cerebral perfusion|After mild to moderate hypothermia is achieved, a cannula will be inserted into the right axillary artery, brachiocephalic or innominate artery to provide continuous flow to the brain. A flow rate of 5-7mL/min/kg will be maintained.
40919505|NCT05382767|DRUG|CKDB-501A|Muscle Spasticity
40919506|NCT05382767|DRUG|Botox®|Muscle Spasticity
40919507|NCT00749710|PROCEDURE|clopidogrel|ORIF - surgical treatment
40919508|NCT00749710|PROCEDURE|no antiaggregant therapy|ORIF - surgical treatment
40919509|NCT05019118|OTHER|Experimental milk|UNICLA milk naturally enriched in selenium and omega-3.
41267536|NCT04478825|DRUG|BBT-401-1S|BBT-401-1S, 8 weeks, once a day
41267537|NCT05019937|BEHAVIORAL|Educational meeting|The investigators will hold a full-day educational meeting. The meeting will include educating 4-5 representatives of each school, and school-district representatives about the guideline and the advantages of adhering to the guideline.
41267538|NCT05019937|BEHAVIORAL|Implementation team|The school-principal forms an implementation team that is responsible for implementing the guideline within their school. The team members (n=4-5) reflect on the implementation progress, make, and refine plans according to Plan-Do-Study-Act, share lessons learned and support each other.
41267539|NCT05019937|BEHAVIORAL|Workshops|"The investigators will hold 5 workshops. Workshops will include providing in-depth knowledge and skills on the guideline recommendations. During each workshop one of the guideline recommendations will be presented and discussed.~Moreover, the concept of Plan-Do-Study-Act will be introduced and how it can be used to implement the guideline recommendation(s). During each workshop, the implementation team will share with the group their developed PLAN and barriers and facilitators that have influenced the execution of the PLAN."
40919510|NCT05019118|OTHER|Experimental yogur|UNICLA yogur naturally enriched in selenium and omega-3.
40919511|NCT05019118|OTHER|Experimental fresh cheese|UNICLA fresh cheese naturally enriched in selenium and omega-3.
40919512|NCT05019118|OTHER|Placebo milk|Conventional milk
40919513|NCT05019118|OTHER|Placebo yogur|Conventional yogur
40919514|NCT05019118|OTHER|Placebo fresh cheese|Conventional fresh cheese
40919515|NCT06047119|PROCEDURE|Blood pressure|Blood pressure targets during general anesthesia and 2 hours after
40919516|NCT06047119|PROCEDURE|Positive end expiratory pressure|Positive end expiratory pressure during general anesthesia
40919517|NCT06047119|PROCEDURE|Tidal volume|Tidal volume during general anesthesia
40919518|NCT06047119|PROCEDURE|Fraction of inspired oxygen|Fraction of inspired oxygen during general anesthesia and 2 hours after
41092776|NCT05879666|BEHAVIORAL|Online educational phthalate course|This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.
41092777|NCT03324685|DRUG|BIIB074|BIIB074 is administered as specified in the treatment arm.
41092778|NCT03324685|DRUG|OC (ethinyl estradiol and levonorgestrel)|OC is administered as specified in the treatment arm.
41092779|NCT04920175|OTHER|Novel Real-time Neonatal Sleep Stage Detection Algorithm|Comparison of Novel Real-time Neonatal Sleep Stage Detection Algorithm to gold standard concurrent polysomnogram.
40919519|NCT03658876|DRUG|Iron Sucrose Solution for Injection|200mg iron sucrose given on 5 successive haemodialysis sessions
40919520|NCT03658876|DRUG|Epoetin Beta|Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
41092780|NCT01687192|BIOLOGICAL|HPV prophylactic vaccine Gardasil|3 injections: at Inclusion visit then 2 and 6 months after.
41267540|NCT05019937|BEHAVIORAL|Plan-Do-Study-Act improvement cycles|The implementation team will implement the guideline in a cyclical manner by using Plan-Do-Study-Act. First a Plan is specified during the workshop by using SMART-goals, next the change is carried out between workshops (Do), the implementation team analyses whether it went well and what needs to be improved (Study), changes are made (Act) and finally the next cycle is planned.
41267541|NCT05019937|BEHAVIORAL|Internal facilitator|Each municipality assigns one or more internal facilitators, for example HR-strategist. The internal facilitator will meet their local implementation teams during the educational meeting and workshops. Further meeting can be scheduled based on the needs of each implementation team. The internal facilitator will create a supportive environment within which knowledge is exchanged, barriers to implementation identified, and processes or solutions to overcome those barriers developed, applied, and refined. Moreover, the internal facilitator will establish ongoing audit and feedback processes.
41267542|NCT04749394|DRUG|Camrelizumab, PD-1 monoclonal antibody|Camrelizumab 200mg IV, Q3W, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
41267543|NCT04749394|DRUG|Apatinib, VEGFR2 antibody|Apatinib 250mg PO, QD, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
41267544|NCT00006187|DRUG|Investigational drug|
40919521|NCT05811234|DRUG|CAL/BDP PAD Cream|As provided in real-world clinical practice.
40919522|NCT01251536|DRUG|Dose escalation of cetuximab|"Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly"
40919523|NCT01251536|DRUG|Standard first line treatment with cetuximab + Folfiri|"Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly."
40919524|NCT00124046|PROCEDURE|Surgery|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
40919525|NCT00124046|PROCEDURE|Medical Treatment|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
41092781|NCT06085807|OTHER|Survey|Groups will receive a survey to assess attitudes about diagnosis, treatment, and genetic testing in ADPKD.
41092782|NCT00893217|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
41092783|NCT00893217|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
40919526|NCT02706964|DEVICE|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
40919527|NCT02706964|DEVICE|Magnetic resonance imaging|A brain MRI will be performed.
40919528|NCT02706964|DEVICE|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
40919529|NCT03553992|BEHAVIORAL|POP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults~Drug: nicotine patch 14-day supply of nicotine patch"
40919530|NCT03553992|BEHAVIORAL|TSP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use~Drug: nicotine patch 14-day supply of nicotine patch"
40919531|NCT00003897|BIOLOGICAL|gp100 antigen|
40919532|NCT00003897|BIOLOGICAL|sargramostim|
40919533|NCT00901732|DEVICE|Caphosol|Oral Mouth Rinse
40919534|NCT00451503|DEVICE|Middle Ear Implant|surgery
40919535|NCT00470509|DRUG|Adalimumab|2 subcutaneous injections on day 0 and 7
40919536|NCT00470509|DRUG|Placebos|2 subcutaneous injections on day 0 and 7
40919537|NCT01030081|DRUG|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
40919538|NCT01030081|DRUG|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
40919539|NCT00675467|BEHAVIORAL|Focus Group - Parent/Caregiver|A 1 1/2 hour group session with other parents/caregivers.
40919540|NCT00675467|BEHAVIORAL|Focus Group - Pediatric Patient|A 1 1/2 hour group session with other pediatric patients.
40919541|NCT04269083|OTHER|BIRC3|BIRC3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and EGJ
40919542|NCT06333600|DRUG|Topical minoxidil|Therapeutic intervention
40919543|NCT06333600|DRUG|Topical Vitamin D|Therapeutic intervention
41267545|NCT06164769|PROCEDURE|blocking both the abdominal trunk and superior mesenteric artery in the pancreatic enucleation|In the pancreatic enucleation, Kocher Maneuver was routinely performed at first. Then free the left side of the abdominal trunk and superior mesenteric artery, loose tissues easy to free.After Kocher Maneuver and other surgical procedures, the abdominal trunk and superior mesenteric artery exposed. Before resection of pancreatic tumors, a vascular occlusion clamp clip was used to block the root of both the abdominal trunk and superior mesenteric artery to control the pancreatic blood flow.
41267546|NCT01868984|DRUG|Paclitaxel|Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
40919544|NCT06333600|DRUG|Saline spray|placebo
40919545|NCT05324904|DRUG|Vitamin D|"- Vitamin D~* The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,~* Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts \> 10 mm need multiple injections at different sites)~* Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions"
40919546|NCT05324904|DRUG|acyclovir|"-Acyclovir~* Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution.~* After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution~* Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions"
40919547|NCT04287543|DRUG|Melatonin|25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months
41092784|NCT03112278|PROCEDURE|Ceramic ultrathin occlusal veneers|Severely eroded teeth will be restored with ultrathin occlusal veneers made of ceramic (e.max CAD/Ivoclar Vivadent) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
41092785|NCT03112278|PROCEDURE|Composite resin ultrathin occlusal veneers|Severely eroded teeth will be restored ultrathin occlusal veneers made of composite resin (Lava Ultimate/3M Espe) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
41267547|NCT01868984|PROCEDURE|Standard Therapy|Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (\>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
41267548|NCT04167345|DRUG|VX-814|Tablet for oral administration.
41092786|NCT06615128|DIAGNOSTIC_TEST|blood sampling|blood sample to detect sCD25 from systemic sclerosis and Healthy control.
41267549|NCT04167345|DRUG|Placebo|Placebo matched to VX-814 for oral administration.
41267550|NCT02886299|DRUG|Fenofibrate|
41267551|NCT02886299|DRUG|Simvastatin|
41267552|NCT03012581|DRUG|Nivolumab|Treatment
41267553|NCT06359184|OTHER|yoga|1 hour yoga practice 2 days a week for 8 weeks
41267554|NCT06359184|OTHER|control|no intervention for 8 weeks
41267555|NCT04390867|DEVICE|TOPS1 DBS|TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
41267556|NCT04390867|DEVICE|TOPS2 DBS|TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
40919548|NCT04287543|DRUG|Placebos|25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
41092787|NCT06614283|BEHAVIORAL|Diabetes self management @ click|A mobile application tailored for patients with Type 2 diabetes, aiming to enhance their self-management practices will be used for the intervention arm. The app includes features such as medication tracking, appointment scheduling, patient data storage, advice for treatment and follow-ups, health education and promotion, and real-time health monitoring.
41267557|NCT04390867|DEVICE|TOPS3 DBS|TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
41092788|NCT06191536|OTHER|Pilates|
41267558|NCT04390867|DEVICE|Standard DBS|Standard is the pattern of stimulation that is usually delivered clinically by a DBS system
41267559|NCT06435702|DRUG|Darolutamide in addition to androgen deprivation therapy|Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration
41267560|NCT06435702|DRUG|androgen deprivation therapy only|The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
41092789|NCT06191536|OTHER|Pelvic floor exercises|
41092790|NCT04002362|DRUG|Triamcinolone Acetonide|An intramuscular injection of triamcinolone acetonide (1 mg/kg, up to 40 mg maximum) will be administered deep in the gluteal muscle by a trained registered nurse.
41092791|NCT05704049|DRUG|Isatuximab|Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
41287105|NCT03903328|OTHER|Sarcopenia assessment|Sarcopenia assessment by measurement of Skeletal Muscle mass index, hand grip strength and usual gait speed for 5 meter distance, as per the guidelines of Asia Working group for Sarcopenia study, was carried out.
41287106|NCT05054946|PROCEDURE|Laparoscopic cystectomy|All surgeries will be performed under general anesthesia by laparoscopically.
41287107|NCT02032875|DRUG|Daclatasvir|
41287108|NCT02032875|DRUG|Sofosbuvir|
41287109|NCT02032875|DRUG|Ribavirin|
41267561|NCT06044896|PROCEDURE|Supine Positioning|The participant will be guided to the Multicare bed and will be positioned supine with the headboard not tilted. At this point, the participant will already have the EIT electrode belt and head, trunk and lower limb cushions around it, providing stability. After the participant has been correctly positioned, ventilatory monitoring will begin using the EIT. The environment must be fully controlled, that is, with adequate lighting, all collection members in silence, as well as the devices in the place, air-conditioned environment, without exposing the participant to heat or cold. Before starting the collection, the volunteer will be asked to try not to sleep or talk, making it clear that any discomfort can be reported at any time. To keep the volunteer awake, visual and sound stimuli can be performed. Furthermore, if you cough or sigh, the collection will restart. The intervention will last 5 minutes and will be repeated twice, with intervals between body lateralization.
40919549|NCT00874926|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
41267562|NCT06044896|PROCEDURE|Body Lateral Positioning|The participant will start from the bench press to the 30-degree lateral position. The cushions placed at the beginning of the collection will provide stability so that the inclination does not compromise the correct positioning of the participant, preventing them from sliding on the bed. Furthermore, it is also a safety measure for the participant. The environment will be controlled throughout the intervention and visual and sound effects will also be performed in lateral positioning. The volunteer will remain in this position for five minutes and shortly after will be placed in the supine position again. To start the protocol for the second and final time, the participant will have a washout time of thirty minutes.
41267563|NCT00004160|DRUG|cisplatin|
40919550|NCT00775047|OTHER|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
40919551|NCT00775047|OTHER|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
41267564|NCT00004160|DRUG|gemcitabine hydrochloride|
41267565|NCT00004160|DRUG|paclitaxel|
41267566|NCT00004160|RADIATION|radiation therapy|
41267567|NCT04727671|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
41267568|NCT04727671|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
41267569|NCT04727671|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
40919552|NCT03708354|DRUG|placebo softgel|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
41092792|NCT05704049|DRUG|Carfilzomib|Investigational medicinal product; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
41092793|NCT05704049|DRUG|Dexamethasone|Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Tablet; Route of administration: Oral
41092794|NCT05704049|DRUG|Dexamethasone IV|Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
41267570|NCT04727671|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
40919553|NCT03708354|DRUG|DeltaGold® Tocotrienol 70%|Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
40919554|NCT05039021|DEVICE|HARMONIC 1100 Shears|HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
40919555|NCT02659748|DIETARY_SUPPLEMENT|Milk Fat|Three daily servings of whole yogurt (3.25% fat).
40919556|NCT02659748|DIETARY_SUPPLEMENT|Control Fat|Three daily servings of fat-free yogurt supplemented with a control fat.
40919557|NCT02909608|OTHER|No interventions / observations only|This is an observational study only
40919558|NCT03220451|PROCEDURE|Adhesive elastic taping|Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
40919559|NCT02753257|OTHER|Non-Interventional|Non-Interventional
41092795|NCT05704049|DRUG|Montelukast|Background Treatment; ATC code: R03DC03; Pharmaceutical form: As per local commercial product; Route of administration: Oral
41092796|NCT05704049|DRUG|Acetaminophen|Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)
40919560|NCT03739034|BEHAVIORAL|Lifestyle Medicine|Treatment modalities consist of encouraging a plant based, whole food diet, physical activity, stress management, healthy sleep, control of unhealthy habits.
40919561|NCT01685398|DRUG|0.5% timolol maleate eye drop|
41092797|NCT05704049|DRUG|Diphenhydramine|Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV
41092798|NCT05704049|DRUG|Methylprednisolone|Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV
41092799|NCT01784913|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
41092800|NCT00304811|DRUG|Vancomycin|
41092801|NCT00304811|DRUG|Vancomycin plus Gentamicin|
41092802|NCT00304811|DRUG|Vancomycin plus Rifampin|
41092803|NCT00304811|DRUG|Vancomycin plus Gentamicin plus Rifampin|
41267571|NCT04578002|OTHER|prehospital telemedical triage|Prehospital Triage of Patients with Suspected Stroke Using Onsite Mobile Telemedicine approach (interactive video and audio streaming). In patients with suspected stroke, a prehospital patient evaluation by end-to-end encrypted real-time audio- and video streaming from the pre-hospital setting to an in-hospital stroke physician, located at the University hospital of Basel, is requested and initiated (telestroke-path). The process is supervised and evaluated by an in-hospital stroke physician in real-time. Patients considered having an acute stroke will be directly transferred to cerebral imaging via CT. All other patients will follow conventional stroke path.
41267572|NCT03589001|OTHER|Activity modification|Activity modification, exercises and gradual return to sport
41287110|NCT04718064|DRUG|Fingolimod|fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days
41287111|NCT04718064|DRUG|placebo|placebo once daily, for three consecutive days,
41267573|NCT02713451|DRUG|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
40919562|NCT01685398|DRUG|Normal saline|
41267574|NCT06547957|DRUG|EOS301984|Multiple doses of EOS301984
41267575|NCT06547957|DRUG|Anti-PD-1 monoclonal antibody|Multiple doses of EOS301984 in combination with Anti-PD-1
41267576|NCT02285179|DRUG|GDC-0032|Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd
41267577|NCT02285179|DRUG|Tamoxifen|daily dose of 20 mg
41267578|NCT02557178|BEHAVIORAL|health coaching|Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
40919563|NCT03241030|DRUG|Sucralfate|Will receive 20mg/kg/dose up to 1 gram.
40919564|NCT03241030|OTHER|Placebo|Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
41092804|NCT02374502|BEHAVIORAL|Brief Intervention|'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
41267579|NCT00189462|DRUG|Montelukast|
41267580|NCT00189462|DRUG|Placebo|
41267581|NCT03437239|DEVICE|Delfi PTS II Portable Tourniquet System|This is a portable tourniquet system that allows for occlusion of venous outflow without inhibiting arterial blood flow. This portable tourniquet system allows for rapid cuff inflation and deflation with a battery. The Delfi PTS is a purpose-built system that allows for precise control of pressure throughout training, despite the natural changes in muscle shape and length. The device has advanced pressure leak detection that monitors the tourniquet cuff, tubing, and connectors for air leaks and safely alerts staff to hazards or follow-up actions required. The device has visual and audio alarms for over and under pressure and elapsed time as well as a large, easily visible display of tourniquet pressure and elapsed time. The Delfi PTS II calibrates and self-tests on startup. It has a safety interlock that limits the normal maximum pressure and integrated tourniquet cuff testing as recommended in current AORN Standards and Recommended Practices
40919565|NCT03241030|DRUG|Acetaminophen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
40919566|NCT03241030|DRUG|Ibuprofen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
41267582|NCT02594644|DEVICE|Microneedle Roller|The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 650 micrometers in length.
40919567|NCT02872844|DEVICE|ICS AirCal3|Each patient will undergo a 30-minute heat stress to one ear. For randomization, the left ear will be treated in patients with a registration number ending with an odd number and the right for even numbers. An ICS AirCal3 Research Strategy (Otometrics) system attached to an Intel Core 15vPro Thinkpad (IBM) laptop is used within the audiometry department of a separate outpatient clinic. The patients will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes. The patients will be allowed to fixate and use whatever means they prefer for entertainment during the intervention.
40919568|NCT04123951|OTHER|Home-based Exercise|Patients in the home-based exercise arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
40919569|NCT01630278|DRUG|Ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
40919570|NCT01630278|DRUG|Placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
40947734|NCT04693546|DIAGNOSTIC_TEST|LifeKit Prevent Colorectal Neoplasia Test|Procedure: Colonoscopy
40947735|NCT04693546|DIAGNOSTIC_TEST|FIT Test|Procedure: Colonoscopy
41092805|NCT05475223|DIAGNOSTIC_TEST|End Tidal Carbon Monoxide Value|A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
41092806|NCT05559099|DRUG|Tecovirimat Oral Capsule|"200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)"
41267583|NCT02594644|DRUG|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
40919571|NCT03598114|BEHAVIORAL|Program Sustainability Action Planning Model and Training Curricula|The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
41267584|NCT02594644|RADIATION|Blue Light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
41092807|NCT05559099|DRUG|Placebo|Capsules to match tecovirimat
41092808|NCT04931680|OTHER|Data collection|During the follow-up consultation, six weeks after inclusion (S6), data will be collected using a standardized digital questionnaire, including clinical features, economic, social and cultural characteristics, housing conditions and therapeutic details (type of environmental decontamination and treatment received). Data will then be compared between patients with therapeutic success or failure. A urine test strip will also be used during the S6 consultation to screen for proteinuria. The prevalence of post-streptococcal glomerulonephritis will be extrapolated from that of proteinuria.
41092809|NCT03829280|BEHAVIORAL|Cognitive Adaptation Training|Psychosocial treatment using environmental supports to bypass cognitive and motivational problems and improve adaptive behavior
41092810|NCT03829280|BEHAVIORAL|Community Treatment|Medication follow-up and case management as provided in usual community care in the setting
41092811|NCT03880656|BIOLOGICAL|Intramuscular administration of autologous BM-MNCs|Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
41267585|NCT01338467|DEVICE|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
41267586|NCT03463070|DRUG|rectal misoprostol 600mg|70 women who received 600 mg misoprostol postoperatively at operating theatre
41267587|NCT02787772|PROCEDURE|Elective Hernia repair|abdominal wall hernia repair using onlay mesh.
41267588|NCT02038348|DEVICE|PET with 18F-FDOPA|
41267589|NCT04782167|BEHAVIORAL|BRACE|"Balance training,Static balance:~1. Romberg with eye open \& eye close \[30 sec repeat 3 times\]~2. Tandem standing with eye open then with eye close. Right foot front first, then left foot front \[10 Sec repeat 3 times\]~3. Single leg stance 5 repetition with sec.~Static/Dynamic/Anti-cipatory Postural Control:~1. Sit to stand: 5 repetition~2. Functional reach test: forward, sideways \& cross reach, practice 1 min for each~3. TUG test: with distance of 10 feet \& time 10 sec. practice 2 min Cognitive exercises~1) Count reverse from 50 Repeat with eyes open and close Reps of 30s for each 2) Push wall and reverse count from 20 3) Remember 5 words, Name 5 animals, Repeat 5 words"
41267590|NCT04782167|BEHAVIORAL|Propirioceptive training|1st Phase - Steady phase (1st set: Eyes Open, 2nd set: Eyes Close) Preserve standup position Equally heels up and down Preserve standup on one leg by turns
41267591|NCT06246773|BEHAVIORAL|Positive Parenting Program|During the first week, women will receive one session of Recovering from Intimate partner violence through Strengths and Empowerment (RISE) and from week 2 they will receive RISE and PALS simultaneously. Participants will receive four to six components of RISE - education on health effects of violence, improving coping and self-care, enhancing social support, and addressing sexual violence, increase safety planning, and assist in making difficult decisions. During each of the PALS sessions, parents will receive instruction on four responsive parenting constructs: contingent responsiveness, warm sensitivity (responses include high levels of affection and understanding of child states), maintaining vs. redirecting attention to objects and topics of conversation, and verbal scaffolding .In addition to direct instruction, parents will video-record themselves interacting with their child and engage in self-reflection of their own parenting behavior.
41267592|NCT06246773|BEHAVIORAL|Usual Care|Participants will receive services available to them at the shelter or housing facility
41267593|NCT05779709|OTHER|exercise|Reformer pilates is a specific type that provides resistance exercise at certain weights with the pulley system relying basically on the same principles. Pilates exercises provide breathing and activation of the deep stabilizing muscles of the trunk in coordination with the PFMs. It includes exercises that focus on pelvic stability, mobility and body alignment. PFMs activation is carried out simultaneously with the trunk muscles in various positions in coordination with breathing.
41267594|NCT05779709|OTHER|Urotherapy|Urotherapy includes education of the child and family, diet (adequate fiber and fluid consumption), regular optimal voiding, daily physical activity, teaching normal toilet use, pelvic floor muscle training and relaxation
41287112|NCT02471963|DRUG|Empagliflozin|
41287113|NCT02471963|DRUG|Placebo|
41092812|NCT03683355|RADIATION|18F-FDG PET/CT|18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
41287114|NCT04066621|DRUG|Ceftriaxone Sodium and Sulbactam Sodium for Injection|daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days
41092813|NCT02851810|BEHAVIORAL|oculomotor parameter recording|visual scanning behavior is assessed during visualization of emotional pictures
41092814|NCT02851810|BEHAVIORAL|attachment scale interview (ASI)|ASI is used to determine the attachment style of each participant
41287115|NCT00883428|OTHER|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
41092815|NCT02851810|BEHAVIORAL|psychophysiological recording|this consists of the measurement of the skin conductance reactivity (SCR) during the picture visualization
41092816|NCT02851810|BEHAVIORAL|psychometric assessment|self administered questionnaires are used to assess anxiety, depression and alexithymia.
41092817|NCT02851810|BEHAVIORAL|parent interview|an interview of the adolescent parent is performed in order to assess the confusion of the parent-child role and the interaction between the child and its parent.
41287116|NCT04350515|OTHER|Cyberball: Other Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, one of the avatars is excluded.
41442345|NCT06561672|DRUG|tramadol plus paracetamol|Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anesthesia (induction agent will be propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)
41267595|NCT04849572|BEHAVIORAL|Sleep Education|"* Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 1) will watch a 10 to 20 minute sleep hygiene video followed by a post-test questionnaire to confirm participation and understanding.~* Week 5: Arm 1 will again view the educational video at week 5~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 1 will continue re-education~* Week 11: Arm 1 continues education~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups."
41267596|NCT04849572|BEHAVIORAL|Delayed Sleep Education|"* Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 2) will be controls with no education.~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 2 will join in for video education along with post-test~* Week 11: Arm 2 will undergo reeducation with post-test for 20 mins~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups."
41267597|NCT04361201|PROCEDURE|Ligament plastic surgery|Ligament plastic surgery of ankle under arthroscopy for recurrent instable ankle reason and failure of medical treatment.
41267598|NCT04361201|DIAGNOSTIC_TEST|RMI and ultrasound|RMI examination at 3 months on operated ankle, and 3 CT scan examinations with elastography module will be performed at planned timeframes.
41267599|NCT03266679|OTHER|Metacognitive Reflection and Insight Therapy - Adapted|The intervention involves the following elements: setting an agenda, developing a therapeutic relationship, therapist transparency and insertion of therapist's mind, analysis of narrative episodes, problem definition, stimulating self-reflection and understanding of others, stimulating mastery, reflecting on therapeutic relationship, and client assessment of outcomes.
41092818|NCT04708821|DRUG|Dexamethasone ophthalmic insert 0.4Mg|Dextenza 0.4Mg Ophthalmic Insert
41267600|NCT02682680|DRUG|Colesevelam|Colesevelam 3.75 g daily for 24 weeks
41267601|NCT02682680|DRUG|Ezetimibe|Ezetimibe 10 mg daily for 24 weeks
41267602|NCT03120169|OTHER|treadmill endurance training|n = 15 patients with COPD. Walking intensity will be initially set at 80 percent of 6-minute Walking test Speed with progressive increase in Duration and intensity.
41267603|NCT03120169|OTHER|cycling endurance training|n=15 patients with COPD. Cycling intensity will initially be set at 60 percent of Peak work rate with progressive increase in Duration and intensity
41267604|NCT06304324|DRUG|0.9% Sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
40919572|NCT05666050|BEHAVIORAL|Mobile health intervention|Pregnant women with 26-28 weeks of gestation(based on world health organization eligibility criteria) will be recruited and baseline data will be collected at selected clusters. Women who will provide informed consent will be asked to complete a post-consent eligibility assessment including access to a mobile phone, and willingness to receive health messages on their mobile phone. Women who meet these eligibility criteria will be enrolled in the study and administered the baseline interview. Intervention will be started among randomly selected clustered pregnant women at 30 weeks of gestation and will be continued up to 6 weeks of post partum period for 4 months.
41092819|NCT04708821|DRUG|0.2% loteprednol etabonate ophthalmic suspension|0.2% loteprednol etabonate ophthalmic suspension
41092820|NCT04708821|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%|olopatadine hydrochloride ophthalmic solution 0.7%
41092821|NCT06239662|BEHAVIORAL|Therapeutic Group|The first part of each meeting, lasting 45 minutes, will be held only with children and young people, while parents will wait in the waiting room. At the end of the first part, for each meeting, the children will be asked to make a commitment relating to the topics covered, which will be verified in the following meeting. Once the part with the patients has concluded, they will be accompanied to an adjacent environment where a pediatrician volunteer will be waiting for them and will offer fun and socialization activities. In the meantime, the parents will be seated and will address, together with the team staff, the same issues discussed with their children, again for a duration of approximately 45 minutes. Parents will also be invited to make a commitment similar to that required of children.
41092822|NCT06239662|BEHAVIORAL|Usual care|The dietician will meet individually each child together with parents. Dietician will provide nutritional advices.
41092823|NCT04990882|OTHER|Interpretation of FAPI-PET/CT scans|Each observer's Group will be asked to review FAPI-PET/CT scans of patients with representative cancer types.
41092824|NCT03672760|DEVICE|CardioBreathApp|Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance
41092825|NCT03672760|DEVICE|IMT PowerBreath|Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure
41092826|NCT03672760|DEVICE|IMT PowerBreath Placebo|Inspiratory Muscle Training (IMT) without load
41092827|NCT02939690|DEVICE|UVC|UVC insertion depth calculated by \[(3× birth weight (Kg) + 9)/2+1)\]
41267605|NCT06304324|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
41267606|NCT06304324|DRUG|0.05ug/kg Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05ug/kg dexmedetomidine for the popliteal nerve block
41267607|NCT02063555|BIOLOGICAL|DAR-901|
41267608|NCT02063555|BIOLOGICAL|BCG|
41267609|NCT02063555|BIOLOGICAL|Sterile saline|
40919573|NCT03743935|OTHER|Gadolinium-enhanced cardiac MRI|Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
41092828|NCT02939690|DEVICE|UVC|UVC insertion depth calculated by umbilicus to nipple distance-1
40919574|NCT00313183|DRUG|pramlintide acetate|single subcutaneous doses of 15mcg and 30mcg
41092829|NCT02939690|DEVICE|Ultrasound|
41092830|NCT02518711|BEHAVIORAL|Behavioral Teacher Program|This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
41092831|NCT04129762|OTHER|Diet without NCS|"A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS."
40919575|NCT03505398|PROCEDURE|microperimetry|define the retinal fixation point and the differential sensitivity threshold of the retina.
40919576|NCT03505398|PROCEDURE|visual acuity|using ETDRS scales
40919577|NCT03505398|PROCEDURE|automated visual field|recording visual attention based on central or peripheral visual information
41092832|NCT04129762|OTHER|Diet with NCS|"A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS."
41092833|NCT02583074|PROCEDURE|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
40919578|NCT03505398|PROCEDURE|eye movements recording|recording of explicit visual attention based on central or peripheral visual information
40919579|NCT04101838|DRUG|Fluzone|inactivated seasonal influenza vaccine
41092834|NCT02583074|PROCEDURE|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
41092835|NCT01363479|DRUG|Oral palonosetron|
41092836|NCT01363479|DRUG|I.V. palonosetron|
41092837|NCT01363479|DRUG|Dexamethasone|
40919580|NCT04101838|DRUG|Flucelvax|inactivated seasonal influenza vaccine
41092838|NCT04902742|PROCEDURE|Fluoroscopy-guided ganglion impar block|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Being most commonly used technic, transsacrococcygeal technique, a 22-gauge, 1.5-inch spinal needle is advanced through the sacrococcygeal disk and positioned carefully anterior to the sacrococcygeal junction. Injection of contrast results in a classical comma sign. A mixture of steroid and local anesthetic is given.
41092839|NCT04902742|PROCEDURE|Fluoroscopy-guided caudal epidural steroid injection|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. An 18-gauge epidural needle (Tuohy) is advanced at an angle of 45° to the skin until a 'give-way' sensation is felt and position of the needle is confirmed by lateral and anteroposterior fluoroscopic images. Then 5 ml of iohexol solution is injected through it to confirm the position. A properly placed needle would produce a classical 'inverted fern tree' appearance in anteroposterior view after dye injection or a 'filling defect'. The needle is introduced up to S3 level for proper spread of the drug. A mixture of steroid and local anesthetics is given.
41092840|NCT00003195|BIOLOGICAL|recombinant interferon alfa|
41092841|NCT00003195|DRUG|busulfan|
41092842|NCT00003195|PROCEDURE|allogeneic bone marrow transplantation|
41092843|NCT00003195|PROCEDURE|peripheral blood stem cell transplantation|
41092844|NCT00003195|RADIATION|radiation therapy|
41092845|NCT00869570|DRUG|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
41092846|NCT00869570|DRUG|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
40919581|NCT04101838|DRUG|Fluzone High-Dose|inactivated seasonal influenza vaccine
41092847|NCT00869570|RADIATION|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
41092848|NCT01809379|DRUG|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
41267610|NCT05213247|DEVICE|electronic apparatus (visocor OM50).|Measurement of blood pressure and heart rate
40919582|NCT04101838|DRUG|Fluad|inactivated seasonal influenza vaccine
40919583|NCT01785862|DRUG|Ibuprofen 25 mg|Lozenge, Oromucosal administration
40919584|NCT01785862|DRUG|Placebo|Lozenge matching V0498 lozenge, Oromucosal administration
40919585|NCT04107389|BEHAVIORAL|Art Psychotherapy, Art Therapy|Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.
41092849|NCT03458780|DRUG|Yellow Fever Vaccine|Yellow Fever Vaccine .5 ml
41267611|NCT01455974|OTHER|Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L|After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
41267612|NCT00473876|DRUG|Metformin|Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
41267613|NCT00473876|DRUG|Matched Placebo (Capsules)|Similar dosing regime as active comparator
40919586|NCT04107389|BEHAVIORAL|Wait List|Wait list control group. Participants randomised to Wait List group or Intervention group.
40919587|NCT05867589|DRUG|68Ga/18F-FAPI-04|Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.
40919588|NCT02208687|BEHAVIORAL|Energetic|Physiotherapy and occupational therapy aimed at reconditioning and social participation.
41267614|NCT01622426|DIETARY_SUPPLEMENT|tolerance to a new aminoacid based formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
41092850|NCT03366272|DRUG|Nivolumab|eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
41267615|NCT01622426|DIETARY_SUPPLEMENT|Amino acid formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
41092851|NCT03366272|DRUG|Rituximab|eight cycles of R-GemOx in 2-wk intervals
41092852|NCT03366272|DRUG|Gemcitabine|eight cycles of (R)-GemOx in 2-wk intervals
41267616|NCT04937504|BEHAVIORAL|STAIR-PC Group|Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) is a face-to-face, individual, brief (5 session) therapy adapted from the STAIR program. STAIR-PC is an appropriate treatment for individuals who have experienced traumatic stressors, and addresses symptom targets by teaching skills to improve coping with emotions and strengthen interpersonal relationships.
41092853|NCT03366272|DEVICE|Oxaliplatin|eight cycles of (R)-GemOx in 2-wk intervals
41092854|NCT00971009|BEHAVIORAL|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
41267617|NCT04937504|BEHAVIORAL|WebSTAIR Group|WebSTAIR is a web-based self-help program adapted from the STAIR program for individuals who have experienced traumatic stressors. WebSTAIR contains 10 self-guided interactive modules that teach skills to improve coping with emotions and strengthen interpersonal relationships.
41267618|NCT04625777|BEHAVIORAL|Mindfulness Based Stress Reduction|"Mindfulness Based Stress Reduction (MBSR) teaches several different kinds of meditation. MBSR is offered as an online course through Duke Integrative Medicine and is based on the national model first developed by Jon Kabat-Zinn at the University of Massachusetts. It includes exercises in awareness of breath, body scans, walking meditation, choiceless open awareness, Loving Kindness Meditation, and bringing awareness to the present moment. The MBSR Distance Learning course consists of 8 weekly sessions via video conference and includes meditation instruction, periods of guided practice, and group discussion."
40919589|NCT02208687|OTHER|Control group|Usual care
41092855|NCT00971009|BEHAVIORAL|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
41092856|NCT02318485|BIOLOGICAL|Limbal epithelial stem cell graft|
41092857|NCT01501929|DRUG|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
41092858|NCT01501929|DRUG|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
41267619|NCT04625777|BEHAVIORAL|Daily Examen spiritual practice|"The Daily Examen is a simple but powerful prayer used by Jesuits every day. It takes only 10-15 minutes and can be used to reflect on positive emotions, move past negative emotions, and align one's work with God's work. The Examen directs the person praying to focus on a five-step routine:~1. Become aware of God's presence;~2. Give thanks to God for everything in your life;~3. Review the events of the day guided by the Holy Spirit;~4. Look at what went well or wrong in the past day; if at fault, ask God for forgiveness; and~5. Look toward tomorrow - what one thing should you do? Listen to what God is telling you."
41092859|NCT01501929|PROCEDURE|Non-invasive measurement of Cardiac Output (CO)|Cardiac Output (CO) will be measured non-invasively at rest and during exercise by thoracic electrical bioimpedance. Stroke volume will be derived from change in impedance/time measured during electrical systole. Cardiac output will be determined as the product of stroke volume and heart rate.
41442346|NCT06561672|DRUG|Fentanyl|Intravenous injection of 1.5 microgram/kg fentanyl will be given to the patient followed by induction agents (propofol 2mg/kg).
40744399|NCT04807530|DEVICE|TMS|The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)
40919590|NCT05962567|OTHER|Non surgical periodontal therapy|scaling and subgingival debridement
40919591|NCT01232803|DRUG|Tenofovir 1% gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
40919592|NCT01232803|DRUG|2% N-9 gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
41092860|NCT01501929|PROCEDURE|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
41092861|NCT01501929|PROCEDURE|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
41092862|NCT06268418|OTHER|Artificial intelligence|Segmentation
41267620|NCT04625777|BEHAVIORAL|Stress inoculation combination|This intervention includes a combination of stress inoculation and general stress reduction activities focused on physiology, with exercises that bypass the brain and work directly on the body to mitigate the symptoms of stress. This system is based on Stress Inoculation Training, which uses breathing to prepare people in advance for stressful episodes and recovery skills for following such episodes. The techniques include a variety of breathing, blood flow, and tension control methods, as well as ways to conduct deep tissue massage on oneself to release muscle tension. The awareness aspect involves understanding stress biology and learning to spot the symptoms of stress in oneself and others.
41267621|NCT03494647|DEVICE|Cheetah Heel Cup|The Cheetah Heel Cup is composed of a rubber waffle that cups the athlete's heel, secured in place by a neoprene sleeve.
41267622|NCT03494647|DEVICE|The X Brace|The X Brace is composed of one thick elastic band that is wrapped around the athlete's arch of the foot. A second band is wrapped around the back of the heel, crossed under the foot, and secured to the thicker band on the bottom of the foot.
41267623|NCT01466244|BIOLOGICAL|cetuximab|
41267624|NCT01466244|DRUG|cisplatin|
41267625|NCT01466244|GENETIC|gene expression analysis|
41267626|NCT01466244|GENETIC|microarray analysis|
41267627|NCT01466244|OTHER|immunohistochemistry staining method|
41267628|NCT01466244|OTHER|laboratory biomarker analysis|
41267629|NCT03201055|DEVICE|Snore PAP System|The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
41267630|NCT02408692|DRUG|ECx1|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of \<25 kg/m2 will have completed study participation.
40919593|NCT01232803|DRUG|HEC Placebo gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
40919594|NCT00935155|PROCEDURE|Acupuncture|Westerns style acupuncture. Twice a week for 12 weeks
40919595|NCT00935155|PROCEDURE|exercises|Coordination, mobilizing, endurance, strength
40919596|NCT03209128|RADIATION|Irradiation prophyllactique cérébrale|Irradiation prophyllactique cérébrale
40919597|NCT04381182|DEVICE|Apollo Wearable Device|Participants wear Apollo device which generates vibration frequencies on skin and can be controlled by the user
40919598|NCT02634190|OTHER|Thinprep® LBC|liquid based cytology
40919599|NCT02634190|OTHER|APTIMA® HPV Assay|in vitro diagnostic test
40919600|NCT02634190|OTHER|HR HC2® HPV DNA|in vitro diagnostic test
40919601|NCT02634190|OTHER|Colposcopy|Colposcopy
40919602|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
40919603|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
40919604|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
40919605|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
40919606|NCT04516395|OTHER|Combined antibiotic regimens|Combined antibiotic combinations defined as the optimal antibiotic combination regimens which are created from in vitro study and the application of PK/PD.
40919607|NCT04516395|OTHER|Standard antibiotic regimens|Standard antibiotic regimens defined as the antibiotic regimens which are generally given to the patients following to the hospital protocol.
40919608|NCT05453734|PROCEDURE|Progressive Muscle Relaxation Exercises|Before data collection, one of the researchers received training and certification from a psychotherapist specialist in this field to be able to apply the PMR exercises. The guidelines on the PMR exercises were prepared in line with the literature and training received by the researcher. In the guidelines, the person is asked to be in a comfortable place and position, to reach the face by following the large muscle groups gradually, starting from the feet, to tense the muscles in each step, and then to release them. It is necessary to take a deep breath after each muscle group, to stop for a while, and release it slowly
41092863|NCT06045637|BEHAVIORAL|Group included in a psychoeducational program based on the cognitive behavioral approach (experiment)|The 9-session cognitive behavioral approach-based psychoeducation program will last 5 weeks. Sessions; It will be carried out in the form of acquaintance, recognition of trauma and its effects, emotion and thought behavior analysis, cognitive errors, automatic thoughts and alternative thought generation, cognitive emotion regulation strategies, coping with negative emotions, instilling hope and termination session.
41267631|NCT02408692|DRUG|ECx2|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
41267632|NCT02507349|BEHAVIORAL|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
41267633|NCT02507349|BEHAVIORAL|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
41267634|NCT03787914|PROCEDURE|Mobile Outreach Approach|TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision
41267635|NCT05140057|COMBINATION_PRODUCT|Moviprep|Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
41267636|NCT02416869|PROCEDURE|Intramuscular application|Patient receive 4mg of Dexamethasone by intramuscular application
41267637|NCT02416869|PROCEDURE|Submucosal application|Patients receive 4mg of Dexamethasone by submucosal application
41267638|NCT02416869|DRUG|4mg Dexamethasone submucosal|Patients receive 4mg of submucosal Dexamethasone
41267639|NCT02416869|DRUG|8mg Dexamethasone submucosal|Patients receive 8mg of submucosal Dexamethasone
40919609|NCT01087788|BIOLOGICAL|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
41442347|NCT06561672|DRUG|propofol and muscle relaxant (cisatracurium)|propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)
40919610|NCT01087788|BIOLOGICAL|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
40919611|NCT01087788|OTHER|Placebo|Matching Placebo to CZP injection.
40919612|NCT00062231|DRUG|amoxicillin-clavulanate potassium|
40919613|NCT00062231|DRUG|ciprofloxacin|
40919614|NCT00062231|DRUG|moxifloxacin hydrochloride|
40919615|NCT00062231|PROCEDURE|management of therapy complications|
40919616|NCT04031209|DEVICE|G7 Acetabular System|All patients will receive G7 Acetabular System
40919617|NCT05714644|OTHER|FIT kit Screening Test|FIT kit mailed to the patient's home
40919618|NCT05714644|OTHER|Cologuard Screening Test|Cologuard test mailed to the patient's home
40919619|NCT01311284|DEVICE|Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope|Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.
40919620|NCT01311284|DEVICE|Macintosh laryngoscope|intubate with the macintosh laryngoscope
40919621|NCT01311284|DEVICE|McGrath|Intubate with McGrath device
40919622|NCT01311284|DEVICE|Airtraq Nasotracheal|intubate with Airtraq Nasotracheal
40919623|NCT05222672|OTHER|His Bundle Pacing|Pacing of the His bundle
40919624|NCT00274833|DRUG|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
40919625|NCT00274833|DRUG|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
40919626|NCT00274833|RADIATION|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
40919627|NCT06329284|DIAGNOSTIC_TEST|ELISA|ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1
40919628|NCT03353233|DRUG|Ropivacaine|Local anesthetic (numbing drug)
40919629|NCT03353233|PROCEDURE|Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block|An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.
40919630|NCT03353233|DRUG|Saline|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
40919631|NCT02398006|OTHER|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
40919632|NCT02398006|OTHER|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
41267640|NCT02416869|PROCEDURE|4mg Dexamethasone preoperative|Patients receive 4mg of Dexamethasone preoperatively
41267641|NCT02416869|PROCEDURE|4mg Dexamethasone postoperative|Patients receive 4mg of Dexamethasone postoperatively
41442348|NCT06561672|DRUG|Propofol|propofol 2mg/kg
41442349|NCT03138967|DRUG|Rocuronium|Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
41092864|NCT04201015|DEVICE|Heart rate optimisation using force frequency data|Programming heart rate rise according to the force frequency relationship
41092865|NCT04173845|DRUG|Tianqi Pingchan Granule|Tianqi Pingchan Granule are given twice a day
41092866|NCT04173845|DRUG|Tianqi Pingchan Granule Placebo|Tianqi Pingchan Granule Placebo
41092867|NCT04159155|RADIATION|External Beam Radiation|Radiation therapy given outside the patient to a particular part of the body.
41092868|NCT04159155|DRUG|Niraparib|Oral drug
41092869|NCT04159155|RADIATION|Vaginal high-dose rate brachytherapy|Internal radiation to the vagina
41092870|NCT04159155|OTHER|Observation - no drugs|Observation
41092871|NCT04789850|DRUG|Itacitinib|200 mg oral for 360 days
41092872|NCT04789850|DRUG|Placebo|200 mg oral for 360 days
41092873|NCT00230451|PROCEDURE|Radiation|
41092874|NCT00230451|DRUG|Paclitaxel|
41092875|NCT00230451|DRUG|Cisplatin|
41092876|NCT00230451|DRUG|5-Fluorouracil|
41092877|NCT04029740|BEHAVIORAL|CBT- both internet and face to face|There are a few common psychotherapies for treating PD, with Cognitive Behavioral Therapy (CBT) as the most common. The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks (D H Barlow, 1997). The ICBT therapy is based on Barlow and Craske's (2007) protocol for treating PD with elaborations (Huppert \& Baker-Morissette, 2003). It includes six modules containing psychoeducation, cognitive restructuring, exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module, participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress.
41092878|NCT04029740|OTHER|No intervention|Healthy controls will not receive any intervention.
41092879|NCT04393103|DRUG|Intralipid, 20% Intravenous Emulsion|"Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.~* Group A (Control Group) : Follow Up of 30 patients.~* Group B (Study Group): 30 patients will receive intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart."
41092880|NCT04393103|DRUG|Intravenous Atropine Sulfate|Atropine will be administered to ALL PATIENTS in Group A and group B by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till complete atropinization. Following this, an infusion of 10-20% of the atropinizing dose was given every hour.
41092881|NCT04992442|DRUG|TAK-935 Oral Tablet|TAK-935 tablet
41092882|NCT04992442|DRUG|[14C]TAK-935 IV Infusion|\[14C\]TAK-935 IV infusion
41092883|NCT04992442|DRUG|[14C]TAK-935 Oral Solution|\[14C\]TAK-935 oral solution
41092884|NCT05536427|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
41092885|NCT02116387|OTHER|Routine Physical Therapy|Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).
41092886|NCT02116387|DEVICE|I-Moove Physical Therapy|Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
41092887|NCT06071104|PROCEDURE|Anterior segment ophthalmic surgery|Cataract surgery during which the crystalline lens (often cloudy) is broken into small pieces and gently removed from the eye with suction (phacoemulsification)
41092888|NCT06071104|DEVICE|UNITY VCS|UNITY Vitreoretinal Cataract System (VCS) with console, remote control, foot controller, UNITY Cataract FMS Pack, and UNITY Anterior Vitrectomy Kit
41092889|NCT05629598|BIOLOGICAL|Recombinant human erythropoietin injection|The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).
41092890|NCT05629598|BIOLOGICAL|Human erythropoietin injection|Refer to the product instructions
41092891|NCT05602116|DRUG|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The Investigational Product is a C2C_ASC cell product (Cell2Cure®, Cell2Cure Aps, Denmark).~C2C_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The excipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
41092892|NCT03804411|DRUG|Automatic system guided treatment|Addition of: 1A -vildagliptin 100 mg/day 2A - sitagliptin 100 mg/day, 3A- dapagliflozin 10 mg/day 4A- empagliflozin 10 mg/day 5A- liraglutide 1,2-1,8 mg/day 6A- exenatide 20 μg/day 7A - glimepiride 8A - gliclazide
41092893|NCT03804411|DRUG|Standard treatment|"Addition of:~1. B -vildagliptin 100 mg/day~2. B - sitagliptin 100 mg/day,~3. B- dapagliflozin 10 mg/day~4. B- empagliflozin 10 mg/day~5. B- liraglutide 1,2-1,8 mg/day~6. B- exenatide 20 μg/day~7. B - glimepiride~8. B - gliclazide"
41092894|NCT01134575|DRUG|CMC-544 (Inotuzumab Ozogamycin)|"First patients \> 16 years and \< 16 years receive CMC-544 at a dose of 1.3 mg/m\^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m\^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m\^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2."
41092895|NCT01134575|DRUG|Rituximab|With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m\^2 IV (by vein) over 2-6 hours every 3-4 weeks.
41267642|NCT01413386|DEVICE|biliary stent|palliative treatment for malignant patients
41092896|NCT05137912|BIOLOGICAL|Immunotherapy|"Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA.~Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy."
41267643|NCT01299727|BIOLOGICAL|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
41267644|NCT01299727|BIOLOGICAL|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
41267645|NCT01299727|BIOLOGICAL|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
41092897|NCT00024466|BIOLOGICAL|GVAX|
41092898|NCT00024466|PROCEDURE|Autologous transplant|
41092899|NCT01702038|DRUG|Rituximab|1000 mg administered intravenously
41092900|NCT03214887|BIOLOGICAL|RV-P1501|Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
41267646|NCT02983604|DRUG|GS-5829|Tablet(s) administered orally once daily
41267647|NCT02983604|DRUG|Exemestane|25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
41267648|NCT02983604|DRUG|Fulvestrant|"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."
41267649|NCT02005120|DRUG|Bevacizumab|Intrapleural administration of bevacizumab
41267650|NCT02005120|DRUG|recombinant human endostatin|Intrapleural administration of recombinant human endostatin
41267651|NCT05046756|DEVICE|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
41092901|NCT06613412|DIAGNOSTIC_TEST|Remote Robotic Bronchoscopy system|Utilization of a remote robotic bronchoscopy system for the biopsy of patients with pulmonary peripheral lesions
41092902|NCT04874610|DRUG|Methylprednisolone|Administration of methylprednisolone Prescribed per Standard of care
41092903|NCT06061484|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (RUTF)|Standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
41092904|NCT06061484|DRUG|Amoxicillin|Standard weight-based dosing per Ehtiopian national guidelines
41092905|NCT04974489|BEHAVIORAL|Emotion-based messages about the harm of VLNC|Participants in this arm will receive 3 emotion-based messages about the harm of VLNC during the survey data collection.
41092906|NCT04974489|BEHAVIORAL|Continued-harm-framed messages about the harm of VLNC|Participants in this arm will receive 3 continued-harm-framed messages about the harm of VLNC during the survey data collection.
41092907|NCT04974489|BEHAVIORAL|Myth-refuting messages about the harm of VLNC|Participants in this arm will receive 3 myth-refuting messages messages about the harm of VLNC during the survey data collection.
41267652|NCT03996772|DRUG|Apixaban Oral Tablet|Factor Xa Inhibitor
41092908|NCT04974489|BEHAVIORAL|Control messages about littering|Participants in this arm will receive 3 control messages about littering during the survey data collection.
41092909|NCT02931162|OTHER|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
41092910|NCT02931162|OTHER|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
41092911|NCT00651677|PROCEDURE|HAL proctectomy|Hand-assisted laparoscopic proctectomy
41092912|NCT00651677|PROCEDURE|"straight laparoscopic proctectomy"|"straight laparoscopic proctectomy"
41092913|NCT00651677|PROCEDURE|Hand-assisted laparoscopic proctectomy|hand-assisted laparoscopic proctectomy
41267653|NCT03996772|DRUG|Dabigatran|Direct Thrombin Inhibitor
41267654|NCT03996772|DRUG|Edoxaban Tablets|Factor Xa Inhibitor
41267655|NCT03996772|DRUG|Rivaroxaban|Factor Xa Inhibitor
41267656|NCT05606237|DEVICE|Low-level Red Light Therapy Device|The treatment device used in this study is a semi-conductor laser product (Eyerising International Pty Ltd, Melbourne, Australia), emitting low-level red-light with a wavelength of 650 ± 10 nm. Based on calculations done by the manufacturer, the device provides light at a power of 2.00 ± 0.50 mW.
41267657|NCT06281392|DEVICE|CADe system|Colonoscopy assisted by an artificial intelligence system (CADe).
41267658|NCT06281392|DEVICE|NBI|Virtual colonoscopy assisted by NBI
41267659|NCT00578357|BEHAVIORAL|personalized feedback intervention|personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
41092914|NCT00651677|PROCEDURE|SL Proctectomy|Straight laparoscopic proctectomy
41092915|NCT05611580|BEHAVIORAL|Chronic Disease Risk Reduction|The intervention involves education information about chronic diseases and way to reduce risk for developing chronic diseases and/or decrease worsening of existing conditions.
41092916|NCT02697721|BEHAVIORAL|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
41267660|NCT03313960|DRUG|"Afrezza plus One Drop | Premium"|"Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop \| Premium (i.e., One Drop \| Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months)."
41267661|NCT03313960|OTHER|"One Drop | Premium"|"Participants in this group will receive One Drop \| Premium (i.e., One Drop \| Experts in-app CDE coaching with the One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months)."
41092917|NCT02697721|OTHER|Control with delayed intervention|Control with delayed intervention
41092918|NCT06384131|DRUG|ABI-4334|10 mg or 50 mg tablets for oral administration
41092919|NCT06384131|DRUG|Placebo|10 mg or 50 mg tablets for oral administration
41092920|NCT05165238|BEHAVIORAL|Impact of four week coaching program on dietary habits|A registered dietitian will provide dietary coaching via online groups to participants.
41092921|NCT04871282|DRUG|AL102|AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
41092922|NCT04871282|OTHER|Placebo|Placebo to match AL102
41092923|NCT02064751|DEVICE|CRT with MultiPoint Pacing|
41092924|NCT02064751|PROCEDURE|Hemodynamic measurements for CRT device programming|
41092925|NCT01879878|DIETARY_SUPPLEMENT|Verum, broccoli sprout grain|Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
41092926|NCT01879878|DIETARY_SUPPLEMENT|placebo|Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
41092927|NCT02390297|GENETIC|Blood tests|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
41092928|NCT04746820|OTHER|single-center prospective pilot study|"fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP"
41092929|NCT05166343|DRUG|Epinephrine Injection|Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).
41092930|NCT04502927|PROCEDURE|Passive extension mobilization of the hand and wrist joints|"The physiotherapist will proceed with the passive mobilization of the spastic hand of the stroke patient or the dominant hand for healthy volunteers.~Two mobilizations will be performed for each participant, i.e. one for each type of medial or lateral grip. The order of mobilization will be determined by randomization."
41092931|NCT04895345|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
41092932|NCT04895345|RADIATION|Intensity modulated radiotherapy|Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
41092933|NCT03614130|DEVICE|LID011121 contact lens|Investigational silicone hydrogel contact lens
41267662|NCT04744974|BEHAVIORAL|Diet intervention|Participants will be given dietician counseling on their assigned diet
41092934|NCT03614130|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
41092935|NCT00116870|DRUG|lovastatin|
41092936|NCT04529057|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
41092937|NCT01630499|BEHAVIORAL|Tailored Lifestyle Intervention (TLI)|The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
41092938|NCT01630499|BEHAVIORAL|Commercial Weight Loss Program (CWLP)|This intervention is a generic, widely-available weight management program.
41092939|NCT02742909|DRUG|rhBNP|rhBNP was administered as a continuous infusion for 24 hours before or after placebo
41092940|NCT02742909|DRUG|placebo|normal saline as a placebo was administered as a continuous infusion for 24 hours
41092941|NCT06068517|DEVICE|Closed incision negative pressure wound therapy|After the completion of abdominal surgery and standardised skin closure with staples, ciNPWT will be applied, using a commercially available device.
41092942|NCT06068517|DEVICE|Standard dressing|After the completion of abdominal surgery and standardised skin closure with staples, standard dressings will be applied.
41287117|NCT04350515|OTHER|Cyberball: Player Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, the subject is excluded by the avatars.
40919633|NCT05090800|DRUG|Definity contrast during ultrasound|Participants will undergo an ultrasound contrast evaluation of both kidneys. This will include placement of an intravenous (IV) catheter in a vein and the delivery of Definity ultrasound contrast agent through the IV. Imaging will be completed for each kidney. The proposed total dose for adult patients will not exceed 20 microliters/kilograms (kg). Each individual dose not to exceed 10 microliters/kg. At initiation of patient studies, the dose will start at 10 microliters/kg for the first injection and a second 10 microliters/kg dose to evaluate the contralateral kidney. However, if ultrasound findings in patient studies demonstrate a dose that is too high (unable to make accurate ultrasound assessment), the dose will be reduced.
40919634|NCT02219802|PROCEDURE|Treatment according arm|
40919635|NCT01450852|BEHAVIORAL|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
40919636|NCT02797002|OTHER|Assessment|
40919637|NCT06533761|DRUG|Eganelisib|eganelisib will be administered as monotherapy
40919638|NCT06533761|DRUG|Eganelisib in combination with cytarabine|eganelisib will be administered in combination with cytarabine
40919639|NCT06293976|OTHER|Changes in the ventilator respiratory rate and tidal volume|"With the ventilator on volume control and Vt at 6 ml/kg of predicted body weight (PBW) (standard clinical practice), an end-expiratory occlusion of 30 seconds on the ventilator will be performed to search for intrinsic respiratory rate (RR). The set RR will be modified from 6 breaths per minute (bpm) below up to 6 bpm above the clinical RR in steps of 2 bpm every 1 minute (random order). The changes in RR described above will be repeated with Vt set at 5, 7 and 8 ml/kg PBW (random order). The steps described above will be aborted at any point if SpO2 drops below 85% for at least two minutes, mean arterial pressure drops below 60 mmHg, or plateau pressure \>35 cmH2O.~If an intrinsic respiratory rate ≥8 bpm is present and P/F ratio is ≥150, it will be propose to the clinician to place the patient in pressure support at a level preferred by clinicians for 5 minutes. If the patient tolerates well, it will be propose to the clinician to maintain the patient in pressure support ventilation,"
40919640|NCT05563870|PROCEDURE|Endoluminal radiofrequency ablation|Endoluminal Radiofrequency ablation (RFA) of the entire stricture length will be performed using the Habib probe. A current of 7W will be delivered for 90s intervals at a time. If multiple ablation sessions are needed in order to ablate the entire stricture lenght, there will be an overlap of ablated areas in order to ensure proper stricture treatment. Dilation of the stricture prior to RFA delivery will be performed if required. After RFA treatment, biliary drainage of all hepatic territories will be ensured.
40919641|NCT05563870|PROCEDURE|Endoscopic biliary stenting|Endoscopic biliary stenting will be performed via ERCP using multiple plastic stents, in order to ensure propper drainage of all accessed hepatic territories.
40919642|NCT04175119|DEVICE|Visual attention/perception tasks in healthy participants|The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation
40919643|NCT01212380|DRUG|carfilzomib|Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.
41092943|NCT05336123|BEHAVIORAL|Hatha Yoga|Weekly hatha yoga classes lasting 10 weeks.
41092944|NCT05336123|BEHAVIORAL|Health Education|Weekly health education classes lasting 10 weeks.
41092945|NCT03341026|OTHER|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 4, 7 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
41092946|NCT03341026|OTHER|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 7, 10 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
41092947|NCT06601907|BEHAVIORAL|alivis|alivis is an interactive online program for independent use by users with Borderline Personality Disorder. It focuses on recognized treatment elements from Dialectical Behavior Therapy, Schema Therapy, Acceptance and Commitment Therapy, and Mindfulness Self-Compassion Therapy.
41092948|NCT00512408|DRUG|testosterone|
41092949|NCT02377219|OTHER|hormonal and blood analysis|
41092950|NCT06271356|BEHAVIORAL|BC-Navigate|BC-Navigate is a website/application to help guide women through care delivery during breast cancer treatment.
41092951|NCT01378897|DEVICE|MedSignals®pillbox,Omron pedometer,VitalSignals®weight scale|Participants will use three home monitoring devices (i.e., weight scale, pedometer, pillbox) for two months. In addition, participants will receive weekly phone calls from the study's bariatric dietician during weeks 1-4 of the study and then receive biweekly calls during the second month. The structured phone calls (approximately 10-15 minutes each call) will focus on discussing the patient's adherence data, discussing any barriers to adherence, and providing tailored patient education.
41092952|NCT04531540|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.
41092953|NCT05805345|DEVICE|Delefilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
41092954|NCT05805345|DEVICE|Lehfilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
41092955|NCT05805345|DEVICE|Lotrafilcon B toric soft contact lens|Commercially available silicone hydrogel contact lens
41092956|NCT05805345|DEVICE|Verofilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
41092957|NCT00462943|DRUG|Omacetaxine mepesuccinate|"Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days.~Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days.~Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study."
41092958|NCT05638659|BEHAVIORAL|Computerized dual-task balance and home program|Portable force plate with aluminum top plate for measuring ground reaction forces, moments and the center of pressure in biomechanics. Through software to collect data from the force plates, converts the trials into useful information and plots the results. The force plates and charge amplifiers are fully remote controlled by software thus making the system extremely flexible and easy to use.
41092959|NCT05638659|BEHAVIORAL|Medical consultation and traditional balance training|Participants were assigned to read the health education flier and were assessed directly.
41092960|NCT04606888|DEVICE|Transcutaneous electrical acupoint stimulation|According to the traditional Chinese medicine 15,three acupuncture points were selected as the target points: bilateral Neiguan ,Yintang and bilateral Zusanli.. A transcutaneous electrical stimulator was used to provide an altered frequency 2/100 Hz,disperse-dense waves,and adjusted intensity which was less than 10mA.
41092961|NCT05387928|DRUG|KL340399 injection|KL340399 injection is a STING-activating. The strength of KL340399 is 0.2 mg/vial，0.2 mg/vial.
41092962|NCT01095224|BIOLOGICAL|rAd35 Env A|1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
41092963|NCT01095224|BIOLOGICAL|rAd5 Env A|1 x 10\^10 PU administered as 1 mL IM in deltoid
41092964|NCT01095224|BIOLOGICAL|rAd5 Env B|1 x 10\^10 PU administered as 1 mL IM in deltoid
41092965|NCT03929731|DIAGNOSTIC_TEST|Indocyanine Green Angiography|Intravenous injection of dye-indocyanine green
41092966|NCT03033732|DRUG|Methadone|Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
41092967|NCT03033732|DRUG|Buprenorphine-Naloxone|Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
41092968|NCT00221130|PROCEDURE|surgical operation of cell transplantation|
41092969|NCT00318513|DRUG|Bevacizumab|
41092970|NCT02335268|DRUG|N-Plate / romiplostim|medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
41092971|NCT00081809|DRUG|autologous human tumor-derived HSPPC-96|
41092972|NCT06426654|DRUG|sintiliman plus LDRT|"All patients will start with one cycle of neoadjuvant therapy of sintilimab: sintilimab 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another three cycles of sintilimab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of sintilimab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with sintilimab for up to 10 cycles."
41092973|NCT01649102|DEVICE|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|"A tunneled cuffed catheter is inserted, randomization between:~* Palindroom~* Hemoglide Bard"
41267663|NCT05527002|OTHER|Satisfaction of patients after medical and surgical treatment for thoracic endometriosis|"It is a retrospectively evaluation of cases of thoracic endometriosis in our clinic over the last 20 years, based on the review of medical records and on outpatient follow-up visits.~The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period.~If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study."
41092974|NCT04559399|PROCEDURE|smiley face shape rod|For treatment of isthmic spondylolithesis a transpedical screws for the same level and rod revolve around spinal process to stabilization of pars interarticularis of the same segment after removes bone at the margine of defects pars till reach to healthy bleed margine then put bone graft at the defect then stablizing pars and bone graft by rods.
41092975|NCT03090217|BEHAVIORAL|Pelvic Physiotherapy|1) daily pelvic floor muscle training (PFMT).
41092976|NCT03090217|BEHAVIORAL|Standard care (SC)|1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
41133192|NCT04373291|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
41133193|NCT00131274|DRUG|Imatinib Mesylate (Gleevec)|
41267664|NCT01316042|DRUG|sugar pill|2 pills per day for 12 months
41267665|NCT01316042|DRUG|Metformin, glucophage|2 212.5mg pills/day for 12 months
41092977|NCT01334541|BEHAVIORAL|SAFE VET|"All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:~1. Risk Assessment~2. Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.~3. Clinical Follow-Up Protocol"
41092978|NCT05355805|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
41092979|NCT05355805|DRUG|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
41092982|NCT03232190|OTHER|Web Application|Parents receive a web application that offers information and support until the age of 2.
41092983|NCT05002361|DRUG|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
41092984|NCT05002361|DRUG|Isotonic saline|6 ml of isotonic saline
41092985|NCT06438757|DRUG|JYB1904|Participants will receive JYB1904 every 8 weeks for 24 weeks.
41092986|NCT06438757|DRUG|Omalizumab|Participants will receive Omalizumab every 2/4 weeks for 24 weeks.
41092987|NCT02741479|OTHER|Airplane Test|"The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time"
41092988|NCT05266261|DRUG|Ibandronate Oral Tablet|150 mg of ibandronate + 24,000 IU of cholecalciferol
41092989|NCT02316314|PROCEDURE|Cardiac magnetic resonance imaging (CMR)|"CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart."
41092990|NCT02316314|PROCEDURE|Exercise-stress test|You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
41092991|NCT02316314|PROCEDURE|Echocardiogram (ECHO)|An echocardiogram is an ultrasound of the heart done at rest.
41092992|NCT02316314|PROCEDURE|Cardiac-related blood studies|The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
41092993|NCT04159506|BEHAVIORAL|mindfulness, emotion didactics, interpersonal skills, experiential learning|mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
41092994|NCT00253240|PROCEDURE|Screening|
41092995|NCT00253240|PROCEDURE|Management|
41092996|NCT02485964|OTHER|Blood draw|One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
41092997|NCT06342258|DRUG|Ultradent Ultra Seal XT Plus|Each child who has erupted, bilateral permanent molars that qualify for the study and agree to participate will have a side (right or left side) of their mouth randomized for bond that will be cured prior to sealant placement. Daily flossing and oral hygiene instructions will be taught to patients of all study groups. Sealant will be placed using a dental suction isolation system, such as DryShield isolation after prophy cup polish with pumice. No enameloplasty will be conducted.
41092998|NCT05515796|DRUG|Terelizumab (aka Tislelizumab)|q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
41092999|NCT05515796|DRUG|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
41093000|NCT05515796|DRUG|Trastuzumab|q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
41093001|NCT05515796|RADIATION|Radiotherapy|25 Gy/5 fractions
41093002|NCT00415155|DRUG|LY2181308|"Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle."
41093003|NCT05342883|DEVICE|Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)|At the initiation of the surgical phase maximal safe resection will be undertaken, and after 25 + 4 from surgery participants will start the concomitant phase and receive daily temozolomide (TMZ, 75mg/m2) and 20 fractions external beam radiation (EBRT). The EBRT treatment will be to the operative bed and any residual disease identified at the time of the imaging obtained for EBRT planning. The EBRT planning will utilize the GT implant dosimetry with the intent that the dose received from the GT will be accounted for during the EBRT treatment planning process. Twenty-eight days ±7 after the completion of concomitant TMZ and EBRT, participants will enter the adjuvant phase and will be treated with TMZ (150-200mg/m2) for 5 days at the start of every 28- day cycle, for 6 cycles.
41093004|NCT04952272|COMBINATION_PRODUCT|CpG-ODN|CAR-T cells secreting scFv against OX40
41093005|NCT00730418|DRUG|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
41093006|NCT00730418|DRUG|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
41093007|NCT01141660|DEVICE|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
41093008|NCT01141660|DEVICE|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
41093009|NCT06204666|DIETARY_SUPPLEMENT|High Dose Hemp Fiber Bar|High dose hemp fiber bar with other ingredients
41093010|NCT06204666|DIETARY_SUPPLEMENT|Low Dose Hemp Fiber Bar|Low dose hemp fiber bar with other ingredients
41093011|NCT06204666|DIETARY_SUPPLEMENT|Placebo|Placebo bar with other ingredients
41267666|NCT00843908|DEVICE|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
41093012|NCT00660166|BIOLOGICAL|NK-Cell Infusion|The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
41093013|NCT00410384|DRUG|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
41093014|NCT00410384|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
41093015|NCT00410384|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
41093016|NCT00336921|DRUG|Alfuzosin|Once daily
41093017|NCT00336921|DRUG|Placebo|Once daily
41093018|NCT06290232|DEVICE|Fetoscopic Laser Photocoagulation|Pregnant patients diagnosed with type II vasa previa will undergo fetoscopic laser photocoagulation of the involved fetal vessels. FLP will be performed laparoscopically using a fetoscope (tiny telescope) and a laser device inside of the womb. This procedure will be completed at 30w0d to 32w6d gestational age.
41093019|NCT04643353|DEVICE|Non-ablative vaginal Erbium YAG laser treatment|Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia) with SMOOTH mode setting, which enables non-ablative, thermal-only operation. The parameters are selected based on extensive preclinical and clinical studies.
41093020|NCT04643353|OTHER|PFE|PFE will be prescribed as it is already implemented in clinical practice (i.e. up to 2x 9 sessions with a pelvic floor physiotherapist of choice). Type of physiotherapy, number of completed sessions and duration of therapy will be recorded.
41093021|NCT02637505|PROCEDURE|Arthroscopic microfracture (MF)|Arthroscopy With microfracture procedure
41093022|NCT02637505|PROCEDURE|Arthroscopic debridement (AD)|Arthroscopy With debridement procedure
41093023|NCT04038476|DIAGNOSTIC_TEST|Standard monitoring + transcutaneous CO2 monitoring|The transcutaneous CO2 Monitoring measures the CO2 partial pressure of the skin and in condition of good circulation these values approximate the arterial/venous CO2 partial pressure. The sensor is placed on the forehead. The physician adapts the sedation Management according to the transcutaneous CO2 monitoring.
41093024|NCT04038476|DIAGNOSTIC_TEST|Standard monitoring|The transcutaneous CO2-sensor is also positioned on the patients' forehead, but the transcutaneous CO2-monitoring is not available for the physician to adapt the sedative management.
41093025|NCT00079937|DRUG|Omalizumab|The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.
41093026|NCT00079937|DRUG|Placebo|Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
41093027|NCT00079937|DRUG|Fluticasone|Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
41093028|NCT00832780|RADIATION|Stereotactic Body Radiation|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
41093029|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.
41093030|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.
41093031|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
41093032|NCT03084861|DRUG|Cord Blood Eye Drops|Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
41093033|NCT03084861|DRUG|Conventional treatment|"1. Artificial tears: Lubristil ®~2. Therapeutic Contact lens: Air Optix Night\&Day"
41093034|NCT05057754|BEHAVIORAL|Cooling|Participants' dominant hand and wrist will be immersed in cool water (20°C) for five minutes. The cool water will be kept to around 20°C (19 - 21°C) by frequently checking the temperature and corrected when it rises to 20.5°C
41093035|NCT05057754|BEHAVIORAL|Heating|A heat pack wrapped in a towel will be applied to participants' dominant hand for five minutes.
41093036|NCT05057754|BEHAVIORAL|Exercising|Participants will be asked to participate in moderate-intensity physical activities to induce an increase in blood pressure. The physical activity will be two sets of 30 jumping jacks, followed by 15 squats. Participants are allowed to rest for 20 seconds between the two sets.
41093037|NCT05057754|BEHAVIORAL|Typing|All participants will be asked to perform a typing task with a standard wired keyboard. All subjects will be asked to type for five minutes.
41093038|NCT05057754|BEHAVIORAL|Using a mouse|"Participants will be asked to draw as many lower-case alphabet characters from a to z as possible using a standardized scroll mouse for five minutes in the Windows Microsoft Paint software."
41133194|NCT06140875|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
41267667|NCT00843908|DEVICE|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
41267668|NCT04726332|DRUG|XL102|oral doses of XL102
41093039|NCT05057754|BEHAVIORAL|Cooking|Participants will be asked to participate in a cooking trial following a prespecified cooking recipe of Rice Krispy Treat. he participant will be asked to follow the procedures as follows: (1) cut and put wax paper in the pan; (2) cut butter into 4 pieces; (3) place butter in a pot over a portable stove and stir until the butter is completely melted; (4) add four oz of marshmallows and stir until melted; (5) add cereal and the rest of marshmallows and stir until all ingredients are combined (6) transfer the ingredients to the pan and use a silicone spatula to pat the ingredients evenly into pan.
41093040|NCT04414722|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
41093041|NCT04414722|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
41093042|NCT04414722|OTHER|Control Yogurt|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
41093043|NCT04455724|DEVICE|Negative pressure incisional wound therapy|A vacuum-style dressing system that is sealed in place over a surgical wound, applying constant negative pressure to the healing tissues.
41093044|NCT04455724|DEVICE|Standard sterile dressing|A standard, sterile island dressing
41093045|NCT03783533|BEHAVIORAL|Behavioral Activation|Intervention: Behavioral Activation (BA) therapy is based on a functional analytic model of depression that highlights the need for increased positive reinforcement (rewards) and decreased anhedonia, or diminished motivation to seek rewards, to maintain normal mood. BA is significantly more effective than Cognitive Behavioral Therapy and comparable to antidepressant medication in reducing depressive symptoms among depressed adults (Dimidjian et al., 2006). McCauley (senior mentor) et al. (2016) adapted BA for adolescents to target anhedonia, effective problem solving and avoidant behaviors with peers, family, and school. McCauley's findings and others show BA is a promising intervention for adolescent MDD (Chu et al., 2009; Cuijpers et al.,, 2007; McCauley et al., 2015; Ritschel et al., 2011). BA focuses on targeting ideographically identified avoidant behaviors and rewarding experiences that affect mood.
41093046|NCT02850627|DRUG|Tongguan capsule|eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
41093047|NCT02850627|DRUG|placebo capsule|eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
41093048|NCT04626921|DRUG|CNM-Au8|30 mg of CNM-Au8
41093049|NCT03452111|DRUG|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.
41093050|NCT03364816|PROCEDURE|TDR|total artificial disc replacement
41093051|NCT02552277|BIOLOGICAL|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
41093052|NCT02552277|DRUG|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
41093053|NCT05824221|DEVICE|rTMS|Non invasive brain stimulation in Cocaine Use Disorder
41093054|NCT00984178|OTHER|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
41093055|NCT00984178|OTHER|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
41093056|NCT00320866|DEVICE|syringe driver|
41093057|NCT02107274|DRUG|Azithromycin|Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
41093058|NCT02107274|DRUG|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
41093059|NCT04216160|OTHER|ACN cream (YUN)|Application of the facial cream ACN (YUN) twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
41093060|NCT04216160|OTHER|Placebo cream (YUN)|Application of the facial placebo cream twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
41093061|NCT03486340|PROCEDURE|Cardiologic assessment|Aggressive ischemic risk factor management
41093062|NCT02060097|DIETARY_SUPPLEMENT|Cocoa flavanol beverage|
41093063|NCT02060097|DIETARY_SUPPLEMENT|Placebo beverage|
41093064|NCT06183047|DIAGNOSTIC_TEST|early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).|early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
41093065|NCT05504694|DRUG|Ofatumumab|"The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.~The first 4 infusions will be administered at study center site; subsequent infusions will be given in the patient's home with a nurse online interview to administer the infusion."
41093066|NCT03732274|DRUG|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
41093067|NCT02365896|PROCEDURE|TLDG or LADG|
41133195|NCT05302882|BEHAVIORAL|Myofascial release|The physiotherapist placed both palms on the two right and left ribs at the T12 level and applied continuous stretching to the superior for 2 minutes. After this application, the physiotherapist placed one hand on the sacrum with the other hand on T12 with his hands crossed, and applied rhythmically 2 seconds of stretching and 2 seconds of relaxation for a total of 2 minutes. Then, myofascial release was terminated by applying deep compression to the paraspinal muscles with palms for 2 minutes on the right and 2 minutes on the left side, respectively.
41093068|NCT06177990|OTHER|Caregiver as Navigator: Develop Skills Online (CAN-DO) program|"Online, asynchronous psychoeducation program for dementia family caregivers. The program is meant to enhance caregivers' knowledge and skills for navigating healthcare, financial, legal, and family systems.~The program has three main sections.~* The first section provides information and how to prepare for using the healthcare system and community-based services in dementia care and support.~* The second provides information about how to be more effective when using the financial and legal system either for yourself or your person.~* The third section of the course provides information about ways to manage and navigate family dynamics present in various caregiving scenarios more effectively."
41093069|NCT06177990|OTHER|Healthy Living online course|"Online program for dementia family caregivers about Healthy Living for the first 4 months post-randomization."
41093070|NCT03035240|BEHAVIORAL|Financial Education|Participants randomized to financial education will undergo a year long financial education. This involves 9 weeks of weekly classes followed by one on one coaching for a year.
41093071|NCT06611761|PROCEDURE|Shoulder arthroscopy|Shoulder arthroscopy in procedures that cause intense postoperative pain
41093072|NCT00262444|PROCEDURE|Different turning frequencies|
41093073|NCT01120574|OTHER|Home mechanical ventilation|Home mechanical ventilation will be performed with a bilevel pressure ventilator.
41093074|NCT03569813|BEHAVIORAL|PrEP@Home System|"The PrEP@Home system includes a home care kit mailed quarterly to participants. The kit has components for self-collection of urine, rectal and pharyngeal swabs, microtube blood collection, and materials for return shipping. Biological tests routinely performed at PrEP follow-up (FU) visits will be done on the specimens. At months 6 and 12, the kit will include materials to assess for protective levels of emtricitabine triphosphate (FTC-TP).~The system includes a study app through which participants may track the mailing of home testing kits, access quarterly surveys, and communicate with study clinicians. The surveys will include domains that physicians assess at PrEP care quarterly FU visits (sexual risk, illicit substance use, PrEP adherence, side effects).~Study Clinicians will review Lab and survey results and if the results show no contraindications for PrEP continuation, the clinician may renew a participant's PrEP prescription. Telemedicine visits will be scheduled as needed."
41093075|NCT03569813|OTHER|Standard of Care|Control participants will receive clinic-based PrEP follow-up. After the baseline assessment, control participants will receive active linkage to standard, clinic-based PrEP care for their next PrEP care follow-up visit. Participants will also download the control version of the study app, which will contain only research elements pertinent to their participation in the control arm of the study including quarterly surveys. At months 6 and 12, control arm participants will be sent materials for DBS self-collection and return shipping to allow for measurement of the study outcome, emtricitabine triphosphate (FTC-TP).
41093076|NCT03238729|BEHAVIORAL|Heart Failure Education and Management App|Patients will be provided with an app on a smartphone that provides a daily checklist with items like reminders for logging weight and food, as well as educational components about heart failure and it's management.
41093077|NCT03238729|BEHAVIORAL|Heart Failure Literature|Patients will be provided standard literature about heart failure and the management of heart failure.
41093078|NCT02720445|DRUG|Nicotine Transdermal Patch|21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.
41093079|NCT02720445|DRUG|Placebo Patch|Matching placebo patches worn during waking hours.
41093080|NCT04234243|PROCEDURE|cytoreduction and HIPEC|cytoreduction CCR 0-1, and HIPEC close technique
41093081|NCT00479947|DRUG|Probiotics (Natural product)|
41093082|NCT00479947|DRUG|Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)|
41093083|NCT05513690|PROCEDURE|Amnioinfusion at room temperature (intervention arm)|Routine amnioinfusion and intrauterine temperature probe sensor
41093084|NCT06445920|OTHER|No Intervention|No Intervention
41093085|NCT06087211|DRUG|Duloxetine and magnesium sulphate|this group will receive Duloxetine 30 mg orally and an intravenous (IV) infusion of magnesium sulphate 50mg/kg mixed with 200ml normal saline (NS) 1 hour before surgery
41093086|NCT06087211|DRUG|Duloxetine|this group will receive Duloxetine 30 mg orally and 200ml NS infusion 1 hour before surgery
41093087|NCT06087211|DRUG|placebo|will receive placebo capsule and an IV infusion of 200ml NS 1 hour before surgery
41093088|NCT05542680|DEVICE|cushion|In the intervention group, the special cushion for semi recumbent position was used
41267669|NCT04726332|DRUG|Fulvestrant|fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.
41267670|NCT04726332|DRUG|Abiraterone|abiraterone 1000 mg administered orally once daily.
41267671|NCT04726332|DRUG|Prednisone|prednisone 5 mg administered orally twice daily.
41267672|NCT05713864|DEVICE|BTL-899|The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered.
41267673|NCT05713864|DEVICE|HPM-6000UF|The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
41267674|NCT02595242|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
41267675|NCT02595242|DRUG|Vincristine|Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.
41267676|NCT02595242|DRUG|Prednisone|Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
41093089|NCT03677024|PROCEDURE|SLN arm|Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
41093090|NCT01104103|DEVICE|BOA(R)-Constricting IV Band|Device applied in accordance with manufacturer's instructions
41093091|NCT01104103|DEVICE|Standard elastic constricting band|Standard therapy
41093092|NCT05269446|PROCEDURE|percutaneous coronary intervention (PCI)|A family of minimally invasive procedures used to open clogged coronary arteries and restore blood flow. This is also a standard treatment for patients diagnosed with STEMI or SA
41093093|NCT05269446|DEVICE|total body PET/CT scan|all participants will receive a total-body PET/CT scan (uExplorer) after enrolment
41093094|NCT05269446|PROCEDURE|Coronary Angiography (CAG)|A procedure that uses X-ray imaging to visualize coronary arteries.
41093095|NCT05269446|DRUG|TSPO injection|Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 before a whole-body scan by uExplorer
41093096|NCT01663337|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
41093097|NCT01663337|BEHAVIORAL|Relapse Prevention (RP)|RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
41093098|NCT04069546|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric device with cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times.
41093099|NCT01452672|RADIATION|Radiotherapy|RT 40 Gy in 15 fractions
41093100|NCT01452672|RADIATION|Irradiation of the chest-wall and supraclavicular fossa|RT 40Gy in 15 fractions
41093101|NCT05656690|OTHER|Exposure to disability|Disability status assessed by functional measures
41093102|NCT03582137|DRUG|Cannabidiol|Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
41093103|NCT03582137|OTHER|Placebo|Subjects randomized to this arm will receive Placebo
41093104|NCT04314661|BIOLOGICAL|Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
41093105|NCT04314661|BIOLOGICAL|Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
41093106|NCT04314661|BIOLOGICAL|Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
41093107|NCT04314661|BIOLOGICAL|Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
41093108|NCT03246672|BEHAVIORAL|maintenance intervention|Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
41093109|NCT03408314|OTHER|PediQUEST Response|PediQUEST Response consists of regular feedback of electronic patient reported outcomes (child symptoms and quality of life) to providers and families coupled with involvement of the palliative care team, who will meet with families and providers within three weeks of randomization and follow-up at least monthly as deemed necessary based on PediQUEST feedback reports and other clinical indications.
41093110|NCT03408314|OTHER|Usual Cancer Care|Patients assigned to the usual cancer care arm, will receive the standard care provided by participating sites + be required to complete PediQUEST surveys (but no reports will be generated).
41093111|NCT00362193|BEHAVIORAL|Telephonic diabetes care|
41093112|NCT04011384|BEHAVIORAL|Behavioral economic intervention of online purchasing at a food pantry|This intervention includes multiple behavioral economic interventions, healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
41093113|NCT05761067|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Alternative treatment
41267677|NCT01151722|PROCEDURE|bevacizumab injection|bevacizumab injection before vitrectomy
41267678|NCT01151722|PROCEDURE|bevacizumab injection|bevacizumab injection after vitrectomy
41267679|NCT02736903|BEHAVIORAL|PennFit mobile individual intervention|PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.
41287118|NCT04350515|OTHER|Mindfulness: Emotion Regulation Task|In this task, subjects listen to an audio file containing a scripted emotion regulation exercise. This exercise is based by the authors Nissen \& Sturm (2018). It takes around 14 minutes to complete the whole task.
41442350|NCT03138967|DRUG|Sugammadex|Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
41093114|NCT00374621|DRUG|Misoprostol with or without isosorbide mononitrate|Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
41093115|NCT05079217|BIOLOGICAL|High-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
41093116|NCT05079217|BIOLOGICAL|Medium-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
41093117|NCT02888795|DRUG|hypertonic dextrose prolotherapy|five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
41093118|NCT00088465|DRUG|Intramuscular olanzapine depot|45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
41093119|NCT03959709|PROCEDURE|immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. A temporary implant sizer is placed in the pocket to assess the position and shape of the prepectoral pocket. The pocket is adjusted where necessary. A sheet of ADM (DermAcell) is then selected. The DermAcell will be prepared as per the manufacture's instructions and fenestrated using size 11 blade. The DermACELL piece will be trimmed to the appropriate shape and sutured to the superior medial and lateral edges of the pectoralis major muscle. The inferior edge will be sutured to the fascia at the level of the inframammary fold. Two closed suction drains will be placed (one below the mastectomy skin flap, and one below DermACELL). The implant will be inserted to the pre-pectoral pocket and several anchor sutures will be used to secure the superior-medial edge of DermACELL to mastectomy flap.
41093120|NCT03959709|PROCEDURE|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. The reconstructive operative procedure will then proceeded with (1) elevation of the pectoralis major muscle with release of inferior attachments; (2) placement of implant subpectorally; (3) placement and suturing of DermACELL to constitute the inferolateral breast pocket; (4) placement of two closed suction drains (one superiorly between the pectoralis major and skin, and one inferiorly between the DermACELL and skin); (5) removal of sizer and placement of permanent to the pocket and (6) suture the inferior edge of DermACELL to the inferior edge of the pectoral major muscle. The skin will be closed and the dressing will be applied as standard protocol.
41093121|NCT03768544|BEHAVIORAL|Self-help guided by a lay provider|Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.
41093122|NCT03768544|BEHAVIORAL|Waiting list where participants wait for delayed treatment|Participants have a 15-week wait period during which they receive a 15-minute telephone call from the local professional research assistant on three occasions separated by four-week intervals. The purpose of these calls is to encourage the participant to persevere until the start of treatment and to identify potential negative effects that could be associated with the waiting period. Participants receive self-help guided by a lay provider after the waiting period.
41093123|NCT03177187|DRUG|AZD5069|10mg and 40mg plain, beige, film-coated tablets packaged in bottles
41093124|NCT03177187|DRUG|Enzalutamide 40 MG|Enzalutamide is presented in 40mg white to off white capsules or tablets. The capsules/tablets are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules/tablets. Each carton contains 4 wallets (112 soft capsules/tablets). Or tablets in bottles (120 per bottle).
41093125|NCT06456931|BEHAVIORAL|Traditional Buddhist mindfulness|Details are provided in the arm/group descriptions.
41093126|NCT06456931|BEHAVIORAL|secular mindfulness based cognitive therapy|Details are provided in the arm/group descriptions.
41093127|NCT06369129|PROCEDURE|Orbital floor reconstruction with Patient Specific Zirconia Implant|Orbital floor reconstruction with Patient Specific Zirconia Implant will be done
41093128|NCT06369129|PROCEDURE|Orbital floor reconstruction with Patient Specific Titanium Implant|Orbital floor reconstruction with Patient Specific Titanium Implant will be done
41287119|NCT04350515|OTHER|Mindfulness: Word Recognition Task|"In this task, subjects listen to an audio file containing a scripted word recognition exercise. It contains both contrary words recognition (e.g. The opposite of loud is ...) and completion of german sayings (e.g. That's where the dog is...). It takes around 14 minutes to complete the whole task."
41093129|NCT03563781|PROCEDURE|Sentinel node detection|Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.
41093130|NCT03673202|DIAGNOSTIC_TEST|Cx bladder Monitor test|Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
41093131|NCT04010175|BEHAVIORAL|Control - Cognitive training in a practitioner's office one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office during 4 months (16 weeks of training = 16 hours of training). This training will include 10 short tasks of increasing difficulty. Performance of these tasks involve cognitive functions such as: executive functions, reasoning, auditive, visual and visuo-spatial memory, speed of processing, short-term memory and working memory. Thus the training aims to exercise all these cognitive functions.
41093132|NCT04010175|BEHAVIORAL|Experimental group 1 - Cognitive training in a practitioner's office one time per week and cognitive distance training one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and one time per week cognitive distance training in her/his place of residence, during 4 months (16 weeks of training = 32 hours of training).
41093133|NCT04010175|BEHAVIORAL|Experimental group 2 - Cognitive training in a practitioner's office one time per week and cognitive distance training four times per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and four times per week cognitive distance training in her/his place of residence during 4 months (16 weeks of training = 80 hours of training).
41093134|NCT01273558|DRUG|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
41093135|NCT04438785|DEVICE|The intervention consists of myofunctional therapy (MT) using the AirwayGym app.|Intervention. Patient newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the App AirwayGym 20 minutes a day during 90 days.
41287120|NCT03921372|DIAGNOSTIC_TEST|Isometric exercise|Squatting for 5 minutes
41442351|NCT03138967|DRUG|Neostigmine|70 mcg/kg by vein to reverse the muscle relaxation.
41442352|NCT03138967|DRUG|Glycopyrrolate|14 mcg/kg by vein to reverse the muscle relaxation.
41093136|NCT00578227|BIOLOGICAL|Cervarix™|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
41093137|NCT00578227|BIOLOGICAL|Twinrix ™ Paediatric|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
41093138|NCT02125513|DRUG|carboplatin and paclitaxel followed by surgery|
41093139|NCT02897284|BEHAVIORAL|Mindfulness 8 weeks|8 sessions of mindfulness
41093140|NCT02897284|BEHAVIORAL|Mindfulness 2 weeks|2 sessions of mindfulness
41093141|NCT00017277|BIOLOGICAL|epoetin alfa|
41093142|NCT00017277|RADIATION|radiation therapy|
41093143|NCT00450892|DRUG|docetaxel+lapatinib|3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC
41093144|NCT00450892|DRUG|docetaxel + trastuzumab|3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100
41093145|NCT00450892|DRUG|docetaxel + trastuzumab + lapatinib|"3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule~+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100"
41093146|NCT04488653|DIETARY_SUPPLEMENT|Oligopin®|French Maritime Pine Bark Extract - 100mg/day
41093147|NCT04488653|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
41287121|NCT04439669|DEVICE|Sham nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to sham. In the following open phase stimulation the treatment targets are the right S2-contralateral M1-left S2."
41442353|NCT04294303|OTHER|web based telemonitoring system|Subjects in the telemonitoring group were given an iPad with installed iHealth application, a scale, and an electronic blood pressure monitor (a mobile web-based telemonitoring system). These devices were interconnected via Bluetooth. The iPad had permanent internet connection. Patients were taught to use the equipment to check and record their weight, blood pressure, and heart rate every morning, for 45 days after the hospital discharge. Data was automatically uploaded via iHealth application in a secure database.
41093148|NCT02646046|BEHAVIORAL|Combi lone-CPR|When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
41093149|NCT02646046|BEHAVIORAL|Conventional lone-CPR|When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
41442354|NCT04294303|OTHER|Conventional|Subjects in the control group received the standard patient teaching, including an instruction to self-monitor their weight.
41093150|NCT03955419|DIETARY_SUPPLEMENT|NO-NPO (Daesang WelLife Co., Ltd., Korea)|800 mL of carbohydrate beverage consists of 12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg.
41093151|NCT00117611|DRUG|Anti-IgE antibody omalizumab or placebo|given subcutaneously oce or twice monthly depending on dose
41093152|NCT00819234|DRUG|Placebo|placebo pramlintide and placebo metreleptin twice daily
41093153|NCT00819234|DRUG|Pramlintide and Metreleptin|Subcutaneous injection, twice daily
41093154|NCT02860091|DRUG|Ropivacaine infusion|Delivered via paravertebral nerve block catheter.
41093155|NCT04699799|OTHER|Present odors to participants while recording brain activity|Present odors to participants while recording brain activity
41093156|NCT01189955|PROCEDURE|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
41093157|NCT01189955|PROCEDURE|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
41093158|NCT06614205|DIAGNOSTIC_TEST|tumoral dosimetry by scintigraphy|The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment
41093159|NCT00927342|OTHER|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
41093160|NCT00927342|OTHER|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
41287122|NCT04439669|DEVICE|Active nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to S2. In the following open phase stimulation the treatment targets are contralateral M1 and left S2. If the patient benefited from active S2 stimulation, but the treatment effect faded in follow-up, the open phase stimulation starts with right S2."
41287123|NCT00765583|DRUG|Restylane|Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
40919644|NCT01212380|OTHER|Cytokine Assessment|TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
41093161|NCT03454243|DRUG|RXDX-106|Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
40758167|NCT04028063|DRUG|Balstilimab|Balstilimab (AGEN2034) is a human monoclonal antibody that targets programmed cell death 1 (PD-1). Engagement of PD-1 by its ligands, programmed death ligand (PD-L1) and PD-L2, leads to signal transduction that inhibits important aspects of T cell function including proliferation, cytokine production and cytolytic activity. Balstilimab (AGEN2034) potently inhibits PD-1 binding to PD- L1 and PD- L2 and is intended to reverse the immunosuppressive effects of this signaling pathway in the context of tumor immuno-surveillance by T cells. Balstilimab (AGEN2034) is intended for development as a treatment for advanced malignancies as a single agent or in combinations.
41093162|NCT00389519|DRUG|ramipril|once a day oral ramipril capsules given for 4 weeks
41093163|NCT00389519|DRUG|placebo|once a day oral placebo capsule for 4 weeks
41093164|NCT02658721|DRUG|Lidocaine|
40919645|NCT01212380|OTHER|Pharmacodynamic Studies|Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
40919646|NCT01212380|OTHER|Proteosome Inhibition Assessment|Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
40919647|NCT01212380|OTHER|Pharmacogenomic Studies|Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
40919648|NCT04586387|DEVICE|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
40919649|NCT04586387|DEVICE|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
40919650|NCT03124927|DEVICE|DCI pulse oximeter sensor|
40919651|NCT06280742|RADIATION|PET-MRI with [18F]-DPA-714|PET-MRI with \[18F\]-DPA-714
40919652|NCT04453553|DIAGNOSTIC_TEST|Q16 testing|Nasal swab tested on a rapid near patient device
40919653|NCT04453553|DIAGNOSTIC_TEST|Nasopharyngeal swab and main laboratory|Standard of care testing
40758168|NCT04028063|DRUG|Zalifrelimab|Zalifrelimab (AGEN1884) is a fully human monoclonal immunoglobulin G1 κ subclass (IgG1κ) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152). Zalifrelimab (AGEN1884) is being developed as a monotherapy for cancer indications with potential for future development in combination with other immunotherapies.
40919654|NCT04145440|DRUG|MOR202|Patients will receive 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing will occur weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
41442355|NCT03076593|OTHER|Exposure: Fall|Participants will be asked about prior falls
41442356|NCT06561789|OTHER|Functionalized Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
41442357|NCT06561789|OTHER|Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
41442358|NCT06561789|OTHER|sodium fluoride mouth wash|The intervention is mouth wash solution for remineralization of demineralized enamel from Oral-B company
41442359|NCT01842477|PROCEDURE|Implantation of bone substitute plus autologous cultured mesenchymal cells|Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
41442360|NCT06547541|BEHAVIORAL|Exercise|A body weight based resistance training.
41442361|NCT00461786|DRUG|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
40919655|NCT05471154|DEVICE|High Definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
40919656|NCT01737593|DRUG|Acetaminophen|
40919657|NCT02587377|OTHER|Non Standard of Care blood samples collection|According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
40919658|NCT03861026|DEVICE|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
40919659|NCT03213171|BEHAVIORAL|Reception staff providing handout.|Reception staff will provide an educational pamphlet to patients that have not yet registered for organ donation
40919660|NCT03213171|BEHAVIORAL|Mobile Tablet (e.g. iPad)|Patients will have the opportunity to immediately register for organ donation using an a mobile tablet (e.g. IPad)
40919661|NCT03144609|PROCEDURE|low PEEP|The control group consisted of obese patients mechanically ventilated by a standardized volume-controlled breathing mode with low respiratory volume without alveolar recruitment maneuver and using low values of PEEP up to 4 cm H2O.
40919662|NCT03144609|PROCEDURE|ARM|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.
40919663|NCT03144609|PROCEDURE|high PEEP|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.
41442362|NCT03972163|BEHAVIORAL|NIA Medication Management - Active Comparator|"As the attention control, we will refer staff in control offices to the National Institution on Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
41442363|NCT03972163|BEHAVIORAL|STOPPFrail (Screening Tool of Older Persons Prescriptions)|A screening tool used by clinicians with frail older adults with life-limiting illness to review medications
40919664|NCT01431638|DRUG|Canakinumab 150mg in prefilled syringe|Canakinumab 150mg in prefilled syringe will be given in a single dose subcutaneously upon demand for gouty arthritis flares
40919665|NCT01644747|DEVICE|transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)|After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
40919666|NCT04475042|DRUG|Dapagliflozin|10mg od
40919667|NCT04475042|DRUG|Placebo|Placebo
40919668|NCT06531967|OTHER|No intervention|No intervention
40919669|NCT00223782|BEHAVIORAL|Gait Training with Feedback|
40919670|NCT00223782|BEHAVIORAL|Gait Training with no feedback|
40919671|NCT00926029|DRUG|Fluoride|Brush twice daily
40919672|NCT00926029|DRUG|Triclosan, fluoride|Brush twice daily
40919673|NCT00926029|OTHER|Metal salt|Brush twice daily
40919674|NCT01336400|OTHER|single cell haplotyping|We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
40919675|NCT00413985|DRUG|Nutrient-enriched human milk|
40919676|NCT00545870|DRUG|bevacizumab|intravitreal application
40919677|NCT00545870|DRUG|Ranibizumab|intravitreal application
40919678|NCT05061043|OTHER|Routine physical therapy treatment|Control group will receive the routine physical therapy treatment that will include EMS, Infrared and Intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes for 5 days a week
40919679|NCT05061043|OTHER|Routine physical therapy along with orofacial therapy|Experimental group will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes)
40919680|NCT02983279|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo caloric restriction diet
41287124|NCT05187195|OTHER|Home-based telerehabilitation with exercise videos|Balance, walking, strengthening, posture videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
41442364|NCT03972163|BEHAVIORAL|"Discontinuing Medication Appropriately and Understanding the Art of Communication about Deprescribing"|Education resoruce used by clinicians to simplify and align medications with goals of care
40919681|NCT02983279|OTHER|Counseling|Undergo counselor-led dietary counseling
40919682|NCT02983279|PROCEDURE|Therapeutic|Undergo standard of care surgery
40919683|NCT02998632|PROCEDURE|Mineralized plasmatic matrix for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
40919684|NCT02998632|PROCEDURE|Autogenous bone for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
41093165|NCT02658721|DRUG|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
41093166|NCT02658721|DRUG|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
41093167|NCT02658721|DRUG|Fentanyl|If the patient had a VAS score of \>4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
41442365|NCT03972163|BEHAVIORAL|"Key Approaches to Support Informal Family Caregivers in Managing Medications"|Education resource used by clinicians to support Family Care Givers (FCGs)
40758169|NCT04028063|DRUG|Doxorubicin|Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%.
40919685|NCT02631993|RADIATION|Photochemotherapy|Oral 8-Methoxypsoralene (8-MOP), (0.4-0.8 mg/kg), are given 1.5-2 hours before phototherapy. Ultraviolet light type A (UVA, 320-400 nm) is administered in a Waldmann UV1000 supine unit through 26 100-W fluorescent PUVA lamps (Waldmann F85), if needed, UVA is given in a half body unit with 15 100-W PUVA-lamps (Waldmann F85), (Waldmann UV3003K), (Waldmann, Villingen-Schwenningen, Germany). Eye protection is applied during 24 h after oral 8-MOP and the genital area are shielded in males during therapy.The UVA is initiated at 0.2-1.5 J/cm2 and is amplified by 0.25-0.5 J/cm2 after two treatments if photo toxicity is absent. PUVA is given to the patients 3-5 times each week.
41442366|NCT06234423|DRUG|CUSP06|Antibody drug conjugate (ADC)
41093168|NCT02658721|DRUG|Atropine|"The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.~In case of bradycardia (HR \<50/min), 0.5 mg intravenous atropine was administered."
41093169|NCT02658721|DRUG|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
41093170|NCT02658721|DRUG|Diclofenac sodium|The patients with a VAS score of \>4 were administered with 75 mg diclofenac sodium via intramuscular route.
41093171|NCT02658721|DRUG|Ephedrine|In the event of hypotension (systolic arterial pressure \<90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
41093172|NCT02658721|DRUG|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
41093173|NCT06108141|BEHAVIORAL|Resident Education And Counseling on Household Firearm Safety|An intervention that includes a self-directed online curriculum and virtual reality simulations, designed to teach firearm screening and counseling among clinicians.
41093174|NCT06108141|BEHAVIORAL|Modified American Academy of Pediatrics Safer|An intervention that includes a self-directed online curriculum.
41093175|NCT01562743|DRUG|SPM 962|Tansdermal patch
41093176|NCT02060253|DRUG|ganetespib|Given IV
41093177|NCT02060253|DRUG|paclitaxel|Given IV
41093178|NCT02060253|BIOLOGICAL|trastuzumab|Given IV
41093179|NCT02060253|BIOLOGICAL|pertuzumab|Given IV
40919686|NCT02069275|OTHER|Immediate mobilization|Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate
40919687|NCT02069275|OTHER|Two hours bedrest|Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
40919688|NCT04475198|DRUG|ST-2427|Investigational drug
40919689|NCT04475198|DRUG|Placebo|5% Dextrose Injection
40919690|NCT01683097|OTHER|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
40919691|NCT03546868|DRUG|[18F]FSPG|Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
41093180|NCT00406809|DRUG|ABT-263|"Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose."
40758170|NCT04028063|DRUG|Botensilimab|Botensilimab (AGEN1181) is a novel, human, fragment-crystallizable (Fc)-engineered immunoglobulin G1 (IgG1) anti-CTLA-4 antibody designed to exploit a novel mechanism by which increased Fc engagement enhances antigen-specific effector T cell responses.
41093181|NCT03771326|BIOLOGICAL|Kisspeptin-10|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
41093182|NCT02735265|BEHAVIORAL|Virtual reality|12 training sessions (90 minutes a time, 2 times a week) IG:45 minute of Kinect for Xbox games and 45 minute of standard treatment.
41093183|NCT02735265|BEHAVIORAL|Standard treatment|CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)
41093184|NCT02409160|PROCEDURE|Standard Roux-en-Y gastric bypass|
41287125|NCT05187195|OTHER|Exercise brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening, posture etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
41287126|NCT04459468|DRUG|Lipiodol|Lipiodol TACE procedure
40758171|NCT01006486|OTHER|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
40919692|NCT05251402|BEHAVIORAL|Group A - Patient Education|"If you are assigned to this group, you will receive education on asthma and health from an ALOHA health coach.~* In months 1-3, you will attend 3 individual and 8 group sessions. Individual sessions will last \~15 minutes and the first one will be in-person. Group sessions will last \~30 minutes and the first 2 of the 8 will be in person. You and your coach will determine if you may attend the remaining individual and group sessions remotely instead, via Zoom or phone. The purpose of these sessions is to provide you with general information about respiratory health topics, including recommendations for asthma care, inhaler use, and lung health.~* In months 4-12, you will complete 11 phone check-ins for \~10 minutes each. The purpose of these phone calls is to provide you with ongoing support and discuss health topics of your choice."
41093185|NCT04467463|PROCEDURE|peripheral nerve block by 0.25% levobupivacaine|SUBMANDIBULAR nerve block will be performed using a 25G 90 mm beveled needle . the entry point of the needle will be situated at the angle formed by the superior edge of the zygomatic arch below and the posterior orbital rim forward .The needle will be inserted perpendicular to the skin and advanced approximately 20 mm depth to reach the greater wing of the sphenoid deep to the pterygopalatine fossa. Injection of 1ml of 0.25% levobupivacaine will be done over 20 seconds afterensuring negative blood aspiration .greater Palatine Nerve will be blocked bilaterally as it leaves on palatal side through the foramen on the opposite direction of the anterior part of the 3rd molar orthe posterior part of the 2nd molar tooth.
40919693|NCT05251402|BEHAVIORAL|Group B - Patient Education with Nutrition Counseling|"If you are assigned to this group, you will receive the same patient education as Group A. In addition, you will receive nutrition counseling from your health coach who is a registered dietitian.~* In months 1-3, the duration of the sessions will increase to \~30 minutes each for the 3 individual sessions and to \~60 minutes each for the 8 group sessions. This is because in addition to providing the same information on asthma and health as in Group A, your health coach will also counsel you on how to follow the DASH diet by adopting effective behavior change techniques such as goal setting, self-monitoring, and problem solving.~* In months 4-12, your health coach will review your progress, provide you with personalized feedback, assist you in problem solving as you continue to work towards the DASH dietary goals, and help you maintain the changes you have made over the long term."
40919694|NCT02429180|OTHER|Rehabilitation|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~* Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~* Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~* Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~* Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
40919695|NCT00238602|PROCEDURE|Stereotactic radiosurgery|
40919696|NCT03181646|DRUG|citicoline|intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
40919697|NCT00076453|DEVICE|Lateral wedge orthotic shoe inserts|Customized lateral wedge orthotic shoe inserts
40919698|NCT00076453|DEVICE|Standard orthotic shoe inserts|Neutral orthotic inserts
40919699|NCT04431674|DRUG|Definity Suspension for Injection|MRI-guided ultrasound-stimulated microbubble-treatment
40919700|NCT03897439|DRUG|Nicotine patch|Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
40919701|NCT03897439|DRUG|Varenicline Tartrate|VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.
40919702|NCT03897439|DRUG|Bupropion|BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.
40919703|NCT04756336|DRUG|LTX-109 gel, 3% w/w|The drug is applied to affected lesions according to treatment regimen
40919704|NCT04900532|DIETARY_SUPPLEMENT|Tocotrienol rich fraction|Supplementation with a Vitamin E compound.
40919705|NCT04900532|DIETARY_SUPPLEMENT|Placebo|Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
40919706|NCT00146484|DRUG|Twice Daily versus Three Times Daily Insulin Injections|
41093186|NCT06549894|PROCEDURE|Performing endoscopic examinations|Performing endoscopic examinations in the conventional framework of patient follow-up. No patient data is collected. The physician performing the act is the subject of the study.
40758172|NCT01006486|OTHER|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
40919707|NCT02587182|DEVICE|Deep Dry needling|The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
40919708|NCT02373085|OTHER|Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
40919709|NCT03530709|OTHER|videoconferencing|Parents/caregivers will use smartphones to videoconference in their SCC provider during PCP visits
40919710|NCT01558128|DRUG|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
40919711|NCT01558128|PROCEDURE|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
40919712|NCT03219775|BIOLOGICAL|Nivolumab/Ipilimumab|"* Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo1 mg/kg i.V. and Ipi3 mg/kg i.V. / Q3W x 2)\*~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~  * since June 5, 2019, the treatment in all four boost cycles (1+2) and (3+4) is performed with nivolumab 1 mg/kg + ipilimumab 3 mg/kg (NIVO1/IPI3)"
40919713|NCT04940468|OTHER|Diet Intervention|The dietary fiber intake target will be 19 g/d for ages 9-18 and females age 19 and older and 23g/d for males age 19 and older.
41093187|NCT03409718|DEVICE|Biomet Comprehensive Shoulder System|Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform
40919714|NCT06505772|DRUG|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine ) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~For example, it begins with an infusion of 4 ml over 10 minutes and then continues the infusion, depending on the weight of the child, at a rate of 1.6 ml/kg/hour.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
40919715|NCT06505772|DRUG|Normal saline|"Normal saline (NS) for intravenous infusion is supplied in pre-filled syringes of 20 ml, 50 ml, and 100 ml. To maintain blinding in this study, NS is handled identically to the study drug, dexmedetomidine. A physician not involved in the study prepares all injections, randomly assigning either NS or dexmedetomidine using a sealed envelope technique. Prepared syringes are then placed in identical, unmarked infusion pumps.~Infusion Protocol:~Anesthesiologists, blinded to the infusion contents, administer the solutions according to the protocol:~For example,Initial Bolus: 4 ml infused over 10 minutes, Maintenance Infusion: Continued at a rate of 1.6 ml/kg/hour, adjusted to the individual patient's weight.~This process ensures both patient and anesthesiologist remain blinded to the treatment arm, minimizing potential bias throughout the study."
40919716|NCT00282347|DRUG|Rituximab|Rituximab was provided as a sterile solution for injection.
40919717|NCT00282347|DRUG|Placebo|Placebo was provided as a sterile solution for injection.
40919718|NCT00282347|DRUG|Mycophenolate mofetil|
40919719|NCT00282347|DRUG|Methylprednisolone|
40919720|NCT00282347|DRUG|Diphenhydramine|
40919721|NCT00282347|DRUG|Acetaminophen|
40919722|NCT00282347|DRUG|Prednisone|
40919723|NCT06246058|BEHAVIORAL|Partner support|The intervention group's survey vignette will include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.
40919724|NCT06246058|BEHAVIORAL|Formal recruiter attire|"The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~FORMAL dress code of the recruiter is the intervention in this case, defined as clinical attire alluding to some clinical authority."
40919725|NCT06246058|BEHAVIORAL|Without Partner support|The intervention group's survey vignette will NOT include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.
40919726|NCT06246058|BEHAVIORAL|Casual recruiter attire|"The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~CASUAL dress code of the recruiter is the intervention in this case."
40919727|NCT05731050|DRUG|NM8074|"NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed."
41093188|NCT05376579|OTHER|siponimod|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.
41093189|NCT02089451|DRUG|Faster-acting insulin aspart|Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
41093190|NCT06295796|DRUG|MK-8527|Oral Capsule
40919728|NCT05711758|PROCEDURE|PSAM Treatment Patients|PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.
40919729|NCT05814653|BEHAVIORAL|Family Based Treatment-Primary Care|Novel treatment that borrows key intervention strategies from standard family-based treatment. It uses trained primary care providers (PCPs), in consultation with a mental health provider, to deliver family-based treatment strategies in community-based clinics to increase caregiver self-efficacy to reverse their child's dietary restriction and weight loss.
40919730|NCT05814653|BEHAVIORAL|Family-Based Treatment|Delivered by a mental health provider in a traditional mental health or eating disorder specialty setting. First-line evidence-based treatment for adolescent eating disorders that targets caregiver self-efficacy as a mechanism to facilitate weight restoration and ultimately symptom remission in adolescents.
40919731|NCT04892368|OTHER|Home-based supervised exercise program|Combination of aerobic and strength training exercises, in addition to home exercise instructions issued during preoperative physiotherapy education.
40919732|NCT04294056|DRUG|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
40919733|NCT04294056|DRUG|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
40919734|NCT00000776|DRUG|Flucytosine|
40919735|NCT00000776|DRUG|Fluconazole|
40919736|NCT00000776|DRUG|Amphotericin B|
40919737|NCT00000776|DRUG|Dexamethasone|
40919738|NCT01156064|DEVICE|Confocal Laser Endomicroscopy (Pentax/Optiscan)|Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.
41093191|NCT00562965|DRUG|inotuzumab ozogamicin|IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
41093192|NCT00562965|DRUG|rituximab|IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
41093193|NCT00562965|DRUG|rituximab|intravenous rituximab at a dose of 375 mg/m2 on day 1
40919739|NCT01156064|DEVICE|Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)|NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
41093194|NCT00562965|DRUG|cyclophosphamide|intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
41093195|NCT00562965|DRUG|vincristine|intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
41093196|NCT00562965|DRUG|prednisone/prednisolone|oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
41093197|NCT00562965|DRUG|mitoxantrone|mitoxantrone 10 mg/m2 intravenous on day 2
41093198|NCT00562965|DRUG|fludarabine|fludarabine 25 mg/m2 intravenous on days 2 through 4
41093199|NCT00562965|DRUG|dexamethasone|oral dexamethasone 20 mg/day on days 1-5
41093200|NCT01238575|OTHER|placebo|Administered for up to 8 weeks.
40758173|NCT03167658|BEHAVIORAL|Workplace wellness program|Multi-prong workplace wellness program, with components such as nutrition counseling, fitness challenges, and stress management workshops, including supports and incentives.
40758174|NCT02219451|OTHER|exercise training|exercise training
41093201|NCT01238575|DRUG|extended-release guanfacine|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
41093202|NCT05189457|DRUG|Luteinizing Hormone Releasing Hormone|During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH
41093203|NCT05189457|DRUG|New Hormonal Agent|During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
40919740|NCT04197310|DRUG|Nivolumab|240mg, intravenously, Day 1 and 15 of a 28 day cycle
40919741|NCT04197310|DRUG|Cabozantinib|40mg, orally, Daily for a 28 day cycle
40758175|NCT00309946|DRUG|cediranib maleate|Given orally
40758176|NCT05931497|DEVICE|whole body hyperthermia|heat will be applied to the participant through a sauna to increase core body temperature
40919742|NCT06013813|PROCEDURE|Radial Artery approach on percutaneous coronary intervention (PCI)|"* Randomized patients with a right patent radial artery.~* The outcomes of the distal radial approach will be compared with those of the conventional radial approach.~* Technique and devices (introducer and compression devices) are the same in both approaches."
40919743|NCT00065429|DRUG|BB-10901|"I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease."
40919744|NCT01528267|OTHER|Autologous blood|50mls of autologous blood injected into each of 3 bronchopulmonary segments.
40919745|NCT01528267|OTHER|Normal saline|50mls of normal saline injected into each of 3 bronchopulmonary segments.
40758177|NCT02403037|DEVICE|True auricular acupressure|A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
41267680|NCT02736903|BEHAVIORAL|PennFit mobile online network intervention|PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
41267681|NCT01614964|DRUG|AQ-13 Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
40919746|NCT00028145|BEHAVIORAL|Adherence assessment|Adherence will be assessed using questionnaires at all study visits.
40919747|NCT06242353|DIAGNOSTIC_TEST|Coagulopathy parameters|"Standard coagulation tests: APT (Activated Partial Thromboplastin Time), PT/INR (Prothrombin Time Test), Protein-C, Protein-S, Fibrinogen, Antithrombin, D-dimers.~Global haemostasis assays: CAT (Calibrated Automated Thrombogram), OHP (Overall Haemostatic Potential), Fibrin clot turbidity assay, microparticle detection by flow cytometry, scanning electron microscopy.~Protein expression profile (mass spectroscopy)~Ultrasound of catheterised neck veins to detect clots"
41093204|NCT05189457|DRUG|Docetaxel|"During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel."
41452960|NCT02565836|DRUG|fixed-dose activated prothrombin complex concentrate|"FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated"
40919748|NCT04264832|OTHER|Clinical data collection|"Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).~A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.~Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.~Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS）, self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life ."
40919749|NCT05049317|PROCEDURE|Laparoscopic FTME surgery|Nerve plane was defined as the overlying tiny membranous tissue including the nerves, the adipose tissue and the extremely tiny capillaries around the nerve. Following the TME principles, the surgical procedure of FTME was guided by the nerve plane and dissected between the proper fascia of the rectum and nerve plane (the first gap), which could ensure completeness of the nerve plane and the proper fascia of the rectum.
40919750|NCT06029517|OTHER|Education Intervention|Receive Indigneous SIPin intervention
40919751|NCT06029517|OTHER|Interview|Complete interviews
41093205|NCT05189457|DRUG|Tislelizumab|During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
40919752|NCT06029517|PROCEDURE|Discussion|Attend focus groups
41093206|NCT06480487|BEHAVIORAL|Feedback provided face to face|Feedback will be provided face-to-face.
41093207|NCT06480487|BEHAVIORAL|Feedback provided by electronic mail|Feedback will be provided by electronic mail.
41093208|NCT06480487|BEHAVIORAL|Feedback provided by researchers|Feedback will be provided by researchers.
41093209|NCT06480487|BEHAVIORAL|Feedback provided by authoritative bodies|Feedback will be provided by authoritative bodies.
41093210|NCT06480487|BEHAVIORAL|Feedback provided with peer comparision|Feedback will be provided with peer comparison.
41093211|NCT06480487|BEHAVIORAL|Feedback provided without peer comparision|Feedback will be provided without peer comparision.
41093212|NCT04259762|BEHAVIORAL|Breast, Colorectal, and Cervical Cancer Screening Interventions|Adult men and women will receive age- and gender-specific interventions. Women age 50-75 years will receive the interventions for breast, colorectal, and cervical cancers screening. Men age 50-75 years will receive the intervention for colorectal cancer screening. Women age 21-49 years will receive the intervention for cervical cancer screening. The 4-week interventions, delivered once a week, will consist of educational sessions that discuss cancer-specific information (i.e., breast, colorectal, and cervical cancer): breast (colorectal, cervical) cancer myths and facts, risk factors and symptoms, screening, and review/action plan. The educational sessions will be complemented by cancer-specific small media (brochure).
40758178|NCT02403037|DEVICE|Sham auricular acupressure|A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
41093213|NCT03952481|DRUG|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
41093214|NCT05310721|BEHAVIORAL|Early time-restricted eating|Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
41093215|NCT05310721|BEHAVIORAL|Late time-restricted eating|Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
41093216|NCT05310721|BEHAVIORAL|Self-selected time-restricted eating|Participants will self-selected an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
40919753|NCT06481462|PROCEDURE|Intrathecal Morphine (ITM)|morphine 100 mcg + 12.5 mg bupivacaine + 10 mcg fentanyl
41093217|NCT04055753|DRUG|Doxil|Doxil 50 mg/m2, as per institutional standard
41093218|NCT04055753|DRUG|Doxorubicin|Doxorubicin 75 mg/m2, IV over 5-15 min OR Continuous infusion over 48-72 hours
40919754|NCT06481462|PROCEDURE|Quadratus Lumborum II (QLB-II) Block|12.5 mg bupivacaine + 20 mcg fentanyl bilateral QLB block (posterior tip 2) 25 cc 0.25% bupivacaine
40919755|NCT04605705|COMBINATION_PRODUCT|Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
41093219|NCT06421831|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
41133391|NCT01184885|DRUG|Hyper-CVAD|"* Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are \< 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses."
40758179|NCT02403037|DRUG|Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)|5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
40758180|NCT00003670|DRUG|arzoxifene hydrochloride|
40919756|NCT04352972|DEVICE|Tele-monitored home exercise program|Tele-monitoring home exercise program used in the home with monitoring by physiotherapists.
40919757|NCT04352972|OTHER|Hospital-based rehabilitation program|Participants will receive a maximum of 8 sessions over 10 weeks with the option of two additional sessions. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion. Participants will also receive a set of home exercises and they will be instructed to exercise on days when not attending rehabilitation.
40919758|NCT05697185|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
41093220|NCT05798104|BEHAVIORAL|Collaborative nurse-pharmacist counseling|At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
41093221|NCT04018729|DEVICE|Zephyr Endobronchial Valve|Endoscopic lung volume reduction therapy.
40919759|NCT03219710|DRUG|Ondansetron|Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
41093222|NCT04018729|BIOLOGICAL|Marrow-derived mesenchymal stromal cell|Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
41093223|NCT01895257|DEVICE|HAI-90Y radioembolization (SIR-spheres injection)|"Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.~1. Hepatic Angiogram~2. Liver-Lung Break-Through Nuclear Scan"
41093224|NCT01895257|DRUG|systemic chemotherapy LV5FU2|"Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.~Cycle 1 onwards:~Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure."
40919760|NCT03219710|DRUG|Dexamethasone|Dexamethasone will be given as 3mg/m2 IV/PO q8h.
40919761|NCT03219710|DRUG|Aprepitant|Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (\>40 kg) - Day 1 -125mg , Day 2 \& Day 3 - 80 mg PO
40919762|NCT03219710|DRUG|Olanzapine|olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
40919763|NCT03007810|DRUG|Hemay005|Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
40919764|NCT03007810|DRUG|Placebos|Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
40919765|NCT05022667|DEVICE|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements.
40919766|NCT04364984|DRUG|Angiotensin converting enzyme inhibitor|routine drug intake
40919767|NCT04364984|DRUG|Angiotensin Receptor Blockers|routine drug intake
40919768|NCT04364984|DRUG|Direct renin inhibitor|routine drug intake
40919769|NCT03033550|BEHAVIORAL|brief negotiated mobile application|The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
40919770|NCT02160132|DRUG|Methylprednisolone(intravenously in the 1st-2nd-3rd month )|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
41093225|NCT05388916|OTHER|Cosentyx|Prospective observational cohort study. There is no treatment allocation. Patients administered Cosentyx by prescription will be enrolled.
40919771|NCT02160132|DRUG|Methylprednisolone(intravenously in the 1st-3rd-5th month)|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
40919772|NCT03647189|DEVICE|Hybrid Fractional Laser|Hybrid Fractional Laser
40919773|NCT03785223|DRUG|Methylphenidate Hydrochloride Controlled-Release Capsules|"25 mg methylphenidate hydrochloride- titrated as tolerated up to a maximum 4 capsules daily (25 mg- 100 mg total dose)~At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. 50 mg of methylphenidate hydrochloride per day (i.e. 2 capsules/day) is the minimum dose that must be achieved. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11, no further dose changes will occur."
40919774|NCT03785223|DRUG|Placebo Capsule|At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
40919775|NCT06351384|DEVICE|miRNA detection test|miRNA sequencing based on Next-Generation Sequencing (NGS) technology
40919776|NCT03206281|DIAGNOSTIC_TEST|Fetal wight estimation|We will estimate the fetal weight by sonographic and clinical estimation
40919777|NCT02370108|DEVICE|electrical muscle stimulation|electrical muscle stimulation at hand muscle for reduction tremor
41093226|NCT06433193|DEVICE|PAK HD Sorbent Therapy|"Study Period 1:~Subjects will receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, one 4h CHD therapy will be performed at a dialysate flow rate (QD) of 300mL/min, identical to the dialysate flow rate of the PAK HD sorbent therapy. Blood and dialysate samples will be collected during treatment and sent for analysis, for comparison with PAK HD sorbent treatment.~Study Period 2:~Subjects will again receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, a 2h PAK HD +/- 2h CHD therapy will be performed. Blood and dialysate samples will again be collected during treatment and sent for analysis, for comparison with the CHD therapy of the first period. After completion of study period 2 (PAK HD +/- CHD), subjects will be observed for a minimum duration of 1 h in the hospital after which they may go home if the post-dialysis period was uneventful."
41093227|NCT03945253|DRUG|ASP8374|Intravenous
40919778|NCT03137745|OTHER|thromboelastography|thromboelastography was done pre HIPEC ,post HIPEC and first and second postoperative days
40919779|NCT04976582|DEVICE|dry needle|modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
40919780|NCT01853488|RADIATION|DXA|Osteodensitometry
41093228|NCT05367674|BEHAVIORAL|Summer Harvest Adventure|Biobehavioral intervention focusing on nutrition and lifestyle behaviors.
41093229|NCT05367674|BEHAVIORAL|My Summer Plate (MSP)|My Summer Plate (MSP)
40919781|NCT01853488|RADIATION|pQCT|Osteodensitometry
40919782|NCT00245167|PROCEDURE|Tracheal Aspirate Fluid|
40919783|NCT05118659|PROCEDURE|sustained natural apophyseal glides|It consists on a sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each
40919784|NCT05118659|PROCEDURE|SHAM SNAG|Subjects on SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension
40919785|NCT06356571|DRUG|Isatuximab SC-OBDS|Pharmaceutical form:Solution for SC-OBDS administration-Route of administration:SC-OBDS
40919786|NCT06356571|DRUG|Montelukast|Pharmaceutical form:As per local commercial product-Route of administration:Oral
40919787|NCT06356571|DRUG|Dexamethasone|Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV
40919788|NCT06356571|DRUG|Acetaminophen|Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV
41093230|NCT03678753|DRUG|Cenobamate|12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.
41442367|NCT06366386|BEHAVIORAL|Screening and treatment of hypertension among PLHIV in DSD models for HIV|In all DSD models of HIV, participants will receive screening for HTN (BP measurement), treatment of hypertension using a simplified protocol of amlodipine, hydrochlorothiazide and Losartan in a stepwise manner and laboratory monitoring for HTN medication adverse events.
41093231|NCT03678753|DRUG|Placebo|Matching Placebo
41093232|NCT03001362|RADIATION|Radical external beam radiotherapy|pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.
40919789|NCT06356571|DRUG|Diphenhydramine|Pharmaceutical form:As per local commercial product-Route of administration:Oral (as premedication) or IV/oral equivalent (for management of infusion reaction)
41093233|NCT06224075|BEHAVIORAL|Task-specific training|"Participants in the intervention group will receive the treatment established for the control group and nursing care based on task-specific training. The intervention was designed with the aim of improving inhaler management in COPD patients. The content of the tasks will be adapted to the different types of devices present in the patient's therapeutic regimen, mainly pressurized cartridge and dry powder devices.~In order to carry out the intervention, several tasks related to education, assessment and/or training will be established with the aim of improving the ability to use the prescribed inhalers. The tasks have been classified into 3 blocks: technique execution, device cleaning and medication administration."
40919790|NCT06356571|DRUG|Methylprednisolone|Pharmaceutical form:As per local commercial product-Route of administration:IV
40919791|NCT06356571|DRUG|Carfilzomib|Pharmaceutical form:As per local commercial product-Route of administration:IV
40919792|NCT03027791|BEHAVIORAL|Virtual Reality|Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.
40919793|NCT03027791|BEHAVIORAL|Group Sessions|12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
41093234|NCT06224075|OTHER|Usual care|All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.
40919794|NCT03276455|GENETIC|Autologous CD34+ cells genetically modified|Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
40919795|NCT00678756|DRUG|Ketokonazol 2% cream|twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week
41093235|NCT01772719|DRUG|Simvastatin and zoledronic acid|"1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly."
41093236|NCT04672460|DRUG|TALZENNA capsule|Current commercial talazoparib formulation 1 mg once daily given under fasting condition
41442368|NCT03431961|DRUG|Triamcinolone Acetonide|220 mcg administered twice daily for 14 days
41442369|NCT03431961|DRUG|Placebo|twice daily for 14 days
41442370|NCT01804608|OTHER|Strength|
41442371|NCT01804608|OTHER|Sensorimotor|
40919796|NCT00678756|RADIATION|UVB-radiation 311nm|3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm
40919797|NCT00985920|DRUG|tranexamic acid|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
40919798|NCT00985920|DRUG|Placebo|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
41267682|NCT01614964|DRUG|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
41267683|NCT00094614|DRUG|Atropine|
40919799|NCT00004040|BIOLOGICAL|recombinant interferon alfa|
41267684|NCT06424496|OTHER|Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression|Quazi-Experimental study (pre/post design) to assess the Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression
40919800|NCT00004040|BIOLOGICAL|rituximab|
40919801|NCT05271500|DEVICE|laser acupuncture|gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks
40919802|NCT05873166|OTHER|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point
40919803|NCT05873166|OTHER|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
40919804|NCT06105905|BEHAVIORAL|"Healthy futures (Futuros Saludables)"|The developed intervention will be delivered in a workshop format by facilitators, over 8 sessions for teens and 2 sessions for parent/guardian(s). Feedback on delivery mode (virtual, in-person, or hybrid) during the co-development sessions. If in-person/hybrid is suggested, feedback will be elicited about preferred location (e.g., a local community center, sports club, etc.). Participants will complete sessions, in either Spanish or English depending on participants' preference, using video conference tools. After the delivery of the intervention, facilitators will take field notes and complete a debriefing questionnaire to assess practicality and fidelity. Parent/guardians will complete a 5 minute pre- and post- intervention survey. Teens will complete a 15 minute survey pre-intervention, immediately post-intervention, three-month, six-month, and twelve-month post-intervention. Surveys will assess acceptability and risk behaviors.
40919805|NCT04395053|DRUG|SHR1459|"TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h."
40919806|NCT00511394|DRUG|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
40919807|NCT00511394|DRUG|Normal Saline|Infusion of 100 mL of Normal Saline
41093237|NCT04672460|DRUG|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition
41093238|NCT04672460|DRUG|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
41133392|NCT01184885|DRUG|Sirolimus|Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
41133393|NCT01653652|DIETARY_SUPPLEMENT|Probiotic|
41133394|NCT01653652|DIETARY_SUPPLEMENT|Maltodextrin|
41267685|NCT02970695|DEVICE|magneto-auriculotherapy (MAT)|Subjects will then receive MAT. The magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.
40919808|NCT02667353|PROCEDURE|ECT|ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) \< 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
40919809|NCT02667353|DRUG|Etomidate|Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
40919810|NCT02667353|DRUG|Succinylcholine|Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
40919811|NCT05867641|BEHAVIORAL|Immersive VR Therapy in Head-Mounted Device (HMD)|"Caregivers will be trained to administer VR\&R therapy to their loved ones with dementia, in their private home/residence. Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, approximately every other day (or as desired), for three weeks. The caregiver will use the custom VR\&R web-based application on their personal device (laptop, tablet, or mobile phone) to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call)."
41093239|NCT03957980|OTHER|Occupational therapy|Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.
41093240|NCT06550115|BEHAVIORAL|Time-restricted eating|Night shift workers will participate in 4 weeks of fasting during the biological nighttime while remaining awake during overnight work shifts.
41093241|NCT06550115|BEHAVIORAL|Control eating|Night shift workers will participate in 4 weeks of Control eating across the daytime and nighttime hours while remaining awake during overnight work shifts.
41093242|NCT04756401|DRUG|Carfilzomib|Given IV
41093243|NCT04756401|BIOLOGICAL|Daratumumab|Given IV
40919812|NCT04866745|DEVICE|Magnetotherapy plus exercise|The VARIMAG-4E magnetotherapy device will be used. It is a pulsed radiofrequency energy device. The device has a voltage of 220V, 4 amps of intensity, 50 Hz of frequency and a maximum power of 100 Gauss. For the active treatment application, the patient will be in supine position and will introduce both knees in the 50 cm coil in case of bilateral knee osteoarthritis. In the case of unilateral knee osteoarthritis, the affected knee will be introduced in the 30cm coil. The duration of the treatment will be 20 minutes, the frequency administered will be 50 Hz and a power of 100 Gauss.
40919813|NCT04866745|DEVICE|Microwave plus exercise|The application of deep heating therapy will be with the patient in a sitting position. The VARITRON 250-EP microwave device will be used with a frequency of 2450 MHz and a maximum output power of 250W. In the case of unilateral knee osteoarthritis, the circular applicator with a diameter of 170mm will be placed approximately 15 cm from the knee. The duration of the session will be 20 minutes, 10 minutes over the internal face and 10 minutes over the external face of the knee. In the case of bilateral knee osteoarthritis, the large lumbar applicator will be placed approximately 15 cm from the anterosuperior face of both knees for 20 minutes. The patient will have to perceive a moderate heat sensation.
40919814|NCT04866745|DEVICE|Sham Magnetotherapy plus exercise|The protocol and device will be the same in the active/placebo treatment. The sham device does not emit an electromagnetic field. The energy from the active device is not felt by the user, and the active device cannot be distinguished in any way from the placebo device.
41093244|NCT04756401|DRUG|Dexamethasone|Given PO
41093245|NCT04756401|OTHER|Quality-of-Life Assessment|Ancillary studies
41093246|NCT04756401|DRUG|Selinexor|Given PO
41093247|NCT03628079|DRUG|ReposMBZ|Capsules 50mg, 100mg, 200mg
41093248|NCT02338609|DRUG|Everolimus|At the discretion of the investigator, pediatric patients could be treated with commercially available everolimus, as per local product information / standard of care. Treatment duration and dose modifications were at the investigator's discretion, as per the local product information.
41093249|NCT00828620|OTHER|Imaging study|PET-CT
41093250|NCT03201809|DEVICE|On-Q|0.2% Ropivicaine at 4 mL/h via On-Q catheter placed sub-pectoral
41093251|NCT03201809|DRUG|Ultrasound guided pectoral nerve block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection
41093252|NCT01616719|DEVICE|DTRAX Graft|DTRAX Graft is an allograft implant inserted to support spinal fusion.
41287127|NCT04801914|PROCEDURE|Percutaneous biliary drainage|Collection of peripheral blood samples before and one month after percutaneous biliary drainage performed for patients with malignant obstructive hyperbilirubinemia for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).
41267686|NCT02970695|DEVICE|Laser auriculotherapy (LAT)|A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
40919815|NCT04273880|DRUG|Methylphenidate|10mg of MPH taken an hour and a half before one of the testing sessions.
40919816|NCT04273880|DRUG|Vitamin C|90 mg of Vitamin C taken an hour and a half before the other testing session
40919817|NCT03543488|DIAGNOSTIC_TEST|Neuromuscular and functional capacity tests|"The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests."
40919818|NCT00770575|DRUG|Pioglitazone and atorvastatin|"Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
41267687|NCT03773302|DRUG|BGJ398|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
41267688|NCT03773302|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
40919819|NCT00770575|DRUG|Atorvastatin|"Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
40919820|NCT03774056|DRUG|HC-1119|oral
40919821|NCT01028300|DEVICE|ProDisc™-L Total Disc Replacement (TDR)|The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
40919822|NCT00978757|DRUG|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
40919823|NCT00978757|OTHER|Placebo|saline solution
40919824|NCT05407740|OTHER|no intervention study|no intervention study
40919825|NCT03762096|DIETARY_SUPPLEMENT|Trans-resveratrol|1 gram, twice a day by mouth Transmax (Biotivia)
40919826|NCT03762096|DIETARY_SUPPLEMENT|Placebo|Placebo
40919827|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
40919828|NCT05166837|DRUG|Placebo|Intravenous injection
41267689|NCT03773302|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
41267690|NCT02439580|DIETARY_SUPPLEMENT|Annona muricata extract|ethanol-soluble fraction of water extract
41267691|NCT02439580|DIETARY_SUPPLEMENT|Placebo|maltose
40919829|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
41287128|NCT02812680|OTHER|Blood Draw|Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
41287129|NCT00852644|PROCEDURE|computed tomography|Standard CT scans
41133395|NCT04955951|DEVICE|polarized light|A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute
41133396|NCT04955951|DRUG|Topical corticosteroid ointment|corticosteroid 1 %.
40919830|NCT05166837|DRUG|Placebo|Intravenous injection
40919831|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
40919832|NCT05166837|DRUG|Placebo|Intravenous injection
40919833|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
40919834|NCT05166837|DRUG|Placebo|Intravenous injection
40919835|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
41133397|NCT02293551|DRUG|Lispro|Administered SC
41287130|NCT00852644|RADIATION|fludeoxyglucose F 18|standard doses with CT scans
41287131|NCT00852644|RADIATION|hypofractionated radiation therapy|4 doses over 2 weeks
41287132|NCT00852644|RADIATION|stereotactic radiosurgery|CyberKnife radiosurgery
40919836|NCT05166837|DRUG|Placebo|Intravenous injection
40919837|NCT00123253|DRUG|TH9507|
40919838|NCT05606471|DRUG|Semaglutide Pen Injector [Ozempic]|Glucagon-like peptide 1 (GLP-1) receptor agonist
40919839|NCT05606471|DIETARY_SUPPLEMENT|Very-low Calorie Diet|Total meal replacement with a limit of 800 kilocalories per day
41093253|NCT06086808|OTHER|Resistance Training|A resistance training program will be used as a progressive, high-intensity protocol. The training stimulus will be provided using free weights. The exercises will consist of bench presses, biceps curls, triceps extensions, Latissimus Dorsi pull-down exercises, hamstring curls, and calf raises. The intensity of the training stimulus will be at a working range of 6 to 8 repetitions (2 sets). The training stimulus will subsequently be increased using the 7-RM (repetition maximum) method when 2 sets of 6 to 8 repetitions are completed with proper form and without discomfort. Other key strength exercises will include mini-squats, mini-lunges, and lunge walks. The number of sets completed and the load lifted for each exercise will be recorded for each participant in every class.
40919840|NCT03820440|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
40919841|NCT03820440|DIAGNOSTIC_TEST|Lung recruitment manovre (LRM)|The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
40919842|NCT02704390|DRUG|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
41093254|NCT06086808|OTHER|General Fitness and Toning|The general fitness and toning program will consist of stretching exercises, range-of-motion exercises, basic core-strengthening exercises, balance exercises, and relaxation techniques. Key balance exercises will include tandem stand, tandem walking, and single leg stance (eyes opened and closed). No additional loading (e.g., hand weights or resistance bands) will be applied to any of the exercises. This group will serve to control for confounding variables such as physical training received by traveling to the training centers, social interaction, and changes in life style secondary to study participation.
41093255|NCT04936217|OTHER|Data collection|For each patient, the following data will be collected and analyzed: age at operation, sex, Body Mass Index (BMI), ASA score, ASIA score, type of bladder dysfunction assessed by urodynamic evaluation, urinary abnormalities assessed by morphological examination (ultrasound and / or computed tomography) and cystoscopy, creatinine clearance, operative indications, initial mictional mode, surgical assembly, immediate and later complications.
41093256|NCT04936217|OTHER|Interview using a validated questionnaire|A telephone survey will be conducted by means of a questionnaire in order to evaluate the patient's quality of life.
41093257|NCT04167358|DRUG|Linerixibat|All participants will receive linerixibat.
41093258|NCT02998489|OTHER|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
41093259|NCT02998489|OTHER|Traditional milk advancement|20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
41133398|NCT04378894|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
41133399|NCT03773471|BEHAVIORAL|Mobile Health App|ArthritisPower App
40919843|NCT01011205|DRUG|Advagraf|Capsule
40919844|NCT01011205|DRUG|Mycophenolate Mofetil|Solution for infusion
41133400|NCT05778409|BIOLOGICAL|Cordyceps cicadae extract|500mg/ day for one month
40919845|NCT01011205|DRUG|Basiliximab|IV infusion
40919846|NCT01011205|DRUG|Corticosteroids|IV bolus
40919847|NCT02526030|DRUG|Aripiprazole|
40919848|NCT02526030|DRUG|Quetiapine|
40919849|NCT02526030|DRUG|Ziprasidone|
40919850|NCT03728283|PROCEDURE|implant placement in combination with connective tissue grafting|A connective tissue graft of standardised dimensions was harvested from the palate under local anaesthesia and was stabilised over the implant's neck
40919851|NCT03728283|OTHER|Implant placement|Implants were placed following teh manufacturer's instructions
40919852|NCT04816968|DRUG|Cefepime|Cefepime from 3 to 6 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
40919853|NCT04816968|DRUG|Piperacillin/tazobactam|Piperacillin/Tazobactam 18 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
40919854|NCT04816968|DRUG|Meropenem|Meropenem 3 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
40919855|NCT04816968|DRUG|Vancomycin|Vancomycin 30 mg/kg, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
40919856|NCT06138860|OTHER|strain counter strain technique|It will be done in accordance with the technique principles in which the therapist will locate trigger point, and then find a position of comfort or mobile point (at least a 70% decrease in tenderness),monitored the tender point, holding the position o f comfort for 90 seconds, It will be conducted three times per session, for twelve sessions three times per week every other day over the course of a month.
40919857|NCT06138860|OTHER|physical therapy exercises|"Physical therapy exercises for twelve sessions, three times a week, over the course of a month.~Exercises will include:~stretching exercises for the hamstring, calf muscles, and back muscles.~strengthening exercises for back muscles and abdominal muscles."
41093260|NCT05052411|OTHER|App usage assessments and analytics|All participants will be given a brief overview of the purpose of the study followed by a survey on participant characteristics and barriers to accessing HIV testing and PrEP uptake and P/SUD support services. The participant will be observed downloading the JomPrEP app and instructed with a brief tutorial on the onboarding process. The participant will be told to keep the app for 1 month and encouraged to use all app components. At 30 days, the participant will complete a post-survey, to which the Systems Usability Scale will be added. App analytics will also be collected (e.g., the number of logins). Participants will be asked to provide feedback on functionality, performance, and errors encountered, motivation to use the app, overall experiences using the app, feedback for further refinement, and subjective impact of the app on HIV prevention.
41093261|NCT05191901|OTHER|Stress Ball|Reducing pain and fear by squeezing a stress ball during the blood draw procedure.
41093262|NCT00465361|PROCEDURE|performance feedback with an educational module|individual performance feedback with an educational module
41093263|NCT05974839|OTHER|Ocrelizumab|Non-interventional
40919858|NCT05621525|DRUG|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
40919859|NCT03834558|OTHER|Mixed exercise program|"A progressive program of high intensity strength and myofascial conditioning will be carried out in 2 non-consecutive weekly sessions (24 weeks). Each session will include:~A) Warm up on a cycle ergometer~B) Strength circuit: 6 exercises will be included to strengthen different muscle groups (2 in the upper extremities, 2 in the trunk and 2 in the lower extremities). 3 sets of 10-15 repetitions until the failure. The load will be set to 70% of 1 maximal resistance.~C) Self-myofascial conditioning: 10 repetitions, in the direction of the fibres of each muscle group, with different materials. 7 muscle groups will be worked (quadriceps, hamstrings, abductors, gluteus, pectoralis, full back and trapezius).~D) At the end, static stretches will be performed"
40919860|NCT06518590|DEVICE|Cycle|Kettler upright bike Giro P:
40919861|NCT01988701|OTHER|Ancillary-Correlative|Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
40919862|NCT05620121|PROCEDURE|Surgery for Incisional hernias|Laparoscopic and laparoscopic abdominal wall repair for Incisional Hernia with/without prosthetic material in urgent/emergent settings, with/without direct closure of the defect (IPOM and IPOM +).
41452961|NCT02565836|DRUG|variable-dose inactivated prothrombin complex concentrate|"Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated."
40919863|NCT01768429|BEHAVIORAL|Fatty fish|
40919864|NCT01768429|BEHAVIORAL|Lean Fish|
40919865|NCT01768429|BEHAVIORAL|Alpha-linolenic acid|
40919866|NCT01768429|BEHAVIORAL|Control|
41093264|NCT02794116|PROCEDURE|Conventional Sealants|It is a preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
41093265|NCT02794116|PROCEDURE|Resin Sealants|It is a resin sealants to preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
41093266|NCT02467153|OTHER|RET|"RET: A supervised group exercise programme with a maximum of n=10-12 participants per group to be attended 3 times per week for 6 months.~The RET programme includes elements of current established programmes for falls prevention/ core stability (i.e., OTAGO, PEPPI) and will tailored to a range of abilities within the target group.~Vitamin D3 supplementation: vitamin D3 given orally as tablets at a dosage of 800 IU/day for 6 months."
41093267|NCT02467153|DIETARY_SUPPLEMENT|Placebo|Placebo given orally as tablets; 1 tablet per day for 6 months.
41093268|NCT02467153|DIETARY_SUPPLEMENT|Vitamin D3|Placebo given orally as tablets; 800 IU as 1 tablet per day for 6 months.
41093269|NCT04602962|PROCEDURE|fertility preservation, several methods|fertility preservation using assisted reproductive techniques or not
41287133|NCT00656214|DRUG|Lycopene|08 mg/day in two divided dosage
41287134|NCT00656214|DRUG|Placebo|Two divided dosage
41452962|NCT05818345|BEHAVIORAL|Pricing intervention|Participants will be provided with a menu with manipulated prices for products with lower kilocalories
40919867|NCT05030285|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention includes 6 sessions via video-conferencing that has been tailored for people living with cognitive impairment. The sessions incorporate the use of psychoeducation and relaxation videos to improve home-based practise for long-term outcomes.
40919868|NCT02073344|PROCEDURE|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
40919869|NCT02073344|OTHER|no intervention|no renal replacement therapy
40919870|NCT00147550|DRUG|PD-0325901|Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
40919871|NCT04696211|OTHER|Music-with-movement exercise|A music-with-movement exercise programme to reduce chronic pain in older adults.
40919872|NCT02683590|DEVICE|Ceramic Implant|The replacement of the sternum by a ceramic implant
40919873|NCT01557634|PROCEDURE|Overnight closed-loop insulin delivery|Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
40919874|NCT06193122|DEVICE|Ultrasound imaging 3D and Spectroscopy|Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
40919875|NCT02439359|DRUG|CF-301|Dose escalation
40919876|NCT02439359|DRUG|Placebo|
40919877|NCT05867979|DIAGNOSTIC_TEST|Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes|The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
40919878|NCT02604901|BEHAVIORAL|Screening and Brief Intervention (BI)|Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR\*S (BI). BI was considered an active intervention method.
40919879|NCT02604901|BEHAVIORAL|Pill Box (PB)|Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
40919880|NCT06531980|OTHER|Modi|"The Modi course, an eight-week mobile application intervention for adolescents with anxiety symptoms, is based on cognitive therapy. Guided by a rule-based chatbot named Anna, users navigate through predefined options and responses, learning about anxiety and recording their challenges. The app includes animated videos, illustrations, and audio files to enhance engagement. Modi consists of six chapters, with a focus on psychoeducation, the cognitive triangle, and exposure exercises. Participants receive guidance from two Modi therapists who provide weekly support via messages and scheduled phone calls, ensuring personalized assistance and addressing any issues throughout the course."
41452963|NCT02452619|OTHER|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
40919881|NCT06531980|OTHER|Treatment as usual|Participants receive usual treatment at their local Child and Family Services. This treatment, known as Treatment as Usual (TAU), is not standardized but reflects the care they would receive in regular practice. It aligns with national clinical guidelines and includes individual therapy, parental counseling, and assessments. Typically, the treatment is provided by a therapist trained in cognitive behavioral therapy (CBT) or a psychologist
40919882|NCT06515795|OTHER|Isometric exercise|In each arm, participants will execute an isometric exercise, in which they will perform 4 repetitions of 2 minutes.
40919883|NCT03149744|DEVICE|RespiraSense Sleep Screener|RespiraSense will be worn at the same time as the standard of care SomnoScreen and it's results will be masked to the site team
40919884|NCT04810689|DRUG|Xuanfei Baidu Granules|Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake
40919885|NCT04810689|OTHER|Placebo|Placebo for Xuanfei Baidu granule made into dissolvable granules for oral intake
40919886|NCT01666340|OTHER|Exercise intervention|Group asked to perform exercise at a given moderate intensity for a set time
40919887|NCT01666340|OTHER|Exercise intervention|High intensity exercise
40919888|NCT03084380|BIOLOGICAL|Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|transcatheter arterial chemoembolization + CAR-T infusion
40919889|NCT03084380|DRUG|Fludarabine|Fludarabine will be administered at dose of 25mg/m2/d
40919890|NCT03084380|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
40919891|NCT02128685|DRUG|Dydrogesterone|
40919892|NCT02128685|DRUG|Placebo|
41287135|NCT04562337|DRUG|SHR1316|Anti-PD-L1 antibody
41287136|NCT04562337|DRUG|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
41267692|NCT01750255|OTHER|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
40919893|NCT05014633|OTHER|EI skills training|EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
40919894|NCT01689194|DRUG|genexolPM + cisplatin|
40919895|NCT03208582|DRUG|Risedronate Sodium|Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate
40919896|NCT03208582|DIETARY_SUPPLEMENT|Calcichew tablets|Participants will take calcichew tablets during the 6 week period of risedronate treatment
40919897|NCT02775019|DIETARY_SUPPLEMENT|Lactobacillus reuteri|2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
40919898|NCT02775019|DIETARY_SUPPLEMENT|Placebo|2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
40919899|NCT00129844|DRUG|Motexafin Gadolinium|
40919900|NCT06277453|OTHER|surgery|radical gastric cancer surgery (R0) and D2 lymph node dissection
40919901|NCT00943449|DRUG|4SC-201|oral administration
41267693|NCT01750255|OTHER|Education|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
41452964|NCT01531816|DEVICE|Early Rehabilitation intervention|"1. Passive mobility: cycle ergometer~2. Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention."
40919902|NCT00943449|DRUG|Sorafenib|oral administration
40919903|NCT03472170|DIETARY_SUPPLEMENT|Enteral administration of bovine lactoferrin (bLf)|The pharmacy service of the hospital will provide the established dose of lactoferrin, according to the regimen of administration of 150 mg / kg / day (maximum 300 mg / day), as well as that of placebo. Both treatments will be administered in liquid form, in the least amount possible. Both the administration of lactoferrin and placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the newborns with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before.
40919904|NCT03472170|OTHER|Enteral administration of placebo|Enteral administration of placebo with similar visual and gustatory characteristics in the first 72 hours of life, and for 4 weeks (6 weeks in the RN ≤ 1000 gr and / or EG ≤ 28 weeks).
40919905|NCT01037894|PROCEDURE|Acupuncture|Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
40919906|NCT01037894|PROCEDURE|Conventional rehabilitation|In-patient physiotherapy, occupational therapy and speech therapy.
40919907|NCT00907452|DRUG|melphalan-prednisone-thalidomide|
40919908|NCT00907452|DRUG|lenalidomide-dexamethasone|
40919909|NCT02801266|BEHAVIORAL|Evidence informed birth control counseling|Counselors underwent training on the use of 10 best practices for contraceptive counseling.
40919910|NCT05539989|BIOLOGICAL|VPM1002 Vaccine|0.1 mL (2-8x10\^5 CFU)
40919911|NCT05539989|BIOLOGICAL|BCG Vaccine|0.1mL (0.075 Mycobacterium bovis)
40919912|NCT05539989|DRUG|Placebo|0.1 mL (sodium chloride for injection 0.9%)
40919913|NCT05795998|OTHER|Adaptation of the Sabotage in Romantic Relationships Scale into Turkish and its validity and reliability analyzes|Approval was obtained from the local ethics committee before starting the study. Permission was obtained from Racquel PEEL, who developed the scale. The scale was administered to 495 participants and they were informed about the study by a specialist psychiatrist. Language validity, construct validity and reliability analyzes of the scale were performed. The findings were discussed in the light of the literature.
40919914|NCT04020861|DEVICE|Active PBM|To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone. The treatment area will be defined according to painful area. In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J. In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
41093270|NCT00547664|DRUG|Hylenex recombinant , morphine, saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
40919915|NCT04020861|DEVICE|Active TENS|To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone. Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS). The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.
40919916|NCT04020861|DEVICE|Placebo PBM|In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
40919917|NCT04020861|DEVICE|Placebo TENS|To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds. This will permit the patient to fell the TENS sensation while applying the settings.
40919918|NCT02204124|DEVICE|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
40919919|NCT02204124|DEVICE|Standard of care scissors, ligatures, clips, and sutures|
40919920|NCT01302145|DRUG|ASP1941|Tablet
40919921|NCT01302145|DRUG|Metformin|Tablet
41267694|NCT01362582|DRUG|SMOF Kabiven|SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
40919922|NCT01302145|DRUG|Placebo|Tablet
40919923|NCT05099094|GENETIC|BD311|Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody
40919924|NCT00899353|DIETARY_SUPPLEMENT|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
40919925|NCT04140760|OTHER|Symprove|A liquid probiotic
40919926|NCT04140760|OTHER|Symprove placebo product|An inert placebo
40919927|NCT02997306|PROCEDURE|Superior/Medial Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
40919928|NCT02997306|PROCEDURE|Inferior/Lateral Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
40919929|NCT00285389|DRUG|Adriblastin|
40919930|NCT00285389|DRUG|dexamethasone|
41452965|NCT03669861|DRUG|Abatacept|Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)
40919931|NCT00285389|DRUG|Chlorambucil|
40919932|NCT00285389|DRUG|rituximab|
40919933|NCT00285389|DRUG|cyclophosphamide|
40919934|NCT00285389|DRUG|alkeran|
40919935|NCT00285389|PROCEDURE|Total body irradiation (8Gy/4fr)|
40919936|NCT00285389|DRUG|vincristine|0,4 mg/day day 1 to day 4
41267695|NCT00930202|DRUG|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
41452966|NCT04998526|OTHER|Experimental group|The cold gel pack will be applied to the nape.
40919937|NCT06292611|DEVICE|Battery operated toothbrush|Device on extrinsic stain removal efficacy
40919938|NCT06292611|DEVICE|Manual toothbrush|Device on extrinsic stain removal efficacy
40919939|NCT00097149|PROCEDURE|Systematic pediatric care|
40919940|NCT05563038|DEVICE|Scrambler Therapy|"Scrambler Therapy is a non-invasive neuromodulator treatment that focuses on relieving chronic pain through the sending of non-pain signals to the brain through the afferent pain sensory nerves. The signals given off by the scrambler therapy machine are intended to mimic neuronal action potentials through the synthesis of 16 unique waveforms that in combination forms a patient specific cutaneous electrostimulation to reduce pain. These information packets are then carried by the afferent C-fibers, an established system that modulates the sensations received instead of blocking them. The modulated signals are received as nonpainful and endogenous by the central nervous system."
40919941|NCT05563038|DRUG|Standard Medication Management|Medications such as: gabapentin, duloxetine and Lyrica are all FDA approved for treatment of neuropathic pain, particularly that caused by diabetes.
40919942|NCT04432727|DEVICE|Flexitouch Plus with Cellular Connectivity (FT-CC)|Daily use of FT-CC
40919943|NCT02862340|GENETIC|Genetic test|
40919944|NCT04308967|OTHER|balance exercises|Three-stage progressive balance exercises will be applied.
40919945|NCT05148195|DRUG|Envofolimab|300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
40919946|NCT05148195|DRUG|BD0801|2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
40919947|NCT05148195|DRUG|Docetaxel|75mg/m2，Q3W
40919948|NCT05148195|DRUG|Irinotecan|180 mg/m2，Q2W
40919949|NCT05148195|DRUG|Leucovorin calcium|400mg/m2，Q2W
40919950|NCT05148195|DRUG|5-Fluorouridine|2400 mg/m2，Q2W
40919951|NCT01043939|OTHER|Purple Grape Juice|6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
41093271|NCT00547664|OTHER|Saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
41442372|NCT06531122|DRUG|Apixaban 5MG|100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
40919952|NCT01043939|OTHER|Apple Juice|6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
40919953|NCT02382484|DEVICE|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
40919954|NCT02499445|DRUG|Remifentanil|administering remifentanil for anesthesia maintenance
40919955|NCT02499445|DRUG|sevoflurane 1|administering sevoflurane 1 for anesthesia maintenance
40919956|NCT02499445|DRUG|sevoflurane 2|administering sevoflurane 2 for anesthesia maintenance
40919957|NCT02499445|DRUG|propofol|administering propofol for anesthesia maintenance
40919958|NCT02499445|DRUG|sufentanil|administering sufentanil for anesthesia maintenance
40919959|NCT01490489|OTHER|blood sample and doppler Ultrasound of uterine arteries|"* 36 ml of blood samples (serum and plasma) will be collected~* After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch"
41093272|NCT04071340|DEVICE|non-contrast MSCT|non-contrast multi-slice computed tomography
41093273|NCT04071340|DEVICE|Abdominal ultrasonography|Abdominal ultrasonography
41093274|NCT04071340|DIAGNOSTIC_TEST|Urine analysis|Urine analysis
41093275|NCT04071340|DIAGNOSTIC_TEST|Urine culture|Urine culture
41093276|NCT05969561|PROCEDURE|ultrasound-guided femoral nerve block|The local analgesia is injected and infiltrated around the femoral nerve under ultrasound guidance.
41093277|NCT05969561|DRUG|Intravenous or intramuscular pain medication|Intravenous or intramuscular pain medication is given for patients with hip fracture.
41093278|NCT02368886|DRUG|Clobetasol Propionate|Given topically
41452967|NCT04998526|OTHER|Placebo group|The gel pack kept at room temperature will be applied to the nape.
41093279|NCT02368886|OTHER|Pharmacological Study|Correlative studies
41267696|NCT03472508|DRUG|Folic Acid|Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
41267697|NCT03472508|DRUG|Enalapril Maleate and Folic Acid Tablets (Yiye)|Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
41452968|NCT01918813|DRUG|vancomycin, mupirocin ointment|contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
41093280|NCT02368886|OTHER|Quality-of-Life Assessment|Ancillary studies
41093281|NCT02368886|DRUG|Regorafenib|Given PO
41093282|NCT05169567|DRUG|Abemaciclib|Administered orally.
41267698|NCT03472508|DRUG|Enalapril|Enalapril used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
41093283|NCT05169567|DRUG|Fulvestrant|Administered IM.
41093284|NCT05169567|DRUG|Placebo|Administered orally.
41093285|NCT05675306|BEHAVIORAL|Dynamic Temporal and Tactile Cueing Treatment|"DTTC is a dynamic, motor-based treatment approach designed for children with severe CAS. This approach is based on Integral Stimulation (Edeal \& Gildersleeve-Neumann, 2011; Maas \& Farinella, 2012; Maas et al., 2019; Strand \& Debertine, 2000; Strand \& Skinder, 1999), in which the clinician instructs the child to listen to me, watch me, and do what I do and systematically taxes and supports the speech motor system to facilitate system-wide change in speech output (Strand, 2020)."
41093286|NCT02605499|OTHER|UV-C light disinfection|UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
41093287|NCT05693662|BEHAVIORAL|Session 1|"* Ensuring group interaction, allowing parents to meet each other,~* Providing information in line with the Awareness-Based Self-Compassion Training Booklet for Parents of Children with Autism Spectrum Disorder prepared as training material,"
41093288|NCT05693662|BEHAVIORAL|Session 2|"* Making explanations about the contents of the training sessions to be held with parents,~* Teaching proper breathing techniques,~* Visual demonstration and application of relaxation techniques"
41267699|NCT05616143|DEVICE|Isthmus Logic|Patient implanted with Isthmus Logic stent for the treatment of peripheral iliac artery disease
41093289|NCT05693662|BEHAVIORAL|Session 3|"* Breathing break with kindness application,~* Thinking and evaluating how threat, impulse and soothing systems develop in individuals' own lives,~* Safe place application,~* Applying kindness meditation,"
41267700|NCT01196442|OTHER|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
41267701|NCT01196442|OTHER|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
41267702|NCT06016478|DIETARY_SUPPLEMENT|L-citrulline|4 weeks of L-citrulline (6 g/day) in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
41267703|NCT06016478|DIETARY_SUPPLEMENT|Placebo|4 weeks of microcrystalline cellulose in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
41442373|NCT06531122|DRUG|Rivaroxaban 20 MG Oral Tablet|100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
41442374|NCT04354363|OTHER|Platelet rich plasma|Giving women PRP before ICSI
41442375|NCT04712045|OTHER|New PPE|The use of a new protocol of level 2 PPE which involves wearing a short-sleeve gown and a single pair of gloves
41442376|NCT04712045|OTHER|Old PPE|The use of a standard protocol of level 2 PPE which involves wearing a long-sleeve gown and double pairs of gloves
41442377|NCT05911152|PROCEDURE|Intracorporeal anastomosis|Surgeons perform totally laparoscopic intracorporeal digestive reconstruction after specimen resection
41442378|NCT05383807|BEHAVIORAL|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
41442379|NCT01310998|BEHAVIORAL|High intensity exercise|4x4 intervals
40919960|NCT04335305|DRUG|Tocilizumab|IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose
40919961|NCT04335305|BIOLOGICAL|Pembrolizumab (MK-3475)|IV infusion over 30 minutes, 200 mg; single dose
40919962|NCT04010578|DIETARY_SUPPLEMENT|MK-7 and vitamin D3|Patients will receive 400 micro-grams of Menaquinone-7 and 80 micro-grams of vitamin D3 per day.
40919963|NCT04010578|OTHER|Placebo|Patients will receive a placebo each day.
40919964|NCT03002467|OTHER|PESI score|
41267704|NCT01180803|DEVICE|pulse oxygen supplementation devices|oxygen therapy delivered by systems using oxygen-saving valves
41267705|NCT01180803|DEVICE|continuous oxygen|oxygen therapy delivered by continuous liquid oxygen devices
41267706|NCT05637255|DRUG|SYL1801|1 drop in the eligible eye
41267707|NCT03499730|DRUG|Midazolam injection|The dose of preoperative midazolam is the predictor variable and will be registered as a continuous variable in a single cohort.
41267708|NCT02548065|OTHER|Balneotherapy|"Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs"
40919965|NCT03624010|DRUG|Levosimendan 2.5 mg/ml Injectable Solution|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
40919966|NCT00470834|DRUG|dutasteride|0.5mg dutasteride (Investigation Product)
40919967|NCT00470834|DRUG|placebo|making placebo
40919968|NCT00470834|DRUG|bicalutamide|50 mg Casodex or generic equivalent
40919969|NCT05289401|OTHER|ultrasound guided blocks|Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Caudal Block in Pediatric
40919970|NCT02091505|DRUG|Ranibizumab|
41093290|NCT05693662|BEHAVIORAL|Session 4|"* Breathing break with kindness application,~* The practice of establishing a compassionate relationship with resistance,~* Kindness meditation: a do-gooder application,~* A hand on the heart application,~* A compassionate companion application,"
41267709|NCT02548065|OTHER|Placebo|Bath with Thermal tap water
41267710|NCT04480619|DIAGNOSTIC_TEST|Ga-68-PEG-Αvβ3-IAC|Clinical management and diagnosis of angiogenic Breast Cancer.
41267711|NCT03062657|DEVICE|PRESTIGE LP™ Cervical Disc|The PRESTIGE LP™ Cervical Disc is an artificial cervical disc comprising of two low-profile metal plates that interface through a ball and trough mechanism, permitting segmental spinal motion. The PRESTIGE LP™ Cervical Disc was approved by the Food and Drug Administration (FDA) to be used at a single and two contiguous levels.
41267712|NCT05708742|DEVICE|Ultrasound|A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
41267713|NCT05708742|DRUG|Bupivacaine Hydrochloride|The ESP block group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%.
41267714|NCT05708742|DRUG|saline solution|The control group underwent the same procedure but had a sham injection (20 ml of saline).
41267715|NCT05708742|DEVICE|Needle|A 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) was inserted in the cranial-caudal direction towards the TP in-plane with the US transducer until the needle touched the TP crossing all three muscles.
41267716|NCT04934826|DIETARY_SUPPLEMENT|Hydrolyzed Proteins|Patients in experimental arm will receive a test meal based on marked hydrolyzed proteins
41093291|NCT05693662|BEHAVIORAL|Session 5|"* Breathing break with kindness application,~* The practice of establishing a compassionate relationship with desire,~* Guided meditation to discover the inner pattern practice,~* Kindness meditation: a good friend application,"
41093292|NCT05693662|BEHAVIORAL|Session 6|"* Pretending practice regarding parents' awareness,~* An expanded version of the practices carried out in previous sessions to raise awareness, the internalizing compassion practice,~* Kindness meditation: a neutral person, kindness towards your body and walking with kindness practices, which are based on mindfulness practices and increase body awareness and mindful movement,"
41267717|NCT04934826|DIETARY_SUPPLEMENT|Intact proteins|Patients in active comparator arm will receive a meal based on intact marked proteins.
41267718|NCT00348621|PROCEDURE|Visual impairment intervention program|enhanced access to eye care services
41287137|NCT04562337|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
41287138|NCT04562337|RADIATION|Radiation therapy|Thoracic radiation therapy ,TRT
41287139|NCT04562337|DRUG|Cisplatin|Cisplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
41287140|NCT03977532|OTHER|Micro-blood sampling|capillary sampling of 40 microliters performed at the fingertip
41287141|NCT04596371|OTHER|pure pulmonary ground glass nodules in women preparing for pregnancy|pure pulmonary ground glass nodules in women preparing for pregnancy
40919971|NCT04988191|DRUG|Toripalimab|"Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles.~Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles."
40919972|NCT04988191|DRUG|Bevacizumab|Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.
41267719|NCT05450614|OTHER|Thrive app|The application has already been developed using the Flutter framework and provides users with the main CBT-based strategies to reduce depressive symptoms. In order to engage users, gamification strategies were also implemented. Some examples are 1) development and achievement: quiz on psychoeducation with rewards; 2) epic sense: like the messages in the psychoeducation session; 3) unpredictability: surprise quiz. An avatar will also be available for the participant, who will gain experience as he interacts with some of the application's functions. Finally, participants will receive weekly videos of less than 5 minutes with tips on how to use the app. There will be a total of 12 videos with psychoeducation tips and how to use the application.
41267720|NCT05450614|BEHAVIORAL|TCCG|In the literature, there is no single protocol for the treatment of depression through CBCT, therefore, a systematized protocol was developed for this study, aiming to structure and unify this intervention. Participants selected for the TCCG group will be randomly divided into 10 groups of 10 members each. The TCCG will be held through weekly meetings, exclusively online. Twelve sessions lasting 90 minutes each will be applied. The structuring of the sessions is based on the cognitive-behavioral model, starting with psychoeducation about the disorder and self-knowledge, starting with cognitive restructuring and relapse prevention. Homework will be part of the protocol. The sessions will be held on a digital platform (Google Meet) and access instructions will be provided to the participants of this group in the evaluation interview.
41267721|NCT03032783|RADIATION|Total-Body Irradiation|Undergo Total Body Irradiation
41267722|NCT03032783|PROCEDURE|Donor Lymphocyte Infusion|Undergo Donor Lymphocyte Infusion
41267723|NCT03032783|DRUG|Cyclophosphamide|Given IV
41267724|NCT03032783|DRUG|Tacrolimus|Given IV
41267725|NCT03032783|DRUG|Mycophenolate Mofetil|Given IV
41267726|NCT03032783|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo Hematopoietic Stem Cell Transplantation
41267727|NCT02300493|BEHAVIORAL|Experimental|Asked to weigh themselves
41267728|NCT00340431|DRUG|MSP1(42)-FVO & MSP1(42)-3D7|
41267729|NCT06443658|OTHER|Hypertonic saline|Patients from intervention group will inhale hypertonic saline solution 5 minutes before performing the morning ELTGOL technique
41267730|NCT06443658|DRUG|Isotonic saline|Patients from placebo group will inhale isotonic saline solution 5 minutes before performing the morning ELTGOL technique
41267731|NCT06443658|OTHER|ELTGOL|Patients from control group will perform the ELTGOL technique twice-daily
41267732|NCT00212043|DRUG|carboplatin and gemcitabine|
41267733|NCT06461598|DRUG|Chemotherapy|All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
40919973|NCT04988191|DRUG|Irinotecan|Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.
40919974|NCT03666156|OTHER|No intervention|No Intervention
41093293|NCT05693662|BEHAVIORAL|Session 7|"* A compassionate letter application, which is carried out by asking parents to think about a situation they have encountered recently or some time ago that still causes distress,~* Kindness meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices,~* Researching how parents can cope with difficulties and implementing a compassionate breath break without words,"
40919975|NCT02123914|OTHER|Aerobic exercise with Vit. C|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
41093294|NCT05693662|BEHAVIORAL|Session 8|"* Revisiting the good application to enable parents to experience the five senses in a pleasant way,~* Practices of self-forgiveness, asking for forgiveness, forgiving others, gratitude, which can be a way of mending the cracks in parents' relationships with themselves and others,~* Expanding the practice into kindness meditation: groups and all beings,"
41093295|NCT05693662|BEHAVIORAL|Session 9|"* The practice of allowing parents to choose a day in their lives for a few minutes to pause mindfully,~* A breather for wise and compassionate action practice,~* Calmness meditation application,~* Sharing the joy meditation application,"
41267734|NCT04488237|DRUG|Vitamin D|oral administration of Vitamin D in patients with acute leukemia treated with methotrexate
41267735|NCT01859377|DRUG|V0498 - A mg|Single oromucosal administration
41267736|NCT01859377|DRUG|Ibuprofen|Single oral administration
41267737|NCT04311658|DRUG|Isosorbide Mononitrate 40 MG|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG- IUD insertion
41267738|NCT04311658|DRUG|Placebo|one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
41267739|NCT03913663|OTHER|vestibuloocular training|using vestibulo ocular training program for training neglect patient
41267740|NCT03913663|OTHER|regular exercise training for hemiplegic patients|Traditional gait training program.
41267741|NCT01953952|PROCEDURE|therapeutic conventional surgery|Undergo transoral eHNS
41267742|NCT01953952|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
41267743|NCT01953952|DRUG|cisplatin|Given IV
41267744|NCT01953952|PROCEDURE|quality-of-life assessment|Ancillary studies
41267745|NCT01953952|OTHER|laboratory biomarker analysis|Correlative studies
41267746|NCT04378166|DEVICE|Smart glass|Practitioner wears smart glasses connected to ultrasound machine during central venous catheterization
41267747|NCT03717376|OTHER|Self-questionnaire YSQ-S3 (Young Schema Questionnaire)|All participants will fill the YSQ-S3 at home and send it back to the main investigator.
41267748|NCT05434884|PROCEDURE|occlusal veneer restorations|"occlusal veneer preparation with circumferential chamfer finish line and proximal slot  proposed modified occlusal veneer design for rehabilitation of moderate level of permanent first molars. OrPatients will receive endocrown restorations for rehabilitation of sever level of permanent first molars"
41267749|NCT05434884|PROCEDURE|endocrown restorations|endocrown restorations
41267750|NCT05699148|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|Triple combination therapy is licensed in the UK for prescription to paediatric patients aged 6 to 11 years. ETI will be started as part of routine clinical care.
41267751|NCT03996447|DRUG|gadopiclenol|single intravenous (IV) bolus injection at a rate of 2ml/second
41267752|NCT03996447|DRUG|Gadobutrol 1Mmol/mL Solution for Injection Vial|single intravenous (IV) bolus injection at a rate of 2ml/second
41267753|NCT00470821|DRUG|Oral melatonin 3mg BID|Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
41267754|NCT00470821|DRUG|Placebo|Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
41267755|NCT04485455|DEVICE|iTBS Device/Motor Threshold Coil|Motor Threshold determination, done prior to starting treatments, determines the location and the intensity for the iTBS treatments. A magnetic field is applied with increasing intensity stimulating the motor region of the brain until there is thumb movement; this indicates the intensity of the treatments; the location for treatment is in the sensory area parallel to this location.
41267756|NCT04485455|DEVICE|iTBS Device/Treatment Coil|iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes, and sessions are provided 20 times (Monday-Friday for 4 consecutive weeks).
40919976|NCT02123914|OTHER|Aerobic exercise|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
41267757|NCT05756725|OTHER|Practice-Level Implementation Strategies|The intervention is implementation of new population health management tools that may better leverage patient navigation and other staff resources to ensure timely abnormal follow up of breast and colorectal cancer screening. The research team will work with CHCs to select implementation strategies that will best facilitate integration of the new tools into practice. The team will use electronic health record data (analyzed at the population level) to determine the impact of the new tools on screening outcomes and qualitative data from up to 3 staff and 2 patients per CHC to evaluate integration of the tools into practice.
41267758|NCT04737148|OTHER|Mortality scores|Revised Baux, BOBI and FLAMES scores
41267759|NCT06069661|DEVICE|Aortic Stenosis|F2 Filter and Delivery system to cover the 3 great cerebral vessels
41267760|NCT05329116|DRUG|Lidocaine 2% Injectable Solution|"Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection"
41093296|NCT05693662|BEHAVIORAL|Session 10|"* Evaluating the entire education by telling parents about the practices they can use where help is needed to develop compassion towards self-healing skills,~* River of Life application, which evaluates awareness in depth,~* Saying goodbye."
41267761|NCT05329116|BIOLOGICAL|Platelet-rich plasma|8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
41267762|NCT01369121|DRUG|XERECEPT|BID dosing, subcutaneous for 1 year
41267763|NCT02500693|BIOLOGICAL|Isolation of circulating tumor cells (CTC) from veinous blood|Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
41267764|NCT05675449|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
40919977|NCT02123914|OTHER|No exercise|"Sedentary control.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
41267765|NCT05675449|DRUG|Carfilzomib|proteasome inhibitor
41267766|NCT05675449|DRUG|Maplirpacept|CD47-SIRP alpha-directed
40919978|NCT02070198|DRUG|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
40919979|NCT02070198|DRUG|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
41267767|NCT01100489|RADIATION|external beam radiation therapy|External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
41267768|NCT01100489|OTHER|questionnaire administration|Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).
41267769|NCT01100489|PROCEDURE|therapeutic conventional surgery|Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins \< 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
41267770|NCT03706573|DRUG|alpelisib|50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
41267771|NCT01019564|DEVICE|Complete Easy Rub Formula MPS|Multi-purpose solution
41267772|NCT01019564|DEVICE|Aquify MPS|Multi-purpose solution
41267773|NCT04349137|DEVICE|HD-tACS|non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.
41267774|NCT04349137|DEVICE|sham HD-tACS|sham non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS)
41267775|NCT04910984|BEHAVIORAL|Chatbot messages|Automated personalized messages containing HIV testing-related information, motivation and skills
41267776|NCT04910984|BEHAVIORAL|Attention-matched educational materials|Attention-matched educational materials manually sent by our research assistant. These educational materials will be retrieved from CDC and WHO websites and curated into short articles (\<200 words) and pictures. All educational materials will be screened by HIV experts from University of Malaya to ensure accuracy before being sent to participants.
41267777|NCT00318292|DRUG|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
41267778|NCT00318292|DRUG|Placebo|20 ml normal saline injection.
41267779|NCT04257331|BEHAVIORAL|Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme|The SREIA program is grounded in applied behavior analysis and developmental theories. It aims to reduce child behavioral problems and promote child development by improving parental attitudes and parenting styles. The program targets parent-child dyads from families of children with ASD aged between three and six years. It is delivered five days a week for 11 weeks. Fourteen two-hour lectures on weekly themes (such as knowledge of ASD, parent-child interaction, and behavior management techniques) are offered throughout the 11 weeks and attended by all participating parents. For the remaining time, additional training in ABA principles and practice are tailored for the different functioning groups. The program offers a combination of individual counselling and group sessions, as well as a mixture of didactic and interactive delivery modes. All sessions are delivered in person. Some sessions are only for parents and others are participated in by both parent and child.
41267780|NCT02840136|DRUG|Piperacillin-tazobactam combination product|
41267781|NCT02840136|DRUG|Meropenem|
41267782|NCT02840136|DRUG|Ceftazidime|
41267783|NCT06314724|BIOLOGICAL|Varicella Vaccine|lyophilized powder,subcutaneous injection
41267784|NCT06314724|BIOLOGICAL|Varivax|lyophilized powder,subcutaneous injection
41267785|NCT01769105|DEVICE|Lipiflow|Patients receive a single Lipiflow-treatment
41267786|NCT01769105|BEHAVIORAL|Lid hygiene regime|Patients receive verbal and written instruction to perform lid hygiene twice daily
41267787|NCT03846245|OTHER|No intervention|No intervention
41267788|NCT02077790|DEVICE|CASIA Cornea/Anterior Segment OCT SS-1000|"The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second."
41267789|NCT02266550|DRUG|[14C] BILL 284 BS|
41287142|NCT01707147|DRUG|Trajenta tablet|Linagliptin
41133401|NCT03606551|DEVICE|EXD-959 Bracket System|EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.
40919980|NCT02070198|DRUG|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
40919981|NCT03596749|DRUG|Sevelamer Carbonate|Sevelamer carbonate 1600mg (p.o. b.i.d) with meals
41267790|NCT04287621|DRUG|DUPIXENT®|There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.
41267791|NCT04149314|OTHER|HPI based hemodynamic optimization algorithm|Interventional patients will be treated by a HPI-based hemodynamic optimization protocol including HPI, Stroke volume, cardiac index and mean arterial pressure.
41267792|NCT00533962|DRUG|Anterior Juxtascleral Depot of Anecortave Acetate|
41267793|NCT03352401|OTHER|Ultrasouund assessment of gastric contents|A qualitative and quantitative ultrasound evaluationof the stomach will be performed when the patient arrives in the pre-anesthesia room. The examination will be held in the right lateral decubitus with a low frequency convex ultrasound probe.
40919982|NCT01724619|DRUG|[F-18] fluorinated dihydrotestosterone (FDHT)|
40919983|NCT03970044|DRUG|Exenatide 2 MG|Glucagon-like peptide-1 receptor
40919984|NCT03970044|DRUG|Dapagliflozin 10 MG|sodium-glucose co-transporter 2 (SGLT2) inhibitor
40919985|NCT01342237|DRUG|HDCT 1(TTC), HDCT2(MEC)|"1. TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~2. MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)"
41267794|NCT06091345|DRUG|Midodrine|• Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10%
41267795|NCT06091345|BIOLOGICAL|albumin|• Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is \< 3.5 gm/dl
41267796|NCT06091345|OTHER|Standard Medical Treatment|Standard Medical Treatment
41267797|NCT00206726|DRUG|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
41267798|NCT04278794|OTHER|Transitional Care Stroke Intervention (TCSI)|"Core components:~1. Comprehensive Hospital Discharge Plan. The Care Coordinator will meet with staff in the in-patient unit along with patients and their caregivers to develop and implement a comprehensive discharge plan.~2. Structured home visits and telephone support. As part of the structured home visits and telephone support, a member of the IP team will provide up to 6 home visits over 6 months. The team will provide: screening and assessment; medication review and reconciliation; self-management support; education; and caregiver assessment.~3. Monthly IP case conferences. 6 monthly IP team case conferences will be held to discuss goals identified by the patient, collectively develop a plan of care, and identify needs.~4. Linkages to services. Facilitate timely follow-up with the primary care provider and build relationships with local health and social service providers. These referrals and links will provide the foundation for continued use post-intervention."
41442380|NCT04045925|OTHER|Taïso|Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
40919986|NCT06020872|OTHER|Health literacy program|Health literacy program was the health education related to healthy plate.
40919987|NCT04185597|OTHER|HFP Intervention: Delivered by Community Farmers|Homestead food production (HFP) supported by community farmers, Social and Behavior Change Communication (SBCC), strengthened health services, and referrals to health and other services
41267799|NCT05918380|BEHAVIORAL|PAL2|"Low CVD risk participants (CAC \< 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2.~PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education."
41287143|NCT03777930|DRUG|Chemotherapy drugs|According to the NCCN Guidelines
41442381|NCT04952857|DRUG|cholecalciferol 6 lakh IU|vitamin D levels and serum calcium will be assessed at day 3,7, 14.
41267800|NCT05918380|OTHER|CINEMA|High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
41267801|NCT05581030|DRUG|Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)|"Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term hyper refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.~Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.~Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient."
41267802|NCT05581030|DRUG|Calaspargase Pegol|Calaspargase pegol 2000 IU/m\^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial.
41267803|NCT05581030|DRUG|Rituximab|Rituximab 375mg/m\^2 will be administered once per cycle for patients with CD20+ ALL.
41267804|NCT00542191|DRUG|Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin|DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
40919988|NCT04185597|OTHER|HFP Intervention: Delivered by agricultural Retailers|HFP supported by retailers, SBCC, strengthened health services, and referrals to health and other services
40919989|NCT04185597|OTHER|Control|Current Standard of Practice
40919990|NCT03567239|DEVICE|Using adaptive device.|Participant uses the specially designed device for a specified length of time (no less than two days) and feedback is then gathered from the participant through questionnaires. These questionnaires include NASA-TLX, PIADS, QUEST, and a single question asking if the device improved their ability to address their specific need.
40919991|NCT03354507|DIETARY_SUPPLEMENT|Sodium bicarbonate|Sodium bicarbonate. See arms.
41267805|NCT00542191|PROCEDURE|Definitive Surgery|Standard of care definitive surgery as determined by medical provider
41093297|NCT05928182|BEHAVIORAL|El Faro Treatment Intervention|"Pre - Measures: complete Child Behavior Checklist (CBCL), ADHD module of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI) administered by study team, ADHD Rating Scale (ADHD-RS; parent and teacher ratings), ADHD Functional Impartment Scale (ADHD-FX), Parenting Sense of Competence (PSOC), demographic information, and medical history. \[All rating scales are parent-report unless noted otherwise\]~Treatment: Complete an 8-week adapted El Faro treatment intervention with homework tasks.~Post-Measures: CBCL, ADHD-RS (parent and teacher ratings), ADHD-FX, and PSOC. We will also acceptability and feasibility via measuring session attendance (rated by the therapist each session), homework completion (rated by the therapist each session), 7 treatment acceptability questions. \[All rating scales are parent-report unless noted otherwise and administered at post-treatment visit unless noted otherwise\]."
41267806|NCT00542191|RADIATION|Radiotherapy|Standard of care RADIATION THERAPY as indicated
41267807|NCT03866187|BIOLOGICAL|ChAd155-hIi-HBV low dose formulation|Subjects in group A1 receive one dose of ChAd155-hIi-HBV low dose formulation at Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
41267808|NCT03866187|BIOLOGICAL|ChAd155-hIi-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm."
41267809|NCT03866187|BIOLOGICAL|HBc-HBs/AS01B-4 low dose formulation|Subjects in group A1 receive two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169 and subjects in group A2 receive four doses of the low dose formulation, one dose each at Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
40919992|NCT04067570|RADIATION|SBRT|Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
40919993|NCT02184572|BIOLOGICAL|Priorix|1 dose administered subcutaneously in the triceps region of left arm at Day 0
40919994|NCT02184572|BIOLOGICAL|M-M-R II|1 dose administered subcutaneously in the triceps region of left arm at Day 0
41267810|NCT03866187|BIOLOGICAL|HBc-HBs/AS01B-4 high dose formulation|Subjects in group B1 receive two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at 169; subjects in group B2 receive four doses, one dose each at Days 1, 57, 113 and 169; subjects in group C1 receive four co-administered doses at Days 1, 57, 113 and 169 and subjects in group C2 receive two co-administered doses at Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
41267811|NCT03866187|BIOLOGICAL|MVA-HBV low dose formulation|Subjects in group A1 receive one dose of MVA-HBV low dose formulation at Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
41267812|NCT03866187|BIOLOGICAL|MVA-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm."
41267813|NCT03866187|DRUG|Placebo|Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
41267814|NCT06468358|DRUG|LB1410|anti-PD-1/TIM3 bispecific antibody
41267815|NCT06468358|DRUG|LB4330|anti-claudin18.2/IL-10 fusion protein
41267816|NCT02891421|BEHAVIORAL|Therapeutic Horseback Riding|Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
41267817|NCT02891421|OTHER|Standard Care|Standard Care: Participants received standard care
41267818|NCT00245947|DRUG|ERB-041|
41267819|NCT02704598|DRUG|Rivaroxaban|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
41267820|NCT02704598|DRUG|Warfarin|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
41267821|NCT01693172|BEHAVIORAL|Early mobilization program|Early postoperative supervised aerobic exercise, resistance and flexibility training
41267822|NCT02218229|DEVICE|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
41267823|NCT05003557|OTHER|Questionnaire administration|"3 different questionnaires are going to be administered to each participant,~* concerning the current health situation~* the SF 36~* the IPQ-R questionnaire"
41267824|NCT06200350|OTHER|Experimental group|Tailored training based on the profile of each participant.
40919995|NCT02184572|BIOLOGICAL|Varivax|1 dose administered subcutaneously in the triceps region of right arm at Day 0
40919996|NCT02184572|BIOLOGICAL|Havrix|1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
40919997|NCT02184572|BIOLOGICAL|Prevnar 13|1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
41267825|NCT06200350|OTHER|Control group|They will continue with the traditional training.
40919998|NCT00874939|DRUG|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
41267826|NCT00358657|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplantation
41267827|NCT00358657|DRUG|Cyclophosphamide|Given IV
41267828|NCT00358657|DRUG|Fludarabine Phosphate|Given IV
41267829|NCT00358657|OTHER|Laboratory Biomarker Analysis|Correlative studies
40919999|NCT00874939|DRUG|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
40920000|NCT00874939|DRUG|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
40920001|NCT00874939|DRUG|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
40920002|NCT00874939|DRUG|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
40920003|NCT04891640|OTHER|Standard TNFi Therapy|Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed.
40920004|NCT04891640|OTHER|TNFi fixed longer dosing intervals|"Participants randomly assigned to this arm will increase the time between TNFi medication doses.~* Adalimumab- from every 2 to 3 weeks~* Certolizumab- from every 2 to 4 weeks~* Etanercept- from every 1 to 2 weeks~* Golimumab- from every 4 to 6 weeks~* Infliximab- from baseline to baseline + 2 weeks"
41267830|NCT00358657|DRUG|Mycophenolate Mofetil|Given PO
40920005|NCT04891640|OTHER|Stop TNFi treatment|Participants randomly assigned to this arm will stop TNFi medication.
40920006|NCT02029300|OTHER|Fiberoptic Intubation through the nasal route|
40920007|NCT02029300|OTHER|Fiberoptic intubation through the oral route|
40920008|NCT06233669|OTHER|Analysis of Burnout|No intervention used.
40920009|NCT04175847|DRUG|RC88|"Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration"
40920010|NCT04458324|DRUG|Buspirone Hydrochloride|Subjects take 30 mg buspirone HCl twice a day for 6 months.
40920011|NCT04458324|DRUG|Buspirone placebo|Subjects take a placebo tablet twice a day for 6 months.
40920012|NCT04458324|DEVICE|Noninvasive Ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
41093298|NCT05805059|DEVICE|Control Contact Lens (stenfilcon A)|one week wear
41267831|NCT00358657|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic bone marrow transplantation
40920013|NCT04458324|DEVICE|Sham Non-invasive ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
40920014|NCT04458324|OTHER|Functional Electrical Stimulation Row Training (FESRT)|Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
40920015|NCT00711178|PROCEDURE|Photodynamic therapy with methyl aminolevulinate|daylight mediated photodynamic therapy
40920016|NCT01261780|DEVICE|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
40920017|NCT01261780|DRUG|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
40920018|NCT06220760|DIAGNOSTIC_TEST|Ultrasound|The use of US to calculate placenta accreta index
40920019|NCT03808467|BEHAVIORAL|Cognitive Remediation Therapy|Nine individual transdiagnostic CRT sessions will be delivered once per week, each session lasting approximately 45 minutes. Building on previously published CRT manuals for anorexia nervosa and obesity, a transdiagnostic CRT manual developed for this project will be used during the course of CRT treatment. The manual comprises an introduction to CRT for eating disorders, and a detailed nine-session structure incorporating cognitive and behavioral tasks in the following domains; (1) planning-impulsivity, (2) flexibility-rigidity and (3) central coherence-attention to details. A certain set of guiding questions will accompany each task with the aim of stimulating metacognition (i.e. thinking about thinking).
41093299|NCT05805059|DEVICE|Test Contact Lens (senofilcon A)|one week of wear
41267832|NCT00358657|DRUG|Sirolimus|Given PO
41093300|NCT02947711|DRUG|E2027|2 x 50 mg capsules, once daily on Day 1 and Day 12
41093301|NCT02947711|DRUG|Diltiazem ER|1 x 300 mg capsule, once daily on Days 7 through 24
41267833|NCT00358657|DRUG|Tacrolimus|Given IV or PO
41267834|NCT00358657|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
41267835|NCT05266404|DRUG|Dapagliflozin/sitagliptin FDC|Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.
41267836|NCT05266404|DRUG|Sitagliptin|Subjects will receive 100 mg single dose of Sitagliptin orally.
41267837|NCT05266404|DRUG|Dapagliflozin|Subjects will receive 10 mg single dose of Dapagliflozin orally.
41267838|NCT03936387|DRUG|Ropivacaine|Erector spinae blocks: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus. Repeated on contralateral side.
41267839|NCT04574596|OTHER|no Intervention|This is an observational study. There is no intervention
41267840|NCT01817790|DRUG|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
41267841|NCT01817790|DRUG|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
41267842|NCT04653519|DEVICE|Virtually guided minimally invasive preparation|Intraoral virtually guided minimally invasive design with an occlusal reduction of 1.5mm, axial reduction will be performed with 6 degrees axial taper and a circumferential chamfer margin of 0.5mm in width and 0.5mm coronal to the gingival margin. A milled guiding occlusal resin template of the teeth will be checked for fitting then fixed using spot etching and will be used to guide the amount of axial reductions and taper degree.
41267843|NCT00000733|DRUG|Ribavirin|
41267844|NCT03957967|OTHER|video taken|Patients enrolled will be operated in our institution. Facial expression will be collected before and after surgery, and pain intensity will be collected at the same time. Facial expression will be analyzed using Facial Action Coding System (FACS) .This step will seek to confirm that the subset of Action Units (AUs) defined in previous studies is correlated with the presence and intensity of an acute pain or to identify a different original subset of facial AUs better correlated to pain intensity. . The developed algorithm (or model) here should be able to correlate facial AUs to pain intensity reported by the patients on the numerical rating scale. The developed model at this stage will be then validated on an additional sample of patients.
41267845|NCT05564767|DIETARY_SUPPLEMENT|B. adolescentis Bif-038|B. adolescentis Bif-038 (probiotic capsule) delivered orally once daily at a minimum of 5 billion CFU/day
41267846|NCT05564767|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12® (probiotic capsule) delivered orally once daily at a minimum of 1 billion CFU/day
41267847|NCT05564767|DIETARY_SUPPLEMENT|Placebo|Placebo capsule delivered orally once daily
41267848|NCT04953871|DRUG|TNF Inhibitor|TNF inhibitors are widely used in patients with spondyloarthritis
41267849|NCT04937010|PROCEDURE|Occipital nerve stimulator implant|Implantation of occipital nerve stimulator and different stimulation parameters
41267850|NCT01187992|DRUG|Atorvastatin|80 mg/day
41267851|NCT03322358|OTHER|Naps|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
41267852|NCT03322358|DEVICE|Home sleep aids|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
41267853|NCT03322358|OTHER|Sleep incentives|After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
41267854|NCT01445535|BIOLOGICAL|Rituximab|Rituximab will be given with siplizumab and etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin every 21 days
41267855|NCT01445535|DRUG|Etoposide|Etoposide will be given with siplizumab and prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
41267856|NCT01445535|BIOLOGICAL|Siplizumab|Siplizumab will be given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
41093302|NCT00483912|DEVICE|Molecular adsorbent recirculating system|
41267857|NCT01445535|DRUG|Prednisone|Prednisone will be given with siplizumab and etoposide, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
41267858|NCT01445535|DRUG|Vincristine|Vincristine will be given with siplizumab and etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab every 21 days
41267859|NCT01445535|DRUG|Cyclophosphamide|Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days
41267860|NCT01445535|DRUG|Doxorubicin|Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
41267861|NCT00855439|DRUG|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
41267862|NCT00855439|DRUG|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
41267863|NCT00192374|BIOLOGICAL|CAIV-T, Liquid|
41267864|NCT01822002|PROCEDURE|Canalith repositioning maneuver|
41093303|NCT05038124|RADIATION|Preoperative Stereotactic Body Radiotherapy (SBRT)|Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction.
41267865|NCT00684177|DRUG|Retapamulin Ointment, 1%|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
41267866|NCT00684177|DRUG|Placebo ointment|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
41093304|NCT03607799|BEHAVIORAL|Dietary Intervention|Individualized diet advice will be developed for each participant by a dietitian familiar with South Asian foods.
41093305|NCT03607799|BEHAVIORAL|Control|Control group participants will be provided with PDFs, website links to encourage healthy eating, physical activity, and other lifestyle factors during pregnancy. They will also receive weekly text messages aimed at increasing walking.
41267867|NCT01348802|BEHAVIORAL|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
41267868|NCT01348802|BEHAVIORAL|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
41267869|NCT03777215|DRUG|Angiotensin-(1-7)|This is a biologically active beneficial hormone of the renin-angiotensin system.
41267870|NCT03777215|DRUG|Saline|Saline will be used as the placebo comparator.
41287144|NCT03777930|DRUG|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
41287145|NCT03777930|OTHER|optimal support treatment|Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks
41093306|NCT06396390|DRUG|Progestin|In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
41093307|NCT06396390|DRUG|GnRH antagonist|In this regimen, Cetrorelix (Cetrotide©, 250 mcg/mL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
41093308|NCT00797862|DRUG|Amlodipine|Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
41267871|NCT06160102|OTHER|Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities|"Collection and analysis of drug lists and information about the users. Open / participatory observations of staff and residents during drug handling. Interviews/focus groups with residents, family, staff in the service, GPs and pharmacy staff. Interdisciplinary drug reviews based on the IMM method drug reviews, further developed by the researchers in the project.~Design thinking. We use a design process with five stages: empathy, define, generate ideas, prototype and test. This involves user participation and experience to design the most optimal solution for the framework.~Evaluate the framework, observations, interviews, questionnaires. Health economic evaluation."
41267872|NCT05490706|BEHAVIORAL|Bodyweight interval exercise|Performing 15 minutes of bodyweight interval exercise after dinner at home by following a video
41093309|NCT00797862|DRUG|hydrochlorothiazide|Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
41093310|NCT00797862|DRUG|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
41093311|NCT02248454|DRUG|Lispro|Increasing insulin doses
41093312|NCT04167891|DIAGNOSTIC_TEST|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
41093313|NCT01190384|OTHER|Couscous plus fiber|Soup with added fiber to equal Bean soup. Subjects' serving size is isocaloric to the experimental Bean soup.
41267873|NCT05490706|BEHAVIORAL|Walking|Performing a 30 minute minute walk after dinner at home
41267874|NCT01597102|OTHER|No interventions|No intervention is planned in this study
41267875|NCT04876547|PROCEDURE|appendectomy|appendectomy performance
41267876|NCT01777763|DRUG|Posaconazole 200 mg|
40920020|NCT03808467|OTHER|Treatment as usual|According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants' received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
41267877|NCT01777763|DRUG|Posaconazole 300 mg|
41267878|NCT06287879|DIAGNOSTIC_TEST|Dry eye examination|"1. Lacrimal river height~2. tear break-up time~3. tear-film lipid layer thickness~4. meibomian glands two-dimensional digital infrared images"
41267879|NCT02162888|DRUG|Test Product (Bendamustine)|
41267880|NCT00638937|DRUG|saracatinib|Given PO
41267881|NCT01781949|OTHER|A: Nontargeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
41267882|NCT01781949|OTHER|B: Enhanced targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS \<30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
40920021|NCT01998568|OTHER|Intraocular pressure measurement|Using different tonometers for intraocular pressure measurement
40920022|NCT03936231|OTHER|NO Intervention|"Given the observational nature of this study, we consider that no intervention is required.~Participation in concomitant studies: given the observational condition of this study, patiens that are included in other observational and/or experimental researches, can be included in the current study."
40920023|NCT00574236|DRUG|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
40920024|NCT01875198|PROCEDURE|Radical Antegrade Modular Pancreatectomy with Splenectomy|
40920025|NCT01875198|PROCEDURE|Radical Antegrade Modular Pancreatectomy without splenectomy|distal pancreatectomy without pancreatectomy
40920026|NCT00301184|BIOLOGICAL|pGA2/JS7 DNA|DNA Vaccine
40920027|NCT00301184|BIOLOGICAL|Modified vaccinia Ankara/HIV62|Recombinant Modified Ankara Vaccine
40920028|NCT00205270|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season
40920029|NCT01239732|DRUG|Paclitaxel|175 mg/m\^2 on Day 1 every 3 weeks or at a dose of 80 mg/m\^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
40920030|NCT01239732|DRUG|Bevacizumab|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
40920031|NCT01239732|DRUG|Carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
40920032|NCT00680641|DRUG|Simvastatin|40mg of Simvastatin once daily
40920033|NCT00680641|DRUG|Placebo|40mg of placebo once daily
41093314|NCT01190384|DIETARY_SUPPLEMENT|Grape seed extract|300 milligrams of grape seed extract in capsule form will be consumed with the low ORAC value soup.
41093315|NCT01190384|OTHER|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
41093316|NCT01505075|RADIATION|Hypofractionated radiation|40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
41093317|NCT05149144|DIAGNOSTIC_TEST|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule
41093318|NCT05149144|BEHAVIORAL|audio signal dataset creation and validation; machine learning analysis, empirical evaluations|The project tests and adapts the technology developed at MIT for vocalization collection and labeling, and contributes to data gathering among Italian subjects (and their quality validation) in order to create a multi-cultural dataset and to enable cross-cultural studies and analyses. Next, the focus is placed on the analysis of harmonic features of the audio in the vocalizations of the dataset to identify recurring individual features and patterns corresponding to specific communications purposes or emotional states. Supervised and unsupervised machine learning approaches are developed and different machine learning algorithms will be compared to identify the most accurate ones for the project goal. Last, an exploratory evaluation of the vocalization-understanding machine learning model is conducted to test the usability and utility of the tool for vocalization interpretation.
40920034|NCT00167492|DRUG|Myfortic|720 mg by mouth every 12 hours
41287146|NCT03777930|DRUG|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
41442382|NCT04485767|BEHAVIORAL|Progressive Resistance Training Exercise|Progressive Resistance Training Exercise 2x weekly for 6 months.
41093319|NCT05218603|DRUG|Bortezomib|Maintenance: Administration as per routine clinical practice.
41093320|NCT05218603|DRUG|Daratumumab|Maintenance: Administration as per routine clinical practice.
41093321|NCT04694560|OTHER|Treatment Free Observation|Participants without evidence of clinical relapse will remain off therapy and continue serial monitoring through end of study at 24 cycles. Participants with clinical relapse will continue to be monitored off therapy through 24 cycles or until meeting criteria for treatment per iwCLL criteria. If participants experience clinical relapse requiring treatment, radiology assessment, disease assessment, and testing for resistance mutations will be performed. Participants will be observed for an additional 12 cycles following start of reintroduction of therapy.
41093322|NCT01631903|DRUG|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily for 4 months
41093323|NCT01631903|DRUG|telepristone acetate 3 mg|3 mg, vaginal capsule, once daily for 3 months
41093324|NCT01631903|DRUG|telepristone acetate 6 mg|6 mg, vaginal capsule, once daily for 3 months
41093325|NCT01631903|DRUG|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily, for 3 months
41093326|NCT01631903|DRUG|telepristone acetate 24 mg|24 mg, vaginal capsule, once daily for 4 months
41093327|NCT05119933|DRUG|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
41093328|NCT03412838|PROCEDURE|graft surgery|A graft surgery using bone allogenic blocks that are screwed over the atrophic sites of the maxilla to obtain bone augmentation to support dental implants
41093329|NCT02783482|BIOLOGICAL|GC5107|GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
41093330|NCT06560840|OTHER|dietary intervention|The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
41442383|NCT04485767|BEHAVIORAL|Flexibility and Balance Exercise|Flexibility and Balance Exercise Training Exercise 2x weekly for 6 months.
41093331|NCT06296706|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks
41093332|NCT06296706|DRUG|Taxotere (docetaxel)|Taxotere, by intravenous infusion, every 3 weeks.
41093333|NCT05192512|DRUG|TQB2928 injection|TQB2928 injection is a CD47 Blocker.
41093334|NCT01077245|DRUG|MIYA-BM Fine Granules (CBM588)|MIYA-BM Fine Granules (CBM588)
41093335|NCT01077245|DRUG|Placebo Fine Granules (without CBM588)|Placebo Fine Granules (without CBM588)
41442384|NCT06455137|DEVICE|Epidural Stimulator|Participants will have a 16-electrode epidural array implanted in the C4-C7 and T11-L2 areas of the spinal cord. Following a 2 weeks recovery period, patients will engage in a structured training of physical rehabilitation and electrical stimulation.
41093336|NCT03063307|PROCEDURE|Atraumatic Restorative Treatment|
41267883|NCT01781949|OTHER|C: Traditional targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
41267884|NCT04416802|COMBINATION_PRODUCT|autologous platelet-rich plasma and low-intensity extracorporeal shockwave therapy|"The patient who encounters sexual dysfunction and visits our Outpatient Department (OPD) could enter this trial if he meets the inclusion criteria and exclusion criteria.~1. To fill the questionnaires of International index of erectile function (IIEF) and erectile hardness score (EHS) before starting treatment.~2. Li-ESWT treatment weekly for three weeks and PRP injection at the same day after the last Li-ESWT treatment.~3. Coming back at the fourth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~4. Li-ESWT treatment weekly for three weeks starts on fifth week and PRP injection at the same day after the last Li-ESWT treatment.~5. Coming back at the eighth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~6. Coming back at the twelfth week and check is there any side effect and fill the questionnaires of IIEF and EHS."
41093337|NCT03063307|OTHER|Silver Diamine Fluoride|
41267885|NCT06108102|OTHER|Presence of stroke, either ischemic or hemorrhagic (intracerebral and subarachnoid)|Presence of ischemic or hemorrhagic stroke confirmed by neuroimaging and clinical diagnosis
41267886|NCT05730387|OTHER|Observational only|This is a non-interventional study
41267887|NCT06225284|DRUG|Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg|After randomization, patients in the experimental arm (Arm A) will receive GnRH agonist injection within 3 days of randomization and during neoadjuvant chemotherapy treatment. The choice of GnRH agonist, including goserelin, leuprorelin and triptorelin giving in monthly, three-monthly or sixth-monthly, will be made by per investigator's discretion.
41267888|NCT00734084|DEVICE|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
41267889|NCT00862251|DRUG|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
41267890|NCT00862251|DRUG|simvastatin 40 mg or atorvastatin 20 mg|simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
41267891|NCT00862251|DRUG|Rosuvastatin|rosuvastatin 10 mg tablets, taken once daily for six weeks.
41093338|NCT00855192|BEHAVIORAL|mindful meditation|interpersonal and psycho-educational
41093339|NCT00855192|BEHAVIORAL|interpersonal therapy|psycho-educational
41093340|NCT02725203|BEHAVIORAL|Activate|The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
41093341|NCT01244828|DRUG|Asenapine|5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
41093342|NCT05646511|RADIATION|SCRT|5x5 Gy: 25 Gy
41442385|NCT05162222|DRUG|Danicamtiv|Specified dose on specified days
41442386|NCT05162222|DRUG|Itraconazole|Specified dose on specified days
41442387|NCT05162222|DRUG|Diltiazem|Specified dose on specified days
40920035|NCT06389656|BEHAVIORAL|Behavioral Weight Management|Prescription of diet and physical activity strategies, paired with behavioral strategies for weight management.
41093343|NCT05646511|DRUG|CAPOX|Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks
41093344|NCT05646511|DRUG|CAPOXIRI|Six cycles of CAPOXIRI capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 150 mg/m2 intravenously on day 1, every 3 weeks, if the initial dose of irinotecan 150 mg/m²/day is tolerated, the dose can be increased to 200 mg/m²/day from the second cycle
41093345|NCT06614348|DRUG|Prednisolone acetate eye drop group|Patients receive prednisolone acetate eye drops 4 times per 30min within 2 hours before cataract surgery
41267892|NCT00862251|DRUG|atorvastatin 10 mg or simvastatin 20 mg|All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
41267893|NCT06091839|OTHER|suturing technique in arteriovenous fistula creation for hemodialysis|End-to-side AV anastomosis was created in upper limb between cephalic vein and brachial or radial artery
41093346|NCT06614348|DRUG|Sodium hyaluronate eye drops|Patients receive sodium hyaluronate eye drops 4 times per 30min within 2 hours before cataract surgery
41267894|NCT04967131|OTHER|PNF exercises|PNF exercises were applied in 3 sets of 15 repetitions based on movement in the diagonal plane, using head, neck and chin patterns. Contractions were sustained for at least 10 seconds.
41093347|NCT04950543|BEHAVIORAL|Meditation|An online survey will be offered to participants who have enrolled in a 21-day meditation online course. The survey will be conducted using mobile website technology before and after the online course and additionally after 3 and 6 months.
41287147|NCT03962049|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
41093348|NCT05472649|BIOLOGICAL|Gene-Modified Cell Therapy|No investigational cell product will be administered
41287148|NCT00335712|DRUG|ONO-5129|
41287149|NCT05413447|COMBINATION_PRODUCT|Digital consult|Consultations will be prepared digitally using the Mychart patient portal, an elearning and questionnaires. The consultation takes place via Teams.
41287150|NCT01057303|GENETIC|RNA analysis|
41442388|NCT05294783|PROCEDURE|ACL reconstruction|ACL reconstruction is a standard surgery for ACL injured patients
41452969|NCT01875055|DEVICE|NIRS and Algorithm|NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
41093349|NCT01938664|DRUG|Candesartan with CBT|8 mg, po (by mouth)
41093350|NCT01938664|OTHER|Placebo with CBT|
41093351|NCT04230161|OTHER|Standard long-lasting insecticidal net|Yahe LN (Yamei Industry) contains a pyrethroid insecticide.
41093352|NCT04230161|OTHER|Chlorfenapyr insecticide treated net|Interceptor G2® (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
41093353|NCT04230161|OTHER|Indoor residual spraying|Fludora Fusion (Bayer Vector Control) is a spray containing two active ingredients: clothianidin, a neonicotinoid insecticide, and deltamethrin, a pyrethroid insecticide.
41093354|NCT00196911|PROCEDURE|Implantation of stimulation electrodes in the STN|
41287151|NCT01057303|GENETIC|gene expression analysis|
41287152|NCT01057303|GENETIC|reverse transcriptase-polymerase chain reaction|
41287153|NCT01057303|OTHER|laboratory biomarker analysis|
41452970|NCT01875055|DEVICE|NIRS derived cerebral oximetry|NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
41452971|NCT02064153|PROCEDURE|Cool dialysate|Each recruited patient undergoes a cool dialysate session ( 35.5ºC) and a warm dialysate session (37ºC). The sessions are minimum a week apart to remove the carryover effect.
41452972|NCT02064153|PROCEDURE|Warm dialysate|All recruited patients will undergo two study sessions - Cool dialysis (35.5ºC) and Warm dialysis (37ºC)
41452973|NCT03791307|OTHER|Traditional Pilates group|The participants will perform only exercises based on the traditional Pilates method, 2 times a week, for 50 minutes, for 16 weeks.
41452974|NCT03791307|OTHER|Modified Pilates group|The participants will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer, 2 times a week, for 50 minutes, for 16 weeks.
41452975|NCT00538863|DRUG|Fentanyl sublingual spray|Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
41452976|NCT02551640|OTHER|FeatForward App (on study smartphone)|"The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group."
41452977|NCT06454747|DRUG|SM-030 gel 0.64%|Topical application to face twice daily for 12 weeks
41452978|NCT06454747|DRUG|Placebo gel|Topical application to face twice daily for 12 weeks
41267895|NCT02024984|DRUG|Clomiphene Citrate|"Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle."
41267896|NCT00426348|DRUG|Valsartan|Valsartan (80-160mg/day)
41093355|NCT01691989|DRUG|aleglitazar|150 mcg orally once a day for 26 weeks
41093356|NCT01691989|DRUG|placebo|oral doses once a day for 26 weeks
41093357|NCT04530344|DRUG|ruxolitinib|ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
41093358|NCT04530344|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
41093359|NCT01270789|DRUG|Liraglutide|Liraglutide administered as once daily sc injection
41093360|NCT01270789|DRUG|placebo|placebo administered as once daily sc injection
41093361|NCT02321540|DRUG|Ibrutinib|"Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily."
41093362|NCT00823589|OTHER|Blood test and clinical test|Blood test and clinical test
41093363|NCT00451698|DRUG|acyanotic erythropoietin|Single dose IV push
41093364|NCT00451698|DRUG|acyanotic placebo|Single dose IV push
41267897|NCT00426348|DRUG|Probucol|Probucol (750mg/day)
40920036|NCT06389656|BEHAVIORAL|Weight Bias Internalization|Addressing weight stigma and improving weight-related self-perception, through challenging weight-related stereotypes, self-compassion, reducing self-criticism, and coping with weight stigma.
40920037|NCT01793870|DRUG|Tab carvedilol 25 mg|Carvedilol 25 mg immediate release tablet
40920038|NCT01793870|DRUG|Tab carvedilol 6.25 mg|Carvedilol 6.25 mg immediate release tablet
40920039|NCT01793870|DRUG|Powder carvedilol up to 2.5 mg|Carvedilol up to 2.5 mg isotopically enriched drug substance powder
40920040|NCT03997292|DRUG|Alteplase|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
40920041|NCT03997292|DRUG|Urokinase|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
41093365|NCT05042063|DEVICE|Hyfe Cough Tracker|"Hyfe Cough Tracker is a digital acoustic surveillance system that uses an artificial intelligence system to discriminate cough from non-cough sounds. Hyfe is an AI-enabled mobile app that records short snippets (\<0.5 seconds) of putative cough explosive sounds and then classifies them as cough or non-cough using a convolutional neural network (CNN) model. Briefly, the acoustic characteristics of recorded sounds are converted into an image file, which is then processed by an algorithm trained to identify graphical differences in images. This creates an adjustable prediction score, with values above it, resulting in a sound being classified as cough, and those below being classified as non-cough."
41267898|NCT00426348|DRUG|Placebo|Placebo
41267899|NCT03047499|DRUG|Botulinum toxin type A|Botulinum toxin type-A injection
41287154|NCT01689506|DRUG|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
41452979|NCT06454747|DRUG|SM-030 gel 0.08%|Topical application to face twice daily for 12 weeks
41452980|NCT00555893|DRUG|Oseltamivir|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight \<=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
41452981|NCT00555893|DRUG|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: \<=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
41452982|NCT05518331|DRUG|avatrombopag|Avatrombopag, 40-60 mg (body weight \< 80 kg, 40 mg per day; body weight \> 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.
41452983|NCT04980170|DRUG|Clindamycin 300 mg|patients will be given clindamycin 300 mg twice daily for 5 days after dental implant
41452984|NCT04980170|DRUG|Amoxicillin with Clavulanic Acid 635mg|patients will be given Amoxicillin with Clavulanic Acid 635mg, three times daily for 5 days after dental implant
41452985|NCT03559907|BEHAVIORAL|Cooking Matters for Parents|Cooking Matters for Parents focuses on teaching parents of young children important lessons about self-sufficiency in the kitchen. Participants have the opportunity to practice fundamental lessons including knife skills, reading ingredient labels, cutting up a whole chicken, and making a healthy meal for a family of four on a budget of ten dollars. Each session includes meal preparation, didactic teaching, and sharing the meal as a group. Instructors share their education and experience and discuss how to choose healthy, affordable fruits and vegetables at the grocery store. Each week, adults take home a bag of groceries after each class so they can practice the recipes taught that day.
41093366|NCT05042063|DEVICE|Hyfe Air|Hyfe Air is a wearable device with an incorporated wireless lapel microphone. The device´s recordings can be run through the same cough-detection algorithm used by Hyfe Cough Tracker, while its results are directly stored in a remote database and are not displayed to participants.
41093367|NCT05792046|DEVICE|Visual field|test for detecting loss in visual function
41133402|NCT04780152|DEVICE|Transcranial Direct Current Stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA). Anodal stimulation will be applied on F3 according to the intentional 10/20 system, and the cathode will be applied on the contra lateral position (F4).
41093368|NCT04514042|PROCEDURE|Peroral endoscopic myotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as peroral endoscopic myotomy. All the procedures will be documented with photographs or videorecordings.
41093369|NCT04514042|PROCEDURE|Flexible endoscopic septotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as flexible endoscopy septotomy. All the procedures will be documented with photographs or videorecordings.
41093370|NCT00239161|DRUG|Levofloxacin|
41093371|NCT06314256|BIOLOGICAL|Injection|İnterdental papilla will be injected by i-PRF.
41267900|NCT03837184|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
41267901|NCT05035121|DIETARY_SUPPLEMENT|milk supplement|Intervention groups provided 200 mL long life milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
41267902|NCT05035121|DIETARY_SUPPLEMENT|soy milk supplement|Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
41093372|NCT06314256|DRUG|Injection|Interdental papilla will be injected by Tesoyal PureSense Glabal Action HA gel.
41267903|NCT05035121|BEHAVIORAL|resistance exercise|The participants joined the resistance exercise training program, three times per week (30 min/time)
41093373|NCT04358861|PROCEDURE|Nonsurgical Root canal therapy|After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.
41093374|NCT04358861|DEVICE|Dental operating microscope|Dental operating microscope; a high magnification and illumination device was used in experimental group for performing nonsurgical root canal therapy.
41093375|NCT05186454|DRUG|Morphine Sulfate|analgesia
41093376|NCT05186454|DRUG|Bupivacaine|Analgesia
41093377|NCT05186454|DRUG|dexamethasone, morphine, midazolam|1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam
41093378|NCT01597518|DRUG|Riluzole|100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
41093379|NCT01597518|DRUG|Placebo|Placebo 2x in first 24 hours; Placebo 2x day 2--14
41093380|NCT02620189|DRUG|Anti-TNF Biologics Therapy|
41093381|NCT05090423|OTHER|balance training alone|"The subjects will warm up to stretch the lower extremity for 5 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
41093382|NCT05090423|OTHER|balance training and neurodynamic intervention for the common peroneal nerve|"The physical therapist will give the patient neurodynamic intervention for the common peroneal nerve, which is performed slider the nerve 2 seconds.~The slider technique is repeated 30 seconds for 4 times, each time can be take a rest 1 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
41093383|NCT02350361|DRUG|Recombinant human endostatin|Recombinant human endostatin 7.5mg/m2
41093384|NCT02350361|DRUG|Placebo|Placebo
41093385|NCT01972087|BEHAVIORAL|Telephone simulation training|The intervention consists of four 20-minute telephone simulation training sessions over a 4 month period (one session each month). Each 20-minute training session will include 3 simulated 9-1-1 calls, performed by a standardized caller (trained actor) and feedback will be provided right away by a trained observer who takes notes during the simulation calls and discusses the teaching points after the session. In total, the 9-1-1 dispatchers will receive 12 different simulated calls.
41093386|NCT00266097|DRUG|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
41093387|NCT00266097|DRUG|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
41093388|NCT00266097|DRUG|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
41093389|NCT00266097|RADIATION|radiation therapy|5040 cGy, every week, up to 6 weeks
41093390|NCT00266097|DRUG|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
41093391|NCT00266097|DRUG|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
41093392|NCT01986374|DRUG|HCG is introduced|must have good blastocysts
41093393|NCT05536466|PROCEDURE|bariatric surgery|bariatric surgery
41093394|NCT05040243|OTHER|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
41093395|NCT05040243|OTHER|placebo acupoint application|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
41093396|NCT01112072|DRUG|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
40920042|NCT06065098|BEHAVIORAL|Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD|The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension, diabetes, and hypercholesterolemia.
40920043|NCT02044107|BEHAVIORAL|Co-packaging and counseling messages|The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc \& ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc \& antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
40920044|NCT06282458|DRUG|Enobosarm|Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.
40920045|NCT06282458|DRUG|Semaglutide|Semaglutide for Chronic Weight Management
40920046|NCT04408222|OTHER|Awake proning|Prone positioning of awake, as tolerated, for up to 24 hours daily.
40920047|NCT00127270|DRUG|Darifenacin|Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
40920048|NCT00127270|DRUG|Darifenacin|Darifenacin tablets 7,5 mg or 15 mg once daily
40920049|NCT00127270|BEHAVIORAL|Behavioral therapy|Behavioral Modification Programme for symptoms of overactive bladder
40920050|NCT04865926|OTHER|Scapular and Neck Proprioceptive Neuromuscular Facilitation exercises|The researcher will perform a total of 12 sessions of scapular and neck pnf exercises for 4 weeks. The participants will apply PNF exercises using rhythmic initiation, rhythmic stabilization and cobination techniques of isotonics. Patterns of anterior elevation, posterior depression, anterior depression, posterior elevation will be used in scapular exercises. Upper cervical flexion, lower cervical flexion, rotation and lateral flexion patterns will be used in neck pnf exercises.
41093397|NCT03047590|BEHAVIORAL|Choice-based Exercise Intensity|Participants are instructed to choose whichever intensity they want, rather than regulate their intensity based on heart rate.
41093398|NCT03047590|BEHAVIORAL|Positive Affect Focus|Participants are instructed to focus on feeling good while exercising.
41093399|NCT03047590|BEHAVIORAL|Heart rate-based Exercise Intensity|Participants are instructed to regulate their exercise intensity based on their heart rate.
41093400|NCT06038071|OTHER|nutrition, IYCF, WASH education|nutrition, IYCF, WASH education
41093401|NCT06038071|OTHER|scheduled anthropometric screening|anthropometric screening by health care workers at 1, 3, and 6 months
41093402|NCT06038071|OTHER|family MUAC|family MUAC training for the primary caregiver present at the time of recovery
41093403|NCT00268411|DRUG|gemcitabine hydrochloride|
41093404|NCT00268411|DRUG|oxaliplatin|
41093405|NCT06268925|OTHER|Exercises|number of exercises will be guided to do through zoom
41093406|NCT04252937|DRUG|Adrecizumab|HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).
40920051|NCT04865926|OTHER|McKenzie and Kendall exercises|Kendall and Mckenzie exercises will be given to the participants as a home workout. The self-stretch exercise methods are as followed: Placing both hands on the shoulders and pushing out the chest, placing one hand over the shoulder and grasp the elbow of the turned hand, with the other hand over the head and slowly pull it inward, throwback the head until it has reached the fully stretched point, look straight ahead and slowly turn the head horizontally until the maximum value is reached, throwback the head, and turn it until it has reached the fully stretched point, lower the head turn it until it has reached the maximal point. Stretching pectoralis muscle, strengthening shoulder retraction, strengthening the deep cervical flexors, strengthening the deep cervical flexors.
40920052|NCT00763503|DRUG|CD 2027|3µg/g Oily Spray
40920053|NCT04510428|DRUG|Ocular Surface Immune Globulin (OSIG)|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
40920054|NCT04510428|DRUG|Placebo|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
40920055|NCT03071757|DRUG|ABBV-368|Intravenous infusion
40920056|NCT03071757|DRUG|ABBV-181|Intravenous infusion
40920057|NCT01604993|OTHER|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
40920058|NCT01604993|OTHER|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
40920059|NCT03140358|DRUG|Atropine sulfate 0.01%|Atropine 0.01%
40920060|NCT03140358|DRUG|Placebo|placebo
40920061|NCT03663556|OTHER|Infant-feeding|Preterm infants hospitalized in the NICU can be feed by three different types of infant feeding, such as breast milk, donor human milk and/or formulas.
40920062|NCT04903314|DRUG|Xcopri|Xcopri will be administered orally not to exceed 400mg/day adult equivalent
40920063|NCT00288899|OTHER|"Enhanced surgical iMedConsent process (with repeat back)"|"Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand."
40920064|NCT00288899|OTHER|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
40920065|NCT05605938|DRUG|Tenoten for children|Oral administration
40920066|NCT05605938|DRUG|Placebo|Oral administration
40920067|NCT01473368|DIETARY_SUPPLEMENT|Saccharomyces boulardii|500 mg, 2 times daily for 14 days
40920068|NCT01473368|DRUG|Amoxicillin Clavulanate|875/125 mg 2 times daily at least 1 hour before meals for 7 days
40920069|NCT00910507|BEHAVIORAL|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
40920070|NCT00910507|BEHAVIORAL|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
40920071|NCT04181814|DEVICE|Ultrasound|Use ultrasound to assess gastric contents in diabetic patients before anesthesia
40920072|NCT04135586|OTHER|Exercise training|Exercise program for 24 weeks (with neo-adjuvant treatment), with two sessions per week including both moderate-to-intense aerobic and resistance training. The intensity of each type of exercise will range between 65% and 100% of the maximum score in the Rated Perceived Exertion (RPE) scale.
41133403|NCT04780152|DEVICE|Placebo-simulation of transcranial direct current stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.
41133404|NCT04780152|DRUG|Fluoxetine Tablets|Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
40920073|NCT04135586|OTHER|Control|Yoga + educational program
40920074|NCT05734417|DIETARY_SUPPLEMENT|Probiotic|Oral administration of Bifidobacterium lactis subsp. infantis B8762 at 0.5x10 log colony forming unit (CFU)/day for 4-weeks
40920075|NCT05734417|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g/sachet of excipient administered daily for 4-weeks
40920076|NCT06385067|DEVICE|Biolimus Coated Coronary Artery Balloon Dilation Catheter|Patients with Coronary Artery Disease will be treated with Biolimus Coated Coronary Artery Balloon Dilation Catheter
40920077|NCT04176484|OTHER|Survey|Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
40920078|NCT02736890|DRUG|Botulinum Toxin A|Subjects will receive subcutaneous Botulinum Toxin A injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
41442389|NCT06480032|DEVICE|Blood Flow Restriction band|Blood Flow Restriction (BFR) band operate by partially occluding arterial blood flow to distal structures, but more significantly impeding venous outflow from under the cuff, thereby also hindering venous return. The compression of vasculature proximal to the skeletal muscle leads to inadequate oxygen supply (hypoxia) within the muscle tissue, resulting in a localized hypoxic environment. Additionally, the reduction in venous blood flow causes blood to accumulate in the capillaries of the occluded limb, often manifesting as visible erythema. This temporary restriction will be maintained for a duration of 8 weeks.
40920079|NCT02736890|DRUG|Placebo|Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
40920080|NCT00967824|OTHER|informational intervention|
40920081|NCT00967824|OTHER|questionnaire administration|
40920082|NCT00967824|OTHER|survey administration|
40920083|NCT00074698|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm description.
40920084|NCT04321447|OTHER|Clinical practice guideline for prevention and management of extravasation injury|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme for nurses
40920085|NCT04359381|OTHER|kinesiotaping application|kinesiotaping was applied once the menstrual pain begins (one day before menstruation) for periods of 4 to 5 days until the pain disappears and then removed it. Kinesiotaping was used for 3 successive menstruations.
40920086|NCT04359381|OTHER|Pilate exercises program|Each girl in group (B) was engaged in a supervised pilate exercises program for 30 minutes per session for 3 days/week for 12 weeks except days of menstruation. Participants would be oriented to wear comfortable clothes .
40920087|NCT00154089|DRUG|EM-1421|EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
40920088|NCT01131819|DEVICE|Nintendo Wii fit ™ balance board|Nintendo Wii fit ™ balance board will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects for a minimum of 6 times in two weeks and a maximum of 18 times in 6 weeks.
40920089|NCT00825253|DRUG|biphasic insulin aspart 30|
40920090|NCT00825253|DRUG|biphasic human insulin 30|
40920091|NCT04565808|PROCEDURE|primary percutaneous coronary intervention|Primary Percutaneous Coronary Intervention (PPCI), also known as angioplasty or coronary angioplasty, is a procedure used to diagnose and treat the narrowed coronary arteries of the heart.
41133405|NCT00003654|DRUG|patent blue V dye|
40920092|NCT01860183|DRUG|Mycophenolate mofetil|Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
40920093|NCT01394640|BIOLOGICAL|Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus|The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.
40920094|NCT05668611|OTHER|Primary Training Phase|A four-day training program taken over the course of two weekends will include materials on RHD and RHD echocardiographic screening using focused artificial intelligence navigational guided echocardiographic acquisition to identify patients who are screen positive or screen negative for RHD. The echo protocol will be limited to the parasternal long axis-view (2D and color Doppler) focusing on mitral and aortic valve morphology and function and a single 2D apical 4 chamber view for auto EF. The curriculum package will include online modules, instructor delivered PowerPoint presentations, and hands on practice on volunteers with and without RHD.
40920095|NCT05668611|OTHER|Primary Assessment Phase|A pre- and post-training test on RHD knowledge and diagnosis will be administered. A rapid competency assessment, including obtaining imaging on volunteers with or without RHD and an online test with pre-recorded cases of RHD, LV dysfunction and Pericardial effusions, will be utilized at the end of the 4-day training sessions. Trainees will be monitored by trained study personnel and at the end of the practicum training, the expert users will blindly review and assess the quality of each study using the standardized scale and competency scorecard provided below. Additionally, they will be asked to pass the knowledge quiz (80% or better). If competency is not achieved, an additional weekend of training can be added.
40920096|NCT05668611|OTHER|Primary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of one month. A minimum total of 400 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants (at least 5 participants per day). At the end of each screen, the trainees will interpret the screen as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
40920097|NCT05668611|OTHER|Secondary Training Phase|Each Primary Trained MOH Nurse will train 3 other nurses from their Health Center using pre-recorded PowerPoints.
40920098|NCT05668611|OTHER|Secondary Assessment Phase|The secondarily trained nurses will be assessed and certified by the nurse trainer.
40920099|NCT05668611|OTHER|Secondary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of two months. A minimum total of 1200 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants. At the end of each screen, the trainees will interpret the study as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
40920100|NCT00300742|DRUG|Topiramate|Topiramate up to 300 mg per day.
40920101|NCT05254145|DIAGNOSTIC_TEST|Next Generation Sequencing|During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.
40920102|NCT05423860|OTHER|no interventions will be performed (observational)|Not applicable. (no interventions will be performed with this observational study
40920103|NCT00597597|DRUG|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
40920104|NCT00108108|DRUG|HCD122|
40920105|NCT03663400|DIAGNOSTIC_TEST|GWAS analysis by Illumina BeadChip|will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
40920106|NCT04583137|DRUG|Lidocain|Layngeal direct fiberoptic examination transnasaly
40920107|NCT05990595|DIETARY_SUPPLEMENT|Adlay with white rice|We will investigate the lipid- and glucose-lowering effects of Adlay rice in comparison to white rice through a randomized cross-over trial.
40920108|NCT05990595|DIETARY_SUPPLEMENT|white rice|white rice
40920109|NCT00502411|DRUG|Doxorubicin|17.5 mg/m\^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
41133406|NCT00003654|PROCEDURE|lymphangiography|
41267904|NCT06056947|DRUG|EVEGYN A|EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
41267905|NCT06056947|DRUG|EVEGYN B|EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
40920110|NCT00502411|RADIATION|Radiation Therapy|Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
40920111|NCT05180396|OTHER|Questionnaires|Application of a study based questionnaire described in the protocol
41133407|NCT00003654|PROCEDURE|radionuclide imaging|
41267906|NCT06056947|DRUG|Gynomax® XL Vaginal Ovule|200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)
41267907|NCT04334382|DRUG|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight \< 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of \>20.
41267908|NCT04334382|DRUG|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
41267909|NCT04223609|DRUG|Oxycodone|5 mg tablet
41267910|NCT04223609|DRUG|Placebo|Oxycodone-matched placebo tablet
41267911|NCT04223609|DEVICE|EyeLink 1000 Plus|Non-invasive video-based eye tracking system
41267912|NCT04223609|DIAGNOSTIC_TEST|Oculo-Cognitive Addition test (OCAT)|Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.
41267913|NCT04223609|DEVICE|VT3mini - Eye Tracking Technology for OEMs|Non-invasive eye-tracking device
40920112|NCT03129399|DEVICE|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
41267914|NCT05986942|DRUG|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
41267915|NCT05986942|DRUG|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
41287155|NCT01689506|DRUG|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
40920113|NCT03129399|DEVICE|McGrath MAC video laryngoscope|nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
40920114|NCT05607212|OTHER|Kettlebell Swing|Participants will perform two-handed kettlebell swings using the interval training protocol outlined in the study carried out by Jay et. al. (2011). The protocol calls for 30 seconds of work, followed by 30-60 seconds of rest for a total of 10 intervals. The mechanics of the kettlebell swing will follow those outlined in the study carried out by McGill et. al. (2012). All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability. The weight is higher than previous and similar study by Brandon et al to ensure measurable differences between experimental and comparison groups.
40920115|NCT05607212|OTHER|Isometric Hold|Participants will perform an isometric hold of a kettlebell for 30 seconds followed by 30 seconds of rest for a total of 10 intervals. Participants will mimic initial kettlebell swing position by standing shoulder width apart with their back straight, and hips and knees flexed. Participants will be cued to squeeze their glutes and look straight ahead while they hold the weight for the 30 second interval. All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability.
40920116|NCT05607212|OTHER|Control|Control group: participants will be educated on the benefit of a kettlebell swing.
40920117|NCT05942781|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 7 days, a 6-day washout period, and a 7-day no-training period.
40920118|NCT05942781|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
40920119|NCT05278351|DRUG|Tislelizumab Combined With Cetuximab and Irinotecan|Tislelizumab (an anti-PD-1 monoclonal antibody) Cetuximab (monoclonal antibody against EGFR) Irinotecan
40920120|NCT05278351|DRUG|Third-line regimens|Trifluridinetipiracil or Regorafenib or Fruquintinib
40920121|NCT04953988|PROCEDURE|Robotic TKA|Robotic TKA
40920122|NCT04953988|PROCEDURE|Manual operation|Manual operation
40920123|NCT05070780|DEVICE|Robot-assisted examination|evaluation of muscle tone with Robot-assisted perturbation
41133408|NCT00003654|PROCEDURE|sentinel lymph node biopsy|
41133409|NCT00003654|RADIATION|technetium Tc 99m sulfur colloid|
41133410|NCT02808234|PROCEDURE|One or two level lumbar interbody fusion surgery|One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.
41133411|NCT02808234|OTHER|Nucel|Allograft derived from human amnion and amniotic fluid
41267916|NCT01422954|DRUG|Chloroquine prophylaxis|Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.
40920124|NCT05981781|PROCEDURE|ultrasound guided peng block in paediatric hip surgery|"On the supine position, under strict aseptic technique, a linear, high-frequency transducer (5-13 MHz) of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed in the transverse plane along the anterior inferior iliac spine (AIIS) to identify the iliopsoas muscle, femoral artery, and femoral nerve. The probe will be then rotated, and aligned with the pubic ramus to visualize the AIIS, iliopubic eminence (IPE), femoral artery, psoas muscle, and the superior pubic ramus.~Under direct visualization, a needle will be advanced in-plane, lateral to medial between the psoas tendon and pubic ramus until the needle contacts the IPE. The needle will be slightly withdrawn, and following negative aspiration, 0.5 ml/kg of bupivacaine 0.25% will be injected."
41093407|NCT05037656|BEHAVIORAL|School-based curriculum|Participants will be randomized, at the school level, to receive either the e-cigarette/tobacco/areca nut use prevention curriculum or the standard of care (i.e., control). The curriculum will be implemented using 5 intensive in-class lessons over the span of 6 weeks. All sessions of the curriculum follow the same basic format: a) an introduction and/or review of the past lesson, b) a cultural wall activity, c) a video, d) 1-2 interactive activities, and e) a wrap-up activity. Lessons are designed such as to help improve knowledge about drugs and correct cognitive misperceptions and to train on skills to resist normative social influence. Participants will complete identical survey questionnaires for assessments at 3 time-points: pretest (baseline, before implementing the intervention), immediate posttest (following the end of the intervention), and six-month follow-up. The surveys will be administered in the classroom, during regular school hours.
41267917|NCT01422954|DRUG|Mefloquine prophylaxis|Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
41267918|NCT01422954|BIOLOGICAL|Immunization|Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
41267919|NCT01422954|BIOLOGICAL|Controlled Human Malaria Infection|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
41267920|NCT01422954|DRUG|Malarone|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
41267921|NCT02765282|DEVICE|Algorithm based programming using Kinesia-based assessment|DBS-Expert includes a tablet-based software application (app) for guiding DBS programming and a Kinesia motion sensor unit for automated motor assessment. Algorithms search the programming parameter space to resolve an optimal set of programming parameters.
41267922|NCT02509559|DRUG|propranololhydrochloride|oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites
41287156|NCT01635569|BEHAVIORAL|Group-based family cognitive-behavioural therapy|Baseline and post-12 sessions
40920125|NCT05981781|PROCEDURE|ultrasound guided caudal epidural block in paediatric hip surgery|On lateral decubitus position, under strict aseptic technique, the sacral hiatus will be visualized at the level of the sacral cornua by employing a linear, high-frequency transducer (5-13 MHz) of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed transversely at the midline to obtain a transverse view of the two cornua, sacrococcygeal ligament, sacral bone, and sacral hiatus. At this level, the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and subsequently placed between the two cornua. A needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. (17) At this level, after confirming absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute while observing an ultrasound longitudinal image.
40920126|NCT02890641|GENETIC|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
40920127|NCT03713905|DRUG|GLS-010|Recombinant Human Anti-PD-1 Monoclonal Antibody
40920128|NCT05250544|OTHER|control group|For the adolescents in the control group; As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
40920129|NCT02558647|BEHAVIORAL|CBT for insomnia (CBT-I)|CBT-I is an online, fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
40920130|NCT02558647|BEHAVIORAL|Psycho-Education about Sleep (PE)|PE provides online information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
40920131|NCT01771809|DRUG|75mg SHP647 (PF-00547659)|75 mg sterile liquid injected subcutaneously every 4 weeks.
40920132|NCT01771809|DRUG|225mg SHP647 (PF-00547659)|225 mg sterile liquid injected subcutaneously every 4 weeks.
40920133|NCT00835029|DRUG|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
40920134|NCT00835029|DRUG|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
40920135|NCT00003076|DRUG|eflornithine|
40920136|NCT04830098|OTHER|Spinal stabilization exercises|It will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
41267923|NCT02509559|DRUG|placebo|oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
41267924|NCT02509559|DEVICE|Net Station® System and compatible Geodesic Sensor Nets®|Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
41267925|NCT02509559|DEVICE|VITAPORT|Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.
41287157|NCT01635569|OTHER|Waitlist|Baseline and post-12 sessions
40920137|NCT04830098|OTHER|Chiropractic manipulation|It will be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
40920138|NCT02956590|DRUG|Pitavastatin|Statin
40920139|NCT02956590|DRUG|Placebo|Placebo
40920140|NCT03931135|DRUG|IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section|"The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped"
40920141|NCT02968056|PROCEDURE|Radiofrequency ablation|Radiofrequency energy is used for ablation in both arms of this study (Hybrid group and MIS group)
40920142|NCT03820700|BEHAVIORAL|Hypnosis (Hypn)|The hypnosis session will consist of a 20-minute hypnosis recording created by Marie-Elisabeth Faymonville and recorded by Anne-Sophie Nyssen, both professionals in hypnosis from University of Liège. The recording includes suggestions about relaxation, corporal sensations, respiratory techniques and visual imaginative stimuli about a beautiful landscape. With this tool, the hypnosis session is standardized for all patients and there is no need of a psychotherapist to deliver hypnosis.
40920143|NCT03820700|BEHAVIORAL|Virtual reality (VR)|VR sessions. This session will consist in using a head-mounted 3D graphical display with goggles. With this tool, participants will be able to visualize a 3D immersive landscape for 20 minutes consisting of a shed near a lake at sunrise followed by a relaxing moment in the clouds. The session ends on the lake's edge.
40920144|NCT03820700|BEHAVIORAL|Virtual reality hypnosis (VRH)|The combined tool sessions. Participants will be simultaneously subjected to the same hypnosis recording and 3D visual stimuli used in the Hypn and VR conditions.
40920145|NCT04668027|DIAGNOSTIC_TEST|impulse oscillation（IOS）|The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.
40920146|NCT04668027|DIAGNOSTIC_TEST|bronchial provocation test(BPT)|Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).
40920147|NCT04668027|DIAGNOSTIC_TEST|bronchial dilation test(BDT)|The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
40920148|NCT02522624|BEHAVIORAL|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
40920149|NCT00001012|DRUG|AL 721|
40920150|NCT04049877|OTHER|None - Observational study|None - Observational study
40920151|NCT00635258|DRUG|triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)|0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.
40920152|NCT00635258|DRUG|GnRH antagonist (Orgalutran®)|GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
40920153|NCT02689921|DRUG|Exemestane|Aromatase inhibitor
40920154|NCT02689921|DRUG|Letrozole|Aromatase inhibitor
40920155|NCT02689921|DRUG|Anastrozole|Aromatase inhibitor
40920156|NCT02689921|DRUG|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
40920157|NCT02689921|DRUG|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
40920158|NCT02689921|DRUG|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
40920159|NCT01221285|BIOLOGICAL|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
40920160|NCT02672696|DEVICE|FluoroMap 3D|Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
40920161|NCT04228133|BEHAVIORAL|Attention Control Training (ACT)|A home-delivered version of ACT will be administered in this study. ACT will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV). In addition, sessions will include video conference with the experimenter. This condition has found to be more effective in PTSD symptom reduction compared to ABM.
41093408|NCT06372483|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
41093409|NCT06372483|DRUG|Placebo|VMX-C001 matched placebo
41093410|NCT06372483|DRUG|Rivaroxaban 20 mg Oral Tablet|Fxa DOAC
41093411|NCT06372483|DRUG|Apixaban 5 mg Oral Tablet|Fxa DOAC
41093412|NCT06372483|DRUG|Edoxaban 60 mg Oral Tablet|Fxa DOAC
41093413|NCT02718469|BIOLOGICAL|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
41093414|NCT02718469|BIOLOGICAL|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
40920162|NCT04228133|BEHAVIORAL|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this study. ABM will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat. In addition, sessions will include video conference with the experimenter. This condition has found to be have an inferior effect on PTSD symptom reduction compared to ACT, and thus, this ABM condition has been chosen as a control condition.
41093415|NCT02718469|BIOLOGICAL|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
41093416|NCT02718469|BIOLOGICAL|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
41093417|NCT05477862|BEHAVIORAL|Clinically Designed Improvisatory Music|Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients.
41093418|NCT03971357|DRUG|Netarsudil|netarsudil opthalmic solution 0.02%
40920163|NCT05289518|DEVICE|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 220mmHg and 5-min deflation.
41093419|NCT03971357|DRUG|Placebo|Placebo eye drops
41093420|NCT01982019|BEHAVIORAL|Meal test taking and hormones measure including 26RFa|Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
41093421|NCT03241888|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
41093422|NCT03241888|DEVICE|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
40920164|NCT05289518|DEVICE|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
40920165|NCT04921813|OTHER|3 dimensional scoliosis exercise|Schroth exercises
40920166|NCT04921813|OTHER|Balance Exercise|Balance-coordination exercises
40920167|NCT04921813|OTHER|Brace treatment|Brace usage
40920168|NCT00950820|DRUG|Oxaliplatin, Capecitabine, Panitumumab|"Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15."
41093423|NCT02135783|PROCEDURE|Decompressive Craniectomy|A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.
41093424|NCT02135783|PROCEDURE|non-Decompressive Craniectomy|a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
41093425|NCT05727956|PROCEDURE|Aneurysmectomy|Complete aneurysmectomy with end-to-end anastomosis for the true aneurysm or partial aneurysmectomy with a direct repair.
41093426|NCT05756439|DRUG|Intravenous Sedatives with or Without Analgesia|Participants having dental surgery with conscious intravenous sedation
41093427|NCT05756439|DRUG|No IV sedation|Participants having dental surgery without conscious intravenous sedation
41093428|NCT06581874|OTHER|Clinical assessment by emergency psychiatrist|After a clinical assessment by the emergency department psychiatrist which does not lead to hospitalization, the patient will be given a psychiatric interview and sent home.
41093429|NCT06581874|OTHER|Psychiatric consultation booked through Med@Psy platform|The patient will be seen within 48 hours after the consultation with his or her general practitioner by a psychiatrist taking part in the study.
41093430|NCT00119743|BIOLOGICAL|undecavalent pneumococcal-protein D conjugate vaccine|
41093431|NCT02739568|DRUG|Pitolisant (BF2.649)|
41093432|NCT02739568|DRUG|Placebo|
41093433|NCT02552550|PROCEDURE|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
41093434|NCT04254679|DRUG|Opioid analgesics|"Current standard of care in the participating centers Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2) and a supply of opioids to be used as a rescue in case of breakthrough pain.~The specific round-the-clock analgesia and rescue opioid regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
41093435|NCT04254679|DRUG|Non-opioid analgesics|"Prescription of around-the-clock non-opioid analgesics (acetaminophen alone or combined with NSAIDs/COX-2).~The specific non-opioid analgesia regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
41093436|NCT04517851|BIOLOGICAL|Elotuzumab|Given IV
41093437|NCT04517851|OTHER|Questionnaire Administration|Ancillary studies
41093438|NCT06614010|DRUG|Dexmedetomidine Injection|Before anesthesia induction, an iliac fascia block was administered using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, dexmedetomidine was infused intravenously at a rate of 0.5 µg/kg/h.
41093439|NCT06614010|DRUG|Ropivacaine and Dexmedetomidine|Before anesthesia induction, an iliac fascia block was administered using a mixture of 0.375% ropivacaine and 1ug/kg dexmedetomidine (30ml) under ultrasound guidance. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
41133412|NCT03965949|DRUG|Hormone Replacement cycle 1|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
40920169|NCT00950820|DRUG|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
40920170|NCT02694757|DEVICE|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
41133413|NCT03965949|DRUG|Hormone Replacement cycle 2|Hormone Replacement cycle with GnRHa suppression
41267926|NCT02509559|DEVICE|ergoselect II 100/200|Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
40920171|NCT05949034|DEVICE|JUUL E-Cigarette Device|We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.
40920172|NCT00909207|BEHAVIORAL|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
40920173|NCT04122469|RADIATION|Stereotactic Body Radiotherapy|The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
40920174|NCT00913458|DRUG|etanercept|
40920175|NCT05471713|OTHER|Autonomic dysfunction|Autonomic dysfunction
40920176|NCT00093405|DRUG|tanespimycin|
40920177|NCT02663934|BEHAVIORAL|Exercise|The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.
40920178|NCT02663934|BEHAVIORAL|Stretching and Social Interaction|Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.
40920179|NCT01714791|OTHER|Usual care|Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
40920180|NCT01714791|OTHER|Osteopathic treatment|"Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:~* Structural High Velocity Low Amplitude-techniques.~* Muscle Energy Techniques.~* General osteopathic mobilisations.~* Functional techniques (Sutherland-, Jones-techniques,...) including inhibition techniques.~* Fascia techniques.~* Soft tissue- and connective tissue techniques.~* Neurovisceral and neurolymphatic reflex techniques.~* Fluidal techniques (lymphatic manipulative techniques,...).~* Visceral manipulations.~* Neurocranial and viscerocranial techniques."
40920181|NCT04705493|OTHER|fluid resuscitation with crystalloid|give two-volume of fluids initial 250ml then another 250 ml
40920182|NCT02779322|PROCEDURE|Minigastric bypass|The patient will be submitted to a minigastric bypass at the time of the operation
40920183|NCT02779322|PROCEDURE|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
40920184|NCT00689260|DEVICE|easypod|Subjects is aware that the device records injection information that can be viewed by user
40920185|NCT00689260|DEVICE|easypod|Subjects is not aware that the device records injection information that can be viewed by user
40920186|NCT05600777|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
40920187|NCT05600777|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
40920188|NCT01853618|DRUG|Tremelimumab|3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
40920189|NCT01853618|PROCEDURE|RFA|Performed on Day 36
40920190|NCT01853618|PROCEDURE|TACE|Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
40920191|NCT01853618|PROCEDURE|Cryoablation|Performed on Day 36
40920192|NCT02895126|BEHAVIORAL|"Appui Parental program"|
40920193|NCT02895126|BEHAVIORAL|Regular parental support|
40920194|NCT05526300|DEVICE|Intelligent Hypertension Management System|The intelligent hypertension management system is used to remotely detect the blood pressure of hypertensive patients
41093440|NCT06614010|DRUG|Sodium Chloride Injection|Before anesthesia induction, an iliac fascia block was performed using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
41093441|NCT05592613|DEVICE|Next-generation Reader and ID-Cap System|The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.
41093442|NCT05592613|DRUG|Truvada for pre-exposure prophylaxis (PrEP)|Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total.
41093443|NCT05592613|DRUG|Biktarvy for antiretroviral therapy (ART)|Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total.
41093444|NCT02162940|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
40920195|NCT05526300|OTHER|The standard care|The standard care
41093445|NCT02162940|OTHER|The SF 36 test|The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
41093446|NCT05168371|BEHAVIORAL|Cognitive-Behavioural Therapy - Online (CBT-O)|"Face-to-face CBT was adapted for web-based self-directed therapy. CBT-O was found to be feasible and usable (Stephenson et al., 2021; Zippan et al., 2020).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to CBT; 2) The cognitive model and thought records; 3) Unhelpful thinking patterns; 4) Cognitive restructuring; 5) Behavioral experiments; 6) Self-touch and sensate focus; 7) Sensate focus with your partner; and 8) Maintaining (and extending) your gains."
41093447|NCT05168371|BEHAVIORAL|Mindfulness-Based Therapy - Online (MBT-O)|"The content of MBT-O was adapted from an efficacious face-to-face mindfulness intervention for women with Sexual Interest/Arousal Disorder (Brotto et al., 2021; Paterson et al., 2017). MBT-O was found to be feasible and usable (Brotto et al., under review).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to mindfulness; 2) Increasing awareness of physical sensations in the body; 3) Exploring movement and body image; 4) Awareness of sexual thoughts and beliefs; 5) Working with aversion, self-touch; 6) Exploring sexual sensations, knowing limits; 7) Integrating the partner into mindful touching; and 8) Maintaining (and extending) your gains."
41093448|NCT05777057|DIAGNOSTIC_TEST|Diagnodent|using DIAGNDENT depends on the principle that when 655nm wavelength of Diode laser is irradiated on dental surface, intraoral bacteria metabolites will absorb it and then metabolites emit a red fluorescence. The dental surface will reflect this fluorescence and gives number between 0 and 99 on the screen of the DIAGNdent.
41093449|NCT06488599|RADIATION|Peri-apical radiographs on the implants|Peri-apical radiographs on the implants supporting the prosthesis
41093450|NCT06122935|DEVICE|Aurora Xi New Nomogram Software 2.0|Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.
41093451|NCT06122935|DEVICE|Aurora Xi Currently Approved Software 1.3|Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System
41093452|NCT01054430|DRUG|avanafil|200 mg avanafil tablets QD
41267927|NCT02509559|DEVICE|SpiroScout|Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
40920196|NCT03162913|DIETARY_SUPPLEMENT|Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
40920197|NCT03162913|OTHER|Placebo|12g red, strawberry-flavored powder, twice daily with water, for 90 days
41093453|NCT04440943|DRUG|CDX-527|CDX-527 is administered by infusion every 2 weeks
40920198|NCT01639729|DRUG|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
41093454|NCT01438229|DEVICE|St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)|Catheter-based RF ablation in renal artery
41093455|NCT01014338|DRUG|Fosinopril|10mg od
41093456|NCT01014338|OTHER|lactose|placebo
41093457|NCT01572077|RADIATION|FTHA, FDG PET imaging.|Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
41093458|NCT04818320|DRUG|Favipiravir|Day 1: 1800mg BD, day 2-5: 800mg BD
41093459|NCT06467864|PROCEDURE|bronchoscope|We will perform bronchoscopy and collect bronchoalveolar lavage fluid (BALF) samples at the time of patient enrollment and three days after the treatment.
41093460|NCT05247489|DRUG|Ruxolitinib 1.5% cream|Ruxolitinib cream 1.5% applied twice a day (BID).
41093461|NCT05247489|DEVICE|NB-UVB phototherapy|NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit
41093462|NCT03185429|BIOLOGICAL|Tumor Specific Antigen-loaded Dendritic Cells|Subjects will be given subcutaneous injection of 5.0x10\^6-1.0x10\^7 TSA-DC on week 1,3,5,11,17,23,35,47.
41093463|NCT03185429|DRUG|Cyclophosphamide|300 mg/m2 by vein before the first cell infusion.
41267928|NCT02509559|DEVICE|Mobil-O-Graph® PWA|Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
40920199|NCT01639729|DRUG|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
40920200|NCT01639729|DRUG|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
40920201|NCT01639729|DRUG|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
41093464|NCT03031639|PROCEDURE|Endoscopic approach thyroidectomy|Thyroid surgery using endoscopy.
41093465|NCT04123002|OTHER|Miswak chewing sticks|Chewing stick are routinely used by this population
40920202|NCT05128708|PROCEDURE|combined medial and caudal approach right hemicolectomy open and laparoscopic|resection of right colon cancer by this radical approach
41093466|NCT00852475|DIETARY_SUPPLEMENT|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA MOVE!diet and exercise program
41093467|NCT00852475|DIETARY_SUPPLEMENT|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA MOVE! diet and exercise program
41093468|NCT01235585|DRUG|Placebo|Oral doses, once a day for 52 weeks
41267929|NCT02509559|PROCEDURE|Saliva collection|Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
41267930|NCT06543433|DEVICE|Skincubator 2|"The Skincubator is a small incubator designed to attach to the caregiver's torso without any barrier between the parent's chest and the baby. It creates an environment with the advantages of a standard neonatal incubator, while enabling Skin to Skin contact for extended periods from birth. It has multiple access points, to allow for common nursing procedures. It is anchored safely to the parent's body and secures ventilator and IV tubing. It also includes side ports for the parents to insert their hands to touch their baby.~The investigators will offer the parents in the intervention group the opportunity to perform Skincubator care for as long as they want to each day during the week after enrolment. The investigators will provide the parents with the aids to accomplish this goal: the Skincubator system with a convenient environment, the option for Skincubator surrogates and, where possible, the option for one of the parents to sleep with the baby safely secured in the Skincubator."
41267931|NCT04828824|DRUG|Ethinyl Estradiol / Norgestimate Oral Tablet|Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.
41093469|NCT01235585|DRUG|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
41093470|NCT01235585|DRUG|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
41093471|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for either transfemoral or transapical access and any of the 3 valve sizes (23, 26 or 29)
41093472|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transapical or transaortic access and any of the 3 valve sizes (23mm, 26mm or 29mm)
41093473|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transfemoral access and requiring a 29mm valve.
41093474|NCT02272699|DRUG|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
41093475|NCT02272699|DRUG|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
41093476|NCT02272699|DRUG|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
41093477|NCT02272699|RADIATION|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
41093478|NCT02272699|PROCEDURE|Surgery|Esophagectomy
41093479|NCT01327469|DRUG|Albendazole, 2 x 400mg|Albendazole 2 x 400mg
41093480|NCT01327469|DRUG|Albendazole 400mg|Albendazole 400mg
41093481|NCT01327469|DRUG|Mebendazole 500mg|Mebendazole 500mg
41267932|NCT03037281|DIAGNOSTIC_TEST|Septic|30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.
41093482|NCT01327469|DRUG|Mebendazole 2 x 500mg|Mebendazole 2 x 500mg
41093483|NCT01327469|DRUG|Pyrantel-oxantel + mebendazole|Pyrantel-oxantel + mebendazole
41093484|NCT06070597|DRUG|Iclepertin|Iclepertin
41093485|NCT06070597|DRUG|Iclepertin Placebo|Placebo to Iclepertin
41093486|NCT06070597|DRUG|Moxifloxacin|Moxifloxacin
41093487|NCT06070597|DRUG|Moxifloxacin Placebo|Placebo Moxifloxacin
41093488|NCT01930279|OTHER|Blood withdrawal|Blood withdrawal
41093489|NCT02905513|BEHAVIORAL|Contraceptive app instant messages|
41093490|NCT02905513|OTHER|Mobile phone app|
41093491|NCT03836664|DRUG|Timolol|Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
41093492|NCT03836664|DRUG|Placebo|Placebo is normal saline solution that will be supplied in container matched to Timolol container.
41093493|NCT05798728|PROCEDURE|Outpatient transcervical foley balloon|These participants will receive a 16-French Foley catheter which will be placed by a physician present in the clinic. The balloon will be inflated with 40 mL of sterile water, and the catheter will then be gently withdrawn so that the balloon applies pressure against the internal os. The catheter will then be taped to the inner thigh.
41093494|NCT05798728|PROCEDURE|Inpatient Vaginal Misoprostol|These participants will receive 25 micrograms of Misoprostol (100- microgram tablet cut into fourths by the hospital pharmacist) inserted vaginally into the posterior fornix every 4 hours and repeated up to a maximum of six doses per our standard hospital protocol.
41093495|NCT04623723|OTHER|PS (DS-016A, EMS® Piezon, Switzerland) scaler tips. )|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using PS (DS-016A, EMS® Piezon, Switzerland) scaler tips
41093496|NCT04623723|OTHER|Conventional (FS-407, EMS® Piezon, Switzerland)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using Conventional (FS-407, EMS® Piezon, Switzerland)
41093497|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement containing adherence markers|The supplement will be provided once daily for 10 days
41267933|NCT00510276|DRUG|Atomoxetine hydrochloride|20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
41093498|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement containing or not containing adherence markers|The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.
41093499|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement not containing adherence markers|The supplement will be provided once daily for 10 days
41093500|NCT05518110|DRUG|Trametinib|2mg of Trametinib (orally) daily.
40920203|NCT00375401|DRUG|CP-945,598 Treatment A|Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling
41093501|NCT05518110|DRUG|Hydroxychloroquine|1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.
41093502|NCT01687270|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
41093503|NCT01687270|DRUG|RBV|Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
41093504|NCT02435901|DRUG|alemtuzumab (Campath IH)|Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
41093505|NCT02435901|DRUG|Fludarabine|Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
41093506|NCT02435901|DRUG|Melphalan|Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
41093507|NCT02435901|DRUG|Cyclosporine|Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
41093508|NCT02435901|DRUG|Mycophenolate mofetil|Immunosuppressant to prevent graft vs host disease is given on Day -1.
41093509|NCT02435901|DRUG|Tacrolimus|Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
41267934|NCT00510276|DRUG|Placebo|twice a day, by mouth for 12 weeks
41267935|NCT05410990|DIAGNOSTIC_TEST|eosinophil and other hematological parameters|
41287158|NCT05102201|DEVICE|Paro (social robot) intervention|Participants in the Paro group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks
40920204|NCT00375401|DRUG|CP-945,598 Treatment B|Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling
40920205|NCT00375401|DRUG|Placebo|Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
40920206|NCT03733990|BIOLOGICAL|FP-1305 (bexmarilimab)|The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
41093510|NCT02435901|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
41093511|NCT05233085|DRUG|AZD4041|Participants will receive oral solution of AZD4041 as stated in arm description.
41093512|NCT05233085|OTHER|Placebo|Participants will receive oral solution of placebo as stated in arm description.
41093513|NCT02518906|BEHAVIORAL|Adolescent Identity Treatment|"Integrative Approach for the treatment of adolescents with Personality Disorder.~Manual was published in 2013."
41093514|NCT02518906|BEHAVIORAL|DBT-A|Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
41287159|NCT03117933|DRUG|Olaparib|Tablet, 100mg and 150mg
41093515|NCT06614166|OTHER|SBD111 Probiotic Medical Food|Medical food comprised of probiotics and prebiotic fibers
41093516|NCT06614166|OTHER|SBD121 Probiotic Medical Food|Probiotic medical food comprised of three lactic acid bacteria and one bacillus
41093517|NCT06314425|PROCEDURE|Immediate dental implants placements on fresh sockets after tooth extraction|Zirconia dental implants (SDS®, Swiss Dental Solution, Kreuzlingen, Switzerland) are to be placed within the fresh extraction sockets. The immediate implants are placed using a minimally invasive technique without vertical releasing incisions. Implant placements are performed following the SDS osteotomy protocol after sulcus marginal and crestal incision or flapless surgery. The same surgeon places implants for all patients. Infected sites are debrided using piezo surgery touch.
41093518|NCT04445844|BIOLOGICAL|Pelareorep|Given IV
41093519|NCT04445844|OTHER|Quality-of-Life Assessment|Ancillary studies
41093520|NCT04445844|OTHER|Questionnaire Administration|Ancillary studies
41287160|NCT03117933|DRUG|Cediranib|Tablet 15mg and 20mg
41093521|NCT04445844|BIOLOGICAL|Retifanlimab|Given IV
41093522|NCT03356015|DRUG|4L Polyethylene Glycol|4L group received double-dose PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes.
41287161|NCT03117933|DRUG|Paclitaxel|Intravenous (IV)
41267936|NCT05438667|BIOLOGICAL|TCR-T therapy|"1.Preprocessing strategy：~1. Cyclophosphamide: 500mg/m², dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 60minutes, and 0.4g Mesna injected at 0hour, 4hours and 8 hours after cyclophosphamide,4days and 5 days before TCR-T cell infusion.~2. Fludarabine: 30mg/m² , dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 30minutes before 3 to 5days before TCR-T cell infusion.~2.Within 3 - 5 days after pretreatment, subjects will receive a single TCR-T reinfusion with an infusion dose of about 1 × 10⁹～1 × 10¹⁰.~3.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 (injection unit: 500000 units /m², once every 12 hours, subcutaneous injection) will be injected intravenously for 14 days (24 times in total).~4.After 3 months of treatment, If the subject did not occur tumor progression and did not occur adverse events (AEs) of level 3 or higher, a second TCR-T cell reinfusion can be performed ."
41267937|NCT05865184|OTHER|Data collection|Data collection of clinically relevant signals using home-based sensor system
41267938|NCT04863963|PROCEDURE|Milligan Morgan|Surgical intervention used in case of Goligher's grade III hemorrhoidal disease
41267939|NCT02771834|OTHER|Biomechanical analysis|
41267940|NCT02771834|OTHER|Kiphosis analysis|
41267941|NCT02771834|OTHER|Vitamin D level|
41267942|NCT04232826|BIOLOGICAL|single dose of CNCT19|"Dose A: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 4.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
41267943|NCT00323284|DEVICE|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
41267944|NCT00323284|PROCEDURE|Cataract surgery only|Cataract surgery only
41267945|NCT05170360|DIAGNOSTIC_TEST|Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:|"1. Assessment of smoking exposure:~   Serum cotinine will be measured by using serum cotinine ELISA kits~2. Assessment of heavy metal exposure:~   Lead and cadmium will be measured using Graphite Tube Atomizer.~3. Assessment of organophosphorus exposure:~   By measuring pseudocholinesterase level by spectrophotometer~4. Mutational analysis of the KRAS and BRAF genes:~the tissue samples will be used to determine the mutation in k-ras and BRAF genes by RCR"
41267946|NCT06252116|DRUG|Pregabalin group|Pregabalin group
41267947|NCT06252116|DRUG|Duloxetine group|Duloxetine group
41267948|NCT04230447|OTHER|No intervention|No intervention
41267949|NCT00240760|DRUG|Memantine Hydrochloride|
41267950|NCT06259799|BEHAVIORAL|Smart Water Bottle|Participants in the intervention group will receive a bottle which measures participant fluid consumption. The bottle will be set to recommend 2.5L for male participants and 2.0L for female participants, consistent with fluid intake recommendations from the European Food Safety Authority for each sex. Participants will be prompted by the bottle (bottle will light up) when they are behind on fluid intake recommendations. Participants will use a validated urine color chart, 9 point Likert scale for thirst, and measure nude body mass on their own each morning. Participants will be informed that higher values for nude body mass and thirst, and lower values for nude body mass each morning may indicate they are less hydrated day-to-day.
41267951|NCT03420534|DRUG|Iloperidone 1 MG|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
41267952|NCT03420534|DRUG|Placebo|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
41267953|NCT03420534|DIETARY_SUPPLEMENT|fasting|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
41267954|NCT03420534|DIETARY_SUPPLEMENT|postprandial|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
41267955|NCT01554657|OTHER|5 Days of Antibiotics|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
41267956|NCT01554657|OTHER|7 Days of Antibiotics therapy for pneumonia|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
41267957|NCT01800942|DRUG|Azithromycin and Placebo|A single oral dose of 2g of Azithromycin will be given to the women in labour
41267958|NCT00540891|DRUG|ALFUZOSIN|
40920207|NCT02850471|DEVICE|electroacupuncture|Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
41267959|NCT04405219|OTHER|The Relationship Between Preoperative Smoking Cessation, Anxiety, Pain|Preoperative anxiety high score suggests stress related to surgery and anesthesia. High anxiety scores independent of post-operative pain showed smoking withdrawal.
41267960|NCT05357456|BEHAVIORAL|Cognitive function assessment; functional magnetic resonance imaging|cognitive function measurement
41267961|NCT05357456|PROCEDURE|laparoscopic adrenal surgery|Only a subgroup of the autonomous cortisol secretion patients will have the laparoscopic adrenal surgery
40920208|NCT06085976|DRUG|Octreotide|"A loading dose of 100 mcgr of octreotide will be administered in the intervention group, diluted in 100 ml of SSF to be passed in 30 minutes.~Subsequently, it will be administered in continuous perfusion at 25 mcgr/h in the intervention group.~The drug can be administered through a peripheral or central venous line at the choice of the anesthesiologist, since the drug has a density that allows its administration by both routes."
41267962|NCT02958943|BEHAVIORAL|On-screen electronic alert|On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
41267963|NCT04239326|DIAGNOSTIC_TEST|targeted Next Generation Sequencing (tNGS)|The index tests used in this trial will include up to three end-to-end, targeted next generation sequencing (tNGS) solutions for diagnosis of DR-TB. Each solution will include all of the equipment, reagents, and software necessary for handling the entire sequencing workflow, including DNA extraction from processed sputum samples (i.e. sediment), library preparation, sequencing, and data analysis/interpretation for clinical result reporting.
41267964|NCT04572009|OTHER|Bio-mathematical model|bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
41267965|NCT04572009|OTHER|Without bio-mathematical model|No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
41267966|NCT05409287|PROCEDURE|Immediate Implant Loading|A single implant crown will be mounted on the implant immediately after implant placement
41267967|NCT05409287|PROCEDURE|Early Implant Loading|A single implant crown will be mounted on the implant 4 weeks after implant placement.
41267968|NCT06206889|OTHER|NAS|NAS Turkish language validation will be carried out. NAS and CNSI scores will be recorded during the shifts of nurses serving patients in Level 3 intensive care units by the nurse in charge and another independent evaluator, and the correlation between the two scores will be investigated.
41267969|NCT06370416|DRUG|Trilaciclib|After pathological diagnosis of NSCLC, 40 eligible subjects who met the inclusion criteria were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing informed consent.
41267970|NCT00046228|DRUG|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
41267971|NCT00046228|DRUG|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
41267972|NCT00046228|DRUG|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
41267973|NCT00046228|DRUG|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
41267974|NCT00046228|DRUG|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
41267975|NCT00046228|DRUG|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
41267976|NCT03011645|DRUG|Ziprasidone|Given by mouth, single dose of 60 mg.
41267977|NCT03011645|DRUG|Lorcaserin|Given by mouth, single dose of 20 mg.
41267978|NCT03011645|DRUG|Placebo Oral Tablet|Given by mouth, single dose.
41267979|NCT03655834|DRUG|Pemetrexed|patients will be administered a microdose with subsequent pharmacokinetic assessment.
41267980|NCT05014477|PROCEDURE|Removal or leaving of LAA occluders|After LAA device embolization there are different approaches to dealing with the occluder dislocation. The aim is to find out which way leads to the best outcomes.
41267981|NCT02296060|PROCEDURE|6 minutes walking test|
41267982|NCT05316714|PROCEDURE|Nanofat grafing|NANOFAT REGENERATIVE SURGICAL GRAFTING IN PRNILE ALBUGIANEA OF PATIENTS AFFECTED BY PEYRONIES' DISEASE
41267983|NCT04338490|DEVICE|Feedback mannequim|The intervention group received rcp training with their performance being evaluated in real time so that they could correct themselves
41442390|NCT06480032|DEVICE|Non-Blood Flow Restriction band|The Occlusion Band/Blood Flow Restriction (BFR) band functions by partially restricting arterial blood flow to distal structures, with a more pronounced effect on venous outflow from under the cuff, thereby impeding venous return. Proximal compression of the vasculature leads to inadequate oxygen supply (hypoxia) in the skeletal muscle tissue. Additionally, reduced venous blood flow causes blood to accumulate in the capillaries of the occluded limb, often manifesting as visible erythema. This temporary restriction will be maintained for a duration of 8 weeks, facilitating targeted exercise training and rehabilitation.
41442391|NCT02704585|DEVICE|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
41093523|NCT03356015|DRUG|3L Polyethylene Glycol|3L group were instructed to drink 1L PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes
41442392|NCT02704585|DEVICE|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
41442393|NCT03578939|PROCEDURE|Biopsy EUS guided|NGS Sequencing on Biopsy samples
41267984|NCT02380755|DRUG|Clomiphene Citrate|50 mg orally daily during 12 weeks
41267985|NCT02380755|DRUG|Placebo|1 pill orally daily during 12 weeks
40920209|NCT06085976|OTHER|Placebo|In the case of the control group, 100 ml of SSF will be administered to be passed in half an hour and then an perfusion of SSF.
40920210|NCT02068898|DRUG|XS003|
40920211|NCT02068898|DRUG|Tasigna|
40920212|NCT03349398|PROCEDURE|Uncut Roux-en-Y reconstruction|Uncut Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
40920213|NCT03349398|PROCEDURE|Roux-en-Y reconstruction|Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Roux-en-Y construction will be used in this group.
40920214|NCT00361634|DRUG|Etanercept|
41093524|NCT06004167|RADIATION|Adaptive Bridging Radiation Therapy (ABRT)|Radiation Therapy
41267986|NCT05758090|PROCEDURE|NIPE monitor|Procedure/Surgery: NIPE protocol. Give intraoperative fentanyl according to NIPE value. NIPE score 50-70 indicates optimal narcotic effect. NIPE score \> 70 indicated overdosage of narcotic and narcotic should be withheld. NIPE score \< 50 indicates inadequate narcotic and narcotic should be given.
41267987|NCT05758090|PROCEDURE|Control|Procedure/Surgery: Standard protocol. Give intraoperative fentanyl according to vital signs.
41267988|NCT01552902|DRUG|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
41267989|NCT01552902|DRUG|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
41267990|NCT01552902|DRUG|Placebo|Daily oral dosing in the AM for 6 weeks
41267991|NCT01727089|BIOLOGICAL|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
41267992|NCT01727089|BIOLOGICAL|Bevacizumab|Given IV
41267993|NCT01727089|OTHER|Laboratory Biomarker Analysis|Correlative studies
41267994|NCT01727089|OTHER|Pharmacological Study|Correlative studies
41267995|NCT03543683|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
41267996|NCT03543683|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
41267997|NCT03529409|BEHAVIORAL|Project Khanya|This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
41267998|NCT00002550|DRUG|cisplatin|
41267999|NCT00002550|DRUG|etoposide|
41268000|NCT00002550|PROCEDURE|conventional surgery|
41268001|NCT00002550|RADIATION|radiation therapy|
41268002|NCT02964598|BEHAVIORAL|Gamified intervention|A new mobile application for assisting in sleep regulation, duration 4-6 weeks
41268003|NCT02964598|BEHAVIORAL|Sleep coaching|A new personalized program, duration 4-6 weeks
41268004|NCT02964598|DEVICE|Bright light|Morning bright light 10 000 lux maximum duration 4-6 weeks
41268005|NCT02964598|OTHER|Control|Minimal information on sleep timing and advancing the sleep rhythm
41268006|NCT02964598|OTHER|Psychoeducation|An extensive information platform in the internet created for this purpose
41268007|NCT02977923|DEVICE|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
41268008|NCT02977923|OTHER|Standard pharmacological treatment|according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
41268009|NCT01231165|DRUG|Amiloride|5mg/daily for 12th months
41268010|NCT01231165|DRUG|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
41268011|NCT02507804|OTHER|Patient diary PROMs|
41268012|NCT02507804|OTHER|Counselling|
41268013|NCT01722513|DRUG|Alprostadil ﹠control|control:Normal salin 1cc/kg/hr before and after angiography
41268014|NCT02432547|DRUG|Aflibercept|Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
41268015|NCT02432547|PROCEDURE|Targeted laser therapy|In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
41268016|NCT06037356|DEVICE|Prostatic Urethral Lift|Prostatic urethral lift uses permanent implants to retract the prostate lobes away from the prostate urethra to allow unobstructed passage of urine. These implants are made of Nitinol, non-absorbable monofilament suture material (Poly Ethylene Terephthalate), Stainless Steel
41268017|NCT06037356|PROCEDURE|TURP|Using monopolar or bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH
41268018|NCT00397332|DRUG|Alefacept|IM Alefacept
41268019|NCT02591264|OTHER|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
41268020|NCT00061256|DRUG|Alendronate|
41268021|NCT00061256|DRUG|Calcium carbonate|
41268022|NCT00061256|DRUG|Vitamin D|
41268023|NCT02921386|DRUG|Oral Testosterone Undecanoate|All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
41268024|NCT01756729|DEVICE|NovoTTF-100A|Multiple four-week courses of continuous NovoTTF-100A treatment.
41268025|NCT00003490|BIOLOGICAL|sargramostim|
41268026|NCT00003490|DRUG|cyclophosphamide|
41268027|NCT00003490|DRUG|prednisone|
41268028|NCT00003490|DRUG|vincristine sulfate|
41268029|NCT04175145|OTHER|Posterior spinal instrumentation|A fusion construct consisting of all pedicle screws except at uppermost instrumented vertebra. Contoured dual 6-mm stainless steel rods were used to connect the construct. Pedicle screw location and density was determined by the surgeon based on perceived curve stiffness and fusion length with an even distribution of fixation points along the construct. Pedicle screw instrumentation was performed by the free hand technique with biplanar fluoroscopic and direct screw EMG impedance testing for confirmation of placement. Reduction was via cantilever-segmental-translation maneuver in all cases.
41268030|NCT04532788|PROCEDURE|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
41268031|NCT04532788|PROCEDURE|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
40920215|NCT03271645|BEHAVIORAL|Space from Depression|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
41093525|NCT04910347|DRUG|Nivolumab|"Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks.~As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs."
41268032|NCT01412229|DRUG|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
41093526|NCT02601703|DRUG|Tacrolimus Ointment 0.1%|apply thin layer of ointment to affected area
41268033|NCT01412229|DRUG|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
41268034|NCT01412229|DRUG|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
41268035|NCT06314087|OTHER|Placebo + conventional treatment including radiotherapy|Placebo + conventional treatment including radiotherapy
41268036|NCT06314087|COMBINATION_PRODUCT|Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine|The peptide vaccine treatment will take 5 months as a treatment course until the treatment suspension event as stipulated in the plan occurred.
41268037|NCT05731921|BEHAVIORAL|The exercise program with the 'Empathy Dress'|The experimental group will be given an exercise program that includes a total of eight sessions (two months) of 'Empathy Dress' and some exercises (stairs going up and down, sitting up, putting on trousers, tying shoes, etc.), every week and 20 minutes per week, by the researchers.
41268038|NCT00582556|DRUG|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
41268039|NCT00582556|DRUG|zometa|GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6
41268040|NCT00582556|DRUG|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
41268041|NCT01352481|OTHER|Early parent-based speech intervention program|Seven 1h sessions during a three-month period.
41268042|NCT00825604|PROCEDURE|Percutaneous coronary angioplasty (PCI)|optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
41268043|NCT00003141|BIOLOGICAL|filgrastim|Given IV
41268044|NCT00003141|DRUG|carboplatin|Given IV
41268045|NCT00003141|DRUG|cisplatin|Given IV
41268046|NCT00003141|DRUG|cyclophosphamide|Given IV
41268047|NCT00003141|DRUG|etoposide|Given IV
41268048|NCT00003141|DRUG|thiotepa|Given IV
41268049|NCT00003141|DRUG|vincristine sulfate|Given IV
41268050|NCT00003141|PROCEDURE|conventional surgery|
41268051|NCT00003141|PROCEDURE|peripheral blood stem cell transplantation|
41268052|NCT03713190|COMBINATION_PRODUCT|Empagliflozin|Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.
41268053|NCT03713190|DRUG|Placebo|A substance without specific pharmacology principles
41268054|NCT00797420|DRUG|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
41268055|NCT00797420|DRUG|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
41268056|NCT03184844|DRUG|Thalidomide|thalidomide:50mg/d p.o at bedtime
41268057|NCT02930174|DEVICE|noninvasive positive pressure ventilation|Application of various levels of positive pressure
41268058|NCT01596179|BEHAVIORAL|Interactive navigational support|Interactive navigational support is provided by a nurse and social worker navigators
41268059|NCT01596179|BEHAVIORAL|Internet access|a netbook computer with internet access is provided to participants on the control arm.
41268060|NCT03567902|DEVICE|C-MAC videolaryngoscope intubation|C-MAC videolaryngoscope intubation
41268061|NCT03567902|DEVICE|Direct laryngoscope intubation|Direct laryngoscope intubation
41268062|NCT04977206|OTHER|Mutual Goal-Setting Education|Nurses will receive both written and verbal instruction on mutual goal-setting with patients using SMART methodology
41268063|NCT02126059|BEHAVIORAL|Reminiscence|"The 10 session topics include Happy to seeing you, Childhood stories, Food flavor, Our old songs, Festival, My family, My Carrier, Unforgettable events, My home, and My award.~small group intervention (8-12 per group), expected total number of group is 5."
41268064|NCT02126059|BEHAVIORAL|Cognitive stimulation|"The 10 session topics include psycial activities, sound, face, food, word association, number and games, being creative, categorizing objects, orientation, and team qiuz.~small group intervention (8-12 per group), total number of group is 5."
41268065|NCT02126059|BEHAVIORAL|Aroma-massage|Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
41268066|NCT02630953|BEHAVIORAL|Original Tailored Intervention|The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
41268067|NCT02630953|BEHAVIORAL|Enhanced Tailored Intervention|Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
41268068|NCT01598376|PROCEDURE|7/0 vicryl suture|7/0 vicryl test suture placed as one of 3 everting sutures
41268069|NCT01598376|PROCEDURE|5/0 vicryl test suture|5/0 vicryl test suture placed as one of 3 everting sutures
41268070|NCT00457496|BEHAVIORAL|Cognitive, behavioral, exercise|Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
41268071|NCT02613455|PROCEDURE|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
41268072|NCT02613455|DRUG|Kenalog (triamcinolone)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
41268073|NCT02613455|DRUG|lidocaine 1% (lidocaine HCl 20mg)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
41268074|NCT04742335|OTHER|Survey|Survey will be applied to the participants.
41268075|NCT02775032|BEHAVIORAL|Advance care planning conversations between patients and their GP|
41268076|NCT06220006|PROCEDURE|Pulmonary vein isolation|Catheter ablation
41268077|NCT02459379|RADIATION|MRI Scan|MRI will be performed for clinical reason for which no other imaging study will provide the data required on patients with pacemaker or implantable defibrillator
41268078|NCT03222427|DRUG|LY3314814|Administered orally
41268079|NCT03222427|DRUG|[13C415N3] LY3314814|Administered as an IV infusion
41268080|NCT00934102|DEVICE|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
41268081|NCT00934102|DEVICE|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
41268082|NCT00934102|DEVICE|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
41268083|NCT02016599|OTHER|Monitoring and biospecimen collection|The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.
41268084|NCT02862769|DRUG|Lidocaine|. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
41268085|NCT02862769|DRUG|Saline|The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
41268086|NCT01578031|DEVICE|Positive Airway Pressure During Sleep (ResMed S9 Elite)|Positive airway pressure during sleep (ResMed S9 Elite).
41268087|NCT01578031|OTHER|Usual Care|Usual care.
41268088|NCT02947919|BEHAVIORAL|Music|A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
41268089|NCT04030000|DRUG|Paclitaxel/Carboplatin|IV paclitaxel in combination with IP carboplatin
41268090|NCT04030000|RADIATION|Pelvic radiation therapy|EBRT and vaginal brachytherapy
40920216|NCT03271645|BEHAVIORAL|Space from Anxiety|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
41268091|NCT04350333|BEHAVIORAL|CBT-I|Strategies and techniques of Cognitive behavioral therapy for insomnia adapted for pregnant women: stimulus control; sleep hygiene; sleep restriction; cognitive control etc.
41268092|NCT04350333|BEHAVIORAL|Assertive communication training|Intervention based on improving assertive communication and regulating emotions.
41268093|NCT04248205|DRUG|Ketamine|Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
41268094|NCT00000148|PROCEDURE|Argon Laser Trabeculoplasty|
41268095|NCT00000148|PROCEDURE|Trabeculectomy|
41268096|NCT06385704|PROCEDURE|DMR Procedure|Endoscopic procedure
41268097|NCT03932552|OTHER|Exercise|aerobic exercise program during 2 + 12 weeks, highly monitored and tailored to individual physical capacity.
41268098|NCT03932552|OTHER|nutritional therapy|individualised nutritional intervention
41268099|NCT06329479|BEHAVIORAL|Cognitive behavioural therapy for Insomnia (CBT-I)|A psychoeducational and evidence-based skills and strategies course for insomnia delivered online over four lessons through ThisWayUp. This will be completed during an 8-week feasibility trial.
41268100|NCT06329479|DEVICE|Bright Light Therapy|Daily bright light therapy for 30 minutes on waking delivered using the Lumie-L light box during an 8-week feasibility trial.
41268101|NCT06329479|BEHAVIORAL|Individualised activity plan|An individualised activity plan is created at baseline and adjusted weekly aiming to increased daytime physical activity and reduce sedentary behaviours. The activity plan takes into consideration personal interests, perceived barriers to activity and develops an activity plan using Specific Measureable Achievable Realistic and Timely (SMART) goals. This will take place during an 8-week feasibility trial.
41268102|NCT06329479|OTHER|Clincial review|Two clinical reviews will take place during an 8-week feasibility trial and consider uncontrolled symptoms, medication and blood test abnormalities which may impact on rest and physical activity levels
41268103|NCT03623789|DRUG|intravenous application of tranexamic acid|intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later.
41268104|NCT03623789|DRUG|Floseal hemostatic matrix|application of Floseal® on potential bleeding sites after prosthesis implantation
41268105|NCT03623789|DRUG|Normal saline|Equivalent volume of saline injection before incision, followed by two boluses (1g TXA) three hours later and six hours later.
41268106|NCT00388947|DEVICE|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
41268107|NCT00002884|DRUG|chemotherapy|
41093527|NCT02601703|DRUG|Protopic® ointment, 0.1%|apply thin layer of ointment to affected area
41093528|NCT02601703|DRUG|Placebo of Tacrolimus Ointment|apply thin layer of ointment to affected area
41093529|NCT00522184|PROCEDURE|intra-articular injection of etanercept|
41268108|NCT00002884|DRUG|cisplatin|
41268109|NCT00002884|DRUG|fluorouracil|
41268110|NCT00002884|RADIATION|brachytherapy|
41268111|NCT00002884|RADIATION|radiation therapy|
41268112|NCT06154967|RADIATION|tereotactic body radiotherapy|In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used
40920217|NCT03271645|BEHAVIORAL|Space from Stress|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014).The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
40920218|NCT03271645|BEHAVIORAL|Face-to-face counselling|Face-to-face counselling
40920219|NCT04451213|DIAGNOSTIC_TEST|MRI head|MRI head
41268113|NCT01592994|BEHAVIORAL|RHANI WIves|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
40920220|NCT02524483|BEHAVIORAL|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
41268114|NCT03568890|DRUG|Rivaroxaban, dabigatran, apixaban, or edoxaban|Duration of treatment: 60 days
41268115|NCT03568890|DRUG|Clopidogrel -75 mg/day|Duration of treatment: 60 days
41268116|NCT03568890|DRUG|Low dose aspirin -80 to 125 mg/day-|Duration of treatment: 60 days
41268117|NCT05349955|OTHER|Intensive guideline algorithm implementation|Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C\<7%, control blood pressure \<130/80mmHg， LDL-c\<1.8mmol/L at very high CV risk patients or \<2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.
41268118|NCT05349955|OTHER|Conventional guideline algorithm implementation|The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.
41268119|NCT05960565|DRUG|Glucagon|A micro-dose of glucagon is added exactly at the same site as insulin is injected.
41268120|NCT05863715|BEHAVIORAL|Visual Search Cue Type|Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.
40920221|NCT02524483|BEHAVIORAL|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
41268121|NCT05085509|PROCEDURE|US guidance and MB staining|Ultrasound guidance and methylene blue staining
41268122|NCT01483677|OTHER|Nintendo Wii|Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
41268123|NCT01483677|OTHER|Playstation 2|Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
41268124|NCT06160401|DRUG|Singletine|Singletine orally administered
41268125|NCT06160401|DRUG|Placebo|Placebo orally administered
41268126|NCT05836454|OTHER|Progressive Muscle Relaxation Group:|Progressive muscle relaxation is a relaxation technique that involves regular and sequential contraction and relaxation of muscles until the whole body is relaxed.
41268127|NCT05836454|OTHER|Myofascial Release Technique Group|It is a physiotherapy technique based on soft tissue mobilization. All enveloping fascia sale prices are positive for mobility, a user used for adhesions and pain.
41268128|NCT05504200|OTHER|Bladder and Pelvic Floor Muscle Training|The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call.
41268129|NCT05184907|BEHAVIORAL|Remote Motivational Enhancement (RME) Intervention Arm|Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing within 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
41268130|NCT05184907|OTHER|Information Only|Participants randomized to the information-only arm will have their CAT-MH, BAM, and PSS screening report results sent to their primary B/N prescriber and will encouraged to set up an appointment with their prescriber within 14 days to discuss the results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
41268131|NCT03849326|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
41268132|NCT03849326|BIOLOGICAL|blood test|complete blood count and cytokine concentration
41093530|NCT00522184|PROCEDURE|intra-articular injection of steroid|
41268133|NCT03849326|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
41268134|NCT03849326|DEVICE|actigraphy|assessment of sleep quality
41268135|NCT03849326|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging (optional)"
41287162|NCT03888495|BEHAVIORAL|Gender Socialization Training workshop|Hands-on training workshops including lectures, group activities, role play and group discussions focused on gender socialization.
41268136|NCT05847478|OTHER|Auricular acupressure of traditional Chinese Medicine|"The participants will be randomly assigned to receive the auricular point patch therapy.~The selected acupoints include Shenmen, hungry point, endocrine, stomach, mouth and subcortical. The opaque patch with vaccaria seed is used for acupoint pressing. Pressing the acupoints once a day before and after eating, each time for 1 minute, lasting for 2-3 days, follow up visit once a week. The intervention period is 3 months."
41268137|NCT05847478|BEHAVIORAL|Intermittent low carbohydrate diet|"The participants will be randomly assigned to the intermittent low carbohydrate diet group.~The intermittent carbohydrate diet includes 7 days of low carbohydrate diet within 2 weeks (consecutive or nonconsecutive, carbohydrate intake be controlled as ≤ 50g per day). The study duration is 3 months, including 1-month intervention period and 2-month self-maintenance period."
41268138|NCT05847478|BEHAVIORAL|Health education|Health education is conducted once a week during 3-month intervention for all participants. Health education including the understanding of childhood obesity and cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
41268139|NCT03859284|OTHER|flowable resin composite|gold standard
41268140|NCT03859284|OTHER|self adhering flowable|moist bonding self adhering flowable composite
41268141|NCT03859284|OTHER|self adhering flowable with adhesive|moist bonding self adhering flowable composite with the aid of an adhesive system.
41268142|NCT01206569|DRUG|Long-acting tacrolimus (Advagraf, Astellas Pharma)|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
41268143|NCT05203250|RADIATION|Heavy-ion therapy (hadrontherapy)|Only data available from routine clinical practice at the National Center for Oncological Hadrontherapy (CNAO), based Pavia, will be collected. Intervention is not assigned.
41268144|NCT06124989|DIAGNOSTIC_TEST|MINERVA Machine Learning model|The MINERVA score for the prediction of the risk of relapse of acute pancreatitis in patients who did not undergo early cholecystectomy after the first episode of acute biliary pancreatitis will be grounded upon a Machine Learning model that takes into account patients' demographic, clinical, and laboratory variables that can be easily collected and recorded at index patient admission.
41268145|NCT02747524|OTHER|Vita Mamba peanut butter paste|
41268146|NCT06050135|OTHER|Roadmap to Parenthood|web-based decision support
41268147|NCT06050135|OTHER|Informational Booklet|web-based informational booklet about young adult cancer survivorship
41268148|NCT00976144|DRUG|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
41268149|NCT02818699|DIETARY_SUPPLEMENT|Placebo|280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
41268150|NCT02818699|DIETARY_SUPPLEMENT|EMIQ|280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
41268151|NCT02773797|DRUG|IN-DEX 1.0 mcg/kg, intranasal saline|
41268152|NCT02773797|DRUG|IN-DEX 1.5 mcg/kg, intranasal saline|
41268153|NCT02773797|DRUG|Placebo - Saline|
41268154|NCT02162862|BEHAVIORAL|Behavioral Counseling|
40920222|NCT03339154|OTHER|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from chickpeas and 3 levels from chickpeas with rice.
40920223|NCT02576184|DEVICE|Biologic Mesh|Biologic mesh placed in retromuscular position during ileostoma closure
41268155|NCT02162862|DRUG|bupropion-SR|
41268156|NCT02203149|DRUG|Grazoprevir|One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
41268157|NCT02203149|DRUG|Elbasvir|One 50 mg tablet taken orally once daily for 12 weeks.
41268158|NCT02203149|DRUG|Placebo to Grazoprevir|One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
41268159|NCT02203149|DRUG|Placebo to Elbasvir|One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
41268160|NCT02772757|BEHAVIORAL|standard hearing aid fitting|standard hearing aid, face-to-face fitting
41268161|NCT02772757|BEHAVIORAL|coupler-based fitting|coupler-based fitting using average RECDs
41268162|NCT02772757|BEHAVIORAL|coupler-based fitting|coupler-based fitting using measured RECDs
41268163|NCT05145621|DRUG|Fingolimod 0.5 mg capsules- Test drug|An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.
41268164|NCT04134650|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
41268165|NCT04134650|DRUG|Metformin|Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
41268166|NCT04371367|BIOLOGICAL|avdoralimab|intravenous administration of avdoralimab
41268167|NCT04371367|OTHER|Placebo|intravenous administration of placebo
41268168|NCT03157531|DEVICE|B-Laser™ Atherectomy System|The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
41268169|NCT02468648|DRUG|Sofosbuvir|An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection
41268170|NCT02468648|DRUG|GS-5816|An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
41268171|NCT02862314|BIOLOGICAL|Blood sample|
41268172|NCT02984800|OTHER|Anesthesia induction|All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.
41268173|NCT02984800|OTHER|PVB injection at L1-L2|Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.
41268174|NCT02984800|OTHER|PVB injections at T12-L1, L1-L2 and L2-L3.|Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.
41268175|NCT03831087|DIAGNOSTIC_TEST|TAVR-CMR|CMR protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
41268176|NCT03831087|DIAGNOSTIC_TEST|TAVR-CT|CT protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
40920224|NCT02576184|DEVICE|Synthetic Mesh|synthetic mesh placed in retromuscular position during ileostoma closure
41268177|NCT05590572|DRUG|Sulfatinib|(1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
41268178|NCT05590572|DRUG|Etoposide|(1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
41268179|NCT05590572|DRUG|Isophosphamide|(1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
40220860|NCT06051994|DEVICE|AI-guided VA ablation|Ablation of ventricular arrhythmia as guided by the ablation index, using Carto 3 electroanatomic mapping system, QDOT Micro ablation catheter, and multipolar mapping catheters (Optrell, Decanav)
41093531|NCT02818816|DRUG|brimonidine tartrate 0.2%|Alpha adrenergic receptor agonist
41268180|NCT02690909|DEVICE|Redy™ Renal Denervation System|Renal Denervation System
41268181|NCT00135629|BIOLOGICAL|Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).|Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).
41268182|NCT00135629|OTHER|Placebo Injection|Placebo Injection
41093532|NCT02818816|OTHER|Carboxymethylcellulose Eye Drops|Ocular lubricants
41268183|NCT00135629|PROCEDURE|Venepuncture: 100ml blood sample taken on 12 separate visits|Venepuncture: 100ml blood sample taken on 12 separate visits
41268184|NCT06428214|DEVICE|Restylane Shaype|Injection
41442394|NCT06124339|BEHAVIORAL|Physical Activity|There will be three sessions a week over the course of 16 weeks.
41442395|NCT06124339|BEHAVIORAL|Cognitive Activity (VR)|There will be three sessions a week over the course of 16 weeks.
40920225|NCT01368562|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the arm.
41093533|NCT00092560|DRUG|MK0653, ezetimibe|
41093534|NCT00092560|DRUG|Comparator: fenofibrate monotherapy|
41093535|NCT02663258|DRUG|Pembrolizumab|
41093536|NCT03379415|DEVICE|Footwear|Different types of footwear will be tested to see if these can be used to help slow the progression of osteoarthritis in meniscectomy patients or even stop it from occurring.
41268185|NCT06428214|DEVICE|Restylane Defyne|Injection
41268186|NCT06428214|DEVICE|Restylane Lyft lidocaine|Injection
41268187|NCT01880411|BIOLOGICAL|PEK Fusion Protein Vaccine|PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
41268188|NCT01690845|DEVICE|MARS|Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
41268189|NCT03180892|OTHER|The investigators did not apply any intervention for the participants.|The investigators did not apply any intervention for the participants.
41268190|NCT05356767|PROCEDURE|Pharmacomechanical thrombolysis|Pharmacomechanical thrombolysis
41268191|NCT04209231|OTHER|1.25(OH)2D3|
41268192|NCT04209231|OTHER|25(OH)D|
41268193|NCT02338102|OTHER|Saline mixture|premeasured salt packets mixed with distilled water
41268194|NCT02719340|PROCEDURE|short segment fixation|posterior short-segment decompression and reconstruction (instrumentation on 1 level above and 1 level below the fractured vertebrae with posterolateral fusion)
41268195|NCT00203684|DRUG|Flunisolide-HFA|
41268196|NCT05590520|PROCEDURE|Botulinum injection|Botox injection to be injected in internal anal sphincter to see the curative response in comparison to gtn cream application
41268197|NCT05590520|DRUG|GTN OINTMENT|0.2%GTN applied on anal canal.
41268198|NCT02351102|DRUG|Valacyclovir|
41268199|NCT02351102|DRUG|Placebo|
41268200|NCT04116021|OTHER|PECS block|Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %
41268201|NCT04116021|OTHER|Local infiltration|Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %
41268202|NCT00808444|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A (different lots)|Intramuscular injection, 3 doses
41268203|NCT00808444|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
41268204|NCT00808444|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, only for Visit 2 in Singapore
41268205|NCT00808444|BIOLOGICAL|Rotarix|Oral, 2 doses
41268206|NCT06464107|DEVICE|PadKit™ from Preprogen|"The interlabial pad is classified as a Class 1 device by the FDA and the device is exempt from requiring a 510(k) approval.~The interlabial pad is worn for 4-6 consecutive hours and collects cells shed from the cervix and uterine cavity. The pad is then removed and placed in the smaller, inner tube that contains the transport solution. After replacing the lid securely, it is then carefully placed back inside the larger outer tube with the outer lid secured and returned to the original box. The entire box is placed in the polybag and mailed back to the lab for analysis."
41268207|NCT06088927|DEVICE|Conduction system pacing|Conduction system pacing (His Bundle Pacing or Left Bundle Branch Area Pacing)
41268208|NCT05444712|PROCEDURE|Chemotherapy + follow up|"* Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
41268209|NCT05444712|PROCEDURE|Chemotherapy + ASCT + follow up|"* Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* The fifth or sixth cycles should be used as stem-cell mobilizing chemotherapy for patients with ASCT strategy~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* Patients with in Complete Response after 6 cycles will receive a High Dose Therapy as conditioning regimen before transplantation~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
41268210|NCT02662478|PROCEDURE|Laparoscopic Surgery|Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
41268211|NCT04272593|DEVICE|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.
41268212|NCT04171739|DRUG|Itraconazole oral solution|200 mg once daily on Days 6 to 15
41268213|NCT04171739|DRUG|Rifampicin Oral Capsule|600 mg once daily on Days 6 to 15
41268214|NCT04171739|DRUG|Olorofim|Single oral dose on Days 1 and 11
41268215|NCT03886844|DIETARY_SUPPLEMENT|Human milk fortifier based on human milk (Prolacta)|Intervention is started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity, afterwards a human milk fortifier based on bovine milk is administered until estimated date of birth or 52 weeks corrected for prematurity (weight \<10. percentile) according to ESPGHAN(=European Society for paediatric gastroenterology, hepatology and nutrition) guidelines
41268216|NCT05373550|BEHAVIORAL|Effectiveness of a nursing educational intervention on quality of life, sexual function, and self-esteem in hysterectomized women: a mixed method approach.|Effectiveness of a nursing educational intervention supported by a technological tool (Libre mujer), on quality of life, sexual function and self-esteem in hysterectomized women: a mixed method approach.
41268217|NCT05105386|DEVICE|SynAir-Child|Monitor the indoor pollutants and their effect on children well being
41268218|NCT00465257|DRUG|artesunate + amodiaquine|
41268219|NCT02567448|OTHER|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
41268220|NCT03527576|DRUG|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
41268221|NCT03527576|DRUG|NaCl 0.0308 MEQ/ML Injectable Solution|Intravenous injection of NaCl 0.9% before the surgery.
41268222|NCT02393911|DIETARY_SUPPLEMENT|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
41268223|NCT05415748|DRUG|Tamsulosin|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
41268224|NCT05415748|DRUG|Placebo|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
41268225|NCT02848755|DEVICE|Cranial ultrasonography|
41268226|NCT03640884|DRUG|Xueshuantong-Injection|Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
41268227|NCT02690701|DRUG|Secukinumab 300 mg|"Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
41287163|NCT03888495|BEHAVIORAL|Financial Literacy Training Intervention|Hands-on training workshops including lectures, group activities, role play and group discussions focused on financial literacy.
41287164|NCT03888495|BEHAVIORAL|Family Planning Counseling and Services|Family planning counseling sessions and linkage to services.
41268228|NCT02690701|BIOLOGICAL|Placebo|"Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
41268229|NCT05923541|DRUG|RD13-02 cell infusion|Universal CAR-T cells targeting CD7
41268230|NCT00423826|DRUG|Busulfan|3 mg/kg intravenously over 3 hours
41268231|NCT00423826|DRUG|Cytarabine|Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.
41268232|NCT00423826|DRUG|Fludarabine phosphate|25 mg/M2/day IV
41268233|NCT00423826|DRUG|mycophenolate mofetil|Orally at the dose of 1 gm every 8 hours.
41268234|NCT00423826|DRUG|tacrolimus|0.015 mg/kg IV every 12 hours by continuous infusion.
41268235|NCT00423826|PROCEDURE|allogeneic hematopoietic stem cell transplantation|10 days post drug intervention
41268236|NCT00423826|PROCEDURE|umbilical cord blood transplantation|10 days post drug intervention
41268237|NCT00423826|RADIATION|total-body irradiation|10 days post drug intervention
41268238|NCT05789992|DRUG|Propofol|Propofol (Random:3-5ug/ml)
41268239|NCT05789992|DRUG|Low Remifentanil|Remifentanil (Random:0-3ug/ml)
41268240|NCT05789992|DRUG|Heigh Remifentanil|Remifentanil (Random:3-5ug/ml)
41268241|NCT05789992|PROCEDURE|Intubation|Endotracheal intubation before surgery
41268242|NCT05789992|PROCEDURE|tetanic electrical stimulation|tetanic electrical stimulation before surgery
41268243|NCT04004052|OTHER|Ultrasound guided injection|
41268244|NCT04004052|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|
41268245|NCT04004052|OTHER|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
41268246|NCT05459376|OTHER|Exercises and dry cupping|Participants in the intervention group will receive an assessment, classification as to MDT syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine
41268247|NCT03803527|PROCEDURE|Esophageal String Test|An EST will be performed for a 1hour sampling period on the same day as the scheduled clinic visit. Subjects will be asked to swallow a capsule and the attached EST string will be taped to the cheek with tegaderm tape. At the completion of the 1-hour sampling period, the EST will be removed and it will immediately be processed and cryopreserved for metabolomics profiling.
41268248|NCT04897490|OTHER|Evaluation of first line treatment with ATO/ATRA outcome|Evaluation of first line treatment with ATO/ATRA outcome (o event free survival and overall survival and toxicity) in adult patients with APL.
41268249|NCT03478384|BEHAVIORAL|Patient coaching|Patients receive regular coaching to test if the coaching alters their perceived self-efficacy.
41268250|NCT02371850|DRUG|Nicoderm patch first, then Aveva patch|This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
41268251|NCT04676854|DEVICE|PRIMA Bionic Vision System|Implantation of PRIMA, Vision training, follow up
41268252|NCT00116025|DRUG|Human acylated ghrelin|
41268253|NCT01511484|BEHAVIORAL|Information-only|"Selected pages from the British National Health Service (NHS) information booklets \[5 A Day, Just Eat More (fruit \& veg); pages i, ii, 12-15, 20 \& 21\] and \[5 A Day, Just Eat More (fruit \& veg): What's it all about?; pages i-ii)\] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
41268254|NCT01511484|BEHAVIORAL|Generic appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
41268255|NCT01511484|BEHAVIORAL|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
41268256|NCT01045954|DRUG|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
41268257|NCT02335502|DEVICE|Implantation with the commercially available Axium neurostimulator|
41268258|NCT01431287|DRUG|tiotropium + olodaterol|fixed dose combination
41268259|NCT01431287|DRUG|tiotropium + olodaterol|fixed dose combination
41268260|NCT01431287|DRUG|tiotropium|low dose or high dose
41268261|NCT01431287|DRUG|tiotropium|low dose or high dose
41268262|NCT01431287|DRUG|olodaterol|one dose only
41268263|NCT01431287|DEVICE|Respimat|Respimat inhaler
41268264|NCT00002285|DRUG|Zidovudine|
41268265|NCT05643430|DEVICE|BioFreedom Ultra|The BioFreedom Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
41268266|NCT04325477|DEVICE|Nolix Device|The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI
41442396|NCT06124339|BEHAVIORAL|Physical and Cognitive Activity|There will be three sessions a week over the course of 16 weeks.
41268267|NCT03544112|BEHAVIORAL|Employ a multifaceted approach to facilitate clinical protocol implementation|Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
41268268|NCT03544112|DRUG|Initiate BUP (SL-BUP or XR-BUP) in the ED|The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
41268269|NCT05881382|DRUG|Dutogliptin + Filgrastim|dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.
41268270|NCT05881382|DRUG|Placebo|Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
41268271|NCT05774327|OTHER|Foam Roller|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. For 6 weeks, in addition to foot core exercises, myofascial release will be applied with foam roller 2 days a week. Myofascial release application areas; thoracolumbal fascia, iliotibial band, hamstring, gastro-soleus, peroneal, plantar fascia.
41268272|NCT05774327|OTHER|Foot Core Exercises|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. Foot core exercises; short foot exercise, toe flexion exercise, heel lift exercise,toe abduction exercise, big toe and other toes extension exercise, front swing exercise, back walking exercises. Participants will do the exercises with the researcher two days a week and the other days follow-up will be provided through the online platform.
41268273|NCT04206826|DEVICE|PREDELFI|It's a natural film which contains a concentrated alpha-GOS (alpha-galacto-oligosaccharide) soy extract, a milk protein concentrate containing caseins and whey proteins and vegetable glycerin
41093537|NCT03379415|PROCEDURE|Gait analysis|Gait analysis will be done during several different tasks wear the footwear
41268274|NCT04206826|DEVICE|CONTROL|It's a natural film which is devoided of active ingredient. It contains sodium alginate; vegetable glycerin, caramel, beta carotene and water.
41268275|NCT05759884|DRUG|Anti-VEGF|Intravitreous injection of anti-VEGF drugs
41268276|NCT05759884|RADIATION|subthreshold micropulse laser|577nm micropulse laser photocoagulation therapy
41268277|NCT02075801|OTHER|Sealing of amalgam margin defects|Comparison between sealing of amalgam margins defects, replacement and non treated groups.
41268278|NCT02075801|OTHER|Sealing of amalgam margin defects|"A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C.Control Group: The defective restorations did not receive any treatment."
41268279|NCT05715216|DRUG|Nivolumab|Given by IV (vein)
41268280|NCT05715216|DRUG|Etigilimab|Given by IV (vein)
41268281|NCT06330779|OTHER|Trauma-adapted yoga|"Trauma-adapted-yoga (TAY) classes The classes, which span eight weeks with a once-a-week frequency, each last approximately 45-50 minutes. These small group classes are structured in a semi-circle arrangement to create a sense of security and empowerment for the participants. The teaching approach is trauma-sensitive, characterized by its inviting nature, provision of choices when facing challenges (A-B choices), and direction toward tangible physical sensations to enhance interoceptive awareness. Each yoga session follows a structured sequence of activities designed to promote participants' well-being and physiological awareness.~Online TAY classes After eight weeks, adolescents in the yoga group can continue their practice online. Exclusive to previous in-person participants, they'll receive a link for recorded classes and they will have the possibility to contact their health care contact any time."
41268282|NCT02731742|BIOLOGICAL|MK-1966|MK-1966 administered as an intravenous (IV) infusion
41268283|NCT02731742|DRUG|SD-101|SD-101 administered as an intratumoral (IT) injection
41268284|NCT02667184|DIETARY_SUPPLEMENT|Low FODMAP Oral Nutrition Supplement|
41442397|NCT00906399|DRUG|BIIB017 (peginterferon beta-1a)|Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
41442398|NCT00906399|DRUG|Placebo|Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
41442399|NCT06426225|OTHER|General Anesthesia|General Anesthesia Applied Group 2 Patients.
41442400|NCT06426225|OTHER|Spinal Aneshtesia|Spinal Anesthesia and Ketofol Sedation Applied Group 1 Patients.
41442401|NCT00617396|DRUG|Quetiapine (50 mg/day-100mg/day)|Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
41442402|NCT02332863|DEVICE|Back-loaded Needle (Device)|"Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
40920226|NCT05086211|OTHER|proprioceptive neuromuscular facilitation|"Each session including three proprioceptive neuromuscular facilitation techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects."
41093538|NCT04893564|BIOLOGICAL|bone marrow sample|8 to 13 ml bone marrow sample for frozen storage within one of the 5 certified biobank of the canceropole area.
41093539|NCT04893564|BIOLOGICAL|blood sample|20 ml blood sample for frozen storage within one of the 5 certified biobank of the canceropole area.
41268285|NCT00582894|DRUG|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
41268286|NCT02666326|PROCEDURE|Accelerated, combined biomarker rule-out strategy for MI|Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is \<9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is \<14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.
41268287|NCT00629395|BEHAVIORAL|Captain's Log Computer Program|12 Computer Program
41268288|NCT03501927|DIAGNOSTIC_TEST|FOCUS (focused cardiac ultrasound)|"A ultrasound of the heart and pleura will be performed. This provide information on~* Left ventricular systolic function~* Left ventricular diastolic function~* Right ventricular systolic function~* Right ventricular pressure overload~* Biventricular sizes~* Pathology of the mitral- and aortic valves~* Pericardial fluid~* Gross fluid status~* Pleural effusion"
41268289|NCT03585855|OTHER|MSC transplantation|MSC transplantation: patients with ABMR treated with MSC transplantation
41268290|NCT01211912|DRUG|Arm 1 (20 patients)|Acetaminophen 1000 mg by mouth once
41268291|NCT01211912|DRUG|Arm 2 (34 patients)|Acetaminophen 1000 mg by mouth once
41268292|NCT00222027|PROCEDURE|Collection of treatment-stratefying prognostic factors|
41268293|NCT01586845|DRUG|voclosporin|Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
41268294|NCT01586845|DRUG|tacrolimus|tacrolimus as per labeled dose
41268295|NCT01989130|DEVICE|Roche AMPLICOR CT/NG|
41268296|NCT01989130|DEVICE|Cepheid Xpert CT/NG Test|
41268297|NCT03311672|DRUG|[18F]F-Ara-G|Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
41268298|NCT03311672|DRUG|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
41268299|NCT03311672|RADIATION|PET/CT scan|Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.
41268300|NCT01466842|PROCEDURE|Catheter ablation using cryothermia|Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
41268301|NCT00859859|DEVICE|Vagus Nerve Stimulation|"1. Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.~2. Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed."
41268302|NCT00211003|DRUG|doripenem|
41268303|NCT01689038|DRUG|F17464|Single dose
41268304|NCT00670826|DEVICE|vitalHEAT vH2 Temperature Management System|The vH2 system utilizes a combination of localized heat and vacuum application to one hand \& forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.
41268305|NCT00670826|DEVICE|Arizant Healthcare Bair Hugger Temperature Management System|The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
41268306|NCT03015103|DEVICE|Intimate Lubrificant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
41442403|NCT02332863|DEVICE|Preloaded Needle (Device)|"Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
41442404|NCT06131437|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
41442405|NCT06131437|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
41442406|NCT06131437|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
41442407|NCT02749266|OTHER|Chiropractic adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
41442408|NCT02749266|OTHER|Sham chiropractic adjustment|Participants will receive a simulated chiropractic adjustment with a handheld adjusting instrument called an Activator.
41268307|NCT04696640|BEHAVIORAL|Remote Patient Monitoring|Participants' glucose data will be monitored by the study team using population analytic reports. Participants who either have excessive hypoglycemia or hyperglycemia on these reports will be contacted by a pediatric endocrinologist (the principal investigator) to discuss any necessary adjustments to their home diabetes management plans. This intervention will be in addition to their usual care (regular visits at the UC Davis Pediatric Endocrinology clinic).
41268308|NCT05678803|OTHER|xrays and CT|A dedicated sheet will be used to record patients' data including all demographic data, detailed analysis of the mechanism of injury, time of injury, time and details of surgery (if any), neurological status on admission and all radiological findings. All patients will undergo plain X-rays and CT imaging. Patients with suspected discoligamentous injuries and/or neurological deficits will also be assessed by MRI.
41268309|NCT02939131|BEHAVIORAL|Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
41268310|NCT02939131|BEHAVIORAL|Enhanced Standard of Care|Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
41268311|NCT03235687|DIAGNOSTIC_TEST|ExoDx Prostate (IntelliScore)|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
41268312|NCT02005055|PROCEDURE|Surgical excision with adjuvant high-dose-rate brachytherapy|The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
41268313|NCT00611247|DRUG|Temozolomide|"Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide"
41268314|NCT04688203|DRUG|Magnesium Sulfate Injection|will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
41268315|NCT04688203|DRUG|Labetalol Injectable Solution|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
41268316|NCT04539093|OTHER|Exposure of interest - Use of left ventricular assist device (LVAD)|Mechanical circulatory support devices such as left ventricular assist device is used as a treatment option for patients with end-stage heart failure.
41268317|NCT02538484|DRUG|Letrozole|Aromatase inhibitor
41268318|NCT02538484|DIETARY_SUPPLEMENT|Fish Oil|Omega-3 free fatty acid
41268319|NCT00838357|DRUG|Generic = Plerixafor|240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
41268320|NCT03474055|BIOLOGICAL|Liquid Rotavirus Vaccine|Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
41268321|NCT01808560|DEVICE|LipiFlow Pre-Treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
41268322|NCT01808560|DEVICE|LipiFlow Post-treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
41268323|NCT04415424|BIOLOGICAL|4CMenB vaccine|A four-component meningococcal B vaccine
41268324|NCT04415424|OTHER|Placebo|0.5 ml of 150 mmol sodium chloride (0.9% saline solution)
41268325|NCT05877131|DRUG|Levobupivacaine|To evaluate the efficacy of low-dose levobupivacaine (0.125%) (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
41268326|NCT05877131|DRUG|Ropivacaine|To evaluate the efficacy of low-dose ropivacaine (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
41268327|NCT00166348|BEHAVIORAL|Cognitive Group Therapy|
41268328|NCT02070107|OTHER|On Plan|"On Plan is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance."
41093540|NCT00196170|PROCEDURE|RF ablation of the cavo-tricuspid isthmus|8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
41093541|NCT00196170|PROCEDURE|cryo ablation of the cavo-tricuspid isthmus|Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
41268329|NCT02388373|DRUG|Fluticasone 250/formoterol 10|
41268330|NCT02388373|DRUG|Fluticasone 250/salmeterol 25|
41268331|NCT02388373|DRUG|Fluticasone 125/formoterol 5|
41268332|NCT05375084|DRUG|BBP-398 with nivolumab|BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)
41268333|NCT05357378|DEVICE|Hip Innovation Technology Reverse Hip Replacement System|Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.
41287165|NCT04138667|OTHER|complex decongestive therapy|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
41442409|NCT04150133|OTHER|Low Residue Diet|Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
41442410|NCT01299662|DRUG|Poly ICLC|One 1.6 mg subcutaneous injection of the study drug, poly ICLC in the upper arm.
41442411|NCT00665470|DRUG|Aldesleukin|"High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks"
41442412|NCT00949143|OTHER|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
41093542|NCT00196170|PROCEDURE|irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus|irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
40920227|NCT05086211|OTHER|pertubation based balance training|Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects
41268334|NCT05357378|DEVICE|Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.|"Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.~* DePuy Synthes Corail® Total Hip System in combination with Pinnacle® Complete Acetabular Hip System.~* Zimmer Biomet Taperloc® Complete Hip System in combination with G7® Acetabular System.~* Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup.~* Smith \& Nephew Anthology® Total Hip System in combination with R3® Acetabular System."
41268335|NCT00750984|PROCEDURE|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
41268336|NCT00750984|PROCEDURE|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
41268337|NCT00750984|DEVICE|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
41268338|NCT00750984|DEVICE|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
41268339|NCT03227874|DIETARY_SUPPLEMENT|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
41268340|NCT03227874|DIETARY_SUPPLEMENT|Muffin|two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
41268341|NCT00200265|BEHAVIORAL|diet|diet
41268342|NCT02519660|DRUG|Lidocaine/Tetracaine patch|
41268343|NCT02519660|DRUG|Lidocaine/Prilocaine cream|
41268344|NCT04213404|DRUG|Ribociclib|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle
41268345|NCT04213404|DRUG|Spartalizumab|Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
41268346|NCT02107755|BIOLOGICAL|ipilimumab|Given IV
41268347|NCT02107755|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
41268348|NCT02107755|OTHER|laboratory biomarker analysis|Blood and tissue samples will be collected for research purposes.
41268349|NCT05211778|BEHAVIORAL|Digital Education Group|Multimedia education provided to the intervention group via a digital tablet
41268350|NCT01770327|BEHAVIORAL|Effect of ingestion of different Sugary Beverages on Thirst Sensation|The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
41268351|NCT00308724|BEHAVIORAL|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
41268352|NCT00308724|BEHAVIORAL|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
41268353|NCT05671276|DRUG|aspirin and clopidogrel|DAPT (until 6 months) + ASA
41268354|NCT05671276|DRUG|Rivaroxaban|half-dose NOAC
41268355|NCT02649257|PROCEDURE|cataract surgery|
41268356|NCT02649257|DEVICE|intraocular lens (MC 6125 AS)|
41268357|NCT02649257|DEVICE|capsular tension ring (CTR 13/11)|
41268358|NCT02472847|DRUG|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
41268359|NCT02472847|DRUG|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
41268360|NCT04106154|BEHAVIORAL|Kinesiology Support|12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
40920228|NCT04320030|DRUG|[18F]-DPA-714 PET/CT scan|Pretherapeutic \[18F\]-DPA-714 PET/CT scan
40920229|NCT02613273|BEHAVIORAL|Experimental: Arm 1 (Aerobic Exercise)|This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
40920230|NCT02613273|BEHAVIORAL|Experimental: Arm 2 (Resist. Exercise)|This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
41093543|NCT00196170|PROCEDURE|cryo 6.5mm tip ablation of the cavotricuspid isthmus|cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
41268361|NCT04158063|BEHAVIORAL|Dual Task Training|"In total 12 Dual Task conditions will be performed in which 3 cognitive tasks are combined with 4 motor tasks:~Cognitive tasks:~* Titrated digit span backwards~* Auditory vigilance with alphabets~* Subtracting by 7~Motor tasks:~* Walking at self-selected speed~* Walking while carrying a cup of water~* Walking while stepping over obstacles~* Walking crisscross"
41268362|NCT04158063|OTHER|Single Mobility Training|standard routine training
41268363|NCT04613986|DEVICE|therapeutic plasmaexchnage|established method to exchange plasma (in order to remove injurious disease mediators, e.g. antibodies) or to replace consumed factors (e.g. vWF cleaving proteases)
41268364|NCT01576640|DRUG|NRT|Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
41268365|NCT01576640|DRUG|Bupropion SR 150mg bid|Subjects were given bupropion SR 150 mg bid throughout the course of the study.
41268366|NCT01576640|OTHER|Relapse Prevention-Oriented Cognitive Behavioral Therapy|Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
41268367|NCT02835430|PROCEDURE|Coronally advanced flap and PRF with DFDBA|• For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
41268368|NCT02835430|PROCEDURE|Coronally advanced flap and PRF without DFDBA|. For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
41268369|NCT00166790|DRUG|chemotherapy agents|
41268370|NCT00166790|PROCEDURE|suction curettage|
41268371|NCT04424563|DEVICE|ventilators|all patients in both groups will be ventilated if shocked and no recordable blood pressure
41268372|NCT04424563|DRUG|aminocaproic acid|4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
41268373|NCT04424563|DRUG|Novo Seven|200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (\>10 gm%) another 2 doses of aFVII received
41268374|NCT00454207|DRUG|sildenafil citrate (UK-92,480)|sildenafil citrate (UK-92,480)
41268375|NCT01474694|OTHER|Abdominal surgery|The patient is placed in a supine position and standard laparotomy (either via subcostal, midline or inverted hockey-stick incision) is performed. After mobilization of the liver, surgical swabs are packed around the organ to prevent unnecessary movement of the liver during the acquisition of the landmarks and the subsequent surgical procedure
41268376|NCT04207476|DEVICE|EMF|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
41268377|NCT04207476|DEVICE|Placebo|No magnetic field exposure will be given while patients are assigned to this arm for a duration of 1 hour.
41268378|NCT01865331|DRUG|insulin degludec|Single dose administered subcutaneously (s.c., under the skin).
41268379|NCT01865331|DRUG|placebo|Administered subcutaneously (s.c., under the skin)
41268380|NCT01865331|DRUG|insulin degludec/insulin aspart 50|Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
41268381|NCT03599700|DIAGNOSTIC_TEST|myeloproliferative neoplasms|BLOOD SAMPLING
41268382|NCT01029730|DRUG|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
41268383|NCT01029730|DRUG|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
41268384|NCT01029730|DRUG|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
41268385|NCT01811511|DIETARY_SUPPLEMENT|Chungkookjang|
41268386|NCT01811511|DIETARY_SUPPLEMENT|Placebo|
41268387|NCT00905957|PROCEDURE|TAP block|TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
41093544|NCT00884611|DEVICE|Predictive Low Glucose Suspend Algorithm ON|The algorithm uses a Kalman filter-based model to predict whether the sensor glucose level will fall below 80 mg/dL within a given time period and suspends the insulin pump if this event is predicted.
41268388|NCT00905957|PROCEDURE|TAP block with placebo|TAP block using a placebo after induction of anaesthesia
41268389|NCT03108716|PROCEDURE|hamate hook removal|The patients were assigned to treat with hamate hook removal.
41268390|NCT03108716|PROCEDURE|microscrew internal fixation|The patients were assigned to treat with microscrew internal fixation after open reduction.
41268391|NCT03108716|OTHER|short-arm tube-type plaster fixation|The patients were assigned to treat with short-arm tube-type plaster fixation (conservative treatment).
41268392|NCT04532489|DRUG|FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
41268393|NCT05494307|DRUG|Terbutaline|Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
41268394|NCT05494307|DRUG|Danazol|Orally danazol at a dose of 200 mg twice daily for 16 weeks
41268395|NCT00331760|DRUG|cisplatin|
41093545|NCT00884611|DEVICE|Predictive Low Glucose Suspend Algorithm OFF|
41093546|NCT04844099|DRUG|Dihydroartemisinin Piperaquine|Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
41268396|NCT00331760|RADIATION|intensity-modulated radiation therapy|
41268397|NCT00403260|DRUG|Pyronaridine - artesunate|once a day for 3 days
41268398|NCT00403260|DRUG|Mefloquine plus artesunate|once a day for 3 days
41268399|NCT06332508|DEVICE|Pulsed electromagnetic fields (PEMFs)|"Device: PEMFs~PEMFs treatment can be delivered up to 7 days prior to day of surgery (dose levels 1-2) or anthracycline-based chemotherapy (dose levels 3-4) to allow subject flexibility of timing and decrease the need for multiple visits. A research staff will be assigned to be with subject during the duration of PEMFs to monitor for any side effects during treatment."
41268400|NCT06332508|DRUG|Anthracycline-based chemotherapy|"Drug: Anthracycline-based chemotherapy (doxorubicin, cyclophosphamide)~At dose levels 3 and 4, two cohorts will be opened: the first cohort will undergo surgical resection immediately after completion of anthracycline-based chemotherapy, and the second cohort will undergo taxane-based chemotherapy following completion of anthracycline-based chemotherapy."
41268401|NCT03765593|PROCEDURE|Biopsy Salivary Gland|A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
41268402|NCT03229720|DEVICE|Nibiru 3D Virtual Reality Headset|This device is a kind of head glass that obstructs the vision with a wide screen showing movies or photos. Earphones are extended from it and inserted in ears. so it obstructs the vision and audio of the surroundings.
41268403|NCT06192979|DRUG|Daratumumab|"Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice."
41268404|NCT06192979|DRUG|Bortezomib|All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.
41268405|NCT06192979|DRUG|Dexamethasone|All patients received 20-40 mg oral or intravenous dexamethasone
40920231|NCT01317550|DRUG|Armodafinil|150 mg by mouth once a day for a 10 week cycle.
41268406|NCT06192979|DRUG|Venetoclax|All patients received venetoclax 400mg daily.
41268407|NCT02162849|DRUG|Varenicline|Varenicline Dosing: 0.5 mg/day by mouth for Days 1-3; 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter.
41268408|NCT02162849|DRUG|Nicotine Patch|Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11 weeks.
41268409|NCT02162849|DRUG|Placebo Patch|Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
41268410|NCT02162849|DRUG|Placebo Tablet|Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
41093547|NCT06075888|DIAGNOSTIC_TEST|Metagenomic diagnosis (mNGS, DISQVER)|Blood sample taken for metagenomic sequencing at inclusion visit.
41268411|NCT02162849|BEHAVIORAL|Questionnaires|Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. Questionnaires should take about 30-45 minutes total to complete. On Days 17, 24, 38, and 73, done over the phone.
41268412|NCT02162849|BEHAVIORAL|Counseling Sessions|Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. These sessions take about 15 minutes each time.
41268413|NCT02162849|OTHER|Lab Session|Participant asked to watch slides. During the lab session, brain electrical activity checked with an electroencephalogram (EEG). Participant completes computer tasks, including questionnaires, that will measure emotions and attention level. These tasks should take about 90 minutes to complete. The lab session may last up to 2 hours.
41268414|NCT02162849|OTHER|Saliva Test|Saliva tested to check cotinine level at baseline, on Days 8 and 17, end of treatment visit, and at 3 months and 6 months after quitting smoking.
41268415|NCT05048082|DRUG|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
41268416|NCT01246206|DRUG|Tacrolimus and Thymoglobulin|"Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours."
41268417|NCT04617808|OTHER|Questionnaire|"The regulatory scheme applied to all investigative centers is as follows:~* Call from Center 15 by a major patient for secondary headache no traumatic. (i.e. not having been the victim of a head trauma during the 48 hours preceding the call)~* Detection of the pattern of non-traumatic headache, by the regulatory assistant medical with registration of the word cephareg in the medical regulation software in order to alert the regulator about the possible inclusion of the patient~* If possible, patient information on the collection of their data for research and possibility of opposing~* Filling of a medical questionnaire by the regulating doctor~* Weekly collection of medical questionnaires by investigating doctors"
41268418|NCT04822532|GENETIC|GSTA1 genotyping|Diplotype determination based on 4 single-nucleotide polymorphisms (SNPs) occurring in the promoter region of the GSTA1 gene
41268419|NCT04663178|OTHER|Warm Salt Water Foot Bath|A training booklet about chemotherapy-induced fatigue + 20-minute warm salt water application to their feet for a week after the treatment by explaining and showing the video prepared about the preparation and practice of warm salt water foot bath.
41268420|NCT01083667|DRUG|Pyrimethamine|Open Label, dose escalating,
41268421|NCT05764486|DEVICE|Hitachi's Heavy Ion Beam Therapy System HyBEAT|treating patients with solid tumor
41268422|NCT03546855|DRUG|Apatinib|Apatinib 500mg/d po,28 days as one cycle
41268423|NCT01983644|DEVICE|RECO flow restoration device|RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
41268424|NCT01983644|DEVICE|Solitaire FR flow restoration device|Solitaire FR flow restoration device has been approved by the FDA and CFDA.
41268425|NCT03013465|OTHER|Control Diet|Participants will receive a controlled diet with 0 g/d of broccoli. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
41268426|NCT03013465|OTHER|Base Diet with Broccoli|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
41268427|NCT01457183|DEVICE|Pulsed lavage (Stryker Pulsavac Plus)|Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
41268428|NCT03750188|DRUG|ProHance|0.1 mmol/kg ProHance intravenous injection
40920232|NCT01317550|OTHER|Placebo|Capsules taken by mouth once a day for a 10 week cycle.
41093548|NCT04187534|OTHER|Albumin Fluid Resuscitation Optimization Intervention|Multi-faceted quality improvement intervention to optimize appropriateness of albumin use for fluid resuscitation
41093549|NCT04187534|OTHER|Usual Practice|Albumin fluid resuscitation according to usual practice
41268429|NCT04992988|DRUG|Toripalimab|Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT
41268430|NCT04550182|PROCEDURE|Positioning schedule|"The Braden scale will be collected every morning. Patients' care will be friction and repositioning applied at a frequency defined by the Braden scale:~6 ≥ Braden ≤ 8: alternate positioning every 2 hours 9 ≥Braden ≤ 13: alternate positioning every 4 hours 14 ≥ Braden ≤ 17: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 6 hours.~18 ≥Braden ≤ 23: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 12 hours.~Positioning will alternate semi-lateral decubitus at 30, semi-Fowler 30° -30°, half-sitting position 45° with elevation of the lower limbs.~A medical prescription as part of the daily reassessed care will ensure the absence of absolute contraindication to the mobilization or contraindication to certain positions.Friction will be performed during repositioning."
41268431|NCT05195528|DRUG|Vonoprazan|Orally via capsule
41268432|NCT05195528|DRUG|Placebo|Orally via capsule
41268433|NCT02533089|OTHER|KT intervention|Multifaceted KT intervention employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
41268434|NCT04754789|DRUG|Atorvastatin|preloading with high dose statins (atorvastatin 80mg) with loading dose of dual antiplatelet( asprine 300 mg and ticagrelor 180 mg) pre-primary PCI
41268435|NCT04754789|DRUG|Aspirin|Loading dose of dual antiplatelet (asprine 300 mg and ticagrelor 180 mg)
41268436|NCT02620020|DRUG|Fasinumab|Participants received fasinumab SC or IV, Q4W or Q8W.
41268437|NCT02620020|DRUG|placebo|Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
41268438|NCT05431296|DEVICE|Dexcom ONE Continuous Glucose Monitoring System|The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.
41268439|NCT05636280|OTHER|schroth exercise|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
41268440|NCT05636280|OTHER|traditional scoliosis exercise|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
41268441|NCT01295060|DRUG|Octreotide|84 mg Octreotide Implant
41268442|NCT05466643|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
41268443|NCT05466643|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
41268444|NCT02475889|PROCEDURE|Hepatic RFA|Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.
41268445|NCT02475889|PROCEDURE|Primary tumor resection|Primary tumor resection were performed pre- or post-RFA for liver metastases.
41268446|NCT03006614|DRUG|NVB|
41268447|NCT03006614|DRUG|EPI|
41268448|NCT03006614|DRUG|DDP|
40920233|NCT01317550|DRUG|Minocycline|100 mg by mouth twice a day for a 10 week cycle.
40920234|NCT01317550|BEHAVIORAL|Questionnaires|Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
41268449|NCT03006614|DRUG|CAP|
41268450|NCT03006614|DRUG|GEM|
41268451|NCT03006614|DRUG|H|
41268452|NCT03006614|DRUG|CTX|
40758181|NCT06433245|PROCEDURE|effect of 3% and 5% sodium hypochlorite on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.|After caries removal and pulp exposure pulp tissue is amputated and hemostasis is achieved with 3% sodium hypochlorite in control group and 5% sodium hypochlorite in experimental group followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
40920235|NCT03896256|DRUG|ketamine infusion|Ketamine will be used in subanesthetic doses for patients with refractory chronic migraine to see if it improves pain after a 5-day continuous infusion.
41268453|NCT03006614|DRUG|T|
40920236|NCT02113397|DRUG|TOBI™ Podhaler™ 112 mg inhaled twice daily|
40920237|NCT02113397|DRUG|Colistimethate 75 mg inhaled two times daily|
41268454|NCT00267527|DRUG|CJC 1295|
41268455|NCT01289015|DRUG|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
41268456|NCT01289015|DRUG|Placebo|Topical; applied once daily for two weeks
41268457|NCT01917786|DEVICE|ECG|
41268458|NCT03228563|OTHER|Probioics|CKD Patients were supplemented with two capsules of probiotics containing 2.5\*10\^9 CFU Lactobacillus acidophilus (TYCA06), Bifidobacterium longum (BLI-02) and Bifidobacterium bifidum (VDD088) twice daily for 12 months.
41268459|NCT01955707|DRUG|natalizumab|Administered as described in the treatment arm
41268460|NCT01955707|DRUG|Placebo|Matched placebo
41268461|NCT06203301|BEHAVIORAL|resistance exercise and walking|"After receiving the cases, they were divided into 4 groups by random allocation:~1. Control group: No exercise intervention measures are performed, and the patients carry out their daily lives according to their past living habits.~2. Resistance exercise group: Resistance exercise training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. The patients are given resistance exercise training for 45 minutes each time, 3 times a week, for 12 consecutive weeks. Afterwards, the patient is asked to regularly perform resistance exercise on his own for at least 1 year.~3. Walking group: Walking training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. They should walk continuously for 15 minutes at least twice a day and continue walking at least 5 days a week. Or walk for at least 150 minutes a week and walk for at least 15 minutes continuously each time for 12 consecutive weeks of walk"
40758182|NCT02214628|DRUG|Fovista® (anti-PDGF BB) plus anti-VEGF|
40920238|NCT02300636|OTHER|Training|Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
40920239|NCT02300636|OTHER|Training|Co-contraction training at 60 knee flexion angle by using leg press machine
40920240|NCT02300636|OTHER|Training|Standard ACL rehabilitation
40920241|NCT02335814|DRUG|FLX925|
40920242|NCT04909476|PROCEDURE|Endotracheal intubation|Airways management in COVID 19 patients pneumonia
40920243|NCT02844062|BIOLOGICAL|anti-EGFRvIII CAR T cells|CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.
40920244|NCT02844062|DRUG|cyclophosphamide|250 mg/m\^2 d1-3
40920245|NCT02844062|DRUG|Fludarabine|25mg/m\^2 d1-3
40920246|NCT02806141|DRUG|Aerosolized plus intravenous colistin|Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
40920247|NCT02806141|DRUG|Intravenous colistin|Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
41268462|NCT05836298|OTHER|Non-surgical periodontal treatment|Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST
41268463|NCT02772861|DIETARY_SUPPLEMENT|Amino Acid Supplement - One dose|20gr
41268464|NCT02772861|DIETARY_SUPPLEMENT|3-Methylhistidine|120mgr
41268465|NCT01027533|OTHER|Implantation of a multifocal Intraocular lens|Bilateral implantation of a multifocal IOl
41268466|NCT04187235|PROCEDURE|Laparascopic repair of parastomal hernia|Laparascopic repair of parastomal hernia
41268467|NCT03409874|OTHER|Dry Needling|Dry needling to the muscle of mastication and temporomandibular joint capsule. 1-2 treatment sessions per week for up to 4 weeks
41268468|NCT03409874|OTHER|Spinal manipulation|Spinal manipulation, targeting the upper cervical spine (C1-C2, C2-C3 or OA). 1-2 treatments per week for up to 4 weeks.
40920248|NCT04004871|DRUG|Nab-paclitaxel, Cisplatin and Fluorouracil|Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
41268469|NCT03409874|OTHER|Interocclusal Appliance|Interocclusal appliance worn every nights for 4 weeks.
41268470|NCT03409874|DRUG|NSAIDs|diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.
41268471|NCT03409874|OTHER|TMJ Mobs|Temporomandibular joint mobilization targeting the temporomandibular joint capsule. 1-2 treatments per week for up to 4 weeks.
41268472|NCT04997239|BIOLOGICAL|Two doses of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
41268473|NCT04997239|BIOLOGICAL|One dose of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
41268474|NCT04345666|DRUG|Testosterone cypionate|The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
41268475|NCT04345666|DRUG|Placebos|The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
41268476|NCT02866864|OTHER|Animal allergy +|Allergic symptom occurs when subject contact animal
41268477|NCT02866864|OTHER|Animal allergy -|Allergic symptom does not occur when subject contact animal
41268478|NCT05916586|DRUG|Prednisone|Prednisone 40 mg orally once a day for 7 days
41268479|NCT05375279|PROCEDURE|Lip Salivary Gland Biopsy|Obtaining few salivary glands from the partipants' lip that will be studied using the Congo Red staining method.
41268480|NCT02048345|DRUG|Suspension Fasted State|
41268481|NCT02048345|DRUG|Suspension Fed State|
41442413|NCT00949143|OTHER|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
41442414|NCT06559917|OTHER|life review|"After consenting, they will complete the first questionnaire before receiving the Happiness Ledger intervention via social media. Family members will have one week to organize photos, after which patients will share the meaning of the photos. This process will be recorded by the researcher and will last approximately 40 to 60 minutes. The researcher will then create a three-minute video using the photos, and the participating family members will assist in uploading the photos to the family LINE group as feedback to the subjects. The second questionnaire will then be completed."
41442415|NCT02523963|OTHER|family work shop|"1. The family work shop has 5 courses, with 6 families in one course.~2. One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods"
41442416|NCT00272519|BEHAVIORAL|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
40920249|NCT04004871|RADIATION|concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
40920250|NCT06148844|OTHER|interactive robot group|Intervention group will receive one day pre-operative preparation intervention applied by researcher. Preparation will be 30-40 minutes long
41268482|NCT02048345|DRUG|Solution Fasted State|
41268483|NCT02048345|DRUG|Solution Fed State|
41268484|NCT00180973|DRUG|Hydroxyurea|
41268485|NCT00773487|OTHER|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
41268486|NCT03219164|DRUG|AZLI|Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
41268487|NCT03219164|DRUG|Placebo|Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
41268488|NCT01631669|DRUG|Celecoxib|200 mg Q 12 hours orally
41268489|NCT04920773|OTHER|Guduchi Ghanvati|500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
41268490|NCT04920773|OTHER|Standard guidelines|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
41268491|NCT05252793|BEHAVIORAL|Education based on the health belief model|After the intervention, it is expected that the scores of the patients on the healthy lifestyle behaviors scale will increase.
41268492|NCT05340504|DRUG|N-Acetyl cysteine|Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
41442417|NCT06065150|PROCEDURE|Standard support|See arm/group descriptions
41268493|NCT05340504|DRUG|Placebo|Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
41268494|NCT05158855|DIETARY_SUPPLEMENT|Bacillus subtilis spore extract|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.
40920251|NCT03264118|PROCEDURE|Scaling and root planing|Furcation treatment by scaling and root planing
41093550|NCT06417905|OTHER|Supervised exercises|strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
41093551|NCT06417905|OTHER|video based exercises|strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
41268495|NCT00687791|DEVICE|ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery|Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
41268496|NCT02629731|DEVICE|custom orthoses with varying degrees of hindfoot posting|The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
41093552|NCT05346692|OTHER|Survey Administration|Complete Survey
41093553|NCT05346692|OTHER|Interview|Complete Interview
41093554|NCT05346692|OTHER|Text Message-Based Navigation Intervention|Complete mindfulness intervention
41093555|NCT05346692|OTHER|Interview|Complete interview
41093556|NCT00696904|DRUG|ABT-333|Capsule, see arms for intervention description
41093557|NCT00696904|DRUG|Placebo|Capsule, see arms for intervention description
41093558|NCT03656900|DEVICE|rTMS BA9/BA46|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 9, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 46.
41093559|NCT03656900|DEVICE|rTMS BA46/BA9|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 46, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 9.
41093560|NCT03656900|RADIATION|brain MRI|T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.
41093561|NCT03656900|OTHER|Medical evaluation|complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)
41093562|NCT03656900|OTHER|Psychological assessment|Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment
41093563|NCT05706662|PROCEDURE|inguinal hernia repair with mesh|inguinal hernia repair with mesh
41093564|NCT05240859|DRUG|Geleli|Adalimumab Biosimilar
41093565|NCT02983214|DRUG|Clopidogrel|
41093566|NCT02983214|DRUG|Cilostazol|
41093567|NCT05572151|PROCEDURE|lymph node number|Lymph nodes were harvested during surgical resection of rectal cancer
40758183|NCT04478734|DRUG|Moderate doses of Thiamine y Biotin|Thiamine 600 mg every day + Biotin 150mg every day
40758184|NCT04478734|DRUG|High doses of Thiamine y Biotin|Thiamine 1200 mg every day + Biotin 300mg every day
40758185|NCT02624479|DRUG|Sodium thiosulfate|oral administration of thiosulfate
41093568|NCT06085950|DEVICE|Transcranial Ultrasonic Stimulation prototype|Transcranial Ultrasonic Stimulation prototype delivers personalized low-intensity ultrasound stimulation
41093569|NCT06398899|DRUG|Group S: sugammadex injection|Reversal agent: sugammadex no TOF (train-of-four) response, Sugammadex 4 mg/kg TOF count is ≥ 1, Sugammadex 2 mg/kg
41093570|NCT06398899|DRUG|Group N: neostigmine/glycopyrrolate|Reversal agent: glycopyrrolate and neostigmine. TOF 2-3, neostigmine 50 µg/kg; TOF 4, neostigmine 20-40 µg/kg For all patients, glycopyrrolate 0.4 mg is co-administered with neostigmine.
41093571|NCT00000989|DRUG|Zidovudine|
41093572|NCT00000989|DRUG|Sargramostim|
41093573|NCT00000989|DRUG|Ganciclovir|
41093574|NCT00998816|DRUG|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
41093575|NCT05780047|DIAGNOSTIC_TEST|Mail-in Urine Test for EDCs|Million Marker provides a mail-in urine test for Bisphenol A (BPA) and phthalates. Users take a comprehensive exposure survey (via the MM app), send back their samples, view their personalized reports with tailored product recommendations, make changes to reduce their exposures, and retest to monitor their progress. Participants will also fill out surveys to assess changes in their environmental health literacy, readiness to change, and analyses of lifestyle behaviors and product use.
41093576|NCT01517022|DRUG|nicotine replacement therapy|nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
41268497|NCT01005160|DRUG|Metformin|CKD-501 0.5mg, metformin 1000mg
41268498|NCT01005160|DRUG|CKD-501|CKD-501 0.5mg, metformin 1000mg
41268499|NCT02120755|BIOLOGICAL|AmnioClear™ Human Allograft Amniotic Membrane|
41268500|NCT02224235|DRUG|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
41268501|NCT02224235|DEVICE|Resolute Integrity DES|Resolute Integrity DES
41268502|NCT02224235|DEVICE|COBRA PzF|
41268503|NCT02224235|DRUG|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
41268504|NCT06253416|OTHER|Exercise|a home exercise program consist of stretching and strengthening exercises , 5 repetitions of each exercise three days a week for 12 weeks
41268505|NCT06253416|OTHER|Control|exercise freely and without supervision with their daily routine
41268506|NCT02532348|OTHER|Blood samples|Blood samples
41268507|NCT00715975|DRUG|halobetasol|The patients will be treated with halobetasol once a day for 15 days.
41268508|NCT00715975|DRUG|clobetasol|The patients will be treated with clobetasol once a day for 15 days.
41268509|NCT00348140|DRUG|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
41268510|NCT00348140|DRUG|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
41268511|NCT00348140|OTHER|Placebo|Placebo
41268512|NCT03030287|DRUG|OMP-305B83|intravenous (in the vein) infusion
41268513|NCT03030287|DRUG|Paclitaxel|administered intravenously
40920252|NCT03264118|DRUG|Toluidine Blue O|Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
41093577|NCT06613620|OTHER|Standard Treatment|"All participants will receive 4 weeks of intervention with a frequency of 3 times/week i.e. 10minutes of hot pack followed by post facilitation stretching and strengthening protocol.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
41268514|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
41268515|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
41268516|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
41268517|NCT00793793|DRUG|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
41268518|NCT00793793|DRUG|Placebo|
41268519|NCT00618748|DRUG|Olanzapine|5-20 mg/day, oral, daily
41268520|NCT02141893|BEHAVIORAL|CALMA plus|Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs
41268521|NCT02141893|BEHAVIORAL|CALMA|Family Education Intervention on management of pediatric asthma
41268522|NCT03502330|DRUG|APX005M|APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
40920253|NCT01642615|DRUG|Dexlansoprazole|Dexlansoprazole capsules
40920254|NCT01642615|DRUG|Dexlansoprazole|Dexlansoprazole capsules
40920255|NCT01642615|DRUG|Placebo|Dexlansoprazole placebo-matching capsules
40920256|NCT06420609|OTHER|Go-TAD|The participants will receive a medical visit that will include the 4 open-ended questions comprising the Go-TAD intervention
41268523|NCT03502330|DRUG|Cabiralizumab|Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
41268524|NCT03502330|DRUG|Nivolumab|Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
41268525|NCT05533060|OTHER|No intervention|patients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected
41268526|NCT01250821|DRUG|Menopur|"The medication used in this study is the follicle-stimulating hormone highly purified human menopausal gonadotrophin (HP-HMG), Menopur, (Ferring a/s).~Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day."
41268527|NCT00102310|DRUG|YM443|
41268528|NCT00441792|DRUG|Etomidate|Etomidate at induction dose based on weight
41268529|NCT00441792|DRUG|midazolam|Midazolam at induction dose based on weight
41268530|NCT02265484|DRUG|Lactulose+Rifaximin +Bromocriptine|
41268531|NCT01015508|OTHER|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
41268532|NCT01015508|OTHER|Weight maintenance|10 months
41268533|NCT01219842|PROCEDURE|INVASIVE (INV) treatment|Modern endovascular and/or open revascularisation according to the TASC II recommendations.
41268534|NCT01219842|OTHER|Best medical treatment (BMT)|Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
41268535|NCT03856944|DEVICE|ReSTOR Toric|ReSTOR Toric bilateral IOL implantation
41268536|NCT03835091|OTHER|BRASS score|Brainstem response on neurologic examination
41268537|NCT04856592|DEVICE|Boston Scientific Vici® Venous Stent System|The Vici Venous Stent System comprises two components: the implantable endoprosthesis and its stent delivery system, a 9F over-the-wire system available in a 100cm length and compatible with 0.035in (0.89mm) guidewires
41268538|NCT04856592|DEVICE|Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter)|The Opticross 35 catheter is designed for use with a guidewire measuring ≤0.035 in (0.89 mm) in diameter and an introducer sheath of 8F (2.67 mm) or larger. The working length of OC35 catheter is 105 cm.
41268539|NCT03566940|BIOLOGICAL|sIPV|Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.
41268540|NCT03566940|BIOLOGICAL|cIPV|Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
41268541|NCT02235506|PROCEDURE|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
41268542|NCT02235506|PROCEDURE|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
41093578|NCT06613620|OTHER|Visual and auditory feedback on SEMG biofeedback unit|Patients will receive SEMG biofeedback assisted post facilitation stretching and strengthening. Patients will receive 50-80%of their maximum voluntary contraction as per the biofeedback and gradually the contraction time will be increased.
41268543|NCT02235506|DEVICE|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
41268544|NCT02235506|DEVICE|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
41268545|NCT01904981|DRUG|Beta-blocker-Atenolol 50mg, PO(peroral), Once daily|
41268546|NCT01904981|DRUG|Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily|
41268547|NCT04899635|OTHER|In-vitro contractile fatigue protocol|Using contractility assays for muscle slices or the work-loop assay for isolated heart cells, the tissue preparation will undergo a series of contraction and relaxation under varying levels of preload, afterload, stimulation frequency and under other experimental conditions such as drug-induced inotropism.
41268548|NCT05859035|DEVICE|KIOS Informational App|"The KIOS informational app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen."
41268549|NCT06255873|DIETARY_SUPPLEMENT|L- Carnitine|L-carnitine was taken after feeds in the form of tablets or dissolved tablets in a dose of 50 mg/kg/day, with maximum dose of 2 g/day.
41268550|NCT06255873|OTHER|ketogenic diet|ketogenic diet (KD) initiated under supervision of expert physician who considered patient's age, type of feeding, needs and preferences of the child and his/her family to select the type and initial ratio of KD therapy, KD ratio ranged from 1:1 to 4:1 of lipids to carbohydrates plus proteins in grams.
41268551|NCT01672957|DRUG|Mycophenolate Mofetil|Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
41268552|NCT01672957|DRUG|Immunosuppressive Therapy|Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
41268553|NCT05249049|DEVICE|e-OPRA Implant System for Transtibial Amputees|The e-OPRA System for transtibial use consists of an anchorage element (Fixture), which is surgically inserted in the medullary canal of the amputated skeleton of the lower limb. The skin penetrating e-Abutment is then inserted and secured with the e-Abutment screw. To allow the system to be used with an external neuro-mechanical prosthesis, soft tissues from the distal limb are preserved incorporated into the residual limb. Muscle electrodes are then placed in the neuro-muscular constructs. After a rehabilitation program, in everyday use, the implanted e-OPRA device will be used by the patient with the Axor TC and their commercially available prosthesis. However, the modified version of the implant will allow the patient to use a powered neuro-mechanical prosthesis during specified testing scenarios.
41268554|NCT04122599|DRUG|Melatonin|Melatonin for prevent post stroke delirium
41268555|NCT03093402|DRUG|JBT-101|Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
40920257|NCT05246865|DRUG|oral androgen challenge with dehydroepiandrosterone (DHEA)|The oral androgen challenge is a safe and well-validated means of studying the androgen generation profiles of different study groups.
40920258|NCT04176419|DRUG|Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
41268556|NCT03093402|DRUG|Placebo|Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
41268557|NCT00054132|BIOLOGICAL|Bevacizumab|Given IV
41268558|NCT00054132|DRUG|Erlotinib Hydrochloride|Given PO
41268559|NCT00054132|OTHER|Laboratory Biomarker Analysis|Correlative studies
41268560|NCT02021409|DRUG|BAY85-3934|Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
41268561|NCT02021409|BIOLOGICAL|Darbepoetin alfa|
41268562|NCT02992574|RADIATION|Post Mastectomy Radiation therapy|Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
41268563|NCT01984515|BEHAVIORAL|Referral Management System|"Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., talking about past trauma will be too difficult for me). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD."
41268564|NCT00289913|BIOLOGICAL|Comparator: VAQTA™|"VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age."
41268565|NCT00289913|BIOLOGICAL|Comparator: Infanrix™|"Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis~Vaccine Adsorbed, GlaxoSmithKline).~One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit."
41268566|NCT00289913|BIOLOGICAL|Comparator: PedvaxHIB™|"PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit."
41268567|NCT01023984|PROCEDURE|TEM - Transanal Endoscopic Microsurgery|TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
41268568|NCT01023984|PROCEDURE|ESD - Endoscopic Submucosal Dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
41268569|NCT00212147|DRUG|General anesthesia with nitrous oxide|
41268570|NCT00212147|DRUG|General anesthesia without nitrous oxide|
41268571|NCT00331006|DRUG|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m\^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
41268572|NCT02781792|DRUG|Temozolomide|-Given standard of care
41268573|NCT02781792|OTHER|Functional Assessment of Cancer Therapy - Brain|"* 23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire \[2\] that includes 27 items.~* Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~* The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia."
41268574|NCT02781792|OTHER|ActTrust Condor Instrument Watch|-Will be required to wear 24 hours per day and will only be removed at specified data collection time points
41268575|NCT00150098|BEHAVIORAL|Enhanced HIV risk reduction and HIV vaccine education|
41268576|NCT01661790|DRUG|Bevacizumab|Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
41268577|NCT01661790|DRUG|Cisplatin|Cisplatin 30mg,intrapleural administration,each 2 week
41268578|NCT02351232|DRUG|Liraglutide|
41268579|NCT02351232|DRUG|Placebo|
41268580|NCT03283631|BIOLOGICAL|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
41268581|NCT03684135|OTHER|Cosmetics|"Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource"
41268582|NCT01431092|DRUG|Placebo|Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
41268583|NCT01431092|DRUG|Melatonin|Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
41268584|NCT06083584|OTHER|RNA sequencing|RNA-Seq (Sureselect XT HS2 RNA) from patient blood sample
41442418|NCT06065150|PROCEDURE|Early surgery proposed according to the radiological score|"* If score ≥ 5: the risk of medical treatment failure is multiplied by 2.9 (Feuerstoss F et al, J Gastrointest Surg 2021). Early surgical treatment is proposed; that is, the procedure is performed within 24 hours of admission. The surgery is initiated by laparoscopy and converted to open surgery if necessary.~* If score \< 5: the risk of medical treatment failure is reduced. Initial medical treatment is therefore offered in accordance with standard management."
41442419|NCT01289262|PROCEDURE|Purse string closure technique|Uterine incision will be closed with purse string closure technique.
40758186|NCT01127204|DRUG|AZT-3TC-LPV/r twice a day|AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
41268585|NCT05547945|BEHAVIORAL|Health Promotion Program|The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
41268586|NCT05547945|BEHAVIORAL|Control group|The control group received as usual care.
41268587|NCT02848079|DRUG|combined TAS-102 and TAS-OX|Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
41268588|NCT00989989|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
41268589|NCT00989989|PROCEDURE|Laser photocoagulation|Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
41268590|NCT00989989|DRUG|Sham ranibizumab|Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
41268591|NCT00989989|PROCEDURE|Sham laser photocoagulation|Sham laser treatment administered at day 1.
41268592|NCT01785355|OTHER|Dental treatment|"1. The preliminary stage deals with:~   * assessment of the clinical state of the patient by completing a detailed dental and periodontal chart~  * education of the patient regarding correct oral hygiene habits;~2. Phase I Therapy:~   * plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)~  * evaluation of response to the treatment~3. Phase II Therapy - surgical phase:~   * extraction of hopeless teeth~  * evaluation of the surgical results.~4. Maintenance phase:~   * periodic reevaluation of plaque and calculus and of periodontal conditions."
41268593|NCT00388050|BEHAVIORAL|Diabetes Medication Choice decision aid|The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
41442420|NCT01289262|PROCEDURE|Continuously locked closure technique|Uterine incision will be closed with continuously locked closure technique
41268594|NCT00388050|BEHAVIORAL|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
41268595|NCT03584763|DIAGNOSTIC_TEST|Umbilical artery Doppler|Umbilical artery Doppler ultrasound will be performed by most expert sonographer in umbilical artery Doppler at the special care unit, using a 3.5MHz transabdominal probe of SAMSUNG MEDISON, SONOACE R5 ultrasound machine, using the standard protocol of the unit for minimizing the interobserver variations.
41268596|NCT00482716|BIOLOGICAL|epoetin alfa|
41268597|NCT00482716|BIOLOGICAL|epoetin beta|
41268598|NCT00482716|DIETARY_SUPPLEMENT|iron dextran complex|
41268599|NCT00482716|DIETARY_SUPPLEMENT|iron sucrose injection|
41268600|NCT00943995|DRUG|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
41268601|NCT05740150|DEVICE|TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)|The TauroLock-Hep100 is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
41268602|NCT05740150|DEVICE|Heparin lock (heparin 100 IU/mL)|The Heparin lock is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
41268603|NCT03009604|DRUG|Simethicone|Simethicone 40mg oral tablets
41268604|NCT03009604|DRUG|Enema|sodium dihydrogen phosphate dihydrate 19.2 gram \& disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
41268605|NCT01324830|DRUG|day 1 to day 5|low to high dose
41268606|NCT01324830|DRUG|day 1 to day 14|low to high dose
41268607|NCT04336163|DEVICE|Optical Coherence Tomography|Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
41268608|NCT03844009|OTHER|Computer integrated debriefing|At the end of each computer-based simulation, the participant had a computer integrated debriefing of his performance during the neonatal resuscitation simulation and a debriefing based on an auto-evaluation of his non-technical skills.
41268609|NCT02153502|DRUG|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
41268610|NCT02153502|DRUG|Placebo|Placebo capsules administered twice a day over a 10-week period
41268611|NCT05095506|OTHER|eHealth Intervention|The intervention platform is interactive, and uses multimedia-assisted components. The system uses three SCI-QOL computer-adaptive tests (CATs) to assess depression, anxiety, and resilience; cut scores are used to tailor multi-media content that specifically addresses users' emotional health concerns.
41268612|NCT05095506|OTHER|Active Control Condition|The active control condition is a static site that displays symptom assessments followed by one educational video each week. These videos, which play in a predetermined order, provide education about managing physical health in individuals with SCI.
41268613|NCT04947644|PROCEDURE|Thoracic epidural analgesia|After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
41268614|NCT04947644|PROCEDURE|Ultrasound guided continuous erector spinae plane block|After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
41268615|NCT02648386|PROCEDURE|Laparoscopic surgery|Completely resected rectal tumor.
41268616|NCT02648386|DEVICE|NeuroRegen scaffold transplantation|After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.
41268617|NCT02648386|BIOLOGICAL|NeuroRegen scaffold/BMMCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
41268618|NCT02648386|BIOLOGICAL|NeuroRegen scaffold/HUC-MSCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
41268619|NCT05112796|PROCEDURE|Class I extractions sites received immediate implants using the Vestibular Socket Therapy|A 1-cm-long vestibular access incision was made using a 15c blade 3 to 4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision
41268620|NCT05112796|PROCEDURE|class I extractions sites received immediate implants using the Partial Extraction Therapy|the hopeless tooth was decoronated 1 mm coronal to the gingival margin using a diamond bur. Then, the facial root segment was separated from the rest of the root using a Lindemann bur in gentle mesiodistal sweeping strokes from the gingival margin to the apex of the root, aiming to separate the palatal and the labial root segments.
41268621|NCT01742429|DRUG|Proton pump inhibitor|
41093579|NCT06613620|OTHER|Electrical muscle stimulation|Electrical muscle stimulation will be provided in addition to visual and auditory feedback by the SEMG biofeedback unit to the weak muscles until the patients achieve the desired level of contractions.
41268622|NCT01742429|DRUG|Bismuth subsalicylate|
41268623|NCT01742429|DRUG|Metronidazole|antibiotic
41268624|NCT01742429|DRUG|Tetracycline|antibiotic
41268625|NCT01742429|DRUG|Amoxicillin|antibiotic
41268626|NCT01742429|DRUG|Levofloxacin|antibiotic
41268627|NCT06410014|OTHER|No intervention is performed|The study is observational
41268628|NCT05359107|BEHAVIORAL|"The Free From Pain Exercise Book"|Contains educational information and exercises to improve musculoskeletal pain and reduce sarcopenia.
41268629|NCT05359107|BEHAVIORAL|"The Back Book"|Contains advice and guidance on how to deal with and reduce back pain.
41268630|NCT00708370|OTHER|COACH|COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
41268631|NCT00708370|OTHER|No intervention for placebo|There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
41268632|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 1|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks.
41268633|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 2|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
41268634|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 3|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
41268635|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 4|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
41268636|NCT06322719|DEVICE|Hyperangulated blade videolaryngoscope|For patients assigned to the Hyperangulated videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
41268637|NCT06322719|DEVICE|Macintosh blade videolaryngoscope|For patients assigned to the Macintosh videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
41268638|NCT00351364|DRUG|Montelukast Sodium|100 mg P.O. One time only
41268639|NCT01147497|DRUG|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
41268640|NCT01147497|DRUG|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
41268641|NCT01908595|DRUG|M518101|
41268642|NCT04120688|DEVICE|3D generated tooth replica|3D generated tooth replicas are compared to conventional procedure
41268643|NCT00112476|DRUG|bryostatin 1|Given IV
41268644|NCT00112476|DRUG|temsirolimus|Given IV
41268645|NCT04030078|OTHER|Survey|Questionnaire-based survey
41268646|NCT06076668|DRUG|Dexmedetomidine|Patients will receive an intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.
41268647|NCT06076668|DRUG|Melatonin 3 MG|Patients will receive oral melatonin tablet 3 mg 9:00 p.m.
41268648|NCT06076668|DRUG|Saline|Patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.
41268649|NCT02440334|DRUG|Optison|Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
41268650|NCT02514759|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
41268651|NCT04232085|DRUG|Alemtuzumab|Preparative regimen
41442421|NCT06216756|PROCEDURE|osteochondral transplant on the femoral condyle|Patients who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 2.0-8.0 cm2 in size, and cystic changes requiring osseous repair present in less than or equal to 12 mm of subchondral bone will undergo a osteochondral transplant by removing the damaged cartilage and replacing that cartilage with a cryopreserved osteochondral allograft core.
41442422|NCT04767347|OTHER|23.0°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~23.0°C WBGT (29°C, 46% relative humidity) @ 60 min exercise per hour"
41442423|NCT04767347|OTHER|25.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~25.5°C WBGT (31°C, 52% relative humidity) @ 45 min exercise per hour"
41268652|NCT04232085|DRUG|Fludarabine|Preparative regimen
41268653|NCT04232085|DRUG|Melphalan|Preparative regimen
41268654|NCT04232085|RADIATION|Low Dose Total Body Irradiation|Preparative regimen
41268655|NCT04232085|DRUG|Cyclophosphamide|GVHD prophylaxis
41268656|NCT04232085|DRUG|Tacrolimus|GVHD prophylaxis
41268657|NCT04232085|DRUG|Mycophenolate Mofetil|GVHD prophylaxis
41268658|NCT00457574|DRUG|GMX1777|
41268659|NCT06109194|OTHER|Joint mobilization|Grade III manual joint mobilization as standard-of-care physical therapy intervention
41268660|NCT00379951|DRUG|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
41268661|NCT01349348|DRUG|Tolvaptan|tablet, 15 mg, Qd, for 7 days
41268662|NCT01349348|DRUG|Tolvaptan|tablet, 7.5 mg, Qd, for 7 days
41268663|NCT01349348|DRUG|placebo|tablet, 7.5/15mg , Qd, 7days.
41268664|NCT01130129|OTHER|Ex-vivo treatments with flavonoids|Ex-vivo treatment of platelets with a range of flavonoids
41268665|NCT02684071|DRUG|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
41268666|NCT02684071|DRUG|topotecan|To be administered in conjunction with methotrexate
41268667|NCT02684071|DRUG|cyclophosphamide|To be administered in conjunction with methotrexate and topotecan
41268668|NCT00771472|DRUG|vorinostat|Parts I \& II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
41268669|NCT03240406|OTHER|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
41268670|NCT03240406|OTHER|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
41268671|NCT03311971|DEVICE|Virtual reality glasses|Patients will be treated with virtual glasses
41268672|NCT03311971|DEVICE|No VR glasses|Patients will not use VR glasses
41268673|NCT01236456|DRUG|Cyclophosphamide|
41268674|NCT00989599|OTHER|compress of Chamomilla recutita infusion|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
41268675|NCT00989599|OTHER|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
41268676|NCT03666351|DRUG|Amlodipine 5mg|Amlodipine 5 mg
41268677|NCT03666351|DRUG|Losartan|Losartan Potassium 50 mg
41268678|NCT03666351|DRUG|Losartan and Amlodipine|Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
41268679|NCT03666351|DRUG|Amlodipine/Losartan/Chlorthalidone|Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
41268680|NCT03666351|DRUG|current treatment|treatment is done by maintaining the current treatment
41268681|NCT06303661|DEVICE|Non-ablative Radiofrequency|There are two electrodes: one active, which will be used on the penis, using a non-lubricated condom from the Blowtex brand, using pharmaceutical glycerin to emit radiofrequency inside and outside the condom, and another electrode, dispersive, wrapped in PVC-type plastic film, coupled to the region of the patient's penis where there is no fibrotic plaque, which will act as earth and the temperature to be used in the treatment will be 38°C. When the desired heating is reached, the device maintains the temperature and thus the radiofrequency application will be maintained for 2 minutes.
41268682|NCT06303661|DEVICE|Low-intensity Shock Wave Therapy|The equipment's applicator is covered with transparent PVC film and non-alcoholic gel is used as a coupling medium between the applicator and the penis. The following parameters are used: frequency of 10Hz, energy of 120mJ and 2,000 shots in the fibrotic plaque.
41268683|NCT03892837|PROCEDURE|PRP|PRP treatment following the conventional treatment for benign airway stenosis which contain a concentrate of platelet-rich plasma protein derived from whole blood.
41268684|NCT03892837|PROCEDURE|Conventional treatment for benign airway stenosis|Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
41268685|NCT02305563|DRUG|BMS-936564|
41268686|NCT02305563|DRUG|Cytarabine|
41268687|NCT04921215|BEHAVIORAL|Morning bright light|All participants will receive phase advancing morning bright light.
41268688|NCT01538056|DEVICE|Fenestrated Endovascular Graft|Modified endovascular graft with fenestrations to allow for blood flow to vital visceral vessels such as the renal arteries and SMA (Superior Mesenteric Artery).
41268689|NCT06077084|OTHER|Physiotherapy|"4months with multimodal physiotherapy. 2 sessions/week. Sessions consisted of two sessions of 1 hour per week, focusing on neck and arm movements. Each session included education and manual therapy (20 minutes), and exercises targeting neck extensors, flexors, and shoulder girdle muscles (40 minutes).~Low-intensity neck resistance training :~Participants have to perform arm, neck flexors and extensors exercise. motor control exercises focusing on deep neck muscles, slow dynamic and static contractions (10 to 20 seconds) with low resistance using TheraBand and weights ranging from 0.5 kg to 1 kg.~High-Intensity Neck resistance training :~neck flexors exercise, neck extensors exercise, and one exercise for shoulder/upper limb. static contractions (10-seconds) and dynamic neck movements using a handheld biofeedback dynamometer or weights from 50% to 80% of the 1-repetition maximum"
41268690|NCT00152633|DRUG|Losartan|
41268691|NCT00152633|DRUG|Metoprolol|
41268692|NCT00152633|DRUG|Losartan|Treatment with Losartan
41268693|NCT04925960|DRUG|Epalrestat|Epalrestat is a noncompetitive and reversible aldose reductase inhibitor (ARI) used for the treatment of diabetic neuropathy in Japan. The drug's ability to safely improve symptoms of neuropathy alone by reducing oxidative stress, increasing glutathione levels, and reducing intracellular sorbitol accumulation make it a desirable medication for PMM2-CDG patients who commonly suffer with various neuropathies. However, work recently conducted by Perlara, a public benefit company with the mandate to screen existing commercially available drugs for possible application in rare diseases, has demonstrated that Epalrestat can also elevate the level PMM2 produced endogenously. This may reduce the severity of the morbidities associated with PMM2-CDG.
41268694|NCT04925960|DRUG|Placebo|The placebo capsule with be identical in appearance to the Epalrestat capsule. It will contain microcrystalline cellulose filler in a gelatin capsule.
41268695|NCT05432531|DRUG|Anti JAK1,2|Induction of remission of active lupus nephritis
41268696|NCT05432531|DRUG|Cyclophosphamid|Induction of remission of active lupus nephritis
41268697|NCT02222402|BEHAVIORAL|INTRA-DIALYTIC EXERCISE TRAINING|
41268698|NCT00961961|DRUG|Lithium / Fluoxetine|Individualized Daily Dosage
41442424|NCT04767347|OTHER|27.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~27.5°C WBGT (33°C, 53% relative humidity) @ 30 min exercise per hour"
41268699|NCT00961961|DRUG|Lithium / Placebo|Individualized Daily Dosage
41442425|NCT04767347|OTHER|28.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~28.5°C WBGT (34°C, 54% relative humidity) @ 15 min exercise per hour"
41268700|NCT02281890|OTHER|Proven sepsis|Exposure is proven sepsis
41268701|NCT04082221|OTHER|no intervention|no intervention
41268702|NCT01302873|DRUG|BGG492A|
41268703|NCT01302873|DRUG|BGG492A|
41268704|NCT03216382|BEHAVIORAL|Attention Training Technique|The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.
41268705|NCT03216382|BEHAVIORAL|Control Condition|In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.
41287166|NCT00392873|BEHAVIORAL|EAMD+Calories|During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
41287167|NCT03613428|DRUG|Ruxolitinib|Dose escalation up to 80 mg administered orally
41268706|NCT03162848|BEHAVIORAL|SystemCHANGE|At initial home visit, the PI will work with the participant to identify important people for medication taking, routines, and cycles of routines. Possible solutions to incorporate medication taking into routines will be identified by the participant and PI and the participant will start implementing these solutions. Medication adherence will continuously be monitored using medication event monitoring systems. At one month, the participant will be sent a report on medication taking and a phone call will occur with the PI to discuss if solutions improved medication adherence or if other solutions need to be implemented. At month two, the intervention will end but participants are urged to continue to use solutions long term.
41268707|NCT00260520|DRUG|Dalteparin|
41268708|NCT04323930|DEVICE|eyeWatch|The eyeWatch system will be implanted as per the manufacturer's instruction, and trabeculectomy will be performed using mitomycin C as per standard surgical protocols.
41268709|NCT01711242|DRUG|Capecitabine|
41268710|NCT01711242|DRUG|Oxaliplatin|
41268711|NCT01711242|RADIATION|Radiotherapy|
41268712|NCT04389177|DRUG|Pembrolizumab Injection [Keytruda]|"Neoadjuvant period:preoperative therapy with three cycles: Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks.~Da Vinci robot radical surgery: Before surgery, head/abdomen/chest CT scan, type B ultrasonic, upper gastrointestinal contrast, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 4-6 weeks after last neoadjuvant treatment finished.~Adjuvant period: Adjuvant treatment with pembrolizumab 200mg every 3 weeks (6 cycles) should be performed within 3-6 weeks after surgery if the surgical pathology result is not pCR. abdomen/chest CT scan will be performed every 3 month after surgery."
41268713|NCT03971721|DEVICE|Wave 4.3|The Wave 4.3 mattress support is an insert, placed underneath the user's existing mattress, that when inflated increases the longitudinal incline of the mattress support, increasing in inclination in the direction of the head of the bed. The resulting mattress contours are such that the mattress has a lateral inclination of approximately 15 degrees in the head section and 10 degrees in the torso section. In addition to the features allowing the user to activate and deactivate creation of this Graduated Lateral RotationTM orientation, this device has sensors and monitoring system allowing for remotely monitoring the status of the system, including confirming that the supports are achieving the prescribed support angles, and that the system is working as planned.
41268714|NCT01409928|DEVICE|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
41268715|NCT04928183|OTHER|Carbon monoxide rebreathe|Carbon monoxide exposure to increase blood (Carboxyhemoglobin) COHb safely to \~10%
41268716|NCT04928183|DRUG|Sodium Nitroprusside|Bolus Sodium Nitroprusside (SNP) injection for endothelium-independent vasodilation measure
41268717|NCT04928183|DRUG|Phenylephrine Hydrochloride|Bolus Phenylephrine injection for observe α1-mediated vasoconstriction during mild exercise
41268718|NCT04576312|DRUG|UNI911 inhalation 1% and intranasal spray 1%|Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.
41268719|NCT04576312|DRUG|Placebo|The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
41268720|NCT05843214|OTHER|Non-invasive neuromonitoring evaluation (transcranial doppler, optic nerve envelope diameter and quantitative pupillometry)|4 days Post-operation follow-up. Data will be gathered before the surgery and at regular times after the surgery until day 4
41268721|NCT01419132|DRUG|Furosemide|125-250 mg furosemide bid
41268722|NCT01419132|DRUG|Furosemide|125-250 mf furosemide bid
41268723|NCT03437603|DRUG|Eltrombopag|Starting Eltrombopag daily on empty stomach (2 hour before breakfast) for 8 weeks.
41268724|NCT01524380|DRUG|Ginkgo biloba extract|400mg/day, twice a day, 10 weeks
41268725|NCT01524380|DRUG|Placebo|twice a day, 10 weeks
41268726|NCT04156321|DIETARY_SUPPLEMENT|Moringa fry|"School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm ."
41268727|NCT04447053|DRUG|Belimumab Injection [Benlysta]|Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.
41268728|NCT02525549|DRUG|Adapalene and Benzoyl Peroxide Gel|
41268729|NCT02525549|DRUG|Adapalene and Benzoyl Peroxide Gel (Reference)|
40758187|NCT01127204|DRUG|ABC-3TC-EFV once a day|ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
41268730|NCT02525549|DRUG|Placebo gel|
41268731|NCT03105739|OTHER|LMA removal|According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
41268732|NCT05114083|OTHER|symptom assessment|symptom assessment
40758188|NCT02970812|DEVICE|Electrical Muscle Stimulation|Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
41268733|NCT05020561|BEHAVIORAL|Group life-coaching|"Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document."
41268734|NCT05020561|BEHAVIORAL|Individual life-coaching|In the individual coaching sessions, the life-coach will provide guidances that help the participants to put tools into actions. All activities are outlined in the After Cancer Passport. Participants will use their Passport for each individual coaching session to outline their objectives and indicators of success. The life coach will also assign activities, such as self-reflection, for the participants to complete between each session.
41268735|NCT01639430|OTHER|rectal, tympanal and temporal artery thermometry|"Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.~Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well."
41268736|NCT05995444|DRUG|Epetraborole and matching placebo|Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)
41268737|NCT05995444|DRUG|Epetraborole|Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)
41268738|NCT05995444|DRUG|Placebo|Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)
41268739|NCT05995444|DRUG|Moxifloxacin|Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)
41268740|NCT02033356|PROCEDURE|Adductor canal block with lidocaine 1%|US-guided adductor canal block
41268741|NCT02033356|DRUG|Lidocaine|
41268742|NCT01628926|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
41268743|NCT01628926|DRUG|Ropinirole|Ropinirole oral administration TID up to 15.0 mg/day
41268744|NCT01628926|DRUG|Placebo|SPM962-placebo patch and Ropinirole-placebo tab
41268745|NCT01216774|OTHER|Strength training|"Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM"
41268746|NCT00308451|DRUG|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
41268747|NCT02221089|DRUG|Escherichia coli Endotoxin|dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
41268748|NCT02221089|DIETARY_SUPPLEMENT|Retaron®|Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
41268749|NCT02221089|OTHER|Placebo|Placebo capsules identical in appearance to Retaron capsules
41268750|NCT05587751|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test to measure lung function
41268751|NCT05587751|DIAGNOSTIC_TEST|Plethysmography|Pulmonary function test to measure lung volume
41442426|NCT04767347|OTHER|35.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~35.5°C WBGT (40°C, 65% relative humidity) @ 15 min exercise per hour"
41442427|NCT04767347|OTHER|26.0°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~26.0°C WBGT (31°C, 55% relative humidity) @ 530 W metabolic heat production"
41268752|NCT04960085|DEVICE|echocardiography|philips IE33
41268753|NCT02471690|DRUG|Oritavancin|IV - Single dose 1200 mg Oritavancin
41268754|NCT02471690|DRUG|Dextrose|D5W 5% in Water
41268755|NCT00312455|DRUG|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
41268756|NCT00312455|DRUG|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
41268757|NCT00312455|DRUG|Placebo|5 capsules/day
41268758|NCT00298714|DRUG|Losartan|
41268759|NCT01765894|OTHER|45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.|
41268760|NCT00003417|DRUG|carmustine|
41268761|NCT00003417|RADIATION|radiation therapy|
41268762|NCT04409678|BEHAVIORAL|activity|physical activity
41268763|NCT03437447|DRUG|Cisticid|Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
41268764|NCT03437447|DRUG|Biltricide|Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
41268765|NCT04224935|PROCEDURE|Leukocyte Platelet rich fibrin membrane|the use of Leukocyte Platelet rich fibrin as grafting materials for treatment of recession
41268766|NCT01207830|DEVICE|Endo Bypass System|Subject is implanted with the device for up to 3 years.
41268767|NCT03964584|OTHER|assessment of neurological and psychiatric disorders by self-administered questionnaires|Patients will be included on the day dolutegravir or bictegravir is prescribed. Neurological and psychiatric disorders will be assessed using self-administered questionnaires, at inclusion, one month, three months and six months.
41268768|NCT03288298|DRUG|luteolin|flavonoid natural extract
41268769|NCT03288298|DRUG|nano-luteolin|nanoparticles of luteolin
41287168|NCT03613428|DRUG|Vincristine|1.4 mg/m2 i.v. weekly for 4 weeks
41287169|NCT03613428|DRUG|Prednisone|1 mg/kg orally 5 consecutive days per week for 4 weeks.
41268770|NCT03018132|OTHER|mental health screening, education and referral program|"I. Psychosocial assessments:~1. Mental health screening for: (1) depressive symptoms with the EPDS, (2) post-traumatic stress symptoms with the IES, (3) for perceived stress with the PSS (4) for anxiety with the OASIS.~2. Exercise, smoking \& substance use, sleep and nutrition.~II. If women are above cutoff values the SCID will be conducted.~III. Education and referral information via Maternal Mental Health NOW:~1. All receive a brochure entitled, Speak Up When You Are Down~2. If above cutoffs, participants will also receive referral information; and will be scheduled for a SCID~3. Trained study staff will review the brochure and show the woman how to use the MMHN online referral system to input their zip code and find preferred maternal mental health practitioners.~IV. Follow up with a survey at 3 months postpartum: acceptability of screening, benefit of referral service, and outcome of this referral."
41268771|NCT02768376|DRUG|Bupivacaine with Fentanyl (Spinal Anesthesia)|Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.
41268772|NCT02768376|DRUG|General anesthesia|Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
41268773|NCT05818670|DRUG|Tamsulosin|long term follow up
41268774|NCT05818670|DRUG|Tadalafil|long term follow up
41268775|NCT04474327|DRUG|Montelukast Sodium|Montelukast sodium (Singulair) will be given at a dose according to body weight. Four mg of the drug will be dissolved in four ml milk and the dose will be given once daily at 9 pm for 10 days.
41268776|NCT05868421|BEHAVIORAL|Support Person Coaching Call|Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The session will be delivered by research staff by phone or video call. Support persons in the intervention group and the control/no intervention group will receive existing written material resources on support strategies to stop smoking, and resources on how to stop smoking by postal mail or email.
41268777|NCT05868421|BEHAVIORAL|SP written materials|Written materials covering tips on effective supportive strategies for smoking cessation
41268778|NCT05868421|BEHAVIORAL|Written Smoking Cessation Materials|Written materials on resource and referral information for VHA and non-VHA EBCT options
41268779|NCT01586988|BEHAVIORAL|IMAGE Intervention|Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
41268780|NCT00840827|DRUG|lenalidomide|Lenalidomide 10mg po daily
41268781|NCT00840827|DRUG|cyclosporine A|CSA 250mg orally twice daily
41268782|NCT03160014|DRUG|SHR3824|Drug: SHR3824 20mg/day, oral tablet, single dose
41268783|NCT04237493|DRUG|Metformin and Glimepiride (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 1.5 or 3 mg \[75% of the pre-Ramadan dose\]; OD \[with Ifṭār\])"
41268784|NCT04237493|DRUG|Metformin and Vildagliptin (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; OD \[with Ifṭār\])"
41268785|NCT04237493|DRUG|Metformin and Insulin Glargine U100 (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 9-33 units \[75% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])"
41268786|NCT04237493|DRUG|Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 6-39 units (75% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 15-33 units before Ifṭār and 6-18 units before Suḥūr \[75% of the pre-Ramadan doses\])"
41268787|NCT04237493|DRUG|Metformin and Glimepiride (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 2 or 4 mg \[100% of the pre-Ramadan dose\]; OD \[with Ifṭār\])"
41093580|NCT00898274|OTHER|immunoenzyme technique|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
40920259|NCT04176419|DRUG|Placebo Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
41268788|NCT04237493|DRUG|Metformin and Vildagliptin (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; BID \[with Ifṭār and with Suḥūr\]\])"
41268789|NCT04237493|DRUG|Metformin and Insulin Glargine U100 (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 11-44 units \[100% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])"
41268790|NCT04237493|DRUG|Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 8-52 units (100% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 12-40 units before Ifṭār and 7-28 units before Suḥūr \[100% of the pre-Ramadan doses\])"
41268791|NCT00274391|DRUG|7% NaCl|
41268792|NCT00274391|DRUG|Amiloride HCl|
41268793|NCT03144648|OTHER|lifestyle|Observational study
41268794|NCT04784962|DEVICE|Revitive Medic Neuromuscular Stimulation Device|Usage of the Revitive NMES device - 1-6 sessions daily (30 minutes per session).
41268795|NCT04784962|DEVICE|Revitive Medic Neuromuscular Stimulation Device (Sham)|Usage of the Sham Revitive NMES device - 1-6 sessions daily (30 minutes per session)
41268796|NCT05152381|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41268797|NCT02619851|BIOLOGICAL|ALLO-ASC-DFU|Dressing for Second Deep degree Burn injury
41268798|NCT02619851|DEVICE|Conventional Therapy|Typical therapy conducted for burn injury patients
41268799|NCT04801407|PROCEDURE|percutaneous radiofrequency trigeminal rhizotomy|percutaneous radiofrequency trigeminal rhizotomy is a perctaneous procedure that ablate the sensory part of the nerve and
41268800|NCT04801407|PROCEDURE|Microvascular decompression of the trigeminal nerve|Microvascular decompression is a procedure that decompress the nerve from vascular conflict
41268801|NCT06351267|OTHER|Core Stability Exercises|Core stability exercises will be used to strengthen the core muscles, which includes sets of exercises like pelvic tilts, wall squatting, bridging, bird dog and heel walking which targets core muscles.
41268802|NCT06351267|OTHER|Back Strengthening exercises|Back strengthening exercises will be used to strengthen the back muscles which include sets of exercises that target back muscles like cat-cow exercise, child pose, heel sits, and kegels.
41268803|NCT02815215|PROCEDURE|Minimally Invasive Carroll's Technique|Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks
41268804|NCT02815215|PROCEDURE|Ponseti method|As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
41268805|NCT00588367|DEVICE|Mayo Interactive Breath Hold Monitor|Biofeedback device
41268806|NCT01712347|DRUG|Bevacizumab|Bevacizumab will be administered as per approved label.
41268807|NCT01712347|DRUG|Chemotherapy|The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
41268808|NCT02868203|DEVICE|OCT|OCT after stent implantation
41268809|NCT02868203|DEVICE|eLuting stent|
41268810|NCT05864235|BEHAVIORAL|Control|Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.
41442428|NCT04767347|OTHER|30.5°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 230 W metabolic heat production"
41442429|NCT04767347|OTHER|30.5°C WBGT - Fixed work-to-rest ratio (high intensity)|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 530 W metabolic heat production"
41442430|NCT02928185|BEHAVIORAL|semi-structured interviews|
41442431|NCT01066598|DRUG|Rituximab|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
40758189|NCT02970812|DEVICE|Transcutaneous Electrical Nerve Stimulation|Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
40758190|NCT01018771|PROCEDURE|Actifuse ABX|bone graft to be used in posterolateral instrumented lumbar fusion
40758191|NCT01018771|PROCEDURE|INFUSE, plus Mastergraft granules|bone graft to be used in posterolateral instrumented lumbar fusion
41268811|NCT05864235|BEHAVIORAL|Goal Support (GS)|Each week for 6-weeks, GS group participants will receive prompts and tailored feedback and support focused on weekly drinking limit goal commitment \& confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.
41268812|NCT05864235|BEHAVIORAL|Coaching for Context-specific Peer Support (CCPS)|Each week for 6-weeks, CCPS group participants will receive weekly motivation and strategies to enlist peer support during drinking episodes.
41268813|NCT01756456|DRUG|rhNGF 10 μg/ml|rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
41268814|NCT01756456|DRUG|rhNGF 20 μg/ml|one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
41268815|NCT01756456|OTHER|vehicle|ophthalmic solution of the same composition as the test product without rhNGF
41268816|NCT01727258|DEVICE|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
41268817|NCT01727258|DRUG|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
41268818|NCT01727258|DRUG|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
41268819|NCT00282126|DIETARY_SUPPLEMENT|Potassium citrate|kcitrate
41268820|NCT05996484|DRUG|Toripalimab|Toripalimab, 240mg, IV., D1, every 3 weeks, 4 cycles.
41268821|NCT05996484|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off, every 3 weeks, 4 cycles.
41268822|NCT05996484|DRUG|Albumin paclitaxel|Albumin paclitaxel, 200-260 mg/m2, IV., D1, every 3 weeks, 4 cycles.
41268823|NCT05996484|DRUG|Cisplatin|Cisplatin, 60-75 mg/m2, IV., D1, every 3 weeks, 4 cycles.
41268824|NCT00024427|DRUG|fluorouracil|High dose 5-FU
41268825|NCT00024427|DRUG|gemcitabine hydrochloride|Normal dose to treat pancreatic cancer
41268826|NCT00024427|DRUG|triacetyluridine|6 grams (12 tablets)
41268827|NCT04699279|DRUG|Rosuvastatin 10mg|Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.
41268828|NCT02423096|DRUG|Risperidone|Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
41268829|NCT03595202|DRUG|TS-143|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
41268830|NCT03595202|DRUG|Placebo|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
41268831|NCT05524779|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
41268832|NCT05546619|DRUG|HIPEC+tislelizumab + targeted therapy|Patients with open liver lobe/segment resection, tumor excision, lymph node dissection will receive medication.
40920260|NCT04176419|DRUG|Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
40920261|NCT04176419|DRUG|Placebo Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
41093581|NCT00898274|OTHER|laboratory biomarker analysis|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
41093582|NCT06292702|PROCEDURE|Traditional Burch colposuspension|Peforming two stitches between the anterior vaginal wall and Cooper's ligament.
41268833|NCT01903941|BEHAVIORAL|Aerobic Exercise|
41268834|NCT01903941|BEHAVIORAL|Only Counseling|
41268835|NCT06310993|OTHER|Exercise|Exercise programme is the intervention for this study
41268836|NCT04236544|BEHAVIORAL|PExMS and DECIMS-Wiki|The intervention consists of an information provision on immunotherapies as a combination of factual and experiential information. PExMS is a multimedia website providing patient experiences with MS in everyday life and with therapies illustrated by video, audio and text files of 48 persons with multiple sclerosis. The development of the intervention followed largely recommendation for standardised qualitative research provided by international DIPEx (Database of Individual Patients' Experience of illness) association, which use standardised qualitative research methods to provide 'balanced' information from original interview data. Data for the website was generated in a qualitative interview study with relapsing remitting multiple sclerosis patients across Germany. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies.
41268837|NCT04236544|BEHAVIORAL|DECIMS-Wiki|The active comparator is DECIMS-Wiki, which is an evidence-based online information platform. It is considered to be excellent factual information about immunotherapies for multiple sclerosis.
41268838|NCT00627237|BEHAVIORAL|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
41268839|NCT00627237|BEHAVIORAL|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
41268840|NCT00092508|DRUG|OPC-6535|
41268841|NCT00092508|DRUG|Asacol®|
41268842|NCT00486902|DRUG|Ketamine|Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
41268843|NCT00486902|DRUG|Placebo|Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
41268844|NCT01247311|DIETARY_SUPPLEMENT|Dietary supplement|Placebo given orally 3xweek for six months
41268845|NCT01247311|DIETARY_SUPPLEMENT|Vitamin D|5000 IU vitamin D given orally 3xweek for six months
41268846|NCT01247311|DIETARY_SUPPLEMENT|Vitamin D|0.5ug 1,25 vitamin D given orally 3xweek for six months
41268847|NCT02060422|BEHAVIORAL|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
41268848|NCT02060422|BEHAVIORAL|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
40758192|NCT05196529|OTHER|Inspiratory muscle training|All participants will undergo inspiratory muscle training.
40920262|NCT04176419|DRUG|Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
40920263|NCT04176419|DRUG|Placebo Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
40920264|NCT04176419|DRUG|Gabapentin|600 mg orally at time of check in to the preoperative unit
40920265|NCT04176419|DRUG|Placebo Gabapentin|600 mg orally at time of check in to the preoperative unit
40920266|NCT04176419|DRUG|Celecoxib|200 mg orally at time of check in to the preoperative unit
40920267|NCT04176419|DRUG|Placebo Celecoxib|200 mg orally at time of check in to the preoperative unit
41268849|NCT03906682|BEHAVIORAL|RAP Club|RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.
41287170|NCT01300143|OTHER|TACE|Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
41442432|NCT06333171|DRUG|4-Aminopyridine|Active study drug
41442433|NCT06333171|OTHER|Placebo|Placebo comparator
41268850|NCT03906682|BEHAVIORAL|Healthy Topics|Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
41268851|NCT00891514|BEHAVIORAL|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
41268852|NCT00891514|BEHAVIORAL|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
41268853|NCT00151892|DRUG|SPD476|2.4 g/day Once Daily (QD)
41268854|NCT00151892|DRUG|Asacol|1.6g/day administered 800 mg Twice Daily (BID)
41093583|NCT06292702|PROCEDURE|Modified Burch colposuspension|Performing lateral tension for the anterior vaginal wall towards the intersection point of the arcus tendineus and the lower edge of the pubic bone then performing two stitches between the anterior vaginal wall and Cooper's ligament.
41093584|NCT00188929|PROCEDURE|PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)|
41268855|NCT02159027|DRUG|Maraviroc|Maraviroc administered twice daily, dosage based on concomitant medication being taken.
41268856|NCT02159027|DRUG|Placebo|Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
41268857|NCT05684380|DRUG|MAZ-101association|Experimental drug
41268858|NCT05684380|DRUG|DYMISTA®|Active comparator
41268859|NCT00516919|DRUG|Xenical + behavioral intervention|120 mg TID; Behavioral weight loss in Spanish
41268860|NCT00516919|BEHAVIORAL|Behavioral intervention + placebo|Behavioral weight loss treatment in Spanish Placebo TID
41268861|NCT05521737|PROCEDURE|Electroacupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. EA is applied for 20 minutes at an alternating frequency of 2 Hz. Acupunctural points are Zusanli (E36), Fenlong (E40), Yinlingquan (B9), Sanyinjiao (B6), Taichong (H3) and Zulinqi (VB41).
41268862|NCT05521737|PROCEDURE|Sham Acupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. Sham acupuncture will be applied using a nonpuncture device without electrical stimulation at the same acupunctural points as in the EA group.
41268863|NCT02953041|DRUG|Glycopyrronium|long-acting muscarinic antagonist
41268864|NCT02953041|DRUG|Indacaterol|ultra long-acting beta agonist
41268865|NCT03838484|DRUG|Nicotine Patch, 7 Mg/24 Hr|Nicotine patch, 7 mg/24 hour will be applied to the skin.
41268866|NCT03838484|DRUG|Placebo patch|Placebo skin patch will be applied to the skin.
41268867|NCT05072444|DRUG|QPX7728|beta lactamase inhibitor
41268868|NCT05072444|DRUG|QPX2014|antibiotic
41268869|NCT04122287|DRUG|Levofloxacin|levofloxacinn-tetracycline-containing quadruple regimens
41268870|NCT04122287|DRUG|tinidazole|tinidazole-tetracycline-containing quadruple regimens
41268871|NCT05396209|PROCEDURE|Hydrated Amniotic Membrane Plug|Using Hydrated Amniotic Membrane plug with vitrectomy to try to close refractory macular hole
41268872|NCT05396209|PROCEDURE|ILM filling|The ILM filling technique - Rossi et al show that ILM filling technique was more efficacious in closing full-thickness macular holes larger than 630μm, in which the free ILM after peeling is plug into the area of the macular hole
41268873|NCT05396209|PROCEDURE|Conventional ILM peeling|Peeling with complete removal of the internal limiting membrane within the vascular arch
41268874|NCT01107444|DRUG|Docetaxel|Administered intravenously
41268875|NCT01107444|DRUG|LY2181308|Administered intravenously
41268876|NCT04917770|DRUG|Sintilimab in combination with Multimodality Radiotherapy|Participants will be treated with sintilimab in combination with multimodality radiotherapy
41268877|NCT02529033|DEVICE|LIDCO Rapid, Pulmonary artery catheter|Hemodynamic monitoring systems
41268878|NCT01354132|DRUG|n-acetylcysteine|900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
41268879|NCT01354132|DRUG|Placebo|Placebo tablets are placed in water or juice in the AM and PM
41268880|NCT02648126|PROCEDURE|Pure Red Cell Aplasia diagnostic confirmation|"Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.~The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa"
41268881|NCT06324461|DRUG|Semaglutide 0.25mg subcutaneous injection|Subject randomized into treatment group will receive single subcutaneous dose of Semaglutide 0.25mg 1 to 4 days prior to surgery
41268882|NCT04920240|BEHAVIORAL|cleaning and disinfection mode for surfaces with high frequency contact|According to the results of the survey on the status of high frequency contact surface, the corresponding frequency and method of cleaning and disinfection are determined. Set up a multidisciplinary quality control team.
41268883|NCT04920240|BEHAVIORAL|Routine procedure|clean the high frequency contact surface like other surfaces
41268884|NCT03190187|OTHER|Spinal Manipulation|Spinal manipulation based on orthopaedic manual therapy approach
41268885|NCT03190187|OTHER|Sham manipulation|Patients will receive simulated spinal manipulation without force application
41268886|NCT06127121|BEHAVIORAL|Digital Art Activity|"* complete a symptom questionnaire~* complete another activity such as listening to meditative music for 10 minutes~* fill out the symptom questionnaire and engage in the digital art activity again"
41268887|NCT06369714|DRUG|Concerta|Methylphenidate Hydrochloride Extended-Release Tablets with the following specifications: 18mg dosage, oral administration, once a day for a duration of 8 weeks.
41268888|NCT06369714|DEVICE|Digital therapeutics|30 sessions of digital therapeutics, each lasting 30 minutes, will be conducted with a frequency of once every 1-2 days over an 8-week period.
41268889|NCT02948361|OTHER|QT Ultrasound Breast Scan|Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per American College of Radiology (ACR) recommendations.
41268890|NCT05833802|OTHER|virtual anti-cancer drug|the virtual anti-cancer drug was formulation generated by computer modeling and artificial intelligence technology
41268891|NCT01321489|DRUG|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
41268892|NCT01321489|DRUG|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
41268893|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI structured group CBT|ReInventing Yourself after SCI intervention integrates positive psychotherapy concepts into structured group cognitive behavioral therapy (CBT) to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle. The intervention consists of six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion.
41268894|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI study-specific workbook|A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.
41268895|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI YouTube videos|YouTube videos containing the content of the ReInventing Yourself after SCI structured group CBT sessions
41268896|NCT05318521|DRUG|Placebo|The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen
41268897|NCT05318521|DRUG|Ibuprofen modified release tablet 800 mg|Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
41268898|NCT04736823|DRUG|AK112|IV infusion
41268899|NCT04736823|DRUG|Pemetrexed|IV infusion
41268900|NCT04736823|DRUG|Paclitaxel|IV infusion
41268901|NCT04736823|DRUG|Carboplatin|IV infusion
41268902|NCT04736823|DRUG|Docetaxel|IV infusion
41268903|NCT02510079|BIOLOGICAL|Autologous human Schwann cells|Schwann cells harvested from the sural nerve will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
41268904|NCT05601245|OTHER|High voltage pulsed current|The treatment session duration is 45 minutes (Reverse the polarity after the first 22 minutes)
41268905|NCT05601245|OTHER|Microcurrent therapy|The treatment session duration is 40 minutes.
41268906|NCT06023667|BEHAVIORAL|SMART-IBD|Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
41268907|NCT03700957|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|100 milligrams of Docosahexaenoic Acid
41268908|NCT03700957|OTHER|placebo|placebo
41268909|NCT00652184|DRUG|ARYS-01 (sorivudine) cream 3% or placebo cream|sorivudine cream 3% or placebo cream twice daily for 10 days
41268910|NCT00652184|DRUG|placebo|placebo cream and placebo valaciclovir
41268911|NCT00652184|DRUG|valaciclovir|active valaciclovir
41268912|NCT05501626|DEVICE|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
41268913|NCT05501626|DEVICE|Sham Theta Burst Stimulation (TBS)|Each session will be comprised of SHAM TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
41268914|NCT05183919|OTHER|Digital Treatment|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
41268915|NCT00828464|DRUG|clobetasol propionate|Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
41268916|NCT01420510|DRUG|Adelmidrol vaginal gel|Application of a Adelmidrol vaginal gel
41268917|NCT01420510|DRUG|Placebo vaginal gel|Application of a placebo vaginal gel
41268918|NCT03467178|DRUG|Decitabine|Nucleic Acid Synthesis Inhibitor
41268919|NCT03467178|DRUG|Carboplatin|Chemotherapy medication
41268920|NCT03467178|DRUG|Pegylated Liposomal Doxorubicin|Chemotherapy medication
41268921|NCT03467178|DRUG|Gemcitabine|Chemotherapy medication
41268922|NCT03467178|DRUG|Paclitaxel|Chemotherapy medication
41268923|NCT04704622|DRUG|Ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
41268924|NCT04704622|DRUG|Midazolam|midazolam intranasal injection,0.2mg/kg, once, 30 min preoperative
41268925|NCT04704622|DRUG|Dexmedetomidine|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
41268926|NCT02066792|DRUG|D-Cycloserine|D-cycloserine is a medication thought to be associated with fear extinction.
41268927|NCT02066792|DRUG|Placebo|Sugar pill
41287171|NCT01300143|OTHER|TACE+ RTC|Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
41287172|NCT02312986|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
41093585|NCT03768245|BEHAVIORAL|Health Education and Physical activity program|Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.
41093586|NCT03768245|DIETARY_SUPPLEMENT|Nutrition Program|Its objective is to maintain lean mass, decrease fat mass and ensure mineral vitamins and fatty acids intake, maintain proper growth under National Specific Action Program: Food and Activity4. From total energy, a fat intake of 25-35%, carbohydrate intake of 45-65%, protein intake of 10-30%, and total calories are adjusted according to age. The Nutrition program consists of three meals: breakfast, a snack for a mid-morning playtime, and lunch at school. Food is prepared daily following sanitary and quality standards of Mexican official regulation. Breakfast is served 40 minutes before starting class time, lunch is served 40 minutes before leaving school.
41093587|NCT04730180|DEVICE|Transcranial Magnetic Simulation|Brain stimulation treatment will be performed using FDA-cleared TMS coils according to their intended use of treatment of medication resistant depression by targeting the dorsolateral prefrontal cortex.
41268928|NCT02066792|BEHAVIORAL|Cognitive Behavioral Therapy|This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
41268929|NCT04386889|OTHER|Vasculitis In SLE|20 SLE female Egyptian patients, among them we are going to study the vasculitic pattern incidence.
41268930|NCT05861505|DRUG|Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)|"Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation"
41268931|NCT05861505|OTHER|Repeat local treatment|"Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection)."
41268932|NCT04266535|DEVICE|Target controlled infusion|Target controlled infusion vs manually controlled infusion
41093588|NCT04730180|DEVICE|Mixed reality neuronavigation|Targeting of the dorsolateral prefrontal cortex will be performed with the help of a mixed reality neuronavigation system.
41268933|NCT04911621|BIOLOGICAL|Dendritic cell vaccination + temozolomide-based chemoradiation|"1. Leukocyte apheresis (before chemoradiation): for dendritic cell (DC) vaccine production.~2. Chemoradiation (1st part standard treatment, initiated as soon as the patient's hematological blood values are adequate after apheresis, but no later than 6 weeks after surgery or confirmed diagnosis): 1.8 Gy once daily 5 days/week for 6 weeks with 90 mg/m² temozolomide daily from the first until the last day of radiotherapy.~3. Induction immunotherapy: intradermal vaccination with autologous Wilms' tumor-1 (WT1) mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 1 week after radiotherapy.~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 3 days (max. 6 months, 2nd part standart treatment) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle."
41268934|NCT04911621|BIOLOGICAL|Dendritic cell vaccination +- conventional next-line treatment|"1. Leukocyte apheresis (upon recovery of hematological blood values following previous anti-glioma treatments and ≥ 4 weeks after the last dose of any investigational agent): for DC vaccine production.~2. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 4 weeks after apheresis.~3. Booster immunotherapy: 6 DC booster vaccinations administered at regular intervals (+- 4 weeks), starting ≥ 3 weeks after the last induction vaccine.~4. (Optional) Concomitant conventional anti-glioma treatment: The decision to continue or re-initiate conventional anti-glioma treatment, and, if applicable, its dose and scheme, are at the Investigator's discretion and will depend on the patient's previous treatment scheme and condition."
41268935|NCT02849639|OTHER|Placebo|Participants will receive educational materials, but will not receive MTM.
41268936|NCT02849639|OTHER|Medication Therapy Management (MTM)|Participants will receive MTM in addition to the educational materials.
41268937|NCT02849639|DRUG|Scopolamine patch|At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.
41268938|NCT04058522|OTHER|Rotator cuff rehabilitation classes|
41268939|NCT04058522|OTHER|Individual Physiotherapy|
41268940|NCT04058522|DRUG|Triamcinolone Injection|Subacromial Injection 40mg/1ml
41268941|NCT03041311|DRUG|Trilaciclib|Trilaciclib IV
41268942|NCT03041311|DRUG|Placebo|Placebo IV
41268943|NCT03041311|DRUG|Carboplatin|Carboplatin IV
41268944|NCT03041311|DRUG|Etoposide|Etoposide IV
41268945|NCT03041311|DRUG|Atezolizumab|Atezolizumab IV
41268946|NCT01997151|BEHAVIORAL|Healthy Pregnancy: Step by Step|
41268947|NCT04452890|DIAGNOSTIC_TEST|Sonourethrography|Ultrasound of the urethra.
41268948|NCT02436941|RADIATION|Proton or Photon|
41268949|NCT06048185|BIOLOGICAL|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
41268950|NCT04025632|DRUG|zilucoplan|Daily subcutaneous (SC) inection
41268951|NCT04025632|OTHER|Placebo|Daily subcutaneous (SC) inection
41268952|NCT01130922|DRUG|moxifloxacin per IV|intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
41268953|NCT01130922|DRUG|moxifloxacin per os|oral administration of 400 mg moxifloxacin in a single dose
41268954|NCT03869255|PROCEDURE|Nasal swab|In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed
41268955|NCT05405647|DEVICE|Shock wave Therapy|a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session and a frequency of 5 Hz., 1 sessions per week for 6 weeks.
41268956|NCT05405647|DEVICE|kinesio tape|kinesio tape application on the affected wrist for 3 days and then one day off and then another 3 days each week for 6weeks.
41268957|NCT04879615|DRUG|Alteplase|Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
41268958|NCT01714986|BEHAVIORAL|Affect School|
41268959|NCT01714986|BEHAVIORAL|Body Awareness Therapy|
41268960|NCT01854346|BEHAVIORAL|Social skills group training, KONTAKT|KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
41268961|NCT00944827|DIETARY_SUPPLEMENT|Green Tea Extract - Catechins|Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks
41268962|NCT00944827|DIETARY_SUPPLEMENT|Placebo|Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks
41268963|NCT00450944|BIOLOGICAL|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
41268964|NCT06129630|PROCEDURE|Conventional occupational therapy sessions.|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
41268965|NCT06129630|PROCEDURE|Conventional occupational therapy sessions + Nintendo Switch|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
41268966|NCT04184687|PROCEDURE|Nanofractures|anterior cruciate ligament reconstruction will be performed in combination with the nanofractures for the treatment of cartilaginous lesions
41268967|NCT04184687|PROCEDURE|no treatment cartilaginous lesions|patient undergoing to the anterior cruciate ligament reconstruction without treatment of the cartilaginous lesions
41268968|NCT06334367|DRUG|CD25 treatment|CD25 prophylaxis
41268969|NCT06334367|DRUG|low-dose ATG|HSCT pre-treatment with 7.5mg/Kg ATG(2.5mg/Kg/d) at day -4, -3 and -2.
41093589|NCT04768062|DRUG|Viltolarsen|Received during weekly intravenous infusions
41268970|NCT04920136|PROCEDURE|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The flap will be then elevated with a split-thickness flap beyond the mucogingival junction where it is sutured at this apical position using a mattress (5-0, monocryl) suture. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.
41268971|NCT04920136|PROCEDURE|Free Gingival graft|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area was sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
41268972|NCT03017209|DIETARY_SUPPLEMENT|Locally-prepared bar|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
41093590|NCT05310084|BIOLOGICAL|BNT162b2|Intramuscular injection
41093591|NCT05310084|OTHER|Placebo|Saline intramuscular injection
41093592|NCT05310084|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|SIIV intramuscular injection
40758193|NCT05426681|DRUG|GlyBURIDE Oral Tablet|"Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.~Intervention: Drug: Glyburide"
40758194|NCT02380157|DRUG|Kaleorid, 750mg (trade name), Potassium chloride (active substance)|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
41093593|NCT04073355|BEHAVIORAL|Physical Activity|Smartphone-delivered physical activity intervention
41093594|NCT01577043|DRUG|Racecadotril|Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
41093595|NCT01577043|OTHER|Placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
41093596|NCT00083421|DRUG|ONO-2506PO|
41093597|NCT03781960|DRUG|Abemaciclib|Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial therapy.
41268973|NCT03017209|DIETARY_SUPPLEMENT|USAID Corn Soy Blend Plus|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
41268974|NCT03017209|OTHER|Placebo|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
41268975|NCT03720314|OTHER|NA observational study|observational study
41268976|NCT03870802|OTHER|Characterization of breast stem & immune system cells infiltrated in the mammary gland|Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.
41268977|NCT01402245|BIOLOGICAL|Pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccine 0.5 ml i.m.
41268978|NCT01402245|BIOLOGICAL|pneumococcal conjugate vaccine|pneumococcal conjugate vaccine 0.5 ml i.m.
41268979|NCT01400256|DRUG|Valsartan|After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
41268980|NCT03480802|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
41268981|NCT03480802|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
41268982|NCT03480802|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
41268983|NCT06151392|DRUG|Probiotic Formula|probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
41268984|NCT06151392|DRUG|Zinc|Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
41268985|NCT02298114|DEVICE|NEUROMUSCULAR ELECTRICAL STIMULATION|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
41268986|NCT02298114|OTHER|Conventional physiotherapy|The control group will receive conventional physiotherapy associated the placebo electrical stimulation
41268987|NCT00158366|BEHAVIORAL|Behavioral training|The behavioral training will teach participants ways to control their diet and increase their physical activity.
41268988|NCT00158366|BEHAVIORAL|Social skills training|The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
41268989|NCT00158366|BEHAVIORAL|Behavioral training booster sessions|During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
41268990|NCT03770403|BIOLOGICAL|ARGX-113|Intravenous administration of ARGX-113
41268991|NCT04364204|OTHER|Kangaroo Mother Care and BEMPU bracelet|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. The BEMPU bracelet, also known as the BEMPU Tempwatch, is a silicone band with a thermistor metal cup that emits an audio alarm and flashes an orange light when the body temperature drops below 36.5⁰C, signaling hypothermia and prompting caregiver to provide thermal care.
40758195|NCT02380157|DRUG|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
40758196|NCT03109769|BEHAVIORAL|Mobile phone application|
41268992|NCT04364204|OTHER|Kangaroo Mother Care|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. This is the current standard of care for low birthweight/preterm infants.
41268993|NCT00000943|BIOLOGICAL|Tetanus Toxoid Vaccine|
41093598|NCT03781960|DRUG|Nivolumab|Nivolumab will be administered at a dose of 480mg IV every 28 days. Treatment with nivolumab will begin after an initial 7-day treatment period with abemaciclib monotherapy.
41268994|NCT00000943|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
41093599|NCT03661970|OTHER|Cognate Speech Synthesizer sound percepts|The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
41093600|NCT06384053|COMBINATION_PRODUCT|Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined|The wIRA device applies hyperthermia by heating the treatment area (with maximum surface temperature set to 43° C), aiming to make cancer cells more sensitive to radiation therapy for non-melanoma skin cancer combined with radiotherapy.
41093601|NCT06384053|RADIATION|Radiotherapy (RT)|Radiotherapy is applied.
41268995|NCT00000943|BIOLOGICAL|HIV-1 Immunogen|
41268996|NCT00000943|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
41093602|NCT00108784|BEHAVIORAL|Reduced-energy-density diet|
41093603|NCT04920214|DIAGNOSTIC_TEST|SonoVue|CEUS examination was performed and corresponding image information of liver lesions was obtained.
41093604|NCT02180711|DRUG|acalabrutinib|
41268997|NCT04041375|BEHAVIORAL|iNSPiRED|The peer intervention will include approximately 5 to 6 contacts over a 3-month period. Peer navigators are responsible for providing emotional and social support, normalizing the difficulty of living with DM, modeling help-seeking behaviors, and connecting patients with VHA and/or CBOs to address mental health and DM self-management needs. Peer coaches are not responsible for health education directly; rather, they encourage patients to use appropriate programs in which mental health and DM self-management services are provided.
41268998|NCT04041375|OTHER|Usual Care|Veterans randomized to the usual care condition will be encouraged to follow-up with their primary care provider and/or specialty providers for management of their health conditions. They will also receive a packet of printed information that includes a list of self-management support resources in the VHA and the local community. They will receive no further specific recommendations
41268999|NCT03281785|OTHER|Pressure controlled mandatory ventilation mode (P-CMV)|Pressure controlled mandatory ventilation mode (P-CMV)
41269000|NCT03281785|OTHER|Pressure synchronized intermittent mandatory ventilation|Pressure synchronized intermittent mandatory ventilation
41269001|NCT03281785|OTHER|Pressure support mode (PS)|Pressure support mode (PS)
41269002|NCT04232657|DRUG|Romosozumab|39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
41269003|NCT04232657|DRUG|Denosumab|Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
41269004|NCT04232657|DRUG|Placebo|Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
41269005|NCT05763602|DRUG|povidone-iodine topical ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
41269006|NCT00546975|DIETARY_SUPPLEMENT|Resource Support®|
41269007|NCT00546975|DIETARY_SUPPLEMENT|Resource Protein®|
41269008|NCT00546975|DIETARY_SUPPLEMENT|Placebo|
41269009|NCT01147614|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting
41269010|NCT01147614|BEHAVIORAL|Specialty mental health care referral (SMHC)|SMHC: specialty mental health care referrals provided
41269011|NCT01646099|BEHAVIORAL|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
41269012|NCT01035190|DRUG|Budesonide|Inhalation, 200 µg/puff
41269013|NCT02497001|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler \[MDI\])
41269014|NCT02497001|DRUG|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
41269015|NCT02497001|DRUG|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
41269016|NCT02497001|DRUG|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
41269017|NCT02043925|DRUG|drugs linked with QT-prolongation|all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
41269018|NCT05689619|DIETARY_SUPPLEMENT|Silibinin|Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
41269019|NCT05689619|OTHER|Placebo|Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
41269020|NCT03649919|OTHER||Patients receive routine diagnostic and treatment medications.
41269021|NCT04671836|DRUG|Lorazepam 1Mg Tablet|"1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI."
41269022|NCT04671836|DRUG|Placebo|Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
41269023|NCT04686422|DEVICE|Tetric PowerFill|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the PowerCure system.
41269024|NCT05030714|DIAGNOSTIC_TEST|Visual Field Testing|Visual field testing using the protocol 24-2 and/or 10-2 Threshold Test
41269025|NCT04607395|RADIATION|pre-operative radiograph|"Three hundred and sixty pre-operative radiographs of deep carious lesions and a contrasted version of the same set have been screened and annotated by 4 evaluators. Annotations were placed at the dentino-enamel junction, at the floor of the carious lesions, and on pulp chamber wall. From these annotations, the ratios residual dentin thickness/ total dentin thickness were derived. First, inter-evaluator agreement and concordance were assessed. A logistic regression that accounted for measurement error was applied to precisely estimate the capacity of the ratio to predict exposure (reported as odds-ratio)."
41269026|NCT04764942|DRUG|Carfilzomib|Given IV
41269027|NCT04764942|DRUG|Dexamethasone|Given PO
41269028|NCT04764942|DRUG|Pomalidomide|Given PO
41269029|NCT04764942|OTHER|Quality-of-Life Assessment|Ancillary studies
41269030|NCT04764942|OTHER|Questionnaire Administration|Ancillary studies
41269031|NCT04764942|DRUG|Selinexor|Given PO
41269032|NCT04764942|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
41269033|NCT04764942|PROCEDURE|Computed Tomography|Undergo PET/CT
41269034|NCT04764942|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41269035|NCT04764942|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
41269036|NCT04764942|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
41269037|NCT04764942|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41269038|NCT02086331|PROCEDURE|Contrast enhanced ultrasound|Infusion of microbubbles to enhance blood vessels in the leg for ultrasound
41269039|NCT02086331|BEHAVIORAL|Treadmill test|Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol
41269040|NCT02086331|PROCEDURE|Contrast enhanced ultrasound|
41269041|NCT06031077|PROCEDURE|cardiac catheterization|An observational, retrospective study will be carried out. Roughly 111 patients were registered at EWMSC and Cardiac Angiograms were done via approached through the left radial access between January 2020 and June 2021 at EWMSC. However since 2021 Cardiac Angiograms were also done via the anatomical snuff box. This study seeks to compare the results of Cardiac Angiograms vs Left Radial Access and the Anatomical Snuff box.
41269042|NCT06154070|DRUG|DaxibotulinumtoxinA|"Patients enrolled who meet eligibility will receive a total of 344 units of DAXI Injections in divided doses over 19 landmarks, including the face, head and shoulders, as identified per the EEG paradigm, at visit 2.~Follow-up visits via combination of phone and in office will occur at V3, week 8 thru V9, week 24."
41269043|NCT00005630|BIOLOGICAL|ras peptide cancer vaccine|
41269044|NCT00005630|BIOLOGICAL|sargramostim|
41269045|NCT01904799|OTHER|Cognitive Assessment test|
41269046|NCT04873492|OTHER|Biological sample collection|Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.
41269047|NCT05675007|DIETARY_SUPPLEMENT|Colon-delivered multivitamin supplement|Colon-delivered multivitamin supplement containing the following dose of the indicated vitamin: vitamin B2 (10 mg), vitamin B3 (4.0 mg), vitamin B6 (1.4 mg), vitamin B9 (400 μg), vitamin C (200 mg) and vitamin D3 (15ug). Vitamin capsules are filled with microcrystalline cellulose and magnesium stearate up to 200 mg. Control of release in the colon is achieved by the Eudragit S 100 coating layer technology that surrounds the vitamins contained in the core capsules.
41269048|NCT05675007|DIETARY_SUPPLEMENT|Placebo capsule|Placebo capsule containing microcrystalline cellulose and magnesium stearate up to 200 mg. Placebo capsules are coated with the Eudragit S 100 coating layer.
41269049|NCT04329026|DEVICE|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
41269050|NCT04329026|DEVICE|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
41269051|NCT01919892|DRUG|Lithium|
41269052|NCT01256541|DRUG|Kristalose|The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
41269053|NCT05787847|BEHAVIORAL|Incentives for Abstinence|Participants in the incentives for abstinence condition will have the opportunity to earn financial incentives for abstaining from stimulant use.
41269054|NCT05787847|BEHAVIORAL|Health Education|The Health Education condition is based on a previous intervention used as a control in a number of other studies. Sessions consist of an educational program addressing a variety of health, wellness, and lifestyle topics adapted from a previously implemented wellness manual.
41269055|NCT00468897|DRUG|RSG XR|RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
41269056|NCT05100537|BEHAVIORAL|Mindfulness Based Stress Reduction|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of emotions, awareness of thoughts, awareness of sensations. It involves full awareness of daily activities, using the breath as an anchor for attention.In addition to mindfulness practices and experiential work, psychoeducation and participants' sharing will clarify the issues of stress, stress management and how mindfulness is applied in daily situations and interpersonal communication.
41269057|NCT05100537|OTHER|continuing a routine life|No intervention will be made in the control group.
41269058|NCT01572155|PROCEDURE|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
41269059|NCT01572155|PROCEDURE|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
40758197|NCT03109769|BEHAVIORAL|Verbal oral hygiene instructions|
41093605|NCT02180711|DRUG|rituximab (IV)|
41093606|NCT02180711|DRUG|Lenalidomide|
41093607|NCT01571089|BEHAVIORAL|DBT-inspired anxiety treatment|In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
41093608|NCT01547104|DRUG|Linagliptin|Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
41269060|NCT01851538|OTHER|Observational study; no intervention.|
41269061|NCT01009307|GENETIC|polymorphism analysis|
41269062|NCT01009307|OTHER|laboratory biomarker analysis|
41269063|NCT01009307|OTHER|medical chart review|
41269064|NCT01290926|DRUG|chemotherapy|sorafenib 600mg/day capecitabine 1250 mg/m²/day
41269065|NCT05621980|BEHAVIORAL|Actuated Virtual Keyboard (AVK) system|"The participant controls an avatar hand by the movement of their own digits. Each avatar digit corresponds to a given virtual key. Sufficient digit flexion results in playing of that key, with visual and auditory feedback of key strike. Participants will wear a soft exoskeleton, the PneuGlove, with embedded bend sensors to provide real-time measurement of digit flexion. Pneumatic resistance to flexion can be applied to each digit independently, along with extension assistance, through air chambers running through the glove. The FES is intended to assist finger flexion by activating extrinsic finger flexor muscles. A high-density 2×8 stimulation electrode grid will be placed over the median and ulnar nerves at the medial side of the upper arm. The stimulator can deliver electrical stimulation to any pair of electrodes. At the beginning of each session, the investigators will identify the electrode pairs which best produce flexion of each digit with minimal discomfort."
41269066|NCT05621980|BEHAVIORAL|Occupational Therapy (OT)|Traditional occupational therapy training sessions.
41269067|NCT01077765|DEVICE|Eutrophill|Polyacrylamide Hydrogel
41269068|NCT03198689|DRUG|Brentuximab Vedotin|Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
41269069|NCT05739773|OTHER|five-element music therapy|music therapy
41269070|NCT00880750|DRUG|Lanthanum carbonate Granule Formulation|3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.)
41269071|NCT00880750|DRUG|Lanthanum carbonate Chewable Tablets (Fosrenol)|3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
41269072|NCT05857267|DRUG|Dorzolamide / Timolol Ophthalmic Solution|Dorzolamide-timolol fixed combination in a preservative-free multidose device
41269073|NCT05857267|DRUG|dorzolamide/timolol|Dorzolamide-timolol BAK-preserved fixed combination
41269074|NCT01050114|DRUG|onaBoNT-A|"onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder."
41269075|NCT01050114|DRUG|Oxybutynin ER|Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
41269076|NCT06408844|BEHAVIORAL|Physical activity behavior change program implemented with 5A model|"According to the 5A model, the personal action plan includes the following items:~1. List specific goals by behavioral period~2. List obstacles and strategies to address them~3. Determine follow-up plan~4. Sharing the plan with the child and family In accordance with this plan, it is aimed to increase physical activity behavior in the classroom and during online meetings for 8 weeks. Additionally, after the training, motivational reminders will be held at regular intervals until the 28th week."
41269077|NCT05228366|OTHER|Heel warming with mild thermofor group|Heel warming will be applied to the newborns in the ıntervention group 1 with a thermofor containing 34-37C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
41269078|NCT05228366|OTHER|Heel warming with hot thermofor group|Heel warming will be applied to the newborns in the ıntervention group 2 with a thermofor containing 38-40C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
41269079|NCT05228366|OTHER|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
41269080|NCT02837679|OTHER|Geriatric Follow up|
41269081|NCT02913248|PROCEDURE|Conventional periodontal treatment|Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
41269082|NCT03733652|DRUG|Interferon Alfa 2a|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
41269083|NCT00435734|BEHAVIORAL|obesity intervention|
41269084|NCT05548088|BIOLOGICAL|LILRB4 STAR-T cells|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4and-3followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg。
41269085|NCT04120922|OTHER|calcium carbonate|See arm description
41093609|NCT01547104|DRUG|Glimepiride|Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
41269086|NCT04120922|OTHER|sevelamer carbonate|See arm description
41269087|NCT01023789|DEVICE|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation
41269088|NCT03454373|BEHAVIORAL|Incentive for linkage to care|"Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care"
41269089|NCT02861417|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
41269090|NCT02861417|DRUG|Busulfan|Given IV
41269091|NCT02861417|DRUG|Cyclophosphamide|Given IV
41269092|NCT02861417|DRUG|Fludarabine|Given IV
41269093|NCT02861417|DRUG|Fludarabine Phosphate|Given IV
41269094|NCT02861417|OTHER|Laboratory Biomarker Analysis|Correlative studies
41269095|NCT02861417|DRUG|Mycophenolate Mofetil|Given PO
41269096|NCT02861417|OTHER|Pharmacological Study|Correlative studies
41269097|NCT02861417|DRUG|Tacrolimus|Given IV or PO
41269098|NCT02861417|DRUG|Thiotepa|Given IV
41269099|NCT01470677|DRUG|Tachosil fibrin patch|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
41269100|NCT01872455|DIETARY_SUPPLEMENT|n-3 rich diet|This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
41269101|NCT01872455|DIETARY_SUPPLEMENT|Usual diet|Usual diet of the patients
41269102|NCT04089956|OTHER|No interventation|A retrospective cohort Observational study with no intervention
41269103|NCT05352685|DRUG|Propofol Injection|1% propofol is used for target-controlled infusion, and gradually increase the effect concentration at 0.2ug/ml. Make the subject's sedation depth reach light sedation and deep sedation respectively. EEG data were collected during wakefulness, light sedation, deep sedation, and recovery.
41269104|NCT01062360|DRUG|Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
41269105|NCT01062360|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
41269106|NCT01062360|DRUG|Pseudoephedrine|Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
41269107|NCT01062360|DRUG|Placebo|Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
41269108|NCT04285775|DEVICE|Application of device which monitors for bleeding - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH)|A stand-alone disc-shaped device (approximately 5 cm in diameter and \<1 cm thick) which can be placed over dressings. Once switched on and put in place, continuous monitoring for bleeding takes place. Detection occurs in 2 phases. First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance. Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient. The device can be used over transparent plastic dressings and does not require direct contact with blood.
41269109|NCT01226290|DEVICE|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
41269110|NCT06021249|PROCEDURE|Traditional ventilation strategies|"1. Tidal volume：10ml/kg predicted body weight（PBW）；~2. 0 cm H2O positive end expiratory pressure（PEEP）；~3. negative pressure extubation"
41269111|NCT06021249|PROCEDURE|Traditional lung-protective ventilation strategies|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；~3. Ventilator-controlled recruitment manoeuvre；~4. CPAP；~5. negative pressure extubation"
41269112|NCT06021249|PROCEDURE|Innovative lung-protective ventilation strategies|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；~3. positive pressure extubation；~4. postoperative breathing training"
41269113|NCT06021249|PROCEDURE|Lung-protective ventilation|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；"
41269114|NCT06021249|PROCEDURE|negative pressure extubation|The suction tube is inserted into the endotracheal tube, continuous negative pressure suction, and at the same time that the balloon is completely deflated, the suction tube, dental pad and endotracheal intubation are pulled out at the same time, and then the patient is instructed to cough independently and remove sputum.
41269115|NCT06021249|PROCEDURE|positive pressure extubation|The adjustable pressure limiting（APL）was adjusted to 30cm H2O, and after the patient breathed spontaneously until the peak airway pressure reached 30cm H2O, and after maintaining this level for 10s, the balloon was quickly cut off to remove the endotracheal tube, so that the patient had an autonomous coughing action, and then the oral sputum was removed.
41269116|NCT06021249|PROCEDURE|postoperative breathing training|Inhale deeply through the nose, hold the breath for 5s, and then slowly spit out the breath through the mouth, cycle 5-6 times, and inflate the balloon. The above steps need to be performed 15 times within 24 hours after surgery.
41269117|NCT06358014|DRUG|Fematon (estradiol/estradiol-norethindrone acetate combination tablet package)+SSRIs|In the combination group, eligible subjects will receive 1 tablet/day of estradiol/estradiol-norethindrone acetate combination tablet for 8 weeks. The estradiol/estradiol-norethindrone acetate combination tablet will be taken orally before bedtime, 1 tablet/day (trade name: Fematon, Abbott Laboratories, USA, this product is a combination package, with estradiol 1 mg in the first 14 days of each treatment cycle, and estradiol 1 mg and norethindrone acetate 10 mg in the last 14 days of each treatment cycle). This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram.
41269118|NCT06358014|DRUG|SSRIs|This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs. During the study, medication doses will be quantitatively adjusted based on the results of each visit assessment combined with drug concentrations.
41269119|NCT05589792|DRUG|Placebo oral capsule|Placebo before sleep for 3 nights before the study (inclusive)
41269120|NCT05589792|DRUG|Acetazolamide|Acetazolamide 250 mg 3 nights before the study at bedtime, Acetazolamide 500 mg for 2 nights before the study (inclusive) at bedtime.
41269121|NCT01886521|PROCEDURE|Lumbar drain|
41269122|NCT01886521|PROCEDURE|Ventricular drain|
41269123|NCT05039229|OTHER|Nozzles (NZ)|Technical intervention targeting alteration of nozzles or nozzle function along the production line, e.g. by manipulation of nozzle dimensions, alteration of operating pressure or shielding of the nozzle's output stream. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
41269124|NCT05039229|OTHER|Cleaning of surfaces (CS)|Behavioural or technical intervention. This can include increased use of swabbing instead of flushing with water hoses or alterations in use of water hoses for cleaning. Examples for the latter are a reduced flushing frequency, reduction of number of employees executing the work, alterations of hose dimension or nozzles on hoses. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
41269125|NCT04772248|DRUG|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
41269126|NCT04772248|DRUG|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
41269127|NCT00712374|DRUG|sulfadoxine-pyrimethamine plus amodiaquine|"SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine"
41093610|NCT05360732|DRUG|FOLFIRINOX|Alternating FOLFOX and FOLFIRI administered via intravenous infusion. FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours. FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours
41093611|NCT02525705|BIOLOGICAL|Oral Glucose|1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
41269128|NCT03152292|OTHER|Real-world, non-interventional|N/A - non-interventional
41269129|NCT00972699|BEHAVIORAL|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
41269130|NCT03529656|BEHAVIORAL|Early rehabilitation program for liver transplantation|Deliver the one of 5-step early rehabilitation program for immediate liver transplant pts on weekday
41269131|NCT01902940|OTHER|Natural History|Assessment of natural history in IBM and CCFDN
41269132|NCT05573802|DRUG|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes.
41269133|NCT05573802|DRUG|Lenalidomide|Lenalidomide will be administered per os.
41269134|NCT05573802|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
41269135|NCT05573802|DRUG|Nirogacestat|Nirogacestat will be administrated each day for all subsequent cycles were Blmf is also administrated.
41269136|NCT03884465|DRUG|Inhaled dry powder treprostinil (LIQ861)|Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.
41269137|NCT06055634|GENETIC|genotyping of SIRT1 in chronic obstructive patients|genotyping of SIRT1 in chronic obstructive patients
41269138|NCT03024216|DRUG|Atezolizumab1200 mg IV|Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.
41269139|NCT03024216|DRUG|Sipuleucel-T|Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
41269140|NCT04529655|DEVICE|Capillary Refill Assessment|Device to quantify capillary refill time
41269141|NCT01323907|DRUG|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
41269142|NCT05888350|DRUG|Beclometasone Dipropionate and Formoterol Inhalation Aerosol|Inhaled Foster (Beclometasone Dipropionate and Formoterol Inhalation Aerosol) , 1puff, BID, 4weeks
41269143|NCT05888350|DRUG|Placebo|Inhaled Placebo, 1puff, BID, 4weeks
41269144|NCT03790592|DEVICE|trifocal IOL|intraocular lens
41269145|NCT03625531|OTHER|Acupuncture|Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. Each treatment session will last for 30-60 minutes, with a maximum of 48 treatment sessions over 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.
41287173|NCT04665544|PROCEDURE|SLN side-specific detection rate using radioactive tracer with/without blue dye and ICG tracer.|"The primary objective of this study is to compare SLN detection rate using two types of intracervical tracers (radioactive tracer with or without blue dye vs. ICG).~The null hypothesis is that the detectionrate does not differ between the two techniques."
41287174|NCT01144637|BIOLOGICAL|IMVAMUNE®|0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
41093612|NCT01879904|PROCEDURE|Endoscopic submucosal dissection (ESD)|This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
41269146|NCT03625531|DRUG|Letrozole|Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
41269147|NCT03625531|DRUG|Placebo letrozole|Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
41269148|NCT00260585|PROCEDURE|Survey of client health, personal habits, family history|A questionnaire is administered at the time of consent.
41269149|NCT00260585|PROCEDURE|Blood specimen for non-DNA and DNA parts|Blood specimen is collected prior to surgery or at the time of scheduled routine surgical procedure(s), and at the time of routine follow-up visits
41269150|NCT00260585|PROCEDURE|Biopsy of esophageal/stomach tissue, lymph nodes, tumor|Tissue from the biopsies is collected intraoperatively.
41269151|NCT00260585|PROCEDURE|Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies|Tissue from the biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushings are collected intraoperatively.
41269152|NCT01278576|DRUG|BOTOX-A®|200 units, single treatment only
41269153|NCT00030784|DRUG|ifosfamide|
41269154|NCT00030784|DRUG|pegylated liposomal doxorubicin hydrochloride|
41269155|NCT03457961|DRUG|Perampanel|This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
41269156|NCT05146141|OTHER|Bent-arm throw exercises|The participants will have to perform bent-arm throw exercises 5 minutes before each training session
41269157|NCT00032084|BEHAVIORAL|smoking cessation intervention|Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
41269158|NCT00032084|DRUG|bupropion hydrochloride|150 mg/day on Days 1-3, 300 mg/day on Day 4-77
41269159|NCT00032084|DRUG|nicotine|21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
41269160|NCT00032084|PROCEDURE|psychosocial assessment and care|The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
41093613|NCT04550039|DEVICE|Body-weight-supported treadmill|Gait training performed on treadmill with overhead harness providing necessary body-weight-support with assistance from trained physical therapist
41093614|NCT04550039|DEVICE|Ekso Bionics EksoNR exoskeleton|Gait training performed overground in EksoNR exoskeleton with assistance from trained physical therapist
41093615|NCT00301379|OTHER|Observation data collection study.|This is a data collection study where the main purpose is to collect information about the treatments patients receive for their unresectable cholangiocarcinoma.
41093616|NCT02782182|DRUG|FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)|FOLFIRINOX administered preoperatively and postoperatively
41093617|NCT01688544|DRUG|Ilaprazole|Ilaprazole 10 mg for 7 days
41269161|NCT00856310|BIOLOGICAL|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
41269162|NCT00888511|DRUG|Tarceva|Tarceva 150 mg/day
41269163|NCT00888511|RADIATION|Radiotherapy|66 Gy/33 F/5 F per week for 5 weeks
41269164|NCT03898635|DRUG|Linezolid|To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.
41269165|NCT04025593|DRUG|Cyclophosphamide|750mg/m2 day 1
41269166|NCT04025593|DRUG|Rituximab|375mg/m2 day 0
41269167|NCT04025593|DRUG|Doxorubicin|50mg/m2 day 1
41269168|NCT04025593|DRUG|Vincristine|1.4mg/m2, max 2mg day 1
41269169|NCT04025593|DRUG|Prednisone|60mg/m2, max 100mg day 1-5
41269170|NCT04025593|DRUG|Ibrutinib|420mg/day qd
41269171|NCT04025593|DRUG|Lenalidomide|25mg day1-10
41269172|NCT04025593|DRUG|chidamide|20mg day 1,4,8,11
41269173|NCT04025593|DRUG|decitabine|decitabine 10mg/m2 day-5 to day-1
41287175|NCT01144637|OTHER|Placebo|0.5 ml TBS
41269174|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Insomnia|The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.
41269175|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Pain Management|The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
41269176|NCT04936321|BEHAVIORAL|Internet-delivered Sleep Education|The program delivers publicly available information about sleep.
41269177|NCT00559689|DRUG|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
41269178|NCT00559689|DRUG|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
41269179|NCT03746561|DIAGNOSTIC_TEST|deep learning|detect and classify spinal stenosis by deep learning
41269180|NCT01219556|DRUG|Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)|Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
41093618|NCT03545490|DIETARY_SUPPLEMENT|Early nutritional intervention|Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
41269181|NCT03541421|OTHER|Patient involvement in administration of drugs|The patient´s own drugs and an updated medication list will be placed in a lockable bedside table. During hospitalization the patient is responsible for taking his own medication. If a new drug is prescribed, the patient will be involved and instructed about it. Furthermore the smallest package will be delivered so that the patient can begin self-administration of the new drug during hospitalization.
41269182|NCT01708057|DRUG|AZD8683|AZD8683 administered via inhalation
41269183|NCT01708057|DRUG|Placebo|Placebo administered via inhalation
41269184|NCT01708057|DRUG|Tiotropium|Tiotropium administered via inhalation
41269185|NCT05345470|OTHER|140 calories per 30 gram test meal|Food
41269186|NCT01540643|DEVICE|Iliac Leg Graft|Zenith® Spiral-Z® AAA Iliac Leg Graft
41269187|NCT01267955|OTHER|Laboratory Biomarker Analysis|Correlative studies
41269188|NCT01267955|OTHER|Pharmacogenomic Study|Correlative studies
41269189|NCT01267955|DRUG|Vismodegib|Given PO
41269190|NCT03043144|OTHER|Worsening of olfaction from enrollment visit to 6 months|Worsening of olfaction from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
41269191|NCT03043144|OTHER|Worsening of taste from enrollment visit to 6 months|Worsening of taste from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
41269192|NCT03043144|OTHER|Serum Zinc|Serum zinc will be evaluated for association with taste and/or smell impairment
41269193|NCT03043144|OTHER|Chronic rhinosinusitis|Chronic rhinosinusitis will be evaluated for association with smell impairment
41269194|NCT03043144|OTHER|Dialysis adequacy|Dialysis adequacy will be evaluated for association with taste and/or smell impairment
41269195|NCT03043144|OTHER|Decayed missing filled teeth index (DMFT)|DMFT will be evaluated for association with taste impairment
41269196|NCT04929990|BEHAVIORAL|Respiratory muscle training|Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks. Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)
41269197|NCT01269164|PROCEDURE|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
41442434|NCT03823924|PROCEDURE|Bone mineral density (BMD)|"The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body)."
41269198|NCT06310148|COMBINATION_PRODUCT|The Chronic Disease Co-Care (CDCC) Pilot Scheme|Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
41269199|NCT03205202|DIETARY_SUPPLEMENT|Cocoa extract|
41269200|NCT03205202|DIETARY_SUPPLEMENT|Multivitamin|
41269201|NCT03205202|DIETARY_SUPPLEMENT|Cocoa extract placebo|
41093619|NCT01492309|DEVICE|Active Transcranial Magnetic Simulation|Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
41093620|NCT01492309|DEVICE|Sham Transcranial Magnetic Stimulation|Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
41093621|NCT01305824|DRUG|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
41093622|NCT01305824|DRUG|Placebo|Placebo administered at the time of AVF creation.
41093623|NCT01305824|DRUG|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
41093624|NCT01023178|DRUG|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
41093625|NCT01023178|DRUG|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
41093626|NCT01023178|DRUG|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
41093627|NCT01023178|DRUG|Progesterone, micronized|Given starting at 18 months
41093628|NCT03134235|OTHER|Dietary Intervention|Subjects consumed a raw, vegan diet for 4-weeks with an emphasis on raw fruit and vegetable consumption.
41093629|NCT04437108|PROCEDURE|Li-SWT (suprapubic approach)|The patient will be asked to lie in flat dorsal position. A commercially used gel for sonography will be applied to the suprapubic region. The applicator will be placed on suprapubic region with two fingers apart from the symphysis pubis tilting to 45°. Shock waves will be directed to 3 different sites; the midline (over the bladder dome) and 3 cm right and left to the midline (over bilateral bladder walls). The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
41093630|NCT04437108|PROCEDURE|Li-SWT (perineal approach)|The patient will be asked to lie in lithotomy position. A commercially used gel for sonography will be applied to the perineum. The applicator will be placed on perineal region. Shock waves will be directed to 3 different sites: the midline and 2 cm above and below the midline. The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
41093631|NCT04437108|PROCEDURE|Li-SWT (combined approach)|The patient will receive 3000 shocks; 1500 shocks through suprapubic approach (500 shocks per site) and another 1500 shocks through perineal approach (500 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
41093632|NCT04437108|PROCEDURE|Sham treatment|The same technique of Li-SWT will be used but the applicator of the shock wave device will be turned off.
41093633|NCT04437108|DRUG|Solifenacin|The patients will be treated by antimuscarinics (solifenacin) which are considered as the conventional treatment of storage symptoms after prostatectomy.
41093634|NCT04045119|OTHER|Topical Moisturizer|The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
41093635|NCT05632601|DIAGNOSTIC_TEST|PET scan|PET scan
41093636|NCT00450502|DRUG|Batracylin|
41093637|NCT02429609|DEVICE|Moorfields Acuity Chart|
41093638|NCT03392662|DEVICE|Hemopatch|Patients received product at the discretion of their surgeon.
41093639|NCT00751790|DRUG|triptorelin embonate (INN)|Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
41093640|NCT00592748|RADIATION|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
41093641|NCT00279422|DRUG|visilizumab|
41093642|NCT00279422|DRUG|visilizumab|
41093643|NCT02107001|PROCEDURE|Lung ultrasound|Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
41093644|NCT00412516|BIOLOGICAL|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
41093645|NCT04675463|DRUG|BGF Inhalation Aerosphere|Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time
41093646|NCT04675463|DRUG|GFF Inhalation Aerosphere|Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time
41093647|NCT06051162|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
41093648|NCT03199885|DRUG|Atezolizumab|Given IV
41093649|NCT03199885|PROCEDURE|Biopsy|Undergo biopsy
41093650|NCT03199885|PROCEDURE|Bone Scan|Undergo bone scan
41269202|NCT03205202|DIETARY_SUPPLEMENT|Multivitamin placebo|
41269203|NCT01085188|BEHAVIORAL|ACC|Weekly community based behavioral counseling and case management
41269204|NCT01085188|BEHAVIORAL|CM|Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results
41269205|NCT01085188|BEHAVIORAL|UCC|recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
41269206|NCT01642355|BEHAVIORAL|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
41269207|NCT01642355|BEHAVIORAL|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
41269208|NCT00318435|DEVICE|Stent or stent-graft deployment|
41269209|NCT04003610|DRUG|Pemigatinib|13.5 mg once a day orally
41269210|NCT04003610|DRUG|Pembrolizumab|200 mg Q3W intravenously
41269211|NCT04003610|DRUG|Gemcitabine|1000 mg/m\^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle
41269212|NCT04003610|DRUG|Carboplatin|Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle
41269213|NCT02144779|BEHAVIORAL|Assigned to palliative care team|Communication and Support through the palliative care team assigned to intervention participants.
41269214|NCT02144779|BEHAVIORAL|Usual Care|usual hospital care, not assigned to palliative care team
41269215|NCT00999830|DRUG|IPH2101|One infusion of IPH2101 every 4 weeks
41269216|NCT00863551|DRUG|Trospium Chloride|Extended release, 60 mg, oral daily
41269217|NCT00393419|BEHAVIORAL|Comprehensive pharmacy care program|
41269218|NCT06273969|OTHER|Osteopathic Manipulative Treatment (OMT)|"The OMT protocol is designed to target the somatic dysfunction associated with TOS. The somatic dysfunction associated with TOS include muscular hypertonicity of the anterior and middle scalene muscles, hypertonicity of the pectoralis muscles, and tension in the fascia of the supraclavicular area between the clavicle and first rib. The OMT protocol will consist of the following four techniques:~Direct Thoracic Inlet Myofascial Release (TIMFR) - Reduce tension at the thoracic inlet fascia located between the thoracic outlet and the cervical spine.~Direct Muscle Energy for the Scalene Muscles -Reduce tension within the scalene muscle group~Direct Muscle Energy for the Pectoralis Muscles - Reduce tension within the pectoralis muscle group~Supraclavicular Fascial Release - Reduce fascial tension within the supraclavicular fossa"
41093651|NCT03199885|PROCEDURE|Computed Tomography|Undergo CT scan
41093652|NCT03199885|DRUG|Docetaxel|Given IV
41093653|NCT03199885|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41093654|NCT03199885|DRUG|Paclitaxel|Given IV
41093655|NCT03199885|BIOLOGICAL|Pertuzumab|Given IV
41093656|NCT03199885|OTHER|Placebo Administration|Given IV
41093657|NCT03199885|OTHER|Quality-of-Life Assessment|Ancillary studies
41093658|NCT03199885|BIOLOGICAL|Trastuzumab|Given IV
41093659|NCT04749693|DEVICE|DBLG1 System|Use of DBLG1 System in real life condition
41269219|NCT04319848|OTHER|TE-EK treatment group|Transplantation of tissue-engineered endothelial graft through DSAEK procedure.
41269220|NCT00095563|DRUG|lapatinib ditosylate|Given orally
41269221|NCT00095563|OTHER|laboratory biomarker analysis|Correlative studies
41269222|NCT04923594|DRUG|mazindol extended release|Dosed orally, once daily for up to 3 weeks
41269223|NCT04923594|DRUG|Placebo|Dosed orally, once daily for up to 4 weeks.
41269224|NCT06416501|OTHER|Mode of detection|Mode of detection
41269225|NCT04222283|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).
41269226|NCT05046288|OTHER|Virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 6 to 7 participants. They meet online one time per week for a 30 to 45 min of a guided tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
41269227|NCT03033329|DRUG|Single intravenous doses of MRX-4|Intravenous single escalating doses of MRX-4
41269228|NCT03033329|DRUG|Single intravenous doses of placebo|Intravenous single doses of placebo to match MRX-4
41269229|NCT03033329|DRUG|Multiple intravenous doses of MRX-4|Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
41269230|NCT03033329|DRUG|Multiple intravenous doses of placebo|Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
41269231|NCT03033329|DRUG|Single dose of intravenous and oral MRX-4|Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
41269232|NCT01583426|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
41269233|NCT01583426|DRUG|Paclitaxel|Paclitaxel 80 mg/m² weekly for 12 weeks
41442435|NCT06448663|DIETARY_SUPPLEMENT|alpha-lactalbumin, fructooligosaccharides, inulin|"The first round supplementation will be administered for 3-month period (i.e. 12 weeks). One dose/day (2g sachet) is intended to be administered orally once a day after dissolving in water.~At the scheduled visits/phone contacts \[i.e., baseline, 12 weeks, and 16 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed."
41442436|NCT06448663|DIETARY_SUPPLEMENT|alpha-lactalbumin, sodium butyrate, fructooligosaccharides, inulin|"The second round supplementation will be administered for 3-month period (i.e. 12 weeks). For participants weighing \<30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥30 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.~At the scheduled visits/phone contacts \[i.e., 28 weeks and 32 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed."
41093660|NCT04968587|PROCEDURE|Sustained Low-Efficiency Dialysis|All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional anticoagulation with Citrate or Regional anticoagulation by Decalcification without Citrate
41269234|NCT03367871|DRUG|Pembrolizumab|IV
41269235|NCT03367871|DRUG|Paclitaxel|Administered intravenously (IV) on day 1
41269236|NCT03367871|DRUG|Cisplatin|Administered intravenously (IV) on day 1
41269237|NCT03367871|DRUG|Carboplatin|Administered intravenously (IV) on day 1
41269238|NCT03367871|DRUG|Bevacizumab|Administered intravenously (IV) on day 1
41269239|NCT00448292|DRUG|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
41269240|NCT00448292|DRUG|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
41269241|NCT03934645|OTHER|Delirium prediction model for ICU patients, version 1|The pre-deliric model version 1 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows for early prediction of delirium and initiation of preventive measures. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found.
41269242|NCT03934645|OTHER|Delirium prediction model for ICU patients, version 2|The pre-deliric model version 2 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found. The model allows for early prediction of delirium and initiation of preventive measures.
41269243|NCT03934645|OTHER|Early prediction model for delirium in ICU patients|The e-pre-deliric model enables the clinician to identify those patients likely to develop delirium following ICU admission using only nine predictors. In the e-pre-deliric model, delirium prediction score is determined by inputting the data of the patient in admission to the intensive care unit.
41269244|NCT04633590|BEHAVIORAL|Home-based exergaming|Participants will undertake one of two 6-week training interventions. In both groups participants will be asked to train 3 times per week (18 sessions total), during which adherence to the training will be measured. To monitor adherence to training and training load (exercise completion, exercise duration and heart rate achieved during workouts) throughout the 6 weeks participants will be given a heart rate monitor.
41269245|NCT00320970|DRUG|Candesartan|
41442437|NCT03703154|DRUG|Envarsus|Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
41442438|NCT03703154|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
41442439|NCT03374176|DRUG|Amoxicillin 500 mg / Metronidazole 250 mg|Subjects were instructed to take a capsule three times a day for 7 days
41442440|NCT03374176|DRUG|Clindamycin 300 mg|Subjects were instructed to take a capsule three times a day for 7 days
41269246|NCT03181113|DRUG|Peginterferon Alfa-2B|pre-received standard peginterferon alfa-2b therapy
41269247|NCT03181113|DRUG|Peginterferon Alfa-2A|pre-received standard peginterferon alfa-2a therapy
41269248|NCT06423248|DIETARY_SUPPLEMENT|Culinary spices|Powdered culinary spices
41442441|NCT05609565|DRUG|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
41442442|NCT05609565|DRUG|spinal anesthesia with bupivacaine|spinal anesthesia with bupivacaine
41442443|NCT01499628|BEHAVIORAL|Supervised Reading|Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
41442444|NCT01499628|BEHAVIORAL|EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
41442445|NCT01499628|BEHAVIORAL|EVT at the TRL|Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
41442446|NCT01885572|DEVICE|TiLOOP Bra|Titaniferously coated polypropylene mesh
41442447|NCT04267276|DRUG|Part 1: BI 1265162 - intravenous|Intravenous solution
41442448|NCT04267276|DRUG|Part 2: BI 1265162 - oral|Oral solution
41442449|NCT06470906|DIETARY_SUPPLEMENT|Probiotic Group|The intervention is a mixture of two probiotics: 1) Lactobacillus acidophilus GLA-14 and 2) Lactobacillus rhamnosus HN001. These products will be combined into a single capsule/sachet with a dose of approximately 10\^10 colony forming units (CFUs) of GLA-14 (ATCC SD5212) and HN001 (ATCC SD5675) in a 4:1 ratio, using similar doses as recent studies using this product.
41442450|NCT06470906|DIETARY_SUPPLEMENT|Placebo Group|The placebo will of be Maltodextrin, a carbohydrate, packaged similarly to the intervention and having the same weight.
41442451|NCT03612440|DRUG|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
41442452|NCT03612440|OTHER|normal saline|receive matching placebo (equal volum of normal saline)
41442453|NCT03572777|DRUG|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days.
40758198|NCT02130037|BEHAVIORAL|application|along standard psychotharpy we use a smartphone application that allows the patient to monitor her meals, behaviours, emotions and thoughts and to communicate them directly in real time to their therapists.
41442454|NCT03572777|DRUG|Concomitant therapy|Clarithromycin ('Makcin') 500 mg bid for 14 days
41442455|NCT03572777|DRUG|Concomitant therapy|Metronidazole ('Medazol') 500 mg bid for 14 days
41442456|NCT03572777|DRUG|Concomitant therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
41442457|NCT03572777|DRUG|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days
41442458|NCT03572777|DRUG|Hybrid therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
41442459|NCT03572777|DRUG|Hybrid therapy|Clarithromycin ('Makcin') 500 mg bid for the last 7 days
41442460|NCT03572777|DRUG|Hybrid therapy|Metronidazole ('Medazol') 500 mg bid for the last 7 days
41442461|NCT02744794|DEVICE|Dermal Cooling System|Treatment with cryotherapy.
41442462|NCT03521973|BIOLOGICAL|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
41442463|NCT03521973|OTHER|Normal Saline|0.9% Sodium chloride
41442464|NCT00679081|DEVICE|CelTx|Single application; split-mouth design
41442465|NCT00679081|OTHER|Autologous sub-epithelial connective tissue graft|Single application; split-mouth design
41442466|NCT04256720|BEHAVIORAL|No intervention|No intervention - questionnaire study
41442467|NCT06558370|OTHER|Empty bladder group|"Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
41442468|NCT06558370|OTHER|Bladder distension group|"Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended .~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
41093661|NCT02747264|DEVICE|eRAPID|eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
41093662|NCT00643838|DRUG|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
41093663|NCT05544136|DIAGNOSTIC_TEST|18F-FMISO PET/CT scan|18F-FMISO PET/CT scan (only 1 injection) that occurs 5-10 treatment days after RT start
41093664|NCT05544136|RADIATION|Chemoradiation therapy|"* 18F-FMISO hypoxia negative patients complete CRT with 70Gy primary tumor and 50Gy de-escalated RT dose to gross nodes (if 50Gy is has pilot efficacy, then 44Gy to gross nodes; if 44Gy has pilot efficacy, then 40Gy to gross nodes).~* 18F-FMISO hypoxia positive patients are taken off study and complete SOC 70Gy CRT to primary tumor and gross nodes."
41093665|NCT05544136|DRUG|Carboplatin|The chemotherapy used in this protocol is the standard of care for head and neck cancer, cisplatin or carboplatin/5-Fluorouracil
41442469|NCT06534996|DRUG|SCD-2101|Tradictional Chinese Medicine formula (SCD-2101)
41442470|NCT05304377|DRUG|ELVN-001|orally once or twice daily
41442471|NCT00979147|PROCEDURE|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
41442472|NCT00979147|PROCEDURE|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
41442473|NCT00979147|DEVICE|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
41442474|NCT00979147|DEVICE|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
41093666|NCT05186844|BEHAVIORAL|survey application|Scales and questionnaires were applied to children and their parents according to age groups.
41093667|NCT02846818|PROCEDURE|Microdialysis|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
41442475|NCT04466553|DEVICE|NICO BrainPath™ System|Patients who are admitted under the neurology service in the Neurocritical Care and Medical ICU will be screened for participation in the trial by their treating physician. Once blood pressure has been stabilized and the best medical treatment has been determined, the patient will need to undergo a standard of care, repeat CT scan 6 hours after stabilization to show that there has been no increase in size of the ICH. Patients that meet eligibility criteria after this CT will be taken to the OR within 24-72 hours for a minimally invasive, navigation guided endoport based evacuation of the clot using the NICO BrainPath™ system.
41452986|NCT03559907|BEHAVIORAL|Mealtime PREP|Parents are trained to deliver each intervention component during mealtimes using a step-wise, behavioral activation approach. The parent-training prong of the Mealtime PREP intervention incorporates four active ingredients of behavioral activation (1. skills training; 2. goal-setting; 3. activity scheduling; and 4. activity monitoring) to help parents build a family meal routine that is enriched with techniques to promote child food acceptance. Each week, parents will take home healthy groceries to practice making healthy snacks and side dishes in the home.
41269249|NCT04274439|OTHER|Internet-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a website created and registered especially for the study that will have the shooting of 1 video of pain education and 1 video of exercises for the subjects of the study, totaling 8 videos of pain education and 8 exercise videos. We will provide complimentary materials along with the triggered videos and a booklet of chronic pain information. We will also make weekly calls for a health coaching service and the sending of smartphone messages for the motivation and accountability of the subjects.
41452987|NCT01994980|DRUG|Default 4 days antibiotic therapy|The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
41093668|NCT00310362|BEHAVIORAL|Use of Interactive Voice Response (IVR) system to improve adherence to GI appointments and prep procedures|Interactive voice response system (IVR) calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
41269250|NCT04274439|OTHER|Online Booklet|An online booklet containing information about chronic pain and suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
41093669|NCT01645111|DRUG|Clevidipine|
41093670|NCT03229798|DRUG|Sumatriptan Succinate Oral Tablet|Sumatriptan succinate commercial Imitrex 100 mg tablet
41269251|NCT06002464|PROCEDURE|Acupuncture|Patient will have session of 30 minutes of acupuncture every day during 3 days
41269252|NCT06002464|PROCEDURE|Bilateral ESP catheter|Analgesia by Bilateral Continuous erector spine plane block catheter at T9 level for 2 days
41452988|NCT05433090|BEHAVIORAL|Inpatient serious illness care program|Inpatient advance care planning intervention that will be delivered by advanced care practitioners or hematology/oncology fellow physicians. The intervention will be an adapted version of the serious illness care program.
41452989|NCT01963260|DRUG|MK-8723|MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
41452990|NCT01963260|DRUG|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
40758199|NCT02130037|OTHER|psychotherapy|standard psychotherapy for eating disorders
41093671|NCT03229798|COMBINATION_PRODUCT|Transdermal delivery of sumatriptan succinate|Sumatriptan succinate transdermal drug delivery system
41452991|NCT04158128|OTHER|non-intervention|non-interventional, prospective cohort study
41452992|NCT02694536|DRUG|Erlotinib|Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
41452993|NCT02694536|DRUG|Gemcitabine|Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m\^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
41452994|NCT00712816|DEVICE|Game Ready Injury Treatment System (CoolSystems Inc.)|Cold with intermittent compression postoperatively for 2 weeks
41452995|NCT00712816|OTHER|Ice with compressive bandages|Cold with static compression postoperatively for 2 weeks
41452996|NCT00167453|PROCEDURE|Exercise, Education|
41452997|NCT05407064|DRUG|MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
41452998|NCT05407064|OTHER|Placebo|A substance that is designed to have no therapeutic value.
41452999|NCT06179173|OTHER|HIIT-RCE|High-intensity interval training on semi-recumbent cycle ergometer
41453000|NCT06179173|OTHER|Conventional physiotherapy|Conventional physiotherapy
41453001|NCT04791813|OTHER|Alginate impressions , Photographic data and panoramic radiographs .|Upper and lower alginate impressions will be poured and dental casts produced and converted to 3D digital cast using a 3D scanner-(3Shape )-the 3D data will be imported to a revers modeling software . Also Photographic data using Canon750 camera and panoramic radiographs to be taken.
41453002|NCT05646277|OTHER|e-Consultation|first orthodontic consultation in remote
41453003|NCT05646277|OTHER|Consultation|first orthodontic consultation in face-to-face
41453004|NCT02155257|DRUG|Modafinil|
41453005|NCT02155257|DRUG|Gabapentin|
41453006|NCT02155257|DRUG|Placebo|
41453007|NCT02620137|DRUG|Multicentrum® (Pfizer, Spain) 3 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
41453008|NCT02620137|DRUG|Multicentrum® (Pfizer, Spain) 12 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
41453009|NCT01092455|DRUG|Heparin N reduction|Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
41453010|NCT01307358|OTHER|Sonicare Interproximal (IP) Cleaning Prototype|Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
41453011|NCT01975116|DRUG|azurin-derived cell-penetrating peptide p28|Given IV
41453012|NCT06301269|OTHER||
41453013|NCT04473326|BEHAVIORAL|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
41453014|NCT00895050|OTHER|Review of clinical records|
41453015|NCT01624272|DEVICE|Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
41453016|NCT01624272|OTHER|Yoga Pranayama breathing exercises|Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
41453017|NCT04406545|OTHER|evaluation of skin microvascular flow and reactivity|evaluation of skin microvascular flow and reactivity using laser Doppler perfusion monitoring
41453018|NCT05526313|DRUG|Prilinostat Mesylate 1.2mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
41453019|NCT05526313|DRUG|Prilinostat Mesylate 2.4mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
41453020|NCT05526313|DRUG|Prilinostat Mesylate 4.0mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
41453021|NCT05526313|DRUG|Prilinostat Mesylate 6.0mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
41453022|NCT05526313|DRUG|Prilinostat Mesylate 8.4mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
41453023|NCT05526313|DRUG|Prilinostat Mesylate 11.2mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
41453024|NCT05526313|DRUG|Prilinostat Mesylate 15mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
41453025|NCT00409942|DRUG|Torasemide Prolonged Release|Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
41453026|NCT00409942|DRUG|Furosemide|Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
41453027|NCT06406257|DEVICE|3M™ Bair Hugger™ Warming Unit|Utilizing the 3M Temperature Management Unit to ensure intraoperative body temperature of elderly hip surgery patients remains consistent with their preoperative baseline, while patients in Group C receive no intervention.
41453028|NCT02245503|DRUG|Tamsulosin|
40758200|NCT01544075|BEHAVIORAL|Pain neurophysiology education (PNE) and psychologic inoculation (PI)|3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.
40758201|NCT01544075|BEHAVIORAL|Neck school (NS)|3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
41287176|NCT04933630|DRUG|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Participants exiting the TRAIT study will have received a 90-day supply of their current protocol-approved antidepressant treatment (ADT) if clinically appropriate, prior to entering the TRAIT-RS study, in addition to a continuity of care letter to be given to their medical provider to facilitate a refill of that medication as desired. (See NCT04748276 for specific formulary and prescribing guidelines).
41453029|NCT03497858|OTHER|Coconut Water|participants will consume coconut water and complete a simulated basketball game
40758202|NCT02336555|DRUG|MK-8291|MK-8291 oral tablets
41453030|NCT03497858|OTHER|Placebo - water|participants will consume Placebo - water and complete a simulated basketball game
41453031|NCT03497858|OTHER|Sports drink|participants will consume a sports drink and complete a simulated basketball game
41453032|NCT04727164|DRUG|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.
41453033|NCT04877145|OTHER|drill|single 3.25 mm stainless steel drill
41453034|NCT00529763|DRUG|Dasatinib|Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
41453035|NCT00354419|RADIATION|total-body irradiation|Undergo radiotherapy
41453036|NCT00354419|DRUG|cyclophosphamide|Given IV
41453037|NCT00354419|BIOLOGICAL|anti-thymocyte globulin|Given IV
41453038|NCT00354419|DRUG|cyclosporine|Given IV
41453039|NCT00354419|PROCEDURE|umbilical cord blood transplantation|Undergo transplantation
41453040|NCT00354419|DRUG|mycophenolate mofetil|Given IV or orally
41453041|NCT00354419|PROCEDURE|bone marrow aspiration|Correlative study
41453042|NCT00354419|GENETIC|DNA analysis|Correlative study
41453043|NCT00354419|BIOLOGICAL|filgrastim|Given IV or SC
41453044|NCT03097692|PROCEDURE|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
41453045|NCT03097692|DRUG|Pharmacologic preconditionig|Pharmacologic preconditionig will be attained by sevoflurane anesthesia
41453046|NCT00235963|DRUG|Simvastatin|
41453047|NCT03382041|DEVICE|Carbon Fiber Implant|A cannulated rod, made of long carbon fiber reinforced polymer, with interlocking holes at its proximal and distal ends. The Nail provides for a slight bend. A Tantalum radiopaque marker along the Nail longitudinal axis provides for its visualization under fluoroscopy. The Nail proximal end is marked by a tantalum marker.
41453048|NCT03382041|DEVICE|Titanium Implant|An intramedullary rod, also known as an intramedullary nail (IM nail) or inter-locking nail or Küntscher nail (without proximal or distal fixation), is a metal rod forced into the medullary cavity of a bone. IM nails have long been used to treat fractures of long bones of the body
41453049|NCT01131260|DEVICE|fetal STAN monitor|The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
41453050|NCT02582307|DRUG|Acetaminophen, Analgesics, Non-Narcotic|Oral single dose
41093672|NCT04164628|OTHER|Quality of life assessment|Quality of life will be assessed with Nottingham Health Profile
41093673|NCT04654351|DRUG|TAK-667|TAK-667 single SC administration
41093674|NCT06121999|BEHAVIORAL|Standard of care acceptance-based behavioral weight loss program|Evidence-based, structured weight loss program for adults with co-morbid conditions of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Published as a workbook for participants and a clinician guide, the intervention consists of twenty-five sessions or modules with accompanying worksheets. Each session covers specific acceptance-based behavioral skills to implement and build upon in subsequent sessions.
41287177|NCT03905772|OTHER|Voluntary exercise|The participants will perform 36 maximal voluntary contractions, 3 times per week for 8 weeks.
41453051|NCT02582307|DRUG|Hyoscine butylbromide, Analgesics, Non-Narcotic|Oral single dose
41453052|NCT04031235|BEHAVIORAL|Sleep Baby, Safe and Snug|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommended safe sleep practices. AAP safe sleep recommendations listed on the back cover.
41453053|NCT04031235|BEHAVIORAL|Read Baby, Every Day|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommendations regarding the importance of reading and talking to infants. Recommendations and benefits of reading with infants are listed on the back cover as well.
41453054|NCT05444205|BEHAVIORAL|Text4Baby or Bright by Text Referral|Passive texting programs where participants receive free text messages on topics such as child development and parenting tips three times per week. Text4Baby serves parents of children under one year. Bright by Text serves parents of children under eight years of age.
41453055|NCT05444205|BEHAVIORAL|Nurture Program Warm Referral|Nurture Program is a nonprofit organization that promotes healthy development in young children by pairing moms with experienced and knowledgeable mentors who use text messaging to answer questions and provide helpful information, while offering support and encouragement throughout the child's first few years of life.
41453056|NCT05444205|BEHAVIORAL|Video Interaction Project|The Video Interaction Project is a program to support parents and their young children. Video Interaction Project is typically offered at a convenient location, such as a pediatric clinic. Parents are observed and videotaped for 3 to 5 minutes while interaction with their child. The Video Interaction Project coach then watches the video with the parent and talks about their interaction, highlighting how best to support the child's growth and language development.
41453057|NCT05444205|BEHAVIORAL|Family Check-UP|"The Family Check-Up is brief, taking place over the course of three sessions, each about an hour long. A Family Check-Up family coach will spend time getting to know the family during an Initial Interview. Second, parents complete questionnaires that assess child and family adjustment, relationships, and other areas that influence children and families. The assessment includes videotaped family interaction tasks, where parents take part in activities with their child like playing together with toys and puzzles. Third, the Feedback session consists of sharing feedback - including strengths and challenges - about child and family well-being based on survey responses and video clips. Parents are invited to set goals for their family to support and maintain strengths and address areas of concern. Parents are paid 25 dollars after the Feedback Session. Parents have the option to continue meeting with the family coach to support the child's development and improve parental well-being."
41453058|NCT05444205|BEHAVIORAL|Smart Beginnings|Smart Beginnings consists of delivering both Video Interaction Project and the Family Check-up packed together as a single intensive intervention.
41453059|NCT05444205|BEHAVIORAL|Healthy Families America Warm Referral|As part of Healthy Families America, professionally trained Nurse Home Visitors provide information during weekly home visits so that parents can provide the best for your new baby. Topics addressed are ways to keep the baby safe, how to take care of the baby, and activities parents can enjoy with their babies.
41453060|NCT05444205|BEHAVIORAL|Family Center Warm Referral|There are 27 Family Centers across Allegheny County provide services to families of young children 5 and under. These centers focus on three primary activities: 1. enhancing child development; 2. facilitating parent education, and 3. ensuring parents are supported and connected.
41453061|NCT05764096|OTHER|No intervention|No intervention
41453062|NCT03010605|DEVICE|Measuring Every Day Device|
41453063|NCT03010605|OTHER|Physical Therapy|
41093675|NCT06121999|BEHAVIORAL|Occupational therapy dietary and lifestyle modifications|Occupational therapy Model of Human Occupation Screening Tool (MOHOST) and Role Checklist version 3 (RCv3) assessments identify areas of need for personalizing participant implementation of the standard of care acceptance-based behavioral weight loss program. Areas of need may include physical activity limitations to be addressed in an exercise plan or social determinants of health that are barriers to dietary and lifestyle modifications. Dietary and lifestyle modifications are based on American Gastroenterology Association (AGA) recommendations published in practice guidelines for this population. Recommendations include a Mediterranean diet, improved self-management of co-morbid chronic conditions, and a total body weight loss of five to ten percent at 1 - 2 pound weekly increments.
41093676|NCT02655692|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
41453064|NCT00085501|DRUG|cetuximab|"Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.~Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14."
40758203|NCT02336555|DRUG|Placebo|Placebo oral tablets
41453065|NCT00085501|DRUG|carboplatin|"Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2~Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1"
41453066|NCT00085501|DRUG|paclitaxel|"Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.~Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1."
41453067|NCT00111787|DRUG|Lapatinib|Daily-monotherapy \[1500 milligrams (mg)\] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks
41453068|NCT00111787|DRUG|Paclitaxel|Weekly (80mg/m\^2) combination therapy (with daily Lapatinib) for 12 weeks
41453069|NCT03732144|BEHAVIORAL|Connect Staff-based PA intervention|After school program sites receiving the Connect intervention will receive a 16 week program that includes three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum. Compared to control ASPs, ASPs receiving the 'Connect' program are expected to show greater improvements from baseline to post- and 6 mo follow-up in PA-related social mechanisms, youth PA, and staff PA.
41453070|NCT03732144|OTHER|Connect Health Curriculum Control|After school program sites receiving the general ASP health curriculum control will address the prevention of several negative health behaviors (e.g., substance use, stress, etc) and also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff. This arm will serve as the comparison group to the Connect Staff-based PA intervention
41453071|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
41453072|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
41453073|NCT03366792|DEVICE|Artemis™ software system|Computerized targeting of mpMRI lesions. The computerized co-registration will then be performed by software within the Artemis™ system and will fuse the MR imaging with real-time ultrasound imaging.
40920268|NCT06437444|BEHAVIORAL|The implementation strategy to encourage the adoption of the Care Pathway|"1. Dissemination of the most novel aspects of the agreed Care Pathway via corporate mail.~2. Audit \& Feedback (A\&F) data reports, sent every two weeks, to each paediatrician on the rate of prescription of bronchodilators administered with a spacer chamber, together with the rates of the other indicators established in the pathway, in their health centre and in the rest of the centres in the participating health areas.~3. Interactive training sessions, in which epidemiological data and data on the health, economic and social impact of asthma attacks were presented, together with data on other indicators associated with the care pathway, and key messages on current treatment recommendations based on the latest clinical practice.~4. Distribution of reminder posters in paediatrics consultations, PEDs and health centers."
40920269|NCT05806489|OTHER|Intermittent Fasting|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 6 hours (while fasting for the remaining 18 hours). Diet plans were matched for energy and macronutrients.
40920270|NCT05806489|OTHER|Control Diet|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 12 hours (while fasting for the remaining 12 hours). Diet plans were matched for energy and macronutrients.
40920271|NCT03977740|OTHER|chest PNF|Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.
40920272|NCT03977740|OTHER|Conventional|conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
40920273|NCT01127789|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
41093677|NCT02655692|DRUG|Placebo/Saline|This is a saline placebo/non-active solution.
41093678|NCT06461156|DRUG|HS-10504|HS-10504 will be administered orally once daily in a continuous regimen. Participants will continue treatment until experiencing objective disease progression or meeting other protocol-specified criteria for discontinuation of study treatment.
41093679|NCT00503568|BIOLOGICAL|Ad100-gp96Ig-HLA A1|Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient
41269253|NCT04508387|PROCEDURE|Group HH (heated-humidified)|Group CD patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia device and the visual analog scale the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form. Both groups received the standard general anesthesia protocol. Laparoscopic surgery was performed in the same manner for all cases by AA.
40920274|NCT04334577|BIOLOGICAL|live attenuated zoster vaccine|subcutaneous injection
41093680|NCT01060566|DRUG|VX-770|In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
40920275|NCT04334577|BIOLOGICAL|placebo|subcutaneous injection
40920276|NCT01149148|DEVICE|INVOS Somanetics Cerebral Oximeter|"Sequence of Interventions To Increase Cerebral Oxygen Saturation~1. Check head and cannula position~2. Increase mean arterial pressure~3. Increase pump flow~4. Increase systemic oxygenation~5. Increase PaCO2 \> 45~6. Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~7. Consider PRBC transfusion for Hct \< 21%"
40920277|NCT01149148|DEVICE|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
40920278|NCT04316832|BEHAVIORAL|Mindfulness based cognitive training|The mindfulness based cognitive training will include three short mindfulness exercises: a) a breathing exercise, b) a body scan exercise, and c) a mindfulness attention exercise.
41269254|NCT01973855|DRUG|Western Medicine|Physical cooling,Hydrocortisone
41269255|NCT01973855|DRUG|TCM and Western Medicine|Third Infectious diseases soup recipe
40920279|NCT04316832|OTHER|Control exercise|Participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
40920280|NCT03595618|DRUG|GLPG1972|Film-coated tablets of GLPG1972 for oral use.
41093681|NCT01060566|DRUG|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
40758204|NCT01104870|DRUG|UT-15C|oral
40920281|NCT03595618|DRUG|Placebo|Film-coated tablets of matching placebo for oral use.
40920282|NCT04414735|OTHER|Extracorporeal Photopheresis|Infusion of autologous cellular products exposed to ultraviolet light (UV), in the presence of a photosensitizer. The cellular product is obtained through leucopheresis and its subsequent exposure to 8-methoxypsoralen (8-MOP) and irradiation with UV-A light.
40920283|NCT02537288|DRUG|Fedovapagon|
41093682|NCT05998590|DIETARY_SUPPLEMENT|High protein supplement|The participants received a 60g protein bolus each evening prior to sleep from week 3 to week 12 of training.
40920284|NCT02537288|DRUG|Moxifloxacin|
40920285|NCT02537288|DRUG|Placebo (for fedovapagon)|
41093683|NCT05998590|DIETARY_SUPPLEMENT|Moderate protein supplement|The participants received a 20g protein bolus each evening prior to sleep from week 3 to week 12 of training.
40920286|NCT02192333|PROCEDURE|Management of Therapy Complications|Receive survivorship care
40920287|NCT02192333|OTHER|Quality-of-Life Assessment|Ancillary studies
41093684|NCT05998590|DIETARY_SUPPLEMENT|Carbohydrate placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep from week 3 to week 12 of training.
41093685|NCT05998590|OTHER|Control: No supplementation|The participants did not receive any supplementation but instead acted as a control group doing BT only
41269256|NCT00474240|DRUG|Atorvastatin 20 mg|
41269257|NCT00474240|DRUG|AEGR-733 5 mg|
40920288|NCT02192333|OTHER|Questionnaire Administration|Ancillary studies
40920289|NCT02192333|BEHAVIORAL|Telephone-Based Intervention|Receive phone-based booster intervention
40920290|NCT01054547|DRUG|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
41269258|NCT00474240|DRUG|AEGR-733 10 mg|
41093686|NCT05006690|OTHER|Clinical Pilates-Based Exercise Training|Clinical Pilates-Based exercise training based on spinal stabilization aim at controlling the position of the trunk over the pelvis to provide optimal energy production and energy transfer to distal segments and involve the cocontraction of muscles, which may restore stability to the spine.
41269259|NCT00474240|DRUG|Placebo|
41269260|NCT00474240|DRUG|AEGR-733 5 mg + atorvastatin 20 mg|
40920291|NCT01054547|DRUG|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
40920292|NCT01539044|DRUG|Neostigmine, atropine|0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
41093687|NCT00531479|DRUG|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
40920293|NCT01539044|DRUG|Sugammadex|4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
40920294|NCT05174182|OTHER|A novel treatment approach|A novel treatment approach, as described before.
40920295|NCT05174182|OTHER|Usual care|Usual care, as described before.
41269261|NCT00474240|DRUG|AEGR-733 10 mg + atorvastatin 20 mg|
41269262|NCT01337349|DRUG|Placebo|Sugar Pill 400mg taken orally three times a day for 6 months
40758205|NCT02430103|DRUG|Goserelin 3.6 MG|In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
40758206|NCT03607669|OTHER|Mangafodipir trisodium|Manganese-based MRI contrast agent
40920296|NCT04884464|DEVICE|Hyaluronic acid-based gel|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
40920297|NCT04884464|DRUG|Chlorhexidine Gluconate|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
40920298|NCT04676256|PROCEDURE|Early vitrectomy|Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
41269263|NCT01337349|DRUG|Pentoxifylline|Pentoxifylline 400mg taken orally Three times a day for 6 months
41269264|NCT00974220|DRUG|fentanyl|single dose, 50 mcg of nebulized fentanyl citrate
41269265|NCT00974220|DRUG|normal saline (placebo)|single dose, 0.9% saline solution
41269266|NCT02310373|OTHER|Nicotine free hookah smoking|Subjects will smoke waterpipe in a controlled research environment
41093688|NCT00531479|DRUG|anidulafungin|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
41269267|NCT04864587|DIAGNOSTIC_TEST|Artificial intelligence used for image recognition in pouchoscopy|The aim of this study is to develop an image recognition algorithm that reliably detects the different graduations of pouch inflammation and neoplasms in the pouch
41442476|NCT05326386|BEHAVIORAL|HTN and Medication Adherence|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
40758207|NCT02553473|DRUG|Doxycycline|
41093689|NCT00531479|DRUG|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
40758208|NCT02553473|DRUG|Placebo|
40758209|NCT05069415|DEVICE|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.
41269268|NCT04644848|DIAGNOSTIC_TEST|Ultrasonographical tattooing of suspicious axillary lymph nodes.|"Patients with clinically negative axillae scheduled for sentinel lymph node biopsy (SLNB) will have axillary ultrasonographical imaging of the ipsilateral axilla with a high-frequency linear probe. Suspicious lymph nodes are identified according to any of the following criteria:~* Round shape.~* Cortical thickness \> 3 mm~* Eccentric cortical thickness.~* Loss of hilum.~For each patient, node dimensions and the presence of each of the above-mentioned criteria are recorded. Tattooing of all suspicious nodes is done using I ml of sterile liquid charcoal."
41269269|NCT04644848|PROCEDURE|Sentinel lymph node biopsy|Sentinel node biopsy is performed with peri-areolar subdermal injection of 3 ml methylene blue 5%. The lymphatics are tracked to the first blue lymph node. All blue, enlarged and /or tattooed nodes are separately biopsied and labelled as SLN and/or tattooed node.
41269270|NCT04644848|DIAGNOSTIC_TEST|Histopathological examination of the axillary nodes|"All tattooed nodes are excised and sent to frozen section examination; labelled tattoo node.~All enlarged or blue stained nodes are excised and sent to frozen section examination; labelled sentinel node.~All nodes are bisected and a single 5 um section examined. All frozen section examinations are followed by routine paraffin section examination."
40758210|NCT05069415|DEVICE|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
40758211|NCT00274950|BIOLOGICAL|bleomycin sulfate|
40758212|NCT00274950|DRUG|carboplatin|
40758213|NCT00274950|DRUG|cisplatin|
41093690|NCT06615180|BEHAVIORAL|Transcultural Nursing Course (new curriculum)|"Multinational Collaboration: Developed with input from institutions across five countries, ensuring a broad, international perspective on transcultural nursing.~Comprehensive Theoretical Framework: Integrates multiple cultural competence models (Purnell, Campinha-Bacote, Papadopoulos) with Leininger's Culture Care Theory, offering a thorough approach.~Extensive Practical Training: Includes 17 hours of hands-on experience, featuring hospital visits and interactions with healthcare professionals.~Interactive Learning Methods: Combines role-playing, reflective essays, and cultural activities (e.g., traditional clothing, dances) for dynamic, multimodal education.~Peer Education: Incorporates peer education and evaluation, enhancing collaborative learning and critical thinking.~Standardized Materials: Educational materials and teaching methods are standardized across institutions to ensure consistency and quality in instruction."
41093691|NCT02338037|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection
41093692|NCT02338037|PROCEDURE|Biopsy|Undergo biopsy
41093693|NCT02338037|DRUG|Eribulin Mesylate|Given IV
41093694|NCT02338037|PROCEDURE|Microdialysis|Undergo intracerebral microdialysis
40758214|NCT00274950|DRUG|etoposide|
40920299|NCT04427826|DRUG|Morphine hydrochloride|A single open-label injection of morphine (T0) at the dose closest to that defined by the model (estimation by Bayesian method) from among the following 4 doses: 0.02; 0.04; 0.07 and 0.1mg/kg will be adminestred to the patients.
41269271|NCT04644848|PROCEDURE|Further axillary management|Further axillary management is performed as per institutional guidelines. If SLNB is negative, no further surgery is required. Axillary lymph node dissection is performed if sentinel lymph node is positive or not identified. Management of positive SLNB as per the American College Of Surgeons' Oncology Group (ACOSOG) Z0011 protocol is not currently adopted on routine basis at the investigators' institution. In this study, patients with tattooed nodes with positive histopathological findings are offered full axillary dissection even if their sentinel nodes are negative.
41269272|NCT03993015|OTHER|Help to diagnosis software|Help to diagnosis software
40920300|NCT05547204|OTHER|Beverage|Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.
41269273|NCT01766947|DEVICE|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
41269274|NCT00055640|BIOLOGICAL|rituximab|Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.
41269275|NCT00055640|DRUG|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
41269276|NCT00055640|DRUG|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
41269277|NCT00055640|DRUG|prednisone|Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
41269278|NCT00055640|DRUG|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
41269279|NCT00055640|GENETIC|microarray analysis|genetic testing
41269280|NCT05360550|DRUG|LSP-5415|pregnancy prevention
40758215|NCT00274950|DRUG|ifosfamide|
40758216|NCT00274950|DRUG|vinblastine sulfate|
40758217|NCT00274950|PROCEDURE|adjuvant therapy|
40920301|NCT04825730|DRUG|JOINTSTEM|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
40920302|NCT02785796|OTHER|CV4|
40920303|NCT02785796|OTHER|SHAM TECHNIQUE|
41269281|NCT01774214|PROCEDURE|Push-Pull technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model."
41269282|NCT01774214|PROCEDURE|Disconnect-Reconnect Technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles."
41269283|NCT04727541|DRUG|Bintrafusp alfa|Neoadjuvant therapy with bintrafusp alfa
41269284|NCT02318758|DRUG|UT-15C|sustained release oral treprostinil
41269285|NCT02318758|OTHER|ethanol|Absolut 100 vodka
41269286|NCT03471026|DIAGNOSTIC_TEST|Advanced MRI sequences|Structural, diffusion and perfusion MRI sequences
41269287|NCT03782337|BEHAVIORAL|multi-discipline disease management program|The multi-discipline disease management program consists of nursing lead education program, dietitian consultation, psychologist consultation and assessment, and cardiac rehabilitation program by physical therapist.The cardiovascular lead nurse will contact the patient by telephone within 3 days after discharge. An appointment at the outpatient clinic will be arranged within 1 to 2 weeks after discharge. The purposes of the telephone call are to reinforce self-management and recognition of HF symptoms and to screen post-discharge health status.
41269288|NCT03291561|PROCEDURE|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
41269289|NCT03291561|PROCEDURE|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
41269290|NCT01746251|DRUG|Afatinib|
41269291|NCT04285060|DEVICE|Samsung GEMS-H|Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.
41269292|NCT02239172|BIOLOGICAL|PA83-FhCMB|
41269293|NCT00067210|DEVICE|Head and Neck Cooling System|
41269294|NCT03545139|BIOLOGICAL|NeoMTA nusmile|A new formulation of MTA was developed in which bismuth oxide was omitted.
41269295|NCT03545139|BIOLOGICAL|White MTA|Revascularization with Conventional white mineral trioxide aggregate as coronal plug.
41269296|NCT06185855|OTHER|Retrospective Ultrasonographic Data Analysis|The intervention involves a detailed retrospective analysis of ultrasonographic data from patients who underwent breast lesion surgery. The study focuses on developing a quantitative nomogram model, which integrates patient age and significant sonographic characteristics of breast lesions. The purpose is to differentiate breast lesions and assess their malignancy in a non-invasive, accurate manner. This analysis uses data collected from January 2020 to June 2023, including clinical and ultrasound examination records from patients who met the inclusion criteria. The intervention does not involve any direct patient interaction or new diagnostic procedures.
41269297|NCT05029050|DRUG|Dexmedetomidine|Continous intravenous infusion
41269298|NCT05029050|DRUG|Clonidine|Continous intravenous infusion
41269299|NCT05029050|DRUG|Natriumchlorid|Continous intravenous infusion NaCl
41269300|NCT06151652|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.
41269301|NCT06151652|DRUG|Placebo|placebo
40758218|NCT00274950|PROCEDURE|conventional surgery|
40758219|NCT04062565|DRUG|Treprostinil Injectable Product|Injection
40758220|NCT04062565|DRUG|Riociguat Pill|Tablet
40758221|NCT01946646|DRUG|S-1-CCRT|
40758222|NCT00480025|BIOLOGICAL|GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Intramuscular administration, 13 doses
40920304|NCT03924557|DIAGNOSTIC_TEST|Genotype-guided Supportive Care|In this arm, supportive care will be administered based on the results of the genotype test.
40758223|NCT00480025|BIOLOGICAL|Placebo Control|Intramuscular administration, 13 doses
41269302|NCT04765605|DEVICE|WeFlow-Tbranch Stent Graft System|The single-embedded branch thoracic aorta stent graft system consists of the thoracic aorta stent graft system and the branch stent system. The main chest embedded stent graft system consists of the main chest embedded stent graft and its system conveyor, and the branch stent system consists of branch stents and its conveyor. The main chest embedded stent graft and the branch stent are pre-installed in the conveyor
41269303|NCT03716479|OTHER|Low Fiber|20 g of acacia gum will be added to orange juice
41269304|NCT03716479|OTHER|High Fiber|40 g of acacia gum will be added to orange juice
41269305|NCT03716479|OTHER|Placebo/Control|No acacia gum will be added to orange juice.
41269306|NCT02964637|OTHER|Observational Study|
41269307|NCT02784093|DRUG|Gastrograﬁn|
41269308|NCT02784093|PROCEDURE|enemas|
41269309|NCT00420511|DRUG|Sitagliptin|sitagliptin 100 mg once a day
41269310|NCT00420511|DRUG|Placebo|placebo once a day
41269311|NCT00420511|DRUG|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
41269312|NCT03772912|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
41269313|NCT05220592|BEHAVIORAL|Internet-based recovery training program|The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention, and inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week. Each module contained psycho education, worksheets, images, cases, audio and video files, and homework assignments.
41269314|NCT06148961|PROCEDURE|botox prior to modified lip repostioning|"botox injection prior to surgical intervention by 5 to 10 days A surgical marker was used to outline the boundaries of the surgical incision region.~the height of the superior incision was measured as 15 mm within the vestibule. Superior and inferior incisions were made with a scalpel blade number 15 and linked bilaterally by two vertical incisions.~A partial thickness dissection was used to remove the strip of the indicated mucosa, exposing the fascia of the connective tissue beneath. When necessary, all salivary glands and frenal attachments were removed. The surgical site was then properly closed using a periosteal simple interrupted suture was put in place prior to the continuous interlocking sutures. It was placed by commencing the needle 2 mm coronal to Per surgery site, 3 to 4 periosteal sutures were typically The new mucosal boundary to the gingiva was stabilized in its new place using this suture"
41269315|NCT00199979|DRUG|Nevirapine|
41269316|NCT00619502|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
41269317|NCT02375867|DRUG|prednisolone|Oral administration of 1 mg/Kg/day
41269318|NCT02375867|DRUG|methylprednisolone|Intravenous injection of 0.8 mg/kg/day
41093695|NCT02338037|OTHER|Pharmacological Study|Correlative studies
41269319|NCT01482702|BEHAVIORAL|weight loss intervention|Behavioral weight loss intervention
41269320|NCT01482702|BEHAVIORAL|Weight Loss|Behavioral weight loss intervention
41269321|NCT01482702|BEHAVIORAL|Weight Loss|Behavioral weight loss intervention
41269322|NCT04024592|DEVICE|Biodex System 4|Reliability and validity of isokinetic strength measurement of the knee, hip and ankle in typically developing children.
41269323|NCT00719199|DRUG|IMO-2055|SC weekly injections
41269324|NCT00719199|DRUG|Cetuximab|given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
41269325|NCT00719199|DRUG|FOLFIRI|Given day 1 of each cycle
41269326|NCT00661583|DRUG|Ranibizumab|0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
41269327|NCT00661583|DRUG|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
41269328|NCT00661583|DRUG|MMC|MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
41269329|NCT05530057|DRUG|Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|"* Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~* Dose reductions for eribulin, but not for SB3, is permitted.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa."
41269330|NCT05530057|DRUG|Eribulin Mesylate|"* Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation."
41269331|NCT04654312|DRUG|Hydrochlorothiazide|Please see arm descriptions
41269332|NCT04654312|DRUG|Placebo|Please see arm descriptions
41269333|NCT05655403|BEHAVIORAL|Step training program|The program will consist of 3 phases: (1) getting familiar, (2) increasing complexity, and (3) consolidating skills. In Phase 1, the participants will be asked to use one foot to step on single-colored stepping panels located in a specific region of the plastic mat (e.g., upper quadrant). In Phase 2, the exercise will progress by introducing the following 4 cognitively challenging stepping tasks. After finishing the 4 stepping tasks in Phase 2, the exercises will progress to Phase 3, which will consolidate the participants' stepping and cognitive skills. The following 4 additional stepping tasks will be introduced. The instructor will tailor the exercises for each participant, based on their training performance.
41287178|NCT03905772|OTHER|Wide pulse responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in responder group in acute fase.
40920305|NCT00912184|DEVICE|Standard polyamide high flux membrane|Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid
41093696|NCT00421902|PROCEDURE|Acupuncture|Patients will be have acupuncture (with electro stimulation)
41093697|NCT03861728|DEVICE|0.01% Hypochlorous acid|Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
41093698|NCT03861728|OTHER|Placebo|Placebo to be used four times a day to the affected eye for 2 weeks
41287179|NCT03905772|OTHER|Wide pulse non responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in non responder group in acute fase.
41287180|NCT03905772|OTHER|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
40920306|NCT00912184|DEVICE|High cut-off (super high flux) polyamide membrane|CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
40920307|NCT02970682|DRUG|SFX-01|Stabilised Sulforaphane
40920308|NCT02970682|DRUG|Fulvestrant|Fulvestrant
40920309|NCT02970682|DRUG|Tamoxifen|Tamoxifen
40920310|NCT02970682|DRUG|Aromatase Inhibitors|
40920311|NCT06269939|BEHAVIORAL|STEM|Memory technique training
40920312|NCT01416597|BIOLOGICAL|Vaccines|Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
40920313|NCT02903459|OTHER|Transversal Study so there is no intervention|
40920314|NCT00883519|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|12 psychotherapy sessions delivered over 16 weeks
40920315|NCT00883519|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents and Parents|12 psychotherapy sessions delivered over 16 weeks
40920316|NCT02292914|PROCEDURE|Robot-assisted surgery|Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
40920317|NCT02292914|PROCEDURE|Conventional Surgery|Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
40920318|NCT06023836|DEVICE|ESWT|Patients in this group received three sessions of ESWT (MASTERPLUS MP 200 ENERGY 2 trademarked ESWT device) at an energy density of 2 bars and a frequency of 2,000 shocks/min at 12 Hz for three weeks, each session once a week. Each of the five most sensitive and painful points was given 400 pulses in the supine position
40920319|NCT06023836|PROCEDURE|Dry needling|Dry needling with Seirin branded 0.6\*50 mm acupuncture needles will be performed for 3 sessions with one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles of the patients in the group.
40920320|NCT05308940|DRUG|TB001|once-daily subcutaneous injection, on Day 1 in SAD stage
40920321|NCT05308940|DRUG|TB001|once-daily subcutaneous injection, on Days 1-7 in MAD stage
40920322|NCT05308940|DRUG|Placebo|once-daily subcutaneous injection, on Day 1 in SAD stage
40920323|NCT05308940|DRUG|Placebo|once-daily subcutaneous injection, on Days 1-7 in MAD stage
40920324|NCT05659160|PROCEDURE|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
40920325|NCT03610529|DEVICE|CardioSenseSystem|CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
40920326|NCT03610529|DEVICE|Philips Intellivue|Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.
40920327|NCT01239992|DRUG|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
40920328|NCT02938715|OTHER|teledermatology feedback|subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
40920329|NCT06110832|BEHAVIORAL|Mindfulness-based Meditation and Yoga program|In the mindfulness-based meditation and yoga program, mindfulness-based formal and informal interventions are conducted for 8 weeks.
40920330|NCT01494493|DEVICE|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
40920331|NCT01494493|PROCEDURE|Autogenous bone/allograft bone dowel|An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
40920332|NCT04193696|DRUG|Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma|The treatment will be started within 1 week after being admitted into the trial. IMRT or SBRT are adopted , and dose of radiation: Dt-PGTV=40Gy/10fractions,Dt-PGTV=30Gy/10fractions,Dt-PGTV=20Gy/10fractions ,and so on.200mg/ of Carelizumab for injection will be given intravenously every 3 weeks for 5 times since the first day of radiotherapy until disease progression, or intolerable toxicity.
40758224|NCT02904096|DEVICE|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
40758225|NCT03389100|DRUG|18F-MK6240 injection|Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
40758226|NCT00397046|DRUG|neratinib|HKI-272
40758227|NCT00299715|DRUG|Paliperidone extended-release|
40920333|NCT02082756|DRUG|Bifidobacterium viable pharmaceutics|
40920334|NCT02082756|DRUG|Berberine Hydrochloride|
41269334|NCT02347631|DEVICE|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the trial. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this experimental arm, Alcon Dailies Total 1 lenses will be worn first."
40920335|NCT05907941|DEVICE|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion (Figure 2). The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
40920336|NCT05907941|OTHER|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
40920337|NCT05907941|PROCEDURE|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
40920338|NCT05596383|DIETARY_SUPPLEMENT|Vitamin D 5000 IU|Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet
41453074|NCT03694236|DRUG|durvalumab|"Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated."
41453075|NCT00973388|DRUG|Telaprevir; Moxifloxacin; Placebo|
40920339|NCT05596383|DIETARY_SUPPLEMENT|Placebo|Placebo
40920340|NCT02414256|OTHER|regional anesthesia in breast surgery|In the Hospitals involved in this study are performed routinely wall blocks (PECS I-II blocks and serratus block) during breast surgery
40920341|NCT06174272|BEHAVIORAL|Transitional Care Program|Intensive monitoring post discharge for cirrhosis and fluid overload
40920342|NCT03947476|DEVICE|thoracic band|Thoracic band fixation
40920343|NCT04369261|DRUG|Synovian®|Synovian® Inj.
40758228|NCT02315976|DRUG|Propatyl Nitrate|Propatyl nitrate 10mg administered orally, three times daily
40758229|NCT05513105|DIAGNOSTIC_TEST|Iron study of neonates|Blood sambles
41287181|NCT02725177|DRUG|Repository Corticotropin Injection|"Treatment with ACTHAR Gel for 24 weeks~* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)"
41453076|NCT02884986|DRUG|Etoricoxib|120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction
41453077|NCT02884986|DRUG|Placebo|120mg of placebo
40758230|NCT00000472|DRUG|tissue plasminogen activator|
41453078|NCT02184715|OTHER|virtual reality system|The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
41453079|NCT02247362|BIOLOGICAL|VAX2012Q|Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
41453080|NCT02247362|OTHER|Placebo|Vaccine Diluent
41453081|NCT00111696|BIOLOGICAL|MEDI-522|Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
41453082|NCT04525027|DIAGNOSTIC_TEST|intra-abdominal pressure in severe acute pancreatitis|daily intra abdominal pressures in patients admitted to ICU will be measured and noted for intial 5 days and followed up until end outcome
41453083|NCT03277963|DEVICE|Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)|From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
41453084|NCT04483596|DRUG|melatonin effect on the Abbreviated Mental Test|"Questionnare~1. Age~2. Time (to nearest hour)~3. Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~4. Year~5. Name of hospital~6. Recognition of two persons (e.g. doctor, nurse)~7. Date of birth~8. Year of any famous event e.g: the last Egyptian revolution~9. Name of the present monarch~10. Count backwards from 20 to 1"
41453085|NCT03780608|DRUG|AZD6738|AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
41453086|NCT03780608|DRUG|Durvalumab|. Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.
41453087|NCT00796562|DRUG|Busulfan|Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.
41453088|NCT00796562|DRUG|Cyclophosphamide|Patient will receive Cy by IV once a day for 2 days.
41453089|NCT00796562|RADIATION|Total body irradiation|Patients will receive TBI once a day for 4 days.
41453090|NCT01004562|OTHER|informational intervention|
41453091|NCT04922827|DRUG|Infliximab|single intravenous administration of 5 milligrams/kilogram
41453092|NCT04922827|OTHER|Standard of Care|Standard of Care
41453093|NCT00209690|DRUG|Taxotere|X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
41453094|NCT00209690|DRUG|5-FU|800 mg/m2, CIV (conti.in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
41453095|NCT00209690|DRUG|Briplatin|15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
41453096|NCT01370863|DRUG|SPD557|0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
41453097|NCT01370863|DRUG|placebo|matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
41453098|NCT03247686|DRUG|RSLV-132|RNase Fc fusion protein
41453099|NCT03247686|DRUG|Placebo|Placebo
41453100|NCT05698407|DRUG|Dexmedetomidine|loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine.
41453101|NCT05698407|DRUG|Sufentanil|loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
40920344|NCT00536211|BEHAVIORAL|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at \~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
40920345|NCT00536211|DRUG|Metformin|oral tablet, 1000 mg daily for 17 days
40920346|NCT03414892|DRUG|Globalagliatin Hydrochloride|once daily, oral
40920347|NCT03414892|DRUG|Placebo|once daily, oral
40920348|NCT00366067|DRUG|Phenytoin|
41269335|NCT02347631|DEVICE|Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the study. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this active comparator arm, Acuvue TruEye lenses will be worn first."
41269336|NCT06426940|OTHER|anesthesia-related critical events|anesthesia-related critical events
41269337|NCT00531193|DRUG|BIIB014|oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
41269338|NCT00531193|OTHER|[11C]SCH442416|11C\]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. \[11C\]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
41269339|NCT03106233|PROCEDURE|LTP flap|A flap is harvested from the upper lateral thigh region based on septocutaneous perforators located in the posterior septum between the tensor fascia latae and gluteus medius muscles.
40758231|NCT00000472|DRUG|heparin|
40920349|NCT02807415|DRUG|Lumacaftor plus Ivacaftor|Oral treatment with lumacaftor/ivacaftor tablets according to the prescribing information
40920350|NCT00456144|DRUG|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
40920351|NCT02660138|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
41269340|NCT05527990|DEVICE|Multimodal PO|Mixed methods diagnostic accuracy and implementation of multimodal PO
41269341|NCT00347815|DRUG|Buprenorphine|
41269342|NCT04134494|DEVICE|Ablative Fractional 2940 nm Laser|"* Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.~* Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.~* Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚."
41269343|NCT03325179|OTHER|Thread-embedding Therapy|
41269344|NCT00830921|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
41287182|NCT02725177|DRUG|Repository Corticotropin Injection -Treatment Extension|24 open label extension permitted in subjects who respond to treatment
41287183|NCT06059937|OTHER|Patient with pre-eclampsia|Cardiovascular risk assessment by the general practitioner in the year following pre-eclampsia
41453102|NCT04220736|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
41453103|NCT03156816|DRUG|Colchicine group (experimental arm)|In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.
41453104|NCT03156816|DRUG|Placebo group (control arm)|In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
40758232|NCT04179656|DRUG|Pyrotinib|400 mg administered orally, once daily, continuously in 21 day cycles
40758233|NCT00692237|DRUG|Sildenafil|100 mg daily (3 capsules/day)
41453105|NCT02508870|DRUG|Atezolizumab|Participants will receive atezolizumab as per the schedule described in individual cohort.
41453106|NCT02508870|DRUG|Azacitidine|Participants will receive azacitidine as per the schedule described in individual cohort.
41453107|NCT06402565|DRUG|NOX1416 plus SOC|Topical Nitric Oxide
41453108|NCT06402565|OTHER|Placebo plus SOC|Placebo plus SOC as provided in the Arm/Group description.
41453109|NCT05390255|DRUG|Mometasone furoate nasal spray hormone|This group of patients received mometasone furoate nasal spray hormone treatment throughout the study.
41453110|NCT05390255|DRUG|Mometasone furoate nasal spray hormone + oral hormone|The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of mometasone furoate nasal spray hormone treatment throughout the course.
41453111|NCT05390255|DRUG|Mometasone furoate nasal spray hormone + omalizumab|The patients in this group were injected with omalizumab once a month under the background of mometasone furoate nasal spray hormone treatment, for a total of 6 times.
41453112|NCT03811145|BIOLOGICAL|Tendoncel|Platelet lysate gel
41453113|NCT03811145|OTHER|Placebo control gel|Placebo control gel
41453114|NCT00749658|DRUG|Bupropion|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
41453115|NCT00749658|DRUG|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
41453116|NCT05219734|DIAGNOSTIC_TEST|Personalized Cancer Monitoring (PCM)|personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease
41453117|NCT00660387|DRUG|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
41453118|NCT00660387|DRUG|Placebo Gel|
41453119|NCT00660387|DRUG|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
41453120|NCT00660387|DRUG|Placebo (PBO) oral capsules|
41453121|NCT00660387|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
41453122|NCT00660387|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
41453123|NCT00660387|DEVICE|J-tube|jejunal tube
41453124|NCT00182260|DRUG|Proton Pump Inhibitors|
41453125|NCT00182260|PROCEDURE|Laparoscopic Nissen Fundoplication|
41453126|NCT01389713|DRUG|Clomifene Citrate|3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle
41453127|NCT01389713|DRUG|GnRH analog and recombinant human FSH|daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
41453128|NCT00898508|GENETIC|gene expression analysis|
41453129|NCT00898508|GENETIC|mutation analysis|
41453130|NCT00898508|GENETIC|proteomic profiling|
41453131|NCT00898508|GENETIC|reverse transcriptase-polymerase chain reaction|
41453132|NCT00898508|OTHER|fluorescent antibody technique|
41453133|NCT00898508|OTHER|immunohistochemistry staining method|
41453134|NCT00898508|OTHER|laboratory biomarker analysis|
41453135|NCT00898508|OTHER|liquid chromatography|
41453136|NCT00898508|OTHER|mass spectrometry|
41453137|NCT00898508|OTHER|medical chart review|
41453138|NCT00898508|PROCEDURE|quality-of-life assessment|
41269345|NCT04894955|DEVICE|MARIA|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to ascertain their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® participant bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts and array are brought into contact with the breast. A scan sequence comprising of two complete scan rotations will then be performed, which takes around 5 minutes. The participant will then be assisted to adjust their positioning, and the scan sequence performed on the other breast.
41269346|NCT04706884|DEVICE|Near infrared spectroscopy|The rSO2 (cerebral oxygen satutation) was continuously monitored by NIRS (Near infrared spectroscopy) with a sensor positioned on the forehead of the patient
41269347|NCT03388593|DRUG|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
40920352|NCT02660138|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
40758234|NCT00692237|DRUG|Placebo|Placebo 100 mg (3 capsules/day)
40758235|NCT04415151|DRUG|Tofacitinib 10 mg|Tofacitinib will be administered in a dose of 10 mg twice daily by mouth (PO BID) until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
40920353|NCT02660138|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
40920354|NCT02660138|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
40920355|NCT00734747|DEVICE|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
40920356|NCT06227182|DIAGNOSTIC_TEST|Muscle ultrasound with surface electromyography and dynamometry|The three procedures are conducted simultaneously for upper and lower extremity muscles. A standard muscle ultrasound preset with a fixed depth of 4 cm or 6 cm will be used, depending on which muscle is visualized in accordance with our routine clinical protocols. During the dynamic approach, the transducer will be placed in a longitudinal fixed position on the muscle using a ProbeFix. All measured contractions in the different muscles will be recorded as short ultrasound videos.
40920357|NCT06227182|DIAGNOSTIC_TEST|MRI scan|In Stage II, all patients and 10 healthy participants will undergo MRI. During the MRI procedure, we evaluate muscle fat fraction, muscle contractile volume, muscle inflammation and edema.
40920358|NCT02432352|BEHAVIORAL|Our Family Our Future|The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
40920359|NCT02338882|DEVICE|Bi flex M multifocal intraocular lens|Multifocal intraocular lens
40920360|NCT02338882|DEVICE|Bi flex 1.8 monofocal intraocular lens|Standard monofocal intraocular lens
40758236|NCT04415151|DRUG|Placebo|Matching placebo tablets will be administered.
40920361|NCT02338232|DRUG|Telmisartan|
40920362|NCT05173545|DRUG|Mitoxantrone Hydrochloride Liposome Injection|"Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes."
41269348|NCT03388593|DRUG|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
41269349|NCT00135057|DRUG|insulin glulisine|
40920363|NCT02263352|DRUG|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
41269350|NCT00135057|DRUG|insulin glargine|
40920364|NCT02263352|DEVICE|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
41269351|NCT00899093|OTHER|Cytology Specimen Collection Procedure|Correlative studies
41269352|NCT00899093|OTHER|Laboratory Biomarker Analysis|Correlative studies
41269353|NCT02992002|OTHER|Fluid Challenge|Infusion of a standardized amount of crystalloid solution (500 ml) to assess fluid responsiveness by means of changes in cardiac output, assessed by transpulmonary thermodilution.
41269354|NCT05830383|BEHAVIORAL|PDCA circular management|"PDCA circular management means PlanDoCheckAction four steps"
41269355|NCT02477345|DRUG|Omegaven IV|"Omegaven will be initiated at a dose of 0.5 gram/Kg/day and is infused over 24 hours for 1-2 days, and then advanced to~1 gram/Kg/day. Omegaven will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven will continue until weaned from PN. Monotherapy with Omegaven can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/Kg/day, advancing to 1 gm/kg/day."
41269356|NCT05926427|DRUG|Orelabrutinib|150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up
41269357|NCT05926427|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
41269358|NCT05926427|DRUG|Chemotherapy|Not specified, recommended regimen according to histopathologic type
41269359|NCT02512458|DRUG|Cabazitaxel|
40920365|NCT01328405|DEVICE|Laryngeal Mask Airway (LMA)|Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
40920366|NCT05111301|DEVICE|Control-IQ technology 1.5|"All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor.~Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level."
40920367|NCT03141294|PROCEDURE|reformative dilation technique|reformative dilation technique was used when operating tracheostomy
40920368|NCT00877123|DRUG|Oral vitamin D 100,000 IU|Oral vitamin D 100,000 IU once a month for three consecutive months.
41269360|NCT00773279|DEVICE|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
41269361|NCT00773279|DEVICE|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
41269362|NCT06380504|BEHAVIORAL|R-SWITCH integrated intervention package|"1. Monthly group meetings of Alliance for Development (AFD) community groups) and their members (caregivers of children 0-59 months of age):~   * Introduction and refresher of Family-led MUAC~  * Active screening of wasting by AFD~  * Group SBCC on Infant and Young Child Feeding (IYCF), health and Water, Sanitation and Hygiene (WaSH) with a focus on SAM~  * Promotion of health services such as GMP~2. Introduction of weight-for-age Z-score \<-3 as screening criterion for passive screening by health extension workers at any contact with children (e.g. during GMP)~3. Promotion of Family-led MUAC screening and SAM awareness to fathers during male agricultural/pastoralist extension activities and by community and religious leaders (creating social support)~4. Follow-up and counselling during home visits by AFD leaders of i) earlier referred cases of SAM, ii) cases enrolled in SAM OTP, iii) and recovered SAM cases discharged from OTP~5. Strengthening communication between HEW and AFDs"
41269363|NCT04623957|DEVICE|ForgTin©|"The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.~The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises."
41269364|NCT00004826|DRUG|clozapine|
41269365|NCT02626676|OTHER|Educational Programme|Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
40920369|NCT00877123|DRUG|Placebo|similar placebo once a month for three consecutive months
40920370|NCT03135418|DEVICE|Intervention|"Patients will use virtual reality d4evice to play task oriented games like bowling, arrow shooting and home activity simulations which focuses upper extremity abduction, flexion and rotation movements. Each session will be a total of 45 minutes divided to 3 15 minute games. Sessions will held for 6 weeks each monday, wednesday and friday at same time for each patient.~In addition to the virtual reality treatment program conventional rehabilitation therapies including neurodevelopmental facilitation techniques, physiotherapy, and occupational therapy and, where necessary, speech therapy will be applied according to the needs of the patient."
40920371|NCT03135418|DEVICE|Control|The control group will be included in the virtual reality program only focusing on visual scenes without upper extremity interaction. Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facial techniques will be applied to the control group for 6 weeks.
40920372|NCT01104532|DRUG|ASP1941|oral tablet
40920373|NCT01104532|DRUG|sitagliptin|oral tablet
40920374|NCT06113679|DEVICE|RDX-19|RD-X19 device with a 5 minute, 32 J/cm2 dose, 2X/day, 7 days. Each treatment at least 6 hours apart.
41093699|NCT04762342|OTHER|Power training|"First a brief warm up on a stationary bike and uni-lateral knee raises is completed.~Power training: Involves exercises performed with fast/explosive muscle contraction during the concentric phase, and slow/controlled (approximately 2-3 s) muscle contraction during the eccentric phase.~Functional- and balance exercises are included from week 9-24.~Progression:~Week 1-4: 3 sets of 12 repetitions at a load of 14 repetitions maximum (RM) with focus on introducing resistance exercise and familiarizing participants with exercises.~Week 5-8: 3 sets of 12 repetitions at a load of 14 RM the power training component.~Week 9-16: 3 sets of 10 repetitions at a load of 12 RM. Week 17-24: 3 sets of 8 repetitions at a load of 10 RM~Strengthening exercises:~* Bilateral leg-press~* Bilateral plantar flexion~* Bilateral knee extension~* Unilateral banded dorsal flexion~* Bilateral lying leg curl~* Back extension~* Shoulder press~* Seated row~* Chest press~* Lat pull-down"
41093700|NCT00000772|DRUG|Ribavirin|
41093701|NCT00000772|DRUG|Didanosine|
41269366|NCT06348121|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study had last 84 days, and each patient will make 4 visits (d0, d28, d56, d84).
40920375|NCT04754945|DRUG|Bortezomib|Given SC
40920376|NCT04754945|DRUG|Cyclophosphamide|Given IV or PO
40920377|NCT04754945|DRUG|Dexamethasone|Given IV or PO
40920378|NCT04754945|BIOLOGICAL|Isatuximab|Given IV
40920379|NCT04653467|DRUG|GLPG4399 oral suspension|GLPG4399 for oral administration
40920380|NCT04653467|DRUG|GLPG4399 capsules|GLPG4399 for oral administration
40920381|NCT04653467|DRUG|Placebo|Placebo oral suspension
40920382|NCT00974584|DRUG|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\\n\\n\\n\\n\\n\\n
40920383|NCT00974584|DRUG|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
40920384|NCT00974584|DRUG|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter\*minute (mg/mL\*min).\\n
41269367|NCT05946590|PROCEDURE|Frenotomy|Frenotomy in which clipping/incised of the lingual frenulum releases the tongue-tie performed by a health care professional
41269368|NCT02299193|BEHAVIORAL|Cognitive Behavioral Therapy|6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep
41269369|NCT02299193|BEHAVIORAL|Healthy Sleep Habits|6 weekly, 20 minute online sessions about healthy sleep practices
41269370|NCT05206461|OTHER|Trunk Control Measurement Scale|Trunk Control Measurement Scale, easy and simple to use, was used to evaluate trunk control
41269371|NCT04594993|DEVICE|INFINITY™ with ADAPTIS™ Technology Total Ankle System|Total Ankle Replacement
41269372|NCT03843047|DRUG|3 mg/mL nicotine strength e-liquid|Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
41269373|NCT03843047|DRUG|6 mg/mL nicotine strength e-liquid|Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
41269374|NCT03843047|DRUG|12 mg/mL nicotine strength e-liquid|Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
41269375|NCT03843047|DRUG|24 mg/mL nicotine strength e-liquid|Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
40920385|NCT00974584|DRUG|cisplatin|Cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of every 3-week cycle.\\n
40920386|NCT00974584|DRUG|paclitaxel|Paclitaxel 200 mg/m\^2 IV on Day 1 of every 3-week cycle.\\n\\n
40920387|NCT00974584|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 IV on Day 1 of every 3-week cycle.
40920388|NCT03272334|DRUG|HER2 BATs with Pembrolizumab|8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
40920389|NCT02108015|PROCEDURE|Brain Imaging (PET)|
40920390|NCT02108015|PROCEDURE|Aterial Line|
40920391|NCT02108015|PROCEDURE|Blood Sampling|
40920392|NCT01548833|DEVICE|Delefilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
40920393|NCT01548833|DEVICE|Narafilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
40920394|NCT01548833|DEVICE|Filcon II 3 contact lens|Silicone hydrogel contact lens for single use, daily disposable wear
40920395|NCT06478381|DRUG|L218CAR19|L218CAR19 is intravenously administered at three dose levels.
40920396|NCT04169971|OTHER|Music|Played through headphones during the operation under spinal anaesthesia
41269376|NCT00003729|DRUG|cytarabine|
41269377|NCT00003729|DRUG|fludarabine phosphate|
40920397|NCT03160794|DIAGNOSTIC_TEST|[18F]DCFPyL PET/MRI scan|PET/MRI imaging using the radiotracer, \[18F\]DCFPyL
41269378|NCT00003729|DRUG|idarubicin|
41269379|NCT05593029|DRUG|SEP-363856|Tablet
41269380|NCT05593029|OTHER|Placebo|Placebo
41269381|NCT03543813|DRUG|CX-2029|CX-2029 Monotherapy
41269382|NCT00799526|PROCEDURE|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
40920398|NCT03160794|RADIATION|Stereotactic Ablative Radiotherapy|SABR as treatment for lesions identified using \[18F\]DCFPyL PET/MRI
40920399|NCT02364336|DRUG|Peginterferon alfa-2a|
40920400|NCT05111015|DEVICE|Concomitant Open Heart Surgical Ablation Procedures|AtriCure's Concomitant Open Heart Surgical Ablation Devices used for the treatment of Atrial Fibrillation.
41269383|NCT00799526|PROCEDURE|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
40920401|NCT05111015|DEVICE|Hybrid (Convergent) Ablation Procedures|AtriCure's Hybrid (Convergent) Ablation Devices used for the treatment of Atrial Fibrillation.
40920402|NCT05111015|DEVICE|AtriCure LAA Exclusion Procedures|AtriCure's LAA Exclusion Devices used to exclude the Left Atrial Appendage for the treatment of Atrial Fibrillation.
40920403|NCT02458937|OTHER|Functional Mobility Assessment|Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
40920404|NCT02458937|OTHER|GAITRite® System|Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
40920405|NCT02458937|OTHER|Range of Motion|Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
41093702|NCT03310463|DRUG|ETX2514SUL|Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
41093703|NCT06187870|OTHER|Collection of biological data|Biological samples will be collected from the patient at the time of their access to the Hospital
41269384|NCT03624816|DEVICE|Restylane Defyne|hyaluronic acid dermal filler gel
41269385|NCT03205579|OTHER|Video group|Using video for educate cancer pain patients
41269386|NCT03205579|OTHER|conventional group|Face to face cancer pain education by trained nurse
40920406|NCT04453943|DEVICE|Exoskeleton Walking - with or without FES|The study involves validation of computer algorithms to estimate and control walking movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Walking movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
41269387|NCT03148730|DEVICE|closed-loop group|Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
41269388|NCT02476318|DEVICE|ArterX Vascular Sealant|
41269389|NCT03085784|DRUG|Aflibercept|The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
41269390|NCT06546033|OTHER|application of different types of diet|application of different types of diet
41093704|NCT04384770|RADIATION|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT
41093705|NCT04384770|RADIATION|MRI-guided Stereotactic Body Radiation Therapy|Undergo MRI-guided SBRT
41093706|NCT04384770|OTHER|Questionnaire Administration|Ancillary studies
41093707|NCT03208556|BIOLOGICAL|iPD1 CD19 eCAR T cells|"iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）.~CAR T cell dose escalation: 1×10\^5 /kg，1×10\^6 /kg，3×10\^6 /kg，and 6×10\^6 CAR T cells/kg"
41269391|NCT02186184|DEVICE|Orthokeratology|
41269392|NCT02186184|DEVICE|Spectacle|
41269393|NCT06052956|DRUG|Methylene Blue|Administration of 0.1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
41269394|NCT06052956|DRUG|Lipid Emulsion|The abscess cavity will be filled with sterile 0.1% lipid emulsion solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
41269395|NCT06052956|DEVICE|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
41269396|NCT06052956|DEVICE|Laser Illumination (pre-defined dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set such that the fluence rate at the abscess wall due to ballistic photons is 20 mW/cm2.
41269397|NCT06052956|DEVICE|Optical Spectroscopy Measurement|The same sterile optical fiber used for treatment will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity, polarized white light will be delivered by a tungsten halogen lamp by the fiber, and captured by the same fiber. Light that has been de-polarized by interaction with tissue will be detected by a spectrometer and analyzed to extract tissue optical properties. Upon completion of these measurements, the fiber optic will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
41269398|NCT06052956|DEVICE|Laser Illumination (patient-specific dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set to deliver a fluence rate of 20 mW/cm2 in 95% of the abscess wall, based upon abscess morphology and optical spectroscopy results.
41269399|NCT06052956|PROCEDURE|Standard of care abscess drainage|Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.
41269400|NCT03314506|OTHER|Exercise|Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
40920407|NCT04453943|DEVICE|Exoskeleton Sitting to Standing - with or without FES|The study involves validation of computer algorithms to estimate and control sitting/standing movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Sitting/Standing movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
41269401|NCT03700047|DEVICE|GAL1704|new dermal filler
40920408|NCT03534479|DRUG|Polyclonal IgG|Measurement of vascular reactivity before and after Infusion of plyclonal Immunoglobulins G in patients with Common variable immunodeficiency
40920409|NCT01528202|DIETARY_SUPPLEMENT|Cherry juice|30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
41269402|NCT03700047|DEVICE|Juvederm Voluma|hyaluronic acid
40920410|NCT01528202|DIETARY_SUPPLEMENT|Fruit juice cordial|fruit flavoured juice concentrate
40920411|NCT00133003|DRUG|Abciximab|0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight
40920412|NCT00133003|DRUG|Placebo|Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
40920413|NCT02907190|OTHER|Bean Type|1/2 cup of freshly boiled beans will be eaten by participants on separate study visits
41093708|NCT03208556|DRUG|Fludarabine and cyclophosphamide|Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
41093709|NCT05756426|OTHER|Prospective|Single arm, healthy adult volunteers for blood donation.
41093710|NCT01518257|BIOLOGICAL|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
41269403|NCT01290627|DEVICE|Subjects implanted with DePuy LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
40920414|NCT02907190|OTHER|Starchy Foods|1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
41269404|NCT01290627|DEVICE|Subjects implanted with DePuy Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
41269405|NCT04484350|DRUG|Labetalol|10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
41269406|NCT04484350|DRUG|Hydralazine|10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
40920415|NCT05132803|DRUG|HPV 16 TA-CIN|No dose escalation or reduction
40920416|NCT04796181|DEVICE|Neteera 130H|The Neteera 130H will used to perform measurements in proximity to study participants.
41269407|NCT04484350|DRUG|Enalapril|1.25 - 2.5 mg IV bolus and then q6h PRN.
41269408|NCT05690659|OTHER|device and exercise|cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging
40920417|NCT04170972|OTHER|Acute exercise|One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
40920418|NCT02459288|DRUG|Clopidogrel first|After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
40920419|NCT02459288|DRUG|Ticagrelor first|After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
40920420|NCT00483756|DRUG|Cyclosporine|Standard of care
40920421|NCT00483756|DRUG|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
41093711|NCT01518257|DRUG|Normal Saline|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
41093712|NCT04079712|DRUG|Cabozantinib S-malate|Given PO
41269409|NCT04668560|BEHAVIORAL|Five ways to wellbeing course|A behavioural course over six sessions. Teaching the participants in doing avtivities to promote wellbeing
41269410|NCT00127127|DRUG|vorinostat|vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration
41269411|NCT01070329|DRUG|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
41269412|NCT01070329|DRUG|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
41269413|NCT00917436|DRUG|Thiocolchicoside|
41269414|NCT00749333|DRUG|AZD8566|solution. Specific dose will be selected by the safety review committee
41269415|NCT00749333|DRUG|Placebo|Single 10ml oral solution.
41269416|NCT01783067|OTHER|Pearl millet|Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
41269417|NCT01783067|OTHER|Biofortified pearl millet|Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
41269418|NCT04217395|BEHAVIORAL|Obese or overweight health subjects involved in the X-Ailes program (at least one contact with the health system navigator)|"The X-Ailes program is a face-to-face or telephone-based support program by health-system navigators and developed by a patients and public association to support overweight or obese care users.~The main objective of the study is to evaluate the efficacy of the X-ailes program on quality of life of overweight and obese people involved in the program.~Secondary objectives are to assess their overall health status, their health literacy level and their empowerment. The implementation study is guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance; Glasgow, Vogt, \& Boles, 1999) theoretical framework to determine whether the intervention objectives are being met and to understand the mechanisms of action of the device."
41269419|NCT00727207|DRUG|everolimus|
41269420|NCT03744455|BIOLOGICAL|Axillary Plexus|Axillary plexus anesthesia technique for hand surgery
41269421|NCT00442598|DRUG|Glufosfamide|
41269422|NCT04159883|OTHER|strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles)|Simple progressive strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles), the program has been evident to be significantly effective in improving self-reported knee pain and function. This program included: 1) Isometric quadriceps contraction, 2) Isotonic quadriceps contraction, 3) Isotonic hamstring contraction, 4) Isotonic quadriceps contraction with resistance band, 5), straight leg raising, 6) Side-lying hip abduction, 7) Partial Squats,
41269423|NCT04159883|OTHER|"My Dear Knee smart phone application"|"The innovative app has been designed for Android and iPhone Operating System (iOS). The app provides guides with the Arabic language. It designed to be attractive for the older adult and easy to use. the exercises are demonstrated with colorful animated images to make easy to follow by the patients.~The app supports features such as alerts, monitoring system by the physical therapist and remote follow-up. The app provides automatic recording of exercise adherence, including the time and the number of sessions completed for the week in the physical therapist's account."
41269424|NCT00501228|DRUG|Filgrastim|5 mg/kg ID Once Daily x 1 Week
41269425|NCT02586805|DRUG|DX-2930 - 300mg/2wk|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
41269426|NCT02586805|DRUG|DX-2930 - 300mg/4wk|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
41287184|NCT00187161|DRUG|Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin|The additional information is contained in the Detailed Description section.
40920422|NCT00483756|DRUG|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
40920423|NCT03363113|DRUG|Botulinum Toxins|Injection of botulinum toxin in the muscles affected by oromandibular dystonia
40920424|NCT02547961|BIOLOGICAL|HER-2-targeting CAR T Cells infusion|HER-2-targeting CAR t cells infusion in breast cancer
40920425|NCT02082938|DEVICE|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
40920426|NCT05901844|DIAGNOSTIC_TEST|Paraffin pathological diagnosis|Perform two diagnostic methods on the same sample
40920427|NCT04471285|PROCEDURE|acupuncture|acupuncture
40920428|NCT04471285|PROCEDURE|Sham acupuncture|Sham acupuncture
40920429|NCT00181597|DRUG|Trilostane|Taken orally once a day for three days then twice daily thereafter.
40920430|NCT00181597|DRUG|Hydrocortisone|Taken orally with trilostane.
41093713|NCT04079712|BIOLOGICAL|Ipilimumab|Given IV
40920431|NCT02379130|BEHAVIORAL|Family Nurture Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
41269427|NCT02586805|DRUG|DX-2930 - 150mg/4wk|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
40920432|NCT02379130|BEHAVIORAL|Play and Nutrition Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
40920433|NCT05514808|OTHER|Nutrition education modules|Nutrition education modules on sports nutrition and dietary supplements over a period of 4 weeks (1 module/week)
40920434|NCT04333303|OTHER|Implementation of a complex regional Advance Care Planning program|"Sustainable implementation of ACP at micro- (qualification of professional ACP facilitators to lead conversations in cooperation with family physicians), meso- (qualification of relevant co-actors, organisational development of participating institutions) and macro-level (regional ACP steering group and network), ensuring that valid ACP is encouraged, facilitated, documented, known and honored.~Core of the intervention is a modular 9-day-training for ACP facilitators. These will be preferably located in regional pools, serving more than one nursing home, and reimbursed, if certified, by German sickness funds based on recent legislation (§ 132g Social Code Book \[SGB\] V: 1 full-time facilitator for 400 residents). ACP conversations will be offered to all residents. Regional intervention at meso- and macro-level comprises various formats of specific ACP training and information for leadership and staff, and aims to support professional change management."
41269428|NCT02586805|DRUG|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
41269429|NCT00454493|DRUG|Omacor (omega-3-acid ethyl esters)|
40920435|NCT00296205|DRUG|Cyclophosphamide|
41269430|NCT00145990|DRUG|methacholine|
41269431|NCT00145990|DEVICE|KoKo Digidoser|
41269432|NCT00145990|DEVICE|Rosethal Dosimeter|
41269433|NCT01571479|PROCEDURE|2- mini-instrument|"The patient was positioned in the supine position with the head and right side up.~Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.~A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups."
41269434|NCT05243849|DEVICE|Optical Coherence Tomography Angiography|Optical coherence tomography angiography (OCTA) is a novel non-invasive, non-dye and high-resolution imaging technique, allowing real-time quantitative evaluation of retinal vasculature and the structure of foveal avascular zone (FAZ).
41269435|NCT00321165|DRUG|taurolidine|
41269436|NCT03452267|DRUG|Metformin|oral, 850 mg twice daily
41269437|NCT03452267|DRUG|Pioglitazone|oral, 45 mg daily
41269438|NCT03452267|DRUG|Placebo|oral, once daily
41269439|NCT01422005|OTHER|Simultaneous Bimanual training|"Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.~Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy."
40920436|NCT01809093|BIOLOGICAL|Blood draw|3-4 tablespoons of blood will be drawn, one time.
41093714|NCT04079712|BIOLOGICAL|Nivolumab|Given IV
41093715|NCT06614244|PROCEDURE|Oral immunotherapy (OIT)|OIT in DOPA group will be implemented as follows. Both the first micro-dose of the offending food and the subsequent micro-increments will be administered at home. Any interruptions and resumptions of OIT, due to intercurrent events (e.g. infections), will be managed via email with or without medical visit via video call. Patients will be provided with ondansetron (sublingual film) and instructions for its use. An explanatory letter will also be provided in case of need for emergency room access.
41269440|NCT01422005|OTHER|Conventional Occupational Therapy|Conventional Occupational Therapy will be given to patients in the control group.
41269441|NCT01695421|PROCEDURE|Medium-frequency alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
40920437|NCT04314791|DEVICE|Ultrasound evaluation, with grayscale and color Doppler imaging|In pregnant women with previous CS and anterior low-lying or placenta previa, the following three sonographic criteria were assessed: (i) the smallest myometrial thickness in the sagittal plane; (ii) presence of placental lacunae and its grade from 0-3; (iii) bridging vessels using color Doppler. The PAI score (up to 9) was calculated for every patient as described by Rac et al.2015.
40920438|NCT04330313|PROCEDURE|Traction|Intermittent traction will be applied to the cervical region in a supine position with the neck at 25-30 ° flexion. The target weight is determined as 10% of the patient's weight. Traction pulling force applied to the target weight will be achieved gradually increasing from low. Traction therapy will be applied intermittent traction for 15 minutes in each session as 60 seconds retention and 60 seconds rest. The therapy will be held for 18 sessions, 3 days / week.
40920439|NCT04330313|PROCEDURE|Laser therapy|Laser therapy will be applied to the participants with a GaAs laser with 904 nm wavelength, 6 points transforaminally, 120 seconds to each point, at 2 J / cm² density, total dose of 12 J laser therapy by keeping the probe in constant contact with the skin.
40920440|NCT04330313|PROCEDURE|Hot pack|The hot pack, which is the superficial heat agent, will be held in the neck area of the participants for 20 minutes in each session.The therapy will be held for 18 sessions, 3 days / week.
41269442|NCT01695421|PROCEDURE|Burst-modulated alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
40920441|NCT04330313|PROCEDURE|Stretching|Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.
40920442|NCT02834754|DRUG|Vedolizumab|Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV
40920443|NCT02834754|DRUG|placebo|Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
40920444|NCT00575341|DRUG|Dehydroepiandrosterone|25 mg DHEA, oral, once daily
40920445|NCT00575341|DRUG|placebo|placebo, oral, once daily
40920446|NCT02886403|OTHER|Standard adhesive strip|A standard adhesive strip (hydrocolloid)
40920447|NCT02886403|OTHER|New adhesive strip|A newly developed adhesive strip
40920448|NCT02575547|DRUG|cisplatin and docetaxel|"NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition"
40920449|NCT05246111|DRUG|[14C]M6620|Participants will receive single intravenous infusion of \[14C\]M6620 on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
40920450|NCT05246111|DRUG|M6620|Participants will receive intravenous infusion of M6620 on Day 2 and Day 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation are met.
41269443|NCT01695421|PROCEDURE|Placebo|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
41269444|NCT01695421|PROCEDURE|Functional electrical stimulation|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
40920451|NCT05246111|DRUG|Topotecan|Participants will receive intravenous infusion of topotecan on Day 1 through Day 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation are met.
40920452|NCT02284425|DRUG|REGN1193|
40920453|NCT02284425|DRUG|Placebo|
40920454|NCT01781468|DRUG|armodafinil 150 mg|given orally
40920455|NCT01781468|OTHER|Placebo|given orally
40920456|NCT01781468|DRUG|armodafinil 250 mg|given orally
40920457|NCT02631473|DRUG|50mg NANO-efavirenz|OD
40920458|NCT02631473|DRUG|400mg NANO-Lopinavir|BID
40920459|NCT02631473|DRUG|200mg NANO-Lopinavir|BID
41269445|NCT05408611|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
41269446|NCT05408611|OTHER|Placebo acupressure|Placebo acupressure is manual pressure applied to unreal acupressure points.
40920460|NCT02631473|DRUG|100mg Ritonavir|BID
40920461|NCT02631473|DRUG|300mg NANO-Efavirenz|OD
40920462|NCT02631473|DRUG|600mg Sustiva|OD
40920463|NCT02631473|DRUG|200mg NANO-Efavirenz|OD
40920464|NCT02631473|DRUG|Kaletra® (lopinavir 400mg/ritonavir 100mg)|BID
40920465|NCT02631473|DRUG|+/- 200mg NANO-Lopinavir|BID
40920466|NCT02631473|DRUG|+/- 200mg ritonavir NORVIR|BID
40920467|NCT02631473|DRUG|400mg Sustiva|
41093716|NCT06614244|DIETARY_SUPPLEMENT|Culprit food elimination diet|The Diet group consists of a population of children affected by acute persistent FPIES subjected to the traditional measure, i.e. the elimination diet of the incriminated food.
40758237|NCT03405753|DIETARY_SUPPLEMENT|Aronia, washout and then placebo|Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
40920468|NCT04070911|OTHER|WATER|ORAL WATER
40920469|NCT04070911|OTHER|ICE APPLICATION|ICE APPLICATION
40920470|NCT00391209|DRUG|simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,6 months
40920471|NCT00391209|DRUG|intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
40920472|NCT05834387|PROCEDURE|EICU Transfer Routine Care|EICU Transfer Routine Care
40920473|NCT05834387|PROCEDURE|Implementing interventions based on a 'health care-family-environment' linkage|"Nursing interventions in the experimental group The interventions were based on the health care-family-environment linkage"
40920474|NCT03141996|OTHER|Vibration to upper posterior neck muscles|Vibration to upper posterior neck muscles using a vibrational tool.
40920475|NCT03141996|OTHER|Standard of Care|Standard of care treatment
40920476|NCT06120270|DEVICE|CeraFlex PFO Closure System|The Lifetech CeraFlex™ PFO occluder device is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
40920477|NCT03689309|PROCEDURE|High Flow Oxygen SBT|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
40920478|NCT01764191|OTHER|18F-Fluorodeoxyglucose (18F-FDG) PET/CT|All subjects suspected of cardiac sarcoidosis will receive an intravenous dose of 18F-FDG (determined by weight, but not to exceed 521 MBq). Following an uptake phase of about 60 minutes, each subject will receive a PET/CT scan to evaluate the presence of cardiac sarcoidosis.
40920479|NCT04610281|DEVICE|Inner Garden|"Care actions adapted to the intensity of the states of agitation (The child can be removed from the group while remaining in the same room on a chair with a caregiver. If the problems are too serious, the child can be accompanied to a soothing room where the carer will take care of him/her individually. In units equipped with Inner Garden, the child can use it under semi- supervision of nurses.)"
40920480|NCT03417713|DEVICE|Fluoroscopic imaging with the OEC Elite Device|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed.
40920481|NCT04083625|DRUG|carbetocin 100 mcg|a 10 cm syringe containing 100 mcg carbetocin just before skin incision of myomectomy.
40920482|NCT04083625|DRUG|placebo|a 10 cm syringe normal saline IV given just before skin incision of myomectomy.
40920483|NCT00304213|DRUG|Testosterone|
40920484|NCT00361413|DRUG|Alefacept (AMEVIVE®)|Alefacept
41269447|NCT00967265|BEHAVIORAL|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
41269448|NCT00967265|OTHER|Usual care|Usual care
40920485|NCT00361413|DRUG|control group|these patients will receive the same treatment as group A, without alefacept
40920486|NCT00628043|DRUG|epoetin beta|Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
40920487|NCT00628043|DRUG|placebo|Subcutaneous administration of placebo once-weekly for 12 weeks
40920488|NCT04125251|BEHAVIORAL|Life Skills Building Training|The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants
40920489|NCT06529926|OTHER|Observational|Only classical physiotherapy application for 4 weeks.
40920490|NCT06529926|OTHER|IASTM Technique Application|IASTM application for 2 sessions per week with classical physiotherapy for 4 weeks.
40920491|NCT04374227|PROCEDURE|Osteopathic Manipulative Treatment|Body regions that were treated included head, cervical, thoracic, ribs, lumbar, pelvis, sacrum, lower extremity, and upper extremity.
41093717|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 1|Medium dose, approximately 10\^4.5 TCID50/mL
41093718|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 2|High dose, approximately 10\^5.5 TCID50/mL
41093719|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 3|TBD, depending on outcome of Part A
40920492|NCT01291485|BEHAVIORAL|Life Steps for Medication Adherence|The intervention was adapted into an electronic version of the empirically supported Life Steps intervention for HIV medication adherence. Education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve medication adherence and clinical outcomes in people living with HIV were also included in the intervention.
40920493|NCT02809222|OTHER|Samples|Blood samples
40920494|NCT02809222|OTHER|Quality of life questionnaire|Questionnaire to assess the quality of life of cancer patients
40920495|NCT04745806|DEVICE|ActiGraft|Whole blood clot (WBC) gel
40920496|NCT02029378|DRUG|Eculizumab|
40920497|NCT00401687|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
41269449|NCT02184637|DRUG|Tafenoquine|A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally
40920498|NCT05469698|BEHAVIORAL|Tobacco Treatment Research Program Standard Care|Participants interested in quitting tobacco will be offered standard tobacco cessation care including nicotine replacement therapy and counseling.
40920499|NCT03081156|DRUG|Glycopyrrolate / Formoterol|Exercise Tolerance
40920500|NCT01779791|DRUG|PCI-32765 (Ibrutinib)|560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
41269450|NCT02184637|DRUG|Dihydroartemisinin + Piperaquine tetraphosphate|"White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally"
41269451|NCT02184637|DRUG|Artemether + Lumefantrine|"Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally"
40920501|NCT02482831|PROCEDURE|Subgluteal sciatic nerve block|All patients (either diabetic or non-diabetic patients) received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml.
41093720|NCT04213846|BEHAVIORAL|Experimental: Mobile Alcohol Expectancy Intervention|Participants randomized to the intervention condition will receive daily intervention messages two times a day for three weeks in the mobile app. The intervention uses participants' own daily responses to personalize messages, when appropriate, that challenges their personal expectations of alcohol's positive effects on mood, social facilitation, and tension reduction, as well as aggression and risk-taking. The intervention messages also focus on intentions to drink and pharmacologically-delayed negative effects. Intervention Messages in general will include feedback based on selected assessment items, weekly summaries generated from the daily assessments, general psycho-educational messages and videos about alcohol, and a toolbox with supplemental information (e.g., personal BAC calculators, resources).
41093721|NCT00255021|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
41269452|NCT04819321|DEVICE|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
41269453|NCT02480530|BEHAVIORAL|Individual Feedback|Patient gets feedback reports on adherence weekly.
41269454|NCT02480530|BEHAVIORAL|Feedback Friend|In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
41269455|NCT02538172|OTHER|T-Track® CMV assay|
41269456|NCT02393209|DRUG|Docetaxel|Docetaxel intravenous infusion
41269457|NCT02393209|DRUG|TAK-117|TAK-117 Tablets
41269458|NCT04096534|PROCEDURE|Normotonic partial nephrectomy|partial nephrectomy performing with avoidance of hypotension: mean blood pressure more or equal 65 mm Hg
41269459|NCT04096534|PROCEDURE|Hypotonic partial nephrectomy|partial nephrectomy performing with using of medical hypotension; avoidance of hypertension: mean blood pressure less than 65 mmHg
41269460|NCT04760184|OTHER|Autologous stem cell transplantation|The study will describe the implications of COVID-19 infection following autologous stem cell transplantation
41269461|NCT00527449|DRUG|Epirubicin, Carboplatin, Docetaxel|75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.
41269462|NCT05112731|DIAGNOSTIC_TEST|BAFF and MGO|measurement of BAFF and MGO levels before reperfusion and after 3 months
41269463|NCT04113967|OTHER|Biodanza program|Biodanza is a form of intervention aimed at promoting health and well-being through the promotion of self-expression and self-regulation through interaction through music and dance. The music accompanied by the movement of the body induces some experiences that present the ability to modify the organism itself both at an organic level, as affective-motor and existential. This intervention constitutes a means for the correct development of human qualities, whose purpose is to integrate the potentials of bond, health and harmony, as well as to develop new alternatives for the life of each individual.
41269464|NCT01906749|DRUG|Colchicine|0.5mg once daily orally
41269465|NCT01906749|DRUG|Placebo|
40920502|NCT04602234|DIAGNOSTIC_TEST|Lung ultrasonography|Investigators performed lung ultrasonography on patients
40920503|NCT05206656|DRUG|Eribulin Mesylate|Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.
41093722|NCT02298374|OTHER|Homecare reablement|
41093723|NCT02298374|OTHER|usual care|
41093724|NCT04531514|OTHER|Sensitivity to phonological rules & referents OR: Toddlers|Assess whether the inclusion of a semantic reference decreases OR phonological rule learning
41093725|NCT04531514|OTHER|Sensitivity to phonological rules & referents FR: Toddlers|Assess whether the inclusion of a semantic reference increases FR phonological rule learning
41093726|NCT05483907|DRUG|BBT-877|BBT-877 24 weeks + Follow-up 4 weeks
41269466|NCT05495048|PROCEDURE|NOSES VIIIA|totally laparoscopic right hemicolectomy with transvaginal natural orifice specimen extraction
41269467|NCT05495048|PROCEDURE|laparoscopic surgery with mini-laparotomy|laparoscopic right hemicolectomy with trans-abdominal extraction from a mini-laparotomy
41269468|NCT03050164|DRUG|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
41269469|NCT03050164|DRUG|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
41269470|NCT05821270|OTHER|Ashtanga Vinyasa Yoga Supta|Ashtanga (asta - eight, anga - parts); Vinyasa (freely sequenced practice); Yoga (practice for evolution); Supta (closed eyes)
41269471|NCT00188578|PROCEDURE|Intensity Modulated Radiation Therapy Boost|All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
41269472|NCT05121402|DRUG|TLL018|a TYK2/JAK1 inhibitor
40758238|NCT03405753|DIETARY_SUPPLEMENT|Placebo, washout and then aronia|Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
40920504|NCT05206656|DRUG|Anlotinib|12 mg Anlotinib is administered for continuous 14 days in 21 day cycles. Patients received Anlotinib untill disease progression.
40920505|NCT05108974|DRUG|Choline Bitartrate|Powdered drink mix for daily consumption
40920506|NCT05418309|DRUG|Tislelizumab Nab paclitaxel|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
40920507|NCT04466709|OTHER|none intervention type|This is an observational study, no intervention
41093727|NCT05483907|DRUG|Placebo|Placebo 24 weeks + Follow-up 4 weeks
41269473|NCT05121402|OTHER|Placebo|a TLL018 Placebo
40920508|NCT05282745|OTHER|Follow-up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
40920509|NCT05251389|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.
40920510|NCT00483132|DRUG|interferon alpha 2a|
40920511|NCT03284918|DIETARY_SUPPLEMENT|Plant stanol ester|
40920512|NCT03284918|DIETARY_SUPPLEMENT|Placebo|
40920513|NCT00121043|DEVICE|SimpleJectTM|
40920514|NCT00121043|DRUG|Kineret® (Anakinra)|
40920515|NCT03972891|OTHER|intervention break of 12 weeks|"The intervention of this study is a break of the intervention for 12 weeks under the following conditions:~* no therapeutic intervention during the break~* no language-specific specific exercises~* language-specific strategies in everyday life can be applied, e.g. modeling techniques"
40920516|NCT05033405|BEHAVIORAL|NEURO-LINGUISTIC PROGRAMMING (NLP)|● One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field
40920517|NCT00601042|OTHER|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
40920518|NCT00601042|OTHER|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
40920519|NCT05787600|DRUG|Perhyal rinse|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
40920520|NCT05787600|DRUG|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
40920521|NCT05787600|DRUG|Placebo|Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
40920522|NCT04644315|DRUG|Alectinib|Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.
40920523|NCT00183729|DRUG|Memantine|Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
40920524|NCT00183729|OTHER|Placebo|Placebo distribution is planned to mimic the active drug.
40920525|NCT01529775|DEVICE|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
41093728|NCT03417843|DEVICE|EUSRA RF electrode|"At the tip of the needle there is a probe that releases the peripheral energy in a continuous and continuous manner. The method is a long 50W power release for 10 seconds or 40W until white bubbles appear in a sonographic image.~Materials that come into contact with the body: electrode and grounding surfaces"
41093729|NCT03995043|BEHAVIORAL|Education|Receive educational SMS (text) messages about contraceptive use and family planning on SRH and access individually tailored educational resources through interactive voice response (IVR) services/system via PREVENT mobile platform.
41093730|NCT03995043|BEHAVIORAL|Personal Support|Contact with a female business owner within the community (hair saloons, tailors, female clothing stores) act as both a confidential, and non-judgmental resource to answer questions and provide counselling in SRH to study participants.
40920526|NCT01529775|DEVICE|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
40920527|NCT01986556|DRUG|Lesinurad 400 mg (Site 1)|
40920528|NCT01986556|DRUG|Lesinurad 400 mg (Site 2, Lot A)|
40920529|NCT01986556|DRUG|Lesinurad 400 mg (Site 2, Lot B)|
40920530|NCT01606215|DRUG|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
40920531|NCT01606215|DRUG|Placebo|Placebo
40920532|NCT00213993|DRUG|antiperspirant|antiperspirant topically once daily to one foot
40920533|NCT04887376|DEVICE|Mirror frame|Combined Mirror and NMES therapy
40920534|NCT04887376|DEVICE|Control|Only NMES therapy
40920535|NCT05683353|OTHER|None intervention|None intervention.
40920536|NCT02303392|DRUG|Selinexor|Given PO
40920537|NCT02303392|DRUG|Ibrutinib|Given PO
40920538|NCT02303392|OTHER|Pharmacological Study|Correlative studies
40920539|NCT02303392|OTHER|Laboratory Biomarker Analysis|Correlative studies
40920540|NCT04508218|DIETARY_SUPPLEMENT|whey protein supplementation powder (Inkospor X-TREME; France)|Protein requirements for burned adults are estimated as 1.5-2.0 g/kg/day. The participants asked to take the calculated serving of whey protein dissolved in 150ml of water two times / day in the morning and in the evening
40920541|NCT04508218|OTHER|Exercise training program|After healing of the burn (6 weeks after injury), participants in group A and group C started resisted exercise program with a qualified therapist for 1 hour three times/week on nonconsecutive days over 12 weeks. In addition, aerobic exercises were conducted on the treadmill. Peak oxygen consumption was assessed for all patients by using the exercise test on treadmill before participation in aerobic exercises.
40920542|NCT04508218|OTHER|traditional burn care|ROM exercises, stretching, ADL activities and scar management
40920543|NCT00319072|BEHAVIORAL|TalkToYourDoc(sm) hormone therapy module|
40920544|NCT04220476|RADIATION|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
40920545|NCT04220476|DRUG|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
40920546|NCT04220476|DRUG|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
40920547|NCT01256190|BIOLOGICAL|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
40920548|NCT01256190|DEVICE|Gelatin sponge|absorbable gelatin sponge for topical use
40920549|NCT00439816|BEHAVIORAL|Group Visits|
40920550|NCT01696162|OTHER|Algorithm based Exercise Videos|The algorithm will adjust the exercises in each session based upon the participant's feedback.
40920551|NCT01696162|OTHER|PDF Exercise Sheets|A sheet of six exercises with descriptions on how to perform them properly
40920552|NCT01696162|OTHER|Limited Exercise Videos|Video of 6 exercises that provide instruction on how to perform the exercises
40920553|NCT03497598|DRUG|Mannose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
41287185|NCT05195879|DIAGNOSTIC_TEST|XTR004|Single dose intravenous injection of XTR004. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
40920554|NCT03497598|DRUG|Lactose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
40920555|NCT06466486|DRUG|Follitropin delta|The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
40920556|NCT06466486|DRUG|FE999302|To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
40920557|NCT06466486|DRUG|FE999302 Placebo|To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
40920558|NCT04745260|DRUG|Intranasal Fentanyl Spray and Intranasal Midazolam Spray|Intranasal Fentanyl 2mcg/kg and Intranasal Midazolam 0.2mg/kg
40920559|NCT04745260|DRUG|Intranasal Midazolam Spray|Intranasal Midazolam 0.3mg/kg
40920560|NCT03063047|OTHER|PD21871AA|A 100s size menthol cigarette.
40920561|NCT03063047|OTHER|PD21872AA|A 100s size menthol cigarette.
40920562|NCT04263584|DRUG|Copanlisib|Copanlisib vials 60 mg
40920563|NCT04263584|DRUG|R-CHOP Chemotherapy|Immunochemotherapy
40920564|NCT06027632|OTHER|Cognitive exercises with supervision|"The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the PRESCO program of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
40920565|NCT06027632|OTHER|Cognitive exercises without supervision|"Patient will have access to the program named PRESCO of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
40920566|NCT02975232|BEHAVIORAL|F&V economic incentive|50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)
40920567|NCT02975232|BEHAVIORAL|Cooking Matters Store Tour|Participants will be asked to attend one Coking Matters store tour during January or February 2017
40920568|NCT06243562|OTHER|combined exercises and progressive muscle relaxation group|Participants in the intervention group will receive a combined exercise program that will last 45-60 minutes, 3 days a week for 8 weeks, and progressive muscle relaxation training that will last 10-15 minutes, under the supervision of a therapist.
40920569|NCT06243562|OTHER|combined exercises group|Patients in the control group will perform a combined exercise consisting of aerobic, strengthening and stretching exercises, which will last 45-60 minutes, 3 days a week for 8 weeks, under the supervision of a physiotherapist. At the end of the combined exercise program, they will rest in the relaxation position for 10-15 minutes each session.
40920570|NCT02651909|OTHER|blood sampling|blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
40920571|NCT03030846|OTHER|Stabilization exercise|18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
40920572|NCT03030846|OTHER|Control group|8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
40920573|NCT02147119|PROCEDURE|Coronary angiography|
40920574|NCT03927482|BEHAVIORAL|CARES mobile smart phone app|The CARES smart phone mobile app contains a number of features to support safety while drinking and reduced alcohol consumption plus regular test messages for personal support
40920575|NCT03927482|BEHAVIORAL|Check Your Drinking|Check Your Drinking is an online alcohol assessment that provides normative feedback on the user's drinking habits relative to his/her peers. Alcohol interventions that provide normative feedback are rated by the NIAAA Alcohol Intervention Matrix as effective and low cost, and with few administrative or structural barriers to implementation thus making it suitable for community colleges.
40920576|NCT01816945|BEHAVIORAL|MOMBA web-based application|Web-based, interactive, social network application.
40920577|NCT00215176|DRUG|modafinil|
40920578|NCT01875679|OTHER|Comprehensive Surgical Coaching|
40920579|NCT01875679|OTHER|Conventional Surgical Training|Surgical training as per participant's residency program
40920580|NCT04475705|DRUG|propofol|intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60
40920581|NCT04475705|DRUG|sevoflurane|sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
40920582|NCT01697280|BEHAVIORAL|Vaccine promotion messages|"The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~1. Vaccines can save a child's life~2. Children who are immunized on time are less likely to become ill~3. Unimmunized children can become disabled for life~4. Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings."
40920583|NCT01697280|OTHER|Vaccination Verification.|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
40920584|NCT01697280|OTHER|Distribution of Plastic Pouches to retain vaccination card|At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
40920585|NCT00228215|BEHAVIORAL|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
41287186|NCT02214173|DIETARY_SUPPLEMENT|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
41287187|NCT02214173|DIETARY_SUPPLEMENT|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
40920586|NCT04226170|DRUG|DAS-001|ondansetron + pyridostigmine
40920587|NCT00847509|DRUG|[F-18]FLT|The individual doses of \[F-18\]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
40920588|NCT03635411|DIETARY_SUPPLEMENT|Nicotinamide Riboside and Pterostilbene|Nicotinamide riboside and pterostilbene manufactured by Basis
40920589|NCT03635411|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Basis supplement.
40920590|NCT03929094|DRUG|Paclitaxel for Injection（Albumin Bound）|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
40920591|NCT03929094|DRUG|Gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
40920592|NCT05396716|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
40920593|NCT02521896|DEVICE|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
40920594|NCT01598142|PROCEDURE|Team 1|experienced endoscopist with a experienced assistant
40920595|NCT01598142|PROCEDURE|Team 2|same experienced endoscopist with a new trained assistant
40920596|NCT03790137|DRUG|Fenfluramine Hydrochloride|Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
40920597|NCT01755026|DRUG|cefazolin|2 gram dose for pre-operative prophylaxis
40920598|NCT01755026|DRUG|cefazolin|4 gram dose for pre-operative prophylaxis
40920599|NCT05738681|DRUG|N acetyl cysteine|N acetyl cysteine 1,200 mg/day for 8 weeks in NAC group
40920600|NCT01051518|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve
40920601|NCT01324518|DRUG|ORM-12741|60mg twice a day
40920602|NCT01324518|DRUG|ORM-12741|200mg twice a day
40920603|NCT01324518|DRUG|Placebo for ORM-12741|Placebo twice a day
40920604|NCT05237206|BIOLOGICAL|SUPLEXA|PBMC-derived autologous cellular therapy derived through an ex vivo activation procedure, resulting in a cell mixture comprised predominantly of NK, NK-T, and T cells stored in cryogenic media.
41093731|NCT03995043|BEHAVIORAL|Access to contraception|Will be provided by the mobile reproductive health team at contraceptive access points, and, at the health facility partners who will be providing full reproductive health services to program participants and will be the access points for Intra-Uterine Device (IUD) insertion where requested and medically suitable. Results of point of care urine HCG (pregnancy) testing (voluntary at enrollment and mandatory when accessing contraceptive services)
40920605|NCT00538083|OTHER|Chocolate|74 grams of single dose solid dark chocolate versus placebo
40920606|NCT00538083|OTHER|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
40920607|NCT00538083|OTHER|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, \& placebo given for six weeks
40920608|NCT00680394|DRUG|mifepristone|200 mg mifepristone
40920609|NCT00680394|DRUG|misoprostol|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
40920610|NCT00680394|DRUG|placebo|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
40920611|NCT03263650|DRUG|Cabazitaxel|25mg/m2 administered intravenously over 60 minutes on day 1 of cycles 1-6; given before carboplatin.
40920612|NCT03263650|DRUG|Carboplatin|AUC 4 administered intravenously over 60 minutes on day 1 of cycles 1-6
40920613|NCT03263650|DRUG|Prednisone 5Mg|5 mg administered by mouth twice daily on days 1-21 of cycles 1-6.
41093732|NCT01796093|DRUG|Digoxin and ivabradine|No more details
41093733|NCT04280029|DEVICE|SELUTION SLR™ DEB|The SELUTION Sustained Limus Release (SLR)™ drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal coronary angioplasty (PTCA) balloon catheter coated with a drug (Sirolimus).
41093734|NCT04280029|DEVICE|Control|POBA or FDA-approved -limus DES
40920614|NCT03263650|DRUG|Olaparib|Administered by mouth twice daily at a dose of 300 mg by mouth twice daily, dispensed on Day 1 of cycle 7 to participants randomized to receive olaparib maintenance and every 21 days thereafter until the participant completes the study, withdraws from the study or the closure of the study.
40920615|NCT02212600|OTHER|Observational|observational cohort of proximal humerus fractures
40920616|NCT02251964|DRUG|Rituximab|2 times 1000mg dose at 14 days interval treatment
40920617|NCT02251964|RADIATION|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
40920618|NCT04960839|RADIATION|Prophylactic contralateral breast irradiation|The whole contralateral breast will be irradiated once daily, 5 days a week, for 5-6 weeks, using 1.8-2 Gy/fx to a total dose of 45-50 Gy.
40920619|NCT02879331|PROCEDURE|10 coils in upper lobes|
40920620|NCT02879331|PROCEDURE|15 coils in upper and lower lobes|
40920621|NCT02879331|PROCEDURE|cycloergometry|
40920622|NCT05807568|OTHER|NCAEM EM-SART Pre-Screen|Participants will be verbally asked the 3 participant questions on the NCAEM EM-SART Pre-Screen either directly or with support of hospital approved telephonic interpreters. Answers will be documented by the investigator digitally. Participants will be interviewed one time for a duration of approximately 15 minutes. No further action will be taken on study participants with negative elder mistreatment screens, unless findings concerning for emotional distress are identified by the investigator. If emotional distress is identified, these observations will be communicated to Geriatric Medicine team in person or via secure/encrypted email, with recommendations to follow-up with the participant about the results and take appropriate care actions. Study participants with positive elder mistreatment will have results shared with the study participant directly and with the Geriatric Medicine primary team via secure/encrypted email.
40920623|NCT05529095|DRUG|Apomorphine Sublingual Film|Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.
40920624|NCT05529095|DRUG|Placebo|Placebo (sugar pill)
40920625|NCT05307913|OTHER|EIT-guided PEEP|PEEP setting according to EIT
40920626|NCT05307913|OTHER|Table-guided PEEP|PEEP setting according to the lower PEEP/FiO2 table
40920627|NCT01801345|OTHER|Fatigued|
41093735|NCT03049696|BEHAVIORAL|ENCOURAGEING START|16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.
40920628|NCT01801345|OTHER|Rested|
40920629|NCT01090583|OTHER|Specimen Collection|We will compare mediators from non-invasive samples (blood, urine, saliva, vaginal or cervical secretions) with traditional gold-standard invasive samples (amniotic fluid and placenta samples).
40920630|NCT00458224|BEHAVIORAL|parental counseling|Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
40920631|NCT03860818|OTHER|Health services delivery|Technology-enabled pharmacist intervention
40920632|NCT06317129|DEVICE|Endoscopic gastric restriction and biliodigestive diversion|The BariTon™ is endoscopically implanted.
41093736|NCT06217029|OTHER|physiotherapy and maxillary traction|"1. Mobility exercises~2. Ultrasound or electric stimulation~3. Application of equipment, such as braces, slings and taping~4. Registered massage therapy~5. Trigger point and myofascial release"
41093737|NCT03207425|DRUG|EDP 305|Each subject will receive a single dose of EDP 305 on Day 1.
41093738|NCT01055782|DEVICE|Endoguide|Use of endoguide to facilitate completion of endoscopy
41093739|NCT02775851|PROCEDURE|Biopsy|Undergo tumor biopsy
41093740|NCT02775851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41093741|NCT02775851|PROCEDURE|Computed Tomography|Undergo CT scan
41093742|NCT02775851|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
41093743|NCT02775851|BIOLOGICAL|Pembrolizumab|Given IV
41093744|NCT02775851|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41093745|NCT02775851|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
41093746|NCT04501224|DRUG|Tenofovir alafenamide fumarate|Patients would take tenofovir alafenamide fumarate, 25mg，once per day
41093747|NCT04501224|DRUG|Entecavir or Tenofovir disoproxil fumarate|Patients would take entecavir 0.5 mg once per day, or tenofovir disoproxil fumarate 300 mg once per day
41093748|NCT02838316|DRUG|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|Autologous muscle derived stem cells
40920633|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
40920634|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
41093749|NCT03537885|DIAGNOSTIC_TEST|Transcranial Direct Current Stimulation|Electrodes are placed on that head to deliver a non-invasive brain stimulation to the target area.
41287188|NCT05513976|DRUG|SHR4640 tablet|SHR4640 tablet 5mg
40920635|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
40920636|NCT02828670|BIOLOGICAL|blood sample|
40920637|NCT02828670|PROCEDURE|spleen sample|
41093750|NCT03537885|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|A coil is held tangential to the head in order to deliver a non-invasive brain stimulation to the target area.
41287189|NCT05513976|DRUG|SHR4640 tablet|SHR4640 tablet 10mg
40920638|NCT03267485|DEVICE|real time PCR|Real Time PCR is based on the detection of the fluorescence produced by a reporter molecule which increases, as the reaction proceeds. These fluorescent reporter molecules include dyes that bind to the double-stranded DNA or sequence specific probes . Moreover, there is no need for the post PCR processing which saves the resources and the time. .
40920639|NCT00291213|DRUG|levetiracetam|
40920640|NCT00291213|DRUG|placebo|
40920641|NCT01588418|DRUG|Exenatide|Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
40920642|NCT01588418|DRUG|Placebo|Placebo was administered in random order 30 min before OGTT-PET study in the same subject
40920643|NCT05367258|OTHER|Patients satisfaction after medical and surgical treatment for umbilical endometriosis|It is a retrospectively evaluation of cases of umbilical endometriosis in our clinic over the last 30 years, based on the review of medical records and on outpatient follow-up visits. The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period. If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study.
40920644|NCT01605630|BEHAVIORAL|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
40920645|NCT01605630|BEHAVIORAL|Control|standard of care
40920646|NCT00052624|BIOLOGICAL|transferrin-CRM107|
40920647|NCT06392373|DIETARY_SUPPLEMENT|CHO+PRO|0.9 g CHO/kg/hr + 0.3 g PRO/kg/hr
41093751|NCT03537885|DIAGNOSTIC_TEST|Electroencephalography (EEG)|A cap is placed on the head with sensors to detect brain activity during the intervention.
41093752|NCT03932617|DEVICE|end tidal carbon dioxide by capnography|"Moreover, since PETCO2 is mainly determined by tissue CO2 production (VCO2), alveolar ventilation and CO, when stable metabolic conditions are assumed and minute ventilation is kept constant, acute changes in PETCO2 have been shown to correlate strongly with changes in CO.~Thus, PETCO2 has been suggested as a simple economic and noninvasive alternative for continuous assessment of CO in different shock states."
41093753|NCT02759198|DRUG|YH23537|Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
41093754|NCT02759198|DRUG|Celecoxib|Drug: Celecoxib 200mg
41093755|NCT02759198|DRUG|YH23537 placebo|Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
40920648|NCT06392373|DIETARY_SUPPLEMENT|CHO|1.2 g CHO/kg/hr
40920649|NCT03763565|BIOLOGICAL|Bivalent or Quadrivalent HPV vaccines|Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
40920650|NCT03763565|OTHER|Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
40920651|NCT00476008|DRUG|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
41093756|NCT05008341|DRUG|Solriamfetol 150 mg Oral Tablet|Single-dose 150 mg tablet orally administered.
41287190|NCT05513976|DRUG|febuxostat tablet|febuxostat tablet 40mg or 60mg or 80mg based on prior medication
40920652|NCT00476008|DRUG|Placebo|One tablet placebo morning and evening (BID) for 12 months
40920653|NCT00553722|DRUG|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
40920654|NCT00553722|DRUG|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
40920655|NCT04769700|BEHAVIORAL|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale is a self-administered questionnaire made up of 10 items scored using a four-point Likert scale (0-3) designed to screen for symptoms of postpartum depression. Postpartum depression represents the end of a continuum of severity of symptoms. The present study used a cutoff point for depressive symptomatology risk of higher than 12.
40920656|NCT04769700|BEHAVIORAL|Breast Feeding Adherence|This will be addressed according to the breastfeeding initiation practices according to the WHO.
40920657|NCT04769700|BEHAVIORAL|Fear of Covid-19 Scale|The Fear of Covid-19 Scale is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. It consists of seven items, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19.
40920658|NCT04153708|BEHAVIORAL|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
40920659|NCT04153708|BEHAVIORAL|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
40920660|NCT00934648|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
40920661|NCT00934648|DRUG|methotrexate|10-25mg weekly
41093757|NCT05574634|BEHAVIORAL|Tablet based adaptive multimodal attention practice program|An adaptive at-home tablet-based program that includes variants of the Flanker Task, the Stroop Task, and a Visual Tracking Task. Each session of practice will include up to ten minutes with each of these task types, and the tasks will increase in difficulty in a way that further taxes attention (such as through more distractors or more incongruent trials) as participant performance improves.
41093758|NCT05574634|BEHAVIORAL|Tablet based adaptive criterion task practice program|An adaptive, at-home tablet-based variant of the criterion task, that is, the selective attention/distraction task used during the scanning portion of the human participant portions of the study, that takes up to 25 minutes to complete each session.
41093759|NCT00577629|DRUG|cyclophosphamide|1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
41093760|NCT00577629|DRUG|etoposide|300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
41093761|NCT00577629|DRUG|rituximab|375mg/m2 each week x 4 weeks of induction, beginning on day 1
40920662|NCT02317744|DRUG|Naltrexone and bupropion combination|
40920663|NCT02317744|OTHER|Pill Placebo|
40920664|NCT00385190|DRUG|HCV-796|
40920665|NCT02929498|DRUG|GSK2879552|GSK2879552 will be administered orally as continuous daily dosing.
40920666|NCT02929498|DRUG|Azacitidine|Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
40920667|NCT01719744|DRUG|ENMD-2076|
40920668|NCT02067975|DRUG|Tryptophan|
40920669|NCT02067975|DRUG|Placebo|
40920670|NCT00224185|PROCEDURE|Bronchopulmonary Lung Lavage|Lung Lavage is a Washing. Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways. Once the fluid has been collected, the fluid is centrifuged and the cells are collected and counted.
40920671|NCT00224185|PROCEDURE|Bronchial Brushing|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently (in up to 20 different sites in the large and small airways) to obtain epithelial cells lining the airway. Cells collected by airway brushing will be washed, counted, and evaluated for viability. They will also be studied for differential cell count by standard procedures. Collected airway cells will be used to carry out studies assess expression of various genes and to study viral gene transfer.
40920672|NCT00224185|PROCEDURE|Bronchial Wall Biopsy|This is a safe and widely used investigative method in pulmonary medicine. In this procedure, a small biopsy forceps is passed through the bronchoscope and, under direct vision, a small biopsy (in up to 5 sites) is obtained from the bronchial wall. A biopsy obtains tissue to a depth of 2-3 mm, and includes epithelial and subepithelial tissue.
40920673|NCT03117439|OTHER|duration of antifungal therapy|Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
40920674|NCT00233454|DRUG|Midostaurin|Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
41093762|NCT00577629|DRUG|cytarabine|3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
40920675|NCT00252252|DEVICE|VPAP non-invasive ventilator|
40920676|NCT00252252|DEVICE|AutoVPAP non-invasive ventilator|
40920677|NCT00593476|OTHER|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
41093763|NCT00577629|DRUG|doxorubicin|45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
41287191|NCT05513976|DRUG|SHR4640 placebo tablet|SHR4640 placebo tablet 5 or 10mg
40920678|NCT00593476|OTHER|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
40920679|NCT04696887|BEHAVIORAL|Tele Tai Chi Intervention for Persons Aging with Long-Term Mobility Disabilities|• 8-week Tele Tai Chi intervention, participants will use a tablet or computer to join a small-group, online class (1hr, twice weekly) from home; during each session, participants will exercise as a group along with the pre-recorded video lessons and have the opportunity for social interaction (via video chat) before and after class.
40920680|NCT02520089|PROCEDURE|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
40920681|NCT02520089|PROCEDURE|Platelet Rich Plasma plus bone autograft|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
40920682|NCT03458013|BEHAVIORAL|Mindfulness Meditation|Guided using an mp3 player and noise cancelling headphones, participants will be led through a series of mindfulness meditations lasting approximately 20 minutes each.
40920683|NCT04371302|DIAGNOSTIC_TEST|Questionnaire|Assessment of demographics, burnout, depression and self-perceived medical errors
40920684|NCT05176171|PROCEDURE|Photorefractive Keratectomy with Corneal Cross-Linking|To our knowledge, this study is one of the first to compare the visual results of non-topography-guided and topography-guided photorefractive keratectomy (PRK) applying sequential and simultaneous corneal cross-linking (CXL) treatment for keratoconus. Considering recent advances in cross-linking and imaging in keratoconus, the outcomes of this study can lead us to several non-invasive algorithm management options.
40920685|NCT04818086|DRUG|Lemborexant|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive 5 mg of lemborexant (first visit) and 10 mg of lemborexant (second visit).
41093764|NCT00577629|DRUG|tositumomab|450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
41093765|NCT04697784|DEVICE|TREO Abdominal Stent-Graft System|The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement.
41287192|NCT05782296|DEVICE|TrueLabor|Non invasive monitoring device
41287193|NCT01277146|DRUG|OMP-59R5|IV infusion
40920686|NCT04818086|DRUG|Placebo|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive a placebo which matches the intervention drug.
40920687|NCT04818086|DRUG|Buprenorphine-naloxone|Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
40920688|NCT04355585|DRUG|Colchicine Tablets|1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)
40920689|NCT04355585|DRUG|Placebo oral tablet|Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
41093766|NCT05727059|DEVICE|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
41093767|NCT02304653|OTHER|Clinical descision making|Chage in diagnosis before and after the presentation of the reults of CRP and Leucocytes
40920690|NCT02184052|DRUG|Meloxicam|7.5 mg or 15 mg
40920691|NCT01812447|DEVICE|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.
40920692|NCT01812447|OTHER|Medical Management|Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
41093768|NCT05718219|DRUG|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
41093769|NCT05718219|DRUG|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
41093770|NCT03530553|OTHER|Hunt Motivational Scale|The Hunt Motivational Scale is a tool to help facilitate weight loss and motivate patients to track, plan, and practice healthy weight loss and weight maintenance practices.
41269474|NCT04460755|OTHER|Control group|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
41453139|NCT01995162|DEVICE|Energy expenditure estimation|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
41453140|NCT00004213|DRUG|triapine|
40920693|NCT03817047|BEHAVIORAL|Physical education|"Physical education (60 minutes): In addition to the ordinary PE-lessons. The pedagogical activities taught in this lesson should be in line with the curriculum of 9th grade and led by the PE-teacher. In the Don't worry - be happy intervention this class was also organized by the students. The students practiced their Be Happy-activities, or they introduced their class peers to their Be Happy-activity. A PE-teacher was present to support the students if necessary."
40920694|NCT03817047|BEHAVIORAL|Physical active learning|The curriculum of the subjects (i.e. maths, English, Norwegian) were taught in a physically active manner. The lesson should last 30 minutes and be led by the teacher of the current subject.
40920695|NCT03817047|BEHAVIORAL|Physical activity|"Without a connection to any specific subject Physical activity should be performed as 30 minutes a week. There are no specific aims to be taught in this lesson, but physical activities that stimulates mastery, joy and well-being should be in focus."
40920696|NCT03817047|BEHAVIORAL|Be happy|The Be Happy classes were self-organized activity groups of at least three students, developed according to activity preferences across regular classes. The Be Happy groups practiced traditional sports and physical activities, lifestyle sports, dancing, out-door recreation, drama etc. - inside or outside school.
40920697|NCT05389852|DRUG|Dexmedetomidine|After completion of supraclavicular brachial plexus block patients will receive intravenous dexmedetomidine 1 mcg/kg
40920698|NCT00926315|DRUG|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
40920699|NCT00926315|DRUG|Calcitriol|calcitriol 0.25 mcg PO bid
40920700|NCT01250444|OTHER|Inspiratory Muscle Training|Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
40920701|NCT03399396|BEHAVIORAL|Practice facilitation for HPV vaccine|The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.
40920702|NCT05453149|BEHAVIORAL|Integrated Physical Activity and Behavioural Change Intervention|"Physical Activity (PA) Component: A group-based PA program geared to the level of injury and mobility delivered through web conferencing software. Participants select at three sessions weekly over 10 weeks. Sessions include 45 mins of exercise (i.e boxercise; aerobics; yoga) and 15 mins of social interaction with the group.~Behavioural Change Component: Participants will also receive synchronous 1:1 sessions (approximately 20 mins/week) with a trained clinician on behavioural strategies to initiate and maintain engagement in PA over the 10-week period. Content of the sessions includes: providing information on PA and the self-management of impairments and related symptoms; evaluating barriers to engagement (e.g. fear of injury); and behavioural strategies."
40920703|NCT02031328|RADIATION|Stereotactic Ablative Radiation|
40920704|NCT05702346|BEHAVIORAL|Enhance Physical Activity (EPA)|EPA is eight weeks with four weekly, hour-long parts: virtual group exercises, virtual group discussions, individual PA participation, and individual phone check-ins.
40920705|NCT02990624|RADIATION|PUVA|36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
40920706|NCT04596436|OTHER|no intervention|no intervention
40920707|NCT01386970|DRUG|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
40920708|NCT02846298|BIOLOGICAL|Drug Monitoring|Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
40920709|NCT01510457|DRUG|Milnacipran|Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
40920710|NCT01510457|DRUG|Placebo|Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
40920711|NCT00533793|PROCEDURE|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
40920712|NCT01578824|OTHER|Methacholine Challenge Test|Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
40920713|NCT04208113|BEHAVIORAL|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the MBSR programme and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b .~The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
40920714|NCT04231552|DRUG|Camrelizumab|Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
40920715|NCT00464880|DRUG|Aliskiren|
41093771|NCT03222284|DEVICE|Cornerstones4Care Powered by Glooko App|Cornerstones4Care Powered by Glooko App is an iOS or Android smartphone application designed to support diabetes management by offering people with diabetes easily accessible, personalized tools for self-monitoring and education. C4C allows people with diabetes to monitor personal health metrics and blood glucose levels, with the aim to achieve participant behavior changes that may contribute to lower hospitalizations, diabetes-related complications and overall healthcare costs.
40920716|NCT03596541|DEVICE|Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)|We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
40920717|NCT00273533|DRUG|Ramipril|
40920718|NCT01862692|BEHAVIORAL|Baby-Net|Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
40920719|NCT01862692|BEHAVIORAL|Developmental Awareness Skills|Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
40920720|NCT05744245|OTHER|Swallow Strength and Skill Training|Practice swallowing exercises with biofeedback and strength and skill targets
40920721|NCT01203644|DRUG|SKY0402|Single dose of SKY0402 administered locally into the surgical wound.
40920722|NCT01203644|DRUG|Bupivacaine HCl|Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
40920723|NCT02730793|DRUG|Oral Aztreonam|Standard Therapy Comparator (Oral Cayston 75mg three times a day)
40920724|NCT02730793|DRUG|Nasal Aztreonam|Study Therapy (nasal Aztreonam 75mg twice per day)
40920725|NCT02730793|DRUG|Nasal Placebo|Placebo (nasal saline twice per day)
40920726|NCT02885467|PROCEDURE|Total knee arthroplasty with Saphenous nerve burial|
40920727|NCT02885467|PROCEDURE|Standard total knee arthroplasty|
40920728|NCT03223168|DEVICE|Hayek RTX ventilator|Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
40920729|NCT03264729|OTHER|Isometric exercise|The isometric exercise is performed standing with the forefoot on a step. The participant is instructed to stand still with the ankle joint in neutral and hold this position. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 5 sets of 45-second isometric holds. The load used is the heaviest possible load that the participant is able to withstand for 1 minute. As with the isotonic exercise, if the participant's body weight is inadequate the participant is fitted with a backpack with books and/or weights.
41093772|NCT03107702|DIAGNOSTIC_TEST|melatonin|the relationship between melatonin level and analgesia requirement.
41093773|NCT05183555|DRUG|68Ga-DOTATOC PET/CT|68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
41093774|NCT05413421|DRUG|ORIC-944|Oral, once daily, continuous
41093775|NCT05413421|DRUG|Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets|Oral, 1000 mg once daily, continuous
41093776|NCT05413421|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|Oral, 240 mg once daily, continuous
41093777|NCT05413421|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|Oral, 600 mg twice daily, continuous
41093778|NCT05413421|DRUG|Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets|Oral, 160 mg once daily, continuous
41453141|NCT03585556|DRUG|Intravitreal anti-VEGF|Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
41093779|NCT05922436|DRUG|QLG2071|intravenous injection
41093780|NCT05922436|DRUG|Cleviprex®|intravenous injection
41093781|NCT04709731|DRUG|Ponatinib 15mg QD|Ponatinib 15 mg tablet, taken orally once daily
41093782|NCT04709731|DRUG|Ponatinib 30mg QD|Ponatinib 30 mg tablet, taken orally once daily
41093783|NCT01235429|BEHAVIORAL|Partners in Care|Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
41093784|NCT01235429|BEHAVIORAL|Partners in Care|Diabetes self-management education
41093785|NCT03486743|BEHAVIORAL|Educational video on LARC|Participants will watch a short educational video on long acting reversible contraceptive or LARC
41093786|NCT00241644|BIOLOGICAL|Rotarix™|Two or Three doses, oral administration
41093787|NCT00241644|BIOLOGICAL|Placebo|One or three doses, oral administration.
41093788|NCT05991505|OTHER|Physical exercise|Multimodal exercises twice a week
41093789|NCT06009783|OTHER|ChatGPT Language Model|ChatGPT Language Model - ability to converse with the model and ask questions regarding vasectomies
41093790|NCT06614946|BEHAVIORAL|Electronic Safety Plan (ESP)|Participants will receive an electronic safety plan in the ED. ESP focuses on developing a personalized coping plan to manage suicidal thoughts and urges.
41093791|NCT06614946|BEHAVIORAL|Text support|Those in the text-based support program will receive up to 2 texts per day for a month with varying levels of tailoring, based on ESP and dynamic personalized feedback.
41093792|NCT06555419|DRUG|Nusinersen|Administered as specified in the treatment arm.
41093793|NCT06555419|DEVICE|ThecaFlex DRx System|Implantated as specified in the treatment arm.
41093794|NCT05004779|PROCEDURE|human stem cell conditioned media was applied after non-ablative laser therapy|After laser treatment on hypertrophic scars, human stem cell media was applied to one side
41093795|NCT05004779|PROCEDURE|normal saline was applied after non ablative laser therapy|physiological saline was applied to the other side.
41453142|NCT03585556|BIOLOGICAL|Intravitreal AAVCAGsCD59|An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
41453143|NCT03585556|DRUG|Oral prednisolone|A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
41453144|NCT03741777|OTHER|Clear oral fluid|clear oral fluid including water, pulp-free juice and tea or coffee without milk.
40920730|NCT03264729|OTHER|Isotonic exercise|"The isotonic exercise is performed standing with the forefoot on a step. The toes are maximally dorsi-flexed by placing a towel underneath them. The participant is instructed to perform a heel-raise to a maximal plantar flexion in the ankle joint, and afterwards to lower the heel to maximal dorsi flexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 4 sets of 8 repetitions with a load of 8RM. The contraction time is 3s concentric, 2s isometric and 3s eccentric and will be guided by a metronome.~If the participant's body weight is inadequate to reach sufficient loading during the exercises the participant is fitted with a backpack with books and/or weights."
40920731|NCT03264729|OTHER|Walking|The walking will be performed barefoot and the participant will be instructed in walking at a pace similar to the pace they would use when walking around in their home. The duration of the walking session will be four minutes to match the duration during the exercises.
40920732|NCT00435253|BIOLOGICAL|BLVR Treatment|BLVR Treatment, 10 mL Hydrogel
40920733|NCT02323100|DRUG|Ravicti low dose|8 am, 4pm and midnight
40920734|NCT02323100|DRUG|Ravicti high dose|8 am, 4pm and midnight
40920735|NCT02323100|DRUG|Placebo|8 am, 4pm and midnight
41269475|NCT04460755|OTHER|Whitening toothpaste 1|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
40920736|NCT01831583|DEVICE|Measurement of PPG waveforms|The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
40920737|NCT01831583|DEVICE|Measurement of Pulse Arrival Time (PAT)|The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
41093796|NCT06239974|DRUG|Vericiguat|Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group
41093797|NCT06239974|DIAGNOSTIC_TEST|Stress Cardiac Magnetic Resonance|All patients will have stress CMR examinations at recruitment and at the end of trial.
41093798|NCT00875147|DRUG|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
41453145|NCT01827696|DIETARY_SUPPLEMENT|Ginseng|Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
41453146|NCT02637180|DRUG|anti-osteoporotic medication|check previous information
41453147|NCT01377441|DRUG|Ibuprofen|Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
40920738|NCT04630886|DRUG|Tranexamic acid injection|subcutaneous injection of 50mg/ml TXA
40920739|NCT04630886|DRUG|Lidocaine Epinephrine|subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
40920740|NCT03255629|DRUG|glucagon|novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
40920741|NCT03255629|DEVICE|Closed loop glucagon pump|a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
40920742|NCT01297777|DRUG|Imatinib Mesylate|"* In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.~* In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity."
40920743|NCT04086498|OTHER|Mediterranean diet|The group received a plan for a isocaloric Mediterranean Diet
40920744|NCT04086498|OTHER|KEMEPHY|The group received a plan for a ketogenic mediterranean with herbal extracts diet
41453148|NCT01377441|DRUG|Placebo/Saline solution|Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
41453149|NCT03101358|DRUG|SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment|One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
41453150|NCT00250354|DRUG|Risperidone oral solution|
41453151|NCT05826301|OTHER|Percutaneous neuromodulation in tibial nerve|The procedure consisted in the application of a square wave biphasic electrical current, with 2-4 Hz frequency, 450 μs pulse during 25 minutes with a needle (0.30mm x 40 mm) inserted proximal to the surface on the tibial nerve.
41453152|NCT05826301|OTHER|Percutaneous electrolysis|"The procedure consist on placed a needle (0.30mm x 40 mm) on the most hyperalgesic plantar fascia location with a galvanic current of 3mA, 3 times during 3 seconds.~1 time per weeK"
41453153|NCT01376882|DIETARY_SUPPLEMENT|Placebo|Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.
41453154|NCT01376882|DIETARY_SUPPLEMENT|Caffeine and Placebo|100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.
41453155|NCT01376882|DIETARY_SUPPLEMENT|Placebo and Caffeine|Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
41453156|NCT01376882|DIETARY_SUPPLEMENT|Caffeine|Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
41453157|NCT04499209|DRUG|XG005|XG005 Capsule
41453158|NCT04499209|DRUG|Combination of Naproxen and Pregabalin|Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica
41453159|NCT04499209|DRUG|Placebos|Placebo Capsule
41453160|NCT00249197|DRUG|levofloxacin|
40920745|NCT04086498|OTHER|KD|The group received a plan for a low carbohydrate ketogenic diet
40920746|NCT05350956|DRUG|TPO-RA (Herombopag)|During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
40920747|NCT05350956|DRUG|TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)|During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
40920748|NCT00443963|DRUG|Esomeprazole Magnesium|PPI compared to H2RA
40920749|NCT00605956|DRUG|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
40920750|NCT00605956|DRUG|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
40920751|NCT00605956|DRUG|Blank Patch|Blank Patch
40920752|NCT03338322|DEVICE|Twisted file adaptive|Endodontic files that are used in preparation of root canals with adaptive motion
40920753|NCT03338322|DEVICE|Reciproc|Endodontic files that are used in root canal preparation with reciprocation motion
40920754|NCT00512057|DRUG|allopurinol|allopurinol 300mg twice a day
40920755|NCT00512057|DRUG|placebo|placebo
40920756|NCT00600119|DRUG|placebo|placebo, oral, once daily (QD)
40920757|NCT00600119|DRUG|NKTR-118|5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
40920758|NCT02721953|DIETARY_SUPPLEMENT|Butyrate|Butyrate
40920759|NCT02721953|OTHER|Placebo|Placebo
40920760|NCT03554343|DIAGNOSTIC_TEST|test for SMN1 exon 7 deletion|Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers
40920761|NCT05509868|DRUG|PBK_L1704 0.35mg|The subject will receive PBK_L1704 0.35mg/ml by PCA
40920762|NCT05509868|DRUG|PBK_L1704 0.5mg|The subject will receive PBK_L1704 0.5mg/ml by PCA
40920763|NCT05509868|DRUG|Placebo|The subject will receive placebo by PCA
40920764|NCT01425463|DRUG|Ferrous (II) Glycine Sulphate Complex|"Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
40920765|NCT01425463|DRUG|Polyferose|"Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
40920766|NCT01425463|OTHER|Placebo to Ferrous (II) Glycine Sulphate Complex|Administered orally with water.
40920767|NCT01425463|OTHER|Placebo to Polyferose|Administered orally with water.
40920768|NCT05330104|BEHAVIORAL|Mobile Ecological Momentary Assessment|mEMA is a tool that allows for scheduled or triggered surveys to assess a participant's CIPN symptoms and/or fall risk
40920769|NCT03371888|BIOLOGICAL|Platelet-Rich Plasma intramuscular injections|A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.
40920770|NCT03371888|BIOLOGICAL|Placebo Comparator: 0,9% NaCl intramuscular injections|A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.
40920771|NCT04618510|DEVICE|SEED 1-dayPure EDOF soft contact lens|Centre-distance contact lens with peripheral add power working on extended depth of focus principle to control myopia
40920772|NCT04618510|DEVICE|Single Vision Spectacles|These are the type of glasses that correct vision for a single distance
40920773|NCT01643785|DRUG|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
40920774|NCT05573269|DIETARY_SUPPLEMENT|FOPE (fish oil + pine extract)|During the experiment period the participants will receive a capsule of pine bark extract (Oligopin® 100mg) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
40920775|NCT05573269|OTHER|FO (fish oil +placebo)|During the experiment period the participants will receive a capsule of placebo (maltodextrin + magnesium stearate) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
40920776|NCT03406091|DRUG|Plerixafor|Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) \[3\]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
40920777|NCT02630043|DRUG|Tolcapone|Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.
41269476|NCT04460755|OTHER|Whitening toothpaste 2|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
40920778|NCT02630043|DRUG|Oxaliplatin|Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
40920779|NCT06530979|DEVICE|Tailored nutritional education program utilizing Saudi-sign language supplied by Saudi-sign language interpreter|The program will be implemented in an experimental group composed of profoundly impaired hearing adults (91 Decibels and above). The experimental group will receive nutrition group counselling via photos, and models, and Saudi-sign language interpreter, including awareness of food groups and their nutrients, choose healthy and balanced items from supermarkets, restaurants or coffee shop menus-traffic lights on nutrition labelling and health problems or diseases related to diet and weight management
40920780|NCT00081094|PROCEDURE|18F-Fluorodeoxyglucose-PET (FDG-PET)|
40920781|NCT00081094|PROCEDURE|11Carbon-Acetate-PET|
40920782|NCT05919836|PROCEDURE|Laparoscopic assisted hernia|Percutaneous assisted laparoscopic hernia
41093799|NCT06614569|DRUG|AXO-AAV-GM2|Participants who received AXO-AAV-GM2 will be tracked in long term follow up
41269477|NCT04460755|OTHER|Whitening toothpaste 3|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
41269478|NCT04460755|OTHER|Whitening toothpaste 4|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
41269479|NCT04460755|OTHER|Whitening toothpaste 5|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
41269480|NCT03698201|OTHER|Non-interventional|Translational, observational study
41269481|NCT01356381|DRUG|Vildagliptin|Dosage 50mg b.i.d.
41269482|NCT01356381|DRUG|Placebo|50mg bid
40920783|NCT05919836|PROCEDURE|Laparoscopic hernia by purse string closure|Laparoscopic purse string closure of hernial sac
41093800|NCT01675830|DEVICE|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
41093801|NCT00409864|PROCEDURE|Endoscopic biliary stenting, Percutaneous biliary stenting|percutaneous 10 F stent, endoscopic 10 F stent insertion
40920784|NCT05919836|PROCEDURE|Total laparoscopic dissection of hernial sac|Total laparoscopic dissection of hernial sac
40920785|NCT00551928|DRUG|Melphalan|High dose Melphalan 200mg/sm with autologous stem cell support
40920786|NCT00551928|DRUG|Lenalidomide|Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
40920787|NCT00551928|DRUG|Prednisone|Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
40920788|NCT00551928|DRUG|Melphalan|Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
40920789|NCT03126344|DEVICE|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
40920790|NCT03126344|DEVICE|McGrath MAC video laryngoscope|nasal intubation using McGrath MAC video laryngoscope Device after general anesthesia induction
41269483|NCT03967821|OTHER|Questionnaire|Each patient complete FQoR-15 questionnaire 3 times (before surgery, on Day 1, on Day 2)
40920791|NCT03126344|DEVICE|Macintosh laryngoscope|nasal intubation using Macintosh laryngoscope Device after general anesthesia induction
40920792|NCT03608358|DRUG|Dapagliflozin 10 mg|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
40920793|NCT03608358|DRUG|Dapagliflozin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
40920794|NCT03608358|DRUG|Dapagliflozin 10 mg placebo to match|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
40920795|NCT03608358|DRUG|Dapagliflozin 5 mg placebo to match|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
40920796|NCT03608358|DRUG|Saxagliptin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
40920797|NCT03608358|DRUG|Metformin|Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
40920798|NCT04635800|DRUG|MHU650|MHU650 powder for solution for injection
40920799|NCT05506228|OTHER|No intervention|
40920800|NCT05302453|OTHER|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), which is among the body-mind approaches, is also frequently used in the rehabilitation of patients with psychiatric disorders, pain, and chronic musculoskeletal system problems.
40920801|NCT05086614|DRUG|Thymosin Alpha1|Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.
41093802|NCT06276595|BEHAVIORAL|Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (TODOS)|The TODOS program consists of 11 weekly sessions conducted with girls ages 8-11 and their female caregivers. Five of the 11 sessions will be taught to small groups, and 6 of the Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room.
41093803|NCT06276595|BEHAVIORAL|Control condition - 3 Monthly Group Activities in the Community|The control condition consists of 3 group sessions delivered monthly for three months. The first group session will occur at a community center and will consist of a meal and ice breaker activities. The second group session will consist of going to a movie at the local movie theatre The third group session will consist of going bowling at the local bowling alley.
41269484|NCT04751721|BIOLOGICAL|CoronoVac Vaccine|CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
41269485|NCT00503256|BEHAVIORAL|Questionnaire|Questionnaires each taking 60 minutes to complete.
41269486|NCT02029976|BEHAVIORAL|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
41269487|NCT02029976|BEHAVIORAL|Mailed monthly newsletters|Newsletters
41269488|NCT04328506|DRUG|CM082 tablet (test product)|Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals
40920802|NCT06119750|DEVICE|NS Solution|This will be administered via skin patch.
40920803|NCT06119750|OTHER|Normal Saline|This will be administered via skin patch.
40920804|NCT06119750|OTHER|SLS|This will be administered via skin patch.
40920805|NCT04987359|BEHAVIORAL|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling.
40920806|NCT04232332|DRUG|Recombinant human nerve growth factor injection,experimental|Intramuscular injection once on the first day according to dose requirements
40920807|NCT04232332|DRUG|Recombinant human nerve growth factor injection,single dose|Intramuscular injection once on the first day according to dose requirements
40920808|NCT04232332|DRUG|Recombinant human nerve growth factor injection,multiple dose|Intramuscular injection once daily for 7 days according to dose requirements
40920809|NCT00781573|DRUG|Clopidogrel|Clopidogrel, 75 mg QD, for one year
40920810|NCT00917644|DRUG|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
40920811|NCT00917644|GENETIC|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
40920812|NCT06022471|PROCEDURE|Stapes surgery|Stapedectomy operation
40920813|NCT05941871|OTHER|Dietary intervention - intervention group|"Low-calorie diet for 4 months with a different daily energy distribution according to the chronotype:~* Morning chronotype: 50% of kcal administered before lunch and 15% in the second part of the day (specifically: 40% at breakfast, 10% in the morning snack, 35% at lunch, 5% at afternoon snack and 10% at dinner)~* Evening chronotype: 15% of kcal given before lunch and 50% in the second half of the day (specifically: 10% of kcal at breakfast, 5% in the morning snack, 35% at lunch, 10% at snack time and 40% at dinner)"
40920814|NCT05941871|OTHER|Dietary intervention - control group|Group that will follow a low-calorie diet with a standard daily energy distribution (20% of kcal at breakfast, 10% in the morning snack, 35% at lunch, 10% at afternoon snack and 25% at dinner) for 4 months
41093804|NCT00315965|DRUG|Nitric oxide, Carbon monoxide, Helium|
41269489|NCT04328506|DRUG|CM082 tablet (reference product)|Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions
40920815|NCT04831632|DIAGNOSTIC_TEST|quantitative and qualitative iFOBTs|They will have their qualitative and quantitative iFOBTs done within the week prior to the VCC study completion. The reading of both of them will be done in Hospital El Cruce's laboratory. The result of the qualitative iFOBT will have two valid expressions: positive or negative.The result of the quantitative iFOBT will be expressed as µg from hemoglobin per gram of fecal matter through the use of automatized equipment for laboratory analysis.
40920816|NCT06031389|DRUG|Henagliflozin|On the basis of hypoglycemic therapy, the patients in the intervention group were given the drug treatment of hengglinide, once a day, 10mg or 5mg each time, taken in the morning, for 12 months.
40920817|NCT06031389|DRUG|Placebo|On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.
40920818|NCT04142177|OTHER|Pain EASE|The internet-based pain self-management program consists of open access to the Pain EASE program (Pain E-health for Activity, Skills, and Education) for the duration of participation in the trial. Pain EASE has 10 pain coping skill modules: pain education, setting personal goals, planning meaningful activities, physical activity (stretching, body mechanics, and a pedometer-based walking program), relaxation, developing healthy thinking patterns, pacing and problem-solving, improving sleep, effective communication, and future planning.
40920819|NCT04142177|PROCEDURE|Tailored exercise|Findings from the initial examination and the Keele STarT Back Screening Tool (Hill, et al., 2011) will be used by the physical therapist to guide and tailor the intervention to individual participants which will involve up to 8 treatment sessions with ongoing home exercise. For most participants, exercise and physical activity will focus on walking in addition to motor control and stabilization exercises for the low back with flexibility exercises when lumbar spine stiffness is present.
40920820|NCT04142177|OTHER|Continued Care and Active Monitoring|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management.
40920821|NCT04142177|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months. The VA's CBT-CP protocol consists of 11 core CBT-CP modules that can be completed in up to 10 sessions. Weekly, individual sessions of 45-50 minutes are recommended, although it is recognized that bi-weekly or other arrangements are often made to fit practical needs.
40920822|NCT04142177|PROCEDURE|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT.
40920823|NCT04142177|PROCEDURE|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace.
40920824|NCT03811236|OTHER|Cold exposure|Two hours of mild cold exposure using a water-perfused vest
40920825|NCT06414785|OTHER|analysis of samples of periprosthetic capsules taken during breast implant change procedure|characteristics of inflammation and the importance of silicone exposure (intact implant, implant rupture in serum or silicone) at the genomic molecular level, by analyzing the level of expression of genes related to the extracellular matrix and inflammation within a periprosthetic capsule fragment
40920826|NCT00614770|PROCEDURE|standard of care colonoscopy|"Standard White Light Colonoscopy~one exam per patient"
40920827|NCT00614770|PROCEDURE|colonoscopy|"Narrow Band Imaging Colonoscopy~one exam per patient"
41269490|NCT03354689|RADIATION|Scintigraphy|Scintigraphy
41269491|NCT02673255|BIOLOGICAL|Tetanus and Diphtheria (Td) Vaccine|
41269492|NCT01860937|PROCEDURE|leukapheresis or collection of PBMCs|
41269493|NCT01860937|DRUG|cyclophosphamide based chemotherapy regimens|
41269494|NCT01860937|BIOLOGICAL|modified T cells|
41269495|NCT01053429|DRUG|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
41269496|NCT01285349|BEHAVIORAL|Couple HIV/STI prevention intervention|
41269497|NCT01285349|BEHAVIORAL|Couple-based HIV/STI prevention|
41269498|NCT01285349|BEHAVIORAL|Individual HIV/STI prevention|
41269499|NCT01285349|BEHAVIORAL|Couple Wellness Promotion|
41269500|NCT02316834|OTHER|Laboratory Biomarker Analysis|Correlative studies
41269501|NCT02316834|DRUG|BMN 673|"BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery."
41269502|NCT00270608|PROCEDURE|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
41269503|NCT00270608|PROCEDURE|MRI of the spine and the right knee|a single time 45 minutes procedure
41269504|NCT00270608|PROCEDURE|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
41269505|NCT04421326|OTHER|Analysis of the clot|Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy
40920828|NCT00614770|PROCEDURE|standard of care colonoscopy|"High Definition White Light Colonoscopy~one exam per patient"
40920829|NCT03827915|DEVICE|Double sequential external defibrillation|DSED is the process of using two defibrillators near simultaneously at their highest allowed energy setting and aims to treat refractory atrial fibrillation. The first set of pads is placed in the traditional anterolateral position and the second set can be either placed adjacent to the first set (antero-lateral) or in the antero-posterior position. Shocks are then delivered simultaneously or near simultaneously
40920830|NCT02185976|OTHER|cartoon|5 different cartoons which will be recorded on a tablet PC.
40920831|NCT04531709|OTHER|Comprehensive Score for financial toxicity (COST)|Measure indirect and direct health care cost that burden patients and their loved ones.
40920832|NCT04531709|OTHER|Functional Assessment of Cancer Therapy: General (FACT-G)|General quality of life instrument
40920833|NCT04531709|OTHER|EORTC QLQ C-30|Assess quality of life in cancer patients
40920834|NCT04531709|OTHER|EORTC QLQ-TC26.|To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.
40920835|NCT00864695|OTHER|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
40920836|NCT05311644|OTHER|Telephone survey|All participants are interviewed by telephone, and are asked to answer a survey.
40920837|NCT03930264|DRUG|Azathioprine 50Mg Tab|tablet
40920838|NCT03930264|DRUG|Azathioprine 10mg/mL oral suspension|oral suspension
40920839|NCT02909387|BEHAVIORAL|Project UPLIFT|UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
40920840|NCT05504239|DRUG|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
40920841|NCT05504239|DRUG|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
40920842|NCT03634241|BIOLOGICAL|Pembrolizumab|Given IV
40920843|NCT03634241|OTHER|Quality-of-Life Assessment|Ancillary studies
40920844|NCT03634241|PROCEDURE|Computed Tomography|Undergo CT
40920845|NCT03634241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40920846|NCT06394882|BEHAVIORAL|Family-Centered Healthy Lifestyle Program (FamCe-HLP)|A multidisciplinary-led healthy lifestyle program will provide a seven-month program comprising two primary therapies: a three-month intensive behavioral therapy (IBT) and a four-month maintenance behavioral therapy (MBT). The program will run on scheduled days using one of the center's offices for the IBT and the center's seminar room for the MBT.
40920847|NCT00518960|DRUG|ProAlgaZyme|
40920848|NCT05176132|OTHER|Life style intervention (dietician+ physiotherapist)|Obese patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dieticians and physiotherapists focusing on health improvement through personal motivation and perceived limitations and body accept.
40920849|NCT05176132|OTHER|Self management|Patients with no obesity related diseases will not be offered lifestyle intervention, but encouraged to physical activity (self management)
40920850|NCT05176132|OTHER|No intervention|Control groups (BMI 20-25 and BMI 25-30)
40920851|NCT04110652|OTHER|pulmonary rehabilitation program|"The pulmonary rehabilitation program consisting of inspiratory muscle training, manual hyperinflation. chest wall mobilization, rib-cage compression, cough function training, postural drainage and secretion removal will be applied to patient group.~The program will be conducted by physical therapists for 30-45 minutes daily during ICU stay.~The exercise intensity will be increased gradually over the course. Each patient's performance during the exercise sessions will be recorded and reported regularly."
40920852|NCT06311877|DIETARY_SUPPLEMENT|mBerry|mBerry tablets (.4 grams), which contain protein within the miracle berry called miraculin.
40920853|NCT06311877|OTHER|No intervention|The control group will not received intervention.
40920854|NCT00906737|DEVICE|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
40920855|NCT00906737|OTHER|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
40920856|NCT02970240|PROCEDURE|Cardiopulmonary testing|A 2-day consecutive testing on an ergometer cycle
40920857|NCT05297318|DEVICE|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
40920858|NCT05297318|OTHER|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
40920859|NCT01467219|PROCEDURE|lymphadenectomy|bilateral pelvic and para-aortic lymph node dissection
40920860|NCT01467219|PROCEDURE|therapeutic conventional therapy|hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
40920861|NCT01467219|PROCEDURE|Positron Emission Tomography/ Computed Tomography|Pre-operative PET/CT scan
40920862|NCT01467219|RADIATION|fludeoxyglucose F 18|5 MBq/kg body weight of FDG (up to 550 MBq)
40920863|NCT01798160|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
40920864|NCT01798160|PROCEDURE|SIRT|Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
40920865|NCT01883453|DEVICE|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
40920866|NCT01883453|DEVICE|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
40920867|NCT06529133|OTHER|Evaluation of postural control|Postural stability, limits of stability, and modified clinical test of sensory interaction in balance tests will be performed with Biodex Balance System (BBS). 1) Postural Stability: The test will be performed on a stable platform and mean, anterior/posterior and medial/lateral stability indices will be calculated. 2) Limits of Stability: The test will be performed on a static platform and directional control will be evaluated and expressed as a percentage value. 3) Modified Clinical Test of Sensory Interaction in Balance: The test will be performed with a static platform setting on a flat surface with eyes open and eyes closed, on a foam floor with eyes open and eyes closed. Half an hour later, the same tests will be repeated during the cognitive dual task. The cognitive tasks given were counting day-month-season, rhythmic forward and backward counting (counting by 2, 3, 5, 10, etc.), counting words related to a given letter (animal names starting with the letter A, city names, etc.).
40920868|NCT00848562|DRUG|Nicorandil|Oral administration of nicorandil (15 mg/day)
40920869|NCT06445452|BEHAVIORAL|Direct SNAP-Ed|Six in-home SNAP-Ed lessons are delivered to participants in the SNAP-Ed arm. Lessons are offered weekly and directed by a bilingual and bicultural community health worker.
40920870|NCT03868527|OTHER|Data collection|Data collection for biostatistical analysis about hematological diseases
40920871|NCT00798278|DRUG|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
40920872|NCT00798278|PROCEDURE|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
40920873|NCT04726540|OTHER|Patient Satisfaction|Patients were then asked to grade their overdentures/dentures on a visual analog scale and written questionnaire to evaluate their overall satisfaction.
40920874|NCT03449784|OTHER|Detection of patients with dyslipidemia|Detection of patients with dyslipidemia
40920875|NCT06275633|DRUG|Levodopa|Medicine response
40920876|NCT03496779|DRUG|Brentuximab Vedotin - induction|Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
40920877|NCT03496779|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
40920878|NCT03496779|DRUG|Brentuximab Vedotin - maintenance|"Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.~Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy"
40920879|NCT03496779|PROCEDURE|autologous or allogeneic stem cell transplantation|Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation
40920880|NCT00550641|OTHER|physical therapy|physical therapy in warm pool performing stretching
40920881|NCT00550641|OTHER|physical therapy|physical therapy in warm pool performing Ai Chi
40920882|NCT00458029|BEHAVIORAL|integrated program of nutrition, activity, behavior, and promotion|implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
40920883|NCT05570916|DEVICE|Zip-stitch(R)|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
40920884|NCT05570916|DEVICE|Reference suture|Standard suture for vaginal cuff closure during laparoscopic hysterectomy
40920885|NCT05516563|OTHER|EDucation and eXercise intervention|"The exercise programme includes 3 key streams:~1. Low-load isometric abduction~2. Functional loading~3. Abductor loading: Graduated abductor loading, designed to improve load tolerance by applying progressively higher loads across the abductor muscles. Daily exercise will be completed three days a week at a 'hard' to 'very hard' level, alternating with three 'light' days and one rest day. The clinic day will constitute one of the 'hard' days.~Education will be delivered via a 20 minute video which focusses on understanding and managing lateral hip pain ( ie pain associated with gluteal tendinopathy). Education will also be tailored to each patient on attendance with the physiotherapist at the 6 clinic visits"
40920886|NCT00859027|DRUG|risedronate|35 mg/week by mouth
40920887|NCT00859027|DRUG|Placebo risedronate oral tablet|One tablet by mouth every week as directed
40920888|NCT03021161|DRUG|Probiotic Formula|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
40920889|NCT03021161|OTHER|Placebo Oral Capsule|Capsule containing no probiotic
40920890|NCT00705744|DRUG|Lactic acid (Dermacyd Femina)|
40920891|NCT01677429|DEVICE|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
41269506|NCT04748263|OTHER|No intervention. Only survey and normal use of eye-tracking|"The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE."
41269507|NCT02292823|DEVICE|MGuard™ Prime Embolic Protection Stent System|
41269508|NCT04480281|DRUG|Lidocaine Iv|Patients in the Lidocaine group received a bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
40920892|NCT01677429|DEVICE|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
41269509|NCT04480281|DRUG|Normal Saline|Patients in Group Placebo received an equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
41269510|NCT05406908|BIOLOGICAL|tozinameran|Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)
41269511|NCT01860560|DEVICE|High-Flow Therapy|Blower-based High Flow Therapy delivered by nasal cannula
41269512|NCT01860560|DEVICE|Continuous Positive Airway Pressure|CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
41269513|NCT02563301|DEVICE|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
41269514|NCT01200784|DRUG|Nicotinamide|dosage
41269515|NCT03624647|DEVICE|Power toothbrush|Experimental power toothbrush
41269516|NCT03624647|DEVICE|Manual toothbrush|Marketed manual toothbrush
41269517|NCT00508729|DRUG|Qingyi granules|
41269518|NCT00924703|DRUG|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
40920893|NCT01677429|BEHAVIORAL|Cognitive Behavioral Therapy|For the treatment of panic disorder
40920894|NCT00061412|BEHAVIORAL|Comprehensive program to improve reading and writing skills|
40920895|NCT02133300|OTHER|electrical stimulation|
40920896|NCT00514852|DRUG|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
40920897|NCT00514852|DRUG|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
40920898|NCT00645450|DRUG|Propranolol|Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
40920899|NCT00645450|DRUG|Placebo|Weekly doses of placebo (inactive pill) following recollection of traumatic memory
40920900|NCT00102778|DRUG|GW873140|
40920901|NCT00102778|DRUG|Kaletra (lopinavir/ritonavir)|
40920902|NCT05427617|DRUG|Control group|Physician chosen treatment
40920903|NCT05427617|DRUG|Case group|Druggable ctDNA alterations-guided therapy
40920904|NCT04795336|DRUG|Melatonin 5 mg|Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg
40920905|NCT04795336|OTHER|Placebo|The placebo ingredients are Microcrystalline Cellulose, Silica, Gelatin, Titanium Dioxide, Red #3, and Blue #1.
40920906|NCT04884451|BEHAVIORAL|Lifestyle modification|Diet and physical activity modification and behavioral approach
40920907|NCT04247542|DRUG|Ibezapolstat|Investigational antibacterial agent
40920908|NCT04247542|DRUG|Vancomycin|Active comparator
40920909|NCT03196388|DRUG|Enzalutamide|"Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is \>95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy"
40920910|NCT02511223|DRUG|OLAPARIB|Olaparib 300 (mg) twice a day per os given every day until disease progression or toxicity
40920911|NCT05747040|DIAGNOSTIC_TEST|monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline t1: pre-treatment t2: post-treatment t3: follow-up"
40920912|NCT05938049|DEVICE|IVC ultrasound & Carotid doppler|"bed side ultrasonographic assessement of inferior vena cava maximum and minimum diameters 2 to 5 cm caudal to its junction with the right atrium over a single respiratory cycle , inferior vena cava collapsibility index (IVC-CI) will calculated as (IVC max - IVC min)/IVC max).~carotid doppler assessment (2-3 cm proximal to the carotid bulb in the longitudinal plane) of corrected carotid flow time(systole time/√cycle time) ,carotid artery peak velocity variation calculated as (\[PV max- PV min\]/PV mean) × 100, where PV mean = (PV max + PV min)/2. during three consecutive respiratory cycles. as part of their routine care and assessment"
40920913|NCT03897140|DIAGNOSTIC_TEST|Diagnostic Test: Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance feedback to users during image acquisition. For this study, RNs will use EchoGPS to perform limited echocardiogram examinations.
40920914|NCT05887778|DRUG|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the supraclavicular brachial plexus block
40920915|NCT05887778|DRUG|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
40920916|NCT05887778|DRUG|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
41093805|NCT03256682|BEHAVIORAL|Stress management counseling|stress management counseling based on CBT and relaxation
41093806|NCT03270020|DRUG|Denosumab 70 MG/ML [Xgeva]|As already described in arm description
41093807|NCT06339905|PROCEDURE|Sonic Activation with EndoActivator|sonic activation
41093808|NCT06339905|PROCEDURE|Control Needle Irrigation|control group
41093809|NCT05203055|DRUG|Peginterferon alpha-2b|180μg/w
41093810|NCT05203055|DRUG|Nucleotide Analog|Etecavir 0.5mg qd or Tenofovir 300mg qd
41093811|NCT05203055|DRUG|pulse peginterferon alpha-2b|180μg/w for 8 consecutive weeks and cessation for 4 weeks
41093812|NCT05906628|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
41093813|NCT05906628|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
41093814|NCT00955461|PROCEDURE|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
41093815|NCT00955461|PROCEDURE|Fractionated Laser treatment|
41093816|NCT02263885|DEVICE|ExAblate Transcranial System|Transcranial MRgFUS
41093817|NCT03746275|DRUG|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
41093818|NCT03746275|DRUG|Acetylsalicylic acid|75 - 100 mg once daily according to local label
41093819|NCT00512824|DIETARY_SUPPLEMENT|low calcium milk of 180 ml|twice daily for 24 weeks
41093820|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml|twice daily for 24 weeks
41093821|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml + probiotics|twice daily for 24 weeks
41269519|NCT06063473|DRUG|Trifarotene Cream 0.005%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
41269520|NCT06063473|DRUG|Placebo|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
41269521|NCT06063473|DRUG|AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
41269522|NCT01935895|BEHAVIORAL|Exercise on Blood Pressure Reactivity|To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
41269523|NCT01067820|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
41269524|NCT01067820|DRUG|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
41269525|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 30% of the cumulative weekly dose achieved with daily rhGH, Once weekly
41269526|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 45% of the cumulative weekly dose achieved with daily rhGH, Once weekly
41269527|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, Once weekly
41093822|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml + probiotics|twice daily for 24 weeks
41093823|NCT03237221|DRUG|Treat patient according to Global Initiative for Asthma (GINA) guideline|Treat patient according to Global Initiative for Asthma (GINA) guideline
41093824|NCT05452629|BEHAVIORAL|Mindfulness induction (MI)|In the MI condition, participants were guided to focus on present experiences regarding the thoughts, emotions and sensations through the three classic mindfulness exercises (i.e., focused breathing, meditation, and body scanning). The duration of MI was 30-minutes.
41093825|NCT05452629|BEHAVIORAL|Relaxation (RI)|In the RI condition, participants were guided to relax each muscle group following the audio for 30-minutes.
41269528|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, every-other week (50% of the two-weekly cumulative dose)
41453161|NCT02634736|DEVICE|Exergame plus usual treatment|An individualised \[i.e. frequency and duration will be set according to each participant's baseline levels\] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
41453162|NCT02958176|BEHAVIORAL|HRV Biofeedback|At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap
41453163|NCT02958176|BEHAVIORAL|Autogenic Training|Autogenic training recording provided on a CD
41453164|NCT04414046|BIOLOGICAL|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
41453165|NCT04179539|DIAGNOSTIC_TEST|V/Q PET/CT|Ventilation images are acquired after inhalation of Galligas prepared using a Technegas generator (Cyclopharm, Sydney, Australia). The patients is placed in a supine position and inhaled Galligas using the standard ventilation technique. Ventilation images are then acquired. Without the patient moving, 68Ga-MAA are then injected. Perfusion PET images are then acquired
41453166|NCT04179539|DIAGNOSTIC_TEST|CTPA|CTPA will be done according to the usual protocol in the radiology department of the investigator center
41269529|NCT06399679|DRUG|Rivastigmine|Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
41269530|NCT06399679|DRUG|Placebo|Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
41269531|NCT05003115|BEHAVIORAL|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
41269532|NCT00452725|DRUG|MAXOMAT ®, biosynthetic growth hormone|2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
41269533|NCT00906438|DIETARY_SUPPLEMENT|2006-RD-05|300 mg daily, once a day for 28 consecutive days
41269534|NCT00906438|DIETARY_SUPPLEMENT|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
41269535|NCT00313573|PROCEDURE|management of therapy complications|
41269536|NCT00313573|PROCEDURE|pain therapy|
41269537|NCT00313573|PROCEDURE|psychosocial assessment and care|
41269538|NCT00313573|PROCEDURE|quality-of-life assessment|
41269539|NCT02750059|DRUG|TDF/3TC/EFV + Telmisartan|The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
41269540|NCT02750059|DRUG|TDF/3TC/EFV only|Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
41269541|NCT03592979|DEVICE|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
41269542|NCT03592979|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
41269543|NCT05533567|DRUG|Remimazolam|The experimental group was sedated with remimazolam.
41269544|NCT05533567|DRUG|Propofol|The control group was sedated with propofol.
41269545|NCT00682656|DRUG|Glucantime®|15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
41269546|NCT00682656|DRUG|Zithromax ®|Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
41269547|NCT06399783|DRUG|Simvastatin|Group of patients will be treated by topical application of simvastatin cubosomal nanoparticled twice daily for 6 months, while another group will be treated by fractional CO2 laser for 6 sessions sessions each will be followed immediately by topical application of topical simvastatin.
41269548|NCT06399783|DRUG|Mometasone Furoate|Patients will be treated by fractional CO2 laser for 6 sessions each will be followed immediately by topical application of Mometasone Furoate.
41269549|NCT06399783|PROCEDURE|Fractional CO2 laser|Fractional CO2 laser will be used for assisted drug delivery for both topical simvastatin and mometasone Furoate.
41269550|NCT03403400|BEHAVIORAL|VRWP Group|The VRWP group will have VR with an instruction to increase their number of steps daily to at least 3,000 steps using the pedometer (VR plus walking plus pedometer group). They will receive pedometers (Fitbit Zip), instructions on how to use the pedometer, step log forms, with home instruction handout to walk more at least more than ten minutes at a time. The participants will record on their activity log the number of steps shown on the step display at the end of the day. The daily step log form will be given to the research staff every visit for recording. The research staff will encourage their participants to increase their daily steps at least 10% until they achieve at least 3,000 steps daily.
40920917|NCT04143178|OTHER|Expressive Writing|The expressive writing is a form of writing therapy developed primarily by James W. Pennebaker in the late 1980s consisting of writing about stressful and traumatic experience for 15-20 min for 3 consecutive days, including one's thoughts and feelings. The expressive writing allows people to express and process emotions, feelings, and thoughts related to the life events and consequent changes and this may favor a mental reorganization of the negative events, a greater expression and regulation of the emotions related to them. This intervention could provoke social, emotional, and consequently, psychophysical changes as is showed in patients with chronic diseases and cancer. In the present study, to all participants in the writing group, 5 days after the transplant, has been asked to write for 3 consecutive days, 20 minutes each days about their deepest emotions and feelings related to the chronic failure, the transplant and their expectations after that.
40920918|NCT04143178|OTHER|Neutral Writing|Five days after the transplant, to the control group participants has been asked to write for 3 consecutive days 20 minutes a day on an assigned neutral theme (eg. describe 1 object in the room) as objectively as possible, without mentioning their emotions or thoughts related to it.
40920919|NCT04229732|DEVICE|ClearMateTM|Passive isocapnic hyperventilation breathing circuit.
40920920|NCT01199367|DRUG|KW-2450 in combination with lapatinib and letrozole|Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
40920921|NCT00718588|DRUG|MTRX1011A|Subcutaneous and intravenous single and repeating dose
40920922|NCT00114790|RADIATION|boronophenylalanine-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
40920923|NCT02791568|PROCEDURE|Ultrasound Scan|The research exam is expected to take 30 minutes for blood flow assessments
41269551|NCT03403400|BEHAVIORAL|VRW Group|The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
41269552|NCT00705237|PROCEDURE|Functional Endoscopic Sinus Surgery with Balloon Dilatation|Luma lightwire technology will be utilized in conjunction with fluoroscopy for patients with sinusitis undergoing functional endoscopic sinus surgery with balloon dilatation. Trans-illumination of the sinus will be compared to fluoroscopy for accuracy
41269553|NCT02953808|DRUG|Placebo|0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
41269554|NCT02953808|DRUG|GSK2315698|200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
40758239|NCT00078195|BIOLOGICAL|omalizumab|A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
40758240|NCT00078195|BIOLOGICAL|Placebo omalizumab|The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
40920924|NCT02791568|PROCEDURE|MRI Scan|MR imaging will take approximately 30 minutes.
40920925|NCT02791568|DRUG|Ferumoxytol|A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
41093826|NCT05033067|BEHAVIORAL|P3BC|The decisional aid will be developed to enhance patients' communication about cystectomy and urinary diversions with the clinicians, patients' decisions and preparation for self-care. Program users will be able to choose from a menu to view and print: a) summaries of their responses to inquiry questionnaire about information needed, b) selected statistics about specific side effects and self-care, and c) streamed video vignettes with patient actors of mixed cancer stages, age, sex, and race talking with a clinician about their treatment outcomes and self-care. An automatically printed 2-page output to facilitate discussion will list: 1) decision role preference; 2) the 4 highest ranked information preference sheets; and 3) a summary of personal factors plus suggested discussion topics to address with the clinician. The 2-pages will be provided to the treating physician by the research coordinator before the patient's next consultation appointment.
40920926|NCT02346773|DIETARY_SUPPLEMENT|ω-3 LC-PUFA|The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.
40920927|NCT02346773|OTHER|Placebo|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
41093827|NCT03328052|DEVICE|MYnd Analytics PEER Online directed antidepressant therapy|"PEER Online is similar to a standard QEEG in that it uses QEEG output variables, but differs from a standard QEEG in that it references the QEEG to a normative and then symptomatic database. By comparing a given patient's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER Online can provide useful information regarding the response of neuro-physiologically similar patients to a wide number of medications. PEER Online may thus have the advantage of providing physicians with useful information as to medication outcomes before a medication regime is started. It has also been used to help select the medication that best matches the QEEG brainwave pattern, regardless of symptom clusters, currently used for diagnostic nomenclature. Patients will receive anti-depressant therapy guide by the results of the PEER Online algorithm."
41093828|NCT03328052|OTHER|Conventional antidepressant therapy|Anti-depressant therapy chosen based on physician best judgement.
41093829|NCT02516579|DRUG|Siklos|
41093830|NCT02506387|DEVICE|mitraclip|The decision to implant mitraclip is not part of this observational study but is made by the heart-team.
41093831|NCT02527850|DEVICE|B-cure laser|
41093832|NCT02292394|BEHAVIORAL|Multicomponent Cognitive Behavioral Telephone Intervention|
41093833|NCT02292394|BEHAVIORAL|Telephone Intervention Pleasant Activities|
41093834|NCT02013232|DRUG|Aripiprazole|
41093835|NCT05656313|DEVICE|Measures of speech intelligibility in a noisy situation with speech from the side and from behind (measured with CC-OLSA Test)|"The Concurrent OLSA test (CC-OLSA) is a speech recognition test with three turn-taking talkers presenting sentences of the Oldenburg sentences test at fixed signal-to-noise ratios.~CC-OLSA is the only one-talker-at-a-time speech test that is sensitive at the desired SNR and uses sentences with an intelligibility function with slopes of 10-17 %/dB."
41269555|NCT01898156|DRUG|BIW-8962|"Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops."
41093836|NCT05656313|DEVICE|Measures of the subjective speech recognition threshold in a noisy situation with speech from the side and from behind (measured with HEISS test)|The measure of the subjective speech recognition threshold is an alternative procedure to evaluate the subjective speech intelligibility in different listening conditions. The subjective speech recognition threshold is defined as the speech presentation level of running speech needed to just follow conversation. Subjects have to adjust the presentation level of speech so that they are just able to understand the speech, using a slider on a touch screen. This adjustment is repeated 10 times. Each adjustment results in a value for the subjective speech recognition threshold in dB SNR. The outcome measure is the mean value of the 10 repetitions. The HEISS-Test will be repeated four times for the secondary objective: test for 2 test conditions (Reference, novel approach) against 2 target directions (better ear side, back).
41093837|NCT05656313|DEVICE|Ability to multitask in the auditory and visual domains in noisy situation with speech from the side and from behind (Multitask test)|This test uses a dual-task-paradigm assessing vigilance for auditory and visual triggers concurrently. The primary task is to listen to a novel (Harry Potter) and respond on two trigger words by pressing the appropriate button (one in each hand). The secondary task is to observe a monitor showing a sequence of random signs and respond on a target sign by pressing both buttons. The test includes at least 100 triggers (50 auditory, 50 visual) and takes 10 minutes per condition (side vs. back; novel approach vs. reference; 40 minutes in total). The multitask test will be repeated four times for the secondary objective: 2 conditions (Refrence, novel approach) against 2 target directions (better ear side, back). Following data are provided from each multitask Test measure: (1) subjective rating of the perceived ability to perform the visual and the auditory test simultaneously. (2) reaction times to auditory and visual tasks, and (3) accuracy.
41269556|NCT04908995|DRUG|EC5026 oral tablet|"12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~* Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~* Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2."
41269557|NCT04908995|OTHER|Placebo oral tablet|"6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period."
41269558|NCT04741373|DIETARY_SUPPLEMENT|oral nutritional supplements|oral nutritional supplements, 400-600kcal/day;
41269559|NCT04741373|BEHAVIORAL|rehabilitation exercise|Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week
41269560|NCT04741373|OTHER|health education|Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
41269561|NCT00004987|DRUG|Dextrin 2-sulfate|
41269562|NCT03777514|DRUG|Ferumoxytol|treatment of iron deficiency anemia with IV iron.
40758241|NCT00078195|BIOLOGICAL|Ragweed rush immunotherapy (RIT)|RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
41269563|NCT03777514|DRUG|Ferrous sulfate|treatment of iron deficiency anemia with oral iron
41269564|NCT03777514|OTHER|Oral vitamin C|Oral vitamin C to be used as a placebo for participants receiving IV iron
41269565|NCT03777514|OTHER|Intravenous normal saline|Intravenous normal saline will be used as placebo for participants receiving oral iron
41269566|NCT02113202|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
41269567|NCT02113202|DEVICE|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
41269568|NCT00355264|DRUG|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
41269569|NCT01206881|DRUG|pegylated liposomal doxorubicin|35 mg/m2, IV, day 1 every 21 days, 4 cycles
41269570|NCT03777306|OTHER|ARM A EARLY INTERVENTION GROUP|"Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~* 1 video/picture/worksheet per week covering the topic to be covered.~* 1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~* 3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress."
41269571|NCT03777306|OTHER|ARM B DELAYED INTERVENTION GROUP|The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
41269572|NCT00046722|DRUG|Smoked Marijuana|
40758242|NCT00078195|BIOLOGICAL|Placebo rush immunotherapy (RIT)|The placebo for rush immunotherapy will contain the diluents and histamine.
40758243|NCT00078195|BIOLOGICAL|Ragweed immunotherapy (IT)|Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
41269573|NCT05932719|OTHER|COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.|"The following items will be collected~* Diagnostic date~* Diagnostic stage~* Date of surgery~* Date of surgery appointment~* First antineoplastic treatment date~* Last antineoplastic treatment date~* Number of treatment cycles recommanded by MDTM"
41269574|NCT05317767|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
41269575|NCT05317767|BIOLOGICAL|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
41269576|NCT01983891|OTHER|Cooking course|6-week nutrition education and cooking course
41269577|NCT05692960|OTHER|Hypnotic Relaxation Intervention (HRI)|HRI is a combination intervention (Replens™ vaginal moisturizer device and hypnotic relaxation behavioral intervention)
41269578|NCT05692960|DEVICE|Vulvovaginal Atrophy (VVA)|VVA is a standard of care intervention (Replens™ vaginal moisturizer device)
41269579|NCT00006227|DRUG|Paclitaxel|Given IV
40758244|NCT00078195|BIOLOGICAL|Placebo immunotherapy (IT)|The placebo for immunotherapy will contain the diluents and histamine.
40758245|NCT05169593|DRUG|Biological Drug|Biological therapy used in daily clinical practice in patients with Crohn's disease to prevent disease recurrence
41269580|NCT05207475|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 years after enrollment.
40920928|NCT04988360|DEVICE|HMD: Immersive VR|"Participants with dementia will view 360-degree films using a commercially-available Virtual Reality head mounted display (HMD) that has built-in speakers. While wearing the HMD, participants with dementia will be able to visually explore the virtual environments by turning their head to face different directions. Caregivers-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the HMD through the screen mirroring function."
40920929|NCT04988360|DEVICE|Tablet: Non-immersive VR|Participants with dementia will view 360-degree films on a commercially-available tablet that has built-in speakers. Participants with dementia will be able to visually explore the virtual environment using the touch screen (dragging the view around with one's finger). Caregiver-participants will take part in the VR experience concurrently by viewing the tablet while sitting or standing beside the participant with dementia.
40920930|NCT05216744|DRUG|Ceftriaxone 1000mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
40920931|NCT05216744|DRUG|Cefixime 800mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
40920932|NCT06180187|DEVICE|Electrical mallet|elevation of the Schneiderian membrane of maxillary sinus using electrical mallet and place bone graft material to augment the residual alveolar ridge and then place dental implant .
40920933|NCT06180187|DEVICE|Osseo-densification burs|elevation of the Schneiderian membrane of maxillary sinus using osseodensification burs and place bone graft material to augment the residual alveolar ridge and then place dental implant .
40920934|NCT05423223|DEVICE|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
40920935|NCT05423223|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
40920936|NCT01980589|DRUG|Carfilzomib|Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².
40920937|NCT01980589|DRUG|Cyclophosphamide|Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
40920938|NCT01980589|DRUG|Dexamethasone|Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
40920939|NCT02114658|DRUG|Sorafenib (Nexavar,BAY43-9006)|Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
41269581|NCT03345186|OTHER|nurse led plus standard of care|structured nurse led patient management programme: Patient education will be done by a specialised nurse and nurse consultations and phone calls will be done.
41269582|NCT02770157|DRUG|DA-3002|
41269583|NCT02770157|DRUG|Genotropin®|
41269584|NCT03119012|DRUG|Clopidogrel|75mg/day
41269585|NCT03119012|DRUG|Ticagrelor|120mg/day
41269586|NCT03119012|DRUG|Aspirin|100mg/day
41269587|NCT02760251|DRUG|romiplostim|
41269588|NCT02210338|DEVICE|Karl Storz C-MAC|
41269589|NCT02210338|DEVICE|Bonfils Intubation Fibrescope|
40920940|NCT00795678|DRUG|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
40920941|NCT00795678|DRUG|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
40920942|NCT00795678|DRUG|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
40920943|NCT00795678|DRUG|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
40920944|NCT00795678|DRUG|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
40920945|NCT00795678|DRUG|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
40920946|NCT00795678|DRUG|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
40920947|NCT00795678|DRUG|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
40920948|NCT05232409|BIOLOGICAL|Zeaxanthin|The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.
40920949|NCT05232409|COMBINATION_PRODUCT|Zeaxanthin Plus Pembrolizumab|"The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.~The dose of pembrolizumab will be administered at a fixed dose of 400 milligrams intravenous every 6 weeks which is an FDA approved dosing schedule to treat cancer patients with pembrolizumab."
40920950|NCT06272227|DRUG|alfacalcidol|Subjects assigned to arm 1 take two doses of alfacalcidol once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
40920951|NCT06272227|DRUG|placebo|Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
40920952|NCT06272227|DRUG|Denosumab|denosumab
40920953|NCT02817529|DEVICE|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
40920954|NCT02817529|DEVICE|RC-Cornet|RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
40920955|NCT04924439|OTHER|foot reflexology|Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks. The control group was only watched.
40920956|NCT02882750|OTHER|EORTC QLQ-C30 (version 3.0).|Quality of Life Questionnaire
40920957|NCT02882750|OTHER|PS Q18|Patients Satisfaction Questionnaire
40920958|NCT02882750|OTHER|Decision Self-Efficacy Scale|Questionnaire
40920959|NCT06466408|DIETARY_SUPPLEMENT|Supplementation Protocol|After the pre-test, the enzyme group consumed 30 mL of vegetable and fruit enzymes (The contents include needle-leaf cherries, cherries, apples, cranberries, blackberries, black currants, blueberries, beets, broccoli, cabbage, carrots, Concord grapes, cranberries, elderberries, kale, oranges, peaches, papayas, parsley, pineapples, raspberries, red currants, spinach, and tomatoes, etc.)(Enzyme Village, Chiayi, Taiwan) mixed with 150 mL of water twice a day (at breakfast and dinner) for 14 consecutive days. The placebo group followed the same protocol but consumed malt syrup (Amazon, USA) instead until the end of the study. Participants returned to the laboratory each morning to receive the daily supplement, which was administered on-site. Following supplementation, participants reported their dinner intake to the researchers, ensuring compliance with the prescribed supplementation regimen.
40920960|NCT06466408|DIAGNOSTIC_TEST|Blood Lactate Test|The blood lactate was measured at five time points: before exercise, after the fourth and eighth bouts of exercise, and at 5 and 10 minutes after exercise. The blood lactate were analyzed using a Biosen Cline blood analysis system (EKF-diagnostic, Germany). Capillary blood samples of 10 μL were collected and added to red blood cell lysis reagent and stored at low temperature until analyzed. Prior to analysis, instrument standardization and test calibration were performed, and the coefficient of variation was determined to be ≤1.5%. The detection range for blood lactate was 0.5-40 mM
40920961|NCT06466408|DIAGNOSTIC_TEST|Training Impulse|In this study, the exercise load was represented by the TRIMP \[32\], which is calculated as the product of exercise intensity and duration. To accommodate the convenience of the experiment, two different TRIMP calculation methods were used, including % HRmax (objective) and RPE (subjective). At the end of each exercise bout (8 bouts in total) and during the recovery period before the next bout (7 bouts in total), participants were asked to report their RPE, and their heart rate was recorded. This process was repeated 8 times.
41269590|NCT05946343|DIAGNOSTIC_TEST|Surface Electromyography (sEMG) Assessment|Surface electromyography (sEMG) will be used to assess the activation patterns of scapular and rotator cuff muscles during functional tasks, such as shoulder flexion, abduction, and external rotation. The sEMG assessment will be conducted using a wireless sEMG system with a sampling rate of 2000 Hz and a bandwidth of 20-500 Hz. Pre-gelled, disposable, self-adhesive Ag/AgCl electrodes will be placed on the muscle belly according to SENIAM guidelines, with an inter-electrode distance of 20 mm.
41269591|NCT00206167|DRUG|Budesonide/formoterol pMDI|
41269592|NCT00206167|DRUG|Formoterol Turbuhaler|
41269593|NCT02484027|DRUG|Rosuvastatin|Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
41269594|NCT04749030|OTHER|Faecal microbiota transplantation (FMT) capsules|The faeces is minimally processed through a series of centrifugation steps and dispensed into double-coated, acid resistant enterocapsules. A single treatment includes approximately 22 capsules (\~50 grams of original donor faeces).
41269595|NCT04749030|OTHER|Placebo capsules|The placebo capsules are produced from a suspension of 50% glycerol, 40% sterile saline and 10% food coloring in enterocapusles
40758246|NCT06250426|DIETARY_SUPPLEMENT|Pre-thickened oral nutritional supplement with a cooling sensation flavour|Pre-thickened oral nutritional supplement (ONS) drink with cooling sensation flavour
40920962|NCT06466408|DIAGNOSTIC_TEST|Exergaming HIIE Test|The sensor system utilized two Nintendo controllers: one mounted on the exercise ring and the other secured to the participant's thigh to enhance gameplay interaction. Through the Ring-Con, participants engaged in diverse physical activities such as weightlifting, yoga, and aerobic exercises. The fitness ring sensor accurately captures and integrates players' movements into the game. The gameplay involves unlocking levels and engaging in fitness challenges that are achieved through actual physical activities. It offers a wide range of exercise routines targeting various muscle groups and provides engaging gaming challenges. The exercise protocol included eight sets of 20-second high-effort exercises, interspersed with 30-second rest intervals, totaling 370 seconds of active exercise time. Specifically, the fitness game mode used was the Adventure Mode in 'Ring Fit Adventure,' comprising exercises targeting the pectoralis major, latissimus dorsi, deltoids, and quadriceps muscles.
40920963|NCT02265159|PROCEDURE|Focal Therapy Using High Intensity Focused Ultrasound|
40920964|NCT03717870|PROCEDURE|Laparoscopic enucleation of ovarian endometrioma.|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
40920965|NCT03717870|PROCEDURE|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
40920966|NCT03717870|PROCEDURE|Assisted Reproductive Technology (ART)|Fresh ART cycle: ovarian stimulation, oocyte retrieval, in vitro fertilization and embryo transfer.
40920967|NCT02908490|DRUG|Sildenafil|Sildenafil 50 mg once daily
40920968|NCT02908490|OTHER|Placebo|Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
40920969|NCT01900210|BEHAVIORAL|WaySafe|
40920970|NCT00196846|DRUG|Goserelin|
40920971|NCT04136847|DEVICE|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
40920972|NCT04580641|OTHER|Questionnaire|A self-administered questionnaire will be completed by each study subject
40920973|NCT05468073|DRUG|Proleukin|Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks
40920974|NCT05468073|DRUG|Placebo|Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
40920975|NCT02296372|DEVICE|Continuous glucose monitoring|"Continuous glucose monitoring by subcutaneous or intravasal device for 72 hours.~In use MEDTRONIC SENTRINO® and Edwards GlucoClear® systems."
40920976|NCT02805504|DRUG|Exparel|This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
40920977|NCT02805504|DRUG|Marcaine|This group will receive intraoperative Bupivacaine HCl injection at the surgical site.
40920978|NCT03127332|OTHER|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their metastatic breast cancer patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
41269596|NCT01068444|DRUG|Pioglitazone|"1. Name: GLITOS（Pioglitazone）~2. Dosage form: Tablets~3. Dose(s): 30mg~4. Dosing schedule: QD~5. Duration: 6 months"
40920979|NCT02949479|BEHAVIORAL|Dissociation Investigation in Sex Offenders|prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools
40920980|NCT03741387|OTHER|Gain-frame questionnaire|Questionnaires focusing on the attitude of saving patients' lives were given to Rh negative blood donors in this group.
40920981|NCT03741387|OTHER|Loss-frame questionnaire|Questionnaires focusing on the attitude of preventing patients from death were given to Rh negative blood donors in this group.
40920982|NCT02102659|GENETIC|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium"
40920983|NCT02102659|GENETIC|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
40920984|NCT02735824|PROCEDURE|blood sampling and skin biopsy|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
40920985|NCT02735824|PROCEDURE|blood sampling or mouth swap|specimen will be used for genetic testing, results compared to patients
40920986|NCT02735824|PROCEDURE|blood sampling|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
40920987|NCT02213406|DIETARY_SUPPLEMENT|yogurt|Subjects will receive yogurt with varying fat concentrations
40920988|NCT02595645|GENETIC|Polypectomy and NGS|NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
40920989|NCT00755209|DRUG|tranexamic acid|Loading 1 gram (\~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (\~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
40920990|NCT01371279|DEVICE|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
40920991|NCT02294968|OTHER|Family Startup (in Danish: Familieiværksætterne)|Manualized parenting support program; see Center for Socialt Ansvar (2013)
40920992|NCT00338182|DRUG|AZD1152 part A|48-hour continuous intravenous infusion
40920993|NCT00338182|DRUG|AZD1152 part B|2-hour intravenous infusion
40920994|NCT03002090|DIETARY_SUPPLEMENT|Iron trained|"1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
40920995|NCT03002090|DIETARY_SUPPLEMENT|Iron Untrained|1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.
40920996|NCT03002090|DIETARY_SUPPLEMENT|BZKL Trained|"1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
40920997|NCT03002090|DIETARY_SUPPLEMENT|BZKL Untrained|1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.
40920998|NCT03002090|DIETARY_SUPPLEMENT|Placebo Trained|1. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
40920999|NCT03002090|DIETARY_SUPPLEMENT|Placebo Untrained|No intervention
40921000|NCT05139511|DEVICE|Study group|The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.
40921001|NCT05139511|OTHER|Control group|Same procedure but without energy
40921002|NCT04036292|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
41269597|NCT01068444|DRUG|placebo|placebo 30 mg/d for 6 months
40921003|NCT04036292|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
40921004|NCT04579887|OTHER|Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations|Parkinsonian patients will undergo a two distinct experimental sessions, conducted in two separate days. In day 1, they will complete a series of validated and lab-tailored clinical evaluations, alongside with semi-structured interviews. These tests are designed to assess, the extent of the movement disorder, the predominance of positive symptoms and presence hallucination, potential cognitive impairment, amongst other relevant measures, for sleep assessment, loneliness, apathy and depression. In day 2 patients will perform the described robotic manipulation task in the MRI.
40921005|NCT00078169|BEHAVIORAL|Behavior Therapy|
40921006|NCT00004005|DRUG|fluorouracil|
40921007|NCT00004005|DRUG|irinotecan hydrochloride|
40921008|NCT00004005|DRUG|leucovorin calcium|
40921009|NCT00004005|PROCEDURE|conventional surgery|
40921010|NCT00004005|RADIATION|radiation therapy|
40921011|NCT00866229|DRUG|Rosuvastatin|10 mg per day for 12 weeks
40921012|NCT00866229|DRUG|Simvastatin|20 mg per day
41269598|NCT03775707|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
41269599|NCT03775707|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
40921013|NCT03829423|DIAGNOSTIC_TEST|Breast MRI interpretation|Analysis and interpretation of breast MRI sequences by a specially developed breast MRI interpretation algorithm
40921014|NCT02220088|PROCEDURE|TAI of FOLFOX|Retreatment with TAI: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
40921015|NCT02220088|DRUG|Sorafenib|Accept sorafenib.
40921016|NCT04385329|OTHER|Shock wave therapy on plantar fascia extended to the gastrocnemius-soleus trigger points|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia and the gastrocnemius-soleus trigger points were clinically targeted and treated with a perpendicular technique.
40921017|NCT04385329|OTHER|Shock wave therapy on plantar fascia only|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia was clinically targeted and treated with a perpendicular technique.
40921018|NCT00321126|DRUG|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
40921019|NCT05519540|DRUG|Xevinapant (Debio 1143)|All participants (Japanese and non-Japanese East Asian) will receive single oral dose of xevinapant (Debio 1143) on Day 1.
40921020|NCT01964768|OTHER|Skin prick-test|
40921021|NCT00979667|DRUG|Oseltamivir|75 mg twice daily for 5 days
40921022|NCT00979667|DRUG|Zanamivir|10 mg twice daily for 5 days
40921023|NCT00979667|DRUG|Placebo of Oseltamivir|twice daily for 5 days
40921024|NCT05664568|DRUG|Cephalexin|Participants in intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
40921025|NCT05664568|DRUG|Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet|Participants in the intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
40921026|NCT05664568|OTHER|Standard of care treatment of tuberculosis|The control group will be given standard of care treatment of tuberculosis consisting of rifampicin, isoniazid, pyrazinamide and ethambutol
40921027|NCT02906982|OTHER|Gum health formulation in intra-oral device|The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
40921028|NCT02906982|OTHER|Gum health formulation on toothbrush|The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
40921029|NCT02280798|PROCEDURE|Endometrial Biopsy|4 endometrial biopsy
40921030|NCT05813223|DRUG|Gefapixant|Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.
40921031|NCT00097981|DRUG|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
40921032|NCT00097981|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
40921033|NCT00097981|DRUG|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
40921034|NCT03316911|BEHAVIORAL|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
40921035|NCT01764139|PROCEDURE|Blood sampling|
40921036|NCT00618345|DRUG|everolimus|
40921037|NCT00618345|GENETIC|DNA analysis|
40921038|NCT00618345|GENETIC|protein analysis|
40921039|NCT00618345|GENETIC|western blotting|
40921040|NCT00618345|OTHER|flow cytometry|
40921041|NCT00618345|OTHER|laboratory biomarker analysis|
40921042|NCT00618345|PROCEDURE|biopsy|
40921043|NCT04155242|DIAGNOSTIC_TEST|Cytosponge test|The Cytosponge will be administered by the study nurse prior to the participant having the endoscopy, usually as part of the same visit to hospital. The capsule along with the string is swallowed by drinking a small glass of water. The participant is asked to hold the Cytosponge in situ for 5 minutes. The sponge contained within expands and is then drawn back by the research nurse up the oesophagus by the attached string, collecting cells as it moves upwards. This device received a letter of no objection by the MHRA for use in the BEST pilot trial (LRQ 0939857) but it is not CE marked. Cytosponge and research endoscopic biopsies will be couriered to the Fitzgerald laboratory, at the MRC Cancer Cell Unit on a regular basis. The specimens will be processed in conjunction with the Cambridge University Hospitals' NHS Foundation Trust tissue bank which is accredited to GLP standards.
40921044|NCT04155242|DIAGNOSTIC_TEST|Assessment of the panel of molecular biomarkers: IM-SCORE, TFF3 protein expression, methylation panel, p53 mutation|Molecular analysis of the specimen obtained by Cytosponge or endoscopic biopsies - TFF3 protein expression, methylation panel, p53 mutation. Endoscopic biopsies will be assessed for the presence of IM (according to the IM-score).
40921045|NCT04155242|DIAGNOSTIC_TEST|Oesophagogastroduodenoscopy|"* Endoscopy will be carried out with white light and NBI with optical magnification or near focus to inspect oesophagus and GOJ.~* NBI magnification will be used to assess systematically the mucosal pit pattern at the GOJ and to look for light blue crest (LBC) sign.~* Targeted biopsies will be taken from either areas with LBC or irregular pit pattern on NBI, followed by random biopsies as per clinical standard. A maximum of 6 biopsies will be taken at the GOJ (maximum 4 targeted and 4 random.. During the first 2 post RFA follow up, at discretion of the endoscopists, neo-suqamous biopsies can be taken in line with local policies.~* Argon plasma coagulation ablation is allowed in a single island up to 5mm or up to 3 islands \<3mm within the study endoscopy as long as this does not represent an obstacle to GOJ biopsies."
40921046|NCT02122068|BEHAVIORAL|Mentalizing Imagery Therapy|4 week long meditation and mindfulness intervention
40921047|NCT02122068|BEHAVIORAL|Relaxation cd|
40921048|NCT06079229|OTHER|Phone call|The only follow-up visit provided for in the protocol was a telephone contact 3 to 30 months after the patient's surgery. The rest of the data required for the study were obtained from the patient's medical records, collected in the course of routine practice.
40921049|NCT02117128|DRUG|Tranexamic acid|
40947736|NCT03339687|BEHAVIORAL|Experimental Mindset Induction|"This induction of a psychological state was extensively studied in cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list positive and negative, short- and long-term consequences of both deciding to act and not to act; indicating the probability of the occurrence of each of these consequences is required.~The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
40947737|NCT01497275|DRUG|Rituximab, Bortezomib,Y90 ibritumomab tiuxetan|Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
40947738|NCT01768052|DEVICE|functional Near Infrared Spectroscopy|fNIRS monitoring during rTMS treatment sessions.
40947739|NCT01210131|DRUG|[18F]HX4|Intravenous injection
40947740|NCT05863273|DRUG|Apremilast|Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
40947741|NCT01254630|BIOLOGICAL|V212|V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.
40947742|NCT01254630|BIOLOGICAL|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
40947743|NCT01658631|DEVICE|arterial pressure measurement (Nexfin, a noninvasive finger cuff system)|
40921050|NCT00435500|DRUG|Fluoride varnish|
40921051|NCT05921045|OTHER|modification of clinical approach in clinical practice at time 0|evaluation of modification in clinical approach after training
40921052|NCT05921045|OTHER|modification of clinical approach in clinical practice at 6 months|evaluation of modification in clinical approach after retraining
40921053|NCT02490345|DRUG|gabapentin|gabapentin usage as adjunctive treatment for pain control
40921054|NCT02490345|DRUG|Placebo|Identical placebo
40921055|NCT01967498|DRUG|Montelukast|
40921056|NCT05622747|OTHER|Passive heating|1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C)
40921057|NCT01426542|DRUG|Topiramate|Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
40921058|NCT01426542|OTHER|No medication, but routine heart surgery|No medication, but routine heart surgery
40921059|NCT03763513|DEVICE|ESWT|Extracorporeal Shock Wave Therapy=ESWT
40921060|NCT03763513|OTHER|Kinesiotaping Application|Kinesiotaping=KT (CT)
40921061|NCT04982003|OTHER|exercise|10 weekly hour-long classes of drumming to music using large-amplitude, whole-body movements
40921062|NCT00117052|DRUG|cinacalcet|All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
40921063|NCT00243646|RADIATION|External beam radiation|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
40921064|NCT00243646|DRUG|Lupron|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
40921065|NCT00243646|DRUG|Casodex|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
40921066|NCT03381794|PROCEDURE|Corneal transplantation|PKP: Penetrating Keratoplasty DALK: Deep Anterior Lamellar Keratoplasty DMEK: Descemet Membrane Endothelial Keratoplasty DSAEK: Descemet's Stripping Automated Endothelial Keratoplasty
40921067|NCT00472680|BEHAVIORAL|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
40921068|NCT00472680|BEHAVIORAL|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
40921069|NCT00472680|BEHAVIORAL|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
40921070|NCT05917431|COMBINATION_PRODUCT|SBRT plus tislelizumab and regorafenib|Participants will receive SBRT plus tislelizumab and regorafenib concurrently
40921071|NCT03467100|DRUG|XEN901|Capsule filled with XEN901
40921072|NCT03467100|DRUG|Inert Ingredients Oral Product|Placebo capsule
40921073|NCT00665314|DRUG|Plerixafor (AMD3100)|0.24mg/kg SC for 2 to 7 days.
40921074|NCT00665314|DRUG|Can be any registered nonpegylated form of G-CSF|10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
40921075|NCT04618627|OTHER|lung ultrasound|Role of lung ultrasonography in prediction of the seveity and the need for surfactant administration in neonates with respiratory distress syndrome.
40921076|NCT05705089|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15 MG once daily orally + Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
40921077|NCT05705089|DRUG|Warfarin|Warfarin (to reach an INR goal of 2-2.5)+ Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
40921078|NCT00862797|OTHER|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
40921079|NCT03496714|BEHAVIORAL|Psychoeducation on trauma reactions|The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.
40921080|NCT03496714|BEHAVIORAL|Psychoeducation on safety behaviors|The psychoeducation handout and video on safety behaviors will discuss safety behaviors that are common in PTSD and tips for how to eliminate them.
40921081|NCT04320758|OTHER|conventional preparation design|chamfer finish line
40921082|NCT04320758|OTHER|biologically oriented preparation technique|shoulder less preparation design
40921083|NCT03444480|DRUG|Remimazolam Tosylate|Initial dose plus supplemental doses
40921084|NCT03940768|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v|Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.
40921085|NCT03940768|DIETARY_SUPPLEMENT|Placebo|Administration of placebo in cancer patients who receive home enteral nutrition.
40921086|NCT01610999|DRUG|Plerixafor|Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
40921087|NCT03541915|DRUG|Mg (magnesium sulfate)|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
40921088|NCT03541915|DRUG|Control (saline)|The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.
40921089|NCT06192394|OTHER|Chewing Gum|Patients will be asked to chew xylitol gum for 20 minutes every 2 hours (17.00-19.00, 19.00-21.00, 21.00-23.00) after drinking the X-M Diet syrup prescribed the day before the colonoscopy procedure. After the enema is given on the day of the colonoscopy, they will be asked to chew gum for 20 minutes every 2 hours until one hour before the scheduled procedure time. Xylitol is a naturally occurring five-carbon sugar alcohol (C5H12O5) found in fruits and vegetables such as plums, strawberries, cauliflower, and pumpkin. It is similar in taste to sucrose but contains 40% fewer calories than other carbohydrates (1 gram of xylitol = 2.4 calories). Xylitol has positive effects on dental health and may also have beneficial impacts on other systems such as immunity, respiratory, and digestive systems. Since xylitol is not digested by human enzymes, it has a laxative effect. In the study, sugar-free gum with xylitol will be used.
40921090|NCT06192394|OTHER|Walking Exercise|Patients will be given a pedometer to count their steps and will be asked to walk at least 3000 steps before the colonoscopy procedure.
40921091|NCT06192394|OTHER|Control|Patients will undergo standard bowel preparation determined by the hospital.
40921092|NCT02710955|DIETARY_SUPPLEMENT|Thickened infant formula|
40921093|NCT00038389|DRUG|Vioxx|Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
40921094|NCT03460509|DRUG|Sugammadex|Dose-response
41093838|NCT05656313|DEVICE|Measure of subjective speech intelligibility and listening effort in noisy situation with speech from the side and from behind (subjective assessment; 100-point scale)|"In addition to the tests mentioned above a subjective assessment will be used to determine the subjective perception as this measure is often a good indication for clinical relevance.~For this purpose, the same speech material as used in the HEISS-test is presented by a loudspeaker in the same noisy environment as in the other three tests. The subjects rate his/her perception of the presented speech using a questionnaire on the dimensions listen effort and speech intelligibility. The subject will rate his perception on the 100 point scale with pencils with different colors to get either absolute and relative ratings.~The subjective assessment will be repeated four times for the secondary objective: 2 test conditions (Rference and novel approach) against 2 target directions (better ear side, back). Following data are provided from assessment: rating on a 100-point scale per condition and per dimension."
40921095|NCT01191567|PROCEDURE|VAC treatment|wound treatment with VAC-therapy
40921096|NCT01191567|PROCEDURE|Conventional treatment|wound treatment with conventional treatment according to the hospitals local routines
40921097|NCT04650451|BIOLOGICAL|chimeric antigen receptor (CAR) T cell therapy|HER2-targeted dual-switch CAR-T cells
40921098|NCT02228616|DRUG|Prucalopride|During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
41093839|NCT05126602|DIETARY_SUPPLEMENT|Vitamin D3 10000 IU|Tablet of 5000 IU of vitamin D3 given twice daily
41269600|NCT03168867|BEHAVIORAL|The 3Ms Intervention|The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
40921099|NCT02228616|DRUG|Polyethylene glycol (PEG)|Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
40921100|NCT02228616|DRUG|Lactulose|Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
40921101|NCT05035602|OTHER|Physical activity assessment|Physical activity patterns will be obtained from google location history, using an Android phone
41093840|NCT05126602|DIETARY_SUPPLEMENT|Vitamin D3 1000 IU|Tablet of 1000 IU of vitamin D3 given once daily
41093841|NCT04717882|DEVICE|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient.
41269601|NCT02747485|DEVICE|Cardiac MRI|
41269602|NCT02747485|BIOLOGICAL|blood samples|Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
41269603|NCT02747485|PROCEDURE|myocardial biopsy|
41269604|NCT02747485|GENETIC|blood samples|extract DNA to look for genomic mutations associated with the disease.
40921102|NCT04332861|OTHER|Initial clinical and laboratory evaluation|"Initial evaluation, prior to administration of any antibiotics if possible, includes history, physical exam, and labs including:~* Urinalysis~* Urine culture~* Blood cultures~* Complete blood count with differential~* Comprehensive metabolic panel~* Lactate~* Procalcitonin~* Other inflammatory markers"
40921103|NCT03950921|BEHAVIORAL|Patient Safety Display|Digital display of catheter and pressure injury information in patient hospital room
40921104|NCT04623853|DEVICE|Variable Stiffness AFO|The Dynamic AFO is able to adjust in stiffness depending on activity.
40921105|NCT04427332|OTHER|Investigation of smell and taste disorders|The study consists of an epidemiological investigation by means of a prospective observational study with the aim of investigating the demographic and clinical factors related to the sense of smell and taste in patients with Sars Cov 2 infection.
40921106|NCT00761644|DRUG|Doxil|Day 1 of each 21 day cycle, beginning dose level 10 mg/m\^2 by vein over 3 hours.
40921107|NCT00761644|DRUG|Bevacizumab|Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
40921108|NCT00761644|DRUG|Temsirolimus|Days 1, 8 \& 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
40921109|NCT00870103|DRUG|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
40921110|NCT04113369|DEVICE|TENS|30 minutes of conventional antalgic TENS to non-paretic forearm
40921111|NCT04113369|PROCEDURE|Conventional rehabilitation|40 minutes of lower limb training and 20 minutes of upper extremity training for stroke
40921112|NCT04113369|DEVICE|EMS|20 minutes of EMS to non-paretic forearm with 5 minutes of pre and post warm-up
40921113|NCT02224196|OTHER|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
40947744|NCT00122109|BEHAVIORAL|12 sessions Anger Management Therapy.|Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
40947745|NCT00917111|DRUG|Nasal CO2|Four times a day for 14 days
40921114|NCT02224196|OTHER|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
40921115|NCT03062254|DRUG|radium-223 dichloride|6 doses of Radium-223
40921116|NCT02777320|DRUG|paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
40921117|NCT02777320|DRUG|Ibuprofen|400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
40921118|NCT02130102|DEVICE|The ModuLAAr Ambient Assisted Living System|"The system consists of the following modules which will be provided to the volunteers according to their needs:~tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies"
40921119|NCT03337828|OTHER|Alcohol-free beer with regular composition|Subjects are provided with 2 alcohol-free beers with regular carbohydrates composition per day and healthy diet counselling during 10 weeks.
40921120|NCT03337828|OTHER|Alcohol-free beer with modified composition|Subjects are provided with 2 alcohol-free beers with modified carbohydrates composition per day and healthy diet counselling during 10 weeks.
40921121|NCT02142387|OTHER|BLS CPR program with dispatcher assisted CPR simulation|the training program more focuses on cooperation with a dispatcher, from recognition to perform DA-CPR and hands-on practice.
40921122|NCT00167778|DEVICE|Transverse plane rotation adaptor pylon|Potential future practice
40921123|NCT00167778|DEVICE|Rigid pylon|Current clinical practice
40921124|NCT00295386|BEHAVIORAL|Cognitive behavior therapy (CBT)|
40921125|NCT00295386|DRUG|Zopiclone|
40921126|NCT02615626|PROCEDURE|Non-surgical Periodontal Treatment.|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
40921127|NCT00815555|OTHER|There is no intervention - this is an observational study|
40921128|NCT05723471|OTHER|Adaptative Physical Activity|12 weeks of a collaborative program of customized, adaptative and supervised physical activity by sports instructor
40921129|NCT02594995|DRUG|NBP|
40921130|NCT05525078|BEHAVIORAL|e-cigarette|Participants will select a Target Switch on which they will stop smoking cigarettes and switch entirely to the e-cigarette product.
40921131|NCT05525078|OTHER|Nicotine patch, Nicotine lozenge|Participants will select a Target Quit Date on which they will stop smoking, using the patches and lozenges provided.
40921132|NCT04915378|OTHER|hypoxia altitude simulation test (HAST) at 760m|Normobaric hypoxia at a FiO2 of 15.1% will be generated by the Everest Summit II altitude generator (Hypoxico Altitude Training Systems, Bickenbach, Germany) and delivered to the patients face via tubes and a tightly fitted mask. Patients will be seated comfortably in a chair and fitted with a full-face mask equipped with a one-way valve. After a baseline period of quiet rest of 5-10 min with ambient air breathing and installation of equipment, patients will breath the hypoxic air mixture via a tightly fitted facial mask. They will be monitored with a finger-tip pulseoximetry to continuously assess SpO2 and heart rate. After at least 15' and steady-state values of the SpO2 (±1%) for at least 5' arterial blood gases will be drawn from a radial artery and immediately analyzed (RapidPoint 500, Siemens, Zürich, Switzerland).
40921133|NCT04915378|PROCEDURE|High Altitude (3100m)|High Altitude (3100m) exposure for 2 days
40921134|NCT01410617|PROCEDURE|hemodialysis|3 sessions hemodialysis before CABG
40921135|NCT05732402|DRUG|povetacicept|Administered by subcutaneous injection every 4 weeks
40921136|NCT05732402|DRUG|povetacicept|Administered by subcutaneous injection every 4 weeks
40921137|NCT02524834|PROCEDURE|Exclusion of thoracoabdominal lesion|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
40921138|NCT02524834|DEVICE|Endovascular Device Implant|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
40921139|NCT06276738|DIAGNOSTIC_TEST|LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas)|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.
40921140|NCT06394934|BEHAVIORAL|Healthscan App|Participants will use the Healthscan mobile application to monitor and record their daily blood pressure at home. The app allows participants to enter their BP measurements, which are then used to calculate blood pressure variability (BPV). The app's use is intended as a non-invasive, practical tool for patient self-management and longitudinal health monitoring in hypertensive individuals.
41269605|NCT06354933|DIAGNOSTIC_TEST|Neurological Soft Signs|Neurological Soft Signs score according to the Heidelberg Manual
41269606|NCT01413958|DRUG|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
40921141|NCT03372759|PROCEDURE|airtamponade|airtamponade is applicated in the study group air
40921142|NCT03372759|PROCEDURE|saline|saline is left in the study Group saline
41269607|NCT01413958|DRUG|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
41269608|NCT01413958|DRUG|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
41269609|NCT03975192|DEVICE|Percutaneous Electrical Nerve Field Stimulation|Placement of the PENFS device immediately following the last scheduled opiate dose in the PICU with active stimulation for 120 hours.
40921143|NCT04617431|BEHAVIORAL|Mobile health application and social media|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
40921144|NCT04668612|DEVICE|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m.
40921145|NCT04668612|DEVICE|Standard bolus|Standard boluses for all meals
40921146|NCT01696682|PROCEDURE|Narrowed Gastric Conduit|The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
40921147|NCT01696682|PROCEDURE|Widened Gastric Conduit|A widened gastric tube will be formed during the surgery
40921148|NCT01447667|PROCEDURE|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
40921149|NCT05767567|BEHAVIORAL|Brief Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
40921150|NCT02149849|PROCEDURE|Modified lateral positioning.|Right before surgery, the patient are posistioned in lateral position with arm elevated (not more than 90 degree from torso). In the intervention, the arm will be lowered and placed in towards the torso for patients enrolled in the experimantal arm.
40921151|NCT00000496|DRUG|aspirin|
40921152|NCT00000496|DRUG|dipyridamole|
40921153|NCT05286645|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
40921154|NCT05286645|DEVICE|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
40921155|NCT02431260|DRUG|INCB054329 Monotherapy|Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria
40921156|NCT03968640|DIETARY_SUPPLEMENT|CoQ10|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
40921157|NCT03968640|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
40921158|NCT06286254|DRUG|Cycloferone|Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
40921159|NCT04642157|OTHER|ELIOS|"ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media.~This includes~* A systematic initial contact with an ELIOS web-clinician~* Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk~* The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician"
40921160|NCT04642157|OTHER|other resources contacts|"Three types of resources will be suggested via the ELIOS website:~* The General Practitioner (GP)~* The closest medico-psychologic center (CMP)~* The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation."
40921161|NCT05484544|DIAGNOSTIC_TEST|High sensitivity troponin T|Collection of hs-cTnT samples
40947746|NCT00917111|DRUG|Inactive Placebo Gas|Placebo
41269610|NCT00460980|BEHAVIORAL|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
40921162|NCT01911910|BEHAVIORAL|Electronic coaching plus standard care|The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
40921163|NCT03984461|BIOLOGICAL|Autologous cell therapy|Biologic material is harvested from the participant and re-injected into an osteoarthritic joint
40921164|NCT04124497|DRUG|Daratumumab|"* Daratumumab 16 mg/kg intravenously at following schedule:~* cycle 1 and 2: days 1, 8, 15, and 22~* cycle 3 through 6: days 1, and 15~* from cycle 7 until disease progression: day 1."
40921165|NCT04124497|DRUG|Pomalidomide|4 mg once daily on days 1-21
40921166|NCT04124497|DRUG|Dexamethasone|Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (\>75 years old) on days 1, 8, 15 and 22
40921167|NCT02765009|DRUG|diuretics|Used to reduce fluid overload as evidenced by weight gain
40921168|NCT02765009|DRUG|albumin|Used to reduce fluid overload in addition with diuretics in hypoalbuminemic patients
40921169|NCT02765009|OTHER|fluid restriction|Used to reduce fluid overload
40921170|NCT02765009|DEVICE|renal replacement|Used to reduce fluid overload in patients with renal replacement
40921171|NCT04851093|DRUG|TCM granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks."
40921172|NCT04851093|DRUG|TCM placebo granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Placebo Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Placebo Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Placebo Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM placebo granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The placebo granule consists of dextrin, bitter and 5% of the TCM granule."
40921173|NCT01014923|BEHAVIORAL|Teen driving intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
40921174|NCT05873907|DRUG|AMG 592|Administered as SC injection
40921175|NCT05873907|OTHER|Placebo|Administered as SC injection
40921176|NCT04698096|OTHER|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
41269611|NCT01964404|DRUG|Marijuana|Smoked plant with THC
41269612|NCT01964404|DRUG|Dronabinol|Capsule with THC
40921177|NCT04698096|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
40921178|NCT04698096|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
40921179|NCT04367051|DRUG|Withdrawal of Spironolactone|Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
40921180|NCT04367051|DRUG|Continuation of spironolactone|Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
40921181|NCT06081322|DRUG|PRRT with 177Lu-EB-FAPI|PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue
40921182|NCT01210040|DIETARY_SUPPLEMENT|Folic Acid|2.8mg
40921183|NCT01210040|DIETARY_SUPPLEMENT|Folic Acid and Iron|60mg Iron and 2.8mg Folic Acid
40921184|NCT05611294|DEVICE|Topography Guided LASIK Surgery|LASIK surgery, using corneal topography data in treatment profile, to correct myopia or myopia with astigmatism refractive error.
40921185|NCT05611294|DEVICE|Small Incision Lenticule Extraction Surgery|Corneal lenticule formation using a femtosecond laser, with subsequent lenticule extraction, to correct myopia or myopia with astigmatism refractive error.
40921186|NCT01303224|DRUG|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
40921187|NCT01303224|DRUG|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
40921188|NCT01303224|DRUG|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
40921189|NCT01303224|DRUG|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
40921190|NCT05634447|DRUG|Drug: CKD-391, QD, PO|Drug: CKD-331, D337 QD, PO
40921191|NCT03428919|PROCEDURE|ICSI|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
40921192|NCT03428919|PROCEDURE|IVF|In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
40921193|NCT03010436|DRUG|Benralizumab|one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.
40921194|NCT00511940|DRUG|acamprosate|999 mg/day - 2997 mg/day, oral
40921195|NCT00511940|OTHER|placebo|oral, placebo
40921196|NCT01467687|DRUG|verapamil controlled release|verapamil 300 mg controlled release capsule as a single dose
40921197|NCT05903209|DEVICE|Chang Gung Pneumothorax Detection Software|"The Chang Gung Pneumothorax Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pneumothorax. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pneumothorax.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
40921198|NCT01734889|DRUG|Nitisinone|Oral suspension
40921199|NCT01105065|DRUG|brimonidine 0.15%|One drop in each eye three times a day for 8 weeks.
40921200|NCT04508140|PROCEDURE|Hepatic Biopsy|In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.
40921201|NCT04508140|DRUG|BO-112 with Pembrolizumab|. The study treatment consists of the combination of BO-112 given intratumorally inside the liver metastasis at the dose of 1gm in 1.2 mL in combination with intravenous pembrolizumab given at the fixed dose of 200 mg. This treatment will be given every 3 weeks, with a maximum duration of 35 cycles (2 years). Of note, during the first cycle, BO-112 will be administered on D1 and D8.
40921202|NCT04271644|BIOLOGICAL|BCMA CAR-T cells|BCMA CAR-T cell therapy
41269613|NCT01964404|DRUG|Placebo|Capsule with no active ingredient
41269614|NCT02627040|DEVICE|InterTan Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail
41269615|NCT02627040|DEVICE|Gamma 3 Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
40921203|NCT00543244|DRUG|Pegylated interferon alfa and ribavirin|"Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: \< 75 kg 1000 mg/day, \>=75 kg 1200 mg/day; genotype 2: 800 mg/day)~HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)"
40921204|NCT05265780|PROCEDURE|kinesiotape|an elastic adhesive tape
40921205|NCT05265780|PROCEDURE|sham taping|a sham taping without the tension
40921206|NCT05948865|DRUG|CPO301|Administered by intravenous injection
40921207|NCT00427115|BEHAVIORAL|Multimodal exercise and psychosocial program|
40921208|NCT06427135|BEHAVIORAL|Exercise interventions|Rehabilitation physician or rehabilitation therapist, to engage in physical exercise or patients, according to the medical examination data (including exercise test and physical strength test), according to their health, physical strength, and cardiovascular function status, with the form of a prescription for the type of exercise, intensity of exercise, exercise time and frequency of exercise, to put forward the precautions to be taken during exercise.
40921209|NCT01797406|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
40921210|NCT01797406|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
40921211|NCT06349759|DRUG|phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist|Once daily dosing
40921212|NCT06349759|DRUG|Placebo|Once daily dosing
40921213|NCT03083444|DIAGNOSTIC_TEST|Ultrasound|Measurement of thickness of radial artery wall thickness by ultrasound
40921214|NCT06212258|PROCEDURE|Abdominal Laparascopy|pneumoperitoneum
40921215|NCT05330910|PROCEDURE|Laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
40921216|NCT05330910|PROCEDURE|Laparoscopic sleeve gastrectomy arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
41269616|NCT00345605|DRUG|Sodium Phenylbutyrate|None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
41269617|NCT00345605|DRUG|Arginine|Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
40921217|NCT05761795|DRUG|IVMED 85|Eye drop
40921218|NCT05761795|DRUG|Placebo|Placebo eye drop
41269618|NCT05302635|OTHER|Simulated group|"Students will be given training on nasogastic tube insertion and practice will be demonstrated in the laboratory based on the demonstration method and checklists, and will continue until students learn. Forms will be applied to students as a pre-test. A pilot scenario will be applied to two volunteer fourth year students.~Prebriefing: Students will be informed. Students will implement the scenario in the simulation laboratory and will wear uniforms. The student will be given 5 minutes for preparation, the application will be taken one by one and 15 minutes will be given for practice. Researchers will only observe during this time. During the application, the student will be scored according to the checklist. Students will be recorded with video.~Debriefing: Immediately after the end of the scenario, a debriefing session will be held with groups of 5 people. Feedback will be given on students' performance. Each session will last 20-30 minutes. Students will be given a post-test."
40921219|NCT00484744|DRUG|Acetaminophen|
40921220|NCT00484744|DRUG|Avicel (placebo)|
40921221|NCT00484744|DRUG|Ibuprofen|
40921222|NCT02980809|DRUG|Apatinib|
40921223|NCT02980809|DRUG|Topotecan|
40921224|NCT01129024|DRUG|Lusutrombopag|tablet
40921225|NCT03686267|OTHER|opaqued titanium abutments|masking metallic color of titanium abutments by opaque porcelain
40921226|NCT03686267|OTHER|lithium disilicate coping (high opacity)|masking metallic color of titanium abutments using lithium disilicate copings
40921227|NCT03686267|OTHER|titanium abutment with no color masking|color masking methods are avoided in this arm
40921228|NCT00643084|PROCEDURE|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
40921229|NCT00643084|PROCEDURE|standard bowel preparation|standard bowel preparation
40921230|NCT02821663|BEHAVIORAL|vocal intervention|10 x 60 min. sessions of vocal intervention
40921231|NCT01489241|PROCEDURE|Telemonitoring|Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
40921232|NCT01757340|BEHAVIORAL|Weight loss with normal protein and leucine intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
40921233|NCT01757340|BEHAVIORAL|Weight loss with protein/leucine supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
40921234|NCT05228379|PROCEDURE|Small Bowel Capsule Endosocopy|A wireless capsule is ingested by the patient. It moves passively along with the peristaltic movements to capture images of the small intestine. The images are processed and recorded by data recorder worn on a belt. The recorded images are downloaded and analyzed by the computer software.
40921235|NCT06058208|BEHAVIORAL|Olfactory stimulation|Olfactory stimulation: Mothers will be made to smell their babies' odor.
40921236|NCT06058208|BEHAVIORAL|Visual stimulation|Mothers will be shown video images of their babies.
40921237|NCT02600819|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
40921238|NCT02600819|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily
40921239|NCT06530472|OTHER|Monitoring|At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.
40921240|NCT03005210|DRUG|Magicbuvir Plus|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
40921241|NCT03005210|DRUG|Harvoni (fist dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
40921242|NCT03005210|DRUG|Harvoni (second dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
40921243|NCT00307008|BIOLOGICAL|Pneumovax 23™|Single dose intramuscular injection
40921244|NCT00710125|DRUG|GPX-150 for Injection|Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
40921245|NCT02788279|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
40921246|NCT02788279|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
40921247|NCT02788279|DRUG|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
40921248|NCT04049409|DRUG|CMAB809|CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
40921249|NCT04049409|DRUG|Trastuzumab|Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
40921250|NCT00007059|DRUG|mycophenolate mofetil|
40921251|NCT06335745|BEHAVIORAL|PediCARE Intervention|A household material hardship intervention with monthly, direct provision of groceries and transportation. Resources will be centrally administered by the Dana-Farber Cancer Institute study team.
40921252|NCT00274092|DRUG|tiotropium inhalation capsules (18 mcg once daily)|
40921253|NCT00274092|DRUG|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
40921254|NCT01870323|BEHAVIORAL|SMART Behavioral Group|Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
40921255|NCT01870323|BEHAVIORAL|SMART Informational Group|Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
40921256|NCT05473585|OTHER|very low nicotine content cigarettes|Investigational combusted cigarettes with very low nicotine content
40921257|NCT05473585|OTHER|normal nicotine content cigarettes|Investigational combusted cigarettes with normal nicotine content
40921258|NCT05473585|OTHER|Study e-cigarette|E-cigarette provided by study
40921259|NCT01710540|OTHER|Metformin GSK 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
40921260|NCT01710540|OTHER|Gluocophage 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
40921261|NCT00000375|DRUG|Nortriptyline-lithium (NOR-Li)|
40921262|NCT00000375|PROCEDURE|Bilateral electroconvulsive therapy (ECT)|
40921263|NCT00000375|DRUG|Continuation therapy|
40921264|NCT00000375|BEHAVIORAL|Continuation ECT|
40921265|NCT02366364|DRUG|Placebo|Single oral administration of placebo consumption on Day 1
40921266|NCT02366364|DRUG|NRX-1074 375 mg|Single oral administration of 375 mg consumption on Day 1
40921267|NCT02366364|DRUG|NRX-1074 500 mg|Single oral administration of 500 mg consumption on Day 1
40921268|NCT02366364|DRUG|NRX-1074 750 mg|Single oral administration of 750 mg consumption on Day 1
40921269|NCT05289167|DRUG|Cyclophosphamide|50 mg/kg IV over 1 hour on Day +3 and +4
40921270|NCT05289167|DRUG|Abatacept|"Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28"
40921271|NCT05289167|DRUG|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
40921272|NCT02166944|DRUG|tamoxifen 40 mg daily for one year|both arms with riluzole daily
40921273|NCT02161692|DRUG|Cyclophosphamide|
40921274|NCT02161692|DRUG|Etoposide|
40921275|NCT02161692|DRUG|Cisplatin|
40921276|NCT02161692|DRUG|Bleomycin|
40921277|NCT02161692|DRUG|Carboplatin|High dose carboplatin
40921278|NCT02333864|DEVICE|POGO® BGMS|SMBG
40921279|NCT02551991|DRUG|nal-IRI|
40921280|NCT02551991|DRUG|5 fluorouracil|
40921281|NCT02551991|DRUG|Leucovorin|
40921282|NCT02551991|DRUG|Oxaliplatin|
40921283|NCT01436617|OTHER|blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test
40921284|NCT04769180|OTHER|Evaluation of extraintestinal manifestations|The researchers evaluated the prevalence and kind of extraintestinal symptoms in NCWS patients and the possible relationship between the clinical, serological, genetic and histological characteristics of the NCWS patients and the number and kind of extraintestinal manifestations, using, as control groups, CD and IBS patients.
40921285|NCT02045030|DRUG|aflibercept + FOLFIRI|Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
40921286|NCT02154828|BEHAVIORAL|Integrative practices|
40921287|NCT01937429|DEVICE|Colonoscopy with blue Indigo Carmin®|
40921288|NCT01937429|DEVICE|Standard colonoscopy with insufflation of air|
40921289|NCT00407680|DRUG|Intensive therapy Valsartan,Fluvastatin|
40921290|NCT03943537|DRUG|Intranasal Insulin|40 units Novolin R administered intranasally using ViaNase device.
40921291|NCT02358356|DRUG|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
40921292|NCT02358356|DRUG|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
40921293|NCT02358356|DRUG|Temozolomide|temozolomide 75mg/m2 b.i.d.
40921294|NCT01248104|DRUG|Tranexamic Acid|Infusion during cardiac surgery
40921295|NCT01248104|DRUG|Aminocaproic Acid|Infusion during cardiac surgery
40921296|NCT02789267|OTHER|Regular dietary support|Systematic and regular dietary support after radiotherapy
40921297|NCT03068351|DRUG|RO6870810|RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram \[mg/kg\] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
40921298|NCT03068351|BIOLOGICAL|daratumumab|Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
40921299|NCT05673798|OTHER|initial chemotherapy response|Initial chemotherapy response is the first imaging examination of SCLC patient after starting chemotherapy
40921300|NCT02076425|BEHAVIORAL|PCIT-ED|
40921301|NCT02081859|DEVICE|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
40921302|NCT02081859|OTHER|Conventional Criteria|
40921303|NCT01779817|BEHAVIORAL|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.|
40921304|NCT04160975|BEHAVIORAL|Video about safety and effectiveness of adult seasonal flu vaccination|The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
40921305|NCT01542567|DRUG|Abitren|SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
40921306|NCT01542567|DRUG|Placebo|Placebo suppositories
40921307|NCT05698875|OTHER|High glycaemic load breakfast meal|Breakfast meal
40921308|NCT05698875|OTHER|High glycaemic load breakfast meal with additional 10g protein|Breakfast meal
40921309|NCT05698875|OTHER|Medium glycaemic load breakfast meal|Breakfast meal
40921310|NCT03207373|DIAGNOSTIC_TEST|Stress test (ECG)|Every study participant undergoes a standard diagnostic stress ECG
40921311|NCT04608539|DRUG|Ferric Derisomaltose|Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1
40921312|NCT04608539|DRUG|Ferrous sulfate|Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up
40921313|NCT04608539|DRUG|normal saline|Single-dose infusion (placebo), postoperative day 1
40921314|NCT05395793|OTHER|Support Group|Support Group with moderator
40921315|NCT00333346|DRUG|Administration of tramadol intravenously|
40921316|NCT05947292|PROCEDURE|Ultrasound-Guided Fascia Iliaca Compartment Nerve Block|Patient's who receive this intervention will have an ultrasound-guided fascia iliaca compartment nerve block performed in the Emergency Department.
40921317|NCT05562401|DEVICE|Coconut Water|Coconut water is the clear fluid inside the coconut, has natural electrolytes such as potassium, sodium and manganese.
40921318|NCT05562401|DRUG|Sport Drink|A type to sport drink is isotonic drink. Is an industrialized drink that containing water, carbohydrates, and 4-8% electrolytes.
40921319|NCT02512484|PROCEDURE|venepuncture, sputum collection, xray|venepuncture, sputum collection, xray
40758247|NCT06250426|DIETARY_SUPPLEMENT|Pre-thickened oral nutritional supplement without a cooling sensation flavour|Pre-thickened oral nutritional supplement (ONS) drink without cooling sensation flavour
40921320|NCT01115192|PROCEDURE|Group A|Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
40921321|NCT01115192|PROCEDURE|Group B|Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
40921322|NCT02480036|RADIATION|IORT with Kyphoplasty|IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
40921323|NCT02480036|DEVICE|Intrabeam®|
40921324|NCT06533995|DEVICE|Visuprime|Visuprime is a medical device (class IIa sterile) with ophtalmic indication, consisting on a 10 ml multidose bottle
40921325|NCT06533995|OTHER|Placebo|placebo eyedrop isotonic buffered saline solution
40921326|NCT00988650|OTHER|isocaloric diet|
40921327|NCT00988650|OTHER|free living conditions|
40921328|NCT04750616|DRUG|Niacinamide|Niacinamide 3 grams on the day of surgery and post-surgical days one and two
40921329|NCT04750616|DRUG|Placebo|Matched placebo on the day of surgery and post-surgical days one and two
40921330|NCT06126250|DEVICE|Power sonic toothbrush|Subjects will brush twice daily for 30 seconds using a fluoride toothpaste.
40921331|NCT06126250|DEVICE|Manual toothbrush|Subjects will brush twice daily for 2 minutes using a fluoride toothpaste.
40921332|NCT04518189|DRUG|lidocaine patch|lidocaine patch applied 3 hours before the procedure
40921333|NCT04518189|DRUG|Sham patch|Sham patch applied 3 hours before the procedure
40921334|NCT02966054|BEHAVIORAL|Digital Health Physical Activity Intervention Group|Print materials on exercise after cancer, Fitbit Flex for 12 weeks, and daily Text Messages for 12 weeks
40921335|NCT01790243|DEVICE|Lutonix Drug Coated Balloon|Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.
40921336|NCT01790243|DEVICE|Standard PTA Balloon|Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.
40921337|NCT03159962|DEVICE|Bonded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
40921338|NCT03159962|DEVICE|Banded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
40921339|NCT03525964|PROCEDURE|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the Achilles tendon and the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon and consist of the free tendon and the fascia \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively. The cut-off at 7% elongation is determined for 75% sensitivity and 65% specificity of elongation.
40921340|NCT03525964|PROCEDURE|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
41093842|NCT06615323|BEHAVIORAL|Polyphonic Lullaby Group|After discharge, mothers will be asked to play the Dandini Dandini Dastana lullaby by vocal artist Mircan Kaya, which they downloaded from the YouTube application, and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by switching the phone to airplane mode just before sleep. In the event of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the polyphonic lullaby volume will be gradually reduced. The polyphonic lullaby will be played at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effects of confounding factors, mothers in the polyphonic lullaby group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the study.
40921341|NCT03525964|PROCEDURE|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
40921342|NCT04753424|PROCEDURE|Surgical technique|Description of novel surgical technique using autologous semitendinosus graft as meniscus transplant.
40921343|NCT00386542|BIOLOGICAL|Vaxigrip® trivalent inactivated influenza vaccine|See full description elsewhere in this record.
40921344|NCT00386542|DEVICE|Intradermal spacer on Biojector® 2000 jet injector|See elsewhere in this record for full description.
41093843|NCT06615323|OTHER|Pish Pish Sound Group|After discharge, mothers will be asked to turn on the Piş Piş sound downloaded from the YouTube application and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by turning the phone to airplane mode just before sleep. In case of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the piş piş sound will be gradually reduced. The polyphonic lullaby played will be at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effect of confounding factors, mothers in the piş piş sound group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the scope of the research.
41093844|NCT06614777|PROCEDURE|skin biopsies and blood extraction|"Two 5 mm skin biopsies: lesional area and non-lesional area, on the trunk.~* One blood sample (20 ml) to extract the plasma.~* 15 successive tape-strippings in a lesional area.~* Scans with two swabs: lesional area (preferably the trunk, 5 cm x 5 cm area) and non-lesional area."
41093845|NCT02400190|OTHER|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
41269619|NCT01693445|DRUG|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
41269620|NCT04820751|DRUG|Cyproheptadine Hydrochloride 4 MG|Cyproheptadine associated to standard care
41269621|NCT04489654|BIOLOGICAL|deproteinized bovine bone mineral (DBBM) by OneXeno Graft. ( OneGraft, Germany)|deproteinized bovine bone mineral (DBBM) put in the gap between implant and labial shield
41269622|NCT06174350|BEHAVIORAL|Cognitive behavioral therapy|Earthquake is a process that affects the lives of many people. It is very important to evaluate the psychological state of individuals after the earthquake and take appropriate action. When studies conducted after the earthquake were examined, no study was found that evaluated the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes. For this reason, this thesis was conducted to evaluate the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes.
41269623|NCT06174350|OTHER|Placebo|Intervention Description not
41269624|NCT03562494|BIOLOGICAL|VY-AADC02|Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain
41269625|NCT03562494|OTHER|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dura penetration
41269626|NCT06300801|DIAGNOSTIC_TEST|Is the preoperative c-reactive protein/albumin ratio successful in predicting postoperative pancreatic fistula in patients undergoing pancreatoduodenectomy?|In this study, predicting pancreatic fistula before surgery will reduce postoperative complications and mortality.
41269627|NCT05679414|DIAGNOSTIC_TEST|RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes|Venous blood sample
41269628|NCT00331305|BEHAVIORAL|Supervised Exercise|
41269629|NCT00331305|BEHAVIORAL|Home-Based Exercise|
41269630|NCT00331305|DRUG|Sertraline (Zoloft)|
41269631|NCT00331305|DRUG|Placebo Pill|
40921345|NCT01491113|DRUG|Levetiracetam 250 mg|Tablet containing Levetiracetam 250 mg
40921346|NCT01491113|DRUG|Levetiracetam 500 mg|Tablet containing Levetiracetam 500 mg
40921347|NCT00103233|BIOLOGICAL|trastuzumab|
40921348|NCT00103233|DRUG|vinorelbine tartrate|
40921349|NCT02823444|OTHER|Magnetic Resonance Angiography|"Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational."
40921350|NCT03320824|DEVICE|New Dermal Filler|hyaluronic acid
40921351|NCT03320824|DEVICE|Device: FDA Approved Dermal Filler|hyaluronic acid
40921352|NCT03802058|DRUG|Nab-paclitaxel|Nab-paclitaxel 40mg/m2 for Injection weekly
40921353|NCT03802058|DRUG|Carboplatin|Carboplatin AUC=2 for Injection weekly
40921354|NCT03802058|RADIATION|Thoracic radiation therapy|Thoracic radiation therapy 60-66Gy/30-33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
40921355|NCT00274924|BIOLOGICAL|filgrastim|Given subcutaneously or intravenous bolus.
40921356|NCT00274924|BIOLOGICAL|rituximab|Given IV
40921357|NCT00274924|DRUG|carboplatin|Given IV
40921358|NCT00274924|DRUG|cyclophosphamide|Given IV
40921359|NCT00274924|DRUG|doxorubicin hydrochloride|Given IV
40921360|NCT00274924|DRUG|etoposide|Given IV
40921361|NCT00274924|DRUG|ifosfamide|Given IV
40921362|NCT00274924|DRUG|prednisone|Taken orally
40921363|NCT00274924|DRUG|vincristine|Given IV
40921364|NCT06472076|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
40921365|NCT06472076|BIOLOGICAL|Belrestotug|Belrestotug will be administered.
40921366|NCT06472076|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered.
40921367|NCT06472076|DRUG|Placebo|Placebo will be administered.
40921368|NCT05996302|BEHAVIORAL|Relocation to sea level|Relocation to sea level by bus and stay for 2 days
40921369|NCT06533865|DRUG|Romosozumab|Six monthly subcutaneous injections. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
40921370|NCT06533865|DRUG|Placebo|Identical to romosozumab but inactive. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
40921371|NCT06533865|DRUG|Zoledronic acid|One intravenous infusion
40921372|NCT00003745|DRUG|topotecan hydrochloride|
40921373|NCT05729867|PROCEDURE|Endoscpic biliary drainage using fully covered metal stent|"After selective cannulation of the bile duct, cholangiography is obtained using contrast agent.~A guide wire is passed through the stricture, and then fully-covered metal stent is inserted under fluoroscopy guidance during ERCP."
40921374|NCT02776202|DRUG|Fludarabine monophosphate|"The HSCT preparative regimen will consist of~* Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~* Fludarabine: 35 mg/m2/day IV on Days -8 through -4~* Melphalan: 140 mg/m2 IV on Day -3~* Rest on Day -2 and -1~* Day 0 is the day of transplant~* GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
40921375|NCT03841747|DRUG|Pembrolizumab|200 mg Pembrolizumab IV Q3W.
40921376|NCT03841747|DRUG|Paclitaxel|80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
40921377|NCT01765959|OTHER|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
40921378|NCT01765959|OTHER|cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future"
40921379|NCT01589653|DRUG|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
40921380|NCT01589653|DRUG|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
40921381|NCT00915499|DEVICE|VPAP Adapt SV|Comparison of ASV and CPAP modes
40921382|NCT04806867|OTHER|SePaRIC-Covid19 cohort|All patients with Chronic Inflammatory Rheumatism who were contacted by telephone as part of the innovative organizational strategy and who did not object to the use of their data.
40921383|NCT02444000|DRUG|PCV chemotherapy alone|"PCV cycles are 6 weeks long~PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally"
40921384|NCT02444000|DRUG|Radiotherapy+PCV chemotherapy|Radiotherapy followed by 6 cycles of PCV
40921385|NCT04772326|OTHER|Questionnaire|Questionnaire
40921386|NCT00300430|DRUG|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
40921387|NCT00300430|DRUG|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
40921388|NCT00300430|DRUG|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
40921389|NCT05786742|RADIATION|grade and compare reported side effects between groups|"Compare experimental ultra hypo fractionation (25 Gy in 5 daily fractions administered starting mid week and ending mid following week) to our standard fractionation (either 37,5 Gy given in 15 daily fractions, or 36 Gy in 12 daily fractions).~* Toxicity analysis will be quantitatively evaluated using CTCAE (v5) at 1, 2 and 5 years post-therapy, and has needed at FU visits. Kaplan-Meier statistical analysis will be used to report toxicity evolution through time.~* median IPSS scores will be reported at 3, 6, 12 months and yearly (1, 2, 3, 4 et 5) post-therapy. IPSS median time to baseline return will be calculated.~* IPSS urinary scores, sexual function (SHIM) and GI toxicity (CTCAE-v5) and quality of life questionnaires ( EPIC-26) will be given at 3, 6 months and yearly thereafter (1, 2, 3, 4 et 5) post-treatment."
41093846|NCT02477943|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
41093847|NCT02477943|DEVICE|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
40921390|NCT03900793|DRUG|Losartan|Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments per Table 1 of the protocol. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily and dose levels 2 and 3 dosing will not exceed 100 mg daily. Doses should be taken at approximately the same time daily and patients should fast for \> 4 hours prior to dosing
40921391|NCT03900793|DRUG|Sunitinib|Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2 per Table 1 of the protocol. Doses should be taken at approximately the same time daily.
40921392|NCT00564057|DRUG|candesartan|tablet 8-16 mg once daily, one year
40921393|NCT00564057|DRUG|lercanidipine|tablets 10-20 mg once daily, one year
40921394|NCT00210158|PROCEDURE|Nitrous oxyde|
40921395|NCT01143701|OTHER|ADHD Collaborative|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
40921396|NCT00947505|DEVICE|HairMax LaserComb 2009, 7 Beam|Device application 3 times week (non-consecutive days), for 26 weeks
40921397|NCT00947505|DEVICE|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
40921398|NCT04473742|BIOLOGICAL|Blood collection|4 EDTA tubes for 24 mL blood collection
40921399|NCT04473742|BIOLOGICAL|Blood sample|2 drying tubes for 12 mL blood collection
40921400|NCT04473742|BIOLOGICAL|Blood sample|1 drying tube for 6 mL blood collection
40921401|NCT02494063|PROCEDURE|Sentinel lymph node biopsy|Bilateral sentinel lymph node biopsy, pathologic ultrastaging
40921402|NCT02494063|PROCEDURE|At least unilateral systematic pelvic lymph node dissection|
40921403|NCT02483767|DRUG|goserelin|Gonadotropin-Releasing Hormone Agonist
40921404|NCT02483767|DRUG|standard chemotherapy|(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
40921405|NCT00983008|BEHAVIORAL|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
40921406|NCT00536393|DRUG|Doxorubicin|
40921407|NCT00536393|DRUG|Doxorubicin pegylated|
40921408|NCT03860558|OTHER|Lifestyle Intervention|Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.
40921409|NCT03860558|OTHER|No Intervention|Participants will not undergo an intervention.
40921410|NCT00936689|PROCEDURE|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
40921411|NCT00936689|PROCEDURE|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
40921412|NCT06172985|OTHER|No intervention|Due to observational study
40921413|NCT04605367|DEVICE|Transcranial stimulation|For both tasks, the training modalities are the same. After the pre-test, this group will physically repeat the correct sequence as many times as possible, during 12 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the real anodal stimulation. The intensity of the current will gradually increase for 30s until it reaches 1mA, will remain constant for 15min, then will gradually decrease for 30s until 0mA is reached. The current density during stimulation will be 0.04 mA/cm². For the manual task the anode will be centered above C4 (according to the international 10-20 EEG system) that is located near the hand area of M1. The cathode will be placed on the supraorbital region ipsilateral to the trained hand (Fp1). For the body task, the anode will be placed in the center of the cortex (Cz) and the cathode will be placed at the medial supraorbital region (Fpz).
40921414|NCT01460511|DRUG|E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
40921415|NCT01460511|DRUG|Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
40921416|NCT02093052|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
40921417|NCT02093052|BEHAVIORAL|Developmental Education for Families|Enhance children's cognitive development. In-home intervention with parents and children present.
40921418|NCT02745145|DRUG|Abituzumab 1500 mg|Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
40921419|NCT02745145|DRUG|Abituzumab 500 mg|Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
40921420|NCT02745145|DRUG|Placebo|Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
40921421|NCT04136782|DRUG|Albumin-bound paclitaxel combined with carboplatin|Albumin-bound paclitaxel combined with carboplatin: Albumin-bound paclitaxel (Abraxis BioScience, LLC., Mclrose Park, IL, USA; certificate number: H20091059) will be intravenously administered at 125 mg/m2 for 30 minutes on days 1 and 8 of each 21-day session of treatment. There will be six 21-day sessions of treatment. At the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; National Drug Approval Number: H20020181) will be intravenously administered at AUC = 2 mg•min/mL for 120 minutes on days 1 and 8 of each 21-day session of treatment. Carboplatin must be hydrated for 3 days before use to prevent nephrotoxicity.
40921422|NCT04136782|DRUG|Epirubicin combined with docetaxel|Epirubicin (Pfizer Pharmaceutical (Wuxi) Co., Ltd., China; National Drug Approval Number: H20000496) will be intravenously administered at 90 mg/m2 for 120 minutes on day 1 of each 21-day session of treatment. At the same time, docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; National Drug Approval Number: J20150083) will be intravenously administered at 75 mg/m2 for 120 minutes. Drug administration will be performed once every other 3 weeks for four times.
40921423|NCT00540618|DRUG|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
40921424|NCT00540618|OTHER|Placebo|
40921425|NCT00540618|DRUG|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
40921426|NCT00540618|DRUG|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
40921427|NCT03635450|BIOLOGICAL|Infusion of hCT-MSC|Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.
40921428|NCT02819232|OTHER|Blood sampling|Detection of bacteria will be performed on a blood sample
40921429|NCT02385656|DRUG|Modafinil|200mg of modafinil daily for 4 weeks
40921430|NCT04209985|BEHAVIORAL|Health coaching|Brief telephonic intervention consisting of up to five phone calls from a health coach
40921431|NCT01398917|PROCEDURE|plastic endoprosthesis|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
40758248|NCT06537466|DIETARY_SUPPLEMENT|Mediterranean diet|This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
40921432|NCT01398917|PROCEDURE|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
40921433|NCT00165802|DRUG|E7974|Maximum Tolerated Dose defined as 0.45 mg/m\^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
40921434|NCT02057328|DRUG|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
40921435|NCT02057328|DRUG|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
40921436|NCT06073145|DEVICE|conventional transcranial Doppler probe and wearable ultrasound patch.|Comparison of the measurements from conventional transcranial Doppler probe and wearable ultrasound patch.
40921437|NCT05224167|DRUG|Melatonin 5 MG Sublingual Tablet|Melatonin 5 mg 12 hours and 2 hours prior to surgery
40921438|NCT05224167|DRUG|Hydroxyzine|Hydroxyzine 1mg/kg 12 hours and 2 hours prior to surgery
40921439|NCT02553356|DRUG|PT2385|
40921440|NCT01717833|PROCEDURE|NEMS|NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
40921441|NCT01717833|PROCEDURE|Sham|Sham sessions of neuromuscular electrical stimulation
40921442|NCT00972140|DRUG|Formoterol|Formoterol-HFA pMDI 12µg twice daily
40921443|NCT00972140|DRUG|Formoterol|Formoterol-DPI 12 µg twice daily
40921444|NCT05165498|PROCEDURE|Real-time ultrasound guidance for thoracic epidural catheter placement.|With an US-guided parasagittal oblique approach, the interlaminar space at the union between laminas and spinous processes at the predefined insertion level will be identified. A skin wheal will be raised with 3 mL of lidocaine 1%. Afterward, an 18-gauge Tuohy epidural block needle will be advanced under direct US vision until the tip is insinuated between the laminas and anchored to the flavum ligament. Then the needle will be attached to a low resistance syringe prefilled with saline solution and advanced until LOR to injection is confirmed. Then a 20-Gauge epidural catheter will be inserted 3-5 cm beyond the needle tip inside the epidural space and the needle removed.
40921445|NCT05904301|OTHER|Usual medical management of patients, additional blood and stool samples for biobanking|"For all systemic diseases the following data will be collected:~Clinical examination, Laboratory data, Current medications, Constitution of biobanking.~For each disease:~Pathology specific Activity score, Global subjective disease activity by patient and by physician."
40921446|NCT02872506|DRUG|Anti TNF|Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
41093848|NCT02466126|BEHAVIORAL|bCBT|"The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health)."
41093849|NCT00913432|DRUG|masitinib|3 mg/kg/day oral route
41093850|NCT00913432|DRUG|masitinib|masitinib 6 mg/kg/day oral route
41093851|NCT05343013|DRUG|TAS-102|GIven by PO
41093852|NCT05864768|DIETARY_SUPPLEMENT|Vegan/vegetarian diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths \>3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values \>20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
41093853|NCT05864768|DIETARY_SUPPLEMENT|Omnivorous diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths \>3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values \>20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
41093854|NCT04088994|OTHER|AOT Pathological Model Experimental Group|The children will participate in a rehabilitation intervention based on the observation of unimanual and bimanual actions performed by a model with the same degree of motor impairment, but an improvement on the participant's current abilities.
41093855|NCT04088994|OTHER|AOT Healthy Model Control Group|The children assigned to the healthy group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
41093856|NCT03350321|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
40921447|NCT02872506|PROCEDURE|ileocecal resection|The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
40921448|NCT02685059|DRUG|MEDI4736 (Anti PD-L1)|"MEDI4736 1.5g total i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
40921449|NCT02685059|DRUG|Placebo|"Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
40921450|NCT02685059|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
40921451|NCT02685059|DRUG|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
41093857|NCT03350321|DRUG|Darbepoetin alfa|Starting dose of darbepoetin alfa once every 2 weeks will be titrated based on the subject's Hb (Hemoglobin) response
41093858|NCT06562725|OTHER|specific ventilator settings|The special ventilator settings used in the intervention group - aimed at reducing airway pressure - include inspiratory flow \<25 L/min, tidal volume = 5m L/Kg, inspiratory time = 1 sec, respiratory frequency \<20 c/min, PEEP = 5 cmH2O, and FiO2 = 100%
41093859|NCT02214251|DEVICE|PK-16CH EXG system|
41093860|NCT05113589|DEVICE|PBM TREATMENT|Participants randomized to this treatment will receive a whole body PBM treatment using a NovoTHOR® whole body light bed. For each treatment session, participants will lie supine in the treatment bed for 20 minutes, with no or minimal attire (underwear). Treatment sessions will be three times weekly for a period of 4 weeks, totalling 12 treatment sessions
41093861|NCT05113589|DEVICE|PLACEBO PBM|The placebo feature of the whole body PBM bed provides controls that select active or placebo (sham) treatments in a way undetectable by participant, operator or observers, such that no-one is aware whether the participant is receiving an active or placebo treatment. There is a switch box that randomises participants to active or placebo; no other randomisation is necessary.
41093862|NCT06131073|OTHER|speed endurance production (SEP) training along with conventional training.|this include speed endurance training for 3 days in a week for 8 weeks.
41093863|NCT06131073|OTHER|conventional training|this include conventional training for 3 days in a week for 8 weeks.
41093864|NCT04648306|DEVICE|Prophylactic Impella support for a non-emergent PCI|Impella percutaneous mechanical circulatory support is placed via the femoral or axillary artery prior to a non-emergent PCI in patients at high risk for periprocedural complications including hemodynamic collapse.
41093865|NCT04135924|OTHER|Rehabilitation|physical exercise and respiratory muscle training
41093866|NCT02724020|DRUG|Everolimus|Everolimus capsules.
41093867|NCT02724020|DRUG|MLN0128|MLN0128 capsules.
41093868|NCT02724020|DRUG|MLN1117|MLN1117 capsules.
40921452|NCT02685059|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
40921453|NCT01949467|DRUG|iron fumarate|All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
40921454|NCT04685174|DEVICE|Invos Model 5100C Cerebral/Somatic Oximeter|To measure the correlation between post arterial and venous anastomoses (reperfusion) NIRS values of transplanted kidney and post-transplant graft failure as manifested in initiation of renal replacement therapy post transplant
40921455|NCT01871480|DRUG|Group A:cytokine-induced killer cell +gefitinib|CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
40921456|NCT01871480|DRUG|Group B:Gefitinib|Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
40921457|NCT01989208|OTHER|SG1002|200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
40921458|NCT01989208|OTHER|Placebo|200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
40921459|NCT03528902|DRUG|Tamoxifen|Tamoxifen 20 mg po daily for 24 weeks.
41093869|NCT00629512|DRUG|Esomeprazole|20mg oral daily
41093870|NCT00629512|DRUG|Esomeprazole|40mg oral daily
41093871|NCT00629512|DRUG|Placebo|
41093872|NCT01439425|BEHAVIORAL|Weight Loss|The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
41093873|NCT02360345|DRUG|ONX-0801|
40921460|NCT03528902|DRUG|Placebo Oral Tablet|Placebo
41093874|NCT00843362|DRUG|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
41093875|NCT00843362|DRUG|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
41093876|NCT05920577|OTHER|exergames and resistance training|"In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software Nintendo Switch Sports will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training."
41093877|NCT05920577|OTHER|Resistance training|The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
41093878|NCT00431509|PROCEDURE|conventional vs. navigated total knee arthroplasty|
41093879|NCT05372003|DRUG|Dupilumab|dupilumab injections will be prescribed and managed by dermatology as standard of care
41093880|NCT05372003|OTHER|Photo therapy|light therapy will be prescribed and managed by dermatology as standard of care
41093881|NCT04484688|DRUG|perindopril-bisoprolol|outpatients with permanent atrial fibrillation and with preserved ejection fraction
41093882|NCT06280729|OTHER|AI-Analyis|The study will investigate classification (ie logistic regression, decision tree, random forest, support vector machine, K nearest neighbour, naive bayes) ML models and treatment effect estimation ML models (T-learner, X-learner..).
41093883|NCT06318754|DEVICE|Inari Triever Aspiration Catheter|Inari Triever Aspiration Catheter for portomesenteric venous thrombosis
41093884|NCT00361998|DRUG|NITROFURANTOIN MACROCRYSTALS|
41093885|NCT00375856|DEVICE|DePuy P.F.C.® Sigma Rotating Platform Knee|no details
41093886|NCT05406986|OTHER|care bundle application|The patients in the experimental group will be given care according to the current care bundle for 14 days
41093887|NCT03139175|DEVICE|balance assessment with Biodex balance system|All subjects of three groups will be assessed with the evaluation device( balance system).
41093888|NCT06278961|OTHER|Observational|Observation of movement patterns through video recordings and neurodevelopmental battery of assessments.
41093889|NCT05890911|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
41093890|NCT05890911|DIAGNOSTIC_TEST|Blood dopamine level measurement|In each of the patients blood dopamine level will be measured
41093891|NCT05890911|DIAGNOSTIC_TEST|Genetical test|Each of the patients will undergo genetical test focusing on selected single nucleotide polymorphisms within genes regulating the concentration of dopamine - the gene responsible for production of the enzyme catechol-O-methyltransferase (COMT) - rs4680 and rs6269 and genes encoding receptors dopamine (DRD1 - rs686, rs5327 and DRD2 - rs1800497).
41093892|NCT01650337|OTHER|Smartphone Application|Smartphone application to help monitor caloric intake and expenditure
41093893|NCT02090309|DRUG|Hydrocortisone|100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
41093894|NCT02090309|DRUG|normal saline 0.9%|IV injection of 5 ml normal saline 0.9% as a single bolus.
41093895|NCT00507611|PROCEDURE|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
40921461|NCT04763681|BEHAVIORAL|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
40921462|NCT02856360|OTHER|Moderate Stiffness Footwear|Standard moderately stiff footwear for typical high school football players will be randomly allocated to each group
40921463|NCT02856360|OTHER|High Stiffness Footwear|Standard highly stiff footwear for typical high school football players will be randomly allocated to each group
40921464|NCT05918471|DIETARY_SUPPLEMENT|Very Low Energy Diet with Liquid Supplementation|"The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows:~1. Consume 4 Optifast 900 packets each day~2. Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks.~3. Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender."
40921465|NCT02900989|BEHAVIORAL|Suicide screening|"Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law."
40921466|NCT05414734|DRUG|HHT120|Capsule, oral administration
40921467|NCT05414734|DRUG|Placebo|Capsule, oral administration
40921468|NCT03679520|OTHER|New programme|"Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~1. Introduction, life-change of becoming a parent and co-parenting~2. Early parenthood~3. Breastfeeding, caring for the baby and early parenthood~4. and 5 Labour, birth and postnatal care"
40921469|NCT03679520|OTHER|Regular programme|"Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~1. (or 1 and 2) Labour, birth and postnatal care~2. or 3 Breastfeeding, caring for the baby and early parenthood"
40921470|NCT05041608|PROCEDURE|Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
40921471|NCT04235413|BEHAVIORAL|Real-Time Incentives Group|The use of a novel computer program with a mobile phone interface to provide real-time financial incentives at the point of purchase for discounts on fruit and vegetables in low-income families. This intervention will be applied to subjects randomized to the intervention arm. They will receive 50% off eligible fruits and vegetable products at the point of purchase, up to $10 a week for 6 months. Maximum amount they can receive is $260 in discounts over the 6 month period.
41093896|NCT01894347|OTHER|TDM, Monitoring of Neuro-and Nephropathology|Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
41093897|NCT02347917|DRUG|BBI608|480 mg orally twice daily (960 mg total daily dose)
41093898|NCT02347917|DRUG|Pemetrexed|500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).
41093899|NCT02347917|DRUG|Cisplatin|75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
41093900|NCT01260974|DRUG|Caspofungin|50mg/dd for 21dd, starting within 24h from Liver Transplantation.
41093901|NCT05322161|BEHAVIORAL|yoga classes|"There will be 6 total yoga classes (one introduced per week for a 6 week period). Each yoga session will be divided into three components, which will vary in duration based on a curriculum designed specifically with the post-partum state of mothers in mind:~1. Yoga postures (Asana) = low impact gentle postures meant to be done individually~2. Breathing techniques (Pranayama) = deliberate modifications of breath such as rapid diaphragmatic breathing, slow/deep breathing, alternate nostril breathing, breath holding~3. Meditation (Dhyana) = guided meditation"
41093902|NCT00723320|DRUG|Atorvastatin|atorvastatin 10mg/d
41093903|NCT00723320|BEHAVIORAL|Aggressive lifestyle intervention|aggressive lifestyle intervention
40921472|NCT00205920|BIOLOGICAL|BLVR Hydrogel|10 mL BLVR Hydrogel
40921473|NCT02642744|OTHER|Nursing care model|Subjects will be randomized into either the attending nursing model of care vs the standard nursing model
41093904|NCT01444066|PROCEDURE|Dilation of the esophagus|Esophagus will be dilated with a Savory dilator.
41093905|NCT06250439|OTHER|ECMO-Flow variations|"The protocol unfolds in 5 steps as follows, each step lasting between 10 and 15 minutes to allow for the patient's hemodynamic adaptation. At each step, invasive and non-invasive hemodynamic evaluation is performed.~1. The 1st step is called 100% flow: it involves recording the patient's hemodynamic measurements at the baseline, i.e., at 100% of their ECMO-VA flow, previously set by the clinician entirely independently of the study.~2. The 2nd step is called 125% flow: the patient's ECMO-VA flow is increased to 125% of the initial flow.~3. The 3rd step is called 150% flow: the patient's ECMO-VA flow is increased to 150% of the initial flow.~4. The 4th step is called 175% flow: the patient's ECMO-VA flow is increased to 175% of the initial flow.~5. The 5th and final step is called 200% flow: the patient's ECMO-VA flow is increased to 200% of the initial flow."
40921474|NCT02123251|BEHAVIORAL|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
41093909|NCT01388543|DRUG|Atazanavir|Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days
41093910|NCT02998164|BEHAVIORAL|augmentative and alternative communication technology|
41093911|NCT02998164|BEHAVIORAL|Usual Care|No change to the therapy care received
41093912|NCT00508885|DRUG|Niacinamide|Niacinamide 250 mg twice daily titrated up to 750 mg twice daily
41093913|NCT00508885|DRUG|Placebo|Placebo
41093914|NCT02117115|RADIATION|Dynamic contrast-enhanced computed tomography|CT scan performed between Day +7 and Day +14.
41093915|NCT02117115|DRUG|Ioversol|To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
41093916|NCT06235892|DRUG|TACROLIMUS|TACROLIMUS 2-3.5 ng/ml
41093917|NCT05365074|DRUG|Chloroprocaine Injection|Spinal anesthesia with 50 mg of 1% Chloroprocaine
41093918|NCT05557019|DEVICE|Booster Balloon Catheter|The Booster balloon therapy (i.e. partial occlusion of the CS lumen with a subsequent backward pressure elevation without obstructing the CS blood flow) will start immediately after a successful PCI of the culprit coronary lesion in the LAD, with TIMI-II flow restoration. The Booster balloon therapy will then be continued for up to 90 min, but not less than 60 min.
41269632|NCT06450665|BEHAVIORAL|VR Social Avoidance Intervention|The intervention is based on cognitive-behavioral approach with a virtual coach acting as the therapist. It will be designed in tandem with input from Hong Kong users to ensure the scenario can resonate with them. By testing beliefs that inhibit confidence in a safe and controlled environment, participants will complete tasks with increasing difficulty in three VR scenarios and learn that they can cope in situations that they previously avoid.
40921475|NCT05520892|DRUG|intravenous immunoglobulin|To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
40921476|NCT04032509|OTHER|2 x 5 mL blood sample|2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
40921477|NCT02679963|DRUG|Olaparib|
40921478|NCT02679963|DRUG|Placebo|
40921479|NCT03163602|DRUG|Control group|Access flap and debridement
41093919|NCT02124460|BEHAVIORAL|Health Coaching|"Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study."
41093920|NCT02365298|DEVICE|etafilcon A|etafilcon A soft contact lens
41093921|NCT02365298|DEVICE|nelfilcon A|nelfilcon A
41093922|NCT02417311|OTHER|Skin biopsy, genotyping and disease phenotyping|Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
41093923|NCT02383550|OTHER|Observational Cognitive assessments|Observational
41093924|NCT00620581|DRUG|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
41093925|NCT03349190|DRUG|ULIPRISTAL ACETATE|Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)
41093926|NCT02007447|DRUG|OCYTOCINA - SPRAY NASAL|The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
40921480|NCT03163602|DEVICE|Test group|Regenerative treatment
40921481|NCT00371553|DRUG|SU011248 (Sunitinib)|
40921482|NCT05101200|OTHER|High Dose Neural Mobilization Technique|Patients in This Group will receive the high dose neural mobilization along with hot pack, strengthening exercises, Neural mobilization technique (slump, sciatic). Participants in the NMG will be asked to actively perform knee extension, ankle dorsiflexion, and head extension in a slumped posture (body and neck semi flexion) followed by simultaneous ankle plantar flexion together with knee and head flexion, Hot pack for 15 minutes, Strengthening exercises of muscles with 10 /8sets. Strengthening exercises of quadriceps with10 rep/8sets, Static stretching exercise for hamstring muscle with 10 rep/8sets, Group A will be given session of 40 min/day, 2 days/week for 4 weeks.
40921483|NCT05101200|OTHER|Low Dose Neural Mobilization Technique|Patients in this Group will receive the same treatment as group A but with less intensity and low dosage. Hot pack: 15 minutes, Strengthening exercises of muscles with 10 rep/4sets, Static stretching exercise for hamstring muscle with 10 rep/4sets. Group B will be given session of 40min/day, 2 days/week for 4weeks.
40921484|NCT06022289|DRUG|Pemigatinib|Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
41093927|NCT03968055|OTHER|Integration with Epic|Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
41093928|NCT01794377|BEHAVIORAL|30 minutes of high intensity training|"This group will carry out a 5-min warm-up period on bicycle ergometer at an intensity corresponding to 50% of Vo2max before performed eight times the intermittent training exercise as follows:~* 30 sec at 120% of Vo2max,~* 1 min at 50% of Vo2max,~* 15 sec at 30-40 revolutions per minute of strength training at 100% of the maximal anaerobic power, which will be first determined by means of a force-velocity test on a Monark ergometer,~* 1 min at 50% of Vo2max.~The training session will be terminated by a 3-min cool-down period at 40% of Vo2max.~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
41093929|NCT01794377|BEHAVIORAL|40 of an endurance training|"The moderate-intensity continuous exercise group will carry out a 40-min session of continuous cycling at a moderate intensity (50 % of Vo2max).~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
41093930|NCT01238029|DRUG|Lapatinib and Capecitabine and Vinorelbine|Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
41093931|NCT00611065|DEVICE|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
41093932|NCT00184028|DRUG|Taxotere|Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
41093933|NCT00184028|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
41093934|NCT02828930|DRUG|Idasanutlin|Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
41093935|NCT02828930|DRUG|Placebo|Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
41093936|NCT02828930|DRUG|[13C]-radiolabeled Idasanutlin|\[13C\]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.
41093937|NCT02828930|DRUG|[14C]-radiolabeled Idasanutlin|\[14C\]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
40921485|NCT05179343|DEVICE|Active AffeX-CT device|(Trans-cutaneous Autonomic Neurostimulation) tAN treatment will be administered using AffeX-CT device (a device based on a totally TENS unit). AffeX device comprises of a battery-operated control unit, two electrode pairs arranged on ear clips and connected to the control unit with electrical leads. The AffeX device generates an electrical signal that is used to stimulate the nerves that naturally control the output from the sympathetic nervous system.
40921486|NCT05179343|DEVICE|Sham AffeX-CT device|Sham Totally TENS device. The device is identical to the active device used in the study, but its only purpose is to act as a placebo. The ear-clip electrodes have been modified so that the electric current is not transmitted to the participant.
40921487|NCT01042041|DRUG|sorafenib tosylate|Given orally
40921488|NCT01042041|DRUG|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
40921489|NCT01042041|DRUG|cisplatin|Given via transarterial/hepatic chemoembolization
40921490|NCT01042041|DRUG|mitomycin C|Given via transarterial/hepatic chemoembolization
40921491|NCT01042041|PROCEDURE|transarterial chemoembolization|
40921492|NCT01042041|PROCEDURE|hepatic artery embolization|
40921493|NCT06367218|DRUG|opioid based strategy|Induction and maintenance of anesthesia with opioids
40921494|NCT06367218|DRUG|opioid-free strategy|Esketamine was used for induction and maintenance of anesthesia
41093938|NCT03912103|OTHER|Interdisciplinary Deprescribing and Medication Optimization Intervention|as current
41093939|NCT02087033|DIETARY_SUPPLEMENT|ritmonutra|2 tablets a day by mouth for 4 weeks
41093940|NCT02087033|DIETARY_SUPPLEMENT|placebo|sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
41093941|NCT00041262|DRUG|cisplatin|
40921495|NCT06367218|PROCEDURE|Laryngeal mask airway; Preserved spontaneous breathing|The patient used a laryngeal mask to maintain spontaneous breathing
40921496|NCT06367218|PROCEDURE|Double lumen tracheal tube; Mechanical ventilation|The patient was mechanically ventilated using a double-lumen tracheal catheter
40921497|NCT06148649|DRUG|HEC88473, Placebo, Dulaglutide|T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
40921498|NCT02241889|DEVICE|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
40921499|NCT02241889|DEVICE|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
40921500|NCT03045224|DEVICE|PTA, balloon angioplasty, stent|
40921501|NCT00166556|DRUG|Campath-1H and Tacrolimus|
40921502|NCT03519542|DRUG|Sunitinib|Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
40921503|NCT03613740|DRUG|Fucoxanthin|Intervention will be administered 30 minutes before breakfast.
41093942|NCT00041262|DRUG|epirubicin hydrochloride|
41093943|NCT00041262|DRUG|fluorouracil|
41093944|NCT00041262|PROCEDURE|conventional surgery|
41093945|NCT00041262|PROCEDURE|neoadjuvant therapy|
41093946|NCT04983888|DRUG|Obinutuzumab|1g IV on day one and 1 g IV on day 15, followed by identical course at month 6
41093947|NCT02851147|DEVICE|SL-D301|Slit Lamp
41093948|NCT02851147|DEVICE|DC-4|Digital Camera Attachment
41093949|NCT02851147|DEVICE|SL-3G|Slit Lamp
41093950|NCT00478556|DRUG|Omnipaque|Oral CT contrast
41093951|NCT00478556|DRUG|Gastroview|Oral CT contrast
41093952|NCT02871765|OTHER|Patient education related Warfarin|Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
41093953|NCT05978609|DRUG|Candonilimab|Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
41093954|NCT05978609|DRUG|Cisplatin|Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
41093955|NCT05978609|DRUG|Gemcitabine|gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
41093956|NCT05628662|DEVICE|Automated Insulin Delivery System (SAFE-AP)|Each subject will undergo a 32-hour in-hospital study, including 4 meals (60 grams of carbohydrates each, except 50 grams for breakfast), one overnight period and 2 unannounced aerobic exercise sessions. Each exercise session consists of three 15-minute sets on a cycle ergometer at 70% of maximum heart rate with 5 minutes of rest between sets.
41093957|NCT05005169|DIAGNOSTIC_TEST|SGB PCR|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
41093958|NCT05005169|DIAGNOSTIC_TEST|SGB culture|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
41093959|NCT00831597|DRUG|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
41093960|NCT00831597|DRUG|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
41093961|NCT00594932|DRUG|mycophenolate mofetil|First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)
41093962|NCT00594932|OTHER|placebo|"oral placebo will be given in ascending doses during the first month and at full dose during the second and third month (or at lower dose if tolerance issues warrant). During the fourth month mycophenolate mofetil will be given in ascending doses to 3 gms/day (or less if tolerance issues arise) and continues until the end of the study at 6 months."
41093963|NCT06054737|PROCEDURE|SPA THERAPY|"Balneotherapy program Four balneotherapy sessions per day, 6 days a week during 3 weeks~The balneotherapy sessions included:~* 10- minute walking session in a specially designed pool with tracks in semideep (80 cm) cool (30°C) water (training of muscle pump function under water compression);~* 20-minute whirlpool bath session with automatic air or submarine bath if hypodermis (aimed at relaxation and mobilization of the superficial skin volume flow); followed by a 10-minute hydrojet bath (2 sessions) with customized underwater strong massaging jets (mobilization and softening of the sclerotic subcutaneous tissues);~* Fresh thermal water compresses at 24°C. The cool temperature of the compresses also has an analgesic and decongestant effect. This treatment is carried out last and is followed by a rest for a total duration of 60 minutes"
41093964|NCT05153174|DRUG|Sulforaphane|This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.
41093965|NCT01051778|DRUG|enoxaparin 40mg plus low dose aspirin|Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.
41093966|NCT01051778|DRUG|Heparin calcium5,000 U twice daily plus low dose aspirin|Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
41093967|NCT04215913|OTHER|The investigators will extract total protein, DNA and RNA from PSC patients.|The investigators will extract total protein, DNA and RNA from PSC patients.
41093968|NCT06079593|PROCEDURE|Gasless Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane flap and ophthalmic viscosurgical device covering
41093969|NCT06079593|PROCEDURE|Standard Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane peel, and C2F6 tamponade
41093970|NCT03291275|OTHER|Follow-up for death and recurrence|All patients are followed up to determine definite date of diagnosis, recurrence and death.
41093971|NCT04179240|OTHER|audio and animated cartoon questionnaire|participants were asked to complete a questionnaire audio and animated cartoon on a platform
41093972|NCT05395143|DRUG|Zinc sulfate|Zinc sulfate tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
40921504|NCT03613740|DRUG|Placebo|Intervention will be administered 30 minutes before breakfast.
40921505|NCT06394167|DRUG|VX-993|Solution for IV administration.
40921506|NCT06394167|DRUG|Placebo|Solution for IV administration.
41093973|NCT05395143|DRUG|Placebo|Placebo tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
40921507|NCT04944680|BEHAVIORAL|Transcranial Direct Current Stimulation therapy|Transcranial Direct Current Stimulation with two saline-soaked electrodes (5cm x 7cm) is applied by our occupational therapist. The anode is placed on the ipsilesional primary motor cortex (C3/C4). The cathode is placed on the contralesional shoulder. The current is 1.5 milliampere and lasts 20 minutes.
40921508|NCT04944680|BEHAVIORAL|Motor imagery therapy|Stroke patients are asked to watch a video about the upper extremity movement. The video lasts 20 minutes. The contents are as follows: the patients are asked to relax the muscles for the first 2 minutes; the action refers to shoulder flexion and extension, elbow flexion and extension, forearm pronation and supination, wrist flexion and extension, finger flexion and extension, and corresponding daily functional activities for 16min; the patients are asked to relax their mind and body for the last 2 minutes.
40921509|NCT04944680|BEHAVIORAL|Transcranial Direct Current Stimulation and motor imagery therapy|The treatment parameters are the same as the above. It should be emphasized that the participants sit and perform the motor imagery task while receiving Transcranial Direct Current Stimulation.
41093974|NCT02952261|DEVICE|template-guided localization|Based on CT data, digital model of the navigational template was created using CAD software and imported to 3D printer. The navigational template serves as a guider to the localizer in lung nodule localization.
41093975|NCT02952261|OTHER|CT-guided localization|Percutaneous lung nodule localization was conducted under the real-time guidance of CT scan. This is the conventional method of transthoracic lung nodule localization.
41093976|NCT04068597|DRUG|CCS1477|Oral capsule
41093977|NCT04068597|DRUG|Pomalidomide|oral capsule
41093978|NCT04068597|DRUG|Dexamethasone|oral tablet
41093979|NCT04068597|DRUG|Azacitidine|Powder suspension for Injection
41093980|NCT04068597|DRUG|Venetoclax|Oral tablet
41093981|NCT03092440|OTHER|serious game|"During three hours, each learner will play with the three different cases of the LabForGames Warning serious game."
41093982|NCT00903721|DRUG|mometasone furoate|"Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months"
41093983|NCT04671628|BEHAVIORAL|Relaxing music|Participants will be asked to listen to relaxing music for 30 minutes each day. They will allowed to choose between several playlists based on their preference.
41093984|NCT03680014|DIAGNOSTIC_TEST|CUSH|Machine learning assisted remote monitoring/ telehealth platform to predict and prevent falls
41093985|NCT00836810|DRUG|Timed Release Tablet Prednisone|Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
41093986|NCT00836810|DRUG|Prednisolone|Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
41093987|NCT05049525|DRUG|Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.|Itraconazole capsules of 100 mg, antifungal agent. Terbinafine tablets 250 mg (as terbinafine hydrochloride), antifungal agent.
41093988|NCT05049525|DRUG|Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.|Matching placebo of itraconazole capsules of 100 mg, antifungal agent. Matching placebo of terbinafine tablets 250 mg, antifungal agent.
41093989|NCT00126113|BEHAVIORAL|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
41093990|NCT00126113|BEHAVIORAL|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
41093991|NCT05981456|OTHER|patient safety competency|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the competence levels of the students.
41093992|NCT05981456|OTHER|satisfaction with the training method|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the satisfaction levels of the students from the education methods.
41093993|NCT01763736|BEHAVIORAL|Music|playlist per patient preference
41093994|NCT05557422|DIAGNOSTIC_TEST|BD OneFlow LST, and B-CLPD T1 to T4 Assays|a panel of fluorochrome-conjugated antibodies for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations on the BD FACSLyric™ flow cytometer with BD FACSuite™ Clinical application.
41093995|NCT02353611|OTHER|6% hydrogen peroxide|
41093996|NCT02353611|OTHER|35% hydrogen peroxide|conventional peroxide whitening compound acted like control
41093997|NCT02782988|OTHER|olfactory tests, otoacoustic emissions (OAE)|Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
41093998|NCT01716832|BEHAVIORAL|Mindfulness Walking|Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
41093999|NCT04478175|OTHER|multidisciplinary assessment and intervention|early multidisciplinary assessment and intervention in addition to usual patient care
41094000|NCT06520683|DRUG|Tislelizumab|- Tislelizumab 200mg (day 1 and day 22), administered after surgery
41094001|NCT06520683|DRUG|Adjuvant chemotherapy|"* Adjuvant therapy is not mandatory.~* Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine."
41094002|NCT04209881|OTHER|ovarian reserve for Ankylosing spondylitis and control groups|"Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis.~Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group.~Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
41094003|NCT06162819|DRUG|Amitriptyline|Amitriptyline will be used for prophylaxis of migraine, also used as antidepressant
41094004|NCT06162819|DRUG|Flunarizine 5mg|Flunarizine will be used for prophylaxis of migraine,
41094005|NCT01695343|BIOLOGICAL|KB001-A|
41094006|NCT01695343|DRUG|Placebo Comparator|
41094007|NCT03840070|DEVICE|Potenfill|Maximum: 22ml
41094008|NCT03589924|PROCEDURE|Immediate IBBR+TiLoop®Bra|Patients will receive immediate implant reconstruction following mastectomy using TiLoop®Bra
41094009|NCT03589924|PROCEDURE|Immediate-delayed IBBR+TiLoop®Bra|Patients will receive immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra
41094010|NCT05292131|DRUG|bimekizumab|Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.
41094011|NCT06471218|DRUG|SHR-1918; SHR-1918 Placebo|SHR-1918/SHR-1918 Placebo,two administration
41094012|NCT00555581|DRUG|Imatinib Mesylate|In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
41094013|NCT00699933|OTHER|CT-guided percutaneous drainage technique|Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
41094014|NCT02320253|BEHAVIORAL|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
41094015|NCT02320253|BEHAVIORAL|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
41094016|NCT02320253|BEHAVIORAL|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
41094017|NCT05642728|OTHER|Case management follow-up program|The case manager will monitor asthma control (asthma control test, ACT) and adherence to treatment with questionnaires (inhaler adherence test, TAI) and electronic prescription withdrawal (e-prescription). The case manager will make decisions based on these results and according to pre-designed medical instructions. In addition, the patient will be able to contact the case manager for advice during periods of worsening symptoms. The patient will contact the case manager via a mobile app with messaging and video call option, as well as a contact phone number and email for consultations.
41094018|NCT00684502|DRUG|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
41094019|NCT00684502|DRUG|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
41094020|NCT03342924|OTHER|Flanker Test and physical fitness test|Socioeconomic status was determined using a trichotomous index. Inbody was used to assess body composition. To assess physical fitness, certain field tests were implemented using devices to quantify precise actions of physicality. Cognitive control was assessed using a computer-based Flanker Task.
41094021|NCT06613698|DRUG|GSK4532990|GSK4532990 will be administered
41094022|NCT06613698|DRUG|Placebo|Placebo will be administered
41094023|NCT02985697|DRUG|Dexmedetomidine|The intervention being tested is intranasal dexmedetomidine
41094024|NCT02985697|DRUG|Midazolam Hydrochloride|Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
41094025|NCT02985697|DRUG|Nitrous Oxide|Nitrous oxide to be administered in conjunction with other interventions, per study design.
41094026|NCT05180721|BEHAVIORAL|Use of patient portal for diabetes management|A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
40921510|NCT02828215|DEVICE|Swept-source optical coherence tomography (SS-OCT)|"The SD-OCT provides faster images and the ability to scan more of the central retina (macula). SD-OCT simultaneously measures multiple wavelengths of reflected light across a spectrum generating up to 40,000 A-Scans (axially sample points) per second. This allows the generation of 3 dimensional faster based volumetric images of the retina. The Spectralis OCT utilises real-time hardware eye tracking to resample lines scan enhancing the signal to noise ratio by improving the image quality.~The swept-source OCT (SS-OCT) uses a tuneable laser light source with a longer wavelength of light (typically 1040-1050 nm) that the light source seen in more conventional SD-OCT devices. The tissue penetration and resolution is greater with fast acquisition speeds and longer line scan lengths."
40921511|NCT00353860|DEVICE|SOLEX 300i Stem Cell Selection|
40921512|NCT02074891|DRUG|coformulated TDF/FTC|Daily oral dose of coformulated TDF/FTC
40921513|NCT04308031|DRUG|Ivabradine 5 mg [Corlanor]|Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)
40921514|NCT04308031|DRUG|Digoxin 0.25 mg|Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)\>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)\<60 Max dose: 0.25 once daily (QD)
40921515|NCT01022008|DEVICE|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
40921516|NCT06238102|OTHER|pure tone audiometry|measuring hearing impairment to select patients with hearing loss to evaluate who can this hearing impairment affects their quality of life
41094027|NCT05730205|DRUG|Nexplanon 68 MG Drug Implant|Progestin contraceptive device
40758249|NCT06537466|DIETARY_SUPPLEMENT|Very Low Ketogenic Diet|The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
40921517|NCT03471624|DRUG|Tenofovir Alafenamide|Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
41094028|NCT00002784|BIOLOGICAL|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
41094029|NCT00002784|DRUG|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
41094030|NCT00002784|DRUG|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
40758250|NCT01878474|DRUG|TA-8995|TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
40921518|NCT02329340|BEHAVIORAL|Am Academy of Pediatrics print materials|Print materials of injury prevention content.
41094031|NCT00002784|DRUG|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
41094032|NCT00002784|DRUG|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
41094033|NCT00002784|DRUG|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
41094034|NCT00002784|DRUG|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
41094035|NCT00002784|DRUG|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
40921519|NCT02329340|BEHAVIORAL|Family safety 1-2-3|Theoretically based school-aged childhood injury prevention videos for families
40921520|NCT04040491|DRUG|PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
40921521|NCT01876940|DEVICE|air-Q, followed by fiberoptic intubation|
40921522|NCT01876940|DEVICE|Free-hand Fiberoptic Intubation|Fiberoptic tracheal intubation will be performed without use of the air-Q and timed. Laryngeal grade of view will also be assessed
40921523|NCT00639652|PROCEDURE|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
40921524|NCT00639652|PROCEDURE|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
40921525|NCT01495312|DEVICE|SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish|SLT (single session; 180 to 360 degrees of angle will be treated)
41094036|NCT00002784|DRUG|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
41094037|NCT00002784|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
40921526|NCT04440605|PROCEDURE|Preoperative staging--D2 gastrectomy--Postoperative staging|Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy
40921527|NCT00947791|DRUG|ketamine|a single IV infusion of ketamine, IV 0.5 mg/kg
41094038|NCT00002784|RADIATION|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
41094039|NCT00002784|RADIATION|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
41094040|NCT04018092|DEVICE|Active NIR-PBM|See Experimental arm for description.
40921528|NCT00947791|DRUG|midazolam|a single IV infusion of midazolam, 0.045 mg/kg
40921529|NCT05315895|OTHER|natural aging process|To observe the relationship between new cases of diseases and health status of people exposed to different factors such as life style, alcohol consumption, eating habits, etc.
41094041|NCT04018092|DEVICE|Sham NIR-PBM|See Sham Comparator arm for description.
41094042|NCT06394336|OTHER|Muscle strengthening|Strengthening exercises for the intrinsic muscles of the foot and hips
40921530|NCT04992858|DRUG|CT053PTSA|CT053PTSA will be administered orally once a day
40921531|NCT04468529|DRUG|Recombinant human Neuregulin for injection|10 hours per day i.v. drip for the first 10 days (0.6ug/kg/day)
40921532|NCT04468529|DRUG|Placebo|10 hours per day i.v. drip for the first 10 days (0ug/kg/day)
40921533|NCT02381483|OTHER|Cold exposure|
41094043|NCT06394336|DRUG|Standard treatment (oral analgesic/anti-inflammatory drug)|oral analgesic/anti-inflammatory drug. Education.
41094044|NCT01994161|PROCEDURE|intracranial stenting|"all the participants in this group will be performed with intracranial stenting~--------------------------------------------------------------------------------"
41094045|NCT04461223|DIAGNOSTIC_TEST|contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)|CMR T1 mapping, T2mapping, T2\* mapping, LGE, ECV
41094046|NCT06614413|OTHER|Neurodevelopment and behaviour assesment 2 years old|Mothers: Monthly visits guided or not by nutritionist (intervention vs control group) will consist in food questionnaires and 3-day food diary collection during pregnancy. Every three months during lactation. Children: From one year of age onwards, the KIDMED questionnaire will be administered quarterly Neurodevelopment and behavior assessment 18-24 months of age
41094047|NCT01972139|DEVICE|Renal Denervation using the Symplicity Renal Denervation System|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
41094048|NCT01972139|OTHER|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
41094049|NCT01972139|DEVICE|Renal Angiography|Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
41094050|NCT01072929|DRUG|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
41094051|NCT01072929|DRUG|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
41094052|NCT02537444|DRUG|Acalabrutinib|
41094053|NCT02537444|DRUG|acalabrutinib and pembrolizumab combination|
40921534|NCT04805489|OTHER|Mask|"The sequence of mask wearing will be done by drawing lots, in double blind. Only the nurse will be informed of the mask sequence. The doctor will take measurements without seeing the type of mask placed between the athlete's face and the VO2 mask.~The patient will not know which mask will be applied. He will have been informed that he will test three masks (a so-called high-tech mask which will in fact be without a mask, a surgical mask and a general public mask). When the mask is put on, the athlete's eyes will be closed, the sequence without a mask, presented to the subject as a high-tech mask, will be done with a mask that will be put on like a surgical mask or a mask for the general public, except that it will be hollowed out in its center.~The effort tests will be done on a carpet with a filter called COVID on the VO2 masks."
40921535|NCT01849887|BIOLOGICAL|bone marrow-derived mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
40921536|NCT01849887|DRUG|Placebo|Placebo
40921537|NCT06419530|OTHER|Probiotic formula capsule|The subjects take 4 capsules a day for 84 days.
40921538|NCT06419530|OTHER|placebo capsule|The subjects take 4 capsules a day for 84 days.
40921539|NCT06419530|OTHER|FMT capsule|The subjects take 4 capsules a day for 84 days.
40921540|NCT01697410|DRUG|Terlipressin|continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
41094054|NCT04152772|DEVICE|transcranial direct current stimulation|Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.
41094055|NCT00715286|OTHER|timing of surgery|Surgery is followed by chemotherapy
41094056|NCT00715286|OTHER|timing of surgery|Chemotherapy is followed by surgery
40758251|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25 mg
40758252|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25 mg
40758253|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25, 50, 100 and 150 mg
40758254|NCT01878474|DRUG|Placebo|Single ascending dose in Caucasian men
40758255|NCT01878474|DRUG|Placebo|Age-effect in Caucasian men
41094057|NCT04934462|PROCEDURE|physiotherapy|Six months physiotherapy aimed at hip stability.
41094058|NCT04934462|PROCEDURE|arthroscopy|Arthroscopic plication of hip joint capsule.
41094059|NCT06441162|DRUG|Nebulized 3% sodium chloride solution|Standardized dose of nebulized 3% sodium chloride will be provided from 4 mL vial and administered be every 6 hours.
41094060|NCT06441162|DEVICE|Chest percussion cups|The chest percussion cup is a small, flexible cup made of vinyl that is used to provide gentle chest wall vibrations to assist with airway clearance and is utilized in patients of all ages with sputum production, such as those with acute bronchiolitis. Administered every 6 hours while on supplemental oxygen therapy.
41094061|NCT01084161|DRUG|N1539|5 mg IV once per day
41094062|NCT01084161|DRUG|N1539|7.5 mg IV once per day
40921541|NCT01697410|DRUG|Norepinephrine|continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
40921542|NCT06316999|DIAGNOSTIC_TEST|Intestinal Ultrasound|Transabdominal and trans perineal ultrasound of the pouch
40921543|NCT05995262|OTHER|Chart Review|Data collection via retrospective chart review of patients from the Cedar Hill Clinic who had at least two visits with the clinical pharmacist between January 5, 2022 through December 31, 2022
40921544|NCT01317108|DRUG|CMF Chemotherapy|
40921545|NCT03276169|PROCEDURE|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
40921546|NCT03276169|PROCEDURE|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
41094063|NCT01084161|DRUG|N1539|15 mg IV once per day
41094064|NCT01084161|DRUG|N1539|30 mg IV once per day
41094065|NCT01084161|DRUG|placebo|IV placebo once per day
41094066|NCT01084161|DRUG|Morphine|morphine 10-15 mg IV once per day
41094067|NCT01084161|DRUG|N1539|60 mg IV once per day
41094068|NCT00310713|BIOLOGICAL|Meningococcal C conjugate vaccine|Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
41094069|NCT02582203|DRUG|Ceftaroline|
41094070|NCT02582203|DRUG|Vancomycin|
41094071|NCT00377598|DRUG|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
41094072|NCT00377598|DRUG|TAK-583|TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
41094073|NCT00377598|DRUG|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
41094074|NCT00377598|DRUG|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
41094075|NCT00377598|DRUG|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
41094076|NCT00248612|DRUG|Venlafaxine|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
41094077|NCT00248612|BEHAVIORAL|CBT|CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
41094078|NCT00248612|OTHER|Progressive muscle relaxation therapy (PMR)|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
41094079|NCT00248612|OTHER|Placebo medication|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
40921547|NCT03276169|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
40921548|NCT03636841|DEVICE|medical device with CE marking (Ultravision ©)|Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
41094080|NCT04438915|BEHAVIORAL|Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery|The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery
41094081|NCT04438811|OTHER|delivery of the spinal anesthetic by a trained medical officer|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
41094082|NCT04438811|OTHER|delivery of spinal anesthetic by a consultant anesthetist|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
40921549|NCT00726843|OTHER|8 weeks of Iyengar Yoga|Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
40921550|NCT00726843|OTHER|8 weeks of Iyengar Yoga|Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
40921551|NCT04134546|PROCEDURE|CBD exoloration|Early versus late intervention after biliary tract injury post cholecystectomy
40758256|NCT01878474|DRUG|Placebo|Gender-effect in Caucasian women
41094083|NCT01513356|DRUG|BKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
41094084|NCT01445639|DRUG|Dexmedetomidine|Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
40921552|NCT01788436|BEHAVIORAL|Cognitive Test Battery 1|The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
41094085|NCT01445639|DRUG|Normal saline|as placebo
40921553|NCT01788436|BEHAVIORAL|Cognitive Test Battery 2|The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
40921554|NCT03667898|PROCEDURE|Lumbar plexus block using NTT|An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.
40921555|NCT03667898|PROCEDURE|Lumbar plexus block without NTT|An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
40921556|NCT02649829|BIOLOGICAL|dendritic cell vaccination plus chemotherapy|"A. Chemoimmunotherapy:~1. four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.~2. four intradermal vaccinations with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; at day 14+/- 3 days after the start of each chemotherapy cycle.~B. Surgery: pleurectomy/decortication; in case of resectable disease, 4-6 weeks after start of the last chemotherapy cycle."
41094086|NCT03106961|DEVICE|Bioresorbable vascular scaffolds, OCT, non-compliant ballooning|Measure the effect of high-pressure, NC ballooning on scaffold embedding by OCT
41094087|NCT02338622|DRUG|olaparib|olaparib BD
41094088|NCT02338622|DRUG|AZD5363|AZD5363 BD
41094089|NCT06615362|PROCEDURE|preparation of dentin membrane from hopeless tooth for Guided Bone Regeneration in Immediate Implant|tooth extraction , preparation of dentin membrane ,immediate implantation ,Xenogeneic bone graft material, application of dentin derived barrier membrane
41094090|NCT06615362|PROCEDURE|Collagen Membrane for Guided Bone Regeneration in Immediate Implant|like group one but with application of collagen membrane
41094091|NCT06614829|DEVICE|Stratafix Suture|Stratafix sutures are barbed and have an antimicrobial coating. The barbs maintain tension during and allows for knotless suturing. The antimicrobial coating inhibits bacterial colonization of the wound.
41094092|NCT06614829|DEVICE|DERMABOND PRINEO|"DERMABOND™ PRINEO™ Skin Closure System is a sterile, liquid topical skin adhesive. It also incorporates a self-adhering mesh that is applied to the approximated skin edges to provide temporary skin edge alignment until the liquid adhesive is applied to achieve skin closure. It forms a strong, flexible, waterproof microbial barrier-as long as the adhesive film remains intact-that falls off naturally after 7-14 days.~Dermabond Prineo system will be applied to the skin for skin closure."
41094093|NCT06233630|DRUG|Control Test - spinal anesthesia|No peripheral nerve block Only spinal anesthesia
41094094|NCT06233630|DRUG|Ropivacaine 0.2% Injectable Solution ESPB|ultrasound guided erector spinae plane block (ESPB) - L2 level, unilateral
40758257|NCT01878474|DRUG|Placebo|Single ascending dose in Japanese men
40921557|NCT03601884|BEHAVIORAL|Optimal Health Program|The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication \& Metabolic Monitoring, Collaborative \& Strategies, Change enhancement, Visioning \& Goal Setting and Maintain Well-being.
41094095|NCT06233630|DRUG|Ropivacaine 0.2% Injectable Solution iPACK+ACB|ultrasound guided iPACK block + Adductor Canal Block
41094096|NCT06319144|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
40921558|NCT03601884|OTHER|Treatment as Usual|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
40921559|NCT00439049|DRUG|modafinil|400 mg daily
40921560|NCT00439049|DRUG|d-amphetamine|60mg daily
40921561|NCT00439049|DRUG|L-Dopa|800/200mg daily
40921562|NCT00439049|DRUG|Naltrexone|50mg daily
40921563|NCT04712240|DEVICE|Respiration rate monitor|A portable continuously monitoring respiration rate monitor will be fitted to each participant. The respiration rate monitor is housed within a comfortable chest strap that be secured to the participant for the duration of the surgical procedure
40921564|NCT02743611|BIOLOGICAL|BPX-701|autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch
40921565|NCT02743611|DRUG|Rimiducid|dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
40921566|NCT00146432|PROCEDURE|Immunoadsorption of LPS, IL-6 and C5a|
40921567|NCT01699867|DEVICE|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
40921568|NCT02907840|DEVICE|Swisstom BB2|Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
40921569|NCT06431971|DRUG|Talineuren|Talineuren infusion weekly
40921570|NCT06431971|DRUG|Placebo|Placebo infusion weekly
40921571|NCT03027544|RADIATION|tomotherapy|"Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles."
40921572|NCT00402233|DRUG|Pramipexole|
40921573|NCT00402233|DRUG|Placebo|
40921574|NCT01337102|PROCEDURE|Physician Receives QoL results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician receives the print out of the results.
40921575|NCT01337102|PROCEDURE|Physician Does not receive the results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician does not receive the print out of the results.
40921576|NCT03254108|DRUG|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
40921577|NCT03254108|DRUG|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
40921578|NCT03254108|DRUG|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
40921579|NCT03254108|DRUG|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
40921580|NCT03254108|DRUG|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
40921581|NCT03225040|DRUG|Pegvisomant|Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
40921582|NCT00627575|DRUG|lamotrigine|Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.
40921583|NCT00627575|DRUG|atorvastatin|Atorvastatin will available as 40 mg tablets.
41094097|NCT06319144|OTHER|0.9% Normal Saline|Patients in the control group were infused intravenously with 0.9% Normal Saline (500 ml/h) in the PACU.
41094098|NCT05504343|DEVICE|"Intensity SL Intraocular Lens"|Cataract surgery and intraocular lens implantation
41094099|NCT00918190|DRUG|Placebo|Saline
41094100|NCT00918190|DRUG|Ondansetron, Dexamethasone|Use of ondansetron and dexamethasone as combined antiemetics
41094101|NCT00918190|DRUG|Midazolam, dexamethasone|use of midazolam and dexamethasone as combined antiemetic
41094102|NCT03936062|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the exposure
41094103|NCT03936062|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
41269633|NCT06395844|DRUG|METR-NK cell(Metabolic Remodeling Nature Killer Cells)|The minimum amount of METR-NK cells infused each time should be no less than 7.5×10\^7 cells, Continuous infusion for 2 days constitutes one course, with 4 courses. The infusion is given every 2 weeks.
40921584|NCT00627575|DRUG|phenytoin|Phenytoin will available as 100 mg capsules.
40921585|NCT04108117|PROCEDURE|Robotic nipple sparing mastectomy|Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.
40921586|NCT01158001|BEHAVIORAL|Prolonged exposure therapy|Twelve sessions (90 minutes each) of prolonged exposure therapy
40921587|NCT03354143|DRUG|Standard Care|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
40921588|NCT03354143|DRUG|Intensive Treatment|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
41094104|NCT05548530|PROCEDURE|Stereotactic intracranial hematoma puncture|Check the CT scan of the patient's brain, find out the largest hematoma level of the patient, measure the coordinates of the puncture center, locate and mark the skull surface according to the coordinates obtained from the measurement, select the puncture point under the stereotaxic instrument, and mainly avoid important blood vessels , nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.
41094105|NCT05548530|PROCEDURE|decompressive craniectomy|Prior to the procedure, all patients obtained endotracheal intubation under general anesthesia following the informed consent provided by their family members. Upon identifying the hematoma's location through CT imaging, the surgeon made a linear or horseshoe-shaped incision on the scalp and subsequently opened the dura mater after creating a bone flap. The hematoma was punctured using a brain needle, allowing for effective decompression. The cerebral cortex was incised along the cerebral gyri, facilitating the separation of brain tissue to eliminate residual hematoma. Once hemostasis was ensured within the operative area, a silicone drainage tube was inserted, and the cranial bone flap was restored to its original position. In cases of severe brain edema or cerebral herniation, bone flap decompression was performed.
41094106|NCT05548530|PROCEDURE|Neuroendoscopic|The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.
41094107|NCT02179918|DRUG|PF-05082566|Starting dose of 0.45 mg/kg q3wks IV, dose escalation
41094108|NCT02179918|DRUG|MK-3475|2 mg/kg q3wks, IV
41094109|NCT06615310|OTHER|ultrasonograpic evaluotion|The distance between the hyoid and thyroid cartilage, the volume of the geniohyoid, digastric anterior, sternohyoid and thyrohyoid muscles will be evaluated by ultrasound.
41094110|NCT00626600|DRUG|Oxycodone Hydrochloride|
41094111|NCT02760862|DRUG|hydrocortisone 100mg.|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
41094112|NCT02760862|DRUG|mannitol 20% intravenous fluid|group (II), received mannitol 20% 100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis. Urinary catheter was inserted for patients in group (II) under complete aseptic conditions by the anesthesia resident before the start of mannitol infusion and removed after its discontinuation, accompanied by the intravenous fluid infusion over 48 hours of 500ml of normal saline or Ringer's solution every 8 hours and the input/output fluid chart for evaluation of fluid balance.
41094113|NCT05630339|DIETARY_SUPPLEMENT|Magnesium chloride|Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.
41094114|NCT05630339|DIETARY_SUPPLEMENT|Vitamin D|Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.
41094115|NCT05630339|DIETARY_SUPPLEMENT|Inert placebo|Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.
41094116|NCT02158065|OTHER|Coaching program|The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
41094117|NCT02999282|DEVICE|Anodal transcranial direct current stimulation|10 sessions of anodal transcranial direct current stimulation (5 days/week for 2 weeks)
41094118|NCT02999282|DEVICE|Sham transcranial direct current stimulation|10 sessions of sham transcranial direct current stimulation (5 days/week for 2 weeks)
41094119|NCT02307123|PROCEDURE|Intubation|HEMS physician prehospital intubation
41094120|NCT02635659|OTHER|Encapsulated nutrients|
41094121|NCT02635659|OTHER|Placebo|
41094122|NCT02882503|DEVICE|endoscopic ultrasound - radiofrequency ablation (EUS-RFA)|Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
41094123|NCT01220674|OTHER|cognitive testing|computer-based cognitive assessment
40921589|NCT04276324|OTHER|Resistance training|Ten weeks of resistance training
40921590|NCT04276324|OTHER|Testing sessions|Testing sessions
40921591|NCT02879487|DEVICE|Monopolar needle electrode|Colpotomy during total laparoscopic hysterectomy
40921592|NCT00941629|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.
40921593|NCT00941629|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
40921594|NCT00206232|DRUG|Spironolactone|Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
40921595|NCT01062178|DRUG|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
40921596|NCT04285840|OTHER|Venous ACT|Matched/paired venous ACT samples will be drawn at the same time as arterial ACT samples to compare the results agreement between venous and arterial ACTs. Subjects undergoing atrial fibrillation ablations will continue to have Heparin dosed on the arterial ACT sample results only per the standard of care. Heparin will not be administered based on venous ACT levels obtained during this study.
41094124|NCT04057456|OTHER|Placebo diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
41094125|NCT04057456|OTHER|Anti-inflammatory diet|"Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes. Occasional cheat foods are built into the anti-inflammatory diet (e.g. two bottles of beer per week)"
41094126|NCT04057456|DRUG|Nabilone Capsules|Capsules will be 0.5mg nabilone. Participants will undergo a 5-week titration period by taking 1 (0.5mg) nabilone capsule per day for a three-day period. The dose will be increased on a fixed schedule by 1 (0.5mg) capsule every three days to a maximum of 8 capsules/day (4mg). Dosage will be maintained if higher doses are not tolerated or if sufficient relief is obtained (at least a 2-point change on the NRS). Once the appropriate nabilone (or placebo) dosage for each participant is determined, participants will begin their respective interventions over the course of the 4-week treatment period.
41094127|NCT04057456|OTHER|Placebo capsules|Placebo capsules contain no active ingredient. Participants on placebo capsules will undergo the same 5-week titration period and intervention period as those on active treatment.
41094128|NCT03478579|OTHER|observational|No intervention, it is observational study
41094129|NCT02763553|DIETARY_SUPPLEMENT|Ketogenic Feed|A low-carbohydrate, high-fat feed designed to induce a ketotic state.
40921597|NCT03189056|DIAGNOSTIC_TEST|Chagas serology|IFI + ELISA method if no biological confirmation of chagas disease is in our possession
41094130|NCT02763553|DIETARY_SUPPLEMENT|Standard Feed|Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
41094131|NCT01648283|DRUG|IV racemic methadone HCl|IV racemic Methadone HC1 6 mg
41094132|NCT01648283|DRUG|Oral racemic methadone HCl|oral d5-methadone HCl 11 mg
41094133|NCT05702203|OTHER|Creative Music Therapy|Creative Music Therapy 3x20 minutes per week during admission, at least 10 session during admission, after discharge once every other week until 6 months of age.
40921598|NCT03189056|BIOLOGICAL|Creatinina|Plasmatic single mesure after consultation 1, to evaluate renal function
40921599|NCT03189056|PROCEDURE|Urodynamic exploration|With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
40921600|NCT03337789|DIETARY_SUPPLEMENT|Polygonatum sibiricum|Polygonatum sibiricum 800mg, 30-60 minutes before sleep, once a day for 4 weeks
40921601|NCT03337789|DIETARY_SUPPLEMENT|Placebo|Placebo 800mg, 30-60 minutes before sleep, once a day for 4 weeks
40921602|NCT02252341|DIETARY_SUPPLEMENT|N-Acetyl-Cysteine|drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
40921603|NCT04938297|DRUG|Rituximab, Lenalidomide, Zanubrutinib|Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.
41094134|NCT06001684|BIOLOGICAL|IBR854 Cell Injection|The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
41094135|NCT03922243|OTHER|retrospective|Retrospective study to assess treatment done by dental students
41094136|NCT06613750|DRUG|Sitagliptin and Gliclazide|Participants in this arm will receive sitagliptin phosphate 100 mg once daily combined with gliclazide sustained-release tablets 30-120 mg once daily for 12 weeks
41094137|NCT06613750|DRUG|Metformin|Participants in this arm will receive metformin 500 mg to 2000 mg per day, divided into two doses, for 12 weeks
40921604|NCT04938297|DRUG|Lenalidomide, Zanubrutinib|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) or Zanubrutinib 160 mg bid. Continuously use for 2 years or until disease progression
40921605|NCT04938297|DRUG|Lenalidomide|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) . Continuously use for 2 years or until disease progression
41094138|NCT02494830|DRUG|Ketamine|Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
41094139|NCT02117869|OTHER|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.
40921606|NCT05863000|OTHER|Online questionnaire/survey|Participants are expected to answer a short survey based on their overall experiences with their own health. No participants will therefore be followed for more than the duration of time it takes a subject to answer the questionnaire (approx 15 minutes). Randomly selected volunteers of around 30 respondents will afterwards be invited to participate in a qualitative interview with the intend to elaborate their questionnaire responds.
41094140|NCT02117869|OTHER|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
41094141|NCT02117869|OTHER|Water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
41094142|NCT05565742|DRUG|LY3819469|Administered SC
41094143|NCT05565742|DRUG|Placebo|Administered SC
41094144|NCT05326373|DRUG|Stannous fluoride|brush twice daily with stannous fluoride toothpaste for 8 weeks
41094145|NCT02473120|BIOLOGICAL|Determination of ESR1 mutations|Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
41094146|NCT06441773|PROCEDURE|Respiratory Rehabilitation|"An initial assessment is conducted upon admission to personalize the program. This includes:~Clinical examination Spirometry Maximum Inspiratory Pressure (PImax) measurement Multidimensional Dyspnea Profile questionnaire at end of TM6 Exercise Functional Testing Measurement of quadriceps strength and endurance Blood gases Educational interview and shared educational assessment London Chest Activity of Daily Living (LCADL) Tobacco and/or dietary consultation~The respiratory rehabilitation program, performed twice a week, includes:~Exercise training on an ergocycle and treadmill (30 minutes at ventilatory threshold for the ergocycle; 30 minutes at 60-80% walking speed for the treadmill; or dyspnea rated 4-6 on the Borg scale after endurance exercise) Quadriceps muscle strengthening Therapeutic education program Group gymnastics Smoking cessation assistance Socio-psychological and nutritional support"
41094147|NCT00471211|DRUG|PBT2|
40921607|NCT04066712|DRUG|LC350189 200 mg|Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
40921608|NCT04486300|PROCEDURE|Pneumatic reduction and Laparotomy|Pneumatic reduction is the main intervention for suitable cases and If failed a laparotomy exploration and surgical reduction is done to save life
40921609|NCT03504046|DEVICE|Artificial Pancreas App|The portable Artificial Pancreas System App (APS APP) is an artificial pancreas system comprised primarily of an insulin pump, a continuous glucose monitor (CGM), and a cellular phone device to connect the components.
40921610|NCT03104660|DEVICE|CE certified mitral valve repair systems|Patients receive a transcatheter mitral valve repair with CE certified transcatheter mitral repair systems.
40921611|NCT05254743|DRUG|Pirtobrutinib|Administered orally.
40921612|NCT05254743|DRUG|Ibrutinib|Administered orally.
40758258|NCT02554838|OTHER|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
40921613|NCT04244305|OTHER|Exercise Therapy|Endurance training in the form of treadmill/cycle-ergometry
40921614|NCT05814302|DRUG|Paracetamol|Emergency physicians were free to administer paracetamol 1000 mg (P), the combination paracetamol 500 mg/ibuprofen 150 mg (PI) or Ibuprofen 600 mg (I)
40921615|NCT00145977|DRUG|Alendronate|alendronate 70 mg once weekly
40921616|NCT00145977|DIETARY_SUPPLEMENT|Calcium Citrate|600 mg of calcium citrate
40921617|NCT00145977|DIETARY_SUPPLEMENT|Vitamin D|500 mg of Vitamin D consumed with the evening meal.
40921618|NCT02321670|PROCEDURE|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
41094148|NCT06230757|DRUG|Psilocybin 25mg|25mg psilocybin capsule
41094149|NCT06230757|DRUG|Placebo (active placebo)|1mg psilocybin capsule
41269634|NCT01284803|BEHAVIORAL|an educational intervention|To elaborate an educational program for the management of depression in primary care
41094150|NCT01445756|DRUG|Lidocaine|During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.
40921619|NCT02321670|PROCEDURE|Graft|Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
40921620|NCT04683601|OTHER|Thoracoscopic esophagectomy in left decubitus|Making surgical field at thoracoscopic esophagectomy in left decubitus
40921621|NCT05831683|OTHER|Introduction of Standard Operating Procedure regarding lung protective ventilation during general anaesthesia.|The Standard Operating Procedure document will be introduced. The SOP document will cover the theoretical background, definition, and recommendations/criteria of LPV. The SOP document will reflect the most recent LPV guidelines.
40921622|NCT01155167|DRUG|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
41094151|NCT01445756|DRUG|Placebo|Placebo; no topical lidocaine administered
41094152|NCT02312440|DRUG|0.9% sodium chloride|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
41094153|NCT02312440|DRUG|tranexamic acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
40921623|NCT01155167|OTHER|Placebo|Placebo
40921624|NCT06405971|DRUG|Metformin|Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.
40921625|NCT04457622|OTHER|Auditory perception tasks in healthy participants|"The participants complete auditory perception tasks while EEG, and MEG record brain signals (primary outcome measure). The tasks acquire behavioral responses with button presses (secondary outcome measure).~All analyses are intra-subject (no analyses are between-subject)."
40921626|NCT05659537|DRUG|Dulaglutide|Administered SC
40921627|NCT01136187|PROCEDURE|Access site in primary PCI|
40921628|NCT00459056|DRUG|Carvedilol CR + Lisinopril|Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
40921629|NCT00459056|DRUG|Lisinopril + HCTZ|Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
40921630|NCT05614856|DEVICE|EVAR off-label use|Normally a femoral access was used, although a brachial approach can be useful for crossing total occlusions. For TASC B and C lesions, predilatation of the iliac lesions is advisable, while for TASC D it is mandatory. In case of total aortic occlusions, the procedure demands that recanalization of the distal aorta occurs as close as possible to the bifurcation.. The key technique is to recanalize from one common iliac artery into the opposing snaring the wire to create a femoral-femoral crossover. The femoral-femoral wire is then replaced with a MPA catheter; the SurePass wire attached to the contralateral limb is then passed through the catheter. The sheath can be placed within 5 cm of the aortic bifurcation, and the AFX can be delivered through the common iliac and aortic occlusion. Predilatation were performed with bilateral 6-8 mm x 150 mm balloons and or progressive dilatators.
40921631|NCT02156271|DRUG|ramelteon|
40921632|NCT02156271|DRUG|placebo|
40921633|NCT04727021|DRUG|20 mg tablet rivaroxaban|Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
40921634|NCT04727021|DRUG|20 mg rivaroxaban, granules for oral suspension|Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.
41094154|NCT02312440|DRUG|tranexamic acid|"The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.~60 Milliliters（ml） by irrigation for 3 minutes before wound closure."
41094155|NCT03251651|DRUG|Propofol|Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.
41094156|NCT03251651|DRUG|Dexmedetomidine|Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
41094157|NCT00362752|DRUG|Norfloxacin|400 mg po bid
41094158|NCT00362752|DRUG|Placebo|Placebo 400 mg po bid
41094159|NCT03176745|DIAGNOSTIC_TEST|multiple breath washout|determination of lung clearance index using SF6 multiple breath washout
41094160|NCT03605186|OTHER|Chamomile oral cryotherapy|The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
41094161|NCT03605186|OTHER|Oral cryotherapy|The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
40921635|NCT02079818|DEVICE|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
40921636|NCT06297785|BEHAVIORAL|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8 sessions), will be given online in a group setting.The hypnosis treatment is administered by a nurse specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment is based on the North Carolina protocol. Patients will assess gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
41094162|NCT03494699|BEHAVIORAL|Multidisciplinary prevention|group cognitive training (every month) App-based Cognitive Training at Home (using smartphone application) physical activity/body weight/smoking \& alcohol cessation monitoring and feedback
41094163|NCT01139697|OTHER|Hair sampling|Hair sampling for the measurement of cortisol and testosterone
40921637|NCT00504946|DRUG|prednisone, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose"
40921638|NCT00504946|DRUG|prednisone, colecalciferol, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose"
40921639|NCT00504946|DRUG|lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose"
40921640|NCT00504946|DRUG|montelukast sodium|Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children \> 14 years old received 10mg oral tablet once daily at bedtime
40921641|NCT00504946|DRUG|lactose|Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
41094164|NCT04559932|OTHER|Tracheostomy Training Course|A standardized competency-based education tracheostomy module has been developed by the investigator group in collaboration with Respiratory Medicine, Complex Care, Respiratory Therapy, Nursing Education, Family Advisory Network and the Learning Institute at SickKids. Instructional methods for the full module are based on principles of adult learning and evidence from the procedure education literature and include the use of interactive, small-group teaching, hands-on simulation-based learning stations with relevant equipment as well as a formal assessment of knowledge and skills using simulation. Pre-learning packages are sent to course attendees at the time of registration to facilitate higher level discussions on the day of the course. While investigators have rigorously developed the curriculum and evaluation measures, the course outcomes remain unknown.
41269635|NCT03971188|PROCEDURE|Trapeziectomy with Internal Brace|Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.
40921642|NCT06173115|DEVICE|Perclose Proglide system|"Preclosure technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site."
40921643|NCT00619320|BEHAVIORAL|Safer Sex Skills Building (SSB)|Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
41094165|NCT02579512|OTHER|Extra-corporeal ECG signal analysis|The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
41094166|NCT00438425|DIETARY_SUPPLEMENT|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
40921644|NCT04297722|OTHER|Dairy products|Dairy consumption including total dairy, full-fat dairy, low-fat dairy, total milk, full-fat milk, low-fat milk, total yogurt, full-fat yogurt, low-fat yogurt, total cheese, hard cheese and fresh cheese
40921645|NCT04669418|DIAGNOSTIC_TEST|RNA expression signature|Whole transcriptome profiling using RNA sequencing
40921646|NCT05808634|DRUG|BA3182|Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
41094167|NCT00438425|DIETARY_SUPPLEMENT|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
41094168|NCT00438425|DIETARY_SUPPLEMENT|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
41094169|NCT02807753|OTHER|Ankle and Knee Ultrasound Joint Assessment|Ultrasound Examination of the ankles and knees
41094170|NCT02807753|OTHER|Ankle and Knee Magnetic Resonance Imaging|Ankle and Knee Magnetic Resonance Imaging
41094171|NCT00192192|BIOLOGICAL|CAIV-T|
41094172|NCT00503074|BEHAVIORAL|TV modification|Parents receive a health behavior-change intervention consisting of 1 in-person visit from a case manager, followed by phone and e-mail contact at least monthly. The intervention is designed to promote healthy TV viewing, including viewing fewer commercials, by the target child aged 2-5 years old, and uses health behavior change theory and social cognitive theory.
40921647|NCT03219658|BEHAVIORAL|Parenting education sessions|If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
41094173|NCT00503074|BEHAVIORAL|safety and injury prevention|Parents receive behavior-change counseling around toddler and preschooler safety and injury prevention.
41094174|NCT02397889|DRUG|Ketamine|This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
41094175|NCT02397889|DRUG|Midazolam|This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
41094176|NCT05144217|DRUG|Placebo|1 capsule per day of placebo
40921648|NCT00742664|BEHAVIORAL|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
40921649|NCT00742664|BEHAVIORAL|Wait-list control|The subject will not receive active treatment during this interval.
40921650|NCT06431867|OTHER|Guidelines for primary care management of osteoporosis|All usual care of osteoporosis in primary care
40921651|NCT04221776|OTHER|Group toilet training in daycare|During the training, children wore underpants, were informed about potty training, were encouraged to drink often and were asked regularly if they felt the need to void. Tutors looked for elimination signals in the child and quickly responded by putting the child on the potty when he/she expressed the need to void or to defecate. Children were positively rewarded. Parents received a leaflet containing practical tips concerning TT and their child's successes of the past two days. They were asked to continue TT at home during the following weekend and longer if necessary. Daycare workers were asked to pay more attention on the TT during the following days and weeks to ensure the effect of the intervention.
40921652|NCT04221776|OTHER|Individual toilet training at home|Parents were encouraged to start TT their child, because they were considered as being ready to initiate TT. Children did not receive any intervention, but parents were asked to start TT in their own manner. Parents were allowed to search for information on methods of TT with their relatives, internet, books,...
40921653|NCT00436540|DRUG|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
40921654|NCT00436540|DRUG|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
40921655|NCT03470727|DEVICE|Citrate dialysate|Change form acetate to citrate dialysate
40921656|NCT04251676|OTHER|Observational study|Observational study
40921657|NCT05488756|OTHER|Group 1|Physical therapy agents and isometric exercise training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and isometric training 3 times a week for 4 weeks by the physical therapist.
40921658|NCT05488756|OTHER|Group 2|Physical therapy agents and deep cervical flexor muscle training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and muscle training 3 times a week for 4 weeks by the physical therapist. Training of the craniocervical flexor muscles is going to be focused on the deep flexor muscles such as longus capitis and longus colli muscles, making neck flexion, not the head.
41094177|NCT05144217|DRUG|2x 140 mg per day|2 capsule per day of silimarit
41094178|NCT05144217|DRUG|3x 280 mg per day|3 capsule per day of silimarit
41094179|NCT05144217|DRUG|1x 1120 mg|8 capsule per day of silimarit
41094180|NCT03556826|BEHAVIORAL|Social Value Learning Training|For each child, two faces will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display.
41094181|NCT02785601|DRUG|Trazodone Hydrochloride prolonged-release tablets|strength 75mg, 150 mg. Oral administration with 200ml water
41094182|NCT01304706|DRUG|Fluocinolone Acetonide|0.2 μg/day
40921659|NCT05488756|OTHER|Group 3|Physical therapy agents and core stabilization training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and stabilization training 3 times a week for 4 weeks by the physical therapist. These exercises will be performed for 10 repetitions with 10 seconds of contraction and 5 seconds of relaxation.
41094183|NCT05062590|OTHER|Recommendations|Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP
41094184|NCT03667248|DEVICE|Sorin Perceval ® Sutureless Valve (Sorin Group Italia Srl, 13040 Saluggia, Italy), available in different sizes (S 19-21mm, M 21-23mm, L 23-25mm, XL 25-27mm)|Sizing of the valve by preoperative CT scan of the heart and comparison of this measurement with the standard procedure (Sizing intraoperatively using the measuring devices provided by the product manufacturer)
41094185|NCT06613438|DEVICE|eGERD device|"The eGERD device is a novel device developed by GerdCare Medical for reducing symptoms of GERD. The device is noninvasive and designed for self-use in the home environment. It is applied on the abdominal skin and generates electrical stimulation pulses.~For optimized effect, the stimulation is synchronized with the breathing phase, such that it is active mainly during inhalation. The stimulation intensity can be adjusted by the user."
41094186|NCT06613438|DEVICE|eGERD_Sham|The eGERD_Sham is a sham version of the eGERD device. It is capable of inducing sensation of electrical stimulation pulses in the target abdominal muscles without a therapeutic effect. Aside from this difference, the eGERD_Sham is identical to the eGERD device.
41094187|NCT06244108|OTHER|Occupational therapy home program|"After evaluating the children, an occupational therapy home intervention program will be developed for each child. The program will be monitored through telephone and computer interviews, as well as video, photo, and audio recordings. The interventions in this study were selected based on successful occupational therapy home programs for children with disabilities. The program consists of five steps.~Step 1 is to establish collaborative relationships with parents. Step 2 is to determine the most appropriate goals for the child and their family. Step 3 involves selecting the most suitable therapeutic activities to achieve these goals. Step 4 is to educate and support parents in performing these therapeutic activities. Finally, Step 5 involves measuring the results and providing feedback."
40921660|NCT06005324|DRUG|Paclitaxel|Given as part of induction chemotherapy.
41094188|NCT02662192|OTHER|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
40921661|NCT06005324|DRUG|Carboplatin|Given as part of induction chemotherapy.
41094189|NCT02662192|OTHER|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
41094190|NCT02708862|DEVICE|Preoxygenation|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
41094191|NCT04157166|DIAGNOSTIC_TEST|to record a whole body 3D of 25 minutes in camera VERITON-CT ™|The procedure of recording of 25 minutes in camera VERITON-CT ™ including the registration whole body 3D coupled to a scanner low dose (CT) will be added to conventional recording followed by complementary images SPECT/CT
41094192|NCT00004886|DRUG|docetaxel|
41094193|NCT00004886|DRUG|dofequidar fumarate|
41094194|NCT02924454|DRUG|metoprolol|One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
41094195|NCT02924454|DRUG|intravenous lipid emulsion|Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
41094196|NCT02924454|DRUG|Sodium chloride 0.9% solution - lipid emulsion dummy|Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
41094197|NCT02924454|DRUG|Sodium chloride 0.9% solution - metoprolol dummy|Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
41094198|NCT04896255|DRUG|peginterferon alpha based regimen|peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
41094199|NCT04896255|DRUG|nucleos(t)ide|peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
41094200|NCT06303986|DEVICE|Neomonki|The Neomonki is a monitoring kit for hospital use in neonates with Neonatal Abstinence Syndrome (NAS).
40921662|NCT06005324|DRUG|Cetuximab|Given as part of induction chemotherapy.
40921663|NCT06005324|RADIATION|Standard Dose Radiation|Radiation given once daily for 5 days for 7 weeks as part of CRT regimen.
40921664|NCT06005324|RADIATION|Low Dose Radiation|Radiation given once daily for 5 days for 6.5 weeks as part of CRT regimen.
40921665|NCT06005324|DRUG|Cisplatin|Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
40921666|NCT06005324|DRUG|TFHX Regimen|Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
40921667|NCT02967757|DRUG|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
40921668|NCT00567255|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
40758259|NCT02554838|OTHER|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
40921669|NCT00567255|DRUG|Placebo|
40921670|NCT00567255|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
40921671|NCT05830617|DEVICE|real tACS|The effect of transcranial alternating current stimulation (tACS) will be investigated in WP3. Patients will undergo standard intensive rehabilitation plus gamma tACS for two weeks.
41094201|NCT06409585|DIAGNOSTIC_TEST|68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR|200MBq of the above named radiotracer will be administered for PET-MR
41094202|NCT06409585|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram at baseline and 1 year follow-up
41094203|NCT06409585|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI at 1 year
41094204|NCT05137951|DEVICE|Rebee sensor|Rebee is a wearable motion sensor package of sensor with its own mobile application, which measures range of joint movement in different planes easily which the patient able to wear the sensor and move easily to measure ROM and record the measurement at the application software Digital goniometer Goniometry has been described as a tool to measure angle. It gives the physician a useful method to diagnose musculoskeletal function in terms of ROM, monitor the progress of an intervention, record the data for future follow-up, and meet statutory and legal requirements for impairment rating and disability determinations where applicable
41094205|NCT02106767|DRUG|Rosuvastatin|Rosuvastatin 20mg po x1
40921672|NCT05830617|DEVICE|sham tACS|In WP3, patients will undergo standard intensive rehabilitation plus sham tACS for two weeks.
40921673|NCT01909791|PROCEDURE|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
40921674|NCT01909791|DRUG|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
41094206|NCT02106767|DRUG|Rosuvastatin plus rifampin|Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
41094207|NCT00839228|DRUG|Perhexiline|100mg o bd for 3 months
41094208|NCT00839228|DRUG|Placebo|Placebo one tablet bd for 3 months
41094209|NCT06347107|DEVICE|Robotic subretinal tPA injection|-The insertion of a 41G subretinal needle adjacent to a subretinal hemorrhage using the stabilizing (tremor-reducing) properties of a robotic instrument in order to slowly inject tPA and evaluate whether the needle can be held in place for up tot 3 minutes.
40921675|NCT01909791|PROCEDURE|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
40921676|NCT01909791|DRUG|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
40921677|NCT00345332|DRUG|Botox|Injected
40921678|NCT00345332|DRUG|Placebo|Injected
40921679|NCT00444678|DRUG|Cetuximab|500 mg/m2, IV every two weeks
41094210|NCT02459964|DRUG|Fentanyl Nasal Spray|Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)
41094211|NCT02459964|DRUG|Hydromorphone Hydrochloride|Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
41094212|NCT02459964|BEHAVIORAL|Phone Call|Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
41094213|NCT05077631|DRUG|ACD856|Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
41094214|NCT05077631|DRUG|Placebo|Placebo oral solution
41094215|NCT05077631|DRUG|ACD856 (fed cohort)|Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
41094216|NCT00542022|DRUG|MK0812 / Duration of Treatment: 12 Weeks|
41094217|NCT00542022|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
41094218|NCT04294082|BEHAVIORAL|Mindfulness based intervention|"A four session, 120 mins per session mindfulness based course delivered weekly oer the course of four weeks. The mindfulness sessions are based on the model delineated by Kabat-Zinn (1992) and will encompass:~* an introduction to mindfulness~* body-scan exercises~* sitting meditation~* mindful movement exercises~* individual and group reflections~* homework exercises"
41094219|NCT02286440|OTHER|AssureRx GeneSight genotyping results|
41094220|NCT02286440|OTHER|Treatment as usual|
41094221|NCT02809911|DEVICE|Provant|
41094222|NCT03427229|BIOLOGICAL|Single-infusion FMT|Patients will receive a single fecal infusion by colonoscopy
41094223|NCT03427229|DRUG|Vancomycin (before randomization)|Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
40921680|NCT00444678|DRUG|Oxaliplatin|85 mg/m2, IV, q 2 weeks
40921681|NCT00444678|DRUG|Capecitabine|2500 mg, po bid x 7 days every two weeks
40921682|NCT02694432|BEHAVIORAL|GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
40921683|NCT02694432|BEHAVIORAL|Minding GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
41094224|NCT03427229|BIOLOGICAL|multiple-infusion FMT|Patients will receive multiple fecal infusions by colonoscopy
41094225|NCT05741411|OTHER|RPM-assisted specialist access|Participants will be prompted to report current symptoms and activity once a day via remote patient monitoring chat technology for up to 28 days following injury. Patients with either escalating or plateauing symptoms will be flagged, with an electronic alert sent via the electronic health record to a nurse navigator. The nurse navigator will have access to the symptom data and facilitate scheduling an in person or telehealth specialist visit as indicated. Symptoms will continue to be monitored through the 28-day acute study period with additional clinical visits occurring according to clinical need.
41094226|NCT00591747|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
41094227|NCT00591747|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
41094228|NCT06340243|RADIATION|radiotherapy|radiotherapy
41094229|NCT01033643|DRUG|MK-3614|Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.
41094230|NCT01033643|DRUG|Placebo for MK-3614|Participants were administered dose matched placebo tablets according to randomization.
40921684|NCT02935426|DEVICE|n-butyl cyanoacrylate and 2-octyl cyanoacrylate|used in cyanoacrylate group
40921685|NCT02935426|DEVICE|5-0 Polytetrafluoroethylene (PTFE) suture|used in suture group
40921686|NCT04043598|DRUG|0.9% Sodium-chloride|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
41094231|NCT00790062|DRUG|Oxytocin|See arms
41094232|NCT05335681|BEHAVIORAL|WARM SHOWER APPLICATION|Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen and groin areas will be applied. Since possible complications may be encountered, pregnant women The researcher will be accompanied and sit safely in the chair. will be provided. VAS scale twice, before and after the intervention will be applied. Birth satisfaction scale before discharge will be applied.
40921687|NCT04043598|DRUG|Ringer's Lactate|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
40921688|NCT01819285|PROCEDURE|Immediate Orchiectomy or depot LHRH|
41094233|NCT01495507|PROCEDURE|MPFL- Reconstruction|
41094234|NCT04155853|PROCEDURE|Interposition Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be filled with a roll of fascia lata and fixed with a K-wire. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
40921689|NCT01819285|PROCEDURE|Delayed Orchiectomy or depot LHRH|
40921690|NCT05504967|DRUG|Oradexon|With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
40921691|NCT05504967|DRUG|Ropivacaine|With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
40921692|NCT05504967|DRUG|Saline solution|With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
40921693|NCT02783079|BEHAVIORAL|CBT|
40921694|NCT02783079|BEHAVIORAL|MBSR|
41269636|NCT03198143|DRUG|Ghrelin|Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.
41269637|NCT03198143|DRUG|Saline|Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
41269638|NCT04095455|PROCEDURE|pectoral nerves block group|ultrasound guided block of nerve supply of surgical site
40921695|NCT03526380|BEHAVIORAL|Behavioral: the OPT-IN Intervention|A private one-on-one brief motivational interviewing intervention administered by non-research staff at community organizations. This will take up to 30 minutes to complete. The goal of the intervention is to improve opioid safety and reduce related overdoses among those who has a history of misusing opioids (prescription and illicit). The session will use techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This intervention will also seek to empower participants by providing content on bystander response as well as peer outreach, which emphasizes ways to discuss overdose risk with others at risk for overdose.
40921696|NCT00771862|PROCEDURE|perineural ropivicaine|Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
40921697|NCT01724554|DRUG|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
41094235|NCT04155853|PROCEDURE|Hematoma and Distraction Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be stabilized with a K-wire without interposition of any material. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
40921698|NCT01049542|DRUG|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
40921699|NCT02678494|OTHER|Neurofeedback training|
41094236|NCT02562014|OTHER|Glucose|75g glucose
41094237|NCT02562014|OTHER|Inulin|75g glucose plus 24g inulin
41094238|NCT02562014|OTHER|Resistant Starch|75g glucose plus 28.2g resistant starch
41094239|NCT04669613|OTHER|CUDI|Analysis of the CEUS data by means of Contrast ultrasound dispersion imaging
41094240|NCT00507637|DRUG|NT 201|Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
41094241|NCT02008058|BEHAVIORAL|Survey|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
41094242|NCT03034382|DRUG|Morphine|5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
41094243|NCT03034382|DRUG|Nalbuphine|5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
41094244|NCT03034382|DRUG|Bupivacaine 0.5%|10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block
40921700|NCT04882345|DRUG|Almonertinib|"Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations.~Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day."
40921701|NCT00003544|DRUG|irinotecan hydrochloride|
40921702|NCT00003544|PROCEDURE|surgical procedure|
40921703|NCT00195208|DRUG|Pantoprazole for approximately 9 weeks|
40921704|NCT00495040|RADIATION|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
40921705|NCT05594862|DEVICE|Lipogems|Micro-fragmented adipose tissue infiltration
40921706|NCT02842034|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the dorsomedial prefrontal cortex for 4 weeks.
41094245|NCT03034382|DRUG|Lidocaine Hydrochloride 1% and epinephrine 1:400,000|10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
41094246|NCT04651179|OTHER|observation|not applicable, observational study
41094247|NCT00846781|DRUG|Denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
40921707|NCT05279573|DIETARY_SUPPLEMENT|Omega-3 and/or botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
40921708|NCT05279573|OTHER|Control product consumption|Product with identical characteristics to the experimental product. Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
40921709|NCT01128764|BEHAVIORAL|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
40921710|NCT01128764|BEHAVIORAL|CBT for depression|Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
40921711|NCT02403466|BEHAVIORAL|Resident Handoff Bundle|1) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
41094248|NCT05590910|OTHER|Music|Fifteen minutes of classical music will be played overhead in the classroom. The students will be instructed not to use other electronic devices such as ear buds or phones during this time.
40921712|NCT00752440|OTHER|Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)
40921713|NCT00464971|DRUG|estradiol, 25 mcg|
40921714|NCT00678678|DEVICE|Incentive Spirometry - RESPIRON|Device that stimulates the deep breathing, flow-oriented
40921715|NCT00678678|DEVICE|Kit Epap®:|Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
40921716|NCT02101164|BIOLOGICAL|denosumab|Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
40921717|NCT02101164|DRUG|pamidronate|Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
40921718|NCT01457352|DRUG|SPARC0921|
40921719|NCT01457352|DRUG|Placebo0921|
40921720|NCT01725659|OTHER|Motor Learning|training of the hemiplegic upper limb with motor learning
40921721|NCT01725659|OTHER|Robotics|subjects perform training of hemiplegic arm using an upper extremity robot
40921722|NCT01725659|OTHER|surface FES|subjects are provided with surface FES to the hemiplegic upper limb
40921723|NCT06492499|PROCEDURE|Zero-Fluoroscopy Radiofrequency Catheter Ablation|Patients undergo zero-fluoroscopy RFCA for atrioventricular nodal reentrant tachycardia (AVNRT) using the superior vena cava (SVC) or inferior vena cava (IVC) approach. The procedure is performed under conscious sedation and local infiltration anesthesia. A large-tip electrode catheter is used for mapping and ablation, guided by the EnSite NavX system, with ablation parameters set at 40 W power and 50°C temperature.
41094249|NCT01605968|DEVICE|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
40921724|NCT01587768|DRUG|Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009|Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
40921725|NCT00561977|BEHAVIORAL|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
40921726|NCT00561977|BEHAVIORAL|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
40921727|NCT00561977|BEHAVIORAL|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
40921728|NCT05788848|BEHAVIORAL|VRCT|The VRCT will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). Thirty-six individuals with mild to moderate AD/ADRD will be enrolled and will utilize the VRCT over seven weeks within their home.
40921729|NCT00118495|DRUG|Non-prescription Zestra(TM): patented formulation|
41094250|NCT01605968|DEVICE|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
40921730|NCT00060359|DRUG|Carboplatin|Given IV
40921731|NCT00060359|DRUG|Paclitaxel Poliglumex|Given IV
40921732|NCT00060359|OTHER|Pharmacological Study|Correlative studies
40921733|NCT01004276|OTHER|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
40921734|NCT01128621|DRUG|GSK1292263|Tablet
40921735|NCT01128621|DRUG|GSK1292263 matching placebo|Tablet
40921736|NCT01128621|DRUG|Sitagliptin|Tablet
41094251|NCT00624104|DIETARY_SUPPLEMENT|Food (fat free meal)|Fat free meal (40% of REE)
41094252|NCT03583437|BEHAVIORAL|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
40921737|NCT02248558|BEHAVIORAL|Conventional Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
40921738|NCT02248558|BEHAVIORAL|Crowdsourced Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
40921739|NCT05623462|DEVICE|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
40921740|NCT05623462|OTHER|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program includes the following:~- Indoor open environment gait training exercises (over-ground gait training exercises.). (using obstacles, cones, stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
40921741|NCT02181270|OTHER|high intensity exercise|Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be \~45 minutes
40921742|NCT02181270|OTHER|continuous moderate exercise|Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
40921743|NCT04561726|OTHER|Connective Tissue Manipulation|Connective tissue manipulation is a soft tissue manipulative technique and also a reflex therapy which is characterized by localised and specific strokes performed in where the fascia is superficial or palpable. A shear force is created between the skin-underlying fascia or dermis-hypodermis and angulatory force is applied to the collagen fibers to produce reflex and mechanical effects.
40921744|NCT04561726|OTHER|Exercise|The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
40921745|NCT00116298|DRUG|stavudine, efavirenz, lamivudine|
40921746|NCT05037578|BEHAVIORAL|Project Grace|A multilevel church-based intervention to encourage cognitive screens and brain health.
40921747|NCT03310307|DRUG|Vit D|50,000 IU
40921748|NCT03310307|OTHER|Placebo|
40921749|NCT03452449|PROCEDURE|planned lumbar spine surgery|planned lumbar spine surgery including decompression, discectomy, foraminotomy, laminectomy
40921750|NCT02445547|OTHER|UC-MSCs by peripheral intravenous infusion|
40921751|NCT02445547|DRUG|received hormone maintenance therapy|
40921752|NCT00254267|DRUG|AMG 706|AMG 706 125mg, oral, once a day
40921753|NCT00329901|BIOLOGICAL|Meningococcal ACWY conjugate vaccine (MenACWY-CRM)|
40921754|NCT00329901|BIOLOGICAL|Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)|
40921755|NCT00329901|BIOLOGICAL|saline placebo|4.5 mg sodium chloride per 0.5 ml dose
40921756|NCT04541277|DRUG|Tislelizumab|Tislelizumab combined with DNA demethylation agent +/- CAG regimen
40921757|NCT02612831|PROCEDURE|Early bariatric surgery|
40921758|NCT02612831|PROCEDURE|Delayed bariatric surgery|
40921759|NCT04274998|DRUG|[18F]NOS|Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer \[18F\]NOS.
40921760|NCT04274998|DRUG|[11C]PBR28|Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer \[11C\]PBR28 in comparison to \[18F\]NOS.
40921761|NCT02461472|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
40921762|NCT04882969|DEVICE|Fractionated Thulium laser|LaseMD Lutronic Laser is a 1927-nm fractionated thulium laser, which is better absorbed by water than non-ablative 1,540-nm erbium glass laser energy. The laser energy and power can be customized to target a specific penetration depth and achieve selective photothermolysis in skin while mitigating injury to surrounding tissue. The thermal energy generated by the laser has been shown to facilitate the delivery of kerafactor, which contain hair growth factors to stimulate follicular progenitor cell proliferation and differentiation into follicular keratinocytes to promote hair growth.
40921763|NCT00557817|DRUG|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to \> 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases \< 13 g/dL. If the Hb decreases to \< 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
41094253|NCT05247840|DIAGNOSTIC_TEST|uroflowmetry|Uroflowmetry will be performed using a uroflow-cystometer (UroDoc Frytech) which determines Qmax, Qave and TQmax. Voided volume (in mL), voiding time (in sec), average and maximum urinary flow rate (Qave and Qmax in mL/sec), and time to maximum urinary flow (TQmax in sec) will be measured; urine flow acceleration (Qacc in mL/sec2) will be calculated. Qmax and Qave are defined according to the International Children's Continence Society. Voided volume will be measured by the uroflow-cystometer device; boys void in a standing, girls in a sitting position. Postvoid bladder diameter (mm) will be measured by ultrasonography and converted to bladder residual volume (mL). The device will be calibrated according to the prescribed instructions for use by a skilled technician. The examinations will take approximately 10 minutes.
41094254|NCT05247840|DIAGNOSTIC_TEST|Cardiovascular autonomic dysfunction test proposed by Ewing et al.|CAD will be assessed by five reproducible and standardized cardiovascular reflex tests described by Ewing et al. Three of the five tests assess parasympathetic function: heart rate response to deep breathing, to standing, and the Valsalva maneuver. Two tests evaluate sympathetic function which are blood pressure responses from lying to standing and at sustained handgrip. Each of these five tests is assigned a score of 0 for normal, 0.5 for borderline, and 1 for abnormal results. The sum of these 5 scores - which is the Ewing score - is used to assess severity of CAD. Patients having Ewing score ≥ 2 form the CAD + group, and patients who have less than 2 form the CAD - group.
40921764|NCT00557817|DRUG|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin \> 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS \> 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation \< 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
40921765|NCT04094415|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
40921766|NCT06341790|OTHER|jowar based products|jowar based products like jowar flakes, jowar aata, jowar vermicelli is given to the intervention group
40921767|NCT06114524|OTHER|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied for 15 min before the procedure.
40921768|NCT01837576|DRUG|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
40921769|NCT04326101|OTHER|Transmission of adherence records|Electronic transmission of patient adherence records by pharmacists into medical EHR (Electronic Health Records)
41094255|NCT05247840|DIAGNOSTIC_TEST|peripheral nerve conduction test|Peripheral neuropathy will be evaluated by nerve conduction test. The device measures motor conduction in the lower extremities. It operates at two dedicated frequencies in order to perform a thick myelin sheath cordless fibre (5Hz) and thin myelinated nerve fibre (2000Hz) examination. The device will be calibrated according to the prescribed instructions for use by a skilled technician.
41094256|NCT04107519|BEHAVIORAL|Goal-Directed Resilience Training|This pilot study seeks to test the efficacy of a resilience skills training intervention for former football players who experience chronic pain. Between 20 to 48 eligible and consented participants from the Atlanta area will be identified (with a goal of 40 completing the study). They will undergo a pre-training test session and will then be randomized to either the Immediate GRIT (ImT) training intervention or the Delayed Training (DeT) control. The immediate (ImT) group will be trained for 4 weeks with 2 biweekly sessions. At the end of GRIT training they will be post-tested. The delayed (DeT) group wait during these 4 weeks and do not receive training. At the end of the 4-week waiting period, they will also be post-tested. At this point, they will be offered GRIT training for 4 weeks with 2 biweekly sessions. At the end of their training, they will be given a second post-testing. This process will then be repeated for two additional groups of 5-12 lmT and 5-12 DeT participants.
41094257|NCT01886469|DRUG|HLD100-B|d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
41094258|NCT01886469|DRUG|HLD100-C|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
40921770|NCT00075192|DRUG|CP-675,206 and leuprolide acetate and bicalutamide|
40921771|NCT00075192|DRUG|leuprolide acetate and bicalutamide|
41094259|NCT01886469|DRUG|HLD100-E|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
41094260|NCT01615809|DRUG|AMPHOTERICIN B|The study drug will be administered by inhalation, to hospitalised patients or outpatients in the day hospital.
41094261|NCT03293862|DEVICE|prophylactic polypropilene mesh|Placement of onlay polypropilene prophylactic mesh after midline fascial closure.
41094262|NCT03293862|PROCEDURE|Midline Fascial Closure|midline fascial closure using uninterrupted PDS 0 suture
41094263|NCT03293862|DEVICE|vacuum drainage system|Placement of a subcutaneous vacuum drainage system
40921772|NCT03814421|DRUG|intermittent (40mg as a bolus injection daily for 72hours)|Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
40921773|NCT05354453|DRUG|BI 1839100|BI 1839100
40921774|NCT05354453|DRUG|Placebo|Placebo
40921775|NCT05354453|DRUG|allyl isothiocyanate (AITC)|allyl isothiocyanate (AITC)
40921776|NCT02700334|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
40921777|NCT02700334|DRUG|Placebo|one per day before breakfast during 12 weeks.
40921778|NCT01147133|DRUG|Plavix|1x75 mg
40921779|NCT01147133|DRUG|Kardogrel|1x75 mg
40921780|NCT05952752|OTHER|giving dexemedetomidine 12 microgram Iv dripping|Patients in the studied groups will receive either or intravenous Dexemedetomidine 12 µg
40921781|NCT05952752|OTHER|Dexamethsone IV|4 mg IV dexamethasone
40921782|NCT02689102|DEVICE|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
40921783|NCT00385164|PROCEDURE|PET/CT scan for RT planning|
40921784|NCT03430076|PROCEDURE|revascularization|open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
40921785|NCT03430076|DEVICE|Propaten®|Propaten®
40921786|NCT03430076|DEVICE|Crude PTFE|Crude PTFE
40921787|NCT05145270|DIETARY_SUPPLEMENT|Escitalopram+Sulforaphane|Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day .
40921788|NCT05145270|DEVICE|Escitalopram+rTMS|Escitalopram(No-specified) 10-20mg/d, once per day; rTMS: rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day.
41094264|NCT06615115|OTHER|Exercise|All participants will perform a total body stretching exercise for 10 minutes, followed by 10 minutes of obstacle course navigation, 10 minutes of balance training (including tandem walking, balance board exercises, single-leg balance, and two-legged reaching exercises), and will conclude with 10 minutes of strength training exercises.
41094265|NCT01178515|OTHER|Modification of the content of fat in milk|Comparison of three levels of fat content in cow´s milk
41094266|NCT01178515|OTHER|Modification of the content of cows milk|Comparison of three levels of fat content in cows' milk
41094267|NCT01178515|OTHER|Modification of the fat content of cows´ milk|Comparison of three levels of fat content in cow´milk
41094268|NCT04391309|BIOLOGICAL|anti-CD14|4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV)
41094269|NCT04391309|OTHER|Placebo|Placebo administered intravenously on Days 1-4
41094270|NCT04391309|DRUG|remdesivir|Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
41094271|NCT02656940|DIETARY_SUPPLEMENT|Group 1 - diet rich in n-3 and n-6 PUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
40921789|NCT05145270|DRUG|Escitalopram|Escitalopram(No-specified) 10-20mg/d, once per day.
40921790|NCT03772288|DRUG|TAK-659|Tablets.
40921791|NCT03772288|DRUG|NKTR-214|Intravenous infusion.
40921792|NCT06493292|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
40921793|NCT04301310|DRUG|BMS-986235 (Treatment A)|Specified dose on specified days
40921794|NCT04301310|DRUG|Rifampin (Treatment B)|Specified dose on specified days
40921795|NCT06248047|PROCEDURE|uretheroplasty|4. When the bulb and bulbar urethra are exposed and before further dissection, the bulbar arteries are located using a directional doppler ultrasound stethoscope and a decision is made to sacrifice the artery with the lowest doppler signal to preserve the contralateral best artery. The bulbar urethra is then mobilized, circumferentially dissected and separated distally from the corpus cavernosum up to the penoscrotal angle to gain sufficient length for a tension-free end-to-end anastomosis without detachment of the bulb from the perineal body. If the dissection is not sufficient to bridge the gap,inter-corporal septal separation or even an inferior pubectomy are performed. The scarred tissue is removed completely, the proximal urethral segment is exposed as usual with spatulation of the healthy urethral ends and end-to-end anastomosis of the urethra over a silicon catheter is performed. No dissection is performed contralaterally at the bulb to preserve the artery of that side.
40921796|NCT02811874|BEHAVIORAL|diabetes education|Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
41094272|NCT02656940|DIETARY_SUPPLEMENT|Group 2 - diet rich in MUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
41094273|NCT02656940|DIETARY_SUPPLEMENT|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
41094274|NCT02138916|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
41094275|NCT02138916|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
41094276|NCT02138916|DRUG|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
41094277|NCT06081361|DRUG|Bedaquiline|Oral, 400mg qd for 2 weeks, then 200 mg 3 times per week
41094278|NCT06081361|DRUG|Delamanid|Oral, 100mg bid
41094279|NCT06081361|DRUG|Contezolid|Oral, 800mg bid
41094280|NCT06081361|DRUG|Levofloxacin|Oral, 400mg qd for weight \<50kg, 600-750mg qd for weight ≥50kg
41094281|NCT06081361|DRUG|Moxifloxacin|Oral, 400mg qd
41094282|NCT06081361|DRUG|Clofazimine|Oral, 100mg qd
41094283|NCT06081361|DRUG|Linezolid|Oral, 600mg qd
41094284|NCT06081361|DRUG|Cycloserine|Oral, 250mg bid
41094285|NCT06081361|DRUG|Prothionamide|Oral, 600mg qd for weight \<50kg, 600-800mg qd for weight ≥50kg
41094286|NCT06081361|DRUG|Pyrazinamide|Oral, 1500mg qd for weight \<50kg, 1750mg qd for weight ≥50kg
41094287|NCT06081361|DRUG|Para-Aminosalicylic Acid|8000mg qd for weight \<50kg, 10000mg qd for weight ≥50kg
41094288|NCT06081361|DRUG|Ethambutol|750mg qd for weight \<50kg, 1000mg qd for weight ≥50kg
41094289|NCT02886988|DRUG|Botulinum toxin type A|50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
41094290|NCT02886988|DRUG|normal saline|0.1mlof normal saline will be injected with a 30G needle.
41094291|NCT04284748|OTHER|Plyometric exercise with blood flow restriction|"Blood flow restriction training is an exercise protocol based on the method of limiting blood flow with external pressure by pneumatic tourniquet from the proximal of the muscle to be strengthened. Blood flow restriction (Occlusion) during pliometric exercises for 8 weeks, a pneumatic tourniquet (Kaatsu Master) proximal to the thigh will be applied to each patient within a safe pressure range. The pressure to be applied to the patient will be calculated with the following formula described in the literature.~Pressure = 0.5 x (systolic blood pressure) + 2 x (thigh circumference) + 5 Application will be done for a maximum of 15 minutes, then rest for 10-15 minutes and other exercises will continue.~Plyometric training with blood flow restriction. Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)"
41094292|NCT04284748|OTHER|Plyometric exercise|Plyometric training Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
41094293|NCT04284748|OTHER|Routine physiotherapy program|Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises
41094294|NCT01724203|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|
41094295|NCT01724203|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
41094296|NCT01724203|DIETARY_SUPPLEMENT|Placebo|
41094297|NCT02655653|DRUG|Epsilon-aminocaproic acid administered|Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
41094298|NCT02655653|DRUG|Tranexamic Acid administered|Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
41094299|NCT01133613|DRUG|Bone morphogenetic protein 7|Single intraarticular injection of BMP-7 or placebo on Day 1
41094300|NCT03554187|DEVICE|Ultrasonic periodontal Debridement, with appropriate device|Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.
41094301|NCT03554187|BIOLOGICAL|Analyzes of periodontopathogenic bacteria|Collection of plaque, to analyze the bacteria in the pocket
41094302|NCT03554187|GENETIC|IL1B test|susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)
41094303|NCT03554187|BIOLOGICAL|Salivary Sampling|Salivette to chew. To analyse salivary microbiota
41094304|NCT03554187|DEVICE|Halitosis measure|With appropriate device : halimeter
40921797|NCT02811874|BEHAVIORAL|education in other areas|Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
40921798|NCT04796870|OTHER|Online Brain and Balance Training Program|The intent of the intervention is to encompass cardiovascular conditioning, cognitive performance and balance performance improvements. To promote cardiovascular conditioning the exercises are structured to keep the participant in motion while maintaining an elevated heart rate using techniques such as squats, marching and upper extremity movements. The video provides adaptations to increase or decrease the challenge based on subject ability. To promote cognitive performance, participants will be asked to complete simple and complex cognitive tasks, such as arithmetic, spatial memory recall and attention while completing the physical exercises. To promote balance performance, the videos include single limb stance and weight shifting tasks. Videos are presented in a progressively challenging manner for all domains.
40921799|NCT03798119|DRUG|Tenofovir Alafenamide|Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
40921800|NCT02811523|DRUG|Doxorubicin|Doxorubicin by In Vivo Lung Perfusion
40921801|NCT01193257|DRUG|Orteronel|Orteronel tablets
40921802|NCT01193257|DRUG|Prednisone|Prednisone tablets
40921803|NCT01193257|DRUG|Orteronel Placebo|Orteronel placebo-matching tablets
41094305|NCT05892575|BEHAVIORAL|improving quality of life, coping with urinary incontinence and kegel exercise training|Face-to-face training will be given to the elderly in the experimental group for a total of 5 weeks, once a week day (60 minutes). In the 4th week, reminder messages will be started over the phone. The 4th week kegel exercise chart and nutrition list will be given. In the 5th week, kegel exercise dance will be watched. Sending reminder messages from the phone will continue for 3 months.
40921804|NCT06449937|PROCEDURE|Radical local Surgery|Radical local resection of liver metastases ( hepatectomy, ablation )
40921805|NCT06449937|DRUG|Systemic therapy|Chemotherapy, targeted drug therapy, immunotherapy treatment.
40921806|NCT06449937|OTHER|Interventional therapy|Transcatheter arterial chemoembolization (TACE) Hepatic arterial infusion chemotherapy (HAIC)
40921807|NCT05299853|OTHER|Robot assisted arm training|Patients will receive 30 minutes of robot-assisted arm training and 30 minutes of conventional arm rehabilitation training. Patients will undergo 30 sessions of combined therapy (robotic+conventional) for a total of 6 weeks (5 sessions/week).
40921808|NCT05299853|OTHER|Conventional rehabilitation|Patients will receive 30 sessions of conventional arm training (60 minutes/day) for a total of 6 weeks (5 sessions/week).
40921809|NCT00650481|DRUG|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fasting
40921810|NCT00650481|DRUG|Ditropan XL® Tablets 5 mg|4x5mg, single dose fasting
40921811|NCT01046435|PROCEDURE|metronidazole and amoxicillin|Metronidazole 250 mg three times a day per 7 days
40921812|NCT01046435|PROCEDURE|Two placebos|Two placebos 3 times a day for 7 days
40921813|NCT00851162|BIOLOGICAL|Trinity multipotent stem cells|Enough to fill voids which vary in size
40921814|NCT00851162|BIOLOGICAL|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
40921815|NCT00855270|DRUG|Placebo|IV saline will be used as placebo for control
40921816|NCT00855270|DRUG|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
40921817|NCT04184388|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 1g/day) for 12 week
40921818|NCT04184388|DIETARY_SUPPLEMENT|Placebo|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 0g/day) for 12 week
40921819|NCT01945710|DRUG|Eribulin-LF|
40921820|NCT05905744|DIAGNOSTIC_TEST|cholangioscopy|cholangioscopy examination and forceps biopsy, followed by brush biopsy from ERCP
40921821|NCT05481957|DRUG|Vortioxetine|5-10mg for 16 weeks
40921822|NCT05481957|DRUG|valprote|500\~1000mg for 16 weeks
40921823|NCT00435045|DRUG|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
40921824|NCT00435045|DRUG|atorvastatin|atorvastatin + placebo
41094306|NCT01872611|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|
41094307|NCT01872611|OTHER|Vehicle|Inactive ingredients used as placebo comparator
41094308|NCT01872611|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
41094309|NCT00824785|DRUG|epirubicin, oxaliplatin, capecitabine (EOX)|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
41094310|NCT00824785|DRUG|EOX + panitumumab|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
41269639|NCT04095455|DRUG|Ketamine plus magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).
40921825|NCT06082973|DEVICE|Automated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID dHmG system, and microdoses of glucagon (GlucaGen®) will be subcutaneously administered based on automatic recommendations for hypoglycemia mitigation. The subcutaneous administration of reconstituted glucagon will be conducted using a 0.5 mL insulin syringe with needle, allowing for precise doses as small as 0.01mg/0.01 mL.
41094311|NCT03830775|PROCEDURE|Platelet-rich plasma (PRP)|"PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)"
41094312|NCT00020189|DRUG|acetylsalicylic acid|
41094313|NCT00020189|DRUG|alvocidib|
41094314|NCT00020189|DRUG|clopidogrel bisulfate|
40921826|NCT06082973|DEVICE|Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID sHC system, along with automatic rescue carbohydrate recommendations for hypoglycemia mitigation. As per the carbohydrate recommendation, participants will received the suggested amount of carbohydrates using an oral glucose gel containing 15g of carbohydrates per unit.
41094315|NCT05978661|DRUG|FKC288|Administration of FKC288 Four dose groups of 0.1×10\^6 CAR-T/kg, 0.3×10\^6 CAR-T/kg, 1.0×10\^6 CAR-T/kg, and 3.0×10\^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
41094316|NCT04465071|DRUG|AEONTM Repair and AEONTM Protect Plus lubricating eye drops|AEONTM Repair and AEONTM Protect Plus lubricating eye drops
41094317|NCT01613118|DRUG|RE-021 (Sparsentan)|Oral, once-daily
41094318|NCT01613118|DRUG|Irbesartan|Oral, once-daily
40921827|NCT05373056|BEHAVIORAL|Scapular program|the patient will be in prone. With the elbow extended, begin by raising the shoulder above the head, keeping the upper extremity in line with the fibers of the lower trapezius. The participant will then remain pronated with the elbow flexed at 90 degrees and the shoulder abducted and externally rotated. Starting from this position, you should exert the force towards external rotation and then return to internal rotation. For the last exercise, the subject will be placed in a standing position holding the elastic band with one hand while the other end will fix it to the ground, while stepping on it with the foot. You will start the movement with a shoulder elevation in the plane of the scapula above 120 degrees and then perform the eccentric returning to the starting position.
40921828|NCT05373056|BEHAVIORAL|Conventional program|They will be performing a combination of concentric-eccentric type contractions adding an isometric contraction
40921829|NCT01007630|DRUG|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
40921830|NCT01007630|DRUG|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
41094319|NCT05190185|BIOLOGICAL|TAA06 injection|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106\~1×108 CAR-T/kg. And the subjects will be administered once.
41094320|NCT02391909|BIOLOGICAL|Vivotif|
41094321|NCT05035836|DRUG|Zanidatamab|Given IV
41094322|NCT05035836|DRUG|Letrozole|Given by PO
41094323|NCT05035836|DRUG|Tamoxifen|Given by PO
41094324|NCT01876043|DRUG|plitidepsin|"Patients received plitidepsin as an i.v. 3-h infusion of 5 mg/m2/day on days 1 and 15 every 4 weeks. Patients discontinued plitidepsin if one of the following occurred: consent withdrawal, unacceptable toxicity, disease progression (RECIST v1.1), intercurrent illness or investigator's decision.~Single-arm phase II clinical trial based on a two-stage optimal Simon's design with 37 evaluable patients (first stage: 17 patients) used to distinguish a favorable true non-progression rate of 40% from a null rate of 20% (90% power and 10% type I error).~* Stage 1(17 participants): if \<=3 non-progressions at 3 months, the study was stopped early. Otherwise, the second group of 20 participants was recruited.~* Stage 2 (37 participants): if \>= 11 non-progressions, Aplidin was considered promising."
41094325|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - CHEST|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
41094326|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - CHEST & FINGER|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~3. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
41094327|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - FINGER|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
41094328|NCT02493790|OTHER|Cognitive and motor performances|
41094329|NCT02109679|DRUG|metformin|multiple doses metformin given as tablet
41094330|NCT02109679|DRUG|BI 187004|multiple doses BI 187004 given as tablets
41094331|NCT02109679|DRUG|BI 187004|multiple doses BI 187004 given as tablets
40921831|NCT04420936|BEHAVIORAL|MAINTAIN PRIME Lifestyle Coaching|Participants will receive two years patient support consisting of supportive coaching via EHR patient portal and tracking tools with EHR. Participants will also receive primary care physician (PCP) support with real time progress reports with counseling tips via EHR prior to visits, notification of weight changes greater or equal to 10 pounds, and annual PCP feedback.
40921832|NCT04420936|BEHAVIORAL|Control tracking|Participants will receive two years of patient support consisting of prevention updates via EHR patient portal and tracking tools within the EHR. Participants in this group will not receive primary care physician (PCP) support.
40921833|NCT06092229|DIAGNOSTIC_TEST|Palpation|identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access
40921834|NCT06092229|DIAGNOSTIC_TEST|Ultrasonography with TACA approach|identification of the cricothyroid membrane, using ULTRASONOGRAPHY with TACA approach , a procedure used to prepare for front of neck airway access
40921835|NCT06530186|DEVICE|LiviWell Postcoital Vaginal Insert|subjects will use Livi within minutes of completion of sex, and will remove study device in under an hour.
40921836|NCT01627834|DRUG|Ropinirole|
40921837|NCT02011139|BEHAVIORAL|Cognitive-behavioral group therapy|
40921838|NCT00583713|DRUG|BLI-800|BLI-800 oral solution (two doses)
40921839|NCT03031002|BEHAVIORAL|Exposure treatment for spider fear|Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
40921840|NCT00917293|DRUG|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
40921841|NCT00917293|DRUG|Placebo|Placebo 2 pills, po bid.
40921842|NCT01957670|DEVICE|Lacrima medical Prototypes|
40921843|NCT02463890|OTHER|Training|
40921844|NCT02463890|OTHER|Control|
40921845|NCT04121078|DRUG|TAK-906|TAK-906 capsule.
40921846|NCT04121078|DRUG|Rifampin|Rifampin infusion.
40921847|NCT05412589|DRUG|mFOLFOX7+Camrelizumab+Apatinib|"Drug: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Drug: Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle. Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Drug: Camrelizumab 200mg infusion on D1 for every 21 days Drug: Apatinib 250mg，po，qd for every 21 days"
41094332|NCT02109679|DRUG|metformin|multiple doses metformin given as tablet
41094333|NCT05699187|PROCEDURE|Face allotransplantation|Facial allotransplantation
41094334|NCT05838183|DIAGNOSTIC_TEST|The relationship between imaging and ROSE and NGS|The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed
41094335|NCT00419068|DRUG|Cholecalciferol|
40921848|NCT04195776|DRUG|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
40921849|NCT04962776|DRUG|Low-concentration carbohydrate and nitrates|Patients in the CHON group will be given 400 mL of a clear carbohydrate drink (12.5 g/100 mL maltodextrin, 50 kcal/100 mL) and 2 capsules of beet root extract 1 gm on the evening before surgery (8 hours) and another 200 mL of the carbohydrate drink and 1 capsule of beet root extract 1 gm on the day of surgery, 2 h before anesthesia induction.
40921850|NCT04962776|DRUG|Low-concentration carbohydrate|Patients in the CHO group will be given the same carbohydrate drink in the CHON group with 2 placebo capsules with the evening drink and one with the morning drink.
40921851|NCT04962776|OTHER|Water with placebo capsules|Patients in the W group will be given equivalent volume of drinking water with placebo capsules by evening and in the morning of surgery.
40921852|NCT02224885|DEVICE|CT-guided percutaneous biopsy or ablation|Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung
40921853|NCT02162407|DRUG|insulin detemir|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
40921854|NCT02162407|DRUG|human soluble insulin|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
40921855|NCT03680846|DEVICE|HF10 Therapy|Senza 10 kHz Spinal Cord Stimulation
40921856|NCT03680846|OTHER|CMM|Conventional Medical Management
40921857|NCT03581461|BEHAVIORAL|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
40921858|NCT05165654|DEVICE|Transcranial Electrical Stimulation|Transcranial electrical stimulation
40921859|NCT00933218|DIETARY_SUPPLEMENT|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
41094336|NCT00419068|DRUG|Migliol Placebo Oil|
41094337|NCT01759121|RADIATION|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
40921860|NCT00933218|DIETARY_SUPPLEMENT|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
40921861|NCT00264758|DEVICE|Conventional hemodialysis|Three times per week in-center hemodialysis
41094338|NCT01759121|RADIATION|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
41094339|NCT05042271|DRUG|meropenem|each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first TPE and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
41094340|NCT00501241|DRUG|ATI-7505|Tablet,placebo, BID
40921862|NCT00264758|DEVICE|Frequent hemodialysis|Six times per week in-center hemodialysis
40921863|NCT06131476|DRUG|Blink® Tears eye drops|Control Drops
40921864|NCT06131476|DRUG|Investigational lipid eye drops|Test Drops
40921865|NCT02036151|DRUG|xylitol|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
40921866|NCT02036151|DRUG|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
40921867|NCT03837522|DIAGNOSTIC_TEST|Procurement Biopsy: Frozen section|Frozen sections are prepared by freezing and slicing the tissue sample; importantly, they can be done in about 15 to 20 minutes. Frozen sections are done when an immediate answer is needed, but do not provide optimal quality.
40921868|NCT03837522|DIAGNOSTIC_TEST|Procurement Biopsy: Permanent section|Permanent sections are prepared by placing the tissue in fixative (usually formalin) to preserve the tissue, processing it through additional solutions, and then placing it in paraffin wax. After the wax has hardened, the tissue is cut into very thin slices, which are placed on slides and stained. The process normally takes several days.
40921869|NCT04062903|BEHAVIORAL|Immediate Appointment|The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
41094341|NCT00501241|DRUG|ATI-7505|ATI-7505 20 mg BID for 4 weeks
40921870|NCT04062903|BEHAVIORAL|Delayed appointment|After a period of delay (Control) The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
40921871|NCT03570463|BEHAVIORAL|GLA:D Back|The intervention aims at improving the participant's ability to self-manage low back pain (LBP). The content is based on a cognitive behavioural approach aimed at supporting pain self-efficacy. An individual session at the beginning and the end of the group sessions involve goal-setting and physical tests. Key messages of the patient education include that pain is not a sign of danger and back pain is explained using a behavioural model of (im)balance between demands and capacity rather than emphasising tissue damage. The exercises aim at restoring natural variation in movement and provides guidance for patients in exploring movement rather than teaching exercises in only one correct manner.
40921872|NCT04871191|DRUG|Rituximab|375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.
41094342|NCT00501241|DRUG|ATI-7505|tablet, 40 mg, BID, $ weeks
40921873|NCT04871191|DRUG|Tocilizumab|Subcutaneous injection of 162 mg per week
40921874|NCT04871191|DRUG|Abatacept|Subcutaneous injection of 125 mg per week
40921875|NCT03387111|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
40921876|NCT03387111|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
40921877|NCT03387111|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
40921878|NCT03387111|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
40921879|NCT03387111|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
40921880|NCT03387111|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
40921881|NCT03387111|BIOLOGICAL|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
40921882|NCT03387111|BIOLOGICAL|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
41094343|NCT00501241|DRUG|ATI-7505|80 mg ATI-7505, BID for 4 weeks
41094344|NCT00501241|DRUG|ATI-7505|120 mg ATI-7505, BID, for 4 weeks
40921883|NCT03387111|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
40921884|NCT03387111|DRUG|Avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
40921885|NCT03387111|DRUG|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
40921886|NCT03387111|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
40921887|NCT03387111|DRUG|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
40921888|NCT03387111|DRUG|Cisplatin|cis-diamminedichloroplatinum(II)
40921889|NCT03387111|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
40921890|NCT03387111|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
40921891|NCT03387111|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
41094345|NCT01656304|BIOLOGICAL|bevacizumab|Given IV
41094346|NCT01656304|OTHER|laboratory biomarker analysis|Correlative studies
41094347|NCT03924245|DRUG|Entinostat|Given by mouth
41094348|NCT03924245|DRUG|Olaparib|Given by mouth
41094349|NCT05685758|OTHER|FTP-based therapeutic mobile-app|Participants are expected to play games within the mobile app and complete the available daily levels of 4 out of 5 games on at least 4 days per week for 8 weeks.
41094350|NCT05593185|BIOLOGICAL|Galinpepimut-S|
41094351|NCT04699448|OTHER|Nutritional intervention.|Diets designed for body weight loss, based on different macronutrient content.
41094352|NCT01271270|DRUG|Palomid 529|
41094353|NCT05954169|DRUG|SHR4640|SHR4640 single-dose
40921892|NCT03387111|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
41094354|NCT00119587|DRUG|darbepoetin alfa|
41094355|NCT04586192|OTHER|Common Elements Toolbox- Adult version (COMET-A)|COMET includes four different modules that teach participants exercises designed to improve mental health and well-being. Participants are asked to complete exercises focused on behavioral activation, cognitive restructuring, gratitude and self-compassion. At the end of the intervention, participants are sent templates that they can you to complete the exercises on, and are encouraged to continue practicing their exercises in their daily life.
40921893|NCT03387111|DRUG|Necitumumab|Necitumumab is a recombinant human lgG1 monoclonal antibody.
40921894|NCT03387111|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
40921895|NCT03387111|BIOLOGICAL|N-803|Recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)
40921896|NCT01066390|BIOLOGICAL|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
40921897|NCT03513341|OTHER|No intervention|No intervention is given to the participants. This is an observational study exploring the students' levels of physical activity and sedentary behaviour in their natural setting.
40921898|NCT00814216|DRUG|QAV680|
40921899|NCT00814216|DRUG|Matching placebo for QAV680|
41094356|NCT04586192|OTHER|Self-awareness Control|A control condition in which participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
41094357|NCT00881335|DEVICE|flutter mucus clearance device|five minutes every sessions, three sessions per day
40921900|NCT00814216|DRUG|Fluticasone Propionate|
40921901|NCT00948220|DRUG|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
40921902|NCT03478865|DRUG|Vitamin A palmitate|Provide vitamin A to participants with pre/post assessments of vision.
41094358|NCT06163521|OTHER|Education|A training consisting of 8 sessions of 40 minutes each will be applied to the children. One session will be done every week. The training will consist of activities including information, discussion and role-playing about children with special needs. The training topics consist of; Children with Special Needs Empathy Differences, Respect for Differences Contact Activity Awareness Benevolence Social Acceptance and Behaviour What can we do?
41094359|NCT05064670|BEHAVIORAL|Exercise|A twice weekly, 3-month supervised exercise program of whole body resistance training using body weight and a resistance band, and moderate to high intensity aerobic activities, consisting of a consecutive series of timed exercises performed one after the other (14-18 on the Borg scale). Classes are conducted live in groups through Microsoft Teams. Participants will not receive any contact or exercise support in the 3-month follow-up period following the initial 3-month intervention
40921903|NCT01633593|DRUG|Donepezil|5 mg PO a day, during 2 weeks
40921904|NCT00118456|DRUG|AEE788|
40921905|NCT01323855|DRUG|Preladenant|After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally
41094360|NCT04378582|OTHER|risk factors|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival
41094361|NCT03201757|DRUG|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
40921908|NCT01974739|DRUG|Hydrochloorthiazide|
40921909|NCT01974739|DRUG|placebo|
40921910|NCT01700387|DRUG|onabotulinumtoxinA|All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
41094362|NCT05571800|OTHER|Mango|120g of fresh Mango
41094363|NCT05571800|OTHER|Placebo|200g isocaloric Granola Bar
41094364|NCT06500572|OTHER|Landmark Guided Intercostobrachial Nerve Block|In addition to the supraclavicular plexus block, the intercostobrachial nerve block block will be performed without ultrasound guidance and based on the traditional method using superficial anatomy and nerve pathway by subcutaneous injection of 20 mL of bupivacaine 0.25% at the site of the pulse.
41094365|NCT06500572|OTHER|Ultrasound Guided Intercostobrachial Nerve Block|The patient's head will be turned to the opposite side while the patient is in the supine position and the shoulder to be treated will be elevated 5- 10 cm. The high-frequency linear ultrasound probe (12-4 MHz) and the region to be treated will be prepared in sterile conditions and placed transversely across the external jugular vein at 3-4 cm above the clavicle. Between the anterior and middle scalene muscles, the imaging of the brachial plexus showed three to five hypoechoic circles. The entry will be in-plane technique using an 80-mm block needle from lateral to medial. After confirming the needle insertion site with 2 mL saline solution, a 20 mL bupivacaine 0.25% will be administered.
41094366|NCT06500572|OTHER|Serratus Plane Block|The patient will be placed in the lateral decubitus position with the area to be treated on the upper side. The high-frequency linear ultrasound probe and the region to be treated will be sterilized. The ultrasound probe will be placed on the anterior line at the level of fourth and fifth ribs. Images of the muscle's latissimus dorsi and serratus anterior, the ribs, and the pleura will be obtained. Subsequently, with the in-plane technique, an 80-mm block needle will be advanced between the latissimus dorsi and the serratus muscles planes in a caudal to the cranial direction. There is no blood or air in aspiration. After confirming the location of the needle with 2 mL of saline solution, (20 mL of bupivacaine 0.25%) will be administered between the two muscles.
41094367|NCT04341064|BEHAVIORAL|SHINE Intervention|\[see arm/group descriptions\]
41094368|NCT00928200|DRUG|Erwinase|"The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion."
41094369|NCT00928200|DRUG|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
40921911|NCT01700387|DRUG|Topiramate|"Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
40921912|NCT01700387|DRUG|Placebo|"Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
40921913|NCT04896970|OTHER|Concert|A musical show in a closed hall, lasting for about 2 hours, in respects of safety measure (masks, hydroalcoholic gel, etc...) with approximately 200 participants.
41094370|NCT00928200|DRUG|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14.
40921914|NCT03086187|DEVICE|Hephaistos unloading orthosis|The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
40921915|NCT03343353|OTHER|LED (Light Emission Diode)|LED light application in cutaneous lesions from the graft donor area (scalp) in patients who are victims of burns
40921916|NCT03207438|DRUG|Quetiapine 50 MG Extended Release Oral Tablet|OD
40921917|NCT03207438|DRUG|Quetiapine Fumarate XR 150-300 mg|Dose ranged from 150 to 300mg, XR preparation, OD
41094371|NCT00928200|DRUG|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
41094372|NCT00928200|DRUG|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
40921918|NCT03207438|DRUG|Placebos|Placebo
40921919|NCT02191215|DRUG|Nevirapine (Viramune®)|
40921920|NCT00796445|DRUG|GSK 2132231A|IM solution, a course of 13 injections administered over 27 months
41094373|NCT00928200|DRUG|Methotrexate|Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
40921921|NCT00796445|DRUG|Placebo|IM solution, a course of 13 injections administered over 27 months
40921922|NCT06225908|PROCEDURE|Serratus posterior superior intercostal plane block|application of local anestesic under serratus posterior superior muscle at the level of second costa
40921923|NCT02208063|DRUG|Telavancin|
40921924|NCT02208063|DRUG|Vancomycin|
40921925|NCT02208063|DRUG|Daptomycin|
40921926|NCT02208063|DRUG|Synthetic penicillin|
40921927|NCT02208063|DRUG|Cefazolin|
40921928|NCT02565134|DRUG|PAC-14028 cream 0.1%|Topical application
40921929|NCT02565134|DRUG|PAC-14028 cream 0.3%|Topical application
40921930|NCT02565134|DRUG|PAC-14028 cream 1.0%|Topical application
40921931|NCT02565134|DRUG|PAC-14028 cream vehicle|Topical application
40921932|NCT02331095|DRUG|Atorvastatin|"Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP)."
40921933|NCT02331095|DRUG|Anticoagulation Therapy|Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
40921934|NCT05781880|OTHER|Oxygen 100%|NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)
40921935|NCT05977738|DRUG|Pitavastatin calcium|Daily Pitavastatin administration
41094374|NCT00928200|DRUG|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
41094375|NCT00928200|DRUG|Dexrazoxane|Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
41094376|NCT03166319|DIAGNOSTIC_TEST|MRI, including intracranial vessel wall imaging|MRI/MRA/intracranial high-resolution vessel wall imaging (HR-VWI)
41094377|NCT02646592|DRUG|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
41094378|NCT02646592|DRUG|sevoflurane or propofol|
41094379|NCT05963776|DEVICE|spirometry|pulmonary function tests using spirometry
41094380|NCT01240356|DEVICE|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
41094381|NCT01240356|DEVICE|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
41094382|NCT02831114|OTHER|Acupuncture|Acupuncture uses tiny needles to promote blood flow, nervous system signaling, and brings the body back into homeostasis which the state of optimum functioning. Treatment for taxane induced peripheral neuropathy will consist of traditional acupuncture and will use points located in the foot (SP 3, ST 41, LR 3, K 3, GB 41), knee (SP 9, ST 36, K 10, GB 34), and arm (LI 11). Participants will continue to take their conventional therapy. Each acupuncture treatment will take place at Oriental Medicine Associates with trained acupuncturist, William Hendry. Each session should last about 30 minutes.
41094383|NCT02206685|DRUG|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
41094384|NCT02206685|DRUG|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
41094385|NCT05893043|DRUG|GSBR-1290|Participants will receive GSBR-1290 oral capsules.
40921936|NCT05324644|BEHAVIORAL|Motivational interview|In the first interviews with the students; It is planned to provide information about acquaintance and research, fill in the scales in 10-15 minutes, make CO measurements, and also conduct an average of 20-40 minutes of motivational interviews in the intervention group. In the second interview in the 1st month, it is planned to summarize the first interview, fill in the scales in 3-5 minutes, make the CO measurements in 10-15 minutes or get the measurement results and apply motivational interview in the average of 20-40 minutes. In the third interview in the 3rd month, it is planned to summarize the second interview in 3-5 min, fill in the scales in 10-15 minutes, make CO measurements or get the measurement results and to apply motivational interviews for an average of 20-40 minutes. In the last interview in the 6th month, it is planned to summarize the 3rd-month interview, to apply the scales for approximately 10-15 minutes, to make CO measurements or to get the measurement results.
40921937|NCT04554836|DRUG|Cetuximab|Patients in Arm A will receive FOLFIRI +cetuximab.
40921938|NCT04554836|OTHER|FOLFIRI|Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)
41094386|NCT05893043|OTHER|Placebo|Participants will receive matching placebo oral capsules.
41094387|NCT00276328|DRUG|Diosmectite (Smecta®)|
41094388|NCT03243656|DRUG|Eltrombopag|An oral thrombopoietin receptor agonist
41094389|NCT03708068|OTHER|Early exclusive enteral nutrition|Infants will be fed at least 80% of reference daily fluid intake from day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards to meet reference daily fluid intake until infant reaches full enteral feed.
41094390|NCT03702400|DRUG|Phenylephrine 100 mcg|Phenylephrine at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug, 5 mL each bolus
41094391|NCT03702400|DRUG|Norepinephrine 5 mcg|Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
41094392|NCT04107649|BEHAVIORAL|Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives|As part of TAC(MI)+FI, participants speak with a health coach at Brigham and Women's Hospital once a week via telephone for weeks 6-13 following surgery, and once every other week for weeks 14-31 after surgery. Participants in this arm can receive financial rewards for achieving weekly physical activity goals, as well as bonus rewards for achieving goals multiple weeks in a row. Over the course of this 6-month long TAC(MI)+FI intervention period, these participants are able to receive up to $680 for meeting physical activity goals, and up to $95 in bonus rewards.
41094393|NCT04107649|BEHAVIORAL|Wrist based activity tracker wear|Activity tracking data will be collected on a weekly basis. Participants who receive this intervention are eligible to be entered into a lottery to win one of two $25 rewards for every week they wear their wrist-based activity tracker \>10 hours for \>4/7 days a week, beginning 6-weeks after surgery.
41094394|NCT04107649|OTHER|Basic Study Activities|Basic study activities begin two-weeks before TKR and end approximately 24-months after TKR. Basic study activities include: two in-person visits at the local clinic site (2 weeks before TKR and 32-weeks after TKR), having check-in calls with study staff weekly from weeks 1-13 after surgery and every other week for weeks 14-31, completing 6 surveys, and wearing an ActiGraph activity tracker (waist-worn) for five one-week periods throughout the study (2-weeks before-TKR, 32-weeks post-TKR, one-year post-TKR, 18-months post-TKR, two-years post-TKR). All participants will be eligible to receive up to $235 for completing these activities over the course of two years.
41094395|NCT03771898|DRUG|SHP611|Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.
41094396|NCT03790397|DRUG|Osimertinib|Patients treated with Osimertinib within the Special Use medication Program (SUMP).
41094397|NCT03484182|BEHAVIORAL|Web-based Home Exercise Program|Home exercises that are guided by a web-based program
41094398|NCT03484182|BEHAVIORAL|Standard Home Exercise Program|Standard paper-based home exercise program
41094399|NCT02288858|DIETARY_SUPPLEMENT|Viviscal Oral Supplement Tablets|Tablet (512 mg)
41094400|NCT05803967|BEHAVIORAL|Baduanjin exercising|baduanjin will be applied 5 times per the week, under supervision, for 12 weeks,
41094401|NCT02831335|OTHER|MRI|Perform MRI studies
40921939|NCT05146102|OTHER|"ethics communication in group, in line with the one to five-step method"|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month."
41094402|NCT02831335|OTHER|MRI|Perform MRI studies
41094403|NCT02831335|OTHER|MRI|Perform MRI studies
40921940|NCT06199583|DIAGNOSTIC_TEST|Shear-wave elastography|Ultrasound shear-wave elastography
40921941|NCT00921895|DEVICE|RPS Adeno Detector IV|One time test with the RPS Adeno Detector IV
41094404|NCT02831335|OTHER|Group 4|Perform MRI studies
41094405|NCT06033300|BIOLOGICAL|blood sample|blood sample
41094406|NCT04927598|DEVICE|plasmapheresis|patients of Gullian Barrie syndrome undergo plasmapharesis
41094407|NCT01816113|BIOLOGICAL|ChAd63 PvDBP 5 x 10^9|1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly
41094408|NCT01816113|BIOLOGICAL|ChAd63 PvDBP 5 x 10^10|1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly
41094409|NCT01816113|BIOLOGICAL|MVA PvDBP 1 x 10^8|1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly
40921942|NCT02941172|OTHER|Cold exposure|Controlled cold exposure is performed before and during PET scan
40921943|NCT02941172|OTHER|[18F]FMPEP-d2|PET radiotracer used in imaging
40921944|NCT02941172|OTHER|[18F]FDG|PET radiotracer used in imaging
41094410|NCT01816113|BIOLOGICAL|MVA PvDBP 2 x 10^8|1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
41269640|NCT04095455|DRUG|Control group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
41269641|NCT05222633|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.05ml intravitreal injection
41269642|NCT05222633|DRUG|Aflibercept|Aflibercept 2.0mg/0.05ml intravitreal injection
41269643|NCT05222633|DRUG|Conbercept|Conbercept 0.5mg/0.05ml intravitreal injection
41094411|NCT04810455|OTHER|Purrble|"The objective of this study is to evaluate the impact of having access to the Purrble intervention, compared to an active control in the form of a non-interactive plush toy, on child daily emotion regulation (primary outcome) as well as a range of secondary outcomes over a period of one month.~The investigators hypothesise that engagement with an in-situ, 'bottom-up' emotion regulation intervention which enables in-the-moment soothing for children, will lead to measurable changes in child self-regulatory behaviours over time."
41094412|NCT04810455|OTHER|Active control toy|The selected active control toy is the Wild Republic 8'' Hedgehog animal. The selection process was guided by: the plush toy needed to have analogous size, weight, quality of materials, and at least similar (if not higher) visual appeal. The investigators also made sure to include the design characteristics our prior work suggested were important for the narrative around the toy. These were selecting a similarly stylised animal (to enable emotion projection and feelings of care), as well as no visible mouth on the toy (to prevent setting an expectation about the toy's emotional state as a mouth would imply an emotional expression). Additionally, the investigators have adapted the one-page parent-facing descriptions of the narrative that come with Purrble also for the active control unit: as such, the active control families will receive the same general narrative-without the explicit mentions of the toy interactivity-and the same suggested activities for parents.
41094413|NCT01019577|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
41094414|NCT03905135|DRUG|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.
41094415|NCT03905135|DRUG|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion at the maximum tolerated dose (MTD) or maximum administered dose (MAD) on days 1-5 of each of six cycles
41094416|NCT03905135|BIOLOGICAL|Avelumab|Avelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.
41094417|NCT00388011|DRUG|Intranasal Morphine (MNS075) 3.75 mg|Intranasal Morphine (MNS075) 3.75 mg
41094418|NCT00388011|DRUG|Intravenous Morphine 7.5 mg|Intravenous Morphine 7.5 mg
41094419|NCT00388011|DRUG|Intranasal morphine (MNS075) 7.5 mg|Intranasal morphine (MNS075) 7.5 mg
40921945|NCT05922800|DEVICE|Electro Press Needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
40921946|NCT05922800|DRUG|Gamma-Oryzanol|The patients in this group were given orally gamma-oryzanol tablets 20mg each time, three times a day, for 6 months.
40921947|NCT00264459|BIOLOGICAL|Grass pollen formulation|"Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter."
40921948|NCT00264459|OTHER|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
40921949|NCT03927378|DRUG|S-ketamine|S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
40921950|NCT03927378|DRUG|Placebo|Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
40921951|NCT00883688|DRUG|Bevacizumab|"10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle)."
40921952|NCT00883688|DRUG|Lapatinib|Pills of 700 mg/m\^2/dose given orally 2 times each day.
40921953|NCT06224751|DIAGNOSTIC_TEST|Near logMAR letter acuity|Comparison of gold standard printed tests and computerised versions
40921954|NCT06224751|DIAGNOSTIC_TEST|Near LogMAR word acuity|Comparison of gold standard printed tests and computerised versions
40921955|NCT06224751|DIAGNOSTIC_TEST|Red Green Stereoacuity|Comparison of gold standard printed tests and computerised versions
40921956|NCT06224751|DIAGNOSTIC_TEST|Auckland Optotype/Auckland Vanishing Optotypes|Comparison of gold standard printed tests and computerised versions
40921957|NCT06224751|DIAGNOSTIC_TEST|Vanishing Optotype Sloan Letters|Comparison of gold standard printed tests and computerised versions
40921958|NCT06224751|DIAGNOSTIC_TEST|Letter Contrast Sensitivity|Comparison of gold standard printed tests and computerised versions
40921959|NCT06224751|DIAGNOSTIC_TEST|Low Contrast Letter Acuity|Comparison of gold standard printed tests and computerised versions
40921960|NCT03948477|DRUG|Pantoprazole 40mg|Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.
40921961|NCT03948477|DRUG|Placebo|Matched placebo
40921962|NCT01122056|OTHER|Physical exercise training|Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
41094420|NCT00388011|DRUG|Intranasal morphine (MNS075) 15 mg|Intranasal morphine (MNS075) 15 mg
41094421|NCT00388011|DRUG|Intranasal morphine (MNS075) 30 mg|Intranasal morphine (MNS075) 30 mg
41094422|NCT00388011|DRUG|Intranasal placebo|Intranasal placebo
41094423|NCT03828695|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
41094424|NCT01737008|DRUG|dacomitinib|Tablets are administered orally or through a G-Tube, and can be taken with or without food.
41094425|NCT01737008|RADIATION|Radiotherapy|Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
40921963|NCT06138730|BEHAVIORAL|Appa Complete|Weekly mentorship meetings \& guided CBT videos. Participants assigned to Appa Complete will have unlimited access to the Appa website and materials described in Appa Lite, along with weekly mentorship meetings with a trained and supervised near-peer mentor with whom they have been matched. Matching is based on preference for mentor gender, racial/ethnic minority status, and LGBTQ status and is designed to increase the sense of identification with the mentor and peer-mentor alliance. Virtual meetings begin with a review and discussion of the video and other materials for the week. Mentors ask about how clients are incorporating their CBT learnings into their life, share ways they have used the focal skills in their own lives, illustrate skills use in popular culture, and provide problem solving strategies. Each week has a specific prompt to ensure that clients are applying the concepts and skills they are learning and can talk about any questions or reflections with their mentors.
40921964|NCT06138730|BEHAVIORAL|Appa Lite|Unguided EBP videos and materials. Participants assigned to the Appa Lite condition will have unlimited access to the Appa website, including short form CBT-based videos and materials such as an emotions wheel pdf and thoughts, feelings, and behavior worksheets. The website is structured so that the materials are presented in a developmentally appropriate manner consistent with evidence-based principles in a 12-week format, beginning with general psychoeducation to define mental health, proceeding to introducing CBT and basic CBT skills such as identifying thoughts, feelings, and behaviors, layering on applying specific CBT skills, and ending with reflective journal exercises. Client progress through the materials will be completely unguided.
40921965|NCT05045989|BEHAVIORAL|Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions)|SARS-CoV-2 asymptomatic saliva testing (as available to all students at staff at the participating university) delivered with relaxed social distancing (behavioural element) in two halls of residence.
40921966|NCT06505733|BEHAVIORAL|postnatal attendant training|"Intervention Group: Training and counselling will be provided to the puerperant and companions before discharge in a quiet and stimulus-free environment using the Companion Training Guide. Research data will be collected three times: pre-test data, after the training and on the tenth day."
40921967|NCT06093074|BEHAVIORAL|self-management program after traumatic injuries|The self-management support (SMS) program is manualized and will include eight weekly 2.5-hour sessions in groups of 5-7 participants. This feasibility trial will assess both face-to-face delivered program and a tele-health program via electronic devices. The tele-health intervention will be delivered with the same SMS content, frequency, and in-group mode.
40921968|NCT06086197|DRUG|Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin|"Anlotinib: 12mg d1\~14 po qd, Rituximab: 375mg/m2 d1, gemcitabine: 1000mg/m2 d1 and d8, oxaliplatin: 130mg/m2 d1;~For subjects ≥75 years of age, appropriate reduction of chemotherapy drugs (not less than 75% of the standard dose, or withdrawal of day 8 gemcitabine) may be decided by the investigator."
40921969|NCT02122783|DEVICE|ADR™ brace resistance|
40921970|NCT02122783|DEVICE|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
41094426|NCT01737008|DRUG|Cisplatin|If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
41094427|NCT06345872|BEHAVIORAL|CBT-I|Includes 8 weekly sessions of CBT-I and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.
41269644|NCT02536248|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
40921971|NCT05303662|DIAGNOSTIC_TEST|Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs|Pooled throat/nose sample and a rectal sample is taken prior to the ERCP
40921972|NCT05303662|DIAGNOSTIC_TEST|MDRO-testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted. Then cultured for presence of MDRO's
40921973|NCT05303662|DIAGNOSTIC_TEST|Microbiome through rectal swab|An rectal swab is collected for microbiome purposes
40921974|NCT05303662|DIAGNOSTIC_TEST|Microbiome testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted for microbiome analysis
40921975|NCT05503745|OTHER|CBT-F+MIT|The aim is to develop healthier strategies for managing negative thoughts and feelings antecedent to ED and for engaging patients in social interactions that meet their relational basic wishes. They will thus understand that perfectionism and the need for control they experience through ED are coping strategies developed within interpersonal patterns of interaction with significant others, where low self-esteem and emotive dysregulation play a central role. MIT aims to improve individuals' capacity to make sense of their own affect and cognitions and become aware of being driven by maladaptive, rigid and biased schemas about self and others, to form a richer understanding of the mind of the others and use this knowledge to react in more adaptive ways to social difficulties or evolutionary selected wishes. MIT also enables individuals to reflect on how these schemas may act as triggers for ED behavior and to develop more effective coping strategies in face of interpersonal stressors.
40921976|NCT05503745|OTHER|CBT-E|In the first Stage, the treatment will be focused on achieving a shared understanding of the patient's eating disorder and the related maintenance factors. In this phase the patient will be helped to regulate and stabilize his eating habits and so to address his weight concerns. In the second stage, progress made is reviewed in detail. In the third stage, the sessions will be focused on the central processes that are maintaining the psychopathology of the patient's eating disorder. In particular, this involves in addressing concerns about weight and body shape, cognitive and caloric dietary restriction, events and emotions that affect nutrition. In phase three and four clinical perfection, low global self-esteem, intolerance of emotions and interpersonal difficulties are also addressed. Towards the end of the third stage and during the fourth stage, procedures will be also implemented to minimize the risk of short- and long-term relapse.
41094428|NCT06345872|BEHAVIORAL|Treatment as usual|Includes 8 weekly sessions of standard treatment and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.
40921977|NCT05170867|DIETARY_SUPPLEMENT|Hafnia alvei HA4597™|One capsule of probiotic supplement, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the dietary supplement contain 5x107 CFU of Hafnia alvei HA4597™, 5 mg of zinc and 20 μg of chromium.
40921978|NCT05170867|OTHER|Placebo|One capsule of placebo, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the placebo contain 5 mg of zinc and 20 μg of chromium.
40921979|NCT01022398|DRUG|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
40921980|NCT03337919|DRUG|Nivolumab|Up to 8 cycles of nivolumab
40921981|NCT05451485|DIAGNOSTIC_TEST|Blood speckle tracking|Blood speckle tracking measurements will be acquired of the carotid artery and superficial femoral artery
40921982|NCT05451485|DIAGNOSTIC_TEST|Ultrasound particle Imaging Velocimetry|Ultrasound particle imaging velocimetry will be acquired of the carotid artery and superficial femoral artery
40921983|NCT05451485|DIAGNOSTIC_TEST|4D flow MRI|4D flow MRI will be acquired of the carotid artery and superficial femoral artery
40921984|NCT05451485|DIAGNOSTIC_TEST|Conventional duplex|Conventional duplex measurements will be acquired of the carotid artery and superficial femoral artery
40921985|NCT05152225|DIAGNOSTIC_TEST|Brain MRI|Brain MRI performed routinely in patients with EI
41094429|NCT06345872|OTHER|Tapered Withdrawal|Individualized gradual tapered withdrawal following CDC guidelines, additional check-ins and motivational interviewing with a therapist.
41094430|NCT00968331|DRUG|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
41094431|NCT02718443|DRUG|VXM01|Oral immunotherapy targeting VEGFR2
41094432|NCT04196985|DIAGNOSTIC_TEST|PET/MRI|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
40921986|NCT05152225|DIAGNOSTIC_TEST|digital subtraction angiography (DSA)|Digital Subtraction Angiography (DSA) performed routinely in patients with EI
40921987|NCT01215929|DRUG|Dextroamphetamine|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
41269645|NCT02536248|DRUG|Placebo|Placebo for 6 weeks
41269646|NCT03055026|DRUG|Rivaroxaban|Tablets
41269647|NCT03055026|DRUG|Placebo|Tablets
40921988|NCT01215929|DRUG|Placebo|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
40921989|NCT05095012|OTHER|Pediatric Acute Care Concussion Clinical Pathway|MD assessment will be partially standardized to assess for patients at higher risk of becoming persistently symptomatic. These patients scoring as 'high risk' will be referred to one of three specialty clinics. High risk is defined as scoring 9 or higher out of 12 on the 5P score.
40921990|NCT02603263|OTHER|Social Norms Poster|"A poster containing a social norms message: Most people here choose to eat vegetables with their lunch"
40921991|NCT01101308|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
40921992|NCT01101308|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
40921993|NCT03712371|DRUG|Chitosan|The starting dose for Chitosan is 500mg twice a day, the second dose level is 1000mg twice a day, the third dose level is 1500mg twice a day, and the fourth dose level is 2000mg twice a day. Each dose level lasts for 28 days.
40921994|NCT00488709|DRUG|Topotecan|
40921995|NCT00488709|DRUG|Fludarabine|
40921996|NCT00488709|DRUG|Cytarabine|
40921997|NCT03665818|DEVICE|oral appliance treatment|mandibular advancement device to enlarge pharyngeal airway space to get rid of apnea and hypopnea events
40921998|NCT02675556|DRUG|Allo-hMSCs|a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells
40921999|NCT02675556|DRUG|Placebo|a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
40922000|NCT03845439|OTHER|Lumbar puncture|Lumbar puncture
40922001|NCT03571698|DEVICE|Neuromuscular Electrical Stimulator|The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
40922002|NCT04800770|DIAGNOSTIC_TEST|4C mortality score|4C mortality score and phosphate levels
41094433|NCT04196985|DIAGNOSTIC_TEST|PET/CT|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
40922003|NCT02258776|DIETARY_SUPPLEMENT|Pomegranate Extract|Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
40922004|NCT02258776|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
40922005|NCT02258776|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken 1/day for 12 weeks.
40922006|NCT03279289|DRUG|Aflibercept|4 mg/kg administered intravenous infusion on day 1
40922007|NCT03279289|DRUG|Irinotecan|180 mg/m2 intravenous infusion
40922008|NCT03279289|DRUG|folinic acid (dl racemic)|400 mg/m2 intravenous infusion
40922009|NCT03279289|DRUG|5Fluorouracil|400 mg/m2 intravenous bolus
40922010|NCT03279289|DRUG|5-FU|2400 mg/m2 continuous intravenous infusion over 46 hours
40922011|NCT03118661|OTHER|For Step 2: Structured treatment interruption|-Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection
41094434|NCT04888455|DIAGNOSTIC_TEST|Quantitative sensory testing (QST)|Demographic data, pain characteristics, health status, emotional well-being, personality and lifestyle are assessed by questionnaires. Additionally, all patients underwent a clinical neurological examination and quantitative sensory testing (QST) according to the German Research Network on Neuropathic Pain (DFNS).
41094435|NCT03961256|DRUG|Exenatide SR|Exenatide SR 2 mg subcutaneous (SQ) weekly
40922012|NCT03118661|PROCEDURE|Peripheral blood draw|-Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
40922013|NCT00008450|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
40922014|NCT00008450|DRUG|Cyclosporine|Given PO or IV
40922015|NCT00008450|OTHER|Laboratory Biomarker Analysis|Correlative studies
40922016|NCT00008450|DRUG|Mycophenolate Mofetil|Given PO or IV
40922017|NCT00008450|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
40922018|NCT00008450|RADIATION|Total-Body Irradiation|Undergo TBI
40922019|NCT01571544|DEVICE|Thermal suit|Thermal suit
40922020|NCT01571544|OTHER|Conventional clothing|Conventional clothing
40922021|NCT03853824|OTHER|Increased postoperative surveillance|Increased postoperative surveillance can include either of the following; i) admission to a higher care ward than had been planned at the time of surgery, ii) an increase in the frequency of nursing observations in the postoperative period, iii) ensuring that the patient is placed in view of the nursing station, and not in a remote location in the postoperative ward, or iv) allowing family members to stay with the patient in the ward in the postoperative period.
40922022|NCT03853824|OTHER|Usual postoperative care|Participating sites randomised to the control arm will provide usual postoperative care to patients. The care will be left to the discretion of the healthcare providers.
40922023|NCT00949494|DEVICE|Synvisc|intra-articular, 3 weekly injections
40922024|NCT02827656|DRUG|Decapeptyl|luteal support as described and vaginal progesterone 200 mg 3 times a day
40922025|NCT02827656|DRUG|hCG luteal support|luteal support as described and vaginal progesterone 200 mg 3 times a day
41094436|NCT00272285|DRUG|Ramosetron|IV, concomitant administration with dexamethasone
41094437|NCT00272285|DRUG|Granisetron|IV, concomitant administration with dexamethasone
41094438|NCT06613776|DRUG|Amoxicillin|4 capsules of amoxicillin 500mg, 2 grams in total, one hour before surgery
41094439|NCT06613776|DRUG|Placebo|4 empty capsules of amoxicillin 500mg (placebo), one hour before surgery
41269648|NCT04454411|DRUG|Brixadi|Extended release injectable Buprenorphine
41094440|NCT04700007|DRUG|Capsaicin|A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.
41094441|NCT04700007|DRUG|Diphenhydramine|Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.
40922026|NCT00998244|OTHER|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
40922027|NCT02724540|DEVICE|Bland Embolization|Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis
41094442|NCT04700007|DRUG|Morphine Chloride|Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.
40922028|NCT02724540|COMBINATION_PRODUCT|Transarterial chemoembolization|Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
40922029|NCT02724540|COMBINATION_PRODUCT|Drug Eluting Beads Embolization|CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.
40922030|NCT03463200|OTHER|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
40922031|NCT03463200|OTHER|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
40922032|NCT03463200|OTHER|Rigid Tape|Application of Micropore tape in the erector spine muscles.
40922033|NCT01850576|BEHAVIORAL|Risk Reduction Intervention|STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
40922034|NCT06514196|DEVICE|Hintermann Series H3 Total Ankle Replacement System|The H3 includes a metal tibial component, a polyethylene sliding insert (PE inlay), and a metal talar component.
41094443|NCT04700007|DRUG|Isotonic saline|injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
41094444|NCT04700007|DRUG|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
41094445|NCT04508530|BIOLOGICAL|Panzyga|Panzyga 10% IVIG
41094446|NCT04508530|OTHER|Placebo|Placebo
41094447|NCT03645356|DEVICE|Fixed Appliances|Using an MBT-prescription of metallic brackets, patients will be treated in the conventional way
41094448|NCT03645356|DEVICE|Clear Aligners|Using a sequence of clear aligners, patients will be give an aligner every two weeks until the completion of treatment
40922035|NCT01410344|DRUG|Fludarabine and Busulfan|"RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m\^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:~* Days -6 to -2: Flu (30 mg/m\^2/day, total dose of 150 mg/m\^2)~* Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m\^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m\^2 IV, respectively)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
41094449|NCT06298630|OTHER|Assessments|Safety and efficacy assessments
41094450|NCT00188409|PROCEDURE|CT scan|
41094451|NCT02538640|OTHER|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
41094452|NCT02538640|OTHER|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
41094453|NCT02887261|DEVICE|"BardPowerPort sip Implantable Port"|capable for power injection for contrast media.
41094454|NCT02887261|DEVICE|Conventional Port|not for power injection for contrast media.
41094455|NCT03079375|OTHER|basic intervention|medication review
41094456|NCT03079375|OTHER|extended intervention|medication review, medication interview before discharge and follow-up
41094457|NCT03310528|BEHAVIORAL|Interview questionnaire|Complete interview questionnaire regarding the composition and timing of their most recent food intake.
41094458|NCT03310528|PROCEDURE|Gastric ultrasound exam|Gastric ultrasound exam prior to upper GI endoscopy procedure.
41094459|NCT03771885|DRUG|BI 705564|Film-coated Tablet
41094460|NCT03771885|DRUG|Placebo|Film-coated Tablet
41094461|NCT03717545|OTHER|second allogeneic stem cell transplantation|"1. Change another donor~2. conditioning regimen: FLU/CY/anti-CD25 moAb"
41094462|NCT06368180|DEVICE|Robotic assisted gait training|is a robotic treadmill training system that uses body weight support to suspend patients by attaching their legs to robotic legs that help them walk
41269649|NCT04454411|DRUG|Vivitrol|Extended release injectable Naltrexone
40922036|NCT01410344|DRUG|Fludarabine and Melphalan|"RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m\^2, Melphalan total dose: less than or equal to 150 mg/m\^2. Recommended regimen:~* Days -5 to -2: Flu (30mg/m\^2/day, total dose of 120 mg/m\^2)~* Day -1: Mel (140mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage."
40922037|NCT01410344|DRUG|Busulfan and Fludarabine|"MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m\^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:~* Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m\^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively)~* Days -5 to -2: Flu (30 mg/m\^2/day, total dose of 120 mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
40922038|NCT01410344|DRUG|Cyclophosphamide and Total Body Irradiation|"MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~* Days -7 to -4: TBI (total dose of 1200-1420 cGy)~* Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight."
41094463|NCT06368180|DEVICE|Body weight supported treadmill training|The Biodex Unweighting System was used to support the child's body weight, by an adjustable harness placed, over the treadmill.
41094464|NCT05910931|DRUG|ICG angiography|"* A first injection with the patient asleep before starting the intervention to visualize the vascular anatomy of each patient and assess the pedicles and incisions.~* A second bolus after breast resection to assess the viability of skin flaps and glandular pedicles.~* A third injection to obtain an angiography after implant placement and wound closure.~For angiography, the SPY System with the SPY-Q software will be used."
41094465|NCT03378479|DRUG|SOC +Posaconazole 18 MG/ML (milligram/milliliter)|.2\*300mg/d IV on day 1, followed by 1\*300mg/d IV from day 2 for 7 days (total 7 days)
41094466|NCT03378479|OTHER|standard of care (SOC)|treatment for influenza pneumonia at the investigators discretion
41094467|NCT02600429|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
41094468|NCT02600429|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
41094469|NCT04208737|PROCEDURE|recruitment maneuver|30 cmH2O pressure 15 seconds
41094470|NCT01664234|OTHER|laryngoscopy with oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
41094471|NCT01664234|OTHER|laryngoscopy without oxygen|Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
41094472|NCT05320913|PROCEDURE|Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 120 mg of ropivacaine, epinephrine 0.2 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 40 mL. + PENG block with ropivacaine 40 mg and epinephrine 0.1 mg with normal saline to a total volume of 20 mL
41094473|NCT05320913|PROCEDURE|isolated periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 150 mg of ropivacaine, epinephrine 0.3 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 50 mL
41094474|NCT05738538|DRUG|ziftomenib|
40922039|NCT01601600|DRUG|BYM338|BYM338
40922040|NCT01601600|DRUG|Placebo|BYM338 Placebo
41094475|NCT05300880|OTHER|Training program|A multi-component intervention based on health coaching. The strategies of this program consisted in five 16-hour sessions using case studies to find out whether nurses were able to empower chronic cardiac patients and debriefing and a 4-hour booster session seven months later.
41094476|NCT06378879|DRUG|Propofol 100 MG in 10 ML Injection|Sedation induction time (minutes), total dose of propofol (mg), recovery time (minutes), any involuntary patient movement, quality of sedation (VAS) and adverse events
41094477|NCT04986917|DEVICE|Hernia repair surgery using the Su2ura® approximation device|. The hernia defect will be measured and the Su2ura® approximation device will then be used to close the defect, placing stainless steel implantable anchors threaded on a Polyethylene braided surgical suture.
41094478|NCT04986917|DIAGNOSTIC_TEST|Physical Examination|All subjects will undergo a standard physical examination by an authorized physician. The physician's evaluation will include diagnosis and documentation of any significant clinical abnormalities or diseases.
41094479|NCT04986917|DIAGNOSTIC_TEST|Vital Signs|Vital signs include blood pressure, pulse, temperature, body weight and height, body mass index (BMI).
41094480|NCT04986917|DIAGNOSTIC_TEST|Blood Tests|"All subjects will undergo Hematology and Biochemistry blood tests. Blood Hematology test will include a complete CBC. Blood Biochemistry test will include the following measures: Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL, LDL, Triglycerides).~5 ml of blood (equals to 1 spoon) will be taken for each test."
41094481|NCT04986917|DIAGNOSTIC_TEST|Urine Pregnancy Test|Urine pregnancy test will be performed during the screening visit (for WOCBP).
41094482|NCT04986917|DIAGNOSTIC_TEST|Abdominal Ultrasound imaging|All subjects will undergo an abdominal ultrasound (US) imaging at 12 Months visit. The US will be performed to verify an absence of hernia recurrence.
41094483|NCT04986917|OTHER|EuraHS-QoL|patients will be asked to fill a questionnaire assessing patient-reported satisfaction and function. questionnaire score range: 0-180; higher score indicates higher pain and discomfort
41094484|NCT04986917|OTHER|Visual Analouge Scale (VAS)|A validated, subjective measure measuring acute and chronic pain. questionnaire score range: 0-10; higher score indicates higher pain level.
41094485|NCT04986917|DIAGNOSTIC_TEST|Clinical evaluation for hernia recurrence and clinical bulging|"The procedure includes:~1. Clinical examination to determine the presence of hernia recurrence and clinical bulging, in an inconclusive physical exam a radiological imaging will be performed such as US or CT.~2. SAE's and SADE's evaluation of the seroma.~3. Taking a photograph of the surgery area without disclosing the subject's identity."
41269650|NCT05962125|OTHER|periodic alveolar recruitment maneuvers|A stepwise increment of tidal volume was used for each ARM.
41269651|NCT05962125|OTHER|positive end-expiratory pressure|a PEEP of 6 to 8 cm H2O
41094486|NCT05892289|PROCEDURE|Robotic assisted proximal gastrectomy with double-flap technique|Patients in this group receive robotic assisted proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p and 11d).The double-flap technique is used for the digestive tract reconstruction.
41094487|NCT03371108|BIOLOGICAL|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
41094488|NCT03371108|BIOLOGICAL|Lantus®|Route of administration: subcutaneous injection
41094489|NCT03843892|DRUG|OFEV|twice daily
41094490|NCT06300840|DEVICE|BalanceBelt|The vibrotactile belt (i.e., Elitac BalanceBelt®) supports patients with severe balance disorders by substituting the missing balance information with vibrations (haptic feedback).
41094491|NCT04912557|OTHER|postoperative pain assess|numerical pain scale and Metameric levels of cold insensitivity
41094492|NCT05814640|DRUG|Fluoxetine|Commonly used oral antipsychotics intervention therapy.
41094493|NCT05814640|DRUG|Sertraline|Commonly used oral antipsychotics intervention therapy.
41094494|NCT05814640|DRUG|Vortioxetine|Commonly used oral antipsychotics intervention therapy.
41094495|NCT05814640|DRUG|Duloxetine|Commonly used oral antipsychotics intervention therapy.
41094496|NCT05814640|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
41094497|NCT05814640|DRUG|Lithium Carbonate|Commonly used oral antipsychotics intervention therapy.
41094498|NCT05814640|DRUG|Olanzapine|Commonly used oral antipsychotics intervention therapy.
41094499|NCT05814640|BEHAVIORAL|GCBT|Commonly used intervention therapy of psychotherapy.
41094500|NCT01824446|DRUG|Radiolabeled SPD602 (FBS0701, SSP-004184)|A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
41094501|NCT04616482|BEHAVIORAL|Digital therapeutic carbohydrate restriction (TCR) program|A 12-week, personalized, online program to teach and coach patients about therapeutic carbohydrate restriction as for obesity and/or T2D (or risk of T2D). The program is intended to enhance the usual clinical care provided for patients.
41094502|NCT06614972|DEVICE|Balloon-expandable drug-eluting stent|Balloon-expandable drug-eluting stent (BDES) is the device comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
40922041|NCT03923244|DIAGNOSTIC_TEST|OSDI survey|"Normal patient consultation schedule for cataract surgery with:~* Preoperative appointment scheduled for the patient~* Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~* Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~* An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~* Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
40922042|NCT02773784|OTHER|immunohistochemistry and/or FISH|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
40922043|NCT00106509|DRUG|tolevamer potassium-sodium (GT267-004)|
40922044|NCT01723644|OTHER|the clinical reassessment arm|In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
40922045|NCT01723644|OTHER|the procalcitonin arm|In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
40922046|NCT01369329|DRUG|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
41094503|NCT04548622|DEVICE|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to both the left and right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
41094504|NCT03683862|OTHER|orthodontic appliance|Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
41094505|NCT04689698|DIAGNOSTIC_TEST|Thomayer test|Testing of the ankle in sagittal line and Thomayer test before and after flossing of sole.
41094506|NCT03293667|OTHER|Exploratory synovial fluid analysis|An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
41094507|NCT05168969|OTHER|Questionnaire|The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).
41094508|NCT02392338|PROCEDURE|Hybrid procedure|Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isolation lesion and box lesions in left atrium
40758260|NCT02554838|BEHAVIORAL|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
40922047|NCT01369329|DRUG|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
40922048|NCT01369329|DRUG|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
40922049|NCT04796064|OTHER|low-intensity aerobic training|"A low-intensity aerobic training group started with 15 minutes of warm-up, which includes static stretching of the upper and lower limb muscles. then participants were instructed to do 30 minutes of low-intensity aerobic training exercises, which include 20 minutes on the treadmill and 10 minutes of cycle ergometer, followed by 10 minutes of cool down.~- In high-intensity training (HAT) the same protocol has been followed, but the intensity of exercises was fixed between 60% to 80 % of maximum heart rate. The strength training includes major group muscles such as shoulder flexors, extensors, and abductors, elbow flexors and extensors, hip flexors\& extensors, knee flexors\&extensors, abdominal and back muscles also were trained. Each group of muscles was trained for 10 repetitions for 3 sets with a rest period of 5 minutes."
40922050|NCT06032013|OTHER|Cardiac rehabilitation program (PROMs)|"The program is multidisciplinary with the following components:~* Medical assessment~* Physical training and counselling on physical activity~* Identification and control of risk factors~* Nutritional assessment and counselling~* Psychological assessment and intervention~* Education and information"
40922051|NCT01552798|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
40922052|NCT01552798|DRUG|Acetaminophen|2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
40922053|NCT01552798|DRUG|Placebo|2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
40922054|NCT00793273|DRUG|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
40922055|NCT02205489|DRUG|Alemtuzumab GZ402673|Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
40922056|NCT02205489|DRUG|cetirizine|Pharmaceutical form:tablet Route of administration: oral
40922057|NCT02205489|DRUG|ranitidine|Pharmaceutical form:tablet Route of administration: oral
40922058|NCT02205489|DRUG|methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
40922059|NCT02205489|DRUG|methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
40922060|NCT02205489|DRUG|aciclovir|Pharmaceutical form:tablet Route of administration: oral
40922061|NCT02205489|DRUG|esomeprazole|Pharmaceutical form:tablet Route of administration: oral
40922062|NCT02205489|DRUG|ibuprofen|Pharmaceutical form:tablet Route of administration: oral
40922063|NCT02205489|DRUG|paracetamol|Pharmaceutical form:tablet Route of administration: oral
40922064|NCT03224559|DEVICE|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation
40922065|NCT00314002|DEVICE|Mechanical Thrombectomy|
40922066|NCT05772585|OTHER|Blood collection|Blood collection (1 to 4 times for each patient) in order to perform metabolomic analyses of the plasmatic fingerprints of patients with hepatic encephalopathy
40922067|NCT00824837|OTHER|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
40922068|NCT00824837|OTHER|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
41094509|NCT01151033|DEVICE|Drug Eluting Stent implantation|ProNOVA XR Drug Eluting Stent implantation
40922069|NCT06300879|PROCEDURE|Performing totally laparoscopic proximal gastrectomy with esophagogastrostomy by fissure technique|"Surgical Operation:~1. Gastric Resection Range:Proximal gastrectomy, preserving 2/3 of the distal stomach.~2. Lymph Node Dissection Range:D1+ to D2 lymph node dissection.~3. Anastomosis Method: esophagogastrostomy by fissure technique.~4. Anastomosis Risk Management Plan:For a rupture with a maximum diameter less than or equal to 5mm, repair with 4-0/3-0 absorbable sutures and proceed with the anastomosis.For a rupture with a maximum diameter greater than 5mm or failed anastomosis, resect that part of the remaining stomach, change to proximal gastrectomy, and perform double-channel anastomosis.~5. Surgical Approach:Totally laparoscopic proximal gastrectomy."
40922070|NCT06095648|OTHER|Dose of platelet transfusion|Intervention is using a lower (5ml/kg) compared to usual (15ml/kg) dose of platelets for transfusion in non-bleeding babies born at or before 32 weeks in NICU
40922071|NCT04704362|BEHAVIORAL|Ensuring Quality in Psychological Support|Trainees are evaluated with the Enhancing Assessment of Common Therapeutic factors structured role play tool and the results are shared with trainers and/or supervisors to modify training based on strengths and weakness on the competency scores.
40922072|NCT04704362|BEHAVIORAL|Standard Training and Supervision|Trainees are trained using a manual for non-specialist-delivered psychological interventions.
40922073|NCT05788289|DRUG|Tafasitamab|Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.
40922074|NCT05788289|DRUG|Lenalidomide|Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).
40922075|NCT03154892|PROCEDURE|Intracameral injection|Intracameral Conbercept injection for the treatment of NVG
40922076|NCT03154892|PROCEDURE|Intravitreal injection|Intravitreal Conbercept injection for the treatment of NVG
40922077|NCT00884767|DRUG|FOLFOX regimen|
40922078|NCT00884767|DRUG|fluorouracil|
40922079|NCT00884767|DRUG|leucovorin calcium|
40922080|NCT00884767|DRUG|oxaliplatin|
40922081|NCT00884767|GENETIC|gene expression analysis|
40922082|NCT00884767|GENETIC|protein expression analysis|
40922083|NCT00884767|GENETIC|proteomic profiling|
40922084|NCT00884767|OTHER|laboratory biomarker analysis|
40922085|NCT00884767|OTHER|pharmacogenomic studies|
41094510|NCT05878353|PROCEDURE|Decontamination of the pocket with local doxycycline|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage. Local doxycycline was administered according to the manufacturer's instruction. Briefly, the plastic needle of the syringe will be inserted into the sulcus and the product will be progressively released in the periodontal pocket up to the gingival margin. The syringe will be then removed and a cotton pellet used to compact the gel into the sulcus. Patients will be then instructed not to floss or use interdental brushes in that area for the following 10 days.
40922086|NCT04690439|DEVICE|Photobiomodulation therapy (PBMT)|The MLS M6 laser from ASA will be used to apply the laser therapy.
40922087|NCT04690439|PROCEDURE|Manual Lymphatic drainage|Patients will receive twice weekly MLT executed by trained physiotherapist
40922088|NCT04375657|COMBINATION_PRODUCT|TRIIM Treatment|Personalized combination of somatropin, metformin, and DHEA
40922089|NCT04375657|COMBINATION_PRODUCT|Active Control|Metformin and DHEA
40922091|NCT04242667|BEHAVIORAL|e-Health (web-based) disclosure portal|Patient uses secure web-based portal to access genetic research results
40922092|NCT04242667|BEHAVIORAL|Provider mediated disclosure|Patient has disclosure of genetic research result by a provider (genetic counselor)
40922093|NCT03998839|OTHER|Community distribution of Sulfadoxine-pyrimethamine (SP)|Community health workers will distribute SP to pregnant women, targeting at least three times during pregnancy.
40922094|NCT05294913|BEHAVIORAL|Contextualized Wish-Outcome-Obstacle-Plan (WOOP) intervention|This intervention will ask students to identify socio-culturally integrated academic or personal goals, so that students may be able to better strategize obstacle-overcoming to attain their future academic aspirations and modulate negative emotions or environments and associated physiological responses.
40922095|NCT05294913|BEHAVIORAL|Placebo|The placebo control group will receive a 5- to 10-minute online goal-setting video tutorial and confirm that they have completed it by filling out an online check-list.
40922096|NCT02593136|DIETARY_SUPPLEMENT|Home Fortification Product (HFP)|"The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)"
40922097|NCT02593136|OTHER|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
40922098|NCT02595632|OTHER|No intervention|
41094511|NCT05878353|PROCEDURE|Decontamination of the pocket with mechanical instrumentation|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage.
41442477|NCT06272266|DEVICE|Kardiopulmonary exercise test (Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system)|"For the cardiopulmonary exercise test, a Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system, supported by analyzers that measure oxygen uptake and carbon dioxide output, and a bicycle ergometer connected to the ergoline rehab system 2 Version 1.08 SPI system were used. At the end of the test, the individual's RER , VAT, VO2peak, VO2AT, VE/CO2, HRR, HRR1 values were recorded. These values were estimated by the device based on the wasserman extended protocol on the Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system.The test was repeated after 15 sessions of aerobic exercise training in the Covid-19 group.This intervention was applied to 14 people in the COVID-19 group and 15 people in the control group. It was repeated at the end of 15 sessions of aerobic exercise training in the COVID-19 group."
41094512|NCT00002956|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
40922099|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.
40922100|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)|A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.
41094513|NCT03279198|BEHAVIORAL|TIWeb|Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
41094514|NCT03279198|BEHAVIORAL|CSC|Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
40922101|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.
40922102|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.
40922103|NCT02509234|DRUG|Combined chemotherapy with trabectedin followed by irinotecan|"Day 1:~Trabectedin 1,1 - 1,5 mg/m²/day i.v.~Day 3-5 and 10-12:~Irinotecan 30- 90 mg/m²/day p.o. or i.v."
41094515|NCT03279198|BEHAVIORAL|UC|Intervention: The usual care group received usual care that varies dependent upon the practice setting.
41094516|NCT03279198|BEHAVIORAL|TIWeb+CSC|Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
41094517|NCT02029053|DEVICE|Vaginal Lubrication Ring for Vaginal Dryness|"Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.~Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.~The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.~The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.~Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study."
41094518|NCT06479564|OTHER|free weight training and machine training|20 participants will be in control group who will only perform free weight and machine training
41094519|NCT06479564|OTHER|Aerobic Exercises|20 participants will be in experimental group giving them aerobic exercise training protocol along with free weight and machine training
41094520|NCT03178201|DRUG|TGR-1202|Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
41094521|NCT00183573|BEHAVIORAL|Brief Motivational Intervention|15-20 minute, motivational one-on-one counseling
41094522|NCT00183573|BEHAVIORAL|Brief Informational Intervention|15 minute informational DVD on safer sex
41094523|NCT00183573|BEHAVIORAL|Intensive Informational Intervention|4-hour, information-only intensive group workshop
41094524|NCT00183573|BEHAVIORAL|Intensive Info-Motivation-Behavioral Skills Intervention|4-hour, intensive group workshop with emphasis on motivation and skills
41094525|NCT03635177|PROCEDURE|Remote ischemic conditioning|Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
41094526|NCT00331214|DRUG|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
40922104|NCT00725842|BIOLOGICAL|Peg-IFN alfa-2b|Peg-IFN alfa-2b administered in accordance with approved labeling
40922105|NCT00725842|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
40922106|NCT03032380|DRUG|Cefiderocol|2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)
40922107|NCT03032380|DRUG|Meropenem|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)
40922108|NCT03032380|DRUG|Linezolid|600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.
40922109|NCT02809716|OTHER|Biomarker Analysis|Correlative studies
40922110|NCT02809716|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue samples
40922111|NCT04764474|DRUG|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
41094527|NCT00331214|DRUG|placebo patch|placebo patch replaced every 3-4 days for 6 months
41094528|NCT00897767|OTHER|biologic sample preservation procedure|
40922112|NCT06194045|DIETARY_SUPPLEMENT|LC-MUFA oil|2 x 1 g capsules containing marine oil from North Atlantic fish
41094529|NCT06189742|BIOLOGICAL|Tezepelumab|Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP).
41094530|NCT02042443|DRUG|Capecitabine|Given PO
41094531|NCT02042443|DRUG|Fluorouracil|Given IV
40922113|NCT06194045|DIETARY_SUPPLEMENT|Placebo|2 x 1 g capsules containing corn oil
41094532|NCT02042443|OTHER|Laboratory Biomarker Analysis|Correlative studies
41094533|NCT02042443|DRUG|Leucovorin Calcium|Given IV
40758261|NCT05996653|DIAGNOSTIC_TEST|Saturation Transfer (ST)-MRI|"Non-contrast magnetic resonance imaging Saturation Transfer scans consisting of magnetization transfer (MT) and chemical exchange saturation transfer (CEST)"
40922114|NCT00798759|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
40922115|NCT00798759|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
40922116|NCT04370340|DEVICE|BabySlide|Application of BabySlide during vacuum-assisted births for perineal protection
40922117|NCT05129033|DRUG|Prednisone tablet|Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.
40922118|NCT05129033|DRUG|itraconazole|Anti-fungal medication to reduce fugal load.
40922119|NCT05129033|BIOLOGICAL|Omalizumab|Anti-IgE monoclonal antibody, used for high IgE allergic disease.
40922120|NCT05337904|DEVICE|On-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is on."
41094534|NCT02042443|DRUG|Trametinib|Given PO
41094535|NCT00438906|PROCEDURE|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
40922121|NCT05337904|DEVICE|Off-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is off."
40922122|NCT05288907|DRUG|Lidocaine Ointment|Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
40922123|NCT00091325|DIETARY_SUPPLEMENT|defined green tea catechin extract|
40922124|NCT00456443|PROCEDURE|Historical records|
40922125|NCT04838808|DRUG|Rivaroxaban 2.5 MG [Xarelto]|Rivaroxaban 2.5mg twice daily for 90-days
41094536|NCT00438906|DRUG|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
41094537|NCT05165290|DRUG|Latanoprost ophthalmic solution, 0.005%|Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control
41094538|NCT05165290|DRUG|TC-002 latanoprost ophthalmic solution, 0.005%|TC-002 is formulated using the commercially available latanoprost drug substance; delivered drop to the eye is preservative-free.
41094539|NCT02256787|DRUG|BILB 1941 ZW - single rising dose part|
41094540|NCT02256787|DRUG|Placebo|
41094541|NCT02256787|DRUG|BILB 1941 ZW - solution|
41094542|NCT02256787|DRUG|BILB 1941 ZW - tablet|
41094543|NCT02256787|OTHER|standardized breakfast|
41094544|NCT04470817|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil
41094545|NCT01501214|DRUG|Atosiban|Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
41094546|NCT01501214|DRUG|Normal saline|Normal saline given
41094547|NCT04166968|DEVICE|Anodal transcranial direct current stimulation (A-tDCS)|Anodal tDCS will be performed for 20 minutes over the affected hemisphere with an intensity set to 2 mA
41094548|NCT04166968|DEVICE|Cathodal transcranial direct current stimulation (C-tDCS)|Cathodal tDCS will be performed for 20 minutes over the unaffected hemisphere with an intensity set to 2 mA
40922126|NCT04838808|DRUG|Placebo|Placebo tablet twice daily for 90-days
40922127|NCT03287271|DRUG|VS-6063|"Phase 1:~* First 3 patient cohort: VS-6063 200 mg PO twice daily~* IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity."
40922128|NCT03287271|DRUG|Paclitaxel|"Phase 1:~* First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity."
40922129|NCT03287271|DRUG|Carboplatin|"Phase 1:~* First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity."
40922130|NCT03262311|OTHER|Hypoxia marker|Single oral dose of pimonidazole 500 mg/m2
40922131|NCT04500847|DRUG|Emtriva Capsule|200mg daily oral dose
40922132|NCT04500847|DRUG|Placebo|200mg daily oral dose
41094549|NCT04166968|DEVICE|Sham stimulation (sham-tDCS)|placebo stimulation
40922133|NCT01463007|RADIATION|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
40922134|NCT01463007|OTHER|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
40922135|NCT03729271|DRUG|Rifaximin|Rifaximin will be given during weeks 2-4
41094550|NCT04166968|BEHAVIORAL|Neuromotor training|conventional neuromotor treatment
41094551|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.125mg/kg injection over 20min
41094552|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.25mg/kg injection over 20min
41094553|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.35mg/kg by injection over 20min
41094554|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.45mg/kg by injection over 20min
41094555|NCT00764179|OTHER|milk enriched in proteins (2.15 g/100ml)|"Neonates will drink the hyperproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
40922136|NCT03729271|DEVICE|Glucose and lactulose hydrogen breath testing|Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
41094556|NCT00764179|OTHER|milk with normal protein concentration (1.45g/100ml)|"Neonates will drink the normoproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
41094557|NCT02219594|DEVICE|CT image for patient with suspected in-stent restenosis|"Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis."
41094558|NCT05274789|DRUG|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
41094559|NCT05274789|OTHER|Saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
41094560|NCT01783457|OTHER|Control|Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.
41094561|NCT01783457|OTHER|Individual psychoeducation|"Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.~Programme of sessions available upon request."
41094562|NCT04091672|PROCEDURE|Control Intervention (Conventional Autograft)|Meshed split-thickness skin graft, with standardized wound dressings (Telfa™ Clear and Xeroform™)
41094563|NCT04091672|DEVICE|Investigational Intervention (RECELL + more widely meshed autograft)|More widely meshed split-thickness skin graft, Spray-on Skin™ Cells prepared using RECELL, and standardized wound dressings (Telfa™ Clear and Xeroform™)
40922137|NCT00043342|DRUG|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
40922138|NCT00792571|DRUG|Beraprost Sodium Modified Release|
40922139|NCT04549402|OTHER|Mirror Therapy group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
40922140|NCT04549402|OTHER|Video group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
40922141|NCT00067938|DRUG|lamotrigine|Lamotrigine
40922142|NCT02447224|DRUG|1 gm IV ertapenem at enrollment|
40922143|NCT02447224|DRUG|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
40922144|NCT02447224|PROCEDURE|Appendectomy|
40922145|NCT01870076|BEHAVIORAL|Healing Touch|
40922146|NCT01870076|BEHAVIORAL|Healing Touch, Sham|
40922147|NCT01870076|BEHAVIORAL|Control, Presence|
40922148|NCT04494100|PROCEDURE|TRONC|injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.
40922149|NCT04494100|PROCEDURE|WALANT|infiltration with 3 to 7 ml of 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine and 8.4% sodium bicarbonate in the subcutaneous area in front of the transverse ligament, between the thenar and hypothenar eminences, from the flexion fold of the wrist over a length of 5 cm.
41094564|NCT02938390|PROCEDURE|Ultrasound for localizing intercostal perforating vessels|Use of an Intra-operative ultrasound during nipple sparing mastectomy to localize intercostal perforating vessels.
41094565|NCT01121874|PROCEDURE|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system
41094566|NCT01121874|PROCEDURE|Ligament Reconstruction with Tendon Interposition (LRTI)|commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.
41094567|NCT01121874|PROCEDURE|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
40922150|NCT04494100|PROCEDURE|Tourniquet|inflation pressure 75 to 100 mmHg above systolic blood pressure.
41094568|NCT03523910|DEVICE|Magnetic Resonance Imaging (MRI) with exercise|MRI scan with a novel exercise device.
40922151|NCT04494100|DRUG|Ropivacaine|troncular blocks with Ropivacaine 3.75 mg/ml
40922152|NCT04494100|DRUG|Lidocaine + Epinephrine|WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
41094569|NCT05085184|DRUG|administration of UI018|Test
41094570|NCT05085184|DRUG|co-administration of UIC201806 and UIC201602|Reference
40922153|NCT00147368|DRUG|intravenous (IV) arginine|
40922154|NCT01395290|DRUG|cholecalciferol|20.000 IU per week, oral
41094571|NCT01642940|DRUG|Prasugrel|Prasugrel 10mg/day
41094572|NCT01642940|DRUG|Ticagrelor|Ticagrelor 90mg twice a day
41094573|NCT04740255|DEVICE|Straberi Epistamp|The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
41094574|NCT05063331|PROCEDURE|Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)|Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.
40922155|NCT05109455|DIETARY_SUPPLEMENT|MANOSAR®|MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
40922156|NCT05109455|DIETARY_SUPPLEMENT|Proanthocyanidins|The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
40922157|NCT00648050|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fasting
40922158|NCT00648050|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fasting
41094575|NCT05063331|PROCEDURE|Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)|The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.
41094576|NCT00082719|BIOLOGICAL|Recombinant Interferon Alfa|"In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose."
41094577|NCT03496961|BEHAVIORAL|Yan Nian Jiu Zhuan Fa|Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
41094578|NCT05692258|OTHER|Acupuncture|"Acupuncture is a kind of therapy used to treat diseases, in which a needle (usually a millimeter needle) is inserted into a patient's skin or tissue at a certain Angle to stimulate a specific part of the body (acupoint).~Disposable sterile acupuncture filiform needle (0.30mm×25mm、0.30mm×40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011."
41094579|NCT03431779|PROCEDURE|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
41094580|NCT03431779|PROCEDURE|Surgical excision|Excision of painful areas
41094581|NCT00691158|DRUG|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
40922159|NCT05631002|DIAGNOSTIC_TEST|Chemical shift encoding-based water-fat MRI|Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
41094582|NCT00691158|DRUG|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
41094583|NCT00691158|DRUG|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
40922160|NCT02775929|DRUG|FTC-TDF PrEP|FTC-TDF PrEP for HIV-1 uninfected partners
40922161|NCT02775929|DRUG|ART|ART for HIV-1 infected partners
40922162|NCT01425580|DRUG|liraglutide|1.8 mg s.c. (QD)
40922163|NCT01425580|DRUG|glimepiride|4 mg p.o. (QD)
40922164|NCT01425580|DRUG|Metformin|500 mg p.o. (BID)
40922165|NCT00436501|DRUG|docetaxel|25 mg/m\^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
40922166|NCT00436501|BIOLOGICAL|ziv-aflibercept|Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
40922167|NCT00436501|OTHER|laboratory biomarker analysis|Correlative studies
40922168|NCT00436501|OTHER|pharmacological study|Correlative studies
40922169|NCT03370705|DRUG|Sulodexide|Sulodexide 250 ULS twice daily per oral route
41094584|NCT00691158|DRUG|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
41094585|NCT05974943|OTHER|Problem Solving And Decision Making Education|"The Problem-Solving and Decision-Making Training Program, which was based on developing problem-solving and decision-making skills of nurse managers in the experimental group (n=30), was prepared. 2 faculty members and the researcher organized the training program consisting of four modules and 16 hours.~In the content of the Training Program; the definition of the concept of problem-solving and decision-making, the process of problem-solving and decision-making and decision-making models, the impact of decision-making on employee, patient and organizational outcomes, and the importance of managers' roles in decision-making, the importance of the role of nurse managers in decision making, the impact of managerial decisions on patient care outcomes, the impact of managerial decisions on nurse outcomes, the impact of administrative decisions on organizational results/performance, problem-solving, and decision-making techniques and case studies."
41094586|NCT01668342|BEHAVIORAL|SMS assessments & feedback|Daily symptom assessments tied to tailored feedback
41094587|NCT00001061|DRUG|Sevirumab|
41094588|NCT00001061|DRUG|Foscarnet sodium|
41094589|NCT00001061|DRUG|Ganciclovir|
41094590|NCT00323089|PROCEDURE|microcoil insertion and excision|The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
41094591|NCT06107517|OTHER|DREAMS-OT|"Patients will receive the DREAMS-OT protocol 3 times per day, 20 minutes per therapy session.~Intervention frequency will be confirmed with a feasibility trial. If not feasible to maintain 3 times per day, the intervention will still be maintained at the same intensity of 1 hour per day, with a graded approach."
41094592|NCT06379360|DRUG|Hypomethylating agent, Azacitidine or Decitabine|All enrolled patients received maintenance therapy consisting of Azacitidine (75mg/m2, subcutaneous injection, days 1-7) or Decitabine (20mg/m2, intravenous infusion, days 1-5), every three months as a cycle, for a maintenance therapy of 4-8 cycles.
41094593|NCT04204564|DEVICE|pactlitaxel PAD device|Peripheral vascular intervention on femoral-popliteal occlusive disease with paclitaxel and non-paclitaxel devices.
40922170|NCT03370705|DRUG|Statin|Statin 20mg once daily per oral route,
40922171|NCT03370705|DRUG|Antiplatelet Agents|Antiplatelet therapy 75mg once daily per oral route
40922172|NCT03370705|DRUG|ACE inhibitor|ACE inhibitor 20mg once daily per oral route
40922173|NCT00606905|BIOLOGICAL|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
40922174|NCT00606905|OTHER|normal saline|equivalent volume of normal saline
40922175|NCT01121809|DRUG|Raltegravir|Changing the dose of raltegravir from 400 mg bid to 800 mg qd
40922176|NCT01121809|DRUG|Etravirine|Changing the dose of etravirine from 200 mg bid to 400 mg qd
40922177|NCT01049009|DRUG|Nebivolol|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
40922178|NCT01049009|DRUG|Metoprolol XL|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
40922179|NCT01444092|DRUG|Entocort|Entocort capsules, oral
40922180|NCT03412565|DRUG|Daratumumab|Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
40922181|NCT03412565|DRUG|Bortezomib|Bortezomib will be administered as 1.3 mg/m\^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
40922182|NCT03412565|DRUG|Lenalidomide|Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
40922183|NCT03412565|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
40922184|NCT03412565|DRUG|Melphalan|Melphalan will be administered as 9 mg/m\^2 orally in Cycles 1 to 9.
41094594|NCT06479980|BEHAVIORAL|Single Session Narrative Therapy|Single-session narrative psychotherapy intervention is an evidence-based strategy on a stepped care continuum that can assist patients in accessing care when they most need it and can lead to the most effective utilization of scarce resources. It offers a transdiagnostic, strengths, solution-oriented, and non-pathologizing intervention to address patients' behavioral health needs.
41094595|NCT04460079|DRUG|Peg-filgrastim|PegaGen® was injected as a single subcutaneous dose after completion of cytotoxic chemotherapy
41094596|NCT00565318|DRUG|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
41094597|NCT00565318|DRUG|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
41094598|NCT00359619|BIOLOGICAL|CervarixTM|Subjects were administered three doses of HPV vaccine
40922185|NCT03412565|DRUG|Prednisone|Prednisone will be administered as 60 mg/m\^2 orally in cycles 1 to 9.
41094599|NCT00359619|BIOLOGICAL|HPV investigational vaccine GSK568893A, different formulations|Subjects were administered three doses of HPV investigational vaccine
41094600|NCT06150716|DRUG|ION356|Administered as intrathecal (IT) injection.
41094601|NCT02911272|DEVICE|2-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
41094602|NCT02911272|DRUG|Oxytocin|Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
41094603|NCT02911272|PROCEDURE|Forewater amniotomy|Forewater amniotomy at the vaginal examination confirming active phase labour
41094604|NCT02911272|DEVICE|4-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
41094605|NCT03687385|DEVICE|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
41094606|NCT03687385|DEVICE|low-flow nasal oxygenation (LFNO)|Active comparator LFNO: O2 flow 5L/min, FiO2 40%
40922186|NCT03412565|DRUG|Carfilzomib|Carfilzomib will be administered as 20 mg/m\^2 IV on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
41094607|NCT01532050|DEVICE|Mandibular Advancement Device ( MAD)|
41094608|NCT03238482|DRUG|salmeterol-fluticasone|Seretide Diskus 50/250 µg/dose
41094609|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
41094610|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
41094611|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
41094612|NCT04223362|OTHER|Community-based physical activity programme|After completing a pulmonary rehabilitation programme, participants will enrol a 6-months personalised community-based physical activity programme, which will include 2 sessions/week, with the aerobic training being the cornerstone. Patients will receive the PICk UP manual and a diary to register their physical activities. During the 1st month the physiotherapist will guide patients through 4 types of outdoors and indoors physical activities. Patients will then be asked to choose and commit to 1 or 2 activities, according to their preferences, which they shall integrate for another 5 months. During this period, the support provided by physiotherapist will decrease over time.
41094613|NCT04223362|OTHER|Pulmonary Rehabilitation|Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.
41094614|NCT04940390|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
41094615|NCT04940390|DRUG|Placebo|Placebo for STS101
40922192|NCT05846607|DIETARY_SUPPLEMENT|Intervention oral supplement|The oral supplement used as intervention for the study will be DongzheSutang(DAISY FSMP,Jiangsu,China). The formula contains only carbohydrate:12.5g in 100ml of product(glucose syrup and maltodextrin)，with a caloric density of 16.32kcal/g.
40922193|NCT03456882|DRUG|RNS60|normal saline plus oxigen in nanobubble
40922194|NCT01578850|DRUG|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
40922195|NCT01578850|DRUG|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
40922196|NCT06356480|BIOLOGICAL|1% Acetic acid dressing|1% acetic acid dressing in chronic diabetic foot and wounds to see early epithelialization and later on graft application.
40922197|NCT04532580|DEVICE|Diagnosis of fracture on X-Ray Radiographs|Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software
40922198|NCT04838717|DRUG|BPG|intramuscular injection of 2.4 million units
40922199|NCT04838717|DRUG|Doxycycline|Oral: at a dose of 100 mg bid for 14 days
40922200|NCT06450119|OTHER|walking training|The walking training alone group would receive walking training for 60 minutes twice weekly for twelve weeks.
40922201|NCT06450119|OTHER|cognition training|The cognition training alone group would receive cognition training for 60 minutes twice weekly for twelve weeks.
40922202|NCT03541395|DRUG|GnRH antagonist|
40922203|NCT02687867|DRUG|Dabigatran (Pradaxa)|As prescribed by treating physicians
40922204|NCT02687867|DRUG|Vitamin K antagonist|As prescribed by treating physicians
41094616|NCT03940469|DRUG|Saline|2 ml normal saline
41094617|NCT03940469|DRUG|Dexamethasone Injection|8 mg dexamethasone
41094618|NCT03940469|DRUG|Dexmedetomidine Hydrochloride|100 microgram dexmedetomidine
40922205|NCT06192810|PROCEDURE|Laparoscopic/open adrenalectomy|
40922206|NCT00522925|DRUG|PS433540|200mg capsule, once daily for 28 days
40922207|NCT00522925|DRUG|placebo|placebo capsule, once daily for 28 days
40922208|NCT00522925|DRUG|PS433540|500mg capsule, once daily for 28 days
41094619|NCT03352388|DIETARY_SUPPLEMENT|Dairy- and berry-based snacks|High-protein dairy-based products and energy-enriched berry products for three months
41094620|NCT05584020|PROCEDURE|ACL Repair|Patients are undergoing arthroscopic anterior cruciate ligament repair. The native ACL is repaired using very strong sutures. This device is used to repair the native ACL and restore knee stability.
40922209|NCT03896893|OTHER|Skin antisepsis|1% aqueous chlorhexidine gluconate
40922210|NCT03896893|OTHER|Emollient|Aquaphor skin cream
41094621|NCT05584020|PROCEDURE|ACL Reconstruction|Patients are undergoing arthroscopic anterior cruciate ligament reconstruction. The torn ligament is removed and replaced with a band of tissue that usually connects muscle to bone. The graft tendon is taken from another part of your knee or from a deceased donor.
41094622|NCT02430181|DRUG|lonafarnib|antiviral farnesyl transferase inhibitor
41094623|NCT02430181|DRUG|peginterferon alfa-2a|immunomodulator
41094624|NCT02430181|DRUG|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
40922211|NCT01811056|DRUG|Mifepristone|Mifepristone use outside of the center
40922212|NCT00095147|DRUG|Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
40922213|NCT00095147|DRUG|Infliximab (INF) + MTX, DB|Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
40922214|NCT00095147|DRUG|Placebo (PLA) + MTX, DB|Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
40922215|NCT00095147|DRUG|PLA + MTX switched to ABA+ MTX, DB|Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
40922216|NCT00095147|DRUG|ABA, open-label (OL)|Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
40922217|NCT04441190|BEHAVIORAL|Digital Action Observation Therapy (Digital AOT)|The participants will be asked to observe videos and then practice what the participants observed.
40922218|NCT04441190|BEHAVIORAL|Digital Mirror Therapy (Digital MT)|The participants will observe the real-time self-recorded visual illusion, and move their upper limbs as could as possible.
40922219|NCT04441190|BEHAVIORAL|Conventional Occupational Therapy|The participants will receive upper-limb training without providing videos for observing neither providing them mirror illusions of movements.
40922220|NCT01075633|PROCEDURE|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
40922221|NCT01075633|PROCEDURE|Colonoscopy with sedation|Colonoscopy with sedation
40922222|NCT05195060|DRUG|casirivimab with imdevimab|Monoclonal antibody
40922223|NCT05195060|DRUG|sotrovimab|Monoclonal antibody
40922224|NCT05195060|DRUG|molnupiravir|antiviral agent
40922225|NCT03162900|DRUG|Glasdegib Therapeutic Exposure|Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.
40922226|NCT03162900|DRUG|Glasdegib Supra-therapeutic Exposure|Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
40922227|NCT03162900|DRUG|Positive Control (Moxifloxacin)|Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.
40922228|NCT03162900|OTHER|Placebo Control|Subjects will receive placebo dose followed by ECG and PK assessments.
41094625|NCT00809874|DIETARY_SUPPLEMENT|Casein|
41094626|NCT00809874|DIETARY_SUPPLEMENT|Whey Isolate|
41094627|NCT00809874|DIETARY_SUPPLEMENT|Whey Hydrolysate|
41094628|NCT00809874|DIETARY_SUPPLEMENT|Alphalact-Albumin|
41094629|NCT05641896|DRUG|[18F]FAPI-74 PET/CT|\[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
41094630|NCT01654705|DRUG|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
41094631|NCT01654705|DRUG|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
41094632|NCT02998827|DRUG|Thalidomide|
41094633|NCT02998827|DRUG|infliximab, azathioprine|other treatment include infliximab, azathioprine
41094634|NCT02998827|OTHER|enteral nutrition|
41094635|NCT05518201|BIOLOGICAL|Placebo among 18-45 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
41094636|NCT05518201|BIOLOGICAL|Placebo among 9-17 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
41094637|NCT06361693|OTHER|Auto-preoxygenation|"Management is not modified. Routine monitoring (ECG, BP, SpO2). As in care, the patient takes the mask and the respirator is started, delivering an inspired oxygen fraction of 100% (FiO2=1).~Monitoring of : inspired fraction of oxygen, expired fraction of oxygenand end-tidal fraction of carbon dioxide. The ventilator also provides the respiratory rate and tidal volume carried out by the patient.~The fresh gas flow is set by default and will be adjusted to 12l/min for patient comfort.After less than a minute, a normal capnia curve and the presence of an FeO2 value appear. Here, time is standardized to 1 min. In the absence of one of these elements, the caregiver always takes control of preoxygenation.Timer is started, it is T0 min. At T 3min, collection of values and decision-making :~* objectives achieved : end of this sequence.~* objectives not achieved, the caregiver takes control again for an additional 2 minutes in order to seek to achieve an FeO2\>90%."
41094638|NCT06361693|OTHER|APAIS scale|APAIS scale
41094639|NCT06361693|OTHER|Visual analog anxiety scale (VAS-A)|Visual analog anxiety scale (VAS-A)
41094640|NCT06361693|OTHER|Visual analog comfort scale (VAS-C)|Visual analog comfort scale (VAS-C)
41094641|NCT02887378|DEVICE|hot clamps|reusable hot biopsy forceps
41094642|NCT02887378|DEVICE|normal clamps|
41094643|NCT02596906|DEVICE|tDCS|Prior to the reasoning training, participants will undergo tDCS. Participants will receive 20 minutes of tDCS using 2mA or less targeting the inferior frontal gyrus prior to each of their 8 reasoning training sessions for a total of 160 total combined minutes. This time does not include set up time which should take no more than 5 minutes. A brief engaging film is shown to participants during the 20 minute session.
41094644|NCT02596906|DEVICE|Sham tDCS|For the sham tDCS group, the device will be turned off after 30s. The only reported sensations from tDCS is an itching or a tingling when the device turns on but disappears quickly. Thus, those receiving sham tDCS will be unaware that the device has turned off, and will experience an initial tingling similar to that received in the tDCS group.
41094645|NCT02377206|OTHER|ADAS-Cog evaluation|\[18F\]DPA-714 PET imaging
41094646|NCT06615297|DIAGNOSTIC_TEST|ultrasonographic evaluation|facial nerve thickness (right/left), depressor labi inferior, depressor anguli oris, buccinator and risorius muscles will be evaluated.
41094647|NCT06419803|DRUG|Insulin|Insulin will be used in gestational diabetics to control blood glucose levels
41094648|NCT01598025|RADIATION|total-body irradiation (TBI)|
41094649|NCT01598025|DRUG|thiotepa|
41094650|NCT01598025|DRUG|fludarabine phosphate|
41094651|NCT01598025|DRUG|melphalan|
41094652|NCT01598025|BIOLOGICAL|anti-thymocyte globulin|
41094653|NCT01598025|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41094654|NCT01598025|BIOLOGICAL|peripheral blood stem cell transplantation|
41094655|NCT01598025|OTHER|laboratory biomarker analysis|
41094656|NCT02723656|BEHAVIORAL|Online Referral NYS Quitline|Care coordinator will make an online referral to the NYS Quitline.
41094657|NCT02723656|BEHAVIORAL|Tobacco cessation counseling and coordination of cessation medications|Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
41094658|NCT04330443|PROCEDURE|Surfactant therapy|To study if lung ultrasound allows an earlier surfactant therapy (within the first 2 hours of life) compare to FiO2 and Chest X Ray
41094659|NCT00603447|DRUG|Carfilzomib|Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
41094660|NCT00603447|DRUG|Lenalidomide|Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
41094661|NCT00603447|DRUG|Dexamethasone|Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
41094662|NCT02698462|OTHER|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
41094663|NCT04906382|PROCEDURE|Biopsy|Undergo biopsy
41094664|NCT04906382|DRUG|Carboplatin|Given IV
41094665|NCT04906382|DRUG|Paclitaxel|Given IV
41094666|NCT04906382|BIOLOGICAL|Tislelizumab|Given IV
41094667|NCT02673008|BIOLOGICAL|donor lymphocyte infusion|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
41094668|NCT00623246|BEHAVIORAL|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
41094669|NCT00623246|BEHAVIORAL|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
41094670|NCT03106025|DEVICE|Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
41094671|NCT03106025|OTHER|Ophthalmology Assessment|Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
41094672|NCT06422026|DIETARY_SUPPLEMENT|APCP I|Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 3 g.
41094673|NCT06422026|DIETARY_SUPPLEMENT|APCP II|Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 4 g.
41094674|NCT06422026|DIETARY_SUPPLEMENT|Placebo|Each subject takes one active bottle per day for 24 weeks.
41094675|NCT01460992|PROCEDURE|Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions|patients will undergo an MRI scan for 30 minutes.
41094676|NCT02870543|DRUG|Phytolacca decandra|Treatment of bruxism
41094677|NCT02870543|DRUG|Melissa officinalis|Treatment of bruxism
41094678|NCT02870543|DRUG|Phyt.decandra + Melissa offic.|Treatment of bruxism
41094679|NCT04589611|DRUG|amobarbital/Gel-One (one dose)|One dose of amobarbital/Gel-One during the initial surgical intervention
41094680|NCT04589611|DRUG|Placebo (single dose)|One dose of placebo during the initial surgical intervention
41094681|NCT04589611|DRUG|amobarbital/Gel-One (two doses)|One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
41094682|NCT04589611|DRUG|Placebo (two doses)|One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
41094683|NCT04356066|DIAGNOSTIC_TEST|serum cxcl10 by ELISA|serum sample
41094684|NCT04669405|DEVICE|High intensity laser therapy|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
41094685|NCT04669405|OTHER|Therapeutic Exercise|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
41094686|NCT06487364|OTHER|Rehabilitation|A routine physical therapy program prescribed by a specialist physician and physiotherapist will be applied.
41094687|NCT04293991|DEVICE|High Flow Nasal Cannula|Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.
41094688|NCT04293991|DEVICE|Non Invasive Ventilation|Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.
41094689|NCT05068037|OTHER|ACUPUNCTURE|standard acupuncture TCM (analgesia, vomiting)
41094690|NCT05068037|OTHER|ANTIEMETICS|NO ACUPUNCTURE, WITH ANTIEMETICS
41094691|NCT05068037|OTHER|NOTHING|NO ACUPUNCTURE, NO ANTIEMETICS
41094692|NCT04100044|OTHER|Exercise Counseling|Meet with physical therapist
41094693|NCT04100044|BEHAVIORAL|Exercise Intervention|Receive personalized home exercise intervention
41094694|NCT04100044|OTHER|Questionnaire administration|Ancillary studies
41094695|NCT04100044|OTHER|Quality-of-Life Assessment|Ancillary studies
41094696|NCT05492890|DEVICE|Dexcom G6|Continuous glucose monitoring
41094697|NCT02060279|OTHER|Lifestyle intervention and carotenoid supplements|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take Jarrow Formulas CaroteneAll® (5000 IU) supplement while at the intervention site for 2 weeks and then will continue to take the supplements for up to 6 months until their participation in the study is complete. Two capsules of supplement will be consumed daily with a meal with 6 oz. of water.
41094698|NCT02060279|OTHER|Lifestyle intervention and placebo|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take a gel-cap placebo while at the intervention site for 2 weeks and then will continue to take the placebo for up to 6 months until their participation in the study is complete. Two capsules of placebo will be consumed daily with a meal with 6 oz. of water.
41094699|NCT03542708|PROCEDURE|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. The patient will be under IV sedation. Record of which ovary was injected will be kept in the online research database and not in the clinical chart.
41094700|NCT04163666|BEHAVIORAL|Mirror therapy|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for mirror therapy, while the remaining 30 minutes will be for task-oriented motor learning
41094701|NCT04163666|BEHAVIORAL|Cognitive therapeutic exercise|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for cognoscitive therapeutic exercise, while the remaining 30 minutes will be for task-oriented motor learning
41094702|NCT00052962|PROCEDURE|Cytoreductive surgery|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
41094703|NCT00052962|PROCEDURE|Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m\^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m\^2 and paclitaxel 125 mg/m\^2.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
41094704|NCT02126397|PROCEDURE|polyps resection with Laser Diode|resection of endometrial polyps by hysteroscopy without anesthesia
41094705|NCT02126397|PROCEDURE|polyps resection with bipolar electrode|
40922229|NCT06531889|OTHER|classical physiotherapy program|Classical physiotherapy program=Classical physiotherapy program included transcutaneous electrical nerve stimulation, infrared radiation for 15 min, continuous ultrasound for 5 min and home exercise program. For active assistive shoulder range of motion (ROM), home exercises included the Codman exercise, flexion exercise at the ladder, and the Wand exercise, as well as some strengthening and stretching exercises performed at the pain limit with 10 repetitions twice a day (six weeks)
40922230|NCT06531889|OTHER|Core Stabilization Exercises|The interventions of the core exercise were applied when the patient lay on his/her back with his/her knees at flexion. The number of repeats for each exercise was five, and these exercises were done 3 times a week for 6 weeks with the same physiotherapist. The further steps in the exercises were extended according to the activation duration of the core muscles, and this extension was elongated 5 s
41094706|NCT02634008|DRUG|Paritaprevir/ritonavir/ombitasvir|
41094707|NCT02634008|DRUG|Dasabuvir|
41094708|NCT02634008|DRUG|Ribavirin|
41094709|NCT02634008|DRUG|Glecaprevir/pibrentasvir|
41094710|NCT01618331|BEHAVIORAL|Regular exercise|Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
41094711|NCT01618331|DIETARY_SUPPLEMENT|Protein-carbohydrate supplementation|Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
41094712|NCT02553382|DIETARY_SUPPLEMENT|Dietary, Herbal|Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
41094713|NCT02553382|DIETARY_SUPPLEMENT|Positive Control|Oat bran blend and wheat bran capsules
41094714|NCT02537899|DRUG|NeuroAiD|
41094715|NCT03106376|OTHER|16% O2 gas in breathed air|"Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
40922231|NCT00727441|BIOLOGICAL|GVAX pancreatic cancer vaccine|Given intradermally
40922232|NCT00727441|DRUG|cyclophosphamide|Given IV (Arm B), given orally (Arm C)
40922233|NCT01584544|DRUG|capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
41094716|NCT03106376|OTHER|26% O2 gas in breathed air|"Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
41094717|NCT04750629|DEVICE|POC CoviDx™ Rapid Antigen Test|All patients will have a nasal swab for CoviDx™ Rapid Antigen testing
41094718|NCT02550054|DRUG|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
41094719|NCT02550054|DRUG|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
41094720|NCT02512146|PROCEDURE|colonoscopy|Patients will undergo colonoscopy and participants will get biopsies from the colon.
41094721|NCT05051397|BIOLOGICAL|HYPERCAPNIA|Controlled moderate hypercapnia PaCO2 50mmHg under general anesthesia with mechanical ventilation
41094722|NCT05051397|BIOLOGICAL|NORMOCAPNIA|Controlled normocapnia PaCO2 40mmHg under general anesthesia with mechanical ventilation
41094723|NCT02408965|DRUG|Methergine|0.2 mg of methylergonovine maleate
41094724|NCT02408965|OTHER|placebo|saline placebo to maintain blinding
41094725|NCT00072475|DRUG|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
41094726|NCT02286856|BEHAVIORAL|diet intervention|The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.
41094727|NCT01218828|OTHER|LVEDP -Based hydration strategy|
41094728|NCT01218828|OTHER|Standard hydration|
41094729|NCT05964257|DRUG|Botulinum toxin type A|Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
41094730|NCT05964257|DRUG|normal Saline|Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
41094731|NCT02944903|OTHER|Audit|Questionnair
41094732|NCT04764019|DIAGNOSTIC_TEST|High resolution intestinal manometry|Evaluation of intestinal manometry by the use a high resolution intestinal manometry catheter with 34 closely spaced sensors.
41094733|NCT05173493|DRUG|Amoxicillin,Furazolidone|Amoxicillin-Furazolidone-containing quadruple group
41094734|NCT05173493|DRUG|Amoxicillin,Levofloxacin|Amoxicillin-Levofloxacin-containing quadruple group
41094735|NCT05173493|DRUG|Tetracycline,Furazolidone|Tetracycline-Furazolidone-containing quadruple group
41094736|NCT04003428|DEVICE|High Intensity Focused Ultrasound|HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
41094737|NCT05767073|BEHAVIORAL|Lifestyle InterVEntion (LIVE)|"The lifestyle intervention Coaching on Lifestyle (CooL) (van Rinsum 2018)),formed the basis of LIVE and was adapted to specific dysfunctional elements in depressed patients regarding motivation and self-management.~The focus is on reducing depressive symptoms, enhancing the quality of life and possibly achieving weight loss.~The lifestyle intervention lasts six months, with 13 weekly 1.5 to 2 hour group sessions and five 45 to 60 -minute individual sessions with at least one person from the patient's support network of friends or family (preferably sharing the same household). All sessions end with individual homework exercises, and each session starts with a 10 to 15-minute positive psychology intervention (PPI) and 5 to 15 minutes of physical activity. These sessions are followed by two booster sessions after about two and six months. Groups consist of 4-8 people."
41094738|NCT00535197|BIOLOGICAL|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
40922234|NCT01584544|DRUG|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
40922235|NCT01584544|DRUG|Capecitabine|oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
41094739|NCT05717335|DRUG|TachoSil|Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.
41094740|NCT02823743|DRUG|Aspirin|Daily medication
41094741|NCT02823743|DRUG|Placebo|Daily intake
41094742|NCT06418906|OTHER|Self-reported questionnaires|After participants agree to participate in this study, they will first fill out the set of questionnaires once. After two weeks, the research team will send them reminders to fill out the same set of questionnaires again.
41094743|NCT05665855|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid ketone monoester supplement.
41094744|NCT05665855|OTHER|Placebo|A liquid placebo that is taste-matched to the ketone monoester supplement.
41094745|NCT03383211|OTHER|RNAseq|Transcriptome profiling of peripheral blood using RNA sequencing technology
41094746|NCT00550732|DRUG|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
41094747|NCT01970943|OTHER|Placebo|Placebo will be compared to No Intervention.
41094748|NCT05695573|DIAGNOSTIC_TEST|ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile|Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis
41269652|NCT01805180|DEVICE|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
41269653|NCT01805180|DEVICE|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
41269654|NCT06355882|PROCEDURE|Anesthetic infiltration|Application of local dental anesthesia with two cartridges (3,6 mL) for dental procedures (tooth extraction or periodontal treatment) in patients with low cardiac output syndrome.
41269655|NCT03607721|DEVICE|Body Motion Evaluation DARI|Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
41269656|NCT02343692|PROCEDURE|EUS guided RFA of cystic tumours of the pancreas|Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
41269657|NCT00699192|DRUG|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
41269658|NCT00699192|DRUG|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
41269659|NCT00699192|DRUG|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
40922236|NCT01584544|DRUG|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
40922237|NCT01584544|DRUG|Capecitabine|oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
40922238|NCT03069521|DEVICE|EndoArt® Artificial Endothelial Layer|device is intended for use as an endothelial kearatoprosthesis
40922239|NCT05896436|BEHAVIORAL|Emotion Focused Therapy|12 sessions of Emotion Focused Therapy (EFT). The focus in EFT is to promote the individual's experiencing and facilitate participants' self-disclosure and openness to their own experience, rather than the therapist's agenda or techniques. Key processes within EFT include helping people overcome their avoidance of emotion, maintaining a collaborative focus on emotions, and exploring emotions in therapy.
40922240|NCT01037088|DRUG|Mild dose cannabis|3.53% THC by weight
40922241|NCT01037088|DRUG|Low dose cannabis|1.29% THC by weight
40922242|NCT01037088|DRUG|Cannabis|0.00% THC by weight
40922243|NCT03545971|DRUG|IBI310|IBI310 is anti CTLA-4 antibody
40922244|NCT03545971|DRUG|Sintilimab|PD-1 monoclonal antibody
40922245|NCT01024725|OTHER|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
40922246|NCT02478567|OTHER|Rotator Cuff Training|four specific band-resisted strength training exercises for scapula
40922247|NCT02478567|OTHER|Scapular Training|four specific band-resisted strength training exercises for rotator cuff
40922248|NCT01236547|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40922249|NCT01236547|DRUG|Paclitaxel|Given IV
40922250|NCT01236547|DRUG|Pazopanib Hydrochloride|Given PO
40922251|NCT01236547|OTHER|Placebo Administration|Given PO
40922252|NCT05107752|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
40922253|NCT05107752|DRUG|Stellate Ganglion Block|SGB is a procedure that has demonstrated efficacy for the reduction of PTSD symptoms. SGB is performed using real-time ultrasonography with an in-plane technique, and consists of 7-10 mL of ropivacaine 0.5%, which is injected around and into the site of the ganglion at the level of the C4 and C6 anterior tubercle (Mulvaney, Curtis et al., 2020). Ropivacaine is a long-acting amide local anesthetic agent and a pure S-enantiomer with a high pKa and relatively low solubility. Patients are not sedated during the procedure. Successful sympathetic blockade is confirmed by the presence of Horner's syndrome, which is characterized by constriction of the pupil (miosis) and drooping of the upper eyelid (ptosis). If Horner's syndrome is not observed within 20 minutes of the first injection, the right-sided SGB is repeated one hour later using the same technique. If Horner's syndrome is not confirmed after the second injection, no additional injections are provided.
40922254|NCT06353022|DRUG|Teclistamab|Maintenance therapy wtih teclistamab (administered via SC injections) for finite duration. Teclistamab will be used in 28 day cycles following initial step up doses
40922255|NCT06353022|DRUG|Talquetamab|Maintenance therapy with talquetamab (administered via SC injections) for finite duration. Talquetamab will be used in 28 day cycles following initial step up doses
41269660|NCT00699192|DRUG|Placebo|1 capsule placebo to match valsartan orally once daily
41094749|NCT03700255|PROCEDURE|PickUpSimTM simulation training program|"The residents will take part in simulation sessions of 30 minutes duration. There will be 4 training sessions with seven simulation scenarios available. During the sessions, the following data will be collected for each scenario success or failure, reason for failure, time needed for completion, and oocyte retrieval rate. All scenarios will be repeated in the same conditions in the second week and data collected again. In the following 15 days, residents will start performing OPU, under direct supervision from senior physicians. For each patient, the resident will puncture one ovary. During the retrieval, the operator will specify the number of follicles punctured for each collected tube. The identity of the operator and the number of follicles punctured (per tube and in total) are noted on a separate sheet entitled the retrieval sheet. After the first month, residents will start performing all the OPUs, including both ovaries, supervised by the senior physicians."
41094750|NCT00867347|PROCEDURE|therapeutic conventional surgery|Patients undergo radical cystectomy
41094751|NCT00867347|RADIATION|radiation therapy|Patients undergo radiotherapy
41094752|NCT03023059|DRUG|Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet|See Arm description
41094753|NCT03882515|OTHER|Myofascial Release|With the right hand in hand exerts caudal pressure in the superior fibers of the muscle, both sides by a minute and a half each. In the ventral decubitus, apply pressure and slip from T12 to the base of the skull nine times. Thumb in the individual's acromion and with the other to hold the pressure and slide in the direction of the other acromion three times. Hand at the base of the skull and with the contralateral tenar region perform pressure and slip in caudal direction on both sides by three times. Hand at the base of the skull and with the contralateral thumb exerting pressure and slip of C3 the distal insertion of the upper fibers on both sides. Thumbs at the base of the skull, exerting lateral traction of the fascia in opposite directions. Dorsal decubitus, thumbs above clavicles, perform detachment of fibers for one and a half minutes. Patient sitting, support the head of the metacarpals beside the spinous process from T1 to T12 and exert pressure and slip three times each.
41094754|NCT03882515|OTHER|Continuous Surface Slip Technique|"1. Individual in the ventral decubitus, position the entire palmar surface bilaterally in the spinous process of T1 in the caudal direction, performing superficial smoothing in a smooth and rhythmic movement up to T12.~2. Return of the hands from the caudal direction towards the cranial direction, bypassing the lateral borders of the trapezius muscle following the direction of the inferior, middle and superior fibers.~3. Continue surface smoothing with a smooth and rhythmic movement until the distal insertion of the trapezius upper fibers into the skull and resume step 1 slowly and continuously for 10 minutes."
41094755|NCT03882515|OTHER|Without intervention|Evaluation and re-evaluation without intervention
41094756|NCT03575962|DRUG|GSK3640254 bis-hydrochloride salt capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
41094757|NCT03575962|DRUG|GSK3640254 Mesylate Salt Capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
41094758|NCT00406289|PROCEDURE|18F-FDG-PET radiotherapy|
41094759|NCT01939158|BIOLOGICAL|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
41094760|NCT01939158|BIOLOGICAL|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
41094761|NCT00303849|DRUG|Carboplatin|Given IA
41094762|NCT00303849|DRUG|Etoposide|Given IV
41094763|NCT00303849|DRUG|Etoposide Phosphate|Given IV
41269661|NCT03172689|DEVICE|CardioQ|comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously
41269662|NCT02168582|BEHAVIORAL|physiotherapy as usual in primary care|
41269663|NCT03825913|BEHAVIORAL|Exercise Intervention|"Training sessions will include a split routine based on the day of the week.~* Session 1 (e.g. Tuesday) - aerobic exercise (20-30 min) followed by resistance training (10 stacked-weight machines: leg press, leg extension, leg curl, chest press, latissimus pull, shoulder press, seated row, triceps press, biceps curl, and chest fly) for 1-2 sets of 8-12 repetitions.~* Session 2 (e.g. Thursday) - resistance bands and body weight exercises (4-6 exercises, 2 sets of 10-20 repetitions) followed by core exercises (2-3 sets of 10-20 repetitions) and aerobic training (20-30 min) at the end.~The starting training intensities will be at 50-55% of each individual's estimated maximum heart rate for aerobic exercise and one-repetition maximum for resistance training (assessed at baseline only for chest press and leg press). We plan a 5% monthly increase in the intensity to reach 65-70%% of one's maximum efforts by the end of the intervention."
41269664|NCT03825913|BEHAVIORAL|Wellness Intervention|In our setting, ten lectures in nutrition, exercise and various complementary and integrative medicine topics (e.g. acupuncture and Chinese medicine, mindfulness, quality sleep, etc.) were implemented among non-cancer individuals and modified based on their feedback.
41442478|NCT06272266|DEVICE|Peripheral muscle strength measurement (microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) and JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook).|Quadriceps and triceps muscle strength was measured in kilograms using the microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) manual muscle strength measurement device in the lower and upper extremity. Hand grip strength was evaluated in the dominant upper extremity using a JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook)This intervention was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
41094764|NCT00303849|OTHER|Laboratory Biomarker Analysis|Correlative studies
41094765|NCT00303849|DRUG|Mannitol|Given IA
41094766|NCT00303849|DRUG|Melphalan|Given IA
41094767|NCT00303849|OTHER|Quality-of-Life Assessment|Ancillary studies
41094768|NCT00303849|DRUG|Sodium Thiosulfate|Given IV
41094769|NCT02821312|DRUG|DA-8010|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010."
41094770|NCT02821312|DRUG|Placebo|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010."
41094771|NCT03547999|DRUG|mFOLFOX6|The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.
41094772|NCT03547999|BIOLOGICAL|MVA-BN-CV301|The experimental arm (Arm B) will receive MVA-BN-CV301 in 4 injections of 4 x 10(8) infectious units/0.5 mL given subcutaneously prior to the start of chemotherapy on days -28 and -14.
41094773|NCT03547999|BIOLOGICAL|FPV-CV301|The experimental arm (Arm B) will receive FPV-CV301 in 1 dose of 1 x 10(9) infectious units/0.5 mL given subcutaneously concurrently with chemotherapy (at least an hour prior to chemotherapy) on days 0, 14, 28 and 42 pre-operatively, and FVP-CV301 boosters on day 0 and 14 and then every 4 weeks (day 42, 70, 98). After day 98, FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
41269665|NCT04076826|DRUG|Dexmedetomidine|Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
41269666|NCT04076826|DRUG|Propofol or Midazolam|Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.
41269667|NCT04076826|DIAGNOSTIC_TEST|Blood sampling|In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
41269668|NCT00386841|DRUG|Escitalopram|Escitalopram 10 mg p.o. per day
41094774|NCT03547999|DRUG|Nivolumab|Nivolumab at a dose of 240 mg as a 30 minute IV infusion every 2 weeks until progression. Arm B will receive Nivolumab starting with the vaccinations. Arm A will begin the Nivolumab with the initiation mFOLFOX.
41094775|NCT02883543|DRUG|icotinib|Icotinib is orally administered three times per day.
41094776|NCT02883543|DRUG|Chemotherapy|"Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2"
41094777|NCT02883543|RADIATION|Radiotherapy|5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
41094778|NCT01174316|DEVICE|AutoVPAP™|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
41094779|NCT01174316|DEVICE|VPAPIIIST-A™|Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
41094780|NCT05968508|DRUG|BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)|A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.
41094781|NCT01982643|DRUG|naltrexone plus bupropion|Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
41094782|NCT04879134|DRUG|Apomorphine Injectable Solution|"Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo"
41094783|NCT04879134|DRUG|Placebo|"0.9% saline placebo injection~Other Names:~• Saline"
41094784|NCT06306846|RADIATION|SBRT+immunochemotherpy|SBRT radiotherapy，followed with PD-1 monoclonal antibody and TP chemotherapy
41094785|NCT06306846|DRUG|Immunochemotherapy|PD-1 monoclonal antibody and TP chemotheapy
41094786|NCT06306846|DRUG|cetuximab+immunochemotharpy|PD-1 monoclonal antibody and TP chemotheapy combined with cetuximab
41269669|NCT00386841|DRUG|Placebo|Placebo
41269670|NCT03670576|PROCEDURE|Optional Bronchoscopy|Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.
41269671|NCT03670576|OTHER|Quality of Life Questionnaires|MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,
41094787|NCT04528355|DRUG|data collection|Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
41094788|NCT02730767|BEHAVIORAL|partially supervised exercise intervention|
41094789|NCT06256445|DRUG|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at concentration of 25 mg/mL
41094790|NCT06256445|DRUG|Matching placebo of AYP-101|Phosphate buffered saline placebo for injection
41094791|NCT05238597|DRUG|A197 Ophthalmic Solution|A197 Ophthalmic Solution
41094792|NCT05238597|DRUG|A197 Vehicle Control|A197 Vehicle Control
41094793|NCT05238597|DRUG|Active Comparator|Active Comparator
41094794|NCT00736749|PROCEDURE|Assessment of Therapy Complications|Complete patient response form and Health Status Update Form
41094795|NCT00736749|OTHER|Questionnaire Administration|"Complete patient response form, Health Status Update Form (called the Keep in Touch form), and Quality of Life Questionnaire (PROMIS)"
41094796|NCT01649726|PROCEDURE|Apnea test - control|
41094797|NCT01649726|PROCEDURE|Apnea test - CPAP|
41094798|NCT04373135|BEHAVIORAL|Brief educational video|A brief educational video will be displayed explaining the mechanics of how SRA policies operate, how they are decided, and what patients' and healthcare workers' rights are surrounding them.
41094799|NCT00903045|DRUG|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
41094800|NCT00903045|DRUG|Placebo|Identical placebo twice a day
41094801|NCT05792540|DRUG|Fluoxetine 20 mg|Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
41094802|NCT05792540|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance
41094803|NCT05792540|DRUG|Atorvastatin 80mg|Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia
41094804|NCT03962192|OTHER|Attitudinal measures|A collection of 3 distinct attitudinal instruments comprise this survey.
41094805|NCT03131141|DRUG|BC-3781|Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
41094806|NCT05837780|OTHER|Nasoalveolar molding device|comparison between using conventionally and digitally constructed nasoalveolar molding devices
41094807|NCT04012606|DRUG|TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo|TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
41094808|NCT00279058|PROCEDURE|Immunotherapy treatment for melanoma|
41094809|NCT03553095|PROCEDURE|Periodontal Surgery|Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.
41094810|NCT00285558|BEHAVIORAL|CBT with peer-enhanced activities|
41094811|NCT00285558|BEHAVIORAL|CBT with supervised aerobic exercise|
41094812|NCT06433895|OTHER|Manual Therapy|Manual Therapy
41094813|NCT06433895|OTHER|Exercise|Isometric and strengthening exercises for the cervical region, which are provided to patients with cervical pain and limitation
41094814|NCT04900363|DRUG|AK112|Subjects receive AK112 intravenously.
41094815|NCT05247216|DRUG|Hemay007 800 mg QD group|daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
41094816|NCT05247216|DRUG|Hemay007 1200 mg QD group|daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
41094817|NCT05247216|DRUG|Hemay007 600 mg QD group|daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
41094818|NCT05247216|DRUG|Hemay007 placebo group|daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
41094819|NCT03193346|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
41269672|NCT03670576|OTHER|Blood Samples for Biomarkers|a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.
41094820|NCT03193346|DRUG|placebo (sodium chloride 0.9 mg)|Placebo matching BOTOX® \[Sodium chloride 0.9 mg\] IM injections in head/neck areas.
41094821|NCT06053931|BEHAVIORAL|white noise music|"Before the mother starts breastfeeding her baby, white noise music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=5NFHiKMCPvw\&t=6478s)."
41094822|NCT06053931|BEHAVIORAL|lullaby music|"Before the mother starts breastfeeding her baby, lullaby music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=h0QO8bgysPg)"
41094823|NCT06549556|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
41094824|NCT06549556|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
41094825|NCT00157053|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
41094826|NCT06008067|RADIATION|tricuspid annular plane systolic excursion (TAPSE)|Echocardiography
41094827|NCT00058058|PROCEDURE|MRI|Breast contralateral to the breast diagnosed with cancer was scanned prior to initiation of chemotherapy and within 90 days of a negative mammogram of the study breast. A recent (within 90 days) negative or benign mammogram (defined by final BI RADS category 1 or 2) and negative or benign clinical breast exam of the study breast were required for entry into the study.
41269673|NCT03670576|OTHER|Home Hand Held Spirometry|Patients will download an app and are given a small hand held device to record their own spirometry at home. This is blinded for the first three months of the study and then requested a week before and a week after the three follow up points (3m, 12m, 24m)
41269674|NCT05253456|PROCEDURE|Derma -Dartos Flap for second layer closure|usage of Derma -Dartos Flap for second layer closure of a distal penile hypospadias in circumcised patients
41269675|NCT02429999|DRUG|Letrezole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
41269676|NCT02429999|DRUG|Standard protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
41269677|NCT03415165|DRUG|green tea buccal tablet|buccal tablet for 8 hrs 3 times aday
41442479|NCT06272266|DEVICE|Standard exercise tolerance test (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|At the beginning of this test, resting pulse and blood pressure were measured and recorded. The test was performed following a bicycle ergometer protocol recommended by the American Cardiovascular and Pulmonary Rehabilitation Society. After a 2-minute warm-up period at 0 load (W), a submaximal exercise test was performed by increasing the load by 25 W in 2-minute periods. At the end of the test, exercise intensity was evaluated with the perceived difficulty level (borg scale), test duration, maximum heart rate, maximum work (W). , metabolic equivalent (MET) values were recorded. VO2peak and VO2peakpredictive levels were calculated. This test was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
41094828|NCT05193630|DIETARY_SUPPLEMENT|Milnutri Sure™|"Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water."
41094829|NCT00699738|BEHAVIORAL|Breastfeeding|Breastfeeding
41094830|NCT00699738|BEHAVIORAL|Bottlefeeding|Bottlefeeding
41269678|NCT03415165|DRUG|Corticosteroids Topical|kenacort in orabase 4 times aday
41269679|NCT06490861|DEVICE|Paragit|Sleeve to quantify symptoms
41269680|NCT06220695|BEHAVIORAL|Dietary intervention|The dietary intervention is a personalized counselling programme implemented in form of a moderate caloric restriction (≈500 kcal/day) to allow for a moderate weight loss (≈5% BW). Each participant will be invited for consultation visits to a study dietitian, lasting up to 30 minutes. During the sessions, participants will be provided with written information material that explains the principles of diet in concern. Dietary interventions for both groups will be standardized in terms of education and one-on-one counseling. Education and dietary prescription will be individualized by the study dietitians within the diet-specific recommendations, to allow for personal food preferences. All subjects will receive equivalent intensity of care in terms of opportunities for contact and availability of individual dietary counseling. Motivational interviewing techniques and behavior change techniques will be adopted by study dietitians to ensure long-term maintenance of dietary modification.
41269681|NCT06301360|BEHAVIORAL|Internet based Emotional Awareness and Expression Therapy (I-EAET)|"In I-EAET with therapist support, the therapist and participants communicate asynchronous using written messages. The therapist gives feedback each week on home-work assignments and is available on demand for support.~In I-EAET without therapist support, the participants works with home-work assignments on their own and only have technical support."
41269682|NCT04007159|OTHER|Serum|Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square \[mL/cm\^2\] of serum in an individual cell of patch)
41269683|NCT04007159|OTHER|Lotion|Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of lotion in an individual cell of patch)
41269684|NCT04007159|OTHER|Cream|Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of cream in an individual cell of patch)
41269685|NCT04007159|OTHER|Normal Saline|Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of normal saline in an individual cell of patch)
41269686|NCT01734876|BEHAVIORAL|Tactile Touch|Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
41269687|NCT01734876|BEHAVIORAL|Rest To Music|Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
40922256|NCT06353022|DRUG|Lenalidomide|"Induction therapy with lenalidomide:~Lenalidomide 25 mg/day oral from Day 1 to Day 21.~Maintenance therapy lenalidomide (administered orally) for finite duration."
40922257|NCT06353022|DRUG|Bortezomib|Induction therapy with Borthezomib Cycle 1 to 6: Bortezomib 1.3 mg/m² SC twice a week on Days 1, 4, 8 and 11
41442480|NCT06272266|DEVICE|Aerobic exercise training (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|Aerobic exercise training was planned for the COVID-19 group with the help of a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI. Aerobic exercise training was applied for a total of 15 sessions, at least 3 days a week, under the supervision of a physician.
41442481|NCT01900691|DEVICE|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
41442482|NCT05498662|DEVICE|T3 Pro dental implant system|treatment of tooth loss with T3 Pro dental implants
41442483|NCT04537663|DRUG|Bacille Calmette-Guérin (BCG)|Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
41442484|NCT04537663|DRUG|Placebo|Intradermal injection of sterile 0.9% NaCl.
41442485|NCT01504763|PROCEDURE|Chair massage|Chair massage for 15 minutes once a week for 10 weeks.
41442486|NCT02436005|DEVICE|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
41442487|NCT02436005|DEVICE|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
41442488|NCT02075463|DRUG|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
41442489|NCT02075463|DRUG|Placebo|Matching placebo tablet for GSK1278863
41442490|NCT02106156|DRUG|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
40922258|NCT06353022|DRUG|Daratumumab|Induction therapy with Daratumumab Cycle 1 to 6 Daratumumab 1800 mg SC on Days 1, 8, 15, 22 of Cycle 1 and Cycle 2 and on Days 1 and 15 of Cycle 3
40922259|NCT06353022|DRUG|Dexamethasone|"Induction therapy with Dexamethasone:~cycle 1 to 3 Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22 Cycle 4 to 6 --\> Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22"
41442491|NCT02106156|DRUG|Ribavirin|Ribavirin administered according to corresponding summary of product characteristics (SmPC).
41442492|NCT01001403|DRUG|Nafamostat|0.2 mg/kg as bolus 1 minute before reperfusion
41442493|NCT01001403|DRUG|Normal saline|10 ml of normal saline
41442494|NCT01978743|DRUG|Raltegravir|Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
41442495|NCT00835081|DRUG|Cefadroxil 500 mg Capsules|1 x 500 mg
41442496|NCT00835081|DRUG|DURICEF® capsules 500 mg|1 x 500 mg
41094831|NCT06170060|OTHER|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a surgical procedure widely used in the treatment of obesity. It's a bariatric procedure, meaning its primary aim is to induce weight loss, and it has gained popularity due to its effectiveness and relatively low complication rates compared to other bariatric surgeries.
41442497|NCT01823263|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
41442498|NCT01823263|PROCEDURE|Blood sample|In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
41442499|NCT01823263|PROCEDURE|Interference task|30-minute interference task
41442500|NCT01823263|BEHAVIORAL|Memory tasks|Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
41442501|NCT01823263|BEHAVIORAL|Intake task|After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
41094832|NCT05290740|DRUG|Norepinephrine 5 mcg|norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension
41094833|NCT05290740|DRUG|Norepinephrine 10 mcg|norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
41094834|NCT04830254|DEVICE|Transcutaneous Electrical Nerve Stimulation(TENS) device|The Patients in group (A) received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs,burst mode) was be applied through 2 output channels surface electrodes with an E2 TENS device, for 45 min per session, supramaximal stimulation to sympathetic ganglions in T12, L1, and L2, which innervate the lower extremity . For 45 min per session, three times per week, and for 12 weeks.
41094835|NCT01008748|DRUG|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke \>10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
41094836|NCT01008748|BEHAVIORAL|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
41442502|NCT01823263|BEHAVIORAL|Working memory function task|Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
41442503|NCT00194454|BEHAVIORAL|Modified cognitive behavioral therapy plus problem-solving|9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
41442504|NCT00194454|OTHER|usual care|Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
41442505|NCT03777826|OTHER|PKU Synergy|PKU Synergy is a citrus flavored, powdered amino-acid mixture (containing traces of Phe, 4,3mg per portion; and 20 gr. Protein Equivalent (PE)) with a tailored amino acid and micronutrient profile adapted for the special requirements of HPA/PKU (Hyperphenylalaninemia/Phenylketonuria) subjects over 10 years of age with an increased Phenylalanine-(Phe) tolerance/intake.
41442506|NCT01653951|OTHER|nurse-led care management or peer-led self management|
41442507|NCT04979910|DRUG|Ixekizumab|a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
41442508|NCT03575585|BEHAVIORAL|BEST assessment only|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels.
41442509|NCT03575585|BEHAVIORAL|BEST assessment plus feedback report|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels. Based on their responses they also receive a personalized feedback report that .provides individualized risk levels in five behavior domains: 1) number of partners, 2) riskiness of partners, 3) condom use, 4) riskiness of sex acts, and 5) sex under the influence of drugs or alcohol.
41442510|NCT03575585|BEHAVIORAL|Standard Counselor Training|2 hours of training on how to use the BEST patient feedback report
41442511|NCT03575585|BEHAVIORAL|Enhanced Counselor Training|Standard training (2 hrs) plus 8 additional hours (4 modules) of motivation/skills training on a) talking about sex with patients, b) basics of using Motivational Interviewing techniques to review a feedback report, c) teaching patients problem solving skills, and d) teaching patients relationship communication skills.
41442512|NCT01385930|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
40922260|NCT02372734|OTHER|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
40922261|NCT02452827|OTHER|Biomechanical parameters|
41094837|NCT01008748|BEHAVIORAL|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
41442513|NCT05966792|DRUG|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
41442514|NCT05966792|DRUG|metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
41442515|NCT04102085|OTHER|no intervention|no intervention
41442516|NCT03772821|OTHER|Data collection|Between D0 and D90: local and general complications, demographic, clinical, paraclinical and biological data
41442517|NCT03772821|OTHER|Incision/scar measurement|Between D0 and D90
41442518|NCT04973137|DRUG|Birtamimab|Intravenous administration of 24 mg/kg birtamimab every 28 days
41094838|NCT01008748|BEHAVIORAL|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
41442519|NCT04973137|OTHER|Placebo|Intravenous 0.9% Saline administration as a placebo every 28 days
41442520|NCT04973137|DRUG|Standard of Care Chemotherapy|Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care
41442521|NCT03769896|DRUG|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
41442522|NCT03769896|DRUG|Placebo|capsule, corn starch, daily basis
41442523|NCT03616405|DRUG|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
41442524|NCT03909607|DRUG|Ketamine 0.75 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg
41442525|NCT03909607|DRUG|Ketamine 1.0 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
40922262|NCT02452827|OTHER|MRI|MRI of cervical spine
41442526|NCT03909607|DRUG|Ketamine 1.5 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
41442527|NCT01683474|DEVICE|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
41442528|NCT04754035|DRUG|Venetoclax|venetoclax 20 mg, 50 mg, 100 mg
41442529|NCT04754035|DRUG|Imbruvica Oral Product|Imbruvica 140 mg
41442530|NCT01983501|DRUG|Tucatinib (ONT-380)|Given twice per day, orally
41442531|NCT01983501|DRUG|T-DM1|Given intravenously once every 21 days
41442532|NCT06121973|BEHAVIORAL|educational group|Experimental group received online video-supported breastfeeding education in an online classroom for 6-8 people and individual counselling via phone and Whatsapp application when needed for 3 weeks.
41442533|NCT05019560|DRUG|Sevoflurane|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
41442534|NCT05019560|DRUG|TIVA|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
41442535|NCT05736835|BIOLOGICAL|CVXGA|CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.
41442536|NCT04654143|DRUG|BVL-GSK098 capsule, placebo|Oral QD
41442537|NCT06201390|BEHAVIORAL|Sleep consistency|Participants will be asked to maintain a consistent bed- and wake-time.
41442538|NCT00006218|DRUG|triapine|
41442539|NCT00350389|BEHAVIORAL|Outdoor use of plain distance glasses with counselling|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
41442540|NCT03958396|DRUG|Remifentanil Infusion|15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min
41094839|NCT02317705|DRUG|OTL38|
41442541|NCT04031001|DEVICE|No-React Non-valved Conduit|Operative replacement of infected graft or implantation in infected area.
41442542|NCT02665715|OTHER|Low carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
41442543|NCT02665715|OTHER|Standard carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
41442544|NCT00380679|BIOLOGICAL|Influenza vaccination|
41442545|NCT00380679|BIOLOGICAL|Pneumococcal polysaccharide vaccination|
41442546|NCT03884894|DIAGNOSTIC_TEST|molecular assay|performed with blood culture simultaneously
41442547|NCT03884894|DIAGNOSTIC_TEST|Blood culture|performed with molecular assay simultaneously
41442548|NCT03887910|OTHER|Enhanced Intervention|Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.
40922263|NCT04424329|DIETARY_SUPPLEMENT|Fibers and probiotics|A blend of fibers and seven probiotics
40922264|NCT05081791|BEHAVIORAL|Exercise Training|12-week exercise training program including a combination of endurance and resistance training for 45 minutes, twice a week.
40922265|NCT05845697|OTHER|Trigger point dry needling|Filiform needle that pierces the skin and is inserted into an identified trigger point in the muscle
40922266|NCT05845697|OTHER|Sham dry needling|A validated sham dry needle that is blunted on the end and does not pierce the skin
40922267|NCT02270996|OTHER|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
40922268|NCT00042341|DRUG|clofarabine (IV formulation)|
41442549|NCT03887910|OTHER|Intervention|Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
41442550|NCT00794547|DRUG|Calcitriol|Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.
41269688|NCT04052841|PROCEDURE|Thermal pulsation|Participants underwent a single LipiFlow® thermal pulsation system (TearScience Inc., Morrisville, NC,USA) treatment on the first visit: after lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) and instillation of anesthetic eye drops (Alcaine, proparacaine hydrochloride 0.4 ml/2mg) in both eyes, sterile eye cups were placed on to the conjunctival sac as instructed by the manufacturer, after 12 minutes of upper and lower palpebral conjunctival surfaces heat while simultaneously graded pulsatile pressure applying, eye cups were removed slightly.
41269689|NCT04052841|PROCEDURE|Intense pulsed light therapy|Lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) before treatment. Intense pulsed light (IPL) with a range of wavelength (570 or 620 nm) was performed every 3 weeks，3 times in total (0, 3w, 6w). 10 pulses were transmited from one tragus through nose to the other tragus was a single pass, each treatment needed to do 2 passes. Manual lid massage was done after per IPL treatment.
41269690|NCT04052841|PROCEDURE|Manual warm compresses|Lids hygiene of both eyes with wet cotton swabs(OCuSOFT, Inc., Texas, USA).Commercial heated eye patch was use for 10 min. Manual lid massage every 2 weeks, 5 times in total(0，2w, 4w, 4w, 8w).
41269691|NCT03379519|BEHAVIORAL|Multi-domain Attention Training (MAT)|The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.
41442551|NCT00794547|DRUG|Calcitriol|In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy
41442552|NCT04408586|DRUG|Phentermine-Topiramate Extended Release|Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily
41442553|NCT04408586|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient
41269692|NCT03379519|BEHAVIORAL|Passive information activities (PIA)|The active control group (Passive information activities) training content included reading online e-books and playing online games.
41094840|NCT02317705|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
41269693|NCT01845545|OTHER|Early provision of microfinance|The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
41442554|NCT04408586|OTHER|Online support system|VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
41442555|NCT04089917|DEVICE|Q Aspiration Catheter|The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.
41442556|NCT04721834|DEVICE|Low-intensity Extracorporeal Shockwave Therapy|Low intensity shockwave energy would be delivered to stimulate angiogenesis in corporal tissue. Therapy would be delivered through a linear probe in 6 sessions. It would be conducted as a day procedure.
40922269|NCT01989468|BIOLOGICAL|Secukinumab|Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
40922270|NCT01989468|BIOLOGICAL|Placebo|Secukinumab placebo provided in 1 mL autoinjector
40922271|NCT05055492|DIAGNOSTIC_TEST|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
40922272|NCT01116778|BIOLOGICAL|eN-Lac®|One capsule with 2x10\^9 colony forming unit (cfu) LP GMNL-32, once daily, po
40922273|NCT01116778|OTHER|Placebo|One placebo capsule, once daily, po
40922274|NCT05923216|DIETARY_SUPPLEMENT|High dose OIT|Patients will receive daily a high dose of the sesame paste (1200 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
41094841|NCT02317705|PROCEDURE|Laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
41442557|NCT04721834|DEVICE|Sham Therapy|Same device as the active treatment arm would be used, with the addition of sham probe which block all shockwaves.
41094842|NCT05209542|PROCEDURE|Hysterosalpingo-Foam Ultrasonography|"* Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging~* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection"
40922275|NCT05923216|DIETARY_SUPPLEMENT|Low dose OIT|Patients will receive daily a low dose of the sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
40744400|NCT05665842|OTHER|Music Application|The Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be applied. After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be reapplied. In the music application, the selecting instrumental music will be used. To determine the music, the researcher will be advice received from the TÜMATA and the a music education expert.
40744401|NCT05665842|OTHER|Sleep Hygiene Training|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal \& Nunes, 2014; Dinis \& Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
40744402|NCT02201576|DRUG|Bortezomib|"1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~3. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)"
40744403|NCT02201576|DRUG|Plasma exchanges and intravenous immunoglobulins|"1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~3. oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)"
40744404|NCT00827242|DRUG|Placebo|Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
40744405|NCT00827242|DRUG|tadalafil|Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
40744406|NCT04234230|OTHER|Prevalence Survey|Questionnaire survey on self-management
40744407|NCT03331406|OTHER|Physical Activity Program|12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
40744408|NCT00330018|DRUG|Valganciclovir|Valganciclovir
40744409|NCT00330018|DRUG|Acyclovir|Acyclovir
41442558|NCT05605535|BIOLOGICAL|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
41442559|NCT05605535|DRUG|Paclitaxel|175 mg/m\^2, every 3 weeks
41442560|NCT05605535|DRUG|Carboplatin|AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)
40744410|NCT02980653|DRUG|Megestrol acetate (MA) 400 mg/day|Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
41442561|NCT05605535|BIOLOGICAL|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
41442562|NCT00246922|DRUG|Roflumilast|
41442563|NCT00031395|DRUG|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults.
41442564|NCT00031395|DRUG|methylphenidate|MPH is FDA-approved for the treatment of ADHD symptoms in children.
41442565|NCT00031395|OTHER|placebo|an inactive substance
40744411|NCT01168440|DRUG|Sunitinib|Sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of treatment followed by 2 weeks of rest).
40744412|NCT01604031|BIOLOGICAL|B-CLL Vaccine|Patients will receive a fixed dose (2X10\^7) of IL-2 secreting B-cells together with (2X10\^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
40744413|NCT01604031|DRUG|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
41094843|NCT05209542|PROCEDURE|Laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
41094844|NCT02121574|DEVICE|Zero flux and ingestible thermometers|
41442566|NCT05906251|GENETIC|SRP-6004|Single IV infusion of SRP-6004
41442567|NCT05044364|DRUG|This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.|Patients with hypertensive emergency and hypertensive sub-emergency who are clinically diagnosed as unsuitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective, and require intravenous medication to quickly control their blood pressure. The qualified subjects will be randomly divided into groups according to the test protocol. The method of administration is to infuse clevidipine butyrate injection for emergency blood pressure reduction treatment to achieve rapid, effective and stable lowering of blood pressure to the target blood pressure, and prevent or reduce further damage to the target organ.
41442568|NCT05443750|BEHAVIORAL|Motivational Behavioral Economic Alcohol Intervention|The intervention combines an alcohol brief motivational intervention (US-THRIVE \[Tertiary Health Research Intervention via Email\]) with the Substance-Free Activity Session (SFAS), shown to reduce drinking and related negative consequences by increasing future orientation and engagement in pro-social alternatives to drinking. The intervention will be delivered using a web-based platform appropriate for the young adult target population whose social networks operate through such communications.
41442569|NCT05443750|BEHAVIORAL|Health Education|Participants view web-based health educational material about alcohol, sleep, and nutrition of a similar length and style to the experimental intervention materials.
41269694|NCT04492566|DEVICE|Automated Insulin Delivery|"Participants will use the Automated Insulin Delivery (AID) iAPS system for 48-60 hours in a medically supervised session.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
40744414|NCT04249778|DRUG|Dapagliflozin|Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
40744415|NCT04249778|DRUG|Placebo|Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
40744416|NCT00471042|DRUG|Buprenorphine|Dose is determined according to the participants' individual need.
40744417|NCT05842980|OTHER|sepsis|collect 5ml blood from patient
40744418|NCT01625767|BEHAVIORAL|AAT experiment|Smokers and nonsmokers complete AAT experiment
41442570|NCT01154712|DEVICE|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
41442571|NCT01154712|DEVICE|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
41442572|NCT00650871|DRUG|GW679769|
41442573|NCT00650871|DRUG|Placebo|
41442574|NCT05136001|DEVICE|polysomnography|Duration of sleep was collected with polysomnography on second postoperative night. (from 20:00pm to 06:00am).
41269695|NCT00883883|DRUG|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
40744419|NCT05575427|DRUG|Minocycline|The patients will receive minocycline oral between 7-28 days
40744420|NCT05575427|DRUG|Levofloxacin or Cotrimoxazole|The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
40744421|NCT05575427|DRUG|Placebo|Capsule without active compound
41269696|NCT00883883|DRUG|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
41269697|NCT00250692|DRUG|Nitrous Oxide|
41442575|NCT05967390|DEVICE|Transcranial Magnetic Stimulation|One time for each day, lasting for three weeks.
41442576|NCT05905640|OTHER|Method of PrEP delivery and consultation|All core PrEP services that include HIV testing, risk assessment, clinical review PrEP initiation, prescription, dispensing, and follow-up will be performed in a one-stop consultation with a single provider.
40744422|NCT02676427|PROCEDURE|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
40744423|NCT00327327|DRUG|imexon|30-60 minutes IV, days 1,8,15 every 28 days
40744424|NCT00327327|DRUG|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
40744425|NCT03787160|DIAGNOSTIC_TEST|initial VOC|Difference in VOC profile between patients with CDH and healthy controls (2 samples per patient will be obtained after obtaining informed consent).
41269698|NCT04952623|OTHER|Rotator Cuff Related Shoulder Pain E-Learning Program|The RCRSP e-learning program is designed according to the ADDIE Instructional Design Model in light of current literature.
41269699|NCT00738816|OTHER|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
41442577|NCT04901169|DRUG|Angiotensin II|Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
41269700|NCT02210156|DIETARY_SUPPLEMENT|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
41269701|NCT02210156|OTHER|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
41269702|NCT02485080|DRUG|Simeprevir|
41269703|NCT02485080|DRUG|Sofosbuvir|
41269704|NCT03751332|DRUG|Tacrolimus|Conversion from either cyclosporin or tacrolimus to tacrolimus modified release
41269705|NCT02251912|DRUG|Intranasal Oxytocin|10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
41269706|NCT02251912|DRUG|Placebo|10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
41269707|NCT04141657|OTHER|Pharmacogenetic test|Buccal swabs are a relatively non-invasive way to collect deoxyribonucleic acid (DNA) samples for testing. A buccal swab will be performed to collect DNA from the cells on the inside of a subject's cheek for phenotyping of CYP3A4.
41269708|NCT05599958|DIAGNOSTIC_TEST|sweat chloride test|assessing chloride (Cl-) concentration in sweat of the patient
41442578|NCT04901169|DRUG|Saline|Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
41442579|NCT05811247|DRUG|AD109|Oral administration at bedtime.
41442580|NCT05811247|DRUG|Placebo|Oral administration at bedtime.
41442581|NCT00404963|DRUG|placebo|
41442582|NCT00404963|DRUG|GSK376501|
41442583|NCT01093963|DRUG|Lisdexamfetamine|oral; 20-70mg/day
41442584|NCT01093963|DRUG|Placebo|oral; 20-70mg/day
41269709|NCT05599958|GENETIC|genetic testing|detection of CFTR mutation
41269710|NCT05064657|PROCEDURE|Bubble blowing method|"The investigators were used Bubble blowing method and ball squeezing method.~To child were used a ball squeezing method during the blood collection process."
41269711|NCT03980340|BEHAVIORAL|Short Nap Intervention|Study participants may be asked to have a 1-2 hour nap in between the breath analysis tests.
41269712|NCT03980340|BEHAVIORAL|No Nap Intervention|Study participants may be asked to sit or lay down remaining awake for 1-2 hours in between breath analysis tests.
41269713|NCT03921996|PROCEDURE|Radical prostatectomy (RP) followed by ePLND|ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
41269714|NCT03921996|PROCEDURE|Radical prostatectomy (RP) only|Radical prostatectomy
41442585|NCT03396276|DRUG|Suboxone|8mg of buprenorphine/2mg of naloxone
41442586|NCT03396276|BEHAVIORAL|Brief counseling in the ED|"Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers."
41442587|NCT03396276|BEHAVIORAL|Referral to outpatient treatment|A referral will be made to one of the affiliated MAT clinics.
41442588|NCT03396276|BEHAVIORAL|Follow-up coaching|A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
41442589|NCT00190840|DRUG|pemetrexed|
41442590|NCT05133804|DRUG|Methylphenidate|Ritalin 10mg
40744426|NCT03787160|DIAGNOSTIC_TEST|initial fecal microbiome|Difference of alpha and beta diversity and relative fecal bacterial abundance between patients with CDH and healthy controls (1 stool sample will be taken per patient after obtaining informed consent)
41442591|NCT05133804|DRUG|Reboxetine|Reboxetine 4mg
40744427|NCT03787160|DIAGNOSTIC_TEST|initial pulmonary microbiome|Difference of alpha and beta diversity and relative pulmonary bacterial abundance between patients with CDH and healthy controls (1 deep induced sputum sample will be taken per patient after obtaining informed consent)
41442592|NCT05133804|DRUG|Placebo|Placebo matched to Reboxetine
41442593|NCT05133804|DRUG|Placebo|Placebo matched to Ritalin
41442594|NCT01501786|DRUG|control|propofol 8mg/kg/h saline 0.24 ml/kg/h
41442595|NCT01501786|DRUG|Ket10|propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
41442596|NCT01501786|DRUG|Ket20|propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
41442597|NCT01346735|OTHER|No intervention|
41269715|NCT06490536|DRUG|Oxaliplatin|"Oxaliplatin is used as part of the chemotherapy regimens for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Oxaliplatin 130 mg/m² is given intravenously on day 1, in combination with capecitabine 1000 mg/m² taken orally twice daily on days 1-14 of each 21-day cycle.~FOLFOX Regimen: Oxaliplatin 85 mg/m² is administered intravenously on day 1, alongside folinic acid 400 mg/m² and fluorouracil 400 mg/m² IV bolus, followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~Dosages are standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results, typically up to 6 months."
41442598|NCT05584397|PROCEDURE|Venipuncture|Draw of peripheral blood (about 20 ml and 40 ml, during the screening and procedure visits, respectively).
41442599|NCT05584397|PROCEDURE|Targeted physical medical exam|"Study participants will be undergoing a physical exam where vitals will be recorded (e.g. temperature, blood pressure, heart rate). The registered nurse (RN) will also perform auscultation of heart and lungs.~Study participants will be also asked to fill out a survey with questions related to his/her medical history, current use of medications, sexual history and substance abuse."
41442600|NCT05584397|PROCEDURE|Urine pregnancy test|Women of childbearing potential will be asked to run an urine pregnancy test during the second (procedure) visit. Pregnant women will not be allowed to participate in the study.
41442601|NCT05584397|PROCEDURE|Anoscopy|The anoscopy is an examination using a small, rigid, tubular instrument called anoscope (also called an anal speculum). This is inserted a few inches into the rectum in order to collect some small samples of mucosal tissue. We will collect 5 rectum biopsy samples and one cytobrush.
41442602|NCT05584397|PROCEDURE|Esophagogastroduodenoscopy (EGD)|The EGD involves looking at the esophagus, stomach, and first and second portion of the duodenum. This procedure involves the use of an endoscope to remove small tissue samples. This procedure uses conscious sedation drugs given by a vein in the arm. The procedure takes about 1½-2 hours, including time for recovery. We will collect 5 duodenal biopsies and one cytobrush.
41442603|NCT05107635|DEVICE|AtriCure Commercially Available Devices|Epicardial and endocardial hybrid ablation procedure used to treat the IST or POTS using AtriCure commercially available devices.
41442604|NCT01537887|DRUG|LY2484595|Administered orally once daily for 10 days.
41442605|NCT01537887|DRUG|Placebo|Administered orally once daily for 10 days.
41442606|NCT01537887|DRUG|Moxifloxacin|Single dose administered orally.
41442607|NCT00005785|DRUG|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
41442608|NCT05092191|DRUG|Cannabis oil vs placebo|"Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being."
41442609|NCT04830462|DRUG|Rifampicin 300 Mg Oral Capsule|Rifampicin 600 mg orally once daily for 4 months
41442610|NCT04830462|DRUG|Isoniazid 300 Mg ORAL TABLET|Isoniazid 300 mg daily for 6 months
40922276|NCT05972525|BEHAVIORAL|Shared decision-making supported by an in-consultation PtDA to patients with severe osteoarthritis in their hip or knee|The intervention group has been involved in the development process of the PtDA. After receiving a training course in SDM and the use of a PtDA, the surgeons will practice SDM supported by an in-consultation PtDA during the consultations with the participant.
41442611|NCT02521493|DRUG|Asparaginase|Given IM or IV
41442612|NCT02521493|DRUG|Asparaginase Erwinia chrysanthemi|Given IM or IV
41442613|NCT02521493|DRUG|Cytarabine|Given IT and IV
41442614|NCT02521493|DRUG|Daunorubicin Hydrochloride|Given IV
41442615|NCT02521493|DRUG|Etoposide|Given IV
41442616|NCT02521493|OTHER|Laboratory Biomarker Analysis|Correlative studies
41442617|NCT02521493|DRUG|Mitoxantrone Hydrochloride|Given IV
41442618|NCT02521493|DRUG|Thioguanine|Given PO
41442619|NCT00135850|GENETIC|VEGF-A165 plasmid|
41442620|NCT00746395|DRUG|Lubiprostone|24 mcg oral administration
41442621|NCT00746395|DRUG|Placebo|Oral administration
41442622|NCT00712959|BIOLOGICAL|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 ml, IM
41442623|NCT00712959|BIOLOGICAL|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 mL, IM
41442624|NCT04708028|OTHER|Dog Therapy|The intervention is a therapy dog interaction (e.g. petting) for up to 2 minutes before their appointment and first interaction with the doctor. The subject can pet the dog for as long as they like up until the 2 minute mark.
41442625|NCT01961947|BIOLOGICAL|ASP7374|subcutaneous
41442626|NCT01961947|BIOLOGICAL|approved egg-derived TIV|subcutaneous
41442627|NCT01143311|GENETIC|Arm A|"4 distinct biopsies will be taken~1. in a non UV-exposed area (inner arm)~2. in a UV-exposed area (external surface of the forearm)~3. in a pretumoral region (actinic keratosis)~4. inside the tumor"
41442628|NCT05462327|PROCEDURE|Low Fresh Gas Flow in Prone Position|In the low fresh gas flow group, the flow rate was reduced to 0.5 L/min
41442629|NCT05462327|PROCEDURE|Normal Fresh Gas Flow in Prone Position|In the normal flow rate group, the gas flow rate was reduced to 2 L/min during the maintenance phase.
41442630|NCT05350163|BIOLOGICAL|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
41442631|NCT03815903|DRUG|Induction chemotherapy|3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
41442632|NCT03815903|COMBINATION_PRODUCT|Chemoradiotherapy|Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
41442633|NCT03151876|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
41442634|NCT03151876|DRUG|Cladribine|6 mg/m2 intravenously daily for 5 days
41442635|NCT03151876|DRUG|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
41442636|NCT03151876|DRUG|Busulfan|3.2 mg/kg intravenously daily for 4 days
41442637|NCT03151876|PROCEDURE|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
41442638|NCT06176534|DRUG|Experimental: chemotheyapy|nab-paclitaxel 130mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2，day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2，from day1 to DAY 14
41442639|NCT06176534|DRUG|Active Comparator: endocrine therapy|palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
41442640|NCT05840133|DIAGNOSTIC_TEST|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
41442641|NCT04466111|DEVICE|Intellis neurostimulator system|The study will use the commercially available IntellisTM neurostimulator and compatible SCS system components from Medtronic using stimulation parameters within the specifications approved for use in the approved indications. The study will stimulate the cervical dorsal columns of the spinal cord.
41442642|NCT00469521|DRUG|Refresh Tears, 9582X|
41442643|NCT04757220|OTHER|Cognitive tasks with EEG recording|questionnaires and cognitives tasks
41442644|NCT04391621|PROCEDURE|Autologous Adipose Derived stem cell transplantation|Through liposuction, harvested lipoaspirate will be processed in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for inflitration. This will then be infiltrated into the affected keloid.
41442645|NCT04391621|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|Triamcinolone Acetanoide 40mg/ml suspension will be diluted into 1ml of 0.5% lignocaine solution and infiltrated into the selected keloid.
41269716|NCT06490536|DRUG|Capecitabine|"Capecitabine is used as part of the chemotherapy regimens for patients with ctDNA+ and ctDNA- results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Capecitabine 1000 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle, in combination with oxaliplatin 130 mg/m² given intravenously on day 1.~Capecitabine Monotherapy for High-Risk ctDNA- Patients: Capecitabine 1250 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle for patients identified as high-risk but with negative ctDNA results.~The dosage of capecitabine is standardized, while the duration of treatment varies based on patient response and monitoring results, typically up to 6 months."
40744428|NCT03787160|DIAGNOSTIC_TEST|Maximum oxygen uptake|Comparison of the maximum oxygen uptake (corrected for body weight and gender) as determined by bicycle spiroergometry between patients with CDH and healthy controls
40744429|NCT03787160|DIAGNOSTIC_TEST|Functional residual capacity|FRC will be determined by spirometry, bodyplethysmography and N2-breath wash out method. FRC will be compared between patients after CDH and healthy controls.
40744430|NCT03787160|DIETARY_SUPPLEMENT|Probiotic treatment|CDH patients will receive OmniBiotic 6(R) (Allergosan, Graz, Austria) probiotic supplementation 1 sachet daily for 3 months.
41269717|NCT06490536|DRUG|Folinic acid|"Folinic acid is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Folinic acid (leucovorin) 400 mg/m² is given intravenously on day 1, in combination with oxaliplatin 85 mg/m² IV on day 1 and fluorouracil 400 mg/m² IV bolus followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~The dosage of folinic acid is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results, typically up to 6 months."
41269718|NCT06490536|DRUG|Fluorouracil|"Fluorouracil is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Fluorouracil 400 mg/m² is given as an intravenous (IV) bolus on day 1, followed by 2400 mg/m² as a continuous IV infusion over 46 hours, in combination with folinic acid (leucovorin) 400 mg/m² IV on day 1 and oxaliplatin 85 mg/m² IV on day 1. This regimen is repeated every 14 days.~The dosage of fluorouracil is standardized, while the duration of treatment is typically up to 6 months, adjusted based on patient response and liquid biopsy results."
40744431|NCT03787160|DIAGNOSTIC_TEST|VOC probiotic|Determination of the VOC profile 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
40744432|NCT03787160|DIAGNOSTIC_TEST|Fecal microbiome probiotic|Determination of the fecal microbiome from 1 sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
41442646|NCT06254781|DRUG|Luspatercept|Erythroid Maturation Agent
41269719|NCT06490536|DRUG|Temozolomide|"Temozolomide is used as part of the tailored chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial, specifically for those with MGMT-negative tumors. It is administered in the following way:~TEMIRI Regimen: Temozolomide 150-200 mg/m² is taken orally once daily on days 1-5 of each 28-day cycle, in combination with irinotecan 250 mg/m² administered intravenously on day 1 of each cycle.~The dosage of temozolomide is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
41442647|NCT02251886|OTHER|Moxibustion in primiparae|Number of primiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
41442648|NCT02251886|OTHER|Moxibustion in multiparae|"Number of multiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment"
41442649|NCT02724605|BIOLOGICAL|Red blood cells unit age 14 days or less|30 Patients who will receive units of packed red blood cells stored stored for 14 days or less
41442650|NCT02724605|BIOLOGICAL|Red blood cells unit age more than 14 days|30 patients who will receive units of packed red blood cells stored for more than 14 days
41442651|NCT00835263|DRUG|Lamotrigine|200 mg Tablet
41269720|NCT06490536|DRUG|Irinotecan|"Irinotecan is used as part of the tailored chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following ways:~TEMIRI Regimen: Irinotecan 250 mg/m² is administered intravenously on day 1 of each 28-day cycle, in combination with temozolomide 150-200 mg/m² taken orally once daily on days 1-5.~FOLFIRI Regimen: Irinotecan 180 mg/m² is given intravenously on day 1, in combination with folinic acid (leucovorin) 400 mg/m² IV, fluorouracil 400 mg/m² IV bolus, followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~The dosage of irinotecan is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
41094845|NCT05566405|PROCEDURE|General Anaesthesia|All patients in the general anaesthesia group will be premedicated with intravenously administered (iv) midazolam (2mg) and fentanyl (100 mcg). Induction will be performed using intravenous propofol (2.5-3mg/kg) and lidocaine (40mg); dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg will also be administered. After successful tracheal intubation, total intravenous anaesthesia will be maintained by administering propofol (0.05 mg/kg/sec iv) and remifentanil (0.2 mcg/kg/sec iv). Pain management will be achieved by paracetamol (1g iv) and tramadol (100mg iv) whereas muscle relaxation by vecuronium (0.6 mg/kg iv).
41269721|NCT06490536|DRUG|Nivolumab|"Nivolumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Nivolumab: 3 mg/kg is given intravenously every 2 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
41269722|NCT06490536|DRUG|Ipilimumab|"Ipilimumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Ipilimumab: 1 mg/kg is given intravenously every 6 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
41269723|NCT06490536|DRUG|Trastuzumab|"Trastuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Trastuzumab: 8 mg/kg as an initial intravenous (IV) loading dose, followed by 6 mg/kg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
41442652|NCT00835263|DRUG|Lamictal®|200 mg Tablet
41094846|NCT05566405|PROCEDURE|Combined (Epidural and Spinal) Anaesthesia|Combined (epidural and spinal) anaesthesia will be performed using an epidural 18G needle and a spinal 27G needle, in the L2-L3 or L3-L4 interspace. Induction will be carried out by spinal intrathecal administration of levobupivacaine (2.6-3ml of 0.5%) and mild sedation by midazolam (5mg iv in bolus). All patients will be administered dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg iv. Maintenance will be performed 75 minutes after induction and obtained using an epidural administration of levobupivacaine (4-5ml of 0.5%).
41442653|NCT00840073|DRUG|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fed
41094847|NCT05566405|PROCEDURE|Open Retropubic Radical Prostatectomy|All patients will undergo a nerve-sparing open retropubic radical prostatectomy
41094848|NCT04478747|PROCEDURE|TVM|Transvaginal mesh operation using BSC mesh (A.M.I., Feldkirch, Austria)
41094849|NCT04478747|PROCEDURE|Colposacropexy|Colposacropexy using EndoGYNious mesh (A.M.I., Feldkirch, Austria)
41094850|NCT00517478|PROCEDURE|Blood Sample|
41094851|NCT03738657|OTHER|Olfactory screening|Therefore prior to gustatory testing, patients will be screened and assessed as having either normal or abnormal olfactory function using the Sniffin' Sticks (Burghart; Wedel, Germany). The test consists of 12 odour pens which represent every-day odours (peppermint, fish, coffee, banana, orange, rose, lemon, pineapple, cinnamon, cloves, leather and liquorice). Patients are presented with an odour and select the perceived smell using a multiple-forced-choice method.
41442654|NCT00840073|DRUG|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fed
41442655|NCT04363554|OTHER|Fluid intake|The participants will intake fluid
41442656|NCT04363554|OTHER|Thirsting|The participants will thirst
41442657|NCT06495892|DRUG|Diuretic therapy|Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach
41442658|NCT05236348|DEVICE|Aktiia.product-us|The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.
41442659|NCT05194059|BEHAVIORAL|Home-based physical activity|Participants will follow a personalized activity pacing program
41442660|NCT06094517|OTHER|Interview|Persistent Lower Back Pain Patients on waiting list under going a usual care pathway following referral to Physiotherapy will be interviewed for views on sleep health
41442661|NCT05215535|RADIATION|Abbreviated MRI of the liver/abdomen|"The MRI examinations of the liver/abdomen will be performed at the same time as the pelvic MRI. A 1,5 T scanner will be used together with a dedicated torso/abdominal coil. An abbreviated MRI liver protocol includes 3 different sequences as follows:~1. Axial T2-weighted respiratory triggered sequence with 5 mm slice thickness.~2. Axial diffusion weighted spin echo respiratory triggered sequence with fatsat with b-factors 50/800 s/mm2 and ADC calculation maps, 5 mm slice thickness~3. An axial breath-hold 3D T1-weighted gradient echo with fatsat with 4 mm slice thickness, gap 2 mm, contrast enhanced venous phase and in a 3 min equilibrium phase, using regular i.v bolus injection of gadolinium contrast medium with standard clinical dose."
41442662|NCT05215535|RADIATION|Combined single venous and 3 min equilibrium phase CT of the abdomen/liver|The CT examination of the liver will be performed as a combined examination in a single venous phase starting with the thoracic region directly followed by the abdomen down to the pelvis. An additional 3 min equilibrium phase of the liver only will end the examination. Regular iodinated low-osmolar non-ionic contrast media will be used of 350 mg I/ml using a power injector, 2-4 ml/s, 100-150 ml dependent on patient weight and kidney function. Reconstructed images in axial, coronal and sagittal plane will be performed.
41442663|NCT03442322|OTHER|transdisciplinary approach|This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
41442664|NCT03442322|OTHER|multidisciplinary approach|This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
40744433|NCT03787160|DIAGNOSTIC_TEST|Pulmonary microbiome probiotic|Determination of the fecal microbiome from 1 deep induced sputum sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
41269724|NCT06490536|DRUG|Pertuzumab|"Pertuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Pertuzumab: 840 mg as an initial intravenous (IV) loading dose, followed by 420 mg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
41442665|NCT03776552|OTHER|Rapid weight loss (RWL) program|16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up
41442666|NCT03776552|OTHER|Gradual weight loss (GWL) program|16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up
41442667|NCT06558708|DRUG|GZR101 Injection|Once daily
41442668|NCT06558708|DRUG|GZR33 Injection|Once daily
40744434|NCT04484181|OTHER|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
41442669|NCT06558708|DRUG|Insulin aspart|Once daily
41442670|NCT04446117|DRUG|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40mg
41442671|NCT04446117|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)
41442672|NCT04446117|DRUG|Abiraterone Acetate|Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid
41442673|NCT04446117|DRUG|Enzalutamide|Supplied as 40 mg capsules; administered orally daily at 160mg
41442674|NCT04446117|DRUG|Prednisone|Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily
41442675|NCT06133933|DEVICE|Pain Threshold using algometer/dolorimeter|These patients who consent to participation in the study will receive a preoperative pain threshold measured using a pain algometer/dolorimeter. We will rely on the completion of the questionnaires, opioid consumption journal, and surveys to establish a correlation between pre-operative pain threshold and post-operative outcomes.
41442676|NCT01163461|BEHAVIORAL|speech therapy|individuals will receive 60 hours of behavioral speech therapy
41442677|NCT04057872|PROCEDURE|Therapeutic plasma exchange|The removed plasma is 'exchanged or replaced' with either IV fluids, albumin, and/or Fresh frozen plasma
41442678|NCT05456763|DIETARY_SUPPLEMENT|sodium butyrate|add-on therapy irrespective of standard treatment depending on severity (according to the guidelines)
41442679|NCT05456763|OTHER|placebo|placebo
41094852|NCT03738657|OTHER|Quantative Gustatory Testing using Taste Strips|"Following screening for olfactory function, whole mouth gustatory function will be assessed using validated taste strips (Burghart; Wedel, Germany). Filter paper test strips are impregnated at one end with 2cm2 of either sweet, sour, salty or bitter taste solutions in four concentrations. In a pseudo-randomised sequence, individual strips will be placed on the tongue and patients will be asked to close their mouth in order to assess whole mouth function. Through a forced-choice procedure patients will be asked to identify the taste stimuli. Scores for individual taste qualities will range from 0-4 and an overall taste score will range from 0-16.~Patients will rinse their mouth with tap water prior the application of each taste strip."
41094853|NCT04274218|OTHER|Perturbation|Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.
41094854|NCT02256969|DRUG|Blephamide|
40744435|NCT04484181|OTHER|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer will be based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
40744436|NCT00748800|BEHAVIORAL|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
40744437|NCT00748800|BEHAVIORAL|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
40744438|NCT03164707|DIAGNOSTIC_TEST|Blood Glucose Level|ON Admission Blood Glucose Level Fasting Blood Glucose Level
40744439|NCT01696968|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
40744440|NCT01696968|PROCEDURE|X-Ray Imaging|Undergo a chest x-ray
40744441|NCT05710172|DEVICE|Auditory Mirror Therapy|21 days, up to 3 hours per day intervention
40744442|NCT01656499|DIETARY_SUPPLEMENT|Arabinoxylanoligosaccharides|
40744443|NCT01656499|DIETARY_SUPPLEMENT|Maltodextrine|
40744444|NCT00548561|DRUG|Dexrazoxane|
40744445|NCT04040855|OTHER|Medication review|Multi-professional medication review
40744446|NCT00315822|OTHER|80% oxygen|Supplemental oxygen will be administered during surgery
40744447|NCT00315822|OTHER|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
40744448|NCT05136638|BEHAVIORAL|dCBTi|The dCBTi adopts a multi-module approach, consisted of 6 weekly modules including psychoeducational on sleep, insomnia, sleep hygiene, sleep restriction and prescription, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep.
40744449|NCT05136638|BEHAVIORAL|Virtual coaching|A virtual coach will be added to the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
40744450|NCT05136638|BEHAVIORAL|Non-therapist coaching|A research intern will answer questions and address concerns raised by the participant at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
40744451|NCT05136638|BEHAVIORAL|Therapist coaching|A clinical psychology trainee will provide therapeutic support to enhance the use and adherence to CBTi treatment strategies at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
40744452|NCT05136638|BEHAVIORAL|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
40744453|NCT02842021|DRUG|S2G6T-1|Twice a day topical cream
40744454|NCT02842021|DRUG|S2G6T-2|Twice a day topical cream
40744455|NCT02842021|DRUG|S2G6T-3|Twice a day topical cream
40744456|NCT02842021|DRUG|S2G6T-4|Twice a day topical cream
40744457|NCT04808453|DRUG|CPI-300|CPI-300 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
40744458|NCT04492514|DRUG|Mavrilimumab|treatment infusion
40744459|NCT04492514|DRUG|Placebo|Placebo infusion
40744460|NCT05941715|DRUG|Aflibercept 40 MG/ML|treat-and-extend
40744461|NCT05941715|DRUG|Faricimab 120 MG/ML|treat-and-extend
40744462|NCT04452838|DRUG|Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)|4 mg administered under fasted condition.
40744463|NCT04452838|DRUG|Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)|4 mg administered under fasted conditions.
40744464|NCT04452838|DRUG|Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)|4 mg administered under fed conditions.
40744465|NCT04452838|DRUG|Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)|4 mg sprinkled on apple sauce administered under fasting conditions
40744466|NCT04452838|DRUG|Fesoterodine BIC SR4 fed (Treatment E in Part B)|4 mg administered under fed conditions
41094855|NCT02256969|DRUG|GenTeal PM Night-Time|
41442680|NCT00532077|DRUG|rhPTH(1-34)|
41442681|NCT00532077|DRUG|SB-751689 100 mg|
40744467|NCT04947280|RADIATION|Fractionated Stereotatic Radiation Therapy|Participants prescribed to receive 9 Gy x 3 or 10 Gy x3 image-guided fractionated stereotatic radiation therapy.
40744468|NCT00444249|PROCEDURE|White Alcon IOL|Implantation of white Alcon IOL
40744469|NCT00444249|PROCEDURE|Yellow Alcon IOL|Implantation of yellow Alcon IOL
41442682|NCT00532077|DRUG|SB-751689 400 mg|
41442683|NCT04874454|DIAGNOSTIC_TEST|ultrasound|evaluate the vocal cord movement among the stroke patients
41442684|NCT03991273|OTHER|Y-M2M©|The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.
41442685|NCT03991273|OTHER|B-M2M©|The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
41442686|NCT06313957|BIOLOGICAL|LUCAR-20SP cells|Prior to infusion of the LUCAR-20SP, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
40744470|NCT00444249|PROCEDURE|White Hoya IOL|Implantation of white Hoya IOL
40744471|NCT00444249|PROCEDURE|Yellow Hoya IOL|Implantation of yellow Hoya IOL
40744472|NCT05348330|PROCEDURE|Thoracic intervertebral foramen block|Under ultrasound guidance the continuous thoracic intervertebral foramen block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
40744473|NCT05348330|PROCEDURE|Mid-point to pleura transverse process block|Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
40744474|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) and dentin (15sec) etching with phosphoric acid~4. Application of ExciTE (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec with 800mW/cm2 light intensity (Cure TC-01, Spring Health Products, Inc, Norristown, PA, USA)~5. Composite-resin application using a transparent cervical matrix (Kerr-Hawe, Orange, CA, USA) and curing for 40sec~6. Finishing and polishing"
40744475|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Application of AdheSE One (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec~4. Composite-resin application using a transparent cervical matrix and curing for 40sec~5. Finishing and polishing"
40744476|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) etching with phosphoric acid~4. Application of AdheSE One and curing for 10sec~5. Composite-resin application using a transparent cervical matrix and curing for 40sec~6. Finishing and polishing"
40744477|NCT04504760|DRUG|ONO-2910|Single ascending dose of ONO-2910 will be administered orally.
40744478|NCT04504760|DRUG|Placebo|Single dose of placebo will be administered orally.
40744479|NCT04504760|DRUG|ONO-2910|Multiple ascending dose of ONO-2910 will be administered orally.
40744480|NCT04504760|DRUG|Placebo|Multiple dose of placebo will be administered orally.
40744481|NCT00356590|BIOLOGICAL|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
40744482|NCT01088893|DRUG|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
40744483|NCT00189384|DRUG|ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin|
40744484|NCT04942210|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection Subcutaneous injection
40744485|NCT04942210|BIOLOGICAL|Yellow fever vaccine|Powder and diluent for suspension for injection Subcutaneous injection
40744486|NCT02212977|DEVICE|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
40744487|NCT02212977|PROCEDURE|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
40744488|NCT01339013|DEVICE|Anesthetic Conserving Device (AnaConDa )|Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
40744489|NCT00306722|DRUG|AQUAVAN® (fospropofol disodium) Injection|
40744490|NCT02096536|DRUG|Vancomycin|vancomycin administration based on decision of treating physician
40744491|NCT01370538|DRUG|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
40744492|NCT04616521|PROCEDURE|Deep brain stimulation|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for moderate-to-advanced stage PD. The targets used in this study are STN and GPi, which are widely accepted and used for symptom control in PD. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the movement disorder specialist.
40744493|NCT04215575|DEVICE|glaucoma implant procedure (Baerveldt)|A 350 mm2 Baerveldt glaucoma implant was placed in the superotemporal quadrant in 25 patients randomized to BGI group. A limbus-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
40744494|NCT04215575|DEVICE|glaucoma implant procedure (Ahmed)|A 184 mm2 Ahmed glaucoma implant was placed in the superotemporal quadrant in 56 patients randomized to AGV group. A fornix-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. The Ahmed tube left patent and viscoelastic substance injected into anterior chamber. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
40744495|NCT05690243|BEHAVIORAL|Group psychotherapy delivered via video telehealth|Small group psychotherapy using psychoeducation and skills training aimed at addressing modifiable factors in MCI.
40744496|NCT04137887|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
40744497|NCT04137887|BIOLOGICAL|Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
40744498|NCT01981928|DRUG|ASP7962|Oral
40744499|NCT01981928|DRUG|Placebo|Oral
40744500|NCT03410537|DRUG|Taurine|
40744501|NCT03410537|DRUG|Placebo|
41442687|NCT00856167|DRUG|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
41442688|NCT00856167|BEHAVIORAL|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
40744502|NCT04664088|PROCEDURE|Acupuncture|"Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions). In each session, needles will be retained for 30 minutes. The acupoints will include Baihui (DU20), Qianding (DU21), Houding (DU19), Yintang (DU29), Fengchi (GB20), Shuaigu (GB8), Tongli (HT5), Hegu (LI4), Taichong (LR3), Fenglong (ST40), Xuanzhong (GB39) and Zulinqi (GB41). The selection of acupoints is on the basis of meridian theory and patients' clinical symptoms.~Patients are not allowed to take prophylactic medications. But in case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented in the patient diary."
40744503|NCT04664088|DRUG|Venlafaxine|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks. In case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented.
40744504|NCT04111783|DEVICE|POU protocol ultrasound|The evaluation method performed a preoperative examination of the patient within 10 minutes by a heart scan and a standard scan of the face, a large vascular scan under the xiphoid, a body cavity scan, and a standard scan of the face and a lung scan. Preparation, providing anesthesia and surgeons with a fast, comprehensive and accurate preoperative judgment with important clinical and social significance.
40744505|NCT02193893|OTHER|Biological: Cell-based therapeutics|Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
40744506|NCT02193893|OTHER|Symptomatic treatment of ALS|Symptomatic neurological treatment of ALS
40744507|NCT05573360|OTHER|NGF5-A test formulation|One drop of investigational product instilled on the eye
40744508|NCT05573360|OTHER|NGF4-B test formulation|One drop of investigational product instilled on the eye
40744509|NCT05573360|OTHER|NGF6-B test formulation|One drop of investigational product instilled on the eye
40744510|NCT05573360|OTHER|NGF6-E test formulation|One drop of investigational product instilled on the eye
40744511|NCT05573360|OTHER|Systane eye drop|One drop of commercial product instilled on the eye
40744512|NCT03096353|OTHER|Placebo|saline
40744513|NCT03096353|DRUG|Naloxone|We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.
40744514|NCT04836130|PROCEDURE|patient specific guide|patient specific guide reduction
40744515|NCT04836130|PROCEDURE|conventional technique|conventional anatomical reduction
40744516|NCT02117154|DEVICE|6-day Continuous Glucose Monitoring System|performed 3 times on a patient, one month apart
40744517|NCT00002470|BIOLOGICAL|recombinant interferon alfa|
40744518|NCT00002470|DRUG|fluorouracil|
40744519|NCT02988388|PROCEDURE|Lung biopsy/lobectomy|Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
40744520|NCT03463447|DEVICE|Electronic Dynamometer|Mensuration of the handgrip strength of each volunteer using an electronic dynamometer.
40744521|NCT03463447|DEVICE|Hydraulic dynamometer|Mensuration of the handgrip strength of each volunteer using a hydraulic dynamometer.
40744522|NCT06261957|DRUG|Salbutamol HFA-134a|100 microgram (μg) (ex-valve) at 30-second intervals per actuation
40744523|NCT06261957|DRUG|Salbutamol HFA-152a|100 μg (ex-valve) at 30-second intervals per actuation
40744524|NCT00920816|DRUG|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg BID with continuous dosing
40744525|NCT00920816|DRUG|Sorafenib|sorafenib will be given at a dose of 400 mg BID continuous dosing
40744526|NCT02536794|BIOLOGICAL|Anti-B7H1 Monoclonal Antibody MEDI4736|Given IV
40744527|NCT02536794|OTHER|Laboratory Biomarker Analysis|Correlative studies
40744528|NCT02536794|OTHER|Pharmacological Study|Correlative studies
40744529|NCT02536794|BIOLOGICAL|Tremelimumab|Given IV
40744530|NCT02717715|BEHAVIORAL|Home base stroke rehabilitation|The intervention consists of physiotherapy exercises targeting functional and physical capacity.
40744531|NCT06282289|BEHAVIORAL|Magnetoencephalography (MEG)|Stimuli will be presented binaurally through headphones at 60 decibel sound pressure level (dB SPL). Conditions are presented in a pseudo-random order with an inter-stimulus interval of \~800 ms on average (range: 600 ms to 1000 ms). The duration of the stimuli is fixed: 2 seconds, in order to guarantee a minimum number of cycles.
40744532|NCT06282289|OTHER|Cognition development questionnaire|Computerised questionnaires completed by parents
40744533|NCT02714959|DRUG|Proleukin|
40744534|NCT04630730|DRUG|Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)|1 dose of VPM1002BC, live, 1-19.2 x 108 colony forming units (CFU) on day 1, 8 (+/- 1 day) and 15 (+/- 1 day)
40744535|NCT04630730|DRUG|Atezolizumab|Neoadjuvant immunotherapy with atezolizumab, 4 cycles 1200 mg fixed dose iv infusion on d1 q3w starting 4-16 weeks after date of surgery
40744536|NCT04630730|DRUG|Cisplatin|Neoadjuvant chemotherapy with cisplatin: 4 cycles 70mg/m2 iv infusion on d1 q3w (starting on d22)
40744537|NCT04630730|DRUG|Gemcitabine|Neoadjuvant chemotherapy with gemcitabine: 4 cycles 1000 mg/m2 iv infusion on d1 and d8 q3w (starting on d22)
40744538|NCT00446784|DRUG|CE-224,535|
40744539|NCT00446784|DRUG|Methotrexate|
40744540|NCT04650945|OTHER|isCGM group|As previously described
40744541|NCT00986232|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
40744542|NCT00986232|BIOLOGICAL|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
40744543|NCT00986232|BIOLOGICAL|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
40744544|NCT05852288|DIAGNOSTIC_TEST|Inflammatory markers|Participants in this cohort will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The evaluation will include assessments of inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity.
40744545|NCT00358280|DRUG|Ropivacaine|
40744546|NCT00358280|DRUG|Bupivacaine|
40744547|NCT03611270|DEVICE|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
40744548|NCT00361153|DRUG|Colesevelam hydrochloride|Welchol tablet 625mg
40744549|NCT00361153|DRUG|placebo|placebo
40744550|NCT04899024|BEHAVIORAL|PARTI|PARTI will provide positive affect skills. Each 1-hour session delivered via Zoom consists of a didactic portion with in vivo skills practice and participants are asked to complete home practice of the skills between sessions. Many sessions include formal exercises that have been utilized in Mindfulness-Based Relapse Prevention to cultivate mindfulness and meta-cognitive awareness.
40744551|NCT04899024|BEHAVIORAL|Attention-Control|Attention-Control will provide a core set of coping and affect measures as well as neutral writing exercises. Each 1-hour attention-control session will be administered via Zoom.
40744552|NCT04899024|BEHAVIORAL|Contingency Management for PrEP Adherence|Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.
40744553|NCT01787903|DEVICE|Real-time continuous glucose monitor|Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
40744554|NCT04614272|BEHAVIORAL|Prayer|Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.
40744555|NCT04614272|BEHAVIORAL|Reading a poem|Reading is a distraction tool for pain management
40744556|NCT04472741|DEVICE|difference between colonoscopes|patients have been randomly assigned for colonoscopy with FUSE or HD SFV endoscopes with or without Endocuff
40744557|NCT02801773|DIETARY_SUPPLEMENT|Treatment Gingivitis with Probiotic|Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months
40744558|NCT02801773|OTHER|Treatment Gingivitis conventional|gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
40744559|NCT04889274|BIOLOGICAL|COVID-19 vaccine|COVID-19 vaccine as offered by NHS England
40744560|NCT04889274|BIOLOGICAL|Concentrate beetroot Juice|Beetroot juice containing approximately 5mmol/l nitrate
40744561|NCT04889274|BIOLOGICAL|Nitrate-deplete beetroot juice|Beetroot juice with nitrate removed
40744562|NCT02606253|DRUG|tolvaptan|Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
40744563|NCT02606253|DRUG|Chlorothiazide|Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
40744564|NCT02606253|DRUG|Metolazone|Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
40744565|NCT00490997|DRUG|Ketamine only|"Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).~Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation"
40744566|NCT00490997|DRUG|Ketamine - Propofol|"Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).~Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation"
40744567|NCT01941056|BIOLOGICAL|multi-CMV epitope modified vaccinia Ankara vaccine|Given IM
40744568|NCT01941056|OTHER|laboratory biomarker analysis|Correlative studies
40744569|NCT00154466|BEHAVIORAL|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
40744570|NCT03412032|OTHER|assessment|different assessments in both arms
40744571|NCT02286674|OTHER|Tablet (Audio/Visual Device)|Subjects will be given a tablet to use before surgery
40744572|NCT00218894|PROCEDURE|Cataract surgery|surgery one one or two eyes by use of two different types of lenses and correcting for refraction
40744573|NCT03562507|DRUG|ESK981|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
40744574|NCT03562507|DRUG|Nivolumab|480 mg/dose IV, Day 1 of each 28-day cycle
40744575|NCT03837938|DRUG|Levopront® syrup 30 mg/5 ml|The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).
40744576|NCT03837938|DRUG|Libexin®|The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.
40744577|NCT05608707|BEHAVIORAL|Physical activity intervention|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
40744578|NCT05608707|DIETARY_SUPPLEMENT|Personalised nutrition intervention|Two Plant-based Protein and Fibre (PPF) product products have been selected from six initially developed, with best amino acid blend, taste, and bioavailability. Participants will be provided with the PPFs to consume daily as part of a personalised diet over 12 weeks.
40744579|NCT03470766|DEVICE|Nevro Senza System (HF10 Therapy)|Nevro 10kHz High Frequency Spinal Cord Stimulation
40744580|NCT02639026|RADIATION|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
40744581|NCT02639026|DRUG|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
40744582|NCT02639026|DRUG|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
41094856|NCT02256969|PROCEDURE|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
40744583|NCT02763995|BEHAVIORAL|Pharmaceutical care|This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
40744584|NCT01859741|DRUG|OMP-59R5|OMP-59R5 administered intravenously
40744585|NCT01859741|DRUG|Etoposide|administered intravenously
40744586|NCT01859741|DRUG|Placebo|administered IV
40744587|NCT01859741|DRUG|Cisplatin or Carboplatin|administered intravenously
40744588|NCT03706352|PROCEDURE|tunneling epidural catheter|The epidural needle was used to horizontally tunnel the catheter for a length of five centimeters on either side of the insertion point.
40744589|NCT02032212|OTHER|EVP unflavoured|
40744590|NCT02032212|OTHER|EVP flavoured|
40744591|NCT02032212|OTHER|Nicotine inhalator|15 mg nicotine Nicorette
40744592|NCT02032212|OTHER|Conventional cigarette|
40744593|NCT00408954|DRUG|UK-369,003|100 mg MR tablet once daily for 2 weeks
40744594|NCT00408954|DRUG|UK-369,003|UK-369,003-100 mg MR formulation for 2 weeks
40744595|NCT05687565|DIETARY_SUPPLEMENT|Control group placebo|Dietary suplementation
40744596|NCT05687565|DIETARY_SUPPLEMENT|Experimental group 1 lauric acid|Lauric acid 1.5 grams once daily
40744597|NCT05687565|DIETARY_SUPPLEMENT|Experimental group 2 lauric acid|Lauric acid 3 grams once daily
40744598|NCT01251679|BEHAVIORAL|Hand washing|hand washing education and material
40744599|NCT01251679|DEVICE|Hand washing and surgical mask|hand washing education and material and paper surgical face masks
40744600|NCT03559309|DIAGNOSTIC_TEST|Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing|Patients treated with Alirocumab in the clinical routine will have additional diagnostic tests as stated above. The clinical trial will be conducted as an open label, single arm study. The diagnostic tests will be done at baseline (BL) and after 10 weeks of treatment (W10) with Alirocumab.
40744601|NCT05678114|DIETARY_SUPPLEMENT|Myo-inositol|Myo-inositol (4g/die)
40744602|NCT02465047|OTHER|Self-help booklet|See Arm/Group Description
40744603|NCT01870037|DRUG|Placebo (PBS-20% sucrose)|
40744604|NCT01870037|DRUG|hMaxi-K|Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
40744605|NCT06268119|OTHER|training nurses and caring for patients to prevent, diagnose, and intervene in postoperative delirium.|The intervention group received care in line with the postoperative delirium prevention, diagnosis and intervention protocol after the delirium training given by the researcher to intensive care unit nurses.
40744606|NCT02347865|DRUG|AMG 162 - Prolia|500 patients
40744607|NCT02347865|DRUG|AMG 162 - Prolia|250 patients, one year later
40744608|NCT05708222|DEVICE|MEB-001|The study is for the development of a software medical device. The study participant will complete study specific questionnaires and undergo a routine sleep study. The medical device will not provide any treatment or interventions.
40744609|NCT04093284|DEVICE|The needle-free jet injector|Continuous insulin therapy for 9 days
40744610|NCT04028505|DRUG|Terlipressin Injectable Product|"Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH."
40744611|NCT06009874|DRUG|Dapagliflozin 10mg Tab|patients will be treated with DAPA 10 mg once daily for three months
40744612|NCT06009874|DRUG|Placebo|patients will be treated with a placebo tab once daily for three months
40744613|NCT05362539|PROCEDURE|Cystoscopy|diagnostic cystoscopy for detection of any bladder lesions
40744614|NCT05362539|DIAGNOSTIC_TEST|Computed tomography|Computed tomography for patients to exclude bladder lesions
40744615|NCT05362539|GENETIC|DNA hypermethylation assay|DNA hypermethylation assay of six genes (GATA4, P16, P14, APC, CDH1 and CD99)
40744616|NCT05362539|DIAGNOSTIC_TEST|Urine cytology|voided urine cytology for all patients
40744617|NCT05031130|OTHER|Empowered program integrated with family support|The empowered program integrated with family support is an intervention consisted of five steps that will be given when pregnant adolescents on gestational age 32 or 33 weeks the second meeting will be when the pregnant adolescents on gestational age 34 or 35 weeks.
40744618|NCT01542099|DRUG|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml."
40744619|NCT01542099|DRUG|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml."
40744620|NCT01597362|PROCEDURE|laparoscopy|Trocar access in laparoscopy
40744621|NCT01597362|PROCEDURE|Laparoscopy|"The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.~The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume."
40744622|NCT01597362|PROCEDURE|Laparoscopy|"Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.~On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field."
40744623|NCT01597362|PROCEDURE|Laparoscopy|A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
40744624|NCT03634150|BIOLOGICAL|Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.|Once weekly treatment, with IV doses of Nerofe (96mg\\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
40744625|NCT03847077|BEHAVIORAL|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application.
41094857|NCT02256969|PROCEDURE|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
40744626|NCT03847077|BEHAVIORAL|Standard Counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
40744627|NCT03422718|BEHAVIORAL|Healthy Behavior Texts|Participants receive motivational health behavior texts
41094858|NCT04401722|PROCEDURE|PANCREATICODUDENECTOMY|dissection and removal of periampulary tumour with 3 reconstruction PJ, HJ, and GJ
41094859|NCT03032796|BEHAVIORAL|Body-Brain Trainer|A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.
41442689|NCT01218867|BIOLOGICAL|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
41442690|NCT01218867|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
40744628|NCT03422718|BEHAVIORAL|No healthy behavior texts|Participants do not receive healthy behavior texts
40744629|NCT03422718|BEHAVIORAL|BP Monitoring Daily Via Text Messaging|Daily text messages will prompt participants for BP by home cuff
40922277|NCT03954340|DEVICE|iRemember Neurofeedback (NFB)|"Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range."
40922278|NCT00565929|DRUG|Placebo|Sterile saline (0.9%).
40744630|NCT03422718|BEHAVIORAL|BP Monitoring Weekly Via Text Messaging|Weekly text messages will prompt participants for BP by home cuff
40744631|NCT03422718|BEHAVIORAL|Physician appointment and transportation scheduling|Participants receive assistance scheduling physician appointment and transportation to those appointments
40744632|NCT03422718|BEHAVIORAL|No physician appointment and transportation scheduling|Participants do not receive assistance scheduling physician appointment or transportation
40744633|NCT00232154|DRUG|Zithromax&#153; (azithromycin) 500mg tablets|
40744634|NCT00232154|PROCEDURE|Endoscopic Sinus Surgery|
40744635|NCT00232154|PROCEDURE|Blood sampling for hematology|
40744636|NCT00232154|PROCEDURE|Blood sampling for plasma chemistry profile|
40744637|NCT00232154|PROCEDURE|Serum pregnancy test (for women of child-bearing potential)|
40744638|NCT05480371|DEVICE|Conventional tracheal suctioning|"Group 1 allocated to conventional tracheal suctioning,all patiemts will be followed up until discharge from ICU or death~Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations."
40744639|NCT05480371|DEVICE|Mechanical insufflation/exsufflation|Group 2 will be allocated to mechanical insufflation-exsufflation which will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions.
40744640|NCT03147287|DRUG|Palbociclib|Palbociclib is a drug that may stop cancer cells from growing
40744641|NCT03147287|DRUG|Fulvestrant|Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
40744642|NCT03147287|DRUG|Avelumab|Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
40744643|NCT02995889|DEVICE|FLT-PET|
40744644|NCT05265754|BEHAVIORAL|sujok therapy|sujok therapy
40744645|NCT03132272|DEVICE|Immunoadsorption with Globaffin|Immunoadsorption for treatment of persons with Alzheimer Dementia
40744646|NCT01794975|DRUG|Ketamine|
40744647|NCT01794975|DRUG|Atomoxetine|
40744648|NCT01794975|OTHER|Cold pressor test|
40744649|NCT01794975|DRUG|Placebo|
40744650|NCT01546298|OTHER|Patch tests|Patch tests for allergic reaction
40744651|NCT06135259|DRUG|erythropoietin|erythropoietin solutions of 150, 300, and 500 IU/mL were mixed with trimethyl chitosan (M) solutions. glycerophosphate solution was then added to the mixture to obtain erythropoietin-loaded hydrogel comprising final concentrations of trimethyl chitosan(5%) and glycerophosphate (20%).
40744652|NCT06135259|DRUG|Triamcinolone acetonide|Each 0.1 mg triamcinolone acetonide in a dental paste containing gelatin, pectin, cream flavor, vanilla flavor and carboxymethylcellulose sodium in Plasticized Hydrocarbon Gel, a polyethylene and mineral oil gel base.
40744653|NCT05647304|DEVICE|RGn550 5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
40744654|NCT05647304|DEVICE|RGn550 10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
40744655|NCT00685282|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
40744656|NCT01946854|BEHAVIORAL|Questionnaire|"Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year."
40744657|NCT01531153|DRUG|Galantamine|8mg or 16mg
40744658|NCT01531153|DRUG|Placebo|Placebo dose.
40744659|NCT04440384|OTHER|Functional evaluation|"Patients will complete these forms and tests :~Box and block test, Purdue peg board, Percival, Nine hole peg, T-GAP, EGF, MAHVIE, DASH, RAND36, CHQ-PF28, CHQ-CF45, CGI-S"
40744660|NCT01149785|DRUG|crizotinib|Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
40922279|NCT00565929|BIOLOGICAL|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10\^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10\^7 or 1X10\^8 TCID 50.
40744661|NCT01149785|DRUG|ketoconazole|Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
40744662|NCT01149785|DRUG|crizotinib|Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
40744663|NCT00395382|DRUG|Alendronate|70mg weekly orally
40744664|NCT00395382|DRUG|Placebo|weekly orally
40922280|NCT04479319|DIAGNOSTIC_TEST|Thorax CT|Subjects in all arms have a Thorax CT and RT-PCR for SARS-CoV-2.
40744665|NCT03150186|OTHER|SHS exposure in homes|The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
40744666|NCT03150186|OTHER|SHS exposure in private cars|The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
40744667|NCT03150186|OTHER|SHS exposure in outdoor settings|In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
40744668|NCT05965934|DRUG|Direct Sodium Removal Infusate 2.0|Direct Sodium Removal via peritoneal ultrafiltration using Infusate 2.0 (30% icodextrin, 10% dextrose). Patients (if not yet on SGLT-2 inhibitors) will receive SGLT-2 inhibitors.
40744669|NCT04358562|DRUG|Gefitinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
40744670|NCT04358562|DRUG|Anlotinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
41442691|NCT01218867|BIOLOGICAL|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
41442692|NCT01218867|DRUG|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
40922281|NCT01789398|DRUG|BF2.649|BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
40922282|NCT01488513|DRUG|sphingosine kinase-2 inhibitor ABC294640|Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
40922283|NCT00347256|DRUG|cisplatin|
40922284|NCT00347256|PROCEDURE|targeted radiation therapy|
41442693|NCT05105633|DRUG|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
41442694|NCT05105633|DRUG|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
41442695|NCT06261294|DIAGNOSTIC_TEST|OncoSweep Lung Spotligh|This study is to develop and validate the performance of OncoSweep Lung Spotlight for detecting circulating miRNA expression, ctDNA methylation status, platelet RNA, and tumor marker expressions by utilizing real-time polymerase chain reaction (qPCR). The method is to collect venous blood from subjects during their routine visit to the healthcare facilities.
40922285|NCT00347256|PROCEDURE|tumor resection|
40922286|NCT01718340|DRUG|Metformin|metformin tablet 500mg three time per day
40922287|NCT01762137|PROCEDURE|Flow Diversion|Endovascular flow diverter placement
41442696|NCT04740658|OTHER|No intervention|There is no intervention
40922288|NCT01762137|PROCEDURE|Coiling|Endovascular coil placement
41269725|NCT06490536|DRUG|Panitumumab|"Panitumumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with multiple wild-type tumors (MSS/MMRp extended RAS/RAF wild-type) in the SAGITTARIUS trial. It is administered in the following way:~Panitumumab: 6 mg/kg is given intravenously every 2 weeks. The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
41442697|NCT05312983|OTHER|Audiological and vestibular tests|"6h of audiological and vestibular tests divide in 3 sessions :~* Session A : objective audiological tests~* Session B ; subjective audiological tests~* Session C : balance tests."
41442698|NCT05312983|OTHER|Blood sampling|A 10 mL blood sample will be collected during the study.
41269726|NCT00688909|DRUG|letrozole|2.5 mg daily by mouth for 6 months
41442699|NCT05312983|OTHER|neurocognitive self-questionnaire|Four self-questionnaires to fill out to measure sleep quality, memory and emotional state
41269727|NCT02335684|OTHER|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
41269728|NCT02335684|OTHER|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
41269729|NCT02047669|BEHAVIORAL|Biopsychosocial|
41269730|NCT02047669|BEHAVIORAL|Reference|
41442700|NCT00834275|DRUG|Cefadroxil 500 mg Capsules|1 x 500 mg
41442701|NCT00834275|DRUG|DURICEF® capsules 500 mg|1 x 500 mg
41442702|NCT06284941|DRUG|Ropivacaine combined with methylene blue for iliac fascia block|Ultrasound guided iliac fascia block, administered with 30ml of 0.25% ropivacaine+0.05% methylene blue
41442703|NCT02952456|OTHER|interview with a psychologist|interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
41442704|NCT04164589|DEVICE|SCENAR 1NT-02.2|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
41442705|NCT00197353|DRUG|Epidural bupivacaine (dose/concentration/volume ranging)|
41442706|NCT01449383|DIETARY_SUPPLEMENT|low meat high fibre|less than 30g red meat and at least 40g dietary fibre per day
41269731|NCT03067090|DEVICE|Aquamid Reconstruction|"AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile.~The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle."
41442707|NCT01449383|DIETARY_SUPPLEMENT|high meat low fibre|at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
41442708|NCT03168126|DEVICE|Pro-AQT|Use of the device for advanced hemodynamic monitoring
41442709|NCT04530994|DRUG|maralixibat|Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor
41442710|NCT02787876|DRUG|Pegteograstim|
41442711|NCT06560957|BEHAVIORAL|Time restricted eating|Time restricted eating involves restricting the window in which calories are consumed to 8-10 hours, without altering diet quality or caloric intake. In this study, time restricted eating will be a consistent 10-h eating window between 06:00 and 19:00, considered an early TRE pattern, for all days of the week, as chosen by the participant. They will need to consume all food and beverages (except water) during this window for the duration of the 8-week intervention.
41442712|NCT06560957|BEHAVIORAL|Eating ad libitum with nutritional counselling|Nutritional counselling will include customized advice delivered by a registered dietician about dietary choices while allowing individuals to eat at any time of day.
41442713|NCT05665205|OTHER|Aerobic plus strength group|A 8 week program of aerobic exercise plus strength exercise of upper and lower limbs in the hospital with a supervised trained physiotherapist
41442714|NCT05665205|OTHER|Aerobic group|This group has a 8 weeks program of only aerobic exercise in the hospital with a supervised trained physiotherapist.
41442715|NCT03523377|OTHER|prolonged overnight fasting|Three phone calls using motivational interviewing, support via SMS text.
41442716|NCT03523377|OTHER|usual care|Eat a heart-healthy diet and exercise for at least 30 minutes five days a week
41442717|NCT04092023|OTHER|nursing education|Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
41269732|NCT00826813|DEVICE|Esophageal stent placement|The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
41442718|NCT02213263|BIOLOGICAL|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
41442719|NCT02213263|BIOLOGICAL|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
40744671|NCT04027621|DEVICE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
41442720|NCT01013077|DRUG|Optive|Use a minimum of 2 drops per day for 1 month.
41269733|NCT03557567|DIAGNOSTIC_TEST|NGS molecular screening|
41442721|NCT01013077|DRUG|Soothe|Use a minimum of 2 drops per day for 1 month.
41442722|NCT01013077|DRUG|New Emulsion|Use a minimum of 2 drops per day for 1 month.
41269734|NCT06054529|PROCEDURE|Surgical removal of the GBM tumor|Surgical removal of the GBM tumor
40744672|NCT04027621|DEVICE|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
40744673|NCT03780062|BIOLOGICAL|S100B protein dosing|Patients under antiplatelet therapy and who have a minor traumatic brain injury will have a blood samples with protein S100B dosage on arrival to the emergency room and after they will have a brain scanner between 4 and 8 hours after the trauma to analyse the negative predictive value with a treshold of 0.105 μg/L
40744674|NCT04464447|BEHAVIORAL|Acceptance and Commitment Therapy|"The treatment ACT for Health in Adolescents (AHEAD) is an ACT-based Group intervention consisting of 9 modules (27 hours in total) delivered over a period of 3 months, with a follow-up meeting (3 hours) 3 months after the last module. Six to eight patients participate in each treatment Group. An information meeting (3 hours) for close relatives is held at the beginning of the Group treatment and the adolescents and their parents were invited to a 1½-hour individual consultation after the 8th module."
40744675|NCT03238469|DEVICE|Microwave ablation|A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
40744676|NCT01846871|DRUG|Tivozanib|
40744677|NCT01470807|DEVICE|portable artificial pancreas system with CTR algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
40744678|NCT02034591|DRUG|Apixaban|
40744679|NCT02034591|DIETARY_SUPPLEMENT|Boost Plus|
40744680|NCT04078399|DRUG|Azacitidine combined with interferon preemptive treatment|Azacitidine combined with interferon preemptive therapy for prevention and treatment of recurrence of allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system
40744681|NCT05842291|DEVICE|Active rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
40744682|NCT05842291|DEVICE|Sham rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days, using sham stimulation coils that comprehensively mimic the active condition. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
40744683|NCT05842291|DEVICE|Active rTMS with long inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 50 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
40744684|NCT05141747|DRUG|MRG002|Administrated intravenously
40744685|NCT03459651|BEHAVIORAL|ANS training|In-home computer-based ANS training
40744686|NCT00790036|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
40744687|NCT00790036|DRUG|Everolimus Placebo|Everolimus placebo was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
40744688|NCT04319536|OTHER|no intervention|self-sampling
40744689|NCT05009420|OTHER|Avocado|avocado served with crackers as breakfast
40744690|NCT05333744|DRUG|Prednisone|Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100\^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.
40744691|NCT05333744|DRUG|Recombinant Human TPO|rhTPO im, 300U/kg per day for 2 weeks, if response (Plt 30-100×100\^g/L), taper to 300U/kg for twice per week until 6 weeks after delivery; if not response, drug withdrawal.
40744692|NCT03106805|PROCEDURE|early insertion|insertion at 4th postpartum week
40744693|NCT03106805|PROCEDURE|late insertion|insertion at 6th postpartum week
41442723|NCT06521021|BEHAVIORAL|AVOID|"Behavioral: Home food environment and grocery delivery (AVOID) Participants will receive coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices~Behavioral: WW Participants assigned to all arms will receive of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills."
41442724|NCT06521021|BEHAVIORAL|RESIST|"Behavioral: Inhibitory control training (RESIST) Participants assigned to RESIST will receive coaching (Zoom and/or email/text) and gamified inhibitory control training.~Behavioral: WW Participants assigned to all arms will receive coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills."
40744694|NCT05193396|DRUG|Hydrocortisone|hydrocortisone
40744695|NCT05193396|DRUG|Placebo|placebo tablets
40744696|NCT04364945|DRUG|dexmedetomidine|administration of dexmedetomidine 1 mcg/kg/hr
40744697|NCT04364945|DRUG|remifentanil|administration of remifentanil 0.1-0.2 mcg/kg/min
40744698|NCT04364945|DRUG|Sevoflurane|Anesthesia is maintained using sevoflurane.
40744699|NCT02079870|DRUG|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
40744700|NCT02079870|DRUG|placebo|Solution for subcutaneous (s.c. - under the skin) injection
40744701|NCT01789775|DRUG|Drug: CD07805/47 gel|
40744702|NCT01789775|DRUG|CD07805/47 gel Placebo|
40744703|NCT01068912|DRUG|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
40744704|NCT01068912|DRUG|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
41269735|NCT06054529|OTHER|d4-NAM infusion|Following the surgical removal of the GBM tumor, GBM patients will be dosed with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness.
41269736|NCT05658224|BEHAVIORAL|Education on effects of Exercise-induced hypoalgesia from exercise|Educational session with participants
40744705|NCT01068912|DRUG|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
40744706|NCT00408447|DRUG|Busulfan|Busulfan 4 mg/kg/d x 4d
40744707|NCT00408447|DRUG|Fludarabine|Fludarabine 30 mg/m2/d x 6d
40744708|NCT00408447|DRUG|Alemtuzumab|Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
40744709|NCT00408447|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
40744710|NCT04230070|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Bioequivalence
40744711|NCT04230070|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Bioequivalence
40744712|NCT01058005|DRUG|BG00002 (natalizumab)|300 mg intravenous injection every 4 weeks
40744713|NCT01058005|DRUG|interferon beta-1a|44 mcg subcutaneous injection 3 times per week
40744714|NCT01058005|DRUG|glatiramer acetate|20 mg subcutaneous injection once daily
40744715|NCT04849832|DIETARY_SUPPLEMENT|SIC|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich
40744716|NCT04849832|DIETARY_SUPPLEMENT|SIC + tea|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich with 2g of tea brewed for 5 minutes
40744717|NCT04849832|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate solution serves as a positive control - and whose absorption is well known.
41269737|NCT04626414|DRUG|Ferric maltol capsule|single dose of 30 mg capsule
40744718|NCT04849832|DIETARY_SUPPLEMENT|FeSO4 + tea|Ferrous sulfate solution given with 2g of tea brewed for 5 minutes - expected iron absorption inhibition
40744719|NCT00000544|BEHAVIORAL|diet therapy|
40744720|NCT05919251|BEHAVIORAL|Ageless Grace|This unique program attempts to combine multiple aspects that easily fit together including music and a group setting for socialization. The use of music to improve cognition as has been shown in other research studies to improve participation in exercise program. By linking cognitive retraining, low intensity exercise, group activities and music, the researchers of this project can determine if a movement program with these attributes can benefit individuals as a program of wellness once their rehabilitation plans have been completed. The researchers are specifically interested in the effect on balance, activity and incidence of falls in people with chronic stroke. Additionally, the researchers will investigate the differences that this structured program will make on older adults who will act as a comparison group. This will bring insight into some of the additional challenges that people with stroke encounter on a daily basis.
40744721|NCT01118091|BIOLOGICAL|Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
40744722|NCT01118091|BIOLOGICAL|CD8 enriched Young TIL|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10\^9 to 2x10\^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x 10\^8) and the administration of high-dose aldesleukin.
40744723|NCT01917773|DRUG|Octreotide|Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide
40744724|NCT01917773|DRUG|Bisacodyl|
40744725|NCT02524678|DRUG|Placebo|
40744726|NCT02524678|DRUG|URC102|
40744727|NCT00132483|BEHAVIORAL|Instruction in physical training program|Instruction in physical training program.
40744728|NCT02323061|PROCEDURE|BCI using EEG signals|A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
40744729|NCT01433770|DRUG|Amevive|Alefacept 15mg subcutaneous; once a week for 12 weeks
40744730|NCT00575302|DRUG|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 300 U
40744731|NCT00575302|DRUG|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 450 U
40744732|NCT04645108|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
40744733|NCT04645108|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss|The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity. During the first week of the study, participants will be introduced to the program, and the Noom app.
40744734|NCT06159036|DEVICE|Inertial Strength training|Low speed strength training with classic movements, derived from Olympic lifting and jumping
41269738|NCT04626414|DRUG|Ferric maltol suspension|single dose of 30mg (5ml) oral suspension
41269739|NCT02319902|DEVICE|Standard cold carbon dioxide gas|Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
41269740|NCT02319902|DEVICE|Heated humidified carbon dioxide gas|Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
41269741|NCT02227576|DRUG|Romiplostim|
41269742|NCT03751267|PROCEDURE|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
41269743|NCT05328570|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
40744735|NCT06139640|OTHER|Damask Rose Essential Oil|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
40744736|NCT01083472|DEVICE|Strattice(TM) Reconstructive Tissue Matrix|Strattice(TM) TM will be used to support the repair of abdominal wall defect
40744737|NCT01083472|PROCEDURE|Suture/suture with absorbable mesh|Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
40744738|NCT04785807|OTHER|Post traumatic, Anxiety and depression evaluation|Family member of person or trust of patient who had a limitation or discontinuation of treatments will be identified and asked to fulfilled a hospitalized anxiety and depression scale and the revised Impact Event scale 7 and 30 days after the limitation or discontinuation of treatments announcement
40744739|NCT02188732|BEHAVIORAL|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
40744740|NCT02188732|BEHAVIORAL|CBHH+SMT|Illness Management and Recovery (IMR) for psychiatric illness combines (1) psychoeducation, which improves knowledge about mental illness management, (2) behavioral tailoring, which improves medication adherence, (3) relapse prevention training, which decreases relapses and rehospitalizations, and (4) coping skills training, which reduces distress related to symptoms. Illness Management and Recovery (I-IMR) by adding chronic medical illness self-management to psychiatric illness self-management. For each psychiatric self-management skill module, there is a corresponding medical illness self-management training component using established methods in self-management of common chronic health conditions (e.g., diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, etc.).
40744741|NCT02188732|BEHAVIORAL|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).
40744742|NCT04685122|PROCEDURE|Phacoemulsification and intraocular lens implantation for cataract|Phacoemulsification and intraocular lens implantation for cataract
40744743|NCT00003720|DRUG|semaxanib|
40744744|NCT03203512|DIETARY_SUPPLEMENT|Fish oil capsules|Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
40744745|NCT03203512|DIETARY_SUPPLEMENT|High-oleic safflower oil capsules|High-oleic safflower oil capsules for 12 weeks
40744746|NCT00890318|DRUG|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
40744747|NCT00890318|OTHER|ketoconazole|Tablet, see Arm Description for intervention information.
40744748|NCT00890318|DRUG|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
40744749|NCT03240380|BEHAVIORAL|joint crisis plan|"Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.~Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare."
40744750|NCT03240380|BEHAVIORAL|crisis card|"Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.~When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office."
40744751|NCT01770730|DEVICE|Urine LAM strip test|This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
40744752|NCT00456612|PROCEDURE|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
40744753|NCT03735342|OTHER|Audio Recording|All participants will be provided with a re-playable audio recording of the discharge discussion on a portable electronic device. In addition, participants will have the option to record the discharge discussion on a personally-owned smartphone or receive access to the recording online, via the Open Recording Automated Logging System (ORALS).
40744754|NCT03997136|PROCEDURE|Supratentorial high grade gliomas resection.|Total, near total or subtotal/debulking resection of the brain supratentorial high grade gliomas
41094860|NCT03032796|BEHAVIORAL|Body Trainer|"A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present"
40744755|NCT04251494|DIAGNOSTIC_TEST|Carotid intima media thickness measurement (CIMT)|CIMT is a measurement of the thickness of the two inner layers of the common carotid artery wall. Using ultrasound, a linear array transducer is placed on the surface of the skin at the neck. Electrocardiogram(ECG) electrodes are placed on each wrist and one on the ankle. An image of the common carotid artery (CCA) is then produced in anterior, posterior and lateral views, and saved along with the ECG recording. The wall thickness can then be measured at the same point in the cardiac cycle using semi-automated detection software (Philips QLAB), which can reduce observer variability. The CIMT will be averaged across left and right CIMTs, as the control reference values use an average of both sides.
40744756|NCT04251494|DIAGNOSTIC_TEST|Pulse Wave Velocity measurement|The PWV measures the speed of a pulse wave travelling between two points in the vascular systems of known distance between them. PWV will be measured by the gold standard carotid-femoral PWV method which is a direct measurement of aortic stiffness. A 3-Lead ECG is connected alongside measurements of the blood velocity trace for the left CCA 2cm proximal to the bifurcation, and for the left common femoral artery origin.
40744757|NCT04251494|DIAGNOSTIC_TEST|Ankle-brachial pressure index (ABPI)|A blood pressure cuff is placed around the ankle and upper arm of the participant. A continuous wave Doppler probe is used over the surface of the skin to locate the artery distal to the cuff (such as the brachial artery in the arm, or the anterior tibial and posterior tibial arteries in the ankle). The cuff is then inflated, and the systolic pressure identified by listening cessation of the sounds produced by the probe corresponding to blood flow in the artery. The ABPI is then the ratio of the highest systolic ankle pressure divided by the highest systolic brachial pressure for the left and right sides of the body.
40744758|NCT04251494|OTHER|Diet questionnaire and diet diary|Dietary information will be collected in two formats. One will be a 14-item questionnaire (Martínez-González et al., 2012), which is a simplified version of a comprehensive food frequency questionnaire. This provides a quick measure of compliance to a Mediterranean dietary pattern and a rough measure of protective and adverse dietary factors that could affect individual CVD risk. The second will be a 3-day diet diary (3DDD). This will consist of participants recording the foods that they consume and the quantities, which will then be analysed for macro- and micronutrient composition once completed.
40744759|NCT04251494|OTHER|Routine blood samples|Blood samples will be taken from participants during their outpatient appointment. Patients routinely have blood samples taken during this clinic. The study will use the results from the routine blood tests, and also extra blood samples to collect data on other biomarkers. The laboratory facilities at Guy's and St Thomas Hospitals will be used to conduct analysis, no other laboratories will be used. Data will be collected on Phenylalanine levels, lipids, vitamin B12 and related biomarkers.
40744760|NCT03595722|DEVICE|High Intensity Focused Ultrasound|High intensity focused ultrasound to rectal/pelvic cancer
40744761|NCT01214720|DRUG|bevacizumab [Avastin]|Intervenous repeating dose
40744762|NCT03248895|DEVICE|Mobile Direct Observation of Therapy (MDOT)|Patients who are enrolled in the study will be randomised into two groups (I-med or D-med) to receive Mobile Direct Observation of Therapy (MDOT). Participants or parents/guardians of participants will be asked to capture a DOT video twice daily (morning and evening) on their mobile devices of ICS use by the patient. In the I-med group, participants will be asked to upload daily video recordings via the internet to a repository for a 6 week period at the start of the study. Participants in the D-med group will be free from DOT for the first 6 weeks of the study and will be asked to carry out their usual therapy management. After that, DOT as described above will be applied for the next 6 weeks.
40744763|NCT00202150|BEHAVIORAL|Application of a management action plan|
40744764|NCT03339453|DRUG|Nasal Glucagon|Administered nasally
40744765|NCT03339453|DRUG|Intramuscular Glucagon|Administered IM
40744766|NCT04328285|DRUG|Hydroxychloroquine|Hydroxychloroquine Oral Tablets
40744767|NCT04328285|DRUG|Placebo of Hydroxychloroquine|Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets
40744768|NCT04328285|DRUG|Lopinavir and ritonavir|LPV/r Oral Tablets
40744769|NCT04328285|DRUG|Placebo of LPV/r Tablets|Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
40744770|NCT01034423|DIETARY_SUPPLEMENT|Omega-3|Capsules with omega-3 fatty acids.
40744771|NCT01034423|DIETARY_SUPPLEMENT|sun flower oil|Capsules with sun flower oil.
40744772|NCT05883488|OTHER|Robot-assisted upper extremity rehabilitation|The robotic rehabilitation program (with the Armeo Spring Pediatric Robotic Rehabilitation system) will be implemented 3 days a week for 30 minutes in addition to the conventional rehabilitation program. Participants will receive a total of 4 weeks of treatment.
40744773|NCT05883488|OTHER|Conventional rehabilitation|Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
40744774|NCT06197282|PROCEDURE|Major surgery involving general anesthesia|EHR documented SAR-CoV-2 PCR nasopharyngeal swab results confirming Covid-19 status within one year of undergoing surgical procedure at Kern Medical Center.
40744775|NCT03589703|OTHER|Target ear points related to chronic low back pain (T-APA)|Light touch using vaccaria seeds on specific points of the ear.
40744776|NCT03589703|OTHER|Non-Target ear Points not related to chronic low back pain (NT-APA)|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
41094861|NCT03032796|BEHAVIORAL|Brain Trainer|"The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks."
41269744|NCT04711096|PROCEDURE|Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.|After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.
40744777|NCT03589703|OTHER|Enhanced Educational Control Group (CG-2)|No contact with the subject. Participants in the enhanced educational control group will be given the cLBP educational booklet.
40744778|NCT04393428|OTHER|[TIMP-2]*[IGFBP-7]|\[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
40744779|NCT04278352|BEHAVIORAL|Mindfulness Based Relapse Prevention|The intervention is a group skills training program that is delivered once weekly for eight weeks. Content focuses on mindfulness and cognitive-behavioral relapse prevention skills, including psychoeducation, experiential exercises, and between session homework assignments.
40744780|NCT00554580|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|"Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:~stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status."
40744781|NCT00554580|PROCEDURE|usual care of acute pulmonary oedema|"Usual treatment of acute pulmonary oedema including :~Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.~Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.~As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min."
40744782|NCT01139879|DEVICE|P400 mattress|The P400 mattress will be placed for a period of 12 weeks.
40744783|NCT05118269|DEVICE|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/World Health Organization , Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary).
40744784|NCT05118269|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
40744785|NCT02722291|DEVICE|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|
40744786|NCT02317549|DRUG|LB1148|
40744787|NCT02317549|DRUG|Placebo|
40744788|NCT04281719|OTHER|Mobile Application (working name: Bright Path)|The Bright Path web-based mobile application is designed to target co-occurring problems, enhance patient treatment engagement, and contribute to lasting improvements in teens' mental health. The central hypothesis is that developmentally tailored mobile applications that incorporate evidence-based treatment principles can facilitate increased patient engagement in and between sessions, thus, improving the efficiency, efficacy, and reach of treatments for this highly vulnerable population.
40744789|NCT00860925|DRUG|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
40744790|NCT00860925|DRUG|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
40744791|NCT00860925|DRUG|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
40744792|NCT00860925|DRUG|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
40744793|NCT03860480|PROCEDURE|ESP with Bupivacaine 0.5%|Regional anesthesia procedure with Bupivacaïne 0.5%
40744794|NCT03860480|PROCEDURE|ESP with Saline 0.9%|Regional anesthesia procedure with Normal Saline
40744795|NCT05494918|DRUG|JSKN003|JSKN003 is to be administered via intravenous (IV) dose
40744796|NCT06064201|OTHER|Short-chain fatty acids (SCFAs)|The SCFAs mixture contains acetate, butyrate, and propionate in a ratio of 60:20:20, and the total daily amount of SCFAs is equivalent to the fermentation of 10g of arabinoxylan oligosaccharides. Participants will be asked to consume these capsules spread at four intervals throughout the day. The nursing staff will distribute the capsules to the participants individually, supervise their intake, and monitor adherence by capsule count.
40744797|NCT06064201|OTHER|Placebo|To serve as a placebo, microcrystalline cellulose will be included in the same type of CDCs.
40744798|NCT02591303|OTHER|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
40744799|NCT04042428|DRUG|Somatropin injection|Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
40744800|NCT02940379|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
40744801|NCT02940379|DRUG|midazolam|"Pharmaceutical form: HCl syrup~Route of administration: oral"
40744802|NCT02940379|DRUG|metoprolol|"Pharmaceutical form: tablet~Route of administration: oral"
40744803|NCT03238872|BEHAVIORAL|Cognitive Behavioural Therapy|
40744804|NCT03238872|OTHER|Treatment as usual|
40744805|NCT06195215|OTHER|Peer Counselling|7 weeks peer counselling process will be carried out.
40922289|NCT03268421|BEHAVIORAL|Fibromyalgia Integrative Training for Teens|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
41269745|NCT04755374|OTHER|Discharged ≤ 21 days|Discharged from palliative care unit in equal less than 21 days
40744806|NCT03805048|PROCEDURE|Percutaneous coronary intervention|PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
40744807|NCT02919631|DRUG|Triheptanoin|Anaplerotic dietary oil
40744808|NCT02919631|DRUG|Placebo oil|Safflower oil
41442725|NCT00864591|PROCEDURE|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
40744809|NCT01116843|DRUG|PF-00299804|PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
40744810|NCT00140439|BEHAVIORAL|Emergency Department based asthma follow-up clinic|"The clinical activities of the intervention followed a fully specified protocol and provided education and care in three domains:~1. Asthma self-monitoring and management: Educators first reviewed the basic physiology of asthma with emphasis on its chronicity. After evaluating asthma severity and treatment history, the physician completed an individualized medical action plan (MAP) and provided any necessary device teaching.~2. Environmental modification and trigger control: After evaluation of potential environmental triggers in the home, each family was educated on their control. Each child was provided hypoallergenic bed encasings.~3. Linkages and referrals to ongoing primary care: Clinic staff stressed the importance of longitudinal asthma care by a PCP. A full report of the clinic visit was mailed to each child's PCP. In addition, the asthma educator scheduled a follow-up appointment with the PCP within 4 weeks"
40744811|NCT01764581|PROCEDURE|Tacrolimus regulation according to ImmuKnow values|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
40744812|NCT01305343|PROCEDURE|Routinely performed surgical correction of spinal deformity|Routinely performed surgical correction of spinal deformity
40744813|NCT03936127|PROCEDURE|Ultrasound (US) Targeted Fusion Biopsy|Ultrasound (US) Targeted Fusion Biopsy
40744814|NCT04795323|DEVICE|TARA v3.1, only non-pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
40744815|NCT04795323|DEVICE|TARA v3.2, both non-pharmacological and pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
40744816|NCT02617290|DRUG|Ticagrelor|Ticagrelor Loading dose of 180mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 90mg bid.
40744817|NCT02617290|DRUG|Clopidogrel|Clopidogrel Loading dose of 300 or 600mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 75mg per day.
41453167|NCT04125186|DIAGNOSTIC_TEST|Baseline EpiNP survey|The survey takes approximately 20 to 30 minutes to complete, and consists of the following: Short Form Health Survey version 2.0 (SF-12v2.0); Lower Urinary Tract Symptoms (LUTS) Tool; Patient Perception of Bladder Condition (PPBC); Self-report Medical History and Current Medication Form; Nocturia Impact Diary (NID); Disease-Specific Healthcare-Seeking Behavior and Treatment; Epworth Sleepiness Questionnaire (ESS); Patient Reported Outcome Measurement Information System Fatigue-Short Form version 1.0 (PROMIS F-SFv1.0); Patient Health Questionnaire (PHQ-8); Work Productivity and Activity Index (WPAI-SHP); Sexual health questions; lifestyle and sociodemographic questions; additionally, only men will complete the International Prostate Symptom Score (IPSS).
40744818|NCT02264041|DRUG|Cilobradine, low dose|
40744819|NCT02264041|DRUG|Cilobradine, high dose|
40744820|NCT02264041|DRUG|Itraconazole|
40744821|NCT02428153|OTHER|stretching exercises|static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
40744822|NCT03476642|DRUG|Ropivacaine|injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
40744823|NCT03476642|DRUG|Epinephrine|injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
41453168|NCT04125186|DIAGNOSTIC_TEST|Bladder diary|It consists of four components: measurement of waist and neck circumference, daily voiding diary (to assess voiding patterns, including frequency, volume, associated urgency, and incontinence episodes over a 24-hour period), NID (to assess nocturia impact), and assessment of morning sleepiness for 3 consecutive days and nights (including the morning of the fourth day).
40744824|NCT02365129|OTHER|Exercise training based on recommendations for adults (WHO)|The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
40744825|NCT05712382|BEHAVIORAL|Parent handbook|Handbook motivating parents to discuss alcohol use with their college student.
40744826|NCT05712382|BEHAVIORAL|Coping with negative emotions|Mindfulness-based techniques are taught to improve ability to cope with negative emotions.
40744827|NCT05712382|BEHAVIORAL|Problem-solving risky situations|Identifying and planning for barriers to change are encouraged.
40744828|NCT05712382|BEHAVIORAL|Recovering from slips|Peer and personalized techniques are discussed to facilitate resumption of moderate drinking after a heavy drinking episode.
40744829|NCT00002246|DRUG|Stavudine|
40744830|NCT01903044|PROCEDURE|BM-MNC injection|BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
40744831|NCT01514175|DRUG|IV Ibuprofen|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
40744832|NCT01514175|DRUG|IV Ketorolac|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
40744833|NCT00005774|DRUG|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
40744834|NCT00005774|DRUG|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
40744835|NCT03734094|DEVICE|Ceramic barrier|The use of a ceramic barrier to induce bone formation during GBR
40744836|NCT03734094|DEVICE|Titanium Mesh|The use of a titanium mesh to induce bone formation during GBR
40744837|NCT06025461|OTHER|no intervention|no intervention
40744838|NCT00855582|DRUG|Tadalafil|tablet once daily by mouth for 12 weeks.
40744839|NCT00855582|DRUG|Placebo|Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
40744840|NCT01804335|DRUG|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
40744841|NCT00363168|DRUG|Ranibizumab|0.3 mg/0.05 ml dose
40744842|NCT00363168|DRUG|Ranibizumab|0.5 mg/0.05 ml dose
40744843|NCT00932802|DRUG|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
41094862|NCT03032796|BEHAVIORAL|Expectancy Matched Control|The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
41094863|NCT03677726|BEHAVIORAL|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
41094864|NCT03677726|OTHER|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
41094865|NCT00010881|DRUG|antioxidants|
41094866|NCT00010881|BEHAVIORAL|stress reduction|
41094867|NCT00003790|GENETIC|polymerase chain reaction|
41094868|NCT00003790|OTHER|flow cytometry|
40744844|NCT05963919|OTHER|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
40744845|NCT05963919|OTHER|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) by ATS/ERS criteria. Forced expiratory volume in 1 second (FEV1) and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
40922290|NCT03268421|BEHAVIORAL|Cognitive Behavioral Therapy|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
41094869|NCT03351829|GENETIC|Gene-modified autologous stem cells|1 infusion for 5x10\^6\~1x10\^7 gene-modified cells; or more infusions depending on the circumstances
41094870|NCT01853917|OTHER|questionaires and structured interviews|We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
40744846|NCT05963919|OTHER|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
40744847|NCT05963919|OTHER|Lower extremity muscle strength test|The 30-Second Chair Test is administered using a folding chair without arms, with a seat height of 17 inches (43.2 cm). The chair, with rubber tips on the legs, is placed against a wall to prevent it from moving. The participant is seated in the middle of the chair, back straight; feet approximately a shoulder width apart, and placed on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance. Arms are crossed at the wrists and held against the chest. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand.
41442726|NCT00864591|PROCEDURE|Stress Adenosine CMR|"CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.~Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography."
41442727|NCT05547711|DIAGNOSTIC_TEST|drawing blood|drawing blood annually measurement of heartrate variability annually determine weight with a bioimpedance scale
41442728|NCT06102850|BEHAVIORAL|Critical Time Intervention for Young Adults with Mental Health conditions|SIx month supportive intervention involving CTI phased based casemanagement, support from a peer support specialist, and support from a mental health liaison
41442729|NCT01249651|DRUG|esomeprazole 40 mg|esomeprazole 40 mg once daily, 8 weeks
40744848|NCT03456323|BEHAVIORAL|Palliative Care Consultation|The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.
40744849|NCT03456323|OTHER|Usual Care|Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
40744850|NCT04937530|DRUG|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months
40744851|NCT04937530|DRUG|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
40744852|NCT02465970|DEVICE|STARSTIM|"Multifocal transcranial direct current stimulation.~* CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.~* The stimulation is applied during a 60 min session"
40744853|NCT02465970|DEVICE|sham TDCS|
41094871|NCT04864561|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide 2 vaccinations 28 days apart
41442730|NCT01808794|DEVICE|Mucograft|Mucograft Collagen Matrix
41442731|NCT01808794|DEVICE|Dynamatrix|Dynamatrix
41442732|NCT01442155|DRUG|Capecitabine|Administered according to the Summary of Product Characteristics.
41094872|NCT04864561|BIOLOGICAL|AZD1222|2 vaccinations 28 days apart AZD1222 is a recombinant, replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein.
41094873|NCT04864561|BIOLOGICAL|VLA2001 - adolescent part|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxid 2 vaccinations 28 days apart and with a booster vaccination on day 208. Placebo group will receive VLA2001 on day 208 and following second vaccination 28 days later.
41094874|NCT04864561|BIOLOGICAL|Placebo|2 vaccinations 28 days apart with placebo (PBS buffer based on Dulbecco's PBS media formulation without Calcium and Magnesium )
41094875|NCT02086708|DEVICE|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
41094876|NCT03693443|BEHAVIORAL|early childhood caries|a questionnaire evaluates the oral health beliefs, knowledge, and behaviors of a sample representing Egyptian mothers toward early childhood caries
41094877|NCT00694811|BEHAVIORAL|Re-feeding duration|1 or 6 weeks of re-feeding after VLED-induced weight loss
41094878|NCT03458897|DIAGNOSTIC_TEST|serial functional magnetic resonance imaging (MRI)|All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
41269746|NCT04755374|OTHER|Prolonged discharge|Discharged from palliative care unit in longer than 21 days
41269747|NCT00820326|DRUG|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
41442733|NCT01442155|BIOLOGICAL|Oxaliplatin|Administered according to the Summary of Product Characteristics.
41442734|NCT02517554|BEHAVIORAL|Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site|Baseline and follow up survey
41442735|NCT02517554|BEHAVIORAL|Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site|Baseline and follow up surveys
40744854|NCT01993758|PROCEDURE|Low tourniquet pressure|Tourniquet pressure set as 120mmHg above the systolic blood pressure just before tourniquet inflation
40744855|NCT01993758|PROCEDURE|Conventional tourniquet pressure|Tourniquet pressure set as 150mmHg above the systolic blood pressure just before tourniquet inflation
40744856|NCT04403282|DRUG|Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
40744857|NCT04403282|DRUG|Placebo Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
40744858|NCT02216409|DRUG|Hu5F9-G4|
40744859|NCT05146765|DEVICE|Mobile application|Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.
40744860|NCT05146765|OTHER|Treatment as usual|The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.
40744861|NCT00327132|DRUG|Omeprazole, Amoxicillin, Clarithromycin|
40744862|NCT05131464|DRUG|CM310|CM310, 300 mg/2 mL, SC, every 2 weeks
40744863|NCT00580398|BEHAVIORAL|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
41442736|NCT02517554|BEHAVIORAL|Patient receives written information on how to find genetic services in their area|Baseline and follow up surveys
40744864|NCT00580398|DRUG|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
40744865|NCT05594160|BEHAVIORAL|Psychotherapy|Patients treated at the inpatient psychotherapy unit of a University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers and physiotherapists.
40744866|NCT04831112|DRUG|Honey|Dressing of necrotizing fascitis wounds with honey.
40744867|NCT04831112|COMBINATION_PRODUCT|EUSOL|Dressing of necrotizing fascitis wounds with EUSOL.
40744868|NCT01019551|DRUG|ART Intensification|Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
40744869|NCT01019551|BIOLOGICAL|Immunomodulation|Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
40744870|NCT03888079|DRUG|Local anesthetic|1% or 2% lidocaine with 1:100,000 epinephrine, augmented by intravenous sedation and analgesia
40744871|NCT03888079|DRUG|general anesthetic|Endotracheal intubation, intravenous narcotic agents, and inhaled agents
40744872|NCT02140827|OTHER|IMP interactive education|The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
40744873|NCT03790969|DEVICE|26 gauge needle|smaller gauge needle
40744874|NCT03790969|DEVICE|23 gauge needle|control group
40744875|NCT06475378|DEVICE|Moonbird|Moondbird is a technology-supported breathing exercise with a tactile breath pacer device
40744876|NCT06475378|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.
40744877|NCT03274661|DRUG|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
40744878|NCT01341041|BIOLOGICAL|chlorine dioxide|one time wash with 50ppm CD solution
40744879|NCT01341041|BIOLOGICAL|saline|one time wash with 50-100 cc normal saline
40744880|NCT04002271|DRUG|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Level of anaesthesia will be titrated to produce a BIS value of between 40-60. For induction, remifentanil 1mcg/kg and rocuronium 0.6 mg/kg will be given intravenously prior to intubation. Sevoflurane will not be given. Air and oxygen will be given, and FiO2 will be kept at between 35-50%. Similarly, to the GAS group, remifentanil will be infused at a rate of between 0.1-0.2mcg/kg/min and titrated according to the haemodynamic parameters stated for the GAS group. Morphine sulphate will be given at a dose of 0.1mg/kg before skin incision. TCI propofol and remifentanil will be switched off at the end of the procedure. Reversal of muscle relaxation will be achieved as for the GAS group.
40744881|NCT04002271|DRUG|Sevoflurane|Patients in the GAS group will be induced with intravenous bolus propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6mg/kg for induction of general anaesthesia and intubation of patient. General anesthesia monitoring will be used. Maintenance of general anesthesia to be provided using sevoflurane, together with air and oxygen. FiO2 will be maintained between 35-50%. Bispectral (BIS) monitoring will be applied and level of anaesthesia will be maintained at a BIS value of 40-60. Remifentanil infusion will be given at between 0.1-0.2mcg/kg/min, to be titrated to maintain mean arterial blood pressure within 20% of baseline (blood pressure in ward before surgery as baseline) and heart rate between 45 to 100 bpm. Morphine sulphate to be given at a dose of 0.1mg/kg before skin incision. Sevoflurane and remifentanil infusion will be switched off at the end. Reversal of muscle relaxation to be achieved using intravenous neostigmine 50mcg/kg and atropine 20mcg/kg after the operation.
40922291|NCT03268421|BEHAVIORAL|Graded Aerobic Exercise|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
41442737|NCT04737707|OTHER|Dialectical Behavior Therapy (DBT)|Dialectical Behavior Therapy (DBT)
41442738|NCT03214952|DRUG|Vonoprazan|Vonoprazan tablets
41442739|NCT06426290|BEHAVIORAL|post-surgery psychological evaluation|"Following questionnaires will be done :~Patient Health Questionnaire (PHQ-9) Generalized Anxiety Disorder (GAD-7) Three Factor Eating Questionnaire (TFEQ-R21) Quality of life for obesity and dietetic questionnaire (EQVOD) Body Esteem Scale (BES) Figure Rating Scale (auto-questionnaire)"
41269748|NCT00820326|DRUG|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
41269749|NCT00299988|DRUG|Intravenous Immunoglobulin|
41269750|NCT00299988|OTHER|Placebo|
41269751|NCT03885778|DRUG|Besifovir dipivoxil|150mg Besifovir dipivoxil, single dose, oral
41269752|NCT03935516|OTHER|Cast|The use of plaster and/or fiberglass for casting of subject arm.
41269753|NCT02643095|DEVICE|scleral contact lens|Scleral contact lens
41269754|NCT04005794|BEHAVIORAL|VR social skills training|Social skills game that we developed in the R21 phase will be used across 10 sessions of training in the lab. Each session is about 1 hour long. Participants come to the lab twice a week for 5 weeks.
41269755|NCT04005794|BEHAVIORAL|Cognitive training|Commercially available cognitive training program will be used to control for the time spent in the lab and associated social interactions as well as the total exposure to computerized games.
41269756|NCT00814385|BIOLOGICAL|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
41269757|NCT00814385|BIOLOGICAL|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
41269758|NCT00814385|BIOLOGICAL|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
41269759|NCT00814385|BIOLOGICAL|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
41269760|NCT00814385|BIOLOGICAL|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
41269761|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
41269762|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
41269763|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
41269764|NCT00814385|BIOLOGICAL|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
41269765|NCT06549075|OTHER|Therapeutic support|The modular intervention consists of three modules, including Dignity Therapy, CALM Therapy and Mindfulness-based training. According to the patient's preferences, the patient will be allocated to one of the three interventions, which will be conducted by trained therapists within two sessions.
40744882|NCT04002271|PROCEDURE|Spinal anaesthesia|Patients in the SA group will receive intrathecal (L4-5, or L3-4 if failed at L4-5) administration of 2.2-2.4ml 0.5% heavy bupivicaine using a 25G Whitacare needle. No intrathecal opioid will be given during the procedure. Light sedation will be given during surgery with target-controlled infusion of propofol using the Marsh effect site model (0.3 -1 mcg/ml). Supplemental oxygen 2L/min will be given via the nasal cannula.
40744883|NCT01424852|DIETARY_SUPPLEMENT|Probiotics in infant milk formula|Probiotic infgant milk formula administered during the forst year of life
40744884|NCT04656665|DRUG|Aspirin|For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy
41094879|NCT06231628|PROCEDURE|Percutaneous cementoplasty|"Percutaneous image guided cementoplasty will be performed as follows:~Low-viscosity radiopaque bone cement will be quickly mixed and transferred to 1-ml syringes to reduce injection resistance. Injection will be initiated 2-4 min after mixing. When the resistance to cement injection becomes high in the beginning, the cement will be pushed in with a stylet, and it will go well afterward. As much bone cement as possible will be injected while avoiding leakage into the hip joint, sciatic notch, or veins under fluoroscopic monitoring. When significant cement leakage occurred at the initial stage, cement injection will be performed via another route or will be stopped and resumed when the cement viscosity increased. The cement will begin to harden after 8 min, and the operator, therefore, will aim to complete the delivery of the injection within 10 min. The injection needles must be removed before the cement hardens completely"
41094880|NCT06132321|BEHAVIORAL|Quality of life questionnaires|Detecting by mean of questionnaires quality of life, urinary function, pain, sexual function and lymphedema status before and after surgery for vulvar cancer, associated or not to vulvar reconstruction
41094881|NCT01819415|DIETARY_SUPPLEMENT|Anti-VEGF plus AREDS-2|Omega-3 metabolites supplementation
41094882|NCT01819415|DIETARY_SUPPLEMENT|Anti-VEGF plus AREDS-1|Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
41094883|NCT00917254|DRUG|YM150|oral
41094884|NCT00917254|DRUG|Placebo|oral
41269766|NCT06549075|OTHER|Standard Specialized Palliative Consultation Service|According to needs standard specialized palliative care will include support of symptom control, shared decision making/ advance care planning, network planning and support of relatives.
41269767|NCT02303925|DEVICE|NESTER COILS|
41269768|NCT00456690|OTHER|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
41269769|NCT05722964|DRUG|SHR-1906|Intravenous injection
41269770|NCT05722964|DRUG|SHR-1906|Intravenous injection
41269771|NCT05722964|DRUG|Placebo|Placebo，Intravenous injection
41269772|NCT06096025|DRUG|pneumoniae bacteremia therapy|To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.
41269773|NCT06376721|DRUG|Linperlisib|Linperlisib: Phase Ib, oral, 80 mg/d, QD; Phase II, oral, RP2D, QD.
41442740|NCT06560593|DRUG|NTQ5082|single ascending dose, randomized, double-blind study，with 8 dose groups preset. The first cohort will be the sentinel group, consisted of 2 subjects receiving NTQ5082 capsules. The remaining cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
40744885|NCT04841174|OTHER|Abdominal massage|The effect on gastric problems by applying abdominal massage to eligible participants in the study will be examined.
40744886|NCT01060176|DRUG|Tranexamic Acid|
41094885|NCT00917254|DRUG|Enoxaparin|injection
41094886|NCT02358187|BIOLOGICAL|Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
41094887|NCT02518893|OTHER|Demographic Data|Demographic data will be collected from up to 50 service members who have participated in health research or who have previously declined research participation.
41094888|NCT02518893|OTHER|Interview|Up to 40 service members will participate in individual, in-depth, semi-structured interviews in person or via telephone.
41094889|NCT04701502|DIETARY_SUPPLEMENT|Viusid|"Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days"
41094890|NCT04701502|DIETARY_SUPPLEMENT|Asbrip|"Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days"
41094891|NCT04701502|DRUG|Standard Care|Standard care for COVID-19
40744887|NCT01060176|DRUG|Saline Solution|
40744888|NCT00985374|DRUG|RAD001|5mg or 10mg po daily
40744889|NCT00985374|DRUG|RG1507|16mg/kg iv every 3 weeks
40744890|NCT02762604|BEHAVIORAL|Imagined Gait Intervention|Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
40744891|NCT02762604|BEHAVIORAL|Visual Imagery Intervention|Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
40744892|NCT03528850|OTHER|Telemedicine evaluation|Weekly virtual visits and daily biometric readings of blood pressure, weight, oxygen saturation and pulse
41094892|NCT00508690|DRUG|cefmetazole|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
41094893|NCT00508690|DRUG|kanamycin/metronidazole|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
41094894|NCT04942054|DRUG|Part 1|Dose escalation cohort
41094895|NCT04942054|DRUG|Part 2|Pharmacodyanamic (PD) dose exploration cohorts
41094896|NCT04942054|DRUG|Part 3|Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort
41094897|NCT00093795|DRUG|Cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles"
41094898|NCT00093795|DRUG|Docetaxel|75 mg/m2 IV every 21 days for 6 cycles
41094899|NCT00093795|DRUG|Gemcitabine|2000 mg/m2 IV every 14 days for 4 cycles
41094900|NCT00093795|DRUG|Paclitaxel|175 mg/m2 IV every 14 days for 4 cycles
41094901|NCT00093795|DRUG|Doxorubicin|"Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles"
41094902|NCT00477412|DRUG|Bortezomib|Given IV
41094903|NCT00477412|DRUG|Cyclophosphamide|Given IV
41094904|NCT00477412|DRUG|Cytarabine|Given IV
41094905|NCT00477412|DRUG|Dexamethasone|Given PO or IV
40744893|NCT03537456|DEVICE|mRDX-02-17|"mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5."
40744894|NCT00784875|DRUG|LY2624803|1 mg, oral capsule, once nightly before bedtime
40744895|NCT00784875|DRUG|LY2624803|3 mg, oral capsule, once nightly before bedtime
40744896|NCT00784875|DRUG|Placebo|matching placebo (capsule or tablet), once nightly before bedtime
40744897|NCT00784875|DRUG|zolpidem|5 or 10 mg, oral tablet, once nightly before bedtime
40744898|NCT03115970|PROCEDURE|capillary and venous lactate level measurement|capillary and venous lactate level measurement
41094906|NCT00477412|DRUG|Doxorubicin|Given IV
41094907|NCT00477412|DRUG|Methotrexate|Given IV
41094908|NCT00477412|BIOLOGICAL|Rituximab|Given IV
41094909|NCT00477412|DRUG|Vincristine|Given IV
41094910|NCT01275053|DRUG|leptin|0.01mg/kg
41094911|NCT04637763|GENETIC|CB-010|CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
41094912|NCT04637763|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
41094913|NCT04637763|DRUG|Fludarabine|Chemotherapy for lymphodepletion
41094914|NCT01066260|DIETARY_SUPPLEMENT|Probiotic formulation|Twice a day for 24 days
41094915|NCT01066260|OTHER|Placebo|Twice a day for 24 days
41094916|NCT05000775|DIETARY_SUPPLEMENT|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
41094917|NCT05000775|DIETARY_SUPPLEMENT|Placebo|Placebo
41094918|NCT04406779|DEVICE|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
41094919|NCT04181632|DEVICE|Buzzy Bee with Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used with an ice pack.
41094920|NCT04181632|DEVICE|Buzzy Bee without Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used without an ice pack.
41094921|NCT04181632|DEVICE|Shot Blocker|Shot Blocker is a device that instantly alleviates the pain and anxiety of needle injections when pressed firmly against the skin at the injection site.
41094922|NCT03867864|DEVICE|Necklace with essential oil for the first 4 weeks|The necklaces contain essential oil.
41094923|NCT03867864|DEVICE|Necklace without essential oil for the first 4 weeks|The necklaces do not contain essential oil.
41094924|NCT03867864|OTHER|Washout|Washout (do not wear the necklace) for one week for two groups, then two groups cross-over.
41094925|NCT03867864|DEVICE|Necklace with essential oil for last 4 weeks|The necklaces contain essential oil.
41094926|NCT03867864|DEVICE|Necklace without essential oil for last 4 weeks|The necklaces do not contain essential oil.
41094927|NCT05283369|DEVICE|Videogame therapy|The usual dose of conventional physical therapy, plus 300 minutes a week of in-home videogame therapy for 8 weeks.
41094928|NCT05283369|OTHER|Conventional therapy|The usual dose of physical and occupational therapy, for 8 weeks.
41094929|NCT03323840|OTHER|Incentivized Care|Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
41094930|NCT05924893|DRUG|Naltrexone Hydrochloride|naltrexone film
41094931|NCT05924893|DRUG|Carboxy methyl cellulose|Carboxy methyl cellulose drops
41094932|NCT04138628|DRUG|Atezolizumab|The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
41094933|NCT04785183|DIETARY_SUPPLEMENT|Melatonin drops|Melatonin oral administration
41094934|NCT04785183|OTHER|Placebo|Oral 5% glucose
41094935|NCT01049139|BEHAVIORAL|1-sided messages|Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
40744899|NCT03489525|BIOLOGICAL|Dose Escalation, MEDI2228, ADC (antibody drug conjugate)|Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels
40744900|NCT03489525|BIOLOGICAL|Dose Expansion, MEDI2228, ADC (antibody drug conjugate)|Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
40744901|NCT06519149|DEVICE|Slow Wave UASD|An oral appliance for the treatment of OSA and snoring
40744902|NCT06477588|BEHAVIORAL|Health Navigation|Participants meet with Health Navigator twice in-person and receive 7 check-ins from the Health Navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services
41094936|NCT01049139|BEHAVIORAL|2-sided messages|Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
41094937|NCT01301664|OTHER|total knee / hip replacement|Human cartilage tissues were harvested from osteoarthritic patient during total knee arthroplasty surgery.
41094938|NCT06393400|DRUG|Fecal Microbiota Transplantation|"Fecal Microbiota Transplantation with 100 g of healthy donor stool in 36-40 oral capsules once~Other Names:~* FMT~* Stool Transplant~* Poop Transplant"
41094939|NCT06393400|DRUG|PEG3350|"Polyethylene Glycol 3350 17 g oral dissolved in 4 litres of water consumed the evening before FMT.~Other Names:~* PEG3350~* RestoraLAX~* MiraLAX"
41094940|NCT06393400|DRUG|Gemcitabine|"Gemcitabine 1000 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~- Gemzar"
41094941|NCT06393400|DRUG|nab-Paclitaxel|"nab-Paclitaxel 125 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~- Abraxane"
41094942|NCT03465111|DRUG|ACTH (adrenocorticotropic hormone) gel|The dose of H.P. Acthar Gel is 80 Units administered subcutaneously
41094943|NCT01049620|DRUG|RAD001, Capecitabine, Oxaliplatin|"Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21"
41094944|NCT00369135|PROCEDURE|combined intervention|
41094945|NCT02379364|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
41094946|NCT04268264|PROCEDURE|Incremental haemodialysis|twice weekly haemodilysis at the start, gradually building up to full dose dialysis over a period of 15 weeks
41094947|NCT04268264|PROCEDURE|Conventional haemodialysis|three times weekly 4-hour long haemodialysis sessions from the start
41094948|NCT05181306|PROCEDURE|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
41269774|NCT06376721|DRUG|Camrelizumab|Camrelizumab for Injection: 200 mg/d, intravenous drip for 30 min (not less than 20 min and not more than 60 min), administered on day 1 of each cycle, observed for 2 hours after infusion. Every 3 weeks is a dosing cycle. Cycle 2 and subsequent cycles of dosing may be administered up to 5 days before or after the day of the scheduled dosing; more than 3 days after the date of the scheduled dosing will be considered a delayed dosing.
40744903|NCT06477588|BEHAVIORAL|Health Navigation, Employment Navigation plus Contingency Management Intervention|Participants meet with health navigator twice in-person and receive 7 check-ins from the health navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services. Participants meeting with the employment navigator twice in-person and receive 10 check-ins from the employment navigator over 12 months. The employment navigator provides participants with referrals to employment and career development opportunities in the community and up to $200 for employment and career development support (e.g., transportation to interview, GED preparation course). Participants also receive up to $140 for HIV/STI care, treatment, and prevention milestones as part of the contingency management interview over a period of 12 months.
40744904|NCT01676350|PROCEDURE|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
40744905|NCT04055493|DRUG|Ribociclib 200Mg Oral Tablet|3 x 200 MG per os
40744906|NCT05134818|OTHER|observer tool|comparison of the efficacy of an observer tool to enhance learning of technical skills of CVC insertion in anesthesiology residents The resident will complete an observer tool each time another resident is observed to insert a CVC on the simulator.
40744907|NCT04607382|DRUG|LEP|LEP dosage up to the discretion of the treating gynecologists.
40744908|NCT04607382|DRUG|NSAIDs and/or Chinese medicine (CM)|Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
40744909|NCT05644509|BIOLOGICAL|Oncolytic Virus Injection（Revottack）+PD-1|Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor
40744910|NCT04622956|DRUG|Methotrexate Injectable Solution|"Phase 1:~* Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9\*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~* Level 0 \[Starting Dose\]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~* Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~* Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial"
40744911|NCT02196545|BEHAVIORAL|Exercise|
40744912|NCT05381870|BEHAVIORAL|Test Preparation-Reference preparation|Under fasting conditions, subjects randomly divided into TR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period.
40744913|NCT05381870|BEHAVIORAL|Reference preparation-Test Preparation|Under fasting conditions, subjects randomly divided into RT group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period.
40744914|NCT01253486|BEHAVIORAL|Disease-related Expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period.
40744915|NCT01253486|BEHAVIORAL|Active Comparator: Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
40744916|NCT01253486|BEHAVIORAL|Sham Comparator: Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
40744917|NCT03228407|PROCEDURE|Confocal endomicroscopy|Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.
40744918|NCT03228407|DIAGNOSTIC_TEST|Endoscopic biopsies|Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.
40744919|NCT03228407|DIAGNOSTIC_TEST|Mucosal impedance (MI)|MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.
40744920|NCT05067270|DRUG|Sodium Citrate|Administered SC infusion.
40744921|NCT05067270|DRUG|Treprostinil|Administered SC infusion.
40744922|NCT05067270|DRUG|Humalog diluent|Administered SC infusion.
40744923|NCT05067270|DRUG|Magnesium Chloride|Administered SC infusion.
40744924|NCT03899493|OTHER|Observation|Patients will be dispositioned to usual obstetric care which may include minimal intervention if spontaneous labor, induction of labor or augmentation of labor as indicated and dictated by the participants obstetrical provider. This study is observational only.
40744925|NCT02042001|DRUG|Immediate switch to TDF/FTC/RPV|
40744926|NCT02042001|DRUG|Switch to TDF/FTC/RPV after 24 weeks|Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV
40744927|NCT05415111|PROCEDURE|Subepithelial connective tissue|Study specific intervention is the placement of a soft tissue autogenous graft (SCTG) in addition to bone grafting of periimplantitis-affected implants.
40744928|NCT05415111|PROCEDURE|Volume stable Collagen Matrix|Study specific intervention is the placement of a soft tissue substitute (VCMX) in addition to bone grafting of periimplantitis-affected implants.
40744929|NCT05415111|PROCEDURE|No soft tissue augmentation|Study specific control intervention is the placement of a bone graft at periimplantitis-affected implants. No soft tissue grafts will be placed.
40744930|NCT05230927|OTHER|Multidisciplinary Rehabilitation|All patients admitted to an inpatient rehabilitation program will undergo medical history collection, physical, clinical, and functional examination, exercise testing, educational sessions, exercise training (cycle ergometer/treadmill, arm ergometer, breathing, and strength exercises where indicated, calisthenics exercises), psychological counseling, and metabolic evaluation with a personalized diet when needed.
40744931|NCT04652310|DEVICE|TFNA extended-short nail (235 mm)|The extended short version of the TFN-advanced proximal femoral nailing system (TFNA)
40744932|NCT04652310|DEVICE|TFNA long nail (260-480mm)|The long version of the TFN-advanced proximal femoral nailing system (TFNA)
41269775|NCT06376721|DRUG|Pegaspargase|"Pegaspargase: 2500 IU/m2, intramuscular injection, divided into three places, administered on the first day of each cycle, observed 2 hours after injection for the occurrence of anaphylactic reaction, if there is no anaphylactic reaction before giving other test drugs. Every 3 weeks as a dosing cycle.~Camrelizumab for Injection should not be applied on the same day as Dexamethasonee."
41269776|NCT06376721|DRUG|Dexamethasone|Dexamethasone, 20 mg/d, days 1-4. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.
41269777|NCT00826735|BEHAVIORAL|Guided imagery|A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
41269778|NCT05931783|PROCEDURE|skeletonized harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in skeletonized technique. Thereby, only the artery itself is harvested.
40744933|NCT00589368|BEHAVIORAL|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
40744934|NCT03126149|DRUG|PF-06667272|Single ascending dose of PF-06667272
40744935|NCT03126149|OTHER|Placebo|Single dose of placebo
40744936|NCT02000271|PROCEDURE|Vaginal packing|
40744937|NCT02000271|PROCEDURE|No vaginal packing|
40744938|NCT05644483|DRUG|Remimazolam|Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)
40744939|NCT05644483|DRUG|Propofol|Propofol: target controlled infusion: 2-3mcg/mL
40744940|NCT06005376|OTHER|Breakfast rolls consisting of wheat flour with and without a E304i/zinc additive|The participants were provided with two Breakfast rolls (a 40 g) a day during the intervention week. In addition, they were provided with gluten-free foods during the whole trial.
40744941|NCT02534961|DRUG|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
40744942|NCT00918450|DRUG|ABT-263|"Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed"
40744943|NCT02852434|DRUG|Lidocaine Gel (2%)|
40744944|NCT02852434|DRUG|Lidocaine Paracervical Block (1%)|
40744945|NCT03909347|BEHAVIORAL|PLAN|The study intervention, PLAN is a multifaceted intervention led by trained CHW. It consists of two main components: dementia literacy education and phone counseling with navigation assistance through (1) 1-hour visit for dementia literacy education and (2)monthly counseling with navigation assistance
40744946|NCT03909347|BEHAVIORAL|Standard of Care|The investigators will refer control group participants to participants' primary physicians for follow-up and provide an Alzheimer's Association brochure about signs of dementia and dementia treatment, which is publicly available in Korean.
40744947|NCT05732545|BEHAVIORAL|enteral nutrition program for patients with abdominal hypertension guided by abdominal pressure|There are 4 aspects of intra-abdominal pressure monitoring, source control and treatment for the etiology of increased abdominal pressure, enteral nutrition program, enteral nutrition tolerance evaluation and treatment
40744948|NCT04713995|OTHER|Dietary recommendations|Dietary recommendations based on microbiome analysis of samples will be given and expected to receive and report in \~3 months survey after following recommendations.
40744949|NCT01901588|DRUG|Dexmedetomidine|intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
40744950|NCT01901588|OTHER|Placebo|intraoperative dose of intravenous placebo
40744951|NCT01044667|BEHAVIORAL|GI and Quality of Life Assessment|
41269779|NCT05931783|PROCEDURE|pedicled harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in pedicled technique. Thereby, the artery will be harvested together with the accompanying veins, the endothoracic fascia and fatty tissue in order to create an 1-2 cm broad pedicle.
41269780|NCT05311384|BEHAVIORAL|Keys Constraint-induced Movement Therapy protocol|All participants will receive the Keys CI Therapy protocol over an 8-week intervention period. Specific CI therapy strategies will be delivered, including: 1) supervised movement training will be carried out for 1 hour for 4 days/week for the first 4 weeks, 2 days/week for weeks 5 and 6, and 1 day/week for weeks 7 and 8; 2) participants will use the restraint mitt on their less-affected UE for most of their waking hours for an 8 week period; 3) transfer package methods will be modified to accommodate the longer time period between clinic visits; and 4) participants will be asked to independently perform additional movement training for 30 minutes each day at home.
40744952|NCT00926120|DIETARY_SUPPLEMENT|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
40744953|NCT00005790|OTHER|laboratory biomarker analysis|
40744954|NCT00005790|PROCEDURE|biopsy|
40744955|NCT00005790|PROCEDURE|magnetic resonance imaging|
40744956|NCT00005790|RADIATION|gadopentetate dimeglumine|
40744957|NCT01491165|PROCEDURE|stem cell transplantation through interventional procedures|one time interventional procedures
40744958|NCT04241731|DRUG|Raltitrexed|Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.
40744959|NCT04241731|DRUG|Cetuximab|Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.
40744960|NCT00249041|DRUG|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
40744961|NCT00249041|DRUG|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
40744962|NCT01122953|DRUG|Phenytoin|Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
40744963|NCT01122953|DRUG|Epamin|Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
40744964|NCT01090206|DIETARY_SUPPLEMENT|Vitamin D and calcium|Doses will be based on Vitamin D levels
40744965|NCT00502437|DRUG|GRANISETRON|
40744966|NCT05463770|DRUG|SEP-363856|SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
40744967|NCT01691313|DRUG|Vanoxerine|single oral dose
41269781|NCT04513483|DEVICE|continuous positive airway pressure|CPAP treatment at night. Treat AF as cardiologist's discretion.
41094949|NCT05181306|PROCEDURE|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
40744968|NCT01691313|DRUG|Placebo|single oral dose
40744969|NCT02988557|PROCEDURE|walking on a treadmill with a sloped surface|walking on a treadmill with a sloped surface
40744970|NCT02988557|DEVICE|treadmill|walking on a treadmill with a sloped surface
40744971|NCT03802357|PROCEDURE|Exercise training|Patients perform an exercise Training program of 3 weeks Duration including endurance Training, resistance Training and squat Training. This program is part of an inpatient pulmonary Rehabilitation.
40744972|NCT01346241|BEHAVIORAL|Intensive Panic Control Treatment (IPCT)|A manualized treatment that consists of psychoeducation about panic disorder
40744973|NCT01484366|PROCEDURE|intramedullary nailing and plating|Surgical intramedullary nailing of the ulna and plating of the radius
41094950|NCT02799056|DEVICE|Thoracic ultrasound|The ultrasound will be performed using the ultrasound system GE Logiq XP equipped with a linear probe of 10 MHz. The diaphragm is visualized as two parallel echogenic lines at the eighth intercostal space in the mid-axillary line. The images will be captured during the inspiratory and expiratory tidal volume to and during maximum inspiration and expiration. Each image will be frozen in B mode and the diaphragm thickness will be measured from the center line pleural half the peritoneal line. The fraction of diaphragmatic thickening it is calculated by the formula: diaphragmatic thickness at the end of inspiration - thickness to diaphragmatic at the end of exhalation / diaphragmatic thickness at the end of exhalation x 100. The number of areas with lines B also will be measured.
41094951|NCT02470104|DIETARY_SUPPLEMENT|Breastmilk|"* A registered dietician will supervise milk provision.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
41094952|NCT01601314|DRUG|Magnesium Sulfate|"At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started."
40744974|NCT01484366|PROCEDURE|plating|Surgical plating of both bonforearm fractures
41094953|NCT01601314|OTHER|Sodium Chloride|"At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started."
40744975|NCT06374290|DRUG|Naltrexone (Vivitrol)|At week 1 the Nurse Practitioner will administer extended-release naltrexone via intramuscular gluteal injection supplied as a standard single-use kit containing 380-mg vial of Vivitrol microspheres. Only one naltrexone injection will be administered over the course of the study
41094954|NCT06095310|BEHAVIORAL|New computer vision methods|Clinical interview: Hamilton scale using multi-modal sensors (cameras, audio, bracelet, fNIRS)
41094955|NCT05242458|DRUG|Ustekinumab|No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice.
40744976|NCT06374290|DRUG|Bupropion|Oral bupropion will be titrated to 450 mg over the course of 3 days. One week's supply of the study medication will be dispensed at each visit. Cell-phone assisted remote observation of medication adherence (CAROMA) will be used to assess compliance. Following Week 3, participants will be provided with enough pills to titrate the dose of bupropion over a period of 4 days. Therefore, participants will receive bupropion pills 3 weeks plus 4 additional days to titrate down the dose.
40744977|NCT06450561|OTHER|cardiovascular event|In this single group observational trial the exposure of interest is a cardiovascular event.
41094956|NCT00013026|BEHAVIORAL|CHF Self-management Education (Web-based Education)|
40744978|NCT00409760|DRUG|valsartan+amlodipine combination, valsartan, amlodipine|
40744979|NCT00769405|DRUG|fluorouracil|Given IV
40744980|NCT00769405|DRUG|leucovorin calcium|Given IV
40744981|NCT00769405|DRUG|oxaliplatin|Given during surgery
40744982|NCT00769405|PROCEDURE|hyperthermia treatment|Given intraperitoneally during surgery
40744983|NCT02846402|OTHER|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
40922292|NCT04735640|BEHAVIORAL|nurse-led teleconsultation|Patients assigned to this group will receive personalized dietary and physical activity advice during 9 months. Behavioural goals and action plans will be developed in a stepwise manner in accordance with baseline levels of nutritional and physical activity adherence to recommendations.
41094957|NCT03720340|DRUG|Recombinant Human Interleukin-11|Recombinant Human Interleukin-11 was administed through respiratory tract.
41094958|NCT03720340|DRUG|Saline|saline was administed through respiratory tract
41094959|NCT04848909|RADIATION|stereotactic body radiotherapy (SBRT)|Stereotactic body or external-beam radiation therapy (SBRT) is a method of delivery of radiation in precision manner to the prostate bed in this study. The SBRT dose prescription will be 3000 cGy in 5 fractions to the prostate bed and 2500 cGy in 5 fractions to the pelvic nodes if elective nodal irradiation (ENI) is used, delivered every other business day.
41269782|NCT04513483|DEVICE|Placebo|Observation. Treat AF as cardiologist's discretion.
40744984|NCT03684057|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
40744985|NCT02783859|DRUG|Amoxicillin-clavulanic Acid|
40744986|NCT02783859|DRUG|Placebo (for Amoxicillin-clavulanic Acid)|
40744987|NCT04085003|PROCEDURE|Endovascular repair or Open surgery|The outcomes of different types of repair will be obtained for intact and ruptured abdominal aortic aneurysm
41094960|NCT01501630|DEVICE|performance of PET/CT and whole-body MRI|For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
41287194|NCT04240743|DEVICE|cephalomedullary nail|For patients in the cephalomedullary nail group, an incision was made in the gluteal area from the tip of the greater trochanter in proximal orientation. A guidewire was placed into the medullary canal from slightly medial to the exact tip of the greater trochanter. The entry point of the greater trochanter and proximal medullary canal were reamed. The cephalomedullary nail was then inserted and fixed to the femoral head with a double screw. The cephalomedullary nail was then locked distally using a guide arm. These cephalomedullary nails were not locked proximally to maintain dynamization and to allow compression across the basicervical fracture line.
40744988|NCT01031615|BEHAVIORAL|Child and Family Traumatic Stress Interv (CFTSI)|4 sessions involving both the target child and a parent/caregiver
40744989|NCT01031615|BEHAVIORAL|Psychoeducational Comparison|4 individually focused sessions including psychoeducation and relaxation.
40744990|NCT00183898|DRUG|oxaliplatin, capecitabine|cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
40744991|NCT05592288|OTHER|PREDIABE-TR mobile app.|"* Module 1: Personal data Containing data on the participant's age, gender, telephone number, email and perception of his/her health (bad, so-so, good, very good).~* Module 2: Medical history of the participant In this module, the participants tick the items that apply to themselves or their first-degree relatives by marking the conditions in their medical history that may increase the risk of prediabetes. Additionally, in line with the recommendations of the Turkish Association of Endocrinology and Metabolism, this module contains the Finnish Diabetes Type-2 Risk Score (FINDRISK) which assesses an individual's risk of diabetes.~* Module 3: Healthy lifestyle behaviors The sub-sections of the module are devoted to nutrition, height-weight-body mass index (BMI) and physical activity."
40744992|NCT04828733|PROCEDURE|laparoscopic one anastomosis gastric bypass with excluded stomach fundoplication: FundoRingOAGB and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use FundoRing method.
40744993|NCT04828733|PROCEDURE|laparoscopic one anastomosis gastric bypass with excluded stomach Nissen fundoplication and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use the Nissen method.
40744994|NCT04828733|PROCEDURE|Standard laparoscopic one anastomosis gastric bypass with cruroplasty. Not used fundoplication.|Laparoscopic gastric bypass with only suture cruroplasty without fundoplication
40744995|NCT04393844|OTHER|turbo-ject PICC set|The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.
40744996|NCT05673850|DRUG|NET or NCT|In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
40744997|NCT02478502|DRUG|cabazitaxel|cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
40744998|NCT03537677|BEHAVIORAL|Reduction in Sedentary Behavior|This 12-week intervention targets a reduction in prolonged sitting and includes provision of a wrist-worn activity prompter and in-person group sessions with behavioral counseling.
40744999|NCT00298194|DRUG|Z-338|
40745000|NCT04779723|PROCEDURE|Comparison of two Techniques of bariatric surgery|We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB
40745001|NCT03888274|DEVICE|ClearUP Sinus Pain Relief|Microcurrent Device Treatment
41094961|NCT02506426|PROCEDURE|Endoscopic sinus surgery + Septoplasty|Opening of the paranasal sinuses along with correcting the nasal septum
41094962|NCT02506426|PROCEDURE|Septoplasty alone|Straightening of the nasal septum without opening the paranasal sinuses
41094963|NCT01394809|BEHAVIORAL|motor cognitive therapies|pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
40745002|NCT02879162|DRUG|Durvalumab|
40745003|NCT02879162|DRUG|Tremelimumab|
40745004|NCT05008770|OTHER|No intervention|No intervention
40745005|NCT04076137|OTHER|Targeted T-cell armed with bispecific antibody (Decitabine)|In this study, 10 patients eligible for the study were clinically screened for intravenous infusion of targeted activated T cells,every participant has a unique identification number and emergency letter which have the information of group.
40745006|NCT02478671|DEVICE|TR Band|The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
40745007|NCT03799120|DRUG|Tamsulosin BID|comparison of once daily versus twice daily tamsulosin
40745008|NCT03799120|OTHER|Placebo|Placebo
40745009|NCT06102941|DEVICE|Cognitive Control Training (CT)|4 weeks of an at-home computerized cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games with individually titrated difficulty to engage cognitive control processes.
40745010|NCT02553070|OTHER|Survey|Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
40745011|NCT05795335|DRUG|CDK4/6 inhibitor|CDK4/6 inhibitors
41094964|NCT06028048|BEHAVIORAL|PLACES|"The PLACES intervention is based on eight IPS principles, ensuring competitive employment, client choice, service integration, personalized benefits counseling, rapid job search, systematic development, and individualized support.~Coaches: Certified IPS coaches receive training from Phrenos IPS knowledge center and Re-turn. Ongoing support includes video lectures, clarifications with researchers, and biannual collective sessions. Coaches, regionally specialized, implement interventions autonomously.~Intervention Phases:~1. Intake and Assessment: Participants meet IPS coaches within three days to discuss goals, procedures, and responsibilities, continuing until objectives are met.~2. Acquisition and Application: Coaches assist job search and placement, aiming for employment within 30 days.~3. Placement and Support: Coaches offer personalized support, adapting to needs, scheduling meetings based on preferences.~The intervention ends at 12 months or when goals are achieved."
40745012|NCT00530075|DRUG|Gusperimus|SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
40745013|NCT00901498|DRUG|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
40745014|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
40745015|NCT00901498|DRUG|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
40745016|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
40745017|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
40745018|NCT01107015|DEVICE|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
40745019|NCT01107015|DEVICE|Patient-physician intervention|"Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed."
40745020|NCT01107015|DEVICE|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
40745021|NCT02587364|DRUG|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
40745022|NCT02587364|DRUG|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
40745023|NCT02587364|DRUG|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
40745024|NCT02587364|DRUG|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
40745025|NCT02587364|DRUG|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
40745026|NCT02587364|DRUG|Placebo|Placebo once daily (QD)
40745027|NCT06304571|DRUG|HC006|Specified dose on specified days
40922293|NCT04735640|BEHAVIORAL|SMS|Patients assigned to this group will receive a total of 150 text messages (4 to 5 messages per week during weekdays) throughout the intervention period (9 months). The content of the text messages includes advice on diet and exercise.
41094965|NCT04639206|BEHAVIORAL|HOBSCOTCH|HOBSCOTCH (Home Based Self-management and Cognitive Training Changes lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The HOBSCOTCH intervention consists of 8 weekly sessions conducted in-person, over the telephone, or via video-conferencing. A smart phone application will be used to collect data on seizure frequency, medication adherence, and patient engagement.
41094966|NCT01147770|DRUG|progesterone|duration
41094967|NCT02476643|OTHER|Integrative Therapy|This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
41094968|NCT02775981|DRUG|RX0041-002|
41442741|NCT06560593|DRUG|Placebo|multiple ascending dose, randomized, double-blind study，with 3 dose groups preset. All cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
40922294|NCT03348189|OTHER|Pulse Oximeter|Pulse Oximeter
40745028|NCT02826499|DEVICE|Pediguard|It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
40745029|NCT02826499|OTHER|Fluoroscopy|The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
40745030|NCT00597675|BIOLOGICAL|Peanut OIT|Defatted peanut flour ingested daily as oral mucosal immunotherapy
40745031|NCT00597675|BIOLOGICAL|Placebo|Oat flour matched by weight and consistency that is ingested daily as a placebo
41094969|NCT03390556|OTHER|Nurse-delivered education|"The nurse will:~1. Give the caregiver and child an overview of asthma, and discuss asthma control, triggers, and medications.~2. Give caregivers information about asthma management written at or below 6th grade reading levels.~3. Provide colored medication labels to distinguish controller from rescue medications following the action plan color scheme (green for controller medications, red for rescue medications). Teach-back methods will be used to elicit understanding of correct indications of use.~4. Demonstrate MDI/spacer technique with teach-back.~5. Discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility.~6. Ask patients to make a 1 month follow-up appointment for asthma care."
40745032|NCT01264471|PROCEDURE|Skin biopsy|A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
40745033|NCT01264471|PROCEDURE|Blood Collection|Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
40745034|NCT01708837|DRUG|Propofol|Propofol infusion rate is titrated to maintain the target BIS values
41094970|NCT02889822|DRUG|Alprostadil Liposomes for Injection|"1. Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~2. Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
40745035|NCT05594199|BEHAVIORAL|Virtual Smoking Cessation Program|"This program consists of an e-learning smoking cessation education module and a tailored email messaging program.~The e-learning module addresses the potential health benefits to quitting smoking regarding surgery or recovering from a fracture. In addition, it provides information on getting support through the process of quitting smoking based on the individual's level of smoking dependence.~Email frequency and content will vary based on the participant's score and level of motivation. Information will include the risks associated with smoking before surgery or how quitting smoking can improve recovery from a fracture injury. Additional information includes the benefits of quitting smoking and developing coping strategies during a quit attempt. Motivational emails and references to free resources for additional smoking cessation support will also be provided."
40745036|NCT00005585|DRUG|cyclophosphamide|Given IV
40745037|NCT00005585|DRUG|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
40745038|NCT00005585|DRUG|daunorubicin hydrochloride|Given IV
40745039|NCT00005585|DRUG|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
40745040|NCT00005585|DRUG|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
40745041|NCT00005585|DRUG|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
40745042|NCT00005585|DRUG|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
40745043|NCT00005585|DRUG|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
40745044|NCT00005585|DRUG|thioguanine|Given orally
40745045|NCT00005585|DRUG|vincristine sulfate|Given IV
40745046|NCT05904366|DIAGNOSTIC_TEST|MR Spectroscopy (MRS)|MR Spectroscopy (MRS)
41094971|NCT04267094|DEVICE|Iterative reconstruction at reduced radiation dose|Evaluating Agatston coronary calcium score using reduced dose acquisitions reconstructed using iterative reconstruction
41094972|NCT06486779|OTHER|Ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
41094973|NCT05960162|DIAGNOSTIC_TEST|90K|Blood test
41287195|NCT04240743|DEVICE|sliding hip screw|For patients in the sliding hip screw group, a lateral incision was made over the lateral proximal aspect of the femur. Under fluoroscopic guidance, the lag screw was placed centrally in the femoral head over the guidewire. A side plate with three holes was then attached to the hip screw.
41287196|NCT05207267|DEVICE|driving pressure guided tidal volume|Volume control mode without spontaneous breathing, PEEP will be set according to best respiratory compliance method, and tidal volume (VT) will be set to reach three levels of driving pressure (High 14-15cmH2O, moderate 10-11 cmH2O, and low 7-8 cmH2O). Each level of VT was maintained 10 minutes in supine and/or prone position.
40745047|NCT05904366|DIAGNOSTIC_TEST|MR Elastography (MRE)|MR Elastography (MRE) with a device that induces shear waves in the body. This device is placed upon the abdomen of the subject and is hold in place by straps. The device will produce low-frequency vibrations (e.g. 30-60 Hz) which are not painful to the participant. A declaration of conformity and a safety document are provided in the study dossier.
40745048|NCT02999321|OTHER|aspartame|will be given 5mg aspartame or 15 mg aspartame
40745049|NCT02999321|OTHER|water|control group
40745050|NCT04067310|OTHER|Spray skin protector|Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.
40745051|NCT04067310|OTHER|moisturizer Dnativ Revita derm|Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
40745052|NCT03523351|RADIATION|Radiation Therapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
40745053|NCT03523351|DRUG|Systemic Therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
40745054|NCT00888849|PROCEDURE|Advant 55 Linear Cutter/Stapler|Advant 55 Linear Cutter/Stapler
40745055|NCT00888849|PROCEDURE|Suturing|Suturing
40745056|NCT00432120|DRUG|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
40745057|NCT01555931|DRUG|Levonorgestrel-releasing intrauterine system|Placement within 48 hours of delivery
40745058|NCT03017261|DEVICE|TSolution One®|Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
40745059|NCT02014454|DRUG|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group."
40745060|NCT01113957|DRUG|ABT-888|Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
40745061|NCT01113957|DRUG|pegylated liposomal doxorubicin|Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
40745062|NCT01113957|DRUG|temozolomide|Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
40745063|NCT05396300|BIOLOGICAL|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
40745064|NCT04899037|OTHER|No intervention|This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.
40745065|NCT02363660|BIOLOGICAL|GINI|
40745066|NCT03971526|OTHER|MRI images review|MR images were reviewed by one junior radiologist and one senior neuroradiologist, both blinded to clinical, therapeutic and follow-up data.
40745067|NCT05181657|BEHAVIORAL|COVID-19 education|This session will be completed within 45 minutes. The LinkUP intervention will be available in English and Spanish.
40745068|NCT00012246|BIOLOGICAL|carcinoembryonic antigen peptide 1-6D|
40745069|NCT00012246|BIOLOGICAL|incomplete Freund's adjuvant|
40745070|NCT00012246|BIOLOGICAL|sargramostim|
40745071|NCT04545697|OTHER|Medcorder|Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.
40745072|NCT01143012|OTHER|Group eczema education session|Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
40745073|NCT01143012|OTHER|Control group|The control group will not attend the group eczema education session.
40745074|NCT01967277|DEVICE|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
40745075|NCT01967277|DEVICE|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
40745076|NCT06023797|DRUG|Neoadjuvant immunochemotherapy|Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
40745077|NCT05797974|OTHER|MyChart enabled virtual weight loss coach|MyChart-enabled virtual coach utilized to aid in preoperative weight loss.
40745078|NCT05797974|OTHER|Standard preoperative weight loss tools|Participants will utilize current standard preoperative weight loss tools.
40745079|NCT05231967|OTHER|Cardioversion|In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
40745080|NCT06475976|DIAGNOSTIC_TEST|Chest computed tomography (CT) with angiography|A CT scan uses a doughnut-shaped machine to take x-rays in a circle around the body. CT scans help doctors learn about the structure of the lungs, heart, and blood vessels in the chest. A CT scan provides more information than regular x-rays. CT w/angiography - injection of intravenous contrast during the CT to image the blood vessels within the chest.
40745081|NCT06475976|DIAGNOSTIC_TEST|Bronchoscopy with bronchoalveolar lavage|During a bronchoscopy, a lung doctor inserts a small flexible camera into the breathing tube and main branches of the airways within the lungs. During the test, a small amount of sterile fluid is placed into the lung and then retrieved (lavage). This fluid is tested for evidence of infection.
40745082|NCT06475976|DIAGNOSTIC_TEST|Echocardiography|An echo uses sound waves to create computer pictures of the heart.
40745083|NCT06475976|DIAGNOSTIC_TEST|"24 hour esophageal pH (potential of hydrogen) - multichannel intraluminal impedance (MII) monitoring (reflux testing)"|24 hour pH/MII testing is used to measure gastroesophageal reflux. A small feeding tube like catheter is passed through the nose or mouth into the esophagus. The catheter is used to measure the frequency and acidity of reflux episodes during a 24 hour monitoring period.
40745084|NCT03854227|DRUG|PF-06939999 dose escalation|PF-06939999 orally at escalating doses on a continuous basis
40745085|NCT03854227|DRUG|PF-06939999 monotherapy|PF-06939999 at the recommended Phase 2 dose orally on a continuous basis
40745086|NCT03854227|DRUG|PF-06939999 in combination with docetaxel|PF-06939999 orally on a continuous basis in combination with docetaxel
40745087|NCT01015196|DRUG|Zavedos|
40745088|NCT01015196|DRUG|Cerubidine|
40745089|NCT05349123|BEHAVIORAL|Mindful Breathing|Subject will be expected to do 12 weeks of home-based rehabilitation, 6 days a week in their home. The proposed project explores the addition of a mindful breathing module, which involves daily guided breathing practice with feedback to encourage mindful breathing.
40745090|NCT05349123|BEHAVIORAL|Home-Based Pulmonary Rehabilitation|Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.
40745091|NCT01124474|OTHER|goal directed therapy|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV\>12%.
40745092|NCT02827968|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
41094974|NCT04417556|DIAGNOSTIC_TEST|Sleep measurement|Sleep measurement with polysomnography, actigraphy, and Thai-version Richards Campbell Sleep Questionnaire.
41094975|NCT03293264|BEHAVIORAL|Exercise training group|"Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .~Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome."
41094976|NCT01311648|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 25-50 IU/kg at least 2x/week for 6 months and at least 50 EDs, IV infusion; Extension study: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study), IV infusion. Exposure day (ED): An ED is a unit of time (1 day) in which replacement treatment of Hemophilia is given to a patient.
40745093|NCT03166176|DRUG|Vistusertib(AZD2014)|vistusertib(AZD2014) is selective inhibitor of mTOR kinases and inhibits signalling of both mTOR complexes, mTORC1 and mTORC2.
40745094|NCT01136915|DRUG|Iopamidol 370|one time administration for PCI
40745095|NCT01136915|DRUG|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
40745096|NCT02295449|DEVICE|biopsy sample performed after the SonoVue® injection|
40745097|NCT06210295|COMBINATION_PRODUCT|Laboratory investigtions|To study causes of anemia in SLE in our environment and causes of refractory type and its relation to bone marrow affection and different drugs used in SLE
40745098|NCT05150288|OTHER|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
40745099|NCT06294353|DEVICE|WELT-ED (CBT based DTx)|The product delivers Cognitive Behavioral Therapy for Eating Disorders (CBT-ED) through a software interface (iOS and Android), designed to engage patients in a structured and interactive manner. It operates by analyzing patterns in the patient's lifestyle and eating data, identifying problematic behaviors associated with their eating disorder. Based on this analysis, the software sets daily learning objectives aimed at fostering positive cognitive and behavioral habits. By providing tailored guidance and support, the product seeks to assist patients in making sustainable changes, ultimately contributing to the improvement of eating disorder symptoms. This approach combines the principles of CBT-ED with the convenience and accessibility of digital technology, offering a personalized therapeutic experience to support patients in their recovery.
40745100|NCT06294353|BEHAVIORAL|Standard Treatment|In the control group, from screening/baseline (Visit 1) to 8 weeks (Visit 5), counseling and support therapy will be conducted at all visits. Participants can continue taking SSRI medications and other antipsychotic drugs that they were already taking for the treatment of eating disorders during the trial period. However, the intake of any additional antipsychotic drugs, other than those already being taken (including SSRIs), is prohibited during the trial period.
40745101|NCT04645706|OTHER|Characteristics of innate T cells|functional and phenotypic characteristics of innate T cells
40745102|NCT02076841|DEVICE|interferon beta-1a|Administered as specified in the treatment arm
40745103|NCT02417181|OTHER|Care provided by Physician Assistants|Patients will receive care at the out-of-hours primary care service by a Physician Assistant instead of a General Practitioner (substitution of care from physicians to nurses).
40745104|NCT05574985|BIOLOGICAL|Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)|Injected one dose of research vaccine
40745105|NCT05574985|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero Cell)|Injected one dose of control vaccine
40745106|NCT04490707|DRUG|Azacitidine|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine
40745107|NCT04490707|DRUG|Lenalidomide|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Lenalidomide
40745108|NCT00243061|DRUG|cediranib maleate|Given orally
40745109|NCT06324240|BIOLOGICAL|Ipilimumab|Given IV
40745110|NCT06324240|BIOLOGICAL|Pembrolizumab|Given IV
40745111|NCT06324240|BIOLOGICAL|Vaccine Therapy|Given TMV vaccine ID
40745112|NCT05963230|OTHER|Ultrasound scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
40745113|NCT02709902|DRUG|Adapalene/BP gel, 0.3%/2.5%|Gel
41287197|NCT00474253|DRUG|Sugammadex|Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex
41287198|NCT00474253|DRUG|Succinylcholine|Single bolus IV dose of 1.0 mg/kg succinylcholine
40745114|NCT02709902|DRUG|EPIDUO® FORTE|Gel
40745115|NCT02709902|DRUG|Placebo|Gel
40922295|NCT03741478|DRUG|OLANZapine 2.5 MG|"Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:~1. Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2~2. Cognitive arm - 5mg on Day 0, 10mg on Day 1"
41287199|NCT00474253|DRUG|Rocuronium|Single bolus IV dose of 1.2 mg/kg rocuronium
40745116|NCT03517215|BEHAVIORAL|Enhanced CB-ASP|The education session will be a 1-hour on site presentation that will cover antimicrobial resistance, antimicrobial stewardship, an introduction to effective primary care interventions for reducing antibiotic prescribing, and a review of the clinic's baseline audit of antimicrobial prescribing for the prior year. E-Modules will be completed online and audit and feedback sessions will be held in person to give an overview of each clinic's prescribing numbers.
40745117|NCT03517215|BEHAVIORAL|Standard CB-ASP|A one hour introductory educational seminar will be offered to prescribers via a web-link. They will be provided with access to e-modules each month by email and sent their audit and feedback reports by email.
40745118|NCT04755725|DEVICE|Epidural catheter|epidural catheter inserted pre induction
40745119|NCT04755725|DEVICE|rectus sheath catheter|The surgeon will place one hand inside the abdomen and with the other hand inserted the Tuohy needle through the skin and fascia. The surgeon will feel when the needle tip is just superfacial to interface between the peritoneum and muscle layer and avoid penetration of inferior epigastric artery. The procedure will be repeated on the contralateral
40745120|NCT06091033|DIETARY_SUPPLEMENT|Fermented rice|1,000 mg of black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks
40745121|NCT06091033|DIETARY_SUPPLEMENT|placebo|1,000 mg of a placebo for 8 weeks
40745122|NCT01845857|BEHAVIORAL|Chronic Disease Self-Management Workshop|6 week, small group self-management workshop
40745123|NCT05130840|DIAGNOSTIC_TEST|MRI|MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks).
40745124|NCT05130840|DIAGNOSTIC_TEST|Lumbar puncture|LP at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA.
40745125|NCT04597450|DRUG|Lu AG06466|Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
40745126|NCT04597450|DRUG|Placebo|Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
40745127|NCT06470464|DRUG|Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)|The oral dose of thalidomide is 1.5-2.5mg/kg/d daily (maximum 28g). Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
40745128|NCT01718067|DEVICE|VAKÜM system|15 minutes, twice a day.
40745129|NCT01718067|OTHER|conventional manual ELTGOL technique|20 minutes twice a day
40745130|NCT00307255|DRUG|gemcitabine hydrochloride|1000 mg/m2 on days 1 and 8 of each 21 day cycle
40745131|NCT00307255|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|260 mg/m2 to 340 mg/m2 (dose will depend on when subject enters the study). Paclitaxel will be given on day 1 of each 21 day cycle (every 3 weeks)
40745132|NCT04691232|BIOLOGICAL|Regulatory T cells|Autologous, ex vivo expanded, regulatory T cells
40745133|NCT01762189|PROCEDURE|Phototherapy|The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
40745134|NCT05265676|DRUG|Enoxaparin Sodium (Venus Remedies Limited)|The test drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Venus Remedies Limited, India
40745135|NCT05265676|DRUG|Enoxaparin Sodium (Sanofi)|The reference drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Sanofi, Germany
40745136|NCT05183620|DEVICE|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and the outer thigh of the test subject to measure skin temperature during erection
40745137|NCT04370600|DRUG|beta hydroxybutyrate (BHB) ester|Ketone supplementation given 3x/day (60mL per dose, or 22g BHB)
40745138|NCT04370600|DRUG|Placebo|Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
40745139|NCT03630601|PROCEDURE|Photoacoustic Imaging|Undergo PAI
41287200|NCT06464406|BEHAVIORAL|Virtual Reality condition|Participants will watch a video on a virtual reality headset during the completion of the maximal cardiorespiratory exercise test.
40745140|NCT03334266|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
40745141|NCT03334266|OTHER|Injury Prevention Education (IPE)|The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
40745142|NCT03334266|OTHER|Optimized Standard Care (OSC)|OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
40745143|NCT05660980|DRUG|Once daily CAB tablet + RPV tablet|Tablet
40745144|NCT05660980|DRUG|Long acting CAB injectable + long acting RPV injectable|Injectable
40745145|NCT05660980|DRUG|Long acting CAB injectable + long acting RPV injectable|Injectable
40745146|NCT03073759|DEVICE|dTCS|Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
40745147|NCT03073759|DEVICE|Sham device|The device will administer a sham.
40745148|NCT03286504|BEHAVIORAL|FANMI - Cohort Care|FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
40745149|NCT06099379|DRUG|∆9-tetrahydrocannabinol|Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled
40745150|NCT02445560|DIETARY_SUPPLEMENT|Probiotic capsule and Fiber Sachet|"A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
40745151|NCT02445560|DIETARY_SUPPLEMENT|Probiotic capsule and Placebo sachet|"A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
40745152|NCT02445560|DIETARY_SUPPLEMENT|Placebo capsule and Fiber Sachet|"A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
40745153|NCT02445560|DIETARY_SUPPLEMENT|Placebo capsule and Placebo sachet|"A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
40745154|NCT00890162|DRUG|Epinephrine|
40745155|NCT00890162|DRUG|Omalizumab (Xolair)|
40745156|NCT00890162|DRUG|Placebos|
40745157|NCT02927483|DIETARY_SUPPLEMENT|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
40745158|NCT02927483|DIETARY_SUPPLEMENT|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
40745159|NCT02596672|BEHAVIORAL|The friendly walking group|A 12 week peer led walking group for adults and older adults (\> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
40745160|NCT05788965|DRUG|Semaglutide|glucagon-like peptide 1 (GLP-1) receptor agonist
40745161|NCT02122952|BIOLOGICAL|AVXS-101|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
40745162|NCT03052673|DRUG|Fentanyl|Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
40745163|NCT03052673|DRUG|ketamine|Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
41287201|NCT06464406|BEHAVIORAL|Control condition|Participants will complete the maximal cardiorespiratory exercise test under control conditions without video, music, or other distractions.
41287202|NCT04943211|DRUG|fluorodeoxyglucose (18F-FDG)|max 6 MGBq/kg, no more than 100
40745164|NCT04389138|OTHER|Physiotherapy Intervention|Physiotherapy intervention will include an assessment to identify individual areas that physiotherapy should target. Intervention will be based on the core areas recommended by the European Physiotherapy Guideline for Parkinson's Disease: physical capacity (muscle power, tone, joint range of movement, exercise tolerance and pain), transfers, manual dexterity, balance and gait. Posture is incorporated as part of these 5 core areas. The intervention will be delivered over 4 visits.
40745165|NCT01044199|BIOLOGICAL|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
40745166|NCT01044199|BIOLOGICAL|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
40745167|NCT04837170|DRUG|Conventional therapy + S (+)-Ketamine|Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction,maintenance or postoperative analgesia.
40922296|NCT03741478|DRUG|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.
41287203|NCT00942682|DRUG|Sorafenib|Taken orally twice daily
41287204|NCT00942682|DRUG|RAD001|Taken orally once daily in the morning
41442742|NCT06562309|OTHER|take feces and blood samples from patients|this study does not involve any intervention
41442743|NCT00447941|DRUG|SCA-136|
41453169|NCT04125186|DIAGNOSTIC_TEST|Testing of EpiNP baseline survey, bladder diary and a qualitative interview|This part briefly reviews the usability of the EpiNP survey and bladder diary. The feedback obtained after qualitative interview will be used to refine and finalize the instructions sent to the participants in the main part.
41453170|NCT04125186|OTHER|No other intervention|No other intervention
41269783|NCT04142645|DEVICE|OptiMEDs|"The OptiMEDs intervention is a multi-faceted intervention combining:~1. an ICT platform:~   * automatic and secure capture of individual prescribing information from the electronic medication administration records in the nursing home~  * a tool for structured nurse observations of side effects, derived from the existing Pharmanurse application (20) (used to list potential medication side effects, based on the individual medication chart of the nursing home residents) to support monitoring of medication safety by nurses.~  * an electronic decision support tool for the appraisal of potentially inappropriate medication (explicit criteria of misuse and underused of medication, based on existing lists of explicit criteria (PIMs)), use of medication with anticholinergic properties and medication inappropriate in view of the limited life expectancy.~2. a multidisciplinary medication review with the input of GPs, trained community-pharmacists and nurses."
40745168|NCT04837170|DRUG|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
40745169|NCT04061629|DEVICE|Cuffed ETT|Cuffed endotracheal tube.
40745170|NCT05467202|DRUG|CLL1 CAR-T|A single infusion of autologous CLL1 CAR-T cells administered intravenously
40745171|NCT03233685|BEHAVIORAL|Visual Training|The visual training will be performed 3 times a week for 40 minutes, at the end of warm up and before the technique training. The subjects will be performed a progression of exercise to improve their visual ability, their velocity of interpretation and transformation. The training will be performed with specific panels approved for visual training (S.V.T.A., Torino, Italy).
40745172|NCT03233685|BEHAVIORAL|Normal Training|Normal training routine
40745173|NCT03033628|DEVICE|injection using DentalVibe comfort system|giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
40745174|NCT03033628|DEVICE|traditional dental injection|giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
40745175|NCT02990962|DRUG|5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.
41269784|NCT02867397|DRUG|Teysuno (S1) in combination with epirubicin and oxaliplatin|
41453171|NCT03900039|DEVICE|Highly Cross Linked Polyethylene and oxidized zirconium femoral head|"Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads"
41453172|NCT00826241|DRUG|Temozolomide|Starting dose 125 mg/m\^2 daily by mouth on days 1-7 \& 15-21 of a 28 day cycle.
41453173|NCT00826241|DRUG|Lapatinib|Starting dose 1250 mg daily by mouth.
41453174|NCT02498938|GENETIC|SERPINA1 gene|2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
41453175|NCT03914105|PROCEDURE|Without music|"The starting condition will be without music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be no music for the duration."
41453176|NCT03914105|PROCEDURE|With music|"The starting condition will be with music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be music for the duration."
41453177|NCT00217503|BIOLOGICAL|bevacizumab|
41453178|NCT00217503|BIOLOGICAL|filgrastim|
41453179|NCT00217503|BIOLOGICAL|pegfilgrastim|
41453180|NCT00217503|DRUG|bortezomib|
41453181|NCT00217503|DRUG|cyclophosphamide|
41453182|NCT00217503|DRUG|doxorubicin hydrochloride|
41453183|NCT00217503|DRUG|etoposide|
41453184|NCT00217503|DRUG|ganciclovir|
41453185|NCT00217503|DRUG|valganciclovir|
41453186|NCT00217503|DRUG|zidovudine|
41453187|NCT04900623|DEVICE|NavDx HPV ctDNA Testing|Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.
41453188|NCT04900623|RADIATION|Radiotherapy|Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
41453189|NCT04900623|DRUG|Chemotherapy drug|"Chemotherapy and radiation therapy are both considered standard treatments~* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy."
41453190|NCT03209505|DEVICE|Acuvue Oasys|FDA approved contact lens, fit for daily wear
41453191|NCT03209505|DEVICE|Air Optix Night & Day Aqua|FDA approved contact lens, fit for daily wear
41453192|NCT05369039|DRUG|Roflumilust|A selective phosphodiesterase 4 Inhibitor
41453193|NCT05369039|DRUG|Prednisolone|Systemic corticosteroid
41453194|NCT05065619|BIOLOGICAL|MT-2766 High dose (3.75 µg)|Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
41453195|NCT05065619|DRUG|Placebo|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
41453196|NCT05065619|BIOLOGICAL|MT-2766 Low dose|Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
41453197|NCT03008941|BIOLOGICAL|FMT|Capsules with fecal microbiota from healthy donors
41453198|NCT03008941|OTHER|Placebo|Placebo capsules
41453199|NCT05203692|DRUG|DS-7011a|Intravenous or subcutaneous administration, single dose
41453200|NCT05203692|DRUG|Placebo|Intravenous or subcutaneous administration, single dose
41442744|NCT06429540|BIOLOGICAL|Partially Demineralized Dentin Block|"The extracted tooth will be dried using air, then ground and partially demineralized with the Tooth Transformer device following the manufacturer's protocol. Dentin particles will be obtained with dimensions of 400-800 μm. The partially demineralized dentin will then be prepared by cutting the Leukocyte-Platelet Rich Fibrin (L-PRF) membranes into small pieces and mixing them with the dentin particles. Liquid fibrinogen will be added to the homogeneous mixture. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming the dentin block. After that, the sockets will be carefully packed with the dentin block and it will be covered with L-PRF membrane. To ensure stability and prevent displacement, the wounds will be secured using non-resorbable sutures."
40745176|NCT02990962|DRUG|1cc 2% Xylocaine+4cc Triamcinolone (40mg)|Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
40745177|NCT00266812|DRUG|Temozolomide and radiotherapy|Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
40745178|NCT00266812|PROCEDURE|Whole brain radiotherapy|2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
40922297|NCT03741478|DRUG|Insulin Lispro 100 UNT/ML|"Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.~For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.~For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures."
40922298|NCT03741478|OTHER|Saline|Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.
40922299|NCT03209739|OTHER|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
40922300|NCT00960726|DRUG|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
40922301|NCT02453815|PROCEDURE|non-cardiac surgery|all surgical procedures except cardiac
40922302|NCT02453815|OTHER|arterial catheter|arterial catheter
40745179|NCT06315088|OTHER|Einkorn Diet|Analysis of the oral microbiota before (T0) and after (T2) introduction of einkorn into the diet by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
41442745|NCT06429540|BIOLOGICAL|Xenograft|In the control group using the Xenograft, the same extraction and socket debridement procedure will be performed. Following that, the extraction socket will be thoroughly filled with deproteinized bovine bone mineral, and a collagen membrane will be employed to cover the socket. The membrane will be shaped to extend 2-3 mm beyond the margins of the extraction socket and positioned just beneath the marginal mucosa. To ensure its stability, a cross-suture will be performed, securing the membrane in place.
40745180|NCT06315088|OTHER|Intermediate oral microbiota|Comparison of the number of total bacteria and pathogens of the interdental microbiota before (T0) and in interim analysis (T1) for evaluation of the minimum period of effectiveness, by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
40745181|NCT06315088|OTHER|Periodontal health status|Analysis of the periodontal and oral clinical parameters (plaque index, gingival index, interdental inflammation, pocket depth and loss of clinical attachment, salivary pH) before (T0) and after (T2) introduction of einkorn into the diet, by sampling and periodontal analysis of all of the participants' teeth
40745182|NCT06315088|OTHER|General health status|Analysis of general health indicators (body mass index, measurement of abdominal circumference, blood pressure, MOS SF-36 quality of life questionnaire and eating habits) before (T0) and after (T2) introduction of einkorn in the diet
40745183|NCT06321393|OTHER|7-week Core stabilization exercise with abdominal drawing-in maneuver technique|A 7-week core stabilization exercise with abdominal drawing-in maneuver technique consists of 2 stages, including the first stage (week 1-2) and the second stage (week 3-7) consisting of exercise program for 20-minute sessions with 3 sessions per week for 7 weeks. These exercise program will be provided to the participants via a weekly video call with the main researcher as a telerehabilitation program.
40745184|NCT00922389|PROCEDURE|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
40745185|NCT00922389|DRUG|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
40745186|NCT00922389|DRUG|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
40745187|NCT02673385|OTHER|Brazelton scale|
40745188|NCT02774083|BEHAVIORAL|Feuerstein Program|Mediated learning cognitive enhancement program
40745189|NCT02774083|BEHAVIORAL|Adler Program|Social and emotional group program
40745190|NCT01121926|DRUG|Trazodone HCl|"Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours."
40745191|NCT01121926|DRUG|Trazodone HCl|"Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours."
40745192|NCT06323993|PROCEDURE|Piezoelectric osteotomy|The piezoelectric technique, another window preparation procedure that does not use a round bur, was first introduced to LSFE in 2001 for its high accuracy of osteotomy and low rate of membrane perforation. Later studies demonstrated that the operation time, postoperative reactions, and perforation rate of this procedure are considered to be acceptable compared with rotary bur. Moreover, the piezoelectric technique allows for the lateral bone window to be cut and preserved relatively completely.
40745193|NCT02260622|DRUG|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
40745194|NCT02260622|DRUG|clopidogrel plus aspirin|Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
40745195|NCT04489056|GENETIC|Swabs for microbiome analysis|After informed consent, vaginal swabs will be collected during speculum examination from the lateral vaginal wall and posterior fornix vaginae using a sterile cotton swab combined with an epithelial brush. A rectal swab will be collected by insertion of a sterile swab into the anal sphincter. Intraoperative swabs of the placenta and uterine cavity will be collected during caesarean section under sterile conditions. Neonatal swabs (buccal mucosa and skin) will be collected directly after delivery and in the neonatal period. Stool samples will be taken from the meconium, defined as first stool of the infant and the stool of the newborn in the neonatal period.
40745196|NCT01324180|DRUG|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
40745197|NCT01324180|DRUG|Vincristine|1.5 mg/m\^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
40745198|NCT01324180|DRUG|Dexamethasone|"* 10 mg/m\^2/day divided BID~* Take dexamethasone by mouth days 2-15"
40745199|NCT01324180|DRUG|PEG-asparaginase|"* 2500 IU's/m\^2/day~* Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~* If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~* Patients will receive Erwinase® 25,000 IU/m\^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol."
40745200|NCT01324180|DRUG|Doxorubicin|60 mg/m\^2/day IV over 15 minutes on day 2
41442746|NCT03340376|DRUG|Atezolizumab|atezolizumab
41442747|NCT03340376|DRUG|Doxorubicin|Doxorubicin
41442748|NCT02191059|DRUG|Icotinib|
41442749|NCT02191059|DRUG|Docetaxel|
40745201|NCT01324180|DRUG|Intrathecal chemotherapy|"IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age."
40745202|NCT04595019|RADIATION|SBRT|Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
40745203|NCT00849472|DRUG|doxorubicin + cyclophosphamide|4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
40745204|NCT00849472|DRUG|paclitaxel + pazopanib|4 cycles of paclitaxel + pazopanib
40745205|NCT00849472|PROCEDURE|surgery|neoadjuvant surgery for breast cancer
40745206|NCT00849472|DRUG|pazopanib monotherapy|6 months of treatment with pazopanib monotherapy
40745207|NCT04075864|BEHAVIORAL|Behavioral Counseling and Exercise|exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation
40745208|NCT04534946|OTHER|This is not an intervention study|This is not an intervention study
40745209|NCT04038398|PROCEDURE|Non-invasive ventilation with different FiO2 settings|CPAP therapy applied with different order of FiO2 settings.
40745210|NCT01381510|DRUG|5-alpha Reductase Inhibitor (5ARI)|A 5ARI: Either dutasteride or finisteride
40745211|NCT03967327|DRUG|Buprenorphine transdermal patches|It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
40745212|NCT03967327|DRUG|Morphine Sulfate Sustained-Release Tablet|It will be administered orally twice (q12h) daily.
40745213|NCT01363440|DRUG|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
40745214|NCT01363440|PROCEDURE|Macular Laser Photocoagulation|Laser therapy
40745215|NCT03983668|DRUG|CMP-001|Immunostimulatory therapeutic agent
40745216|NCT03983668|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy
40745217|NCT00228852|DRUG|Busulfan, Fludarabine and ATG|
40745218|NCT03235414|DEVICE|MRI|Will receive a one time research MRI (MR elastography)
40745219|NCT03235414|DIAGNOSTIC_TEST|Blood draw|Will receive a one time blood draw to confirm healthy liver status
40745220|NCT05301777|DEVICE|Computed tomography|Computed tomography
40745221|NCT03657953|OTHER|surgical approach|
40745222|NCT04614779|DRUG|CN128 Tablets|Iron chelator, oral tablets
40745223|NCT02323334|DRUG|LY3202626|administered orally
41287205|NCT03163238|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
40745224|NCT02323334|DRUG|Placebo (Part A, B, C)|administered orally
40745225|NCT02323334|DRUG|Itraconazole|administered orally
40745226|NCT01580644|DRUG|GLPG0187 prodrug|
40745227|NCT01640561|BEHAVIORAL|MISC|The Mediational Interventions for Sensitizing Caregivers
40745228|NCT01640561|BEHAVIORAL|UCOBAC|This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by a non-governmental organization (NGO) operating in Uganda called Uganda Community Based Association for Child Welfare (UCOBAC) with support from UNICEF.
40745229|NCT00447278|DRUG|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
40745230|NCT00447278|DRUG|Other standard therapy for ADHD|Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
40745231|NCT01452217|DRUG|Secretin|Secretin 1 IU/kg over 3 min
40745232|NCT05880485|RADIATION|online adaptive radiotherapy|PTV with 5-10 margins covers CTV
40745234|NCT01150682|GENETIC|RNA analysis|
40745235|NCT01150682|GENETIC|reverse transcriptase-polymerase chain reaction|
40745236|NCT01150682|OTHER|enzyme-linked immunosorbent assay|
40745237|NCT01150682|OTHER|immunohistochemistry staining method|
40745238|NCT01150682|OTHER|laboratory biomarker analysis|
40745239|NCT03621670|BIOLOGICAL|Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)|Bexsero is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group.
40745240|NCT03621670|BIOLOGICAL|Prevnar13|Prevnar13 (PCV13) is to be administered intramuscularly on upper side of the left thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
40745241|NCT03621670|BIOLOGICAL|Pediarix|Pediarix (DTPa-HBV-IPV) is to be administered intramuscularly on lower side of the left thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
40745242|NCT03621670|BIOLOGICAL|Hiberix|Hiberix (Hib) is to be administered intramuscularly on lower side of the right thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
40745243|NCT03621670|BIOLOGICAL|Rotarix|Rotarix (HRV) is to be administered orally as a 2-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) to all subjects in the MenB+PCV group and Placebo+PCV group.
40745244|NCT03621670|BIOLOGICAL|M-M-R II|M-M-R II (MMR) is to be administered subcutaneously on upper side of the right arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
40745245|NCT03621670|BIOLOGICAL|Varivax|Varivax (VV) is to be administered subcutaneously on upper side of the left arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
40922303|NCT05843786|DRUG|Interferon gamma|Daily subcutaneous administration of Interferon gamma during 5 days
40745246|NCT03621670|BIOLOGICAL|Placebo (saline water)|Placebo is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the Placebo+PCV group.
40745247|NCT03621670|BIOLOGICAL|Prevnar 20|Prevnar 20 (PCV13) is to be administered intramuscularly as a booster dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.
40745248|NCT05188794|PROCEDURE|lateral tap block|In the axial plane on the midaxillary line between the subcostal margin and the iliac crest with a linear probe using a 12 cm insulated nerve block needle is advanced in planely from skin, external, and internal oblique muscles to the target of fascial plane between the internal oblique and the transversus abdominis muscles.
40745249|NCT05188794|PROCEDURE|posterior tap block|In the axial plane on the midaxillary line a linear probe using a 12 cm insulated nerve block needle is advanced posteriorly to the most posterior limit of the TAP between the internal oblique and transversus abdominis muscles.
40745250|NCT03255954|OTHER|Interpersonal Counseling for University Counseling Centers|Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
40922304|NCT05843786|DRUG|Placebo|Placebo during 5 days
40745251|NCT00078494|DRUG|EBV-LMP-2|
40745252|NCT04770974|OTHER|Biomarkers and proteomics|Biomolecular, proteomic, metabolomic and spectroscopy characterization of urothelial bladder neoplasia, on a 3D culture model (organoid) obtained from bladder tumor tissue
40745253|NCT01957800|BEHAVIORAL|Website|Website will have action planning with social interactions and support features for sharing, reusing, and recommending strategies for improving habits.
40745254|NCT01957800|BEHAVIORAL|Usual Care|Participants will record their weight and complete surveys online.
40745255|NCT05142059|DIAGNOSTIC_TEST|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A|The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.
40745256|NCT02315625|DRUG|Sunitinib|37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity
40745257|NCT02315625|DRUG|Everolimus|10 mg daily will continue until progression or unacceptable treatment-related toxicity
40745258|NCT00323544|DRUG|zidovudine and lamivudine (Combivir®)|
40745259|NCT00323544|DRUG|emtricitabine and tenofovir DF|
40745260|NCT04832061|OTHER|Respiratory supports|The respiratory supports used in this patient population included conventional oxygen therapy (COT) via nasal cannula or face mask, non-invasive ventilation (NIV), and invasive mechanical ventilation (IMV). NIV has three different methods, including high-flow nasal cannula (HFNC), bilevel positive airway pressure (BiPAP), and continuous positive airway pressure (CPAP).
40745261|NCT03073447|OTHER|Specific blood sample of women under 50 years with acute MI|The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
40745262|NCT05574049|DRUG|Tetrahydrocannabivarin|The subjects will take once daily oromucosal strip with intervention drug for 90 days.
40745263|NCT05574049|OTHER|Placebo|The subjects will take once daily oromucosal strip with no drug on it for 90 days
40745264|NCT00477022|DEVICE|Vasotrain-447|
40745265|NCT02751905|DRUG|BIIB074|Administered orally as specified in treatment arm
40745266|NCT01851512|DRUG|T-R (Test-Reference drug)|
40745267|NCT01851512|DRUG|R-T (Reference-Test drug)|
40745268|NCT01617967|DRUG|Patisiran|Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks \[Q3W\]: Day 0 and Day 21) and an alternative premedication regimen.
40745269|NCT02386579|PROCEDURE|Blood sample measurements|Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
40745270|NCT01290731|DRUG|TMC435|100-mg capsule once daily for 12 weeks
40922305|NCT02081885|PROCEDURE|Tricalcium Phosphate / Chitosan|
41094977|NCT01311648|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development, IV infusion; Extension study: For participants having reached at least 50 EDs in main study - Part B: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study), IV infusion. For participants who developed an inhibitor in main study - Part B: up to 200 IU/kg per day or 100 IU/kg twice a day at the discretion of the investigator and coordinating investigator until successful eradication of the inhibitor, or until failure, for up to18 months (treatment beyond 18 months required an agreement with the sponsor and coordinating investigator), IV infusion
40922306|NCT02081885|PROCEDURE|Autologous Graft|
40922307|NCT01830400|DRUG|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
40922308|NCT03982134|DRUG|PDR001|PDR001 is a humanized IgG4 antibody
40922309|NCT03982134|DRUG|Panobinostat|Panobinostat is a Histone deacetylase inhibitor (HDACi).
40922310|NCT00170690|DRUG|Treosulfan|Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc
40922311|NCT00170690|DRUG|Treosulfan|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
40745271|NCT01290731|DRUG|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
40745272|NCT01290731|DRUG|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
40745273|NCT02736812|BIOLOGICAL|French Lyophilized Plasma|"During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of FLYP"
40745274|NCT02736812|BIOLOGICAL|Normale Saline Solution|"During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of Normale Saline Solution"
40745275|NCT06293144|DRUG|Ciprofol|Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
40745276|NCT04663672|OTHER|Experimental Scent|Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
40745277|NCT04663672|OTHER|Control Scent|Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
40745278|NCT04663672|OTHER|No-Scent Control|Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
40745279|NCT04663672|BEHAVIORAL|In-Vivo Exposure|Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
40745280|NCT02145676|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
40745281|NCT02145676|DRUG|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
40745282|NCT00571090|PROCEDURE|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
40745283|NCT01873885|DRUG|Placebo Single IV (Intravenous) Infusion|0.9% Sodium Chloride - 30 minute IV infusion
40745284|NCT01873885|DRUG|Experimental: Single IV Infusion Vasomera (PB1046)|
40745285|NCT04981054|PROCEDURE|Cystocele repair|Repair of endopelvic fascia and anterior colporrhaphy
40745286|NCT01078428|OTHER|Topical silicone gel|Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
40745287|NCT01078428|OTHER|Vaseline|Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
40745288|NCT01554813|BIOLOGICAL|Influenza split vaccine of 15 μg HA|60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
40745289|NCT01554813|BIOLOGICAL|Influenza split vaccine of 15 μg HA|558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
40745290|NCT01554813|BIOLOGICAL|Influenza split vaccine|280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
40745291|NCT05315258|DRUG|Tebentafusp|Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
40922312|NCT03841084|DRUG|Oxygen|"Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit"
40745292|NCT00557102|BIOLOGICAL|cetuximab|
40745293|NCT00557102|BIOLOGICAL|filgrastim|
40745294|NCT00557102|DRUG|fluorouracil|
40745295|NCT00557102|DRUG|irinotecan hydrochloride|
41287206|NCT03163238|DRUG|Normal saline|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
40745296|NCT00557102|DRUG|leucovorin calcium|
40745297|NCT03051009|DRUG|Desmopressin ODT 25 μg|
40745298|NCT03051009|DRUG|Desmopressin ODT 50 μg|
40745299|NCT02890888|OTHER|hyperbaric oxygen treatment|Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
40745300|NCT02456558|DRUG|Intravenous deferiprone|In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
40745301|NCT02456558|DRUG|Placebo|In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
40745302|NCT01677065|DRUG|Oxycodone controlled-release test formulation|single dose administration of test formulation under fasted conditions
40745303|NCT01677065|DRUG|Immediate-release reference drug|single dose administration of reference drug under fasted conditions
40745304|NCT01937442|DRUG|Thalidomide Celgene™|200mg once daily and by mouth
40745305|NCT03435419|DIAGNOSTIC_TEST|LoopampTM Leishmania Detection Kit|LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection
40745306|NCT03435419|DIAGNOSTIC_TEST|CL DetectTM Rapid Test|CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection
40745307|NCT04049565|DIAGNOSTIC_TEST|Procalcitonin biomarker and CRP biomarker|collecting blood samples to measure serum CRP and Procalcitonin
40745308|NCT05935488|OTHER|EVOCs emulsion|Continuous breath sampling directly into SIFT-MS equipment. The instrument is equipped with a mouthpiece connected to the SIFT inlet where the subject blows in and the breath is analyzed in real-time
40745309|NCT00906581|BEHAVIORAL|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
40745310|NCT01509105|BIOLOGICAL|13-valent pneumococcal vaccine|0.5mL IM (Intramuscular administration) as per recommended schedule
40922313|NCT00178503|DRUG|Methylphenidate-extended release|Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
40745311|NCT05998239|OTHER|Bootle Boot Camp Home Exercise App - with Virtual Coach Botley|Bootle Boot Camp exercise sessions offered with movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the no feedback condition for a period of 4 weeks (4 sessions/week). Movement feedback will be guided by skeletal data captured by the 3D motion tracking camera and based on predefined movement acceptability criteria for each exercise. Feedback will take the form of visual markers, text/audio cues and rewards.
40745312|NCT05998239|OTHER|Bootle Boot Camp Home Exercise App - without Virtual Coach Botley|Bootle Boot Camp exercise sessions offered without movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the movement tracking feedback condition for a period of 4 weeks (4 sessions/week).
40745313|NCT03679884|DRUG|Daridorexant 10 mg|Daridorexant 10 mg film-coated tablets
40745314|NCT03679884|DRUG|Daridorexant 25 mg|Daridorexant 25 mg film-coated tablets
40745315|NCT03679884|DRUG|Daridorexant 50 mg|Daridorexant 50 mg film-coated tablets
40745316|NCT03679884|DRUG|Placebo|Matching placebo film-coated tablets
40745317|NCT00653757|DRUG|goserelin acetate|
40745318|NCT00653757|DRUG|leuprolide acetate|
40745319|NCT00653757|RADIATION|image-guided radiation therapy|
40745320|NCT00653757|RADIATION|intensity-modulated radiation therapy|
40745321|NCT02027194|DRUG|Cure-Allergic Rhinitis Syrup|Delivered one bottle for two weeks to the participants twice
40745322|NCT02027194|DRUG|Yu-ping-fung San|Delivered one bottle for 2-week usage to the participants twice
40745323|NCT02027194|DRUG|Placebo|Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
40745324|NCT02605239|DRUG|Bleaching teeth|bleaching teeth with carbamide peroxide 10% for 3 weeks
40745325|NCT00744835|PROCEDURE|Ablation procedure and/or cardioversion|Ablation Frontiers Cardiac Ablation System
40745326|NCT03655470|BEHAVIORAL|Safety Planning|Safety planning is an individual coping intervention to reduce suicidal risk in adolescents
40745327|NCT03655470|BEHAVIORAL|Standard care|Standard care entails sending an adolescent for an emergency evaluation for suicidal risk in an Emergency Department
40745328|NCT02492919|DEVICE|Medixair®|Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
41269785|NCT00430755|DEVICE|Computer-assisted history|"Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition \[history-taking\] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
41269786|NCT00430755|PROCEDURE|physician taken history|Convential history taking by physicians
40745329|NCT06389162|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation is a type of non-invasive brain stimulation that involves passing a weak current between two electrodes placed on the scalp.
40745330|NCT00331487|DRUG|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
41269787|NCT00430755|OTHER|Computer-assisted history taking|
41269788|NCT00631631|DRUG|Mifamurtide (L-MTP-PE)|Solution for intravenous infusion
41269789|NCT05288582|DEVICE|NovaTears|Over-the-counter eye drop
41269790|NCT05953636|DIETARY_SUPPLEMENT|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session)|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) given in group A (predialytic: 1 hour before the start of the session), in group B (intradialytic: 2 hours after the start of the session ), in group C (interdialytic: in non-dialysis days )
40745331|NCT00331487|DRUG|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
40745332|NCT02885675|OTHER|blood sampling|sample no more than 3ml
40745333|NCT03554109|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
40745334|NCT03554109|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
40745335|NCT03554109|DRUG|Aldoxorubicin HCl|albumin-binding prodrug of doxorubicin HCl
40745336|NCT03554109|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
40745337|NCT03554109|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
40745338|NCT03554109|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
40745339|NCT03554109|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
40745340|NCT03554109|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
40745341|NCT03554109|BIOLOGICAL|GI-6207|CEA yeast vaccine
40745342|NCT03554109|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
40745343|NCT03554109|DRUG|Avelumab|Avelumab
40745344|NCT03554109|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
40745345|NCT03554109|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\]
40745346|NCT03554109|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
40745347|NCT03554109|DRUG|Doxorubicin HCL|Doxorubicin HCL
40745348|NCT03554109|DRUG|paclitaxel|paclitaxel
40745349|NCT02803541|BEHAVIORAL|12 day mainstream summer camp experience|see arm description
40745350|NCT01413646|DIETARY_SUPPLEMENT|Walnut Supplementation|Eight weeks of walnut supplementation
40745351|NCT01413646|DIETARY_SUPPLEMENT|No walnut supplementation|Eight weeks without walnut supplementation
40745352|NCT04325347|OTHER|Virtual Reality application|Virtual Reality application with a VR goggle
40745353|NCT02810327|GENETIC|Genetic Sequencing|Sequencing of the SERPINA1 gene
40745354|NCT00489268|DEVICE|HALO Ablation System|"Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~\*\*\*\*\*\*Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose."
40745355|NCT05319405|DEVICE|Sana Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
40745356|NCT00141375|DRUG|Pregabalin|
40745357|NCT02537470|DRUG|Biphasic Remogliflozin Etabonate|Experimental Drug
40745358|NCT02537470|OTHER|Placebo|Placebo Comparator
40745359|NCT01641432|BEHAVIORAL|Tonic and Phasic Attention Training|"The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes."
40745360|NCT01641432|BEHAVIORAL|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
40745361|NCT05015023|BEHAVIORAL|Behavioral intervention|A cluster-randomized controlled trial will be conducted.
40745362|NCT05672069|PROCEDURE|Osteosynthesis|Foot pathologies
40745363|NCT05946772|DRUG|Cyclosporine A|2.5mg/kg body weight Cyclosporine A as an intravenous bolus
40745364|NCT05946772|DRUG|Placebo|The same amount of 0.9% sodium chloride (NaCl0.9%) will be applied in an indistinguishable package as an intravenous bolus
40745365|NCT03182712|DIETARY_SUPPLEMENT|n-3 PUFA Group|Participants received n-3 PUFA capsules (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
40745366|NCT03182712|DIETARY_SUPPLEMENT|Placebo Group|Participants received capsules containing 500 mg of gelatin.Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
40745367|NCT03042637|DRUG|Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
40745368|NCT02949453|BEHAVIORAL|Semi-directed interview performed by a social sciences researcher|"Two semi-directed interviews performed by social sciences researcher:~* first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~* second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour"
40745369|NCT05967910|OTHER|chronic psychological stress|Chronic psychological stress includes symptoms of anxiety and depression.
40745370|NCT04377386|DIETARY_SUPPLEMENT|1000 IU D vitamin|Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.
40745371|NCT04377386|DIETARY_SUPPLEMENT|200 IU D vitamin|Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.
40745372|NCT06216340|DRUG|Henagliflozin|10mg of Henagliflozin and diet-exercise therapy
40745373|NCT06216340|DRUG|Placebo|Placebo and diet-exercise therapy
41094978|NCT05066451|OTHER|%5 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
41287207|NCT00919022|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
40745374|NCT01993368|OTHER|flow cytometry|"These populations will be identified by different combinations of antibodies to identify:~* T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~* Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~* Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)"
40745375|NCT04215770|DRUG|inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day|Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness
40745376|NCT01481779|DRUG|Glargine|Administered by SC injection via a pen device.
40745377|NCT01481779|DRUG|LY2605541|Administered by SC injection with a pen device.
40745378|NCT01481779|DRUG|Insulin Lispro|Administered by SC injection with a pen device.
40745379|NCT00552162|PROCEDURE|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
40745380|NCT00552162|PROCEDURE|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
40745381|NCT06060886|DRUG|Aripiprazole|Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.
40745382|NCT06060886|DRUG|Paliperidone|Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
41269791|NCT04402047|OTHER|Electroacupuncture|We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.
41269792|NCT04402047|DRUG|Topical diclofenac sodium gel|The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
41269793|NCT05744427|DRUG|JSKN003|JSKN003 should be given on the first day of administration every 3 weeks by intravenous drip.
41269794|NCT06217393|DRUG|Itopride Hydrochloride 150 mg extended release tablets|"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"
41269795|NCT06217393|DRUG|Itopride Hydrochloride 50 mg film coated tablets|"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"
41269796|NCT02913313|DRUG|BMS-986207|Specified dose on specified days
41269797|NCT02913313|BIOLOGICAL|Nivolumab|Specified dose on specified days
41269798|NCT02913313|BIOLOGICAL|Ipilimumab|Specified dose on specified days
41269799|NCT02882256|OTHER|Video discharge instructions|Discharge instructions provided in video form
41269800|NCT03871894|OTHER|Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)|Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day
41269801|NCT03871894|OTHER|Standard and fixed nutritional intervention till patient in ICU|Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator
40745383|NCT01197235|DRUG|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
40745384|NCT01197235|DRUG|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
40745385|NCT05607758|BEHAVIORAL|StressProffen©™|An app-based program for stress management consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
40745386|NCT05664945|BEHAVIORAL|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 4-6 patients who exercise at home and communicate via tablet-camera.~Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks (primary endpoint).~Specific exercises are evidence-based; been used in several intervention studies on patients with COPD.~Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations.~The education sessions consist of dialogue, reflections around empowerment and better living with COPD.~Every fourth education session consists of 25 min Mindfulness exercises developed for COPD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
40745387|NCT05664945|BEHAVIORAL|home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle-endurance based exercise; 3-days/weekly for 10-weeks (primary endpoint).~Exercises are evidence-based; used in several intervention studies on patients with COPD and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of mindfulness exercises and educationbook.~The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to COPD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients' preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
41094979|NCT05066451|OTHER|%15 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
41094980|NCT04893798|COMBINATION_PRODUCT|Sayana Press|Sayana Press is a drug-device combination and is considered a medical product in the EU.
41094981|NCT01928511|DRUG|peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|
41094982|NCT01928511|DRUG|Nucleos(t)ide analogue therapy|
41269802|NCT06248957|COMBINATION_PRODUCT|Immunomodulation|Variable protocols for combined immunomodulatory therapies currently in use for different forms of immune dysregulation
41269803|NCT04600167|DRUG|Isoniazid and Rifapentine (INH-RPT)|Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
41094983|NCT03904719|DRUG|CM082 plus JS001|CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
41094984|NCT06323408|DIAGNOSTIC_TEST|Tissue, blood, cerebrospinal-spinal fluid|Processing, analysis
41094985|NCT00498537|DRUG|spironolactone|
41094986|NCT06466668|DIAGNOSTIC_TEST|Sleep study|All subjects will undergo a polysomnography at home
41442750|NCT05883215|OTHER|Pain catastrophizing scale|"The pain catastrophizing scale is a self-report questionnaire used to assess an individual's tendency to engage in catastrophic thinking when experiencing pain. It measures the extent to which a person magnifies, feels helpless, and feels unable to cope with pain. The scale typically consists of several items that ask individuals to rate the degree to which they experience specific thoughts or emotions related to pain catastrophizing, such as I worry all the time about whether the pain will end or I feel like I can't stand it anymore. Participants provide responses on a Likert scale indicating the intensity or frequency of their agreement with each statement. The scale helps researchers and healthcare professionals gain insights into an individual's cognitive and emotional responses to pain, which can have implications for pain management strategies and overall well-being."
41442751|NCT05883215|OTHER|Beck Anxiety Inventory|"Beck Anxiety Inventory (BAI), which is designed to measure the severity of anxiety symptoms in individuals. The BAI is a self-report questionnaire consisting of 21 items that assess various symptoms of anxiety, such as nervousness, fear, and physiological manifestations of anxiety. Participants rate the intensity of their symptoms over the past week on a scale ranging from 0 (not at all) to 3 (severely). The scores obtained on the BAI can help clinicians and researchers evaluate the presence and severity of anxiety symptoms, monitor changes over time, and guide treatment decisions. It is important to note that the BAI is not a diagnostic tool but rather a measure of self-reported anxiety symptoms."
41442752|NCT05883215|OTHER|Social Media Use Integration Scale|The Social Media Use Integration Scale (SMUIS) is a self-report measure that assesses the degree to which individuals integrate social media into their daily lives. It aims to capture the extent to which individuals incorporate social media use into various aspects of their routines, behaviors, and identity. The scale typically consists of items that assess factors such as the frequency and duration of social media use, the importance and impact of social media on personal relationships, the integration of social media into daily activities, and the emotional connection to social media.
41442753|NCT05883215|OTHER|Fibromyalgia Impact Questionnaire|"The Fibromyalgia Impact Questionnaire (FIQ) is a widely used self-report measure specifically designed to assess the impact of fibromyalgia on various aspects of a person's life. It is a multidimensional questionnaire that evaluates the physical functioning, social functioning, and overall well-being of individuals with fibromyalgia.~The FIQ typically consists of items that ask individuals to rate the impact of fibromyalgia on their ability to perform daily activities, such as work, household chores, and recreational activities. It also assesses the severity of fibromyalgia symptoms, including pain, fatigue, sleep disturbances, and cognitive difficulties. Additionally, the questionnaire may include items related to emotional well-being, social support, and overall quality of life."
41442754|NCT02917525|DIETARY_SUPPLEMENT|Vitamin K2|
41442755|NCT02917525|OTHER|Placebo|
41442756|NCT05007470|DRUG|VSL #3 112.5 Capsule|VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).
41442757|NCT05007470|OTHER|Placebo|100 mg sugar
41442758|NCT03536091|DIAGNOSTIC_TEST|Magnification endoscopy|All IBD patients will undergo magnification endoscopy with 136-fold optical magnification in conjunction with optical chromoendoscopy
41442759|NCT05167474|OTHER|breast milk smell|yenidoğanlara fototerapi tedavisi esnasında anne sütü kokusu uygulanmıştır.
41442760|NCT01419093|OTHER|5 A communication intervention|This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on \[feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
41442761|NCT03221530|BEHAVIORAL|Early Intervention for Suicide Risk Among Immigrant Youth|The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.
41442762|NCT03221530|BEHAVIORAL|Enhanced usual care|This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
41442763|NCT04567082|DIAGNOSTIC_TEST|Examination of saliva|Collection of saliva samples
41094987|NCT06466668|DIAGNOSTIC_TEST|stress-related biomarkers and microbiome composition will be assessed using saliva samples|stress and stress-related inflammatory biomarkers will be tested using saliva sample
41094988|NCT06466668|DIAGNOSTIC_TEST|Audiological tests|Pure tone audiometry, Uncomfortable Loudness Levels, Distortion-Product Otoacoustic Emissions, tablet test for hyperacusis, tablet test for hearing screening
41094989|NCT06206473|OTHER|mEEG assessment|mEEG assessment (V1) will be performed at the patient's bed within 72 hours of the diagnosis of delirium. The mEEG recording, which lasts approximately 2 hours, will be performed by one of the investigators with expertise in electrophysiological acquisition. This non-invasive assessment consists of placing an EEG net on the scalp of the participants and earphones through which the auditory stimuli will be delivered.
41269804|NCT04600167|DRUG|Placebo|Participants in the control group will receive placebo once weekly for 12 weeks
41094990|NCT00188240|DRUG|Pegasys; Copegus.|
41094991|NCT04002089|DRUG|Exparel Injectable Product|bupivacaine liposome injectable suspension
41094992|NCT04002089|DRUG|Bupivacaine|1.3%, 13.3 mg/mL
41094993|NCT04188288|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
41094994|NCT04188288|DEVICE|Control feedback|Participants provided with control type of feedback (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
41094995|NCT04188288|DEVICE|fMRI|fMRI will be used to assess brain activity
41094996|NCT02544282|DRUG|Levobupivacaine|Pecs II Block
41094997|NCT02544282|DRUG|NaCl 0.9%|Placebo Pecs II block
41094998|NCT02544282|DRUG|Sevoflurane|General Anesthesia
41094999|NCT02544282|DRUG|Propofol|General Anesthesia
41442764|NCT03173872|PROCEDURE|Reiki Protocol Hand Placement Procedures|Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
41442765|NCT06319976|OTHER|open chain exercises for rotator cuff muscles|open chain exercises for rotator cuff muscles, three times per week for six weeks.
41442766|NCT06319976|OTHER|Advices for postural correction|Advices for postural correction like neutral position of head and neck, aliening the shoulder and hip and using a foot stool to rest the feet.
41442767|NCT05349695|DEVICE|Spinal cord stimulation|Eligible patients will undergo a SCS trial period for three weeks (as legally defined by the reimbursement authorities). The leads can be placed both surgically of percutaneously with an external trial stimulator. Surgical implantation of an implanted pulse generator (IPG) is performed if the patient achieves at least 50% pain reduction and a reduced pain medication use (reimbursement requirements) during the trial period. Subsequently, the implanted devices are programmed to the optimal parameters in collaboration with a nurse specialized in SCS treatment. The patients are educated on the use of the patient programmer.
41442768|NCT04936581|PROCEDURE|Open Total Mesorectal Excision|Open approach for Total Mesorectal Excision
41442769|NCT04936581|PROCEDURE|Laparoscopic Total Mesorectal Excision|Laparoscopic approach for Total Mesorectal Excision
41442770|NCT04936581|PROCEDURE|Robotic Total Mesorectal Excision|Robotic approach for Total Mesorectal Excision
41442771|NCT04936581|PROCEDURE|Transanal Total Mesorectal Excision|Transanal approach for Total Mesorectal Excision
41442772|NCT01163435|DRUG|high dose dual therapy|rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
41442773|NCT01163435|DRUG|sequential therapy|rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
41442774|NCT01163435|DRUG|clarithromycin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
41442775|NCT01163435|DRUG|levofloxacin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
41442776|NCT02247791|PROCEDURE|Uncemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
41442777|NCT02247791|PROCEDURE|Cemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
41442778|NCT06563310|OTHER|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with real neurofeedback and answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
41442779|NCT06563310|OTHER|fMRI with Sham-NF|Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with neurofeedback that looks similar to real neurofeedback but does not reflect their true brain signal. Afterwards, they will answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
41442780|NCT02891980|BIOLOGICAL|Ad26 Zaire Ebola Vaccine|A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
41442781|NCT02891980|BIOLOGICAL|MVA Multi-Filo Ebola Vaccine|A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
41442782|NCT02486081|DEVICE|smart soccer ball|smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
41442783|NCT05760144|DRUG|DMPA|The participant will receive the contraceptive injectable, Depo-Provera at the enrollment visit and at 3, 6, 9, and 12 months. Participants will have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
41442784|NCT05760144|DRUG|Etonogestrel implant|The participant will receive the contraceptive implant, Nexplanon at the enrollment visits and have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
41095000|NCT02544282|DRUG|Sufentanil|General Anesthesia
41095001|NCT02544282|DRUG|Atracurium|General Anesthesia
41095002|NCT02544282|DRUG|Paracetamol|Pain Relief
41095003|NCT02544282|DRUG|Tramadol|Pain Relief
41095004|NCT02544282|DRUG|Piritramide|Pain Relief
41095005|NCT05612776|OTHER|HIIT|HIIT training will consist of performing high intensity intervals along with passive rests. The intensity of the exercise will be progressively increased and the rest time will be decreased. All participants will perform the same training according to the maximum heart rate reached in the Bruce test.
41095006|NCT05612776|OTHER|HRV|The intervention group will perform HRV-based training, measuring HRV every day before training in order to obtain HRV normality ranges for each participant. If the HRV value is within the normal range, the participant will perform a high intensity training but if the HRV value is below the normal range, the participant will perform a continuous training at low intensity as active rest.
41442785|NCT00561834|DRUG|ranibizumab|All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
40745388|NCT05664945|BEHAVIORAL|Control|"Receive usual care; medication, scheduled follow-up visit and possible phone contact with GP and the outpatient respiratory department.~Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.~If a patient changes his/her mind and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation)."
40745389|NCT04781465|DEVICE|Immersive Virtual Reality|"Dedicated virtual reality sessions.~* Duration 20 minutes per session.~* The virtual reality session will be supervised by a health professional trained in this tool after 1.5 hours of training by the team responsible for the equipment (use of the equipment, and use of the 20 minutes of VR). This supervising professional may be a doctor, an occupational therapist, a caregiver or any other health professional trained in the tool under this protocol.~* The exercises proposed will be standardized virtual reality exercises with the same exercises for all, but adapted to the level and abilities of each patient."
40745390|NCT03429205|OTHER|No external heating used during surgery|Deviation from external heating for all surgery standard
40745391|NCT03429205|OTHER|External heating blanket used during surgery|Standard external heating plan used in all surgery types
40745392|NCT02714738|PROCEDURE|Ultrasound guided peripheral nerve block|Ultrasound guided peripheral nerve block
41095007|NCT02078830|DEVICE|3M™ Tegaderm™ CHG I.V. Securement Dressing|Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.
41095008|NCT02078830|DEVICE|Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
40745393|NCT00471354|DRUG|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
40745394|NCT05084456|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
40745395|NCT03676829|DEVICE|Arterial Embolization of the Shoulder|Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
40745396|NCT05484947|DIAGNOSTIC_TEST|Elisa HIV testing|HIV testing on a voluntary basis
40745397|NCT06379126|DIAGNOSTIC_TEST|Test thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM）|Test TAT, PIC, tPAI·C and TM of blood of SIC patients.
40745398|NCT06532916|OTHER|Experimental: Group1: Estelite Sigma Quick|Preheated conventional composite (Estelite Sigma Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Sigma Quick is a resin composite with the following composition (Silica-zirconiasupra-nano, monodispersingc spherica, Bis-GMA, UDMA, TEGDMA).
41095009|NCT06107920|DRUG|Neoadjuvant chemotherapy|Diverting stoma- neoadjuvant chemotherapy - colectomy - +/- adjuvant chemotherapy
41095010|NCT04172987|DRUG|Tirzepatide|Administered SC
41095011|NCT04172987|DRUG|EE/NGM|Combination oral contraceptive administered orally
41095012|NCT03874975|DRUG|oral vitamin D|vitamin D and UVB versus UVB alone in psoriatic patients and evaluate patients by PASI score before and after treatment and measure serum vitamin D before and after treatment
41095013|NCT05491161|OTHER|Longitudinal study|Longitudinal study following infant development from birth to 1 year of age
40745399|NCT06532916|OTHER|Experimental: Group 2: Estelite Flow Quick|Second group: Injectable flowable (Estelite Flow Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Flow Quick is a resin composite with the following composition (Silica-zirconia, supra-nano monodispersing spherical, Bis-GMA, UDMA,TEGDMA).
40745400|NCT00139035|DRUG|cyclosporine A|
41095014|NCT02661646|DEVICE|Advanced Pneumatic Compression Device|Advanced Pneumatic Compression Device
41095015|NCT06099821|DRUG|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
40922314|NCT00178503|DRUG|Methylphenidate-immediate release|Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
40745401|NCT03016637|DEVICE|SharkCore (TM) FNB Exchange System|
40745402|NCT01365611|DRUG|Ketorolac tromethamine|A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
40745403|NCT01365611|DRUG|Fluticasone Propionate|Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
41095016|NCT06099821|DRUG|Regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
41095017|NCT06099821|DRUG|Apatinib|Apatinib is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. It has been also reported to have anti-tumor efficacy in other kinds of digestive system cancers.
41095018|NCT04488250|OTHER|Robot Therapy|Robot Therapy
41095019|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 placebo
41095020|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 200 mg
41095021|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 placebo
41095022|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 80/CoQ10 100 mg
41095023|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 100 mg
41442786|NCT03267381|OTHER|Blood draw (before surgery)|Blood will be drawn before surgery
41442787|NCT03267381|OTHER|Blood draw (every 3 months)|Blood will be drawn every 3 months
41442788|NCT03267381|OTHER|Blood draw (at diagnosis)|Blood will be drawn at time of diagnosis
41442789|NCT02269657|DEVICE|EOS® imaging system|The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
41442790|NCT01202734|DRUG|Methylphenidate HCl|Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
41442791|NCT05133180|DRUG|Oxervate|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
41442792|NCT05133180|OTHER|Vehicle|Vehicle will be instilled with the same scheme of the test product
41442793|NCT04890353|DRUG|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
41442794|NCT00938795|OTHER|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
41442795|NCT00938795|OTHER|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
41442796|NCT02651948|PROCEDURE|Transperineal, MRI-guided, prostate biopsy|
41442797|NCT02651948|PROCEDURE|Transrectal prostate biopsy (TRB):|
41442798|NCT00834535|DRUG|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose non-fasting
41442799|NCT00834535|DRUG|OMNICEF® Capsule 300 mg|1 x 300 mg, single-dose non-fasting
41442800|NCT04816461|DRUG|Amodiaquine Sulfadoxine-Pyrimethamin administration|SMC treatment
41442801|NCT04816461|DRUG|Dihydroartemisinin-Piperaquine|Roommates treatment if they are positive to malaria
41442802|NCT04816461|DIAGNOSTIC_TEST|Standard HRP2-RDT|Roommates screening with standard HRP2-RDT
41442803|NCT04816461|DIAGNOSTIC_TEST|Highly sensitive RDT|Roommates screening with highly sensitive RDT
40922315|NCT00178503|OTHER|Placebo|Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
40922316|NCT04678687|PROCEDURE|Liver, lung, heart and kidney biopsy|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
40922317|NCT00835731|DRUG|misoprostol|400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D\&E
41442804|NCT03556813|OTHER|survey|non-inferiority study, randomized, blind, excluding health product, with no risk or constraint, in which all the acts are performed in the usual way and do not modify the patient's management.
41442805|NCT05928156|OTHER|Myeloma Coach or CLL Coach Mobile App|"Symptom Tracking: Subjects will be asked to track their symptoms on a weekly basis, as well as given the opportunity to track these symptoms whenever they would like. Subjects will receive feedback tailored to their symptom severity with coaching on self management, including encouraging them to reach out to their health care team when symptoms are new, severe or increasing in severity. Subjects will also be able to look at graphs of symptom severity over time and share them with family and their health care team.~Medication Adherence Reminders and Tracking, Activities - tools based on CBT (cognitive behavioral therapy) principles can be utilized at any time to manage emotional distress. Learn - information on cancer, its treatment, self managing physical and emotional symptoms, and supportive resources."
41442806|NCT05928156|OTHER|Springboard Beyond Cancer informational website|Springboard Beyond Cancer (https://survivorship.cancer.gov) is designed to make it easy for those in treatment and post-treatment to access essential information to help them manage ongoing cancer-related symptoms, deal with stress, improve healthy behaviors, communicate better with healthcare teams, and seek support from friends and family.
41442807|NCT04405102|DRUG|Ozanimod|The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.
41442808|NCT04405102|OTHER|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
41442809|NCT05900648|DRUG|Regorafenib|Given by PO
41442810|NCT05900648|DRUG|XmAb20717|Given by (IV) vein
41442811|NCT02151981|DRUG|Chemotherapy|Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio
41442812|NCT02151981|DRUG|Cross-over to Osimertinib|"Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with Osimertinib 80mg, once daily. These subjects may continue treatment with Osimertinib even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.~Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to Osimertinib."
41442813|NCT04402151|DRUG|PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
41442814|NCT04402151|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive standard of care radiation therapy (SBRT)
41442815|NCT03494127|DEVICE|Use of GEL BALL FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
41442816|NCT03494127|DEVICE|Use of SQUISHINS FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
41442817|NCT00624286|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
41442818|NCT00624286|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
41442819|NCT00829530|DRUG|Ramipril 10 mg capsule|1 x 10 mg
41442820|NCT00829530|DRUG|Altace® 10 mg capsule|1 x 10 mg
41442821|NCT06560775|COMBINATION_PRODUCT|Standard Treatment for SLE|Standard Treatment for SLE
41442822|NCT04596670|DRUG|68Ga-ICAM-1pep|68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
41442823|NCT06562764|OTHER|Counselling by the Trained Pharmacist|The intervention group 1 is verbally counselled about the proper use of their inhaler devices.
41442824|NCT06562764|OTHER|Pictograms Cards and Counselling by the Trained Pharmacist|The investigator developed pictogram cards for the use of inhalers (MDI and DPI) and pictogram cards are attached to the inhalers of patients in the intervention group with counselling by the trained pharmacist.
41442825|NCT06252662|DRUG|Dexmedetomidine|block duration extension additive
41442826|NCT06252662|DRUG|Liposomal bupivacaine|Control arm, comparison for block duration with dexmedetomidine
41442827|NCT05464186|BEHAVIORAL|Whole milk|Weekly home delivery of whole milk, daily text messages, monthly virtual visits
41442828|NCT05464186|BEHAVIORAL|Nonfat milk|Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
41442829|NCT05795504|OTHER|resistive exercise|They will perform combined upper and lower resistive exercises, 30 min, 3 sessions / week for 12 weeks in addition to calcium and vitamin D supplements.
41442830|NCT05795504|OTHER|high intensity interval training|They will perform HIIT for three sessions/ week for 12 weeks, 30 minutes/ session in addition to calcium and vitamin D supplements.,
41442831|NCT05795504|DIETARY_SUPPLEMENT|calcium and vitamin D|they will receive calcium and vitamin D supplements only.
41442832|NCT05337540|DEVICE|EVI-01|Single intra-articular injection of high molecular weight hyaluronic acid
41442833|NCT05337540|DEVICE|Active comparator Synvisc-One|Single intra-articular injection of active comparator Synvisc-One
41442834|NCT06589414|OTHER|Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP)|"A summary consultation with the patient's general practitioner (GP) will take place within 15 days of the consultation to announce the cancer diagnosis. This patient-general practitioner consultation will complement the initial consultation.~At the end of the summary consultation, the patient's satisfaction and that of the GP will be assessed using satisfaction questionnaires.~In addition, patients will be asked to complete a patient diary for the duration of their participation in the study (6 months), in order to record the dates of consultations with the GP and the dates of consultations and/or hospitalisations at the referral care centre."
41442835|NCT06477354|DIETARY_SUPPLEMENT|ACEMg|Softgel capsules
41442836|NCT05963035|DRUG|18F-PFPN|For patients clinically suspected or confirmed clear cell sarcoma of soft tissue, integrated PET/MR or PET/CT imaging will be performed using targeted melanin-specific imaging agent 18F-PFPN. Meanwhile, multiple parameters will be compared with the general imaging agent 18F-FDG.
41442837|NCT04665596|DEVICE|Ultrasound treatment|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacemen
41442838|NCT05347719|BEHAVIORAL|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions involving training in mindfulness meditation and cognitive-behavioral methods. Sessions will be designed to increase participant awareness of internal reactions that trigger relapse in MDD and to provide participants with techniques to detach from dysfunctional cognitive processes and redirect their attention to experiences. Outside of the sessions, participants will be assigned daily homework exercises and provided with handouts and audio recordings of mindfulness exercises to use in their practice.
41442839|NCT04725747|DRUG|Midazolam/Ketamine HCl 3mg-50mg sublingual|Single sublingual administration of Midazolam/Ketamine HCl 3mg-50mg sublingually prior to surgery
41442840|NCT04725747|DRUG|Midazolam 3mg Sublingual|Single sublingual administration of Midazolam 3mg sublingually prior to surgery
41442841|NCT04725747|DRUG|Ketamine 50mg Sublingual|Single sublingual administration of Ketamine HCl 50mg sublingually prior to surgery
41442842|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
41442843|NCT02057835|DRUG|BI 691751 high dose|BI 691751 high dose
41442844|NCT02057835|DRUG|BI 691751 middle dose|BI 691751 middle dose
41095024|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 80 /CoQ10 200 mg
41095025|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 200 mg
41095026|NCT01125202|BEHAVIORAL|SCT-based behavioral intervention|Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
41095027|NCT01125202|BEHAVIORAL|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
41442845|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
41442846|NCT02057835|DRUG|BI 691751 low dose 1|BI 691751 low dose 1
41442847|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
41442848|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
41442849|NCT02057835|DRUG|BI 691751 low dose 2|BI 691751 low dose 2
41442850|NCT03362294|DRUG|GA Depot 40mg once monthly|Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)
41442851|NCT03362294|DRUG|GA Depot 25mg once monthly|Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)
41269805|NCT01646359|DEVICE|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
41442852|NCT06218394|PROCEDURE|microneedling|The microneedling technique (Electric microneedle, F6, China Bohui Meicui Bioengineering Technology Guangzhou Co., LTD.) performed in the targeted areas using a sterile micro needles stamp. In this study, the needle length was adjusted to 0.7\~1 mm according to the grade of hair loss and the degree of tolerance of the patient. Before microneedling treatment, the scalp was disinfected with 75% alcohol, and then 1 ml of nutritional dressing for the scalp was applied externally, and the microneedle pen was gently touched to the scalp vertically for pricking. Patients are instructed to refrain from shampooing, warm baths, and strenuous exercise for 8 hours after treatment. Each patient was treated by microneedling once every 2 weeks for a total of 12 treatments.
41442853|NCT06218394|PROCEDURE|Autologous Concentrated Growth Factor|"1. 27\~36ml of autologous venous blood is collected in a sterile Vacuette tube without anticoagulant solution, and centrifuged by Medifuge variable speed centrifuge (Silfradent company, Italy) for about 13min (accelerated for 30s; 2700 r/min, 2 min; 2400 r/min, 4min; 2700r/min, 4min; 3300r/min, 3 min; decelerated for 36s to stop). The lowest layer retains 2.5ml of CGF per 9ml of venous blood.~2. The scalp is cleaned, disinfected and anesthetized, CGF is extracted with a 2.5ml syringe, and the disposable sterile needle roller handle is slowly rolled in the hair loss area, and the CGF is applied to the corresponding scalp part for introduction treatment while rolling, and the force is uniform and stable, repeating back and forth several times, to the extent that the patient can tolerate and the skin in the treatment area is slightly red. The operation time is about 15\~20 minutes."
41442854|NCT06218394|DRUG|5% minoxidil|topical 5% minoxidil, 1 ml, once daily
41442855|NCT05133479|BEHAVIORAL|Let's Know! small-group or TierL 2 Intervention|Let's Know! is an 22-week intervention spanning 1 school year. Each week features 4-5, 30 minute lessons targeting lower-level and higher-level language skills. There are 2 narrative and 2 expository units. Within units, instructors and children progress through specific types of lessons to meet language-focused learning objectives. Lesson types include (a) Read to Me, designed to engage children with text and promote discussion, inferential language, and comprehension monitoring, (b) Words to Know, designed to unit vocabulary, (c) Integration, to teach and practice retelling, inferencing and comprehension monitoring (d) Show Me What You Know, instructors administer CAMs to monitor children's progress and (e) Stretch and Review, to provide teachers time to review key concepts. Included in the lessons are practice opportunities for students to collaborate with peers with teacher guidance and feedback. A manual provides scope of instruction, teaching strategies, lessons and materials.
41442856|NCT05841654|DRUG|Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI|The patient's ECG information will be monitored through the ECG monitoring patch, and the time of the first atrial fibrillation event will be recorded. Monitoring whether the patient's blood pressure is controlled dynamically, using echocardiography to evaluate cardiac function, and using scales to assess the quality of life.
41442857|NCT02901379|DRUG|Atorvastatin 80mg|Subject will be given atorvastatin 80mg for two weeks
41442858|NCT02901379|DRUG|Atorvastatin 10mg|Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
41442859|NCT06626984|DRUG|Imatinib|Pre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.
41442860|NCT06626984|DRUG|Compound sodium lactate solution|Total of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.
41442861|NCT00835575|DRUG|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose fasting
41442862|NCT00835575|DRUG|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose fasting
41442863|NCT00702377|OTHER|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
41442864|NCT00702377|OTHER|Optive|Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
41442865|NCT04801589|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr. For example, a 10 kg patient on an infusion of 1 mcg/kg/hr of dexmedetomidine would receive 10 mcg of study drug per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
41442866|NCT04801589|DRUG|Midazolam|For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr. For example, a 10 kg patient on an infusion of 0.15 mg/kg/hr of midazolam would receive 1.5 mg of midazolam per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
41442867|NCT04594252|DRUG|ALXN1840|Administered orally as tablets.
41442868|NCT06524921|PROCEDURE|dental pulpectomy using metapex|Metapex: A dental pulpectomy treats tooth with irreversible pulpitis in primary and teeth by removing infected pulp tissue using files and irrigation in the radicular part. The procedure involves anesthesia, decay removal, pulp chamber access, filing and irrigation till we reach cleaned dried canals and applying a medicament like Metapex . The tooth is then restored with a filling, often a stainless steel crown. The loss of pulp tissue weakens the tooth's structure and increases the risk of fracture and infection.
41442869|NCT06524921|PROCEDURE|dental pulpectomy using biodentine|Biodentine: A dental pulpotomy treats tooth decay or trauma in primary and young permanent teeth by removing infected pulp tissue in the crown while preserving healthy root pulp. The procedure involves anesthesia, decay removal, pulp chamber access, hemostasis, and applying a medicament like MTA or Biodentine. The tooth is then restored with a filling, often a stainless steel crown. Pulpotomies preserve tooth structure, relieve pain, and are less invasive than full root canals, but require regular follow-up.
41442870|NCT00571935|DRUG|insulin aspart|
41442871|NCT00571935|DRUG|soluble human insulin|
41442872|NCT05609617|DEVICE|injection|Intradermal injection on the face and neck/or décolleté by the NCTF135 HA
41442873|NCT05609617|OTHER|Cream application|Application of hydra filler cream on the face and neck/or décolleté
40922318|NCT00835731|DEVICE|Dilapan-S, vitamin B-12|One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D\&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D\&E
41095028|NCT06452407|OTHER|Implementation of elleFA smartphone application|Participants will download the elleFA application on their smartphone. Through this application, the user will be prompted to complete a short modified Biberoglu and Behrman (B\&B) questionnaire and a longer EHP-30 questionnaire monthly, for a period of 6 months. Optionally, patients may complete an additional weekly summary of their mental health symptoms, pain localization, and other symptoms. Also optionally, they may record any daily symptoms, separated into categories from lifestyle to physical pain, objectified through a 6-point Likert scale.
41442874|NCT00373256|DRUG|Sunitinib|Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
41442875|NCT00373256|DRUG|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
41442876|NCT00373256|DRUG|bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks.
41442877|NCT00373256|DRUG|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
41442878|NCT06279039|DRUG|Exosome liquid dressing|This study mainly adopted a randomized double-blind self-half face control method. The double-blind method was that the subjects and researchers did not know the experimental group and the control group. 38 sets of matched use sets (left and right, only the manufacturer knew the specific ingredients) were respectively applied to both sides of the cheeks of patients after Q-switched laser. The blind was unblinded after the experiment.
41442879|NCT03948100|OTHER|Educational Intervention|Undergo dyadic education program
41095029|NCT05484024|DRUG|Sintilimab|PD-1 inhibitor
41442880|NCT03948100|OTHER|Quality-of-Life Assessment|Ancillary studies
41442881|NCT03948100|OTHER|Questionnaire Administration|Ancillary studies
40922319|NCT06491368|PROCEDURE|Cesarean Delivery|A Pfannenstiel abdominal incision is made. The skin and rectus sheath are transversely opened using sharp dissection, and the rectus sheath is separated from the underlying rectus abdominis muscles. The peritoneum is then longitudinally opened using sharp dissection. A transverse incision is made in the lower segment of the uterus, which is subsequently closed with two layers of continuous sutures. Both peritoneal layers are closed with continuous sutures. The fascia is closed using either continuous or interrupted sutures. Finally, the skin is closed with either interrupted sutures or a continuous intracutaneous suture.
41442882|NCT03948100|PROCEDURE|Yoga|Undergo dyadic yoga
41442883|NCT06018285|BEHAVIORAL|Stepped Approach to Reducing Risk of Suicide in Primary Care|Intervention consists of implementation of clinical pathway for youth suicide risk
41442884|NCT05426395|DRUG|Vitamin B12 2.6 µg|There are four groups of women (n = 20 total) who will receive B12 dosing once daily, including group 1a (sufficient baseline B12, pregnant), group 1b (sufficient baseline B12, non-pregnant), group 1c (insufficient baseline B12, pregnant), and group 1d (insufficient baseline B12, non-pregnant).
41442885|NCT05426395|DRUG|Vitamin B12 10 µg|There are two groups of women (n = 10 total) who will receive B12 dosing once daily, including group 2a (sufficient baseline B12, pregnant) and group 2b (insufficient baseline B12, pregnant).
41442886|NCT05426395|DRUG|Vitamin B12 50 µg|The participants (n = 20 total) will be randomly assigned to receive either a once per day B12 dose or a twice per day B12 dose. The four groups at this dose level include: group 3a (sufficient baseline B12, pregnant, Q12), group 3b (sufficient baseline B12, Q24), group 3c (insufficient baseline B12, pregnant, Q12), group 3d (insufficient baseline B12, Q24).
41442887|NCT05442034|BIOLOGICAL|growth factors to help in regeneration|regenerative therapy
41442888|NCT05450107|PROCEDURE|Open Reduction Internal Fixation|Surgical intervention by lag screw or plate fixation
41442889|NCT05450107|PROCEDURE|Cast immobilisation|Cast immobilsation for a total of 6 weeks with gradual increase in weight bearing after 2 weeks
41442890|NCT06120803|DRUG|Esomeprazole 40 mg|Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy.
41442891|NCT02042547|OTHER|Tissue samples from the right atrium|
40922320|NCT03698344|OTHER|Biodiesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute biodiesel exhaust via mask.
40922321|NCT03032302|DIETARY_SUPPLEMENT|Swisse Womens 50+ Ultivite Multivitamin|Single tablet taken once daily
40922322|NCT03032302|DIETARY_SUPPLEMENT|Holland and Barrett Triple Strength Omega-3 Fish Oil|Single capsule taken once daily
41095030|NCT05484024|RADIATION|Short-course radiotherapy|Pelvic radiation
41095031|NCT05484024|COMBINATION_PRODUCT|CAPOX/mFOLFOX|chemotherapy regimen
41095032|NCT05587140|DEVICE|Acupuncture like TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: 3/10 painful sensation with muscle contraction , time: 30 minutes
41442892|NCT02042547|OTHER|Blood samples|
41442893|NCT03644888|OTHER|Cycle ergometer training|Already in arm/group descriptions
41442894|NCT03644888|OTHER|Airway clearance program|Already in arm/group descriptions
41442895|NCT03644888|DEVICE|Vibration therapy|Already in arm/group descriptions
41442896|NCT03644888|DEVICE|Sham vibration therapy|Already in arm/group descriptions
41442897|NCT06541886|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I was developed as a treatment for adults with insomnia. There are more than 100 studies showing that CBT-I is effective in treating insomnia in adults, and several studies suggest it is also effective in treating insomnia in teens.
41442898|NCT02877433|DEVICE|Roxolid short implant, 4 mm length (4)|Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
41442899|NCT02877433|DEVICE|Roxolid short implant, 4 mm length (2)|Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
41442900|NCT03113708|DRUG|Heparin Sodium|Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
40745404|NCT01483651|DRUG|Glucagon|The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
40745405|NCT01483651|DRUG|Insulin|Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
40745406|NCT04757584|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
40745407|NCT01640106|DIETARY_SUPPLEMENT|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
40745408|NCT01640106|DIETARY_SUPPLEMENT|Placebo|Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
40745409|NCT03223194|GENETIC|AT342|AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
40745410|NCT05496010|OTHER|Dry Needling and Ischemic Compression Technique|"For Group A, Dry needling will be applied into trigger points which are active and present in the muscles, efficiently and within the safe limits taking all the safety precautions.~For group B, Ischemic Compression Technique will be applied on trigger points.~The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved for both the groups."
40745411|NCT01973400|DIETARY_SUPPLEMENT|Tocotrienol|Palm-Oil derived Vitamin E, tocotrienol
40745412|NCT01973400|DIETARY_SUPPLEMENT|Placebo|Placebo
40745413|NCT03192020|PROCEDURE|Percutaneous needle fasciotomy (PNF)|The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure. If patient seeks for a treatment and the recurrence of the disease can not be treated by the PNF or patient is not willing to new PNF patient will be treated with LF.
40745414|NCT03192020|DRUG|Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]|CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.
40745415|NCT03192020|PROCEDURE|Limited fasciectomy (LF)|LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
40745416|NCT00780039|DRUG|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
41442901|NCT04740632|BEHAVIORAL|Personalized Nutritional Counseling by a multidisciplinary team|Active diet therapy, instructions on reading labels, cross-contamination, allergen-free, foods recipes
40745417|NCT00780039|DRUG|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
40745418|NCT02619513|DRUG|Dexmedetomidine|Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
40745419|NCT02619513|DRUG|Ropivacaine|Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
40745420|NCT02619513|DEVICE|Mindray M7 series|Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
40745421|NCT00676052|DRUG|GSK233705 12.5mcg|Once daily via dry powder inhaler
40745422|NCT00676052|DRUG|GSK233705 25mcg|once daily via dry powder inhaler
40745423|NCT00676052|DRUG|GSK233705 50mcg|Once daily via dry powder inhaler
40745424|NCT00676052|DRUG|GSK233705 100mcg|Once daily via dry powder inhaler
40745425|NCT00676052|DRUG|GSK233705 200mcg|Once daily via dry powder inhaler
40745426|NCT00676052|DRUG|Placebo|Once daily via dry powder imhaler
40745427|NCT04136301|OTHER|Informative Video group|Informative Video group before labor in nulliparous women
40745428|NCT02280954|DRUG|Indocyanine Green (ICG)|
40745429|NCT01828684|OTHER|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks.
40745430|NCT01828684|OTHER|Sham Lens Coating|Each subject will wear a sham lens coating for 2 weeks.
40745431|NCT06373939|DEVICE|Digital lung auscultation|"Two 30-second recordings will be made using CE-marked Littmann® CORE digital stethoscopes and the Pneumoscope at two bilateral lung positions on the posterior chest wall, focusing on the lower lobes. Spectral comparison and audio quality indices will be assessed between the Pneumoscope and the Littmann® CORE digital stethoscope.~Comparator: The Gold Standard Littmann® CORE picks up sounds, such as heart and lung sounds, from a patient's body. After amplification and filtering, the sounds are sent to the user through a binaural headset. The stethoscope chest piece is designed for use with adult, pediatric, and infant patients."
41095033|NCT05587140|DEVICE|Conventional TENS|Frequency: 100 Hz, pulse duration: 200 μs, intensity: strong but comfortable tingling sensation , time: 30 minutes
41095034|NCT05587140|DEVICE|Sham TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: tingling sensation, time: turn on the electricity for 15 seconds, then turn off the machine for 30 minutes
41095035|NCT03888365|DRUG|Treprostinil|Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
41442902|NCT06182722|DIAGNOSTIC_TEST|Mental assessments|Patients will receive psychiatric rating scales evaluation every visit.
40745432|NCT06373939|DEVICE|Pulse oximetry measurement|"Pulse oximetry and heart rate will be measured using the CE-marked Masimo Rad-G® and iHealth® Air oximeters, as well as the Pneumoscope's built-in oximeter. Agreement between the Pneumoscope's oximeter and the reference oximeters will be evaluated. Measurement will take 30 second on the right index finger.~Comparators:~1. The Gold Standard Masimo Rad-G® sensor is indicated for the continuous noninvasive peripheral monitoring of arterial oxygen saturation (SpO2) and pulse rate. Its use consists in positioning the emitting window of the sensor attachment envelope on the top of the finger nail bed, while the detector is placed opposite the emitter on the other side of the same finger.~2. The Gold Standard iHealth® Air works by projecting two beams of light through a clip with a transmitter and a detector that is placed around a finger, nail side down and screen side up."
40745433|NCT06373939|DEVICE|Non invasive body temperature measurement|"Comparison of body temperature measurements between the Pneumoscope's built-in thermometer and Gold Standard thermometers (Terumo® C205 and VisioFocus Pro 06480).~Comparators:~1. The Gold Standard Terumo® C205 is an axillary thermometer. Its use consists in placing the probe in the armpit, then lowering the arm and holding the device firmly until the temperature is stabilised and the temperature is read and displayed on the thermometer screen.~2. The Gold Standard VisioFocus Pro 06480 is an infrared thermometer that detects the infrared radiation naturally emitted by the body and in particular from the human forehead. Its use consists in holding the thermometer close to the forehead but without direct contact with the skin. The temperature reading is then projected on the patient's forehead using a symbol system."
40745434|NCT01692587|OTHER|Protein restrictive diet|To begin a reduced protein diet
40745435|NCT04761354|PROCEDURE|Unilateral adrenalectomy|
40745436|NCT00308282|DRUG|LY2127399|30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
40745437|NCT00308282|DRUG|Placebo|IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
40745438|NCT00360204|BEHAVIORAL|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
40745439|NCT04177199|OTHER|TRIAGE HF Pathway|A new care pathway (Triage-HF Plus) for the remote monitoring and management of heart failure stability in a cohort of device patients at 3 hospital sites in North West England.
40745440|NCT01185366|DRUG|Everolimus|10 mg by mouth once a day.
40745441|NCT01185366|DRUG|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
40745442|NCT05886023|DIETARY_SUPPLEMENT|High nitrate vegetables|Vegetable burger containing high nitrate vegetables
40745443|NCT05886023|DIETARY_SUPPLEMENT|Low nitrate vegetables|Vegetable burger containing to low nitrate vegetables
40745444|NCT01333566|BEHAVIORAL|Intervention Group|The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
40745445|NCT01333566|BEHAVIORAL|Placebo Comparator: Control Group|Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
41095036|NCT03888365|DRUG|Non-Treprostinil PAH Medications|Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
40745446|NCT00968942|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
40745447|NCT00968942|DRUG|Placebo|Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
40745448|NCT05129085|DRUG|Dexamethasone 4mg|For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the ESI group, 8mg of dexamethasone (4mg/ml) added to 1 ml of normal saline will be given (total 3ml volume).
40745449|NCT05129085|PROCEDURE|epidural platelet rich plasma injection|For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the EPRP group, 3 ml of PRP will be injected. The total volume of injectate for both groups of patients is 3ml.
40745450|NCT01522027|PROCEDURE|Percutaneous tracheostomy|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
41095037|NCT05708833|DEVICE|Intraosseous venous access|Immediate placement of humeral intra-osseous venous access (after a first failed attempt of peripheral venous access)
41095038|NCT05708833|DEVICE|Peripheral venous access|Looking for peripheral venous access, changing the site of puncture, the caliber of the catheter and/or the operator and/or assistance tools (ultrasound, infra-red guidance...) and/or using another route (oral, rectal, subcutaneous, intramuscular route and central venous access)
41095039|NCT03580967|DRUG|Vortioxetine|Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.
41095040|NCT03937687|DRUG|Caffeine+TeaCrine+Dynamine|combination of caffeine, TeaCrine, and Dynamine
41095041|NCT03937687|DRUG|Placebo|Placebo
41095042|NCT03937687|DRUG|Caffeine|Caffeine
40745451|NCT05148507|DEVICE|PROKERA|Amniotic membrane is the sac that encloses the baby during pregnancy. Amniotic membrane has been used to treat many ocular (eye) diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States food and drug administration (FDA) in 2001. PROKERA is considering it investigational for the study
40745452|NCT03123588|DRUG|Ruxolitinib|Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
40745453|NCT03123588|DRUG|Anagrelide|Anagrelide administered orally at a starting dose of 1 mg BID.
40745454|NCT03123588|DRUG|Placebo|Anagrelide-placebo administered orally BID
40745455|NCT03123588|DRUG|Placebo|Ruxolitinib-placebo administered orally BID.
40745456|NCT02250638|OTHER|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
40745457|NCT03939832|OTHER|Fraction of inspired oxygen level|A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.
40745458|NCT03459586|OTHER|9zest app facilitated exercise|The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease
40745459|NCT06422208|BIOLOGICAL|Autologous midbrain dopamine neurons|The autologous midbrain dopamine neurons are a experimental cryopreserved cell product derived from human autologous induced pluripotent stem cells. The autologous midbrain dopamine neurons will be surgically administered into the putamen, unilaterally, in a single surgical session.
40745460|NCT04698486|OTHER|Hyperinsulinemic euglycaemic clamp|"Infusion of constant intravenous insulin to achieve hyperinsulinemia and concomitant infusion of glucose to maintain euglycemia (plasma glucose at 5 mM).~Infusion of palmitate and VLDL-triglyceride tracer. PET/CT scans of heart and liver, both in basal period and during intervention."
40745461|NCT04261166|DRUG|A1|Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)
40745462|NCT04261166|DRUG|A2|Medical Cannabis oil diluted in Olive oil. CBD 0.6 mg, THC 3.1 mg (1 drop)
40745463|NCT04261166|DRUG|A3|Medical Cannabis oil diluted in Olive oil. CBD 3.1 mg. THC 3.1 mg (1 drop)
40745464|NCT04261166|DRUG|A4|Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)
40745465|NCT04261166|DRUG|A5|Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)
40745466|NCT04261166|DRUG|B1|Sublingual tablets. CBD 40 mg, THC 2 mg (1 tablet)
40745467|NCT04261166|DRUG|B2|Sublingual tablets. CBD 30 mg, THC 5 mg (1 tablet)
40745468|NCT04261166|DRUG|B3|Sublingual tablets. CBD 40 mg (1 tablet)
40745469|NCT04261166|DRUG|B4|Sublingual tablets. CBD 40 mg (1 tablet)
40745470|NCT03893214|BEHAVIORAL|virtual reality exposure for acrophobia|"The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase."
40745471|NCT03893214|BEHAVIORAL|movie|Participants will watch a movie without height content for the same amount of time as the virtual reality exposure will need.
40745472|NCT00520468|DRUG|Erythropoietin|40,000 units injected under the skin (SQ) weekly
40745473|NCT00520468|DRUG|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
40745474|NCT00520468|DRUG|G-CSF|300 mcg injected under the skin (SQ) two times per week
40745475|NCT00520468|DRUG|Prednisone|60 mg per day for 7 days, taper over 1 month
40745476|NCT04205825|OTHER|The New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
40745477|NCT05501379|OTHER|No intervention - observational study only|No intervention - observational study only
41442903|NCT03635320|DEVICE|TFNA|intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation
40745478|NCT02891330|BEHAVIORAL|Dietary and nutritional recommendations conducted by a nurse|Supplementary dietary and nutritional education
40745479|NCT06298409|DEVICE|CapScan collection capsule|The CapScan collection capsule is a single-use device that collects fluids from the gastrointestinal tract for analysis ex-vivo.
40745480|NCT01601795|DRUG|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
40745481|NCT01601795|DRUG|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
40745482|NCT02786667|DRUG|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
40745483|NCT02786667|DRUG|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
40745484|NCT03390660|OTHER|WIC program participation|WIC program is a welfare program in the U.S. to provide nutritional supplements to low-income women, infants, and children.
40745485|NCT02487199|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
40745486|NCT02487199|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
40745487|NCT02505971|DRUG|Nadolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
41095043|NCT02578602|DRUG|Gadoxetate Disodium|Given IV
41442904|NCT03635320|DEVICE|PFNA-II|intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation
41095044|NCT02578602|DEVICE|Magnetic Resonance Imaging|Undergo MRI with gadoxetate disodium
41442905|NCT00834249|DRUG|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
41442906|NCT00834249|DRUG|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
40745488|NCT02505971|DRUG|Propranolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.~In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
40745489|NCT03070652|BEHAVIORAL|NBO, Newborn behavioral observation|
40745490|NCT03070652|BEHAVIORAL|Practice as usual|
40745491|NCT02549378|DEVICE|confocal microscopy|microvessel diameter measured by confocal microscopy
40745492|NCT04118972|BEHAVIORAL|Mirror exposure and text prompt responses|Participants in the active interventions have three weekly mirror exposure sessions that are either guided with specific instructions as to where to look and how (only in functionality condition)
40745493|NCT00229216|DRUG|Tinidazole|
40745494|NCT06142552|DRUG|FRSW117|once a week, 50 weeks and as needed
41095045|NCT03717987|DRUG|Botulinum toxin type A|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015)."
41095046|NCT03717987|DIETARY_SUPPLEMENT|Zinc supplementation|zinc supplementation will be given to patients in the intervention arm 4 days prior to Botulinum toxin type A injection
41095047|NCT04900883|OTHER|survey|anonymous survey
41095048|NCT03881657|BEHAVIORAL|Reverse Colocated Integrated Care|A reverse colocated integrated care model is one where primary care and preventive services are embedded within a behavioral health service setting.
41095049|NCT03881657|BEHAVIORAL|Usual Care|Behavioral health services without primary care or integrated care services
40745495|NCT03507283|PROCEDURE|Double head pterygia excision and repair|Complete excision of the pterygia was done. A free conjunctival autograft was obtained. The graft was divided vertically into two parts then secured into conjunctival defects.
40745496|NCT01905683|DRUG|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
40745497|NCT01673945|DEVICE|EUS-guided fine needle aspiration|Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
40745498|NCT01699828|DRUG|Buspirone|The buspirone will be given once as a tablet and encapsulated for blinding.
40745499|NCT01699828|DRUG|Placebo|Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
40745500|NCT00248547|DRUG|aprepitant|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
40745501|NCT00248547|DRUG|dexamethasone|For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
40745502|NCT00248547|DRUG|ondansetron|For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
40745503|NCT00248547|DRUG|placebo|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
40745504|NCT06447051|OTHER|Kasai Surgery|As per institute treatment protocol
40745505|NCT00046943|DRUG|atrasentan hydrochloride|
40745506|NCT02658474|BEHAVIORAL|Acceptance and Commitment Therapy|Group based Acceptance and Commitment Therapy
40745507|NCT00932854|PROCEDURE|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
41442907|NCT01370083|BEHAVIORAL|Tongue Pressure Profile Training|60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.
40745508|NCT03033901|DEVICE|Polysomnography - Level 1 and Level 3|Participants will undergo simultaneous administration of Level 1 and 3 polysomnography on the rehabilitation unit with study funded sleep technologist present to meet Level 1 standards.
40745509|NCT03033901|DEVICE|Actigraphy monitoring|Participants will undergo actigraphy monitoring to assess habitual sleep duration to determine readiness for polysomnography and examine trajectory and duration of sleep.
40745510|NCT03033901|OTHER|Sleep Apnea Screening|Participants and their family member or proxy, and clinical staff will be asked to answer questions in order to complete the three standardized sleep apnea screening measures.
40745511|NCT02328274|PROCEDURE|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
40745512|NCT06520059|COMBINATION_PRODUCT|Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration|"Group 1 will receive two intraosseous injections of PRP and a subsequent/synchronous intra-articular injection of PRP on the same day.~Group 2 will only receive two intra-articular injections of PRP, separated by one week."
40745513|NCT03942731|OTHER|Behavioral allergy testing protocol|skin tests followed by drug provocation test and skin retesting between 6 weeks and 6 months
40745514|NCT05007444|DRUG|P2Et (Caesalpinia spinosa extract)|Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
40745515|NCT05007444|DRUG|Placebo|After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
40745516|NCT04232137|BEHAVIORAL|Postpartum coffee ceremony|The promise of a postpartum coffee ceremony
41442908|NCT01370083|BEHAVIORAL|Tongue-Pressure Strength-and-Accuracy Training|60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
40745517|NCT00544882|DRUG|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
40745518|NCT00544882|DRUG|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
40745519|NCT00544882|DRUG|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
40745520|NCT02582632|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet
40745521|NCT02582632|DRUG|dasabuvir|Tablet
40745522|NCT02245373|DRUG|Antidepressants|
40745523|NCT02245373|OTHER|Active Monitoring|
40745524|NCT04964232|DEVICE|Infrared Camera|The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.
40745525|NCT04964232|DEVICE|Esophageal Temperature Probe|In patients undergoing general anesthesia, the Esophageal temeperature parameters are measured using an Esophageal probe.
40745526|NCT04964232|DEVICE|Skin temperature probe|In patients undergoing general anesthesia, the skin spot temeperature parameters are measured using an skin adhesive probe.
40745527|NCT06349954|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
41442909|NCT04931810|BEHAVIORAL|All Nations Breath of Life|Same.
40745528|NCT06349954|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
40745529|NCT03134807|OTHER|Observation prospective|No intervention
40745530|NCT01180777|DEVICE|etafilcon A (A)|Daily wear contact lens
40745531|NCT01180777|DEVICE|etafilcon A (B)|Daily wear contact lens
40745532|NCT01180777|DEVICE|etafilcon A (C)|Daily wear contact lens
40745533|NCT04267042|DRUG|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
40745534|NCT04267042|DEVICE|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
40745535|NCT04267042|DEVICE|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
40745536|NCT05776719|BEHAVIORAL|Health & Wellness|PowerPoint slide decks will be shown via shared screen. The wellness group will be largely educational in nature and will encourage discussion, setting goals, and making healthy choices. Similar topics covered in this group have been used previously in health promotion classes.
40745537|NCT05776719|BEHAVIORAL|Warrior Renew|The group format includes warm-up community building exercises, psychoeducational presentation of material standardized by the use of PowerPoint slides, followed by discussion of the information and interactive exercises, and closes with exercises to improve affect management skills, such as mindfulness or guided imagery.
40745538|NCT05967468|BEHAVIORAL|Family Based, Internet-Based Cognitive Behavioral Therapy|Family-based cognitive behavioral therapy employing internet-delivered modules and videos
40745539|NCT05967468|BEHAVIORAL|Bibliotherapy, low therapist contact SPACE|Parent-based bibliotherapy for treating anxiety disorders in youth
40745540|NCT05967468|OTHER|Relaxation and Mentorship|Relaxation based treatment
41095050|NCT04784741|OTHER|Conventional static hamstring muscle stretching|Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle.
40745541|NCT05946187|BEHAVIORAL|Apolo_Bari Stepped-care intervention|"Step 1 - Low-intensity intervention that will run on a private Facebook® group. Weekly, a subtopic and related activities are posted as short text/images. Patients are encouraged to participate by viewing publications, commenting, and posting their content.~Step 2 - Will consist of an adjusted version of the Cognitive Behavior Treatment (CBT) program developed by Conceição et al. (2016). The intervention will last for 12-months and be delivered online by Facebook's functionalities, namely chat and calls. The intervention offered includes three components: 1) a psychoeducational cognitive-behavioral-based self-help manual that consists of 12 different modules. Each month a different topic will be covered and divided into four weekly sub-topics, which are supported with a set of related CBT tasks; 2) interactive call sessions with a psychologist (30 min at the beginning of each month); 3) monthly monitoring of risk-behaviors responded every session."
40745542|NCT05946187|OTHER|Treatment as Usual for Bariatric Surgery|Treatment as Usual for bariatric surgery in portuguese public hospitals.
40745543|NCT00849329|DRUG|lapatinib|1250mg lapatinib
40745544|NCT00849329|DRUG|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
40745545|NCT03404375|DEVICE|Gauss Triton system|"The Triton system (Gauss Surgical, Inc., Palo Alto, CA) is a novel mobile monitoring platform that combines mobile computing with Gauss Feature Extraction Technology (FET) to directly assess Hb mass (mHb) absorbed by surgical sponges from an image. The device is an iPad like imaging device that will assess blood loss via imaging of the surgical sponges used in the surgery.~The device will be used to calculate blood loss on every patient enrolled in the study."
40745546|NCT06023407|OTHER|Water Immersion Heat Therapy|10-weeks of 3 days per week in 1 of the 2 arms
40745547|NCT05202405|DRUG|AD-221|AD-221 Oral Tablet
40745548|NCT05202405|DRUG|AD-221A and AD-221B|AD-221A Oral Tablet + AD-221B Oral Tablet
40745549|NCT00766818|DRUG|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
40745550|NCT02960685|PROCEDURE|Echocardiography|
40745551|NCT05711147|PROCEDURE|Abutment removal|4 times healing abutment removal during prosthesis making (impressions, metal try-in, ceramic try-in, prosthesis loading)
40745552|NCT05711147|PROCEDURE|Placement of definitive abutment|Placement of the final prosthetic abutment at the moment of implantation
40745553|NCT05569941|DRUG|ABI-4334 Tablet|ABI-4334 Tablet
40745554|NCT05569941|DRUG|ABI-4334 Placebo|Placebo to ABI-4334 Tablet
40745555|NCT00910390|OTHER|Slow freezing|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
40745556|NCT00910390|OTHER|VIT-Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
40745557|NCT00910390|OTHER|Vit-Vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
40745558|NCT02011763|BIOLOGICAL|Avaxim 80U Pediatric: Inactivated Hepatitis A Virus|0.5 mL, Intramuscular (2 injection 6 months apart)
40745559|NCT02487121|BEHAVIORAL|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
40745560|NCT02487121|BEHAVIORAL|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
40745561|NCT04615507|DEVICE|JJVC Investigational Multifocal Contact Lens|TEST Lens
40745562|NCT04615507|DEVICE|Dailies Total 1® Multifocal Contact Lens|CONTROL Lens
40745563|NCT03947723|DEVICE|Radiofrequency ablation|The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
40745564|NCT03033043|DEVICE|Relay Pro Stent-Graft|Endovascular treatment of an aortic dissection
40745565|NCT03759184|DRUG|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at dose levels of 0.5,1 or 2 mcg/kg/day on days 1-5 of cycles 1-6
40745566|NCT03759184|DRUG|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at the maximum tolerated dose or the maximum administered dose of 2 mcg/kg/day on days 1-5 of cycles 1-6
40745567|NCT03759184|BIOLOGICAL|Obinutuzumab|Intravenous (IV) Obinutuzumab will be administered at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of cycle 1: then 1,000 mg on day 4 of each subsequent cycle
40745568|NCT02756468|OTHER|pts operated for pancreatic cancer|measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection
40745569|NCT04607551|PROCEDURE|Prone positionning|4 to 5 persons required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube, the jugular ECMO cannula and the ventilator lines and another dedicated to the femoral ECMO cannula. The person at the head of the bed will coordinate the steps. The other persons will stand at each side of the bed. The direction of the rotation will be decided giving priority to the side of the central venous lines. The length of vascular and ventilator lines will be checked for appropriateness, the endotracheal tube and gastric tube will be secured, and the patient's knees, forehead, chest, and iliac crests will be protected using adhesive pads. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. Patients will be proned at least four times during the first days on ECMO. Each prone session will stand for at least 16 hours
40745570|NCT04607551|PROCEDURE|Supine position|Patients assigned to supine will remain in a semi-recumbent position.
40745571|NCT04065620|DIAGNOSTIC_TEST|ambulatory blood pressure measurement|24-hour ABPM will be made using validated devices, following ABPM device should be programmed to take measurements every 30 minutes . Patients will be instructed in their use. Periods of activity and rest will be pre-determined in short windows: for Asian and European Countries daytime period will be defined between 10:00 and 8:00 pm; and night-time period between 00:00 am and 6:00 am. For Latin American Countries daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 00:00 am and 6:00 am. For Africa daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 11 PM and 5 AM In addition, the duration of ABPM (hours), the percentage of valid readings, and the mean SBP/DBP values during periods of activity, rest and in 24 hours will be recorded. Records with a duration \<24 hours, those without one good reading per hour and those with \<70% of satisfactory readings will be excluded
40745572|NCT02551575|DRUG|Treatment of MTX and HCQ|"Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks."
40745573|NCT02551575|DRUG|Treatment of TCM|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks."
40745574|NCT02551575|DRUG|Integrative Medicine|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks."
40745575|NCT03466372|BEHAVIORAL|biofeedback|treadmill walking with biofeedback regarding propulsion and other gait parameters
40745576|NCT06347588|OTHER|Observational: Blood sample of HVB-specific Elispot assay, HBSAg, HBV-DNA|Blood sample at baseline, week 4, month 3, 6, 9,12.
40745577|NCT05504278|DRUG|pemetrexed|500mg/m\^2, Q3W, day1, i.v.
40745578|NCT05504278|DRUG|cis-platinum|75mg/m\^2, Q3W, day1, i.v.
40745579|NCT05504278|DRUG|Sintilimab|200mg, Q3W, day1, i.v.
40745580|NCT05504278|DRUG|IBI351|recommended dose, po
40745581|NCT05504278|DRUG|carboplatin|AUC=5, Q3W, day1, i.v.
40745582|NCT04617327|RADIATION|Hypofractionation|"Shorter radiation therapy means that a higher dose will be given on a daily basis. The goal is to target microscopic disease and decrease the chances of local recurrence.~Organs at risk (OAR) will receive doses following the constraints from the Timmerman tables used for reference when using 5 or more fractions of EBRT.~Treatment will be delivered every 2nd day, for a maximum of 3 fractions per week. Daily pretreatment Image Guided Radiotherapy Images (IGRT) (Cone-Beam CT - CBCT) will be co-registered with the CT simulation dataset to adjust patient position before each treatment by matching the bone adjacent to the planned tumour volume (PTV). Treatment will be administered if there is \<3 mm in any dimension, or rotation is \<3 degrees. If the isocentre set-up exceeds 3 mm at any given treatment session, the treatment couch will be translated to restore its planned position."
40745583|NCT05737147|DEVICE|Zero Heat Flux Thermometer|Comparison of the accuracy and precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature Measurement
40745584|NCT01910532|DRUG|Clevidipine|Clevidipine for the treatment of acute hypertension defined SBP \> 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
41095051|NCT04784741|DEVICE|Low amplitude whole body vibration therapy|"Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.~Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle."
41095052|NCT04784741|DEVICE|Biodex Balance System|Pre and post balance assessment by Biodex balance system
40745587|NCT00474565|PROCEDURE|Placement of an aortic root pigtail catheter.|Seldinger technique for placement of catheter.
40745588|NCT00433290|DRUG|Duloxetine|duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
40745589|NCT00433290|DRUG|Placebo|placebo every day (QD), by mouth (PO) for 13 weeks
40745590|NCT00003090|BIOLOGICAL|aldesleukin|
40745591|NCT00001647|PROCEDURE|White blood cell infusion|
40745592|NCT03555786|OTHER|minimum effective volume|"The determination of MEV90 and its 95% confidence interval (CI) will be based on a biased coin up-and-down sequential design"
40745593|NCT05910398|DRUG|pyrotinib|an irreversible anti-HER2 tyrosine kinase inhibitor
40745594|NCT00009893|DRUG|fluorouracil|
40745595|NCT00009893|DRUG|gemcitabine hydrochloride|
40745596|NCT00009893|DRUG|leucovorin calcium|
40745597|NCT04825899|OTHER||
40745598|NCT06225453|OTHER|Individualized perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at no less than -20% of the baseline values of each patient.
40745599|NCT06225453|OTHER|Conventional perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at ≥65 mmHg and ≥90 mmHg, respectively, in all patients.
40745600|NCT02732730|DRUG|Truvada|400 women who accept to initiate PrEP
40745601|NCT05010967|OTHER|High intensity interval training|"HIIT 3 times a week for 8 weeks. For week 1 to 4 , Warm up 5 minutes jogging in place, 6 series of 30 seconds Burpees, 30 seconds recovery, 30 seconds skipping, 30 seconds recovery, 30 seconds lunge, 30 seconds recovery, 30 seconds 1-legged squats, 30 seconds recovery, 30 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches.~For week 5 to 8 , Warm up 5 minutes jogging in place, 6 series of 45 seconds Burpees, 45 seconds recovery, 45 seconds skipping, 30 seconds recovery, 45 seconds lunge, 30 seconds recovery, 45 seconds 1-legged squats, 30 seconds recovery, 45 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches."
40745602|NCT05010967|OTHER|Yoga Training|Yoga 3 times a week for 8 weeks. 30-50 minutes session, 5 minutes breathing, 15-35 minutes yoga poses (Cat-cow, child's pose, downward dog, plank, Cobra), followed by 10 minutes supine meditation.
40745603|NCT00103506|DRUG|Bortezomib (VELCADE)|1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
40745604|NCT00103506|DRUG|Bortezomib (VELCADE)|1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
40745605|NCT00103506|DRUG|Doxorubicin hydrochloride (DOXIL/CAELYX)|mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
40745606|NCT03489564|BEHAVIORAL|Active|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.
40745607|NCT03489564|BEHAVIORAL|Sedentary|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
40745608|NCT03524378|BEHAVIORAL|Ergonomic and movement modifications|Introduction of basic ergonomic and self-management principles, participants will review video clips of the prioritized and revised solutions. Adjustments in work tasks, movement strategies or self-management techniques will be self selected by workers after an educational session using videotapes of work processes.
40745609|NCT05658991|DIAGNOSTIC_TEST|Retinal electrophysiology|Retinal electrophysiology to assess retinal function before and with fasting during ramadan in both groups.
40745610|NCT05468307|BIOLOGICAL|Membrane Bound Cytokine Modified TIL|Adoptive transfer of 2x10\^8-1x10\^10 autologous TIL engineered with membrane-binding cytokine to patients i.v. in 30-120 minutes.
40745611|NCT00790933|DRUG|Vedolizumab|Vedolizumab intravenous infusion
40745612|NCT02845349|DRUG|Vortioxetine|The study drug, vortioxetine received approval from the U.S. Food and Drug Administration (FDA) to treat adults with major depressive disorder. This study is being done to determine its effectiveness in a specialized population, i.e. those who have developed major depression after a traumatic brain injury. As patients who have sustained a TBI are medically fragile and sensitive to side-effects of medications, it is important to test the effectiveness and safety of vortioxetine in this population.
40745613|NCT02845349|DRUG|Placebo|A placebo comparator will be used in one subset of patients.
40745614|NCT01098578|DRUG|Floseal|Received 1 syringe of Floseal as treatment for posterior epistaxis.
40745615|NCT01895647|DEVICE|EMS|Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
40745616|NCT01330524|DRUG|Avastin and Triamcinolone|1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
40745617|NCT01330524|OTHER|placebo|2mg placebo
40745618|NCT03549195|PROCEDURE|ICG|The ICG powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
41095053|NCT04784741|PROCEDURE|Range of motion of hamstring muscle|Straight Leg Raising to check pre and post Range of Motion by using Goniometer
40745619|NCT03549195|PROCEDURE|ICG-CP|The ICG-CP powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
40745620|NCT03549195|PROCEDURE|ICG-TMTP1|The ICG-TMTP1 powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
40745621|NCT05130697|OTHER|eMPowEr App|A mobile app to support participants in the management of malignant pleural effusions at home
40745622|NCT01746160|DRUG|C1 Implant|Patients treated with dental implants.
40745623|NCT02697422|OTHER|Community-based peer health coach intervention|The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
40745624|NCT06370975|DRUG|3% hypertonic Saline|"the patients received 3% HS at the rate of 4 mL/kg for 30 minutes. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
40745625|NCT06370975|DRUG|Ringer's lactated solution|"the patients received ringer's lactated solution at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
40745626|NCT06370975|DRUG|0.9% Normal saline|"the patients received 0.9% Ns at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
40745627|NCT00407030|DRUG|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)"
41095054|NCT02594176|DEVICE|FLEXISEQ®|applicable gel
41095055|NCT02594176|DEVICE|Placebo|applicable gel
41095056|NCT02540941|OTHER|non|
41095057|NCT06613399|PROCEDURE|MTI-TME|Multi-Technology Tntegrated Total Mesorectal Excision，MTI-TME
40745628|NCT00407030|DRUG|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)"
40745629|NCT00407030|DRUG|Placebo|Placebo
40745630|NCT01533220|DRUG|naphazoline hydrocloride|02 drops into each nostril, 04 times a day for 03 days
40745631|NCT01533220|DRUG|Naphazoline hydrocloride + Pheniramine Maleate + Panthenol|02 drops into each nostril each 12 hours for 03 days
40745632|NCT04151498|BEHAVIORAL|Reengagement and Assessment Mobile Program|Participants will participate in mobile clinic visit that will include an educational interview, adherence counseling, and standard blood draws for HIV reengagement. The goal of this intervention is to motivate participants to become reengaged in traditional HIV care by making an in person clinic appointment.
40745633|NCT04151498|OTHER|Qualitative Interview|Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
40745634|NCT00442156|PROCEDURE|Laser photocoagulation|modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
40745635|NCT01309880|DEVICE|Test lens|Investigational silicone hydrogel contact lens worn on a daily wear basis
40745636|NCT01309880|DEVICE|Air Optix Aqua|Air Optix Aqua contact lens worn on a daily wear basis
40745637|NCT02318979|DEVICE|Otto Bock prosthesis|Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
40745638|NCT02318979|DEVICE|Ossur prosthesis|Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
40745639|NCT02318979|DEVICE|Freedom Innovations prosthesis|Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
40745640|NCT03622840|BEHAVIORAL|Cognitive Remediation|Weekly 30-45mins Cognitive Remediation Sessions over 11 weeks
40745641|NCT04345432|DRUG|Gabapentin|"Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study."
40745642|NCT05310773|BEHAVIORAL|Community Stigma Awareness and Education Workshop|Key aspects of the workshop include community stigma awareness of people living with HIV, use of antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP) for prevention of HIV and attitudes towards people who use alcohol and drugs. The workshop adapts a stigma-reduction curriculum based on a stigma-reduction toolkit and community HIV prevention project with community peers with skits to address stigmatizing attitudes and behaviors toward young women and men who use AODs and who may need health services, including HIV treatment and prevention. Selected modules were modified from the existing clinic-based training to fit community stigma awareness and attitudes to focus on aspects of stigma specific to young women and men who engage in syndemic-related behaviors who live in their communities. The stigma awareness and education workshop will be delivered in communities randomized to receive workshops (N=12 communities).
40745643|NCT05310773|BEHAVIORAL|Couples Health CoOp Plus (CHC+)|The Couples Health CoOp Plus (CHC+) was adapted from the initial Couples Health CoOp (CHC)-an empowerment-based intervention developed for South African couples that addresses the syndemic of alcohol and other drug (AOD) use, gender-based violence (GBV), and HIV risk. It is grounded in Social Cognitive Theory and promotes prevention strategies that address the relational context of equality in which sexual risk takes place. The adapted Couples Health CoOp Plus (CHC+) incorporates antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) for a biobehavioral approach with an emphasis on uptake and good adherence (N=12 communities; estimated N=240 couples).
40745644|NCT00478036|DRUG|Acular LS|Details covered in arm description
40745645|NCT00478036|DRUG|Pred Forte|Details covered in arm description
40745646|NCT00478036|OTHER|Refresh Tears|Placebo
40745647|NCT04706221|DEVICE|CM-1500|Blood volume monitor CM-1500
40745648|NCT06462872|OTHER|observational study|It is an observational study
41095058|NCT06613399|PROCEDURE|C-TME|Conventional Total Mesorectal Excision，C-TME
41095059|NCT06081855|DIAGNOSTIC_TEST|CT|Measuring aortic root diameter by CT
41095060|NCT06114329|DRUG|AL01211|AL01211 is a novel, proprietary, selective GCS inhibitor with high potency against GCS with limited off target activity.
41095061|NCT03888820|DRUG|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
41095062|NCT03888820|DRUG|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
40745649|NCT03083379|DEVICE|Volumetric Incentive Spirometry|"A study investigator will provide instruction on Incentive Spirometry procedure performance before supervised therapy and monitoring begins.~* Five minutes of eupneic ventilation EIT monitoring will occur before I.S. therapy commences.~* Study participants will be asked to take 10 deep breaths through the incentive spirometer's mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last I.S. lung expansion therapy breath cycle.~* Incentive Spirometry therapy and monitoring session will last about 15 minutes"
41095063|NCT06026189|DIAGNOSTIC_TEST|urine-first strategy|Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
41095064|NCT03406429|DEVICE|Active rTMS|All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
40745650|NCT03083379|DEVICE|EzPAP® POSITIVE AIRWAY PRESSURE|"* A study investigator will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins. A second study investigator will perform EIT device set-up and monitoring only.~* Five minutes of eupneic ventilation EIT monitoring will occur before EzPAP® therapy commences.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last EzPAP® lung expansion therapy breath cycle.~* EzPAP® therapy and monitoring sessions will last about 15 minutes"
40745651|NCT04088253|PROCEDURE|umbilical herneal repair|reduction of the herneal content an repair of the defect with IPOM
40745652|NCT01617213|DRUG|Melphalan|200 mg/m2/IV
40745653|NCT01617213|DRUG|Lenalidomide|10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
40745654|NCT02984137|OTHER|testing, evaluation, sampling|neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.
40745655|NCT05232526|OTHER|Mental imagery (MI) and exercise program|Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample
41095065|NCT03406429|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
41269806|NCT01646359|DEVICE|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
40745656|NCT05232526|DEVICE|Mental Imagery and Exercise program|Questionnaires and functional tests are going to be used to evaluate balance, functional status, cognitive ability, depression and quality of life of the sample.
40745657|NCT01144806|BEHAVIORAL|Nutrition education|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
40745658|NCT01144806|DIETARY_SUPPLEMENT|RUTF|Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group
40745659|NCT01532375|DIETARY_SUPPLEMENT|Kochujang|Kochujang (32g/day) for 12weeks.
40745660|NCT01532375|DIETARY_SUPPLEMENT|placebo|placebo(32g/day) for 12weeks
40745661|NCT05571488|OTHER|Electronic surveys|Online questionnaires will be used to collect data, at recruitment and follow-up once a year
40745662|NCT05571488|OTHER|Qualitative Interviews|Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years
40745663|NCT01906164|DRUG|ALS-008176|
40745664|NCT01906164|DRUG|Placebo|
40745665|NCT02324322|DEVICE|Exoskeleton Training|Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
40745666|NCT02324322|OTHER|Muscle Biopsies|"Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.~To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking."
40745667|NCT02324322|OTHER|MRI|MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
40745668|NCT04481282|DRUG|Terbutaline|2.5mg po tid for 12 weeks
40745669|NCT04481282|DRUG|Danazol|200mg po bid for 12 weeks
40745670|NCT01011725|DRUG|MK 0773|25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
40745671|NCT01011725|DRUG|Placebo|Placebo oral tablet b.i.d for 12 weeks
41095066|NCT04830514|OTHER|Recommended Dietary Allowance of Protein|0.8 g/kg/day protein intake
41095067|NCT04830514|OTHER|Habitual protein intake|1.0 g/kg/day protein intake
41095068|NCT04830514|OTHER|Optimal Protein Intake|1.5 g/kg/day protein intake
41269807|NCT01905475|DRUG|POL6326|
41269808|NCT01905475|DRUG|Placebo|
41269809|NCT00242918|DRUG|docetaxel|
40745672|NCT03828669|BEHAVIORAL|Recovery Toolkits|"Recovery Toolkits are presented to patients in a branded bag and include a brochure, a self-help behavioral pain medicine book, a downloadable app, earbuds, and access to digital behavioral medicine (the My Surgical Success program including online educational videos)"
40745673|NCT03269006|DEVICE|Inesfly Paint|"Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).~Others intervention such as IRS, ITN and IDWLcontain Delthamethrin"
40745674|NCT03269006|DEVICE|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies
40745675|NCT03269006|DEVICE|ITN (KO-Tab 123)|Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin
40745676|NCT03269006|DEVICE|IRS (Delthamethrin)|Indoor residual spraying with Delthamethrin in the living rooms
40745677|NCT02448082|OTHER|Shampoo (inactive)|Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.
40745678|NCT02448082|OTHER|Sodium shale oil sulponate 1% shampoo|Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
41269810|NCT00242918|DRUG|ZD1839|
41269811|NCT00435422|PROCEDURE|Stroke volume optimization|Stroke volume optimization
41269812|NCT00841451|DRUG|Lovaza (Fish Oils)|Double blinded placebo controlled
40745679|NCT00267670|DRUG|Pentoxifylline|400mg PO TID
40745680|NCT00267670|DRUG|Placebo|1 pill PO TID
40745681|NCT00038610|DRUG|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
40745682|NCT00038610|DRUG|Cyclophosphamide|300 mg/m\^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m\^2) for courses 1, 3, 5, 7.
40745683|NCT00038610|DRUG|Doxorubicin|50 mg/m\^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
40745684|NCT00038610|DRUG|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
40745685|NCT00038610|DRUG|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
40745686|NCT00038610|DRUG|Methotrexate|"12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours on day 1 of courses 2, 4, 6, 8."
40745687|NCT00038610|DRUG|Cytarabine|"100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8."
40745688|NCT00038610|DRUG|Mesna|600 mg/m\^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
40745689|NCT00038610|DRUG|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
40745690|NCT05638984|DRUG|Decitabine Injection|Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion
40745691|NCT05638984|DRUG|tirelizumab|10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.
40745692|NCT04491994|DRUG|HCQ|Tab HCQ 400mg 12 hourly day 0 followed by tab HCQ 200mg 12 hrly for next 5 days
40745693|NCT04627753|DRUG|Rituximab, lenalidomide|Maintenance for 2 years
40745694|NCT00535834|PROCEDURE|diagnostic procedure|
40745695|NCT00535834|PROCEDURE|molecular diagnostic method|
40745696|NCT00535834|PROCEDURE|protein expression analysis|
40745697|NCT04249635|DIETARY_SUPPLEMENT|DHA|Women received supplementation of Based on Schizochytrium oil, 100% DHA (DSM) from 14 weeks of pregnancy until delivery.
40745698|NCT03608332|DEVICE|diaphragmatic ultrasound|Diaphragmatic excursion; Diaphragmatic movement will be measured with a 3.5-MHz US probe (Mindray machine, DC-N6).
40745699|NCT00870155|DRUG|dirucotide|500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination
40745700|NCT06295952|DRUG|Pasireotide|Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.
40745701|NCT06295952|OTHER|SF-36 and HADS|Baseline assessment will be conducted within 30 days of starting treatment, week 12, 24 and week 28.
40745702|NCT01192698|DRUG|IV interferon|IV interferon 5MU during anhepatic phase
40745703|NCT01835756|DEVICE|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
40745704|NCT01835756|DEVICE|Placebo Laser|The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
40745705|NCT05350423|DEVICE|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
40745706|NCT05350423|DEVICE|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
40745707|NCT01594268|DRUG|Everolimus|A prospective, open-label study to assess safety of Certican in kidney transplant patients
40745708|NCT02387918|DRUG|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
40745709|NCT02387918|DEVICE|Acupuncture|Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
40745710|NCT03093870|DRUG|Varlitinib|Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
40745711|NCT03093870|DRUG|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
41269813|NCT00295269|DRUG|Mythylprednisolone|
41269814|NCT02954380|DEVICE|Zio|long term continuous monitoring
40745712|NCT03093870|DRUG|Placebo (for Varlitinib)|oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
40745713|NCT03280030|DRUG|Midostaurin|Midostaurin 50 mg \[two 25 mg capsules\] will be administered twice per day by mouth on day 8-21 during induction and consolidation phase; then continuously during continuation phase
40745714|NCT03280030|DRUG|Placebo|Placebo two capsules will be administered twice per day by mouth on day 8-21 during induction and consolidation phase ; then continuously during continuation phase.
40745715|NCT05166642|DEVICE|Bandgrip Micro-Anchor Wound Closure|This treatment group will utilize a suture closure technique for the deep dermal layers with Bandgrip being applied to the most superficial layer of the surgical incision
40745716|NCT05166642|DEVICE|Suture closure|This treatment gourd will utilize suture closure technique for all layers of the surgical incision.
40745717|NCT02194491|OTHER|[11C]AS2471907|intravenous radiotracer
41269815|NCT03482869|DIAGNOSTIC_TEST|walking ability|Included patients will perform a 6 min walk test
41269816|NCT03540186|DIETARY_SUPPLEMENT|Epigenorm Antivir|1 capsule of Epigenorm Antivir twice daily for 3 months
40745718|NCT02194491|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
40745719|NCT02194491|DRUG|ASP3662|oral
40745720|NCT00446277|PROCEDURE|cataract surgery|
40745721|NCT00231933|BEHAVIORAL|Person-centered planning (PCP)|PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
40745722|NCT00231933|BEHAVIORAL|Community integration (CI)|CI includes recovery group sessions and community integration activities.
40745723|NCT00231933|BEHAVIORAL|Illness management recovery (IMR)|IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
40745724|NCT01111292|DRUG|Inositol|Given PO
40745725|NCT01111292|OTHER|Placebo|Given PO
40745726|NCT03432689|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
40745727|NCT03432689|DRUG|Cycloserine|Cycloserine 100mg
40745728|NCT03432689|DRUG|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
40745729|NCT01527981|BEHAVIORAL|Cognitive behavioral therapy for adherence and depression|Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
40745730|NCT06512233|DRUG|LMW Heparin 5000 U/ML-Aspirin 75 MG|Arm 1
40745731|NCT06512233|DRUG|LMW Heparin 5000 U/ML|Arm 2
40745732|NCT03682640|DRUG|Azithromycin Monohydrate|Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
40745733|NCT03682640|DRUG|Insulin Lispro|Solution for intravenous or subcutaneous use
40745734|NCT03682640|BEHAVIORAL|Dietician support|Dietary advice
40745735|NCT02842099|DRUG|TA or TAC|Taxol, Epirubincin, with or without Cyclophosphamide
40745736|NCT02842099|DRUG|X|Capecitabine
40745737|NCT02668419|DEVICE|Neuromuscular Electrical Stimulator|"Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min."
40745738|NCT02668419|OTHER|Physical Therapy Session|each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure \>15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as \>200 mmHg; 6) a rise in diastolic blood pressure during exercise \>110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
40745739|NCT03188471|DRUG|GnRH antagonist|GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients
40745740|NCT03188471|DRUG|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
40745741|NCT01209468|DEVICE|monobloc oral appliance|one piece oral appliance
40745742|NCT01209468|DEVICE|twinblock oral appliance|two-piece oral appliance
40745743|NCT00552058|BIOLOGICAL|certolizumab pegol (CDP870, CZP)|Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
40745744|NCT00552058|OTHER|Placebo|Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
40745745|NCT05791591|DIETARY_SUPPLEMENT|NUV001 - IR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) immediate release gel capsule formulation for 90 days in total
40745746|NCT05791591|DIETARY_SUPPLEMENT|NUV001 - GR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) gastro resistant gel capsule formulation for 90 days in total
40745747|NCT05791591|DIETARY_SUPPLEMENT|Placebo|Placebo containing starch Powder (1000 mg, daily in two administration orally for 90 days)
40745748|NCT01374386|BEHAVIORAL|Exergaming|Participants will have access to Exergaming equipment (video games that require physical activity)
40745749|NCT04221152|DRUG|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
40745750|NCT01446653|BEHAVIORAL|Motivational Interviewing plus feedback|Provides an MI + feedback intervention supplemented with video and brochures-based information
40745751|NCT01446653|BEHAVIORAL|Video|Video arm will provide information via documentary video
40745752|NCT01446653|BEHAVIORAL|Informational Brochure|Informational Brochures are given to participants following baseline assessment.
40745753|NCT04510753|DEVICE|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform and blood pressure values.
40745754|NCT04510753|DEVICE|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
40745755|NCT04510753|DEVICE|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
40745756|NCT00981175|BIOLOGICAL|Live attenuated Japanese encephalitis virus, then ChimeriVax diluent|ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28
40745757|NCT00981175|BIOLOGICAL|ChimeriVax diluent, then Live attenuated Japanese encephalitis virus|ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.
40745758|NCT02274428|DRUG|pneumostem|human umbilical cord blood derived mesenchymal stem cells
40745759|NCT02050295|PROCEDURE|Nerve block washout|Saline will be infused through the perineural catheter to reverse motor block.
40745760|NCT02050295|PROCEDURE|Sham washout|Infusion of saline to maintain catheter patency.
40745761|NCT02050295|DRUG|Saline|
40745762|NCT00762177|DRUG|Fluoride|Brush twice a day for 14 days
40745763|NCT00762177|DRUG|Fluoride, Triclosan|Brush twice daily for 14 days
40745764|NCT00762177|DRUG|Stannous Fluoride|Brush twice daily for 14 days
40745765|NCT00775086|DRUG|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
40745766|NCT01294072|DIETARY_SUPPLEMENT|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
40745767|NCT01294072|DIETARY_SUPPLEMENT|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
40745768|NCT01294072|OTHER|No intervention|no treatment
40745769|NCT00845000|DRUG|SCH 420814 10 mg|one 10-mg capsule, orally, at hour 0 of treatment period
40745770|NCT00845000|DRUG|SCH 420814 100 mg|single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
40745771|NCT00845000|DRUG|Placebo|Placebo capsule, oral, at hour 0 of treatment period
40745772|NCT00845000|DRUG|Levodopa|levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
40745773|NCT00845000|DRUG|Carbidopa|one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
40745774|NCT00705822|DRUG|Docetaxel + Estramustine + Hydrocortisone|"Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks"
41095069|NCT05564988|OTHER|Preconditionning|"Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.~Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days."
40745775|NCT00705822|DRUG|Docetaxel + Prednisone|Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
40745776|NCT01056575|DRUG|OC000459|OC000459 100mg tablet, twice daily
40745777|NCT02119000|DRUG|PEG/electrolytes 2L/2L split dose|Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
40745778|NCT02119000|DRUG|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|"Bisacodyl 15 mg x 3~At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:~PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes"
40745779|NCT05354258|DRUG|Albendazole|Anthelminthic drugs for the treatment of soil-transmitted helminths
40745780|NCT05354258|DRUG|Praziquantel|Anthelminthic drugs for the treatment of schistosomiasis
40745781|NCT05354258|DRUG|Amodiaquine|SMC partner drug
40745782|NCT05354258|DRUG|Sulfadoxine pyrimethamine|SMC partner drug
40745783|NCT05779644|DRUG|Liraglutide|Liraglutide is injected once a day.
40745784|NCT05779644|DRUG|Semaglutide|Semaglutide is injected once a week.
40745785|NCT05779644|DRUG|Metformin|Metformin is taken orally daily.
40745786|NCT01344200|DRUG|Celecoxib|In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
40745787|NCT01344200|DRUG|Placebo|In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
40745788|NCT06147154|OTHER|16S rRNA amplicon sequencing and untargeted metabolomics|"16S rRNA sequencing is a method for large-scale identification of community composition, expression abundance, and phylogenetic analysis by polymerase chain reaction (PCR) amplification of specific variable regions of 16S rRNA, combined with high-throughput sequencing and bioinformatics analysis. It also enables large-scale identification of the entire flora in a given habitat to study microbial diversity.~Untargeted metabolomics refers to the use of Liquid Chromatograph Mass Spectrometer (LC-MS), Gas Chromatograph Mass Spectrometer (GC-MS), and nuclear magnetic resonance (NMR) technology. The dynamic changes of small molecular metabolites in cells, tissues, organs or organisms before and after stimulation or disturbance were detected without bias. The differential metabolites were screened by bioinformatics analysis, and the pathway analysis of differential metabolites was performed to reveal the physiological mechanism of their changes."
40745789|NCT02113215|PROCEDURE|Stable Isotope Infusion|9-hour infusion of stable isotope tracers
40745790|NCT06545864|DRUG|Streptokinase Injection|250000 IU as a loading dose over 30 min. Followed by 100000 IU/hour over 12:24hours or accelerated regimen 1.5 million IU over 2 hours
40745791|NCT06545864|DEVICE|Penumbra System|"which comprised of several devices:~* RED Reperfusion Catheters~* Penumbra JET Reperfusion Catheters~* ACE Reperfusion Catheters~* MAX Reperfusion Catheters~* 3D Revascularization Device~* Penumbra ENGINE Aspiration Source~* Penumbra ENGINE Canister~* Aspiration Tubing"
40745792|NCT00111332|BEHAVIORAL|Progressive resistance and aerobic training|
40745793|NCT04047472|DRUG|Brolucizumab 6mg|Subjects will receive Brolucizumab 3 x q4w up to Week 8 followed by q12w / q8w up to Week 40 or Week 44, depending on disease activity status.
40745794|NCT04047472|DRUG|Aflibercept 2 mg|Subjects will receive Aflibercept 3 x q4w up to Week 8 followed by q8w up to Week 40.
40745795|NCT02783989|OTHER|white wine|A dietary beverage: a market white wine, 13º alcohol
40745796|NCT02783989|DIETARY_SUPPLEMENT|tyrosol|tyrosol in capsules
40745797|NCT01111669|DRUG|Tranexamic Acid|The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
40745798|NCT01111669|DRUG|Normal Saline (placebo)|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
40745799|NCT06181851|OTHER|Analysis of microbiome and metabolomics|Analysis of microbiome and metabolomics through the assessment of blood and semen parameters
40745800|NCT01618877|DRUG|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
40745801|NCT01618877|OTHER|Placebo|15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
40745802|NCT03752931|DRUG|Celiprolol|receiving 1 tablet per day of Celiprolol 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
40745803|NCT03752931|DRUG|Diltiazem|receiving 1 tablet per day of Diltiazem 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
40745804|NCT02068599|DRUG|TV-45070|TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
40745805|NCT02068599|DRUG|Placebo|Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
40745806|NCT05586360|DRUG|Simvastatin 40mg|Simvastatin 40mg taken orally daily for 8 weeks
40745807|NCT03267589|DRUG|Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562|Three different combination are being tested. Each cohort has different combination
40745808|NCT05308693|OTHER|Education material - Patient Compatible Stoma Educational Material|It is an educational material made of rubber, similar to a stoma, that can be placed on the patient.
40745809|NCT06114199|BEHAVIORAL|Produce Prescription Program (PPRx) Standard|Participants will receive biweekly deliveries of 20 lbs (\~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.
40745810|NCT06114199|BEHAVIORAL|Smartphone App|Participants will be given access to a smartphone app that allows women to interact with an artificial intelligence (AI) chatbot to obtain real-time cooking suggestions.
40745811|NCT04796896|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
40745812|NCT04796896|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
40745813|NCT04796896|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
40745814|NCT02912377|BIOLOGICAL|Neulasta, B12019|GCSF, Growth Colony Stimulating Factor
40745815|NCT00712049|DRUG|simvastatin|simvastatin 40 mg
40745816|NCT00712049|DRUG|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
40745817|NCT02829814|DRUG|TNX-102 SL Tablet, 2.8 mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
40745818|NCT02829814|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
40745819|NCT04914663|BEHAVIORAL|Exercise training|Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.
40745820|NCT03780725|DRUG|BI 754111|Solution for infusion
40745821|NCT03780725|DRUG|[89Zr]Zr-BI 754111|Solution for infusion
40745822|NCT03780725|DRUG|BI 754091|Solution for infusion
40745823|NCT03651492|BEHAVIORAL|questionnaire administration|All the patients will be administered the Pittsburgh Questionnaire after completion of ABPM.
40745824|NCT03802110|DEVICE|commercially released subcutaneous implantable cardioverter defibrillator (S-ICD) and the Investigational S-ICD Adapter.|The S-ICD System is a Subcutaneous (under the skin) Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. A new electrode configuration will be tested for Defibrillation testing ( DFT). The unit of measure will be in Joules. VF will be induced and the device will deliver a shock at a certain defined energy level as described in the protocol
41095070|NCT05526508|DEVICE|Rebound exercise|Exercise training on the rebounder/ mini-trampoline with stability handles attached
40745825|NCT06543290|DRUG|Azithromycin Pill|Azithromycin 2 grams to be administered prior to start of induction for those randomized to the study arm
40745826|NCT01406912|OTHER|Recreational Activity|Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
40745827|NCT01406912|OTHER|Wii Gaming System Arm|Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
40745828|NCT01227395|DRUG|Azithromycin|"Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults."
40745829|NCT03483220|DIAGNOSTIC_TEST|MRI brain|"1. Emotion Regulation Questionnaire (ERQ): A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale .~UPPS-P Impulsive Behavior Scale- Short form: The UPPS-P impulsivity scale is a 20-item scale designed to assess five distinct personality traits to impulsive behavior: Negative Urgency, Lack of Perseverance, Lack of Premeditation, Positive Urgency and Sensation Seeking .~Magnetic resonance imaging examination:~The MR examination of brain was done using 1.5T MR scanner (Achieva, Philips Medical Systems, The Netherlands) with a 16 channel head coil without using any sedation."
40745830|NCT04560218|DRUG|sublingual Misoprostol|apply drug by Anesthesiologist
40745831|NCT04560218|DRUG|Intrauterine Misoprostol|apply drug by surgeon at uterine cornu
40745832|NCT02056132|OTHER|Exhaled Breath Condensate|Lab results of Exhaled Breath Condensate
40745833|NCT04488185|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg administered s.c. (2 single-use prefilled syringes of 150 mg/mL), on Days 1, 8, 15, 22, 29, 57, 85.
40745834|NCT04488185|OTHER|Placebo|Placebo administered s.c. (2 single-use prefilled 1 mL syringes) on Days 1, 8, 15, 22, 29, 57, 85.
40745835|NCT04398966|DEVICE|Prostatic Artery Embolization (HydroPearl® compressible microspheres)|Embolic material
40745836|NCT02473874|DEVICE|Skin Spect dermoscope|Skin imaging
40745837|NCT02473874|DEVICE|Spatially modulated quantitative|Skin imaging
40745838|NCT02744768|DRUG|Dasatinib|Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.
40745839|NCT02744768|DRUG|Blinatumomab|"Upon induction:~patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary."
40745840|NCT02015156|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
40745841|NCT02015156|BIOLOGICAL|Herceptin®|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
40745842|NCT05447832|DEVICE|Lung function monitoring equipment at home - 2 weeks|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once daily for 2 weeks.
40745843|NCT05447832|DEVICE|Lung function monitoring equipment at home - 4 months|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once weekly for 4 months.
40745844|NCT05447832|DIAGNOSTIC_TEST|Inflammation and remodelling from clinical indicted bronchoscopy|For patients who are undergoing clinically indicated bronchoscopy, consent will be obtained to use any surplus clinical samples for this study. The samples to be collected are broncho-alveolar lavage and endobronchial biopsies. Both of these are taken from the airways during clinical bronchoscopy.
40745845|NCT02732145|DIAGNOSTIC_TEST|"Three Rings Vulvoscopy (TRIV)"|"Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme."
40745846|NCT02732145|PROCEDURE|Histopathology|Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
40745847|NCT01567085|DRUG|Eculizumab|
40745848|NCT00153920|DRUG|bortezomib|
40745849|NCT05921500|DRUG|sodium peborate|Internal bleaching of discolored primary anterior teeth by using sodium peborate
40745850|NCT03035539|OTHER|Cardiac rehabilitation|AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
40745851|NCT03035539|OTHER|Standard treatment|Standard treatment
40745852|NCT03022630|OTHER|Comprehensive Palliative Care services|Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.
40745853|NCT03022630|OTHER|Usual hepatic care|Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
40745854|NCT03729479|BEHAVIORAL|DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
41095071|NCT00256308|DRUG|Oxaliplatin|70mg/m2 IV over 120 min once a week during radiation
41095072|NCT00256308|PROCEDURE|Radiation|200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
41095073|NCT01890161|DRUG|AXP1275|AXP1275 50 mg (2 × 25-mg capsules)
41095074|NCT01890161|DRUG|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules)
40745855|NCT03729479|BEHAVIORAL|Very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
41095075|NCT06321159|OTHER|mobile application|mobile application for diet, exercises and medication adherence
41095076|NCT02582411|DEVICE|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
40745856|NCT03729479|BEHAVIORAL|Extras|Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.
40745857|NCT06165874|RADIATION|[68Ga]Ga-NOTA-RW102 PET Imaging|Intravenous injection of 1.8 MBq\[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RW102 in a single dose.
40745858|NCT02679092|DRUG|Misoprostol|400 mcg buccal 60-90 minutes prior to procedure
40745859|NCT02679092|DRUG|Mifepristone|200 mg PO on the day prior to D\&E
40745860|NCT02679092|DEVICE|Hygroscopic cervical dilators|osmotic cervical dilators inserted through the internal os
40745861|NCT03295916|RADIATION|Stereotactic Body Radiotherapy|Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
40745862|NCT00694161|DRUG|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
40745863|NCT05546528|DEVICE|Photobiomodulation|G1 will receive the photobiomodulation application with the Laser Therapy XT device, (DMC, São Paulo, Brazil). The laser will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
40745864|NCT05546528|DEVICE|Photobiomodulation- Sham|G2 will receive the photobiomodulation application with the Laser Therapy XT device off. The laser off will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
40745865|NCT00582452|OTHER|Telephone survey|Telephone survey
40745866|NCT01674855|DRUG|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
40745867|NCT01674855|DRUG|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
40745868|NCT00837330|DRUG|ranibizumab 0.5 or 0.3 mg/0.05 cc|ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
41095077|NCT02582411|DEVICE|Doppler Optical Coherence Tomography|"A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time."
41269817|NCT03540186|PROCEDURE|Acupuncture|Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion
40745869|NCT05833932|DRUG|Suhexiang Pill|Suhexiang Pill is an approved traditional Chinese patent medicine.
40745870|NCT03343574|OTHER|Abdominal Strengthening Exercise|Abdominal strengthening exercises involve the muscles of the abdomen. These exercises are to be done in different positions like lying down (recumbent) position, sitting and standing positions. The person performing the exercise contracts the abdominal muscles for a predetermined number of times (up to 10 times), holds the contracted position for up to 10 seconds and then releases the contraction to relax and return to the original state. These exercises are done for three times everyday.
40745871|NCT00152854|DRUG|Acetaminophen|acetaminophen 1g po qid
40745872|NCT00152854|DRUG|acetaminophen|acetaminophen 1g po qid for 7 days
40745873|NCT00152854|DRUG|placebo, sugar pill|
40745874|NCT00427596|DRUG|Solabegron|
40745875|NCT06470724|BEHAVIORAL|Structural visual approach|"The intervention comprised seven behavior approaches in this research defined as follows:~A successive approach: An approach to familiarization with the unfamiliar environment of the simulated dental office.~Tell-Feel-Show-Do (T-F-S-D): A dental approach explained to the patient's treatment by telling the patient what would happen, what he felt or did, and what had been done.~Visual pedagogy: Introduced dentistry to autistic children through visual media, such as pictures and photographs.~Audiovisual modeling: A learning process through audiovisual media, such as video and animation.~In-vivo modeling: Learning new activities by watching them in front of the model.~Behavioral trials: A learning strategy conducted through practicing the recent activity by him/herself.~Auto-modeling: A learning process following the activity of editing pictures during the prior visit of the patient."
40745876|NCT00915187|DRUG|CCS/C|Adjuvant to influenza vaccine
40745877|NCT00915187|BIOLOGICAL|Influenza Vaccine|Influenza vaccine
40745878|NCT02058277|DRUG|bosutinib or bosutinib + aprepitant|Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)
40745879|NCT06036238|BEHAVIORAL|Healthy Living Intervention (HLI)|The Healthy Living Intervention (HLI) is a brief alcohol counseling intervention developed using the Information, Motivation, and Behavioral skills (IMB) model, a framework in which information, motivation, and behavioral skills are key determinants of health behavior. Participants initiating PrEP will be randomized to either HLI or standard of care alcohol counseling.
40745880|NCT06036238|BEHAVIORAL|Standard of Care|Participants who are randomized to the control arm will receive basic alcohol counseling through the Ministry of Health if it is provided as standard of care.
40745881|NCT01446588|BEHAVIORAL|Yoga Intervention|Three yoga classes per week for 8 weeks.
40745882|NCT03901209|DEVICE|Mid-face osteotomy|The mid-face osteotomy - typically according to LeFort I - is performed using a pulsed erbium-doped yttrium aluminium garnet (Er:YAG) laser driven by the CARLO robot arm.
40745883|NCT05840406|DRUG|Postoperative pain management with acetaminophen|During the 24 hours postoperatively, participants will receive 1 g acetaminophen intravenously (i.v.) three times a day. On the second and third postoperative days, participants will receive 1g acetaminophen per os three times a day.
40745884|NCT05840406|PROCEDURE|Bilateral TAP Block with levobupivacaine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine will be administered to the participant on each side.
40745885|NCT05840406|PROCEDURE|Bilateral TAP Block with levobupivacaine and dexmedetomidine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine with the addition of 0,5 μg/kg dexmedetomidine will be administered to the participant on each side.
40745886|NCT05840406|DRUG|Postoperative pain management with tramadol|During the 24 hours postoperatively, participants will receive 500 mg tramadol + 500 ml 0,9% NaCl i.v. continuously 30ml/h.
40745887|NCT05840406|DRUG|Postoperative pain management with ketoprofen|During the 24 hours postoperatively, participants will receive 100 mg ketoprofen + 100 ml of 0,9% NaCl i.v. twice a day. The first dose will be administered in the theatre at the end of the surgical procedure.
40745888|NCT05840406|DRUG|Postoperative pain management with ibuprofen|On the second and third postoperative days, participants will receive 600 mg ibuprofen per os three times a day.
40745889|NCT05679505|DEVICE|Auricular transcutaneous vagus nerve stimulation|Transcutaneous vagus nerve stimulation (taVNS) was performed with an FDA-approved Vagustim stimulation device and an electrode-shaped earpiece. In the participants included in the study and randomized to two groups, i) left ear taVNS was applied to the first group and ii) double-ear taVNS was applied to the second group.
40745890|NCT02952677|BEHAVIORAL|Remind-to-move|Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
40745891|NCT02952677|BEHAVIORAL|Sham|Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
40745892|NCT02952677|OTHER|Control|Participants received usual care
40745893|NCT02522182|BEHAVIORAL|Nurse-led Intensive Secondary Prevention Programme|Information related to intervention description have been already included in arm/group description
40745894|NCT02522182|BEHAVIORAL|Usual Treatment|Information related to intervention description have been already included in arm/group description
40745895|NCT03587597|PROCEDURE|socket shield technique|socket shield technique with immediate temporization
40745896|NCT03587597|PROCEDURE|conventional immediate implant placement with immediate temporization|conventional immediate implant placement with immediate temporization
40745897|NCT00138294|BIOLOGICAL|live attenuated and inactivated influenza vaccines|Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
40745898|NCT04498104|OTHER|Psychological assessment|Psychological assessment with the repertory grid technique (RGT) in order to quantify cognitive conflicts.
40745899|NCT06348212|DIETARY_SUPPLEMENT|Lactobacillus paracasei PS23|2 caps daily use
40745900|NCT06348212|DIETARY_SUPPLEMENT|microcrystalline cellulose|2 caps daily use
40745901|NCT05834153|DEVICE|kinesiotaping|"This group underwent a KT application on rectus abdominis muscle (RAM), oblique abdominal muscles (OAM) and cesarean incision twice a week for a period of 4 weeks. First, the scar technique will apply using I band with a tension of 50 % on cesarean incision when the patient will be in supine position. Then, tape will apply on RAM using muscle technique from origin to insertion of the muscle with a tension between 15 and 25 %.~Band will start on symphysis pubis with no tension, and then the patient was asked to stretch the abdominal region by deep abdominal respiration, and it will ended on xiphoid process.~Finally, it will perform on the right and left external oblique muscles. The procedure will start with no tension from the bottom end of the 6-12th ribs and then the hip will placed in flexion and rotation to the opposite direction and the band will taped on pubic bone with a tension between 15 and 25 %"
40745902|NCT05834153|DEVICE|electrical muscle stimulation|"It consists of 24 patients who will receive NMES and core stabilization exercises.~The subjects will explain to relax their abdominal muscles while application Stimulation will apply by four large rectangular electrodes placed over the origin (pubic crest) and insertion (xiphoid process) of the rectus abdominis muscles bilaterally. Straps will used to fix the electrodes in place. A frequency of 80 pulses/min and with a pulse width of 0.1-0.5ms, will the parameter settings apply in this study. The total time for the application of stimulation will 30mins and until a good enough observable muscle contraction will achieve a gradual increase in intensity will perform"
40745903|NCT05863416|DRUG|Dexmedetomidine infusion|Intraoperative dexmedetomidine infusion
40745904|NCT04939389|DIAGNOSTIC_TEST|Orthelligent Pro|The sensor is attached to the knee of the participant and eight different movement exercises are performed
40745905|NCT06480357|PROCEDURE|laparoscopic adrenalectomy|laparoscopic transabdominal approach.
41095078|NCT06184789|DIAGNOSTIC_TEST|Echocardiographic assessment|Echocardiographic and hemodynamics assessment of Mitraclip results
41095079|NCT02516774|DRUG|Adalimumab|
41095080|NCT04496674|DRUG|CC-1 and Toczilizumab|Adminsitration of CC-1 and Toczilizumab
41095081|NCT00502281|DRUG|highly purified urinary FSH|
41095082|NCT00502281|BEHAVIORAL|timed intercourses, intrauterine insemination|
40745906|NCT03976128|BEHAVIORAL|Nordic Walking Training|The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
40745907|NCT03976128|BEHAVIORAL|Conventional endurance training|15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
40745908|NCT06154174|DIETARY_SUPPLEMENT|C-RUTF (Ready-to-Use Therapeutic Food with added choline)|Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
40745909|NCT06154174|DIETARY_SUPPLEMENT|S-RUTF (Ready-to-Use Therapeutic Food without added choline)|Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
40745910|NCT06154174|DRUG|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
40745911|NCT00169260|BEHAVIORAL|motivational counseling|behavioral motivational counselling
40745912|NCT00169260|BEHAVIORAL|placebo|
40745913|NCT04744662|DRUG|ONL1204 Ophthalmic solution|Liquid formulation administered by intravitreal (IVT) injection
40745914|NCT04744662|PROCEDURE|sham injection|sham injection is done by touching the eye surface with a syringe without a needle
40745915|NCT04229576|DEVICE|TENs|Assessing the efficacy of TENs in pain relieve during office hysteroscopy .
40745916|NCT04073576|DEVICE|AHCL|Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.
40745917|NCT04073576|DEVICE|SAP+PLGM|Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
40745918|NCT06277726|OTHER|Emotional freedom technique group|Emotional freedom technique will be applied to women in this group before intrauterine device application.
40745919|NCT06277726|OTHER|Music group|Women in this group will wear headphones and listen to music throughout the intrauterine device application.
40745920|NCT06277726|OTHER|Control group|No intervention will be applied to women in the control group.
40745921|NCT03985995|DRUG|CBD 800 mg p.o|cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.
40745922|NCT03985995|DRUG|Placebo p.o|single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
40745923|NCT03407586|DIAGNOSTIC_TEST|Point-of-care STI testing|All participants underwent point-of-care STI testing (GeneXpert), and if diagnosed with a STI were offered immediate therapy, and expedited therapy, if indicated.
40745924|NCT06241443|OTHER|hybrid simulation|"During the hybrid simulation, a student and a standardized patient participated. The patient wore a wearable pregnancy model. Before the start of the Natural Birth Approach Scenario, a pre-briefing session was conducted. The student's performance during the simulation was recorded on video, and each simulation lasted approximately 30 minutes. After the simulation, a debriefing session was held with the student, and feedback was given. Scales were used to evaluate the implementation of the practices."
40745925|NCT06241443|OTHER|video-modeling|"The students in the group had the opportunity to learn through an educational video that followed the Natural Birth Approach Scenario. Afterward, they put their knowledge into practice and were evaluated using the Birth Approach Clinical Skills Guide. A feedback session followed the practice session. Finally, they were assessed using scales to measure their performance."
40745926|NCT01908842|DRUG|BNX sublingual tablets|Buprenorphine/naloxone sublingual tablets
40745927|NCT01908842|DRUG|BNX sublingual film|Buprenorphine/naloxone sublingual film
40745928|NCT01908842|DRUG|Buprenorphine|Buprenorphine sublingual tablets
40745929|NCT05142085|DIETARY_SUPPLEMENT|nano-PSO|This active treatment will be delivered to 3 out of 5 patients
40745930|NCT05142085|OTHER|placebo|This treatment will be assigned to 2 out of 5 patients
40745931|NCT06433063|DIAGNOSTIC_TEST|F-MISO PET|Evaluation of tumor hypoxia with F-MISO PET
40745932|NCT04742179|OTHER|Manteinance and care intervention on the green areas.|Manteinance and care intervention on the green areas.
40745933|NCT00369083|PROCEDURE|Hospital at home treatment|
41095083|NCT03329833|BEHAVIORAL|Motivational Interviewing|Motivational interviewing will consist of weekly phone calls for two months, bi-weekly phone calls for two months, and monthly phone calls for two months.
40745934|NCT03812250|PROCEDURE|ERCP assisted trans-papillary drainage for malignant biliary obstruction|ERCP assisted trans-papillary drainage for malignant biliary obstruction
40745935|NCT03812250|PROCEDURE|EUS-guide biliary drainage for malignant biliary obstruction|EUS-guide biliary drainage for malignant biliary obstruction
40745936|NCT02305615|OTHER|Bevacizumab|Bevacizumab at a dose and schedule according to approved label and SmPC. The recommended dose of bevacizumab, administered as an intravenous infusion, is either 5 milligrams per kilogram (mg/kg) or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. Bevacizumab is always used in combination with chemotherapy for the treatment of participants with metastatic CRC. It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.
40745937|NCT02305615|COMBINATION_PRODUCT|Chemotherapy|Fluoropyrimidine-based doublet chemotherapy (5-Fluorouracil \[5-FU\] or capecitabine plus oxaliplatin or irinotecan) as first-line treatment; and continued fluoropyrimidine treatment with or without treatment modification for oxaliplatin or irinotecan, as per treating physician discretion.
41095084|NCT03329833|BEHAVIORAL|Web-based application|Web-based application participants will be asked to log activity at least on a daily basis.
41269818|NCT02502864|DRUG|Standard of Care: Docetaxel|Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m\^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.
41269819|NCT02502864|DRUG|Standard of Care: Cyclophosphamide|Cycle 1: 600 mg/m\^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
40745938|NCT05492435|DEVICE|transcranial direct current stimulation|tDCS can regulate cortical excitability by influencing membrane polarity, where anodic current increases excitability and cathodic current reduces excitability. Therefore, in post-stroke patients when the anode is applied to the cerebral hemisphere ipsilesional to the lesion or the cathode to the contralesional hemisphere, the balance between the interhemispheres tends to be restored.
40745939|NCT05585775|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|MBCT classes are comprised of weekly, 2.5-hour classes in which participants learn cognitive therapy techniques and practice meditation exercises. Participants will complete group and/or individual orientation to MBCT with the MBCT instructor, 1-2 weeks prior to the first scheduled MBCT class. Additionally, MBCT requires 45-minutes of daily home practice, and a full day, 8-hour silent meditation retreat. MBCT classes are delivered via the protocol and curriculum developed by the MBCT founders. Participants randomized to MBCT will receive 8-weeks of MBCT classes.
40745940|NCT05585775|BEHAVIORAL|Wellness for Wellbeing|Wellness for Wellbeing will serve as the active control for MBCT. Participants randomized to Wellness for Wellbeing will receive 1-hour group delivered classes, once per week, for 8-weeks. Participants will receive an orientation to Wellness for Wellbeing 1-2 weeks prior to the first class. Classes will be delivered by a research therapist. Topics for Wellness for Wellbeing include: nutrition, caffeine, preventing cancer, diabetes, heart health, sleep, being a smart patient, and complementary and alternative medicine. Wellness for Wellbeing classes are interactive and do not include components designed to impact affective cognition in any way. Because participants may have varying levels of health literacy, the research therapist tailors presentation of the material to the participants' level of knowledge of the topic. Information presented in Wellness for Wellbeing is regularly updated with current health guidelines.
40745941|NCT01509807|DRUG|IV morphine sulfate or Sponsor-approved equivalent|Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.
40745942|NCT01509807|DRUG|EXPAREL|Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
40745943|NCT05531097|DRUG|HSK31679|Single or multiple oral doses of HSK31679
40745944|NCT05531097|DRUG|Placebo|Matching placebo
40745945|NCT01615718|PROCEDURE|low-intensity transcranial electrical stimulation|Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
40745946|NCT01615718|PROCEDURE|transcranial ultrasound|Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
40745947|NCT01286649|OTHER|Human autologous hair follicle cells|Human autologous hair follicle cells suspended in cell medium
40745948|NCT01286649|OTHER|Cell medium|Cell medium
40745949|NCT02974231|RADIATION|Intensity-modulated radiation therapy|
40745950|NCT03491917|DEVICE|DBT plus S-View|DBT plus S-View images
41095085|NCT04053829|DEVICE|HOLOBalance|"The HOLOBalance tele-rehabilitation system will be used to deliver an evidence based, multi-sensory balance rehabilitation programme to participants, and will deliver a series of exercises prescribed by an expert balance physiotherapist following an initial balance assessment.~The HOLOBalance system will use a head mounted augmented reality display to deliver exercises and games to participants and will record task performance via a combination of body worn sensors and a depth camera. The HOLOBalance tele-rehabilitation system will provide feedback to the supervising clinical team regarding task performance, participant usage and user feedback. The system will have daily presence in the users' home with users expected to complete their prescribed rehabilitation on a daily basis, which mirrors the prescribed exercise routines often provided by balance physiotherapists."
41095086|NCT04053829|OTHER|OTAGO Home Exercise Programme|The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. It is well-established and widely used in clinical practice in the UK, and has been shown to reduce falls rate in older adults by 35-40%. It is well tolerated in older adults in community settings with good adherence rates.The OTAGO has also been used as the standard intervention in previous investigations of MSR interventions in older adults. To match intervention and control interventions, participants in the OTAGO group will be asked to complete the OTAGO programme every day for the duration of the 8 week programme.
41095087|NCT06548477|DRUG|Human albumin|Patients in intervention arm will also receive intermittent boluses of 20 percent human albumin (in addition to standard fluid therapy) that will be administered with dosage regimen of 1.25gm/kg of body weight per 24 hours. The maximum total calculated dose/volume of albumin for the patient will be infused @ 34 ml/hour (over 3 hours) and will be divided in 3 boluses, spaced at 8 hours intervals. During intervention period, duration of treatment (7-day study period) will cover the peak period of cerebral vasospasm from day 4th until 10th day. Albumin administration will be tailored according to the targeted values set for euvolemic fluid balance in each patient. Before randomization (within 72 hours post-ictus) and after day-10 (from day 11th-14th, patient will only receive standard fluid therapy.
41095088|NCT02109393|OTHER|MIRT|"It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues, cycloergometer, treadmill-plus. The third is a session of occupational therapy. The last session includes one hour of speech therapy.~All patients undergo 20-minutes treadmill-plus training per day, 5 times a week, for 4 weeks."
40745951|NCT03491917|DEVICE|FFDM alone|FFDM alone images
40745952|NCT06063343|DRUG|KAND145|In Part 1 of the study, single ascending doses of KAND145 will be administered; in Part 2 of the study, multiple ascending doses (BID for 8 days) of KAND145 will be administered.
41095089|NCT02109393|OTHER|MIRT+Lokomat|It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues and cycloergometer. The third is a session of occupational therapy to improve autonomy in activities of daily life. The last session includes one hour of speech therapy. All patients undergo 20-minutes Lokomat® training per day in spite of treadmill-plus.
41442910|NCT03417960|DEVICE|iTBS|"The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold.~In study 1, the accelerated paradigm will consist of 10 such sessions separated by 15 minutes, for three treatment days per week. There will be 2 weeks of 10 sessions on each of three days for a total of six treatment days, divided by one treatment-free week between treatment weeks. In study 2, the accelerated paradigm will consist of 12 sessions per day for 5 total treatment days. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method."
41442911|NCT03420053|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.
41442912|NCT03420053|OTHER|Normal Saline Placebo|0.9% sodium chloride solution
41442913|NCT03420053|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
41442914|NCT00264108|DRUG|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
41442915|NCT00264108|DRUG|Epoetin alfa|40,000 IU once weekly, variable treatment length.
41442916|NCT04349553|BIOLOGICAL|ZH9PA and ZH9|150mL vaccine for oral administration
41442917|NCT04349553|BIOLOGICAL|Placebo|150mL vaccine for oral administration
41442918|NCT04349553|BIOLOGICAL|ZH9PA|150mL vaccine for oral administration
41442919|NCT00395980|DEVICE|surgical table pressure mat|
41442920|NCT03865563|DRUG|Retrograde venous infusion of gemcitabine/lipiodol|Access will be gained into the portal vein via a transhepatic approach. The pancreatic tumor-draining veins will be accessed via a catheter positioned in the portal vein, superior mesenteric vein or splenic vein. The catheter is then advanced into the vein draining the segment in which the targeted tumor is located. Tumor location and its venous drainage will be confirmed with sub-selective pancreatic venography and cone-beam CT. Once correct catheter positioning is confirmed, the gemcitabine/Lipiodol® emulsion will be administered under real-time fluoroscopic guidance until the entire dose is administered or until stasis is achieved in the vein through which the drug is being delivered.
41442921|NCT04584138|BEHAVIORAL|Study of eye movements|The assessment of eye movement during autobiographical retrieval (i.e., retrieval of personal memories) in patients with Alzheimer's Disease.
41442922|NCT06445049|OTHER|brief test|"The intervention is a simple brief test as follows: With the ventilator set with the patient clinical settings, it will be performed an up to 30sec-long or two inspiratory effort and-expiratory occlusion maneuver on the ventilator and/or switch the patient to pressure support for up to 30sec-long to assess the presence of intrinsic respiratory rate.~If an intrinsic respiratory rate ≥8 breaths per minute is present and P/F ratio is ≥150 it will be performed a 5-minute test in pressure support ventilation with the pressure support level to match the clinical setting of the patient. If the patient tolerates well 5 minutes in pressure support (see criteria below) the clinical team will be informed:~- It will be indicated that the patient tolerated 5 min of PSV and suggest to the clinicians and physician in charge to transition the patient to pressure support ventilation plus suggest reducing sedation."
41442923|NCT04626050|BEHAVIORAL|Medical Music|Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks
41442924|NCT04626050|BEHAVIORAL|Narrative Writing|Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks
41442925|NCT04626050|BEHAVIORAL|Prolonged Exposure Therapy|Psychotherapy including imaginal exposure for PTSD
41442926|NCT04626050|BEHAVIORAL|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning
41442927|NCT05329103|DRUG|PEEL-224|Lyophilized powder reconstituted with D5W
41442928|NCT01112254|PROCEDURE|MRI±biopsy|A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
41442929|NCT01895335|DRUG|Teriflunomide|Pharmaceutical form: film-coated tablet; Route of administration: oral
41442930|NCT00910221|DRUG|Atorvastatin|Atorvastatin tablet
41442931|NCT00910221|DRUG|Placebo|Placebo tablet
41442932|NCT04979663|COMBINATION_PRODUCT|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
41442933|NCT05954728|BEHAVIORAL|Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)|CBT-AR is a four-stage modular treatment for ARFID delivered by a mental health clinician. The four stages include: 1) Psychoeducation and early change; 2) Treatment planning; 3) Addressing maintaining mechanisms; and 4) Relapse prevention. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
41442934|NCT05954728|BEHAVIORAL|Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder|Nutrition counseling will be provided by skilled registered dietitians at the MGH Translational and Clinical Research Center (TCRC). Sessions focus on the foods necessary for a healthy diet, how to meet nutritional needs, how to incorporate healthy exercise, and support for making these changes. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
40745953|NCT06063343|DRUG|Placebo|Participants randomized to the placebo arms will receive placebo at the same dosing frequency as the experimental arms.
41442935|NCT03811418|DRUG|Trastuzumab|"administered as combined therapy with pertuzumab and vinorelbine or docetaxel.~Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) on day 1 of cycle 1 (1 cycle length = 21 days), and 6 mg/kg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
41442936|NCT03811418|DRUG|Pertuzumab|"administered as combined therapy with Kanjinti® and vinorelbine or docetaxel.~Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
41442937|NCT03811418|DRUG|Vinorelbine|"administered as combined therapy with Kanjinti® and pertuzumab.~Vinorelbine will be administered as an IV dose of 25 milligrams per kilogram (mg/kg) on days 1 and 8 of cycle 1 (1 cycle length = 21 days), and 25mg/kg up to 30 mg/kg (as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
41442938|NCT03811418|DRUG|Docetaxel|"administered as combined therapy with Kanjinti® and pertuzumab.~Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m\^2) on day 1 of cycle 1 (1 cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
41442939|NCT01153503|PROCEDURE|TAP block|"Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
41442940|NCT03046550|DRUG|NTM-1634|NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
41442941|NCT03046550|DRUG|Placebo|placebo
41442942|NCT01948167|BEHAVIORAL|Interpersonal Psychotherapy- Adolescent Skills Training|A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.
41442943|NCT01948167|BEHAVIORAL|Coping with Stress|A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
41442944|NCT04559386|OTHER|Survey|Questionnaire
41442945|NCT04456842|OTHER|Patient Registry Data|To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.
41442946|NCT00295477|GENETIC|VRX496|In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.
41442947|NCT05036070|DEVICE|Model C0001|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
41442948|NCT05036070|DEVICE|Model ZCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
41442949|NCT04629963|OTHER|Pain Evaluation and BPISF|Current diagnostic approaches guide evaluators to use the United Nations Istanbul Protocol (UNIP) for the assessment of torture survivors. The proposed investigation offers a novel diagnostic paradigm by which participants are evaluated by the UNIP and a validated pain screen (Brief Pain Inventory Short Form).
41442950|NCT04629963|OTHER|Surveys, a fingerstick blood sample, EMAs, and a digital wearable device|The following surveys: BPI-SF, RHS-15, RTHC, SOIS-SF, RPMS, WHOAQ, QVSFS, a fingerstick blood sample, EMAs, and a digital wearable device
41442951|NCT04647526|DRUG|[Lu-177]-PNT2002|Participants randomized to Arm A will receive 6.8 GBq (±10%) of \[Lu-177\]-PNT2002 every 8 weeks for 4 cycles
41442952|NCT04647526|DRUG|Abiraterone|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
41442953|NCT04647526|DRUG|Enzalutamide|Enzalutamide (160 mg orally qd)
41442954|NCT06395246|BEHAVIORAL|Active Comparator: Continuous calorie restriction|Individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
41442955|NCT06395246|BEHAVIORAL|eTRE|early (morning) time-restricted eating pluss individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
41442956|NCT02951858|BEHAVIORAL|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
41442957|NCT02951858|BEHAVIORAL|Control Group|The participants only receive the materials about the harm of substance use.
41442958|NCT02083328|DIETARY_SUPPLEMENT|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
41442959|NCT02083328|DIETARY_SUPPLEMENT|Placebo (Mannitol)|Mannitol filled in gelatine capsules
41442960|NCT06318117|OTHER|Rice infant formula|Any commercially available rice infant formula whom the pediatrician has previously deemed, or is deeming it useful to consume.
41442961|NCT05212363|DEVICE|Lower extremity compression garments|Compression garments are used to exert external pressure on the lower extremities to reduce vascular wall tension and prevent gravity form pooling blood in the lower extremities which will improve venous return and lymphatic output. Following the resting measurements, subjects will be instructed to wear the garments and moved to the seated gaming position for 2 hours.
41442962|NCT05212363|BEHAVIORAL|Active break|"An active break is currently considered gold standard for increasing blood flow after prolonged sitting. The 6-minute walk will be conducted indoors next to the esport lab in the Wisser library at NYIT, Old Westbury. Participants will be asked to walk for 6 minutes on a flat surface back and forth following one hour of game play."
40745954|NCT02957825|DEVICE|Continuous wireless monitoring|Continuous wireless monitoring of vital signs
41442963|NCT05168735|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
41442964|NCT05168735|BEHAVIORAL|Brief Mindfulness Exercises|30min guided training in mindfulness meditation immediately prior to infusion
41442965|NCT05168735|BEHAVIORAL|Academic Exercises|30min of mental math and other academic cognitive puzzles completed silently/mentally
41095090|NCT04371926|DRUG|Hydroxychloroquine Sulfate|"Patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff will receive HCQ sulfate 400mg/week for 4 weeks"
41442966|NCT04632927|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
41442967|NCT04632927|BIOLOGICAL|Ustekinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
41442968|NCT03221543|DEVICE|ReeVue Indirect Calorimeter|The ReeVue Indirect Calorimeter will be used in this study to measure the resting metabolic rate. The test takes approximately ten minutes to complete. The subject should prepare for the test by avoiding stimulants and exercise on the day of the test, as well as eating meals four hours before the test. The subject will be seated during the test. They will be given a nose clip that looks like a clothes pin to be placed on their nose. A plastic mouth piece that allows all of the air they breathe to come in through the top of the mouth piece and the air they breathe out to go into the ReeVue Calorimeter will also be provided. The subject will remain in this position for ten minutes until the testing is complete.
41442969|NCT00942968|DRUG|dalteparin|Daily subcutaneous injection 200IU/kg dalteparin
41442970|NCT01126762|BEHAVIORAL|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
41442971|NCT01126762|BEHAVIORAL|Control|Advice regarding healthful diet during pregnancy, not focused on fish intake
41442972|NCT02075645|OTHER|Team training course|"A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
41442973|NCT00583453|DRUG|Celecoxib|"Celecoxib 200 mg capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
41442974|NCT00583453|DRUG|Placebo|"Placebo capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
41442975|NCT01250080|DIETARY_SUPPLEMENT|Total Parenteral Nutrition with Glutamine|daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
41442976|NCT01250080|OTHER|Total Parenteral Nutrition without glutamine|The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
41442977|NCT03964935|DRUG|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After SRP, the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
41442978|NCT03964935|DRUG|Minocycline HCl 1mg Oral Powder|Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
41442979|NCT03964935|OTHER|Distilled water|Used to irrigate periodontal pockets after SRP
41442980|NCT01643135|DRUG|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
41442981|NCT01643135|DRUG|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
41442982|NCT04313751|BEHAVIORAL|Education, Physical Activity, and Stress Management Program|Twelve weekly classes for one hour focused on CVD risk factor education using the Su Corazón Su Vida curriculum and coping skills training followed by a 45 minute exercise class and 15 minute stress management session. Then they will return for one hour for continued support, a forty-five minute exercise class, and fifteen minute stress management session.
41442983|NCT04313751|OTHER|Wait-list|The wait-list control group will receive 12 weekly one hour education and coping skills training sessions followed by a 45 minute exercise class and a 15 minute stress management session.
41442984|NCT03072030|BIOLOGICAL|GamEvac-Combi (vaccine)|vaccination
41442985|NCT03072030|BIOLOGICAL|Placebo|vaccination
41442986|NCT00256230|DRUG|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
41442987|NCT02189226|DEVICE|Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)|Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
41442988|NCT00175487|PROCEDURE|Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.
41442989|NCT05909085|DEVICE|Traditional ultrasound|Labor epidural will be performed after marking patient skin using traditional ultrasound guidance
41442990|NCT05909085|DEVICE|Automated ultrasound|Labor epidural will be performed after marking patient skin using an automated ultrasound device
41442991|NCT06464315|PROCEDURE|Functional Substrate-Only Mapping without VT Induction|In this arm, invasive maps will be constructed by annotating the latest deflection and peak frequency during voltage mapping of stable intrinsic rhythm to localize areas of slow conduction. Annotated algorithms are cleared by the FDA. No VT will be purposefully induced in this experimental arm.
41442992|NCT06464315|PROCEDURE|Standard-of-Care Mapping/Imaging|Conventional invasive scar (voltage) and electrical VT (entrainment, activation, pace) mapping will be used to guide VT ablation. Functional substrate mapping will not be used in this arm. VT will be induced using standard protocols.
41095091|NCT04056156|BEHAVIORAL|HIV-screening advice|To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail
41442993|NCT00179231|DRUG|olanzapine vs. clozapine|
41442994|NCT06196515|DRUG|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
41442995|NCT06196515|DRUG|nano calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
41442996|NCT05327608|OTHER|Short-Term Fasting|Undergo intermittent fasting
41442997|NCT04176835|DRUG|Oxytocin nasal spray|Single-dose oxytocin will be administered intranasally
41442998|NCT04176835|DRUG|Placebo|
41442999|NCT00573599|DRUG|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
41443000|NCT00573599|DRUG|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
41443001|NCT05658393|BEHAVIORAL|ReLiver-N App|Web-based mobile health application for patients with liver cirrhosis
41443002|NCT04266340|DRUG|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
41443003|NCT04266340|DRUG|midazolam|0.5mg/kg oral midazolam
41443004|NCT04266340|DRUG|midazolam|0.05mg/kg intravenous injection midazolam
41443005|NCT04266340|DRUG|Saline|no premedication
41443006|NCT03100422|DEVICE|ARMin|arm therapy robot
41443007|NCT03100422|OTHER|Occupational Therapy|bilateral arm training
41443008|NCT03864094|DRUG|Ephedrine|0,1 mg/kg
41443009|NCT03864094|DRUG|Phenylephrine|1 microg/kg
41443010|NCT03864094|DRUG|Norepinephrine|0,1 microg/kg
41443011|NCT03864094|DRUG|Sodium chloride|0,1 ml/kg
41443012|NCT03864094|DRUG|Propofol|2 mg/kg
41443013|NCT03864094|DRUG|Remifentanil|1,7 microg/kg
41443014|NCT01944072|OTHER|Aerobic exercise training intensity|
41443015|NCT01010503|DRUG|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
41443016|NCT03123315|DEVICE|Ureteral Illuminating Catheter|This is a very thin tube that goes into a ureter to more effectively find and track the ureter during surgeries
41443017|NCT04534621|OTHER|Electronic survey|Brazilian chiropractors will be invited by email and social media to answer an electronic survey.
41443018|NCT06627764|BEHAVIORAL|SER Familia|SER Familia is a six-session intervention co-developed and delivered by community health workers (CHWs) that uses strategies to reduce acculturative stress, promote resilience, improve parent-child and family level health, while simultaneously helping families maintain strong social networks and better navigate community resources to address social determinants of health (SDOH).
41443019|NCT00076817|BIOLOGICAL|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine
41443020|NCT00076817|BIOLOGICAL|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine placbo
41443021|NCT00835692|DRUG|Clarithromycin|500 mg Tablet
41443022|NCT00835692|DRUG|Biaxin®|500 mg Tablet
40745955|NCT04518410|BIOLOGICAL|bamlanivimab 7000mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
40745956|NCT04518410|BIOLOGICAL|BRII-196+BRII-198|1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
40745957|NCT04518410|BIOLOGICAL|AZD7442 (IV)|300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
40745958|NCT04518410|BIOLOGICAL|AZD7442 (IM)|Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
40745959|NCT04518410|DRUG|SNG001|1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
40745960|NCT04518410|DRUG|Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
40745961|NCT04518410|BIOLOGICAL|BMS-986414 + BMS-986413|Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.
40745962|NCT04518410|BIOLOGICAL|SAB-185 (3,840 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
40745963|NCT04518410|BIOLOGICAL|SAB-185 (10,240 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
40745964|NCT04518410|DRUG|CASIRIVIMAB + IMDEVIMAB|600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
40745965|NCT04518410|DRUG|Placebo for Bamlanivimab 7000mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
40745966|NCT04518410|DRUG|Placebo for Bamlanivimab 700mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
40745967|NCT04518410|DRUG|Placebo for BRII-196+BRII-198|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
40745968|NCT04518410|DRUG|Placebo for SNG001|Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
40745969|NCT04518410|DRUG|Placebo for Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
40745970|NCT04518410|DRUG|Placebo for SAB-185 (low dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
40745971|NCT04518410|DRUG|Placebo for BMS-986414 + BMS-986413|Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
40745972|NCT04518410|DRUG|Placebo for AZD7442 (IV)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
40745973|NCT04518410|DRUG|Placebo for AZD7442 (IM)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
40745974|NCT04518410|DRUG|Placebo for SAB-185 (high dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
40745975|NCT04518410|BIOLOGICAL|bamlanivimab 700mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
40745976|NCT03522168|DRUG|Risperidone|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
40745977|NCT03522168|DRUG|Aripiprazole|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
40745978|NCT05573282|OTHER|Regorafenib combine with ICIs|Regorafenib: 80mg/day, PO, QD, d1～d21, Q4W ICIs: 200mg/day, IV, d1,Q3W
40745979|NCT02646059|OTHER|Text message|Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
40745980|NCT02646059|OTHER|Telephone|Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
40745981|NCT01666405|DEVICE|Urgent(R) PC Neuromodulation System|The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
40745982|NCT03819699|DRUG|Lu AF20513|Lu AF20513 suspension for injection
40745983|NCT03819699|BIOLOGICAL|booster vaccine|booster vaccine (Cohort 2) - to be administered as per national recommendations
40745984|NCT03632330|DRUG|Dexmedetomidine|Dexmedetomidine group
40745985|NCT03632330|DRUG|Midazolam|Midazolam group
40745986|NCT03632330|DRUG|Propofol|Propofol group
40745987|NCT03632330|DRUG|Midazolam/Propofol|Midazolam/Propofol group
40745988|NCT03594552|DRUG|Arbaclofen_15|Single oral dose (15mg)
40745989|NCT03594552|DRUG|Arbaclofen_30|Single oral dose (30mg)
40745990|NCT03594552|DRUG|Placebo|Single oral dose placebo (oral tablet)
40745991|NCT02142621|OTHER|transpyloric feeding|
40745992|NCT02142621|OTHER|gastric feeding|
40745993|NCT05593458|DRUG|Oxaliplatin by arterial infusion plus S-1|3 cycles oxaliplatin by arterial infusion plus S-1 every 21 days as neoadjuvant chemotherapy.
40745994|NCT05593458|DRUG|SOX neoadjuvant|3 cycles of SOX neoadjuvant chemotherapy every 21 days.
40745995|NCT05593458|DRUG|Sintilimab neoadjuvant|3 cycles of neoadjuvant immunotherapy every 21 days.
40745996|NCT05593458|PROCEDURE|gastrectomy plus D2 lymph node dissection|All patients, whose lesions are resectable and medically operable after 3 cycles neoadjuvant chemotherapy, will receive gastrectomy plus D2 lymph node dissection.
40745997|NCT05593458|DRUG|SOX adjuvant, Sequential S-1|"3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation."
40745998|NCT05593458|DRUG|Sintilimab adjuvant|3 cycles of adjuvant immunotherapy every 21 days.
40745999|NCT03687255|DRUG|cefepime/AAI101 combination|cefepime 2 g / AAI101 500 mg
40746000|NCT03687255|DRUG|Piperacillin/tazobactam|piperacillin 4 GM / tazobactam 500 MG
40746001|NCT05098990|DRUG|Jinfukang oral liquid|Jinfukang koufuye is a Chinese herbal prescription, which is used in treatment for patients with NSCLC in clinical practice. It has been proved to be capable of preventing the occurrence of metastasis, stabilizing tumor lesions, improving the response rates when combined with chemotherapy, and prolonging the survival period of lung cancer patients.
40746002|NCT05098990|DRUG|Platinum-based doublet chemotherapy|Platinum-based doublet chemotherapy as first line therapy has been shown to be efficacious against non-small cell lung cancer.
40746003|NCT00679198|BEHAVIORAL|nurse-patient communication|"We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.~Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting."
40746004|NCT06493799|DRUG|LAENNEC (Human Placenta Hydrolysate) IV|Intravenous Injection
40746005|NCT06493799|DRUG|LAENNEC (Human Placenta Hydrolysate) SC|Subcutaneous Injection
40746006|NCT03257397|DEVICE|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions
40746007|NCT03257397|DEVICE|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions
40746008|NCT06271980|OTHER|ENCORE|A panel of microRNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
40746009|NCT02395770|OTHER|Rehabilitation program|"Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.~Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.~Stretching \& Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.~Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports"
40746010|NCT00898807|DRUG|citalopram|target dose 30mg daily for 9 weeks
40746011|NCT00898807|DRUG|placebo|daily for 9 weeks
40746012|NCT00114777|DRUG|Cyclosporin A|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
40746013|NCT00114777|DRUG|Belatacept Less Intensive Regimen (LI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
40746014|NCT00114777|DRUG|Belatacept More Intensive Regimen (MI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
40746015|NCT04245761|DIETARY_SUPPLEMENT|Sonidor®|Sonidor® triple layer release tablets are developed with a specialized process to improve stability and bioavailability of the formulation based on hawthorn, lavender and hop extracts. The hawthorn, lavender and hop extracts used to product Sonidor® have an elevated content of vitexin (3%), monoterpens (4% as linalool) and flavonoids (4%), respectively.
40746016|NCT04899206|DRUG|With an Antidepressant Drug|Current users of an antidepressant drug.
40746017|NCT04899206|DRUG|Without an Antidepressant Drug|Non-current users of an antidepressant drug.
40746018|NCT02760888|DRUG|Tramadol|Women will receive a oral Tramadol 100mg 1 hour before the procedure
40746019|NCT02760888|DRUG|Diclofenac|Women will receive oral Diclofenac 100mg 1 hour before the procedure
40746020|NCT02760888|DRUG|Placebo|Women will receive a Placebo 1 hour before the procedure
40746021|NCT03991039|RADIATION|Gamma knife|Microvascular decompression
40746022|NCT01029821|DRUG|Low-Molecular-Weight Heparin|Isolated Ankle Fracture Single planned operation
40746023|NCT01227811|DRUG|Darifenacin|Single oral dose Darisec(R) 15.0 mg
40746024|NCT01227811|DRUG|Darifenacin|Single oral dose Enablex(R) 15 mg
40746025|NCT03934801|OTHER|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
40746026|NCT03934801|OTHER|Ranking Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
40746027|NCT03934801|OTHER|Ranking Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
40746028|NCT03934801|OTHER|Ranking Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
41095092|NCT04056156|BEHAVIORAL|HIV-testing advice plus group-level training|To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.
40746029|NCT05226000|DRUG|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
40746030|NCT02487836|DEVICE|Type WallFlex or Evolution biliary, stent system|Laying of a stent biliary
40746031|NCT02723422|PROCEDURE|Prehabilitation visit/increased physical therapy post-TAVR|Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
40746032|NCT02723422|PROCEDURE|Standard of Care Arm|Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
40746033|NCT01125553|DRUG|insulin degludec/insulin aspart|Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
40746034|NCT06047327|DIAGNOSTIC_TEST|EUS guided liver biopsy|Procedure will be performed by 19G Franseen needle.
40746035|NCT06047327|DIAGNOSTIC_TEST|Percutaneous Liver Biopsy|procedure will be done by 18G BioPince Needle
40746036|NCT01054248|DRUG|dihydroartemisinin-piperaquine|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
41095093|NCT03206294|OTHER|pharmacist assessment|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
41095094|NCT00205530|BEHAVIORAL|Brain Injury Family Intervention (BIFI)|The Brain Injury Family Intervention (BIFI) was developed over the last decade based upon considerable clinical experience and research review. The BIFI is a structured approach to helping families address their most common and salient issues, concerns, and challenges. The BIFI is implemented in five 90-minute sessions.
41095095|NCT05426265|DEVICE|MEL-T01|A 12 week intervention with MEL-T01.
41095096|NCT05426265|DEVICE|MEL-S01|A 12 week intervention with MEL-S01.
40746037|NCT01054248|DRUG|Artesunate-mefloquine|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
40746038|NCT01054248|DRUG|arthemeter-lumefantrin|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
40746039|NCT04625972|DRUG|AZD7442|Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.
40746040|NCT04625972|DRUG|Placebo|Single dose (× 2 IM injections) of saline placebo on Day 1.
40746041|NCT00382070|DRUG|Letrozole|Letrozole 2.5 mg taken orally once daily for 5 years
40746042|NCT00382070|OTHER|Placebo|Placebo tablet taken orally once daily for 5 years
40746043|NCT02310308|DIETARY_SUPPLEMENT|Chewing gum administration|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
40746044|NCT00377481|DRUG|darbepoetin alfa|30 micrograms sc weekly (2 doses)
41095097|NCT02609555|PROCEDURE|TEM perineal rectopexy|perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
41095098|NCT03095508|DRUG|Angal S, topical spray [Menthol]|0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
41095099|NCT03095508|DRUG|ANTI-ANGIN® FORMULA, topical metered spray|"0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution"
41095100|NCT01462019|DEVICE|Photobiomodulation|"the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.~The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions."
40746045|NCT00377481|DRUG|epoetin beta [NeoRecormon]|6000 IU sc weekly (2 doses)
41095101|NCT02828605|DEVICE|Virtual Interactive Platform (VIP) Transplant|
40746046|NCT05943704|DIETARY_SUPPLEMENT|beef broth|It indicates if the child has allergy of Beef or not.
40746047|NCT01526382|DEVICE|PiCCO monitoring (PULSION)|Patients are monitored with PiCCO system.
41095102|NCT03455413|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device and NeoSensor Belts will be used to assess lung aeration, ventilation distribution and strech during invasive ventilation in perioperative care.
41095103|NCT01805362|OTHER|Randomization that determine the time of treatment|
41095104|NCT01941316|DRUG|Carfilzomib|20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
41095105|NCT01941316|DRUG|Irinotecan|125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
41095106|NCT00378872|DRUG|IV Tranexamic acid 10mg/kg pt body weight|
41095107|NCT00378872|DRUG|Quixil topical sealant|
41095108|NCT03315221|OTHER|Test product|HMF with added lipids - Intervention group
40746048|NCT01526382|PROCEDURE|central venous catheter|patients in this arm can receive central venous catheter
40746049|NCT03415269|DRUG|Ambroxol Hydrochloride|single lozenge of 20mg ambroxol
40746050|NCT02315820|PROCEDURE|Induction of labor group (Group I)|Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
40746051|NCT02909595|DEVICE|Balloon catheter|Balloon stone extraction was carried out with a balloon catheter \[Extractor Pro RX \[M00547000, M00547010, or M00547020\]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
40746052|NCT02909595|DEVICE|Basket catheter|Basket stone extraction was performed with a basket catheter (Flower Basket V \[FG-V435P or FG-V425PR\]; Olympus Corp., Shang hai,China).
40746053|NCT04114370|DRUG|18F-fluciclovine|Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.
40746054|NCT00870701|RADIATION|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
40746055|NCT00870701|OTHER|absence of radiotherapy|absence of radiotherapy
41095109|NCT03315221|OTHER|Control product|Commercially available HMF (without lipids) - control group
41095110|NCT01111890|DRUG|Azarga (brinzolamide 1% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
41095111|NCT01111890|DRUG|Cosopt (dorzolamide 2% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
41095112|NCT05476822|DIAGNOSTIC_TEST|Obtain antibody titers|Obtain blood samples for antibody titers at the time of enrollment, at three months, six months and nine months post vaccine booster (+/- ten days).
41095113|NCT01214902|DEVICE|Constraint induced movement therapy (CIMT)|soft mitten worn on the non hemiplegic hand
41095114|NCT01214902|BEHAVIORAL|play|play which encourages the use of the hemiplegic hand
41095115|NCT04463082|PROCEDURE|Intravenous administration of fluids|Intravenous administration of fluids (20ml/kg, but the maximum volume will be limited up to 500ml) within 60 minutes.
41095116|NCT06022848|PROCEDURE|occipital nerve stimulator|Quantitative sensory testing
41095117|NCT03968237|DRUG|Buprenorphine/Naloxone|Controlled substances
41095118|NCT02746900|PROCEDURE|Cervical cerclage|McDonald cervical cerclage
41095119|NCT04670575|PROCEDURE|Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL|Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
41095120|NCT03415022|BEHAVIORAL|computer-based treatment|30 minute sessions of free viewing of faces and listening to music
41095121|NCT05521399|DIAGNOSTIC_TEST|MRI Sequencing|MRI test-retest (select healthy volunteers) for development of MRI sequence.
41095122|NCT05521399|DIAGNOSTIC_TEST|MRI Testing (pediatric)|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children.
41095123|NCT05521399|DIAGNOSTIC_TEST|MRI Testing|Cardiac MRI to improve HTx monitoring for ACR and CAV as well as outcome prediction
41095124|NCT05635266|DIAGNOSTIC_TEST|Specimen sample|The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.
41095125|NCT04783181|BIOLOGICAL|AAV BBP-631|intravenous
41095126|NCT00029380|DRUG|Sangstat|
41095127|NCT00029380|DRUG|Cyclophosphamide|
41095128|NCT00029380|DRUG|Busulfan|
41095129|NCT00029380|DRUG|Mycophenolate Mofetil|
41095130|NCT00029380|DRUG|Cyclosporine|
41095131|NCT00029380|PROCEDURE|Cord Blood Transplantation|
41095132|NCT01922570|DIETARY_SUPPLEMENT|nutrition|comparion of enteral versus enteral and supplemental parenteral nutrition
41095133|NCT01382810|DRUG|Altaire Gel forming solution|Three times a day for two months
41095134|NCT01382810|DRUG|Refresh Tears|Three times a day for two months
41095135|NCT03367364|BEHAVIORAL|Patient education bundle (PEB),|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
41095136|NCT03367364|BEHAVIORAL|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
41095137|NCT03666429|DEVICE|Bulb suction|Parents will use the bulb suction on their child in the emergency room then complete a 7 point likert survey.
40746056|NCT06011226|OTHER|focus groups|A dozen patients with Chiari malformation and syringomyelia (n = 4) or isolated Chiari malformation (n = 4) or isolated syringomyelia (n = 4) will be brought together in at least two focus groups. Each focus group will include 5 to 8 patients and will last approximately 1 to 2 hours. The focus groups will be recorded (audio only, no personal data will be collected during these sessions) and will be conducted in the presence of a neurosurgeon and a psychologist, who will moderate the session.
41095138|NCT03666429|DEVICE|NoseFrida|Parents will use the NoseFrida in the emergency department and complete a 7 point likert survey.
41095139|NCT03364959|OTHER|Corticosteroids inhalation|Flixotide inhalation followed by Qvar inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
41095140|NCT03364959|OTHER|Corticosteroids inhalation|Qvar inhalation followed by Flixotide inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
41095141|NCT02122848|DEVICE|BiLevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
41095142|NCT05684003|OTHER|Neuromuscular exercise based injury-prevention program|Neuromuscular exercise based injury-prevention program
40746057|NCT06011226|OTHER|questionnaire|developed questionnaire will be proposed to the patients in phase 2 and 3
41095143|NCT04210856|OTHER|Contemplative landscape exposure|landscapes classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to non-contemplative ones.
41095144|NCT01203553|PROCEDURE|Abdominal surgery|Intraoperative mesh implantation
40746058|NCT02703025|DIETARY_SUPPLEMENT|GCB-70|green coffee bean extract
41095145|NCT01995370|DRUG|aspirin|Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
40746059|NCT03969420|DRUG|Alvocidib (flavopiridol) and cytarabine (Ara-C)|Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection
40746060|NCT03969420|DRUG|Alvocidib (flavopiridol)|Administered intravenously
40746061|NCT02663505|PROCEDURE|Patients receiving the surgery planned for them|"For each patient the following potential influence (risk) factors are documented:~sex, urgency of the operation, BMI, age, ASA classification, preconditions, physical fitness, Hb value.~In phase 2 only selected influence factors will be recorded.~No intervention will be performed apart from the surgery planned for each patient."
40746062|NCT05031221|BEHAVIORAL|Yoga + behavioral weight loss|A 12-week, one-arm proof-of-concept and feasibility study will be conducted at the University of Colorado Anschutz Medical Campus (CU-AMC) to assess the processes critical for the success of future randomized trials including: a) Evaluating the feasibility and acceptability of adding a multi-component yoga program to a standard BWL intervention and b) Examining pre-post changes in relevant clinical/cardiometabolic, psychological, and energy balance/behavioral outcomes to inform the design of future trials. Participants will receive a comprehensive, group-based BWL intervention consistent with current guidelines for obesity treatment and a carefully designed multi-component yoga intervention delivered through pre-recorded videos delivered through a cloud-based platform that will be completed in-person and at-home (BWL+yoga).
40746063|NCT00945620|DRUG|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
40746064|NCT00945620|DRUG|placebo|Placebo
40746065|NCT00875667|DRUG|Lenalidomide|"For patients with a creatinine clearance of ≥ 60 mL/min: 25 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.~For patients who have a moderate renal insufficiency (creatinine clearance is ≥ 30 mL/min but \< 60mL/min: 10 mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity."
40746066|NCT00875667|DRUG|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
40746067|NCT01119222|DRUG|Gabapentin|Capsule, single 1200mg dose
40746068|NCT01119222|DRUG|Diphenhydramine|Tablet, single 50mg dose
40746069|NCT01119222|DRUG|Morphine|IV, single 10mg dose
40746070|NCT01119222|DRUG|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
40746071|NCT00549328|DRUG|Pazopanib (GW786034)|Pazopanib monotherapy
40746072|NCT04527250|DRUG|ASC41|ASC41,1mg/table;5mg/table
41095146|NCT01995370|DRUG|clopidogrel|Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
41095147|NCT01995370|DRUG|cilostazol|Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
40746073|NCT04527250|DRUG|ASC41 placebo|ASC41 placebo,1mg/table;5mg/table
40746074|NCT01427946|DRUG|IPI-504|
40746075|NCT01427946|DRUG|Everolimus|
40746076|NCT02416141|DRUG|fast release oro dispersible tramadol 50 mg|idem arm 1
40746077|NCT03876548|DEVICE|Cadexomer Iodine Gel|Subjects will apply gel product to keloid scar site every other day for 28 days following keloid scar revision surgery.
40746078|NCT03319121|DRUG|Empirical therapy group|Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
40746079|NCT03319121|DRUG|Guided therapy group|Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
41095148|NCT05753917|DEVICE|Piezo-surgery insert OR Conventional Drills|piezo-surgery: Group A (piezoelectric device with IM1, IM2, IM2-3, or IM3 piezo-inserts according to the manufacturer's protocol (Piezosurgery, Mectron Medical Technology, Carasco, Italy) Conventional drill: Group B (conventional drills according to the manufacturer's protocol (Premium, Sweden \& Martina, Due Carrare, Padova, Italy)
41095149|NCT03566680|DEVICE|Orthokeratology|Orthokeratology is a type of contact lens that is worn over night to reduce refractive error, so patients do not need to wear vision correction during the day.
40746080|NCT05404841|DIETARY_SUPPLEMENT|CoffeeBerry Supplement|A Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc.,
40746081|NCT05404841|DIETARY_SUPPLEMENT|Placebo|Placebo
40746082|NCT00623376|DRUG|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
40746083|NCT00623376|DRUG|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
40746084|NCT00585650|BIOLOGICAL|Etanercept|Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.
40746085|NCT00585650|OTHER|Placebo injections|Placebo injections twice weekly for 12 weeks.
40746086|NCT04411407|DEVICE|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
40746087|NCT05015179|PROCEDURE|mixed reality technology in laparoscopic partial nephrectomy|All patients undergo contrast-enhanced computed tomography before surgery. DICOM files are converted to a 3D model. This model is then sent to HoloLens 2 smart glasses using HLOIA software
40746088|NCT04687397|BEHAVIORAL|Rehabilitation|Multidisciplinary rehabilitation
41095150|NCT05577962|DRUG|T group|OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
41095151|NCT04411940|DRUG|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
40746089|NCT02813720|RADIATION|HR-pQCT High resolution peripheral quantitative CT-scan|"HR-pQCT is a powerful device providing low dose irradiation already used in bone field.~It is a high resolution tool (voxel size=82µm) that the investigators adapted to look after the distal joint involved by onycholysis. An anteroposterior scout view is used to define the region of interest (ROI), which spanned from the top of the distal phalange to the distal part of the intermediate phalange in order to contain the distal joint of the target finger. Images are then analysed for erosions, osteophytes and volumetric bone mineral density."
40746090|NCT03442062|OTHER|Assessment Feedback Incentives and eXchange|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
40746091|NCT03442062|OTHER|Physician-to-physician engagement|Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.
40746092|NCT03442062|OTHER|Active Intervention Control|Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
41095152|NCT04411940|DRUG|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
41095153|NCT05461924|OTHER|questionnaire survey|questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR
41095154|NCT06358638|DRUG|Daratumumab|Daratumumab is a cytotoxic monoclonal antibody (IgG1k) to CD38 and is commercially approved to treat multiple myeloma. CD38 is expressed on several types of blood cells including B-cells, antibody-secreting plasma blasts and plasma cells. As a result, it has been used to treat antibody-mediated diseases, including children with antibody-mediated cytopenias post-HCT.
41453201|NCT04289805|DRUG|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: letrozole is orally administered (5mg/d) from cycle day 2-3 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
40746093|NCT04845971|DIETARY_SUPPLEMENT|Saisei Maf capsules|Dietary supplement name: Colostrum MAF, Saisei MAF immunomodulator. Formulation: 148 mg acid-resistant coated capsules, containing 2.3 mg of enzymatically treated bovine colostrum powder and supplementary ingredients The dietary supplement substances: Active ingredien: Enzymatically treated bovine colostrum powder 2.3 mg 1.6 % Supplementary ingredients: Lactase (Derived from yeast) 0,15 mg 0.1 % HPMC (Hydroxypropyl Methylcellulose) acid-resistant capsule 47 mg 31.8 % Microcrystalline cellulose (Derived from pulp) 98,4 mg 66.5 % Dosage for adults: 2 - 10 capsules daily (stronger version 9 capsules daily) Route of administration: oral Contraindication: allergy to dairy product components Precaution: pregnancy and lactation Storage: Can be stored in at + 5 to +25°C, on dry place for up to two years Manufacturer: Saisei Pharma, Osaka, MORIGUCHI city, OKUBO-cho, 3-34-8. Japan
40746094|NCT00164723|PROCEDURE|Capsule endoscopy|Capsule endoscopy and colonoscopy
40746095|NCT03695094|DRUG|Padsevonil|Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed
40746096|NCT03695094|DRUG|Oxcarbazepine|Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage
40746097|NCT03695094|DRUG|Levetiracetam|Concomitant administration of levetiracetam (LEV) at therapeutic dosage
40746098|NCT03695094|DRUG|Lamotrigine|Concomitant administration of lamotrigine (LTG) at therapeutic dosage
40746099|NCT03695094|DRUG|Brivaracetam|Concomitant administration of brivaracetam (BRV) at therapeutic dosage
40746100|NCT04292886|DRUG|Tamoxifen and femoston|oral
40746101|NCT04292886|DRUG|Vitamin C and femoston|Vitamin C and femoston
40746102|NCT04976972|DEVICE|NAVIO/CORI Surgical System|Total knee replacement with robotic assistance
40746103|NCT04976972|PROCEDURE|Non-robotic conventional instrumentation|Total knee replacement with non-robotic conventional instrumentation
40746104|NCT00003685|PROCEDURE|fatigue assessment and management|
40746105|NCT00003685|PROCEDURE|nausea and vomiting therapy|
40746106|NCT00003685|PROCEDURE|pain therapy|
40746107|NCT00003685|PROCEDURE|quality-of-life assessment|
40746108|NCT00003685|RADIATION|radiation therapy|
40746109|NCT04995159|DRUG|Single anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.
41095155|NCT06358638|DRUG|Alemtuzumab|Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52.
41095156|NCT06358638|DRUG|Sirolimus|Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections as well as treat lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors.
41095157|NCT06358638|RADIATION|Total Body Irradiation|Total body irradiation is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell transplantation. The radiation is given in a low dose so that normal tissues can repair themselves.
41095158|NCT02005666|DRUG|Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
41095159|NCT02005666|DRUG|DUAC® Gel|Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
41095160|NCT02005666|DRUG|Placebo|Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
41095161|NCT04399707|DEVICE|Transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
41095162|NCT04399707|DEVICE|Placebo transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
41095163|NCT00802919|DRUG|Varenicline|Varenicline 1-2 mg/day
41095164|NCT00802919|DRUG|Placebo for varenicline|Placebo
41095165|NCT00149630|DRUG|Disulfiram|Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
40746110|NCT04995159|DRUG|Dual anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.
40746111|NCT01482728|DRUG|Dasatinib|100 mg dasatinib, the day before surgery and the day of surgery
40746112|NCT01482728|DRUG|Dasatinib|200 mg dasatinib the day before surgery and the day of surgery
40746113|NCT04482790|PROCEDURE|Conventional celluloid matrix technique in management of black triangle|conventional restorative technique in management of black triangle
40746114|NCT04482790|PROCEDURE|Bioclear cervical matrix with injection molding technique|New restorative technique in management of black triangle restorative papilla regeneration
40746115|NCT03994120|OTHER|RTMS|Altering the connectivity of trans-synaptic pathways
40746116|NCT03565653|OTHER|High dietary salt|\~4,000 mg Na+/day
40746117|NCT03565653|OTHER|Placebo|dextrose
40746118|NCT00726557|BIOLOGICAL|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
40746119|NCT00726557|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
40746120|NCT00541775|DRUG|Sitagliptin|Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
40746121|NCT00541775|DRUG|Comparator: Rosiglitazone|Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
40746122|NCT00541775|DRUG|Comparator: Placebo|placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
41095166|NCT00149630|DRUG|Methadone|Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
40746123|NCT00541775|DRUG|Comparator: Metformin|Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
40746124|NCT00854854|BIOLOGICAL|TKCell|"TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8"
40746125|NCT02350205|BIOLOGICAL|Self assembled skin substitute (SASS)|All patients in Phase B will receive Self assembled skin substitute (SASS)
40746126|NCT04692051|DRUG|Nab-paclitaxel + Cisplatin|Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
40746127|NCT04692051|DRUG|Gemcitabine + Cisplatin|Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
40746128|NCT00593255|DRUG|soluble human insulin|
40746129|NCT00593255|DRUG|insulin aspart|
40746130|NCT00593255|DRUG|insulin NPH|
40746131|NCT03087552|PROCEDURE|Transradial balloon aortic valvuloplasty|Mini-invasive balloon aortic valvuloplasty consisting in transradial access
40746132|NCT03087552|PROCEDURE|Transradial balloon aortic valvuloplasty|Rapid pacing using the 0.035-in. retrograde left ventricular support wire
40746133|NCT00504309|DRUG|4/day of 4g P-OM3 capsules|4/day of 4g P-OM3 capsules for 8 weeks
40746134|NCT00504309|DRUG|4/day of 1g P-OM3 capsules|4/day of 1g P-OM3 capsules for 8 weeks
40746135|NCT00504309|DRUG|Corn Oil Placebo, 4 capsules/day for 8 weeks|4 capsules per day of corn oil placebo for 8 weeks
40746136|NCT02407015|OTHER|Nintendo 3DS gameplay|
40746137|NCT05099445|DRUG|INCB000928|INCB000928 200 mg will be administered on Day 1 of each treatment period.
40746138|NCT00260390|DRUG|Testoviron|
40746139|NCT02802722|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.
40746140|NCT02802722|BIOLOGICAL|Peripheral blood and induced sputum sampling|To attain samples for immunological testing
40746141|NCT02802722|RADIATION|Chest computerised tomography (CT) scans|For volumetric quantification of lung abnormalities
40746142|NCT02802722|OTHER|Symptom questionnaire|Symptom questionnaire for recent symptom history
40746143|NCT02802722|OTHER|Placebo|To be dispensed using an electronic dispenser to allow real time logging of adherence.
40746144|NCT02164188|BEHAVIORAL|Flourishing protocol|This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
40746145|NCT05064800|DRUG|Dabigatran|A single dose of Dabigatran on Day 1
40746146|NCT05064800|DRUG|PF-07321332/ritonavir + Dabigatran|PF-07321332/ritonavir twice daily (BID) for Days 1 and 2 Single dose of Dabigatran on Day 2
40746147|NCT05064800|DRUG|Ritonavir + Dabigatran|Ritonavir BID on Days 1 and 2 Single dose of Dabigatran on Day 2
40746148|NCT03395990|PROCEDURE|Active comparator: chloroprocaine|15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
40746149|NCT03395990|PROCEDURE|Sham comparator: saline|15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
40746150|NCT03004456|OTHER|Distraction|Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
40746151|NCT02242006|OTHER|serial serum sampling for quantification of drug concentration|
40746152|NCT06114966|OTHER|CADCAM|Milling of Final prosthesis over dental implants using CADCAM milling machine
41095167|NCT00149630|BEHAVIORAL|CBT|1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
41095168|NCT00149630|OTHER|Lactose|Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
41095169|NCT06382142|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
41095170|NCT06382142|DRUG|Eribulin|Administration by intravenous bolus for a cycle of 3 weeks.
41095171|NCT06382142|DRUG|Vinorelbine|Administration by intravenous infusion for a cycle of 3 weeks.
41095172|NCT06382142|DRUG|Gemcitabine|Administration by intravenous infusion for a cycle of 3 weeks.
41095173|NCT06382142|DRUG|Capecitabine|Oral administration for a cycle of 3 weeks.
41095174|NCT05435963|BEHAVIORAL|Pulmonary rehabilitation (PR)|A typical PR program will include exercise training, disease-specific and self-management strategies education, and will last 6 - 8 weeks
41095175|NCT01168453|BEHAVIORAL|head position change|AL-US distance measure using the ultrasound in two different head position
41269820|NCT02502864|OTHER|Function Assessment of Cancer Therapy (FACT) Surveys|Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
41269821|NCT05759299|PROCEDURE|Tracheal intubation|Advanced airway management with tracheal intubation performed after induction with hypnotic and/or opioid drugs and laryngoscopy
41269822|NCT04668508|DRUG|Anlotinib|concurrent using anlotinib combined with radiation plus adjuvant anlotinib after radiotherapy until disease progress or develop into serious adverse events.
41269823|NCT04931836|BEHAVIORAL|Physical Activity Intervention|Three walking sessions/week for a total of 8 weeks (24 total sessions) - Walking sessions will either take place on new commercial treadmills in the Epidemiology Clinical Research Center or remotely at or around a participant's home. Regardless of the walking location, walking sessions will be 30 min in duration during intervention weeks 1 through 4 and a minimum of 45 min each during intervention weeks 5 through 8.
41269824|NCT03805126|BEHAVIORAL|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
41269825|NCT03805126|BEHAVIORAL|Usual Care|Usual care includes consultation with a social worker and a community health worker.
41269826|NCT02308644|DRUG|intravitreal bevacizumab injection(1.25mg)|intravitreal bevacizumab injection(1.25mg) / Sham injection
40746153|NCT05054881|OTHER|sciatic nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the sciatic nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
40922323|NCT05402605|PROCEDURE|ICSI with AOA|"Step 1: All post-ICSI oocytes will be added in the medium drop in AOA dish, these oocytes will be placed in the incubator at 37oC, 6% CO2, and 5% O2 for 20 minutes.~Step 2: After 20 minutes, calcium ionophore stock (Sigma-Aldrich - USA) will be diluted into 10µM drops in AOA dish.~Step 3: After 10 minutes of incubation, all post-ICSI oocytes will be moved to the AOA drop, then this dish will be put back in the incubator for 10 minutes.~Step 4: After 10 minutes, all the oocytes in drop AOA will be moved to another drop for rinsing and then put back in the incubator for 20 minutes.~Step 5: After 20 minutes, the oocytes will be moved into drop AOA and then put back in the incubator for 10 minutes.~Step 6: After 10 minutes, all post-ICSI oocytes will be added in the medium drop, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2"
41095176|NCT01719289|BEHAVIORAL|PROGRAVIDA|Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
41095177|NCT03873324|DRUG|CPL500036 compound|IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
41095178|NCT03873324|DRUG|Placebo|matching placebo capsules
41095179|NCT04285996|PROCEDURE|PET Scan|
41095180|NCT06290544|OTHER|Standard of care plus additional examinations|The patient will undergo good clinical practice examinations according to guidelines plus The patient will undergo to the evaluation of endothelial dysfunction with ENDOPAT 2000 and whole blood sampling for future omics studies
41095181|NCT03127345|DRUG|Omegaven|Intravenous omega 3 fatty acid administration
41095182|NCT03127345|DRUG|Intralipid|Standard of care
41095183|NCT04955795|BEHAVIORAL|Alcohol Brief Intervention (BI)|The BI we will use was based on CETA's substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring change, goal setting, identifying the reasons, and skill building) including a 2-week alcohol timeline follow back assessment, which is completed by the therapist. BI will be provided by a trained research assistant who has completed consent, enrollment, and randomized procedures with the client.
41269827|NCT00247104|DRUG|Cranberries - Vaccinium macrocarpon|
41269828|NCT03339492|DEVICE|RCStim Model 1114|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
41269829|NCT01832961|DEVICE|Flutter valve exercises|30 minutes of flutter exercises
41269830|NCT01832961|DEVICE|Flutter Sham exercises|30 minutes of flutter-sham exercises
41269831|NCT01832961|DEVICE|Flutter and bronchodilator exercises|Flutter + bronchodilator exercises with an interval of 3 to 5 days
41269832|NCT02116621|BEHAVIORAL|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
41269833|NCT02116621|DEVICE|smartphone|
41269834|NCT00680836|DRUG|Placebo|orally two times per day for 14 days
41269835|NCT00680836|DRUG|Rifaximin|550 mg orally two times per day for 14 days
41269836|NCT03560973|DRUG|Gemcitabine|ramucirumab/ placebo was added to gemcitabine
41269837|NCT03560973|DRUG|Ramucirumab|ramucirumab/ placebo was added to gemcitabine
41269838|NCT01930786|DRUG|onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
41269839|NCT01957956|OTHER|Laboratory Biomarker Analysis|Correlative studies
41269840|NCT01957956|BIOLOGICAL|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
41269841|NCT01957956|DRUG|Temozolomide|Given PO
41095184|NCT04955795|BEHAVIORAL|Common Elements Treatment Approach (CETA) via Telemedicine|CETA consists of nine key elements (i.e. engagement and education; safety assessment and planning; psychoeducation/introduction; substance use reduction; behavioral activation; cognitive coping/restructuring; relaxation; exposure; and problem solving) that address common mental health problems such as trauma, PTSD, depression, and anxiety. Participants randomized to CETA will be assigned to a CETA provider (clinical psychology or social work graduate student or master's degree substance abuse counselor). Enrolled participants will be discussed at weekly supervision meetings. An individualized treatment plan will be designed for each participant including type and order of CETA modules. The counselor will contact the participant by phone to schedule CETA sessions and follow up any missed appointments. Counselors, who will also be given a unique ID# for documentation and analysis, will carry 3-10 active CETA cases at a time depending on their experience level.
41269842|NCT04000477|DEVICE|Cytobrush|the brush would be inserted in full until the display of the brush in the endocervical canal disappears. A neck quadrant scan (= quarter turn) will be performed from front to back while simultaneously rotating the brush clockwise, for a total of 3 laps. This would represent 4 sweeps per turn, ie 12 sweeps in total
41269843|NCT04000477|DEVICE|Kevorkian curette|the colposcopist holds the curette horizontally and scrapes the endocervical canal all the way around. He realizes 1 small firm and linear movement by quarter turn or 4 movements to realize a complete turn. During this act, the curette must remain inside the canal, and during its extraction, care should be taken not to rotate it so as not to spill the collected tissue contained in the basket of the curette. The tissue material thus obtained must be rapidly immersed in formalin
41095185|NCT01174329|DEVICE|"Automatic neuro-electrostimulation by Saliwell Crown"|"Continuous stimulation of the lingual nerve by Saliwell Crown"
41095186|NCT01174329|DEVICE|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"On-demand stimulation of the lingual nerveby Saliwell Crown"
41095187|NCT00705991|PROCEDURE|ROTEM|
40746154|NCT05054881|OTHER|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
40746155|NCT06162234|OTHER|observational|none (observational study)
40746156|NCT01996540|OTHER|Interventional arm: Early best palliative care|Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
41095188|NCT04376476|BIOLOGICAL|Blood sample|blood samples will be taken as below: Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0
41095189|NCT04376476|BIOLOGICAL|Low or upper respiratory tract sample|"Low or upper respiratory tract sample will be collected in order to take virology measurements:~Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0"
41095190|NCT04376476|BIOLOGICAL|Stool collection or fecal swab|"The stool collection or fecal swab will be collected in order to take virology measurements:~Group E1: / Group E2: At day 0, day 7, day 14 Group E3: At day 0"
41095191|NCT04376476|OTHER|phone call|phone calls will be performed to collect data regarding patients' symptoms at: Group E1: Day 14 Group E3: Day 14
41269844|NCT03772327|DEVICE|"Adheretech smart bottle"|"A smart pill bottle that measures the exact number of pills in the bottle in real-time, sends this HIPAA-compliant data to a central server, and based on the results, can remind participants to take their medication through a phone call or text message."
40746157|NCT06061055|DEVICE|Intubation with VentiBronc Anchor endobronchial double-lumen tube|Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).
40746158|NCT06061055|DEVICE|conventional double-lumen intubation|Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).
41095192|NCT05213403|DIAGNOSTIC_TEST|Evaluation with new scoring system|"Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes"
41095193|NCT01149135|DEVICE|Blue enriched light with a low intensity|30 minutes in the morning, 750 lux
41095194|NCT01149135|DEVICE|standard light treatment|standard light treatment, 30 minutes, 10 000 lux
41269845|NCT03772327|BEHAVIORAL|Routine adherence counseling|Participants will be provided with routine adherence counseling
41269846|NCT01116050|DRUG|Misoprostol|5 tablets of 200 microgram geach intra rectal by opaque introducer
41269847|NCT01116050|DRUG|Placebo|5 tablets in opque introducer
40746159|NCT05954689|OTHER|Femoral artery block|Injection on the antero-medial side of the femoral artery of 10mL 0.5% ropivacaine with ultrasound guidance.
41269848|NCT00624221|PROCEDURE|Descemet's stripping endothelial keratoplasty|Small incision corneal transplant procedure to treat dysfunctional endothelium.
41269849|NCT00859755|DRUG|ARRY-403, glucokinase activator; oral|single dose, escalating
41269850|NCT00859755|DRUG|Placebo; oral|matching placebo
41269851|NCT03822884|DRUG|Epoetin Alfa 40000 UNT/ML|40.000 UI subcutaneous single dose
41269852|NCT04265066|DIAGNOSTIC_TEST|microcirculation|measurement of microcirculation
40746160|NCT03767894|DEVICE|EMG Band|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear an EMG band to control and activate the MyHand orthosis.
40746161|NCT03767894|DEVICE|Shoulder harness|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear a shoulder strap to control and activate the MyHand orthosis, either with shoulder elevation or shoulder depression.
41095195|NCT00575978|DRUG|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
41095196|NCT02527889|OTHER|Exercise training|8-week resistive exercise training
41095197|NCT00003802|DRUG|pyrazoloacridine|
40746162|NCT06015334|PROCEDURE|cataract surgery with implantation of intraocular lens|Cataract surgery with implantation of bilateral trifocal IOL (TECNIS Synergy) implantation or bilateral monofocal IOL (Tecnis monofocal) with monovision.
40922324|NCT05402605|PROCEDURE|ICSI without AOA|Conventional ICSI procedure will be performed without the application of AOA.
40922325|NCT03373227|DRUG|Envarsus|Patients will take once daily Envarsus
40746163|NCT04195412|DEVICE|tDCS + upper limb rehabilitation|Stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. Stimulation intensity will be 2 mA with current ramping up and down of 10 seconds each. The stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
40746164|NCT04195412|DEVICE|Sham tDCS + upper limb rehabilitation|Sham stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each sham stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. The anode will be placed to the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off automatically after 30 seconds. The sham stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
40746165|NCT05099406|DEVICE|Transcranial electrical stimulation|"By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session."
40746166|NCT00021255|DRUG|Doxorubicin|
40746167|NCT00021255|DRUG|Cyclophosphamide|
40746168|NCT00021255|DRUG|Docetaxel|
40746169|NCT00021255|DRUG|Herceptin|
40746170|NCT00021255|DRUG|Carboplatin|
40746171|NCT03850106|DIETARY_SUPPLEMENT|Placebo|Placebo
40746172|NCT03850106|DIETARY_SUPPLEMENT|Indus810|Active product
40746173|NCT02347007|DIETARY_SUPPLEMENT|Almond|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
40746174|NCT02347007|DIETARY_SUPPLEMENT|Cereal Bar|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
40746175|NCT04740190|DRUG|Talazoparib|low dose whole brain radiation, followed by combination talazoparib and carboplatin
40746176|NCT00610038|DRUG|glibenclamide|Switching the patients from subcutaneous insulin to oral glibenclamide therapy
40746177|NCT04700605|BEHAVIORAL|Dual task balance test|Participants will be conducting two dual task tests; an 8m gait test and a Wii Balance Board test with simultaneous various cognitive tests.
40746178|NCT00509600|DRUG|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
40746179|NCT04429594|OTHER|blood sampling|blood sampling at J0, M6, M12, M24, M36, M48, M60
40746180|NCT04086459|DEVICE|Repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
40746181|NCT04481659|PROCEDURE|Lap partial ISR|A direct laparoscopic surgery with completely abdominal approach laparoscopic partial intersphincteric resection
40746182|NCT04481659|COMBINATION_PRODUCT|NCRT+Lap partial ISR|Preoperative radiation and chemotherapy + laparoscopic completely abdominal approach laparoscopic partial intersphincteric resection
40746183|NCT06375720|BEHAVIORAL|Lower frequency, shorter period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3 sessions/week for 12 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
40746184|NCT06375720|BEHAVIORAL|Higher frequency, shorter period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 12 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
40746185|NCT06375720|BEHAVIORAL|Lower frequency, longer period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3 sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
41095198|NCT02420587|DRUG|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
41095199|NCT02420587|BEHAVIORAL|Questionnaire|Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
41095200|NCT03569683|PROCEDURE|External bevel gingivectomy|External bevel gingivectomy will be performed on 30 patients wherein the suprabony pockets will be eliminated with the help of a Bard parker blade no 15. The incision would be given 1mm apical to the pockets which would be marked by a Crane and Kaplan pocket marker, then the incision would be given and the tissue would be removed with the help of kirkland and orbans knives and the gingiva would be shaped. After the surgical procedure the patients would be treated either with the Diode laser(Group A), Hyaluronic acid gel (Group B), or Herbal gel(Group C).
41095201|NCT03569683|DEVICE|Diode laser Biostimulation|After gingivectomy, laser irradiation will be done using bio-stimulation tip in the anterior sextants of the mouth. (Group A)
40746186|NCT06375720|BEHAVIORAL|Higher frequency, longer period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
40746187|NCT06375720|BEHAVIORAL|Standard Health Education|Participants would take standard health education 0.5 hour/ session, 2 sessions/month for 6 months.
40746188|NCT03237091|OTHER|bihemispheric transcranial pulsed current stimulation (tPCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
40746189|NCT03237091|OTHER|unihemispheric transcranial pulsed current stimulation (tPCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
40746190|NCT03237091|OTHER|bihemispheric transcranial direct current stimulation (tDCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
40746191|NCT03237091|OTHER|unihemispheric transcranial direct current stimulation (tDCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
40746192|NCT03237091|OTHER|sham-control|Sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply stimulation to the scalp via the sponges for 1-2 minutes. The stimulator will then be turned off.
40746193|NCT04278092|DRUG|Paclitaxel|Paclitaxel 175 mg/m2, q21
40746194|NCT04278092|DRUG|Cetuximab|Cetuximab 400mg/m2 loading dose followed by weekly 250mg/m2
40746195|NCT00002051|DRUG|Thymopentin|
40746196|NCT05434676|DEVICE|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 & S4|To assess the safety and effectiveness of IVL treatment used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries
40746197|NCT03174522|DRUG|REX-001|REX-001 is administered through an intra-arterial catheter.
40746198|NCT03174522|DRUG|Placebo|Placebo is administered through an intra-arterial catheter.
40746199|NCT04721262|DEVICE|Hyperfine Portable MRI|The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
40746200|NCT04517539|DRUG|rhGM-CSF，Peginterferon alfa-b2，radiation|"Radiation:~If there are two measurable lesions totally, One lesion received radiotherapy for 30 Gy in 5 fractions and rested for one week; If there are three measurable lesions totally, two lesion received radiotherapy for 30 Gy in 5 fractions separately.~drug: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy. Peginterferon alfa-b2 90 ug in d8 in each cycle.~And the 1 month after the end of all radiotherapy courses, 4 weeks as a course of treatment, once per course of treatment, each dose is 90μg until desease progress."
40746201|NCT00696150|PROCEDURE|determination of method with highest efficacy (ultrasound or nerve stimulator)|Use of ultrasound to guide the insertion of anterior psoas compartment block
40746202|NCT00696150|PROCEDURE|nerve stimulator|The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
40746203|NCT00696150|PROCEDURE|loss of resistance|Use of ultrasound to guide the insertion of anterior psoas compartment block
40746204|NCT03363035|DRUG|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
40746205|NCT03363035|DRUG|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
40746206|NCT03363035|DRUG|Enoxaparin|Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
40746207|NCT06309329|BEHAVIORAL|Strength at Home Parents|Strength at Home parents is an 8 week trauma-informed and cognitive behavioral tele-health group intervention that aims to improve parenting behaviors and overall parent-child and family functioning among U.S. military Veterans with post-traumatic stress disorder symptoms
40746208|NCT06309329|BEHAVIORAL|VA treatment as usual|VA treatment as usual includes referral to the online resources at veterantraining.va.gov/parenting .
40746209|NCT05702151|PROCEDURE|ESP Block|After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed. Ropivacaine 0.2% infusion at a 10ml/h rate is started during the surgery.
41095202|NCT03569683|OTHER|Hyaluronic acid (Gengigel) topical application.|After gingivectomy, Hyaluronic acid gel(Gengigel) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group B)
40746210|NCT05702151|DRUG|Morphine injection|Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
40746211|NCT00308685|DRUG|Albuterol|Albuterol 90mcg
40746212|NCT00308685|DRUG|Placebo|Placebo
41095203|NCT03569683|OTHER|Herbal gel (Hiora SG) topical application|After gingivectomy, Herbal gel(Hiora SG) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group C)
41095204|NCT03667547|DRUG|Raltegravir|Raltegravir 600 mg tablet
41095205|NCT01394770|DRUG|Aliskiren|Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
40746213|NCT03400553|DIAGNOSTIC_TEST|Blood analysis|The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
40746214|NCT02326090|DRUG|cis-UCA ophthalmic solution 1.0%|
40746215|NCT02326090|DRUG|cis-UCA ophthalmic solution 2.5%|
41095206|NCT03014687|DRUG|Placebo|PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
41095207|NCT03014687|DRUG|Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole|Oral antibiotics (cefdinir \[Omnicef®\] 300 mg PO BID or trimethoprim/sulfamethoxazole \[Bactrim DS™\] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
41095208|NCT00800371|PROCEDURE|intra-articular steroid injection|Steroid injection into otherwise noncontrollable arthritis.
41095209|NCT06614374|DIETARY_SUPPLEMENT|Low-dose fish oil capsules|Patients in the low-dose group will receive four fish-oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs per day.
40746216|NCT02326090|DRUG|Placebo ophthalmic solution|
40746217|NCT02513082|PROCEDURE|Sono guided nerve block|Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
40746218|NCT02037074|DRUG|Drug: EVP-6308|Arms 1, 2, 3
40746219|NCT02037074|DRUG|Placebo|Arm 4
40746220|NCT03185507|DEVICE|CryoHelmet|Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
40746221|NCT04753177|DRUG|Ribocyclib, fulvestrant, triptorelin|Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
40746222|NCT04753177|DRUG|Doxorubicin, cyclophosphamide, paclitaxel|Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
41095210|NCT06614374|DIETARY_SUPPLEMENT|High-dose fish oil capsules|Patients in the high-dose group will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day.
40746223|NCT03873688|OTHER|expiratory muscle training|The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
40746224|NCT01120197|OTHER|Exercise group|Weekly exercises
41095211|NCT06614374|DIETARY_SUPPLEMENT|Refined olive oil|Participants in the control group will receive 4 g refined olive oil daily
41095212|NCT03186807|DIAGNOSTIC_TEST|ultrasonographic scan of fetal brain|"1. Routine measurement of BPD, HC, OFD, cisterna magna, cerebellum, lateral ventricle(1).~   specific measurements as follow:~2. Parietoccipital fissures will be measured from the most external border of cortex to the luminar line.~3. Lateral fissure depths will be measured from the most external border of the insular cortex to the interface confirmed between the subarachnoid space and the skull.~4. Cingulate fissures will be measured in the mid-coronal plane tracing a perpendicular line from the median longitudinal fissure to the apex of the cingulate fissures.~6. Calcarine fissures will be measured in the coronal transcerebellar plane as tracing a perpendicular line from the median longitudinal fissure to the apex of the calcarine fissures."
41095213|NCT02131740|OTHER|Eye rubbing|eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest \& eye rubbing for a further 1 minute.
41095214|NCT02131740|OTHER|No eye rubbing|This eye will not be rubbed
41269853|NCT00800215|DRUG|iv SPM 927 and oral placebo tablet|60-minute infusion iv SPM 927 and oral placebo tablet
41269854|NCT00800215|DRUG|oral SPM 927 tablet and iv placebo|60-minute infusion placebo and oral SPM 927 tablet
41095215|NCT04368403|DRUG|KHK4827|210 mg every 2 weeks (Q2W), subcutaneous (SC) injection
41269855|NCT00800215|DRUG|iv SPM 927 and oral placebo tablet|30-minute infusion iv SPM 927 and oral placebo tablet
40746225|NCT01120197|OTHER|Control Group|No Intervention, control group only
40746226|NCT03008577|OTHER|Change in ambient operating room temperature|
40746227|NCT05244837|DRUG|Tislelizumab 200 mg|Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)
40746228|NCT05244837|DRUG|Carboplatin AUC 5|Carboplatin AUC 5 IV Q3W
40746229|NCT05244837|DRUG|pemetrexed 500mg/m2|Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer
40746230|NCT05244837|DRUG|Paclitaxel 175mg/m2|Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer
40746231|NCT05244837|DRUG|Nab-paclitaxel 260 mg/m2|nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer
40746232|NCT01272778|DRUG|Lorazepam|Oral capsule, 0.2 mg, single acute dose
40746233|NCT01272778|DRUG|Lorazepam|oral capsule, 0.5 mg, single acute dose
40746234|NCT01272778|DRUG|Lorazepam|oral capsule, 1.0 mg, single acute dose
40746235|NCT01272778|DRUG|Lorazepam|oral capsule, 2.0 mg, single acute dose
40746236|NCT01272778|DRUG|Placebo|oral capsule, single acute dose
40746237|NCT02852733|OTHER|end-of-life emergencies' management|
40746238|NCT04899128|DRUG|Pyrotinib|Pyrotinib-based therapy
40746239|NCT06248528|PROCEDURE|Liver resection|Patients in the intervention group received liver resection and postoperative adjuvant therapy
40746240|NCT06248528|PROCEDURE|Locoregional therapy|Patients in the control group received locoregional therapy and systemic therapy
40746241|NCT04935619|BEHAVIORAL|Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
40746242|NCT04935619|BEHAVIORAL|Non-Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
40746243|NCT05527522|COMBINATION_PRODUCT|nutritional and educational intervention|individualized diet plus educational intervention with/without nutritional supplements
40746244|NCT05527522|OTHER|standard practice|The patients received the usual treatment and clinical practice
40746245|NCT03904186|BEHAVIORAL|QUIT|QUIT is a transdiagnostic Cognitive Behavioral Therapy-based smoking cessation protocol designed to address distress intolerance, anxiety sensitivity, and anhedonia in people living with HIV who smoke. QUIT is delivered in 9 60-minute individual weekly sessions over a 10-week period. Sessions are active, with treatment components practiced within and outside of the session. Participants will also receive the transdermal nicotine patch for 8 weeks, starting when they attempt to quit smoking during week 7 of the study.
40746246|NCT03904186|BEHAVIORAL|Time-Matched Control (TM)|Participants will receive a standard smoking cessation treatment, based on the clinical practice guidelines from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence. Treatment will be delivered in nine, 60-minute sessions over a ten-week period. The treatment is based on a treatment protocol developed and used previously by Dr. Zvolensky. Because clinical guidelines recommend that all smokers attempting to quit smoking receive pharmacotherapy, participants will also receive the transdermal nicotine patch for 8 weeks.
40746247|NCT06476249|OTHER|without|without
40746248|NCT01751685|BEHAVIORAL|Kyphosis-specific spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
40746249|NCT01751685|OTHER|Control|monthly educational lectures on various topics
40746250|NCT02410174|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
40746251|NCT03418480|DRUG|BNT113|Intradermal vaccine
40746252|NCT05178979|BEHAVIORAL|Training|This training program integrates evidence-based strategies to reduce provider bias, adapted to address gender bias in the context of HIV care in Uganda. The content aims to increase providers' knowledge, motivation, skills, and empathy to equitably deliver Ugandan Ministry of Health ART program guidelines to male and female patients (e.g., increasing awareness of HIV gender disparities, increasing empathy/skills to counsel men and women's gendered barriers to care, promoting shared decision-making). The intervention is delivered in a series of group training sessions with HIV providers.
40746253|NCT06088446|PROCEDURE|Supplementary anesthetic injections|Supplementary anesthetic injections after failed primary nerve block
40746254|NCT03580187|DRUG|Morphine (+)|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still\> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success. After 30 minutes, if VAS still\> 4, we concluded to a failure of morphine nebulization.~The patients were divided into two groups:~morphine (+) group: good response to morphine in nebulization morphine (-) group: failure of morphine in nebulization"
40746255|NCT00668408|OTHER|LTOT (oxygen therapy)|Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
40746256|NCT00668408|OTHER|Pharmacological therapy of COPD and CHF|"Optimal pharmacologic treatment will include :~* Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)~* Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)~* Beta-blockers~* Diuretics~* Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics~* Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).~The treatment of the deseases will follow the international guidelines."
40746257|NCT02070991|DRUG|Macitentan|oral tablet, 10 mg once daily
40746258|NCT02070991|DRUG|Placebo|matching placebo
40746259|NCT06081062|BIOLOGICAL|Fabagal® (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
40746260|NCT06081062|DRUG|Active comparator (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
40746261|NCT00580099|OTHER|assisted exercise|4 weeks of passive range of motion exercise
40746262|NCT00580099|OTHER|cuddle|cuddle infant for 20 minutes
40746263|NCT02368236|BEHAVIORAL|Tailored Printout|The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
40746264|NCT02708173|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
40746265|NCT02708173|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
40746266|NCT05121922|BEHAVIORAL|Metacognitive Therapy|Psychological treatment provided by the patient's regular general practitioner
41269856|NCT00800215|DRUG|oral SPM 927 tablet and iv placebo|30-minute infusion placebo and oral SPM 927 tablet
41269857|NCT01284790|DEVICE|Cochlear implants|
40746267|NCT04997421|DEVICE|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (intervention arm)or mere CVVHDF using the Oxiris®-AN69 membrane (control arm).
40746268|NCT04997421|DEVICE|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (control arm)
40746269|NCT05838872|DEVICE|Minuteful - Kidney Urine Analysis Test System|Urine samples were collected and tested by a lay user, using the Minuteful - Kidney test device. The lay user test results were compared to the results obtained by testing the same urine sample on the comparison device, the URiSCAN Optima.
40746270|NCT06407440|OTHER|control|There will be no interference ergonomics training
40746271|NCT06407440|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
40746272|NCT00668564|PROCEDURE|Stem Cell Transplantation|The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
40746273|NCT00668564|DRUG|Cyclophosphamide|"Days before Transplant Drug Frequency~* 4 Cyclophosphamide Once, given over 2 hours~* 3 Cyclophosphamide Once, given over 2 hours~* 2 Cyclophosphamide Once, given over 2 hours~* 1 Cyclophosphamide Once, given over 2 hours"
41095216|NCT02034149|BEHAVIORAL|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
41095217|NCT02034149|BEHAVIORAL|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
41095218|NCT02034149|BEHAVIORAL|peer-assisted management|The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
41095219|NCT02224833|BEHAVIORAL|Pharmacist intervention|"Systematic review of treatments:~Identification of reasons for PPI.~* Determination of recommended pharmacotherapeutic alternatives.~* Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.~After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP."
41095220|NCT03344289|DIAGNOSTIC_TEST|Colonoscopy|Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE
41095221|NCT00418847|DRUG|miglustat|Target dose of 320 mg/m\^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA \> 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
41095222|NCT04157842|PROCEDURE|total hip replacement with subtrochanteral osteotomy|applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve
41095223|NCT04157842|PROCEDURE|total hip replacement with no osteotomy|just total hip replacement
41095224|NCT04816890|DRUG|M1 Pram P037|Subcutaneous administration of M1 Pram P037 in combination with a basal insulin.
41095225|NCT04816890|DRUG|Insulin lispro|Subcutaneous administration of insulin lispro in combination with a basal insulin.
41095226|NCT00818025|BEHAVIORAL|Pocket PATH (Personal Assistant for Tracking Health)|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
41095227|NCT01749787|DRUG|PRTX-100 at 1.5 mcg/kg|
41095228|NCT01749787|DRUG|PRTX-100 at 3.0 mcg/kg|
41095229|NCT01749787|DRUG|PRTX-100 at 6.0 mcg/kg|
41095230|NCT01749787|DRUG|PRTX-100 at 12.0 mcg/kg|
41095231|NCT01749787|DRUG|PRTX-100 at 240 mcg|
41095232|NCT01749787|DRUG|Placebo|Placebo administered via infusion once per week for 5 weeks
41095233|NCT01749787|DRUG|PRTX-100 at 420 mcg|
41095234|NCT05249179|OTHER|Pacifier|Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.
41095235|NCT05249179|OTHER|Oral stimulation|Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.
41095236|NCT01293461|DRUG|CBX129801|Subcutaneous injection
41095237|NCT01293461|DRUG|Placebo|Subcutaneous injection
41095238|NCT01997840|DRUG|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
41095239|NCT06204185|DRUG|Metformin|Locally delivered Metformin gel in the treatment of periodontitis patients
41095240|NCT06204185|DRUG|Placebo|Placebo gel consist of drug without the active component.
41095241|NCT00035230|DRUG|Topiramate|
41095242|NCT02377531|OTHER|Early glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
41269858|NCT01993888|BIOLOGICAL|EVARREST® Fibrin Sealant Patch|
40746274|NCT00668564|DRUG|Campath-1H|"Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours"
40746275|NCT00668564|DRUG|Busulfan|"Days before Transplant Drug Frequency~9 Busulfan Four times per day~8 Busulfan Four times per day~7 Busulfan Four times per day~6 Busulfan Four times per day"
40746276|NCT02722135|DRUG|Volasertib|
40746277|NCT00001818|DRUG|Hydroxyurea|
40746278|NCT01456338|BEHAVIORAL|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
40746279|NCT01456338|BEHAVIORAL|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
40746280|NCT03526146|BEHAVIORAL|Behavioral: Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
40746281|NCT01436500|DRUG|Ifetroban Injection|Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
40746282|NCT01436500|DRUG|Placebo|Sterile water with 5% Dextrose
41095243|NCT02377531|OTHER|Standard glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
41095244|NCT00009958|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given SC
41095245|NCT00009958|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
41095246|NCT00009958|BIOLOGICAL|sargramostim|Given SC
41095247|NCT00009958|OTHER|laboratory biomarker analysis|Correlative studies
41095248|NCT00233129|BEHAVIORAL|Top Down|Six months
41095249|NCT00233129|OTHER|cognitive rehabilitation day treatment program|six months
41095250|NCT01032850|DRUG|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
41095251|NCT00175240|BEHAVIORAL|Evidence summaries endorsed by local opinion leaders|
40746283|NCT03924297|DEVICE|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
40746284|NCT04240847|PROCEDURE|Skin incision|Skin incision on medial or lateral to tibial tubercle
41095252|NCT03460717|OTHER|Peripheral Nerve Field Stimulation by Thermal Micro-Cautery|The most painful points over the knee received an intense heat by a metal rod for 0.5 seconds.
41095253|NCT01079598|DEVICE|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
40746285|NCT00380523|DRUG|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
41095254|NCT06376019|PROCEDURE|solitary Implant loading with ball attachment|ball attachment will be attached to the dental implant on the day of implant placement
41095255|NCT06376019|PROCEDURE|splinted Implant loading with intra oral welding|Titanium bar will be welded to the dental implant on the day of implant placement
41095256|NCT06376019|PROCEDURE|complete denture|Mucosa supported conventional complete denture will be fabricated without supporting implants
41095257|NCT02283255|OTHER|Aerobic Exercise Training|Supervised aerobic and light muscle resistance exercise training
41095258|NCT02283255|OTHER|Inspiratory Muscle Training|Inspiratory muscle training with POWERbreathe device
40746286|NCT03501277|DRUG|Alogliptin|Alogliptin tablets.
40746287|NCT03501277|DRUG|Pioglitazone|Pioglitazone tablets.
41095259|NCT02283255|OTHER|No Exercise Training|Usual care
41095260|NCT05378581|DEVICE|Virtual reality mask|virtual reality mask Deepsen® with age-appropriate software Birdy®
41095261|NCT05378581|OTHER|control arm|usual process
41095262|NCT04676802|DRUG|NSAID capsules|1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
41095263|NCT04676802|DRUG|Opioid capsule|1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
41095264|NCT02891369|OTHER|No intervention. Descriptive study|
41095265|NCT04157712|DRUG|ALZ-801 or matching placebo|
41095266|NCT06388421|OTHER|Prospective study assessments|Patients will complete prospective assessments at 6- and 12-month intervals for up to 5 years. There will be 1 check in at the first 3 months of enrollment. Follow up visits will include a ±45 day visit window. If an assessment is performed within 45 days of the visit window as part of the patient's standard of care, those values will be used in place of a prospective assessment.
41095267|NCT02616367|DRUG|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
41095268|NCT02616367|DRUG|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
41095269|NCT00270114|DRUG|epoetin alfa|
41095270|NCT03815916|DRUG|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
40746288|NCT03501277|DRUG|SYR-322-4833 BL|SYR-322-4833 BL FDC tablets.
40746289|NCT00025233|BIOLOGICAL|bevacizumab|Given IV
40746290|NCT00025233|OTHER|laboratory biomarker analysis|Correlative studies
40746291|NCT00369759|OTHER|Emergency Dept. Subjects with LRI or Apnea|No intervention; Epidemiological Study
40746292|NCT02708706|DRUG|hyaluronic acid (hyruan)|2cc hyaluronic acid
40746293|NCT02708706|OTHER|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
40746294|NCT00454142|DRUG|pazopanib hydrochloride|Given PO
41095271|NCT00472147|PROCEDURE|shock efficacy|
41095272|NCT03450109|DRUG|LY01005|One gluteal IM injection
41095273|NCT03450109|DRUG|Zoladex|One Subcutaneous injection in the abdominal wall
41095274|NCT04470726|DRUG|AIV001|Intradermal/intratumoral
40746295|NCT00454142|OTHER|pharmacological study|Correlative studies
40746296|NCT00454142|PROCEDURE|computed tomography|Correlative studies
41095275|NCT02539758|OTHER|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
41095276|NCT02539758|DEVICE|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
40746297|NCT01027416|DRUG|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
40746298|NCT06104293|OTHER|Grass Pollen Allergen Exposure|"After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations."
40746299|NCT01877954|DRUG|Extra-fine hydrofluoroalkane beclometasone dipropionate|
40746300|NCT01877954|DRUG|Fluticasone propionate|
40746301|NCT02898831|OTHER|Cold Compress|Cold Compress placed on lower abdomen prior to and during IUD insertion.
40746302|NCT01243424|DRUG|linagliptin|linagliptin tablets 5mg QD
40746303|NCT01243424|DRUG|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
40746304|NCT01243424|DRUG|linagliptin placebo|linagliptin placebo
40746305|NCT01243424|DRUG|glimepiride placebo|glimepiride placebo
40746306|NCT02968290|PROCEDURE|Cataract Surgery|Implant of intraocular lens hydrophobic or Implant of intraocular lens hydrophilic (Device)
40746307|NCT02968290|DEVICE|Alcon AcrySof SA60AT|Implant of intraocular lens hydrophobic
40746308|NCT02968290|DEVICE|Bausch Lomb AkreosA|Implant of intraocular lens hydrophilic
40746309|NCT04740970|DRUG|JNJ-64304500|JNJ-64304500 injection will be administered subcutaneously.
41095277|NCT02539758|DEVICE|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
41095278|NCT06083714|OTHER|Scapular Stabilization Exercises|Home-based scapular stabilization exercises (Inferior Glide, Low Row, Scapular Clock, Wall Push Up, Wall Slide and Squat Robbery) will be performed once or twice a day, 3 sets x 20 repetitions, 3 days a week for 8 weeks.
41095279|NCT06083714|OTHER|Schroth Exercises|It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.
41095280|NCT03677947|BEHAVIORAL|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, participants will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention). Exercises will consist of both exposure in vivo (i.e. exposure in real life situations) and/or imaginal exposure according to recommendations.
41095281|NCT03677947|OTHER|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning that gives rise to obsessional doubts and overvalued ideas. IBCT does not include exposure in vivo, but instead, aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
40746310|NCT04740970|DRUG|Placebo|Matching placebo injection will be administered subcutaneously.
40746311|NCT03537430|PROCEDURE|TNT uniportal VATS mediastinal tumor resection|TNT uniportal video-assisted thoracoscopic surgery refers to the use of conventional uniportal video-assisted thoracoscopic surgery, the use of laryngeal mask anesthesia instead of tracheal intubation anesthesia, intraoperative catheter was not retained, postoperative chest catheter placement.
40746312|NCT03537430|PROCEDURE|Traditional uniportal VATS mediastinal tumor resection|The surgical procedures followed principles of mediastinal tumor resection，uniportal video-assisted thoracoscopic surgery in mediastinal tumor resection.
40746313|NCT04453007|BEHAVIORAL|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
40746314|NCT04453007|BEHAVIORAL|Feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
40746315|NCT01566162|DRUG|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
40746316|NCT05771623|DEVICE|Iontophoresis drug delivery device|"Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.~The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session.~This can be done through the Iontophoresis drug delivery device. Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months)."
40746317|NCT05771623|BEHAVIORAL|Traditional physical therapy|Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).
40746318|NCT00005021|BIOLOGICAL|filgrastim|
40746319|NCT00005021|DRUG|carboplatin|
40746320|NCT00005021|DRUG|paclitaxel|
40746321|NCT00005021|DRUG|topotecan hydrochloride|
40746322|NCT06347822|BEHAVIORAL|Therapy Session|Single-session intervention (SSI) based on acceptance and commitment therapy (ACT) and solution-focused brief therapy (SFBT) principles
40746323|NCT03432429|OTHER|REIMS iKnife|Use of REIMS iKnife in breast conserving surgery
40746324|NCT06235541|DRUG|GENA-104A16|GENA-104A16 is administered as a 1 hour (h) \[-5 minutes and +60 minutes , i.e., 55-120 minutes as window time\] as intravenous (IV) infusion on q2w.
40746325|NCT04073407|DIETARY_SUPPLEMENT|AXA1957|Amino acids, food study
40746326|NCT04073407|DIETARY_SUPPLEMENT|Placebo|placebo
40746327|NCT04964388|DRUG|GLP-1 receptor agonist|Diabetes medication
40746328|NCT06505148|DRUG|Acetaminophen|administered alternatively with other drug
40746329|NCT06505148|DRUG|Ibuprofen|administered alternatively with other drug
40746330|NCT05697692|DRUG|Heparin sodium|Lung transplantation on central veno-arterial ECMO with standard additional heparin
40746331|NCT05697692|DRUG|Placebo|Lung transplantation on central veno-arterial ECMO without additional heparin
40746332|NCT00741949|DRUG|Propofol|Sedation in TCI with propofol
41095282|NCT06153888|PROCEDURE|Ultrafiltration rate|Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).
41095283|NCT02724878|DRUG|Bevacizumab|
40746333|NCT00741949|DRUG|Placebo|Isotonic saline solution infusion
40746334|NCT00481104|DRUG|Tesofensine|
40746335|NCT05876871|DIAGNOSTIC_TEST|Pelvic Binder Radiography|One series of radiographic exposures
40746336|NCT05993169|OTHER|Body Composition optimization visits|Patients who are selected into the body composition optimization (BCO) visits group will attend an extra one hour in-person check-up with Olivia Johnson as part of their regular clinic follow-ups. During their initial BCO visit, patients will complete a hard copy intake form. These BCO visits will take place in the same clinic as the regular visits. These visits will focus on individual concerns and goal-setting. These visits may be changed to online/video follow ups if the patients are finding it difficult to return to main campus that often.
40746337|NCT04199039|OTHER|Effect on Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction|"When the study started, the first 43 patients were assigned to the control group and the following 43 patients were assigned to the study group in the CVS ICU. ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted. ET fixation of the patients in the study group was performed with an ET holder (AnchorFast Oral Endotracheal Tube Fastener, Hollister, Liberlyville, USA) when they arrived at the CVS ICU.~The patients' SBP, DBP, HR and SpO2 values, which were displayed on the bedside monitor (Nihon Kohden, Tokyo), were recorded on the Hemodynamic Parameters Form just before, during, and at the end of endotracheal suction, and in the following 5th and 15th minutes."
40746338|NCT04370899|OTHER|lifestyle assessment|"A semi-quantitative assessment of the consumption of different food groups will be carried out using a frequency questionnaire validated by the Spanish population27. This questionnaire consists of 137 food items and will be obtained by the dietitian of our Unit (see annex).~The child population and/or their parents will be instructed on how to fill the data in the food diary for a period of 3 days, in order to be able to analyse the nutritional composition of the intake and the effect on the lipid profile. The first food register, will be obtained at the collection visit before starting any type of treatment. Another food diary will be included after one year.~Physical activity will be collected from the Minnesota Test and we will ask about the consumption of tobacco."
40746339|NCT01279993|PROCEDURE|Kerato refractive Surgery|This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
40746340|NCT04853290|DEVICE|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
40746341|NCT04853290|DEVICE|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by the registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture protocol instituted in the hospital where the study will be conducted
40922326|NCT01888432|DRUG|Everolimus + reduced tacrolimus|Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.
40746342|NCT06139458|BEHAVIORAL|Cryotherapy|Participants will receive cryotherapy on both hands and feet
40746343|NCT06139458|BEHAVIORAL|Compression|Participants will receive compression on both hands and feet
40746344|NCT00368485|DEVICE|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
40922327|NCT01888432|DRUG|Standard tacrolimus|Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
40922328|NCT05189860|DEVICE|C-MIC system|This study aims to follow up patients already treated with a C-MIC System over a period of 2 years following the initial treatment with the device, to assess the long term results.
40922329|NCT04734678|DRUG|Tocilizumab|400 mg IV only once
40922330|NCT04734678|DRUG|Infliximab|5 mg/kg/day IV for 2 doses 12-24 hours
41095284|NCT02724878|DRUG|Atezolizumab|
41095285|NCT06470204|DRUG|Ropivacaine|Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2ml 0.9% NaCl)
41095286|NCT06470204|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2mg Dexamethasone)
41095287|NCT01442168|DRUG|Sevuparin sodium + atovaquone/proquanil|Sevuparin 4 times per day and malanil according to label
41095288|NCT01442168|DRUG|atovaquone/proquanil|malanil according to label
41095289|NCT00361621|DRUG|bortezomib|Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
41095290|NCT00361621|DRUG|Rituximab|Given intravenously on day 1 of a 21-day cycle for 6 cycles
41095291|NCT00361621|DRUG|Cyclophosphamide|Given intravenously on day 1 of a 21-day cycle for 6 cycles
41095292|NCT00361621|DRUG|Doxorubicin|Given intravenously on day 1 of a 21-day cycle for 6 cycles
41095293|NCT00361621|DRUG|Vincristine|Given intravenously on day 1 of a 21-day cycle for 6 cycles
40746345|NCT03342794|PROCEDURE|cataract surgery|To diagnose the preexisting posterior capsule defects in congenital cataracts after the cataracts are removed by surgery and observe the characteristics
41095294|NCT00361621|DRUG|Prednisone|Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
41095295|NCT00361621|RADIATION|Radiation therapy|After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy
41095296|NCT00174720|DRUG|Ciclesonide (XRP1526)|
40746346|NCT00150527|DRUG|Citalopram|40 mg, pill, single dose
40746347|NCT00150527|DRUG|Escitalopram|20 mg, pill, single dose
41095297|NCT02833454|PROCEDURE|direct insertion anterior cruciate ligament reconstruction|ACL reconstruction based on direct insertion of ACL.
40746348|NCT00150527|DRUG|Dexamethasone|1 mg, pill, single dose
41095298|NCT02833454|PROCEDURE|single bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using single bundle technique
41095299|NCT02833454|PROCEDURE|double bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using double bundle technique
41095300|NCT04308447|DEVICE|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
41095301|NCT01893320|DRUG|Vosaroxin|"Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I."
41095302|NCT01893320|DRUG|Decitabine|Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
41095303|NCT03810885|OTHER|Bread with reduced salt content|Bread with gradually lowered salt content
41095304|NCT03810885|BEHAVIORAL|Dietary advice|Participants will receive information on how to lower salt and increase potassium intake
41095305|NCT03810885|OTHER|Bread with standard salt content|Bread with normal salt content
41095306|NCT01126021|BEHAVIORAL|Financial incentives|Participants are eligible for incentives if they participate in at least 30 games per day.
41095307|NCT01126021|BEHAVIORAL|No incentives|Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
41095308|NCT04541641|PROCEDURE|New Reverse Drilling technique|a new technique of dental implant drilling that promote osseodensification by rotating the drills anti-clockwise rather than clockwise to promote bone condensation rather than bone cutting
41095309|NCT04541641|PROCEDURE|osteotome technique|a technique for dental implant placement by using the osteotome to condense the bone and create an osteotome rather than cutting the bone
41095310|NCT02535338|DRUG|Erlotinib Hydrochloride|Given PO
41095311|NCT02535338|OTHER|Laboratory Biomarker Analysis|Correlative studies
41095312|NCT02535338|DRUG|Onalespib Lactate|Given IV
41095313|NCT02535338|OTHER|Pharmacological Study|Correlative studies
40746349|NCT00150527|BEHAVIORAL|Cold Pressor Test|single test
40746350|NCT03066076|DRUG|Antithyroid Drug|Antithyroid drug
40922331|NCT06156293|BEHAVIORAL|Cognitive behavioral prevention program for insomnia (CBP-I)|CBP-I will be provided to participants once their districts are exposed.
40746351|NCT03066076|PROCEDURE|Total thyroidectomy|Operation
40746352|NCT02665936|DRUG|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
40746353|NCT02665936|DRUG|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
40746354|NCT02665936|DRUG|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
40746355|NCT02092428|OTHER|Image Quality|"The following procedures may be conducted as part of this study:~* Coronary MRI scan with no contrast~* Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg~* MRI scan with an oral beta blocker (metoprolol)~* Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)~Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions."
41095314|NCT00607035|DRUG|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
41095315|NCT00607035|DRUG|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
41095316|NCT05857293|DEVICE|Catheter-guided PDA stent implantation|PDA stent is the primary treatment for patients with duct-dependent pulmonary circulation. It serves as a temporary bridge for later surgical repair by keeping the duct patent to improve oxygen saturation
41095317|NCT01619254|BEHAVIORAL|Hand washing with soap and hand finger nail clipping|Assess the impact of hand washing with soap and nail clipping on child health
41095318|NCT04793139|DRUG|Camrelizumab|Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
41095319|NCT01281761|DRUG|cetuximab/irinotecan/simvastatin|D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- \[C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min\] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV \[over 90min\] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
41095320|NCT05166174|PROCEDURE|Transvaginal ultrasound in the third trimester pregnancy|Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)
41095321|NCT01773122|DRUG|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
41095322|NCT01773122|DRUG|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
41095323|NCT01773122|DRUG|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
41095324|NCT01773122|DRUG|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
41095325|NCT03519451|OTHER|Internet-Based Intervention|Given KickAsh smartphone mobile application
40746356|NCT02092428|OTHER|Diagnostic Accuracy|Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
40746357|NCT01008540|BIOLOGICAL|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
40922332|NCT05446337|OTHER|Open-Ended Semi-Structured Interview|Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process
40922333|NCT06518434|DRUG|Medical Cannabis|Medical cannabis oil three times daily
40922334|NCT05293392|BEHAVIORAL|Culturally-Tailored COVID-19 Vaccine Uptake Intervention|This is a multi-component intervention to increase COVID-19 vaccine uptake among youth that was co-created with community partners and refined with qualitative feedback from Black and Latino youth and parents. The intervention consists of culturally-tailored educational materials to increase awareness about the COVID-19 vaccine, culturally-sensitive communication strategies employed by pediatric primary care providers and community health workers, and strategies to facilitate and standardize access to the COVID-19 vaccine in the primary care clinic.
40922335|NCT05293392|BEHAVIORAL|Standard Care|Standard care includes routine offer of the COVID-19 vaccine and counseling about the COVID-19 vaccine by pediatric primary care providers.
40922336|NCT02785770|DRUG|PF-04447943|Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
40922337|NCT02785770|DRUG|Placebo|Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
40922338|NCT02785770|DRUG|Moxifloxacin|Single oral dose of moxifloxacin administered as tablet
40922339|NCT05331859|DRUG|Insulin|Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.
41095326|NCT03519451|OTHER|Internet-Based Intervention|Given Breathe2Relax smartphone mobile application
41095327|NCT03519451|OTHER|Questionnaire Administration|Ancillary studies
41095328|NCT01282775|BEHAVIORAL|WEB + Environment|Participants receive weekly lessons via the Web along with additional tools for weight loss support
41095329|NCT01282775|BEHAVIORAL|WEB + Cash Incentive for Weight Loss|Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
41095330|NCT05464589|OTHER|Transcutaneous tibial nerve stimulation along with pelvic floor muscle srengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening.~Transcutaneous electrical stimulation of Tibial Nerve:~Transcutaneous Tibial nerve stimulation is a form of treatment technique that involves the use of electrical impulses to address urinary symptoms and target the lower urinary tract."
41095331|NCT05464589|OTHER|Pelvic floor muscles strengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening."
41095332|NCT05955040|DRUG|Nifedipine|Standard of care for treatment of elevated blood pressure during pregnancy
41095333|NCT05955040|DRUG|Labetalol|Standard of care for treatment of elevated blood pressure during pregnancy
41095334|NCT04311203|BEHAVIORAL|Mental Health First Aid|The intervention has 3 parts:1.Two-day MHFA training provided by MHFA England. A manualised programme designed to provide individuals with: an in-depth understanding of mental health and the factors that can affect wellbeing, practical skills to spot triggers and signs of mental health issues, confidence to step in, reassure and support a person in distress, enhanced interpersonal skills such as non-judgemental listening, knowledge to help someone recover their health by guiding them to further support - whether that's self-help resources, through their employer, the NHS, or a mix. 2.Raising awareness of the presence of MHFA in the organisation. 3.The application of MHFA to participants in the workplace using the manualised five-stage approach, ALGEE: Approach the person, assess and assist with any crisis; Listen and communicate non-judgementally; Give support and information; Encourage the person to get appropriate professional help and Encourage them to seek other forms of support.
40922340|NCT05331859|DRUG|autologous serum (AS)|Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
41095335|NCT04327596|PROCEDURE|RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter|Ablation of AF is standard of care in the management of patients with paroxysmal or persistent AF. The most common triggers initiating AF arise from pulmonary veins (PV) and successful electrical isolation of PV's can significantly reduce the burden of AF. Therefore, the main objective in patients undergoing ablation of AF is to achieve PV isolation.
41095336|NCT00910884|OTHER|laboratory biomarker analysis|No supplements are given
41095337|NCT00910884|PROCEDURE|therapeutic dietary intervention|Given orally daily for 12 months
41095338|NCT00291707|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
41095339|NCT00291707|DRUG|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if \>6000 cGy to be delivered)
41095340|NCT00291707|PROCEDURE|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
41095341|NCT05080595|OTHER|Transportation assistance (Lyft rides)|Lyft rides will be provided to patients for any transplant-related medical visits
41095342|NCT03429309|DRUG|Propofol|Anesthesia was induced by intravenous infusion of propofol via the syringe pump at a rate of 30 mg/kg/h.
41095343|NCT02758262|DEVICE|Noninvasive brain stimulation|
41269859|NCT01993888|OTHER|Standard of Care (SoC)|
40746358|NCT04063020|BEHAVIORAL|Psychological monitoring|"Discussions with the psychologist PhD student before and after every surgery times : 3 discussions.~* Before the first surgery (about 1 month before) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)~* Before the second surgery (3 months later the first surgery) Clinical interview Drawing a person~* After the second surgery (15 months later the first surgery) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)"
40746359|NCT03927391|DRUG|Enzalutamide|enzalutamide treatment
41269860|NCT02221609|OTHER|Treatment based on Movement System Impairment model|The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.
40746360|NCT05883878|GENETIC|PRS|genetic test for the evaluation of PRS cardiovascular risk
40746361|NCT05883878|DEVICE|Digital app and wearable device|a wearable device connected with its app
40746362|NCT01913470|DRUG|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
40746363|NCT04881721|PROCEDURE|Urethropexy|Suture based (Mesh-free) surgery to stabilize the urethra for the treatment of stress urinary incontinence
40746364|NCT02406612|DEVICE|X-Seal 6F Vascular Closure Device|
40746365|NCT00378859|BEHAVIORAL|Skim milk|
40746366|NCT00378859|BEHAVIORAL|Lean meat|
40746367|NCT05872126|PROCEDURE|VATS-Surgical pleurodesis|VATS drainage and surgical abrasion.
40746368|NCT05872126|PROCEDURE|Tube Drainage|Tube drainage for malignant pleural effusion
40746369|NCT03148340|DIAGNOSTIC_TEST|VIPS Monitoring|Bioimpedance asymmetry
40746370|NCT03693898|OTHER|Observeational|No intervention, observational
40746371|NCT03637374|DEVICE|Visceral Manifold and Thoracic Bifurcation|Endovascular stent graft system
40746372|NCT03637374|DEVICE|Unitary Manifold|Endovascular stent graft system
40746373|NCT03637374|DEVICE|TAAA Debranching Stent Graft System|Endovascular stent graft system
40746374|NCT04503200|PROCEDURE|Double guidewire|After the 3rd passage of the guidewire into the pancreatic duct, the catheter will be removed leaving the guidewire in place. The catheter will be re-inserted and a second guidewire will be used and directed above the pancreatic wire in the 11-12 o'clock direction to attempt cannulation of the common bile duct.
40746375|NCT04503200|PROCEDURE|Transpancreatic precut|After the 3rd passage of the guidewire unintentionally into the pancreatic duct, the guidewire will be left in the pancreatic duct, a sphincterotome will be used to cut in the direction of 11-12 o'clock attempting to deroof the pancreatic duct and gain access into the common bile duct. The wire will then be retracted and reinserted in the direction of the cut to attempt cannulation of the common bile duct.
41269861|NCT02221609|OTHER|General exercise|The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
41269862|NCT03478618|DRUG|Lactated Ringer|"Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia.~Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups"
41269863|NCT02828176|PROCEDURE|electric cardiometry|"The following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance.~these parameters are measured on arrival to operating room before subarachnoid block in three different angles of lateral uterine tilt ( 0, 15 and 30 degrees )"
40746376|NCT01744821|DIETARY_SUPPLEMENT|Arm A: Vitamin D3 Group|
40746377|NCT01744821|DIETARY_SUPPLEMENT|Placebo|
40746378|NCT01757847|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.
40922341|NCT05331859|DRUG|conventional|Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
40922342|NCT04592718|BEHAVIORAL|Slow deep breathing plus breath counting|Participants will perform a daily 5-min slow deep breathing exercise for 4 weeks. A breathing rate of 6 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
40746379|NCT01757847|BEHAVIORAL|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
40746380|NCT01653418|DRUG|Bortezomib|
40746381|NCT01653418|DRUG|Carmustine|
40746382|NCT01653418|DRUG|Etoposide|
40746383|NCT01653418|DRUG|Cytarabine|
40746384|NCT01653418|DRUG|Melphalan|
40746385|NCT01653418|PROCEDURE|Stem cell infusion|
40746386|NCT03563612|DEVICE|cpap|application of cpap to the non-dependent lung, during one lung ventilation
40746387|NCT02112552|DRUG|Paclitaxel|Given IV
40746388|NCT02112552|DRUG|Carboplatin|Given IP
40746389|NCT02112552|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
40746390|NCT02112552|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40746391|NCT02112552|OTHER|Quality-of-Life Assessment|Ancillary studies
40746392|NCT02112552|OTHER|Laboratory Biomarker Analysis|Correlative studies
40746393|NCT05194488|DEVICE|Low level laser therapy|Patients will receive low-level laser therapy on the temporomandibular joint disc
40746394|NCT05194488|DRUG|Botulinum toxin type A|Patients will receive Botulinum toxin type A injection into the lateral pterygoid muscle under Electromyography (EMG) guidance.
40746395|NCT05194488|DEVICE|Anterior repositioning appliance|Patients will receive hard maxillary anterior repositioning appliance.
40746396|NCT06548243|BEHAVIORAL|Act with Nature Programme|The participants in the intervention group are offered a 12-week nature-based programme, which includes independent exercises and information on an online learning environment, as well as online or in-person group meetings.
40746397|NCT01759641|DEVICE|Hypotension-prone patients|Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
40746398|NCT01115621|OTHER|Glutenfree diet during the first year of life|Glutenfree diet during the first year of life
40746399|NCT04508075|BIOLOGICAL|SARS-CoV-2 vaccine (inactivated)|SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac
40746400|NCT04508075|BIOLOGICAL|Placebo|Placebo manufactured by PT. Bio Farma
41095344|NCT01580943|DRUG|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
41269864|NCT02828176|PROCEDURE|IV line insertion|two Iv lines are inserted and 500cc crystalloid is administered to parturient .
40746401|NCT01328119|OTHER|4-hour HD, 4-hour HDF, 8-hour HD and 8-hour HDF|Prevalent conventional HD (CHD) patients (dialysing 3 days a week during 4 hours per dialysis session) will undergo, in random order, a mid-week 4-hour HD session, a mid-week 4-hour HDF session, a mid-week 8-hour HD session, and a mid-week 8-hour HDF session with a 2-week interval between every session to assess the influence of treatment duration and of convection on the removal of uremic toxins and on the haemodynamic responses and autonomic nervous regulation. In between the study dialysis sessions these patients will receive routine CHD treatments.
40746402|NCT02845492|OTHER|Qigong|Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
40746403|NCT02845492|OTHER|Complete Health Improvement Program (CHIP)|The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
40746404|NCT02049879|DRUG|Corticosteroids injection|A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
40746405|NCT02506036|OTHER|Brain HQ|Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
40746406|NCT02369926|PROCEDURE|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
40746407|NCT02369926|PROCEDURE|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
40746408|NCT02298283|DRUG|brentuximab vedotin|is 1.8 mg/kg administrated by IV infusion
40746409|NCT02298283|DRUG|Cyclophosphamide|1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
40746410|NCT02298283|DRUG|Adriamycin|35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
40746411|NCT02298283|DRUG|Oncovin|1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
40746412|NCT02298283|DRUG|Bleomycin|10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
40746413|NCT02298283|DRUG|Etoposide|200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
40746414|NCT02298283|DRUG|Procarbazine|100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
40746415|NCT02298283|DRUG|Prednisone|40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
40746416|NCT02298283|DRUG|G-CSF|5 µg/kg/j, SC, D9 until GB 1.0x109/L
40746417|NCT02298283|RADIATION|30 Grays|30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
40746418|NCT01540734|DRUG|Marketed paracetamol|Marketed formulation
40746419|NCT01540734|DRUG|Experimental paracetamol formulation|Experimental formulation
40746420|NCT03738748|OTHER|Ultrasound- guided Percutaneous Neuromulation|The experimental group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L-3, once a week for 4 weeks.
40746421|NCT03738748|OTHER|TENS Therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region, once a week for 4 weeks.
40746422|NCT01758081|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
40746423|NCT01758081|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
40746424|NCT01758081|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
40746425|NCT01758081|DIETARY_SUPPLEMENT|fish oil placebo|
40746426|NCT02097277|BIOLOGICAL|BMS-986036|
40746427|NCT02097277|BIOLOGICAL|Placebo (Matching with BMS-986036)|
40746428|NCT00016302|DRUG|prednisone|Given orally
40746429|NCT00016302|DRUG|vincristine sulfate|Given IV
40746430|NCT00016302|DRUG|daunorubicin hydrochloride|Given IV
40746431|NCT00016302|DRUG|asparaginase|Given IM
40746432|NCT00016302|DRUG|methotrexate|Given IT and orally
40746433|NCT00016302|DRUG|cyclophosphamide|Given IV
40746434|NCT00016302|DRUG|cytarabine|Given IV or SC
40746435|NCT00016302|DRUG|mercaptopurine|Given orally
41095345|NCT01580943|DRUG|Chlorhexidine|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
41095346|NCT02735187|DEVICE|Blue light treatment|Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.
41095347|NCT02735187|DRUG|Vitamin D|Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)
41095348|NCT00112723|DRUG|alvocidib|Given IV
41095349|NCT01585181|BIOLOGICAL|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
41095350|NCT01585181|BIOLOGICAL|Placebo|Approx 2 grams of lactose reconstituted in water
41095351|NCT06336746|DEVICE|Esophageal Doppler|Esophageal Doppler: measuring cardiac performance. INVOS: measuring regional saturation of the brain.
41095352|NCT04415112|BEHAVIORAL|Mediterranean Diet|A list of foods high consumption of vegetables, fruits, non-refined cereals, legumes and potatoes, moderate consumption of fish and poultry and low consumption of full fat dairies, red meat and its products and homemade sweets.
41095353|NCT04415112|BEHAVIORAL|Low Fat Diet|These children are forbidden to eat high-fat foods such as fried foods, butter, cream cheese, while foods such as fruits, vegetables (starchy and non-starch), cereals, poultry, lean meat and low-fat dairy products are allowed.
41095354|NCT03492632|OTHER|Hormone panel|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH,LH,PRL,E2 and AMH hormone levels.
40746436|NCT00016302|DRUG|leucovorin calcium|Given IV or orally
40746437|NCT00016302|DRUG|dexamethasone|Given orally
40746438|NCT00016302|DRUG|doxorubicin hydrochloride|Given IV
40746439|NCT00016302|DRUG|thioguanine|Given orally
40746440|NCT00016302|RADIATION|radiation therapy|Undergo cranial irradiation
40746441|NCT00016302|DRUG|nelarabine|Given IV
40746442|NCT00016302|DRUG|pegaspargase|Given IM
40746443|NCT00016302|RADIATION|radiation therapy|Undergo craniocervical radiotherapy
40746444|NCT00016302|OTHER|pharmacological study|Correlative studies
40746445|NCT00016302|OTHER|laboratory biomarker analysis|Correlative studies
40746446|NCT00057070|PROCEDURE|Smoking cessation information, collection, and dissemination|
41095355|NCT06218186|DEVICE|Medical Device: Wesper Lab Home Sleep Test|Wesper Lab is a medical device that is used for the diagnosis of sleep apnea. Wesper lab is composed of two flexible biosensors that adhere to the abdomen and thorax with medical grade adhesive. A FDA approved pulse oximeter is worn on a finger.
41095356|NCT00000568|BEHAVIORAL|smoking cessation|
41095357|NCT00000568|DRUG|ipratropium|
41095358|NCT06240039|OTHER|Evaluating the acute effect of an amino acid infusion with and without a concomitant infusion of the somatostatin analogue octreotide to eliminate endogenous production of glucagon|"The experimental days consist of four study days:~1. Assessment of liver fat and visceral fat by magnetic resonance imaging (MRI; 6-point Dixon) (study day A)~2. Somatostatin infusion (4 hours) plus amino acid infusion (45 minutes) (study day B)~3. Saline infusion (4 hours) plus amino acid infusion (45 minutes) (study day C)~4. Somatostatin infusion (4 hours) plus saline infusion (45 minutes) (study day D)~The subjects will participate in the experimental days (study day B to D) in randomized order on three different days. For study day B to D, at timepoint t = -75, subjects will receive either; a 240-minute intravenous infusion of a somatostatin analogue (at 200 ng/kg/min (infusion rate will not exceed 1000 µg/hour) or saline. After 75 minutes (timepoint t = 0), the subjects will receive a 45-minute intravenous infusion of amino acids or saline at 3.885 ml/kg/hour.~In total, blood will be sampled 11 times over a period of 6 hours and 15 minutes."
41269865|NCT02828176|PROCEDURE|spinal anesthesia ( subarachnoid block )|Subarachnoid block (SAB) was performed in sitting position under complete asepsis using 25 g spinal needle. SAB was achieved by intrathecal injection of 10 mg hyperbaric bupivacaine plus 25ug fentanyl. Success of SAB was tested within five minutes after drug injection. SAB was considered successful if adequate block reached T4 dermatome.
40746447|NCT03126734|OTHER|Infant Massage course|"Infant massage courses consist of 5 sessions. Investigators explain parents how to make an infant massage technique to their babies and which should be the general conditions of the environment.~This massage is based on the methodology of the International Association of infant massage (IAIM) created by Vimala Schnneider. The courses will make individually."
41095359|NCT02162238|DEVICE|LSF-filtering device|Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
41095360|NCT00515086|DRUG|Everolimus|Tablets taken once a day with a full glass of water.
41095361|NCT00515086|PROCEDURE|Surgery|Salvage surgical resection
41095362|NCT05903807|DRUG|68Ga-FAPi-46|Ovarian cancer patients undergo 68Ga-FAPI-46 at primary staging and at restaging
40746448|NCT00683384|DRUG|Etanercept (Enbrel)|
40746449|NCT00442689|DRUG|flutamide|250 mg twice daily
40746450|NCT00442689|DRUG|ethinyl estradiol 35 mcg and drospirenone 3 mg|one active pill per day for three weeks and then 1 sugar pill per day for one week
41095363|NCT04001504|BIOLOGICAL|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV (30µg Hemagglutinin)
40746451|NCT00442689|OTHER|placebo|
40746452|NCT04545372|OTHER|aerobic exercise|
40746453|NCT02147080|BEHAVIORAL|UV4me|Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator
40746454|NCT02147080|BEHAVIORAL|Skin Cancer Foundation website|Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.
40746455|NCT06278168|OTHER|Awareness training with using Oculus.|"The protocol consists of 2 phases:one conducted in groups,one individually. In the first session, through interactive activities such as passing a wool ball while sharing passions and interests, and filling out personal cards, participants get to know each other and develop an atmosphere of mutual acceptance.~In the second session,participants explore neurodiversity through viewing videos, guided discussions and creating symbols representative of the group concept. Optical illusions are explored to understand differences in individual perception.In addition, issues of hypersensitivity and hyposensitivity are addressed,encouraging participants to reflect on their special interests and ways of presenting themselves. The second phase consists of 12 individual meetings to promote emotional well-being and self-awareness. During the meetings, the Oculus device will be used in which relaxation videos will be shown. In addition, heart rate will be detected with sensors placed in the chest."
41095364|NCT04001504|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV (15µg Hemagglutinin)
40746456|NCT06278168|OTHER|Awareness training without using Oculus|The control group will carry out the same steps as the experimental group, heart rate will be taken through the use of sensors but in this case the Oculus device will not be used to watch relaxation videos.
40746457|NCT04831554|PROCEDURE|single chest tube drainage|place single chest tube after surgery of PSP
40746458|NCT00333307|DRUG|recombinant human relaxin|
40746459|NCT01410604|DRUG|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
40746460|NCT01410604|DRUG|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
40746461|NCT06021496|BEHAVIORAL|face to face health education|Face-to-face health education with home visit
40746462|NCT06021496|BEHAVIORAL|online health education|online health education with video call
41095365|NCT02637271|OTHER|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
41095366|NCT02637271|OTHER|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
41095367|NCT06121570|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
40746463|NCT03447795|PROCEDURE|Alveolar ridge preservation|grafting procedure using autogenous tooth.
41095368|NCT06121570|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
40746464|NCT02129556|DRUG|MK-3475|The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
40746465|NCT05372900|OTHER|Test Product|Whey Protein Isolate with Mulberry leaf extract
40746466|NCT05372900|OTHER|Control Product|Wheat Protein Hydrolysate
40746467|NCT00793611|BEHAVIORAL|Behavioral therapy standard of care|controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
40746468|NCT00793611|OTHER|hypnotherapy|Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
40746469|NCT06369051|OTHER|Self-employment support intervention|A new intervention developed to assist stroke survivors in becoming self-employed by developing entrepreneurial skills. It consists of one home visit, three online individual sessions, and four online group sessions held once a week for eight weeks.
41095369|NCT06121570|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
41095370|NCT06121570|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
40746470|NCT06442969|OTHER|Education and resources provided by community health workers|The intervention will consist of implementing existing tools provided by EPA's Design for the Environment program, CalOSHA and NIOSH sector-specific guidance for agricultural workers, the Imperial County Department of Public Health and materials from California Department of Toxics Substances Control. The investigators will utilize and adjust existing educational tools such as the Heat Illness Prevention plan developed by CalOSHA. In addition to the educational materials, the investigators will give each farmworker cooling working gear to be worn during their work-shift with (specialized clothes that has been used in other occupational settings). The investigators will provide all participants with a low-cost fan filter, known as Corsi-Rosenthal box built jointly by the community health/research team to reduce chemicals at home, and a small A/C unit to reduce heat stress.
40746471|NCT04344093|DEVICE|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
40746472|NCT02993341|DRUG|Tranexamic Acid|
40746473|NCT02993341|OTHER|Saline Wash|
40746474|NCT00602784|BIOLOGICAL|IC41|
40746475|NCT01784185|PROCEDURE|virtual bronchoscopy guided transbronchial needle aspiration|
40746476|NCT01784185|PROCEDURE|endobronchial ultrasound guided transbronchial needle aspiration|endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
40746477|NCT00661219|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
40746478|NCT00661219|DRUG|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
40746479|NCT06251427|DIETARY_SUPPLEMENT|Multiple micronutrient fortified maize with milk|The study product is a multiple micronutrient fortified maize pap with milk
40746480|NCT05995366|DRUG|ABBV-903|Solution; Oral
40746481|NCT03756935|PROCEDURE|All monitoring|Dicpleth and PI are obtained a posteriori from the PPG waveform reconstruction and blindly from ABP values. Dicpleth is defined as the ratio of the height of the dicrotic notch (from nadir point of the complex to the notch) to the height of the systolic peak (from nadir point of the complex to the pic), measured at end-expiratory time (average of 3 consecutive complex). PI is calculated as the ratio of the pulsatile component of the PPG signal and the continuous component.
40746482|NCT00991432|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
40746483|NCT02040220|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|2 mg of Eylea will be treated per one injection at more than one months interval usually.
40746484|NCT03630887|DEVICE|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room during different time periods.
40746485|NCT06403501|DRUG|Clascoterone|Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
40746486|NCT06403501|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
40746487|NCT00728923|DRUG|NPL-2003|Minocycline (NPL-2003) daily for 12 weeks
40746488|NCT04398914|DRUG|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
40746489|NCT04398914|DRUG|Trastuzumab|"Trastuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.~Adjuvant treatment: 8 mg/kg loading dose, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab"
41269866|NCT02828176|PROCEDURE|electric cardiometry|after SAB the following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance at three different angles of left uterine lilt (0,15,30 degrees)
40746490|NCT04398914|DRUG|Pertuzumab|"Pertuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.~Adjuvant treatment: 840 mg loading dose, followed by 420mg for remaining cycles till completion of 1 year pertuzumab"
40746491|NCT04398914|DRUG|Nab-paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
40746492|NCT04398914|DRUG|EC chemotherapy|Epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks for 4 cycles (Cycles 5-8)
40746493|NCT04398914|DRUG|Physician's choice|Physician decided chemotherapy for 0-4 cycles.
41095371|NCT06121570|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
41095372|NCT06121570|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
41269867|NCT00670007|BIOLOGICAL|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
41269868|NCT00756548|DRUG|BLI850|multi-dose preparation for oral administration prior to colonoscopy
41269869|NCT00756548|DRUG|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
40746494|NCT04398914|DRUG|T-DM1|T-DM1 IV infusion in 3-week cycles. 3.6 mg/kg by intravenous (IV) infusion every 3 weeks for 14 cycles
40746495|NCT04398914|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
40746496|NCT01651598|DRUG|Placebo to BI 144807|multiple dose (bid)
40746497|NCT01651598|DRUG|BI 144807|multiple dose (bid, low to high dose)
40746498|NCT03215615|PROCEDURE|Periodontal surgery|Coronally advanced flap for root coverage
40746499|NCT03215615|PROCEDURE|Total Etch adhesive|Total-etch adhesive system (two step)
40746500|NCT03215615|PROCEDURE|Universal Adhesive|One-step self-etching adhesive system
41269870|NCT00950170|PROCEDURE|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
41269871|NCT02155400|DEVICE|Bair Hugger|Forced Air Warming Blanket placed over the body of the patient during surgery
40746501|NCT03215615|PROCEDURE|Nanofilled Composite|Partial nanofilled-resin composite restoration
40746502|NCT03215615|PROCEDURE|Micro-Hybrid Composite|Partial micro-hybrid composite restoration
40746503|NCT02827708|DRUG|semaglutide|Oral administration once daily.
40746504|NCT02827708|DRUG|placebo|Oral administration once daily.
40746505|NCT02470767|DRUG|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
40746506|NCT00600782|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)|Intramuscular injection, 2 doses at 0, 1 month
40746507|NCT05137145|DRUG|Linaclotide|The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.
40746508|NCT05137145|DRUG|Compound Polyethylene Glycol Electrolyte Powder|The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
40746509|NCT06132997|PROCEDURE|Thoracoscopy procedure|is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.
40746510|NCT06132997|PROCEDURE|Chest tube thoracostomy|Insert chest intercostal tube without thoracoscopy
40746511|NCT00694343|DRUG|HES 130/0.4 (6%) in sodium chloride (solution for infusion)|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
40746512|NCT00694343|DRUG|Ringer's Lactate solution|1000 mL Ringer's Lactate solution
40746513|NCT00003456|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
40746514|NCT00770094|DEVICE|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
40746515|NCT00770094|DEVICE|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
40746516|NCT00770094|DEVICE|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
40746517|NCT01390935|OTHER|guideline adherence|guideline adherence of physician
40746518|NCT00645931|BEHAVIORAL|protein and calorie controlled diet and self-hypnotic relaxation|daily
41095373|NCT06121570|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|Participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
41269872|NCT02155400|DEVICE|Prototype / Experimental device|Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
40746519|NCT03018938|DRUG|Insulin Analog Mid Mixture|Administered SC
40746520|NCT03018938|DRUG|Basal Insulin Analog|Administered SC
40746521|NCT01574560|BEHAVIORAL|Brochure|Information regarding secondhand smoke and creating a healthy home environment.
40746522|NCT01574560|BEHAVIORAL|Counseling|Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
40746523|NCT06544395|DEVICE|Non invasive neuromodulation therapy|"In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1 of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement."
40746524|NCT06544395|OTHER|Manual therapy|Common manual therapy administered for said pathology by traditional physiotherapy and therapeutic exercise.
40746525|NCT06544395|DEVICE|Placebo with non invasive neuromodulation|"In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The treatment was carried out with the machine turned off."
40746526|NCT02716285|DRUG|Ileocolonic release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
40746527|NCT02716285|DRUG|Placebo|Placebo capsule, containing microcrystalline cellulose
40746528|NCT02716285|DRUG|Small intestinal release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
40746529|NCT04324489|DRUG|DAS181|Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
41095374|NCT06121570|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
41269873|NCT03979976|DRUG|Ramipril|Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence
41269874|NCT00612599|DRUG|biphasic insulin aspart|
40746530|NCT05480384|DRUG|Nivolumab|Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)
40746531|NCT05480384|DRUG|Trastuzumab deruxtecan|Given in combination with Nivolumab.
40922343|NCT04592718|BEHAVIORAL|Normal-paced breathing plus breath counting|Participants will perform a daily 5-min normal-paced breathing exercise for 4 weeks. A breathing rate of 15 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
40922344|NCT00202475|PROCEDURE|eythrocytapheresis|machinal collection of erythrocytes
40922345|NCT00202475|PROCEDURE|whole blood collection|collection of whole blood
40746532|NCT05788198|OTHER|Integrated care|"The intervention will be modelled based on the most frequently reported patient, family physician and specialist barriers in depression management. In this project, multiple interventions aiming to tackle these barriers will be set up, with the WHO Framework on Integrated People-Centred Health Services (IPCHS) serving as conceptual backbone to the study (Table 1). The IPCHS distinguishes five interdependent strategies supporting a shift in healthcare delivery, management and funding towards universal health coverage. These strategies are:~1. empowering and engaging people and communities;~2. strengthening governance and accountability;~3. reorienting the model of care;~4. coordinating services within and across sectors;~5. creating an enabling environment."
40746533|NCT00872157|DRUG|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
40746534|NCT03512158|OTHER|Non-invasive respiratory support mode|A mode of providing respiratory support via nasal masks or prongs
40746535|NCT00164866|DRUG|Omeprazole|
40746536|NCT05162911|BEHAVIORAL|Ask, advise, Assist and refer to the Quitline|A nurse will ask, advise, assist and refer patient to the Quitline
40746537|NCT05162911|BEHAVIORAL|Ask, advise, Assist and referral to onsite counselor|A nurse will ask, advise, assist and refer patient to a counselor
40746538|NCT05162911|BEHAVIORAL|Ask, advise, Assist and referral to onsite counselor and NRT|A nurse will ask, advise, assist and refer patient to a counselor and provide nicotine replacement therapy in the form of gum
40746539|NCT00805220|OTHER|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
40746540|NCT05763316|OTHER|CRIB II|Calculate Clinical Risk Index for Babies II score
40746541|NCT05763316|OTHER|SNAP-II|Calculate Score for Neonatal Acute Physiology II
40746542|NCT05763316|OTHER|SNAPPE-II|Calculate Score for Neonatal Acute Physiology Perinatal Extension II
40746543|NCT05763316|OTHER|STOPS|Calculate Sensorium, temperature, oxygenation, perfusion, skin color, and blood sugar score
40746544|NCT05763316|OTHER|MSNS|Calculate Modified Sick neonatal Score
40746545|NCT05763316|OTHER|nSOFA|Calculate neonatal sequential organ failure assessment
40746546|NCT01956942|DEVICE|Micropulse Laser Trabeculoplasty|
40746547|NCT01956942|DEVICE|Selective Laser Trabeculoplasty|
40746548|NCT02760511|DIETARY_SUPPLEMENT|Anthocyanin|Capsules with different anthocyanin content
40746549|NCT02760511|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
40746550|NCT03556176|BEHAVIORAL|Exercise|Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).
40746551|NCT03556176|BEHAVIORAL|Quiet rest|Quiet rest during 30 min
40746552|NCT05442632|DRUG|Hetrombopag|The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day
40746553|NCT05442632|DRUG|Placebo|The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
40746554|NCT03367585|DIETARY_SUPPLEMENT|Physical exercise + Vitamin D3|Strength exercise + Supplementation of vitamin D3 50,000 IU / week
40746555|NCT03367585|OTHER|Physical exercise|Strength exercise
40746556|NCT03112551|DRUG|Adminstration of magnesium Sulphate for treatment of eclampsia|A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).
40746557|NCT04717583|PROCEDURE|Intense pulsed light (IPL) treatment|"After randomization, one side of the face will be treated with IPL using the M22™ Universal IPL device, once every 4 weeks for 3 consecutive times.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
40746558|NCT06501937|OTHER|Influencer marketing|Participants watched online survey-imbedded promotional videos featuring influencers
40746559|NCT02324595|PROCEDURE|Laparoscopic interval debulking surgery|"Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm flexible tip videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered"
40746560|NCT02756442|OTHER|Respiratory disorder assessment during sleep|
40746561|NCT03059342|PROCEDURE|single event multilevel surgery|
40746562|NCT03367702|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
40746563|NCT03367702|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
40746564|NCT00408915|DRUG|Continuous Subcutaneous Lisuride Infusion|
40746565|NCT03243890|DIETARY_SUPPLEMENT|Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).|Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
40746566|NCT03243890|DIETARY_SUPPLEMENT|Placebo|Half of the patients are randomized to placebo treatment (no active treatment).
40746567|NCT03833258|BEHAVIORAL|Rehabilitation with no precautions|Patients will recover from total hip replacement surgery being guided by pain only and not by the precautions imposed upon them by clinicians.
40746568|NCT02555098|DEVICE|Sapphire contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
40746569|NCT02555098|DEVICE|senofilcon A contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
40746570|NCT05565547|DEVICE|META|The META device is used for a comprehensive ophthalmic examination.
40746571|NCT05565547|DEVICE|Commercial devices|Commercial devices (including near and far eye charts, refractometer, optical biometry, slit lamp microscopy, fundus camera and OCT) are used for a comprehensive ophthalmic examination.
40746572|NCT05872399|OTHER|Attitudes Towards Psychiatry - 30|The participants will answer their beliefs in 30 statements about psychiatry and mental health.
40746573|NCT01851369|DRUG|TRC102|Methoxyamine hydrochloride (TRC102) has been shown to potentiate the activity of temozolomide by preventing base excision repair (BER) and allowing cleavage of TRC102 bound deoxyribonucleic acid (DNA), which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with Temozolomide (TMZ) and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
40746574|NCT01851369|DIAGNOSTIC_TEST|CT scan|CT scans will be performed at baseline, and repeat scans will be performed every 2 cycles (every 3 cycles for participants on study more than one year).
40746575|NCT01851369|OTHER|Lomotil|If diarrhea develops and does not have an identifiable cause other than study drug administration, anti-diarrheal's such as Lomotil (diphenoxylate hydrochloride (HCl) 2.5 mg + atropine sulfate 0.025 mg/tablet) dosed according to package insert or loperamide 4 mg by mouth (po) after the first unformed stool with 2 mg po every 2 hours as long as unformed stools continue (4 mg every 4 hours while asleep). No more than 16 mg of loperamide should be taken in during a 24-hour period.
40746576|NCT01851369|OTHER|Prochlorperazine|If a participant develops nausea/vomiting, an anti-emetic such as prochlorperazine may be given.
40746577|NCT01851369|OTHER|Metoclopramide|If a participant develops nausea/vomiting, an anti-emetic such as metoclopramide may be given.
40746578|NCT01851369|OTHER|5-HT3 antagonist|If a participant develops nausea/vomiting, an anti-emetic such as 5-HT3 antagonist may be given.
40746579|NCT01851369|OTHER|Aprepitant|If a participant develops nausea/vomiting, an anti-emetic such as aprepitant may be given.
40746580|NCT01851369|PROCEDURE|Biopsy|Tumor biopsies will be optional during the escalation phase.
40746581|NCT04330898|DEVICE|Biotronik peacemakers, implantable cardioverter-defibrillators and cardiac resynchronizers|Any of these Biotronik cardiac stimulation devices with the Home Monitoring function activated for the remote control of patients
40746582|NCT04197960|PROCEDURE|Microwave ablation|Use thermal energy to destroy tumor
40746583|NCT04197960|PROCEDURE|Surgical resection|Resect tumors
40746584|NCT03251599|DRUG|Glyceryl trinitrate 0.2|These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
40746585|NCT03251599|DRUG|Glyceryl trinitrate 0.5|These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
41095375|NCT06121570|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
40746586|NCT04764539|BEHAVIORAL|Video Assisted Speech Therapy (VAST)|Six children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the VR-integrated and the tablet-based VAST application. Three subjects received a 3D VR-integrated, bone conduction VAST prototype, while the remaining group of three received a tablet with a 2D version of the software. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).
40746587|NCT00601107|DRUG|Doxercalciferol|
40746588|NCT00601107|DRUG|Placebo|
40746589|NCT00550004|DRUG|RP101|190 mg oral tablet
40746590|NCT00550004|DRUG|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
40746591|NCT03854032|BIOLOGICAL|Nivolumab|Given IV
40746592|NCT03854032|BIOLOGICAL|IDO1 Inhibitor BMS-986205|Given PO
40746593|NCT03854032|PROCEDURE|Therapeutic Conventional Surgery|Undergo Surgery
40746594|NCT03854032|OTHER|Questionnaire Administration|Ancillary studies
40746595|NCT06302361|PROCEDURE|Lymphovenous anastomosis (LVA)|Surgical procedure with supermicrosurgical anastomosis between distal lymph vessel and proximal venule.
40746596|NCT02491450|DRUG|Heterosofir|1 tablet contains 400 mg sofosbuvir
40746597|NCT02491450|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
40746598|NCT04775134|DIAGNOSTIC_TEST|Lung biopsy|Biopsy of residuary material from a medically indicated pulmonary resection
40746599|NCT04883853|PROCEDURE|Mild _moderate Ptosis tucking|A modified levator muscle tucking procedure.The level of sutures was determined according to the levator muscle function and the desired eyelid height. The middle (main) suture was taken first at the level of the medial part of the pupil and was tightened to keep the lid height at the superior limbus and the other two sutures (medial and lateral) were then adjusted. A spindle-shaped, horizontal part of the levator aponeurosis (2.5-3 mm wide and 0.5 mm deep) was excised at the site of insertion into the tarsus before tightening the central suture to induce strong fibrosis and adhesion between the tucked levator aponeurosis and the tarsus
40746600|NCT02004171|OTHER|electronic cigarette|V2 Cigs with 24 mg nicotine cartridges
40746601|NCT02004171|DRUG|nicotine inhaler|nicotine inhaler with 10 mg nicotine cartridges
40746602|NCT01783938|BIOLOGICAL|Nivolumab|
40746603|NCT01783938|BIOLOGICAL|Ipilimumab|
40746604|NCT03250195|DIAGNOSTIC_TEST|PET/MRI|PET/MRI scan
40746605|NCT01995435|DEVICE|Telemedicine refraction|
40746606|NCT01995435|DEVICE|Traditional refraction|
40746607|NCT01129895|BEHAVIORAL|Health promotion|In each intervention clinic 5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
40746608|NCT02565472|OTHER|White grape juice|
40746609|NCT02565472|OTHER|Apple juice|
40746610|NCT01609192|DRUG|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
41095376|NCT05318014|DIETARY_SUPPLEMENT|Intervention group|dietitian regular nutrition education which was following a low protein diet and supply one serving per day of 6 % low protein formula (200mL,2kcal/ml) for 24 weeks
40746611|NCT04868903|DIETARY_SUPPLEMENT|Vitamin D3|Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.
40746612|NCT03608085|BEHAVIORAL|Pharmacist Heart failure MTM training|"The MTM training for pharmacists will consist of:~1. Online material for home self-study (10 contact hours);~2. Didactic coursework to obtain a national American Pharmaceutical Association (APhA) MTM certification (8 contact hours); and HF pharmacotherapy (4 contact hours);~3. 1 60-minute sessions of point of care training in the community pharmacy practice lab setting by URI faculty;~4. Monthly coaching conference calls/webinars with URI and Brown Faculty;"
40746613|NCT03608085|BEHAVIORAL|Patient Heart failure MTM intervention|"The baseline visit will take place \>= 7 but \<= 30 days post discharge from the HF hospitalization. Follow-up visits will occur either in person at the patients local pharmacy or via telephone at 30, 60, 90 and 120 days post baseline and will consist of the following:~Preparation: Develop personal medication record (PMR). Assessment: Medication therapy reconciliation; Education: Review heart failure basics and behavioral goals Planning: Documentation of a medication related action plan and identify medication related problems Implementation: Communication of medication related action plan and changes in heart failure symptoms to the patients providers.~Follow up: Monitor and evaluate the care plan in collaboration with the patient's providers."
40746614|NCT01927289|PROCEDURE|Proximal Brachial Plexus vs Distal Forearm Block|"Proximal Brachial plexus block: 15 mls saline injected in distal forearm nerve block and 15 mls of 1.5% Mepivacaine injected to the brachial plexus via the supraclavicular approach.~Distal forearm block: 15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach"
40746615|NCT03508297|DIAGNOSTIC_TEST|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
40746616|NCT02320825|RADIATION|single-fraction SRS|
41269875|NCT06166550|BEHAVIORAL|Parent's Emotional Intelligence Network|A two-day in-person training session will be arranged for the participating parents at least one week apart. The psychologists will conduct the training session on emotional intelligence. A training of the trainer manual will be developed to train the psychologists. The training session will include a power point presentation and certain group and individual activities to practice emotional intelligence. The participants will also be given a diary and a mobile app in order to practice emotional intelligence at home.
41269876|NCT06166550|DEVICE|Diary|A diary will be developed that contain different practice materials regarding emotional intelligence. It will be a personal diary given to the participants to take to home.
41269877|NCT06166550|DEVICE|Mobile App|It will be a mobile app, developed based on the concept of emotional intelligence. It will contain different videos, audios, and texts related to emotional intelligence. It will also provide a communication platform where users can communicate through texts and upload documents.
41269878|NCT01975103|PROCEDURE|Topcon Endpoint Management|
41269879|NCT02382094|DRUG|Bicalutamide|
40746617|NCT02320825|RADIATION|high-dose hypofractionated SRS|
40746618|NCT02320825|BEHAVIORAL|Quality of Life Measures|
40746619|NCT05328544|PROCEDURE|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) with the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw with the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
41095377|NCT05318014|OTHER|Regular nutrition education|dietitian regular nutrition educataion which was following a low protein diet
41095378|NCT04994262|OTHER|Menthol Lozenge|"In the study, Oka Menthol, a herbal lozenge produced by Otacı, will be used. Its formula contains: menthol 0.26%, eucalyptol 0.065%, thymol 0.0002%, camphor 0.0002%, anise oil, thyme oil, coltsfoot, marshmallow flower, bovine tail flower extracts, glucose and sucrose.~Medical properties: Otacı Oka Menthol Pastil shows antibacterial and fungicidal properties with eucalyptol in its composition. Menthol is effective against local anesthetic, local antitussive and irritation. It also plays a mild analgesic role with camphor in its content. It has an antibacterial and antifungal effect with thymol, a phenolic antiseptic. Otaco Oka Menthol Pastilles also contain extracts of coltsfoot, cow's tail flower and marshmallow flower which are anti-irritant and expectorant."
41095379|NCT00272610|DRUG|0.4% Retinol Cream|
41095380|NCT01495637|DRUG|GM-CSF|GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
41269880|NCT04139122|DRUG|SJP-0132|SJP-0132 is administered as an eye drop
41269881|NCT04139122|DRUG|Placebo|Placebo is administered as an eye drop
41269882|NCT02469129|DRUG|[18F]FluorThanatrace|"For the Dosimetry Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.~For the Kinetic Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection."
41269883|NCT03462251|COMBINATION_PRODUCT|Ribociclib and aromatase inhibitor or fulvestrant|Combination of ribociclib and aromatase inhibitor or fulvestrant
41269884|NCT03462251|COMBINATION_PRODUCT|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab|Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab
41269885|NCT05650021|DEVICE|SpaceOAR Vue|CBCT images acquired during the first five fractions of radiotherapy
41269886|NCT02586714|OTHER|No intervention|Observation only
41269887|NCT01486420|PROCEDURE|Corticosteroid injections|Corticosteroid injections in and around A1-pulley.
40746620|NCT05328544|PROCEDURE|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) without the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw without the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
40746621|NCT00143143|DRUG|Pregabalin|
40746622|NCT01601977|DEVICE|AVAPS-AE|Novel ventilation mode (Omnilab - AVAPS AE algorithm)
40746623|NCT01601977|DEVICE|Usual care|Non-invasive ventilation with standard ventilator
40746624|NCT05345587|OTHER|THESS monitoring|Consultation with the pharmacist to look for possible medication interactions between the oral therapy and the patient's usual treatments and to inform the patient about his treatment to improve QOL and compliance. Consultation and follow-up by a nurse. Weekly notification by THESS Application of the symptoms experienced by the patient over the last 7 days
40746625|NCT05683626|DRUG|Humira|subcutaneous injection
40746626|NCT04764604|DEVICE|Acapella Choice|3 minutes of exercise consisting of blowing through the device (on setting '5') and phonating at the same time.
40746627|NCT04764604|DEVICE|Tube-in-water|3 minutes of exercise consisting of blowing through a silicone tube (10mm internal diameter) submerged in 5 cm of water whilst phonating at the same time.
40746628|NCT04971824|PROCEDURE|Physiotherapeutic intervention|The physiotherapy consists in performing visceral manipulation of the pelvic and abdomen organs as well as doing special exercises (volunteers get a handout with instructions on how to exercise). The exercises include ones from the Mojzis´s method, Dynamic neuromuscular stabilisation, yoga or other therapeutic methods used by physiotherapists.
40746629|NCT01346553|DEVICE|ESVV device|wearing the ESVV device for 6 hours
40746630|NCT00222261|DRUG|aspirin|Aspirin 160 mg once daily for two years
40746631|NCT00222261|DRUG|clopidogrel|clopidogrel 75 mg once daily for two years
40746632|NCT01435915|DRUG|Ropinirole|"Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.~Single and repeat dose treatment periods will be separated by 7 days of washout period."
40746633|NCT05228964|DEVICE|Focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min.
40746634|NCT06523946|BEHAVIORAL|Diabetes Prevention Program (DPP) (shortened)|The investigators will adapt the protocol of the 'Ohana project. The 'Ohana protocol was developed based on CDC's Diabetes Prevention Program (DPP) curriculum and designed to fit PcI's cultural background. It includes a 8-lesson curriculum delivered in 8 weeks (shortened from the original 16-lesson, 24-week core curriculum of DPP while retaining all original foci and behavior change strategies). Specifically, the first four lessons, delivered every week, focus on getting the participants started on increasing PA and improving diet (e.g., introduction; getting started on PA and diet; utilizing goal setting; making the process fun). The second four classes will be taught every other week and will focus on how to handle various challenges involved in maintaining healthy lifestyle behaviors. The investigators will deliver the curriculum in group settings of 15 people in a separate room in the National Tongan American Society.
40746635|NCT03289000|DEVICE|iTotal Posterior Stabilized (PS) Knee Replacement System|Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
40746636|NCT00113126|DRUG|Treatment interruption|
40746637|NCT02233153|OTHER|Elder-Friendly Surgical Unit|
40746638|NCT04573530|BEHAVIORAL|We Walk Plus Intervention|The frequency and content of weekly personalized SMS are based on each participant's preference. Prior to implementation of intervention, the investigators will conduct focus groups to learn participants' social network activities and preferences, strategies that can be used to encourage engagement via a private Fitbit community network.
40746639|NCT01892852|PROCEDURE|Acupuncture|Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
40746640|NCT00795405|BEHAVIORAL|Exposure to sporting events|Exposure to sporting events
40746641|NCT00795405|BEHAVIORAL|No exposure to sporting events|No exposure to sporting events
40746642|NCT00429299|DRUG|lapatinib|Arm B 1250mg/d PO Arm C 750mg/d PO
40746643|NCT00429299|BIOLOGICAL|trastuzumab|First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
41269888|NCT01486420|PROCEDURE|Open surgery|Open A1-pulley release
40746644|NCT00429299|DRUG|paclitaxel|80mg/sqm 1 hour infusion for 12 weeks
40746645|NCT00429299|DRUG|fluorouracil|600mg/sqm iv day 1 q21 days for four coursess
40746646|NCT00429299|DRUG|epidoxorubicin|75mg/sqm iv day 1 q21 days for four courses
40746647|NCT00429299|DRUG|cyclophosphamide|600mg/sqm day 1 q21 days for four courses
40746648|NCT06494813|DIAGNOSTIC_TEST|conventional pcr|conventional pcr to study matrix metalloproteinase -9 gene polymorphismin rheumatoid arthritis
40746649|NCT05014828|DRUG|lenvatinib|Capsules administered orally
40746650|NCT05014828|DRUG|Tislelizumab|intravenous (iv) infusion
40746651|NCT04986813|DRUG|Tranexamic acid injection|1 g of TXA in 100 ml of normal saline
40746652|NCT04986813|OTHER|Normal Saline|100 ml
40746653|NCT01356888|DEVICE|Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)|Stenting
40746654|NCT01356888|DEVICE|Percutaneous Coronary Intervention (Orsiro DES)|stenting
41269889|NCT04807959|OTHER|20Lighter anti-obesity program|A customized expert supervised 3-phase program including non-invasive proprietary nutritional, behavioral, and physiological components.
41269890|NCT00302393|DRUG|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
40746655|NCT04914000|BEHAVIORAL|Self-help Materials|Self-help booklet targeted by cancer type to increase smoking cessation motivation
40746656|NCT02301091|PROCEDURE|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
40746657|NCT02301091|PROCEDURE|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
40746658|NCT02301091|DRUG|pirarubicin,mitomycin and lobaplatin|They were cytotoxic drugs used in the TACE procedure.
40746659|NCT00263536|PROCEDURE|Interpersonal Psychotherapy|
40746660|NCT01293877|PROCEDURE|Laparoscopy surgery for morbid obesity|The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/
40746661|NCT06248203|BEHAVIORAL|Tealeaf-Mansik Swasta (Tealeaf) as adapted for Adolescents|"The investigators will test Tealeaf (Teachers Leading the Frontlines - Mansik Swastha \[Mental Health in Nepali\]) as adapted for adolescents. Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Created in Darjeeling, Tealeaf centers on training and supervising teachers to deliver education as mental health therapy (Ed-MH) to children (age 5-12). Ed-MH is the investigators' novel, task-shifting, therapy modality that minimizes the time teachers need to deliver care by fitting it into their work. In Ed-MH, teachers use evidence-based therapeutic techniques adapted for use in their existing interactions with students in need (e.g., while teaching) and streamlined for care for any diagnosis (transdiagnostic). Tealeaf-A's adaptation (inclusive of Ed-MH) is supported by a Doris Duke Charitable Foundation (DDCF), Fund to Retain Clinical Scientists (FRCS), Caregivers at Carolina COVID award."
40746662|NCT06248203|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
40746663|NCT01444170|DIETARY_SUPPLEMENT|dicreatinol sulfate|nutritional supplement
40746664|NCT01444170|DRUG|placebo sugar pill|
40746665|NCT01951027|DRUG|GX-G3 12.5 μg/kg or Placebo|Single SC injection
40746666|NCT01951027|DRUG|GX-G3 25 μg/kg or Placebo|Single SC injection
40746667|NCT01951027|DRUG|GX-G3 50 μg/kg or Placebo|Single SC injection
40746668|NCT01951027|DRUG|GX-G3 100 μg/kg or Placebo|Single SC injection
40746669|NCT06237127|DIETARY_SUPPLEMENT|Goji berry|Participants will be instructed to consume 28 grams of goji berries 5 days a week for 6 months
40746670|NCT06237127|DIETARY_SUPPLEMENT|Fiber|Participants will be instructed to consume the fiber supplements 5 days a week for 6 months
40746671|NCT04726488|PROCEDURE|Periareolar Approach in Minimally Invasive Cardiac Surgery (PAMI Technique)|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
40746672|NCT04726488|PROCEDURE|inframammary approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
40746673|NCT04379115|DEVICE|Active Comparator: Active tDCS + Active TUS|"Device: Active comparator device: Active transcranial Direct Current Stimulation (tDCS). Subjects will receive 20 minutes of active tDCS. During each Active stimulation session, stimulation will be applied for the full 20 minutes.~Device: Active comparator device: Active Transcranial Ultrasound (TUS). Subjects will receive 20 minutes of active Transcranial Ultrasound (TUS). During active stimulation the (TUS) will be active for the full 20 minutes."
40746674|NCT04379115|DEVICE|Sham Comparator: Sham tDCS + Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of sham tDCS. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of sham TUS. During sham stimulation the ultrasound will not be active for the full 20 minutes."
40746675|NCT05320588|DRUG|BIO-106|BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
40746676|NCT05320588|DRUG|Pembrolizumab|Programmed death receptor-1 (PD 1)-blocking antibody
40746677|NCT05096221|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec.
40746678|NCT05096221|GENETIC|placebo|Single IV infusion of matching placebo.
40746679|NCT00899457|GENETIC|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
40746680|NCT00899457|OTHER|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
40746681|NCT00899457|OTHER|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
40746682|NCT00899457|PROCEDURE|bronchoscopy|Collection of breath condensate.
40746683|NCT03611127|OTHER|pulmonary rehabilitation|pulmonary rehabilitation standardized program
40746684|NCT05047120|BEHAVIORAL|Hypnosis enhanced cognitive behavioral therapy|This therapy entails subjects being induced into a state of relaxation and the receiving cognitive behavioral therapy for pain associated with a new spinal cord injury.
40746685|NCT05047120|BEHAVIORAL|Pain Education|This therapy entails subjects learning about the causes, mechanisms, and ways to reduce pain associated with a new spinal cord injury.
40746686|NCT03128060|OTHER|Home-based palliative care|The HBPC model consists of home visits by an interdisciplinary primary palliative care team (a physician, nurse, social worker, and chaplain). This team provides pain and symptom management, psychosocial support, advance care planning, spiritual counseling, grief counseling, and other services to meet patient and caregiver needs. Within the first week of a patient's enrollment, team members separately visit the patient at home to assess his/her needs as well as the needs of his/her caregiver. Following the patient's initial assessment, subsequent home visits are based on the patient's and caregiver's needs. At a minimum, a core team member visits the patient at home once per week. Additionally, a 24/7 helpline provides access to nurse counseling and after-hours home visits as needed. As a patient's health declines and he/she becomes eligible for hospice care, HBPC clinicians will refer the patient to hospice.
40746687|NCT03128060|OTHER|Enhanced usual care|"Usual primary care consists of: 1) appointment-based access to primary care providers (PCPs) as requested by the patient; 2) case management services; and 3) provider support through palliative care consultation. These PCPs provide family/internal medicine services as well as access to specialist care. They also offer disease case management and pain and symptom management.~These usual care services are enhanced through training in palliative care provided to PCPs. The training addresses core elements of palliative care, specifically these 6 topics: a palliative care overview; strategies for improving patient-provider communications; instruction in ACP; instruction in managing patients' pain and symptoms; care coordination; and preventing medical crises."
41269891|NCT00302393|DRUG|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
40746688|NCT02595554|RADIATION|Concurrent chemoirradiation|External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy
40746689|NCT02595554|DRUG|Paclitaxel|New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
40746690|NCT02595554|PROCEDURE|Radical Surgery|Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
40746691|NCT02595554|DRUG|Cisplatin|New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2
40746692|NCT03006575|RADIATION|split-course radiotherapy|split-course chest radiation at 40-51 Gy/10-17f and 15-24 Gy/5-8f
40746693|NCT03006575|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
40746694|NCT01442636|DEVICE|stent|Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
40746695|NCT02846454|OTHER|inulin|Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
40746696|NCT02846454|OTHER|arabinoxylan|Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
40746697|NCT06177353|OTHER|Sampling|Blood sampling Skin biopsy Collection of soiled bandages
40746698|NCT05049694|DEVICE|zirconia crowns|esthetic crowns for capping permanent molars with caries
40746699|NCT05049694|DEVICE|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
40746700|NCT00552903|BEHAVIORAL|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
40746701|NCT00693264|DIETARY_SUPPLEMENT|Hoodia Gordonii|750 mg capsule will be taken one time
40746702|NCT00693264|DIETARY_SUPPLEMENT|Placebo|Placebo capsule to be taken one time
40746703|NCT01272895|DEVICE|Coronary Intervention (GENOUS stent)|GENOUS stent (Coronary Intervention)
40746704|NCT01160900|PROCEDURE|Coronary angioplasty all lesions|treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
40746705|NCT02523638|DRUG|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
40746706|NCT03952741|BEHAVIORAL|Physical Therapy|
40746707|NCT04069520|OTHER|aNMT Biofeedback|"aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention. The aNMT biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks."
40746708|NCT04069520|OTHER|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases. The sham biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks.
40746709|NCT01732692|DRUG|MOVIPREP|MOVIPREP solution
40746710|NCT04663217|OTHER|Exercise|After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
40746711|NCT04494815|DRUG|SR419|Each participant will receive 1 dose of 20 mg SR419 oral suspension.
40746712|NCT04494815|DRUG|active control|Each participant will receive 1 dose of 300 mg active control capsule.
40746713|NCT04494815|DRUG|SR419 placebo|Each participant will receive 2 doses of SR419 placebo oral suspension.
40746714|NCT04494815|DRUG|active control placebo|Each participant will receive 2 doses of active control placebo capsule.
40746715|NCT01127477|DRUG|1: Hydroxyethyl starch 130/0.4, 6 %|1: Up to 50 ml 6 % hydroxyethyl starch 130/0.4/kg body weight administered intravenously from start of surgery (skin incision) until two hours after end of surgery.
40746716|NCT06274021|DEVICE|Transcutaneous spinal stimulation at 100 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 100 Hz, performed at a sub-motor threshold for 30 minutes.
40922346|NCT01600625|DRUG|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
40746717|NCT06274021|DEVICE|Transcutaneous spinal stimulation at 50 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.
40746718|NCT06274021|COMBINATION_PRODUCT|Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a single dose of baclofen, a centrally-acting muscle relaxant belonging to the class of gamma-aminobutyric acid (GABA) analogs. Its primary mechanism involves acting on the GABA receptors in the brain and spinal cord to decrease spasticity. Participants will receive baclofen orally at a single dose of 10 mg."
40746719|NCT06274021|COMBINATION_PRODUCT|Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a medication called tizanidine, which is an alpha-2 adrenergic agonist. This medication works by inhibiting presynaptic motor neurons, resulting in a reduction of muscle spasticity. It is commonly used to manage spasticity caused by neurological disorders. Each participant will be given a single oral dose of 4 mg of tizanidine as part of this trial."
40746720|NCT06274021|DEVICE|Sham transcutaneous spinal stimulation|Sham Transcutaneous spinal stimulation (TSS) involves placing two surface electrodes midline on the lower back (T11-12 spinal processes). The stimulation frequency during the intervention is 50 Hz, performed for 30 minutes.
40746721|NCT01408498|DRUG|Testosterone|Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
40746722|NCT05756907|BIOLOGICAL|SON-1010|SON-1010 +/- Atezolizumab
40746723|NCT00038415|BIOLOGICAL|CLL vaccine using DNA plasmid vector|
40746724|NCT03853837|DIAGNOSTIC_TEST|rest-exercise echocardiography|an echocardiogram performed during rest and exercise
40746725|NCT06326918|DIAGNOSTIC_TEST|Duodenal mucosal brushing|Duodenal mucosal brushing will be performed at duodenal bulb.
40746726|NCT06326918|DIAGNOSTIC_TEST|Duodenal mucosal biopsy|Duodenal mucosal biopsy will be performed at duodenal bulb.
40746727|NCT03419871|OTHER|Monitoring Sleep|An accelerometer will be placed on the wrist or ankle of the child while the child sleeps in their home. Caregivers will be instructed to keep the accelerometer on their toddler's ankle to measure sleep duration, latency and sleep efficiency. Seven nights of data will be obtained because actigraphy is most reliably measured in young children over this time frame.
40746728|NCT03419871|OTHER|stress biomarkers|"Salivary and hair cortisol measurements were used to obtain a change in baseline from 12 to 24 months. Data on the timing of the saliva collection will be collected using a Medical Electronic Monitoring System (MEMScapTM) - a digital memory cap that records the timing and frequency of opening.~Cortisol will be measure in the morning and bedtime samples. A small amount of hair (30mg) will be cut from the posterior vertex of the child's head. Due to the expected variability in hair length of toddlers, documentation of hair length will be completed. Each centimeter represents 1 month history of stress and ideally 3 cm of hair length will be collected to provide a three month history of stress."
40746729|NCT03298100|OTHER|Scoring model|Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
40746730|NCT03510702|DIAGNOSTIC_TEST|Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.|"Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.~Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers."
40746731|NCT03851991|DRUG|Arbidol|oral
40746732|NCT03851991|DRUG|Placebos|controle
40746733|NCT05120232|BEHAVIORAL|Unified Protocol|A transdiagnostic, cognitive behavioral therapy.
40746734|NCT05120232|BEHAVIORAL|Modified Unified Protocol (UP+)|A transdiagnostic, cognitive behavioral therapy.
40746735|NCT03821532|OTHER|Constipation Action Plan|Action plan, adapted from Autism Speaks Network, demonstrating Red, Yellow, and Green levels of symptoms with corresponding steps for treatment or action by parent/guardian, tailored by care provider to the child's condition.
40746736|NCT03237663|BIOLOGICAL|The oral O1 / O139 cholera vaccine (enteric capsules)|
40746737|NCT05666856|BEHAVIORAL|Community Reinforcement And Family Training|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
40746738|NCT05666856|BEHAVIORAL|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
40922347|NCT00653432|DEVICE|Monovisc®|Intra-articular injection
40746739|NCT02423720|BEHAVIORAL|Audio-Based Mindfulness|Audio-based mindfulness tracks (MP3 format).
40746740|NCT00732693|DRUG|Ethinylestradiol / Norethisterone|"Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days"
40746741|NCT00732693|DRUG|Estradiol / Progesterone|Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
41095381|NCT02949648|DEVICE|Electronic cigarette|Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
40746742|NCT03453970|BEHAVIORAL|Therapeutic Education Program|The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
40746743|NCT00321412|DRUG|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
40746744|NCT06203795|OTHER|Anticoagulation dosing|Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday
40746745|NCT06203795|OTHER|Blood sampling|Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.
40746746|NCT06203795|OTHER|Duration of the dialysis session|Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday
40746747|NCT06203795|DEVICE|Choice of the hemodialyzer|Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.
40746748|NCT02384343|DRUG|Dexmedetomidine|An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
40746749|NCT02384343|DRUG|Normal saline|An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
40746750|NCT02162433|DRUG|Normal Saline|to arms 2,4. Serves as the placebo.
40746751|NCT02162433|DRUG|Dexmedetomidine|to arms 1,3
40746752|NCT01426646|DRUG|S-1|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
40746753|NCT01426646|DRUG|S-1 plus cisplatin|"S-1 plus cisplatin every 3 weeks, a total of eight cycles~* S-1: 40mg/m2 orally twice daily (days 1-14)~* Cisplatin: 60mg/m2 IV on day 1"
40746754|NCT05351034|DEVICE|Anorectal manometry|Anorectal manometry in diagnosis of Functional anorectal disorders
40746755|NCT06122064|OTHER|Best Practice|Receive standard of care
40746756|NCT06122064|OTHER|Communication Intervention|Use shared decision-making conversation tool
40746757|NCT06122064|OTHER|Electronic Health Record Review|Ancillary studies
40746758|NCT06122064|OTHER|Survey Administration|Ancillary studies
40746759|NCT06122064|OTHER|Video Recording|Ancillary studies
40746760|NCT05309889|OTHER|no intervention|no intervention
40746761|NCT03362593|DRUG|MEDI7219|Experimental Drug
40746762|NCT03362593|DRUG|Placebo|Placebo
40746763|NCT03362593|DRUG|Formulation without Active Drug|Formulation without Active Drug
41095382|NCT05173571|COMBINATION_PRODUCT|Comprehensive patient support program (educational, physiotherapy, nutritional, emotional)|Identification of patient needs and non-pharmacological holistic approach, including education, emotion and nutrition (nurse) and optimization of physical activity (respiratory physiotherapist)
41095383|NCT01720043|DRUG|Velcade|Single dose of Velcade (1.0-1.3 mg/m2 dose)
41095384|NCT03601143|OTHER|Blood samples prior to a new line of AR-targeted therapy|Blood will be drawn at baseline prior to a new line of AR-targeted therapy.
41095385|NCT01498874|DRUG|Placebo|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
40746764|NCT05196139|OTHER|retrospective study|vitrectomy performed in case of submacular bleeding
40746765|NCT04551924|DRUG|HR18034|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
40746766|NCT04551924|DRUG|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
40746767|NCT06252337|OTHER|bioceramic sealer group|epoxy resin based + carrier based technique group. The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
40746768|NCT02455180|DRUG|Ascorbic Acid|Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
40746769|NCT03745781|DRUG|Placebos|placebo pills
40746770|NCT04464083|DIAGNOSTIC_TEST|IOP Measurment|To determine IOP readings before and after accelerated corneal collagen crosslinking (CXL)
40746771|NCT05890586|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
40922348|NCT00653432|OTHER|Saline|0.9% Sterile Saline
41095386|NCT01498874|DRUG|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
41095387|NCT01498874|DRUG|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
41095388|NCT03281564|OTHER|Quality of life after Essure® removal|Questionnaire to assess the quality of life 1, 3, 6 and 12 months after laparoscopic removal of Essure® device
40746772|NCT05890586|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
40746773|NCT05564923|DRUG|there is no intervention|there is no intervention
40746774|NCT04227717|DIAGNOSTIC_TEST|MRI with custom MRI spine coil|Participants will undergo MRI with custom MRI spine coil
40746775|NCT02580344|DRUG|Ibuprofen|The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
40746776|NCT02669108|DEVICE|PET/ MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
40746777|NCT00746720|DRUG|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
40746778|NCT00746720|DRUG|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
40746779|NCT00746720|DRUG|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
40746780|NCT00746720|DRUG|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
40746781|NCT05775705|DRUG|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg/m2 day 1; etoposide 75 mg/m2 day1; methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14; PEG-aspargase 6000iu/m2 day2, day4; PD-1 antibody injection 200mg day 5.
40746782|NCT01609140|DRUG|MPSK3169A|Dose regimen A, repeating subcutaneous injections every 4 weeks
40746783|NCT01609140|DRUG|MPSK3169A|Dose regimen E, repeating subcutaneous injections every 4 weeks
40746784|NCT01609140|DRUG|MPSK3169A|Dose regimen D, repeating subcutaneous injections every 4 weeks
40746785|NCT01609140|DRUG|MPSK3169A|Dose regimen C, repeating subcutaneous injections every 4 weeks
40746786|NCT01609140|DRUG|MPSK3169A|Dose regimen B, repeating subcutaneous injections every 4 weeks
40746787|NCT01609140|DRUG|Placebo|Repeating subcutaneous injections of placebo every 4 weeks
40746788|NCT01945242|DRUG|Alogliptin|Alogliptin tablets
40746789|NCT00997126|DRUG|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
40746790|NCT00997126|DRUG|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
40746791|NCT02201082|PROCEDURE|Airway clearance technique|
40746792|NCT02201082|DRUG|Amikacin nebulization|
40746793|NCT01029483|OTHER|Low carbohydrate diet|Ad libitum low carbohydrate diet (\<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
40746794|NCT01029483|OTHER|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
40746795|NCT01029483|OTHER|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at \~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
40746796|NCT00574951|DRUG|motesanib diphosphate|
40746797|NCT02933476|DEVICE|Vibrotactile Stimulation|The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
40746798|NCT00559715|DRUG|bevacizumab|1.25 mg intravitreally monthly/on demand
41095389|NCT05202379|DRUG|CC-42344|CC-42344 capsules
40746799|NCT00559715|DRUG|ranibizumab|0.5 mg intravitreally monthly/on demand
40746800|NCT04667429|OTHER|Food|HEC83518 40mg will be taken orally fasted or with food
40746801|NCT04667429|DRUG|HEC83518|HEC83518 will be taken orally before sleep for 15 days
41095390|NCT05202379|DRUG|Placebo|Placebo capsules
41095391|NCT04424485|PROCEDURE|Total thyroidectomy (TT)|Standard TT procedure for thyroid carcinoma, for both groups
41095392|NCT04424485|PROCEDURE|Central lymph node dissection (CLND)|Standard CLND for thyroid carcinoma, for both groups
40746802|NCT04667429|DRUG|placebo|The placebo will be administered before sleep for 15 days.
40746803|NCT04408079|DRUG|TQB3558|TQB3558 is a kinase inhibitor of the TRK protein family.
40746804|NCT00651807|DRUG|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
40746805|NCT00651807|DRUG|Placebo|Every day one tablet up to 8 weeks
40746806|NCT03590327|DEVICE|Transcranial Magnetic Stimulation|rTMS
40746807|NCT02000037|DEVICE|IR Reflexotherapy|"18 IR reflexotherapy sessions :~* Once a week for 12 weeks at the beginning of the study~* Once a week for 3 weeks, 9 months after the beginning of the study~* Once a week for 3 weeks, 15 months after the beginning of the study"
40746808|NCT02000037|BEHAVIORAL|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
40746809|NCT03122366|DIAGNOSTIC_TEST|Detection of single nucleotide polymorphisms (SNP)|Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood
40746810|NCT03050931|DEVICE|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
40746811|NCT05520775|DRUG|Semaglutide|Semaglutide (subcutaneous)
40746812|NCT05520775|DRUG|Sham/placebo|Sham subcutaneous injection
40746813|NCT05890820|OTHER|Preoperative nutritional assessment|Preoperative nutritional assessment and postoperative pulmonary complications
40922349|NCT02206178|DRUG|N-acetylcysteine combination with acetaminophen|
40922350|NCT02206178|DRUG|Placebo|
40746814|NCT05849753|DEVICE|Advanced artificial pancreas closed-loop technology|Study is an observational capture of data in patients that qualify, before and after the use of any FDA-approved closed-loop system of Subject's/Family's choosing that uses a CGM that does not require fingerprick calibrations. Devices prescribed available through their insurance (including Medicaid).
40746815|NCT05655988|DIAGNOSTIC_TEST|inguinal ultrasonography|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
40746816|NCT03349047|BEHAVIORAL|Behavioral intervention group|Patients will hold the peanut or tree nut in a cup and will be asked to touch the nut with their finger.
40746817|NCT03349047|BEHAVIORAL|Education|The group will be educated about what can occur with contact with or being in proximity of peanuts or tree nuts.
40746818|NCT01258855|BIOLOGICAL|Aldesleukin|Given IV
40746819|NCT01258855|OTHER|Laboratory Biomarker Analysis|Correlative studies
40746820|NCT01258855|BIOLOGICAL|Ziv-Aflibercept|Given IV
40746821|NCT06294366|DEVICE|Bipolar Bowa device|Bipolar Bowa device used in prostatic resection and enucleation
40746822|NCT02422901|DRUG|vitamin C|According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
40746823|NCT01484002|DEVICE|Total hip arthroplasty|Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
40746824|NCT06193967|BEHAVIORAL|Caregiver Praise|Caregivers will provide praise for child's engagement in dietary self-monitoring behaviors as a form of positive reinforcement
40746825|NCT06193967|BEHAVIORAL|Gamification|DSM logs will include gamification (points, levels, virtual pets) as positive reinforcement for child's engagement in dietary self-monitoring behaviors
40746826|NCT00778180|DRUG|furosemide 80 mg tablets|
40746827|NCT05340595|OTHER|Orthodontic retainer bonding|Self-etch primer (Transbond XT Primer; 3M Unitek, California) was administered to the teeth's lingual surfaces.
40746828|NCT05474820|OTHER|Samples collection and ELISA analyses|"The serum and unstimulated saliva samples were taken from all patients between 8:00 and 10:00 in the morning. Saliva samples were centrifuged at 10,000 rpm (10 min) whereas venous blood samples were centrifuged at 4000 rpm for 10 min.~For the analysis of irisin and IL-6 specific ELISA Kits (Elabscience, Houston, Texas, USA) were used to determine the molecules in both serum and saliva samples in accordance with the manufacturer's instructions. All samples were run in duplicate, and values have been averaged."
40746829|NCT05474820|DIAGNOSTIC_TEST|Evaluating periodontal paramètres|The clinical periodontal parameters (plaque index (PI), probing pocket depth (PD), gingival recession (GR), clinical attachment loss (CAL), and bleeding on probing (BOP)) were recorded on periodontal charts in each patient
41269892|NCT05359393|COMBINATION_PRODUCT|a combination therapy including tislelizumab|"Patients will receive tislelizumab in combination with neoadjuvant radiotherapy and chemotherapy, and will be evaluated 2-3 weeks after completion of the treatment. Those patients who achieve complete clinical regression of the lesion can choose observation, but for those without CCR, surgical resection (TME of the primary lesion, surgical resection of metastases or other destructive local treatment) will be applied. Patients will continue to receive tislelizumab for one year after surgery or during observation.~For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx.~Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w x6, i.v). Chemotherapy adopts CAPEOX plan, including Capecitabine(1000mg/m2 bid, d1-14, p.o) and oxaliplatin(130mg/m2, d1, i.v)."
40746830|NCT02428647|DIETARY_SUPPLEMENT|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
40746831|NCT02428647|DIETARY_SUPPLEMENT|preventive zinc supplement|7 mg zinc daily as dispersible tablet
40746832|NCT02428647|DIETARY_SUPPLEMENT|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
41269893|NCT05136833|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
41269894|NCT05136833|BIOLOGICAL|Placebo|Normal saline will be used as a placebo.
41269895|NCT03813030|PROCEDURE|Intravenous infusion of lidocaine|Lidocaine is intravenously administered in clearance visit and blood samples are taken to calculate individual clearance of each participant.
40746833|NCT02428647|DIETARY_SUPPLEMENT|preventive placebo supplement|dispersible daily placebo tablet
40746834|NCT02428647|DIETARY_SUPPLEMENT|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
40746835|NCT02428647|DIETARY_SUPPLEMENT|placebo powder|placebo powder
40746836|NCT05404659|OTHER|Oscillatory Mobilization|conventional physical therapy treatment, postural correction and maitland's oscillatory mobilizitions.
40746837|NCT05404659|OTHER|Mckenzie Retraction Exercises|conventional physical therapy treatment, postural correction and Mckenzie retraction exercises.
40746838|NCT03006120|PROCEDURE|Retroperitoneal hematoma due to cardiac catheterization|
40746839|NCT02512159|PROCEDURE|drenovac handcrafted|under local anesthesia, sepsis and antisepsis, place sterile field, prepared area go out all devitalized or necrotic tissue using liquid soap surgical and irrigation back saline 0.9%. We introduce a device to distribute the negative pressure or vacuum on ulcer; conducted margins make recommendations 5-12 mm over the edge of the wound, applying negative pressure or vacuum retracted sponges, likewise for the spare fewer gauze was placed Sterile adhesive film covering the defect to seal the system cover adequately the probe output nelaton not to submit drain the system. Connect the probe to the sterile nelaton this hose and a suction system with pressure gauge, pressure -80-125 mmHg. Change it every 72 hours.
41095393|NCT04424485|DIAGNOSTIC_TEST|Sentinel lymph node (SLN) bopsy|Intrathyroidal injection of ICG for SL biopsy, for only experimental group
41095394|NCT04424485|DIAGNOSTIC_TEST|Identification of parathyroid glands (PGs)|Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
40746840|NCT02512159|PROCEDURE|Healing|"Were handled as follows:~1. Under local anesthesia, prior asepsis and antisepsis of the skin ulcer with iodinepovidone sterile fields are placed, we proceeded to debridement of all necrotic tissue or devitalized then a cure with liquid soap surgery was performed and was irrigated with 1000 cc of solution physiological 0.9%, and finally the ulcer was covered with sterile gauze.~2. healing of skin ulcers were performed every 24 hours.~3. the evolution of skin ulcers was evaluated every 3 days, requesting a differential valuing of clinical and biochemical form the aforementioned variables."
40746841|NCT00465868|PROCEDURE|PCI (percutaneous coronary intervention)|Outcome of PCI following AMI
40746842|NCT06022809|BEHAVIORAL|Dada Kwa Dada (individual-level)|Dada Kwa Dada (DKD) intervention is an adapted version of Sister to Sister (S2S) intervention (a brief, health profession-led, individual-level intervention proven to increase condom use and decrease STIs among African American women). Intervention is a 1hr to 1.5hrs session and offered in English or French.
40746843|NCT06022809|BEHAVIORAL|DADA (group-level)|DADA intervention is an adapted version of Sisters Informing Sisters about Topics on AIDS (SISTA) intervention (a peer-led, group-level intervention proven to increase condom use and decrease STIs among African American women). This is a 6hrs intervention implemented in two three-hour sessions and offered in English or French.
40746844|NCT05133570|DEVICE|vista care|Prospective, open-label, multi-centre study evaluating the performance of the VistaCare® wound healing device in routine practice.
40746845|NCT04954820|DRUG|Lutathera|2 additional infusions of Lutathera®
40746846|NCT02703363|DRUG|Minocycline|
40746847|NCT02703363|DRUG|Celecoxib|
40746848|NCT02703363|DRUG|Placebo|
40746849|NCT00487630|DRUG|recombinant alpha-galactosidase A|
40746850|NCT01590615|DRUG|Anti-HBV nucleoside/nucleotide therapy|Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
40746851|NCT05639205|DIAGNOSTIC_TEST|Lateral Flow Device|Regular asymptomatic staff testing with a Lateral Flow Device including support payments if unwell.
40746852|NCT01331005|DRUG|nepafenac 0.1% drops|One drop three times per day for one year
40746853|NCT01331005|OTHER|Nepafenac Vehicle|Placebo
40746854|NCT02823561|DIETARY_SUPPLEMENT|Garcinia mangostana|
40746855|NCT02823561|BEHAVIORAL|Control group|
40746856|NCT02094235|DRUG|E6005 0.05%|
40746857|NCT02094235|DRUG|Placebo|0.5 g placebo ointment
40746858|NCT02094235|DRUG|E6005 0.2%|
40746859|NCT01131585|PROCEDURE|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
40746860|NCT01131585|DRUG|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
40746861|NCT01131585|DRUG|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
40746862|NCT03812328|DRUG|SelK2|I.V., single-dose
40746863|NCT03812328|BIOLOGICAL|Enoxaparin|SC, QD for up to 10 ± 2 days
40746864|NCT03219736|PROCEDURE|Standard of Care therapies|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).
40746865|NCT03219736|DEVICE|NiPPV Therapy|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.
40746866|NCT03219736|PROCEDURE|Routine Respiratory Care|It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
40746867|NCT06154473|PROCEDURE|Open heart surgery group.|Patients undergoing open heart surgery.
40746868|NCT06154473|PROCEDURE|Percutaneous cardiovascular surgery group.|Patients undergoing percutaneous cardiovascular surgery.
40746869|NCT04404556|BEHAVIORAL|Diabetes Journey|Web-based telehealth intervention focused on adherence barriers and problem-solving
40746870|NCT04404556|BEHAVIORAL|Enhanced Standard of Care|General education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) will be provided.
40746871|NCT05552131|DEVICE|T-wave coronary lithotripsy catheter system|Subjects who plan to receive possible interventional therapy meet all admission criteria and do not meet any exclusion criteria, and enter the screening stage of this clinical trial after signing informed consent. All subjects who sign the informed consent will be provided with a unique subject screening number. All subjects who met the inclusion criteria and did not meet the exclusion criteria were enrolled and lumen pretreated with a coronary shock catheter system followed by the implantation of drug-eluting stents.
41095395|NCT02560103|OTHER|Transmeridian travel across multiple time zones|
41095396|NCT05373719|OTHER|No intervention; observational|No intervention; observational
41269896|NCT03813030|DRUG|"Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)"|Topical application in dermal-sampling visit
41269897|NCT03813030|DRUG|"Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)"|Intravenous infusion in clearance visit
40746872|NCT06457932|BEHAVIORAL|Heart rate variability biofeedback training|An 8-week intervention based on daily 10-minute HRV biofeedback training at rest using the Pulse HRV smartphone application.
40746873|NCT06457932|BEHAVIORAL|Guided meditation|An 8-week intervention based on daily 10-minute guided meditation sessions led by an instructor with over 20 years of experience in teaching meditation.
40746874|NCT01092156|BEHAVIORAL|Education|Education on Infant-led latching
40746875|NCT06103682|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
40746876|NCT03372915|BEHAVIORAL|Standard Exposure|Exposure therapy conducted according to standard clinical care practices
40746877|NCT03372915|BEHAVIORAL|Exposure + Inhibitory Learning|Exposure therapy conducted according to practice recommendations based derived from research on inhibitory learning theories of fear extinction
40746878|NCT06300047|OTHER|Non-Medical Transition Coordinator|Participants in this intervention arm will have access to the non-medical transition coordinator to support their transition from pediatric to adult care.
40746879|NCT02153827|OTHER|Eccentric Shoulder External Rotator Training|Eccentric training exercise for the external rotators, 3 sets of 15 daily.
40746880|NCT02153827|OTHER|General Shoulder exercise|general exercise consisting of active shoulder movements
40746881|NCT05758792|OTHER|Muscle Quality Index|Evaluations are applied to older adults to compare the results of muscle quality.
40746882|NCT01926639|BIOLOGICAL|Radiotherapy, rituximab and DC|Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
40746883|NCT01675700|DRUG|Nitroglycerin patch|Nitroglycerin 0.1 mg/hr patch
40746884|NCT03750084|OTHER|questionary|The intervention consists of a digitally distributed questionary.
40746885|NCT03409458|DRUG|PT-112|"The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15."
40746886|NCT03409458|BIOLOGICAL|avelumab|Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15.
40746887|NCT03688737|OTHER|low level laser|LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative
40746888|NCT03688737|OTHER|placebo|placebo like device as it like low level laser device shape but with no effect to blind the intervention
40746889|NCT05983055|DRUG|Dexamethasone 20mg|Periarticular dexamethasone injection
40746890|NCT00585585|DRUG|betahistine dihydrochloride|oral, 50-300 mg, daily
40746891|NCT02162563|DRUG|FOLFOX/ FOLFIRI with bevacizumab|"FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
40746892|NCT02162563|DRUG|FOLFOXIRI with bevacizumab|FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
40746893|NCT02162563|DRUG|FOLFOX/ FOLFIRI with panitumumab|"FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
40746894|NCT04048083|BEHAVIORAL|Mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement. During each training session they will perform 3 practice trials by following the instructions, after practicing 3 trials, the instructions will be discontinued, and subjects will perform 30 mental movements by following auditory cues.
40746895|NCT04048083|BEHAVIORAL|Computer-aided trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of visual feedback of reaching-to-grasp movement. During each training session they will be sitting on a chair, in front of a computer screen observing simple tasks of reaching and precision fine grasping of a small object with 4 fingers of virtual upper extremity using the visualization software that will be coded specifically for the purpose of this experiment.
41269898|NCT03813030|DEVICE|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
41269899|NCT03813030|DEVICE|Dermal Microdialysis|"Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
41269900|NCT03813030|PROCEDURE|Blood sampling in dermal sampling visit|1 sample is taken pre-dose and 12 samples are taken post-dose.
41269901|NCT03813030|PROCEDURE|Blood sampling in clearance visit|1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
41269902|NCT02960282|PROCEDURE|Biospecimen Collection|Undergo collection of fecal specimens
41269903|NCT02960282|OTHER|Laboratory Biomarker Analysis|Correlative studies
40746896|NCT04048083|BEHAVIORAL|Computer-aided and mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement that will be supplemented by visual feedback of this task by the visualization software that will be coded specifically for the purpose of this experiment (they will receive trainings that link the features of the two mentioned above types of training (MT and CAT).
40746897|NCT04048083|OTHER|No trainings|Healthy controls without any kind of training
40746898|NCT02997670|OTHER|Algorithmic Cardiac Resynchronisation Therapy Optimisation|Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
41269904|NCT01917123|DRUG|L-Citrulline malate|L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
41269905|NCT04214652|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
41269906|NCT04214652|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
41269907|NCT03599180|DEVICE|microdialysis|Use microdialysis skill to collect dialyzate at sensitization acupoints
41269908|NCT06340217|OTHER|washed microbiota transplantation|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive two doses of WMT for DGP.
41269909|NCT06340217|OTHER|placebo|A carrier fluid with matching volume and consistent appearance to the infusion of washed microbiota.
41269910|NCT02382133|DEVICE|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
41269911|NCT06154902|DRUG|Idecabtagene vicleucel|According to approved product label in France
41269912|NCT06154902|OTHER|Not treated|Eligible for idecabtagene vicleucel treatment but not treated
41269913|NCT01193686|OTHER|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
41269914|NCT02195492|DRUG|Synvisc®|
41269915|NCT05042726|DEVICE|cTBS First|Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 33.2s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group.
41269916|NCT05042726|DEVICE|Pseudo-stimulation First|The transcranial magnetic stimulator operating system has a built-in control group option, in which the stimulation parameters are set consistent with the research group, which can realize the operation of only sound without stimulation.
41269917|NCT02797119|DRUG|tranexamic acid 1 g (TA1)|1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
41269918|NCT02797119|DRUG|tranexamic acid 0.5 g (TA1/2)|0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
41269919|NCT02797119|DRUG|Saline Solution (TA0)|
41269920|NCT04211129|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
41269921|NCT04211129|OTHER|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
41269922|NCT01965249|DEVICE|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HR48 mm
40746899|NCT00520442|DRUG|ibuprofen|
40746900|NCT00520442|DRUG|acetamin w codeine|
40746901|NCT04029051|OTHER|Focus thoracic ultrasound for dyspnea diagnosis|Focus thoracic ultrasound is composed by an advanced cardiac ultrasound with Doppler measures and a lung ultrasound.
40746902|NCT02271802|DIETARY_SUPPLEMENT|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
40746903|NCT02271802|DIETARY_SUPPLEMENT|NaCl|
40746904|NCT05328232|OTHER|Olive oil|The parents of the babies included in the experimental group were asked to fill in the questionnaires. The infant's skin condition was assessed using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants. Each time the diaper was changed, the diaper area was cleaned with water and cotton wool and dried, 1-2 cc of natural extra virgin olive oil was applied, and the new diaper was fastened. At the end of each day, the diaper area was evaluated by the researcher and a nurse by using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants.
41269923|NCT01965249|DEVICE|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
41269924|NCT05059990|OTHER|Low Intensity Aerobic Exercises Group|Intervention Low Intensity Aerobic Exercises i.e. stationary cycle(supervised) Intensity 55-65% of HRmax Frequency 3 times a week Duration 30 min each session
41269925|NCT05059990|OTHER|Active Exercises Group|Intervention Upper and lower limb ROM \& stretching exercises Intensity As per tolerance Frequency 12 repetition/4sets per exercise 3 times/week Duration 30 minutes each session
41269926|NCT01012908|DIETARY_SUPPLEMENT|Norzyme - Bergamo|2 - 8 tablets per day.
41269927|NCT01012908|DIETARY_SUPPLEMENT|Creon|2 - 8 tablets pet day
40746905|NCT00599313|DRUG|Sunitinib|50 mg/day orally each of Days 1-28 of each 6 week cycle
40746906|NCT04921163|DIETARY_SUPPLEMENT|sodium aluminium phospate (SALP)|1 pancake daily for 4 days
40746907|NCT04921163|DIETARY_SUPPLEMENT|Aluminium-free pancake|1 pancake daily for 4 days, without aluminium
40746908|NCT04087590|DRUG|Formoterol-glycopyrronium co suspension (PT003)|Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
40746909|NCT00766103|OTHER|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
41269928|NCT02906254|OTHER|ECIL-4 guidelines group|Antibiotics were stopped when patients had been afebrile for more than 48 hours
41269929|NCT02906254|OTHER|Short-course antibiotic therapy|Antibiotics were stopped on day 5 in febrile or afebrile patients
41269930|NCT04972877|OTHER|Treatment group protocol|"For treatment group, two groups of acupoints will be used alternatively. The first group consists of some acupoints. The patients will be asked to stay in supine position. Disposable sterilized needles (Size: 0.25\*40/50 mm) will be inserted into a depth of 15\~35 mm and stimulated manually to evoke needle sensation. And then some acupoints will be thereafter connected to electrical stimulators and stimulated with low-frequency and the maximum tolerated intensity of the patients. The other needles without electrical stimulators will be manually stimulated to evoke Deqi every 10 minutes.~The second group consists of other acupoints. Patients will be asked to stay in prone position. The stimulation will be in the same way as the first group."
40746910|NCT05714397|DEVICE|Cingal|A single Cingal injection will be administered by fellowship-trained physicians through ultrasound-guided injection using a 20-gauge needle into the joint space of the knee under sterile conditions. The needle track will be anesthetized with local anesthetic.
40746911|NCT01350973|DRUG|Omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
40746912|NCT01350973|DRUG|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
40746913|NCT05278091|OTHER|None, pure observationnal study|None, pure observationnal study
40746914|NCT00152230|DRUG|UFT (uracil, tegafur)|to receive oral uracil-tegafur 400 mg square meter for one year
40746915|NCT00152230|PROCEDURE|Surgery alone|Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.
40746916|NCT06135545|COMBINATION_PRODUCT|Bupivacaine Liposome SAPB|Dilute 266mg of bupivacaine liposome with saline solution to 30ml.The patients are placed in the lateral position and the probe is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The investigators count the ribs inferiorly and laterally, until The investigators identify the fifth rib in the midaxillary line. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) are then easily identifiable by ultrasound overlying the fifth rib.
40746917|NCT06135545|COMBINATION_PRODUCT|Traditional TPVB|The TPVB was recommended by the American Society of Anesthesiologists.The transducer is placed sagitally over a transverse process(TP), placing it at the center of the ultrasound image. Alternatively, the space in-between two adjacent transverse processes may be positioned at the center. The needle is inserted using an out-of-plane technique and advanced until the central TP is contacted, or else the cranial of the two, with no or minimal angulation in the sagittal plane or the transversal plane. Subsequently, the needle is walked off the TP into the TPV space and advanced 1 to 1.5 cm beyond the TP without further visualizing the needle tip on ultrasound. Entering of the needle tip into the TPV space can result in a loss of resistance to normal saline and by visualizing anterior displacement of the pleura upon injection. Select the fifth TP as the insertion point, and inject 20ml of 0.5% ropivacaine (Hengrui, Jiangsu) into the TPV space.
40746918|NCT01452087|OTHER|Exercise|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
40746919|NCT01603914|DEVICE|central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )|"Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site."
40746920|NCT04167462|DRUG|BMS-986165|Specified dose on Specified Days
40746921|NCT04167462|OTHER|Placebo|Specified dose on Specified days
40746922|NCT01263379|BIOLOGICAL|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets|"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."
40746923|NCT02132468|DRUG|fosbretabulin tromethamine|60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
40746924|NCT04758637|BEHAVIORAL|Overdose Notification|We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.
40746925|NCT00837447|DEVICE|Total knee replacement with NexGen CR knee prosthesis|comparison of functional outcome in patients receiving either NexGen posterior cruciate-retaining or a high-flexion posterior cruciate-retaining total knee prosthesis
40746926|NCT00837447|DEVICE|Total knee replacement(TKR) with Nexgen CR-flex|TKR using Nexgen CR-flex implant
40746927|NCT02287519|BEHAVIORAL|Group Session|
40746928|NCT02287519|BEHAVIORAL|Telephone Coaching Session|
40746929|NCT02287519|BEHAVIORAL|Webinar|
40746930|NCT04234542|OTHER|Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be increased along with intensity as the stages progress.
41095397|NCT05350436|BEHAVIORAL|Balance Conditions|"Balance Conditions: (\~ 5 minutes in total)~* Balance Condition 1 (Feet 20cm apart)~* Balance Condition 2 (Feet together)~* Balance Condition 3 (Tandem stance)~Initial measurements of balance conditions serve two purposes: it generates a postural control baseline for us without the attribution of singing conditions, furthermore it allows us to separately measure long-term singing experience's effect on postural control, by assessing tasks differing in difficulty level. Balance conditions will be randomised to prevent a learning effect."
40746931|NCT04234542|OTHER|Sham Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be progressed, but power will always be set to 1%..
40746932|NCT02866383|DRUG|Nivolumab|3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)
40746933|NCT02866383|DRUG|Ipilimumab|1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)
40746934|NCT02866383|RADIATION|Radiotherapy|15 Gy x 1 fraction given on day 1
41269931|NCT04972877|OTHER|Control group protocol|"For control group, four pseudo-acupoints are used, with two points on each shoulder and the two on each upper arm, which are not located on any meridians. The patients will be asked to stay in supine position and keep the whole body relaxed and comfortable. Disposable sterilized needles (Size: 0.18\*25 mm) will be inserted superficially to a depth of \< 5 mm without any manual stimulus and the needle sensation (Deqi in TCM) should not be evoked. Electrodes are connected to the needles, but the stimulators should be turned on at an intensity of zero. Each intervention lasts for 30 minutes."
41269932|NCT05555004|OTHER|TEST1|Toddler milk with preconditioned L. reuteri and containing GOS
41269933|NCT05555004|OTHER|TEST 2|Toddler milk with standard/non-preconditioned L. reuteri and not containing GOS.
41269934|NCT04790227|DEVICE|MRI|MRI
40746935|NCT06150443|OTHER|Osteopathic manipulative treatment (OMT)|Two osteopathic primary care physicians will performing osteopathic manipulative techniques with a minimum of three direct techniques focused on carpal tunnel. These techniques will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. They will also evaluate and treat the cervical spine, with particular attention to the C5-7 levels, all the way to the wrist and hand as they see fit based on the findings of their osteopathic structural exam.
40746936|NCT06150443|OTHER|Conservative treatment|Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical therapy will be excluded from the conservative therapy regimen.
40746937|NCT02184247|DRUG|anhydrous theophylline, 350 mg|
40746938|NCT02184247|DRUG|anhydrous theophylline, 300 mg|
40746939|NCT03977688|DEVICE|Cytokin Adsorption|Haemadsorption with Cytokin Adsorber (Cytosorb)
40746940|NCT00514527|DRUG|oritavancin|Oritavancin as a single, infrequent or daily dose.
40746941|NCT02016508|DRUG|autologous bone marrow derived stem cells|intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
40746942|NCT03719664|DRUG|Albuvirtide|Intravenous infusion of Albuvirtide
40746943|NCT03719664|DRUG|3BNC117|Intravenous infusion of 3BNC117
40746944|NCT03719664|DRUG|Baseline ART|Subjects continuing on baseline ART
40746945|NCT04909788|BEHAVIORAL|a long-distance running (over 3 km)|Complete a long distance running（over 3 km） within the specified time (30 minutes)
40746946|NCT04324697|PROCEDURE|Horizontal alveolar bone augmentation|Horizontal augmentation in anterior maxilla using allograft shell and autogenous chips with no need for a second surgical site
40746947|NCT00219271|DRUG|Zoledronic acid|
40746948|NCT01271972|DRUG|nesvacumab (REGN910/ SAR307746)|
40746949|NCT02919605|DRUG|Single dose of Pentamidine|The patients will come to the hospital to take a single dose of the Pentamidine.
40746950|NCT02919605|DRUG|Two doses of Pentamidine|The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
40746951|NCT02919605|DRUG|Three doses of Pentamidine|The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
40746952|NCT02507284|DRUG|SRX246|
40746953|NCT02507284|DRUG|Placebo|
40746954|NCT05389787|DEVICE|Transcranial Magnetic Stimulation|The TMS will be administrated using the MagVenture Mag Pro R30 device equipped with a B-70 coil. The FDA-approved iTBS sequence will be applied: 10 bursts of three biphasic pulses at 50 Hz, repeated at 5 Hz, for 10 seconds for a total of 600 pulses, and will be repeated for three times. The total stimulation time is \~10 min per session (day). Patients will receive five sessions (days) of rTMS each week, and the total treatment will last for four weeks.
40746955|NCT00016172|DRUG|pegylated liposomal doxorubicin hydrochloride|
40746956|NCT00016172|DRUG|picoplatin|
40746957|NCT00899275|OTHER|Cytology Specimen Collection Procedure|Correlative studies
40746958|NCT06125990|OTHER|Experimental: Study Group (SGr)|For 6 weeks, in addition to institutional conventional exercise 2 days a week, one day a week of home exercise, breathing exercises to increase lung volumes and 7 sets of video-based breathing exercises were applied, each set consisting of 2 minutes of performance and 1 minute of rest.
40746959|NCT06125990|OTHER|Sham Comparator: Control Group (CGr)|Only institutional conventional rehabilitation was implemented.
40746960|NCT05180058|OTHER|Wrapping + Breastmilk Group|Interventions applied during orogastric tube insertion
40746961|NCT02314247|DRUG|Selinexor|"20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.\<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment."
40746962|NCT04033913|OTHER|Self questionnaire|Patients who have successfully perform self-catheterization complete a self questionnaire on the importance of each criterion in choosing the catheter they have made.
40746963|NCT04307394|BEHAVIORAL|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge.
40746964|NCT02612467|OTHER|Stratified care|"Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.~Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability."
40746965|NCT02612467|OTHER|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
40746966|NCT03242733|OTHER|Ultrasound assessment of gastric contents|Ultrasound assessment of gastric contents is performed in fasted elderly patients for hip fracture surgery.
40746967|NCT02451319|PROCEDURE|Retrograde Intrarenal Surgery|Endoscopic treatment of Kidney Stones
40746968|NCT00026338|DRUG|erlotinib hydrochloride|150 mg po daily
40746969|NCT00026338|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
40746970|NCT03406975|DEVICE|Overstitch Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), an endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
40746971|NCT03406975|BEHAVIORAL|Lifestyle Intervention|Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.
40746972|NCT02726269|DRUG|CLA (Clarithro+Lanso+Amoxi)|Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
40746973|NCT02726269|DRUG|PLA (Panto+Levoflox+Azithro)|Tablets of oral administration to subjects randomized to this group once daily for 10 days.
40746974|NCT01987674|DIETARY_SUPPLEMENT|Pre-meal protein drink|
40746975|NCT01987674|OTHER|Water drink|
40746976|NCT02508207|DRUG|Tezacaftor/Ivacaftor|Tezacaftor/Ivacaftor FDC
40746977|NCT02508207|DRUG|Ivacaftor|
40746978|NCT02508207|DRUG|Tezacaftor/Ivacaftor matching placebo|
40746979|NCT02508207|DRUG|Ivacaftor matching placebo|
40746980|NCT01453647|OTHER|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
40746981|NCT02463877|PROCEDURE|Minimally-Invasive Procedure|Laparoscopy
40746982|NCT05752864|BEHAVIORAL|spine manual therapy|The manual treatment method applied to the sacroiliac joint used high-velocity, low amplitude (HVLA).
40746983|NCT05752864|DEVICE|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
40746984|NCT05740592|PROCEDURE|micro-osteoperforations ,microincision|Patients in MOPs group will be subjected to minimal 6 MOPs 2mm apart and corticoperforation will be conducted by using drilling bure and only 1 or 2mm bicortical in the mid-palatal suture area. Patients with the piezocision group will be subjected to minimal 3 micro incisions spaced 4mm apart and a piezoelectric device with diamond surgical tip (size: 4 mm, thickness: 0.5mm) will be used.. The MARPE technique comprises the insertion of four bicortical miniscrews adjacent to the mid-palatal suture, being two mesial and two distal to the expanding screw. Each MARPE have two arms and will be fixed to molar band by soldering.
40746985|NCT04035083|DEVICE|Laser activated irrigation|Diode laser at 980 nm, power of 1.5W, for 5 seconds inside the canal along with sodium hypochlorite, repeated 4 times with a gap of 10 seconds in between
40746986|NCT04035083|DEVICE|Passive ultrasonic irrigation|ultrasonic activation inside the canal for 1 min
40746987|NCT04400747|DRUG|Vitamin D3|one group will take weekly oral 50000 IU Vitamin D3, other group will take daily oral 6000 IU Vitamin D3.
40746988|NCT00387127|DRUG|Lapatinib oral tablets|Lapatinib is administered orally once daily.
40746989|NCT00387127|DRUG|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
40746990|NCT00387127|DRUG|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
40746991|NCT01328626|DRUG|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
40746992|NCT02815956|DEVICE|percutaneous tibial nerve stimulation|
40746993|NCT02815956|DEVICE|Placebo|
40746994|NCT01101555|DRUG|subcutanious administration|drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
40746995|NCT01101555|OTHER|Placebo|Placebo will be given to one member of each cohort.
40746996|NCT05371704|DIETARY_SUPPLEMENT|Multivitamin Supplementation|Participants will supplement daily with an over-the-counter oral multivitamin pill
40746997|NCT05371704|OTHER|Dietary Replication|Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial
40746998|NCT00116909|DRUG|OSI 7904L|
40746999|NCT06043570|DEVICE|Remote Monitoring arm|Patients will be follow-up using remote monitoring. In the RM follow-up arm, the patients are not mandated to visit the clinic unless there is unscheduled call due to adverse event notification.
40747000|NCT05188612|COMBINATION_PRODUCT|Observational (registry)|Observational (Patient Registry)
40747001|NCT01284764|DRUG|Mosapride|Mosapride 10mg, one dosage, once evening of the day before the endoscopy
40747002|NCT00272090|DRUG|Insulin glargine|
40747003|NCT02919332|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
40747004|NCT02919332|RADIATION|Fludeoxyglucose F-18|Given IV
40747005|NCT02919332|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT
40747006|NCT04253860|DEVICE|Transcutaneous electrical neurostimulation|Sessions of 30 minutes of TENS will be applied three times a week during 90 days
40747007|NCT03899090|BEHAVIORAL|Float pool|Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
40747008|NCT03899090|BEHAVIORAL|Float chair|Subject floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
40747009|NCT00949663|DRUG|Placebo|Intravenous infusion of 1% human albumin in normal saline
40747010|NCT00949663|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
40747011|NCT00949663|DRUG|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
40747012|NCT00949663|DRUG|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
40747013|NCT01972178|DRUG|PRC-4016|
40747014|NCT01972178|DRUG|Placebo|
40747015|NCT01972178|DRUG|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
40747016|NCT00608738|OTHER|informational intervention|
40747017|NCT00608738|OTHER|medical chart review|
40747018|NCT00608738|OTHER|questionnaire administration|
40747019|NCT00608738|PROCEDURE|assessment of therapy complications|
40747020|NCT00608738|PROCEDURE|management of therapy complications|
40747021|NCT00074191|DRUG|cytarabine|
40747022|NCT00074191|DRUG|dexamethasone|
40747023|NCT00074191|DRUG|lomustine|
40747024|NCT00074191|DRUG|methotrexate|
40747025|NCT00074191|DRUG|procarbazine hydrochloride|
40747026|NCT03191201|DRUG|Ferric Carboxymaltose|Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
40747027|NCT03191201|DRUG|0.9% sodium chloride solution|250 mL of a commercially available sterile 0.9% sodium chloride solution.
41269935|NCT03761329|PROCEDURE|mini-Bier's block with lidocaine 0.5% 25ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the forearm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (25ml lidocaine 0.5%). The tourniquet remains inflated for 10 minutes to reduce systemic toxicity reactions postoperatively.
41269936|NCT03761329|PROCEDURE|Conventional Bier's block with lidocaine 0.5% 40ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the upper arm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (40ml Lidocaine 0.5%). The tourniquet remains inflated for 25 minutes to reduce systemic toxicity reactions postoperatively.
41269937|NCT00002948|BIOLOGICAL|filgrastim|
41269938|NCT00002948|DRUG|topotecan hydrochloride|
41269939|NCT00002948|PROCEDURE|bone marrow ablation with stem cell support|
41269940|NCT00002948|PROCEDURE|peripheral blood stem cell transplantation|
41269941|NCT02932267|DRUG|Adapalene 0.3% / BPO 2.5% gel|Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
41269942|NCT02744976|DRUG|Metformin|In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months
40747028|NCT06179875|DRUG|Intervention/Treatment|VRDN-001 10 mg/kg (5 infusions of VRDN-001 10 mg/kg)
41269943|NCT02744976|BEHAVIORAL|Lifestyle recommendations|Standard lifestyle recommendations
41269944|NCT03346330|DRUG|TRK-750|TRK-750 capsule
41269945|NCT03346330|DRUG|Placebo|Placebo capsule
41269946|NCT04601480|BEHAVIORAL|Choice Architecture Nudge|During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.
41269947|NCT04601480|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
41269948|NCT05974982|BIOLOGICAL|PRP|PRP is a volume of autologous plasma that has a platelet concentration above baseline i.e., five times more than normal platelet counts. PRP enhances wound healing by promoting the healing process by seven growth factors present in it. They are platelet derived growth factor (αα, αβ, αβ), fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, transforming growth factor.
41269949|NCT05974982|OTHER|Conventional therapy|Conventional therapy
40747029|NCT03039725|OTHER|Observational|Retrospective chart review on vaccine compliance
40747030|NCT03934307|DRUG|ALN-AGT01|ALN-AGT01 will be administered by subcutaneous (SC) injection.
40747031|NCT03934307|DRUG|ALN-AGT01-Matching Placebo|Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
40747032|NCT03934307|DRUG|Irbesartan|Irbesartan will be administered orally.
40747033|NCT03934307|DRUG|Irbesartan-Matching Placebo|Irbesartan-matching placebo will be administered orally.
40747034|NCT03805139|DIETARY_SUPPLEMENT|Ajwa Date (phoenix dactylifera)|Effect of Ajwa on Dyslipidemia
40747035|NCT04317027|DEVICE|New Fighting Clothing|VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity
40747036|NCT01060956|OTHER|reporting of two different bacteria in urine culture|reporting of two different bacteria in urine culture
40747037|NCT01060956|OTHER|"reporting mixed growth on urine culture"|"reporting mixed growth on urine culture"
40747038|NCT03589053|DEVICE|Limb remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.
40747039|NCT03589053|DEVICE|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
40747040|NCT04785885|DIAGNOSTIC_TEST|iStat Handheld Blood Analyzer|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
40747041|NCT04785885|DIAGNOSTIC_TEST|Hemochron|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
40747042|NCT03116269|DRUG|Cilostazol 100mg|
40747043|NCT03116269|DRUG|Aspirin|
40747044|NCT00864513|DRUG|pemetrexed|pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
41269950|NCT04887402|DRUG|Clomiphene Citrate|"All patients will be treated with CC starting with 50 mg/day on the day 2 of their cycle for 5 days, a transvaginal ultrasound will be done 1 week after the last pill, if all follicles are below 10 mm the dose will subsequently be increased to 100mg/day for 5 days then 150mg/day for 5 days if a transvaginal is done a week from the last pill and showed no response (all follicles being below 10 mm ).Maximum cc dose will be 150 mg (ASRM, 2013). Medroxyprogesterone (10 mg/d Provera for 10 days)will be given to induce withdrawal bleeding to start these steps again in a new cycle. These steps will be repeated for 3cycles before declaring the patient CC resistant.~o Response: Response to CC will be assessed by ovulation. TVS will be done by the same observer using a Samsung ultrasound machine, HS40.~A scan will be done 1 week after the last pill of each dose. No response: if all follicles are below 10 mm (ASRM, 2013), follicles \>10mm, follow up till ovulation"
41269951|NCT01144585|PROCEDURE|remote ischemic preconditioning and postconditioning|"RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done after CPB."
41269952|NCT01144585|PROCEDURE|Control|This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
41269953|NCT04196257|DRUG|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)|Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.
41269954|NCT04196257|DRUG|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel|Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.
41269955|NCT03045003|BEHAVIORAL|RESIL Intervention|Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.
41269956|NCT03783949|DRUG|Ganetespib|Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)
41269957|NCT03783949|DRUG|Niraparib|Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
41269958|NCT03783949|DRUG|Carboplatin|In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)
41095398|NCT05350436|BEHAVIORAL|Singing|"Singing Conditions: (\~ 15 minutes)~* Warmup - including jaw and breathing exercises~* Singing Condition 1 (Spoken Happy Birthday - Traditional Tempo)~* Singing Condition 2 (Sung Happy Birthday - Traditional Tempo~* Singing Condition 3 (Spoken Happy Birthday - Fast Tempo)~* Singing Condition 4 (Sung Happy Birthday - Fast Tempo)~* Singing Condition 5 (Spoken Happy Birthday - Slow Tempo)~* Singing Condition 6 (Sung Happy Birthday - Slow Tempo)~Link to singing instructional video:~https://www.dropbox.com/s/tro58i6vx6i6w3a/Singing%20Balance%20Exercise%20Video.mp4?dl=0~Time stamps for the video:~* Warmup (including jaw exercises and breathing exercises) - beginning at 2:55 until 6:06~* Happy Birthday protocol - beginning at 15:26 until 20:21"
41095399|NCT01841840|OTHER|Low-Frequency Passive Vibration|10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
41095400|NCT01841840|OTHER|High-Frequency Pasive Vibration|10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
41095401|NCT03422510|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
41095402|NCT03437798|OTHER|Disease status|Women who reported periodontal disease diagnosis/condition
41095403|NCT05037994|PROCEDURE|Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine|"The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap."
41269959|NCT03783949|DRUG|Paclitaxel|Paclitaxel dose will be 175mg/m² (q3w)
41269960|NCT03783949|DRUG|Gemcitabine|Gemcitabine dose will be 1000mg/m² (q3w, d1 \& d8)
41269961|NCT00166387|PROCEDURE|Blood draw|A single blood draw.
41095404|NCT03985709|OTHER|Probiotic product|Probiotic (Lactobacillus casei) once daily taken by 3 months.
41269962|NCT01903265|DRUG|TNX-102 SL 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
41269963|NCT01903265|DRUG|Placebo|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
41269964|NCT05682014|BEHAVIORAL|Mindful Breastfeeding Program|"A web-based Mindful Breastfeeding Program, which is applied to pregnant women in groups of 5, consisting of 8 sessions, 2 sessions per week for 4 weeks.~Mindful breastfeeding program will consist of breastfeeding education, introduction to the concept of mindfulness, mindful breastfeeding, practical suggestions to pregnant women by the researcher, providing a discussion environment for them to share their experiences, and homework on the content of the program.~A web site with written material, video and audio recordings will be created and presented to the participants as a support element.~In order for them to use mindfulness practices in their daily lives, motivational WhatsApp short messages will be sent by the researcher daily during the training, weekly during the post-training period, and daily in the postpartum period."
41269965|NCT02139956|DEVICE|ultrasonography|open
41269966|NCT01091961|PROCEDURE|Preoperative ACEi/ARB management|Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
40747045|NCT02560792|BEHAVIORAL|Positive Affect Condition|"Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good."
41269967|NCT06229392|BIOLOGICAL|Fluzone Quadrivalent|Successive cohorts of participants (3 participants per tumor type per cohort) will each be started on a fixed dose of the influenza vaccine. For the first cohort, patients will receive Fluzone Quadrivalent - (Sanofi Pasteur) - 60mcg/0.5mL (standard dose IT flu shot, or dose level 0) intratumorally on day -6 +/- 1 day and day 0 or 1. For the second cohort, patients will receive Fluzone High-Dose Quadrivalent - (Sanofi Pasteur) - 240mcg/0.7mL (high dose IT flu shot, or dose level 1) intratumorally on day -6 +/- 1 day and day 0 or 1. has context menu
41095405|NCT04109690|DRUG|CPX-351|Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
41095406|NCT06367413|DIETARY_SUPPLEMENT|Placebo|Participants will receive three servings of carbohydrate per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of maltodextrin per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of maltodextrin per kg of body weight in the pre-sleep serving (1.1 gr maltodextrin/kg BW/day).
40747046|NCT02560792|BEHAVIORAL|Negative Affect Condition|"Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad."
41095407|NCT06367413|DIETARY_SUPPLEMENT|NAC|Participants will receive three servings of N-acetylcysteine per day during the 4-day experimental period. In specific, they will be supplemented with 13.33 mg of N-acetylcysteine per kg of body weight per serving (40 mg NAC/kg BW/day).
41095408|NCT06367413|DIETARY_SUPPLEMENT|NAC + Whey Protein|Participants will receive three servings of N-acetylcysteine + whey protein per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the pre-sleep serving (1.1 gr Whey protein + 40 mg NAC /kg BW/day).
41095409|NCT00715806|DEVICE|Open MRI scanner.|Imaging in an Open MRI scanner.
41269968|NCT05265767|BIOLOGICAL|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene administered by IV infusion following conditioning regimen.
41269969|NCT02965378|DRUG|Docetaxel|Given IV
41269970|NCT02965378|DRUG|FGFR Inhibitor AZD4547|Given PO
41269971|NCT02965378|OTHER|Laboratory Biomarker Analysis|Correlative studies
41269972|NCT00630045|DRUG|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
41095410|NCT00715806|DEVICE|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
41095411|NCT06157879|DEVICE|WVI-MIS-01-2022|Microwave scans
41095412|NCT04337489|DEVICE|SensiumVitals wearable sensor|A waterproof, light, wearable sensor measuring vital signs (heart rate, respiratory rate, temperature) continuously.
41095413|NCT05441696|DEVICE|ezCVP measurement|"* Measuring device: non-FDA-cleared patient monitor (740E, Zoe Medical, MA, US), which has software to measure ezCVP.~* Sensor: an FDA-cleared pulse oximeter sensor for adults (K012891: DS-100A, Nellcor, CA, US).~* Cuff: an FDA-cleared NIBP cuff for adults (K080342: YP-713T, YP-714T or TP-715T, Nihon Kohden Corporation, Tokyo, Japan)."
41269973|NCT00630045|PROCEDURE|resection of liver metastasis|surgery with the aim of R0 resection
41269974|NCT01597063|DEVICE|SEQureDx Trisomy Test|Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
41269975|NCT06414096|DRUG|Follicle Stimulating Hormone|Pulsatile FSH administration via a portable pump.
41269976|NCT03776656|DRUG|Allopurinol|Daily oral administration
41269977|NCT02857218|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
41269978|NCT02857218|PROCEDURE|Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
41269979|NCT06020794|BEHAVIORAL|Exercise|quadriceps isometric exercises, straight leg raises, semi-squat exercises, hip flexors, hamstring and iliotibial band stretching exercises, strengthening exercises for hip abductors and adductors
41269980|NCT06020794|BIOLOGICAL|LP-PRP|The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
41269981|NCT00412256|DRUG|Omegaven (10% fish-oil emulsion; Fresenius-Kabi)|
41269982|NCT04284969|BEHAVIORAL|PROADAPT program|"* A pre-intervention activity by telephone follow-ups every week for 12 weeks and then every month.~* Pre-operative physical training including strength, endurance and breathing exercises.~* A nutrition activity.~* An activity to educate patients (on nutrition, exercise).~* The implementation of standardised intervention procedures, established in agreement with the surgeons' representatives.~* A pharmaceutical drug conciliation activity: optimization of the patient's different treatments with pharmaceutical expertise.~* A transition activity from the hospital to the home, and a telephone follow-up up to 12 weeks after the surgery."
41269983|NCT00595231|DRUG|SYN111|500 mg for 1 week followed by 1000 mg for 7 weeks
41269984|NCT00595231|DRUG|Placebo|0 mg tablets
40747047|NCT02560792|BEHAVIORAL|Control Condition|Participants receive no information about affective response
40747048|NCT00266981|DEVICE|APOS - exercise component|
40747049|NCT04831385|BEHAVIORAL|Cognitive Behavioural Therapy|CBT is a first line therapy for insomnia
40747050|NCT04217356|BIOLOGICAL|Hematopoietic stem cell transplant|Intravenous infusion of hematopoietic stem cells from a donor.
40747051|NCT04217356|DRUG|Ruxolitinib|Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).
40747052|NCT04217356|DRUG|Hydroxyurea|Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).
41095414|NCT04162509|OTHER|AR app|Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.
40747053|NCT04090749|BEHAVIORAL|Caregiver-Support|intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
40747054|NCT01305629|BEHAVIORAL|Spiritual Self-Schema Therapy|"The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life."
41095415|NCT06480656|PROCEDURE|Rehabilitation with eccentric cycling exercise|Instead of normal cycling, patients will exercise on the eccentric bike.
41269985|NCT05753956|DRUG|5 Methoxy N,N Dimethyltryptamine|GH002 administered via i.v. bolus injection(s)
41269986|NCT05753956|DRUG|Placebo|GH002 placebo administered via i.v. bolus injection
41269987|NCT00686556|DRUG|cyclophosphamide|60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
41269988|NCT00686556|DRUG|cyclosporine|Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
41269989|NCT00686556|DRUG|Fludarabine|25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
41269990|NCT00686556|DRUG|mycophenolate mofetil|Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients \<40 kg, 3 gm/day for patients \>40 kg.
41095416|NCT06480656|PROCEDURE|normal rehabilitation|Normal rehabilitation will be conducted
41269991|NCT00686556|RADIATION|total marrow irradiation|Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
41269992|NCT00686556|PROCEDURE|umbilical cord blood transplantation|product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
41269993|NCT00686556|BIOLOGICAL|Granulocyte colony-stimulating factor|5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10\^9/L for 3 consecutive days.
41269994|NCT00686556|BIOLOGICAL|HLA-matched related donor bone marrow|Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
41269995|NCT02825121|DEVICE|Monitoring Neuromuscular Blockade the Flexor Hallucis|
41269996|NCT02825121|DEVICE|Monitoring Neuromuscular Blockade adductor of the thumb.|
41269997|NCT03170830|DIAGNOSTIC_TEST|the diagnosis value of cUck2 in acute myocardial infarction.|Collect blood at different time points and compare cUck2 in three groups.
41269998|NCT00679458|DRUG|buprenorphine and low-dose naloxone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
41269999|NCT00679458|DRUG|buprenorphine alone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
40747055|NCT04947267|DRUG|3% Mepivacaine Hydrochloride|1.8 ml of 3% mepivacaine (3% Scandonest, Septodont) was administered to Group B patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
40747056|NCT04947267|DRUG|2% Mepivacaine with 1:100,000 epinephrine|1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
40747057|NCT04616352|OTHER|Resistance to cefuroxime|Non susceptibility in vitro testing
40747058|NCT01356810|OTHER|Environmental Intervention|The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
40747059|NCT01356810|OTHER|Standard Care|Delirium management by the attending physician's preferences.
40747060|NCT05161936|DRUG|Lumasiran|Lumasiran will be administered by SC injection.
40747061|NCT05161936|DRUG|Placebo|Placebo will be administered by SC injection.
40747062|NCT02500355|PROCEDURE|Carpal Tunnel Release via limited approaches|Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.
40747063|NCT02500355|PROCEDURE|Carpal Tunnel Release via standard approach|Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.
40747064|NCT02500355|PROCEDURE|Endoscopic Carpal Tunnel Release|Carpal tunnel release under endoscope.
40747065|NCT02500355|DEVICE|endoscope or an arthroscopic device|
40747066|NCT01245049|BIOLOGICAL|Boostrix PolioTM|Single dose, intramuscular administration.
40747067|NCT01245049|BIOLOGICAL|RepevaxTM|Single dose, intramuscular administration.
40747068|NCT01245049|BIOLOGICAL|PriorixTM|Single dose, intramuscular or subcutaneous administration.
40747069|NCT00140114|DRUG|Misoprostol (Cytotec®)|50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
40747070|NCT00809146|DRUG|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
40747071|NCT00809146|DRUG|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
40747072|NCT02255695|OTHER|School-based exercise program|The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
40747073|NCT00662701|PROCEDURE|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
40747074|NCT00662701|PROCEDURE|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
40747075|NCT01635647|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 1 x 10\^8 pfu heterologous prime-boost immunisation
41095417|NCT02837380|DRUG|FF|FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
41270000|NCT02863198|DEVICE|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
41270001|NCT05246514|DRUG|Trastuzumab deruxtecan|administered as an IV infusion
41270002|NCT02959814|OTHER|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
41270003|NCT02498210|OTHER|In Vitro Maturation Procedure|POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
40747076|NCT01635647|BIOLOGICAL|Rabies vaccine|Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
40747077|NCT02011464|DRUG|Exparel|Exparel is infiltrated into posterior compartment for pain control
40747078|NCT02011464|OTHER|Saline|Saline is infiltrated into posterior compartment for control
41095418|NCT02837380|DRUG|VI/UMEC|VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
40747079|NCT06386042|OTHER|no intervention, observational study|no intervention, observational registry of the prescription of medical therapy according to the European Society of Cardiology Heart Failure guidelines (quality of care).
40747080|NCT00191919|DRUG|Duloxetine Hydrochloride|
40747081|NCT00191919|DRUG|Placebo|
40747082|NCT03661580|BEHAVIORAL|Behavioural Activation|The BA intervention will be the outpatient version of the Life Enhancement Treatment for Substance Use (LETS ACT; Daughters et al., 2008). This brief, manualised BA intervention has been specifically developed to meet the needs of patients with comorbid substance misuse and depression in drugs and alcohol treatment settings. LETS ACT targets the link between mood, substance use and behaviour, and focuses on identifying and increasing rewarding, substance-free activities that are based on the patient's own personal values.
40747083|NCT03661580|BEHAVIORAL|Treatment as Usual|The control intervention in this study is Treatment as Usual at the CDAT service. Treatment as Usual consists of planned key-working sessions every 2-4 weeks with an allocated caseworker plus monthly prescribing review appointments with a medical practitioner for patients who require drug treatment medication. Key-working sessions are primarily focused on addressing substance misuse issues using a range of intervention techniques such as motivational interviewing and brief solution-focused therapy.
41095419|NCT00350532|DRUG|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
41095420|NCT00350532|DRUG|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
40747084|NCT02473601|DRUG|Mivacurium Chloride|"Anesthesia induction:~Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.~Anesthesia maintenance:~Two groups of sevoflurance 1%\~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 \~ 60. PetCO2 was 30 \~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane."
40747085|NCT04786574|DRUG|Tolvaptan (OPC-41061)|Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 2 years.
40747086|NCT04585477|DEVICE|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
40747087|NCT04585477|DRUG|Durvalumab|1500mg intravenous dose or 20mg/kg if weight is 30kg or less, manufactured by AstraZeneca
40747088|NCT00295685|DRUG|Antacids|
40747089|NCT03640182|OTHER|Health management model of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
40747090|NCT00552500|DRUG|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
40747091|NCT03390153|OTHER|semi flexible socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
40747092|NCT03390153|OTHER|rigid fiber socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
40747093|NCT05587647|OTHER|Transition to Adulthood Education Program|"YEGEP was developed by the authors based on the information in the literature, based on the needs of mothers of children who have reached adulthood or are going through. Three training modules are planned in line with current requirements. Education will also be supported by audio-visual and written materials. It is planned that the trainings, which will last for 3 weeks in total, for 1 hour a week for each group, in the form of 3 sessions of 1 hour with these contents, will be held at a disabled center. Titles of training modules:~1. Developmental Period Characteristics of Young Adults with Intellectual Disabilities (Transition to Adulthood, Future Planning / Social Life (employment, peers, etc.)~2. Protecting and Sustaining the Health of Young Adult with Intellectual Disabilities~3. Coping with Stress"
40747094|NCT05615441|DEVICE|Analgesia Nociception Index monitor|Patients will receive remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
40747095|NCT05615441|DEVICE|Standard monitoring|Patients will receive remimazolam-based total intravenous general anesthesia based on hemodynamic monitoring and without nociception monitoring
40747096|NCT01368770|OTHER|Coronary CTA|Coronary CTA using standard protocols
40747097|NCT01368770|OTHER|Stress MPI SPECT|Stress MPI using standard protocols
40747098|NCT00768638|DRUG|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
41270004|NCT00981526|DRUG|Telmisartan|"Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks."
41270005|NCT00981526|DRUG|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
40747099|NCT00768638|DRUG|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
40747100|NCT05551988|OTHER|Retrospective observational study of diabetic foot ulcer|This is a retrospective observational study of antibiotic resistance and risk factors of amputation in diabetic foot ulcer patients
40747101|NCT04710433|DEVICE|Non-invasive Neuromodulation|Sacral nerve stimulation via two adhesive electrodes (single current).
41095421|NCT00077883|DRUG|TLK286, cisplatin|TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).
41095422|NCT05800665|DRUG|RO7656594|RO7656594 will be administered orally at specified dose on specified days.
41095423|NCT01101919|DRUG|CP-690,550|Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
41095424|NCT00666120|OTHER|Enfamil LIPIL with iron|cow's milk based infant formula
41095425|NCT00666120|OTHER|Good Start Supreme with DHA and ARA|partially hydrolzed cow's milk protein
41095426|NCT04357418|OTHER|it is a survey|this interview can be carried out face to face or remotely.
41095427|NCT05121207|DEVICE|Terahertz scanning|Short scans using Terahertz device
41095428|NCT06076759|DRUG|Intrathecal morphine or dexmedetomidine|Intrathecal injection
41095429|NCT04737590|DEVICE|Bioactive glass|Comparison of bioactive glass to allogenic bone in pediatric bone cysts
41270006|NCT00981526|DRUG|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
40747102|NCT04710433|OTHER|Medical and Behavioral Therapy|Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.
40747103|NCT03818932|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
40747104|NCT03818932|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
40747105|NCT03818932|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
40747106|NCT03818932|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
40747107|NCT03818932|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
40747108|NCT03818932|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
40747109|NCT00239980|DRUG|dalteparin|50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
40747110|NCT06341283|DRUG|Abemaciclib and Letrozole/Anastrozole|Take the treatment with Abemaciclib and Letrozole/Anastrozole at the same time.
40747111|NCT06341283|DRUG|Letrozole or Anastrozole|Take the treatment with Letrozole or Anastrozole.
40747112|NCT06341283|DRUG|Abemaciclib and Fulvestrant|Take the treatment with Abemaciclib and Fulvestrant at the same time.
40747113|NCT06341283|DRUG|Fulvestrant|Take the treatment with Fulvestrant only.
40747114|NCT00990769|OTHER|Depth of anesthesia|The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
40747115|NCT01011283|DRUG|decitabine|decitabine 20 mg/m\^2 /day intravenous (IV) infusion for 5 days every 28 days
40747116|NCT01011283|DRUG|azacitidine|azacitidine 75 mg/m\^2 /day subcutaneous (SC) injection for 7 days every 28 days
40747117|NCT04267315|PROCEDURE|Trigger point injection|1mL injections of 1% lidocaine in the muscles identified active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
40747118|NCT04267315|PROCEDURE|Subcutaneous saline injection|0.2mL subcutaneous saline injections superficial to the muscles identified with active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
40747119|NCT04267315|OTHER|Comprehensive Rehabilitation program|Patients in both groups will undergo standard of care rehabilitation delivered by a Physiatrist, which may include Physical Therapy, Occupational Therapy, Exercise Physiologist, Rehabilitation Nurse, Psychologist, as per Physiatrist's prescription. Both the comprehensive rehabilitation program and pain medications will continue to be managed by participant's Physiatrist, who will be blinded to patient's allocation. The researchers will be responsible for TPI and for data collection.
40747120|NCT02717962|DRUG|VAL-083, Dianhydrogalactitol|The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
40747121|NCT03288831|DIETARY_SUPPLEMENT|Gluten|Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.
40747122|NCT03288831|DIETARY_SUPPLEMENT|Placebo|Subjects will drink a mixture of rice water and Tang flavoring one time.
40747123|NCT01093885|DRUG|Ambrisentan|"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."
40747124|NCT02916329|OTHER|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
40747125|NCT04116047|DRUG|Cisplatin|
40747126|NCT04116047|DRUG|Durvalumab|
40747127|NCT04116047|PROCEDURE|Radiotherapy|
40747128|NCT01112267|DRUG|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
40747129|NCT01112267|DRUG|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
40747130|NCT01112267|DRUG|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
40747131|NCT01112267|DRUG|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
40747132|NCT04747002|DRUG|DSP-7888|Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides
41270007|NCT00981526|DRUG|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
40747133|NCT05786300|DEVICE|NMES+|"The Treatment Group will follow the rehabilitation protocol with the addition of the NMES+.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz."
40747134|NCT05786300|PROCEDURE|Rehab|"The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
40747135|NCT00326495|DRUG|Cetuximab|Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
40747136|NCT00326495|DRUG|BAY 43-9006|Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
40747137|NCT00422435|DEVICE|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter|Paclitaxel-Eluting Coronary Stent
40747138|NCT00231192|DRUG|Repaglinide and Insulin|
40747139|NCT01325766|OTHER|Yoga|Yoga 2 sessions per week for 8 weeks
40747140|NCT05929586|OTHER|"The combined C-it DU-it intervention: community data use for ANC"|"Combining data linkage (C-it) with work improvement teams for community data use (DU-it) to improve antenatal clinic uptake. Our short name C-it DU-it (pronounced see-it; do-it) is an acronym intended to convey 'seeing' linked data (C-it) and 'doing' or acting on the data (DU-it)"
40747141|NCT00292994|BEHAVIORAL|Exercise|
40747142|NCT00292994|BEHAVIORAL|Weight Loss|
41270008|NCT00728065|DIETARY_SUPPLEMENT|White Bread|About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water
40747143|NCT05327738|BIOLOGICAL|Atezolizumab|Given IV
40747144|NCT05327738|PROCEDURE|Biopsy|Undergo biopsy
40747145|NCT05327738|DRUG|Cabozantinib S-malate|Given PO
40747146|NCT05327738|RADIATION|Yttrium Y 90 Glass Microspheres|Given intra-arterially
40747147|NCT06329336|BEHAVIORAL|Social Emotional Competence for Children and Parents|This preventive parenting intervention combines behavioral parenting and mindfulness-based well-being practices to support effective parenting.
40747148|NCT00972257|DRUG|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
40747149|NCT00972257|DRUG|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
40747150|NCT03169075|BEHAVIORAL|Supervised physical exercise programs|"A weekly supervised physical activity session of 60 min at the patient's home is planned for 3 months.~These sessions will be supervised by an educator or physiotherapist trained, with respect to the pathology and the clinical study, specifically for this activity (Fédération Française Sport et Cancer) . The proposed exercises will be normalized and adapted to each patient's profile.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ, Evaluation by a coach VAE"
40747151|NCT03169075|BEHAVIORAL|Adapted physical activity|"Program based on the recommendations for performing a physical activity. A booklet containing physical activity recommendations will be given to the patients after randomization.~The weekly sessions at the patients home for the experimental group (Program A) must begin as soon as possible within the 15 days after starting oral targeted therapy.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ"
40747152|NCT06131593|DRUG|TAPB with dexamethasone as an adjuvant to local anesthetics|patients will receive TAPB with dexamethasone as an adjuvant to bupivacaine and lidocaine local anesthetics
40747153|NCT06131593|DRUG|TAPB with methylprednisolone as an adjuvant to local anesthetics|patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
40747154|NCT04041518|PROCEDURE|Autotransplantation|Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
40747155|NCT02413346|DRUG|Sarecycline|Administered based on participant's body weight.
40747156|NCT05903443|DIAGNOSTIC_TEST|ancillary tests|electroencephalogram, short latency somatosensory evoked potential, transcranial Doppler
40747157|NCT00997815|DRUG|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
40747158|NCT00997815|DRUG|Normal saline injection|Using normal saline 2.5 ml injected in control side
40747159|NCT01457027|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
41270009|NCT00728065|DIETARY_SUPPLEMENT|White bread with added 7.32g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
40747160|NCT00372320|GENETIC|Gene Transfer|
40747161|NCT00372320|DRUG|AdhAQP1|
40747162|NCT06398639|OTHER|Polygenic Risk Score (PRS)|"Participants will be put into PRS cohorts based on their genetic data.~All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score."
40747163|NCT04064671|OTHER|Implantation of the Zephyr ZSI 475 FTM erectile implant|Until recently, all penile implants were manufactured for erectile dysfunction in biological males and thus presumed the presence of two corpora cavernosa. In 2016 however, the Swiss company, Zephyr Surgical Implants (ZSI), created a 3-piece inflatable erectile device specifically for female-to-male transsexuals: the Zephyr ZSI 475 FTM. This prosthesis has a realistic gland shape, only one cylinder, and a specific anchorage device made of titanium and silicone to anchor the system to the pubic bone of the patient. These specific features could potentially address the aforementioned issues with implanting erectile devices in the neophallus and hopefully lead to better surgical outcomes in these particular patients.
40747164|NCT01699685|DRUG|QAB149|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
40747165|NCT01699685|DRUG|Placebo|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
40747166|NCT01699685|DRUG|NVA237|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
40747167|NCT05695482|OTHER|Neuromuscular training exercises|The 6-week exercise intervention consists of 25-minute group sessions of Neuromuscular training supervised by a researcher.
40747168|NCT05695482|OTHER|Hip abductors muscular strength exercises|The 6-week exercise intervention consists of of 20-minute group sessions of progressive resistance training, supervised by a researcher.
41270010|NCT00728065|DIETARY_SUPPLEMENT|White bread with added 15.58g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
41270011|NCT00728065|DIETARY_SUPPLEMENT|White bread with added Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water
40747169|NCT03308643|DRUG|Oxytocin|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
40747170|NCT03308643|OTHER|saline|Patients will receive intravenous normal saline infusion just before the surgery after the induction of general anesthesia.
40747171|NCT02744547|DIETARY_SUPPLEMENT|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
40747172|NCT05877612|DEVICE|Implantable spinal cord stimulator|Spinal cord stimulation is possible thanks to implantable spinal cord neurostimulators. These are medical devices, which include a stimulation electrode and an implantable box, designed to deliver electrical stimulation for pain relief. The electrode is implanted in the epidural space in order to stimulate the posterior cords of the spinal cord through the dura mater, at the dorsal or cervical level.
41095430|NCT04944693|OTHER|Different ATS values.|"Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts."
41095431|NCT02253186|DEVICE|Auto-Adjustable MOBIDERM Armsleeve|
41270012|NCT00728065|DIETARY_SUPPLEMENT|Rice milk|Rice milk containing 50g of available carbohydrates
41270013|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 7.32g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica
40747173|NCT06114550|OTHER|High intensity resistance training|The HIRT protocol comprised five exercises (bench press, barbell back squat, deadlift, seated leg flexion, and reverse arm curl) at 80% of 1RM, and 4-5 sets of 12 repetitions with 1-2 minutes of rest period between sets for approximately 60 minutes.
40747174|NCT06114550|OTHER|Low intensity resistance training|For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.
40747175|NCT02588534|DEVICE|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
40747176|NCT02588534|OTHER|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
40747177|NCT04080934|BEHAVIORAL|Swimming|Patients will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum.
40747178|NCT01769365|DRUG|7-day quadruple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
40747179|NCT01769365|DRUG|10-day sequential therapy|pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
40747180|NCT01769365|DRUG|7-day standard triple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
40747181|NCT04231006|RADIATION|High dose rate brachytherapy|High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT
40747182|NCT02715752|DIETARY_SUPPLEMENT|Gene-Eden-VIR/Novirin|
40747183|NCT03184675|OTHER|Functional action observation training|the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.
40747184|NCT03184675|OTHER|General action observation training|step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
40747185|NCT02063269|DRUG|Rivastigmine|9-18mg/rivastigmine for 52 weeks
40747186|NCT05957341|DEVICE|active rTMS: 20min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 20 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
40747187|NCT05957341|DEVICE|active rTMS: 50min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 50 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
40747188|NCT05957341|DEVICE|sham rTMS: 20min inter-session interval|The parameters in this group are the same as in the active rTMS: 20min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
40747189|NCT05957341|DEVICE|sham rTMS: 50min inter-session interval|The parameters in this group are the same as in the active rTMS: 50min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
40747190|NCT00804479|OTHER|No intervention.|
40747191|NCT02526394|BIOLOGICAL|Meningococcal vaccine|Meningococcal vaccination
40747192|NCT02526394|DRUG|Pertussis containing vaccine|Pertussis containing vaccination
40747193|NCT05122715|DEVICE|Additional PET/CT Scan|The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.
40747194|NCT03306121|DRUG|TPF+CCRT|"Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
40747195|NCT03306121|DRUG|CCRT+ PF|"Patients receive cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles 4 weeks after radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
40747196|NCT03432962|OTHER|no intervention - recoding of food recall only|recoding of food recall
40747197|NCT03794063|OTHER|Robson 10 group classification system|WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
41095432|NCT05505929|DEVICE|Biofreedom Ultra|The BioFreedomTM Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
40747198|NCT02546141|OTHER|skimmed milk (UHT)|
40747199|NCT02546141|OTHER|skimmed milk (pasteurized)|
40747200|NCT02546141|OTHER|skimmed yoghurt|
40747201|NCT02546141|OTHER|full-fat milk (UHT)|
40747202|NCT02546141|OTHER|non-homogenized full-fat milk (pasteurized)|
40747203|NCT02546141|OTHER|full-fat cheese (semi-matured)|
40747204|NCT02546141|OTHER|whey protein|
40747205|NCT02546141|OTHER|micellar casein|
40747206|NCT05000437|OTHER|HIIT|3x/week high intensity interval training for 12 weeks
40747207|NCT05556018|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
40747208|NCT05444127|OTHER|Saliva samples|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
40747209|NCT05444127|OTHER|Questionnaire OHIP-14|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
40747210|NCT05444127|OTHER|Thorough dental examination|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
40747211|NCT00299221|DRUG|Tacrolimus|tacrolimus
40747212|NCT00299221|DRUG|combination therapy|MMF
40747213|NCT03017664|OTHER|Peptide-based enteral formula|Peptide-based, higher protein and higher calorie enteral formula
40747214|NCT03017664|OTHER|Retrospective review of enteral tube feeding formula|Enteral formula tube feeding will be retrospectively reviewed
40747215|NCT05480098|DRUG|Brimonidine Topical|Topical brimonidine intraoperatively for hemostasis
40747216|NCT05452512|OTHER|Self monitoring|Self monitoring using smart clinical trial application
40747217|NCT05452512|OTHER|Smart watch assisted monitoring|Smart watch-assisted adherence monitoring
40747218|NCT05452512|DRUG|Vitamin D|Vitamin D self-administration for 3 months
40747219|NCT02029547|DRUG|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
40747220|NCT03345004|BIOLOGICAL|Diamyd|Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)
40747221|NCT03345004|DIETARY_SUPPLEMENT|Vitamin D|Oil suspension of Vitamin D
40747222|NCT03345004|BIOLOGICAL|Placebo for Diamyd|Alhydrogel® only
40747223|NCT03345004|DIETARY_SUPPLEMENT|Placebo for Vitamin D|Placebo oil suspension for Vitamin D
40747224|NCT05428228|OTHER|TP1|Participants will be administered TP1 during one of the experimental visits.
40747225|NCT05428228|OTHER|TP2|Participants will be administered TP2 during one of the experimental visits.
40747226|NCT05428228|OTHER|Placebo|Participants will be administered placebo during one of the experimental visits.
40747227|NCT02105870|DRUG|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
40747228|NCT05376306|BEHAVIORAL|Stress Reduction: MBSR|Four activities, one each week - raising body awareness, sitting meditation, mindful yoga, expanding awareness meditation.
40747229|NCT05376306|BEHAVIORAL|Stress Reduction : PMR|Progressively tensing and releasing each muscle group from head to toe in a specific order.
40747230|NCT00601237|BEHAVIORAL|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
40747231|NCT00601237|BEHAVIORAL|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
40747232|NCT04767412|DEVICE|aerobic exercise training, inspiratory muscle training|All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.
40747233|NCT02246985|DIETARY_SUPPLEMENT|Control|The bread and mayonnaise in this meal does not have vegetable powders incorporated into them. Hence this meal does not contain carotenoids.
40747234|NCT02246985|DIETARY_SUPPLEMENT|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids.
40747235|NCT02246985|DIETARY_SUPPLEMENT|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
40747236|NCT02246985|DIETARY_SUPPLEMENT|Vegetable bread with plain mayonnaise|A vegetable powder (Carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids
40747237|NCT05331482|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
40747238|NCT05331482|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with conventional training protocol.
40747239|NCT03197688|OTHER|Notapplicable|Not applicable as non-interventional study
40747240|NCT03237312|PROCEDURE|Laparoscopic ovarian drilling|The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
40747241|NCT03237312|BIOLOGICAL|Antimullerian hormone|"1. In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~2. In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed."
41095433|NCT00964717|PROCEDURE|real chiropractic|real chiropractic manipulation
41095434|NCT00964717|PROCEDURE|Sham Chiropractic|Placebo stimulation using 'activator' thumper
41095435|NCT01594060|DRUG|Insulin, regular - act rapid|4 shots of regular insulin: 3 before meals and one at bedtime.
41095436|NCT01594060|DRUG|Insulin glulisine, Insulin glargine|1 shot glargine at bedtime 3 shots glulisine before meals
41095437|NCT01982344|DEVICE|mini-exchange-room|
41095438|NCT06300398|DRUG|IAMA-6|IAMA-6 liquid suspension
40747242|NCT01643187|DIETARY_SUPPLEMENT|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
40747243|NCT01643187|DIETARY_SUPPLEMENT|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
40747244|NCT04352296|PROCEDURE|Individualized blood pressure|Individualized blood pressure management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit
40747245|NCT04352296|PROCEDURE|Standard blood pressure|Standard blood pressure management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure \<140 mm Hg, and treatment of hypertension defined by a systolic blood pressure \> 180 mm Hg or diastolic blood pressure \>105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
40747246|NCT01958684|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|LNG-IUS once inserted will be effective for 5 years.
40747247|NCT01958684|DEVICE|Copper-IUD|Copper-IUD once inserted will be effective for more than 10 years.
40747248|NCT03426007|PROCEDURE|Uterine lavage|embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
40747249|NCT04694638|OTHER|Body position change|combined use of prone positioning and high-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) can reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to COVID-19 infection.
40747250|NCT03529149|COMBINATION_PRODUCT|Urapidil Hydrochloride Injection|"Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV\>37cm/s of （middle cerebral artery)MCA, PI \< 1.34cm/s, aMFV\>40cm/s of (basilar artery)BA, PI \< 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure."
40747251|NCT01810107|PROCEDURE|Children Examined with the OCT Probe|The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
40747252|NCT00858052|DEVICE|Saline-filled breast implant [IDEAL IMPLANT (R)]|Breast augmentation
40747253|NCT02087592|BEHAVIORAL|Structured exercise training plus mediterranean diet|
40747254|NCT02382900|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine|dose scheme (0 and 6 month)
40747255|NCT05924230|OTHER|RL 10ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 1) will receive Ringer's lactate 10ml/kg before induction in the receiving area
40747256|NCT05924230|OTHER|RL 15ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 2) will receive Ringer's lactate 15ml/kg before induction in the receiving area
40747257|NCT05313464|OTHER|parent-pushed enteral feeding|skin-to-skin enteral nutrition pushed by the parent
40747258|NCT05313464|OTHER|syringe-push enteral feeding|skin to skin nutrition with syringe pump
40747259|NCT05019053|BEHAVIORAL|Coping Crew|Coping Crew consists of five 60-minute virtual intervention sessions coinciding with five weeks of EMI. Participants will receive psychoeducation, challenge cognitive biases or mythbust, and participate in behavioral exposure and behavioral experiments. An EMI component of this treatment will be included for the purpose of treatment monitoring and homework tracking. Participation in this EMI component involves the daily report of levels of anxiety, depression, stress, and loneliness. When participants endorse elevated levels on any of these constructs, they will receive a targeted message reminding them of the topics covered in COPING CREW. One month after the intervention session, COPING CREW participants will complete follow-up questionnaires and interview. Participants will also participate in a feedback session 3 months after the intervention.
40747260|NCT00902525|DRUG|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
40747261|NCT04512872|BIOLOGICAL|CT-P41|60 mg/mL single dose, Solution for injection in PFS
40747262|NCT04512872|BIOLOGICAL|EU-approved Prolia|60 mg/mL single dose, Solution for injection in PFS
40747263|NCT03159949|OTHER|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second cycling sprints on an exercise bike with three minutes rest in between, and a one-minute cool-down.
40747264|NCT03159949|OTHER|PR-REHIIT|"PR-REHIIT participants will come into the lab on 3 separate occasions on the training days, which occur 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint on a cycle ergometer, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
40747265|NCT01727154|BIOLOGICAL|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
40747266|NCT00871000|BIOLOGICAL|Boostrix Polio™ 711866|Single dose, intramuscular administration.
40747267|NCT00871000|BIOLOGICAL|Priorix Tetra TM 208136|Single dose, subcutaneously.
40747268|NCT00871000|BIOLOGICAL|Tetravac TM|Single dose, intramuscular administration.
41095439|NCT06300398|DRUG|Placebo|Placebo-to-match IAMA-6 liquid suspension
41095440|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
40747269|NCT02471742|PROCEDURE|NAC-sparing mastectomy|patients treated with mastectomy with conservation of nipple-areola complex
40747270|NCT02471742|PROCEDURE|conventional mastectomy|patients treated with mastectomy without conservation of nipple-areola complex
40747271|NCT04060745|OTHER|cooling using a water-perfused vest|"BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed"
40747272|NCT04060745|OTHER|thermoneutrality|In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
40747273|NCT01362270|DEVICE|Verum Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
40747274|NCT01362270|DEVICE|Sham Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
40747275|NCT01355367|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
40747276|NCT05703776|BEHAVIORAL|Nordic Walking|Nordic Walking (NW) is an aerobic physical activity where regular walking is enhanced by the addition of the active use of specifically designed NW poles. The physical strain is distributed in a balanced way to various muscle groups of the whole body.
40747277|NCT03342859|DRUG|Vilaprisan, BAY1002670|Daily single oral doses of 2 mg vilaprisan over 8-12 weeks
40747278|NCT03342859|DRUG|Ulipristal|Daily single oral doses of 5 mg ulipristal over 8-12 weeks
40747279|NCT06025370|OTHER|Prone Position|"All healthy volunteers will be positioned in prone position, on a bed equipped with a mapping pressure system.~The volunteers will spend 5 minutes in each of the positions corresponding to the study groups."
40747280|NCT04949295|DEVICE|ocular surface analyzer|Using ocular surface analyzer for Inspection
40747281|NCT05285150|OTHER|Survey|It´s a survey
40747282|NCT00211939|DRUG|calcium acetate|667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
40747283|NCT00211939|DRUG|sevelamer|1-3 tablets t.i.d, titrated to serum phosphorus level
40747284|NCT00211939|DRUG|atorvastatin|20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
40747285|NCT00076609|DRUG|PHY906|
40747286|NCT00076609|DRUG|capecitabine|
40747287|NCT04145934|BEHAVIORAL|ADSTEP|ADSTEP is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. ADSTEP focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid.
40747288|NCT00188838|BEHAVIORAL|Psychoeduction|
40747289|NCT00188838|BEHAVIORAL|Cognitive-Behavioral Therapy|
40747290|NCT05616897|BEHAVIORAL|Physiological responses during sustained CPR|
41270014|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 15.58g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica
41095441|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
40747291|NCT01026038|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
40747292|NCT04192344|DRUG|ABSK021|ABSK021 oral capsule
41095442|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
40747293|NCT03870386|PROCEDURE|EUS-BD with LAMS|Endoscopic ultrasound guided insertion of lumen apposing metal stent forming a choledochoduodenostomy
40747294|NCT03870386|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography to localize and cannulate the bile duct using the guidewire-assisted technique.
40747295|NCT00236431|DRUG|Galantamine hydrobromide|
40747296|NCT02557789|DRUG|Lefamulin|Lefamulin administered iv or orally in the fasted state and orally in the fed state
40747297|NCT04171999|OTHER|Community Rx-Hunger (CRx-H)|"The CRx-H Intervention provides dosages of health content that offer assistance for food insecurity and other health-related social needs. A caregiver randomized to the intervention will receive a hard-copy print-out of their tailored list of resources to address food insecurity. A member of our research team will deliver this list and provide a brief educational component which includes: a brief, structured script about the common problem of food insecurity in households with children and co-occuring HRSNs, review of the resource list which includes nearby, vetted resources to address these needs and coaching on how to activate resources on the list. Prior to discharge, the caregiver will receive a duplicate copy of the list of resources. After discharge, the caregiver will receive text messages at a frequency based on the Critical Time Intervention (CTI) Model, from baseline to 3 months post discharge, in order to receive ongoing support by a research team member."
40747298|NCT00083707|DRUG|Thalidomide|
40747299|NCT04754074|BEHAVIORAL|Education|Weekly education related to behavior change
41095443|NCT00031291|DRUG|Anthrax Immune Globulin|
41095444|NCT01497444|DRUG|hypoxia-activated prodrug TH-302|
41095445|NCT01497444|DRUG|sorafenib tosylate|
41095446|NCT04551417|PROCEDURE|Free graft urethroplasty|Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
41095447|NCT03990025|DIAGNOSTIC_TEST|Linked Color Imaging|Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.
41270015|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 24g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
41270016|NCT00079378|DRUG|decitabine|Given IV
40747300|NCT04754074|BEHAVIORAL|Personalized coaching|Weekly calls with personalized coaches in behavior modification, nutrition, and physical activity/exercise.
40747301|NCT04754074|BEHAVIORAL|Weekly behavior modification challenges|Weekly challenges to address behavior change
40747302|NCT02686255|OTHER|complete blood count|complete blood count during follow up in the heart institute
40747303|NCT01140139|BIOLOGICAL|HIV DNA Vaccine|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
40747304|NCT03316560|BIOLOGICAL|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
40747305|NCT05662943|DRUG|Intravitreal aflibercept injection|Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
40747306|NCT04656119|OTHER|there is no intervention in our study|there is no intervention in our study
40747307|NCT01793935|DRUG|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
40747308|NCT01793935|DRUG|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
40747309|NCT02782468|DRUG|Pevonedistat 25 mg/m^2|Pevonedistat 25 mg/m\^2 intravenous infusion.
40747310|NCT02782468|DRUG|Pevonedistat 44 mg/m^2|Pevonedistat 44 mg/m\^2 intravenous infusion.
40747311|NCT02782468|DRUG|Pevonedistat 10 mg/m^2|Pevonedistat 10 mg/m\^2 intravenous infusion.
40747312|NCT02782468|DRUG|Pevonedistat 20 mg/m^2|Pevonedistat 20 mg/m\^2 intravenous infusion.
40747313|NCT02782468|DRUG|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.
40747314|NCT05145114|PROCEDURE|THERAPEUTIC POSITIONS|Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.
40747315|NCT02603029|OTHER|Placebo cream|Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
40747316|NCT02603029|OTHER|Belinal cream|Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
40747317|NCT04374552|DRUG|Hydroxychloroquine sulfate &Azithromycin|Drug - Hydroxychloroquine sulfate \&Azithromycin
40747318|NCT04374552|DRUG|Placebo|Drug - placebo
40747319|NCT02898506|DRUG|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
40747320|NCT02898506|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
40747321|NCT05698212|DIAGNOSTIC_TEST|MetriDx|Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record
40747322|NCT01104012|BIOLOGICAL|"Classification as asthmatic or rhinitis only via proteomic analysis"|Proteomic profiles are established for each patient using plasma and serum samples
40747323|NCT01104012|BIOLOGICAL|"Classification as asthmatic or rhinitis only according to a metacholine test"|A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
40747324|NCT00180453|DEVICE|Coronary artery drug eluting stent placement|Coronary artery drug eluting stent placement
40747325|NCT00180453|DEVICE|Coronary artery stent placement|Coronary artery stent placement
40747326|NCT00727337|BEHAVIORAL|LACE-computer|Computerized Auditory Training
40747327|NCT00727337|BEHAVIORAL|PLACEBO-Directed listening|Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along
40747328|NCT00727337|BEHAVIORAL|CONTROL|No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids
40747329|NCT00727337|BEHAVIORAL|Lace-DVD|DVD based Auditory Training
40747330|NCT00290238|DEVICE|Vertis Percutaneous Neuromodulation Therapy (PNT)|"* Ten PNT sessions in eleven weeks~* On average, one PNT session per week~* Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Continuous 50 Hz current~ * Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform~ * Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level"
40747331|NCT00290238|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"* Ten TENS sessions in eleven weeks~* On average, one TENS session per week~* Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Current at 2 Hz-low frequency~ * Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec~ * Intensity titrated according to subject's sensory threshold~ * To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device."
40747332|NCT03712852|PROCEDURE|PRF+CAF treated patients|Patients will be treated by coronally advanced flap with addition of PRF membrane
40747333|NCT03712852|PROCEDURE|SCTG+ CAF treated patients|Patients will be treated by coronally advanced flap with addition of SCTG graft
40747334|NCT03712852|PROCEDURE|CAF treated patients|Patients will be treated by coronally advanced flap
40747335|NCT01460771|DEVICE|TDCS (Transcranial Direct-current Stimulation)|active TDCS
40747336|NCT01460771|DEVICE|sham TDCS (Transcranial Direct-current Stimulation)|TDCS at 0mA
40747337|NCT05403073|PROCEDURE|Ultrasound guided Suprainguinal Iliac Fascia Nerve Block.|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
40747338|NCT03142750|DEVICE|Gastrostomy tube dressing|Two types of dressings to secure gastrostomy tube in children
40747339|NCT04396275|OTHER|Food-1|Cooked whole navy beans (300 kcal)
40747340|NCT04396275|OTHER|Food-2|Cooked whole yellow split peas (300 kcal)
40747341|NCT04396275|OTHER|Food-3|Cooked rice considered as control (300 kcal)
40747342|NCT05474677|PROCEDURE|closure of the abdominal fascia|The abdomen will be closed in intervention group with continuous PDS 2\\0 sutures and size zero in control group.
40747343|NCT03411551|PROCEDURE|regional anesthesia|The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release
40747344|NCT00837460|OTHER|rehabilitation|4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
40747345|NCT02288871|RADIATION|Cardiac CT-scan|"ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).~In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves."
40747346|NCT04764253|BEHAVIORAL|Modified Sodium Watcher Program + Digital Self-Monitoring|Participants randomized to the experimental group will be asked to follow the modified Sodium Watchers Program intervention along with goal setting for low salt foods. Each participant will be registered to assign a unique ID in the Connected Health Platform developed by the Center on Smart and Connected Health Technologies at UT Health Science Center San Antonio and each account from the individuals' wireless and wearable devices (Fitbit and BP monitor) will be connected to his or her unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor. Through the Connected Health Platform, the Fitbit app and BP monitor will transmit the data of the intervention group to the research team.
40747347|NCT04764253|BEHAVIORAL|Usual care + Digital Self-Monitoring|Participants randomized to the control group will be asked to follow usual care which is based on their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium-restricted diet and take medications as prescribed. The participants will receive wireless and wearable devices (Fitbit wristband, BP monitor). Each participant will be registered to assign a unique ID in the Connected Health Platform at the baseline and each account from the individual's wireless and wearable devices (Fitbit and BP monitor) will be connected to their unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
40747348|NCT01422902|OTHER|Plasticity-based Cognitive Training|
40747349|NCT01422902|OTHER|Non-plasticity-based Training|Computer games
40747350|NCT02390375|DRUG|DW-0929|5/10mg
40747351|NCT02390375|DRUG|DW-0929|10/10mg
40747352|NCT02390375|DRUG|DW-0929|20/10mg
40747353|NCT02390375|DRUG|Rosuvastatin|5mg F/U study: DW-0929 5/10mg
40747354|NCT02390375|DRUG|Rosuvastatin|10mg F/U study: DW-0929 10/10mg
40747355|NCT02390375|DRUG|Rosuvastatin|20mg F/U study: DW-0929 20/10mg
40747356|NCT05025917|DIETARY_SUPPLEMENT|Shatavari|Shatavari root powder
41095448|NCT03990025|DIAGNOSTIC_TEST|White Light Imaging|White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.
41095449|NCT02949817|DEVICE|digital rehabilitation system with wearable multi-IMU(inertial measurement unit) sensors (Rapael kids)|1.The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with pediatric brain injury patients. 20 of All 40 children will receive the conventional occupational therapy and additional video-game based rehabilitation therapy, 30 minutes daily 5 times per week, for 4 weeks.
41270017|NCT00079378|DRUG|valproic acid|Given orally
40747357|NCT05025917|DIETARY_SUPPLEMENT|Magnesium stearate|Magnesium stearate powder
40747358|NCT04723069|DRUG|Control Group|metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.
40747359|NCT04723069|DRUG|Test Group|metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
40747360|NCT00361244|DRUG|SU011248|Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
40747361|NCT00361244|DRUG|Irinotecan|Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
40747362|NCT00361244|DRUG|Cetuximab|Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
40747363|NCT05182177|DEVICE|SurgiMend PRS|SurgiMend® PRS and SurgiMend® PRS Meshed are intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend® PRS and SurgiMend® PRS Meshed are specifically indicated for plastic and reconstructive surgery, including breast reconstruction.
40747364|NCT02737059|DRUG|Naloxegol|25mg daily
40747365|NCT02737059|DRUG|Codeine|30mg 4 times daily
40747366|NCT02737059|DRUG|codeine placebo|4 times daily (placebo will be made to match the codeine)
40747367|NCT02737059|DRUG|naloxegol placebo|placebo will match naloxegol, given daily
40747368|NCT03870321|OTHER|Core training|"In the first week different types of abdominal exercises will be performed: standard, with trunk rotation, extension of the back raising the upper extremity of the body and legs, extension of the back raising one arm and the contralateral leg. In the same way, the subject will raise from the quadruped position one arm and the contralateral leg on each side, and we will ask for the exercise of the front plate, positioning itself in a position of four support points: feet and elbows. When performing the rear bridge exercise the subject will raise the trunk resting on both feet, while in the lateral bridge exercise will be done with support on the right and left side. All exercises will be done for 30 seconds, in 3 series).~During the next three weeks we will continue with the same training, but for each week we will increase 10 seconds per exercise."
41270018|NCT00079378|OTHER|pharmacological study|Correlative studies
40747369|NCT01334853|OTHER|No drug will be used|Biomarker
40747370|NCT01334853|OTHER|No drug will be used|Biomarker
40747371|NCT04606719|PROCEDURE|Advanced Platelet Rich fibrin|Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
40747372|NCT01398475|DRUG|LY3009104|Administered orally
40747373|NCT01334775|PROCEDURE|Open anterior inguinal hernia repair|Placement of a surgical mesh in open anterior inguinal hernia repair.
40747374|NCT06018168|OTHER|Skincare Routine|"Morning:~1. GENTLECLEAN - Wash with a quarter-sized amount of lukewarm water. Pat skin dry after.~2 CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin 3. YOUARESUNSHINE - Apply generously and evenly as the last step in the skincare routine (before makeup).~Night:~1. VITAMINSCRUB - Wet your face with lukewarm water \& apply a quarter-sized amount to wet palms. Lather until foamy. Gently massage the scrub using circular motions for 5-10 seconds. Rinse with lukewarm water and pat dry.~2. CLEARITY - Apply 2-3 pumps and massage into the skin avoiding the eye area. Let sit for 10-15 minutes. Do not wash off.~3. CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin~4. HYDRAGLOW - Apply a dime-size amount of lotion and massage into the face"
40747375|NCT06018168|DIETARY_SUPPLEMENT|MINDBODYSKIN Supplement|Participants will take 3 capsules daily with a meal. The MINDBODYSKIN acne supplement contains Vitamin A (6,100mcg per serving of 3 capsules), Vitamin B12, Vitamin B-5, 5-Hydroxytryptophan (5-HTP), 3,3'-Diindolymethane (DIM), a proprietary liver blend of milk thistle, dandelion extract and L-glutathione, turmeric root extract, a proprietary digestive blend of protease and betaine hydrochloride, and silicon dioxide.
40747376|NCT01366105|DEVICE|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
41095450|NCT02949817|OTHER|Conventional OT group|2. Conventional OT group will recieve the conventional occupational therapy and one more conventional occupational therapy additionally. The additional occupational therapy training will be performed 30 minutes daily 5 times per week, for 4 weeks.
41095451|NCT00353067|DRUG|veliflapon (DG-031)|
41095452|NCT00657280|DRUG|Sitagliptin|No one is blinded to the treatments.
41270019|NCT00079378|OTHER|laboratory biomarker analysis|Correlative studies
40747377|NCT04131192|DRUG|Z650|250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal
40747378|NCT04131192|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles
40747379|NCT01142921|DEVICE|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
40747380|NCT01142921|DEVICE|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
40747381|NCT06121232|DEVICE|Abbott® DRG / Abbott®/Medtronic® SCS|Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.
40747382|NCT06121232|OTHER|Control Group|Participants will not receive any intervention
40747383|NCT02200575|DRUG|Telmisartan|
40747384|NCT03520387|PROCEDURE|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves, using electrode placement parallel to the medial branches, 18G electrodes or larger, and 2 lesions per nerve.
40747385|NCT03520387|PROCEDURE|Simulated LRFA with targeted steroid injections|Performed in an identical fashion to the experimental arm (LRFA), except for medial branch lesioning, which will not be done in simulated LRFA, and 2) the simulated LRFA control group will receive an injection of triamcinolone acetonide at each site where a radiofrequency lesion would normally be applied.
40747386|NCT03520387|BEHAVIORAL|AcTIVE-CBT|AcTIVE-CBT involves a standardized CBT protocol for pain, delivered via a video telehealth interface. AcTIVE-CBT also incorporates use of an activity tracker to provide objective feedback on activity levels, which can inform participants' and providers' impressions of goals and progress.
40747387|NCT03520387|BEHAVIORAL|TBSCE|TBSCE control is a focused program of CBT involving an initial 60-minute telephone education session by a psychologist; the provision of printed educational materials on chronic pain self-management, and a workbook for CBT self-management; and structured, written plans for weekly practice, reading and homework using the workbook.
40747388|NCT02369692|DEVICE|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
40747389|NCT01890005|DRUG|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
40747390|NCT01890005|DRUG|Placebo|Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
40747391|NCT01767389|OTHER|The GLP-1 receptor agonist users|The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide
40747392|NCT01767389|OTHER|DPP-4 inhibitor users|DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
41095453|NCT03120676|DRUG|Atezolizumab|All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
40747393|NCT01767389|OTHER|Other ADA users|Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
41095454|NCT04600180|PROCEDURE|sigmoidoscopies and and venous blood sampling|Sigmoidoscopies will be performed at baseline and during immunotherapy. During these procedures biopsies will be taken from the sigmoid and rectum. At the same timepoints, venous blood samples will be taken.
41095455|NCT03161522|DRUG|Capecitabine|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
41095456|NCT03161522|DRUG|Chemotherapy|Receive induction chemotherapy
41095457|NCT03161522|PROCEDURE|Conventional Surgery|Undergo surgery
41095458|NCT03161522|DRUG|Fluorouracil|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
41095459|NCT03161522|RADIATION|Radiation Therapy|Undergo RT
41270020|NCT01995929|PROCEDURE|transnasal functional endoscopy|
41270021|NCT05920213|DRUG|Polyethylene Glycols|280g/ 24 hours for 5 days
41270022|NCT05920213|DRUG|Lactulose oral solution|60-120 ml per day for 5 days
40747394|NCT05520047|BEHAVIORAL|COVID19-severe Patient|Behavioral and social test assessment
40747395|NCT05520047|BEHAVIORAL|family of COVID19-severe Patient|Behavioral and social test assessment
40747396|NCT02828085|BIOLOGICAL|Nasal swab|Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
40747397|NCT04015687|DRUG|AG-881|Supplied as uncoated tablets.
40747398|NCT04015687|DRUG|Lamotrigine|Supplied as tablets of LAMICTAL® or generic equivalent.
40747399|NCT03259308|DRUG|Ontamalimab|Participants will receive 1 mL of ontamalimab sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
40747400|NCT03259308|DRUG|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
40747401|NCT05860530|DRUG|The test olaparib tablet (T)|The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours
40747402|NCT05860530|DRUG|The reference olaparib tablet (R)|The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours
40747403|NCT03390192|DEVICE|Dual-mode stimulation|1Hz rTMS over contralesional primary motor cortex and anodal tDCS over ipsilesional primary motor cortex are simultaneously simulated.
40747404|NCT03390192|DEVICE|Single sham stimulation|1Hz rTMS over contralesional primary motor cortex and sham tDCS (no stimulation) over ipsilesional primary motor cortex are simultaneously simulated.
40747405|NCT05456893|PROCEDURE|Procedure: endoscopic biopsy|Per-endoscopic biopsies
40747406|NCT05456893|PROCEDURE|Blood sampling|Blood sampling
40747407|NCT05456893|PROCEDURE|stool sampling|stool sampling
40747408|NCT00663351|DEVICE|Reflection Ceramic-Ceramic Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
40747409|NCT00663351|DEVICE|Reflection FSO V Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
40747410|NCT00250861|DRUG|Rituximab|
40747411|NCT00250861|DRUG|Aldesleukin|
40747412|NCT03536377|OTHER|very low calorie liquid diet|Phase 1: very low calorie liquid formulation Phase 2: Nutritionally balanced solid diet Phase 3: Educational material
40747413|NCT03175458|PROCEDURE|sinus lift,implant placement,tenting|elevation of the sinus membrane then insertion of the implants without any bone graft material( graft-less) for augmentation
40747414|NCT03175458|PROCEDURE|sinus lift,implant placement,bovine bone|sinus membrane elevation then placement of the implants together with deproteinized bovine bone substitute as a graft material for augmentation
40747415|NCT00283582|DRUG|rhTPO|
40747416|NCT01016002|DRUG|Temoporfin|"Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan"
40747417|NCT01773902|DIETARY_SUPPLEMENT|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if \<1500g b.w. or 4.0g/kg/d of enteral protein if \>1500g b.w. until 1 week before discharge
40747418|NCT01773902|DIETARY_SUPPLEMENT|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
40747419|NCT01773902|DIETARY_SUPPLEMENT|Standard Protein Supplementation|Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
40747420|NCT00303043|PROCEDURE|Mixed venous saturation monitoring|Mixed venous saturation monitoring
40747421|NCT00229528|DRUG|Paxil-CR|
40747422|NCT04834115|DRUG|Ivermectin Tablets|Oral ivermectin at a one time dose
40747423|NCT04834115|OTHER|Placebo|Oral placebo at a one time dose
40747424|NCT03941821|DRUG|Glecaprevir/Pibrentasvir|Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment
40747425|NCT01197027|BEHAVIORAL|Standard counseling|Standard HIV counseling
40747426|NCT04488094|DRUG|[18F]FSPG|A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of \[18F\]FSPG.
40747427|NCT04681300|OTHER|Skin biopsy|a skin sample will be taken using a 4 mm punch biopsy in lesional skin
40747428|NCT04681300|OTHER|Plastic surgery remnants|healthy skin from plastic surgery interventions
40747429|NCT02959762|DIETARY_SUPPLEMENT|Placebo-Control|two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
40747430|NCT02959762|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
40747431|NCT02959762|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
40747432|NCT04077359|DIAGNOSTIC_TEST|CT|the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.
40747433|NCT00577408|DRUG|depot naltrexone|On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).
40747434|NCT00577408|DRUG|Oral Naltrexone|For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
40747435|NCT01276418|DEVICE|CO2 laser|Ablation and coagulation of soft tissue
40747436|NCT03699800|OTHER|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
40747437|NCT05842707|DRUG|dualCAR-NK19/70 cell|Given by IV (vein)
40747438|NCT02819375|DRUG|Propofol|1 mg/kg propofol
40747439|NCT02819375|DRUG|Propofol+Remifentanil|0.5 mg/kg propofol+0.5 mg/kg remifentanil
40747440|NCT02819375|DRUG|Propofol+Ketamine|0.5 mg/kg propofol and 0.5 mg/kg ketamine
40747441|NCT04995107|DEVICE|Electro Press needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
40747442|NCT00724503|DEVICE|SIR-Spheres yttrium-90 microspheres|"SIR-Spheres microspheres (yttrium-90 \[Y-90\] labelled resin microspheres), hepatic artery injection administered on Day 3 or 4 of cycle 1.~mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
40747443|NCT00724503|DRUG|Systemic chemotherapy (FOLFOX)|"mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
41095460|NCT05507203|DRUG|ABX464|Administered once daily in the morning with food
41095461|NCT05507203|DRUG|Placebo|Administered once daily in the morning with food
41095462|NCT01949584|DEVICE|nasal continuous positive airway pressure less than or equal to 6 cm H2O|Low level continuous positive airway pressure delivered during sleep.
41095463|NCT06140849|DIAGNOSTIC_TEST|artificial intelligence model|artificial intelligence model of anterior open bite diagnosis
41095464|NCT05916885|OTHER|short-intensity modified CIMT and conventional therapy|an experimental group receiving short-intensity modified CIMT and conventional therapy
40747444|NCT03331081|OTHER|Bladder Training|The patient will participate in a class in which the physiotherapist will provide the following information: on the anatomy and function of the MAP, using figures; on bladder function; guidelines on the positioning and voiding habits and the definition and main risk factors responsible for urinary incontinence. The bladder training will consist of a program of time micturition to increase bladder capacity and the interval between urinations. Urge suppression strategies will be targeted, and include distraction, relaxation, breathing, and MAP contraction (quick flicks).
40747445|NCT03331081|OTHER|TMAP|There will be 36 monthly series of home training (totaling at the end of the 3 months of treatment 108 series) performed 3x / week, 3x / day. The training protocol consists of three daily TMAP series. One series consists of 8 maximum voluntary contractions, with maintenance of the contraction of 6 to 10 seconds (type I muscle fibers), with twice the rest time between contractions, followed by three to five rapid contractions (muscle fibers type II ). The protocol will total 24 contractions of MAP per day performed, which will be divided in the morning (8 contractions), late (8 contractions) and night (8 contractions).
40747446|NCT03331081|OTHER|Bladder Training + TMAP|Will perform the exercises of the bladder training group and the TMAP in an associated way.
40747447|NCT05814835|DRUG|2-4 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
40747448|NCT05814835|DRUG|4-6 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
40747449|NCT05814835|DRUG|6-8 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
40747450|NCT00002940|DRUG|hydroxyurea|
40747451|NCT05599425|BEHAVIORAL|Enhanced Healthy Living Education|24-session healthy living education program, with enhanced content about health beliefs and mechanisms of behavior change
41095465|NCT05916885|OTHER|conventional therapy alone|a control group receiving conventional therapy alone.
41095466|NCT06199687|OTHER|Use of Virtual Reality|Use of Virtual Reality after After Thyroid-Parathyroid Surgery
41270023|NCT05920213|DRUG|L-ornithine L-aspartate|30g/24 hours in 3 divided doses for 5 days
41270024|NCT05617521|DEVICE|Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device
40747452|NCT05599425|BEHAVIORAL|Basic Healthy Living Education|24-session healthy living education program
40747453|NCT01172301|DIETARY_SUPPLEMENT|Essential amino acid intake + Leucine vs total AA supplement|7 g as bolus
40747454|NCT03155477|DIETARY_SUPPLEMENT|"Cholecalciferol and C. Xanthorrhiza"|Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months
40747455|NCT03155477|DIETARY_SUPPLEMENT|"Cholecalciferol and placebo"|Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
40747456|NCT04862208|DIETARY_SUPPLEMENT|Maltodextrin supplement|maltodextrin (25g in 12 oz water) 1 hour pre-exercise
40747457|NCT04862208|DIETARY_SUPPLEMENT|Whey supplement|whey (25g in 12 oz water) 1 hour pre-exercise
40747458|NCT04862208|DIETARY_SUPPLEMENT|Water|non-caloric control (12 oz flavored water) 1 hour pre-exercise
40747459|NCT04862208|DIETARY_SUPPLEMENT|Maltodextrin supplement|maltodextrin (25g in 12 oz water) with no exercise
40747460|NCT01724190|DRUG|Vitamin D|
40747461|NCT01724190|DRUG|Placebo|
40747462|NCT06034379|DEVICE|eSpectacle Clinical prototype (CP1) device|The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.
40747463|NCT06034379|DRUG|0.01% atropine|Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
40747464|NCT03144206|DRUG|Hyperbaric oxygen|Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
40747465|NCT00902967|DRUG|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
40747466|NCT00902967|DRUG|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
40747467|NCT01879657|DIAGNOSTIC_TEST|68Ga-DOTATATE injection and PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
40747468|NCT02383485|BEHAVIORAL|Exercise|Heart rate monitors worn by each child at each session
40747469|NCT02383485|BEHAVIORAL|After-school program|Supervised recreational program with token economy
40747470|NCT06494163|BEHAVIORAL|Exercise|The MICT and HIIT intervention groups will complete supervised virtual exercise sessions for 12 weeks using Zoom care or Microsoft Teams as a backup resource. The appointments will be scheduled and conducted 2 days per week. Initially, exercise intensity will be determined from participants' peak HR achieved during a baseline CPET.
40747471|NCT05333367|OTHER|Samples collection|Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)
40747472|NCT05838040|OTHER|General exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
40747473|NCT05838040|OTHER|General exercises with tranversus abdmoinis contraction|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. In addition to these exercises, the Back to Fitness Program includes the activation of the transverse abdominis muscle, which is an important stabilizing muscle in the core. The activation of this muscle is done through specific exercises and techniques, and is intended to improve core stability and reduce the risk of further back injuries.
40747474|NCT04279262|OTHER|attendance by community first responders for medical emergencies|The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).
40747475|NCT01175720|PROCEDURE|Periodontal surgery to gingival recessions|Test and control technique to treat gingival recessions.
40747476|NCT05720247|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is a safe and effective test using ultrasound to measure liver elasticity and can detect early signs of liver disease even before a patient shows symptoms.
40747477|NCT05720247|BEHAVIORAL|Brief Intervention|Short counselling session to discuss drinking behavior, risks to health and available sources of treatment and support.
40747478|NCT00881244|DRUG|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
40747479|NCT05375799|OTHER|Clinical Observation|"This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO.~All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects )."
41095467|NCT04837495|PROCEDURE|right stellate ganglion block|The skin should be anaesthetised with lidocaine 2%. Using a lateral approach and in-plane imaging, a blunt regional anaesthesia needle should be advanced deep to the carotid sheath towards the longus colli muscle. Following careful aspiration, inject 10 ml lidocaine 2% that will result in expansion of the fascia of the longus colli. Confirmation of the SGB success can be detected by warming of left upper limb and left Horner's syndrome.
40747480|NCT02820636|BEHAVIORAL|S-CBT|The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 9 sessions (1 family, 5 individual \& 3 caretakers sessions). Topics include: understanding the suicidal crisis, identity in adolescence, chain analysis, communication skills, the power of thought and decision making, parenting skills, rearing in a different culture, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, emotional regulation, social interactions, activities, substance abuse, family communication \& trauma). The treatment plan is adjusted to adolescents' needs. Family and primary caregiver sessions are flexible, depending on the family/caregivers' needs. Participants have received an adequate course of treatment if they at least complete the core sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.
40747481|NCT02820636|BEHAVIORAL|Treatment as Usual|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
40747482|NCT03915899|BEHAVIORAL|WIN (Welcome Incoming Neighbor)|WINs will conduct active community surveillance to rapidly identify and welcome in-migrants, provide them with information about the availability of CHP, utilize a motivational interviewing approach to encourage CHP adoption, refer in-migrants to free services, and follow-up in-migrants to assess and further encourage engagement in CHP.
40747483|NCT02339207|DRUG|AL-335 matching placebo|
40747484|NCT02339207|DRUG|AL-335|
40747485|NCT03605056|DRUG|chidamide|20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle
40747486|NCT03605056|DRUG|lenalidomide|25 mg/d, will be administered orally on Days 1-14 each 21 day cycle
40747487|NCT03605056|DRUG|dexamethasone|40mg weekly, will be administered orally or intravenously
40747488|NCT02855983|PROCEDURE|Fat Grafting|Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
40747489|NCT00694122|DRUG|Lantus (glargine)|Described in Arm Description
40747490|NCT01170130|DRUG|Lidocaine 1% (sterile)|during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
40747491|NCT05791331|OTHER|Surfactant administration following lung mechanics assessment in addition to clinical assessment|Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O\*s /L
40747492|NCT05791331|OTHER|Surfactant administration following clinical assessment|Surfactant is administered following oxygenation-based criteria
40747493|NCT01653886|OTHER|Breakfast (1-2 hours, in the morning)|You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
40747494|NCT01653886|OTHER|Lunch (1-2 Hours, at midday)|You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
40747495|NCT01653886|OTHER|Dinner (1-2 hours, in the afternoon)|You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
40747496|NCT00000987|DRUG|Bleomycin sulfate|
40747497|NCT00000987|DRUG|Vincristine sulfate|
40747498|NCT00000987|DRUG|Doxorubicin hydrochloride|
40747499|NCT00000987|DRUG|Zidovudine|
40747500|NCT06144307|PROCEDURE|plane block|injection of local anesthetic to the myofascial plane
40747501|NCT04107051|DRUG|Nalmefene Hydrochloride Hydrate|Oral administration of nalmefene hydrochloride hydrate
40747502|NCT06283030|DEVICE|Hypoglossal nerve stimulation|Device-mediated stimulation of the hypoglossal nerve
40747503|NCT03707730|DIETARY_SUPPLEMENT|AGY|oral AGY taken prior to meals
40747504|NCT03707730|OTHER|placebo|oral placebo taken prior to meals
40747505|NCT05478746|DEVICE|BioNourish, a component of the Flourish HEC kit|BioNourish is a vaginal moisturizing gel which obtained FDA 510k clearance in 2020. It is one component of the full system being tested. The main intervention is to use this kit to improve the vaginal microbiome.
40747506|NCT05478746|OTHER|Control - no intervention|No intervention; participants only receive routine care.
40747507|NCT05162274|DRUG|Lazertinib(G001)|Current formulation
40747508|NCT05162274|DRUG|Lazertinib(G002)|New formulation
40747509|NCT05455866|DEVICE|central venous catheter|collection and descriptionof central venous catheter-related complications
40747510|NCT06091384|OTHER|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths per day at 75% of maximal inspiratory pressure, six days a week, during 6 weeks.
41270025|NCT05617521|DEVICE|Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device. It will be loosened just prior the procedure.
41270026|NCT06211855|DIAGNOSTIC_TEST|doppler assesment|In all cases, the measurement, including UA PI and MCA PI, was measured with a 6-4 MHz convex transabdominal probe. All measurements were made by an obstetrician (Ş.D.) with 28 years of experience. Doppler measurements were collected from the proximal third of the MCA and the free-floating segment of the umbilical cord, ensuring that the angle of insonation was as close to zero as feasible and that fetal movements were absent
40747511|NCT04109963|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).
40747512|NCT01006408|PROCEDURE|Low Level Laser|Low Level Laser twice a week for 8 weeks
40747513|NCT01006408|PROCEDURE|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
40747514|NCT02032784|DRUG|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
40747515|NCT02032784|OTHER|No Octreotide|No drug
40747516|NCT01164969|DRUG|Antibiotics to which H. pylori can not develope resistance|Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
40747517|NCT02054195|BEHAVIORAL|Training|Training model is consist of effort to provide intra uterine device post placental by organising a special guided training model for post-placental IUD insertion by pushing the head of IUD using index and middle finger close enough to fundal part of uterus to prevent expulsion.
40747518|NCT02054195|BEHAVIORAL|No Training|Control of Training model is without training on effort of pushing the head of IUD using index and middle finger to uterine fundus.
40747519|NCT05335018|DRUG|Glofitamab, Poseltinib, Lenalidomide|"Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
40747520|NCT03915379|DRUG|JNJ-67571244|JNJ-67571244 will be administered.
40747521|NCT05345314|PROCEDURE|Narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
40747522|NCT04003571|BEHAVIORAL|Augmented Reality with Functional Electrical Stimulation group|Experimental group contains 30 minutes augmented reality combined with functional electrical stimulation training, and 30 minutes traditional physiotherapy. Augmented reality includes treadmill and balance exercise. Functional electrical stimulation applies on tibialis anterior muscle. Traditional physiotherapy includes rolling, sitting, standing, overground walking, facilitation of the paretic limbs, and so on.
40747523|NCT04003571|BEHAVIORAL|Traditional physiotherapy|Traditional physiotherapy includes treadmill and balance training for 30 minutes as well as rolling, sitting, standing, overground walking, facilitation of the paretic limbs for another 30 minutes .
40747524|NCT01933425|DRUG|rocuronium|
40747525|NCT01933425|DRUG|sugammadex|
40747526|NCT01933425|DRUG|placebo|
40747527|NCT01433588|DEVICE|The Calmer|This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
40747528|NCT01433588|OTHER|Standard of Care|Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
40747529|NCT05741502|DRUG|Clozapine|We will assess inflammatory/immune marker labs
40747530|NCT05741502|DRUG|Antipsychotics,Other (non-Clozapine)|We will assess monitor inflammatory/immune marker lab
40747531|NCT01365572|DEVICE|Xiene V stent, Endeavor Resolute stent|for each lesion, randomized either Xience V stent or Endeavor Resolute stent
40747532|NCT05934253|DRUG|Chloroprocaine ophthalmic gel 3%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
40747533|NCT06447675|OTHER|Hyperthermic Baths|The intervention will consist of 12 weeks of repeated (2x/day) 20-min body immersions.
40747534|NCT05752409|DRUG|The median dose of esketamine|1mg•kg-1propofol and 0.5 mg•kg-1esketamine for general anesthesia induction.
40747535|NCT05752409|DRUG|The high dose of esketamine|1mg•kg-1propofol and 0.75 mg•kg-1esketamine for general anesthesia induction.
40747536|NCT05752409|DRUG|Propofol|2mg•kg-1propofol for general anesthesia induction.
40747537|NCT00092469|BIOLOGICAL|V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine|
40747538|NCT03983109|DEVICE|EpiFaith loss of resistance detect syringe|An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.
40747539|NCT01850940|DRUG|Tolvaptan|Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
40747540|NCT01850940|OTHER|conventional thearpy|conventional therapy with salt limitation ,et al
40747541|NCT00315315|PROCEDURE|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
40747542|NCT00315315|PROCEDURE|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
40747543|NCT00315315|PROCEDURE|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
41095468|NCT00885508|DRUG|Lenalidomide|"1. Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~2. Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~3. Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
41095469|NCT06314594|PROCEDURE|Conventional treatment|Patients will randomly assigned to routine treatment group (control group) and individualized treatment model group (intervention group). All patients will observed and intervened for 4 months. Patients in the control treatment group will follow the treatment plan in the 2016SOSORT guidelines
40747544|NCT05540067|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified challenges related to the COVID-19 pandemic, mental health, and social support. Interventionists will help participants identify potential challenges to acceptance. At the second session, participants will practice acceptance-based coping skills and a social support behavioral plan will be developed. These discussions will help the participant clarify how best to align their values with decisions on how to manage their mental health and social support in the context of the COVID-19 pandemic.
40747545|NCT05540067|OTHER|Treatment-as-Usual (TAU)|TAU includes brief mental health screening, consultation with providers, and referrals to psychotherapy and/or psychiatric medication.
40747546|NCT05349500|BEHAVIORAL|OA CARE Intervention|"Once assigned, participants will be contacted by the OA CARE Navigator to coordinate initiating a YMCA Medical Membership. Then, YMCA personnel will contact the participant to schedule the first Weight Loss Program (Program) group session. The Program will be delivered in groups with other OA CARE participants. Participants will also have access to all exercise facilities and programs at the YMCA during the study, and will be assigned a YMCA health coach.~After initiation of the YMCA Medical Membership, the OA CARE Navigator will discuss participant's interests in referrals to other services related to osteoarthritis (OA) management. The Navigator will provide the participant's primary care provider (PCP) with a summary of this discussion and help the participant connect to any programs or resources that do not require provider referrals."
40747547|NCT05349500|BEHAVIORAL|Usual Care control group|Participants assigned to the usual care group will receive no additional treatment from the study for about 12 months. However, this group will be offered a 12-month Medical Membership to a local YMCA after completing the final assessment.
40747548|NCT04613570|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy|"In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;~* Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;~* EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:~* If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;~* If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;~* Antrum, incisura and corpus fragments should be sent in 3 separate vials;"
40747549|NCT05033457|PROCEDURE|unilateral biportal endoscopy technique or percutaneous endoscopic transforaminal discectomy|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group.Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group.
40747550|NCT04957524|DEVICE|iStim TENS unit and Transvaginal Probe|"iStim TENS unit and Transvaginal Probe are both commercially available products. TENS units work by delivering small electrical impulses through electrodes either attached to the skin or through a transvaginal probe.~iStim transvaginal probe will be inserted vaginally to provide transvaginal electrical stimulation."
40747551|NCT01982227|DRUG|indocyanine green|intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
40747552|NCT00440570|DEVICE|Low levels of amplitude-modulated electromagnetic fields|
40747553|NCT00440570|DEVICE|Emitter of low levels of amplitude-modulated electromagnetic fields|
40747554|NCT00362323|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
40747555|NCT00362323|DRUG|Metformin|500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
40747556|NCT00294567|DRUG|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
40747557|NCT02122523|PROCEDURE|Near-Infrared (NIR) dye Indocyanin Green (ICG)|
40747558|NCT06305546|DRUG|Chlorhexidine Gluconate|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
40747559|NCT06305546|DRUG|Metronidazole|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
40747560|NCT06305546|DRUG|combination gel (chlorhexidine and metronidazole)|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
40747561|NCT06305546|DRUG|Placebo|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
40747562|NCT05858229|DRUG|RP1|Recombinant Herpes Simplex Virus Type 1 - hGM CSF/GALV-GP-R-
41095470|NCT06314594|BEHAVIORAL|intervention treatment|"Patients will be input into the health management platform. The optimal treatment scheme will be then determined through data calculation and sent to individuals (or their families) or schools for implementation under the guidance of the platform. It is important to note that the specific treatment plan varied from person to person. Patients were observed and intervened for a period of 4 months.~1. Massage therapy~2. Posture guidance~3. Schroeder\&#39;s gymnastics therapy~4. Bioelectric stimulation therapy"
41270027|NCT03521947|DIAGNOSTIC_TEST|Complete blood picture|Iaboratory investigation
41270028|NCT02000609|DRUG|CHF 1535 NEXThaler 800/48|
41095471|NCT00240643|DRUG|SB424323|
41270029|NCT02000609|DRUG|CHF 1535 NEXThaler 200/12|
41270030|NCT02000609|DRUG|CHF 1535 NEXThaler PLACEBO|
41270031|NCT02000609|DRUG|CHF 1535 pMDI 200/12|
41270032|NCT02000609|DRUG|CHF1535 pMDI 800/48|
41270033|NCT04175470|DRUG|Bevacizumab|10 mg/kg intravenously every three weeks
41270034|NCT04175470|DIETARY_SUPPLEMENT|Tocotrienol|Capsules, 300 mg orally three times daily
40747563|NCT01841853|BEHAVIORAL|Senior meetings|The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
40747564|NCT01943825|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
40747565|NCT01943825|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
41270035|NCT03539432|DRUG|Gemfibrozil 600 MG|Gemfibrozil capsules (600 mg) taken twice per day
41270036|NCT03539432|DRUG|Placebo oral capsule|Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
41270037|NCT00014092|BIOLOGICAL|aldesleukin|
41270038|NCT00014092|BIOLOGICAL|recombinant interferon alfa|
41270039|NCT00014092|BIOLOGICAL|sargramostim|
41095472|NCT01702896|DRUG|Interleukin-2|Interleukin-2
41095473|NCT02321358|BEHAVIORAL|Two-time implementation intention|Will be given intervention and booster at six weeks
41095474|NCT02321358|BEHAVIORAL|One-time implementation intention|Will only be given the intervention once
41095475|NCT02321358|BEHAVIORAL|Sham Comparator|Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
41095476|NCT02321358|BEHAVIORAL|Physical Activity Materials|Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
41095477|NCT00038792|DRUG|Recombinant Human Keratinocyte Growth Factor|
41095478|NCT06116019|RADIATION|Online adaptive radiation therapy|Daily cone-beam CT based online adaptive radiation therapy
41095479|NCT04295538|DRUG|Elezanumab|Solution for infusion; Intravenous (IV)
41270040|NCT00014092|DRUG|temozolomide|
41270041|NCT00124280|DRUG|RAD001|
40747566|NCT01943825|BIOLOGICAL|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
40747567|NCT01943825|BIOLOGICAL|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
40747568|NCT06309758|OTHER|Breinzorg|"The BreinZorg multidomain lifestyle website comprises 16 domains, namely (1) physical activity, (2) healthy diet, (3) smoking, (4) alcohol, (5) sleep, (6) cognitive activity (7) social activity, (8) diabetes, (9) blood pressure, (10) cholesterol, (11) heart- and vascular diseases, (12) kidney diseases, (13) hearing damage, (14) obesity, (15) anxiety, and (16) depression. These 16 modules are separated into three big themes: mood, lifestyle, and body.~Each module consists of the following:~1. General information on the risk factor;~2. Tips on how to improve and decrease the risk;~3. Quiz questions about the risk factor, giving extra knowledge/ in a playful and interactive manner;~4. Examples of SMART goals fitting the risk factor (goal examples are given in a Specific, Measurable, Achievable, Relevant, and Time-Bound manner)."
40747569|NCT04368910|DRUG|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.
40747570|NCT04368910|DRUG|Chloroquine|Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.
40747571|NCT05880043|DRUG|GIC-102|GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
40747572|NCT05880043|DRUG|GIC-102|GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
40747573|NCT01495273|PROCEDURE|Transtracheal injection|Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
40747574|NCT01495273|PROCEDURE|Transtracheal injection|Control group will undergo transtracheal injection with a standard needle/syringe assembly.
41095480|NCT04295538|DRUG|Placebo|Solution for infusion; Intravenous (IV)
41095481|NCT05397808|OTHER|Pilates Training|The group that received pilates training.
41095482|NCT05397808|OTHER|breathing and relaxation exercises|The group who received breathing and relaxation exercises with a home program.
41095483|NCT02890693|BEHAVIORAL|interdisciplinary lifestyle and psychosocial intervention|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
41270042|NCT00709826|DRUG|gemcitabine|Gemcitabine: per package insert.
41095484|NCT03315403|DIAGNOSTIC_TEST|LytA targeted quantitative polymerase chain reaction (qPCR)|LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)
41095485|NCT05493722|OTHER|PS and OS stimulation order 1|PS, OS, OS
41095486|NCT05493722|OTHER|PS and OS stimulation order 2|OS, PS, OS
41095487|NCT05493722|OTHER|PS and OS stimulation order 3|OS, OS, PS
41270043|NCT00709826|DRUG|placebo|placebo: 100 mg tablets, 400 mg/day
41270044|NCT00709826|DRUG|Erlotinib|Erlotinib - per package insert.
41270045|NCT00709826|DRUG|apricoxib|apricoxib: 100mg tablets, given orally
41270046|NCT03823391|DRUG|ABBV-3373|ABBV-3373 is administered as intravenous (IV) infusion
41270047|NCT03823391|DRUG|Placebo for ABBV-3373|Placebo for ABBV-3373 is administered as IV infusion
41270048|NCT03823391|DRUG|Adalimumab|Adalimumab is administered as subcutaneous (SC) injection
41270049|NCT03823391|DRUG|Placebo for adalimumab|Placebo for adalimumab is administered as subcutaneous (SC) injection
41270050|NCT01790490|DRUG|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
41270051|NCT01790490|DRUG|Ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
41270052|NCT01790490|DRUG|Lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
41270053|NCT01321047|DRUG|Propofol|propofol (0.5 mg/kg body weight; 10 mg if age \> 70 or ASA class III-IV)
40747575|NCT04354571|PROCEDURE|Erector spinae plane block|An ultrasound-guided Erector spinae plane block was performed with the patient lying on the his side and the surgical side on the top. After skin disinfection, sterile draping was be placed and the ultrasound probe was sheathed. The level of the block was the transverse process of L2. The block was performed using a 9-12 MHz linear probe (LOGIQe, GE Healthcare, USA), which was placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) was identified, and a 22 G, 50 mm insulated needle (Sonoplex Stim, Pajunk, Germany) was inserted cranio-caudally in plane between the transverse process and the fascia of the ESM. After negative aspiration, 0.3 ml/kg of 0.25% bupivacaine was injected to confirm the correct position by visualizing the solution lifting the ESM off the transverse process.
40747576|NCT04354571|PROCEDURE|caudal block|caudal block was performed using anatomical landmarks and ultrasound guided and confirmed with a concentration of bupivacaine of 0.25%.
40747577|NCT04332120|PROCEDURE|tubal sterilization|
40747578|NCT00177632|BEHAVIORAL|behavioral weight loss|
40747579|NCT02130011|OTHER|with feeding/fluid instruction|No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
40747580|NCT00888082|DRUG|Goserelin acetate|3.6 mg depot injectable preparation
40747581|NCT00875459|DRUG|VIAject™|Subcutaneous injection 25 IU/mL
40747582|NCT03959319|OTHER|Movement Pattern Training|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
40747583|NCT03959319|OTHER|Manual Therapy|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
40747584|NCT01586182|RADIATION|Stereotactic Body Radiotherapy|Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
40747585|NCT01452789|DRUG|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
40747586|NCT01452789|DRUG|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
40747587|NCT06178913|OTHER|Exercise intervention|The exercise intervention method is a circuit training method that combines strength training and aerobic exercise forms and consists of a total of 12 movements. Performing movements 1 to 12 in order is 1 set. After completing the set, when the heart rate returns to the plateau (less than 59% of maximum heart rate), proceed to the next set, for a total of 3 sets.
40747588|NCT05669066|BEHAVIORAL|Mindful meditation|Adding mindful meditation to pre- and post-operative care for patients who are having a TKA
40747589|NCT02955927|DRUG|0.01% atropine eye drops|
40747590|NCT02955927|DEVICE|ortho-k|
40747591|NCT03751787|OTHER|cranial osteopathy|two sessions at three weeks intervals
40747592|NCT03751787|OTHER|comfort massage|manipulation, comfort massage, standardized and not affecting the skull
40747593|NCT05967559|OTHER|Online Flipped Learning Group|The experimental group is the group that receives online flipped learning training.
40747594|NCT05967559|OTHER|Traditional learning Group|The control group is the group that received traditional learning training.
40747595|NCT00604383|DRUG|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
40747596|NCT00604383|DRUG|placebo|1 tablet, orally, daily, up to 42 months
40747597|NCT02826551|DRUG|Marcaine|Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
40747598|NCT02826551|OTHER|Ice|
40747599|NCT02826551|DRUG|Percocet|
40747600|NCT02826551|DEVICE|Knee Brace and Crutches|
40747601|NCT05298839|DIAGNOSTIC_TEST|Evaluation of core muscle endurance, hand grip strength, upper extremity functional performance, reaction time, agility performance and 3 minutes step test|"Core muscle endurance was evaluated with extensor muscle endurance test, flexor muscle endurance test and lateral muscle endurance test.~Hand Grip Strength was evaluated with Jamar hand dynamometer. Upper extremity functional performance was evaluated with health ball throwing test.~Reaction time was evaluated with Fitlight Trainer. Agility performance was evaluated with Pro-agility test. Cardiovascular endurance was evaluated with the 3-minute step test."
40747602|NCT04817579|DEVICE|Digital photography combined with eLABor_aid shade analyzing software|ELABor_aid is a new approach to objective shade communication and shade reproduction in dentistry, based on numeric quantification obtained from standardized RGB (red-green-blue) images, and the formulation of a patient personal shade recipe using trichromatic subtractive color mixing laws, thus abandoning the use of visual assessment and shade guides entirely. This approach is currently enjoying increasing popularity for its ease of use, reliability as well as for its practically oriented features like its imaging ability or the digital try-in.
41095488|NCT01070056|BEHAVIORAL|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
40747603|NCT04817579|DEVICE|Spectrophotometer|Spectrophotometric measurement methods employing computer calculations, based on color science and theories, allow quantitative evaluation which is objective and appears to be more accurate.
40747604|NCT04817579|DEVICE|Conventional visual shade matching|Visual shade matching is the most common method, in which a color standard from a commercially available dental shade guide is compared to and matched with the target tooth.
40747605|NCT01332201|DRUG|Advagraf|oral
40747606|NCT01332201|DRUG|Prograf|oral
40747607|NCT02425488|BEHAVIORAL|Nursing therapeutics education|"Educational intervention will focus on~1. Appropriate lifestyles~2. Early recognition of signs/prodromal symptoms of HF~3. Early recognition of signs of inflammation of the ICD-pocket~4. Good management of the device~1) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI"
40747608|NCT05706285|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
40747609|NCT03033693|OTHER|Bispectral index will be targeted at 50|The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
40747610|NCT03033693|OTHER|Bispectral index will be targeted at 35|The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
40747611|NCT03234452|DIETARY_SUPPLEMENT|Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
40747612|NCT03234452|DIETARY_SUPPLEMENT|Placebo Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
40747613|NCT04107363|PROCEDURE|Oropharyngeal aspiration before changing the position of the patient|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes. After the oropharyngeal aspiration was completed, the patient's position was changed."
40747614|NCT04107363|OTHER|Control group:|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
40747615|NCT01198548|DRUG|leucovorin calcium|Given IV
40747616|NCT01198548|BIOLOGICAL|bevacizumab|Given IV
40747617|NCT01198548|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
40747618|NCT01198548|DRUG|fluorouracil|Given IV
40747619|NCT01198548|DRUG|oxaliplatin|Given IV
40747620|NCT01198548|OTHER|pharmacological study|Correlative studies
40747621|NCT03005756|DEVICE|Needle guiding robot|This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.
40747622|NCT02261142|DEVICE|Multifocal TENS garment (Mollii®)|Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
40747623|NCT00291915|DRUG|Adalimumab|
40747624|NCT00291915|DRUG|Methotrexate|
40747625|NCT02313597|PROCEDURE|SETON|In seton treatment, initially Hydrogen peroxide will be applied to the external opening with a 10-cc syringe, and the internal opening will be located by direct visualization of the anal canal via proctoscope. A probe will be inserted into the external opening and carefully maneuvered through the internal opening. Silk 1/0 suture will be then tied to the tip of the probe, which will be then squeezed out of the external opening. The suture will be then tied around the sphincter and through fistula tract. Later, the seton will be tightened at four-week intervals under local anesthesia until the suture cut through the sphincter.
40747626|NCT02313597|PROCEDURE|VAAFT|Patients assigned to the VAAFT group will receive the following procedure. The external opening will be widened with a probe, and a fistulascope will be inserted to delineate the primary and secondary tracts and locate the internal opening. The internal opening will be then stitched with Vicryl™ (Polyglactin 910) 2-0 suture through the anal route with the help of a proctoscope. The tract of the fistula will be washed and debrided through the scope and cauterized. Finally, the external opening will be excised and will be sent for biopsy.
40747627|NCT05501405|OTHER|Electroencephalogram and eye-tracking recordings|"Participants will perform two tasks: recognize the expression (explicit recognition of the expression) or detect the change in color of the cross (implicit processing of the expression). Each participant will perform two tasks x 6 models x 5 expressions, i.e. 60 stimulations, for a stimulation duration of approximately 30 minutes.~Recognition of the emotional facial expression with a choice among 5 possibilities. Two neutral faces of the same person will be presented side by side. When the participant has looked at the central fixation cross for one second, one of the two faces will produce an expression. The participant will have to indicate as quickly as possible which expression it is, while his or her eye movements are recorded. Each participant will have to recognize 5 expressions x 8 models, i.e. 40 trials for a duration of approximately 5 to 10 minutes"
40747628|NCT03299335|OTHER|Blood collection|assay of CPK and anti-cN-1A antibodies
40747629|NCT04706403|BEHAVIORAL|Communication from a physician about the COVID-19 Vaccine|Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.
40747630|NCT03573856|BEHAVIORAL|Active Living|Participants will be provided with education and support for diet and lifestyle modification related to healthy eating and active living.
40747631|NCT03573856|OTHER|Health and Safety|Participants will be provided with education related to general health and safety topics.
40747632|NCT00309244|DRUG|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
40747633|NCT00309244|DRUG|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
40747634|NCT03483090|DIETARY_SUPPLEMENT|Swisse High Strength Deep Sea Krill Oil|Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.
40747635|NCT03483090|OTHER|Placebo|No therapeutic effect
40747636|NCT06258291|DEVICE|Hemosystem REBOOT|The HemoSystem REBOOT will selectively remove three mediators largely contributing to sepsis-induced immunosuppression, from extracorporeal circulation based on magnetic beads.
40747637|NCT02113566|DRUG|Acetaminophen 1000mg|Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
40747638|NCT06195605|DEVICE|Restylane-L|Using a small gauge metal hub needle, two injections of CL-HA dermal filler (Restylane-L) will be performed, each into a small area (approximately 2 x 2 cm) of the mid-dermis of a forearm of a subject. Each injection will be 0.5 cc in volume, and will be approximately 2 cm apart from each other
40747639|NCT06195605|DEVICE|Vehicle|Two injections of vehicle will be performed in the same manner as Restylane-L and in the same forearm, totaling 4 injections. A plastic template will be used to track the location of the injections, relative to landmarks on the skin.
40747640|NCT01635179|PROCEDURE|Cricoid pressure|The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
40747641|NCT02669537|DEVICE|GoPro Camera|The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
40747642|NCT00000975|DRUG|Itraconazole|
40747643|NCT01106950|BIOLOGICAL|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is \< or = 8 x 10\^7 nucleated cells/kilogram.
40747644|NCT01106950|DRUG|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
40747645|NCT01106950|DRUG|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
40747646|NCT01106950|DRUG|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
40747647|NCT01106950|PROCEDURE|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
40747648|NCT01106950|DRUG|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m\^2 every other day for 6 doses).
40747649|NCT04680143|DRUG|Systemic erythropoietin injection|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
40747650|NCT05212142|BEHAVIORAL|verbal education|Participants will receive oral health anticipatory guidance in the form of verbal and written education alongside the same preventive follow up and recall appointment schedule.
40747651|NCT05212142|BEHAVIORAL|verbal education, visual aids, and motivational interviewing|Participants will receive oral health anticipatory guidance through a combination preventive strategy using motivational interviewing, individualized goal setting, visual aids, and verbal education alongside a preventive follow up and recall appointment schedule
40747652|NCT03828383|DEVICE|In-home technology|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using a trusted circle of friends and family who are encouraged to stay in contact and share photos and videos with the caregiver and person with dementia via the digital display.
40747653|NCT03828383|DEVICE|Limited in-home technology|Intelligent bot monitors the in-home water leak sensor and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome conditions occur.
40747654|NCT04891653|DRUG|BR790|Subjects will receive oral administration of BR790.
40747655|NCT05930470|OTHER|Magnetic Mitohormesis Therapy|The MMT device that will be used in the trial will be the QuantumTx BIXEPS Fitness and Wellness. The apparatus will provide pulsed electromagnetic fields at flux densities 1.5 mT. During the treatment period, participants will receive PEMF therapy during two ten-minute sessions each week for a total of 12 weeks. The treatment period will be preceded or followed by 12 weeks of twice-weekly sham treatments depending on randomization.
40747656|NCT02470377|DEVICE|Transcranial Magnetic Stimulation|A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
40747657|NCT05424692|DRUG|5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
40747658|NCT00523666|DRUG|Galantamine (Reminyl®)|8mg - 24mg
40747659|NCT00523666|DRUG|Placebo/Galantamine (Reminyl®)|"Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg"
40747660|NCT00682838|BEHAVIORAL|Self-management|Self-management
40747661|NCT00682838|BEHAVIORAL|Telemonitored care|Telemonitored care
40747662|NCT04922762|BEHAVIORAL|Moderate Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 3 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
41270054|NCT01321047|DRUG|BPS|midazolam (0.05 mg/kg body weight; 1 mg if age \> 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age \> 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
40747663|NCT04922762|BEHAVIORAL|High Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 31 minutes/day 10 minute warm up at 50% of heart rate maximum 2 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 7 minute cool down at 50% of heart rate maximum~Week 2 3 days/week for 38 minutes/day 10 minute warm up at 50% of heart rate maximum 3 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 2 TIMES 7minute cool down at 50% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day 10 minute warm up at 50% of heart rate maximum 4 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 3 TIMES 7 minute cool down at 50% of heart rate maximum"
40747664|NCT04922762|BEHAVIORAL|Moderate Intensity, High Volume Exercise Training|"Week 1 5 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 5 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 5 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
40747665|NCT01426451|OTHER|Group tutoring program|Academic in-class intervention that focuses on differentiated academic instruction and improved overall academic adjustment. In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes, once a week), with the teacher present in the classroom.
40747666|NCT01426451|OTHER|Theatre workshops|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
40747667|NCT02625740|DEVICE|Local exposition of target lesion to high intensity, low-frequency ultrasound|Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
40747668|NCT02625740|DEVICE|drug eluting ballon angioplasty|Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
40747669|NCT02625740|DEVICE|Flow occlusion with an angioplasty balloon|Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
40747670|NCT02625740|DRUG|Local Paclitaxel infusion|Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
40747671|NCT02625740|PROCEDURE|Angiographic control|A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
40747672|NCT02320396|DRUG|Desloratadine 5 mg|Desloratadine 5 mg tablets
40747673|NCT02320396|DRUG|Placebo|Placebo tablets
41270055|NCT00692367|BEHAVIORAL|Physical Activity|1. Physical activity group: Subjects will be progressed to 4-5 days per week, 30-45 min per session (120-180 min per week) of moderate intensity exercise. 2. Control (educational) group: Subjects will receive their usual care following surgery that in addition to their weight loss.
40747674|NCT02451735|BEHAVIORAL|Video and Booklet|Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.
40747675|NCT02451735|BEHAVIORAL|Factsheet|Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
40747676|NCT00129896|DRUG|Myocet|Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
40747677|NCT00129896|DRUG|Taxotere|Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
40747678|NCT00129896|DRUG|Herceptin|Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles
40747679|NCT06130202|DEVICE|Echocardiographic findings|Echocardiographic findings as Markers of Subclinical Cardiac dysfunction in Patients with Non-Alcoholic Fatty Liver Disease
40747680|NCT00977561|DRUG|figitumumab|Figitumumab (20 mg/kg)
40747681|NCT00977561|DRUG|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
40747682|NCT00977561|DRUG|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
40747683|NCT00977561|DRUG|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
40747684|NCT00977561|DRUG|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
40747685|NCT04209842|DEVICE|gastric balloon|non surgical weight loss via placement of gastric balloon
40747686|NCT03722030|OTHER|Baseline Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
40747687|NCT03722030|BEHAVIORAL|Strength-Training|2 sessions per week (20-40 min), home-based resistance training
40747688|NCT03722030|OTHER|Mid-point Measures|Accelerometer (steps)
40747689|NCT03722030|OTHER|Post-Study Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
40747690|NCT00143351|DRUG|Ziprasidone|
40747691|NCT02887586|OTHER|auricular needling|Patients will be treated with auricular needling for 4 weeks. 4-8 specific auricular acupoints are selected unilaterally at a time, and alternate to another side every 2-3 days, treatment will last for 4 consecutive weeks. The following 4 ear acupoints points will be selected for every patient: Ear Shenmen, Stoma, Spleen, and Subcortex. Other ear acupoints including Triple Energizer, Liver, Sympathetic Nerve and Smallintestine will be selected based on the condition of patients. Treatment will be performed by a registered Chinese medicine practitioner.
40747692|NCT06293950|BIOLOGICAL|WJMSC|- Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.
40747693|NCT04508985|OTHER|Temporarily holding the RAAS inhibitor [intervention]|Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
41270056|NCT04507009|DEVICE|Ozone|topical gaseous ozone application
40747694|NCT04508985|OTHER|RAAS inhibitor [continued standard of care]|No intervention, Continuation RAAS inhibitor \[continued standard of care\].
40747695|NCT04717180|BEHAVIORAL|aphasia rehabilitation using software program or conventional therapy|Patients were randomized into two groups: group I who received therapy using the software aphasia rehabilitation program and group II who received conventional (traditional) language therapy
40747696|NCT06222047|OTHER|breast milk|give breast milk before the OG catheter insertion
40747697|NCT06222047|OTHER|dextrose|give %20 dextrose before the OG catheter insertion
40747698|NCT00211900|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine|single IM dose totalling 200 mcg of conjugate
40747699|NCT00396669|DRUG|Bupropion|We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
40747700|NCT00396669|DRUG|Bupropion|Brain imaging after treatment with Bupropion
40747701|NCT00002619|BIOLOGICAL|filgrastim|
40747702|NCT00002619|DRUG|carboplatin|
40747703|NCT00002619|DRUG|thiotepa|
40747704|NCT00002619|PROCEDURE|autologous bone marrow transplantation|
40747705|NCT00002619|PROCEDURE|peripheral blood stem cell transplantation|
40747706|NCT01539889|RADIATION|99mTC-PulmoBind|DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
40747707|NCT03413917|OTHER|Analysis of genomic markers in uterine atony|No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.
40747708|NCT02874352|DEVICE|high resolution impedance manometry with Automated Impedance Manometry analysis|
40747709|NCT04329741|BEHAVIORAL|6-week basic dog obedience training course|The class focused on teaching owners how to better communicate with their dog and covered basic commands (e.g., sit, down, watch), loose leash walking, and polite greetings, among other skills. The importance of dog walking was implied, but not specifically emphasized. Classes were held once per week for 45 minutes, with 5-8 students per class.
40747710|NCT01659541|DEVICE|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
40747711|NCT01659541|PROCEDURE|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
40747712|NCT02993302|DRUG|1α-D3|patients were given PTU and 1α-D3
40747713|NCT02993302|DRUG|Placebos|patients were given PTU and placebos
40747714|NCT03770975|PROCEDURE|delayed implant with immediate provisionaliztion and soft tissue graft|delayed implant placement in the esthetic zone with immediate provisinalization and placement of a connective tissue graft buccal
40747715|NCT03770975|PROCEDURE|delayed implant placement with immediate provisionalization|delayed implant placement with immediate provisionalization
40747716|NCT00038246|DRUG|Estramustine|140 mg by mouth (po) three times a day on Days 1-5, 8-12
40747717|NCT00038246|DRUG|Thalidomide|200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.
40747718|NCT00038246|DRUG|Paclitaxel (Taxol)|100 mg/m\^2 by vein (IV) over 3 hours Day 3 and Day 10
40747719|NCT00032487|DRUG|Insulin|Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
40747720|NCT00032487|DRUG|Glimepiride|Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
40747721|NCT00032487|DRUG|Rosiglitazone|Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
40747722|NCT00032487|DRUG|Metformin|Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
40747723|NCT06163638|BEHAVIORAL|GRANDPACT Project|To investigate whether grandparents and grandchildren are more co-physically active, have a better cognitive and physical function, psychosocial well-being, quality of the family relationship due to the intervention, we compare the intervention phase (B) with a pre phase (A), a in between period (A) and another intervention period (B)
40747724|NCT00943202|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine, 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm or in the anterolateral thigh muscle (1 injection in each arm or each thigh if receiving 2 doses).
40747725|NCT00943202|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Licensed seasonal trivalent influenza vaccine (TIV) (2009-2010 season). For subjects greater than or equal to 6 - \<36 months, licensed TIV will be administered as a single 0.25 mL intramuscular (IM) injection in the deltoid muscle of the arm or in the anterolateral thigh muscle. For subjects greater than or equal to 36 months - 17 years, licensed TIV will be administered as a single 0.5 mL IM injection in the deltoid muscle of the arm or in the anterolateral thigh muscle.
40747726|NCT03476252|DIAGNOSTIC_TEST|pentraxin 3|serum pentraxin 3 level will be assessed using ELISA kits
40747727|NCT05240885|OTHER|Stable tracer infusion in a postabsorptive state|Multiple stable-labeled tracers of amino acids, ketoacids, glycerol, short-chain fatty acids
40747728|NCT01009697|DRUG|Codeine Sulfate|15 mg, 30 mg, and 60 mg tablets
40747729|NCT00884598|DRUG|cilengitide|
40747730|NCT00884598|OTHER|pharmacological study|
40747731|NCT00884598|RADIATION|radiation therapy|
40747732|NCT04386837|OTHER|Turkish Aphasia Rapid Test|Same
40747733|NCT00005795|DRUG|arsenic trioxide|
40747734|NCT00560404|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
40747735|NCT00560404|DRUG|Epoetin alfa|As prescribed
41270057|NCT04507009|OTHER|CGF|concentrated growth factor (CGF) application
40747736|NCT00950092|DEVICE|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
40747737|NCT00000446|DRUG|sertraline (Zoloft)|
40747738|NCT01572688|DRUG|Melphalan|powder for injection, 200mg/m2, uses after reconstituted within 24 hours
40747739|NCT02802475|BIOLOGICAL|vena punction|
40747740|NCT00004859|DRUG|carboplatin|Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
40747741|NCT00004859|DRUG|paclitaxel|Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour
40747742|NCT00004859|DRUG|thalidomide|Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.
40747743|NCT00004859|RADIATION|radiation therapy|Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
40747744|NCT02922660|DRUG|desflurane|method of anesthesia maintenance with desflurane ranged from 0.5\~1.5 MAC during the procedure
40747745|NCT02922660|PROCEDURE|total intravenous anesthesia|method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
40747746|NCT02922660|PROCEDURE|inhalation anesthesia|method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
40747747|NCT02922660|DRUG|Propofol|using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI
40747748|NCT02922660|DRUG|Remifentanil|using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
40747749|NCT03693508|DRUG|Genvoya®|Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
40747750|NCT00999570|OTHER|Specialty training for knee surgeons|
40747751|NCT00066937|DRUG|Nortriptyline Oral Capsule|Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.
40747752|NCT00066937|DRUG|Benztropine Oral Product|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.
41270058|NCT04507009|OTHER|Traditional treatment|Alvogyl application
41270059|NCT03775837|DIETARY_SUPPLEMENT|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
41270060|NCT03775837|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks
41270061|NCT00208637|BEHAVIORAL|moderate carbohydrate, high protein diet (MCHP)|
41270062|NCT00208637|BEHAVIORAL|high carbohydrate-high fibre (HCHF) diet|
41270063|NCT06141083|DIETARY_SUPPLEMENT|TCI188 Probiotic|take two tablets per day
41270064|NCT06141083|DIETARY_SUPPLEMENT|Placebo|take two tablets per day
40747753|NCT00066937|BEHAVIORAL|CBT|Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.
40747754|NCT00066937|BEHAVIORAL|Disease MGT|Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.
40747755|NCT05364489|DRUG|Bevacizumab combined with Oxaliplatin and TAS-102|"Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).~Oxaliplatin: 85 mg/m2, repeated every 2 weeks, by intravenous infusion (ivgtt). TAS-102: 35 mg/m2 (maximum single dose 80 mg), orally, twice a day, on days 1 to 5, repeated every 2 weeks.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
40747756|NCT05466253|PROCEDURE|Fixed Orthodontic treatment|All the patients will receive the indicated periodontal surgical treatment. and the patients will then be randomly divided into two groups - test group and control group Orthodontic treatment will be started in the test group (EARLY)10 days after periodontal surgery whereas the control group will receive orthodontic intervention (DELAYED) 3 months after periodontal surgery.
40747757|NCT03362957|DEVICE|Geniculate Artery Embolization|Gel-Bead Microspheres will be used for geniculate artery embolization (GAE) in subjects with knee osteoarthritis.
40747758|NCT03362957|DIAGNOSTIC_TEST|Sham Procedure|Patients will receive a sham procedure, which will include a diagnostic angiogram
40747759|NCT02569905|DRUG|parecoxib sodium|parecoxib sodium 40mg
40747760|NCT02569905|DRUG|flurbiprofen|flurbiprofen 50mg
40747761|NCT02569905|DRUG|saline|normal saline
40747762|NCT06093659|OTHER|Pulze device with heated tobacco sticks (Product A)|Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
40747763|NCT06093659|OTHER|Pulze device with heated tobacco sticks (Product B)|Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
40747764|NCT06093659|OTHER|Pulze device with nicotine-infused heated herbal sticks (Product C)|Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
40747765|NCT06093659|OTHER|Pulze device with nicotine-infused heated herbal sticks (Product D)|Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
40747766|NCT06093659|OTHER|Conventional Cigarette (Product E)|Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
40747767|NCT02643784|DRUG|Rosuvastatin|"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
40747768|NCT02643784|OTHER|Control|"Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
40747769|NCT04259489|BEHAVIORAL|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
40747770|NCT04258098|DRUG|Oral antibiotics ( Streptomycin ,metronidazole )|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
40747771|NCT01377506|BEHAVIORAL|lifestyle counseling|21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators
40747772|NCT01377506|BEHAVIORAL|Cognitive Training|21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
40747773|NCT00771602|DRUG|Rituximab|375 mg/m\^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
40747774|NCT00771602|DRUG|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
40747775|NCT03466164|BEHAVIORAL|Mindfulness Based Stress Reduction Program|8 week, 10-session course of mindfulness training
40747776|NCT01846143|BIOLOGICAL|pBCAR3-phosphopeptide|
40747777|NCT01846143|BIOLOGICAL|pIRS2-phosphopeptide|
40747778|NCT01846143|BIOLOGICAL|2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)|
40747779|NCT02216851|DEVICE|Restylane Perlane|Intradermal injection
40747780|NCT03686111|DIAGNOSTIC_TEST|oocytes collect|After stimulation, an echo-guided oocyte puncture is performed under anesthesia
40747781|NCT05129202|DRUG|immune therapy|The patient receives immunotherapy
40747782|NCT02334410|DEVICE|Whole body vibration (WBV)|Side-alternating WBV
40747783|NCT04843904|DRUG|Venetoclax|Tablet, taken by mouth
40747784|NCT04843904|DRUG|Obinutuzumab|Given as an infusion into the vein (intravenous, IV).
40747785|NCT04843904|DRUG|Rituximab|Given as an infusion into the vein (intravenous, IV).
40747786|NCT05298501|OTHER|No intervention/exposure|No interventions/exposures will be administered or evaluated
40747787|NCT00412451|DRUG|ocriplasmin|Intravitreal injection, single administration
40747788|NCT00412451|OTHER|Sham injection|Sham intravitreal injection
40747789|NCT05182892|OTHER|Change of stimulation amplitudes in dopaminergic OFF drug state|Change of stimulation amplitudes during experiment in dopaminergic OFF drug state.
40747790|NCT00118794|DRUG|Chlorproguanil-dapsone (Lapdap)|
40747791|NCT00118794|DRUG|Lumefantrine-artemether (Coartemether )|
40747792|NCT02541487|DIETARY_SUPPLEMENT|Alli-nutritional supplement|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
40747793|NCT03469973|PROCEDURE|Partial adenoidectomy|"The procedure will be completely visualized with a 45 degrees, 4- mm nasal endoscope; the upper part of the adenoid will be removed using the microdebrider, while the lower part will be preserves to maintain the velopharyngeal competence.~• Adenoid enlargement causing Obstructive Sleep-Disordered Breathing (OSDB) with velopharyngeal insufficiency (proved or suspected)."
40747794|NCT03128086|PROCEDURE|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
40747795|NCT00946036|DRUG|Sertraline Hydrochloride|
40747796|NCT04376632|DIETARY_SUPPLEMENT|Pecan ADD|Raw pecan halves without dietary substitution instructions
40747797|NCT04376632|DIETARY_SUPPLEMENT|Pecan SUB|Raw pecan halves with instructions to substitute pecans with isocaloric foods in the habitual diet
40747798|NCT00400088|DRUG|paroxetine|Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
40747799|NCT00400088|DRUG|lithium|start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
40747800|NCT04877639|DRUG|Esmketamine,Dexmedetomidine|Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
40747801|NCT03055507|DRUG|Ibuprofen 400 mg|Addition of ibuprofen to standard pain regimen.
40747802|NCT03055507|DRUG|Acetaminophen 650 mg|Standard analgesic provided post-operatively to patients undergoing sinus surgery
40747803|NCT03055507|DRUG|OxyCODONE 5 Mg Oral Tablet|Standard PRN medication offered post-operatively for breakthrough pain
40747804|NCT02638441|OTHER|hospital anxiety and depression scale|Detection of infertility effect on emotional status
40747805|NCT05865249|OTHER|Spirometry decision support software (ArtiQ.Spiro)|ArtiQ.Spiro is a decision support software that combines two sub-components - one focussing on quality assessment (ArtiQ.QC), and one on spirometry interpretation (ArtiQ.PFT). It is intended to be used as an adjunct to spirometry to assist with the grading of spirometry quality and the interpretation of spirometry by providing the probability of six disease / or no disease categories.
40747806|NCT06235957|OTHER|Cast 3 weeks|patients will be treated either in a cast or a brace, patients in group A are treated by cast immobilization for 3 weeks
40747807|NCT06235957|OTHER|Brace 1 week|patients will be treated either in a cast or a brace, patients in group B are treated in a brace for 1 week
40747808|NCT05676645|DRUG|Artemether-lumefantrine|National policy recommendation for treatment of uncomplicated malaria in Uganda
40747809|NCT06449248|OTHER|Checking of appropriateness of OLP diagnosis|The above mentioned interventions will be carried out through the accurate analysis of patients' clinical records
40747810|NCT05979077|OTHER|MyChart Questionnaire|Prior to clinic visits, families completing the MyChart Questionnaire will enter details about their current management and visit goals, automatically populating their electronic health record for subsequent review/revision by the health care team before and during the visit, reallocating clinic time previously used for data acquisition to individual patient priorities
40747811|NCT03612700|OTHER|CPFA-rich foods|Daily consumption of Grana Padano cheese (50 g) and whole milk (250 mL) for 3 weeks.
40747812|NCT01316900|DRUG|GSK573719/GW642444 125/25|125/25 mcg once-daily
40747813|NCT01316900|DRUG|GSK573719/GW642444 62.5/25|62.5/26 mcg once-daily
40747814|NCT01316900|DRUG|GW642444|25 mcg once-daily
40747815|NCT01316900|DRUG|tiotropium bromide|18 mcg once-daily
40747816|NCT01229553|DRUG|decolonization|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
40747817|NCT02331121|BEHAVIORAL|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
40747818|NCT02331121|BEHAVIORAL|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
40747819|NCT00393380|DRUG|Parathyroid Hormone (teriparatide)|Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC\>2000/microL: PTH 100 mcg
40747820|NCT06214715|DEVICE|Philips ultrasonography system|RRI will be measured by renal ultrasonography with a C5-1 convex probe using a Philips ultrasonography model device.
40747821|NCT05492903|BEHAVIORAL|COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)|A peer-led and supportive group program (10 weekly sessions) designed to address the needs of HCWs with chronic or elevated pain. The intervention will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain self-management.
40747822|NCT05198310|DRUG|KPL-404|Humanized monoclonal antibody
40747823|NCT05198310|DRUG|Placebo|Matching placebo
40747824|NCT05206695|BEHAVIORAL|Multi-condition Pathway Intervention|See Experimental/Arm 1 description
40747825|NCT05683080|OTHER|Routine Clinical Care|Participants completing the research study will receive routine clinical care
41270065|NCT06075381|COMBINATION_PRODUCT|Pulmonary Expansion Device (PED)|The Pulmonary Expansion Device constitutes an innovative instrumental technique for lung expansion, designed for use in patients with or without an artificial airway. This device is attached to the artificial airway, the oronasal mask, or the patient's mouth. It enables voluntary control through a system of one-way valves that restrict the air's escape from the lungs to the outside. This creates an environment conducive to retaining air within the lungs, thereby increasing intrapulmonary pressure. Additionally, it reduces the risk of pulmonary complications associated with conventional management, employing a strategy free from exogenous application of positive pressure to the airway. This approach doesn't necessitate expensive equipment or electrical power.
40747826|NCT04730375|DRUG|Dexmedetomidine Injection [Precedex]|two different doses dexmedetomidine bolus then maintenance infusion till end of surgeries and evaluation of lung mechanics and oxygenation
40747827|NCT04251156|DRUG|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
40747828|NCT04251156|DRUG|Placebo (semaglutide)|Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
40747829|NCT04869930|OTHER|specimen collection|participants will submit at minimum two of four required samples: fecal, urine, finger/toe-prick blood, and cheek swab, collected at home via commercially available kits
40747830|NCT00527878|DRUG|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
40747831|NCT00527878|DRUG|Placebo|
40747832|NCT02867826|DEVICE|Cap|Cap-assisted endoscopy
40747833|NCT05942989|OTHER|Reiki implementation|Reiki is implied by putting hands on the patient and it is believed that energy is transferred to patients by hands.
40747834|NCT05089175|DRUG|Low-dose aspirin|FIGO adopts and supports that in high-risk women, defined by the first-trimester combined test, aspirin \~150 mg/night should be commenced at 11-14+6 weeks of gestation until either 36 weeks of gestation, when delivery occurs, or when pre-eclampsia is diagnosed.
40747835|NCT05796973|BEHAVIORAL|Guided physical exercise|Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions.
40747836|NCT05796973|DRUG|Atorvastatin|Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. In addition to the exercise program they will be given atorvastatin 40 mg QD medication.
40747837|NCT05796973|OTHER|Independent exercise|The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own.
40747838|NCT03592992|DRUG|Spinal Hydromorphone|75 mcg of hydromorphone will be prepared in a non-identifiable syringe by central hospital pharmacy. The resulting solution will then be added to the spinal anesthetic mixture(fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
40747839|NCT03592992|DRUG|Spinal Morphine|150 mcg of morphine will be prepared in a non-identifiable syringe by central hospital pharmacy.The resulting solution will be added to the spinal anesthetic mixture (fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
40747840|NCT01567020|OTHER|Diagnostic|All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
40747841|NCT02979054|DEVICE|T4020|
40747842|NCT02979054|DEVICE|Placebo|
40747843|NCT04541342|PROCEDURE|initial arthroscopy with medial opening-wedge high tibial osteotomy fixed by a plate system then second look arthroscopy with plate removal|It is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. The procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space.Many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy.All patients will undergo initial arthroscopy before high tibial osteotomy (HTO). During arthroscopy, debridement of the degenerate tissues and meniscal tears if present will be performed. Then opening-wedge high tibial osteotomy (OWHTO) will be performed and fixed by a plate system. Second-look arthroscopy will be conducted at the time of plate removal after healing of the osteotomy. This will be after about 6 months up to one year.
40747844|NCT02636322|DRUG|Cyclophosphamide|Given IV
40747845|NCT02636322|DRUG|Doxorubicin Hydrochloride|Given IV
40747846|NCT02636322|DRUG|Etoposide|Given IV
40747847|NCT02636322|DRUG|Ibrutinib|Given PO
40747848|NCT02636322|DRUG|Lenalidomide|Given PO
40747849|NCT02636322|DRUG|Prednisone|Given PO
40747850|NCT02636322|BIOLOGICAL|Rituximab|Given IV
40747851|NCT02636322|DRUG|Vincristine Sulfate|Given IV
40747852|NCT02319083|PROCEDURE|Coronary artery bypass surgery|Patients will undergo coronary artery bypass grafting
40747853|NCT00222274|BEHAVIORAL|RSA Biofeedback|RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J\&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
41270066|NCT06075381|PROCEDURE|Conventional management|The conventional management includes: Adequate postoperative pain control, global postural reeducation, reeducation of breathing pattern, airway hygiene, early mobilization, respiratory and scapular waist exercises, and in patients with evidence of lung atelectasis or mild persistent hypoxemia, conventional management will involve the use of intermittent positive pressure ventilation in the airway.
41270067|NCT05303454|BEHAVIORAL|Cartoons|cartoons were found to be effective in reducing children's pain and fear levels.
41270068|NCT05303454|BEHAVIORAL|musical-moving toys|musical-moving toys were found to be effective in reducing children's pain and fear levels.
40747854|NCT00222274|BEHAVIORAL|EEG Biofeedback Condition|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J\&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
40747855|NCT05349370|OTHER|Isotopically labeled lactate|A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn
40747856|NCT06353516|DRUG|Propofol|delivered via intravenous route
40747857|NCT06353516|DRUG|Sevoflurane|delivered via inhalation route
40747858|NCT03968627|OTHER|Rehabilitative intervention|intensive multidisciplinar rehabilitation
40747859|NCT04715100|OTHER|Observational group|The study dependent variables will be: pain (vas scale), joint status (Hemophilia Joint Health Score), perception of quality of life (SF-36 questionnaire), list of roles (Oakley questionnaire), performance of basic activities of daily life (Barthel index) and the performance of instrumental activities of daily living (Lawton and Brody scale).
40747860|NCT03281915|PROCEDURE|High inguinal Varicocelectomy|Semen parameters after high inguinal varicocelectomy will be collected
40747861|NCT03281915|PROCEDURE|Subinguinal varicocelectomy|Semen parameters after subinguinal Varicocelectomy will be collected
40747862|NCT05311163|PROCEDURE|MitraClip|Transcatheter Mitral Edge-To-Edge Repair
40747863|NCT00406237|DRUG|tigecycline|Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
40747864|NCT05797090|DRUG|Crystalloid Cardioplegic solution|To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
40747865|NCT04294238|BEHAVIORAL|Aerobic exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
40747866|NCT04169659|DEVICE|Kyphoplasty with insertion of Sctructured Titanium Microspheres|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce structured titanium microspheres until the dome is full of material.
40747867|NCT04169659|DEVICE|Kyphoplasty with Polimethylmetacrilate (convetional surgery)|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce Polimethylmetacrilate until the dome is full of material.
40747868|NCT04822571|OTHER|Reliability of 3D motion analysis protocol|The intrinsic and extrinsic reliability of the designed 3D motion analysis protocol is measured in cases of high velocity dynamic movement such as kicking a soccer ball.
40747869|NCT04027387|BIOLOGICAL|TMB-365|An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
40747870|NCT01197898|BIOLOGICAL|Collagenase Santyl Ointment|Topical daily application
40747871|NCT01197898|OTHER|Placebo Comparator|Topical daily application
40747872|NCT06006221|BEHAVIORAL|Qi-gong relaxation exercise|Qi-gong relaxation exercise is a mindfulness-based exercise and is a type of exercise that consists of breathing-compatible body movements and relaxation used to relax the body and mind, reduce stress, distract attention from negative thoughts, accelerate blood flow, and improve emotions.
40747873|NCT06131463|DEVICE|Electrocardiogram (ECG) feature in smart watches|A study participant that is randomly assigned to the experimental group should enable the ECG function on his or her smart watch and make sure that there is synchronization with a corresponding application on his or her mobile phone. The ECG function must stay enabled, and the participant should wear the smartwatch every day for 30 days.
40747874|NCT02644811|DRUG|Topical anesthesia (buccal and palatal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
40747875|NCT02644811|DRUG|Local anesthesia (buccal and palatal)|Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
40747876|NCT02644811|PROCEDURE|Extraction of the maxillary first premolars|Careful extraction of the maxillary first premolars after mobilization.
40747877|NCT02644811|DRUG|Topical anesthesia (buccal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
40747878|NCT02644811|DRUG|Local anesthesia (buccal)|Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
40747879|NCT02644811|DEVICE|Molarblock|Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.
40747880|NCT02644811|DEVICE|Spider Screw K1 short neck|The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
40747881|NCT02322515|OTHER|Intervention taping|A rigid patellar taping will be used for the correction in lateralization of the patella and more stabilization of the knee.
40747882|NCT02322515|OTHER|Placebo Taping|A rigid patellar taping will be used in the vertical position and without no correction in lateralization of the patella and/or stabilization of the knee.
40747883|NCT00235313|PROCEDURE|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
40747884|NCT00235313|DRUG|nicotine patch|normal following with a nicotine patch
40747885|NCT03662971|DRUG|Germinal peptide eye drops|Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%
41270069|NCT05726214|OTHER|Exercise|"The face-to-face multicomponent program entailed:~* Strength training of upper and lower limbs. Familiarization phase included 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets lasted 1-3 minutes.~* Balance exercises included proprioception, agility and weight transfer exercises. Difficulty progressively increased by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~* Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~The Vivifrail exercise wheel corresponding to each participant was given according to their functional level type."
40747886|NCT06520423|PROCEDURE|Urethral stent tube irrigation|During urethroplasty, a Fr3 ureteral catheter will be placed in the reconstructed urethra, with the proximal end extending approximately 2 cm beyond the urethral wound. The distal end will connect to an F6 single-lumen ureter and a urinary bag. On the second postoperative day, the urethra will be irrigated with 5 ml of saline twice daily. This irrigation routine will continue until the catheter is removed.
40747887|NCT06520423|PROCEDURE|Urinary catheter drainage|During urethroplasty, intraurethral retention of urethral catheters is used to drain urine from the bladder.
40747888|NCT01280500|BEHAVIORAL|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
40747889|NCT01280500|OTHER|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
40747890|NCT01280500|OTHER|usual care|No EMR
40747891|NCT01280500|OTHER|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
40747892|NCT01280500|OTHER|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
40747893|NCT01391949|BEHAVIORAL|Detailed feedback|Once a week subjects will receive feedback about the total time spent cycling and walking in the previous week. Subjects in this intervention group will also receive feedback about average cycling speed, distance pedaled, average walking speed, and distance walked in the previous week.
40747894|NCT01391949|BEHAVIORAL|Basic feedback|Once a week subjects will receive feedback about total time spent cycling and walking in the previous week.
40747895|NCT05362019|DRUG|Compound Norethisterone Enanthate Injection|Combined injectable contraceptive use
41270070|NCT05726214|OTHER|Recommendations for active lifestyle|After the baseline assessments, all participants received individualized counseling for following physically active lifestyle and reducing sedentary behaviors. Participants were encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home. The recommendations were transmitted verbally and through written material.
41270071|NCT02948439|OTHER|Aerobic exercise|Brisk walking 3-4 times per week for up to 40 minutes of activity.
41270072|NCT04574999|DRUG|Estriol|Gel for vaginal application
41270073|NCT04574999|OTHER|Placebo|Gel for vaginal application
41095489|NCT01070056|BEHAVIORAL|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
41095490|NCT00354029|DRUG|S (+) Ketamine|0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
41095491|NCT00354029|DRUG|Placebo|isotonic saline
41095492|NCT06040645|OTHER|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
41270074|NCT03170752|BEHAVIORAL|Cardiovascular Assessment Screening Program (CASP)|Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
41270075|NCT01763164|DRUG|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
41270076|NCT01763164|DRUG|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
40747896|NCT05362019|OTHER|One-to-one Service|"A mobile phone based service system will be used to pushing contraceptive knowledges, reminding injection, providing consultation on adverse reactions and ect."
40747897|NCT05362019|OTHER|Family Planning Service|routine family planning service and contraceptive service.
41270077|NCT01956214|OTHER|FES Exercise|receive FES while exercising
41270078|NCT01956214|OTHER|Mock FES Exercise|participants will receive Mock FES
41270079|NCT02463461|DEVICE|ActiSleep Activity Monitor|Subjects in this group will wear a ActiSleep Activity Monitor.
41270080|NCT02463461|DEVICE|Jawbone Activity Monitor|Subjects in this group will wear a Jawbone Activity Monitor.
41270081|NCT02463461|DEVICE|Actiwatch 2 Activity Monitor|Subjects in this group will wear a Actiwatch 2 Activity Monitor.
41270082|NCT02463461|DEVICE|FitBit Activity Monitor|Subjects in this group will wear a FitBit Activity Monitor.
41270083|NCT02463461|DEVICE|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
41270084|NCT01332448|DRUG|Orlistat 120|Orlistat 120mg tid
41270085|NCT01332448|DRUG|Orlistat 60|Orlistat 60mg tid
41270086|NCT00404521|DRUG|PM02734|Administered every 3 weeks, intravenously, over 30 minutes
40747898|NCT03990688|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
40747899|NCT03990688|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
40747900|NCT02370394|BEHAVIORAL|ROSE Program|The ROSE Program was specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It was tailored to the current IPV risk assessment, pregnancy or postpartum status of each participant, was designed to reach participants across levels of motivation for change. The content of ROSE was theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
40747901|NCT00069745|DRUG|Satraplatin|
40747902|NCT00069745|DRUG|Prednisone|
41270087|NCT06100783|DEVICE|Depot-medroxy Progesterone Acetate Injectable Contraceptives|Depot-medroxy progesterone acetate injectable contraceptives
41270088|NCT03216460|DEVICE|Insulet automated glucose control system|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
41270089|NCT00375544|DEVICE|Low level light therapy|
41270090|NCT04061083|DEVICE|Smart Cuff Manager|Participant will be attached to the smart cuff manager within 4 hours after intubation. They will remain attached during the first 48 hours of intubation in the intensive care unit
41270091|NCT04061083|DEVICE|Manometer|Participant will be attached to the manometer within 4 hours after intubation. They will assess 3 times per day during the first 48 hours of intubation in the intensive care unit
41270092|NCT05698290|OTHER|HELP Pain Training Program|A training program to teach school providers nonpharmacologic (e.g., cognitive behavioral and mindfulness meditation) strategies to use with students with pain symptoms.
41270093|NCT04108429|BEHAVIORAL|IntelliCare for College Students|Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
40747903|NCT00353574|DRUG|Darusentan|Darusentan capsules administered orally once daily
40747904|NCT04984408|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"* The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~* Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius"
40747905|NCT04984408|BIOLOGICAL|influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)|"* The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)~* Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults)~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius"
40747906|NCT01953237|BEHAVIORAL|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
40747907|NCT01953237|DEVICE|Smartphone|
40747908|NCT02491060|DRUG|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
40747909|NCT02491060|DRUG|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
40747910|NCT06309797|DEVICE|Interdental brush+HA|interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm) +20 mL of 0.2% HA gel (Gengigel; Ricerfarma, Milan, Italy)
40747911|NCT06309797|DEVICE|Interdental brush|interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm)
40747912|NCT04852653|PROCEDURE|Supplementary blood samples collection during the normal follow up of the patients|Supplementary blood samples collection during the normal follow up of the patients
40747913|NCT05484167|DRUG|Natesto Nasal Product|Nasal Gel used for 90 days then crossed over to placebo gel
40747914|NCT05484167|DRUG|Placebo|A nasal gel with no active ingredients
40747915|NCT01121575|DRUG|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
40747916|NCT01121575|DRUG|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
40747917|NCT01121575|DRUG|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
40747918|NCT01121575|DRUG|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
40747919|NCT05254210|DEVICE|RF Device (Potenza™)|Test spots may be performed prior to the first treatment. Following test spots, for the treatment, the tip will be placed in contact with the skin. Parameters may be adjusted throughout the treatment and will determined by the Clinician.
40747920|NCT00005922|BEHAVIORAL|Partial schedule of pharmacotherapeutic reinforcement|Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.
40747921|NCT00005922|DRUG|Dose control for Arm B|Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
40747922|NCT00005922|OTHER|Standard pharmacotherapeutic protocol|Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
40747923|NCT03475043|BEHAVIORAL|Auditory training: temporal cues|Behavioral training for 6-9 hours in listening to specific characteristics of acoustic signals. Listeners receive correct-answer feedback on each trial.
40747924|NCT02280499|DEVICE|standard PROMOS prosthesis|
40747925|NCT00948207|BEHAVIORAL|My Living Story|"Components include:~1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2) Edited transcript is delivered in a word format on...;~3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks."
40747926|NCT00948207|BEHAVIORAL|My Own Resources|"miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks."
40747927|NCT01824004|DRUG|S-1|
40747928|NCT04273789|DEVICE|Far infrared reflecting sleepwear|100% microlyocell sleepwear (shorts + shirt) with a ceramic print that reflects far infrared light (FIR, 5.6-1000 µm) emitted by the human body. Since FIR active garments are not powered, but reflect recycle light energy emitted by the body of the wearer, they have irradiances between 0.1-5 mW/cm\^2.
40747929|NCT04273789|DEVICE|Placebo sleepwear|100% microlyocell sleepwear (shorts + shirt)
40747930|NCT06376227|PROCEDURE|with or without Left Colic Artery Preservation|low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA
40747931|NCT00929032|RADIATION|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
40747932|NCT01163877|DIETARY_SUPPLEMENT|Fe-57 orally, Fe-58 intravenously|Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.
40747933|NCT03558672|DEVICE|Flexitouch system with Head and Neck Garments|Flexitouch system or Flexitouch Plus Head and Neck Treatment, as prescribed
40747934|NCT00666341|DRUG|placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
40747935|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
40747936|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
41270094|NCT01096914|PROCEDURE|percutaneous radiofrequency ablation|"Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge cool-tip needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
41270095|NCT01096914|PROCEDURE|percutaneous laser ablation|Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
41270096|NCT03228121|PROCEDURE|Treatment Then Placebo|Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.
41270097|NCT03228121|PROCEDURE|Placebo Then Treatment|Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.
41270098|NCT05904626|DRUG|ELGN-2112|To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
41270099|NCT05904626|DRUG|Placebo|A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
41270100|NCT04580147|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
41270101|NCT04580147|OTHER|Sham control|Sham procedure at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
41270102|NCT02151513|DEVICE|Intrathecal Pump Placement|
41270103|NCT03072602|DIETARY_SUPPLEMENT|Study diet|Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
41270104|NCT03072602|OTHER|Glucose Challenge|Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
41270105|NCT05995392|DRUG|Topical spironolactone ophthalmic solution, 0.005 mg/cc|Used four times a day in both eyes for 4 weeks.
41270106|NCT05995392|DRUG|Placebo|Used four times a day in both eyes for 4 weeks.
41270107|NCT01042444|DEVICE|GARDEX™|"GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires."
41270108|NCT03261115|PROCEDURE|No topical anesthesia|Lack of use of topical anesthesia application prior to infiltration injection intra-orally
41270109|NCT03320499|PROCEDURE|echo doppler at the bed|we practise the echo doppler at the patient 's bed
41270110|NCT03320499|PROCEDURE|echo doppler in the vascular exploration platform|as usual , practising echo doppler in the medical platform
41270111|NCT02844465|DEVICE|Visualase MRI-Guided Laser Ablation|All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
41270112|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).|Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
41270113|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test to determine the effectiveness of SABR.|Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
41270114|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test for Oligometastatic Cancer (OC).|Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.
41270115|NCT05430269|OTHER|Faecal bacteriotherapy (FBT)|Enema of 350 ml of standardised mixed transplantate prepared from faeces of 7 healthy donors.
41270116|NCT05430269|OTHER|standard-of-care protocolised treatment of postantibiotic diarhea|standard-of-care protocolised treatment of postantibiotic diarhea
40747937|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
40747938|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
40747939|NCT05895500|DRUG|Injection for SC administration (120mg/syringe)|Injection
40747940|NCT05895500|DRUG|Tablet (50mg/tablet), oral|Tablet
41270117|NCT06412692|OTHER|The Motivational Interviewing Technique|Motivational interviewing technique applied to adolescents with epilepsy; It is thought that it will be effective in reducing social anxiety and increasing the quality of life of adolesce.
41270118|NCT00245271|DRUG|OMS103HP|Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
41270119|NCT00245271|DRUG|Vehicle|Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
41441015|NCT04230525|DIAGNOSTIC_TEST|non invasive whole body bioimpedence system|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia. The whole-body bioimpedance method will be used to monitör the hemodynamic changes non invasively. This method can evaluate such as cardiac output, cardiac index, stroke volüme, stroke index, stroke volüme variations, cardiac reserve, etc. Parameters with a completely noninvasive method by using only electrots. The device consists of a laptop, a software which calculates cardiac parameters and two electrodes. The measurement is done by the following process: one of these electrodes, which looks like ECG electrodes, is stuck to the wrist and the other one to the opposite ankle or each one to two wrists.
40747941|NCT03066375|DEVICE|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
40747942|NCT06477510|PROCEDURE|non-surgical periodontal therapy|change in self perception of esthetics and clinical periodontal parameters will be assessed after non-surgical periodontal therapy.
40747943|NCT01186419|DRUG|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
40747944|NCT01666314|DRUG|Orteronel|Orteronel tablets
40747945|NCT01666314|DRUG|Orteronel Placebo|Orteronel placebo-matching tablets
40747946|NCT01666314|DRUG|Prednisone|Prednisone 5 mg
40747947|NCT01852136|DEVICE|BD NEXT 31G x 5 mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
40747948|NCT01852136|DEVICE|BD NEXT 31G x 8mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
40747949|NCT01852136|DEVICE|BD NEXT 32G x 4mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
40747950|NCT00053742|DRUG|Modified Vaccinia Virus Ankara TBC-MVA|
40747951|NCT04786925|OTHER|Control diet|Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.
40747952|NCT04786925|OTHER|Nutriprecision diet|Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.
40747953|NCT03675555|DRUG|Mirtazapine|Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
41270120|NCT05769231|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia in Chatbot|Digital interventions can relieve the worldwide burden of mental disorders. The low set-up costs and barriers of online platforms make digital interventions very cost-effective. By using the Internet as a delivery medium, many people can enjoy unrestricted access to self-help information. Unlike traditional face-to-face intervention, the effects of digital self-help interventions are scalable. The current study attempts to extend the boundary of digital interventions from accommodating didactic and informational content to providing interactive, intelligent, and most importantly, patient-centered conversational agents. AI chatbots can provide suitable recommendations and training materials to users according to their behavioral, mental, and motivational readiness. Since existing AI chatbots are developed for Western societies, a culture-specific Chinese chatbot will fill the research and service gaps.
41270121|NCT00157833|DRUG|Artekin / Coartemther|
41270122|NCT03141944|OTHER|Starkstein scale of Apathy|"The degree of apathy will be evaluated with the Starkstein scale of Apathy"
40747954|NCT03675555|DRUG|Dexamethasone phosphate|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
40747955|NCT03675555|DRUG|Placebo|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
40747956|NCT01898091|DRUG|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
40747957|NCT01898091|DRUG|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
40747958|NCT05916248|BIOLOGICAL|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
40747959|NCT01139372|OTHER|FID 115958D (Lubricant Eye Drop)|1 drop in each eye at least twice daily
40747960|NCT05675696|OTHER|Esophageal Catheter|Newly designed external monitor that will capture esophageal pressure from a proprietary nasogastric tube combined with simultaneous pressure, flow, and volume measurements from the ventilator tubing.
40747961|NCT00027443|DRUG|Muromonab-CD3|
40747962|NCT00027443|DRUG|Cyclosporine|
41270123|NCT05299658|DRUG|CNMAu8|CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
41270124|NCT03526289|BIOLOGICAL|GIP1-42 infusion|5-hour GIP1-42 infusion (time point 0-300 minutes)
40747963|NCT04657692|PROCEDURE|Anesthesia; general or regional|General anesthesia: general anesthesia with endotracheal tube Regional anesthesia: spinal anesthesia, epidural anesthesia, combined spinal epidural anesthesia
40747964|NCT04391907|PROCEDURE|IPL|Intense pulse light (IPL) laser is used for the treatment of dry eye originated from meibomian gland dysfunction. IPL laser will be performed to patients who are planned to cataract surgery to improve dry eye.
40747965|NCT05562635|COMBINATION_PRODUCT|5% polymer gel with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
40747966|NCT05562635|COMBINATION_PRODUCT|10% polymer gel with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
40747967|NCT05562635|COMBINATION_PRODUCT|Placebo intervention|Application of placebo without CBD
41270125|NCT03526289|OTHER|Saline|5-hour infusion of saline (placebo) (time point 0-300 minutes)
41270126|NCT01392183|DRUG|Pazopanib|800 mg by mouth daily in 4 week study cycle.
40747968|NCT03640377|DRUG|Praziquantel|Praziquantel given as crushed tablets (40 or 80 mg/kg)
40922351|NCT06173700|BEHAVIORAL|web-based group problem solving and coping training|"The group included one-hour, weekly Zoom sessions, that were facilitated by an occupational therapy doctoral candidate (first author) for 7 consecutive weeks. During the first session, the candidate explained adaptive and maladaptive coping strategies and asked each participant to identify one adaptive coping strategy that they currently use and will continue to use in the future. The candidate then explained the FOCUS problem-solving approach. For each session afterward, the candidate presented a topic-related scenario for parents to identify an effective solution using the FOCUS steps (APA, 2011). Parent-chosen topics included recreation, assistive technology, motivating and advocating, physical activity, skin integrity, and adaptive fashion. The general process of the meetings is presented in Figure 1. After every meeting the candidate sent out a summary of resources that were discussed during the meeting, ultimately putting them all together in an Empowering Caregiver Guide."
40747970|NCT00756834|DEVICE|Screening|The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review
40747971|NCT03896360|BEHAVIORAL|Food order behavioral intervention plus standard care|Subjects in the Food order behavioral intervention plus standard care will receive standard counseling by a registered dietitian and additional carbohydrate last food order behavioral counseling by a member of the research team at baseline and Weeks 4, 8 and 12.
40747972|NCT03896360|BEHAVIORAL|Standard Care|Subjects will receive standard counseling by a registered dietitian at the baseline visit. Standard counseling will be similarly reinforced at weeks 4, 8 and 12.
41270127|NCT01392183|DRUG|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
41270128|NCT01392183|BEHAVIORAL|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
41270129|NCT01392183|DRUG|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
41270130|NCT05936762|DEVICE|Neoial HC|Patients with severe knee osteoarthritis were enrolled in the clinical study and treated with 3 injections of 40 mg NEOIAL HC (HA sodium salt at 2% with two molecular weights 20% with pm at 400 kD and 80% between 1200 and 1500 kD t + collagen) at a distance of 1 week from each other, followed by a fourth infiltration of the same product at a distance of 1 month from the third.Patients were followed up with baseline clinical evaluation, reporting of adverse events after each single infiltration and subsequently at the end of treatment, 3, 6 months follow-up.
40747973|NCT02551107|DEVICE|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
40747974|NCT02774720|BEHAVIORAL|Centre-based exercise|Participants will come to a centre (University of Waterloo or Toronto Rehabilitation Institute) for a one-hour, small group exercise class each week. The classes will include progressive aerobic and resistance exercise. They will be prescribed additional exercise to be performed independently (either at home or in the community).
40747975|NCT02774720|BEHAVIORAL|Home-based exercise|Participants will be prescribed aerobic and resistance exercise to be performed independently (either at home or in the community). They will receive monthly phone calls to discuss achievements and barriers and to tje adjust exercise prescription.
40747976|NCT02846727|DEVICE|skin perfusion image|Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
41270131|NCT04947475|BEHAVIORAL|SBIRT|First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. In our BI, we will provide evidence-based information on Opioid Agonist Therapy (OAT) that is available to them in the community upon release or in the community. We will inform them of the risks and benefits of OAT and explain to them how OAT can be accessed in the community. OAT is provided at no cost to Ukrainian, Moldovan, and Kyrgyz citizens with opioid dependence. The BI will last approximately 20 minutes and time will be made available for them to ask questions. The BI will not be audio recorded.
41270132|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
41270133|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
41270134|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
41270135|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
40922352|NCT00899496|OTHER|immunological diagnostic method|
40922353|NCT00899496|OTHER|physiologic testing|
40747977|NCT05750082|DEVICE|CCTA CT-FR CAG OCT|Per the protocol, patients will have a CCTA (coronary computed tomography angiography), CT-FFR (fractional flow reserve derived from CTA), ICA (invasive coronary angiography), OCT (optical coherence tomography).
40747978|NCT04304378|BEHAVIORAL|Stabilization Techniques (ST)|The Stabilization Techniques intervention provides an opportunity to improve emotion/affect regulation and coping skills. The overarching goal of these sessions is to introduce different ways of managing emotional distress through imagery and stress reduction techniques. ST sessions focus on providing coping mechanisms for managing important symptoms of PTSD (i.e., hyperarousal, negative emotions, and physical symptoms).
40747979|NCT04304378|BEHAVIORAL|Stabilization Techniques with Behavioral Activation (ST+BA)|The Stabilization Techniques with Behavioral Activation intervention includes stabilization techniques as well as sessions targeted at increasing time engaged in physical activities during times outside of the intervention session. Preferred activities are selected by the participant. Strategies to foster engagement in the selected activities will include self-monitoring, structuring and scheduling daily activities, rating the degree of pleasure and accomplishment experienced during engagement in specific daily activities, exploring alternative behaviors related to achieving goals, and using role-play to address specific barriers. Establishing/maintaining routines and behavioral strategies to reduce avoidance and mange negative emotions are emphasized.
40747980|NCT04304378|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|EMDR is an exposure-based treatment that is the standard of care for PTSD delivered by the research team in Phnom Penh. EMDR utilizes sensory stimulation when participants are engaged in mental processing of traumatic material. EMDR follows a sequential framework targeting 1) past memories, 2) present symptoms, and 3) future actions.
40747981|NCT05331833|RADIATION|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.|
40747982|NCT06264622|DIETARY_SUPPLEMENT|Low dose|2 tablets per day during the morning for 12 weeks.
40747983|NCT06264622|DIETARY_SUPPLEMENT|High dose|2 tablets per day during the morning for 12 weeks.
40747984|NCT06264622|DIETARY_SUPPLEMENT|Placebo|2 tablets per day during the morning for 12 weeks.
40747985|NCT05028088|DRUG|sugammadex|This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.
40747986|NCT04981561|DRUG|GATE-251|Single dose of GATE-251
40747987|NCT04981561|DRUG|Placebo|Placebo
40747988|NCT03313193|OTHER|Acupressure for Children in Treatment for a Childhood Cancer|This study will describe the benefits and risks of an acupressure intervention to decrease nausea/vomiting and other treatment-related symptoms compared to a control group receiving usual care. Children in Arm A will receive usual symptom management care + acupressure 5 days/week for \~20 treatments. Parents will be taught how to provide acupressure as well. Children in Arm B will receive usual care alone.
40747989|NCT02247856|OTHER|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
40747990|NCT02247856|DEVICE|Jet Nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min"
40747991|NCT02247856|DEVICE|Vibrating Mesh Nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
40747992|NCT00120848|BIOLOGICAL|HPV 16/18 VLP AS04|
40747993|NCT04099420|BEHAVIORAL|Lifestyle counseling|An in-depth analysis of the lifestyle of Italian and Spanish university students will be carried out for the first time, with assessment of the frequency of self-medication and use of drugs and supplements/nutraceuticals. The composition of the oral microbiota in relation to eating habits will be determined for the first time. The results of this study will be useful for designing promotion programs for the correct use of drugs/supplements and for healthy diets and lifestyles in university students
40747994|NCT03043820|DRUG|Raloxifene|Oral selective estrogen receptor modulator (SERM).
40747995|NCT03043820|DRUG|Placebo|Tablets identical in form and color to intervention.
40747996|NCT04137315|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
40747997|NCT05380596|BEHAVIORAL|Telepharmaceutical Care|The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3). In the opportunities, aspects related to pharmacotherapy and health status, non-pharmacological approaches, treatment adherence and evaluation of problems related to pharmacotherapy (PRM) will be discussed.
40747998|NCT00189514|DRUG|pramlintide acetate|Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
40747999|NCT00189514|DRUG|placebo|subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
40748000|NCT01666613|DRUG|AZD8683|Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
40748001|NCT01666613|DRUG|AZD8683|Solution to be administered orally Total dose of 950 µg AZD8683
40748002|NCT01666613|DRUG|AZD8683|Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
40748003|NCT01666613|DRUG|AZD8683|Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
40748004|NCT03487666|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.
40748005|NCT03487666|DRUG|Capecitabine|Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
40748006|NCT00025311|DRUG|topotecan hydrochloride|
40748007|NCT06438952|PROCEDURE|Transforaminal steroid injection combined with lumbar sympathetic blockade|Transforaminal steroid injection will be made with 2 mg dexamethason + 20 mg lidocaine + 5mg bupivacaine + 5 mcg fentanyl + 100mg magnesium under US-guidance Lumbar sympathetic blockade will be made with 5 ml 0.5% bupivacaine + 6 mg dexamethason + 10 ml NaCl
40748008|NCT06438952|PROCEDURE|Transforaminal steroid injection only|Transforaminal steroid injection will be made with 2 mg dexamethason + 20 mg lidocaine + 5mg bupivacaine + 5 mcg fentanyl + 100mg magnesium under US-guidance
40748009|NCT01479530|DRUG|Placebo|Once daily; tablet; orally; 16 weeks
40748010|NCT01479530|DRUG|Azilect®|1 mg daily; tablet; orally; 16 weeks
40748011|NCT00416949|DEVICE|Patient-specific dosimetry|Patient-specific 3D-RD dosimetry was applied to the data collected
40748012|NCT02237274|OTHER|High altitude exposition|High altitude exposition
40748013|NCT03465605|DIAGNOSTIC_TEST|frailty test|questionnaire
40748014|NCT05456217|OTHER|admission to ICU|admission to an intensive care unit or high dependency unit in Kenya
40748015|NCT00477724|BEHAVIORAL|exercise and respiratory therapy|exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
40748016|NCT00477724|OTHER|sedentary control group|control group with no specific training
40748017|NCT05665647|DRUG|Cohort 1: SIM0417/ritonavir and itraconazole|SIM0417/Ritonavir: Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1-Day2, Day9-Day10, BID; Day3,Day11(once only in the morning); Itraconazole：Dose: 200mg once；Day6-Day13, QD
40748018|NCT05665647|DRUG|Cohort 2: SIM0417/ritonavir and rifampicin|SIM0417/Ritonavir:Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1,Day11(once only in the morning); Rifampicin：Dose: 0.6g once; Day4-Day12, QD
40748019|NCT05665647|DRUG|Cohort 3: SIM0417/ritonavir and midazolam|SIM0417/Ritonavir: 750 mg SIM0417 coadministered with 100 mg ritonavir, Day3-Day6, BID; Day7(once only in the morning) Midazolam：Dose: 2mg once; Day1, Day6, QD
40748020|NCT04113486|OTHER|Blood test|About 4 ml of blood draw
40748021|NCT02376335|BIOLOGICAL|Rituximab|The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
40748022|NCT02376335|OTHER|Placebo|Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
40748023|NCT02194686|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
40748024|NCT02194686|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
40748025|NCT03827642|DRUG|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
40748026|NCT03827642|DRUG|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
40748027|NCT03827642|DRUG|Treatment C: Naloxone HCl Intravenous (IV) Injection|Participants received naloxone HCl IV injection following a 10 hour fast.
40748028|NCT03827642|DRUG|Treatment D: Naloxone HCl Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
40748029|NCT02346916|DRUG|Capsaicin|1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
40748030|NCT03769974|BEHAVIORAL|Motor imagery|Two series of 30 seconds training of motor imagery in each manual engine gesture
40748031|NCT03769974|BEHAVIORAL|Action observation|Two series of 30 seconds training of action observation training in video format in each manual engine gesture
40748032|NCT03769974|BEHAVIORAL|Placebo intervention|Two series of 30 seconds of observation and imagination of a landscape during for each manual motor sequence
40748033|NCT02614664|DEVICE|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
40748034|NCT01108055|DRUG|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
40748035|NCT01108055|DRUG|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
40748036|NCT02154659|DEVICE|24hr pH monitoring|
40748037|NCT05121493|OTHER|Platelet Poor Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet free fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of white blood cells (WBC), red blood cells (RBC), and platelets when compared to the concentration before processing.
40748038|NCT05121493|OTHER|Platelet Rich Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of WBC and RBC and 100 x 10³ μl or ≥ 50% recovery of platelets when compared to the pre-platelet count.
40748039|NCT00117000|DRUG|testosterone undecanoate|
40748040|NCT01968785|RADIATION|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
40748041|NCT01968785|RADIATION|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
40748042|NCT05100147|PROCEDURE|Uterine closure during Cesarean section|The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)
40748043|NCT01713127|DRUG|remifentanil infusion|
40748044|NCT01713127|DRUG|Placebo|
40748045|NCT04608864|PROCEDURE|varicocelectomy|microsurgical subinguinal varicocelectomy
40748046|NCT05729191|BIOLOGICAL|Anti Covid 19 vaccination campaign for pregnat women|Assessment of vaccine hesitancy and Covid-19 disease knowledge
40748047|NCT05911386|OTHER|study of biological samples and echocardiographic data and link with need of hemodynamic support|observational study : there is no intervention
40748048|NCT06433726|DRUG|BY101921 tablets|An oral PARP7 Inhibitor
40748049|NCT04970108|DRUG|Egito|EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
40748050|NCT04970108|DRUG|Empagliflozin + telmisartan|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.
40748051|NCT01485835|DRUG|Ganetespib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
40748052|NCT01485835|DRUG|Bortezomib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
40748053|NCT01485835|DRUG|Dexamethasone|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
40748054|NCT00452257|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
40748055|NCT02547987|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
40748056|NCT02547987|DRUG|Carboplatin|Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
40748057|NCT02819388|BEHAVIORAL|Contraceptive counseling|A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
40748058|NCT05003999|DEVICE|HPC - SpeediCath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter
40748059|NCT05003999|DEVICE|Non-HPC - Self-Cath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter; Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
40748060|NCT02619656|PROCEDURE|CO2 insufflation|Patients were randomized to insufflation with CO2.
40748061|NCT02619656|PROCEDURE|Ambient air insufflation|Patients were randomized to insufflation with ambient air.
40748062|NCT00851136|DRUG|bevacizumab|Intravenous repeating dose
40748063|NCT00851136|DRUG|FOLFOX|Intravenous repeating dose
40748064|NCT00851136|DRUG|PRO95780|Intravenous repeating dose
40748065|NCT01836822|PROCEDURE|EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|
40748066|NCT01836822|PROCEDURE|EBUS guided transbronchial needle aspiration (EBUS-TBNA)|
40748067|NCT01836822|PROCEDURE|large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|
40748068|NCT01836822|PROCEDURE|Bronchoalveolar lavage (BAL)|
40748069|NCT01836822|PROCEDURE|Endobronchial forceps biopsy|
40748070|NCT04803435|OTHER|Telemedicine Consultation|Brief telemedicine consultation, blindedto subsequent face-to-face evaluation.
40748071|NCT04803435|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
40748072|NCT01420978|PROCEDURE|CSF Diversion|CSF drainage
40748073|NCT06211790|DRUG|Anlotinib, Everolimus and Tislelizumab|Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)
40748074|NCT02661373|DRUG|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.
40748075|NCT02661373|DRUG|Cobicistat|Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
40748076|NCT01663831|OTHER|Mosquito topical repellent|Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
40748077|NCT00215956|DRUG|topotecan|Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
40748078|NCT00215956|PROCEDURE|radiation|Preoperative radiation
40748079|NCT00215956|PROCEDURE|surgery|surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
40748080|NCT03294655|BEHAVIORAL|Pilot Resilience Building Intervention|The intervention will include a brief one-on-one visit in which psychoeducational information on building resilience will be given via a PowerPoint presentation, which will include exercises for the participants to engage in over the following four weeks in their daily lives. After the presentation participants will also develop a personalized intervention plan where they will choose at least five areas of the American Psychological Association 10 Strategies for Building Resilience on which to specifically focus. Participants will also receive a pamphlet of abbreviated information from the PowerPoint presentation.
40748081|NCT03718260|DIAGNOSTIC_TEST|[18F]-DCFPyL PET/ CT scan (PSMA PET)|Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).
40748082|NCT03888690|DEVICE|Virtual Reality Headset|Standardized procedures, with or without Virtual Reality Headset.
40748083|NCT03336866|DRUG|Placebo|Normal saline
40748084|NCT03336866|DRUG|IXT-m200|IXT-m200 is an anti-methamphetamine monoclonal antibody
40748085|NCT02787798|DRUG|valsartan/sacubitril 100 mg|Treatment with 100 mg tablets during 2 to 4 weeks
40748086|NCT02787798|DRUG|valsartan/sacubitril 200 mg|Treatment with 200 mg tablets during 2 to 4 weeks
40748087|NCT02787798|PROCEDURE|Microneurography|Microneurography recording of sympathetic nervous system activity in muscle destiny
40748088|NCT05022537|DEVICE|retrograde nephrostomy|this will consist of one visit to a urologist for retrograde nephrostomy placement using a Retroperc device with lithotomy performed in the same visit and follow up at 4 weeks and 6 months.
40748089|NCT05022537|DEVICE|antegrade nephrostomy|this will consist of two visits, first to the interventional radiologist for antegrade nephrostomy placement followed by another visit to the urologist for lithotomy with follow up at 4 weeks and 6 months
40748090|NCT06236997|DRUG|Adebrelimab|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
40748091|NCT06236997|RADIATION|Radiation Therapy|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
40748092|NCT06236997|DRUG|etoposide, carboplatin(EC)|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
40748093|NCT00000853|BIOLOGICAL|rgp120/HIV-1MN|
40748094|NCT06304727|OTHER|clinical data review|Medical records review to gather and analyze demographic, clinical, care and virological data
40748095|NCT05225168|PROCEDURE|laparoscopic burch colposuspension operation|By pushing the urethra medially, two sutures are placed on the bladder at trigon level and midurethral and suspended on the bilateral iliopectineal ligament and colposuspension is supplied.
40748096|NCT05225168|PROCEDURE|minisling suburethral sling|A vertical vaginal incision is made 1 cm below the external urethral meatus. It is followed by minimal vaginal dissection from the inferior portion of the ascending ramus of the ischiopubic bone to the obturator muscle. The arms of the mesh are fixed on both sides of the obturator internus muscle with the help of a trocar. After leaving a 1-2 mm gap between the mesh and the urethra, the vaginal wall is closed by suturing.
40748097|NCT00284934|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
40748098|NCT00284934|DRUG|Tacrolimus|
40748099|NCT00284934|DRUG|Corticosteroids|At a dose of at least 5 mg/day.
40748100|NCT05058456|DEVICE|Shockwave Medical Mini S Peripheral IVL Catheter|The Shockwave Medical Mini S Peripheral IVL Catheter is intended for lithotripsy-enhanced catheter dilatation of lesions, including calcified lesions found in the peripheral vasculature, such as the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. The Mini S IVL Catheter is not for use in the coronary or cerebral vasculature.
40748101|NCT02372032|PROCEDURE|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
40748102|NCT02372032|PROCEDURE|ozone therapy|percutaneous intradiscal ozone injection
40748103|NCT04135001|BEHAVIORAL|HBM Training|A computer-based training to reduce hostile bias and interpersonal conflict as a mechanism to improve trust and cohesion within an operational military unit across the deployment cycle. The computer training is based on the Go/No-Go task (Fillmore et al., 2006) and Lexical Decision Task (Lepore \& Brown, 2002). The training reduces HAB by affecting two cognitive mechanisms: prime seeking non-hostile concepts when presented with ambiguous cues and conditioning inhibition in response to hostile cues. Thus, the training induces a non-hostile attribution bias while simultaneously training the inhibition of hostile attribution bias and aggressive behavior in response to ambiguous cues.
40748104|NCT04135001|OTHER|Placebo Training|Volunteers in the placebo condition will be told to complete the fragments with the first word that comes to mind. This placebo still exposes volunteers to the training stimuli and computer task, but does not train inhibition or selectively prime non-hostility, which are the hypothesized mechanisms of the training.
40748105|NCT01604200|BEHAVIORAL|focus group|key informant review
40748106|NCT05937100|DRUG|Formocresol|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute
40748107|NCT05937100|DRUG|Biodentine|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps
40748108|NCT05937100|DRUG|Hyaluronic acid gel|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes.
40748109|NCT03974958|GENETIC|Tissue-library|circulating biomarkers (miRNA panel) analysis of blood samples
41270136|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
41270137|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
41270138|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
41270139|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
41270140|NCT00342368|PROCEDURE|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
41270141|NCT05190952|DRUG|Bupivacaine|Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
40748110|NCT05145894|DEVICE|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
40748111|NCT02882516|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
40748112|NCT04270786|PROCEDURE|Early de-escalation|In de-escalating group, the empirical antibiotics will be stopped and then prophylaxis levofloxacin will be resumed.
40748113|NCT04270786|PROCEDURE|Standard|In the control arm, empirical antibiotics will be continue until recpvery of neutropenia or at least 7 days after afebrile.
40748114|NCT01196234|DRUG|Paclitaxel/Carboplatin/Gefitinib|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
40748115|NCT01196234|DRUG|Paclitaxel/Carboplatin|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
40748116|NCT03157791|DRUG|Simethicone 180Mg Cap|Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
40748117|NCT02909647|PROCEDURE|Preoperative planning|preoperative planning using 3D digital planning software or conventional template
40748118|NCT02909647|PROCEDURE|Osteosynthesis|osteosynthesis using volar locking plate
40748119|NCT02112175|DRUG|Lenalidomide|
41441016|NCT04935164|OTHER|Psychiatric evaluations|At different time points, several psychiatric evaluations will be performed on patients and volunteers for study purposes
40748120|NCT05442892|PROCEDURE|Multicomponent exercise training programme|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individuals functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 30-60% of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L. Torrejón de Arroz, Madrid, Spain) combined with balance and gait retraining exercises that progressed in difficulty and functional exercises such as rises from a chair.
40748121|NCT02384460|DRUG|SD-101-6.0 cream|applied topically once a day for 90 days
40748122|NCT02384460|DRUG|Placebo (SD-101-0.0) cream|applied topically once a day for 90 days
40748123|NCT05189197|DRUG|Zanubrutinib + R-CHOP|"Zanubrutinib 160 mg BID administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved CR will continue to receive zanubrutinib 160mg BID for 1 year."
40748124|NCT06318286|DRUG|Lenvatinib|Induction treatment: lenvatinib, 8 mg QD on Day 1 of a 21-day cycle for 4-6 cycles. Maintenance treatment: Lenvatinib, 20 mg QD may be given for up to a total of 35 cycles.
40748125|NCT06318286|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2 will be given by intravenous (IV) infusion on Day 1 of a 21-day cycle for 4-6 cycles.
40748126|NCT06318286|DRUG|Cisplatin/Carboplatin|Carboplatin (AUC 5 mg/mL/min) or Cisplatin (75 mg/m2) will be given by IV infusion on Day 1 of a 21-day cycle for 4-6 cycles.
40748127|NCT06318286|DRUG|Pembrolizumab|Pembrolizumab, 200 mg will be given by IV infusion on Day 1 of a 21-day cycle for up to a total of 35 cycles.
40748128|NCT00474968|DEVICE|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector \[SoftPAP(R)\]
40748129|NCT00474968|DEVICE|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
40748130|NCT00516854|DRUG|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
40748131|NCT00064454|DRUG|OPC-6535 Tablets (drug)|
40748132|NCT05608083|BEHAVIORAL|HEARTS classes|HEARTS teaches autistic adults about friendship and healthy dating relationships. HEARTS is 6-sessions long and meets weekly over zoom. Each session is 90 minutes long.
40748133|NCT05608083|BEHAVIORAL|Online discussion group|A 90-minute discussion group will meet online weekly for 6 weeks to discuss friendships and healthy dating relationships for autistic adults.
40748134|NCT05367830|BEHAVIORAL|the Bone@BC app|The bone@BC app is a diary for patients with breast cancer that they can use if they want to.
40748135|NCT02792127|BEHAVIORAL|Online Program for Social Anxiety|This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
40748136|NCT03087357|OTHER|SmartNIPT|A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.
40748137|NCT04342585|DRUG|Micronised vaginal progesterone|A diary will be given to participants to ensure compliance.
40748138|NCT04342585|DEVICE|Vaginal pessary|The internal diameter size will be decided based on the clinical assessment of the cervix.
40748139|NCT00893295|OTHER|informational intervention|
40748140|NCT00893295|OTHER|medical chart review|
40748141|NCT00893295|OTHER|screening questionnaire administration|
40748142|NCT00893295|OTHER|study of socioeconomic and demographic variables|
40748143|NCT00893295|PROCEDURE|barium enema injection|
40748144|NCT00893295|PROCEDURE|colon imaging study|
40748145|NCT00893295|PROCEDURE|screening colonoscopy|
40748146|NCT00893295|PROCEDURE|sigmoidoscopy|
40748147|NCT05535088|DEVICE|Virtual reality|Virtual reality consists for about a minute and a half 6 times per session. During the first and the second session, subjects will experiment virtual reality while sited. Moreover, during the third and the fourth session subjects will be standing with a side by side stand. During the last two experimental sessions subjetcts will be standing with a semi tandem stand.
40748148|NCT02217007|DRUG|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
40748149|NCT05313633|OTHER|Designed physical therapy|Attention was given to improve strength, enhance postural control, promote normal walking-pattern, and optimize function. The program incorporated manual passive and functional flexibility, progressive strengthening, postural and advanced balance exercises, and functional walking exercises
40748150|NCT05313633|OTHER|Occupational therapy|Both groups received a designed occupational therapy program for 30 minutes that included exercises facilitating hand skills, such as reaching, grasping, carrying, releasing, in-hand manipulation, and bilateral hand use. The children performed these exercises while they sat on a chair, with the therapist sitting beside to guide and assist them in performing the exercises correctly
40922354|NCT04119271|OTHER|Breathe Easy at Home Kit Products|HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
41095493|NCT06040645|OTHER|E-consult|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
41095494|NCT04380844|OTHER|Beprevent|10 will become part of the intervention group. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
41095495|NCT05931484|DRUG|Gemfibrozil|Oral Solution
41095496|NCT05931484|DRUG|Placebo|Daily dose of Placebo
41095497|NCT05417997|DIETARY_SUPPLEMENT|Kunamin®|Grape juice, seed, stem and rice extracts supplement containing KH good healthy cells (proteins)
41095498|NCT05417997|DRUG|Favipiravir|Antiviral medication used to treat influenza
41095499|NCT05417997|DRUG|Enoxaparin|Anticoagulant medication
41095500|NCT05417997|DRUG|Lansoprazole|Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.
41095501|NCT05417997|DRUG|Paracetamol|Analgesic to treat minor aches and pains, and fever reducer.
41095502|NCT05417997|DRUG|Ceftriaxone/ Clarithromycin|Inhibits the production of pneumolysin
41095503|NCT05417997|DRUG|Methylprednisolone|Treat inflammation, severe allergies, flares of chronic illnesses
41095504|NCT05989737|BEHAVIORAL|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
41095505|NCT06488170|DRUG|Tildrakizumab|As provided in real world clinical practice.
41095506|NCT02693626|BEHAVIORAL|intensive cessation message|Mobile phone-based text message （three to five messages per day） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
41095507|NCT02693626|BEHAVIORAL|Not intensive cessation message|Mobile phone-based text message （three to five messages per week） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
41095508|NCT03589482|DEVICE|Electrical Impedance Tomography|Electrical impedance tomography (EIT) is a new technique that enables real-time visualization of the distribution of ventilation at the bedside. This technique allows clinicians and investigators to immediately determine how applying higher or lower PEEP levels affect stress and strain in the lung. The investigators propose to apply this new technique to test a strategy for finding the optimal level of PEEP that prevents lung injury and improves outcomes in critically ill patients.
41095509|NCT03589482|OTHER|ExPRESS-derived PEEP level|The ExPRESS algorithm is a traditional approach to selecting PEEP based on respiratory mechanics.
41095510|NCT05838560|DRUG|Dasatinib + quercetin|dasatinib 100mg / quercetin 1250mg The intervention will involve the participant taking both dasatinib and quercetin combined.
41095511|NCT04811287|DEVICE|Carpal Tunnel Release with Platelet-Rich Plasma|CTR is performed with adjuvant PRP placed intra-operatively.
41095512|NCT04811287|PROCEDURE|Carpal Tunnel Release without Platelet-Rich Plasma|CTR is performed without adjuvant PRP placed intra-operatively.
41095513|NCT04379986|DEVICE|Senbiosys|The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.
41095514|NCT06622499|DRUG|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 1 liter of Ringer's lactate either cold (10°C, 50°F), or at room temperature (22°C, 71.6°F) with 100 ml/min. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
41095515|NCT05515367|DRUG|Desidustat|Oral tablet
41095516|NCT03203161|PROCEDURE|bariatric surgery|Roux-and-Y Gastric Bypass or Sleeve gastrectomy
41095517|NCT06075745|DRUG|CMV-MVA Triplex|The dosage used will be 5.0 x 10\^8 pfu, administered under sterile conditions intramuscularly. The CMV-MVA Triplex vaccine lots range in titre from 5.0 to 9.0 x 10\^8 pfu/mL in a supplied volume of 1.0 mL
41095518|NCT06075745|DRUG|Placebo for CMV-MVA Triplex|Arm 2 participants receive two doses of matching placebo CMV-MVA Triplex
41095519|NCT01746394|BEHAVIORAL|Parents as Teachers Enhanced|Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
41270142|NCT05190952|DRUG|Ketamine|In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes.
40748151|NCT05313633|OTHER|Plyometric training|"The designed plyometric training program basically focuses on upper extremity strength training and is developed according to the guidelines of the National Strength and Conditioning Association. The exercise load is progressively increased and conducted in two phases; each phase lasted for six weeks. To ensure safety and optimal performance, every child performed a pre-workout warming up before each session for five minutes including static and dynamic stretching and moving through the exercises planned for each day's workout at a lower intensity. Another set of cool down exercises for five minutes is considered to stretch and relax the entire body after each session.~The exercises include:~Two-hand chest pass Downward slam throw Push-ups against wall Clap push-ups against wall Bench push-ups Two-hand overhead throw Two-hand underhand side throw Single-Arm Throw"
40748152|NCT05313633|OTHER|Wii training|The dose of Wii training was 40 minutes, three times a week for 12 weeks which is an interactive motion-based device. The Wii has a multiplayer mode and different levels of difficulty. The content of Wii training consisted of practicing four Wii games: (1) tennis; (2) boxing; (3) bowling; and (4) basketball. These games are chosen because they target the upper limbs, are fun, provide immediate feedback, and are easy to learn and play, and progression is built into the game. Also, fine motor coordination and sensory deficits are targeted through pressing buttons and vibration feedback from the Wii Remote. The children are instructed that they could stop at any point if discomfort or undue fatigue is experienced. The therapist randomly presented the games to eliminate any effect of order
40748153|NCT00369863|DRUG|Triamcinolone acetonide|
40748154|NCT03471949|OTHER|CGM in a population with normal OGTT|The population with normal OGTT will use CGM and document their values as well as be documenting a capillary blood glucose value
40748155|NCT00500929|DRUG|CMI X-11S|
40748156|NCT00476541|DRUG|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
40748157|NCT05009550|PROCEDURE|Group ESP|Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group
40748158|NCT05009550|OTHER|Non-blocked Group|This Group is received no intervention.Patients will be sedated as standard and radiofrequency procedure will be applied.
40748159|NCT06447896|DEVICE|Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000)|"Cardiovascular autonomic reflex tests (CARTs) and heart rate variability analysis (HRV) are conducted with Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000). CARTs include five standardized tests, which are heart rate response to lying-to-standing, Valsalva maneuver, deep breathing, and blood pressure response to lying-to-standing and sustained isometric handgrip. These series of movements act as standardized stimuli to trigger hemodynamic changes in the body, altering vagal and sympathetic activity through mechanisms such as the baroreflex, thereby producing changes in heart rate and blood pressure. The sensor-monitoring interactive design of the device ensures the standardization of these maneuvers."
40748160|NCT06447896|DIAGNOSTIC_TEST|Conventional method of CARTs|Conventional method are conduced using blood pressure kit with manual sphygmomanometer and ECG machine. Conventional method and the investigated device are used simultaneously to record electrocardiograms. Conventional blood pressure taking are carried out in sequence with the investigated device. CARTs results from the conventional method are used as control.
40748161|NCT06447896|DEVICE|Ambulatory holter station Model i12 plus|Model i12 plus (manufactured by RENCARE) is an ambulatory holter station, which was approved by the Center for Medical Device Evaluation (CMDE), China National Medical Products Association (NMPA). It can analyze electrocardiogram and generate HRV indices, which include SDNN, RMSSD, NN50, pNN50, triangular index, average RR, deceleration capacity (DC), deceleration runs (DRs), VLF, LF, HF, LF/HF, and total power. Model i12 plus is used to analyzed the same ECG signals as the investigated device.
40748162|NCT02273466|DRUG|Desipramine tablet|
40748163|NCT02273466|DRUG|Crobenetine infusion|
40748164|NCT02273466|DRUG|Placebo infusion|
40748165|NCT03709095|OTHER|Sprint interval training|Participants utilized the arm ergometer for improving aerobic exercise capacity
40748166|NCT03709095|OTHER|moderate intensity continuous training|Participants utilized the arm ergometer for improving aerobic exercise capacity
40748167|NCT00947388|DRUG|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
41270143|NCT05190952|DRUG|Dexamethasone|In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes.
41270144|NCT03931174|BEHAVIORAL|Addiction Technology Transfer Center (ATTC) Training Strategy|Participating organizations will receive training consisting of 3 components: 1) didactic workshop - full-day workshop led by a contingency management (CM) expert for both CM staff and leaders, 2) performance feedback - submission of CM session recordings for review and performance feedback at least monthly for 9 months for CM staff, and 3) staff coaching - monthly provider coaching calls led by a CM expert for 9 months for both CM staff and leaders.
41270145|NCT03931174|BEHAVIORAL|Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy|Participating organizations will receive all of the elements of the ATTC control condition. In addition, organizations will receive two additional elements: 1) Implementation Sustainment Facilitation - monthly coaching calls for CM leaders and staff focused on sustainment, 2) Pay for Performance - participating CM staff will have the opportunity to earn monthly monetary bonuses for achieving pre-defined implementation goals for 9 months.
41453202|NCT04289805|OTHER|standard-stimulated cohort|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: Gonadotrophins started from cycle day 2-3 throughout the ovarian stimulation until ovulation triggering.~Random start protocol: Gonadotrophins started at any time of the cycle and throughout the stimulation.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
40748168|NCT00947388|BIOLOGICAL|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
40748169|NCT05419258|DEVICE|UPLUG Hemodialysis Connection Device|use of the device UPLUG during 1 month
40748170|NCT00350506|DEVICE|64 Channel VCT|
40748171|NCT00313898|DRUG|sildenafil (viagra)|
40748172|NCT04819620|DRUG|PN-232|Active Drug
40748173|NCT04819620|DRUG|Placebo|Matching Placebo
40748174|NCT01838889|BEHAVIORAL|Culturally adapted psychological intervention (Positive Health Programme)|This study will evaluate the efficacy of a group psychological intervention (PHP) based on the principles of Cognitive Behaviour Therapy in treating depression in postpartum women.
40748175|NCT00051506|DRUG|ALIMTA|
40748176|NCT00051506|DRUG|carboplatin|
40748177|NCT00051506|DRUG|cisplatin|
40748178|NCT05540275|DRUG|Tislelizumab plus Bevacizumab|200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks
40748179|NCT01155609|PROCEDURE|quality-of-life assessment|Ancillary studies
40748180|NCT01155609|PROCEDURE|management of therapy complications|Discontinue supplement; treat symptomatically
40748181|NCT01155609|DIETARY_SUPPLEMENT|L-lysine|Given PO
40748182|NCT01354535|PROCEDURE|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
40748183|NCT01354535|PROCEDURE|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
40748184|NCT01501513|DRUG|PEG-3350 based bowel preparation|solution for oral administration prior to colonoscopy
40748185|NCT01501513|DRUG|BLI800 approved preparation regimen|solution for oral administration prior to colonoscopy
40748186|NCT01501513|DRUG|BLI800 investigational preparation regimen|solution for oral administration prior to colonoscopy
40748187|NCT03126266|RADIATION|re-irradiation|if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
40748188|NCT01213771|PROCEDURE|Preoperative preparation 2010|Preoperative optimisation Supportive care LEAN in patient pathways
40748189|NCT04224051|DRUG|Metformin|Metformin target dose 2 g daily
40748190|NCT04224051|OTHER|Standard care|Abdominal aortic aneurysm surveillance
40748191|NCT05992038|PROCEDURE|Osteotomy with putty|Synthetic ceramic putty
40748192|NCT05992038|PROCEDURE|Conventional osteotomy|conventional osteotomy
40748193|NCT03390491|BEHAVIORAL|OnTrack>TheGame (OTG)|OTG clients will be informed that the game can be played on a computer or a tablet and the time estimate for completing the game is approximately 5-8 hours. OnTrack\>The Game offers players the opportunity to immerse in a fictional neighborhood that centers around four domains for supportive recovery as defined by SAMHSA: health, home, purpose and community. The player interacts with other game characters including new acquaintances, friends/peers, a family member, and a treatment team, allowing the player to practice social and communication skills, while fostering personal relationships and building a support network. Additionally, the game provides players with helpful resources including psychoeducation materials and videos of real people who have experienced a first episode of psychosis, sharing their stories of hope and recovery. As a whole, the game provides a safe environment to promote goal attainment and recovery.
40748194|NCT03390491|BEHAVIORAL|Recovery Videos (RV)|As described, RV clients will have access to a website that includes recovery videos and static psychoeducation materials. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website.
40748195|NCT03268187|DEVICE|Biofeedback|The skin conductance of the patient is measured and fed back to the patient via screen.
40748196|NCT03268187|BEHAVIORAL|Self-Alert Training|Self-Alert Training
40748197|NCT03268187|BEHAVIORAL|Relaxation Training|Relaxation Training
40748198|NCT00267319|DRUG|Glatiramer acetate|
40748199|NCT02039570|OTHER|Transvaginal scan|transvaginal scan conducted using duplex ultrasonography
40748200|NCT03514225|OTHER|Metacognitive Therapy for Social Anxiety|The transdiagnostic Metacognitive model posits that psychological disorder stems from the activation of a perseverative thinking style called the CAS (Cognitive Attentional Syndrome). This has 3 key elements: worry/rumination, threat-focussed attention and unhelpful coping behaviours. Each of these elements results in extended cognitive responses to negative thoughts, prolonging negative emotions and maintaining an individual's sense of threat. The CAS arises from an individual's positive and negative metacognitive beliefs (beliefs about cognition). Metacognitive Therapy (MCT) aims to bring the CAS under control by modifying metacognitive beliefs and enabling individuals to develop new reactions to negative thoughts.
40748201|NCT06007443|OTHER|pain related variables assessment|Pressure pain threshold, conditioned pain modulation, temporal summation, and two-point discrimination will be evaluated on the upper trapezius muscle. Average pain intensity will be asked.
40748202|NCT01978574|BEHAVIORAL|Intellectual Enrichment daily activities|A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).
40748203|NCT01978574|BEHAVIORAL|Intellectual Enrichment documentary videos|Participants watch daily documentary videos.
40748204|NCT03650270|DRUG|Phenobarbital|Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
40748205|NCT02053584|DEVICE|Dario™ Blood Glucose Meter|Each subject will undergo a finger prick and also provide a venous blood sample
40748206|NCT02053584|DEVICE|YSI2003|Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
40748207|NCT06001307|BEHAVIORAL|Program STARS (Supporting Trans Affirmation, relationships, and Sex)|See description to the left.
40748208|NCT06001307|BEHAVIORAL|Relaxation and Stress Reduction|See description to the left.
40748209|NCT04686409|BIOLOGICAL|COVID-19 vaccines|Participants will be vaccinated with one of the approved COVID-19 vaccines
40748210|NCT04617223|PROCEDURE|Endoscopic sinus evacuation|Evacuation of the sinus by using endoscope
40748211|NCT00127933|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
40748212|NCT00127933|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
40748213|NCT00127933|DRUG|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
40748214|NCT00127933|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
40748215|NCT00127933|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
40748216|NCT01763957|BEHAVIORAL|Paula Method|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
40748217|NCT01763957|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
40748218|NCT00964678|DRUG|Carvedilol|twice daily oral treatment in escalating dose
40748219|NCT03753477|DRUG|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)
40748220|NCT03753477|DRUG|Sevikar and Crestor|Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
40748221|NCT01799278|DRUG|MLN8237|MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
40748222|NCT01363271|DRUG|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
40748223|NCT01363271|DRUG|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
40748224|NCT01363271|DRUG|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
40748225|NCT01363271|DRUG|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
40748226|NCT00907088|OTHER|Healthy milk intake|In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
40748227|NCT00907088|OTHER|Standard nutrition counselling|Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
40748228|NCT04948125|DRUG|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
40748229|NCT04948125|DRUG|Apatinib Mesylate|250 mg qd
40748230|NCT03783884|DEVICE|Lungpacer Diaphragm Pacing Therapy|Transvenous phrenic nerve stimulation to induce diaphragm contraction.
40748231|NCT02396797|BEHAVIORAL|The new atWork intervention|"atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting."
40748232|NCT02396797|BEHAVIORAL|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
40748233|NCT06386120|OTHER|PEEP setting strategy|The attending physician selects different PEEP setting strategies
40748234|NCT03419468|OTHER|Self Geriatric Assessment Measure (SGAM)|Self Geriatric Assessment Measure
40748235|NCT05124860|DIAGNOSTIC_TEST|Indirect calorimetry|Measurement of metabolic rate (kcal/day) by respiratory gas analysis.
40748236|NCT05135325|BEHAVIORAL|Patient portal message|Portal message encourages patients to donate blood
40748237|NCT05135325|BEHAVIORAL|Social responsibility|Message specifies that there is a shortage of the patient's blood type
40748238|NCT03464838|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
41095520|NCT01746394|BEHAVIORAL|Parents as Teachers|Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
41095521|NCT06037616|OTHER|powerpoint and tutor|Powerpoint on indication of skin suture and tutor for the skill to perform skin suture
41095522|NCT06037616|OTHER|video skill|Video showing skill to perform a skin suture
41095523|NCT06037616|OTHER|video errors|Video showing errors of skin suture
41095524|NCT02915809|BIOLOGICAL|GC3110B vaccine|0.5mL, Intramuscular
41095525|NCT02915809|BIOLOGICAL|GCFLU Quadrivalent Inj. vaccine|0.5mL, Intramuscular
40748239|NCT03464838|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
40748240|NCT03399123|OTHER|Tidal volume|After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
40748241|NCT00327171|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
40748242|NCT00327171|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
40748243|NCT05849974|OTHER|Structural and fonctional phynotyping|"The additioan acts in this research are:~Fonctionnal phenotyping:Retinal sensitivity and fixation stability assessment using microperimetry, assessment of long-term fixation stability Structural Phenotyping: Anterior segment examination with OCT anterior Blood sample collection"
40748244|NCT00943904|DEVICE|Interstim implant for SNS|stimulates third sacral nerve root
40748245|NCT02773628|DEVICE|Acar'up system|
40748246|NCT02773628|DEVICE|Acar'up placebo system|
40748247|NCT04776876|BIOLOGICAL|Retifanlimab|Given IV
40748248|NCT04776876|DRUG|Telotristat Ethyl|Given PO
40748249|NCT02353663|OTHER|Echocardiography|Echocardiography examination
40748250|NCT06494956|PROCEDURE|Implant device|A subcutaneous tunnel was established under general anesthesia, the electrode was connected to the stimulator, and the pulse generator was implanted in the skull.
40748251|NCT02337946|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
40748252|NCT02337946|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
40748253|NCT00105508|DRUG|Sarizotan|Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.
40748254|NCT00105508|DRUG|Placebo|Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
40748255|NCT05922085|OTHER|Ultrasound|performed within 3 hours prior to extubation
40748256|NCT05922085|OTHER|nasofibroscopie|performed within 24 to 36 hours after extubation
40748257|NCT05800704|DIETARY_SUPPLEMENT|Nagasin|Lactobacillus, Lactococcus and Bifidobacteria strains with antimicrobial effect against C. difficile
40748258|NCT05800704|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin (placebo comparator)
40748259|NCT00940459|DEVICE|Senofilcon A contact lens (Acuvue Oasys)|Silicone hydrogel contact lens CE-marked for the intended usage.
40748260|NCT00940459|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens CE-marked for the intended usage.
40748261|NCT00940459|DEVICE|Lotrafilcon B contact lens (Air Optix)|Silicone hydrogel contact lens CE-marked for the intended usage.
40748262|NCT00940459|DEVICE|Balafilcon A contact lens (PureVision)|Silicone hydrogel contact lens CE-marked for the intended usage.
40748263|NCT00940459|DEVICE|Etafilcon A contact lens (Acuvue 2)|Hydrogel contact lens CE-marked for the intended usage.
40748264|NCT00940459|DEVICE|Contact lens care system (EasySept)|Contact lens care system CE-marked for the intended usage.
40748265|NCT00032760|BEHAVIORAL|Meditation|
40748266|NCT02753673|BEHAVIORAL|qualitative interviews with patients|
40748267|NCT02753673|BEHAVIORAL|questionnaires|
40748268|NCT03275610|GENETIC|Blood sample|5 mL of blood withdrawn from patients with history of pulmonary embolism post total hip arthroplasty or total joint arthroplasty
40748269|NCT01814332|DRUG|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
40748270|NCT01814332|DRUG|Placebo|Placebo compound treatment for comparison with IP
41453203|NCT04179396|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
40748271|NCT00523380|DRUG|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
40748272|NCT00523380|DRUG|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
40748273|NCT00929097|OTHER|Implementation aids|"* Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~* Clinicians receive the guidelines and a risk communication tool, as well as education"
40748274|NCT00929097|OTHER|Control|Dissemination of guidelines
40748275|NCT00004032|BIOLOGICAL|ALVAC-hB7.1|Given IP
40748276|NCT00004032|BIOLOGICAL|recombinant interferon gamma|Given IP
40748277|NCT00004032|OTHER|laboratory biomarker analysis|Correlative studies
40748278|NCT01701648|OTHER|Laser CO2|Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
40748279|NCT06194669|OTHER|Blood and urine sample collection|One whole blood sample per individual (3 ml) will be collected. Up to 5 urine samples per individual will be collected
40748280|NCT02985281|DRUG|Sofosbuvir Oral Product|direct acting antiviral drug for HCV infection
40748281|NCT02985281|DRUG|Ribavirin|antiviral drug for HCV infection
40748282|NCT06169085|DRUG|Leritrelvir|Oral
41270146|NCT04673097|OTHER|Icon® resin infiltration|low viscosity resin that can flow through the pores in the enamel surface
41441017|NCT03711760|BEHAVIORAL|telepsychology|CBT delivered by telepsychology
41453204|NCT04179396|DRUG|Enzalutamide|"Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved."
41453205|NCT04179396|DRUG|Abiraterone|Abiraterone will be administered once daily with prednisone
41453206|NCT02626260|OTHER|adhesive strip|Adhesive strip with a standard adhesive base
41453207|NCT04712838|DRUG|SHR0302|Group A subjects were given oral F1 、F2 and F3 version SHR0302
40748283|NCT02694250|DEVICE|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
40748284|NCT01049672|DRUG|Alfentanil|Titrated to a maximum dose of 50mg in 24 hours subcutaneously
40748285|NCT01049672|DRUG|Diamorphine|Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
40748286|NCT03170921|OTHER|Angola|The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
40748287|NCT03170921|OTHER|Benguela|The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
40748288|NCT03170921|OTHER|São Bento|The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
40748289|NCT05545488|DEVICE|Virtual reality|I had the women wear virtual reality glasses and watch the video they wanted for at least 5, maximum 15 minutes during the examination.
40748290|NCT03457584|PROCEDURE|air arm|epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye
40748291|NCT03457584|PROCEDURE|BSS arm|epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
40748292|NCT03682081|DEVICE|Isometric tongue strengthening facilitated by Iowa Oral Performance Instrument (IOPI)|An air-filled pressure bulb is placed on the surface of the oral tongue and pressed against the hard palate during exercise. Each patient is given a target pressure value to aim for as determined by the baseline one repetition maximum (1RM) lingual pressures. During week one of the regimen, the target value of each repetition will be 60% of the 1RM. For the remaining seven weeks, the target value will be increased to 80% of the 1RM. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
40748293|NCT03682081|DEVICE|Biotene Oral Balance Gel|Participants will be instructed to apply an amount equivalent to about 1 cm of Biotene® Oral Balance Gel with a finger to the tongue and most intensely affected areas of the oral cavity three times a day after brushing their teeth for 8 weeks.
40748294|NCT01909401|DRUG|boceprevir|
40748295|NCT06324578|DIAGNOSTIC_TEST|AT Testing|Analysis of blood specimens and neck ultrasonography
40748296|NCT03344393|DRUG|Ketamine Hydrochloride|intravenous ketamine infusion intraoperatively
40748297|NCT03344393|DRUG|Normal saline|intravenous normal saline infusion intraoperatively
40748298|NCT01363830|BEHAVIORAL|Two-Week Post-Operative Restriction|Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.
40748299|NCT01363830|BEHAVIORAL|Six-Week Post-Operative Restriction|Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
40748300|NCT04939584|DEVICE|MultiPulse Therapy|Electrical Stimulation
40748301|NCT02633657|DRUG|HORIZANT 300 mg|HORIZANT 300 mg once daily
40748302|NCT03614988|OTHER|Evening Levothyroxine Administration|Bedtime levothyroxine intake, with 60-minute meal-free interval
40748303|NCT03614988|OTHER|Morning Levothyroxine Administration|Morning levothyroxine intake, 60 minutes before breakfast.
40748304|NCT03312907|DRUG|Belimumab|Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
40748305|NCT03312907|DRUG|Rituximab|Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
40748306|NCT03312907|DRUG|Rituximab-placebo|Saline will be administered as IV infusions at Week 4 and Week 6
40748307|NCT03312907|DRUG|Standard therapy (Including Immunosuppressants)|Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
40748308|NCT03312907|DRUG|Standard therapy (Excluding Immunosuppressants)|Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to \<= 5 mg/day will administered through Week 104.
40748309|NCT03312907|DRUG|Steroid Taper|Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
40748310|NCT02508064|DRUG|BMS-663068|BMS-663068
40748311|NCT01371760|PROCEDURE|Venous PTA|PTA of the internal jugular and/or azygous vein
40748312|NCT01371760|OTHER|Catheter Venography|The patients will undergo catheter venography but not PTA
40748313|NCT00114478|DRUG|Epinephrine|
40748314|NCT00114478|DRUG|albuterol (salbutamol)|
40748315|NCT01556100|DRUG|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
40748316|NCT01691482|DRUG|Albuterol/salbutamol|Albuterol/salbutamol (daily)
40748317|NCT01691482|DRUG|Ipratropium|Ipratropium (daily)
40748318|NCT04607447|BEHAVIORAL|low intracranial pressure strategy treatment|"1. Supine position for 16h-18h daily, with head toward the affected side in most of the time, and 15-20 cm elevation of lower limbs.~2. Abdominal belt compression"
40748319|NCT04607447|DRUG|Atorvastatin plus Dexamethasone|Atorvastatin plus Dexamethasone
40748320|NCT00131300|DEVICE|Synvisc (hylan G-F 20)|
40748321|NCT05438420|DRUG|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.
40748322|NCT05438420|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle
40748323|NCT05290298|DIETARY_SUPPLEMENT|NITRATE|Multi-component nutritional formula
40748324|NCT05290298|DIETARY_SUPPLEMENT|PLACEBO|Placebo
40748325|NCT03358953|DEVICE|Electron Cigarette|Blended Tobacco flavour, 18mg/ml
40748326|NCT03358953|DEVICE|Nicotine Replacement Patch|NiQuitin 21mg
40748327|NCT06259838|OTHER|no intervention|no intervention
41453208|NCT04712838|DRUG|SHR0302|Group B subjects were given oral F1 、F3 and F2 version SHR0302
41453209|NCT04712838|DRUG|SHR0302|Group C subjects were given oral F2 、F1 and F3 version SHR0302
40748328|NCT05257044|DRUG|Cannabigerol|Participants will ingest CBG and placebo in a double-blind randomized cross-over design
40748329|NCT05257044|OTHER|Placebo|Placebo
40748330|NCT00108537|DRUG|bupropion and transdermal patch|
40748331|NCT00108537|DRUG|transdermal patch and nicotine inhaler|
40748332|NCT03593447|DRUG|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg
40748333|NCT03593447|DRUG|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group2: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg
40748334|NCT03593447|DRUG|non-cirrhotic subjects. low TG-2349+ low DAG181|Group 3: TG-2349 200 mg + DAG181 100 mg
40748335|NCT03593447|DRUG|non-cirrhotic subjects. high TG-2349+ high DAG181|Group 4: TG-2349 400 mg + DAG181 200 mg
40748336|NCT03593447|DRUG|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group 5: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg_
40748337|NCT03593447|DRUG|cirrhotic subjects. high TG-2349+ high DAG181|Group6: TG-2349 400 mg + DAG181 200 mg
40748338|NCT01551823|BIOLOGICAL|Influenza Virus Vaccine(no Preservative )|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
40748339|NCT01551823|BIOLOGICAL|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
40748340|NCT06460129|OTHER|Brugger's Exercises|"1. The participant will sit upright and wrap an elastic resistance band around each hand, leaving the palms open. They will perform thumb and finger abduction and extension, wrist extension, and forearm supination. This will be followed by scapular retraction with shoulder external rotation, elbow extension, shoulder abduction, and extension, holding this position for 10 seconds.~2. In both sitting and standing positions, the participant will sit at the edge of a seat, naturally lifting the sternum, with legs spread at a 45-degree angle and feet slightly turned out. Shoulders should be relaxed, chin tucked, and elbows fully extended. The participant will keep their shoulders down, imagining the scapulae pressing together and downward into a V shape, with thumbs turned out, palms up, and fingers spread. This position is held for 10 seconds."
40748341|NCT06460129|OTHER|Kendal Exercise|"1. In a supine position, the participant will place a towel around their neck. With their head on the floor, they will tuck their chin and use the towel to apply gentle resistance, holding for 10 seconds to strengthen the deep flexor muscles of the cervical spine.~2. In a prone position, the participant will point their thumbs toward the ceiling and extend their arms fully while leaning forward, then return to the starting position. They will then extend their arms horizontally and hold for 10 seconds.~3. The participant will place both hands on the back of their head, lift their elbows upward, pull them back, and simultaneously spread their arms out to the side. This position will be held for 10 seconds before returning to the starting position."
40748342|NCT02439619|OTHER|TechCare|The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
40748343|NCT04366583|DEVICE|argon plasma coagulation|Olympus electrosurgical unit/argon plasma coagulation unit (PSD-60/Endoplasma, Olympus Corp., Tokyo, Japan)
40748344|NCT04366583|DEVICE|hemoclipping|clipping device (Olympus HX 110/610, Olympus Corp., Tokyo, Japan)
40748345|NCT04772131|DEVICE|Desara® One Single Incision Sling|Single incision sling
40748346|NCT04772131|DEVICE|Desara® Blue Transobturator Sling|Standard mid-urethral sling
40748347|NCT01765621|OTHER|DDI+ System and Pharmacogenetic Data|
40748348|NCT03402087|DRUG|Methotrexate|Specified dose on specified days
40748349|NCT03402087|DRUG|Leucovorin|Specified dose on specified days
40748350|NCT03402087|DRUG|BMS-986165|Specified dose on specified days
40748351|NCT04027946|DRUG|LMB-100|Participants will receive LMB-100 on days 1, 3 and 5 of a 21-day cycle for up to 2 cycles.
40748352|NCT04027946|DRUG|pembrolizumab|Participants will receive pembrolizumab on day 1 of each subsequent 21-day cycle.
40748353|NCT04027946|DIAGNOSTIC_TEST|Mesothelin Expression|Testing for mesothelin expression performed at screening
40748354|NCT04027946|DIAGNOSTIC_TEST|TrueSight Oncology 500|Testing for ROS oncogene 1 (ROS1) gene, anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) variations performed at screening.
41453210|NCT04712838|DRUG|SHR0302|Group D subjects were given oral F2 、F3 and F1 version SHR0302
41453211|NCT04712838|DRUG|SHR0302|Group E subjects were given oral F3 、F1 and F2 version SHR0302
41453212|NCT04712838|DRUG|SHR0302|Group F subjects were given oral F3 、F2 and F1 version SHR0302
40748355|NCT04200209|OTHER|Implementation of a quality indicator feedback mechanism|"1. Audit and feedback: A summary of clinical performance and hospital safety culture over a specified period of time.~2. Benchmarking Achievable: benchmarks are calculated from the performance of all members of a peer group and represents a realistic standard of excellence attained by the top performers in that group (i.e. comparing to the top 10% of peers).~3. Educational outreach: A trained independent person or investigator will meet with health professionals or managers in their practice setting to provide information (e.g. feedback of quality indicators).~4. Action planning: The purpose of action planning is to support quality improvement efforts by identifying opportunities for improvement, strategies and steps to accomplish the work."
40748356|NCT06548958|PROCEDURE|Second Stem Cell Transplantation (SCT2)|"1. Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally; Day -6: Total Body Irradiation (TBI) 4Gy; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion;~2. Donor Stem Cell Infusion (Second Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg)."
40748357|NCT03290729|PROCEDURE|wedge shape implants insertion|Narrow dental implants inserted in narrow ridges
40748358|NCT05331937|COMBINATION_PRODUCT|repetitive transcranial magnetic stimulation (rTMS)|rTMS (real versus sham) is used as adjuvant to ERP
40748359|NCT01050842|DRUG|bicalutamide|Given orally
40748360|NCT01050842|DRUG|raloxifene|Given orally
40748361|NCT01050842|PROCEDURE|quality-of-life assessment|Ancillary study
40748362|NCT00127010|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
41453213|NCT00005040|DRUG|arsenic trioxide|
40748363|NCT05430295|PROCEDURE|phacoemulsification|cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients
40748364|NCT05430295|PROCEDURE|monofocal intraocular lens implantation|implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
40748365|NCT05124678|DRUG|Isoniazid Tablets|High dose of isoniazid
40748366|NCT05202496|DRUG|Calcitriol 0.25Mcg Cap|After orthodontic levelling and alignment, experimental group subjects are administered one capsule of calcitriol 0.25 mcg on a daily basis during the study period. Also, serum vitamin D levels are monitored at monthly intervals and rate of canine retraction is measured at monthly intervals
40748367|NCT05202496|PROCEDURE|orthodontic treatment|experimental group subjects undergo orthodontic treatment after extraction of premolars
40748368|NCT05061355|PROCEDURE|Heart valve surgery|Heart valve surgery will be performed as soon as possible and preferably within 48 hours
40748369|NCT06417671|DIETARY_SUPPLEMENT|Postbiotics supplementation|The participants will consume one capsule per day.
40748370|NCT06417671|DIETARY_SUPPLEMENT|Placebo supplementation|The participants will consume one capsule per day.
40748371|NCT01791296|DRUG|Dexmedetomidine|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
40748372|NCT01791296|OTHER|Placebo|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
40748373|NCT02677389|OTHER|Educational Intervention|Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
40748374|NCT02677389|OTHER|Internet-Based Intervention|Receive email and technical or how-to support from study coordinator
40748375|NCT02677389|DEVICE|Monitoring Device|Wear a Fitbit web-integrated physical activity tracker
40748376|NCT02677389|OTHER|Quality-of-Life Assessment|Ancillary studies
40748377|NCT02677389|OTHER|Questionnaire Administration|Ancillary studies
40748378|NCT03209960|DIAGNOSTIC_TEST|Bedside Referral Tool|Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents. Each primary care provider will perform elements of a physical exam guided by the bedside referral tool to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
40748379|NCT03209960|OTHER|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
40748380|NCT00949936|DEVICE|CAdisc™-L (Total Disc Replacement)|
40748381|NCT05898880|OTHER|Self-acupressure|In the self-acupressure group, before the application, the tissue sensitivity will be reduced by heating and rubbing for 20 seconds without direct pressure on the acupressure points, and the points will be made ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point. Afterwards, acupressure will be applied to themselves by participants
41095526|NCT06395363|PROCEDURE|fixation method|The fixation methods were either involved trans-articular fixation through the acromioclavicular joint, supplemented with an additional cerclage wire tension band for enhanced stability. Or, creating a tunnel in the sub-acromial space posterior to the acromioclavicular joint and inserting the hook into this tunnel.
41095527|NCT04550156|PROCEDURE|Colorectal Bundle|"1. Preoperative optimization of the nutritional status: Perform nutritional risk screening (NRS), measure albumin or prealbumin preoperatively and initiate nutritional support~2. Preoperative showering with an antiseptic agent~3. Administer preoperative antibiotic prophylaxis~4. Hair removal in the operative field with clippers~5. Peri-, intra-, and postoperative warming to maintain body temperature~6. Peri- and intraoperative glucose control~7. Usage of a wound protection device~8. Change of gloves and instruments after anastomosis~9. Anastomosis only with experienced senior surgeon present in theatre for any elective and emergency procedures"
41095528|NCT03893591|DIAGNOSTIC_TEST|Anti Xa levels|one Blood sample
40748382|NCT05898880|OTHER|Acupressure by therapists|In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.
40748383|NCT05898880|OTHER|Control group|No intervention will be made in the control group.
40748384|NCT00346528|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
40748385|NCT00346528|DRUG|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
40748386|NCT04149353|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
40748387|NCT04356443|DEVICE|AirGo Respiratory Monitor|AirGo™ is composed of a wearable, miniaturized recorder unit and a medical grade Holter worn over the floating ribs of patients both at rest and during normal activity. The recorder measures live circumference changes.
41095529|NCT06552689|DEVICE|Sutra Hemi-valve Transcatheter Mitral Valve Replacement (TMVR) System|Trans-septal Sutra Hemi-valve TMVR System to treat mitral regurgitation
41095530|NCT05169281|OTHER|Medication Disposal Packet|The disposal packet (DisposeRx Inc.) contains a powder that sequesters unused opioids in a polymer gel. The kits reached patients four days following their surgery based on prior data to leverage availability bias, or a tendency to think or act on things that are most present in one's mind, and provided patients with a disposal technique when they were likely to be finished with their opioids. The process of mailing the disposal packet is simple, low cost (\~$1.50/ mailed packet) and scalable.
41095531|NCT06370325|PROCEDURE|VPOD Wireless Tens Unit|The VPOD unit will deliver NMES to participants in the Intervention Group.
41095532|NCT06370325|PROCEDURE|Physical Therapy|Physical therapy as per standard of care.
41095533|NCT06370325|DEVICE|Biodex|Used to assess strength, endurance, power, and range of motion.
41095534|NCT05822440|DRUG|PF-07817883|Single oral dose (period 1) or co-administered with itraconazole (period 2)
41095535|NCT05822440|DRUG|Itraconazole|Interacting drug which will be given for 7 days in period 2
41270147|NCT04673097|OTHER|MI paste plus|s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.
41270148|NCT01054066|BEHAVIORAL|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
41270149|NCT02224898|BEHAVIORAL|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
40748414|NCT06380608|PROCEDURE|Local anesthesia|Patients who will undergo a dental surgery under local anesthesia
40748415|NCT06380608|PROCEDURE|General anesthesia|Patients who will undergo a dental surgery under general anesthesia
40748416|NCT01529216|DEVICE|DIAMOND System|Electrical stimulation to the fundus
40748417|NCT04555148|BIOLOGICAL|GC5131|COVID19 Hyper-Immunoglobulin
40748418|NCT04555148|OTHER|Placebo|Placebo
40748419|NCT05598307|DRUG|magnesium bolus followed by normal saline infusion|a bolus dose of magnesium will be followed by normal saline infusion
40748420|NCT05598307|DRUG|magnesium bolus followed by magnesium infusion|a bolus dose of magnesium will be followed by a magnesium infusion
40748421|NCT05598307|DRUG|normal saline bolus followed by normal saline infusion|a bolus of normal saline will be followed by normal saline infusion
40748422|NCT05105971|DRUG|BAT6026|Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
40748423|NCT02781701|DEVICE|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
40748424|NCT05756478|OTHER|Medication review|This is a feasibility study of implementing a pharmacist-led medication review using prescribing tools (e.g. STOPP/START, Beers Criteria)
40748425|NCT06190119|OTHER|none intervention|This study has no intervention
40748426|NCT01127061|BEHAVIORAL|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
40922355|NCT04277806|BEHAVIORAL|New Oral feeding process|From the beginning of 32 weeks, try oral feeding once a day, suck pacifier for 10 minutes before feeding. When she/he can finish 50% of the amount of one meal in consecutive two days, and there is no adverse events happened, then we will try oral feeding twice a day. In the same way, in the oral feeding she/he can finish 50% of this meal in consecutive two days, there is no adverse events happened, then we will try three oral feedings three times a day. We wil continue the process until the infant can be fully oral fed by herself/himself.
40922356|NCT05880290|PROCEDURE|gynaecological examination in lateral decubitus|Single group: gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful
41270150|NCT03135249|DRUG|Alemtuzumab|Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
41270151|NCT05539014|OTHER|Data collection|Prospectif data collection
41270152|NCT00410176|BEHAVIORAL|sanitation and personal hygiene|
41270153|NCT04032340|OTHER|dog presence|This project seeks to assess positive impacts of companion dog presence in elderly living at home ; to assess loneliness and isolement between eldlery with a companion dog and without, at home
41270154|NCT01106924|OTHER|Probiotic|daily probiotic consumption
40748427|NCT00777673|DRUG|Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim|"Eligible patients will receive:~* nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~* Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~* Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~* Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."
40748428|NCT05998499|OTHER|Description|This study aimed to understand the situation of Latin American HIV-positive migrants seeking asylum in Spain and identify the challenges they encounter in getting HIV treatment. The main result measured was the proportion of participants with an HIV-1 RNA level of 50 copies/mL or higher at their first clinic visit
40748429|NCT00731003|DRUG|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
40748430|NCT00731003|OTHER|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
41270155|NCT01106924|OTHER|Placebo|daily placebo consumption
41270156|NCT03494556|OTHER|Data Collection|Paramedic will use data collected during routine care to complete four risk stratification tools.
41270157|NCT01970176|DRUG|Tadalafil|Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.
41270158|NCT01970176|DRUG|Placebo|Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
40748431|NCT00731003|OTHER|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
40748432|NCT00731003|DRUG|Placebo capsule|Placebo for 5-HTP
40748433|NCT06174701|BEHAVIORAL|Problem Solving Therapy (PST)|PST intervention in the form of one-on-one coaching in preparation for surgery and post-operative care. This coaching consists of educating and guiding the patient in developing problem-solving skills. Please refer to the PST Handbook for further detail on the therapy sessions.
40748434|NCT00508846|BEHAVIORAL|Questionnaire|Two-part telephone questionnaire lasting about 60 minutes total.
41095536|NCT04569578|OTHER|Policy|"The intervention will include:~i. Formalized physical activity policies implemented in preschools including the following:~1. A minimum of 3 hours of total daily outdoor time scheduled both in the morning and in the afternoon~2. At least 10 minutes teacher-led active play per day~3. A minimum of 1 weekly outdoor excursion~4. Meet the children outdoors when they arrive at preschool and/or picked up by their parents~5. Only use screen tablets and computers for educational teaching purposes~6. Communicating to, and encouraging, the parents to actively transport their children to and from preschools~ii. A study website with an activity bank also serving as a platform for inter-professional education that preschool teachers can share and communicate about engaging activities and experience~iii. Weekly follow-up and feedback by web-based questionnaires"
41095537|NCT03303105|DRUG|TEV-48125|TEV-48125 will be administered subcutaneously once every 4 weeks.
41270159|NCT02903004|DRUG|Trabectedin|
41270160|NCT02903004|DRUG|Pegylated Liposomal Doxorubicin|
40748435|NCT05210946|DRUG|Pemigatinib|"Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0."
40748436|NCT00720200|BEHAVIORAL|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
40748437|NCT00720200|BEHAVIORAL|Usual Care|Family Members receiving usual care/clinical interaction
40748438|NCT03331588|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
40748439|NCT03331588|PROCEDURE|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
41270161|NCT02903004|DRUG|Topotecan|
41270162|NCT02903004|DRUG|Gemcitabine|
41270163|NCT02903004|DRUG|Weekly Paclitaxel|
41270164|NCT02903004|DRUG|Carboplatin|
41441018|NCT00748072|DRUG|DDAVP|0.3 mcg/kg subcutaneous
41441019|NCT00748072|DRUG|saline solution|saline solution 1 ml subcutaneous
40748440|NCT04249193|OTHER|Transfusion|pRBC and non-pRBC transfusions
40748441|NCT04120675|DIETARY_SUPPLEMENT|Early Harvest Extra Virgin Olive Oil|Participants will take 3 tablespoons on a daily basis
40748442|NCT04151732|BEHAVIORAL|Physical activity, alcohol, tobacco|Physical activity, alcohol, tobacco - selfreported in the 1990's
40748443|NCT04151732|OTHER|Hormonal factors|Hormonal factors - selfreported in the 1990's
40748444|NCT04151732|OTHER|Cardiovascular disease|Cardiovascular disease - selfreported in the 1990's
40748445|NCT04151732|OTHER|Anthropometric measures|Height, length, BMI
40748446|NCT01997255|DRUG|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
40748447|NCT03041870|DEVICE|PET-fMRI scan|fMRI scan include MR sequences: BOLD and fMRI. The PET acquisition will be carried out in dynamic for 90 consecutive minutes following intravenous administration of 4 MBq / kg dose of \[11C\]DASB bolus.
40748448|NCT05132946|PROCEDURE|Nerve block|unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
40748449|NCT03842800|OTHER|MRI|Patients and volunteers will receive an MRI.
40748450|NCT03842800|DRUG|Ketamine|Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.
40748451|NCT05039385|OTHER|Exercise Program focused on resistance training|"The program will be carried out by a personal trainer. To ensure correct execution, given that the groups will be of a maximum of 5 people. Each session will include:~A) Warm up: movility exercises and coordination games B) Main part: 3 exercises will be included to strengthen different muscle groups (pull , bench press and back squat). Velocity based training (VBT) will be used to control load. 3 sets of 16-30 repetitions mantaining the speed between Light (estimated loss of speed of the series 5-10%).~C) Cool down: feedback with patients based on the work of Stiles-Shields (2015).~Specific training content will focus on safety, while re-educating patients on proper exercise methods, motivation-related attitudes, and transparency on health benefits and potential harms as a result of increased exercise."
40748452|NCT04389671|DRUG|Lucinactant|Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
40748453|NCT02074137|DRUG|CABAZITAXEL XRP6258|Pharmaceutical form:Solution Route of administration: Intravenous
40748454|NCT02074137|DRUG|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
40748455|NCT02074137|DRUG|Prednisolone|Pharmaceutical form:Tablet Route of administration: Oral
40748456|NCT00807404|PROCEDURE|histopathologic examination|
40748457|NCT00807404|PROCEDURE|optical coherence tomography|
40748458|NCT02285244|DRUG|sotrastaurin acetate|Given PO
40748459|NCT02285244|OTHER|pharmacological study|Correlative studies
40748460|NCT02285244|OTHER|laboratory biomarker analysis|Correlative studies
40748461|NCT05342688|BEHAVIORAL|Task-specific practice of upper extremity functions|The intervention will consist of training of items from the Wolf motor function test.
40748462|NCT00512083|DRUG|AS1411|AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
40748463|NCT03910946|DRUG|Tuberculin, Purified Protein 5Unt/0.1 mL Solution|Tuberculosis (diagnosis)-Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered
40748464|NCT06421766|DEVICE|BAHS|Implantation of a percutaneous bone-anchored hearing system
40748465|NCT01559623|PROCEDURE|retrospective data analysis|retrospective data analysis
40748466|NCT03061851|BEHAVIORAL|conventional treatment|the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
40748467|NCT03061851|OTHER|Maltose app|"1. Weekly diabetes-related science articles.~2. Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.~3. Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.~4. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.~5. Personalize the development of diet, exercise program.~6. different insulin and oral hypoglycemic drug medication time to remind.~7. hypoglycemic drug side effects query."
40748468|NCT03687697|BIOLOGICAL|Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media|A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.
40748469|NCT03472677|OTHER|Ice Pack and Cooling Device|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
40748470|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling wrap vs ice pack cooling after single IA injection of 1 mg CNTX-4975-05 in each arm after single IA (15 mL) injection of 2% lidocaine (without epinephrine).
40748471|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling parameters will be determined after evaluation of data from prior Cohort(s) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
40748472|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling with knee device vs no cooling (determined after evaluation of data from previous cohorts) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
40748473|NCT03472677|DRUG|Capsaicin|Four intradermal injections of capsaicin, two on each forearm.
40748474|NCT00425139|BEHAVIORAL|Re-Mission|
40922357|NCT01229917|OTHER|Fruit juice with Lactobacillus rhamnosus GG, version 1|
41095538|NCT03303105|DRUG|TEV-48125|TEV-48125 will be administered subcutaneously once every 12 weeks.
41095539|NCT05561855|BEHAVIORAL|lifestyle intervention|"During the 3-month lifestyle intervention period, the participants need to complete the weight monitoring, behavioral goal recording, diet and exercise recording, online course learning by using the WeChat official account module of Weight Loss and Glucose Control.They will receive corresponding feedback and integral rewards every week, and receive monthly follow-ups to complete health education, goal review, motivational interview as well as collecting medication changes and blood glucose monitoring data."
40748475|NCT05586100|DRUG|Toripalimab+cetuximab|"Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing \<50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
40748476|NCT01750281|DRUG|Selumetinib 75 mg|Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.
40748477|NCT01750281|DRUG|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
40748478|NCT01750281|DRUG|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
40748479|NCT01750281|DRUG|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily.
40748480|NCT02918799|BEHAVIORAL|Mpowerment|MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
40748481|NCT00004201|DRUG|carboplatin|
40748482|NCT00004201|DRUG|cisplatin|
41095540|NCT05556356|DRUG|Acetaminophen|pre-operative acetaminophen (1000mg)
41095541|NCT05556356|OTHER|Placebo: Multivitamin|pre-operative Multivitamin
40748483|NCT00004201|DRUG|gemcitabine hydrochloride|
40748484|NCT05700838|BEHAVIORAL|Cough Skill Training - with Variable Practice|"Variable practice will involve three targets that reflect a range of cough airflows, including strong, moderate, and weak coughs."
40748485|NCT02822755|OTHER|Home Exercise Program and Adherence Logs|Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
40748486|NCT05144282|PROCEDURE|intravitreal injection of anti VEGF|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF).
40748487|NCT05144282|PROCEDURE|laser photocoagulation|The treatment for ROP was either primary laser photocoagulation.
40748488|NCT01281306|DRUG|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
40748489|NCT01281306|DRUG|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
40748490|NCT01281306|DRUG|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
40748491|NCT01281306|DRUG|Placebo|Placebo was supplied as tablets in blister cards.
40748492|NCT04285684|DRUG|ketamine in lactation|2 dose IM by weight and assessing concentrations of ketamine in expressed milk at intervals
40748493|NCT03973593|BEHAVIORAL|Enhancing contraceptive counseling on method continuation and switching|Health care workers and Community Health Volunteers will be trained on a contraceptive counseling package that enhances information on method continuation and switching. This will be done in the ten intervention facilities prior to enrollment of clients into the cohort study.
40748494|NCT02804646|DRUG|recombinant human endostatin|endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
40748495|NCT02804646|DRUG|pemetrexed plus cisplatin or carboplatin|the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
40748496|NCT04947787|BEHAVIORAL|Physical activity referral scheme (PARS)|Participants of the intervention group will receive brief physician advice and be referred to an exercise professional (e.g., physiotherapist, sports therapist) for a more intensive counseling intervention. The counseling intervention consists of an initial assessment, individual physical activity counseling (360'), a final assessment after 12 weeks, and a follow-up assessment after 24 weeks.
40748497|NCT04947787|BEHAVIORAL|Physical activity advice (PAA)|Participants of the control group will only receive brief physician advice regarding the promotion of physical activity and as an information sheet with tips on how to adopt a more physically active lifestyle.
40748498|NCT03989570|PROCEDURE|transversus abdominis plane block|The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected
40748499|NCT03989570|PROCEDURE|erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes
40748500|NCT03989570|OTHER|control group|placebo
40748501|NCT05481281|DRUG|Dexmedetomidine|I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion
40748502|NCT05481281|DRUG|Ketamine|0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion
40748503|NCT01297114|DRUG|Florbetaben|This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
40748504|NCT00440024|DRUG|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
40748505|NCT00440024|DRUG|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
40748506|NCT00440024|DRUG|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
40748507|NCT04835753|DEVICE|shock wave|true radial ESWT.A rESW pneumatic device (SHOCK MED, Italy) was used to provide one session per week (for a total of 12-week)
41095542|NCT05245656|DRUG|RB/RBAC alternating|"Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 70mg/m2, IV, D2-3~* Cytarabine 500mg/m2, IV, D2-4"
40748508|NCT04835753|OTHER|traditional physical therapy program|lower limbs muscles stretch and strength in addition to balance and gait training
40748509|NCT04291833|BEHAVIORAL|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
40748510|NCT04291833|BEHAVIORAL|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
40748511|NCT04291833|BEHAVIORAL|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
40748512|NCT05103592|DIAGNOSTIC_TEST|Tartrate- resistant Acid Phosphatase marker|marker could be diagnostic for osteoporosis
40748513|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
40748514|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 2~10 mg/kg I.V., once every other week for 4 weeks"
40748515|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 3~15 mg/kg I.V., once every other week for 4 weeks"
40748516|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 4~21 mg/kg I.V., once every other week for 4 weeks"
40748517|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 5~27 mg/kg I.V., once every other week for 4 weeks"
40748518|NCT03874403|PROCEDURE|DSA|The changes on DSA on NIVATS and VATS
40748519|NCT06529705|DEVICE|EkiYou V2|Use of a mobile application that help users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.
40748520|NCT01135056|DEVICE|SIR-Spheres|One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
40748521|NCT01135056|DRUG|Sorafenib tosylate|Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
40748522|NCT03400189|DRUG|Sulthiame|Single dose (50, 100, 200 mg)
40748523|NCT05112588|BEHAVIORAL|Intervention|The women randomized to intervention will get support from the Child Health Care unit (CHCU) at every visit with the baby. Before the visit the women will have blood-samples taken and waist and weight measured. The women will also get support from a digital solution, specially developed for this purpose (MyMOWO). The nurse at the CHCU will include information and support to the mother at every visit accort´ding to a special protocol. All women will be carefully examined at baseline, after one and four years will blood-tests, anthropometric measurements and maximal oxygen uptake (VO2max).
40748524|NCT05864014|DRUG|Hetrombopag|Hetrombopag
40748525|NCT05864014|DRUG|Hetrombopag plus Placebo|Hetrombopag plus Placebo
40748526|NCT05864014|DRUG|Placebo|Placebo
40748527|NCT01123564|DRUG|ranibizumab|applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
40748528|NCT01123564|RADIATION|Argon laser treatment|Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
40748529|NCT05017402|DRUG|Alglucosidase Alfa|Standard dose: 20-25 mg/kg every other week; Higher dose: \>25 mg/kg every other week.
40748530|NCT02939781|DEVICE|Indirect calorimetry|Indirect calorimetry measurement at baseline (stable state), at onset of fever and continued till fever dehiscence
40748531|NCT05391074|DIETARY_SUPPLEMENT|postbiotics (IGENH35.3A)|postbiotics to induce microbiota epigenetic factors
40748532|NCT05391074|DIETARY_SUPPLEMENT|vitamins (AREDS formulation and recommended daily dose)|vitamins (AREDS to prevent AMD progression
40748533|NCT00640432|DRUG|Diclofenac|75 mg oral capsule twice daily for 7 days
40748534|NCT00640432|DRUG|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
40748535|NCT05749185|DEVICE|radiofrequency high voltage|nvolved a high voltage PRF technique, where the voltage started at 65 V and could be adjusted up to 80 V based on patient tolerance. Both protocols involved two cycles of PRF application, with each cycle lasting 240 seconds and comprising alternating periods of current application and deactivation. The pulse rate frequency was set at 2 Hertz (Hz), resulting in two active phases/second (20 milliseconds (ms) of current application followed by 480 ms without stimulation)
40748536|NCT05749185|PROCEDURE|standard RF|A standard voltage PRF technique, administering PRF at a fixed voltage of 45 volts (V)
40748537|NCT05753475|OTHER|renal transplantation|patients undergoing renal transplantation
40748538|NCT01732211|BIOLOGICAL|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
40748539|NCT01732211|OTHER|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
40748540|NCT03172000|DIAGNOSTIC_TEST|Colonoscopy and biopsy|Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
40748541|NCT04250259|DRUG|Placebo|2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
40748542|NCT04250259|DRUG|SAMe 400 mg tablet|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
40748543|NCT02279251|BEHAVIORAL|VÅG|Low-intensity CBT intervention
40748544|NCT02279251|BEHAVIORAL|CHILLED|Standard length CBT intervention
40748545|NCT05071833|DIETARY_SUPPLEMENT|Peppermint oil.|Peppermint oil.
40748546|NCT05071833|OTHER|Placebo|Placebo
40748547|NCT01498666|DIETARY_SUPPLEMENT|L. reuteri protectis|1 tablet once daily for 4 weeks
40748548|NCT01498666|DIETARY_SUPPLEMENT|Placebo tablet|1 tablet once daily for 4 weeks
40748549|NCT05236127|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
40922358|NCT01229917|OTHER|Fruit juice with Lactobacillus rhamnosus GG, version 2|
40922359|NCT01229917|OTHER|Standard fruit juice|
40748550|NCT05236127|OTHER|Intermittent Fasting|The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
40748551|NCT02172599|BEHAVIORAL|Sit-stand workstation provision|The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
40748552|NCT04926493|BIOLOGICAL|microbiological characterization|microbiological characterization of endotracheal tube biofilm
40748553|NCT01849809|PROCEDURE|Gamma Ventral Capsulotomy|
40748554|NCT02594878|DRUG|Pamidronatdinatrium|
40748555|NCT02594878|OTHER|Natrium chloride 9mg/ml|
40748556|NCT05832983|BEHAVIORAL|Guided Meditation|In private exam room, the study registered nurse (RN) will read a prepared two minute guided meditation to patient.
40748557|NCT05832983|OTHER|Aromatherapy|In private exam room, study RN will first affix an Elequil Aromatab to patient's clothing on either their upper arm or chest (whichever the patient prefers and/or as clothing allows).
40748558|NCT01975480|DRUG|Desvenlafaxine|
40748559|NCT02285309|PROCEDURE|Cardiac Surgery and enoximone|Does diastolic function change with cardiac surgery +/- enoximone
40748560|NCT05507684|OTHER|Nature-based social prescribing group intervention|"Groups of 5-12 persons will formed from one assisted living facility. All of them will undergo an individual interview to assess their wishes for the nature-based activities.~Participants meet in a closed group for 9 times once a week for 10 weeks. All 2-4 hour sessions will include nature-based activities and mutual discussions about the experiences of nature and loneliness.~2 professionals will facilitate and observe the group more thoroughly, give feedback to each other, and make use of group dynamics. They write diaries on each session and receive feedback from their trainers. The groups are objective oriented (aiming to alleviate loneliness, to improve participants' self-efficacy), client oriented and aim with favorable group dynamics to mature, self-directing group in which the participants have made friends with each other and want meet with each other without the facilitators after the official group intervention is over."
40748561|NCT01296113|DRUG|Chemotherapy|"Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~* Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~* Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total"
40748562|NCT02403778|DRUG|VESANOID|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
40748563|NCT02403778|DRUG|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
40748564|NCT01111188|DRUG|PD 0332991|"PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.~(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg"
40748565|NCT01111188|DRUG|bortezomib|"Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.~(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2"
40748566|NCT00581997|DRUG|QAX576|
40748567|NCT00581997|DRUG|Placebo|
40748568|NCT05880030|DRUG|Cholecalciferol|cholecalciferol 10000 UI
40748569|NCT05880030|OTHER|placebo|sunflower oil
40748570|NCT04250675|DEVICE|Intermittent pneumatic leg compressions|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (120 mmHg) of both legs for 2 hours daily for 3 months.
40748571|NCT04250675|DEVICE|Sham|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (30 mmHg) of both legs for 2 hours daily for 3 months.
40748572|NCT05001503|DEVICE|Stability UO|STABILITY UO is a standalone software, based on a Bayesian model, which quantifies the risk of an individual patient developing severe oliguria (0.3mg/kg/hr for 6 hours). The model identifies at risk patients by predicting future urine output, using only previously recorded urine output values for that individual, allowing clinicians to see the predicted risk of a patient developing severe oliguria in real time.
40748573|NCT00663143|PROCEDURE|Stromal Cells Sample|Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
40748574|NCT00415259|DEVICE|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
40748575|NCT00415259|DEVICE|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
40922360|NCT02256397|OTHER|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
40922361|NCT02256397|OTHER|enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~* If between 2 and 5 years old--\> will receive Home-centered comprehensive care with the propeller~* 5 and above--\> will receive home-centered comprehensive care with propeller and PIKO"
41095543|NCT05245656|DRUG|RB|"Every 4 weeks for 6 cycles~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2"
41441020|NCT06407622|OTHER|Foot Reflexology|In previous studies, no study was found investigating the effect of foot reflexology on sleep quality and bowel functions in patients undergoing surgical intervention. This study is thought to be the first to evaluate the effect of foot reflexology on sleep quality and bowel functions in surgical patients. In this respect, it is a study that will contribute to the literature.
40748576|NCT06450704|OTHER|Physical Exercise|"Daily walking. Participants will be given an activity band to self-monitor the number of steps they walk each day during the 12-week intervention period. Each participant must reach a certain number of daily steps with a progressive goal adjusted to the number of steps from the previous week. The goal is set considering the superior number to the median of steps of the preceding week.~Weekly combined exercise sessions (aerobic + strength exercise) 2 sessions of 60 minutes per week in a 12-week program. The exercise intervention will combine the use of elastic bands and the body weight. First, 5 minutes of warm-up; second, training circuit with low-intensity strength exercises alternating work and rest times using rhythmic music. Upper, lower and middle body exercises will alternate. The program will progress in intensity, work: rest ratio, and technical difficulty of the exercises. At the end of the main part, there will be a cool-down and stretching for 5 minutes."
40748577|NCT04530695|OTHER|Scaling and Root Planing|Periodontal treatment by scaling and root planing (SRP), deep cleaning
40748578|NCT02931110|DRUG|CBL0137|CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
40748579|NCT03796130|PROCEDURE|Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (1): myomectomy will be performed before ART~In group (2):women will have their trial of ART without myomectomy~In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
40748580|NCT00191152|DRUG|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
40748581|NCT00191152|DRUG|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
40748582|NCT00191152|DRUG|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
40748583|NCT00666471|PROCEDURE|MICE|MICE
40748584|NCT00666471|PROCEDURE|SPA ligation|SPA ligation
40748585|NCT00986895|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
40748586|NCT00989027|DRUG|Oxytocin|Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
40748587|NCT00989027|DRUG|Ergonovine|Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
40748588|NCT00989027|DRUG|Carboprost|Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
40748589|NCT00989027|DRUG|Oxytocin and Ergonovine|Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
40748590|NCT00989027|DRUG|Oxytocin and Carboprost|Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
40748591|NCT04561531|OTHER|3%NaCl|Intervention is infusion of 3%NaCl which is defined in arms of experiment.
40748592|NCT03811873|DIAGNOSTIC_TEST|Dual x-ray absorptiometry|DEXA is a means of measuring bone mineral density (BMD) using spectral imaging. Two X-ray beams, with different energy levels, are aimed at the bones. Soft tissue absorption is subtracted out, then the bone mineral density (BMD) can be determined from the absorption of each beam by bone.
40748593|NCT03811873|OTHER|Vertebral Fracture Assessment|Lumbar/thoracic spine x-ray and labs assessed for bone turnover markers.
40748594|NCT00088101|DRUG|STA-5312|
40748595|NCT05174507|DRUG|empagliflozin|Empagliflozin (Jardiance®; Boehringer Ingelheim (Schweiz) GmbH) is a highly selective, reversible inhibitor of the sodium glucose co-transporter 2 (SGLT2). Treatment consists of a single oral tablet of 25 mg of empagliflozin (Jardiance®) two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
40748596|NCT05174507|DRUG|anakinra|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) in a 100 mg/0.67ml solution for SC injection. Treatment consists of a single subcutaneous injection of 100 mg Anakinra (Kineret®) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
40748597|NCT05174507|OTHER|saline subcutaneous (s.c.) (placebo)|Placebo for anakinra is 0.67 ml of sterile 0.9 % saline solution s. c. Treatment consists of a single subcutaneous injection of matched placebo (0.67 ml of 0.9 % saline) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
40748598|NCT05174507|OTHER|tablet per oral (p.o.) (placebo)|Placebo for empagliflozin is Winthrop P® (Zentiva, Frankfurt/Main) lactose tablet. Treatment consists of a single oral tablet of matched placebo two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
40748599|NCT00121953|DRUG|Rosiglitazone|
40748600|NCT05166928|DEVICE|carriere motion appliance|after finished treatment with carrirere motion appliance in the two group (group 1 have upper wisdom teeth ,group 2 have not upper wisdom teeth ) the pre and post casts will be scanned and superimposed to determine amount upper molar distalization
40748601|NCT03225222|DIAGNOSTIC_TEST|biopsy|prostate biopsy
40748602|NCT00435721|BEHAVIORAL|Psychoeducation|
40748603|NCT02950584|OTHER|Titanium dioxide denture|Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
40748604|NCT02950584|OTHER|Rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
40748605|NCT05738889|DEVICE|Fixed lingual retainers applied with Bis-GMA containing composite|Bonding materials of fixed lingual retainers applied with Bis-GMA containing composite
40748606|NCT05738889|DEVICE|Fixed lingual retainers applied with Bis-GMA-free composite|Bonding materials of fixed lingual retainers applied with Bis-GMA-free composite
40748607|NCT05738889|DEVICE|Vacuum-formed retainers|vacuum-forming machine and vacuum formed plates
40748608|NCT05738889|DEVICE|Hawley retainers|Acrylic based hawley retainers
40748609|NCT04014088|DEVICE|hCPAP vs fCPAP|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.
40748610|NCT02842671|OTHER|Assigned Ambassador|If assigned to the intervention group, participants will be contacted by the assigned medical student ambassador at least 1 day prior to the procedure. A brief discussion will take place to review the child's history and survey results. The family will be met by the Ambassador at the hospital and stay with the family until the patient is in the post anesthesia recovery unit. The ambassador is expected to make accommodations for the child as determined by the accommodations survey results. The family will be required to allow the Ambassador to stay through check-in and the procedure.
40748611|NCT06225752|DRUG|Probucol|Inclusion Days 1-30: Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
40748612|NCT06225752|DRUG|Placebo probucol|Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
40748613|NCT04299620|DEVICE|Digital Image Analysis|Analysis of images
40748614|NCT04299620|PROCEDURE|Radical Prostatectomy|Undergo standard of care radical prostatectomy
40748615|NCT04299620|PROCEDURE|Transrectal Ultrasound|Undergo transrectal ultrasound
40748616|NCT02040064|DRUG|Gefitinib|Oral tablet
40748617|NCT02040064|DRUG|Tremelimumab|IV
40748618|NCT03591536|OTHER|Pentoxifylline|400 mg pentoxifylline oral tablet from 3 days before surgery and on the day of surgery
40748619|NCT03591536|OTHER|Placebo|oral placebo tablets from 3 days before surgery and on the day of surgery
40748620|NCT01774539|OTHER|Diffusion MRI|Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
40748621|NCT00540267|OTHER|No Intervention|No Intervention
41270165|NCT05510960|OTHER|Video game & Robotic surgery simulator success|"A questionnaire was administered to all participants, asking about their demographic information, surgical experience, hobbies, and previous video game playing experiences.~After the questionnaire, the participants were asked to play the Temple Run (Imangi Studios, NC, USA) and Piano Tiles 2™ mobile games for one month. At the end of the period, with the da Vinci® Skills Simulator™ for one hour, all participants performed four different robotic surgery simulator tasks (Camera Targeting 1, Energy Switching 1, Ring \& Rail 2, Vertical Defect Suturing) that require the ability to apply basic robotic surgery rules and measure surgical skills."
40748622|NCT01842178|PROCEDURE|scratching|"Endometrial Injury~* Done between 18-24 days prior to embryo transfer cycle.~* Using transfer catheter.~* Introduction of the same to the uterine fundus.~* Systematic scrapping of the four uterine walls, lengthwise.~* Performed by a skilled doctor.~* Subsequent ultrasound control."
40748623|NCT03583866|DRUG|Candesartan|7 days of Candesartan (16mg/day)
40748624|NCT03583866|DRUG|Placebo|7 days of Placebo
40748625|NCT06289881|DRUG|Sildenafill-Test product|Test-Product: Sildenafil 100 mg tablets Manufactured by: Actigen Co., Ltd., Thailand
40748626|NCT06289881|DRUG|Sildenafill-Reference product|Reference-product: Viagra 100 mg tablets Manufactured by: FAREVA AMBOISE, France
40748627|NCT00673829|BIOLOGICAL|Gene Modified T Cells|Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
40748628|NCT00673829|BIOLOGICAL|Gene Modified T Cells and Interleukin 2|One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
41270166|NCT05790486|BEHAVIORAL|Take a Break plus Nicotine replacement therapy (NRT) Sampling|"Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At week 1 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and facilitate an abstinence goal."
40748629|NCT02368509|OTHER|Perform sensory tests|
40748630|NCT02298569|BEHAVIORAL|multi-pronged program to improve early postpartum discharge|"Better team integration and changes to promote interprofessional collaboration and communication between healthcare providers involved in pre- and post-natal care in a perinatal network.~Transition optimization: all involved healthcare professionals will complete a specific form during pregnancy and hospitalization to coordinate support safe process, and to improve quality transitions to outpatient midwives and pediatrician. A check-list will be completed by the mother to assess whether she agrees to early discharge and that she is aware of its conditions Implementation of best practices about early discharge after delivery to improve safety of early discharge particularly for neonates at risk (jaundice and dehydration)."
40748631|NCT05539170|BEHAVIORAL|Immediate positive parenting feedback|Individual positive feedback concerning their parenting and their child's behavior.
40748632|NCT00991562|DRUG|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
40748633|NCT00629213|DRUG|acarbose|
40748634|NCT00629213|DRUG|placebo|
40748635|NCT02361684|BEHAVIORAL|Blended CBT treatment|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.
40748636|NCT02361684|OTHER|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
40748637|NCT05787223|OTHER|Baseline Treatment|Control Group that will be provided with be given baseline treatment of static balance training (static exercise like standing on balance board, bounce on one foot, heel rises/toe rises, standing on one foot, jumping on trampoline)
40748638|NCT05787223|OTHER|Dynamic Training|Experimental Group that will be provided with base line treatment along with dynamic balance training (cross, side \&tandem walking, step up and down, jumping \&hopping on floor). Exercises Will be given the 40 minutes with 2 sessions per week over the period of 08 weeks
40748639|NCT00665886|DEVICE|Open Intravenous System - Vasocan®|Vasocan® Safety catheter 18 G x 45 mm (Ref. 4248139S), 20 G x 33 mm (Ref. 4248112S) y 22 G x 25 mm (Ref. 4248090S)with wings and a passive safety mechanism. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3) from BD (ref 394995)will be added.
40748640|NCT00665886|DEVICE|Closed Intravenous System - Nexiva®|BD Nexiva® Catheter (18G x 45 mm, 20 G x 32 mm, 22 G x 25 mm) (Ref. 383609,Ref. 383606,Ref. 383602) BD QSyte®, Ref. 385100 Catheter material is Vialon®. The entire system is Latex and PVC free.
40748641|NCT06302283|OTHER|Survey|Survey (online or paper) on caregiving burden and bereavement
40748642|NCT02517489|DRUG|Hydrocortisone|Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
40748643|NCT02517489|DRUG|Placebo|Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
40748644|NCT03786575|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS) detection|The NGS detection panel is designed by our team and covers genes that are clinically useful and have definite guiding significance for endocrine therapy
40748645|NCT06392126|DRUG|nL-CHCHD-001|Personalized antisense oligonucleotide
40748646|NCT04797728|DRUG|Elacestrant|Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD) for 4 weeks (+/- 2 days)
40748647|NCT01946802|DEVICE|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
40748648|NCT04772547|DRUG|Vigabatrin Only Product|enteral medication administration, serial blood draws, and outcome assessment
40748649|NCT01513928|DRUG|Pf-04937319|Formulation A) Pf-04937319 50 mg - administered as tablet
40748650|NCT01513928|DRUG|Pf-04937319|Formulation B) Pf-04937319 50 mg - administered as capsule
40748651|NCT01513928|DRUG|Pf-04937319|Formulation C) Pf-04937319 50 mg - administered as capsule
40748652|NCT02590510|DRUG|methotrexate|The quantity of methotrexate is different in the two groups.
40748653|NCT02989389|DRUG|LY3323795|Administered orally
40748654|NCT02989389|DRUG|Itraconazole|Administered orally
40748655|NCT02989389|DRUG|Placebo|Administered orally
40748656|NCT01576965|DRUG|Fleet Enema (sodium biphosphate and sodium phosphate)|Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
40748657|NCT00973973|DRUG|Placebo|Matching placebo tablets taken orally once a day
40748658|NCT00973973|DRUG|Elagolix|Immediate release (IR) tablets taken orally once a day
40748659|NCT02450474|DEVICE|Intermittent pneumatic compression device|Flowtron, Circulation Booster and Sports XL devices will be used.
40748660|NCT02450474|DEVICE|Neuromuscular electrical stimulation|Flowtron, Circulation Booster and Sports XL devices will be used.
40748661|NCT05509374|DRUG|Carfilzomib 56 MG [Kyprolis]|Carfilzomib 56 mg/m2 (Day1, 8, 15) (Cycle1 Day1, 20 mg/m2)
40748662|NCT05509374|DRUG|Pomalidomide|Pomalidomide 4 mg per os (Day1-21)
40748663|NCT05509374|DRUG|Dexamethasone|Dexamethasone 40 mg (D1, 8, 15, 22) (20 mg for patients ≥ 75 years old)
40748664|NCT04439409|DEVICE|Holter electrocardiogram|Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.
40748665|NCT04455295|DEVICE|Transdermal Vagus Nerve Stimulation (tVNS)|Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.
40748666|NCT01486394|OTHER|Focused Sonography of the heart, lungs and deep veins|The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
40922362|NCT04918342|OTHER|Multidimensional Exercise Program|The multidirectional exercise program will include cardiovascular training, strengthening, balance training, and flexibility training. This will be delivered 2 times per week for 8 weeks using telehealth and will be delivered by a physical therapist. The exercises will be modified to meet the participants needs. Intensity of exercise interventions will be monitored through patient self report and use of continuous heart rate monitoring.
41270167|NCT05790486|BEHAVIORAL|The Comparison|The comparison group will receive Nicotine Replacement Therapy sampling and will be balanced in all variables except the Take a Break Intervention.
41441021|NCT04798144|DEVICE|Distilled water irrigation kept at 2.5°C degree|The use of cold distilled water for final irrigation of root canal system during root canal treatment
41441022|NCT04798144|DEVICE|Distilled water irrigation kept at room temperature|The use of distilled water kept at room temperature for final irrigation of root canal system during root canal treatment
40748667|NCT06023537|BEHAVIORAL|Behavioral weight loss program|All participants will participate in the same remote, behavioral weight loss program. As part of the baseline assessment, participants will be asked to watch a series of custom-made videos on the study's dietary and physical activity prescriptions, dietary self-monitoring, self-weighing, and cognitive-behavioral skills to facilitate engagement in study prescriptions. Participants will be prescribed a reduced-calorie diet that will be individualized based on the individual's starting weight and weight loss goal (recommended goal of 5-10% weight loss over 12 weeks). Participants also will be prescribed a goal of 150 minutes of moderate-to-vigorous physical activity per week. They are also given, free of cost, a Fitbit Charge 5 health tracker, the Fitbit Aria Air digital scale, and a MyFitnessPal Premium subscription for the duration of the study.
40748668|NCT00745160|OTHER|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
40748669|NCT00177489|BEHAVIORAL|multicomponent psychosocial intervention|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
40748670|NCT00177489|OTHER|Control arm|"Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention."
40748671|NCT02460380|DRUG|Vitamin D3|Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
40748672|NCT02460380|OTHER|Placebo|Women in the placebo arm received once capsule of placebo once weekly for eight weeks
40748673|NCT01018953|DRUG|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
40748674|NCT03718000|DEVICE|Daily self-weighing (DSW)|DSW was conducted using digital WiFi scales during the holiday season. Participants received electronic graphic feedback of their weight fluctuations immediately after weight measurement.
40748675|NCT02559960|DRUG|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
40748676|NCT02917499|DEVICE|TMS|Transcranial magnetic stimulation
40748677|NCT03831555|BEHAVIORAL|PREP-C|"The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:~1. Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment~2. Information: knowledge about HCV treatment and one's own HCV disease status~3. Medication Adherence: current prescribed medications and adherence to them in the prior month~4. Self-efficacy: self-confidence about adhering to HCV treatment~5. Social Support and Stability: stability of financial, housing, and social support resources~6. Alcohol and substance use: alcohol and substance use behaviors and current treatment~7. Psychiatric Stability: current psychiatric status, previous and current treatment~8. Energy Level: sleep and fatigue~9. Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory."
40748678|NCT00365963|DEVICE|Comprehensive Health Enhancement Support System|computer based support and education
40748679|NCT03831438|DRUG|AVID200|Intravenous infusion of AVID200 Q2 weeks for 3 doses
40748680|NCT00954655|GENETIC|mutation analysis|
40748681|NCT00954655|GENETIC|polymorphism analysis|
40748682|NCT00954655|OTHER|laboratory biomarker analysis|
40748683|NCT03938870|OTHER|L-Leucine 13C6|
40748684|NCT00225030|DRUG|antihypertensive drugs according to current guidelines|
40748685|NCT03463239|BIOLOGICAL|Autologous tissue engineered corpora|penile tissue construct
40748686|NCT05328895|OTHER|Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day."
40748687|NCT05363800|DRUG|HRS-3738|HRS-3738 will be administrated per dose level in which the patients are assigned.
40748688|NCT06166823|OTHER|EMR alert|EMR alert for medication optimization
40748689|NCT04678310|OTHER|Support from the hospital palliative and end of life care volunteer service (developed for this study).|Hospital palliative and end of life care volunteer service: a volunteer service to provide support to patients dying in the hospital and their families. The volunteer service has been designed to provide presence and companionship to dying patients at the end of life, and their families.
40748690|NCT00347087|DRUG|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
41441023|NCT03663322|PROCEDURE|OMT Protocol|Selected hands-on OMT techniques intended to improve pancreatic function will be administered during the treatment sessions
41441024|NCT03663322|PROCEDURE|OMT-Sham Protocol|Selected hands-on Sham-OMT techniques that are not intended to affect pancreatic function will be administered during the treatment sessions
40748691|NCT01870570|OTHER|Reference Glucose|
40748692|NCT01870570|OTHER|Food Product A: Corn Flakes|
40748693|NCT01870570|OTHER|Food Product B: Ginger Bread|
40748694|NCT01870570|OTHER|Food Product C:Sandwiched Breakfast Biscuit|
40748695|NCT01870570|OTHER|Food Product D: Crackers Nature|
40748696|NCT01870570|OTHER|Food Product E: Breakfast Biscuit|
40748697|NCT01870570|OTHER|Food Product F: White Bread|
40748698|NCT03443544|PROCEDURE|Aggressive debridement|Aggressive debridement of the tissues undergoing fascitis
40748699|NCT01952678|OTHER|DaTscan™ - Non-Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
40748700|NCT01952678|OTHER|DaTscan™ - Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
40748701|NCT03848351|BEHAVIORAL|Oral Hygiene Instruction (OHI)|OHI will be given focusing on electric toothbrushing as first instance and subsequently focusing on interdental cleaning. OHI will be delivered by trained dental hygienist/periodontist. In the first phase the clinician will explain and show the technique to the patient. The patient will be then invited to perform the technique. Each phase will be assisted and monitored by the clinician. Overall, this sequence may be repeated as many times as the clinician would deem appropriate.
40748702|NCT03848351|PROCEDURE|Professional supragingival scaling and polishing|Patients will receive a session of professional supragingival scaling and polishing, that consists of removal of dental plaque and dental calculus from the surface of a tooth, with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed. Instrumentation will be performed by a trained dental hygienist/periodontist.
40748703|NCT04613869|DRUG|High-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
40748704|NCT04613869|DRUG|Low-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
40748705|NCT04613869|DRUG|Hydromorphone|No esketamine added
40748706|NCT01646216|BEHAVIORAL|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
40748707|NCT04803903|DEVICE|Flotraq Sensor with EV1000 incorporating the HPI algorithm|"The HPI algorithm is only available on the EV1000, Hemosphere and Flotrac monitoring systems and requires the use of a Flotrac sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The Flotrac sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart . If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immedietaly. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere/EV1000 with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension."
40748708|NCT04309630|PROCEDURE|intercostal block|pain control by intercostal block
40748709|NCT04309630|PROCEDURE|erector spina plane block|pain control by erector spina plane block
40748710|NCT03251105|DEVICE|supraglottic airway intubation|
40748711|NCT05991479|OTHER|Pilates exercises|"Pilates exercises:~The subjects will receive Pilates training (3 sessions/week) for 8 weeks. The Pilates training protocol will take 60 min per session, including 10 min of warm up prior to initiating the Pilates technique, 40 min for Pilates exercises and 10 min for cool down. The number of repetitions will be 10 times. The patient will perform the following Pilates exercises: (Hundred exercises, spine stretch, single leg stretch , double leg stretch, criss cross, swimming, one leg kick, side kick, clam, one leg circle, shoulder bridge, hip twist, roll up and down and standing footwork)."
40748712|NCT05991479|OTHER|Traditional physical therapy programme:|"All patients will receive a traditional physical therapy programme consisting of 45 minutes per session of a supervised and individualized exercise programme for three sessions per week for eight weeks which will include:~Stretching exercises for calf and hamstring muscles. Strengthening exercises for hip, knee, ankle, and foot muscles. Deep friction massage for scar management."
40748713|NCT01192360|PROCEDURE|Phase contrast flow velocity mapping (PC)|An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
40748714|NCT01192360|PROCEDURE|Dynamic contrast-enhanced magnetic resonance imaging|Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
40748715|NCT03418675|DRUG|Rexulti|Atypical antipsychotic
40748716|NCT03418675|DRUG|Placebo|Pill that contains no medicine
40748717|NCT00723242|DRUG|Viraferon-peg and Rebetol|
40748718|NCT02745405|OTHER|Fat Suit|Participants wear a fat suit.
40748719|NCT02745405|OTHER|Control Condition|Participants wear same clothing as intervention, but in their own size.
41270168|NCT05790486|OTHER|Community Paramedicine Standard Plus Enhanced Implementation Program|Counties randomized to the enhanced program will receive the standard implementation program plus the following enhancements. We will engage and train local implementation champions. The EMS Implementation Champion will go through the Take a Break Intervention but will not receive NRT sampling. The local implementation champions are internal facilitators with additional knowledge and experience related to the electronic referral process. The champions will also be leaders in their county by trying to improve referrals, remind EMS personnel, and distribute feedback on the performance of the county.
41270169|NCT05790486|OTHER|Community Paramedicine Standard Implementation Program|In counties randomized to the standard program, we will engage EMS leaders and train local personnel. The training will be applying the Ask-Advise-Refer model and the use of an eRefer tool in EMS situations and conditions. The EMS will then engage smokers in the field or community to use the Ask-Advise-Refer training to submit electronic referrals with the eRefer tool.
41270170|NCT00212329|PROCEDURE|T Cell Proliferation and Autoreactivity Assays|
41270171|NCT00212329|PROCEDURE|Cellular Immunoblot Assays|
41270172|NCT00212329|PROCEDURE|Tetramer Studies|
41270173|NCT00212329|PROCEDURE|Cytokine ELISPOT|
41270174|NCT04141371|DRUG|Molar Sodium Lactate|daily 3-hour infusion of sodium molar lactate during the vasospasm period
41270175|NCT04141371|DRUG|physiological serum|daily saline infusion over 3 hours during the vasospasm period
41270176|NCT01523483|DRUG|Progesterone|Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
41270177|NCT01523483|DRUG|placebo vaginal capsules|Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
41270178|NCT00548548|DRUG|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
41270179|NCT00548548|DRUG|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
41270180|NCT00548548|DRUG|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
41270181|NCT00548548|DRUG|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
41270182|NCT00548548|DRUG|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
41270183|NCT02505256|OTHER|No intervention|
41270184|NCT03809897|DRUG|Varenicline|All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.
41270185|NCT03809897|DRUG|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
41270186|NCT04315467|DRUG|SGM-101|A one-time infusion of SGM-101
41270187|NCT04315467|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
41270188|NCT03968419|DRUG|Canakinumab|200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks
41270189|NCT03968419|DRUG|Pembrolizumab|200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks
41270190|NCT01725880|OTHER|Observation|
41270191|NCT04568330|OTHER|best support care|Best support care
41270192|NCT04568330|OTHER|moisture cream|BSC plus moisture cream
41270193|NCT04568330|OTHER|10% urea-based cream|BSC plus 10% urea-based cream.
41270194|NCT03706586|PROCEDURE|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
41270195|NCT03706586|PROCEDURE|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
41270196|NCT03911622|DEVICE|MRI|medical device that is used as an imaging tool for soft tissues
41270197|NCT04359784|BIOLOGICAL|Anakinra|Given IV (previously SC)
41270198|NCT04359784|PROCEDURE|X-Ray Imaging|Undergo x-ray
41270199|NCT04359784|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41270200|NCT04359784|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
41270201|NCT04359784|PROCEDURE|Bone Marrow Aspiration|Undergo BMA
41270202|NCT04359784|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41270203|NCT04359784|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
41270204|NCT04359784|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41270205|NCT01495143|PROCEDURE|Posterolateral lumbar fusion surgery|Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
41270206|NCT02236689|PROCEDURE|Non operative|no surgical intervention
41270207|NCT02236689|PROCEDURE|Arthroscopic tennis elbow release|Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).
41270208|NCT00833092|DIETARY_SUPPLEMENT|Sugar Pill|Sugar pill supplementation for 9 weeks
41270209|NCT00833092|DIETARY_SUPPLEMENT|magnesium|300 milligrams daily for 8 weeks
41270210|NCT06381193|DIETARY_SUPPLEMENT|Probiotic|oral, daily
41270211|NCT06381193|DIETARY_SUPPLEMENT|Prebiotic|oral, daily
40748720|NCT03186924|BEHAVIORAL|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
40748721|NCT04338997|DRUG|IZD174|Small molecule inhibitor of NLRP3
40748722|NCT05192876|RADIATION|Radiotherapy|Outcomes and adverse events using radiation therapy
40748723|NCT02926612|OTHER|Next Generation Genomic Sequencing|DNA and RNA are extracted from biospecimens, amplified, sequenced, and then compared to known microbe databases, allowing for quantitative identification of non-host organisms
40748724|NCT00033345|DRUG|Indole-3-carbinol|400 mg pill taken daily
40748725|NCT00033345|DRUG|Indole-3-carbinol|800 mg pill taken daily
40748726|NCT00033345|OTHER|Placebo|Placebo pill taken daily during run-in period
40748727|NCT03068520|DIAGNOSTIC_TEST|PET MR|PET MR with 18 Fluorodopa (\[18F\]-DOPA) will be performed on patient at set intervals
40748728|NCT03745469|DEVICE|Smartphone|A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
40748729|NCT06455254|DRUG|Candonilimab (AK104)|Cadonilimab (AK104): 6mg/kg, i.v. q2w.
40748730|NCT06455254|DRUG|Regorafenib|Regorafenib: 80 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).
40748731|NCT01016015|BIOLOGICAL|Cixutumumab|Given IV
40748732|NCT01016015|OTHER|Laboratory Biomarker Analysis|Correlative studies
40748733|NCT01016015|DRUG|Temsirolimus|Given IV
40748734|NCT02502071|DRUG|sodium bicarbonate|All participants will receive 2 doses of 1950mg sodium bicarbonate
40748735|NCT01684033|DEVICE|Opti-Free® PureMoist® MPDS|
40748736|NCT01684033|DEVICE|Biotrue™ MPS|
40748737|NCT01684033|DEVICE|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
40748738|NCT04076215|BEHAVIORAL|Stressogenic stimulus|Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting
40748739|NCT04076215|DEVICE|Biobeat smart watch and adhesive biosensor patches.|Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.
40748740|NCT01895179|OTHER|Time-Restricted Feeding|Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.
40748741|NCT01895179|OTHER|Grazing|Grazing involves eating meals spread out over the course of the day.
40748742|NCT00882388|DRUG|aspirin|aspirin 100 mg qd for 7 days
40748743|NCT00882388|DRUG|celecoxib|celecoxib 200 mg bid \* 7 days
40748744|NCT00882388|DRUG|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
40748745|NCT00882388|DRUG|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
40748746|NCT00882388|DRUG|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
40748747|NCT00107588|BEHAVIORAL|Reinforcement for homework completion|Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills
40748748|NCT00107588|BEHAVIORAL|Reinforcement for Abstinence|Provides contingent reinforcement for submitting marijuana-free urine specimen
41270212|NCT06381193|DIETARY_SUPPLEMENT|Probiotic + Prebiotic|oral, daily
40748749|NCT00107588|BEHAVIORAL|Case Management|Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
40748750|NCT05523739|DRUG|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
40748751|NCT04162275|DRUG|Finamine tablets|taken Finamine tablets orally
40748752|NCT04162275|DRUG|Placebo tablets|taken Placebo tablets orally
40748753|NCT02595710|OTHER|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
40748754|NCT02595710|OTHER|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
40748755|NCT02595710|OTHER|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
40748756|NCT01298466|DRUG|Pregabalin|The investigator will administer pregabalin in a flexible dose-escalation regimen as follows: 150 mg per night for 1 week, 300 mg per day for 1 week, 450 mg per day for 1 week, then 600 mg per day through to the end of the study. Patients may change the dose of medication based on individual response and tolerability as determined by the investigator.
40748757|NCT06257121|DEVICE|OSMS position management|Patient position management in real time during radiation using an optical Surface Management System (OSMS) (Vision RT)
40748758|NCT00927082|DRUG|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
40748759|NCT04419350|PROCEDURE|Microneedling|One session of microneedling will be performed by using dermaroller 1.5 mm. The microneedling done from the edge of the normal skin towards the center of the hypopigmented lesion in all the directions (horizontal, vertical. diagonal).
40748760|NCT03366415|DRUG|gemcitabine and cisplatin (Induction and adjuvant chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before IMRT and after IMRT.
41270213|NCT06381193|DIETARY_SUPPLEMENT|Placebo|oral, daily
41270214|NCT03452839|DRUG|Meropenem|Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
41270215|NCT05122130|DRUG|Melatonin|The donor site will be dressed with melatonin loaded gelatin sponge
41270216|NCT05122130|DRUG|Carbopol|The donor site will be dressed with carbopol loaded gelatin sponge (placebo).
41270217|NCT05949307|DEVICE|acupuncture|acupuncture
40748761|NCT03366415|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor
40748762|NCT03366415|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before concurrent chemoradiotherapy.
40748763|NCT03366415|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4Gy to the primary tumor, concurrently with cisplatin 30mg/m² every week.
40748764|NCT06070532|BIOLOGICAL|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
40748765|NCT02318277|DRUG|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
40748766|NCT02318277|DRUG|INCB024360|INCB024360: Oral daily dosing
40748767|NCT01178411|DRUG|Tivantinib|Tivantinib 360 mg (3 x 120 mg tablets or capsules) twice daily by mouth.
40748768|NCT01178411|DRUG|Anti-Cancer Combination Therapy|Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the same dose and schedule in which they were administered in the original (previous) study.
41270218|NCT05949307|DEVICE|laser acupuncture|laser acupuncture
41270219|NCT05949307|DEVICE|Sham-laser acupuncture|Sham-laser acupuncture
40748769|NCT00349076|DRUG|5-FU and oxaliplatin|"Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles"
40748770|NCT00349076|DRUG|5-FU|"Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
40748771|NCT01797185|DRUG|SPARC1104 modified dose regimen I|Subjects who exited study CLR_09_21
40748772|NCT01797185|DRUG|SPARC1104 modified dose regimen II|Subjects who received prior treatment regimen I
40748773|NCT01797185|DRUG|SPARC1104 modified dose regimen III|Subjects who received no prior treatment regimen
41270220|NCT03455673|DIAGNOSTIC_TEST|ATE score|"The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (\> 270 ng/ml) = 1"
41270221|NCT06224114|DEVICE|Coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a coloured-light torch to the study eye.
41270222|NCT06224114|DEVICE|Different coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a different coloured-light torch to the study eye.
41270223|NCT01371630|BIOLOGICAL|Blinatumomab|Given CIVI
41270224|NCT01371630|DRUG|Cyclophosphamide|Given IV
41270225|NCT01371630|DRUG|Cytarabine|Given IT and IV
41270226|NCT01371630|DRUG|Dexamethasone|Given IV or PO
41443023|NCT06558734|PROCEDURE|Tooth Preperation|After the caries were removed, the teeth were prepared according to the manufacturer's recommendations for Figaro Crowns. Fiberglass crowns (Figaro Crowns Inc., USA) of the most suitable size in terms of the mesio-distal dimension of the tooth were selected. Following the establishment of anesthesia, the teeth were prepared using diamond cutting burs with a high-speed, water-cooled turbine handpiece. In order to achieve adequate interocclusal space, an occlusal reduction of 1-2 mm was executed along with a proximal reduction reaching 1 mm below the gingival margin. A more conservative reduction was applied to the buccal and lingual surfaces. After preparation, any remaining decayed dentin tissue was removed using a steel round bur with a low-speed micromotor. To ensure occlusal harmony, diamond burs were used to perform abrasion on the crown edges, and the trimmed crown edges were polished using rubber aids before cementation.
41443024|NCT06558734|PROCEDURE|Cementation|Figaro crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
41443025|NCT00377260|DRUG|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
41443026|NCT00377260|DRUG|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
41443027|NCT01094054|PROCEDURE|Adjustable gastric banding|Placement of adjustable gastric band - laparoscopically
40748774|NCT05157763|DRUG|EscharEx 5% (EX-02 formulation)|EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
40748775|NCT03509155|OTHER|National portion & IYCF counseling|Eight or twelve pieces of Biscuits supplementation per day as serving size recommendation based on the requirement from Ministry of Health, accompanied by IYCF Counseling emphasizing on local food optimization. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
40748776|NCT03509155|OTHER|Adjusted portion & local food counseling|four pieces of Biscuits supplementation per day as serving size recommendation, accompanied by IYCF Counseling. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
40748777|NCT01117545|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Six sessions of EFT
40748778|NCT01456923|OTHER|Treatment with chemotherapy|
40748779|NCT01456923|OTHER|Only chemotherapy treatment for study cohort|Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy
40748780|NCT01456923|PROCEDURE|surgery|
40748781|NCT04590183|DRUG|FK-506 (Drug)|Twice a day
40748782|NCT04590183|DRUG|Prednisolone Acetate 1% Oph Susp|Four times a day
40748783|NCT00607594|DRUG|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
40748784|NCT02342951|OTHER|Lung clearance index determination|Lung clearance index determination
40748785|NCT03648970|DRUG|Pravastatin|The participant will be given pravastatin 2 x 20 mg per oral daily
40748786|NCT02635789|DRUG|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
40748787|NCT02635789|DRUG|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
40748788|NCT01986322|BIOLOGICAL|DTP/HB/Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
40748789|NCT01986322|BIOLOGICAL|DTP/HB and Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
40748790|NCT01684592|BEHAVIORAL|Phone-based postpartum continuing care|PPCC Counselors will make initial contact with participants in the experimental group at 36 weeks gestation (i.e., one week prior to full-term), will call again within one week after the baby's birth, and eight additional times over the course of the first six months postpartum. The PPCC protocol will be developed based on the 5 A's (standard of care during pregnancy) and the Recovery Management Checkup model where relapse is expected and efforts are made to take a more proactive approach to identify women who are having cravings or have relapsed and re-intervene with them as soon as possible to assist them in regaining smoking abstinence. Women in the experimental group will also have the option of calling the PPCC line 24 hours a day, 7 days a week.
40748791|NCT01684592|BEHAVIORAL|Standard care|All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by American College of Obstetricians and Gynecologists (ACOG) for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.
40748792|NCT05016050|DEVICE|HPDT-DA-013|Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).
40748793|NCT03745456|DIAGNOSTIC_TEST|Blood samples for ROTEM and platelet function.|Thormoboelastometry is based on the measurement of elasticity of blood by continuous graphical logging of the firmness of a blood clot during clot formation and subsequent fibrinolysis
40748794|NCT03983005|PROCEDURE|EUS-B-FNA|Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
40748795|NCT03050489|PROCEDURE|On-Pump CABG.|Standard On-Pump CABG.
40748796|NCT03050489|PROCEDURE|Off-Pump CABG.|Standard Off-Pump CABG.
40748797|NCT03050489|PROCEDURE|BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
40748798|NCT05389839|DEVICE|Wechat program|The experimental group used wechat program to calculate insulin dose to guide insulin treatment .
40748799|NCT01149252|OTHER|Psoralait|Cream to be used as instructed.
40748800|NCT01149252|OTHER|Placebo cream.|Cream to be used as instructed
40748801|NCT03749863|PROCEDURE|Serial PRP injections|Autologous platelet-rich plasma will be injected into the vocal fold mucosa in a serial fashion, once per month for a total of 4 injections.
40748802|NCT00428077|BIOLOGICAL|bcr-abl peptide vaccine|Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.
40748803|NCT00428077|GENETIC|reverse transcriptase-polymerase chain reaction|"A baseline reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a baseline circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction."
41270227|NCT01371630|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
40748804|NCT02015936|BEHAVIORAL|Six Week Physical Activity Intervention|Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.
40748805|NCT02015936|OTHER|Progress Reporting|Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
40748806|NCT03922971|OTHER|Option 1: National comparison|Ability to view center's rate compared with all others.
40748807|NCT03922971|OTHER|Option 2: National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
40748808|NCT02907827|OTHER|follow up DW MRI|Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis
40748809|NCT01573377|DRUG|Metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
40748810|NCT01573377|DRUG|Ethinylestradiol and Cyproterone Acetate|from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
40748811|NCT02540434|DEVICE|ROTEM|ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
40748812|NCT02540434|OTHER|Cryoprecipitate|Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
40748813|NCT02540434|DRUG|RiaSTAP|Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
40748814|NCT00411541|DRUG|vincristine|
40748815|NCT00411541|DRUG|dexamethasone|
41270228|NCT01371630|OTHER|Laboratory Biomarker Analysis|Correlative studies
41270229|NCT01371630|DRUG|Mercaptopurine|Given PO
40748816|NCT01400633|DRUG|decitabine injection|decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
40748817|NCT04584983|DRUG|usual prescribed intralipid (UL) regimen|Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
40748818|NCT04584983|DRUG|restricted prescribed intralipid (RL) regimen|Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
40748819|NCT05103735|DRUG|Propofol|awake neurosurgery under propofol-remifentanil sedation
41270230|NCT01371630|DRUG|Methotrexate|Given IT, IV, and PO
41270231|NCT01371630|DRUG|Prednisone|Given PO
41270232|NCT01371630|BIOLOGICAL|Rituximab|Given IV
41270233|NCT01371630|DRUG|Vincristine|Given IV
41270234|NCT02207114|OTHER|Biomarker Algorithm Intervention|The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
41270235|NCT00480857|DRUG|Docetaxel (Taxotere)|Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
41270236|NCT00539019|OTHER|calories measured 5x following wound healing|measure REE at various time points postburn
41270237|NCT05305482|DEVICE|Drug-coated stent|The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.
41270238|NCT05305482|DEVICE|Drug-eluting stent|The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
41270239|NCT05244239|DRUG|Lurbinectedin|Given IV
41270240|NCT05244239|RADIATION|Palliative Radiation Therapy|Undergo RT
41270241|NCT06428890|DIETARY_SUPPLEMENT|Grape Seed Extract|dietary supplements that rich in polyphenolic compounds
41270242|NCT06428890|DIETARY_SUPPLEMENT|Placebo|Starch
41270243|NCT05585255|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay(ELISA)|After allowing to stand at room temperature for 2h, blood samples are centrifuged at 4 ℃ for 15 min (12000 rpm) to collect the supernatant. Then, the levels of DKK2, IL-6, IL-1β, TNF-α, and IL-10 in the supernatants are tested by ELISA detection.
40748820|NCT00515593|DRUG|Parathyroid hormone (PTH) (Preotact)|Patients with severe postmenopausal osteoporosis
40748821|NCT05509673|OTHER|Lipofilling (sublesional fat grafting)|
40748822|NCT01698008|OTHER|Diabetes Doctor Mobile app|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
40748823|NCT04607590|OTHER|Best Practice|Receive usual care
40748824|NCT04607590|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
40748825|NCT04607590|OTHER|Questionnaire Administration|Ancillary studies
40748826|NCT04607590|PROCEDURE|Yoga|Participate in yoga sessions
40748827|NCT03521336|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
40748828|NCT03521336|DRUG|Placebo|Saline，Sham operation
40748829|NCT03243188|OTHER|Qualitative interview|Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
41270244|NCT03160560|DRUG|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse.
41270245|NCT03160560|DRUG|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse.
41270246|NCT03160560|OTHER|Placebo|Subjects in Placebo group will receive Placebo Rinse.
41270247|NCT03878485|DEVICE|MRIdian Linac System from ViewRay|"* 0.35T MRI combined with a linear accelerator~* This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy"
41270248|NCT03878485|RADIATION|Stereotactic MRI-guided Adaptive Radiotherapy|-The MR-linac will be delivering the radiation
41270249|NCT01511731|DRUG|Famotidine|Famotidine Tablets 40 mg
41270250|NCT01511731|DRUG|Pepcid|40mg tablets
40748830|NCT05460988|PROCEDURE|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
40748831|NCT05460988|PROCEDURE|Non surgical re-instrumentation|The sites showing remaining pockets (PD\>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
40922363|NCT05900440|OTHER|Ultrasound with Artificial Inteligence Engabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
41270251|NCT05401747|OTHER|Healthy lifestyle|Nutrition consultation and teaching: A registered dietitian has the responsibility of teaching and explaining the diet. Plan: One meeting per 12 weeks. The exercise program is based on the Physical Activity Guidelines Advisory Committee and American Heart Association guideline and a modified version of Dose-Responses to Exercise Training study protocol for older adults summarized our weekly plans in detail. Plan: 2 meetings per week. Cognitive enhancement: Participants can select any of the following activities:methods requiring mental activities, physical activity, and social activity, enjoying music and our weekly dance classes (Waltz).
41270252|NCT05559307|DRUG|Xingnaojing injection|Xingnaojing injection 20 ml+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 7 days.
41270253|NCT06299189|BEHAVIORAL|MinADHD|Guided self-help, 7 modules Interventions
41270254|NCT03711227|DIAGNOSTIC_TEST|Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
40748832|NCT05206097|DEVICE|Accelerometer|For the following study, each patient will be asked to wear a portable device over a 7-day period. The accelerometer will be previously set up according to anthropometric data of the patient and scheduled to automatically start and stop accelerations registration. The patient will be asked to wear the sensor as frequently as possible, with the exception of sleep period and during aquatic activities. A diary will be delivered to the patient in order to notify any problem/issue observed during the evaluation week (for example forgetting to wear the sensor). The accelerometry assessment will be associated to a questionnaire. Each patient will have to fill in it during the evaluation week. The questionnaire is composed of various questions from three different questionnaires: Ricci \& Gagnon for subjective evaluation of PA level, CFQ-14+ for the evaluation of quality of life specifically in CF and EQ-5D for a more generic evaluation of quality of life.
40748833|NCT03279965|DIAGNOSTIC_TEST|MRI|MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
40748834|NCT05449873|PROCEDURE|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Triple Cooled-Wet electrodes|Radiofrequency ablation will be performed by using triple cooled-wet electrodes. Two or three electrodes will be places around the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C.
40748835|NCT04456283|BEHAVIORAL|Survival|5 year survival after Chemoradiation theraphy for Rectal Cancer
40748836|NCT05985551|OTHER|SLND or TAD by the magnetic technique (SPIO)|All patients will receive Radioisotope according to standard of care. They will also receive SPIO in a timeframe of clinical convenience, depending on whether primary response is planned by means of MRI. For patients that are ycN0, SLND or TAD will be performed. For those that convert from cN1 to ycN0, the index lymph node will be marked with a paramagnetic marker. Axillary surgery will be undertaken with the magnetic technique and each retrieved lymph node will be controlled for radiation. Upon the completion of the procedure, a background control will be performed with the radioactive signal as guide, to ensure standard of care best practice. Any palpable lymph nodes that are not sentinels with either tracer may be removed at surgeon discretion but will be reported seperately.
40748837|NCT00397930|PROCEDURE|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
40748838|NCT00397930|PROCEDURE|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
40748839|NCT01647685|DRUG|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
40748840|NCT01647685|DRUG|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
40748841|NCT01647685|DRUG|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
41270255|NCT00000573|PROCEDURE|enteral nutrition|
40748842|NCT04225143|PROCEDURE|urostim bilateral|Treatment by bilateral neurostimulation of the tibial nerve
40748843|NCT04225143|PROCEDURE|urostim unilateral|Treatment by unilateral neurostimulation of the tibial nerve
40748844|NCT04869436|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)
40748845|NCT03017287|DEVICE|GlucoMe App|Assessment of the the GlucoMe App
41270256|NCT03192904|DEVICE|Energy Instruments|Energy Instruments, including electrocautery, harmonic scalpel and LigaSure.
41270257|NCT03192904|DEVICE|Stapling Device|Stapling Device, including linear stapler and curved stapler.
41270258|NCT03251326|DRUG|Nabilone|Nabilone capsules (4 mg)
40748846|NCT01386177|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
41270259|NCT03251326|DRUG|Cannabis|Cigarettes (0.0 and 5.6% THC)
41270260|NCT03251326|DRUG|Propranolol|Propranolol capsules (40mg)
41270261|NCT03251326|DRUG|Placebo|Placebo capsules
41270262|NCT05315609|BEHAVIORAL|VR Meditation|This 4-week VR program will use the Oculus Pro-Quest 2 headsets for the 15-minute seated VR meditation twice per week for a total of 8 sessions over the 4 weeks.
41270263|NCT03306654|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
41270264|NCT01526525|DRUG|Tramadol|Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
41270265|NCT01526525|DRUG|Ketamine|ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
41270266|NCT01526525|DRUG|Tramadol|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
41270267|NCT01526525|DRUG|Morphine|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
41270268|NCT01526525|PROCEDURE|sedation|If the patient had sedation score \>2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
40748847|NCT01386177|DRUG|Doxazosin|"3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.~1 day (-16h) before MDMA: 8 mg doxazosin per os."
40748848|NCT01386177|DRUG|placebo|capsules identical to MDMA or doxazosin
40748849|NCT03986268|DRUG|Vit D|The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
40748850|NCT02726295|DRUG|E. coli Nissle 1917(Mutaflor®)|
40748851|NCT02726295|DRUG|Placebo|
40748852|NCT02480361|DEVICE|acupuncture|Acupuncture treatment after gastric cancer surgery during 5 postoperative days
40748853|NCT03418974|DRUG|Pitavastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
40748854|NCT03418974|DRUG|Atorvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
40748855|NCT03418974|DRUG|Rosuvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
40748856|NCT01716156|DRUG|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
40748857|NCT01716156|DRUG|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
40748858|NCT03368430|DIETARY_SUPPLEMENT|Melatonin|After performing scaling and root planing (SRP) in the test group, melatonin 10 mg oral capsule was taken once daily at night prior to bedtime for only 2 months during the 6-month study period
40748859|NCT03368430|DRUG|Placebo|After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
40748860|NCT03081923|DRUG|Durvalumab|anti-PD-L1 mono therapy
40748861|NCT03081923|DRUG|Tremelimumab|anti-CTLA4 drug Tremelimumab mono therapy
40748862|NCT04220281|DRUG|Propofol|propofol infusion during surgery
40748863|NCT04220281|DRUG|Nitroglycerin|nitroglycerin infusion during surgery
40748864|NCT05017636|DEVICE|shock wave therapy|The participants received the treatment protocol established by the manufacturer of the Thork Shock Wave® device, IBRAMED- Industria Brasileira de Equipamentos Electromédicos, Amparo, São Paulo approved by Anvisa No. 10360310036. (Figure 1). The parameters were, 4,000 thousand shots with energy of 180mJ and frequency of 15Hz with 15mm stainless steel tip and 2,000 shots with energy of 100mJ and frequency of 15Hz with 15mm plastic tip, and for the tip slip, Neutral Thork® Lotion, RMC was used. Seven ESWT sessions were held, the average time of each was seven minutes, twice a week and the seventh session was held minutes before the surgical procedure of bariatric surgery, therapy was performed in an area of 150cm² on the left side of the abdominal region following the midline. The right side of the participants' abdomen did not receive ESWT and was termed as control.
40748865|NCT06024265|DRUG|ER2001 injection|The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.
40748866|NCT05711407|GENETIC|Gene Polymorphisms of MMP-8|Saliva Samples
40748867|NCT05018559|BEHAVIORAL|BuG lesson|Participants of the intervention group in nursing care received a co-created setting-specific intervention to promote physical activity called BuG lesson. The BuG lesson comprises a weekly 90-minute lesson for apprentices of nursing care during regular school hours, covering physical activity and health in theory and practice. Previously, the nursing teachers voluntarily underwent a qualification process as physical activity instructors, enabling them to conduct the BuG lessons independently.
40748868|NCT05018559|BEHAVIORAL|Tutoring system|Participants of the intervention group in automotive mechatronics received a co-created setting-specific intervention to promote physical activity called tutoring system. In the tutoring system, automotive mechatronics apprentices act as physical activity promotors for their fellow apprentices. In the sense of a peer-to-peer approach, apprentices voluntarily participate in a workshop to be qualified as tutors. Subsequently, the tutoring system takes place every two weeks for about ten to fifteen minutes during regular working hours, allowing the tutors to discuss the issues of physical activity and health among their peers.
40748869|NCT02685865|DEVICE|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
40748870|NCT02685865|DEVICE|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
40748871|NCT01447472|DRUG|MDMA|One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
40748872|NCT01194700|DRUG|Seretide 250(8puffs) via Evohaler actuator|8 puffs of Seretide250/Placebo via Evohaler actuator
40748873|NCT01194700|DRUG|Seretide 250 (8 puffs)/placebo via Volumatic spacer|8 puffs of Seretide 250/placebo via volumatic spacer
40748874|NCT01194700|DRUG|Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Seretide 250/placebo 8 puffs via Aerochamber Plus
40748875|NCT01194700|DRUG|Seretide 250/placebo via Synchro-Breathe|Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
40748876|NCT04833608|DEVICE|Vktory insoles|Patients were randomized into either the Carbon fiber insole group or Morton's extension group.
40748877|NCT04833608|DEVICE|Morton's extension insoles|Patients were randomized into either the Vktory carbon fiber insole group or Morton's extension insole group.
40748878|NCT03134638|DRUG|SY-1365 (Part 1)|"Two dosing schedules will be evaluated in dose escalation and a dose(s)/schedule(s) will be determined for Part 2:~* Twice weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle.~* Weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28 day) cycle."
40748879|NCT03134638|DRUG|Carboplatin|Carboplatin will be administered on Day 1 of each 3 week (21-day) cycle (Part 2 only)
40748880|NCT03134638|DRUG|Fulvestrant|Fulvestrant will be administered as an intramuscular (IM) dose of 500 mg every 2 weeks for the first 3 doses on Day 1 and Day 15 of the first 28-day cycle (Cycle 1), and on Day 1 of the second 28 day cycle (Cycle 2), and monthly thereafter starting on Day 1 of Cycle 3 (Part 2 only)
40748881|NCT03134638|DRUG|SY-1365 (Cohort 2)|In combination with carboplatin, SY-1365 will be administered by intravenous infusion over 1 or 2 hours for 2 weeks of each 3 week (21-day) cycle (Part 2 only)
40748882|NCT03134638|DRUG|SY-1365 (Cohort 5)|In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)
40748883|NCT03134638|DRUG|SY-1365 (Part 2 Single Agent)|SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
40748884|NCT01193985|DEVICE|TIGR Matrix Surgical Mesh|Lichtenstein repair of inguinal hernia using TIGR Matrix Surgical Mesh
40748885|NCT01804907|BEHAVIORAL|Cognitive Behavioral Therapy|
40748886|NCT01804907|BEHAVIORAL|Behavioral Modification|
40748887|NCT02082483|OTHER|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
40748888|NCT06367114|BIOLOGICAL|ssCART-19|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
40748889|NCT06367114|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
40748890|NCT06367114|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
40748891|NCT02292225|DRUG|IPI-145 (duvelisib)|25mg and/or 5mg oral capsule
40748892|NCT02292225|DRUG|Obinutuzumab|1000mg/40mL single-use vials
40748893|NCT02958670|OTHER|18F-AV-1451 (Tau-PET tracer)|Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
40748894|NCT05854667|DRUG|Treatment as Usual plus Placebo|Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.
40748895|NCT05854667|DRUG|Treatment as Usual plus Placebo plus Contingency Management|Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.
40748896|NCT05854667|DRUG|Treatment as Usual plus lisdexamfetamine (LDX-01)|"Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15)."
40748897|NCT05854667|DRUG|Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management|"Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15). Engagement-focused contingency management will be provided for 12 weeks, Week 2-13."
40748898|NCT05663788|OTHER|E-learning module|"The intervention is a structured e-learning module on a web-based platform (www.trainingopticaldiagnosis.com) that consists of:~* 10 modules, including theoretical knowledge and multiple exercises.~* 2 seminars with a tutor (after Module 5 and Module 10)~* feedback from the tutor on three cases recorded by the participant.~* 20-images test before and after the content described above (10 Modules, 2 seminars with tutors and feedback on three cases)~All the Gastroenterologists participating in the study will predict deep submucosal invasion in their routine colonoscopies and will register clinical outcomes during 12 months. The randomisation and intervention will be conducted 6 months after starting to predict deep submucosal invasion and registering clinical outcomes."
40748899|NCT01558570|PROCEDURE|Blood Draw|One time blood draw
40748900|NCT00815737|DRUG|rhubarb|14 days of rhubarb
40748901|NCT00815737|DRUG|Placebo|14 days of Placebo
41270269|NCT01526525|PROCEDURE|rescue analgesia|Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
41270270|NCT01526525|DRUG|Parecoxib|An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
41270271|NCT01526525|DRUG|paracetamol|30min before the end of the surgery paracetamol 20mg/kg (IV).
41270272|NCT01736956|PROCEDURE|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
41270273|NCT01755832|PROCEDURE|Pool exercise|Group exercise in heated pool one hour per week for 12 weeks.
40922364|NCT05900440|OTHER|Ultrasound without Artificial Intelligence Enabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
40748902|NCT00133211|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation
40748903|NCT01295892|DRUG|Estrogen|transdermal 17-β-estradiol 1mg/day during three months
41270274|NCT00105872|BEHAVIORAL|Cognitive-Behavioral Therapy|
40748904|NCT02053116|DRUG|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
40748905|NCT02053116|DRUG|Placebo|Tablet, 0 mg, twice daily, 2 weeks
40922365|NCT01395784|DRUG|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
40922366|NCT02603965|RADIATION|Copper Cu 64 TP3805|Given IV
40922367|NCT02603965|PROCEDURE|Positron Emission Tomography|Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
40922368|NCT02603965|PROCEDURE|Computed Tomography|Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
41270275|NCT02349126|DRUG|ARC-520 Injection|ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
40748906|NCT06181500|OTHER|Home-based multicomponent exercise intervention program|A novel home-based multicomponent exercise intervention program was designed using a multimodal training circuit. This 24-week circuit program was created to improve functional (resistance) and aerobic health. Participants will be asked to train two to three times a week for 45 minutes. They will be supervised via videoconference by a trained kinesiologist from the EPIC Center at the Montreal Heart Institute. If desired, participants can complete their exercises with a partner, friend, or relative to facilitate communication. Participants will be asked to document the perceived intensity of their exercises in a booklet after each workout. The perceived intensity of their exercises will be measured by a validated effort perception scale graduated from 0 to 10 (Borg scale; Williams, 2017). Progressions will increase every five weeks and will be subject to modification if not properly tolerated or if found to be below a 3 on the Borg rate of perceived exertion scale (moderate intensity).
40748907|NCT02825459|BEHAVIORAL|Abstinence from e-cigarettes|Abrupt cessation for 6 days
40748908|NCT00169325|PROCEDURE|Magnetic resonance imaging|
40748909|NCT06414018|DRUG|Alfentanil|alfentanil 10ug/kg is used for anesthesia induction
40748910|NCT01030575|DRUG|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
40748911|NCT01030575|DRUG|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
40748912|NCT01030575|DRUG|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
40748913|NCT01030575|DRUG|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
40748914|NCT03306381|OTHER|Dietary intervention|Elimination of certain products.
40748915|NCT06033664|BEHAVIORAL|Fresh Funds|Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.
40748916|NCT04967703|PROCEDURE|Group A|Patients received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes), in addition to a conventional physiotherapy program consisting of calf muscles stretching, plantar fascia stretch, strengthening exercises and manual massage for 3 sessions per week, for 4 weeks
40748917|NCT04967703|PROCEDURE|Group B|Patients received radial shock wave therapy protocol with the following parameters (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz, in addition to the same conventional physiotherapy program given for group A
40922369|NCT02603965|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
40748918|NCT04967703|PROCEDURE|Group C|Patients received both ultrasound and radial shock wave therapy, in addition to the same conventional physiotherapy program given for group A
40748919|NCT04071483|PROCEDURE|Cervical transforaminal epidural steroid injection|Cervical transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of cervical radicular pain.
40748920|NCT02944266|OTHER|Pre operative Focus assessed Transthoracic echocardiographic assessment.|
40748921|NCT00588276|RADIATION|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three \*IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
40748922|NCT00368849|DRUG|atomoxetine|This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.
40748923|NCT00368849|DRUG|Matching Placebo|This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
40748924|NCT05004298|OTHER|Animal Assited therapy|The intervention will be structured in 10 group sessions, with a weekly frequency and one hour duration.
40748925|NCT01911325|DRUG|Buparlisib|
40748926|NCT01911325|DRUG|Buparlisib matching placebo|
40748927|NCT01911325|DRUG|Docetaxel|
41441025|NCT04742543|DEVICE|SootheVR: AppliedVR, Los Angeles, California a head-mounted display|"For the study group, virtual reality content will be shown to the participant for the duration of the conization procedure through a head-mounted display, RelieVRTM. The default VR content for the trial will be swimming with dolphins or any other content chosen by the participant"
41443028|NCT01094054|BEHAVIORAL|Dietary and lifestyle modification|"Dietary and lifestyle modification~Subjects will meet with a dietitian and a psychologist on a weekly basis and consume a diet matched to that of the banding arm"
40748928|NCT03097471|DEVICE|BPK-S Integration (Ceramic)|primary total knee endoprosthesis
40748929|NCT03356561|BIOLOGICAL|Ad26.ZIKV.001 5*10^10 vp|Participants will receive Ad26.ZIKV.001 at a dose of 5\*10\^10 vp via IM route.
40748930|NCT03356561|BIOLOGICAL|Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at a dose of 1\*10\^11 vp via IM route.
40748931|NCT03356561|BIOLOGICAL|Placebo|Participants will receive placebo via IM route.
40922370|NCT02603965|OTHER|Laboratory Biomarker Analysis|Correlative studies
40922371|NCT03317327|DRUG|Nivolumab|Nivolumab is a humanized antibody used in cancer immunotherapy.
40922372|NCT03317327|RADIATION|Radiotherapy (RT)|Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks
40922373|NCT01298908|PROCEDURE|Operative treatment|In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
40922374|NCT01298908|PROCEDURE|Laser ablation|In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
40748932|NCT05213390|OTHER|Dora|DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards.
40748933|NCT04657900|OTHER|Observational|Observational - no intervention given
40748934|NCT02817204|BEHAVIORAL|Aerobic Exercise|Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
40748935|NCT02817204|BEHAVIORAL|Health Education|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
40748936|NCT01642966|DRUG|Prasugrel|Prasugrel 10mg/day for 15 days
40748937|NCT01642966|DRUG|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
40748938|NCT02802085|DEVICE|VEGA Knee|TKA
40748939|NCT04505111|OTHER|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
40748940|NCT04505111|OTHER|Enhanced Recovery After Surgery|ERAS protocol
40748941|NCT02740010|DEVICE|EDOF Mini WELL Ready IOL|implant
40748942|NCT05080270|BIOLOGICAL|Tolerogenic Fibroblasts|administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion
41270276|NCT02617238|OTHER|Cardiovascular risk management based on PWV|"Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).~1. In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.~2. In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician"
40748943|NCT00004485|DRUG|cyclosporine|
41270277|NCT03883269|DRUG|Erythromycin 4% topical gel formulation|Erythromycin 4% topical gel formulation, BID, 4 weeks
40748944|NCT00004485|DRUG|fludarabine|
40748945|NCT00004485|DRUG|mycophenolate mofetil|
40748946|NCT00004485|PROCEDURE|Bone Marrow Transplantation|
40748947|NCT03561740|DRUG|capecitabine|additional metronomic chemotherapy of capecitabine
40748948|NCT02492386|DEVICE|Bioabsorbable everolimus-eluting stent deployment|Bioabsorbable everolimus-eluting stent deployment
40748949|NCT01419925|BIOLOGICAL|Two Multimeric-001 administrations followed by TIV|Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
41270278|NCT03883269|DRUG|Clindamycin 1% topical lotion formulation|Clindamycin 1% topical lotion formulation, BID, 4 weeks
40748950|NCT01419925|BIOLOGICAL|One administration of Multimeric-001 followed by TIV|One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
40748951|NCT01419925|BIOLOGICAL|One administration of adjuvanted M-001 followed by TIV|One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
40748952|NCT01419925|BIOLOGICAL|One administration of placebo followed by TIV|One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
40748953|NCT05838599|DRUG|Imiquimod|5% cream applied topically 5 days/week for 6 weeks
40748954|NCT05838599|RADIATION|Radiation Therapy|2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.
40748955|NCT00649948|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
40748956|NCT00649948|DRUG|Glucophage XR 500 mg|500mg, single dose fed
40748957|NCT02460003|BEHAVIORAL|Physiotherapy|A program of physiotherapy including manual therapy, exercise, pain education.
40748958|NCT02460003|OTHER|Home exercise program|Home exercise program
41270279|NCT03883269|DRUG|70% topical ethanol solution|70% topical ethanol solution, BID, 4 weeks
40748959|NCT03458091|DEVICE|THRIVE|Oxygenation during apnea using transversal humidified oxygen
40748960|NCT03458091|DEVICE|Endotracheal intubation|Ventilation during the procedure is governed by an endotracheal tube in the trachea and mechanical ventilation
40748961|NCT05132452|DIAGNOSTIC_TEST|The Test of Mastication and Swallowing Solids (TOMASS) and the Timed Water Swallow Test (TWST)|Participants swallowed one cracker for the TOMASS. They swallowed 150 mL of water for the TWST.
40748962|NCT05703412|BEHAVIORAL|Transition-FOCUS mHealth Intervention|tFOCUS integrates evidence-based strategies for self-management of severe mental illness (SMI) into a comprehensive mobile assessment and treatment system that is grounded in theoretical SMI models. The application promotes self-management strategies aimed at improving medication adherence to manage biologically driven psychiatric symptoms, increase social support to reduce the negative impact of social withdrawal, improve sleep hygiene to reduce levels of fatigue, and promote strategies for coping with persistent symptoms. tFOCUS application strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience
40748963|NCT05703412|BEHAVIORAL|Check-In|Check-in includes a discharge and safety plan (with medication instructions, crisis services, etc.), a timely follow-up appointment with a mental health provider, and phone check-ins by case managers immediately following post-discharge for care coordination purposes.
40748964|NCT01526746|DRUG|Tasimelteon|20mg capsule, once
40748965|NCT01526746|DRUG|Tasimelteon|20mg, once
40748966|NCT02800252|DRUG|Placebo|One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
40748967|NCT02800252|DRUG|3g omega-3 plus 100mg aspirin daily for 60 days|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
40748968|NCT02800252|DRUG|omega-3 plus aspirin before periodontal therapy|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
40748969|NCT06466252|BEHAVIORAL|Psychometric Group|There are no interventions
40748970|NCT02218268|DRUG|Pre-meal bolus|Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
40748971|NCT02218268|DRUG|No meal bolus|Long Acting insulin as scheduled per usual routine (given once daily)
40748972|NCT04230239|DRUG|CPX-351|"CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine"
40748973|NCT04958590|RADIATION|whole spine X-ray|Group 1 underwent whole spine X-ray in standing and sitting positions.
40748974|NCT00594555|DRUG|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
40748975|NCT00594555|DRUG|CLAG|"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"
40748976|NCT06296693|DEVICE|Pocket-size lung ultrasound for etiological definition of pneumonia and surveillance of complications in children hospitalized|The investigators will study the diagnostic accuracy of a pocket-size POCUS device vs. CXR for the etiological diagnosis of CAP, in paediatric age. During 1 year, all children aged \>12 months and \<18 years admitted to the Paediatric Department with the diagnosis of CAP on admission will be included. At least 76 participants will be required. Two investigators will perform, independently, a POCUS at admission, daily during hospitalization, 15 days and 1 month after discharge. All children will also undergo a CXR upon admission and whenever necessary. A third investigator will classify the CXR independently. It will be used the General Electrics Vscan AirTM®, with Bluetooth connection to smartphone/tablet. It will be collected the systematized description of POCUS and CXR, sociodemographic, clinical and therapeutic variables.
40748977|NCT02401295|DRUG|ATRA|
40748978|NCT02401295|DRUG|Celecoxib|
40748979|NCT02401295|DRUG|Itraconazole|
40748980|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level -1|(1 x 10\^3 T cells/Kg)
40748981|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 1|(1 x 10\^4 T cells/Kg)
40748982|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 2|(1 x 10\^5 T cells/Kg)
40748983|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 3|(1 x 10\^6 T cells/Kg)
40748984|NCT00586547|BIOLOGICAL|T-Cell Infusion- Dose Level 4|(5 x 10\^6 T cells/Kg)
40748985|NCT05042882|DIETARY_SUPPLEMENT|Early enteral nutrition|Enteral nutrition via nasojejunal tube
40748986|NCT00639379|DEVICE|senofilcon A toric|silicone hydrogel toric lens, 2 wk replacement, daily wear
40748987|NCT00639379|DEVICE|alphafilcon A toric|hydrogel toric lens, 2 wk replacement, daily wear
40748988|NCT03107000|PROCEDURE|Trabeculectomy|Incisional surgery for glaucoma
40748989|NCT03107000|PROCEDURE|Phako-trabeculectomy|Incisional surgery for glaucoma plus cataract
40748990|NCT05176574|BEHAVIORAL|Questionnaire|A questionnaire will be developed via the Delphi method, will be pilot tested and implemented to assess physicians' perceptions and behaviors on physical activity and exercise in chronic, non-communicable diseases.
40748991|NCT06485180|PROCEDURE|Active comparator|"Participants from conservative group were selected as uterine curettage (D\&C) cohort , hysteroscopy cohort, Uterine Artery Embolization (UAE) in Combination with D\&C, without MTX cohort, UAE in Combination D\&C with MTX cohort and UAE+ D\&C+hysteroscopy.~Participants from CSP excision plus hysterotomy closure group were selected as transvaginal CSP excision cohort, hysteroscopy-assisted laparoscopic CSP excision cohort and abdominal CSP excision cohort."
40748992|NCT03057327|BEHAVIORAL|Improve awareness of checking moles|"Intervention:~1. Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.~2. Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant."
40748993|NCT03057327|OTHER|Comparator|Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
40748994|NCT04483947|DRUG|AZD2693|Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
40748995|NCT04483947|OTHER|Placebo|Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort
40748996|NCT05111769|DRUG|Recombinant human brain natriuretic peptide|1. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
40748997|NCT05543382|DEVICE|Axonics System|The Axonics System will be implanted as standard care
40748998|NCT02286830|DRUG|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
40748999|NCT02449577|OTHER|Beverage sequence ABCD|Participants receive test beverages in the randomised order ABCD
40749000|NCT02449577|OTHER|Beverage sequence CADB|Participants receive test beverages in the randomised order CADB
40749001|NCT02449577|OTHER|Beverage sequence DACB|Participants receive test beverages in the randomised order DACB
40749002|NCT02449577|OTHER|Beverage sequence CBAD|Participants receive test beverages in the randomised order CBAD
40749003|NCT02449577|OTHER|Beverage sequence ABDC|Participants receive test beverages in the randomised order ABDC
40749004|NCT02449577|OTHER|Beverage sequence DABC|Participants receive test beverages in the randomised order DABC
40749005|NCT02449577|OTHER|Beverage sequence DCAB|Participants receive test beverages in the randomised order DCAB
40749006|NCT02449577|OTHER|Beverage sequence DBCA|Participants receive test beverages in the randomised order BDCA
40749007|NCT02449577|OTHER|Beverage sequence ADCB|Participants receive test beverages in the randomised order ADCB
40749008|NCT02449577|OTHER|Beverage sequence BADC|Participants receive test beverages in the randomised order BADC
40749009|NCT02449577|OTHER|Beverage sequence ACDB|Participants receive test beverages in the randomised order ACDB
40749010|NCT04448080|DEVICE|Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)|Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
40749011|NCT03879109|DRUG|Chemotherapy FOLFIRINOX, 6 cycles|"* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)"
40749012|NCT03879109|RADIATION|Radiochemotherapy|Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
40749013|NCT03879109|PROCEDURE|Surgery|"Surgery will be performed at:~* Arm A: 8 weeks (±1) after the end of treatment~* Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~* Total mesorectal excision (TME)~* Extended-TEM (e-TME)~* Pelvic exenteration (PE)"
40749014|NCT04832308|BEHAVIORAL|Exercise Therapy|This is a health coach driven exercise prescription for patients recommending 30 minutes or more of moderate effort walking 3-5 days a week with expected walk-rest-walk-rest intervals.
40749015|NCT00468000|BIOLOGICAL|Ixmyelocel-T|IM injection
40749016|NCT00468000|BIOLOGICAL|Placebo|IM Injection
40749017|NCT00332098|BEHAVIORAL|Family-Focused Treatment Plus Pharmacotherapy|Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.
40749018|NCT00332098|BEHAVIORAL|Enhanced Care Plus Pharmacotherapy|Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.
40749019|NCT05830643|BEHAVIORAL|Social skills group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
40749020|NCT05830643|BEHAVIORAL|Adult interest group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
40749021|NCT03899597|DRUG|Oxytocin|The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
40749022|NCT03899597|OTHER|Normal saline|The control group (SA) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery placebo exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
40749023|NCT03423953|DEVICE|Comprehensive Nano|Patients requiring the Comprehensive Nano shoulder system.
40749024|NCT02002208|DRUG|OC000459|Oral CRTH2 antagonist
40749025|NCT05033535|DRUG|Sacubatril Allisartan medoxomil|Sacubatril Allisartan medoxomil ：A randomized, double-blind, placebo and positive drug parallel controlled, multi-center phase II clinical study on the effectiveness and safety of treating mild and moderate essential hypertension
40749026|NCT05033535|DRUG|Olmesartan Medoxomil|Efficacy for lowering blood pressure of Olmesartan medoxomil
40749027|NCT02739646|DEVICE|Functional MRI scan|7.0 Tesla functional MRI scan
40749028|NCT04097184|DEVICE|Neurostimulation with non-implanted electrodes|Neurostimulation with non-implanted electrodes
41270280|NCT03667001|DRUG|Lidocaine Hydrochloride|The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
40749029|NCT02541903|DRUG|Gilotrif|Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
40749030|NCT05282407|DRUG|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
40749031|NCT05282407|DRUG|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
40749032|NCT03178942|DRUG|Permethrin Cream, 5%|Permethrin Cream 5%
40749033|NCT03178942|DRUG|Elimite™ Cream (permethrin) 5%|Permethrin Cream 5%
40749034|NCT00335075|DRUG|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
40749035|NCT00335075|DRUG|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
40749036|NCT02493855|DRUG|Ombitasvir/ABT-450/Ritonavir|Ombitasvir/ABT-450/ritonavir combination tablets
40749037|NCT02493855|DRUG|Dasabuvir|Dasabuvir tablets
40749038|NCT02493855|DRUG|Ribavirin (RBV)|Ribavirin tablets
40749039|NCT02614014|BEHAVIORAL|Cognitive-behavior interventional program|
40749040|NCT05970211|DEVICE|Phonak Audeo Lumity Receiver in Canal Hearing Aid|bilateral receiver in canal hearing aids provided as part of a best practices hearing loss intervention including devices, hearing centered counseling, and self management skills training for hearing loss
40749041|NCT05198362|OTHER|Placebo|Inactive comparator
40749042|NCT05198362|DRUG|Tesomet|Fixed-dose combination
40749043|NCT03181009|DRUG|Omalizumab|All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
40749044|NCT03181009|DRUG|Food Flour Allergens|The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
40749045|NCT02924116|DEVICE|Bioboosti|Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
40749046|NCT03949231|DRUG|PD1/PDL1 inhibitor|Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
40749047|NCT03954730|OTHER|Eccentric Training|First session will be performed 24 hours after pre-training tests i.e. on 4th post- operative day and subsequent sessions will be performed with lapse of 48 hours. During pre-testing, weight for the eccentric training will be determined using Standardized Brzycki formulas for lower limb. Participants will perform one set of 10 repetitions with selected weight. Intensity will be increased every week by decreasing the time of performance. Volume will be increased by increasing one set after two weeks. Eccentric training will be performed in sitting position on dynamic constant external resistance equipment.After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
40749048|NCT03954730|OTHER|Active Release Technique|Isometric Quadriceps' contractions against therapist's resistance lasting for 10 seconds will be performed by the patient in inner range of knee extension and after relaxing; actively perform maximum full knee flexion. Patient will perform extension at knee joint again; when reaches the innermost range, therapist will apply pressure on deep fascia either through knuckles/fingers or forearm in the direction towards the hip joint and patient is asked to perform knee flexion simultaneously. The procedure is applied onto vastus lateralis, rectus femoris and vastus intermedialis thrice in a session. After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
40749049|NCT05505890|OTHER|suprainguinal fascia iliaca block|Suprainguinal fascia iliaca block will be performed after the end of surgery for postoperative analgesia.
40749050|NCT01867476|OTHER|Automated Adherence Monitoring System|
41270281|NCT03667001|DRUG|Saline Solution|The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
41270282|NCT04217369|DEVICE|Diabits Predictions|Participants will be able to view predictions of future blood glucose. These predictions will indicate where the participant's blood glucose will travel over the next hour given that the participant's state does not change. Based on this, the participant is expected, but not required to make decisions about their activity, food, and insulin, in order to maintain blood glucose in a healthy range. The intervention does not require a specific method of glucose management, or event that a participant takes any action after viewing a prediction, the intervention is simply to display the prediction.
40749051|NCT01067911|DIETARY_SUPPLEMENT|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
41270283|NCT03695029|DRUG|Tenofovir Alafenamide|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
41270284|NCT03501979|DRUG|Tucatinib|Tucatinib study drug is given in tablet form and taken daily.
40749052|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
40749053|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
40749054|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
40749055|NCT05751928|BIOLOGICAL|BCD-217|BCD-217 (anti-CTLA4 agent nurulimab + anti-PD1) once every 3 weeks in the neoadjuvant setting
40749056|NCT05751928|BIOLOGICAL|anti-PD1|anti-PD1 agent in the adjuvant setting
40749057|NCT05751928|PROCEDURE|Excision of the primary lesion|Excision of the primary lesion will be performed per standard of care.
40749058|NCT05751928|PROCEDURE|Regional lymphadenectomy|Regional lymphadenectomy will be performed per standard of care.
40749059|NCT00700089|BEHAVIORAL|Assertive intervention|8-20 assertive contacts after suicide attempt
40749060|NCT00700089|OTHER|Standard treatment|In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
40749061|NCT05192785|PROCEDURE|Incentive Spirometry Group|"The inspiration and expiration applications of incentive spirometry (IS) involved 10-20 breaths every one to two hours, depending on the tolerance of the patients.~During the inspiration application of IS, the head of the bed was elevated to a 45° angle, and the patient was placed in a long sitting position. The patient was requested to surround and fix the IS mouthpiece well, ensuring no gap was left between the lips. The patient was told to breathe slowly and deeply, and was asked to hold their breath for 2-3 seconds, and then to breathe normally with the IS mouthpiece in his/her mouth. The patient was advised to repeat the exercise 5-10 times, and to try to cough after every 5 exercises.~For the applied IS expiration technique applied in the study, which had not been previously encountered in literature, the patient was requested to turn the IS upside down (clockwise,180°) and to place the mouthpiece in his/her mouth and expiration application it."
40749062|NCT02533674|DRUG|Gemcitabine plus PM060184|
40749063|NCT05399355|DEVICE|Active Pulsed Shortwave Treatment with BioElectronics Model 088|Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088
40749064|NCT05399355|DEVICE|Sham Treatment|Application of 7-30 days of a nonfunctional sham device(s)
40749065|NCT04619173|OTHER|Thoracic manipulation|hot pack ,transcutaneous electrical nerve stimulation and manipulation along with stretching'
40749066|NCT04619173|OTHER|Conventional physical therapy Program|hot pack ,transcutaneous electrical nerve stimulation and stretching
40749067|NCT01975649|DRUG|Tribulus Terrestris|patients will use 750 mg/day during 120 days
40749068|NCT01975649|OTHER|Placebo|patients will use placebo pills with the same shape of the drug
40749069|NCT06132750|OTHER|No intervention|No intervention
40749070|NCT02696577|DRUG|Low dose aspirin|
40749071|NCT02696577|DRUG|Omega 3|
40749072|NCT01967875|DRUG|Capecitabine+Cisplatin|Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
40749073|NCT01967875|DRUG|Docetaxel+Capecitabine|Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
40749074|NCT03609840|DRUG|Thiotepa|Given IV
40749075|NCT04401774|DRUG|Nivolumab|Nivolumab will be given every 4 weeks at 480mg flat dose intravenously for one year (total of 13 nivolumab doses).
40749076|NCT02700256|BEHAVIORAL|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
41270285|NCT03501979|DRUG|Trastuzumab|Trastuzumab is approved by the FDA and is available commercially. Trastuzumab must be prepared and is administered intravenously.
40749077|NCT01472835|DRUG|Midazolam|Used for anxiolysis
40749078|NCT01472835|DRUG|Fentanyl|Used for analgesia and as a sedative
40749079|NCT02822287|DRUG|Acetylcystine|Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
40749080|NCT03878459|DRUG|Pioglitazone 45 mg|patients will be started on 15 mg and the dose escalated to the maximal tolerated dose
40749081|NCT03878459|DRUG|Placebo|PATIENTS WILL RECEIVE PLACEBO
40749082|NCT05406895|DRUG|2% Lidocaine with 1:100,000 epinephrine|2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
40749083|NCT05915169|OTHER|Topical haemoglobin wound care spray|It is a wound care spray used in the care of chronic wounds.
40749084|NCT00927186|DRUG|Teriparatide|"20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
41270286|NCT03501979|DRUG|Capecitabine|Capecitabine is approved by the FDA and is available commercially as an oral drug.
41453214|NCT03983135|OTHER|Laparoscopic mini gastric by-pass|Adhesions will separated along the left edge of the stomach and the left lobe of the liver. The remnant stomach will transected at the incisura angularis level with 60 mm Endo-GIA stapler(ATW 35, EthiconEndo-SurgeryInc., Cincinnati, OH, USA). Later ante-cholic distal of the Treitz ligament hadgastro-jejunal anastomosisof nearly 150 cm jejunal loop performed with 44 mm Endo-GIA stapler. Routinely, the omentum will be divided in two and omentopexy will be performed around the anastomosis. The stapler line will supported by absorbable stitches.
40749085|NCT00927186|DRUG|Zoledronic Acid|"5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
40749086|NCT06466265|DRUG|DNP002|Anti-CEACAM6 monoclonal antibody
40749087|NCT04656548|DEVICE|HydroPICC|PICC lines
40749088|NCT00776425|DRUG|Epoetin beta|Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
40749089|NCT01902303|DRUG|Matching Placebo|Sublingual micro dosing of placebo for 7 days
40749090|NCT01902303|DRUG|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
40749091|NCT04479384|OTHER|Manual therapy - osteopathic techniques|"* HVLAT if any somatic dysfunction in T1-T5~* Stretch intrathoracic fascia x 3~* Recoil sternum x 3~* Cranial base release, 4 phases"
40749092|NCT03926598|BEHAVIORAL|Patient and/or Family Member Intervention|On the Patient Login Screen, log in using your last name and session ID provided by the research team on the Surveys Screen, click on a pending survey when the survey opens, respond to the survey submit the survey log out of the Guide-Goals Application.
40749093|NCT03926598|BEHAVIORAL|Certified Diabetes Educator Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
40749094|NCT03926598|BEHAVIORAL|Physician Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patient Screen, add a new patient on the Edit Patient Screen, add the Diabetes Family Responsibility Questionnaire on the Edit Patient Screen, create a survey access code to share with the patient.
40749095|NCT03926598|BEHAVIORAL|Front Desk Staff Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
40749096|NCT03926598|BEHAVIORAL|Nurse Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status screen, change HbA1C value to 10% on the Visit Status screen, change Nephropathy evaluation to Abnormal log out of Guide to Goals application.
40749097|NCT03450135|BEHAVIORAL|Trier Social Stress Test|Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.
40749098|NCT03450135|BEHAVIORAL|Emotional go/no-go task|Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
41270287|NCT06055257|DRUG|modified PENTOCLO (mPENTOCLO)|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) treatment phase consisting of 800 mg pentoxifylline (400 mg morning and night) and 800 IU tocopherol (400 IU morning and night) taken orally 5 days per week (Monday to Friday with no medications on Saturday and Sunday). If the patient deteriorates (i.e., worsening of ORN T 6 or 9-month follow-up) then clodronate 1600 mg once daily (Monday to Friday) for the rest of the study period will be added."
41270288|NCT06055257|DRUG|sham mPENTOCLO|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) of sham treatment phase (placebo)."
41270289|NCT05594784|DRUG|Olverembatinib|a third-generation TKI
41270290|NCT05594784|DRUG|Venetoclax|a selective inhibitor of B-cell lymphoma 2 (Bcl-2)
40749099|NCT03514537|PROCEDURE|Microcannula harvest adipose stromal tissues|Use of disposable, closed syringe microcannula harvest autologous adipose stroma and stem/stromal cells
40749100|NCT03514537|DEVICE|Centricyte 1000|Centricyte 1000, closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
40749101|NCT03514537|PROCEDURE|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery including 150 micron in-line filtration
40749102|NCT03514537|DRUG|Liberase|Liberase TM for use to enzymatically isolate cellular stromal vascular fraction
40749103|NCT03514537|DRUG|Saline Solution|Sterile, Normal Saline 500 for Intravenous use
40749104|NCT02197988|DRUG|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
40749105|NCT02197988|DRUG|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
41270291|NCT05594784|DRUG|prednisone|Glucocorticoids
41270292|NCT05594784|DRUG|Vincristine|Anti-tumor alkaloids
41270293|NCT00340470|BEHAVIORAL|Driver Education|
41270294|NCT01907386|OTHER|QSE-LSME - SSWI Ultrasound|Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
41270295|NCT04285320|DRUG|Intravesical antibiotic instillation|"Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:~* Amikacin-30 mg in 60 ml of sterile water~* Gentamycin-80mg in 60ml sterile water~* Tobramycin-80 mg in 100 ml of sterile water"
40749106|NCT02557893|BEHAVIORAL|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
40749107|NCT02557893|OTHER|Education|Bimonthly pregnancy education classes
40749108|NCT02557893|OTHER|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
40749109|NCT00350220|OTHER|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb \>13.0 g/dl
40749110|NCT00350220|OTHER|Low Hb transfusion group|RBCs will not be transfused unless the Hb \< 9.0 g/dl
40749111|NCT02167360|DRUG|CTL019|A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 transduced cells.
40749112|NCT00729807|DRUG|pentamidine|
40749113|NCT05223712|OTHER|Diagnostic Test: Chronic Kidney Diseases|The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.
41270296|NCT04285320|DRUG|Antibiotic oral suppressive therapy|"In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:~* Trimethoprim daily (100 mg)~* Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)~* Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (50 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (100 mg)~* Cephalexin daily (125 mg)~* Cephalexin daily (250 mg)~* Fosfomycin every 10 days (3 grams)"
40749114|NCT00224354|BIOLOGICAL|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
40749115|NCT00224354|BIOLOGICAL|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
40749116|NCT00224354|BIOLOGICAL|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
40749117|NCT00224354|DRUG|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
40749118|NCT00224354|BIOLOGICAL|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
40749119|NCT00574899|OTHER|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
40749120|NCT00574899|OTHER|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
40749121|NCT02170012|DRUG|PF-06743649|20 mg tablet once daily dosing for 14 days
40749122|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
41270297|NCT04586829|OTHER|Diet|\<50 grams of total carbohydrates per day. Monosaturated fats consumption will be encouraged over saturated fats.
41270298|NCT00430144|DRUG|Belotecan(CKD-602)|Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
41270299|NCT04417257|DRUG|LAU-7b|LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
41270300|NCT04417257|DRUG|Placebo oral capsule|Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
41270301|NCT02273245|RADIATION|Thoracic aortogram CT|With and without contrast dye
41270302|NCT01724957|PROCEDURE|Intracoronary ECG|Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
40749123|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
40749124|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
40749125|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
40749126|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
40749127|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
40749128|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
40749129|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
40749130|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
40749131|NCT06062069|DRUG|CT-868|CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
40749132|NCT06062069|DEVICE|CT-868 Pen Injector|The CT-868 pen injector is a multi-dose, single-participant, disposable pen.
40749133|NCT06062069|DRUG|: CT-868 Pen Injector, Placebo|The placebo pen injector is identical and contains the same ingredients except for CT-868.
40749134|NCT04225832|BEHAVIORAL|CBT Coping Intervention|A cognitive behavior therapy group intervention for HIV-negative Latinx sexual minority men aimed at increasing HIV testing and prevention strategies.
40749135|NCT03927430|PROCEDURE|pars plana vitrectomy with membrane peeling|23-gauge pars plana vitrectomy with peeling of the epiretinal and internal limiting membrane as well as air- or gastamponade
40749136|NCT00821821|DRUG|MCI-186|"Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion"
41270303|NCT05530096|DIAGNOSTIC_TEST|Standard of care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy
41270304|NCT06302621|DRUG|Afatinib|Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
40749137|NCT00821821|DRUG|Placebo|"Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo"
40749138|NCT05242744|DRUG|[18F]FluorThanatrace|Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression
40749139|NCT01390584|DRUG|Doxorubicin|IV
40749140|NCT01390584|DRUG|Bleomycin|IV
40749141|NCT01390584|DRUG|Vinblastine|IV
40749142|NCT01390584|DIAGNOSTIC_TEST|PET|fludeoxyglucose F 18 Imaging exam
40749143|NCT01390584|RADIATION|INRT|selective external radiation therapy
41270305|NCT06302621|DRUG|Pemigatinib|Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
41270306|NCT04545957|DEVICE|MRI Simulator|Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.
40749144|NCT01390584|DRUG|Dacarbazine|IV
40749145|NCT01390584|DRUG|Etoposide|IV
40749146|NCT01390584|DRUG|Cyclophosphamide|May be given orally, IV push, or by IV infusion
40749147|NCT01390584|DRUG|Vincristine|IV
40749148|NCT01390584|DRUG|Procarbazine|PO
40749149|NCT01390584|DRUG|Prednisone|PO
40749150|NCT00676637|DRUG|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
40749151|NCT00676637|DEVICE|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
40749152|NCT02869139|OTHER|Mentholated lip moisturizer and ice popsicle|Mentholated package of measures
41270307|NCT04545957|RADIATION|Radiation Therapy|In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.
41270308|NCT01548261|PROCEDURE|Donating oral mucosal cells|Donating oral mucosal cells
41270309|NCT03377920|DEVICE|In-check Dial device (Clement Clarke International Ltd, Harlow, UK)|"* pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up).~* 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's"
40749153|NCT02869139|OTHER|Non-mentholated lip moisturizer and ice popsicle|Non-mentholated package of measures
40749154|NCT04521166|DEVICE|Hearing aid|Settings in a wearable hearing aid will be adjusted within a clinically-relevant range for two features. The features include wide dynamic range compression and microphone directionality.
40749155|NCT05892159|BEHAVIORAL|HRV biofeedback|An HRV biofeedback tool will be employed and utilized by individuals each day for the first 5 weeks during the intervention period.
41270310|NCT04402502|DEVICE|Ultrasound Imaging|The participant will go to the Rheumatology clinic (St. Joseph's Hospital) and have 3D hand ultrasound performed on their hands.
41270311|NCT05522426|DEVICE|SyntrFuge System|Microsized Adipose Tissue
41270312|NCT06005454|DIETARY_SUPPLEMENT|Fish oil (Omega)|We will use a dietary supplement source of omega 3 fatty acids from the available syrup ( each 5 ml contain 640 mg of high DHA Fish oil) so we will give it in a dose 2.7 ml twice daily for children between 1 and 3 years and 3.5 ml twice daily for children between 4 and 5 years.
41270313|NCT05320939|DRUG|Mepolizumab 100 MG|30 subjects (≥ 300 eosinophils/ul) will receive mepolizumab 100 mg subcutaneously every 4 weeks for 5 complete doses.
41270314|NCT04959123|OTHER|pharmacokinetic analysis|Non-compartmental descriptive pharmacokinetic analysis (i.e. without the need for mathematical modelling), with determination of the pharmacokinetic parameters of interest either directly from the experimental points (Cmax, Tmax), or from simple mathematical equations (calculation of the area under the curve (AUC) by the trapezoidal method, calculation of the terminal slope of elimination)
41270315|NCT00100048|DRUG|Comparator: MK0518 monotherapy|MK0518 twice daily for 10 days
41270316|NCT00100048|DRUG|Comparator: MK0518 combination therapy|MK0518 twice daily for 48 weeks
40749156|NCT02848352|OTHER|Placebo nasal spray|
40749157|NCT02848352|OTHER|Film Sequence|
40749158|NCT05777720|DEVICE|Filtration Fan|Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.
40749159|NCT05777720|BEHAVIORAL|Safe-home pamphlet|The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.
40749160|NCT05777720|BEHAVIORAL|Mid-week phone call|On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
40749161|NCT00894725|PROCEDURE|laparoscopic left colonic resection|laparoscopic colonic resection
40749162|NCT00894725|PROCEDURE|open left colonic resection|conventional open colonic resection
40749163|NCT02205359|DEVICE|aCRT ON|CRT device with AdaptivCRT enabled (AdaptivBiV and LV)
40749164|NCT02205359|DEVICE|aCRT OFF|CRT device with AdaptivCRT disabled
40749165|NCT03997201|PROCEDURE|Ripple Mapping guided ischaemic VT ablation|"Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal late electrical activity within ventricular scar tissue."
40749166|NCT04419142|PROCEDURE|Total infrapatellar fat pad excision|Exposure for total knee arthroplasty (TKA) commonly includes total excision of the infrapatellar fat pad (IPFP). The rationale behind this is to obtain improved access to the lateral tibial plateau allowing a more accurate bone cut, baseplate placement and easier management of soft tissue interposition in the bone and cement interface. However, there is growing concern that as the IPFP is a highly vascularized and innervated fibrous adipose tissue filling the anterior compartment of the knee, its complete excision may have a detrimental effect on knee biomechanics and ultimately, TKA outcome. The reason for this effect has been suggested to be patellar tendon (PT) scarring and shortening via ischemic contracture following impaired vascularization, maintenance and biological repair of the tendon.
40749167|NCT04419142|PROCEDURE|Partial infrapatellar fat pad excision|It has been suggested in the literature that partial infrapatellar fat pad excision instead of total excision would diminish the potential negative effect on patellar tendon and knee biomechanics. However, there is only limited data in the literature and choice of total/partial infrapatellar fat pad excision in TKA remains debatable.
40749168|NCT01972971|OTHER|patient education|one by one patient education
40749169|NCT06284837|OTHER|Access site|The SAFER-TAVI trial is randomized study comparing secondary access via a transradial versus transfemoral approach among patients undergoing transfemoral TAVI for aortic valve disease. Secondary access is gained along with primary access at the commencement of the TAVI procedure and is used for aortography before and after valve deployment and for assessment of the primary femoral access site after closure to confirm haemostasis. For patients assigned to radial access, the radial sheath will be removed using a radial band at the end of the procedure. For patients assigned to femoral access, the puncture site will be obtained under ultrasound guidance and fluoroscopic landmark identification. Unless contraindicated, the use of vascular closure devices will be recommended for all femoral cases. The choice of closure device is at the discretion of the operator. Catheters used in the access groups will be 5 or 6 French size at the discretion of the operator.
41270317|NCT00100048|DRUG|Comparator: efavirenz|efavirenz 600 mg every night at bedtime for 48 weeks
41270318|NCT00100048|DRUG|Comparator: tenofovir|tenofovir 300 mg daily for 48 weeks
41270319|NCT00100048|DRUG|Comparator: lamivudine|lamivudine 300 mg daily for 48 weeks
41270320|NCT00100048|DRUG|Placebo monotherapy|Placebo to MK0518 twice daily
41270321|NCT02201758|DIETARY_SUPPLEMENT|Flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
41270322|NCT02201758|OTHER|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
41270323|NCT05480969|OTHER|Heart failure educational intervention|Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.
41270324|NCT02673333|DRUG|Pembrolizumab|
41270325|NCT02853760|BEHAVIORAL|walking|
41270326|NCT02853760|DEVICE|Treadmill|
41270327|NCT00899652|GENETIC|Southern blotting|
41270328|NCT00899652|GENETIC|chromosomal translocation analysis|
41270329|NCT00899652|GENETIC|cytogenetic analysis|
41270330|NCT00899652|GENETIC|gene rearrangement analysis|
41270331|NCT00899652|GENETIC|mutation analysis|
41270332|NCT04232670|PROCEDURE|EUS + SHAM|Endoscopic Ultrasound
41270333|NCT04232670|PROCEDURE|EUS + Pancreatic Endotherapy|Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement.
40749170|NCT00454402|DRUG|Alfuzosin|
41270334|NCT05369819|DRUG|Midazolam|. Patients of the midazolam group will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously a waiting area 3 minutes before transportation to an operating room
41270335|NCT05369819|DRUG|Saline|Control group patients are treated with 3 cc normal saline in a waiting area 3 minutes before transportation to an operating room
40749171|NCT04915066|OTHER|Medical data collection|Collection of medical data from patients'medical records
41270336|NCT03945279|DRUG|BIIB100|Administered as specified in the treatment arm.
41270337|NCT03945279|DRUG|Placebo|Administered as specified in the treatment arm.
41270338|NCT05981066|DRUG|Neoantigen vaccine, I.M injection|Patients will receive a fixed applicable dose of ABOR2014(IPM511) administered.
41270339|NCT06543628|DRUG|Tadalafil 5mg|Participants will take tadalafil once daily at a dose of 5 mg for 6 months.
41270340|NCT06543628|DEVICE|LIPUS (Low Intensity Pulsed Ultrasound)|Participants will receive LIPUS treatment applied twice a week for 4 weeks, with the cycle repeated after a 4-week interval without treatment.
41270341|NCT02933918|OTHER|Probiotics|Safety of nasal irrigation with probiotics in healthy volunteers
41270342|NCT05149638|DIAGNOSTIC_TEST|Cosyntropin stimulation test|In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.
41270343|NCT05693402|PROCEDURE|opioid anesthesia|opioid-free general anesthesia vs non opioid-free general anesthesia
41270344|NCT02964156|OTHER|Supersole|A 4-mm thin, individually customized insole of a malleable plastic material (CI-Core®) with synthetic textile material on the upper side.
41270345|NCT02964156|OTHER|No intervention|No intervention
40749172|NCT06158880|BEHAVIORAL|Alcoholic Beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
40749173|NCT06158880|BEHAVIORAL|Non-alcoholic Beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
40749174|NCT06158880|BEHAVIORAL|Partner Negative Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
40749175|NCT06158880|BEHAVIORAL|Partner Positive Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
40749176|NCT00806026|DRUG|placebo and pregabalin|following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
40749177|NCT00806026|DRUG|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
40749178|NCT00806026|DRUG|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
40749179|NCT00806026|DRUG|Pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
40749180|NCT00806026|DRUG|pramipexol|pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
40749181|NCT00806026|DRUG|pramipexol|pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
40749182|NCT03220555|DEVICE|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
41270346|NCT06358495|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Digital CBT-I is an online, six-module, self-guided CBT-I intervention. It includes videos and read information on behavioral (e.g., stimulus control, relaxation) and cognitive (e.g., restructuring, reducing arousal, and problem-solving) techniques, as well as psychoeducation (e.g., sleep hygiene). Participants complete homework following each session and track their sleep using an online diary. Young people could choose to involve their parents, for example, through completing sessions together. However, we will add a virtual session for parents as their involvement may improve adolescent engagement with the intervention as well as outcomes for adolescent sleep problems (Gradisar et al., 2011). This module will include an overview of the program components (behavioural, cognitive, and educational), goals and homework, and addresses parents' beliefs about sleep.
40749183|NCT03220555|DRUG|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
40749184|NCT00999011|PROCEDURE|once daily mobility activity|in bed and out-of-bed activity including range of motion, chair sitting, sitting at edge of bed without weightbearing, standing, walking.
40749185|NCT00999011|PROCEDURE|twice daily mobility activity|as with once daily. Goal is to progress intensity and duration of activity over time as patient condition improves for both arms
40749186|NCT00674232|DRUG|600 mcg misoprostol|single dose of misoprostol taken orally
40749187|NCT00674232|PROCEDURE|Surgical treatment|Either dilation and curettage or manual vacuum aspiration, as per local protocol
40749188|NCT00882765|DIETARY_SUPPLEMENT|genistein|Given orally
40749189|NCT02569983|OTHER|Observational cohort|No intervention - observational study
40749190|NCT05081934|BEHAVIORAL|A-CRA|12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. The average time for a placement within SiS is for boys 5,9 months and for girls 4,5 months. To further adjust A-CRA to the closed institutional care, frequency of sessions may be increased to twice a week. This is to facilitate maintaining of focus in treatment and closely follow treatment progress. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Example of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to youth individual goals and needs.
40749191|NCT05081934|BEHAVIORAL|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
40749192|NCT03004092|PROCEDURE|blood sample|Twice weekly blood sample, and at every outpatient visit
41095544|NCT00552734|DEVICE|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
40749193|NCT01402700|DEVICE|Visi-Pro™ Balloon Expandable Stent System|Implantation of one or more study devices in the common and/or external iliac artery.
40749196|NCT01421134|DRUG|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
40749197|NCT01421134|DRUG|Placebo|Placebo
40922375|NCT01298908|PROCEDURE|Foam sclerotherapy|Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
40922376|NCT00506636|BEHAVIORAL|Tissue engineering for hair follicle regeneration|
40749198|NCT01447771|BEHAVIORAL|Decision control preference scale|At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
40749199|NCT01109381|DRUG|GT08|GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
40749200|NCT04658147|DRUG|Nivolumab|Nivolumab 480mg will be administered as a 30 minute IV infusion (-/+15min) at cycle 1 day 1 and at cycle 2 day 1 (28 days) then every month for up to 12 months. Intravenous administration of Nivolumab (480 mg) will occur on Cycle 1 and 2 of the study then every 28 days up to a year. Nivolumab will be administered on Day 1 of each cycle for 10 doses/ months (whichever occurs first) for adjuvant.
40749201|NCT04658147|DRUG|Relatlimab|Patients will receive 480 mg Relatlimab intravenously (-/+15min) on cycle 1 day 1 and at cycle 2 day 1 (every 28 days) for up to 1 year co-administered with Nivolumab.
40749202|NCT00961012|PROCEDURE|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
40749203|NCT04286958|DRUG|Camrelizumab|Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)
40749204|NCT02232321|OTHER|PsA MDA|
40749205|NCT04640987|BIOLOGICAL|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
40749206|NCT04640987|DEVICE|CliniMACS Prodigy System|Device used for production of T-allo10 cells.
40749207|NCT04640987|DRUG|T-allo10 cells addback|T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.
40749208|NCT02821000|BIOLOGICAL|Pembrolizumab|Intravenous infusion
40749209|NCT04495478|DRUG|Ramucirumab - IV|Administered IV.
40749210|NCT04495478|DRUG|Placebo - IV|Administered IV.
40749211|NCT04495478|DRUG|Ramucirumab - SC|Administered SC.
40749212|NCT04495478|DRUG|Placebo - SC|Administered SC.
40749213|NCT02289378|DRUG|Docetaxel, Oxaliplatin and 5-Fu|To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
40749214|NCT02662465|PROCEDURE|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
40749215|NCT02705157|PROCEDURE|Stabilisation of (impending) pathological fracture|Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method
40749216|NCT02705157|RADIATION|Radiotherapy of bone metastasis|Radiotherapy of bone metastasis, single or multi-fractionated
40749217|NCT00179179|DRUG|nutritional supplementation|2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
40749218|NCT00179179|BEHAVIORAL|exercise|resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
40749219|NCT06516731|DIETARY_SUPPLEMENT|pH Balanced Cleanser|Participants will use the pH Balanced Cleanser daily during showers. The cleanser should be applied to the vulva with clean hands, gently worked into a lather, and rinsed clean. Participants will complete baseline and weekly questionnaires and vaginal pH tests over an 8-week period to evaluate the effects on vulvar and vaginal health, including odor and pH levels, and assess the tolerability of the product.
40749220|NCT03780387|BIOLOGICAL|Felis Catus|Inhalation of Felis Catus allergen in subjects allergic to Felis Catus
40749221|NCT04873661|BEHAVIORAL|Hypnosis group intervention|See arm description
40749222|NCT04873661|BEHAVIORAL|Cognitive trance group intervention|See arm description
40749223|NCT04873661|BEHAVIORAL|Meditation group intervention|See arm description
40749224|NCT01475500|PROCEDURE|Sputum sample|This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
40749225|NCT01475500|PROCEDURE|Pulmonary function tests|A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.
40749226|NCT01475500|RADIATION|Computerized tomography (CT) scan of the chest|A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.
40749227|NCT01475500|OTHER|Buccal epithelium collection|Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.
41095545|NCT00967369|DRUG|Bortezomib|Given IV
41095546|NCT00967369|DRUG|Carboplatin|Given IV
40749228|NCT01475500|PROCEDURE|Nasal brushings|A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
40749229|NCT01475500|PROCEDURE|Bronchoscopy|A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
40749230|NCT01475500|PROCEDURE|Bronchoalveolar lavage|During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
41270347|NCT06358495|OTHER|Active Control|Participants are encouraged to continue any care they are already receiving and will be placed on a wait-list for digital CBT-I after their final assessment. All activities participants try for improving their own sleep problems between assessments will be recorded and coded for.
41270348|NCT03047525|BIOLOGICAL|Cytokine-induced Killer Cells|Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
40749231|NCT01475500|PROCEDURE|Blood sample collection|A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
40749232|NCT01475500|PROCEDURE|Urine sample|Urine will be collected for routine urine tests at baseline and yearly to year 5.
40749233|NCT01475500|PROCEDURE|Questionnaire-data collection|A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.
40749234|NCT05740384|DEVICE|Sonotubometry Assessment|"The exact order of the measurements will be randomised:~* Recording type 1: No sound applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Recording type 2: White noise applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Ask for subjective feedback (did you hear a change in the sound in your ear on swallowing?) after each recording~* This is repeated using the contralateral ear and nostril. After successful recording, the microphone will be removed.~For comparison, tubomanometry measurements will be performed on each ear. Tubomanometry is an alternative method to assess the middle ear and Eustachian tube. Afterwards, the participant's involvement in the study will be complete. The entire involvement will take about 50 minutes."
40749235|NCT02974426|RADIATION|PORT-first|PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
40749236|NCT02974426|RADIATION|PORT-last|PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
40749237|NCT02974426|DRUG|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
40749238|NCT02196909|OTHER|motor function and strength assessment|
40749239|NCT02196909|OTHER|NMR assessment|
40749240|NCT02196909|OTHER|24h urine and serum collection|
40749241|NCT02487355|DRUG|Dexmedetomidine|Dexmedetomidine 1 μg/ kg
40749242|NCT02487355|DRUG|Magnesium Sulphate|Magnesium Sulphate 50 mg
40749243|NCT02487355|DRUG|Bupivacaine|1ml/kg of 0.25%of bupivacaine
40749244|NCT02487355|DRUG|Dexmedetomidine + Magnesium Sulphate + Bupivacaine|Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine
40749245|NCT02444377|BEHAVIORAL|Interval training|
41270349|NCT00212407|BIOLOGICAL|Umbilical Cord Blood Transplantation|
41270350|NCT03099681|OTHER|Treatment for Epitheloid Sarcoma|Treatment Epitheloid Sarcoma according the disease guideline
41270351|NCT04343651|DRUG|Placebo|Placebo
41270352|NCT04343651|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
40749246|NCT01321645|DRUG|Azadirachta Indica|To start with subjects will be prescribed Azadirachta Indica in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
40749247|NCT03055195|DRUG|Mepolizumab 100 mg|Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
40749248|NCT03055195|DRUG|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
40749249|NCT05012930|OTHER|Baby Foods - Meat|Commercially available baby foods
40749250|NCT05012930|OTHER|Baby Foods - Dairy|Commercially available baby foods
40749251|NCT05012930|OTHER|Baby Foods - Plant|Commercially available baby foods
40749252|NCT05012930|OTHER|Foods from the home|Caregiver will provide participant with usual foods from the home
40749253|NCT03539198|RADIATION|Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)|Patients will be receiving proton SBRT
40749254|NCT03539198|RADIATION|Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients will receive proton SBRT.
40749255|NCT03539198|DRUG|Nivolumab 3 mg/kg IV q2 weeks|Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.
40749256|NCT03539198|RADIATION|Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.
40749257|NCT03778333|BIOLOGICAL|Autologous mesenchymal stem cells|IV therapy with autologous bone-marrow derived mesenchymal stem cells
40749258|NCT02713841|DRUG|inhaled human insulin (INH)|recombinant human insulin administered with Adagio-01 inhaler device
40749259|NCT02713841|DRUG|sc insulin lispro (LIS)|insulin lispro administered subcutaneously
40749260|NCT03020888|DEVICE|Magseed and Sentimag|Magseed marker and Sentimag probe for lesion localization
40749261|NCT04077606|OTHER|ceramo-metallic crown prepartion|tooth will be prepared to receive ceramo-metallic crowns
40749262|NCT04077606|OTHER|full anatomical monolithic zirconia crown|tooth will be prepared to receive monolithic zirconia crowns
40749263|NCT03709589|OTHER|Modified Early Warning Score|Modified Early Warning Score
40749264|NCT04588363|OTHER|SARS-CoV-2 and/or MIS-C Exposure|This is an observational cohort study.
40749265|NCT00856102|BEHAVIORAL|Exercise|Home-base walking program
40749266|NCT00856102|BEHAVIORAL|Control|Usual care
40749267|NCT05654207|BEHAVIORAL|WeCare|WeCare combines two evidence-based strategies -- universal screening using the Computerized Adaptive Screen for Suicidal Youth and an adapted version of the SAFETY-ACUTE, which incorporates PI Lindsey's extensive work with Black youth, their families, and community stakeholders to develop culturally tailored strategies for addressing treatment barriers.
40749268|NCT02149160|DRUG|FRM-0334|
40749269|NCT02149160|DRUG|Placebo|
40749270|NCT03925714|OTHER|life style|life sryle control only
40749271|NCT03925714|DRUG|Metformin|metformin twice daily
40749272|NCT03925714|DRUG|Nigetella salivata|NS twice daily
40749273|NCT04743596|DEVICE|High-Definition Videobronchoscopy|Endoscopic inspection and endobronchial biopsy with standard forceps during high-definition videobronchoscopy.
40922377|NCT04039100|OTHER|Family Caregiver Ambassador Support|Family Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks
40922378|NCT02721394|BEHAVIORAL|Functional Communication Training|Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
40922379|NCT02585661|DIETARY_SUPPLEMENT|Dairy product fortified with enriched Fe-54 salt (1)|2.5mg of Fe per 100g of product
40749282|NCT00894920|DIETARY_SUPPLEMENT|biotin|capsule approximately 30 mcg daily 21 days
40749283|NCT00894920|DIETARY_SUPPLEMENT|biotin|capsule 300 mcg daily 21 days
40749284|NCT05084404|DRUG|Experimental: 4 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
40749285|NCT05084404|DRUG|Experimental: 8 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
40749286|NCT02623270|DEVICE|Noninvasive Ventilator, V60 (Philips)|The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
40749287|NCT02623270|DEVICE|Manual Bag|Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
40749288|NCT06388213|DEVICE|Gastric Ultrasonography|Evaluation of cross sectional area of the antrum by gastric ultrasonography in healthy patients and in patient treated by GLP-1 receptor agonists after a fasting period (6 hours for solid and 2 hours for clear liquids). For the GLP-1 receptor agonists group the gastric ultrasonochography will be repeated each 2 days during 7 days. In the non GLP-1 receptors agonists group the evaluation will be executed one time.
40749289|NCT01776203|DRUG|Medroxyprogesterone 17-Acetate|MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
40749290|NCT01208051|DRUG|Cediranib|Given PO
40749291|NCT01208051|DRUG|Cediranib Maleate|Given PO
40749292|NCT01208051|OTHER|Laboratory Biomarker Analysis|Correlative studies
40749293|NCT01208051|DRUG|Lenalidomide|Given PO
40749294|NCT00220714|DRUG|atypical antipsychotics:oral vs. long-acting route|
40749295|NCT00220714|BEHAVIORAL|Family Psychoeducation|
40749296|NCT03079583|DIETARY_SUPPLEMENT|Intervention-group|Biofortified Rice is grown by foliar Zn application
40749297|NCT03079583|DIETARY_SUPPLEMENT|Control-group|Control Rice with normal zinc levels
40749298|NCT03020082|DRUG|Danoprevir|Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
40749299|NCT03020082|DRUG|Ritonavir|Ritonavir administered orally 100mg BID for 12 weeks;
40749300|NCT03020082|DRUG|peginterferon alfa-2a|PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
41095547|NCT00967369|DRUG|Etoposide|Given IV
41270353|NCT05148871|BIOLOGICAL|Spikogen/Covax-19|Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant
40749301|NCT03020082|DRUG|RBV|RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
40749302|NCT04243837|DRUG|LYT-100 BCRL|BCRL patients will receive LYT-100 BID for 6 months
40749303|NCT04243837|DRUG|Placebo BCRL|BCRL patients will receive Placebo BID for 6 months
40749304|NCT00003969|DRUG|tanespimycin|
40749305|NCT01628809|BEHAVIORAL|Mindfulness-Based Stress Reduction|three-day mindfulness-based meditation retreat program
40749306|NCT06459973|DRUG|intravenous (IV) infusion|YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle
40749307|NCT01708525|DEVICE|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
40749308|NCT01708525|OTHER|Heavy Water|A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
40749309|NCT04279678|PROCEDURE|Mitral valve repair|surgical repair of moderate ischemic mitral regurgitation using pericardial patch or rigid semi-annular ring
40749310|NCT00508300|PROCEDURE|Epidural analgesia|Thoracic epidural analgesia until day 2
40749311|NCT00508300|PROCEDURE|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
40749312|NCT03880409|DRUG|2% lidocaine with 1:000,000 epinephrine|2% lidocaine with 1:000,000 epinephrine is dental local anesthesia
40749313|NCT03880409|DRUG|4% articaine with 1:000,000 epinephrine|4% articaine with 1:000,000 epinephrine is dental local anesthesia
40749314|NCT01925820|DRUG|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
40749315|NCT06417411|DRUG|Aspirin 100mg|Daily use of low dose aspirin.
40749316|NCT02440399|DRUG|Tramadol hydrochloride|Please see arm description
40749317|NCT02440399|DRUG|Morphine|Please see arm description
40749318|NCT02440399|DRUG|Paracetamol|
40749319|NCT02440399|DRUG|Diclofenac|
40749320|NCT02440399|DRUG|TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)|
40922380|NCT02585661|DIETARY_SUPPLEMENT|Dairy product fortified with enriched Fe-57 salt (2)|2.5mg of Fe per 100g of product
40922381|NCT05933109|BEHAVIORAL|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound S1 is associated with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, the investigators want to accelerate the remission of traumatic nightmares and PTSD symptomatology.
41095548|NCT00967369|DRUG|Ifosfamide|Given IV
41095549|NCT04968847|DEVICE|FemaSeed Localized Directional Insemination|Subjects undergoing FemaSeed Artificial Insemination
41270354|NCT00003200|DRUG|Taxotere|
41270355|NCT00003200|RADIATION|Radiation therapy|
41270356|NCT00004396|DRUG|heme arginate|
41270357|NCT00004396|DRUG|tin mesoporphyrin|
41270358|NCT01124825|DEVICE|IGEL|iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation
40749321|NCT05078970|BEHAVIORAL|Safety Planning Intervention+ (SPI+)|SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
41095550|NCT05182437|RADIATION|LINAC-based Stereotactic Radiotherapy|Target definition: the target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations (e.g. 3, 7 Tesla MRI or Stereo-EEG) of the presurgical path. Planning target volume (PTV) = GTV. A single fraction SRT with a prescribed isotoxic dose of 24 Gy to the 100% surrounding isodose. Dose is depending on the proximity and maximum tolerable dose to the radiosensitive organs at risk and EZ volume resulting in a V12\<= 10 cc reducing the risk on radionecrosis.
41095551|NCT06087068|DRUG|Thyroxine|The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
41095552|NCT05879718|DRUG|Placebo|Placebo (intravenous infusion)
41095553|NCT05879718|DRUG|PF-06823859|PF-06823859 (intravenous infusion)
41095554|NCT05416281|OTHER|Robotic Vacuum|Participants will be provided with a Roomba iRobot vacuum and will be asked to use the vacuum in their home for 8 weeks. Exposure to environmental exposures will be evaluated before and after the intervention using silicone wristbands.
41095555|NCT03813056|DRUG|Glanatec|Rho kinase Inhibitor
41095556|NCT03813056|DRUG|Optive, Ophthalmic Solution|artificial tears (placebo)
41095557|NCT03813056|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
41095558|NCT04355637|DRUG|Inhaled budesonide|adding budesonide to standard of care for pneumonia in COVID19 positive patients
41095559|NCT02161510|DRUG|MK-2248|MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
41095560|NCT04146818|BEHAVIORAL|Adapted Tango Dancing|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months) consisting in music therapy, engagement in social activities, cognitive training and psycho-education.
41095561|NCT04146818|BEHAVIORAL|Control|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
41270359|NCT01124825|DEVICE|King airway|KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
41270360|NCT03821584|OTHER|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest
41270361|NCT04513691|DIAGNOSTIC_TEST|EOS Calculator|Neonatal Early-Onset Sepsis Risk Calculator which is a tool that determines the risk of EOS for a particular newborn by looking at maternal risk factors and the newborn's clinical picture as opposed to just laboratory tests alone
41270362|NCT06484335|BIOLOGICAL|VRC07-523LS|VRC07-523LS (VRC-HIVMAB075-00-AB) is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site
41270363|NCT06484335|BIOLOGICAL|PGDM1400LS|PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region.
41270364|NCT06484335|BIOLOGICAL|ChAdOx1.tHIVconsv1|ChAdOx1.tHIVconsv1 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv1.
41270365|NCT06484335|BIOLOGICAL|ChAdOx1.HIVconsv62|ChAdOx1.HIVconsv62 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv62.
41270366|NCT06484335|BIOLOGICAL|MVA.tHIVconsv4|MVA.tHIVconsv4 is a recombinant, non-replicating Modified Vaccinia Ankara (MVA) virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated tHIVconsv4.
41095562|NCT02392156|BIOLOGICAL|rFVIIIFc|As described in the treatment arm
41095563|NCT02392156|BIOLOGICAL|rFIXFc|As described in the treatment arm
41095564|NCT02392156|DRUG|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
41453215|NCT03983135|OTHER|LaparoscopicRe-sleeve gastrectomy|Adhesions will be separated with blunt and sharp dissections, then the remnant stomach will completely freed. Due to dilated antral pouch or fundus, the remnant stomach will resect as a tube stomach between the pillory and left crus with 60 mm Endo-GIA stapler accompanied by 36F bougie.
41453216|NCT03983135|OTHER|Laparoscopic Roux-en-Ygastric bypass|all adhesions will separated then after the stomach pouch will formed by the linear stapler, 100 cm of jejunum will transected from the Treitz ligament. Side-to-side gastrojejunostomy will performed for the distal jejunum with the linear stapler. The anterior face of the anastomosis will manually sutured. Proximal jejunum end hadside-to-side jejuno-jejunostomy performed 150 cm distal of the gastrojejunostomy anastomosis with linear stapler on the posterior wall and manual suturing of the anterior wall.
41453217|NCT05344118|OTHER|Survey|REDCap survey
41453218|NCT01981044|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
41453219|NCT03390257|DEVICE|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during Balloon Sinus Dilation
41453220|NCT03789487|DEVICE|Device programming of CRT pacemaker or defibrillator|Stimulation vector optimization then AV delay optimization in order to obtain the highest systolic blood pressure (SBP) by using the Finapress® NOVA noninvasive device
40749322|NCT05078970|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS)|CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
40749323|NCT05078970|BEHAVIORAL|Treatment As Usual|This assigned condition tracks the care received in typical circumstances.
40749324|NCT01291875|PROCEDURE|non-surgical periodontal treatment|Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted. After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.
40749325|NCT01291875|PROCEDURE|Supragingival biofilm control|Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
40749326|NCT03478787|DRUG|risankizumab|Subcutaneous (SC) injection
40749327|NCT03478787|DRUG|secukinumab|Subcutaneous (SC) injection
40749328|NCT04803500|DRUG|Simvastatin|single injection of simvastatin gel in the gap around immediately placed implant
40749329|NCT04803500|DRUG|Placebo|single injection of the solid lipid nanoparticle carrier in the gap around immediately placed implant
40749330|NCT01524705|DRUG|Insulin Glargine|Glargine-injectable, variable, once daily (QD), 6 months
40749331|NCT01524705|DRUG|Metformin|Metformin-oral, up to 1000mg, twice daily (BID), 6 months
40749332|NCT01524705|DRUG|Prandial insulin|Aspart or glulisine or lispro
40749333|NCT01524705|DRUG|Exenatide|Injectable, 5mcg, twice daily (BID), 6 months
40749334|NCT03383939|DRUG|Group A|one nebulization with 250mg alpha-1-antitrypsine diluted in 10ml injectable solution once a day during 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
40749335|NCT03383939|DRUG|Group B|10ml of 0.9% NaCl saline solution nebulised once daily for 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
40749336|NCT01660685|BEHAVIORAL|Tracking|Participants will record their daily weight, physical activity steps and meal replacements online
40749337|NCT01660685|BEHAVIORAL|Journaling|Participants will journal to two online writing prompts: one on positive focus and one on goal setting
40749338|NCT01660685|BEHAVIORAL|Website|Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
40749339|NCT01660685|BEHAVIORAL|Enhanced Usual Care|Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
40749340|NCT04667169|PROCEDURE|Haemorrhoidal Artery Ligation|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
40749341|NCT04667169|PROCEDURE|Laser Haemorrhoidoplasty|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
40749342|NCT04549168|DRUG|Lemborexant|Lemborexant 10 mg tablet.
40749343|NCT04549168|DRUG|Placebo|Placebo tablet matched to lemborexant 10 mg tablet.
40749344|NCT03509597|BEHAVIORAL|Aerobic Exercise|Physical exercise training consisting of aerobic exercise and strength/resistance training.
40749345|NCT03509597|BEHAVIORAL|Cognitive Training|Cognitive remediation program using REHACOP rehabilitation program.
40749346|NCT03509597|BEHAVIORAL|Treatment as usual|Standard care for schizophrenia + Leisure and free time activities.
40749347|NCT03509597|BEHAVIORAL|Occupational Activities|Engagement in activities aimed to keep patients actively involved in demanding tasks.
40749348|NCT00006215|BIOLOGICAL|filgrastim|
40749349|NCT00006215|DRUG|docetaxel|
40749350|NCT00006215|DRUG|vinorelbine tartrate|
40749351|NCT04951960|OTHER|Higher PEEP setting|PEEP levels are determined according to the higher PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
41095565|NCT02392156|DRUG|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
40922382|NCT05933109|BEHAVIORAL|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without association with the sound S1.
41095566|NCT05198453|BIOLOGICAL|vaccination|patients who received COVID-19 vaccine
41453221|NCT03008616|BIOLOGICAL|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
41453222|NCT03008616|OTHER|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
40749352|NCT04951960|OTHER|Lower PEEP setting|PEEP levels are determined according to the lower PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
40749353|NCT01678690|DRUG|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
40749354|NCT02571231|DEVICE|HFV + and - VG|High frequency ventilation with and without volume guarantuee
40749355|NCT01932580|DRUG|FLOT (5-fluorouracil, oxaliplatin, docetaxel)|Administration of FLOT chemotherapy before and after surgery
40749356|NCT02606539|PROCEDURE|Total abdominal hysterectomy and methotrexate|After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
40749357|NCT02606539|DRUG|Methotrexate plus folinic acid alone|methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
40749358|NCT00842036|BEHAVIORAL|Community Reinforcement and Family Training|Community Reinforcement and Family Training (CRAFT) is an intervention designed for the concerned significant other (CSO) of a drug or alcohol using loved one. The CRAFT intervention consists of approximately 12 sessions lasting 45-60 minutes. The goal of the CRAFT intervention is to train the CSO in new ways to interact with the person of concern (PC). There are four components that the CSO is trained on which include awareness training, community reinforcement training, treatment entry training, and CSO mood enhancement.
40749359|NCT00842036|BEHAVIORAL|Treatment Entry Training|Treatment Entry Training (TEnT) is a component of the Community Reinforcement and Family Training intervention and it is currently under investigation to determine if it is sufficient to produce the primary and most consistent outcome of CRAFT- treatment entry of the drug user. The intervention will consist of a minimum of 4 sessions and a maximum of 6 sessions that are each 45-60 minutes long. TEnT will include awareness training, safety training, and the Treatment Entry Training component of CRAFT.
40749360|NCT00842036|BEHAVIORAL|12- step Al/Nar- Anon Facilitation|The underlying philosophy of the 12- step approach for concerned significant others (CSO) is that the CSO is powerless to control the drinker/drug user and must detach, focusing instead on accepting the situation and on strengthening his or her mental health. Eight content areas are discussed with the CSO over the course of the intervention. There will be a minimum of 8 sessions and a maximum of 12 sessions that are each 45-60 minutes long.
40749361|NCT00185900|DRUG|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
40749362|NCT00185900|DRUG|Nifedipine|Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
40749363|NCT05431179|DRUG|Zilovertamab|After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
40749364|NCT05431179|DRUG|Ibrutinib|All participants will receive oral Ibrutinib (560mg) daily.
40749365|NCT05431179|DRUG|Placebo|After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
40749366|NCT05581264|BEHAVIORAL|Diabetes Self-Management Education Program|diabetes self-management education and counseling program with follow-up via phone for the intervention group for 24 weeks
40749367|NCT05812495|PROCEDURE|Esophagogastric Side to Side Anastomosis|Esophagogastric Side to Side Anastomosis
40749368|NCT05812495|PROCEDURE|Esophagogastric End to Side Anastomosis|Esophagogastric End to Side Anastomosis
40749369|NCT01734928|DRUG|Pomalidomide|Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
40749370|NCT01734928|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
40749371|NCT01734928|DRUG|Dexamethasone|Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
40749372|NCT03291015|DEVICE|radiographic|using plain x ray to determind the treatment plan
40749373|NCT03291015|DEVICE|arthroscopy|using wrist arthroscopy to determind the treatment plan
40749374|NCT04044287|DRUG|200 micrograms of misoprostol|200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
41443029|NCT06559904|OTHER|Mediterranean diet|"The 'Mediterranean Diet Education Document', prepared by the researcher, which includes general information about the characteristics of the Mediterranean diet and the portion sizes that should be followed daily and weekly, and information on how often, how much and when to consume food groups, was provided as a diet education, and information was provided on how to record three-day food consumption.~A nutrition education compatible with the Mediterranean diet, organized by the researcher according to the individual's daily needs, was provided and a sample menu was explained to the individual face to face."
40749375|NCT04044287|DRUG|Placebo Oral Tablet|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
40749376|NCT01395537|DRUG|Carboplatin AUC|Carboplatin AUC 6 IV over 30 minutes on day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
40749377|NCT01395537|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV over 3 hours day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
40749378|NCT01395537|DRUG|lapatinib|Lapatinib should be taken once daily, at the same time daily, on an empty stomach, either 1 hour before, or 1 hour after meals.
40749379|NCT05172310|DRUG|68Ga-FAPI-46|"* \[68Ga\] Ga-FAPI-46 Solution for Injection is manufactured at the Karolinska University Hospital Radiopharmacy facilities, for imaging studies with Positron Emission Tomography (PET).~* It is a radiolabelled Fibroblast Activation Protein Inhibitor (FAPI) used for PET of a number of different cancer entities.~* Depending on the labelling yield 50 - 370 megabecquerel (MBq) of \[68Ga\] Ga-FAPI-46 Solution for Injection will be administered intravenously 60 minutes prior to whole-body PET image acquisition."
40749380|NCT05172310|DEVICE|PET/CT|"* Combined PET and computed tomography (CT) imaging with 68Ga-FAPI-46 will be performed using the same protocol on a Biograph 6 PET/CT scanner (Siemens, Erlangen, Germany) and General Electrics (GE) Discovery 710, Milwaukee, Wisconsin, USA at the Department of Nuclear Medicine, Karolinska Huddinge within 2 weeks before surgery.~* PET/CT imaging will be performed in dynamic mode at one bed position centered over the primary tumor for 45 minutes.~* At 60 minutes post injection, a whole-body PET will be acquired."
40749381|NCT01791400|DRUG|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
40749382|NCT01791400|DRUG|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
40749383|NCT02112227|OTHER|PACT-HF Model|PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
40749384|NCT02580552|DRUG|Cobomarsen|
40749385|NCT05983406|DEVICE|Doppler investigation|Doppler investigation
40749386|NCT05649774|PROCEDURE|Therapy|Only Myofascial Release will be provided
40749387|NCT05649774|PROCEDURE|Taping technique|Only Kinesiotaping will be provided
40749388|NCT05649774|PROCEDURE|Therapy with taping|Myofascial release will be provided followed by Kinesiotaping
40749389|NCT05649774|PROCEDURE|SHAM|Placebo Treatment will be given
40749390|NCT04127929|OTHER|Restoration of cavities using glass carbomer material (GCP Dental)|Detection of caries then restoration of cavities
40749391|NCT04127929|OTHER|Restoration of cavities using nanocomposite resin (Tokuyama Estelite Posterior)|Detection of caries then restoration of cavities
40749392|NCT00195052|DIAGNOSTIC_TEST|Intrinsic signal imaging of human cortex|Light is shined on the brain at 540 nm and 610 nm and images are acquired at 10 frames per second.
40749393|NCT01829165|DEVICE|rTMS Treatment|MRI-compatible TMS stimulator
40749394|NCT01829165|DEVICE|Sham rTMS Treatment|
40749395|NCT02729168|BIOLOGICAL|Human rabies vaccine|
40749396|NCT05696158|DEVICE|MHNA-003|MHNA-003 is a self-guided digital program for people living with tinnitus
40749397|NCT05742750|DRUG|Camrelizumab and Apatinib Plus GP|"Patients received apatinib orally at 250 mg once a day irrespective of the patient weight.~Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks.~GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason."
40749398|NCT01052142|BIOLOGICAL|Lipovaxin-MM|Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
40749399|NCT02158507|DRUG|Combination of Veliparib + Lapatinib|Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
41443030|NCT03664063|DRUG|Azithromycin|Treatment with Azithromycin single dose - weight based dosing max 2gm
40749400|NCT02194088|DRUG|Diclofenac and Atropine combination drug|Diclofenac will be associated with a small dose of atropine 1.2mg
40749401|NCT02194088|DRUG|Placebo|For each capsule of active medication, a capsule of placebo will be provided, identical looking.
40749402|NCT05476718|OTHER|Kinesio taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th- 5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
40922383|NCT06476054|PROCEDURE|Optimal timing for laparoscopic cholecystectomy|To compare early and late cholecystectomy after cholecystostomy.
40749403|NCT05476718|OTHER|placebo taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th-5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
40749404|NCT01720602|DRUG|vorinostat|Given PO
40749405|NCT01720602|DRUG|anastrozole|Given PO
40749406|NCT01720602|DRUG|letrozole|Given PO
40749407|NCT01720602|DRUG|exemestane|Given PO
40749408|NCT01720602|PROCEDURE|positron emission tomography|Correlative studies
40749409|NCT01720602|RADIATION|F-18 16 alpha-fluoroestradiol|Correlative studies
40749410|NCT01720602|RADIATION|fludeoxyglucose F 18|Correlative studies
40749411|NCT01720602|OTHER|laboratory biomarker analysis|Correlative studies
40749412|NCT04259242|PROCEDURE|SRP|scaling and root planing with ultrasonic scaler and manual instruments
40749413|NCT01370642|DRUG|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
40749414|NCT01370642|DRUG|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
40749415|NCT01370642|BIOLOGICAL|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
40749416|NCT01370642|DRUG|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
40749417|NCT04184908|DRUG|gel xerostomia|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
40749418|NCT04184908|OTHER|gel placebo|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
40749419|NCT03309475|BEHAVIORAL|SocialMIND|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
40749420|NCT03309475|BEHAVIORAL|Psychoeducational multicomponent intervention|The psychoeducational multicomponent intervention addresses and discuss several aspects of great importance for persons who suffer a first episode of psychosis, such as biased perception and thinking, delusions-related anxiety or the nature of hallucinations. Its aim is to encourage patients to reflect upon their experiences from a critic perspective.
40749421|NCT03309475|BEHAVIORAL|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
40749422|NCT03309475|DRUG|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
40749423|NCT06494423|BEHAVIORAL|Work Support (WorkS)|The WorkS intervention entails two structured visits with a research team member initiated 6-months post-HSCT, which is the earliest point at which most HSCT survivors can safely consider returning to work. The sessions are focused on 1) identifying challenges of navigating work and illness; 2) linking survivors with psychological, rehabilitative, governmental, and community resources that can promote recovery and well-being; and 3) communicating with employers regarding the necessary work modifications to achieve mutual goals.
40749424|NCT00104715|DRUG|antiandrogen therapy|
40749425|NCT00104715|DRUG|docetaxel|
40749426|NCT00104715|DRUG|goserelin acetate|
40749427|NCT00104715|PROCEDURE|orchiectomy|
40749428|NCT03967314|OTHER|TLIP block group (group T)|In group T, the block was performed bilaterally under aseptic conditions using the US device with a high-frequency 12-MHz linear US probe. The probe was covered with a sterile sheath and placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe was moved forward in a lateral direction to visualize the longissimus and iliocostal muscles. Using the in-plane technique, a 22-G, 50-mm block needle was inserted between the muscles in a medial-to-lateral direction in the interfascial plane. Once the needle tip was placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 ml of saline was injected to confirm the accuracy of the injection site. A dose of 0.25% bupivacaine (20 ml) was then injected in each side (total 40 ml).
40749429|NCT03967314|OTHER|Wound infiltration group (group W)|In group W, a dose of 0.5% bupivacaine (20 ml) was injected for wound infiltration into the surgery site.
41270367|NCT06484335|BIOLOGICAL|A244d11 gp120|A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF_01AE A244 derived from the CM244 CRF_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine.
40749430|NCT02182700|DRUG|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
40749431|NCT06109753|PROCEDURE|Robotically Assisted Laparoscopic Surgery|robotically assisted surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
40749432|NCT06109753|PROCEDURE|Conventional Laparoscopic Surgery|conventional surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
40749433|NCT02198131|PROCEDURE|laser therapy|Undergo pulsed dye laser
40749434|NCT02198131|OTHER|questionnaire administration|Ancillary studies
40749435|NCT02296801|DRUG|Letrozole|
40749436|NCT02296801|DRUG|palbociclib|
40749437|NCT01283386|DRUG|Chlorambucil|10 mg/m\^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
40749438|NCT01283386|DRUG|Cyclophosphamide|150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
41270368|NCT06484335|BIOLOGICAL|ALFQ|ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic
41270369|NCT06484335|OTHER|Placebo|Normal saline (0.9% sodium chloride for injection) will be used as a placebo.
41443031|NCT03664063|DRUG|Albendazole|"Single dose of Albendazole weight based dosing~- 400mg"
40749439|NCT01283386|DRUG|Fludarabine|20 mg/m\^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
40749440|NCT01283386|DRUG|Rituximab|375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
40749441|NCT06468475|DRUG|Magnesium Sulphate infusion|Magnesium sulphate 24 hours apart by intravenous infusion at 250 mg/kg/dose (0.5 mL/kg/dose of injection magnesium sulphate 50% w/v diluted in 5 mL/kg of 5% glucose) over a duration of half an hour by an infusion pump
40749442|NCT06100445|BEHAVIORAL|Semi structured interviews|Gaining qualitative data
40749443|NCT00295776|DRUG|Lamictal in the treatment of Post-Herpetic Neuralgia|
40749444|NCT00045955|DRUG|Fexofenadine, Comparator = Montelukast|
40749445|NCT03889795|DRUG|Metformin|Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
40749446|NCT03889795|DRUG|Simvastatin|Simvastatin oral pill will be taken daily in the evening.
40749447|NCT03889795|DRUG|Digoxin|Digoxin oral pill will be taken once daily.
40749448|NCT02517138|OTHER|Parabolic flight|
40749449|NCT02517138|OTHER|Measurements of eye movements and perception|
40749450|NCT03604627|OTHER|Coronal calcium score measurement|"A medical interview with clinical examination by a cardiologist for screening cardiovascular risk factors, including smoking, and looking for symptoms of heart disease as part of routine care.~In accordance with routine care, a fasting and fasting blood test will be performed performed on exam day at Bichat Hospital or at another time, close to the patient's home according to his availability. The biological blood test will include the measurement of plasma triglyceride concentrations, total cholesterol and its HDL and LDL fractions, blood glucose, glycated hemoglobin and serum creatinine with estimated glomerular filtration rate according to the CKD-EPI formula. Sample urinalysis will include measurement of creatinine, proteinuria, and microalbuminuria.~An electrocardiogram (ECG) rest, a cardiac ultrasound, a test and respiratory function tests (EFR) will be performed as part of routine care. Coronal calcium score measurement will be performed as part of the research."
40749451|NCT00176254|RADIATION|Radiotherapy|80 centigray (cGy) on Day 1 \& 2 and 22 \& 23 of chemotherapy
40749452|NCT00176254|DRUG|Paclitaxel|225 mg/m2 intravenously over three hours on Days 1 and 22
40749453|NCT00176254|DRUG|Carboplatin|Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
40749454|NCT01834651|DRUG|Cabozantinib|Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
40749455|NCT03886324|COMBINATION_PRODUCT|GIE Medical Drug Coated Balloon|Stricture patients treated by DCB
40749456|NCT03099356|DRUG|Cyclophosphamide|Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
40749457|NCT03099356|DRUG|Sirolimus|Sirolimus 4 mg, PO, days 1-28
40749458|NCT04268212|DIETARY_SUPPLEMENT|Bitter melon juice (100 ml)|Fresh bitter melon fruits were purchased from certified local groceries. The seeds of bitter melon were removed, and the juice was obtained from the raw fruit using a blender. Every 140 g of bitter melon fruit produced approximately 100 ml bitter melon juice.
40749459|NCT04268212|BEHAVIORAL|Exercise|The walking exercise was started 15 minutes after the glucose load. Walking speed was determined to elicit 65% of the maximum heart rate (HRmax) during exercise for each participant. HRmax was estimated using the America College of Cardiology prediction model, HRmax=208 - 0.7 × age. All participants wore a heart rate monitor (Polar, Vantage, XL) around the chest to assess exercise intensity. A rate of perceived exertion was assessed every 2 minutes based on the Borg's scale.
40749460|NCT05024786|OTHER|continuous quality improvements|We implement the continuous quality improvement strategy in CQI group, and observe the effect of the strategy on the mortality of patients supported with ECMO .
41443032|NCT03664063|DRUG|Ivermectin|Ivermectin weight based dosing - max 21mg
40749461|NCT00739570|DEVICE|AAI signature IV AMCT|Chiropractic adjustments of the lumbar spine following the activator basic scan protocol
40749462|NCT01183286|BEHAVIORAL|CFFONE|A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.
40749463|NCT01183286|BEHAVIORAL|CF website|A CF-related educational website which has some areas of CF information and services relevant to adolescents.
40749464|NCT03000751|OTHER|Simple Audit Report|The simple audit provides comparison and feedback on radiation doses.
40749465|NCT03000751|OTHER|Multi-Component Intervention|The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
40749466|NCT03000751|OTHER|In-Person Meeting|Collaborator meeting with an emphasis on quality improvement.
40749467|NCT02816970|DRUG|Vildagliptin|1 tablet contains 50 mg vildagliptin
40749468|NCT02816970|DRUG|Vildagliptin|1 tablet contains 50 mg vildagliptin
40749469|NCT05130983|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
40749470|NCT03156621|DRUG|Alirocumab|Alirocumab SC Q2W
40749471|NCT03156621|DRUG|Placebo|Matching placebo SC Q2W
40749472|NCT01515527|DRUG|Cladribine|"Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
40749473|NCT01515527|DRUG|Cytarabine|"Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
40749474|NCT01515527|DRUG|Decitabine|Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
40749475|NCT04633720|OTHER|Changes in positive end-expiratory pressure and tidal volume|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
40749476|NCT02573467|DRUG|Bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
40749477|NCT02573467|DRUG|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
40749478|NCT04331379|DEVICE|Nasal Elevator|A device aiming to elevate the clefted nostril extraorally and fixed on the forehead.
40749479|NCT04331379|DEVICE|Taping Alone|Horizontal tape alone.
40749480|NCT03597555|DRUG|Sodium Oxybate Oral Solution 500 MG/ML|"First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
40749481|NCT03597555|DRUG|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
40749482|NCT00270569|DRUG|PhyxolTM, Cisplatin|
40749483|NCT05396781|DRUG|Proflavine|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
40749484|NCT05396781|DEVICE|Mobile, Augmented High Resolution Microendoscope|The marHRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
40749485|NCT01505335|DEVICE|US depth measurements|Measurement of the distance between the apex of the drilled implant site and the IAC
40749486|NCT04867590|DEVICE|Endorotor|"The treatment itself is preceded by a sub-mucosa saline and adrenalin solution injection administered by an endoscopic sclerotherapy needle lifting the submucosa and thus reducing the risk of perforation and hemorrhage.~The interventional tool is then applied tangentially to be brought into contact with the lifted mucosa, visual monitored by endoscope. The aspiration and sectioning system is activated by use of a pedal and a generator specially made for the system, used in every procedure. The entire surface area of the targeted mucosa must be covered by the probe. The residual tissue is then removed via the aspiration system and caught by a filter. The specimens are then easily retrievable at the end of the procedure and can be stored in formalin fixing solution for histological analysis."
40749487|NCT04867590|DEVICE|Radiofrequency|"Endoscopic treatment using the HALO® 360 or 90 system is a thermal method for destroying the superficial mucosa. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.~For circumferential BEs, a single-use 360 Express® probe is used to make it possible to size the diameter of the esophagus and the treatment used. The length of the treatment area is 5 cm and several points of impact can be achieved by overlapping the catheter at two consecutive heights, with the zone spanned measuring one centimeter, in order to cover the entire pathological area requiring treatment.~For non-circumferential lesions a palette applicator is used in a variety of sizes, and in this context no sizing of the esophagus is required."
40749488|NCT02767245|DRUG|Thiamine|Thiamine IV 100 mg/day
40922384|NCT02192424|DRUG|Metformin alone|
40922385|NCT02192424|DRUG|Metformin + Intermittent Insulin Therapy|
40749489|NCT05439837|PROCEDURE|Infraclavicular and subomohoid block|Its blockade of subscapular nerve in the subscapular fossa and axillary nerve as it curves around humeral And blocking of brachial plexuses cord and supra scapular nerve And blocking of the brachial plexuses cord and supra scapular nerve
40749490|NCT05439837|PROCEDURE|Paracoracoid subscapularis plane block|Blocking of suprascapular nerve in supra scapular fossa and axillary nerve as it curves the humeral head
40749491|NCT01656746|PROCEDURE|therapeutic laparoscopic surgery|Undergo single incision laparoscopic surgery
40749492|NCT05582603|BEHAVIORAL|CCT Long COVID|A 15-day training protocol in which every 48 hours participants' complete a series of different cognitive tasks in the form of games selected among a pool of 12 games from CogniFit (CogniFit Inc., San Francisco, USA) whose difficulty level is tailored to each individual by the a patented Individualized Training System™ (ITS) software that automatically chooses the activities and difficulty levels for each person in every session.
41095567|NCT05154916|OTHER|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
40749494|NCT01429623|DRUG|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
40749495|NCT01429623|DRUG|Placebo|Placebo comparator
40749496|NCT00484900|DRUG|Co-Arinate FDC|
40749497|NCT00484900|DRUG|Coartem|
40749498|NCT02427217|BIOLOGICAL|FCH|FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
40749499|NCT03278145|GENETIC|Genetic analyses|Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
40749500|NCT01496703|OTHER|no intervention, this is an observational retrospective trial|no intervention, this is an observational retrospective trial
40749501|NCT06469853|DRUG|MBF-015 16 mg oral capsules|MBF-015 oral capsules HDAC inhibitor
40749502|NCT06093503|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
40749503|NCT06093503|DRUG|Osimertinib|Oral: Tablet
40749504|NCT06093503|DRUG|Cisplatin|IV Infusion
40749505|NCT06093503|DRUG|Carboplatin|IV Infusion
40749506|NCT06093503|DRUG|Pemetrexed|IV Infusion
40749507|NCT00371631|BIOLOGICAL|Insertion of urinary catheters coated with E. coli 83972|All patients in this pilot study were in the treatment arm, which consisted of receiving a urinary catheter that had been pre-coated with a biofilm of E. coli.
40749508|NCT05485350|DRUG|Anlotinib Hydrochloride|12 mg/d, d1-14, q3w
40749509|NCT05485350|DRUG|penpulimab|200mg, ivgtt, d1, q3w
40749510|NCT05485350|RADIATION|SBRT|55-180Gy
41443033|NCT03664063|DRUG|Diethylcarbamazine|Diethylcarbamazine weight based dosing - max 500mg
40749511|NCT00003151|DIETARY_SUPPLEMENT|bismuth subcitrate|
40749512|NCT00003151|DRUG|amoxicillin|
40749513|NCT00003151|DRUG|clarithromycin|
40749514|NCT00003151|DRUG|metronidazole hydrochloride|
40749515|NCT00003151|DRUG|omeprazole|
40749516|NCT00003151|DRUG|tetracycline hydrochloride|
40749517|NCT01306994|OTHER|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
41453223|NCT05834751|DRUG|PEG-rhG-CSF|48-72 hours after chemotherapy,9 mg of PEG-rhG-CSF was injected subcutaneously for mobilization
40749518|NCT01306994|PROCEDURE|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
40749519|NCT01306994|OTHER|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
40749520|NCT01306994|OTHER|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
40749521|NCT01306994|OTHER|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
40749522|NCT01306994|OTHER|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
40749523|NCT01306994|OTHER|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
40749524|NCT05708664|PROCEDURE|precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction|Local anesthesia was induced by using 1% lidocaine before wire location. The wire (localization set, PAJUNK) was placed in the superior, inferior, lateral and interior edge of the tumor through a 20-gauge needle using US guidance one day before BCS, respectively. Then, the patient underwent an immediate supine contrast enhanced CT (Philips Brilliance iCT) scan of the breast. The radiologist performed 3D reconstruction of CT images prior to surgery. Finally, the surgical procedures were performed by experienced breast surgeons combing 3D reconstruction of CT images and wire localizations one day after the localization.
40749525|NCT02857959|DRUG|Benzathine Penicillin G|
41453224|NCT05834751|DRUG|RhG-CSF|After clinical evaluation, rhG-CSF was given 10μ g/kg/d for mobilization until the stem cell collection was completed.
40749526|NCT03123107|DRUG|Ascorbic Acid|Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
40749527|NCT02521194|BEHAVIORAL|Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
40749528|NCT05907499|DRUG|Decitabine|Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
40749529|NCT05907499|DRUG|Granulocyte Colony-Stimulating Factor|5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
40749530|NCT05907499|DRUG|Thrombopoietin Receptor Agonist|Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
40749531|NCT05907499|DRUG|Recombinant human erythropoietin|10000 U/day when hemoglobin ≤ 85 g/L
40749532|NCT00311805|BIOLOGICAL|Autologous Stem Cells (CD34+)|Intramuscular Injections
40749533|NCT04902144|OTHER|Electronic Health Record Review|Medical data collected
40749534|NCT04902144|OTHER|Questionnaire Administration|Complete questionnaires
40749535|NCT04902144|BEHAVIORAL|Behavioral Intervention|Receive coaching
40749536|NCT03666793|OTHER|global care|Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
40749537|NCT03830411|DRUG|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
40749538|NCT03830411|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
40749539|NCT03830411|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
40749540|NCT04375592|DIETARY_SUPPLEMENT|Phenylalanine-free protein substitute in tablet form (XPhe minis)|Intervention is a Phenylalanine-free protein substitute in tablet form. Subjects who currently take a concentrated second stage phenylalanine-free protein substitute will be recruited. Subjects will take the study product for 7 days and daily questionnaires will be completed. Subjects will replace some or all of their usual protein substitute with the new product. The amount of study product prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Daily acceptability and tolerance questionnaires will record information on ease of preparation and administration; how it is taken; and any problems or gastrointestinal effects. Additional questions at the beginning and end of the study will record information on taste, appearance, smell, presentation and packaging of the product. Routine weekly finger prick blood spots will be collected and analysed for phenylalanine and tyrosine as usual.
40749541|NCT01970358|BIOLOGICAL|Poly-ICLC|
40749542|NCT01970358|BIOLOGICAL|Peptides|
40749543|NCT03280680|OTHER|Female+male group sessions|Female and male group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
40749544|NCT03280680|OTHER|Female group sessions|Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
40749545|NCT03280680|OTHER|No group sessions|Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
40749546|NCT02046187|DIETARY_SUPPLEMENT|Ketogenic Diet|Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.
40749547|NCT02046187|RADIATION|Radiation therapy|Patients receive standard dose (60Gy/30 fractions) external beam radiation
40749548|NCT02046187|DRUG|Temozolomide|patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
40749549|NCT01381588|OTHER|Fracture evaluation|DEXA(Dual-energy X-ray absorptiometry), X-ray
40749550|NCT00753142|DRUG|Intralipid 20%|Participants receive a 48-hour infusion with Intralipid at 40 milliliters per hour (mL/hr).
40749551|NCT00753142|DRUG|Glucose infusion|Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m\^2/min for 20 hours.
41095568|NCT05681520|BEHAVIORAL|PEEPS|Working with a peer specialist for six 30-minute sessions to enhance engagement in pain management approaches/treatments
41095569|NCT02928939|OTHER|drug-drug or drug-disease interaction|
41453225|NCT02753985|OTHER|Survey|
40749552|NCT02747225|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue.
40749553|NCT00834587|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose non-fasting
40749554|NCT00834587|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose non-fasting
40749555|NCT00184509|BEHAVIORAL|integrated psychosocial treatment (behavior)|
40749556|NCT05777278|DRUG|Savolitinib|Savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID)
40749557|NCT05777278|DRUG|Docetaxel|Docetaxel (60 mg/m2, ivgtt, q3w)
40749558|NCT01506375|BIOLOGICAL|gpASIT+TM|1 subcutaneous injection every 7 days during 29 days
40749559|NCT01506375|BIOLOGICAL|gpASIT+TM + adjuvant|1 subcutaneous injection every 7 days during 29 days
40749560|NCT05268237|DRUG|Liraglutide|Sublingual or subcutaneous liraglutide
40749561|NCT05268237|DRUG|Placebo|Sublingual placebo
40749562|NCT06535737|DRUG|Cabozantinib|Cabozantinib (Cabometyx) 60, 40 and 20 mg
40749563|NCT05756387|DEVICE|Non-invasive ventilation|NIV as in standard care
40749564|NCT00689286|DEVICE|BION|"They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.~In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises."
40749565|NCT05257161|DEVICE|Emboshield NAV6™|Embolic Protection System for Carotid Artery Revascularization ( distal - filter) + stent CGuardTM™
40749566|NCT05257161|DEVICE|Mo.Ma™|Embolic Protection System for Carotid Artery Revascularization ( proximal - occlusion) + stent CGuardTM™
40749567|NCT06378866|DRUG|Abiraterone|Given abiraterone
40749568|NCT06378866|DRUG|Apalutamide|Given apalutamide
40749569|NCT06378866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40749570|NCT06378866|PROCEDURE|Bone Scan|Undergo bone scan
40749571|NCT06378866|PROCEDURE|Computed Tomography|Undergo CT
40749572|NCT06378866|DRUG|Darolutamide|Given darolutamide
40749573|NCT06378866|DRUG|Degarelix|Given degarelix
40749574|NCT06378866|DRUG|Enzalutamide|Given enzalutamide
41443034|NCT03492320|OTHER|Health Quality of Life Questionnaire Assessment|Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Self-Rated Questionnaire SF36 and Health Related Quality of Life (HRQoL) 15D questionnaire were used as outcome measurement for functionality and disability assessment.
40749575|NCT06378866|DRUG|Goserelin|Given goserelin
40749576|NCT06378866|DRUG|Histrelin|Given histrelin
40749577|NCT06378866|DRUG|Leuprolide|Given leuprolide
40749578|NCT06378866|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40749579|NCT06378866|OTHER|Patient Observation|Undergo watchful waiting
40749580|NCT06378866|PROCEDURE|Positron Emission Tomography|Undergo PET
40749581|NCT06378866|DRUG|Prednisone|Given prednisone
40749582|NCT06378866|OTHER|Questionnaire Administration|Ancillary studies
40749583|NCT06378866|DRUG|Relugolix|Given relugolix
40749584|NCT06378866|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
40749585|NCT06378866|DRUG|Triptorelin|Given triptorelin
40749586|NCT03739554|DRUG|CYC065|intravenous infusion
40749587|NCT03739554|DRUG|Venetoclax|oral capsule
40749588|NCT00004015|DRUG|sodium borocaptate|
40749589|NCT00004015|PROCEDURE|adjuvant therapy|
40749590|NCT00430859|DRUG|Alkaline Phosphatase|Intravenous over a period of 24 hours
40749591|NCT00430859|DRUG|Placebo|Saline over a period of 24h
40749592|NCT06165965|DRUG|SGLT2 inhibitor|SGLT2 dual inhibitor
40749593|NCT03428204|PROCEDURE|Balloon dilation during 180 seconds|Percutaneous angioplasty with balloon dilation during 180 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
40749594|NCT03428204|PROCEDURE|Balloon dilation during 300 seconds|Percutaneous angioplasty with balloon dilation during 300 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
40749595|NCT05474209|OTHER|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes"|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes for 12 months"
40749596|NCT04700462|BEHAVIORAL|Sm-EMA|Self-monitoring ecological momentary assessment behavior change tool to promote adherence to a desired behavior (i.e. COVID-19 preventative behaviors).
40749597|NCT01010620|BEHAVIORAL|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
40749598|NCT03830970|DIETARY_SUPPLEMENT|Canned beans of multiple varieties|Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
40749599|NCT03830970|DIETARY_SUPPLEMENT|White Rice|Minute Rice Long Grain White Rice
40749600|NCT06293859|OTHER|Probiotic oat flakes|2 x 10\^9 cfu/g Lactococcus cremoris immobilized on oat flakes
40749601|NCT06293859|OTHER|Conventional oat flakes|Commercial oat flakes
40749602|NCT05154929|BEHAVIORAL|Dietary and physical activity JITAI delivered through the myBPmyLife app|A Fitbit smartwatch and home blood pressure monitor will be mailed to participants (in both the experimental and control arms). Participants in the intervention arm then will set up and utilize the myBPmyLife app. This app includes push notifications to promote increased physical activity and improve low-sodium food choices, establish goal setting for weekly step count and low sodium food choices, and deliver feedback on achieving the goals using a dashboard visualization within the mobile application.
40749603|NCT05154929|OTHER|Control Group|Participants will receive the myBPmyLife app, a smartwatch, and blood pressure cuff. The myBPmyLife app will not be fully activated (as they are in the control arm). They will be provided with the option of downloading and installing a mHealth app that is publicly available. In this arm they will also perform the blood pressure monitoring, but do not receive the intervention components through the myBPmyLife app.
40749604|NCT02388789|OTHER|active movement|same as arm description
40749605|NCT03115658|BEHAVIORAL|Physical Activity|12 week print based intervention
40749606|NCT01270867|DEVICE|Mechanical Thrombectomy|Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
40749607|NCT00414609|DRUG|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
40749608|NCT00414609|DRUG|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
40749609|NCT02959606|DRUG|Sarpogrelate SR 300mg|
40749610|NCT02959606|DRUG|Clopidogrel|
40749611|NCT03996460|DRUG|Placebo|"Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food."
40749612|NCT03996460|DRUG|192 mg powder of K0706|Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.
40749613|NCT03996460|DRUG|384 mg powder of K0706|Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
40749614|NCT00585169|DRUG|Memantine Hydrochloride|10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
40749615|NCT00200083|DEVICE|Transcend II Model 8848|"All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up."
40749616|NCT01261377|DEVICE|Bi-level positive airway pressure (BPAP)|The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.
41270370|NCT01070420|OTHER|FFR via central venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via Rt central femoral vein.
40749617|NCT01261377|DRUG|Oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
40749618|NCT01261377|DEVICE|CPAP|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
40749619|NCT00480311|OTHER|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
40749620|NCT03189433|DRUG|Ryanodex (dantrolene sodium) for injectable suspension|Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
40749621|NCT03927755|OTHER|Education|Physicians will undergo training on how to rapidly obtain appropriate images.
40749622|NCT04634903|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
40749623|NCT04634903|BEHAVIORAL|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
40749624|NCT04634903|BEHAVIORAL|Growth Mindset SSI|Online, 30-minute self-administered program for youth
40749625|NCT01580722|PROCEDURE|early reconstruction|patients underwent \< 8 weeks reconstruction after injury
40749626|NCT01580722|PROCEDURE|delay reconstruction|patients underwent \> 8 weeks reconstruction after injury
40749627|NCT02545127|DRUG|Merotocin|Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
40749628|NCT02545127|DRUG|Placebo|Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
40749629|NCT03055221|DRUG|Intravenous Treprostinil|Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
41095570|NCT00854139|DRUG|Cyclophosphamide, anti-thymocyte globulin|"Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications"
41270371|NCT01070420|OTHER|FFR via peripheral venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via continuous peripheral vein.
41270372|NCT04325503|DRUG|carbidopa|carbidopa and carbidopa-levodopa standard treatment
41443035|NCT00296062|BIOLOGICAL|bevacizumab|Phase II: IV over 30-90 minutes on days 1 and 15 of each course.
40749630|NCT04989738|BEHAVIORAL|THRIVE intervention|Parents learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
40749631|NCT04989738|BEHAVIORAL|Active Control|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
40749632|NCT02321501|DRUG|Ceritinib|Given PO
40749633|NCT02321501|DRUG|Everolimus|Given PO
40749634|NCT02321501|OTHER|Laboratory Biomarker Analysis|Correlative studies
40749635|NCT02321501|OTHER|Pharmacological Study|Correlative studies
40749636|NCT03957057|DRUG|Iron Carboxymaltose|Intravenous iron carboxymaltose application
40749637|NCT03957057|DRUG|Iron Isomaltoside|Inravenous iron isomaltoside application
40749638|NCT03957057|DRUG|Ferrous sulphate|Oral ferrous sulphate application
40749639|NCT04774354|DIAGNOSTIC_TEST|POSSUM|These scales will be calculated and compared to the outcomes obtained in our center.
40749640|NCT02234180|OTHER|Placebo|Given PO
40749641|NCT02234180|DRUG|Regorafenib|Given PO
40749642|NCT04479735|DEVICE|Virtual Reality Goggles|Virtual reality goggles will placed at least 2 min prior to venipuncture to deteremine if it mitigates perceived anxiety or perceived pain scores.
40749643|NCT00320580|DRUG|norelgestromin/ethinyl estradiol|
40749644|NCT02585102|OTHER|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
40749645|NCT02585102|OTHER|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
40749646|NCT03494192|OTHER|Scapula Retraction Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up."
40749647|NCT03494192|OTHER|Scapula Retraction +Glenohumeral Rotational Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic and also rotator cuff muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up"
40749648|NCT00559351|PROCEDURE|transthoracic esophagectomy 2-field extended lymphadenectomy|right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
40749649|NCT00559351|DRUG|neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
40749650|NCT00559351|RADIATION|neoadjuvant chemoradiotherapy|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
40749651|NCT02520440|BIOLOGICAL|Monitoring of plasmatic levels of Citrulline|Measured plasma amino-acids levels
40749652|NCT02520440|DEVICE|Intra-abdominal pressure monitoring|Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
40749653|NCT02520440|BIOLOGICAL|Monitoring of plasmatic levels of Arginine and Glutamine|Measured plasma amino-acids levels
40749654|NCT01115010|DEVICE|Colonoscope stiffening device|"Colonoscopy is performed with the unassisted colonoscope (Olympus CF-100TL). The standard stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying. If difficulty is again encountered, the firm wire replaces the standard wire. Further difficulty requires removal of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
40749655|NCT01115010|DEVICE|Colonoscope stiffening device|"Standard stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the standard wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
40749656|NCT01115010|DEVICE|Colonoscope stiffening device|"Firm stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the standard wire and so on until cecal intubation is achieved or the procedure is abandoned."
41095571|NCT00854139|PROCEDURE|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
41095572|NCT00854139|RADIATION|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
41453226|NCT03570060|BIOLOGICAL|Blood sample|2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
40749657|NCT01665378|DIETARY_SUPPLEMENT|Multiple Micronutrient|"There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)\* 2800 Iron (mg)\* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
40749658|NCT01665378|DIETARY_SUPPLEMENT|Iron and Folic Acid|The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
40749659|NCT01665378|DIETARY_SUPPLEMENT|Folic Acid|It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
40749660|NCT05361759|DEVICE|Cardiac Implantable Electronic Devices|Description of Cardiac Implantable Electronic Devices
40749661|NCT05818787|BEHAVIORAL|Vestibular Perceptual Learning|The participants will be tilted and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject response, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the tilt stimulus. After each trial, a 3 second period of rest will be given. Each day of training will include three blocks of one-hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Noise cancelling earpieces (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
40749662|NCT05818787|BEHAVIORAL|Placebo Intervention|The placebo (or control) task will consist of oculomotor exercises that the subject will complete at home (i.e., outside of the lab). The oculomotor exercises will include saccadic eye movements performed in the horizontal and vertical planes. All movements will be completed within a limited, comfortable range of motion with the head remaining stationary. As the control intervention will be performed with the head stationary and in a seated position, no change in self-motion perception or balance is expected to result from the control (i.e., placebo) task.
40749663|NCT01926392|DRUG|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
40749664|NCT01926392|DRUG|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
40749665|NCT00398450|BIOLOGICAL|recombinant interferon alfa-2b|
40749666|NCT00398450|DRUG|azacitidine|
40749667|NCT06404775|DRUG|mastalgia-oil, tamoxifen placebo|external mastalgia-oil 1 ml/d per breast plus oral tamoxifen placebo 10mg/d for 3 consecutive menstrual cycles
40749668|NCT06404775|DRUG|mastalgia-oil placebo, tamoxifen|oral tamoxifen 10mg/d plus external mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
40749669|NCT02499536|DEVICE|ultrasound|Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
40749670|NCT01939275|RADIATION|copper Cu 64-DOTA-trastuzumab|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
40749671|NCT01939275|DEVICE|positron emission tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
40749672|NCT01939275|OTHER|laboratory biomarker analysis|Correlative studies
40749673|NCT01939275|PROCEDURE|Computed Tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
40749674|NCT04546620|DRUG|R-CHOP|Arm A patients will receive R-CHOP alone.
40749675|NCT04546620|DRUG|R-CHOP + acalabrutinib|Arm B patients will receive R-CHOP in combination with acalabrutinib.
40749676|NCT05787509|DRUG|Progesterone Sustained-release vaginal gel|the treatment time of vaginal progesterone
40749677|NCT05023655|DRUG|Tazemetostat|800mg po twice daily
40749678|NCT05428917|BEHAVIORAL|Simple task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform flexion / extension movements of the fingers of the left hand at 0.5 Hz."
40749679|NCT05428917|BEHAVIORAL|complex task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform an exercise based on the nine hole peg test"
40749680|NCT01084486|DRUG|Metformin|
40749681|NCT01028053|DRUG|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
40749682|NCT04242602|DEVICE|Transcranial Doppler|Record flow velocity tracing of middle cerebral artery using a transcranial doppler.
40749683|NCT04261595|OTHER|Dates fruit as functional Food|Two groups will receive Dates; The number per group is dependant on the child age. For children aged 3-6 years; they will receive the minimum numbers of dates (3 pieces). For children aged more than 6-12 years will receive 5 pieces of Dates the choice of the minimum numbers of dates (3 pieces) in this current trial is based on a study that was done by Al Jaouni and his colleagues, 2019 which proved the effects of three pieces of Ajwa on infection, hospitalization, and survival among 26 pediatric cancer patients in a university hospital; for which their treatment outcome was improved due to their intake of this amount of Ajwa during their standard treatment
40749684|NCT04261595|BEHAVIORAL|behavioral modification and stimulation|Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)
40749685|NCT04261595|OTHER|nutritional Guidance|The nutritional education sessions are based on educating parents on providing their autistic children with a nutritious, balanced diet. Because children with ASD often have restricted diets as well as difficulty sitting through meal times, they may not be getting all the nutrients they need, particularly calcium and protein
40749686|NCT01886157|PROCEDURE|Corticosteroid injection + Trigger Splint+ Education and Home exercises|Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.
40749687|NCT01886157|PROCEDURE|Corticosteroid injection|Standard trigger finger corticosteroid injection.
40749688|NCT04214236|DEVICE|ciNPT group|Closed-incision negative pressure therapy (ciNPT) will be applied for 7 day using continuous suction at 125 mmHg. To deliver ciNPT we will use a commercially available, FDA-approved device, used according to the manufacturer' indications (PREVENA™ Incision Management System (KCI, San Antonio, Texas, USA). After the first 7 post-operative days, subjects will discontinue the ciNPT and follow a standard wound care protocol.
40749689|NCT04214236|OTHER|Control group|Standard non-adherent surgical dressing (Vaseline petrolatum gauze) will be used for management of incisional wounds in the control group. Dressing changes will be performed per standard wound care protocol.
40749690|NCT03753542|OTHER|Multimedia education, booklet Providence and tele-nursing follow-up|Multimedia education, booklet and weekly tele-nursing follow-up is about chemotherapy and side effects management
40749691|NCT02769052|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy through self-applied device .
40749692|NCT01552889|BEHAVIORAL|Collaborative Care|No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
40749693|NCT01598220|BEHAVIORAL|Computer-assisted cognitive remediation therapy|"Comparison of two groups:~The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.~The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient."
40749694|NCT01598220|OTHER|attentional task|The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
40749695|NCT02416271|DRUG|Teriparatide|Administered SC
40749696|NCT02416271|DRUG|Alendronate|Administered orally
40749697|NCT02416271|DIETARY_SUPPLEMENT|Calcium|Administered orally
40749698|NCT02416271|DIETARY_SUPPLEMENT|Vitamin D|Administered orally
40749699|NCT02416271|DRUG|Placebo-Oral|Administered orally
40749700|NCT02416271|DRUG|Placebo-SC|Administered SC
40749701|NCT01098695|OTHER|Ecological Family Intervention and Treatment (EcoFIT)|Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
40749702|NCT04213339|BEHAVIORAL|Kegel Exercises|"Kegel exercise group will get exercise within duration of 3 to 6 weeks based on age factor. Kegel exercise can be performed at any time and at any place without any restrictions.~following steps will be followed by kegel exercises group members:~1. Tighten and hold pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).~2. Relax pelvic muscles and perform 10 to 20 Kegel exercises three to four times each day.~3. Squeeze the muscles in anus like holding a bowel movement focus penile area~4. Relax the pelvic floor muscles after each attempt.~5. Repeat this exercise 10 to 20 times.~6. While performing Kegel exercises:~Do not hold the breath. Do not push down. Squeeze the muscles together tightly and imagine, trying to lift this muscle up. Do not tighten the muscles in the stomach, buttocks, or thighs.~While the control group did not participate in any kegel exercises"
40749703|NCT06245707|DRUG|prednisone,methylprednisone and cyclophosphamide|In the first month, methylprednisolone 500mg/d was given intravenously for 3 days, and then prednisone 0.5 mg/(kg d) \* for 27 days. Oral cyclophosphamide 2.0 mg/(kg d) \* 30 days in the second month. After that, the first month and the second month plan were repeated twice.
40749704|NCT06245707|DRUG|Rituximab|The dosage of rituximab depends on peripheral blood B cells. After the treatment of rituximab, the peripheral blood B cells were in a clear state and then stopped. After monitoring the recovery of B cells, additional doses were given.
40749705|NCT04359615|DRUG|Favipiravir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Favipiravir in COVID-19 patients.
40749706|NCT04359615|DRUG|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
40749707|NCT00520572|DRUG|AZD9056|
40749708|NCT00520572|DRUG|Etanercept|
40749709|NCT00520572|DRUG|Placebo|
41270373|NCT01286584|DRUG|varenicline|one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
41453227|NCT03570060|PROCEDURE|Long term ECG monitor|Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
41453228|NCT03570060|PROCEDURE|Monitoring ECG|Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
40749710|NCT03022214|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose capsules x 5 morning and night with meals for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
40749711|NCT03022214|DIETARY_SUPPLEMENT|Intervention|"Daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~* EnduraCell broccoli sprout powder: 3 capsules~* Bulk Powders Green tea extract: 1 capsule~* Bulk Powders Cinnamon Bark Extract: 1 capsule taken for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal"
40749712|NCT02269449|DEVICE|6Fr Glidesheath Slender sheath|6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
40749713|NCT02269449|DEVICE|5Fr sheath|5Fr Hydrophilic coating sheath from Terumo.
40749714|NCT02269449|PROCEDURE|Hemostasis with TR band|Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
40749715|NCT02269449|PROCEDURE|Any hemostasis procedure|Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
40749716|NCT04630262|DEVICE|ATTUNE Cementless CR Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and CR or (Medial Stabilized) MS Tibial Insert.
40749717|NCT04630262|DEVICE|ATTUNE Cementless PS Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and PS Tibial Insert.
40749718|NCT06028737|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
40749719|NCT06028737|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
40749720|NCT06028737|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
40749721|NCT06028737|DRUG|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
40749722|NCT04935515|DRUG|Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins|Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
40749723|NCT04935515|DRUG|Oral low dose steroid|Low dose oral methyl prednisolone was added.
40749724|NCT04935515|DRUG|Intravenous Antibiotics with Low dose steroid.|Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
40749725|NCT04935515|DRUG|Oral anti-coagulant|Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
40749726|NCT03485456|DRUG|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
40749727|NCT02664883|PROCEDURE|Computed Tomography|Correlative studies
41270374|NCT01286584|DRUG|placebo|lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
41453229|NCT00796913|OTHER|Stop medication|Stop medication Stop medication + se supplement
40749728|NCT02664883|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
40749729|NCT02664883|OTHER|Laboratory Biomarker Analysis|Correlative studies
40749730|NCT02664883|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
40749731|NCT05316987|RADIATION|Narrow band ultraviolet B|48 sessions of narrow band ultraviolet
40749732|NCT00512863|DRUG|Humira (adalimumab)|
40749733|NCT05639868|OTHER|Video-assisted CPR|Participants in V-CPR group get video-based (vocal and visual) instructions from the dispatcher.
40749734|NCT05639868|OTHER|Telephone-assisted CPR|Participants in T-CPR group get voice-based (vocal) instructions from the dispatcher.
40749735|NCT01220154|DRUG|Paclitaxel|Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
40749736|NCT01220154|DRUG|Carboplatin|Intraperitoneal Day 1 cycles 1-6 AUC
40749737|NCT01220154|DRUG|Bevacizumab|Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
40749738|NCT04777903|OTHER|collect date about all participants|a standardized and structured questionnaire that included information on age, residence, education, pregnancy history, disease history, height, and conception method, after obtaining the consent of all participants.
40749739|NCT04784975|OTHER|No intervention|No intervention
40749740|NCT06461559|OTHER|ileostomy infusion|infusing patient's own ileostomy content into the diverted intestine
40749741|NCT03177850|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
40749742|NCT03177850|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
40749743|NCT01232842|GENETIC|cytogenetic analysis|
40749744|NCT01232842|OTHER|HUMARA assay|
40749745|NCT01232842|OTHER|fluorescence activated cell sorting|
40749746|NCT01232842|OTHER|laboratory biomarker analysis|
40749747|NCT02202720|DRUG|Sevoflurane|Short term sedation with sevoflurane in ICU
40749748|NCT03128164|DRUG|HMPL-689|Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
40749749|NCT01733888|DEVICE|Office Bleaching|Teeth will be cleaned with pumice first, followed by placing cheek retractors and covering of the lip surface with petroleum gel. Thereafter, teeth will be dried and gingival barrier will be applied to both arches - slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds. This is followed by homogeneous mixing of the powder and liquid in a powder pot the application of a thick layer of the resulting gel to all teeth undergoing treatment (35 % Hydrogen Peroxide, Pola Office, SDI, Australia). The gel will be left in place for 8 minutes and subsequently removed using a surgical aspirator tip.
40749750|NCT01733888|DEVICE|Resin Infiltration|Fluorosed teeth will be isolated using a rubber dam and the resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. In short, tooth surface will be dried using cotton rolls and air syringe. This is followed by an etching (Icon Etch) and drying step (Icon-Dry) to open the lesion surface. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds and subsequent cleaning of the surface with pumice and rubber polishing cup as well as rinsing with water for 30 sec.
40749751|NCT01733888|DEVICE|Resin Infiltration twice|"The intervention will be done similar to the Resin infiltration arm, which the exception that the icon infiltration step will be done twice."
40749752|NCT01733888|DEVICE|Bleaching + Resin Infiltration|"In this arm, the fluorosed teeth of the patients will first be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia) as explained in the intervention arm Office bleaching; followed by wash over period of 20 days. After these 20 days, patients will be recalled and the fluorosed teeth will treated according to the description in the Resin infiltrant intervention arm using the resin infiltrant (Icon, DMG, Hamburg, Germany) as per manufactures' instructions."
40749753|NCT03794323|DRUG|BI 764122|Tablet
40749754|NCT03794323|DRUG|Placebo|Tablet
40749755|NCT02866266|OTHER|Retrospective database review|
40749756|NCT02839460|PROCEDURE|Outpatient Muscle Biopsy|Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle
40749757|NCT00086463|DRUG|Iloprost or placebo|
40749758|NCT01760980|DRUG|Reference product (A) Aromasin (Exemestane)|Aromasin tablets will be administered under fasting conditions on two occasions
40749759|NCT01760980|DRUG|Test product (B) Exemestane|Exemestane tablets will be administered under fasting conditions on one occasion
40749760|NCT00452400|DRUG|BI 1744CL|
40749761|NCT04802785|DRUG|Citicoline|Citicoline 500 mg (Vitaae®) per os
41270375|NCT03632642|DRUG|Benzylpenicillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
41270376|NCT03632642|DRUG|Flucloxacillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
41270377|NCT00217633|PROCEDURE|Conventional Surgery|
40749762|NCT04802785|DRUG|Cytochrome C6|Cytochrome10 mg per os
40749763|NCT04802785|DRUG|Sodium Chloride Oral Product|Sodium Chloride (NaCl) 2.6 g. per os
40749764|NCT04802785|DRUG|Potassium Chloride Oral Product|Potassium Chloride 1.5 g per os
40749765|NCT04802785|DRUG|Sodium Citrate Oral Product|Sodium Citrate 2.90 g per os
40749766|NCT04802785|DRUG|Dextrose Oral Tablet, Chewable|Dextrose 13.5 g per os
40749767|NCT04802785|DRUG|Domperidone Oral Product|Domperidone 1 tablet per os
40749768|NCT04802785|DRUG|Simethicone|3-4 capsules per os
40749769|NCT04802785|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 150 mg per os
40749770|NCT04802785|DRUG|Magnesium hydroxide|magnesium hydroxide 30 mg per os
40749771|NCT04802785|DRUG|Probiotic Formula|1 capsule per os.
40749772|NCT04802785|DRUG|Melatonin 5 mg|Melatonin 5 mg per os.
40749773|NCT01590966|DRUG|administration of Cimzia®|Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
40749774|NCT01590966|DRUG|Immunoscintigraphy with radiolabeled Cimzia®.|All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
40749775|NCT03408145|DEVICE|Hyaluronic Acid|Injection of 3x 2.5ml of Hyaluronic Acid
40749776|NCT03408145|DEVICE|Amniotic Tissue Allograft|Injection of 1x 1ml of Amniotic Tissue Allograft
40749777|NCT03408145|DRUG|Saline|Injection of Saline
40749778|NCT02117817|DRUG|BKM120|
40749779|NCT02117817|DRUG|Nabpaclitaxel|Given IV
40749780|NCT03180502|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|Undergo IMRT
40749781|NCT03180502|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
40749782|NCT03180502|DRUG|Temozolomide|Chemotherapy drug
40749783|NCT01471574|DRUG|Daclatasvir|Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks
41270378|NCT02115308|DRUG|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
40749784|NCT01471574|DRUG|Ribavirin|Tablets; oral; for patients weighing \<75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing \>75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response
40749785|NCT01471574|DRUG|PEG-Interferon alfa 2a|Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
40749786|NCT04405388|DRUG|Placebo|Placebo will be given orally as capsule (same size and weight as Spermidine capula)
40749787|NCT04405388|DRUG|Spermidine|Spermidine will be given orally as capsule (4mg/day)
40749788|NCT00578058|OTHER|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
40749789|NCT00728182|DRUG|NA-1|single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
40749790|NCT00728182|DRUG|Placebo|single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
40749791|NCT04211155|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
40749792|NCT04211155|OTHER|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
40749793|NCT02282384|DRUG|oseltamivir|They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
40749794|NCT02282384|OTHER|Placebo|
40749795|NCT02056288|DRUG|Fentanyl|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
40749796|NCT02056288|DRUG|Ropivacaine|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
40749797|NCT00949078|DRUG|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
40749798|NCT04918628|DRUG|Sintilimab|A humanized anti-PD-1 monoclonal antibody
40749799|NCT00652652|DRUG|nesiritide, furosemide|
40749800|NCT03149861|PROCEDURE|PET/MR-ultrasound guided Fusion biopsy|All focal lesion with PI-RADS \>=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy
40749801|NCT03149861|PROCEDURE|Systemic TRUS guided biopsy|Transrectal ultrasound guided systemic prostate biopsy
40749802|NCT03358706|DRUG|Ustekinumab IV Infusion|Participants will receive a single IV infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8.
40749803|NCT03358706|DRUG|Ustekinumab SC Injection|Participants will receive a Ustekinumab 90 mg SC maintenance dose on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator.
40749804|NCT03358706|DRUG|Midazolam 2 mg|Participants will receive 2 milligram per milliliter (mg/ml) syrup of midazolam as a component of the Cytochrome P 450 probe cocktail orally.
40749805|NCT03358706|DRUG|Warfarin 10 mg|Participants will receive 10 mg tablet of warfarin as a component of the Cytochrome P 450 probe cocktail orally.
40749806|NCT03358706|DRUG|Vitamin K 10 mg|Participants will receive 10 mg tablet of vitamin K as a component of the Cytochrome P 450 probe cocktail orally.
40749807|NCT03358706|DRUG|Omeprazole 20 mg|Participants will receive 20 mg capsule of omeprazole as a component of the Cytochrome P 450 probe cocktail orally.
40749808|NCT03358706|DRUG|Dextromethorphan 30 mg|Participants will receive 30 mg capsule of dextromethorphan as a component of the Cytochrome P 450 probe cocktail orally.
40749809|NCT03358706|DRUG|Caffeine 100 mg|Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.
40749810|NCT03782103|DRUG|ZuraPrep Clear Solution|Apply topically.
40749811|NCT03782103|DRUG|ChloraPrep|Apply topically.
40749812|NCT03782103|DRUG|ZuraPrep Vehicle|Apply topically.
40749813|NCT03997838|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
40749814|NCT03997838|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
40749815|NCT02568254|DEVICE|Lens 1 (etafilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
40749816|NCT02568254|DEVICE|Lens 2 (nelfilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
40749817|NCT02568254|DEVICE|Lens 3 (nesofilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
41270379|NCT01243268|DRUG|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
40749818|NCT06190015|BIOLOGICAL|Advanced platelet rich fibrin (APRF) clots|15 minutes before surgery, phlebotomy will be performed and two vacutainers containing 10ml of blood will be placed in the centrifuge for 8 min and 200g. Acquired APRF clots will be placed in the extraction alveolus
40749819|NCT06190015|DEVICE|Enamel matrix derivative (EMD) group|After third molar removal, Pref Gel (EDTA) will be placed on the root surface for 2 min and then removed. Emdogain (EMD) will be placed on the collagen sponge (Botiss, Collacone) and then applied in the wound so that the side of the sponge which is covered with Emdogain is in contact with the root surface.
40749820|NCT00624078|DRUG|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
40749821|NCT01619449|PROCEDURE|Renal replacement therapy|Liver transplant recipients receiving continuous renal replacement therapy for duration of liver transplant surgery.
40749822|NCT06413771|DRUG|Letrozole 2.5mg|Letrozole pretreatment during ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
40749823|NCT06413771|DRUG|Gonadotropin|Ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
41270380|NCT01106547|DRUG|Methylprednisolone 125mg|Single dose 60-90 minutes preoperatively
41270381|NCT01106547|DRUG|Sodium Chloride 2 ml|Single dose 60-90 min preoperatively
41270382|NCT03288948|OTHER|Binocular games for treatment of amblyopia|playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
40749824|NCT05695430|BEHAVIORAL|Brief Cognitive Behavioral Therapy for People with Physical Disabilities|12 sessions of of Brief Cognitive Behavioral Therapy that has been adapted for people with physical disabilities will be administered through telehelath.
40749825|NCT06406816|COMBINATION_PRODUCT|Neoantigen Vaccine plus Capecitabine|"1. Capecitabine.Twice a day, 30 minutes after breakfast, swallow with water, continue for 2 weeks, then stop for 1 week, constitutes one cycle; three weeks make one cycle, lasting for 8 cycles.~2. Neoantigen Vaccine . Every 3 weeks, once every 21 days, for 4 to 8 cycles. The injection is administered on the first day after cessation of capecitabine. Treatment can last for up to 6 months without occurrences such as the researcher determining no further clinical benefit, intolerable toxic reactions, initiation of new anti-tumor treatment, withdrawal of informed consent, loss to follow-up, death, or other circumstances specified in the protocol that require treatment termination."
40749826|NCT05138640|OTHER|Not applicable. The study is designed as an observational cohort study|Not applicable. The study is desigend as an observational cohort study
40749827|NCT02887599|PROCEDURE|Blood collection|1ml of blood specimen collection
40749828|NCT03548415|DRUG|IONIS-GHR-LRx|IONIS GHR-LRx administered subcutaneously.
41095573|NCT00854139|PROCEDURE|Bone marrow transplant from a related donor|• Donor bone marrow (\> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is \> 60 seconds, the protamine treatment shall be repeated
41095574|NCT02689375|DEVICE|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
41095575|NCT00686621|DRUG|Posaconazole|Posaconazole oral suspension 400 mg twice daily with meal or nutritional supplement. Alternatively, if meal or nutritional supplement is not tolerated, posaconazole should be administered at a dose of 200 mg four times a day.
41270383|NCT01166048|DRUG|Duloxetine|"Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)~day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg~day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg"
41270384|NCT01166048|DRUG|Duloxetine|2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
41270385|NCT04427254|DRUG|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
41270386|NCT03798288|BEHAVIORAL|selfBACK|Participants will use the selfBACK system and app in addition to receiving usual care
41095576|NCT00073970|DRUG|celecoxib|400mg, given twice daily
41095577|NCT02074566|OTHER|Cryoballoon ablation|PVI using cryoballoon
40749829|NCT03548415|DRUG|Placebo|Placebo administered subcutaneously.
40749830|NCT03774472|DRUG|Hydroxychloroquine|Given PO
40749831|NCT03774472|DRUG|Letrozole|Given PO
40749832|NCT03774472|DRUG|Palbociclib|Given PO
40749833|NCT04549428|DRUG|Atezolizumab|Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.
40749834|NCT03586232|DIETARY_SUPPLEMENT|Arnica Montana|Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.
40749835|NCT03586232|DIETARY_SUPPLEMENT|Bromelain|Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.
40749836|NCT03586232|OTHER|Placebo|A pharmacologically inert preparation
40749837|NCT04275414|DRUG|Bevacizumab Injection|Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min
40749838|NCT02220556|PROCEDURE|Blood sampling|
41095578|NCT03017456|BEHAVIORAL|Survivorship Care Plan|"SCP-Intervention: Patients in the SCP-Int arm will attend a one-time appointment with a trained oncology nurse while the patients in the UC arm will receive care according to the hospital standards for follow-up care. The intervention will be delivered during a regular follow-up appointment, face-to-face and will inform and educate patients on self-management and support as well as promote access to and coordination of post-treatment care. The appointment will focus on empowering the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support. Nurses will integrate a number of active behavior change ingredients including the integration of motivational interviewing techniques which are effective in increasing healthy behaviors."
41095579|NCT04122924|OTHER|Abdominal muscle training|The intervention starts 6-12 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
41095580|NCT01065272|DRUG|Dexamethasone|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days"
41095581|NCT01065272|DRUG|Placebo|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days"
41270387|NCT03798288|OTHER|Usual care|Participants will receive usual care
41453230|NCT01586208|DRUG|valproic acid (VPA)|Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
40749839|NCT03309605|DRUG|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
40749840|NCT03309605|DRUG|Placebo|Placebo
40749841|NCT04289298|BEHAVIORAL|Engage-A|Therapist will encourage participants to engage in physical and social activities that are pleasurable or rewarding. Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
40749842|NCT04289298|OTHER|Training and utilizing Engage-A therapy|Therapist will be trained in Engage-A therapy and given supervision while utilizing this therapy.
40749843|NCT03019588|BIOLOGICAL|Pembrolizumab|IV infusion
40749844|NCT03019588|DRUG|Paclitaxel|IV infusion
40749845|NCT02171208|DRUG|dimethyl fumarate - Reference form|single dose 240 mg
40749846|NCT02171208|DRUG|dimethyl fumarate - Test form|single dose 240 mg
40749847|NCT05259293|OTHER|No intervention - retrospective study|This is a retrospective study. No intervention.
40749848|NCT00684138|DEVICE|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
40749849|NCT00684138|DEVICE|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
40749850|NCT04346238|OTHER|Reuse of existing data from patients' medical records|Reuse of existing data from patients' medical records
40749851|NCT03813251|DEVICE|ForConti Contix Fecal Incontinence Management System (FIMS)|Use the device for up to 12 hours per use for 4 weeks
40749852|NCT00120250|DRUG|Eszopiclone|The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
40749853|NCT04723368|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=5 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 14 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
40749854|NCT01534403|BIOLOGICAL|Epratuzumab|Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)
40749855|NCT04631978|DIAGNOSTIC_TEST|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
40749856|NCT05610267|DEVICE|Retrospective chart review|The retrospective chart review will include the full consecutive series of patients between 22 years and 80 years old who underwent abdominal wall reconstruction for achart hernia with Integra Gentrix® Surgical Matrix during the time period between November 1, 2017, and present (90 days prior to the start of data collection).
40749857|NCT04934072|DRUG|FKS518|Participants will receive FKS518 via subcutaneous injection, every 26 weeks.
41095582|NCT03907397|BIOLOGICAL|Peanut Protein|up to 3 level teaspoons peanut butter or equivalent (approximately 3400 mg)
40749858|NCT04934072|DRUG|US-licensed Prolia|Participants will receive US-licensed Prolia via subcutaneous injection, every 26 weeks.
40749859|NCT03120923|DRUG|Lidocaine 3 cc|
40749860|NCT03120923|DRUG|Lidocaine 9 cc|9mL of 1% lidocaine plus 1mL of 40mg triamcinolone acetonide
40749861|NCT03120923|DRUG|Triamcinolone Acetonide|
40749862|NCT04034680|OTHER|TIME|The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
40749863|NCT04034680|OTHER|Education-only intervention|Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
40749864|NCT01570582|DRUG|carboplatin and paclitaxel|Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
40749865|NCT01266928|DRUG|vitamine C and E|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
40749866|NCT05583058|OTHER|Hormone Overdose and Misuse|This is an observational study. Hormone Overdose and Misuse is an exposure.
40749867|NCT00335192|DRUG|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
40749868|NCT00335192|DRUG|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
40749869|NCT00335192|DRUG|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
40749870|NCT04400955|DIAGNOSTIC_TEST|Audiometry tablet diagnostic tool and web-based test|as above
40749871|NCT03666702|OTHER|Upper limb physiotherapy programme|Web-based physio programme
41453231|NCT01196598|OTHER|Exercises|"Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist."
40749872|NCT03666702|OTHER|Usual care|Usual physiotherapy care
40749873|NCT00247793|DRUG|Oral Impact (preoperative enteral nutritional supplement)|
40749874|NCT05871489|DRUG|Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)|Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
40749875|NCT05871489|DRUG|Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)|Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
40749876|NCT05871489|DRUG|Bdq, Lzd, Lfx, Z, Dlm (9-12 months)|Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed
40749877|NCT00138970|DRUG|Zenapax®, CellCept® and prednisolone|
40749878|NCT00138970|DRUG|Sandimmun Neoral®, CellCept® and prednisolone|
40749879|NCT04679818|DRUG|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
41095583|NCT05161403|DRUG|Hyaluronic acid|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
41095584|NCT05161403|DIETARY_SUPPLEMENT|honey|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~Use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
41095585|NCT00530374|DIETARY_SUPPLEMENT|Oral Iron Supplement|Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
41095586|NCT00530374|DIETARY_SUPPLEMENT|Placebo|Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
41095587|NCT04677569|DRUG|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes
41095588|NCT04677569|DRUG|Azithromycin|Oral tablet
41095589|NCT04677569|DRUG|Ethambutol|Oral tablet
41095590|NCT04677569|DRUG|ELC (matching placebo for ALIS)|Inhalation via nebulization over approximately 6 to 15 minutes
41095591|NCT04609293|COMBINATION_PRODUCT|camrelizumab+apatinib+hyperfractionated radiotherapy|Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy
41095592|NCT03767764|DIAGNOSTIC_TEST|Test Yliver|Test Yliver is used to detect autoantibodies against alpha fetoprotein in serum by an ELISA technique
40749880|NCT04679818|DEVICE|PMD-200 Nol-guided opioid administration|PMD-200 Nociception level (NOL) values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends
40749881|NCT02417337|PROCEDURE|Root Canal Treatment|A standardized endodontic procedures performed.
40749882|NCT02417337|DRUG|Paracetamol|
41095593|NCT02112929|DRUG|Hyperpolarized xenon|Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
41095594|NCT00690469|OTHER|Laboratory Biomarker Analysis|Correlative studies
41095595|NCT00690469|OTHER|Questionnaire Administration|Ancillary studies
41095596|NCT05718297|DRUG|Brigatinib|"Brigatinib is administered for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent, whatever occurs first. After the treatment period of 3 years, patient's ongoing treatment will be managed according to local standard and best clinical practice.~Brigatinib should be taken approximately at the same time each day. It may be taken with or without food. Patients shall be instructed to swallow the tablets whole and not crush or chew them."
41095597|NCT05718297|DRUG|Durvalumab|Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
40749883|NCT02417337|DRUG|Ibuprofen|
40749884|NCT02417337|DRUG|Mefenamic acid|
40749885|NCT02417337|DRUG|Diclofenac|
41095598|NCT02095704|DRUG|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
40749886|NCT01796444|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel lymph nodes are identified with the combining use of intraoperative gamma detector and/or blue dye.
40749887|NCT01796444|PROCEDURE|Intraoperative Pathological Examination|touch imprint cytology and/or frozen section and/or OSNA
40749888|NCT01796444|PROCEDURE|Axillary Lymph Node Dissection|Axillary lymph node dissection involving removal of at least level I and II nodes.
40749889|NCT01796444|PROCEDURE|Pathological Evaluation|H\&E and IHC
40749890|NCT01796444|DRUG|Adjuvant Systemic Therapy|Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
40749891|NCT01796444|RADIATION|Radiation Therapy|Whole-breast opposing tangential-field radiation therapy.
40749892|NCT00817102|PROCEDURE|FFR, IVUS, VH, or combination of the three|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
40749893|NCT04744532|DRUG|Bosutinib (Phase 1 part)|Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.
40749894|NCT04744532|DRUG|Bosutinib (Phase 2 part)|Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.
40749895|NCT03434366|DRUG|ketamine and dexmedetomidine|intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder
40749896|NCT03434366|DRUG|ketamine|intranasal ketamine for treatment for autism spectrum disorder
40749897|NCT03434366|DRUG|Saline|intranasal saline for treatment for autism spectrum disorder
40749898|NCT01834261|DRUG|Syntocinon Nasal Spray, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
40749899|NCT01834261|DRUG|Syntocinon Placebo Formulation, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
40749900|NCT01320098|BEHAVIORAL|Home-Based Parenting Program|"The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.~1. Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.~2. Increasing the quality and quantity of positive interactions between you and your child~3. Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.~4. Improving your parenting skills. This program also includes between-session homework tasks so that you can practice the skills you have learned throughout the week."
40749901|NCT01320098|BEHAVIORAL|Clinic-Based Parenting Program|"The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.~The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.~Parents learn techniques and skills to promote positive interactions with their child, including:~1. Increasing the positive attention you give to your child.~2. Reducing the inappropriate use of commands, questions and criticisms.~3. Appropriate use of praise and physical attention (e.g., hugs) as rewards.~4. Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors."
40749902|NCT01320098|BEHAVIORAL|Wait-List Control Group|If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
40749903|NCT05113602|DEVICE|URGOnight|EEG dry electrodes portable device
40749904|NCT05113602|DEVICE|Enobio|EEG wet electrodes portable device
40749905|NCT04696770|BEHAVIORAL|Mindfulness|Mindfulness techniques will be taught to the participants
40749906|NCT01309191|OTHER|Minoxidil|Over the counter Rogaine, twice a day for 8 weeks
40749907|NCT01309191|OTHER|Placebo|
40749908|NCT03720171|DEVICE|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb to be used with amputation limb prosthesis
40749909|NCT06141681|OTHER|photoplethysmography|Photoplethysmography (BluePoint, Frankfurt, Germany) is the pulse wave measured by a pulse oximeter. It is obtained based on the absorbance of red/infrared light in a given tissue. The signal is made up of two components: 1) the alternating component (AC), which is the pulse wave itself, which is determined by the absorbance of pulsatile arterial blood. 2) The continuous component (DC), which represents the absorbance of venous blood and the rest of the tissues. Within these tests the investigators find vascular occlusion, elevation of the legs, raising or lowering the tested hand above/below the phlebostatic level, cold/heat test, etc. Each of them evaluates different aspects of circulation such as endothelial function, myogenic response to blood flow, perfusion pressure, autonomic reflexes, preload-dependence, or venous flow among other aspects of microcirculation.
40749910|NCT01823887|DEVICE|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
40749911|NCT02605694|DRUG|Duvelisib|25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
40749912|NCT02605694|DRUG|Rituximab|375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
40749913|NCT02605694|DRUG|R-CHOP|"IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~* Cyclophosphamide (750 mg/m2)~* Doxorubicin hydrochloride (50 mg/m2)~* Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~* Rituximab (375 mg/m2)"
40749914|NCT02605694|DRUG|Prednisone|100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
40749915|NCT06494982|PROCEDURE|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy
40749916|NCT06494982|PROCEDURE|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
40749917|NCT00852878|BEHAVIORAL|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
40749918|NCT00852878|BEHAVIORAL|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
40749919|NCT02622594|DRUG|Aminolevulinic Acid (ALA)|
40749920|NCT02622594|DEVICE|Environ Cosmetic Roller|
40749921|NCT02622594|DEVICE|BLU-U IIlluminator|
40749922|NCT00289900|DRUG|MK-0524A|
40749923|NCT00289900|DRUG|Atorvastatin|
40749924|NCT00289900|DRUG|Simvastatin|
41095599|NCT02095704|DRUG|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
41453232|NCT04826250|PROCEDURE|Timing of medication|Either morning or nighttime medication
40749925|NCT02357485|BIOLOGICAL|ADSC|Single injection of ADSC
40749926|NCT03083041|BIOLOGICAL|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg
40749927|NCT03083041|DRUG|Apatinib|Apatinib tablet will be administered orally,once daily until progression
40749928|NCT01133106|BEHAVIORAL|Brief pleasurable events/behavioral therapy|"Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.~Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients."
40749929|NCT01133106|OTHER|Standard care|The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
40749930|NCT03889262|OTHER|Hippotherapy|Hippotherapy is a therapeutic method in which a mechanical horse is used for therapeutic purposes.
40749931|NCT03889262|OTHER|Neurodevelopmental Therapy|Neurodevelopmental therapy (NDT) is a hands-on treatment approach used by physical therapists, occupational therapists, and speech-language pathologists. NDT was developed to enhance the function of children who have difficulty controlling movement as a result of neurological challenges, such as cerebral palsy and head injury. During treatment interventions, repeated experience in movement ensures that a particular pattern is readily accessible for motor performance. The more a patient performs certain movements, the easier these movements becomes.
40749932|NCT06138080|DIAGNOSTIC_TEST|Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography|We have no specific intervention. We investigate different diagnostic modalities of VUR.
40749933|NCT05659420|BEHAVIORAL|Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor|aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
40749934|NCT05469308|OTHER|questionary|When the patients renew their treatment in community pharmacy, they have an adherence record with a pharmacist who calculates the PDC score, and perform questionaries on adherence to the DOACs, and collects data about clinical history and pharmacological information on the prescribed DAOCs, demography.
40749935|NCT00290758|DRUG|placebo|Given orally
40749936|NCT00290758|DRUG|genistein|Given orally
40749937|NCT00290758|OTHER|laboratory biomarker analysis|Correlative studies
40749938|NCT03588000|OTHER|Strengthen self-monitoring of blood glucose|Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
40749939|NCT00063232|DRUG|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
41453233|NCT01283763|DRUG|Topical Imiquimod|16 weeks
40749940|NCT05898373|DRUG|vedicitumomab (Edisil, RC48）|intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
40749941|NCT05898373|DRUG|vedicitumomab in combination with pyrrolizidine|vedicitumomab in combination with pyrrolizidine
40749942|NCT05898373|DRUG|RC48 in combination with a platinum-based chemotherapeutic agent|RC48 in combination with a platinum-based chemotherapeutic agent
40749943|NCT05898373|DRUG|RC48 in combination with teraplizumab|RC48 in combination with teraplizumab
40749944|NCT03986541|DIAGNOSTIC_TEST|Immunohistochemistry|Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
40749945|NCT05231941|DRUG|Lidocaine IV|Bolus and infusion of lidocaine will be administered
40749946|NCT05231941|DRUG|Ropivacaine|Bilateral TAP block will be given to these patients
40749947|NCT02400580|DRUG|IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
40749948|NCT02400580|DRUG|placebo|The patients in the placebo arm will receive normal saline.
40749949|NCT02923180|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.
40749950|NCT06151938|DRUG|Standardised allergen extract from house dust mites|Drug: Allergen immunotherapy \[ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet\] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.
41095600|NCT06502015|DIAGNOSTIC_TEST|biomaker levels|this study will discover and validate novel biomarkers (including blood, feces, bone marrow and lymph nodes etc al) of various neurological autoimmune diseases
40749951|NCT00850187|BIOLOGICAL|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
41453234|NCT01283763|PROCEDURE|Conization|Large loop excision of the transformation zone
40749952|NCT03439514|DRUG|ARRY-371797 (PF-07265803)|400 mg twice daily (BID)
40749953|NCT03439514|OTHER|Placebo|BID
40749954|NCT04799665|DIAGNOSTIC_TEST|Breast CT|This is a cross-sectional clinical study to determine the feasibility of breast CT for breast density assessment and association of CT-derived density measures with metabolic syndrome in overweight/obese Mexican-origin women in Southern Arizona. There is no intervention.
40749955|NCT05504421|OTHER|Sustainability education in nursing to be given with two different teaching methods|Sustainability education in nursing to be given with two different teaching methods (cooperative learning versus traditional learning) and the effects of two different teaching methods on the sustainability knowledge, attitude and skill acquisition of nursing students will be compared.
40749956|NCT01538407|OTHER|Strength Training|The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
40749957|NCT02137356|RADIATION|standard dose pelvic radiation therapy|"radiation therapy to pelvis delivered using standard conformal or IMRT techniques.~50.4-55 Gy"
40749958|NCT02137356|DRUG|standard dose capecitabine|825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
40749959|NCT02137356|DRUG|dose-escalated selinexor treatment|Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
40749960|NCT04886037|OTHER|sestrin|Serum sestrin levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group.
40749961|NCT00917982|OTHER|vision therapy|
40749962|NCT03694652|BEHAVIORAL|PACE|Patient-centered Assessment and Counseling for Exercise \[PACE\] program
40749963|NCT03694652|BEHAVIORAL|Diet|Motivating healthy dietary habits
40749964|NCT03694652|OTHER|App|Using an app to deliver communication to the participant.
40749965|NCT03694652|OTHER|Face-to-face|Using in person meetings and/or phone communication with the participant.
40749966|NCT05845190|OTHER|aerobic exercises|aerobic exercises in form of walking on treadmill
40749967|NCT05845190|OTHER|resistance exercises|60% of One-repetition maximum 3 sets ( 8 to 12 ) repetitions
40749968|NCT05610280|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
40749969|NCT05610280|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
40749970|NCT04920994|PROCEDURE|M-TAPA block|A high-frequency linear ultrasound probe will be used, probe will be placed on the costochondral angle in the sagittal plane and angled deeply to view the lower aspect of the chondrium in the midline, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced into the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
40749971|NCT04920994|PROCEDURE|SCTAP block|A high-frequency linear ultrasound probe will be placed obliquely on the upper abdominal wall, along the subcostal margin near the midline. After identifying the rectus abdominis muscle, the ultrasound probe will be gradually moved laterally along the subcostal margin until the transversus abdominis muscle will be identified lying posterior to the rectus muscle, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced medially and directed towards the transversus abdominis plane until its tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles on entering the neurofascial plane. The same procedure will be repeated on the contralateral side.
40749972|NCT04920994|DRUG|Bupivacaine Hydrochloride|20 ml 0.25% bupivacaine will be injected after the negative aspiration test.
40749973|NCT05788354|PROCEDURE|IUD insertion during cesarean section|placement of IUD during cesarean section after placental delivery
40749974|NCT02614768|DEVICE|Glucose Sensor|"The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received conformité européenne (CE) certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled for investigative use only."
40749975|NCT04242134|DEVICE|Drug-coating balloon|Provisional stenting technique with DCB
40749976|NCT00194090|DRUG|celecoxib|
40749977|NCT01879852|BEHAVIORAL|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
40749978|NCT01879852|BEHAVIORAL|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
41095601|NCT03610633|DRUG|Oxytocin|The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.
41095602|NCT03610633|DRUG|Placebo|Saline solution.
40749979|NCT03324009|DIAGNOSTIC_TEST|2-stage screen|Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.
40749980|NCT00448357|BIOLOGICAL|rabbit anti-thymocyte globulin (ATG)|.5 mg/kg on day -3 and 2.5 mg/kg on day -2
40749981|NCT00448357|BIOLOGICAL|therapeutic allogeneic lymphocytes|minimum total cluster of differentiation (CD34+) cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
40749982|NCT00448357|DRUG|busulfan|PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.
40749983|NCT00448357|DRUG|fludarabine phosphate|30 mg/m\^2/day x 5 days intravenous piggyback (IVPB) over 30 minutes on Days -7 through -3
40749984|NCT00448357|DRUG|tacrolimus|The suggested starting dose is 0.03 mg/kg po bid starting on day -1
40749985|NCT00448357|PROCEDURE|allogeneic hematopoietic stem cell transplantation|A minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and maximum of 8 x 10\^6 cells/kg will be infused on day 0
40749986|NCT00448357|PROCEDURE|peripheral blood stem cell transplantation|minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
40749987|NCT00448357|DRUG|methotrexate|5 mg/m\^2 on days +1, +3 and +6
40749988|NCT03832088|DIAGNOSTIC_TEST|Berg Balance Scale|Berg Balance Scale performed for balance disorder
40749989|NCT03832088|DIAGNOSTIC_TEST|Timed Up and Go Test|Timed Up and Go Test for walking speed
40749990|NCT03832088|DIAGNOSTIC_TEST|Jamar hand dynamometer|Jamar hand dynamometer for grip strength which correlates with muscle strength of patient
40749991|NCT03832088|DIAGNOSTIC_TEST|Calf circumference|Calf circumference for muscle mass evaluation. Calf circumference is an anthropometric measurement which correlates with muscle mass.
40749992|NCT05459714|DEVICE|MCE for obese patients|Sequence of stomach examination: The stomach examination is performed sequentially according to the order of fundus, cardia, gastric body, angulus, antrum, and pylorus, which should ensure the integrity of the observation of each part of the stomach and achieve the purpose of comprehensive observation by means of different observation distances such as distant view and close view, and different observation angles such as front and side.
40749993|NCT04361045|BEHAVIORAL|StriveWeekly|"The intervention (app.striveweekly.com) delivered eight modules: introduction module, six skills modules, and wrap-up module. The two program brand name versions had identical content, but different aesthetic schemes. Modules were released week-by-week, and participants self-guided through content. To facilitate skills practice, every module was accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displayed user progress. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity.~Strategies/skills included: Psychoeducation; Self-monitoring; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Maintenance planning."
40749994|NCT04033536|RADIATION|Involved Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Involved Target using IMRT/VMAT/RapidArc
40749995|NCT04033536|RADIATION|Elective Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Elective Target using IMRT/VMAT/RapidArc
40749996|NCT02665455|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (pre-meals and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
40749997|NCT05357079|DRUG|Tranexamic Acid|Topical application
40749998|NCT05357079|DRUG|Normal saline|Topical application
40749999|NCT03428854|DRUG|LNG-IUS|Levnorgestrel containing IUD
40750000|NCT06035198|OTHER|Stroke|No intervention
40750001|NCT04705584|DRUG|Prednisolone (as Acetate)|Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.
40750002|NCT04705584|DRUG|CycloSPORINE Ophthalmic Suspension|This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.
40750003|NCT04705584|DRUG|LTacrolimus Topical|This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.
40750004|NCT03920020|OTHER|the concentric isokinetic exercise group|concentric isokinetic exercises
40750005|NCT03920020|OTHER|the eccentric isokinetic exercise group|eccentric isokinetic exercises
40750006|NCT03920020|OTHER|the control group|conventional physiotherapy and standard therapeutic exercises predetermined by us
40750007|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 3 Secs|3 attempts of 19 inhalations, 3 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
40750008|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 2 Secs|3 attempts of 28 inhalations, 2 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
40750009|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 4 Secs|3 attempts of 14 inhalations, 4 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
40750010|NCT06413407|BEHAVIORAL|Tai Chi Exercise|Tai Chi Exercise will be applied to this group.
40750011|NCT06413407|BEHAVIORAL|Receptive Music Therapy|Receptive Music Therapy will be applied to this group.
40750012|NCT06413407|BEHAVIORAL|Experimental|Tai Chi Exercise and Receptive Music Therapy techniques will be applied together to this group.
40750013|NCT04773977|DRUG|IBI362 liquid formulation|Administered by subcutaneous injection
40750014|NCT04773977|DRUG|IBI362 lyophilized powder|Administered by subcutaneous injection
40750015|NCT02475837|DRUG|Vorapaxar sulfate|The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.
40750016|NCT02475837|DRUG|Placebo|The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
40750017|NCT02799290|BIOLOGICAL|ADIPOSE TISSUE EXTRACT|Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
40750018|NCT02799290|BIOLOGICAL|PLATELET-RICH PLASMA GEL|Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
40750019|NCT01881295|DIETARY_SUPPLEMENT|Placebo control|
40750020|NCT01881295|DIETARY_SUPPLEMENT|Low dose potassium gluconate|
40750021|NCT01881295|DIETARY_SUPPLEMENT|Medium dose potassium gluconate|
40750022|NCT01881295|DIETARY_SUPPLEMENT|High dose potassium gluconate|
40750023|NCT01881295|DIETARY_SUPPLEMENT|Low dose potato|
40750024|NCT01881295|DIETARY_SUPPLEMENT|Medium dose potato|
40750025|NCT01881295|DIETARY_SUPPLEMENT|High dose potato|
40750026|NCT01881295|DIETARY_SUPPLEMENT|High dose French fries|
40750027|NCT01881295|DIETARY_SUPPLEMENT|Basal diet control|
40750028|NCT06494514|DRUG|nal-IRI+Oxaliplatin+5-FU/LV+PD-1|These drugs are given on d1, d15, 28 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
40750029|NCT06494514|DRUG|Gemcitabine + albumin-paclitaxel+PD-1|These drugs are given on d1, d8, 21 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
40750030|NCT01374464|OTHER|Interscalene brachial plexus block|"4 different administrations of levobupivicaine will be applied:~1. High Volume, High Concentration = 15mls of 0.75% levobupivicaine~2. High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~3. Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~4. Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine"
40750031|NCT06493942|OTHER|BioCoat® by Premier®|BioCoat is a 56% filled resin formula that provides added strength and excellent long-term resistance to wear ؤomparable to flowable composites.
40750032|NCT06493942|OTHER|UltraSeal XT™ plus by Ultradent|UltraSeal XT plus is a 58%-filled resin fluoride-releasing sealant. It is strong and has high wear resistant
40750033|NCT05838170|DRUG|Lotilaner Gel, 2.0%|Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).
40750034|NCT05838170|OTHER|Vehicle control gel|Aqueous gel
40750035|NCT05332795|DRUG|Metformin|gouty patients, will receive metformin tablets (1000 mg) once daily for about 3 months.
40750036|NCT05332795|DRUG|Placebo|gouty patients, will receive placebo tablets once daily for about 3 months.
40750037|NCT01495728|PROCEDURE|Thrust Manipulation - Thoracic Spine|Mid and Upper Thoracic Spine
40750038|NCT01495728|PROCEDURE|Sham Manipulation|Mid and Upper Thoracic Spine
40750039|NCT03808454|DRUG|PRP|The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma
40750040|NCT03808454|OTHER|Rehabilitation|strengthening ex, posture training,...
40750041|NCT03808454|COMBINATION_PRODUCT|PRP+Rehabilitation|combine PRP and Rehabilitation
41095603|NCT03013842|DEVICE|Raydiant Oximetry Sensor System|Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
40750042|NCT00086307|DRUG|Pramipexole|Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
40750043|NCT00086307|DRUG|Escitalopram|Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
40750044|NCT05628350|OTHER|No UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
40750045|NCT05628350|OTHER|Standard UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet maintaining usual UPF intake (59% energy). Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
40750046|NCT04049084|BIOLOGICAL|autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)|ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
40750047|NCT05932030|OTHER|Survey|Submission of a survey to solid organ transplant patients and health professionals working in transplantation to assess their knowledge and perception of the use of artificial intelligence in transplantation
40750048|NCT04095936|DRUG|Romiplostim|Subcutaneous administration of 0 to 20ug/kg for 6 months
40750049|NCT01014156|DRUG|epoprostenol|titration up to 4 ng/kg/min
40750050|NCT01623284|DRUG|C-11 PiB|One time intravenous administration of 740 megabecquerel (MBq) of \[N-methyl-11C\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
40750051|NCT01623284|DRUG|F-18 FDG|One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
40750052|NCT01837095|DRUG|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
40750053|NCT03189953|RADIATION|68Ga-NODAGA-exendin 4 PET/CT|68Ga-NODAGA-exendin 4 PET/CT
40750054|NCT05371197|DRUG|Neoadjuvant therapy with PD-L1 inhibitor|Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab), 300mg, Q3W for 4 cycles
40750055|NCT04928586|DRUG|Pirfenidone|CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose
40750056|NCT04928586|DRUG|DMARDs|CTD-ILD patients treated with DMARDs according to the condition of the disease
40750057|NCT02141724|OTHER|Positioning consultation|Assessment of pain,bedsores and postural troubles
41270388|NCT00550160|DRUG|Amodiaquine plus Artesunate co-administration|"Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days."
41270389|NCT00562809|DRUG|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
41270390|NCT00315861|DRUG|pemetrexed|
40750058|NCT05150470|OTHER|prevention|dental digital fingerprinting
41270391|NCT00315861|DRUG|topotecan|
41270392|NCT01349140|DRUG|SKY0402|Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
41270393|NCT02118792|DRUG|AN2728 Topical Ointment, 2%|
40750059|NCT00004785|DRUG|dexamethasone|
40750060|NCT00004785|DRUG|methylprednisolone|
40750061|NCT00501085|DEVICE|LAP-BAND AP Adjustable Gastric Banding System|Reduction of food intake due to creation of smaller stomach pouch.
41270394|NCT02118792|DRUG|Matching vehicle control|
41270395|NCT05312957|OTHER|erector spinae plane block|Group ESP (Arm 1)The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected .When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed.Then, 20 ml of 0.25% bupivacaine was administered to this area, Group Control (Arm 2) :No intervention
41270396|NCT05172544|BIOLOGICAL|HydroVax-002 YFV|Inactivated YFV vaccine
41270397|NCT05172544|OTHER|Placebo|NaCl 0.9%, Normal Saline
40750062|NCT01975584|BEHAVIORAL|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
40750063|NCT02663440|RADIATION|Hypofractionated IMRT|Hypofractionated IMRT
40750064|NCT02663440|BIOLOGICAL|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
40750065|NCT02663440|DRUG|Temozolomide|Temozolomide
40750066|NCT03528577|DRUG|Zero-dose|Treatment A
40750067|NCT03528577|DRUG|90 mcg of PROAIR® HFA|Treatment B
40750068|NCT03528577|DRUG|180 mcg of 90 mcg of PROAIR® HFA|Treatment C
40750069|NCT03528577|DRUG|90 mcg of albuterol sulfate inhalation aerosol|Treatment D
40750070|NCT04626362|OTHER|Cranberry juice|Cranberry juice cocktail will be provided by Ocean Spray Cranberries, Inc.
40750071|NCT04626362|OTHER|Placebo juice|Apple juice added with flavor and colorants will be provided by Ocean Spray Cranberries, Inc.
40750072|NCT06468020|OTHER|The Gather.town gaming intervention|The online game-based learning intervention (oGBL): The investigator will develop the oGBL intervention based on Rational Emotive Behavior Therapy (REBT), which consists of 5 sessions and plays a game through the Gather.Town platform.
40750073|NCT05349266|BIOLOGICAL|ThisCART19A|each patient will receive a dose level per body weight(kg) for only once.
40750074|NCT05930353|OTHER|COHORT|this evaluation includes a brief interview with perma profiler scale
40750075|NCT03897192|DRUG|Bevacizumab|Anti-vascular endothelial growth factor (VEGF)
40750076|NCT04688944|OTHER|observation|observation the difference between two groups
40750077|NCT02966925|DEVICE|Cellular Matrix BCT-HA Kit|Submucosal injections in the vulva, in the posterior vaginal wall and in the perineum of a combination product made of PRP and HA prepared using the Cellular Matrix BCT-HA medical device
40750078|NCT03423693|OTHER|No any intervention|No any intervention is applied to any groups in this study
41270398|NCT00923637|DRUG|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
40750079|NCT03808857|BIOLOGICAL|GB226|GB226 is administrated at the dose of 3mg/kg, once per 2 weeks (±3 days), and distributed in 100ml of 0.9% sodium chloride solution. The concentration of GB226 shall be strictly controlled at 1mg/ml\~10mg/ml, the duration is 60 min (±10 min) for the first infusion of the drug, and can be reduced to 30 min (±10 min) for the subsequent infusion of the drug if there is infusion related adverse reaction.
40750080|NCT01622335|DRUG|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
40750081|NCT01622335|OTHER|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
41443036|NCT00296062|DRUG|capecitabine|Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
40750082|NCT03750669|DRUG|AG regimen|Combination of Nab-paclitaxel 125 mg/m\^2 and Gemcitabine 1000 mg/m\^2
40750083|NCT03750669|DRUG|mFolfirinox|Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2
40750084|NCT02511158|PROCEDURE|Ligament of the knee reconstruction|Reconstruction of ligaments of the knee by autografts
40750085|NCT02581423|DRUG|Capecitabine|Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m\^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
40750086|NCT06420908|DRUG|Adebrelimab+TP/FP+ radiation therapy|"Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage:~TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs."
40750087|NCT06420908|DRUG|Adebrelimab+FP/TP+ radiation therapy|"Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage: (switch to a different chemotherapy drug which not used during the earlier induction phase)~FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs."
40750088|NCT01304719|BEHAVIORAL|Computer Assisted Healthy Families America Home Visitation|Computer modules added to home visitation protocol for Healthy Families America
40750089|NCT01304719|BEHAVIORAL|Healthy Families America Home Visitation|Healthy Families America Home Visitation Treatment as Usual
40750090|NCT00499538|DRUG|SKI-606|
40750091|NCT01507389|DRUG|liraglutide|Single dose of 0.75 mg injected subcutaneously (under the skin)
40750092|NCT05326100|OTHER|Conventional Therapy (CPT)|The exercises may include traditional vestibulo-ocular reflex (VOR) exercises, cervical musculoskeletal exercises, somatosensory exercises, habituation, gait exercises, and aerobic conditioning. The treating PT will modify specific exercises as appropriate based on the participant's symptoms.
40750093|NCT05326100|DEVICE|CAREN Therapy|The CAREN, an FDA-registered exempted Class I device, is a VR-based system which includes a six degree-of-freedom motion platform with an embedded, instrumented treadmill surrounded by an immersive 180-degree screen. The CAREN can display a variety of virtual environments (VEs), where the difficulty level and task requirements can be easily modified by the treating clinician to target patient-specific needs.
40750094|NCT05326100|DEVICE|Augmented Reality (AR) Therapy|AR head-mounted displays are designed to provide immersive virtual environments similar to the CAREN, but with the portability to be used in most outpatient clinical settings and potentially for at-home therapy as well as significantly reduced cost compared to the CAREN. AR devices have integrated eye-tracking and inertial measurement units (IMUs) which can be used to objectively quantify characteristics of eye, head and body movement.
41270399|NCT02029742|BEHAVIORAL|Community Health Worker (CHW)|CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.
41453235|NCT00922896|DRUG|Gemcitabine, Cisplatin, Erlotinib (Tarceva)|"* Erlotinib 100 mg po q d daily AND~* Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~* Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks"
40750095|NCT00810745|PROCEDURE|starr|stapled transanal rectal resection
40750096|NCT02362932|OTHER|Sanitation|Shared sanitation
40750097|NCT05299450|DIETARY_SUPPLEMENT|Beet It shots|In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/
40750098|NCT05299450|BEHAVIORAL|Exercise|In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.
41095604|NCT02197689|DEVICE|Personalized Medication Management Platform for SMS Reminder|The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
40750099|NCT05299450|OTHER|Control group|Women will be supplied with a wearable device to measure physical activity, weighing scales and a home blood pressure monitor. They will be asked to record minutes of physical activity, exercise undertaken, resting blood pressure, resting heart rate and weight daily for 12 weeks.
40750100|NCT04193527|DRUG|DaTSCAN™ Ioflupane (123I) Injection|All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.
40750101|NCT02676622|DRUG|mobilization of stem cells to prepare for Leukapheresis|"Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis."
40750102|NCT02676622|OTHER|Leukapheresis- Collection of stem cells|"Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight."
40750103|NCT02676622|DRUG|Preparative regimen 4-6 weeks after Leukapheresis|"Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1"
41270400|NCT02029742|BEHAVIORAL|Education|Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
40750104|NCT02676622|OTHER|Stem Cell Transplant|"Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks"
40750105|NCT02676622|DRUG|Low-dose IL-2 administration|"IL-2 Subcutaneous injections will start once ANC is \> 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits."
40750106|NCT03461861|DRUG|AGB101 220 mg|AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
40750107|NCT03461861|OTHER|Placebo|Placebo, oral capsule given once-daily.
40750108|NCT05312060|DEVICE|PC Pneumatic compression|Pneumatic compression of the operated limb
40750109|NCT05312060|OTHER|AE Antithromboembolic exercises|Exercises for the edema
40750110|NCT02755090|DRUG|Nitrous Oxide|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
40750111|NCT02755090|DRUG|IV Saline|
40750112|NCT06122493|DRUG|Tirelizumab|immunotherapy, 200 mg on day 1 per 3 weeks
40750113|NCT06122493|DRUG|Nab paclitaxel|chemotherapy, 175 mg/m² on day 1 per 3 weeks
41443037|NCT00296062|DRUG|irinotecan hydrochloride|Phase I: irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Phase II: receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses)
41443038|NCT00296062|DRUG|oxaliplatin|"Phase I: oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Phase II: oxaliplatin (during even-numbered courses) as in phase I"
41443039|NCT00785603|DRUG|Paroxetine|tablets of 20 mg paroxetine
40750114|NCT06122493|DRUG|Carboplatin|chemotherapy, AUC=5 on day 1 per 3 weeks
40750115|NCT06122493|RADIATION|Radiotherapy|Patients without disease progression after four cycles of chemoimmunotherapy receive radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy delivered over 28 fractions.
40750116|NCT05520177|DRUG|601 1.25mg|loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
40750117|NCT05520177|DRUG|ranibizumab 0.5mg|loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
40750118|NCT02852746|BEHAVIORAL|Performance measures of the upper extremity|Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
40750119|NCT00710970|DRUG|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
40750120|NCT06433011|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
40750121|NCT06433011|DRUG|r-tPA|Pulse spray and infusion
40750122|NCT00383825|PROCEDURE|Anterior segment indocyanine green angiography|
40750123|NCT02492776|DRUG|Omeprazole|20 mg oral capsules administered once daily for 8 days
40750124|NCT02492776|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
40750125|NCT02492776|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
40750126|NCT03641729|OTHER|individualized exercise training program|The exercise training program was performed once daily, included 2- to 5-minute warm-up session (stretching, coordination and balance exercises), 10 to 20 minutes of moderate-intensity aerobic exercise using a cycle ergometer, 3 - to 5-sets to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve.
41443040|NCT00785603|DRUG|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
41443041|NCT00785603|DRUG|Tramadol|Capsules of 50 mg tramadol
41443042|NCT05150691|BIOLOGICAL|DB-1303/BNT323|Administered IV
40750127|NCT02443129|DEVICE|DRI-1 Swept source OCT, Atlantis, Topcon|Fundus imaging
40750128|NCT01260415|DRUG|Panitumumab, Oxaliplatin, 5-FU|"* Panitumumab 6 mg / kg, given over 60 minutes~* Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~* Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~* 5FU 400 mg / m2, by bolus infusion~* 5FU 2400 mg / m2, given over 46 hours"
40750129|NCT03300336|BEHAVIORAL|STRIDE|Implementation of STRIDE inpatient hospital mobility program
40750130|NCT00508508|BEHAVIORAL|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
40750131|NCT00508508|BEHAVIORAL|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
40750132|NCT06417307|BEHAVIORAL|Supervised exercise training|Participants perform Intradialytic cycling exercise training in the hospital for 6 months (24 weeks) and 3 months (12 weeks) at home. Exercise prescription: 50-60% maximal workload for 20-30 minutes, including low intensity warm-up and cool down (30% of maximal workload).
40750133|NCT06417307|BEHAVIORAL|Control group|Maintain daily lifestyle until the end of the study. Receive no intervention/supplements.
40750134|NCT01905267|BEHAVIORAL|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
40750135|NCT04826614|OTHER|optimized treatment|early adjust dose or change drug
40750136|NCT00770484|DRUG|Propranolol then Placebo|Propanolol 20 mg, given orally within 1 hour prior to exercising
40750137|NCT00770484|DRUG|Placebo then Propranolol|Placebo, matching pill given orally within 1 hour prior to exercising
40750138|NCT03171870|DIAGNOSTIC_TEST|high resolution computed tomography|high resolution computed tomography is an essential component of the diagnostic pathway in idiopathic pulmonary fibrosis. Unusual interstitial pneumonia is characterized on high resolution computed tomography by the presence of reticular opacities, often associated with traction bronchiectasis
40750139|NCT00066170|DRUG|Xyrem|Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.
40750140|NCT00066170|DRUG|Xyrem Placebo|Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
40750141|NCT00066170|DRUG|Modafinil at established dose|Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.
40750142|NCT00066170|DRUG|Modafinil (Placebo)|Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.
40750143|NCT00485849|DRUG|Atomoxetine Hydrochloride|
40750144|NCT00576342|DRUG|AL-3862+timolol ophthalmic suspension|
41443043|NCT05150691|DRUG|Pertuzumab Injection|Administered IV
40750145|NCT00576342|DRUG|Dorzolamide+timolol ophthalmic solution|
40750146|NCT03348397|PROCEDURE|right ventricular outflow tract reconstruction with contegra|Contegra pulmonary valved conduit is an animal jugular vein that contains a valve with three leaflets that are similar to a human heart valve.
41443044|NCT05150691|DRUG|Ritonavir|Administered oral
41443045|NCT05150691|DRUG|Itraconazole|Administered oral
40750147|NCT03348397|PROCEDURE|right ventricular outflow tract reconstruction with pulmonary homograft|cryopreserved pulmonary homografts
40750148|NCT02691377|DEVICE|acupuncture group|Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.
40750149|NCT02691377|DEVICE|Sham Acupuncture group|The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
40750150|NCT02619812|OTHER|Serum-derived bovine immunoglobulin/protein isolate (SBI)|SBI 10 grams (The subject will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)
40750151|NCT02619812|DRUG|Colesevelam|Colesevelam 1.875 g (The subject will take a total of 12 capsules of Welchol 1.875g per day; taken as 6 capsules twice a day by mouth).
40750152|NCT02619812|OTHER|Double Placebo|Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).
40750153|NCT00754286|OTHER|Aromatherapy Scented Wand|"The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety."
41443046|NCT06627010|OTHER|description|study of file
41443047|NCT05628311|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
41443048|NCT05628311|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
41443049|NCT00265681|BEHAVIORAL|Phone counseling and written materials|
41453236|NCT02921958|BEHAVIORAL|occupational therapy|Family-centered occupational therapy services
40750154|NCT00754286|OTHER|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
40750155|NCT03581747|DEVICE|Nevisense|Measurement of electrical impedance
40750156|NCT02046200|DRUG|Ivermectin|Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
40750157|NCT02046200|DRUG|Placebo|Matched placebo
40750158|NCT02046200|DRUG|Alcohol|
40750159|NCT04039438|OTHER|No intervention|No intervention will be provided during the study nor participants will be receiving any intervention anywhere else.
40750160|NCT05290974|OTHER|Self exploring of available online material on supraclavicular brachial plexus block|Potential new method of learning a specific regional anesthesia technique
40750161|NCT05290974|OTHER|Conventional in-person teaching on supraclavicular brachial plexus block|Conventional method of learning a specific regional anesthesia technique
40750162|NCT00430664|PROCEDURE|Pleurodesis with either talc or iodopovidone|
40750163|NCT04701320|DRUG|Conventional glass ionomer|Conventional glass ionomer with enhanced mechanical and esthetic proberties
40750164|NCT04701320|DRUG|Nano hydroxyapatite reinforced glass ionomer|Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
40750165|NCT01623752|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
40750166|NCT01623752|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
40750167|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days
40750168|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days
40750169|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
40750170|NCT00441740|DRUG|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
40750171|NCT00441740|DRUG|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
41270401|NCT04139083|PROCEDURE|LSC mesh suspension|Long mesh, a synthetic T-shaped mesh (Gynemsh, Ethicon, San Lorenzo, Puerto Rico), is delivered into the pelvic cavity. Bilateral mesh arms are extracted outside trocar wounds bilaterally to stabilize mesh position. The center piece is fixed to the cervix with 5mm ProTack screws (Covidien, New Haven, Connecticut). Fixation is strengthened with Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany), followed by Tisseel fibrin sealant (Baxter, Deerfield, Illinois) for better hemostasis among surrounding tissues. An extraperitoneal tunnel is created along the left round ligament until reaching 2cm medial to the anterior superior iliac spine (ASIS). One arm of the long mesh is pulled out along the tunnel underneath round ligament and fixed with the fascia of oblique abdominis. The same procedure is repeated for the contralateral side. Bilateral round ligaments and the mesh arms are sutured continuously with Stratafix 2-0.
41270402|NCT04139083|PROCEDURE|TVM|Transvaginal mesh kit is delivered into the pelvis via vagina route.
41270403|NCT06418178|DRUG|Midomafetamine|One to five MDMA-assisted therapy sessions, each followed by three non-drug psychotherapy sessions (see behavioral intervention below)
41270404|NCT06418178|BEHAVIORAL|Psychotherapy|Standardized psychotherapy performed by therapy team
41270405|NCT06454708|DRUG|Clascoterone Cream 1%|Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
41270406|NCT01976806|DRUG|Aspirin|
41270407|NCT01976806|DRUG|Docosahexaenoic acid|
40750172|NCT00441740|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
40750173|NCT00441740|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
40750174|NCT04582643|BEHAVIORAL|6P intervention|6P assessment targeting on diet, activity and mentality, along with education provided based on the 6P components. The 6P tool serves the functions to help the women to self-monitor and be aware of their negative lifestyle choices.
41270408|NCT01976806|DRUG|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
40750175|NCT01954173|RADIATION|3D conformal radiation therapy|Undergo conformal radiation therapy
40750176|NCT04889651|DRUG|BR9004|BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.
40750177|NCT04889651|DRUG|BR9004-1|BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
40750178|NCT06367179|OTHER|Virtual reality and AI use|The experimental group will receive interventions of virtual reality and artificial intelligence wound detecting system.
40750179|NCT06367179|OTHER|Health education leaflet|The control group maintained the traditional pressure injury health education with oral introduction and health education leaflet.
40750180|NCT02567292|OTHER|Human Milk|Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants \<37 weeks PMA and/or or weight \<2,200g or PBCLN-002 for infants \>37 weeks PMA and/or weight \>2,200g)
40750181|NCT02979158|PROCEDURE|CPB Low Dose|Performing CPB with low dose heparin and coated equipment
40750182|NCT02979158|PROCEDURE|CPB High Dose|Performing CPB with high dose heparin and uncoated equipment
40750183|NCT01899703|DRUG|GSK2330672|GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
40750184|NCT01899703|DRUG|Placebo|Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
40750185|NCT01899703|DRUG|Ursodeoxycholic acid|UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.
40750186|NCT02287025|DRUG|Regorafenib (Stivarga, BAY73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
40750187|NCT02287025|OTHER|iPAD application|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
40750188|NCT02287025|OTHER|Bayer specialist|The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
41270409|NCT01232478|BEHAVIORAL|Comprehensive Adherence Program (CAP)|The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
40750189|NCT02454764|DRUG|Tenofovir + Interferon alpha 2b|
40750190|NCT02454764|DRUG|Tenofovir disoproxil Fumarate|
40750191|NCT02256800|GENETIC|UGT1A1 genotyping (6,6)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2."
40750192|NCT02256800|GENETIC|UGTIA1 genotyping (6,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2."
40750193|NCT02256800|GENETIC|UGTIA1 genotyping (7,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2."
40750194|NCT02256800|GENETIC|UGT1A1 non-genotyping|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks."
40750195|NCT02256800|DRUG|bevacizumab (Avastin)|bevacizumab as target therapy
40750196|NCT02256800|DRUG|irinotecan|irinotecan as escalating dose according to UGT1A1 genotyping
40750197|NCT02256800|DRUG|Leucovorin|combined with 5-FU
40750198|NCT02256800|DRUG|5-FU|combined with irinotecan
40750199|NCT03685435|OTHER|Bedside ultrasound|Checking for gastric content using bedside ultrasound
40750200|NCT02345343|DRUG|Apixaban|
40750201|NCT04017910|DEVICE|EchoMark/EchoSure|Each subject will have an EchoMark implanted at the time of arteriovenous fistula creation, and undergo EchoSure and duplex imaging follow-up.
40750202|NCT00353015|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
40750203|NCT00353015|DRUG|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
40750204|NCT03811405|DEVICE|Active biphasic pulse stimulation---Home Settings|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
40750205|NCT03811405|DEVICE|Active biphasic pulse stimulation---VIN Biphasic|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
41270410|NCT01823809|DEVICE|adenosine stress Cardiac Magnetic Resonance Imaging|
41270411|NCT04313725|DEVICE|Tangible Boost|Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.
41270412|NCT04313725|OTHER|Placebo|Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.
41270413|NCT01587989|DRUG|methotrexate|15-25 mg orally weekly, Weeks 1-12
41270414|NCT01587989|DRUG|methotrexate|15-25 mg orally weekly, Weeks 13-24
40750206|NCT03811405|DEVICE|Active biphasic pulse stimulation---Stimulator Off|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
40750207|NCT05316051|DEVICE|Inverted foot orthoses|Inverted functional orthoses will be used in this study based on Blake (1986) inverted orthotic technique. Two groups of foot orthosis will be fabricated with two different inverted angles: 25° inverted angle and 15° inverted angle.
40750208|NCT04079725|PROCEDURE|Combined trabeculotomy-trabeculectomy with mitomycin c|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases then histopathological examination of iris tissue to detect the nature of the disease
40750209|NCT05916066|DIETARY_SUPPLEMENT|Nicotinamide|Tabletts of 500mg Nicotinamide (B3-vitamin)
40750210|NCT03888482|DEVICE|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
40750211|NCT03888482|DEVICE|Somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
40750212|NCT01528774|OTHER|Blood Draw|Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
40750213|NCT00747071|DRUG|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
40750214|NCT06124677|DRUG|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
40750215|NCT02746380|DRUG|LBAL|Adalimumab
40750216|NCT02746380|DRUG|Humira®|Adalimumab
40750217|NCT03389750|DRUG|Intravenous Challenge Drug|Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
40750218|NCT02446938|PROCEDURE|Esophagus balloon catheter insertion.|Esophagus balloon catheter will be inserted and the position of the balloon will be confirmed by a air injection test.A bolus of 30 ml of air was injected to the gastric lumen of the catheter just next to the distal edge of the balloon, during the onset of end-expiratory phase. The presence of a positive disturbing wave (PDW) in esophageal pressure waveform to this air injection will be the indicator of the right balloon position.
40750219|NCT05025371|OTHER|Systemic immune-inflammatory markers|Systemic immune-inflammatory markers used in this study: total neutrophil count, total lymphocyte count, total monocyte count, total platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI)
40750220|NCT02211157|DRUG|BIBR 796 BS|
40750221|NCT02211157|DRUG|Placebo|
40750222|NCT02211157|OTHER|high fat breakfast|
40750223|NCT00195429|DRUG|Tacrolimus|
41095605|NCT03301922|BEHAVIORAL|Metacognitive therapy and work-focused interventions|Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
41095606|NCT03301922|OTHER|Waiting list|Waiting list
41095607|NCT06631547|DRUG|Progesterone|Hormonal treatment
41270415|NCT01587989|DRUG|placebo|methotrexate placebo orally weekly, Weeks 13-24
41270416|NCT01587989|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 24 weeks
41270417|NCT01517880|DRUG|Sialic Acid Extended Release (SA-ER)|SA-ER will be administered in doses of 3000mg per day or 6000mg per day
41443050|NCT05734677|BEHAVIORAL|Emotion regulation group|90 minute sessions once a week for 8 weeks, in groups of eight participants. DBT, MBT and MBI inspired, psychoeducative intervention.
40750224|NCT00195429|DRUG|Sirolimus|
40750225|NCT00195429|DRUG|prednisone|
40750226|NCT02381327|DEVICE|Mandometer|Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
40750227|NCT05358782|DEVICE|Dental implant positioning|observational study of the effect of implant malposition
40750228|NCT04725643|DEVICE|Track bleeding patterns before and after implant|Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart. Participants will also complete weekly surveys regarding their satisfaction with their bleeding. We will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.
41095608|NCT06631547|DRUG|The usual head trauma care|the basic treatment
41095609|NCT03423901|OTHER|Blood sampling|Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)
41095610|NCT05287932|BEHAVIORAL|Brief physical activity intervention|See arm/group descriptions
41270418|NCT01517880|DRUG|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
41443051|NCT06366113|OTHER|Pulmonary rehabilitation|"Pulmonary rehabilitation includes :~* Exercise re-training with resumption of physical activities~* therapeutic patient education"
41443052|NCT03675269|OTHER|HBOT|Standard practice
41443053|NCT03675269|BEHAVIORAL|Standard wound care|Standard wound care
41453237|NCT02845154|OTHER|bolus purge|complete and uninterrupted purge
41453238|NCT02845154|OTHER|Intermittent purge|intermittent portal purge
41453239|NCT03051776|OTHER|Kinesio Taping|
41453240|NCT03051776|OTHER|Compression Garment|
41453241|NCT00096850|DRUG|Atazanavir|From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
41453242|NCT00096850|DRUG|Rifampin|From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
41453243|NCT00096850|DRUG|Ritonavir|From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
41453244|NCT04130464|DRUG|Ropivacaine Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine at 8 mL/hour for 72 hours
41453245|NCT04130464|DRUG|Ropivacaine + Ketorolac Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours
40750229|NCT02978768|OTHER|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
40750230|NCT02978768|DEVICE|Computer-based cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
40750231|NCT02978768|DEVICE|Physico-Mental rehabilitation Wii|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
40750232|NCT01802671|OTHER|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
40750233|NCT01802671|BEHAVIORAL|cognitive behavioural therapy (CBT)|"Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~* Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~* Cognitive restructuring techniques~* Behavioural therapy and activity pacing~* Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions."
40750234|NCT01802671|BEHAVIORAL|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
40750235|NCT01192477|OTHER|Ozone|All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
40750236|NCT05420025|OTHER||
40750237|NCT02380872|PROCEDURE|Connective tissue graft|gingival recession treated with connective tissue graft
40750238|NCT02380872|PROCEDURE|Platelet Rich Fibrin|gingival recession treated with platelet rich fibrin
40750239|NCT01691742|DRUG|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
40750240|NCT01691742|DRUG|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
40750241|NCT01691742|DRUG|Rescue Laxative|All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
40750242|NCT00411658|DEVICE|Investigational Device|
40750243|NCT00411658|DEVICE|Experimental|
40750244|NCT00411658|OTHER|Cryopreserved|
40750245|NCT01482286|DRUG|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
40750246|NCT01482286|BEHAVIORAL|Dietary Restriction|Subjects randomized to the dietary restriction group will reduce their energy intake by 25% of their weight maintenance energy intake determined at baseline. Total energy expenditure as measured by a 14-day doubly labeled water (DLW) study will be used to determine the baseline energy intake of each subject. There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
40750247|NCT01482286|BEHAVIORAL|Exercise Training|"For the aerobic training component, subjects are required to meet a weekly energy expenditure target of 10 kcal per kg of body weight per week (KKW).~The resistance training program will be performed 2 days a week. The resistance program includes 9 exercises. The 9 primary exercises are seated chest press, seated row, shoulder press, lat pull down, double leg press, leg extension, leg curl, back extension and abdominal crunch."
40750248|NCT04633876|BEHAVIORAL|Individual coaching|Individual coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
40750249|NCT04633876|BEHAVIORAL|Group coaching|Group coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
40750250|NCT04633876|OTHER|Control group|Group receives no lifestyle coaching but did get baseline results from assessments which might motivate for lifestyle change.
40750251|NCT03868566|DRUG|SNP-612 dose1|Subjects will take dose1 once a day orally for 12 weeks
40750252|NCT03868566|DRUG|SNP-612 dose2|Subjects will take dose2 once a day orally for 12 weeks
40750253|NCT02106559|DRUG|porfimer sodium|Given IV
40750254|NCT02106559|PROCEDURE|therapeutic conventional surgery|Undergo tumor resection and/or radical pleurectomy
40750255|NCT02106559|DRUG|photodynamic therapy|Undergo PDT
41095611|NCT04920890|DEVICE|Radiofrequency therapy with manual therapy|Monopolar Capacitive Resistive Radio Frequency at 448 kHz (INDIBA®) (RFMCR) with manual therapy.
40750256|NCT05933174|OTHER|Prompt-sheet|Simple prompt sheet with which participants will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
40750257|NCT05933174|OTHER|Usual education|Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
40750258|NCT03297827|OTHER|Serum and Urine measurement of cytokines.|To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic \& hemorrhagic stroke.
40750259|NCT00464529|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
40750260|NCT05406999|DRUG|ADT|The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
40750261|NCT05406999|DRUG|Abiraterone Acetate|1000 mg (250 mg×4 tablets) once daily, orally
40750262|NCT05406999|DRUG|Prednisolone tablets|5 mg once daily, orally.
40750263|NCT05406999|DRUG|Enzalutamide|160 mg (40 mg× 4 tablets) once daily, orally.
40750264|NCT05406999|DRUG|Apalutamide|240 mg (60 mg×4 tablets) once daily, orally.
40750265|NCT05406999|DRUG|Darotamide|600 mg (300 mg × 2 tablets) twice daily, orally.
40750266|NCT05406999|DRUG|Rezvilutamide|240 mg (80 mg × 3 tablets) once daily orally
40750267|NCT05406999|DRUG|PARP inhibitor|The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
40750268|NCT05406999|PROCEDURE|Robot-assisted radical prostatectomy|Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
40750269|NCT02583009|DRUG|PAC-14028 cream 0.1%|Topical application
40750270|NCT02583009|DRUG|PAC-14028 cream 0.3%|Topical application
40750271|NCT02583009|DRUG|PAC-14028 cream 1.0%|Topical application
40750272|NCT02583009|DRUG|PAC-14028 cream vehicle|Topical application
40750273|NCT06050993|OTHER|Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.|During the preoperative procedure scheduled at the Paul Brousse hospital, 3 additional blood tubes (total volume 12 ml) will be withdrawn in addition of samplings already done for the patient's standard of care.
40750274|NCT05409638|BEHAVIORAL|Cognitive Behavioral Therapy to manage cancer-related fatigue|Participation will consist of attending 90-minute virtual groups for 4 consecutive weeks on cancer-related fatigue. During the 4 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework.
40750275|NCT04252118|BIOLOGICAL|MSCs|3 times of MSCs(3.0\*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
40750276|NCT01558414|PROCEDURE|SILS Cholecystectomy|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
40750277|NCT01558414|PROCEDURE|FSIS cholecystectomy|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
40750278|NCT01558414|PROCEDURE|Conventional laparoscopy|Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
40750279|NCT05270356|OTHER|MRI|Magnet Resonance Imaging of the Brain without Contrast
40750280|NCT01271829|DIETARY_SUPPLEMENT|Avocado supplement|Calories from avocados replace calories of the control lunch
40750281|NCT01271829|DIETARY_SUPPLEMENT|Avocado included|Calories from avocados will be added to calories from the control lunch
40750282|NCT02985710|DEVICE|Sudoscan|The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
40750283|NCT02985710|PROCEDURE|Skin biopsy|For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
41095612|NCT04920890|DEVICE|Placebo without radiofrequency.|The device will be used without turning on the patient, thus administering a placebo treatment.
41095613|NCT04920890|OTHER|Manual therapy.|Common manual therapy administered for said pathology by traditional physiotherapy.
41095614|NCT03995810|DIETARY_SUPPLEMENT|Carnosine, capsulle, 2 g/day, 8 weeks|We will administer supplemental carnosine (2 grams per day) for 8 weeks
41095615|NCT00536666|DRUG|Iron oligosaccharide|
41095616|NCT01230034|DRUG|Ramipril|pill, 5 and 10 mg/day, od, 24 weeks
41095617|NCT01230034|DRUG|Imidapril|pill, 10 and 20 mg/day, od, 24 weeks
40750284|NCT02985710|PROCEDURE|QSART|QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
40750285|NCT03304587|DIAGNOSTIC_TEST|Polysomnography (PSG)|Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.
40750286|NCT03304587|DIAGNOSTIC_TEST|Rectal thermistor 400 Series|Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
40750287|NCT03304587|OTHER|Bright blue-green light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
40750288|NCT03304587|OTHER|Dim red light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
40750289|NCT03304587|DIAGNOSTIC_TEST|Digital foot candle datalogging light meter|"On 2 random days during the 2-week bright light treatment, ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter (Extech Instruments, Waltham, MA) Model SDL400. The 7.1 x 2.9 x 1.0 light meter (12.21 oz) has the capacity to measure up to 10,000 footcandles (accuracy: ± 4% reading). The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck."
40750290|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue. PROMIS-Fatigue was developed based on rigorous methodologies. The psychometric properties have been established across chronic illnesses including cancer.
40750291|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.
40750292|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression|8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84
40750293|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function|8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.
40750294|NCT03304587|OTHER|Pittsburgh Sleep Quality Index (PSQI)|19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
40750295|NCT03304587|OTHER|Center for Epidemiological Studies - Depression|20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
41095618|NCT04636710|PROCEDURE|Lymphoscintigraphy|An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
41095619|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
41095620|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
41095621|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
41095622|NCT05074498|DRUG|TB006|intravenous infusion
40750296|NCT03304587|OTHER|Montreal Cognitive Assessment (MoCA)|The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
40750297|NCT03304587|OTHER|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)|The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
41270419|NCT03388814|DRUG|Local infiltration of bupivacaine|Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.
41270420|NCT03388814|DRUG|Pectoralis Nerve block|Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
41270421|NCT05014854|DEVICE|Usage of the SensoGrip-System comprised of the SensoGrip pen and a tablet app.|Intervention consists of the usage of the SensoGrip-System in at least 6 and up to 8 therapy session together with the participating child. It is assumed that the standard frequency of therapy sessions is once a week, resuming in a span of 6-8 weeks. 10 minutes of every therapy session during the intervention phase must involve the application of the SensoGrip-System. Sample exercises are made available, therapists can freely choose which exercises are used.
41270422|NCT06195228|DRUG|dabrafenib plus trametinib with or without PD-1 antibody|advanced thyroid cancer patients who harbor BRAF V600E mutation
41270423|NCT06195228|DRUG|entrectinib or larotrectinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor NTRK mutation
41270424|NCT06195228|DRUG|pralsetinib or selpercatinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
41270425|NCT06195228|DRUG|anlotinib or anlotinib plus anti-PD-1 antibody|For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
41270426|NCT06195228|DRUG|lenvatinib plus anti-PD-1 antibody|Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
41270427|NCT06195228|DRUG|Other Targets: precise treatment based on the target|Advanced thyroid cancer patients who had other treatment targets not included above
41270428|NCT03241446|DRUG|Tilmanocept|Intravenously administered Technetium Tc 99m tilmanocept
41270429|NCT05293730|BEHAVIORAL|eFRIEND|eFRIEND is a 6-month CWH-led intervention. All CHW will be part of the research team to ensure successful recruitment and interaction with patients, and all CHW will be certified and have participated in the North Carolina Community Health Worker Standardized Core Competency Training.
41270430|NCT05293730|OTHER|Usual Care|Routine treatment in primary care
41270431|NCT02952976|DEVICE|Abthera|ABThera group technique the dressing will be done according to the description and the manufacturer's instructions (Acelity, San Antonio, TX).
41270432|NCT02952976|DEVICE|Barker|In Barker Group a fenestrated plastic will be used and that will be in contact with viscera followed by four pads with a suction drain and an adhesive finishing layer.
41270433|NCT04073550|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
41270434|NCT04073550|DRUG|Placebos|Anlotinib blank analog capsule.
41270435|NCT04073550|DRUG|Topotecan|A topoisomerase I inhibitor.
41270436|NCT00103012|DRUG|Gingko Biloba|Ginkgo Biloba 120 mg twice daily for 14 days
41270437|NCT00103012|DRUG|Echinacea purpurea|Echinacea purpurea 500 mg three times daily for 14 days
41270438|NCT00103012|DRUG|Panax ginseng|Panax ginseng 500 mg twice daily
41270439|NCT03084133|BEHAVIORAL|Therapeutic Education Strategy|"In the experimental arm of the study (intervention group), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the intention of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a competence approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002)."
41270440|NCT01026584|DRUG|Aripiprazole|6 week prospective study
41270441|NCT03679325|DIETARY_SUPPLEMENT|vitamine D|a dose once a week
41270442|NCT03679325|OTHER|whole body vibration (WBV)|03 months of WBV training three times per week
41453246|NCT04130464|DRUG|Normal Saline Infusion from ON-Q Pump|Infusion of 0.9% normal saline at 8 mL/hour for 72 hours
41453247|NCT02392858|OTHER|influenza cohort|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
41095623|NCT05074498|DRUG|Placebo|intravenous infusion
41453248|NCT00327145|DRUG|valsartan|
41095624|NCT03236233|DRUG|PC786 - Single doses|Safety and tolerability of single doses
41453249|NCT00327145|DRUG|hydrochlorothiazide|
41453250|NCT00327145|DRUG|amlodipine|
40750298|NCT03304587|OTHER|Daily Log|-A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue \& sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
40750299|NCT05378542|BEHAVIORAL|Mobile application usage|The implementation of the research was carried out in two stages. In the first stage, a mobile application was created, in the second stage, training and counseling was given to the experimental group with the mobile application, and no attempt was made to the control group.
40750300|NCT03705611|DIAGNOSTIC_TEST|HIV self-testing only|Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.
40750301|NCT03705611|BEHAVIORAL|HIV self-testing secondary accuracy|A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
40750302|NCT01023464|OTHER|FID114657|artificial tears
40750303|NCT01023464|OTHER|SootheXP Emollient (Lubricant) Eye Drops|artificial tears
40750304|NCT03457597|DRUG|Midazolam hydrochloride|Midazolam hydrochloride 2.5 mg
40750305|NCT03457597|DRUG|Metoprolol tartrate|Metoprolol tartrate 100 mg
40750306|NCT03457597|DRUG|Pioglitazone hydrochloride|Pioglitazone hydrochloride 15 mg
40750307|NCT03457597|DRUG|Tolbutamide|Tolbutamide 500 mg
40750308|NCT03457597|DRUG|Omeprazole|Omeprazole 20 mg
40750309|NCT03457597|DRUG|Relacorilant|Relacorilant 350mg
40750310|NCT01204281|OTHER|Mechanical ventilation mode (PAV+ vs. ACV)|Compare two ventilatory modes in the acute phase of illness
40750311|NCT00449969|DEVICE|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
40750312|NCT00449969|DEVICE|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
40750313|NCT04784494|DEVICE|Magnetic Seizure Theapy (MagPro XP MST)|"MST treatment will be administered over the frontal/vertex cortex using 100 Hz stimulation using the MagPro XP MST with Cool TwinCoil. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~MST treatments will be administered twice a week, for up to 16 treatments. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
40750314|NCT05156814|DRUG|Femoston® 1, Femoston® 2|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
40750315|NCT05156814|DRUG|Duphaston|Duphaston®, 10 mg
40750316|NCT05156814|DRUG|Klimadynon|Cimicifuga racemosa rhizomatum extract
40750317|NCT05156814|DRUG|Divigel|Divigel, 0.1%
41270443|NCT06293924|DIAGNOSTIC_TEST|Pericardiocentesis|"Enrolled patients will not undergo any invasive investigations outside of normal clinical practice. Patients with acute pericarditis and non-inflammatory pericardial effusion will undergo pericardiocentesis for diagnostic or therapeutic purposes.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes."
41270444|NCT06293924|DIAGNOSTIC_TEST|Pericardiotomy|"During any type of cardiac surgery involving pericardiotomy, 4 ml of pericardial fluid will be collected and analyzed upon opening the pericardial sac of enrolled patients.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes."
40750318|NCT00355550|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
40750319|NCT00355550|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
40750320|NCT05496738|DRUG|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously in single ascending doses
40750321|NCT05496738|DRUG|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously in multiple ascending doses
40750322|NCT05496738|OTHER|Intravenous placebo|Placebo will be administered intravenously in single ascending doses
40750323|NCT05496738|OTHER|subcutaneous placebo|Placebo will be administered subcutaneously in multiple ascending doses
40750324|NCT04769362|DRUG|Discontinuation of β-blocker|Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
40750325|NCT01404260|DRUG|Gefitinib|Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression
40750326|NCT01404260|DRUG|Gemcitabine +Carboplatin|Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
41095625|NCT03236233|DRUG|Placebo - Single doses|Safety and tolerability of single doses
41095626|NCT03236233|DRUG|PC786 - Repeat doses|Safety and tolerability of repeat doses
41095627|NCT03236233|DRUG|Placebo - Repeat doses|Safety and tolerability of repeat doses
41453251|NCT00450567|PROCEDURE|computed tomography|
41453252|NCT00450567|PROCEDURE|positron emission tomography|
41453253|NCT00450567|RADIATION|fludeoxyglucose F 18|
41453254|NCT01812239|DRUG|Vaginal Progesterone gel.|Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
41453255|NCT01812239|PROCEDURE|fetal fibronectin swab.|Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
41095628|NCT02388555|PROCEDURE|Posterior osteotomy correction|The DLS patients underwent osteotomy including pedicle subtraction osteotomy (PSO) or Smith-Petersen osteotomy (SPO)
41095629|NCT06193330|PROCEDURE|antibiotic-coated plate|A plate for fixing long bone fractures is coated with antibiotics cement prepared in theatre
40750327|NCT06328894|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
40750328|NCT06328894|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
40750329|NCT06328894|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
40750330|NCT00791882|BEHAVIORAL|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
40750331|NCT03777176|DRUG|Dasiglucagon|Glucagon analog
40750332|NCT03777176|OTHER|Standard of Care|Standard of care according to site and/or country
40750333|NCT01260753|DRUG|UR-63325|UR-63325
40750334|NCT01260753|DRUG|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray
40750335|NCT01260753|DRUG|Placebo|Placebo to UR 63325 and fluticasone propionate nasal spray
40750336|NCT05926193|DIETARY_SUPPLEMENT|Tailor Food Bags|The treatment group will participate in 6 nutrition workshops over the course of 6 months as well as receive weekly food bags that have been tailored for a DASH diet.
40750337|NCT00612768|BIOLOGICAL|TRUE Test allergens Fragrance Mix and Thimerosol|"* Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose~* Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone~* Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin~* Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin~Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours."
40750338|NCT03757676|BEHAVIORAL|No Play|Participants in this group were asked not to download or play Pokémon Go during the study period and were asked to simply continue with their normal daily activities. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
40750339|NCT03757676|BEHAVIORAL|At Will Play|Participants in this group were asked to download Pokémon Go and play for at least 30 minutes initially, then play as much or as little as desired during the 4 week intervention period, with no specific instruction or goals for play. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
40750340|NCT03757676|BEHAVIORAL|Goal Oriented Play|Participants in this group were asked to download and play Pokémon Go and achieve a minimum player level of 20 within the game during the study period. They were given materials that described game features and functions to show them how to play the game. There were no restrictions on which features to pursue within the game to achieve this goal nor on how long or how frequent their play sessions should be. Upon reaching their goal (Level 20), participants were encouraged to continue to play as much or as little as they desired. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
40750341|NCT04579211|DIAGNOSTIC_TEST|urine lipoarabinomannan (LAM)|Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
41095630|NCT06193330|PROCEDURE|external fixator|external fixators are applied to participants with severe long bone fractures
41095631|NCT04140058|DRUG|Ondansetron|ondansetron was administered 20 minutes prior to spinal anesthesia.
41095632|NCT04140058|DRUG|Normal saline|Placebo of 10 mL normal saline was administered.
41095633|NCT00000816|DRUG|Sulfamethoxazole-Trimethoprim|
40750342|NCT04337255|OTHER|Behavioral Dietary intervention ( MIND Diet)|The MIND diet is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet dementia field. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetables and berries as well as food component servings that reflect the nutrition dementia evidence.
40750343|NCT04337255|OTHER|Behavioral Usual Care Diet Intervention|The Usual Care diet is comprised of both westernized (e.g. Steak, Mac n Cheese) and healthy ( veggie chili) food components
40750344|NCT04145271|DEVICE|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a minimally invasive damage control procedure for life-threatening abdominal and/or pelvic haemorrhage. It involves temporary occlusion of the aorta with an endovascular balloon, providing proximal control to the site of vascular injury whilst supporting cerebral and myocardial perfusion
40750345|NCT01713140|OTHER|1 strength training set performed until contraction failure|Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
40750346|NCT01960842|DRUG|Levodopa-carbidopa intestinal gel|Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
40750347|NCT01960842|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
40750348|NCT01960842|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
40750349|NCT01960842|DEVICE|J-tube|jejunal tube
40750350|NCT02797535|PROCEDURE|Endoscopy procedures|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
40750351|NCT04995926|PROCEDURE|Labial mucosal epithelium grafting for corneal limbus substitution|Labial mucosa epithelium grafting for corneal limbus substitution will be used to treat limbal stem cell deficiency by way of corneal surface re-epithelization
40750352|NCT01866592|DRUG|Adalimumab|Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
40750353|NCT00145327|DRUG|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
40750354|NCT00145327|DRUG|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
40750355|NCT05489523|DRUG|Tafamidis 61 MG|Tafamidis 61 mg by mouth daily for 12 months
40750356|NCT03932383|DEVICE|Custom CPAP mask|Modified CPAP mask based on 3D image capture
40750357|NCT05431751|DIETARY_SUPPLEMENT|Whole Algae|Whole Euglena gracilis algae, produced by proprietary fermentation.
40750358|NCT05187637|DRUG|intravenous iron|One dose of intravenous iron carboxymaltose calculated according to ganzoni's formula. If after thirty days of the first dose, a second dose of 500mg will be administered if the patient continues to meet the inclusion criteria.
40750359|NCT05153486|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
40750360|NCT05153486|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
40750361|NCT05153486|PROCEDURE|Surgical ablation|Patients receive surgical ablation.
40750362|NCT01176994|DEVICE|Formulations for in-vivo fixation|Formulations are comprised of non-toxic ingredients used in dermatology.
40750363|NCT00482456|DRUG|Nitrous oxide|
40750364|NCT00051350|OTHER|CARB|
40750365|NCT04978831|DEVICE|PEP Device|The breathing exercise device is a device that simulates pursed-lip breathing by creating positive expiratory pressure (PEP). Before starting to use the device, it will be explained that they need to put the mouthpiece on the device and put the nose clip on their nose, and the participants will be shown how it is done. The device will be used at 5 cmH2O pressure. A single exercise session consists of 3 exercise cycles, and a single exercise cycle consists of 15 breathing-exhalation activities. Participants will complete 3 cycles (a total of 45 inhales and exhales) in a single session. 1 loop lying on the left side, 1 loop lying on the right side, and 1 loop in sitting upright position. Participants held these sessions in the morning, afternoon, and evening. After completing each cycle, the participants will remove their nose clips and cough 2-3 times. Each participant will perform a total of 135 breathing exercises in one day.
40750366|NCT04978831|OTHER|Reading Aloud|"The patients in this group were given a book that they chose from among the book types within the scope of the study, according to their wishes. For the selection of books, opinions were taken from the experts in the education faculty of the same university and it was stated that any book separation was not important. The books that the participants wanted to read were provided by the researcher. They were asked to read this book aloud during the day, sitting upright on a chair or sofa, for 15 minutes, three times a day.~They were able to stop reading when the participant was tired or felt too short of breath to continue reading."
40750367|NCT01260792|OTHER|questionnaire|The teachers or the professors complete questionnaires on the child on their behavior in classes
40750368|NCT01260792|OTHER|Questionnaire|The parents complete a questionnaire on the behavior of their child and on their own behavior
40750369|NCT00272558|DRUG|Carboplatin and Vinorelbine|
40750370|NCT03338023|DRUG|LY2963016|Administered SC
40750371|NCT03338023|DRUG|Lantus®|Administered SC
41453256|NCT01812239|DRUG|Placebo gel|weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
41453257|NCT01310855|DRUG|cediranib maleate|
40750372|NCT03338023|DRUG|Insulin Lispro|Administered SC
40750373|NCT02528136|DRUG|Carbetocin|
40750374|NCT02528136|DRUG|Oxytocin|
40750375|NCT03183440|DIETARY_SUPPLEMENT|PREBIOTICS|women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery
40750376|NCT03183440|OTHER|PLACEBO|women will daily take placebo (maltodextrin) from inclusion to delivery
40750377|NCT00122187|DEVICE|Electronic Consult System|Consult system is an event notification system programmed to function within the VA electronic medical record system.
40750378|NCT02656342|DRUG|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
40750379|NCT02656342|DRUG|Placebo|Predicted to have no enhancing effect
40750380|NCT02971189|DEVICE|Librata Endometrial Ablation|The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
40750381|NCT00299754|DRUG|Misoprostol|
40750382|NCT02944825|DRUG|Ciprofloxacin|first line prophylactic oral antibiotic
40750383|NCT02944825|DRUG|trimethoprim/sulfamethoxazole|second line prophylactic oral antibiotic
40750384|NCT02944825|DRUG|No Intervention|No intervention
40750385|NCT05224908|DEVICE|EOS|pelvimetry by EOS in standing and sitting position
40750386|NCT00748930|OTHER|Retrospective Chart Review and Data collection|Retrospective Chart Review and Data collection
40750387|NCT00182637|DRUG|bortezomib|
40750388|NCT03919266|PROCEDURE|Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the realization of a nasopharyngeal swab in the two strategies, and the PCT assay at D1, D3 and D7 in the pathogen-directed strategy
40750389|NCT03919266|PROCEDURE|Control: usual antibiotic treatment|usual antibiotic treatment
40750390|NCT00190892|DRUG|olanzapine|
40750391|NCT00190892|DRUG|carbamazepine|
40750392|NCT02120079|DRUG|Lotemax|Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
40750393|NCT02120079|DRUG|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
40750394|NCT02120079|DIAGNOSTIC_TEST|In Vivo Confocal Microscopy (IVCM)|In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
40750395|NCT04180878|BEHAVIORAL|Intervention|Participants received a interactive physical activity monitoring system that allowed study personnel to monitor their activity level.
40750396|NCT04180878|BEHAVIORAL|Intervention 2|Participants received an interactive physical activity monitoring system, an electronic scale to report weekly body weight, weekly hour long conference calls with structured interactive educational lessons led by Health Educator, dietary recalls were completed at three different time points during their participation, and study personnel monitored physical activity levels weekly.
40750397|NCT05648916|OTHER|Celecoxib|Retrospectively comparing patients with and without heterotopic ossification who have been exposed to celecoxib and underwent cementless total hip joint replacement surgery.
40750398|NCT02645708|PROCEDURE|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
40750399|NCT02645708|PROCEDURE|EPVL after RIRS|Patients in Group 2 undergo EPVL after RIRS
40750400|NCT00558493|DRUG|Clevudine|clevudine 30 mg qd for 24 seeks
40750401|NCT05961384|DRUG|baxdrostat|a blood pressure lowering drug, oral dose
40750402|NCT00593073|BEHAVIORAL|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
40750403|NCT00593073|BEHAVIORAL|General Reminder Message|General CRC health education message and reminder to get screened.
40750404|NCT05102838|OTHER|Anti-virus treatment|Anti-virus treatment
40750405|NCT04250974|OTHER|electroacupuncture|acupuncture with electricity
40750406|NCT02557165|PROCEDURE|Muscle biopsies|Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
40750407|NCT00115531|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
41095634|NCT01253824|DRUG|NPC-01|NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
41453258|NCT01310855|DRUG|gefitinib|
41453259|NCT01310855|DRUG|Placebo|
41453260|NCT01625390|DRUG|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
41453261|NCT01625390|DRUG|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
41453262|NCT01625390|DRUG|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
41453263|NCT03190239|DRUG|Apatinib|Apatinib 250mg qd
41453264|NCT03190239|DRUG|Pemetrexed|Pemetrexed 500mg/m2 qm
41453265|NCT03926650|DEVICE|Masimo Sedline Monitor Patient State Index|Masimo Sedline Monitor shows frontal electromyography and patient state index, Train of four monitor shows muscle strength on adductor pollicis muscle
41453266|NCT03045536|DEVICE|MML (Fa. ESKA/Orthodynamics)|Classification of complications according to MSTS
41453267|NCT00515216|DRUG|5-fluorouracil|
41453268|NCT00515216|DRUG|Oxaliplatin|
40750408|NCT00115531|BIOLOGICAL|Trivalent inactivated influenza vaccine|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
41095635|NCT01253824|DRUG|IKH-01|IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
40750409|NCT01494857|DRUG|Adalimumab|Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
40750410|NCT04428593|DRUG|Treamid 5 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
40750411|NCT04428593|DRUG|Treamid 15 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
40750412|NCT04428593|DRUG|Treamid 50 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
40750413|NCT04428593|DRUG|Placebo|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
40750414|NCT05553210|BEHAVIORAL|FOREST+|The intervention will be delivered as an internet-based stress recovery intervention consisting of six weekly modules: introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. Each module consists of a psychoeducational and an exercise component. During the program, a therapist provides individual feedback on the completed exercises and can also be available on request.
40750415|NCT02882984|DRUG|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib|radiation given along with one of kind TKI
40750416|NCT02882984|RADIATION|WBRT|3750 cGy in 15 fractions given within 3 weeks time.
40750417|NCT02882984|RADIATION|HFSRS|All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
40750418|NCT04599257|DEVICE|BTL-899|The device applicator combines high-intensity focused electromagnetic procedure and radiofrequency energy to induce visible muscle contractions along with heating of the subcutaneous fat.
40750419|NCT00451984|BIOLOGICAL|Twinrix|
40750420|NCT00451984|BIOLOGICAL|interleukin-2|
40750421|NCT06203665|DIAGNOSTIC_TEST|Recruitment Maneuver|The surgery would be performed under general anaesthesia according to the common practice using protective lung ventilation ( Vt= 6 ml /Kg ideal body weight , RR to maintain end-expiratory CO2 35-45 cmH2O and PEEP= 6- 8 cm H20). An incremental and decremental positive end-expiratory pressure alveolar recruitment maneuver would be performed after release of pneumoperitoneum.
40750422|NCT04885712|DRUG|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
40750423|NCT04885712|DRUG|Pioglitazone 15mg|Subjects take the investigational products once a day for 24 weeks.
40750424|NCT04885712|DRUG|Pioglitazone 30 mg|Subjects take the investigational products once a day for 24 weeks.
40750425|NCT04885712|DRUG|Pioglitazone 15mg Placebo|Subjects take the investigational products once a day for 24 weeks.
40750426|NCT04885712|DRUG|Pioglitazone 30mg Placebo|Subjects take the investigational products once a day for 24 weeks.
40750427|NCT04885712|DRUG|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
40750428|NCT03338686|PROCEDURE|Free Gingival Graft (FGG)|Free Gingival Graft (FGG) was performed on all study sites in this arm.
41453269|NCT00515216|DRUG|Leucovorin|
41453270|NCT03690063|OTHER|Follow up|Follow up of treatment, behavior, co-morbidity
40750429|NCT03338686|PROCEDURE|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft followed by Laser Gingivoplasty one month later on all study sites in this arm.
40750430|NCT04082676|DRUG|Hyperbaric bupivacaine spinal|In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
40750431|NCT04082676|DRUG|Hyperbaric bupivacaine spinal|In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
40750432|NCT01249443|DRUG|vorinostat|Given PO
41453271|NCT05215496|DIAGNOSTIC_TEST|[18F]fluoro-PEG-folate PET/CT scan|A dynamic FR-targeted PET scan, a low-dose CT scan without contrast agents, and a static FR-targeted PET scan will be obtained
41453272|NCT01724463|OTHER|Severe Sepsis Management Bundle|"Management Bundle includes:~1. Securing Intravenous Access~2. Obtaining Blood Culture~3. Antibiotic Administration~4. Goal Directed Fluid Bolus Therapy~5. Oxygen Administration~6. Measuring Serum Lactate Levels"
41453273|NCT00163124|PROCEDURE|spinal manipulation & patient education/nutrition|
41453274|NCT01406080|DRUG|Adapalene|Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
41453275|NCT01406080|DRUG|Tretinoin|Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
41453276|NCT05963750|OTHER|virtual reality|virtual reality
41453277|NCT00761163|OTHER|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
40750433|NCT01249443|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
40750434|NCT01249443|OTHER|pharmacological study|Correlative studies
40750435|NCT01249443|DRUG|carboplatin|Given IV
40750436|NCT01249443|DRUG|paclitaxel|Given IV
40750437|NCT04063904|DRUG|Mifepristone|One 200 mg pill (oral)
40750438|NCT04063904|DRUG|Misoprostol|Two 400 mcg pills (sublingual)
40750439|NCT06134128|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Addictions Group|8-week manualized group-based behavioral intervention delivered via telehealth
40750440|NCT02560415|DEVICE|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
40750441|NCT02560415|BEHAVIORAL|Comparator|Treatment as usual
40750442|NCT03513146|PROCEDURE|Oropharyngeal Administration of Mother's Milk (OPAMM)|0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol
40750443|NCT03917264|PROCEDURE|Peri-implantitis debridement|Mechanical cleaning of titanium implants, peri-implantitis debridement.
40750444|NCT03917264|OTHER|Dental hygiene procedures|Titanium scalers and nylon brushed used for implant cleaning
40750445|NCT05036460|PROCEDURE|Ultrasonography|"The transducer will be placed over the anterior neck just above the suprasternal notch, in the transverse orientation. The position of the transducer could be adjusted to visualize both the esophagus and trachea. It will be considered as esophageal intubation if esophageal dilation or double-tract sign are noted."
40750446|NCT05036460|PROCEDURE|Direct visualization|While performing the intubation, the intubator will report ETI if visualizing the tracheal tube passing through the glottis. Otherwise, it will be regarded as esophageal intubation.
40750447|NCT01327365|PROCEDURE|trans-radial PCI (TRI)|TRI performed using the sheathless guiding approach
40750448|NCT01327365|PROCEDURE|trans-radial PCI (TRI)|TRI performed using a conventional guiding approach
40750449|NCT01057940|PROCEDURE|DBE PEJ placement|One time procedure with follow-up telephone call.
40750450|NCT01718106|DEVICE|implantation of a bioabsorbable polymer DES|implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
40750451|NCT05726227|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
40750452|NCT05726227|DRUG|Placebo|Placebo will be administered subcutaneously once-weekly.
40750453|NCT05769595|BIOLOGICAL|MK-2060|Lyophilized powder diluted in normal saline for IV infusion
40750454|NCT05769595|DRUG|Placebo|IV infusion
40750455|NCT03380988|OTHER|Acute test meal with fiber-enriched buckwheat pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
40750456|NCT03380988|OTHER|Acute test meal with corn pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
40750457|NCT05593640|OTHER|biological samples|blood and synovial liquid will be sampled
40750458|NCT00373711|DRUG|Iodine-124|2 mCi, oral
40750459|NCT00373711|DRUG|Iodine-123|2 mCi, oral
40750460|NCT00373711|DRUG|F-18 FDG|10-15 mCi, iv
40750461|NCT01570192|DRUG|IV meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
40750462|NCT01570192|DRUG|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage"
40750463|NCT01570192|DRUG|Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h|a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
40750464|NCT01570192|DRUG|Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.|Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
40750465|NCT01570192|DEVICE|tobramycin nebulization|tobramycin nebulization 600mg/day
40750466|NCT02438085|OTHER|prospective collection of data and follow-up|prospective collection of data and follow-up of all patients admitted to hospital for ACS
40750467|NCT02346370|DRUG|PEGylated recombinant human hyaluronidase PH20|
40750468|NCT02346370|DRUG|Docetaxel|
40750469|NCT01712464|DRUG|Oxytocin vs. Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
40750470|NCT00129558|DRUG|PT-523 for Injection|
40750471|NCT00731536|OTHER|No intervention|This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
40750472|NCT03292978|DIETARY_SUPPLEMENT|probiotics intervention|The probiotics intention is provided with 4 strains of probiotics as a 2g sachet powder, dried with corn starch for 4 weeks.
40750473|NCT03292978|DIETARY_SUPPLEMENT|non-probiotic control|The placebo is corn starch alone provided and the shape, color, flavor and taste are same with the powder of probiotics intervention.
40750474|NCT00326040|DEVICE|Glaucoma Surgery|
40750475|NCT03979989|DRUG|Tapentadol IR capsule|Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.
40750476|NCT03979989|DRUG|Omeprazole capsule|Omeprazole capsule containing 40 mg omeprazole.
40750477|NCT06025383|DIETARY_SUPPLEMENT|L-Citrulline|2 weeks of L-Citrulline supplementation (6 grams/day)
40750478|NCT06025383|DIETARY_SUPPLEMENT|Placebo|2 weeks of microcrystalline cellulose supplementation (8 capsules/day)
40750479|NCT04465149|PROCEDURE|Third Molar Germectomy|Surgical extraction of Third Molars that exhibits at least a third of its root in formation, with a periodontal ligament discernible on panoramic x-ray (defined as germectomy).
40750480|NCT04545138|OTHER|cognitive training combine treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight), and ensures that patients can be cognitively trained at the same time. The cognitive training tasks will be projected on the screen and the participant have to answer the task orders during treadmill training simultaneously.
40750481|NCT04545138|OTHER|Treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight).
40750482|NCT02875600|OTHER|Nutri Drink|To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
40750483|NCT02347956|PROCEDURE|Reduced port robotic distal gastrectomy|
40750484|NCT00328809|DRUG|spironolactone|spironolactone administered to ESRD patients at low dose
40750485|NCT03364010|BEHAVIORAL|Evaluation of proprioception|Velocity perception and Position perception
40750486|NCT03364010|BEHAVIORAL|Evaluation of motor learning|Motor accurancy and State Estimation with visual perturbations
40750487|NCT03364010|BEHAVIORAL|Evaluation of written language|Text reading, Identifying words and Phonological awareness: phonemic blending and phonemic elision
40750488|NCT01984060|OTHER|HOME-EX|"Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.~Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise"
41453278|NCT00761163|OTHER|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
40750489|NCT01856660|BEHAVIORAL|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to \> 40 min per day, 5 times/week.
40750490|NCT01856660|BEHAVIORAL|Low-fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
40750491|NCT03560596|BEHAVIORAL|Adherence Intervention|9 sessions with bilingual health coaches who will utilize a culturally tailored adherence checklist to identify patients specific medication adherence barriers.
40750492|NCT03560596|BEHAVIORAL|Usual Care|standard hypertension treatment recommendations as determined by PCP
40750493|NCT00483392|DRUG|metformin, rosiglitazone|
40750494|NCT00863460|RADIATION|cranial radiotherapy|40 Gy
40750495|NCT00863460|DRUG|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
40750496|NCT00863460|DRUG|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80
40750497|NCT01529151|OTHER|Osteopathic Manipulative Treatment (OMT)|Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
40750498|NCT01529151|OTHER|Vestibular Rehabilitation Therapy (VRT)|Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
40750499|NCT02677285|OTHER|Different type of wound|
40750500|NCT02866448|DRUG|Vehicle control|Described in arm
40750501|NCT02866448|DRUG|Isoquercetin|Described in arm
40750502|NCT02866448|DRUG|Aspirin|Described in arm
40750503|NCT02866448|DRUG|Isoquercetin plus Aspirin|Described in arm
40750504|NCT05673655|DRUG|intraoral trigger point injection by botox|intraoral injection of trigger point of masseter muscle by botulinum toxin
40750505|NCT05673655|DRUG|transcutaneous trigger point injection by botox|transcutaneous injection of masseter muscle by botulinum toxin
40750506|NCT01438944|DRUG|Nicabate 21mg transdermal NRT|Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
40750507|NCT05369156|OTHER|Chiropractic Care|The actual force applied to the patient's spine depends on the chiropractor, the patient, and the spinal location of the subluxation, the general shape of the force-time history of spinal adjustments is very consistent and the duration of the thrust is always less than 200 milliseconds.
41453279|NCT00761163|OTHER|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
40750508|NCT05369156|OTHER|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
40750509|NCT05901961|DRUG|Whitfield solution|The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
40750510|NCT05901961|DRUG|Zinc oxide nanoparticles solution|The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
40750511|NCT05901961|DRUG|Combined Whitfield and Zinc oxide nanoparticles solution|The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
40750512|NCT05931900|DEVICE|moderate-severe or greater (MR ≥ 3+) functional mitral regurgitation (FMR) patients|Functional mitral regurgitation (FMR) is common in patients with myocardial infarction or dilated cardiomyopathy, and portends a poor prognosis despite guideline-directed medical therapy (GDMT).
40750513|NCT02845427|DEVICE|closed suction drain|using closed suction drain system postoperative
41270445|NCT06293924|DIAGNOSTIC_TEST|Cytofluorometry and Gene expression analysis|"A 30 ml sample of peripheral venous blood in K3 EDTA tubes will be collected by enrolled patients who participating in the translational substudy and stored with pericardial fluid samples.~Pericardial fluid cells by lineage and expression of inflammatory cytokines will be characterized through cytofluorometry and expression profile analysis of transcribed RNAs. Cytokine concentrations in peripheral blood and pericardial fluid will be analyzed by molecular assay. Peripheral blood mononucleated cells (PBMCs) and pericardial fluid cells will be cultured in vitro and exposed to the main therapies used during pericarditis, to verify the effects on gene expression and inflammatory molecules."
40750514|NCT02845427|PROCEDURE|no suction drain|the surgical wound will be closed with no suction drain
40750515|NCT05633446|BIOLOGICAL|PepGNP-COVID19 (One vaccination)|One dose with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
40750516|NCT05633446|OTHER|Water for injection (One vaccination)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
40750517|NCT05633446|BIOLOGICAL|PepGNP-COVID19 (Two vaccinations)|Two vaccinations with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
40750518|NCT05633446|OTHER|Water for injection (Two vaccinations)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
40750519|NCT06480812|DIETARY_SUPPLEMENT|Synbiotic|"The proposed protocol will provide a simple but robust intervention study using a synbiotic (pre and probiotic combination) in order to improve our understanding of the mechanisms linking nutrition to health outcomes that are mediated by the gut microbiome.~This pilot study will comprise a controlled randomised intervention in which participants will be grouped into the active synbiotic arm or the control arm. The ratios will be 10g of the prebiotic supplement and 170ml of kefir. Randomisation will control for equal distribution of age and biological sex; characteristics that may confound between group comparisons and will be assessed by analysis of baseline data."
40750520|NCT04662632|COMBINATION_PRODUCT|VT-X7 Treatment System with Tobramycin Sulfate|Seven-day local antibiotic irrigation with tobramycin sulfate via the VT-X7 Knee or Hip Spacer.
40750521|NCT04662632|DRUG|Standard of Care|Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per standard of care. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
41270446|NCT06413004|OTHER|Elimination and re-introduction of CLE or COLAP positive food item(s)|Elimination (4 weeks) and re-introduction (4 weeks) of all CLE or COLAP positive food item(s)
41270447|NCT04581720|DEVICE|Train-of-four (TOF)|Give 4 electrical stimulants on the ulnar nerve to see if the 4 responses (T1 \~ T4) of adductor pollicis fade or not. If there's no neuromuscular block, it shows no fade, or it fades. When an operation is over under general anesthesia, we use the ratio of the height of T4 to T1, and the ratio is over 90%, the neuromuscular block is recovered enough to extubation.
40750522|NCT04662632|PROCEDURE|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
40750523|NCT04662632|COMBINATION_PRODUCT|VT-X7 Treatment System with Vancomycin Hydrochloride|Seven-day local antibiotic irrigation with vancomycin hydrochloride via the VT-X7 Knee or Hip Spacer.
40750524|NCT01155323|DEVICE|etafilcon A|1-day soft contact lens
40750525|NCT01155323|DEVICE|omafilcon A|1-day soft contact lens
40750526|NCT00347945|PROCEDURE|Pencil Push-ups|
40750527|NCT00347945|PROCEDURE|Office-based Vision Therapy|
40750528|NCT00347945|PROCEDURE|Placebo Office-based Vision Therapy|
40750529|NCT05177263|OTHER|Placebo|Sterile Water
40750530|NCT05177263|DRUG|10% Oral Dextrose Solution|10% Oral Dextrose Solution
40750531|NCT05177263|DRUG|20% Oral Dextrose Solution|20% Oral Dextrose Solution
40750532|NCT05177263|DRUG|30% Oral Dextrose Solution|30% Oral Dextrose Solution
40750533|NCT04760457|PROCEDURE|Implant placement with flapped surgery|Four mini implants will be placed reflecting a flap.
40750534|NCT04760457|PROCEDURE|Implant placement with flapless surgery|Four mini implants will be placed without reflecting a flap.
40750535|NCT04760457|PROCEDURE|Implant immediate loading|Four mini implants will be immediately loaded.
40750536|NCT04760457|PROCEDURE|Implant delayed loading|Four mini implants will be loaded after a 6-week healing period.
40750537|NCT00977184|PROCEDURE|50 HZ Repetitive TMS|
40750538|NCT00977184|PROCEDURE|Sham rTMS|
40750539|NCT04307355|DEVICE|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
40750540|NCT04679025|OTHER|Exposure - postoperative hyperglycemia|Postoperative hyperglycemia (blood or capillary glucose \> 10.0 mmol/L) within 72 hours of a surgical procedure
40750541|NCT06136234|BEHAVIORAL|Caring Contacts|Caring Contacts are brief, periodic messages sent over 1 year that express unconditional care and concern
40750542|NCT06136234|BEHAVIORAL|Best Available Resources Alone|Participants will be offered information about best available resources and will receive an email summarizing the resources with links and contact information. These resources are tailored to best serve the participant based on information they share during the online survey or during conversations with study staff.
41270448|NCT05448625|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
40750543|NCT05916924|OTHER|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting
41270449|NCT02850302|OTHER|PET with FDG|A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.
41270450|NCT02850302|OTHER|Tumor exome analysis|A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
40750546|NCT02096224|DRUG|Sevoflurane|Sevoflurane will be used.
40750547|NCT02096224|DRUG|Desflurane|Desflurane will be used
40750548|NCT03963830|BEHAVIORAL|MOVE UP|Each of the 12-group-sessions will focus on incremental behavioral strategies for maintaining recommended healthy eating, activity, and weight loss behaviors. Participants will monitor body weight and weight loss behaviors. Body weight will be measured at each in-person session and participants will also be encouraged to measure their body weight on their own. Beginning in Session 3, participants are given a home physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
40750549|NCT06530095|OTHER|prone positioning|prone positioning
40750550|NCT05897554|DRUG|intra-arterial alteplase|For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed immediately after intra-arterial thrombolysis.
40750551|NCT05357170|OTHER|Human feces collection|Human feces collection and blood sampling
40750552|NCT00285675|DRUG|DN-101 (calcitriol) - Drug|
40750553|NCT03462563|DEVICE|INTERCEED™|when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)
40750554|NCT03462563|DEVICE|Placebo|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
40750555|NCT05214950|DEVICE|ORI monitoring|Oxygen reserve index monitoring during the surgery
40750556|NCT00563212|DRUG|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
40750557|NCT04367935|DRUG|Pentoxifylline|Pentoxifylline tablets 400mg three times daily for 2 months
40750558|NCT00937911|DRUG|YM150|oral
40750559|NCT05664815|BIOLOGICAL|Human Amniotic Membrane|"After conventional/standard treatment, hAM will be applied in a single layer against the bone defect with, if possible, a burial of a few millimeters under the mucous edges.~With the idea of apprehending a possible dose effect, the hAM will be adapted to the size of the bone/mucous defect, mesenchymal side against the bone.~For closure after hAM grafting : 2 options are possible:~Edge-to-edge closure if sufficient mucosal laxity, Edge rapprochement by cross points. If necessary: possible incision of the periosteum to give laxity to the mucosa."
40750560|NCT05664815|OTHER|Conventional/Standard treatment|"Surgical procedure: Endo-oral approach:~* Trimming of the mucous edges if they are necrotic or inflamed (granulation tissue)~* For the bone: either simple sequestrectomy (the mobile sequestered bone is grabbed using forceps); either reaming until bleeding is obtained; either resection with the rongeur; either monobloc resection of the entire necrotic fragment with a saw or with a piezzotome (ultrasound); or a combination of different techniques. Rq: the resection of the necrotic bone (according to the practices of the center) will operate until the appearance of an apparently healthy bone (bone bleeding, clean appearance of the bone site)~* Closure of the mucosa with possible incision of the periosteum to provide laxity: Suture points by points separated in one plane with non-absorbable braided thread of the 3.0 silk thread type and round needle."
40750561|NCT01002391|PROCEDURE|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the first postoperative day
40750562|NCT01002391|PROCEDURE|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the sixth postoperative day
40750563|NCT00205608|DEVICE|Positron Emission Tomography|camera is new
40750564|NCT02945046|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
41270451|NCT00321516|DRUG|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
40750565|NCT02945046|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
40750566|NCT02626351|OTHER|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: \[1\] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; \[2\] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; \[3\] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; \[4\] Follow up.
40750567|NCT02626351|OTHER|Baseline data collection (active comparator)|Endpoint data collection only
40750568|NCT02965976|BIOLOGICAL|Botulinum Toxin Type A|Given IM
40750569|NCT02965976|PROCEDURE|Esophagectomy|Undergo esophagectomy
40750570|NCT02965976|OTHER|Quality-of-Life Assessment|Ancillary studies
40750571|NCT02691663|DIETARY_SUPPLEMENT|Oral bicarbonate supplementation|
40750572|NCT02691663|DIETARY_SUPPLEMENT|Placebo|
40750573|NCT01148420|DRUG|Medroxyprogesterone 17-Acetate|Medroxyprogesterone 20mg orally 3 times a day for 3 days
40750574|NCT01148420|DRUG|medroxyprogesterone acetate|Depo Provera 150mg Intramuscular injection
40750575|NCT01034527|OTHER|Neuromuscular Training|Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
40750576|NCT03890939|DEVICE|BiPAP AutoSV Advanced System One|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
40750577|NCT03890939|DEVICE|Dreamstation BiPaP AutoSV|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
40750578|NCT03890939|DEVICE|ResMed S7 VPAP Adapt Device|A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
40750579|NCT05391087|OTHER|Mean arterial pressure based management|Mean arterial pressure group: Low MAP will be intervened in accordance with the protocol as described in the arm
40750580|NCT05391087|OTHER|Cardiac index based management|Cardiac index group: Low CI will be intervened in accordance with the protocol as described in the arm. Additionally, if MAP is lower than target MAP along with a normal CI, this will be intervened with noradrenalin infusion/titration
40750581|NCT04950907|DIAGNOSTIC_TEST|vats|Use uniportal tubeless VATS to obtain the biopsy
40750582|NCT04950907|DIAGNOSTIC_TEST|CT-guided fine needle biopsy|Use CT-guided fine needle to obtain the biopsy
41095636|NCT05098236|OTHER|Training in the Blind Field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
41270452|NCT00365989|DEVICE|ExAblate Enhanced Sonication|
41270453|NCT05662514|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis BLa80|"Test product contain 3 × 109 colony-forming units \[CFU\] Bifidobacterium animalis subsp. lactis BLa80 strains, for each packet.~Subjects ingested one packet (3 g/packet) of Test product per day (2 hours after taking antibiotics in the evening), for 14 days."
41270454|NCT05662514|OTHER|Placebo|To maintain the blinding, patients in the control group received placebo included in identical packets. Control product per day (2 hours after taking antibiotics), for 14 days.
40750583|NCT03737032|DEVICE|Intermittent Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
40750584|NCT03737032|DEVICE|Continuous Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
40750585|NCT03737032|DEVICE|Sham Theta Burst Stimulation|For the sham of theta burst stimulation, the device providing Theta Burst Stimulation can be placed in the same position and turned on, creating a similar experience for the participant, without providing any neural stimulation. Sham TBS will be delivered with a Cool-B65 Active/Placebo Coil, which includes a sham setting, and MagLink research software.
40750586|NCT03153293|DRUG|rAAV2-ND4|a Single IVT Injection
40750587|NCT04251936|BEHAVIORAL|Exercise training|The moderate-intense aerobic exercise training will involve supervised aerobicycle ergometer training for 30 min with 60-80% HRmax three times per week for 12 weeks.
40750588|NCT04251936|BEHAVIORAL|Smoking cessation group program|Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
40750589|NCT00720811|DRUG|Artemether-lumefantrine combination|20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
40750590|NCT00720811|DRUG|amoxycillin|amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
40750591|NCT00720811|DRUG|paracetamol|paracetamol 500mg tablet \<36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
40750592|NCT00720811|DEVICE|malaria rapid diagnostic test, respiratory rate timer|malaria dipstick, and breath timer
40750593|NCT00720811|DRUG|Artemether-lumefantrine combination|20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
40750594|NCT04026451|DEVICE|Sedation guided by SEF95 (10-13 Hz) from SedLine® monitor|Dosage of propofol and fentanyl will be guided by SEF95 value between 10-13 Hz. If SEF95 is lower than 10 Hz, the infusion rate of propofol and fentanyl will be diminished; if SEF95 is higher than 13 Hz, the infusion rate of propofol and fentanyl will be increased; and if SEF95 is between 10-13 Hz, then the infusion rate will be kept.
40750595|NCT04026451|BEHAVIORAL|Sedation guided by SAS scale (1-2)|Dosage of propofol and fentanyl will be guided by SAS to keep a value of 1-2. If SAS is higher than 1-2, then the infusion rate of propofol and fentanyl will be increased; and if SAS is 1-2, then the infusion rate of propofol and fentanyl will be maintained.
40750596|NCT04026451|DRUG|Deep sedation with propofol andfentanyl|Propofol and fentanyl will be infused to reach a score in the SAS of 1-2
40750597|NCT04026451|PROCEDURE|Mechanical Ventilation|Critically ill patients will be ventilated mechanically following the clinical indication.
40750598|NCT00811109|DEVICE|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
40750599|NCT00811109|DEVICE|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
40750600|NCT00811109|DEVICE|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
40750601|NCT02544724|BIOLOGICAL|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
40750602|NCT00944021|DRUG|PA-824|50mg
40750603|NCT00944021|DRUG|PA-824|100mg
40750604|NCT00944021|DRUG|PA-824|150 mg
40750605|NCT00944021|DRUG|Rifafour e-275 mg|275 mg
40750606|NCT00944021|DRUG|PA-824|200 mg
40750607|NCT06137547|DEVICE|Hypotension prediction index (HPI)|The hypotension prediction index (HPI) is a value derived from the arterial pressure waveform. It was invented by Edwards Lifesciences through a machine-learning algorithm, and can be calculated with Acumen Hypotension Prediction Index software incorporated in HemoSphere advanced monitoring platform (EV1000). This value, ranging from 0 to 100, predicts the likelihood of a patient trending towards a hypotensive event, which is defined as mean arterial pressure below 65 mmHg for at least one minute.
40750608|NCT04348578|OTHER|QMix 2in1|In QMix 2in1 group root canals were irrigated with Mix as a final irrigation.
40750609|NCT05427916|DEVICE|Avance Solo|Avance® Solo will include the collective description for a complete device capable of delivering negative pressure to the incision site and managing exudate generated by the incision.
40750610|NCT05427916|OTHER|Optifoam|Optifoam is a silicone backed foam that is conformable, with a border that is waterproof, flexible and breathable for increased comfort, with a wear time of up to seven days. It is a standard of care product that is given to patients for surgical wounds.
41443054|NCT04982094|BEHAVIORAL|Mental Health First Aid and Relationship Building Training|"Relationship Building Training (RBT) is a 2 hour training session conducted live over zoom, that aims to equip business advisors the communications skills they need to enhance trustworthiness and quality of the relationship with their clients.~Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~Two Booster sessions are delivered 1- and 3-months after the last MHFA session that aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program."
40750611|NCT02148770|DEVICE|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
40750612|NCT00950924|DEVICE|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
40750613|NCT00950924|DEVICE|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
40750614|NCT04228653|DEVICE|Renishaw Drug Delivery System|Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.
40750615|NCT04210245|BIOLOGICAL|aldafermin|aldafermin
40750616|NCT04210245|OTHER|Placebo|Placebo for aldafermin
40750617|NCT05888779|OTHER|Beverage One (Milk)|Participant will consume beverage one (milk) and complete novel cognitive assessment questionnaire on paper.
40750618|NCT05888779|OTHER|Beverage Two (Juice)|Participant will consume beverage two (fruit drink) and complete novel cognitive assessment questionnaire on paper.
40750619|NCT00305279|OTHER|Dietary|Dietary
40750620|NCT00305279|OTHER|Dietary|Dietary
40750621|NCT00305279|OTHER|Dietary|Dietary
40750622|NCT06300229|DRUG|Denosumab|Subcutaneous injection with 60 mg Denosumab once
40750623|NCT06300229|DRUG|sodium chloride|Subcutaneous injection with NaCl once
40750624|NCT03058016|OTHER|Personalized recommendations for diet|Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions
40750625|NCT04652843|PROCEDURE|Rectosignoidoscopy|Rectosignoidoscopy for colonic biospsies collection
40750626|NCT04652843|PROCEDURE|Coloscopy|Coloscopy for colonic biospsies collection
40750627|NCT05058638|DRUG|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
40750628|NCT00673114|BIOLOGICAL|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
40750629|NCT00852982|BEHAVIORAL|Exercise|Nordic walking, with walking poles, five hours per week during four months
40750630|NCT01717859|DRUG|Tocilizumab|All subjects will start at 4mg/kg. After 3 months, if DAS28 \> 3.2, dosage will be escalated to 8 mg/kg.
40750631|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).
40750632|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|
40750633|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|35mg/35 infusion time is 3.5 minutes
40750634|NCT04878926|PROCEDURE|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block
40750635|NCT04878926|PROCEDURE|IV midazolam and propofol-based sedation with Local Anesthetic infiltration|IV midazolam and propofol-based sedation with Local Anesthetic infiltration
40750636|NCT01953354|BIOLOGICAL|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
40750637|NCT01953354|BIOLOGICAL|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
40750638|NCT02739828|BIOLOGICAL|Adalimumab|Adalimumab
40750639|NCT03360487|RADIATION|Photobiomodulation in the sublingual region|In the group submitted to sublingual irradiation, disposable plastic wrap will cover the application pen for the purposes of hygiene, and irradiation will take 10 minutes.
40750640|NCT03360487|RADIATION|Photobiomodulation in the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
40750641|NCT03360487|RADIATION|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
40750642|NCT01386320|PROCEDURE|Ultrasound guided ankle block|Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
40750643|NCT01386320|PROCEDURE|Medial forefoot block|Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
40750644|NCT05465876|BIOLOGICAL|EVUSHELD|EVUSHELD is a combination of 2 monoclonal antibodies (mAbs), Tixagevimab and Cilgavimab. The single dose, is to be administered intramuscular, each mAb sequentially into the deltoid
40750645|NCT05085405|BEHAVIORAL|Clinician notification|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
41453280|NCT02420353|DRUG|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
40750646|NCT05085405|BEHAVIORAL|Clinician Notification with Nurse Facilitation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
40750647|NCT05085405|BEHAVIORAL|Clinician Notification / Patient Activation|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
40750648|NCT05085405|BEHAVIORAL|Clinician Notification with Nurse Facilitation / Patient Activation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
40750649|NCT01132690|DRUG|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
40750650|NCT05486702|OTHER|Time Restricted Eating|Time restricted eating (TRE) can be divided into early TRE (eTRE) and late TRE (lTRE), depending on the time of day of the eating window.
40750651|NCT01279187|DRUG|Teriparatide|20ug per day,via subcutaneous injection, for 7 weeks
40750652|NCT01279187|DRUG|Placebo|20ug per day, self administered injection, for 7 weeks
40750653|NCT06509919|DIAGNOSTIC_TEST|Blood draw|Before undergoing a prostate biopsy, participants will have about 10 mLs of venous blood drawn. Blood will be sent to Geneseeq Technology Inc. for whole genome high-throughput sequencing of plasma cfDNA.
40750654|NCT01289587|BEHAVIORAL|Physical activity intervention|36 sessions of physical activity offered at different frequencies
40750655|NCT06355687|DRUG|Melatonin|Obese patients undergoing laparoscopic cholecystectomy will receive melatonin oral (0.2 mg /kg) 45 minutes before general anesthesia.
40750656|NCT06355687|DIETARY_SUPPLEMENT|Vitamin Supplement|Obese patients undergoing laparoscopic cholecystectomy will receive placebo medication (Vitamin Supplement) 45 minutes before general anesthesia.
40750657|NCT02712242|OTHER|Platelet Rich Fibrin|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.
40750658|NCT02712242|OTHER|Butyl cyanoacrylate|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.
40750659|NCT02712242|OTHER|Wet gauze|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.
40750660|NCT05789342|DRUG|GP681|GP681, tablet, oral
40750661|NCT05789342|DRUG|Rosuvastatin|Rosuvastatin, tablet, oral
40750662|NCT05789342|DRUG|Digoxin|Digoxin, tablet, oral
40750663|NCT05789342|DRUG|Itraconazole|Itraconazole, capsule, oral
40750664|NCT05789342|DRUG|Oseltamivir|Oseltamivir, capsule, oral
40750665|NCT00919490|DRUG|ABT-333|Tablet, see arms for interventional description
40750666|NCT00919490|DRUG|Placebo|Tablet, see arms for interventional description.
40750667|NCT03676725|DRUG|Lidocaine gel|Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)
41270455|NCT04355988|PROCEDURE|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
40750668|NCT01795131|DIETARY_SUPPLEMENT|Vitamin B12|
40750669|NCT01795131|DIETARY_SUPPLEMENT|Placebo|
40750670|NCT00792389|OTHER|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
40750671|NCT00792389|OTHER|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
40750672|NCT01111370|DEVICE|DexCom™ G4 Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
40750673|NCT01610388|DRUG|500mg IV GSK1322322/placebo|500mg IV
40750674|NCT01610388|DRUG|1000mg oral GSK1322322/placebo|1000mg oral
40750675|NCT01610388|DRUG|1000mg IV GSK1322322/placebo|1000mg IV
40750676|NCT01610388|DRUG|1500mg oral GSK1322322/placebo dose|1500mg oral
40750677|NCT01610388|DRUG|1500mg IV GSK1322322/placebo|1500mg IV
41270456|NCT03335540|BIOLOGICAL|Nivolumab|Specified dose on specified day
40750678|NCT01610388|DRUG|2000mg IV GSK1322322J/placebo|2000mg IV
40750679|NCT01610388|DRUG|3000mg IV GSK1322322J/placebo|3000mg IV
40750680|NCT01610388|DRUG|1000mg IV GSK1322322J/placebo|1000mg IV
40750681|NCT00787488|DEVICE|Hyperthermia|Every 3 weeks
40750682|NCT05268120|DRUG|doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
40750683|NCT05268120|DRUG|trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
40750684|NCT03158779|COMBINATION_PRODUCT|SBRT and chemotherapy|Patients affected by locally unresectable pancreatic cancer receive integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and a Stereotactic Body Radiation Therapy with a total dose of 54 Gy in 6 fractions of 9 Gy /fractions.
40750685|NCT03142451|DRUG|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
40750686|NCT03142451|DRUG|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
40750687|NCT05302232|DIAGNOSTIC_TEST|depomedrone 40mg/ml + 1% lidocaine|Response to intra-articular injection of lidocaine as a diagnostic marker of peripheral pain
40750688|NCT05302232|DIAGNOSTIC_TEST|depomedrone 40mg/ml+ 0.9% saline|Response to intra-articular injection of steroid only as a placebo
40750689|NCT05302232|OTHER|painDETECT questionnaire|painDETECT questionnaire
40750690|NCT00351104|DRUG|Ketoprofen Topical Patch 20%|
40750691|NCT03868800|OTHER|SDM-DC|The SDM-DC intervention is designed for patients with kidney failure who must make a decision regarding type of dialysis: haemodialysis or peritoneal dialysis. SDM-DC consists of patient and his or her relative(s) being given a patient decision aid called 'Dialysis choice' and booked for meetings with a dialysis coordinator. There were optional videos describing other patients' experiences making this decision. The dialysis coordinators were trained in the why, what and how in relation to SDM-DC and to deliver the intervention by tailoring to patients' needs and using three different communication skills: mirroring, active listening and value clarification.
40750692|NCT00366535|DRUG|Placebo|4 tabs b.i.d.
40750693|NCT00366535|DRUG|Neurotropin|4 tabs b.i.d.
40750694|NCT01704560|OTHER|Coversheet to Informed Consent|The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
40750695|NCT04612621|DIAGNOSTIC_TEST|combination of diagnostic tests|capsule endoscopy, MRE , intestinal ultrasound, fecal microbiota, blood and serum biomarkers as described
40750696|NCT00655746|DRUG|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
40750697|NCT00647023|DRUG|metformin|1000 mg metformin x 2 daily during 8 months
40750698|NCT03053830|DRUG|Ketamine|0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval
40750699|NCT05682144|BIOLOGICAL|Autologous Plasmablasts (B cells)|Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
40750700|NCT03506308|DEVICE|LUTONIX 035 Drug Coated Balloon PTA Catheter|All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
40750701|NCT02885922|DRUG|anti-diabetic drug|Add-on anti-diabetic drug in type 2 diabetic patients
40750702|NCT04799873|DRUG|AAT( Alpha 1 Antitrypsin)|AAT administration based on clinical indication
41270457|NCT03335540|BIOLOGICAL|Relatlimab|Specified dose on specified day
40750703|NCT01857154|DIETARY_SUPPLEMENT|Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate."
40750704|NCT01857154|DIETARY_SUPPLEMENT|Non-Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate."
40750705|NCT01857154|DIETARY_SUPPLEMENT|Vitamin D3|All subjects in the study cohort will be administered 800 IU Vitamin D3.
40750706|NCT05916287|BIOLOGICAL|Blood and urine samples|Blood and urine samples
40750707|NCT05916287|GENETIC|Blood samples|Blood samples
40750708|NCT05916287|OTHER|Cardiovascular assessment|Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).
40750709|NCT05916287|BEHAVIORAL|Dietary intake|Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire
40750710|NCT05916287|OTHER|Anthropometric parameters|Measurement of height, weight, abdominal circumference, hip circumference, arm circumference
40750711|NCT05916287|OTHER|Hemodynamic parameters|Systolic pressure index measurement
41270458|NCT03335540|BIOLOGICAL|Cabiralizumab|Specified dose on specified day
41270459|NCT03335540|BIOLOGICAL|Ipilimumab|Specified dose on specified day
41270460|NCT03335540|DRUG|IDO1 Inhibitor|Specified dose on specified day
41270461|NCT03335540|RADIATION|Radiation Therapy|Specified dose on specified day
40750712|NCT05916287|OTHER|Hemodynamic parameters|Heart rate measurements, blood pressure measurements, orthostatic BP measurements
40750713|NCT05916287|OTHER|Hemodynamic parameters|"Blood pressure measurements by unattended BP monitor over 5 min"
40750714|NCT05916287|OTHER|Hemodynamic parameters|Electrocardiogram
40750715|NCT05916287|BEHAVIORAL|Assessment of compliance with antihypertensive treatments for treated participants|EVALOBS scale and compliance questionnaire
40750716|NCT05916287|OTHER|Ambulatory 24 hours measurment of blood pressure|For the first 100 patients willing to participate
40750717|NCT05916287|BIOLOGICAL|24 hours urinary collection|For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick
40750718|NCT05916287|OTHER|General questionnaires|Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)
40750719|NCT05916287|OTHER|Women specific questionnaire|Women specific questionnaire
40750720|NCT05916287|BEHAVIORAL|Women specific questionnaire|Women specific questionnaire
40750721|NCT05916287|DIAGNOSTIC_TEST|NYHA dyspnea questionnaire|Determination of NYHA class.
40750722|NCT05916287|BEHAVIORAL|Anxiety questionnaire|Assessment of anxiety
40750723|NCT05916287|BEHAVIORAL|Epworth Sleepiness Scale|sleep quality assessment
40750724|NCT05916287|OTHER|"A questionnaire on the perception of the management of cardiovascular risk factors"|Patient's evaluation of cardiovascular risk factors by the health system
40750725|NCT05916287|BEHAVIORAL|A questionnaire on eating behaviors|Assessment of eating behaviors
40750726|NCT05916287|BEHAVIORAL|A questionnaire on eating habits to determine consumer profiles|Assessement of eating habit to create a consumer profile
40750727|NCT05916287|DIETARY_SUPPLEMENT|A questionnaire on food supplements use|Evaluation od food supplements intake
40750728|NCT05916287|OTHER|SARS-CoV-2 Infection Questionnaire|SARS-CoV-2 Infection Questionnaire
40750729|NCT05916287|OTHER|Instantaneous expired air analysis|Carbon monoxyde analysis in expired air
40750730|NCT05916287|BIOLOGICAL|Capillary sampling|Capillary sampling for pollutant analysis (Optional)
41095637|NCT05098236|OTHER|Training in the Sighted Field|This training will take place in lab at the University of Rochester Medical Center. Subject will perform one daily training session, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the visual field. The computer program will automatically create a record of patient performance during each training session. Subjects will train daily (about 30-40 minutes total), 5 to 7 days per week for at 7 - 14 days.
41095638|NCT04759339|DRUG|AG-920|AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%
41095639|NCT05376488|OTHER|One meal|One meal given to assess impact on ammonia levels serially
40750731|NCT01248390|BEHAVIORAL|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
40750732|NCT01899287|BEHAVIORAL|group education|"The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
40750733|NCT04607785|DRUG|Miswak mouthwash group|Twice daily for seven days for two months
40750734|NCT04607785|DEVICE|Chlorhexidine gluconate mouthwash|Twice daily for seven days for two months
40750735|NCT02820103|BEHAVIORAL|Text+Visual BCT-based intervention|Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.
40750736|NCT02820103|BEHAVIORAL|Text-only BCT intervention|Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.
40750737|NCT02820103|BEHAVIORAL|Leaflet information (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
40750738|NCT02548364|DRUG|Calcifediol|calcifediol treatment
40750739|NCT02548364|DRUG|Placebo|placebo control group
40750740|NCT00335621|DRUG|Inhaled Tiotropium|
40750741|NCT04464902|DEVICE|brace1|The brace1 can provide resistance when patients want to extend their knee.
40750742|NCT04464902|DEVICE|brace2|The brace1 can't provide resistance when patients want to extend their knee.
40750743|NCT04464902|OTHER|No Intervention|Control Group don't have any brace.
40750744|NCT03685240|BEHAVIORAL|SafelyYou Fall Prevention System|Technology + Quality Assurance Services Provided by SafelyYou
41095640|NCT01696565|DRUG|PG2|Injectable
40750745|NCT04757844|DEVICE|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octamon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
40750746|NCT02256878|DRUG|BIRT 2584 XX|
40750747|NCT02256878|DRUG|Amitriptyline|
40750748|NCT01011296|DRUG|PF-04427429|Single 0.2mg dose of intravenous infusion
40750749|NCT01011296|DRUG|PF-04427429|Single 1mg dose of intravenous infusion
40750750|NCT01011296|DRUG|PF-04427429|Single 3 mg dose of intravenous infusion
40750751|NCT04419974|DIAGNOSTIC_TEST|Molecular Diagnosis|Double-blind molecular diagnosis for the SCA3/MJD mutation.
40750752|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Baseline|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
40750753|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Baseline|"Blood collection on baseline for evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
40750754|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Baseline|Participants fill out 2 self-reported quality of life questionnaires.
40750755|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Follow-up 12 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.
40750756|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Follow-up 12 months|"Blood collection 12 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
40750757|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Follow-up 12 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
40750758|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Follow-up 24 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.
40750759|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Follow-up 24 months|"Blood collection 24 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
40750760|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Follow-up 24 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
40750761|NCT01181765|BIOLOGICAL|Infliximab 5 mg/kg body weight infused over 2 hours|Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
40750762|NCT06013085|BEHAVIORAL|cognitive behavioral therapy|6 weeks cognitive behavioral therapy
40750763|NCT00098293|DRUG|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
40750764|NCT00098293|DRUG|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
40750765|NCT00098293|DRUG|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
40750766|NCT02178189|OTHER|High Calorie Infant formula|Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
41453281|NCT02420353|DRUG|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
40750767|NCT02178189|OTHER|Standard Calorie Infant Formula|Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
40750768|NCT03074643|BEHAVIORAL|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
40750769|NCT03074643|BEHAVIORAL|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
40750770|NCT03074643|DIETARY_SUPPLEMENT|Carbohydrate supplement for months 0-6|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (\~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
40750771|NCT03074643|DIETARY_SUPPLEMENT|Protein supplement for months 0-6|Participants in the higher protein / lower CHO diet groups (6-mon HiProt and 18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
40750772|NCT03074643|DIETARY_SUPPLEMENT|Protein supplement for follow-up months 7-18|Participants in the higher protein / lower CHO diet (18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 12-month follow-up.
40750773|NCT01603511|DEVICE|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
40750774|NCT01714388|DRUG|Remifentanil|1mcg/kg iv dose, followed by 5 minutes ECG recording
40750775|NCT01428128|DRUG|Arsenic Trioxide|IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
40750776|NCT03760731|BEHAVIORAL|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
41095641|NCT03988062|DEVICE|TrelliX Embolic Coil System|Embolic coil with shape memory polymer
40750777|NCT03760731|BEHAVIORAL|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right.
40750778|NCT05852574|DRUG|CP-101|"CP101 is an investigational oral microbiome drug designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent CDI.~CP101 contains live microbial communities, derived from rigorously screened human donor stool that is tested, stabilized, characterized, and formulated into capsules designed specifically for delivery into the small bowel for release, to avoid potential degradation by gastric acid."
40750779|NCT05852574|DRUG|CP-101 + Placebo|The placebo in this trial will be presented in capsules that are identical in size, smell, texture, and appearance to those of the CP101 capsules. These will be produced by the BWH investigational drug service
40750780|NCT00620802|DRUG|CGT-2168|(CGT-2168, one capsule each daily)
40750781|NCT00620802|DRUG|Plavix|(clopidogrel, 75 mg)
40750782|NCT02407977|OTHER|Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter ( nanoFOD) for real time dosimetric monitoring of external beam radiotherapy.
40750783|NCT02831036|OTHER|training program|subjects in the trial group will follow a training program which includes 3 times a week running on a treadmill.
40750784|NCT02831036|OTHER|VO2max test|each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.
40750785|NCT02831036|OTHER|spatial orientation test|each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
40750786|NCT00923702|BIOLOGICAL|Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)|The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.
40750787|NCT00404300|DRUG|Optivate|Plasma-derived Factor VIII
40750788|NCT03315559|DRUG|[14C]-GSK2269557 IV infusion|The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
40750789|NCT03315559|DRUG|GSK2269557 via DPI|GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
40750790|NCT03315559|DRUG|[14C]-GSK2269557 oral solution|The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
40750791|NCT00193986|DEVICE|Arbitrary Waveform Defibrillator|
40750792|NCT02399800|PROCEDURE|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
40750793|NCT02399800|PROCEDURE|No Celiac Block|EUS but no celiac block performed
40750794|NCT02399800|DRUG|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
40750795|NCT05199038|DRUG|Octreotide|Octreotide infusion for 2 days in patients with bleeding esophageal varices.
40750796|NCT00689988|BEHAVIORAL|speech-language therapy with AAC intervention|speech-language intervention in weekly 40-minutes sessions, without the presence of parents or caregivers, and 5 to 10-minutes to parents training and orientation
40750797|NCT01370889|DRUG|resveratrol|Given PO
40750798|NCT01370889|OTHER|laboratory biomarker analysis|Correlative studies
40750799|NCT05343429|DRUG|Benzydamine hydrochloride|In BN group,15 ml of 0.15 % Benzydamine hydrochloride (BN) will be dissolved in 15 ml plain water in a sterile container and given to participants before anesthesia for surgery
40750800|NCT05343429|DRUG|Aspirin|In group AP, Aspirin (AP) 600 mg Aspirin tablets dissolved in 30 ml of plain water in a sterile container will be given to participants for gargling before anesthesia for surgery
40750801|NCT01641783|DRUG|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
40750802|NCT00478140|BIOLOGICAL|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
40750803|NCT00478140|OTHER|laboratory biomarker analysis|Correlative studies
40750804|NCT01801969|OTHER|Rehabilitation service|"* Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.~* Size of the municipality responsible for providing rehabilitation services after discharge from hospital"
40750805|NCT00512044|PROCEDURE|Local anesthesia (pudendal block)|local anesthesia as indicated
40750806|NCT00512044|PROCEDURE|general anesthesia (spinal and general)|general according to guidelines
40750807|NCT00469027|BIOLOGICAL|eNOS transfected EPCs will be delivered via a PA line|incremental dosing over 3 days
40750808|NCT02449447|BEHAVIORAL|Cognitive behavioral therapy|CBT based on behavioral activation and cognitive therapy techniques including homework
40750809|NCT02449447|OTHER|Treatment as usual|Treatment as usual in primary care including antidepressants and counselling
40750810|NCT02458300|OTHER|Nebulization of hypertonic saline|application of hypertonic saline serum through a mask fogging or a box fogging
40750811|NCT02458300|OTHER|Prolonged slow expiration technique (PSE)|Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
40750812|NCT02458300|OTHER|Patient coughing Provocation (TP)|Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
40750813|NCT02458300|OTHER|inspiratory maneuver to rhinopharyngeal cleaning DRR|After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
40750814|NCT02458300|OTHER|Aspiration of secretions|Suctioning with a probe by a vacuum system installed on the wall.
40750816|NCT02468375|DRUG|mirabegron 50mg|434 OAB patient intake mirabegron 50mg/day for 12 weeks.
40750817|NCT03331562|DRUG|Pembrolizumab|pembrolizumab solution for infusion
40750818|NCT03331562|DRUG|paricalcitol|Paricalcitol solution for injection
40750819|NCT03331562|DRUG|placebo|normal saline solution for injection
40750820|NCT04162483|DEVICE|Neuroform Atlas Stent System|Stenting Assisted coiling procedure
40750821|NCT06383143|OTHER|no intervention|no intervention
40750822|NCT02105142|BEHAVIORAL|ADHD Group Visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
40750823|NCT02105142|BEHAVIORAL|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
40750824|NCT02105142|BEHAVIORAL|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
40750825|NCT00812097|DEVICE|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
40750826|NCT05845593|OTHER|Decision Support Test|LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE
40750827|NCT03409146|DEVICE|Monica Novii Wireless Patch System|The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.
40750828|NCT05099276|DRUG|Tranexamic Acid Pill|1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
40750829|NCT05099276|DRUG|Placebo|Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
40750830|NCT00832962|GENETIC|Genotyping|Whole blood sample
40750831|NCT00832962|OTHER|Usual prophylaxis|Prophylactic anti-RhD
40750832|NCT06005155|DRUG|Lithium|Sustained long-term exposure
40750833|NCT05632900|PROCEDURE|Endoscopic ultrasound guided drainage of walled off pancreatic necrosis|It is Therapeutic procedure to treat walled off pancreatic necrosis.
40750834|NCT05768464|DRUG|Toripalimab|240mg intravenously every 3 weeks
40750835|NCT05768464|DRUG|Axitinib|5mg orraly twice daily
40750836|NCT01371682|DRUG|Ropinirole XL|Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
40750837|NCT01430884|OTHER|Aspirated Coronary Blood|Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
40750838|NCT03930108|OTHER|SOFA score|Variables of sequential organ failure assessment score, including: P:F ratio; MAP or vasoactive treatment; creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS.
40750839|NCT04772924|BEHAVIORAL|fasting|more than 12 hour of fasting as ceremony of Ramadan
40750840|NCT04772924|BEHAVIORAL|not fasting|preferred not to take long term fasting
40750841|NCT04322695|BEHAVIORAL|Rehabilitation Education Care Program|The RECP contained the following domains: (1) assessment and detection of disability; (2) home exercise; (3) activities to improve mobility; (4) dietary management; (5) patient education; and (6) vocational counseling.
40750842|NCT04632030|BEHAVIORAL|Tobacco power wall size and tobacco products displayed|The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.
40750843|NCT01783782|BEHAVIORAL|DIET|clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
40750844|NCT01783782|DRUG|polyethylene glycol 4000 solution with simethicon|patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
40750845|NCT01783782|DRUG|simethicon|Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
40750846|NCT06323720|OTHER|Quantitative Sensory Testing|Assessment of the heat and cold pain thresholds, temporal summation, conditioned pain modulation, pressure pain thresholds, electrical pain thresholds, and withdrawal reflex.
40750847|NCT01144351|DRUG|ELND002|
40750848|NCT01144351|DRUG|Placebo|
40750849|NCT00236678|DRUG|Epoetin alfa|
40750850|NCT04583826|DEVICE|CAVA|CAVA is a medical device containing 5 face-mounted ECG electrodes which are used to record the movement of the eyes.
40750851|NCT01559285|DRUG|0.75% ropivacaine concentration|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
40750852|NCT01559285|DRUG|0.375% ropivacaine concentration|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
40750853|NCT01559285|DRUG|0.2% ropivacaine concentration|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
40750854|NCT00992394|DRUG|etanercept|etanercept 50 mg once weekly as requested.
40750855|NCT00992394|DRUG|etanercept|etanercept 25 mg or 50 mg as requested.
40750856|NCT04165980|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
40750857|NCT04640961|DEVICE|Cingal|Single injection into the shoulder joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
40750858|NCT00732459|DEVICE|Electro-acupuncture preconditioning|electro-acupuncture
40750859|NCT00513630|DRUG|Glipizide|
40750860|NCT00513630|DRUG|Metformin|
40750861|NCT01216280|DRUG|placebo capsule|2 x 10 mg placebo capsules administered orally with water, b.i.d.
40750862|NCT01216280|DRUG|10 mg Natura-alpha capsule and 10 mg placebo capsule|10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
41270462|NCT03633188|BIOLOGICAL|Patients treated by antibiotherapy|"Biological samples (stool, blood, swabs) will be collected :~* Blood sampling (12 ml) at baseline (week 0) at the end of treatment (W6/W24),and 15 days after antibiotherapy stop (optional) (W8/W26),~* Feces collection at baseline (week 0) during antibiotic treatment (W2), at the end of treatment (W6/W24),15 days after antibiotherapy stop (W8/W26), and W26 after baseline~* Swab samples (nasal and rectal) at baseline at week 0 and at the end of treatment (W6/W24),"
40750863|NCT01216280|DRUG|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
40750864|NCT04718389|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be provided in a single-use prefilled syringe (PFS).
40750865|NCT04718389|BIOLOGICAL|Mepolizumab|Mepolizumab will be provided in a single-use PFS.
40750866|NCT04718389|BIOLOGICAL|Benralizumab|Benralizumab will be provided in a single-use PFS.
40750867|NCT04718389|BIOLOGICAL|Placebo|Placebo will be a sterile liquid formulation.
40750868|NCT04718389|DRUG|Standard of care (SoC)|Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
40750869|NCT04718389|DEVICE|Pre-filled Syringes (PFS)|PFS will include glass barrel with pre-staked needle and plunger.
40750870|NCT05467137|DEVICE|MSOT|MSOT imaging (after ICG injection)
40750871|NCT00002316|DRUG|Lobradimil|
40750872|NCT00002316|DRUG|Amphotericin B|
40750873|NCT01766089|DRUG|Remifentanil|Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
40750874|NCT01766089|DRUG|Dexmedetomidine|dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
40750875|NCT01521364|DRUG|Addition of different doses of clarithromycin.|"At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks."
40750876|NCT01991574|DRUG|Calcium acetate|
40750877|NCT01991574|DIETARY_SUPPLEMENT|Iron Hydroxide Adipate|
40750878|NCT01991574|DRUG|Placebo|methylcellulose capsules
40750879|NCT06482424|OTHER|intervention group|"Actions to be taken to the Intervention Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. The aromatic oil given to patients in the intervention group will be placed in 10ml dark glass bottles with droppers and a numbered label will be attached to the bottle.~Procedures to be Performed on the Placebo Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. Sesame oil given to patients in the placebo group will be placed in 10 ml dark glass bottles with droppers and a number two label will be attached to the bottle."
40750880|NCT06011200|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
40750881|NCT06011200|BIOLOGICAL|MSPV4|1 dose of MSPV4 on Day 0
40750882|NCT02990143|PROCEDURE|Ologen|Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
40750883|NCT04942873|OTHER|adherence|PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
40750884|NCT04506710|BEHAVIORAL|Audio recording of the counseling conversation|The patient will have an audio-recorded counseling conversation. Audio recording will be carried out using a portable recorder ZOOM H2n. The audio recordings of the counseling conversations will be performed by the health workers selected to participate in the study.
40750885|NCT05451888|BEHAVIORAL|Spa treatment|A 40 minute period of lying in the spa treatment pool
40750886|NCT00795795|PROCEDURE|Preimplantation Genetic Screening|Preimplantation Genetic Screening
40750887|NCT00795795|PROCEDURE|IVF without PGS|IVF without PGS
40750888|NCT00394537|DRUG|Labetalol 10mg iv|
40922386|NCT04870697|BEHAVIORAL|ACT intervention|"The components of ACT intervention will include six processes to foster parental PF according to the ACT framework.~Session one - Generate creative hopelessness and build acceptance. The objective is to help parents know about the ACT intervention and realize the experiential avoidance or emotional control strategies do not work, finally turn attention to more useful strategies.~Session two - Create space for your thought. The objective is to help parents create a distance from their thoughts and facilitate parents' ability of not being trapped by thoughts.~Session three - Focus on here and now. The objectives to facilitate parents' experiences of observing self and contact with the present moment but not trapped in the past or future.~Session four - Commit actions in line with the value. The objectives to help parents identify their inner value and take value-based actions even facing the challenges in current difficulties of their children with cancer."
41270463|NCT05148026|DRUG|Unfractionated heparin + RCA first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA / UFH
41270464|NCT05148026|DRUG|Unfractionated heparin first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH / UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA
40750889|NCT01761227|DRUG|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
40750890|NCT01761227|DRUG|Placebo|Placebo for 3 tablets per time, 3 times per day for 24 weeks
40750891|NCT02400736|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is the evidenced based model of supported employment.
40750892|NCT02400736|OTHER|Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)|Vocational Rehabilitation Treatment as Usual includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW).
40750893|NCT00295243|DRUG|Topotecan|
40750894|NCT04126668|DRUG|CM082 with fed or fasting|The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
40750895|NCT03329248|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
40750896|NCT03329248|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
40750897|NCT03329248|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
40750898|NCT03329248|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
40750899|NCT03329248|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
40750900|NCT03329248|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
40750901|NCT03329248|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
40750902|NCT03329248|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
40750903|NCT03329248|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
40750904|NCT03329248|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
40750905|NCT03329248|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
40750906|NCT03329248|DRUG|lovaza|Omega-3-acid ethyl esters
40750907|NCT03329248|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
41270465|NCT04223245|BEHAVIORAL|exercise+multi-modal sensory feedback (MMSF)|home program of 3 stepping exercises and 3 balance exercises with progression of speed, step distance and reduced vision. Real-time sensory feedback during ex. using ankle, wrist wts., laser on chest and mat with footpads and clickers (auditory feedback during stepping)
41270466|NCT04223245|BEHAVIORAL|Exercise only|3 stepping and 3 balance exercises which are to progress in speed and distance of movement as well as progress to eyes closed while performing.
40750908|NCT03329248|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
41270467|NCT05782829|DIETARY_SUPPLEMENT|L-tyrosine supplementation|L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia
41270468|NCT05782829|DIETARY_SUPPLEMENT|Placebo supplementation|Placebo supplementation before surgery for inguinal hernia under general anaesthesia
40750909|NCT04555369|GENETIC|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
40750910|NCT00991003|PROCEDURE|Colon capsule endoscopy|The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.
41270469|NCT04409847|DIAGNOSTIC_TEST|ABPM|24 hour ambulatory blood pressure monitoring
40750911|NCT00991003|PROCEDURE|Conventional Colonoscopy|
41270470|NCT04409847|DIAGNOSTIC_TEST|ECG|Electrocardiogram
41270471|NCT04409847|DIAGNOSTIC_TEST|FMD|Flow mediated dilatation
41270472|NCT04409847|DIAGNOSTIC_TEST|PWV|Pulse wave velocity
41270473|NCT04409847|DIAGNOSTIC_TEST|Rarefaction|nailbed capillaroscopy
41270474|NCT05541783|PROCEDURE|laparoscopy-assisted distal gastrectomy Group|LADG
40750912|NCT01864694|BEHAVIORAL|TLC-Diet|Participants receive diet intervention through an automated telephone system
40750913|NCT01864694|BEHAVIORAL|WEB-Diet|Participants receive diet intervention through a web-based system
40750914|NCT01864694|OTHER|Assessment-only control|Assessment-only control
40750915|NCT02968394|DRUG|omalizumab|
40750916|NCT03165903|BEHAVIORAL|Cue and Implementation Intention-Based Intervention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption. The intervention consisted of a 90-minute meeting with a trained Health Coach, two 20-minute phone calls, 4 tailored newsletters, and a series of emails and text messages. Cues for snacking and sweetened beverage consumption were removed or relocated and implementation-intentions were created to trigger alternative behaviors to snacking and sweetened beverage consumption in the presence of cues. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
40750917|NCT03165903|BEHAVIORAL|Control arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
40750918|NCT00073047|DRUG|Daclizumab|
40750919|NCT05573737|OTHER|education|education about ubilical cord care
41270475|NCT05541783|PROCEDURE|Totally laparoscopic distal gastrectomy|TLDG
40750920|NCT03072875|DEVICE|CAMS-RAS|
40750921|NCT04636138|OTHER|Exercise|Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.
40750922|NCT06107673|DRUG|Dalpiciclib|Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks. It is recommended to take the medication approximately at the same time each day, with warm water, preferably on an empty stomach. Fasting for at least 1 hour before and after medication is advised.
40750923|NCT06107673|DRUG|Aromatase inhibitor|AI: Take according to the instructions provided.
40750924|NCT06107673|DRUG|Docetaxel injection|Administered as a 75 mg/m2 intravenous infusion over approximately 30 minutes. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
40750925|NCT06107673|DRUG|Epirubicin Hydrochloride Injection|Administered as a 75 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
40750926|NCT06107673|DRUG|Cyclophosphamide injection|Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
40750927|NCT06271070|OTHER|Non-intervention|Non
40750928|NCT02813824|DRUG|Acetylsalicylic acid lysinate 300 mg|Daily dose during 4 years
40750929|NCT02813824|DRUG|Placebo (for Aspirin 300)|Daily dose during 4 years
40750930|NCT02813824|DRUG|Acetylsalicylic acid lysinate 100 mg|Daily dose during 4 years
40750931|NCT02813824|DRUG|Placebo 100 (for Aspirin 100)|Daily dose during 4 years
40750932|NCT01243125|DRUG|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
40750933|NCT01243125|DRUG|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
40750934|NCT02201628|DEVICE|Nasopharyngeal and oesophageal temperature probes|
40750935|NCT03246854|DRUG|DBPR112|DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
40750936|NCT04333654|DRUG|Hydroxychloroquine SAR321068|Pharmaceutical form:Tablet Route of administration: Oral
40750937|NCT04333654|DRUG|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
40750938|NCT03907956|OTHER|Dry Needling with Fascial Winding Technique|"For placement of Dry Needling (DN) needles with Fascial Winding Technique (FWT) according to the Four-pole Carpal Dry Needling (FCDN) approach model, only anatomical references are used, in all cases from a carpal ventral approach. The needles used are the Chinese type with silver handle and guide tube, measuring 25x0.30 mm., Agupunt® brand. Four needles are placed, at the level of the bones: scaphoid, pisiform, trapezius and hamate. The four needles follow an oblique direction, always on the back and looking for the midline of the center of the carpal tunnel, with an inclination of approximately 45º, both in the cranio-caudal and medial-lateral directions. In each of the needles, it deepens until it reaches a firm elastic stop, attributable to the Transverse Carpal Ligament. Next, the FWT is applied to each of the needles, consisting of rotating them in the same direction until you feel the final stop of the needle grasp."
40750939|NCT06255587|OTHER|Screening|cross sectional
40750940|NCT06017375|OTHER|Questionnaire based intervention|Three validated questionnaires amended from hepatitis B to D (Chronic liver disease questionnaire, self-stigma scale and HBV virus knowledge scale) will be used.
40750941|NCT03708289|RADIATION|DXA scan|total and hip and spine dual energy x-ray absorptiometry
41095642|NCT03265873|OTHER|Systematic consideration of the advice of the ENT surgeon in the determination of the radiotherapy target volumes in head and neck cancers.|The contouring of the different target volumes will be first performed by the radiotherapists. During the Head and Neck Tumor Board, the volumes initially determined by the radiotherapists will be analyzed jointly by the radiotherapists and the patient's ENT surgeon to carry out, if necessary, modifications, taking into account clinical observations, intraoperative findings (if any) and endoscopy findings. Concordance parameters will be calculated in a second time with the determined volumes (in particular, index of concordance, coefficient of similarity).
41095643|NCT01809964|BIOLOGICAL|ANT-1401|
40750942|NCT03708289|OTHER|Achilles bone US|
40750943|NCT03708289|OTHER|Medical body composition measurements|
40750944|NCT03708289|OTHER|Resting energy expenditure measurement|
40750945|NCT00003812|BIOLOGICAL|filgrastim|
40750946|NCT00003812|DRUG|carboplatin|
40750947|NCT00003812|DRUG|etoposide|
40750948|NCT00003812|DRUG|paclitaxel|
40750949|NCT00003812|DRUG|topotecan hydrochloride|
40750950|NCT00003812|RADIATION|radiation therapy|
40750951|NCT01060111|DRUG|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
40750952|NCT01060111|DRUG|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
40750953|NCT01060111|DRUG|Propranolol booster|Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
40750954|NCT01450267|DRUG|Inhaled Reduced Glutathione|10 mg/kg, twice daily, 12 months
40750955|NCT01450267|DRUG|Physiological solution|0,13 ml/kg body weight, twice daily, 12 months
40922387|NCT04870697|OTHER|Usual care|Usual care in this study setting includes providing general information, education, psychological support, and consultation.
40922388|NCT02972385|PROCEDURE|Mouthwash sample|A one time mouthwash sample will be performed.
41095644|NCT01809964|BIOLOGICAL|Vehicle|
41095645|NCT03061955|BIOLOGICAL|influenza vaccination|administration of influenza vaccination
40750956|NCT04443777|OTHER|Resistance Training|Both groups will perform the resistance training protocol that will consist of a warm-up on the bench press and leg press, both with workload at 50% of 1-RM. After a 2-minute rest, the resistance training session will be started. It will consist of 4 sets of bench press and leg press exercises at 65% of 1-RM with maximum repetitions until concentric failure, with the execution speed of 2x2. The bench press exercises will be followed by the leg press exercises with no interval between them. A 2-minute interval will allowed after each series of exercises.
40750957|NCT03116087|DRUG|Testosterone patch|300 mcg testosterone patches or placebo applied twice weekly
40750958|NCT03116087|DRUG|Placebo|Placebo patch
40750959|NCT04228315|DRUG|Primaquine|radical cure dosing
40750960|NCT00667589|DRUG|urea 40% cream|urea 40% cream applied twice per day to affected areas
40750961|NCT00667589|DRUG|fluocinonide 0.05% cream|fluocinonide 0.05% cream applied twice per day to affected areas
40750962|NCT00667589|DRUG|tazarotene 0.1% cream|tazarotene 0.1% cream applied twice per day to affected areas
40750963|NCT00667589|DRUG|bland emollient cream (Udderly smooth® Udder Cream)|bland emollient cream applied twice per day to affected areas
40750964|NCT02474901|BIOLOGICAL|Quadrivalent Live Attenuated Influenza Vaccine|
40750965|NCT06500715|DEVICE|Acupuncture|Acupuncture will be administered bilaterally on points PC6, LI 4, CV6, SP6, SP10 and ST36 on the first day of each cycle (d1), prior to administration of chemotherapy; and on d8, each session lasting between 30 to 45 minutes. Patients will continue from d1 to d8 with press-tack acupuncture needles on points PC 6, LI4, SP 6 and ST 36. On d8, patients will again undergo acupuncture, and continue with self-acupressure on the same points as the press-tack needles, until the next chemotherapy cycle.
40750966|NCT00135161|PROCEDURE|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
40750967|NCT03430570|BEHAVIORAL|Tablet TRAC Emotion Regulation Intervention|The intervention focuses on developmentally appropriate strategies for emotion regulation during difficult situations, particularly those related to risk, using 3 primary groups of strategies identified during qualitative work in Project TRAC (R34 MH078750): 1) getting away (physically or cognitively) from triggers for strong emotions, 2) releasing emotional energy in healthy ways (physically or verbally) or 3) changing cognitions and appraisals about emotional triggers. Using strategies effective in TRAC, teens will engage in games to practice and apply strategies to risk scenarios, as well as personalize content learned.
40750968|NCT04311580|COMBINATION_PRODUCT|intravesical electromotive administration of mitomycin|
40750969|NCT02916433|DRUG|Octreotide|
40750970|NCT05875077|DRUG|Dexmedetomidine|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
40750971|NCT05875077|DRUG|Propofol|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
40750972|NCT05014230|DIETARY_SUPPLEMENT|Open Placebo|Zeebo
40750973|NCT05014230|OTHER|Opioid medication as part of standard care|Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.
40750974|NCT05343507|DRUG|Ketalar 50 MG/ML Injectable Solution|Intravenous solution (other info already provided)
40750975|NCT05343507|DRUG|Placebo|Saline Solution
40750976|NCT03691870|PROCEDURE|Standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
40750977|NCT03691870|PROCEDURE|Trans-Venous Embolization (TVE)|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session.~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion."
40750978|NCT00746161|PROCEDURE|Reconstruction after total gastrectomy|Roux-en-Y
40750979|NCT00746161|PROCEDURE|Reconstruction after total gastrectomy|double tract reconstruction
40750980|NCT01319461|DEVICE|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
40750981|NCT01319461|DEVICE|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
40750982|NCT03667729|BEHAVIORAL|progressive muscle relaxation|intervention group: The experimental group received muscle relaxation training once a week for 3 consecutive months. The results were measured and followed up after 3 months.
40750983|NCT01053052|DEVICE|Sonography with FemVue, and HSG|Sono HSG for FDA 510(k) cleared indication for use
40750984|NCT03396458|DIAGNOSTIC_TEST|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg, anti-HBs and anti-HBc).
40750985|NCT03396458|OTHER|Questionnaire|Participants will be asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection (e.g. sharing toothbrushes, HBV infected family member) and HBV vaccination status.
40750986|NCT00163735|DRUG|Administration of wine fined with potential food allergens|
40750987|NCT02216162|OTHER|Arm A: adapted physical activity + enhanced geriatric follow-up|"Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36)."
40750988|NCT02216162|OTHER|No intervention|Usual clinical follow-up
40750989|NCT00112307|PROCEDURE|Brachytherapy|
40750990|NCT05018819|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41270476|NCT01412853|OTHER|MR-Spectroscopy|response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
40750991|NCT06500728|DIAGNOSTIC_TEST|Fluorescein and Indocyanine green Angiography|The ophthalmologist frequently recommends fluorescein (FAG) and indocyanine green angiography (ICGA) at baseline (T0) to evaluate retinal and choroidal vascularisation. They can be repeated also after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4) or 26 ± 2 weeks (T5).
40750992|NCT06500728|DIAGNOSTIC_TEST|High-resolution Optical Coherence Tomography|The ophthalmologist often suggests performing HR-OCT initially (T0) to assess the width of the macula and optic nerve with potential signs of ischemic lesions in these areas. This assessment can also be repeated after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
40750993|NCT06500728|DIAGNOSTIC_TEST|Angio-Optical Coherence Tomography|The ophthalmologist often suggests OCT-A at the beginning (T0) to assess the retinal and choroidal vascularization. These tests can also be done after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
40750994|NCT06328231|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
40750995|NCT03907423|DRUG|Rosuvastatin10 mg tablet|Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
40750996|NCT03907423|DRUG|Placebo Oral Tablet|Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
40750997|NCT06460909|OTHER|Psychological support|An interview with the psychologist before surgery.
40750998|NCT01986751|DRUG|Clonidine|
40750999|NCT01986751|DRUG|ropivacaine|
40751000|NCT00500110|DRUG|Docetaxel|30 mg/m\^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
40751001|NCT00500110|DRUG|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
40751002|NCT00500110|DRUG|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
40751003|NCT00500110|DRUG|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
40751004|NCT02113046|PROCEDURE|pancreatico-jejunal anastomosis|
40751005|NCT02113046|PROCEDURE|traditional anastomosis|
40751006|NCT05075681|DRUG|Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide.~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
40751007|NCT06323525|BIOLOGICAL|TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T)|Phase 1 dose escalation (3+3): dose 1 (1 × 10\^6 cells/kg), dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2: dose of RP2D.
40751008|NCT06323525|DRUG|Fludarabine|Intravenous fludarabine 25\~30 mg/m\^2/day on days -5, -4, and -3.
41453282|NCT04396392|BEHAVIORAL|VR-based training|"All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to."
40751009|NCT06323525|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
40751010|NCT02692261|PROCEDURE|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
40751011|NCT02692261|PROCEDURE|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
40751012|NCT00417729|DRUG|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
40751013|NCT03197935|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab was administered as per schedule described in respective arm.
41095646|NCT06439862|OTHER|Children with PUV|Male children aged 6 to 17 years old treated for PUV in their first year of life between 2006 and 2018 in Lyon, and managed in the Femme-Mère-Enfant Hospital in Lyon
40751014|NCT03197935|DRUG|Placebo|Placebo matched to atezolizumab was administered as per schedule described in respective arm.
40751015|NCT03197935|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered as per schedule described in the arms.
40751016|NCT03197935|DRUG|Doxorubicin|Doxorubicin was administered as per schedule described in the arms.
40751017|NCT03197935|DRUG|Cyclophosphamide|Cyclophosphamide was administered as per schedule described in the arms.
40751018|NCT03197935|DRUG|Filgrastim|Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
40751019|NCT03197935|DRUG|Pegfilgrastim|Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
40751020|NCT05807750|OTHER|Post-discharge income supplement|$300 income supplement
40751021|NCT05807750|OTHER|Enhanced care planning|Enhanced care planning provided by a nurse care manager
40751022|NCT03016403|BEHAVIORAL|Stepped-Care Intervention|The intervention delivered evidence-based CBT and stress management across eight counseling sessions.
40751023|NCT03016403|BEHAVIORAL|Enhanced Usual Care|Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
40751024|NCT04187690|DRUG|Jin-shui Huan-xian granule|Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
40751025|NCT04187690|DRUG|Jin-shui Huan-xian granule placebo|Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
40751026|NCT02372084|DRUG|osilodrostat|
40751027|NCT01749566|DRUG|maraviroc|Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
40751028|NCT02596984|DRUG|Caspofungin|Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation
40751029|NCT02765971|OTHER|gums|Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
40751030|NCT02765971|DRUG|picolax drops|Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
40751031|NCT02765971|DRUG|normal saline|Group C received 500 cc of normal saline, Intravenous fluid
40751032|NCT02919345|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
40751033|NCT02919345|DRUG|Glibenclamide 5 mg|Glibenclamide 5 mg in addition to Metformin 1500 mg/day
40751034|NCT03352180|PROCEDURE|arthroscopic reapir of subscapularis tendon|arthroscopic reapir of massive rotator cuff tears involving the subscapularis.
40751035|NCT03352180|PROCEDURE|arthroscopic debridement of subscapularis tendon|arthroscopic debridement of massive rotator cuff tears involving the subscapularis.
40751036|NCT05605080|DEVICE|Gelfoam|Use Gelfoam as a hemostatic agent after anal surgery.
40751037|NCT05605080|OTHER|Bosmin gauze|Use bosmin gauze as a hemostatic agent after anal surgery.
40751038|NCT03276481|DIAGNOSTIC_TEST|Oral microbiota assessment|Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
40751039|NCT03276481|DIAGNOSTIC_TEST|Comprehensive chemical gustometry|Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
40751040|NCT03276481|DIAGNOSTIC_TEST|Measurement of salivary flow|Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
40751041|NCT03276481|BEHAVIORAL|Surveys assessing taste disturbances|Surveys will be administered and examine taste disturbances pre and post HCT.
40751042|NCT03028922|DEVICE|creos xenogain|GBR procedure will be performed using creors xenogain bone graft substitute in patients that need horizontal bone augmentation prior to implant placement. The defect should be located in the pre-molar and molar region of the mandible
41270477|NCT04505683|DRUG|Benapenem|Benapenem for IV injection administered as a 1-gram IV infusion
40751043|NCT06480110|DRUG|Docetaxel + Ebastine|Ebastine is administered once daily.
40751044|NCT06480110|DRUG|Docetaxel|docetaxel every three weeks
40751045|NCT01630811|DRUG|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
40751046|NCT01630811|OTHER|Placebo|Placebo will be given once daily for 7 days.
40751047|NCT05013086|DRUG|1.48 GBq of 177Lu-AB-3PRGD2|accepted intravenous injection of 177Lu-AB-3PRGD2
41270478|NCT04505683|DRUG|Ertapenem|Ertapenem for IV injection administered as a 1-gram IV infusion
41270479|NCT01151683|DIETARY_SUPPLEMENT|magnesium|Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
41270480|NCT01151683|DIETARY_SUPPLEMENT|placebo|Two capsules of placebo per oral twice a day
41270481|NCT06546020|DIETARY_SUPPLEMENT|Haskap berry smoothie|A smoothie blend of berries and water
41270482|NCT06546020|DIETARY_SUPPLEMENT|Placebo comparator|A smoothie with no polyphenolic content and matched in carbohydrate composition to the experimental haskap smoothie
40751048|NCT01436292|DRUG|5% human albumin solution (HAS)|"Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; \< 10 gr/L: 150 g of 5% HAS."
40751049|NCT01277068|PROCEDURE|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
40751050|NCT00003107|BIOLOGICAL|recombinant interleukin-12|
41270483|NCT03855501|OTHER|Mineral trioxide aggregate|Apexification treatment was done with mineral trioxide aggregate
41270484|NCT03855501|OTHER|Calcium hydroxide|Apexification treatment was done with calcium hydroxide
40751051|NCT03566550|DIAGNOSTIC_TEST|MRI scans|Repeated MRI scans imaging digestion of standard meals
40751052|NCT00198744|BEHAVIORAL|Medifast FIT! for Kids|
40751053|NCT00198744|BEHAVIORAL|standard recommendations for dietary intake in children|
40751054|NCT00198744|BEHAVIORAL|both diet plans with and without a parent dieting|
40751055|NCT02706548|BEHAVIORAL|Integrative Medication Self Management (IMedS) Intervention|Half of participants received a manualized 30-minute occupational therapy intervention, Integrative Medication Self-Management Intervention (IMedS). During IMedS, the interventionist and client progress through three steps in which the pair: 1) reflect on past performance of medication management, 2) set a medication goal, and 3) generate strategies to reach the goal. During strategy generation, the interventionist uses therapeutic use of self and motivational interviewing to help the client self-generate new medication management strategies, specifically addressing 1) altering the activity, 2) advocacy, 3) education, 4) assistive technology, 5) environmental modifications, and 6) securing timely refills.
40751056|NCT02706548|BEHAVIORAL|Standard Care Educational Intervention|The standard care educational intervention was a 30-minute pamphlet based educational session. In the standard care intervention group, participants and interventionist first reviewed the pamphlet, Managing Your Medicines: Our Guide to Effective Medication Management (American Heart Association \& American Stroke Association, 2013). Then, the interventionist engaged in active listening, where she asked open-ended questions about the participant's medication routines and provided simple reflections. For the standard care procedures, the interventionist was prohibited from providing affirmations, complex reflections, summaries, problem-solving, or suggesting any specific interventions.
40751057|NCT05154162|DIAGNOSTIC_TEST|PSMA PET/CT|PSMA PET/CT (limited to the pelvis)
40751058|NCT05154162|PROCEDURE|Transperineal template prostate biopsy|Transperineal template prostate biopsies will be performed as per treating urologist's usual practice. No specific template for biopsy is prescribed for the purposes of the study. However, template sampling of the prostate is required, with a minimum of 12 cores, dependent on prostate volume. MRI will be available for any additional targeted biopsies required. Transperineal template biopsies must be labelled appropriately and sent for histopathological analysis.
40751059|NCT05154162|PROCEDURE|Transperineal targeted prostate biopsy|If the PSMA PET/CT is normal, transperineal prostate biopsy would be omitted If the PSMA PET/CT is abnormal, transperineal prostate biopsies would be performed targeting the MRI (done prior to study) and PSMA PET/CT images
40751060|NCT00901095|BEHAVIORAL|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
40751061|NCT05922280|OTHER|subtalar and talo-crural mobilization|"Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory mobilizations of 2Hz with 120 oscilations per minute, 3 sets for 5 minutes with 1 min of rest between sets at subtalar and talocrural joint would be performed. The mobilization would be large amplitude rhythmic oscillations from the joint mid into end-range muscle spasm/stiffness (translation taken to tissue resistance). Duration will be 20 minutes with 2 sessions per week, total 12 sessions would be performed on each patient in the total period of 6 weeks.~Patients will be guided to follow self foot care examination given by IWGDF Guidelines."
40751062|NCT05922280|OTHER|International Working Group of the Diabetic Foot care guidelines|"Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, self- examination for callus, pre-ulcerative signs or deformity. They will be restrict barefoot walking in-door and outdoors. To wash their feet daily with careful drying, to use emollients to prevent dryness and cut their nails straight across. Monitor the foot skin temperature for inflammation, wear orthotic insoles for preventing abundant callus.~Patients will perform active ROM exercises 5 times per week for duration of 30 minutes for 6 weeks:Ankle pumps, Supination and Pronation, Drawing score from 0 to 9, Leg Flexion and Extension"
40751063|NCT05726279|DEVICE|NIRS based personalized blood pressure management|In lieu of predetermined blood pressure treatment thresholds, an optimal MAP range will be chosen based on limits of autoregulation calculated in real-time for the previous four hours for each participant. Choice of medications and dosing will be left to the primary clinical obstetrics team.
40751064|NCT04791852|DIAGNOSTIC_TEST|Donor-derived Cell Free DNA|We will compare ddcfDNA with coronary angiogram determined CAV grading, according to ISHTL2010 classification
40751065|NCT00153478|BEHAVIORAL|Brief Motivational Counseling|
40751066|NCT00094666|DRUG|MK0928, gaboxadol / Duration of Treatment - 6 weeks|
40751067|NCT00094666|DRUG|Comparator: placebo / Duration of Treatment - 6 weeks|
40751068|NCT01489358|BIOLOGICAL|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
40751069|NCT04678297|BEHAVIORAL|Physical activity + emotion regulation intervention|The intervention meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention will be led by certified instructors trained in working with back pain patients. The instructor leads participants through a series of physical activity exercises at a slow-moderate pace. Participants will be asked to practice every day for 20 minutes to maximize the benefit of the intervention. Participants also receive a home practice manual containing some basic, safe postures that can be performed on days they are not attending the formal in-person sessions.
40922389|NCT02972385|PROCEDURE|Blood Draw|Patients who are receiving a blood draw during their regular clinical appointment will be asked for a blood sample of 15 milliliters. Genomic DNA will be isolated for genotyping and patient plasma samples will also be stored.
40922390|NCT06299371|DRUG|Adebrelimab|Adebrelimab IV
40922391|NCT06299371|DRUG|paclitaxel for injection (albumin bound)|paclitaxel for injection (albumin bound) IV
40922392|NCT06299371|DRUG|Cisplatin or Carboplatin|Cisplatin or Carboplatin IV
40922393|NCT05592860|DEVICE|Mobile application|participants in intervention group will use smart phone application and update glucose level and investigator will adjust the insulin accordingly
40751070|NCT04678297|BEHAVIORAL|Physical activity control intervention|The interventions meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention is designed to require a similar amount of physical exertion. Classes involve conventional exercises appropriate for patients with CLBP, including a comprehensive set of exercises that stretch all the major muscle groups, with an emphasis on the trunk and legs. The intervention will include all 12 stretching exercises used in the exercise intervention of previous studies that have successfully used it in comparison to yoga, plus 3 additional stretches (hip internal rotators, hip adductors and hip flexion).Participants will be asked to practice every day for 20 minutes home as well. Printed handouts will be provided to facilitate home practice. In addition, a video demonstrating all the exercises will be provided to assist participants in practicing safely. Classes will be led by a licensed physical therapist who has previous experience leading exercise classes.
40751071|NCT01783015|DRUG|Etanercept|Etanercept 50 mg once-weekly
40751072|NCT01783015|DRUG|Etanercept|Etanercept 50 mg once-weekly
40751073|NCT01783015|DRUG|Placebo|Etanercept placebo once-weekly
40751074|NCT01783015|DRUG|Placebo|Etanercept placebo once-weekly
40751075|NCT06500897|DEVICE|VEST|External MEsh Support for safein vein
40751076|NCT01722734|BEHAVIORAL|Text message reminders|Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
40751077|NCT04172064|DIAGNOSTIC_TEST|Myocardial perfusion scintigraphy|
40751078|NCT02585167|PROCEDURE|operation|the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.
40751079|NCT02585167|DEVICE|VAAFT|Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
40751080|NCT06300905|DRUG|test product|toothpaste containing 0.45% stannous fluoride
40751081|NCT06300905|DRUG|Control product|toothpaste containing 0.76% sodium monofluorophosphate
40751082|NCT04167761|DRUG|Ertugliflozin|Consenting participants in the Ertugliflozen group will be supplied with 2-week course of medication prior to cardiac surgery. Participants will be educated on use and have blood glucose monitored during the medication course. The surgeon will then collect a small amount of fat near the heart during surgery.
40751083|NCT04167761|DRUG|Glipizide|Consenting participants in the Glipizide group will be supplied with 2-week course of medication prior to cardiac surgery. Participants will be educated on use and have blood glucose monitored during the medication course. The surgeon will then collect a small amount of fat near the heart during surgery.
40751084|NCT01091532|DRUG|UK-396,082|"100mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
40751085|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
40751086|NCT01091532|DRUG|UK-396,082|"300mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
40751087|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
40751088|NCT01091532|DRUG|UK-396,082|"1000mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
40751089|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
40751090|NCT01091532|DRUG|UK-396,082|"UK-396,082 given orally, once on Days 1 \& 14, and twice daily on Days 3-13.~The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
40751091|NCT01091532|DRUG|placebo|given orally, once on Days 1 \& 14, and twice daily on Days 3-13.
40751092|NCT04656080|BEHAVIORAL|CPET exercise testing|"* The cardiopulmonary exercise testing (CPET) is done.~* EKG testing will be done as part of the CPET test. Allosure testing will be done at baseline and then at 1 hr, 4 hrs, 1 day, 7 days after CPET."
40751093|NCT00356421|DRUG|Inhaled Human Insulin (Exubera®)|Preprandial inhaled insulin regimen and administration of insulin glargine QD
40751094|NCT00356421|DRUG|Insulin lispro (Humalog)|Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
40751095|NCT03363438|OTHER|no intervention survey|there was no intervention this was a survey
40751096|NCT06293287|DRUG|Subcutaneous enoxaparin sodium|Subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily
40751097|NCT06293287|DRUG|Placebo|placebo (0.9% saline solution)
40751098|NCT00452530|DRUG|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
40751099|NCT00452530|DRUG|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
40751100|NCT00452530|DRUG|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
40751101|NCT00452530|DRUG|Apixaban-matching placebo|Oral tablet administered twice daily
40751102|NCT04935294|DRUG|Danicopan|Oral tablet.
40751103|NCT03428555|BEHAVIORAL|Integrated Care Pathway|The intervention is a integrated care pathway based on the NICE Clinical Practice Guidelines and measurement-based care in the form of a flow chart. Each decision point on the pathway is guided by results of self-report measures for depression (the Mood and Feelings Questionnaire), functional impairment (Columbia Impairment Scales) and family functioning (the McMaster Family Assessment Device). The results of these scales and protocol recommendations are fed back to the patients, families and clinicians in order to make further treatment decisions
40751104|NCT03428555|BEHAVIORAL|Treatment As Usual|Treatment As Usual represents what clinicians would typically do when presented with an adolescent with depression. There is no algorithm provided to guide clinical decision-making and no systematic measurement-based care.
40751105|NCT04171310|DRUG|SAR442168|Pharmaceutical form:oral solution Route of administration: Oral
40751106|NCT06458400|DRUG|Tegileridine|single dose+PCA dose
40751107|NCT06458400|DRUG|Oliceridine|single dose+PCA dose
40751108|NCT06458400|DRUG|Morphine|single dose+PCA dose
40751109|NCT03812874|DRUG|PTX-9908 Injection|"Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II)."
40751110|NCT03812874|DRUG|Placebo|"water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)"
40751111|NCT05708599|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy
40751112|NCT06059079|OTHER|No Intervention|No Intervention
40751113|NCT02655809|RADIATION|Fluoroscopic examination|
40751114|NCT02227966|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
40751115|NCT02227966|DEVICE|Sham-Yband (YDT-201N)|tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
40751116|NCT01885234|OTHER|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
40751117|NCT01885234|OTHER|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
40751118|NCT03555045|PROCEDURE|conducting the slanted recession technique on the superior and inferior poles|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
40751119|NCT03555045|PROCEDURE|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
40751120|NCT00416754|OTHER|counseling intervention|subjects will receive genetic counseling
40751121|NCT04645056|OTHER|Stretching and Mobility exercises for neck and shoulder|9 specific stretching and mobility exercises performed 3 times every day the first 4 weeks after surgery.
40751122|NCT00567801|PROCEDURE|conventional embolectomy/thrombectomy|
40751123|NCT00567801|PROCEDURE|embolectomy/thrombectomy with controlled reperfusion|
40751124|NCT00620035|DRUG|Radiopaque Etonogestrel Implant|One implant inserted for a 3-year treatment period
40751125|NCT00002390|DRUG|Abacavir sulfate|
40751126|NCT05721027|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg PO every 8 hours as needed for 7 days
40751127|NCT05721027|DRUG|Dexamethasone Oral|Dexamethasone 16 mg PO during ED visit and next day
40751128|NCT05721027|BEHAVIORAL|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
40751129|NCT00762788|DEVICE|senofilcon A|1 week extended wear contact lens
40751130|NCT00762788|DEVICE|lotrafilcon A|1 week extended wear contact lens
40751131|NCT00762788|DEVICE|lotrafilcon B|1 week extended wear contact lens
40751132|NCT00762788|DEVICE|balafilcon A|1 week extended wear contact lens
40751133|NCT00762788|DEVICE|comfilcon A|1 week extended wear contact lens
40751134|NCT00762788|DEVICE|etafilcon A|1 week extended wear contact lens
40751135|NCT02223130|BEHAVIORAL|Cognitive Behavioral Therapy techniques|Participants attend 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who use Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions and behaviors in response to stressful/discrimination experiences.
40751136|NCT00006457|DRUG|oltipraz|
40751137|NCT02061592|DEVICE|etafilcon A|
40751138|NCT02061592|DEVICE|etafilcon A|
40751139|NCT00582829|OTHER|Generic Print Intervention|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
40751140|NCT00582829|OTHER|Tailored Print Intervention|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
40751141|NCT00582829|OTHER|Tailored print plus tailored phone intervention|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
40751142|NCT00964444|DEVICE|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
40751143|NCT03598764|PROCEDURE|Classic head extraction during Cesarean section|by putting the fingers of the right inside the lower uterine segment to deliver the head
40751144|NCT03598764|PROCEDURE|External pop out technique|The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
40751145|NCT00270075|DRUG|epoetin alfa|
40751146|NCT01301001|DRUG|Placebo oral capsule|Placebo 2 capsules am and 3 capsules pm
40751147|NCT01301001|DRUG|Gabapentin|Gabapentin 1200 mg am and 1800 mg pm
40751148|NCT03479684|OTHER|Gene-directed dosage of warfarin|the first day given model prediction dose \* 1.5 times（\<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
40751149|NCT03479684|OTHER|standard dosage of warfarin|the first day given 4.5mg; adjusted dose based on INR from the second day
40751150|NCT02468700|DRUG|Dexamethasone|
40751151|NCT02468700|OTHER|Placebo Vehicle|
40751152|NCT04411095|OTHER|Measuring thoracic rotation mobility|Measuring the thoracic rotation mobility with a goniometer, from a standardized position
40751153|NCT02131493|DRUG|S-1, Gemcitabine|
40751154|NCT01451203|DRUG|Placebo|Subcutaneous (SC)
40751155|NCT01451203|DRUG|CZP|SC
40751156|NCT01451203|DRUG|methotrexate (MTX)|oral
40751157|NCT04457778|DRUG|M6223|Participants will receive an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.
40751158|NCT04457778|DRUG|Bintrafusp alfa|Participants will receive an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.
40751159|NCT04457778|DRUG|M6223|Participants will receive an IV infusion of M6223 at escalated doses Q2W on Day 1 of each Cycle (Each cycle is of 21 days) according to the recommendation of the SMC until the MTD has been reached or confirmed disease progression.
40751160|NCT05471661|BIOLOGICAL|Pentavalent-specific T cells (penta-STs)|Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
40751161|NCT01423890|GENETIC|ONCOTYPEDX Test|Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
40751162|NCT03938415|PROCEDURE|Acupuncture|Acupuncture involving the Koffman protocol (body acupuncture) for anxiety control (needles will be placed at bilateral LR-3, bilateral LI-4, GV 24.5 and GV 20) and Auricular ATP Plus (ear) for pain control (needles will be placed at points hippocampus, amygdala, hypothalamus, prefrontal cortex, Point Zero, Shen Men, vagus, insula, external genitalia). Subjects who tolerate the auricular needles will be offered replacement with ASP acupuncture needles for continued pain management post-procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
40751163|NCT03938415|OTHER|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone (which include diazepam 5 mg by mouth (PO) x1 30 minutes prior to the procedure, an additional 5 mg PO x1 15 minutes later if desired effect is not achieved; and oxycodone/acetaminophen 5/325 mg PO x 1 30 minutes prior to the procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
40751164|NCT04078308|BIOLOGICAL|Intravenous Injection of autologous mesenchymal stem cells|Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 \& 3
40751165|NCT04078308|OTHER|Intravenous injection of placebo|Intravenous injection of normal saline (sodium chloride 0.9%)
40751166|NCT06217146|DRUG|Medical Cannabis|MediCane's medical cannabis oil
40751167|NCT06217146|DRUG|Placebo Oil|Placebo Oil
40751168|NCT02216877|DRUG|Mablet 360 mg|
40751169|NCT02216877|DRUG|Placebo|
40751170|NCT01530256|BIOLOGICAL|ALD518|160 mg IV q 4 weeks for 4 doses
40922394|NCT05592860|BEHAVIORAL|Daily Diary|participants will use daily diary to record glucose level
40922395|NCT02470637|DRUG|SAR439065|"Pharmaceutical form:dry powder insulin~Route of administration: inhalation"
40922396|NCT02470637|DRUG|Insulin lispro|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
40751171|NCT01530256|BIOLOGICAL|ALD518|320 mg IV q 4 weeks for 4 doses
40751172|NCT01530256|BIOLOGICAL|ALD518|640 mg IV q 4 weeks for 2 doses
40751173|NCT02802865|DRUG|Clomiphene|
40751174|NCT02802865|DRUG|Letrozole|
40751175|NCT02569242|DRUG|Nivolumab|
40751176|NCT02569242|DRUG|Docetaxel/Paclitaxel|
40751177|NCT00576394|DRUG|IV Insulin drip|IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
40751178|NCT00576394|DRUG|Insulin|IV insulin drip to keep serum glucose between 80-120mg/dl.
40751179|NCT04056637|OTHER|Choice of follow-up option|Participant will be given the opportunity to choose from 3 follow-up options.
40751180|NCT04056637|DEVICE|Multi-level pregnancy test|The Multi-level pregnancy test (MLPT) strategy involves the use of the MLPT to estimate a pregnant person's baseline hCG range prior to beginning their abortion (i.e. prior to mifepristone administration). A follow-up test is then administered one week later to again estimate the woman's hCG range. A decline in hCG range reliably signifies absence of an ongoing pregnancy. Among clients ≤63 days' LMP at initiation of treatment, this strategy has shown to be highly effective: 100% of clients (n=1487/1487) with a decline in hCG range did not have an ongoing pregnancy and 100% of clients (n=21/21) with an ongoing pregnancy showed steady or increase in hCG range on their follow-up MLPT.
40751181|NCT05296655|OTHER|Reflux Symptom Index Inventory (diagnostic survey)|Kazakh versions of the Reflux Symptom Index Inventory will be filled patients
40751182|NCT05296655|OTHER|Reflux finding score|laryngoscopy with a score RFS
40751183|NCT03434509|OTHER|Continuous Tai Chi and Mindful Movement classes|"Participants will be enrolled in ongoing Tai Chi and mindful movement classes throughout the year, for 1 hour twice a week.~Class sessions will consist of warm up (yoga- and mindfulness-based practices), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing)."
40751184|NCT01236807|PROCEDURE|MR perfusion guidance|Coronary revascularization guided by MR perfusion imaging
40751185|NCT01236807|PROCEDURE|FFR guidance|Coronary revascularization guided by invasive angiography and FFR
41095647|NCT04816682|DRUG|Silymarin|Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
40751186|NCT05507892|DRUG|canagliflozin|Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is a used to treat type 2 diabetes. Canagliflozin lowers blood sugars by causing the kidneys to excrete more glucose in the urine.
40751187|NCT05507892|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure renal plasma flow (RPF) PAH (Basic Pharma, Geleen, Netherlands) has been used to measure RPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
40751188|NCT00302666|DRUG|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
40751189|NCT00302666|DRUG|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
40751190|NCT01356485|DRUG|MP4CO|43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution
40751191|NCT01356485|DRUG|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
40751192|NCT04264962|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
40751193|NCT04264962|OTHER|Routine medical care|Routine medical care
40751194|NCT01311583|BEHAVIORAL|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
40751195|NCT02242110|BEHAVIORAL|ERRT-Bipolar Disorder|The nightmare treatment, called Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder, is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
40751196|NCT00744419|DRUG|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose \[0.4 mg/kg (\< 44 wks PMA) or 0.8 mg/kg (44 wks to \< 1 yr)\] and the last 6 subjects in each age group will receive high dose \[0.8 mg/kg(\< 44 wks PMA) or 1.6 mg/kg(44 wks to \< 1 yr)\]
40751197|NCT03519607|BEHAVIORAL|FertiStrong App|The FertiStrong mobile app is similar to FertiCalm, which is designed for women with infertility. FertiCalm (www.FertiCalm.com) can be downloaded for free anywhere in the US, for both Apple and Android phones. Each app contains twelve main categories and each main category contains up to five tailored situations. For each situation, there are six options. Three of the options are the same for all situations (humor, self-nurture, relaxation) and three are unique (cognitive solutions, behavioral solutions, social solutions).
40751198|NCT05469061|DRUG|Tislelizumab|The 1st to 3rd doses were administered concurrently with FP regimen chemotherapy, 200 mg Tislelizumab each, on D1, D22 and D43 by intravenous infusion. In patients with successful conversion, one dose of 200 mg was administered 21 days after surgery in concurrent with the 4th to 6th cycles of 5-Fu, then 6 cycles of 200 mg Tislelizumab as adjuvant therapy; in patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
40751199|NCT05469061|DRUG|5-FU|A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. 3 cycles of 5-Fu 850mg/m\^2 d1-4 adjuvant chemotherapy were started at 21 days after surgery in patients with a successful conversion. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
40751200|NCT05469061|DRUG|cis Platinum|A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
40751201|NCT01992471|BEHAVIORAL|Pre-test Assessment|Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
40751202|NCT01992471|BEHAVIORAL|Pre test Counseling|Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
40751203|NCT01992471|OTHER|Blood draw|After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.
40751204|NCT01992471|BEHAVIORAL|Post-test counseling, and post-test assessment|When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
40751205|NCT01992471|BEHAVIORAL|Follow-up assessments (6 and 12 months)|At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
40922397|NCT04922047|DRUG|tislelizumab and BCG|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).
40922398|NCT00773045|OTHER|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
40922399|NCT03769610|OTHER|Inpatient Foley catheter|
40751206|NCT06456268|DEVICE|VibraCool mechanical stimulation and neuromodulatory therapeutic device|"Multiple studies have shown that vibration sources applied to muscles prior to exercise reduced soreness and lactate dehydrogenase production, and increased range of motion at 48 and 72 hours. Acute pain results from fast A nerves transmitting nociceptive information to the dorsal column, where the substantia gelatinosa's interneurons prioritize competing A mechanoreceptor and C-fibers to slow pain transmission. One study observed that stimulation of A mechanoreceptors shut the gate on pain transmission, an inhibitory mechanism known as gate control. Multiple physical methodologies leverage gate control physiology for pain relief, such as vibratory massage therapy and electrical stimulation to varying degrees. However, the use of vibratory massage to improve pain control and reduce opioid use following ACLR has not been well studied, and to our knowledge there are no randomized control trials (RCTs) evaluating the use of this modality compared to standard ice or cryocompression."
40751207|NCT06456268|DEVICE|Cryocompression (Game Ready, Bregs) device|Cryotherapy has also been used as an adjunctive post-operative therapy to reduce pain and inflammation following anterior cruciate ligament reconstruction (ACLR). It has been shown to decrease local metabolism, resulting in reduced pain and inflammation. Multiple studies have shown the benefits of using cryotherapy after ACLR, and more recently dynamic intermittent compression has been shown to improve circulation while reducing the risk of skin necrosis associated with static permanent compression. A recent meta-analysis including ten RCTs found significant reductions in post-operative VAS pain scores and breakthrough opioid consumption when using cryotherapy, such as Game Ready or Breggs ice therapy, following ACLR.
40751208|NCT06456268|DEVICE|Standard ice packs|Cold also provides peripheral gate-control relief via small, slow C-Fibers that transmit low level pain. In addition to local pain relief, intense cold can raise the A pain threshold distant to the location. The mechanism has been called descending or diffuse noxious inhibitory relief, or more recently conditioned pain modulation (CPM). Injections, aches, and infiltration of local anesthesia and dermal fillers are relieved by applying cold. For acute injury, near freezing cold relieves pain by suppressing the local metabolic production of inflammation and concomitant tissue ischemia from hypoxia due to the increased metabolic rate.
40751209|NCT05911009|DRUG|BC 007 or matching placebo|Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
40751210|NCT05628415|PROCEDURE|Non-powered AeonTM Endostapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the non-powered Aeon™ Endostapler (Lexington medical) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
40751211|NCT05628415|PROCEDURE|Echelon FLEX™ Powered plus Stapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the Echelon FLEX™ Powered plus Stapler (Ethicon) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
40751212|NCT02734914|DEVICE|SF-URS with automatic control of RPP|A new F-URS monitoring and control of RPP using intelligent pressure control device
40751213|NCT02734914|DEVICE|conventional F-URS|Ureteroscopy will be conducted using the ureteral access sheath from Cook Medical to treat renal calculi.
40751214|NCT01302171|DRUG|granulocyte colony stimulating factor (GCSF)|10mcg/kg per day 5 days
40751215|NCT01302171|PROCEDURE|bone marrow mononuclear cells|intra coronary injection of stem cells or placebo
40751216|NCT05045599|BEHAVIORAL|Capacity Building of Health care workers and providers to deliver integrated Family Planning and Maternal, Newborn and Child Health|Community engagement to improve awareness, and use of family planning products and services
40751217|NCT03168087|OTHER|Plasmalyte-148|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.
40751218|NCT02636491|DEVICE|MD-Logic-Automated Insulin Delivery System|"Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment."
40751219|NCT02636491|DEVICE|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
40922400|NCT03769610|OTHER|Outpatient Foley catheter|
40922401|NCT04363190|DIAGNOSTIC_TEST|Cytogenetic analysis|"1. FISH study using the UroVysion kit in interphase peripheral lymphocytes, that allows the study of numerical aberrations for chromosomes 3, 7 and 17 and locus 9p21.~2. G banding study to analyse the whole karyotype study regarding both numerical and structural aberrations during metaphase.~3. Sister chromatid exchanges (SCE) analysis with bromodeoxyuridine (BrdU) staining for the whole karyotype during metaphase: analizing the proportion of SCE per metaphase (NSM)."
41270485|NCT02357420|DRUG|Relamorelin|Double blind relamorelin was given subcutaneously BID for 12 weeks.
41270486|NCT02357420|DRUG|Placebo|Placebo given subcutaneously for 12 weeks.
41270487|NCT00997516|PROCEDURE|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
41270488|NCT00997516|PROCEDURE|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
41270489|NCT03630055|DRUG|Rivaroxaban 15 MG Oral Tablet [Xarelto]|Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.
40751220|NCT05379608|PROCEDURE|Intermittent hypoxic-hyperoxic training|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~Each patient will undergo a hypoxic test to assess the individual response to hypoxia. The minimum safe SpO2 value is 82%, and the maximum allowable heart rate increase during exercise is + 50% of the starting value. When these parameters are reached, an automatic switch to the supply of a hyperoxic gas mixture (35-40% oxygen) occurs till the SpO2 level is 100%. During each training session a hypoxic gas mixture is supplied to the patient in an intermittent mode, alternating with the supply of a hyperoxic gas mixture. On average, each workout includes 6 of the above cycles. The total time of inhalation of a hypoxic gas mixture during one procedure is 20-30 minutes."
40751221|NCT05379608|PROCEDURE|Intermittent hypoxic-hyperoxic training/control|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~A control group of 30 patients will undergo a simulated IHHT course (with the same exposure time and number of sessions as intervention group - 15 sessions, 40-minutes long each, 5 workouts per week for 3 weeks). Patients of this group will breathe normoxic gas mixture (ordinary humidified air is supplied through the mask) during the entire session."
40751222|NCT06072261|OTHER|kinesio tape application|"Before the standard rehabilitation program, kinesio taping was applied to both upper extremities in the form of a Y tape from the medial epicondyle to the wrist flexors, with 15-20% tension, to the patients hospitalized in the orthopedic service after lower extremity surgery. The tape should remain on the patient's arm throughout the hospital stay"
40751223|NCT06427174|DRUG|Fascia iliaca block|For the group who will receive the fascia iliaca block .... After induction of the general anesthesia and before skin incision, fascia iliaca block will be performed in the patient while he is in the supine position
40751224|NCT06427174|DRUG|Caudal block|second group will receive the caudal block, we use bupivacaine 0.5 mg / kg.
40751225|NCT02510482|OTHER|No intervention|
40751226|NCT05663593|DRUG|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
40751227|NCT05663593|DRUG|Placebo, tablet|Matching placebo
40751228|NCT04037956|PROCEDURE|Tubeless NOSES|The whole procedures undergo by total laparoscopic surgery with no specimen extraction incision in the abdominal wall. The specimen then will be removed through natural orifice such (anal).
40751229|NCT04037956|PROCEDURE|traditional laparoscopic radical resection|The traditional laparoscopic operation undergo and then a small incision(5-8cm) is made in the middle of the lower abdominal wall to remove the specimen.
40751230|NCT05839509|DRUG|GH001|GH001 administered via inhalation
40751231|NCT06122051|RADIATION|Dynamic chest x-ray|Group A and Group B- posterior-anterior dynamic chest x-ray film (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
40751232|NCT06122051|DIAGNOSTIC_TEST|Spirometry|Group A and Group B- Spirometry lung function test (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
40751233|NCT03092037|PROCEDURE|Blood draw|The Investigators will collect serum and whole blood from participants.
40751234|NCT00276393|DRUG|Basal insulin|
40751235|NCT05340660|RADIATION|[ 18 F]PSS232|\[ 18 F\]PSS232 for imaging metabotropic glutamate receptor subtype 5 and comparing expression of the receptor in healthy persons and ALS patients
40751236|NCT05496699|BEHAVIORAL|Mckenzie Exercises|"1. Cervical Retraction Exercise in Sitting Position The participant sits on the chair, puts the second and third fingers on his chin and pushes his head posteriorly and inferiorly.~2. Cervical Rotation Exercise in Sitting Position~3. Cervical Retraction Exercise in Supine Position~4. Cervical Rotation Exercise in Supine Position The participant turns his head to the right and left, respectively, while taking his head back in the supine position with his head out of the bed.~5. Cervical Lateral Flexion Exercise~6. Cervical Flexion Exercise in Sitting Position"
40751237|NCT05496699|BEHAVIORAL|Mulligan Exercise|"The exercises to be applied are listed below.~1- C1-C2 Self Mobilization Slip is applied for natural apophyseal cervical right rotation. The belt is put on level C1. At the same time, the participant actively pulls the belt and turns his head to the right. To facilitate the rotation of the belt in C1, pressure is applied to the belt in the same direction as C2 and rotation of the head towards the restricted side is requested. It waits like this for 3 seconds. These movements are done in the painless range."
40751238|NCT03780712|OTHER|Non applicable|No intervention as it is an observational study
40751239|NCT03446573|DRUG|DTG + 3TC|DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.
40751240|NCT03446573|DRUG|TAF based regimen (TBR)|Participants will continue to receive their TBR.
40751241|NCT01657500|OTHER|Corneal donor storage in Optisol GS media solution|Donor tissue is preserved in the Optisol media until ready for implantation
40751242|NCT01657500|OTHER|Life 4°C solution for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
40751243|NCT00510562|PROCEDURE|Cranial osteopathic manipulation|This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
40751244|NCT00510562|PROCEDURE|Sham/Placebo|A laying on of hands with no treatment being performed.
40751245|NCT00597792|DEVICE|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
40751246|NCT00517062|DRUG|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
40751247|NCT00517062|DRUG|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
40751248|NCT04656431|DRUG|Hyperpolarized pyruvate (13C)|Given intravenously (IV) injection prior to imaging
40751249|NCT04656431|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan takes an image of brain and/or spinal cord and will take up to 45 minutes to complete
40751250|NCT04201210|OTHER|TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation|Haploidentical 5+/10 HSCT from a relative, α/β T-depleted
40751251|NCT04201210|OTHER|Matched sibling donor transplantation|10/10 HSCT - matched family donor
40751252|NCT03847090|DRUG|Reloxaliase|Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day
40751253|NCT03847090|DRUG|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
40751254|NCT02728726|DRUG|Sugammadex|Sugammadex will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
40751255|NCT02728726|DRUG|Placebo|Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
40751256|NCT04286503|DRUG|Carrimycin|Carrimycin
40751257|NCT04286503|DRUG|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
40751258|NCT04286503|DRUG|basic treatment|basic treatment
40751259|NCT01733693|DRUG|Buprenorphine|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
40751260|NCT01733693|DRUG|Methadone|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
40751261|NCT03686722|DRUG|Metformin|Metformin is used primarly in treatment of diabetes type II
40751262|NCT03686722|DRUG|Daclatasvir|Daclatsvir is a direct acting antiviral drug
40751263|NCT00715897|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
40751264|NCT00676754|PROCEDURE|Statens Serum Institut RT23 2TU tuberculin|
40751265|NCT02511769|BEHAVIORAL|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
40751266|NCT02511769|BEHAVIORAL|WEB-MAP CBT|Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
40751267|NCT00318864|BEHAVIORAL|Cognitive behavioral therapy|
40751268|NCT00823888|DEVICE|pneumatic brace|pneumatic knee brace with three trial conditions: air bladders inflated at 0psi, 7 psi, and 12 psi
40751269|NCT04102644|OTHER|Observation|Documentation of course and outcome of hospitalization, labor, delivery, and postpartum period
40751270|NCT01210911|DRUG|gemcitabine|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
40751271|NCT01210911|DRUG|erlotinib|Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
40751272|NCT01210911|DRUG|metformin|Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
40751273|NCT01210911|DRUG|placebo|Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
40751274|NCT03978156|DRUG|Dronabinol 2.5 MG|Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.
40751275|NCT03978156|DRUG|Microcrystalline cellulose|Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.
40751276|NCT02623439|DRUG|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
40751277|NCT02294019|DRUG|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
40751278|NCT03164356|DEVICE|Bioimpedance monitor|Participant in aim 1 will be monitored using the bioimpedance monitor. Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
40922402|NCT02766556|DRUG|dexmedetomidine|ISB with ropivacaine with dexmedetomidine or normal saline
40922403|NCT02766556|PROCEDURE|ISB|ISB with ropivacaine with dexmedetomidine or normal saline
40751279|NCT03710733|RADIATION|Sequential boost|Boost (10 Gy/4 fx/1 week) is given after whole breast irradiation
40751280|NCT03710733|RADIATION|Concomitant boost|Boost (8 Gy/15 fx/3 weeks) is given with whole breast irradiation
40751281|NCT00002226|DRUG|SU5416|
40751282|NCT00726427|DRUG|AZD1656|Dose escalation to achieve maximum tolerated dose
40751283|NCT00726427|DRUG|AZD1656|Oral single dose
40751284|NCT05431907|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
40751285|NCT06471166|DIAGNOSTIC_TEST|Amh hormone|Ovarian reserve
40751286|NCT00000483|DRUG|estrogen|
40751287|NCT00000483|DRUG|clofibrate|
40751288|NCT00000483|DRUG|dextrothyroxine sodium|
40751289|NCT00000483|DRUG|niacin|
40751290|NCT02998099|DRUG|Rivipansel|A single dose of IV rivipansel over 20 minutes.
40922404|NCT02766556|DRUG|Ropivacaine|ISB with ropivacaine with dexmedetomidine or normal saline
40751291|NCT05759377|DEVICE|V-A ECMO AUTO Mode algorithm|"The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings (events) has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software."
40751292|NCT04359680|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
40751293|NCT04359680|DRUG|Placebo|Placebo administered orally twice daily for six weeks
40751294|NCT04359680|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
40751295|NCT00784927|BIOLOGICAL|rituximab|
40751296|NCT00784927|DRUG|cyclophosphamide|
40751297|NCT00784927|DRUG|dexamethasone|
40751298|NCT00784927|DRUG|lenalidomide|
40751299|NCT04619030|OTHER|Augmented Reality|The patient leaflet has an Augmented Reality model that appears out of the leaflet when viewed with a smartphone
40751300|NCT04619030|OTHER|Traditional leaflet|Traditional leaflet with no Augmented Reality capability
40751301|NCT00007501|BIOLOGICAL|Varicella-zoster vaccine|Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
40751302|NCT00007501|BIOLOGICAL|Placebo|Placebo vaccine
40751303|NCT00713180|PROCEDURE|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
40751304|NCT05832814|BEHAVIORAL|Integrated training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm. For singing training, patients follow the audios and videos to take training at home, which are recorded by singing teachers and physiotherapists prior to the trial. Each session includes technical instructions in order to achieve better respiratory control during singing.
40751305|NCT05832814|BEHAVIORAL|Rhythm-guided exercise training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking test(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm.
40751306|NCT05623605|DRUG|Moringa mouthwash|using Moringa mouthwashes in 3 different concentrations (5,10,15%) twice per day for 7 days
40751307|NCT05623605|DRUG|star anise mouthwash|using star anise mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
40751308|NCT05623605|DRUG|Indian costus mouth wash|using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
40751309|NCT03097159|PROCEDURE|Costoclavicular block|Group C for costoclavicular block Group S for supraclavicular block
40751310|NCT06016660|OTHER|Physiotherapy|Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation
40751311|NCT04094636|BEHAVIORAL|In-bed cycling|Patients will daily perform 30 min of supervised in-bed cycling
40751312|NCT04094636|BEHAVIORAL|Exercise booklet|Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet
40751313|NCT05538650|BEHAVIORAL|Mindfulness-Based Social Work and Self Care (MBSWSC)|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory. This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The programme has been the subject of an initial RCT, which has helped to inform the current programme content and structure. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
40751314|NCT05538650|BEHAVIORAL|Mindfulness-Based Self-Care (MBSC)|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion/self-care. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
40751315|NCT01618708|DEVICE|Synvisc-One (hylan G-F 20)|6-mL IA injection
40751316|NCT01618708|DEVICE|Placebo|6 mL injection of phosphate buffered saline
40751317|NCT05012969|DEVICE|Hipstop bandage|12 weeks use of a bandage to prevent hip dislocations in patients with previous dislocations
40751318|NCT02737787|BIOLOGICAL|WT1 Vaccine|
40751319|NCT02737787|DRUG|Nivolumab|Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
40751320|NCT02737787|BIOLOGICAL|NY-ESO-1 Vaccine|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.
40751321|NCT03277274|DRUG|TAK-954|TAK-954 intravenous infusion.
40751322|NCT06088628|DIAGNOSTIC_TEST|Facial expression; Electroencephalogram; MRI|Recording facial expressions of participants, EEG recordings, and MRI scans.
40751323|NCT04213638|OTHER|Single Microneedle Radiofrequency therapy|Subjects are treated with three consecutive sessions of Single Microneedle Radiofrequency therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment. Each treatment session took approximately 30-60 minutes.
40751324|NCT04213638|OTHER|Photodynamic therapy|Subjects are treated with three consecutive sessions of Photodynamic therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment.
40922405|NCT01870934|DEVICE|Camera|No real intervention, but a comparison of different methods including the new medical device 3D camera.
40751325|NCT04623060|OTHER|Combination of Low-volume interval treadmill training and Resistance Training|"Low-volume interval training (LV-ITT) protocols included a 5 min warm-up (30%-50%VO2peak) up to 20min of LV-ITT and a 5 min cooling down (30%-50% VO2peak). The LV-ITT will repeat 60s bursts of fast treadmill walking at maximum tolerate speed (0% incline), alternate with pre-specified recovery periods about 4 minutes according to protocol. Each time the participants completed a burst successfully, treadmill speed will be increased by 0.1 mph for the next burst. The recovery periods will be 4 minutes. The intervention will be conducted for about 30 minutes.~Resistance training will be conducted by using a horizontal leg press machine. They are encouraged to focus on an explosive concentric movement and a controlled eccentric movement such that the time on each phase was in the ratio 1:2."
40751326|NCT03125356|OTHER|Diet Soda|Subjects will be asked to consume diet soda three times daily for eight weeks.
40751327|NCT06120530|DRUG|Bupivacaine|Intraperitoneal Bupivicaine without epinephrine 30 mg administered following completion of pelvic organ prolapse repair.
40751328|NCT06120530|OTHER|Saline|Placebo
40751329|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 10|One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg
40751330|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 20|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg
40751331|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 40|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg
40751332|NCT05007509|BIOLOGICAL|Commercial COVID-19 vaccine|One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine
40751333|NCT02552654|BEHAVIORAL|Stress Film|Film scene with severe physical and sexual violence.
40751334|NCT02552654|DRUG|Hydrocortisone|10mg
40751335|NCT02552654|DRUG|Placebo|
40751336|NCT06469580|OTHER|NPLUS (neonatologist performed lung ultrasound)|"NPLUS is conducted with an ultrasound scanner using a high-frequency (12-15 MHz) linear transducer probe (scanning depth approximately 4-5 cm). The neonate is placed in a supine position. The anterior, lateral and posterior chest areas are scanned using the presets lung or small parts. Landmarks are the anterior and posterior axillary line (longitudinal) on each hemithorax. A sequential scan from right to left, anterior to posterior is performed. (6 lung areas). In the study NPLUS is performed to quantify the lung ultrasound score at time points T0, T1 and T2. Sequences of 3-5 seconds are saved and assessed according to the lung ultrasound score adapted by Rodriguez-Fanjul et al. (0- to 3 point score for each area, resulting in a total score ranging from 0 to 18). To ensure inter-observer reliability the anonymous video sequences are then rated by two independent neonatologists."
40751337|NCT05515263|DIETARY_SUPPLEMENT|Intervention snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
40751338|NCT05515263|DIETARY_SUPPLEMENT|Control snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
40751339|NCT05574400|DRUG|Dextrose Water|Dextrose 5% in water
40751340|NCT05574400|DRUG|Caffeine citrate|Low-dose caffeine citrate (1.5 mg/kg)
40751341|NCT05574400|DRUG|Caffeine citrate|High-dose Caffeine citrate (3 mg/kg)
40751342|NCT04616235|DRUG|Tocilizumab Injectable Product|The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
40751343|NCT04616235|OTHER|Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour|The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
40751344|NCT04607616|BEHAVIORAL|Baseline sessions TAU|TAU consists of sessions lasting around one/one and a half hour ; the consultant is practicing as usual. The interventions focus on child's behavior, parent infant relationship, with moments of play with the child, advices, informations about child development and Autism.
40751345|NCT04607616|BEHAVIORAL|Interactive guidance therapy|"The objective is to reinforce the identification, deciphering, interpretation, and answer to child's signals by the parent, in order to to promote a synchronous and attuned response to the child's needs.~Sessions last around one/one and a half hour. Parent plays 7-10 minutes with the child, in the presence of the therapist, with toys chosen according to the child's developmental stage. Then therapist proposes an immediate viewing of the play session. The therapist selects short moments of positive interaction. He has determined a  focus , depending on the play, previous sessions, the child's difficulties and parent's interventions. He accompanies, guides and supports the parent to describe the interaction, the alternance in play, joint attention, shared affect, in a co-construction: the parent discovers the child's and his own skills."
40751346|NCT04607616|DIAGNOSTIC_TEST|Developmental and diagnostic assessments|MSEL, CARS, ECAR, CIM10, DMS5, ADOS, ADIR
40751347|NCT04607616|BEHAVIORAL|Developmental assessment -Parental scales|Vineland II, IFDC, IDE
40751348|NCT04607616|BEHAVIORAL|Qualitative analysis|Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).
40751349|NCT01033227|DRUG|sodium nitrite injection, usp|Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
40751350|NCT04595812|DRUG|Misoprostol 200mcg Tab vaginal|2 tablets vaginally 1 hour before surgery
40751351|NCT04595812|DRUG|Oxytocin|30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h
40751352|NCT04595812|DRUG|Carbetocin|100 μg IV Carbetocin (1ml) in 5 ml saline over 1 minute
41095648|NCT00748969|DRUG|Somatropin (DNA origin)|The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
41095649|NCT00192153|BIOLOGICAL|CAIV-T or TIV|
41095650|NCT00003429|PROCEDURE|biopsy|
41095651|NCT00003429|PROCEDURE|computed tomography|
41095652|NCT00003429|PROCEDURE|positron emission tomography|
41095653|NCT00003429|RADIATION|fludeoxyglucose F 18|
41095654|NCT04370093|DRUG|Pioglitazone 45 mg|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
40751353|NCT04595812|PROCEDURE|pericervical hemostatic tourniquet|a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision,The time of tourniquet administration will be recorded, and will be released not later than 45 minutes after its application. For those requiring multiple applications, the tourniquet will be reapplied after a period of at least 15 minutes.
40751354|NCT01793909|OTHER|Single Leg Exercise Training|Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
40751355|NCT01835431|DRUG|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
40751356|NCT01835431|DRUG|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
40751357|NCT01835431|DRUG|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
40751358|NCT01835431|DRUG|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
40751359|NCT02313272|RADIATION|Hypofractionated Stereotactic Irradiation (HFSRT)|Radiation therapy treatment (FSRT) which will be given to participants over 5 days.
40751360|NCT02313272|DRUG|Pembrolizumab|"Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.~Dose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase."
40751361|NCT02313272|DRUG|Bevacizumab|Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a \> 10% change in weight.
40751362|NCT05358535|DRUG|Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
40751363|NCT05358535|DRUG|Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
40751364|NCT04728464|PROCEDURE|Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Fixed appliance will be placed for every patient, then surgical procedure will be applied after reflecting a full-thickness labial flap.
40751365|NCT05754112|OTHER|B lymphocyte profiling|All individuals will undergo peripheral venous blood sampling and ultrasound-guided synovial tissue biopsy following a standardized procedure. B-lymphocytes will be sorted from PBMCs isolated by Ficoll gradient method using magnetic CD19-microbeads whereas tissue B-lymphocytes will be isolated from synovial tissue biopsies digested with Liberase. CD19 positive cells from PBMC will be incubated with pro-inflammatory molecules in presence or absence of Ubadacitinib. After stimulation, CD19 positive cells will be collected and processed for single cell RNA sequencing. Moreover, the impact of JAK-1 selective inhibition on B-lymphocyte cultures stimulation will be tested using ELISA method for the assessment of cytokines/chemokines production. Synovial tissue and synovial tissue B-lymphocyte subpopulations will be assessed through FACS analysis using IgD/CD27 classification. Finally, we will compare the transcriptomic profile of synovial tissue B lymphocytes from 5 subject groups.
40751366|NCT01829607|OTHER|Functional electrical stimulation of peripheral muscles|
40751367|NCT01407978|BIOLOGICAL|Vaccination with Fluval P monovalent influenza vaccine|"* Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
40751368|NCT01407978|BIOLOGICAL|Vaccination with Fluval AB|"* Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
40751369|NCT01407978|BIOLOGICAL|Vaccination with Fluval AB Novo|"* Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
40922406|NCT03359018|DRUG|Apatinib|Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
41270490|NCT06018701|DEVICE|"A dental device made of zirconia. This is a new invention and does not exist generically. The given generic name of the invention (dental device) is Dantya Nikhan."|Dental device is surgically placed and cemented with PMMA bone cement on edentulous region.
41270491|NCT02100384|PROCEDURE|Peri-implant maintenance|The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
41270492|NCT05987748|BEHAVIORAL|Exercise training|Mixed exercise training containing strength and endurance elements carried out under supervision
40751370|NCT03847805|OTHER|Scapulothoracic and glenohumeral stabilization exercises|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue. Three series, with 10 repetitions of each exercise, with one minute rest between series.
40751371|NCT03847805|OTHER|Glenohumeral stability exercises|the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
40751372|NCT01666652|BIOLOGICAL|4 µg TDENV-PIV with Alum adjuvant|
40751373|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with AS03B1 adjuvant|
40751374|NCT01666652|OTHER|Phosphate buffered saline|
40751375|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with Alum adjuvant|
40751376|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with AS01E1 adjuvant|
40751377|NCT02245893|PROCEDURE|open reduction internal fixation (ORIF)|The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
40751378|NCT03683901|DEVICE|TENS|Electrical Stimulation
40751379|NCT03683901|DEVICE|t-NMES|Electrical Stimulation
40751380|NCT03683901|OTHER|No stimulation|No stimulation
40751381|NCT02476682|OTHER|blood or stool samples will be collected|blood or stool samples will be collected
40751382|NCT04242654|PROCEDURE|Handheld fetal doppler ultrasound|Handheld fetal doppler ultrasound will be used to assess heart rate in high-risk neonates.
40751383|NCT03053999|OTHER|Genome Sequencing|Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
40751384|NCT03053999|OTHER|Data Review|Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
40751385|NCT02903381|DRUG|Nivolumab|Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and
40751386|NCT02903381|DRUG|Lenalidomide|Oral, predetermined dosage, Days 1-21 of cycle 1-12
40751387|NCT02903381|DRUG|Dexamethasone|Oral, Days 1, 8, 15 of cycle 1-6
40751388|NCT04983511|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
41095655|NCT04370093|BEHAVIORAL|Weight Loss|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
41095656|NCT04370093|OTHER|Pioglitazone + Weight Loss|Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
41095657|NCT03860246|DIAGNOSTIC_TEST|Portable ECG monitor|Recording of ECG rhythm on a portable monitor (Kardia Mobile)
40751392|NCT02516111|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
40751393|NCT02516111|BIOLOGICAL|OFD with PRF|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
40751394|NCT02516111|DRUG|OFD with ALN|Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect
40751395|NCT02516111|DRUG|OFD with ATV|Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
40751396|NCT00358579|DRUG|Adrenaline|1 mg
40751397|NCT00358579|DRUG|Vasopressin|40 IU
41453283|NCT05487664|DEVICE|Transcutaneous Auricular Neruostimulation (tAN)|The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
40751398|NCT04006756|BEHAVIORAL|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
40751399|NCT04006756|BEHAVIORAL|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
40751400|NCT02477046|BIOLOGICAL|tOPV|administered per protocol
40751401|NCT02477046|BIOLOGICAL|bOPV|administered per protocol
40751402|NCT02477046|BIOLOGICAL|IPV|administered per protocol
40751403|NCT05377671|DIAGNOSTIC_TEST|IRM multimodale a ultra-haute camp|The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
40751404|NCT01624207|DRUG|generic formulation of atorvastatin (Atorva®)|Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
41095658|NCT06021990|DRUG|Clopidogrel Bisulfate 75Mg Tab|Severe COPD patients who meet eligibility criteria will be given Clopidogrel Bisulfate 75 mg Tablet daily, along with standard of care treatment till the completion of the study duration or any side effects that warrants stoppage of the drug
41095659|NCT04216303|DIAGNOSTIC_TEST|hemoglobin A1c|The hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.
41095660|NCT05015972|BIOLOGICAL|CTA30X UCAR-T injection|CTA30X UCAR-T injection is an allogeneic CAR-Ttargeted CD19 . A single infusion of CART cells will be administered intravenously.
41095661|NCT02274246|DRUG|gadobutrol|Gadobutrol administration in healthy volunteers
41095662|NCT04536077|DRUG|CDX-301|The drug will be supplied free of charge by Celldex
41095663|NCT04536077|DRUG|CDX-1140|The drug will be supplied free of charge by Celldex
40751405|NCT01624207|DRUG|branded formulation of atorvastatin (Lipitor®)|Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
40751406|NCT02369159|DRUG|Peramivir|
40751407|NCT02369159|DRUG|Oseltamivir|
40751408|NCT02541201|DIETARY_SUPPLEMENT|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
40751409|NCT02541201|DIETARY_SUPPLEMENT|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
40751410|NCT01166945|DRUG|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
40751411|NCT01166945|DRUG|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
40751412|NCT02604667|OTHER|Blood tests|"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."
40751413|NCT02604667|OTHER|Transcranial Doppler Microemboli Detection Study|Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
40751414|NCT03958487|BEHAVIORAL|Video feedback, Feedback online|The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
40751415|NCT02334254|DRUG|rivaroxaban and ticagrel therapy|Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
40751416|NCT02334254|DRUG|triple antithrombotic regimen with warfarin, asipirin and clopidogrel|
40751417|NCT04599985|OTHER|star excursion balance training (SEBT)|The SEBT is aimed to be maintained the single limb stance on one leg while reaching farthest possible with the swing leg. An individual can reach farthest with the swing leg while maintaining the balance on the stance leg
40751418|NCT04599985|OTHER|Simplified star excursion balance training (SSEBT)|It is one of the training protocols, in a simplified way, with respect to star excursion balance test. It consists a series of reaching tasks for the lower limbs in three-directions i.e., anteromedial, medial and posteromedial.
40751419|NCT03473301|BIOLOGICAL|Infusion of allogeneic umbilical cord blood|Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.
40751420|NCT03473301|BIOLOGICAL|Infusion of MSCs|Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).
40751421|NCT05698628|PROCEDURE|Distal perfusion catheterization|Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.
40751422|NCT04724200|DIAGNOSTIC_TEST|Echocardiogram|Echocardiography plays a crucial role in the diagnosis of HF; it is the standard of care imaging modality used to confirm the diagnosis, it permits real-time imaging of the heart and quantitative assessment of cardiac structure and function, crucial for diagnosis.
40751423|NCT05460000|DRUG|3 cycles chemotherapy instead of 6 cycles chemotherapy|We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.
40751424|NCT05460000|DRUG|6 cycles chemotherapy|Standard chemotherapy as comparator
40751425|NCT04763408|DRUG|Lenvatinib|Oral capsules.
40751426|NCT04763408|DRUG|Sorafenib|Oral tablets.
40751427|NCT00373087|DRUG|entacapone|entacapone
40751428|NCT00373087|DRUG|l dopa versus placebo|l dopa versus placebo
40751429|NCT03850587|DRUG|Celecoxib 200mg|comparator medication
40751430|NCT03850587|DRUG|Tramadol 37.5Mg+ Celecoxib 200mg|experimental medication
40751431|NCT03850587|DRUG|Tramadol 75mg+ Celecoxib 200mg|experimental medication
40751432|NCT03850587|DRUG|Tramadol 150mg+ Celecoxib 200mg|experimental medication
40751433|NCT05713370|DIETARY_SUPPLEMENT|high fat meal|A high fat meal (milkshake) will be administered on the morning after the intervention of no exercise and no SR the night before.
40751434|NCT03688113|BEHAVIORAL|Tinnitus application|Use of tinnitus application
40751435|NCT05752331|BEHAVIORAL|Physical activity behavioural modification|8-week intervention consisting motivational interview, individualised action plan and weekly consultations regarding activities of daily living and symptom management.
40751436|NCT02234986|DRUG|ENMD-2076|250 mg oral dose, QD for 28 day cycles
40751437|NCT02410876|PROCEDURE|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
40751438|NCT02410876|PROCEDURE|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
40751439|NCT06260839|PROCEDURE|magnetic resonance neurography|preoperative magnetic resonance neurography and assisted design of surgical approach
40751440|NCT06260839|PROCEDURE|no magnetic resonance neurography|Preoperative magnetic resonance neurography was not performed, and general minimally invasive surgery was performed
40751441|NCT05803954|OTHER|Sustained natural apophyseal glides (SNAGS)|SNAGS will be applied with the patient sitting comfortably on a stool. The therapist stand behind the patient and the medial border of one thumb's distal phalanx is placed on the articular pillar on the chosen side of the suspected site of lesion. The thumb nail slope at approximately 45 degree (in the direction of the eyeball). SNAGS mulligan will be given by active movement followed by passive overpressure based on the movement restricted by frequency of treatment will be three sets of ten repetitions. SNAG the anteroposterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s depending on response. A maximum of 6 repetitions will be given if there is a reduction in headache intensity at the time of the first application. A total of 20 oscillations (1 oscillation/1 second) will be given to each joint with a total duration of 15 minutes
40751442|NCT05803954|OTHER|Neural mobilization|Neural mobilization will be applied with grade three neural mobilization and traditional therapy: Subjects will be placed in supine position and remained relaxed with the feet uncrossed. The patient will be slightly angled obliquely for easier access to the scapula. The therapist will be depressed the scapula with concomitant upper extremity joint positioning as per median nerve bias i.e., ULTT2 (shoulder abduction, elbow extension with forearm supination, wrist and fingers extended and ulnar deviated and thumb abduction). The wrist will be used as a tension factor and at the point where tension was felt by the therapist and perceived by the subject. Grade 3 oscillations were given rhythmically and slowly to each joint from proximal to distal. A total of 20 oscillations (1 oscillation/1 second) were given to each joint with a total duration of 15 minutes.
40751443|NCT05803954|OTHER|Traditional physical therapy|traditional therapy will be applied in the form of stretching for bilateral upper and middle trapezius muscles and bilateral neck rotators and isometric strengthening exercises for neck rotators, extensors, side bending muscles. Exercise was repeated for ten repetitions per session. In addition to hot pack was placed over the neck and upper part of shoulders musculature. This was being applied for ten min, over middle trapezius trigger Point itself.
40751444|NCT06499649|DIETARY_SUPPLEMENT|IBSA Probiotics|Lactobacillus acidophilus and Bifidobacterium animalis Probiotic strains (LAC6; BLA8; BLC6).
40751445|NCT06499649|DIETARY_SUPPLEMENT|Placebo|The placebo does not contain functional components, and the appearance is indistinguishable from the comparison product.
40751446|NCT06381843|BIOLOGICAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
40751447|NCT06381843|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
40751448|NCT02391584|DEVICE|XprESS|Balloon dilation of the Eustachian tube
40751449|NCT02391584|OTHER|Control|Continued medical management
40751450|NCT05381168|DIETARY_SUPPLEMENT|Calcium from fish bone|Calcium from fish bone contained calcium 312 mg and vitamin D 100 IU per capsule.
40751451|NCT05381168|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate contained calcium 600 mg and vitamin D 200 IU per capsule.
40751452|NCT04279600|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 1 gram of taurine powder, total dosage: 3 grams/day
40751453|NCT04279600|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation in capsules of 1 gram of starch powder, total dosage: 3 grams/day
40751454|NCT04279600|OTHER|Exercise training|4 weeks of combined exercise training (alternating strength and aerobic exercise), with a frequency of 3 times/week with 55 min/day.
40751455|NCT01089543|DRUG|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
40751456|NCT01089543|DRUG|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
40751457|NCT01089543|DRUG|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
40751458|NCT01089543|DRUG|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
41095664|NCT04536077|PROCEDURE|Research blood draw|At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery
40751459|NCT05510973|OTHER|Enhanced package for AHD care|The enhanced package of AHD care includes CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis \[TPT and CPT\], offered through a hub-and-spoke facility system, with continuous quality improvement (QI)
40751460|NCT01242046|DIETARY_SUPPLEMENT|Caffeine|400 mg of caffeine in tablet form
40751461|NCT01242046|DIETARY_SUPPLEMENT|Placebo|Inert tablet
40751462|NCT00376506|DEVICE|Neurostimulation device for dysphagia|A neurostimulation device that is surgically implanted in the swallowing muscles.
40751463|NCT00376506|DEVICE|External vibrotactile device|A vibrotactile device that is placed on the neck during swallowing.
40751464|NCT04624997|OTHER|biological sample|biological sample
40751465|NCT04928066|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
40751466|NCT04928066|DRUG|Tofacitinib|Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
40751467|NCT04928066|DRUG|Pred|Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
40922407|NCT03359018|DRUG|SHR-1210|Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
40922408|NCT03800394|OTHER|Observational PK study|Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
41095665|NCT05213429|OTHER|non interventional study|non interventional
40751468|NCT02968875|DEVICE|Endurance Training|40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.
41270493|NCT04265664|BEHAVIORAL|Telerehabilitation|Participants in the telerehabilitation program will receive a graded exercise and self-management intervention. This program will be delivered in a ≤2:1 participant:therapist ratio. Each participant grouping will receive two 60-90 minutes telerehabilitation sessions per week for 4 weeks focusing on lower extremity recovery (total 8-12 hours), with a therapist trained in the use of technology for the provision of rehabilitation. Participants will also be asked to complete at least one additional independent self-managed exercise session each week. This independent exercise session will include selected exercises from the telerehabilitation sessions that will be safe to perform without therapist oversight, and jointly agreed upon by the participant and therapist.
40751469|NCT02968875|OTHER|therapeutic education meetings|Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
40751470|NCT02415803|DRUG|low-dose ticagrelor|90 mg loading dose, then 45 mg twice daily for 5 days
40751471|NCT02415803|DRUG|conventional-dose ticagrelor|180 mg loading dose, then 90 mg twice daily for 5 days
40751472|NCT02415803|DRUG|Clopidogrel|300 mg loading dose, then 75 mg once daily for 5 days
40751473|NCT02263690|PROCEDURE|Group Drops|The patients in the group Drops received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. The patients in the group Drops received a second drop of proparacaine 0.5% 5 minutes after the drop of povidone iodide 5%
40751474|NCT02263690|PROCEDURE|Group SC|The patients in the group SC received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. In the patients in the group SC, a subconjunctival bleb of anesthesia was created by injecting 0,4 mL of lidocaine 1% into the subconjunctival space 4 mm posterior to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-mL syringe.
40751475|NCT02263690|PROCEDURE|Group gel|For the patients in group gel, the gel was placed on the eye before receiving the peri-ocular drop of povidone iodide 5%.
40751476|NCT04333459|BIOLOGICAL|Hataan DNA Vaccine/Puumala DNA Vaccine|Vaccine compared in High and Lose Doses.
40751477|NCT03520569|DRUG|Octreotide|we are using it to block insulin secretion from the pancreas
40751478|NCT03520569|DRUG|Insulin|we are using to replace basal insulin and in two protocols to raise insulin concentrations during the insulin clamp
40751479|NCT03520569|DRUG|Dextrose 20% solution|We are using dextrose to maintain glycemia level
40751480|NCT04429971|OTHER|PrEP screening program|ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool
40751481|NCT04429971|OTHER|PrEP starter pack|emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil
40751482|NCT00008268|BIOLOGICAL|filgrastim|
40751483|NCT00008268|DRUG|melphalan|
40751484|NCT02576366|DRUG|Voriconazole|
40751485|NCT02576366|DRUG|Rifampin|
40751486|NCT03056430|BEHAVIORAL|Training|
40751487|NCT03615898|OTHER|Medication errors analysis|TEN YEAR ANALYSIS OF MEDICATION ERRORS IN THE SPANISH INCIDENTS REPORTING SYSTEM IN ANAESTHESIA
40751488|NCT00908661|DEVICE|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
40751489|NCT01477411|DRUG|PA21|The maximum dose of PA21 will be 15.0 g/day.
40751490|NCT01477411|DRUG|Digoxin|The maximum dosage of Digoxin will be 0.5 mg/day
40751491|NCT03760068|DRUG|MYL-1601D Product|(100 U/mL)
40751492|NCT03760068|DRUG|FlexPen NovoLog®|(100 U/mL)
40751493|NCT01560988|DRUG|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
40751494|NCT01560988|DIETARY_SUPPLEMENT|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
40751495|NCT04132180|OTHER|Early Mobilization|Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
40922409|NCT03137264|DRUG|Other|Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
40922410|NCT02923024|BEHAVIORAL|Patient Ping|The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.
40922411|NCT01975857|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
41095666|NCT00557843|DRUG|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
40751496|NCT04132180|OTHER|Late Mobilization|The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
40751497|NCT02434614|DRUG|Docetaxel,Cisplatin,Fluorouracil|Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
40751498|NCT02434614|RADIATION|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
40751499|NCT02434614|DRUG|Cisplatin|Concurrent chemotherapy: patients received weekly intravenous cisplatin at 30 mg/m2 for 6-7 weeks.
40751500|NCT06128343|OTHER|collection of biological samples|Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas
40751501|NCT04808895|DRUG|Acetylsalicylic acid|administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered
40751502|NCT04808895|DRUG|Placebo|administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
40751503|NCT01426555|OTHER|FES-Rowing|FES- Rowing Exercise
40751504|NCT01426555|DRUG|Zoledronic acid|5 mg IV single dose
40751505|NCT03272165|DRUG|MEDI1341|Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
40751506|NCT03272165|DRUG|Placebo|Participants will receive IV infusion of placebo matched to MEDI1341.
40751507|NCT03912805|BIOLOGICAL|botulinum toxin, Type A|topical liniment
40751508|NCT03912805|BIOLOGICAL|Vehicle|Vehicle Formulation
40751509|NCT03364686|BIOLOGICAL|Biotin-Labeled Red Blood Cells|We will collect 500 mL of blood. The blood will be processed and split into two bags and labeled with a naturally occurring vitamin, biotin. The blood will then be re-infused back into the same participant at 2 time points (5-7 days and 35-42 days after storage).
40751510|NCT04887038|DRUG|SRT-015|Each study part (A,B and C) will be completed sequentially, but with partial overlapping. The first cohort of Part B (Cohort B1) may be initiated after safety, tolerability and available PK data are assessed and deemed suitable to continue for a single dose on Part A that is equal to or greater than the total exposure of cohort B1. Part C (Cohort C1 \& C2) may be initiated after safety, tolerability and PK data are assessed and deemed suitable to continue for a single dose in part A that is at least double the specified dose from part C.
40751511|NCT04887038|OTHER|Matching Placebo for SRT-015|Matching Placebo
40751512|NCT05020522|DIAGNOSTIC_TEST|Luminal Index MRI (LI-MRI)|Multiecho T2 sequence; eventual biopsy of lesion(s) detected with LI-MRI only.
40751513|NCT05020522|DIAGNOSTIC_TEST|LI-MRI targeted prostate biopsy|Biopsy targeted to suspicious lesions detected with LI-MRI only
40751514|NCT05020522|DIAGNOSTIC_TEST|Plasma methylation signature (ctMethSig)|Blood sample.
40751515|NCT02504385|DEVICE|Virtual Reality Timocco|Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.
40751516|NCT02504385|OTHER|Conventional OT intervention|Traditional Occupational Therapy intervention will be givven to the control group.
40751517|NCT03346512|PROCEDURE|Cardiac surgery|Cardiac surgery
40751518|NCT00552838|BEHAVIORAL|Academic Detailing by the Antimicrobial Utilization Team (AUT)|Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
40751519|NCT02525432|BIOLOGICAL|Placebo Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
40751520|NCT02525432|BIOLOGICAL|Autologous BMMNC Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
40751521|NCT04968743|DEVICE|Transcranial magnetic stimulation (TMS)|TMS will be administrated with a Magstim 70mm figure-8 coil allowing for focal stimulation. Single-pulse TMS will be applied at different phases, (0, 90, 180, 270 degrees - 4 stimulation conditions), of the ongoing mu-rhythm. Positioning of the TMS coil will be neuronavigated based on individual MRI scans. Stimulation will be applied in a closed-loop fashion while the participant is at rest and their EEG activity is recorded.
40751522|NCT04383015|OTHER|Exercise strategies|Strategies for exercise in type 1 diabetes to maintain glucose control
40751523|NCT00403065|DRUG|dexamethasone|
40751524|NCT00403065|PROCEDURE|quality-of-life assessment|
40751525|NCT00403065|RADIATION|radiation therapy|
40751526|NCT06337409|DRUG|Generic empagliflozin 25 mg film-coated tablets|Empagliflozin 25 mg film-coated tablets
40751527|NCT01971593|DRUG|Eplerenone|
41270494|NCT02926807|OTHER|FDG-PET Scan|a 18FDG-PET to quantify vascular inflammation
41270495|NCT02926807|OTHER|MDCT|a MDCT to calculate the Agatston score
41270496|NCT02926807|OTHER|biopsy and blood collection|biopsy and blood collection to assess biomarkers
40751528|NCT01696214|DRUG|Fluticasone 250 mg/salmeterol 50 mg|Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
40751529|NCT01696214|DRUG|Montelukast 10mg|Participants will be assigned to montelukast once a day for 24 weeks.
40751530|NCT01696214|DRUG|Theophylline 400 mg|Participants will be assigned to theophylline once a day for 24 weeks
40751531|NCT01696214|DRUG|ipratropium|Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
40751532|NCT05932680|OTHER|Off Drug Surveillance|After stopping teclistamab, participants will be monitored monthly by standard serum paraprotein studies for disease progression. Participants will resume teclistamab at time of disease progression. After Teclistamab therapy re-initiation on-study, monthly response assessments and data for other study endpoints will be obtained. All participants will undergo peripheral blood collection for correlative research studies at baseline and every two months on-study. Participants who enroll on the biomarker sub-study will undergo bone marrow examination and peripheral blood collection for correlative studies at study entry, at time of disease progression and at six months from enrollment.
40751533|NCT04091438|DRUG|TAK-925|TAK-925 IV infusion.
40751534|NCT04091438|DRUG|TAK-925 Placebo|TAK-925 placebo-matching IV infusion.
40751535|NCT00565760|DRUG|Q8003|Capsules
40751536|NCT00565760|DRUG|Placebo|Capsules
40751537|NCT05038514|OTHER|musıc therapy|After the prone position was given to the patients, according to the randomization table, the intervention group was given 30 minutes by the nurse. nature-based music therapy will be applied.
40922412|NCT01975857|BEHAVIORAL|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
40922413|NCT06299410|DRUG|ITI-1284 10 mg|ITI-1284 tablet
40922414|NCT06299410|DRUG|ITI-1284 20 mg|ITI-1284 tablet
40922415|NCT00129662|BEHAVIORAL|Pictorial action plan|
40922416|NCT01534858|DEVICE|Prontosan Wound Gel X|Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
41270497|NCT04856137|DRUG|Rituximab Paclitaxel Ruxolitinib|Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)
41270498|NCT01484964|DRUG|ASP015K|oral
40751538|NCT04264195|OTHER|Constraint-induced movement therapy: PEPS-MIT|"All participants of control and experimental groups received standard stroke rehabilitation. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~• Specific for the experimental group was that patients performed all manipulation tasks with forced use of the paretic hand/arm by wearing a soft-padded mitten at the non-paretic hand, preventing manipulation with that hand. Patients were encouraged to wear the mitten also for 3 hours/day at home, while performing ADL and learned exercises. Behavioural strategies included a treatment contract and daily use of the home activity checklist which was checked by patient's caregiver and signed by both patient and caregiver. Each treatment day the activity checklist was submitted to the therapist who gives feedback."
40751539|NCT04264195|OTHER|Bimanual manipulation exercises (PEPS-Bimanual)|"All participants of control and experimental groups received standard stroke. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~Specific for the control group was that patients performed all manipulation tasks bimanually, as they used to do in occupational therapy activities. Patients were also asked to document their 'at home' activities in an activity checklist that was regularly checked by the therapists."
40751540|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (hyaluronic acid) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
40751541|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (Platelet-Rich-Plasma) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
40751542|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (methylprednisolone acetate) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
40751543|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (Serum Saline) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
40751544|NCT03486106|OTHER|Music|Music will be provided via Spotify, which is an Internet streaming music service, and will be played through headphones; this way, no other individual in the operating room will be distracted or influenced by the patient's music selection.
40751545|NCT03486106|OTHER|Headphones|All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.
40751546|NCT03486106|DRUG|Propofol|All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.
40751547|NCT00924651|BEHAVIORAL|exercise|home based walking and progressive resistance training exercise
40751548|NCT00800384|DEVICE|Implantable defibrillator|Implantable defibrillator to detect and terminate ventricular arrhythmias
40751549|NCT04559672|PROCEDURE|Cervical laminoplasty surgery|The posterior standard cervical laminoplasty procedure with ARCH mini-plate fixation
40751550|NCT04559672|PROCEDURE|Cervical laminectomy and fusion surgery|The posterior standard cervical laminectomy and fusion surgery procedure with lateral mass screws fixation
40751551|NCT02983942|DIETARY_SUPPLEMENT|ketogenic diet|Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
40751552|NCT02983942|DIETARY_SUPPLEMENT|Routine diet|Routine diet is given without blood ketone requirement
40751553|NCT01141790|OTHER|Music and voice message|
40751554|NCT04867070|DIAGNOSTIC_TEST|NAS score|Participants will be recorded according to the NAS and W-BAS pain scores
40751555|NCT00899847|PROCEDURE|Autologous peripheral blood stem cells (auto-PBSC) transplantation|"Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.~and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective"
40751556|NCT00899847|PROCEDURE|Allogeneic peripheral blood stem cells (allo-PBSC) transplantation|Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
40751557|NCT00899847|DRUG|Filgrastim|"Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.~Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.~Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection."
40751558|NCT00899847|DRUG|Cyclophosphamide|Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
40751559|NCT00899847|DRUG|Melphalan|Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
40751560|NCT00899847|DRUG|Cyclosporine|Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
40751561|NCT00899847|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
41270499|NCT03486392|DRUG|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.
41270500|NCT03486392|DRUG|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.
41270501|NCT03486392|DRUG|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.
40751562|NCT00899847|BIOLOGICAL|Rabbit anti-thymocyte globulin|ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
40751563|NCT00899847|DRUG|Mycophenolate Mofetil 250mg|MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
40751564|NCT00899847|DRUG|Solumedrol|Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
40751565|NCT00899847|DRUG|Diphenhydramine|Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
40751566|NCT00899847|DRUG|Acetaminophen|Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
40751567|NCT00899847|DRUG|Hydrocortisone|Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
40751568|NCT02269488|DRUG|MEDI3250|MEDI3250
40751569|NCT02827370|BEHAVIORAL|Behavioral Dietary Intervention|Receive dietary counseling
40751570|NCT01326936|BEHAVIORAL|Online education|A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
40751571|NCT05507216|DRUG|ABX464|Administered once daily in the morning with food
40751572|NCT05507216|DRUG|Placebo|Administered once daily in the morning with food
40751573|NCT01191385|DRUG|Any treatment for unresectable HCC as chosen by the physician|Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
40751574|NCT00710554|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
40751575|NCT00710554|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
40751576|NCT00635180|BEHAVIORAL|isometric exercise|
40751577|NCT02793778|DRUG|CROWN|A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
40751578|NCT02793778|DRUG|CROWN Placebo|Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
40751579|NCT05848375|PROCEDURE|Arthroscopic rotator cuff repair|The operation involves systematic acromioplasty during the supra +/- infraspinatus repair and sometimes requires a tenotomy of the long biceps if it is pathological.
40751580|NCT05848375|DRUG|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.
40751581|NCT05848375|DRUG|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
40751582|NCT05414773|OTHER|measurement of axial length and keratometry by sonographers with a topographic module|measurement of axial length and keratometry by sonographers with a topographic module
40751583|NCT05280808|DEVICE|Experimental phone app used for self-fitting of hearing aids|This software allows participants to set up hearing aids as appropriate for their hearing loss
40751584|NCT02285972|DRUG|saline|before the anesthesia induction, 2mL saline iv injection
40751585|NCT02285972|DRUG|dexketoprofen|before the anesthesia induction, 50 mg (2mL) iv dexketoprofen
40751586|NCT02285972|DRUG|tenoxicam|before the anesthesia induction, 20 mg (2mL) iv tenoxicam
40751587|NCT04802915|PROCEDURE|Intraoperative ERM and ILM staining with their assessment and removal|ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM
40751588|NCT02452658|OTHER|Changed menu|After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
40751589|NCT02003027|DRUG|BT injection|
40751590|NCT02830633|PROCEDURE|LNTME|Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
41095667|NCT00557843|DRUG|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
41270502|NCT03486392|DRUG|Liraglutide|Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
41270503|NCT03486392|DRUG|Placebo|Participants will receive matching placebo SC once-weekly until Week 26.
40751591|NCT02830633|PROCEDURE|OTME|Patients in this group received traditional open TME for treatment of rectal cancer
40751592|NCT03168997|DRUG|Memantine Hydrochloride|Memantine Hydrochloride treatment according to clinical routine treatment
40751593|NCT03599466|DRUG|BF-Lisinopril Tablets 20mg|BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
40751594|NCT03599466|DRUG|Zestril Tab 20mg|Zestril Tab 20mg will be used as a reference drug in this study
40751595|NCT06279403|DRUG|Toripalimab|Preoperative Treatment with Toripalimab: Administer 240mg of Toripalimab via intravenous infusion every 3 weeks for a total of 4 cycles.
40751596|NCT06279403|PROCEDURE|Cytoreductive Nephrectomy|"Radical Nephrectomy: Complete resection of the tumor and affected kidney within the renal fascia.~Partial Nephrectomy: Complete resection of the tumor while preserving maximal kidney function.~Lymph Node Dissection: For patients with evident enlargement of retroperitoneal lymph nodes preoperatively, perform lymph node dissection at the renal hilum, along the ipsilateral major vessels, and anterior to the ipsilateral major vessels. Lymph node dissection is not required for patients without evident enlargement of retroperitoneal lymph nodes preoperatively."
40751597|NCT06279403|DRUG|Axitinib|Preoperative Treatment with Axitinib: Administer 5mg of axitinib orally twice daily for a duration of 3 months.
40751598|NCT01520714|DEVICE|Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead|1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
40751599|NCT05249400|PROCEDURE|Off-site assistance|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom.
40751600|NCT01703221|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
40751601|NCT01703221|DRUG|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
40751602|NCT01703221|DRUG|Placebo to omarigliptin|Placebo to omarigliptin 25 mg capsule administered orally once weekly
40751603|NCT01703221|DRUG|Placebo to sitagliptin|Placebo to sitagliptin 50 mg tablet administered orally once daily
40751604|NCT00710788|DRUG|sevelamer phosphate-binders|1600 mg/day for 2 years
40751605|NCT00710788|DRUG|Calcium Carbonate|Calcium carbonate 1 g/day for 2 years
40751606|NCT01968408|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|10(9) CFU/daily
40751607|NCT01968408|DIETARY_SUPPLEMENT|Placebo|
40751608|NCT05873621|PROCEDURE|ICG-guided lymphadenectomy|Excision of ICG-fluorescent lymph nodes in addition to standard laparoscopic total mesorectal excision in rectal cancer patients after neoadjuvant chemoradiation
40751609|NCT04627584|COMBINATION_PRODUCT|MW33 injection|a recombinant fully human antibody to coronavirus
40751610|NCT04627584|COMBINATION_PRODUCT|MW33 injection placebo|Placebo
40751611|NCT06214962|BEHAVIORAL|(multiple training modalities, MTM)|"1. Invite experts to discuss the course content of each unit of MTM, and then invite teachers to take pictures , and combine them into one course for the benefit of the elderly in the institution.~2. Select 3 units to try out in the dementia base, and make corrections based on the feedback of the elders and the base staff.~3. Continue to complete other units based on the experience of the first 3 units.~(2) In the Rizhao part, experts are mainly used to develop various course modules suitable for the elderly with dementia in Rizhao, and each module unit is tested on the elderly with dementia and then revised The planning task is mainly to establish a solution strategy. The method is to set up an activity course module planning or design group to develop various course modules suitable for Rizhao demented elders."
40751612|NCT01035307|GENETIC|gene expression analysis|
40751613|NCT01035307|GENETIC|microarray analysis|
40751614|NCT01035307|GENETIC|proteomic profiling|
40751615|NCT01035307|OTHER|laboratory biomarker analysis|
40751616|NCT03931785|DRUG|MD-7246|Oral tablet
40751617|NCT03931785|DRUG|Placebo|Matching oral tablet
41095668|NCT01414166|DRUG|ERN/LRPT|ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
41095669|NCT01414166|DRUG|placebo|ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
41270504|NCT00929240|DRUG|bevacizumab [Avastin]|15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
41270505|NCT00929240|DRUG|capecitabine [Xeloda]|1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
41270506|NCT01071187|DRUG|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
40751623|NCT06469268|DEVICE|Epro software|EPRO software：patients with symptoms will fill in report forms via the software, when the data upload to the terminal, the doctor according to the results of the upload ePRO corresponding medical assessment,and give advises.
40751624|NCT06465602|DRUG|Nicotinamide|The subjects will receive 1.5 grams per day of Nicotinamide, orally, for 30 days.
40751625|NCT06465602|DRUG|Placebo|The subjects will receive 1.5 grams per day of placebo, orally, for 30 days.
40751626|NCT05689515|BEHAVIORAL|Mobile health app|A mobile app provided to participants to assess effectiveness in managing HIV
40751627|NCT02571244|BEHAVIORAL|Motivational Interview plus text message|After discharge the experimental group has received extended care including a counseling session and text messages. The session provided basic information about smoking and successful quitting. The counselor has used motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The focus was to increase motivation to make quit attempt, including confidence building, medication use, and cessation planning. The session lasted approximately 30 minutes. Participants in the experimental arm were offered up to 30 text messages to help them to implement the quit plan discussed during the phone call. Patients motivated to quit in the next 30 days or those that had already quit have received 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages followed the self efficacy theory.
40751628|NCT03928327|DRUG|TAK-788|TAK-788 Capsules
40751629|NCT03928327|DRUG|Itraconazole|Itraconazole Oral solution
40751630|NCT03928327|DRUG|Rifampin|Rifampin Capsules
40751631|NCT04313439|OTHER|Online cognitive therapy (I-CT)|"The treatment is an online cognitive therapy consisting of a structured self-help program over ten weeks, divided into eight modules, administered in an encrypted web platform. The program is based on the treatment manual The treatment of Obsessions by Stanley Rachman. In this treatment, the participant is recommended to perform daily exercises in order to identify and modify interpretations made about the importance of their obsessive thoughts. A designated therapist have email contact with the participant within the encrypted platform."
40751632|NCT02914678|OTHER|Fentanyl|Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport
40751633|NCT01557816|DRUG|Naproxen|Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
40751634|NCT01557816|DRUG|Placebo|Placebo for seven days given BID during either of the 2 treatment periods.
40751635|NCT00652613|RADIATION|3 Dimensional Radiation Therapy|Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
40751636|NCT00652613|RADIATION|Intensity Modulated Radiation Therapy|IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
40751637|NCT01152385|DRUG|AZD1656|Oral tablet administered twice daily during 4 months
40751638|NCT01152385|DRUG|Placebo|administered twice daily during 4 months
41270507|NCT01071187|DRUG|Placebo|Placebo
40751639|NCT04953260|OTHER|APRF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of APRF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of APRF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with APRF film
40751640|NCT04953260|OTHER|CGF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of CGF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of CGF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with CGF film
40751641|NCT01271166|DRUG|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
40751642|NCT00132912|DRUG|SCH 530348|
40751643|NCT00776997|DEVICE|Magnetic Sphincter Augmentation|The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
40751644|NCT02123875|OTHER|Physiotherapy|
40751645|NCT02123875|OTHER|Control arm|Routine hospital based physiotherapy
40751646|NCT04983498|DRUG|Ondansetron 4 MG|PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis.
40751647|NCT04983498|DRUG|Lactated Ringers, Intravenous|Goal directed IV fluids to be administered starting preop per the NMH Colorectal ERAS protocol (LR @ 5mL/kg/hr).
40751648|NCT04983498|OTHER|Early Mobilization|Patient transferred up to the chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters and patient safety.
40751649|NCT04983498|OTHER|Early PO Intake|Patient will be offered PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters and patient safety.
40751650|NCT00513448|OTHER|Group wellness intervention|
40751651|NCT00513448|OTHER|Individualized physical rehabilitation|
40751652|NCT02345577|OTHER|Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention|Physiotherapeutical intervention
40751653|NCT02345577|OTHER|Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention|Sham physiotherapeutical intervention
40751654|NCT03753503|BEHAVIORAL|exercise|exercised three times a week in the 8-week HIIT program
40751655|NCT03753503|BEHAVIORAL|conventional physical therapy|
40751656|NCT02453191|DRUG|Talimogene Laherparepvec|Talimogene Laherparepvec
40751657|NCT02453191|RADIATION|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
40751658|NCT03418207|PROCEDURE|trans-perineal template-guided mapping biopsy|new super saturation of prostate biopsy technique
40751659|NCT00142597|DEVICE|Acupuncture|"Involves the insertion and manual stimulation of thin acupuncture needles into specific points in the body.~Fibromyalgia participants will be randomized to receive 9 acupuncture treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
40751660|NCT00142597|OTHER|Sham treatment|"Fibromyalgia participants will be randomized to receive 9 sham treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
40751661|NCT02352142|OTHER|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
40751662|NCT02352142|BEHAVIORAL|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
40751663|NCT04108260|DRUG|Albutrepenonacog Alfa 1 UNT [IDELVION]|Clinical data will be collected from patients who suffered from hemophilia B, and switch from other FIX products to Idelvion as prophylaxis, prevention of bleeding (e.g. surgery) or treatment of bleeding.
40751664|NCT03412890|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily
40751665|NCT03412890|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1 mg) and NETA (0.5 mg) administered orally once daily
40751666|NCT03189511|DRUG|Fluvastatin|Fluvastatin 40 mg twice daily per mouth for 14 days.
41270508|NCT05449457|OTHER|2-Octyl cyanoacrylate|Involves closure supplemented by 2-octyl cyanoacrylate (3 layers)
40751667|NCT04425278|DEVICE|transcranial direct current stimulation with real current|transcranial direct current stimulation with real current is a noninvasive technique to activate and modify the activity of the neurons
40751668|NCT04425278|DEVICE|transcranial direct current stimulation with sham current|transcranial direct current stimulation with sham current is a placebo
40751669|NCT04644757|OTHER|Music Listening|The study will employ an individual receptive relaxation music method with participants selecting music based on their preference from a selection of various styles from the MUSIC CARE© app. The music intervention will last 20 minutes per session and will be administered twice daily for 4 consecutive days. Participants will be given an electronic tablet with the MUSIC CARE© app loaded on it and trained on how to access the app to select their preferred style of music.Participants will be instructed to use the provided headphone during all interventions and to sit in a quiet area while wearing an ocular mask to avoid distractions.The PI will remotely monitor each of the music intervention sessions in real-time monitoring via a secured video conferencing interface to ensure adherence to study protocol.
40751670|NCT00290420|DRUG|Chloroquine profilaxis|"Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes"
40751671|NCT03075631|OTHER|Questionnaire|Questionnaires
40751672|NCT02329275|PROCEDURE|Testicular biopsy|
40751673|NCT05450120|OTHER|Functional Rehabilitation|Functional rehabilitation protocol
40751674|NCT05450120|OTHER|Neuromuscular Electrical Stimulation|Neuromuscular electrical stimulation protocol
40751675|NCT02825537|DEVICE|Compression stocking|A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
40751676|NCT02825537|OTHER|No use of compression stocking|No use of compression stocking
40751677|NCT05234333|DRUG|SARS-CoV-2 vaccine|SARS-CoV-2 vaccination
40751678|NCT03112850|DEVICE|Hearing aid|LOF hearing aid
40751679|NCT03112850|BEHAVIORAL|Auditory Training|
40751680|NCT04129970|DEVICE|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
40751681|NCT01873833|DRUG|capecitabine|Given PO
40751682|NCT01873833|DRUG|cyclophosphamide|Given PO
40751683|NCT01873833|DRUG|lapatinib ditosylate|Given PO
40751684|NCT01873833|BIOLOGICAL|trastuzumab|Given IV
40751685|NCT01873833|OTHER|laboratory biomarker analysis|Correlative studies
40751686|NCT00507507|DRUG|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
40751687|NCT00507507|DRUG|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
40751688|NCT00507507|DRUG|Placebo|Placebo to match FTC taken once daily
40751689|NCT05150886|DIAGNOSTIC_TEST|rox index|After HFNC during reassessment, the ROX Index can help suggest which patients will fail HFNC and need to progress to intubation for further ventilatory support.
40751690|NCT04807868|PROCEDURE|Standard of care liver biopsy|Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
40751691|NCT04807868|OTHER|Fibroscan|A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
40751692|NCT04807868|OTHER|Biospecimen Collection|Blood and urine will be collected.
40751693|NCT01177488|BEHAVIORAL|Behavioral Activation Therapeutic Exposure (BATE)|This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
40751694|NCT02272010|OTHER|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
40751695|NCT02272010|OTHER|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
40751696|NCT01157429|DRUG|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
41270509|NCT05554120|OTHER|Supermarket tobacco sales ban|In 2024, a ban on the sales of tobacco for supermarkets is planned by the Dutch government. Supermarkets accounted for approximately 40% of tobacco outlets in the Netherlands in 2021.
40751697|NCT01157429|DRUG|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
40751698|NCT01157429|BEHAVIORAL|CBT|12-session CBT protocol, called Youth PTSD Treatment.
40751699|NCT04714580|OTHER|Animal Fun Program|This program permits the operators to propose different activities, by following the needing of the children. As the name of this program suggests, all the activities involve an animal description, and ask the children to move like this animal, in a proper, correct and supervised way.
40751700|NCT00401830|DRUG|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
40751701|NCT00401830|OTHER|Placebo|Matching placebo tablet administered twice daily
40751702|NCT05682469|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~All participants will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
40751703|NCT05682469|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
40751704|NCT00330278|DRUG|Cefazolin|
40751705|NCT03398109|DEVICE|Customized toric IOL for post-DALK atigmatism|
40751706|NCT00513864|DRUG|Dextromethorphan|one time dose - 0.3mg/kg PO
40947747|NCT05403658|BEHAVIORAL|Family Navigation|FN will be delivered by navigators who will provide support and services that complement obesity management care provided by multidisciplinary teams at the study clinical sites. With advanced training in motivational interviewing and patient- / family-centered care, navigators will access a bundle of logistical and relational strategies to help families derive the greatest possible benefit from their care, which will include working to reduce barriers to care, improve access, and optimize treatment outcomes related to obesity management that is part of their Usual Care. Navigators will provide various resources/supports to study participants including, but not limited to, offering communication via text message, flexible navigator appointments, parking/transit passes, community-based resources, and liaising with members of the multidisciplinary clinical teams at each site.
41270510|NCT05840614|BEHAVIORAL|The remote family support program|"Remote family support programs consist of interpersonal psychotherapy (IPT) and family psychoeducation.~Each session consisted of a lecture, followed by role playing and supportive group therapy. In the first session, we informed the participants about the symptoms of eating disorders and mechanism of IPT; in the second session, we shared details about the characteristics of adolescents; and during the third and fourth sessions, we provided information on effective communication according to IPT."
41270511|NCT05827796|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
40751707|NCT00513864|DRUG|Codeine|one time dose - 2mg/kg PO
40751708|NCT00513864|DRUG|Morphine|one time dose - 0.15mg/kg IV
40751709|NCT01891838|PROCEDURE|Volume controlled ventilation|
40922417|NCT04422340|OTHER|Group1|"* Comorbidities (CIRS-G scale),~* Functional status of the patient with~  * Clinical frailty scale (1 month before infection)~ * ADL score (1 month before infection)~* Biological data~  * Blood group~ * TP, D-dimers, CRP, creatinine level at the patient's entry, triglyceridemia, fibrinogen, ferritin~ * Parameters derived from the platelet formula count on D1 of the start of intensive care (lymphocytes, neutrophils, platelets, average platelet volume, red blood cell distribution index), SYSMEX data (IG: Immature granulocytes; HFLC: high fluorescent lymphocyte count)~* Resuscitation outcomes~  * LDH rate at the start of intensive care~ * PaO2 / FiO2 ratio at the start of intensive care~ * IGSII / SASPII score (simplified acute physiology score) on D1 of the start of intensive care~ * SOFA score (sepsis-related organ failure assessment): a posteriori estimate based on IGSII / SASPII~ * Delay between the appearance of the first signs of infection and admission to intensive care"
40922418|NCT00870584|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
40751710|NCT01891838|PROCEDURE|Pressure-controlled ventilation|
40922419|NCT00870584|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
40922420|NCT02607748|OTHER|18F-NaF PET and coronary CTA imaging|
40922421|NCT01332461|DRUG|fluticasone propionate/salmeterol xinafoate combination|Patients filling a prescription for fluticasone/salmeterol combination as index drug
40922422|NCT01332461|DRUG|Other maintenance Treatments (OMT)|OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
40922423|NCT04196387|DIAGNOSTIC_TEST|urine culture|urine culture and antibiotic susceptibility test
40922424|NCT03337672|DRUG|Dexmedetomidine|Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
40922425|NCT03337672|DRUG|Midazolam|Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
40922426|NCT03933995|OTHER|no Intervention|no Intervention
40751711|NCT04612127|DIETARY_SUPPLEMENT|Dietary supplement consumption and physical exercise|"The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week."
40751712|NCT03832452|DRUG|Lucerastat (Treatment A)|2000 and 4000 mg; hard capsules for oral administration
40922427|NCT02150694|PROCEDURE|Forearm venous occlusion plethysmography|Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
40922428|NCT02150694|PROCEDURE|Aellig hand vein technique|Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
40922429|NCT02150694|OTHER|Apelin agonist infusion|Escalating doses of apelin (1/10/100nmol/min) will be administered.
40922430|NCT02150694|OTHER|Apelin receptor antagonist infusion|Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
41270512|NCT05827796|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
40922431|NCT05370183|PROCEDURE|Hyperambulatory tenotomy|Using mini-optics a minimally invasive device, hypermabulatory tenotomy is performed in consultation, with a local anethesia
40922432|NCT05370183|PROCEDURE|Operating room tenotomy|Operating room tenotomy is performed according standard practice, with general anesthesia.
40922433|NCT02793622|DRUG|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|
40922434|NCT02793622|DRUG|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|
40922435|NCT04682119|DRUG|LY3526318|Administered orally.
40922436|NCT04682119|DRUG|Placebo|Administered orally.
40922437|NCT02207946|DRUG|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
40922438|NCT02207946|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
40922439|NCT04241978|OTHER|Patient Decision Aid (PtDA)|Patient Decision Aid (PtDA) are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
40922440|NCT04241978|OTHER|Brochure with general information about osteoarthritis|Participants of the control group will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
40922441|NCT01782391|DEVICE|Stimulation|
40922442|NCT01782391|DEVICE|SHAM|no stimulation
40922443|NCT05738434|DRUG|Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib|camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investigator' choice： paclitaxel 135\~150 mg/m2, i.v. d1,q3w; paclitaxel-albumin 150\~180 mg/m2, i.v. d1,q3w. up to 4 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w
40922444|NCT05738434|DRUG|Camrelizumab+Chemotherapy→Camrelizumab|camrelizumab 200 mg, i.v. d1,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investgator' choice： paclitaxel 175 mg/m2, i.v. d1,q3w; paclitaxel-albumin 200 mg/m2, i.v. d1,q3w up to 6 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w;
40922445|NCT04564300|PROCEDURE|Training|Both groups will perform a standardized training protocol
40922446|NCT00853970|DRUG|Bromfenac Ophthalmic Solution|sterile ophthalmic solution
40922447|NCT00853970|DRUG|Placebo Comparator|sterile ophthalmic solution
41270513|NCT05827796|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
41270514|NCT05827796|DRUG|KN046|KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
41270515|NCT02673229|DRUG|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
41270516|NCT02673229|DRUG|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
41270517|NCT00348166|DRUG|cyclopentolate|
40922448|NCT04546984|DRUG|HEC96719|Part 2：Mulltiple doses up to 10 days
40922449|NCT02589600|DRUG|Zoledronic acid|Annual intravenous 5.0 mg
40922450|NCT02589600|DIETARY_SUPPLEMENT|vitamin D|800 IU daily
40922451|NCT02589600|DIETARY_SUPPLEMENT|calcium|approximately 1200 mg (dietary and supplement)
40922452|NCT02589600|OTHER|Saline|Annual intravenous saline placebo
40922453|NCT06273137|BEHAVIORAL|Positive affect treatment|PAT includes 15 weekly, 1-hour sessions. The treatment is composed of three modules targeting behaviors (Sessions 1-7), cognitions (Sessions 8 -10), and compassion (Sessions 11-14), with skills being reinforced in a cumulative manner in subsequent sessions. The final session in the original treatment (Session 15) addressed relapse prevention, which will be adapted to focus on further reinforcing and generalizing learned skills. The treatment includes guided activities that target different aspects of positive affectivity such as reward approach-motivation, reward learning, and reward attainment.
40922454|NCT05094310|DEVICE|Acupuncture|Patients with breast cancer who experienced fatigue were measured by the Brief Fatigue Inventory(BFI) scale and other Fatigue related questionnaire. Breast cancer patients diagnosed with cancer related fatigue are included in our clinical study，and those patients will receive acupuncture treatment. The position of acupuncture refers to the principle of acupuncture treatment of traditional Chinese medicine. According to ICD-10-CD code R53.0, the diagnosis of CRF is determined by the experience of diminished energy or other physical and psychological symptoms every day or almost every day for two consecutive weeks in the past month. We collected patients' blood to detect fatigue related SNP.
40922455|NCT00981942|DRUG|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
40922456|NCT02174588|DRUG|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
40922457|NCT02174588|DRUG|propofol|propofol are used for sedation drug
40922458|NCT01012674|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
40922459|NCT01012674|OTHER|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
40922460|NCT04865523|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage is a technique that through gentle passes facilitates the flow of lymph through manual therapy techniques based on Vodder therapy. This technique is being studied to know its effectiveness in pain and for this reason we want to carry out this research.
40922461|NCT03562767|BEHAVIORAL|Group-based Cognitive Behavioral Intervention|This intervention will include six 1-hour group sessions held biweekly for twelve weeks. Each sixty-minute session will consist of 15 minutes of diabetes education regarding exercise and food planning and approximately 45 minutes of CT-CB presentations/engagement activities. Participants will be encouraged to bring along their family members or friends for support.
40922462|NCT03562767|BEHAVIORAL|Web-based Cognitive Behavioral Intervention|This intervention will include six 1-hour web-based sessions held biweekly for twelve weeks. Subjects in the web-based CT-CB will be asked to reserve a 1 hour period for a web call from the Behavioral Interventionist team. Text reminders will be sent to the participants prior the sessions. During this period, approximately 15 minutes will be reserved for diabetes exercise and food planning education and approximately 45 minutes of CT-CB engagement activities.
40922463|NCT03562767|BEHAVIORAL|Usual Care|Usual care group participants will continue to receive care and follow up from their primary care providers as per the American Diabetes Association guidelines with log books, education regarding self-management strategies and appropriate referrals as needed.
41270518|NCT01453881|DEVICE|Spacer|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
40922464|NCT04248725|BEHAVIORAL|E-TIPS|Chronic pain self-management strategies for employed individuals with physical disabilities
40751713|NCT03832452|OTHER|Placebo|hard capsules for oral administration
40751714|NCT03832452|DRUG|Moxifloxacin|400 mg; film-coated tablets for oral administration
40751715|NCT03832452|DRUG|Lucerastat (Treatment B)|1000 mg; hard capsules for oral administration
40751716|NCT03832452|DRUG|Lucerastat (Treatment C)|4000 mg; hard capsules for oral administration
40751717|NCT02408770|DRUG|ulipristal acetate|selective progesterone receptor modulator
40751718|NCT05877664|DRUG|ZG0895 Hydrochloride for Injection|The dose escalation of ZG0895.HCl is set as 0.06, 0.12, 0.18, 0.37, 0.75, 1.50, 2.25, 3.00, and 3.75 mg/m\^2 groups, subcutaneous (SC) injection once a week (QW)
41270519|NCT01453881|DEVICE|Comparator|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
41270520|NCT05850078|OTHER|FB101|Intervention will test effects on changes to the vaginal microbiome of FB101 versus diluted FB101 versus placebo
40751719|NCT03486639|OTHER|IPSS questionnaire|IPSS is an 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of patients with lower urinary tract symptoms. It was validated for both genders.
40751720|NCT03161847|OTHER|Non-interventional study|Non-interventional study
40751721|NCT02457286|DRUG|Metformin|Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
40751722|NCT02457286|BEHAVIORAL|Lifestyle modifications|Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
40751723|NCT02457286|DEVICE|Fibroscan device (Echosens)|This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
41270521|NCT03341884|DRUG|Ipatasertib|A single oral dose of 100 mg ipatasertib will be administered.
41270522|NCT01105390|BIOLOGICAL|rilotumumab|Given IV
41270523|NCT01105390|DRUG|cisplatin|Given IV
41270524|NCT01105390|DRUG|pemetrexed disodium|Given IV
41270525|NCT01105390|OTHER|laboratory biomarker analysis|Correlative studies
41270526|NCT04610476|DRUG|Prednisolone|Prednisolone oral 1-5 mg/day
41270527|NCT04610476|DRUG|Sulfasalazine|Sulfasalazine oral 2 x 1000 mg/day
41270528|NCT04610476|DRUG|Leflunomide|Leflunomide oral 20 mg/day
40751724|NCT04334811|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SAbR) delivers of a potent, ablative or nearly ablative dose of radiation in oligofractions (ie, five or fewer fractions) primarily to create a compact dose delivered accurately to the intended target with steep gradients in all directions (geometric avoidance) and avoid damaging normal tissues.
40922465|NCT02650921|DEVICE|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
40922466|NCT03090048|DRUG|Vitamin A|Vitamin A 2-3 % concentration
40922467|NCT03090048|DRUG|Azithromycin|azithromycin monohydrate
40922468|NCT04863183|BIOLOGICAL|CELLISTEM-OA|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
40922469|NCT04863183|DRUG|Triamcinolone acetonide|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
40922470|NCT00755300|PROCEDURE|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
40922471|NCT03566667|DRUG|Metoprolol|Betablocker
40922472|NCT03566667|DRUG|Standard care|Standard care
40922473|NCT05599568|OTHER|Exercise|Either concentric or excentric exercise
40922474|NCT01317459|BEHAVIORAL|Guided self-determination|Group counselling
40922475|NCT04239430|DIAGNOSTIC_TEST|Serum Bactericidal Assays|Blood samples will be taken from participants at two time points in the study. Serum Bactericidal Assays from participant serum using relevant MenB and MenACWY strains will be undertaken at 18 and 30 months post two doses of 4CMenB (Bexsero, GSK) and MenACWY-conjugate (Menveo, GSK) vaccine. The Vaccines were given to participants during an earlier clinical trial (Propositive). This trisal is a follow up study.
40922476|NCT04641689|DEVICE|Desk Only|Provision of height-adjustable desk
40751725|NCT05792332|OTHER|Telemonitoring|Patients are followed up by a nurse specialist in parkinsonism who interacts with the treating neurologist and a multidisciplinary team
40751726|NCT05792332|OTHER|Standard-of-care|Patients are managed only by the neurologist according the institution's clinical practice
40751727|NCT05152095|OTHER|Vaccaria seed (Wang Bu Liu Xing) pre-attached to adhesive tape used for auricular acupressure|Apply on auricular acupoints, Shenmen and Occiput, apply pressure for 3 minutes, 5 times per day, at the interval of 2 \~ 3 hours, for 5 days.
40751728|NCT05152095|OTHER|Plain ear adhesive tape|Apply on Shenmen and Occiput without applying pressure for 5 days.
40751729|NCT02740582|DRUG|Tolcapone|
40751730|NCT02740582|DRUG|Placebo|
40751731|NCT06195111|DRUG|Trifluridine/Tipiracil|This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription
40751732|NCT05936853|OTHER|Intravenous approach to anaesthetic maintenance|Anaesthetic agents given directly into the bloodstream via a cannula.
40751733|NCT05936853|OTHER|Inhalational approach to anaesthetic maintenance|Volatile-based anaesthetic drugs are breathed in and then absorbed into the bloodstream through the lungs.
40922477|NCT04641689|BEHAVIORAL|Program Only|Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
40922478|NCT01385397|OTHER|Preceptorship and virtual community|
40922479|NCT02303418|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the baby
40922480|NCT02303418|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the baby
40922481|NCT02734901|DIETARY_SUPPLEMENT|400 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
40922482|NCT02734901|DIETARY_SUPPLEMENT|200 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
40922483|NCT02734901|DIETARY_SUPPLEMENT|Placebo|1x daily intake of 600 mL raspberry deprived supplement
40922484|NCT02819908|DRUG|Imprimis Dropless|Tri-Moxi-Vanc transzonular intravitreal injection
40922485|NCT02819908|DRUG|Imprimis Less Drops|Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
40922486|NCT00770380|BEHAVIORAL|behavioral relapse prevention counseling|Behavioral relapse prevention counseling conducted in two one-hour sessions
40922487|NCT00770380|OTHER|hypnosis for relapse prevention|Hypnosis for relapse prevention conducted in two one-hour sessions
40947748|NCT05403658|BEHAVIORAL|Usual Care|Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.
40947749|NCT00202059|DRUG|Zoledronic acid|
40947750|NCT00202059|BEHAVIORAL|Physical activity intervention|
40751734|NCT02459925|BEHAVIORAL|CBT- Mental Health Program|Manualized Stress Management class; brief individual behavioral counseling.
40751735|NCT02459925|BEHAVIORAL|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
41270529|NCT04610476|DRUG|Methotrexate|Methotrexate oral \> 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week
41270530|NCT04610476|DRUG|Tofacitinib|Tofacitinib oral 2 x 5 mg/day/ 1 x 5 mg/day/11 mg/day
40751736|NCT03065738|OTHER|tibial reduction osteotomy in total knee replacement|reduction osteotomy :downsizing of tibial tray with lateralization
40751737|NCT01142687|DIETARY_SUPPLEMENT|dihydrocapsiate capsule|"* Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~* Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~* Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner"
40947751|NCT02595359|DRUG|Moxifloxacin|Moxifloxacin intracameral
40947752|NCT05886816|DRUG|Mitoquinone/mitoquinol mesylate|Mitochondrial antioxidant
40947753|NCT05886816|OTHER|Placebo|Placebo pills
41270531|NCT04610476|DRUG|Apremilast|Apremilast oral 2 x 30 mg/day/1 x 30 mg/day
41270532|NCT04610476|DRUG|Etanercept|Etanercept s.c. 2 x 25 mg /week OR 1 x 50 mg/week
41270533|NCT04610476|DRUG|Adalimumab|Adalimumab s.c. 40 mg every 2 weeks
40751738|NCT03723239|DEVICE|TricValve® System|The TricValve® Delivery System is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is unsheathed at the implantation site and positions itself as per the anatomy - self expanding frame.
40751739|NCT02269605|OTHER|Placebo|Group 1: Placebo (sodium chloride 0.8 %) at single dose
40751740|NCT02269605|DRUG|Bryostatin 1 (10ug/m2)|Group 2: Bryostatin 1 (10ug/m2) at single dose
40751741|NCT02269605|DRUG|Bryostatin 1 (20ug/m2)|Group 3: Bryostatin 1 (20ug/m2) at single dose
40922488|NCT04687176|DRUG|Oral Arsenic Trioxide Formulation|"Patients will be recruited to oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA) based-induction for 42 days. Daunorubicin or idarubicin will only be used during induction in patients \<65 with presenting white blood cell count (WBC) ≥ 10 x 10\^9/L. In patients not receiving daunorubicin, hydroxyurea if WBC ≥ 5 x 10\^9/L within the first 14 days of induction. A reassessment bone marrow aspirate will be performed on day 28 of induction for assessment of morphologic remission.~Four weeks after the completion of induction phase, all patients, regardless of initial WBC, will receive two cycles of chemotherapy-free AAA consolidation (14 days every 28 days).~Four weeks after completion of consolidation, all patients will receive 12 cycles of chemotherapy-free AAA maintenance (14 days every 8 week)."
40922489|NCT01331421|DRUG|exemestane|25 mg tablet
40922490|NCT02848729|DRUG|Oral Acetaminophen|Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
40922491|NCT02848729|DRUG|IV Acetaminophen|Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)
40922492|NCT02848729|DRUG|IV Morphine|Morphine for IV administration (0.125 mg/kg)
40751742|NCT04187703|DRUG|5-azacytidine|5-azacytidine 50 mg/m\^2 Day 1 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
40751743|NCT04187703|DRUG|Decitabine|Decitabine 5 mg/m\^2 Day 4 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
40751744|NCT04677166|DEVICE|Negative pressure wound therapy coupled with instillation|Use of V.A.C. VeraFlo to treat skin grafts with NPWT coupled with instillation.
40751745|NCT04677166|DEVICE|Standard Negative Pressure Wound Therapy|standard negative pressure wound therapy via V.A.C. Ulta device at 125mmHg suction.
40751746|NCT04987970|DRUG|CKD-386(2)|QD, PO
40751747|NCT04987970|DRUG|D013, D326, D337|QD, PO
40751748|NCT05364255|DRUG|[14C]AZD9833 Oral Solution, 75 mg|Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted
40751749|NCT06134414|DRUG|MY008211A tablets|dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
40751750|NCT04218851|DRUG|Posaconazole IV|Posaconazole (POS) 6 mg/kg body weight by IV infusion
40751751|NCT04218851|DRUG|Posaconazole PFS|POS PFS 6 mg/kg body weight taken orally
40922493|NCT02848729|DRUG|Placebo Tablets|Placebo tablets matching oral acetaminophen
40922494|NCT02848729|DRUG|Saline|Saline placebo matching IV acetaminophen
40922495|NCT05293899|DIAGNOSTIC_TEST|exome sequencing approach|Depending on the primary results in the proteomic and the metabolic profiling, this pilot study will search for genetic associations, using an exome sequencing approach to individuals. The findings will be compared to individuals without depression, and to relatives of depressed patients who suffer from autoimmune diseases.
40922496|NCT00317291|PROCEDURE|Acupuncture/Moxibustion|Acupuncture/Moxibustion: 16 scheduled sessions
40922497|NCT00317291|OTHER|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
40922498|NCT01479283|DRUG|24-Hour Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered."
41270534|NCT04610476|DRUG|Infliximab|Infliximab i.v. 5 mg/kg BW every 8 weeks
41270535|NCT04610476|DRUG|Certolizumab pegol|Certolizumab pegol s.c. 1x 200 mg every 2 weeks/1x400 mg every 4 weeks
41270536|NCT04610476|DRUG|Golimumab|Golimumab s.c. 1x 50 mg every 4 weeks
41270537|NCT04610476|DRUG|Abatacept|Abatacept s.c. 1x125 mg/week OR Abatacept i.v. 500-1000mg (adapted to BW) every 4 weeks
41270538|NCT04610476|DRUG|Secukinumab|Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks
40751752|NCT04218851|DRUG|Posaconazole tablet|POS tablet 300 mg taken orally
40751753|NCT04055389|DRUG|Antithrombin III|"Patients with reversal of flow or sluggish flow in the main portal vein (\<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life \~4 days) at a weight-based dosage according to the following formula:~\[Desired level of AT (100%) - Subject level of AT (%)\] \* subject weight (kg) 1.4~or placebo for 24 weeks of therapy."
40751754|NCT04055389|OTHER|Placebo|No study drug
40751755|NCT03885388|DRUG|MTX|multicourse methotrexate chemotherapy
40751756|NCT03885388|DRUG|MTX+ACTD|combination use of methotrexate and actinomycin
40751757|NCT03167710|OTHER|Dry Needling, manipulation, stretching|HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
40751758|NCT03167710|OTHER|manual therapy, exercise, ultrasound|Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
40751759|NCT00449007|DRUG|fluoxetine|6 months
40751760|NCT00449007|DRUG|bupropion|6 months
40751761|NCT01259882|DRUG|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
40751762|NCT01259882|DRUG|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
40922499|NCT01479283|DRUG|5-Days Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered."
40922500|NCT02486341|DRUG|Insulin|Continuous glucose monitoring system over 120-hour period.
40922501|NCT00315757|BIOLOGICAL|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
40922502|NCT00315757|BIOLOGICAL|Mapatumumab|20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
40922503|NCT00315757|DRUG|Bortezomib|1.3 mg/m\^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
40922504|NCT03936452|DRUG|Sintilimab|Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy
40922505|NCT00618098|BIOLOGICAL|Octaplex (human prothrombin complex concentrate)|INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was \< 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).
40922506|NCT00618098|BIOLOGICAL|Fresh frozen plasma|INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of \< 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was \< 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
40922507|NCT05371808|OTHER|EQ-5D-5L Instrument|This instrument is a measure of health status for use in evaluating health and healthcare.
40922508|NCT05371808|OTHER|Work Productivity and Daily Activity Impairment (WPAI) survey|The questionnaire includes three open-ended questions that determines: 1) hours absent from work due to health problems; 2) hours absent from work due to other reasons; and (3) hours actually worked over the past 30 days. Additional questions ask about the impact of health problems on work productivity and daily activities and are scored along a vertical visual analog scale. The WPAI provides estimates on absenteeism, presenteeism, global measures of lost productivity (absenteeism+presenteeism) and daily activity impairment (impaired ability to perform non-work activities including work around the house, child care, exercise, studying, and leisure activities)
40922509|NCT05371808|OTHER|Resource Utilization Form (SMRC)|Resource utilization data collection will be supplemented by a self-administered resource utilization form (Stanford SMRC) to document non-protocol specified utilization. This will include hospitalizations (including days in hospital), emergency room visits, and non-protocol specified ambulatory visits.
40922510|NCT05991544|BEHAVIORAL|Training and Follow-up According to the Neuman Systems Model|Neuman Systems Model (NSM) it presents a holistic approach to patients by including physiological, spiritual, sociocultural and five major developmental variables
40922511|NCT04330729|DRUG|Acetylsalicylic acid|Se arm description
40922512|NCT06467136|BEHAVIORAL|Sound production treatment|Evidence based treatment for apraxia of speech, developed by Julie Wambaugh.
40922513|NCT06467136|BEHAVIORAL|Motor Imagery Practice|Practice of target items using motor imagery during home practice
40922514|NCT05482750|OTHER|Resistance training in the fasted state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
40922515|NCT05482750|OTHER|Resistance training in the fed state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
41270539|NCT04610476|DRUG|Ixekizumab|Ixekizumab s.c. 1x 80 mg every 4 weeks
41270540|NCT04610476|DRUG|Ustekinumab|Ustekinumab s.c. Maintenance dose 1x45 mg every 12 weeks
41270541|NCT00191373|DRUG|Gemcitabine|
41270542|NCT00191373|DRUG|Trastuzumab|
41270543|NCT04234737|BEHAVIORAL|Hypnotherapy|Hypnotherapy
41270544|NCT00542620|DRUG|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
41270545|NCT00542620|DRUG|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
40922516|NCT04774458|PROCEDURE|Fluoroscopic-guided cervical epidural access|After identifying the target level of the cervical spine under a fluoroscopy-guided anteroposterior image, an 18-Tuohy needle is inserted through a paramedian approach after local infiltration with 1% lidocaine. When feeling a strong resistance through the needle by a ligamentum flavum, the image intensifier is rotated to 50 degrees contralateral oblique (CLO) direction. After then, the needle is advanced to just before the ventral interlaminar line in CLO view. It is subsequently advanced further until it is in the epidural space using a LOR-to-air technique. Correct epidural access is confirmed by the injection of contrast medium. After identifying epidural space in AP and CLO view without abnormal dispersion of contrast,(vascular uptake, intrathecal spreads, etc.), a 3-4ml mixture of 0.5% lidocaine with dexamethasone 5mg is injected.
40922517|NCT04926597|DIETARY_SUPPLEMENT|nutritional supplement|daily use of one or more specific oral nutritional supplement with high energy/protein content (i.e., Resource Ultra, Resource 2.0 (Fibre), Resource Ultra Fruit).
40922518|NCT04926597|OTHER|individualized nutritional guidelines|nutritional plan supervised by an experienced study dietician based on the usual home nutrition with possibility to increase intake by adaptation to patient preferences, between meal snaking and food enrichment/fortification. Every 2-4 weeks phone call by unblinded study dietician to follow nutritional intervention.
40922519|NCT04926597|OTHER|general nutritional information|general information about health food behavior upon hospital discharge
40922520|NCT06095271|DIAGNOSTIC_TEST|serum Neurofilament Filament Light chain (sNfL) monitoring|the intervention consist of a blood draw and providing the sNfL information to the treating physician
40922521|NCT04634305|PROCEDURE|Total elbow arthroplasty|Total elbow arthroplasty by a single operator
40922522|NCT03756493|PROCEDURE|Periodontal Surgery with OFD+ABG+L-PRF|Patients will be treated by periodontal surgical flaps with the addition of L-PRF+ Autogenous Bone Graft filling material.
40922523|NCT03756493|PROCEDURE|Periodontal Surgery with OFD+ABG|Patients will be treated by periodontal surgical flaps with the addition of Autogenous Bone Graft filling material.
40922524|NCT03756493|PROCEDURE|Periodontal Surgery OFD|Patients will be treated by Open Flap Debridement without use of filling material.
40922525|NCT01466257|BIOLOGICAL|cetuximab|
40922526|NCT01466257|DRUG|cisplatin|
40922527|NCT01466257|GENETIC|DNA analysis|
40922528|NCT01466257|GENETIC|gene expression analysis|
40922529|NCT01466257|GENETIC|mutation analysis|
40922530|NCT01466257|OTHER|laboratory biomarker analysis|
40922531|NCT00865423|DRUG|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
40922532|NCT00865423|DRUG|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
40922533|NCT04401020|DRUG|SAR442257|Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
40922534|NCT05331417|DIAGNOSTIC_TEST|Patients with herpes-simplex infection requiring bronchoscopy|Due to the observational design of the study, no study-specific interventions are performed. The indication for bronchoscopy is determined by the responsible ICU physicians. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.
40922535|NCT01253811|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
40922536|NCT02604329|DEVICE|"Oncolase Digi therapy laser diode"|"The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).~* Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).~* Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm."
40922537|NCT03140215|DEVICE|laryngeal mask insertion (Baska)|
40922538|NCT03140215|DEVICE|laryngeal mask insertion (I-gel )|
40922539|NCT02618213|DEVICE|Optiflow Junior|Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
40922540|NCT02618213|DEVICE|Continous Positive Airway Pressure|Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
40922541|NCT02886208|BEHAVIORAL|Measurement|The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
40922542|NCT00199043|DRUG|Allopurinol|
40922543|NCT00199043|DRUG|Rasburicase|
40922544|NCT02480946|DRUG|MBS2320|As described in the arm descriptions
41095670|NCT01500551|DRUG|Tofacitinib|"Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165)~5 mg BID Dose Level:~Body Weight (Dose in tablet \[mg BID\] or solution \[ml BID\]) 5 - \< 7 kg (2 mg or 2 ml) 7 - \< 10 kg (2.5 mg or 2.5 ml) 10 - \<15 kg (3 mg or 3 ml) 15 - \<25 kg (3.5 mg or 3.5 ml) 25 - \<40 kg (4 mg or 4 ml) \>=40 kg (5 mg or 5 ml)~Oral solution (1 mg/mL concentration) will be used for subjects weighing \<40 kg. Oral tablets (5 mg) will be used for subjects weighing \>=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.~Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing."
40922545|NCT02480946|DRUG|Placebo|As described in the arm descriptions
40922546|NCT02480946|DRUG|Methotrexate|Background therapy as described in the arm descriptions
40922547|NCT03320876|DRUG|filgotinib|one filgotinib oral tablet once daily.
40922548|NCT03697135|BEHAVIORAL|Respondent Driven Sampling|Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C
40922549|NCT05791383|DEVICE|transcutaneous auricular neurostimulation|All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device. We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. taVNS sessions are considered complete after 30minutes. Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion. All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.
40922550|NCT05881070|BEHAVIORAL|Mobile-health self management|Mobile-health self management
40922551|NCT01640574|DRUG|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
40922552|NCT01640574|DRUG|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
40922553|NCT01640574|DRUG|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
40922554|NCT01640574|DRUG|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
40922555|NCT00064064|DRUG|gemcitabine hydrochloride|
40922556|NCT00064064|DRUG|triapine|
40922557|NCT00559494|DRUG|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
40922558|NCT00559494|DRUG|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
40922559|NCT00559494|PROCEDURE|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
40922560|NCT00559494|PROCEDURE|SCPP control|maintenance of Mean arterial pressure of \>65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
40922561|NCT04693052|OTHER|No interventions|This is a self-reported survey study about receiving mental health care during the COVID-19 pandemic
40922562|NCT05028361|BIOLOGICAL|mRNA COVID-19|ACIP-CDC recommended vaccine
40922563|NCT05028361|BIOLOGICAL|IIV4|ACIP recommended vaccine
40922564|NCT05028361|OTHER|Placebo (saline)|Saline Control
40922565|NCT00551304|DEVICE|Ardian Catheter|
40922566|NCT05207345|OTHER|Interventional programme|"90-minute session divided into:~* 45 minutes of core stability treatment~* 45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training)."
40922567|NCT05207345|OTHER|General exercise programme|90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
40922568|NCT03319745|BIOLOGICAL|Pembrolizumab|Given IV
40922569|NCT02630901|DRUG|PRX003|
40922570|NCT02630901|OTHER|Placebo|
40922571|NCT03462511|BEHAVIORAL|HABIT Intervention|Dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
40922572|NCT03462511|OTHER|Standard of Care|Standard of care used to treat patients with SCD
40922573|NCT03462511|OTHER|Education materials|Education materials provided to all patients enrolled in the trial
40922574|NCT03970980|OTHER|fraction of inspired oxygen (FIO2)|Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
40922575|NCT05504772|GENETIC|Whole Genome Sequencing|Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.
40922576|NCT05504772|GENETIC|RNA seq|Results will be used for bioinformatics analysis for fusion transcripts and gene expression.
40922577|NCT05504772|GENETIC|DNA Methylation|Genome-wide assessment of DNA methylation will be conducted on all samples where possible.
40922578|NCT05504772|GENETIC|Targeted Panel Sequencing|"Targeted panel sequencing may be performed:~1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available~2. When mosaicism is suspected~3. When indicated for a disease type"
40922579|NCT05504772|GENETIC|High Throughput Sequencing (in vitro)|High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival \<30%) and selected tumor types.
40922580|NCT05504772|GENETIC|Patient Derived Xenograft (PDX)(in vivo)|In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types.
40922581|NCT05504772|OTHER|Liquid Biopsy|Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.
40922582|NCT05908643|DRUG|pTTL|pTTL is an autologous cell product for adoptive cancer immunotherapy containing in vitro expanded T cells stimulated with patient-specific tumour neoantigens derived from tumour-draining lymph nodes.
40922583|NCT00200343|DRUG|Ursodeoxycholic acid 150mg / day|Ursodeoxycholic acid, 150mg/ day, three times a day at meals
40922584|NCT00200343|DRUG|Ursodeoxycholic acid 600mg / day|Ursodeoxycholic acid, 600mg/ day, three times a day at meals
40922585|NCT00200343|DRUG|Ursodeoxycholic acid 900mg / day|Ursodeoxycholic acid, 900mg/ day, three times a day at meals
40922586|NCT04195542|OTHER|Questionnaire|questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not
40922587|NCT03347292|DRUG|Regorafenib(Stivarga, BAY73-4506)|Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
40922588|NCT03347292|DRUG|Pembrolizumab|200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
40922589|NCT03708887|DRUG|Low dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
40922590|NCT03708887|DRUG|High dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
40922591|NCT03708887|DRUG|Control drug|Matching placebo capsules,3 g/d by mouth for 1 year
40922592|NCT03675854|DRUG|Cefazolin|3 weeks
40922593|NCT03843671|DRUG|Hyperbaric oxygen|Hyperbaric oxygen therapy
40922594|NCT03843671|DEVICE|Hyperbaric chamber|Hyperbaric chamber
40922595|NCT01185353|DRUG|LY3009104|Administered orally
40922596|NCT01185353|DRUG|Placebo|Administered orally
40922597|NCT01185353|DRUG|Methotrexate|Administered orally as background therapy
40922598|NCT03459690|BEHAVIORAL|Meditation|Isha Kriya meditation is simple meditation practice which can be easily learned by employing online guided tools. Isha Kriya meditation requires approximately 12 minutes, twice a day of practice. This regimen was chosen because of its simplicity making it an excellent way to introduce meditation to beginners. Isha Kriya does not incorporate a spiritual or religious focus.
40922599|NCT03459690|DEVICE|Enobio 32- EEG machine|This study utilizes the Enobio 32 EEG device made by Neuroelectrics (an FDA-cleared 24-bit EEG data reader which is a wearable wireless device) to analyze EEG changes after subjects have undergone meditation. This study does not evaluate the Enobio device, and the IRB of record approved an Investigational Device Exemption for this study.
40922600|NCT00107484|DRUG|ferumoxtran-10|
40922601|NCT00107484|PROCEDURE|magnetic resonance imaging|
40922602|NCT00107484|PROCEDURE|sentinel lymph node biopsy|
40922603|NCT05633030|PROCEDURE|using UAS during flexible ureteroscopy and using PCN during flexible ureteroscopy|under general anesthesia and given appropriate antibiotic cover. a clssic flexible ureteroscopy procedure is done and appropriately sized UAS was then inserted over the wire and positioned just distal to the PUJ or below upper ureteric stone under fluoroscopic guidance. We then perform a flexible ureteroscopy using Olympus URF-V2 (8.5 Fr) flexible ureteroscope to inspect the proximal ureter if there is upper ureteric stone, renal pelvis, and calyces for the presence of stones. Irrigation with 0.9% saline solution via a pressure-infusing system. Next, Holmium laser lithotripsy with a holmium:YAG laser \[20 W; Lumenis (UK) Ltd., Elstree, UK\] using a 272 micron laser fiber (Lumenis, Inc.) is carried out and/or stone extraction with a basket device, in the other group we add inserted trans papillary in the lower calyx of the kidney by an expert intervention radiologist
40922604|NCT03602560|DRUG|seladelpar 5-10 mg|Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
40922605|NCT03602560|DRUG|seladelpar 10 mg|Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study
40922606|NCT03602560|DRUG|Placebo|One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
40922607|NCT01230177|DRUG|etanercept (genetical recombination)|10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
40751763|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.
40751764|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
40751765|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
40751766|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
40751767|NCT03865251|DEVICE|Kinesiology tape|Application for 0%, 50%, and 100% of maximal KT stretch to the calf muscle during lying and standing positions
40751768|NCT04665791|BIOLOGICAL|Intranasal inoculation with Neisseria lactamica|Lyophilised Neisseria lactamica will be reconstituted and administered to participants intranasally.
40751769|NCT05171335|DRUG|Lenvatinib|"Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of \<60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time."
40751770|NCT05171335|PROCEDURE|Transcatheter Arterial Chemoembolization|Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
40751771|NCT01922414|DEVICE|Laser|Patients will undergo laser lithotripsy durin PNL
40751772|NCT01922414|DEVICE|Ultrasonic|Patients will undergo ultrasonic lithotripsy during PNL
40751773|NCT04010253|DEVICE|SIMEOX|Instrumental airway clearance by the medical device SIMEOX
40751774|NCT04010253|OTHER|Autogenic drainage|Manual aiway clearance by autogenic drainage
40751775|NCT01960478|BIOLOGICAL|(for each intervention)|
40751776|NCT01960478|OTHER|Blood test|
40751777|NCT05302518|BEHAVIORAL|Cognitive behavioral therapy with exposure in virtual reality|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells. The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in VR:~We will use 360° 3D videos for exposure using an HTC Vive Pro headset. Six different videos will be used for exposure: 1) Taking a seat on a bench in a public park, 2) Being introduced as a new employee, 3) Performing a presentation at a meeting, 4) Entering and shopping in a grocery store, 5) Visiting a café and 6) Using public transportation. The therapist can choose the length of the exposure as well as the difficulty of the exposure. While the participant is in the VR-scenario HR and EDA are measured. These data are collected to continuously estimate the anxiety levels."
40751778|NCT05302518|BEHAVIORAL|Cognitive behavioral therapy with exposure in vivo|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells.The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in vivo:~Exposure is taking place at Centre for Telepsychiatry and the surrounding areas. The therapist is planning the exposure with the participant and is accompanying the participant during the exposure."
40751779|NCT05052307|DRUG|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
40751780|NCT05052307|DRUG|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
40751781|NCT05052307|DRUG|ChAdOx1 nCoV-19 Covid-19 Vaccine|ChAdOx1 nCoV-19 Covid-19 Vaccine
40751782|NCT05052307|DRUG|Ad26.COV2.S COVID-19 Vaccine|Ad26.COV2.S COVID-19 Vaccine
40751783|NCT01420003|PROCEDURE|Bone Marrow Aspiration|3 per study
40751784|NCT01420003|PROCEDURE|Tonsil Biopsy|Optional upon completion of study
40751785|NCT02629458|PROCEDURE|Treatment by Surgical resection|
40751786|NCT02629458|PROCEDURE|Stereotactic Ablative Radiotherapy (SABR)|
40751787|NCT02742974|DEVICE|FloTrac™ and EV1000™|Interventions to improve cardiovascular performance will be made in all patients whose cardiovascular function is sub-optimal in accordance with routine clinical management during trauma resuscitation. Patients who meet inclusion criteria will be assigned to the intervention or control arm of the study based on the process outlined in the protocol. Patients assigned to the intervention arm will have intra-operative hemodynamic monitoring performed by the anesthesia staff and cardiovascular interventions will be based off of the algorithm described in the protocol. Members of anesthesia or the surgical team can initiate interventions as indicated during routine ICU care or intra-operatively.
40751788|NCT03614780|BEHAVIORAL|30 minutes outdoors|Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
40751789|NCT04303403|DRUG|Trametinib|Taken orally once daily
40751790|NCT04303403|DRUG|Ruxolitinib|Taken orally twice daily
40751791|NCT02818062|BIOLOGICAL|Cytokines dosage in Aqueous humor|Specify details not covered in associated Arm Description.
40751792|NCT03255590|BEHAVIORAL|Configuration task|Training the impaired hand on a configuration task
40751793|NCT01807104|PROCEDURE|Anterior Approach / Posterior Approach|compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
40751794|NCT01807104|PROCEDURE|Anterior versus Posterior Approach for total hip replacement|Compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
40751795|NCT03435315|OTHER|Treadmill Exercise- behavioral approach|12-session, 6-week treadmill exercise program utilizing behavioral techniques while walking
40751796|NCT03435315|OTHER|Treadmill Exercise- traditional approach|12-session, 6-week traditional treadmill exercise program
40751797|NCT06288178|DIETARY_SUPPLEMENT|Bread consumption|There were four groups: whole wheat (WWB), buckwheat (BWB), corn bread (CB) and reference bread.
40751798|NCT02830087|PROCEDURE|Tourniquet Cuff Pressure|Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
40751799|NCT06444100|PROCEDURE|Impact of structural training on child abuse|"A focus group discussion to delve into teachers' perceptions of child abuse. Based on the findings, the training module will be modified as need-based.~Phase II: Randomly selected samples will be invited, with the researcher explaining the study procedures and obtaining verbal and written consent from teachers and assent from children. A dedicated room will be arranged for data collection, and participants will be instructed on how to respond to child abuse questions on tablets.~Phase-III A pretest will be conducted to assess the existing knowledge level and attitude of the teachers toward child abuse. A 5-hour training session, led by an expert team, will follow the pretest questionnaire administration to all participants. Teachers will also be educated on how to report instances of child abuse. A post-test will be administered using the same questionnaires two weeks after the training."
40751800|NCT01412983|DEVICE|Bausch & Lomb Test lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
41095671|NCT01500551|DRUG|Tofacitinib|For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
41095672|NCT04071236|DRUG|Avelumab|Given IV
41095673|NCT04071236|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41095674|NCT04071236|PROCEDURE|Bone Scan|Undergo bone scan
41095675|NCT04071236|PROCEDURE|Computed Tomography|Undergo CT
41095676|NCT04071236|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41095677|NCT04071236|DRUG|Peposertib|Given PO
41095678|NCT04071236|OTHER|Questionnaire Administration|Ancillary studies
41095679|NCT04071236|RADIATION|Radium Ra 223 Dichloride|Given IV
41095680|NCT02862327|DRUG|intravenous dexamethasone|intravenous injection of dexamethasone
40751801|NCT01412983|DEVICE|Ciba Vision soft contact lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
40751802|NCT04633304|DEVICE|EndoAVF System for endovascular AV fistula creation|AV fistula creation
40751803|NCT02801227|DRUG|Oxytocin|Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
40751804|NCT02801227|DRUG|Prostaglandin E2|PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
40751805|NCT03421080|BEHAVIORAL|MoodGYM|The MoodGYM Internet intervention will employ the latest version of MoodGYM (Mark 4) which has been updated to support mobile devices. The core design and function of the program has not been altered. A major focus of this intervention is to provide individuals with behavioral and cognitive strategies to improve depression symptoms.
40751806|NCT03421080|BEHAVIORAL|Check Your Drinking|Internet intervention designed to assess and provide feedback on hazardous alcohol use. The CYD has been subjected to seven randomized trials from two independent research groups, all of which displayed a significant impact of the CYD to reduce hazardous alcohol consumption compared to controls.
41095681|NCT02862327|DRUG|intravenous placebo|intravenous injection of placebo
40751807|NCT00004931|DRUG|leucovorin calcium|Given IV
40751808|NCT00004931|DRUG|fluorouracil|Given IV
40751809|NCT00004931|DRUG|oxaliplatin|Given IV
40751810|NCT00004931|OTHER|laboratory biomarker analysis|Correlative studies
40751811|NCT05759455|DIETARY_SUPPLEMENT|vitamin d|Assessment of Vitamin D level in Children with Autism in assiut university children hospital
40751812|NCT06082544|OTHER|mini-screw implant|JEIL SCREW 1.6\* 8 MM 16-G2-008 or JEIL SCREW 1.6\*10 MM 14-G2-010
40751813|NCT06082544|DEVICE|removable partial denture|Acrylic removable partial denture
40751814|NCT03923842|DRUG|Denosumab Inj 120 MG/1.7ML|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
40751815|NCT03923842|DRUG|Chemotherapy as clinical standard of care|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
40751816|NCT04890171|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection by a endoscopist using endoscopic devices
40751817|NCT04890171|PROCEDURE|Surgery|Gastrectomy with lymph node dissection by a surgeon
40751818|NCT03264950|DIAGNOSTIC_TEST|Elastography|"an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.~Similarly an acoustic window will be selected for the pancreas as well"
40751819|NCT04093700|DEVICE|SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
40751820|NCT00635583|OTHER|Increased Dairy Consumption|"3 additional servings of dairy (two of which must be milk or yogurt)~* 8 oz milk~* 6 oz yogurt~* 1.5 oz cheese"
40751821|NCT05538468|OTHER|Assessment|Thirty stroke patients were included in the study. After the demographic information was obtained from all patients who accepted to participate in the study by complying with the inclusion criteria; The kinesiophobia scores of the patients were evaluated, depression severity, postural control and pain severity.
40751822|NCT05940636|OTHER|Activity-based rehabilitation+electrical stimulation|Balance training will occur three times per week for four weeks, totaling 12 two-hour sessions. In both groups, you will be asked to stand on a force plate while playing visual feedback training (VFT) games as part of the standing balance training. A force plate is similar to a bathroom scale that you can stand on which measures your body sway during movement. Visual feedback training (VFT) is a type of activity that includes weight-shifting movements in the upright stance. VFT will be done in both groups. There will be different games as shown in figure 1 and the order of the games will be randomly chosen in each session. During each game, there will be targets that will be presented on the screen and you will have to navigate toward them . You will be able to rest between games as needed.
40751823|NCT06308445|DRUG|Rapamycin|This is a 2-dose rapamycin safety study, with a target through level of 3 to \<5 ng/ml for the first 3 months and 5-8 ng/ml for the next 3 months for each of the included patients. To avoid the possible cumulative effect, the two treatment phases will be separated by a 3-weeks wash-out period.
40751824|NCT05248243|PROCEDURE|Recruitment assessment|"Intervention Details:~Construction of the P/V curve with subsequent measurement of HR and Vmax."
41095682|NCT02862327|DRUG|perineural ropivacaine|brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
41095683|NCT02862327|OTHER|ultrasound guidance|ultrasound guidance for brachial plexus block in the axillary fossa
41270546|NCT00542620|DRUG|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
41270547|NCT00542620|DRUG|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
40751825|NCT01666080|DRUG|Busulfan|0.4 mg/kg (0.5 mg/kg if \<4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
40751826|NCT01666080|DRUG|Fludarabine|40 mg/m\^2 intravenously (IV) over 1 hour on days -6 through -2.
40751827|NCT01666080|RADIATION|Total body irradiation|200 cGy on Day -1
40751828|NCT01666080|BIOLOGICAL|Stem cell transplant|stem cell infusion on day 0
40751829|NCT01666080|DRUG|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
41095684|NCT05295082|PROCEDURE|guided trephination-based drilling protocol|the implant site preparation in this group will be done by guided trephination protocol which uses the surgical guide to trephine the implant site then remove the guide and continue the drilling in a freehand manner
40751830|NCT05337748|DEVICE|Lexie Self Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
40751831|NCT05337748|DEVICE|Lexie Professional Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
40751832|NCT03914014|OTHER|connective tissue manipulation|From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area.
40751833|NCT03914014|OTHER|placebo ultrasound|From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose.
40751834|NCT05267002|PROCEDURE|Suture removal timing|Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.
40751835|NCT02164721|DEVICE|Three-lead CRT-D (Defibrillator)|The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
40751836|NCT05140980|OTHER|Data collection|evaluation of women's knowledge concerning sexuality
40751837|NCT04599335|DEVICE|2% HA|2% HA
40751838|NCT05004168|OTHER|Day Gel-0120|Two milligrams of test article applied to the test area. The test products are Day Gel-0120C and Day Gel-0120-D. The products are applied together on the test area with
40751839|NCT05004168|OTHER|P5 Reference Standard (SPF 35 reference)|The reference product is P5 according to ISO 24444:2019. The application of reference product is similar with test product.
40751840|NCT00319891|PROCEDURE|Computer-based Cognitive Training|
40751841|NCT03204747|OTHER|Observational study : gait speed|No intervention, only propose water and wait for need to void
40751842|NCT01210209|OTHER|genome-wide association study|
40751843|NCT02636283|DRUG|Entresto|Oral pills
40751844|NCT02636283|DRUG|Placebo group|The placebo pills
40751845|NCT05693805|BEHAVIORAL|Tai Chi|The remote delivery Tai Chi protocol that will be developed in this study for Veterans with PTSD and pain will be adapted from a protocol that has been well-tested in previous trials All components of the program derive from the classical Yang-style Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Sessions will last 60 minutes, twice a week for 12 weeks. Experienced instructors will follow the Tai Chi protocol with rigorous quality control procedures. We will provide the patients with printed materials on the Tai Chi program, including Tai Chi principles, practice techniques, and safety precautions. Every session will include: warm up and a review of Tai Chi principles; breathing techniques; meditation with Tai Chi movement; and relaxation.
40751846|NCT05693805|BEHAVIORAL|Wellness program|The Wellness intervention that will be developed for this study will consist of 60-minute sessions that meet twice a week for 12 weeks, and will be facilitated by doctoral level psychology staff and/or psychology trainees who will be supervised by staff. The Wellness intervention will be based on the VA Whole Health Program which helps individuals identify and achieve their personal health goals. The Whole Health Program include modules that address physical activity, personal development, healthy eating and drinking, stress management, relationships, personal surroundings, and spirituality. Using the SMART goals model, participants will set health and wellness goals each week. Discussions about ways to address potential barriers will be included in this condition.
40751847|NCT00490412|DIETARY_SUPPLEMENT|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
40751848|NCT00490412|OTHER|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
40751849|NCT06419309|OTHER|Dietary intervention|"Four different dietary interventions are planned.~* Gluten-free, lactose-free diet,~* Diet enriched with Aronia Melanocarpa,~* Gluten-free, lactose-free and enriched with Aronia Melanocarpa diet,~* Healthy diet"
40751850|NCT02239484|DRUG|Tadalafil|
40751851|NCT02239484|DRUG|Tamsulosin|
40751852|NCT02239484|DRUG|Tadalafil + Tamsulosin|
40751853|NCT00532857|DRUG|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
40751854|NCT02369250|DRUG|Rosuvastatin|Rosuvastatin, is a statin group of drug.
40751855|NCT02369250|BIOLOGICAL|platelet rich fibrin|AUTOLOGUS PLATELET GROWTH FACTOR
40751856|NCT03024164|OTHER|Treatment following current guidelines|Treatment following current guidelines
40751857|NCT02382263|DRUG|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
40751858|NCT02382263|DRUG|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
40751859|NCT02382263|DRUG|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
40751860|NCT02382263|DRUG|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
40751861|NCT01441414|BIOLOGICAL|PF-04856884|15 mg/kg/week intravenously \[IV\] until toxicity or disease progression
40751862|NCT01441414|DRUG|Axitinib (AG-013736)|5 mg PO BID
40751863|NCT01441414|DRUG|Axitinib (AG-013736)|5 mg PO BID
40751864|NCT02466581|DRUG|Sulphasalazine + Hydroxychloroquine OR Prednisolone|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
40751865|NCT02466581|BIOLOGICAL|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
40751866|NCT02466581|BIOLOGICAL|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
41095685|NCT05295082|PROCEDURE|guided Conventional drilling-based protocol|the implant site preparation in this group will be done by a guided conventional drilling protocol which uses the surgical guide to guide the sequential drills up to the final drill
40751867|NCT02466581|BIOLOGICAL|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
40751868|NCT03072342|PROCEDURE|Intensive Periodontal Treatment|
40751869|NCT03072342|PROCEDURE|Control Periodontal Treatment|
40751870|NCT00360854|DRUG|erlotinib hydrochloride|
40751871|NCT00360854|GENETIC|mutation analysis|
40751872|NCT00360854|GENETIC|polymorphism analysis|
40751873|NCT00360854|OTHER|laboratory biomarker analysis|
40751874|NCT00360854|OTHER|pharmacological study|
41095686|NCT04348370|BIOLOGICAL|BCG Vaccine|BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.
41095687|NCT04348370|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.
41095688|NCT03146351|OTHER|Family based early intervention program (NDT-Bobath based)|Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
40751875|NCT00360854|RADIATION|radiation therapy|
40751876|NCT05092503|DRUG|JINZHEN Granules for Oral Solution|JINZHEN granules will be dissolved in drinking water and administered orally.
40751877|NCT05092503|DRUG|Placebo|Placebo granules will be dissolved in drinking water and administered orally.
40751878|NCT02849223|DEVICE|Anodal Transcranial Direct Current Stimulation|2 milliamps (mA) of anodal stimulation will be applied to the left dorsal lateral cortex for 20 minutes concurrent with working memory training.
40751879|NCT02849223|DEVICE|Sham stimulation|30 seconds of anodal TDCS stimulation will be applied to the left dorsal lateral cortex concurrent with working memory training
40751880|NCT00268398|DRUG|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1\&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1\&2) continuous 5FU 600mg/m² (day 1 to 2)
40751881|NCT00268398|DRUG|oxaliplatin, irinotecan, folinic acid, fluorouracil|"FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)"
40751882|NCT05373836|DIAGNOSTIC_TEST|prognostic nutritional index calculated from laboratory parameters|Calculated nutritional index using laboratory results of serum albumin, lymphocyte count, and cholesterol
40751883|NCT03397719|BEHAVIORAL|Treatment Condition|This group will receive three hours of parent coaching per week, one hour per week will involve feedback on parent usage of coached strategies based on parent recorded interactions with their children.
40751884|NCT03397719|BEHAVIORAL|Control Group|This group will receive in-vivo parent coaching three hours per week.
40751885|NCT04794998|DRUG|Recommended treatment schedule|Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle Oxygen therapy
40751886|NCT04794998|DRUG|Control treatment schedule|Treatment regimens different from the recommended one according to family phisicians personal practice.
40751887|NCT04322045|DIAGNOSTIC_TEST|multi-parametric MRI|Multi-parametric MRI will be suggested for those PSA ≥4 ng/mL, PI-RADS v2 score will be used to evaluate images.
40751888|NCT03130322|OTHER|Imagery and Sleep questionnaires|Participants complete a motor imagery questionnaire to assess their ability to form vivid mental images, as well as sleep questionnaires to control the quality of their sleep
40751889|NCT03130322|OTHER|MEG recordings (pre-test)|"Participants of the Day group perform two motor tasks (a finger sequential motor task and an adaptation motor task using a trackball) in the MEG, during a pre-test (Day 1 - 9h).~Task 1: Participants perform an 8-digit motor sequential task where each finger (except the thumb) is used twice. Performance is assessed by using a 4-keys keyboard. Participants are required to keep their fingers on the keys to minimize amplitude are instructed to tap the sequence as few errors as possible Task 2: Participants perform a motor adaptation task requiring scrolling a trackball to superimpose a geometric shape on another one, strictly similar but presented from another angle, as fast as possible."
40751890|NCT03130322|OTHER|Practice session|Participants of the Day group perform a block of motor imagery practice of the two motor tasks.
41095689|NCT05206357|DRUG|Epcoritamab|Subcutaneous Injection (SC)
41095690|NCT00800124|PROCEDURE|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
41095691|NCT04451733|PROCEDURE|Endotracheal intubation|Perform the endotracheal intubation during CPR
41095692|NCT02157402|BEHAVIORAL|Social marketing activities and pop-up events to promote healthy lifestyles|
41095693|NCT05707052|OTHER|Neck-Trunk Stabilization Exercises and conventional physical therapy|Neck-Trunk Stabilization Exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
41095694|NCT05707052|OTHER|Bobath Therapy and conventional physical therapy|Bobath based exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
40751891|NCT03130322|OTHER|MEG recordings (Post-test)|Participants perform the two motor tasks in the MEG (post-test, strictly similar to the pre-test)
40751892|NCT03130322|OTHER|MRI|The registration of the brain anatomy of each participant will be done by MRI 3D / T the week before the first experimental session.
40751893|NCT00664040|OTHER|Aspirin|The aspirin intervention (81 mg per day) will last a total of 14 days. Pills will be provided in a pre-loaded pillbox. The field team will visit the subject at his/her home at least once to insure adherence to the aspirin intervention and to monitor for adverse side effects. On day 14 of the aspirin intervention, the subject will visit the clinic for a fasting blood draw for platelet aggregation and inflammatory marker studies. A pill count will be performed to assess adherence. The subject can miss up to four aspirin doses over the two-week period; however, an aspirin must be taken each day for the three days prior to clinic visit 2. The aspirin intervention can be extended for up to three days (17 days total) to meet the latter criteria. If more than four doses were missed, then the physician should be contacted and the patient should be withdrawn from the aspirin intervention. Platelet aggregation will be measured 1 hour after the last dose of aspirin.
40751894|NCT00664040|OTHER|Cold Pressor Test|This intervention consists of the participant placing his or her hand and wrist into ice water for 2½ minutes. The blood pressure is taken before and after the arm is removed from the water. An ultrasound machine is used to take pictures of the brachial artery in the left arm before and after the arm is removed from the water.
40751895|NCT00664040|OTHER|High Fat Meal|The participants are given a high fat milk shake consisting of 83% fat. Blood samples are drawn from a catheter placed in the participant's arm prior to the test. The samples are drawn before the milk shake and at 1, 2, 3, 4, and 6 hours after the milk shake is consumed. Before and at 2, 4 and 6 hours following the meal the ultrasound is used to obtain images of the brachial artery.
40751896|NCT00664040|OTHER|Dietary Salt|The salt intervention will consist of 6 days of an isocaloric high salt diet (270 mmol/d) followed by a washout period of at least 8 days and then a low salt diet (40 mmol/d). All food will be prepared by a registered dietician and dietary technicians in a specially equipped kitchen. The specific foods will consist of approximately 50% carbohydrates, 35% fat, and 15% protein. Dietary potassium will remain constant at 120 mmol/d. A food diary will be kept for each diet and subjects will be instructed to eat only the food provided. A field nurse will visit the home on days 3 and 5 of each diet to insure that neither diet is acutely affecting the health status of the subject. A first AM void spot urine will be obtained to measure sodium, potassium and creatinine on the 4th, 5th, and 6th days of each diet to insure compliance. Blood pressure will be measured using an ambulatory blood pressure monitor for 24 hours on the last day of each diet.
40922608|NCT00611754|DRUG|Oxaliplatin, 5-FU|Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
40751897|NCT03838328|DRUG|Tranexamic Acid|Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
40751898|NCT03024632|PROCEDURE|Trial of labor|trial of labor after 3 or more previous cesarean deliveries
40751899|NCT03572114|DIAGNOSTIC_TEST|3Tesla MRI|"1. A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content~2. Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes).~3. 1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo)~4. conventional FLAIR sequence"
40751900|NCT03572114|BEHAVIORAL|Burke-Fahn-Marsden Dystonia Rating scale|internationally standardized examination/quantification of dystonia
40751901|NCT03572114|BEHAVIORAL|MDS-United Parkinsons Disease Rating Scale, Part III|most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society
40751902|NCT03572114|BEHAVIORAL|Beck Depression Inventory|internationally standardized examination to quantify traits of anxiety and depression
40751903|NCT03572114|BEHAVIORAL|MoCA: Montreal Cognitive Assessment:|internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism
40751904|NCT04100187|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
40751905|NCT00494884|DRUG|vildagliptin|
40751906|NCT00505362|PROCEDURE|Rectus closure|Reapproximation of the rectus muscles with three-interrupted sutures
40922609|NCT02874170|OTHER|Spectroscopy magnetic resonance of phosphorus 31|
40922610|NCT03995329|OTHER|IQOS|Acute effects of IQOS on pulmonary function, oxygen saturation, exhaled CO, heart rate and arterial blood pressure.
40751907|NCT04837742|DRUG|ESPB group|ESPB injection at T10 region with Chirocaine 100mg(20 cc)+ Omnipaque 10cc
40751908|NCT04837742|DRUG|Control group|ESPB injection at T10 region with Normal saline 20cc + Omnipaque 10cc
40922611|NCT01481532|DRUG|Crotoxin|Intra patient dose escalation
40751909|NCT03473158|DEVICE|Transvaginal ultrasound|using the 6.5mHz intra-cavitary probe (65EC10EA) of ultrasound machine DP-50 (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., P.R.China) to determine the number, site, size and cardiac activity of the fetuses, and monitor the fetal reduction procedure
40751910|NCT03473158|PROCEDURE|Mechanical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
40751911|NCT03473158|PROCEDURE|Chemical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
40751912|NCT01599676|DIETARY_SUPPLEMENT|Citrulline|The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
40751913|NCT01599676|DIETARY_SUPPLEMENT|Non essential amino acid|Non essential amino acid supplementation
40751914|NCT03148925|BIOLOGICAL|SELA-070|Sub-cutaneous injection, multiple dose
40751915|NCT03148925|BIOLOGICAL|Saline|Sub-cutaneous injection, multiple dose
40751916|NCT00003327|DRUG|paclitaxel|
40922612|NCT02236351|DEVICE|Pinch Patch/ flat Patch|
40922613|NCT04540510|DEVICE|OPEP therapy|Oscillatory Positive Expiratory Pressure therapy
40751917|NCT01834300|BEHAVIORAL|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
40751918|NCT01834300|BEHAVIORAL|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
40751919|NCT00001082|DRUG|Levocarnitine|500 mg tablet taken orally daily
40751920|NCT00001082|DRUG|Adefovir dipivoxil|120 mg tablet taken orally daily
40922614|NCT04540510|OTHER|Standard care|Standard pneumonia care
40922615|NCT05002244|DRUG|CTL0801 (Azilsartan)|CTL0801 (Azilsartan), single dose, daily, repeated oral administration
40922616|NCT05002244|DRUG|CTL0802 (Rosuvastatin)|CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
40751921|NCT00001082|DRUG|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
40751922|NCT00279513|DRUG|Traumeel S|
40751923|NCT01855568|PROCEDURE|Single-dose Methotrexate|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell \<15% between day 11 and 14."
40751924|NCT01855568|PROCEDURE|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell \<15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
40751925|NCT02454582|DEVICE|Somanetics INVOS Cerebral Oxymeter 5100C|Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
40751926|NCT03305211|OTHER|sample|Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine.
40922617|NCT05002244|DRUG|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
40922618|NCT00700167|BIOLOGICAL|dendritic cell vaccine|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months."
40751927|NCT04924452|PROCEDURE|Laser conditioning and Sealant application|Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; laser conditioning of the occlusal enamel surface. The parameter settings used will be: tip-to-tissue distance 1.5mm from the tooth surface; tip diameter 600 µm; laser energy 70 mJ; pulse frequency 10 Hz; water spray level 8; average power 0.7 W; energy density 67 J/cm2; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
40751928|NCT04924452|PROCEDURE|Sealant application|Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
40922619|NCT03608150|DEVICE|Luminopia One|Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.
40922620|NCT03608150|DEVICE|Refractive Correction|Standard of care refractive correction (ex. spectacles)
40922621|NCT02423967|BIOLOGICAL|Transplant uses frozen anonymous stool|The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
40922622|NCT02423967|BIOLOGICAL|Transplant uses fresh familial stool|The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
40922623|NCT02757638|OTHER|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
40922624|NCT01944280|OTHER|massage|
40922625|NCT02568891|DIETARY_SUPPLEMENT|Probiotic|multispecies probiotic
40922626|NCT02568891|DIETARY_SUPPLEMENT|Placebo|matrix
40922627|NCT00724711|DRUG|emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|FTC 200 mg/TDF 300 mg tablet, once a day
40922628|NCT00724711|DRUG|abacavir (ABC)/lamivudine (3TC)|ABC 600 mg/3TC 300 mg tablet, once a day
40922629|NCT02428127|DIETARY_SUPPLEMENT|Carbohydrate beverage powder|Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
40922630|NCT02428127|DIETARY_SUPPLEMENT|Calorie matched beverage powder|Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
40922631|NCT02428127|OTHER|Water|lukewarm water
40922632|NCT02991664|OTHER|Equia Forte|Glass ionomer restorative system
40922633|NCT02991664|OTHER|G-aenial Posterior|Micro hybrid composite resin
40751929|NCT04924452|DEVICE|Er:YAG laser therapy|Er:YAG laser (LiteTouch, Light Instruments LTD), emission wavelength 2940 nm will be used for caries removal - parameters: enamel removal - energy 100-200mJ; density 9.84-13.03 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface; dentin removal - energy 100mJ; density 9.84 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface. Restoration with compomer.
40751930|NCT04924452|PROCEDURE|Conventional therapy|Conventional rotary instruments will be used for caries removal - high-speed and low-speed dental handpieces. Restoration with compomer.
40751931|NCT04821011|DEVICE|electronic stethoscope|Record of maternal heart sounds (heartbeats) with an electronic stethoscope during 10 minutes.
40751932|NCT04821011|DEVICE|acoustic listening of mother's heartbeats|Each newborn included will have 20 minutes of an acoustic listening of their mother heartbeats previously recorded.
40751933|NCT04821011|DEVICE|Recording of the newborn's heart rate|"Recording of the newborn's heart rate: one hour before the acoustic listening, during the acoustic listening and one hour after the acoustic listening .~The variations of the autonomic nervous system will be analyzed.~An coupled Heart rate variability recording (ECG signal obtained from a Philips® IntelliVue MX700 monitor) and NIPΣ index of comfort (MDMS® NIPΣ monitor) will be used."
40751934|NCT04648241|BIOLOGICAL|TBE vaccine 0.5 mL|TBE vaccine 0.5 mL (intramuscular injection).
40751935|NCT04648241|BIOLOGICAL|TBE vaccine 0.25 mL|TBE vaccine 0.25 mL (intramuscular injection).
40751936|NCT02297035|BEHAVIORAL|Behavioural testing|
40751937|NCT02297035|OTHER|Brain imaging|MRI, PET
40751938|NCT02297035|GENETIC|Genetic screening|APOE, Progranulin
40751939|NCT03682393|DRUG|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
40751940|NCT03682393|DRUG|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
40751941|NCT05996705|OTHER|Determining the relationship of fatigue with some parameters|Determining the relationship of fatigue with physical function, pain values at rest and in motion, gender, age, pain, disease activity, gender and disease duration in RA patients.
40751942|NCT02211742|DRUG|Dapagliflozin|euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
40751943|NCT06265805|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
40751944|NCT06265805|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
40751945|NCT06265805|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
40751946|NCT03993678|DRUG|IP-001|Dose and route: Immediately (within 15 - 30 min) after thermal ablation, IP-001 will be injected in and around the ablated lesion. The amount of IP-001 injected depends on the dose level.
40751947|NCT03993678|DEVICE|Thermal Ablation|"The medical device includes a laser unit. The system continuously measures the temperature of the tissue, guiding the user to perform precise and safe treatments.~Treatment time: 30 min"
40751948|NCT03815604|BEHAVIORAL|Independent Housing and Support (IHS)|Direct placement of people with SMI in an independent accommodation in the community, usually in a flat rented by the service user. Support is provided by a coach according to individual needs in a permanent housing situation without time limit.
40751949|NCT03815604|BEHAVIORAL|Residential Care Settings and other Treatment as Usual (RCS/TAU)|Placement in a common residential home or supportive housing setting with the aim to gain psycho-social stability before being able to maintain independent housing.
40751950|NCT01160744|BIOLOGICAL|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
40751951|NCT01160744|DRUG|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
40751952|NCT01160744|DRUG|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
40751953|NCT01160744|DRUG|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
40751954|NCT01160744|DRUG|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
40947754|NCT04185038|BIOLOGICAL|SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel|Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
41095695|NCT01460381|DRUG|LY2216684|
41095696|NCT01460381|DRUG|Quinidine|
41095697|NCT05139056|BIOLOGICAL|Neural Stem Cells-expressing CRAd-S-pk7|Given intracerebrally
41095698|NCT05139056|PROCEDURE|Resection|Undergo surgical resection
41095699|NCT02341989|DRUG|Bleomycin Etoposide and Cisplatin|
41095700|NCT02341989|DRUG|Carboplatin|
40922634|NCT04096378|BEHAVIORAL|EMBRace Intervention Group|The EMBRace intervention will consist of five weekly sessions (weeks 2 - 6) that will be facilitated by EMBRace-trained therapists. Throughout the 8-week intervention, families will be scheduled for 2-hour blocks with sessions being administered to each parent and adolescent for 90 minutes (individually for 30 minutes, 15-minute break, and 45-minutes session with parent and adolescent together). The sessions will cover research-based types of Racial Socialization, including cultural pride, preparation for bias, and attentiveness and balance towards societal racism. Parents and youth will also learn and practice five literacy skills to process and manage the stress of racial encounters including the ability to recognize racial discrimination, accurately appraise the stress of self and others, reduce one's stress, engage instead of avoid, and finally resolve toward healthy outcomes.
40922635|NCT04096378|BEHAVIORAL|EMBRace Waitlist Group|The waitlist group will be asked to complete a pretest and posttest while the treatment group goes through the EMBRace intervention. During this time, the waitlist group will not have any additional requirements and will not be given any form of comparative treatments. Upon the completion of the treatment from the intervention group, the waitlist group will be consented for entry into the intervention arm of the study and will follow the procedures for the intervention group above.
40751955|NCT01160744|DRUG|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
40751956|NCT01467804|DRUG|Sertraline plus placebo of JWXYJN|oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
40751957|NCT01467804|DRUG|JWXYJN plus placebo of Sertraline|JWXYJN 3.6g/d plus placebo of sertraline
40751958|NCT06401109|DEVICE|AquaPass|"The AquaPass system works by activating the body's natural sweating mechanism to remove excess fluid from the interstitial compartment. This process is achieved by wearing a garment that creates optimal microclimate conditions around the skin.~The system is controlled by a portable unit that delivers warm air to the wearable component while ensuring patient safety."
40751959|NCT01312077|DRUG|Levobupivacaine|peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
40751960|NCT01312077|DRUG|Intrathecal morphine|intrathecal morphine bolus 200 micrograms
40751961|NCT00626860|BIOLOGICAL|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
40751962|NCT00741221|DRUG|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
40922636|NCT04136015|DRUG|Dasatinib 100 MG|The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group
40922637|NCT02224118|DRUG|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
41095701|NCT04892303|COMBINATION_PRODUCT|Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)|To safely administer a minimum cumulative dose of external beam radiation to up 3 index tumors per patient, supplemented radiation dose delivered by radioactive iodine (RAI)
41095702|NCT02639962|RADIATION|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
40751963|NCT00741221|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
40922638|NCT02224118|DRUG|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
41095703|NCT05801042|DIETARY_SUPPLEMENT|Maltodextrin|Placebo product
41095704|NCT05801042|DIETARY_SUPPLEMENT|Encapsulated Lactocaseibacillus rhamnosus|Probiotic product
41095705|NCT05801042|DIETARY_SUPPLEMENT|Non-encapsulated Lactocaseibacillus rhamnosus|Probiotic product
41095706|NCT03980756|DRUG|AD-206 20mg|1 tablet administered before the breakfast during 7 days
41095707|NCT03980756|DRUG|Esomeprazole 20mg|1 tablet administered before the breakfast during 7 days
41095708|NCT03980756|DRUG|AD-206 40mg|1 tablet administered before the breakfast during 7 days
41095709|NCT03980756|DRUG|Esomeprazole 40mg|1 tablet administered before the breakfast during 7 days
41095710|NCT01649427|DRUG|Prograf|Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
41095711|NCT01649427|DRUG|Tacrolimus Hexal|"Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg."
41095712|NCT02543450|OTHER|Cardiovascular and task-oriented training|
40751964|NCT00848315|BEHAVIORAL|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
40751965|NCT05874011|OTHER|understanding of prosody|The inverse correlation test consists of having the same word heard twice, and asking which of the two sounds the most like a question. The exercise will be repeated several times, for a task that will take a total of about thirty minutes
40751966|NCT05995418|OTHER|There was no intervention as this was an observational study.|There was no intervention as this was an observational study.
40751967|NCT04129333|OTHER|Hypnosis|"The hypnosis session :~* Creation of the therapist-patient link~* Choice of a theme and the preferred sensory channel by the patient~* Collection of the theme chosen by the patient~* Orientation in the here and now.~* Induction~* Realization of the gesture and hypnosis~* At the end of the procedure, reassociation of the patient in the here and now"
40751968|NCT04129333|OTHER|No hypnosis|No hypnosis
40751969|NCT02402231|DRUG|Omalizumab|Omalizumab is the treatment during oral immunotherapy with peanuts as protection
40751970|NCT03313765|BEHAVIORAL|Motivational interviewing (MI)|Brief MI intervention
40922639|NCT02224118|DRUG|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
40922640|NCT02224118|DRUG|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
40922641|NCT02224118|DRUG|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
40922642|NCT03565367|OTHER|Gadolinium|gadolinium enhanced MRI
40922643|NCT03565367|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
40922644|NCT03565367|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40922645|NCT03565367|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
40922646|NCT00004082|DRUG|carboplatin|
40922647|NCT00004082|DRUG|docetaxel|
40922648|NCT00004082|DRUG|gemcitabine hydrochloride|
40922649|NCT05330884|BIOLOGICAL|BCG vaccine|0.1ml BCg vaccine to be given intradermally
40922650|NCT05330884|DRUG|Oral Chemoprophylaxis|Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
40922651|NCT01788813|DRUG|GSK2245035|Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
40922652|NCT01788813|DRUG|Placebo|Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
40922653|NCT03174002|DRUG|Oxygen|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
40922654|NCT03174002|DRUG|Oxygen|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
40922655|NCT01757145|DRUG|Eltrombopag|"From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.~If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count \< 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count \>50,000/microliter will be reached again)."
40922656|NCT02921464|OTHER|none - registry clinic followup only|
40922657|NCT05858775|DEVICE|Pregnolia System|Cervical stiffness assessment with the Pregnolia System at 3 locations on the uterine cervix.
40922658|NCT06163378|DEVICE|Rubato Life App|An algorithmically enhanced personalized music-based intervention
40922659|NCT04097951|DRUG|Combinations|Montelukast and Bepotastine Combination
40922660|NCT01529138|DRUG|Axitinib|Combination treatment with temsirolimus and axitinib
40922661|NCT01529138|DRUG|Temsirolimus|Combination treatment with temsirolimus and axitinib
40922662|NCT01455909|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
40922663|NCT01455909|DRUG|sitagliptin|sitagliptin oral 100 mg/day
40922664|NCT02858700|BIOLOGICAL|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP|
40922665|NCT00305929|DRUG|Treatment with Tookad VTP|
40922666|NCT00305929|DRUG|Treatment with Tookad VTP|Tookad 2 mg/kg
40922667|NCT00305929|DRUG|Treatment with Tookad VTP|2 mg/kg
40922668|NCT01056302|PROCEDURE|Surgical repair of mandibular fractures|Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated surgical outcome using the proposed software tool.
40922669|NCT03079544|COMBINATION_PRODUCT|L-Asparaginase or or Pegaspargase containing chemotherapy|Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.
40922670|NCT06013215|OTHER|Cochlear implant (Oticon) stimulation parameter optimization|The pulse amplitude and/or the pulse phase duration will be optimize to improve the intensity resolution of the cochlear implant which may benefit speech perception
40922671|NCT00275821|DRUG|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
40922672|NCT00275821|DRUG|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
40922673|NCT00275821|DRUG|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
40922674|NCT03717272|DRUG|AEF0117|AEF0117 capsules
40922675|NCT03717272|DRUG|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
40922676|NCT00753740|DRUG|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
40922677|NCT00753740|DRUG|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
40922678|NCT00753740|DRUG|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
40922679|NCT01883856|DEVICE|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
40922680|NCT01883856|DEVICE|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
40947755|NCT00662688|DRUG|daltéparine|
40922681|NCT03353337|BEHAVIORAL|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 months.
40922682|NCT03353337|BEHAVIORAL|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
40922683|NCT02535572|DEVICE|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
40922684|NCT02535572|DEVICE|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
40922685|NCT00966914|DRUG|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
40922686|NCT00966914|DRUG|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
40922687|NCT04036123|OTHER|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
40922688|NCT06080672|OTHER|Experimental: Group 1 (dental examination-training-tooth brushing) Experimental: Group 2 (dental examination-training-plaque disclosing-tooth brushing)|All participants will be examined and their decay, filling and extracted teeth, plaque index and gingival index measurements will be recorded. Plaque disclosing will be applied to Group 2 after brushing training.
40922689|NCT05859737|BEHAVIORAL|Disaster Preparedness Education Program|The SIMAH Program includes interactive group training for three months, public education materials prepared by AFAD, and reminder phone messages will apply.
40922690|NCT05859737|OTHER|Disaster and Emergency Management Presidency Education|Public education materials prepared by the Disaster and Emergency Management Presidency (AFAD) will give.
40922691|NCT02262208|OTHER|Aerobic Exercises|"Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.~Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test."
40922692|NCT02262208|OTHER|Eccentric Exercise|Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.
40922693|NCT02262208|DEVICE|Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)|Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
40922694|NCT04725357|DRUG|Meloxicam 15 mg|Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery
40922695|NCT04725357|PROCEDURE|Preoperative Interscalene Nerve Block|Preoperatively participants will standardly receive an interscalene nerve block
40922696|NCT04725357|PROCEDURE|arthroscopic labral repair|participant will have their standard surgical procedure done
40922697|NCT02181517|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
40922698|NCT02181517|DRUG|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
40922699|NCT02181517|OTHER|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
40922700|NCT03670420|OTHER|Medical honey|The investigators use Medihoney®, a medical honey released by the DermaSciences.
40922701|NCT00635024|BIOLOGICAL|anti-thymocyte globulin|2.5 mg/kg
40922702|NCT00635024|DRUG|melphalan|16 mg/m\^2
40922703|NCT03769376|DEVICE|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction.
40922704|NCT03769376|DEVICE|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction.
40922705|NCT04962256|PROCEDURE|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
40922706|NCT04220593|OTHER|tDCS associated with Tcog|2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
40922707|NCT05115864|DEVICE|PFMT with device|The wearable PFMT device (XFT-0010CK) is made by two parts. One part is the screen device which is able to show the real-time vaginal resting pressure and voluntary contraction pressure in units of mmHg. The other part is a vaginal air-filled probe. The two parts are combined with a thin air tube. The whole device is connected to a smartphone app by Bluetooth to record the progress of PFMT. There are two modes of the device, one is assessment mode, when it comes to the assessment mode that the device is able to assess the grade of type I and II pelvic floor muscle fiber strength by the patients themselves, the other mode is practice mode by displaying real-time visual pressure value according to the completeness of the PFMT program.
40922708|NCT01418508|BEHAVIORAL|low protein diet plus α-keto acid|low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
40922709|NCT01418508|BEHAVIORAL|very low protein diet plus α-keto acid|very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
40922710|NCT03907839|OTHER|clinical trials|examined two type of training on cognitive parameters for COPD patients
40947756|NCT00662688|DRUG|Chemotherapy at the investigator's discretion|
40947757|NCT03178331|OTHER|Study questionnaires|filled by parents, school nurse and teacher
40947758|NCT03237078|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
40922711|NCT03834649|PROCEDURE|partially de-epithelized connective tissue graft|graft procedures to obtain simultaneous tissue augmentation in the horizontal and vertical dimensions. The donor site was prepared with a full-thickness coronal dissection and a partial-thickness apical dissection.The objectives were to use a single procedure to achieve simultaneously apico-coronal and buccolingual augmentation,to have a smaller open wound in the donor site and less patient discomfort, and to guarantee better revascularization of the onlay section aided by the submerged connective tissue section of the graft.
40922712|NCT03834649|PROCEDURE|Mucograft|"For preprosthetic defects, a standard mucosal augmentation procedure, which is well reported in the literature, was performed. The surgical site produced by the surgery leaves a denuded area supraperiosteally that is addressed by grafting with a xenogeneic collagen membrane (Mucograft).~purpose of the surgery is to improve the quantity of attached mucosa to facilitate the final dental reconstruction"
40922713|NCT00401180|DRUG|docetaxel|administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.
40922714|NCT00401180|DRUG|temozolomide|administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.
40922715|NCT03777462|DRUG|Neoadjuvant gemcitabine plus nab-paclitaxel|Neoadjuvant gemcitabine plus nab-paclitaxel is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. Surgical resection will be performed after neoadjuvant chemotherapy.
40922716|NCT03777462|DRUG|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
40922717|NCT03777462|DRUG|Neoadjuvant S-1 plus nab-paclitaxel with SBRT|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
40922718|NCT02653703|OTHER|Topical L-menthol 40%|Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
40922719|NCT02653703|OTHER|Vehicle, topical ethanol 96%|Organic solvent CAS Number: 64-17-5
40922720|NCT01547780|DRUG|[11C]PBR28 and Positron Emission Tomography (PET)|Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.
40922721|NCT05128422|OTHER|Normobaric oxygen therapy|it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours.This therapy should begin in the emergency room as early as possible when patients meet the inclusion criteria and are randomized to the experimental group
40922722|NCT05929573|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin|Neutrophil Gelatinase-Associated Lipocalin, which can be measured from serum or urine, can detect acute kidney failure that may occur after surgery in the early stages.
40922723|NCT05929573|DIAGNOSTIC_TEST|Renal Doppler Resistive Index|Renal Doppler Resistive Index (RDRI) is a non-invasive index believed to reflect renal vascular perfusion. RDRI measurement is a repeatable, inexpensive, and easy-to-apply technique. RDRI has been found to be associated with AKI in conditions such as renal dysfunction, hypertension, and post-traumatic hemorrhagic shock. Furthermore, due to the impact on renal perfusion in patients undergoing major surgery, RDRI, which reflects renal vascular resistance, can serve as an indicator of kidney perfusion.
40922724|NCT00225264|DRUG|Pioglitazone|Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
40922725|NCT00225264|DRUG|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
40922726|NCT01873521|PROCEDURE|Non invasive ventilation|
40922727|NCT02113800|DRUG|Everolimus (Afinitor®)|Formulation: 10 mg/day Route: oral (tablet)
40922728|NCT00425178|DRUG|FGF-1|
40922729|NCT01827683|OTHER|Hyperbaric oxygen|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
40922730|NCT03893253|OTHER|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
40922731|NCT03893253|OTHER|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
40922732|NCT05946356|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
40922733|NCT00239135|DRUG|PEP005|
40922734|NCT02931708|OTHER|Diaphragm functional electrical stimulation|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
40922735|NCT05857553|OTHER|Unconditional Cash Transfer|Unconditional monthly transfer of $500 to household
40922736|NCT05857553|OTHER|No Direct Cash Transfer|No intervention
40922737|NCT03615508|DRUG|10% phenylephrine|10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
40922738|NCT03776370|PROCEDURE|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
40922739|NCT03776370|PROCEDURE|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery.
40922740|NCT01648556|OTHER|Blood tests and bone marrow biopsy repeated|"Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal."
40751971|NCT03313765|OTHER|Standard-of-care|Standard-of-care education and counseling
40922741|NCT01688206|BIOLOGICAL|Atezolizumab [TECENTRIQ]|Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
40922742|NCT01688206|BIOLOGICAL|Vanucizumab|Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram \[mg\] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
40922743|NCT04844710|COMBINATION_PRODUCT|acupuncture and standard care|manual acupuncture in acupoint LI4, LI11, ST36 every 2 days for 6 times standard care
40922744|NCT04844710|DRUG|standard care|standard care only
41095713|NCT02543450|OTHER|Upper limb strength training program|
40922745|NCT05122598|DRUG|COT|The COT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
40922746|NCT05122598|DRUG|Sham|Sham COT uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks.
40922747|NCT05154305|BEHAVIORAL|multidisciplinary intervention|"* individually adjusted physical program consisting of strength and endurance training \> 3 times a week, 2 times guided by a physical therapist at the University Hospital or at a private practice, and ones a week by themselves at home recorded by an activity tracker. Follow-up is foreseen on monthly basis.~* multidisciplinary coaching (discipline depending on personal needs of patient) on a monthly basis. These coaching sessions could be in small groups or individual."
40922748|NCT05076864|OTHER|No intervention|No intervention
40922749|NCT05153889|OTHER|Hospitalized in Intensive care unit|Patient hospitalized in Intensive care unit with ECG monitoring
40922750|NCT05153889|OTHER|Hospitalized in General cardiology ward|Patient hospitalized in General cardiology ward without ECG monitoring. patients randomized in this group will not be hospitalized in intensive care unit unless an event require intensive care unit monitoring.
40922751|NCT01193296|DRUG|Vildagliptin|
40922752|NCT01193296|DRUG|Sitagliptin|
40922753|NCT05052931|DRUG|Nab-paclitaxel combined with oxaliplatin and S-1|Nab-paclitaxel 100mg/m\^2, D1, Q3W; oxaliplatin 85 mg/m\^2, D1, Q3W; S-1 60 mg/m\^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.
40922754|NCT04734197|DRUG|SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)|combination of a topical immunosuppressant and a topical corticosteroid solution
40922755|NCT04734197|DRUG|Mycophenolic Acid 0.1%|topical immunosuppressant
40922756|NCT04734197|DRUG|Mycophenolic Acid 0.3%|topical immunosuppressant
40922757|NCT04734197|DRUG|Betamethasone Sodium Phosphate 0.01%|topical corticosteroid solution
40922758|NCT04734197|DRUG|Placebo Comparator: Vehicle|topical vehicle solution
40922759|NCT04734197|DRUG|Cyclosporine 0.05% Ophthalmic Emulsion|topical ophthalmic emulsion
40922760|NCT04734197|DRUG|Lifitegrast 5% Ophthalmic Solution|topical ophthalmic solution
40922761|NCT02122913|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
40922762|NCT01913587|DEVICE|Acupuncture|Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).
40922763|NCT01913587|PROCEDURE|Nerve block|Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
40922764|NCT01397734|DRUG|Arsenic trioxide|0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
40922765|NCT05282056|DIAGNOSTIC_TEST|CAD analysis|CAD shows the radiologist automatically delineated areas of potential COVID-19 affection, together with an overall lung affection percentage.
40922766|NCT04240795|DIETARY_SUPPLEMENT|Low lubricity (LL) hydrogels containing fibre-based beads|The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
40922767|NCT05662124|OTHER|Remote monitoring|"Patients will download the patientMpower app and be provided with a spirometer (Spirobank Smart, MIR) and oximeter (Nonin) to record their spirometry and pulse oximetry which will upload to the application via Bluetooth for clinical review.~Patients will be asked to upload measurements three times per week."
40922768|NCT01698307|OTHER|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
40922769|NCT01698307|OTHER|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
40922770|NCT06084975|PROCEDURE|Splenic vessels preservation|preservation the splenic vessels
40922771|NCT02624947|BIOLOGICAL|RSV F vaccine with adjuvant|
40922772|NCT02624947|BIOLOGICAL|Formulation buffer|
40922773|NCT05056428|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
40922774|NCT03520127|DEVICE|Intact Breast Lesion Excision System (BLES)|Intact BLES is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. It is uniquely suited to maintain lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical procedure.
40922775|NCT05425316|BEHAVIORAL|Home Recordings|If patients are willing to download the Winterlight application to their personal iOS devices this will be done at study visit 1. The application will send a notification to the patient once per month, requesting that they perform a paragraph reading task, a picture description task, and an animal naming task.
40922776|NCT05425316|BEHAVIORAL|In-patient Recordings|If patients are admitted to UM hospital for suspected or confirmed OHE, with patient assent, physician study staff will assist the patient in recording a paragraph reading task, a picture description task, and an animal naming task.
40922777|NCT05425316|BEHAVIORAL|Same-Day Study Visit - Regular Appointment|Staff will call patients in anticipation of in-person regular visits to set up a same-day study visit. Patients will record the three speech tasks at this time.
40922778|NCT05425316|BEHAVIORAL|Same-Day Study Visit - Procedure|Staff will call patients in anticipation of in-person procedure visits to set up a same-day study visit, prior to procedure if sedation is planned. Patients will record the three speech tasks at this time.
40922779|NCT05425316|BEHAVIORAL|Phone Call Follow-up Visits|Non-physician study staff will call the patients every 3 months and, using a phone script, will ask them survey questions about their hepatic health.
40922780|NCT04504851|DRUG|Rosuvastatin 10mg|10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)
40922781|NCT04504851|DRUG|Rifampicin|Rifampicin 10mg/kg
40922782|NCT04504851|DRUG|Isoniazid|Isoniazid 5mg/kg
40922783|NCT04504851|DRUG|Pyrazinamide|Pyrazinamide 25mg/kg
40922784|NCT04504851|DRUG|Ethambutol|Ethambutol 15mg/kg
40922785|NCT02341937|OTHER|Diagnostic tests for suspected deep vein thrombosis|Pre-test clinical probability (Wells score), D-dimer, compression ultrasonography
40922786|NCT03908489|PROCEDURE|vital pulpotomy primary molars using garlic oil|vital pulpotomy using garlic oil
40922787|NCT03908489|PROCEDURE|vital pulpotomy using mta|mta vital pulpotomy
40922788|NCT00608569|DRUG|Lopinavir/ritonavir|Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
40922789|NCT00608569|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
40922790|NCT00608569|DRUG|Tenofovir disoproxil fumarate|300-mg tablet taken orally once daily
40922791|NCT00608569|DRUG|Zidovudine|300-mg tablet taken orally twice daily
40922792|NCT00608569|DRUG|Emtricitabine|200-mg tablet taken orally once daily
40922793|NCT04097587|BEHAVIORAL|experimental group|This program was carried out for 50 min/week over 8 weeks to empower parents with knowledge and self-efficacy about children's screen use, and motivate them to monitor and change their children's screen behaviors. Teaching strategies included lectures, group discussions, reflection, role playing, and peer sharing (Table 1). Topics included 1) parents' and children's screen use, 2) the relationship between network equipment and children's internet use, 3) the positive and negative effects of excessive screen use on children's physical and psychological development, 4) limiting screen use at mealtimes and bedtime, 5) strategies for screen-related devices, 6) alternative activities to screen use, such as board games and outdoor activities, 7) setting a target of appropriate screen times, and 8) encouraging the signing of a contract between parents and children to limit screen time. We also provided parents with a handbook of the course content.
40922794|NCT04097587|OTHER|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
40922795|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
40922796|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
40922797|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
40922798|NCT04552678|BEHAVIORAL|Healthy Eating + Active Play|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
40947759|NCT05400863|BEHAVIORAL|avoid sugary and NNS drinks plus start Metformin|Subjects will receive education and counseling to avoid all sweetened drinks (drink water only). Participants will be asked to consume minimum of 3 drinks/day
40947760|NCT05400863|BEHAVIORAL|avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin|Subjects will avoid drinks sweetened with sugar (can have diet drinks sweetened with NNS). Participants will be asked to consume minimum of 3 drinks/day
40751972|NCT01571609|OTHER|first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer|"FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:\[9,10-3H\]-palmitate 0,3 µCi/min. Duration 60 minutes."
40751973|NCT03879577|DRUG|Docetaxel|Administered to all patients for a minimum of 4 cycles for 12 weeks.
40751974|NCT03879577|DRUG|Herceptin|Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.
40751975|NCT03879577|DRUG|FEC|Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
40751976|NCT03879577|DRUG|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
40751977|NCT03879577|DRUG|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
40922799|NCT04552678|BEHAVIORAL|Healthy Eating, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
40922800|NCT04552678|BEHAVIORAL|Healthy Eating + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
40751978|NCT03879577|DRUG|LHRH agonist|Administered to all premenopausal patients.
40751979|NCT00270166|DRUG|epoetin alfa|
40751980|NCT03479346|DRUG|GGT|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
40922801|NCT04552678|BEHAVIORAL|Healthy Eating + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
40922802|NCT04552678|BEHAVIORAL|Healthy Eating Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy.
40922803|NCT04552678|BEHAVIORAL|Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
40947761|NCT04644991|OTHER|Kinesiology taping|Y-type kinesiology tape will be applied to the thoracolumbar fascia in experimental gruoup.
40751981|NCT03479346|DRUG|Placebo|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
40751982|NCT03587103|BEHAVIORAL|Protocol initiate with A|The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
40751983|NCT03587103|BEHAVIORAL|Protocol initiate with C|The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
40751984|NCT03587103|BEHAVIORAL|Protocol initiate with D|The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
40751985|NCT05303974|OTHER|Ultrasound guided joint injection|The participants will perform two ultrasound guided joint injections on a mannequin. The performance of both procedures are videorecorded. All videos will be rated by two blinded raters using the modified IUSE assessment tool.
40751986|NCT00679601|DRUG|AN2690|AN2690 7.5% Solution, once daily for 28 days
40751987|NCT03368560|OTHER|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga (SKY): A 12-week training course conducted by certified instructors from the Art of Living Foundation. SKY training will take place in group-format (group sizes of 8-15 participants) in an appropriately sized and accessible community hall in London, Ontario.SKY training involves attending a week-long (5 days) course that teaches the basic principles of SKY over 2.5-3 hour daily sessions. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period and log practice frequency and any other noteworthy observations in a log sheet that will be provided to them . Nutritional snacks will be provided during the 5 day SKY training course.
40947762|NCT04644991|OTHER|Six minutes walking test|Participants will be asked to walk as fast as they can for 6 minutes.
41095714|NCT00599677|OTHER|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
40751988|NCT00388141|BEHAVIORAL|NIDCAP|Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
40751989|NCT03357705|PROCEDURE|alveolar ridge preservation with synthetic bone|after tooth extraction
40751990|NCT03357705|PROCEDURE|alveolar ridge preservation with bovine collagen|after tooth extraction
40751991|NCT00680173|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
41095715|NCT00599677|DRUG|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
40751992|NCT00471107|DEVICE|DC brain polarization|0.08 mA/cm2
40751993|NCT03902990|OTHER|Dual task|The patients in the dual task group received cognitive tasks during treadmill training sessions.
40751994|NCT03902990|OTHER|Treadmill Training|Standard treadmill training
40751995|NCT03902990|OTHER|Standard exercise programme|Standard exercise programme for Parkinson Disease
40751996|NCT00002370|DRUG|Itraconazole|
40751997|NCT00797901|OTHER|Collaborative Care|
40751998|NCT02994277|DEVICE|1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm|The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.
40922804|NCT04552678|BEHAVIORAL|Active Play + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
40922805|NCT04552678|BEHAVIORAL|Active Play + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
40922806|NCT04552678|BEHAVIORAL|Active Play Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
40922807|NCT04552678|BEHAVIORAL|Self-Regulation + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
40922808|NCT04552678|BEHAVIORAL|Self-Regulation Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
40922809|NCT04552678|BEHAVIORAL|Food Literacy + Parent Education|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
40922810|NCT04552678|BEHAVIORAL|Food Literacy Only|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy.
40922811|NCT03601234|PROCEDURE|laparoscopic and endoscopic cooperative surgery|compare to the traditional surgery to resect the tumor,we will add the endoscopy during the operation to improve the safety and effectiveness of surgery
40922812|NCT03601234|PROCEDURE|laparoscopic surgery|the traditional surgery
40922813|NCT05054660|OTHER|caring chatbot|The investigators will use the developed caring chatbot to provide care to the cases and to collect case treatment data and interaction data between the case and the caring chatbot.
40922814|NCT03317301|DRUG|HL151|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
40922815|NCT03317301|DRUG|Talion Tab|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
40922816|NCT03438721|BEHAVIORAL|Infant obesity prevention|Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content
40922817|NCT03438721|BEHAVIORAL|Financial coaching|Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
40922818|NCT04195191|OTHER|ANM|communication intervention
40922819|NCT04195191|OTHER|Placebo|regular assistance in community pharmacies
40922820|NCT00003001|DRUG|fluorouracil|
40922821|NCT00003001|DRUG|gemcitabine hydrochloride|
40922822|NCT00003001|DRUG|leucovorin calcium|
40922823|NCT01180179|DRUG|Lansoprazole|30mg once daily
40922824|NCT01180179|DRUG|Famotidine|40mg once daily
40922825|NCT04267224|DRUG|Ticagrelor 90mg|Ticagrelor is a direct-acting inhibitor of the platelet P2Y12 receptor with a rapid antiplatelet effect. It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with Clopidogrel, and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI.
40922826|NCT00002280|DRUG|Didanosine|
40922827|NCT00178529|BEHAVIORAL|Psychoeducation, Counseling and Skill Training|
40922828|NCT00590928|DRUG|esomeprazole|40mg once daily
40922829|NCT00590928|DRUG|ranitidine|50mg every h hours
40922830|NCT03041129|DIAGNOSTIC_TEST|oral glucose tolerance test|6 hours OGTT
40922831|NCT03041129|DIAGNOSTIC_TEST|MRI of liver|MRI of the liver and use of DIXON method
40947763|NCT04644991|OTHER|Shame Kinesiology Tape|Sham kinesiology tape will be applied to the thoracolumbar fascia in sham gruoup.
40922832|NCT05188157|OTHER|mirror therapy|The patients in IG will receive exercise program before mirror theraphy. The patient will continue to do the exercises in front of the mirror for the remaining 20 minutes of the exercise. While doing the exercise with the healthy side in front of the mirror, the patient will try to do the same movement with the shoulder diagnosed with impingement syndrome on the other side of the mirror. The patient will try to do the movement correctly with the reflection in the mirror.
40922833|NCT05188157|OTHER|conventional physiotherapy|The conventional physiotherapy program included, wand exercises for shoulder abduction, flexion, hyperextension and internal and external rotation, Codman exercises and isometric and resistive exercises of the shoulder girdle. The exercise program is performed under the supervision of an experienced physiotherapist. The isometric exercises will be used during the painful period, and the resistance exercises will be added after the pain began to relieve.under the supervision of a physician in the first 30 minutes of their exercise.
40922834|NCT05639244|BEHAVIORAL|Time restricted eating (TRE)|Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.
40922835|NCT05639244|BEHAVIORAL|Regular diet|Participants have to consume their regular diet within an unrestricted time period for 2 weeks
40922836|NCT02048241|BEHAVIORAL|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
40922837|NCT02048241|OTHER|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
40922838|NCT02048241|DRUG|Intuniv|Weekly administration of medication in doses as per protocol
40922839|NCT01346995|OTHER|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
40922840|NCT01346995|OTHER|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
40922841|NCT02899078|DRUG|Ibrutinib|Given PO
40922842|NCT02899078|DRUG|Nivolumab|Given IV
40922843|NCT01594801|DEVICE|InsuPad|Use of the InsuPad for at least 3 times a day.
40922844|NCT01848782|BEHAVIORAL|interpretation of the abstract of the systematic review|
40922845|NCT01214057|DRUG|Propofol and Remifentanyl|Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
40922846|NCT01214057|DRUG|Sevoflurane and Remifentanyl|Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
40922847|NCT01685333|DRUG|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
40922848|NCT05448820|DRUG|YH001|Anti-CTLA4 antibody
40922849|NCT05448820|DRUG|Envafolimab|Anti-PD-L1 antibody
40922850|NCT05448820|DRUG|Doxorubicin|Anthracycline
40922851|NCT03681223|DEVICE|Vertessa® Lite Y mesh|Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.
40922852|NCT03681223|DEVICE|Restorelle® Y mesh|Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.
40922853|NCT03681223|PROCEDURE|Laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
40922854|NCT03681223|PROCEDURE|Robotic assisted laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
40922855|NCT00471614|DRUG|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
40922856|NCT02825290|DRUG|Choriogonadotropin alfa|
40922857|NCT02825290|DRUG|Triptorelin acetate|
40922858|NCT05624333|OTHER|Vegan diet (intervention)|The intervention diet will be a fully controlled vegan diet that will be consumed for a duration of 10 days. No animal-based food products will be included in the diet.
40922859|NCT05624333|OTHER|Omnivorous diet (control)|The control diet will be an a priori composed controlled omnivorous diet with a duration of 10 days. The omnivorous diet and the vegan diet will be isocaloric and isonitrogenous.
40922860|NCT02184455|BIOLOGICAL|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
40922861|NCT05402371|DRUG|Rencofilstat|Rencofilstat soft gel capsule
40922862|NCT05402371|DRUG|Placebo|placebo soft gel capsule
40922863|NCT01612845|PROCEDURE|Arthroscopic repair without platelet rich fibrin|after the tendon is repaired, no additional procedures are performed and no PRF is administered
40922864|NCT01612845|BIOLOGICAL|PRF (vivostat ®) administration after rotator cuff repair|7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
40947764|NCT02154074|DRUG|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
40947765|NCT02154074|DRUG|Isoflurane|inhale Isoflurane 1.5MAC
40922865|NCT01566812|BEHAVIORAL|Breast feeding optimization|Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support
40922866|NCT01566812|BEHAVIORAL|Usual care|Usual care applied in the hospital
40922867|NCT01661582|OTHER|CT/PET Myocardial Perfusion Imaging using O-15 water|
40922868|NCT01661582|OTHER|Coronary blood flow measured by doppler echocardiography|
40922869|NCT02825797|DRUG|3BNC117|Intravenous infusion of 3BNC117
40922870|NCT02825797|DRUG|10-1074|Intravenous infusion of 10-1074
40922871|NCT02825797|OTHER|Analytical treatment interruption|Analytical treatment interruption
40922872|NCT02825797|DRUG|Placebo|Intravenous infusion of placebo (sterile saline)
40922873|NCT05424315|DRUG|Dapagliflozin 10mg|10mg Tab once daily
40922874|NCT05424315|DRUG|Glucose Tab|Placebo Oral Tablet
40922875|NCT03706547|BIOLOGICAL|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
40922876|NCT03706547|DRUG|Fludarabine|30mg/m2/d
40922877|NCT03706547|DRUG|Cyclophosphamide|300mg/m2/d
40922878|NCT05910671|BEHAVIORAL|Physical Activity Phone Calls and Notebook|This intervention encouraged parents to model physical activity behaviors and co-participate in physical activity with their young child. Each week behavioral strategies for promoting physical activity change will be discussed to help parents work towards meeting their activity goals. As part of the physical activity intervention parents will receive a physical activity notebook that has newsletters, suggested activities that can be done with their child, and other material that will help the parent and child be active active together. The behavioral strategies and the information in the notebook will will be discussed weekly for 30 minutes via telephone.
40922879|NCT03196700|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
40922880|NCT00176956|PROCEDURE|Skin Biopsy|Skin biopsy.
40922881|NCT02858817|DRUG|atovaquone/proguanil 250mg/100mg (A/P)|Combination drug for chemo-prophylaxis or treatment of malaria
40922882|NCT02858817|BIOLOGICAL|PfSPZ Challenge (NF54)|cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
40922883|NCT02858817|OTHER|NaCl 0,9%|0.9% NaCl solution for injection
40922884|NCT00299468|BEHAVIORAL|Patient Activation Measure Intervention Package|
40922885|NCT05925543|PROCEDURE|Kasai portoenterostomy operation.|Kasai portoenterostomy operation for biliary atresia patients.
40922886|NCT05145738|BEHAVIORAL|C-Raven with avatar|Computer delivered intervention with the investigators' avatar; with linkage to community health worker.
40922887|NCT05145738|BEHAVIORAL|C-Raven without avatar|Computer delivered intervention without the investigators' avatar; with linkage to community health worker.
40922888|NCT01816451|OTHER|running training|The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
40922889|NCT00685009|DRUG|Estrogen hormone therapy|Estrogen pill daily
40922890|NCT00685009|DRUG|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
40922891|NCT00685009|DRUG|Placebo|Placebo pill daily
40922892|NCT00477841|PROCEDURE|Esophageal stent placement|
40922893|NCT00477841|PROCEDURE|dysphagia scores|
40922894|NCT00477841|PROCEDURE|complications of therapy|
40922895|NCT00477841|PROCEDURE|survival time of therapy|
40922896|NCT06215768|DRUG|Dexmedetomidine and Midazolam|"This will be a prospective, double-blind, randomized controlled study conducted between October 2023and June 2024 .~Patients aged( 2_12) years, American Society of Anesthesiologists class (ASA) I or II, scheduled for tonsillectomy with and without adenoidectomy will be randomized to receive intravenous dexmedetomidine 0.5 μg/kg Or intravenous midazolam 0.1 mg /kg(Group A) or (Group B) over 10 minutes after induction of anesthesia. The primary outcome is the incidence of ED within 30 minutes after extubation. Other outcomes are the incidence of pain, extubation time, post-anesthesia care unit (PACU) length of stay after extubation, adverse events, and the incidence of negative postoperative behavioral changes (NPOBCs)."
40922897|NCT04583722|DIETARY_SUPPLEMENT|AX-olive oil-PP emulsion|single dose and plasma samples
40922898|NCT05323825|DIETARY_SUPPLEMENT|Probiotic|Fermented milk product containing a probiotic
40922899|NCT05323825|DIETARY_SUPPLEMENT|Placebo|Product with identical characteristics to the experimental product.
40922900|NCT02578719|DRUG|bupivacaine|marcaine %0.5 20 ml flacon
40922901|NCT02578719|DRUG|saline|%0.9 sodium chloride
40922902|NCT04592952|DRUG|Calcitonin Gene-Related Peptide|Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.
40922903|NCT04592952|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
40922904|NCT01100476|DEVICE|Endovascular Diagnostic Procedures|Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
40922905|NCT04580810|BEHAVIORAL|CBT4CBT in the Black Church|Use of Computer Based Treatment for Cognitive Behavioral Therapy for alcohol use disorder offered in a Black church setting
40922906|NCT06158529|DEVICE|spinal cord stimulator|A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain.
40947766|NCT02154074|DRUG|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
40922907|NCT06158529|DEVICE|high frequency spinal cord stimulation|A spinal cord stimulator is an implanted device that sends low levels and high frequency of electricity directly into the spinal cord to relieve pain.
40922908|NCT01588756|DRUG|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
40922909|NCT01588756|DRUG|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
40922910|NCT04914013|OTHER|no intervention|no intervention
41095716|NCT05521867|DEVICE|Endoscopic balloon dilation|EBD procedures will be performed with wire guided CRE pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA 0of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 ATM pressure. Balloon was inflated for at least 2 minutes and slowly deflated. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them.
40751999|NCT06426576|OTHER|Standard one-off instruction using a scale|"The permitted weight is demonstrated to the patient once using a scale in the static position. The patient repeatedly places the foot with the permitted weight on a scale in order to develop a feeling for the load. After this exercise in the static position, the patient applies the perceived load to dynamic activities of daily living without receiving any feedback.~The instruction is given by a trained physiotherapist. Simultaneously with the instruction, the effective weight applied on the leg will be measured using instrumented insoles without any feedback."
40922911|NCT05901389|DRUG|Lidocaine|After the thoracoscopic surgery, lidocaine will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
40922912|NCT05901389|DRUG|normal saline|After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
40922913|NCT02324634|DEVICE|NeuroTrac Rehab dual channel device|ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
40922914|NCT03393247|DRUG|infliximab and azathioprine combination at week 0|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Experimental group will receive azathioprine at week 0.
40922915|NCT03393247|DRUG|infliximab and azathioprine combination at week 14|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Control group will receive azathioprine at week 14.
40922916|NCT05579067|PROCEDURE|ACL Reconstruction using an autograph of the peroneus longus tendon, folded twice.|The use of a peroneus longus tendon autograft taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
40922917|NCT05579067|PROCEDURE|ACL Reconstruction using an autograph of Hamstrings muscle tendons.|The use of Hamstring muscle tendon autograft (Semitendinus and slender muscle) taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
40922918|NCT02868827|DRUG|Cholecalciferol|400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
40922919|NCT02868827|OTHER|Milk (Nestle)|45 ml of Nestle milk will given to patients assigned as placebo
40922920|NCT04792242|DEVICE|cv line insertion|Svo2 and central venous pressure measurements
40922921|NCT04792242|DEVICE|Urinary catheter insertion|urine output measurement
40922922|NCT04792242|DEVICE|Arterial line|Arterial blood gases measurment
41095717|NCT05521867|DEVICE|Endoscopic stricturotomy with or without stricturoplasty|Endoscopic stricturotomy would be done using either a triple-lumen needle-knife (Boston Scientific, Marlborough, MA) or with a electrosurgical IT knife2 (Olympus Medical Systems, Tokyo, Japan) in the setting of endoscopic retrograde cholangiopancreatography (ERCP) Endocut on Erbe medical device (USA Incorporated Surgical Systems, Marietta, GA) with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3). Strictures will be incised in a circumferential or radial fashion until an adequate passage of the scope. Endoclips may be applied post stricturotomy to act as keep treated stricture open and to prevent delayed bleeding (referred as stricturoplasty). Choice of endoclips and decision to perform stricturoplasty would be at the discretion of endoscopist.
40922923|NCT04718545|PROCEDURE|Mucogingival surgery|The gingival recession at mandibular incisor site will be covered by a gingival graft harvested from the palate.
40922924|NCT01954927|DRUG|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
40922925|NCT01954927|DRUG|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
40922926|NCT05212129|DEVICE|Percutaneous vagal nerve stimulation (pVNS) device|Subjects in Treatment Arm B will enter a six-week, prospective open label treatment trial with the FDA-approved and commercially available device IB-Stim. This is an ambulatory, neurostimulation device which consists of a battery powered, externally affixed generator with 4 wire leads attached to electrode/needle arrays affixed to the outer ear. The device delivers low voltage (3.2V) stimulation in alternating frequencies for a total of 5 days (around the clock).
40947767|NCT02154074|DRUG|normal saline|the same volume of saline + Isoflurane during operation
40922927|NCT05212129|OTHER|Acoustic vagal nerve stimulation (aVNS) treatment|All subjects receiving acoustic therapy via active VNS (aVNS; n=30) or sham VNS (sVNS; n=30) will enter a four-week, randomized, double-blind clinical trial during which they will listen to either computer altered/filtered vocal music (active treatment) that has been designed to stimulate vagal calming vs. regular non-filtered music (sham treatment). The stimuli will mirror the acoustic intervention known as the Safe and Sound Protocol. This protocol has been found to reduce auditory hypersensitivities and calming the autonomic nervous system by increasing vagal regulation of the heart via brainstem ventral vagal complex. The acoustic intervention may be played by an electronic device (i.e. smartphone, tablet, laptop, mp3) and delivered virtually with the help of trained coaches.
40922928|NCT02325843|OTHER|human bone marrow MSC|The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
40922929|NCT05986201|DEVICE|TachoSil®|TachoSil®, a carrier-bound fibrin sealant (CBFS), is a haemostatic tissue sealant composed of a collagen sponge, made from horse tendons, coated on one side with dried human fibrinogen and human thrombin.
40922930|NCT02878057|DRUG|Apatinib|Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
40922931|NCT01270802|DRUG|Tenofovir/emtricitabine|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
40922932|NCT01270802|DRUG|Tenofovir/emtricitabine/efavirenz|Continued therapy with tenofovir/emtricitabine/efavirenz
40922933|NCT01270802|DRUG|Raltegravir|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
40922934|NCT02816567|DRUG|propofol|
40922935|NCT02816567|DRUG|NMBA - cisatracurium|
40922936|NCT02816567|DRUG|placebo - isotonic saline serum|
41095718|NCT00504920|BEHAVIORAL|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
40922937|NCT02816567|DRUG|sufentanil|
40922938|NCT02816567|PROCEDURE|laparoscopic surgery|
40922939|NCT06088602|PROCEDURE|Cryoneurolysis|Local anesthesia is injected in the skin. The superficial genicular nerves, more specifically the ISN and the AFCN, are visualized. A nerve stimulator is used to verify the visualized nerves., 2-3 ml of ropivacaine 5 mg/ml is injected around the nerves. After 5-15 minutes the effect is evaluated by assessing pain in the surgical area and asking the patient whether there is a pain relief. Following this evaluation, cryoneurolysis (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland) is performed unilaterally along a treatment line, the location of which was guided by visualization and palpation of anatomic landmarks. The ISN treatment line is located along the line that connects a point located 5 cm medial to the lower pole of the patella and a point located 5 cm medial to the tibial tubercle. The AFCN treatment line is located at one-third the length of the distance from the center of the patella to the top of the femur, with a width equal to the width of the patella.
40922940|NCT06088602|PROCEDURE|Sham|The exact same procedure as in the cryo-group is performed, except that the nerves are not frozen with the cryoneurolysis apparatus. Sound effects from the machine are replicated to give the patient the same experience as in the active intervention group.
40922941|NCT01490801|GENETIC|DNA analysis|
40922942|NCT01490801|GENETIC|RNA analysis|
40922943|NCT01490801|GENETIC|cytogenetic analysis|
40922944|NCT01490801|GENETIC|in situ hybridization|
40922945|NCT01490801|GENETIC|mutation analysis|
40922946|NCT01490801|GENETIC|polymerase chain reaction|
40922947|NCT01490801|GENETIC|western blotting|
40922948|NCT01490801|OTHER|flow cytometry|
40922949|NCT01490801|OTHER|immunohistochemistry staining method|
41095719|NCT04639947|DEVICE|EyeCheck|EyeCheck is a newly developed device to provide intraocular pressure (IOP) measurements of the eyes.
40922950|NCT01490801|OTHER|medical chart review|
41095720|NCT04639947|DEVICE|Traditional Tonometer (Goldmann and Tonopen)|Standard of care intraocular pressures will be taken using the Goldmann and Tonopen to compare to the EyeCheck.
40922951|NCT04246931|OTHER|No intervention (survey)|No intervention -\> survey at 1 timepoint
40922952|NCT05411627|DEVICE|Shockwave Therapy|Participants will receive shockwave therapy once per week for three weeks.
40922953|NCT00839176|DRUG|RX-10100|Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks
40922954|NCT01868919|BEHAVIORAL|Positive Parenting Program|Level 3 or 4 of Triple P
40922955|NCT00663949|DRUG|Captopril|25 mg captopril tablet q8h
40922956|NCT00663949|DRUG|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
40922957|NCT03416062|DRUG|Remaxol®|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
40922958|NCT03416062|DRUG|Ringer's Solution|Solution for intravenous infusion, 400 or 800 ml
41095721|NCT04808869|OTHER|Exercise|Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
41095722|NCT00521716|DEVICE|Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
41095723|NCT00521716|DEVICE|WaisFix100i for Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
41095724|NCT02800161|DRUG|Trehalose|Trehalose 70g/die
41095725|NCT02800161|DRUG|Maltose|Maltose 70g/die
41095726|NCT04848896|DEVICE|CORI Robotics|Total knee arthroplasty (TKA) treated with CORI Robotics System.
41095727|NCT04848896|PROCEDURE|Conventional Procedure|Total knee arthroplasty (TKA) treated with conventional approach with conventional manual instrumentation.
41095728|NCT06169241|DIETARY_SUPPLEMENT|Beetroot extract|Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
41095729|NCT06169241|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
41095730|NCT00483262|DRUG|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
40922959|NCT03205592|DIAGNOSTIC_TEST|Ultrasound examination of the antrum|Ultrasound assessment of gastric content will be performed : prior to suction of gastric content through a gastric tube (method to assess the residual gastric content volume), after this suctioning of gastric content, then after reinjection of the content suctioned into the stomach (max 250 ml) and 1h30 later
40922960|NCT03648866|OTHER|interview|"Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds"
40922961|NCT03126552|BIOLOGICAL|Necator americanus L3 larvae|50 Necator americanus L3 larvae
40922962|NCT03469869|OTHER|balanced and sustainable diet|"the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp."
40922963|NCT00422084|DRUG|Pyronaridine artesunate|Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)
40922964|NCT00422084|DRUG|Coartem® (artemether lumefantrine)|AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
40922965|NCT04316975|OTHER|Study Driven Procurement of Biopsies|Four research biopsies collected at the midpoint of current BE or IMC at Baseline and after reaching CEIM. Biopsies will be used to calculate ML scores both pre and post EET.
40922966|NCT02402725|DRUG|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
40922967|NCT03459391|DRUG|XC221 60 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
40922968|NCT03459391|DRUG|XC221 200 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
40922969|NCT03459391|DRUG|Placebo|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
40922970|NCT04811534|BEHAVIORAL|Interview|Mixed exploratory study, mixing a mainly qualitative study (semi-directed interviews) with a descriptive observational study (short self-questionnaire of the interviewees).
40922971|NCT03812237|OTHER|(EWB) Early Weight Bearing (2 Weeks Post-op)|Patient were permitted to progressively weightbear on their heel at 2 week post-op.
40922972|NCT03377140|DIETARY_SUPPLEMENT|Hesperidin|2 capsuls
40922973|NCT03377140|OTHER|control|2 capsuls
40922974|NCT04944056|OTHER|conventional physiotherapy|"* Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion."
40922975|NCT04944056|OTHER|compression mobilization|"* Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Compression mobilization 1 set x 10 reps x 3sets.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion."
40922976|NCT02512627|BEHAVIORAL|Cognitive training|visuospatial, attention, memory, and executive abilities
40922977|NCT02512627|BEHAVIORAL|Physical exercise|endurance, balance, and mobility
40922978|NCT00885820|DRUG|Tacrolimus|Oral
40922979|NCT00885820|DRUG|MMF|Oral
40922980|NCT00885820|DRUG|Corticosteroids (Prednisone)|Oral
40922981|NCT01175681|PROCEDURE|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
40922982|NCT04363151|OTHER|No intervention.|
40922983|NCT03273218|DEVICE|Tiger catheter|
40922984|NCT03273218|DEVICE|Judkins catheter|
40922985|NCT00494767|DRUG|GW869682|GW869682 tablet with a dose strength of 250 mg will be available for subjects
41095731|NCT00483262|DRUG|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
41095732|NCT00733460|DRUG|BFPET|
40922986|NCT00494767|DRUG|GSK189075|GSK189075 tablet with a dose strength of 250 mg will be available for subjects
40922987|NCT00494767|DRUG|GSK189075-Placebo|Placebo tablets to match GSK189075 250 mg will be available for subjects
40922988|NCT00494767|DRUG|GW869682-Placebo|Placebo tablets to match GW869682 250 mg will be available for subjects
40922989|NCT03839043|BEHAVIORAL|Brief behavioral intervention|"Quit for a bit- \*advice to quit from the am. of surgery until one week post-surgery, a special emphasis on morning abstinence\* risks of smoking to perioperative outcomes, includes wound infections, breathing problems, and heart problems\*reduction of these risks if able to quit for a bit\*the fact that most smokers don't experience cravings or increased stress around the time of surgery. Subjects will receive written summarizing instructions and a brief abstinence brochure. Quit for good- 3 out of the 5A's smoking cessation intervention, including Asking, Advising and Assistance will be provided. The advice endorses immediate, sustained quitting (quit for good), accent on the health and economic benefits of long-term abstinence. Assistance includes a method of setting the date of surgery as the quit date, enlisting social support, anticipation of withdrawal symptoms, and the need for complete abstinence. Subjects will receive written summarizing instructions and a 5As brochure."
40922990|NCT03839043|OTHER|SMS Program|"Quit for a bit- Subjects will get SMS messages focused on maintaining abstinence from the morning of surgery until one week after surgery. SMS content focus on the benefits of abstinence to surgical recovery rather than sustained benefits to overall health. Around day 7 postoperatively, messages will encourage subjects to consider extending their abstinence beyond 7 days.Quit for good- Subjects will get SMS messages focused on general advice for maintaining abstinence, focusing on the long-term health benefits rather immediate benefits to recovery from surgery. SMS content focus on the the surgical date as the quit date, general advice and support for quitting based on the standard Truth Initiative (UbiQUITxt) message library and there will be no references to effects of short-term abstinence on surgical outcomes."
40922991|NCT05990218|DEVICE|Artificial intellegence. CADe syste,|The patient received endoscopy under CADe system for polyp detection during second endoscopic withdrawal.
41095733|NCT00589862|DRUG|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
40922992|NCT05990218|DEVICE|control|The patient received endoscopy under conventional white light for polyp detection during second endoscopic withdrawal.
40922993|NCT03978143|DRUG|Treatment A|Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
40922994|NCT03978143|DRUG|Treatment B|A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.
40922995|NCT03978143|DRUG|Treatment C|A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
40922996|NCT03978143|DRUG|Treatment D|A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
40922997|NCT03978143|DRUG|Treatment E|250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.
40922998|NCT03978143|DRUG|Treatment F|250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.
40922999|NCT03978143|DRUG|Treatment G|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
41095734|NCT05167747|DIETARY_SUPPLEMENT|Dietary Supplement|"Dietary supplement formulated with magnesium, standardized extract of orthosiphon, standardized extract of hawthorn and standardized extract of hibiscus. Each tablet contains: 0.1 g magnesium, 0.25 g standardized extract of orthosiphon (Orthosiphon stamineus Benth), 0.16 standardized extract of hawthorn (Crataegus curvisepala Lind.) and 0.08 g standardized extract of hibiscus (Hibiscus sabdariffa L.).~Oral administration: 2 tablets/day at evening meal"
41095735|NCT05167747|OTHER|Placebo|Oral administration: 2 tablets/day at evening meal
41095736|NCT06556004|BIOLOGICAL|TRIMELVAX|The safety of this immunotherapeutic compound will be tested in patients with advanced melanoma and will secondarily evaluate the induced immune response.
41095737|NCT06507254|DIETARY_SUPPLEMENT|Polyphenol Supplement|Dietary supplement taken twice daily for 12 months.
41095738|NCT06507254|DIETARY_SUPPLEMENT|Placebo Supplement|Dietary supplement taken twice daily for 12 months.
41095739|NCT00354094|DRUG|[S,S]-Reboxetine|
41095740|NCT00004645|PROCEDURE|Plasma exchange|
41095741|NCT00961805|BEHAVIORAL|Dance|Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.
41095742|NCT00961805|OTHER|Control Group|The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
41095743|NCT04975581|BIOLOGICAL|Allograft Patch|Rotator Cuff repair with Allograft Patch (Graftjacket Now)
41095744|NCT04907448|OTHER|Physical Therapy|"The IsoK-ST group received their usual physical therapy program for 45 minutes, three times a week for eight successive weeks, which comprised advanced balance training, weight-bearing exercises, gait training, postural and flexibility exercises, and strength training exercises.~Additionally, the IsoK-ST group received an IsoK-ST program, thrice/week for eight successive weeks.~The control group received the usual physical rehabilitation program only for 45 minutes, three times a week for eight successive weeks."
41095745|NCT00931229|DRUG|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
41095746|NCT06042114|BEHAVIORAL|Surah Inshirah|Patients in the experimental group will be listened to the Surah al-Inshirah after surgery and its effect on pain and anxiety levels will be evaluated.
40923000|NCT03978143|DRUG|Treatment H|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
41095747|NCT01793740|BEHAVIORAL|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
40923001|NCT06304467|BEHAVIORAL|Contingency Management|Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.
40923002|NCT06448416|PROCEDURE|UBE|Patients with HDL were treated with UBE
41095748|NCT03946202|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
41095749|NCT02518243|OTHER|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games"
41095750|NCT03898687|DEVICE|SLN Biopsy with Magtrace®/Sentimag®|Identification of SLN by means of Magtrace®/Sentimag® and SPIO-MRI
41095751|NCT01380119|BIOLOGICAL|V7|experimental arm
41095752|NCT01380119|OTHER|placebo|placebo pill
41095753|NCT00990756|DRUG|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
41095754|NCT00990756|DRUG|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
41095755|NCT00232011|DRUG|Pimecrolimus Cream 1%|Pimecrolimus cream 1 %
40923003|NCT05676775|OTHER|No intervenetion|Observational inception cohort, with remote follow-up via participants and data record linkage
40923004|NCT02065388|BEHAVIORAL|Standard of care dosing for warfarin|
40923005|NCT02065388|GENETIC|Genotype-guided dosingTaiwan algorithm for warfarin|
40923006|NCT02065388|GENETIC|Genotype-guided dosing IWPC algorithm for warfarin|
40923007|NCT00740376|DEVICE|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
40923008|NCT00740376|DEVICE|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
40923009|NCT01836276|DRUG|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
40923010|NCT00186953|DRUG|Optison|"Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m\^2 and escalated at 0.15 ml/m\^2 increments, to 0.275 ml/m\^2 and 0.425ml/m\^2 and 0.500ml/m\^2. We will now continue to escalate the dose of Optison at 0.300ml/m\^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer."
40923011|NCT03579602|DRUG|tozuleristide|Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.
40923012|NCT03579602|DEVICE|Canvas System|All subjects enrolled in the study will have their tissue imaged with the Canvas System.
40923013|NCT01606917|OTHER|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
40923014|NCT04754217|DEVICE|VAVGJ|Replacement of the aortic valve and ascending aorta
40923015|NCT04754217|DEVICE|CAVGJ|Replacement of the aortic valve and ascending aorta
40923016|NCT01204723|DRUG|Placebo Aprepitant|Placebo Aprepitant 0 mg once daily for 5 days
40923017|NCT01204723|DRUG|Active Aprepitant|Active Aprepitant 160 mg once daily for 5 days
40923018|NCT05550207|DRUG|AXS-07 (meloxicam-rizatriptan)|AXS-07 tablets, taken orally for the acute treatment of migraine
40923019|NCT05090319|DIAGNOSTIC_TEST|complete blood count|Complete blood count will be performed on the patient. Accuracy of micro-hematology analyzer will be assessed.
40923020|NCT04865874|OTHER|PPV-GDT|fluid-therapy based on PPV monitoring
40923021|NCT04865874|OTHER|Zero-balance|fluid-therapy based on urinary output balance
40923022|NCT02748382|OTHER|higher chloride crystalloid|Normal saline
40923023|NCT02748382|OTHER|higher chloride albumin|5% Octalbin
40923024|NCT02748382|OTHER|lower chloride crystalloid|Ringers Lactate
40923025|NCT02748382|OTHER|lower chloride albumin|5% Plasbumin
40923026|NCT06481280|DIETARY_SUPPLEMENT|Test Formula|Infants will receive an extensively hydrolyzed formula during the double-blind placebo-controlled food challenge (DBPCFC) and will continue on this formula during the open-label feeding phase if they tolerate it.
40923027|NCT06481280|DIETARY_SUPPLEMENT|Placebo Formula|Infants will receive a placebo formula during the DBPCFC to compare against the test formula.
40923028|NCT05718518|DRUG|ASC11 tablets|"Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)"
40923029|NCT05718518|DRUG|Placebo|Part 1 and 2: Subjects will be randomized to receive placebo.
40923030|NCT05718518|DRUG|RTV tablets|"Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)"
40923031|NCT05014737|OTHER|no intervention|this is an abservational study and no intervention will be involved
40923032|NCT02979860|BEHAVIORAL|Sleep duration 90 min|Sleep duration: time in bed increased by 90 minutes
40923033|NCT02979860|BEHAVIORAL|Sleep duration 45 min|Sleep duration: time in bed increased by 45 minutes
40923034|NCT02979860|BEHAVIORAL|Sleep timing|Sleep timing: bed time kept consistent
40923035|NCT02061527|PROCEDURE|Reconstruction with ADM.|If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.
40923036|NCT02061527|PROCEDURE|Skin or nipple sparing mastectomy|Mastectomy for invasive or pre-invasive breast cancer
40923037|NCT02061527|PROCEDURE|Reconstruction with implant|Immediate breast reconstruction with implant
40923038|NCT02061527|PROCEDURE|Total submuscular coverage|Implant based breast reconstruction with total submuscular coverage
40923039|NCT02061527|PROCEDURE|Partial submuscular coverage|Implant based breast reconstruction with partial submuscular coverage
40923040|NCT00308581|BIOLOGICAL|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
40923041|NCT00308581|BIOLOGICAL|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
40923042|NCT00308581|OTHER|Placebo|placebo administered 4-weekly in Active 1
40923043|NCT00130247|DRUG|Ethambutol|Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
40923044|NCT00130247|DRUG|Isoniazid|Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
40923045|NCT00130247|DRUG|Pyrazinamide|1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
40923046|NCT00130247|DRUG|Rifampin|1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
40923047|NCT00513825|DRUG|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
40923048|NCT02139059|PROCEDURE|initial urinary drainage|initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.
40923049|NCT02139059|PROCEDURE|direct ureteroscopy|direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
40923050|NCT03650946|DIAGNOSTIC_TEST|Ga-68 PSMA PET|Ga-68 PSMA PET
40923051|NCT04698577|BEHAVIORAL|Attention Training|The training was delivered face-to-face in groups of three participants. Participants were involved in a game of table tennis with two players and one spectator. The roles were rotated every 5 minutes so that each participant experienced 10 minutes of play and 5 minutes of observation. The game was played as normal with one point awarded to the player for every score achieved. All 3 players were asked to keep the score of the game in their minds during each 5-minute round. Participants had two objectives 1) to play and win the game and 2) to silently keep the score of the game. The researcher watched the game and accurately kept score, using a notepad. At the end of every 5-minute round, the researcher paused play and asked each child to write down the score they were holding in their mind. The researcher then revealed the true score, asked participants to swap roles and commence another round.
40923052|NCT04698577|BEHAVIORAL|Active Control|The control group was the same as the training group except for the core training mechanism; children were not required to mentally keep score. The researcher kept score by continually calling out the updated score as each point was won. The observing child was simply told to wait his/her turn.
40923053|NCT01886027|BEHAVIORAL|Emotional Awareness and Expression Training|An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.
40923054|NCT01886027|BEHAVIORAL|Relaxation Training|Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
40923055|NCT04365101|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
40923056|NCT03706924|DRUG|VM-1500FDC|A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets
40923057|NCT03706924|DRUG|Elpida®|Elpida®, capsules, elsulfavirine 20 mg
40923058|NCT03706924|DRUG|Truvada®|Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets
40923059|NCT00603486|DEVICE|GE DINAMAP with SuperSTAT algorithm monitor|Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
40923060|NCT01467635|DEVICE|Endobronchial ultrasound guided lymph node sampling|Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
40923061|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to stay on the prophylactic treatment (prospective)
40923062|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to switch to on-demand treatment (prospective)
40923063|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects remaining on-demand treatment (retrospective)
40923064|NCT00985829|RADIATION|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
40923065|NCT03167567|BEHAVIORAL|Presence of a medical clown during labor|Presence of a medical clown during labor
40923066|NCT00043550|BEHAVIORAL|Supportive Expressive Therapy|The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.
40923067|NCT00043550|DRUG|Sertraline|Participants will receive sertraline.
40923068|NCT00043550|DRUG|Pill Placebo|Participants will receive a pill placebo.
40923069|NCT00043550|DRUG|Venlafaxine|Participants will receive venlafaxine.
40923070|NCT02917057|DRUG|exenatide once weekly|Exenatide treatment in customary clinical care in the USA
40923071|NCT02917057|DRUG|basal insulin|basal insulin tretament in the customary clinical care in USA
40923072|NCT02047344|DRUG|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
40923073|NCT05615935|OTHER|Experiential HIV Testing|The content of experiential HIV Testing includes HIV testing, counselling, and education and discussion.
40923074|NCT05832775|BIOLOGICAL|MRx0029|Megasphaera massiliensis MRx0029 (Treatment A) and Placebo
40923075|NCT05832775|BIOLOGICAL|MRx0005|Parabacteroides distasonis MRx0005 (Treatment B) and Placebo
41095756|NCT01257503|DRUG|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
40923076|NCT02105753|DEVICE|1210nm Diode Laser treatments|
40923077|NCT02465554|PROCEDURE|Myocardial contrast echocardiography|Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
40923078|NCT05766358|BEHAVIORAL|Intensive lifestyle change therapy|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
40923079|NCT05766358|DRUG|Tirzepatide|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
41095757|NCT01257503|DRUG|placebo|liquid made to look like the active homeopathic remedy
41095758|NCT02507310|OTHER|thermostat|ambient temperature as modified by thermostat
41095759|NCT02862054|PROCEDURE|splenectomy|
40923080|NCT05410756|DIAGNOSTIC_TEST|Assessment of Voice Quality and Function|An acoustic voice analysis (fundamental frequency (F0), jitter, shimmer, noise to harmonic ratio (NHR), harmonic to noise ratio (HNR)) and an aerodynamic analysis (maximal phonation time (MPT)) were performed by an experienced otolaryngologist specialized in voice disorders for evaluation of objective voice quality and function. These analyses were performed on all the volunteers from both groups, and the results obtained were compared between the groups.
40923081|NCT03387644|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
40923082|NCT03387644|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
40923083|NCT03365388|DRUG|Sodium Hyaluronate|Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form
40923084|NCT03365388|DRUG|Aerzhi|Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
40923085|NCT00005862|DRUG|semaxanib|
40923086|NCT04585971|DIAGNOSTIC_TEST|Signal intensity gradient|"Signal intensity gradient:~In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
40923087|NCT00951613|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
40923088|NCT01788410|PROCEDURE|Cryoablation under image guidance|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
40923089|NCT01788410|DEVICE|MRI Seednet Cryotherapy System (Galil Medical)|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
40923090|NCT02108678|BEHAVIORAL|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
40923091|NCT02108678|BEHAVIORAL|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
40923092|NCT03751657|DRUG|Insulin icodec|Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)
40923093|NCT03751657|DRUG|Placebo (insulin 287)|Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.
40923094|NCT03751657|DRUG|Metformin|Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.
40923095|NCT03751657|DRUG|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.
40923096|NCT03751657|DRUG|Insulin glargine|Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).
40923097|NCT03751657|DRUG|Placebo (insulin glargine)|Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.
40923098|NCT01149954|DRUG|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
40923099|NCT03980353|OTHER|Questionnaires|The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
40923100|NCT03535727|DRUG|Nab-paclitaxel|IV over 30 minutes; Days 1 and 15
41095760|NCT05532813|DRUG|Treatment taken|Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.
41095761|NCT02214459|BEHAVIORAL|DASH Mobile mhealth enhanced coaching|Phone calls with a health coach that utilize the tracking data collected by the app and devices.
40923101|NCT03535727|DRUG|Gemcitabine|IV over 30 minutes; Days 1 and 15
40923102|NCT03535727|DRUG|Capecitabine|PO twice daily (BID); Days 1-7, 15-21
40923103|NCT03535727|DRUG|Cisplatin|IV over 60 minutes; Days 1 and 15
40923104|NCT03535727|DRUG|Irinotecan|IV over 30 minutes; Days 1 and 15
40923105|NCT03535727|DRUG|Nab-paclitaxel|IV over 30 minutes; Days 4 and 11
40923106|NCT03535727|DRUG|Gemcitabine|IV over 30 minutes; Days 4 and 11
40923107|NCT03535727|DRUG|Capecitabine|PO BID; Days 1- 14
40923108|NCT03535727|DRUG|Cisplatin|IV over 60 minutes; Days 4 and 11
40923109|NCT03535727|DRUG|Irinotecan|IV over 30 minutes; Days 4 and 11
40923110|NCT04269382|DEVICE|Combined non-invasive intermittent (oscillometric arm cuff), non-invasive continuous (finger cuff and ClearSight device), and invasive continuous (intra-arterial catheter) BP measurements|Continuous (finger cuff) noninvasive and invasive BP measurements, over a 30-min period. Pairs of noninvasive/invasive BP recorded each minute). In the same time, 3 pairs of oscillometric NIBP (cuff placed around a calf), and invasive BP measurements, at 30-sec intervals. The cuff is then placed around an arm and triplets of BP (arm cuff, finger cuff, intra-arterial catheter) will be taken over a 20-min period, at 3-min intervals and every time the invasive and/or the continuous finger cuff measurements cross the threshold of 65 mmHg for the mean BP. If clinically indicated, a cardiovascular intervention that can be either vascular volume expansion or initiation of vasoactive drug therapy, can be administered during this period. Finally, the cuff placed around the arm will be once again placed around the calf to take 3 pairs of oscillometric NIBP measurement with cuff placed around a calf, and simultaneous invasive BP measurement, at 30-second intervals.
41095762|NCT04547543|OTHER|Videoconsultation|Patient randomized on video-consultation group will have a video-consultation with the investigator within 3 months after the randomization. During this consultation, the investigator performs a clinical interrogation in order to collect anthropometric parameters: (sex, age, weight, height, body mass index (BMI)), blood pressure (by blood pressure monitor at home), the level of physical activity (by Actimetry over 7 days), smoking status and alcohol status
41095763|NCT05091762|BEHAVIORAL|exercise|Upper limb resistance training with blood flow obstruction
40923111|NCT00586092|DRUG|bevacizumab, ABT-510|"* Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID\*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days\*~* Stage 2 (RPTD) ABT-510: X mg SC BID\*\*, bevacizumab: Y mg/kg IV every 14 days\*\*~  * Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~    * \*Both agents begin on Day 1 of Cycle 1.~      * \*\*At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination."
40923112|NCT00662675|DRUG|Pancrease MT 10.5, or MT 21|Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
40923113|NCT00662675|DRUG|Placebo for Pancrease MT 10.5 or MT 21|Capsules with Pancrease MT excipients without the active enzymes
40923114|NCT00456664|GENETIC|IE gene|
40923115|NCT04202042|OTHER|Psychological first aid|PFA responders (peer support workers) are trained to deliver 8 core actions: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services
40923116|NCT04202042|OTHER|Usual organisational intervention|Emergency intervention by workplace psychologist and limited therapeutic sessions with employee aid program
40923117|NCT03134456|DRUG|Pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
40923118|NCT03970356|OTHER|antibiotic stewardship intervention|The intervention is multifaceted, consisting of the implementation of an algorithm for restrictive use of antibiotics as proposed in recent guidelines (Verenso, Dutch guideline), tailored in close collaboration with local stakeholders to the specific implementation setting, by means of a modified participatory-action research (PAR) approach. To support the process of intervention-tailoring and -implementation, a toolbox comprising of materials, aids and actions is developed to be used at the discretion of the local stakeholders to support implementation of the algorithm.The algorithm is congruent with the Swedish and Norwegian guidelines, which also promote more restrictive use of antibiotics in case of non-specific symptoms, even though the algorithm is more detailed.
40923119|NCT00027833|BIOLOGICAL|ALVAC-CEA-B7.1 vaccine|
41095764|NCT05536284|DRUG|Bisoprolol Fumarate Tablets|Antihypertensive drug used for acute coronary syndrome patients
40923120|NCT00027833|BIOLOGICAL|tetanus toxoid|
40923121|NCT00027833|DRUG|FOLFIRI regimen|
40923122|NCT00027833|DRUG|fluorouracil|
40923123|NCT00027833|DRUG|irinotecan hydrochloride|
40923124|NCT00027833|DRUG|leucovorin calcium|
40923125|NCT01055873|BIOLOGICAL|A single blood sample (30 mL)|A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
41095765|NCT03349684|DRUG|Acarbose|Uptitrated in the treatment phase from 50 mg per day for 1 week, followed by 100 mg per day for another week, and 150 mg per day for the rest 14 weeks, oral, with the first mouthful of main meal
41095766|NCT03349684|DRUG|Metformin|500 mg 3 times daily, oral, with the first mouthful of main meal
40923126|NCT02024152|DRUG|JDP-205 IV high dose|
40923127|NCT02024152|DRUG|JDP-205 IV low dose|
40923128|NCT02024152|DRUG|JDP-205 IM|
40923129|NCT02024152|DRUG|Control: Zyrtec|
40923130|NCT02587611|OTHER|Elemental liquid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
40923131|NCT02587611|OTHER|Standard semi-solid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
41095767|NCT03349684|DRUG|Placebo|Acarbose matching placebo, oral
41095768|NCT06217068|BEHAVIORAL|Elliptical Activity|8 minutes of elliptical exercise at a moderate intensity based on heart rate reserve. There will be a 2-minute warm-up and 2-minute cool down period in addition to the 8 minutes at moderate-intensity.
41453284|NCT04166162|BEHAVIORAL|Brief Intervention Motivational Interviewing (BIMI) Intervention|BIMI is a 15-minute brief interview in person or via video chat with participating youth. The interview will be focused on discussing the impact of drinking alcohol on one's health and how to set personal goals so that alcohol use does not become a problem. A follow up phone or video call at 3 and 6 months post initial interview will also be conducted which will track on the progress of setting and keeping personal goals.
41095769|NCT06231082|PROCEDURE|Group one - percutaneous (P)|Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.
41270548|NCT04567563|DEVICE|Remote Ischemic conditioning (RIC)|Intervention Group: Patients will self-administer RIC treatment with the LifeCuff device 3 times a week. Treatment will be delivered at the patient's home and compliance will be monitored by the LifeCuff device. Control Group: Patients undergo typical standard of care treatment. Assessment of Ulcer Closure: Ulcers will be assessed as completely closed by the Principal Investigator through clinical judgement and photographic support. Patients that completely heal their ulcer during the healing period will complete the study and no further blood or tissue measurements will be taken
41095770|NCT06231082|PROCEDURE|Group two - EUS FNB (E)|"EUS guided liver FNB will be performed under deep sedation with propofol under anesthesiology monitoring. A 19G gauge Franseen needle (Acquire 19G, Boston Scientific, USA) will be used with the wet suction technique. Before inserting into the operating channel, the stylet will be removed, and the needle will be primed with heparin (500UI/5ml). After liver puncture, the 20ml aspiration syringe will be attached. Three needle actuations will be performed, one or two passes in the left liver lobe. At the end of the 3rd actuation, the syringe aspiration will be stopped, the needle will be left in place in the liver parenchyma for 2 to 3 minutes. The liver needle path will be examined with Doppler ultrasound to look for possible bleeding. If present, about 25% of the needle content will be pushed in the liver path, as previously described - the blood patch technique."
41095771|NCT05625399|DRUG|Nivolumab + Relatlimab|Specified dose on specified days
41095772|NCT05625399|DRUG|rHuPH20|Specified dose on specified days
41095773|NCT04522375|DRUG|FP-045|activator of aldehyde dehydrogenase
41095774|NCT06355817|DEVICE|Vibration|Vibration Assist Device, held to the forehead
41095775|NCT06355817|OTHER|Tapping|Tapping on the forehead
41270549|NCT05233358|PROCEDURE|Hepatic Artery Infusion Chemotherapy|HAIC adopts FOLFOX chemotherapy regimen, hepatic arteriography through a radial artery or femoral artery cannulation, routine hepatic artery cannulation, imaging, infusion of chemotherapy drugs into hepatic artery: oxaliplatin 85 mg/m2 on the first day for 0-3 hours, folinic acid 400 mg/m2 for 3-4.5 hours on day 1, fluorouracil 400 mg/m2 for 4.5-6.5 hours on day 1, and fluorouracil 2500 mg/m2 for 46 hours on days 1-3.
41270550|NCT05233358|PROCEDURE|Transarterial Chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
41270551|NCT05233358|DRUG|Regorafenib|Regorafenib is administered for 28 days per treatment cycle, with oral regorafenib on days 1-21, 80-160 mg once daily. The dose is adjusted according to adverse reactions, with a minimum of 80 mg.
41270552|NCT05233358|DRUG|Immune Checkpoint Inhibitors|Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab. Treatment is based on the immune checkpoint inhibitor before the patients are randomized into the group, and it is not recommended to replace the immune checkpoint inhibitor. The dosage is 200 mg, intravenous infusion, D1, once every 21 days (Q3W). Dosing interruption or dose reduction may be necessary based on individual safety and tolerability considerations; dosing with immune checkpoint inhibitors should not be suspended for more than 4 weeks.
41270553|NCT00000981|DRUG|Fiacitabine|
41270554|NCT03371563|DRUG|Antibiotics|Patients were treated with antibiotics for Lyme disease.
41270555|NCT03371563|OTHER|no intervention|controls were not given antibiotics
41270556|NCT03973476|OTHER|Phone care support by midwife|Mothers can call the midwife's telephone every working day from 8 a.m. to 8 p.m.
41270557|NCT00868790|DRUG|MK-3577|MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
41270558|NCT00868790|DRUG|Placebo to MK-3577|Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
41270559|NCT00868790|DRUG|Metformin|Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
41270560|NCT00868790|DRUG|Placebo to Metformin|Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
41270561|NCT04684654|BIOLOGICAL|BMS-986325|Specified dose on specified days
41270562|NCT04684654|OTHER|Placebo for BMS-986325|Specified dose on specified days
41270563|NCT00619008|OTHER|Ad libitum low carbohydrate diet|6 week ad libitum low carbohydrate diet
41270564|NCT00619008|OTHER|Ad libitum High Complex Carbohydrate Diet|6 week ad libitum high complex carbohydrate diet
40923132|NCT01203852|DRUG|Metoprolol|"Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily."
40923133|NCT01203852|DRUG|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
40923134|NCT02845219|DRUG|semaglutide|Oral administration once daily alone or together with oral contraceptive.
41095776|NCT01693094|BEHAVIORAL|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
40923135|NCT02845219|DRUG|SNAC|Oral administration once daily together with oral contraceptive.
40923136|NCT02845219|DRUG|Microgynon®|Oral administration once daily alone or together with oral semaglutide or SNAC.
40923137|NCT05566483|BEHAVIORAL|Exercise|exercise protocol
40923138|NCT04511377|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to rotator cuff repair post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 6 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 6 to 12 weeks post surgery."
40923139|NCT04511377|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
40923140|NCT01699347|DRUG|Intracystic injection of OK432 under US guiding|Intracystic injection of OK432 under US guiding
40923141|NCT00858572|DRUG|STA-9090 (ganetespib)|Chemotherapy agent
40923142|NCT06005129|BEHAVIORAL|Personality-Based Therapy|Participants will be randomized to a 2- or 4-week assessment-only baseline period. After the baseline period, participants will receive the personality-based treatment module corresponding to their highest clinical elevation (i.e., neuroticism, \[low\] conscientiousness, \[low\] agreeableness). Treatment will consist of six weekly 50-60-minute sessions. After the 6-week intervention period, participants will complete a 4-week follow-up period to determine the sustainability of effects observed
40923143|NCT04660838|OTHER|ACB intervention|Stopping and/or switching ACB medication to an alternative
40923144|NCT05282953|DRUG|KIO-301|KIO-301 intravitreal injection at ascending doses
40923145|NCT00324298|BIOLOGICAL|bleomycin sulfate|
40923146|NCT00324298|DRUG|cisplatin|
40923147|NCT00324298|DRUG|etoposide|
40923148|NCT00324298|PROCEDURE|management of therapy complications|
40923149|NCT03963167|DRUG|BDP/FF/G fixed combination|Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
40923150|NCT06068426|DIAGNOSTIC_TEST|Transabdominal ultrasound Shear wave elastography|TUS SWE will be performed using a Canon Aplio i800 ultrasound system and a curved 1-6 MHz transducer. 2D SWE will be performed with measurement of shear wave speed in the head, body and tail of the pancreas.
40923151|NCT06421129|PROCEDURE|anal fistula surgery|anal fistula surgery consists of;Fistulotomy and Fistulotomy with seton placement
40923152|NCT04480853|DRUG|Fingolimod|Fingolimod 0.5 mg QD, oral
40923153|NCT05444140|BEHAVIORAL|Health coaching|The health coaching programme includes four monthly health coaching sessions for three months.
40923154|NCT05049083|DRUG|New Process SHR2554 tablet、Former Process SHR2554 tablet|New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
41095777|NCT03365856|OTHER|observational study|as clinical practice
41095778|NCT03824652|OTHER|walnuts|2 ounces of walnuts daily for 4-10 weeks
40923155|NCT05049083|DRUG|Former Process SHR2554 tablet、New Process SHR2554 tablet|Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
41095779|NCT03824652|OTHER|usual diet|Subject continues usual diet
41095780|NCT03824652|OTHER|phone counseling with dietitian|Weekly calls with dietitian
41095781|NCT01408680|DIETARY_SUPPLEMENT|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
41095782|NCT01408680|DIETARY_SUPPLEMENT|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
41095783|NCT01408680|DIETARY_SUPPLEMENT|Placebo|Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
41095784|NCT05630495|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
40923156|NCT02671162|DRUG|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
40923157|NCT02671162|DRUG|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
40923158|NCT04099394|BEHAVIORAL|Behavioral Health|Ten, group-based classes lasting one hour each that teaches symptom management and promotes physical activity.
40923159|NCT04099394|BEHAVIORAL|Health Education|Ten, group-based classes lasting one hour each that teaches topics related to aging and health (e.g., blood pressure control, maintaining healthy bones, cancer screening, immunizations).
40923160|NCT03409978|DEVICE|in-Motion app|mobile phone application for recording fidgety movements at home
40923161|NCT02539056|DEVICE|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
40923162|NCT01357850|DRUG|GSK716155|GSK716155
40923163|NCT01357850|DRUG|Placebo|Placebo
40923164|NCT00594724|PROCEDURE|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
40923165|NCT04424277|OTHER|diaphragm ultrasound|respiratory loading
40923166|NCT04662970|DEVICE|Device programming|Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming
40923167|NCT05690256|BEHAVIORAL|Resilience Clinic|A psychoeducational caregiver-child intervention based in primary care, designed to mitigate toxic stress and promote child resilience. Participants engage in 6 weekly visits in primary care using an interactive curriculum based in the evidence-based Circle of Security Parenting along with mindfulness principles.
40923168|NCT05690256|BEHAVIORAL|Enhanced primary care|In addition to usual pediatric primary care, enhanced primary care (the control condition for this study) provides navigational services to link to community resources based on screening for unmet social needs (e.g., food insecurity, housing, financial strain).
40923169|NCT05449015|DRUG|1% atropine|Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia
40923170|NCT02020720|PROCEDURE|Biopsy|Undergo image-guided biopsy
40923171|NCT02020720|PROCEDURE|Computed Tomography|Undergo 18F-DOPA-PET/CT
40923172|NCT02020720|PROCEDURE|Diffusion Weighted Imaging|Undergo DTI
40923173|NCT02020720|DRUG|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
40923174|NCT02020720|OTHER|Laboratory Biomarker Analysis|Correlative studies
40923175|NCT02020720|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo pMRI
40923176|NCT02020720|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
40923177|NCT02020720|PROCEDURE|Therapeutic Conventional Surgery|Undergo stereotactic craniotomy
40923178|NCT02660840|DRUG|0.5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
40923179|NCT02660840|DRUG|1 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
41095785|NCT04248764|OTHER|Foam roller application|Following the fatigue protocol, foam roller application will be applied to the quadriceps femoris muscle for five minutes in the prone position.
41270565|NCT00619008|OTHER|Energy-restricted high complex carbohydrate diet|6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
40923180|NCT02660840|DRUG|5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
40923181|NCT02660840|DRUG|0.5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
40923182|NCT02660840|DRUG|1 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
40923183|NCT02660840|DRUG|5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
41270566|NCT05358132|DEVICE|Pneumowave Device placement and data capture|"Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.~Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,"
40923184|NCT04469829|DRUG|Secukinumab|standard doses of secukinumab for psoriasis
40923185|NCT04469829|DRUG|Methotrexate|Methotrexate 15 mg/week
40923186|NCT00000724|DRUG|Trimetrexate glucuronate|
40923187|NCT00000724|DRUG|Leucovorin calcium|
40923188|NCT03740984|OTHER|Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.|During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.
40923189|NCT03894722|PROCEDURE|Control|During the third molar extraction the saline solution will be used in the control group.
40923190|NCT03894722|PROCEDURE|0.5% concentration of PVP-I|During the third molar extraction 0.5% concentration of PVP-I solution will be used in the test group.
40923191|NCT03894722|PROCEDURE|1 % concentration of PVP-I|During the third molar extraction 1 % concentration of PVP-I solution will be used in the test group.
40923192|NCT03894722|PROCEDURE|3 % concentration of PVP-I|During the third molar extraction 3 % concentration of PVP-I solution will be used in the test group.
40923193|NCT03495583|OTHER|Early introduction|Consumption of 2g/week of cow's milk, hen's egg, wheat, peanut, sesame and fish protein from 3 months of age (alongside breastfeeding)
40923194|NCT02720107|DRUG|fingolimod|
40923195|NCT01903252|DRUG|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
40923196|NCT01903252|DRUG|Asacol 400 mg|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
40923197|NCT03364829|DRUG|Indacaterol/Glycopyrronium|
40923198|NCT00729469|DRUG|Ospemifene 60 mg|60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
40923199|NCT00729469|DRUG|Placebo|oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
40923200|NCT04224688|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
40923201|NCT04224688|OTHER|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
40923202|NCT06029257|DRUG|Tildrakizumab|As provided in real-world clinical practice.
41095786|NCT04248764|OTHER|Massage application|Following the fatigue protocol, sports massage will be applied to the quadriceps femoris muscle for five minutes.
41095787|NCT04730336|DEVICE|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
40923203|NCT00322972|DRUG|Mass treatment with oral azithromycin to an entire community|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
40923204|NCT04743570|DRUG|Placebo treatment|Active drug/placebo is given for the first 5 days of admission.
40923205|NCT04743570|DRUG|Methylnaltrexone treatment|Active drug/placebo is given for the first 5 days of admission.
40923206|NCT00303589|DRUG|Standard care|As prescribed
40923207|NCT00303589|DRUG|beta-lactam|750mg iv q8h
40923208|NCT00303589|DRUG|beta-lactam|1500mg iv q8h
40923209|NCT04175990|DRUG|Dydrogesterone Pill|started from day 1 of menses till trigger day
40923210|NCT00321646|DRUG|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
40923211|NCT00321646|DRUG|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
40923212|NCT01931085|DRUG|Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).
40923213|NCT01362010|DRUG|Topical Minocycline Foam FXFM244|Topically applied once a day.
40923214|NCT01849744|DRUG|VS-4718|
40923215|NCT01546272|DEVICE|Insorb resorbable staples|Subcutanous suture using resorbable staples
40923216|NCT01546272|DEVICE|Monocryl resorbable wire|Subcutanous suture using resorbable wire
40923217|NCT02536404|DRUG|Etrasimod|
40923218|NCT02536404|DRUG|Placebo|
40923219|NCT04223492|DIAGNOSTIC_TEST|Liquid biopsy|A blood sample containing circulating tumor DNA and circulating tumor cells.
40923220|NCT04223492|DIAGNOSTIC_TEST|Multi-parametric MRI|Multi-parametric MRI combines different imaging protocols in one session to measure more functional items than perfusion alone, addressing different aspects of tumor biology.
40923221|NCT04966858|OTHER|Individualized Caloric Refeeding (ICR)|Meal-based refeeding in hospital, starting at 50 calories per kilogram of body weight, and increasing by 200 calories per day until caloric goal achieved
40923222|NCT04966858|OTHER|Higher Calorie Refeeding (HCR)|Meal-based refeeding in hospital, starting at 2000 calories per day, and increasing by 200 calories per day until caloric goal achieved
40923223|NCT06286709|BIOLOGICAL|Faecal Microbiota Transplant|FMT is 50mL aliquots of filtered suspension of stool (0.6g/mL). FMT for administration via colonoscopy will be made up of 150g stool in 250mL (5 aliquots). FMT for administration via enema will be made up of 30g stool in 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
40923224|NCT06286709|OTHER|FMT Placebo|FMT Placebo is 50mL aliquots containing 0.9% w/v saline and glycerol in a ratio of 9 parts saline: 1 part glycerol v/v. FMT Placebo for administration via colonoscopy will be made up of 250mL (5 aliquots). FMT Placebo for administration via enema will be made up of 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
40923225|NCT04647981|OTHER|Xpert® Bladder Cancer Monitor Test|The urine sample is analyzed with the Xpert® Bladder Cancer Monitor test.
40923226|NCT03852680|PROCEDURE|aneurysm clipping|treatment of wide necked intracranial aneurysms using different modalities as open surgery by clipping or endovascular techniques as coiling and flow diversion
40923227|NCT01456767|DIETARY_SUPPLEMENT|Probiotics|"Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells."
40923228|NCT02819778|PROCEDURE|usual care|
40923229|NCT02819778|PROCEDURE|S100B|
40923230|NCT02285062|DRUG|lenalidomide|
41095788|NCT05032235|DRUG|Fluzoparib|Normal Renal Function:A single oral dose of Fluzoparib will be administered.
41095789|NCT05032235|DRUG|Fluzoparib|Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.
40923231|NCT02285062|DRUG|Placebo|
40923232|NCT02285062|DRUG|Rituximab|
40923233|NCT02285062|DRUG|Cyclophosphamide|
40923234|NCT02285062|DRUG|Doxorubicin|
40923235|NCT02285062|DRUG|prednisone|
40923236|NCT02285062|DRUG|vincristine|
40923237|NCT02843997|GENETIC|Endophenotype and sequencing|Draw an endophenotype and genetic study
40923238|NCT00270842|BEHAVIORAL|Tai Chi|This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
40923239|NCT00270842|BEHAVIORAL|Functional Balance|This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
40923240|NCT00270842|BEHAVIORAL|Education Control group|This control group participated in 10 weeks of general health education classes.
41095790|NCT05032235|DRUG|Fluzoparib|Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
41095791|NCT00071643|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
40923241|NCT02489929|OTHER|blood samples|This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia
40923242|NCT02489929|DRUG|azacytidine|
40923243|NCT06237192|DRUG|blinatumomab for B-ALL, venetoclax for T-ALL|MRD-associated based therapy for Ph-negative acute lymphoblastic leukemia
40923244|NCT04157673|BEHAVIORAL|Episodic Future Thinking|This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability. This intervention will be introduced following a 6-week, 8-week or 10-week baseline period.
40923245|NCT01239719|DRUG|Dexamethasone + clemastine|Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.
40923246|NCT01239719|DRUG|Dexamethasone|Dexamethasone 0.5 mg: 01 tablet every 12 hours.
40923247|NCT00256971|PROCEDURE|meniscectomy|
40923248|NCT02412813|DEVICE|LEGION OXINIUM|Investigational Group
40923249|NCT02412813|DEVICE|LEGION Cobalt Chrome|Control Group
41270567|NCT02103140|BEHAVIORAL|Facility-based Exercise|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
41270568|NCT02103140|BEHAVIORAL|Home-based Exercise|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
40923250|NCT00766753|BIOLOGICAL|Dendritic vaccine pulsed with multiple peptides|Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
40923251|NCT00766753|BIOLOGICAL|The first booster vaccine phase:|This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
40923252|NCT00766753|BIOLOGICAL|The second booster vaccine phase:|"At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.~2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays"
40923253|NCT00663247|DEVICE|Mesalazine|3 grams daily for 3 months
40923254|NCT00663247|DRUG|Placebo|3 grams daily for 3 months
40923255|NCT02226445|OTHER|Combined ADHD medication and psychosocial counseling|"The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.~ADHD medication:~First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.~When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.~If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.~If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine."
40923256|NCT05657574|DRUG|D377|oral, once daily, 8 weeks
40923257|NCT05657574|DRUG|CKD-331|oral, once daily, 8 weeks
40923258|NCT05657574|DRUG|D086|oral, once daily, 8 weeks
40923259|NCT05657574|DRUG|Placebo (for D377)|oral, once daily, 8 weeks
40923260|NCT05657574|DRUG|Placebo (for CKD-331)|oral, once daily, 8 weeks
40923261|NCT05657574|DRUG|Placebo (for D086)|oral, once daily, 8 weeks
40923262|NCT02384642|BEHAVIORAL|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
40923263|NCT02384642|BEHAVIORAL|COMPASS plus parenting|The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
40923264|NCT04176172|DRUG|Varenicline|Participants will receive open-label varenicline for 12 weeks.
40923265|NCT04176172|DRUG|Nicotine patch|Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)
41270569|NCT05202626|DIAGNOSTIC_TEST|Nasopharyngeal Endoscopy image-guided Biopsy|For each participant presenting with a suspicious nasopharyngeal lesion, the attending physician will assess the lesion and determine the appropriate biopsy approach. The physician may decide on multiple biopsies from the lesion area, including one sample from within the lesion itself, another from 5-8 mm outside the lesion, and a third from 8-10 mm beyond the lesion. Alternatively, a single biopsy may be deemed sufficient based on the clinical judgment. Each of these specimens will undergo pathological examination to confirm whether they are carcinomatous or non-carcinomatous.
41270570|NCT01114789|OTHER|Proteolysis|protocol designed to examine the effect of obesity on muscle proteolysis in hemodialysis and control
41270571|NCT06164405|DEVICE|arterial dp/dtmax|to assess the variations of the arterial dp/dt max after drugs or fluids administration
40923266|NCT04176172|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.
40923267|NCT04176172|BEHAVIORAL|Standard treatment + Managed Problem Solving (MAPS) adherence intervention|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.
40923268|NCT03796845|OTHER|No limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
40923269|NCT04118452|BEHAVIORAL|Telephone-based early childhood developmental care coordination|The 211LA care coordinator will review developmental screening results and provide referral recommendations to the family and use 211LA's extensive resource directory and agency relationships to identify appropriate referrals. The 211LA care coordinator will provide a report to the clinical provider containing recommendations for follow-up and a care coordination plan. The report will be scanned into the EMR by clinic staff and be available for provider review. The 211LA care coordinator will also make all recommended referrals and will call the family monthly until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
40923270|NCT00933413|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
40923271|NCT04415242|OTHER|positioning|different positioning prior surgery
40923272|NCT00995566|DRUG|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
40923273|NCT03961698|DRUG|IPI-549 (eganelisib)|IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.
40923274|NCT03961698|DRUG|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.
40923275|NCT03961698|DRUG|nab-paclitaxel|Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol), a mitotic inhibitor chemotherapy, with less toxicity than solvent-based (sb) paclitaxel and achieves a 33% higher tumor uptake in preclinical models. Nab-paclitaxel will be administered intravenously (IV) at 100 mg/m2 on days 1, 8 and 15 of each 28-day cycle for patients with TNBC.
40923276|NCT03961698|DRUG|Bevacizumab|Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) recombinant monoclonal antibody that is approved by the FDA for the treatment of multiple solid tumors in combination with chemotherapy. It will be administered at 15 mg/kg IV on day 1 of each 21-day cycle to patients with RCC.
40923277|NCT01900912|OTHER|CLTS|The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
40923278|NCT01109732|OTHER|Systematic physical training with instructor|Training 3 times per week for 6 months, the first 3 months with an instructor
40923279|NCT05337020|OTHER|Survey|Each patient will be asked to fill in the questionnaire to assess their vision on telemedicine
41095792|NCT00071643|DRUG|Escitalopram|Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
41095793|NCT00071643|OTHER|Placebo|Participants will receive a placebo pill.
41095794|NCT05843565|DEVICE|Cobalt video laryngoscope blade|Non-standard hyperangulated Cobalt video laryngoscope blade
41095795|NCT05843565|DEVICE|Miller video laryngoscope blade|Standard Miller video laryngoscope blade
41095796|NCT01217580|DRUG|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
41095797|NCT01217580|DRUG|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
41095798|NCT03421444|OTHER|No intervention|No intervention
40923280|NCT03704753|DRUG|Ropivacaine|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients
40923281|NCT03704753|DRUG|Sodium chloride 0.9%|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).
40923282|NCT04837326|OTHER|Heel Lance Blood Sampling in Facilitated Tucking Position|
40923283|NCT04837326|OTHER|Heel Lance Blood Sampling When the Infant is Embraced by the Mother|
40923284|NCT04837326|OTHER|Heel Lance Blood Sampling Using White Noise|
40923285|NCT04164693|DRUG|Low molecular weight heparin|patients began to use low molecular weight heparin or warfarin sodium tablets.
40923286|NCT04164693|OTHER|non anticoagulant therapy group|no anticoagulant was used after operation.
40923287|NCT03176017|PROCEDURE|Ejaculatory sparing TUIP|The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum
40923288|NCT03176017|PROCEDURE|Conventional TUIP|the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.
40923289|NCT06491966|OTHER|observation|data collected includes demographic information, clinical outcomes (mortality rate, ICU stay length), inflammatory markers (e.g., IL-2, IL-10, TNF-α), and treatment details (mechanical ventilation, CRRT, ECMO, antibiotics). Culture results, NGS findings, and imaging reports were also documented.
40923290|NCT03367247|BEHAVIORAL|BOLSTER|BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
40923291|NCT03367247|OTHER|Enhanced Discharge Planning (EDP)|EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
40923292|NCT05694377|BEHAVIORAL|electroencephalography-based neurofeedback (EEG-NFB)|The EEG-NFB training program will involve nine training sessions (three times a week over a 3-week period) each lasting 30 min. EEG-NFB training will be conducted with ProComp Infiniti Encoder and BioGraph Infiniti Software v.5.1.3. The training protocol will be set to decrease the EEG TBR value. For the 12 training sessions, all participants will be subjected the same EEG-NFB protocol at C3 electrode. The EEG-NFB training sessions consists of a 20-s baseline period (i.e., with no feedback), 30-min feedback presentation, and another 20-s baseline period. Subjects will be seated in front of a computer screen and animations will be used as feedback; the animation starts when the subject is sufficiently focused for 20 s. Three 10-min animations (flying duck, roller coaster ride, and moving ball) will be shown to the subject during each EEG-NFB training session. The raw EEG signal, TBR value over time, EEG signal noise, and EEG theta and beta wave amplitudes will be recorded.
40923293|NCT05673174|DIAGNOSTIC_TEST|Non-Invasive Estimation of Left Ventricular Diastolic Pressure|Modified blood pressure cuff used to detect arterial waveforms used for the estimation of LVDP
40923294|NCT00154323|DRUG|Oxcarbazepine|
40923295|NCT02083549|OTHER|Blood collection|After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
40923296|NCT02799251|OTHER|Collection of plasma cell rate|Lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery. The rates are assessed before surgery (day 0) and at days 1, 3, 5 and 8 after surgery. Anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. Clinical and biological signs of infection are collected.
40923297|NCT00159822|DRUG|Voriconazole|"Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours"
40923298|NCT01624311|OTHER|Therapeutic Hypothermia|After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.
41270572|NCT00770848|DRUG|AMG 102|Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
40923299|NCT01624311|OTHER|Standard of Care Therapy|Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
40923300|NCT05580445|DRUG|CT-707|Focal Adhesion Kinase (FAK) inhibitor
40923301|NCT05580445|DRUG|Toripalimab|Programmed Death 1(PD-1) antibody
41270573|NCT00770848|DRUG|AMG 102|Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
41270574|NCT00770848|DRUG|Mitoxantrone|Administered Q3W for a maximum of 12 cyles
41270575|NCT00770848|DRUG|Placebo|Placebo
40923302|NCT05580445|DRUG|Gemcitabine|nucleoside inhibitor
40923303|NCT02262182|OTHER|KP group|
40923304|NCT02262182|OTHER|KM group|
40923305|NCT03005873|DRUG|TLC599 LD group|Single dose via intra-articular injection
40923306|NCT03005873|DRUG|Normal Saline|Single dose via intra-articular injection
40923307|NCT03005873|DRUG|TLC599 HD group|Single dose via intra-articular injection
40923308|NCT05391178|OTHER|Lumiton yarn sleeve|Sleeve made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
40923309|NCT05391178|OTHER|Lumiton yarn hat|Hat made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
40923310|NCT05391178|OTHER|Lumiton yarn shirt|Shirt made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
40923311|NCT01466829|DRUG|Parathyroid hormone|100 microgram daily. S.c
40923312|NCT01466829|DRUG|Placebo|Placebo; saline injection.
41270576|NCT00770848|DRUG|Prednisone|5 mg orally BID
41270577|NCT06363162|DIAGNOSTIC_TEST|Immunohistochemistry or genetic test|Perform two diagnostic methods on the same sample
40923313|NCT02767362|DRUG|Atorvastatin|Once enrolled on this pre-operative window study, patients with endometrial cancer will be treated with the standard clinical dose of atorvastatin (80 mg once daily orally) for an average of 2-4 weeks prior to surgical staging. Patients will need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging.
40923314|NCT03259620|DRUG|CLS006|Furosemide Topical Gel
40923315|NCT03259620|DRUG|CLS006 Vehicle|Vehicle Topical Gel
40923316|NCT00355836|BEHAVIORAL|Mental Imagery|
40923317|NCT04176601|BEHAVIORAL|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
40923318|NCT04751214|PROCEDURE|APPENDICECTOMY|
40923319|NCT03772002|DIAGNOSTIC_TEST|HCV screening|HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
40923320|NCT04083729|PROCEDURE|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
40923321|NCT06261281|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
40923322|NCT06261281|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
40923323|NCT06261281|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
40923324|NCT05084729|DEVICE|Imagio OA/US|Imagio optoacoustic
40923325|NCT03005184|DRUG|Valsartan 80 mg bid|oral medication during run-in and washout period
40923326|NCT03005184|DRUG|Enalapril 10 mg bid|oral medication
40923327|NCT03005184|DRUG|Sacubitril-Valsartan 200 mg bid|oral medication
40923328|NCT03005184|DRUG|Icatibant|intravenous medication
40923329|NCT03005184|DRUG|Placebo|intravenous medication
40923330|NCT01970904|DRUG|Alisporivir|Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration
40923331|NCT01970904|DRUG|Ribavirin|Ribavirin tablets of various strengths for oral administration
40923332|NCT01970904|DRUG|Peg-IFNα2a|Peg-IFNα2a solution for subcutaneous injection
40923333|NCT02108340|PROCEDURE|Microwave radiometry|Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
40923334|NCT03642795|OTHER|Questionnaire|Patients are asked to complete several questionnaires
40752000|NCT06426576|DEVICE|Plantar pressure insoles|The insoles are used in both static and dynamic conditions such as walking straight along the hallway or walking stairs if applicable. Initial instruction is given by a trained physiotherapist and will be continuously applied at home using the smartphone app for 5 out of 7 days per week during the first 2 weeks after surgery.
40923335|NCT05617313|DRUG|Pembrolizumab|200 mg intravenously on Day 1 of cycle.
40923336|NCT05617313|DRUG|GT103|10mg/kg taken intravenously on Day 1 of cycle.
40923337|NCT02726542|DRUG|somatropin|Norditropin (growth hormone) given by injection using a pen-device
40923338|NCT01782001|DIETARY_SUPPLEMENT|vitamin A|vitamin A with placebo
40923339|NCT01782001|DIETARY_SUPPLEMENT|vitamin A and zinc|combination of vitamin A and zinc supplements
40923340|NCT00811642|DRUG|Posaconazole|400mg BID oral suspension for 12 weeks
40923341|NCT02823639|PROCEDURE|Transcranial direct current stimulation|
40923342|NCT03927560|PROCEDURE|Robotic Assisted Percutaneous Coronary Intervention|Robotic Assisted Percutaneous Coronary Intervention
40923343|NCT02434471|DEVICE|Respiratory-triggered T1w DISCO LAVA|"The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~1. Respiratory-triggered T1w DISCO LAVA precontrast~2. Respiratory-triggered T1w DISCO LAVA in the portal venous phase~3. Respiratory-triggered T1w DISCO LAVA in the equilibrium phase"
40923344|NCT05315869|PROCEDURE|Appendectomy|Surgical procedure for removal of the appendix
40923345|NCT00400036|BEHAVIORAL|Cod protein NCEP-diet|
40923346|NCT03707275|DEVICE|Alexa+|Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.
40923347|NCT03707275|OTHER|Standard of Care Arm|This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
40923348|NCT03835728|DRUG|Ocrelizumab|Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
40923349|NCT03835728|DRUG|Saline|This will be the matching placebo used in the study.
40923350|NCT03851172|DRUG|Ketorolac Ophthalmic|Preoperative administration of Ketorolac 0.5% eye drops
40923351|NCT03851172|DRUG|Nepafenac Ophthalmic|Preoperative administration of Nepafenac 1 mg eye drops
40923352|NCT03851172|DRUG|Cyclopentolate Ophthalmic|Preoperative administration of Cyclopentolate eye drops
40923353|NCT02289716|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
40923354|NCT02289716|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
40923355|NCT02289716|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
40923356|NCT03685890|DRUG|Nivolumab|One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes
40923357|NCT03685890|PROCEDURE|Isolated limb perfusion (ILP)|Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
40923358|NCT03473548|DEVICE|Portable sleep monitor|Type III at home portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis
40923359|NCT03473548|OTHER|In-laboratory Polysomnography|Polysomnography testing will determine the sleep stages, apnea hypopnea index (AHI), blood saturation oxygen nadir (SPO2 nadir), and average blood oxygen saturation. A McGill Oximetry Score will also be calculated for the in-laboratory PSG.
40923360|NCT02247648|DRUG|tramadol|Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
40923361|NCT02247648|DRUG|Placebo|"Patients from control group received a shame tramadol pill on day one, two, and 3"
40923362|NCT05595759|OTHER|Violence against women education supported by creative drama|Violence against women supported by creative drama training will be applied to male patients diagnosed with addiction every day for 5 days.
40923363|NCT05595759|OTHER|Routine service operation|No additional training will be applied to the control group and SAMBA trainings in the service operation will be applied.
40923364|NCT00562315|DRUG|FACBC|Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan
40923365|NCT00562315|OTHER|ProstaScinct|ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.
40923366|NCT01348477|PROCEDURE|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
40923367|NCT05735210|DEVICE|Polso™ Watch blood pressure measurement compared to a reference blood pressure measurement|The referenced blood pressure measurements are taken by dual auscultators.
40923368|NCT03206164|OTHER|Asynchronous, eLearning Intervention|20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.
41095799|NCT04571073|PROCEDURE|Fascial Distortion Model|"Using physical exam and manual manipulation skills informed by the FDM, he identified and treated locations of presumed fascial distortion about the plantar area of the foot; distortions could include any of the six reported fascial anomalies in the FDM: continuum distortions, trigger bands, herniated trigger points, folding distortions, cylinder distortions, and tectonic fixations. Each distortion is associated with a recommended reparative manipulation. The purported mechanism of action is that the distortion-specific manipulation restores normal fascial homogeneity."
41095800|NCT00273455|DRUG|bimatoprost 0.03%|
40923369|NCT02645838|BEHAVIORAL|Motivational interviewing|1. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
40923370|NCT05550727|OTHER|PorchLight|The PorchLight Project intervention consists of three components: 1) CARES® Dementia Care Specialist online training modules; 2) a PorchLight Project training course; and 3) monthly check-in sessions.
40923371|NCT04707859|DIAGNOSTIC_TEST|Head to head comparison: Rubidium vs 15O-water PET|Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation
40923372|NCT02895425|OTHER|Registry (No intervention)|
41095801|NCT00273455|DRUG|dorzolamide 2%/timolol maleate 0.5% fixed combination|
41095802|NCT00273455|DRUG|placebo|
41095803|NCT05180045|BEHAVIORAL|LINKED-BP Program|The intervention arm will include training on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. Patients will be trained to measure their BP in the morning and evening for 7 days. Patients enter data using Bluetooth device transmission or manual entry. Guidance is provided on accurate BP measurement. The app stores and securely relays data to the cloud. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal. Other components of usual care at the practices may include dietary counseling, on-site clinical pharmacists, social workers, case managers as needed for BP follow up, and assistance with medications and appointments as needed. The intervention period for each study participant is 12 months.
41095804|NCT00870259|DIETARY_SUPPLEMENT|Optifast VLCD|Meal replacement, three times daily for 8 weeks
40923373|NCT04250077|BEHAVIORAL|Community Reinforcement And Family Training (CRAFT)|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
40923374|NCT04250077|BEHAVIORAL|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
40923375|NCT02698995|DRUG|Dexamethasone|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
40923376|NCT02698995|DRUG|Ropivacaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
40923377|NCT02698995|DRUG|Paracetamol|After the block regression, at the first analgetic request the patients received the same analgesia protocol
40923378|NCT02698995|DRUG|Morphine|After the block regression, at the first analgetic request the patients received the same analgesia protocol
40923379|NCT02698995|DRUG|Lidocaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
40923380|NCT05165693|OTHER|Experimental Formula|Diabetes-specific study formula
40923381|NCT05165693|OTHER|Test Meal|Instant oatmeal
40923382|NCT01198522|DRUG|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|"Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29."
40923383|NCT02446171|DRUG|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
40923384|NCT02446171|DRUG|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
40923385|NCT02446171|DRUG|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
40923386|NCT02446171|DRUG|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
40923387|NCT02069340|DRUG|zoledronic acid|Given IV
40923388|NCT02069340|OTHER|pharmacological study|Correlative studies
40923389|NCT06119243|DEVICE|Vivior|The Vivior is a wearable clip-on sensor that objectively quantifies near viewing distance and duration, and ambient illumination. The Vivior will be attached to the spectacles frame of children undergoing myopia control treatment.
40923390|NCT01413347|PROCEDURE|pillow|bronchoscopic confirmation of double-lumen tube position with a head on a pillow
41095805|NCT05356026|OTHER|Online postpartum follow-up|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
40923391|NCT01413347|PROCEDURE|neutral|bronchoscopic confirmation of double-lumen tube position in neutral position of a head
40923392|NCT02600871|DRUG|Provodine|
40923393|NCT02600871|PROCEDURE|Incision and Drainage|
40923394|NCT02929043|OTHER|air puffs|
40923395|NCT00184171|DRUG|Budesonide|Budesonide 9 mg
40923396|NCT00184171|DRUG|Bismuth|Bismuth mixture
40923397|NCT00184171|DRUG|Fiber|Fiber for control
40923398|NCT04967040|PROCEDURE|medial plantar artery flap|Medial plantar artery flap is a fasciocutaneous island flap raised from the non-weightbearing instep of the plantar foot. The dominant vascular pedicle of the flap consists of the medial plantar artery and venae comitantes
40923399|NCT04967040|PROCEDURE|Distally based sural artery flap|Distally based sural artery flap is a fascio-cutaneous island flap taken from the posterior aspect of the middle third of the leg and fed by the lower peroneal septo-cutaneous perforators in reverse fashion. Its vascular basis is the close association between the median superficial sural artery and peroneal artery perforators
40923400|NCT01634425|DEVICE|Alere Triage Meter Pro|Troponin and BNP measured on point of care meter.
40923401|NCT05775523|DRUG|No intervention|No intervention
40923402|NCT05997394|OTHER|A prayer concert will be held for the participants.|Participants who are in the experimental group will be given a prayer audience.
40923403|NCT01595022|DRUG|Placebo: Flexi ring FR01|Intrauterine device, inserted once for 3 months
40923404|NCT01595022|DRUG|Placebo: Flexi ring FR20|Intrauterine device, inserted once for 3 months
40923405|NCT01595022|DRUG|Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)|Intrauterine device, inserted once for 3 months
41270578|NCT04397484|DRUG|0.5% Levobupivacaine|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
41270579|NCT04397484|DRUG|2% Xylocaine with adrenaline 1:200,000|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
41270580|NCT03912584|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
41270581|NCT03912584|DEVICE|P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
41270582|NCT02087332|DRUG|Prolonged release Torasemide (Britomar)|
41270583|NCT02087332|DRUG|Torasemide (Diuver)|
41270584|NCT01889602|DRUG|Lorazepam|Lorazepam: 2mg, po, 1x
41270585|NCT01889602|OTHER|Placebo|Non-active placebo, po, 1x
40923406|NCT00528970|DRUG|MOA-728|MOA-728 will be administered per the dose and schedule specified in the arm.
40923407|NCT00528970|DRUG|Placebo|Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
41270586|NCT01889602|DRUG|Topiramate 100mg|Topiramate: 100 mg, po, 1x
41270587|NCT01889602|DRUG|Topiramate 150mg|Topiramate: 150 mg, po, 1x
41270588|NCT01889602|DRUG|Topiramate 200mg|Topiramate: 200 mg, po, 1x
41270589|NCT02688517|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood samples
41270590|NCT02688517|OTHER|Laboratory Biomarker Analysis|Correlative studies
41270591|NCT05159414|DEVICE|Pulse Electrical Stimulation|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
41270592|NCT00872222|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
40752001|NCT03468946|OTHER|salty taste perception|"salty taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate salty taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors(high caries risk, medium caries risk, low risk )."
40923408|NCT00228982|DRUG|Ceftobiprole medocaril|
40923409|NCT00228982|DRUG|Vancomycin|
40923410|NCT05738590|PROCEDURE|muscle biopsy|true cut needle biopsy
40923411|NCT06207188|OTHER|Non-Interventional Study|Non-interventional study
40923412|NCT03279393|DRUG|fluorodeoxyglucose (FDG)-PET/MRI|Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
40923413|NCT05884164|PROCEDURE|Thoracic erector spinae plane block|After induction of general Anaesthesia,a high frequency ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinal muscle and the transverse processes are identified, spinal needle will be inserted after standard skin disinfection in a caudal to cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep to the erector spinal muscle. After hydrolocalization with ml normal saline, this plane will be opened and 20 ml of 0.25 %bupivacaine will be administered for block performance
41095806|NCT01427907|DRUG|Calcium acetate oral solution (COS)|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
41095807|NCT01427907|DRUG|Sevelamer carbonate|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
41095808|NCT01744691|DRUG|Ibrutinib|All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
41095809|NCT01974921|DEVICE|ALAIR Catheter. Radiofrequency system.|Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
41270593|NCT00758784|DRUG|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
41270594|NCT00864240|DRUG|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
41270595|NCT03268356|DEVICE|AGN1 Femoral Local Osteo-Enhancement Procedure Kit|A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.
41270596|NCT02489214|DRUG|donafenib tosilate tablets|200mg bid
40923414|NCT05884164|PROCEDURE|Thoracic paravertebral plane block|After induction of general Anaesthesia ,with the probe in the longitudinal paramedian position, it is then moved from medial to lateral direction to appreciate the saw tooth appearance of the facet joints close to the midline which changes to long finger-like shadow of the transverse process as the probe is moved slightly laterally. Repositioning the probe over the transverse process ensuring the space of interest is in the middle of the probe once again one should appreciate the intercostal muscles and the dense bright white line of the pleura in between the shadows of the transverse processes. The needle is then introduced at the caudal end of the probe in plane in a caudal to cranial direction aiming for the angle between the bottom of the transverse process and the pleura. Once position is confirmed, 20 ml of 0.25% bupivacaine will be administered for the block performance.
40923415|NCT05614934|DRUG|standard Clarithromycin triple therapy|Oral administration of proton pump inhibitor standard or double dose twice daily, clarithromycin 500 mg twice daily and, Amoxicillin1g twice daily for 14 days
40923416|NCT05614934|DRUG|Vonoprazan triple therapy|Oral administration of Vonoprazan 20mg twice daily, clarithromycin 500 mg twice daily, and, Amoxicillin1g twice daily for 14 days
40923417|NCT05614934|DRUG|Vonoprazan dual therapy|Oral administration of Vonoprazan 20mg twice daily and, Amoxicillin1g three times daily for 14 days
40923418|NCT04620798|BEHAVIORAL|Immediate vs. delayed provision of antibody test results|The primary experiment will be assessing whether provision of the antibody test results leads to behavior change with respect to personal protective behaviors. To that end, we will randomize all participants to a trial arm that immediately receive results (within 24 hours) or a trial arm with a delayed provision of results (after 4 weeks).
40923419|NCT01713933|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
40923420|NCT02782858|DRUG|GNbAC1|Monthly IV repeated dose
40923421|NCT02782858|DRUG|Placebo|Monthly IV repeated dose
40923422|NCT04636853|BIOLOGICAL|Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)|"A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.~A complete morpho-functional ophthalmological evaluation will be performed in all patient at each control."
40923423|NCT05613712|OTHER|Patients|Description by the patients through the questionnaire of the elements limiting the good ambulatory follow-up
40923424|NCT05613712|OTHER|Referring physician|Description by the referring physicians through the questionnaire of the elements limiting the applicability of the recommendations issued by the rheumatology department of the CHU Grenoble Alpes
40923425|NCT06251401|BEHAVIORAL|In-person supervised cardiac rehabilitation|In-person CR consists of weekly group-based supervised exercise training at Women's College Hospital, supplemented with home-based exercise training, with the goal of reaching Canadian Physical Activity Guidelines of 150 minutes a week of moderate-intensity exercise per week. Exercise prescriptions are individualized at baseline by the cardiac rehabilitation team. Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
40923426|NCT06251401|BEHAVIORAL|Virtual cardiac rehabilitation|Virtual CR consists of once-weekly telephone or video conferencing-based follow-ups (according to participant preference and access to internet/smart device) by one of the cardiac rehab providers. Similar to the in-person program, the virtual program also encourages participants to set goals to achieve 150 minutes a week of moderate-intensity exercise. The exercise prescription is individualized to each participant's ability and can vary in number of sessions per week and duration of each exercise session, as per the cardiac rehab provider's discretion. Unlike the in-person program, all these sessions are completed at home in an unsupervised manner. Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
40923427|NCT05459090|OTHER|ex-vivo study|ex-vivo experiments in tissue slices obtained from biopsies
40923428|NCT00812760|DRUG|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
41095810|NCT03686683|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with recombinant fusion protein composed PAP linked to GM-CSF (PA2024), a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
41095811|NCT05854628|PROCEDURE|skin biopsy|Skin biopsies will be obtained at different time points.
41095812|NCT06450184|DRUG|Pimavanserin 34 mg|1 capsule of Pimavanserin Capsule 34mg
41095813|NCT06450184|DRUG|NUPLAZID 34 MG Oral Capsule|1 capsule of Pimavanserin Capsule 34mg
40923429|NCT02230488|OTHER|Intensive Diabetes Case Management|"A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE~--------------------------------------------------------------------------------"
40923430|NCT06163677|BIOLOGICAL|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
40923431|NCT04572555|OTHER|Heat Treatment|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak.
40923432|NCT04583709|DEVICE|ECG Belt|"ECG Belt Research System Procedure LBBP Native conduction RV pacing if available Bipolar LBBP Unipolar LBBP - nonselective and selective (different outputs) Fusion pacing with native conduction at different Atrioventricular (AV) delays~HOT-CRT Native conduction HBP / LBBP HOT-CRT AV delay optimization. Medtronic Device (pacemaker/ICD) based Holter recording during the ECG belt recording"
40923433|NCT01076127|BEHAVIORAL|Ketllebell training|Kettlebell training 3 x 20 min a week for 8 weeks
40923434|NCT01076127|BEHAVIORAL|Control|Receives a health examination before and after the intervention period, and are advised to stay active.
41270597|NCT03377634|BEHAVIORAL|MORPH|Participants will engage in 12 weekly group coaching sessions discussion behavioral approaches to pain management, weight loss, and daily physical activity. The first three sessions (i.e., weeks 1 - 3) will occur in-person, and the remaining 9 will take place via telephone. All intervention participants will receive access to an activity monitor, smart scale, and smartphone app that aims to provide support for daily physical activity and weight loss.
41270598|NCT02076165|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Insomnia|Participants attended 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) with a trained instructor.
40923435|NCT04178278|DIAGNOSTIC_TEST|Shuttle walking test|Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea
41270599|NCT02076165|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Participants attended 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
41270600|NCT01883505|DRUG|Levodopa and carbidopa|Subcutaneous continuous administration
41270601|NCT01883505|DRUG|Placebo|Subcutaneous continuous administration
41270602|NCT06214988|PROCEDURE|selective approach defunctioning stoma|With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.
41270603|NCT05858190|PROCEDURE|Parallel Assignment|intervention group: treated with drug eluting balloon（paclitaxel-coated balloon； Orchid, Acotec Scientific Holdings Limited, Beijing, China)； control group :treated with plain old balloon
41270604|NCT03204630|DIETARY_SUPPLEMENT|Lfer|Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716
41270605|NCT03204630|DIETARY_SUPPLEMENT|Bifido|Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263
40923436|NCT04178278|DIAGNOSTIC_TEST|Exercise stress test|Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.
40923437|NCT04178278|DIAGNOSTIC_TEST|6 minutes walking test|When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
41095814|NCT04015986|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food-2|MDCF prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth
41095815|NCT04015986|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
41095816|NCT02196012|BEHAVIORAL|Intervention group|
41095817|NCT02196012|BEHAVIORAL|attention control condition|
41095818|NCT05189587|DEVICE|transcranial electrical stimulation (TES)|Transcranial electrical stimulation (tES) is a noninvasive brain stimulation technique that passes an electrical current through the cortex of the brain to alter brain function. The electrical current is applied to an individual's scalp usually via two or more electrodes, and whilst a large amount of the current is conducted between electrodes through soft tissue and skull (Vöröslakos et al. 2018), a portion of the current penetrates the scalp and is conducted through the brain, where it can alter neuronal excitability. By altering the activity of brain regions involved with a behaviour of interest, investigators can observe the resulting behavioral changes and so establish a causal link between the two (Reed et al. 2018).
41095819|NCT01801319|DEVICE|Libra Deep Brain Stimulation System|
41095820|NCT05283044|BIOLOGICAL|biopsy liquid|Patient performs a blood test at treatment baseline
41095821|NCT06197802|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 45 day and 6 month.
41095822|NCT06197802|BIOLOGICAL|Gardasil®9|Three doses administered intramuscularly at 0, 45 day and 6 month.
41095823|NCT02883504|PROCEDURE|Echo-Doppler examination and left heart catheterization|
41095824|NCT03000712|BIOLOGICAL|Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml|biological : Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml drug: saline solution
41095825|NCT01456663|DRUG|AFQ056|
41095826|NCT02055482|DRUG|Molidustat (BAY85-3934)|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
41270606|NCT03204630|OTHER|Control|Standard infant formula
41270607|NCT03211390|DIAGNOSTIC_TEST|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
41270608|NCT03211390|DIAGNOSTIC_TEST|Teleneurological Examination|A Vanderbilt neurologist will examine all consented residents using a telemedicine platform, with the assistance of a nurse at the subject's bedside. The neurologist will guide the nurse to perform elements of a physical examination to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
41270609|NCT06502561|DRUG|Aramchol meglumine|Aramchol meglumine is a salt form of Aramchol free acid
41270610|NCT06502561|DRUG|Aramchol free acid|Aramchol free acid is a fatty acid-bile acid conjugate
40923438|NCT02925416|DRUG|Oritavancin|Administered intravenously
40923439|NCT02925416|DRUG|Placebo (D5W)|Administered intravenously
40923440|NCT03265223|DRUG|0.2% ropivacaine|Intraperitoneal instillation versus intraincisional infiltration
40923441|NCT00940667|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
40923442|NCT00940667|DRUG|Amlodipine|amlodipine 5mg q.d.
40923443|NCT05083780|DRUG|Chlorphenesin Carbamate, Hydroxychloroquine|In addition to the mFOLFIRINOX therapy(backbone therapy), chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.
40923444|NCT03877640|DEVICE|BTL EMSELLA|High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.
40923445|NCT00620932|BEHAVIORAL|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
40923446|NCT02249637|PROCEDURE|Novel technique Circumcision Incision Orchidopexy|The novel technique starts with retraction of the prepucial skin off the glans penis and double incision circumcision done with mucosal sparing, then degloving of the penis on the side of the undescended testis. Dissection via Dartos' layer into the inguinal area until the palpable testicle was identified and extracted with mobilization of the spermatic cord. Hernia sac was then separated and suture ligated as high as the area of internal ring opening. Spematic cord lengthening was done until adequate length achieved for fixation into the inferior aspect of the scrotum. Then development of the Dartos' pouch via the circumcision site was done. A double or single suture testicular fixation using Vicryl 3-0 simple interrupted sutures on the everted Dartos' pouch inner surface was done. Subsequent placement of the testicle into the Dartos' pouch was done as the inner surface was inverted. The last step was the completion of the circumcision closure using Chromic 4-0 interrupted sutures.
40923447|NCT02052765|DEVICE|ECG continuous recording (Analyze ST)|During the ajmaline test, continuous ECG recording was forced to record ST shift
40923448|NCT03495609|DRUG|Ovitrelle|Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
40923449|NCT06362733|BEHAVIORAL|Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth|This is a 12-week intervention program (1 hour/week) of treatment to target insistence on sameness in youth with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of combination of parent-training and child-focused intervention.
40923450|NCT04057716|BEHAVIORAL|Sleep restriction|Participants will be asked to restrict their time in bed to 8 hours each night for one week.
40923451|NCT04057716|BEHAVIORAL|Sleep extension|Participants will be asked to extend their time in bed to 11 hours each night for one week.
40923452|NCT05661188|DRUG|Atezolizumab plus Tiraglolumab|All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
40923453|NCT03112954|DRUG|Buccal-relaxant formula|Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
40923454|NCT03112954|DRUG|Placebo|30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
40923455|NCT05973149|DRUG|QLH12016|according to the scheme description
40923456|NCT04148144|OTHER|No intervention included|No intervention included
40923457|NCT05373888|DEVICE|Flexima®/Softima® stoma bags|"One piece stoma bags for enterostomates available as:~* Closed (flat and convex)~* Drainable with Roll'Up (flat and convex)~* High flow with tape outlet (flat)"
40923458|NCT00746200|PROCEDURE|(electro)acupuncture|Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
40923459|NCT00746200|PROCEDURE|sham acupuncture|Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
40923460|NCT03253562|DRUG|Metformin Pill|a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
40923461|NCT03253562|DRUG|Vildagliptin 50 mg|Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
41095827|NCT02055482|BIOLOGICAL|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
41095828|NCT04413279|PROCEDURE|LipiFlow Thermal Pulsation|To manage patients with dry eye disease secondary to MGD
41095829|NCT04413279|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation|to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
41095830|NCT04937738|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
40923462|NCT01947062|DRUG|Intravenous Cisplatin & etoposide|Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
41095831|NCT04937738|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
40923463|NCT01947062|DRUG|Intravenous Cisplatin & etoposide along with oral cyclophosphamide|Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
40923464|NCT00535288|DRUG|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
40923465|NCT00535288|DRUG|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
40923466|NCT05304780|BEHAVIORAL|needs-tailored nurse-led recovery program|The needs-tailored nurse-led recovery program were divided into five major stages of care, which were build partnership, conduct integrated needs assessment, set needs-based recovery goals and provide empowerment-oriented care, conduct continuous monitoring of goals, and conduct effectiveness evaluations.
40923467|NCT05536388|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)
40923468|NCT03085849|DRUG|Durvalumab|1500 mg IV on day 8 (flat dose) until progression
40923469|NCT03085849|DRUG|Tremelimumab|75 mg IV on day 8 (flat dose) x 4 doses
40923470|NCT03085849|DRUG|SGI-110|"SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"
40923471|NCT05823740|OTHER|Bioelectrical impedance Analysis (BIA)|Bioelectrical impedance analysis (BIA) is a method for estimating body composition, in particular, body fat and muscle mass, where a weak electric current flows through the body and the voltage is measured in order to calculate the impedance (resistance) of the body. BIA will be done at baseline, during the study related to routine medical imaging, and end of the study.
40923472|NCT05823740|OTHER|D3-Creatine Dilution (D3Cr)|The D3-Creatine dilution method is a safe and noninvasive measure of skeletal muscle mass that has previously been validated in adults, neonates, healthy children, and children. D3-Creatine Dilution will be done at baseline, during the study related to routine medical imaging, and end of the study.
40923473|NCT05823740|OTHER|6-Minute Walk Test (6MWT)|Cardiovascular fitness will be measured with the 6-minute walk test (6MWT). 6MWT will be done at baseline, during the study related to routine medical imaging, and end of the study.
40923474|NCT05823740|OTHER|Timed Up and Go (TUG)|Balance and mobility will be assessed by the timed-up-and-go test (TUG). TUG will be done at baseline, during the study related to routine medical imaging, and end of the study.
40923475|NCT05823740|OTHER|30-second Sit-to-Stand (STS)|Strength and muscular function will be evaluated by modified 30-second sit-to-stand (STS). STS will be done at baseline, during the study related to routine medical imaging, and end of the study.
41095832|NCT04937738|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
40923476|NCT05823740|OTHER|Hand Grip Strength (GS)|Strength and muscular function will be evaluated by grip strength (GS). GS will be done at baseline, during the study related to routine medical imaging, and end of the study.
40923477|NCT05823740|OTHER|PBTL p16 expression|Peripheral Blood biospecimen for PBTL p16 expression will be used for the assessment of biological aging. Blood biospecimens will be collected at baseline and end of the study for PBTL p16 analysis.
40923478|NCT05823740|OTHER|CT, MR and PET Imaging|Participants will undergo routine imaging with either computed tomography (CT), Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan. Skeletal muscle mass and fat mass will be calculated at several different vertebral levels from imaging studies.
40923479|NCT03201081|OTHER|Motivational resistance-training programme|The experimental group exercised at a moderate intensity (8 to 12 repetitions). The load was increased during the 12 weeks from 65% 1-RM to 80% 1-RM. This training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions), following the OMNI-RES scale and a hard effort perception level.74 A 1-2 minutes resting period was allowed between sets. During the sessions, the participants were verbally encouraged to perform the complete range of motion for each exercise and received motivational strategies.
40923480|NCT05480345|DIAGNOSTIC_TEST|Impedance cardiography|Transthoracic impedance cardiography recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany): electrodes attached to both sides of the patient's neck (4 electrodes in total) and along the midaxillary line of the left and right sides of the chest (4 electrodes in total), employing the xyphoid process as a reference line.
40923481|NCT03609593|DRUG|Bendamustine|Subjects will receive Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days.
40923482|NCT03609593|DRUG|Venetoclax|"Venetoclax: 12 cycles~Venetoclax will then be started after 3 cycles of BR. Dosing for venetoclax will be in a step wise fashion as follows:~* Cycle 4 days 1-7 (Week 1): 20 mg once daily~* Cycle 4 days 8-14 (Week 2): 50 mg once daily~* Cycle 4 days 15-21 (Week 3): 100 mg once daily~* Cycle 4 days 22-28 (Week 4): 200 mg once daily~* Cycle 4 day 29 and thereafter (Week 5 and on): 400 mg once daily; continue until disease progression, unacceptable toxicity, or 12 cycles duration."
41095833|NCT04937738|DRUG|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
41095834|NCT04937738|DRUG|Capecitabine|1000 mg/m² two times per day (BID), d1-14
41095835|NCT04937738|DRUG|Oxaliplatin|130 mg/m² d1 i.v. every 3 weeks
41095836|NCT00395811|PROCEDURE|Bone Marrow Stem Cell Therapy combined CABG|Bone Marrow Stem Cell inject into myocardium
41270611|NCT05477186|BIOLOGICAL|CV0501 (3 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
41270612|NCT05477186|BIOLOGICAL|CV0501 (6 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
41270613|NCT05477186|BIOLOGICAL|CV0501 (12 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
41270614|NCT05477186|BIOLOGICAL|CV0501 (25 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
40923483|NCT03609593|DRUG|Rituximab|For cycles 1 through 3, subjects will receive BR on days 1 and 2. For cycles 5-10, subjects will receive rituximab monotherapy at 375 mg/m2 (cycle 5) or rituximab at 500 mg/m2 (cycles 6-10) on day 1 (or days 1 and 2 if split-dose).
40923484|NCT06076291|DRUG|SG1827|PhaseⅠa will use an accelerated titration and Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.02mg/kg, 0.2mg/kg, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg, and 15mg/kg by IV infusion. Accelerated titration (1 patient) will be only applied to the first cohort.
40923485|NCT00505778|DRUG|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
40923486|NCT00505778|DRUG|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
40923487|NCT06272175|OTHER|Open Kinetic Chain Activity|PNF Flexion-Abduction-External Rotation and Flexion-Adduction-External Rotation patterns will be actively performed on the hemiplegic upper extremity.
40923488|NCT06272175|OTHER|Closed Kinetic Chain Activity|Weight-bearing on the hemiplegic hand with extended elbow in standing position
40923489|NCT00626470|PROCEDURE|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
40923490|NCT05286879|BEHAVIORAL|Patient Navigator|Linkage to services for OUD/SUD treatment including MOUD, Hepatitis C virus (HCV) testing and treatment; those not living with HIV infection will be provided access to PrEP services, and those living with HIV will receive assistance with gaining initial or continued access to ART services during the 6-month post-release intervention period
40923491|NCT05286879|BEHAVIORAL|Mobile Health Unit|Participants will receive HIV PrEP/ HIV ART, MOUD, harm reduction services on the MHU and or assistance from a community health worker in linking to appropriate community-based OUD and other medical and behavioral health providers across the 6 month post-release intervention period
40923492|NCT00910624|DRUG|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
40923493|NCT00910624|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
40923494|NCT00910624|DRUG|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
41095837|NCT05753709|PROCEDURE|Hand sewn end-to-end anastomosis|Hand sewn end-to-end anastomosis (EE) Holding sutures were taken through a seromuscular bite with PDS (Polydiaxonone) 3-0 or Silk 2-0 RB (Round Bodied needle), one each at the mesenteric and antimesenteric ends of the stoma. A posterior layer of Lembert sutures was taken first. The first bite was taken at the anti-mesenteric end and a knot was applied. A Connell stitch was applied at the corner and then the posterior layer was closed using an inverting interlocking continuous stitch till the mesenteric end. Another Connell stitch was applied here to secure the corner and the suture was continued on to the anterior layer which was then closed in a similar manner using a continuous interlocking stitch. The final bite crossed the initial knot and the final knot was applied. An anterior layer of Lembert sutures was taken to reinforce the anastomotic line.
41270615|NCT05477186|BIOLOGICAL|CV0501 (50 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
40923495|NCT03234140|GENETIC|Genome Wide Association Studies|Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
40923496|NCT03234140|GENETIC|Single-nucleotide polymorphisms's genotyping|Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
40923497|NCT05554562|OTHER|Adductor strength assessment|Adductor strength will be evaluated with HHD (handheld dynamometer) and forceplates (Forceframe), both injured leg and healthy will be assess in order to compare both limbs
40923498|NCT04685239|DEVICE|dual mobility cup|The use of a Sunfit dual mobility cup
40923499|NCT04685239|DEVICE|unipolar cup|The use of a TMT cup
40923500|NCT02078076|DEVICE|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
40923501|NCT06398743|DEVICE|MRD|ctDNA MRD test
40923502|NCT03683732|BEHAVIORAL|Individual semi-structured interviews|Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
40923503|NCT00990418|DRUG|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
40923504|NCT03680235|OTHER|Informational Intervention|Receive standard information about breastfeeding and pregnancy
40923505|NCT03680235|OTHER|Informational Intervention|Receive information about breastfeeding and cancer
40923506|NCT03680235|OTHER|Interview|Participate in focus groups
40923507|NCT03680235|OTHER|Survey Administration|Ancillary studies
40923508|NCT02926521|DEVICE|2-octyl cyanoacrylate|Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
40923509|NCT02926521|DEVICE|Gum Mastic|Addition of gum mastic liquid adhesive to nerve catheter dressing
40923510|NCT04787523|RADIATION|Radiotherapy|Patients have received neoadjuvant radiotherapy
40923511|NCT06306872|DRUG|Sequence A ABSK-011|Subjects in sequence A will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
41270616|NCT05477186|BIOLOGICAL|CV0501 (75 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
41270617|NCT05477186|BIOLOGICAL|CV0501 (100 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
41270618|NCT05477186|BIOLOGICAL|CV0501 (150 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
40923512|NCT06306872|DRUG|Sequence B ABSK-011|Subjects in sequence A will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
40923513|NCT02470715|GENETIC|Molecular profile|Patients and their treating physician will obtain the patient's genetic risk assessment
40923514|NCT05260541|DRUG|60 mg PRAX-114 or 40 mg PRAX-114|Once daily oral treatment for 4 weeks
40923515|NCT05260541|DRUG|Placebo|Once daily oral treatment for 4 weeks
40923516|NCT05260541|DRUG|40 mg PRAX-114|Once daily oral treatment for 8 weeks
40923517|NCT03386045|RADIATION|Optimal SBRT|Two thirds of the participants in this group will get the SBRT (5 treatments) and one third will get standard treatment (60 Gy in 20 treatments)
40923518|NCT03386045|RADIATION|Optimal Booster|"Two thirds of the participants in this group will get the two high precision radiotherapy plus 20 doses of standard external beam radiotherapy (ie the Booster approach\|) and one third will get the standard treatment (60 Gy in 20 treatments)"
40923519|NCT02358317|BEHAVIORAL|Video Game Motor Training|
40923520|NCT02358317|BEHAVIORAL|Sedentary Video Game Training|
40923521|NCT03830723|DRUG|Follitropin delta|Study medication doses during all 3 insemination will be personalized using a suggested algorithm
40923522|NCT02251548|DRUG|Ibrutinib|Oral BTK inhibitor
40923523|NCT02251548|DRUG|Fludarabine|IV purine analogue chemotherapy agent
40923524|NCT02251548|DRUG|Cyclophosphamide|IV alkylator chemotherapy agent
40923525|NCT02251548|DRUG|Rituximab|IV anti-CD20 monoclonal antibody
40923527|NCT05471583|OTHER|Main group|no intervention; observational only
40923528|NCT03472547|DRUG|diacerein 1% ointment|All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
40923529|NCT00649597|DRUG|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
40923530|NCT00649597|DRUG|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
40923531|NCT00393510|DRUG|TCM|"The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The formula consisted of 12 herbs, viz:~Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae"
40923532|NCT00393510|DRUG|Placebo|"Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The placebo was made with starch and colouring materials."
40923533|NCT02491944|DRUG|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
41095838|NCT05753709|PROCEDURE|Hand sewn side-to-side anastomosis|Hand sewn side-to-side anastomosis (HSSA) Each end of the stoma was closed using either a single layer of inverting interlocking continuous sutures with PDS 3-0 or Silk 2-0 RB, or a Linear Stapling device. The two closed stumps were then brought adjacent to each other in an anti-peristaltic arrangement. A posterior layer of Lembert sutures was applied using Silk 2-0 RB. The bowel wall was incised using electrocautery close to the suture line. The incision was lengthened up to a width of at least 5-6 cm. The posterior and anterior layer was now closed using the same technique as in HS using PDS 3-0. An anterior layer of Lembert sutures was applied. The mesenteric defect was then closed using a superficial interrupted layer of Silk 2-0 RB.
40923534|NCT02491944|DRUG|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of \[14C\] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
40923535|NCT03391193|BIOLOGICAL|Multi-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
40923536|NCT03391193|BIOLOGICAL|Single-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
40923537|NCT05304936|DRUG|HCW9218|Bifunctional TGF-β antagonist/IL-15 protein complex
40923538|NCT04169932|BIOLOGICAL|CD20 CAR-T|The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 \^ 6 cells/kg,2 × 10 \^ 6 cells/kg,4 × 10 \^ 6 cells/kg,8 × 10 \^ 6 cells/kg).
40923539|NCT00928590|DRUG|Travoprost/Timolol Maleate Fixed Combination solution|
40923540|NCT05409560|OTHER|Swimming participants in the 6-hour cold water swim|The 6-hour cold water swim was the qualifying swim for the English Channel swim during the Channel Swim Camp Dinard 2021 and participants were the swimmers registered for the 6-hour cold water swim who volunteered to participate in this study
40923541|NCT02936661|DRUG|Tranexamic Acid|
40923542|NCT02936661|DRUG|Placebo|
40923543|NCT00450385|DRUG|Rituximab|Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
40923544|NCT00450385|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
40923545|NCT00450385|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
40923546|NCT00450385|DRUG|Prednisone|Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
40923547|NCT00450385|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
41095839|NCT05753709|PROCEDURE|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis or Functional End-to-end anastomosis (SSSA/FEEA) The two limbs of a Linear Cutter SR55 are placed into the proximal and distal bowel loops of the stoma, facing as far away from the mesenteric border as possible and then fired. If both lumens are of similar size, traction sutures are applied with Silk 2-0 RB at the anterior and posterior termination ends of the staple line. The two ends are pulled away from each other, and a Linear Cutter SR75 is applied just below the edge of the bowel and fired. However, in case of an ileo-colostomy, after the first linear cutter SR55 is fired, the two suture lines are approximated in such a way that they do not get apposed but rather lie adjacent to each other. The lumen is then clamped in SR75 which is then fired.
40923548|NCT04268602|OTHER|local anesthetic injection|1% lidocaine
40923549|NCT00954096|DRUG|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
40923550|NCT05648669|DRUG|Elagolix|200 mg tablet
40923551|NCT05648669|DRUG|Elagolix placebo|Elagolix-matched Placebo tablet
40923552|NCT04673279|DIAGNOSTIC_TEST|serology|An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.
40923553|NCT02619539|PROCEDURE|plasma fibrinogen measurement|plasma fibrinogen measurement
40923554|NCT00000682|DRUG|Zidovudine|
40923555|NCT00000682|DRUG|Zalcitabine|
40923556|NCT05464953|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema
40923557|NCT05464953|DRUG|Formulated Triamcinolone|Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate
40923558|NCT05342038|DEVICE|T-02|Stent retriever
40923559|NCT05893953|DEVICE|immediately feedback device|Sitting in a standard chair with immediate feedback device
40923560|NCT05893953|DEVICE|Unstable chair|sitting in an unstable chair
40923561|NCT05893953|OTHER|Standard chair|Sitting in a standard chair
40923562|NCT04567901|OTHER|Death|Mortality group
40923563|NCT04567901|OTHER|Survive|Survival group
40923564|NCT04529356|DEVICE|Transcranial magnetic stimulation|By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.
40923565|NCT04529356|DRUG|Acetaminophen|Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
41095840|NCT02939001|DEVICE|iris recognition scanner|
41095841|NCT02973126|PROCEDURE|FFRct and SPECT|enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
40923566|NCT05111288|DEVICE|Pulsed electromagnetic field therapy (PEMF)|Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields.
41095842|NCT00875641|OTHER|Health Insurance Database|Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
41095843|NCT04374318|DRUG|Dexmedetomidine|INTRATHECAL AND INTRAVENOUS
41095844|NCT05209399|PROCEDURE|Ultrasound guided injection|All intraarticular hip injections will be performed under real-time ultrasound guidance using a GE LOGIQ P9 ultrasound machine with a C1-5-RS 1-5 MHz curvilinear transducer (GE Healthcare, Chicago, IL, USA). For the procedure, patients will be placed in a supine position. The curvilinear transducer and ultrasound machine will be used to visualize the anterior aspect of the hip joint in a sagittal oblique plane. Sterile technique will be used to perform the procedure.
40923567|NCT05111288|DEVICE|Inactive Pulsed electromagnetic field therapy (PEMF)|PEMF device that turns on but does not provide any electromagnetic stimulation
40923568|NCT00930748|DEVICE|MR imaging with endorectal coil|MR imaging with endorectal coil
40923569|NCT00930748|DEVICE|MRI with endo-rectal coil|MRI with endo-rectal coil
40923570|NCT02433431|BEHAVIORAL|Mindfulness Training|Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
40923571|NCT02433431|BEHAVIORAL|Mindful Attention Only Training|Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
40923572|NCT02433431|BEHAVIORAL|Analytic Thinking Training|Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
40923573|NCT06024512|DEVICE|Burn|This study is being done to collect pictures of burns using an investigational device called the Spectral MD Deep View Snapshot Handheld (DV-H), similar to a camera. The data collected will be used to assess the performance of the DV-H device, and to determine the device's ability to differentiate healing versus non-healing burn tissue. This device, if approved, is expected to give caregivers a better understanding of what parts of burn wounds will likely not heal on their own and as a tool used by the military in the field. This current study involves the collection of images over the course of your clinical treatment and follow-up according to your routine standard of care. The device will not be used to diagnose or prescribe treatment for your burn.
40923574|NCT05987488|BIOLOGICAL|ShigETEC live, attenuated, oral vaccine|"Vaccine will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the vaccine 3 times 14 days apart in a dose escalating setting with two different doses.~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the vaccine 3 times 14 days apart in a dose escalating setting with three different doses."
40923575|NCT05987488|OTHER|Placebo|"Placebo will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the placebo 3 times 14 days apart~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the placebo 3 times 14 days apart."
40923576|NCT05966337|PROCEDURE|CPAP|Use of non-invasive ventilation in patients in group 2 with CPAP.
40923577|NCT05966337|PROCEDURE|BIPAP|Use of non-invasive ventilation in patients in group 3 with BIPAP.
40923578|NCT05966337|PROCEDURE|Usual care in phisicaltherapy|Patients undergoing usual physiotherapy treatment, consisting of a kinesiotherapy protocol
40923579|NCT00985036|PROCEDURE|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
40923580|NCT05229861|BEHAVIORAL|HIIT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants will perform five high-intensity intervals (95% HRpeak) at high pedalling rates of 80-100 rpm for 90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20W, 60-70rpm) aimed to return to 60% HRpeak (approximately 1-1.5 min). The duration of a HIIT sessions is approximately 25 minutes.
40923581|NCT05229861|BEHAVIORAL|MCT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants perform continuous bicycle ergometry at moderate intensity (60% HRpeak) and 60-70 rpm for the duration of 30 minutes.
40923582|NCT03417401|PROCEDURE|Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg.|Standard 3-port pars plana vitrectomy with surgical stabilizer assisted ( surgical robot) retinal vein cannulation with recombinant tissue Plasminogen Activator (Actilyse-0.25mg/ml) infusion with a maximal dose of 1mg..
40923583|NCT03417401|DRUG|Intravenous Infusion|Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
40923584|NCT00323817|DRUG|Z-338|
40923585|NCT03400267|DRUG|Paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
40923586|NCT03400267|DRUG|Fentanyl|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
40923587|NCT00936728|OTHER|therapeutic nutritional supplementation|Given orally
40923588|NCT00936728|DIETARY_SUPPLEMENT|white wine|Given orally
40923589|NCT00936728|OTHER|questionnaire administration|Ancillary studies
40923590|NCT04896450|PROCEDURE|Guided tissue regeneration (GTR)|GTR is handled with the utilization of a coronally advanced flap, followed by a thorough debridement of the denudated root surface and the intrabony component. Regenerative materials are resorbable collagen membrane (BioGide, Geistlich Phara AG, Wolhusen, Switzerland) and deproteinized bovine bone mineral (BioOss, Geistlich Phara AG), finally surgery is finished with multilayer suturing technique.
40923591|NCT04896450|DEVICE|Orthodontic tooth movement (OTM)|An early initialization of the tooth movement with the help of a multibond fixed orthodontic device utilizing low level of continuous orthodontic forces.
40923592|NCT00588861|DEVICE|Answer® hip stem|Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
40923593|NCT00588861|DEVICE|Answer® hip stem|Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
40923594|NCT06491901|OTHER|PS was given according to lung ultrasound score|If the lung ultrasound confirms RDS and LUS is more than 8, a full dose of PS will be promptly administered at 200 mg/kg (Poractant Alfa, Curosurf®). If the lung ultrasound does not indicate RDS or if LUS is 8 or less, clinical monitoring will continue. Should the clinical criteria for NRDS be met, a full dose of PS will be administered at 200 mg/kg (Poractant Alfa, Curosurf®). In terms of the administration method, less-invasive surfactant administration (LISA) will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube.
40923595|NCT06491901|OTHER|PS was given according to clinical criteria|In cases where clinical diagnosis confirms NRDS, PS will be administered at a dosage of 200 mg/kg (Poractant Alfa, Curosurf®). LISA will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube. If clinical manifestations do not meet the diagnosis of NRDS, PS will not be administered.
40923596|NCT04605614|RADIATION|Copper Cu 64-DOTA-pembrolizumab|Given IV
40752002|NCT03468946|OTHER|bitter taste perception|"bitter taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate bitter taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
40923597|NCT04605614|BIOLOGICAL|Pembrolizumab|Given IV
40923598|NCT04605614|PROCEDURE|Positron Emission Tomography|Undergo PET
40923599|NCT04925856|OTHER|blood sample|"•Blood sample:~* 1 heparinized tube (4 mL) for collection of plasma and storage~* 1 heparinized tube (4 mL) for immunophenotyping,~* 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
40923600|NCT01001299|DRUG|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
40923601|NCT01001299|DRUG|RO5185426|960 mg orally twice daily
40923602|NCT00286559|DRUG|SonoVue|
40923603|NCT00286559|DRUG|Optison|
40923604|NCT05662670|DRUG|WJ13404 tablets|"Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied."
40923605|NCT05630391|DEVICE|High-Fidelity Simulation Manikin|A high-fidelity simulator was developed to teach skills in nursing education, and it is sized to represent an adult male patient. The mannequin can be controlled using a computer program, it can breathe, and its vital signs can be monitored using a bedside monitor.
40923606|NCT05630391|OTHER|Education|Training for 26 nursing students who constituted the control group performed personnel protective equipment (PPE) wearing-removal practice
40923607|NCT05970354|DRUG|EMLA Cream|Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)
40923608|NCT05970354|DRUG|VersaPro Cream Base for Compounding|Placebo
40923609|NCT06299488|OTHER|Sip2Sleep: Montmorency Cherry and Apocynum Venetum|See arm description
40923610|NCT05967039|OTHER|Physiotherapy|Physiotherapy in respiratory rehabilitation
40923611|NCT04130308|OTHER|Retrun to run protocol|Progressive return to run protocol for patients after ACL-R
40923612|NCT00555308|OTHER|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
40923613|NCT00833417|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
40923614|NCT00546598|DEVICE|Total hip replacement/arthroplasty|Hip replacement
41095845|NCT02942056|DRUG|Cinnamon|Cinnamon tablets to treat type 2 DM
40923615|NCT00659347|DRUG|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
40923616|NCT00659347|DRUG|Placebo|Capsules,25 mg,BID,6weeks
40923617|NCT00646932|DRUG|paricalcitol|paricalcitol 0.04 mcg/kg three times a week
40923618|NCT00646932|DRUG|paricalcitol|paricalcitol 0.08 mcg/kg three times a week
40923619|NCT00646932|DRUG|paricalcitol|paricalcitol 0.16 mcg/kg three times a week
40923620|NCT00646932|DRUG|paricalcitol|paricalcitol 0.24 mcg/kg three times a week
40923621|NCT01247298|COMBINATION_PRODUCT|Stereotactic Body Radiation Therapy (SBRT)|This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
40923622|NCT03115281|DEVICE|PCI|PCI
40923623|NCT02971033|DRUG|20mg ezetimibe|Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
40923624|NCT02971033|DRUG|Placebo|Participants assigned to this intervention will receive placebo every day for 12 weeks
40923625|NCT02971033|DRUG|40mg ezetimibe|Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
40923626|NCT02914028|PROCEDURE|transversus abdominis plane block|A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
40923627|NCT02914028|DRUG|Tramadol and paracetamol|Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
40923628|NCT04810780|DEVICE|DUO Extended Set|to evaluate saftey and efficacy of DUO extended set combined with glucose sensor
40923629|NCT03048383|DRUG|OnabotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
40923630|NCT03048383|DRUG|AbobotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
40923631|NCT03048383|DRUG|Incobotulinumtoxin A Injectable Product|Administered to treat facial synkinesis
40923632|NCT04329624|DRUG|Levosimendan|Levosimendan 2.5 mg/ml injection contains levosimendan 2.5 mg, povidone 10.0 mg, citric acid, anhydrous 2.0 mg and ethanol, anhydrous to 1.0 mL. Levosimendan injection is a clear, yellow to orange solution. Immediately after skin incision patients allocated to the verum group will receive a dose of 12.5 mg in 500 mL of levosimendan.
40923633|NCT04329624|DRUG|Placebo|"Placebo 2.5 mg/ml injection contains riboflavine sodium phosphate 0.4 mg, dehydrated alcohol 100 mg and water for injection to 1 mL.~Immediately after skin incision patients allocated to the placebo group will receive 500 mL of 5% Glucose."
40923634|NCT06219798|DIAGNOSTIC_TEST|GFR|Exit of the study due to death, dialysis, or transplantation
40923635|NCT06294210|DEVICE|Mobile app and wrist-worn monitor|A mobile app was developed based on students feedback about their wellbeing needs gathered in a previous study through focus groups, surveys and design activities. This app includes features for students to track wellbeing habits, enter goals, access evidence-based resources related to their wellbeing topics of interest, and see heart rate variability summary metrics. These metrics will stream via bluetooth from the wrist-worn wearable device that has been developed at the Royal College of Surgeons in Ireland. This device includes a PPG sensor, charging port, and light indicator. There is no screen, so all data will be displayed through the mobile app.
40923636|NCT04240080|DEVICE|Accuvein® Veinfinder|Near-infrared light reflection utilized by healthcare providers to see superficial veins under the skin.
40923637|NCT00588159|DRUG|Gabapentin|gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
40923638|NCT00588159|DRUG|Diphenhydramine|Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
40923639|NCT00791973|DRUG|fluticasone furoate|2 puffs in each nostril once daily for 1 week
40923640|NCT00791973|DRUG|Placebo|2 puffs in each nostril once daily for 1 week
40923641|NCT00409175|DRUG|Fx-1006A|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
40923642|NCT00409175|DRUG|Placebo|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
40923643|NCT03160313|BEHAVIORAL|InFuSE|Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.
40923644|NCT03160313|BEHAVIORAL|Patient Education/Group Discussion|Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
40947768|NCT06169293|BEHAVIORAL|I-AM-WELL|"The I-AM-WELL program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher.~Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics.~Overall, the program will be delivered over in one week lasting six hours."
41095846|NCT02942056|DRUG|placebo|placebo
41095847|NCT02770664|DRUG|Placebo|Placebo
41095848|NCT02770664|DRUG|LC28-0126 Dose A|LC28-0126 Dose A
40923645|NCT01092832|DRUG|voriconazole|"Subjects 12 - \<18 yrs (excluding subjects 12 - 14 yrs weighing \<50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - \<12 yrs, and subjects 12 - 14 weighing \<50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days."
40923646|NCT05452642|BEHAVIORAL|DASH diet|Participants in this arm will be taught a DASH diet plus psychological skills to support dietary adherence.
40923647|NCT05452642|BEHAVIORAL|Very low-carbohydrate diet|Participants in this arm will be taught a very low-carbohydrate diet plus psychological skills to support dietary adherence.
40923648|NCT04347603|PROCEDURE|TAVR|Femoral percutaneous aortic prosthesis (TAVR)
40923649|NCT03789409|DIETARY_SUPPLEMENT|Intermittent Fasting|The aforementioned intermittent fasting in arm/group descriptions.
40923650|NCT03426982|DRUG|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by APTT
40923651|NCT03426982|DRUG|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by anti-Xa
40923652|NCT04440423|DRUG|Clotiazepam 5 mg Test Product Coated Tablets|Investigational Medicinal Product
40923653|NCT04440423|DRUG|Clotiazepam 5 mg Reference Product Coated Tablets|Rize (Trademark)
40923654|NCT03946722|DRUG|GnRH analogue downregulation|"Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Participants will be exposed to one week of downregulation using a GnRH analogue in the standard downregulation arm and 6 weeks of downregulation using a GnRH analogue in the modified downregulation arm."
40923655|NCT03946722|OTHER|Participant questionnaire|Participant will be offered the opportunity to complete an adenomyosis symptom assessment questionnaire at the start of their treatment, and again two months after completion of treatment.
40923656|NCT05852041|PROCEDURE|Biopsy of Prostate|Undergo MRI/PET prostate biopsy
40923657|NCT05852041|GENETIC|Decipher Prostate Cancer Test|Undergo decipher
40923658|NCT05852041|OTHER|Flotufolastat F-18 Gallium|Given IV
40923659|NCT05852041|PROCEDURE|Magnetic Resonance Imaging|Undergo PET-MRI
40923660|NCT05852041|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
40923661|NCT05852041|PROCEDURE|Positron Emission Tomography|Undergo PET-MRI
40923662|NCT05852041|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
40923663|NCT01496937|DRUG|GLPG0974|
40923664|NCT01496937|DRUG|GLPG0974|
40923665|NCT05179174|GENETIC|blood sample examination|droplet digital PCR in blood sample for research of mutations of GNA11 and GNAQ genes and the following microRNAs: miR - 506-514 cluster, hsamiR - 592 and hsa - miR - 199a - 5p.
40923666|NCT03540719|PROCEDURE|Osteosynthesis|Osteosynthesis of posterior tibial plateau fracture with a posterior tibial plateau plate
40923667|NCT05278598|PROCEDURE|Erector Spinae Plane Block|"After skin sterilization, ESP block will be performed at the level of T9. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T9 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. Sonographic confirmation of the local anesthetic spread will be seen as an anechoic shadow in the paravertebral spaces from T7 to T12.~This procedure will be done on both sides."
40923668|NCT05278598|PROCEDURE|Thoracic Paravertebral Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be used to visualize the T10 paravertebral space in the paramedian sagittal plane. An injection into the paravertebral space will spread to multiple adjacent dermatomes, so exact identification of a specific level will be not necessary. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe and slowly be directed from lateral to medial until its tip was located at the apex of the paravertebral space and the endpoint for successful block will be anterior displacement of the pleura by injected local anesthetic where a single injection of 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
40923669|NCT05278598|PROCEDURE|Quadratus Lumborum Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be positioned horizontally in the anterior axillary line halfway between the subcostal margin and iliac crest, to locate the triple abdominal muscle layers, then the probe will be relocated subsequently to the posterior axillary line until the quadratus lumborum muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process, this is a well-recognizable pattern of a shamrock with three leaves. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe passing in posterior to anterior direction through the quadratus lumborum to reach the border between it and psoas major, where 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
40923670|NCT04717206|OTHER|Plyomtric training to male badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
40923671|NCT04717206|OTHER|Plyomtric training to female badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
40923672|NCT03640780|OTHER|observation|The surgical ages and other information between two groups were compared.
40923673|NCT04658940|DEVICE|AcQBlate® Force Sensing Ablation System|Percutaneous catheter ablation of the cavotricuspid isthmus
41095849|NCT02770664|DRUG|LC28-0126 Dose B|LC28-0126 Dose B
41095850|NCT02770664|DRUG|LC28-0126 Dose C|LC28-0126 Dose C
41095851|NCT00651885|DRUG|treprostinil dienthanolmine sustained release|UT-15C SR 1mg tablet
41095852|NCT00651885|DRUG|Placebo|Placebo
41095853|NCT03299491|OTHER|MWA intervention|The MWA intervention will involve upgrading existing maternity waiting areas to ensure that essential supplies and services are available to create a comfortable environment for women to temporarily reside in and have easy access to skilled obstetric services.
41095854|NCT03299491|OTHER|IEC intervention|"Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.~Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.~Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences."
41095855|NCT05866510|DRUG|Utidelone and anlotinib|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle.~Utidelone will be given at 30 mg/m2/d administered intravenously on days 1-5 and Anlotinib 8mg/d took orally on days 1-14 every 21 days."
41095856|NCT02250144|DEVICE|Foot orthoses|
40923674|NCT04044144|DIETARY_SUPPLEMENT|Probiotic Dietary Supplement|Dietary supplement containing a combination of 8 probiotic strains
40923675|NCT01891045|BEHAVIORAL|OQ-45.2 no feedback|Completion of the OQ-45.2 before each session, but no feedback to therapists or patients
40923676|NCT01891045|BEHAVIORAL|OQ-45.2|Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program
40923677|NCT04008927|DIAGNOSTIC_TEST|HCV screening|All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
40923678|NCT04008927|DIAGNOSTIC_TEST|Diagnosis of hepatitis C|HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA\>10 UI/mL). In addition a measure of the liver stiffness will be performed.
40923679|NCT04008927|DRUG|HCV treatment|Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
40923680|NCT02024178|PROCEDURE|Ultrasound Imaging|
40923681|NCT00045942|DRUG|Itraconazole|Itraconazole was commercially available.
40923682|NCT00045942|DRUG|PKC412|PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
40923683|NCT02061319|BEHAVIORAL|Nordic Walking|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
40923684|NCT03278119|DIAGNOSTIC_TEST|PET Scan and nocturnal polysomnography|Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables
40923685|NCT00088556|DRUG|TLK286|Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
40923686|NCT00088556|DRUG|carboplatin|AUC 6 mg/mL/min Once every 3 weeks
40923687|NCT00088556|DRUG|paclitaxel|200 mg/m² Once every 3 weeks
40923688|NCT06532240|DRUG|Methylene Blue|Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution.The patient will receive Methylene Blue bolus with a dose of 1 mg/kg (Ideal Body Weight) over 30 minutes,followed by 0.25mg/kg/h as a continuous infusion for 6 hours for 5 days or discontinution of norepinephrine or until ICU discharge, whichever occurred first.
40923689|NCT06532240|DRUG|Placebo|An identical volume of 5% dextrose solution from the placebo drug bag will be administered to patients using the same protocol as intervention arm.
40923690|NCT01892384|DRUG|Placebo|matching placebo
40923691|NCT01892384|DRUG|BI 409306|BI 409306
41095857|NCT06454292|DRUG|Oliceridine Fumarate|After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and a starting dose of 6ug/kg/h of oliceridine fumarate was continuously pumped, and the time of oliceridine fumarate initiation was recorded as T0. Subjects were assessed for sedation using the RASS score, and for analgesia using the CPOT score. Waiting for the original sedative-analgesic drug to elute until CPOT ≥ 3 and RASS \> 0. Adjust the infusion rate of oliceridine fumarate according to the CPOT score (recommended to be adjusted by 2ug/kg/h, the range of adjustment is 2-20 ug /kg/h, and the maximum infusion rate is not more than 20 ug /kg/h) until the analgesic score of the subject is CPOT\<3. The interval between two trial drug rate adjustments should be ≧5 min, and a CPOT score should be performed before each drug adjustment.
41270619|NCT05477186|BIOLOGICAL|CV0501 (200 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
41270620|NCT04003714|DEVICE|Repetitive Transcranial Magnetic Stimulation|Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).
40923692|NCT03964558|DRUG|[14C]-acebilustat solution|Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
40923693|NCT05796830|OTHER|Puzzle application|Five expert opinions will be taken for the puzzle application to be applied after the surgery, and the application and difficulty level of the puzzle will be decided.
40923694|NCT05744440|DRUG|allogenic NK cells|The relapsed/refractory AML after allo-HSCT patients will receive allogenic NK cells infusion up to 2 dose levels (1x10\^7/kg, 5x10\^7/kg) after chemotherapy with azacitidine
40947769|NCT06400875|DEVICE|InnovaMatrix® AC Sterilized, Porcine Placental Extracellular Matrix (ECM)|weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and compression therapy
40923695|NCT01855373|DIETARY_SUPPLEMENT|PEAK ATP® with GlycoCarn®|PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
40923696|NCT01855373|DIETARY_SUPPLEMENT|PEAK ATP®|PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
40923697|NCT01855373|DIETARY_SUPPLEMENT|GlycoCarn®|GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
40923698|NCT01855373|OTHER|Placebo|Placebo: 2 capsules twice daily on an empty stomach
40923699|NCT05874206|DEVICE|Cratos™ Stent Graft|Cratos™ Stent Graft TEVAR procedure for the treatment of aortic lesions.
40923700|NCT03077087|DEVICE|thin Integra® (125 cm2)|125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
40923701|NCT04002518|DEVICE|Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.|Treatment of identified conditions, i.e. fracture fixation, arthrodesis, osteotomy, with a cannulated screw.
40923702|NCT05637060|DRUG|Test Drug|One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
40923703|NCT05637060|DRUG|Reference Drug|One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
41095858|NCT06454292|DRUG|Remifentanil|After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and remifentanil was continuously pumped at a starting dose of 1.5ug/kg/h. The time of remifentanil initiation was recorded as T0. Subjects were assessed for sedation using the RASS score and analgesia using the CPOT score. We waited for the original sedative-analgesic drugs to elute until CPOT ≥ 3 and RASS \> 0. The infusion rate of remifentanil was adjusted according to the CPOT score (1.5ug/kg/h is recommended, the range of adjustment is 1.5\~12μg/kg/h, and the maximum infusion rate is not more than 12μg/kg/h) until the subject's analgesic score of CPOT\<3, and the interval between the two experimental rate adjustments of the drug should be ≧5min, and the CPOT score should be performed before each adjustment of the drug. The CPOT score should be performed before each drug adjustment.
41095859|NCT05471726|BEHAVIORAL|Prospective audit-and-feedback|The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge.
41095860|NCT02123966|DRUG|Sirolimus|
41095861|NCT04653714|PROCEDURE|Scaling and root planing|Patients with periodontitis in the test group will be treated by conventional non-surgical root debridement and in the control group by low-intensive supragingival plaque removal with mechanical brush and professional tooth paste only.
41095862|NCT04653714|DEVICE|Probiotic lozenges|Patients with gingivitis in the test group will be treated with supragingival debridement and with probiotic lozenges with strains of Lactobacillus brevis and Lactobacillus plantarum once a day for 3 months and in the control group by low-intensive supragingival plaque removal, as a placebo treatment, and placebo probiotics lozenges.
40923704|NCT05633550|DIAGNOSTIC_TEST|Flexion-extension radiographs|Participants will undergo (regular) flexion-extension radiographs.
40923705|NCT03560700|DIETARY_SUPPLEMENT|lactobacillus probiotic strain|Approved Dietary supplement
40923706|NCT03560700|OTHER|placebo|placebo comparator
40923707|NCT00754221|DRUG|[S,S]-Reboxetine|Once a day, oral treatment, of 4, 6, 8 or 10 mg
40923708|NCT00281658|DRUG|Lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
40923709|NCT00281658|DRUG|Paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
40923710|NCT00281658|DRUG|Placebo|Paclitaxel Matching Placebo
40923711|NCT04320641|OTHER|ACUPRESSURE|Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.
40923712|NCT02051699|PROCEDURE|radiographic of standing knee|the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
40923713|NCT05520164|OTHER|Listening the maternal heart sound during the invasive interventions|Heart sounds of the newborns' own mothers were recorded on the voice recorder with the help of a hand doppler device. This sound was listened by the newborns in the experimental group during the heel blood procedure.
40923714|NCT03706651|DEVICE|Infants hospitalized in health facilities performing Tele-expertise|
40923715|NCT03156647|DIAGNOSTIC_TEST|Level of alpha-synuclein|Test of levels of total and ratio total:oligomeric in saliva
40923716|NCT06194578|OTHER|Sterile Saline|Sterile saline will be administered subcutaneously.
40923717|NCT01306929|DRUG|pridopidine|45mg bid
40923718|NCT06036004|DRUG|Intranasal OXT|"Syntocinon® contains the synthesized peptide OXT in a solution formulated to promote absorption through the nasal mucosa. Additional ingredients are E216 (propyl-4-hydroxybenzoate), E218 (methyl-4-hydroxybenzoate), and chlorobutanol hemihydrate. One bottle contains 5 ml, i.e., 200 IU of OXT in total. Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.~OXT (24 IU twice daily) is given for 28 (± 2) days of treatment."
40923719|NCT06036004|OTHER|Placebo nasal spray|"The placebo will contain no OXT but, otherwise, be identical to the intranasal OXT product with respect to the other ingredients.~Placebo is given twice daily for 28 (± 2) days of treatment."
40923720|NCT02730195|DRUG|Pioglitazone|Given PO
40923721|NCT02730195|DRUG|Tyrosine Kinase Inhibitor (TKI)|Given TKI therapy
40923722|NCT00799851|DEVICE|Variceal band ligation|
40923723|NCT00799851|DRUG|cyanoacrylate injection|cyanoacrylate injection
40923724|NCT03594942|DIAGNOSTIC_TEST|procto sigmoidoscopy and biopsy if required|procto sigmoidoscopy of patients presenting with per rectal bleed will be carried out to locate the source of bleeding and biopsy if required.
40923725|NCT02508558|OTHER|motion perception and locomotor operation performance measurements|
41095863|NCT01027871|DRUG|LY2605541|subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
41095864|NCT01027871|DRUG|insulin glargine|subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
40923726|NCT02508558|OTHER|parabolic flight|
40923727|NCT01009840|DRUG|IV busulfan|PK-directed dosing of IV busulfan for 4 days
40923728|NCT01009840|DRUG|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m\^2.
41095865|NCT06102343|DEVICE|Alma Harmony|Acne scars treatment using non-ablative ER:Glass 1540 nm laser module.
41095866|NCT06141057|BIOLOGICAL|Matrix M with RH5.1|50 µg of Matrix-M adjuvant with RH5.1 at different doses on days 0 and 28.
41095867|NCT01671475|DEVICE|microEEG (Bio-Signal microEEG)|"At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1."
41095868|NCT03286725|BEHAVIORAL|Physical Education (PE) Programme|"A programme of activities for PE lessons has been developed by Oxford Brookes University (in collaboration with Oxfordshire Sport and Physical Activity) to try to optimise the benefit of PE for brain function. Staff from Oxford Brookes University will train PE teachers to deliver this programme.~The Intervention involves roughly 20 minutes of prescribed activities per week, to be delivered within school PE lessons."
41095869|NCT05883800|RADIATION|On-couch adaptive radiotherapy|A new treatment plan, guided by volumetric images, is created at each treatment session
41095870|NCT03381391|BEHAVIORAL|Personalized Feedback Intervention|The current intervention included personalized feedback regarding their alcohol consumption, alcohol-related consequences, gender-specific normative drinking comparisons, personal risk factors (e.g., dependence symptoms, family history of alcoholism), and alcohol expectancies. The intervention also included didactic material related to alcohol (e.g., effects at different BAC levels, tolerance) and drinking moderation strategies. The feedback was presented graphically in a feedback report with the individual's information.
41095871|NCT05507697|BIOLOGICAL|HUC-MSCs|5 × 10\^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb
41095872|NCT05507697|BIOLOGICAL|Lipoic Acid|Lipoic Acid Injection，600 mg/d for 15 consecutive days
41095873|NCT02813499|OTHER|CARE Rule|Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
41095874|NCT03526120|OTHER|Pistachio|Dailly 44 g unsalted pistachios snack for 12 weeks
41095875|NCT03742843|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium
41095876|NCT05305911|DRUG|SGLT-2 inhibitors|SGLT2 inhibitor once daily for six months
41095877|NCT05305911|DRUG|Placebo|Placebo once daily for six months
41095878|NCT02824003|DRUG|ISIS-GCGRRx|once weekly dosing for 13 weeks
41095879|NCT02824003|DRUG|Placebo|once weekly dosing for 13 weeks
41095880|NCT00912587|DRUG|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
41095881|NCT02576418|OTHER|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
41095882|NCT03605329|OTHER|to explore the severity of NAC in case of OSAS|"After overnight polysomnography, cardiovascular autonomic neuropathy will be evaluated by different methods: study of HRV, cardiovascular autonomic reflex test (Ewing), measurements of urinary levels of catecholamines and measurements of sweat gland dysfunction using Sudoscan.~The severity of CAN will be evaluated in T1D patients with moderate to severe OSAS (apnea hypopnea index (IAH) ≥15 / hour) compared to T1D patients with IAH \<15 / hour."
41095883|NCT00788424|DRUG|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
41095884|NCT06614140|BIOLOGICAL|Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors|"This intervention involves a personalized neoantigen peptide vaccine composed of peptides containing tumor-specific mutations, such as SNVs, indels, and frameshift mutations. Neoantigens are selected based on criteria that enhance expression and immunogenicity.~The vaccine is administered alongside Poly-ICLC, a TLR3 agonist, to enhance immune activation. After the initial vaccine doses, checkpoint inhibitors (e.g., anti-PD-1 or anti-PD-L1) are introduced once neoantigen-specific T-cell responses are detected, preventing immune exhaustion and sustaining a strong immune response.~During the follow-up phase, both checkpoint inhibitors and Poly-ICLC are continued to maintain immune activity and ensure a lasting anti-tumor effect."
41095885|NCT02157714|DRUG|PRX002|
41095886|NCT02157714|OTHER|Placebo|
41095887|NCT06630819|OTHER|1.8 ml of 4% Articaine|Buccal infiltration of 1.8 ml of 4% Articaine
41095888|NCT06630819|OTHER|3.6 ml of 4% Articaine|Buccal infiltration of 3.6 ml of 4% Articaine.
41095889|NCT05698940|PROCEDURE|Infundibultomy|Infundibultomy on one side of patient
41095890|NCT01365338|DRUG|Placebo|Administered as specified in the treatment arm
41095891|NCT01365338|DRUG|PF-04958242|Administered as specified in the treatment arm
41095892|NCT00186810|DRUG|Busulfan, Cyclophosphamide, Horse ATG|Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
41095893|NCT00186810|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
40923729|NCT01009840|PROCEDURE|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
40923730|NCT05176847|BEHAVIORAL|Podcasts and tips of the day (within app)|Participants will receive twice weekly podcasts and daily tips of the day, with nutrition and exercise information, audio diary and goal setting.
40947770|NCT05815173|DRUG|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles.
40923731|NCT05176847|BEHAVIORAL|mLIFE app (self-regulation features)|Diet (track by in app database), physical activity (tracked with FitBit and synced with mLIFE app), and weight (tracked with FitBit scale and synced with mL app) tracking app components. App notifications and reminders and newsfeeds.
40923732|NCT05176847|BEHAVIORAL|mLIFE app (social support features)|"The gamified mLIFE app contains several components to help facilitate social gaming and support. This includes a newsfeed, to view the progress of other users, the ability to send others encouragement (likes/thumbs-up) for achieving goals, user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members.~For the experimental group, the app also includes features that facilitate healthy competition among participants through receipt of points for provision of social support and tracking health behaviors."
40923733|NCT05176847|BEHAVIORAL|standard mLIFE app (social support features)|"The standard mLIFE app has the ability to send others encouragement (likes/thumbs-up) for achieving goals and a user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members."
40923734|NCT03512457|BEHAVIORAL|Minimal Intervention|Women view an educational poster in changing room, and they receive a brochure.
40923735|NCT03512457|BEHAVIORAL|Intensive Intervention|Women view an educational poster in changing room, and they receive a brochure.
40923736|NCT06419777|DRUG|Insulin|Insulin will be used in gestational diabetics to control blood glucose levels
40923737|NCT05864092|OTHER|Virtual Reality Goggles|We will offer patients virtual reality goggles with guided meditation software in addition to standard medical therapy (NSAID and opioid).
40923738|NCT06134011|OTHER|Without any intervention|There were no special interventions for the two groups.
40923739|NCT01542424|DRUG|biphasic insulin aspart 30|Prescribed at the discretion of the physician
40923740|NCT01542424|DRUG|insulin detemir|Prescribed at the discretion of the physician
40923741|NCT00227708|DRUG|docetaxel|
40923742|NCT00227708|PROCEDURE|quality-of-life assessment|
40923743|NCT06328478|DEVICE|Observational prospective study.|Observational prospective study
40923744|NCT04607798|DEVICE|Radiofrequency and pulsed electro-magnetic fields treatment|Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.
40923745|NCT02858544|OTHER|The Concussion Identification Index|Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms
40923746|NCT02858544|OTHER|ImPACT|Patient- completed computerized neurocognitive test battery
40923747|NCT00362180|DRUG|mipomersen|200 mg subcutaneous injections
40923748|NCT00362180|DRUG|Placebo|subcutaneous injections
40923749|NCT00220922|PROCEDURE|Alcohol Wipes vs. No Alcohol Wipes|
40923750|NCT00334178|DRUG|Laxymig ER (drug)|
40923751|NCT03848299|OTHER|Experimental: Single Arm|"All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.~Day 2 and 3: 110 g white bread.~Day 4 and 5 : 110 g white bread and 30 g butter or 55 g white bread, 50 g dark chocolate for lactose intolerant.~Day 6 and 7: Glucose drink (50g).~The bread will be replaced by gluten-free bread for gluten intolerant participants."
40923752|NCT02622997|OTHER|Cervico-vaginal self-sample taken with first flocked swab|Cervico-vaginal self-sample taken with first flocked swab
40923753|NCT02622997|OTHER|Cervico-vaginal self-sample taken with a second flocked swab|Cervico-vaginal self-sample taken with a second flocked swab
40923754|NCT02622997|OTHER|Cervico-vaginal self-sample taken with a HerSwab device|Cervico-vaginal self-sample taken with a HerSwab device
40923755|NCT01210417|OTHER|Non invasive monitoring|Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
40923756|NCT03310762|OTHER|Alma Sana Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
40923757|NCT03310762|OTHER|Simple Silicon Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
40923758|NCT05063071|DRUG|Tenofovir Alafenamide 25 MG|After orthotopic liver transplant, all patients will receive Tenofovir Alafenamide monotherapy without HBIG for HBV Prophylaxis.
40923759|NCT04118257|DIETARY_SUPPLEMENT|Sugary beverage: Fruit juice|Participants consumed 100% fruit juice (\~710mL) daily for three weeks, along with their habitual diets.
40923760|NCT04118257|DIETARY_SUPPLEMENT|Sugary beverage: Soda|Participants consumed soda (\~710mL) daily for three weeks, along with their habitual diets.
40923761|NCT04118257|DIETARY_SUPPLEMENT|Control: Water|Participants consumed water (\~710mL) daily for three weeks, along with their habitual diets.
40923762|NCT04924413|DRUG|Tislelizumab|PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion
40923763|NCT00917215|DEVICE|Disposable stainless steel acupuncture (0.2mmx4mm)|"For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.~For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks."
40923764|NCT04695613|DRUG|Aminoacid|amino acid infusion 150 ml/kg/hr starting preoperative
40923765|NCT04695613|DRUG|Magnesium sulfate|magnesium sulphate bolus and infusion 60 mg/kg starting preoperative
40923766|NCT06433856|OTHER|Cold Water Immersion|Cold water immersion consists in 12 min standing in 10 °C water
40923767|NCT06433856|DEVICE|Percussive Massage Therapy|Percussive massage therapy is performed with a massage gun on the thigh muscles for 12 min
40923768|NCT00492063|BIOLOGICAL|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
40923769|NCT00492063|BIOLOGICAL|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
40923770|NCT03467009|BEHAVIORAL|iPACT Intervention|Brief in-person + tailored, daily 8-week text-message secondary prevention intervention.
41095894|NCT00000746|BIOLOGICAL|rgp120/HIV-1 SF-2|
40923771|NCT03467009|OTHER|Control: Enhanced Usual Care (EUC)|EUC group participants will receive standardized information on cyberbullying.
40923772|NCT03467009|BEHAVIORAL|iPACT Intervention- app|Brief in-person + tailored, daily 8-week message secondary prevention intervention delivered via app.
40923773|NCT02666157|DRUG|Dabigatran etexilate|this drug is administered twice per day for the entire study period
40923774|NCT02666157|DRUG|Rivaroxaban|this drug is administered once per day for the entire study period
40923775|NCT02666157|DRUG|Apixaban|this drug is administered twice per day for the entire study period
40923776|NCT05974462|DRUG|Methylprednisolone 125 MG|125 mg daily for 3 days diluted in saline solution 250 mL
40923777|NCT05974462|OTHER|IV saline solution 0.9%|Saline solution 0.9% 250 mL
40923778|NCT00412373|DRUG|Placebo|for 6 weeks
40923779|NCT00412373|DRUG|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
40923780|NCT00412373|DRUG|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
40923781|NCT03356704|OTHER|no intervention|Observational study
40923782|NCT00353470|BEHAVIORAL|Cognitive behavioral therapy|CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
40923783|NCT00353470|BEHAVIORAL|Applied relaxation training (ART)|ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
40923784|NCT00353470|BEHAVIORAL|Panic focused psychodynamic psychotherapy (PFPP)|PFPP will include 19 to 24 sessions over 12 weeks.
40923785|NCT00523263|DEVICE|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
40923786|NCT00523263|DEVICE|Human umbilical vein femoro-popliteal bypass|
40923787|NCT04837352|OTHER|Study of the role of sociocognitive factors|Questionnaires
40923788|NCT05667415|DRUG|disulfiram and cisplatin|on the first day of treatment, patients were given intravenous drip of 80mg/m2 cisplatin, and 21 days was a course of treatment, lasting for 6 courses. Take 400mg disulfiram orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of disulfiram can be re-evaluated during the treatment, and the lowest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 3 weeks as a cycle.
40923789|NCT05667415|DRUG|cisplatin|on the first day of treatment, patients were given 80mg/m2 cisplatin intravenously, and 21 days was a course of treatment, lasting for 6 courses.
40923790|NCT01238627|DRUG|Nicotine Sublingual Tablet Mint (NSTM)|A single dose of an experimental NSTM, with a 36-hour washout between visits
40923791|NCT01238627|DRUG|Marketed Nicotine Tablet|A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
40923792|NCT06089785|DEVICE|elastography|evaluation of degree of spleen stiffness in liver cell failure patient by elastography.
40923793|NCT02739178|OTHER|GSF Intervention|Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
40923794|NCT00000590|DRUG|immunoglobulins|
40923795|NCT01806662|DRUG|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
40923796|NCT01806662|OTHER|Placebo|Injection of placebo
40923797|NCT02691871|DRUG|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
40923798|NCT02691871|DRUG|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
40923799|NCT02691871|DRUG|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
40923800|NCT05426499|DRUG|Patients requiring cefotaxime treatment|Dosage according to SmPC
40923801|NCT05426499|DRUG|Patients requiring meropenem treatment|Dosage according to SmPC
40923802|NCT05426499|DRUG|Patients requiring fluconazole treatment|Dosage according to SmPC
40923803|NCT05426499|DRUG|Patients requiring isavuconazole treatment|Dosage according to SmPC
40923804|NCT05426499|DRUG|Patients requiring anidulafungin treatment|Dosage according to SmPC
40923805|NCT02935751|OTHER|Lab tests for plasma levels of apixaban and anti-10a factor|All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.
40923806|NCT05014061|DRUG|Adenosine|Adenosine infusion 70 µg/kg/min for 6 hours
40923807|NCT02779361|DIETARY_SUPPLEMENT|Green tea|"Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (\*), 10:30 am, 13:00 pm (\*), 15:30 pm, 18:00 pm (\*), 20:30 pm on day 7.~One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (\*)."
40923808|NCT06427083|DRUG|Envlo Tablet|Enavogliflozin 0.3mg
41095895|NCT00000746|BIOLOGICAL|Env 2-3|
41095896|NCT00000746|BIOLOGICAL|HIVAC-1e|
40923809|NCT06427083|DRUG|Envolomet SR Tablet|Enavogliflozin 0.3mg/Metformin1,000mg
40923810|NCT02373371|DRUG|Metvix®|
40923811|NCT02373371|PROCEDURE|Photodynamic Therapy Blue light|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug
40923812|NCT02373371|PROCEDURE|Photodynamic Therapy Daylight|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug
40923813|NCT01129583|DRUG|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
40923814|NCT01129583|DRUG|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
41095897|NCT00000746|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
41095898|NCT02289560|DEVICE|Transcranial ExAblate|Transcranial ExAblate
41095899|NCT03528954|DRUG|Propofol|Those who received intravenous propofol
41095900|NCT04349384|PROCEDURE|Colorectal resection|Colon or rectal resection for colorectal adenocarcinoma
41270621|NCT04003714|DEVICE|Sham Repetitive transcranial Magnetic Stimulation|Control group received sham r-TMS.
41270622|NCT04399382|DRUG|Biologics|The exposure of interest in this observational study is the biological therapy of Tumor Necrosis Factor (TNF) inhibitor, specifically etanercept biosmilar/ infliximab/ adalimumab/ golimumab.
41270623|NCT00159094|DRUG|Doxil and Vinorelbine|
40923815|NCT05382000|DIAGNOSTIC_TEST|Advanced triage tool for Gynecology and Obstetrics emergencies based on artificial intelligence algorithms.|"After the conventional triage, a second independent doctor will make the suit with the Mediktor Hospital tool.. In less than 3 minutes and with an average of 14 questions, Mediktor performs an interrogation very similar to what an emergency doctor would do. The professional version allows the health professional to modify the course of the questions in the middle of the evaluation, if he considers it necessary to go deeper into some aspect of the anamnesis. The system allows you to see in real time the diseases that Mediktor considers possible during the evaluation.~At the end of the triage process, Mediktor offers the level of urgency and a list of possible diagnoses based on the signs and symptoms answered. The professional can change the level of urgency if he considers it beneficial for the patient.~Once the two triages (Conventional and Mediktor) have been carried out, the patient will be seen according to the care protocols of the center."
40923816|NCT00125346|DRUG|Tobramycin Inhalation Powder|
40923817|NCT00125398|DRUG|AQUAVAN (fospropofol disodium; GPI 15715 )|
41270624|NCT05595538|BIOLOGICAL|Multiple doses of anti-SARS-CoV-2 Convalescent Plasma|SARS-CoV-2 Convalescent Plasma(1-2 units; \~300-600 mL with the presence of IgG anti-SARS-CoV-2.
41270625|NCT01746433|OTHER|Sitting up|"The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient."
41270626|NCT02847884|BIOLOGICAL|Infliximab|Patients will be prescribed Infliximab as a standard of care regardless of study participation.
41270627|NCT05195788|BEHAVIORAL|Cardiac rehabilitation|The cardiac rehabilitation program is based on 3/week exercise training's sessions including aerobic and muscle building exercises. All exercises are individualized, supervised by a certified kinesiologist at the research center, and in line with the latest recommendations for physical activity in individuals with congenital heart disease. Participants are encouraged to do a minimum of 1 supervised session per week at the research center and may, with the agreement of the cardiologist and the kinesiologist, do the other training sessions at home (hybrid program). The characteristics of the activities are recorded with a heart rate sensor. Each session lasts a maximum of 60 minutes in total and includes approximately 30 minutes of aerobic exercise, and approximately 20 minutes of muscle strengthening exercises, with 5 to 10 minutes of warm-up and cool-down.
41270628|NCT02577263|OTHER|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
41270629|NCT04590456|OTHER|PEMF|group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy
41270630|NCT05110079|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage with guidewire is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the complete procedure is to achieved more than 70% opening."
41270631|NCT03618641|DRUG|CMP-001|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
41270632|NCT03618641|BIOLOGICAL|Nivolumab|A fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
41270633|NCT03839108|OTHER|Paraffin wax|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
41270634|NCT03839108|DRUG|Prolotherapy|. Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
40923818|NCT00131924|BIOLOGICAL|esterified estrogens|
40923819|NCT00233909|DRUG|Zosuquidar|
40923820|NCT00233909|DRUG|gemtuzumab ozogamicin|
40923821|NCT00319267|DRUG|Bosentan|Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
40923822|NCT03044600|OTHER|Chart Review|Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.
40923823|NCT03044600|OTHER|HRPT2 Mutation Evaluation|Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
40923824|NCT03028337|RADIATION|Spine Radiosurgery|"Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction)."
40923825|NCT03028337|BEHAVIORAL|Questionnaires|"Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up."
40923826|NCT04276558|DRUG|Udonitrectag|Eye drop solution in single dose unit.
40923827|NCT04276558|OTHER|Vehicle|Eye drop solution with no active substance in single dose unit.
40923828|NCT03251131|OTHER|Restrictive fluid management|Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.
40923829|NCT04635605|DRUG|Methylene Blue|Treatment Group. Methylene Blue 100 mg capsules, twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
40923830|NCT04635605|DRUG|Control Test|Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
40923831|NCT00709709|PROCEDURE|multislice coronary scan|multislice coronary scan
40923832|NCT04286997|DEVICE|GRAIL population|each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
40923833|NCT03885167|OTHER|Specimen Collection|No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
40923834|NCT05746884|PROCEDURE|duodenal mucosectomy|Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.
40923835|NCT05746884|PROCEDURE|ampullectomy|Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
40923836|NCT03619967|DEVICE|Multispectral imager|"Device: Bio-inspired multispectral imager~-Manufactured at University of Illinois at Urbana Champaign"
40923837|NCT04017195|DRUG|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
40923838|NCT04017195|DRUG|High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
40923839|NCT05902650|DIAGNOSTIC_TEST|imaging|imaging
40923840|NCT04933643|OTHER||
40923841|NCT03328884|DRUG|Irinotecan Hydrochloride|"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan hydrochloride, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered with a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy."
40923842|NCT04678076|DRUG|Ketoprofen Lysine|A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
40923843|NCT04678076|DRUG|Ketoprofen Oral Product|A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
40923844|NCT04610957|DRUG|Rosafem (FEMININE FORMULA)|Rosafem is the only phytoestrogen product with the convenient dose which provides significant improvement of menopausal related symptoms premenstrual syndrome symptoms
40923845|NCT05908006|DEVICE|Velacur|Imaging Procedures Comparison
40923846|NCT05557825|RADIATION|Photobiomodulation Therapy|Focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
40923847|NCT00802113|DRUG|Fludarabine|Fludarabine 30 mg/m2 x 5 days
40923848|NCT00802113|DRUG|Busulfan|Busulfan 3.2 mg/kg/day x 2 days
40923849|NCT00802113|DRUG|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days
41133414|NCT02565966|OTHER|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
40923850|NCT02216110|PROCEDURE|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
40923851|NCT00745849|DRUG|esomeprazole|40mg by mouth twice daily
40923852|NCT00745849|DRUG|placebo|
40923853|NCT04193514|OTHER|Acceptance and Commitment Therapy|The intervention is a 7-day self-guided acceptance-based intervention using a published Acceptance and Commitment Therapy self-help work book. This therapy is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of depression, anxiety and/or stress. The therapy includes two components: (a) educating patients about the exacerbation of stress and negative affect through rigid attempts at experiential avoidance, and (b) introducing acceptance and the willingness to experience pregnancy-related sensations and cognitions as an alternative to experiential control, through the practice of intentional and non-judgmental paying attention to one's thoughts, feelings, images and bodily sensations (including aversive symptoms) and learning to see thoughts as an ongoing process distinct from self rather than merely an event with literal meaning.
40923854|NCT02968862|OTHER|observational|The study will involve adult patients undergoing elective thoracolumbar-sacral spine surgery involving 1-5 spine levels, at the Brigham and Women's hospital that have an anticipated post surgical hospital stay of one to three days. These patients will be randomly assigned by the BWH Investigational Drug Service to one of three different groups, each consisting of 33 patients. This is an observational studies with subjects in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive a therapeutic intervention, but the investigator does not assign specific interventions to the subjects of the study.
40923855|NCT00875134|OTHER|Verbal prompt|Patient hears a voice recording
40923856|NCT00875134|OTHER|Skin Stimulus|Patient receives either a skin stimulus
40923857|NCT02614521|OTHER|pulmonary veins ablation's successful outcome|Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.
40923858|NCT01875224|DRUG|Belatacept|
40923859|NCT01875224|DRUG|Tacrolimus|Standard administration of tacrolimus
40923860|NCT03137667|OTHER|School-located Influenza Vaccination|Children in the intervention arm are enrolled in schools in Monroe County, New York that are offering school-located influenza vaccination clinics during school hours
40923861|NCT03995251|DRUG|Testosterone Supplementation|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
40923862|NCT03995251|DRUG|Standard Medical Treatment|Standard Medical Treatment
40923863|NCT03995251|OTHER|Exercise|Exercise
40923864|NCT02507037|DIETARY_SUPPLEMENT|gum+PEG|chew sugarless gum
40923865|NCT02507037|DRUG|polyethylene glycol|2L PEG
40923866|NCT01520428|BEHAVIORAL|Motivational Interviewing, CBT and E-mail support|Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
40923867|NCT01097031|OTHER|Infusion Intermittent|
40923868|NCT00486655|PROCEDURE|NOTES-Assisted Cholecystectomy|
40923869|NCT02910505|DEVICE|enLighten Laser|Laser for tattoo removal
40923870|NCT04797624|PROCEDURE|Gastric cancer surgery|Appropriate gastric cancer surgery types for the convenient patients
40923871|NCT00245219|BEHAVIORAL|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
40923872|NCT00245219|BEHAVIORAL|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
40923873|NCT02243423|PROCEDURE|SUPINE|"Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.~A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline."
40923874|NCT02243423|PROCEDURE|TILT|"Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.~A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline."
40923875|NCT02991989|BEHAVIORAL|Exercise Snacking|"Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.~Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours."
40923876|NCT02991989|DIETARY_SUPPLEMENT|Yogurt|Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
40923877|NCT01128023|OTHER|Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT|Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
40923878|NCT00602199|DRUG|ABT-510|
40923879|NCT00602199|OTHER|immunoenzyme technique|
40923880|NCT00602199|OTHER|immunohistochemistry staining method|
40923881|NCT00602199|OTHER|laboratory biomarker analysis|
40923882|NCT00602199|OTHER|pharmacological study|
40923883|NCT00602199|PROCEDURE|biopsy|
40923884|NCT00935090|DEVICE|3'-deoxy-3'-[18F]fluorothymidine|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
40923885|NCT06138223|OTHER|Exercise intervention|During 12 weeks, patients will visit twice a week a trained oncology physiotherapist for one hour per session. This training includes supervised aerobic and resistance exercises to increase aerobic condition and muscle resistance, based on their own fitness level as assessed at baseline. Additionally, physiotherapists will educate participants on how to increase their daily activity. To this end, all participants will receive an activity tracker to monitor their daily activities.
41270635|NCT02197377|DEVICE|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
41270636|NCT02197377|DEVICE|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
40923886|NCT06138223|OTHER|Nutrition intervention|Once every two weeks patients in the intervention group will receive a nutritional assessment and intervention by a trained dietician for optimization of their nutritional intake to improve their nutritional status, following the ESPEN guideline on nutrition in cancer patients and the national guidelines of the National Nutritionists Oncology Working Group (NNOWG; in Dutch: Landelijke Werkgroep Diëtisten Oncologie, LWDO). Moreover, an amount of 15-25 grams of protein within 1-2 hours after exercise will be advised, to prevent muscle protein breakdown and enhance muscle protein synthesis.
40923887|NCT03351205|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
40923888|NCT03351205|PROCEDURE|dried biological amnion graft|"Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis.~Other Name: Human amnion membrane"
40923889|NCT03351205|DRUG|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
40923890|NCT05828810|DRUG|surgical antiseptic skin preparation with either chlorhexidine or iodine-based solution|"Patients will be randomized to receive surgical antiseptic skin preparation with either chlorhexidine or iodine-based solution.~Specifically, the first treatment arm will undergo skin antisepsis with 4% chlorhexidine gluconate pre-wash, followed by 2% chlorhexidine gluconate with 70% isopropyl alcohol skin preparation.~The second treatment arm will undergo skin antisepsis with 7.5% povidone-iodine detergent pre-wash, followed by 10% povidone-iodine skin preparation."
40923891|NCT05366400|DIAGNOSTIC_TEST|ECHO|Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.
40923892|NCT03721029|DEVICE|Intraoperative nerve monitoring,|Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.
40923893|NCT03721029|PROCEDURE|standard of care robotic-assisted radical prostatectomy|With out the usage of intraoperative nerve monitoring
40923894|NCT06251531|OTHER|Goal-Directed Therapist-Guided Play-Based Intervention (GD-TG-PBI)|The GD-TG-PBI used play to improve performance in targeted functional activities. The program was planned by a physiotherapist with 25 years' experience and an occupational therapist with six years' experience in play. The sessions were based on motor-learning principles supporting cortical plasticity. Individual-specific goals were transformed into play activities that increase occupational participation with regard to the child's abilities, needs, and learning potential. A top-down approach based on direct gamification was adapted without dividing it into components, instead of a component-based, bottom-up approach. Thus, a structured play program was created and an individual-specific intervention was applied in line with the occupational goals and detailed motor evaluations. Positive, active experiences facilitated the adaptation of the learned skills to daily life.
40923895|NCT00779259|DRUG|Theophylline 300mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
41095901|NCT05793099|OTHER|Effect of aqueous propolis gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given aqueous propolis gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing aqueous propolis gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
41133415|NCT00937014|OTHER|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
41133416|NCT00937014|OTHER|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
41270637|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
41270638|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
41270639|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
41270640|NCT00167258|BEHAVIORAL|Voucher Reinforcement|
41270641|NCT00167258|BEHAVIORAL|Extra Counseling Services|
41270642|NCT00167258|BEHAVIORAL|Voucher Reinforcement + Extra Counseling Services|
40923896|NCT00779259|DRUG|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
40923897|NCT00779259|DRUG|Theophylline 300 mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
40923898|NCT00779259|DRUG|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
40923899|NCT00158132|DRUG|Propranolol|Propranolol 100mg/day in 3 divided doses
40923900|NCT00158132|DRUG|Amantadine|Amantadine 100mg three times daily
40923901|NCT00158132|DRUG|Placebo|Placebo pills
40923902|NCT00046800|DRUG|OSI-211 (Liposomal Lurtotecan)|
40923903|NCT01255748|RADIATION|Proton Therapy, Photon Therapy, SRS, Brachytherapy|Outcomes Tracking
40923904|NCT05270447|OTHER|Massage and patient education|"Connective tissue manipulation: The patients were informed about CTM and its mechanism of action before starting the CTM application. CTM was performed by a trained physiotherapist as the patient was in a sitting position.~Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off."
40923905|NCT05270447|BEHAVIORAL|Routine care and advising|Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off.
40923906|NCT02173262|DRUG|G-CSF|
40752003|NCT03468946|OTHER|sour taste perception|sour taste perception in high caries risk, medium caries risk, low caries risk. The aim of this study was to evaluate sour taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk ).
40923907|NCT02173262|DRUG|Ciprofloxacin|
40923908|NCT04549207|DRUG|Bone modifying agent|Use of bone modifying agent
40923909|NCT02735889|OTHER|No Carbonation|500 ml of beverage consisting of water + 10% glucose and no carbonation
40923910|NCT02735889|OTHER|Low carbonation|500 ml of beverage consisting of water + 10% glucose and low carbonation
40923911|NCT02735889|OTHER|High carbonation|500 ml of beverage consisting of water + 10% glucose and high carbonation
40923912|NCT00001068|DRUG|Lamivudine|
40923913|NCT00881543|DRUG|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
40923914|NCT04740905|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
40923915|NCT04740905|DRUG|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
40923916|NCT04740905|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
40923917|NCT01123993|DEVICE|Music CD|During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
40923918|NCT05581901|DRUG|Methadone (Dose1)|Dose: 0.10mg/kg
40923919|NCT05581901|DRUG|Methadone (Dose 2)|Dose: 0.15mg/kg
40923920|NCT05581901|DRUG|Methadone (Dose 3)|Dose 0.20mg/kg
40923921|NCT01936090|DRUG|Bortezomib|Given IV
40923922|NCT01936090|RADIATION|Total-Body Irradiation|Undergo TBI
40923923|NCT01936090|DRUG|Melphalan|Given IV
40923924|NCT01936090|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplant
40923925|NCT01936090|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
40923926|NCT01936090|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
40923927|NCT01936090|OTHER|Laboratory Biomarker Analysis|Correlative studies
40923928|NCT05681559|BEHAVIORAL|Medi for All|Please see description of Medi for All arm
40923929|NCT05681559|DIETARY_SUPPLEMENT|Standard Fiber Supplementation|Please see description of Fiber Supplementation arm
40923930|NCT00129909|DRUG|fixed dose combination therapy|
40923931|NCT01120782|DEVICE|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
40923932|NCT01120782|DEVICE|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
40923933|NCT06255678|DIAGNOSTIC_TEST|Angiography-based vessel fractional flow reserve (vFFR) calculation|vFFR is calculated from routinely taken angiography images during PCI using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands)
40923934|NCT00853996|DRUG|acolbifene hydrochloride|Given orally
40923935|NCT00201162|DIETARY_SUPPLEMENT|Soy|Dietary supplement of isolated soy protein containing isoflavones
40923936|NCT00201162|DIETARY_SUPPLEMENT|Placebo|dietary supplement casein placebo
40923937|NCT02230969|DRUG|peginterferon beta-1a|Administered as specified in the treatment arm
40923938|NCT02890108|DIETARY_SUPPLEMENT|Sugar sweetened beverages|350 cc (1 can) of sugar sweetened beverage
40923939|NCT02890108|DIETARY_SUPPLEMENT|Artificially sweetened beverages|350 cc (1 can) of artificially sweetened beverage
40923940|NCT02126345|DEVICE|MASTER SL femoral stem and DELTA TT acetabular cup|
40923941|NCT00588068|OTHER|Tumor and Marrow Markers|Tumor and Marrow Markers
40923942|NCT03240744|BIOLOGICAL|Inactivated EV71 vaccine (human diploid cell, KMB-17)|3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
40923943|NCT06065111|OTHER|study tendon damage in osteogenesis imperfecta patients|"* To identify and characterize alterations of tendons and ligaments in patients with osteogenesis imperfecta (OI) and to improve clinical management of the disease.~* To analyze interactions of different parameters, such as laxity or administration of bisphosphonates, on the evolution of the disease."
41270643|NCT04799561|BEHAVIORAL|Multimodal Teleprehabilitation|"Exercise Prescription: patients will be instructed on how to perform aerobic exercise (5 times/week: minimum 30-minute/day) and resistance training (3 times/week: 2-3 sets of 6-8 exercises repeated 8-12 times) at home. Exercise counseling will be weekly, using the video-conferencing application (Zoom).~Nutrition: nutritional status and dietary intake will initially be assessed by the nutritionist using zoom. All patients will receive daily whey protein supplements. Special precautions will be considered if patients have specific medical conditions.~Psychosocial intervention: Patients will have access to 1.5 hours of mental relaxation and coping mechanisms session within the first week of enrolment, using Zoom.~Smoking Cessation: Patients with smoking habits will meet with a respiratory specialist using Zoom, who will establish recommendations and contact the physician for the recommended smoking cessation protocol.~More counseling sessions will be provided as needed."
41270644|NCT02736747|OTHER|Cryotherapy|
40923944|NCT00331110|DEVICE|Laterally-Wedged Insole with Ankle Strapping|
40923945|NCT00331110|DEVICE|Laterally-Weged Insole|
40923946|NCT02104037|PROCEDURE|Lumbar puncture|
40923947|NCT03740893|DRUG|AZD6738|"PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle."
40923948|NCT03740893|DRUG|Olaparib|"PART 1: Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.~PART 2: 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle."
40923949|NCT03740893|DRUG|Durvalumab|"PART 1: Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.~PART 2: 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle."
40923950|NCT02094768|DIETARY_SUPPLEMENT|Reduced Fat Milk|Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
40923951|NCT02094768|DIETARY_SUPPLEMENT|Sugar Sweetened Soda|Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
40923952|NCT01265264|DRUG|ulodesine|Oral dose administered daily for 84 days.
40923953|NCT01265264|DRUG|Placebo|Oral dose administered daily for 84 days.
41095902|NCT05793099|OTHER|Effect of placebo gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given placebo gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing placebo gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
41095903|NCT01684046|DEVICE|Opti-Free® PureMoist® MPDS|
41095904|NCT01684046|DEVICE|RevitaLens MPDS|
41095905|NCT01684046|DEVICE|Habitual Contact Lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
41133417|NCT05764057|DRUG|Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)|"Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines\* for 6 months (experimental group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
41270645|NCT02736747|OTHER|Placebo|
40923954|NCT04805879|BIOLOGICAL|FMT oral Capsules|Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool donated by a healthy indvidual that was screened to have no mental health issues or chronic or contagious doseases. Each capsule will contain 0.67 ml of pelleted intestinal microbes. Therefore it is considered that the 20 capsules are equivalent to 100 grams of stool
40923955|NCT04805879|BIOLOGICAL|Placebo Capsules|Placebo Capsules that will look and weigh the same as the FMT oral capsules.
40923956|NCT05671809|OTHER|NCRT with surgery, or NCT with surgery, or surgery|The eligible patients who voluntarily sign the consent form will undergo either NCRT with surgery, or NCT with surgery, or surgery according to treatment guidelines.
40923957|NCT04613778|PROCEDURE|Laser acupuncture|Laser acupuncture is a low-level laser technique with no invasive procedure
40923958|NCT06457672|DIAGNOSTIC_TEST|Group I|Complete Crown technique of superimposition
40923959|NCT06457672|DIAGNOSTIC_TEST|Group II|Gold standard technique of superimposition
40923960|NCT00305461|DRUG|Ciclesonide|Effect of Ciclesonide on Quality of Life
40923961|NCT00691119|BEHAVIORAL|Relaxation and Visualization Therapy|Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.
40923962|NCT00691119|OTHER|Health education|Facilitated health education sessions, twenty minutes, five times a week for six weeks.
40923963|NCT01680198|DRUG|Paracalcitol|Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
40923964|NCT01680198|DRUG|placebo|
40923965|NCT06305884|PROCEDURE|Bioelectric Impedance Analysis|Undergo BI
40923966|NCT06305884|OTHER|Exercise|Pedal an exercise bike
40923967|NCT06305884|PROCEDURE|Photoplethysmography|Undergo PPG
40923968|NCT06305884|BEHAVIORAL|Questionnaire Administration|Ancillary studies
40923969|NCT04955678|DRUG|Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes|ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.
40923970|NCT04955678|DRUG|Placebo|Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.
40923971|NCT00002952|BIOLOGICAL|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
40923972|NCT00002952|BIOLOGICAL|recombinant MAGE-3.1 antigen|
40923973|NCT00002952|BIOLOGICAL|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
40923974|NCT00938886|DRUG|Naltrexone|Daily 50 mg naltrexone
40923975|NCT00938886|DRUG|Placebo|Matched naltrexone placebo
40923976|NCT00220779|DRUG|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|
40923977|NCT00220779|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|
40923978|NCT04145843|PROCEDURE|endoscopic retrograde cholangiopancreatography|ERCP is a procedure that enables the physician to examine the pancreatic and bile ducts and remove gallstones.
40923979|NCT04551313|BEHAVIORAL|social skill group|We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
40923980|NCT06044311|DRUG|Vactosertib|200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.
40923981|NCT06044311|DRUG|Standard of Care Chemotherapy|Neoadjuvant chemotherapy treatment as per standard of care.
40923982|NCT06044311|RADIATION|Concurrent Radiation|Neoadjuvant radiation treatment as per standard of care.
40923983|NCT02836639|DRUG|Busulfan|Busulfan 0.8 mg/kg four times per day from day -7 to day -5
40923984|NCT02836639|DRUG|Etoposide|Etoposide 400 mg/m2 from day -5 to day -4
40923985|NCT02836639|DRUG|Bendamustine|Bendamustine 200 mg/m2 starting dose on day -3 and -2
40923986|NCT00347373|DRUG|Tonalin Conjugated linoleic acid (dietary supplement)|
40923987|NCT01908946|BEHAVIORAL|SMS reminders|SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
40923988|NCT00647569|PROCEDURE|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
40923989|NCT00647569|PROCEDURE|Conventional facial closure|The abdominal facia is closed with with continuous running suture
40923990|NCT03421769|PROCEDURE|EA and AMLK|A 7-9mm diameter corneal epithelial tissue will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
40923991|NCT03421769|PROCEDURE|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
40923992|NCT04909619|PROCEDURE|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|The maxillary nerve, V2, is purely a sensory branch of the trigeminal nerve. V2 exits the skull through the foramen rotundum and courses through the pterygopalatine fossa, a small pyramid-shaped depression located posterior to the maxilla. As the maxillary nerve exits the pterygopalatine fossa, it divides into numerous branches that supply sensation to the posterior nasal cavity, palate, sinuses, and maxilla. It is within the pterygopalatine fossa that the maxillary nerve is targeted and anesthetized during the block. With the patient in the supine position after nasotracheal intubation, a needle is inserted perpendicularly between the upper border of the zygomatic arch and posterior orbital rim until it reaches the greater wing of the sphenoid, where the needle is then retracted by a few millimeters and redirected toward the nasolabial fold until it hits the pterygopalatine fossa.
40923993|NCT04909619|PROCEDURE|Local anesthetic infiltration of the palate|Local anesthetic infiltration of the palate during cleft palate repair is universally practiced. The benefits of local anesthetic infiltration are twofold: to provide anesthesia to the terminal branches of the nasopalatine and greater palatine nerves that are in the immediate area of the injection sites and to achieve hemostasis during closure when the medication is mixed with epinephrine. To administer local anesthetic infiltration of the palate, a 25 gauge needle is inserted next to the incision into the soft tissue. The tissue is first aspirated to determine safety of injection at that site. The medication is then injected parallel to the incision on both sides.
40923994|NCT05365685|BEHAVIORAL|Low energy turnover|"Low Energy Turnover. The adolescents with ingest low energy intake at lunch and breakfast and will not perform physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~Moderate Energy Turnover. The adolescents with ingest moderate energy intake at lunch and breakfast and will perform one 45 minutes physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~High Energy Turnover. The adolescents with ingest high energy intake at lunch and breakfast and will perform two 45-minute physical exercises during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals."
41270646|NCT04939857|DRUG|Trimetazidine|The experimental group will be treated with trimetazidine, and the control group will not be intervened
40923995|NCT03935113|OTHER|Kinesio taping|In KT group, KT was applied using the insertion-origin muscle and space-correction technique of affected upper limb with stroke patients.
40923996|NCT04514783|DEVICE|Debridement with Debritom+ micro water jet device|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with Sodium chloride (NaCl) 0.9% solution on the wound (5 minutes)~* Debridement using Debritom+ micro water jet technology~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
40923997|NCT04514783|OTHER|Debridement with|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Debridement using scalpel and curette~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
40923998|NCT05401058|DRUG|Droperidol Injection|About 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.
40923999|NCT05401058|DRUG|Saline|About 30min before the end of operation, Normal saline 0.5ml will be administered by intravenous injection.
40924000|NCT03438474|PROCEDURE|Standard surgical procedure for endometrial cancer|total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)
40924001|NCT03438474|PROCEDURE|systematic lymphadenectomy (LNE)|systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels
40924002|NCT04339842|OTHER|Assessment of Dietary Changes in Adults in the Quarantine|The online survey will help to collect demographic data from the volunteers. Personal information and contact details, such as email, will not be asked. The survey will include questions about any increase or decrease in the consumption of main meals, snacks and fluid intake. If the participants of the study have observed changes in their dietary pattern since the beginning of the quarantine, details of these changes, such as an increase in the amount of main meal consumption, will be questioned.
40924003|NCT05634356|BEHAVIORAL|vocal-social reinforcement|experimental manipulation of social reinforcement in response to vocalizations
40924004|NCT00307320|BEHAVIORAL|Relaxation Training|Relaxation techniques training
40924005|NCT04843683|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
40924006|NCT04150367|DRUG|Isoniazid|Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.
40924007|NCT04150367|DRUG|Rifampicin|Participants will get the dosage according to the instruction for use.
40924008|NCT04150367|DRUG|Ethambutol|Participants will get the dosage according to the instruction for use.
40924009|NCT04150367|DRUG|Rifampicin|Participants will get the dosage according to the instruction for use.
40924010|NCT04150367|DRUG|Isoniazid|. Participants will get the dosage according to the instruction for use.
40924011|NCT04150367|DRUG|Ethambutol|Participants will get the dosage according to the instruction for use.
40924012|NCT03355469|DRUG|Low Intensity Exercise + Metformin|Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with metformin.
40924013|NCT03355469|DRUG|High Intensity Exercise + Metformin|High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with metformin.
40924014|NCT03355469|DRUG|Low Intensity Exercise + Placebo|Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.
40924015|NCT03355469|DRUG|High Intensity Exercise + Placebo|High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.
40924016|NCT00715143|DEVICE|Novation Ceramic|This treatment is the study device (which will be compared to a similar historic control device)
40924017|NCT05507359|OTHER|clove gel|4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel
40924018|NCT05507359|OTHER|Benzocaine gel|20% Benzocaine gel (Opahl gel)
40924019|NCT00053898|DRUG|anastrozole|1 mg/day and placebo for 5 years
40924020|NCT00053898|DRUG|tamoxifen citrate|20 mg/day and placebo for 5 years
40924021|NCT00053898|RADIATION|Radiation Therapy|Adjuvant radiation therapy
40924022|NCT00308464|DRUG|PHA-794428|
40924023|NCT00329849|BIOLOGICAL|Meningococcal ACWY-CRM conjugate vaccine|MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.
40924024|NCT00329849|BIOLOGICAL|Meningococcal ACWY-PS polysaccharide vaccine|MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
40924025|NCT00662532|DRUG|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
40924026|NCT04565327|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV prior to imaging
40924027|NCT04565327|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
40924028|NCT02719561|BEHAVIORAL|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
40924029|NCT02874131|BEHAVIORAL|Behavioral Activation|Behavioral activation
40924030|NCT02874131|BEHAVIORAL|Cognitive Processing Therapy|Cognitive processing therapy
41270647|NCT00199004|DRUG|Cyclophosphamide|
40924031|NCT04203277|OTHER|IVY|a combination of practice education and quality improvement interventions
40924032|NCT03810729|DIAGNOSTIC_TEST|Smartphone assessment|The smartphone app will be performed on participants randomly assigned to receive this test.
40924033|NCT03810729|DIAGNOSTIC_TEST|Modified Allen's Test|The modified Allen's test will be will be performed on participants randomly assigned to receive this test.
40924034|NCT04908943|BEHAVIORAL|RENEW|RENEW is a 12-week, peer-led, web-based program to help people with scleroderma learn skills that can be used to manage disease symptoms and improve well-being.
40924035|NCT01800461|OTHER|OPC-Stroke|Occupational therapy coaching intervention
40924036|NCT01800461|OTHER|Usual care|Usual community care
40924037|NCT02121665|DRUG|Probiotic (Inersan)|Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
40924038|NCT02121665|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
40924039|NCT02996058|DRUG|Dexmedetomidine 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
40924040|NCT02996058|DRUG|Dexmedetomidine 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
40924041|NCT00571584|DRUG|activated recombinant human factor VII|
40924042|NCT01621815|BEHAVIORAL|Video Game|Playing various video games: RPG, Race, FPS, Strategy
40924043|NCT04113590|PROCEDURE|Laparoscopic Assisted Transvaginal Cholecystectomy|Perform transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization
40924044|NCT04087330|OTHER|Group 1 Experimental group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars.~Whole body vibration."
40924045|NCT04087330|OTHER|Group 2 Control group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars."
40924046|NCT05705635|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
40924047|NCT05705635|DRUG|Taxotere|Taxotere, by intravenous infusion, every 3 weeks.
40924048|NCT03269162|DRUG|Jinfukang Koufuye|30ml per time, tid, po (d6-21, q21)
40924049|NCT03269162|DRUG|Docetaxel|75mg/m2,ivgtt 30mins, d1
40924050|NCT03269162|DRUG|Pemetrexed|500mg/m2, ivgtt 30mins, d1
40924051|NCT03269162|DRUG|Cisplatin|75mg/m2, ivgtt \>2h, d1
40924052|NCT02395302|DEVICE|Dual Action Pneumatic Compression|Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
40924053|NCT03499964|DEVICE|Optilume Drug Coated Balloon (DCB)|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
40924054|NCT03499964|DEVICE|Control Treatment|A control subject may be dilated with either a rod, uncoated balloon or DVIU until the desired result is reached, based on standard of care for the clinical site and treating physician
40924055|NCT00878436|DRUG|Panobinostat|
41095906|NCT01979978|OTHER|Healthy Buddies Curriculum|"Each week, intermediate students will receive a 45-minute healthy-living lesson plan from their classroom teacher. Later that week, intermediate students will serve as peer mentors (Buddies), teaching a 30-minute lesson to their younger students. The Physical activity (i.e.Go Move!) component of the lesson plans includes 30-minutes of structured aerobic fitness sessions, called fitness loops, with the student pairs twice weekly. The dietary (Go Fuel!) component includes lessons about distinguishing nutritious and from unhealthy (nutrient poor-energy rich) foods and beverages. The body image (Go Feel Good!) component, the students are taught to value classmates based on individual traits rather than peer influence."
41270648|NCT00199004|DRUG|Dexamethasone / Prednisolone|
40924056|NCT00878436|DRUG|Bicalutamide|
40924057|NCT01503671|DRUG|Atorvastatin|Atorvastatin 40 mg/day
40924058|NCT03453372|DEVICE|MRgFUS Treatment|Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
40924059|NCT03453372|OTHER|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
40924060|NCT00182481|PROCEDURE|Induced sputum cell counts|
40924061|NCT00182481|DRUG|inhaled corticosteroids and other asthma drugs|
40924062|NCT01287182|DRUG|Ateronon|Ateronon daily for 3 months
40924063|NCT02867553|DRUG|rituximab|
40924064|NCT02867553|RADIATION|Multi-fields radiotherapy|
40924065|NCT04335214|OTHER|one to one interview|one to one interviews with older people from moroccon origin in Belgium
40924066|NCT05082597|DEVICE|Low energy ESWT|Therapeutic sessions: 4(once a week, for 4 weeks) Total dosage: 2500 shoots over axillary cord lesion (1000 over most fibrotic area, 500 over upper arm, 500 over forearm, 500 over other area) Energy: 0.056-0.065mJ/mm2
40924067|NCT02532166|OTHER|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
40924068|NCT04375319|DEVICE|OCT|OCT can provide clear in vivo imaging and evaluate the vascular repair after stent implantation by measuring the optical echo of near-infrared light reflection
40924069|NCT02830438|DEVICE|Shear wave elastography|Ultrasound technique of the kidneys to assess wave elastography.
40924070|NCT01794195|BEHAVIORAL|Diffusion tensor imaging and fibres tracking|
40924071|NCT05795634|BEHAVIORAL|Trier Social Stress Test|Acute psychosocial stress procedure; 5 minutes of public speaking and 5 minutes of mental arithmetic
41270649|NCT00199004|DRUG|Vincristine|
40924072|NCT06481176|BEHAVIORAL|12-Week RLS Exercise Program|"Participants will complete 12 weeks of an evidence-based exercise program that has been used for people with RLS, designed for people with RLS, and was informed by exercise guidelines outlined by the American College of Sports Medicine (ACSM) and the American Heart Association, and Center for Disease Control.~The program includes three sessions per week for 12 weeks including:~* cardiovascular exercise (e.g., walking/jogging, bicycling) for 30 minutes/day on at least 3 days/week at a moderate-to-vigorous intensity~* strength training on 2 non-consecutive days/week targeting major muscle groups for approximately 30 minutes~* Stretching all major muscle groups on three or more days per week"
40924073|NCT05605951|OTHER|non-interventional study|observational study
40924074|NCT02299401|DRUG|Misoprostol|Women will receive three 800 mcg doses of misoprostol.
40924075|NCT02299401|DEVICE|Semi-quantitative pregnancy test|All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
40924076|NCT05780268|BIOLOGICAL|LY3819253|LY3819253 is a neutralizing immunoglobulin G (IgG)-1 monoclonal antibody (mAb) to the receptor binding domain (RBD) of the S protein of SARS-CoV-2
40924077|NCT05780268|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
40924078|NCT05780268|BIOLOGICAL|Remdesivir|Antiviral agent
40924079|NCT02224248|BEHAVIORAL|Health checks with fitness testing|Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
40924080|NCT02224248|BEHAVIORAL|Health checks without fitness testing|The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
40924081|NCT00040846|BIOLOGICAL|alemtuzumab|Given IV
40924082|NCT00040846|DRUG|fludarabine phosphate|Given IV
40924083|NCT00040846|RADIATION|total-body irradiation|Undergo TBI
40924084|NCT00040846|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
40924085|NCT00040846|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
40924086|NCT00040846|DRUG|mycophenolate mofetil|Given PO
40924087|NCT00040846|DRUG|cyclosporine|Given IV or PO
40924088|NCT00510653|DRUG|Imatinib Mesylate|600 mg by mouth daily for 6 Weeks
40924089|NCT01943253|DEVICE|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
40924090|NCT01943253|DEVICE|Hybridknife ESD|Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
41095907|NCT06200402|DRUG|Antibiotic loaded|This is the intervention for the study group. It involves the use of bone cement mixed with antibiotics (typically gentamicin or similar) in the hip prosthesis surgery. The purpose of this intervention is to assess whether the antibiotic-loaded cement reduces the incidence of postoperative infections compared to standard cement
40924091|NCT00950885|BIOLOGICAL|Low Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
40924092|NCT00950885|BIOLOGICAL|Placebo|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
40924093|NCT00950885|BIOLOGICAL|High Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
40924094|NCT04582123|PROCEDURE|crossed pin configuration|comparison of two crossed pin fixation methods
40924095|NCT01139008|DRUG|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
41095908|NCT06200402|OTHER|Placebo|Placebo
41095909|NCT00819910|DRUG|Rosiglitazone|Rosiglitazone 8mg daily for 12 weeks
40924096|NCT01139008|DRUG|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
40924097|NCT06453057|BIOLOGICAL|GT307 injection|GT307 injection to treat solid tumours
41095910|NCT00819910|DRUG|Placebo (Rosiglitazone)|Placebo (Rosiglitazone) 8mg daily for 12 weeks
41095911|NCT00819910|DRUG|Placebo (Fenofibrate)|Placebo (Fenofibrate) 145 mg daily for 12 weeks
41095912|NCT00819910|DRUG|Fenofibrate|Fenofibrate 145 mg daily for 12 weeks
41095913|NCT06310122|DEVICE|Extracorporeal shockwave therapy|"Devices used to improve foot function pain and gait pattern~Patients will be placed in prone position, therapist locate the point of maximum tenderness. treatment area will be prepared with coupling gel to minimize the loss of shockwave therapy at the interface between applicator tip and skin. Each patient will receive 2000 impulses ,3 bar energy,15mm depth applicator at frequency (10 HZ) per session / week for 4 weeks"
41095914|NCT06310122|DEVICE|ultrasound|"Devices used to improve foot function pain and gait pattern~Participants in the study group will be treated with 5 minutes of therapeutic ultrasound at a frequency of 1 MHz and continuous current at a pulse intensity of 1.8 W/cm2 (when the sensitivity level was too high and the procedure hurt the patient, the therapist reduced the intensity . 3 sessions /week for 4 weeks"
41095915|NCT01110174|DIAGNOSTIC_TEST|HD PET/CT|imaging
40924098|NCT05066542|BEHAVIORAL|NDPP + Basketball (BB)|DPP Hoops: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30- minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and biweekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
41270650|NCT00199004|DRUG|Daunorubicin|
40924099|NCT05066542|BEHAVIORAL|NDPP Standard of Care SOC|DPP: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
40924100|NCT02490969|PROCEDURE|Routine management observation|Early rule out of myocardial infarction with combined copetine and troponin testing at admission
40924101|NCT00023699|DRUG|gefitinib|
40924102|NCT03373331|BEHAVIORAL|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
40924103|NCT03373331|BEHAVIORAL|Placebo Control Exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
40924104|NCT00828100|DEVICE|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
40924105|NCT00828100|DEVICE|BinaxNOW® Influenza A & B|The BinaxNOW Influenza A \& B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
40924106|NCT03131427|DRUG|Standard of care|Standard of care according to the updated national and/or international guidelines
40924107|NCT03229343|OTHER|Supportive care|supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
40924108|NCT00726401|DRUG|COLD-fX|200mg BID for 4 weeks
40924109|NCT00726401|DRUG|Placebo|200mg BID for 4 weeks
40924110|NCT05253001|DEVICE|smartphone|Use the mobile chatbot approach for intervention groups to improve prenatal education.
40924111|NCT02965768|DRUG|Naltrexone HCl|4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
40924112|NCT00532675|DRUG|LBH589|PAN 5 mg and PAN 20 mg capsules
40924113|NCT00532675|COMBINATION_PRODUCT|Lenalidomide|Lenalidomide 5mg or 25 mg
40924114|NCT03001271|DRUG|Angiotensin 1-7|
40924115|NCT03001271|OTHER|Placebo|
40924116|NCT06174168|OTHER|Modified Frailty Index -11|MFI-11: the parameter included in the score is history of congestive heart failure, presence of diabetes mellitus, history of chronic obstructive pulmonary disease or pneumonia, functional health status/dependence, history of hypertension, history of myocardial infarction, cardiac problems, cognitive impairment, history of transient ischemic attack or cerebrovascular accident, history of peripheral vascular disease is questioned. Patients will be monitored according to standard non-operating room anesthesia procedures.
40924117|NCT02730143|OTHER|Altitude exposure|Altitude exposure
41095916|NCT04454567|DRUG|ABI-H0731|Participants will receive ABI-H0731 tablets orally once daily
41270651|NCT00199004|DRUG|Asparaginase|
41270652|NCT00199004|DRUG|Methotrexate|
40924118|NCT01165762|DRUG|Immune Tolerance|"Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.~The IDE used in this study is the column used for hematopoietic cell sorting."
40924119|NCT00708084|BIOLOGICAL|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
40924120|NCT00708084|BIOLOGICAL|HRIG|HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
41095917|NCT04454567|DRUG|Placebo|Participants will receive placebo to ABI-H0731 tablets orally once daily
41270653|NCT00199004|DRUG|Cytarabine|
41270654|NCT00199004|DRUG|Mercaptopurine|
41270655|NCT00199004|DRUG|G-CSF|
41270656|NCT00199004|DRUG|Vindesine|
41270657|NCT00199004|DRUG|VP16|
41270658|NCT00199004|DRUG|Adriamycin|
41270659|NCT00199004|DRUG|Thioguanine|
41270660|NCT00199004|DRUG|VM26|
41270661|NCT00199004|DRUG|Rituximab|
40924121|NCT02320201|DEVICE|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
40924122|NCT00846183|PROCEDURE|local injury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed
40924123|NCT05186415|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations.
40924124|NCT03105466|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
40924125|NCT03105466|DEVICE|Acellular Porcine Cornea|
40924126|NCT03105466|DRUG|Tacrolimus eye drops|
40924127|NCT03105466|DRUG|Tobradex eyedrops|
40924128|NCT04869501|DRUG|TJ004309|Antibody to CD73
40924129|NCT04869501|DRUG|Atezolizumab|Humanized monoclonal antibody to PD-L1
40924130|NCT01624246|DRUG|Ceftaroline fosamil/Avibactam (CXL)|IV infusion of CXL (combination of ceftaroline fosamil \[600 mg\] plus avibactam \[600 mg\]) infused over 60 (± 5) minutes.
40924131|NCT06316310|OTHER|acupoint thread embedding|Acupoint embedding therapy:Main acupoints: Shangguan (CV-13), Xiaguan (CV-10), Tianshu (ST-25), Daheng (SP-15), Fenglong (ST-40), Qihai (CV-6), Zhongguan (CV-12), Zusanli (ST-36), Quchi (LI-11), Guanyuan (CV-4), Wailing (ST-26), Daju (ST-27), Shuidao (ST-28), Daimai (GB-26), Liangmen (ST-21), Ashi acupoints , where local fat accumulation in the abdomen. Methods of operation: With the patient in the prone position and all acupoints routinely sterilized, the acupuncturist will use sterile forceps to insert a 3-0 × 2-cm poly-p-dimethyl-hydroxy-oxazolone (PDO) thread into the tip of the #6 (0.6 mm × 60 mm) disposable embedded thread needle. The tissue around the area of the acupuncture point will be lifted with the thumb and forefinger of the non-dominant hand and the needle will be inserted into the acupuncture point to a depth of 1.5 cm with the dominant hand. Each treatment will last maximum of 10 minutes and the intervention will be repeated every 2 weeks for a total of 6 sessions.
40924132|NCT04668261|OTHER|Advanced imaging investigation|MRI imaging
40924133|NCT04740645|OTHER|NOCDURNA Cohort|Non intervention
40924134|NCT04740645|OTHER|LUTS Cohort|Non intervention
40924135|NCT06071429|DEVICE|MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold|CLTI patients treated with MAGNITUDE BRS
40924136|NCT06071429|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|CLTI patients treated with PTA
40924137|NCT03190733|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
40924138|NCT02664623|PROCEDURE|Individual dietary consultations|Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.
40924139|NCT02664623|PROCEDURE|Dietary advice sheet|"At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio."
40924140|NCT03096587|DEVICE|XP Endo Finisher|a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature
40924141|NCT03096587|DEVICE|ultrasonic activated irrigation|by Satelec,Acteon, France
40924142|NCT02385227|OTHER|Exclusive blu™ e-cigarette A1|Classic Tobacco rechargeable e cigarette
40924143|NCT02385227|OTHER|Exclusive blu™ e-cigarette A2|Magnificent Menthol rechargeable e cigarette
40924144|NCT02385227|OTHER|Exclusive blu™ e-cigarette A3|Cherry Crush rechargeable e cigarette
40924145|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B1|Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
40924146|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B2|Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
40924147|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B3|Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
40924148|NCT02385227|OTHER|Nicotine product cessation C|Nicotine cessation
40924149|NCT02226133|DEVICE|LAAx, Inc. TigerPaw® System II|Exclusion of Left Atrial Appendage.
40924150|NCT00189774|DRUG|nateglinide|
40924151|NCT05855876|PROCEDURE|subanesthetic ketamine infusions and bilateral cervical sympathetic blocks|Combined protocol of subanesthetic ketamine infusions and bilateral cervical sympathetic blocks
40924152|NCT06518850|DRUG|Rifaximin|Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.
40924153|NCT00959400|DRUG|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
40924154|NCT01650870|DRUG|Crystalline Lactulose|
40924155|NCT00317278|OTHER|massage therapy|massage therapy to stable preterm infants
40924156|NCT00317278|OTHER|Sham|Sham (placebo) provided to the control group
40924157|NCT01456624|DRUG|Megace|800mg
40924158|NCT01456624|DRUG|DW-ES(B)|625mg
40924159|NCT04898205|OTHER|Treadmill Exercise|The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.
40924160|NCT04898205|OTHER|Concentrated Oxygen|Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.
40924161|NCT04898205|OTHER|Concentrated Air|Room air will be delivered through an concentrator provided via nasal cannula.
40924162|NCT04179409|DRUG|Amondys 45|This drug is used to target skipping of exon 45 of the dystrophin gene.
40924163|NCT04179409|DRUG|Exondys 51|This drug is used to target skipping of exon 51 of the dystrophin gene.
40924164|NCT04179409|DRUG|Vyondys 53|This drug is used to target skipping of exon 53 of the dystrophin gene.
40924165|NCT01528423|PROCEDURE|XtremeCT|The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
40924166|NCT05662709|PROCEDURE|Tooth extraction|Tooth extraction in the most atraumatic way
40924167|NCT05662709|PROCEDURE|Alveolar ridge preservation with L-PRF|Blood will be drawn from the patient, centrifugued and leukocyte and platelet-rich fibrin (L-PRF) will be obtained. L-PRF plugs and membranes will be prepared and placed in the socket after extraction
40924168|NCT00265148|DRUG|Rosiglitazone|Extended Release Tablets
40924169|NCT00265148|OTHER|Placebo|Placebo dummy to match
40924170|NCT00093444|DRUG|lyso-thermosensitive liposomal doxorubicin|
40924171|NCT00093444|PROCEDURE|radiofrequency ablation|
40924172|NCT05212857|DRUG|Leuprolide acetate|Given subcutaneously or as an injection
40924173|NCT05212857|DRUG|Goserelin acetate|Given subcutaneously or as an injection
40924174|NCT05212857|DRUG|Triptorelin acetate|Given subcutaneously or as an injection
40924175|NCT05212857|DRUG|Degarelix acetate|Given subcutaneously or as an injection
40924176|NCT05212857|DRUG|Abiraterone acetate|Given orally
40924177|NCT05212857|DRUG|Apalutamide|Given orally
40924178|NCT05212857|DRUG|Enzalutamide|Given orally
40924179|NCT05212857|PROCEDURE|Local treatment for primary lesion|Radical prostatectomy to remove prostate primary lesion
40924180|NCT05212857|RADIATION|Radiotherapy for primary lesion|Radical radiotherapy for primary lesion
40924181|NCT05212857|RADIATION|Radiotherapy for metastatic lesion|Stereotactic body radiation therapy or proton and heavy ion radiation therapy is preferred, which could treat all the lesions at once or treat different lesions in stages.
40924182|NCT00924040|DRUG|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
40924183|NCT00958438|DRUG|Placebo|Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
40924184|NCT00958438|DRUG|Rilonacept|Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
40924185|NCT00958438|DRUG|Rilonacept|Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
40924186|NCT00744354|DRUG|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
40924187|NCT00744354|DRUG|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
40924188|NCT00744354|DRUG|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
40924189|NCT02756988|DRUG|Coppertone (BAY987704)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: X71-109)
40924190|NCT02688322|DRUG|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
40924191|NCT00389402|DRUG|saquinavir/ritonavir|
40924192|NCT00389402|DRUG|atazanavir/ritonavir|
40924193|NCT00390026|DRUG|Bevacizumab (Avastin)|
41095918|NCT04454567|DRUG|NrtI|Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
41095919|NCT02648529|PROCEDURE|MRI|"Patients are investigated with the following sequences:~* High-resolution 3D T1-weighted anatomical MRI.~* DTI with 48 directions (to examine white matter)"
41270662|NCT00199004|PROCEDURE|CNS irradiation|
40924194|NCT00390026|DRUG|Verteporfin photodynamic therapy (PDT)|
40924195|NCT01114230|DRUG|AGS-16M8F|IV
40924196|NCT03320551|BEHAVIORAL|Immersion program|Evaluate the impact of an already established one week long lifestyle immersion program sponsored by Whole Foods, Inc for their employees on anthropomorphic, clinical labs such as lipid levels, blood sugar and other markers of nutrition, quality of life and activity levels at baseline, at the end of the program and at 3 and 6 months
40924197|NCT05342480|OTHER|EMDR and PE combined treatment|Daily program monday to friday with daily PE and EMDR sessions, physical activity between sessions, in vivo exposure treament and psychoeducational groups. Daily rotation of both EMDR and PE therapists. Multidisiplinary team attached to each pati
40924198|NCT00864916|DRUG|Combination antiretroviral therapy (cART)|Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
40924199|NCT00864916|DRUG|Pentoxifylline|Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
40924200|NCT00864916|DRUG|Placebo|Participants will receive placebo three times per day for 48 weeks.
40924201|NCT03841578|DIETARY_SUPPLEMENT|Healthy|25g of dark chocolate (70%) will be provided to participants on Phase 1 (organoleptic assessment). On Phase 2 (gastrointestinal motility assessment), they will ingest a standard liquid meal (NutriDrink, 200ml), consisting of 10g of lactulose and 12g of fat
40924202|NCT00463021|DRUG|Hectorol (doxercalciferol capsules)|
40924203|NCT00463021|DRUG|Zemplar (paricalcitol injection)|
40924204|NCT05365945|OTHER|NDT Bobath therapy|Their physiotherapy was based on exercises that heavily employed the core muscles to equalize tension and strength, according to the NDT Bobath concept. The duration of the treatment session for each patient in both groups was 120 minutes.
41270663|NCT00199004|PROCEDURE|Mediastinal irradiation (if residual TU)|
41270664|NCT00199004|PROCEDURE|Stem cell transplantation|
41270665|NCT02144272|DRUG|LY3114062 SC|LY3114062 administered SC.
41133418|NCT05764057|DRUG|Placebo comparator|"Placebo daily on top of standard of care as recommended in current guidelines\* for 6 months (control group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
40752004|NCT03468946|OTHER|sweet taste perception|"sweet taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate sweet taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
40752005|NCT04918797|BIOLOGICAL|COVAXIN|Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)
40752006|NCT02316132|DRUG|Stress|Corticotropin-Releasing Hormone
40752007|NCT02316132|DRUG|Control|Saline 0.9%
40752008|NCT00303628|DRUG|oxaliplatin|Given IV
40752009|NCT00303628|DRUG|fluorouracil|Given IV
40752010|NCT00303628|DRUG|leucovorin calcium|Given IV
40752011|NCT00303628|DRUG|bevacizumab|Given IV
40752012|NCT02441114|DRUG|HCP0910 and HGP1011|Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
40752013|NCT02366130|DRUG|Ra-223 dichloride|55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.
40752014|NCT02366130|DRUG|Denosumab|120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
40752015|NCT02366130|DRUG|Hormone Therapy|A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
40752016|NCT03158311|DRUG|QVM149|Indacaterol acetate / glycopyrronium bromide / mometasone furoate
40752017|NCT03158311|DRUG|Salmeterol/fluticasone plus tiotropium|Free triple arm of salmeterol / fluticasone plus tiotropium
40752018|NCT01347957|OTHER|Nitric Oxide (NO) Gel|Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
40752019|NCT01347957|OTHER|Placebo gel|The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
40752020|NCT00429455|BEHAVIORAL|Survey|3-Part Questionnaire
40752021|NCT02475057|DRUG|Degarelix (LHRH antagonist)|Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
40752022|NCT02475057|DRUG|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
40752023|NCT02475057|DEVICE|EndoPAT2000|Peripheral arterial plethysmography using an EndoPAT2000 device
40752024|NCT03810794|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. The electric stimulator will be applied to DU 24, GB 12, HT 7, and LR 3 or SP 6 with a disperse-dense wave of 2/50 Hz, 0.5-1.0 mA. There are three sessions per week with each session lasting for 30 min. There will be 12 weeks of treatment for each participant in total.
40752025|NCT03810794|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks. After the clinical trial, participants will be given conventional treatment clinically.
40752026|NCT05821595|DRUG|JYB1907|for injection
40752027|NCT04382079|DIETARY_SUPPLEMENT|honey|"Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
40752028|NCT04382079|DIETARY_SUPPLEMENT|propolis|"Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
40752029|NCT04394832|BEHAVIORAL|Brief cognitive intervention|See the information provided in the experimental arm description.
40752030|NCT02631694|DRUG|Propranolol|Intake of propranolol pill (40 milligram)
40752031|NCT02631694|DRUG|Placebo|Intake of placebo pill (40 milligram)
40752032|NCT02631694|OTHER|Carbon dioxide|Inhalation of 35% carbon dioxide
40752033|NCT02631694|OTHER|Compressed air|Inhalation of air
40752034|NCT03094221|DEVICE|Rhythmia Mapping System|Arrhythmia mapping will be performed using the Rhythmia mapping system, including its mapping catheter, either in the atria or ventricles depending on the clinical arrhythmia being treated. Detailed mapping will be performed to determine tissue voltage and arrhythmia mechanism/location according to standard clinical practice. This part of the study will take approximately 90-120 minutes. The catheter position and contact will be visualized with intra-cardiac echocardiography, which is also routinely used during these procedures, and to monitor for potential clinically related complications. Images will be recorded to establish criteria for mapping.
40752035|NCT05785000|OTHER|Physical exercise programme as an add-on|Consists of an individually tailored bike exercise program guided by symptoms, pulse rate and patient specific judgement of exertion monitored also by BORG RPE and VAS and progressively increasing time and level of resistance below symptom provocation
40752036|NCT05785000|OTHER|Control patients receiving usual care|No exercise intervention
40752037|NCT03843970|DRUG|Levobupivacaine Hydrochloride 0.5%|The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.
40752038|NCT03843970|DRUG|Isobaric bupivacaine 0.5%|The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
40752039|NCT01794169|DRUG|Azacitidine|
40752040|NCT01794169|DRUG|DA|
40752041|NCT01426659|BEHAVIORAL|parental stimulation according to protocol|"verbal stimulation every day image of the Protocol Dire et Faire"
40752042|NCT03492268|BIOLOGICAL|BCMA-CART|After a conditioning therapy, each patient will receive a treatment of BCMA-CART originated from their own peripheral blood mononuclear cells
40924205|NCT05365945|OTHER|The classic exercises.|"They underwent classical neurological rehabilitation. such as passive exercises, but also an approximation. In addition, the patients performed self-assisted exercises on a manual rotor, and in order to relieve the directly affected limb, the patients exercised in a suspension system. As the physiotherapy progressed, the patients performed active exercises, and then active exercises with resistance, e.g. using the Thera Band. Patients also exercised their balance with the use of large gymnastic balls or sensor pads. A large part of the physiotherapy was locomotion training and gait re-education.~The duration of the treatment session for each patient in both groups was 120 minutes."
40924206|NCT01135563|DRUG|Vinblastine and Sirolimus|"Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.~Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough"
40924207|NCT01589770|OTHER|cardiac Magnetic Resonance imaging|
40924208|NCT04559711|OTHER|Strengthening coverage and quality of nutrition services during ANC|Intervention clusters will receive inputs both at facility level and community level. The supply side inputs will include efforts for improving facility readiness, quality of nutrition services during ANC, multiple micronutrient supplementation(MMS) and strengthening monitoring and supervision for ANC. On the other hand, community mobilization interventions will be carried out for demand creation. All public health facilities providing ANC services in the intervention area will be included; Union Health \& Family Welfare Center, Community Clinic and Satellite Clinic.
40924209|NCT05120063|DEVICE|SPS monoblock stem, Symbios|hip prosthesis
40924210|NCT05120063|DEVICE|Quadra-H, Medacta|hip prosthesis
40924211|NCT05120063|PROCEDURE|3D planning of THR|primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)
40924212|NCT05120063|PROCEDURE|2D planning of THR|primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)
40924213|NCT02821143|OTHER|usual palliative care|Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
40924214|NCT02821143|OTHER|Telemedicine consultation|"Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~* Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~* Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~* Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~* In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above."
40924215|NCT06519435|DEVICE|Mayo Dopplex ABIlity|Device used to measure lower extremity venous hemodynamic pressure
40924216|NCT06519435|DEVICE|Intermittent Pneumatic Compression (IPC)|Device used to measure lower extremity venous hemodynamic pressure
40924217|NCT01932879|OTHER|Blackberry|Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.
40924218|NCT01932879|OTHER|Jello|
40924219|NCT00866008|DRUG|Ovarian stimulation|"1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG."
40924220|NCT00941577|DRUG|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
40924221|NCT00941577|DRUG|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
40924222|NCT00956098|DRUG|oltipraz|60mg bid 90mg qd
40924223|NCT00956098|DRUG|placebo|
40924224|NCT05736575|GENETIC|BDNF analysis (Elisa KIT)|Analysis of peripheral BDNF will be performed
40924225|NCT00211744|DRUG|topiramate|
40924232|NCT01822314|DRUG|Abraxane|Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
40924233|NCT01822314|DRUG|Paclitaxel|Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
41133419|NCT05608070|DRUG|Oxytocin|Oxytocin 30 IU in 500 ml IV at a rate of 5 IU/h (83.33 ml/h). The infusion will be started intra-operative once the uterus is removed and will continue to run until completion of the medication or discharge from PACU criteria are met, whichever occurs first.
40924234|NCT05050591|DEVICE|Patient-Specific Silicone Airway Stent|The Patient-Specific Airway Stent is a silicone stent indicated for use in adults that have stenosis of the airway. Current silicone stents have stock dimensions that do not conform to the patient's airway anatomy. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally design the stent to his/her desired dimensions. Finally, according to the physician's design, a patient-specific stent can be manufactured using additive manufacturing technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
40924235|NCT01758445|RADIATION|Proton Radiotherapy|Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol \& physician.
40924236|NCT05307835|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;
40924237|NCT05307835|BIOLOGICAL|GM-CSF|4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses
40924238|NCT05027360|DRUG|SNP - Sodium Nitroprusside|The primary objective of our study is to assess the efficacy and safety of SNP as part of the treatment regimen of AHF patients and to identify predictors of efficacy.
40924239|NCT04214288|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally.
40924240|NCT04214288|DRUG|Fulvestrant|Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
40924241|NCT05240443|PROCEDURE|Bariatric Surgery + Medical Management of CKD.|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
40924242|NCT05240443|OTHER|Medical Management for CKD|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
40924243|NCT06154577|DIAGNOSTIC_TEST|Ultrasonography|Assessment of tongue morphology and posterior airway space using ultrasonography (AmCAD-UO, CE mark NB1639)
40924244|NCT00918008|GENETIC|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
40924245|NCT01491438|PROCEDURE|PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|"PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.~Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing"
40924246|NCT01491438|PROCEDURE|Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|Twice a week (days 1 and 4) during 12 weeks
40924247|NCT00164476|BEHAVIORAL|Preventive Services Prevention Kit|
40924248|NCT00164476|BEHAVIORAL|peer mentors (control group)|
40924249|NCT04064008|DEVICE|PROFEMUR® Z Revision Femoral Stem|Total Hip Total Hip Arthroscopy
40924250|NCT00720447|BIOLOGICAL|alemtuzumab|
40924251|NCT00720447|BIOLOGICAL|donor lymphocytes|
40924252|NCT00720447|DRUG|carmustine|
40924253|NCT00720447|DRUG|cytarabine|
40924254|NCT00720447|DRUG|etoposide|
40924255|NCT00720447|DRUG|melphalan|
40924256|NCT00720447|PROCEDURE|allogeneic bone marrow transplantation|
40924257|NCT00720447|PROCEDURE|peripheral blood stem cell transplantation|
40924258|NCT04933370|OTHER|Stimulation parameters|Different device stimulation parameters
40924259|NCT00852371|DRUG|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
40924260|NCT00852371|DRUG|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
40924261|NCT00852371|DRUG|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
40924262|NCT00852371|OTHER|Placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
40924263|NCT00534313|DRUG|Abatacept|Solution, intravenous, monthly, short-term = 24 weeks (6 months)
40924264|NCT00534313|DRUG|Placebo|Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
41133420|NCT05608070|DRUG|Placebo|0.9% saline infusion at the rate of 83.3 ml/h.
41133421|NCT05019859|BEHAVIORAL|low carb diet|low carb diet
41133422|NCT00431054|DRUG|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
41133423|NCT00431054|DRUG|Docetaxel|75 mg/m\^2 by vein over 1 hour every 4 weeks
40924265|NCT02058745|BEHAVIORAL|CAU+ (Enhanced Care as Usual)|"CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period."
40924266|NCT02058745|BEHAVIORAL|Beating the Blues|"Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple homework after each lesson."
40924267|NCT02058745|BEHAVIORAL|SmartCare|SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
40924268|NCT02654964|DRUG|Combination Drug Therapy|"Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
40924269|NCT06329128|OTHER|Experimental: Study Group|"A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary.~In the manual therapy group, in addition to the above treatment, manual therapy will be given 3 days a week. The content of the manual therapy program is as follows;~* Patellofemoral joint superior-inferior mobilization~* Medial-lateral mobilization with active knee flexion~* Tibiofemoral joint ventral (anterior-posterior) mobilization~* Tibiofemoral traction mobilization"
40924270|NCT06329128|OTHER|Active Comparator: Control Group|"A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary."
40924271|NCT05951465|DRUG|Esketamine|esketamine dose will be 0.3 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
40924272|NCT05951465|DRUG|Esketamine|esketamine dose will be 0.6 mg/kg. Propofol dose for the first patient will be 2.0 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
40924273|NCT05951465|DRUG|Propofol|propofol
40924274|NCT01608022|DRUG|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
40924275|NCT03537469|DEVICE|CTU Mega 20 real device|The CTU Mega 20 diamagnetic acceleration system discharges high-field magnetic impulses (with a duration of 5 ms and a period of 1000 ms), generating a magnetic field up to 2 Tesla, with a frequency of 7500 Hz in a volume of approximately 27 cm3.
40924276|NCT03537469|DEVICE|CTU Mega 20 sham device|A CTU Mega 20 sham device (with an identical appearance to that of the real device) to avoid treatment identification by the patient or experimenter was used. Of course, the application of this sham device did not provide any magnetic field.
40924277|NCT04232969|DRUG|Exenatide extended release 2mg (Bydureon)|Subcutaneous Injection
40924278|NCT01966432|BEHAVIORAL|Referral to Treatment|Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
40924279|NCT01966432|BEHAVIORAL|Brief Intervention|Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
40924280|NCT04062136|COMBINATION_PRODUCT|stem cell transplantation|Transplantation of umbilical cord mesenchymal stem cells
40924281|NCT00289029|DRUG|Iopamidol 370 mgI/mL|
40924282|NCT00680238|DRUG|Human derived FSH|Customized for each patient
40924283|NCT02974751|PROCEDURE|Aquablation|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue.
40924284|NCT05228847|DIETARY_SUPPLEMENT|Human milk-derived HMF|Fortification with human milk-derived product
40924285|NCT05228847|DIETARY_SUPPLEMENT|bovine milk-derived HMF|bovine milk-derived HMF
40924286|NCT00388583|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal
40924287|NCT00388583|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular
40924288|NCT02337231|DIETARY_SUPPLEMENT|soybean oil and borage oil|Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
40924289|NCT00043329|DRUG|Actimmune Registry|as administered by physician
40924290|NCT03968939|DRUG|Diphenhydramine (Benadryl)|Oral Diphenhydramine (Benadryl), 25 mg
40924291|NCT03968939|DIETARY_SUPPLEMENT|Melatonin|Oral Melatonin, 3 mg
40924292|NCT03968939|BEHAVIORAL|Sleep Hygiene Education|"Brochure containing information about getting a good night's sleep."
40924293|NCT03676101|BIOLOGICAL|9-valent HPV Recombinant Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
40924294|NCT03676101|BIOLOGICAL|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
41270666|NCT02144272|DRUG|Placebo|Placebo administered SC.
41270667|NCT02144272|DRUG|LY3114062 IV|LY3114062 administered IV.
40924295|NCT02434588|DEVICE|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
40924296|NCT00197158|BIOLOGICAL|Hepatitis B vaccine|
40924297|NCT04879147|DIAGNOSTIC_TEST|Evalution of thyroid function|Determination of TSH, free T4, free T3, SPINA-GT, SPINA-GD and Jostel's TSH index
40924298|NCT00852332|DIETARY_SUPPLEMENT|Curcumin|
40924299|NCT00852332|DRUG|Taxotere|
40924300|NCT02057042|BEHAVIORAL|Peer-assisted computerized CBT|Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
40924301|NCT02057042|BEHAVIORAL|Enhanced usual care|Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
40924302|NCT00692354|DRUG|CHR-2797 (tosedostat)|Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
40924303|NCT05397782|DEVICE|BioNourish, a component of Flourish HEC|BioNourish, one of three parts of the Flourish HEC system, is a vaginal moisturizing gel - a Class II medical device with FDA 510k clearance obtained in 2020.
40924304|NCT00479271|BEHAVIORAL|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
40924305|NCT00479271|BEHAVIORAL|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
40924306|NCT03849573|BEHAVIORAL|"OncoTool Intervention (MBSR + HT education)"|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with stress and improve health-related quality of life. OncoTool provides mindfulness-based education and management for dealing with the numerous physical and mental side effects associated with hormone therapy (e.g., muscle and joint pain, vaginal dryness, depressive symptoms). OncoTool is a website designed to improve hormone therapy adherence by improving quality of life, and hormone therapy associated symptom burden. Both intervention and active comparator conditions are administered to participants for 8 weeks.
40924307|NCT03849573|BEHAVIORAL|"Oncotool Control (health +HT education)"|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to breast cancer survivors, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar HT education content as the experimental content but without the CBT and MBSR state. Both intervention and active comparator conditions are administered to participants for 8 weeks.
40924308|NCT02556164|PROCEDURE|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
40924309|NCT02556164|OTHER|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
40924310|NCT00105053|BIOLOGICAL|HyperAcute-Prostate Cancer Vaccine|Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
40924311|NCT01863589|DRUG|Adefovir tablets|Administered according to the prescribing information in the locally approved label by the authorities.
41453285|NCT04166162|BEHAVIORAL|Tomando Buenas Decisiones (TBD) Intervention|The program is adapted from the Guiding Good Choices (GGC) program and will be conducted by a trained facilitator lasting for about 2 hours per session. The program discusses about the best ways to help one's child make good decisions with regards to avoiding alcohol, drugs, and other problem behaviors that may not be healthy to them as well as ways to have good communication and good connections within one's family.
40924312|NCT03104816|DRUG|Acetaminophen IV Soln 10 MG/ML|
40924313|NCT03104816|DRUG|Acetaminophen|
40924314|NCT03104816|DRUG|Hydromorphone|
40924315|NCT04319497|DEVICE|Subjective refraction|Subjective refraction measurements will be performed by two testers for all the patients included
40924316|NCT04319497|DEVICE|Autorefraction|Five autorefraction measurements will be performed for all the patients included
40924317|NCT04319497|DEVICE|Wavefront aberrometry|Five wavefront measurements will be performed for all the patients included
40924318|NCT05873127|BEHAVIORAL|web-based guided self-help Enhanced Cognitive Behavioral therapy|The subjects would learn and practice CBT-E course through the online learning platform for 12 times, and were required to complete the course once a week.
40924319|NCT05873127|BEHAVIORAL|online Enhanced Cognitive Behavioral therapy|A closed structured group would be established by online video conference for group CBT-E therapy. Each group would receive 12 group sessions, once a week for 120 minutes each time. Each group would be led by two CBT therapists, all of whom are nationally registered psychotherapists with systematic professional training.
40924320|NCT02789319|DEVICE|Blood Glucose Meter Systems|
40924321|NCT04643600|DRUG|L-Arginine, 500 Mg Oral Capsule|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
40924322|NCT05322044|BEHAVIORAL|Financial incentives|Financial incentives dependent upon adherence will be given to participants alongside additional EMD associated app features for 12-weeks.
40924323|NCT03448874|DEVICE|Seal-G MIST System|Seal-G MIST is an adjunct device that will be applied adjunctively to cover standard closure techniques.
40924324|NCT01650012|DRUG|eplerenone|target 50 mg per day titrated down for hyperkalemia or hypotension
40924325|NCT01650012|DRUG|Placebo|Placebo
40924326|NCT05944328|OTHER|systematic and structured review of patient pharmacotherapeutic treatment plans|"The intervention consisted of a systematic and structured review of patient pharmacotherapeutic treatment plans to identify problems or situations of risk related to pharmacological treatments and to propose changes or improvements to optimise them. phases:~Individualised review of pharmacological treatment plans to detect drug-related problems:~Indication, Appropriateness, Effectiveness, Safety When a drug-related problem was detected according to the above criteria, the pharmacist proposed an adjustment to the pharmacotherapeutic plan. The proposals could include: discontinuation of the drug, change of drug, change to a therapeutic equivalent, initiation of treatment, change of dosage, change of frequency or intensified monitoring.~The proposals made by the pharmacist were assessed and agreed upon by a committee comprising the doctors responsible and the pharmacist. Thereafter, the consensual proposals for change were discussed with the patient."
40924327|NCT01819818|DRUG|No intervention|This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
40924328|NCT04774211|DIAGNOSTIC_TEST|SOS-PD|Validation of SOS-PD bedside assessments comparing the Danish SOS-PD scale with a Child Psychiatrist using DSM-V as the reference standard
40924329|NCT04096183|OTHER|Ventilation of healthy volunteers|Ventilation of healthy volunteers in different clinical situations
40924330|NCT02555501|OTHER|PDT + Low level laser|"Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium)."
40924331|NCT02555501|RADIATION|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
40924332|NCT01561196|PROCEDURE|arterial catheterisation|arterial catheterisation in Arterial Radialis
40924333|NCT02956902|OTHER|Clinician supported smartphone application intervention|
40924334|NCT02299778|DIETARY_SUPPLEMENT|13C6-p-aminobenzoic acid|
40924335|NCT03977311|DEVICE|Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU)|-To be used in conjunction with radiation therapy in the treatment of locally advanced cervical carcinoma patients
40924336|NCT03977311|RADIATION|Radiation therapy|-Standard of Care
40924337|NCT00000843|DRUG|Adefovir dipivoxil|
40924338|NCT04948931|OTHER|Lavender aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
41270668|NCT04831060|PROCEDURE|Periodontal treatment|"For Cases :~* Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection; Teaching of oral hygiene techniques.~* Non-surgical periodontal treatment~* At 3 months = periodontal reevaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~* If periodontal pockets greater than 5mm and bleeding persist: periodontal surgery and gingival explant sampling~* At 3 months post-surgery = periodontal re-evaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~* Maintenance~For Controls:~* Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection, teaching of oral hygiene techniques.~* Plastic or pre-prosthetic surgery = gingival explant sampling~* Healing control at 15 days"
40924339|NCT04948931|OTHER|Rosemary aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
40924340|NCT04948931|OTHER|Control|The application will be once a day, every day for four weeks. Each session will take five minutes.
40924341|NCT02225054|DRUG|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
40924342|NCT02225054|DRUG|Ropivacaine|15 ml 0.5%
40924343|NCT02225054|DRUG|Normal Saline|1 mL 0.9%
40924344|NCT04832100|DRUG|Pregabalin 150mg, imipramine 25mg|Conventional treatment for fibromyalgia was given to patients. Clinical follow-ups with questionnaires and interview were arranged then.
40924345|NCT01037192|DRUG|vancomycin|vancomycin 30 mg/kg intravenous administered once daily
40924346|NCT01037192|DRUG|vancomycin|vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
40924347|NCT03649308|DEVICE|Negative Pressure Wound Therapy|An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.
40924348|NCT03649308|PROCEDURE|Conventional treatment|Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
40924349|NCT05377697|OTHER|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
40924350|NCT04769999|BEHAVIORAL|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
40924351|NCT03625908|DEVICE|OCT-guided PCI|Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.
40924352|NCT03625908|DEVICE|Angiography-guided PCI|Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
40924353|NCT00860600|DRUG|PG2|500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time
40924354|NCT02604537|DRUG|betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone
40924355|NCT02604537|DRUG|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
40924356|NCT01106417|BIOLOGICAL|NeoFuse|Single Dose NeoFuse Surgical Implantation
40924357|NCT01106417|DEVICE|MasterGraft Granules|Single Dose MaterGraft Granules Surgical Implantation
40924358|NCT03802214|DRUG|Vedolizumab|standard vedolizumab induction (300mg IV at week 0, 2, 6)
40924359|NCT01737229|DEVICE|Application of Biodentine™ (RD94), dentin substitute|
40924360|NCT01302977|PROCEDURE|Fetal tracheal occlusion|Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
40924361|NCT00000477|DRUG|lovastatin|
40924362|NCT04902300|OTHER|Data collection|evaluation of internet addiction
40924363|NCT00001131|DRUG|Aldesleukin|Subcutaneous injection of IL-2 in the amount of 2.0 X 10\^6 mIU per day for the entire duration of therapy
40924364|NCT00001131|DRUG|HAART|Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
40924365|NCT00171470|DRUG|Tegaserod|
40924366|NCT01211431|DRUG|Reference|Intrathécale morphine is used for post-cesarean pain control
40924367|NCT01211431|DRUG|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
40924368|NCT02710162|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
40924369|NCT02710162|DEVICE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
40924370|NCT02710162|DEVICE|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
40924371|NCT02710162|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
40924372|NCT02710162|PROCEDURE|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
40924373|NCT02710162|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
41270669|NCT00496392|DRUG|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
41270670|NCT05027386|DRUG|Apatinib, Irinotecan, Temozolomide|The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.
41453286|NCT04166162|BEHAVIORAL|Social Development Strategy (SDS) Intervention|SDS is a 2 hour broad-focused environmental intervention consisting of short presentations and workshops designed to provide skills and models for positive human interaction between employees to fellow employees, employees to their children and employees to their supervisors.
40924374|NCT02710162|OTHER|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
40924375|NCT02710162|OTHER|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
40924376|NCT02710162|OTHER|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
41270671|NCT03426176|DRUG|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
41270672|NCT03426176|DRUG|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
41453287|NCT04166162|BEHAVIORAL|BTC Training Session|BTC training session consists of trainings, discussions and tools focused on community mobilization for the assessment and implementation of evidence-informed preventive interventions addressing community health and behavior problems. Each training session lasts about 4 hours.
40924377|NCT02710162|OTHER|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
40924378|NCT02710162|OTHER|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
40924379|NCT02710162|OTHER|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
40924380|NCT05205577|DEVICE|Tens Eco Plus|30min/day of stimulation at 25Hz frequency, 100 microsc pulse with intensity escalation up to 25 mA max
40924381|NCT06123013|BEHAVIORAL|Music Assisted Relation Intervention (MARI)|A standardized 30-minute MARI intervention, personalized to the participant's music and imagery preferences. During the MARI intervention, the board certified music therapist (MT-BC) will provide live guitar accompaniment personalized to the participant's music preferences and read from a standardized script directing the participant to relax muscles of the body, practice deep breaths, and explore a relaxing place.
40924382|NCT03779243|DIETARY_SUPPLEMENT|Melatonin 5mg and Sleep Education|Melatonin 5mg daily and sleep education for 6 weeks following injury or surgery.
40924383|NCT03779243|OTHER|Placebo|Daily placebo pills for 6 weeks following injury or surgery.
40924384|NCT03702244|DIAGNOSTIC_TEST|cCTA with selective FFRct|PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall
40924385|NCT01246817|DRUG|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
40924386|NCT06191211|BEHAVIORAL|Motivational Interviewing, AIMS|Motivational interviewing (MI). MI is an approach to patient engagement which promotes a collaborative conversation style for strengthening a person's own motivation and commitment to change. With MI, the doctor facilitates patient exploration of potential reasons for behaviour change in the context of what is important to the patient, rather than the physician directly telling the patient what to do. MI has been found more effective than other approaches to patient engagement and health behaviour change and can be effectively taught to primary care providers.
40924387|NCT06191211|BEHAVIORAL|Facility engagement|A letter to the facility from the local health officials; a meeting with the facility manager and health staff to formally announce that we would like providers to encourage COVID-19 vaccinations; deploying a tracking sheet for vaccinations.
40924388|NCT03199755|DRUG|ACT|Current approved drug for treating malaria
40924389|NCT03199755|DRUG|DLA1|Experimental drug treatment, single dose.
40924390|NCT03199755|DRUG|DLA2|Experimental drug treatment, doubled the dose of DLA1.
40924391|NCT03489746|OTHER|ICS withdrawal protocol|A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.
40924392|NCT03489746|OTHER|Standard care|Normal clinically indicated inhaled therapy
40924393|NCT01350544|BEHAVIORAL|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
40924394|NCT06229171|OTHER|adherence support system based on a vocal assistant|"Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken.~Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre."
40924395|NCT04612608|PROCEDURE|upright bed|moving the bed into an upright position
40924396|NCT01800175|DEVICE|Punctum Plug|
40924397|NCT02535780|PROCEDURE|Transcranial magnetic stimulation|TMS
40924398|NCT02535780|PROCEDURE|Transcranial direct current stimulation|tDCS
40924399|NCT01967381|DRUG|Methamphetamine (Desoxyn®)|The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
40924400|NCT04903821|DRUG|BAY3427080|Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
40924401|NCT06289205|DRUG|Methotrexate|Methotrexate will be utilised in two different ways to prevent development of proliferative vitreoretinopathy after vitrectomy for rhegmatogenous retinal detachment
40924402|NCT00348608|DRUG|iodixanol|
40924403|NCT04267601|DRUG|Anagliptin|Anagliptin treatment for 24weeks
40924404|NCT04093063|OTHER|Micro-stellated Icosahedron|A portable, inexpensive microsurgery training model that requires the following materials for completion. a stereoscopic dissecting microscope, two jeweler style forceps, a pair of curved-tip micro scissors , 1 meter of monofilament nylon thread, 0.5 meter of polyimide microtubule material , one 15 cm metal ruler, a scalpel blade (#15), and double-sided tape. For a microsurgically-naive subject, a total of 20 hours are required to complete this model.
41453288|NCT05807958|DEVICE|Skin Prick Automated Test|A skin prick automated test will be performed in each participant.
40924405|NCT01246908|DRUG|Placebo|Placebo administered twice per day for six weeks.
40924406|NCT01246908|DRUG|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
41270673|NCT03426176|DRUG|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
41270674|NCT03426176|DRUG|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
41270675|NCT00669617|DRUG|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
41270676|NCT00669617|DRUG|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
41270677|NCT00669617|DRUG|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
41453289|NCT05200442|DRUG|VS-6766/avutometinib|An oral anti-cancer medication.
41453290|NCT05200442|DRUG|Cetuximab|A chemotherapy drug used to treat head, neck and colorectal cancer.
41453291|NCT05200442|OTHER|Pill Diary|A diary where participants in phase 2 of study will log their medications and times they are taken on study.
41453292|NCT05621252|DRUG|PLN-74809|160 mg PLN-74809
40924407|NCT02728427|DEVICE|Suprapubic catheterization using central venous catheter(CVC-2 7F)|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.
40924408|NCT02728427|DEVICE|Transurethral catheterization using Foley catheter|Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.
40924409|NCT02397018|BIOLOGICAL|allogeneic umbilical cord blood|Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10\^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
40924410|NCT04215757|PROCEDURE|peripheral nerve block|peripheral nerve blocks with low dose lignocaine in acute radiculopathy
40924411|NCT01388556|BEHAVIORAL|Tango dancing|Twice weekly tango dance classes
40924412|NCT06442631|BEHAVIORAL|MyStroke|MyStroke is a video-based educational platform that curates brief educational videos to inform patients and caregivers about key aspects of their stroke. Upon registering a user, information regarding the patient's stroke etiology, relevant stroke risk factors, and stroke prevention medications are used to populate educational content that is relevant to the individual. Users receive automated nudges to revisit MyStroke after hospital discharge on day 1, 3, 5, 7, and weekly thereafter.
40924413|NCT04925154|BEHAVIORAL|The only intervention will be the information brochure that will be given after the first questionnaire.|The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).
40924414|NCT00430131|PROCEDURE|Cognitive Orientation to Occupational Performance|
40924415|NCT00430131|PROCEDURE|Contemporary Treatment Approach|
40924416|NCT02282293|DRUG|Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)|
40924417|NCT02282293|DRUG|Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)|
40924418|NCT01512667|DRUG|MK-0822|A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
40924419|NCT03508791|OTHER|Arterial carbon dioxide monitoring|Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
40924420|NCT03508791|OTHER|End-tidal carbon dioxide monitoring|End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
40924421|NCT03508791|OTHER|Transcutaneous carbon dioxide monitoring|Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
40924422|NCT03826368|DIETARY_SUPPLEMENT|Hemp-derived botanical dietary supplement|Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
40924423|NCT00061282|DRUG|Clotrimazole|One retention enema, administered nightly
40924424|NCT01046409|OTHER|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
40924425|NCT01263912|DIETARY_SUPPLEMENT|LCPUFA Supplement|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
40924426|NCT01263912|DIETARY_SUPPLEMENT|Placebo|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
40924427|NCT00258843|BIOLOGICAL|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
40924428|NCT00258843|BIOLOGICAL|Inactivated Poliomyelitis vaccine|0.5 mL, IM
40924429|NCT05383001|DRUG|combination regimen tremelimumab /durvalumab|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Durvalumab 1500 mg fixed dose plus tremelimumab 300 mg fixed bolus dose~Maintenance Therapy:~Durvalumab 1500 mg fixed dose Q4W up to 12 cycles within the study"
40924430|NCT05383001|DRUG|platinum-based chemotherapy (SoC)|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Continuation of second-line chemotherapy with 2-4 further cycles (Q3W) platinum-based combination therapy.~Maintenance Therapy:~Optional continued maintenance therapy with pemetrexed according to marketing authorization will be allowed for a maximum of 13 cycles."
40924431|NCT04641338|DRUG|Fixed dose combination Dipyrone and Codeine|Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.
40924432|NCT04641338|DRUG|Dipyrone|use of 1000 mg dipyrone every 6 hours if necessary.
40924433|NCT04641338|DRUG|Codeine|30 mg codeine every 6 hours if necessary.
40924434|NCT04757428|PROCEDURE|Endocrown|Endocrown
40924435|NCT05185206|DEVICE|Class 1 cavity preparation using conventional steel bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with convention steel bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog Scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm)."
41270678|NCT00669617|DRUG|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
41270679|NCT00669617|DRUG|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
41270680|NCT00669617|DRUG|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
41270681|NCT03182738|BEHAVIORAL|VIP app without HIV-related symptom strategies.|The control group will receive the VIP app without HIV-related symptom strategies
40924436|NCT05185206|DEVICE|Class 1 cavity preparation using polymer bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with polymer bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm)."
40924437|NCT05062954|DIETARY_SUPPLEMENT|Polyphenol-rich cranberry extract supplement standardized in proanthocyanidins|Participants will be randomly assigned to the consumption of one capsule of Polyphenol-rich cranberry extract standardized in PACs.
40924438|NCT05062954|DIETARY_SUPPLEMENT|Placebo supplement|Participants will be randomly assigned to the consumption of one capsule of placebo per day for 56 consecutive days.
40924439|NCT00357591|DEVICE|Continuous Aortic Flow Augmentation|1.0-1.5 lpm augmented blood flow
40924440|NCT05895526|PROCEDURE|Self etch dentin adhesive, Fluoride varnish|After an informed consent, in one group 5% sodium fluoride varnish will be applied in affected area, while the other group will receive self etch dentin adhesive.
40924441|NCT05094973|DEVICE|Carriere Motion Appliance®|To analyze the distalization or distal tooth displacement and derotation angle produced by Carriere Motion Appliance® in a period of 4 months.
40924442|NCT01116856|OTHER|Exercise|Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
40924443|NCT00481507|OTHER|Kefir|The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.
40924444|NCT00481507|OTHER|Placebo|The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
40924445|NCT02386189|BEHAVIORAL|Patient Care Coordination Training|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
40924446|NCT01144299|BIOLOGICAL|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
40924447|NCT00373061|DRUG|Xolair®|This being an observational study, the study protocol does not specify any dose regimen.
40924448|NCT04023838|PROCEDURE|artery puncture and coronary angiography|We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).
40924449|NCT03700541|DRUG|Morphine|Morphine intravenous
40924450|NCT03700541|DRUG|Piritramid|Piritramid intravenous
40924451|NCT00952380|DRUG|dalteparin|dalteparin subcutaneous injection
40924452|NCT04045418|DEVICE|Laser doppler|"A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~1. Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~2. Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively."
40924453|NCT05779371|BEHAVIORAL|Integrated-based Laughing Qigong Program|The protocol of the Integrated-based Laughing Qigong Program (IB-LQP) combined laughter intervention and mental health promotion courses. It was a two-hour community activity held twice a week for six weeks. The content was 50-60 minutes of a laughter practice program and 50 minutes of mental health lectures, separated by a 10-minute break.
40924454|NCT00481975|DRUG|rimonabant (SR141716)|
40924455|NCT00520585|DRUG|atorvastatin|atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
40924456|NCT06055335|OTHER|Medium flow anesthesia|Group MeFA; after reaching the MAC 1 value with 4lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, medium flow anesthesia was started with 2 lt/min 50% O2 - 50% air with MAC 1 concentration desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
40924457|NCT06055335|OTHER|Minimal flow anesthesia|Group MiFA; after reaching the MAC 1 value with 4 lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, minimal flow anesthesia was started with 0.50 lt/min 50% O2 - 50% air with MAC 1 concentration of desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
40924458|NCT02516540|BEHAVIORAL|Structured exercise training plus mediterranean diet|Structured exercise training plus mediterranean diet
41270682|NCT03182738|BEHAVIORAL|VIP app that delivers HIV-related symptom strategies.|The Intervention group will receive the VIP app that delivers HIV-related symptom strategies
40752043|NCT02785705|BIOLOGICAL|poliovirus vaccine|Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
40924459|NCT02376959|BEHAVIORAL|"Spiritist passe"|"For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.~The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique."
40924460|NCT02229656|RADIATION|radiotherapy|Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.
40924461|NCT02229656|DRUG|Olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
40924462|NCT01335802|GENETIC||Genetic counseling
40924463|NCT02727530|OTHER|VISCERAL MANUAL THERAPY-ADVICES|The subjects of this group will receive an amount of two sessions of visceral manual therapy that will be applied within two weeks. In the first session will be applied procedures in the most superficial body structures. And, in the second session will be applied procedures in the most deep body structures.
40924464|NCT02727530|OTHER|ADVICES|Advices for parents to improve the management of infant colic
40924465|NCT03351101|DEVICE|Senofilcon C|Senofilcon C Contact Lens
40924466|NCT03351101|DEVICE|Samfilcon A|Samfilcon A Contact Lens
40924467|NCT00108368|DRUG|Risperidone|
40924468|NCT00108368|DRUG|Olanzapine|
40924469|NCT05961345|OTHER|experimental group|Early mobilization of patients after surgery is supported. The relationship between early mobilization and pain level was examined. The experimental group is 80 people.
40924470|NCT04152993|DEVICE|NeuroPace® RNS® System|In this intervention, patients suffering from PTSD undergo a surgical procedure to implant the responsive neurostimulation device (RNS, NeuroPace). This procedure involves the placement of a depth lead bilaterally in the amygdala and hippocampus following a trans-occipital trajectory. The two leads are then connected to a pulse generator fixated to the skull. RNS is able to detect specific signals from the target and to respond with a programmed electrical stimulation. One month after the implantation of the system, the patients will undergo 3 tasks: a fear conditioning task, the international affective picture system and the subsequent memory recall paradigm. These tasks will yield electrophysiological biomarkers of arousal and re-experiencing. We will then program RNS to detect and respond to those biomarkers. The patients will be followed longitudinally for improvement and evidence of target engagement as seen on cerebral metabolism and global electroencephalography.
40924471|NCT01126047|OTHER|eCO testing|exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
40924472|NCT05725759|BEHAVIORAL|Rehabilitation|Particapants currently receiving tofersen treatment will be referred to outpatient physical and/or occupational therapy.
40924473|NCT04915950|DRUG|Temanogrel|Participants will receive a single oral dose of temanogrel during the treatment visit.
40924474|NCT04915950|DRUG|Placebo|Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
40924475|NCT01151943|OTHER|Transversus Abdominis Plane (TAP) Block|Bilateral injection of levobupivacaine (20 mL, 3.75 mg/mL)
40924476|NCT01151943|OTHER|Incisional Infiltration of Local Anesthetic|continuous administration of levobupivacaine (1,25 mg/mL,5 mL/h) during 48 hours.
40924477|NCT04311593|DIAGNOSTIC_TEST|CD4, CD19, CD38, CD56 and CD11b|measuring CD markers by flowcytometry
40924478|NCT00002501|BIOLOGICAL|filgrastim|
40924479|NCT00002501|DRUG|cyclophosphamide|
40924480|NCT06226532|DRUG|lidocaine spray|Group SL: Spray 10% lidocaine for 4 puffs at the endotracheal tube cuff, also prepare for spray at the laryngeal inlet for 4 puffs (total approximately 1.5mg/kg)
40924481|NCT06226532|DRUG|Intravenous Lidocaine|2% lidocaine 1.5 mg/kg IV will be given 2 minutes after cisatracurium injection (3 minutes prior intubation).
40924482|NCT01488474|PROCEDURE|peripheral nerve stimulation|defining the minimal current threshold for distal motor response
40924483|NCT00000939|DRUG|Hydroxyurea|
40924484|NCT00000939|DRUG|Efavirenz|
40924485|NCT00000939|DRUG|Stavudine|
40924486|NCT00000939|DRUG|Didanosine|
40924487|NCT01905423|DRUG|Albendazole (annual)|Albendazole 400 mg pnce annually
40924488|NCT01905423|DRUG|Diethylcarbamazine (annual)|Diethylcarbamazine 6 mg/kg once annually
40924489|NCT01905423|DRUG|Albendazole (semiannual)|Albendazole 400 mg twice annually
40924490|NCT01905423|DRUG|Diethylcarbamazine (semiannual)|Diethylcarbamazine 6 mg/kg twice annually
40924491|NCT04978519|PROCEDURE|Cryotherapy|Cryotherapy is administered by using perineal needles, placed under ultrasound guidance to freeze the target tissue.
40924492|NCT02586506|DRUG|Placebo ELLIPTA inhaler|The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
40924493|NCT02586506|OTHER|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
40924494|NCT00006212|DRUG|cisplatin|
41270683|NCT02154399|DRUG|EF5|Given IV
40924495|NCT00006212|DRUG|vinblastine sulfate|
40924496|NCT00006212|RADIATION|phosphorus P32|
40924497|NCT00006212|RADIATION|radiation therapy|
40924498|NCT06151080|DRUG|Lenalidomide combined with G-CHOP (LO CHOP)|Lenalidomide combined with G-CHOP to treat newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL)
40924499|NCT03532607|OTHER|Music|Patients will listen to soothing music for 30 minutes before their standard of care botox injection
40924500|NCT00100334|DRUG|PPI-1019 (APAN)|
41270684|NCT02154399|OTHER|Laboratory Biomarker Analysis|Correlative studies
41270685|NCT02154399|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery/thoracotomy
40924501|NCT03243708|BEHAVIORAL|Risk calculator|Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
40924502|NCT06210360|DRUG|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14 day cycle
40924503|NCT06210360|DRUG|Oxaliplatin|60 mg/m² on Day 1 of a 14 day cycle
40924504|NCT06210360|DRUG|5-FU|2400 mg/m² continuous IV infusion in 46 h
40924505|NCT06210360|DRUG|LV|400 mg/m² on Day 1 of a 14 day cycle
40924506|NCT05269121|BIOLOGICAL|Phage Therapy|Patient will undergo a DAIR procedure. After the DAIR, phage therapy will be administered in conjunction with antibiotic treatment.
40924507|NCT00636350|DIETARY_SUPPLEMENT|Pepper|pepper carotenoids as meals
40924508|NCT02810444|BIOLOGICAL|IgG Next Generation (BT595)|
40924509|NCT03130647|DEVICE|Focused ultrasound|Focused ultrasound
40924510|NCT06339476|DIAGNOSTIC_TEST|Serum ADMA, MDA and M30 levels mesurment|Blood samples collected from patienst, only 7 mL
40924511|NCT00213694|DRUG|docetaxel and celecoxib|
40924512|NCT01887054|DEVICE|Tower of Hanoi|
41095920|NCT02648529|PROCEDURE|functional MRI (fMRI)|"fMRI investigations will be focused on :~* language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~* Social cognition: investigations on social cognition skills~* Memory :~* Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~* Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups."
41095921|NCT02648529|BEHAVIORAL|neuropsychological assessment|Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
41095922|NCT01540435|DRUG|Bevacizumab|Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
41095923|NCT00716664|OTHER|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
41095924|NCT00716664|OTHER|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
41095925|NCT05262972|OTHER|Conservatory treatment|Personalized plantar orthosis
41095926|NCT05262972|OTHER|Innovate treatment|Personalized plantar orthosis + percutaneous electrolysis
41095927|NCT04389255|OTHER|Star Excursion Balance Test|The Star Excursion Balance Test (SEBT) is a dynamic test that requires strength, flexibility, and proprioception. It is a measure of dynamic balance that provides a significant challenge to athletes and physically active individuals. The test can be used to assess physical performance, but can also be used to screen deficits in dynamic postural control due to musculoskeletal injuries (e.g. chronic ankle instability), to identify athletes at greater risk for lower extremity injury, as well as during the rehabilitation of orthopeadic injuries in healthy active adults.\[
41270686|NCT02154399|OTHER|Tissue Oxygen Measurement|Undergo tumor hypoxia measurement
40924513|NCT01887054|OTHER|Placebo group - non use of Tower of Hanoi|
40924514|NCT00357760|BIOLOGICAL|VEGF Trap|Given IV
40924515|NCT02346890|DRUG|AZD1722|
40924516|NCT02346890|DRUG|Renvela|
40924517|NCT00790309|PROCEDURE|Weight loss surgery|Weight loss surgery
40924518|NCT00790309|PROCEDURE|Laparoscopic abdominal surgeries|laparoscopic abdominal surgeries
40924519|NCT00392145|DRUG|Standard IV rehydration|A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
40924520|NCT00392145|DRUG|Rapid intravenous rehydration (RIVR)|A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
40924521|NCT01375855|PROCEDURE|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
40924522|NCT01964456|OTHER|Joint perception task|
40924523|NCT01964456|BEHAVIORAL|Body Shape Questionnaire|
40924524|NCT01964456|OTHER|Measure of the heart rate|
41270687|NCT01982591|OTHER|laboratory biomarker analysis|Correlative studies
41270688|NCT01982591|OTHER|questionnaire administration|Ancillary studies
41270689|NCT06260514|DRUG|APR-1051|WEE1 Inhibitor
41270690|NCT01798914|DRUG|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
40924525|NCT04672954|DRUG|Placebo|Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.
40924526|NCT04672954|DRUG|2.5 milligram (mg) BI 474121|2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
40924527|NCT04672954|DRUG|10 milligram (mg) BI 474121|10 mg BI 474121 administered as uncoated tablets (1 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
40924528|NCT04672954|DRUG|20 milligram (mg) BI 474121|20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.
40924529|NCT04672954|DRUG|40 milligram (mg) BI 474121|40 mg BI 474121 administered as uncoated tablets (4 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 2 of the study: non-randomised, open-label.
40924530|NCT02518464|DRUG|Ticagrelor 90 mg twice per day|Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
40924531|NCT03906916|DIAGNOSTIC_TEST|1,3-β-D-glucan quantification|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be evaluated by 1,3-β-D-glucan test and by means of blood culture to confirm the diagnosis
41095928|NCT04389255|DEVICE|Balance Master device|The Balance Master (Neurocom International, Inc Clackamas,) device is a computerized posturography device. The device consists of a fixed support surface consisting of a force table and individuals, a variety of ground elements and a computer screen that will provide visual feedback and conduct test protocols. Posturography tests a person's ability to integrate visual, vestibular and somatosensory inputs and suppress inappropriate sensory information. Thus, it can quantitatively score the person's balance and examine balance problems in detail with the tests it contains. There are various protocols that evaluate balance differently in Balance Master (BMc). Limits of Stability Test (LOS) and Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) were used in the BMc.
41270691|NCT03670030|DRUG|ABI-009|rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
40924532|NCT03906916|DRUG|Micafungin|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
40924533|NCT02030431|DEVICE|Dynaloc|
40924534|NCT02030431|DEVICE|Cancellous screws|
40924535|NCT02859805|OTHER|validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients|
40924536|NCT05163015|OTHER|Data collection|Description: quality of life assessment
40924537|NCT00533754|PROCEDURE|drawing blood|
40924538|NCT06476639|DIAGNOSTIC_TEST|High-resolution bilateral groin ultrasound monitoring|Participants in the Interventional Group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, participants will receive a groin node ultrasound every 2 months and a clinical examination every 3 months, for a follow up period of 12 months. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
40924539|NCT05713669|BEHAVIORAL|Encounter visit with Patients|Participants in this encounter group will be asked to complete a pre and post-intervention survey, participate in a meeting with a former ICU patient at a post-ICU clinic, and undergo an in-person interview within fourteen days following the encounter.
40924540|NCT05713669|BEHAVIORAL|Non-encounter surveys|Surveys will be completed pre and post patient follow-up.
40924541|NCT01917877|DRUG|Bevacizumab|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
40924542|NCT01917877|DRUG|Dexamethasone|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
40924543|NCT03591770|BIOLOGICAL|SHINGRIX|"SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
40924544|NCT01922401|OTHER|inverse ratio ventilation|change the I: E ratio 1:2-1:1-2:1
40924545|NCT04573023|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
40924546|NCT04573023|DRUG|Idursulfase|IV infusion
40924547|NCT04573023|DRUG|JR-141 or Idursulfase|"The subjects who have achieved the pre-specified criteria\* are able to change the drug.~\*If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141.~If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase."
40924548|NCT03254615|BEHAVIORAL|"I Prefer Plain Water"|The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.
40924549|NCT00606047|RADIATION|Magnetic resonance imaging (MRI)|Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.
40924550|NCT01716962|OTHER|Infusion of 6% tetrastarch for a total of 500 ml|
40924551|NCT05860270|DRUG|Cholecalciferol|Patients in the intervention group will receive oral cholecalciferol 4000U per day.
40924552|NCT05860270|DRUG|Placebo|Patients in the control group will receive placebo 2 capsules per day.
40924553|NCT01642628|OTHER|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
40924554|NCT06245278|OTHER|ELISA (Enzyme-Linked ImmunoSorbent Assay)|A total of 60 individuals, 15 with IBD and periodontitis, 15 with IBD and periodontal health, 15 with systemic health and periodontitis, and 15 with systemic and periodontal health, will be included in the study. At the beginning of the study, periodontal clinical measurements (gingival index, plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and serum, saliva and gingival samples will be obtained from all individuals. Individuals with periodontitis will receive non-surgical periodontal treatment in half jaws within 2 weeks. Clinical measurements, serum and saliva sample collection will be repeated 3 months after the treatment. Biomarker levels in serum and saliva samples will be analysed by ELISA.
40924555|NCT05291468|RADIATION|FDG-PET/CT|Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
40924556|NCT05583513|DIAGNOSTIC_TEST|MLHFQ (Minnesota Living with Heart Failure Questionnaire)|The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL
40924557|NCT05583513|DIAGNOSTIC_TEST|KCCQ (the Kansas City Cardiomyopathy Questionnaire)|The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL
40924558|NCT00832832|OTHER|Eyelid closure|Eyelid will be closed after eye drop instillation
41095929|NCT01106287|DRUG|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
41095930|NCT01106287|DRUG|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
41095931|NCT03720015|BEHAVIORAL|Physical exercise|Physical exercise controlled program supervised by an accredited exercise specialist
41095932|NCT03720015|DIETARY_SUPPLEMENT|Nutritional management|Nutritional management controlled by a PhD clinical and sport nutrition specialist
41095933|NCT01855464|PROCEDURE|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
41095934|NCT01855464|PROCEDURE|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
41095935|NCT02058914|DIETARY_SUPPLEMENT|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage
41095936|NCT02058914|DIETARY_SUPPLEMENT|High Glucose sweetened beverage|HG-sweetened beverage
41095937|NCT00004209|DRUG|cisplatin|
41443055|NCT04982094|BEHAVIORAL|Mental Health First Aid|"Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions in addition to online reading, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~MHFA online training is conducted two-weeks before the two MHFA sessions (with a 1 day break in between each MHFA). Two Booster sessions are delivered 1- and 3-months after the last MHFA session. The Booster sessions aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program."
41095938|NCT00004209|DRUG|mitomycin C|
41095939|NCT00004209|DRUG|vinblastine sulfate|
41095940|NCT03465488|DRUG|Albendazole Pill 400mg (GSK)|One single dose of 400mg Albendazole is provided at baseline.
41095941|NCT04846101|OTHER|OMNISHADE|Anterior dental cavities (Class III, Class IV) will be restored with an omnishade composite material
41443056|NCT02102191|DEVICE|e-cigarette|smoking cigarette without tobacco
40924559|NCT00832832|OTHER|No intervention will be assigned|No intervention will be assigned to this arm
40924560|NCT05045937|DRUG|Ivermectin|Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
40924561|NCT01700868|OTHER|Vegan diet|A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.
41095942|NCT04846101|OTHER|MULTISHADE|Anterior dental cavities (Class III, Class IV) will be restored with conventional multishade composite material.
41270692|NCT05589142|BEHAVIORAL|Time Restricted Eating|Eating calories only during a specific feeding window.
40924562|NCT01700868|OTHER|American Diabetes Association guidelines|Participants will follow individualized diet plans following ADA guidelines
40924563|NCT01863654|DRUG|Montelukast 5 mg chewable tablets|Reference product
40924564|NCT01863654|DRUG|Montelukast 5 mg chewable tablets|Test product
40924565|NCT00073853|PROCEDURE|Autologous Incubated Macrophages (cell therapy)|
40924566|NCT05299983|OTHER|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
40924567|NCT05299983|OTHER|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites:~1. North American Menopause Society: https://www.menopause.org/for-women~2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
41095943|NCT04846101|DIAGNOSTIC_TEST|Instrumental Shade Analysis|Assessment will be performed by single operator using spectrophotometer (EASYSHADE) to detect color difference between tooth and restoration
41095944|NCT04846101|OTHER|Visual Shade Analysis|Visual assessment will be performed by two calibrated specialists to evaluate shade matching between the tooth and restoration
41095945|NCT04846101|OTHER|Patient satisfaction|Patient satisfaction of the final shade match will be assessed on a visual analogue scale
41095946|NCT00479180|BIOLOGICAL|Vascugel|One time implant on the day of surgery
41095947|NCT00479180|BIOLOGICAL|Placebo Comparator|One time implant on the day of surgery
41095948|NCT06273072|DRUG|Metformin hydrochloride extended-release tablets|titrated to 2000 mg once daily
41095949|NCT06273072|DRUG|Visually identical placebo Metformin hydrochloride extended-release tablets|placebo
41095950|NCT05764824|DIETARY_SUPPLEMENT|Blueberry powder|20 g per day of blueberry powder
41095951|NCT05764824|OTHER|Controlled and matched powder|20 g per day
41095952|NCT05023434|PROCEDURE|Intraoperative Brain Simulation - Alternate Stimulation Parameters|Additional stimulation parameters outside of standard of care during intraoperative brain stimulation to aid in motor mapping.
41095953|NCT03539159|OTHER|Allogeneic conventional sized serum eye drops|allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
41095954|NCT03539159|OTHER|Allogeneic micro sized serum eye drops|Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
41095955|NCT04925180|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|As prescribed by the treating physician
41095956|NCT00948844|DEVICE|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
41095957|NCT01264718|BEHAVIORAL|Parent Mentors|After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
41095958|NCT05655507|DRUG|Zuranolone|Administered as capsules
41095959|NCT00246298|DRUG|epoetin alfa|
41095960|NCT00421915|DRUG|Enbrel (etanercept)|
41095961|NCT04135495|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)
41095962|NCT04135495|DRUG|Ivacaftor|CFTR potentiator
41443057|NCT02102191|DEVICE|cigarette|smoking cigarette with tobacco
41095963|NCT00361309|DRUG|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
41095964|NCT05167253|BIOLOGICAL|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
41095965|NCT03425292|DRUG|Temozolomide|concomitant and 5-day adjuvant temozolomide
40924568|NCT04914260|OTHER|Questionnaire|The participants will have to fill in an on-line questionnaire regarding quality of life, their level of knowledge of the rehabilitation through sport program and their level of satisfaction toward this program.
41095966|NCT03425292|RADIATION|conformal brain radiation therapy|standard radiation therapy for newly diagnosed glioblastoma
41095967|NCT03425292|DRUG|Nivolumab|nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
41095968|NCT03425292|DRUG|Ipilimumab|ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses
41095969|NCT03425292|DRUG|Bevacizumab|bevacizumab 5 mg/kg IV every 2 weeks (up to 10 mg/kg at treating physician's discretion)
41095970|NCT03425292|DRUG|5-day Temozolomide|150 mg/m\^2 oral, once daily on Days 1-5 of each 28-day cycle (stepwise titration every cycle up to 200 mg/m\^2 permitted)
40924569|NCT01718418|OTHER|test meal|
40924570|NCT01718418|OTHER|reference|
40924571|NCT04803682|BEHAVIORAL|Preventive Intervention|Participate in ASPIRE and mentorship program
40924572|NCT04803682|BEHAVIORAL|Questionnaire Administration|Ancillary studies (pre and post questionnaire)
40924573|NCT03857347|OTHER|Psychoeducation Group for FND|he intervention is a psychoeducation based group.
40924574|NCT04673123|OTHER|Core stabilization exercises|"In our study, core stabilization exercises to be applied in the intervention group are arranged according to the patients with stroke and will be at three different difficulty levels. Exercises will be done on the back (hooked) and sitting positions where the risk of falling is low. First of all, activation of the transversus abdominis muscle, which is the basis of core stabilization, will be taught to patients. With this activation at the first level, the healthy side, at the second level the affected side, and at the third level, reciprocal upper and lower extremity movements will be requested. In addition to these, there will be exercises to bridge and curl up in supine position, and weight transfer in sitting position. In order to increase the difficulty level of the exercises, first of all, the number of exercises will be increased and then it will be asked to move on to the next level."
40924575|NCT04673123|OTHER|Multifactorial Education Program|The content of this program includes rehabilitation practices that are routinely applied in stroke rehabilitation and that patients will receive at the specified hospital. In the content of these applications; patient-specific upper and lower extremity stretching, and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training are included. he content of multifactorial fall prevention training includes the first brochure titled '' General Recommendations for the Prevention of Fall in Chronic Stroke Patients '', which will include general recommendations for preventing falling according to the fall risk factors specific to the stroke, and the recommendations to minimize the risk of falling in the home. A second brochure titled 'Suggestions for Making Your Home Safer' will be given. The information in these brochures will also be communicated to patients face to face verbally
40924576|NCT06096610|OTHER|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
40924577|NCT02153229|RADIATION|Photodynamic Therapy|
40924578|NCT02153229|PROCEDURE|Radical Pleurectomy|
40924579|NCT02153229|RADIATION|Chemotherapy|
40924580|NCT02153229|DRUG|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
40924581|NCT02527200|DRUG|liraglutide|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
40924582|NCT02527200|DRUG|placebo|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
40924583|NCT02728713|PROCEDURE|Cranial Manipulation|Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
40924584|NCT02728713|PROCEDURE|Sham/Placebo|A laying on of hands with no actual treatment being performed.
40924585|NCT04503187|BEHAVIORAL|Visuomotor leg reaching task|Similar to a hand reaching task in which participants were asked to reach to a tea-cup, in a visuomotor leg reaching task, participants will be seated and given real-time visual feedback about their leg movements via a cursor display on a computer screen. The task is to control a foot mouse/marker attached to the foot and move the cursor from a start location to the target displayed on a wall screen. Three different targets, equidistant from the start location at top, top-left, and top-right screen positions, will be used for leg reaching. In each trial, one of three targets will be randomly presented and subjects will be instructed to make forward, or rightward, or leftward foot reaches to guide the cursor to one of the targets. Throughout the entire experiment, subjects are blocked from viewing leg movements by a cardboard.
40924586|NCT02306031|DRUG|Prescribe ARTIFICIAL TEAR|From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
40924587|NCT02306031|DRUG|Prescribe diclofenac sodium drop 0.1%|From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
40924588|NCT00022347|DRUG|canfosfamide hydrochloride|
40924589|NCT02156245|OTHER|conventional rehabilitation program (including concentric cycle ergometer)|
40924590|NCT02156245|OTHER|cycling included into a conventional rehabilitation program|
40924591|NCT01223443|DEVICE|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
41095971|NCT03425292|DRUG|5-day Temozolomide|100 mg/m\^2 oral, once daily on Days 2-6 of each 6 week course (stepwise titration every cycle up to 200 mg/m\^2 permitted)
41095972|NCT03425292|DRUG|Lomustine|100 mg/m\^2 oral, on Day 1 of each 6 week course
41095973|NCT03425292|DRUG|Nivolumab monotherapy|nivolumab 300 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
41095974|NCT05831280|BEHAVIORAL|Laughter Yoga|"* Warm-up exercises (5 minutes),~* Deep breathing exercises (5 minutes),~* Childlike playfulness (5 minutes),~* Laughter exercises (15 minutes)."
41095975|NCT03054220|DRUG|Dextromethorphan 5 MG|
41095976|NCT03054220|DRUG|Tramadol 10 mg|
41095977|NCT03054220|DRUG|Duloxetine 60mg|
41095978|NCT03054220|DRUG|Paroxetine 20 mg|
41095979|NCT02078934|PROCEDURE|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
41095980|NCT01928940|DRUG|dabrafenib|150 mg twice daily
40924592|NCT06161896|DIAGNOSTIC_TEST|Stool samples|Analysis of microbiome, mutations, alterations in body composition and lifestyle
40924593|NCT02081248|OTHER|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
40924594|NCT02081248|OTHER|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
40924595|NCT01098955|BEHAVIORAL|Acceptance and Commitment Therapy|6 x 60-minute counseling sessions delivered over a 5-week period
40924596|NCT01098955|BEHAVIORAL|Motivational and Behavioral Counseling|6 x 60-minute counseling sessions delivered over a 5-week period
40924597|NCT01098955|DRUG|Varenicline|2 mg daily for 12 weeks
40924598|NCT02168387|DEVICE|continuous high frequency oscillator (CHFO)|
40924599|NCT02168387|DRUG|Acetylcysteine|
40924600|NCT02168387|DRUG|dornase alfa|
40924601|NCT03700684|BEHAVIORAL|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.
40924602|NCT03700684|DEVICE|SpeechVive|Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.
40924603|NCT03700684|BEHAVIORAL|Control|Persons assigned to the non-treatment control group will not participate in voice treatment.
40924604|NCT00515424|DRUG|RKI983|
40924605|NCT00004071|DRUG|leflunomide|
40924606|NCT00004071|DRUG|mitoxantrone hydrochloride|
40924607|NCT00004071|DRUG|prednisone|
40924608|NCT04476173|DRUG|Methoxyflurane - Penthrox|ACS patients who received inhaled methoxyflurane as analgesic treatment
40924609|NCT04476173|DRUG|Morphine|ACS patients who received intravenous morphine as analgesic treatment
40924610|NCT04055428|DRUG|Sacubitril, Valsartan 97-103 mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.
40924611|NCT04055428|DRUG|Valsartan 160 mg|The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.
40924612|NCT04055428|OTHER|Intravenous Glucose Tolerance Test|An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
40924613|NCT04055428|DIETARY_SUPPLEMENT|Standardized Meals|Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.
40924614|NCT04055428|OTHER|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
40924615|NCT03038477|DRUG|Durvalumab|1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
40924616|NCT01675089|DRUG|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
40924617|NCT01654913|DEVICE|hemoglobin measurement|"Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :~* at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),~* with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),~* with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin)."
40924618|NCT03101111|BIOLOGICAL|MV-CHIK|Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose
40924619|NCT03101111|BIOLOGICAL|MMR-vaccine|Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
40924620|NCT04479371|DRUG|Liposomal bupivacaine|Injecting liposomal bupivacaine for a penile block for analgesia for hypospadias repair
40924621|NCT04479371|DRUG|Bupivacaine|Standard bupivacaine
41095981|NCT01928940|DRUG|trametinib|2 mg once daily
41095982|NCT02374957|DRUG|Cilostazol|100 mg twice daily for 90 days
41095983|NCT04792099|PROCEDURE|Continuous positive airway pressure|After study entry, CPAP will be provided via mask or binasal prongs in order to have a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery. A PEEP of 5 will be used for uniformity.
41095984|NCT04792099|PROCEDURE|Nasal Cannula|After study entry, flow will be set to 0.5 L/kg with 1L maximum while on NC during the study period to reduce the risk of inadvertent PEEP with higher flows. Initial FiO2 can be titrated to achieve target saturations, and may be increased up to 100% while on NC.
41133424|NCT05215249|PROCEDURE|Transnasal humidified high-flow oxygen delivery|The Optiflow system consists of an apparatus that is capable of delivering humidified oxygen, room air, or a mixture of variable oxygen concentration. The oxygen concentration can be precisely varied from 21-100% (or 0.21 - 1.00 FiO2). The gas is warmed to 37°C with a 100% relative humidity. The humidified and warmed gas can be delivered to the patient at high-flows (up to 70 L/min) using various delivery mechanisms. The investigators will be using a nasal cannula to deliver high flow oxygen (2-3 L/kg/min) to the patient.
41095985|NCT05246553|PROCEDURE|Electrical stimulation of the vestibular system|Patients are implanted with a modified cochlear implant (CI) which comprises one to three extracochlear electrodes that are placed in the proximity of vestibular afferents (i.e., vestibular nerves or the ampullae of each semicircular canal), and an intracochlear array. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the implanted electrodes (cochlear or vestibular) and modulated via computer-controlled signals, audio signals (captured with a microphone) or by signals captured by head-mounted motion sensors.
41095986|NCT05246553|PROCEDURE|Electrical stimulation of the auditory system|A cochlear implant (CI) is a device providing a sense of sound to a person who suffers from severe to profound sensorineural hearing loss. A CI comprises the following parts, a microphone (capturing the sound from the environment), a speech processor (receiving and encoding the sounds captured by the mircophone), a transmitter-receiver antenna pair (transmitting the information from the external to the implanted components), an implanted stimulator (converting the signal into a tonotopically arranged set of electrical pulses) and an electrode array inserted in the cochlea that will deliver the electrical pulses to different portions of the auditory nerve. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the electrodes in the cochlear array and modulated via computer-controlled signals or audio signals (captured with a microphone).
41095987|NCT05246553|DIAGNOSTIC_TEST|Bilateral vestibulopathy Patients (BV)|Diagnosis established on the basis of the consensus document of the Classification Committee of the Bárány Society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
41095988|NCT05246553|DIAGNOSTIC_TEST|Unilateral vestibulopathy Patients (UV)|Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
41095989|NCT00573703|PROCEDURE|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
41095990|NCT00573703|PROCEDURE|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
41095991|NCT02260739|OTHER|Blood samples|
41095992|NCT06459661|OTHER|Diet|Intake of unrefined, intact plant foods
41095993|NCT05895760|OTHER|Multi-component physical exercise online intervention|"A multicomponent exercise program was implemented consisting of a combined program of endurance, strength, coordination, balance, and flexibility exercises depending on the level of functional capacity.~Three types of physical exercise programs were designed according to the physical performance level of each participant. The first type of exercise program training was performed for frail adults with an SPPB score of 4 to 6, the second was for the pre-frail adults with an SPPB score of 7 to 9 and the third for robust adults with an SPPB of 10 to 12."
41095994|NCT00000106|DEVICE|Whole body hyperthermia unit|
41095995|NCT00415675|PROCEDURE|Motion CT Scans|A total of up to 12 scanning sessions used to understand how the tumor and other organs move while breathing.
41095996|NCT03137914|BIOLOGICAL|Autologous chondrocyte transplantation|intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid
41095997|NCT03137914|PROCEDURE|orthognathic surgery|Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
41095998|NCT06099561|BEHAVIORAL|National specialized medical care unit for severe self-harm behaviour-Consultation model|Extensive assessments. Consultation and training for existing treatment providers and caregivers. Network-meetings for providers and caregivers.
41095999|NCT04303117|DRUG|NHS-IL12|An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.
41096000|NCT04303117|DRUG|M7824|1200 mg administered IV every two weeks while on NHS-IL12.
41096001|NCT01961557|DEVICE|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
41096002|NCT04215198|DIETARY_SUPPLEMENT|Move3™ (NEM® brand eggshell membrane + KD PUR® brand fish oil)|Dietary supplement combination for the support of joint health.
41096003|NCT04215198|DIETARY_SUPPLEMENT|Placebo|Placebo
41096004|NCT04716803|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
41096005|NCT04716803|DEVICE|Angel Concentrated Platelet Rich Plasma (cPRP) System|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
41443058|NCT04814095|BEHAVIORAL|QOL|QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +/- 2 weeks
41443059|NCT04814095|DIAGNOSTIC_TEST|CT imaging|CT radiographic imaging every 12 weeks +/- 2 weeks
40924622|NCT00370045|DRUG|Bivalirudin with and without eptifibatide|
40924623|NCT00445237|DEVICE|H1 and H2 deep TMS coils|
41096006|NCT00317655|DRUG|Glucosamine sulphate|
41443060|NCT02906540|PROCEDURE|Transpubic symphysis reset therapy group|The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
41443061|NCT02906540|PROCEDURE|Physiotherapy group|The patients in the control group will undergo physiotherapy and a sham treatment.
41443062|NCT05138003|DIAGNOSTIC_TEST|cardiac MRI|"T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed.~Cardiac ventricular volumes, function and LV mass will also be quantified."
41443063|NCT05138003|DIAGNOSTIC_TEST|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.
41096007|NCT00317655|DRUG|Ginger|
41096008|NCT00317655|DRUG|Ginger-Avocado-Soya|
41096009|NCT00317655|DRUG|Ginger-ibuprofen|
41096010|NCT06250075|DIETARY_SUPPLEMENT|Formulation with probiotics|Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)
41096011|NCT06250075|OTHER|Non-intervention for Clinical Outcomes -G5|only observation of clinical outcomes in the postoperative period
41096012|NCT05258006|PROCEDURE|Autogenous demineralized dentin nanoparticles|Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect
41096013|NCT04630457|DEVICE|Conventional ankle prosthesis|At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.
41096014|NCT04630457|DEVICE|Meridium® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.
41096015|NCT04630457|DEVICE|RoFT® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.
41096016|NCT04281264|BEHAVIORAL|Passive Hypoxia|During 30 minutes of session, the participants will perform an intellectual activity while they will be exposed to normobaric hypoxic conditions in a hypoxic chamber (CAT 310, Lousiville, Colorado). They will inspire oxygen fraction (FiO2) set to 16.1% (0.16)
41096017|NCT04281264|BEHAVIORAL|Normoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
41096018|NCT04281264|BEHAVIORAL|Hypoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
41096019|NCT04281264|BEHAVIORAL|Normoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performed on platform.~Subjects will inspire FiO2 of 21.0% (0.21)"
41096020|NCT04281264|BEHAVIORAL|Hypoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performance on the platform.~Participants will inspire a fraction of inspired oxygen (FiO2) of 16.1% (0.16)"
41096021|NCT06094543|BEHAVIORAL|Patient Engagement Tool|8 week daily patient education and engagement tool
41096022|NCT01119703|BIOLOGICAL|Tetanus & Diphtheria booster vaccine (Td)|Tetanus \& Diphtheria booster vaccine (Td), single intramuscular dose
41096023|NCT01119703|BIOLOGICAL|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM \[Hepatitis A Inactivated \& Hepatitis B (Recombinant) Vaccine\], intramuscular, two doses of standard three dose regimen (opposite arms)
41096024|NCT01119703|BIOLOGICAL|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
41096025|NCT03531905|DRUG|Bempedoic acid + Ezetimibe FDC Oral Tablet|Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
41096026|NCT03531905|DRUG|Ezetimibe 10 mg Oral Tablet|Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
41096027|NCT03531905|DRUG|Placebo Oral Tablet|Placebo tablet, matched for the FDC product for blinding purposes
41096028|NCT03531905|DRUG|Placebo oral capsule|Placebo over-encapsulated for blinding purposes
41096029|NCT02680093|OTHER|Cervical length in pregnant women.|"Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes."
41096030|NCT06281821|BEHAVIORAL|mhealth-pc|Participants meet with an interventionist who explains the rationale for the mobile app. They complete video and survey-based intervention content each week for 8 weeks. App-based sessions are supplemented with brief chat-based coaching weekly.
41096031|NCT01250002|DRUG|Placebo|Placebo will receive the same volume of saline infusion.
41096032|NCT01250002|DRUG|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
41096033|NCT01368120|DEVICE|IV Clear™ Dressing|Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
41096034|NCT01368120|DEVICE|Tegaderm CHG™|Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
41096035|NCT01368120|DEVICE|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
41096036|NCT00286689|DRUG|Growth Hormone|
41096037|NCT00286689|PROCEDURE|Whole body Protein turnover|
41096038|NCT00286689|PROCEDURE|DEXA scan|
41096039|NCT02540213|DEVICE|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
41096040|NCT06161064|DRUG|Hyaluronic acid|hyaluronic acid is temporary material using for augmentation of vocal folds in patients with glottal insufficiency
41096041|NCT06632145|OTHER|Cog Fun Ageing intervention|Cog Fun Ageing is a group-based occupation-centered intervention aimed at promoting positive occupational experiences despite cognitive challenges in day to day life. The intervention includes 14 weekly 120-minute group sessions led by experienced occupational therapists. Sessions incorporate learning about the bio-psycho-social factors of SCD and strategies to manage and cope with occupational challenges resulting from SCD.
41096042|NCT03038256|DRUG|concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
41096043|NCT03038256|DRUG|concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
41096044|NCT06628791|DIETARY_SUPPLEMENT|BK329|Lactococcus lactics. subsp. lactis CAB701(KCCM13360P) 400 mg/day for 12 weeks
41096045|NCT06628791|DIETARY_SUPPLEMENT|Placebo|Placebo 400 mg/day for 12 weeks
41096046|NCT00005890|DRUG|corticotropin|
41096047|NCT02272517|DRUG|Vortioxetine 10-20 mg|
41096048|NCT02272517|DRUG|Escitalopram 10-20 mg|
41096049|NCT02509390|PROCEDURE|Blood samples|Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
41096050|NCT02588482|DEVICE|high-density electroencephalography|Auditory stimulations during electroencephalography recording
41096051|NCT02588482|DEVICE|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
41096052|NCT06366074|DEVICE|Watch-TEA group|"Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance."
41096053|NCT06366074|DEVICE|Tethered TEA device|"Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance."
41096054|NCT03416218|BEHAVIORAL|Prognosis|Prognosis will be a single-player 2D, digital simulation game and supporting multimedia website. Players are situated as a major official of Hexacago, and tasks them with managing the city's finances, education levels, and health concerns to lower rates of teenage pregnancy and sexually transmitted infections. In the game Prognosis, player dispatches professionals from a variety of fields to different neighborhoods around the city, observing the effects of their resource allocation decisions across multiple systems over many in-game months. The supporting multimedia website will house curriculum and learning tools to support the learning objectives of Prognosis.
40924627|NCT01264575|DRUG|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
40924628|NCT01264575|DRUG|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
40924629|NCT01264575|DRUG|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
40924630|NCT01264575|DRUG|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
40924631|NCT01264575|DRUG|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
40924632|NCT01264575|DRUG|intrathecal bupivacaine 11 mg with epinephrine 100 mcg|intrathecal bupivacaine 11 mg with epinephrine 100 mcg
40924633|NCT01264575|DRUG|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
40924634|NCT01264575|DRUG|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
41096055|NCT01564875|DRUG|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
41096056|NCT01564875|DRUG|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
41096057|NCT02744079|BEHAVIORAL|Low carbohydrate diet|45 subjects will be randomized to a dietary arm consisting of a complete, prepared very low carbohydrate diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal
41096058|NCT02744079|BEHAVIORAL|Low fat diet|20 subjects will be randomized to a dietary arm consisting of a complete, prepared low fat diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal.
40924635|NCT01264575|DRUG|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
40924636|NCT01264575|DRUG|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
40924637|NCT01264575|DRUG|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
40924638|NCT01264575|DRUG|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
40924639|NCT02086643|PROCEDURE|Retroclavicular block|Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
40924640|NCT06081088|OTHER|Graded Motor Imagery (GMI) training|"GMI consists of three basic components:~1. Left / Right Discrimination training (Lateralization training): For lateralization training, patients will be trained by asking them to distinguish between right and left with images taken at various angles and positions in the RecogniseTM (NOI-Australia) applications (shoulder and hand sections) (In weeks 1 and 2).~2. Motor Imagery (Explicit Motor Imagery): At this stage, the participant will be asked to imagine doing various functional activities (brushing teeth, combing hair, etc.) in the position they feel most comfortable in and in a quiet environment (In weeks 2 and 3).~3. Mirror Therapy (providing visual feedback through a mirror): In this phase, active ROM exercises and progressive resistance exercises with simultaneous movement of the affected and unaffected extremities will be applied using a standard size posture mirror (In weeks 3-6).~This program will be applied for 6 weeks (3 sessions per week)."
40924641|NCT06081088|OTHER|Conventional Physiotherapy|Conventional physiotherapy program includes passive, active-assistive (wand exercises) and active ROM exercises for shoulder joint, passive / active posterior and anterior capsule stretching exercises, superior-inferior, mediolateral and distraction techniques for scapular mobilization exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, static and dynamic stabilization exercises for proprioception exercises. To reduce the pain that may occur after exercises, cold application and Transcutaneous Electrical Nerve Stimulation (TENS) will be applied to benefit from their analgesic effects. Cold application will be applied around the shoulder using a coldpack (gel pack) cold therapy for 15 minutes. Conventional TENS application around shoulder will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes for 15 minutes.This program will be applied for 6 weeks (3 sessions per week).
40924642|NCT06081088|OTHER|Home Exercise Program|The home exercises program includes shoulder jonit active ROM exercises, active posterior and anterior shoulder capsule stretching exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, shoulder proprioception exercises, and cold therapy. This program will be applied for 6 weeks (3 sessions per week).
40924643|NCT03753581|DEVICE|Care protocol plus microcurrents|"CARE NURSING PROTOCOL: postural treatment every 4 hours more standardized cure according to the guide of recommendations based on evidence in prevention and treatment of pressure ulcers in adults of Osakidetza health service.~MICROCURRENTS: the electrodes will be placed on the edge of the dressing on the sides of the ulcer's longer length during 12 hours a day until the ulcer is completely healed or for a maximum of 25 days.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.5 s and pause of 300 ms, voltage 21 mV and intensity 42μA with a current density of 4.2 μA."
40924644|NCT03753581|DEVICE|Care protocol plus placebo microcurrents|The same nursing care protocol described for the experimental group will be applied more 12 hours per day of 2 electrodes of microcurrents around the ulcer, which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
40924645|NCT01555385|DIETARY_SUPPLEMENT|Breakfast juice|single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
40924646|NCT01143389|DRUG|Riboflavin|Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
40924647|NCT01143389|DEVICE|UVX light|UVX 365 nm wavelength light source is applied with continued application of riboflavin.
40924648|NCT01012648|DRUG|Fluid resuscitation|Volume resuscitation
40924649|NCT01012648|DRUG|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
40924650|NCT00204438|DRUG|0.15mg desogestrel /0.03mg ethinyl estradiol|
40924651|NCT05133960|OTHER|Questionnaire assessment|Validity and reliability of the Turkish Version of the Activity Diversity Questionnaire
40924652|NCT01910311|DRUG|Baricitinib|Administered orally
40924653|NCT01910311|DRUG|Rifampicin|Administered orally
40924654|NCT01376440|OTHER|household water treatment|household water treatment with 1.25% sodium hypochlorite
40924655|NCT01789918|DEVICE|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
40924656|NCT01315821|DRUG|Saccharomyces boulardii|5 million units/day for 3 months
40924657|NCT01315821|DRUG|Placebo|Placebo for 3 months
40924658|NCT01286961|DRUG|bowel preparation using split dose of polyethylene glycol|polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
40924659|NCT02015221|DEVICE|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
40924660|NCT02015221|DEVICE|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
40924661|NCT02122601|DRUG|LBSA0103 (BDDE cross-linked sodium hyaluronate gel)|
40924662|NCT00960583|OTHER|Exercise program|24 group exercise sessions during 12 weeks
40924663|NCT00960583|OTHER|Routine follow-up|Advice to stay active
40924664|NCT04473235|BEHAVIORAL|Literacy training|Teaching adults how to read and write using the analytical and phonemic method
40924665|NCT04473235|BEHAVIORAL|Non-Literacy training|Attending classes in geography, history, sciences, without receiving the specific training in literacy
40924666|NCT00075270|DRUG|Paclitaxel|Active Comparator
40924667|NCT00075270|DRUG|GW572016 (Lapatinib)|Oral GW572016 Lapatinib
41133425|NCT00779194|DRUG|Rapamycin|Rapamycin, is given to this group at a starting dose of 2 mg/day.
41096059|NCT05909943|DRUG|Ruxolitinib|Treatment with ruxolitinib will be initiated in an initial dose regimen of 5-10 mg twice daily. Two months later, the dose of ruxolitinib will be increased to 10-15 mg twice daily.
41096060|NCT06460363|DEVICE|Transcranial alternating current stimulation (TACS)|Transcranial alternating sinusoidal current at frequency of 40 Hz applied for 60 min through a pair of saline-soaked surface sponge electrodes.
41096061|NCT06460363|DEVICE|Sham TACS|Sham treatment with few seconds of actual electrical current and same electrode configuration
41096062|NCT04863105|DRUG|Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)|"Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
41096063|NCT01700569|DRUG|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
41096064|NCT01700569|DRUG|folinic acid at pharmacological dose is the escalated drug|
41096065|NCT01700569|RADIATION|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
41270693|NCT06195202|DRUG|AIs|Patients with AIs
41270694|NCT06195202|DRUG|OFS+AIs|Patients with OFS+AIs
40924668|NCT01843647|DRUG|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
40924669|NCT01843647|DRUG|Chemotherapy|"After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression."
40924670|NCT02073383|PROCEDURE|Axillary brachial plexus block|
40924671|NCT05795478|DRUG|Oxycodone and Pregabalin|Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1\~7,75mg QD for POD8\~14
40924672|NCT05795478|DRUG|Oxycodone and placebo capsules|Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point
40924673|NCT05795478|DRUG|Pregabalin and NS|Pregabalin: 150mg preoperatively, 75mg BID for POD1\~7,75mg QD for POD8\~14 NS: Equal volume NS for 3 days postoperatively
40924674|NCT05795478|DRUG|placebo capsules and NS|placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively
40924675|NCT03997578|PROCEDURE|NIPSA (Non-incised papilla surgical approach)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the regenerative biomaterials will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
40924676|NCT03997578|PROCEDURE|NIPSA plus connective tissue graft|In these patients, the following methodology will be added to the technique described for the NIPSA group: once the biomaterials are applied, a connective tissue graft, taken at the level of the first upper molar, will be sutured to the base of the soft supra-alveolar tissue and to the palatal tissue, which has not been disinserted, using simple sutures.
40924677|NCT06097221|BEHAVIORAL|CRT-Advance|Psychotherapy with focus on advancing sleep timing, using diaries on sleep and zeitgebers.
40924678|NCT06097221|BEHAVIORAL|Treatment as usual|Treatment as usual in the outpatient psychiatric unit.
40924679|NCT05647278|DRUG|Tegoprazan|Tegoprazan 50 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.
40924680|NCT05647278|DRUG|Esomeprazole|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
40924681|NCT01690897|BEHAVIORAL|Mindfulness-based treatment|The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
40924682|NCT01690897|BEHAVIORAL|Sex therapy, education, and support treatment|The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
40924683|NCT01845623|DRUG|QAB149 75 mg Concept 1|QAB149 delivered via the concept 1 device.
40924684|NCT01845623|DRUG|QAB149 75 mg Epic Test Fixture|QAB149 delivered via the EPIC test fixture
40924685|NCT01845623|OTHER|Placebo Concept 1|Placebo administered via the Concept 1 device.
40924686|NCT01845623|OTHER|Placebo EPIC Test Fixture|Placebo administered via the EPIC Test Fixture.
40924687|NCT03861494|BEHAVIORAL|Enhanced Stroke Education|In addition to the general stroke education materials and verbal education, the enhanced stroke education group will receive a personalized verbal and written information addressing the patient's specific risk factors including their current status and goals, laboratory values and goals, and current blood pressure and goal. Specific stroke type and etiology is discussed, medication including indication, dose, frequency, physical activity goals, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, and education over the importance of keeping follow up appointments including Stroke Clinic. Verbal feedback of key points is encouraged.
41096066|NCT05014724|DRUG|Rozanolixizumab|Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.
41096067|NCT05343884|RADIATION|Myocardial perfusion imaging|Myocardial perfusion imaging
41096068|NCT01597128|DEVICE|Flex HD|Flex HD mesh for hernia repair
41096069|NCT01597128|DEVICE|Strattice|Strattice mesh for hernia repair
41096070|NCT03318120|BEHAVIORAL|Progressive Resistance Training|Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
41096071|NCT02999217|DRUG|Iron isomaltoside|"Intravenous injection 1 g given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
41096072|NCT02999217|DRUG|Saline|"Intravenous injection given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
41096073|NCT00142766|BEHAVIORAL|Nurse Implemented Goal-Directed Comfort Algorithm|See description
41096074|NCT05657912|DEVICE|ECG monitoring|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
41096075|NCT01385865|DIETARY_SUPPLEMENT|Mulberry leaf extract|18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
41096076|NCT01385865|DIETARY_SUPPLEMENT|Placebo|18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
41096077|NCT02943655|DRUG|combined contraceptive pills (microcept)|oral combined contraceptive once daily
41096078|NCT02943655|DRUG|medroxyprogesterone acetate (progest)|oral 5 mg medroxyprogesterone acetate daily
41096079|NCT02943655|DRUG|mefenamic acid (ponstan forte)|oral 500 mg mefenamic acid three times per day
41096080|NCT01626274|DEVICE|LAVIMO in- ear sensor system|Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night
41096081|NCT03007459|OTHER|Psychological health|Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period
41096082|NCT03007459|OTHER|Physiological health|Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
41096083|NCT00090272|DRUG|MK0826, ertapenem sodium|
41096084|NCT00090272|DRUG|Comparator: cefotetan|
41096085|NCT02054247|DEVICE|ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions
41096086|NCT02054247|DEVICE|pulsed ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
41096087|NCT02054247|DEVICE|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
41096088|NCT05349877|BEHAVIORAL|Expressive writing|Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.
41096089|NCT05349877|BEHAVIORAL|Self-affirmation|Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.
41096090|NCT05349877|BEHAVIORAL|Placebo|Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.
41096091|NCT01756287|OTHER|Chinese ocular exercise|A kind of massage around the acupuncture points around the eye.
41096092|NCT00363285|BIOLOGICAL|gonadotrophin releasing hormone|
41096093|NCT00363285|DRUG|cyproterone acetate|
41096094|NCT00363285|PROCEDURE|quality-of-life assessment|
41096095|NCT04945694|OTHER|Ultrasound-guided bilateral pecto-intercostal fascial block|- PATIENT IN SUPINE POSITION, SKIN WILL BE DISINFECTED, A HIGH-FREQUENCY LINEAR PROBE WILL BE PLACED PARALLEL TO LONGITUDINAL AXIS OF STERNUM ON LATERAL BORDER AND SCANNED LATERALLY TO IDENTIFY 4TH AND 5TH COSTAL CARTILAGE. THE PECTORALIS MAJOR MUSCLE (PMM), INTERNAL INTERCOSTAL MUSCLE (IIM), TRANSVERSUS THORACIS MUSCLE (TTM), RIBS, AND PLEURA WILL BE IDENTIFIED. COLOR DOPPLER ULTRASONOGRAPHY WILL BE USED TO DETERMINE PERFORATING BRANCHES OF INTERNAL THORACIC ARTERY, WHICH TRAVEL ANTERIORLY THROUGH THE ANTERIOR CHEST WALL, PIERCING THE INTERCOSTAL MUSCLE AND PMM. A 22G NEEDLE WILL BE INSERTED IN PLANE WITH PROBE, IN CAUDAL-TO-CRANIAL DIRECTION UNTIL THE TIP IS POSITIONED IN INTER- FASCIAL PLANE BETWEEN THE PMM AND IIM. NORMAL SALINE WILL BE USED TO DETERMINE CORRECT PLACEMENT OF NEEDLE TIP IN INTER-FASCIAL PLANE, AS SHOWN BY SEPARATION OF FASCIAL LAYERS THEN LOCAL ANESTHETIC WILL BE INJECTED
41096096|NCT04945694|DRUG|Intravenous fentanyl|In this group, patients will receive only incremental doses of intravenous fentanyl
41270695|NCT06195202|DRUG|FUL|Patients with FUL
41096097|NCT04945694|DRUG|Propofol|Propofol anesthesia
41096098|NCT04945694|DRUG|Sevoflurane|Sevoflurane anesthesia
41096099|NCT04945694|DRUG|Atracurium|Intravenous atracurium
41096100|NCT04945694|DEVICE|ultrasound|ultrasound-guided block
41270696|NCT01596257|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
41270697|NCT01596257|DEVICE|CliniMACS|
41096101|NCT03634189|DRUG|Cannabidiol|Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
41096102|NCT02416635|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
41096103|NCT02416635|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
41096104|NCT06224270|BIOLOGICAL|Adjuvanted Recombinant Zoster Vaccine (RZV)|The RZV vaccine is indicated for prevention of herpes zoster (HZ) in adults aged 18 years and older who are or will be at increased risk of HZ. Patients with IBD on immunosuppressive therapy are at increased risk for HZ.
41096105|NCT04139694|DIETARY_SUPPLEMENT|Food plan with cinnamon supplementation|cinnamon twice daily plus follow Cardiometabolic diet
41096106|NCT04139694|BEHAVIORAL|Food plan without cinnamon supplementation|Cardiometabolic diet only
41096107|NCT00539903|BEHAVIORAL|Physical activity (PA) and immigrants|
41096108|NCT00753987|DRUG|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
41096109|NCT05779722|DEVICE|Vapor barrier|Vapor barrier
41096110|NCT04068545|DEVICE|Device: Thoraguard Surgical Drainage System|Fluid drainage following thoracic surgery
41096111|NCT02322216|DRUG|Olopatadine Hydrochloride Ophthalmic Solution 0.2%|
41096112|NCT02322216|DRUG|Olopatadine Hydrochloride Ophthalmic Solution 0.1%|
41096113|NCT02322216|DRUG|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
41096114|NCT06125678|DIAGNOSTIC_TEST|Small intestinal contrast enhanced ultrasound followed by Computed tomography/Magnetic resonance enterography|First small intestinal contrast enhanced ultrasound shall be done followed by CT enterography or MR enterography
41096115|NCT02735915|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
41096116|NCT06607913|OTHER|Exercise|The participants will exercise 2 days a week for 16 weeks. The exercises will include 4 movements: squats, shoulder press, seated row, and bicep curl focusing on internal load and contraction velocity.
41096117|NCT03572413|PROCEDURE|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
41096118|NCT03572413|DRUG|Rocuronium bromide|Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
41096119|NCT04133363|PROCEDURE|Ridge preservation using L-PRF/FDBA layered technique|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
41096120|NCT04133363|PROCEDURE|Ridge preservation using L-PRF/FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
41096121|NCT04133363|PROCEDURE|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF
41096122|NCT03699735|DEVICE|Bolero B90-SP|Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
41096123|NCT05394402|DRUG|SHR0410 Injection|SHR0410 Injection
41096124|NCT05394402|DRUG|Placebo for SHR0410 Injection|SHR0410 Injection blank preparation
41096125|NCT02248142|DRUG|Pramipexole|
41096126|NCT00286741|OTHER|Diabetes Group Management Visits|Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medication management by a physician and pharmacist.
41096127|NCT05482386|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
41096128|NCT02888613|PROCEDURE|mini laparotomy|The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
41096129|NCT02888613|PROCEDURE|mini lumbotomy|"After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).~Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft."
41270698|NCT00158184|DRUG|oxycodone 15 mg|15 mg/70 kg oxycodone administered once per day, orally.
41096130|NCT06357572|DIAGNOSTIC_TEST|Thrombin generation assay (EnzySystem HemA version A - whole blood)|Whole blood obtained by venipuncture is immediately tested with the EnzySystem HemA version A), before and 0, 30, 120 and 240 minutes after administration of FEIBA.
41096131|NCT06357572|DIAGNOSTIC_TEST|Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma)|Whole blood is centrifuged to obtain plasma. The fresh plasma is tested using the Ceveron s100.
41096132|NCT06357572|DIAGNOSTIC_TEST|Additional coagulation tests|"Plasma samples are frozen for later coagulation testing. The following tests are performed:~Factor VIII activity von Willebrand Factor antigen levels von Willebrand Factor ristocetin activity levels Prothrombin Fragment 1+2 levels ADAMTS13 activity FVIII antigen levels Nijmegen Hemostasis Assay"
41096133|NCT02756104|OTHER|phenotyping Tcells|Collecting blood for analyses of the T cells phenotypes
41096134|NCT02756104|OTHER|Supplementation in vitamin D|Supplementation in vitamin D for the patients who are deficient on vitamin D
41096135|NCT00926393|DRUG|Quetiapine Immediate Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
41096136|NCT00926393|DRUG|Quetiapine Extended Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
41096137|NCT03980964|DEVICE|Active NMES|Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
41096138|NCT04668183|PROCEDURE|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
41096139|NCT04668183|PROCEDURE|Dorsal penile nerve block group|Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
41096140|NCT00360126|DRUG|lamotrigine|
41096141|NCT01701154|OTHER|respiratory muscle strength training|
41096142|NCT04518930|OTHER|Peanuts or plain Greek yogurt|Two different types of dietary snacks
41096143|NCT05931198|OTHER|Modified illusion of the rubber (syncrhone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis at the same time (synchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
41096144|NCT05931198|OTHER|Modified illusion of the rubber (asynchrone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis not at the same time (asynchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
41096145|NCT00586274|PROCEDURE|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
41096146|NCT00586274|DRUG|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m\^2
41096147|NCT00586274|BIOLOGICAL|T cell infusion|"At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are \> 1000/ul.~Dose level -1 (1 x 10\^3 T cells/Kg); Dose level 1 (1 x 10\^4 T cells/Kg); Dose level 2 (1 x 10\^5 T cells/Kg); Dose level 3 (1 x 10\^6 T cells/Kg); Dose level 4 (5 x 10\^6 T cells/Kg)"
41096148|NCT00586274|BIOLOGICAL|Campath 1h|10 mg iv over 4 hours day-8 through day-6
41096149|NCT00586274|BIOLOGICAL|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
41096150|NCT04836793|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected
41096151|NCT01760044|DEVICE|Tissue oxygenation monitoring|The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
41096152|NCT01353482|DRUG|Cisplatin|Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
41096153|NCT01353482|DRUG|Pemetrexed|Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
41096154|NCT01353482|DRUG|Vorinostat|The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.
41096155|NCT01353482|DRUG|Placebo|Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
41096156|NCT02714829|DEVICE|Inject BMP|Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.
41096157|NCT02714829|DEVICE|ExcelOS-inject|Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
41096158|NCT06390592|DEVICE|PD cycler|"Patients are treated continuously during Peritoneal dialysis with the PD cycler sleep•safe harmony with different FlexPoint settings.~According to their randomization the patients are treated with Treatment A, B or C in a different order:~* standard (default) FlexPoint settings (Treatment A)~* minimum value FlexPoint settings (Treatment B)~* maximum value for permitted peritoneal residual volume (50%) of FlexPoint settings (Treatment C)"
41096159|NCT00312078|DIETARY_SUPPLEMENT|Yogurt Supplementation|
40924688|NCT03861494|BEHAVIORAL|Usual Stroke Education|The usual stroke education group will receive general stroke education including written and verbal information about signs and symptoms of stroke, best practice to engage medical treatment if stroke occurs, general information about heart healthy diet and need for daily physical activity as well as need for compliance with medication recommendations. The education is incorporated with routine patient care and as allowed during quiet times. On the day of discharge, the patient will receive written materials reviewing stroke symptoms, risk factors, heart healthy diet and follow up appointments. The patient will receive written and verbal information about medications including indication, dose, frequency, physical activity goal, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, the importance of keeping follow up appointments including Stroke Clinic.
41096160|NCT00823979|DRUG|UK-453,061 Dose 1|UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
41096161|NCT00823979|DRUG|UK-453,061 Dose 2|UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
41096162|NCT00823979|DRUG|Etravirine|Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
41096163|NCT00515840|OTHER|Physiotherapist|Physiotherapist administered breathing retraining programme
41096164|NCT02824432|DRUG|TAK-085|TAK-085 capsules
41096165|NCT03093610|PROCEDURE|Traditional|Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
41096166|NCT03093610|PROCEDURE|Test|Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
41096167|NCT06494124|DEVICE|transcranial Alternating current stimulation (tACS)|It is a non-invasive brain stimulation technique that uses small, pulsed alternating current (1mA) to modulate lasting cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviours, with proven efficacy in various neuropsychiatric disorders.
41096168|NCT06494124|DEVICE|transcranial Direct current stimulation (tDCS)|It is a non-invasive brain stimulation technique that uses constant, low direct current to modulate lasting cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviours, with proven efficacy in various neuropsychiatric disorders.
41096169|NCT06494124|DEVICE|Sham controlled|1mA current will be applied for the first 30 seconds to provide the initial sensation of real stimulation, and then the current will be stopped, thus minimizing the stimulatory effects. It is known to have no effect on psychopathology/neuro-cognition and means to mimic the tDCS/tACS (in order to help blinding of the participants).
41096170|NCT04831580|DEVICE|da Vinci|Minimally invasive robotic-assisted radical or simple hysterectomy
41096171|NCT04831580|OTHER|open surgery|open radical or simple hysterectomy
41096172|NCT00469118|DEVICE|DRX9000™|Nonsurgical spinal decompression
41096173|NCT05349864|DRUG|PF-07284890 Treatment A|PF-07284890 tablet by mouth while fasting
41096174|NCT05349864|DRUG|PF-07284890 Treatment B|PF-07284890 tablet after low fat meal
41096175|NCT05349864|DRUG|PF-07284890 Treatment C|PF-07284890 tablet after high fat meal
41096176|NCT01567059|DRUG|tosedostat|Given PO
41096177|NCT01567059|DRUG|cytarabine|Given IV
41096178|NCT01567059|DRUG|decitabine|Given IV
41096179|NCT02710968|DEVICE|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
41096180|NCT06177795|BEHAVIORAL|Post-visit patient text messaging|Patients will be sent text message reminders 4 days and 14 days after their primary care visit. The message delivered 4-days post-visit will remind the patient that a screening mammogram was recently ordered by their doctor, that appointments have been reserved for them, and to pre-commit to scheduling. The message delivered at 14-days post-visit will remind the patient of their recent screening mammogram order and encourage them to schedule their appointment, if one has not already been scheduled.
41096181|NCT06177795|BEHAVIORAL|Default pended order|A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
41443064|NCT05138003|DIAGNOSTIC_TEST|RootiRx for the ECG monitoring during the cycling ride|The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate \> 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
40924689|NCT05401396|OTHER|Swimming immediately after eating|After having the last bite of lunch, the participants will swim in the pool with a specific distance.
40924690|NCT05579951|PROCEDURE|Patient specific instrumentation|Total knee replacement with patient specific instrumentation
40924691|NCT05579951|PROCEDURE|Conventional|Total knee replacement with conventional instrumentation
40924692|NCT05579951|DEVICE|Patient specific instrumentation|Medacta GMK Sphere MyKnee Patient specific Instrumentation
40924693|NCT01982968|PROCEDURE|Surgery|Full fundoplication surgery for the treatment of abnormal GER
40924694|NCT05711446|OTHER|Double Voiding|Participant will be instructed to void twice.
40924695|NCT05711446|OTHER|Regular Voiding|Participant will void as usual
40924696|NCT05384951|DIETARY_SUPPLEMENT|HMB + Vitamin D3|The supplement will be taken orally twice daily. Participants will take 2 blended HMB + Vitamin D3 tablets in the morning and 2 tablets in the evening for 12 weeks.
40924697|NCT04430075|DEVICE|Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System|Transcatheter Valve Repair with Edwards PASCAL and PASCAL Precision System
40924698|NCT00868517|OTHER|True group auricular acupuncture|Received true group auricular acupuncture
40924699|NCT00868517|OTHER|Sham group auricular acupuncture|Received sham auricular acupuncture.
40924700|NCT00868517|OTHER|Wait-List Control Group|Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
40924701|NCT05977881|OTHER|CHECKIT!|"Participants will not be assigned to the intervention as it will be available to everyone.~Check it will be a van-based HIV- and overdose-prevention program offered in the four areas of Baltimore city from which study participants are recruited. Intervention services will include point-of-care drug checking and PrEP assessment, prescription, and management, and they will be available to everyone, regardless of whether they are part of the SCOPE study cohort or not.~Individual-level service usage data collected by intervention staff will not be considered in analysis of outcomes. However, study participants will self-report Check it utilization on the internally-developed surveys at 6, 12, and 18 months."
40924702|NCT00773227|PROCEDURE|Autologous myoblasts transplantation and myotomy|Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
40924703|NCT02980952|OTHER|High-fat overfeeding|
40924704|NCT02980952|OTHER|Forearm immobilization|
40924705|NCT06516835|OTHER|Enteral fluid|GNAK will be administered to the gastrointestinal tract with EN in the same volume.
40924706|NCT06516835|OTHER|Intravenous fluid|Undiluted EN will be given to the gastrointestinal tract. GNAK, in the same volume, will be administered intravenously.
40924707|NCT02171910|DRUG|Doxapram|
41096182|NCT06177795|BEHAVIORAL|High risk bidirectional post-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component after their visit. This intervention will query the patient about common questions or concerns about breast cancer screening. The bi-directional text messaging intervention will provide additional educational materials based on patient response as well as information about resources to help navigate to screening.
41096183|NCT05687500|DRUG|Glibenclamide|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
41270699|NCT00158184|DRUG|oxycodone 30 mg|30 mg/70 kg oxycodone administered once per day, orally.
41453293|NCT05621252|DRUG|Placebo|Matching placebo
40924708|NCT02171910|DRUG|Placebo|An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
40924709|NCT02437123|BEHAVIORAL|The Cedar Project mHealth intervention|
40924710|NCT04811300|OTHER|There is no intervention|There is no intervention
40924711|NCT05478629|OTHER|Survey|Questioning through google forms
40924712|NCT04337710|PROCEDURE|Exclusive Enteral Nutrition|Mom's milk or donor milk at 60-80 ml/kg/day after randomization within the first 24 hours.
40924713|NCT04337710|PROCEDURE|Progressive Enteral Nutrition|Mom's milk or donor milk at 20-30 ml/kg/day after randomization within the first 24 hours.
40924714|NCT02331160|BEHAVIORAL|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
41453294|NCT00422253|BEHAVIORAL|dietary intervention|
41096184|NCT05687500|BIOLOGICAL|Pharmacokinetics study|"0.2 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.~PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant ,apparent clearance and volume of distribution"
41096185|NCT05687500|BIOLOGICAL|C-peptide proinsulin ratio|blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio
41096186|NCT05687500|BIOLOGICAL|Blood glucose on fluorinated tube|0.3 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.
41096187|NCT05687500|BIOLOGICAL|Routine biological monitoring|If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.
41096188|NCT05687500|BIOLOGICAL|glycose holter monitor|glucose levels will be collected with a smarter continuous glucose monitoring system, placed on inclusion and until the end of treatment
41096189|NCT06631820|DIETARY_SUPPLEMENT|Epicatechin extract|In the experimental phase, patients will take 50 mg of (-)- Epicatechin twice a day for 8 weeks (total dose 100mg/day). The nutraceutical will be supplied as monodose sachets from Aayam Therapeutics.Study participants will mix the sachet powder with juice (10-20mL) in the morning 15 minutes before breakfast and in the evening 15 minutes before sleeping or 1h after dinner.
41096190|NCT06098027|DRUG|[14C]CS0159|Single oral administration of 4mg \[14C\]CS0159
41096191|NCT00697892|DRUG|lopinavir/ritonavir|Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
41096192|NCT00697892|DRUG|efavirenz|One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
41096193|NCT00697892|DRUG|artemether/lumefantrine|4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
41096194|NCT02922972|DEVICE|Autologous Platelet Rich Plasma obtained with RegenKit®-BCT|After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
41096195|NCT02071511|PROCEDURE|Ablation of ventricular arrhythmias|control group: Ablation of ventricular arrhythmias
41096196|NCT02071511|PROCEDURE|Ablation of ventricular arrhythmias + renal denervation|Intervention group: Ablation of ventricular arrhythmias + renal denervation
41096197|NCT00364442|DRUG|fluticasone propionate/salmeterol|investigational drug
41096198|NCT01429779|DRUG|Movicol|Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
41096199|NCT05210842|OTHER|Endoscopy|The procedures are performed using a flexible therapeutic linear array echoendoscope.
41096200|NCT03455361|PROCEDURE|Stark Implant with low primary stability|
41096201|NCT00301509|DRUG|peginterferon and ribavirin|
41096202|NCT04732676|OTHER|Smartphone application|"Ecological Momentary Assessment (EMA)~: ambulatory assessment of behaviors/symptoms in real-time on smartphones"
41096203|NCT05097573|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, stretch marks, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
41270700|NCT00158184|DRUG|Placebo 0 mg|0 mg placebo dose administered once a day, orally.
40924715|NCT01088607|DRUG|ursodeoxycholic acid (UDCA)|Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
40924716|NCT04996472|BEHAVIORAL|Sensitivity to phonological rules: Adults|Assess whether adults are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon.
41096204|NCT05165914|DRUG|Intravenous midazolam before emergence from general anesthesia|Intravenous administration of 0.03 mg/kg midazolam just before emergence from anesthesia.
41096205|NCT05165914|DRUG|Intravenous normal saline before emergence from general anesthesia|Intravenous administration of normal saline just before emergence from anesthesia.
41096206|NCT04699669|DRUG|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.~No PK samples will be collected in this cohort."
41096207|NCT04699669|DRUG|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized."
41096208|NCT04699669|DRUG|CBL-514|Both sides of the abdominal region will receive CBL-514.
41096209|NCT00028301|DRUG|Atazanavir|
41096210|NCT00028301|DRUG|Lopinavir/Ritonavir|
41096211|NCT06062706|PROCEDURE|Donor hepatectomy|"Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques.~As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach."
41270701|NCT00003414|BIOLOGICAL|aldesleukin|
41096212|NCT01393470|PROCEDURE|Screening for cervical cancer|Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
41096213|NCT03331328|DEVICE|MonaLisa Touch|MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
41096214|NCT05585580|DRUG|Serplulimab|300mg d1 q3w
41096215|NCT05585580|DRUG|Lenvatinib|8mg po qd
41096216|NCT05585580|DRUG|Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome|135\~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w
41096217|NCT04706013|DRUG|Pyridoxal Phosphate|Oral tablets 50 mg
41096218|NCT00000988|DRUG|Stavudine|
41096219|NCT04151121|BEHAVIORAL|MBCT (Mindfulness Based Cognitive Therapy)|MBCT is recognized behavior therapy for patients with recurrent depression. The program will be adapted for patients with chest pain.
41096220|NCT05835050|DIAGNOSTIC_TEST|serum interleukin 10 level|b. Serum levels of IL-10 were measured using a quantitative enzyme-linked immunosorbent assay (ELISA)
41096221|NCT00287573|DEVICE|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
41096222|NCT00287573|PROCEDURE|Brachytherapy (beta source)|Brachytherapy (beta source)
41096223|NCT04820621|DRUG|Runcaciguat (BAY1101042)|Given as 1 x 15 mg modified release \[MR\] tablet
41096224|NCT05177341|OTHER|Determining Preferred Walking Speed|In the beginning, sensors of the gait analysis system (RehaGait®), which can record the time-distance characteristics of consecutive multiple steps (step length, step width, double step length, and timing information, etc.) will be installed. The 7 sensors of this system are attached to the shoes of the individual, proximal to the ankle, distal thigh, and sacroiliac joint level (Aminian et al., 2014). Individuals will be required to wear casual athletic shoes and comfortable, non-knee-covering shorts. Next; Each individual will walk freely on the treadmill at their own pace. To find the preferred walking speed of the individual, Hinton et al. protocol will be used (Hinton et al., 2018). The speed of the treadmill will be increased or decreased in line with the direction of the participants. After being determined according to the protocol, the individual will practice walking at this speed for 4-5 minutes. The individual will rest as much as he or she wants.
41096225|NCT04570761|DEVICE|Dreem headband|acoustic stimulation
41096226|NCT04570761|DEVICE|Dreem headband|acoustic stimulation
41096227|NCT00106808|DRUG|Muraglitazar|
41443065|NCT05138003|DIAGNOSTIC_TEST|Blood sample|Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.
40924717|NCT04996472|BEHAVIORAL|Sensitivity to semantic category cues: Adults|Assess whether adults show improved learning of OR or family resemblance rules when a semantic category cue is used.
40924718|NCT01464905|BIOLOGICAL|NU100|0.25 mg SQ, every other day for 12 months
40924719|NCT01464905|BIOLOGICAL|Placebo|1 mL SQ, every other day for 4 months
40924720|NCT01464905|BIOLOGICAL|rhIFN beta-1b|0.25 mg SQ, every other day for 12 months
41096228|NCT00106808|DRUG|Pioglitazone|
41096229|NCT01912495|DRUG|Boceprevir|
41096230|NCT05507281|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|ultrasound-guided ipsilateral Erector Spinae Plane Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
41096231|NCT05507281|PROCEDURE|Retrolaminar Block|ultrasound-guided ipsilateral Retrolaminar Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
41096232|NCT05507281|PROCEDURE|Control|General anesthesia
41096233|NCT04878380|DEVICE|Fitbit|A consumer sleep tracker will be used to monitor sleep patterns throughout the study
41096234|NCT04878380|BEHAVIORAL|Sleep education tips|Sleep tips will be provided before the intervention phase
41096235|NCT04878380|BEHAVIORAL|Goal-setting|During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.
41096236|NCT05448066|DIAGNOSTIC_TEST|Component resolved diagnosis|Physicians in this group will have access to allergen molecular component sensitization profile, using ImmunoCAP ISAC E112i and to all standard diagnostic tolls
41096237|NCT05448066|DIAGNOSTIC_TEST|Standard diagnosis|Physicians will only have access to standard diagnostic tools namely skin prick tests and sIgE sensitization (not molecular IgE) and clinical history.
41096238|NCT02933320|BIOLOGICAL|BI-1206 single agent dose escalation phase|BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.
41096239|NCT02933320|BIOLOGICAL|Combination of BI-1206 with rituximab escalation phase|An investigation of combination treatment of BI-1206 with rituximab.
41096240|NCT02933320|BIOLOGICAL|BI-1206 single agent expansion phase|BI-1206 single agent expansion phase at the RP2D.
41096241|NCT02933320|BIOLOGICAL|Combination of BI-1206 with rituximab expansion phase|BI-1206 in combination with rituximab at the RP2D.
41096242|NCT02908464|DEVICE|Lumosity|A neurocognitive training program designed to enhance cognitive abilities
41096243|NCT04327037|BIOLOGICAL|Expanded Haploidentical Natural Killer cells|One dose (from 20x to \>100x 10\^6 /kg) of expanded haploidentical NK cells
41096244|NCT04327037|DRUG|IL-2|6 doses of IL-2 (1 × 10\^6 units/m2) from -1 day every other day.
41096245|NCT04795102|COMBINATION_PRODUCT|immediate implant placement with ATBG and L-PRF|immediate implant placement using ATBG as a graft material, with L-PRF
41096246|NCT04795102|COMBINATION_PRODUCT|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without L-PRF
41096247|NCT00154713|BIOLOGICAL|CEA pulsed dendritic cells|
41096248|NCT05955599|OTHER|ACL Injury Prevention Training|Supervised ACL injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
41096249|NCT05955599|OTHER|Control - Shoulder Injury Prevention Training|Supervised shoulder injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
41096250|NCT00916006|DRUG|PEP005 Gel|0.015%, three day treatment
41443066|NCT05822375|BEHAVIORAL|Better Together Physician Coaching|Better Together Physician Coaching Program thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
41096251|NCT00916006|DRUG|Vehicle gel|Vehicle gel, three day treatment
41096252|NCT03874156|DRUG|Atorvastatin 40mg|Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS
41096253|NCT03874156|DRUG|Placebo Oral Tablet|Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
41096254|NCT02934958|BEHAVIORAL|Colon Cancer Screening Navigation|Patients with FIT Positive results that have been given the choice will be followed and navigated from referral to colonoscopy to assist in obtaining colonoscopy.
41096255|NCT02934958|BEHAVIORAL|Standard of Care|Patients will be tracked to compare how effective are usual care methods
41096256|NCT06628479|OTHER|interleukin, enzyme, hormone|Relaxin, MMP-2 and IL-6 values from vaginal washing fluid, peritoneal washing fluid and serum samples
41096257|NCT01704846|DRUG|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
41096258|NCT01704846|DRUG|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
41096259|NCT01704846|DRUG|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
41096260|NCT01704846|DRUG|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
41096261|NCT05441280|DRUG|pimavanserin|pimavanserin 34mg PO at bedtime
41096262|NCT05441280|OTHER|Placebo|The placebo is a pill that looks like a study medication but has no medication in it
41443067|NCT05455996|DRUG|MDMA|MDMA-assisted therapy
41096263|NCT03712293|DEVICE|BBB Disruption with Chemotherapy Arm|The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.
41096264|NCT06530030|DRUG|efanesoctocog alfa|All treatment decisions must be made independent of study participation and study-related visits/assessments are not intended to inform treatment decisions. No study medication is provided as part of study participation.
41096265|NCT03046290|PROCEDURE|circumcision|
41096266|NCT03046290|DRUG|Lidocaine|
41096267|NCT03046290|DRUG|Ropivacaine|
41096268|NCT01249040|PROCEDURE|Physical therapy|
41096269|NCT01249040|PROCEDURE|steroid intraarticular injection|
41096270|NCT03468920|DRUG|IV Acetaminophen|IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
41096271|NCT03468920|DRUG|PO Acetaminophen|Acetaminophen PO 1000mg once pre-operatively
41096272|NCT03468920|DRUG|PO Placebo|PO placebo capsule compounded to match PO Acetaminophen capsule
41096273|NCT03468920|DRUG|IV Solution Placebo|This will serve as the placebo for the IV Acetaminophen intervention
41096274|NCT02393898|DRUG|Bevacizumab|Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.
41096275|NCT02393898|DRUG|Carboplatin|Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
41443068|NCT05967286|DRUG|Alpelisib|Given PO
41443069|NCT05967286|PROCEDURE|Biopsy|Undergo biopsy
41096276|NCT02393898|DRUG|Paclitaxel|Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
41096277|NCT02274402|BIOLOGICAL|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
41096278|NCT05809076|DEVICE|real tACS|tACS is a non-invasive method to induce brain modulation. It will be applied at a frequency of 40 Hz (gamma-tACS) with a peak-to-peak intensity of 2 mA. During the real tACS condition, the alternating current will be administered for 20 minutes.
41096279|NCT05809076|DEVICE|sham tACS|In the sham tACS condition, the current will be delivered only for the first 30 seconds and then stopped, in order to simulate the same somatosensory sensations as real tACS, but without inducing modulation.
41096280|NCT04221035|DRUG|Vincristine|1.5 mg/m2 (max dose 2 mg)
41443070|NCT05967286|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41443071|NCT05967286|PROCEDURE|Bone Scan|Undergo bone scans
41443072|NCT05967286|PROCEDURE|Computed Tomography|Undergo CT
41443073|NCT05967286|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41443074|NCT05967286|DRUG|Olaparib|Given PO
41443075|NCT05967286|PROCEDURE|Positron Emission Tomography|Undergo PET
41443076|NCT05012254|DRUG|Ipilimumab|"Patients will receive Ipilimumab 1mg/Kg administered by IV infusion every 42 days (Q6W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a fully human monoclonal antibody with two heavy chains and two kappa light chains linked together by way of disulfide bonds. The molecular weight is approximately 148 kDa and it exists in solution at a physiologic pH of 7.0.~Route of administration: Intravenous infusion."
41096281|NCT04221035|DRUG|Carboplatin|750 mg/m2
41096282|NCT04221035|DRUG|Etoposide|175 mg/m2
41096283|NCT04221035|DRUG|Vindesine|3 mg/m2/day (max dose 6 mg)
41096284|NCT04221035|DRUG|Dacarbazine|200 mg/m2/day
41096285|NCT04221035|DRUG|Ifosfamide|1500 mg/m2/day
41096286|NCT04221035|DRUG|Doxorubicin|30 mg/m2/dose
41096287|NCT04221035|DRUG|Busulfan|\< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \>23 kg to 34 kg: 0.95 mg/kg/dose \>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses
41096288|NCT04221035|DRUG|Melphalan|140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose
41096289|NCT04221035|DRUG|Thiotepa|300 mg/m2/day over 2 hours
41096290|NCT04221035|RADIATION|Radiotherapy|21.6 Gy 21.6 Gy + boost de 14.4 Gy
41096291|NCT04221035|DRUG|Dinutuximab Beta|Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day
41096292|NCT04221035|DRUG|Cisplatin|80 mg/m2/24h
41096293|NCT04221035|DRUG|Temozolomide 100 MG|100 mg/m²/Day
41096294|NCT04221035|DRUG|Irinotecan|50 mg/m²/jour de J0 à J4
41096295|NCT04221035|DRUG|Cyclophosphamid|Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.
41096296|NCT01963026|OTHER|ToCUEST featuring a 'variable practice' approach.|Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module \[17\] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. \[17\]. Intervention B will be called 'ToCUEST variability' in the present project.
41096297|NCT01963026|OTHER|ToCUEST featuring a 'constant practice' approach.|Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
41096298|NCT03404609|DEVICE|MagPro X100 by MagVenture|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
41096299|NCT04274751|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation
41096300|NCT03353584|OTHER|Virtual Reality Therapy|The VR intervention consists of an interactive audio and visual underwater experience designed to serve as a calming distraction activity. The VR software (Kind VR® Aqua) was developed by KindVR specifically for the purpose of pain distraction in a hospital setting.
41096301|NCT04266561|OTHER|hernia repair|Two 3-mm needle holders were used for stitching the wide IIR. Then the suture was continued along the upper margin of IIR, but in a deeper plane to include the peritoneum and the deeper fascia transversalis.
41096302|NCT06123117|PROCEDURE|single transversus abdominis laparoscopy-guided plane block|please see arm/group descriptions
41096303|NCT06123117|PROCEDURE|local trocar site ropivacaine infiltration|please see arm/group descriptions
41096304|NCT00946192|DRUG|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
41096305|NCT00946192|DRUG|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
41096306|NCT00946192|DIETARY_SUPPLEMENT|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
41096307|NCT05216237|DRUG|Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)|for 2-6 cycles followed by Sindilizumab plus Tegafur gimeracil oteracil potassium capsules.
41096308|NCT00002563|PROCEDURE|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
41096309|NCT00002563|PROCEDURE|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
41096310|NCT02028884|DRUG|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
41096311|NCT02028884|DRUG|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
41096312|NCT02028884|DRUG|Baseline Treatment|As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
41096313|NCT01155869|DRUG|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
41096314|NCT01155869|DRUG|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
41096315|NCT05171933|BEHAVIORAL|Survey|This study is based on a survey made on COVID-19
41096316|NCT05365529|BEHAVIORAL|Time-Restricted Eating|Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
41096317|NCT05365529|BEHAVIORAL|Standard of Care|Participants in the Standard of Care group will continue to follow their physician's treatment plan for type II diabetes mellitus.
41096318|NCT03999944|DEVICE|positive airway pressure system|Positive Airway Pressure System
41096319|NCT01168401|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|"2 Doses 28 days apart Cohort A: 18-49 Years~Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)~Cohort A2: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (15/15 mcg)~Cohort A3: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort A4: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (150/150 mcg)~Cohort B: 50-64 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort C: 65-85 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort D: 18-49 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)"
41096320|NCT01168401|BIOLOGICAL|Saline|Two doses 28 days apart
41096321|NCT05824338|DRUG|Spinal anesthesia for lumbar surgery: ropivacaine|The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally
41096322|NCT05824338|DRUG|Spinal anesthesia for lumbar surgery: bupivacaine|The anesthesiologist will administer 3 mL of bupivacaine 0.5% plus fentanyl 15 mcg intrathecally.
41096323|NCT05824338|DRUG|General anesthesia for lumbar surgery|Patient will be intubated and ventilated under general anesthesia.
41096324|NCT02870270|OTHER|Cancer treatment|Patients undergoing treatment for cancer in the head and neck region
41096325|NCT01261065|DRUG|carvedilol|Patients with heart failure and LVEF \< 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight \> 80 kg.
41096326|NCT03943719|DIAGNOSTIC_TEST|FilmArray blood culture identification panel|FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection
41096327|NCT00878384|DRUG|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of \<80bpm and \<110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
41096328|NCT00878384|PROCEDURE|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
41096329|NCT04928872|COMBINATION_PRODUCT|Predefined meal|Nine predefined meals are administered in a randomized fashion, one meal per one study day, 2-3 study days per week. Meals have a form of drinks with different compositions of protein, carbohydrates and fat in relation to the US diet
41096330|NCT06628193|DEVICE|Low intensity focused ultrasound|low-intensity focused ultrasound for neuromodulation applied to the head.
41096331|NCT06628193|DEVICE|Sham (No Treatment)|Sham LIFU application
41096332|NCT03901729|DRUG|BAY 1753011|Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral
41096333|NCT03901729|OTHER|Placebo BAY 1753011|Tablet; Once daily in the morning; Oral
41096334|NCT03901729|DRUG|Furosemide|Tablet; 40mg unit; 80mg once daily in the morning; Oral
41096335|NCT03901729|OTHER|Placebo Furosemide|Tablet; Once daily in the morning; Oral
41096336|NCT02223793|BEHAVIORAL|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
41096337|NCT02223793|BEHAVIORAL|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
41096338|NCT02223793|BEHAVIORAL|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
41096339|NCT04215341|BEHAVIORAL|Physiotherapy|A course of breathing retraining delivered by a physiotherapist and practiced by the participant at home.
41096340|NCT05304520|DRUG|Natalizumab|Administered as specified in the treatment arm.
41096341|NCT05120440|OTHER|Breakfast omission|Breakfast omission will consist of not eating breakfast on the morning of afternoon resistance training performance assessment.
41096342|NCT05120440|OTHER|Breakfast consumption|Breakfast consumption will consist of eating a standardized breakfast on the morning of afternoon resistance training performance assessment.
41096343|NCT04986982|DRUG|Opicapone 50 mg|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI) (L-dopa/DDCI).
41096344|NCT04986982|OTHER|Matching placebo|Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
41096345|NCT00350831|DRUG|XL820|
41096346|NCT05091164|PROCEDURE|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis.
41443077|NCT05012254|DRUG|Nivolumab|"Patients will receive Nivolumab 360 mg administered by IV infusion every 21 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~Route of administration: Intravenous infusion."
40924721|NCT02034344|PROCEDURE|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
41096347|NCT04166643|BEHAVIORAL|WHHIP PLUS|Worksite health promotion and occupational health and safety (total worker health)
41096348|NCT04166643|BEHAVIORAL|Education only control|Education at the start of the project
41096349|NCT06548009|DIAGNOSTIC_TEST|Metabolomics and other blood samples|Blood samples taken with the objective of identifying a diagnostic test
41096350|NCT06286982|OTHER|Oral Symptom Assessment Scale|The Oral Symptom Assessment Scale is a patient-rated oral (or mouth) symptom assessment tool
41096351|NCT02896894|OTHER|Big White Wall (BWW)|"The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe."
41096352|NCT00438555|BEHAVIORAL|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
41096353|NCT00438555|BEHAVIORAL|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
41096354|NCT06064929|DRUG|Felzartamab|Specified dose on specified days
41096355|NCT02219490|DRUG|ABT-450/r/ABT-267|Tablet for oral use
41096356|NCT02219490|DRUG|ABT-333|Tablet for oral use
41096357|NCT02219490|DRUG|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight,1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
41096358|NCT03882489|DRUG|Isobaric 2-chloroprocaine|The doses of isobaric 2-chloroprocaine will be administrated intrathecally and will be adjusted according to the observed responses in the previous subjects.
41096359|NCT01386086|DRUG|aripiprazole|The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
41096360|NCT05824351|DEVICE|Tanzanian beeswax-pine resin|Thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
41096361|NCT05824351|DEVICE|Domestic beeswax-pine resin|Thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
41096362|NCT05824351|DEVICE|Hollister's AdaptTM Barrier Rings|Thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
41096363|NCT01740557|BIOLOGICAL|Aldesleukin|Given IV
41096364|NCT01740557|BIOLOGICAL|CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
41096365|NCT01740557|DRUG|Cyclophosphamide|Given IV
41096366|NCT01740557|DRUG|Fludarabine Phosphate|Given IV
41096367|NCT01740557|OTHER|Laboratory Biomarker Analysis|Correlative studies
41096368|NCT01740557|BIOLOGICAL|NGFR-transduced Autologous T Lymphocytes|Given IV
41096369|NCT01740557|OTHER|Quality-of-Life Assessment|Ancillary studies
41096370|NCT04457141|COMBINATION_PRODUCT|Effect of pelvic floor for the use of minimalist shoes versus shod in woman.|Measure the activity of the pelvic floor and others muscles with EMG during treadmill running with different speeds and different shoes: minimalist and shod.
41096371|NCT05428436|DRUG|BI 1015550 ICF|BI 1015550 intended Commercial Formulation (iCF)
41096372|NCT05428436|DRUG|BI 1015550 TF2|BI 1015550 trial formulation 2 (TF2)
41096373|NCT05584124|DEVICE|High frequency repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
41096374|NCT05584124|DEVICE|Sham repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
41096375|NCT02814266|OTHER|difficult intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
41096376|NCT02814266|OTHER|easy intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
41096377|NCT03426072|OTHER|modified IHI breakthrough series|"There are five main elements to the intervention:~1. Establishment of the team and set up~2. Establishing baseline performance and knowledge~3. Ongoing developmental support~4. Learning sessions (3)~5. Action periods (3)~6. The actual facilitative actions (e.g., coaching, guiding, mentoring, supporting) occur in combination with limited teaching, largely during telephone conferences but also in any visit, which may occur up to quarterly.~5. The concluding session is an opportunity for networking, sharing successes and making plans for the continuation of project work following the end of formal support"
41096378|NCT02664220|DRUG|Povidone-iodine irrigation|"Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.~1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister."
41096379|NCT02664220|PROCEDURE|No irrigation|Patients allocated to the control group will not undergo intra-abdominal irrigation.
41096380|NCT04497584|DRUG|Afatinib + Prednisone|Afatinib (40mg) will be taken by mouth daily starting on Cycle 1, Day -7. Prednisone (40mg) will be taken by mouth daily starting on Cycle 1, Day 1.
41096381|NCT05823987|DRUG|H101|a modified human recombinant type 5 adenovirus with genetic modifications
41096382|NCT05823987|DRUG|Tislelizumab|a PD-1 immune check inhibitor
41096383|NCT05823987|DRUG|Lenvatinib|Lenvatinib capsules
41096384|NCT00021112|DRUG|cisplatin|
41096385|NCT00021112|DRUG|etoposide|
41096386|NCT00021112|PROCEDURE|conventional surgery|
41096387|NCT00021112|RADIATION|radiation therapy|
41096388|NCT04315220|OTHER|Corestability training|"Level -1: Mat exercises~Abdominal muscle contraction,bridging,cat stretch,single limb circle and superman.:~Level- 2: Swiss Ball Exercises Abdominal contraction,bridging and squats."
41096389|NCT04315220|OTHER|No Intervention|No Intervention
41096390|NCT00124826|DRUG|Insulin|
41096391|NCT02731521|DEVICE|3 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
41096392|NCT02731521|DEVICE|7 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
41096393|NCT01784380|DRUG|Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin|
41096394|NCT03446508|DEVICE|Active frontal|1) active HD-tDCS will be administered
41096395|NCT03446508|DEVICE|Active parietal|2) active HD-tDCS will be administered
41096396|NCT03446508|DEVICE|Sham|3) sham HD-tDCS - no current
41096397|NCT06294951|DIAGNOSTIC_TEST|fMRI|The fMRI is acquired using a Siemens 3.0T MRI scanner. BOLD functional images are scanned using an echo planar imaging (EPI) sequence. The scanning parameters are: TR=2s, matrix size of 64\*64, number of layers=30, layer thickness=3.75\*3.75\*4.5mm, and bottom-up interval scanning. A total of 540 whole brain functional images are acquired.
41096398|NCT05724550|DRUG|Sugammadex|"* Sugammadex(100mg/mL), 2mg/kg~* After confirming Train-of-four counts 4, patients allocated to sugammadex group receive sugammadex 2mg/kg for reversal of rocuronium at the end of the surgery."
41096399|NCT05724550|DRUG|Neostigmine|"* Neostigmine methylsulfate(0.5mg/mL) 0.02mg/kg~* After confirming Train-of-four counts 4, patients allocated to neostigmine group receive neostigmine 0.02mg/kg (maximum 5mg) combined with atropine 0.02mg/kg for reversal of rocuronium at the end of the surgery."
41096400|NCT03511248|DIETARY_SUPPLEMENT|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
41096401|NCT03511248|DIETARY_SUPPLEMENT|Nitrate-deplete Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
41096402|NCT00803426|PROCEDURE|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
41096403|NCT00003891|DRUG|lurtotecan liposome|
41096404|NCT01123161|DEVICE|hypothermia and anti-shivering treatment|Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
41096405|NCT01123161|DRUG|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
41096406|NCT03518541|PROCEDURE|Femoral Derotation Osteotomy (FDO)|Correction of malrotation of the femoral bone by osteotomy, derotation and osteosynthesis
41096407|NCT00441675|PROCEDURE|Symptom Score|Symptom Score
41096408|NCT00441675|PROCEDURE|Symptom Score and PD20|Symptom Score and PD20
41096409|NCT01571778|BEHAVIORAL|Hand Hygiene before Donning Non-sterile Gloves|"In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens~In the Experimental arm, they will be instructed to don gloves without washing their hands as described."
41096410|NCT03658941|PROCEDURE|No dural tenting techniques|Not applying dural tenting sutures during closure of a craniotomy
41096411|NCT03658941|PROCEDURE|Dural tenting techniques|Applying at least 3 dural tenting sutures during closure of a craniotomy
41096412|NCT06016556|DRUG|nirmatrelvir, ritonavir|single cohort
41096413|NCT01953809|DRUG|GSK1322322|Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
41096414|NCT01953809|DRUG|EE/NE|Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
41096415|NCT01953809|DRUG|GSK1322322 Placebo|GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
41096416|NCT01953809|DRUG|EE/NE Placebo|EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
41096417|NCT04320264|PROCEDURE|Weight loss surgery|Severely obese women (BMI \>40) undergo sleeve gastrectomy
41096418|NCT03288350|DRUG|mDCF + Avelumab|Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
41096419|NCT04375644|OTHER|Questionnaires on psychological quality of life|Assessement of evolution of the psychological quality of life of health professionals during the confinement period linked to the COVID-19 pandemic by two questionnaires (one during the confinement period and the second one month after the end of the confinement period)
41096420|NCT00312312|BIOLOGICAL|Specific immunotherapy|
41096421|NCT05966519|DEVICE|Total Knee Replacement (TKR)|Damaged cartilage of knee due to degenerative disease is replaced with metallic and plastic protheses
41096422|NCT05623995|DRUG|PCSK9 inhibitor|Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..
41096423|NCT05623995|DRUG|Statin|Guideline recommended statin therapy.
41096424|NCT06492031|DRUG|Icodextrin Peritoneal Dialysis Solution|The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.
41096425|NCT06492031|DRUG|Glucose Peritoneal Dialysis Solution|The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.
40924722|NCT02034344|PROCEDURE|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
40924723|NCT02034344|PROCEDURE|Urine collection|Urine will be collected from all participants.
40924724|NCT03876301|DRUG|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
40924725|NCT01119937|DRUG|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
41096426|NCT04461106|OTHER|Social Marketing Campaign|aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (\<5yrs) and pregnant/lactating women
41096427|NCT05373901|DRUG|Dinutuximab Beta|Dinutuximab beta was administered intravenously at a dosage of 10 milligrams/ meters squared (mg/m2) per day for 10 consecutive days
41096428|NCT05373901|DRUG|13-cis-Retinoic Acid|13-cis-Retinoic Acid was administered orally at a daily total dose of 160 mg/m2, divided into approximately two equal doses given twice daily for 14 days following the conclusion of dinutuximab beta infusion.
41096429|NCT00476203|BEHAVIORAL|Yoga|Instructor-led yoga classes 1/time per week + 4 days of home practice
41096430|NCT00476203|OTHER|Delayed yoga classes|Delayed yoga classes (after 6 months) offered \[wait list control group\]
41096431|NCT05608967|DEVICE|PREHapp|Prehabilitation programme through the PREHapp platform
41270702|NCT00003414|BIOLOGICAL|recombinant interferon gamma|
41270703|NCT00003414|DRUG|busulfan|
41270704|NCT00003414|DRUG|cyclophosphamide|
41096432|NCT05832723|DEVICE|650 nm low-level red-light|Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.
41096433|NCT00587132|DRUG|Synthetic Human Secretin|0.2mcg/kg one time dose.
41096434|NCT02970461|OTHER|Gamified Group|See Gamified Group in Arms description.
41096435|NCT02970461|OTHER|Control Group|See Control Group in Arms description.
41096436|NCT04074499|OTHER|No intervention|There is no intervention.
41096437|NCT04656236|BIOLOGICAL|3-hydroxybutyrate|3-hydroxybutyrate is a metabolite, produced in the human body.
41096438|NCT00237341|DRUG|fentanyl|
41096439|NCT02303769|DRUG|Tamsulosin HCL 0.4mg|Tamsulosin HCL 0.4mg once a day
41096440|NCT02303769|DRUG|Tamsulosin HCL 0.2mg|Tamsulosin HCL 0.2mg once a day
41096441|NCT03638219|OTHER|Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up till 2020.|Data collection, follow up and bioscore calculation at the end of study
41096442|NCT02929108|BEHAVIORAL|Facebook|Participants will be enrolled in a Secret Facebook group for social support and education
41096443|NCT02929108|BEHAVIORAL|ACCESS|"Intervention will have two components.~1. Participants will be enrolled in a Secret Facebook group for social support and education~2. Participants will use web conferencing technology to participate in their interdisciplinary team meeting"
41096444|NCT04340245|OTHER|NA (Observational)|No interventions will be carried out. Comparisons will be made between patients whose cancer has progressed over the course of one year and patients whose cancer hasn't.
41096445|NCT00321477|DRUG|GW679769 oral tablets|
41096446|NCT06426082|BEHAVIORAL|Thermoneutral condition|Participants will be exposed 2 hours/day at 32ºC for 5 days/week
41096447|NCT06426082|BEHAVIORAL|Cold condition|Participants will be exposed 2 hours/day at 18ºC for 5 days/week
41096448|NCT06426082|BEHAVIORAL|Aerobic exercise condition|Participants will perform aerobic exercise training 5 days/week at 65% heart rate reserve for 60 minutes each training session
41096449|NCT06426082|DRUG|Salbutamol|Participants will take salbutamol 12 mg/day. 7 days week
41096450|NCT01721564|DRUG|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
41096451|NCT03244566|DIAGNOSTIC_TEST|positron emission tomography|patients who had esophagectomy with 3-field lymphadenectomy underwent examination of positron emission tomography prior to surgery within 2 weeks.
41096452|NCT00776711|DRUG|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
41096453|NCT00776711|DRUG|VRC-AViDNA036-00-VP|
41096454|NCT05616221|BIOLOGICAL|AP-PA02|Bacteriophage administered via inhalation
41096455|NCT05616221|OTHER|Placebo|Inactive Placebo administered via inhalation
41096456|NCT01387490|BEHAVIORAL|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
41096457|NCT01387490|OTHER|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
41096458|NCT03942822|DIETARY_SUPPLEMENT|Milled chia seeds|8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia
41096459|NCT00403208|PROCEDURE|Analgesia based sedation in ICU patients|
41096460|NCT02778308|DRUG|Gemcitabine + Cisplatin|Day 1 and day 8 Gemcitabine Day 1 cisplatin
41096461|NCT00647413|BEHAVIORAL|bio-chemical feedback and expert system intervention ETS|"Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants"
41096462|NCT00785772|DRUG|Gabapentin|100-200mg once a day
41096463|NCT00785772|DRUG|Gabapentin|200-500mg once a day
41096464|NCT00785772|DRUG|Gabapentin|400-1000mg (200-500 mg twice a day)
41096465|NCT04127539|BEHAVIORAL|Strong & Steady exercise program|The community-based group exercise program S\&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S\&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S\&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
41096466|NCT04724369|DRUG|18F-MFBG|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
41096467|NCT00635817|DRUG|Leuprolide acetate 11.25 mg|Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
41096468|NCT00635817|DRUG|Leuprolide acetate 30 mg|Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
41096469|NCT02892409|DRUG|Clarithromycin|Clarithromycin tablets
41096470|NCT02892409|DRUG|Amoxicillin|Amoxicillin capsules
41096471|NCT02892409|DRUG|Tripotassium bismuth dicitrate|Tripotassium bismuth dicitrate tablets
41096472|NCT02892409|DRUG|Lansoprazole|Lansoprazole capsules
41096473|NCT02892409|DRUG|TAK-438|TAK-438 tablets
41096474|NCT00553215|PROCEDURE|quality-of-life assessment|
41096475|NCT00553215|PROCEDURE|questionnaire administration|
41096476|NCT01094171|BIOLOGICAL|Poliorix TM|Intramuscular administration, 3 doses
41096477|NCT01094171|BIOLOGICAL|Infanrix TM|Intramuscular administration, 3 doses
41096478|NCT01436409|OTHER|echography|echography during labor
40924726|NCT01119937|DRUG|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
40924727|NCT03707028|DRUG|Rivoceranib|Film-coated tablet
40924728|NCT03707028|DRUG|Paclitaxel|Solution administered intravenously
40924729|NCT02678598|DRUG|Micafungin|Intravenous
40924730|NCT05315011|OTHER|Whole-body cryotherapy|"The term cryotherapy refers to the process of chilling the body for medicinal purposes. WBC is carried out in a dedicated temperature and humidity controlled cryogenic chamber, which includes a brief exposure to extremely cold air. To avoid frostbite, only a few layers of clothes will be worn during the exposure. To avoid skin burns and necrosis, each participant must first remove their sweat before entering the cryochamber and a surgical mask is also worn to prevent moist air from being exhaled. Subjects will move their fingers and legs in the cryochamber and avoid holding their breath. The exposure time will be 4 minutes and 30 seconds in -85°C."
40924731|NCT05315011|OTHER|Placebo cryotherapy|The patient will be placed in a -85°C chamber for 1 minute as part of the placebo treatment.
40924732|NCT03584529|DRUG|Vitamin D 3|Non-Vitamin D3 Drops group Patients in this group would take nothing.
40924733|NCT03252600|DRUG|Cyclophosphamide|Given IV
40924734|NCT03252600|DRUG|Dexamethasone|Given IV
40924735|NCT03252600|BIOLOGICAL|Elotuzumab|Given IV
40924736|NCT03252600|OTHER|Laboratory Biomarker Analysis|Correlative studies
40924737|NCT03252600|DRUG|Lenalidomide|Given PO
40924738|NCT03252600|OTHER|Pharmacological Study|Correlative studies
40924739|NCT05838989|DEVICE|Prefabricated Orthoses|Participants in this group will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist. Participants will be instructed to wear the orthoses as directed by their healthcare provider.
40924740|NCT05838989|OTHER|general and lumbrical muscle stretching|Participants in this group will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks. The stretching exercises will be performed under the supervision of a trained therapist and will include a series of exercises designed to stretch the muscles in the hands, wrists, and forearms. In addition, participants will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist.
40924741|NCT05838989|OTHER|Placebo|Participants in this group will receive placebo treatment consisting of gentle wrist and hand movements. The movements will be performed under the supervision of a trained therapist and will consist of gentle range of motion exercises designed to mobilize the joints in the hands and wrists. Participants will not be provided with any orthoses to wear during the study.
40924742|NCT05198375|DIAGNOSTIC_TEST|Lung ultrasound score (LUS)|LU score (LUS) will be performed between 1 and 3 hours of life. LUS will be calculated by performing longitudinal scans of the chest in the anterior (midclavicular line), lateral (anterior axillary line) and posterior (posterior axillary line) area bilaterally using high-frequency linear or micro linear (hockey stick) probe. A score from 0 to 3 will be assigned to each area based on the ultrasound detected pattern.
40924743|NCT05898997|BEHAVIORAL|Acupressure|Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.
40924744|NCT01597167|DIETARY_SUPPLEMENT|Magnesium sulfate|4 grams magnesium sulfate in 100 ml IV over 4 hours
40924745|NCT01671527|PROCEDURE|Transcranial magnetic stimulation (TMS)|We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.
40924746|NCT00329056|DRUG|MitoQ|Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
40924747|NCT06044766|PROCEDURE|Surgical exatrction of impacted lower third molars|Surgical exatrction of impacted lower third molars to verify the form of the root
40924748|NCT02847676|PROCEDURE|Tissue sample donation|Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
40924749|NCT00000750|DRUG|Zidovudine|
40924750|NCT02051075|BIOLOGICAL|PXN sperm treatment|immotile sperm activation with PXN
40924751|NCT02051075|BIOLOGICAL|Sperm activation with PXN and oocyte activation|
40924752|NCT04538209|RADIATION|Abdominal computed tomography with angiography.|technique of combing a Computed Tomography scan with the injection of dye to create pictures of the portal circulation and portosystemic collaterals veins.
40924753|NCT05315908|OTHER|Community outreach method|The method includes automated call and text messaging to increase testing for COVID-19
41096479|NCT00185484|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
41096480|NCT01126840|BEHAVIORAL|Telephone Interview|The phone interview should take 30-45 minutes to complete.
41096481|NCT01126840|BEHAVIORAL|Questionnaire|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.
41096482|NCT04841486|OTHER|Data collection|evaluation of women's stress
41096483|NCT04481906|PROCEDURE|Vaginal mesh for female cystocele|Vaginal mesh procedures (e.g. Perigee) were susgested for women with POP-Q stage III or more cystocele
41270705|NCT00003414|DRUG|cyclosporine|
41096484|NCT05873556|BEHAVIORAL|Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)|This is an online personalized feedback intervention that contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
41096485|NCT00779571|BEHAVIORAL|Crispbread|8 week low calorie diet
41096486|NCT05583240|DRUG|Essences and Essential Oils|Participants will received Essential Oils through a nasal stick during 4 weeks.
41096487|NCT05730764|DIAGNOSTIC_TEST|Accurate prediction of fertilization disorders and clinical decision support systems assist doctors in decision-making|With the assistance of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predict and judge the probability and key factors of fertilization disorders of patients, and formulate and implement personalized diagnosis and treatment plans based on the prediction results
41096488|NCT05730764|DIAGNOSTIC_TEST|Clinicians follow a routine protocol|Treatment is performed by the clinician according to the usual protocol.
41096489|NCT01739556|DRUG|Antiplatelet Regimen Modification (aspirin or ticagrelor)|
41096490|NCT06582563|DIAGNOSTIC_TEST|Whole Blood Clotting Time|Comparator
41096491|NCT02721511|DRUG|Furosemide Injection Solution 8mg/mL|Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
41096492|NCT05798208|DIAGNOSTIC_TEST|blood pressure measurement|Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
41096493|NCT01242085|PROCEDURE|trumatch group|these patient will have CT based customized knee instruments used for surgery
41096494|NCT01242085|PROCEDURE|control group|these patients will have standard instrumentation used for for knee replacement
41096495|NCT00828945|DEVICE|Lipid Self Test|Self test for lipid levels, twice during study period
41096496|NCT05553561|PROCEDURE|IPRL device|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
41096497|NCT05553561|PROCEDURE|pharmacological therapy & Eyelid hygiene|traditional methods of MGD treatment as Eyelid hygiene, topical preservative free lubricant, topical \& systemic antibiotics \& anti-inflammatory agent
41096498|NCT03226730|BEHAVIORAL|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The relais will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male relais will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
41270706|NCT00003414|PROCEDURE|peripheral blood stem cell transplantation|
41270707|NCT00003414|RADIATION|radiation therapy|
41443078|NCT05012254|DRUG|Carboplatin|"Patients will receive Carboplatin AUC 5 or 6 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosa or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
41453295|NCT05959915|DEVICE|device e-patch Implantation|"The ePatch device (Phillips) was used. This device is attached to the sternum, using a specific dressing adapted for the device itself. Manufacturer's recommendations for skin preparation and placement will be followed.~The device will remain in place for 4-5 days, at which time the patient will be readmitted for data extraction and reading.~The team of research nurses will analyze the data through the ePatch platform and later, the electrophysiologists will review the results and make a diagnosis."
40924754|NCT06267378|OTHER|Frailty measure|"All participants will be asked to complete baseline assessments and a blood test.~30 participants out of the 100 will be selected to wear a digital motion device before their surgery for seven days. (15 participants will be non-frail and 15 patients will be frail).~Where possible, all baseline assessments will be scheduled to coincide with a routine clinic/hospital visit. The first assessment will complete functional, frailty, nutritional, and quality of life questionnaires. A blood test will be taken for baseline tests and metabolomic assessment. Participants who opt into having a digital motion device will also be shown how to use the device and will wear this for seven days. Written instructions to fit the device will also be given."
40924755|NCT04931888|BEHAVIORAL|EMPOWER|EMPOWER is an adapted social emotional learning (SEL) and wellness education initiative delivered to a community of refugee families that was developed through a pre-pilot in the New Haven Afghan refugee community in 2020. Unlike traditional school-based SEL curricula, EMPOWER partners with community organizations to provide translated and trauma-informed wellness education to family units. The program combines in-person (socially distant) and remote delivery of culturally-informed physical, emotional, and medical wellness tools adapted from evidenced-based behavioral medicine, refugee trauma and recovery, and community health research.
40924756|NCT04717830|DRUG|Gamezumab|solution for infusion
40924757|NCT00472758|BIOLOGICAL|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
40924758|NCT00472758|OTHER|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
40924759|NCT00547001|DRUG|Estradiol|1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
40924760|NCT04379492|DRUG|Hydroxychloroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
40924761|NCT04379492|OTHER|Placebo|Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.
40924762|NCT00894959|BIOLOGICAL|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
40924763|NCT00894959|BIOLOGICAL|Heparin sodium APP|Heparin sodium APP 5.000 USP
41096499|NCT03226730|BEHAVIORAL|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week developed by Pathfinder International and derived from Population Council/UNFPA's Safe Spaces curriculum. The husband groups will follow a curriculum adapted from Promundo's Program P6 and supplemented by the tools and activities developed by Pathfinder International. These groups of husbands will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
41096500|NCT04239339|DRUG|Escitalopram 20 mg|20mg daily for approximately 3 weeks.
41096501|NCT04239339|DRUG|Placebo|Placebo daily for approximately 3 weeks.
41096502|NCT02817373|OTHER|Ultrasound scan performed through a vaginal probe|5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
41096503|NCT00155610|DEVICE|intravesical current perception test|
41096504|NCT01430702|DEVICE|Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
41096505|NCT03127709|BEHAVIORAL|Trail Making Test, Parts A & B|Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.
41096506|NCT03127709|BEHAVIORAL|Brief Test of Attention|Assesses auditory working memory
41096507|NCT03127709|BEHAVIORAL|Symbol Span|Assesses visual working memory
41096508|NCT03127709|BEHAVIORAL|Controlled Oral Word Association Test|The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).
41096509|NCT03127709|BEHAVIORAL|The Hopkins Verbal Learning Test-Revised|HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.
41096510|NCT03127709|BEHAVIORAL|Brief Visuospatial Memory Test-Revised|The BVMT-R is a test of visuospatial learning and memory.
41096511|NCT03127709|BEHAVIORAL|Hospital Anxiety and Depression Scale|The HADS is a brief assessment validated in many cancer populations.
41443079|NCT05012254|DRUG|Cisplatin|"Patients will receive Cisplatin 75mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: (CAS No. 15663-27-1, MF-Cl2H6N2Pt; NCF-119875), cisplatinum, also called cis-diamminedichloroplatinum(II), is a metallic (platinum) coordination compound with a square planar geometry. It is a white or deep yellow to yellow-orange crystalline powder at room temperature.~Stability: Do not store above 25°C. Do not refrigerate or freeze. Keep container in the outer carton to protect from light. Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20°C.~Route of administration: Intravenous infusion. Guidelines of Cisplatin administration: According to the standard of each center."
40924764|NCT03513107|OTHER|ospeoporosis score|"* Scores will be calculated as indicated in their respective studies after collecting the data pertaining to them (Crandall, 2015); (Cass \& Shepherd, 2013); (Reginster, et al., 2004); (Adler, et al., 2003); (Cadarette, et al., 2000); (Weinstein \& Ulery, 2000); (Black, et al., 1998); (Lydick, et al., 1998).~* Data will be treated as dichotomous for both DXA T-scores and screening scores (i.e. Osteoporosis (Yes or NO) versus positive/negative score)."
40924765|NCT00164697|BEHAVIORAL|Parenting group|Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
40924766|NCT00537615|DRUG|PD 0332334|
40924767|NCT04822805|DRUG|Anlotinib hydrochloride|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
41096512|NCT03127709|BEHAVIORAL|McGill Quality of Life Scale|This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.
41096513|NCT03127709|DIAGNOSTIC_TEST|MR Brain Imaging|Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.
40924768|NCT02025153|OTHER|pain testing|physical testing, psychological testing, genetics testing and functional brain imaging
40924769|NCT03507114|BEHAVIORAL|Rumination-Focused CBT (RFCBT)|RFCBT consists of six online modules that include psycho-education, mood diaries, on-line experiential exercises using audio-recordings \& vignettes of participants experiences of the therapy.
40924770|NCT06506591|DRUG|WD-890|Administered P.O.
40924771|NCT06506591|DRUG|WD-890 Tablets Placebo|Administered P.O.
40924772|NCT01568528|DRUG|Oxytocin|OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
40924773|NCT01568528|DRUG|Placebo|The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
41096514|NCT03127709|DIAGNOSTIC_TEST|Resting state functional MRI|Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.
41096515|NCT03127709|BEHAVIORAL|Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)|This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.
41096516|NCT04213222|DRUG|Bevacizumab|bevacizumab combined with chemotherapy
41096517|NCT04393896|BEHAVIORAL|WeChat-based integrative family intervention (WIFI)|The WIFI program will include three key components: psycho-education through WeChat Official Account publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call
41096518|NCT00140166|DRUG|niacinamide|
41096519|NCT00140166|DRUG|pyridoxine|
41096520|NCT00140166|DRUG|ascorbate|
41096521|NCT04809402|OTHER|remote monitoring after cataract surgery|remote monitoring after cataract surgery
41096522|NCT06435468|GENETIC|Blood sample for genetic analysis|genetic analysis (WES, WGS) for the identification of germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood
41096523|NCT06435468|OTHER|Blood sample for immunological response assessments|Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases
41096524|NCT06435468|OTHER|Blood sample to identify relevant biomarker of the disease|Research biomarkers for diagnosis, prognosis and monitoring of disease activity
41096525|NCT03518983|DEVICE|Dornier Aries2 device|The Dornier Aries2 device and will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft and the 2 crura(two sites).
41096526|NCT03518983|DEVICE|Dornier Aries2 device (sham probe)|The Dornier Aries2 device and will be used for the purpose of the study but the active probe will be replaced by an identical sham probe.
41096527|NCT05653089|PROCEDURE|Choice and adjustment of the wheelchair according to the patient's needs|"After a personalized analysis of the patient and his needs, the occupational therapists define the equipment necessary for the good positioning of the patient:~* Choice and adjustments of the wheelchair~* Choice and adjustments of the wheelchair/patient interface"
41096528|NCT02416674|PROCEDURE|abdominal wall transplantation|transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.
41096529|NCT02416674|DRUG|Immunosuppressive Agents|Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
41096530|NCT00657774|DRUG|FlutiForm 250/10 ug|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
41096531|NCT00657774|DRUG|FlutiForm 100/10 ug|SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
41096532|NCT00657774|DRUG|Oral Prednisone 10mg|2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
41096533|NCT00657774|DRUG|Placebo|2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
41096534|NCT04298840|DIETARY_SUPPLEMENT|Creatine Monohydrate Supplementation|Participants in the creatine monohydrate supplementation arm will consume 5 grams per day of creatine monohydrate.
41096535|NCT04298840|DIETARY_SUPPLEMENT|Placebo Supplementation|Participants in the placebo supplementation arm will consume 5 grams per day of maltodextrin placebo.
41096536|NCT00049114|DRUG|doxorubicin hydrochloride|
41096537|NCT00049114|DRUG|cyclophosphamide|Given IV
41096538|NCT00049114|DRUG|tipifarnib|Given orally
41096539|NCT00049114|BIOLOGICAL|filgrastim|Given subcutaneously
41096540|NCT00049114|PROCEDURE|therapeutic conventional surgery|Undergo complete resection
41096541|NCT00049114|OTHER|laboratory biomarker analysis|Correlative studies
41096542|NCT05069935|DRUG|FT538|FT538 is an allogeneic natural killer (NK)-cell immunotherapy
41096543|NCT05069935|DRUG|Cyclophosphamide|Lympho-conditioning agent
41096544|NCT05069935|DRUG|Fludarabine|Lympho-conditioning agent
41096545|NCT05069935|COMBINATION_PRODUCT|Monoclonal antibody - Dose Escalation|either avelumab, trastuzumab or cetuximab
41096546|NCT05069935|COMBINATION_PRODUCT|Monoclonal antibody - Dose Expansion|either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab
41096547|NCT03401398|DRUG|Hydrocortisone, sodium succinate|Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
41096548|NCT03401398|DRUG|Normal saline|Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
41096549|NCT01005992|PROCEDURE|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
41096550|NCT01005992|PROCEDURE|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
41096551|NCT06518499|PROCEDURE|Pilonidal sinus surgery|Bascom's Pit-Pick procedure, Primary Closure, Karydakis procedure
41443080|NCT05012254|DRUG|Paclitaxel|"Patients will receive Paclitaxel 200mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
41443081|NCT05012254|DRUG|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrol \[2,3 d\]-pyrimidine based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
41443082|NCT00781794|DRUG|NSA-789 at 2 different doses|
41096552|NCT03299387|DRUG|Nitrofurantoin|Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
41096553|NCT03299387|DRUG|Gentamicin|Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
41443083|NCT06430294|OTHER|Spinal mobilisation|Application of a force on pediatric manikins.
41443084|NCT00014768|DRUG|glucose|
41443085|NCT00014768|DRUG|insulin|
41443086|NCT00014768|DRUG|leucine|
41443087|NCT04905082|OTHER|Best Practice|Receive usual care
41443088|NCT04905082|OTHER|Educational Intervention|View HOPE-Genomics tool after genomic test results are available
41443089|NCT04905082|OTHER|Educational Intervention|View HOPE-Genomics before sequencing results are available
41096554|NCT02396056|OTHER|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
41443090|NCT04905082|PROCEDURE|Genomic Profile|Receive genomics test results
41443091|NCT04905082|OTHER|Survey Administration|Ancillary studies
41443092|NCT06562738|DRUG|Hetrombopag|Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\^9/L, and take blood routine examination weekly, drug administration was resumed when PLT \< 100 ×10\^9/L. When PLT ≤30× 10\^9/L or ≥300 ×10\^9/L, take blood routine examination every 3 days.
41443093|NCT06561191|OTHER|Hemodialysis mode, dialyzer type|Change of hemodialysis mode and dialyzer type
41443094|NCT01564394|BEHAVIORAL|Qigong|Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.
41443095|NCT01564394|BEHAVIORAL|Non-aerobic stretching|The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
41443096|NCT05204979|OTHER|Vaginal Versus Sublingual misoprostol|Insertion failures of intra uterine devices and cervical problems seem to occur more often among women who have never delivered vaginally. Several studies have shown the benefit of misoprostol as a cervical ripening agent in nonpregnant women. This trial will compare the effect of vaginal versus sublingual misoprostol prior to insertion of an intrauterine device in multiparous women delivered by CS.
41443097|NCT01498939|DRUG|insulin detemir|Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
41443098|NCT00990535|DRUG|Octreotide-LAR|Octreotide-LAR 30 mg administered every 21 days until progression
41443099|NCT06067438|DRUG|Amiodarone Hydrochloride|Given IV and via feeding tube
41443100|NCT06067438|OTHER|Saline|Given IV
41443101|NCT06095401|OTHER|Inelastic adjustable compression garment (INCOM)|Immediately following surgery, participants randomized to INCOM will wear an inelastic adjustable compression garment set to a minimum of 30mm Hg of compression utilizing a standardized garment tensioning tool. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
41443102|NCT06095401|OTHER|Elastic compression garment (CONTROL)|Immediately following surgery, participants randomized to CONTROL will wear a thigh-length elastic compression garment (thromboembolism-deterrent \[TED\] hose) for the first 3 weeks after TKA. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
41443103|NCT03125135|DEVICE|MightySat RX Pulse Oximeter Sensor|Noninvasive pulse oximeter finger sensor.
41443104|NCT01621945|BIOLOGICAL|MenBvac|Blood test
41453296|NCT00842127|DRUG|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
41453297|NCT03640741|PROCEDURE|Laparoscopy|The studies are carried out on patients who undergoes gynecological procedure that involves laparoscopy.
41096555|NCT02396056|OTHER|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
41096556|NCT04027972|DRUG|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
41096557|NCT04027972|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
41096558|NCT02328820|OTHER|Percutaneous coronary intervention (PCI)|For lesions with both FFR\<=0.8 and CFR\<2.0
41096559|NCT02328820|OTHER|Optimal medical therapy (OMT)|For lesions with FFR\>0.8 or CFR\>=2.0 or both
41096560|NCT03296371|PROCEDURE|Biospecimen Collection|Undergo saliva or buccal mucosa collection
41096561|NCT03296371|OTHER|Laboratory Biomarker Analysis|Correlative studies
41096562|NCT03296371|OTHER|Questionnaire Administration|Ancillary studies
41096563|NCT04796285|DEVICE|Lab Clasp|Finger-based interstitial fluid assessment device
41453298|NCT00635687|DEVICE|Fibroscan|transient elastography measure - Liver stiffness
40924774|NCT01568528|OTHER|Control|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will NOT receive oxytocin or PBO. They will only receive psychiatric screening interview, MCCB Consensus Cogntive Battery assessment, urine drug screen, vision testing, and the three social cognition tasks.
40924775|NCT01306578|DRUG|IVIG|Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
40924776|NCT01306578|PROCEDURE|Plasma Exchange|Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
40924777|NCT03540251|OTHER|Auricular Points Sticking|"Auricular Points Sticking is a kind of acupunture based on Meridians Theory of traditional Chinese Medicine.Sticking and pressing predefined therapeutic auricular points can relieve the frequency and severity of hot flashes and other climacteric symptoms.~Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points or placebo auricular points treatments."
40924778|NCT03073551|OTHER|Wii Group|Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
40924779|NCT02781740|DEVICE|Continous Positive Air Pressure Device|
40924780|NCT02087267|PROCEDURE|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
40924781|NCT05292898|BIOLOGICAL|LCAR-AIO Cells|LCAR-AIO Cells before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
40924782|NCT00693862|DRUG|levodopa, carbidopa, entacapone|
40924783|NCT00693862|DRUG|levodopa, carbidopa|
40924784|NCT05784285|BEHAVIORAL|Engagement in a 8-week community-based activity program|Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.
40924785|NCT04042246|BEHAVIORAL|Information Provision|Provide the information on the importance of the vaccination and tailored vaccination schedule
40924786|NCT04329221|DRUG|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriol (Calcipotriene) is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
40924787|NCT04329221|DRUG|Vaseline|Placebo
40924788|NCT04329221|DRUG|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
40924789|NCT02245425|OTHER|Supine Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
40924790|NCT02245425|OTHER|Prone Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
40924791|NCT03996369|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
40924792|NCT03996369|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
40924793|NCT04989153|DIAGNOSTIC_TEST|pepsinogen|serum pepsinogen diagnosed gastric cancer and precanceous lesion
40924794|NCT05814276|BEHAVIORAL|Training on non-pharmacological therapies' methodology|"The San Rocco study encompasses a training on the non-pharmacological therapies' methodology. It allows the professional caregiver to methodological definition of the non-pharmacological interventions and a comparison of shared readings of the challenging behaviors by the group of colleagues. Participants will follow:~* Five meetings, lasting 11 hours overall, on the multidimensional assessment, the shared readings of behavioral disorders of each person and identification of the objectives through the discussion of cases, and administration of non-pharmacological therapies within the framework of the personalization of the interventions~* Five meetings, lasting five and a half hours, for the supervision of the staff which implement the non-pharmacological therapies.~As usual control group Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training."
40924795|NCT05252260|PROCEDURE|Diode Laser|Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
40924796|NCT05252260|PROCEDURE|Conventional Surgery|A local anesthetic was administered bilaterally to the mental area and waited for 5 min for diffusion of the solution. Then, a horizontal incision was prepared at the mucogingival junction with a scalpel blade no. 15c. All the muscle fibers over the periosteum were resected carefully. Following, the mucosal flap was sutured to the depth of the vestibule sulcus with 4-0 polypropylene suture material, once every 4 mm, from a total of 5 regions.
41096564|NCT05515094|BEHAVIORAL|Empowerment Counseling Intervention|The intervention entails case managers conducting first-line support (i.e., a brief psychosocial support session), and a safety and health assessment, adapted from current case management content and the Safe and Sound intervention.
41096565|NCT06472089|BEHAVIORAL|BMT-CARE|Therapist-delivered psychosocial intervention comprised of 6 sessions
41096566|NCT06472089|BEHAVIORAL|Usual Care|Meeting a transplant social worker prior to HCT and as needed for extra visits
41096567|NCT03361592|PROCEDURE|Spinal Manipulative Therapy|Lumbar (SMT) was performed using Diversified techniques, aiming to correct vertebral dysfunctional lumbar segments. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
41096568|NCT03361592|PROCEDURE|SHAM|"The SHAM (pre-load positioning SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
41096569|NCT03102242|DRUG|Atezolizumab|Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.
41096570|NCT06554652|PROCEDURE|Lymph node tracer navigated selective neck dissection|Selective lateral lymph node dissection (after injection of tracer, lymph nodes in compartment III-IV are dissected; if there is dyed lymph node in compartment IIA, then IIA is dissected).
41096571|NCT06554652|PROCEDURE|Modified neck dissection|Lymph nodes in compartment IIA, IIB, III, IV, VB are dissected.
41096572|NCT00322699|PROCEDURE|Whole bladder laser light treatment as an alternative to radical cystectomy|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
41096573|NCT00322699|DRUG|Photofrin|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
41096574|NCT04045366|OTHER|Sample collection|Plasma and BAL sample collection
41096575|NCT02943382|OTHER|Fingerprick autologous blood (FAB)|Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
41096576|NCT01554592|DRUG|Withdrawal of statin therapy|Participants currently received statin therapy will have their statin stopped for 12 weeks.
41443105|NCT05574101|DRUG|Cemiplimab|Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.
40924797|NCT05252260|OTHER|Low level laser therapy (LLLT)|Vestibuloplasty surgery was performed via diode laser. Following, LLLT was applied in continuous wave mode for 1 minute without contacting the tissue, using a phototherapy probe (power output, 0.5W; total energy of 6 J / cm²) at a distance of 1-2 mm from the tissue. LLLT was repeated immediately after the surgery, on the 1st, 3rd and 7th days
41096577|NCT01554592|DRUG|Statin therapy|Participants will continue on stable statin therapy.
41096578|NCT04570644|DRUG|ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)|"Drug : ALZT-OP1a~1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~ALZT-OP1b anti-inflammatory~Device: Dry Powder Inhaler The inhaler will be used to deliver ALZT-OP1a via oral inhalation for dosing on study."
41096579|NCT00684970|DRUG|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118
41096580|NCT06446674|PROCEDURE|mini monaka|mini monaka,perforated plugs
41096581|NCT00689156|DRUG|Epirubicin, cyclophosphamide and docetaxel|Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
41096582|NCT00689156|DRUG|docetaxel, cyclophosphamide|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
41096583|NCT01526603|DRUG|Carboplatin|Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
41096584|NCT01526603|BIOLOGICAL|Autologous stem cell infusion|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
40924798|NCT03355547|OTHER|questionnaire about the severity of their symptoms of upper respiratory tract infection|Before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. The questionnaire consists of 8 types of symptom about upper respiratory infections and each symptom was checked from 0 to 3 according to severity by their patients.
41096585|NCT01526603|BIOLOGICAL|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) \> 2000/μL for 3 consecutive days.
41096586|NCT01526603|RADIATION|Radiation therapy|It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring \>1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.
41133426|NCT06451159|BIOLOGICAL|KYV-101 (Biological) - 0.33 ×10^8 cells|KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
41443106|NCT05574101|RADIATION|Radiotherapy|Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab
40924799|NCT00182585|PROCEDURE|computer-based HIV, STD & Hepatitis Education|
41096587|NCT01526603|DRUG|Isotretinoin (13-cis-retinoic acid)|Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients \>12 kg isotretinoin (accutane) should be administered at 160 mg/m\^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
41096588|NCT01526603|DRUG|Melphalan|Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
41443107|NCT00893685|DEVICE|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
41096589|NCT01526603|DRUG|Etoposide|Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
41096590|NCT05288101|DIETARY_SUPPLEMENT|Proteinex and Enterex DBT Victus Laboratories|The supplement was provided five days per week. Three days a week, the supplement was given at the beginning of the HD session and the patients were instructed to consume it slowly during the next 3 hours. The remaining two days, the supplement was consumed at home and instructed to be consumed between meals. The ONS consisted of one can of polymeric formula (Enterex DBT, Victus Laboratories) and 5.6 g of a protein powder supplement (Proteinex, Victus Laboratories). The final mixture provided 240 kcal, 17 g protein, 8.1 g lipids, 25 g carbohydrates, 4 g dietary fiber, 201 mg sodium, 490 mg calcium, 356 mg phosphorus and 371 mg potassium
41096591|NCT05288101|PROCEDURE|Dry weight adjustment through BIVA|Those participants with post-dialysis vectors located within the 50 or 75% ellipses, were considered to be in dry weight, so they did not require any fluid removal adjustment. However, participants with vectors outside the 75% ellipse were considered overhydrated or dehydrated and dry weight was adjusted. In these patients, if the vectors fell outside the 75% ellipse but within the 95%, above or below the major axis, the established dry weight was adjusted by 0.5 Kg. If the vectors fell outside the 95% ellipse, the weight was adjusted by 1.0 Kg.
41096592|NCT02387346|DEVICE|Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation|
41096593|NCT02387346|DEVICE|Magstim Rapid 2 Sham Stimulation|
41096594|NCT04456920|OTHER|phone consultation|At D1, D2 and D3, patients in the experimental group 1 will receive a call from a neuro-psychologist during which pain, anxiety and esthetical biopsy impact will be assessed using numeric or visual analog scales during a semi-direct interview. During this call, any adverse events related to the breast biopsy will also be noted, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken linked to the biopsy. If detected, pain or significative distress would be specifically managed.
41096595|NCT04456920|OTHER|e-PRO self-completed via connected objects (tablet/phone)|Patients in the experimental group 2 will be asked by SMS or notification to connect to the application in order to complete online the numeric and visual anog scales of pain, anxiety and esthetical impact. Any adverse events related to the breast biopsy will also be noted online, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy. If detected, pain or significative distress would be specifically managed
41096596|NCT04456920|OTHER|phone consultation|At D4 post biopsy, all patients (of the 3 groups) will receive a phone call from a neuro-psychologist to assess pain, anxiety and esthetical impact, using numeric scales, and to collect adverse events. If detected, pain or significative distress would be specifically managed.
41096597|NCT04456920|OTHER|visit|And at D10 (+/- 2 days), all patients will physically come to the Cancer center in the consultation of biopsy results announcement. At the beginning of this consultation, pain, anxiety and esthetical impact will be assessed using numeric scales. . The adverse events related to the breast biopsy will be collected as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy and its findings. Insomnia will be evaluated by the Insomnia Severity Index. If detected, pain or significative distress would be managed as usually in the center.
41096598|NCT02678052|DRUG|Vedolizumab|Vedolizumab exposure
41443108|NCT04587557|BEHAVIORAL|Storytelling with social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
41443109|NCT04587557|BEHAVIORAL|Storytelling without social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
41443110|NCT04587557|OTHER|Children with ASD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
41443111|NCT04587557|OTHER|Children with TD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
41443112|NCT06354023|DRUG|Recombinant human growth hormone|All participants will receive six weeks of treatment. Once per week, they will receive one intra-articular injection of 2cc (15IU) recombinant human growth hormone in their affected knee. The injection will also contain 1cc (1%) Lidocaine and 1cc (0.5%) Marcaine and Epinephrine for anesthetic purposes. The participants will receive a total of 6 growth hormone injections.
41096599|NCT02678052|BIOLOGICAL|Other Biological Agent|Other Biological Agent exposure
41096600|NCT03265704|OTHER|AGA - Control group|Data processing from Patient Medical Files
41096601|NCT03265704|OTHER|SGA - Control group|Data processing from Patient Medical Files
41096602|NCT03265704|OTHER|AGA-PIH Study group|Monitoring PIH-related changes in the newborn
41096603|NCT03265704|OTHER|SGA-PIH Study group|Monitoring PIH-related changes in the newborn
41096604|NCT05286424|PROCEDURE|fat grafting|Fat will be removed from abdomen or legs, processed and re-injected into grafting sites.
41096605|NCT01113515|DRUG|Esmolol hydrochloride|
41443113|NCT00070915|BEHAVIORAL|Tai chi|
41443114|NCT00070915|BEHAVIORAL|Mindfulness-based Stress Reduction program|
41096606|NCT01113515|DRUG|Esmolol hydrochloride|
41096607|NCT01113515|DRUG|Esmolol hydrochloride|
41096608|NCT01113515|DRUG|Placebo gel|
41096609|NCT04290429|DRUG|Teduglutide|Treatment of patients with SR-GI-GVHD with teduglutide
41096610|NCT01440244|PROCEDURE|Cervical mediastinoscopy|minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
41096611|NCT01450878|DRUG|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
41096612|NCT05996133|DRUG|Bupivacain|30 mL of 0.25% bupivacaine
41096613|NCT05996133|DRUG|Dexamethasone|0.5 mL (5 mg) preservative-free dexamethasone
41096614|NCT05996133|DRUG|Epinephrine|0.1 mL epinephrine 1:400,000.
41096615|NCT05996133|DRUG|Normal saline|3 mL normal saline
41096616|NCT04282902|DRUG|pirfenidone|Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer
41096617|NCT03398135|DRUG|risankizumab|subcutaneous (SC) injection
41096618|NCT03398135|DRUG|placebo for risankizumab|subcutaneous (SC) injection
41096619|NCT05407220|DRUG|HCP1904-1|take it once per period
41096620|NCT05407220|DRUG|HCP1904-3|take it once per period
41096621|NCT04376164|RADIATION|low level laser therapy|mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5J/cm2energy density, for 10 seconds at 10 points (0.2 J/point) on facial and lingual aspects. This protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months
41096622|NCT05060185|DEVICE|the Flow Diverter|Those who meet the inclusion criteria but do not meet the exclusion criteria will be enrolled through the electronic central registration system. The investigator log in to the central registration system, fill in the subject information and submit it who enroll in the study. The investigator complete the surgery and conduct relevant evaluation according to the protocol.
41096623|NCT04797533|DEVICE|The Body Information Management Systems (BIMS)|"The Body Information Management Systems (BIMS) are advanced biological sensors which monitor human behaviour, activity and basic vital signs. There is a combination of four separate ultra-sensitive weighing scales attached to each of the individual legs of a hospital bed measuring:~* Micro-changes in weight distribution~* Activity/sleep pattern~In addition to the bed-based system, there will be a wrist worn wearable (Samsung fit gear) that will monitor participants when they are both in and out of bed. These are about the size of a small watch, light weight, water resistant, and will be worn 24/7 by participants. These measure:~* Movement and sleep~* Heart rate"
41096624|NCT03748732|PROCEDURE|sclerectomy|scleral flap
41096625|NCT04444180|DIAGNOSTIC_TEST|Virtual hand illusion (VHI)|Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.
41096626|NCT00227981|BEHAVIORAL|Interpersonal Psychotherapy|
41096627|NCT00227981|DRUG|Fluoxetine|
41096628|NCT02793609|OTHER|Intervention is to let patient to go home.|Intervention is to let patient to go home.
41096629|NCT02793609|OTHER|Intervention is to observe women in the ward.|Intervention is to observe women in the ward.
41096630|NCT05582616|DEVICE|Transcranial Direct Current Stimulation|See treatment arm description
41096631|NCT05582616|DEVICE|Sham Transcranial Direct Current Stimulation|See sham comparator arm description
41096632|NCT06417489|DRUG|Combination therapy|Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day.
41096633|NCT06417489|DRUG|Sequential treatment group|Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels were measured. For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)\&gt;7mmol/L, postprandial blood glucose (PPG)\&gt;10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added. If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG\&gt;7mmol/L, PPG\&gt;10mmol/L), 100 mg qd of Ruigeliflozin was added
41096634|NCT06615479|DRUG|BMS-986393|Specified dose on specified days
41443115|NCT00070915|PROCEDURE|Therapeutic massage|
41096635|NCT06615479|DRUG|Cyclophosphamide|Specified dose on specified days
41096636|NCT06615479|DRUG|Fludarabine|Specified dose on specified days
41096637|NCT06615479|DRUG|Daratumumab|Specified dose on specified days
41096638|NCT06615479|DRUG|Pomalidomide|Specified dose on specified days
41096639|NCT06615479|DRUG|Dexamethasone|Specified dose on specified days
41096640|NCT06615479|DRUG|Carfilzomib|Specified dose on specified days
41096641|NCT03321760|RADIATION|Stereotactic Ablative Radiation Therapy (SABR)|SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
41096642|NCT01575470|BIOLOGICAL|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
41096643|NCT06478043|DRUG|ivonescimab|20mg/kg, IV, D1, Q3W
41096644|NCT06478043|DRUG|irinotecan liposome|56.5mg/m\^2, IV, D1, Q2W
41096645|NCT02334306|BIOLOGICAL|AMG 557/MEDI5872|Participants will receive a fixed SC dose of 210 mg MEDI5872 (AMG 557/MEDI5872) QW for 3 weeks (Days 1 to 15) and then Q2W for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, all participants from double-blind period will receive a fixed SC dose of 210 mg MEDI5872 from Day 99 to Day 183 (QW from Days 99 to 113 for participants from Placebo arm and on Days 99 and 113 for participants from MEDI5872 210 mg arm; and Q2W from Days 127 to 183 for participants from both arms).
41096646|NCT02334306|OTHER|Placebo|The SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, an additional dose of blinded placebo will be administered on Day 106 for participants who will receive MEDI5872 210mg in double-blinded period.
41096647|NCT01188486|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Standard of care diagnostic radiotherapy procedure
41096648|NCT01188486|RADIATION|Computed Tomography (CT)|For each participant, 3 chest CT scans will be obtained, 1 before and 2 after interstitial injection of the water-soluble contrast
41096649|NCT01188486|DEVICE|Cyberknife|Linear accelerator for producing high energy x-rays for radiation therapy.
41096650|NCT01188486|DEVICE|Trilogy|Linear accelerator for producing high energy x-rays for radiation therapy.
41096651|NCT01188486|DEVICE|True Beam|Linear accelerator for producing high energy x-rays for radiation therapy.
41443116|NCT02730650|OTHER|Platelet Rich Therapy (PRT)|Platelet Rich Therapy (PRT) involves injection of patient's own platelets and fibrin.Topical anesthetic will be applied to the face for a period of fifteen minutes prior to the injection. For PRP preparation, 8 cc of blood will be collected from each patient just before each procedure. Approximately 0.3-0.4 cc of PRP will be injected into each standardized injection point in a superficial manner. The injections points are 6 points on each side of the face along the inferior border of cheek and mid-cheek (12 total). The PRP injection will be followed by 10-15 minutes of icing.
41443117|NCT04946864|DRUG|APG-2575|APG2575 monotherapy
41096652|NCT01188486|DRUG|Iohexol|Aqueous solution of a nonionic, water-soluble radiographic contrast medium in prefilled cartridges with a molecular weight of 821.14 (iodine content 46.36%), available at 140, 180, 240, 300, and 350 mgI/mL.
41096653|NCT01188486|DRUG|Iodixanol|Aqueous solution of a nonionic, water-soluble, dimeric, isosmolar, radiographic contrast medium with a molecular weight of 1550.20 (iodine content 49.1%), available in 2 concentrations, (270 mgI/mL and 320 mgI/mL.
41096654|NCT00108524|BEHAVIORAL|Low carbohydrate ketogenic diet|A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
41096655|NCT00108524|DRUG|Orlistat|In addition to the low fat diet, Orlistat is taken 3 times daily.
41096656|NCT00108524|BEHAVIORAL|Low-fat diet|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
41096657|NCT03612115|DEVICE|Neuromuscular electrical stimulation|"Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.~Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France)"
41096658|NCT06413303|BEHAVIORAL|Experiential Classroom|Experiential classroom emphasizes putting pregnant women at the center, based on their subjective willingness and previous knowledge and experience, creating an environment for free discussion, exchange, and reflection, and utilizing peer education to fully mobilize the subjective initiative of pregnant women. This approach allows them to explore, discuss, reflect, and learn autonomously, aiming to truly absorb, master, and apply theoretical knowledge.
41096659|NCT04965883|PROCEDURE|Excision and Grafting|reconstruction of deep burn by grafting
41096660|NCT04965883|PROCEDURE|dressing then delayed grafting|multiple dressing and delayed grafting
41443118|NCT04946864|DRUG|Palbociclib|combination APG2575+pablociclib
41443119|NCT03475303|BEHAVIORAL|early hospital discharge|early hospital discharge at 8-12 hours for women undergone elective cesarean section
41443120|NCT05419739|OTHER|Glasgow coma scale|This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).
41443121|NCT03502148|DRUG|PRV111 (Cisplatin Transmucosal System)|Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
41443122|NCT04486794|DEVICE|Restylane®|Hyaluronic acid
41096661|NCT03329391|BEHAVIORAL|Nurse-led cognitive-behavioral-based group intervention|The intervention focused on the following topics of symptom awareness(i.e. provision of literacy in depression and stress), stress management, lifestyle restructuring and emotional self-care. These topics have been integrated as four major domains for discussions in the eight-weekly sessions. Each session starts with open discussion for participants' daily concerns to activate group dynamics, followed by second part of domain-oriented discussions, and then the third part of session review and homework reminder.
41096662|NCT00000456|DRUG|naltrexone (Revia)|
41096663|NCT00000456|BEHAVIORAL|cognitive behavior therapy|
41096664|NCT00000456|BEHAVIORAL|motivational enhancement therapy|
41096665|NCT04759131|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form: solution for injection Route of administration: IV
41096666|NCT02703129|OTHER|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
41096667|NCT05309486|OTHER|Online and Face-to-face Pilates trainings|Key elements of Pilates, including breathing, focusing, rib cage position, shoulder position, and head and neck positions, will be taught in both groups on the first day. Individuals will be asked to maintain the smoothness of these critical elements throughout the exercises. Different imagery techniques will be used in the exercises, and the exercises will be combined with breathing exercises. The intensity of the exercises will be increased by using different positions and elastic bands (Theraband Elastic Band Hygienic Corporation, Akron, Ohio). Band Resistances will be increased in biweekly periods. Stretching and posture exercises will be used during the cool-down period. The subjects in pilates group will be informed about the side effects such as shortness of breath, dizziness, headache, and muscle pain. Participants will be asked to stop the exercise in case of any side effects.
41096668|NCT04487587|DRUG|Cediranib, Olaparib|Cediranib film coated tablet, Olaparib film coated tablet
41443123|NCT02820350|DEVICE|SCD-F40|CRRT with SCD
41443124|NCT06249360|OTHER|Veins with reflux|This group included patients who used only recipient veins with reflux
41443125|NCT06249360|OTHER|Reflux-free recipient veins|This group included patients who utilized only reflux-free recipient veins
41096669|NCT03441984|DRUG|Treatment A|TRIUMEQ (Adult) administered as a, single dose, fixed dose combination (FDC) tablet - DTG 50 mg/ABC 600 mg/3TC 300 mg as 1 conventional tablet, orally as direct-to-mouth.
41096670|NCT03441984|DRUG|Treatment B|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/ 3TC 30 mg, orally as 10 dispersible tablets
41096671|NCT03441984|DRUG|Treatment C|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/3TC 30 mg, orally as direct-to-mouth.
41096672|NCT03441984|DRUG|Treatment D|"DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth."
41096673|NCT03441984|DRUG|Treatment E|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.
41096674|NCT03441984|DRUG|Treatment F|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
41096675|NCT04045743|DRUG|MABp1 (Bermekimab) OR Placebo|Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks
41096676|NCT04045743|DRUG|MABp1 (Bermekimab)|Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks
41096677|NCT05985915|DRUG|Ianalumab (VAY736)|VAY736 300 mg /2 mL, PFS, Solution for injection for subcutaneous use
41096678|NCT05985915|OTHER|Placebo|Placebo 0 mg/2 mL, PFS, Solution for injection for subcutaneous Use
41096679|NCT03955640|DRUG|Olaparib|Given PO
41096680|NCT03955640|PROCEDURE|Hyperthermia Treatment|Undergo hyperthermia treatment
41096681|NCT03955640|OTHER|Questionnaire Administration|Ancillary studies
41096682|NCT03955640|OTHER|Quality-of-Life Assessment|Ancillary studies
41096683|NCT02664376|OTHER|Sarcopenia detection|"The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~* Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~* Walking speed measurement~* Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected."
41096684|NCT05866081|DEVICE|Standard of care stent placement|Participants will have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
41096685|NCT05866081|OTHER|No stent placement|Participants not have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
41096686|NCT05866081|OTHER|Surveys|"All participants in the trial cohort and observational arms will be asked to complete survey instruments (evaluating their pain, quality of life, and experiences following ureteroscopy, as well as surveys evaluating their opinions and preferences around ureteral stenting, etc.).~Participants will also have routine clinical data (preoperative, perioperative, and postoperative) to be collected and analyzed for research purposes."
41096687|NCT00001421|DRUG|methimazole|
41096688|NCT00567879|DRUG|Panobinostat|Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m\^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
41096689|NCT00567879|DRUG|Trastuzumab|Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
41096690|NCT01182870|DRUG|choleclaciferol|800-6000 IU cholecalciferol per day
41096691|NCT03970811|PROCEDURE|Immediate Implants|dental implants are immediately placed after tooth extraction
41096692|NCT03970811|PROCEDURE|temporary restoration|temporary restoration will be placed immediately after implant placement
41096693|NCT03970811|PROCEDURE|final restoration|final restoration (loading) will be placed 3 months postsurgical
41096694|NCT02777879|PROCEDURE|Bronchoscopy|Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
41096695|NCT02476773|BIOLOGICAL|Na-GST-1/Alhydrogel plus GLA-AF|
41096696|NCT02476773|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel|
41443126|NCT00974558|DEVICE|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
41096697|NCT02476773|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel plus GLA-AF|
41096698|NCT02476773|BIOLOGICAL|Sterile Saline Placebo|
41096699|NCT05425264|OTHER|Tele-exercise|Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
41096700|NCT06306859|BEHAVIORAL|Using m-health for monitoring and education provision|The intervention group will be given access to m-health. The m-health aims to monitor patient's status i.e blood pressure, heart rate, fluid intake, dietary intake. In addition, there will be education provided through the m-health. The education will be on fluid and diet adherence
41096701|NCT06306859|OTHER|Standard care|The comparator group will be given standard and routine care
41096702|NCT00466791|DRUG|Methylphenidate Transdermal System|Placebo
41096703|NCT01434303|DRUG|Entinostat|Given PO
41096704|NCT01434303|OTHER|Laboratory Biomarker Analysis|Correlative studies
41096705|NCT01434303|DRUG|Lapatinib Ditosylate|Given PO
41096706|NCT01434303|BIOLOGICAL|Trastuzumab|Given IV
41096707|NCT05880238|BEHAVIORAL|Intervention group|The intervention consisted of a total of 3 modules, 20 sessions. These modules are: Module A: I explore my inner and outer world Module B: I am learning self-editing methods C module: discovering self-editing In these modules, students were trained to use sensorimotor strategies for self-regulation. The intervention program was carried out in one-hour sessions, twice a week, for a total of 10 weeks.
41096708|NCT05880238|OTHER|Control group|The control group will continue their education according to the preschool education curriculum.
41096709|NCT06281717|DEVICE|Fetal Endotracheal Occlusion (FETO)|The FETO insertion procedure will be performed between gestational age 27 weeks 0 days and 29 weeks and 6 days. The Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus using the Delivery Microcatheter (BALTACCI-BDPE100). The fetal tracheal balloon will be removed between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
41096710|NCT02704481|DRUG|Mifepristone|200mg oral mifepristone
41096711|NCT02704481|DRUG|Misoprostol|800mcg buccal misoprostol
41096712|NCT02704481|DRUG|Placebo mifepristone|Matching placebo pill of 200mg mifepristone
41096713|NCT02704481|DRUG|Placebo misoprostol|Matching placebo pills of 800mcg misoprostol
41096714|NCT01367561|DRUG|Naloxone|
41096715|NCT01367561|DRUG|IV Methylnaltrexone (MNTX)|
41096716|NCT01367561|DRUG|Placebo|
41096717|NCT03795701|DRUG|Saxenda®|Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
41096718|NCT03795701|OTHER|Placebo|Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
41096719|NCT01501435|DRUG|CJ-30039|single dose
41096720|NCT01501435|DRUG|fenofibric acid|single dose
41096721|NCT04511663|COMBINATION_PRODUCT|Assertive community treatment|The intervention team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers. The specific services provided by the team include individual service plan. Each patient got a comprehensive evaluation within one month to establish treatment goals and individual intervention plan, rehabilitation training, family intervention peer support group, individual psychological counseling and crisis intervention.
41096722|NCT04511663|COMBINATION_PRODUCT|Basic public health services.|The control group received regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge. The frequency was once a quarter.
41096723|NCT06149585|OTHER|Microbial Sampling|Pool microbial sampling will be performed and changes in the microbiome will be evaluated and compared for differences
41096724|NCT03688854|DIETARY_SUPPLEMENT|SCFA mixture|Intracolonic administration
41096725|NCT00003743|BIOLOGICAL|aldesleukin|
41096726|NCT05160675|OTHER||No intervention
41096727|NCT04751747|PROCEDURE|Computed Tomography|Undergo CT simulation
41096728|NCT04751747|OTHER|Contrast Agent|Given IV
41096729|NCT04642261|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg daily
41096730|NCT04642261|DRUG|Placebo pills|Identical in appearance to empagliflozin 10mg daily
41096731|NCT00486733|DEVICE|DermaGold|The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
41096732|NCT02932293|DRUG|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
41096733|NCT06504875|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
41096734|NCT06504875|DRUG|Interleukin-2|Interleukin 2 100IU HD,QOD d1-d14
41096735|NCT06504875|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-d14
41096736|NCT06504875|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 ivd, d1
41096737|NCT04549051|DEVICE|Tenex|Local anesthetic plus Tenex into the coracohumeral ligament for adhesive capsulitis
41096738|NCT04549051|DRUG|Local anesthetic|Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
41096739|NCT04010643|BEHAVIORAL|online cognitive behavioural therapy|oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey \& O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
41096740|NCT04010643|BEHAVIORAL|online neurocognitive remediation therapy|NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
41443127|NCT06562569|DEVICE|non-invasive cervical vagal nerve stimulation ncVNS|The ncVNS device is a rechargable, handheld device that generate a proprietary frequency-modulated electrical stimulus at low voltage (max 24V) with a max current output of 60mA. The signal consists of 1ms bursts of 5kHz sine waves repeated at 25Hz. Two stainless steel contact surfaces coated with conductive gel deliver the stimulus to the neck in the vicinity of the vagus nerve.
41096741|NCT04261712|DRUG|Paltusotine|Paltusotine, once daily by mouth
41096742|NCT04584021|DEVICE|Xiaomi MiBand3|Recording of sleep, activity and heart rate data to study their association with stress.
41096743|NCT04584021|OTHER|Socio-demographic questionnaire|Self-made questionnaire to be filled by the participants at the beginning of the study with the following personal data: age, gender, marital status, residential environment, cohabitation unit, educational level, socio-economic level, contract, working hours, overtime or not, number of overtime hours in a day, overtime frequency and perceived stress level
41096744|NCT04584021|OTHER|EuroQol-5D-5L|Quality of life questionnaire to be filled by the participants at the beginning, mid-term and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
41096745|NCT04584021|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Questionnaire to be filled by the participants whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning, mid-term, and completion of the study.
41096746|NCT04584021|OTHER|State-Trait Anxiety Inventory (STAI)|Questionnaire to be filled by the participants which measures the anxiety level. To be given at the beginning, mid-term and completion of the study.
41096747|NCT04584021|OTHER|Perceived Stress Scale-10 (PSS-10)|Questionnaire to be filled by the participants which measures the stress level. To be given at the beginning, mid-term and completion of the study.
41096748|NCT04584021|OTHER|Stress questionnaire|Questionnaire designed by a work stress psychologist professional from the research group which is focused on stress and daily functioning. This questionnaire was given for the participants to fill. It is composed by 3 daily items and 4 weekly items.
41096749|NCT00578214|DRUG|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
41096750|NCT00578214|OTHER|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
41096751|NCT00578214|DRUG|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
41096752|NCT00578214|DRUG|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (\>45 to 77 kg, 10 mg; \>77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
41096753|NCT06562608|DRUG|Anticholinergic Deprescription|per routine clinical care, people in the active arm of the study will undergo deprescription of benztropine or trihexyphenidyl per routine clinical care.
41096754|NCT06562608|DRUG|No Anticholinergic Deprescription|In this arm, no deprescription of benztropine or trihexyphenidyl will occur.
41096755|NCT01551615|DRUG|Metformin 1000 mg|2 x 500 mg oral tablets
41096756|NCT01551615|DRUG|Vandetanib 800 mg|2 x 300 mg and 2 x 100 mg oral tablets
41096757|NCT04408183|DRUG|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
41096758|NCT04408183|DRUG|Placebo|Placebo is given as a nasal spray using an atomizer
41096759|NCT02823496|OTHER|Sunscreen Lotion , BAY 987521|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
41096760|NCT02823496|OTHER|Untreated skin|One site is patched without treatment as control
41096761|NCT04007302|OTHER|measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)|measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method
41096762|NCT04007302|OTHER|completion of questionnaires|igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
41096763|NCT04007302|OTHER|completion of questionnaires for pain|analogical visual and numerical scale and Borg scale
41096764|NCT02483299|DRUG|Metformin|
41096765|NCT02483299|DRUG|Glucophage tablets and Victoza|
41096766|NCT03881254|OTHER|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
41096767|NCT03881254|OTHER|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
41096768|NCT03881254|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
41096769|NCT03881254|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
41096770|NCT02008864|DRUG|Senna|(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
41096771|NCT02008864|DRUG|Placebo|Placebo tablet/ 2 times per day
41443128|NCT06042738|COMBINATION_PRODUCT|proxeed plus|Group 1 was recommended to receive a food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg selenium, 3750 µg vitamin B12 and 500 µg folic acid as one sachet in the morning and evening
41096772|NCT03383887|DRUG|Placebo oral capsule|Placebo before sleep
41096773|NCT03383887|DRUG|DAW1033D oral capsule|DAW1033D before sleep
41096774|NCT03451643|PROCEDURE|ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT|PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
41096775|NCT02530151|DRUG|Morphine with clonidine|see arm description
41096776|NCT02530151|OTHER|Normal saline|see arm description
41096777|NCT00013143|BEHAVIORAL|Patient risk profiling (potential ADEs) w/provider feedback|
41096778|NCT03078920|DEVICE|Naída CROS|At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
41096779|NCT06434857|PROCEDURE|Strength training in older adults with mild or non existent cognitive impairment|Strength training program applied to strength training group
41096780|NCT06434857|PROCEDURE|Multimodal excercise in older adults with mild or non existent cognitive impairment|Multimodal exercise program applied to multimodal exercise group
41096781|NCT04449874|DRUG|GDC-6036|The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).
41096782|NCT04449874|DRUG|Atezolizumab|A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
41096783|NCT04449874|DRUG|Cetuximab|Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.
41096784|NCT04449874|DRUG|Bevacizumab|A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.
41096785|NCT04449874|DRUG|Erlotinib|150 mg of erlotinib will be administered PO QD in 21 day cycles.
41096786|NCT04449874|DRUG|GDC-1971|The starting dose of GDC-1971 will be determined from its single-agent dose escalation.
41096787|NCT04449874|DRUG|Inavolisib|The starting dose of inavolisib will be determined from its single-agent dose escalation.
41096788|NCT00387062|DEVICE|Computer-based Cognitive Training|
41096789|NCT06407934|DRUG|Amlitelimab|"Pharmaceutical form: Injection solution~Route of administration: Subcutaneous (SC) injection"
41096790|NCT06407934|DRUG|Placebo|"Pharmaceutical form: Injection solution~Route of administration: SC injection"
41096791|NCT04815057|BEHAVIORAL|Wellness Education|The wellness education given to fifth grade students and the quality of life, its effect on physical activity status
41096792|NCT01202851|OTHER|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
41096793|NCT01202851|BEHAVIORAL|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
41096794|NCT01202851|OTHER|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
41096795|NCT00589732|DRUG|Valsartan|Valsartan 160mg per day
41096796|NCT05629091|DEVICE|FibDex|Nanofibrillar cellulose wound dressing
41096797|NCT05629091|DEVICE|Epicite hydro|Wound dressing
41096798|NCT05629091|DEVICE|Epiprotect|Wound dressing
41096799|NCT00690456|DRUG|Rimonabant|Tablet, oral administration
41096800|NCT00690456|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
41096801|NCT00690456|DRUG|Metformin|Metformin continued at stable dose as background therapy
41096802|NCT03919617|DRUG|REMD-477|4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.
41096803|NCT06130878|OTHER|Rhythmic exercise|"A multicomponent rhythmic physical training will be carried out, with a predominance of QMT, following the principles of Animal Flow \[46\] and including the following components: wrist mobilizations; activations; specific stretching positions; special locomotor movements or traveling forms; interruptions and transitions with dynamic movements and choreographic sequences of Flow. Aspects related to the control of intensity, volume and progression strategy have yet to be defined."
41096804|NCT01600911|OTHER|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
41096805|NCT00284401|PROCEDURE|Evaluation of the placement of the Delta prosthesis|
41096806|NCT02549443|DIETARY_SUPPLEMENT|Amino acids|AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
41096807|NCT04895566|BIOLOGICAL|Monoclonal antibody (Mab) sB24M|200 mg monoclonal antibody (Mab) sB24 by injection into the affected areas.
41096808|NCT01392755|DRUG|danoprevir|oral doses of danoprevir
41096809|NCT01392755|DRUG|omeprazole|oral doses of omeprazole
41096810|NCT01392755|DRUG|ranitidine|oral dose of ranitidine
41096811|NCT01392755|DRUG|ritonavir|oral doses of ritonavir
41096812|NCT02219906|DIETARY_SUPPLEMENT|Resveratrol|1000mg tid
41096813|NCT02219906|DIETARY_SUPPLEMENT|Placebo|1000mg tid placebo
41096814|NCT03298932|PROCEDURE|Aortic valve surgery|Aortic valve surgery
41096815|NCT01588015|BIOLOGICAL|tetanus-CMV fusion peptide vaccine|Given SC
41096816|NCT01588015|OTHER|laboratory biomarker analysis|Correlative studies
41096817|NCT05545462|DRUG|Doxycyclin|THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA
41443129|NCT01118598|DRUG|tredaptive (nicotinic acid/ laropiprant)|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
41443130|NCT01118598|DRUG|placebo|placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
41096818|NCT05545462|OTHER|COMMON SALT|THE USE OF COMMON SALT IN TREATMENT OF UMBILICAL GRANULOMA
41096819|NCT04222244|OTHER|No intervention will be administered. We are only performing tests and measures.|No intervention will be administered. We are only performing tests and measures.
41096820|NCT00282438|BIOLOGICAL|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cells will be injected after conditioning
41096821|NCT00282438|BIOLOGICAL|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
41096822|NCT01407900|DRUG|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
41096823|NCT01407900|DRUG|5% Dextrose in Water|four hour infusion IV
41096824|NCT04895579|DRUG|Durvalumab|Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w.
41096825|NCT04895579|DRUG|Copanlisib|Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days.
41096826|NCT01751997|DRUG|Transplants from 8/8-matched Unrelated donors|"* Myeloablative conditioning~  1. Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~ 2. Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~ 3. Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* Reduced-intensity conditioning; older patients (age \> 55 years) and/or patients with comorbidities~  1. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m\^2)~ 2. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~ 3. Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11"
41133427|NCT06451159|BIOLOGICAL|KYV-101 (Biological) - 1 ×10^8 cells|KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
41133428|NCT06451159|DRUG|Chemotherapy: cyclophosphamide (CYC)|Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.
41096827|NCT01751997|DRUG|Transplants from family-mismatched/haploidentical donors|"* Reduced-intensity conditioning~  1. Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~ 2. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m\^2)~ 3. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11"
41096828|NCT02956499|DRUG|APX001 single dose 1|
41096829|NCT02956499|DRUG|APX001 single dose 2|
41096830|NCT02956499|DRUG|APX001 single dose 3|
41096831|NCT02956499|DRUG|APX001 single dose 4|
41096832|NCT02956499|DRUG|APX001 single dose 5|
41096833|NCT02956499|DRUG|APX001 single dose 6|
41096834|NCT02956499|DRUG|APX001 multiple dose 1|
41096835|NCT02956499|DRUG|APX001 multiple dose 2|
41096836|NCT02956499|DRUG|APX001 multiple dose 3|
41096837|NCT02956499|DRUG|APX001 multiple dose 4|
41096838|NCT02956499|DRUG|Matching Placebo|
41096839|NCT05383872|DEVICE|Focused Ultrasound (Exablate Model 4000)|BBB opening via Exablate Type 2 system with microbubble resonators and drawing blood before and after opening
41096840|NCT02441075|OTHER|70% Ethanol|the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
41096841|NCT01871818|BEHAVIORAL|Combined program|Combined program with physiotherapy, endurance training and resistance training
40924800|NCT00182585|PROCEDURE|educator-delivered HIV, STD and Hepatitis education|
40924801|NCT04951167|DRUG|Norepinephrine|in the form of infusion
41443131|NCT02462681|DRUG|paravertebral block|Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
41443132|NCT01043952|DRUG|Propofol|Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
41443133|NCT01043952|DRUG|Remifentanil|Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
40924802|NCT04951167|DRUG|Norepinephrine|in the form of bolus
41096842|NCT01871818|BEHAVIORAL|Physiotherapy in private practice|Physiotherapy in private practice
41096843|NCT04167709|OTHER|Education in clinical competence in detecting signs of postpartum depression in immigrant mothers|Groupbased educational intervention aimed at nurses in the Child Health Services in strengthening clinical competence in detecting signs of postpartum depression in non-native-speaking immigrant mothers
40924803|NCT03442868|DEVICE|high frequency rTMS|Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex (M1), supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) at different sessions. Walking performance is evaluated before and after the brain stimulation.
40924804|NCT00121862|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
40924805|NCT02502006|DRUG|Celecoxib|
40924806|NCT02502006|DRUG|Naproxen|
40924807|NCT02502006|DRUG|Placebo|
40924808|NCT06343857|DIAGNOSTIC_TEST|self-assessment questionnaire|Completion of the anatomical site-specific self-assessment questionnaire.
40924809|NCT05406115|DRUG|AMG 786|Oral tablet
40924810|NCT05406115|OTHER|Placebo|Oral tablet
40924811|NCT04613401|OTHER|questionnaire (observational study)|questionnaire about hospitalisation rates, complications (bleeding, infection, thrombosis), quality of life (Kansas-Score), depression (PHQ8)
41096844|NCT06081114|DIETARY_SUPPLEMENT|Micronutrient Supplement|A packaged food supplement providing calories and protein and fortified with micronutrients provided at an approximate RDA.
41096845|NCT00470795|OTHER|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
41096846|NCT00470795|PROCEDURE|placebo/sham acupuncture|acupuncture at sham points without skin penetration
41096847|NCT05892913|DRUG|Slow dose preemptive Atropine|it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)
41096848|NCT05892913|DRUG|Ephedrine|For sympathetic blockade (SBP\<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.
41096849|NCT06341374|BIOLOGICAL|Influvac Tetra|All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.
41096850|NCT06554483|OTHER|Exercise|supportive reliable exercise programs
41133429|NCT06451159|DRUG|Chemotherapy: fludarabine (FLU)|Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.
41133430|NCT03396107|DRUG|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
41133431|NCT03396107|DRUG|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
41133432|NCT01181232|DRUG|Zolpidem MR|oral
41133433|NCT01181232|DRUG|Zolpidem IR|oral
41133434|NCT00006045|BIOLOGICAL|lintuzumab|
41096851|NCT06555172|BEHAVIORAL|Action In Mindfulness (AIM)+|"AIM+ is a smartphone-based app that teaches mindfulness meditation to professionals working with legal-involved youth over a 30-day path. Each day of the path consists of a brief (approximately 5- to 10-minute) audio-guided meditation practice, with brief videos interspersed to illustrate key concepts and promote engagement. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they can use as relevant to their workday (e.g., for professionals to listen to before attending a meeting). AIM+ also includes a menu of audio-guided meditation practices that officers can share with the youth on their caseloads (e.g., for youth to listen to before attending court)."
41096852|NCT06555172|BEHAVIORAL|Resource+|Resource+ is a smartphone-based app that is matched to AIM+ for time and structure, but it includes information on community resources that professionals can provide to the youth with whom they work in place of the meditation content featured in AIM+.
41096853|NCT04463264|DRUG|Nitazoxanide|NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
41096854|NCT04463264|DRUG|Placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
41096855|NCT05731661|OTHER|Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse|During this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.
41096856|NCT05731661|OTHER|Delivery of useful information according to support care needs, concerning support care professionals in the city|Delivery of useful information according to support care needs, concerning support care professionals in the city
41096857|NCT05731661|OTHER|Delivery of a personalized post-cancer plan|Delivery of a personalized post-cancer plan
41096858|NCT00002556|DRUG|vincristine sulfate|Given IV
41096859|NCT00002556|DRUG|carmustine|Given IV
41096860|NCT00002556|DRUG|melphalan|Given PO
41096861|NCT00002556|DRUG|cyclophosphamide|Given IV
41096862|NCT00002556|DRUG|prednisone|Given PO
41096863|NCT00002556|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
41096864|NCT00002556|OTHER|laboratory biomarker analysis|Correlative studies
41096865|NCT03114722|DRUG|Citrate 4%|In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
41096866|NCT03114722|DRUG|Heparinised saline (10U/ml)|In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
41096867|NCT04036240|OTHER|Finger feeding|After discharge, subjects will be given HMF supplementation by finger feeding method using finger feeder
41096868|NCT04166682|BEHAVIORAL|Home-based cardiac rehabilitation|cardiac rehabilitation done at home
41096869|NCT04166682|BEHAVIORAL|Routine care|Routine care and followup
41096870|NCT00349908|DEVICE|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
41096871|NCT00349908|DEVICE|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE to treat wide-necked aneurysms
41096872|NCT04216823|DEVICE|perfusion index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
41096873|NCT06378372|BEHAVIORAL|Music therapy based on piano learning|The intervention will consist of pianistic training. Patients will receive piano classes adapted to their competence designed to achieve motor, sensory and behavioral control.
41096874|NCT00069862|DRUG|Deferitrin (GT56-252)|
41096875|NCT00069862|DRUG|desferoxamine (DFO)|
41096876|NCT01525433|BEHAVIORAL|DVD|Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening
41096877|NCT01525433|BEHAVIORAL|Promotora|Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
41096878|NCT01757509|OTHER|Intervention group|"Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.~Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling."
41096879|NCT00569946|DRUG|AG-013736|"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops."
41096880|NCT04639154|PROCEDURE|Erector spinea plane block|ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
41133435|NCT00006045|DRUG|cytarabine|
41133436|NCT00006045|DRUG|etoposide|
41133437|NCT00006045|DRUG|mitoxantrone hydrochloride|
41133438|NCT02281266|PROCEDURE|curative resection|
41096881|NCT06135831|OTHER|Functional olive paste|Homogenised olive pastes, enriched with mountain tea, were supplied by two ac-credited Greek olive oil and olive products companies, Arcadian Taste and GAEA. The fortified olive pastes, contained 7.5 g of extra virgin olive oil, 3.75 g of salt, 3.75 g of grated oregano, 3.75 g of grated pepper, 7.5 g of grated garlic, 6.25 g of orange juice, 65 g of Kala-mon olives without seeds and 3 g of mountain tea and weighted 100 gr per portion size, as well.
41096882|NCT06135831|OTHER|Calciovitmag (CDCaMg)|Vitamin C (1000 mg), vitamin D3 (500 mg), Calcium (Ca) (500 mg ) and Magnesium (Mg) (300 mg)/day
41096883|NCT06135831|OTHER|Phosporovitmag (PDCaMg)|Bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)/daily
41096884|NCT06135831|OTHER|Control|Vitamin D3 (500 mg), Calcium (500 mg) and Magnesium (300 mg)/daily
41096885|NCT03832660|BEHAVIORAL|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
41096886|NCT03832660|DRUG|Sacubitril/Valsartan|Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
41096887|NCT03735771|DRUG|Bupivacaine|0.25% bupivacaine plus fentanyl 8 mcg/ml
41096888|NCT01843465|OTHER|Maneuvers for documenting the disconnection|
41096889|NCT01027286|DEVICE|Vitagel|Vitagel applied just prior to closure during primary total knee arthroplasty
41096890|NCT06268028|BEHAVIORAL|Training|Discharge training
41096891|NCT04893980|DRUG|Recombinant human interleukin-2 (rhIL-2)|During Day 0-14, patients in this group will receive treatment with antihistamines at the same dosage as pre-recruitment, together with a low-dose recombinant human Interleukin-2 (rhIL-2) at a dosage of 1 million international units every other day by intramuscular injection (rhIL-2, 1 MIU, im, Qod). During Day 15-28, the injections of rhIL-2 will be continued at the same dosage and the dose of antihistamines may be adjusted according to the control of symptoms.
41096892|NCT04893980|DRUG|Control group|During Day 0-14, patients in the control group receive treatment with only antihistamines at the same dosage as pre-recruitment, but no injection of rhIL-2. During Day 15-28, treatment with low dose recombinant human Interleukin-2 (rhIL-2), i.e., 1 million international units every other day by subcutaneous or intramuscular injection (rhIL-2, 1MIU, im, Qod), will be added.
41096893|NCT02862704|BIOLOGICAL|MG7-CART|Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
41096894|NCT02396940|DEVICE|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
41096895|NCT02396940|DEVICE|2D HD laparoscopy|Placebo
41096896|NCT01103973|BEHAVIORAL|Mind/Body Program|Ten week group mind/body program
41096897|NCT01103973|BEHAVIORAL|Control|Spa gift certificates
41096898|NCT05560828|OTHER|Zio XT service|There will be no intervention. Standard of care at participating NHS organizations will not be affected.
41096899|NCT05471232|GENETIC|Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
41096900|NCT05471232|OTHER|EHR-Based Network Model|EHR-based network will be created to predict psychiatric outcomes in youth with IDDs
41096901|NCT00000821|DRUG|Aldesleukin|
41096902|NCT04291521|DRUG|Ketamine|Administering ketamine as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
41096903|NCT04291521|DRUG|Etomidate|Administering etomidate as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
41096904|NCT04291521|DRUG|Propofol|Administering propofol as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
41096905|NCT04763317|GENETIC|Prostate cancer risk gene panel|A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
41096906|NCT03826602|DRUG|Tucatinib|150mg administered orally twice daily
41096907|NCT03826602|DRUG|Metformin|850mg administered orally
41096908|NCT03826602|DRUG|Iohexol|1500 mg administered intravenously (IV)
41096909|NCT04310059|DIETARY_SUPPLEMENT|Folic acid|women will be randomised into one of the three groups. Group A - Folic acid 5mg/day Group B - Folic acid 0.5mg/day Group C - Materna one tablet/day (a pregnancy supplement containing 0.6mg folic acid)
41096910|NCT04310059|DIETARY_SUPPLEMENT|Materna|Materna
41096911|NCT03547505|PROCEDURE|R-Pilot®|Glide path preparation using R-Pilot® in reciprocating manner.
41443134|NCT01043952|DEVICE|Bispectral Index Monitor|Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
41096912|NCT03547505|PROCEDURE|ProGlider®|Glide path preparation using ProGlider® in a rotating manner.
41096913|NCT03547505|PROCEDURE|Manual preparation|Glide path preparation using manual K-files numbered from 08 to 15.
41133439|NCT02281266|DRUG|thymalfasin|1.6mg twice a week, 12 months
41133440|NCT02281266|DRUG|nucleoside analog (suggest to use entecavir)|
41096914|NCT02728271|BIOLOGICAL|HPC cell infusion|"Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.~Patients will not receive any cyclosporin A, rituximab, or azathioprine post transplant."
41096915|NCT04800302|PROCEDURE|Continous Quadratum Lumborum Block III|Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum \& psoas major muscles with ultrasound guidance.
41096916|NCT04800302|PROCEDURE|Single dose Quadratum Lumborum Block III|Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
41096917|NCT04800302|PROCEDURE|Intra-venous Morphine|Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
41096918|NCT02947815|DRUG|Clostridium Botulinum Toxin Type A|
41096919|NCT02947815|DRUG|Clostridium Botulinum Toxin Type A|
41096920|NCT00306683|DRUG|DIAZOXIDE|
41096921|NCT05094284|DEVICE|BioFreedom Ultra|this is a registry only
41096922|NCT01528124|DRUG|LY3025876|Given as a subcutaneous injection
41096923|NCT01528124|DRUG|Placebo|Given as a subcutaneous injection
41096924|NCT03276039|DIAGNOSTIC_TEST|plasma pentraxin-3|Plasma pentraxin-3 was measured using ELISA
41096925|NCT01348087|DRUG|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.
41096926|NCT02327039|DRUG|Dapagliflozin|Sodium glucose cotransporter-2 inhibitor
41096927|NCT02327039|DRUG|Placebo|Tables of Dapagliflozin placebo
41096928|NCT06055595|DIAGNOSTIC_TEST|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
41096929|NCT02292043|DRUG|HTEA|HTEA
41096930|NCT05203172|DRUG|Binimetinib only treatment|Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Parent Studies C4211001 and C4211003 with water irrespective of food, continuously, starting on Day 1.
41096931|NCT05203172|DRUG|Encorafenib only Treatment|Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent Study.
41096932|NCT05203172|DRUG|Encorafenib & Binimetinib Treatment|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
41443135|NCT04757883|OTHER|Study of the synthesis of antibodies directed against SARS|Between 5 mL and 45 mL of additional blood will be collected to study the synthesis of antibodies against CoV-2 SARS and to investigate whether specialised immune cells also show an effective response against the virus.
41096933|NCT05203172|DRUG|Treatment of Encorafenib & Binimetinib & Ribociclib|Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binimetinib tablets BID. The study drugs will be administered as a flat-fixed dose, and not by body weight or body surface area.
41096934|NCT05203172|DRUG|Treatment of Encorafenib & Binimetinib & Cetuximab|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
41096935|NCT02899585|OTHER|Questionnaires|
41096936|NCT02899585|OTHER|Score|
41096937|NCT00543725|DRUG|TMC278|25 mg tablet once daily for 96 weeks
41096938|NCT00543725|DRUG|efavirenz|600 mg tablet once daily for 96 weeks
41096939|NCT01385280|BIOLOGICAL|therapeutic estradiol|Given orally (PO)
41096940|NCT01385280|DRUG|exemestane|Given PO
41096941|NCT01385280|OTHER|laboratory biomarker analysis|Correlative studies
41096942|NCT01385280|OTHER|enzyme-linked immunosorbent assay|Correlative studies
41096943|NCT05091593|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional.
41096944|NCT05091593|BEHAVIORAL|Enhanced Usual Care|Usual care from health providers
41096945|NCT03664661|DRUG|BCMA nanobody CAR-T cells|"step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
41096946|NCT05032755|OTHER|SPECTRUM NRC 102/103 investigational cigarettes|Very low nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
41096947|NCT05032755|OTHER|SPECTRUM NRC 600/601 investigational cigarettes|Normal nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
41096948|NCT02096003|DRUG|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
41096949|NCT02096003|DRUG|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
41096950|NCT06103461|PROCEDURE|Autologous fat grafting|Autologous fat grafted at contour defects with pigmentary changes
41096951|NCT01106703|DIETARY_SUPPLEMENT|PG102, a water soluble extract from Actinidia arguta|PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks
41096952|NCT01106703|OTHER|placebo|placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks
41096953|NCT00135967|DRUG|mycophenolate mofetil orally 1000 mg twice a day (BID)|
41096954|NCT00135967|DRUG|prednisone 0,5 mg/kg orally on alternate days|
41096955|NCT00135967|DRUG|intravenous (i.v.) methylprednisolone 1000 mg, total 9|
41096956|NCT01374490|DRUG|Crofelemer|Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
41096957|NCT03646669|BEHAVIORAL|PEF Feedback|Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.
41096958|NCT03646669|BEHAVIORAL|Asthma education|General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device.
41096959|NCT00991744|DRUG|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
41096960|NCT00991744|DRUG|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
41096961|NCT01037933|OTHER|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
41096962|NCT01037933|OTHER|Non-humor intervention (distraction)|"A 45-minute non-humorous DVD (The A to Z of Steam Railways) using a portable DVD player"
41096963|NCT02458846|OTHER|Crowded HOTV Acuity Test|This is one of the most sensitive tests of acuity for vision screening of young children. The child is asked to recognize a letter (H,O,T,V) that is surrounded by bars to induce the crowding effects typical of amblyopia. Children were tested monocularly and was required to achieve at least 20/32 in each eye to pass. Children already wearing glasses were tested with their glasses on.
41096964|NCT02458846|OTHER|Preschool Randot Stereoacuity Test|"This is a reliable screening test for stereo depth perception for young children. Children wear polarized stereoglasses and are asked to identify or match shapes that are hiding in the snow, which cannot be perceived if the child has abnormal binocular vision. Children were required to achieve at least 60 arcseconds of disparity to pass. Children already wearing glasses were tested with their glasses worn under the stereo glasses."
41096965|NCT02458846|DEVICE|Plusoptix Autorefractor|Autorefractors are electronic devices that measure refractive errors by focusing a light onto the child's eyes and recording how their reflections from the retina return to the camera. The Plusoptix has been shown to have high sensitivity and specificity in previous research. AAPOS (2013) guidelines were used to determine the referral criteria.
41096966|NCT02458846|OTHER|Comprehensive Eye Exam|Children who did not pass all three screening tests were referred for full cycloplegic optometry exams, with a parent/guardian present. Optometrists assessed visual history, monocular visual acuity (near \& far), strabismus, binocular function, abnormalities of the anterior segment, and cycloplegic refraction. If the optometrist prescribed glasses, frames were chosen at the time of the exam and the glasses were dispensed either at school (with an optician) or at the optometrist's office.
41096967|NCT03615001|DEVICE|TDOC NXT|Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
41096968|NCT05753852|DRUG|Tauroursodeoxycholic Acid|Tauroursodeoxycholic acid (TUDCA) 250 mg capsules Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal Mode of administration: orally Duration: 18 months
41096969|NCT05538091|DRUG|Vismodegib|A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
41096970|NCT05538091|DRUG|Atezolizumab|Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
41096971|NCT03354533|DRUG|L-fucose|Oral ORL-1F
41096972|NCT00207129|DRUG|Ixabepilone|Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
41443136|NCT06106490|OTHER|the effect of adding pulsed radiofrequency (PRF) modality to suprascapular nerve injection with ultrasound glenohumeral steroid in chronic shoulder pain patients|"Suprascapular nerve block group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine~Pulsed radiofrequency group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine with application of pulse PRF at 42 Celsius of suprascapular nerve for 480 seconds."
41096973|NCT00207129|DRUG|Capecitabine|Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
41133441|NCT00415649|BIOLOGICAL|VRC-HIVDNA016-00-VP|
41133442|NCT00415649|BIOLOGICAL|VRC-HIVADV014-00-VP|
41443137|NCT05253443|BEHAVIORAL|Mentalizing Imagery Therapy and caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training and Mentalizing Imagery Therapy techniques with optional weekly group meetings.
41133443|NCT00415649|BIOLOGICAL|Vaccine placebo|Placebo comparator
41133444|NCT03929471|OTHER|Target weight correction protocol|The intervention group will undergo target weight correction process based on time averaged fluid overload measurement (by bio-impedance).
41096974|NCT00282776|BEHAVIORAL|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
41096975|NCT00282776|BEHAVIORAL|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
41096976|NCT00535067|BEHAVIORAL|Questionnaire|Questionnaires taking 60 minutes total to complete.
41096977|NCT03570255|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
41096978|NCT02028130|PROCEDURE|LAA electrical isolation + occlusion|LAA electrical isolation + Watchman device implantation to occlude LAA
41096979|NCT03055013|PROCEDURE|Nephrectomy|Undergo nephrectomy
41096980|NCT03055013|BIOLOGICAL|Nivolumab|Given IV
41096981|NCT03055013|OTHER|Patient Observation|Undergo observation
41096982|NCT03055013|OTHER|Quality-of-Life Assessment|Ancillary studies
41096983|NCT03055013|OTHER|Questionnaire Administration|Ancillary studies
41096984|NCT04171661|BIOLOGICAL|SASS|SASS applied on chronic skin wounds as skin graft
41096985|NCT03239925|RADIATION|Electromagnetic field of cell phone in ''on'' mode.|In experimental group, participants would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
41096986|NCT03239925|RADIATION|Electromagnetic field of cell phone in 'off' mode.|In control group, participants would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode.
41096987|NCT03767114|DIAGNOSTIC_TEST|RT-PCR for ERAP1 detection|Reverse transcriptase -Polymerase Chain Reaction for ERAP1 detection
41096988|NCT03742713|DRUG|CPC634 (CriPec® docetaxel)|Docetaxel containing CriPec® nanoparticles
41096989|NCT04599114|BEHAVIORAL|VIRTUES|VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
41096990|NCT06068166|COMBINATION_PRODUCT|TEA plus GDMT|Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to T4 levels in thoracic and abdominal surgical procedures. Since 1995, Professor Liu Fengqi has pioneered the use of TEA to treat end-stage HFrEF and achieved surprising results. TEA could reduce the enlarged heart cavity, halt and reverse cardiac remodeling, and improve cardiac systolic and diastolic function. Currently, thousands of HFrEF patients have received TEA procedure. All the patients received maximally tolerated guideline-directed medical therapy (GDMT).
41096991|NCT06068166|DRUG|GDMT|All the patients received maximally tolerated guideline-directed medical therapy (GDMT) alone.
41096992|NCT03688828|DRUG|Saccharomyces boulardii|500mg bid
41096993|NCT03688828|DRUG|Esomeprazole|20mg bid
41096994|NCT03688828|DRUG|Amoxicillin|1.0g bid
41096995|NCT03688828|DRUG|Clarithromycin|0.5g bid
41096996|NCT03688828|DRUG|Bismuth potassium citrate|0.22g bid
41096997|NCT03247348|BEHAVIORAL|ReSeT-FM intervention|The ReSeT-FM intervention focuses on behavior changes strategies aimed at reducing sedentary time and includes: education, goal setting, self-monitoring of behavior and behavioral prompts to move via an activity tracker and phone app, and feedback on behavior via weekly meetings with study coaches.
41096998|NCT01511250|BIOLOGICAL|TDV|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
41096999|NCT01511250|BIOLOGICAL|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
41097000|NCT02918916|OTHER|Phototherapy|The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
41097001|NCT02918916|OTHER|Placebo|The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
41443138|NCT05253443|BEHAVIORAL|Caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training with optional weekly group meetings.
41443139|NCT04518059|PROCEDURE|punch skin biopsy|An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.
41443140|NCT03380845|DEVICE|Fraxel Restore|Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.
41097002|NCT02142439|BEHAVIORAL|Strength training|Three times per week with strength training
41097003|NCT03061344|BIOLOGICAL|DVIU treated with liquid buccal mucosal graft|DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)
41097004|NCT00603356|DRUG|OSI-930 and erlotinib|OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
41097005|NCT06530667|DEVICE|broadband collaborative pulse ablation|Via CT guided, patients with malignant pulmonary nodules would be treated by broadband collaborative pulse ablation
41097006|NCT02636413|DRUG|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
41097007|NCT02636413|DIETARY_SUPPLEMENT|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
41097008|NCT03550027|DEVICE|PleurX|Positioning of drainage PleurX
41097009|NCT03550027|DEVICE|Pleurocath|Positioning of drainage Pleurocath
41097010|NCT00841282|PROCEDURE|Colonoscopy for colorectal cancer screening|
41097011|NCT00841282|PROCEDURE|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
41097012|NCT00841282|PROCEDURE|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
41097013|NCT04018417|DRUG|Amphotericin B|Drug concentration: 0.255 μg/mL
41097014|NCT03976609|PROCEDURE|Maxillary Expansion|The patients with maxillary transverse deficiency were treated with Haas expander is a tooth and tissue-borne appliance with a jackscrew located at the anterior region of the arch with its arms bent posteriorly and soldered to the first permanent molar bands. Once activated, the appliances opens the palatal suture and increase the transverse dimension of the maxilla.
41097015|NCT05776576|BEHAVIORAL|Evaluation|Within the scope of the evaluation, first of all, physical activity levels of children and adolescents with physical disabilities, barriers that prevent them from participating in physical activity, and motivators that can increase their participation will be determined, accompanied by an interactive roundtable meeting. Afterwards, posture analyzes of children and adolescents with special needs with physical disabilities will be performed by physiotherapists.
41097016|NCT05776576|BEHAVIORAL|Education|"In the education part, interactive informative seminars titled Physical Activity in Individuals with Special Needs will be given and after the objective posture assessments, postural disorders of children and adolescents with special needs will be determined and accordingly, posture and ergonomics training will be given to the participants individually."
41097017|NCT05776576|OTHER|Experimentation|In the experimentation part, group exercises, dance therapy programs and technology-supported exercise educations with various technological equipment will be implemented in the company of physiotherapists, taking into account the posture assessments.
41097018|NCT03453385|BEHAVIORAL|Electronic Cigarette|An e-cigarette and four weeks of e-liquid provided to participants.
41097019|NCT04859764|DEVICE|Reparel knee sleeve|Unlabelled thermo-active knee sleeve that improves bloodflow to knee and decreased pain
41097020|NCT04859764|DRUG|Corticosteroid injection|intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)
41097021|NCT04859764|DEVICE|Placebo knee sleeve|unlabeled compression knee sleeve
41097022|NCT02712619|DRUG|Metformin|
41097023|NCT01387256|DRUG|medical abortion|pregnancy termination with drugs
41097024|NCT01120275|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
41097025|NCT01120275|OTHER|laboratory biomarker analysis|Correlative studies
41097026|NCT04332653|DRUG|NT-I7|Administered by intramuscular (IM) injection
41097027|NCT04332653|DRUG|pembrolizumab (KEYTRUDA®)|Administered by intravenous (IV) injection
41097028|NCT04455841|DRUG|INCB000928|INCB000928 will be administered at protocol defined dose.
41097029|NCT04455841|DRUG|ruxolitinib|Ruxolitinib will be administered at protocol defined dose.
41097030|NCT03545789|DRUG|[18F]MNI-958|Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
40752044|NCT01935505|BEHAVIORAL|Consulting|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
41097031|NCT03076450|DEVICE|Lung Ultrasound|Adjust PEEP real-time in term of LUS-RAS chang.
41097032|NCT03076450|DIAGNOSTIC_TEST|Maximum Oxygenation|Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
40924812|NCT03450330|DRUG|AZD4205|Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
40924813|NCT01585519|DIETARY_SUPPLEMENT|High/ Low Epicatechin Apples/ Apple Extract/ Granules|"(Group 1) Low Apple Diet (i.e. \<1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily."
41097033|NCT06055621|DRUG|Dasatinib|Daily orally administration of DASATINIB
41097034|NCT02180113|DEVICE|Fibroscan® examination|Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
41097035|NCT00005581|DRUG|cyclophosphamide|
41097036|NCT00005581|DRUG|epirubicin hydrochloride|
41097037|NCT00005581|DRUG|fluorouracil|
41097038|NCT00005581|DRUG|paclitaxel|
41097039|NCT05417204|BEHAVIORAL|Abdominothoracic biofeedback|A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.
41097040|NCT02375321|BEHAVIORAL|CPAP and Psychological support|Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
41443141|NCT03380845|DEVICE|Fractora|Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
40752045|NCT01935505|DRUG|Nicotine patch|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
40924814|NCT00423527|DRUG|levetiracetam|Levetiracetam tablets 500 mg, total daily dose 3000 mg
40924815|NCT02400164|DEVICE|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
40924816|NCT03430453|PROCEDURE|Measure of the minimal intensity of stimulation during ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed. The Minimal Intensity of Stimulation is recorded before injection of local anesthetic
41097041|NCT00624546|DRUG|Prevacid Solutabs|BID Prevacid Solutabs
41097042|NCT00624546|PROCEDURE|Antireflux surgery|Lap Nissen
41097043|NCT04181931|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
41097044|NCT04181931|PROCEDURE|Surgery alone|hepatic resection remove the liver tumor and portal vein tumor thrombus
41097045|NCT04590989|OTHER|Personalized Nutrition Plan|"* Personalized breakfasts and dinners designed and cooked by Simplefeast, delivered twice a week (eaten 6 days per week) + access to Simplefeast's App for recipes of other meals not provided (i.e. lunches and Saturdays) which are designed to match the individual nutritional recommendations.~* Personalized behavioral change program via electronic push notifications by ONMI"
41097046|NCT04590989|OTHER|Non-Personalized Nutrition Plan|"* Standard meals of breakfasts and dinners designed and cooked by Simple feast, based on general dietary recommendations, and delivered to participants twice a week. In addition, they will also have access to Simple feast's recipe App for other meals not provided. The recipes presented are generic, not personalized.~* Subjects in the control group will also be enrolled in the behavioral program by ONMI, but the program will not be personalized nor based on the same behavior change methodology as in the PP group. In other words, the control group will get information more than is triggered to take actual action (i.e. general guidelines that is available from the National Health Service and World Health Organization)."
41097047|NCT04332757|OTHER|Training intervention.|The investigators have designed a phased 18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation. The rehabilitation element of the programme will specifically target pelvic floor function and core strength and stability (known collectively as Core Reconnection training) from weeks 6 to 24 postpartum, and the training element of the programme will contain resistance and high-intensity interval training (HIIT) from weeks 12 to 24 postpartum.
41097048|NCT03363256|BEHAVIORAL|TES-NAV|Internet-delivered psychosocial treatment grounded in the community reinforcement approach plus contingency management adapted for AI/AN
41097049|NCT03363256|BEHAVIORAL|TAU|Standard outpatient addiction treatment
41097050|NCT01888406|BEHAVIORAL|Guided Self-Help|
41097051|NCT01888406|BEHAVIORAL|Pure Self-Help|
41097052|NCT05680012|DIETARY_SUPPLEMENT|Gluten containing snack bar|Ingest snack bars containing 3 grams of gluten every day for 6 weeks.
41097053|NCT04054661|DIAGNOSTIC_TEST|SD Biosensor STANDARD G6PD Test|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
41097054|NCT04054661|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
41097055|NCT04054661|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
41097056|NCT04506190|PROCEDURE|Revisional bariatric surgery|Subjects who undergo revisional bariatric surgery
41097057|NCT00274989|DRUG|Bendamustine|"First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6~2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6"
41097058|NCT00274989|BIOLOGICAL|Rituximab|"First-Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6~2nd to 4th -Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6"
41097059|NCT05763004|DRUG|IOS-1002|monotherapy
41097060|NCT05763004|DRUG|IOS-1002 + KEYTRUDA® (pembrolizumab)|combination therapy
41097061|NCT01051882|BIOLOGICAL|MSC-NTF cells transplantation (IM)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
41097062|NCT01051882|BIOLOGICAL|MSC-NTF cells transplantation (IT)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
41097063|NCT05784935|DEVICE|Real time AI detection model|Bowel preparation will be conducted according to usual local practices. During colonoscopy, the colonoscope will be first advanced to the cecum in all patients as confirmed by identification of the appendicular orifice and ileocecal valve or by intubation of the ileum, as per the standard of care by experienced endoscopists. During the insertion, no action will be taken. After cecal intubation is performed, the colonoscope will be slowly withdrawn to the splenic flexure by the primary endoscopists. Real time AI detection model will be activated with the output displayed in real time on a separate monitor and will be only viewed by an independent investigator, who is an experienced endoscopists (or a person trained in polyp recognition). The primary endoscopists will be blinded to the AI real time detection result
41097064|NCT06631781|OTHER|GOLD-Cog+|6 weeks of combined cognitive intervention (GOLD-Cog+),which includes participation in 9, one hour long Cognitive-Orientation to Occupational Performance(CO-OP)-based group sessions and 24 individual and independent 30-minute computerized cognitive training (CCT) program using the Effectivate platform (Israeli-based CCT developed for older adults. Available in both Hebrew and English).
41097065|NCT06121115|DRUG|Norepinephrine|Norepinephrine administered in midline catheter according to clinical routine
41097066|NCT06629493|BEHAVIORAL|Fitbit Versa 3|Fitbit Versa 3 is a commercially available activity tracker
41097067|NCT06629493|BEHAVIORAL|In-patient alcohol use disorder treatment|In-patient alcohol use disorder treatment, including group therapy, counseling, and occupational activities
41097068|NCT05852366|DRUG|Toothpaste Preparation|Dentifrice for management of dentinal hypersensitivity
41443142|NCT03899077|DRUG|Apalutamide|Apalutamide 240mg daily for 6 months (i.e. 6 28-day cycles); oral use
41443143|NCT03899077|DRUG|Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial|Leuprorelin acetate 45mg for 6 months; subcutaneous use
41097069|NCT03485729|DRUG|ONC201|ONC201
41097070|NCT01674569|DRUG|X-82 oral|X-82 oral for 24 weeks or until unacceptable toxicity develops
41097071|NCT01674569|DRUG|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
41097072|NCT06629948|DEVICE|x ray|whole spine x ray posterioanterior and lateral views
41097073|NCT06629948|DIAGNOSTIC_TEST|the cranio-cervical flexion test|measure of deep neck flexors muscles endurance
41097074|NCT03232268|BIOLOGICAL|HLA-mismatched microtransplantation|3 administrations of hematopoietic stem cells without immunosupression
41097075|NCT05512390|DRUG|ABBV-319|Intravenous (IV); Infusion
41097076|NCT03885037|DRUG|Infliximab [infliximab biosimilar 3]|\<Rheumatoid arthritis\> The usual dose is 3 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks. This drug should be given in combination with methotrexate.
41097077|NCT05397457|DEVICE|low-level light therapy|"Device: Hair Boom 69~All participants within the experimental group will undergo low-level light therapy sessions 3 times a week for the total duration of 4 weeks starting at their last CT administration.~If the participants can not cooperate to receive the therapy 3 times a week due to personal reasons, we will recommend that they undergo 2 courses of the therapy per week at least and finish the 12 courses of the intervention in 6 weeks."
41097078|NCT05427357|OTHER|Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)|"Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats."
41097079|NCT06547645|OTHER|Sub-Acute Rehab at Home|Patients randomized to the intervention group will receive skilled nursing and rehabilitative care at home upon discharge from the hospital, or when eligible for skilled-nursing facility care when requiring a step up in services at home. Home care will be delivered and overseen by a multidisciplinary clinical team, which will develop individualized care plans based on diagnosis, specific rehabilitation objectives, and broader goals of care.
41097080|NCT06629246|DRUG|Conventional heart failure treatment|Conventional heart failure treatment, which may include pharmacological therapies such as diuretics, ACE inhibitors/ARBs, beta-blockers, or aldosterone receptor antagonists, based on the clinical requirements of the condition.
41097081|NCT06629246|DRUG|Pogejiuxin decoction combined with conventional heart failure treatment|In addition to receiving standard heart failure treatment, patients are also administered Pogejiuxin Decoction.The formula of Pogejiuxin Decoction is as follows : Processed Aconite 60g (decocted initially for 1 hour), Dried Ginger 60g, Honey-fried Licorice 60g, Cornus officinalis 60g, Ginseng 30g (decocted separately), Raw Dragon Bone 30g (decocted initially for 1 hour), Raw Oyster Shell 30g (decocted initially for 1 hour), Living Magnetite 30g, for a total of 7 prescriptions. Usage: Uniformly decocted with a herbal medicine decoction machine to obtain the medicinal liquid, one prescription per day, taken twice daily in the morning and evening, each time 100ml, for a continuous treatment of 7 days.
41097082|NCT06628661|PROCEDURE|Surgery for HCC larger than 6.5 cm|Surgery for HCC larger than 6.5 cm without mVI
41097083|NCT06628661|PROCEDURE|Surgery for HCC larger than 2 cm|Surgery for HCC larger than 2 cm with mVI
41097084|NCT06321172|DEVICE|FES Bike|Six months of FES-cycling trainings twice a week is performed for each pilot. Each session includes at most 30 minutes of stimulation. At the beginning of the training period, a conditioning phase is performed until the pilot reaches pedalling autonomy. This period is also used to define the stimulation parameters (minimum and maximum values of current intensity and pulse width), reference cadence and gear, specific for the ability of each pilot. Then the training period starts and is performed indoor, setting the resistance of the smart trainer at 10% for all the participants. The sessions are organized as follows: a 3-minute warmup followed by four sets of 6 minutes of pedalling and a 3-minute cool down.
41097085|NCT06336356|DRUG|Baxdrostat|Baxdrostat will be administered orally once daily.
41097086|NCT06336356|DRUG|Placebo|Placebo will be administered orally once daily.
41270708|NCT06123312|DIAGNOSTIC_TEST|Tri-modality biopsy|When the lung nodule is visualized by ultrathin bronchoscope (3mm) with RP-EBUS, Tri-modality biopsy is performed.
41270709|NCT02965157|BIOLOGICAL|CART20|
41270710|NCT05215184|DEVICE|Zeto WR19 EEG Recording|15 minutes of EEG recording to be obtained from eligible participants
41443144|NCT03899077|DRUG|Goserelin Acetate 10.8 MG Subcutaneous Implant|Goserelin acetate 10.8mg for 6 months; subcutaneous use
41443145|NCT03899077|DRUG|Triptorelin Pamoate|Triptorelin pamoate 22.5mg for 6 months; intramuscular use
41443146|NCT03899077|DRUG|Degarelix acetate|Degarelix acetate 80mg for 6 months; subcutaneous use
41443147|NCT04977739|DIAGNOSTIC_TEST|No intervention|No intervention
41443148|NCT05293106|BIOLOGICAL|Platelet Transfusion|All platelet transfusions will be given as 10mL/kg as is considered standard of care.
40752046|NCT01935505|BEHAVIORAL|Telephone intervention|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
41097087|NCT06631794|BEHAVIORAL|A short talk about the importance of HPV vaccination|"Investigator plan to set up a short talk to 3rd grade classes in addition to the usual sexual health training. The issue of HPV vaccination will be systematically addressed for 10 minutes to encourage catch-up vaccination.~The usual training include different themes such us : definition of sexual health, anatomy, sexually transmitted infections contraception/condoms, menstrual cycles, voluntary interruption of pregnancy, consent, sexual abuse/violence/harassment, pornography, anti-discrimination....~A 45-minute talk will include 2 or 3 topics from the above list. A ten minutes of talk will be added to the usual training to explain the HPV vaccination (a topic not usually addressed in sexual health training), covering the following elements: definition of HPV infection"
41097088|NCT02246621|DRUG|Abemaciclib|Administered orally
41097089|NCT02246621|DRUG|Anastrozole|Administered orally
41097090|NCT02246621|DRUG|Letrozole|Administered orally
41097091|NCT02246621|DRUG|Placebo|Administered orally
41097092|NCT04172844|DRUG|Azacitidine|75mg/m\^2 Days 1-7 given IV
41097093|NCT04172844|DRUG|Venetoclax|100 mg on cycle 1 day 1, 200 mg daily on cycle 1 day 2, 400 mg on cycle 1 day 3 and thereafter from cycle 1. Venetoclax is given for a minimum of 21 days and a maximum of 28 days. Administered orally.
41097094|NCT04172844|DRUG|Pevonedistat|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
41097095|NCT06629766|DEVICE|Microfluidic sperm separation device|An aliquot of 850ul will be used for the Zymot sperm selection device. The sperm processing via Zymot will be per manufacturer's guidelines
41097096|NCT06629766|OTHER|Density grade centrifugation|5ul of the ejaculated sample will be assessed for DGC via Makler assessment. If the sample for DGC is adequate per lab standard operating procedures, then routine DGC sperm preparation and embryologist sperm selection for the ICSI procedure will occur.
41097097|NCT04630652|DRUG|Risankizumab-Rzaa|Risankizumab at a dose of 150 mg with injections administered at baseline, week 4 and week 16 following FDA-approved dosage and time periods
41097098|NCT04630652|PROCEDURE|Punch biopsies of the skin at baseline visit|Two 6 mm punch biopsies of the skin at baseline visit
41097099|NCT04630652|PROCEDURE|Punch biopsies of the skin at week 28 visit|One 6 mm punch biopsy of the skin at week 28 visit
41097100|NCT06575959|DRUG|Enlicitide|Oral tablet
41097101|NCT06631001|OTHER|Abdominal Massage|Abdominal massage will be administered twice a day for 15 minutes over three days. This intervention aims to evaluate its effects on defecation frequency, gastric residual volume, and abdominal distension.
41097102|NCT06250855|DEVICE|Mini Toric IOL|Adults (males and females) ≥18 years with cataract and pre-existing corneal astigmatism who have undergone monocular or binocular Mini Toric Ready implantation after cataract surgery in which the cataract lens was removed by phacoemulsification, with circular capsulorhexis, leaving the posterior capsule intact.
41097103|NCT01398930|OTHER|acupuncture|This is a 3-armed single-blinded randomized sham-controlled trial, comparing acupuncture along with pharmacological treatment, sham acupuncture including pharmacological treatment, and pharmacological treatment alone.
41097104|NCT03736785|DRUG|LY3209590|Administered SC
41097105|NCT03736785|DRUG|Insulin Degludec|Administered SC
41097106|NCT05489224|BIOLOGICAL|CT-P47|CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)
41097107|NCT05489224|BIOLOGICAL|EU-approved RoActemra|EU-approved RoActemra, 8 mg/kg (not exceeding 800 mg/dose) by IV infusion Q4W
41097108|NCT02211768|PROCEDURE|MRI, FDG-PET/CT scans|Standard of care to be obtained as part of the study
41097109|NCT02211768|DRUG|[18F]-FLT-PET/CT scans|FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
41097110|NCT04244318|BEHAVIORAL|Video-feedback ODISEA 3.0|Video-feedback intervention ODISEA 3.0 (Gómez \& Maureira, 2022), which incorporates an attachment theory framework. This intervention was constructed within the ODISEA's comprehensive and formative model of parenthood which was developed in Chile by Dr. Esteban Gómez Muzzio (Gómez, 2022).
41097111|NCT04244318|BEHAVIORAL|ODISEA-DTP: parental therapy|Parental Therapy (ODISEA-DTP, Gómez \& Maureira, 2022): is a parental therapy strategy that works over 5 sessions with the history of caregivers in a systematic way, allowing to explore their past, present and expected future concerning parenting, child rearing, attachment and child abuse, between other issues. The DTP is a protocolized model of parental therapy, each session is carefully designed to elicit memories, emotions and to stimulate reflective function (about the past and their own childhood) and parental reflective function (about the present with the child).
41097112|NCT04244318|BEHAVIORAL|Treatment as usual|"Psychosocial intervention (parental education, family counseling, home visits and school and Court coordination) for child abuse and neglect, implemented by six Family Therapeutic Programs (AFT) of the NGO Protectora de la Infancia"
41097113|NCT06628596|DIETARY_SUPPLEMENT|Paraxanthine 200mg and 300mg|Participants consumed 200 mg paraxanthine (PXN 200), 300 mg paraxanthine (PXN 300), or placebo (PLA) after an overnight fast. Supplements were ingested 30 minutes before a mixed meal in double-blind, randomized, placebo-controlled, crossover fashion.
41097114|NCT02463162|OTHER|Conversations Matter videos|2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
41097115|NCT06226974|OTHER|Static Stretching|"* Shoulder extension - shoulder extension with the hand resting on a door;~* Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~* Shoulder flexion - arms above the head against a wall;~* Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~* Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~* Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
41097116|NCT00991276|DRUG|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
41097117|NCT00991276|DRUG|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
41097118|NCT00991276|DRUG|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
41097119|NCT05982600|DIAGNOSTIC_TEST|Single Assessor Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.
41097120|NCT05982600|DIAGNOSTIC_TEST|2 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.
41097121|NCT05982600|DIAGNOSTIC_TEST|3 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
41097122|NCT05982600|DIAGNOSTIC_TEST|5 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
41097123|NCT06125522|DRUG|vepdegestrant|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
41097124|NCT06125522|DRUG|Samuraciclib|Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
41097125|NCT05977491|DIAGNOSTIC_TEST|Health care practitioner is informed of POCT results for CT and NG|Molecular, PCR based near-POCT performed by the research assistant on self -collected urine. The outcome is positive or negative
41097126|NCT05977491|DIAGNOSTIC_TEST|Health care practitioner is informed about POCT result for TV and BV|The pH of vaginal secretion is measured from a self-collected swab by the research assistant, and if above 4.5 a dropp of KOH is added. If it smells fishy, the whiff test is positive.
41097127|NCT05977491|OTHER|addressing psycholsocial problems|"1. Participants screening positive for anxiety, depression or domestic violence will be offered psychological counseling or referral to a crisis management center in the POCT-PLUS arm~2. All participants of the POCT-PLUS arm receive audio- visual and written education on vaginal discharge and antibiotics"
41097128|NCT05654181|DRUG|PF-07328948|investigational drug administered orally
41097129|NCT05654181|DRUG|Placebo|Placebo matching active drug administered orally
41097130|NCT00244257|BIOLOGICAL|GMA161|0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
41097131|NCT00244257|BIOLOGICAL|GMA161|0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
41097132|NCT00244257|BIOLOGICAL|GMA161|0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
41097133|NCT00244257|BIOLOGICAL|GMA161|1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
41097134|NCT00244257|BIOLOGICAL|GMA161|3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
41097135|NCT03397160|BEHAVIORAL|Decision Support Intervention (DSI)|"A question list (QL) that includes areas of patient concern are created by the health coach for use by the patient and the urologist at their first consultation visit where they discuss the extent of their cancer and consider treatment options. The coach uses the Prostate Cancer SCOPED model to complete a Prostate Cancer SCOPED Model Form. The SCOPED model uses concepts such as the situation, choices (treatment), objectives (personal goals and priorities), people (involved in supporting a treatment decision), evaluation and decisions (clarifying which choice is best and next steps)."
41097136|NCT06416085|DRUG|Psilocybin|Single high-dose (25mg) capsule of psilocybin taken orally in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy
41097137|NCT01456780|DRUG|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
41097138|NCT01456780|DRUG|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
41097139|NCT01456780|DRUG|B+L Advanced Eye Relief Lubricant Drop|Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
41097140|NCT06343285|DEVICE|Encora Therapeutics Tremor Reduction Device|The proposed therapeutic device uses vibration motors positioned around the wrist that provide on-demand-therapy to suppress resting, postural, or action tremors of the hand.
41097141|NCT03737669|BIOLOGICAL|Mirasol-treated Fresh Whole Blood|Standard issue FWB, which gave negative serological assay results for HIV, HBV, HCV, and syphilis will subsequently be treated with Mirasol PRT, then stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
41097142|NCT03737669|BIOLOGICAL|Standard Fresh Whole Blood|Fresh whole blood that gave negative serological assay results for HIV, HBV, HCV, and syphilis will be stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
41097143|NCT03523091|DRUG|OnabotulinumtoxinA 100Unit Injection|Initial treatment with the option of repeat injections every 3 months
41097144|NCT04676399|DRUG|Hydrochlorothiazide 12.5mg|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days.
41097145|NCT04676399|DRUG|Placebo|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days
41097146|NCT06043271|BEHAVIORAL|The EMPOWER Program|The EMPOWER Program is a web-based, self-administered SSI for parents that takes about 30 minutes to complete.
41097147|NCT02258295|DRUG|Intragel|Intragel has an average molecular weight of 800-1200 kDaltons.
41097148|NCT02258295|DRUG|Saline|Saline
40752047|NCT01935505|BEHAVIORAL|Consulting+Telephone+Drug intervention|Include all the above interventions
40752048|NCT03880890|PROCEDURE|sphenoidotomy versus sphenoid nasalisation|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
41097149|NCT06510686|OTHER|İnspiratory muscle training|exercises to strengthen inspiratory muscles
41097150|NCT06510686|OTHER|Core training|exercises to strengthen inspiratory and core muscles
40924817|NCT03395119|DRUG|Ozone|After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
40924818|NCT03395119|DIETARY_SUPPLEMENT|Fish Oil|3 (1-gram) soft-gels daily Commercially available, enteric-coated, soft-gels formulated to deliver \>60% eicosapentaenoic/docosahexaenoic acids (EPA/DHA)
41097151|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Pain Intensity 3a|PROMIS Scale v2.0 - Pain Intensity 3a is a 3-question short form in which patients rate their worst, average, and current level of pain during the past 7 days.
41097152|NCT06627582|BEHAVIORAL|PROMIS 29+2|PROMIS 29+2 (PROMIS-Preference, PROPr) is a compilation of item banks to assess pain intensity
41097153|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Nociceptive Pain Quality 5a|5-question short form that identifies patients who have experienced nociceptive pain during the past 7 days
41097154|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Neuropathic Pain Quality 5a|5-question short form that identifies patients who have experienced neuropathic pain during the past 7 days
41097155|NCT03956199|PROCEDURE|pulpotomy|removal of the pulp from pulp chamber
41097156|NCT03956199|PROCEDURE|Root canal treatment|Removal of at the entire content of the root canal system and root canal obturation
41097157|NCT03033914|DRUG|doxorubicin|Doxorubicin: 25 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
41097158|NCT03033914|DRUG|Bleomycin|Bleomycin: 10 units/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
40924819|NCT03395119|DIETARY_SUPPLEMENT|Olive Oil|3 soft-gels daily Commercially available soft-gels containing 1 gram of USDA organic certified, cold pressed, extra virgin, olive oil
41097159|NCT03033914|DRUG|vinblastine|Vinblastine: 6 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
41097160|NCT03033914|DRUG|dacarbazine|Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
41097161|NCT03033914|DRUG|Nivolumab|nivolumab 240mg q14 days
41443149|NCT04481919|DRUG|Protocolized diuretic therapy|The urine sodium, urine creatinine and serum creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance.
41097162|NCT06434051|OTHER|Traditional Chinese cervical manipulation|The CMP will first palpate the transverse processes of C1 and C2. The transverse process with apparent tenderness will be regarded as the pain side. The right side will be the painful side for the following example). During the manipulation, the CMP will use his left hand to support the lower jaw and passively rotate the neck to the left side by 70-75 degrees (or to the maximum angle without discomfort). The physician's right-hand fingers will support the left-side transverse processes of C1 and C2, and the thumb and thenar muscle will be placed on the spinous process and occipital area. While maintaining a passive left neck rotation, the physician will increase the rotation angle by 5-10 degrees with both hands under a sudden pulling force. The above procedure will be repeated on the right side (pain side).
41443150|NCT00835666|DRUG|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
41097163|NCT06434051|OTHER|Sham manipulation|The posture and position of the participant and the practitioner and the procedure are the same as the CCM technique. The right side will be regarded as the pain side once again. When performing the sham technique, the CMP uses the left hand to support the lower jaw position and passively rotates the neck to the left side by 70-75 degrees or to the maximum angle. The right hand presses the upper inner corner of the right scapula. While maintaining the passive left rotation of the neck, the right hand slowly exerts force downwards and outwards on the inner side of the scapula. The left hand only maintains the left rotation of the neck without any pulling force. After completion, repeat the above actions on the right side. After the technique is completed, participants can get up after resting for 5-10 minutes.
41097164|NCT02095158|DRUG|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
41097165|NCT02974010|DRUG|NRX-101 Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
41443151|NCT00835666|DRUG|PROSCAR®|1 x 5 mg, single dose fasting
41097166|NCT02974010|DRUG|Lurasidone Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
41097167|NCT02974010|DRUG|Ketamine Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
41097168|NCT02974010|DRUG|Saline Solution Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
41097169|NCT00099918|DRUG|vildagliptin|
41097170|NCT02900365|PROCEDURE|early cataract surgery & IOL implantation|first week cataract extraction and IOL implantation.
41097171|NCT02900365|PROCEDURE|late cataract surgery & IOL implantation|first month cataract extraction and IOL implantation.
41097172|NCT06630754|OTHER|No Intervention: Observational Cohort|No intervention; observation cohort study
41097173|NCT03614234|DRUG|pegunigalsidase alfa|Recombinant human alpha galactosidase A
41443152|NCT06561373|BEHAVIORAL|Calm & Alert yoga and mindfulness|The Calm \& Alert protocol is multisensorial, with successive opportunities to practice the explicit concepts taught throughout the lessons using yoga and mindfulness-techniques. Each class has a similar structure of songs, breathing, warm-ups, yoga poses, mindful games, and rest involving meditation with child-friendly language. The study includes the recommended materials of a Hoberman sphere (breathing ball), chime, mind/body/breath icons, two small mason jars (one with mud and one with clear water), yoga mats for students, pictures of feelings (happy, sad, angry, scared, surprised, disgusted), and an on/off switch.
41443153|NCT06396286|PROCEDURE|single rod|surgical correction of severe adolescent idiopathic scoliosis with screws and a single rod.
41097174|NCT05290766|PROCEDURE|placement of four dental implants|"placement of four dental implants according to the  All on four concept"
41097175|NCT05290766|PROCEDURE|placement of two dental implants|"placement of two dental implants according to  All on two concepts"
41097176|NCT05290766|DEVICE|mandibular full arch prosthesis|loading of the mandibular fixed full-arch screw-retained metal acrylic prosthesis
41270711|NCT01400932|DRUG|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
41270712|NCT01400932|DRUG|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
41270713|NCT00185861|DRUG|Arsenic Trioxide|
41270714|NCT00185861|PROCEDURE|Stereotactic radiosurgery|
41443154|NCT03397251|DEVICE|AMDS|The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
41443155|NCT04788823|DRUG|Prednisone|Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.
41443156|NCT05574647|DIAGNOSTIC_TEST|bpMRI|biparametric MRI takes 30-40 minutes and requires a contrast injection called gadolinium (like a dye). This is also called long MRI and is most commonly used in the NHS.
41097177|NCT03007758|PROCEDURE|open ventral hernia repair|An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.
41097178|NCT03007758|PROCEDURE|robotic ventral hernia repair|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
41097179|NCT06123988|BEHAVIORAL|Prolonged Overnight Fasting|"Participants will undergo a 12-week program of prolonged overnight fasting (POF) during which they will abstain from consuming food or drink after 8pm, and wait 12 to 14 hours before resuming eating the next day. Participants will fast overnight for six nights each week, with one night off, and log their fasting start and stop times and timing of food intake daily via text messaging, or via study-provided app accessible by web browser or smart phone, or via paper journal returned by mail at the end of each month.~Participants will also complete one weekly session with a health coach to review their fasting log and any barriers to and/or facilitators of meeting the POF goals. Sessions may be delivered in-person, by telephone, or by video call based on participant preference. Sessions will last 15 to 30 minutes each, for a total of 12 sessions.~Participants will be provided with a notebook with information and support to encourage meeting the POF goals."
41097180|NCT06123988|BEHAVIORAL|Moderate-Intensity Exercise|"Participants will undergo a 12-week program consisting of three weekly sessions of moderate-to-vigorous aerobic and resistance exercises, under the supervision of a health coach. Sessions may be delivered either in-person or virtually via telehealth. Sessions will be tailored to the individual participant based on fitness level and symptoms at study entry, and limited to daylight hours as much as possible. Each session will last 30 to 50 minutes, as tolerated by the participant, for a total of 36 sessions.~Participants will receive a Fitbit device to track their activity, and to provide heart rate monitoring during each session. Participants without access to wi-fi will be loaned cellular-enabled tablets to allow them to participate in telehealth sessions. Participants will also receive a notebook with information and support to encourage exercise."
41097181|NCT06123988|BEHAVIORAL|General Health Education Sessions|Participants will receive a general health education resource manual at study entry, followed by six bi-weekly sessions with a health coach to review the information. Six topics, one topic for each session, will be selected based on topics of potential interest to a population living with advanced breast cancer, focusing on general nutrition, healthy lifestyle, and quality of life, with no discussion of prolonged overnight fasting or exercise. Each session, administered via telephone or video call, will last about 15 to 30 minutes, and have a specific topic and call script for the health coach to follow to minimize any intervention drift and/or contamination. Participants will receive a Fitbit activity monitoring device and additional study materials at the end of their participation in the study.
41097182|NCT00015457|DRUG|Amlodipine plus Botulinum toxin|
41097183|NCT01621581|GENETIC|Convection enhanced delivery/AAV2-GDNF|Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) Administered via Bilateral Stereotactic Convection-Enhanced Delivery
41097184|NCT01619943|OTHER|no intervention|clinical follow up
41097185|NCT01619943|OTHER|no intervention|no intervention
41097186|NCT01468324|DRUG|AZD7451|Depending on dose level, AZD7451 will be given once daily for 28 day cycles.
41097187|NCT00569738|PROCEDURE|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
41097188|NCT03483337|OTHER|MRI examinations|Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
41097189|NCT03483337|OTHER|MRI examinations|Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
41097190|NCT06630325|DRUG|Abemaciclib|Given PO
41097191|NCT06630325|PROCEDURE|Biopsy|Undergo tumor biopsy
41097192|NCT06630325|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41097193|NCT06630325|DRUG|Carboplatin|Given IV
41097194|NCT06630325|PROCEDURE|Echocardiography|Undergo echocardiography
41097195|NCT06630325|DRUG|Exemestane|Given PO
41097196|NCT06630325|DRUG|Fulvestrant|Given IM
41097197|NCT06630325|DRUG|Gefitinib|Given PO
41097198|NCT06630325|DRUG|Gemcitabine|Given IV
41097199|NCT06630325|DRUG|Letrozole|Given PO
41097200|NCT06630325|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41097201|NCT06630325|DRUG|Olaparib|Given PO
41097202|NCT06630325|DRUG|Osimertinib|Given PO
41097203|NCT06630325|DRUG|Paclitaxel|Given IV
41097204|NCT06630325|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
41097205|NCT06630325|DRUG|Pemetrexed|Given IV
41097206|NCT06630325|OTHER|Survey Administration|Ancillary studies
41097207|NCT06630325|DRUG|Tamoxifen|Given PO
41097208|NCT06630325|DRUG|Temozolomide|Given PO
41097209|NCT06619236|DRUG|Rina-S|IV infusion
41443157|NCT05574647|DIAGNOSTIC_TEST|Image-Fusion targeted and systematic Biopsy|During image fusion targeted biopsy, the biopsy operator uses the MRI scans that were taken beforehand but laid on top of the live ultrasound images during the biopsy. This uses software and takes a few minutes longer to perform. Once the MRI images and ultrasound images are 'fused', the actual biopsies are taken as normal.
41097210|NCT06619236|DRUG|Paclitaxel|IV infusion
41097211|NCT06619236|DRUG|Topotecan|IV infusion
41097212|NCT06619236|DRUG|Pegylated liposomal doxorubicin (PLD)|IV infusion
41097213|NCT06619236|DRUG|Gemcitabine|IV infusion
41097214|NCT06292182|DEVICE|Near-infrared light|daily application of near-infrared light
41097215|NCT05692401|BEHAVIORAL|Nutrition and Exercise Instruction|Eating and exercise patterns. Educational handouts and instructions will be provided, which are intended as a guide for subjects in intervention group. Subjects will also be given a Patient Diary to complete their daily meal intake and physical exercises. Use of and return of the diary is optional but encouraged. It has been found that use of a patient diary to record food intake keeps one from eating more than they planned and can be a useful tool in weight control.
41097216|NCT02050594|DRUG|Ipilimumab|
41097217|NCT00508443|RADIATION|Radiation Therapy|Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
41097218|NCT01343654|BEHAVIORAL|Text messaging plus EMA|Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
41097219|NCT01343654|BEHAVIORAL|Treatment as usual|usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
41097220|NCT03278197|OTHER|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
41097221|NCT03278197|OTHER|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
41097222|NCT03278197|OTHER|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
41097223|NCT03278197|OTHER|Interviews with stakeholders|Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
41097224|NCT01487564|DRUG|Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
41097225|NCT00387361|PROCEDURE|Osteopathic Manipulative Treatment|20 minute post-operative osteopathic manipulation as described in the protocol
41097226|NCT03764345|DRUG|Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
41097227|NCT05186545|DRUG|surufatinib + fulvestrant + chidamide|surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
41097228|NCT06036030|DRUG|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
41097229|NCT06036030|DRUG|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
41097230|NCT06036030|DRUG|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
41097231|NCT06036030|OTHER|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
41097232|NCT05708261|BEHAVIORAL|MR Intervention|Grounded in Social Cognitive Theory, the intervention delivers five 2-hour sessions with 3 post-session group check-in's to develop skills in partnership communication, HIV disclosure and prevention. The intervention utilizes self-assessments on skills learned and then action plan for these developed and then finalized in the last session.
41097233|NCT05708261|OTHER|Be Well Attention Match|Attention match control arm providing one-way SMS of general health content delivered once per week during the first 5 weeks after enrollment.
41097234|NCT05972239|OTHER|Standard pulmonary rehabilitation program|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load (watts) determined starting from the 6MWT using the Hill equation and will be increased to reach a perception of moderate-intense fatigue and/or dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be calibrated to allow the execution of 12 consecutive repetitions and will be progressively increased by 0.5 kg in order to cause a moderate/intense fatigue and/or dyspnea. Group exercises aimed at improving flexibility of the trunk, lower and upper limbs, lasting at least 30 minutes, 5/6 days a week, for a total of 12-14 sessions.
41097235|NCT05972239|OTHER|Balance training added on standard pulmonary rehabilitation|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load determined from the 6MWT (Hill equation) and will be increased based on dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be progressively increased. Supervised balance training sessions lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The sequence of the exercises will be personalized according to the result of the Berg Balance Scale and modified according to the progress.
41443158|NCT02950805|DRUG|Placebo|Subjects will receive a placebo in either period 1 or period 2 by inhalation.
41443159|NCT02950805|DRUG|AZD5634|Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
41097236|NCT01243801|DRUG|Ketamine|Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
41097237|NCT04017884|COMBINATION_PRODUCT|Remin Pro Forte|a combination of chemicals with natural products cream .
41443160|NCT05109377|DIAGNOSTIC_TEST|Endocan|Endocan will measured before and after treatment
41443161|NCT05109377|DRUG|tadalafil|tadalafil
40924820|NCT06422234|OTHER|Exergame|Video-based game exercises will be performed 3 days a week for 6 weeks. Participants will be taught how to play the games before starting the game called Ring Fit Adventure, one of the Nintendo Switch games. Among the games within Ring Fit, games that aim to increase lower extremity muscle strength, core stabilization and balance have been selected, and game types and number of repetitions are changed every week.
40924821|NCT06422234|OTHER|Game-free Exercise|All activities in the exergame group were done without games and screens. The progression of the exercises proceeds in the same way as the other group.
41443162|NCT06455514|DRUG|Magnesium Sulfate|4 g of magnesium sulfate intravenously within 2 hours of Return of Spontaneous Circulation (ROSC), followed by a continuous drip (16 g) over 24 hours
41097238|NCT04017884|COMBINATION_PRODUCT|Remin Pro|a combination of chemicals
41097239|NCT02111343|OTHER|Computer-based auditory training (CBAT)|"There are 3 listening games (i.e. Doggy, Who-Is-Right, Story-in-noise) that target on speech-in-noise training and 1 listening game (i.e. TATP) that aims to train dichotic listening.~Patient was required to undergo the training for 30 minutes per day, 5 sessions per week, for a duration of 12 weeks. Parents were advised to keep a journal to record child's training hour of the day."
41097240|NCT05739123|DRUG|Relugolix-Containing Product|Any relugolix-containing therapy
41097241|NCT05090891|DRUG|INCB000928|INCBG000928 will be administered QD orally.
41097242|NCT05090891|DRUG|placebo|placebo will be administered QD orally
41097243|NCT03437668|DRUG|WSE|WSE tablets
41097244|NCT03437668|DRUG|Placebo Oral Tablet|Placebo tablet
41097245|NCT05612243|OTHER|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes and polyphenols|Participants will consume a meal including 200g of yogurt enriched with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of functional yogurt on postprandial glycemia and lipemia
41097246|NCT05612243|OTHER|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes|Participants will consume a meal including 200g of yogurt with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
41097247|NCT05612243|OTHER|Consumption of a meal with plain Yogurt with oat flakes|Participants will consume a meal including 200g of plain yogurt containing 1g of oat flakes, as a placebo, as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
41097248|NCT05120869|BEHAVIORAL|Tailored HPV Education and Professional Skills Intervention Group|The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
41097249|NCT05120869|BEHAVIORAL|General HPV Education and Communication Skills Control Group|The general provider education intervention will involve audio and visual content and will be delivered in the English language.
41097250|NCT04483843|OTHER|No intervention|No intervention will be performed while it is retrospective observational study.
41097251|NCT04887688|DEVICE|exciflex|untethered electronic bandage with all the components of a surface stimulation system mounted on a flexible substrate.
41097252|NCT03239210|DRUG|Ondansetron|5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
41097253|NCT03239210|DRUG|Placebo|placebo equivalent
41097254|NCT05392764|DRUG|Empagliflozin 10 MG|once-daily oral empagliflozin 10 mg
41097255|NCT05392764|DRUG|Placebo|Placebo matching empagliflozin 10 mg
41097256|NCT01571921|DIETARY_SUPPLEMENT|Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction|Single oral TRF or Gamma-Delta Tocotrienol dosage
41097257|NCT01076218|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
41097258|NCT01371201|DRUG|Sunitinib|sunitinib 37.5 mg per day
41097259|NCT01371201|DRUG|Placebo|Placebo 37.5 mg per day
41097260|NCT00664846|DRUG|Aspirin / Clopidogrel, Atorvastatin / Simvastatin|Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
41097261|NCT00664846|DRUG|Asprin / Clopidogrel, Atorvastatin / Simvastatin|Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
41443163|NCT06455514|DRUG|Saline|Control subjects will receive an equivalent volume of normal saline intravenously.
41443164|NCT06412016|BEHAVIORAL|Peer Nutritional Counseling + Urban Gardening|Peer nutritional counseling and urban gardens
41097266|NCT03307980|BIOLOGICAL|PF-06838435 (formerly SPK-9001)|Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
41097267|NCT03163862|PROCEDURE|Endometrial scratch|the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
41453299|NCT04070222|OTHER|Hysteroscopy|"1. Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~2. Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~3. ART will be carried out with standard protocol and the clinical outcome will be recorded;~4. The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate."
41097268|NCT03163862|DRUG|G-CSF administration|1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
41097269|NCT03163862|DRUG|Saline Solution|saline infusion every day from the day of embryo transfer through the day of beta HCG test
41097270|NCT03947112|BEHAVIORAL|Physical activity registration|At start, participants and parents fills out a Self-report questionnaire and the UngKan-3 Questionnaire, before a seven day physical activity registration takes place by use og ActiGraph. A physical activity diary are filled out every evening while the physical activity registration takes places.
41097271|NCT02516176|BEHAVIORAL|treadmill training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
41097272|NCT04820582|OTHER|Delphi Questionnaire|Evaluation of a list of PROMs and CROMs specific for endometriosis (previously selected from a litterature review) on a Likert scale of 1 to 9 for their relevance and feasibility
41097273|NCT05464134|RADIATION|x-ray|plain radiographs of lower limb anteroposterior and lateral views , lumbar spine plain radiographs (anteroposterior, lateral, lateral in flexion and lateral in extension views )
41097274|NCT03732820|DRUG|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
41097275|NCT03732820|DRUG|abiraterone acetate|1000 milligrams (mg) once daily
41097276|NCT02575391|DIETARY_SUPPLEMENT|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
41097277|NCT01821911|BIOLOGICAL|Zagreb2-1-1|Injection on day 0、7、21
41097278|NCT01821911|BIOLOGICAL|Essen|Injection on day 0、3、7、14、28
41097279|NCT04776486|DRUG|Iohexol|"Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).~Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose."
41097280|NCT01885364|DRUG|Normal saline|intravenous injection with normal saline before injection of propofol
41097281|NCT01885364|DRUG|Esmolol|intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
41097282|NCT01885364|DRUG|Remifentanil|intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
41097283|NCT01885364|DRUG|propofol|intravenous injection after pretreatment
41097284|NCT04251351|DRUG|Paracetamol|Paracetamol 15 mg/kg/dose IV 6 hourly for 72 hours
41097285|NCT04251351|PROCEDURE|Mechanical antipyresis|"Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.~If a temperature \>38.5°C persists despite mechanical antipyresis, or if deemed necessary by the treating clinician, then paracetamol can be administered according to local practice (paracetamol IV 15 mg/kg as needed)."
41097286|NCT05683301|DRUG|Amlodipine + Perindopril|Single pill combination of dual antihypertensive agent
41097287|NCT05683301|DRUG|Perindopril + Indapamide|Single pill combination of dual antihypertensive agent
41097288|NCT05683301|DRUG|Amlodipine + Indapamide|Single pill combination of dual antihypertensive agent
41097289|NCT02805387|DIETARY_SUPPLEMENT|Treatment|Bicarbonate was ingested
40924822|NCT01222156|PROCEDURE|Remote magnetic navigation|Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias
40924823|NCT01222156|DEVICE|Magnetecs Catheter Guidance Control and Imaging system|Magnetecs Catheter Guidance Control and Imaging (CGCI) system
41097290|NCT00372216|DRUG|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
41097291|NCT05634213|DRUG|normal saline|Once the patient is placed on cardiopulmonary bypass, the product will be injected into the left atrial wall using a 27 gauge needle as 4 injections of 200 μL each. Two will be placed in the atrial appendage. The remaining 2 injections will be placed equidistant on the anterior atrial free wall. Each injection will be performed just under the surface of the atrial epicardium over 30 seconds. The needle will stay in place for 10 seconds after the injection to limit back flow from the site of injection.
41097292|NCT04360941|DRUG|Palbociclib|Highly selective oral inhibitor of CDK4 and CDK6.
41097293|NCT04360941|DRUG|Avelumab|Fully human IgG1 monoclonal antibody (mAb) binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
41097294|NCT02324114|DEVICE|Hsp90|Detect plasma Hsp90α concentration
41097295|NCT04735939|RADIATION|radiotherapy|Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.
41097296|NCT04470102|PROCEDURE|mitral valve repair by edge-to-edge technique|transaortic access for mitral valve repair edge-to-edge
41097297|NCT04470102|PROCEDURE|Septal myectomy|isolated extended septal myectomy
41097298|NCT03111095|OTHER|Mobile Health|Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
41097299|NCT05217446|DRUG|Encorafenib|capsule
41097300|NCT05217446|BIOLOGICAL|Cetuximab|IV
41097301|NCT05217446|BIOLOGICAL|Pembrolizumab|IV
41097302|NCT04163484|OTHER|Iodinated contrast|Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
41097303|NCT06627738|RADIATION|Cyberknife irradiation|Additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in inoperable patients with locally advanced non-small cell lung carcinoma
41097304|NCT05609578|DRUG|Adagrasib oral dose of 400 mg twice daily tablets|oral dose of 400 mg twice daily tablets
41097305|NCT05609578|COMBINATION_PRODUCT|Pembrolizumab|IV infusion once every 3 weeks
41097306|NCT05609578|COMBINATION_PRODUCT|Chemotherapy: Pemetrexed|IV infusion once every 3 weeks
41097307|NCT05609578|COMBINATION_PRODUCT|Cisplatin/Carboplatin|IV infusion once every 3 weeks
41097308|NCT04917757|DIAGNOSTIC_TEST|1mg Dexamethasone test|For each patient a 1mg dexamethasone test has been performed.
41097309|NCT04995419|DRUG|Enfortumab vedotin|Intravenous Infusion
41097310|NCT05057494|DRUG|Acalabrutinib|Dose formulation: Capsule or Tablet
41097311|NCT05057494|DRUG|Venetoclax|Dose formulation: Tablet
41097312|NCT05057494|DRUG|Obinutuzumab|Dose formulation: Injection
41097313|NCT06628739|DRUG|Imatinib|The long-term maintenance dose of every patient was determined by the physician based on the guidelines and the patients' individual conditions such as adverse reactions.
41097314|NCT03669042|DEVICE|PhotoFix|PhotoFix Patch Implantation
41097315|NCT01224678|DIETARY_SUPPLEMENT|vitamin D|Given orally
41097316|NCT01224678|OTHER|placebo|Given orally
41097317|NCT06453356|DRUG|Zavegepant 10mg|intransal spray 10mg
41097318|NCT04816526|BIOLOGICAL|Descartes 08|Car T-cells
41097319|NCT02391662|DRUG|Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 days 1,8 \& 15 in a 28 days cycle
41097320|NCT02391662|DRUG|Gemcitabine 1000 weeks 1,2,3/4|Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
41097321|NCT04096313|DIAGNOSTIC_TEST|HbA1c, Lipids, UACR|compare diagnostic tests to reference methods
41097322|NCT05037851|DRUG|Opelconazole|Nebulizer suspension
41097323|NCT05037851|DRUG|Standard of Care|Standard of Care
41097324|NCT04094012|DRUG|isoniazid and rifapentine|This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)
41097325|NCT04144985|OTHER|Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.|Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.
41097326|NCT00279474|BEHAVIORAL|cognitive-behavior groups|
41097327|NCT01895140|DEVICE|Renal denervation device|
41097328|NCT03433274|DEVICE|Tendyne Mitral Valve System|Mitral valve replacement
41097329|NCT03433274|DEVICE|MitraClip System|Percutaneous mitral valve repair using the MitraClip system.
41097330|NCT05989048|DRUG|Zavegepant|The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
41097331|NCT05989048|DRUG|Placebo|Single dose of matching placebo taken within Treatment Phase.
41097332|NCT06416280|OTHER|Assessment of the TRiP(cast) score|"In patients presenting to the emergency department with trauma to a lower limb, the TRiP(cast) score is assessed in accordance with the recommendations. If the patient does not object. The attending physician will then be asked to fill in his implicit assessment of the risk of venous thromboembolism on a paper CRF and then to complete his assessment of the TRiP(cast) score. He will then be free to decide whether or not to anticoagulate the patient.~At the same time, a doctor not involved in the patient's care will assess the TRiP(cast) score and record it on a paper CRF. The second doctor's assessment will be independent and will have no impact on the patient's management.~The CRFs will then be analysed and stored. Data will be anonymised during data collection and each patient will be assigned an anonymity number."
41097333|NCT04485741|DEVICE|RESP|The RESP device will be placed on the patient for periodic recording of auscultory sound.
41097334|NCT03798626|DRUG|Gevokizumab|60 mg/mL concentration; administered intravenously (IV)
41097335|NCT03798626|DRUG|Bevacizumab|25 mg/mL concentration; administered IV
41097336|NCT03798626|DRUG|Modified FOLFOX6|Oxaliplatin \[5 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
41097337|NCT03798626|DRUG|FOLFIRI|Irinotecan \[20 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
41097338|NCT03798626|DRUG|Ramucirumab|10 mg/mL concentration; administered IV
41097339|NCT03798626|DRUG|Paclitaxel|6 mg/mL concentration; administered IV
41097340|NCT03798626|DRUG|Cabozantinib|60 mg tablet; administered orally
41097341|NCT03743012|OTHER|Integrated cardiac rehabilitation|Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.
41097342|NCT03743012|OTHER|Usual Care|Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
41097343|NCT05488782|BEHAVIORAL|TEAM-Red|Five 60-minute group sessions with 6-10 patients. These sessions will be held weekly and delivered remotely via videoconference
41097344|NCT05488782|OTHER|Waitlist|After the week 12 follow up visits subjects in the Waitlist group will receive the TEAM Red intervention
41097345|NCT02214667|BEHAVIORAL|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
41097346|NCT02214667|BEHAVIORAL|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
41097347|NCT02214667|BEHAVIORAL|Jail and community-based behavioral health services|Existing behavioral health service programs
41097348|NCT04087772|BEHAVIORAL|Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH)|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
41133445|NCT03779672|DRUG|Memantine Hydrochloride 10 mg|"* Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps"
41097349|NCT04087772|BEHAVIORAL|Racial/Ethnic Discrimination Interventions (RED)|Racial/Ethnic Discrimination Interventions are a set of components to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
41097350|NCT06629454|DEVICE|Adherence to digital incentive spirometer in the postop period after major chest surgery.|Major chest surgery can lead to respiratory compromise and traditional breathing exercises are not supervised or monitored. The primary objective of this study is to evaluate the effect of a multifeatured digital IS and integrated phone app on patient adherence to incentive spirometry. Together the device and app will include the following functions: an auditory and haptic reminder cue, visual and auditory cues to guide exercise completion, exercise gamification, and data tracking and visualization features.
41097351|NCT05726864|DRUG|ELI-002 7P|ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
41097352|NCT06479785|OTHER|Educational Intervention Program for machine workers|A detailed Educational Intervention Program for marble factory workers working on Machines.
41097353|NCT06479785|OTHER|Educational Intervention Program for manual workers|A detailed Educational Intervention Program for marble factory workers working manually.
41097354|NCT05380232|BEHAVIORAL|Leisure-time physical activity|Self-reported leisure-time physical activity, categorized as; zero (reference), \>0-7.49 MET-hrs/week, 7.5-14.9 MET-hrs/week, or ≥15 MET-hrs/week.
41097355|NCT06191744|DRUG|Epcoritamab|Subcutaneous (SC) Injection
41097356|NCT06191744|DRUG|Prednisone|Oral Tablet
41097357|NCT06191744|DRUG|Rituximab|Intravenous (IV) Infusion
41097358|NCT06191744|DRUG|Lenalidomide|Oral Capsule
41097359|NCT06191744|DRUG|Doxorubicin|IV Injection
41097360|NCT06191744|DRUG|Vincristine|IV Injection
41097361|NCT06191744|DRUG|Cyclophosphamide|IV Injection
41097362|NCT06191744|DRUG|Obinutuzumab|IV Infusion
41097363|NCT06191744|DRUG|Bendamustine|IV Infusion
41097364|NCT05243992|OTHER|CTS-PAD device imaging|Participants in the CTS-PAD Study will undergo a conventional ABI (cABI) evaluation, followed by the non-contact imaging evaluation with the CTS-PAD device. The supplemental CTS-PAD testing will add approximately ten (10) minutes to the overall evaluation time.
41097365|NCT06381674|OTHER|Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback|During physical therapy sessions participants will wear sensors on their head, chest, waist, and feet for real-time instrumented audio and visual biofeedback on quality of therapeutic exercise.
41097366|NCT06381674|OTHER|Vestibular therapy for mTBI|During physical therapy sessions participants will go through vestibular therapeutic exercise WITHOUT audio and visual real-time biofeedback.
41097367|NCT02040844|DRUG|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]|
41097368|NCT02040844|DRUG|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]|
41097369|NCT02040844|DRUG|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]|
41097370|NCT03424928|DRUG|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
41097371|NCT03424928|DRUG|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
41097372|NCT06629532|OTHER|medical management, surgical interventions, and rehabilitative strategies|By leveraging a wide array of treatment data - including medical management, surgical interventions, and rehabilitative strategies - the RESEARCH registry intends to provide a granular view of current treatment landscapes and their direct impact on patient recovery and quality of life.
41097373|NCT01644773|DRUG|Crizotinib|"Starting dose level:~* Initial Treatment Plan: 130 mg/m\^2 per dose~* Modified Treatment Plan per Amendment 1.0: 165 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day"
41443165|NCT05637333|DIAGNOSTIC_TEST|Contrast Stress Echocardiography|Dipyridamole will be infused at 0.56mg/kg of body weight over 4mins. After 2 minutes, if the patient has tolerated the infusion well, a further 0.28mg/kg will be infused over 2 minutes. Tolerance will be determined by the absence of 1) myocardial ischaemia (significant chest pain with ECG ST depression or T wave inversion or wall motion abnormality on ECHO) 2) a significant drop in blood pressure 3) significant arrhythmia and 4) intolerable symptoms. One minute after completion of Dipyridamole infusion Sonazoid will be infused at the same rate as was used during acquisition of the rest images. After 45 seconds when steady state is reached, the ultrasound images will be acquired as stated below in contrast imaging. If the Dipyridamole is not well tolerated by one minute after the 0.56mg/kg infusion, we will move straight to the infusion of Sonazoid with no extra 0.28mg/kg infusion.
40924824|NCT04355728|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.
41097374|NCT01644773|DRUG|Dasatinib|"Starting dose level: 50 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day"
41097375|NCT06631274|BEHAVIORAL|counseling|The intervention (IVY; Intervention for Victimized Youth) is an 8 week group counseling intervention delivered in a virtual environment.
41097376|NCT00263679|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus and pertussis|
40924825|NCT04355728|OTHER|Vehicle + Heparin along with best supportive care|Best supportive care treatment per the treating hospital protocol.
41097377|NCT03557333|COMBINATION_PRODUCT|INP104|No more than 2 doses within 24 hours, 3 doses within 7 days. 1.45 mg in a divided dose, one actuation per nostril.
41097378|NCT00723294|PROCEDURE|cryosurgery|
41097379|NCT00723294|PROCEDURE|therapeutic conventional surgery|
41097380|NCT04374877|DRUG|CHS-388|CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
41097381|NCT04374877|DRUG|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
41097382|NCT04374877|DRUG|Toripalimab|Toripalimab by IV infusion
41097383|NCT03556605|OTHER|OneTouch Reveal® Mobile APP system|Improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitor and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).
41097384|NCT03556605|OTHER|Current Blood Glucose Monitor|Subjects continue to use current Blood Glucose Monitor without connection to mobile diabetes apps.
41097385|NCT04651361|DRUG|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
41097386|NCT04651361|DRUG|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
41097387|NCT03837925|DRUG|Atorvastatin 40mg Tablet|Patient participation for 6 weeks of treatment
41097388|NCT03837925|DRUG|Placebo comparator|Patient participation for 6 weeks of treatment
41097389|NCT00250224|DEVICE|Radiotherapy stent|
41097390|NCT01663610|BEHAVIORAL|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
41097391|NCT05688280|DRUG|1.0% IP-001 for Injection|4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
41097392|NCT05126277|DRUG|ianalumab s.c. q4w|ianalumab s.c. q4w in addition to SoC
41097393|NCT05126277|DRUG|ianalumab s.c. q12w|ianalumab s.c. q12w in addition to SoC
41097394|NCT05126277|DRUG|placebo s.c.|placebo s.c. q4w in addition to SoC
41097395|NCT06102174|DRUG|Placebo|Placebo
41097396|NCT06102174|DRUG|Active|Sisunatovir
41097397|NCT06442228|DIAGNOSTIC_TEST|spermiogram test|"Approximately 7 mL of blood sample will be taken by the health personnel in a vacuum gel tube for hormonal and biochemical analyses. The blood samples will be centrifuged at 1000xg for 20 minutes by the researchers. In the next step, the supernatant portion will be separated and transferred to 3 mL ependorfs. Serum samples will be stored in the -800C deep freezer of our hospital until the time of analysis.~Sperm samples from individuals will be collected in our hospital in accordance with the protocol and the results will be reported."
41097398|NCT00868231|DRUG|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
41097399|NCT00868231|DRUG|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
41097400|NCT00868231|DRUG|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
41097401|NCT05329623|DRUG|JDQ443|All the participants will receive a single oral dose of JDQ443.
40924826|NCT01917656|DRUG|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
41097402|NCT06613074|DEVICE|Ali Pay intelligent navigation applet|"The intelligent navigation applet comprises of three function modules:~1. Stroke knowledge public education: information regarding prevention and emergency treatment of stroke would be push to users\&#39; mobile phones regularly;~2. Stroke recognition: questionaires, voice interaction, and facial recognition are employed to identify patients with AIS and large vessel occlusion;~3. Hospital recommendation: this module combines real-time traffic and average in-hopital delay of each stroke center nearby, recommending the stroke center in which patients are mostly likely to receive reperfusion therapy"
41097403|NCT05358730|OTHER|Standard Exercise|Glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises were performed under the supervision of a physiotherapist two days per week for six weeks at the clinical setting (Celik and Kaya Mutlu, 2016).
41097404|NCT05358730|OTHER|Instrument Assisted Soft Tissue Mobilization (IASTM)|IASTM treatment was applied to the posterior-anterior-middle deltoid, latissimus dorsi, teres major, teres minor, supraspinatus and infraspinatus muscle fibers, superficial and deep fascia. IASTM was applied in parallel and vertical direction to the muscle fibers treated with the instrument at a 45° angle, each technique (SWEEP, BRUSH (straight short steps) techniques) for 20 seconds (Ikeda, Otsuka, Kawanishi, and Kawakami, 2019). It was performed two days per week for six weeks.
41097405|NCT05358730|OTHER|Home Exercise|"Hme exercise program consisted of glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises.~It was asked to perform two days per week for six weeks."
41097406|NCT02024308|DRUG|Fludarabine|50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
41097407|NCT02024308|DRUG|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
41097408|NCT04782999|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Standard test of glucose tolerance with ingestion of 75 g glucose followed by blood sampling.
41097409|NCT04782999|DIAGNOSTIC_TEST|Hyperglycemic clamp with infusion of saline, GLP-1 or GIP|"Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.~Primed co-infusion of either:~* Saline~* GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)~* GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min)."
41097410|NCT03920163|OTHER|Enhanced Recovery Measures|Perioperative measures
41097411|NCT05019781|OTHER|Therapeutic tape|Tape was applied to sternocleidomastoid, upper trapezius, deltoid, flexor palmaris longus muscles as suggested by Kase et al. (Kase, Wallis, Kase, \& Association, 2003). The tape was applied to the left side of the participants while sitting position because the violin is traditionally played by placing it on the left shoulder, balancing the neck using the left hand, and bowing with the right arm.
41097412|NCT05019781|OTHER|Placebo tape|The placebo tape was applied transverse to the muscle groups in two levels (a point of 10 cm above to wrist and elbow) with no tension when the participants were sitting position with the shoulder flexed at 90°, and the elbow flexed at 90°.
41097413|NCT02615522|DEVICE|BPK-S Integration|
41097414|NCT02973919|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, \& Renssen, 1999; de Jongh, Holmshaw, Carswell, \& van Wijk, 2011; Lapsekili \& Yelboga, 2014; Muris, Merckelbach, van Haaften, \& Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
41097415|NCT02973919|BEHAVIORAL|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger \& Pauli, 2011).
41097416|NCT06206421|DRUG|Fezolinetant|oral
41097417|NCT06206421|DRUG|Placebo|oral
41097418|NCT06629506|DEVICE|MicroMatrix® Flex|MicroMatrix® Flex is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, partial thickness burns, skin tears), draining wounds. The device is intended for one-time use.
41097419|NCT06629506|DEVICE|MicroMatrix® UBM Particulate|MicroMatrix® UBM Particulate is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
41097420|NCT06629506|DEVICE|Cytal® Wound Matrix 2-Layer|Cytal® Wound Matrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
41097421|NCT06161506|DEVICE|Elidah Device|The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.
41097422|NCT01244100|DRUG|PL2200 fasted|Fasted state
41097423|NCT01244100|DRUG|PL2200 fed|Fed state
41097424|NCT05766098|GENETIC|Genotyping|Characterization of genetic profile of tumor tissues
41097425|NCT05228886|BEHAVIORAL|SINCERE|"Each goal setting session will involve templated prompts in 211's ServicePoint to guide the creation of a patient-centered action plan specifying what, when, how much, and how often patients will engage in a behavior (e.g., I will work on filling out eligibility paperwork for 30 minutes on Wednesday evening). Again, following clear prompts, ISs negotiate the action plan with patients until patients can rate their level of confidence for achieving this behavior a 7 on a scale from 0 to 10."
41097426|NCT05228886|BEHAVIORAL|Scheduled Follow-Up|Adding to the standard Call + Resources protocol, those assigned to scheduled follow-up will receive a proactive call from 211 every 2 weeks for 3 months to explore additional service needs. These calls will be unstructured, guided by participant requests and 211 IS prompts.
41097427|NCT05228886|OTHER|Standard of Care|211 ISs contact referred patients, provide referral services, and follow up in an ad-hoc manner.
41097428|NCT05541757|DRUG|In vitro heparin|In vitro heparin and in vitro LMWH
41097429|NCT06133972|DRUG|Placebo|Placebo s.c. monthly
40752049|NCT06262997|OTHER|Pilates|Pilates training will be given to groups of 3 people for 8 weeks, 2 days a week. Exercises will start with 10-12 repetitions and the number of repetitions will be increased to 20 starting from the 4th week. Before the Pilates training, basic principles such as breathing, concentration, focusing on the center, control, precision and fluid movement will be taught in a special session to inform individuals about the training principles and exercises. Each exercise will be demonstrated by the physiotherapist and cues such as tactile, verbal and imagery will be used to control the participants throughout the training. The difficulty level of Pilates training will be progressed by changing body positions, exercise ball and band use according to the performance of the patients and Pilates principles. The exercise program will start with warm-up exercises and end with 40 minutes of basic Pilates exercises followed by cooling exercises.
41097430|NCT06133972|DRUG|Ianalumab|Ianalumab s.c. monthly Ianalumab s.c. quarterly
41097431|NCT06619639|BEHAVIORAL|Social-emotional learning curriculum|EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context.
41097432|NCT05618301|DRUG|Motixafortide|Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg
41097433|NCT05618301|DRUG|Natalizumab|Natalizumab will be administered as an IV infusion at a flat dose of 300 mg
41097434|NCT05618301|PROCEDURE|Leukapheresis|Leukapheresis consisting of a 1 Blood Volume procedure
41097435|NCT05588674|DIETARY_SUPPLEMENT|Probiotic Supplement|8.5 week supplementation period. One capsule daily.
41097436|NCT05588674|OTHER|Placebo Capsule|8.5 week supplementation period. One capsule daily.
40924827|NCT01917656|DRUG|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
41097437|NCT05610696|OTHER|Low impact immersion|Consists of a sequence of shoulder, trunk and hip movements. In this modality, the aim will be to understand the physiological effects of immersion in heat water. Resisted movements (either by turbulence or by floats) or interventional maneuvers in the knee joints will not be performed. Considering the period of 5 minutes for acclimatization to the liquid environment, the program will last approximately 47 minutes.
41097438|NCT05610696|OTHER|Conventional aquatic physiotherapy|include warm-up, strengthening and calming down activities. Aquatic steppes will be used to ensure that all participants will maintain the waterline level approximately in the xiphoid appendix. For strengthening activities, the exercises must be performed at an adequate speed, which ensures a comfortable level for the activity. For this purpose, a subjective feedback will be extracted from the participants constantly. The warm-up sequence consists of six different active hip and knee movements performed at maximum range of motion and contributes to neuromuscular activation. For strengthening, each movement should be performed for 1 minute (30 seconds for each lower limb) followed by a period of 30 seconds of rest between each movement.
41097439|NCT05610696|OTHER|High intensity aquatic physiotherapy|In this modality subjects will perform the same sequence of exercises of the Conventional Aquatic Physiotherapy program will be respected. However the work load and speed will be adjusted to the maximum level. For strengthening, each movement should be performed for 2 minutes (1 minute for each lower limb) followed by a period of 30 seconds of rest between each movement. To guarantee the maximum effort of the participants, verbal stimuli will be constantly provided. The program will last approximately 68 minutes.
41097440|NCT06525246|DRUG|ONO-7475|Specified dose, once daily
41097441|NCT06525246|DRUG|Osimertinib Mesylate|Specified dose, once daily
41097442|NCT06331312|BIOLOGICAL|Secukinumab|2 x 150mg/1mL PFS secukinumab
41097443|NCT03034733|DRUG|Dexamethasone|intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
41097444|NCT03034733|DRUG|Sodium Chloride, (24)NaCl 0,9%|intravenous placebo
41097445|NCT04432974|DEVICE|Automatic closed-loop anesthesia|Total intravenous anesthesia performed with the ACTIVA automatic control system
41097446|NCT00220935|DEVICE|Orthotrac Pneumatic Vest|
41097447|NCT06191263|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
41097448|NCT06191263|DRUG|Venetoclax|Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis
41097449|NCT03613103|DEVICE|Video laryngoscopy|Intubation with videolaryngoscopy with highly curved blade
41097450|NCT03613103|DEVICE|Direct laryngoscopy|Intubation with direct laryngoscopy with macintosh blade
41097451|NCT01710150|PROCEDURE|CTI ablation alone|
41097452|NCT01710150|PROCEDURE|CTI ablation and Pulmonary vein isolation (PVI)|
41097453|NCT01268761|DRUG|GnRH antagonist (Cetrorelix)|•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
41097454|NCT01268761|DRUG|Placebo (saline solution)|• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
41097455|NCT06435572|OTHER|Suction|Each patient will be evaluated as both the experimental and control group. In the study, open suction applied to the patient will be evaluated as control, and closed suction will be considered as the experimental group. The first suction of the same patient during the day will be done as open suction, and the second suction will be done as closed suction.
41097456|NCT01013675|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
41097457|NCT01013675|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
41097458|NCT04773002|OTHER|Different anesthesia methods|Total intravenous anesthesia (TIVA)and volatile anesthesia
41097459|NCT00821925|PROCEDURE|bone densitometry|All patients do a bone densitometry after the inclusion.
41097460|NCT04315142|DEVICE|Experimental TTNS|30-minute TTNS intervention is performed 2 days a week during a treatment period of 6 weeks
41097461|NCT04315142|DEVICE|Sham TTNS|30-minute sham intervention is performed 2 days a week during a treatment period of 6 weeks
41097462|NCT06110195|DRUG|Xevinapant|Given orally during study treatment on days 1-14 of a 21-day treatment cycles. It will be given continuously during treatment with carboplatin, paclitaxel, and radiation (chemoRT). After completely of the chemoRT dosing, an additional 3 cycles of Xevinapant along will be given.
41097463|NCT06110195|DRUG|Carboplatin|Given with radiation weekly for 7 doses.
41443166|NCT03989648|OTHER|Esmarch bandages|Esmarch bandage (also known as Esmarch's bandage for surgical haemostasis or Esmarch's tourniquet) in its modern form is a narrow (5 to 10 cm wide) soft rubber bandage that is used to expel venous blood from a limb (exsanguinate) that has had its arterial supply cut off by a tourniquet.
41443167|NCT03989648|OTHER|simple leg elevation|simple leg elevation 45 degree for 2 minutes is used to expel venous blood from a limb
41097464|NCT06110195|DRUG|Paclitaxel|Given with radiation weekly for 7 doses.
41097465|NCT06110195|RADIATION|Radiation Therapy|Radiation will be given together with paclitaxel and carboplatin for 7 weeks.
41097466|NCT01323660|DRUG|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
41097467|NCT01323660|DRUG|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
41097468|NCT01323660|DRUG|GSK573719 125|125mcg QID
41097469|NCT01323660|DRUG|GSK573719 62.5|62.5mcg QID
41097470|NCT01323660|DRUG|GW642444 25|25mcg QID
41097471|NCT01323660|DEVICE|placebo|Comparator QID
41097472|NCT00364598|DRUG|Anginera, a human tissue replacement therapy|
41097473|NCT02817633|DRUG|TSR-022|TSR-022 will be administered.
41097474|NCT02817633|DRUG|Nivolumab|Nivolumab will be administered.
41097475|NCT02817633|DRUG|TSR-042|TSR-042 will be administered.
41097476|NCT02817633|DRUG|TSR-033|TSR-033 will be administered.
41097477|NCT02817633|DRUG|Docetaxel|Docetaxel will be administered.
41097478|NCT02817633|DRUG|Pemetrexed|Pemetrexed will be administered.
41097479|NCT02817633|DRUG|Cisplatin|Cisplatin will be administered.
41097480|NCT02817633|DRUG|Carboplatin|Carboplatin will be administered.
41097481|NCT06631573|OTHER|fixed all-on-four prosthesis reinforced with PEEK framework.|Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with PEEK framework.
41097482|NCT06631573|OTHER|Fixed all-on-four prosthesis reinforced with Co-Cr framework|Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with Co-Cr framework
41097483|NCT00602589|DRUG|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
41097484|NCT04733300|BEHAVIORAL|Mindfulness-Based College for Young Adults|"MB-College (MBC) is a 9-week, 9 session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to young adults (18-29). The curriculum, which is based on the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum is designed to teach participants how to integrate and apply mindfulness in their everyday lives to the range of challenges arising from medical and psychological conditions and life stresses.~MBC will be administered live, online via a video conferencing platform to participants enrolled in the active arms of the study: (1) standard dose MBC and (2) low-dose MBC. Standard dose MBC meets once a week for 2.5 hours for 9 weeks, while low-dose MBC meets for 1.5 hours per week for 9 weeks. There is an all-day retreat that takes place around week six of the program that applies to both MBC programs."
41097485|NCT04733300|OTHER|Health Education for Young Adults|The health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
41097486|NCT01688973|DRUG|Erlotinib Hydrochloride|150 mg (1 tablet) by mouth on days 1-28, once daily, until disease progression
41097487|NCT01688973|OTHER|Laboratory Biomarker Analysis|Correlative studies
41097488|NCT01688973|DRUG|Tivantinib|360 mg (3 tablets) by mouth, Twice daily (720 mg total daily dose) on days 1-28, until disease progression
41097489|NCT05791201|DRUG|VX-264|Allogeneic human stem cell-derived islets.
41097490|NCT06554964|PROCEDURE|performing chromotubation during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube|Performing chromotubation )injection of blue dye to the fallopian tube via cevical catheter) during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube
41097491|NCT06021574|DRUG|VDJ001|a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody
41097492|NCT06021574|DRUG|Placebo|Placebo
41097493|NCT05481411|DRUG|Olpasiran|Subcutaneous injection
41097494|NCT00567164|DRUG|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
41097495|NCT00567164|DRUG|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
41097496|NCT00567164|DRUG|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
41097497|NCT01759979|PROCEDURE|Laser and mechanical lithotripsy|Patients will undergo cholangioscopy guided laser treatment in addition to treatment with mechanical lithotripsy using basket and balloon techniques.
41097498|NCT01759979|PROCEDURE|Mechanical Lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloons to facilitate stone removal but not laser lithotripsy.
41097499|NCT06288919|OTHER|Erythritol prophylactic powders|erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)
41097500|NCT06288919|OTHER|Ultrasonic scaler with peek inserts|ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
41097501|NCT03180034|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
41097502|NCT03180034|OTHER|Questionnaire Administration|Ancillary studies
41097503|NCT03180034|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
41097504|NCT03180034|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
41097505|NCT03910478|DEVICE|DBS Self-Collection Kit|Kit for self-collection of Dried Blood Spot (DBS) samples
41097506|NCT03910478|OTHER|Standard Control Strategy|Standard of care with office-based testing.
41097507|NCT02423057|DRUG|TdCyd|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. TdCyd offers an improvement over current DNMT inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
41097508|NCT00170573|DRUG|Caelyx|Caelyx 40 mg/ m2biweekly
41097509|NCT03018145|DEVICE|Wagon|
41097510|NCT03018145|DEVICE|Standard stretcher car|
40924828|NCT01917656|DRUG|sulphonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
41097511|NCT05235750|BEHAVIORAL|Self-affirmation writing|Writing with a focus on self-affirmation at the time following a diagnosis of an advanced cancer
41097512|NCT05971381|DEVICE|RECELL® Autologous Cell Harvesting Device|The RECELL Device is for use at the patient's point-of-care for the safe and rapid preparation of Spray-On SkinTM Cells from a small sample of a patient's own skin.
41097513|NCT04731714|DEVICE|Rhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
41097514|NCT04731714|DEVICE|Arrhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
41097515|NCT02611427|BEHAVIORAL|Education/Self-efficacy|The education/self-efficacy group will 1) receive information about benefits of physical activity and national activity guidelines, 2) receive instruction on how to increase lifestyle walking, 3) use movement monitoring devices, 4) make a walking contract and 5) receive interval contract-directed encouragement from study personnel.
41097516|NCT02611427|BEHAVIORAL|Education|The education group will receive information about safe physical activity.
41097517|NCT05607966|DEVICE|ORIGIN® CR devices|It is planned to include consecutive eligible subjects which will be treated with the ORIGIN® CR devices.
41097518|NCT06629025|DIAGNOSTIC_TEST|High-resolution impedance manometry|High-resolution impedance manometry (HRIM) can calculate the bolus motion parameters and the ratio of complete esophageal transit
41097519|NCT06546449|DRUG|LH-001|LH-001 will be administered oral
41097520|NCT06546449|DRUG|Placebo|Placebo will be administered oral
41097521|NCT05334082|OTHER|FIFA 11+|15 progressive exercise drills for training preparation (warm-up)
41097522|NCT05882318|DEVICE|eCoin Peripheral Neurostimulator System|The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
41097523|NCT04045470|DEVICE|Microdevices|The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.
41097524|NCT04045470|OTHER|Standard of care therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
41097525|NCT04045470|OTHER|Standard of care systemic therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
41097526|NCT01569906|RADIATION|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
41097527|NCT06630312|DIETARY_SUPPLEMENT|Alpha galactosidase|Alpha galactosidase capsule, 600 GALU, manufacturer Equate brand, Walmart. Powder contents from one capsule were stirred into 16 g spaghetti sauce and served before the main meal.
41097528|NCT06630312|DIETARY_SUPPLEMENT|Placebo|Placebo is 16 gm of spaghetti sauce served before the meal in a condiment cup. It is the same set up as the intervention except the \&#39;intervention\&#39; contains the AGS.
41097529|NCT03684733|DIAGNOSTIC_TEST|MRI|Clinical MRI breast screening examination
41097530|NCT04984876|DRUG|ligelizumab|Subcutaneous injection once every 4 weeks
41097531|NCT04984876|DRUG|Placebo|Subcutaneous injection once every 4 weeks
41097532|NCT06089629|PROCEDURE|Lingual frenuloplasty|Surgical release of ankyloglossia with suture reorientation of the wound to improve lingual mobility, done under local or general anesthesia
41097533|NCT06625151|BEHAVIORAL|Perfectionism and Coping Processes Model - Explanatory Feedback Intervention (PCPM-EFI)|The PCPM-EFI provides individualized explanatory feedback of daily diary data demonstrating how stress and coping processes for each participant trigger and maintain their negative and positive mood. The feedback consists of five separate modules: (a) how changes in perceived criticism, self-blame, perceived control, avoidant coping, and event stress are connected to increases negative affect; (b) how changes in perceived social support, positive reinterpretation, perceived control, avoidant coping, and problem-focused coping are linked to increases in positive affect; (c) how self-critical perfectionism and maladaptive stress and coping tendencies explain enduring mood problems; (d) how healthy striving, adaptive appraisal, and coping tendencies can identify personal strengths; and, most important, (e) what the person needs to do to manage and improve his or her mood.
41097534|NCT06625151|BEHAVIORAL|Perfectionism and Emotion Regulation Processes Model - Explanatory Feedback Intervention (PERPM-EFI)|The PERPM-EFI provides individualized explanatory feedback of daily diary data demonstrating how stress and emotion regulation processes for each participant trigger and maintain their negative and positive mood. The feedback consists of five separate modules: (a) how changes in event stress, mindfulness, self-compassion, experiential avoidance, and rumination are connected to increases in negative affect, (b) how changes in event stress, mindfulness, reappraisal, self-compassion, and experiential avoidance are linked to increases in positive affect, (c) how self-critical perfectionism and maladaptive stress and emotion regulation tendencies explain enduring mood problems, (d) how healthy striving, adaptive appraisal, and emotion regulation tendencies can identify personal strengths, and, most important, (e) what the person needs to do to manage and improve his or her mood.
41097535|NCT04898803|OTHER|conventional DGVS training|see above
41097536|NCT04898803|OTHER|extended simulator training|see above
41097537|NCT02023944|OTHER|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
41097538|NCT05711498|OTHER|Transcutaneous spinal direct current stimulation (tsDCS)|tsDCS will be carried out using a direct current stimulator (DC-Stimulator Plus, neuroConn, Ilmenau, Germany), with one electrode placed above the thoracic spinal cord and the other electrode placed on the right shoulder. We will employ rectangular electrodes of 7 x 5 cm size (neuroConn, Ilmenau, Germany) covered by electrode paste (Ten20 Conductive Paste, Weaver and Company, Aurora, USA). Stimulation will consist of the following phases: a fade-in period of 15 seconds, a plateau period of 20 minutes (with stimulation at 2.5mA either anodally or cathodally) and a fade-out period of 15 seconds. Sham stimulation will follow the anodal montage with 15-second fade-in and fade-out periods, but only 45 seconds of plateau stimulation at 2.5 mA. Such a combination of stimulation and electrodes results in a current density of 0.071mA/cm2, well below thermal and histological limits for current density.
41097539|NCT03964285|OTHER|rumination induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. For example, they will be led, in the rumination condition, to reflect on the causes, meanings and consequences of the amount of tension they feel in their muscles.
41097540|NCT03964285|OTHER|distraction induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. In the distraction condition they will, for example, imagine a ship crossing the Atlantic.
41097541|NCT04322656|DEVICE|Lipiflow treatment|Patients will be treated on one eye with Lipiflow
41097542|NCT03969277|OTHER|Graded Motor Imagery|"The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks."
41097543|NCT03969277|OTHER|Standard Rehabilitation|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.
41097544|NCT03969277|OTHER|Home Exercise Program|Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
41097545|NCT03969277|OTHER|Cold Application|Cold application around the elbow joint for 15 minutes in every session.
41097546|NCT03783455|PROCEDURE|Non arthroscopic joint lavage|Instillation of 4 litters of cold physiological serum
41097547|NCT03783455|PROCEDURE|Non arthroscopic joint lavage plus corticosteroid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of triamcinolone
41097548|NCT03783455|PROCEDURE|Non arthroscopic joint lavage plus hyaluronic acid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of hyaluronic acid
41097549|NCT03783455|PROCEDURE|Intraarticular injection of corticosteroid|Intraarticular injection containing 40 mg of triamcinolone acetonide.
41097550|NCT03783455|PROCEDURE|Intraarticular injection of hyaluronic acid|Intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
41097551|NCT04835584|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
41097552|NCT04835584|DRUG|Dasatinib|Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
41097553|NCT04835584|DRUG|Nilotinib|Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
41097554|NCT01195675|DRUG|BI 10773 (low)|single oral dose
41097555|NCT01195675|DRUG|Moxifloxacin|single oral dose
41097556|NCT01195675|DRUG|BI 10773 Placebo|2 times single dose
41097557|NCT01195675|DRUG|BI 10773 (high)|single oral dose
41097558|NCT01171924|DRUG|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
41097559|NCT01171924|DRUG|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
41097560|NCT05568719|DIAGNOSTIC_TEST|Testing of hepatic AAV Vector integration|Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated
41097561|NCT05123638|DEVICE|Virtual reality cycling exercise|Daily voluntary cycling for up to 30 minutes with the virtual reality technology
41097562|NCT05123638|BEHAVIORAL|Unsupervised stationary cycling exercise|Daily voluntary cycling for up to 30 minutes (WITHOUT the virtual reality technology)
41097563|NCT05244447|OTHER|Primary Services|Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 6 weeks. Participants also receive life coaching and ongoing job readiness support.
41097564|NCT05088226|DRUG|Ruxolitinib combined with Chidamide.|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
41097565|NCT04781140|DRUG|100mg SPN-812|100mg SPN-812 will be administered once daily and compared to Placebo
41097566|NCT04781140|DRUG|Placebo|Placebo will be administered once daily
41443168|NCT06627634|PROCEDURE|Metastatectomia and standard treatment for resectable disease.|Rather than palliative chemotherapy, the intervention offered to participants is preoperative chemotherapy, resection of primary tumour and metastatectomia of oligometastatic spread to the liver. If fit for post-operative chemotherapy, this is offered as well.
41097567|NCT03863717|OTHER|Arm Endurance Exercise Training|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
41097568|NCT03863717|OTHER|Control|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
41097569|NCT03571243|OTHER|no intervention|observational study
41097570|NCT02892799|OTHER|NICOM-Guided Diuresis|NICOM-based assessment of PLR-induced change in cardiac index
41097571|NCT02892799|OTHER|Standard of Care|
41097572|NCT00248287|DRUG|Irinotecan + Carboplatin|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
41097573|NCT00248287|DRUG|irinotecan + Carboplatin + erbitux|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
41097574|NCT02469064|OTHER|Respiratory muscle training|Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
41443169|NCT05636735|OTHER|data collection|evaluation of self -confidence
41097575|NCT02469064|OTHER|Cardiopulmonary Physical Therapy|Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
41097576|NCT04850118|BIOLOGICAL|rAAV2tYF-GRK1-hRPGRco|Adeno-associated virus vector expressing a human RPGR gene
41097577|NCT04850118|DRUG|Control|Untreated Control Group 3
41097578|NCT02606734|DEVICE|Coronary Angiography|The DyeVert System will be used during coronary angiographic procedures which include: diagnostic only, diagnostic + PCI or PCI only cases.
41097579|NCT06447142|OTHER|Open kinetic chain strengthening exercise|A web-based 8-week exercise program consisting of stretching exercises, open kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
41097580|NCT06447142|OTHER|Closed kinetic chain strengthening exercise|A web-based 8-week exercise program consisting of stretching exercises, closed kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
41097581|NCT06631196|PROCEDURE|Jacobson's PMRT|each child in the intervention group will perform five sessions of Jacobson's PMRT. Each session lasted for 15-20 minutes under the supervision of the researcher.
41097582|NCT06411418|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and medium wide-necked (neck width ≥ 4 mm or dome-to-neck ratio \< 2) saccular or fusiform intracranial aneurysm (IAs) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.
41097583|NCT02062827|BIOLOGICAL|M032 (NSC 733972)|A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
41097584|NCT00318968|DRUG|Esomeprazole|
41097585|NCT01112735|BIOLOGICAL|FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
41097586|NCT01112735|PROCEDURE|Standard of care|Standard of care
41097587|NCT04940052|DRUG|Dabrafenib|Dabrafenib will be administered orally twice daily
41097588|NCT04940052|DRUG|Trametinib|Trametinib will be administered orally once daily
41097589|NCT04940052|DRUG|Trametinib placebo|Trametinib will be administered orally once daily
41097590|NCT04940052|DRUG|Dabrafenib placebo|Dabrafenib placebo will be administered orally twice daily
41097591|NCT05671705|DIAGNOSTIC_TEST|DEXA Scan|Fu of diagnostic tests
41097592|NCT00990678|DRUG|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
41097593|NCT00990678|DRUG|Vitamin D|tablets, vitamin D3, 30 microgram daily
41097594|NCT00990678|DRUG|Calcium|tablets, 400 mg calcium, 3 times daily
41097595|NCT03610477|DIETARY_SUPPLEMENT|Medium chain triglycerides|Gel capsules, each containing 1 gram
41097596|NCT03610477|DIETARY_SUPPLEMENT|Long chain triglycerides|Gel capsules, each containing 1 gram
41097597|NCT06475677|DEVICE|OrthoCor Advanced System|The OrthoCor Advanced System is a portable battery-operated non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) plus heat therapy for general use pain relief. It utilizes a wrap that positions the device over painful areas and joint motion tracking recorded by a smart device application to monitor recovery metrics and therapy compliance.
41097598|NCT00070954|DRUG|ginkgo biloba|EgB 761
41097599|NCT00070954|OTHER|matched placebo|Inactive look-alike placebo
41097600|NCT05860881|DRUG|Sirolimus Topical Cream|The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months
41097601|NCT05860881|OTHER|Placebo|Cream containing only the base, or vehicle.
41097602|NCT04315454|DRUG|Levobupivacaine|A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
41097603|NCT06076343|BEHAVIORAL|DBT skills-training and Family Connections interventions|"DBT skills-training program includes four modules: 1. Mindufulness, 2. Distress Tolerance, 3. Emotion Regulation, 4. Interpersonal effectiveness.~FC program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills."
41097604|NCT00611832|BEHAVIORAL|"Triple P Media Series -- Standard Information-Only version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
41097605|NCT00611832|BEHAVIORAL|"Triple P Media Series -- Enhanced Behavior Activation version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
41097606|NCT06631417|DRUG|BI 1291583|formulation 1
41097607|NCT06631417|DRUG|BI 1291583|formulation 2
41097608|NCT06631417|DRUG|BI 1291583|formulation 3
41097609|NCT04108910|DIAGNOSTIC_TEST|Guidance UTI|
41097610|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 1 x 10^10 vp|Low dose cAd3-EBO Z
41097611|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 2.5 x 10^10 vp|Medium dose cAd3-EBO Z
41097612|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 5 x 10^10 vp|High dose cAd3-EBO Z
41097613|NCT02240875|BIOLOGICAL|4.4x10^8 TCID50s MVA-BN® Filo|High dose MVA-BN® Filo
41097614|NCT02240875|BIOLOGICAL|2.2x10^8 TCID50s MVA-BN® Filo|Low dose MVA-BN® Filo
41097615|NCT02240875|BIOLOGICAL|4.4 x 10^7 TCID50s MVA-BN® Filo|Very low dose MVA-BN® Filo
41097616|NCT06080711|OTHER|AI assistance|Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
41097617|NCT05951595|DRUG|Artemether-Lumefantrine-Amodiaquine (ALAQ)|A new fixed-dose combination containing artemether, lumefantrine and amodiaquine (ALAQ) will be used in the trial. Each paediatric (dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine, 40 mg amodiaquine. Adult (hard) tablets will contain either 50 mg or 60 mg of artemether, 300 or 360 mg of lumefantrine and 100 or 120 mg of amodiaquine. The treatments will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine, 22.5-45 mg/kg of amodiaquine).
41097618|NCT05951595|DRUG|Artemether-Lumefantrine (AL)|A fixed-dose combination of AL will be used in the trial. Each paediatric (dispersible) or adult (non-dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine and will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine).
41097619|NCT05951595|DRUG|Artesunate-Amodiaquine (ASAQ)|ASAQ will also be administered as a fixed dose combination. The tablets will contain 25 mg of artesunate and 67.5 mg of amodiaquine in the paediatric formulation and 100 mg artesunate, 270 mg amodiaquine in the adult formulation. The dosing will be administered once a day for 3 days at H0, H24 and H48 according to the schedule currently recommended by the WHO.
41097620|NCT05975294|DRUG|amixture 0.125% bupivicaine with fentanyl|ultrasound guided continuous erector spinae plane block with abolus 0.3ml /kg of amixture 0.125% bupivicaine with fentanyl of 2 mic per ml then Infusion of 0.1 ml /kg/hr of the same mixture.
41097621|NCT05975294|DRUG|100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset|PCA device of 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset and normal saline at a rate of 2 ml/h.
41097622|NCT04914676|DRUG|Cytarabine|Subjects on this arm will prospectively receive consolidation therapy with cytarabine. Subjects will be treated with 1000 mg/m2 cytarabine intravenously every 12 hours on Days 1-3 of each consolidation cycle. Subjects will receive up to four consolidation cycles.
41097623|NCT04914676|DRUG|Cytarabine|Subjects on this arm will have received consolidation therapy with cytarabine between 2/1/2017 and 2/1/2019. Subjects will have received 1000 mg/m2 cytarabine intravenously every 12 hours on days 1, 3, and 5 of each consolidation cycle and will have received up to 4 consolidation cycles.
41097624|NCT06158958|DRUG|ABBV-303|Intravenous (IV) Infusion
41097625|NCT06158958|DRUG|Budigalimab|IV Infusion
41097626|NCT02941146|DEVICE|The ZELTIQ System|The CoolSculpting System will be used to perform the treatments with the CoolAdvantage family of applicators.
41097627|NCT04921761|PROCEDURE|Conventional epidural|In this group, a 20-gauge multi-orifice catheter was threaded through the cephalic-directed tip of the epidural needle 5 cm into the epidural space.
41097628|NCT04921761|PROCEDURE|Dural puncture epidural|In this group, the dura was punctured by 25G Whitacre needle. After confirmation of CSF flow, the needle was removed and the epidural catheter was threaded.
41133196|NCT05302882|BEHAVIORAL|Classical massage|Classical massage was applied to the lumbar region for 9 minutes. Classical massage was applied with the patient in the prone position. A small amount of solid vaseline was taken and a gentle stroke was applied for 1 minute to spread it sufficiently to the lumbar region. Then, superficial stroking was applied to the right paraspinal region for 1 minute from distal to proximal by the physiotherapist. After the same procedure was performed on the right paraspinal region for 1 minute. Then, both hands were placed on the right and left paraspinal region and friction was applied for 2 minutes. Afterwards, the patient's right paraspinal region was kneeding for 1 minute and then the same procedure was applied to the left paraspinal region for 1 minute. As the last procedure, the fingertips of both hands were placed on the right and left paraspinal region and the classical massage was completed by performing 2 minutes of deep euphlorage from the L5-S1 level to the T12 level.
41133197|NCT06211595|DEVICE|DragonFire Transcatheter Myocardial Radiofrequency Ablation System|The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
41133198|NCT04805736|PROCEDURE|Microwave Ablation|Image-guided microwave ablation 7-10 days prior to surgery
41133199|NCT04805736|DRUG|Camrelizumab|Camrelizumab 200 mg was given a few days after microwave ablation
41133200|NCT04805736|PROCEDURE|Breast Surgery|Standard of care breast conserving surgery or radical mastectmoy
41133201|NCT05331872|BIOLOGICAL|Human umbilical cord-derived mesenchymal stem cell infusion|Human umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis
41133202|NCT00859300|GENETIC|Blood sample|Blood sample Determination of genetic background
41133203|NCT00859300|GENETIC|Blood sample|Blood sample Determination of genetic background
41133204|NCT04092322|DEVICE|Actical accelerometers (Philips Respironics)|patients with stroke will be evaluated by using PASE scale and accelerometer results (accelerometer will be held from Monday to Friday
41133205|NCT04092322|OTHER|PASE|Physical Activity Scale for Elderly
41133206|NCT06472713|DRUG|Mitoxantrone hydrochloride liposome injection|mitoxantrone hydrochloride liposome injection combined with PD-1 blockade once every 3 weeks for up to 8 cycles, following the uniform PD-1 blockade alone once every 3 weeks for two years, or until intolerable toxicity, subject withdrawal of informed consent, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
41133207|NCT04000750|OTHER|Time Restricted Eating|Diet will be tracked and reported every day to a qualified dietitian.
41133208|NCT04000750|OTHER|Normal Feeding|Diet will be tracked and reported every day to a qualified dietitian.
41133209|NCT04000750|OTHER|Resistance Training|8 weeks of supervised and programmed whole body resistance training, performed 4x per week
41133210|NCT04000750|DIETARY_SUPPLEMENT|Whey Protein|Consumed on all exercise days.
41133211|NCT05535959|DRUG|VX-121/TEZ/D-IVA|FDC tablet for oral administration.
41443170|NCT01649921|DRUG|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
41133212|NCT05119543|OTHER|outdoor time|This cohort study aimed to assess the change of refractive status in Chinese school children under different outdoor time
41443171|NCT01649921|OTHER|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
41097629|NCT06388707|DEVICE|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2, burst length: 3 ms, duration: max. three consecutive 10-minute FUS exposures with two 5-minute intermission intervals.
41097630|NCT04286022|OTHER|Speed Loss 20% Strength Training|Strength training based on the control of speed loss in execution.
41097631|NCT04286022|OTHER|Reduced Rest Time Strength Training|Strength training based on a protocol that includes reduced rest times between sets.
41097632|NCT06630780|RADIATION|Head and Neck Cancers|All patients received intensity-modulated conformal radiotherapy (IMRT). To ensure study quality, all IMRT plans were reviewed by the research team at Sun Yat-sen University Cancer Center. The delineation principles for the radiotherapy target volume of the primary tumor bed and normal tissues followed the consensus guidelines.
41097633|NCT06083233|DIAGNOSTIC_TEST|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and cerebrospinal fluid sampling (sample 1 in measurement)
41097634|NCT06083233|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
41097635|NCT06083233|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
41097636|NCT06083233|PROCEDURE|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of cerebrospinal fluid (5 days, 1 month a 2 months after surgery)
41097637|NCT06083233|PROCEDURE|Blood sampling #1|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours prior surgery
41097638|NCT06083233|PROCEDURE|Blood sampling #2|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours after surgery
41097639|NCT06083233|PROCEDURE|Blood sampling #3|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 5 days after surgery
41097640|NCT06083233|PROCEDURE|Blood sampling #4 and #5|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
41097641|NCT04648046|DRUG|Cyclophosphamide|Non-ablative conditioning with cyclophosphamide.
41097642|NCT04648046|BIOLOGICAL|LVgp120duoCAR-T cells, low dose|A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused.
41097643|NCT04648046|BIOLOGICAL|LVgp120duoCAR-T cells, high dose|A single dose of 1 x 10\^6 cells/kg LVgp120duoCAR-T cells will be infused.
41097644|NCT04648046|OTHER|Analytic Treatment Interruption|HIV antiretroviral therapy medications will be paused.
41097645|NCT00133588|BIOLOGICAL|Trivalent split Inf|
41097646|NCT06481124|DEVICE|electrical impedance tomography|Measurement of ventilation and perfusion during mechanical ventilation with different positive end-expiratory pressure by electrical impedance tomography
41097647|NCT05457361|DRUG|VEN combined with azacitidine plus homoharringtonine|VEN begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and HHT (1 mg/m²) on days 1-7.
41097648|NCT05457361|DRUG|VEN combined with azacitidine|The use of VEN is just the same as it dose in VAH regimen except lasting for 28 days. The use of azacitidine is exactly the same as VAH group does.
41097649|NCT05578092|DRUG|MRTX0902|SOS1 inhibitor
41097650|NCT05578092|DRUG|MRTX849|KRAS G12C inhibitor
41097651|NCT05446389|DEVICE|Pacifier Activated Lullaby ®|Pacifier Activated Lullaby (PAL®) is a medical device that encourages and reinforces the development of non-nutritive sucking (NNS) of premature infants. This is accomplished by giving positive feedback in the form of music/mother's voice as an auditory input in direct response to effective sucking.
41097652|NCT06630026|OTHER|The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society in Parkinson patients and to make its validity and reliability in Turkish.|• The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society and to make its validity and reliability in Turkish. It has 5 questions. This study will be conducted with Parkinson patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
41097653|NCT06209060|BEHAVIORAL|Hammock Position|Researchers will make a hammock by using a soft rectangular cotton cloth with ropes that pass through the circular openings of the incubator and are tied on the upper part of it. Babies will be placed in this hammock in a supine position with their extremities in the midline. The spine of the preterm neonate will support while arms and knees are flexed. Additionally, a small rectangular roller will be placed between the cervical and scapular region of the newborn in the hammock position to ensure that no hyperflexion or hyperextension position of the head occurs, which may impair respiratory function.
41097654|NCT06209060|BEHAVIORAL|Nesting|In the nesting group, a nest will be made using rolls prepared with materials such as towels and blankets, and the baby will be placed in this nest. The baby's head and body will be positioned on the same axis, its extremities will be positioned in the midline, and its hands will be positioned close to its face.
41097655|NCT06340347|DRUG|Osivelotor|"a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367"
41097656|NCT06428786|OTHER|Female Sexual Function Index|As part of the study, data on the socio-demographic characteristics of the individuals is collected by means of personal interviews using a questionnaire. The results of laboratory tests required for the diagnosis of PCOS will be taken from hospital records. The Female Sexual Function Index (FSFI), the Beck Depression Inventory and the KF-36 quality of life assessment form will be completed in person and the total scores will be analyzed taking into account four different PCOS phenotypes.
41443172|NCT05975905|BIOLOGICAL|Dose A KER-012|Dose A KER-012 (Q4W);
41443173|NCT05975905|BIOLOGICAL|Dose B KER-012|Dose B KER-012 (Q4W);
41443174|NCT05975905|BIOLOGICAL|Dose C KER-012|Dose C KER-012 (Q4W);
41097657|NCT02148406|BEHAVIORAL|Yoga Skills Training (YST)|Undergo YST
41097658|NCT02148406|OTHER|questionnaire administration|Ancillary studies
41097659|NCT02148406|OTHER|fatigue and depressive symptom assessment and management|Ancillary studies
41097660|NCT02148406|OTHER|psychological stress assessment|Ancillary studies
41097661|NCT02148406|OTHER|laboratory biomarker analysis|Correlative studies
41097662|NCT02148406|OTHER|Attention Control|
41097663|NCT03563053|COMBINATION_PRODUCT|EryDex System|"EryDex System was a combination product that was used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product which was infused into the patients.~EryDex treatment consisted of a dose range correspondent to the ATTeST High Dose (obtained by loading 125 mg of DSP to the EryDex process and that, in the ATTeST, resulted in a mean of 17.4 ± 5.4 mg (mean ± standard deviation) of DSP infused to patients) administered via ex vivo encapsulation into EDS that were infused into the patient with A-T.~The dose of EryDex treatment was selected to allow collection of long-term safety data on the dose of erythrocyte encapsulated DSP that was considered more effective among the two different doses that were employed in the ATTeST study, based on the analysis of the ATTeST blinded, Phase 3 study data."
41097664|NCT04363762|BEHAVIORAL|Internet-based multimodal pain program|A guided internet-based multimodal pain program for chronic TMD pain
41097665|NCT04363762|DEVICE|Occlusal splint|Occlusal splint, standard
41097666|NCT05380531|DIAGNOSTIC_TEST|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
41097667|NCT04301674|DEVICE|Breath Biopsy|ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)
41097668|NCT03460353|DRUG|Dexamphetamine|Patients are tested for their normal prescription dexamphetamine medication
41097669|NCT03426514|PROCEDURE|Three-port Laparoscopic Surgery|Patients undergo three-port laparoscopic surgery. The surgery will be completed by a surgeon and a camera-person without another assistant. The surgeon will adjust surgical position to expose the operative field with the help of gravity. All the orther operative procedures are the same as conventional laparoscopic surgery.
41097670|NCT03426514|PROCEDURE|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery（4 or more ports）.The surgery will be routinely completed by a surgeon，a camera-person and another assistant to provide counter-traction.
41097671|NCT02419521|DEVICE|Resolute Onyx Stent - 2.25 mm - 4.0 mm|
41097672|NCT03035656|DRUG|Ropivacaine|Administration of Ropivaciane via epidural injection intra-operatively
41097673|NCT03035656|OTHER|Saline|Administration of saline via epidural injection intra-operatively
41097674|NCT03679546|DRUG|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
41097675|NCT03679546|DRUG|Vedolizumab Injection|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
41097676|NCT02690103|DRUG|pegylated IFN|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
41097677|NCT02690103|DIETARY_SUPPLEMENT|Biobran|Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.
41097678|NCT02690103|DRUG|Ribavirin|Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
41097679|NCT02667418|DRUG|Fidaxomicin|200 mg PO twice daily for 10 days
40924829|NCT02631382|PROCEDURE|wet cupping|"In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).~In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected."
41097680|NCT02667418|DRUG|Vancomycin with Taper/Pulse|125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
41097681|NCT02667418|DRUG|Vancomycin|125 mg PO for times daily for 10 days
41097682|NCT02302209|DRUG|Oxytocin|
41097683|NCT02302209|OTHER|Placebo Comparator|
41097684|NCT02280161|OTHER|cytology specimen collection procedure|Correlative studies
41097685|NCT03043066|PROCEDURE|Scaling and root planing|subjects underwent full mouth supragingival and subgingival scaling
41097686|NCT03043066|DRUG|scaling and root planing along with antibiotic intervention|subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
41097687|NCT06628674|BEHAVIORAL|core muscle exercise|Patients in experiment group will do core muscle exercise with online interactive videos
41097688|NCT06628674|BEHAVIORAL|pelvic muscle exercise|Patients in experiment group will do pelvic muscle exercise without online interactive videos
41097689|NCT06629610|BEHAVIORAL|DAiLY|The 2-year intervention includes three components, all supported by social media. Home-Based Workshops will be delivered by community members to increase knowledge and skills related to food choices, and to emphasize the importance of physical activity. Emphasis is placed on the benefits of consuming subsistence foods, as well as healthy store-bought foods. Food store modifications will increase access to healthy foods in local stores by working with store managers to stock and promote affordable healthy foods, and will provide participants with opportunities to implement what they have learned in HBWs. Point of purchase promotions, educational displays, taste tests and cooking demonstrations, will identify and promote these foods to community members. Physical activity promotion will include community-wide traditional activities, such as traditional dance, sports events, and berry festivals. Fitbits will be used as a motivational tool for participants to track their progress.
41097690|NCT03766438|BEHAVIORAL|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
41097691|NCT05974072|DRUG|Usual Care|The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
41443175|NCT05975905|BIOLOGICAL|Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks|Treatment Period (24 weeks): Placebo SC (Q4W) Extension Period (72 weeks after Placebo treatment): KER-012 (Dose B) SC (Q4W)
41097692|NCT05974072|OTHER|PAINDOC Program|"The PAINDOC Program consists in:~* Therapeutic education: The therapeutic education block consists of two parts: an education session called Empowered Relief (ER) and two pain neuroscience education (NDT) sessions.~* Psychotherapy: The psychotherapy part consists of one group session of one hour, face-to-face and with groups of up to 15 people, given by the psychologist of the pain unit.~* Mindfulness Meditation: The Mindfulness Meditation consists of one group session of one hour, face-to-face and with groups of up to 15 people. These are given by a nurse from the pain unit. T~* Therapeutic exercise: The therapeutic exercise module consists of three sessions of one hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit."
41097693|NCT04160585|OTHER|There is no intervention.|There is no intervention.
41097694|NCT03588065|DIAGNOSTIC_TEST|FMS|"The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception"
41097695|NCT03588065|OTHER|TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
41097696|NCT03588065|OTHER|CONFERENCE|The face-to-face educational intervention (conference) consisted of four educational sessions, distributed over four weeks during the sports transition period of the Equity sub-20 team. During these sessions, workshops (conferences) were held with the players following a face-to-face methodology . All these activities were concerted with the multidisciplinary team of the Equity football team and were carried out by the researcher at the University of La Sabana, a physiotherapist, who was studying the needs of the prevention of musculoskeletal injuries in football.
41097697|NCT03799341|BEHAVIORAL|Prize-Based Contingency Management|"Participants assigned to Prize-based Contingency~Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8~prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment."
41133213|NCT05040828|BEHAVIORAL|Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.|Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
41443176|NCT00675779|DRUG|oral contraceptive (Mercilon)|oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
40752050|NCT06262997|OTHER|Pilates and Kinesiotape|Patients in the Pilates and Kinesiotape group will receive exactly the same Pilates training as in the Pilates group. At the end of each exercise session, Kinesio Tex Gold FP elastic tape (5 cm) will be applied with mechanical correction technique for postural correction and the tape will be renewed in each session. Waterproof, porous, adhesive, 0.5 mm thick tape will be applied to the upper trapezius.
40924830|NCT04568824|OTHER|GraphoLearn reading intervention|This is an Edtech reading intervention
40924831|NCT04568824|OTHER|Vektor math control intervention|This is an Edtech math/cognition intervention
40924832|NCT06449365|DEVICE|midazolam by nasal atomizer|midazolam
40924833|NCT06449365|DRUG|intravenous midazolam|midazolam
40924834|NCT00948584|OTHER|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
40924835|NCT04670250|DIAGNOSTIC_TEST|non invasive markers|non invasive markers (IL6, serum ferritin, fecal lactoferrin) used for monitoring of newly diagnosed patients with ulcerative colitis
40924836|NCT01343901|DRUG|Bevacizumab|Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
40924837|NCT01062373|DIETARY_SUPPLEMENT|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
40924838|NCT01062373|DIETARY_SUPPLEMENT|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
40924839|NCT00639743|DRUG|placebo ( group B)|placebo ( group B)
40924840|NCT00639743|DRUG|tenecteplase (group A)|tenecteplase (group A)
40924841|NCT06174142|DEVICE|High-Frequency ESWT|Participants will receive extracorporeal shock wave therapy at a frequency of 15 Hz and intensity/pressure level 3, with a total of 1800 impulses per session. This intervention will be conducted once per week for six weeks, alongside a standard physical therapy regimen
40924842|NCT06174142|DEVICE|Low-Frequency ESWT Group|"Participants will be treated with extracorporeal shock wave therapy at a frequency of 10 Hz and intensity/pressure level 4, also with a total of 1800 impulses per session. This protocol will be delivered weekly for six sessions, accompanied by standardized physical therapy exercises."
41097698|NCT03799341|BEHAVIORAL|Treatment As Usual Outpatient Substance Use Treatment|All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
41097699|NCT02959151|DRUG|CAR-T cell|CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.
41097700|NCT04691778|PROCEDURE|CTO PCI with the first-choice Gladius guidewire|CTO PCI using antegrade wiring strategy with the first-choice Gladius guidewire
41097701|NCT04691778|PROCEDURE|CTO PCI without the first-choice Gladius guidewire|CTO PCI using standard antegrade wire escalation strategy
41097702|NCT05821127|BEHAVIORAL|Virtual Reality Assisted Neurodynamic Exercises and Patient Education with Telerehabilitation Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. In addition, 2 sessions of patient education will be provided with videoconference calls, and with the mobile application to be installed on the phones of the patients as non-immersive virtual reality support, it will be possible to practice median nerve and tendon gliding exercises in the form of 5 repetitions and 6 sets every day with video support for 16 weeks. In this application, the user will use the front camera of phone as a sensor to detect hand movements. A screen on which exercises will be played at the top of the screen and a virtual image of the user's hand in the lower half of the screen will be displayed in the field of view of the camera. Each exercise position will take 5 seconds. Patient education will include neuroscience, etiology, pathophysiology and treatment options of carpal tunnel syndrome, ergonomics and posture education.
41097703|NCT05821127|BEHAVIORAL|Neurodynamic Exercises and Patient Education with Traditional Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. Patients will be asked to do the exercises in the form of 5 repetitions and 6 sets every day and to wear the night splint every night for 16 weeks. Each exercise position will take 5 seconds. A brief verbal education will be given to the patients under the same topics as the intervention group, as in the outpatient clinic.
41097704|NCT04384146|RADIATION|Cyclical Hypofractionated Palliative Radiation (Quad Shot)|3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break.
41097705|NCT04384146|BEHAVIORAL|EORTC QLQ-C30 questionnaire|at baseline, each cycle of Quad Shot, and at 3 weeks, 3 months and 6 months after last cycle of Quad Shot.
41097706|NCT06526078|BEHAVIORAL|Cognitive Training|Sessions of cognitive training exercises (15-20min each) self-administered via a web app
41097707|NCT06526078|BEHAVIORAL|Sham Training|Sessions of sham training exercises (15-20min each) self-administered via a web app
41097708|NCT00049517|BIOLOGICAL|sargramostim|Given IV or as an injection
41097709|NCT00049517|DRUG|busulfan|Given IV
41097710|NCT00049517|DRUG|cyclophosphamide|Given IV
41097711|NCT00049517|DRUG|cytarabine|Given as a continuous infusion
41097712|NCT00049517|DRUG|gemtuzumab ozogamicin (GO)|Given IV
41097713|NCT00049517|DRUG|Daunorubicin|Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
41097714|NCT00049517|PROCEDURE|Autologous HCT|Autologous hematopoietic cell transplantation
41097715|NCT00049517|PROCEDURE|Allogeneic HCT|Allogeneic hematopoietic cell transplantation
41097716|NCT02474511|OTHER|general anesthesia and local anesthesia|the patient received generalanesthesia and local anesthesia randomly
41097717|NCT03521323|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
41097718|NCT03521323|DRUG|Placebos|Placebos: Saline，Sham operation
41097719|NCT03261661|BEHAVIORAL|Reading|Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.
41097720|NCT03261661|BEHAVIORAL|Mindset|Blended learning program with online and teacher-directed activities related to how the brain functions, learns, and remembers, and how it changes in a physical way when we exercise it. Instruction in how students are in control of their brain and its development, and how to apply this to their schoolwork with practical strategies for tackling academic challenges.
41097721|NCT03261661|BEHAVIORAL|Reading Embedded with Mindset|Mindset training explicitly linked to the reading content through lesson openers, feedback prompts, and self-monitoring of mindset during reading work.
41097722|NCT03261661|BEHAVIORAL|Business as Usual|Reading interventions already provided to students with reading difficulties as per typical procedures at the participating school
41097723|NCT05627557|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
41097724|NCT05627557|DRUG|MMF|MMF will be administered as per schedule specified in the respective arm.
41097725|NCT05627557|DRUG|Prednisone|Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.
41097726|NCT05627557|DRUG|Methylprednisolone|Methylprednisolone 80 mg (or 1.5 mg/kg if \</=45 kg) IV will be administered as premedication prior to infusions.
41097727|NCT05627557|DRUG|Acetaminophen/ Paracetamol|Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.
41097728|NCT05627557|DRUG|Diphenhydramine Hydrochloride|Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.
41443177|NCT00675779|DRUG|atorvastatin + oral contraceptive|atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
41097729|NCT03907007|DEVICE|Percutaneous electrical nerve stimulation|Stimulation and medication at the same instant
41097730|NCT03907007|DEVICE|Percutaneous electrical nerve stimulation|Stimulation is given without administering medication
41097731|NCT05552547|DEVICE|Home Blood Pressure Machine|Participants will be asked to measure blood pressure twice daily for three days in a row at home.
41097732|NCT05552547|DEVICE|24-Hour Blood Pressure Machine|Participants will be asked to wear the machine for 24 hours.
41097733|NCT03618095|DEVICE|LOTUS Edge Valve System|TAVR with the LOTUS Edge Valve System
41097734|NCT06540196|DIAGNOSTIC_TEST|NodeAI|The ultrasound video and images of each LN will be analyzed by NodeAI, which will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
41097735|NCT06540196|DIAGNOSTIC_TEST|Surgeon|The ultrasound video and images of each LN will first be analyzed by the surgeon, who will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
41097736|NCT02466295|OTHER|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
41097737|NCT02466295|OTHER|Pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
41097738|NCT06398223|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA): Surgical procedure to remove the plaque buildup in the carotid artery.
41097739|NCT06398223|PROCEDURE|Carotid artery stenting|Carotid artery stenting: Treatment of the stenosis with a stent. The plaque in the artery wall is not removed but the narrowing is dilated.
41097740|NCT05338242|DEVICE|Real-Time Exposure Feedback|Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
41097741|NCT03879967|DEVICE|Allograft block graft|The graft used is a mineralized, cortico-cancellous, delipidized, lyophilized allogenic block.
41097742|NCT05543811|DIETARY_SUPPLEMENT|Food for special dietary use|Food for special dietary use (spread) with modified ingredients' content will be included to the diet of 70 patients without significant organic pathology for 14 days receiving standard diet, modified by the inclusion of two portions of the spread, 20 grams each for breakfast and dinner
41097743|NCT04472338|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and/or tissue samples
41097744|NCT04472338|OTHER|Laboratory Biomarker Analysis|Correlative studies
41097745|NCT04472338|OTHER|Quality-of-Life Assessment|Ancillary studies
41097746|NCT04472338|OTHER|Questionnaire Administration|Ancillary studies
41097747|NCT05457491|BIOLOGICAL|Human platelet extract (cosmetic product)|A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
41097748|NCT05457491|OTHER|Vanicream Gentle Facial Cleanser|A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
41097749|NCT05457491|OTHER|EltaMD UV Daily Broad-Spectrum SPF 40|A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
41097750|NCT05457491|OTHER|EltaMD PM Therapy Facial Moisturizer|A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
41097751|NCT05457491|OTHER|Vanicream Lite Lotion|Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
41097752|NCT06567743|DRUG|Cretostimogene Grenadenorepvec|Cohort A, Arm 1 and 2
41097753|NCT06567743|DRUG|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
41097754|NCT06632054|BEHAVIORAL|Text Message Reminders|Text message reminders (instead of usual care - phone call reminders) to complete FIT for colon cancer screening.
41097755|NCT06566534|BEHAVIORAL|Reminder|Flu shot messages via SMS
41097756|NCT05419557|BEHAVIORAL|Virtual Family-Based Healthy Plate Club|IHPC provides produce boxes, nutrition and meal-preparation, education, and supportive counseling to address barriers related to obtaining produce and food. The intervention provides participants with a bi-weekly produce box for 12 weeks and helps families identify sustainable ways to obtain vegetables once the produce boxes end. The CHW will support families by coaching them on how to prepare these unfamiliar vegetables, give tips on finding sales at grocery stores, as well as by navigation to food assistance sites including food pantries. Parents will learn strategies to increase vegetable consumption by addressing perceived barriers - such as the child doesn't like vegetables. Curriculum will also include topics such as how to increase physical activity and reduce screen time.
41097757|NCT03441048|BIOLOGICAL|Lintuzumab-Ac-225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of relapsed/refractory acute myeloid leukemia.
41097758|NCT03441048|DRUG|Cladribine|Cladribine is a purine antimetabolite.
41097759|NCT03441048|DRUG|Cytarabine|Cytarabine is an antineoplastic anti-metabolite.
41097760|NCT03441048|DRUG|Mitoxantrone|Mitoxantrone is an anthracenedione antineoplastic agent.
41097761|NCT03441048|DRUG|G-CSF|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.
41097762|NCT02751099|OTHER|transplanted patients|bone biopsy, echocardiogram, blood samples
41097763|NCT06630091|DRUG|Golidocitinib|150 mg once per day by PO
41097764|NCT06630091|DRUG|Cyclophosphamide|750 mg/m2 by IV
41097765|NCT06630091|DRUG|Doxorubicin|50 mg/m2 by IV
41097766|NCT06630091|DRUG|Vincristine|1.4 mg/m2 (max: 2 mg) by IV
41097767|NCT06630091|DRUG|Prednisone|100 mg by PO
41097768|NCT05520827|DRUG|BI 1584862|BI 1584862
41097769|NCT05520827|DRUG|Placebo|Placebo
41097770|NCT01802203|DEVICE|truFreeze Spray Cryotherapy|spray cryotherapy
41097771|NCT01969890|DRUG|G-CSF administration|Zarzio - 5 microg/kg bis in die for 6 days
41097772|NCT06630624|DRUG|IP-001|Intra-tumoral injection of IP-001 following ablation (RFA, MWA or IRE).
41097773|NCT01535430|DIAGNOSTIC_TEST|Brain mapping|Brain mapping will be employed pre-, intra-, and post-operatively to evaluate specific functions.
41097774|NCT04401917|DRUG|[18F]NOS|Participants will undergo approximately 60 minutes of dynamic whole-body scanning, including the brain, starting at approximately the time of injection of \[18F\]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of \[18F\]NOS.
41097775|NCT05626543|BEHAVIORAL|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs will be used combinedly. CBT will be constructed based on the CBT model of Beck, (2021) and mindfulness practice will be implemented based on the MBSR program developed by Williams et. al. (2011).
41097776|NCT03722446|DEVICE|Arrow Catheter Kit.|The group will be randomized to receive this labor analgesia kit.
41097777|NCT03722446|DEVICE|B.Braun Catheter Kit|The group will be randomized to receive this labor analgesia kit.
41097778|NCT04362501|BIOLOGICAL|dupilumab|300mg dupixent SC every two weeks for six months
41097779|NCT04362501|DRUG|placebo|placebo SC injection every two weeks for six months
41097780|NCT04442672|PROCEDURE|acute compartment syndrome model of health volunteer|the acute compartment syndrome model of health volunteer is induced by pressurizing the calves by the cuff, and the cuff is inflated and pressurized to a pressure value of 20, 30, 40, 50, 60, 70, 80 mmHg. the pressure inside the cuff was up to 10 s during pressurization and maintained stable for 1 min, measured and the above indicators were recorded within 3 min.
41097781|NCT04442672|PROCEDURE|sham|surrounding the cuff but not inflate it.
41097782|NCT04515810|OTHER|Internet-Based Intervention|Use smartphone application
41097783|NCT04515810|OTHER|Best Practice|Engage in standard care
41097784|NCT04515810|OTHER|Questionnaire Administration|Ancillary studies
41097785|NCT05735847|PROCEDURE|Total Knee Arthroplasty (TKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with TKA involves the replacement of both the medial and lateral compartments of the knee.
41097786|NCT05735847|PROCEDURE|Unicompartmental Knee Arthroplasty (UKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with UKA involves the replacement of one compartment.
41097787|NCT01474538|DRUG|Insulin Lispro|Insulin lispro (100 U/mL) administered by CSII pump
41097788|NCT01474538|DRUG|Insulin Aspart|Insulin aspart (100 U/mL) administered by CSII pump
41097789|NCT05913739|OTHER|Oxygen Therapy|Nocturnal oxygen therapy minimum 6 hours
40752051|NCT05760677|DRUG|pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone|the pioglitazone group： classic treatment: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
40752052|NCT05760677|DRUG|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD)
41097790|NCT06441006|DRUG|Bedaquiline|Frequency: daily Route of administration: oral
41097791|NCT06441006|DRUG|Linezolid|Frequency: daily Route of administration: oral
41097792|NCT06441006|DRUG|Pretomanid|Frequency: daily Route of administration: oral
41097793|NCT06441006|DRUG|Moxifloxacin|Frequency: daily Route of administration: oral
41097794|NCT06441006|DRUG|Control Arm FQ-S MDR/RR-TB regimen, designed according to latest WHO guidelines|The local SOC regimen consistent with preferred regimen(s) in international guidelines. In most cases this will be 26 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM). Doses and durations of each component may change based on the latest WHO guidelines and the local SOC.
41097795|NCT05233527|PROCEDURE|Episiotomy Closure|indicated episiotomy with Novosyn® Quick after spontaneous vaginal delivery
41097796|NCT04071223|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41097797|NCT04071223|PROCEDURE|Bone Scan|Undergo bone scan
41097798|NCT04071223|DRUG|Cabozantinib S-malate|Given PO
41097799|NCT04071223|PROCEDURE|Computed Tomography|Undergo CT
41097800|NCT04071223|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41097801|NCT04071223|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET or NaF-PET
41097802|NCT04071223|OTHER|Quality-of-Life Assessment|Ancillary studies
41097803|NCT04071223|OTHER|Questionnaire Administration|Ancillary studies
41097804|NCT04071223|RADIATION|Radium Ra 223 Dichloride|Given IV
41097805|NCT05550480|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring for 50 days
41097806|NCT05808764|DRUG|Risdiplam|Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
40752053|NCT00758043|DRUG|telaprevir|750 mg every 8 hours (q8h) for 12 weeks
41097807|NCT02537392|DIETARY_SUPPLEMENT|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
41097808|NCT02537392|DIETARY_SUPPLEMENT|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
41097809|NCT02537392|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid.
41097810|NCT00445406|DRUG|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
41097811|NCT00445406|DRUG|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
41097812|NCT00320489|DRUG|olanzapine|10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.
41097813|NCT00320489|DRUG|olanzapine pamoate depot|405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
41097814|NCT02834689|BEHAVIORAL|Walking|Walking on a treadmill at 3.5 METS for 50 minutes
41097815|NCT02834689|BEHAVIORAL|Seated Control|Sitting for 50 minutes
41097816|NCT02195479|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
41097817|NCT02195479|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
41097818|NCT02195479|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
41097819|NCT02195479|DRUG|Daratumumab IV|Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study .
41097820|NCT02195479|DRUG|Dexamethasone|Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute.
41097821|NCT02195479|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. Following amendment 7, participants can switch from daratumumab IV to daratumumab SC.
41097822|NCT04571333|DEVICE|Mi2000 Totally Implantable Cochlear Implant|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
41097823|NCT01219855|DRUG|Cohort 1 CTAP101 Capsules- 60µg|60µg of CTAP101 capsules given once daily for 42 days.
41097824|NCT01219855|DRUG|Cohort 1 CTAP101 Capsules - 90µg|90µg of CTAP101 capsules given once daily for 42 days.
41097825|NCT01219855|DRUG|Cohort 1 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
41097826|NCT01219855|DRUG|Cohort 2 CTAP101 Capsules - 30µg|30µg of CTAP101 capsules given once daily for 42 days.
41097827|NCT01219855|DRUG|Cohort 2 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
41097828|NCT05448755|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
41097829|NCT06337110|DRUG|Lu AF28996|Oral solution containing radiolabelled \[14C\]-Lu AF28996.
41097830|NCT00686023|PROCEDURE|internal fixation (DHS - richard nail)|internal fixation
41097831|NCT00686023|PROCEDURE|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
40924843|NCT06174142|DEVICE|Sham ESWT Control Group|"Participants in this control group will undergo a sham ESWT procedure that mimics the treatment experience without actual therapeutic effects, ensuring the blinding of participants. This sham therapy will be scheduled once a week for six weeks, in conjunction with the same physical therapy program as the other groups."
41097832|NCT02175537|BEHAVIORAL|Microclinic Social Induction Diabetes and Obesity Program|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
41443178|NCT05402202|OTHER|Healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
41443179|NCT05402202|OTHER|Customized healing abutment|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment fabricated by intraoral scanning by scan body
40752054|NCT00758043|DRUG|ribavirin|1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
40924844|NCT02050178|DRUG|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
40924845|NCT02243462|DEVICE|Forced Air Warmer|"A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable blanket. The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket."
41097833|NCT03074851|DIETARY_SUPPLEMENT|low sodium salt|To give free low sodium salt intervention for 2 months
41097834|NCT03074851|OTHER|informational intervention|to give reporter informational intervention.
41097835|NCT01106729|DIETARY_SUPPLEMENT|Cyanidin 3 glucoside|Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
41097836|NCT03778593|DRUG|5-Fluorouracil|D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks
41097837|NCT03778593|DRUG|Leucovorin|D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks
41097838|NCT03778593|DRUG|Irinotecan|D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks
41097839|NCT03778593|DRUG|Oxaliplatin|D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks
41097840|NCT03778593|DRUG|5% dextrose water|mix fluid with 5-FU, leucovorin, irinotecan, and oxaliplatin
41097841|NCT05710744|BEHAVIORAL|Shared decision making tip sheet|Physicians will view tip sheets containing best practices for shared decision making with diverse families.
41097842|NCT05649098|DRUG|Dupilumab|The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.
41133214|NCT05040828|BEHAVIORAL|Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.|10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
41443180|NCT02995720|DRUG|Fimasartan/Amlodipine combination drug, Rosuvastatin|
41443181|NCT00404105|PROCEDURE|PRK|
41443182|NCT00404105|PROCEDURE|LASIK|
41097843|NCT04995887|DEVICE|Jada® System|The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
41097844|NCT06630143|OTHER|Combined Virtual and Clinical Simulation|Participants will complete a preeclampsia case scenario through virtual simulation first and then engage in a clinical simulation involving the same case. This sequential intervention is designed to reinforce knowledge and skills.
41097845|NCT06630143|OTHER|virtual simulation|Participants will complete the preeclampsia case scenario using the vSim® platform, allowing them to engage in virtual clinical decision-making.
41097846|NCT06630143|OTHER|clinical simulation|Participants will manage a preeclampsia case using a high-fidelity manikin in a simulated clinical setting, practicing hands-on skills and clinical decision-making.
41097847|NCT03564626|OTHER|Health-IT +/- Scheduled Follow Up|"* Training patient and caregiver on Patient Buddy and EncephalApp~* Counseling regarding readmission~* Daily contact through app~* Standard of care counseling regarding readmission and discharge instructions~* Follow up phone calls at Week 1 and Week 3~* In-person follow up visits at Week 2 and Week 4"
41097848|NCT06555029|BEHAVIORAL|EHR Changes|"Practice-Level:~Changes to the Epic EHR system will include the AAAC process to ask 5 oral health questions, advise for dental attendance, assess the type of referral, and connect with referral and resources"
41097849|NCT06555029|BEHAVIORAL|Medical Staff EHR Training, Clinician CSM theory-based didactic education and skills training|"Provider-Level:~Medical staff to complete EHR training and then deliver the ask, advise, assess, connect (AAAC) strategies to screen, refer, and provide resources for oral health.~Clinician will receive Common-Sense Model of Self- Regulation (CSM) and Social Cognitive Theory based education and skills training for the physician/nurse practitioner to communicate core OH facts to the patient and provide reinforcement of the importance of dental visits to overall health. Clinicians will also document the encounter in EHR."
41097850|NCT06555029|BEHAVIORAL|Standard ADA Oral Health Training|"Provider-Level:~Clinician only: Clinicians will receive standard American Dental Association (ADA) based oral health hygiene training (brushing, flossing, fluoridated water, cleaning dentures) and asked to follow their current oral health care with their patients. The usual care currently is to address oral health issues if the patient complains or has a question. The clinicians will not have skills training nor visual resources for the patient encounter."
41097851|NCT03391908|DIAGNOSTIC_TEST|cardiac imaging tests|Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
41097852|NCT02148809|RADIATION|1mL of I-131 Human Serum Albumin is injected prior to the measurements|
41097853|NCT05376605|OTHER|assessment|Evaluations of the patients will be made with scales, questionnaires and physical tests.
41097854|NCT00180102|DRUG|Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|
41097855|NCT00180102|PROCEDURE|early allogeneic PBSCT within induction therapy|
41097856|NCT00180102|PROCEDURE|autologous PBSCT|
41097857|NCT00134810|BIOLOGICAL|Botulinum toxin type A|
41097858|NCT03986606|BIOLOGICAL|PSB205|PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
41097859|NCT03210727|BEHAVIORAL|Ready to CARE program|"The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion."
41097860|NCT03049436|OTHER|Program of adapted physical activity|
41097861|NCT02431143|DRUG|Miltefosine|
41443183|NCT05479552|DIAGNOSTIC_TEST|Syn-One Test|CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.
41097862|NCT05166161|DRUG|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
41097863|NCT04046523|DEVICE|Video ophthalmoscope|Use of a custom video ophthalmoscope with either a CCD or CMOS camera lens. The healthy controls group (first 20 subjects) will provide data to help determine which lens might be best for measuring ICP patients (Groups A and B) in the second phase of the study.
41097864|NCT01750957|DRUG|Placebo|orally daily, 12 weeks
41097865|NCT01750957|DRUG|RO4917523|Dose A orally daily, 12 weeks
41097866|NCT01750957|DRUG|RO4917523|Dose B orally daily, 12 weeks
41097867|NCT06024564|DEVICE|Sonu Acoustic Resonance Therapy|Participants will receive Sonu treatment twice a day for 90 days
41097868|NCT06630715|DRUG|Upadacitinib 15 MG [Rinvoq]|15 mg/ day
41097869|NCT04348123|OTHER|Survey|Survey questionnaire seeks to collect data relevant to mammogram completion, barriers, and facilitators
41443184|NCT06120465|OTHER|Yoga|Yoga classes
41443185|NCT03243786|BEHAVIORAL|Lifestyle- Supportive Care|The intervention examines dietary and activity patterns, body composition, biomarkers and quality of life in breast cancer patients undergoing radiation therapy
40752055|NCT00758043|BIOLOGICAL|peginterferon alfa-2a|180 mcg/week for either 24 or 48 weeks
40752056|NCT03247712|DRUG|Nivolumab|Nivolumab 240mg IV q2wks or 480mg IV q4wks
40752057|NCT03247712|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
40752058|NCT03247712|RADIATION|Radiation (5 days)|8Gy x 5 (Mon-Fri) GTV+3mm
40752059|NCT03247712|RADIATION|Radiation (3 days)|8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
40752060|NCT02892708|PROCEDURE|Surgery|partial or complete resection followed by radiotherapy
41097870|NCT04348123|BEHAVIORAL|Education Session|After the survey, clinic staff will conduct brief, culturally-appropriate educational session about breast health and mammography delivered by a female public health educator with experience in the underserved community. Educational session will explain screening options and address common barriers
41097871|NCT05787444|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative and differential detection of nucleocapsid viral antigens from SARS-CoV-2, influenza A, and influenza B in an anterior nares sample (from both nostrils) collected by a healthcare professional for individuals aged 2 years and older. The test is authorized for individuals with symptoms of COVID-19, influenza A and B within the first 6 days of symptom onset.
41097872|NCT06628817|RADIATION|The Intensive Care Bundle with Mortality Reduction|a continuous automated medical quality monitoring and feedback system on the online platform, self-feedback and teamwork based on video conferencing, multidisciplinary online education, offline on-site supervision, and standardized intervention in the behavior of medical actors in the process of stroke treatment.
41097873|NCT01921543|DEVICE|ITP Stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
41097874|NCT01921543|DEVICE|CI/BNST stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
41097875|NCT01921543|DEVICE|No stimulation|
41097876|NCT01594502|DRUG|Dutasteride|0.5 mg daily
41097877|NCT01594502|DRUG|Placebo|Placebo Comparator
41097878|NCT00906282|DRUG|Pemetrexed|500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
41097879|NCT00906282|DRUG|Carboplatin|AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
41097880|NCT01611909|DRUG|p-menthane-3,8-diol oil|Apply topically to affected area twice daily
41097881|NCT03165734|DRUG|Pacritinib|Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
41097882|NCT03165734|DRUG|Physician's Choice medications|Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
41097883|NCT06561165|DEVICE|Standard HD-tDCS intervention|Participants will have three sessions along with behavioral assessments.
41097884|NCT06561165|DEVICE|Multifocal network targeted HD-tDCS intervention|Participants will have three sessions along with behavioral assessments.
41097885|NCT06561165|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|Participants will have an MRI before or after having HD-tDCS intervention.
41097886|NCT05251285|PROCEDURE|Nipple-Sparing Mastectomy|Nipple-Sparing Mastectomy using da Vinci X/Xi Surgical System
41097887|NCT00814281|OTHER|placebo|Placebo
41097888|NCT00814281|DRUG|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
41097889|NCT01306669|BIOLOGICAL|Trivalent influenza vaccine|single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm
41097890|NCT01306669|BIOLOGICAL|Normal saline|Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
41097891|NCT02350595|OTHER|Lean fish|
41443186|NCT03299829|DRUG|Trientine|Trientine is a chelating agent for removing the copper from the body
41097892|NCT02350595|OTHER|Fatty fish|
40752061|NCT02892708|RADIATION|radiotherapy|radiotherapy after a brain biopsy
41097893|NCT06478680|BEHAVIORAL|Exoskeleton mediated gait training|"1 session of Forward Walking with EksoGT per week~1 session of conventional neurorehabilitation intervention per week~* Transfer training~* Gait training~* Balance (sitting/standing; static/dynamic)~* Strength~* Neuromuscular re-education~* Orthotics~* Positioning~* Caregiver education~* Assistive device~* Wheelchair assessment and mobility~* Endurance training"
40752062|NCT01433874|PROCEDURE|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
40752063|NCT01433874|PROCEDURE|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity
41097894|NCT06478680|BEHAVIORAL|High intensity gait training|"2 sessions of High-Intensity Gait Training at a target heart rate of 60-80% of the maximum heart rate or target RPE of 15-18~* Forward stepping practice~* Backwards stepping practices~* Sidestepping~* Stairs~* Balance and compliant surface training while walking~* Propulsion~* Lateral balance training~* Stability training~* Stance control training~* Limb advancement"
41097895|NCT04581837|DIAGNOSTIC_TEST|2D-speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography (2D-STE) allows for an angle-independent evaluation of myocardial strain, and provides comprehensive information on LV myocardial contractility. Thus, 2DSTE is superior in detecting subtle deteriorations of contractility. we will take 2D speckle tracking views for LV and RV strain (4ch, 2ch, 3ch, RV modified view).
41097896|NCT03219502|OTHER|Best Practice|Receive standard of care
41443187|NCT04159103|BIOLOGICAL|mRNA-3927|mRNA-3927 dispersion for IV infusion
41443188|NCT04521426|OTHER|No other than standard care|No other than standard care.
41443189|NCT06627959|DEVICE|Statseal|This is a vascular closure device which works independently of the clotting cascade to seal access sites
41443190|NCT06627959|DEVICE|Figure of eight suture|The figure of eight suture is commonly used for vascular access closure
41443191|NCT04962594|OTHER|Experimental formulas (EF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
41097897|NCT03219502|OTHER|Quality-of-Life Assessment|Ancillary studies
41097898|NCT03219502|OTHER|Questionnaire Administration|Ancillary studies
41097899|NCT03219502|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
41097900|NCT03219502|PROCEDURE|Sham Intervention|Undergo sham rTMS
41097901|NCT04545606|BEHAVIORAL|In-Person CBT for insomnia in children with autism|"7 modules administered in-person~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares"
41097902|NCT04545606|BEHAVIORAL|Remote CBT for insomnia in children with autism|"7 modules administered over telehealth/videoconferencing~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares"
41097903|NCT04545606|BEHAVIORAL|Remote sleep hygiene and related education (SHARE) for insomnia in children with autism|"7 modules administered over telehealth/videoconferencing~1. Sleep Education~2. Sleep Architecture \& Parasomnias~3. Physical Activity \& Sleep~4. Nutrition, My Plate, \& Breathing during Sleep~5. Stress, Sleep, Dreams, \& Nightmares Connections~6. Mood, Self-Esteem, \& Sleep~7. Light \& Dark Cycle"
41097904|NCT06433037|DIETARY_SUPPLEMENT|Chicory inulin|Chicory inulin (12g/day) divided over two dosages (6g per dose)
41097905|NCT06433037|DIETARY_SUPPLEMENT|Resistant dextrin|Resistant dextrin (14g/day) divided over two dosages (7g per dose)
41097906|NCT06433037|DIETARY_SUPPLEMENT|Seaweed polysaccharide|Seaweed polysaccharide (1g/day) divided over two dosages (0.5g per dose). Additionally contains 7g/day of placebo as a volumetric and isocaloric filler.
41097907|NCT06433037|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (7g/day) will be provided in two divided doses (3.5g per dose)
41097908|NCT02337010|DEVICE|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
41097909|NCT02337010|DEVICE|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
41097910|NCT02337010|DRUG|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
41097911|NCT02337010|DRUG|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
41097912|NCT03113487|BIOLOGICAL|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
41097913|NCT03113487|BIOLOGICAL|Pembrolizumab|Given IV
41097914|NCT05920122|DRUG|2% Chlorhexidine gluconate with 70% alcohol|Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
41097915|NCT05920122|DRUG|4% Chlorhexidine Gluconate aqueous solution|Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
41097916|NCT06457607|DEVICE|LinearZ|High Intensity Focues Ultrasound
41097917|NCT01353638|DRUG|Dipeptiven (Alanyl-glutamine-dipeptide)|Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
41097918|NCT04226469|PROCEDURE|Tooth movement|The subject's canines will be retracted distally and crevicular fluid is collected
41097919|NCT06427603|BEHAVIORAL|physical activity|workshops and mobile apps: break sedentary behavior by activity breaks
41097920|NCT05777889|OTHER|Forward Looking InfraRed Camera|"Forward Looking InfraRed Camera:~1. We will use a FLIR T420 or T62101 camera with a resolution of 320\*240.~2. Each image will be captured perpendicularly with a 1-inch gap on all four sides.~3. A Myler blanket placed in the background will separate the feet from the background.~4. The camera will be normalized to a temperature range of 15°C to 40°C.~5. The images will be saved in radiometric JPEG format.~6. Once the images have been transferred to a computer, we will remove the background.~7. Next, we'll make a temperature histogram with 0.1°C temperature bin resolution.~8. The before and after histograms (IB, IA) will be compared to see which one indicates more extreme temperature distributions.~9. Those who improve by 30% or more are considered to have had a successful spinal cord stimulation."
40924846|NCT02243462|OTHER|No pre-op warming|No forced air warming of the patient prior to being taken in for surgery
40924847|NCT04204980|DRUG|Daratumumab dose escalation|- Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab
40924848|NCT04204980|DRUG|Daratumumab full dose|- Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab
40924849|NCT03914846|PROCEDURE|Ultrasound|Undergo ultrasound with elastography
41097921|NCT06347926|PROCEDURE|Questionnaires given before and after photobiomodulation|Questionnaires given at 1 month, 6 months and 12 months
41097922|NCT06353958|DRUG|MiSaver|"MiSaver vials was thawed using a thermostat-controlled mini bath, drawn into a 20ml syringe, and diluted with normal saline and intravenous infused following standard operating procedures, consecutively, until reasching the dosage.~Patients were premedicated with intravenous antihistamines (such as diphenhydramine) and corticosteroids (such as hydrocortisone) 30-60 minutes before the stem cell infusion. Any unused solution was discarded, and the total volume of injected solution was adjusted to accommodate the total daily fluid volume administered."
41097923|NCT05275478|DRUG|TNG908|TNG908, a selective PRMT5 inhibitor, will be administered orally
41097924|NCT01068249|DRUG|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
41097925|NCT01068249|DRUG|RAD001 (Everolimus)|10 mg by mouth daily
41097926|NCT01369589|DRUG|P-552|P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
41097927|NCT01369589|DRUG|Placebo|Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
41097928|NCT06220058|PROCEDURE|"Closure of the midline laparotomy using the small bites technique"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). No Redon drainage system will be left in the subcutaneous tissue."
41097929|NCT06220058|PROCEDURE|"Closure of the midline laparotomy using the small bites technique with an absorbable PP mesh"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). A partially absorbable low-density polypropylene suprapubic mesh (Ultrapro®, Ethicon) will be added. Mesh fixation will be done with absorbable staples (Ethicon SecurestrapTM) +/- slow-absorbing resorbable sutures at the discretion of the surgical team.~In the case of a diverting stoma, the prophylactic mesh will not encircle it. A Redon-type drainage will be left at the subcutaneous tissue level. One or two drains will be left at the discretion of the surgical team. Closure of the subcutaneous tissue will be performed with 2/0 or 3/0 absorbable, multifilament, interlocking sutures."
41097930|NCT05415215|DRUG|Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)|PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
41097931|NCT05415215|DRUG|Pertuzumab IV|Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
41097932|NCT05415215|DRUG|Trastuzumab IV|Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.
41097933|NCT05415215|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
41097934|NCT05415215|DRUG|Investigator's Choice of Chemotherapy|Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).
41097935|NCT05415215|PROCEDURE|Surgery|After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.
41097936|NCT05415215|RADIATION|Radiotherapy|After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.
41097937|NCT03109015|DRUG|Sunitinib|Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
41097938|NCT03109015|DRUG|Sunitinib|Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
41443192|NCT04962594|OTHER|Control formulas (CF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
41443193|NCT04962594|OTHER|Breast feeding (BF)|Exclusive breast feeding up to 4 months
41097939|NCT04083599|BIOLOGICAL|GEN1042|Intravenous
41097940|NCT04083599|DRUG|Pembrolizumab|Intravenous
41097941|NCT04083599|DRUG|Cisplatin|Intravenous
41443194|NCT03196284|DRUG|Concizumab|A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
40924850|NCT02585570|DRUG|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
41097942|NCT04083599|DRUG|Carboplatin|Intravenous
41097943|NCT04083599|DRUG|5-FU|Intravenous
41097944|NCT04083599|DRUG|Gemcitabine|Intravenous
41097945|NCT04083599|DRUG|Nab paclitaxel|Intravenous
41097946|NCT04083599|DRUG|Pemetrexed|Intravenous
41097947|NCT04083599|DRUG|Paclitaxel|Intravenous
41443195|NCT03196284|DRUG|Eptacog alfa|A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
41443196|NCT00360763|DRUG|candesartan cilexetil|
41443197|NCT02742194|DIETARY_SUPPLEMENT|Dry extract of ginger|Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
41097948|NCT03070106|DIETARY_SUPPLEMENT|Functional Medicine|Subjects randomized to the Functional Medicine plus the usual care arm will receive nutrition therapy and dietary supplements. Functional Medicine labs will be used in part to determine which supplements will be prescribed.
41097949|NCT03585361|BEHAVIORAL|Health centers provide PPFP counseling and services|Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.
41097950|NCT03585361|BEHAVIORAL|HEWs provide PPFP counseling and services|HEWs trained in PPFP counseling with a refresher on implant insertion skills. Training also included how to use tools to document PPFP services, method choice, and pregnancy risk at every contact during pregnancy and up to 12 months after birth. Follow up supervision ensured skill improvement and retention.
41097951|NCT03585361|BEHAVIORAL|Volunteers (Development Army) promote PPFP|HEWs orient volunteers on promoting PPFP and how to use a pictoral tool to remind women to access ANC, immunization, and PPFP services and to document women's method preferences and pregnancy risk at every contact during pregnancy and up to 12 months after birth.
41097952|NCT03585361|BEHAVIORAL|Health centers conduct data reviews|Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.
41097953|NCT03585361|BEHAVIORAL|HEWs and volunteers track PPFP|HEWs and volunteers track PPFP counseling, choice of method, receipt of methods, and pregnancy risk starting in pregnancy through 12 months postpartum. HEWs and volunteers meet and review data.
41097954|NCT06628427|DIAGNOSTIC_TEST|MoCA Test|MoCA (Montreal Cognitive Assessment or The MoCA Test) was validated as a highly sensitive tool for early detection of mild cognitive impairment (MCI) in hundreds of peer-reviewed studies since 2000. MoCA has been widely adopted in clinical settings and used in academic and non-academic research around the world. The sensitivity of MoCA for detecting MCI is 90%, compared to 18% for the MMSE. Prospective participants meeting the eligibility criteria, as determined by the Montreal Cognitive Assessment (MoCA) test, will be invited to the Brain- Computer Interface (BCI) laboratory at the Kroto Research Centre on the University of Sheffield north campus to participate in the study.
41097955|NCT06628427|DEVICE|Random Dot Motion (RDM) task|Random Dot Motion task (RDM) has been widely used in research on spatial attention, and decision-making ability, etc., and its results (accuracy and reaction time) can be used as indicators to detect spatial attention. During the assessment, participants were required to monitor a series of dots in constant random motion on the screen. The dots sometimes moved coherently together to the left or right, and participants were required to press the left mouse button when they perceived them moving to the left and the right mouse button when they observed them moving to the right. We are going to use the motion coherence level of 50%. The higher the coherence level, the greater the number of dots moving together, and the combination of the moving direction and coherence level of the dots appear randomly during the task.
41097956|NCT06628427|DEVICE|P300-BCI task without feedback|Two different speller matrix sizes: 3×3 and 5×5, two inter-stimulus intervals (ISIs): 117ms (i.e., commonly used ISI for healthy adults) and 175ms (i.e., 50% longer than the widely used ISI) and two spelling words (QUICK and JUMP) are designed in this experiment to explore the calibration accuracy of these eight parameter combinations in the young and old groups and obtain the best parameter combination. The matrix contains letters and digits, and the target letters will be displayed below the matrix letter by letter. When the speller runs, the rows and columns in the matrix will flash 15 times each randomly. Each flash will last for 55ms, and the subsequent ISI will last for different times according to different parameter designs. Participants only need to focus on the target letter and silently count the number it flashes, as flashing target letters can generate P300 if well attended.
41097957|NCT06521892|BEHAVIORAL|social surveillance and health education interventions|"Social surveillance: In the intervention group retail pharmacies posted or hung signs antibiotics need to be purchased by prescription, if found without prescription sales, welcome to call 12315 hotline to report, to form social supervision intervention.~Health education: On-site training for retail pharmacy staff, inviting respiratory physicians and pediatricians to give health education lectures on disease diagnosis, treatment and medication."
41097958|NCT04236804|DEVICE|Flowly (TMC-CP01)|TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.
41097959|NCT02836678|BIOLOGICAL|Ridge splitting, immediate implant, Nanobone with PRF.|"* Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* Alloplast bone graft material (Nanobone)~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
41097960|NCT02836678|BIOLOGICAL|Ridge splitting, immediate implantand PRF.|"* Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
41097961|NCT00501020|DRUG|Rosiglitazone|
41097962|NCT06475807|DIETARY_SUPPLEMENT|High-fermented food|Step 1: patients will consume high-fermented food
41097963|NCT06475807|DIETARY_SUPPLEMENT|High fiber supplementation|Step 2: High fiber supplementation
41097964|NCT05757076|PROCEDURE|Blood test for ARR|Blood test for calculating aldosterone and renin ratio (ARR)
41097965|NCT06629805|DIETARY_SUPPLEMENT|Aureobasidium pullulans produced β-glucan|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
41097966|NCT06629805|DIETARY_SUPPLEMENT|Placebo|Placebo 1,000 mg/day for 12 weeks
41097967|NCT03553446|DRUG|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
41097968|NCT04527614|DIAGNOSTIC_TEST|qRT-PCR and serology|qRT-PCR and serology
41097969|NCT05142722|DRUG|Placebo|placebo tablet made to resemble active
41097970|NCT05142722|DRUG|Obicetrapib|10mg obicetrapib tablet
41097971|NCT06630481|DRUG|neoadjuvant therapy|Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.
41097972|NCT06629714|OTHER|Exposure: emotional distress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a sum score of PHQ-9 and GAD-7 ≥ 10 were categorized as the stressed group.
41097973|NCT05080192|DRUG|Fenofibrate|145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)
41097974|NCT05080192|DRUG|Placebo|Matching placebo (once/day) for 10 days
41097975|NCT05781269|OTHER|VLCKD|VLCKD diet treatment with medical food
41097976|NCT05781269|OTHER|r-MedDiet|Mediterranean diet treatment
41097977|NCT00712166|DRUG|AZLI 75 mg three times daily (TID)|
41097978|NCT00712166|DRUG|Placebo three times daily (TID)|
41097979|NCT03891953|DRUG|DKY709|Novel immunomodulatory agent
41097980|NCT03891953|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
41097981|NCT04311229|DEVICE|Negative-Pressure Wound Therapy group|The wounds were initially evaluated for any necrotic findings and debrided if needed, and then washed with an antiseptic solution. 3-DWM was used to measure the pressure sores by taking pictures.The length and width of wounds were measured with disposable paper rulers. Wound depth was determined in centimeters with a sterile cotton-tip applicator by measuring against a ruler. The wound was closed using a Wound Care Kit that includes foam dressing, film drape, TRAC pad with tubing and a drainage canister. Foam material was placed inside the wound and was attached to the canister through tubing.The canister was attached to the Vacuum-Assisted Closure device, which is a portable device that applies intermittent or continuous negative pressure.The device was operated at 125 mmHg pressure for 5 minutes with and 2 minutes without active vacuum.Wound dressings were changed every 48 hours.Wound area was measured after all three rounds of treatment.
41097982|NCT04311229|OTHER|contol group|Wounds were finally covered with gauze dressing soaked with saline. Wounds were treated three times a day, and measurements were repeated every 48 hours. Every wound was measured a total of four times: one pre-treatment (baseline) and three post-treatment measurements.
41097983|NCT05128305|DRUG|traditional Chinese medicine1 and traditional Chinese medicine 2|We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
41097984|NCT05925712|DEVICE|AeroFit Seal-In Liner / Socket|Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.
41097985|NCT05925712|DEVICE|Seal-In Silicone Liner|Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.
41097986|NCT05905406|OTHER|Electrical estimulation|Electrical estimulation during the fatigue protocol. Frequency = 100 Hz, pulse duration = 500 µs, time ON = 20 s (including rise time = 1.0 s and descent time = 1.0 s) and off time = 20 sec
41097987|NCT03172403|DIAGNOSTIC_TEST|Height and weight|Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)
41097988|NCT03172403|DIAGNOSTIC_TEST|Blood samples|Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)
41097989|NCT03172403|DIAGNOSTIC_TEST|Skeletal muscle force|Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
41097990|NCT03172403|DIAGNOSTIC_TEST|Skeletal muscle index|Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
41097991|NCT03172403|DIAGNOSTIC_TEST|Muscle biopsy|Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)
41097992|NCT02127476|DRUG|KHK6640|Single ascending dose and multiple ascending doses administration
41097993|NCT02127476|DRUG|Matching Placebo|Single ascending dose and multiple ascending doses administration
41443198|NCT02742194|DIETARY_SUPPLEMENT|Placebo|Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
41443199|NCT02125435|DRUG|ASP2408|intravenous
41443200|NCT02125435|DRUG|Placebo|intravenous
41097994|NCT05013606|DIETARY_SUPPLEMENT|Hydrogen water|This is an over the counter pill supplement that is dissolved in water.
41097995|NCT00906698|DRUG|BIBW 2992 low (20mg) dosage|Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
41097996|NCT00906698|DRUG|BIBW 2992 medium (40mg) dosage|Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
41097997|NCT00906698|DRUG|BIBW 2992 high (50mg) dosage|Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
41097998|NCT00906698|DRUG|Vinorelbine per os 60 mg/m²|Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
41097999|NCT00906698|DRUG|Vinorelbine per os 80 mg/m²|Patients will receive 80 mg/m² Vinorelbine per os at J22
41098000|NCT00906698|DRUG|Vinorelbine i.v. 25 mg/m²|Patients will receive 25 mg/m² of Vinorelbine i.v.
41098001|NCT05302791|DEVICE|Muscle Cooling|Cooling wrap will be set to 10°C
41098002|NCT05302791|OTHER|Resistance Exercise|Resistance Machines (Leg Press and Knee extension). 12 rep Max
41098003|NCT03433261|DIETARY_SUPPLEMENT|Ketogenic Diet|Eat a ketogenic diet (low carbohydrate, high fat diet) for 72 hrs prior to the experiment and consume a dietary ketone supplement 60 minutes before the experiment.
41098004|NCT04066751|DRUG|Ivacaftor|Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
41443201|NCT04013841|OTHER|Oral-agents/Enema|"1. Oral-agents for mechanical bowel preparation prior to left-side colorectal resection~2. Enema for mechanical bowel preparation prior to left-side colorectal resection"
41443202|NCT05881798|DEVICE|Celect Platinum Vena Cava Filter|Inferior vena cava filter
41443203|NCT06558825|BEHAVIORAL|Integrated Intervention to Promote PrEP Uptake|Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting.
41443204|NCT06558825|OTHER|Standard Treatment Condition|Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
41098005|NCT00966966|DRUG|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
41098006|NCT04878042|DEVICE|Hydrogen peroxide|Mouth wash and nasal spray 3 times a day for 3 days
41098007|NCT04878042|DEVICE|Placebo|Mouth wash and nasal spray 3 times a day for 3 days
41098008|NCT05478902|PROCEDURE|Exercise Therapy|Exercise protocol for rotator cuff related shoulder pain
41098009|NCT05478902|PROCEDURE|Extracorporeal Shockwave Therapy|High Energy Extracorporeal Shockwave Therapy
41098010|NCT05478902|PROCEDURE|Ultrasound-Guided Percutaneous Irrigation|Two sessions of Ultrasound-Guided Percutaneous Irrigation
41098011|NCT03681730|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
41098012|NCT03201614|DEVICE|A-CP HA Kit|Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2
41098013|NCT03201614|DEVICE|ArthroVisc 40|Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2
41098014|NCT03201614|DRUG|Placebo|Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
41098015|NCT04417621|DRUG|LXH254|LXH254 will be supplied as tablet for oral use.
41098016|NCT04417621|DRUG|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
41098017|NCT04417621|DRUG|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
41098018|NCT04417621|DRUG|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
41098019|NCT03879642|BEHAVIORAL|REDCHiP|10 week video-based telemedicine intervention to reduce hypoglycemia fear
41098020|NCT06631911|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|"Emotional Awareness and Expression Therapy (EAET) is a manualized, short-term psychodynamic therapy that, in this instance, is delivered in a group format.~The core of Emotional Awareness and Expression Therapy (EAET) involves helping individuals identify, understand, and express their emotions in a therapeutic setting. The therapy emphasizes the connection between unprocessed emotions and physical symptoms, encouraging participants to explore the emotional underpinnings of their distress. Through guided discussions, psychoeducation, and expressive exercises, participants learn to recognize patterns of emotional avoidance, develop self-compassion, and improve interpersonal communication. This process aims to reduce somatic symptoms and enhance overall emotional well-being by fostering a greater awareness of emotional experiences."
41098021|NCT01335789|DRUG|Oxytocin|40 IUs
41098022|NCT01335789|DRUG|Saline|40 IUs
41098023|NCT06628843|OTHER|cesarean section rate|Incidence of cesarean sections in the two periods, Rate of adverse outcomes within vaginal and cesarean deliveries
41098024|NCT01789203|DRUG|Ciprofloxacin|Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
41098025|NCT01789203|DRUG|placebo|Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
41098026|NCT05751200|OTHER|No Intervention.|No Intervention.
41443205|NCT06345053|BEHAVIORAL|Narrative Exposure Therapy|The intervention period will be from (May 2021- October 2024). All patients will participate in standard treatment at MBS. Dialectical Behaviour Therapy -Substance Use Disorder skills training (DBT-SUD skills) will be offered to all patients at MBS in the project period that experience difficulties in emotion regulation and manage to commit to participating in the DBT- skills training evaluated by their DBT therapist. Narrative Exposure Therapy (NET) will be offered to all patients with relevant traumatic experience and symptoms of PTSD depending on clinical evaluation.
41098027|NCT04671108|DEVICE|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
41098028|NCT02047461|DRUG|ORGN001 (formerly ALXN1101)|IV infusion
41098029|NCT04991259|PROCEDURE|Continuous Renal Replacement Therapy (CRRT)|Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.
41098030|NCT04991259|OTHER|Standard Medical Treatment|In the L- ICU, patients will be managed by a multidisciplinary team. Intubation and ventilation will be undertaken for standard indications in addition to the development of grade 3 encephalopathy or evidence of cerebral edema on CT-scan. Fluid management will be done with crystalloids, with the use of colloids (5% albumin) in patients with severe hypoalbuminemia (serum albumin less than 2.5gm/dl). Norepinephrine will be the primary vasopressor used to target a mean arterial pressure of 65-70 mm of Hg. with adjunctive use of intravenous low dose hydrocortisone and vasopressin in patients not responsive to initial therapy.
41098031|NCT00926939|BEHAVIORAL|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
41098032|NCT00926939|BEHAVIORAL|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
41098033|NCT01045317|DRUG|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
41098034|NCT02333630|OTHER|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
41098035|NCT02333630|OTHER|Asthma education|A website with links to written asthma education and videos
41098036|NCT00631475|DRUG|Bosentan|"For patients who were administered Bosentan during BUILD 3 (NCT00391443):~continue on same dose~For patients who were administered placebo during BUILD 3 (NCT00391443):~Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs \< 90 lbs.)"
41098037|NCT06346262|BEHAVIORAL|SMART RM|The SMART-RM will consist of 8 group-format, 45-60 minute sessions (up to 11 participants per group), which will be collaboratively delivered by a Nurse Educator (NE) and a Peer Educator (PE).
41443206|NCT03598894|OTHER|Ambulatory blood pressure measurements|Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
41098038|NCT06346262|DRUG|Valtoco Nasal Product|Medication dosing will follow recommendations in the Valtoco package insert and managed by the epilepsy clinician.
41098039|NCT02041676|PROCEDURE|Chest physiotherapy|
41098040|NCT02041676|PROCEDURE|Usual surveillance|Usual surveillance of the non invasive ventilation without chest physiotherapy.
40924851|NCT00839033|DEVICE|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
40924852|NCT00839033|DEVICE|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
40924853|NCT00977457|GENETIC|DNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
40924854|NCT00977457|GENETIC|DNA methylation analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
40924855|NCT00977457|GENETIC|RNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
40924856|NCT00977457|GENETIC|gene expression analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
40924857|NCT00977457|GENETIC|polymerase chain reaction|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
40924858|NCT00977457|OTHER|diagnostic laboratory biomarker analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
40924859|NCT00977457|PROCEDURE|therapeutic conventional surgery|
40924860|NCT05291169|DEVICE|Omeza® OCM™|"Omeza® OCM™ is a wound care matrix comprised of coldwater fish peptides (device) and cod liver oil (drug).~OCM™is supplied in a sterile single use vial."
40924861|NCT00369629|DRUG|Gemcitabine|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m\^2.
40924862|NCT00369629|DRUG|Pemetrexed|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m\^2.
40924863|NCT00146055|PROCEDURE|Reduced intensity conditioning with allogeneic transplant|
40924864|NCT00745589|DRUG|sevelamer hydrochloride|First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
40924865|NCT00318942|DRUG|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
40924866|NCT00318942|DRUG|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
40924867|NCT00318942|DRUG|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
40924868|NCT00318942|DRUG|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
40924869|NCT04813003|OTHER|Functional Brain Imaging and neurobehavioural tasks|"Combination of 3 neurobehavioural tasks:~Task 1 consists in subjective value rating of 64 food items. Participants are asked to rate how much they would want to eat the presented food item while fMRI (functional magnetic resonance imaging ) scanning is performed.~Task 2 consists in rating of subjective nutrient factor of the same 64 food items. Participants will answer the following four categorical questions in randomized order for each item: low or high in added sugar/protein/fat and healthy or unhealthy.~Task 3 consists of a decision-making task. Participants will be presented with two food items (out of the 64 food items), and asked to choose which of the two items they prefer to consume at the end of the experiment."
40924870|NCT01470989|DRUG|ACZ885|canakinumab 150 mg s.c., given on demand upon new flares
40924871|NCT01470989|DRUG|Triamcinolone acetonide 40 mg|Participants received 40 mg intramuscular (IM)
40924872|NCT05624047|BEHAVIORAL|Breastfeeding education using hybrid simulation method|In addition to the verbal breastfeeding training given to the pregnant women assigned to the experimental group, breastfeeding training will be given using the hybrid simulation method consisting of a wearable breast model and standard patient practice.
40924873|NCT05624047|BEHAVIORAL|Routine verbal breastfeeding education|Women in this group will receive oral breastfeeding training, which is routinely given in the pregnant education class and consists of one session.
40924874|NCT03381534|DEVICE|stenting with EPD|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
41098041|NCT00787956|BEHAVIORAL|Internet Chronic Disease Self-Management Program (ICDSMP)|
41098042|NCT03758339|DRUG|tucatinib|Single dose of 300 mg of \[¹⁴C\]-tucatinib containing approximately 150 μCi of \[¹⁴C\] radioactivity
41098043|NCT06253130|DRUG|IMP1734|PARP1 selective inhibitor
41098044|NCT04966208|PROCEDURE|xenogeneic collagen matrix|xenogeneic collagen matrix called mucoderm used for root coverage for treatment of gingival recession instead of harvesting from the patients connective tissue
41098045|NCT05753137|OTHER|Acupuncture|The treatment will take place once a week, over six weeks. The needles will placed in the body for 20 minutes. A total of 12 Needles(6 acupoints, bilaterally) will be used in each session.Participants in the treatment group will undergo acupuncture targeting ophthalmology-related acupuncture points, aiming to elicit the 'De Qi' sensation.
41098046|NCT05753137|OTHER|Acupuncture placebo|A total of 12 Needles(6 acupoints, bilaterally) will be used in each session. Acupuncture points are different from the experimental group.The control group will receive minimum acupuncture stimulation targeting non-ophthalmic acupuncture points without the intention of achieving the 'De Qi' sensation.
41133215|NCT05040828|DRUG|No oral drug therapy throughout the pollen period|Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
41098047|NCT06631183|BEHAVIORAL|Self-help information based on principles of behavioral activation|Participants will engage with the self-help tool e-couch (https://ecouch.com.au). In the first week, they will complete the depression information submodule from the depression program. Over the following four weeks, they will complete submodules on behavioral activation and physical activity.
41098048|NCT06631183|BEHAVIORAL|Self-help information based on principles of cognitive restructuring|Participants will engage with the self-help tool e-couch (https://ecouch.com.au). In the first week, they will complete the depression information submodule from the depression program. Over the following four weeks, they will complete submodules on cognitive restructuring.
41098049|NCT04413565|PROCEDURE|Simultaneous bilateral total knee arthroplasty|Two surgeon bilateral TKA group
41098050|NCT04413565|PROCEDURE|Sequenced bilateral TKA|Single surgeon bilateral TKA group
41098051|NCT05460169|DEVICE|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
41098052|NCT03254329|OTHER|Assessment of human milk nutrient composition|Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.
41098053|NCT03015831|DRUG|Colchicine|Colchicine will be given to open heart surgery patients
41098054|NCT03015831|DRUG|Placebo Oral Tablet|Placebo Oral Tablet will be given to open heart surgery patients according to randomization
41098055|NCT01912326|DEVICE|Pacemaker Implantation|Implantation of a dual chamber pacemaker
41098056|NCT06629259|DRUG|Guanfacine Extended Release (XR)|3mg tablet once daily
41098057|NCT06629259|DRUG|Placebo|placebo tablet once daily
41098058|NCT03852433|DRUG|Bulevirtide|Administered via subcutaneous injections
41098059|NCT03852433|DRUG|Peginterferon Alfa-2a (PEG-IFN alfa)|Administered via subcutaneous injections
41098060|NCT04934228|DRUG|Hydrochlorothiazide 12.5Mg Tab|"Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day"
41098061|NCT04934228|DRUG|Clonidine Pill|"Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~1. Condition/disease indication(s): Vascular function and blood flow~2. Subject population: Hypertension~3. Dose(s): 0.1 mg (oral)~4. Administration: Oral~5. Dosing regimen: 0.1 mg twice daily by mouth"
41098062|NCT04934228|DRUG|Placebo|Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
41098067|NCT04222270|BEHAVIORAL|Champion Caregiver peer mentoring support to caregivers on child care and medication adherence to enhance achievement of viral suppression|Caregiver to caregiver peer support intervention through group/one-on-one education and counselling
41098068|NCT02611648|OTHER|Double HLD|Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
41098069|NCT02611648|OTHER|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
41098072|NCT03947164|OTHER|biopsy|"For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.~Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination."
41098073|NCT05837676|BEHAVIORAL|Problem Solving Training for Concussion|PST-Concussion is a combined treatment consisting of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.
41098074|NCT05837676|OTHER|Treatment as usual|Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
41098075|NCT04312191|OTHER|Mantra Meditation|Mantra-based meditation will be taught using a standard one-word mantra (Om). Om is a non-English word that will help with focus as opposed to an English word which may cause distraction based on the word itself.
41098076|NCT04881799|DRUG|Phentermine/Topiramate (Qsymia)|Maximum dose of 15 mg/92 mg orally once daily in the morning. The dose will be titrated to this level (described earlier).
41098077|NCT04881799|DRUG|Placebo|Daily injection
41098078|NCT00303303|BIOLOGICAL|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
41098079|NCT00303303|BIOLOGICAL|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
41098080|NCT00303303|BIOLOGICAL|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
41098081|NCT01989442|DEVICE|binasal prongs|patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support
41098082|NCT01989442|DEVICE|nasal mask|patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
41133216|NCT02785159|DRUG|IDP-118 Lotion|Lotion
41133217|NCT02785159|DRUG|Tazorac Cream|Cream
41098083|NCT03064074|DRUG|Fresolimumab|The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
41098084|NCT06629974|BEHAVIORAL|Parental empowerment program|"The empowerment program consisted of two parts: the empowerment training program for parents and motivational interviews.~The empowerment training program was prepared to enable parents to carry out the care process more effectively in areas where parents have difficulties caring for their children with autism. Within the scope of the empowerment training program, parents were trained on the importance of play and communication, problems and management in the field of nutrition, sleep problems and management, safety and protection from accidents, and problems and management in the field of self-care.~Ten days after the empowerment training program, two face-to-face motivational interviews were conducted with each participant in the intervention group. Each participant had a one-week break between the first and second motivational interviews. Each motivational interview session lasted approximately 25-30 minutes."
41098085|NCT00704756|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
41098086|NCT00704756|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (\<65 kg : 800 mg, 65 - 85 kg : 1000 mg, \>85 kg : 1200 mg) orally for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
41098087|NCT06172660|DRUG|Nirsevimab|Immunoprophylaxis against RSV
40752064|NCT01433874|PROCEDURE|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.
41098088|NCT01763047|DEVICE|etafilcon A|To be worn in a daily wear modality for a minimum of 6 hours per day.
41098089|NCT01763047|DEVICE|lotrafilcon B|Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
41098090|NCT05158192|DRUG|Diosmin/Hesperidin (90/10) 500 mg Test Drug|Investigational Medicinal Product
41098091|NCT05158192|DRUG|Diosmin/Hesperidin (90/10) 500 mg Reference Product|Daflon (Trademark)
41098092|NCT03744117|OTHER|Palliative care consultation|A palliative care consultation will occur via telemedicine with patients receiving maintenance dialysis.
41098093|NCT01297972|BIOLOGICAL|Intravenous bone marrow mesenchymal stem cells infusion|After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.
41098094|NCT04513028|DIETARY_SUPPLEMENT|Beta-Glucan|500mg (1 capsule) by mouth twice a day for 21 days.
41098095|NCT05114109|DRUG|Isatuximab Injection|Isatuximab will be given intravenously at 10mg/kg at day 0, week (W)1, W2, W3, and W4 then every 2 weeks for a total of 12 infusions.
41098096|NCT05795829|DEVICE|disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument|Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.
41098097|NCT00398502|DRUG|MOA-728|
41098098|NCT04094064|DEVICE|Continuous Glucose Monitor|Use of a continuous glucose monitor during study period.
41098099|NCT06448754|DRUG|Volrustomig|Participants will receive volrustomig via intravenous (IV) infusion.
41098100|NCT06448754|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion.
41098101|NCT06448754|DRUG|Pemetrexed|Participants will receive pemetrexed via IV infusion.
41098102|NCT03517579|DEVICE|Cervical Collar Therapy Indicator (COTI)|"Study Device; The CoTI has 3 components;~* A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions.~* A cable that connects the collar unit to the Control Unit~* A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet.~Two types of collar devices will be used: the lower activity and the medium activity~1. Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131.~2. Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131."
41098103|NCT04293783|DIETARY_SUPPLEMENT|L.Reuteri|daily supplementation with two tablet for six months
41098104|NCT04293783|DIETARY_SUPPLEMENT|Placebo|daily supplementation with two tablet for six months
41098105|NCT04675255|PROCEDURE|Frequently sampled glucose tolerance testing|Frequently sampled glucose tolerance testing
41098106|NCT04675255|PROCEDURE|abdominal subcutaneous adipose tissue biopsy|abdominal subcutaneous adipose tissue biopsy
41098107|NCT04675255|PROCEDURE|MRI scan to assess intrahepatic triglyceride content|MRI scan to assess intrahepatic triglyceride content
41098108|NCT03944343|OTHER|Cereal based products|The cereal products are made from common Swedish cereals.
41098109|NCT03864484|DEVICE|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, the experimental group will watch movies using the iPad application for 3 minutes, once daily for 5 weeks.
41098110|NCT03864484|BEHAVIORAL|Usual rehabilitation|The control group receives usual rehabilitation.
41133218|NCT02785159|DRUG|IDP-118 Vehicle Lotion|Lotion
40752065|NCT01433874|PROCEDURE|Control group|Co2 was removed by passive exsufflation through the port site.
40752066|NCT01297244|DRUG|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
40752067|NCT03600727|DRUG|Propofol|Propofol will be used to offer intraoperative sedation for patients in Propofol group.
41098111|NCT05512260|DEVICE|Individual decision aid (iDA)|A web-based iDA (accessible online with various content), will be developed towards individuals approached to cancer screening, although public and accessible to all who are interested in cancer and screening. DAs in screening usually include information on the disease, screening, screening tests, benefits and harms and some value clarification exercise (e.g., interactive questions) aiming at shedding light on the individual´s values and preferences, knowledge and lifestyle.
41098112|NCT06111508|DEVICE|Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs|A Continuous Glucose Monitoring (CGM)-based once weekly titration algorithm of basal insulin as implemented in DiAs Cloud platform
41098113|NCT05921409|DIETARY_SUPPLEMENT|Extra Virgin Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Extra Virgin Olive Oil (treatment group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
41098114|NCT05921409|DIETARY_SUPPLEMENT|Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Olive Oil (placebo group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
41098115|NCT04499131|DRUG|Progesterone|Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
41098116|NCT04499131|OTHER|Artificial Cycle (no intervention)|Control group of 19 subjects in the context of a natural cycle with only endogenous progesterone present
41098117|NCT05554692|DIAGNOSTIC_TEST|Diagnostic tests of cochlear implant function|Because the subjects in the study will use CI devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of CI function. This will include perceptual tests of temporal discrimination and speech understanding.
41098118|NCT05554692|DIAGNOSTIC_TEST|Diagnostic tests of auditory function|The intervention here will be to carry out diagnostic tests of hearing. This will include perceptual tests of temporal discrimination and speech understanding.
41098119|NCT03456817|DRUG|Treatment Arm - high dose ATG|Patients agreeing to high dose ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 \& -2, ATG will be infused after fludarabine \& busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 \& over at least 4 hrs on days -3, -2, -1 \& 0. Dose is based on actual body wt, \& rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in \>5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic. Meperidine 25-50 mg IVPB every 4 hours will be given as needed for rigors. MTX is given 15 mg/m2 IV on day +1 \& 10 mg/m2 on days +3, +6 \& +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.
41098120|NCT03456817|DRUG|Control Arm - standard of care|The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).
41098121|NCT04449744|OTHER|MySafeRx Inspire Plus|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
41133219|NCT02785159|DRUG|IDP-118 Vehicle Cream|Cream
41133220|NCT02269852|BIOLOGICAL|trivalent seasonal influenza vaccine|"* Infants: 0.25 ml/ dose;~* Adults: 0.5 ml/ dose;~* Seniors: 0.5 ml/ dose;"
41133221|NCT05575505|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
41133222|NCT02301806|OTHER|dieting|
41443207|NCT01628835|BEHAVIORAL|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
41443208|NCT01628835|BEHAVIORAL|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
41443209|NCT06425055|DRUG|Vonafexor|"* One tablet of a low dose of vonafexor QD from Day 1 to Week 4~* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8~* One tablet of a high dose of vonafexor QD from Week 9 to Week 24"
41443210|NCT00818558|BIOLOGICAL|ISET Methode|Sampling of blood - ISET Methode
41443211|NCT05754983|DRUG|Solid tumor patients receiving immunotherapy for the first time were included in the study|Solid tumor patients receiving immunotherapy were included in the study. Baseline information before treatment (including demographic characteristics, basic diseases and their medication history, tumor and anti-tumor history, quality of life scores, etc.) and follow-up information after treatment (PFS, OS, etc.) were collected to summarize factors that may affect the efficacy and prognosis of patients receiving immunotherapy
41443212|NCT04047641|DRUG|Cladribine|Given Intravenous
41098122|NCT04449744|OTHER|MySafeRx Inspire Flex|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study by their clinical team.
41098123|NCT04647162|PROCEDURE|hematoma evacuation by craniotomy|The intervention method of hematoma evacuation is under craniotomy.
41098124|NCT04647162|PROCEDURE|hematoma evacuation by stereotactic puncture|The intervention method of hematoma evacuation is under stereotactic puncture.
41098125|NCT04647162|PROCEDURE|hematoma evacuation by neuroendoscopy|The intervention method of hematoma evacuation is under neuroendoscopy.
41098126|NCT04647162|OTHER|life support|The treatments in medical group includes life support, nutrition support, and rehabilitation therapy。
41098127|NCT02377362|DRUG|GLWL-01, Part A|Capsules administered orally, in 2 out of 3 periods
41098128|NCT02377362|DRUG|Placebo, Part A|Capsules administered orally in 1 out of 3 periods
41098129|NCT02377362|DRUG|GLWL-01, Part B|Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
41098130|NCT02377362|DRUG|Placebo, Part B|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
41098131|NCT02377362|DRUG|GLWL-01, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
41098132|NCT02377362|DRUG|Placebo, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
41098133|NCT06630559|BIOLOGICAL|CT-P55|CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).
41098134|NCT06630559|BIOLOGICAL|EU-approved Cosentyx|European Union (EU)-approved Cosentyx, 300 mg by 2 SC injections of 150 mg/mL via PFS every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by Q4W for 11 doses (up to Week 48).
41098135|NCT03503773|DRUG|Alcohol|Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
41098136|NCT03503773|OTHER|Sham control|endovascular, renal angiography
41098137|NCT05605743|BEHAVIORAL|breathing exercise|Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
41098138|NCT04257851|DRUG|Theophylline Anhydrous Oral Tablet|Theophylline tablet (150 mg/12h)
41098139|NCT04257851|DRUG|Sumatriptan Succinate Oral Tablet|Sumatriptan tablet (25 mg/12h)
41098140|NCT03016130|OTHER|Diet|Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
41098141|NCT01549379|RADIATION|Dynamic Contrast Enhanced CT scan|The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
41098142|NCT04638777|DEVICE|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
41098143|NCT04638777|DEVICE|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and sham repetitive transcranial magnetic stimulation with H-coil over PFC
41098144|NCT04638777|DEVICE|rTMS with H-coil|Sham repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
41443213|NCT04047641|DRUG|Cytarabine|Given Intravenous
41443214|NCT04047641|DRUG|Idarubicin|Given Intravenous
41443215|NCT04047641|DRUG|Quizartinib|Given by mouth
41098145|NCT03870360|BEHAVIORAL|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
41098146|NCT03870360|BEHAVIORAL|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
41098147|NCT03870360|BEHAVIORAL|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
41098148|NCT03870360|BEHAVIORAL|HOLA Component 4|One booster walking session twice a month for six months post intervention for reinforcement, then one booster walking session a month for eighteen months.
41098149|NCT03870360|BEHAVIORAL|Healthy lifestyles education program|Biweekly telephone check in calls for the first 16 weeks followed by monthly check in calls during the two year follow up period.
41098150|NCT02683824|DIAGNOSTIC_TEST|Computed Tomography|Undergo CT scan
41098151|NCT02683824|OTHER|Laboratory Biomarker Analysis|Correlative studies
41098152|NCT02683824|DIAGNOSTIC_TEST|PET/MRI scan|Undergo PET/MRI scan
41098153|NCT02683824|DRUG|[18F]FP-R01-MG-F2|radioactive tracer
41098154|NCT04083651|DRUG|Methylnaltrexone bromide|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
41098155|NCT04083651|DRUG|Placebo|Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
41133223|NCT02301806|DRUG|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
41133224|NCT02301806|DRUG|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
41443216|NCT05329922|BEHAVIORAL|ALICE: Audiological rehabilitation|Persons who are randomised into this arm of the study will be asked to train their listening and communication skills using the ALICE app.
41443217|NCT03969628|DIAGNOSTIC_TEST|ICCMS|Risk caries assessment will consider ICCMS criteria
41443218|NCT03306394|DRUG|Trifluridine/Tipiracil hydrochloride (S95005)|
41443219|NCT06559137|DRUG|Ropivacaine 0.2% Injectable Solution|Patients who are randomized to the peripheral nerve block group will receive a pre-operative perineural injection of 0.2% plain Ropivacaine regardless of weight.
41443220|NCT06033274|DEVICE|Transcatheter Tricuspid Valve Replacement|All patients undergoing Transcatheter Tricuspid Valve Replacement for native tricuspid valve disease
41098156|NCT03722433|DRUG|Vigiis 101-LAB and sequential therapy|Vigiis 101-LAB is the probiotic containing Lactobacillus paracasei subsp. Paracasei, which is the isolate from Taiwanese by Prof. Pan. This strain is resistant to gastric acid and bile acid. Therefore, its survival rate in the gastrointestinal tract could be as high as 95%. Previous studies showed that Vigiis 101-LAB can modulate the gut microbiota, with 10% increase in Bifidobacterium species and 20% reduction in Clostridium difficile.
41098157|NCT03722433|DRUG|Placebo and sequential therapy|Placebo without Vigiis 101-LAB component
41098158|NCT05668507|BEHAVIORAL|REACHOUT Virtual Mental Health Support|"REACHOUT is a mobile app which delivers peer-led mental health support to adults with type 1 diabetes. The mobile app has three support features:~1. One-on-one support delivered by a Peer Supporter. Participants will be able to review Peer Supporter profiles and connect with one of their choosing.~2. Group support delivered via a 24/7 chat room~3. Face to face support delivered via virtual happy hours"
41098159|NCT03359031|OTHER|Patient education|This group will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
41098160|NCT02842658|OTHER|A high-intensity interval exercise group|To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
41098161|NCT02842658|OTHER|An Attention-Control Group|Patients will be contacted weekly to access physical activity. To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
41098162|NCT05483374|OTHER|observation|Not applicable, it is an observational registry
41098163|NCT04135144|OTHER|Group 1 (printed materials)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
41098164|NCT04135144|OTHER|Group 2 (video phone reminder)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
41098165|NCT04122807|PROCEDURE|Cardiac catheter ablation|Cryoablation
41098166|NCT04598529|OTHER|A2 milk|a variety of cow's milk that contains only A2 beta-casein (and therefore lacks of A1 beta-casein).
41098167|NCT04598529|OTHER|Conventional milk|cow's milk with a mixture of A1 and A2 beta-casein.
41098168|NCT04591184|BIOLOGICAL|Covigenix VAX-001 placebo|Placebo vaccine
41098169|NCT04591184|BIOLOGICAL|Covigenix VAX-001|Active Covigenix VAX-001
41098170|NCT05895929|DRUG|Mepolizumab|In vitro exposure of human nasal epithelial cells to mepolizumab
41098171|NCT01176799|DRUG|Arm A|Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
41098172|NCT01176799|DRUG|Arm B|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
41098173|NCT03060187|OTHER|KU Score|Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
41098174|NCT06630182|OTHER|Bortner self-questionnaire|14 items
41098175|NCT06630182|OTHER|Self-questionnaire BFI-10|10 items
41098176|NCT02266810|DEVICE|PROPEL Mini Sinus Implant.|Placement of sinus implant following frontal sinus surgery
41098177|NCT02266810|PROCEDURE|Sinus Surgery alone|Sinus surgery only, without implant placement
41098178|NCT02266810|DEVICE|Propel Nova Sinus Implant|Placement of sinus implant following frontal sinus surgery
41098179|NCT04204408|DRUG|NNC0365-3769 (Mim8)|Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
41443221|NCT04327128|DEVICE|LifePod|The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
41443222|NCT03407677|DEVICE|ROTO track®|An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.
41098180|NCT04204408|DRUG|Placebo (Mim8)|Mim8 placebo administered subcutaneously (s.c., under the skin)
41098181|NCT05095623|OTHER|Natural History Observation|This is a natural history study.
41098182|NCT06628622|DRUG|BI 1356225|BI 1356225
41098183|NCT06628622|DRUG|Placebo|Placebo
41098184|NCT06630923|DRUG|Human albumin|Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.
41098185|NCT05476939|DRUG|Everolimus|Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.
41098186|NCT05476939|DRUG|ONC201|Capsules of 125mg. The prescribed dose is 375mg/m², once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.
41443223|NCT00919230|DRUG|Ferrous sulphate tablets|200mg twice daily for four weeks
41443224|NCT04904705|OTHER|The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach is a cognitive-based approach. This is a person-oriented, performance-solving problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills.~The main objectives of this approach are; define and transfer domain-specific strategies to other motor-based tasks to gain skills, learn problem-solving strategy (goal, plan, do, check) and adapt to other environments (such as home, school)."
41133225|NCT01205633|PROCEDURE|venous angioplasty|catheter venous angioplasty via femoral vein approach
41098187|NCT05476939|RADIATION|Radiotherapy|"All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation."
41098188|NCT00121940|BEHAVIORAL|Guided Care|"Specially trained registered nurse (Guided Care Nurse) based in a primary care practice collaborates with two primary care physicians to provide seven services for 40-60 high-risk patients: comprehensive assessment and care planning; best practices for chronic conditions; self-management; healthy lifestyles; coordinating care; educating and supporting unpaid caregivers; and accessing community resources."
41098189|NCT02857283|OTHER|Ozone|Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08
41098190|NCT02857283|OTHER|Filtered Air|Participants will be exposed to filtered clean air
41098191|NCT02857283|DEVICE|Health and Exposure Tracker (HET)|Ozone and heart rate tracker
41098192|NCT06631365|DEVICE|PrEPsmart mobile app|"The PrEPsmart mobile app is an innovative and comprehensive app to support sexual minority men (SMM) using on-demand pre-exposure prophylaxis (PrEP) or daily PrEP. The PrEPsmart app consists of the following components:~1. PrEP 211 dosing/sex diary and reminders~2. Feedback on PrEP protection levels~3. Quick tips~4. Bi-directional secure messaging"
41098193|NCT06631365|DRUG|Truvada|Combination medication used in Human immunodeficiency virus (HIV) prevention, it blocks virus pathways to infection.
41098194|NCT05337072|DIAGNOSTIC_TEST|Microbiome study|Investigation of the vaginal and endometrial microbiome
41098195|NCT06628505|OTHER|Speech in Noise Training|The active controls will receive frequency discrimination training that uses the same visual landscape and basic task of controlling the wisp based on judgments about acoustic cues. The task requires participants to avoid obstacles by swiping upward or downward on the touchscreen to indicate whether a test frequency associated with the obstacle was higher or lower, respectively, than a target sound presented slightly before the test sound.
41098196|NCT06628505|OTHER|Spatial Hearing Training Group|"Stimulus presentation and response measurement (Aim 2): Acoustic stimuli will be presented with a 360° speaker array that are fixed in place behind an opaque, nearly sound transparent, acoustic fabric curtain to avoid visual influences. Manual responses will be collected using a keyboard. Custom Matlab scripts control all relevant variables with millisecond precision. A webcam monitors the participant (not recorded) for the sole purpose of making sure the participant is always facing straight ahead.~Sound localization task and training: Participants will judge the location of a target white noise sound (1000 ms, 70 dB SLP, 10-10,000 Hz) by moving an auditory pointer that appears 2 seconds after the offset of the target sound.~The training group are given feedback about how their perceived location related to the actual sound location."
41098197|NCT06628505|OTHER|Spatial Hearing Control Group|"Stimulus presentation and response measurement (Aim 2): Acoustic stimuli will be presented with a 360° speaker array that are fixed in place behind an opaque, nearly sound transparent, acoustic fabric curtain to avoid visual influences. Manual responses will be collected using a keyboard. Custom Matlab scripts control all relevant variables with millisecond precision. A webcam monitors the participant (not recorded) for the sole purpose of making sure the participant is always facing straight ahead.~Sound localization task and training: Participants will judge the location of a target white noise sound (1000 ms, 70 dB SLP, 10-10,000 Hz) by moving an auditory pointer that appears 2 seconds after the offset of the target sound.~The training group are NOT given feedback about how their perceived location related to the actual sound location."
41098198|NCT05067127|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
41098199|NCT05067127|OTHER|Placebo|Sterile solution of equal volume to active arm
41098200|NCT02540044|BEHAVIORAL|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
41098201|NCT02540044|BEHAVIORAL|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
41098202|NCT01255033|DEVICE|Monitoring of tissular oxygenation|"Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices~Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device"
41098203|NCT04474925|PROCEDURE|Brain Surgery|Surgery to remove brain metastases
41098204|NCT04474925|RADIATION|Stereotactic Radiosurgery|SRS uses many focused radiation beams to treat tumors within the brain
41098205|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 150mg|leaves of the mango food plant
41098206|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 300mg|leaves of the mango food plant
41098207|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 600mg|leaves of the mango food plant
41098208|NCT05580146|DIETARY_SUPPLEMENT|Placebo|Sunflower oil matched for appearance
41098209|NCT06622148|DRUG|Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)|For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) .
40752068|NCT03600727|DRUG|Dexmedetomidine|Dexmedetomidine will be used to offer intraoperative sedation for patients in Dexmedetomidine group.
40752069|NCT02340676|PROCEDURE|Extracorporeal Photopheresis (ECP)|Participants receive ECP treatment twice a week for 16 weeks
41098210|NCT06622148|DRUG|Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)|For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
41098211|NCT06610344|DIETARY_SUPPLEMENT|R-1,3-Butanediol|R-1,3-Butanediol 35 mL
41098212|NCT06548490|DRUG|Semaglutide Pen Injector|Semaglutide will be provided using an injection pen
41098213|NCT06548490|DRUG|Placebo|Placebo will be a dry needle stick; no substances will be injected
41098214|NCT02624778|BIOLOGICAL|LY3002813|Administered IV
41098215|NCT02624778|DRUG|Placebo|Administered IV
41098216|NCT04428554|RADIATION|Experimental arm|Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
41098217|NCT06629467|BEHAVIORAL|Cognitive-behavioral therapy for smoking cessation|Treatment components will include psychoeducation on the consequences of tobacco use and the benefits of quitting; therapeutic commitment; self-monitoring of cigarette smoking; brief advice on healthy eating behaviors and sleep hygiene, physiological feedback (based on CO levels), training in self-control strategies, stimulus control, management of craving with alternative activities, diaphragmatic breathing, weekly personalized physical activity objectives, and relapse prevention strategies. The protocol consists of a nicotine fading procedure, which consists of a weekly reduction in nicotine intake of 30% (based on both tobacco brands and the number of cigarettes) from the first to the fifth session.
41098218|NCT06629467|BEHAVIORAL|Personalized PA plan|The treatment provider will fix an objective (e.g. go for brisk walking for 30 minutes 3 times this week) for each participant every week according to his/her current PA level, time availability, likes, and fitness level.
41098219|NCT06629467|DEVICE|Fitbit Versa 3|Wearable activity tracker with the functionalities of a watch function, including time, date, calendar, and weather (connection to the internet is required). Physical activity monitoring (steps per day, active minutes per day, plants climbed, heart rate monitoring, time, intensity, caloric expenditure, and exercise type of exercise session), sleep monitoring (sleep time, sleep phases time, sleep quality), stress levels managing and guided breathing application are the main health-related functionalities.
41098220|NCT04473950|DRUG|Naloxone Hydrochloride|An intramuscular (IM) injection of naloxone will be given.
41098221|NCT04473950|DRUG|Placebo|An IM injection of 0.9% normal saline will be given.
41098222|NCT05221840|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
41098223|NCT05221840|DRUG|Oleclumab|Oleclumab IV (intravenous infusion)
41098224|NCT05221840|DRUG|Monalizumab|Monalizumab IV (intravenous infusion)
41098225|NCT05221840|OTHER|Placebo|Placebo IV (intravenous infusion)
41098226|NCT00366353|OTHER|Sedation during SBT|
41098227|NCT00366353|OTHER|No sedation|
41098228|NCT06311227|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41098229|NCT06311227|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40752070|NCT02340676|DRUG|Interleukin-2|Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
40752071|NCT04453254|OTHER|Whole Food Meal|Isocaloric/ macronutrient whole food meal
40752072|NCT04453254|OTHER|Supplement Food Meal|Isocaloric/ macronutrient supplement food meal
41098230|NCT06311227|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41098231|NCT06311227|PROCEDURE|Computed Tomography|Undergo CT scan
41098232|NCT06311227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41098233|NCT06311227|DRUG|Venetoclax|Given PO
41098234|NCT06504394|BIOLOGICAL|Pembrolizumab Coformulated With Hyaluronidase|SC injection
41098235|NCT03965702|DEVICE|Use of a decision support system on the EV1000 monitoring (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical decision support system for fluid administration called AFM (assisted fluid management) Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
41098236|NCT03965702|OTHER|Manual application of the GDFT protocol (standard of care)|Manual application of a GDFT protocol to guide fluid administration. Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
41098237|NCT04423393|BIOLOGICAL|VIR-3434|VIR-3434 given by subcutaneous injection or intravenous infusion.
41098238|NCT04423393|OTHER|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
41098239|NCT03355053|DRUG|Dexmedetomidine|"Dex (Precedex, Dexmedetomidine HCl Injection) is produced by Pfizer Inc, NY, Ny (formerly Hospira). Dex is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89. Dex is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg (0.1mg) of dexmedetomidine and 9 mg of sodium chloride in water. The solution is preservative-free and contains no additives or chemical stabilizers. The MGH Pharmacy currently obtains Dex from the supplier as a solution in 50 mL clear-glass bottles, as a clear liquid, at a concentration of 4mcg/mL."
41098240|NCT03355053|DRUG|Placebo|"From the package insert: 0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is produced by Pfizer Inc, NY, Ny (formerly Hospira). It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+ ) 154 mEq; chloride (Cl- ) 154 mEq. The osmolarity is 308 mOsmol/L (calc.). The pH is 5.6 (4.5 to 7.0). This solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required, the unused portion should be discarded. 0.9% Sodium Chloride Injection, USP is a parenteral fluid and electrolyte replenisher. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H2O."
41098241|NCT03022903|PROCEDURE|Aminolevulinic Acid (ALA)|Photosensitizing
41098242|NCT06631157|DEVICE|Essential pro|Patients in whom treatment with (Essential Pro) has been attempted
41098243|NCT02766504|DEVICE|airway ultrasound|airway assessment using ultrasound
41098244|NCT06565390|DEVICE|Babies in the Owlet monitor group|The Owlet group will be given an Owlet OSS 3.0 monitor to wear when sleeping. The Owlet alarms if the baby has a very low heart rate or very low oxygen levels. In addition, caregivers in the Owlet group with a smart phone and Wi-Fi access will be able to use an application to monitor the baby's vital signs and sleep state.
41098245|NCT06631040|BIOLOGICAL|anti CD19 CAR NK cells|Ten eligible patients with relapsed Acute Lymphoblastic Leukemia will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of anti-CD19 CAR NK cells with close monitoring using one of the following dose levels: • Dose Level 1: 1×10\^7/Kg • Dose Level 2: 5×10\^7/Kg • Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow International Lymphoma Party (LWP) Group guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease.
41098246|NCT06629792|OTHER|Gentle Cleanser|The cleanser was instructed to be used twice daily over the course of 12 weeks
41098247|NCT06629792|OTHER|Facial Moisturizer|The Moisturizer was instructed to be applied to the global face twice daily over the course of 12 weeks.
41098248|NCT06629792|OTHER|sunscreen SPF 30|The Sunscreen was instructed to be applied once daily in the morning, with re-application with extended sun exposure per FDA guidelines over the course of 12 weeks.
41098249|NCT06629922|OTHER|No intervention|This is a observational study and the participants will not receive any intervention
41098250|NCT03214562|DRUG|Cytarabine|Given IV
41098251|NCT03214562|BIOLOGICAL|Filgrastim|Given SC
41098252|NCT03214562|DRUG|Fludarabine|Given IV
41098253|NCT03214562|DRUG|Idarubicin|Given IV
41098254|NCT03214562|BIOLOGICAL|Pegfilgrastim|Given SC
41098255|NCT03214562|DRUG|Venetoclax|Given PO
41098256|NCT03836417|DIAGNOSTIC_TEST|Microarray analysis|Microarray analysis to identify gene expression profiles that distinguish IPF from NSIP
41098257|NCT04168814|OTHER|Observational test|Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site. Covid-19 diagnosis.
41098258|NCT05893303|OTHER|1st Group|1st group is going to undergo scapula-oriented PNF techniques (diagonal) which are anterior elevation and posterior depression - posterior elevation and anterior depression with 20 repetitions with rhythmic initiation and repeated contractions facilitation techniques during all patterns. In addition to PNF techniques, gait training is going to be applied as standing with balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
41098259|NCT05893303|OTHER|2nd Group|2nd group is going to undergo only gait training and balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
41098260|NCT04917432|PROCEDURE|intravascular ultrasound (IVUS)|Intravascular imaging using a specialized catheter delivered through intra-arterial approach to reach the coronaries to guide CTO-PCI procedure and optimize the results after wire crossing.
41098261|NCT04917432|PROCEDURE|Conventional CTO PCI (non-IVUS guided)|Non-IVUS guided CTO PCI for wiring but may be used for results optimization after wire crossing
41443225|NCT04904705|OTHER|Home Program|Home Program are activities that a participant can apply at home to improve their skills.
41453300|NCT03712891|DIETARY_SUPPLEMENT|Coffee|Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)
41098262|NCT06429618|DIETARY_SUPPLEMENT|Low carbonhydrate diet|Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same dietitian. Whether the patients adhere to the diet and which components the prescribed diet consists of is recorded in detail. After 3 months of standard application, the patient is examined again by the gynecologist and obstetrician at the PCOS clinic.
41098263|NCT02214108|OTHER|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
41098264|NCT05470374|PROCEDURE|Intraoperative sonography|ultrasound scanning of brain to search tumor remnants
41098265|NCT06492954|PROCEDURE|Surgical Resection|Removal of all lung nodules, including the radiated nodule, per the standard of care for osteosarcoma patients with lung metastasis.
41098266|NCT06492954|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Dose level 1: 8 Gy\* 3 (Total 24 Gy) Dose level 2: 18 Gy\* 3 (Total 54 Gy)
41098267|NCT06492954|DRUG|Atezolizumab|For subjects \<18 years of age at the time of enrollment, Atezolizumab will be administered IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg (maximum dose of 1200 mg). Subjects ≥ 18 years old will receive a flat dose of 1200 mg IV on Day 1 of each 21-day cycle
41098268|NCT05826548|BEHAVIORAL|Telerehabilitation group|Patients will undergo the experimental intervention for 1 hour/day, for 5 days, for 4 weeks.
41098269|NCT05826548|BEHAVIORAL|Conventioanl treatment group|Patients will undergo the control intervention for 1 hour/day, for 5 days, for 4 weeks.
41098270|NCT06532760|OTHER|Blood sampling|Blood sampling to study sodium fragment kinetics
41098271|NCT06226545|DRUG|LASN01|Low dose of LASN01 will be administered intravenously.
41098272|NCT06226545|DRUG|LASN01|High dose of LASN01 will be administered intravenously.
41098273|NCT06226545|DRUG|Placebo|Placebo will be administered intravenously.
41098274|NCT06226545|DRUG|LASN01|High dose of LASN01 will be administered intravenously.
41098275|NCT06156813|DIAGNOSTIC_TEST|Diagnostic test|Measurements for validity and reliability
41098276|NCT05903066|PROCEDURE|Magnetic Resonance Enterography (MRE)|MRE performed as part of the standard of care follow up of the patient, the exam will be recorded for the study and analysed by central readers.
41098277|NCT04745702|COMBINATION_PRODUCT|Low Calorie Meals Rich in Plant Components|Twice a day reduced calorie frozen ready meals (rich in plant components) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
41098278|NCT04745702|COMBINATION_PRODUCT|Low Calorie Balanced Meals|Twice a day reduced calorie frozen ready meals (balanced composition) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
41098279|NCT01125228|DRUG|Ziodovudine and Alpha Interferon|
41098280|NCT03829332|BIOLOGICAL|Pembrolizumab|IV infusion
41098281|NCT03829332|DRUG|Lenvatinib|oral capsule
41098282|NCT03829332|DRUG|Placebo for lenvatinib|oral capsule
41098283|NCT06388109|OTHER|Positive Peers mobile app|Positive Peers is a multifunctional mobile app using a mind, body, spirit theme aimed to improve HIV care outcomes.
41098286|NCT06630962|OTHER|Financial Navigation Program|"A salaried financial navigator will be hired by the study sites. All responsibilities of the navigator will revolve around the structured financial navigation program. There is currently no research indicating that such a role has been incorporated at cancer centers in sub-Saharan Africa.~Through this program, the financial navigator will educate participants on financial literacy, insurance plans and payment options available through charities and financial assistance programs. In addition to providing financial counseling, the financial navigator will verify participant insurance documents, maintain records of financial agreements, and coordinate payments with insurance companies."
41098287|NCT04241796|DEVICE|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
41098288|NCT05588791|DIAGNOSTIC_TEST|whole-body computed tomography|whole-body computed tomography prescription in the emergency department : an identification tool for low risk patients
41453301|NCT05152745|OTHER|Placebo OGGT|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
41098289|NCT03853733|RADIATION|rectal cancer radiotherapy|Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
41098290|NCT04182087|BEHAVIORAL|Cognitive tasks|Attention, language, memory, decision-making or executive functions
41098291|NCT05169255|DRUG|Antibiotic administration|Individuals received either azithromycin or amoxicillin for 3 or 7 days
41098292|NCT03223883|DRUG|Curcumin|Oral supplement for 12 months
41098293|NCT03223883|OTHER|Placebo|Oral placebo for 12 months
41098294|NCT06628895|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Exercise training that consists of flexibility, aerobic, balance and strengthening regime. The exercise given three times a week, for 12 weeks.
41098295|NCT06629116|DRUG|Patients with AIS receive intravascular therapy, and within 10 minutes after the surgery, they are administered 100ml of 20% human albumin intravenously (infused within 30 minutes).|Whether to administer albumin to AIS patients after intravascular thrombectomy and reperfusion.
41098296|NCT04778410|DRUG|Magrolimab|Administered intravenously
41098297|NCT04778410|DRUG|Azacitidine|Administered either subcutaneously or IV, 75 mg/milligram per square (m\^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
41098298|NCT04778410|DRUG|Venetoclax|Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
41098299|NCT04778410|DRUG|Mitoxantrone|Administered intravenously, 8 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
41098300|NCT04778410|DRUG|Etoposide|Administered intravenously, 100 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
41098301|NCT04778410|DRUG|Cytarabine|Administered intravenously, 1000 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
41098302|NCT04778410|DRUG|CC-486|Administered orally, 300 mg on Days 1-14 during each cycle
41098303|NCT05108896|DIAGNOSTIC_TEST|3-Screenings Protocol|The 3-Screenings Protocol is a modified bedside swallow exam (BSE) consisting of a study developed five-item decision tree algorithm including voice quality assessment and a 2-ounce water consistency assessment, the Yale Swallow Test, with a scored 3-ounce Water Swallow Test (3-WST), and the Toronto Bedside Swallowing Screening Test (TOR-BSST).
41133226|NCT06509581|DIETARY_SUPPLEMENT|vitamin E|Vitamin E will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
41098304|NCT05108896|DIAGNOSTIC_TEST|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
41098305|NCT05108896|DIAGNOSTIC_TEST|Tracheal Ultrasound|Ultrasound imaging of the trachea, measuring tracheal diameter and endotracheal tube (ETT) size ratio within 72 hours prior to extubation
41098306|NCT05092958|DRUG|Avelumab|Given IV
41098307|NCT05092958|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41098308|NCT05092958|PROCEDURE|Bone Scan|Undergo bone scan
41098309|NCT05092958|DRUG|Cabozantinib S-malate|Given PO
41098310|NCT05092958|PROCEDURE|Computed Tomography|Undergo CT
41098311|NCT05092958|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41098312|NCT05092958|OTHER|Quality-of-Life Assessment|Ancillary studies
41098313|NCT05092958|OTHER|Questionnaire Administration|Ancillary studies
41098314|NCT04996667|DRUG|inhaled nitric oxide (iNO)|"Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
41098315|NCT05009446|PROCEDURE|endoscopic surgery|endoscopic surgery or endoscope-assisted surgery open surgery
41098316|NCT05009446|RADIATION|intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy|radiotherapy was administrated before surgery
41098317|NCT05009446|DRUG|Chemotherapy drug|Chemotherapy was administrated before surgery. Chemotherapy may also be administrated after surgery in selected cases.
41098318|NCT00849147|BIOLOGICAL|Haploidentical Bone Marrow Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5~* Total body irradiation (TBI): 200 centigray (cGy) on Day -1~Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor."
41098319|NCT00849147|BIOLOGICAL|GVHD prophylaxis|"The GVHD prophylaxis regimen will consist of the following:~* Cy: 50 mg/kg IV on Days 3 and 4~* Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL~* Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID~* Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm\^3 for 3 consecutive days"
41098320|NCT05001828|DRUG|ADI-PEG 20|ADI-PEG 20 in combination with venetoclax and azacitidine
41098321|NCT05448261|BEHAVIORAL|Emotion-centered problem-solving intervention (EPi)|"The EPi is built upon the model of relational/problem-solving model of stress and is aimed at supporting caregivers in (1) revisiting stressful caregiving and associated problem from a psychological distanced perspective; (2) adopting problem orientation toward one's experience in the present moments with curiosity, openness and acceptance; and (3) applying the problem-solving skills learned for the enhancement of their psychosocial wellbeing in the stressful caregiving context. To reduce the incongruence between caregivers and stroke survivors in problem-solving, we will adopt a shared problem, shared action plan approach for the family caregivers and stroke survivors."
41098322|NCT05448261|OTHER|stroke education|Information is related to stroke and recurrent stroke and strategies for assisting stroke survivors in day-to-day activities.
41098323|NCT05650333|DRUG|Ritlecitinib 20 mg|orally administered, Ritlecitinib 20 mg once daily (QD)
41098324|NCT02978521|OTHER|Pulmonary rehabilitation|Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
40752073|NCT02981693|PROCEDURE|Root canal sealer|Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
40752074|NCT00965094|DRUG|Everolimus|One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
41098325|NCT02911103|PROCEDURE|DBS surgery|Unilateral thalamic DBS therapy
41098326|NCT06631638|DEVICE|EMPHASYS Cup with VHN|Total Hip Replacement with EMPHASYS Acetabular shell and Non-Invasive Navigation
41098327|NCT05747599|BEHAVIORAL|Intervention with contingent incentives and text-based support|Contingent incentives on abstinence from alcohol, tobacco, and cannabis; Text-based support based on educational components
41098332|NCT05946824|RADIATION|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two dose levels - one to the area of radiologic recurrent nodal disease, and a lower, prophylactic dose to the standard post-prostatectomy and larger pelvic node fields
41098333|NCT05946824|RADIATION|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two areas - a high dose to the area of radiologic recurrence, and a lower, prophylactic dose to the standard post-prostatectomy fields
41098334|NCT05461547|DIAGNOSTIC_TEST|Lung Ultrasound|LUS will be performed and interpreted in real-time to guide acute management.
41098335|NCT05461547|OTHER|Usual Care|Usual care to decide diagnosis and treatment
41098336|NCT03729804|DRUG|Carfilzomib|"Carfilzomib will be given by IV on Days 1, 2, 15 and 16 of each cycle during cycles 1-8.~Carfilzomib will be given by IV on days 1, 2, 15 and 16 of each cycle during cycles 9-24."
41098337|NCT03729804|DRUG|Lenalidomide|"Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.~Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24."
41098338|NCT03729804|DRUG|Dexamethasone|"Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.~Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24."
40752075|NCT00965094|DRUG|Tacrolimus (FK506)|Capsules 0.5 mg, 1 mg. Dosing according to blood level.
41098339|NCT03729804|DRUG|Bortezomib|Bortezomib will be give by IV on days 1, 4, 8 and 11 of each cycle during cycles 1-8.
41098340|NCT05684796|DRUG|Anticoagulation|Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)
41098341|NCT05684796|DEVICE|mechanical aspiration thrombectomy|Mechanical aspiration thrombectomy with the Indigo Aspiration System.
41098342|NCT06383988|OTHER|Support for Caregiver - Generic List|Receive a generic resource list
41098343|NCT06383988|OTHER|Support for Caregiver - Personalized List|Receive personalized resource list
41098344|NCT06383988|OTHER|Internet-Based Intervention - CONNECT|Receive access to CONNECT tool
41098345|NCT06383988|BEHAVIORAL|Patient Navigation|Complete calls with caregiver navigator
41098346|NCT06230874|BEHAVIORAL|HOME Protocol|The HOME Protocol is a newly developed nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Five components of the HOME Protocol include Reflect (1 minute of self-reflection and self-talk), Reset (2 minutes for breathing with stillness/silence and body check), Reach (3 minutes for stretching and progressive muscular relaxation), Renew (2 minutes for breathing with meditation/gratitude), and Re-engage (1 minute for self-reflection and self-talk).
41098347|NCT06230874|BEHAVIORAL|Control Journaling Protocol|The control journaling protocol is a nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness self-talk and journaling strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Three components of the control journaling protocol include Reflect (1 minute of self-reflection and self-talk), Write (journaling), and Re-engage (1 minute for self-reflection and self-talk).
41098348|NCT02490176|DRUG|liraglutide|Liraglutide were taken daily for 7 days
41098349|NCT02490176|DRUG|placebo|Placebo were taken daily for 7 days
41098350|NCT06629311|DEVICE|Autotransfusion device|Standard cardiac surgery using I-SEP and SAME™ autotransfusion device
41098351|NCT05876910|BEHAVIORAL|Speech Production Tasks|View visual cues and undergo speech production for 30 minutes. Electrical stimulation of speech related brain regions in the middle of speech production.
41098352|NCT04587479|DRUG|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
41098353|NCT02727621|DRUG|Dexmedetomidine|Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
41098354|NCT02727621|DRUG|propofol|Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
41098355|NCT06437002|BEHAVIORAL|Mental Motor Chronometry (MMC) Task Hands and Feet and Whole Body|"The MMC will be used as a measure of MI and it is adapted for use in hands, feet, and the whole body as well as for online experimentation. The task is comprised of two conditions, MI, and motor execution, in which respectively participants will be asked to imagine and execute a movement sequence with both hands and feet and the whole body.~Hand movements: index and thumb opposition; thumb extension from the fist; middle finger crossed on the index finger; and extension of the index and the little fingers.~Foot movements: foot internal rotation, foot external rotation, foot dorsiflexion, and foot plantarflexion.~Whole-body movements: take a small bow, lift arms over the head and stand on the tips of the toes (stretch), extend hands forward and lower the backside (squats) and a small jump.~The types of movements required to be executed by participants are simple and do not require much energy. Therefore, people affected by AN and BN should be able to perform them without problems."
41098356|NCT04606264|DRUG|Neuraxial Analgesia|This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).
41098357|NCT04606264|DRUG|Regional Block 1: Paravertebral|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
41098358|NCT04606264|DRUG|Perphenazine|This randomized group will receive 8 mg of perphenazine orally preoperatively.
41098359|NCT04606264|DRUG|Aprepitant|This randomized group will receive 40 mg of aprepitant orally preoperatively.
40752076|NCT00965094|DRUG|Basiliximab|One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.
40752077|NCT00965094|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
40752078|NCT00965094|DRUG|Corticosteroids|Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
41098360|NCT04606264|DRUG|Dimenhydrinate|This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.
41098361|NCT04606264|DRUG|Ondansetron 4 MG|This randomized group will receive 4 mg of ondansetron orally.
41098362|NCT04606264|DRUG|Dexamethasone|This randomized group will receive 4-5 mg of dexamethasone intravenously.
41098363|NCT04606264|DRUG|Regional Block 2: QL1|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
41098364|NCT04544995|DRUG|Niraparib|Niraparib will be administered as TfOS (Tablet for oral suspension)
41098365|NCT04544995|DRUG|Dostarlimab|Dostarlimab will be administered as IV infusion
41098366|NCT04544995|DRUG|Niraparib|Niraparib will be administered as tablet
41098367|NCT06628908|DRUG|Suzetrigine|Tablets for oral administration.
41098368|NCT06628908|DRUG|Pregabalin|Capsules for oral administration.
41098369|NCT06628908|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
41098370|NCT06628908|DRUG|Placebo (matched to Pregabalin)|Placebo matched to Pregabalin for oral administration.
41098371|NCT05846165|DEVICE|Field-Cycling Imaging (FCI)|FCI scan
41098372|NCT05755035|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
41098373|NCT05755035|BIOLOGICAL|HYQVIA|Participants will receive SC infusion of HYQVIA.
41098374|NCT01137903|PROCEDURE|Conservative surgery|Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy
41098375|NCT01137903|DRUG|Ciprofloxacin|500 mg/ 12 hours during 90 days
41098376|NCT01137903|DRUG|Amoxicillin-Potassium Clavulanate Combination|875/125 mg/12 hours during 90 days
41098377|NCT01137903|DRUG|Sulfamethoxazole trimethoprim|Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.
41098378|NCT06629064|BEHAVIORAL|Working Memory Training|Computer-administered working memory training program. WMT is a modified working memory capacity task designed to train working memory functioning. WMT is designed to contain high interference across trials and is adaptive to performance. As participants improve working memory, the task becomes more difficult.
41098379|NCT06629064|OTHER|Sham Training|The Sham condition requires participants to complete a similar computer task for the same length of time. The Sham Training is a modified working memory capacity task designed to place less demands on working memory.
41098380|NCT05402891|DRUG|Lithium Carbonate|Patients will be administered lithiumcarbonate by an oral tablet of 300mg once a day for a duration of 6 months. Starting dose is 200mg for the first 5 days, dosage will be then increased to 300mg. To limit adverse events and side-effects, the lowest effective dose will be administered. The target serum level of lithium is 0.20 - 0.40 mmol/L and this will be maintained by regular lithium level testing.
41098381|NCT05887323|DEVICE|Implantation of the Tendril 2088 lead in the LBBA|Conduction system pacing is achieved by delivering a pacing stimulus to the Left Bundle Branch area of the heart with Abbott's Tendril 2088 lead.
41098382|NCT05541237|DIETARY_SUPPLEMENT|Food|Food
41098383|NCT06631313|DEVICE|PureWick System|The PureWick System consists of the PureWick Urine Collection System used with either the PureWick Male External Catheter or the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
41098384|NCT06631690|OTHER|Isokinetic and functional balance tests|Isokinetic and functional balance tests
41098385|NCT03126409|PROCEDURE|No-Touch vein harvesting technique|The No-Touch technique focuses on saphenous vein graft harvesting, featured by preserving the surrounding tissue of the vein while at the same time avoiding manual distension.
41098386|NCT03126409|PROCEDURE|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
41098387|NCT04797767|DRUG|Cladribine|Given IV
41098388|NCT04797767|DRUG|Cytarabine|Given IV
41453302|NCT05152745|OTHER|Ginger aqueous extract|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The intervention group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water, followed by 100mL of ginger extract (0.2g). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
41098389|NCT04797767|DRUG|Mitoxantrone|Given IV
41098390|NCT04797767|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
41098391|NCT04797767|DRUG|Venetoclax|Given PO
41098392|NCT03645174|DEVICE|Using long tube|Fiberoptic-guided intubation through LMA, using long tube
41098393|NCT03645174|DEVICE|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
41098394|NCT02333851|DRUG|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
41098395|NCT02333851|DRUG|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
41098396|NCT06629623|OTHER|No intervention|No intervention
41098397|NCT06631404|DIAGNOSTIC_TEST|renal doppler|doppler srudy on renal arteries bilaterally , and detection of RI of renal artery
41098398|NCT06630208|OTHER|Myofascial release|The experimental group will undergo a 5-day consecutive myofascial release treatment, administered as Osteopathic Manipulative Treatment (OMT), with each session lasting a maximum of 15 minutes. The treatment will consist of three phases targeting the entire mediastinum: Thoracic Inlet (Indirect) Myofascial Release, Rib Raising with continued stretch of the paraspinal muscles to the L2 vertebral level, and Soft Tissue Cervical Paraspinal Muscle Stretch with Suboccipital Muscle Release. Participants will be positioned in a supine posture to enhance diaphragmatic excursion, with each session following a fixed, prearranged sequence of these techniques.
41098399|NCT06630208|OTHER|Breathing exercises|Following the 3 phases of myofascial release, breathing exercises will be done for patients.
41098400|NCT06630208|DRUG|Pharmacological treatment|Patients will take pharmacological treatment prescribed by the cardiologist.
41098401|NCT00925730|DRUG|Pimecrolimus|
41098402|NCT06220045|COMBINATION_PRODUCT|Polyvinylidene fluoride mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polyvinylidene fluoride mesh."
41098403|NCT06220045|COMBINATION_PRODUCT|Prophylactic polypropylene mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polypropylene mesh."
41098404|NCT05404230|DIETARY_SUPPLEMENT|Fish oil|Fish oil containing poly unsaturated fatty acids.
41098405|NCT05404230|DIETARY_SUPPLEMENT|Corn oil|Corn oil
41098406|NCT06554444|PROCEDURE|Dental Implant Surgery|Dental implants will be placed in edentulous areas.
41098407|NCT04990401|BEHAVIORAL|Behavioral Activation Teletherapy|A total of 10 teletherapy sessions to be delivered over 12-14 weeks, designed to increase physical activity among depressed individuals.
41098408|NCT06632158|BEHAVIORAL|MindBoba|MindBoba is a smartphone app that uses strategies based on Problem-Solving Therapy to help decrease stress and anxiety, and teach new skills.
41098409|NCT06632158|BEHAVIORAL|Mindshift CBT|MindShift® CBT uses strategies based on Cognitive Behavioural Therapy (CBT) to help you learn to relax and be mindful, develop more effective ways of thinking, and use active steps to take charge of your anxiety.
41098410|NCT06629870|DEVICE|virtual reality|patients who received distraction using virtual reality glasses
41098411|NCT06629870|OTHER|control group|no any anxiety-reducing application
41098412|NCT06629870|OTHER|hypnotherapy|patients receiving hypnotherapy
41098413|NCT06629870|OTHER|mindfulness|patients who underwent mindfulness-based meditation
41098414|NCT05139160|DIETARY_SUPPLEMENT|Protein quality|the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.
41098415|NCT06631924|DEVICE|Implant|Intramedullary headless hardware systems were utilized to place hardware in85 a retrograde manner from the metacarpophalangeal joint.
41098416|NCT06028932|DRUG|Sacituzumab govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
41098417|NCT03988387|BEHAVIORAL|Peer Support (PS)|Participants randomized to the PS arm will be assigned a trained peer supporter. The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general. The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g. tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers). PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits. Participants will be encouraged to contact their PSrs in case of questions or concerns. For any clinical question, the peer supporter will direct the participant to the study nurse.
41098418|NCT03988387|BEHAVIORAL|Reminder and Resource Transfer (RRT)|"Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with a brief answer. Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points."
41098419|NCT03988387|DRUG|daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]|All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) \[FTC/TDF\] for the first month of enrollment.
41098420|NCT00533039|DRUG|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
41098421|NCT00533039|DRUG|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
41098422|NCT06630507|BEHAVIORAL|Educational module|1 hour pre-recorded educational module created by Dr. Sharma.
41098423|NCT05121155|DEVICE|ICP wave morphology comparison between a non-invasive (Brain4care) and a invasive method|We prospectively collected data of adults admitted to an intensive care unit (ICU) with subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH) or ischemic stroke (IS) in whom invasive ICP monitoring placed. Measures had been simultaneously collected from the following non-invasive indices: optic nerve sheath diameter (ONSD), pulsatility index (PI) using transcranial Doppler (TCD), a 5-point visual scale designed for Computed Tomography (CT) and two parameters (time-to-peak \[TTP\] and P2/P1 ratio) of a non-invasive ICP wave morphology monitor (Brain4care\[B4c\]). Intracranial hypertension was defined as an invasively measured ICP \> 20 mmHg for at least five minutes
41098424|NCT04815824|BEHAVIORAL|Exercise Mode|Stationary cycling or treadmill walking
41098425|NCT06629194|DIAGNOSTIC_TEST|interferon gamma releasing assay (IGRA)|All patients who suspected CD or TB will be tested for interferon-gamma releasing assay. An interferon-gamma release assay is a blood test that measures the body\&#39;s immune response to Mycobacterium tuberculosis, the bacteria that causes tuberculosis.
41098426|NCT00618280|DRUG|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
41098427|NCT06629090|DEVICE|MRI|Participants will undergo an MRI scan while performing breathing and simulated postural change tasks.
41098428|NCT06629090|DRUG|Prazosin|A dose of prazosin will be administered based on body weight
41098429|NCT06629090|DRUG|Placebo|Oral placebo
41098430|NCT01766167|DRUG|MP-424|Low
41098431|NCT01766167|DRUG|MP-424|Middle
41098432|NCT01766167|DRUG|MP-424|High
41098433|NCT01766167|DRUG|MP-424|Multiple
41098434|NCT04927975|DRUG|Upadacitinib|Oral tablets
41098435|NCT04927975|DRUG|Placebo|Oral tablets
41098436|NCT06477926|DRUG|ABBV-668 IR|• Oral Capsule
41098437|NCT06477926|DRUG|ABBV-668 ER|• Oral Tablets
41098438|NCT04873362|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.
41098439|NCT04873362|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.
41098440|NCT04873362|DRUG|Placebo|Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.
41453303|NCT01851876|DEVICE|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
41098441|NCT04873362|DRUG|Trastuzumab|Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
41098442|NCT01311713|DRUG|CEP-9722|CEP-9722 will be administered per dose and schedule specified in the arm description.
41098443|NCT05702723|BEHAVIORAL|Smart-3RP|9 sessions of mind-body group treatment program via Zoom platform.
41098444|NCT05702723|BEHAVIORAL|Enhanced Usual Care|14-week group-based, online support group through CancerCare.org.
41098445|NCT00102414|DRUG|Gemcitabine|
41098446|NCT01636206|DRUG|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: \~1 year
41098447|NCT01636206|DRUG|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: \~1 year
41098448|NCT06411665|DRUG|Oliceridine|Patient-controlled intravenous analgesia with oliceridine for up to 3 days after surgery.
41098449|NCT06411665|DRUG|Morphine|Patient-controlled intravenous analgesia with morphine for up to 3 days after surgery.
41098450|NCT06631248|OTHER|Coordinative exercise protocol|During the eight-week period, all children in the structured coordinative exercise intervention group participated in 30-minute sessions twice a week on the same day and time. The purpose-oriented basic movement patterns created in the coordinative exercise content were organised in a play-oriented manner suitable for the preschool age range.
41098451|NCT06545175|DRUG|Intracochlear application of VSF1.01|During cochlear implant operation, patients receive intracochlear VSF1.01 prior to insertion of the electrode array.
41098452|NCT04857944|BEHAVIORAL|IDEA program (Improving depressive symptoms through personalised exercise and activation)|The program will consist of six 90-minute group sessions composed of four to six participants. These short intervention sessions will be distributed in one month, with a frequency of once or twice a week depending on the week of the program. Of the six sessions, two will be exercise-oriented and will include on-site practice. The remaining four sessions will include definitions of depressive symptomatology, the relationship between depression and having an active lifestyle, motivation and barriers towards exercise, and maintenance strategies.
41098453|NCT04857944|DEVICE|IDEApp|An ad-hoc app (IDEApp) combined with a fitness tracker to register and store participants' physical activity, exercise compliance, and sleep patterns. The app will deliver motivational or awareness messages when the fitness tracker detects non-compliance with the exercise prescription, physical activity decreases, or altered sleep patterns.
41098454|NCT04959175|DRUG|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
41098455|NCT04959175|PROCEDURE|Allogeneic HSCT|Stem cell transplant
41098456|NCT04959175|DRUG|Fludarabine|30 mg/m2 IV infusion over 30-60 minutes once daily for 5 days (Pre-Transplant days -6 through -2).
41098457|NCT04959175|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 with no taper. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
41098458|NCT04959175|DRUG|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously, until the absolute neutrophil count is \> 1,000/mm3 over the course of three days or \> 5,000/mm3 on one day. Rounding to the nearest vial is allowed. G-CSF may be stopped early or not administered if required by the clinical circumstance. Additional G-CSF may be administered as warranted.
41098459|NCT04959175|DRUG|Cyclophosphamide|Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
41098460|NCT04959175|DRUG|Mesna|25 or 35 mg/kg (equal to the cyclophosphamide dose) as IV infusion concomitant with cyclophosphamide. Mesna may or may not be given with the pre-transplant cyclophosphamide depending on institutional practice.
41098461|NCT04959175|PROCEDURE|Total Body Irradiation (TBI)|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice daily. Pre-Transplant Day -1 (or Day 0 prior to graft administration)
41098462|NCT01735929|PROCEDURE|Neck Liposuction and Ultrasound Treatment|
41098463|NCT01735929|PROCEDURE|Sham Treatment|
41098464|NCT05283460|BEHAVIORAL|mandala|The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
41098465|NCT04557150|DRUG|Forimtamig|Forimtamig will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. Forimtamig will be administered as per the dosing schedule defined in Part I.
41098466|NCT01019616|DRUG|paclitaxel/anthracycline|standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
41098467|NCT05042791|COMBINATION_PRODUCT|radiation combined with pyrotinib and capecitabine|This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases
41098468|NCT06529809|RADIATION|Hypofractionated external beam radiation|Central pelvis (20 Gy in 10 fractions), nodal basins (40 Gy in 15 fractions), with a simultaneous integrated boost to grossly positive lymph nodes (48 Gy in 15 fractions)
41098469|NCT06529809|DRUG|Chemotherapy|Concurrent chemotherapy are not dictated by the protocol and will follow standard of care guidelines
41098470|NCT06529809|RADIATION|Image-guided brachytherapy|HDR boost 7.3 Gy x 6 fractions
40752079|NCT01077895|PROCEDURE|CVVH|"CVVH is started using following parameters:~* Blood flow is started at 150 mL/min~* Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~* In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~* Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)"
41098471|NCT06628635|BEHAVIORAL|Exercise|Exercise involving aerobics, isometrics, and stretching
41098472|NCT06628635|BEHAVIORAL|Resting|Resting
41098473|NCT03425526|BIOLOGICAL|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given IV
41098474|NCT06354764|OTHER|no intervention|no intervention
41098475|NCT03403699|BIOLOGICAL|Generation of inducible pluripotent stem cells|Generation of inducible pluripotent stem cells from peripheral blood cells.
41098476|NCT05506930|DRUG|Intrathecal Morphine|One group of subjects will receive intrathecal morphine: spinal (neuraxial) dose of preservative free morphine (Duramorph), usually about 4-5mcg/kg. This is injected into the cerebrospinal fluid under sterile technique by a pediatric anesthesiologist while the subject is already under general anesthesia. This procedure is well-described in the pediatric population and used regularly for postoperative pain relief for a variety of procedures including ureteral reimplantation.
41098477|NCT05506930|DRUG|Quadratus lumborum block|The second group of subjects will have bilateral quadratus lumborum blocks: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per/ kg per side (total dose approximately 1mL/kg). This is injected in the subject's flank in the fascial plane between the quadratus lumborum muscle and the psoas muscle. Ultrasound guidance is used for needle and structure localization and this procedure is done by a pediatric anesthesiologist while the subject is already under general anesthesia. Quadratus lumborum blocks are regularly used in clinical practice for postoperative pain relief for a variety of abdominal procedures.
41098478|NCT00182520|DRUG|Topiramate|25 mg - 400 mg/day x 12 weeks
41098479|NCT00182520|DRUG|placebo|25 - 400 mg/day x 12 weeks
41098480|NCT06631612|DRUG|ferric hydroxide polymaltose complex|participants will receive oral iron supplementation according to body weight every other day
41098481|NCT06631612|DRUG|ferric hydroxide polymaltose complex|participants will receive oral iron supplementation dose according to body weight daily
41098482|NCT06631612|DRUG|Albendazole.|both arms will receive Albendazole 400mg once at the beginning f the study to be repeated after 1 week
41098483|NCT04461756|DRUG|PPP001|inhalation (vape)
41098484|NCT05943795|DRUG|SI-B001|Administration by intravenous infusion
41098485|NCT05943795|DRUG|Docetaxel|Administration by intravenous infusion
41098486|NCT01766856|OTHER|Eustachian tube function testing|Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
41098487|NCT06631131|DEVICE|Distalization with clear aligners supported by Class II elastics|Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. ). In group 1, with the beginning of the movement of the upper first molars, Class II intermaxillary elastics were used from precision cuts of the upper canines to the buttons on the lower first molars for supporting distalization movement.
41098488|NCT06631131|DEVICE|Distalization with clear aligners supported by miniscrew|Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. In group 2, IZC miniscrews were inserted in the IZC region between the upper molars in both sides before first molar movement started. The same intramaxillary elastics were used from precision cuts of the upper canines to the IZC miniscrew for supporting distalization movement.
41098489|NCT00233792|DEVICE|sirolimus coated Bx VELOCITY stent - fast release|
41098490|NCT00233792|DEVICE|sirolimus coated Bx VELOCITY stent - slow release|
41098491|NCT02027935|BIOLOGICAL|Aldesleukin|Given SC
41098492|NCT02027935|BIOLOGICAL|Autologous CD8+ Melanoma Specific T Cells|Given IV
41098493|NCT02027935|DRUG|Cyclophosphamide|Given IV
41098494|NCT02027935|BIOLOGICAL|Ipilimumab|Given IV
41098495|NCT02027935|OTHER|Laboratory Biomarker Analysis|Correlative studies
41098496|NCT06628388|BEHAVIORAL|Nurse-Led Risk-Based 5As Primary Healthcare Model|The intervention is developed based on the 5As model (ask, advice, assess, assist, arrange). In this model, nurse will play the central role in delivering the service as a case manager. In Ask, all participants will be assessed on the demographics, health related status, and health risk stratification (i.e. 3-tier risk stratification). In Advice, all participants will be given the education booklet. Those assessed to be at low risks will receive general advice, while those at medium risk will receive condition-specific advice instead. High risk participants will be provided with referral suggestions. The assessment of medium or high risk participants willingness and any barriers in seeking changes will be conducted in Assess. In Assist, active referrals will be provided to high risk participants, with weekly advice messages provided to medium and high risk participants. In Arrange, all participants will receive their follow-ups.
41098497|NCT06628388|BEHAVIORAL|Minimal Intervention|Consisting general advice on women health with the education booklet. No risk-based services nor active referral will be offered during the waitlist control exposure. Participants will be switched to receive intervention from 6-month.
41098498|NCT06631118|PROCEDURE|pericapsular nerve group block for group A,low dose intravenous Propofol [0.7mg/kg] over 30 seconds for group B|Patients in group A will receive ultrasound guided pericapsular nerve group block (PENG) while patients in group B will receive low dose intravenous Propofol0.7mg/kg\] over 30 seconds followed by spinal anesthesia in both groups
41098499|NCT03598257|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41098500|NCT03598257|DRUG|Olaparib|Given PO
41098501|NCT03598257|RADIATION|Radiation Therapy|Undergo radiation therapy
41098502|NCT03598257|OTHER|Survey Administration|Ancillary study
41098503|NCT06187701|BEHAVIORAL|Co-Active Therapeutic Theatre (Co-ATT)|There will be one group drama therapy session per week, for a total of twelve weeks (i.e., total twelve sessions) followed by a single performance (with composition of the audience determined by unanimous agreement of the participants) of the dramatic work (script) produced by the participants during the course of the drama therapy intervention.
41133227|NCT06509581|OTHER|PLACEBO|placebo will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
41133228|NCT01613417|DRUG|gadoteridol|ProHance 0.1 mmol/kg
41133229|NCT01613417|DRUG|gadobutrol|Gadovist/Gadavist 0.1 mmol/kg
41133230|NCT05688605|DRUG|MRG003+HX008|Administered intravenously
41133231|NCT03003104|DRUG|DMT210 Topical Gel 5%|
41133232|NCT03003104|OTHER|Vehicle Control|
41098504|NCT05581160|DIAGNOSTIC_TEST|Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)|"Proposal of the study to all eligible adult patients coming for pre-exposure prophylaxis (PrEP) consultations from the Infectious Diseases Department of Saint-Antoine and Tenon Hospitals (with delivery of a patient's information and signing an informed consent form).~During each visit (D0, M3, M6, M9, M12 and intermediate visits), patients will be asked to:~* Respond to a questionnaire on their history of taking antibiotics, STIs, their foreign travels, their consumption of tobacco, drugs, alcohol and their sexual practices.~* Perform the following additional samples at each visit, including the intermediate: rectal and throat swabs, urine sample and swab from the lesions in the case of ulceration presence due to STIs.~The diagnosis of STIs (NG and MG) will be carried out using 2 techniques: the reference technique and the Next-Generation-Sequencing (NGS) technique.~A serum sample will be collected during routine care. All samples will be stored after the analysis under -80° C."
41098505|NCT01683695|DRUG|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
41098506|NCT01683695|DRUG|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
41098507|NCT06629727|OTHER|VR Group|the experimental group was shown a video through VRG during the lithotripsy procedure.
41098508|NCT06629727|OTHER|Control group|Patients received standard care during the procedure
41098509|NCT03410667|BEHAVIORAL|Phase One: Exploration|"Spina Bifida patients from the pediatric urology clinic at Riley Hospital and their caregivers will participate in discussions of UI goals. These patients will self report their experiences and perspectives using a Day in the Life diary tool-kit."
41098510|NCT03410667|BEHAVIORAL|Phase Two: Creation|Patients, caregivers and providers will work to create a goal setting tool to help patients and physicians appropriately address the issue of UI in patients with spina bifida.
41098511|NCT03410667|BEHAVIORAL|Phase Three: Reflection|This is a validation step to test whether the goal-setting tool is widely applicable and functional in a clinic setting. There will be cognitive interviews after the tool is completed to gather patient impressions.
41098512|NCT03410667|BEHAVIORAL|Aim 3|This will be a large scale validation of the app, with assignment to standard care for the first year of enrollment.
41098513|NCT01090609|DEVICE|Stent implantation|Stent implantation
41098514|NCT05254418|DRUG|dulaglutide injection|All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
41098515|NCT04833192|DIAGNOSTIC_TEST|experimental group|DHEAS.24h-UFC,ACTH and cortisol are measured in the experimental group
41098516|NCT02359838|OTHER|Baseline Geriatric Screening/Assessment|All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
41098517|NCT02359838|OTHER|Geriatrician Co-Management|A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
41098518|NCT04657991|DRUG|Encorafenib|Encorafenib
41098519|NCT04657991|DRUG|Binimetinib|Binimetinib
41098520|NCT04657991|DRUG|Pembrolizumab|Pembrolizumab
41098521|NCT02473562|DRUG|Varenicline|Tablet 1 mg BID
41098522|NCT02473562|DRUG|Placebo (for varenicline)|Tablet 1 mg BID
41098523|NCT02711826|BIOLOGICAL|Polyclonal Regulatory T Cells|Participants randomized to polyTregs group will receive a single infusion of 550 ± 450 x 10\^6 polyTregs.
41098524|NCT02711826|DRUG|Everolimus|
41098525|NCT02711826|DRUG|Tacrolimus|
41098526|NCT02711826|DRUG|Mycophenolate mofetil|All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
41098527|NCT02711826|DRUG|Mycophenolic acid|All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
41098528|NCT02711826|DRUG|Acetaminophen|650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
41098529|NCT02711826|DRUG|Diphenhydramine|25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.
41098530|NCT02711826|PROCEDURE|Biopsy, Kidney|
40924875|NCT03381534|DEVICE|stent assisted angioplasty|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
41098531|NCT02711826|PROCEDURE|Blood Draw|
41098532|NCT02711826|PROCEDURE|Leukapheresis|
41098533|NCT02711826|PROCEDURE|IS regimen conversion|Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
41098534|NCT06631664|OTHER|Traditional physical therapy|Participants received a traditional physical therapy program three times a week, for three successive months. Each session lasted for approximately 30 minutes and composed of the following: 1) Massage (spiral effleurage, longitudinal and transverse thumb effleurage for 5 minutes or until hyperemia), 2) Facilitation of muscle contraction through a variety of tactile and proprioceptive stimulation techniques - this was applied for the shoulder flexors, abductors, and external rotators, elbow flexors, and wrist/finger extensors. In patients whose lesion extend to involve C7, The facilitation techniques were also applied to elbow extensors. 3) Weight-bearing exercise, considering the developmental milestone (prone forearm support, prone full hand support). 4) Range of motion exercises - all joints of the affected side were moved through the full range of motion. 5) Sucking exercise.
41098535|NCT06631664|DEVICE|A computerized electrical stimulator (Vectra®2C; Chattanooga, TS, USA)|"The patient was positioned in supine lying position with the affected arm beside the body and elbow extended, the skin over the anterior and posterior comportment of the upper arm was cleaned using medical cotton sacked in alcohol before the application.~The first two stimulating electrodes for the biceps muscle were placed at the superior and inferior 1/3 of anterior surface of the upper arm with a distance in between the two electrodes at least the size of one of them, while the other two electrodes for the triceps muscle were placed at the superior and inferior 1/3 of the posterior surface of the upper arm.~One millisecond pulse duration and a frequency of 50Hz with a rectangular shaped pulse were utilized and stimulation was applied for 15 minutes. At first a low-intensity current is applied and gradually increased till a gentle contraction of the muscles appears and allow time for the child to become accustomed to the current and maintained sufficient and observable contraction."
41098536|NCT03681691|DRUG|Estradiol patch|transdermal 17β-estradiol patch
41098537|NCT04678934|PROCEDURE|TAVR|Transcatheter aortic valve replacement
41098538|NCT06124118|RADIATION|carboplatin chemotherapy|"Concurrent chemoradiation will be given per standard of care within 24 hours of initiation of standard of care radiation therapy. Treatment will include a paclitaxel/carboplatin chemotherapy regimen administered during the radiotherapy course (over 6-7 weeks).~Paclitaxel (50 mg/m2) will be administered intravenous over 1 hour followed by Carboplatin AUC = 2 mg/min/mL intravenous weekly (every 7 days ± 3 days) during radiotherapy 11, NCCN Non-small cell lung cancer guidelines 2023).~If a patient has a hypersensitivity reaction to weekly paclitaxel, weekly nab-paclitaxel is allowed to replace paclitaxel at the discretion of the treating medical oncologist 37. The recommended starting dose of weekly nab-paclitaxel is 40 mg/m2 to 50 mg/m2 38 39. Standard premedications with steroids, diphenhydramine, H2 receptor antagonist, and 5-HT3 receptor antagonist antiemetics must be administered per individual institutional guidelines."
41098539|NCT06124118|DEVICE|NovoTTF-200T (TTFields) System|"The NovoTTF-200T (TTFields) System is an investigational medical device delivering 150 kHz TTFields to the thorax for the treatment of patients at the age of 22 years or older. The device is a portable, battery operated system which delivers TTFields at 150 kHz to the thorax by means of insulated Transducer Arrays. The NovoTTF-200T produces electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz to the thorax will be continuous for at least 11 hours a day on average, with a recommended duration of at least 18 hours a day. Subjects may take breaks for personal needs (e.g. showering, array exchange). TTFields may be continued as long as there is no disease progression per RECIST 1.1 or any of the treatment discontinuation conditions for subject withdrawal or termination."
41098540|NCT06124118|DRUG|Durvalumab|Consolidation Durvalumab will be given per standard of care and institutional guidelines every 4 weeks for up to 12 cycles. Refer to package insert for detailed pharmacologic, dosing, and safety information.
41098541|NCT04883762|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Undergo FMT via colonoscopy.
41098542|NCT03404336|BEHAVIORAL|Well-Being Therapy|Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.
41098543|NCT03404336|OTHER|Control condition|Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
41098544|NCT06316297|BIOLOGICAL|Acne mRNA vaccine|Pharmaceutical form:Liquid suspension for injection-Route of administration:intramuscular
41098545|NCT06316297|OTHER|Placebo|Pharmaceutical form:Liquid solution for injection-Route of administration:intramuscular
41098546|NCT06140524|DRUG|Linvoseltamab|Administration by intravenous (IV) infusion
41098547|NCT05969860|PROCEDURE|Clinical Encounter|Receive treatment in clinic
41098548|NCT05969860|OTHER|Home Health Encounter|Receive at-home treatment
41098549|NCT05969860|OTHER|Quality-of-Life Assessment|Ancillary studies
41098550|NCT05969860|OTHER|Questionnaire Administration|Ancillary studies
41098551|NCT06627439|BEHAVIORAL|Comadres Saludables|Comadres Saludables is a web-based healthy living training for community health workers aimed at addressing obesity in Latinas. Comadres Saludables will combine both theory and evidence-based practices to provide participants with the self-efficacy, knowledge, and skills required to effectively implement an obesity intervention for Hispanic women. Participants (CHWs) will build their skillset through interactive quizzes, exercises, and video role-playing scenarios. Additionally, Comadres Saludables allows participants to utilize interactive mHealth tools to enhance implementation with Hispanic women. Participants will access the training for three months.
41098552|NCT06627439|BEHAVIORAL|Control|Participants will access the web-based HHS Promoting Healthy Choices and Community Changes that includes a variety of content via text, audio, and video. The information is designed to educate CHWs on how to implement health interventions for positive community change. They are asked to review it for three months.
41098553|NCT06557785|BIOLOGICAL|CH505M5 N197D mRNA-gp160|To be administered intramuscularly as a split dose
41098554|NCT06557785|BIOLOGICAL|CH505 TF mRNA-gp160|To be administered intramuscularly as a split dose
41098555|NCT06631352|OTHER|Hepatopancreatoduodenectomy|Pancreatoduodenectomy with liver resection
41098556|NCT06288152|DRUG|Sodium Thiosulfate|0.15 mL administered
41098557|NCT00994149|DRUG|Diazoxide|10mg/kg/d divide every 8 hours
41098558|NCT00994149|DRUG|Ora-plus|placebo, give every 8 hours.
41098559|NCT05761509|DRUG|Doravirine|The study treatments will used during 28 days according to the routine care of each investigator center.
41098560|NCT04886596|BIOLOGICAL|Placebo|Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV_1 dose group.
41098561|NCT04886596|BIOLOGICAL|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV_annual group.
41098562|NCT06631495|OTHER|Observation|not available-observation study
41098563|NCT06629558|DRUG|Silver Nitrate|bronchoscopic lung volume reduction in management of localized emphysema
41098564|NCT06629558|DRUG|Nano-silver nitrate|bronchoscopic lung volume reduction in management of localized emphysema
41098565|NCT06629558|DEVICE|Bronchoscopic lung volume reduction|bronchoscopic lung volume reduction in management of localized emphysema
41098566|NCT00006421|DRUG|2-Fluorodeoxyglucose|
41098567|NCT03529864|OTHER|Exercise Therapy|
40924876|NCT02639858|DRUG|Docetaxel-PM|Docetaxel PM 75mg/m2 IV infusion
40924877|NCT06046742|BIOLOGICAL|M1-c6v1|Intravenous drip administration
41098568|NCT06226883|DRUG|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
41098569|NCT06226883|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
41098570|NCT03898986|BIOLOGICAL|Live attenuated influenza vaccine (LAIV4)|LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
41098571|NCT03898986|BIOLOGICAL|Inactivated Influenza Vaccine (IIV4)|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
41098572|NCT06630741|OTHER|alternative midwifery units (AMU)|"Alternative midwifery birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative midwifery birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative midwifery birth units named Filière physiologique co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room"
41098573|NCT06225999|DRUG|Irinotecan liposome injection (S095013)|Irinotecan liposome injection (S095013) will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
41098574|NCT06225999|DRUG|Oxaliplatin|Oxaliplatin will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
41098575|NCT06225999|DRUG|LLV (levoisomer form of leucovorin)|LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
41098576|NCT06225999|DRUG|5- FU (5-Fluorouracil)|5-FU will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
41098577|NCT01895517|OTHER|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
41098578|NCT01895517|OTHER|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
41098579|NCT05879978|DRUG|BI 764532|BI 764532
41098580|NCT05879978|DRUG|Ezabenlimab|Ezabenlimab
41098581|NCT02620072|DRUG|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
41098582|NCT02620072|OTHER|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
41098583|NCT06007144|DEVICE|SPIRION Laryngeal Pacemaker System Implantation and follow-up|"Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only~Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives"
41098584|NCT04590651|PROCEDURE|Cataract surgery|Routine phacoemulsification cataract surgery using the Alcon Centurion® device.
41098585|NCT04590651|PROCEDURE|Cataract surgery with extra anterior chamber angle aspiration|Routine phacoemulsification cataract surgery using the Alcon Centurion® device. At the end of the case a one minute extra anterior chamber angle aspiration will be preformed after the removal of the viscoelastic agent.
41098586|NCT06631677|DRUG|Dupilumab|Administered per protocol
41098587|NCT00667693|DEVICE|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
41098588|NCT00667693|DEVICE|Pentax AWS|Intubation with Pentax AWS
41098589|NCT01850992|DEVICE|Active CPAP|Effective CPAP will be administered
41098590|NCT01850992|DEVICE|Sham CPAP|This is placebo CPAP
41098591|NCT03374046|PROCEDURE|Apneic Oxygenation|Supplemental oxygen will be provided via nasal cannula during intubation attempt
40924878|NCT01561898|DRUG|Paliperidone extended-release (JNS007ER)|Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
40924879|NCT00660881|BIOLOGICAL|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
41098592|NCT05903027|DRUG|Rimegepant 75 MG Disintegrating Oral Tablet|Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
41098593|NCT03983343|DEVICE|exofin®|Perineal skin will be closed by adhesive glue - exofin® (Octyl-2-cyanoacrylate).
41098594|NCT06494748|OTHER|Follow up Decision|"0: No need to follow up in Intensive Care Unit~1: Need to follow up in Intensive Care Unit"
41098595|NCT05145413|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
41098596|NCT05145413|DRUG|Placebo|Placebo Capsules
41133233|NCT03827200|DRUG|Ambrisentan|Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
41133234|NCT06456359|DRUG|Signifor|Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).
41098597|NCT06611631|PROCEDURE|Hyaluronic acid pulpotomy|"1. After complete hemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder to reach suitable consistency (1:1 ratio by volume) then gentle condensation in the pulp chamber will be done by a moistened cotton pellet and then the rest of the pulp chamber will be filled by glass ionomer restoration .~2. Tooth will be restored with stainless steel crown."
41098598|NCT06611631|PROCEDURE|mineral trioxide aggregate pulpotomy|"1. After complete hemostasis, MTA+ saline will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of glass ionomer restoration.~2. Tooth will then be restored with stainless steel crown."
41098599|NCT06629753|BEHAVIORAL|Differentiated service delivery model|The differentiated service delivery (DSD) intervention is a clinic-level intervention in which PMTCT clients are differentiated into those who are clinically stable or unstable, with each group offered a different package of services to meet their needs. The DSD model that is being tested in this study is an individual-focused, facility-based model designed for implementation within maternal-child health clinics offering integrated HIV services.
41098600|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 1|Administration of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
41098601|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 2|Administration of concentration 2 of AAV2-hAQP1 via Stensen's duct to each parotid gland
41098602|NCT05926765|OTHER|Placebo|Administration of diluent via Stensen's duct to each parotid gland
41098603|NCT04628494|BIOLOGICAL|Epcoritamab|Following mandatory pre-medication subject will be administered epcoritamab as a subcutaneous injection.
41098604|NCT04628494|DRUG|Investigator's Choice Chemotherapy|Following mandatory pre-medication subject will be administered intravenously either BR or R-GemOx.
41098605|NCT03921489|PROCEDURE|Subchondroplasty|Calcium phosphate mineral compound injected into the bone marrow lesions
41098606|NCT06062017|DIETARY_SUPPLEMENT|Water and Potassium supplementation|All Participants will be given cases of water and instructed to drink at least an extra 1L per day. Additionally, participants will be given 2000 mg of potassium via potassium citrate powder.
41098607|NCT06630728|BEHAVIORAL|Reduced Nicotine Content Cigars|Participants will complete 3 smoking sessions using a different product each session to examine each product's abuse liability
41098608|NCT06630728|BEHAVIORAL|Normal nicotine content cigar|Participants will smoke a normal nicotine content filtered little cigar
41098609|NCT06630728|BEHAVIORAL|Usual brand cigar|Participants will smoke their usual brand filtered little cigar
41098610|NCT00866762|DRUG|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
41098611|NCT06631703|OTHER|Group receiving Oral Colostrum Administiration|Description: Colostrum secreted in the first 3-5 days was oropharyngeal administered to the intervention group by withdrawing 0.2 ml of colostrum to be taken from the mother with the help of an insulin injector every three hours before each feeding meal in accordance with the literature.In the premature infants in the intervention group in which oropharyngeal colostrum was administered, the application was performed as follows: The oropharyngeal colostrum administration technique consists of slowly inserting a sterile 1 mL syringe without a needle with the tip of the syringe into the baby's mouth along the right buccal mucosa (0.1 mL) towards the oropharynx, then moving the syringe towards the inside of the cheeks and on the tongue, and repeating the same procedure on the left buccal mucosa (0.1 mL) without removing it (slow administration in approximately 1 minute). The routine feeding procedure was then continued
41098612|NCT00598013|DRUG|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
41098613|NCT04002830|DRUG|Elelyso|Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
41098614|NCT04910269|BIOLOGICAL|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.
41098615|NCT04910269|OTHER|Placebo|Infusion of 35 milliliters standard isotonic saline
41098616|NCT02541643|DRUG|Elotuzumab|"Elotuzumab will be administered intravenously at a dose of 10mg/kg weekly (Days 1, 8, 15, and 22 of a 4-233k cycle) of the first 2 cycles and every 2 weeks (Day 1 and Day 15) thereafter.~A window of -1 to +3 days is permitted in Cycles 1 and 2. In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be skipped. In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically indicated. If unable to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab continues per the guidance document defined schedule. In addition the following premedication must also be administered 30-90 minutes prior to any elotuzumab:~* H1 blocker: diphenhydramine (25-50mg PO or IV) or equivalent~* H2 blocker: ranitidine (50mg IV) or equivalent~* acetaminophen (650-1000mg PO)"
40924880|NCT02901327|PROCEDURE|Lumbar Stabilisation Exercise|"McGill protocol starting with:~1. 'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each~2. 'curl-up' exercise 10 repetitions with 7 seconds hold each~3. 'side-bridge' exercise 10 repetitions with 7 seconds hold each~4. 'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance."
41098617|NCT06629818|DRUG|Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)|qw cycle 1-2, q2w cycle 3-6, q4w cycle 7-12
41098618|NCT06629818|DRUG|Venetoclax|400mg po qd for 1 year
41098619|NCT06629818|DRUG|Dexamethasone|Dexamethasone 20mg po qw for the first 6 months, then 10mg po qw for the next 6 months
41098620|NCT06629545|OTHER|irrigation activation with PUI|The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device. The power setting of the ultrasonic device was 30% (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 2.5% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 1 mm behind the working length without touching the canal walls.
41098621|NCT06629545|OTHER|irrigation with sonic activation|A suitable-size activator tip (#25/.04) attached to an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA) was inserted into the canal 1 mm short of the working length. 3 ml of 2.5% NaOCl solution was activated in three periods of 20 s (1 ml of 2.5% NaOCl in each cycle). Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
41098622|NCT05092373|BIOLOGICAL|Atezolizumab|Given IV
41098623|NCT05092373|DRUG|Cabozantinib S-malate|Given PO
41098624|NCT05092373|DRUG|Nab-paclitaxel|Given IV
41098625|NCT05092373|PROCEDURE|Tumor Treating Fields Therapy|Receive TTF
41098626|NCT02828683|DEVICE|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)
41098627|NCT02828683|DEVICE|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
41098628|NCT06330064|DRUG|Ifinatamab deruxtecan|Intravenous administration
41098629|NCT06630494|DRUG|Recombinant human thrombopoietin for injection (rhTPO)|Single abdominal subcutaneous injection of the study drug will be given on D1. The administration and follow-up observation period will be 29 days (D1\~D29). Participants may be discharged at D7 at the judgment of the investigator. PK blood samples will be collected from D-1 to D14, tolerance and safety will be observed from D1 to D29, and blood samples for PD and anti-drug antibody (ADA) will be collected from screening to D29. After completion of relevant assessments on D29, participants will be considered as having completed this study.
41098630|NCT04056221|OTHER|Acupuncture|Acupuncture stimulation was done manually, using single-use acupuncture needles that will be inserted on the selected acupoints (R6, E6, E2, Ig4, VC24, TA23, B2) once a week,for 8 weeks, 20 minutes sessions with 12 weeks of follow up.
41098631|NCT04056221|OTHER|Sham acupuncture|The sham acupuncture consists of needles that achieves no skin penetration and are holden on the points by an adhesive pad.
41098632|NCT04143646|BEHAVIORAL|Web-based prevention program|"Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.~In a substudy evaluation of disclosure of genetic risk."
41098633|NCT03426579|DEVICE|NeuroSENSE ®in children|Before induction of anesthesia NeuroSENSE ® monitoring will be applied to all subjects.General anesthesia with dexmedetomidine and remifentanil is titrated based on the evaluation of respiratory clinical signs (cough, spasm, movement) and immobility of the vocal cords. The anesthesiologist performing anesthesia will be blinded for the Wavelet-based Anesthetic Value for Central Venous System (WAVCNS) index assessed by NeuroSENSE ® and will adjust dexmedetomidine according to clinical signs, which is standard of care. Retrospectively data obtained by NeuroSENSE ® will be compared to evaluate whether they are useful in predicting upcoming unwanted airway reflexes.
41098634|NCT05933720|DRUG|Polypeptides|The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.
41098635|NCT05933720|DEVICE|Femoral-popliteal bypass grafting with a synthetic graft above the knee|The patients with undergo an arterial revascularization - Femoral-popliteal bypass grafting with a synthetic graft above the knee
41098636|NCT05933720|OTHER|Routine conservative treatment|The patients will undergo routine conservative treatment as per clinical guidelines (acetylsalicylic acid 100mg daily, atorvastatin 20mg daily)
41098637|NCT05527483|DRUG|[68Ga]PSMA|Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
41098638|NCT05527483|DRUG|Flourine-18 [F-18] Sodium Fluoride (NaF)|Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
41098639|NCT05527483|DIAGNOSTIC_TEST|PET/CT|Patients will receive \[68Ga\]PSMA with a PET/CT and Flourine-18 \[F-18\] Sodium Fluoride (NaF) with a PET/CT
41098640|NCT03631199|DRUG|canakinumab|canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)
41098641|NCT03631199|DRUG|canakinumab-matching placebo|canakinumab placebo every 3 weeks (squamous and non-squamous)
41098642|NCT03631199|DRUG|pembrolizumab|200 mg every 3 weeks (squamous and non-squamous)
41098643|NCT03631199|DRUG|carboplatin|Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)
41098644|NCT03631199|DRUG|cisplatin|75 mg/m\^2 every 3 weeks (non-squamous)
41098645|NCT03631199|DRUG|paclitaxel|200 mg/m\^2 every 3 weeks (squamous)
40924881|NCT02901327|PROCEDURE|treadmill walk exercise|"Bruce protocol~This include:~1. '5 minutes warm up' at zero degree inclination.~2. '20 minutes active exercise with increasing speed and inclination'~3. '5 minutes cool down'"
40924882|NCT03873675|DIAGNOSTIC_TEST|parathyroid hormone|10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
41098646|NCT03631199|DRUG|nab-paclitaxel|100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)
41098647|NCT03631199|DRUG|pemetrexed|500 mg/m\^2 every 3 weeks (non-squamous)
41098648|NCT06628414|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation
41098649|NCT04596579|DIAGNOSTIC_TEST|SARS-CoV-2 Antibody Analysis|10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
41098650|NCT04596579|DIAGNOSTIC_TEST|Weck-cel Swab Collection|A Weck-cel swab will be used to collect secretions from the mucosal epithelium
41098651|NCT04596579|BEHAVIORAL|Web Based Questionnaire|A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
41098652|NCT04011033|BIOLOGICAL|iNKT cells|5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.
41098653|NCT04011033|DRUG|Human recombinated Interleukin-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
41098654|NCT04011033|PROCEDURE|TAE/TACE|TAE/TACE will be conducted to all patients at 0th week and 4th week.
41098655|NCT05995574|BEHAVIORAL|avatar communication training|Avatar simulates a mother and a daughter for the pediatrician to practice communication about contraception.
41098656|NCT04004702|DRUG|Levetiracetam|Levetiracetam 500mg twice a day
41098657|NCT06174896|PROCEDURE|Group 1|The LMA Proseal will be inserted directly by hand, without the use of any laryngoscope, as recommended in the instruction manual. The cuff will be gently guided along the hard palate where it is pushed into the hypopharynx and increased resistance is felt, and the cuff will be placed towards the hypopharynx.
41098658|NCT06174896|PROCEDURE|Group 2|Appropriately sized laryngoscope blade will be used and after the location of the epiglottis is determined, the tongue and epiglottis will be lifted forward. Then, LMA Proseal will be placed at the point where resistance is felt at a level where the proximal edge of the mask can be seen.
41098659|NCT06174896|PROCEDURE|Group 3|After the video laryngoscope is placed with an appropriately sized blade, the location of the epiglottis and vocal cords will be determined and the LMA Proseal will be placed at the point where slight resistance is encountered after the epiglottis is lifted. proximal aspect of LMA
41098660|NCT00580801|DRUG|Telaprevir|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.
41098661|NCT00580801|DRUG|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
41098662|NCT00580801|DRUG|Placebo|Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
41098663|NCT00580801|DRUG|Ribavirin|Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
41098664|NCT05233137|BEHAVIORAL|PA coaching|PA coaching: Patients receive a step counter together with a coaching application (m-PAC, AppsOnly, KU Leuven) installed on a smartphone. The step counter and coaching application are connected via Bluetooth. The coaching application has the goal of PA promotion as well as detecting any new AECOPD.
41098665|NCT05233137|OTHER|Exercise training|"Each session will include at least the following components:~* Resistance training of the lower limbs: Exercises for 6 muscle groups using minimal (e.g. ankle weights or elastic resistance bands) or no (body weight) equipment are foreseen. Each exercise will be performed in 3 series of 8 repetitions.~* Functional training: Sit to stand exercise and stair climbing. During the first 2 weeks of the exercise training program, at least 3 strength exercises and 1 functional exercise will be performed each session.~Starting from the 3rd week of the exercise training program, whole body exercise training (interval training for walking, cycling, stair climbing and high knees) will be added. From this moment on, at least 1-2 whole body exercises and 2-3 strength and functional exercises will be performed during each physiotherapy session. By doing this, each session will consist of a minimum of 4 exercises in total."
41098666|NCT06118736|PROCEDURE|Temporary Medial Hemi-epiphysiodesis of the proximal femur|Temporary Medial Hemi-epiphysiodesis of the proximal femur
41098667|NCT06077968|BIOLOGICAL|Prior standard of care receipt of Pfizer's ABRYSVO vaccine|Participants will receive Pfizer's ABRYSVO vaccine as part of standard of care. Vaccine is not administered in this study.
41098668|NCT03597321|BIOLOGICAL|prophylactic donor lymphocyte infusion (DLI)|DLI will be collected from the donor by leukapheresis according to local standard procedures of each center. Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines. A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI. DLI procedure will be performed according to local guidelines of each center.
41098669|NCT00713739|DRUG|Alfuzosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
41098670|NCT00713739|DRUG|nifedipine|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
41098671|NCT00713739|DRUG|doxazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
41098672|NCT00713739|DRUG|prazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
41098673|NCT05976243|DRUG|Remibrutinib|Remibrutinib treated groups and arms
41098674|NCT05976243|OTHER|Placebo|Placebo treated groups and arms
41098675|NCT05905289|OTHER|observational study|no intervention as it is an observational study
40924883|NCT02647450|OTHER|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
41098676|NCT06628570|DIAGNOSTIC_TEST|HRA + Biopsy|High-Resolution Anoscopy, or HRA, is a standard of care procedure for screening and detection of premalignant lesions of the anus. Using a small, thin round tube called an anoscope, the anal canal is examined with a high-resolution magnifying instrument called a colposcope. The application of a mildly acidic liquid on the anal canal facilitates the evaluation of abnormal tissue such as anal dysplasia. Biopsies for histological confirmation of disease will be taken. Biopsies' reporting will follow the terminology, criteria, and recommendations of the Lower Anogenital Squamous Terminology (LAST) project. Histology results will be reported as benign, condyloma acuminatum, AIN grades 1-3, or cancer. For the proposed project, aHSIL+ will be defined as AIN2 (p16 block-positive), AIN3, and cancer at the HRA encounter. All other cases will be classified as \<aHSIL, including benign, condyloma acuminatum, and AIN1
41098677|NCT06628570|DIAGNOSTIC_TEST|Anal Cytology|Anal cytology collection (swab samples) will be performed as part of the standard of care during this study. The collected cells, suspended in the SurePath liquid-based medium, will be placed on a slide and microscopically examined by a board-certified pathologist. The sample will then be interpreted using the Bethesda System: negative for intraepithelial lesion or malignancy (NILM), ASCUS, LSIL, ASC-H, or HSIL. Pathologists interpreting the anal cytology will be blinded from hrHPV testing and biopsy histology.
41098678|NCT06628570|DIAGNOSTIC_TEST|Genotyping of anal hrHPV infection|Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. To identify the infecting HPV genotype, DNA will be extracted from swab samples collected with the MagNA Pure LC DNA Isolation Kit III and an LC MagNA Pure system (Roche Diagnostics GmbH, Mannheim, Germany), followed by HPV typing using the TypeSeq assay, a laboratory prepared high-throughput next-generation sequencing assay developed by NCI will be performed as described. The assay uses three sequential PCR steps resulting in barcoded L1 amplicons sequenced and submitted to a bioinformatics pipeline for typing. This TypeSeq assay qualitatively detects and identifies 51 HPV genotypes (HPV types 3, 6, 11, 13, 16, 18, 26, 28, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 97, and 114), including 14 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68)
41098679|NCT06628570|DIAGNOSTIC_TEST|CINtec®PLUS|Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. Dual immunostaining with p16/Ki-67 will be performed on the residual cytologic specimen by Roche MTM Laboratories (Heidelberg, Germany), using the CINtec®PLUS Kit according to the manufacturer's instructions. The anal cytology material will be stained with a mouse monoclonal antibody directed against human p16INKa (p16) protein (clone E6H4) and recombinant rabbit monoclonal antibody directed against human Ki-67 protein (clone 274-11AC3V1), using the BenchMark ULTRA instrument (Ventana Roche). Samples with insufficient cellularity will be excluded from the evaluation. A trained cytotechnologist will review all cases for cells staining positively with both markers. A slide will be considered positive if 1 or more squamous epithelial cell(s) stained positive for both p16 and Ki-67 and dual stain-positive cells will be semi-quantitatively assessed (0, 1, 2-5, 6-50, \>50).
41098680|NCT06555575|DRUG|Ubiquinone 200 Mg Oral Capsule|By mouth three times daily for three months
41098681|NCT06555575|DRUG|Ubiquinol 100 MG Oral Capsule|By mouth three times daily for three months
41098682|NCT06631989|DRUG|WSD0922-FU|"Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO"
41098683|NCT03274102|BIOLOGICAL|Concomitant administration of EV71 vaccine with EPI vaccines|"1. The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
41098684|NCT03274102|BIOLOGICAL|Single injection of EPI vaccine|"1. The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
41098685|NCT03274102|BIOLOGICAL|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
41098686|NCT04371718|DRUG|JKB-122|JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
41098687|NCT04371718|OTHER|Placebo|A capsule has same component but active drug
41098688|NCT05750095|BEHAVIORAL|Incredible Years Autism Spectrum and Language Delay Programme|Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
41098689|NCT05750095|BEHAVIORAL|First Aid for Parents|"First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders"
41098690|NCT06250816|OTHER|The hospital gown with cartoon characters|The patient will be asked to choose one of the hospital gowns with cartoon characters they want to wear and put it on with parental assistance.
41098691|NCT04109118|BEHAVIORAL|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is a psychosocial intervention. It is paired with a benzodiazepine taper. The aim of the psychosocial intervention is to improve individuals' ability to tolerate distress in order to assist benzodiazepine discontinuation in patients treated with OAT. There will be 5 sessions between therapist and participant prior to the start of the benzodiazepine taper. The taper for both the intervention and control conditions occurs over 9 weeks and involves weekly meetings with a benzodiazepine prescriber during which a gradual benzodiazepine dose reduction will take place. The DT-BD intervention combines elements of existing psychosocial interventions. Specifically, interoceptive exposure techniques will be paired with elements of acceptance and commitment therapy (ACT) and relapse prevention (RP).
41098692|NCT04109118|DRUG|BZD discontinuation protocol|All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 9 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
41098693|NCT02155829|DRUG|Riluzole|
41098694|NCT02155829|DRUG|Placebo (for Riluzole)|
41098695|NCT01582945|DRUG|Ketamine|Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
41098696|NCT01711918|DRUG|Domperidone|oral tablet; dose is 10mg per tablet given up to 3 times daily.
41098697|NCT00002620|DRUG|carmustine|
41098698|NCT00002620|DRUG|chemotherapy|
41098699|NCT00002620|DRUG|mitolactol|
41098700|NCT00002620|RADIATION|low-LET cobalt-60 gamma ray therapy|
41098701|NCT00002620|RADIATION|low-LET photon therapy|
41098702|NCT03997123|DRUG|Capivasertib|400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.
41098703|NCT03997123|DRUG|Paclitaxel|80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
41098704|NCT03997123|DRUG|Placebo|Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
41098705|NCT06501079|PROCEDURE|ultrasound guided Erector Spinae Plane Block using 27ml bupivacaine 0.25%|"ESP block will be performed U/S at the level of T 10 paraspinal level. The ultrasound transducer should be placed in the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level.~Erector spinae muscle should be identified superficial to the transverse process. The needle inserted superior to the ultrasound probe in the cephalad to caudal direction. Once the needle tip is below the erector spinae muscle.~This separation from the transverse process confirms the proper needlemposition.~The local anesthetic should then be injected in 5 ml increments. The block will be performed preoperatively."
41098706|NCT05819190|DEVICE|Healsea Rescue*|Subjects will be administered with Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
41098707|NCT05819190|DEVICE|Placebo|Subjects will be administered with isotonic saline nasal spray indistinguishable from the Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
41098708|NCT03677154|DRUG|Mosunetuzumab Intravenous (IV)|Participants in cohorts A and B will receive IV mosunetuzumab.
41098709|NCT03677154|DRUG|Mosunetuzumab Subcutaneous (SC)|Participants in Cohort C will receive SC mosunetuzumab.
41098710|NCT03677154|DRUG|Polatuzumab Vedotin|Participants in Cohort C will receive IV polatuzumab vedotin.
41098711|NCT03677154|DRUG|Tocilizumab|Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
41098712|NCT02451943|DRUG|Olaratumab|Administered IV
41098713|NCT02451943|DRUG|Doxorubicin|Administered IV
41098714|NCT02451943|DRUG|Placebo|Administered IV
41098715|NCT06630975|DEVICE|Hemiepiphysiodesis|8 plate
41098716|NCT06630975|PROCEDURE|Eight-Plates first described by Stevens are simple to use|fewer complications in terms of implant loosening and fracture can be expected.Good results as well as low rebound and complication rates have been recorded
41098717|NCT06630975|DEVICE|Hemiepiphysiodesis by eight Plate|Extraperiosteal eight plate insertion
41098718|NCT02108054|DEVICE|7T MRI|Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation
41098719|NCT05256381|DRUG|Nanrilkefusp Alfa|Subcutaneous (SC) injection.
41098720|NCT05256381|DRUG|Pembrolizumab|Intravenous (IV) infusion via peripheral or central venous line.
41098721|NCT06631170|DRUG|Roflumilast Cream 0.15%|Roflumilast cream 0.15% is applied once daily for 4 weeks
41098722|NCT06631170|DRUG|Vehicle cream|Vehicle cream is applied once daily for 4 weeks
41098723|NCT00612001|BIOLOGICAL|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
41098724|NCT03315507|DRUG|PB1046 Subcutaneous Injection|Eight weekly doses of PB1046.
41098725|NCT04443153|DEVICE|Personalized Feedback|Provides tailored information to the user about what glycemic risk they may be facing as well as how glycemic control and system use looked in the past week. Treatment decision and therapy changes are entirely left to the decision of the user.
41098726|NCT04443153|DEVICE|Decision Support System|CGM-based system that includes Personalized Feedback (PF) and further assists with treatment recommendations for common metabolic challenges
41098727|NCT04443153|DEVICE|Sensor Augmented Mode|A mode in Diabetes Assistant (DiAs) that combines Diabetes Assistant, Insulin pump or Multiple Daily Injections, CGM, ketone meters, and glycemic treatment guidelines together to manage diabetes.
41098728|NCT05586321|BIOLOGICAL|GEN1056|GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1.
41098729|NCT05986149|BEHAVIORAL|Conversation about arts and culture|intergenerational conversation about arts and culture between older adults and international students who native language is not English.
41098730|NCT00100659|DRUG|Pegylated Interferon/ribavirin|
41098731|NCT04618913|DRUG|Apixaban|Anticoagulant
41098732|NCT04618913|DRUG|Rivaroxaban|Anticoagulant
41098733|NCT04618913|DRUG|Edoxaban|Edoxaban
41098734|NCT04618913|DRUG|Dabigatran|Dabigatran
40752080|NCT01077895|PROCEDURE|ultrafiltration|"ultra filtration is started at 100 mL/h and increased according to following protocol~* Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:~* Vasopressor or inotrope medication dose is increased by \> 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)~* When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV \> 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h~* If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued."
41098735|NCT04618913|DRUG|VKA|Vitamin K antagonist
41098736|NCT04618913|DRUG|LMWH|Low Molecular Weight Heparin
41098737|NCT06264830|DEVICE|Alcon-NGENUITY®(NG)-system|During operation, the Alcon NGENUITY® (NG) System is mounted on microscope, while the surgeon will wear 3D glasses, watch 3D screen, and perform operation
41098738|NCT06264830|PROCEDURE|Standard cataract operation|Standard, modern cataract extraction with standard phacoemulsification technique, and posterior chamber intraocular lens implantation.
41098739|NCT05658562|DRUG|MT-2111|i.v. infusion
41098740|NCT03172208|BIOLOGICAL|Caplacizumab Dose 1 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 1
41098741|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 2
41098742|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 sc (single-dose)|Single subcutaneous (sc) administration of Caplacizumab Dose 2
41098743|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 sc (multiple-dose)|Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
41098744|NCT03172208|OTHER|Placebo iv (single-dose)|Single intravenous (iv) administration of Placebo
41098745|NCT03172208|OTHER|Placebo sc (single-dose)|Single subcutaneous (sc) administration of Placebo
41098746|NCT03172208|OTHER|Placebo sc (multiple-dose)|Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
41098747|NCT06630897|OTHER|Text Messages|small amounts of digital support will be in the form of text messages
41098748|NCT04599946|DIETARY_SUPPLEMENT|Infant formula and follow-on formula made from whole goat milk|Infant formula and follow-on formula made from whole goat milk
41098749|NCT04599946|DIETARY_SUPPLEMENT|Infant formula and follow-on formula made from cow's milk ingredients|Infant formula and follow-on formula made from cow's milk ingredients
41098750|NCT02812966|DEVICE|Lutonix|Drug Coated Balloons
41098751|NCT02812966|DEVICE|IN.PACT|Drug Coated Balloons
41098752|NCT06410508|OTHER|Just Do You|"As described in further detail previously, the experimental intervention is a brief psychotherapeutic intervention informed by principles of CBT and motivational interviewing that is co-delivered by a mental health clinician and peer support worker. This intervention will be a version of the initial intervention delivered in the Just Do You trial by Munson et al.(2022), adapted for increased suitability with our clinical population."
41098753|NCT05048355|DEVICE|Power Knee Mainstream Dynamic|Powered Microprocessor controlled prosthetic knee. The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face.
41098754|NCT05048355|DEVICE|Passive microprocessor controlled knee|Any passive microprocessor controlled prosthetic knee on the market
41098755|NCT04504903|BEHAVIORAL|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will go to 12 weekly group sessions and will learn healthy thinking about work, positive behavioral coping related to work, and will form a work success plan based on their work goals.
40752081|NCT01077895|PROCEDURE|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
41098756|NCT04504903|BEHAVIORAL|Psychoeducation|Veterans will go to 12 weekly group sessions and will learn more information about their mental health conditions. Psychoeducation modules are from the Illness Management and Recovery program.
41098757|NCT01943162|BEHAVIORAL|CPT|
41098758|NCT03321539|DRUG|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.
41098759|NCT03321539|DRUG|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles 4 weeks after radiotherapy.
41098760|NCT05384132|OTHER|SRP + Livfresh Dental Gel|SRP at baseline with use of LDG (test dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use LDG as their primary dentrifice (toothpaste) for the next 6 months. They're instructed to use LDG twice daily with toothbrushing for 2 minutes. LDG in previous studies have been reported to be superior to conventional over-the-counter toothpaste in terms of reducing bacterial plaque and gingival inflammation due to its EDTA (ethylenediaminetetraacetic acid) ingredient. EDTA prevents adhesion of bacterial plaque to teeth.
41098761|NCT05384132|OTHER|SRP + standard flouride dentifrice|SRP at baseline with use of standard fluoride dentifrice (control dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use standard fluoride toothpaste (commercial over-the-counter toothpaste) as their primary dentrifice (toothpaste). They're instructed to use standard fluoride toothpaste twice daily with toothbrushing for 2 minutes.
41098762|NCT05403307|BIOLOGICAL|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
41098763|NCT05403307|BIOLOGICAL|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
41098764|NCT04118374|OTHER|Standard Carb Diet|Approximately 50% of caloric intake will come from carbohydrate consumption.
41098765|NCT04118374|OTHER|Low Carb Diet|Approximately 25% of caloric intake will come from carbohydrate consumption.
41098766|NCT04663399|OTHER|Prospective patient|The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.
41098767|NCT05181449|BEHAVIORAL|Twin Precision Treatment|Combination of Artificial Intelligence algorithms based on daily sensor input and live nutrition, exercise, sleep and breath coaching to help treat type 2 diabetes
41098768|NCT04159948|DIETARY_SUPPLEMENT|Carbohydrate drink|"This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes."
41098769|NCT05676294|DRUG|Olanzapine|5 mg of oral olanzapine one hour prior to ambulatory surgery
41098770|NCT05676294|DRUG|Placebo|oral matched placebo one hour prior to ambulatory surgery
41098771|NCT01901770|OTHER|educational intervention|Receive HPV vaccination educational materials
41098772|NCT01901770|OTHER|educational intervention|Receive influenza vaccination educational materials
41098773|NCT05868226|DRUG|ALX148|CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPα) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.
41098774|NCT05868226|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor
41098775|NCT05868226|DRUG|Zanidatamab|Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
41098776|NCT05868226|DRUG|Tucatinib|Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).
41098777|NCT06631261|OTHER|No intervention; Observational study|No intervention
41098778|NCT00346931|PROCEDURE|Phacoemulsification, implantation of intraocular lens|
41098779|NCT00346931|PROCEDURE|Phacoemulsification, Implantation of IOL, trabeculotomy|
41098780|NCT03982199|BIOLOGICAL|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.
41098781|NCT03982199|BIOLOGICAL|Placebo|Participants will receive a single IM injection of placebo control on Day 1.
41098782|NCT02901821|GENETIC|salivary RNA collection|collection of saliva for microRNA (small noncoding RNA) processing
41098783|NCT04985487|OTHER|brolucizumab|Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
41098784|NCT06540287|OTHER|Observational|No intervention
41098785|NCT00781612|DRUG|Docetaxel|Docetaxel will be administered as per local prescribing information.
41098786|NCT00781612|DRUG|Paclitaxel|Paclitaxel will be administered as per local prescribing information.
41098787|NCT00781612|DRUG|Pertuzumab|Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
41098788|NCT00781612|DRUG|Trastuzumab|Trastuzumab will be administered as per local prescribing information.
41098789|NCT00781612|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
41098790|NCT00781612|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)
41098791|NCT01599325|DRUG|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m\^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
41098792|NCT05553041|DRUG|18F-Fluciclovine PET-MRI|18F-Fluciclovine will be injected via IV prior to Positron emission tomography (PET)-Magnetic resonance imaging (MRI)
41098793|NCT06629337|GENETIC|H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)|Subjects ingested fexofenadine (540 mg, tablet) at least 50 minutes before and famotidine (40 mg, tablet) 1 hour 50 minutes before the onset of each protocol because these dose of oral fexofenadine and famotidine reaches its peak concentration at around 1 h and 2 h, respectively
41098794|NCT04388488|DEVICE|CONNECT TF adaptable socket system|Prefabricated, adaptable socket system
41098795|NCT04388488|DEVICE|Any conventional handmade socket|Subjects current socket
41098796|NCT01007149|DRUG|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
41098797|NCT01007149|DRUG|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
41098798|NCT02089243|PROCEDURE|Vagus nerve stimulation therapy|The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.
41098799|NCT02089243|PROCEDURE|Resective surgery|The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
41098800|NCT06391242|RADIATION|Standard Conventional Radiotherapy|20Gy in 5 fractions
41098801|NCT06391242|RADIATION|Stereotactic Body Radiotherapy|30 or 35Gy in 5 fractions
41098802|NCT05266352|OTHER|Supervised exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises under control of the physiotherapist in the clinic."
41098803|NCT05266352|DIAGNOSTIC_TEST|Home exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises at home. Patients will visit the clinic every 2 weeks and progression of exercise program will be made."
41098804|NCT02521844|DRUG|ETC-1922159|Oral administration
41098805|NCT02521844|DRUG|Pembrolizumab|IV administration
41098806|NCT03916614|BEHAVIORAL|Screening Tool for Relief of Trauma (START)|The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,\[30\] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
41098807|NCT03916614|BEHAVIORAL|standard of care|Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
41098808|NCT06611163|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter
41098809|NCT06611163|DRUG|Placebo|Placebo SC injection at Day 1 and Week 4
41098810|NCT06489171|PROCEDURE|Received laparoscopic-assisted vaginal radical trachelectomy|"The LAVRT procedure began with laparoscopic pelvic lymphadenectomy, and all lymph nodes were removed for frozen pathological analysis. The laparoscopic-assisted vaginal radical trachelectomy procedure was continued only if the nodes were negative. The pararectal pouch was revealed, and the uterine arteries were divided from their origin to the internal iliac artery. The ureters were freed from the posterior leaf of the broad ligament down to the level where they entered the ureteral tunnel and then displaced laterally. The uterosacral ligaments, cardinal ligaments, and parametrial portions were then divided and dissected. The section of the procedure was performed laparoscopically. The vaginal epithelium was circumferentially incised approximately 3 cm distal to the endocervix. Frozen section analysis confirmed no cancer involvement at the endocervical or vaginal margin. The vaginal mucosa was sutured to the cervical stump to form a new cervical os."
41098811|NCT02132702|DEVICE|Ekso|
41098812|NCT05700539|BEHAVIORAL|Internet-based cognitive behavioral therapy|A ten-week treatment based on cognitive behavioral therapy for ADHD, including two mandatory modules and at least four self-selected modules (out of ten available modules). The treatment consists of reading material and exercises to be completed each week.
41098813|NCT06361940|DRUG|Aromatase inhibitors or tamoxifen|Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status.
41098814|NCT01366196|DRUG|Pregabalin 150 mg|Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
41098815|NCT01366196|DRUG|Placebo|Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
41098816|NCT02781584|DRUG|SEL|Administered orally once daily
41098817|NCT02781584|DRUG|FIR|Administered orally once daily
41098818|NCT02781584|DRUG|CILO|Administered orally once daily
41098819|NCT02781584|DRUG|FENO|Administered orally once daily
41098820|NCT02781584|DRUG|VAS|Administered orally two times daily
41098821|NCT04858425|DRUG|Niclosamide|Niclosamide tablets 400 mg 3 times daily for 14 days
41098822|NCT04858425|DRUG|Placebo|Matched placebo tablets 400 mg 3 times daily for 14 days
41098823|NCT06629402|DRUG|PF614|Experimental oxycodone prodrug
41098824|NCT06629402|DRUG|Placebo|Inactive medication
41098825|NCT06629480|DRUG|Bictegravir|The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir based-regimen. A randomized open clinical trial was developed with men PLH who started ART randomized to BIC/FTC/TAF or DTG/3TC/ABC.
41098826|NCT03573362|DEVICE|ViziShot FLEX 19G needle|EBUS-TBNA using the ViziShot FLEX 19G needle
41098827|NCT03573362|DEVICE|Vizishot 22G needle (standard)|EBUS-TBNA using the Vizishot 22G needle (standard)
41098828|NCT02805244|DRUG|JTZ-951, 14C-JTZ-951|
41098829|NCT03148938|OTHER|Digital Assessment on mobile|"The digital assessment is composed on 4 tests:~* walking test~* coordination test~* attention test~* vision test"
41098830|NCT06031441|DRUG|RO7566802|RO7566802 solution for infusion will be administered as specified in each treatment arm.
41098831|NCT06031441|DRUG|Atezolizumab|Atezolizumab solution for infusion will be administered as specified in each treatment arm.
41098832|NCT05929807|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
41098833|NCT05198089|OTHER|Internet-Based Intervention|Use MyInspiration website
41098834|NCT05851417|DEVICE|Fast Field-Cycling (FFC) imaging|FFC scan
41098835|NCT03404843|DRUG|Fasudil Hydrochloride|10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.
41098836|NCT03404843|OTHER|Saline|100 mL saline bag.
40752082|NCT01052428|DRUG|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
41098837|NCT04458831|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
41098838|NCT04458831|DRUG|Pomalidomide|Pharmaceutical form: oral
41098839|NCT04458831|DRUG|Dexamethasone|Pharmaceutical form: oral
41098840|NCT04458831|DRUG|Carfilzomib|Pharmaceutical form: solution for infusion
41098841|NCT04579510|BIOLOGICAL|Novel monovalent oral poliovirus vaccine type 2 (nOPV2)|nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells. To improve genetic stability, nucleotide sequence modifications were made in the major determinant for attenuation in the Sabin 5'-untranslated region. Additionally, two modifications in the polymerase 3D were made to further improve stability of the attenuation, and a key replication element from the 2C coding region was relocated to the 5'-untranslated region to inhibit recombination.
41098842|NCT04579510|BIOLOGICAL|Bivalent oral poliovirus vaccine (bOPV)|The live types 1 \& 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 \& 3 attenuated Polio viruses (Sabin strains).
41098843|NCT02454907|OTHER|Communication with the clinic|Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
41098844|NCT06631937|OTHER|Human Milk Oligosaccharides|Human Milk Oligosaccharides provided in a commercially available infant formula powder, fed daily ad libitum from enrollement to 6 months of age
41098845|NCT06631937|OTHER|Placebo|An identical commercially available infant formula powder without Human Milk Oligosaccharides, fed daily ad libitum from enrollement to 6 months of age
41098846|NCT02759744|DEVICE|ultrasound image-guided ablation device|ultrasound image-guided focal ablation - may be either laser ablation or cryotherapy
41098847|NCT06631599|OTHER|Physical training|The intervention consisted of physical exercise according to various protocols
41098848|NCT03719209|OTHER|HealthVoyager|HealthVoyager is a virtual reality application that allows providers to create customized representations for patients and share the results of endoscopic procedures via an interactive platform. The app can show both normal and abnormal endoscopic findings and anatomy. Families will also receive a web link so that they may access the procedure results via the app at home on their smartphone or tablet.
41098849|NCT03719209|OTHER|Standard Practice|Patients and families will receive handouts with printed images of their endoscopic findings, as per standard practice at Boston Children's Hospital.
41098850|NCT01231282|OTHER|diffusion-weighted MRI|MRI scan without contrast administration and without radiation exposure
41098851|NCT00186680|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
40924884|NCT01566214|BEHAVIORAL|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
40924885|NCT01901796|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
40924886|NCT01484288|DEVICE|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
41098852|NCT04417712|DEVICE|KONAR-MF™ VSD Occluder|All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).
41098853|NCT02197871|DIETARY_SUPPLEMENT|enteral nutrition emulsion|The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
41098854|NCT06171789|DRUG|PRO1107|Intravenous infusion of PRO1107
41098855|NCT05275842|BEHAVIORAL|Cognitive Processing Therapy- Lifesteps (CPT-L)|"CPT-L is designed to help people with HIV and PTSD take their medications as prescribed. Cognitive Processing Therapy (CPT) uses education and cognitive training to help individuals identify thoughts and feelings about their trauma and gives them tools to help them change unhelpful beliefs. Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will receive a 12-session Cognitive Processing Therapy-Lifesteps (CPT-L) treatment program at the Ryan White clinic. The CPT-L program will be delivered twice a week for 6 weeks. Each session last about 90-minutes."
41098856|NCT05275842|BEHAVIORAL|Lifesteps|"Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will complete one Lifesteps education session. This session lasts about 60 minutes. Participants may attend this session either in-person or over the internet if they have an internet ready device with audio."
41443226|NCT06560372|PROCEDURE|Additional realization of a brain perfusion scan sequence which would allow the radiological diagnosis of CV|"Neurological monitoring by daily TCD will be carried out.~* If monitoring finds, between 3rd and 12th day of treatment, a neurological deterioration or an uncontrolled increase in intracranial pressure, a new cerebral CT scan will be performed, as recommended in such a case.~* As part of this research, a specific interventional act will be implemented: additional brain perfusion scan sequence which would allow the radiological diagnosis of CV.~* Interventions related to improving cerebral perfusion and reducing intracranial pressure recommended in head trauma patients will be implemented without modification of management linked to protocol.~The additional perfusion sequences will be analyzed independently and blindly by 2 experienced interventional neuroradiologists (double reading blinded to the patient's characteristics)."
41443227|NCT06561594|DRUG|recombinant human follicle-stimulating hormone-CTP Fusion protein injection|IF Weight \> 60kg，150ug, H. Administer the drug once every 14 days for 64 weeks；IF Weight \>≤60kg，100ug, H. Administer the drug once every 14 days for 64 weeks
41443228|NCT06561594|DRUG|recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo|0.5ml, H. Administer the drug once every 14 days for 64 weeks
40924887|NCT03539809|DIETARY_SUPPLEMENT|L-Amino Acids|6 different ratios of the Branched-chain Amino Acids (BCAA) will be tested for 8 hours each.
41443229|NCT04916548|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
41443230|NCT05350072|BIOLOGICAL|VAY736|ianalumab s.c.
40924888|NCT01446614|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
40924889|NCT02977182|OTHER|Complete Decongestive Therapy (CDT)|CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
40924890|NCT05922670|BEHAVIORAL|The Behavioral Health-Works Suicide Prevention Program for Sexual and Gender Minority Youth|BH-Works is a web-based, comprehensive program for suicide prevention. The BH-Works program is a systems-level intervention that provides tools and resources to make organization adoption more feasible.
41098857|NCT05975554|DRUG|Interleukin-2 [IL-2]|5 sequential days of treatment (1.5MIU/day subcutaneously)
41098858|NCT05975554|PROCEDURE|Standard care - Carotid Endarterectomy|Standard care for patients with carotid stenosis undergoing carotid endarterectomy
41443231|NCT05350072|OTHER|Placebo|placebo s.c.
41443232|NCT05226702|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
41098859|NCT06631898|OTHER|SaaTwae Bio-Natural Moisturizing Cream|A 0.04 gm of test products along with controls (negative and positive) will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
41098860|NCT04962100|OTHER|Analysis of capacitation-associated tyrosine phosphorylation in human sperm by flow cytometry|"After the assessment of the macroscopic and microscopic characteristics of the sample, we will wash the sample and process it using three layers of density gradients.~In the case of samples for diagnostic analysis, the remaining volume will be incubated in at 37ºC, and 0.1-0.2 ml aliquots will be taken from the end of the processing at t0 (just before introducing the sample in the incubator), at t1 (after one hour of incubation) and at t3 (after 3 hours of incubation). Additionally, a sample will be taken after washing, prior to processing the sample with the density gradients. In the case of samples processed for insemination, an additional aliquot will be taken at the exact moment in which the insemination is carried out and the elapsed incubation time will be noted.~The evaluation of the capacitation will be carried out by analyzing the state of phosphorylation of tyrosines by flow cytometry."
41098861|NCT06475599|DRUG|Anlotinib hydrochloride capsule + TQB2450 injection|"Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time.~TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response."
41098862|NCT06475599|DRUG|Chemotherapy drug|Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.
41098863|NCT02851030|BEHAVIORAL|Move, Play, Learn!|Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
41098864|NCT03985579|OTHER|Kinesiology taping application|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
41098865|NCT04244591|DRUG|methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
41098866|NCT04244591|OTHER|Standard care|Standard care
41098867|NCT06628583|OTHER|Magnetic Resonance Imaging with Contrast|The study was retrospective and did not set interventions
41098868|NCT05397496|BIOLOGICAL|PIT565|Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
41098869|NCT06630117|BIOLOGICAL|V330|Intramuscular injection
41098870|NCT06630117|BIOLOGICAL|Placebo|Intramuscular injection
41098871|NCT04201119|DEVICE|Oxiris|Oxiris membrane used on the Prismaflex device (Baxter) dedicated to that type of membrane at blood pump flow of 450 ml min-1
41098872|NCT05365607|DEVICE|NightWare|A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
41098873|NCT05365607|DEVICE|Sham NightWare|NightWare device will not deliver an intervention (i.e., no vibration)
41098874|NCT03124108|DRUG|Elafibranor 80 mg|Two coated tablets daily for 12 weeks
41098875|NCT03124108|DRUG|Elafibranor 120 mg|Two coated tablets daily for 12 weeks
41098876|NCT03124108|DRUG|Placebo|Two coated tablets daily for 12 weeks
41098877|NCT01107626|DRUG|Paclitaxel|Given IV
41098878|NCT01107626|DRUG|Carboplatin|Given IV
41098879|NCT01107626|BIOLOGICAL|Bevacizumab|Given IV
41098880|NCT01107626|DRUG|Pemetrexed Disodium Heptahydrate|Given IV
41098881|NCT04708743|DIAGNOSTIC_TEST|Automatic Tongue Diagnosis System|tongue image capture tongue images by Automatic Tongue Diagnosis System
41098882|NCT03365609|DRUG|triple therapy|Omeprazole+Amoxicillin+Clarithromycin
41098883|NCT03365609|DRUG|sequential therapy|the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole
41098884|NCT03365609|DRUG|bismuth quadruple therapy|Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate
41098885|NCT03365609|DRUG|concomitant therapy|Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
41098886|NCT05759819|DEVICE|Standard stenting|The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.
41133235|NCT00369460|OTHER|physiologic testing|Weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
41133236|NCT01641900|DRUG|eszopiclone|3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
40752083|NCT01052428|DRUG|Placebo|Placebo 100 mg once a day for 2 years
40924891|NCT03441217|DRUG|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).
41098887|NCT02622230|DRUG|Mianhuahua Flavonoids Tablets|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)"
41098888|NCT02622230|DRUG|Placebo|Placebo to match with experimental groups
41098889|NCT06219785|DEVICE|Low-Intensity Shockwave therapy (LiSWT)|Participants will receive once-a-week LiSWT treatments of 0.2 mJ/ mm² over the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis once a week for six weeks, with a total of 6 treatments once a week.
41098890|NCT04655118|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.
41098891|NCT04655118|DRUG|Placebo|Placebo to match TL-895
41098892|NCT05515770|DRUG|Cabotegravir Injection|Long action cabotegravir injection
41098893|NCT02637544|OTHER|acupuncture|classical acupuncture therapy
41098894|NCT02543216|DIETARY_SUPPLEMENT|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
41098895|NCT05567159|DRUG|Donanemab|Administered IV.
41098896|NCT06631651|PROCEDURE|Brachioradialis release|During distal radius fracture surgery (open reduction+internal fixation) partial brachioradialis release from the insertion of brachioradialis muscle was performed in order to perform reduction of fracture
41098897|NCT06631651|PROCEDURE|Brachioradialis not released|During distal radius fracture surgery (open reduction+internal fixation) brachioradialis release was not performed.
41098898|NCT05275686|DRUG|Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray|Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
41098899|NCT05275686|OTHER|Placebo Nasal Spray|The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day
41098900|NCT04874012|DRUG|Active comparator Taurine|Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
41098901|NCT04874012|OTHER|Placebo Comparator|Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle
41098902|NCT05398640|BIOLOGICAL|OOS AMTAGVI|Patients will undergo preparative lymphodepleting chemotherapy. Infusion of lifileucel is then given and is followed by administration of IL-2.
41098903|NCT01899209|PROCEDURE|STARR|
41098904|NCT01899209|PROCEDURE|Laparoscopic Ventral Rectopexy|
41098905|NCT05689047|DRUG|M5717 330 mg|Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.
41098906|NCT05689047|DRUG|M5717 500 mg|Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
41443233|NCT05226702|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
40752084|NCT03084679|OTHER|Aerobic exercise in treadmill|30-40min of aerobic exercise in treadmill. The aerobic intensity will be established by heart rate levels that corresponded to anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test. This intensity corresponded to 60-72% peak V̇o2. During the exercise sessions, when a training effect will be observed, as indicated by a decrease by 8 to 10% in heart rate, the treadmill velocity or inclination will be increased to return to the target heart rate levels.
41443234|NCT06386094|DIAGNOSTIC_TEST|Echocardiographic assessment|M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
41443235|NCT06133101|DRUG|Standard Soy Milk|Consumption of commercially available soy milk
41443236|NCT06133101|DRUG|2% Fat Cow's Milk|Consumption of commercially available 2% cow's milk
40924892|NCT03441217|DRUG|Saline Solution|Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).
41098907|NCT05689047|DRUG|M5717 660 mg|Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
41098908|NCT05689047|DRUG|Pyronaridine 360 mg|Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.
41098909|NCT05689047|DRUG|Pyronaridine 360 mg|Participants with weight \>=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.
41098910|NCT05689047|DRUG|Pyronaridine 540 mg|Participants with weight \>=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
41098911|NCT05689047|DRUG|Pyronaridine 720 mg|Participants with weight \>=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
41098912|NCT05689047|DRUG|Pyronaridine-artesunate (Pyramax) 360 mg/120 mg|Participants with weight \>=24 to \<45 kg will receive dose of 360/120 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.
41443237|NCT04278391|DRUG|DWJ1421|1 tablet administered in fasting condition
41098913|NCT05689047|DRUG|Pyronaridine- artesunate (Pyramax) 540 mg/180 mg|Participants with weight \>=45 to \<65 kg will receive 540/180 mg dose of Pyronaridine-artesunate (Pyramax) tablets under fasting condition.
41098914|NCT05689047|DRUG|Pyronaridine-artesunate (Pyramax) 720 mg/240 mg|Participants with weight \>=65 kg will receive 720/240 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.
41098915|NCT03425539|DRUG|Lucerastat|Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.
41098916|NCT03425539|DRUG|Placebo|Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
41098917|NCT06629285|PROCEDURE|Continuous compression cryotherapy|Using continuous compression cryotherapy around knee after anterior cruciate ligament reconstruction for 3 postoperative days
41098918|NCT06629285|PROCEDURE|Conventional ice treatment|Using icepack around knee after anterior cruciate ligament reconstruction for 3 postoperative days
41098919|NCT06629688|DRUG|semaglutide|Patient demographic and clinical data was collected and entered into a database made specifically for the study. The patients were examined, and their vital signs and body measures were recorded. Before the introduction of semaglutide therapy all participants completed an oral absorption iron test (OIAT). As described in previous studies, OIAT was conducted in an outpatient setting. Following the initial OIAT therapy with semaglutide was started. Each subject received parenterally administered one-weekly semaglutide. To enhance glycaemic control, the therapy was up-titrated every four weeks. Initially, the dose was set at 0.25 mg once a week, four weeks later, it was raised to 0.5 mg once weekly, and four weeks after that, it was increased to 1 mg once weekly. After reaching the maximum maintenance dosage of 1 mg for two weeks, each T2DM patient completed a follow-up OIAT at week 10 of the study. Data from the first and subsequent OIATs were analysed statistically.
41098921|NCT06083480|DRUG|GlyNAC (combination of glycine and n-acetylcysteine)|GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
41098922|NCT06083480|DRUG|Placebo|Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
41098923|NCT05526911|DRUG|TBAJ-876|"* Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~* Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~* Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~* Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
41098924|NCT05526911|DRUG|Midazolam|Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted
41098925|NCT05526911|DRUG|Digoxin|Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
41098926|NCT06629376|DRUG|Pegylated Recombinant Candida Utilis Uricase for Injection|According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
41098927|NCT06630377|DIETARY_SUPPLEMENT|GOS|During the study period, subjects are instructed to take one pocket of galactooligosaccharide per day during the first week, followed by two pockets of galactooligosaccharide per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
41098928|NCT06630377|DIETARY_SUPPLEMENT|Placebo|During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
41098929|NCT06630351|BEHAVIORAL|Behavioral Counseling|Participate in MCP-C
41443238|NCT04278391|DRUG|DWC201903|1 tablet administered in fasting condition
41098930|NCT06630351|OTHER|Discussion|Participate in virtual group discussions
41443239|NCT04362293|DRUG|hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3 and low dose total body irradiation (TBI) 200 cGY on day -2 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
41098931|NCT06630351|OTHER|Health Promotion and Education|Receive reading exercises and workbook materials
41098932|NCT06630351|OTHER|Interview|Ancillary studies
41098933|NCT06630351|OTHER|Questionnaire Administration|Ancillary studies
41453304|NCT02711644|BEHAVIORAL|Supportive Lifestyle Counselling|Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
41098934|NCT05640596|DRUG|Betamethasone|
41098935|NCT02697799|BEHAVIORAL|High-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
41098936|NCT02697799|BEHAVIORAL|Mid-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
41098937|NCT06628856|OTHER|Quality of life|The study proposes a 3-time longitudinal design, with evaluations at baseline, 2.5 months, and 5 months, to measure the impact of an intervention on terminally ill patients and their families, focusing on health status, quality of life, and emotional well-being.
41098938|NCT06099769|DRUG|Enzalutamide|mouth once daily (160 mg/day)
41098939|NCT06099769|DRUG|Mifepristone|mouth once daily 300-mg tablet
41098940|NCT06099769|DRUG|TPC|"The treating physician must select from one of the following regimens:~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~* Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~* Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~* Carboplatin AUC 6 IV Day 1 in a 21-day cycle~* Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle"
41098941|NCT06500286|DRUG|Marciane|Group A caudal block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
41098942|NCT06500286|DRUG|Marcaine|Dorsal penil block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
41098943|NCT06617689|OTHER|Various levels of patient education|"The three interventions:~GROUP BASED TEACHING In groups of 8-12 patients, 30 minutes of standardised teaching is given. The teaching focuses in particular on the changes in diet and the impact this has on oral pH, enamel erosion and caries; recommended oral hygiene; and good drinking habits.~WEBSITE Website providing recommendations for oral hygiene and drinking habits, as well as in depth information on the topic.~DENTAL HYGIENE SAMPLES These are samples relevant for maintaining proper oral hygiene, distributed free, together with a description of how to use them."
41098944|NCT02174211|DRUG|Ranibizumab|Intravitreal injection of ranibizumab
41098945|NCT02174211|DRUG|Aflibercept|Intravitreal injection of aflibercept
41098946|NCT03666741|DEVICE|AVR with or without CABG|Surgical aortic valve implantation with INSPIRIS RESILIA Aortic Valve™
41098947|NCT03683472|BEHAVIORAL|Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety"
41098948|NCT04059562|COMBINATION_PRODUCT|Combination of Lonsurf® and Irinotecan|"Trifluridine/Tipiracil (Lonsurf®) and Irinotecan~* Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.~* Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose."
41098949|NCT06630884|BIOLOGICAL|Typhoid VI Polysaccharide Vaccine Injectable Solution|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
40924893|NCT03759808|BEHAVIORAL|Psychological Intervention|Psychological treatment protocol designed to treat anxiety and avoidance in an adolescent/young adult population. The focus of treatment will be to address cognitive and behavioral factors associated with prolonged symptoms. Cognitive factors that may be addressed include, but are not limited to, catastrophizing, black or white thinking, and false expectations. Behavior factors that may be addressed include, but are not limited to, avoidance, relaxation, and behavioral activation. The psychological intervention is also designed to help reduce psychophysiological arousal associated with anxiety and stress. Participants will also be taught controlled shallow breathing exercises designed to normalize the ratio of sympathetic/parasympathetic activity.
41098950|NCT06630884|OTHER|Saline Placebo (0.5mL injection)|The placebo injection will consist of 0.5mL of saline.
41098951|NCT01007708|DRUG|IDP-108|Topical application once a day for 48 weeks
41098952|NCT01007708|DRUG|Vehicle|Topical application once a day for 48 weeks
41098953|NCT03368001|BEHAVIORAL|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
40924894|NCT00083252|DRUG|talabostat (PT-100) tablets|
41098954|NCT03368001|BEHAVIORAL|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
41098955|NCT06317636|DRUG|Ketamine|0.5 mg/kg ketamine infused intravenously over 40 minutes
41098956|NCT06317636|DRUG|Normal saline|0.9% normal saline infused intravenously over 40 minutes
41443240|NCT04362293|DRUG|hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3, plerixafor (0.24mg/Kg) subcutaneously every 12 hours on days -3 and -2 and low dose total body irradiation (TBI) 200 cGY on days -2 and -1 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be cyclophosphamide (50mg/Kg) intravenously on days +3 and +4 and sirolimus with a loading dose 3 mg/m2 starting on day +5. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
41443241|NCT04165252|DIAGNOSTIC_TEST|Collection of vaginal, neonatal buccal and placental samples|Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
41443242|NCT06481475|BIOLOGICAL|YY003|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
40924895|NCT00083252|DRUG|cisplatin|
41098957|NCT04960280|DEVICE|©VoqX stethoscope|Computerized auscultation detects both infrasound and audible sounds and is capable of amplifying auscultated sounds by a factor of thirty.
41133237|NCT01641900|DRUG|placebo|placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
41133238|NCT05555901|DRUG|Fruquintinib+ chemotherapy|"Second-line treatment : Fruquintinib+FOLFIRI Drug: Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off, q4w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Fruquintinib+Capecitabine Drug: Fruquintinib 4mg, orally, once daily, 2 weeks on/ 1 week off, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
41098958|NCT05644262|DRUG|T2:C100|"The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil. T2:C100 is a full spectrum oral solution with five non-reactive ingredients: delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a pharmaceutical grade medium chain triglyceride (MCT) oil, and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL study drug (T2:C100) twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL study drug twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).~Participants who enter the Open Label Extension will receive 1mL study drug (T2:C100) twice daily for Week 12 - Week 13 (approximately 1 week), and will then increase to 2mL study drug twice daily for the remainder of the Open Label Extension (Week 13 - Week 26 (approximately 23 weeks))."
41098959|NCT05644262|DRUG|Placebo|"Matching placebo in a digestible oil. The placebo contains only three non-reactive ingredients: medium chain triglyceride (MCT) oil and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL placebo twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL placebo twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks))."
41098960|NCT06609928|BIOLOGICAL|FOLR1 CAR T-cells|Given IV
41098961|NCT06609928|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
41098962|NCT06609928|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41098963|NCT06609928|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41098964|NCT06609928|DRUG|Cyclophosphamide|Given IV
41098965|NCT06609928|PROCEDURE|Echocardiography|Undergo ECHO
41098966|NCT06609928|DRUG|Fludarabine|Given IV
41098967|NCT06609928|PROCEDURE|Pheresis|Undergo apheresis
41098968|NCT06609928|PROCEDURE|Positron Emission Tomography|Undergo PET
41098969|NCT00196365|DRUG|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily
41098970|NCT00196365|DRUG|levonorgestrel/EE 0.15/0.03 mg tablets and placebo|1 tablet daily
41098971|NCT03034252|PROCEDURE|Patients with Liposarcoma|Evaluation of Liposarcoma treated in a single center
41098972|NCT06056154|DEVICE|LIO ASQELIO TM monofocal QLIO130C|Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.
41098973|NCT05471167|BIOLOGICAL|BCG|Exposure is defined as having received the BCG vaccine during the first year of life.
40752085|NCT03084679|OTHER|Local strengthening exercises|15 min of local strengthening exercises will be performed in major muscle groups (legs, arms and trunk muscles): three series of each exercise, 12-15 repetitions.
40924896|NCT02006095|OTHER|Magnetic resonance imaging|arterial spin labeling, diffusion tensor imaging, and diffusion weighted imaging sequences will be used
41098974|NCT00109174|DEVICE|3T and 7T device|3T and 7T device
41098975|NCT00687115|BEHAVIORAL|Weight Loss|liquid diet at 50% of weight maintaining intake
41098976|NCT00687115|BEHAVIORAL|Overfeeding|Overfeeding at 150% of weight maintaining intake
41098977|NCT00687115|BEHAVIORAL|Overfeeding Low Pro|Overfeeding 150% of normal intake at \<5% protein
41098978|NCT04888585|DRUG|ABBV-154|Subcutaneous Injection
41098979|NCT04888585|DRUG|Placebo|Subcutaneous Injection
41098980|NCT06631768|OTHER|Casual labor subsidy|Eligible participants will be offered a voucher that can be redeemed for a set number of days of agricultural labor from casual laborers hired by local One Acre Fund offices. Casual laborers receive standard training in line with the trainings currently offered by the organization to participating farmers.
41098981|NCT06629701|DEVICE|External support for vein grafts|Group A will consist of a group of patients who will be sutured with external support for vein grafts.
41098982|NCT06242834|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41098983|NCT06242834|PROCEDURE|Computed Tomography|Undergo CT scan
41098984|NCT06242834|PROCEDURE|Echocardiography|Undergo echocardiography
41098985|NCT06242834|BIOLOGICAL|Pembrolizumab|Given IV
41098986|NCT06242834|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41098987|NCT06242834|DRUG|Tazemetostat|Given PO
41098988|NCT05749029|BEHAVIORAL|Four Week Self-Compassion Course|"This is a four-week self-compassion course supplied by Balanced Minds. The owner of Balanced Minds is a Consultant to this study, who will be providing access to participants.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~1. The Foundations of Self-Compassion~2. Developing your Compassionate Self~3. Deepening the Compassionate Relationship with Yourself~4. Self-compassion in Everyday Life."
41098989|NCT04740359|OTHER|Functional training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The functional reach (forward-lateral-cross), trunk rotation exercises were performed in the sitting positions.(25min) Facilitation of trunk extension and elongation in the prone position (10 min). Thoracic mobilization on exercise ball (10min).
41098990|NCT04740359|OTHER|Routine training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The strengthening exercises were applied on the mat (3x10 for the first 4 weeks and 3x15 repetition for the last 4 weeks). Eyes open-closed perturbation training was performed for trunk control in sitting and standing positions (10 min.).
41098991|NCT05822141|DIETARY_SUPPLEMENT|Fish Oil|For 12 weeks subjects will ingest 6 capsules per day of fish oil (7.8 g/day total omega--3 fatty acids: 3.75 g/day EPA and 1.5 g/day DHA)
41098992|NCT05822141|DIETARY_SUPPLEMENT|Placebo|For 12 weeks subjects will ingest 6 capsules per day of olive oil (each capsule contains 990 mg of olive oil)
41098993|NCT05717686|DRUG|AHB-137 injection|AHB-137 will be administered
41098994|NCT05717686|DRUG|Placebo|Placebo will be administered
41098995|NCT01338727|BEHAVIORAL|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
41443243|NCT06481475|BIOLOGICAL|Vehicle Control|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
41443244|NCT02537457|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule15mg for one day
41098996|NCT06242964|BEHAVIORAL|Promoting Resilience in Stress Management - Social Needs (PRISM-SN)|The Promoting Resilience in Stress Management - Social Needs (PRISM-SN) intervention is a brief, skill-based psychosocial program. Five core sessions are delivered one-on-one, 1-2 weeks apart, in-person or via videoconference. Sessions teach evidence-based behavioral skills for managing stress, setting goals, reframing negative thoughts, meaning-making, and connecting with others. Each session lasts \<60 minutes and is supported by paper-and-pencil or mobile app-based worksheet(s) for learning and practice. A final review session may be completed individually or with a family member, caregiver, or significant other.
41098997|NCT06055712|DRUG|Cefazolin|Intravenous dose(s).
41098998|NCT06055712|DRUG|Cephalexin|Five days oral.
41098999|NCT00300456|DRUG|ABT-335|135 mg, daily, 12 weeks
41099000|NCT00300456|DRUG|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
41099001|NCT00300456|DRUG|Placebo|Daily, 12 weeks, see Arm Description for placebo information
41099002|NCT04616365|PROCEDURE|Semi-Elective Lung Transplantation|When suitable donor lungs become available for a consented recipient, the transplant procedure (anesthesia starting time) will be allowed to begin earliest at 6am with the lungs being preserved at 10°C cold static preservation upon organ arrival to our hospital using a specific incubator, regardless of when donor cross clamp occurs. The maximum time allowed between donor cross clamp and recipient anesthesia initiation will be 12h.
41099003|NCT03152799|PROCEDURE|RIPC Remote Ischaemic Pre-Conditioning|intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
41099004|NCT03152799|OTHER|Sham Control|intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
41099005|NCT03578731|DEVICE|app|"The app is used to record the study parameters for a period of 90 days.~The following measures are used for data collection:~* Interview during regular consultation with doctor~* Web-App for gathering doctors data~* Consilium Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message.~* Well-being through a patient rating on a visual analog scale~* Registration of symptoms and treatment side effects is done through the app~After completion of the study patients will be questioned according to:~• Usability and usefulness of the Smartphone app"
41099006|NCT05224362|DEVICE|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability.|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. Bertec force plate analysis will be performed to assess the acute effects on balance and stability. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/ dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
41099007|NCT05967442|DRUG|Magnesium Sulfate|Magnesium Sulfate 2gm in 50ml D5W over 20 minutes
41099008|NCT05967442|DRUG|Metoclopramide 10mg|Metoclopramide 10mg in 50ml D5W over 20 minutes
41099009|NCT05967442|DRUG|Prochlorperazine (Compazine) Injection|Prochlorperazine 10mg in 50ml D5W over 20 minutes
41099010|NCT01356225|DRUG|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
41099011|NCT01356225|DRUG|Placebo|IN placebo
41099012|NCT01121783|OTHER|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
41099013|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube. After 15 minutes tap water will be administered as a bolus via the intragastric tube.
41099014|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
41099015|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes tap water is administered as a bolus via intragastric tube.
41099016|NCT05451108|DEVICE|PCL Pectus Scaffold implantation and autologous fat grafting|A small incision is made in the chest and pre-sternal pocked is defined. Following this, an empty scaffold is implanted at the site of the defect with skin closed directly over it. At the same stage, autologous fat transfer will be performed, harvesting fat from available donor sites such as the thighs and abdomen - depending on scaffold volume and patient morphology. The area will be infiltrated with local anaesthetic tumescent fluid, liposuction performed, and fat transferred to syringes for filtration prior to injection into the scaffold. Fat will not be processed beyond simple filtration to separate liquid from fat to be injected. The scaffold provides structural stability to the chest during the infiltration of the tissue inside the scaffold.
41099017|NCT02577523|DRUG|ND0612 (Levodopa/Carbidopa solution)|The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.
41099018|NCT02577523|DRUG|ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD|The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
41099019|NCT01565928|DRUG|MDV3100|4 x 40 mg capsules, orally, once per day
41099020|NCT05358717|DRUG|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
41099021|NCT05358717|DRUG|Placebo|Placebo matching to PTC518 will be administered per schedule specified in the arm.
41099022|NCT04935177|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
40924897|NCT02006095|BEHAVIORAL|Neuropsychological testing|
40924898|NCT00330161|DRUG|vorinostat|Given orally
40924899|NCT00330161|OTHER|laboratory biomarker analysis|Correlative studies
40924900|NCT05874570|DRUG|Esomeprazole|Proton pump inhibitor
40924901|NCT05874570|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
40924902|NCT05874570|DRUG|Tetracycline|Antibiotics for H. pylori eradication
40924903|NCT05874570|DRUG|Doxycycline|Antibiotics for H. pylori eradication
40924904|NCT05874570|DRUG|Metronidazole|Antibiotics for H. pylori eradication
40924905|NCT00129311|DRUG|Selegiline|5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
40924906|NCT00129311|DRUG|Placebo|
41099023|NCT04935177|PROCEDURE|PLEX|PLEX is performed according to the respective site's standard procedure for desensitization.
41099024|NCT04935177|DRUG|IVIg|IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.
41099025|NCT04935177|DRUG|Anti-CD20 antibodies|Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.
41099026|NCT04935177|DRUG|Eculizumab|Eculizumab according to the respective site's standard procedure for desensitization.
41099027|NCT04935177|OTHER|Remain on wait list|Remain on wait list for a more compatible organ offer if desentization with institutional protocol is not appropriate
41099028|NCT02180087|DRUG|Ketoprofen|
41099029|NCT00449657|DRUG|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
40924907|NCT06435065|DRUG|Biodentine|DIRECT PULP CAPPINGWILL BE DONE USING BIODENTINE
41099030|NCT00449657|PROCEDURE|Radiotherapy|"Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.~Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5"
41099031|NCT00449657|DRUG|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 \& 9
41099032|NCT00449657|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 \& 9
41099033|NCT03834493|BIOLOGICAL|Pembrolizumab|IV infusion
41099034|NCT03834493|DRUG|Enzalutamide|Capsules/Tablets
41099035|NCT03834493|DRUG|Placebo|IV infusion
41099036|NCT02949271|OTHER|Programmed Intermittent Epidural Bolus|
41099037|NCT02949271|OTHER|Continuous Epidural Infusion|
40924908|NCT06435065|DRUG|Mineral Tri-Oxide Aggregate|DIRECT PULP CAPPINGWILL BE DONE USING MTA
40924909|NCT06435065|DRUG|THERACAL LC|DIRECT PULP CAPPINGWILL BE DONE USING THERACAL LC
40924910|NCT06435065|DRUG|TRISTRONTIUM ALUMINATE|DIRECT PULP CAPPINGWILL BE DONE USING TRISTRONTIUM ALUMINATE
41099038|NCT02949271|DRUG|Ropivacaine|
41099039|NCT02949271|DRUG|Fentanyl|
41099040|NCT05943938|OTHER|Epic Sepsis Model Version - 1|The Epic Sepsis Model (ESM) version 1, a proprietary sepsis prediction model.
41099041|NCT05943938|OTHER|Epic Sepsis Model Version - 2|The Epic Sepsis Model (ESM) version 2, a proprietary sepsis prediction model.
41099042|NCT05943938|OTHER|Emory Sepsis Model|Emory internal algorithm
41099043|NCT04692948|OTHER|Chimeric antigen receptor T cells (car-t)|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
41099044|NCT05478863|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants.
41099045|NCT05478863|DRUG|Oral THC|THC will be orally self-administered by study participants.
41099046|NCT05478863|DRUG|Oral CBD|CBD will be orally self-administered by study participants.
41099047|NCT05478863|DRUG|Oral Caffeine|Caffeine will be orally self-administered by study participants.
41099048|NCT03105128|DRUG|placebo for risankizumab|Placebo for risankizumab administered by intravenous infusion
41099049|NCT03105128|DRUG|risankizumab IV|Risankizumab administered by intravenous infusion
40752086|NCT03084679|OTHER|Stretching exercises|5-min stretching exercises will be performed in major muscle groups (legs, arms and trunk muscles)
40752087|NCT00632970|DRUG|Raltegravir|1, 400mg tablet twice a day, with Truvada 1 tablet once a day
40924911|NCT05568940|DRUG|Tibolone 2.5 Mg Oral Tablet|Tibolone oral therapy for 2-3 months: All participants will take a Tibolone 2.5 mg tablet orally daily, at the same time each day, following a scheduled, luteal-phase injection of leuprolide acetate 11.25mg intramuscular (IM).
41099050|NCT03105128|DRUG|risankizumab SC|Risankizumab administered by subcutaneous (SC) injection
41099051|NCT06630260|DRUG|Avutometinib|Supplied as 0.8mg capsules.
41099052|NCT06630260|DRUG|Defactinib|Supplied as 200mg tablets.
41099053|NCT06630260|DRUG|Temozolomide|Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.
41099054|NCT04859777|DRUG|MPT-0118|MPT-0118 is an inhibitor of MALT1 protease
41099055|NCT04859777|DRUG|MPT-0118 + pembrolizumab|MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
41099056|NCT06417450|DEVICE|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
41099057|NCT06417450|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
41443245|NCT02537457|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet15mg for one day
41443246|NCT01414933|OTHER|Biopsy|Breast metastases biopsy
41443247|NCT00750243|DRUG|LT-NS001|1200 mg b.i.d. p.o. for 7.5 days
41099058|NCT05722652|BEHAVIORAL|CONFIDENCE|"This clinic-based, multicomponent intervention consists of 3 parts:~1. Webinar training for clinicians and clinic staff about how to communicate with vaccine-hesitant parents~2. Parent-facing educational materials about COVID-19 vaccination~3. Support in creating a personalized poster campaign featuring providers and clinic staff sharing personal stories about COVID-19 vaccination"
41099059|NCT04025905|BEHAVIORAL|Social Cognition Training|Evaluate the impact of the social cognition training on employment maintaining in transitional Workforce Assistance Facilities and Services.
41099060|NCT04025905|BEHAVIORAL|Informations|informations about work environment, social environment, stress management, sleep management, treatments
41099061|NCT03370406|DRUG|5-fluorouracil|Intralesional injections of 50mg/ml over a 3 week period.
41099062|NCT03370406|DRUG|Imiquimod 5% cream|Topical application of 5% cream over a 3 week period.
41099063|NCT02882646|DEVICE|Bi-ADLER|Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
41099064|NCT03758625|BIOLOGICAL|a1DC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
41099065|NCT03758625|BIOLOGICAL|a1DC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
41099066|NCT03758625|BIOLOGICAL|a1DC + no antigen|Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
41099067|NCT03758625|BIOLOGICAL|pgDC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
41099068|NCT03758625|BIOLOGICAL|pgDC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
41099069|NCT03758625|BIOLOGICAL|pgDC + no antigen|Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
41099070|NCT04802824|OTHER|PET/CT|18F-fluoropivalate PET/CT scan.
41099071|NCT05586451|BEHAVIORAL|Traditional High Load Resistance Exercise (HLRE)|Participants will then perform 75% of tested 1RM for 3 sets of 12 repetitions at a pace of 1 repetition every 2 seconds on the dominant leg with one-minute rest between sets. After completing the HLRE protocol, participants will perform 2 post-exercise maximal voluntary contractions.
41099072|NCT05586451|BEHAVIORAL|Low Load Resistance Exercise with Blood Flow Restriction (LLBFR)|Participants will then perform 25% of tested 1RM for sets of 30, 15, 15, and 15 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
41099073|NCT05586451|BEHAVIORAL|Moderate Load Resistance Exercise with Blood Flow Restriction (MLBFR)|Participants will then perform 50% of tested 1RM for sets of 15, 8, 7, and 7 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
41099074|NCT02490982|DRUG|Teriflunomide|The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
41443248|NCT00750243|DRUG|Naprosyn®|500 mg b.i.d. p.o. for 7.5 days
41443249|NCT06626958|BEHAVIORAL|Stress Ball|Stress Ball app
41099075|NCT01119950|DRUG|NVA237 12.5 µg once daily|NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
41099076|NCT01119950|DRUG|NVA237 25.0 µg once daily|NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
41443250|NCT06516692|DIAGNOSTIC_TEST|Inferior Vena Cava Collapsibility/distensibility Index (IVC CI/DI) assessment|Assessment of hydration status in critically ill patient recruited to this arm will be intervened through an ultrasound guided calculation of collapsibility and distensibility index of Inferior Vena Cava. This method of intervention will be continued and repeated as needed throughout the stay of the participant in intensive care unit.
41443251|NCT02311361|BIOLOGICAL|Durvalumab|10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
41443252|NCT02311361|BIOLOGICAL|Tremelimumab|75 mg IV, every 4 weeks for 16 weeks
41443253|NCT02311361|RADIATION|Sterostatic body radiation therapy (SBRT)|8 Gray (Gy) x 1; 5Gy x 5
41099077|NCT01119950|DRUG|NVA237 12.5 µg twice daily|NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
41099078|NCT01119950|DRUG|NVA237 50.0 µg once daily|NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
41099079|NCT01119950|DRUG|NVA237 25.0 µg twice daily|NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
41099080|NCT01119950|DRUG|NVA237 100.0 µg once daily|NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
41099081|NCT01119950|DRUG|NVA237 50.0 µg twice daily|NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
41099082|NCT01119950|DRUG|Placebo to NVA237 once daily|Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
41099083|NCT03192085|DIAGNOSTIC_TEST|SITA FAST VISUAL FIELD TEST|Diagnostic test for glaucoma
41099084|NCT03192085|DIAGNOSTIC_TEST|SITA STANDARD VISUAL FIELD TEST|Diagnostic test for glaucoma
41099085|NCT01516892|BIOLOGICAL|onabotulinumtoxinA|Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
41099086|NCT06632067|DRUG|sugammadex|sugammadex used for neuromuscular reversal
41099087|NCT06632067|DRUG|Neostigmine + Atropine|Neostigmine and Atropine used for neuromuscular reversal
41099088|NCT01769391|DRUG|Necitumumab|Administered IV
41099089|NCT01769391|DRUG|Paclitaxel|Administered IV
41099090|NCT01769391|DRUG|Carboplatin|Administered IV
41099091|NCT06630468|OTHER|Task-oriented occupational therapy (TOOT)|The task-oriented occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
41099092|NCT06630468|OTHER|Control group|Routine upper-extremity-based occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
41099093|NCT03327155|DRUG|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)|One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
41099094|NCT02374333|BIOLOGICAL|huCART19|
41099095|NCT06311513|BIOLOGICAL|Concentrated Bone Marrow Aspirate Injection|Intraoperatively, bone marrow will be harvested from the iliac crest with a commercial kit, it will then be prepared via centrifugation and an injection of the resulting concentrated product (cBMA) will be administered in the operative knee. cBMA is an autologous biologic product.
41443254|NCT02924363|DIAGNOSTIC_TEST|Cardiac MRI with or without contrast dye|MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.
40752088|NCT00632970|DRUG|Lopinavir/Ritonavir|2 tablets twice a day, with Truvada 1 tablet once a day
41099096|NCT06311513|PROCEDURE|Sham Incision|A 2 mm sham incision will be made in the anatomical site where bone marrow would be harvested.
41099097|NCT06311513|PROCEDURE|Revision Anterior Cruciate Ligament Reconstruction|This is the standard-of-care surgical procedure.
41099098|NCT03537573|BEHAVIORAL|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
41099099|NCT03537573|BEHAVIORAL|Opioid Justification|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
41099100|NCT03537573|BEHAVIORAL|Provider Comparison|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (\> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (\> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
41099101|NCT04722276|OTHER|positive end expiratory pressure|7cmH2O of positive end expiratory pressure with fraction of inspired oxygen 80% applied during induction of anesthesia
41099102|NCT04722276|OTHER|fraction of inspired oxygen 80%|fraction of inspired oxygen 80% applied during induction of anesthesia
41099103|NCT04878627|DRUG|Cannabidiol|patients receive cannabidiol at various doses for 3 weeks
41099104|NCT04878627|DRUG|Placebo|patients receive placebo for 3 weeks
41099105|NCT03460574|BEHAVIORAL|INFORMATION|After receiving expectation-disconfirming positive performance feedback, participants receive standardized information that stresses the relevance of this experience. In particular, participants are told that the performance test they worked on is highly relevant for both professional success and personal life satisfaction.
41443255|NCT02924363|DIAGNOSTIC_TEST|Blood sample|Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
41443256|NCT03407963|PROCEDURE|Embolization|Embolization by microparticles (300-500 microns)
41443257|NCT05676749|BIOLOGICAL|C-TIL051|C-TIL051 given in combination with IL-15 (NKTR-255) and pembrolizumab
41443258|NCT04371081|DEVICE|Amplatzer Piccolo Occluder|Interventional placement of vascular occluder
41099106|NCT03460574|BEHAVIORAL|SALIENCE|After receiving expectation-disconfirming positive performance feedback, partcipants in this condition are instructed to remember how well they performed on the performance test. Using a visual analogue scale, they were asked to specify how they performed relative to the other participants.
41099107|NCT03460574|BEHAVIORAL|ATTENTION|Before working on the performance test, participants are instructed to pay attention to the feedback they receive. In particular, they are asked to enter what would be a personally good result for them. It is supposed that this shift of attention increases the salience of the expectation-disconfirming feedback.
41099108|NCT03460574|BEHAVIORAL|CONTROL|This group does not receive any further intervention. Instead, participants of this group pass through the standard procedure of the EXPEC paradigm.
41099109|NCT06617169|DRUG|MNPR-101-PCTA-177Lu|MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.
41099110|NCT06628882|PROCEDURE|Infraclavicular Block|types of anesthesia used in upper extremity surgeries
41099111|NCT06628882|PROCEDURE|Wide-Awake Local Anesthesia with No Tourniquet|types of anesthesia used in upper extremity surgeries
41099112|NCT05227313|DIETARY_SUPPLEMENT|Eefooton oral solution|Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
41099113|NCT05227313|DIETARY_SUPPLEMENT|Placebo oral solution|oral solution matched placebo
41099114|NCT02938650|DRUG|Nitrosomonas eutropha|Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
41099115|NCT04895007|BIOLOGICAL|Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine|Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.
41099116|NCT03185663|OTHER|traction-stuck|continuous pulling method: tensile force is exerted directly on the skin by means of adhesive strips, connected to weight
41099117|NCT03185663|OTHER|a pillow between the legs|setting up a pillow between the legs before the care
41099118|NCT05540990|DEVICE|Robot assisted gait training|15 sessions of robot-assisted gait training (two times per week with a maximum of 45 minute each).
41099119|NCT05540990|OTHER|Conventional physiotherapy|individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
41099120|NCT00145002|DRUG|VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|
41099121|NCT00145002|DRUG|biweekly-CHOP with G-CSF and intrathecal prophylaxis|
41099122|NCT02072005|OTHER|mSMART smartphone application|This application is an interface that provides subjects with information and questionnaires related to their medication.
41099123|NCT02205151|DRUG|Fimasartan|
41099124|NCT02205151|DRUG|Amlodipine|
41099125|NCT02205151|DRUG|Fimasartan/Amlodipine combination|
41099126|NCT05464212|PROCEDURE|USG Guided Greater Occipital Nerve Block|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
41099127|NCT05464212|PROCEDURE|USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
41099128|NCT02135809|DEVICE|WallFlex Pancreatic Stent|Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis. Stent will be removed after 3-6 months indwell.
41099129|NCT05848141|BEHAVIORAL|Exercise training|This is a single site center-based supervised exercise intervention.
41099130|NCT02760381|DEVICE|NBI + Acetic Acid (AA)|Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
41099131|NCT05231122|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IV
41099132|NCT05231122|BIOLOGICAL|Bevacizumab|Given IV
41099133|NCT05231122|BIOLOGICAL|Pembrolizumab|Given IV
40752089|NCT00632970|DRUG|Truvada|1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
41099134|NCT05231122|OTHER|Quality-of-Life Assessment|Ancillary studies
41099135|NCT05231122|OTHER|Questionnaire Administration|Ancillary studies
41099136|NCT02973243|DEVICE|Automatic RR Measurement|Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
41443259|NCT03893487|DRUG|Fimepinostat|Fimepinostat capsules
41099137|NCT06629896|DIAGNOSTIC_TEST|Contrast Enhancement Mammography|In the experimental arm women will receive two rounds of CEM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk non mutated women at each participating center.
41099138|NCT06629896|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI) and digital mammography (DM)|women will receive two rounds of MRI+DM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk nonmutated women at each participating center.
41099139|NCT05200650|COMBINATION_PRODUCT|TumoCure|TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.
41099140|NCT02485743|OTHER|Active Diet Products|A range of Active Diet Products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein, and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
41099141|NCT02485743|OTHER|Placebo Diet Products|A range of Placebo Diet Products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
41099142|NCT06629883|BEHAVIORAL|REPS w/BANDS|This theory-informed, one-arm proof-of-concept study provided participants (n=10) with an SHVD, exercise equipment (exercise bands, stability ball), and 2 supervised RE sessions per week for 12 weeks via the SHVD's video feature and incorporated strategies from self-determination theory to meet the psychological needs of autonomy, competence, and relatedness. Participants were randomly paired with a buddy.
41099143|NCT04247711|BEHAVIORAL|OTCH|OTCH is structured in three phrases (i. engagement and initial needs assessment, ii. ongoing intervention and monitoring, and iii. transition to long-term services) and lasts an average of two years. OTCH will maintain the central characteristics of the OnTrack model, as well as its core principles, which include (1) Person-centered care, (2) Shared decision-making, (3) Recovery orientation, and (4) Culturally-competent care.
41099144|NCT04247711|BEHAVIORAL|Usual FEP Services|These include services such as psychiatric medication, psychotherapy, and psychoeducation for people with FEP and are usually provided at outpatient mental health clinics.
41443260|NCT03893487|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41099145|NCT06101030|DEVICE|Signal On|InSee monitor patient signals are on.
41099146|NCT02465359|DRUG|Immune Globulin Subcutaneous (Human)|Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
41099147|NCT05737550|DEVICE|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
41099148|NCT01924065|PROCEDURE|Cardioversion|Electrical cardioversion
40924912|NCT02217774|DEVICE|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
40924913|NCT00427401|DRUG|PF-00915275|
40924914|NCT00539175|DEVICE|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
41099149|NCT01924065|DRUG|Oral Anticoagulant|warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
41099150|NCT04090320|DEVICE|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
41133239|NCT05555901|DRUG|Bevacizumab+ chemotherapy|"Second-line treatment : Bevacizumab+FOLFIRI Drug: Bevacizumab 5mg/kg on day 1, q2w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Bevacizumab+Capecitabine Drug: Bevacizumab 7.5mg/kg on day 1, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
41443261|NCT04078022|BIOLOGICAL|SF2a-TT15 Shigella Vaccine|0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
41443262|NCT04078022|OTHER|Placebo|0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
41443263|NCT04078022|BIOLOGICAL|S. flexneri 2a strain 2457T Challenge Agent|Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.
41443264|NCT04322292|DRUG|C-CAR088|"Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10\^6 CAR+T cells/kg),medium(3.0-6.0×10\^6 CAR+T cells/kg) and high(6.0-9.0×10\^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell."
41443265|NCT04174105|GENETIC|zocaglusagene nuzaparvovec|AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter
41443266|NCT02281994|DEVICE|Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD|Active devices emit PEMF signal; control devices do not emit PEMF signal.
40924915|NCT00539175|DEVICE|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
40924916|NCT05993013|OTHER|LudoFit|Game-based, technology-enabled home exercise software, done at least 3 times per week. Video games for a variety of exercises that promote balance, strength, endurance, and coordination.
40924917|NCT06145048|DRUG|VGT-309|Intravenous drug to be given over 15-20 minutes by syringe pump.
40924918|NCT06144762|BIOLOGICAL|Biological/Vaccine: Blood sample and tissue sample|"During the surgery :~Tissus sample : primary tumor and metastasis blood sample : 3 EDTA tubes ex vivo MRI data"
40924919|NCT00890045|DEVICE|HeRO Vascular Access Device|HeRO Vascular Access Device
41099151|NCT01339702|OTHER|The National Prehospital TBI Management Guidelines|"In the post-implementation (after) cohort, implementation of the entire bundle of the TBI treatment guidelines with special emphasis on prevention and treatment of hypotension (IV crystalloids), prevention and treatment of hypoxia (pre-oxygenation with high-flow O2 via non-rebreather mask, bag-valve-mask, extraglottic airways/intubation when basic maneuvers have failed), and prevention of hyperventilation (in intubated patients) and prevention/treatment of hypoventilation (in all patients)."
41099152|NCT06392932|DEVICE|QDOT Micro ablation catheter|QDOT Micro ablation catheter
41099153|NCT06392932|DEVICE|ST SF ablation catheter|ST SF ablation catheter
41099154|NCT00005813|BIOLOGICAL|bispecific antibody MDX447|
41099155|NCT00005813|BIOLOGICAL|lymphokine-activated killer cells|
41099156|NCT00005813|PROCEDURE|conventional surgery|
41099157|NCT06631092|BIOLOGICAL|Oral DNA Vaccine|Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
41099158|NCT04566874|DEVICE|ALIF|Anterior Lumbar Interbody Fusion
41099159|NCT06631963|BEHAVIORAL|Emotional Awareness and Expression Therapy|Emotional Awareness and Expression Therapy (EAET) is a form of psychotherapy designed to help individuals identify, process, and express emotions that may be linked to physical symptoms or chronic pain. It emphasizes the role of unresolved emotional experiences, such as trauma or interpersonal conflicts, in contributing to physical distress. Through EAET, patients learn to connect their emotions to their physical symptoms, express those emotions in a healthier way, and ultimately reduce both emotional and physical suffering. This therapy has been shown to be effective in treating conditions such as chronic pain, irritable bowel syndrome, and fibromyalgia.
41099160|NCT02929303|DRUG|Omegaven IV lipid emulsion|Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.
41099161|NCT06630416|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
41099162|NCT06630416|PROCEDURE|Computed Tomography|Undergo CT
41099163|NCT06630416|DRUG|Pemetrexed|Given IV
41099164|NCT06616688|OTHER|Organoid-guided treatment|After specimen removal as per clinical practice and pathological examination, a small piece of tumor tissue will be sent to the Axo-Glial Interaction Unit and cultured to build up organoid cultures
41099165|NCT06357143|OTHER|REMOVE|"INITIAL STAGE:~* Aim: Recover mobility~* Exercises: Passive therapy, isometric exercises focused on middle deltoid.~* Goal: 80º passive flexion, 45º abduction, 5 N of abduction force STRENGTHENING STAGE~* Aim: Enhance scapulohumeral rhythm and strength rotator cura~* Exercises: Active-assisted therapy, isotonic exercises between 45-90º of forward flexión and abduction with dumbbells and isometric exercises focused on internal and external rotation.~* Goal: 100º passive flexion, 90º lateral abduction, 10 N of abduction force INTENSIVE STAGE~* Aim: Improve motor control and increase cross-sectional muscular área~* Exercises: Rowe with resistance band, wall push ups, lateral elevation with dumbbles, active external and internal rotation.~* Goal: 15 N of abduction force FUNCTIONAL STAGE~* Aim: Develope daily life activities~* Exercises: Overhead tasks, rowe with Kettlebell, internal and external rotations with resistance bands~* Goal: 20 N of abduction force"
41099166|NCT06357143|OTHER|CONTROL|Patients will undergo standard care which consists of an initial consultation with the physiotherapist to receive some recommendations about exercises, progression and health education
41099167|NCT06631378|PROCEDURE|Transverse groin incision|The transverse incision is made parallel to the inguinal ligament either superiorly or inferiorly to the skin crease directly over the femoral artery. The subcutaneous tissue is dissected in the transverse direction till Scarpaes fascia after which the dissection is performed in the longitudinal direction along the line of the vessels. The lymphatic vessels are spared as much as possible. Any damaged lymph vessels are closed with surgical clips. Damages lymph nodes are either removed or the capsule is sutured to prevent lymph leakage. In case of difficulty with proper access to the femoral arteries, the incision can be extended either medially, laterally, or vertically.
41099168|NCT06631378|PROCEDURE|Longitudinal incision|The longitudinal incision is made directly over the femoral artery from the inguinal ligament. The subcutaneous tissue is dissected along the line of the vessel sparing the lymphatic vessels as much as possible. Any damaged lymph vessels are closed with clips. Damages lymph nodes are either removed or the capsule is sutured to prevent lymph leakage.
41099169|NCT01131247|DRUG|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
41099170|NCT02775435|BIOLOGICAL|Pembrolizumab|IV infusion
41099171|NCT02775435|DRUG|Paclitaxel|IV infusion
41099172|NCT02775435|DRUG|Nab-paclitaxel|IV infusion
40924920|NCT00890045|DEVICE|Conventional ePTFE hemodialysis graft|Conventional ePTFE hemodialysis graft
40924921|NCT04801264|DRUG|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga-PSMA will be used to image lesions of adenoid cystic carcinoma by PET/CT.
41099173|NCT02775435|DRUG|Carboplatin|IV infusion Carboplatin dose should not to exceed 900 mg.
41099174|NCT02775435|DRUG|Saline placebo for pembrolizumab|IV infusion
41099175|NCT05794022|OTHER|MRI|1 MRI at 1 month with gadolinium injection
41099176|NCT05794022|BIOLOGICAL|Biocollection|Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
41099177|NCT05794022|BEHAVIORAL|Quality of life questionaries|EQ-5D-5L and HAD questionaries at 1 month and 1 year.
41099178|NCT05161702|OTHER|MAG-SPM treatment on isolated PBMC cells|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
41133240|NCT02773732|DRUG|Ciprofloxacin 750 MG|750 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
41133241|NCT02773732|DRUG|Etoposide|Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
41099179|NCT05161702|OTHER|Isolated PBMC cells without treatment.|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
41099180|NCT04452955|BIOLOGICAL|PRL3-zumab|Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
41099181|NCT04853576|GENETIC|EDIT-301|Administered by IV infusion after myeloablative conditioning with busulfan.
41099182|NCT06099639|DRUG|HER3-DXd|5.6 mg/kg Q3W \[on Day 1 of each 21-day cycle\]) infused IV over approximately 90 minutes
41099183|NCT01174550|PROCEDURE|Coronary Angiography|Use of standard equipment for usual-care testing
41099184|NCT01174550|PROCEDURE|Stress Echocardiogram|Use of standard equipment for usual-care testing
41099185|NCT01174550|PROCEDURE|Nuclear Stress Test|Use of standard equipment for usual-care testing
41099186|NCT01174550|PROCEDURE|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
41099187|NCT04936789|DEVICE|IMES|Surgical implantation of IMES
41099188|NCT03396913|DEVICE|IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
41099189|NCT03396913|DEVICE|Sham IPL|Sham intense pulsed light (IPL) will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of10-15 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
41099190|NCT03396913|PROCEDURE|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
41099191|NCT06269874|DIAGNOSTIC_TEST|microvascular function assessment|mircovascular function parameters will be measured by administering adenosine in two different pathways
41099192|NCT00546520|DRUG|Ciclesonide|
41099193|NCT05301556|OTHER|Experimental Product|"* Before the surgery: FSMP provides daily target energy needed by participants~* 1-2 days after surgery: Start FSMP and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase FSMP intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. FSMP provides daily target energy needed by participants"
41099194|NCT05301556|OTHER|Control Product|"* Before surgery: TPF-T provides daily target energy needed by participants~* 1-2 days after surgery: Start TPF-T and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase TPF-T intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. TPF-T provides daily target energy needed by participants"
41099195|NCT04954430|DIAGNOSTIC_TEST|pupillometer|The dynamic changes of PLR were measured using the PLR-3000 pupillometer (NeurOptics, CA, USA), a hand-held portable device. Determination of PLR with automated pupillometry can be performed with a rubber cup covering the measured eye and the subject's hand covering the non-measured eye. A flash of visible white light with a duration of 0.8 sec and a pulse intensity of 50 µW is delivered to induce a pupillary reflex, and repeated video images at more than 30 frames/sec are stored for 6.65 sec. The device provided the examiner with maximum and minimum pupil size (Init and End), constriction percentage (%PLR), latency (LAT), constriction and dilation velocity (CV and DV), and T75.
41099196|NCT05728866|PROCEDURE|VR immersive therapy|Participants will be asked to participate in 5 consecutive, 1-hour, 1:1 therapy sessions focused on rehabilitation of their weakened arm. Each session will involve use of a Virtual Reality (VR) system to deliver an immersive environment to encourage movement of the arm. The system also relies on 6 body-worn sensors that will detect movements of participant's arms and trunk. VR use will encompass 30-minutes of the therapy session, the remainder of the session will involve working with the therapist in addressing the functional tasks that are most meaningful for the participant and that involve the upper extremities.
41099197|NCT04798521|OTHER|Tele-HCV|Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.
41099198|NCT04798521|OTHER|Community Linkage to Care|Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.
41099199|NCT06386913|OTHER|Training|Measurement-Based Care Training
41099200|NCT06627205|BEHAVIORAL|Sleep Restriction Therapy|Therapist led sleep restriction therapy sessions.
41133242|NCT02773732|DRUG|Ciprofloxacin 1000 MG|1000 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
41133243|NCT02773732|DRUG|Ciprofloxacin 500 mg|500 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
41099201|NCT06356207|DIAGNOSTIC_TEST|Tilt Table Test|The main goal of the study is to evaluate the time elapsed between the T-LOC during Video Tilt Table Testing and the asystole at the ECG using a national registry and to assess its predictive value in patients undergoing invasive treatment. The hypothesis is that a vasodepressive component could lessen the effect of pacing in a patient, leading to cerebral hypoperfusion and syncope despite maintaining a stable rhythm.
41099202|NCT05779007|DRUG|Pirfenidone|Pirfenidone
41099203|NCT05779007|DRUG|Nintedanib|Nintedanib
41099204|NCT00012467|DRUG|Itraconazole|
41099205|NCT00012467|DRUG|Flucytosine|
41099206|NCT00012467|DRUG|Fluconazole|
41099207|NCT00012467|DRUG|Amphotericin B|
41099208|NCT00012467|DRUG|Interferon gamma-1b|
41099209|NCT04131829|DRUG|Fluoxetine - immediate treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
41099210|NCT04131829|DRUG|Fluoxetine - delayed treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
41099211|NCT01102322|BEHAVIORAL|Quality|Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
41099212|NCT00639015|DRUG|Phenylephrine|Titrated phenylephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
41099213|NCT00639015|DRUG|Norepinephrine|Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
41099214|NCT00459264|DRUG|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
41099215|NCT00459264|DRUG|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
41099216|NCT05992064|OTHER|Measuring gait|"Measurements are performed by PA trackers. The measurements include:~* Lower limb 3D linear accelerations according to gait bouts collected and stored as time-series of linear accelerations with a frequency of 12.5 Hz.~* Details on the amount of time spent lying down, sitting, and standing, as well as the number of steps and sit-to-stands completed throughout the day. This information will be stored in 15-minute epochs and then summarized into daily summaries for analysis."
41443267|NCT01192932|RADIATION|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm"
41099217|NCT05365139|OTHER|Structured clinical diagnostic interview for PGD (PGD-I)|"Participants were administered the Structured clinical diagnostic interview for PGD (PGD-I) and screened with clinical interviews for PTSD, anxiety and depression. Whether the Aarhus PGD-scale should be answered before or after the interview was randomized.~The PGD-I and self-report scale were readministered to 50 participants 7-14 days after the initial administration."
41099218|NCT04747106|BIOLOGICAL|plasma exchange|when ADP inhibition \>30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
41099219|NCT05923255|PROCEDURE|LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）|Preserve the ileocolic blood vessels, and perform dissection of lymph node groups 203, 202, and 201d along the root of ICV(Ileocolic artery)/ICA(Ileocolic vein). Group 201d lymph nodes are defined as the distal lymph nodes of the ileocolic vessels (colonic branch). Use an intracavitary cutting and sealing device to transect the proximal colon along the predetermined margin, and transect the transverse colon at 10cm distal to the tumor. Perform ileocecal-transverse colonic anastomosis.
41099220|NCT05923255|PROCEDURE|TRH（Traditional Laparoscopic Right Hemicolectomy）|Transect the root of the ileocolic vessels and perform dissection of lymph node groups 203, 202, and 201; sever the roots of the right colic and middle colic vessels, and clear the surrounding lymphoadipose tissue (lymph node groups 211/212/213 and 221/222/223). Transect the transverse colon 10cm distal to the tumor and cut the terminal ileum 10cm from the ileocecal junction. Perform ileum-to-transverse colon anastomosis.
41099221|NCT03627962|OTHER|gaze-directed oculomotor training|"Device: Tobii PCEye~Protocol: Visual span was calculated by the distance between human-computer and dpi of fonts. Pointer speed was programmed 120pixels (5 degrees)/1sec for image drift of reading.~Dosage: 1) gaze-access required 20 to 10 degrees per fixation to activate text-to-speech (TTS) read-aloud function; about 30 repetitions of saccade and fixation.~2) gaze-directed OMT limited to 10-5 degrees. Chinese characters recognition in multiple choice format, about 60 repetitions.~Target behavior - gaze-directed access by Tobii PCEye: reading from left to right (=horizontal mouse mover); read-aloud function by gaze dwell \> 500ms. To enhance purposeful and repetitive eye movement.~Frequency: 2 session/wk x 8 wks~Duration: 30 min/session"
41099222|NCT05886751|OTHER|Black Doctor Screening Video|Participants will view an online video with a Black doctor speaking about prostate cancer screening.
41099223|NCT05886751|OTHER|White Doctor Screening Video|Participants will view an online video with a White doctor speaking about prostate cancer screening.
41099224|NCT05886751|OTHER|Black Patient Screening Video|Participants will view an online video with a Black patient speaking about prostate cancer screening.
41099225|NCT05886751|OTHER|White Patient Screening Video|Participants will view an online video with a White patient speaking about prostate cancer screening.
41443268|NCT03354858|PROCEDURE|Follicular flushing|Repeated follicle flushing up to 5 times using a double lumen needle for oocyte recovery
41453305|NCT02711644|BEHAVIORAL|Standard Lifestyle Counselling|Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
41099226|NCT05886751|OTHER|Black Doctor Clinical Trials Video|Participants will view an online video with a Black doctor speaking about prostate cancer clinical trials.
40924922|NCT04801264|DRUG|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
41099227|NCT05886751|OTHER|White Doctor Clinical Trials Video|Participants will view an online video with a White doctor speaking about prostate cancer clinical trials.
41099228|NCT05886751|OTHER|Black Patient Clinical Trials Video|Participants will view an online video with a Black patient speaking about prostate cancer clinical trials.
41099229|NCT05886751|OTHER|White Patient Clinical Trials Video|Participants will view an online video with a White patient speaking about prostate cancer clinical trials.
41099230|NCT05483842|OTHER|Reiki|"Consisting of the words rei meaning spirit and ki meaning universal life force, Reiki means spiritually directed life force energy. Reiki practice has an important place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, is safe, effective and economical.~In the Reiki method, which is one of the complementary and alternative methods, energy is transferred through the hands. Its basis is based on the principle that when there is a blockage in an energy center, disease occurs and the energy transferred by touching, strengthens and heals the body's self-healing ability by opening the blockages. Reiki practitioners who have received training and initiation perform the practice by holding their hands in certain positions on the recipient's body."
41099231|NCT05483842|OTHER|Sham Reiki|Sham means to pretend; therefore, in this study, the sham Reiki placebo provider pretended to perform a Reiki session by moving her hands on the patient's body in a specific order for a 30-minute period following strictly operationalized measures.
41099232|NCT03523962|DRUG|DuraPrep|The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.
41099233|NCT03523962|DRUG|ChloraPrep|The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® \[CareFusion Inc., Leawood, KS, USA\] will be the product used.
41099234|NCT06406543|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|an oral solution of vitamin D in a refined olive oil solution
41099235|NCT04183166|DRUG|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks
41099236|NCT06308575|DRUG|Rivoceranib|Given by PO
41099237|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 1-month pre-intervention visit
41099238|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 1-month post-intervention visit
41099239|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 3-months post-intervention visit
41099240|NCT05573555|DRUG|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
41099241|NCT05573555|DRUG|Ribociclib|Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days
41099242|NCT03568162|DRUG|ISB 830 - Part 1 Group 1|Subcutaneous injection (SC) every 2 weeks
41099243|NCT03568162|DRUG|ISB 830 - Part 1 Group 2|Subcutaneous injection (SC) every 2 weeks
40924923|NCT03905252|OTHER|sample analysis|blood, Random urine sample and 24-hour urine samples
40924924|NCT04628533|BEHAVIORAL|Four Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 16 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
40924925|NCT04628533|BEHAVIORAL|Six Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 24 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
40924926|NCT04352426|OTHER|Exercise Test|Tests were conducted to evaluate exercise capacity.
40924927|NCT03726567|PROCEDURE|Bariatric surgery|Roux-en-Y surgery
40924928|NCT05857280|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on MS related symptoms."
40924929|NCT05553743|BIOLOGICAL|COVID-19 Exposure|Have been or may have been exposed to COVID-19.
40924930|NCT05553743|DRUG|Antibiotic|Have or have not been prescribed one of several commonly used antibiotics including azithromycin, amoxicillin and clavulanic acid, amoxicillin, or nitrofurantoin.
41099244|NCT03568162|DRUG|ISB 830 - Part 1 Group 3|Subcutaneous injection (SC) every 2 weeks
41099245|NCT03568162|DRUG|Placebo - Part 1 Group 4|Subcutaneous injection (SC) every 2 weeks
41099246|NCT03568162|DRUG|ISB 830 - Part 2 Group 5|Subcutaneous injection (SC) every 2 weeks
41099247|NCT03568162|DRUG|Placebo - Part 2 Group 6|Subcutaneous injection (SC) every 2 weeks
41099248|NCT06208696|OTHER|"Tomando control de su salud (Spanish Chronic Disease Self-Management)"|"Tomando control de su salud (Spanish Chronic Disease Self-Management) is a culturally appropriate program developed in Spanish to support Hispanics patients to build confidence in their ability to manage their health. This intervention was developed by Lorig et al. at Stanford University and has been widely used by the Puerto Rico Department of Health since it is recommended by the CDC as an evidenced-based intervention for chronic disease management."
41099249|NCT06388447|BIOLOGICAL|Umbilical cord-mesenchymal stem cells|One injection will be given at each papilla set with the volume of 0.1mL with 2.0 x 10⁶ cells per syringe at every visit. A total of 3 injections will be given at the interval of 6 weeks, with a total of 6.0 x 10⁶ cells for each interdental papilla at the end of the 3 injections. Every injection starts with locally application of local anesthetic. For the control group, participants will be injected with 0.9% sodium chloride after locally application of local anesthetic
41099250|NCT05733598|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
41099251|NCT05733598|BIOLOGICAL|Bevacizumab|Anti-VEGF therapy.
41099252|NCT05733598|BIOLOGICAL|Atezolizumab|Anti-PD-L1 monoclonal antibody.
41099253|NCT06629675|DEVICE|Music walking application BeatClearWalker (BCW)|The music walking application (BCW) is a smartphone application that can monitor the walking pace and allow individuals to listen to music and give immediate feedback so they can correct their walking pace to match their target walking speed, as prescribed by the healthcare professional. The application provides real-time audio feedback in the form of music; the music sound quality will reduce whenever the walking speed drops below or exceeds the participant\&#39;s target walking speed. Simply, the application will work to supervise service users while exercising walking. The investigators are trying to assess the feasibility of this application with service users during their Pulmonary Rehabilitation programme (at the hospital/ home) to find out how participants interact with listening to music while exercise walking and how well they're able to keep to their target speed.
41099254|NCT02242162|PROCEDURE|phrenic nerves magnetic stimulations|
41099255|NCT00606866|DRUG|placebo|Placebo for four weeks
41099256|NCT00606866|DRUG|Sorafenib|Sorafenib 200 mg twice daily
41099257|NCT00606866|DRUG|Sorafenib|Sorafenib, 400 mg twice daily
41099258|NCT00455754|DRUG|Esomeprazole|
41099259|NCT06630442|OTHER|Educational Intervention|Attend a food safety educational training program
41099260|NCT06630442|OTHER|Questionnaire Administration|Ancillary studies
41099261|NCT00465751|DRUG|chenodeoxycholic acid|chenodeoxycholic acid 500 mg capsules tid po
41099262|NCT00465751|DRUG|placebo capsules|placebo capsules containing mannitol tid po
41099263|NCT02887313|DRUG|mFOLFOX6|Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
41099264|NCT02887313|RADIATION|Radiotherapy|Patietns received preoperative radiotherapy, 1.8-2.0GY/23-25F
41099265|NCT05553145|DIAGNOSTIC_TEST|Autoimmune Antibody Assays|GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab
41099266|NCT01701609|BEHAVIORAL|Cognitive Remediation Therapy|
41099267|NCT05266365|OTHER|The video-based exercise (VBE) group|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The physiotherapist will create a video record for the patients, including a detailed description of each exercise.~This video recording will be watched at home, and the patients will do video-based exercises by following the instructions in the video."
41099268|NCT05266365|OTHER|The standard exercise group (SE)|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~An exercise program will be performed at the clinic."
41099269|NCT06629324|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cell Transfusion|Bone marrow was collected under general anesthesia from both anterior superior iliac crests, taking 15-20 minutes, with a maximum volume of 350 mL for older children. Mononuclear cells were isolated using Ficoll density gradient centrifugation and prepared for infusion. The infusion, performed in the L4-L5 spinal space, lasted about 30 minutes at a rate of 20 mL per hour. Cerebrospinal fluid (CSF) was withdrawn before infusion, with the amount based on the child's weight. Patients received Rocephin for infection prevention and pain relief with alternating doses of Ibuprofen and Efferalgan for 2 days post-procedure. Seduxen was given once on the first night after bone marrow collection.
41099270|NCT06629324|OTHER|Rehabilitation|Rehabilitation methods involve various therapies tailored to the patient\&#39;s mobility level. (1) Physical therapy focuses on exercises to control the head, neck, and trunk, manage muscle tone, and reduce spasticity. Patients gradually practice essential movements like rolling, sitting, crawling, standing, and walking, aligned with developmental milestones. (2) Occupational therapy aims to enhance fine motor skills and daily activities. Through hand function exercises, patients improve upper limb functionality, strengthen their ability to grasp and hold objects and refine coordination between both hands and hand-eye coordination. (3) Speech therapy improves communication, cognitive abilities, and chewing and swallowing functions. Specific exercises target lip and mouth movements, helping patients express and understand language better. Additionally, there are activities to strengthen jaw and facial muscles, which are essential for improving chewing and swallowing abilities.
41099271|NCT05511454|OTHER|Salivary and crevicular samples|The samples will be taken from patients in both groups who meet the selection criteria during consultations at the Montpellier University Hospital's Odontology Department. During these consultations, a sample will be taken after rinsing the oral cavity with a glass of water. The samples will be taken before the periodontal assessment in order to avoid bleeding.
41099272|NCT03220139|OTHER|fat intake|Observational study on fat intake and mortality
41099273|NCT00982254|DRUG|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
41099274|NCT00982254|DRUG|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
41099275|NCT04103736|DIETARY_SUPPLEMENT|Beet It Sport Shot|Source of naturally occurring dietary nitrates
40924931|NCT00000128|DEVICE|Bifocal Spectacle Lenses|
41099276|NCT04103736|DIETARY_SUPPLEMENT|Nitrate-depleted placebo|Placebo
41099277|NCT05647356|DRUG|Bicalutamide 50 mg|Bicalutamide at a dose of 50mg once daily for 28 days.
41099278|NCT03538054|DRUG|Dextromethorphan|(1)10 mg, by mouth, twice daily every 12 hours.
41099279|NCT03538054|DRUG|Placebo|1 capsule, by mouth, twice daily every 12 hours.
41099280|NCT06629077|DEVICE|MRI|Participants will undergo an MRI scan while performing breathing and a simulated postural change task.
41099281|NCT06629077|DRUG|Prazosin|A dose of prazosin will be administered based on body weight.
41099282|NCT06629077|DRUG|Placebo|Oral placebo
41099283|NCT05499832|DRUG|Tenecteplase|Patients randomized to IA treatment will receive IA TNK via a standard approved microcatheter positioned as close as possible to the residual occlusion site or as distal as possible in the originating vessel if multiple residual occlusions exists.
41099284|NCT02462655|OTHER|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
41099285|NCT02462655|OTHER|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
41099286|NCT05035225|OTHER|Survey|Multiple Pharmacy Use Survey
41099287|NCT01024205|DRUG|sunitinib malate|
41099288|NCT01024205|OTHER|laboratory biomarker analysis|
41099289|NCT01024205|PROCEDURE|adjuvant therapy|
41099290|NCT01024205|PROCEDURE|neoadjuvant therapy|
41099291|NCT01024205|PROCEDURE|therapeutic conventional surgery|
41099292|NCT06548334|COMBINATION_PRODUCT|Advanced Physiotherapy|The physiotherapist used the regression techniques for 1 hour of session 2 times for 8 weeks. The caudal component involved the spinous process of the treated segment touching the therapist's hand and not applying force as though mobilising the segment at grade 2. These were applied if there is a suspected case of a posterolateral disc prolapse where the aim is to increase the diameter of the foramen and decrease the tension exerted on the nerve root. Applied posteroanterior was used to distract the anterior intervertebral end plate and to approximate the posterior end plates so as to pull back the protruded nuclear material by creating a negative pressure.
41099293|NCT06548334|OTHER|Conventional Physiotherapy Techniques|In traditional physiotherapy, the patient underwent two sessions per week for eight weeks. Each session lasted one hour and included 20minutes of TENS treatment. The flexibility exercises consisted of hamstring stretches and single and double knee-to-chest stretches. The strengthening exercises were partial sit-ups, quadruped lifts, and double leg hold; pelvic tilts were performed with 10-15 repetitions, each held for 20-30 seconds and repeated three times.
41099294|NCT03784326|DRUG|Atezolizumab|Given IV (vein)
41099295|NCT03784326|PROCEDURE|Conventional Surgery|Undergo surgical resection
41099296|NCT03784326|DRUG|Fluorouracil|Given IV (vein)
41099297|NCT03784326|DRUG|Oxaliplatin|Given IV (vein)
41099298|NCT03784326|DRUG|Tiragolumab|Given IV (vein)
41099299|NCT01749761|OTHER|BioLogic RR|Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
41099300|NCT01749761|OTHER|Hemodialysis without biofeedback|patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
41099301|NCT04204330|DEVICE|CardioQvark cardiac monitor and software, single-lead ECG|"Registration certificate for the medical device No. РЗН 2019/8124 dated February 15, 2019.~Product form: phone case.~Way of applying:~1. Download the CardioQVARK mobile application; create a profile.~2. Fill out the questionnaire:~   * age;~  * date of birth;~  * sex;~  * weight;~  * height;~  * blood type;~  * eye color;~  * hair color;~  * occupation;~  * town;~  * alcohol consumption;~  * tobacco use;~  * overeating;~  * insufficient sleep;~  * hypertension;~  * type 2 diabetes;~  * pacemaker;~  * the 10th revision of the International Classification of Diseases (ICD-10) code;~  * medicines.~3. Place index fingers on sensors that are on the case's backside and record 1-lead ECG of up to 3 minutes duration.~Recorded parameters:~* time parameters of the ECG intervals (RR, P, PR, QRS, QT, QTc);~* abnormal rhythms;~  * heart rate variability;~ * additional function - blood pressure and blood sugar diary. All recorded and calculated parameters are passed to the server."
41099302|NCT04937153|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV) once every 21 days.
41099303|NCT04937153|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV once every 21 days.
41099304|NCT06418529|DRUG|tofacitinib|New index treatment of tofacitinib
41099305|NCT06418529|DRUG|tumor necrosis factor inhibitors (TNFi)|New index treatment of TNFi
41099306|NCT06418529|DRUG|abatacept|New index treatment of abatacept
41099307|NCT06418529|DRUG|tocilizumab or sarilumab|New index treatment of tocilizumab or sarilumab
41099308|NCT06316674|BEHAVIORAL|sixth finger illusion|Participants will undertake the sixth finger illusion that is a body illusion which elicits the presence of an extra numerary finger due to visuo-tactile stimulation.
41099309|NCT06141577|DRUG|UI059|take UI059 1cap/day for 7 days
41099310|NCT06141577|DRUG|UIC202201|take UIC202201 1cap/day for 7 days
41099311|NCT06630598|BEHAVIORAL|Online Family Violence Education Resource|"The VEGA Family Violence Education Resources (© 2020 VEGA Project, McMaster University) is an on-line suite of educational resources that target professionals who are likely to encounter survivors of family violence in professional and clinical settings. The resources provide information about family violence, appropriate clinical responses, legal obligations, and more. The resources are broken down into several training modules and include three interactive learning scenarios. The training modules include:~Know About Family Violence in Canada Creating Safety Recognizing and Responding Safely to Child Maltreatment Recognizing and Responding Safely to Intimate Partner Violence Voices of those with Lived Experiences of Family Violence"
41099312|NCT06029296|DRUG|Diclofenac|100 mg
41099313|NCT06029296|DRUG|Placebo|Sugar pill
41099314|NCT04889664|DRUG|Ketamine|Repeated intravenous Ketamine infusions.
41099315|NCT04889664|BEHAVIORAL|Written Exposure Therapy|WET is a brief, 5-session evidence-based written trauma-focused therapy
41099316|NCT05117450|DEVICE|Decrease per-dialytic heparin therapy|Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)
41133244|NCT00978159|DRUG|esomeprazole|esomeprazole 20 mg po for 4 weeks
41133245|NCT00978159|DRUG|Famotidine|Famotidine 40 mg po for 4 weeks
41099317|NCT04559724|DEVICE|Indego Therapy|Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
41099318|NCT06173570|DRUG|AZD0780|AZD0780 administered orally, once daily for 12 weeks
40924932|NCT04634045|BEHAVIORAL|Web Based Treatment|The literature regarding the efficacy of web-based platforms for behavioral weight management interventions in pediatric populations continues to grow. Considering the continued increase in technology and internet use among youth, web-based interventions have the potential to serve as a more cost-effective and personalized approach to pediatric behavioral weight management. Extant research supports this consideration. More research that compares web-based vs. traditional delivery of acceptance-based pediatric behavioral weight management interventions is necessary to understand the utility of this platform as well as which aspects are most effective.
40924933|NCT00721253|DEVICE|ReSTOR|Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
41099319|NCT06173570|DRUG|Placebo|Placebo administered orally, once daily for 12 weeks
41099320|NCT01254981|PROCEDURE|Percutaneous coronary intervention (PCI)|Implantation of coronary stent
41099321|NCT04160689|BIOLOGICAL|implantology|placing of implant
41099322|NCT05911256|BEHAVIORAL|Pharmacist Only|Clinical pharmacists conduct encounters with patients by videoconferencing or phone. Pharmacists conduct a broad range of activities including ongoing evaluation of medication and lifestyle adherence, setting therapeutic goals, formulating a provider-approved plan of care, and documenting the plan in the electronic health record. Pharmacists propose medication changes based on algorithms and protocols derived from national guidelines under physician guidance.
41099323|NCT05911256|DEVICE|Continuous Glucose Monitor (CGM)|Patients will receive the Continuous Glucose Monitoring (CGM) system. The instruction on use of device is the intervention being tested, not the effectiveness of the device itself. Participants will receive instruction and training on how to use the device and will wear the device for 14 days.
41099324|NCT05911256|BEHAVIORAL|Community Health Worker (CHW)|Patients are connected to a community health worker(CHW). CHWs conduct home visits and facilitate 3-way Telehealth visits (Patients, pharmacists, and CHWs) via an iPad with cellular plan. Additional CHW activities include social determinants of health screening, health behavior education, problem solving, goal setting, and medication adherence support.
41099325|NCT02293421|OTHER|Obstructive sleep apnea|
41099326|NCT06264531|DRUG|Bevacizumab|Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections
41099327|NCT06264531|DRUG|Placebo|NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections
41099328|NCT05639114|DRUG|Ianalumab|ianalumab s.c. monthly or quarterly
41099329|NCT05639114|DRUG|Placebo|placebo s.c. monthly
41099330|NCT00394381|PROCEDURE|Infusion of autologous CIK cells|Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
41099331|NCT02033096|DRUG|Stannsoporfin|No intervention was administered during this observational study
41099332|NCT02033096|DRUG|Placebo Control|No intervention was administered during this observational study
41099333|NCT02033096|OTHER|Phototherapy (as needed)|No intervention was administered during this observational study
41099334|NCT06492577|OTHER|Pulmonary rehabilitation protocol|In the initial phase (days 1-7), aerobic exercise sessions will be 20-30 minutes, strength training will include 1-2 sets at 50% of 1RM, and breathing exercises will last 10 minutes daily. In the progressive phase (days 8-14), aerobic exercise sessions will increase to 30-40 minutes, strength training to 2-3 sets at 60% of 1RM, and breathing exercises to 10-15 minutes daily. In the advanced phase (days 15-21), aerobic exercise sessions will be 40-45 minutes, strength training will be 2-3 sets at 70% of 1RM, and breathing exercises will continue for 10-15 minutes daily.
41099335|NCT06492577|OTHER|Progressive muscle relaxation protocol|Participants in this arm will undergo a 21-day progressive muscle relaxation (PMR) program aimed at reducing anxiety and improving sleep quality in patients with long-term COVID-19 symptoms. Each daily session lasts 20 minutes and involves systematic muscle tensing and relaxation, starting from the feet and progressing to the head, combined with slow, deep breathing. During the initial phase (days 1-7), the focus is on introducing PMR techniques and targeting different muscle groups. In the progressive phase (days 8-14), full-body PMR sessions enhance relaxation and breathing techniques. The advanced phase (days 15-21) maximizes relaxation and incorporates visualization techniques.
40924934|NCT00721253|DEVICE|Tecnis|Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
40924935|NCT00721253|DEVICE|Acri.LISA|Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
41099336|NCT00076180|BIOLOGICAL|Hu-MiK-Beta-1|Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.
41099337|NCT06628466|DRUG|Nuberol Forte|Quality of Life study
41099338|NCT02271048|DEVICE|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
41099339|NCT03996239|BEHAVIORAL|exercise (walking)|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., \~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
41099340|NCT03996239|OTHER|plasma samples|Plasma samples will be obtained at baseline.
41099341|NCT03996239|OTHER|blood draw|fasting blood
41099342|NCT05082883|DIAGNOSTIC_TEST|Risk Assessment Cognitive Screening|Completion of a risk assessment cognitive screening app that includes working memory and voice-based tasks
41099343|NCT00866996|DRUG|Methylphenidate extended-release; Atomoxetine|
41099344|NCT04975243|DEVICE|GentleMax Pro Plus 755nm and 1064nm laser system|The GentleMax Pro Plus is a 755nm and 1064nm laser system. The GentleMax Pro PlusTM is indicated for stable long-term or permanent hair reduction using varying spot sizes and fluences.
41099345|NCT00673296|DRUG|Intravitreal Bevacizumab|Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
41099346|NCT06322342|DRUG|RVP-001|MRI contrast agent
41099347|NCT06630793|RADIATION|IMPT (Intensity Modulated Proton Therapy)|Proton therapy is a form of radiation treatment in which high doses can be delivered within the tumour while relatively sparing the surrounding normal tissues. This may help further reduce the side-effects of radiation treatment observed with IMRT.
41099348|NCT06630793|RADIATION|IMRT (Intensity Modulated Radiation Therapy)|The standard management of carcinoma of the anal canal is radiotherapy using the IMRT technique along with concurrent chemotherapy. The use of IMRT has reduced the treatment-related side-effects as compared to older radiation techniques. However, further reducing these side effects poses a major challenge.
41099349|NCT06178315|PROCEDURE|EUS-guided celiac plexus block|Under EUS-guidance, celiac plexus block will be performed with injection of bupivacaine and triamcinolone into the area of celiac plexus.
41099350|NCT06178315|PROCEDURE|Sham procedure|Celiac plexus will not be performed in this arm.
41099351|NCT00831792|DRUG|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
41099352|NCT06487975|DIETARY_SUPPLEMENT|Bacillus Subtilis|Bacillus Subtilis 1 capsule once daily in the morning (consisting of 10x10\^9 Colony Forming Units)
41099353|NCT06487975|OTHER|Placebo|1 visually identical placebo capsule once daily in the morning using the same carrier (microcrystalline cellulose) as the active (but not containing Bacillus Subtilis)
41099354|NCT00316784|DRUG|IDEA-033 (and rescue medication)|
41099355|NCT05100966|OTHER|FitJoints Multi-modal Intervention|"Exercise: The study physiotherapist will prescribe an exercise program tailored to the participant's individual ability and preference with functional movements to mimic activities of daily living.~Nutritional consultation and protein supplement: The site research assistant will coach participants to improve their nutrition, determine their daily protein target, and provide educational tools on how to achieve their target. Protein supplements will be provided to participants.~Vitamin D: Participants will be provided with vitamin D3 (1000 IU) tablets to reduce the risk of falls and to preserve muscle strength and functional ability. They will be instructed to take one tablet daily for the duration of the intervention period.~Medication optimization: The study pharmacist will conduct a medication review and provide, if required, recommendations for medication optimization."
41099356|NCT03030950|DRUG|Dexmedetomidine|to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block
41099357|NCT03030950|DRUG|Normal saline|to give normal saline to the other group as a placebo
41099358|NCT03751878|BEHAVIORAL|Evaluation of reporting inconsistencies|"1. The completed CONSORT checklist submitted by authors of manuscripts randomised to the intervention group will be assessed by the lead investigator (DB) as to whether it is consistent with the information that was actually reported in the manuscript. This evaluation will be focused on 8 core CONSORT items.~2. DB will produce a standardised report containing precise requests for authors in order to improve the completeness of reporting of the items where reporting inconsistencies were found. This report will consist of a brief introduction followed by a point by point description of the inconsistencies found together with precise requests related to the information missing and examples extracted from CONSORT. DB will upload this report to the submission on the managing system of the journal (Scholar One) to make it accessible to the handling editor of the manuscript.~3. This editor will include the report in the letter to authors alongside the standard peer review reports."
41099359|NCT03751878|BEHAVIORAL|Standard Peer Review.|Manuscripts will undergo the usual peer review process.
41099360|NCT02661035|DRUG|Allopurinol|300 mg/day (for peds -150 mg/m\^2/day), day -6 and continue through day 0 or longer if clinically indicated
41099361|NCT02661035|DRUG|Fludarabine|30 mg/m\^2 IV over 1 hour, day -6, -5, -4, -3 and -2
40924936|NCT04683731|BEHAVIORAL|Decision aid without personalized message|The decision aid without personalized message consists of a PowerPoint presentation converted to mp4 (video) with text, photos, and an audio track, that is advanced by the viewer and can be viewed online. It begins with a 60 sec video on CRC screening produced by the Centers for Disease Control and Prevention (CDC), followed by slides summarizing the advantages and disadvantages of colonoscopy and stool testing with the fecal immunochemical test (FIT) and DNA+FIT (Cologuard). The presentation is approximately 10 minutes long.
41099362|NCT02661035|DRUG|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
41099363|NCT02661035|DRUG|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
41099364|NCT02661035|RADIATION|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
41099365|NCT02661035|DRUG|Tacrolimus|"All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.~An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.~Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.~The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:~* Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.~* Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT."
41099366|NCT02661035|DRUG|MMF|"3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, MMF will continue as long as clinically indicated."
41099367|NCT02661035|BIOLOGICAL|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
41099368|NCT02661035|BIOLOGICAL|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10\^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
41099369|NCT05966389|OTHER|No interventions|No interventions
41099370|NCT02243592|OTHER|Laboratory Biomarker Analysis|Undergo sequencing and SNP analysis
41099371|NCT05159141|BEHAVIORAL|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
41099372|NCT02744508|DRUG|palonosetron|
41099373|NCT02744508|DRUG|palonosetron with dexamethasone|
41099374|NCT03999021|DRUG|NAC effervescent tablets|After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
41099375|NCT02772614|DRUG|BIA 3-202 (200 mg)|200 mg powder for oral use of unlabelled BIA 3-202
41099376|NCT05564325|DEVICE|Deflectable guidewire|A deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
41099377|NCT05564325|DEVICE|Standard of care guidewire (different models may be used)|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
41099378|NCT03795077|OTHER|Experimental group|Experimental group followed the 3-months programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used.
41099379|NCT02801929|DRUG|Coppertone (BAY987518)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - SR15-72_V27-010).
41099380|NCT00243334|OTHER|Integration of advanced clinical decision support with ambulatory computerized physician order entry|Actiobable Reminders related to medication monitoring, preventive care and chronic disease management, and test result follow-up are administered either during the visit or between visits.
41099381|NCT04550416|OTHER|ProMark Information and Test Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
41099382|NCT04663802|BEHAVIORAL|Default order set|With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 milliliters per kilogram of predicted body weight (cc/kg PBW; as determined by each patient's height and gender). The physician will have the option to opt out of any of the specified LPV settings and select other values.
41099383|NCT04663802|BEHAVIORAL|Physician-targeted accountable justification|When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg PBW, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.
41099384|NCT04663802|BEHAVIORAL|Respiratory therapist (RT)-targeted accountable justification|If an RT enters a tidal volume in a flowsheet documentation field value greater than 6 cc/kg PBW, an alert will appear requiring them to enter a reason for entering a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The RT will not be able to save the documentation in the EHR until after a response is entered.
41133246|NCT00764582|DRUG|1.5% levofloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery"
41099385|NCT04697251|DIAGNOSTIC_TEST|FOT measurements in newborns and small infants|Measurements will be performed using the device TremoFlo N-100, at bedside, with the infant in the supine position during quiet natural sleep. After proper cleaning and decontamination, the face mask of the device will be preheated at 37oC (to avoid awakening) and will be placed on infant's face. The duration of each measurement will be predetermined at 10 s. At least 3 technically acceptable measurements will be performed per infant, with 30 s intervals between them. The validity of each measurement will be assessed according to the coherence function (automatically determined by the operating system of the device).
41099386|NCT03256812|DEVICE|ICT-based ECG monitoring|Continuous monitoring will begin from the time of participation in the trial in the ICT-based centralized monitoring group. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group. If heart rate drops below 40 beats/min or increases above 120 beats/min on ECG during ICT-based ECG home monitoring, the participant will be notified first through an alarm function.
41099387|NCT03256812|DEVICE|Holter monitoring|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups
41099388|NCT03419780|BIOLOGICAL|Blood Transfusion|Patients are randomized to receive 1 or 2 units of packed red blood cells for initial transfusion.
41099389|NCT05300451|BIOLOGICAL|Daratumumab and hyaluronidase-fihj|Daratumumab and hyaluronidase-fihj for subcutaneous (under the skin) injection has different dosing and administration instructions compared to daratumumab for intravenous (in the vein) infusion. Daratumumab and hyaluronidase-fihj contains recombinant hyaluronidase, which mimics hyaluronidase, a naturally occurring substance that increases permeability of subcutaneous tissue. This makes it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes. Subjects will receive a 1800mg/30000u injection subcutaneously weekly for a total of 8 doses
41099390|NCT06249633|DRUG|Nitric Oxide|Inhaled nitric oxide
40924937|NCT04683731|BEHAVIORAL|Decision aid with personalized message|The decision aid with personalized message will first present the decision aid without personalized message followed by additional PowerPoint slides converted to mp4 (video) with text, photos, and an audio track briefly explaining the risk tool, the participant's score on the 5 risk factors, total score, ACN risk, and implications for screening and test choice. The presentation is approximately 14 minutes long.
40924938|NCT04683731|BEHAVIORAL|Provider notification without personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will be sent to them through the EHR within 24 hours of their visit with the enrolled patient.
40924939|NCT04683731|BEHAVIORAL|Provider notification with personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will also include the patient's ACN risk (very low, low, moderate, high-average) and implications for screening decisions and test choice. Links to a web landing page containing a more detailed explanation of the risk tool and additional references will be included. The notification will be sent to them through the EHR within 24 hours of their visit with the enrolled patient.
40924940|NCT01964040|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia"
40924941|NCT05898529|DIAGNOSTIC_TEST|Rapid antigen test|COVID-19 rapid antigen testing of nasal swab
40924942|NCT05956444|OTHER|Neurodevelopmental Therapy (NDT)|In the treatment program; vestibular and proprioceptive training on the balance board; dynamic balance training in sitting with eyes open and closed, kneeling upright and standing; balance exercises in front of the mirror; standing on one leg with eyes open and closed to increase proprioceptive input; vestibular and proprioceptive training on exercise balls of the appropriate size; balance training on the trampoline; footpad sensory stimulation with different materials; weight-bearing training in sitting, crawling, kneeling and standing positions; functional reaching and throwing-holding exercises in different positions; multitasking pieces of training; gait exercises in various ways and training for climbing and descending stairs appropriate to the child's situation (assisted, unaided, symmetrical, reciprocal) took place.
40924943|NCT05956444|OTHER|Conventional Physiotherapy|Classical physiotherapy applications for balance.
40924944|NCT05320744|PROCEDURE|surgical extraction of impacted lower third molar|surgical removal of impacted third molar under local anesthesia.
40924945|NCT05524116|BEHAVIORAL|Mindful Exercise program|In this 8-week intervention, components of Mindful Based Stress Reduction Program will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis. The goal of this program is to train participants how to be mindful during their exercises.
40924946|NCT05524116|BEHAVIORAL|Exercise|In this 8-week intervention, participants will be given recommended strengthening and neuromuscular exercises for knee osteoarthritis. Participants in both the intervention and control group will receive these exercises.
40924947|NCT00613067|DRUG|escitalopram|"* Start with escitalopram 10mg~* According to patient's symptoms, stay on 10mg or increase up to 20mg~* Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages~* Length of washout period will be at least 2 weeks for any psychotropic drugs"
40924948|NCT03452527|BIOLOGICAL|ICON-1|ICON-1 0.6 mg by intravitreal injection
40924949|NCT03452527|BIOLOGICAL|aflibercept|aflibercept 2 mg by intravitreal injection
40924950|NCT05541887|OTHER|Muscadine Wine Polyphenol|dealcoholized muscadine wine with alcohol content \<0.5% with addition of 50ppm of sodium metabisulfite for preservation
40924951|NCT05541887|OTHER|Placebo|this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention. 50ppm of sodium metabisulfite for preservation
40924952|NCT06047951|PROCEDURE|Stereotactic RadioSurgery (SRS)|"All treatments will be performed using the Gamma Knife Perfexion or Icon system (Elekta). The following treatment parameters will be used:~* The head will be immobilized using a stereotactic Leksell Model G frame, installed using local protocols~* Targeting will be performed by using a stereotactic CTA. No MRI will be performed.~* Only one aneurysm will be treated per patient~* The aneurysm, including its neck, will be contoured and targeted using a combination of 4mm isocenters as deemed appropriate by the treating team~* A prescription dose of 25 Gy at the margin of the target will be used~* The maximal dose on optic pathways will be kept below 10 Gy~* The brainstem 12-Gy volume will be kept below 1cc"
41099391|NCT06127810|DEVICE|CE MRI on 0.064T Scanner|Pt will undergo contrast enhanced images using Gadopiclenol on Hyperfine MRI
41099392|NCT06127810|DRUG|Gadopiclenol|Subjects will receive Gadopiclenol instead of standard of care contrast
41099393|NCT05656092|DRUG|HIP0612|Test drug
41099394|NCT05656092|DRUG|HPP2202|Placebo drug
41099395|NCT05656092|DRUG|RLD2204|Reference drug
41099396|NCT05656092|DRUG|HPP2201|Placebo drug
41099397|NCT04884399|DRUG|CMAB818|vascular endothelial growth factor (VEGF) inhibitor
41099398|NCT04884399|DRUG|Lucentis®|vascular endothelial growth factor (VEGF) inhibitor
41099399|NCT00308958|DEVICE|High frequency chest wall oscillator|
41099400|NCT06597942|DEVICE|TMS|rTMS Stimulation Parameters Pulse count: 1600 pulses Frequency: 20Hz Pules per train: 40 pulses Inter-train interval: 28 seconds Intensity: 100% Motor Threshold (depth-corrected from MRI) Target: Precuneus using structural MRI navigation with MNI coordinates
41099401|NCT06597942|DEVICE|Transcranial Magnetic Stimulation Sham|Sham coil placed in same location and set with same parameters as active treatment coil. However, this device will not output active treatment and scalp electrodes will mimic the sensation of rTMS for the participant.
41099402|NCT06222619|PROCEDURE|Potal vein embilization|Portal vein of involved bile duct is embolized to increase the volume of remnant liver.
41099403|NCT01839877|DRUG|HIA DEBIRI + systemic FOLFOX|
41099404|NCT00207649|BEHAVIORAL|Shared decision-making for PSA screening tool|Interventions to Improve Shared Decision-Making: Prostate Cancer Screening is a prospective study of educational interventions to improve shared decision-making of physicians and their patients about prostate cancer screening. Physicians will be randomized by practice site to receive standard informational brochures (control group) or a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In addition, patients at intervention sites will be randomized to receive either the brochure or a patient-oriented interactive curriculum covering content similar to that contained in the physician tool. Physicians in all groups will also see one unannounced standardized patient (SP) trained to portray a patient interested in discussing PSA.
41099405|NCT06471322|DEVICE|Continuous Glucose Monitoring (CGM)|Patients will wear a continuous glucose monitor upon discharge from the hospital for 6 months
41099406|NCT06471322|OTHER|Standard of Care|Standard of Care - retrospective review
41099407|NCT01547741|DRUG|Doxorubicin|
41099408|NCT01547741|DRUG|Cyclophosphamide|
41099409|NCT01547741|DRUG|Docetaxel|
41099410|NCT01547741|DRUG|Paclitaxel|
41099411|NCT05567952|DRUG|nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
41099412|NCT05567952|DRUG|ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
41099413|NCT05567952|DRUG|placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
41099414|NCT00477100|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, and stool
41099415|NCT00477100|OTHER|Interview|Participate in interview
41099416|NCT00477100|OTHER|Medical Chart Review|Undergo collection of medical data
41099417|NCT00477100|OTHER|Questionnaire Administration|Ancillary Studies
41099418|NCT06206837|DRUG|vepdegestrant|Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
41099419|NCT06206837|DRUG|PF-07220060|Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
41099420|NCT06631430|DRUG|BI 3810477|BI 3810477 formulation A
41099421|NCT06631430|DRUG|BI 3810477|BI 3810477 formulation B
41099422|NCT06631430|DRUG|Placebo|Placebo
41099423|NCT01450943|DEVICE|SECONDARY dressing gauze and tape|SECONDARY dressing gauze and tape
41099424|NCT01450943|PROCEDURE|debridement, irrigation|debridement, irrigation
41099425|NCT01450943|DEVICE|Dermagraft|Dermagraft per company protocol
41099426|NCT01450943|DEVICE|Oasis|Oasis per company protocol
41099427|NCT04682756|DIAGNOSTIC_TEST|The model of machine learning|Early diagnosis of NTEMI patients by machine learning model
41099428|NCT06180148|DEVICE|Mechanical insufflator-exsufflator|"In the active comparator group a mechanical insufflator-exsufflator will be used in the postoperative period 6 and 24 hours after extubation as follows (coughing maneuver): application of inspiratory pressure of 40-70 cm of water (the minimum value to achieve a peak cough flow of 300 l/min) for 2 seconds with the subsequent creation of an expiratory vacuum of -40 cm of water within 2 seconds. During inhalation and exhalation, the patient will apply oscillations with a frequency of 10 Hz and an amplitude of 10 cm of water. A series of 10 such maneuvers will be used, with a pause of a few seconds to ensure patient comfort. The coughing maneuver will be performed through an oronasal mask tightly pressed to the face."
41099429|NCT00507208|DEVICE|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
41099430|NCT00507208|OTHER|Tongue Depressors|Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
41099431|NCT06629168|DIAGNOSTIC_TEST|lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and 10-meter-walking test prior and 4 hours after lumbar puncture. Mini-mental state examination is done.
41099432|NCT06629168|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
41099433|NCT06629168|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally). Telemetric prechamber placement according the randomization (www.randomization.com) and the envelope method of choosing of patients.
41099434|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #1|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 3 month after surgery. Brain CT control.
41099435|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #2|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 6 month after surgery. Brain CT control.
41099436|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #3|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 9 months after surgery. Brain CT control.
41099437|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #4|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score a month after surgery. Brain CT control, 10-meter-walking test, MMSE, self-assessment.
41099438|NCT06629168|DIAGNOSTIC_TEST|Telemetric prechamber reading|Non-invasive reading of telemetric prechamber made during each follow-up control.
41099439|NCT06629168|OTHER|Valve setting change|Changing of valve setting according patient's actual condition. Decission based on clinical state, radiological finding on CT and values readed from telemetric prechamber. Timing - each follow-up control.
41099440|NCT04495634|DEVICE|Stationary Head CT (s-HCT)|The system consists of a total of three x-ray sources and nine x-ray detectors with an estimation of approximately 150 projection angles per slice, with less than a minute per slice reconstruction. Radiation dose will be configured as to not exceed that of a conventional head CT, or 2 mSv. The subjects will be positioned on a medical procedure table that will move the subject through the scanning system at the rate of roughly 1 cm per second, during which the necessary x-ray projections will be acquired. The head will be positioned in a carbon fiber head holder from a clinical CT scanner that is secured to the table.
41099441|NCT05478122|DEVICE|Trachospray for awake videolaryngoscopy|Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device
41099442|NCT03736005|OTHER|Exposure of significant critical illness|Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.
41099443|NCT04333069|PROCEDURE|cataract surgery|cataract surgery in form of phaco emulsification or irrigation aspiration
41099444|NCT06118892|DEVICE|MISHA Knee System|The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
41099445|NCT06389318|DRUG|buccal midazolam +oral placebo syrup|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
41099446|NCT06389318|DRUG|oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
41099447|NCT04419181|DRUG|Docetaxel|Dose: 75 mg/m2 q3w
41099448|NCT04419181|DRUG|Carboplatin|Dose: area under the concentration-time curve \[AUC\] 6 q3w
41099449|NCT04419181|DRUG|Trastuzumab|Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w
41099450|NCT04419181|DRUG|Pertuzumab|Dose: 840-mg loading dose, 420-mg maintenance dose q3w
41099451|NCT04419181|DRUG|Trastuzumab emtansine|Dose: 3.6mg/kg q3w
40924953|NCT02588001|DRUG|Enzalutamide|All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
40924954|NCT02820532|DEVICE|Protura Treatment table|The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
40924955|NCT05926375|DIETARY_SUPPLEMENT|HINEX Jelly ( jelly high protein supplement)|In self-controlled phase,which intake 400\~500 kcal breakfast, or in supplement phase consume one servings of jelly high protein supplement (303 kcal, 15 g protein and 2400 mg BCAA per serving) and 100\~200 kcal food at breakfast per day, for 8 weeks.
40924956|NCT04135105|OTHER|Normal hearing group|Observational
40924957|NCT05324761|DRUG|Pregabalin 75mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
40924958|NCT05324761|DRUG|Gabapentin 300mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
40924959|NCT04399746|DRUG|Ivermectin|6mg once daily in day 0,1,7 and 8
40924960|NCT04399746|DRUG|Azithromycin|500mg once daily for 4 days
41099452|NCT00710307|PROCEDURE|Blood sampling|Blood samples will be collected at visit 1 (day 1) and at visit 2 (day 14 to 45).
41099453|NCT00710307|GENETIC|Genetic analysis|The sample for genetic analyses may be taken at Visit 1. The blood sample volume will be 6 mL.
41099454|NCT01249092|DRUG|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
41099455|NCT05773274|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41099456|NCT05773274|PROCEDURE|Computed Tomography|Undergo CT scan
41099457|NCT05773274|DRUG|Everolimus|Given PO
41099458|NCT05773274|DRUG|Lutetium Lu 177 Dotatate|Given IV
41099459|NCT05773274|OTHER|Quality-of-Life Assessment|Ancillary studies
41099460|NCT05773274|OTHER|Questionnaire Administration|Ancillary studies
41099461|NCT02672813|PROCEDURE|Pectoral nerve I and II block|Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
41099462|NCT03059082|BEHAVIORAL|Recovery Navigator on an as needed basis up to 6 months|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months and then have a 3 month and 6 month follow-up visit."
41099463|NCT03059082|BEHAVIORAL|Recovery Navigator prior to hospital discharge|This group will undergo one interaction with Recovery Navigator prior to hospital discharge and then have a 3 month and 6 month follow-up visit.
41099464|NCT03059082|OTHER|No interaction with Recovery Navigator|This group will not have any interaction with Recovery Navigator. They will have a 3 month and 6 month follow-up visit.
41099465|NCT00950144|OTHER|medical chart review|
41099466|NCT00950144|OTHER|questionnaire administration|
41099467|NCT00950144|OTHER|study of socioeconomic and demographic variables|
41099468|NCT00950144|PROCEDURE|quality-of-life assessment|
40752090|NCT02236767|DEVICE|Neurostar Transcranial Magnetic Stimulation Therapy System|Treatment will entail daily (5 days/week) sessions of repetitive transcranial magnetic stimulation for 6 weeks employing right-sided, low frequency stimulation (1 Hz, 900 pulses/session for 30 sessions, 27,000 total pulses, intensity at 90% of the passive motor threshold) to the dorsolateral prefrontal cortex (DLPFC).
41099469|NCT06628726|DIAGNOSTIC_TEST|Liver biopsy|surgical biopsy from liver
41099470|NCT06293547|DRUG|Silver Diamine Fluoride|Silber Diamine Fluoride, a colorless, odorless alkaline solution, effectively halts carious lesions in various populations, including children and elderly patients, or those averse to invasive treatments. Its high fluoride content facilitates remineralization, caries arrest, and prevention. SDF application is simple, non-invasive, cost-effective, and does not stain intact enamel, making it suitable for treating dentin hypersensitivity. Its ease of use is advantageous for children, patients with special needs, and the elderly. Particularly beneficial for high-risk patients with salivary dysfunction or multiple carious lesions, SDF offers potential in pediatric dentistry and community oral health by streamlining procedures, requiring rapid application without sharp instruments or anesthesia.
41099471|NCT01835340|DEVICE|Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.|
41099472|NCT03781804|DRUG|OPN-375|OPN-375, BID
41099473|NCT04026191|DEVICE|OrthoVisc®-T (OVT)|Sodium hyaluronate supplied as a 2 mL (15mg/mL) unit dose in a 3 mL glass syringe.
41099474|NCT05302713|DIETARY_SUPPLEMENT|Ionic Calcium|Ionic calcium (IC), a calcium in a free ionic state (i.e., non-protein bound), is purported to improve calcium uptake and homeostasis leading to improved cellular signaling that may have been disrupted through environmental and lifestyle stressors.
41099475|NCT05302713|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate supplementation in a solution identical in appearance, consistency, and taste to the intervention supplement.
41099476|NCT00164489|BEHAVIORAL|Weight control and physical activity promotion|
41099477|NCT05818943|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
41099478|NCT06213051|DEVICE|• COPAN Self-collection FLOQSwabs® (COPAN, Italy)|COPAN swabs evaluated on Roche COBAS and Cepheid Xpert PCRs
41099479|NCT03797235|PROCEDURE|Dominant Arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
41099480|NCT03797235|PROCEDURE|Non-dominant arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
41099481|NCT01268345|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being
41099482|NCT01268345|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
41099483|NCT06460519|OTHER|Non-invasive blood pressure measurements|Non-invasive blood pressure measurements to the tension cuff three times in a row on each side (right arm and left arm)
41099484|NCT05919849|BEHAVIORAL|Brief online writing intervention|Participants will be instructed to write for 20 minutes across 3 consecutive days. They will be writing based on the prompts given to them.
41099485|NCT05919849|OTHER|Control condition|Participants will be instructed to write in order to control for time and writing engagement.
41099486|NCT05299333|OTHER|Exercise|High repetition muscle endurance and strengthening exercises Walking
41099487|NCT03724370|BEHAVIORAL|Telehealth Monitoring System|TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.
41099488|NCT03724370|OTHER|VHA-SRM|Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
40752091|NCT00693108|DRUG|Transdermal testosterone|
40924961|NCT04399746|DRUG|Cholecalciferol|400 IU twice daily for 30 days
41099489|NCT06189716|DEVICE|High flow oxygen through nasal cannula|High flow oxygen through nasal cannula and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions.
41099490|NCT05132205|PROCEDURE|Radiofrequency Ablation|Radiofrequency Ablation using RFMedical device.
41099491|NCT06628518|BEHAVIORAL|FAmily oriented Mindfulness informed Legal Education (FAMiLE)|The FAmily oriented Mindfulness informed Legal Education (FAMiLE) is a low-intensity intervention involving four sessions. The session will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The Family oriented component will include stress management, including coping techniques and problem-solving, positive communication, behaviour modification and parenting, and a session on consolidation including sustaining gains. The intervention will also incorporate positive parenting and interactions with children.
41099492|NCT06416527|DEVICE|Photobiomodulation (Experimental)|The photobiomodulation with a diode emitting light (LED) cluster device will be positioned on the cervical region of each patient (for 10 minutes each).
41099493|NCT06416527|PROCEDURE|Pompage Technique (manual therapy)|To perform cervical Pompage the patient lies comfortably on their back or sits upright. The therapist locates the target area on the cervical spine. Using gentle pressure, the therapist applies traction to the cervical spine, stretching the muscles and fascia. The traction is held for 20 seconds. The therapist then releases the traction, allowing the cervical spine to return to its neutral position. This process will be repeated 3 times, with adjustments made based on the patient's response and comfort level.
41099494|NCT06416527|DEVICE|Photobiomodulation (Placebo)|The photobiomodulation with a diode emitting light (LED) cluster device will be positioned on the cervical region of each patient (for 10 minutes each) with the device turned off (inactive), simulating the time with a recorded beep sound.
41099495|NCT06629571|OTHER|Education|Training for the patient before surgery
41099496|NCT06343987|BEHAVIORAL|Physical Activity|12-week physical activity program with training 3 times a week. The training consists of high-intensity training such as weight-lifting and cardiovascular training, and low-intensity training such as relaxation and stretching.
41099497|NCT04555044|DRUG|Clinolipid|Lipid injectable emulsion, USP 20%
41099498|NCT04555044|DRUG|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion. 20% (lipid injectable emulsion, USP)
41099499|NCT06631066|RADIATION|neoadjuvant chemoradiation|Neoadjuvant chemoradiation will be prescribed as: 4 cycles of Adriamycin and Cyclophosphamide followed by radiotherapy concurrently with taxanes/ taxanes and carboplatin. followed by surgery as indicated.
41099500|NCT05930067|DEVICE|Pinnacle Gription Acetabular Cup|Pinnacle Gription cup with Corail/ACTIS stem
41099501|NCT05930067|DEVICE|Pinnacle Dual Mobility|Bi-Mentum AltrX liner
41099502|NCT03949686|DRUG|Saline Solution|0.5 ml/kg saline
41099503|NCT03949686|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
41099504|NCT05803330|DRUG|Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma|Abandonment of intravenous volume expansion with alpha-blockers during preoperative preparation in patients with pheochromocytoma
41099505|NCT06103240|OTHER|Lacticaseibacillus rhamnosus LRa05|Bacterial count:100 billion CFUs Take one sachet per day for 4 weeks.
41099506|NCT05468606|BIOLOGICAL|GA2|GA2 sporozoites administered by 50 mosquito bites
41099507|NCT05468606|BIOLOGICAL|BCG|0.1 mL BCG vaccine intradermally
41099508|NCT05468606|BIOLOGICAL|YF-17D (fractional ID dose)|0.1 mL YF17D vaccine intradermally
41099509|NCT05468606|DRUG|Imiquimod|250mg imiquimod 5% cream topical
41099510|NCT05468606|OTHER|Mock immunization|50 bites by uninfected mosquitoes
41099511|NCT00447434|DRUG|Natto extract (Nattokinase)|
41099512|NCT01802229|PROCEDURE|Prophylactic mesh placement|Placement of a Omega 3 mesh, fixed to the border of the fascia
41099513|NCT01802229|PROCEDURE|Fascial suture|The port-site hole is closed with simple suture of the fascia
41099514|NCT01813903|BEHAVIORAL|Intensified dietary counseling|The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
41099515|NCT01813903|BEHAVIORAL|Mobile application|Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
41099516|NCT04617600|DRUG|MTA|Survival rate using MTA in cariously exposed vital primary molars
41099517|NCT04617600|DRUG|TheraCal PT|Survival rate using TheraCal PT in cariously exposed vital primary molars
41099518|NCT06627907|OTHER|fluid challenge|"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M"
41133247|NCT00764582|DRUG|0.5% moxifloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery"
41133248|NCT05618041|BIOLOGICAL|CAR-T Autologous T cell injection|Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine；Procedure: Leukapheresis
41099519|NCT06627907|DIAGNOSTIC_TEST|end-expiratory occlusion test|"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M"
41099520|NCT03617107|OTHER|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
41099521|NCT05012644|DRUG|Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
41099522|NCT05012644|DRUG|Aromatase inhibitor|Aromatase inhibitor
41099523|NCT04593797|DIAGNOSTIC_TEST|carotid blood flow measurement with ultrasound|carotid blood flow measurement with ultrasound vs transpulmonary thermodilution calibrated continuous cardiac output measurements
41099524|NCT04785066|DRUG|Administration of dornase alfa|Patient treated for a cerebral thrombectomy will be administred dornase alfa treatment by intravenous
41099525|NCT00598897|DRUG|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
41099526|NCT04489784|DEVICE|Infrared Laser|An aluminum gallium arsenide (AlGaAs) diode laser device (Twin laser, MMOptics, São Carlos, SP, Brazil) was used. The irradiation parameters were as follows: infrared laser (808 nm wavelength) with a spot area of 0.04 cm2, and an average optical power of 100 mW operated in a continuous mode during 1 minute per point, leading to an irradiance of 2,500 mW/cm2, energy of 6 J and fluence of 125 J/cm2 per point. The laser was applied on ballerina's feet twice a week during three months.
41099527|NCT02020018|DEVICE|Prevena Incision Management System|negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days
41099528|NCT02020018|OTHER|Conventional sterile dry wound dressing|regular dressing that is applied immediately postoperatively for high risk patients in the operating room after sternotomy
41099529|NCT04813393|OTHER|Questionnaire Development|To evaluate psychometric the properties of the Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire (CPHP-Q), a caregiver-report for adherence and frequency of home program implementation of parents of children with Cerebral Palsy.
41099530|NCT02952755|DRUG|Co-administration of DWC20155/DWC20156|
41099531|NCT02952755|DRUG|DWC20162|
41099532|NCT04904757|DEVICE|Contrast-enhanced spectral mammography (CESM)|CESM is a mammogram performed after the injection of IV contrast. CESM is used most often when additional information is needed after a standard mammogram. CESM has also been used to determine the extent of a known breast cancer, to screen patients at high risk for developing breast cancer due to a family history or positive cancer genes, and for women with dense breast tissue. Two images are taken almost at the same time during the exam, after the iodine based contrast injection is administered. The first image is comparable to a regular mammogram. The second image shows areas that take up the contrast (enhance) showing increased blood flow. Breast cancers often enhance with contrast due to a greater amount of blood vessels. Non-cancerous lesions can also have greater blood flow.
41099533|NCT03794804|DEVICE|ColdZyme|"ColdZyme® Mouth Spray, a CE -marked device with the following composition of the spray solution: glycerol, purified water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme is a non-sterile mouth spray packaged in a primary container consisting of a 20 ml semi-transparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap."
41099534|NCT03794804|DEVICE|ColdZyme Placebo|The placebo mouth spray solution has the following composition: ethanol (\<1 %), menthol and water. The placebo mouth spray is packaged in a primary container consisting of a 20 ml semitransparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.
41099535|NCT00368719|DRUG|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
41099536|NCT00326027|DRUG|Pantoprazole|Efficacy of Pantoprazole
41099537|NCT05468658|OTHER|Designing the birthing unit according to the philosophy of Feng Shui|"1. The cabinets will be painted using salmon and pastel green.~2. It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~3. Live nature videos and sounds will be projected onto the wall.~4. Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~5. Natural plants will be placed.~6. Lighting will be used.~7. Bed linen will be designed according to the Feng Shui.~8. Wooden bell will be used.~9. Turtle, elephant and Wu Lou objects will be placed.~10. The Bagua mirror will be placed.~11. Crystals will be placed.~12. Natural stones will be placed.~13. The fountain will be placed in the east compass direction of the unit.~14. Straw bamboo separator will be used."
41099538|NCT02711982|PROCEDURE|Optic canal and optic nerve sheath decompression|within 5 days from trauma
41099539|NCT02711982|DRUG|methylprednisolone|within 5 days from trauma
41099540|NCT00012987|BEHAVIORAL|Quality Improvement|
40752092|NCT00002836|BIOLOGICAL|Filgrastim (G-CSF)|For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
41099541|NCT06631053|OTHER|velocity-based FIT (VBFIT)|"Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study. Those assigned to the exercise group will perform a both high-intensity resistance and aerobic exercise three times per week"
41099542|NCT06631053|OTHER|No Exercise|"Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study."
41099543|NCT05962385|DEVICE|Brain state while receiving TMS|Brain state whilst receiving TMS - cognitive control or perceptual. Repeated measures design, so all participants receive the same procedures.
41099544|NCT03852836|OTHER|ultra-rapid acquisition of bile ducts images|On top of the conventional SPACE sequence, 2 supplementary sequences will be performed with the ultra-rapid sequence (sequence CS-SPACE) either acquired in apnoea or synchronized with the breath.
41099545|NCT03014102|DRUG|Recombinant Human Thrombopoietin|Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
41099546|NCT06359379|DRUG|Ropidoxuridine|Ropidoxuridine is administered daily, 5 days a week, for 7 weeks, starting one week prior to radiotherapy, and then concurrently with a standard 60 Gy radiotherapy, followed by a 4-week rest period.
41099547|NCT02771938|OTHER|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
41099548|NCT03302156|DRUG|PSMA-based 18F-DCFPyL PET tracer|PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
41099549|NCT03775447|PROCEDURE|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
41099550|NCT02404454|PROCEDURE|Hysteroscopic metroplasty|
41099551|NCT02404454|DEVICE|Autocross-linked acid hyaluronic gel|Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
41099552|NCT02404454|PROCEDURE|Office second look hysteroscopy|Second-look hysteroscopy after three months
41099553|NCT01306331|DRUG|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
41099554|NCT01306331|DRUG|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
41099555|NCT05425836|DEVICE|Standard oxygen therapy|nasal cannula
41099556|NCT05425836|DEVICE|HFNC|High flow nasal cannula
41099557|NCT06630806|DRUG|SAR446523|Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
41099558|NCT02491931|DIETARY_SUPPLEMENT|Supplement/placebo intake|Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
41099559|NCT02471391|DRUG|ABT-199|
41099560|NCT02471391|DRUG|Ibrutinib|
41099561|NCT05775094|DRUG|Romosozumab|Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).
41099562|NCT03595943|DIETARY_SUPPLEMENT|Low glycemic index, pulse-based diet|Diet that includes pulses (i.e. meals that contain chickpeas, lentils, beans, or peas)
41099563|NCT03595943|DIETARY_SUPPLEMENT|Moderate glycemic index hospital diet|Diet that is derived from a regular hospital menu for patients
41099564|NCT06631326|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
41099565|NCT06631326|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
41099566|NCT01738555|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
41099567|NCT01738555|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
41099568|NCT06507657|DRUG|empagliflozin|"intake of a 10mg empagliflozin oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."
41099569|NCT06507657|DRUG|Placebo tablet|"intake a placebo oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."
41099570|NCT03028363|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
41099571|NCT03028363|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
41099572|NCT01286415|BEHAVIORAL|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy (CPT) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
41099573|NCT01286415|BEHAVIORAL|Group Present Centered Therapy|Present Centered Therapy (PCT) is a supportive group intervention typically used within the Department of Veterans Affairs (VA) healthcare systems to address problems of veterans with PTSD (Rosen, et al., 2004). PCT focuses on problem-solving current difficulties that may be related to past traumatic events, but does not address specific memories or cognitions about the trauma. Sessions will be conducted twice weekly for 6 weeks; sessions are 90 minutes.
41099574|NCT04238104|OTHER|no intervention|it's only observational study. No interventions.
41099575|NCT06629415|DRUG|Indocyanine Green|"injecting 7.5 mg (3 ml of a 25 mg/10 ml solution) intravenously in the pre-operative holding area at least 20 minutes before surgery.~Before dissecting the adhesions surrounding the hepatoduodenal ligament, fluorescence cholangiography (FC) is carried out to determine the anatomy of the extrahepatic bile ducts by converting the full-color images to fluorescence images using filter switches on the camera head and/or light source in the laparoscopic imaging system (Fig. 1). The \&amp;#34;critical view of safety\&amp;#34; is then reached by dissecting Calot\&amp;#39;s triangle and using FC to verify whether the accessory bile ducts are present or absent throughout the procedures. It is necessary to acquire fluorescence image"
41133249|NCT00914641|DRUG|Apixaban IR|immediate release tablet, 10 mg, single dose
41099576|NCT06629415|DRUG|Indocyanine Green Drug|1.25 mg of ICG powder was dissolved in 3 cm of saline, and the concentration was roughly 0.04 mg after each 1 cm of saline was diluted by 9 cm of saline. In order to prevent dye leakage that might result in false FC results, a veress needle was inserted through the abdominal wall and into the gall bladder fundus through the liver bed. The puncture site was then cauterized.
41099577|NCT03384537|COMBINATION_PRODUCT|Listerine total care zero|reducing intra-oral cariogenic microorganism.
41099578|NCT03384537|COMBINATION_PRODUCT|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
41099579|NCT06607731|OTHER|Collecting data from medical records|Data collected: clinical data (particularly pain), biological data, imaging.
41099580|NCT01087177|OTHER|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
41099581|NCT06468657|OTHER|mortality rates|mortality rates
41099582|NCT01837641|BIOLOGICAL|LY3002813-IV|Administered IV
41099583|NCT01837641|BIOLOGICAL|LY3002813-SC|Administered SC
41099584|NCT01837641|DRUG|Placebo-IV|Administered IV
41099585|NCT05052983|DRUG|Nemolizumab|Participants received either 1 \[30 milligram (mg)\] or 2 (2\*30 mg) subcutaneous (SC) injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).
41099586|NCT05052983|DRUG|Placebo|Participants received either 1 (30 mg) or 2 (2\*30 mg) SC injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
41099587|NCT01201187|DRUG|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
41099588|NCT01201187|DRUG|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
41099589|NCT06445231|DIAGNOSTIC_TEST|Implementation of echocardiography in nursing homes|An ultrasound will be carried out in the EHPAD, the result of which will be interpreted by a cardiologist then sent to the establishment and the attending physician with instructions to follow.
41099590|NCT02612584|DEVICE|Pinhole Soft Contact Lens apply for presbyopia|
41099591|NCT05460663|BEHAVIORAL|Stress Management and Resilience Training (SMART)|The Stress Management and Resilience Training (SMART) program was developed by Dr. Amit Sood. SMART focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. The SMART program incorporates practices that focus on six individual factors that have been found to promote individual-level resilience: positive coping, positive affect, positive thinking, realism, behavioral control, and altruism. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) and in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks.
41099592|NCT03199417|DRUG|Multiprofen|A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
41443269|NCT05059028|OTHER|Oxytocin massage AND music therapy|"Oxytocin massage: It is a massage that will accelerate the work of the parasympathetic nerves in order to transmit the oxytocin production stimulus to the posterior lobe of the brain. Massage the scapula from the cervical 7th to the 5th-6th spine, spinal (vertebral), 1-2 cm around the spine, both thumbs up and then 2-3 times down, in a small circular clockwise, downward and upward movements. It is a form of massage by pressing hard.~Music intervention: In order to decide on the type of music to be played to the mothers during breastfeeding, three samples (Pentatonic, Büzürk makam and classical music) selected by the researcher will be asked to the postpartum mother, and the music preferred by the mothers will be determined. It will be ensured that mothers listen to the music determined 5 minutes before the breastfeeding session for 7 days and continue breastfeeding while the same music is playing."
41443270|NCT03676764|DRUG|Azithromycin|biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
40752093|NCT00002836|DRUG|Carmustine|Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
40752094|NCT00002836|DRUG|Cisplatin|As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
41099593|NCT03199417|OTHER|Placebo|An identically packaged placebo cream
41099594|NCT06630637|BEHAVIORAL|Glucose-Ketone Index (GKI) monitoring|Ketone and blood glucose monitoring with Abbott Optium Neo up to 10 times per day to observe GKI dynamics for gamification of adherence.
41099595|NCT06630637|BEHAVIORAL|Continuous Glucose Monitoring (CGM)|Monitoring with an Abbott Freestyle Libre to observe glucose dynamics for gamification of adherence.
41099596|NCT06630637|OTHER|Digital dynamometer|Grip strength measurements, right and left hand, up to 20 readings per day per hand.
41099597|NCT06630637|DEVICE|Wearables|All Apple Watch 9 and Whoop data daily \[heart rate variability (HRV), resting heart rate, cardio recovery, sleep duration, composition (stages of sleep) and analogous scores, potential maximum rate of oxygen consumption attainable during physical exertion (VO2 max), basal metabolic rate and potential respiratory rate\].
41099598|NCT06630637|DIAGNOSTIC_TEST|Blood tests|Pre- and Post-fast (48h) testing of lipid panel, ApoB, ApoA1, CRP, interleukin panel, omega 3:6 ratio, and autophagy analysis. Potential CBC, renal and liver panels to be taken where appropriate.
41099599|NCT06630637|DIAGNOSTIC_TEST|Stool tests|"15 g of stool will be collected from the subject pre- and post-fast for microbiome assessment and pre- and post- the first week (the three meal phase). After the first week, the maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast)."
41099600|NCT06630637|DIAGNOSTIC_TEST|Saliva tests|Saliva samples will be collected from the subject pre- and post-fast for microbiome assessment. Maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast).
41099601|NCT06630637|BEHAVIORAL|Fitness intervention|90 minutes of strength and/or cardiovascular training for a minimum of 5 days per week.
41133250|NCT00914641|DRUG|Apixaban MR1|modified release tablet 1, 10 mg, single dose
41133251|NCT00914641|DRUG|Apixaban MR2|modified release tablet 2, 10 mg, single dose
41133252|NCT00914641|DRUG|Apixaban MR3|modified release tablet 3, 10 mg, single dose
41099602|NCT06630637|BEHAVIORAL|Cold & heat intervention|"Cold plunge: at least 3 days per week, 2 sessions of maximum 5 minutes each (minimum 2 minutes between sessions) at a minimum of 6 degrees Celsius. Potential inclusion of GKI measurements before and after plunge.~Heat Therapy: maximum of 2 sessions of 20 minutes each of dry sauna blanket (minimum 5 minutes break between sessions) following the cold plunge intervention."
41099603|NCT06630637|DEVICE|Airofit|"Airofit is a smart breathing training device designed to improve respiratory strength and efficiency. It is used for enhancing sport performance, well-being, and overall health. The device works by providing adjustable resistance to breathing muscles.~5-10 minutes of daily use."
41099604|NCT06630637|BEHAVIORAL|18h fasting|Minimum of 18 hours fasting per day, with feeding window to occur between 5pm-8pm or 12pm-3pm. The fasting procedures will occur only after the Three Meal Phase.
41099605|NCT06630637|BEHAVIORAL|48h fasting|48h fasting maximum twice monthly, at least one week apart. Multivitamin and electrolytes with water, and black coffee or tea (0-calorie drinks) will be consumed.The fasting procedures will occur the Three Meal Phase.
41099606|NCT06630637|BEHAVIORAL|Three meal phase|During the first week of the study, the participant will follow a regime of three meals per day.
41099607|NCT06630637|BEHAVIORAL|Mediterranean-inspired diet|"Regimen of Mediterranean-inspired nutrition comprised of Olive Oil, Olives, Leafy Green Vegetables, Lean Protein (Beef, Chicken, Lamb, Pork, Duck, Salmon, Tuna), Chia Seeds, Pecans, Macadamia, Pumpkin Seeds, Walnuts, Greek Yogurt, Salt, Pepper, Paprika, Cumin, Garlic powder, onion powder; Fruit: Blueberry, Grapefruit; Carbohydrates: Rolled Oats; Hydration: Water, Black Coffee, Black Tea, Coke Zero and 100 Zero sparingly, Ultima electrolytes.~Photographs of meals will be taken to create a visual record of the diet followed. Photographs of the devices will be taken to create a visual record of the blood glucose and ketone concentration results."
41099608|NCT06630637|DIETARY_SUPPLEMENT|Supplements|Multivitamin (Centrum), Vitamin D (Up to 2000 IU per day), Creatine (Up to 2000mg), Fisetin (1 pill), Omega-3 (1 tablet), Turmeric, Pre-Probiotic, Blueberry Extract, Holy Basil Extract.
41099609|NCT06630637|BEHAVIORAL|Generative AI|Feeding ketone data, glucose data (from finger prick and/or CGM), any/all Apple Watch Data, and dietary images into a generative AI platform to convert data into images using any selected prompts, with the intent of the images serving as immediate, visual readouts as a function of activity and/or inactivity.
41099610|NCT06630637|OTHER|Interviews|Three interviews, of 30-60 minutes each one, at baseline, end of three meal phase and end of study, to gain insights into the participant's experience. Exploration of daily routines including diet, exercise and the use of technology and aspects of a healthy lifestyle.
41099611|NCT06073171|BIOLOGICAL|Blood sample|7.5 mL will be sampled on EDTA tube for each patient
41099612|NCT06073171|BIOLOGICAL|Cutaneous biopsy|4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients
41099613|NCT06073171|GENETIC|High troughput sequencing of human's exome|Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.
41099614|NCT01432158|BIOLOGICAL|Prevenar 13|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
41099615|NCT01432158|BIOLOGICAL|Pneumovax II|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
41099616|NCT01985061|DRUG|BX2|
41099617|NCT01985061|DRUG|BX3|
41099618|NCT01985061|DRUG|BX4-Suspended|Suspended
41099619|NCT05688956|DIETARY_SUPPLEMENT|Fortimel Advanced, Nutricia|Per 200 mL serving size: 300 kcal, 21 g whey protein, 3 g leucine \& 10 µg Vitamin D.
41099620|NCT05688956|OTHER|Resistance Exercise programme|Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.
41099621|NCT05688956|OTHER|Dietary advice|Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.
41099622|NCT03625037|BIOLOGICAL|Epcoritamab|Administered as specified in the treatment arm.
41099623|NCT05914558|DIAGNOSTIC_TEST|Clinical appointment|One clinical interview and examination to confirm the diagnosis of trigeminal neuralgia and temporomandibular disorder.
41099624|NCT01048151|BIOLOGICAL|TNFerade™ Biologic|AdGVEGR.TNF.11D
41099625|NCT06630429|OTHER|Biospecimen Collection|Undergo collection of blood and stool samples
41099626|NCT05305040|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
41099627|NCT05305040|BIOLOGICAL|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
41099628|NCT06632015|PROCEDURE|root canal treatment and intracanal medicament|Root canal treatment and intracanal medicament procedures explained in arm descriptions.
41099629|NCT02205931|OTHER|Ketogenic diet|The ketogenic diet is a high fat diet designed to mimic the effects on the body of starvation. The premise is the main energy intake is fat, which is utilised in the body and produces ketones.
41099630|NCT02205931|DRUG|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
41099631|NCT05199688|DRUG|Satralizumab|Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
41099632|NCT03491956|DEVICE|DFPP|Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
41099633|NCT01972152|DRUG|G-Pen(TM) 1 mg|
41099634|NCT01972152|DRUG|Lilly Glucagon(TM) 1 mg|
41099635|NCT01972152|DRUG|G-Pen(TM) 0.5 mg|
41099636|NCT03861949|OTHER|5 cmH2O CPAP|
41099637|NCT03861949|OTHER|head-up position|
41099638|NCT03378739|PROCEDURE|Cardiogenic Shock team activation|Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.
41099639|NCT05203913|DRUG|Nivolumab|The recommended dose for nivolumab is 480 mg administered as 30 minutes IV infusions every 28 days for 13 infusions.
41099640|NCT05203913|DRUG|Nab paclitaxel|The recommended dose for nab-paclitaxel is 60 mg per square meter administered as 30 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
41099641|NCT05203913|DRUG|Cisplatin|The recommended dose for cisplatin is 20 mg per square meter administered as 60 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
41099642|NCT05203913|RADIATION|Radiotherapy|Radiotherapy will be delivered over approximately 5 weeks.The total radiotherapy dose will be: 60 Gray in 25 fractions over 5 weeks on original bladder tumour, 50 Gray in 25 fractions over 5 weeks on whole bladder and pelvic nodes if included, administered as concomitant boost. Radiation therapy will be delivered once daily (Monday-Friday) continuously without a planned break for tumour response assessment during treatment.
41099643|NCT04037735|DEVICE|ATTUNE S+ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE S+ Knee Prosthesis by DePuy
41099644|NCT04037735|DEVICE|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
41099645|NCT01208467|OTHER|Laboratory Biomarker Analysis|Correlative studies
41099646|NCT03450876|OTHER|Non-Interventional|Non-Interventional
41099647|NCT01624558|DEVICE|In-line Carbon filter (Vapor-Clean)|Carbon filter placed in anesthesia breathing circuit.
41099648|NCT02703155|DEVICE|Home Oral Glucose Tolerance Test kit|Providing Home Oral glucose tolerance test kit to children with Cystic fibrosis for screening Cystic Fibrosis Related Diabetes
41099649|NCT01874184|OTHER|counseling intervention|Take part in weekly group counseling sessions
41099650|NCT01874184|BEHAVIORAL|behavioral dietary intervention|Set goals for changing dietary habits
41099651|NCT01874184|BEHAVIORAL|exercise intervention|Attend group exercise activities
41099652|NCT01874184|OTHER|questionnaire administration|Ancillary studies
41099653|NCT01874184|OTHER|laboratory biomarker analysis|Correlative studies
41099654|NCT00439933|BEHAVIORAL|low fat and polysaccharide rich diet|
41099655|NCT00439933|BEHAVIORAL|specific physical training program for obese children|
41099656|NCT06556212|OTHER|Real-time feedback using smart swim goggles|Smart swim goggles (Form Athletica Inc.) with activity metrics (such as heart rate, swimming pace, and workout instructions) displayed in real-time during a swimming activity.
41099657|NCT00182416|DEVICE|pacemaker|
41099658|NCT02309567|OTHER|Blood Collection|
41099659|NCT02496806|DIETARY_SUPPLEMENT|Seaweed extract|Treatment capsule containing seaweed extract (treatment)
41099660|NCT05091372|DRUG|Belantamab mafodotin|"Belantamab Mafodotin~Belantamab mafodotin dose levels:~Dose level -2 = 1.4 mg/kg IV every 12 weeks Dose level -1 = 1.9 mg/kg IV every 12 weeks Dose level 0 = 1.9 mg/kg IV every 8 weeks~Cycles 1 - 6:~All patients will start at dose level 0.~Cycles 7 and onwards\*:~Patients previously on dose level 0 (1.9 mg/kg IV every 8 weeks) will change to dose level -1 (1.9 mg/kg IV every 12 weeks) Patients previously on dose level -1 (1.9 mg/kg IV every 12 weeks) will continue at the same dose level.~Patients previously on dose level -2 (1.4 mg/kg IV every 12 weeks) will continue at the same dose level.~\*Reduction to a lower dose level is allowed in case of development of adverse effects or poor tolerance as determined by the treating physician."
41099661|NCT05091372|DRUG|Lenalidomide|"Lenalidomide dose levels:~Dose level 0 (starting dose): Lenalidomide 10 mg/day PO continuously. Dose level -1: Lenalidomide 10 mg/day PO. One week off after every three weeks of treatment.~Dose level -2: Lenalidomide 5 mg/day PO. One week off after every three weeks of treatment."
41443271|NCT03676764|DRUG|Placebos|biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
41443272|NCT02810886|DRUG|68Ga-(HBED-CC)-PSMA|68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
41443273|NCT06625463|BEHAVIORAL|Home based cardiac rehabilitation|12 week home based cardiac rehabilitation include Physical exercise, dietary management, smoking cessation and stress management
41443274|NCT03392454|PROCEDURE|T+LRTI|T+LRTI is the most commonly used procedure, it removes the entire trapezium
40924962|NCT03654573|DEVICE|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
41099662|NCT06234865|OTHER|Control Group|Patients in the control group will receive standard education plus a brochure education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The brochure education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
41099663|NCT06234865|OTHER|Video Education Group|Patients in the experimental group will receive standard education plus a video education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The video education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
41099664|NCT00005106|DRUG|Lamivudine/Zidovudine|
41099665|NCT00005106|DRUG|Abacavir sulfate|
41099666|NCT00005106|DRUG|Nelfinavir mesylate|
41099667|NCT00005106|DRUG|Lamivudine|
41099668|NCT00005106|DRUG|Stavudine|
41099669|NCT02456883|DRUG|gilteritinib|oral
41099670|NCT02456883|DRUG|14C-labeled gilteritinib|oral
41099671|NCT05014204|DEVICE|The Endogenex Device|The Endogenex device is designed to induce duodenal mucosal regeneration using pulsed electric field. The Endogenex procedure is a non-surgical, endoscopic procedure.
41099672|NCT00283374|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
41099673|NCT00462969|PROCEDURE|Sonohysterography|Sonohysterography
41099674|NCT01645852|DIETARY_SUPPLEMENT|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
41443275|NCT03392454|PROCEDURE|PT+TI|The PT+TI is less invasive than the T+LRTI as only part of the trapezium is removed
41099675|NCT06628492|DEVICE|stainless steel printed surgical guide|the patient will wear the stainless steel surgical guide for the insertion of one implant
41099676|NCT06628492|DEVICE|resin printed surgical guide|the patient will wear the resin surgical guide for insertion of adjacent another implant implant
41099677|NCT06631859|OTHER|Cosmetic products containing 0% Assam tea|Cosmetic products containing 0% Assam tea
41099678|NCT06631859|OTHER|Cosmetic products containing 2.5% Assam tea|Cosmetic products containing 2.5% Assam tea
41099679|NCT06442384|OTHER|Tobacco and non-tobacco e-cigarettes|Participants with no e-cigarette restrictions.
41099680|NCT06442384|OTHER|Tobacco only e-cigarettes|Participants restricted to tobacco flavored e-cigarettes only.
41099681|NCT05949203|DRUG|Cabotegravir Injection|Administration of HIV pre-exposure prophylaxis with cabotegravir 600 mg/3mL extended release injectable suspension every other month.
41099682|NCT00815321|BIOLOGICAL|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
41099683|NCT02755363|OTHER|osteopathic manual therapy|"* suboccipital decompression - atlanto-occipital joint relaxation technique.~* deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~* thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~* stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs."
41099684|NCT02755363|OTHER|control group|"* manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~* manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres."
41099685|NCT05835115|DIAGNOSTIC_TEST|A deep learning-based myopia and myopic maculopathy detection and prediction system|This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.
41099686|NCT03357640|DRUG|combined oral contraceptive pills|one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
41099687|NCT06473519|BIOLOGICAL|RSVpreF MDV|RSVpreF with 2-PE formulated in an MDV
41099688|NCT06473519|BIOLOGICAL|RSVpreF SDV|RSVpreF without 2-PE formulated in an SDV
41099689|NCT01991912|PROCEDURE|open lumbar decompression|A posterior midline incision is performed over the affected levels. Bilateral subperiosteal dissection of the paraspinal muscles is performed. Bilateral hemilaminotomies, foraminotomies and lateral recess decompression is performed followed by wound closure
41099690|NCT00362843|DRUG|[15-O]water|
41099691|NCT03514199|OTHER|Mediterranean-type diet|"Recommendations: ingest whole grains; three or more servings/day (various fresh fruits/vegetables); three or more servings/week of fish or seafood; white meat to red and processed meat (red meat to one serving or less/day); oilseed mix - 30g/day (nuts: 15g/day, almonds: 7.5g/day, hazelnuts: 7.5g/day); extra virgin olive oil (30ml/day: 2 soup spoons/day) as the main source of fat in the salads; two or more servings per week of sofrito; two servings/day of low-fat dairy products; limit to one serving/week the intake of fatty and cured cheeses; recommendation of 7 glasses per week of red wine (recommendation for habitual drinkers): 1 cup/day of 100ml for women and 1-2 cups/day of 150ml for men; limit to one serving/week the intake of chocolate with more than 50% cocoa."
41099692|NCT03514199|OTHER|Low fat diet|Recommendations: choose grilled, cooked, baked or soaked preparations; avoid frying (sweet or salty); avoid excess fat in the preparations and season the foods with herbs at will (marjoram, basil, oregano, onion, green seasoning, sweet pepper, sage, etc.); avoid frequent ingestion of sausages such as ham, turkey breast, among others; avoid eating fatty meats and strip the skin of poultry before preparation; avoid eating sweets and fatty foods; avoid ingesting bakery products, such as leafy, tart, savory pasta.
41099693|NCT04258410|DRUG|Placebo oral soft chew|placebo identical to experimental drug contained in soft chew
41099694|NCT04258410|DRUG|Quercetin|experimental drug contained in soft chew
41099695|NCT06631300|DRUG|Prednisone|A prednisone taper will be given to the subjects as follows: prednisone 40mg for 3 days, prednisone 30mg for 3 days, prednisone 20mg for 3 days, prednisone 10mg for 3 days, prednisone 5mg for 3 days, then off for a total of 15 days.
41099696|NCT06631300|DRUG|Placebo|A placebo taper will be given to match the same number of pills administered in each stage of the prednisone taper.
41133253|NCT05430555|BIOLOGICAL|Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR|Single-dose intravenous infusion of MAGE-A1 directed TCR-transgenic T cells following a conditioning chemotherapy
40924963|NCT03283605|RADIATION|SBRT|SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
41099697|NCT00106431|DRUG|romidepsin (depsipeptide, FK228)|Study patients received romidepsin at a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
41099698|NCT01643291|PROCEDURE|Ultrasound|Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
41099699|NCT04127058|DRUG|Iloperidone|Oral Tablet
41099700|NCT05709457|BEHAVIORAL|Cash transfer in prior study|Women were offered a cash transfer conditional on attending prenatal and postnatal visits and delivering in a facility
41099701|NCT04570475|DRUG|Vitamin D|Participants will receive vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
41099702|NCT04570475|DRUG|multivitamin|Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
41099703|NCT04570475|DRUG|Placebo|Participants will receive placebo+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
41099704|NCT06630520|COMBINATION_PRODUCT|Periarticular injection|"A 50ml periarticular injection was introduced intraoperatively before the time of closing. The injection contained 150mg bupivacaine (3mg/mL), 60mg ketorolac(1.2mg/mL) and 1mg morphine.~Before wound closure, periarticular cocktail was injected around the knee joint including the adductor canal from the hamstring harvest side in PAI group. All patients had oral paracetamol 500mg, 4 times/day and diclofenac 75mg, 1 times/day after surgery."
41099705|NCT04124263|OTHER|Educational short message texts|Educational messages for patient engagement
41099706|NCT04124263|OTHER|Adherence short message texts|Reminder messages of medication use time
41099707|NCT00143650|BEHAVIORAL|House dust|
41099708|NCT03723512|DEVICE|Non contrast-enhanced magnetic resonance imaging|Non contrast-enhanced magnetic resonance imaging
41099709|NCT04173962|DRUG|Ketamine|administered 1 week prior to a laboratory-induced stress
41099710|NCT04173962|DRUG|Midazolam|administered 1 week prior to a laboratory-induced stress
41099711|NCT05449002|BEHAVIORAL|Practicing the Opposite (PTO)|This 30-45-minute digital program is designed to help youths on the waitlist feel better prior to treatment and may also improve their treatment engagement and outcomes.
41099712|NCT05449002|OTHER|Usual Clinical Care|Usual care provided by participating youth mental health clinics in the United States.
41099713|NCT02688972|OTHER|cold water immersion|The volunteers stayed immerged up to the iliac crest, in the water with water. The temperature utilized was 10 degree C and the time was 10 minutes
41099714|NCT02688972|OTHER|Control group|The volunteers stayed in rest about 10 minutes
41099715|NCT06356584|DRUG|Sintilimab|Immunotherapy
41099716|NCT02561403|BEHAVIORAL|EVO multitask video game|Participants will play a multitasking game for 4 weeks
41099717|NCT02561403|BEHAVIORAL|EVO words video game|Participants will play a word puzzle game for 4 weeks
41099718|NCT06630052|OTHER|adductor canal clinical examination|clinical examination of the adductor canal in patients with knee pain not matching the radiological changes
41099719|NCT05629702|DRUG|Nabiximols|Oromucosal spray
41099720|NCT05629702|DRUG|Temozolomide|Oral capsule
41099721|NCT05629702|DRUG|Nabiximols-matched placebo|Nabiximols-matched placebo oromucosal spray
41099722|NCT05502211|DRUG|Fentanyl|induction of anaesthesia using fentanyl
41099723|NCT05502211|DRUG|Lidocaine IV|induction of anesthesia using lidocaine
41099724|NCT00762658|DRUG|AN2728 Ointment, 5%|
41099725|NCT00762658|DRUG|AN2728 Ointment, 2%|
41099726|NCT00762658|DRUG|AN2728 Ointment, 0.5%|
41099727|NCT00762658|DRUG|AN2728 Ointment Vehicle|
41099728|NCT00762658|DRUG|Betnesol®-V Creme, 0.1%|
41099729|NCT00762658|DRUG|Protopic® Ointment, 0.1 %|
41099730|NCT04900155|DRUG|Atorvastatin 80mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
41099731|NCT04900155|DRUG|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
41099732|NCT02709174|PROCEDURE|blood draw|blood draw
41443276|NCT00781339|DRUG|sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate|0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
41099733|NCT02499328|DRUG|AZD9150|AZD9150
41099734|NCT02499328|DRUG|MEDI4736|MEDI4736
41099735|NCT02499328|DRUG|AZD5069|AZD5069
41099736|NCT02499328|DRUG|tremelimumab (treme)|tremelimumab
41443277|NCT00045786|DRUG|CC-1088|400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
41099737|NCT00184561|DRUG|biphasic insulin aspart|
41099738|NCT00893373|DRUG|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
41099739|NCT00893373|DRUG|placebo|Standard AML chemotherapy plus placebo
41099740|NCT00590850|PROCEDURE|ORIF with Plate and Screws|ORIF with plate and screws
41099741|NCT00590850|PROCEDURE|Pin Fixation|Clavicle fixation with clavicle pin
41099742|NCT01719536|DRUG|Icotinib|Icotinib: 125 mg is administered orally three times per day.
41099743|NCT01719536|DRUG|Chemotherapy|First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
41099744|NCT05020795|PROCEDURE|Endovascular thrombectomy|Clot retrieval for large vessel occlusion in acute ischaemic stroke
41099745|NCT00975806|DRUG|Lenalidomide|Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination
41099746|NCT00975806|DRUG|Sunitinib|Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
41099747|NCT05686356|DRUG|Sutezolid|Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
41099748|NCT05686356|DRUG|N-acetyl cysteine|NAC will be given at a dose of 1800 mg BID in arm 3
41099749|NCT05686356|DRUG|Pretomanid|Pretomanid will be given at its approved dose
41099750|NCT05686356|DRUG|Bedaquiline|Bedaquiline will be given at its approved dose
41099751|NCT05686356|COMBINATION_PRODUCT|Rifafour|Fixed dose combination tablets for TB treatment will be given at approved doses
41099752|NCT06085820|BEHAVIORAL|Experimental (birth ball)|"It is a large and firm ball made of soft, thick plastic, inflated with air. It can be easily inflated and deflated, washable, available in different sizes (55-65-75 cm in diameter) and strong enough to carry weight up to 136 kg.~When the literature was examined, it was seen that birth balls between 55-75cm were generally used in accordance with the intended use. Appropriate ball size will be determined by the participant's height. In order for the pregnant woman to continue balance exercises, she should be allowed to sit on the round birthing ball with her knees and hips at an angle of approximately 90°, with an upright spine.~birth ball; It is performed in sitting (pelvic rocking movement, forward-backward and right-left rocking, forward-supported sitting, springing movement), kneeling and squatting (hugging the ball and pelvic rocking movement) positions."
41099753|NCT06085820|BEHAVIORAL|Experimental (birth dance)|"Thanks to the birth dance, the expectant mother perceives less pain. In fact, it is known that a change in position is effective in the perception of pain. On the other hand, if the woman focuses on a point other than the pain during the act, it makes it easier for her to perceive the pain less. The low cost of this application increases its usability.~The most appropriate time for the birth dance is from the active phase of the first phase of labor until the end of this phase . The expectant mother dances with rhythmic movements accompanied by soothing and soothing music with the help of a birth supporter (midwife, relative, spouse or partner). Optionally, sacral massage can be added to the birth dance. In fact, in addition to reducing the pain experienced through freedom of movement, upright position and massage, it is also aimed to provide emotional support to the woman."
41099754|NCT05481294|OTHER|Transpersonal Supportive Coaching|Coaching is given for four months (two times a month) with a 45-minute duration per coaching by a professional coach
41099755|NCT05481294|OTHER|Standard Support|Standard support is given for four months using a support system provided by Peer Support Foundation
41099756|NCT04638647|BIOLOGICAL|Secukinumab s.c. injection|Secukinumab pre-filled syringes (PFS) for s.c. injection
41099757|NCT04151082|DRUG|Methylprednisolone|Given IV
41099758|NCT04151082|DRUG|Prednisone|Given PO
41099759|NCT04151082|OTHER|Quality-of-Life Assessment|Ancillary studies
41099760|NCT04151082|OTHER|Questionnaire Administration|Ancillary studies
41099761|NCT06226987|DIAGNOSTIC_TEST|68Ga-DOTATATE PET/MRI|PET/MRI scanning
41099762|NCT05972694|DIETARY_SUPPLEMENT|Freeze dried grape powder|46g/d freeze-dried grape powder
41099763|NCT05507463|DRUG|KBP-7072|KBP-7072
41099764|NCT05507463|DRUG|Placebo|Placebo
41099765|NCT03429387|DIAGNOSTIC_TEST|FDG-PET/CT|FDG-PET performed with low dose CT
41099766|NCT03429387|DIAGNOSTIC_TEST|Conventional CT|HRCT and CT of sinuses +/- other regions as per clinician's discretion
41099767|NCT05994092|BEHAVIORAL|Voluntary Isocapnic Hyperpnea|The protocol of 3' of breathing with 20 breaths·min-1 frequency. The Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc, Kelowna, Canada) with 6-liter bags were used. The protocol was performed in a seating position.
41099768|NCT00777556|DRUG|DR-104|One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
41099769|NCT02971306|DRUG|standard medical therapy|Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
41099770|NCT02971306|DRUG|G-CSF|G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
41099771|NCT02971306|DRUG|n-Acetylcysteine|n-Acetylcysteine at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution
41099772|NCT03780309|BEHAVIORAL|Exercise Self-Monitoring|Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
41099773|NCT03780309|BEHAVIORAL|Blood Pressure Self-Monitoring|Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
41099774|NCT04470193|OTHER|MyChildCMC app|Patients/parents will self-monitor their symptoms daily using the MyChildCMC app completing the daily vitals form. After patient/parents complete the daily form, the app provides in-app alerts and graphs showing symptom data over time.
41099775|NCT05829096|OTHER|The COMBINED approach|"1. Patient-level intervention:~   * Assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~  * Brief intervention to support health behaviour change: smoking cessation, increasing physical activity levels and consuming a healthy diet~  * Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring.~2. Clinician-level implementation toolkit:~   * Training package including a face-to-face workshop, training manual, recorded role play simulations and an online follow-up training session~  * Additional supporting resources; a step-by-step guide to The COMBINED approach, scripts, patient signposting information to support services and a lay summary infographic to explain the links between the health behaviours and RC disorders to patients~  * Audit and feedback via observations of consultations to address any 'drift' from the intervention delivery as intended"
41099776|NCT02990858|DRUG|PRO 140 SC injections|
41099777|NCT05392738|DEVICE|I-Stent implantation|I-Stent implantation
41099778|NCT04300335|OTHER|Individual Exercise|Supervised body weight \& resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
41099779|NCT04300335|OTHER|Group Exercise|Supervised body weight \& resistance band resistance exercises in a Group setting plus home based aerobic exercise
41133254|NCT00598390|DRUG|[11C]MePPEP|
41099780|NCT01723670|DRUG|CHF 5074 1x|oral tablet, 1x, once a day for 24 months
41099781|NCT01723670|DRUG|CHF 5074 2x|oral tablet, 2x, once a day for 24 months
41099782|NCT01723670|DRUG|Placebo|oral tablet,once a day for 24 months
41099783|NCT04587167|OTHER|Project ECHO|"Using proven adult learning techniques and interactive video technology, the ECHO Model promotes knowledge exchange between experts or specialists at centers of excellence (the hub) and primary care providers (the spokes), typically located in rural settings. Through regular real-time collaborative sessions, the spokes connect with the hub and with other spokes to discuss 1) best practices in care and 2) complex cases managed within their practice."
41099784|NCT04587167|OTHER|Announcement Approach Training|Train physicians and their clinic staff to make strong HPV vaccine recommendations by using presumptive announcements. If parents show vaccine hesitancy, the Training train physicians a 3-step approach (Connect, Clarify, Counsel) to share effective, evidence-based messages about HPV vaccine.
41099785|NCT04587167|OTHER|Recall notices|Notify parents that their child is behind for HPV vaccination. Recall notices will include research-tested messages to specifically address parent concerns. Recall notices will be sent to parents via patient portal or email communication.
41099786|NCT02949570|DRUG|Inecalcitol|Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.
41099787|NCT06631976|DRUG|1ml of Depo-Medrol® injection|1ml of methylprednisolone acetate (40mg/ml) injection into subacromial bursa.
41099788|NCT06631976|OTHER|Rehabilitation|Rehabilitation
41099789|NCT06631976|DRUG|Nerve block with 4ml of 2% lidocaine|Nerve block with 4ml of 2% lidocaine around the suprascapular nerve
41099790|NCT06631976|DRUG|Tropocells® PRP injection|Tropocells® PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.
41099791|NCT00835016|BEHAVIORAL|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
41099792|NCT06630702|DEVICE|SCS electrode stimulation 1|300Hz/300us
41099793|NCT06630702|DEVICE|SCS electrode stimulation 2|130Hz/300us
41099794|NCT06630702|DEVICE|SCS electrode stimulation 3|60Hz/300us
41099795|NCT01805921|BIOLOGICAL|PanAd3-RSV given intra-nasally (high dose)|High dose = 5x10\^10 vp
41099796|NCT01805921|BIOLOGICAL|MVA-RSV given by intra-muscular injection (high dose)|High dose = 1x10\^8 pfu
41099797|NCT01805921|BIOLOGICAL|PanAd3-RSV given by intra-muscular injection (high dose)|High dose = 5x10\^10 vp
41099798|NCT01805921|BIOLOGICAL|PanAd3-RSV given intranasally (low dose)|Low dose = 5x10\^9 vp
41099799|NCT01805921|BIOLOGICAL|MVA-RSV given by intra-muscular injection (low dose)|Low dose = 1x10\^7 pfu
41099800|NCT01805921|BIOLOGICAL|PanAd3-RSV given by intra-muscular injection (low dose)|Low dose = 5x10\^9 vp
41099801|NCT00097253|BEHAVIORAL|Exposure to relaxant and stimulant odors|A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
41099802|NCT06628765|DEVICE|8.6 Fr single-use fURS (XFGC-FU-660RC)|Comparative device
41099803|NCT06628765|DEVICE|6.3 Fr single-use fURS (Hugemed, HU30S)|Device being tested
41099804|NCT01784068|DRUG|Nilotinib followed by treatment-free|Nilotinib is being used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. Treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
41443278|NCT06253533|BIOLOGICAL|ICVAX|ICVAX is a HIV therapeutic DNA drug developed by Immuno Cure Group based on the PD-1-Enhanced DNA Vaccine Technology platform. The unit dose strength is 2 mg in 1 mL. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
41099805|NCT02455687|DRUG|Hi-dose iv MgSO4|
41099806|NCT02455687|DRUG|Nebulized budesonide|
41099807|NCT02455687|DRUG|Std-dose iv MgSO4|
40752095|NCT00002836|DRUG|Cyclophosphamide (CTX)|In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
41099808|NCT02455687|DRUG|Nebulized normal saline|
41099809|NCT00782041|DRUG|Oxaliplatin|85 mg/m²
41099810|NCT00782041|DRUG|5-FluoroUracil|2,000 mg/m²
41099811|NCT00782041|DRUG|Folinic acid|20 mg/m²
41099812|NCT05621798|OTHER|Hearing Aid Manufacturer's Software|"When using hearing aid manufacturer's software (s.c. first-fit or initial fit) the fitting will follow the guided fitting procedure in the fitting software."
41133255|NCT00239512|DRUG|Indomethacin and Ibuprofen|
41133256|NCT03989388|BEHAVIORAL|Occupational self-analysis|"The Occupational Self-Analysis program provides participants with a space where they can learn to analyse the barriers and supports for occupational participation."
41133257|NCT03989388|BEHAVIORAL|Vocational guidance|To explore participant´s job interests and learned how to find a job and define a professional profile.
41133258|NCT03989388|BEHAVIORAL|Usual Rehabilitation|Usual rehabilitation: occupational therapy and/or physiotherapy.
41099813|NCT05621798|OTHER|REM (Real Ear Measurements)|Participants' hearing aids are fitted by using REM. In this method REM measurement tube is placed inside participant's ear canal near the tympanic membrane and the Real Ear Unaided Gain (REUG) is measured. REUG is used to measure the ear canal without any hearing device and shows the patients ear acoustics. Next the hearing aid is placed on the patients ear together with the REM measurement tube. In REM measurements the Real-Ear Occluded Gain (REOG) is measured with the hearing aid off. REOG allows consideration of the attenuation caused by the earpiece and its obstructing effect of external sounds. Next Real Ear Aided Response (REAR) is measured with the hearing device on. REAR allows measurement of the hearing device's amplification effect within the patients' ear and includes the effect of the patient's ear acoustics.
41099814|NCT06627426|OTHER|VR-based patient informed consent|"The intervention group will be the on receiving VR-based patient informed consent. One surgeon from the study team will be guiding the patient through their VR model first with demonstration of the technology and the model, afterwards the patient will be enabled to use the VR system by themselves. During the whole process the patient will be able to ask questions. Depending on the planned surgery, the surgical approach as well important anatomical structures will be explained."
41099815|NCT01333514|DRUG|aspart|Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
41099816|NCT01333514|DRUG|aspart- Insulin|0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
41099817|NCT06206408|DRUG|Fezolinetant|oral
41099818|NCT06206408|DRUG|Placebo|oral
41099819|NCT04215978|DRUG|BGB-A445|Administered as specified in the treatment arm
41099820|NCT04215978|DRUG|tislelizumab|Administered as specified in the treatment arm
41099821|NCT04831684|DRUG|Placebo|Participants will be getting placebo for 8 days of dosing.
41099822|NCT04831684|DRUG|GET73|Participants will be getting GET73 for 8 days of dosing.
41099823|NCT01841827|DRUG|Cilostazol|
41099824|NCT01841827|DRUG|Placebo|
41099825|NCT01496638|PROCEDURE|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with no side branch treatment
41099826|NCT01496638|PROCEDURE|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
41099827|NCT05085496|BIOLOGICAL|Atezolizumab|Given IV
41099828|NCT05085496|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41099829|NCT01723436|OTHER|Hypothetical scenarios and related decisions|Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
41099830|NCT04088513|DRUG|Aspirin|This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
41099831|NCT04088513|DRUG|Clopidogrel|This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
41099832|NCT00000433|DRUG|Anti-Tumor Necrosis Factor|
41099833|NCT05379127|OTHER|Patient-empowered follow up|"The patient-empowered follow-up protocol consists of patient-reported outcome measures (PROMs), self-assessment tools and clinical assessment including physical examination. Radiographs will only be taken when progression of the scoliosis (curve progression) or postoperative complications are suspected based on test results and based on the criteria of so called 'sense of alarm'.~Note: Sense of alarm ('niet pluis') is based on any deterioration on the above-mentioned PROMs, self-assessment tool, and clinician-based measurement instruments, which is a signal for the treating physician to consider when a radiograph is appropriate. Sense of alarm is described as any other concern by the orthopaedic surgeon, parent or child which warrants a radiograph. For both the Bunnell Scoliometer (clinical assessment tool) and the Scolioscoop (patient self-assessment tool) a threshold of ≥4° is used."
41099834|NCT05379127|OTHER|Standard follow-up|Routine radiographs are taken at each follow up visit during standard care (to detect possible curve progression or rule out postoperative complications).
41099835|NCT06630572|DRUG|Rifaximin|Patients randomized to receive Rifaximin for 14 days
41099836|NCT06630572|DRUG|Placebo|Patients randomized to receive Placebo for 14 days
41099837|NCT04822129|BEHAVIORAL|Treatment as Usual|Treatment as usual will provide participants with basic information that is readily available as well as the encouragement to develop a brain health program that may be available from medical professionals.
41099838|NCT04822129|BEHAVIORAL|Cogtrastim Model|The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model.
41099839|NCT00069459|DRUG|Extended-release Bupropion Hydrochloride|Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
41099840|NCT05671835|DRUG|TTI-101|Orally via a tablet.
41099841|NCT05671835|DRUG|Placebo|Orally via a tablet.
41099842|NCT00001258|DRUG|Oxygen-15 Water|
41099843|NCT00820118|DRUG|Structured treatment interruption|"The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~* atazanavir : 300 mg/d~* ritonavir : 100 mg/d~* abacavir 600 mg and lamivudine 300 mg : once a day~* tenofovir 245 mg and emtricitabine 200 mg : once a day"
41099844|NCT04517994|BEHAVIORAL|Active Treatment|See arm description.
41099845|NCT04517994|BEHAVIORAL|Supportive Treatment|See arm description.
41099846|NCT05993403|OTHER|Intercultural Sensitivity Education Program|The training program consists of three sessions. In the Intercultural Sensitivity training for nurses, it was aimed to develop the level of intercultural sensitivity, and it was aimed to provide proficiency in providing services to raise awareness and knowledge about intercultural sensitivity.
41099847|NCT02534896|DRUG|Treatment I|Sunpharma1505 and Placebo
41099848|NCT02534896|DRUG|Treatment II|Sunpharma1505 and Placebo
41099849|NCT02534896|DRUG|Treatment III|Reference1505 and Placebo
41099850|NCT04679935|BIOLOGICAL|Brolucizumab|Intravitreal injection
41099851|NCT04497961|DRUG|Lenalidomide|dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle.
41099852|NCT04497961|DRUG|Daratumumab|1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36
41099853|NCT04497961|BEHAVIORAL|Questionnaires|EORTC QLQ-C30, EORTC QLQ-MY20, PRO-CTCAE)
41099854|NCT04497961|OTHER|Dietary Intervention|The intervention, consisting of fully prepared whole foods plant based (WFPBD) meals and behavioral coaching provided by Daily Harvest. Patients receive self-selected WFPBD meals (lunch/dinner) for 12 weeks, along with guidance for snacks and breakfast. Behavioral counseling will be provided by health coaches and a research dietitian. The first 15 participants on each arm interested in this intervention will be enrolled on C13D1 or C25D1.
41099855|NCT06408207|BEHAVIORAL|CGM Academy|Educational materials as well as online sessions with diabetes educators.
41099856|NCT05312541|PROCEDURE|pre emptive local anaesthetic wound infiltration|Before skin incision by 15 min the surgeon will infiltrate the wound by syringe containing 20 ml mixture of (10 ml xylocaine 2%and 10 ml bupivacaine 0. 5%) in both groups
41099857|NCT01834235|DRUG|Gemcitabine|Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
41099858|NCT01834235|DRUG|nab-paclitaxel|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
41099859|NCT01834235|DRUG|NPC-1C|NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
41099860|NCT02221700|PROCEDURE|Massage Therapy|Undergo massage therapy
41099861|NCT02221700|OTHER|Quality-of-Life Assessment|Ancillary studies
41099862|NCT02221700|OTHER|Questionnaire Administration|Ancillary studies
41099863|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
41099864|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
41099865|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
41099866|NCT00880490|DRUG|Inhaled placebo|single dose, inhaled
41099867|NCT00880490|DRUG|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
41099868|NCT04746859|OTHER|Prevention Visit|Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.
41099869|NCT04746859|BEHAVIORAL|Peer health coaching|Patients will be invited to register with the software platform used to facilitate peer health coaching. Once they have registered, they will be matched to a peer health coach who will connect with the patient to initiate the process. The coach will work collaboratively with the patient to help her follow through on a step-wise, personalized plan to achieve health goals that were developed with their prevention practitioner. The coach's approach will be informed by principles of brief action planning and motivational interviewing. Coaches will also provide social support, help to navigate to relevant information and community resources, and advise about options for self-monitoring. Coaching will occur over 12-16 sessions via phone calls, text messages, video calls and/or in-person meetings as desired/convenient and in accordance with local public health guidelines.
41099870|NCT04957615|BIOLOGICAL|Nivolumab|Given IV
41099871|NCT02228811|DRUG|DCC-2701 tablet|
41099872|NCT05652530|DRUG|Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)|This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
41099873|NCT06631339|OTHER|Light Intervention|LEDs mimicking the spectrum of sunlight (4000K) administered daily for 1 academic year, every school day, for the entire school day. The light levels generated by these LEDs will fluctuate throughout the day but will remain under 1000 lux.
41099874|NCT06631339|BEHAVIORAL|Digital Intervention|Smart-phone application (LightUP) will be synced daily to a child-worn light and activity sensor and will allow parents to track their children's outdoor time and exposure to brighter light levels across the day. The application will also nudge parents to increase their child's exposure to light (e.g., increase time outdoors, or sitting next to a window indoors) after school hours for better myopia prevention and control. i-LightUP aims to gradually assist parents in helping their children reach the ultimate goal of spending at least 2 hours per day in brighter light conditions (e.g., above 1000 lux).
41099875|NCT06631339|OTHER|Control Group|Standard Classroom Lighting + Sham LightUP phone application
41099876|NCT05623280|DRUG|Indocyanine green|Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL
41099877|NCT03037190|OTHER|withdrawal of gluten from the diet|Gluten free diet the same recommendations as for patients with diabetes and known celiac disease
41099878|NCT06629363|OTHER|biobank|"The following samples will be collected :~* Serum samples and plasma sample: inclusion visit and follow up visit~* Urines samples : inclusion visit and follow up visit~* blood DNA: inclusion visit~* Blood RNA: inclusion visit and follow up visit"
41099879|NCT06596668|DRUG|bomedemstat|Oral tablet
41099880|NCT06596668|DRUG|carbamazepine|Oral extended-release capsule
41099881|NCT06353243|BEHAVIORAL|Bilateral alternating stimulation|positive touch intervention provided by parent to infant using alternating stimulation
41099882|NCT03768206|BEHAVIORAL|Standard Physical Therapy|Participants will receive standard outpatient physical therapy that is typical following knee replacement
41099883|NCT03768206|BEHAVIORAL|Physical therapist discuss aerobic physical activity|Physical therapists will provide recommendations to increase aerobic physical activity and set goals during standard physical therapy sessions after knee replacement.
41099884|NCT03768206|BEHAVIORAL|Physical activity session|Participants will receive a one hour coaching session on aerobic physical activity and goal setting after knee replacement.
41099885|NCT04950751|BIOLOGICAL|candidate vaccine, SCB-2020S|a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
41099886|NCT04157257|DRUG|TDF tablet|TDF tablet 300mg QD
41099887|NCT04157257|DRUG|Entecavir Tablet|Entecavir tablet 0.5mg QD
41099888|NCT04157257|DRUG|QL-007|QL-007 tablets 200mg BID
41099889|NCT06629012|PROCEDURE|Breast reconstruction with neurotization|Patients received breast reconstruction with neurotization procedure
41099890|NCT06629012|PROCEDURE|Breast reconstruction without neurotization|Patients received breast reconstruction without neurotization
41099891|NCT06628999|OTHER|Visual Training|16-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness
41099892|NCT06628999|OTHER|Control Group|16-week of active lifestyle based on healthy habits
41099893|NCT06628999|OTHER|Visual Training-detraining|8-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness, followed by 8 week with no specific training protocol
41099894|NCT04816825|DEVICE|Alkit eSence|Home-based rehabilitation program including computer games and supervised by a physiotherapist.
41099895|NCT04816825|OTHER|Standard rehabilitation|Standard rehabilitation program at the COPD-Center
41099896|NCT06630247|DRUG|XL495|oral doses of XL495
41099897|NCT06630247|DRUG|ADC cytotoxic agents|intravenous infusion of anti-cancer combination agent
41099898|NCT03877471|GENETIC|Cell therapy|Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.
41099899|NCT06628544|BIOLOGICAL|BCG vaccination|BCG vaccination
41099900|NCT06628544|DRUG|Metformin is administered on the day 0|Metformin is administered on the day 0
41099901|NCT06628544|OTHER|Placebo|Placebo
41099902|NCT06628544|DRUG|Metformin is administered on the day 9|Metformin is administered on the day 9
41099903|NCT06628544|DRUG|Metformin is administered on the day 85|Metformin is administered on the day 85
41099904|NCT00404079|DRUG|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
41099905|NCT00404079|DRUG|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
41099906|NCT04084769|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: IM
41099907|NCT04084769|BIOLOGICAL|Meningococcal Group B vaccine (Trumenba®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
41099908|NCT04084769|BIOLOGICAL|Meningococcal group B vaccine (Bexsero®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
41099909|NCT00817050|DRUG|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
41099910|NCT00817050|DRUG|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
41099911|NCT04460573|DEVICE|Boot|Smart boot in one of three configurations provided to participants
41099912|NCT03916926|DEVICE|"A simple medical strategy consisting of silver diamine fluoride (SDF)"|Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL)
41099913|NCT03916926|DEVICE|"B typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride varnish (FV)"|GC Fuji (for ART) and FluoriMax Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL (for FV)
41099914|NCT06018129|BIOLOGICAL|GEN3017|Subcutaneous injection
41099915|NCT06620614|COMBINATION_PRODUCT|0.5% Heavy Bupivacaine|There are two groups.
41099916|NCT05192707|DIAGNOSTIC_TEST|TcPO2 measurement on the upper limb|Measurement of the transcutaneous Oxygen Pressure in the upper limb of 30 healthy volunteers and of at least 30 patients.
41099917|NCT06630910|PROCEDURE|Pancreaticojejunostomy without stenting and omental patch|A traditional pancreaticoduodenectomy with pylorus preservation was performed on each patient. A pancreaticojejunostomy was created by double-layered, end-to-side, duct-to-mucosa anastomosis between the primary pancreatic duct and jejunal wall without stenting or omental patch.
41133446|NCT02515123|DEVICE|E-Motion System|"E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.~E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.~By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding."
41099918|NCT06630910|PROCEDURE|Pancreaticojejunostomy with stenting and omental patch|A traditional pancreaticoduodenectomy with pylorus preservation was performed on each patient. A pancreaticojejunostomy was created by double-layered, end-to-side, duct-to-mucosa anastomosis between the primary pancreatic duct and jejunal wall, a nelaton stent 6f was inserted into the pancreatic duct and jejunum of each patient receiving PJ. The larger omentum was separated longitudinally over an avascular zone, and one or two omental branches of the gastroepiploic arteries were preserved using pedicle omental flaps. The omental flap was pushed between the posterior surface of PJ and the portal vein, then wrapped over the anterior surface of PJ. The omentum was rolled up and secured with a few PDS sutures.
41099919|NCT06521736|DEVICE|AAC-BCI device|Participants without speech and severe movement disorders will be trained on the augmentative and alternative communication, brain-computer interface (AAC-BCI) system, using it for at least 10 hours per week in their homes for communication and other control functions. Participants will have daily support for using the AAC-BCI from trained caregivers along with intervention support from consultants and speech language pathologists.
41099920|NCT05212428|PROCEDURE|Biospecimen Collection|Undergo collection of saliva, blood, urine and stool samples
41099921|NCT05212428|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
41099922|NCT05212428|OTHER|Genetic Counseling|Receive genetic counseling
41099923|NCT05212428|OTHER|Questionnaire Administration|Complete family history
41099924|NCT05212428|OTHER|Questionnaire Administration|Ancillary studies
41099925|NCT03971747|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|Autologous T cells transduced with lentivirus encoding AFP specific TCR gene
41099926|NCT01191086|DRUG|USL255|
41099927|NCT06630676|BEHAVIORAL|Control|Brief 4-slide presentation without a separate session for questions and answers
41099928|NCT06630676|BEHAVIORAL|Education|Patients will review 27 slides that discuss the different etiologies (causes) of back pain, how common they are, what causes them (e.g., wear and tear, trauma), factors that exacerbate and alleviate the pain, how they are diagnosed and treated, and have an opportunity to ask questions.
41099929|NCT01357044|DIETARY_SUPPLEMENT|Extracts of Punica granatum and Alpinia galanga|Tablets, two in the morning and two in the evening
41099930|NCT01357044|DIETARY_SUPPLEMENT|Placebo|Tablets, two in the morning and two in the evening
41099931|NCT03960255|OTHER|Normal standard care|Both groups will receive standardized treatment and care for diabetic foot ulcers
41099932|NCT05043818|OTHER||This study is an observational study and does not involve intervention.When the patient comes to the hospital or on the first to the second day of admission, the subject will be given a full scale check once（Screening related scales for anxiety and depression symptoms (PHQ9, SDS, HADS, HAMA, HAMD), inflammatory bowel disease quality of life scale (IBDQ), modified Mayo score for patients with ulcerative colitis/ simplified CDAI score for patients with Crohn's disease , Stool characteristics, degree of abdominal pain, gastrointestinal symptom scale (GSRS), etc.）. The stool sample will be collected once and 16S rRNA sequencing.
40752096|NCT00002836|DRUG|Etoposide|CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
41099933|NCT04084288|OTHER|Acupuncture|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed
41099934|NCT04084288|DEVICE|Peripheral Nerve Stimulator|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus).
41099935|NCT00719823|DRUG|Maraviroc|Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
41099936|NCT05129982|DEVICE|whole body vibration|whole body vibration is a modality of physical therapy
40752097|NCT00002836|DRUG|Thiotepa|Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
40752098|NCT00002836|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
40752099|NCT00003474|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41099937|NCT02140554|GENETIC|lovo-cel|lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.
41099938|NCT06280209|DRUG|BMN 351|Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
41099939|NCT04542148|DRUG|Sliding Scale Insulin|After antenatal corticosteroid administration, women will continue to receive long- and short-acting subcutaneous insulin injections as prescribed at home. In addition, they will receive supplemental short-acting insulin using a sliding scale based on postprandial glucose values. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
41099940|NCT04542148|DRUG|Up-Titration of Home Insulin|After antenatal corticosteroid administration, women will receive long- and short-acting subcutaneous insulin injections at increased dosages compared to that prescribed at home. Insulin will be increased by 30% on the day that they receive their 1st dose of antenatal corticosteroids (day 1), 50% on day 2, 50% on day 3, 30% on day 4, and 15% increase on day 5. On day 6 they will return to their home insulin regimen. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
41099941|NCT04542148|DRUG|Continuous Insulin Infusion|After antenatal corticosteroid administration, women will discontinue their home insulin regimen and be placed on a continuous insulin infusion with insulin boluses and titration of infusion rate per institutional L\&D protocol. Capillary blood glucose values will be measured with fingersticks every hour.
41099942|NCT04542148|DEVICE|Dexcom G6 Professional Continuous Glucose Monitor|Masked Dexcom G6 Pro devices will be worn for 10 days.
41099943|NCT03149406|OTHER|Comparing the expression of miRNAs|by PCR, in symptomatic and asymptomatic carotid plaques.
41099944|NCT05040750|OTHER|laboratory investigation|observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients
41099945|NCT06570798|DRUG|Inebilizumab|Intravenous (IV) Infusion
41099946|NCT06570798|DRUG|Blinatumomab|SC Injection
41099947|NCT01714557|DRUG|Piperacillin|4.0g q8h 3-5 days
41099948|NCT01714557|DRUG|Piperacillin-tazobactam combination product|4.5g q8h 3-5 days
41099949|NCT01254591|OTHER|18F-fluoromisonidazole|
41099950|NCT01254591|OTHER|fluorescence angiography|
41099951|NCT01254591|OTHER|laboratory biomarker analysis|
41099952|NCT01254591|PROCEDURE|infrared thermography|
41099953|NCT01254591|PROCEDURE|magnetic resonance imaging|
41099954|NCT01254591|PROCEDURE|therapeutic conventional surgery|
41099955|NCT01254591|RADIATION|[18F]-ML-10|
41099956|NCT01254591|RADIATION|fludeoxyglucose F 18|
41099957|NCT01254591|RADIATION|rubidium Rb-82|
41099958|NCT06632093|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
41099959|NCT06632093|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
41099960|NCT00151606|PROCEDURE|Reinforced isolation + Muciprocine|
41099961|NCT01605136|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
41099962|NCT01605136|DRUG|Placebo|One placebo subcutaneous implant every 2 months for 6 months
41099963|NCT03593070|BEHAVIORAL|Chronic Grief Management Intervention-Video|The CGMI-V participant manual will be provided to participants either mailed or emailed. We will mail hard copies of the manual to caregivers who prefer them over the e-format. The technology assistant will review with each participant the use of technology Cisco WebEx and iPads) via e-mailed step-by-step written instructions and over-the-phone conferencing. Group sessions will take place using WebEx (an internet platform providing video connection) and iPads, at mutually agreed-upon times and days of the week. All group sessions will be audio and video-recorded for fidelity purposes, with caregivers' approval documented in the informed consent. The interventionists will label each recorded meeting group identification number, session number, and date.
41099964|NCT00773435|BIOLOGICAL|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
41099965|NCT00773435|OTHER|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
41099966|NCT01178762|DRUG|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
41099967|NCT02696629|PROCEDURE|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
41099968|NCT02696629|DEVICE|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
41099969|NCT02696629|BEHAVIORAL|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
41099970|NCT05245487|DIAGNOSTIC_TEST|DNA repair gene mutation analysis|Prospective monitoring of patients with next-generation sequencing for blood mutations
41099971|NCT00609648|BEHAVIORAL|Computer Assisted Relaxation Learning|A self-paced computer program for reducing dental injection fear.
41099972|NCT00609648|BEHAVIORAL|Pamphlet|A pamphlet reassuring patients about dental injections.
41099973|NCT02113163|DRUG|Metformin Eicosapentaenoate|
41099974|NCT02113163|DRUG|Metformin HCl and Vascepa|
41099975|NCT05960773|DRUG|Decitabine/cedazuridine|Decitabine/cedazuridine (INQOVI) oral tablet (35 mg decitabine and 100 mg cedazuridine) taken 3 consecutive days during the first week of every cycle (1 cycle=28-days) for 6 cycles (i.e., 1 course). Additional 6 cycles (i.e., Course 2) for subjects with stable disease or disease regression. Max (total) of 2 treatment courses.
41099976|NCT05677282|DRUG|Rifaximin 550 MG|Rifaximin 550 mg as a single dose administered orally.
41099977|NCT05677282|DRUG|Azithromycin 500 MG|Azithromycin 500 mg as a single dose administered orally.
41099978|NCT05677282|DRUG|Loperamide|4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
41099979|NCT06630065|BEHAVIORAL|fMRI with emotional task and pupillometry|"Anatomical and functional magnetic resonance imaging (fMRI) imaging sequences with pupillometry (\~90 min)~A functional sequence - Task (\~20min):~* Emotional task in fMRI: Instructions: simply look images, then evaluate the emotions triggered at the end of each block; rating on a valence and intensity scale and intensity (arousal) scale.~* Experimental conditions: positive, negative and neutral~* Paradigm: block validated image banks: IAPS, GAPED, EMOPICS, OASIS, etc. Pupillometry: In order to collect objective data on emotional bias, we will use pupillometry (or eye-tracking) during functional MRI sequences."
41099980|NCT06630065|BEHAVIORAL|Behavioral task with emotional facial expressions|Description of the recognized emotion joy - sadness. Test to assess the hedonic value of an olfactory stimulus (10 min)
41099981|NCT06630065|GENETIC|Biological investigation|Standard biological assessment, immuno-inflammatory profile and the association of 8 mRNA editing variants
41099982|NCT06629129|DRUG|Latanoprost (0.005%)|MEAN OCULAR PERFUSION PRESSURE WAS MEASURED AND CORRELATED TO THE IOP AND OPTIC NERVE PERFUSION IN RESPONSE TO LATANOPROST TREATMENT
41099983|NCT04763213|DIAGNOSTIC_TEST|Coronary Angiography|Patients diagnosed with occlusive or nonocclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
41099984|NCT04763213|DIAGNOSTIC_TEST|Coronary Angiography|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
41099985|NCT02577484|DEVICE|RXi System|"Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.~Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.~The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics."
41099986|NCT02577484|DEVICE|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
41099987|NCT04346888|DRUG|HBM9161 Injection (680mg and 340 mg)|HBM9161 Injection (680mg and 340mg)
41099988|NCT04346888|DRUG|Placebos|Placebo, HBM9161 Injection (340mg)
41099989|NCT04346888|DRUG|HBM9161 Injection (340 mg)|HBM9161 Injection (340 mg)
41099990|NCT04258774|OTHER|Carbon Dioxide|The study team will administer inhaled carbon dioxide to the participants during an MRI at a level
41099991|NCT01646775|DRUG|epidural fentanyl|withold epidural fentanyl
40924964|NCT03283605|DRUG|Durvalumab|Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
41099992|NCT03136263|DRUG|Oxytocin nasal spray|Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
41099993|NCT03136263|DRUG|Placebo nasal spray|Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
41099994|NCT05039918|BEHAVIORAL|Affective touch|Gentle stroking at CT-optimal speed
41099995|NCT06629428|DRUG|Ublituximab|The participants will receive 48 weeks of treatment with ublituximab.
41099996|NCT04044664|DRUG|Placebo oral capsule|Matching placebo capsules.
41099997|NCT04044664|DRUG|NYX-783|NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
41099998|NCT00542386|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
41099999|NCT00542386|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
41100000|NCT00545844|DRUG|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
41100001|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
41100002|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
41100003|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
41100004|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
41100005|NCT05133362|DEVICE|Gait training with EksoNR|Participants will receive forward gait training with EksoNR
41100006|NCT05133362|PROCEDURE|Backward gait training with EksoNR|Participants will receive backward gait training with EksoNR
41100007|NCT06165731|BEHAVIORAL|Diaphragmatic Breathing Exercises|Mindful deep breathing cycle comprised of a 3-second inhale causing abdominal wall movement followed by a 5-second exhale, which will be completed for a total of 10 minutes of daily exercise
41100008|NCT06165731|BEHAVIORAL|Bladder Hygiene Education|Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association
41100009|NCT03210402|DEVICE|Elevated night pacing on|Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times
41100010|NCT03210402|DEVICE|Elevated night pacing off|Device will be programmed to normal lower rates
41100011|NCT06209359|DRUG|Ammonium Chloride|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
41100012|NCT06209359|DRUG|Placebo|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
41100013|NCT06149481|DRUG|Retifanlimab|500 mg infused via IV over 30 minutes every 28 days
41100014|NCT06149481|BIOLOGICAL|Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform|5x10\^11 virus particles per 1 mL administered via subcutaneous injection in the upper arm and anterolateral upper thigh on Day 1 of Cycles 1, 2, 3 and every 3 cycles after that
41100015|NCT06149481|DRUG|N-803|15 ug/kg administered via subcutaneous injection to the abdomen every 28 days
41100016|NCT06149481|DRUG|SX-682|100 mg administered orally twice per day on days 6-26 of every cycle
41100017|NCT01359137|BEHAVIORAL|Probation as usual|Routine probation with do deferred jail condition.
41100018|NCT01359137|BEHAVIORAL|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
41100019|NCT01359137|BEHAVIORAL|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
41100020|NCT05407129|BEHAVIORAL|Family safety reporting intervention|Family safety reporting intervention for patients/families
41100021|NCT03332134|BEHAVIORAL|Intimate Partner Violence (IPV) Prevention Intervention|The IPV intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of session 1, 2-6, and the 3-month follow-up are 120 minutes, and 60-90 minutes, respectively.
41100022|NCT06053788|DIAGNOSTIC_TEST|PocDoc|Point of care digital lipid test
41100023|NCT02329041|DEVICE|McGrath Series 5|one kind of videolaryngoscopes, which are widely used in airway management.
41100024|NCT02329041|DEVICE|Airtraq|another kind of videolaryngoscopes, which are also widely used in airway management.
41100025|NCT01080131|DRUG|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
41100026|NCT01080131|DRUG|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
41100027|NCT01080131|DRUG|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
41100028|NCT01080131|DRUG|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
41100029|NCT02759731|DRUG|Baricitinib|Cycle=28 days: Baricitinib: 1mg-4mg by mouth (PO) every day (QD)
41100030|NCT01530074|PROCEDURE|Temporary blocking of mandibular nerve|IM. Lidocaine 2% 7.2ML
41100031|NCT03659201|DRUG|Neosil complete|Oral, during 24 weeks.
41100032|NCT03659201|DRUG|Pantogar|Oral, placebo for 12 weeks and pantogar for 12 weeks.
41100033|NCT03659201|DRUG|Neosil|Oral, during only 12 weeks.
41100034|NCT02723851|DEVICE|Corsens|Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index \[MCI\] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
41100035|NCT02932358|OTHER|Flexible Family Visitation Model (FFVM)|Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
41100036|NCT02932358|OTHER|Restrictive Family Visitation Model (RFVM)|Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
41100037|NCT00146978|PROCEDURE|intra-arterial treatment|
41100038|NCT04252066|DRUG|migalastat|This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
41100039|NCT00119899|PROCEDURE|FDG-PET scan|
41100040|NCT04610294|DEVICE|Functioning Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be active and will be sealed to prevent operating room personnel from opening the system and determining a unit's status."
41100041|NCT04610294|DEVICE|Deactivated Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be inactivated and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. Units will be inactivated by removing the activated carbon, high-efficiency particulate filter, and ionization chamber. However, the fan will remain active as will the run lights."
41100042|NCT02121418|DRUG|Cytarabine|Given IV
41100043|NCT02121418|DRUG|Decitabine|Given IV
41100044|NCT02121418|OTHER|Laboratory Biomarker Analysis|Correlative studies
41100045|NCT05826444|DIAGNOSTIC_TEST|Echocardiography|Echocardiography with afterload change
41100046|NCT05826444|DIAGNOSTIC_TEST|Magnetic resonance imaging|Stress-MRI
41100047|NCT05826444|DIAGNOSTIC_TEST|Magnetocardiography|Magnetocardiography
41100048|NCT05826444|DIAGNOSTIC_TEST|Histology|Histological analysis
41100049|NCT05826444|DIAGNOSTIC_TEST|Genetics|miRNA sequencing
41100050|NCT05826444|DIAGNOSTIC_TEST|calcium signaling|cardiomyocyte calcium signaling
41100051|NCT05826444|DIAGNOSTIC_TEST|IMR|Index of microvascular resistance measurement
41100052|NCT05826444|DIAGNOSTIC_TEST|Angio-IMR|Angiography derived post-processing index if microvascular resistance
41100053|NCT06134505|PROCEDURE|Use of Barrier cream group 1 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that Barrier cream 1 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
41100054|NCT06134505|PROCEDURE|Use of Barrier cream 2 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that barrier cream 2 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
41100055|NCT06134505|PROCEDURE|Use of olive oil in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that olive oil would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
41100056|NCT05664581|DEVICE|Rapid Acoustic Pulse|Subcutaneous Rapid Acoustic Pulse Treatments
41100057|NCT01071694|DRUG|Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)|Patients receiving Betaferon according to routine clinical practice
41100058|NCT05714033|PROCEDURE|Ventilatory Strategy To Prevent Atelectasis|Given
41100059|NCT05714033|PROCEDURE|Lateral Decubitus Strategy (LADS)|Given
40924965|NCT03283605|DRUG|Tremelimumab|Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
41100060|NCT04441242|OTHER|Ambient lighting|Use of ambient lighting (75-150 lux) in endoscopy room.
41100061|NCT04441242|OTHER|Low lighting|Use of low lighting (\<75 lux) in endoscopy room.
41100062|NCT04876781|DRUG|Tofacitinib XR|Tofacitinib XR 11mg
41100063|NCT05732428|DRUG|ARV-471|ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles
41100064|NCT03389477|DRUG|Palbociclib|Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
41100065|NCT03389477|DRUG|Cetuximab|-Cetuximab must not be administered as an IV push or bolus
41100066|NCT03389477|DRUG|Cisplatin|-Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
41100067|NCT03389477|RADIATION|Intensity-Modulated Radiation Therapy|-Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
41100068|NCT03389477|PROCEDURE|Tumor biopsy|"* Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~* If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline."
41100069|NCT03389477|PROCEDURE|Peripheral blood draw|Baseline and post-treatment
41100070|NCT01329328|DEVICE|vibrating platform (Bioplate RF)|whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
41100071|NCT05608499|DRUG|Duobrii|topical contains active drug lotion, once daily for 4 weeks then twice daily for 8 weeks
41100072|NCT05608499|DRUG|Placebo|Topical does not contain active properties of study drug
41100073|NCT05608499|DRUG|Bryhali|Bryhali will only be used as a rescue treatment - in case of irritation with Duobrii. Bryhali lotion once daily up to 12 weeks only if Duobrii is not tolerated.
41100074|NCT04635436|OTHER|Split-belt treadmill walking.|"The intervention will consist of split-belt treadmill walking. During the test session, participants will walk on a split-belt treadmill mounted on force sensors with the belts running at the same or at different velocities. They will walk freely without any support. The test sequence will be the following:~1. Baseline phase. 3 minutes walking at increasing speed, speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Habituation phase. 30 seconds walking at 0.2 m s-1.~3. Adaptation phase. The velocity of the belt under the non-affected lower limb will be increased to 0.6 m s-1, while the other belt will maintain its velocity of 0.2 m s-1 for 6 minutes.~4. Post-adaptation phase. Belts' velocities will be restored at 0.2 m s-1 for 6 minutes.~Participants will be informed before the changes in belts' velocities with a verbal warning.~Participants will repeat the same protocol with the affected lower limb on the fast belt after one week."
41100075|NCT00454662|DRUG|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
41100076|NCT00454662|DRUG|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
41100077|NCT02004613|DRUG|Dexmedetomidine|Dexmedetomidine
41100078|NCT02004613|DRUG|Placebo|Normal saline administration matching dexmedetomidine rate of infusion
41100079|NCT04660370|DRUG|CKD-348|QD, PO
41100080|NCT04660370|DRUG|CKD-828, D097, D337|QD, PO
41100081|NCT06162351|DRUG|PLX038|"Study treatment will be at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection).~Patients with a clinical benefit could be treated as long as study is ongoing. Patients are followed from inclusion until documented disease progression, withdrawal of consent, or death."
41100082|NCT06306365|BEHAVIORAL|Modern board game-based learning|Modern board game-based learning involves using contemporary board games as educational tools. It emphasizes active participation, critical thinking, and social interaction among participants. By integrating strategic thinking and problem-solving within a game context, this approach aims to enhance learning experiences in an engaging and enjoyable manner. In this study, board games have been selected to target and engage executive functions.
41100083|NCT06630988|OTHER|Failure rates|Describe the management failure rate for hand infections, including panariasis, phlegmons and arthritis.
41100084|NCT04565249|DRUG|PLN-74809|PLN-74809
41100085|NCT04565249|DRUG|Placebo|Placebo
41100086|NCT02520154|DRUG|Carboplatin|Given IV
41100087|NCT02520154|OTHER|Laboratory Biomarker Analysis|Correlative studies
41100088|NCT02520154|DRUG|Paclitaxel|Given IV
41100089|NCT02520154|BIOLOGICAL|Pembrolizumab|Given IV
41100090|NCT02520154|OTHER|Pharmacological Study|Correlative studies
41100091|NCT05741944|OTHER|Care with the use of PERSARC|PERSARC is a personalized risk assessment tool which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options
41100092|NCT05741944|OTHER|standard care|All patients in control condition receive usual care.
41100093|NCT06629051|DRUG|Berberine Hydrochloride|post-intervention of berberine
41100094|NCT06629051|DRUG|Placebo|Looks the same as berberine
41100095|NCT06117254|BEHAVIORAL|Communication Counseling|Individuals randomized to this group will receive information on how to improve their ability to hear and communicate including general tips on environmental modification and communication repair strategies and personalized tips to help with patient-specific listening difficulties. This is consistent with current audiological standard of care.
41100096|NCT06117254|DEVICE|Hearing Aids|Hearing aids will be provided with amplification settings programmed specific to each participant's pure-tone hearing thresholds with subsequent adjustments based upon participant preferences. Standard noise cancelation and signal-to-noise ratio improvement strategies will be activated.
41100097|NCT06117254|DEVICE|Remote Microphones|Remote microphone systems will be provided for use with hearing aids.
41100098|NCT05617014|RADIATION|Neuraceq|Amyloid PET imaging with Florbetaben (Neuraceq) injection
41100099|NCT05617014|RADIATION|Amyvid|Amyloid PET imaging with Amyvid (Florbetapir) injection
41100100|NCT05617014|RADIATION|Tauvid|Tau PET imaging with Tauvid (Flortaucipir) injection
41100101|NCT05617014|RADIATION|MK-6240|Tau PET imaging with MK-6240 injection
41100102|NCT05617014|RADIATION|NAV4694|Amyloid PET imaging with NAV4694 injection
41100103|NCT05617014|RADIATION|PI-2620|Tau PET imaging with PI-2620 injection
41100104|NCT06631209|DEVICE|Transcranial Magnetic Stimulation (TMS)|Specifically, Continual Theta Burst Stimulation
41100105|NCT06631209|OTHER|Sham|Sham TMS
41100106|NCT06414980|BEHAVIORAL|Experimental|The effect of suggestion given to patients with the olfactory memory method before the surgical operation on vital signs and systemic evaluation scoring during awakening.
41100107|NCT05317962|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Abbreviated transthoracic echocardiogram
41100108|NCT01947179|BEHAVIORAL|Anxiety Risk Reduction|Involves psychoeducation and interoceptive exposure exercises
41100109|NCT01696721|OTHER|No intervention|
41100110|NCT04827459|BEHAVIORAL|Sleep Coach App|Participants will be encouraged to interact with the mobile app daily for as much time as they wish, or for as little as 5 - 10 minutes, over a 7-week period.
41100111|NCT04661670|DEVICE|occlusal stabilization splints|an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions
41100112|NCT01553513|OTHER|[18F]-FDG positron emission computed tomography|"Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest."
41100113|NCT01553513|PROCEDURE|Invasive coronary angiography|ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
41133259|NCT05519306|BEHAVIORAL|Mental Practice|Each patient will perform the following two activity-based tasks via MP: wiping a table and picking up a cup. Prior to a scheduled OT session patients will perform MP of the assigned motor task. Following MP, a research therapist will facilitate repetitive task practice of the same motor task. MP sessions will be completed 5x/week for 2 weeks, (3x/week in combination with RTP, and 2x/week independently). The MP will be completed at an MP station equipped with a tablet and noise-canceling headphones. The audio recording will be from a first-person view as if they are performing it with their own UE. Each task will consist of 20 repetitions and will be facilitated by the use of multisensory cues (visual, tactile, auditory, and kinesthetic). For example, the task of picking up a cup will include describing how the drink looks (water with ice) and the temperature and feel of the cup (cold/moist).
40924966|NCT06258473|COMBINATION_PRODUCT|Multicomponent decentralized care|"1. Training and support on Simple app for HTN/DM management \& training NCD corner clinicians on clinical guidelines and establish team-based care for Upazila level NCD corner~2. CHCPs conduct BP/BG screening, monitoring, lifestyle counseling, dispensing of medications, follow-up overdue patients at CCs \& CHCP care coordination supported by Simple app at community clinics~3. CHWs assist in screening, counselling, referral, and follow-up for CHW at village level"
40924967|NCT06258473|COMBINATION_PRODUCT|mHealth|Training and support on Simple app for HTN/DM patient management \& training NCD corner clinicians on clinical guidelines of Upazila Health complex
40924968|NCT02149771|PROCEDURE|chemoembolization|Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
40924969|NCT02149771|DEVICE|endovascular stents implantation|Bare stents implant within portal vein.
40924970|NCT02149771|PROCEDURE|iodine-125 seed strand implantation|Iodine-125 seed strand implant within portal vein.
40924971|NCT02802046|RADIATION|Computed tomographic angiography of coronary artery|
40924972|NCT02588404|DRUG|LHRH therapy|These patients will be treated with LHRH agonist as standard therapy.
40924973|NCT02885116|DEVICE|Nasal high flow (NHF) supplementation|use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
40924974|NCT02885116|DEVICE|oxygen supplementation|hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
40924975|NCT05158400|RADIATION|Ultrasound|Ultrasound examination on the hand
40924976|NCT01488123|BEHAVIORAL|Individualized manualized Ayurvedic intervention|The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
40924977|NCT03661879|DRUG|NNC9204-1706|Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
40924978|NCT03661879|DRUG|Placebo (NNC9204-1706)|Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
40924979|NCT05763745|DIAGNOSTIC_TEST|Point of Care Ultrasound|Use Point of Care Ultrasound to evaluate the gastric content/bleed prior to upper endoscopy
40924980|NCT00879879|DRUG|losartan|50 mg losartan taken daily by mouth in capsule form for 1 year
40924981|NCT02776748|DRUG|FTC/TDF PrEP|Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
40924982|NCT02870023|OTHER|Balance training|
40924983|NCT02870023|OTHER|Strength training|
40924984|NCT04850781|BEHAVIORAL|Bi-weekly frozen meal home delivery|All participants randomized to this arm will receive 10 frozen meals that are mailed to their home every two weeks from a MOW vendor, TRIO foods.
40924985|NCT04850781|BEHAVIORAL|Daily home meal delivery|All participants randomized to this arm will receive meals delivered to their home multiple times per week from a MOW program employee/volunteer with a wellness check and socialization.
41100114|NCT01553513|PROCEDURE|Intravascular ultrasound and virtual histology|"During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.~A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.~Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque."
41100115|NCT01553513|OTHER|Serum biomarkers|"A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers."
41100116|NCT05702710|OTHER|Surgery (PIRS)|"Laparoscopic procedure for repair of inguinal hernia as described in:~1) Thomas DT, Göcmen KB, Tulgar S, Boga I. Percutaneous internal ring suturing is a safe and effective method for the minimal invasive treatment of pediatric inguinal hernia: Experience with 250 cases. J Pediatr Surg. 2016 Aug;51(8):1330-5. doi: 10.1016/j.jpedsurg.2015.11.024. Epub 2015 Dec 11. PMID: 26777889."
41100117|NCT06630845|DRUG|Fluorodeoxyglucose F18|Given IV as part of routine imaging
41100118|NCT06630845|PROCEDURE|Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)|Imaging procedure
41100119|NCT06630845|PROCEDURE|Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)|Imaging procedure done concurrently with PET/MRI
41100120|NCT06630845|DEVICE|General Electric (GE) SIGNA PET/MR|Imaging device
41100121|NCT05268198|DRUG|APR002|Active Investigational Product
41100122|NCT05268198|DRUG|Placebo|Placebo
41100123|NCT04335591|DRUG|75 mg linzagolix tablet|For oral administration once daily
41100124|NCT04335591|DRUG|200 mg linzagolix tablet|For oral administration once daily
41100125|NCT04335591|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
41100126|NCT04335591|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
41100127|NCT04335591|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
41100128|NCT04335591|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
41100129|NCT04241341|PROCEDURE|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
41100130|NCT04241341|PROCEDURE|Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|Current standard treatment at Memorial Sloan Kettering \[MSK\]).
41100131|NCT04241341|OTHER|quality-of-life questionnaires|Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
41100132|NCT04241341|OTHER|measured by arm volume|Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
40924986|NCT03693560|DRUG|Vildagliptin 50 mg Oral Tablet|Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.
40924987|NCT03693560|DRUG|Metformin 1000 mg Oral Tablet|Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.
40924988|NCT03693560|DRUG|Glimepiride upto 4 mg Oral Tablet|Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet
40924989|NCT01997112|DRUG|Paracetamol|
40924990|NCT01997112|DRUG|Placebo oral capsule|
41100133|NCT03714750|PROCEDURE|DK crush|revascularization of true coronary bifurcation stenosis in DK crush technique
41100134|NCT03714750|PROCEDURE|Reverse TAP|revascularization of true coronary bifurcation stenosis in Reverse TAP technique
41100135|NCT05409404|OTHER|Aerobic exercise + hot water immersion|Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of hot water immersion at 40°C.
41100136|NCT05409404|OTHER|Aerobic exercise + thermoneutral water immersion|Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of thermoneutral water immersion at 34°C.
41100137|NCT03256344|BIOLOGICAL|Talimogene Laherparepvec|Virally based anti-cancer immunotherapy given by direct injection into tumors.
41100138|NCT03256344|BIOLOGICAL|Atezolizumab|A monoclonal antibody given by intravenous injection.
41100139|NCT01506843|BIOLOGICAL|Mite, Mite and Bacterial or Placebo|All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
41100140|NCT00258518|PROCEDURE|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
41100141|NCT06631755|DEVICE|Xience Skypoint stent over calcified coronary lesions|Patients with Xience Skypoint stent implanted after OCT assesment of calcification
41100142|NCT05348577|DRUG|capivasertib|"320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.~Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment."
41100143|NCT05348577|DRUG|docetaxel|Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
41100144|NCT05348577|OTHER|placebo|matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
41100145|NCT05348577|DRUG|docetaxel|Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
41100146|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 1|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
41100147|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 2|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
41100148|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 3|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
41100149|NCT03490851|OTHER|Cream of Rice|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
41100150|NCT06529042|OTHER|Non-Interventional|Non-Interventional
41100151|NCT04606251|OTHER|Exercise|The intervention to be carried out in the study consists of physical exercises for the neck, upper and lower extremities, and trunk; It is a program that includes the addition of cognitive tasks such as memory, word finding, processing during each repetition.
41100152|NCT04912362|DEVICE|YAG iridotomy|YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
41100153|NCT06628440|OTHER|oral condition assessment tool|Use of the Mat assessment tool by a nurse on the participant
41100154|NCT04587791|DRUG|400mg Cannabidiol|Participants will receive 400mg
41100155|NCT04587791|DRUG|800mg Cannabidiol|Participants will receive 800mg
41100156|NCT04587791|DRUG|1200mg Cannabidiol|Participants will receive 1200mg
41100157|NCT04587791|DRUG|Saline|Participants will receive saline
41100158|NCT04227678|DRUG|Heparin|an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal
41100159|NCT04227678|DIETARY_SUPPLEMENT|liquid meal|low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes
41100160|NCT00271258|DRUG|SODIUM DIVALPROATE|
41100161|NCT05245097|DEVICE|Tango Belt|The Tango Belt is a patient-contacting electronic device made out of medical grade plastics and biocompatible fabrics worn around the waist. The Tango Belt contains a fall-in-progress detection algorithm which can detect a serious hip-impacting fall-in-progress using built-in sensors and deploy an automotive-grade cold-gas airbag to protect the hips from ground impact forces. When connected to Wi-Fi, the Tango Belt can send automated fall and impact alerts to caregivers and Healthcare Providers (HCPs) while recording motion and event data, which can then be analyzed for usage-based metrics viewable via a companion mobile app and/or desktop app. Alerts are sent in the form of short message service (SMS) texts and emails to alert recipients designated in the mobile or desktop Companion App. The Tango Belt can also detect non-serious hip-impacting or non-hip impacting falls in which the wearer may have incurred a minor injury (i.e., not a major hip injury) and/or may be unable to get up.
41100162|NCT06326463|DRUG|Fludarabine|40mg/m2, Day -4, -3 and -2
41100163|NCT06326463|DRUG|Cyclophosphamide|"Day -3 and Day-2~REST DAY, -1"
41100164|NCT06326463|DRUG|CD70-CAR T cell infusion (Autologous)|Day 0 or +1
41100165|NCT06326463|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide
41100166|NCT05068713|OTHER|Usual Care + High Target of Mean Arterial Pressure|Targeting the weaning of vasopressors to a mean arterial pressure of 85-90mmHg in the first 24h after liver trasnplant.
41100167|NCT05068713|OTHER|Usual Care|Targeting the weaning of vasopressors to a mean arterial pressure of 65-70mmHg in the first 24h after liver trasnplant.
41100168|NCT03586544|DRUG|Albuterol Sulfate|Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
41100169|NCT03586544|BEHAVIORAL|Interval Warm-up exercise|Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
41100170|NCT00725413|DRUG|etonogestrel implant (Implanon)|subdermal etonogestrel implant
41100171|NCT00822913|DRUG|Intravesical injection of Botulinum A toxin|One treatment, 200 U vials diluted in 20 ml normal saline
41100172|NCT06630403|OTHER|Demographic Data|Demographic data (age, height, weight, BMI) will be collected verbally through an assessment form.
41100173|NCT06630403|OTHER|Disease History|The number of exacerbations in the last 1 year, hospitalization and medications used will be questioned.
41100174|NCT06630403|OTHER|Pulmonary Function Test|Pulmonary Function Test will be performed with a spirometer.
41100175|NCT06630403|OTHER|Reaction Time|Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test.
41100176|NCT06630403|OTHER|Functional Capacity|Functional capacity will be evaluated with 6 minute walk test
41100177|NCT06630403|OTHER|Dyspnea Perception|Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea
41100178|NCT06630403|OTHER|Quality of Life|"Quality of life will be assessed with the Quality of Life Scale for Children\&#34;"
41100179|NCT06630403|OTHER|Fear of movement|Fear of movement will be evaluated with Tampa Kinesiophobia Scale
41100180|NCT06630403|OTHER|Ability of Motor Imagery|Motor Imagery ability will be assessed by Movement Imagery Questionnaire-3 and Vividness of Movement Imagery
41100181|NCT06630403|OTHER|Cognitive Functions|Cognitive functions will be assessed with Trail Making Test and Stroop Test
41100182|NCT02794064|DEVICE|Tri-modal imaging|This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified
41100183|NCT00942058|OTHER|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
41100184|NCT00099437|DRUG|Fulvestrant|intramuscular injection
41100185|NCT06630611|BIOLOGICAL|NMA-LD regimen|The use of the NMA-LD regimen (cyclophosphamide and fludarabine) prior to cell administration is expected to lead to myelosuppression in all patients.
41100186|NCT06630611|BIOLOGICAL|Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion|On Day 0 (at least 24h after the last dose of fludarabine) patients will be hospitalized in a dedicated unit. Autologous TIL infusion will be administered intravenously.
41100187|NCT06630611|BIOLOGICAL|High dose IL-2|"Only for patients in Arm A.~IL-2 begins between 3 and 24 hours after the completion of the TIL infusion and is given as a bolus administration every eight hours (minimum interval) to 24 hours (maximum interval) with a maximum of six doses from the beginning of each administration."
41100188|NCT06630611|BIOLOGICAL|IL-2 analog|"Only for patients in Arm B~ANV419 will be administered between 3 and 24 hours after the completion of the TIL infusion with a slow IV infusion over 15-30 minutes + 5 minutes once, at 243µg/kg."
41100189|NCT01051583|PROCEDURE|Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin|The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
41100190|NCT05869318|OTHER|ECIG own|Participants will vape using their own ecig device
41100191|NCT05869318|OTHER|ECIG Vuse|Participants will vape a VUSE e-cigarette (GOLD 5%)
41100192|NCT02702674|DRUG|propranolol|propranolol 20 mg given before induction of labor
41100193|NCT02702674|DRUG|placebo|starch tablet containing no active drug material given before induction of labor
41100194|NCT02702674|DRUG|Oxytocin|intravenous infusion of oxytocin
41100195|NCT06041087|BEHAVIORAL|High-Intensity Exercise|A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
41100196|NCT06041087|DIETARY_SUPPLEMENT|Carbohydrate (Maltodextrin powder mixed with water)|50g consumed immediately after exercise and 1h after exercise.
41100197|NCT06041087|DIETARY_SUPPLEMENT|Skim Milk|500ml consumed immediately after exercise and 1h after exercise.
41100198|NCT06041087|DIETARY_SUPPLEMENT|Greek yogurt|200g consumed immediately after exercise and 1h after exercise.
41100199|NCT06041087|DIETARY_SUPPLEMENT|Water|500ml consumed immediately after exercise and 1h after exercise.
41100200|NCT02954055|DRUG|Paclitaxel|Arm A
41100201|NCT02954055|DRUG|Cyclophosphamide|Arm B
41100202|NCT02954055|DRUG|Capecitabine|Arm B
41100203|NCT02954055|DRUG|Vinorelbine|Arm B
41100204|NCT06526949|BEHAVIORAL|Reiki|To provide patients with a suitable environment during the intervention, screens will be lowered and earplugs will be used to ensure a quiet environment. The reiki practitioner will place his/her hands lightly on or above the patient's head and eyes, upper body from the neck to the pelvic area, arms and legs (standard reiki hand positions) for the duration of the therapy (30 minutes total duration).
41100205|NCT06526949|OTHER|(Sham Reiki)|In the sham (Sham Reiki) group, sham practitioners (not involved in the research) who have no experience in energy work will prepare a screen and headphones for the patients as in the intervention group. Then, they will place their hands gently on or above the patient's head and eyes, upper body from the neck to the pelvic region, arms and legs (standard reiki hand positions) for 30 minutes every other day for 2 days in a row or 2 times (Day 1 and Day 3) like the practitioner in the intervention group. Patient data will be recorded on forms before and after placebo administration as in the intervention group.
41100206|NCT00533416|DRUG|ON 01910 Na|
41100207|NCT04832646|PROCEDURE|atrial fibrillation ablation|persistent atrial fibrillation ablation with both AF and sinus rhythm map available
41100208|NCT00403884|PROCEDURE|Selective RPE laser treatment|interventional SRT laser treatment
41100209|NCT00586014|PROCEDURE|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
41100210|NCT00420589|DRUG|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
41100211|NCT00420589|DRUG|Comparator: placebo|Placebo capsules once daily. Treatment for 52 weeks
41100212|NCT06545708|OTHER|Patients|This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.
41100213|NCT03985150|OTHER|Biomechanical analysis of femoralis superficialis atherosclerotic tissue|Tissue collection during above-knee amputation; mechanical testing of tissue; microstructural testing of tissue
41100214|NCT03985150|RADIATION|CT or MR angiogram|Obtaining in vivo geometry of diseased artery
41100215|NCT01530009|DRUG|Amoxicillin|A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
41100216|NCT01530009|OTHER|Placebo|A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
41100217|NCT02867046|DRUG|S1 transforaminal epidural steroid(dexamethasone) injection|"medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen"
41100218|NCT06049108|DRUG|[14C]-LY3871801|Administered orally
41100219|NCT06629272|BEHAVIORAL|D-THIO (Deprescribing Thyroid Hormone In Older Adults)|"D-THIO consists of evidence-based pharmaceutical opinion letters to providers advising deprescribing for their patients 65 years and older with thyroid hormone overtreatment/misuse and EMPOWER (Eliminating Medications through Patient Ownership of End Results) brochures to their patients."
41100220|NCT06629272|BEHAVIORAL|Enhanced usual care|American Thyroid Association \[ATA\] provider guidelines, ATA patient brochure
41100221|NCT02780362|DRUG|Prodactariv|1 tablet contains 60 mg Daclatasvir
41100222|NCT02780362|DRUG|Clatazev|1 tablet contains 60 mg Daclatasvir
41100223|NCT04855513|DRUG|Metformin|Metformin is a medication used for treatment of diabetes. In this study it will be used to explore is potential role in prevention of preeclampsia. The drug will start before 12 week of pregnancy and continue till delivery
41100224|NCT03333655|PROCEDURE|Biopsy|Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.
41100225|NCT06632106|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
41100226|NCT06632106|DRUG|Tyrosine kinase inhibitor (TKIs)|TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab
41100227|NCT06632106|DRUG|Immune Checkpoint Inhibitors|ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab
41100228|NCT06064032|BEHAVIORAL|cognitive behavioral therapy|In control group there is 10 min session of PMR, 2 min deep breathing exercises,3 min training for life style modification which include use of planner, setting alarms breaking a task into parts positive reinforcement and communication.
41100229|NCT06064032|BEHAVIORAL|Motor Learning Techniques|In experimental group, participants will be given a 10 min PMR ,2 min deep breathing exercises, 3 min training for life style modification which include the use of planners setting alarms, breaking a difficult task into parts, positive reinforcement and communication combined with 3 min session of drawing a specific pattern with installing pegs on pegboard, 2 min session of balance board training, 3 min session of jigsaw puzzle training, 1 min session of squeezing a ball with maximum repetition and 1 min session of finding beads in puttey.
41100230|NCT00319943|PROCEDURE|Computer-based training for Mild Cognitive Impairment (MCI)|
41100231|NCT04902586|DEVICE|TTFields|The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.
41100232|NCT04697576|BIOLOGICAL|Ipilimumab|immune checkpoint inhibitor
41100233|NCT04697576|BIOLOGICAL|Nivolumab|immune checkpoint inhibitor
41100234|NCT04697576|BIOLOGICAL|Pembrolizumab|immune checkpoint inhibitor
41100235|NCT04697576|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Given IM and intratumorally. For this protocol the U.S. F.D.A recently approved the use of recently expired influenza vaccine (only until new seasonal vaccine is available anticipated Sept 1). Use of expired vaccine will not exceed 4 months past June 30th expiry date (October 30th).
41100236|NCT04697576|PROCEDURE|Resection|Undergo surgical resection
41100237|NCT04697576|BIOLOGICAL|Nivolumab + Relatlimab|immune checkpoint inhibitor
41100238|NCT06406933|DRUG|Carbomer Gel/Jelly|The drug is for dry eye syndrome by providing temporary relief from discomfort and irritation.
41100239|NCT01002443|DRUG|Helicobacter pylori eradication|Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
41100240|NCT01002443|DRUG|placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
41100241|NCT00256243|DRUG|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
41100242|NCT00256243|DRUG|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
41100243|NCT00256243|DRUG|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
41100244|NCT00256243|DRUG|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
41100245|NCT00256243|DRUG|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
41100246|NCT00256243|DRUG|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
41100247|NCT06629636|DIETARY_SUPPLEMENT|NMN capsule|Total of 900mg/day for 8 weeks
41100248|NCT06629636|OTHER|Placebo|NMN-free placebo capsules for 8 weeks
41100249|NCT06550193|DEVICE|Ultrasound-guided procedure using AR/VR technology|Participants will receive the intervention, which involves utilizing AR/VR technology during ultrasound-guided procedures (e.g., regional anesthesia, line placement). All participants will receive standard pre- and post-block or line care as they normally would for the ultrasound-guided procedure.
41100250|NCT00218556|BEHAVIORAL|Cognitive behavioral treatment for depression|Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
41100251|NCT01771900|BEHAVIORAL|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
41100252|NCT01771900|BEHAVIORAL|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
41100253|NCT02533167|OTHER|skin to skin|initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
41100254|NCT06631950|OTHER|Educational intervention|The educational intervention group will be provided with information that should allow them to correctly answer questions on fecundity knowledge and fecundity risks factors. The fecundity information will be provided through a short animated educational video (3 minutes) that will be sent out digitally. The control group is not receiving such information.
41100255|NCT00583843|PROCEDURE|Ultrasound|Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
41100256|NCT03728725|DEVICE|Cepheid Gene Xpert MTB/XDR|The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.
41100257|NCT06230562|BIOLOGICAL|Blood sample|The intervention is to take a blood sample every 6 months for 1 year which is not part of health routine care
41100258|NCT06230562|BIOLOGICAL|Blood sample|The intervention is to take a blood sample at baseline.
41100259|NCT05632068|DRUG|Xian-Hua-Cha|Zizyphus jujuba Mill., Nelumbo nucifera Gaertn, Citrus reticulata Blanco, Rosa rugosa Thunb., Cassia obtusifolia L., Stevioside, resistant starch, and water
41100260|NCT04878341|OTHER|Erector Spinae Plane Block|The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
41100261|NCT05025449|DIAGNOSTIC_TEST|Focused Assessment with Sonography for Trauma (FAST)|The Focused Assessment with Sonography for Trauma (FAST) exam is widely used and accepted as part of Advanced Trauma Life Support (ATLS) protocol. After consent, a baseline FAST exam will be performed and documented. This FAST will be distinct from the initial ATLS resuscitation FAST in order to avoid any interference in the trauma evaluation. The investigator will use a phased array or curvilinear transducer to record video of their baseline FAST exam.
41100262|NCT05025449|DRUG|Bubble-Enhanced FAST (BEFAST)|Following the FAST exam and using the same machine, a BEFAST exam will be performed using a low mechanical index setting in contrast-specific imaging mode. A 2.4 mL IV dose of Lumason will be injected into the subject's IV, followed by saline flush. The contrast will be injected once for the right side of the body, and once for the left side of the body looking for disruptions in the normal enhancement pattern and evidence of active bleeding. To examine the right side of the body: the liver will be imaged first in arterial phase, followed by the right kidney, before returning to image the liver in venous phase. To examine the left side of the body: the pancreas will be imaged first, followed by the kidney and the spleen. The investigator will note evidence of solid organ injury, free fluid, or active extravasation on both sides of the body; lacerations will be graded by the American Association for the Surgery of Trauma (AAST) criteria.
41100263|NCT03855709|DIAGNOSTIC_TEST|microbiological culture and sensetivity|microbioloical culture will be used to detect microbiological profile in hepatic patients with infections, drug sensitivity to detect resistent bacteria which will be confirmed using PCR detection of resistent gene
40924991|NCT02727543|OTHER|Medisafe|"Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements"
40924992|NCT05616689|OTHER|Bundled hyperpolypharmacy|Bundled hyperpolypharmacy playbook to be used by pharmacist, with physician approval, in shared decision making with participant,
40924993|NCT01106092|BIOLOGICAL|GSK2036874A vaccine|Intramuscular, single dose
40924994|NCT01106092|BIOLOGICAL|Zilbrix™/Hib vaccine|Intramuscular, single dose
40924995|NCT01106092|BIOLOGICAL|Poliorix™|Intramuscular, single dose
41100264|NCT06629649|OTHER|Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.|Participants who have the glaucoma screening will undergo an Artificial Intelligence Remote Optic Nerve Assessment (AI-RONA). The AI information may or may not be used by the FQHC provider to refer their patient for follow-up eye exam. It is information that the provider may find useful in making a referral.
41100265|NCT02888535|OTHER|Internal Medicine consultation|
41100266|NCT04278989|DRUG|Anti-tumor B|1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).
41100267|NCT03566017|DRUG|pegunigalsidase alfa|Recombinant human alpha galactosidase A
41100268|NCT03678116|DRUG|Sugar Pill (placebo)|Taken orally in capsule form
41100269|NCT03678116|DIETARY_SUPPLEMENT|Caffeine (plus Teacrine and Cayenne)|Taken orally in capsule form
41100270|NCT03678116|DIETARY_SUPPLEMENT|Caffeine (plus Teacrine)|Taken orally in capsule form
41100271|NCT02396992|OTHER|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
41100272|NCT06630663|BEHAVIORAL|A Wearable Device and AI-Supported Diet and Exercise intervention|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
41100273|NCT06630663|BEHAVIORAL|standard care|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
41100274|NCT06631222|BEHAVIORAL|cognitive behavioral therapy|The therapeutic patient education (TPE) program was based on a biobehavioral approach and was divided into the following three parts: cognitive, operant, and respondent. The purpose of the TPE program was to modify erroneous beliefs about pain and disability, as well as to provide coping strategies and improve patient self-efficacy through a graded activity.
41100275|NCT06631222|OTHER|sub-occipital inhibitory pressure|The suboccipital musculature will be palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure was applied, pushing the atlas anteriorly. The occiput will be rested on the hands of the therapist while the atlas is supported by the fingertips. Finger pressure will be maintained for 10 minutes to produce the proposed therapeutic effect of inhibiting the suboccipital soft tissues.
41100276|NCT06631222|OTHER|deep friction massage|Friction massage is performed with the fingertips placed on the trigger points. Pressure was applied and the fingertips move in a circular manner, while the pressure is gradually increased. This massage will be applied until the patient report a reduction in pain at the trigger point
41100277|NCT06631222|OTHER|Spinal manipulation|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateral flexion will be used. Application will be bilateral. First, cephalic decompression will be performed lightly, followed by small circumductions. Selective tension will be applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique will be applied with the aim of increasing occiput, atlas, and axis joint mobility.
41133260|NCT06285409|DRUG|Carbetocin|Carbetocin first bolus 10-8 M (equivalent to 100 mcg) will be added to the muscle bath to create ex-vivo environment similar to Cesarean delivery, and after 20 minutes the baths will be washed three time with physiological salt solution (PSS).
41133261|NCT06285409|DRUG|Oxytocin|Oxytocin 10-5M will be added to all strips for 2 hours to induce desensitization.
41133262|NCT06285409|DRUG|Carbetocin|Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-5 M to 10-5 M
41133263|NCT06285409|DRUG|Oxytocin|Increasing concentrations of oxytocin from 10-10 M to 10-5 M
41133264|NCT06285409|DRUG|Ergonovine|Increasing concentrations of ergometrine from 10-10 M to 10-5 M
41443279|NCT06253533|OTHER|Placebo|Phosphate buffered saline of the same volume will be administered. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
41443280|NCT01609257|BIOLOGICAL|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
41443281|NCT01609257|BIOLOGICAL|Saline Comparator|2 doses IM 28 days apart
41443282|NCT00704639|DRUG|Cetuximab|Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
41443283|NCT00704639|DRUG|Carboplatin|Weekly intravenous carboplatin (AUC 2) for the duration of the RT
40924996|NCT00796926|DRUG|Systane Ultra eyedrops|Four times a day
41100278|NCT06631222|OTHER|Exercises for forward head posture|"Scapular stabilization exercises:~1. In quadruped position, the patient lift¬ up his arms alternatively with shoulder abduction and 120 ° flexion.~2. In sitting position, with 90° knee flexion on a stool or bed without backrest, patient hold a pair of dumb¬bells (2 kg) in each hand and lift them up laterally while maintaining scapulae's height below 80°. The patient was instructed to hold each stage for 10 seconds and then re-turn to the starting position and three sets of 10 repetitions with 30-second pause in between were completed.~3. As for the progression of scapular stability exercise, T to Y the patient was instructed to lie in prone lying position on Swiss ball with arms abducted to 90° (the letter T); then she asked to flex elbows to 90°, retract scapulae and externally ro¬tate arms while keeping arm in 90° abductions. While maintaining the retraction of scapula, the patient is asked to raise his arms above head and extend the elbow while his arm flexed and abducted to 120°"
41443284|NCT00704639|RADIATION|Radiotherapy|"The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended)."
41100279|NCT06221332|OTHER|% 0.25 bupivakain 20cc|Pregnant women in group S will be given 0.25% bupivacaine, 10 cc on each side.
41100280|NCT06221332|OTHER|20 cc saline|Pregnant women in Group K will be given 10 cc of saline on both sides.
41100281|NCT02844764|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Day 7, 14 and 30 \[PRP\]
41100282|NCT03842150|DIAGNOSTIC_TEST|biliary atresia screen score|The investigators aim to develop a scoring system according to clinical, laboratory, imaging features of biliary atresia in the derivation dataset and tested in the validation datasets.
41100283|NCT02714803|BEHAVIORAL|"Connective tissue massage and Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
41100284|NCT02714803|BEHAVIORAL|"Classic massage group and Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
41100285|NCT02714803|BEHAVIORAL|"Sham massage group and Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
41100286|NCT04585347|DRUG|ALZ-801 170 mg Fasting|
41100287|NCT04585347|DRUG|ALZ-801 205 mg Fasting|
41100288|NCT04585347|DRUG|ALZ-801 205 mg After Food|
41100289|NCT04585347|DRUG|ALZ-801 342 mg Fasting|
41443285|NCT06272669|DEVICE|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
41100290|NCT01175707|DRUG|Daptomycin|
41100291|NCT01175707|DRUG|Vancomycin|
41100292|NCT01539603|DEVICE|Drug eluting balloon + Bare metal stent|PCI using Sequent Please and then Coroflex Blue
41100293|NCT01539603|DEVICE|drug eluting stent (Zotarolimus-eluting stent)|conventional PCI using Endeavor Integrity
41100294|NCT04679363|OTHER|Active release technique|ART will be performed on upper trapezius and sternocleidomastoid, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. ART will be performed in supine position with a pillow under knees. After the shortened area of the targeted muscle is identified, soft tissue mobilization with active movement and passive overpressure will be applied. The active movement in technique will be from shortened position of muscle to lengthened position.
41100295|NCT04679363|OTHER|Post isometric relaxation|PIR will be performed on upper trapezius and sternocleidomastoid muscles, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. The patient will be instructed to move the ear towards the shoulder of the affected side, against the resistance of the therapist's hands with minimum force (only 20% of their total force). The patient will be instructed to perform isometric contraction of the affected side along with inhalation and position for 10 seconds. Then the patient will exhale completely and relax. During this relaxation phase head and neck are taken further away from ipsilateral shoulder and ipsilateral shoulder is pushed downward until next restriction is met.
40924997|NCT00796926|DRUG|Refresh eye drops|Four times a day
41100296|NCT03095209|DRUG|Carboplatin|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
41100297|NCT03095209|DRUG|Paclitaxel|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
41100298|NCT03095209|RADIATION|Radiation Therapy|The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
41133265|NCT06285409|DRUG|Carboprost|Increasing concentrations of carboprost from 10-10 M to 10-5 M
40924998|NCT01049945|DRUG|bendamustine hydrochloride|Given IV
40924999|NCT01049945|DRUG|lenalidomide|Given orally
40925000|NCT01049945|DRUG|dexamethasone|Given orally or IV
41133266|NCT04153838|OTHER|Cognitive test administration|Specifically chosen cognitive tests will be administered to all participants twice; with an approximate 12 month gap between initial testing and follow-up testing.
41100299|NCT03071497|DIAGNOSTIC_TEST|Non-invasive analysis of Zinc protoporphyrin|In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
41100300|NCT03526081|OTHER|Chamomile Tea|Chamomile Tea in 300mL hot water
41100301|NCT03526081|OTHER|Parsley based drink|3.2 g dried parsley in 300mL hot water
41100302|NCT03526081|OTHER|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
41100303|NCT03526081|OTHER|Apigenin|Apigenin capsule mixed with 300mL hot water
41100304|NCT03526081|OTHER|Parsley-based drink (II)|3.2 g dried parsley in 300mL hot water
41100305|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
41100306|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
41100307|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
41100308|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
41100309|NCT01004328|OTHER|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
41100310|NCT01124162|DRUG|Losartan|100 mg Tablet
41100311|NCT01124162|DRUG|Cozaar®|100 mg Tablet
41100312|NCT05533866|COMBINATION_PRODUCT|APR-TD011|APR-TD011 wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician. Based on its product profile, APR-TD011 has been granted an FDA Orphan Drug Designation for epidermolysis bullosa.
41100313|NCT06629142|BEHAVIORAL|Default Order|A specialist PC consult is automatically ordered for patients meeting a certain threshold of 1-year mortality risk (dependent on arm). An EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
41100314|NCT06629142|BEHAVIORAL|Accountable Justification|An EHR-based Our Practice Advisory alert asks generalist clinicians to self-report whether they have provided primary PC by clicking which of 4 key PC domains they have addressed or to provide a brief justification as to why not.
41100315|NCT06629142|BEHAVIORAL|Standardized Usual Care|Moderately high-risk patients (e.g., with a 1-year mortality risk between 60% and 94%) will receive usual care. For very high-risk patients (e.g., with a 1-year mortality risk of ≥ 95%), an EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
41100316|NCT01304394|DRUG|Ped3CB|The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
41100317|NCT03881631|BEHAVIORAL|Mindfulness Based Stress Reduction Program|Group-based intervention
41100318|NCT03881631|BEHAVIORAL|Living Well Program|Group-based intervention
41100319|NCT00886613|BIOLOGICAL|V212|Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31
41100320|NCT00886613|BIOLOGICAL|Comparator: Zostavax™|Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31
41100321|NCT00886613|BIOLOGICAL|Comparator: Placebo|Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31
41443286|NCT06272669|DEVICE|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
41443287|NCT00838539|DRUG|Neratinib|
41443288|NCT00838539|DRUG|Temsirolimus|
40925001|NCT02268929|DEVICE|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
41443289|NCT04914351|DRUG|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
41443290|NCT02792816|DRUG|First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)|Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
41443291|NCT05041075|DEVICE|Weighted Blanket|Weighted blankets provide Deep Pressure Stimulation (DPS) or Deep Touch Pressure (DTP) which has advantages in both physical and psychological domains.
41443292|NCT00313937|DRUG|Insulin glargine|
41100322|NCT00886613|OTHER|VZV Skin Test|Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.
41100323|NCT00886613|OTHER|Saline|One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
41100324|NCT03203798|PROCEDURE|Training of pelvic floor muscles|The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.
41133267|NCT02861456|OTHER|Standard Model of Care|
41133268|NCT02861456|OTHER|Alternative Model of Care|
41100325|NCT03203798|PROCEDURE|Hipopressive abdominal gymnastics|The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
41443293|NCT03646175|DIETARY_SUPPLEMENT|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
41100326|NCT04138862|BEHAVIORAL|Product Labelling and Sensory modifications|the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).
41100327|NCT01003015|DRUG|BAY73-4506|160 mg BAY73-4506
41100328|NCT02962336|DRUG|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|Oral, crossover
41100329|NCT02962336|DRUG|Tribenzor Tablets of Daichi Sankyo Inc, USA|Oral, crossover
41100330|NCT02540135|OTHER|fluorescein|fluorescein and conventional neuro-navigation
41100331|NCT02540135|OTHER|intraoperative MRI|conventional neuro-navigation and iMRI
41100332|NCT05778071|COMBINATION_PRODUCT|eneboparatide|Supplied as a solution (concentration of 250 mcg/mL or 500 mcg/mL) in single-patient-use prefilled pens
41100333|NCT05778071|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution (containing the excipient solution for eneboparatide) in single-patient-use prefilled pens
41100334|NCT04036162|BEHAVIORAL|Cognitive tasks|MagnetoEncephaloGraphy (MEG) records
41100335|NCT03315390|OTHER|"Narrative Exposure Therapy-oriented intervention"|Narrative Exposure Therapy (NET) in an Primary-care adapted Version in 3 sessions (S) 6 weeks (S1), 8 weeks (S2) and 12 weeks (S3) after baseline data collection at T0.
41100336|NCT03315390|OTHER|improved treatment as usual (iTAU)|improved standard primary care for PTSD according to Guidelines, customized to patients' needs and symptoms during 3 consultations between T0 and T1
41100337|NCT01268891|DRUG|Placebo|Once daily; tablet; orally; 18 weeks
41100338|NCT01268891|DRUG|Azilect®|1 mg daily; tablet; orally; 18 weeks
41100339|NCT00221351|PROCEDURE|CRP point of care testing|
41100340|NCT03795740|DIAGNOSTIC_TEST|3-D CT scanning|For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques
41100341|NCT02299921|OTHER|Characterize alcohol and drug use|Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
41443294|NCT03646175|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
41443295|NCT04169633|DIAGNOSTIC_TEST|Cognitive Function Evaluation|Evaluation of cognitive function and evaluation of daily cognition
41443296|NCT06544200|DEVICE|Polymeric Hydrogel Matrix|application of Polymeric Hydrogel Matrix along the suture line at the completion of lung resection
41443297|NCT01161420|DEVICE|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
41443298|NCT05650632|DRUG|ABBV-383|Intravenous Infusion
41443299|NCT04034290|BIOLOGICAL|GamFluVac|The drug is a vaccine that induces high-level immunity against influenza A viruses
40925002|NCT02268929|DEVICE|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out from blood glucose meter devices
40925003|NCT02929654|DEVICE|OneTouch Verio®|Colour Enhanced Blood Glucose Meter.
41443300|NCT04034290|OTHER|Placebo|Placebo
40925004|NCT02929654|DEVICE|OneTouch Verio® Flex|Colour Enhanced Blood Glucose Meter.
40925005|NCT02929654|DEVICE|Subject's Own Blood Glucose Meter|Subject's Own Blood Glucose Meter
40925006|NCT03040570|PROCEDURE|Conservative oxygenation target|Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
41100342|NCT03183232|PROCEDURE|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
41100343|NCT03183232|BIOLOGICAL|γδ T cell|γδ T cells will be used against Lung Cancer
41100344|NCT03183232|OTHER|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
41100345|NCT06142240|OTHER|exercise programe|"The components of the exercise programe will be: muscle strength training and continuous-variable aerobic training or HIIT with loads between 70-90% of maximum heart rate. The aerobic training will last about 30 minutes and will then be completed with muscle training of the upper and lower limbs with loads determined according to the perception of effort (loads around 50-70%). The sessions will be monitored with pulse oximetry (heart rate and oxygen saturation), perception of fatigue and sensation of suffocation (Borg scale). The intensity of each component of the programme will be individualised according to the conditions of each subject.~Adherence to the programme will be recorded as successful when participation in the sessions is greater than 80% of the total number of sessions."
41100346|NCT00618319|DRUG|BIIB021|Dose, schedule, and duration specified in protocol
41100347|NCT04691544|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Delivered by enema
41100348|NCT03570333|DIAGNOSTIC_TEST|progenitor potential of Gingival Mesenchymal cells|tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
40925007|NCT03040570|PROCEDURE|Liberal oxygenation target|Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining \>94%.
40925008|NCT01642732|OTHER|Everolimus, lupron, bicalutamide, and radiation|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
40925009|NCT04023929|PROCEDURE|Cord blood sampling|A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
41100349|NCT01879371|DRUG|Ibuprofen+caffeine FDC|oral dose
41100350|NCT01879371|DRUG|Ibuprofen (Nurofen Immedia®)|oral dose
41100351|NCT01879371|DRUG|Ibuprofen (Brufen®)|oral dose
41100352|NCT01117441|DRUG|PEG-L-asparaginase|see detailed protocol description
41100353|NCT01117441|DRUG|cyclophosphamide|see detailed protocol description
41100354|NCT01117441|DRUG|cytarabine|see detailed protocol description
41100355|NCT01117441|DRUG|daunorubicin hydrochloride|see detailed protocol description
41100356|NCT01117441|DRUG|dexamethasone|see detailed protocol description
41100357|NCT01117441|DRUG|doxorubicin hydrochloride|see detailed protocol description
41100358|NCT01117441|DRUG|etoposide|see detailed protocol description
41100359|NCT01117441|DRUG|ifosfamide|see detailed protocol description
41100360|NCT01117441|DRUG|mercaptopurine|see detailed protocol description
41100361|NCT01117441|DRUG|methotrexate|see detailed protocol description
41100362|NCT01117441|DRUG|prednisone|see detailed protocol description
41100363|NCT01117441|DRUG|thioguanine|see detailed protocol description
41100364|NCT01117441|DRUG|vincristine sulfate|see detailed protocol description
41100365|NCT01117441|DRUG|vindesine|see detailed protocol description
41100366|NCT01117441|DRUG|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
41100367|NCT01117441|DRUG|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
41443301|NCT05698589|BEHAVIORAL|Compassion Focused Therapy|CFT is an experiential therapy. As such, in addition to psychoeducation components (e.g.: compassion from an evolutionary and neuroscientific perspective, the tricky brain problem, emotion regulation systems) and explicit learning of emotion regulation skills (in particular, shame), experiential exercises are provided in-sessions (e.g. : chair work, role plays, guided mental imagery, ...) and between sessions practices will be provided with video guides, made available for the participants online (e.g. : soothing rhythm breathing, safe place imagery, compassionate self-imagery, ...). The overall aim of the CFT program is to help participants shift from a hostile and critical self-to-self relationship to a more compassionate relationship to self.
41443302|NCT05698589|BEHAVIORAL|Ending Self Stigma|Psychoeducation sessions cover topics such as the path from public stigma to self-stigma and modifying self-stigmatizing thoughts. Participants will be encouraged to do home practices (e.g. writing about the pros and cons of self-stigmatizing thoughts) between sessions. The overall aim of the ESS program is to help participants address self-stigma with concrete tools to increase their self-esteem and achieve their goals
41443303|NCT05574114|RADIATION|Bridging radiotherapy (BRT)|RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).
41443304|NCT05574114|DRUG|Conditioning chemotherapy|Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy
41100368|NCT01117441|RADIATION|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
41100369|NCT04235283|DEVICE|Primary total knee replacement by pinless navigation (Orthomap Express,Stryker, Michigan)|The varus/valgus, extension/flexion, thickness of distal cut of femur was determined and done by pinless navigation system. After cutting, the instant information of resection level can show on the display screen. If the alignment is satisfying, the anterior/posterior femoral cut, chamfer cut and box resection were done by conventional jig
41100370|NCT04235283|PROCEDURE|Primary total knee replacement by traditional jig and minimally invasive technique|The femoral alignment was determined by intramedullary guide. The femoral alignment jig was set to 5-7 degree valgus dependent on the preoperative radiograph. A bone plug is impacted into the entry hole of femoral medullary canal before prosthesis placement.
41100371|NCT03772964|DRUG|MetFORMIN Hydrochloride ER|Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
41100372|NCT03772964|DRUG|Placebo|Subjects will be exposed to placebo, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
41100373|NCT05709873|BEHAVIORAL|Imagery rehearsal therapy|Therapy to reduce nightmares, delivered via videoconference sessions
41100374|NCT05709873|BEHAVIORAL|Targeted dream control|Therapy to reduce nightmares, delivered in videoconference sessions and lab session. Lab session will involve a sleep study during a daytime nap.
41100375|NCT01213706|DEVICE|Whole Body Periodic Acceleration (WBPA)|Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.
41100376|NCT01213706|DEVICE|Sham WBPA|The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
41100377|NCT06046833|DEVICE|FreeStyle Libre 3 continuous glucose monitoring sensor|The Freestyle Libre 3 sensor is a small real-time continuous glucose monitor device that measures glucose levels every minute
41100378|NCT06046833|OTHER|Nutritional drink|Balanced nutritional drink (Boost plus 8 ounces/237 mL)
41100379|NCT03089346|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
41100380|NCT03089346|DIAGNOSTIC_TEST|Computed tomography (CT)|Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
41100381|NCT00941356|DIETARY_SUPPLEMENT|Bio-K+ CL1285|2 capsules per day before breakfast
41100382|NCT00941356|DIETARY_SUPPLEMENT|Placebo|2 capsules per day before breakfast
41100383|NCT00678158|RADIATION|intensity modulated radiation therapy|Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
41100384|NCT03213678|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
41100385|NCT03213678|PROCEDURE|Computed Tomography|Undergo CT
41100386|NCT03213678|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
41100387|NCT03213678|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41100388|NCT03213678|DRUG|Samotolisib|Given PO
41100389|NCT03213678|PROCEDURE|X-Ray Imaging|Undergo x-ray
41100390|NCT04299685|OTHER|Interview|Qualitative family interviews of 20 family units, or more until data saturation, of at least one parent and one adolescent (aged 10-19 year old) will be conducted based on deductive thematic approach. Each interview will last for about an hour, be conducted in Cantonese, and audio-taped for transcription in verbatim in Chinese.
41100391|NCT00006204|DRUG|naltrexone (Revia)|
41100392|NCT00006204|DRUG|fluoxetine (Prozac)|
41100393|NCT06554132|OTHER|Scleroderma Group|Scleroderma patients will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
41100394|NCT06554132|OTHER|Healthy group|Healthy people will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
41100395|NCT02096289|DRUG|Thioridazine|
41100396|NCT03994471|DRUG|XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght|XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine
41100397|NCT03994471|DRUG|1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution|Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.
41100398|NCT01899222|DEVICE|Handheld fundus photography|diagnostic imaging with two types of retina camera
41100399|NCT03416751|BIOLOGICAL|Fecal Microbial Transplant|Fecal transplant from a donor in the OpenBiome Registry
41100400|NCT03416751|OTHER|Placebo|Placebo enemas
41100401|NCT00431795|DRUG|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m\^2 IV every 4 weeks for 6 consecutive cycles
41100402|NCT00431795|DRUG|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m\^2 IV every 3 weeks for 6 consecutive cycles
41100403|NCT06629441|DIETARY_SUPPLEMENT|Probiotic group|taking 10 billion CFU probiotic one sachet one time, lasting 56 days.
41100404|NCT06629441|DIETARY_SUPPLEMENT|Placebo group|taking maltodaxtrin one sachet one time, lasting 56 days.
41100405|NCT02763124|PROCEDURE|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
41100406|NCT02652234|DRUG|Endostar|Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
41100407|NCT02652234|DRUG|Chemotherapy|
41100408|NCT03208062|OTHER|collection of waste materials|osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
41100409|NCT02715063|BEHAVIORAL|High Intensity Interval|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
41100410|NCT02715063|BEHAVIORAL|Resistance training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
41100411|NCT02715063|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
41100412|NCT02715063|OTHER|Usual clinical care|Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
41100413|NCT04414878|DEVICE|VitaFlow™ II Transcatheter Aortic Valve System|VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire
41100414|NCT00138632|DRUG|PTK787|Visudyne® + PTK787, 500 mg/day
41100415|NCT00138632|DRUG|PTK787|Visudyne® + PTK787 1000 mg/day
41100416|NCT00138632|DRUG|Placebo|Visudyne® + Placebo
41100417|NCT06443021|DEVICE|PD cycler|"After a training phase and a run-in period of up to 6 weeks, depending on the PD cycler used prior to the study, the interventional phase will be initiated.~* Study phase A, variation of dwell duration: Duration of short cycles (cycle 1 and 2) 30 min, 60 min, 90 min, 120 min (and 150 min depending on the patient´s constitution and at the discretion of the treating physician)~* Study phase B, variation of dialysis fluid glucose composition: 1st cycle: 1.5% glucose concentration, 2nd cycle: 2.3% glucose concentration, 3rd cycle: 1.5% glucose concentration, 4th cycle: 2.3% glucose concentration; all following cycles to be applied as prescribed by the treating physician.~* Study phase C, variation of fill volume: 60% fill volume, 80% fill volume, 100% fill volume and 120% fill volume. (Volume of 120% will only be applied in case the patient tolerates these volumes according to the IPP."
41100418|NCT04437056|PROCEDURE|Cognitive nerve transfers to spastic upper extremity muscles in stroke patients|Based on the fact that upper motor neuron syndrome after stroke is presented with variable clinical features, usually without affecting in the same way the entire upper extremity, we aim to investigate the efficacy of nerve transfers to spastic muscles after stroke using as donor nerves that innervate unaffected ipsilateral volitionally controlled muscles.
41100419|NCT05872321|OTHER|Complication|whether or not complications occur
41100420|NCT00841958|PROCEDURE|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
41100421|NCT04791124|OTHER|Electroencephalography|"EEG evaluation Composed by three consecutive tests~1. Resting state EEG, with either eyes open or closed~2. Auditory steady-state response (ASSR)~3. Auditory evoked potential"
41100422|NCT06629662|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy with laparoscopic or robotic approach
41100423|NCT02000505|DEVICE|PocketCPR|5 minutes chest-compression-only CPR, using Zoll PocketCPR
41100424|NCT02000505|DEVICE|Metronome|5 minutes chest-compression-only CPR, using a metronome
41100425|NCT02000505|DEVICE|110bpm Song|5 minutes chest-compression-only CPR, using a song with 110bpm for support
41100426|NCT00048529|DRUG|T900607-sodium intravenous|
41100427|NCT03861221|DEVICE|CBBCT|To compare the differences between various lesions' presentation on CBBCT and on other approaches under diverse breast conditions.
41100428|NCT02787967|DRUG|CHF 1535 35/4µg NEXThaler®|4 (four) inhalations (total dose: BDP/FF 140/16 µg)
41100429|NCT02787967|DRUG|free comb. beclomethasone DPI and formoterol DPI|2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
41100430|NCT06016686|OTHER|VNS stimulation and intraneural recordings|A minimum of three stimulation frequencies (1, 10 and 30 Hz), each up to 60s in duration, will be delivered via the VNS device. Intraneural recordings proximal or distal to the VNS electrodes during delivery of VNS will be performed. Approximately two to five fascicles will be explored in each nerve.
41100431|NCT06016686|OTHER|Record multi-unit activity from intraneural sites|Perform a more detailed vagal nerve mapping study by recording from single nerve fibers, including those fibers supplying the heart, lungs, airways and other end-organs. The investigators shall perform functional mapping of the left and right vagus nerves, such as those with cardiac-related and/or respiratory-related neural activity. The research team will also record activity from other nearby fibers to map the differences in neurological behavior in fascicles that control the heart, lungs, airways and other systems.
41100432|NCT05181579|OTHER|Manuel therapy|Some sacroiliac manipulation and mobilization techniques will be applied to patients by an experienced physiatrist. Patients in the manual therapy group will receive 5 sessions of sacroiliac joint manipulation once a week.
41100433|NCT05181579|OTHER|Sacroiliac joint injection|Corticosteroid (1 ml 40 mg methylprednisolone) and local anesthetic (1 ml 1% lidocaine) will be injected into the sacroiliac joint using a 22 G spinal needle, guided by fluoroscopy (C-arm fluoroscopy) by an experienced physiatrist. It will be applied just one time.
41100434|NCT01611376|DEVICE|Niccomo™ (Medis, Ilmenau, Germany) impedance cardiography|
41100435|NCT03044769|PROCEDURE|Malformations resection|Resection of the malformation lung sections with a healthy adjacent part
41100436|NCT03031444|DRUG|Cetuximab plus FOLFIRI/FOLFOX|cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy
41100437|NCT03031444|DRUG|FOLFIRI/FOLFOX/CapeOX|to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
41100438|NCT04243343|DEVICE|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program for treatment of plantar fasciosis.
41100439|NCT04243343|OTHER|Standard of care|Standard of care prescribed home exercise program for treatment of plantar fasciosis.
41100440|NCT03552770|DRUG|Bevacizumab|pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
41100441|NCT01960803|RADIATION|Intraoperative Electron Radiotherapy|Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
41100442|NCT05850130|OTHER|Acupuncture intervention|"6 weeks of acupuncture once a week. The acupuncture intervention will consist of weekly session administered over a period of 6 weeks (± 4 days). A two-way verum acupuncture treatment protocol will employ 8 selected acupoints.~After week 7, patients included in Arm A may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist."
41100443|NCT05850130|OTHER|No acupuncture|The patient in the Arm B will not receive acupuncture treatment for a period of 6 weeks after randomization (weeks 1-6) and during the following weeks 8-13 (acupuncture intervention) if its NRS score is \<4/10 at week 7. If the patient' NRS score is ≥ 4/10 at week 7, the patient in control Arm B will receive the same acupuncture intervention that the patient in the Arm A (6 weeks).
41100444|NCT03313206|DRUG|Pembrolizumab|"Neo-adjuvant therapy :~* Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.~* Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).~Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy."
41100445|NCT03313206|PROCEDURE|Surgery|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
41100446|NCT03313206|RADIATION|IMRT|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
41100447|NCT03313206|DRUG|Lenvatinib|up to 26 evaluable patients will be treated with pembrolizumab combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
41100448|NCT00208104|BEHAVIORAL|Motivational Interviewing|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
41100449|NCT03317353|DEVICE|Vestibular rehabil.: CDP|Vestibular rehabilitation, ten sessions
41100450|NCT03317353|DEVICE|Vestibular rehabil.: optokinetic stimuli|Vestibular rehabilitation, ten sessions
41100451|NCT03317353|OTHER|Vestibular rehabil.: home exercises|Exercises performed twice a day for two weeks. Approximate duration of each session: 15 minutes
41100452|NCT04573374|PROCEDURE|Pulpotomy|Pulpotomy is the term for removal of the coronal pulp with the intent of maintaining the vitality of the remaining radicular pulp tissue.
41100453|NCT02891629|DEVICE|EyeControl device|Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
41100454|NCT06282835|DRUG|Eravacycline Injection|Eravacycline at the recommended dose and administration method according to the instructions: 1 mg/kg intravenous administration, every 12 hours. The intravenous infusion duration is approximately 60 minutes. For patients with severe liver impairment (Child-Pugh class C), administer 1 mg/kg of this product every 12 hours on the first day, followed by 1 mg/kg every 24 hours starting from the second day.
41100455|NCT06631885|PROCEDURE|regenerative endodontic procedure using blood clot according to AAE|regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using AAE protocol
41100456|NCT06631885|PROCEDURE|regenerative endodontic procedure using photo activated nanochitosan 2%|regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using photosensitized nanochitosan for root canal disinfection
41100457|NCT02702024|PROCEDURE|Double uterine incision technique in uterus preserving surgery for placenta percreta|
41100458|NCT00023725|DRUG|semaxanib|
41100459|NCT00023725|PROCEDURE|conventional surgery|
41100460|NCT00023725|RADIATION|radiation therapy|
41100461|NCT04624230|DRUG|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
41100462|NCT00731107|PROCEDURE|laparoscopic surgery|XCEL bladeless trocar laparoscopic entry
41100463|NCT00731107|PROCEDURE|laparoscopic surgery|Veress Needle laparoscopic entry
41100464|NCT03663218|RADIATION|Dose escalation|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
41100465|NCT02037243|BEHAVIORAL|Standard Public Health Intervention with Water Treatment|Compound level meeting
41100466|NCT02037243|BEHAVIORAL|Standard Public Health Intervention with Water Treatment & Hand Washing|Compound level meeting
41100467|NCT02037243|BEHAVIORAL|Disgust and Shame Based Intervention with Water Treatment|Compound level meeting
41100468|NCT02037243|BEHAVIORAL|Disgust and Shame Based Intervention with Water Treatment & Hand Washing|Compound level meeting
41443305|NCT05574114|BIOLOGICAL|CAR T-cell product|Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.
41100469|NCT05805124|DIAGNOSTIC_TEST|Preop evaluation|"All preop evaluations prescribed in the preadmission clinic will be recorded, especially:~* renal function tests~* hematologic tests~* coagulation tests~* hepatic function tests~* ECG~* cardiac function tests~* pulmonary function tests~* endocrine function tests"
41100470|NCT01805414|OTHER|Modified Carbohydrate Breakfast|
41100471|NCT01805414|OTHER|Control Breakfast|
41100472|NCT04097899|OTHER|implementation of antimicrobial stewardship comprehensive care bundle program on ventilator associated pneumonia patients|"Construction of a comprehensive care bundle educational program. This program consisted of many elements: Antimicrobial stewardship programs, VAP bundles and infection control policy implementation and the investigators studied the impact of this program on:~* Antibiotics cost.~* Appropriates of antibiotic use (initiation, duration \& time of discontinuation).~* Rate of resistance~* Clinical outcome, infection rate \&length of stay."
41100473|NCT06374056|DEVICE|Kintsugi Voice Device|"The Kintsugi Voice Device is intended to be used to screen for the presence of voice signals consistent with a current moderate to severe depressive episode in patients aged 22 and older. The device is intended to be used by care providers licensed to screen for depression and in settings where the screening for depression occurs. The device is neither to be used in lieu of a complete patient evaluation nor to supplant any of the clinician's standard assessments for the screening or diagnosis of depression.~The Kintsugi Voice Device is comprised of a software API and machine learning model that utilizes recorded voice samples as inputs and outputs the detection of signals consistent with current moderate to severe depressive episode as outputs."
41100474|NCT02165891|DRUG|insertion of a chest drain with urokinase instillation|Other interventions except drainage procedure are the same in both arms
41100475|NCT02165891|PROCEDURE|primary video-assisted thorascopic surgery|
41100476|NCT06138951|OTHER|Endurance exercise|On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.
41100477|NCT06442254|OTHER|Virtual Reality|In the application, which will be done with VR glasses, a video of walking on Istiklal Street in Istanbul's Beyoğlu district will be watched.
41100478|NCT03198546|BIOLOGICAL|GPC3 and/or TGFβ targeting CAR-T cells|Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
41100479|NCT01419730|DRUG|Vitamin D3|Vitamin D3 50,000 IU
41100480|NCT01419730|BEHAVIORAL|Physical Activity|Progressive walking and resistance band exercise prescription for a period of 24 weeks
41100481|NCT05288517|BEHAVIORAL|Lock to Live|Lock to Live is an anonymous web-based self-administered decision aid for safe firearm and medication storage (Public URL: http://lock2live.com/).
41100482|NCT04966156|BEHAVIORAL|CaRE-4-alloBMT plus usual care group|CaRE-4-alloBMT uses emerging eHealth technologies to reduce barriers to accessing and providing cancer rehabilitation which includes: 1) Individualized progressive exercise prescriptions that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials; 2) Individualized nutrition plans and stepped stratified care such as education, counselling, intervention based on nutritional status and delivered by registered dietitians; 3) On-line e-modules provide interactive education to promote self-management skills for stress management, nutrition, managing common symptoms, etc.; 4) Remote monitoring using FitbitTM devices to monitor patients physical activity, caloric intake, and sleep for duration of the program. CRS and alloBMT clinicians will have access to real-time Fitbit data through our clinical dashboard; 5) Remote clinical support: check-ins and health coaching sessions with a member of the CRS team (phone or MS Teams video).
41100483|NCT02438800|BEHAVIORAL|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
41100484|NCT00114933|DRUG|Stopping nucleosides and continuing lopinavir/ritonavir monotherapy|
41100485|NCT00423007|DRUG|Bromfenac|
41100486|NCT00423007|DRUG|Placebo|
41100487|NCT06193785|OTHER|Hypnosis|hypnosis realised by expert practitioner, before and during the electromyogram procedure
41100488|NCT02968004|DRUG|MOD-4023|Once weekly subcutaneous injection using pre-filled pen device.
41100489|NCT02968004|DRUG|Somatropin|Once daily subcutaneous injection of Genotropin using pre-filled pen device.
41100490|NCT02169310|DEVICE|tDCS|There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.
41100491|NCT02169310|DRUG|[11C] Raclopride|\[11C\] Raclopride is administered under an IND 054135. This IND is sponsored by the NIH Clinical Center and \[11C\] Raclopride is dispensed by the NIH PET Department. Quality Assurance for Radioactive Drug: \[11C\] Raclopride, is assayed for radiochemical purity under the supervision of the NIH PET Department prior to dispensing the drug for administration. Given that IND PET drugs manufactured at the NIH PET Department are used in a single site and that there is no intent for their commercialization, submission of IBs has not been required by FDA for any of the NIH Office of Research Support and Compliance-sponsored IND applications.
41100492|NCT03862170|DRUG|Ciprofloxacin|Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy
41100493|NCT03862170|DRUG|Cefazolin|
41100494|NCT01769781|DRUG|anastrazole|combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
41443306|NCT04852978|DRUG|casirivimab+imdevimab|Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
41443307|NCT04852978|BIOLOGICAL|Moderna mRNA-1273 vaccine|Single intramuscular (IM) injection
41443308|NCT04374864|DRUG|Trelagliptin|Anti diabetic
41443309|NCT02145273|BEHAVIORAL|Interpersonal Psychotherapy for Depression -Group|
41443310|NCT06562231|OTHER|quality of life scale|This study will be conducted on women diagnosed with symptomatic isthmocele after cesarean section. Researchers will prepare scale questions, and the survey questions will be developed after obtaining an expert opinion from 20 experts to be evaluated by psychiatry, obstetrics, and public health experts. The patient will fill out the questionnaire form with the diagnosis of isthmocele. Oral and written consent will be obtained from the patients.
41100495|NCT01769781|DRUG|GnRH analog alone|treatment for three months with GnRH analog (leuprolide acetate) alone
41100496|NCT02403674|DRUG|Doravirine, Tenofovir, Lamivudine|One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.
41100497|NCT02403674|DRUG|ATRIPLA™|One ATRIPLA™ tablet taken q.d. by mouth
41100498|NCT02403674|DRUG|Placebo|Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
41100499|NCT00641472|DRUG|Budesonide inhalation suspension|0.5mg
41100500|NCT00641472|DRUG|Montelukast Sodium|4mg or 5mg
41100501|NCT02750709|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
41100502|NCT02750709|DRUG|Nitisinone 10 mg Tablet High Compritol|A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
41100503|NCT02750709|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
41100504|NCT02770859|PROCEDURE|POEM (Per Oral Endoscopic Myotomy)|Per-Oral endoscopic myotomy (creating a muscle \[esophagus\] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle \& sphincter of the LES for the treatment of achalasia
41100505|NCT04005313|DEVICE|vibroacoustic device|the participants will receive the vibroacustic device or music therapy
40925010|NCT03483922|DIAGNOSTIC_TEST|ctDNA methylation in and it's Correlation wth Development and prediction of HCC|Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
40925011|NCT05090176|OTHER|povidone-soaked suture|suture soak with povidone solution for 3 mins
40925012|NCT05090176|OTHER|ordinary suture|suture no need to soak with povidone solution
41100506|NCT02700867|DEVICE|NIO|Intraosseous access device NIO (Defibtech)
41100507|NCT01710514|DRUG|FE 999913 vaginal tablet|
41100508|NCT05138172|DEVICE|"Forced Air Heating Temperature control Twinwarm II"|"For this purpose, we will use a device that is already routinely used in all operation rommss at MHH, the so-called warm air device Twinwarm, Generation III. This device has a valid CE mark and will be used according to its purpose pre-, intra- and postoperative maintenance of the normothermic body temperature of the patient. The device will be used strictly according to the existing in-house SOP Heat Management of 04/2021 of the Department of Anesthesiology and Intensive Care Medicine of the MHH.~Convective air heating has been shown to be effective in many studies and can be used flexibly with a variety of different ceiling models."
41100509|NCT01975467|DEVICE|CRx|The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
41100510|NCT01267409|OTHER|STN stimulation|Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area (through the 4 DBS contacts) after the surgery
41100511|NCT01362491|DRUG|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
41100512|NCT01362491|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
41100513|NCT01362491|DRUG|Placebo|Single-dose of placebo
41100514|NCT02347163|DRUG|Zoledronate|Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
41100515|NCT03459183|DEVICE|Infrasound (85 dB; 6Hz) source|the infrasound source will emit inaudible 6Hz sound for 8 consecutive hours during participant's night sleep, local sound pressure (at participants head) will be calibrated at 85 dB
41100516|NCT03459183|DEVICE|Ultrasound (10dB below hearing threshold; 22.4 kHz) source|the ultrasound source will emit inaudible 22.4 kHz sound for 8 consecutive hours during night sleep
41100517|NCT03459183|DEVICE|Infrasound dummy source|the infrasound dummy source looks exactly like the according verum infrasound source but produces absolutely no sound
41100518|NCT03459183|DEVICE|Ultrasound dummy source|the ultrasound dummy source looks exactly like the according verum ultrasound source but produces absolutely no sound
41100519|NCT02837237|DRUG|KBP-5074|"In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session."
41100520|NCT03955445|DRUG|LNP023|LNP023 capsules
41100521|NCT02023372|OTHER|NuCel with Autograft|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Local autograft is bone that comes from the patient's own vertebrae and surrounding bony structures.
41100522|NCT01726140|PROCEDURE|Helmet CPAP|the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be \>200, the patient will stop the treatment.
41443311|NCT05372744|OTHER|Active Placebo labelled as antidepressant|Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.
41100523|NCT01726140|PROCEDURE|Venturi Mask|the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be \>200, the patient will stop the treatment.
41100524|NCT00065390|DRUG|Pyrimethamine|
41100525|NCT00125151|DRUG|C1 inhibitor concentrate (C1-esteraseremmer-N)|
41100526|NCT00996372|DRUG|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
41100527|NCT00996372|DRUG|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
41100528|NCT02874261|DEVICE|Whole Body Periodic Acceleration|oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
41100529|NCT01280591|DRUG|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
41100530|NCT01280591|DRUG|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
41100531|NCT01280591|DRUG|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
41100532|NCT01280591|DRUG|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
41100533|NCT06618898|OTHER|online questionnaire|The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.
41100534|NCT05094115|BEHAVIORAL|Psychological Flexibility Training (PFT)|"A 2-day workshop lasting approximately 8 hours per day. Day 1: an overview of the training and to describe the posture or stance that prepares one to respond to challenging situations in a psychologically flexible manner.~Day 2: identifies common coping strategies that typically fail or even backfire over the long term and to practice skills that promote psychological flexibility. Experiential exercises will be integrated throughout the training.~Following the PFT, 4 optional, monthly, one-hour booster sessions to supply refresher information.~* An experiential exercise to highlight one or more process/concept that was introduced during the 2-day training.~* Questions from the attendees about applying the concepts in their lives.~* Comments and questions from the booster session facilitators to encourage application of the concepts."
41100535|NCT04977271|DRUG|Venlafaxine|The Immediate Release generic formulation of this drug will be used due to its ability to be crushed for those patients who rely on parenteral administration of medications.
41100536|NCT05328076|DRUG|Indocyanine green|Indocyanine green is used to perform intraoperative angiography.
41100537|NCT05328076|DEVICE|SPY Portable Handheld Imaging (SPY-PHI)|The device is used to perform intraoperative angiography.
41100538|NCT06631716|DEVICE|CVT|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is CVT.
41100539|NCT06631716|DEVICE|HFCWO|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is HFCWO.
41100540|NCT06631716|DEVICE|MetaNeb|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is MetaNeb.
41100541|NCT05512949|BIOLOGICAL|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10\^8 to 3.95 x 10\^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.
41100542|NCT06277622|DEVICE|PFUN|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
41100543|NCT06277622|DEVICE|PFNA|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
41100544|NCT02869958|OTHER|Digital action plan for asthma exacerbations + Written action plan|Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
41100545|NCT02869958|OTHER|Written action plan|
41100546|NCT01043406|DEVICE|Seizure Advisory System|Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
41100547|NCT00631917|DRUG|Aliskiren|Aliskiren 300 mg once a day
41100548|NCT00631917|DRUG|Ramipril|Ramipril 10 mg once a day
41100549|NCT00631917|OTHER|Placebo to Ramipril|Placebo capsules to match ramipril.
41100550|NCT00631917|OTHER|Placebo to Aliskiren|Placebo tablets to match aliskiren.
41100551|NCT03284749|OTHER|Copper impregnated wound dressing|Copper impregnated wound dressing
41100552|NCT03284749|OTHER|Normal wound dressing|Normal wound dressing
41100553|NCT03284749|OTHER|Copper impregnated maternity pads|Copper impregnated maternity pads
41100554|NCT03284749|OTHER|Normal maternity pads|Normal maternity pads
41100555|NCT06480123|DRUG|Skin drug prepared with exome originated from stem cell|Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.
41100556|NCT02869620|OTHER|Data collection|
41100557|NCT03107611|DRUG|Pimecrolimus Cream, 1%|
41100558|NCT03107611|DRUG|Placebo Cream|
41100559|NCT03107611|DRUG|Pimecrolimus Cream, 1%|
41100560|NCT04878796|DIAGNOSTIC_TEST|Serum collection, adverse events collection|Measuring Abs variation at different timepoints compared to baseline. LIAISON SARS-Cov-2 TrimericS IgG and Elecsys anti-SARS-Cov-2 tests will be adopted. The level of Abs will be evaluated at baseline and 30(±7), 180(±7),365(±7)days after the 2nd dose of vaccine
41100561|NCT04652076|DRUG|NP137|Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
41100562|NCT04652076|DRUG|Pembrolizumab|Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
41100563|NCT04652076|DRUG|Paclitaxel|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
41100564|NCT04652076|DRUG|Carboplatin|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
41100565|NCT02689349|DEVICE|Implantation of Esteem|Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
41100566|NCT03147456|DIETARY_SUPPLEMENT|(Cubitan Protein, Nutricia, Netherlands).|Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient.
41100567|NCT03147456|DIETARY_SUPPLEMENT|(preOp, Nutricia, Netherlands).|contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes
41100568|NCT02165605|DRUG|HylaCare|cream
41100569|NCT02165605|DRUG|Placebo|placebo
41100570|NCT02923128|DRUG|Dexmedetomidine|Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
41100571|NCT02923128|DRUG|Sufentanyl|Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
41100572|NCT02923128|DRUG|Saline|Saline is used to dilute other drugs
41100573|NCT01391013|DRUG|Darunavir(DRV)|Oral administration of tablet DRV 800 mg (2 tablets of 400 mg) once daily at the same time, within 30 minutes after food for 48 weeks
41100574|NCT01391013|DRUG|Ritonavir|Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks
41100575|NCT01391013|DRUG|2 nucleoside reverse transcriptase inhibitors (NRTIs)|2 NRTIs will be administered as per the package inserts.
41100576|NCT03392337|DEVICE|Narrowband UVB phototherapy|Ultraviolet B phototherapy
41100577|NCT05790941|COMBINATION_PRODUCT|Latanoprost and Minoxidil|Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.
41100578|NCT00995709|DRUG|AIN457|
40752100|NCT06469125|PROCEDURE|Endoscopic Prostate Interventions for Anatomic Enucleation|The intervention in this study involves performing anatomic endoscopic enucleation of the prostate (AEEP) using different energy sources. Following the enucleation, the resected prostate tissue will be morcellated within the bladder using various morcellators to remove the enlarged prostate tissue minimally invasively. The process will also involve evaluating and categorizing any resulting bladder injuries using the BICEP classification system.
41100579|NCT00995709|DRUG|AIN457|
41100580|NCT00995709|DRUG|Placebo|
41100581|NCT04299360|DEVICE|Cardiac Resynchronization Therapy device programming|Implanted CRT-D devices settings will be programmed based on the best acute hemodynamic response assessed non-invasively
41100582|NCT03206931|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
41100583|NCT06217354|DRUG|Carbetocin 100 Microgram/mL Solution for Injection|All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. \[PabalVR, Ferring AG, Baar, Switzerland\]).then assess uterine contractility and postpartum bleeding measuring
41100584|NCT02410291|OTHER|Educational video|Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
41100585|NCT04989322|DRUG|Pembrolizumab|200 mg Q3W
41100586|NCT04989322|DRUG|Lenvatinib|8 mg daily
41100587|NCT04989322|DRUG|Pemetrexed|500 mg/m2 Q3W
41100588|NCT04989322|DRUG|Carboplatin|AUC5 Q3W
41100589|NCT00957086|DRUG|Nimotuzumab|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
41100590|NCT00957086|DRUG|Placebo|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
41100591|NCT01823341|DEVICE|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
41100592|NCT03357224|DRUG|Atezolizumab|Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
41100593|NCT01537133|DRUG|fluticasone|Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
41100594|NCT01537133|DRUG|Placebo|Dry Powder Inhaler: Placebo
41100595|NCT02894307|DRUG|Rivaroxaban|In patients with mechanical valves and unstable INR
41100596|NCT01247558|OTHER|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for \>120 days
41100597|NCT01247558|OTHER|Not treated with Metanx®|Non-treated comparative cohort
41100598|NCT05754463|OTHER|The effect of plyometric training on balance and proprioception in athletes in different branches|Investigating the effect of plyometric training on balance and proprioception in athletes in different branches
41100599|NCT02677974|DEVICE|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
41100600|NCT00247143|DRUG|Kaletra (drug)|
41133269|NCT05632666|OTHER|Inspiratory and expiratory muscle training at a therapeutic intensity|"The active treatment group will receive inspiratory muscle training starting at a therapeutic intensity of 30% of maximum inspiratory mouth pressure (PImax) and expiratory muscle training starting at a therapeutic intensity of 30% of maximum expiratory mouth pressure (PEmax) for 4 months.~In the active treatment group, the inspiratory and expiratory threshold (intensity) will be adjusted to the perceived exertion (measured with a Borg scale)."
41133270|NCT05632666|OTHER|Inspiratory and expiratory muscle training at a non-therapeutic intensity|The sham-control group will receive the same training protocol as the active treatment group but with a low (10% of PImax and PEmax) and stable non-therapeutic intensity.
41100601|NCT06588751|OTHER|Scalp block|After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.
41100602|NCT04744597|BEHAVIORAL|Real execution of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties. Once each task will be solved, they will receive a new, more demanding task
41100603|NCT04744597|BEHAVIORAL|Motor imagery of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties, same as RE group but the exception of doing it mentally - motor imagery of Fitts's law tasks with eyes open.
41100604|NCT04744597|BEHAVIORAL|Skip counting|Children in SCg will silently count (one number per second) in the same working blocks as both experimental groups with a task of saying the number they reached during each block - control condition to keep them mentally active at very low mental engagement.
41100605|NCT02023554|DRUG|Theophylline with azithromycin|"Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.~Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7."
41100606|NCT02023554|DRUG|Theophylline alone|Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
41100607|NCT03584295|DEVICE|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation
41100608|NCT03584295|OTHER|Conventional Care|Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
41100609|NCT06065800|DEVICE|STEELEX® Sternum Set|Sternal Closure with stainless steel suture (STEELEX®) in patients undergoing cardiac surgery
41100610|NCT00536380|DRUG|5-mg Desloratadine|5-mg desloratadine tablets, once daily for four weeks.
41100611|NCT00536380|DRUG|10-mg Desloratadine|10-mg desloratadine tablets, once daily for four weeks.
41100612|NCT00536380|DRUG|20-mg Desloratadine|20-mg desloratadine tablets, once daily for four weeks.
41100613|NCT02989012|DRUG|GanMaoKangNing Granules|3 times a day, 2 bags each time.
41100614|NCT02989012|DRUG|Analogous Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
41100615|NCT02989012|DRUG|Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
41100616|NCT02989012|DRUG|Analogous GanMaoKangNing Granules|3 times a day, 2 bags each time.
41100617|NCT02992275|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks
41100618|NCT02992275|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
41100619|NCT00440986|PROCEDURE|Eritrocytoapheresis|
41100620|NCT05391048|DRUG|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
41100621|NCT05391048|DRUG|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
41100622|NCT03685188|DRUG|Oxycodone Hydrochloride|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.
41100623|NCT03685188|DRUG|Sufentanil Citrate|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
41100624|NCT04163458|DRUG|MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL|Solution for injection in pre-filled pen, subcutaneous administration
41100625|NCT04163458|DRUG|MENOPUR powder and solvent for solution for injection, 75 IU|Solution for injection in vials (powder and diluent), subcutaneous administration
41100626|NCT04163458|OTHER|Placebo (for MENOPUR solution for injection in pre-filled pen)|Solution for injection in pre-filled pen, subcutaneous administration
41100627|NCT04163458|OTHER|Placebo (for MENOPUR powder and solvent for solution for injection)|Solution for injection in vials (powder and diluent); subcutaneous administration
41100628|NCT06466473|DRUG|Phenytoin (Ascoli)|Phenytoin 50mg chewable tablets
41100629|NCT06466473|DRUG|Phenytoin (Vega Baja)|Phenytoin 50mg chewable tablets
41100630|NCT01771887|BEHAVIORAL|education program|education program in 6 hours and monitoring phone every 15 days
41100631|NCT04898192|OTHER|questionnaire|questionnaire - the complex of 6 questionnaires aimed to recognize the fear of delivery, perinatal anxiety, depressive disorder, obsessive-compulsive disorder, general anxiety disorder, postpartal depression and domestic violence.
41100632|NCT00452465|BEHAVIORAL|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
41100633|NCT05215652|OTHER|adherence monitoring package (AMoPac)|"AMoPac is a tool that consists of~* an electronic monitoring device,~* data management and data analysis,~* feedback on patient's performance,~* clinical-pharmaceutical evaluation of medication adherence,~* transmission of an adherence report."
41100634|NCT01090024|DRUG|BI 671800|BI 671800
41100635|NCT01090024|DRUG|Placebo|Placebo matching BI 671800
41100636|NCT00290706|DRUG|bortezomib|Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
41100637|NCT00290706|DRUG|gemcitabine hydrochloride|Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
41100638|NCT00771667|DRUG|Placebo (IP)|Induction phase (Week 0-8) (IP) - Placebo IV group
41100639|NCT00771667|DRUG|Ustekinumab 1mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
41100640|NCT00771667|DRUG|Ustekinumab 3 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
41100641|NCT00771667|DRUG|Ustekinumab 6 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
41100642|NCT00771667|DRUG|Placebo IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
41100643|NCT00771667|DRUG|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
41100644|NCT00771667|DRUG|Ustekinumab IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
41100645|NCT00771667|DRUG|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
41100646|NCT00771667|DRUG|Ustekinumab IV - Nonresponder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
41100647|NCT00771667|DRUG|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
41100648|NCT02540642|DIETARY_SUPPLEMENT|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
41100649|NCT03350737|OTHER|Physical rehabilitation|Standard treadmill exercise session
41100650|NCT03350737|DRUG|Heparin|Heparin i.v.
41100651|NCT03350737|OTHER|Placebo|Sodium Chloride 0.9% i.v.
41100652|NCT03298464|BIOLOGICAL|NGM313|Subcutaneous injection
41100653|NCT03298464|DRUG|Pioglitazone|White to off-white round tablet
41100654|NCT04871607|BIOLOGICAL|Basiliximab|Given IV
41100655|NCT04871607|DRUG|Carmustine|Given IV
41100656|NCT04871607|DRUG|Cytarabine|Given IV
41100657|NCT04871607|DRUG|Etoposide|Given IV
41100658|NCT04871607|BIOLOGICAL|Genetically Engineered Hematopoietic Stem Progenitor Cells|Given via infusion
41100659|NCT04871607|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC or IV
41100660|NCT04871607|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
41100661|NCT01129778|DRUG|Zegerid (proton pump inhibitor)|
41100662|NCT01129778|PROCEDURE|Bravo pH monitoring|
41100663|NCT02376036|DRUG|MGD010|MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
41100664|NCT02376036|DRUG|Placebo|Placebo comparator.
41100665|NCT02376036|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine, inactivated
41100666|NCT02963220|BEHAVIORAL|CBT-AR|20-30 sessions of cognitive behavioral therapy for avoidant/restrictive food intake disorder (CBT-AR), held once per week in an outpatient setting
41100667|NCT00864682|DRUG|Saline|3.3 mL normal saline
41100668|NCT00864682|DRUG|Lidocaine / propofol admixture|lidocaine 50 mg plus propofol 50 mg intravenous (iv)
41100669|NCT00864682|DRUG|lidocaine pretreatment|lidocaine 50 mg iv under tourniquet-control
41100670|NCT04564313|DRUG|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
41100671|NCT03180190|DRUG|Hydroxychloroquine Oral Tablet|"slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)"
41100672|NCT06409195|DRUG|SM-020 1% Gel|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.
41100673|NCT00574886|BIOLOGICAL|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
41100674|NCT01278693|DRUG|L-carnitine|500 mg,twice daily, 16 weeks
41100675|NCT01278693|DRUG|placebo|500 mg,twice daily, 16 weeks.
41100676|NCT00114803|DRUG|Calcitonin nasal spray (salmon)|
41100677|NCT06632132|OTHER|Antimicrobial resistance Training in Hemodialysis Units|"The educational program developed by the researcher is meticulously designed, drawing on extensive insights from the WHO curricula guide (nurses' education and training on antimicrobial resistance; 2019) and the literature review addressed the use of antibiotics and prevention of AMR in hemodialysis facilities. The curriculum, using simple English, provides a broad set of learning objectives tailored to the expected roles of nurses.~The education program includes four main modular outline:~1. Foundations that build awareness of antimicrobial resistance~2. Appropriate use of antimicrobial agents~3. Infection prevention and control~4. Diagnostic stewardship and surveillance~The educational material was sent by a study researcher (X) to the WhatsApp number for all members of the experimental group via Chatbot software, which was designed by software engineer. The educational materials were sent in the form of written materials, photos, and videos."
41100678|NCT02833155|DRUG|Entinostat|Given PO
41100679|NCT02833155|DRUG|Exemestane|Given PO
41100680|NCT02210702|DRUG|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
41100681|NCT02210702|DRUG|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
41100682|NCT06629597|DRUG|YL201|YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.
41100683|NCT06629597|DRUG|Docetaxel|Docetaxel will be administered intravenously at 75 mg/m2 on Day 1 of each 3-week cycle.
41100684|NCT06629597|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 twice a day (BID) on Days 1 to 14 of each 3-week cycle
41100685|NCT06629597|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Day 1 and 8 of each 3-week cycle
41100686|NCT02017106|PROCEDURE|Endovenous Laser ablation and concomitant phlebectomies|
41100687|NCT02017106|PROCEDURE|Endovenous Laser ablation and sequential phlebectomies|
41100688|NCT04296032|BEHAVIORAL|virtual reality game traning|The controllers were attached to upper extremity to control the game. The game could train the shoulder, elbow, and wrist control.
41100689|NCT04296032|BEHAVIORAL|standard treatment|The program included bilateral hand, grasp/release, and pinch activities.
41100690|NCT02343744|DRUG|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
41100691|NCT03690856|OTHER|inflammatory, neuropsychological and neuroimaging assessment|"Acts add by research:~pregnancy test; Centralized: IL1, IL6, TNF~Neuropsychologic tests at M6 and M24:~Edinburgh Ladder Lateral Test, Direct and Inverse Verbal Empan, Matrices (WAIS IV), Similarities (WAIS IV), Vertebral fluences, STROOP test, TMT test (Delis Kaplan), WCST test, CPT III, WAIS IV (code)"
41100692|NCT02345200|PROCEDURE|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
41100693|NCT02345200|PROCEDURE|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
41100694|NCT01489176|DRUG|Regadenoson; Optison|A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
41100695|NCT05060562|OTHER|COVID 19 positive|Diagnosed as COVID 19 patient using Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab with suggestive symptoms.
41100696|NCT05060562|OTHER|COVID 19 negative|Suspected COVID 19 patients who were tested negative using either Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab.
41100697|NCT04735354|DRUG|sacubitril/valsartan|There was no treatment allocation. Patients administered sacubitril/valsartan by prescription that started before inclusion of the patient into the study were enrolled.
41100698|NCT03440190|DRUG|Methylphenidate|Patients are tested for their normal prescription methylphenidate medication
41100699|NCT03721016|DRUG|MT10109L|MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
41100700|NCT03721016|DRUG|Placebo|Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
41100701|NCT00413491|PROCEDURE|MR mammography|MR mammography
41100702|NCT00413491|PROCEDURE|MR|MR
41100703|NCT04659031|DRUG|ABC008|ABC008
41100704|NCT02647749|DEVICE|Cardioinsight® mapping system|
41100705|NCT02647749|OTHER|Conventional method without non-invasive mapping|
41100706|NCT00764413|DRUG|methylprednisolone|1 gram intravenous a day for 3 days
41100707|NCT00764413|DRUG|Sodium chlorid|Sodium chlorid 9mg/ml 500 ml per day in 3 days
41443312|NCT06533943|OTHER|Exercise program|Each intervention session is divided into three different parts according to the specific aim such as warm-up (about 15 minutes) at the beginning, main exercises (about 30 minutes), and stretching and relaxation (about 15 minutes) at the end.
41100708|NCT00679276|PROCEDURE|Prolift|surgical repair of vaginal prolapse
41100709|NCT03532191|OTHER|PrEP Optimization Intervention (PrEP-OI)|PrEP-Rx + PrEP Coordinator
41100710|NCT03719677|BEHAVIORAL|Habit development intervention|Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning
41100711|NCT06076434|OTHER|The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region|The injection site on the upper arm of each patient was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected into the tissue at a 90° angle with a 27 gauge needle. The heparin was injected in approximately 10 seconds without aspirating the syringe. After the injection, pressure was applied to the area with dry cotton for specified periods (10 second, 35 second and 60 second).
41100712|NCT00768066|BIOLOGICAL|Autologous human mesenchymal cells (hMSCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
41100713|NCT00768066|BIOLOGICAL|Autologous human bone marrow cells (hBMCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
41100714|NCT00768066|BIOLOGICAL|Placebo|Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
41100715|NCT06397612|OTHER|Low Dose|Patients will be intervened with stimulation continuously, at a frequency of 20 Hertz, a pulse width of 200 µs and for a total of 20 minutes. The intensity will be set at the maximum tolerated by the patient.
41443313|NCT03168763|BEHAVIORAL|Video|Participants shown Video 1A or 1B, then shown Video 2A or 2B.
41100716|NCT06630104|PROCEDURE|Biospecimen Collection|Undergo hair and saliva sample collection
41100717|NCT06630104|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41100718|NCT06630104|OTHER|Electronic Health Record Review|Ancillary studies
41100719|NCT06630104|PROCEDURE|Follow-Up|Undergo CFU
41100720|NCT06630104|OTHER|Genetic Counseling|Receive genetic counselor consultation
41100721|NCT06630104|OTHER|Genetic Testing|Undergo sequencing analysis
41100722|NCT03915262|BIOLOGICAL|Search for exocrine pancreatic insufficiency at week 0 and 12|"We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin.~We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease.~We will gather the total caloric and fat intake with a diet record."
41100723|NCT03098290|PROCEDURE|Catheter-based endovascular revascularization|(e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
41100724|NCT03098290|PROCEDURE|Bypass-Surgery|Venous or alloplastic or comparable Bypass
41100725|NCT03098290|PROCEDURE|Endarterectomy|Endarterectomy, Patchplasty
41100726|NCT06369090|DEVICE|Electrical impedance tomography (EIT)|Non-invasive, radiation-free bedside lung monitoring using small alternating currents with no known side effects.
41100727|NCT00728845|BIOLOGICAL|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
41100728|NCT00728845|DRUG|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
41100729|NCT00728845|DRUG|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
41100730|NCT00728845|DRUG|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
41100731|NCT03644537|PROCEDURE|Orthodontic intrusion|"27 female patients coming to the Orthodontic department, Cairo University seeking orthodontic treatment, where their age ranges from 15 - 18 years, where their treatment plan include extraction of upper first premolars, and using the split-mouth technique, one side will be control group without application of force where the other side will receive intrusive mechanics for the same patient in the upper arch (one side will not receive any force and the same tooth on the other side of the arch will suffer intrusive mechanics, that's why named SPLIT MOUTH TECHNIQUE - as if the arch is split into two subjects, one control subject (tooth) and the other study subject (tooth) . According to the amount of force of the working side, the total number of patients will be divided into 3 groups.~Each of 9 subjects, the first group where a light force will be applied (10 gm), the second group where moderate force will be applied (25gm), the third group where heavy force will be applied(100 gram)."
41100732|NCT06631625|DRUG|Lidocaine Intravenous Infusion|Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.
41100733|NCT06631625|DRUG|Lidocaine and ketamine|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.
41100734|NCT06631625|DRUG|lidocaine and dexmedetomidine infusion|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.5 μg/kg dexmedetomidine intravenously as a bolus dose, followed by intravenous infusion of 0.4 μg/kg/h using a 50cc syringe pump intra-operatively.
41100735|NCT00124956|DRUG|Doxorubicin|
41100736|NCT03620929|DRUG|Estradiol Valerate|In all cases hormone therapy will be started from the day of operation, consisting of estradiol valerate at a dose of 4mg/d for 21 days, with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy. After the withdrawal bleed, the hormone therapy will be repeated for another cycle. Second-look hysteroscopy will be carried out in the early proliferative phase, 4 weeks after the initial operation; a third-look hysteroscopy will be carried out 8 weeks after the initial operation. After assessment of the extent and severity of any reformed adhesion, hysteroscopic adhesiolysis will be carried out at the time of the second-look or third-look procedure, if adhesion had recurred.
41100737|NCT03653975|OTHER|no intervention|no intervention
41100738|NCT04242758|DRUG|Dapagliflozin 10 MG|SGLT2-inhibitor: Diabetic oral drug with diuretic properties
41100739|NCT04242758|DRUG|Hydrochlorothiazide 12.5mg|Best known thiazide class diuretic.
41100740|NCT03342651|OTHER|Vitamin D|Vitamin D, general anesthesia, respiratory complications
41100741|NCT01768143|BEHAVIORAL|unexperienced endoscopy nurses|
41100742|NCT01768143|BEHAVIORAL|Experienced endoscopy nurses|
41100743|NCT02359435|DRUG|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
41100744|NCT02359435|DRUG|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
41100745|NCT06628453|DEVICE|CGM|Real-time continuous glucose monitoring
41100746|NCT04866056|DRUG|Jaktinib|Jaktinib PO BID
41100747|NCT04866056|DRUG|azacitidine|Azacytidine SC
41100748|NCT01638624|DRUG|Propofol|Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
41100749|NCT01638624|DRUG|Placebo|
41100750|NCT05980468|OTHER|music therapy|Music intervention sessions will be applied to each participant for 5 weeks, 3 days a week, 20 minutes per session.
41100751|NCT06421948|DRUG|Linperlisib and chidamide|A combination of linperlisib and chidamide will be administered for 6 cycles in patients responded to treatment.
41443314|NCT03168763|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, after each video viewing, and at completion.
41100752|NCT06421948|DRUG|cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone|A combination of cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) will be administered for 6 cycles in patients responded to treatment.
41100753|NCT04467515|DRUG|CAM-H2|All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.
41100754|NCT03493178|DIETARY_SUPPLEMENT|Glycine|Dietary Supplement: glycine will be supplemented in the active arm for 12-weeks
41100755|NCT03493178|DIETARY_SUPPLEMENT|N-acetylcysteine (NAC)|Dietary Supplement: NAC will be supplemented in the active arm for 12-weeks
41100756|NCT03493178|DIETARY_SUPPLEMENT|Alanine|Dietary Supplement: Alanine will be supplemented in the placebo arm for 12-weeks
41100757|NCT03780790|DRUG|Bupivacaine|% 0,25
41100758|NCT00001999|DRUG|Globulin, Immune|
41100759|NCT00001999|DRUG|Ganciclovir|
41100760|NCT06275386|DEVICE|Paclitaxel Drug-coated balloon|Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.
41100761|NCT02082366|DEVICE|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
41100762|NCT00199641|DEVICE|enteral nutrition|
41100763|NCT04971018|DEVICE|Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
41100764|NCT04971018|DEVICE|Sham Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
41100765|NCT04899284|OTHER|Early Intensive Bimanual Stimulation|Early intensive bimanual stimulation program for infants showing early signs of UCP, delivered by the family environment, in the child's familiar surroundings, under the guidance of a therapist, over a period of 2 months.
41100766|NCT00913328|DRUG|Montelukast (Singulair)|10 mg tablet once daily
41100767|NCT00913328|DRUG|Placebo|Oral placebo once daily
41100768|NCT00639613|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
41100769|NCT00639613|OTHER|Standard meal test|"Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations."
41100770|NCT02520362|DRUG|denosumab|subcutaneous injection
41100771|NCT02520362|DRUG|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate \[Fosamax®\], risedronate \[Actonel®\], ibandronate \[Boniva®/Bonviva®\] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate \[Reclast®/Aclasta®\].
41100772|NCT05037266|BIOLOGICAL|COVID-19 Vaccine Janssen (Ad26.COV2-S)|one dose (0.5mL) at D1 and one dose (0.5mL) at D57
41100773|NCT01964859|BIOLOGICAL|autologous skin fibroblasts|
41100774|NCT04303182|PROCEDURE|Standard 3 port TEP|3 port TEP inguinal hernia repair with 10mm. port under the umbilicus and two 5mm. port in line under the 10mm. port
41100775|NCT04303182|PROCEDURE|LESS TEP|TEP inguinal hernia repair with one vertical skin incision under the umbilicus
41100776|NCT03097237|OTHER|Wholegrain rye|Cereal products based on wholegrain rye
41100777|NCT03097237|OTHER|Refined wheat|Cereal products based on refined wheat
41100778|NCT01565161|BEHAVIORAL|Home-Based Health Coaching|"The 6-month intervention arm consists of 3 components:~1. In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.~2. Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.~3. Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months."
41100779|NCT01565161|BEHAVIORAL|Mailed materials|"We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.~Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's Positive Parenting Tips for Healthy Child Development, and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials."
41100780|NCT04138433|DEVICE|Real tDCS|Anodal tDCS 2 ma
41100781|NCT04138433|DEVICE|Sham tDCS|Sham tDCS 2 ma
41100782|NCT03072355|OTHER|Elastic Band|Localized muscle resistance test for shoulder
41100783|NCT03072355|OTHER|Isokinetic dynamometer|Localized muscle resistance test for shoulder
41100784|NCT03812159|DEVICE|iCSPlan|"The Investigator will acquire a routine pre-operative CT-scan to help assess the synostosis severity. A week before the surgery a routine preoperative visit will be done. If the potential subject agrees to participate in the study, a presurgical plan will be built, and based on the CT scan, it will (1) quantify shape differences between pathological and healthy cranial shapes; (2) compensates for brain and cranial growth during the months between diagnosis, treatment and recovery; and (3) guides bone-cuts and bone-placement for the simplest and optimal surgical procedure.~Finally this plan will be recorded in a software, iCSPlan, which will be reviewed by the surgeon. If it is accepted, it will be available during the surgery as a rely-on tool which may or may not be followed."
41100785|NCT02836665|PROCEDURE|Telemedicine for dermatological emergency patients|"Study-related photographs of the skin lesion made by a tablet and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal without being on site."
41100786|NCT00151996|DRUG|Methylphenidate + SPD503 (Guanfacine hydrochloride)|
41100787|NCT00151996|DRUG|Amphetamine + SPD503|
41100788|NCT06631456|OTHER|PRP injection|A total of 3 doses of intra-articular PRP were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
41100789|NCT06631456|OTHER|Ozone therapy|A total of 3 doses of intra-articular ozone therapy were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
41100790|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|50 µmol capsules, taken orally, once a day for 28 days
41100791|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|100 µmol capsules, taken orally, once a day for 28 days
41100792|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|200 µmol capsules, taken orally, once a day for 28 days
41100793|NCT03182036|DEVICE|Portable pulsed oxygen|Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
41100794|NCT05716542|OTHER|Physical Activity Intervention|Fitbit wearable device, home exercise sessions, and telehealth appointments with physical therapist.
41100795|NCT02694848|DRUG|Salvianolate injection|Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
41100796|NCT02694848|DRUG|Aspirin|Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
41100797|NCT06445738|RADIATION|Arm A: Radiotherapy Omission|Omission of radiotherapy based on pre-surgical MRI and pathology findings at surgery.
41100798|NCT06445738|OTHER|Arm B: Standard Treatment|Ineligible for RT omission on study; includes management of MRI-detected lesions.
41100799|NCT01345292|DEVICE|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
41100800|NCT01345292|DRUG|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
41100801|NCT01345292|DRUG|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
41100802|NCT03152149|DRUG|Tiotropium & olodaterol|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
41100803|NCT03152149|DRUG|fluticasone furoate & vilanterol|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
41100804|NCT01536730|BEHAVIORAL|Homework Intervention Strategy|"Participants assigned to intervention will receive a condom ditty bag containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention."
41100805|NCT01286402|DRUG|Bupropion SR|"* 150mg, taken orally, taken daily for the 1st 3 days~* 300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment"
41100806|NCT01286402|OTHER|Placebo|-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment
41100807|NCT04806113|BIOLOGICAL|Moderna COVID-19 vaccine|Two doses from the Moderna vaccine will be administered intramuscularly. The time between dose 1 and dose 2 of the vaccine will be 28 days.
41100808|NCT03635567|BIOLOGICAL|Pembrolizumab|IV infusion
41100809|NCT03635567|DRUG|Paclitaxel|IV infusion
41100810|NCT03635567|DRUG|Cisplatin|IV infusion
41100811|NCT03635567|DRUG|Carboplatin|IV infusion
41100812|NCT03635567|BIOLOGICAL|Bevacizumab|IV infusion
41100813|NCT03635567|DRUG|Placebo to pembrolizumab|IV infusion
41100814|NCT00116740|DRUG|APD356|
41100815|NCT01134419|OTHER|Computerized handoff tool|Informatics tool to aid in transfer of patient care information
41100816|NCT01134419|OTHER|Team training|Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
41100817|NCT04392635|DEVICE|TauTona Pneumoperitoneum Assist Device (TPAD)|The TPAD is an experimental device used to assist with placement of Veress needle during laparoscopic surgery.
41100818|NCT04392635|PROCEDURE|Standard of Care (SOC)|Standard of Care was used for Veress needle insertion.
41100819|NCT00817635|DRUG|LCI699|LCI699 oral capsules
41100820|NCT00817635|DRUG|Eplerenone|Eplerenone oral capsules
41100821|NCT00817635|DRUG|LCI699-matching Placebo|LCI699-matching placebo oral capsules
41100822|NCT00817635|DRUG|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
41100823|NCT05579080|DEVICE|noninvasive ventilation|The medical records whose patients used some type of non-invasive ventilatory device and devices that promote oxygen supplementation will be analyzed.
41100824|NCT06188962|BEHAVIORAL|CBT-informed school-based counselling|Knowledge Insight Tools (KIT) is a CBT-based model of one-to-one therapy for secondary school pupils who are struggling with low mood and/or anxiety. KIT incorporates the key features of CBT (e.g., agenda setting, formulation around maintenance cycles, inter-session work involving exposure and/or behavioural activation) but is delivered in a semi-structured way that meets the young person's needs and pace of learning. Whilst there is an emphasis on symptom reduction, the primary focus is on the young person's goals for living and co-producing an understanding of how symptoms can interfere with these goals. Practitioners are encouraged to incorporate different therapeutic tools and modalities that complement the young person's strengths and ways of learning, including non-verbal forms of expression like arts and crafts, music, and dance. By being flexible, person-led, goal-focused, and integrative, KIT was designed to suit the needs of secondary school students.
41100825|NCT05207982|BEHAVIORAL|Family Based weight management program|"Weight management program that involve the patient AND a family member or a care taker. Families will receive a 12-week FBT adapted for first episode psychosis. This will be delivered in 12 weekly meetings with a trained case manager and two eating plan education sessions. Both the patient with psychosis and parents are targeted for eating and activity/exercise change to ensure a change in the shared family environment, which will also help weight control in both sets of participants, as well as medical issues that accompany obesity, including glycemic control, hypertension and hyperlipidemia. If parents are not overweight/obese, they will still target improved health behaviors. They will learn about GREEN, YELLOW, and RED foods (healthy vs. unhealthy foods), energy density, glycemic index of foods, reducing serving sizes, eating less, healthy lifestyle and programmed activity programs and recording their diets and activity."
41100826|NCT01300858|DRUG|EGEN-001-301|Patients will be treated with EGEN-001 intra-peritoneally (IP) once every week for 12 weeks and then once every two weeks until disease progression or intolerable toxicity, but for no more than one year. Patients who develop progressive metastases will receive standard chemotherapy concomitant with EGEN-001. Hence, the initial EGEN-001 treatment period will be without chemotherapy. The standard chemotherapy regimen will be FOLFOX or FOLFIRI administered every 2-3 weeks. Patient with progressive disease a second time will be taken off-study. Those who remain progression-free will receive EGEN-001 for up to one year.
41100827|NCT02050958|DRUG|OXP001|
41100828|NCT02050958|DRUG|Ibuprofen|
41100829|NCT05926050|DIETARY_SUPPLEMENT|Treatment (CopaPrime+ (USANA Health Sciences)|Participants received and consumed 2 treatment tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained extracts of Bacopa monnieri (150 mg), Coffea arabica (50 mg), and Panax quinquefolius L. (50 mg)
41100830|NCT05926050|OTHER|Placebo|Participants received and consumed 2 placebo tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained microcrystalline cellulose. The size, shape and appearance of the placebo tablet was identical to the treatment tablet.
40925013|NCT02962843|BEHAVIORAL|IY TCM|The Incredible Years Teacher Classroom Management program is a manualized program for teachers and staff in school and day-care settings to strengthen teacher classroom management strategies, to reduce negative behavior and promote prosocial behavior, as well as school readiness in children. Two qualified IY TCM group-leaders (facilitators) train teachers and staff in groups through six full-day workshops (a total of 42 hours).Workshop 1: Building Positive Relationships with Students, Workshop 1b: Preventing Behavior Problems -The Proactive Teacher, Workshop 2: The Importance of Teacher Attention, Coaching and Praise, Workshop 3: Motivating Children Through Incentives, Workshop 4 \& 5: Decreasing Inappropriate Behavior and Workshop 6: Emotional Regulation, Social Skills \& Problem Solving.
40925014|NCT04457388|OTHER|Tele-Yoga Therapy|Yoga practices combining with joint loosening exercises (Sukshma Vyayama), postures (Asana), breathing exercises (Pranayama), relaxation techniques and chanting ( A, U, M, and AUM { ૐ}) syllable chants meditation. Each session ended with home practice exercises given to the participants to practice everyday.
40925015|NCT00316108|DEVICE|WALLSTENT® Endoprosthesis™|Carotid Artery Stent
40925016|NCT06273371|OTHER|Damira 2000 Infant formula|100% extensive casein hydrolysate Infant formula
40925017|NCT00030004|PROCEDURE|spinal manipulation|
40925018|NCT00030004|DRUG|midazolam|
40925019|NCT06000267|PROCEDURE|Intubation|All the patients will be ventilated with face mask and intubated before elective surgery
40925020|NCT06131762|OTHER|Active release technique|This include active release technique for 4 weeks
40925021|NCT06131762|OTHER|Positional release technique|This include positional release technique for 4 weeks
40925022|NCT01801371|DRUG|68Ga-BNOTA-PRGD2|Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
40925023|NCT01264601|BIOLOGICAL|Trivalent Influenza Vaccine|Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
41100831|NCT00742573|DRUG|Antidepressants through Texas Medication Algorithm (TMA)|Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
41100832|NCT00742573|BEHAVIORAL|Brief Interpersonal Psychotherapy (IPT-B)|IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
41100833|NCT01898676|DRUG|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
41100834|NCT01898676|DRUG|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
41100835|NCT00586339|BIOLOGICAL|Cervarix|Intramuscular injection, 3 doses
41100836|NCT00586339|BIOLOGICAL|Placebo Control|Intramuscular injection, 3 doses
41100837|NCT02772315|OTHER|omics|diagnostic procedures applying omics results
41100838|NCT00270426|DRUG|Benazepril|
41100839|NCT04654936|BEHAVIORAL|MIND diet|12 week MIND diet study: Participants access a website that is theory driven using the Behaviour Change Wheel to help motivate and promote MIND diet adherence. Participants are to consume MIND diet foods daily and meet MIND diet weekly recommendations
41100840|NCT04654936|BEHAVIORAL|MIND diet with no support|Participants are to consume MIND diet food recommendations over a 12 week period with no support except for a self-monitoring resource and MIND diet guidelines
41100841|NCT06204796|DRUG|vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case. In addition, a vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
41100842|NCT06204796|DRUG|Systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case.
41100843|NCT00019318|DRUG|romidepsin|
41100844|NCT02405390|PROCEDURE|Video Laryngoscopy|Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
40925024|NCT00998218|DRUG|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
40925025|NCT00998218|DRUG|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
40925026|NCT03029884|DEVICE|Open-Loop DBS|Conventional brain stimulation that is tonically providing stimulation, without feedback
40925027|NCT03029884|DEVICE|Sham Stimulation|No Active Stimulation
40925028|NCT03029884|DEVICE|Closed-Loop DBS|Feedback enabled brain stimulation, where stimulation is provided on demand in response to pain biomarkers.
40925029|NCT03498053|BEHAVIORAL|Marlboro|Participants smoke Marlboro during the first experimental day, ad libitum.
40925030|NCT03498053|BEHAVIORAL|Marlboro Prime|Participants smoke Marlboro Prime during the second experimental day, ad libitum.
40925031|NCT03498053|BEHAVIORAL|Marlboro Prime (ventilation holes taped)|Participants smoke Marlboro Prime (filter ventilation holes taped) during the third experimental day, ad libitum.
40925032|NCT01414920|DRUG|Placebo|TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
40925033|NCT01414920|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
40925034|NCT01414920|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
40925035|NCT01414920|DRUG|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
40925036|NCT01414920|DRUG|TAK-875 and Sitagliptin|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
40925037|NCT01414920|DRUG|TAK-875 and Sitagliptin|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
40925038|NCT01935310|DRUG|Imiquimod|"From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.~During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved."
41100845|NCT02405390|PROCEDURE|Direct Laryngoscopy|Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
41100846|NCT02405390|DEVICE|Storz C-Mac® laryngoscope|
41100847|NCT04455048|OTHER|Cervicothoracic thrust manipulation|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. Thrust manipulation will be applied at the end of exhale.
41100848|NCT04455048|OTHER|Cervicothoracic thrust manipulation sham|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. A soft compression will be applied at the end of exhale without a thrust.
41100849|NCT04031417|OTHER|Hypoxia|
41100850|NCT04031417|OTHER|Low Humidity|
41100851|NCT05310929|DRUG|Labetalol and Glyceril trinitrate|for control of blood pressure
41100852|NCT00385658|DRUG|Fluvastatin extended release, fenofibrate|
41100853|NCT00385658|DRUG|Fixed combination simvastatin/ezetimibe|
41100854|NCT02153606|DRUG|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
41100855|NCT02153606|OTHER|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
41100856|NCT03398811|DRUG|Depot medroxy-progesterone acetate|Injection every 3 months
41100857|NCT03398811|DRUG|Etonogestrel|68 mg implant
41100858|NCT03398811|DRUG|Desogestrel 75 µg|one pill every day for 28 days without pill-free interval.
41100859|NCT01473719|BEHAVIORAL|motivational intervention|7-session individual motivationally-based intervention
41100860|NCT01473719|BEHAVIORAL|health education|7 individual sessions focusing on health education
41100861|NCT02735486|DIETARY_SUPPLEMENT|Ginger drink|300 ml ginger drink
41100862|NCT02735486|DIETARY_SUPPLEMENT|Placebo: Super pure water|Placebo: Super pure water
41100863|NCT01484106|OTHER|Fluid Resuscitation|"In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR)."
41100864|NCT01484106|OTHER|Standard of Care|Standard of Care
41100865|NCT05426291|OTHER|BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?|In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.
41100866|NCT02989662|DRUG|Mifepristone|Participants receive 6 doses.
41100867|NCT02989662|DRUG|Placebo - Cap|Participants receive 6 doses
41100868|NCT04962334|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
41100869|NCT04962334|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (powder added to water) without added vitamins and minerals
41100870|NCT02325050|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
41100871|NCT02325050|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
41100872|NCT02325050|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
41100873|NCT02325050|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 1\*10\^11 viral particles (vp).
41100874|NCT02325050|OTHER|Placebo|One 0.5 mL IM injection of 0.9% saline.
41100875|NCT01605331|DRUG|sustained-release recombinant human GH (SR-rhGH)|
41100876|NCT04343807|PROCEDURE|PECS Block|PECS nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.
41100877|NCT04343807|OTHER|Control Group|No nerve block will be performed and only intravenous nalbuphine will be given.
41100879|NCT03452306|DRUG|Metformine|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition"
41100880|NCT03452306|DRUG|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition"
41100881|NCT03452306|DRUG|Metformin|"Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
41100882|NCT03452306|DRUG|Glucophage® Long|"Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
41100883|NCT04672473|BIOLOGICAL|DC-CTL|DAC combined with Ag-CTL
41100884|NCT04622826|BIOLOGICAL|immune plasma|immune covid 19 plasma infusion
41100885|NCT05737784|DRUG|PRAX-222 - Initial Dose|PRAX-222
41100886|NCT05737784|DRUG|PRAX-222 - Initial Ascending Doses|Ascending doses of PRAX-222
41100887|NCT05737784|DRUG|PRAX-222 - Optional Ascending Doses|Escalation of PRAX-222 dose(s)
41100888|NCT05737784|DRUG|PRAX-222 - Fixed Doses|Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
41100889|NCT05737784|PROCEDURE|Placebo|Placebo procedure
41100890|NCT00000676|DRUG|Clotrimazole|
41100891|NCT00000676|DRUG|Fluconazole|
41100892|NCT04472767|DRUG|Nivolumab|Given IV
41100893|NCT04472767|DRUG|Ipilimumab|Given IV
41100894|NCT04472767|DRUG|Cabozantinib|Given PO
41100895|NCT04472767|PROCEDURE|Transarterial Chemoembolization|TACE treatment will be administered using either the DEB-TACE or cTACE modality in a series of up to 3 individual procedures within the 9-12 weeks following Day 21 (= cycle 1 day 21) of a patient's first infusion of nivolumab/ipilimumab. The first TACE treatment should start no more than 7 working days after being cycle 1 day 21.
41100896|NCT04101123|OTHER|Non-Interventional|Non-Interventional
41100897|NCT02380729|GENETIC|Gene Panel Sequencing|Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
41100898|NCT02380729|GENETIC|Whole Genome Sequencing (WGS)|Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
41100899|NCT02578212|OTHER|Placebo|
41100900|NCT06285175|OTHER|Tele-REINVENT|Tele-REINVENT consists of EMG-biofeedback of the affected arm to control games on a computer screen.
41100901|NCT01760291|DEVICE|WATCHMAN LAA Closure Technology|
41100902|NCT00953485|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10\^6 cells/kg body weight).
41100903|NCT00668174|BEHAVIORAL|Exercise|Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
41100904|NCT00002896|DRUG|chemotherapy|
41100905|NCT00002896|DRUG|fluorouracil|
41100906|NCT00002896|DRUG|leucovorin calcium|
41100907|NCT00002896|PROCEDURE|conventional surgery|
41100908|NCT00002896|RADIATION|low-LET cobalt-60 gamma ray therapy|
41100909|NCT00002896|RADIATION|low-LET photon therapy|
41100910|NCT01444287|DEVICE|narafilcon B|test product
41100911|NCT01444287|DEVICE|Polymacon|marketed product
41100912|NCT01444287|DEVICE|Lotrafilcon A|marketed product
41443315|NCT05978986|DIAGNOSTIC_TEST|Determining of the clinical class of chronic venous disorders by artificial intelligence|The doctor takes pictures of the lower extremities and uploads them to the IVENUS application, which automatically determines the clinical class according to CEAP. Further, the doctor independently determines the clinical class according to CEAP and enters the data into the register.
41443316|NCT06525389|DRUG|Liposomal Amphotericin B (LAmB)|Antifungal dosed at 10 mg/kg/day IV x one single dose.
41443317|NCT06525389|DRUG|Flucytosine (5FC)|Antifungal dosed at 25mg/kg oral 3x daily.
41443318|NCT06525389|DRUG|Flucytosine (5FC) placebo pill|Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.
41443319|NCT06525389|DRUG|Deoxycholate Amphotericin B (DAmB)|Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.
41443320|NCT06462547|DRUG|INZ-701|INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
41443321|NCT01464450|DRUG|Rivaroxaban|Single 20 mg-dose
41100913|NCT01444287|OTHER|Spectacles|None - subject used own spectacles
41100914|NCT00508963|DRUG|sodium stibogluconate (Pentostam)|20 mg/kg IV every day for 20 or 28 days
41100915|NCT03557385|DRUG|Iopamidol|"aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~* Rate of 4 mL/sec, volume of 10 cc (left coronary system)~* Rate of 3 mL/sec, volume of 6 cc (right coronary system)."
41100916|NCT03557385|DRUG|adenosine|FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
41100917|NCT03557385|DEVICE|Navvus® Catheter|the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing
41100918|NCT03557385|DEVICE|CVi® Contrast Delivery System|The CVi® Contrast Delivery System will be used to deliver the contrast medium
41100919|NCT02606292|PROCEDURE|Photoacoustic endoscopy|
41100920|NCT02606292|PROCEDURE|Endoscopic ultrasound (standard of care)|
41100921|NCT02606292|PROCEDURE|Endoscopic surgery (standard of care)|
41100922|NCT06145763|PROCEDURE|Biospecimen Collection|Ancillary studies
41100923|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use iCanQuit smartphone app
41100924|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use NCI QuitGuide smartphone app
41100925|NCT06145763|OTHER|Survey Administration|Ancillary studies
41100926|NCT05891977|OTHER|Intervention A - Tomato paste|Participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
41100927|NCT05891977|OTHER|Intervention B - Control|Participants will consume the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
41100928|NCT06179095|OTHER|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI just before the intrauterine device insertion procedure, and again with STAI after the procedure.
41100929|NCT04601311|BEHAVIORAL|Guided self-determination|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'....~The goal is registered.~Patients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2.~A relative may take part in one session completing an analogue reflection sheet as preparation.~Participants continue usual care."
41100930|NCT04601311|BEHAVIORAL|Personal support in goal-pursuing|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'....~The goal is registered.~Patients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session.~Participants continue usual care."
41443322|NCT04328935|BEHAVIORAL|WET|The manual is based on established CBT interventions in trauma such as exposure. In short, the treatment is that the participant should be able to approach their intrusive memories and by doing this repeatedly, the memory will give rise to less discomfort.
41443323|NCT01101022|DRUG|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
41443324|NCT01101022|OTHER|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
41443325|NCT05400694|OTHER|Food|Dairy products with reduced sugar content
41443326|NCT06626776|PROCEDURE|lateral sinus lift with using allograft and collagen membrane|sinus floor elevation with placing allograft and collagen membrane
41443327|NCT06626776|PROCEDURE|lateral sinus lift with using exteneded platelet rich fibrin|sinus floor elevation with placing eprf
41443328|NCT05362344|PROCEDURE|Stool tests|Non-invasive, stool-based tests for colorectal cancer screening.
41443329|NCT06253403|BEHAVIORAL|psychotherapy|psychotherapy related to sexual intervention
41443330|NCT06440343|DIETARY_SUPPLEMENT|Carbohydrates|60g of maltodextrin + fructose, 2:1 ratio
41443331|NCT06440343|DIETARY_SUPPLEMENT|Placebo|Placebo
41443332|NCT03825328|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.
41100931|NCT03877796|DEVICE|Drug Response Predictor® (DRP)|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
41100932|NCT00640666|BEHAVIORAL|Exercise Behavior Change|Multidisciplinary
41100933|NCT05390476|DRUG|Capecitabine|500mg orally three times a day (continuously)
41100934|NCT05390476|DRUG|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
41100935|NCT02195557|DRUG|Synvisc®|
41100936|NCT05095428|BEHAVIORAL|PARTS Program|The PARTS Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
41100937|NCT05095428|BEHAVIORAL|NBSR-T Program|The NBSR-T Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
41100938|NCT00886808|DRUG|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
41100939|NCT02701361|BEHAVIORAL|mobile mindfulness|Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
41100940|NCT02701361|BEHAVIORAL|standard mindfulness|Receives weekly calls from mindfulness expert for 4 weeks.
41100941|NCT02701361|BEHAVIORAL|education|Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
41100942|NCT03697213|OTHER|Online study|20 hypothetical patient summaries
41100943|NCT00964314|OTHER|music|"Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done."
41100944|NCT00857480|DRUG|NRL972|Single intravenous administration of 2 mg NRL972
41100945|NCT00857480|DRUG|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
41100946|NCT00857480|DRUG|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
41100947|NCT06554171|OTHER|Hippotherapy group|In addition to conventional physiotherapy, training will be given in the Hippotherapy Simulator for 15 minutes a day, 5 days a week for 4 weeks. The hippotherapy simulator serves a wide range of purposes from recreational use that mimics the movements of a real horse or can make similar movements, to fitness, exercise, sports, education and therapy and is suitable for use by individuals with cerebral palsy.
41100948|NCT06554171|OTHER|Control group|In addition to conventional physiotherapy, the control group will be allowed to sit in the Hippotherapy Simulature for 15 minutes a day, 5 days a week for 4 weeks. However, the simulator will be kept in closed position to prevent oscillations.
41100949|NCT04213560|DEVICE|weighted waist-hooping|weighted waist-hooping
41100950|NCT03827187|OTHER|Motor imagery based EEG-BCI|Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
41100951|NCT06631742|OTHER|Exergaming on Dividat Senso|"The active dance video game is played with the Dividat Senso (Dividat \| Senso: cognitive-motor training). It consists of a dance disc with four arrows (up, down, left, right), and the game is played on a large screen (which is connected to the PC). The screen indicates which arrow the person should step on, thus controlling the game through body movements. The games give the person feedback in the form of auditory, visual, and somatosensory stimuli."
41100952|NCT06631742|OTHER|Usual Care|Standardised care with meal service, individual activities (e.g. hiking group, walking group, exercise group, handicrafts, gardening group, singing, painting or lunch) and customized care and support as required.
41100953|NCT01842971|PROCEDURE|two stage hepatectomy|
41100954|NCT04667988|DIAGNOSTIC_TEST|JAK expression|JAK2 assessment in blood by PCR
41100955|NCT02467491|DEVICE|Jintronix|The participants will perform light exercises using the Jintronix software. Jintronix is an easy-to-use virtual physical activity platform designed for physical and occupational therapy. It combines common exercise movements, virtual games and motion sensing cameras to offer a fun and effective tool for physical activity.
41100956|NCT00904527|BEHAVIORAL|relaxation (Schultz)|Patients have relaxation consultations during 2 months
41100957|NCT02279342|DRUG|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
41100958|NCT03960983|DEVICE|Treatment with tongue scraper|Treatment with tongue scraper. the evaluation of halitosis will be repeated before this step.
41100959|NCT03960983|PROCEDURE|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
41100960|NCT03960983|RADIATION|Photodynamic Therapy|Treatment with Photodynamic therapy. The evaluation of halitosis will be repeated before this step
41443333|NCT03825328|DRUG|S-1|a combination preparation of tegafur, gimeracil, and oteracil potassium
41100961|NCT03960983|PROCEDURE|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
41100962|NCT00281762|DRUG|NSAID|
41100964|NCT06364033|BIOLOGICAL|serologic response evaluation|Blood samples collection
41100965|NCT04480814|DIAGNOSTIC_TEST|PIK3CA kit|Prospective investigation of clinical samples for evaluation of IVD clinical performance
41100966|NCT03586167|DEVICE|LID014341 contact lenses|Investigational monthly replacement silicone hydrogel contact lenses with water gradient coating
41100967|NCT03586167|DEVICE|Comfilcon A contact lenses|Silicone hydrogel contact lenses
41100968|NCT04977128|DRUG|89Zr-KN035|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
41100969|NCT00387491|DRUG|MOA-728|
41100970|NCT06165549|OTHER|Light therapy|The light therapy will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at 5000 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
41100971|NCT06165549|OTHER|Light placebo therapy|The light placebo intervention will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at less than 200 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
41100972|NCT06165549|OTHER|Emotion Bias Modification Training|The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, selecting a fixed word of the word-pair will be associated with a high probability (eighty percent) of getting a monetary reward and a low probability (twenty percent) of no reward, and probabilities will be reversed for the other word. Each training run will comprise 100 gaming picture trials and 100 healthy-activity picture trials, presented in a pseudo-randomized order. Participants will receive two training runs every day. The whole training includes 14 days.
41100973|NCT01762371|OTHER|Khalifa Therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin.
41100974|NCT00554801|PROCEDURE|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
41100975|NCT06221618|OTHER|High-frequency carotid arteries ultrasound, CCTA, Cranial MRA|CCTA and carotid high-frequency ultrasound for all patients in the coronary heart disease cohort. Cranial MRA and carotid high-frequency ultrasound for all people in the stroke cohort.Carotid high-frequency ultrasound for all patients in the normal control group.All patients were treated optimally according to guidelines
41100976|NCT04758897|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
41100977|NCT04820101|DRUG|Dexmedetomidine|administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure
41100978|NCT04923984|PROCEDURE|Embolization of the middle meningeal artery|embolization of the middle meningeal artery with an embolic agent.
41100979|NCT04043767|PROCEDURE|Measurements of thyromental distances, hyomental distances and neck circumferences|thyromental distances, hyomental distances and neck circumferences using measurement tape by two independent investigators.
41100980|NCT05899335|DEVICE|SmartCP (mobile phone app)|As described
41100981|NCT03545984|OTHER|Simulation-based learning|Simulation-based teaching involves using done on a mannequin to simulate actual conditions
41100982|NCT03545984|OTHER|interactive problem based learning|Standard teaching (problem based learning discussion) during cardiac/vascular rotation
41100983|NCT03244176|DRUG|Avelumab|"All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles."
41443334|NCT03825328|DRUG|Oxaliplatin|The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
41443335|NCT03825328|DRUG|Gemcitabine|Gemcitabine is a synthetic pyrimidine nucleoside prodrug-a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
41100984|NCT02908620|COMBINATION_PRODUCT|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
41443336|NCT05244863|OTHER|Test|Measurements
41443337|NCT02305225|BEHAVIORAL|Sleep Deprivation|
41443338|NCT04633564|BIOLOGICAL|Bevacizumab as MYL-1402O|Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
41443339|NCT04633564|BIOLOGICAL|Bevacizumab as Avastin|Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
41443340|NCT04285814|DIAGNOSTIC_TEST|Whole Fetal Cell (WFC) Testing|Performing WFC testing on blood specimens.
41443341|NCT03155503|DRUG|SUVN-911|Oral Tablet
41443342|NCT03155503|DRUG|Placebo|Oral Tablet
41443343|NCT01666262|BIOLOGICAL|Vaccine A/17/CA/2009/38 (H1N1)|Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
41443344|NCT01666262|OTHER|Placebo:Stabilizer|5% sucrose
41100985|NCT02908620|DRUG|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
41100986|NCT02908620|COMBINATION_PRODUCT|Two sprays CTY-5339-A|Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.
41100987|NCT02908620|DRUG|One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)|A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
41100988|NCT01559480|DRUG|Desogestrel|Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
41100989|NCT01559480|DRUG|Placebo|Placebo capsule takes 1 capsule before bedtime for 6 months
40925039|NCT02043340|DRUG|indocyanine green|ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
40925040|NCT02043340|DEVICE|LASER|LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
40925041|NCT02043340|PROCEDURE|Scaling and Root Planing|SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
40925042|NCT02683746|DRUG|Lyophilized albiglutide DCC pen injector|A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
40925043|NCT02683746|DRUG|Lyophilized albiglutide DCC pen injector matching placebo|A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
40925044|NCT02683746|DRUG|Albiglutide liquid auto-injector|A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
40925045|NCT02683746|DRUG|Albiglutide liquid auto-injector matching placebo|A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
40925046|NCT06257602|PROCEDURE|Tragal graft tympanoplasty|Comparison study between Endoscopic and microscopic tympanoplasty using tragal graft
40925047|NCT05443139|BEHAVIORAL|Well-being online|Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).
40925048|NCT02775240|DRUG|Digoxin|0.5 mg (2 x 0.25 mg) Digoxin oral dose
40925049|NCT02775240|DRUG|Maribavir|200mg twice a day for 8 days
40925050|NCT02775240|DRUG|Dextromethorphan|30 mg oral dose
40925051|NCT02793648|DRUG|Ascorbic Acid|Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
40925052|NCT02793648|DRUG|Alpha tocopherol|Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
40925053|NCT02793648|DRUG|PLACEBO|Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
40925054|NCT03626298|DRUG|Adapalene|third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
40925055|NCT03626298|DRUG|Nicotinamide, ABA and Zinc PCA|combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
40925056|NCT03626298|DRUG|Placebos|Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
40925057|NCT03325751|DIAGNOSTIC_TEST|Visual field testing|Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.
40925058|NCT00633542|DRUG|thalidomide|100 mg/day orally until progression or severe toxicity
40925059|NCT00633542|DRUG|interferon alpha|3 MU 3 times a week until progression or severe toxicity
40925060|NCT01579812|DRUG|Metformin|"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."
41100990|NCT00247156|PROCEDURE|Acupressure treatments and NAET treatments|
40925061|NCT02490020|BIOLOGICAL|mesenchymal stem cell|
41100991|NCT00864812|DRUG|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
41100992|NCT00864812|DRUG|tiotropium|COPD patients treated with tiotropium
41100993|NCT01459549|PROCEDURE|Roux-en-Y choledochojejunostomy|Roux-en-Y choledochojejunostomy must be operated
41100994|NCT03917329|OTHER|ACT and PBS group workshop|Acceptance and Commitment Therapy and Positive Behaviour Support Group Workshop. Three sessions of approximately three hour duration. Groups will consist of 5-10 parents or 5-10 members of education staff. The group will include both didactic and experiential elements.
41100995|NCT01544062|DRUG|IV acetaminophen|Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
41100996|NCT01544062|DRUG|Placebo|Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
41100997|NCT04567615|BIOLOGICAL|Nivolumab|Specified dose on specified days
41100998|NCT04567615|BIOLOGICAL|Relatlimab|Specified dose on specified days
41100999|NCT03668327|OTHER||
41101000|NCT01506362|DRUG|BL-7040|"BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.~Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.~BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days."
41101001|NCT02712866|DRUG|Vedolizumab|Administration of intravenous Vedolizumab in inflammatory bowel disease patients
41101002|NCT02169102|OTHER|No additional Intervention (control)|No additional intervention previously to the urgency endodontic treatment (Control)
41101003|NCT02169102|RADIATION|Sham Laser Irradiation|Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.
41101004|NCT02169102|RADIATION|Laser 1 (at 0,16 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
41101005|NCT02169102|RADIATION|Laser 2 (1,6 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
41101006|NCT03392558|OTHER|Burt's Bees Skin Care Regimen|Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)
41101007|NCT03392558|OTHER|Control Regimen|Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)
41101008|NCT01761396|BEHAVIORAL|CBT|
41101009|NCT01761396|BEHAVIORAL|UC|
41101010|NCT05230680|DRUG|ACHOP|"1. Phase I Azacitidine D-2\~D1, starting from dose level 1. Based on the BOIN design described above, if no DLT is identified in level 1, the dose will be escalated stepwise to levels 2, 3, and then 4.~   Azacitidine combined with CHOP regimen every 3 weeks as below:~  * Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~  * Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~  * Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~  * Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~   Azacitidine at each level will be combined with the corresponding CHOP regimen as follows:~  * Cyclophosphamide 750mg/m2 d1~  * Doxorubicin 50 mg/m2 d1~  * Vincristine 1.4 mg/m2 (Max: 2 mg) d1~  * Prednisolone 100mg PO d1-5~2. Phase II~   * Azacitidine determined dose daily for D-2, -1, 1~  * CHOP (Cyclophosphamide 750mg/m2 d1, Doxorubicin 50 mg/m2 d1, Vincristine 1.4 mg/m2 (Max: 2 mg) d1, Prednisolone 100mg PO d1-5), 6 cycles in total"
41101011|NCT03852758|BEHAVIORAL|Outdoor Exercise|2 outdoor exercise sessions per week
41101012|NCT03852758|BEHAVIORAL|Indoor Exercise|2 indoor exercise sessions per week
41101013|NCT06326866|DIAGNOSTIC_TEST|Otoacoustic emissions (non-invasive)|There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
41101014|NCT00465985|DRUG|ACZ885|
41101015|NCT00465985|DRUG|Placebo|
41101016|NCT00424216|PROCEDURE|DC Polarization|
41101017|NCT03380975|DRUG|Montelukast 10mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening
41101018|NCT03742219|BEHAVIORAL|Lifestyle Modification|"1. Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~2. Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters."
41101019|NCT03474562|DRUG|Duowell®|Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
41101020|NCT03474562|DRUG|Monorova® + Amlopin®|Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
41101021|NCT01735474|OTHER|Manual technique|"A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.~The manual technique includes:~stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles."
41101022|NCT01735474|OTHER|Placebo|Usual care
41101023|NCT00340613|DRUG|glargine insulin|
41101024|NCT04411836|DRUG|Tafenoquine|patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).
41101025|NCT04411836|DRUG|Primaquine|patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
41101026|NCT03386929|DRUG|Avelumab|A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
41101027|NCT03386929|DRUG|Axitinib|A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
41101028|NCT03386929|DRUG|Palbociclib|A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
41101029|NCT03095911|OTHER|News items with spin|Interpretation of news items with spin
41101030|NCT03095911|OTHER|News items without spin|Interpretation of news items without spin
41101031|NCT02301221|PROCEDURE|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
41101032|NCT02301221|DRUG|Vancomycin and bowel lavage|An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
41101033|NCT02286765|DEVICE|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
41101034|NCT05885828|OTHER|White bread|After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
41101035|NCT05885828|OTHER|Whole wheat bread|After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
41101036|NCT05885828|BEHAVIORAL|Plant-based diet|After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.
41101037|NCT05885828|OTHER|Conventional diabetic diet|Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.
41101038|NCT05885828|OTHER|Follow-up visit every 1-2 years|Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.
41101039|NCT01019343|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation involves the application of weak direct currents, delivered between two surface electrodes, placed over the scalp.
41101040|NCT01019343|DEVICE|Eye-tracking Device|The purpose of this device is to assess eye movement. Participants may sit down in front of a computer screen or a real-world environment, stand on a treadmill, or lie down in an MRI scanner. Small infrared cameras attached to the cap or glasses will be positioned in front of their eyes. Eye tracking might be performed alone, or in conjunction with EEG, EMG, fMRI or treadmill. The eye- tracking device is FDA approved and commercially available.
41101041|NCT01019343|DEVICE|Pulsed vibrator|This device would be used in experiments to see if gait can be improved and, if so, what parameters of stimulation are optimal.
41101042|NCT01019343|OTHER|Gait Trainer Treadmill (GTT)|The Gait Trainer is a specialized rehabilitation treadmill, which operates in both the forward and backwards mode allowing subjects to both train and undergo performance tasks in a relatively safe and expedient manner. The GTT is equipped with a mounted deck with built in sensors which monitors and records subjects gait speed, step length, right to left time distribution, and symmetry in real time in both forward and reverse modes.
41101043|NCT01019343|OTHER|Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA|Scales of motor function, cognitive function and psychiatric function are valuable supplements to clinical assessments of patients, giving quantitative information concerning these different aspects of brain function. Selected scales would be used only when potentially useful in a sub-study where such quantitative information would be correlated with a physiological or imaging result.
41101044|NCT01019343|DEVICE|iMobility|This test uses the iMobility system. iMobility Device is a small device designed to measure movement through sensors (test monitors) worn by a patient via Velcro straps around an ankle or wrist or worn as a pendant around the neck to lie over the sternum. The device is a nonsignificant risk device.The iMobility Device has been used before, in the same format with a similar paradigm, in previous NIH studies.
41101045|NCT01019343|DEVICE|QMAT|The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.
41101046|NCT01019343|DIAGNOSTIC_TEST|Treadmill Test|Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.
41101047|NCT01019343|DEVICE|Arm Intellistretch Device|The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non-significant risk device by the CNS IRB.
41101048|NCT01019343|PROCEDURE|Transcranial Sonography (TCS)|Transcranial sonography will be conducted by a physician in the Clinical Center using the Acuson Antares ultrasound machine. This techniques uses ultrasound signals to image the brain. It entails having the subject sit in a chair or lay in a bed while the sonographer places a lubricated 2-inch ultrasound probe over the skin of the temporal area just above the patient s ear. Ultrasound images are then recorded. The procedure is not invasive and will last about 45 minutes.
41101049|NCT01019343|OTHER|Behavioral tasks|To assess the changes in cerebral physiology in the brain, subjects will be presented sensory stimuli (e.g., primary visual stimulation with flashing lights or checkerboard, auditory with tone or speech, or olfactory stimuli), or will be asked to perform non-exercise motor tasks (e.g., tapping of fingers, squeezing ball, moving joystick), to perform cognitive tasks such as a working memory task (e.g., n-back with or without catch rules, word finding), or to just rest or sleep.
41101050|NCT01019343|PROCEDURE|TMS single/paired pulse|For MEP acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles (see sub-section EMG 7.1.3.1 for the details of the procedure).
41443345|NCT02659358|DEVICE|Fitbit Charge HR®|A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
41443346|NCT00363077|BIOLOGICAL|GSK1247446A Group|Low dose influenza vaccine adjuvanted with AS03 compared
41101051|NCT01019343|PROCEDURE|MEG|MEG recordings will be performed together with experienced personnel in the NIMH MEG lab in the NMR center in Building 10. For these recording sessions, subjects will sit in a chair or lay down with a helmet placed over the head. The helmet used for MEG does not require the application of conductive gel. Scan times vary from 20 minutes to 2 hours.
41101052|NCT01019343|PROCEDURE|EEG|EEGs will be recorded by, or together with, experienced personnel in the HMCS EEG lab in Building 10, or in the NMR center.
41101053|NCT01019343|PROCEDURE|MRI techniques|MRI sub-studies will be conducted on 3.0 T or 7T units in the NMR Research Center. All volunteers will comply with the yearly requirement of a standard clinical diagnostic MRI scan of the head performed at 3.0T, to be submitted to the Diagnostic Radiology Department of the Clinical Center for interpretation. If the subject does not have a clinical scan performed within 12 month of the exam, a standard clinical MRI will be performed and reviewed before the research MR. The standard examination takes approximately 15 minutes to complete; after that, the research MR scans will be performed. Standard clinical MRI of the head will be repeated on an annual basis and read by the Diagnostic Radiology Department of the Clinical Center.
41101054|NCT01019343|PROCEDURE|Peripheral Nerve Stimulation|Constant-current, 0.1 to 0.5 ms square-wave single pulses of electrical stimulation will be delivered through standard bar electrodes to nerves of the upper limb or of the lower limb. To study somatosensory evoked potentials, for example, the stimulus intensity will be set at just above the motor threshold for evoking a slight limb movement. Location of the electrical stimulation will depend on the specific objective of the sub-study. Peripheral nerve stimulation might be delivered during other types of experiments as well.
41101055|NCT01019343|PROCEDURE|EMG|EMG measures the electrical activity of muscles. For our research purposes, only surface EMG will be used to measure the effects of central and peripheral nervous system stimulation. For surface EMG, electrodes will be coated with a conductive gel and taped to the skin. For motor evoked potential (MEP) acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles.
41101056|NCT01019343|PROCEDURE|Trancutaneous spinal direct current stimulation (tsDCS)|Direct current (DC) stimulation is a non invasive tool used to promote plasticity of the central nervous system. Recently, DC stimulation has been applied to the human spinal cord, and known as transcutaneous spinal direct current stimulation (tsDCS).
41101057|NCT06281080|PROCEDURE|En-Bloc Resection of Bladder Tumours|Patients underwent En-Bloc Resection of Bladder Tumours using Agilis Robotic System.
41101058|NCT06631014|DIAGNOSTIC_TEST|Early Rehab|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation.
41101059|NCT06631014|COMBINATION_PRODUCT|Delayed Rehab|The 2nd group of 25 patients that was fitted with Prosthesis after the time period of 6months after amputation. No physical rehab was done during this time period including physiotherapy and prosthetic treatment. Main aim was to check the significant impact of delayed rehabilitation.
41101060|NCT00778804|BEHAVIORAL|telemedicine|Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
41101061|NCT03651531|DRUG|Insulin|Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.
41101062|NCT03651531|DRUG|Metformin|Will be initiated at dose of 500 mg twice daily. If glycemic control is suboptimal, the dose of metformin will be increased to 1000 mg twice a day. Metformin will be titrated prior to increases in insulin.
41101063|NCT01632930|OTHER|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
41101064|NCT00565708|OTHER|placebo|Placebo Comparator
41101065|NCT00565708|DRUG|Acetylsalicylic acid|Adjuvant Therapy
41101066|NCT01403792|DRUG|P2G12|A single intravaginal administration of 1ml P2G12/placebo.
41101067|NCT00030381|DRUG|4'-iodo-4'-deoxydoxorubicin|Given IV
41101068|NCT00030381|OTHER|pharmacological study|Correlative studies
41101069|NCT04480593|DRUG|Brazilian Green Propolis Extract (EPP-AF)|Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.
41101070|NCT04480593|OTHER|Standard care|Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO).
41101071|NCT00087269|DRUG|erlotinib hydrochloride|Given orally
41101072|NCT00087269|PROCEDURE|therapeutic endoscopic surgery|Undergo surgical resection
41101073|NCT00087269|OTHER|laboratory biomarker analysis|Correlative studies
41101074|NCT04061408|RADIATION|Fractionated stereotactic radiotherapy(FSRT)|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
41101075|NCT06406101|OTHER|Floor|Uninterrupted 2-minute chest compressions on a manikin that has been moved from the bed to the floor in a simulated scenario of out-of-hospital cardiac arrest
41101076|NCT06406101|OTHER|Bed|Uninterrupted 2-minute chest compressions on a manikin that is laying on bed in a simulated scenario of out-of-hospital cardiac arrest
41101077|NCT00290732|DRUG|Intraductal arm|Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
41101078|NCT00290732|DRUG|Intravenous arm|Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
41101079|NCT02390557|OTHER|Survey|PDQS survey reports only
41101080|NCT02390557|OTHER|YESHealth|Arm 3: YESHealth and PDQS survey reports to providers
41101081|NCT04958811|DRUG|Tiragolumab|600mg IV administered every 3 weeks.
41101082|NCT04958811|DRUG|Atezolizumab|1200mg IV administered every 3 weeks.
41101083|NCT04958811|DRUG|Bevacizumab|15mg/kg IV administered every 3 weeks.
41101084|NCT05338905|OTHER|Palliative Therapy|Receive standard symptom management
41443347|NCT00363077|BIOLOGICAL|Fluarix™|GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.
41443348|NCT04513912|DRUG|Seltorexant|Participants will receive seltorexant over-encapsulated tablet orally.
41443349|NCT04513912|DRUG|Matching placebo to Seltorexant|Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
41443350|NCT04513912|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
41443351|NCT04513912|DRUG|Matching placebo to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
41443352|NCT06300411|DRUG|SRG-514|SRG-514 monotherapy
41443353|NCT04654182|DRUG|Chlorhexidine Gluconate|Product used in accordance with manufacturers Hand Hygiene instructions
41443354|NCT06563362|RADIATION|De-escalation of irradiated volume|De-escalation of elective clinical target volumes as recommended by a model-based approach
41443355|NCT03832361|DRUG|IMGN853|IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
41443356|NCT04075578|DRUG|OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States|Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
41443357|NCT05921760|DRUG|Ivosidenib|ivosidenib taken once daily
41443358|NCT05921760|DRUG|Recommended Combination Dose (RCD) of ivosidenib|The RCD of ivosidenib taken once daily
41443359|NCT05921760|DRUG|Nivolumab|Nivolumab taken by intravenous infusion
41443360|NCT05921760|DRUG|Ipilimumab|Ipilimumab taken by intravenous infusion
41443361|NCT04972864|OTHER|Exercise training group|A regular advanced exercise program was given and followed.
41443362|NCT04972864|OTHER|Control training group|Basic exercises was given at the beginning and did the same exercises
41443363|NCT06356103|DIETARY_SUPPLEMENT|Whey-Based Partially Hydrolyzed Formula|Peptamen junior, 100 kcal/100 ml (Nestlé Health Science, Vevey, Switzerland).
41443364|NCT06356103|DIETARY_SUPPLEMENT|received 50% of their caloric requirements as isocaloric polymeric formula (standard ) and 50% standard nutritional feeding according to ESPGHAN guidelines|protein and micronutrient requirements according to the recommended dietary allowance (RDA)
41443365|NCT02956525|DRUG|Dexibuprofen|Dexibuprofen 200 mg
41443366|NCT06319495|BEHAVIORAL|Rehabilitation therapy|"During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
41443367|NCT06319495|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40925062|NCT04645277|DEVICE|Scanning with magnetic resonance imaging|Facial nerves and adjacent blood vessels are scanned using MRI in the patients with hemifacial spasm (HFS). Then multiplanar reconstruction (two dimensional), along with curved planar reconstruction and magnetic resonance virtual endoscopy (three dimensional), will be performed in the different groups of HFS.
40925063|NCT01375075|DRUG|LY2484595|Administered orally
40925064|NCT01375075|DRUG|Placebo|Administered orally
40925065|NCT01375075|DRUG|Atorvastatin|Administered orally
40925066|NCT02257762|DIETARY_SUPPLEMENT|LNS|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients
40925067|NCT02257762|DIETARY_SUPPLEMENT|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
40925068|NCT02257762|DIETARY_SUPPLEMENT|Sprinkles|Multiple micronutrient powder packaged in sachet.
40925069|NCT00021372|DRUG|estramustine phosphate sodium|
40925070|NCT00021372|DRUG|paclitaxel|
40925071|NCT01859546|BEHAVIORAL|Short message service|Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
40925072|NCT03870958|PROCEDURE|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
40925073|NCT03870958|PROCEDURE|Control|Children allocated to this group will receive the same dietary advices and brushing instructions.
41101085|NCT05338905|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
41101086|NCT05338905|OTHER|Questionnaire Administration|Complete quality of life questionnaire
41101087|NCT06388941|DRUG|Iptacopan|LNP023 administered orally
41101088|NCT06388941|DRUG|Placebo|Matching placebo administered orally
41101089|NCT06388941|DRUG|Rituximab|Standard of care
41443368|NCT06319495|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41443369|NCT06319495|BEHAVIORAL|placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41101090|NCT00768781|BEHAVIORAL|Mindfulness-Based Stress Reduction|The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
41101091|NCT00768781|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
41101092|NCT00768781|BEHAVIORAL|Wait-List + Behavioral Therapy for Insomnia|This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
41101093|NCT00126009|DRUG|Amisulpride|
41101094|NCT02207075|DRUG|[C11]PK-1195 PET scan|PET scan with tracer \[C11\]PK-1195
41101095|NCT06164249|OTHER|strength training|Strength training, three times a week, during nine weeks.
41101096|NCT05141890|DIETARY_SUPPLEMENT|Lactobacillus Plantarum|Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.
41101097|NCT03610750|OTHER|psychiatric medications and evidence-based psychotherapies|Patients who screen positive with any psychiatric condition are referred for evaluation and treatment according to the treatment arm. This may combine psychiatric medications or evidence based psychotherapies according to treatment.
41101098|NCT03771027|OTHER|The low FODMAP diet.|The low FODMAP group had reduced the intake of FODMAP. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
41101099|NCT03771027|OTHER|The diet based on NICE guidelines.|The control group based on NICE guidelines received diet contained products with different FODMAP content. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
41101100|NCT00088673|DRUG|3APS|
41101101|NCT00390403|DRUG|R-(-)-gossypol acetic acid|
41101102|NCT00390403|DRUG|temozolomide|
41443370|NCT00394485|DRUG|Procaterol|
41101103|NCT00390403|GENETIC|gene expression analysis|
41101104|NCT00390403|GENETIC|mutation analysis|
41101105|NCT00390403|GENETIC|protein expression analysis|
41101106|NCT00390403|OTHER|laboratory biomarker analysis|
41101107|NCT00390403|OTHER|pharmacological study|
40925074|NCT05714319|OTHER|Data collection|"Variables collected will include:~* demographics (sex, age)~* comorbidities (type 2 diabetes mellitus, familiar history of CAD, smoke habit, dyslipidaemia, hypertension, history of CAD)~* echocardiographic (left ventricle ejection fraction at admission, the presence and grade of diastolic dysfunction, and the presence and grade of any valvulopathies)~* angiographic data (presence of non-obstructive CAD (any coronary lesion \<50% diameter stenosis), the presence of myocardial bridge and, if this latter is present, its localization and length)~* laboratory measurements (hematologic variables (haemoglobin and white blood cells), creatinine, high sensitivity cardiac troponin I (hs-cTnI), and C-reactive protein (CRP) at the time of admission)~* medical therapy at admission~* response to intracoronary provocative test with ACh."
40925075|NCT05714319|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACCE in the past months will be investigated and collected.
40925076|NCT01814280|OTHER|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
40925077|NCT00328302|DRUG|Candesartan|
40925078|NCT00328302|DRUG|Placebo|
41101108|NCT00390403|PROCEDURE|adjuvant therapy|
41101109|NCT00390403|RADIATION|radiation therapy|
41101110|NCT05264467|BIOLOGICAL|Platelet rich fibrin on colorectal anastomosis|Platelet rich fibrin on colorectal anastomosis
41101111|NCT06631846|OTHER|Music therapy|"Participants in the music therapy group (MTG) will be comfortably lying on the bed in a reclined position of 30-45 degrees. Using a headphone, participants will be instructed to select a volume that is comfortable to their ears and listen to the music titled as The Best Relaxing Piano and Flute Music Ever which will be played for 30-minutes every day for 1-week. Patients will be encouraged to focus on the music and let it fill their senses."
41443371|NCT00394485|DRUG|Tiotropium|
41443372|NCT00352989|DRUG|Smecta (Diosmectite), duration of treatment - 7 days|
41443373|NCT03502889|PROCEDURE|SPANK Block (Sensory Posterior Articular Nerves of the Knee)|Injection of local anesthetic into the tissues on the posterior aspect of the knee to provide sensory blockade of the articular nerves of the knee.
41101112|NCT06631846|OTHER|Mindfulness meditation|Mindfulness meditation group (MGT)will be listening to audio of Guided Mindfulness Meditation Series 1 by Jon Kabat-Zinn. Similar to MTG, participants in MMG will be lying on the bed in a reclined position of 30-45 degrees. A headphone to listen to the audio of guided MM will be provided to all the participants. Participants will begin with relaxation technique by focusing on deep breathing to help calm their body and mind. This will be followed by focusing on the present moment, letting go of any thoughts or distractions that come up. Participants can focus on their breath, bodily sensations, or a specific object in their environment. Finally, the session will end by expressing a gratitude for their body and mind and setting an intention to carry the feelings of relaxation and mindfulness with them throughout the day. Similar to MTG, MMG will engage in 30-minutes of MM every day for 1-week.
41101113|NCT06631846|OTHER|Music therapy and mindfulness meditation|Music therapy and mindfulness meditation group will be receiving both music therapy and mindfulness meditation in the same body position as MTG and MMG. Firstly, participants will listen to MT for 30-minutes followed by MM for another 30-minutes. In between the 2 interventions, a 15-minute of break will be provided to all participants. Intervention will be carried out every day for 1-week.
41101114|NCT06631846|OTHER|Cardiac rehabilitation|Control Group will not receive any other therapy except the conventional post-operative cardiac rehabilitation. Other 3 intervention groups will also be participating in the usual cardiac rehabilitation program. Cardiac rehabilitation will be conducted during phase I, where rehabilitation will focus on early mobilization and ambulation of participants with a target heart rate of resting heart rate + 30 beats, with the non-strenuous exercises in the bed or at the bedside, focusing on a range of motion and limiting hospital deconditioning.
41101115|NCT06630338|OTHER|Non-Interventional Study|Non-interventional study
41101116|NCT01603719|DIETARY_SUPPLEMENT|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
41101117|NCT06366594|BEHAVIORAL|Authentic leadership training program|37 first-line nurse managers received authentic leadership training program
41101118|NCT03437746|DRUG|injection of methylprednisolone at anesthetic induction|intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
41101119|NCT03437746|BIOLOGICAL|Blood samples|Blood samples (D0, D1, D2, D3, D4)
41101120|NCT06495424|DRUG|Capsaicin 8% Patch Kit,1|Repeat applications every 12 weeks in patients with PDPN of the feet.
41101121|NCT00832884|DRUG|Lacosamide|"0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes"
41101122|NCT01670110|DRUG|Pasireotide LAR|Injectible, 60mg per month
41101123|NCT01670110|DRUG|Placebo|To be injected once per month
41101124|NCT02442466|DRUG|Endothelin Receptor B inhibitor BQ788|
41101125|NCT02442466|DRUG|PBS|
41101126|NCT06081803|DRUG|Repatha®|Repatha® 140mg x 3 pens subcutaneous injection
41101127|NCT00457990|DRUG|Oral administration of ferrous sulphate|
41101128|NCT05818800|DEVICE|digital solution|randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions
41101129|NCT05818800|OTHER|Standard Care|randomised controlled trial where patients with hypertension will be randomised r to standard care
41101130|NCT00169780|RADIATION|High definition helical CT (64 head scanner)|"Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone anatomy which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs."
41101131|NCT01809808|PROCEDURE|Surgery for acromegaly|(non-experimental) standard procedure
41101132|NCT01809808|DRUG|Medications for acromegaly|(non-experimental) standard procedure
41101133|NCT01809808|DIAGNOSTIC_TEST|Total body magnetic resonance imaging|Subjects will undergo total body MRI with spectroscopy of the muscle and liver before and 3-6 months, 12 and 24 months after surgery or medical therapy for acromegaly.
41101134|NCT01809808|PROCEDURE|Adipose Tissue Biopsy|Subjects will undergo biopsy of subcutaneous adipose tissue before and 12 and 24 months after surgery or medical therapy for acromegaly.
41101135|NCT02930343|DRUG|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
41101136|NCT02930343|DRUG|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
41101137|NCT02930343|DRUG|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
41101138|NCT02930343|DRUG|Prednisolone|Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
40925079|NCT02898285|BEHAVIORAL|Team sports|Participants will choose from a list of team sports and will be signed up with the team.
41101139|NCT02930343|DRUG|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
41101140|NCT02930343|DRUG|Sulfasalazine|5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
41101141|NCT00147355|DRUG|ondansetron, ibuprofen, paracetamol|ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
41101142|NCT00147355|DRUG|Ondansetron, ibuprofen, paracetamol|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
41101143|NCT00147355|DRUG|metoclopramide, ibuprofen, paracetamol|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
41101144|NCT00147355|DRUG|Metoclopramide, codeine phosphate, ibuprofen, paracetamol|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
41101145|NCT00580073|DRUG|FOLFOX4|oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
41101146|NCT00580073|DRUG|Cetuximab|Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
41101147|NCT03966794|DEVICE|Epidural Electrical Stimulation|Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
41101148|NCT03966794|COMBINATION_PRODUCT|Functional scaffold & Epidural Electrical Stimulation|Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
41101149|NCT02313844|BIOLOGICAL|Viralym-B|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
41101150|NCT01413113|DRUG|pazopanib hydrochloride|Given PO
41101151|NCT01413113|RADIATION|iodine I 131|Given IM
41101152|NCT04409210|BEHAVIORAL|Establishment of individual health records|Patients could upload self-test data (such as blood pressure, blood glucose, heart rate and weight) and medical institution examination data (such as blood lipids, ECG, echocardiography, etc.) through App. AND then the App can automatically generate health reports to reflect the dynamic changes of the data in the form of charts and whether the data is normal or not. It is convenient for patients to have a clear understanding of their health management, and if there are outliers, they can intervene in time.
41101153|NCT04409210|BEHAVIORAL|Cardiovascular risk assessment|The China-PAR risk prediction tool can be used to stratify the 10-years atherosclerotic cardiovascular disease (ASCVD) risk. Those with predicted risks of \<5%, 5-10%, and ≥10% could be classified into categories of low-, moderate-, and high-risk for ASCVD, respectively. It is a risk prediction tool for Chinese developed by the team of Professor Gu Dongfeng of Fuwai Hospital of the Chinese Academy of Medical Sciences. When patients are aware of their risk of cardio-cerebrovascular diseases, it is helpful for patients to take the initiative to manage their cardio-cerebrovascular health.
41101154|NCT04409210|BEHAVIORAL|Popularization of medical knowledge|Health education is divided into nine modules, such as introduction of cardio-cerebrovascular diseases, diet, exercise, sleep, psychology, medicine, cardiopulmonary resuscitation and cardiac self-rescue technology. The presentation of health education includes three modules: text, video and voice. Video and voice modules are more suitable for illiterates or people are inconvenient to read text. It mainly takes into account the fact that most of the high-risk population of cardio-cerebrovascular diseases are the elderly.
41101155|NCT04409210|BEHAVIORAL|Personalized Reminders|"1. Abnormal data reminder App can automatically judge whether the data is normal. If abnormal data is found, it will inform the patient in red font and remind the patient to consult the doctor in time. Patients can consult their family doctors directly online through App or go to the hospital.~2. Medication reminder After patients upload their own medication information, the App will automatically generate a medication alarm clock to remind patients to take the drugs.~3. Follow-up reminder According to the clinical diagnosis and conditions of patients, make personalized follow-up time. Family physicians could use the App to remind patients to fill in the follow-up form or go to the hospital."
41101156|NCT04409210|DRUG|Routine treatment|Family physicians conduct the corresponding treatment and management according to the diagnosis and conditions of the patients.
41101157|NCT05465811|OTHER|Program of physical exercises and health education by telerehabilitation|"To carry out the telerehabilitation program, the Google Meet platform will be used in order to provide the synchronous service model. This will occur for a period of 16 weeks, three weekly sessions lasting 50 minutes, (total of 48 sessions). The sessions will be given by physiotherapists and students in their final year of graduation in physiotherapy, which will consist of the following phases: initial rest, warm-up, resistance exercises, stretching exercises, relaxation and final rest.~In addition, in exchange for the warm-up phase, every 12 sessions, the telerehabilitation program also will have an approach through health education, using presentations, digital booklets and direct conversation between therapist and participants. The themes exhibited (importance of physical exercise in the pandemic context, reduction of the risk of falls through changes in the home environment and physiological changes resulting from aging) will intend to make them aware of better lifestyle habits."
41101158|NCT04511806|OTHER|Registry|This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
41101159|NCT03264456|DIAGNOSTIC_TEST|[18F] Fluciclovine PET/MRI|\[18F\] fluciclovine PET/MRI
41101160|NCT03264456|DRUG|[18F] fluciclovine|\[18F\] fluciclovine
41443374|NCT03502889|PROCEDURE|Adductor Canal Block|Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee
41443375|NCT03502889|DRUG|Ropivacaine Hcl 0.5% Inj Vil 30Ml|Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.
41101161|NCT06432842|OTHER|Laser Treatment|In the study group, low-dose laser treatment was applied in addition to conventional treatment. Chattanoga Group Therapeutic Laser device was used for laser treatment. Laser treatment was applied to 8 sensitive points around the knee for 1 minute, for a total of 8 minutes. Laser treatment was applied continuously, with a wavelength of 830nm and a power of 6J.
41101162|NCT00548964|DRUG|Lithium|600-900mg of Li carbonate
41101163|NCT00548964|DRUG|Ketamine|0.5mg/kg of ketamine
41101164|NCT04730999|DRUG|Etoposide|Induction phase: 100 mg/sqm on days 1-3, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
41101165|NCT04730999|DRUG|Carboplatin|Induction phase: AUC 5 on day 1 for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
41101166|NCT04730999|DRUG|Bevacizumab|"Induction phase: 7.5 mg/kg on day 1, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration.~Maintenance phase: 7.5 mg/kg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal."
41101167|NCT04730999|DRUG|Atezolizumab|"Induction phase: flat dosing of 1200 mg on day 1, for a maximum of 6 cycles ( each one of 21 days duration). Intravenous administration.~Maintenance phase: flat dosing of 1200 mg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal, loss of clinical benefit."
41101168|NCT00610753|BEHAVIORAL|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
41101169|NCT00610753|BEHAVIORAL|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
41101170|NCT00647205|DEVICE|QuantiFERON TB Gold In-Tube|
41101171|NCT00647205|DEVICE|T-SPOT.TB®|
41101172|NCT02236559|DEVICE|Noninvasive positive pressure ventilation (NIPPV)|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 \> 88%."
41101173|NCT02236559|DEVICE|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 \> 88%.
41101174|NCT03700658|DRUG|TV-46046|TV-46046 will be administered per dose and schedule specified in the arm.
41101175|NCT03700658|DRUG|Depo-subQ 104|Depo-subQ 104 will be administered per dose and schedule specified in the arm.
41101176|NCT03700658|DRUG|TV-46046 Placebo|TV-46046 Placebo will be administered per schedule specified in the arm.
41101177|NCT00202865|BIOLOGICAL|infliximab|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
41101178|NCT00202865|BIOLOGICAL|Placebo|Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
41101179|NCT01806714|OTHER|Text-based reminder for recommended HPV vaccine or WCC|Patients due for a well visit or HPV vaccine received a text reminder
41101180|NCT01806714|OTHER|Non-specific text-based reminder (general health tip)|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
41443376|NCT03502889|DEVICE|Pajunk sonoplex stim needle|Echogenic needle used for ultrasound guided nerve blockade.
40925080|NCT02898285|BEHAVIORAL|Individual sport condition|Participants will choose from a list of individual sports.
40925081|NCT02898285|BEHAVIORAL|Night out|"Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children)."
41443377|NCT00834444|DRUG|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
41443378|NCT00834444|DRUG|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
41101181|NCT04228055|BEHAVIORAL|CLIPP2|Diabetes Prevention Program and Comprehensive Lifestyle Improvement Program with emphasis on a low carbohydrate and Keto diet, physical activity, sleep optimization and stress management.
41101182|NCT06631872|BEHAVIORAL|Tele-prehabilitation education session: Surgery School|Online telehealth education program using videos and a live clinician facilitator
41101183|NCT06631872|BEHAVIORAL|Individualised Inspiratory Muscle Training and Walking Program|An individualised inspiratory muscle training and walking program delivered by a Physiotherapist using telehealth.
40925082|NCT05444998|DRUG|Intuzumab, pyrrolidone, nab-paclitaxel|"Pyrrolidone 400 mg, qd; nab-paclitaxel 125 mg/m2, qw, D1/8/15; inituzumab 6 mg/kg (first dose 8 mg/kg) q3w, D1; 4 cycles in total (q3w as 1 cycle).~The patient's postoperative adjuvant therapy was 4 cycles of epirubicin + cyclophosphamide + physician's choice of anti-HER2 targeted therapy.~Multiple drug interruptions for adverse events were allowed throughout."
41101184|NCT06631872|OTHER|Usual Care|Usual care alone. Usual care will be reviewed every four months during the trial and site leads will be asked to provide information about any changes to usual hospital and medical care at their site.
41101185|NCT05553119|BEHAVIORAL|Home Rehabilitation Monitoring System|Established home-based pulmonary rehab system consists of three commercial devices (Garmin Vívofit™ activity monitor, Nonin 3150 WristOx2® Pulse Oximeter, Android tablet) and two software applications for telemonitored home pulmonary rehabilitation.
41101186|NCT05553119|BEHAVIORAL|Health coaching calls|Coaching calls based on motivational interviewing principles will occur weekly for twelve weeks following a standard protocol, lasting no more than 5-10 minutes.
41101187|NCT04720599|DIAGNOSTIC_TEST|ExoDx Prostate(IntelliScore)|The ExoDx Prostate test result supports the biopsy decision process by stratifying patients based on risk for high grade prostate cancer
41101188|NCT01076335|DRUG|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
41101189|NCT01076335|DRUG|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
41101190|NCT05542342|DRUG|Tislelizumab|200 mg IV once every 3 weeks
41101191|NCT05542342|DRUG|Sitravatinib Malate|100 mg orally once daily
41101192|NCT06345833|DRUG|1%Tranexamic acid with standard local|1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control.
41101193|NCT06345833|DRUG|3% TXA|3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control.
41101194|NCT06345833|DRUG|1% TXA with local plus 3% TXA-soaked pledgets|1% TXA with local plus 3% TXA-soaked pledgets with saline as the control.
41101195|NCT03278028|DRUG|A-101 Topical Solution|A-101 Topical Solution
41101196|NCT03278028|DRUG|A-101 Vehicle Solution|A-101 Vehicle Solution
41101197|NCT06552429|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 135 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
41101198|NCT06552429|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 180 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
41101199|NCT04330430|DRUG|T-VEC|The treatment schedule is based on 4 courses of intralesional T-VEC and 3 courses of intraveneous Nivolumab. T-VEC first, in order to achieve the best synergistic effect with influx of CD8+ T-cells prior to the first Nivolumab dose. T-VEC monotherapy with the dose 10\^8 PFU/mL is given every 2 weeks after 3 weeks of the first T-VEC dose (with the first dose of T-VEC 10\^6 PFU/mL to allow for seroconversion), and Nivolumab will be given every 2 weeks.
40925083|NCT00321581|DRUG|Cediranib, AZD2171, RECENTIN|
40925084|NCT06333197|PROCEDURE|ORIF through transparotid approach|The Retromandibular Transparotid approach is a surgical method used to access structures in the parotid gland region by making an incision behind the mandible.
40925085|NCT06333197|PROCEDURE|ORIF through retroparotid approach|The Retromandibular Retroparotid approach, also known as the Modified Blair Incision, is a surgical technique used to access structures within the parotid gland region by creating an incision behind the mandible and extending it into the parotid region.
40925086|NCT03690336|DRUG|Nonacog beta pegol|Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician.
40925087|NCT04628377|DEVICE|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
40925088|NCT02682979|OTHER|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
40925089|NCT05697978|DEVICE|Monofocal intraocular lens Clareon (Alcon LLC)|monofocal aspheric lens implanted in eyes of patient during routine cataract surgery
41101200|NCT04732039|OTHER|Measurement of peak oxygen uptake|Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).
41101201|NCT06631508|OTHER|Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge|Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge
41101202|NCT06319664|PROCEDURE|retrosigmoid approach (RSA)|The skull base approach choice was fundamentally followed by the modified classification.
41101203|NCT06319664|PROCEDURE|subtemporal transtentorial transpetrosal approach (STTA)|The skull base approach choice was fundamentally followed by the modified classification.
41101204|NCT06319664|PROCEDURE|extended pterional transtentorial approach (EPTA)|The skull base approach choice was fundamentally followed by the modified classification.
41101205|NCT06319664|PROCEDURE|pretemporal trancavernous anterior transpetrosal approach (PTCA)|The skull base approach choice was fundamentally followed by the modified classification.
41101206|NCT06319664|PROCEDURE|presigmoid combined supra-infratentorial approach (PCA)|The skull base approach choice was fundamentally followed by the modified classification.
41101207|NCT06319664|PROCEDURE|inoperable|The skull base approach choice was fundamentally followed by the modified classification.
41101208|NCT01762072|DIETARY_SUPPLEMENT|Fish oil|
41101209|NCT01762072|DIETARY_SUPPLEMENT|vitaminB12|
41101210|NCT01906060|DEVICE|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Laryngeal Mask.
41101211|NCT03264248|DEVICE|E-Scale|Daily bodyweight system used under legs of bed
41101212|NCT04285125|OTHER|cerebral MRI|Patients who agree to participate in the study will perform an MRI with ultra high resolution sequences added by the research MRI of control will be done at one year and two years
41101213|NCT03467724|DEVICE|Fractional Radiofrequency (FRF)|Fractional radiofrequency will be delivered to the area of the surgical scar.
41101214|NCT04231474|DEVICE|Urodynamic testing|All data were obtained using the MMS Alfa 4T by the same urologist with use of an 8 Charr catheter.
41101215|NCT03155152|OTHER|DECT|The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
41101216|NCT03155152|OTHER|HIIT|The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
41101217|NCT04914936|DRUG|ACP-196|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.
41101218|NCT04914936|DRUG|Calcium carbonate|Participants will receive a single oral dose of calcium carbonate 1 g tablet on Day 1 of Period 2 in Part 1.
41101219|NCT04914936|DRUG|Omeprazole|Participants will receive multiple oral doses of omeprazole 40 mg capsules QD for 5 consecutive days in Period 2 of Part 2.
41101220|NCT04914936|DRUG|Rifampin|Participants will receive multiple oral doses of rifampin 600 mg capsule QD for 9 consecutive days in Period 2 of Part 3.
41101221|NCT03467555|DEVICE|Class II correction using miniplates in zygomatic region|
41101222|NCT02814305|BEHAVIORAL|Financial|Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy
41101223|NCT02814305|BEHAVIORAL|Educational|Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
41101224|NCT03061513|DRUG|Ubiquinol|Ubiquinol caplets 600mg/day
41101225|NCT03061513|DIETARY_SUPPLEMENT|Placebo|placebo
41101226|NCT01711307|PROCEDURE|operative|
41101227|NCT01711307|PROCEDURE|non-operative|casting within 48 hrs
41101228|NCT06443060|BEHAVIORAL|Virtual Reality Group|Before starting the Prick procedure, the child in the virtual reality group, which is determined by randomisation, will be given a brief information about how the allergy test will be performed and about virtual reality. Before the Prick test (approximately 2 minutes before the Prick test), the child will start to watch a film deemed appropriate by the experts by wearing virtual reality and headphones. After the child starts watching the film, the child will be asked to extend his/her left arm and solutions will be dripped on the forearm and the puncture will be performed with a lancet. The child will continue to watch the film during the whole procedure.
41101229|NCT06443060|BEHAVIORAL|Buzzy Application Group|Before starting the prick procedure, the child in the buzzy group, which was determined by randomisation, will be given a brief information about how the allergy test will be performed and the buzzy device. The children in the buzzy experimental group will be connected to the buzzy cold and vibration device at least 8-10 cm above the area to be treated (upper part of the left arm antecubital fossa) 5-10 seconds before starting the procedure and the prick test application will be started.
41101230|NCT06443060|OTHER|Control Group|Before starting the prick procedure, the children in the control group determined by randomisation will be given routine explanations according to the outpatient clinic procedure before starting the procedure and the prick test will be applied.
41101231|NCT00001129|DEVICE|Electronic Medication Reminder System|
41101232|NCT00001129|BEHAVIORAL|Medication Manager|
41101233|NCT00590382|DEVICE|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
41101234|NCT00778739|DRUG|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
41101235|NCT05794373|PROCEDURE|Standard physiotherapy for low back pain in a municipality setting|Patients (N=100) referred to a municipality-based rehabilitation for low back pain are included. The physiotherapists choose the rehabilitation strategy based on what they consider relevant for the patients. After the first 100 patients have been discharged from municipality care, the physiotherapists will participate in an educational intervention (12 sessions) focusing on the management of low back pain within a multidimensional framework. In the educational intervention, the participants will learn how to identify the presence of unhelpful thoughts and emotions and how to address these as part of the intervention. The course will thus be a mix of theoretical and practical teaching, including case supervision and feedback. Following the educational intervention, an additional 100 patients referred to the rehabilitation program will be included. The intervention is aimed at the physiotherapists where the patients will receive the best available care, before or after the intervention.
41133271|NCT01883193|DIETARY_SUPPLEMENT|Comprehensive Maternal Nutrition Intervention|The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
41443379|NCT05253950|OTHER|Questionnaire|answered questions from two standard questionnaires the Internet Addiction Test (IAT) which examines students' dependence on the internet and the Nordic Muscuskeletal Questionnaire (NQS) which examines the onset of symptoms from the musculoskeletal system
41443380|NCT05985772|OTHER|Non-Operative Pain Management|The non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing. This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks. Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.
40925090|NCT04648969|DRUG|kisspeptin 112-121|20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
40925091|NCT04648969|DRUG|GnRH|1 intravenous dose of GnRH
41101236|NCT01299974|OTHER|Parents and Residents in Session|Family Faculty members agreed to participate in meetings with pediatric residents who agree to participate. Standardized meetings include discussions of the following: 1. Impact of hospitalization on the behavior and development of each participating parent's child. 2. Effective communication with a parent 3. How to gain trust 4. The family meeting: who participates, the agenda 5. Troubleshooting: how to deal with difficult situations (the parents will present a few instances, from their own experience, which they think might be challenging to the clinicians who treated their children). Other core components will be added (or existing ones deleted) based on participants' feedback. The meeting will be attended by two residents, a family council member, and a senior faculty who will serve as monitor. Following the meeting, the residents will have an opportunity to ask questions and offer comments about the experience in a dedicated feedback interview with a senior faculty member.
41101237|NCT05881733|DEVICE|POLARx FIT cryoballoon|Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.
41101238|NCT04074551|DRUG|HCP1701|HCP1701
41101239|NCT04074551|DRUG|Losartan|Losartan
41101240|NCT04074551|DRUG|Amlodipine|Amlodipine
41101241|NCT04074551|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin and Ezetimibe
41101242|NCT03537651|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
41101243|NCT03537651|DRUG|IVA|Tablet for oral administration.
41101244|NCT04338165|DRUG|Evolocumab 140 MG/ML [Repatha]|3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
41101245|NCT05640817|DRUG|Pentoxifylline 400 mg SR tablets|a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases
41101246|NCT05640817|DRUG|cisplatin with standard hydration with normal saline|chemotherapy
41101247|NCT06476925|PROCEDURE|sonar guided stellate ganglion injection|using high frequency probe, sonar guided stellate ganglion block with 8 ml saline 0.9%
41101248|NCT06476925|PROCEDURE|sonar guided stellate ganglion block|using high frequency probe, sonar guided stellate ganglion block with 8 ml bupivacaine 0.25%
41101249|NCT06563375|DRUG|NP-101|Given by mouth
41101250|NCT01396109|PROCEDURE|Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System|Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA\* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
41101251|NCT01396109|PROCEDURE|Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh|Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
41101252|NCT01514734|DRUG|Brinzolamide/timolol maleate fixed combination|Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
41101253|NCT02315885|OTHER|Alcohol administration; Placebo administration|consumption of 3 alcohol doses (2 regular and one placebo) each within 2h on separate days
41101254|NCT06237062|OTHER|erenumab|This is an observational study, there is no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients will be directed through a link to the full survey.
41101255|NCT05000450|GENETIC|ALLO-605|ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product
41101256|NCT05000450|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
41101257|NCT05000450|DRUG|Fludarabine|Chemotherapy for lymphodepletion
41101258|NCT05000450|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
41101259|NCT06003608|DEVICE|Fluid biopsy capsule|Ingestion of two SIMBA capsules
41101260|NCT06003608|DRUG|Levodopa-Carbidopa Immediate Release|Single dose, Levodopa-Carbidopa Immediate Release
41101261|NCT04742855|DIETARY_SUPPLEMENT|Probiotics|Study product is packaged as powders in a sachet. Participants and their parents will be instructed to dissolve the powder in water or milk, and to drink it in the morning and/or evening.
41101262|NCT01207908|DRUG|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
41101263|NCT05720546|OTHER|Baseline Survey|A survey that measures participant satisfaction will be offered to participants during infusion at baseline.
41101264|NCT05720546|OTHER|Semi-structured interviews|Semi-structured interviews will be conducted in the same infusion spaces.
41101265|NCT05720546|OTHER|Follow-up Survey|A survey that measures participant satisfaction will be offered to participants during following infusion.
41101266|NCT06442995|DRUG|Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space|When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to the injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg
41101267|NCT06442995|DRUG|Injection of Isotonic saline + 2 mg morphine into the epidural space|When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to Injection of morphine 2 mg into the epidural catheter + isotonic saline. This is the protocol the investigators use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies
41101268|NCT02770040|DRUG|Infliximab|INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
41101269|NCT02294643|DRUG|Sarpogrelate|
41101270|NCT02294643|DRUG|Aspirin|
41101271|NCT02294643|DRUG|Clopidogrel|
41101272|NCT02294643|DRUG|Placebo (for Sarpogrelate)|
41101273|NCT03612804|BEHAVIORAL|Unsigned note to provider about cessation medication prescription|For patients of providers assigned to the proactive study group, a local coordinator will review the patient's cessation medication history. If the patient is not currently being provided cessation support medication, the coordinator will enter a note for the provider about the recommended medication indicated by VA formulary guidelines.
41101274|NCT03612804|BEHAVIORAL|Proactive Telephone Counseling from VA Quitline|Patients of providers assigned to the proactive study group will be contacted by specially trained counselors at the VA Quitline. Counselors will attempt to provide two sessions of proactive telephone support.
41101275|NCT03273530|OTHER|Integrated Supported Employment|vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
41101276|NCT04582344|BIOLOGICAL|CoronaVac|Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
41101277|NCT04582344|BIOLOGICAL|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
41101278|NCT00920686|DRUG|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
41101279|NCT00920686|DRUG|placebo|administered as 3 placebo hard gelatin capsules
41101280|NCT00920686|DRUG|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
41101281|NCT06183710|BEHAVIORAL|Contingency management|Psychosocial intervention
41101282|NCT00404794|DRUG|prednisolone and mycophenolate mofetil|
40925092|NCT05290376|PROCEDURE|surgical placement of long dental implants|Two interforaminal implants were placed in the canine region
40925093|NCT05290376|DEVICE|overdenture supported by RTX attachment system|Control group: Implants were loaded after three months by RTX supported overdenture study group: Implants were loaded after four weeks by RTX supported overdenture
40925094|NCT04630574|OTHER|Speech evaluation with the clinical evaluation of dysarthria|A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.
40925095|NCT04630574|OTHER|complete assessment of the MonPaGe computerized protocol|The application records directly and anonymously stores speech productions made by the patient.
40925096|NCT05018351|BEHAVIORAL|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
40925097|NCT05018351|BEHAVIORAL|Peer Navigation|Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on health-related goals, attending health care appointments. and facilitating follow-up activities related to healthcare appointments).
40925098|NCT04404218|DIETARY_SUPPLEMENT|Açaí palm berry extract - natural product|Patients will be prescribed to take 1 capsule (520mg) of Açaí Palm Berry every 8 hours for a total of 3 capsules a day, during 30 days. Total dose: 1,560mg/day of Açaí Berry extract.
40925099|NCT04404218|OTHER|Placebo|Patients will take 1 placebo pill every 8 hours (total of 3 capsules a day) for 30 days.
40925100|NCT06004492|BEHAVIORAL|blended learning program|8 hours of workshops and four months of practical learning on technology platforms
40925101|NCT04762901|DRUG|Niraparib|Oral tablet
40925102|NCT04762901|DRUG|Doxorubicin|IV
40925103|NCT04762901|DRUG|Cyclophosphamide|IV
40925104|NCT04762901|DRUG|Paclitaxel|IV
40925105|NCT04762901|DRUG|Pegfilgrastim|Injection
40925106|NCT04762901|DRUG|Carboplatin|IV
40925107|NCT06286176|BEHAVIORAL|Videos with breastfeeding education material and encouraging messages|Distributed videos aim to increase breastfeeding related knowledge and to receive support
40925108|NCT06286176|BEHAVIORAL|Whatsapp group|The Whatsapp group is used in the intervention as a platform for interpersonal exchange of information and experience, in addition to peer support.
40925109|NCT03492008|OTHER|Conventional technique|Nasogastric tube insertion with patient's head in neutral position
40925110|NCT03492008|OTHER|Contralateral cricothyroid pressure|Cricothyroid pressure is applied externally in the contralateral direction of selected nostril before nasogastric insertion.
40925111|NCT03492008|OTHER|Ipsilateral head turning|Patient's head is turned to the ipsilateral side of the selected nostril before nasogastric tube insertion.
40925112|NCT06390072|BEHAVIORAL|Self-Hypnosis|Participants listened to an 8-minute audio-guided self-hypnosis related to improving their physical performance
40925113|NCT06390072|BEHAVIORAL|Ankle Education|Participants listened to an 8-minute video on ankle sprain diagnosis, prognosis, and treatment
41101283|NCT00404794|DRUG|prednisolone and tacrolimus|
41101284|NCT00623922|BEHAVIORAL|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
41101285|NCT00897637|OTHER|laboratory biomarker analysis|Correlative studies
41101286|NCT03581968|DEVICE|Artificial Pancreas|"The system is composed of 3 main components:~1. Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~2. Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~3. MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump."
41101287|NCT00946751|DRUG|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
41101288|NCT00946751|DRUG|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
40925114|NCT06504745|OTHER|Peer education|experimental group
40925115|NCT06504745|OTHER|control group|instruction training
41101289|NCT02814825|OTHER|ViviGen|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
41101290|NCT06411405|OTHER|Maternal medical history|See above; multiple factors to be collected broadly grouped into maternal medical, obstetric, and sociodemographic/lifestyle factors.
41101291|NCT02380742|DRUG|lidocaine-prilocaine cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
41101292|NCT02380742|DRUG|Placebo cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
41101293|NCT03031756|DEVICE|glycine powder air-polishing (Air-Flows)Perio Powder|
41101294|NCT03031756|DEVICE|ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)|
41101295|NCT01928004|DEVICE|Implant placement|Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
41101296|NCT01928004|PROCEDURE|Conventional reline|conventional reline of the existing mandibular complete denture
41101297|NCT04261855|DRUG|Avelumab|All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
41101298|NCT04261855|RADIATION|External Beam Radiation Therapy (EBRT)|Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart
41101299|NCT04261855|RADIATION|Lutetium-177 (177Lu)-DOTATATE|Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart
41101300|NCT02116829|OTHER|Danish butter|The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)
41101301|NCT02116829|OTHER|Olive oil|
41101302|NCT05918159|OTHER|Sarcopenia Assessment|The prevalence of sarcopenia in a group of elderly people and its correlation with other health variables was determined.
41101303|NCT04529993|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
41101304|NCT03093792|OTHER|Control|
41101305|NCT03093792|OTHER|American Heart Association plus exercise|
41101306|NCT03093792|OTHER|Curves Complete - I plus exercise|
41101307|NCT03093792|OTHER|Curves Complete - II plus exercise|
41101308|NCT05580796|DRUG|KSH01 injection|TCR-T cell injection
41101309|NCT03601507|DRUG|Alpelisib|Given PO
41101310|NCT03601507|OTHER|Laboratory Biomarker Analysis|Correlative studies
41101311|NCT03601507|OTHER|Pharmacodynamic Study|Correlative studies
41101312|NCT03601507|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41101313|NCT06630546|DEVICE|first generation iStent (Glaukos, San Clemente, CA, USA) insertion|In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL). Then, in adequate patient who wish to receive iStent insertion, we further inserted a preloaded micro-bypass stent (model GTS100L) through the temporal corneal incision into the nasal Schlemm's canal and checked the position. Adequate intraocular pressure (IOP) was assessed by palpation at the end of the surgery.
41101314|NCT06630546|DEVICE|phacoemulsification|A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).
41101315|NCT05112315|DEVICE|Predigraft|The Subject randomized to the Predigraft will benefit from Predigraft, a remote monitoring software that issues an alert to the investigator when the allograft survival prediction calculated by the iBox algorithm is decreasing. This follow-up is on top of the site's standard of care.
41101316|NCT02323386|DEVICE|Primary Total Knee Arthroplasty (ATTUNE Knee System)|"The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.~The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected."
41101317|NCT05817331|OTHER|Carer Treatment Preference Myelodysplasia Questionnaire|Caregiver-reported outcome measure in MDS
41101318|NCT05817331|OTHER|Clinician Treatment Preference Myelodysplasia Questionnaire|Clinician-reported outcome measure in MDS
41101319|NCT05817331|OTHER|Patient Treatment Preference Myelodysplasia Questionnaire|Patient-reported outcome measure (PROM) in MDS
41101320|NCT05678296|DIAGNOSTIC_TEST|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
41101321|NCT05678296|DRUG|Analgesic|Analgesics are prescribed for the patients for all groups.
41101322|NCT05678296|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
41101323|NCT05678296|BIOLOGICAL|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
41101324|NCT05678296|DRUG|Antibiotic|no systemic antibiotics are prescribed for the patients for all groups.
41101325|NCT00038103|DRUG|Exemestane|Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
41101326|NCT00038103|DRUG|Celecoxib + Exemestane|Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
41101327|NCT05857358|PROCEDURE|lipoaspiration|"Adipose tissue harvest will be conducted by a surgeon under under local and intra-veinous sedation anesthesia. Once the patient is asleep and just before the laying of the operating drapes, the skin will be thoroughly disinfected, in order to avoid bacteriological contamination. Each entry point will be disinfected with betadine before and regularly during the procedure and will receive local anesthesia.~The lipoaspiration sites will be infiltrated using a closed system, thanks to a Khoury canula. Adipose tissue will be harvested after waiting at least 5 minutes, in order to limit hematoma and excessive blood harvesting. A 3mm incision will be made then the tissue collection will be performed using a canula, manually, by gentle aspirations into a syringe then directly transferred into a connected sterile bag.~The incision will be closed with 1 stitch of 6-0 absorbable and a paraffin gauze dressing. Then, patient will be awaken and transported to the recovery room."
41101328|NCT05857358|DRUG|Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)|"Autologous uncultured (AD-SVF) will be isolated by digestion and centrifugation of adipose tissue from lipoaspiration.~Then, AD-SVF will be injected in 6 sites :~* 2 for the accessory labial glands (0.5mL in the upper lip and 0.5mL in the lower lip)~* 2 for the sublingual glands (0.5mL for each gland)~* 2 for the inner face of cheeks (0.5mL for each side)~The volume of injection will be of 3 mL containing 30 millions of AD-SVF viable nucleated cells for the total safety dose."
41101329|NCT01250548|BIOLOGICAL|apremilast|30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
41101330|NCT01250548|OTHER|Placebo|
41101331|NCT00605904|DRUG|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
41101332|NCT00605904|DRUG|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
41101333|NCT00605904|DRUG|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
41101334|NCT00605904|DRUG|Saline|"Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)"
41101335|NCT03761654|DIAGNOSTIC_TEST|Global Longitudinal Strain measure|Global Longitudinal Strain measure on day 1 of hospitalization
41101336|NCT04288492|BEHAVIORAL|Respiratory biofeedback|Repeat the inspiration and exhalation breaths for a fixed period of time using a biofeedback device (ResCalm)
41101337|NCT00920296|DRUG|GSK1265744|GSK drug
41101338|NCT06054269|BIOLOGICAL|FLUAD Quadrivalent|0.5 mL intramuscular dose of FLUAD Quadrivalent
41101339|NCT06054269|BIOLOGICAL|FluQuadri|0.5 mL intramuscular dose of FluQuadri
41101340|NCT00629200|DRUG|Sodium Stibogluconate|400 mg/m\^2 IV daily on days 1-5.
41443381|NCT05985772|PROCEDURE|Operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment|The operative treatment group (ARM 2) will be treated acutely with a transtibial medial meniscus root repair and will be non-weight bearing for 6 weeks as well. For ARM 1 subjects if no subjective improvement is seen at 3 months, crossover will be allowed to a transtibial medial meniscal root repair (acute operative pathway (ARM 2)
41101341|NCT00629200|DRUG|Interferon Alpha-2b|3x10\^6 units subcutaneously three times weekly
41101342|NCT04749433|DRUG|[11C]CPPC Injection|A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
41101343|NCT05401916|DRUG|Tramadol|Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
41101344|NCT05401916|DRUG|Paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
41101345|NCT05401916|DRUG|Ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
41101346|NCT03686813|DRUG|Sildenafil Citrate|Oral sildenafil, 50 mg
41443382|NCT00007423|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
41443383|NCT00007423|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
41443384|NCT00303940|DRUG|carboplatin|
41443385|NCT00303940|DRUG|talabostat mesylate|
41443386|NCT00303940|DRUG|temozolomide|
41443387|NCT00303940|OTHER|pharmacological study|
41443388|NCT03579303|OTHER|Homoeopathic Remedies|comparison between homoeopathic treatment and integrated approach of homoeopathy and yoga in menstrual disorders of females with PCOS
41443389|NCT05920720|BEHAVIORAL|Self-guided Personalized Treatment|Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
41443390|NCT00830349|DRUG|Risperidone|1 mg Tablet
41101347|NCT03686813|DRUG|Placebo Oral Tablet|Placebo
41101348|NCT01269606|DRUG|insulin aspart|At the first treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. At the second treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
41101349|NCT01269606|DRUG|insulin human|At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
41101350|NCT01269606|DRUG|insulin aspart|At the first treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. At the second treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
41101351|NCT01269606|DRUG|insulin human|At the first treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. At the second treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
41101352|NCT05547191|DEVICE|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
41101353|NCT02414230|DRUG|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
41101354|NCT02759029|DRUG|eradication of Helicobacter pylori|"clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk"
41101355|NCT04619654|PROCEDURE|Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold|Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent
41101356|NCT00702429|OTHER|Blood sampling|Analysis of the PNN, analysis of the monocytes
41101357|NCT00702429|OTHER|Blood sampling|Analysis of the PNN, analysis of the monocytes
41101358|NCT04659616|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41101359|NCT04659616|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
41101360|NCT04659616|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiratie
41101361|NCT04659616|DRUG|Cytarabine|Given IV
41101362|NCT04659616|DRUG|Daunorubicin|Given IV
41101363|NCT04659616|PROCEDURE|Electrocardiography|Undergo ECHO
41101364|NCT04659616|DRUG|Pemigatinib|Given PO
41443391|NCT00830349|DRUG|Risperidone|1 mg Tablets
41443392|NCT06412861|DRUG|Ketamine|0.5 mg/kg ketamine + 1 mg/kg propofol, Ramsey Sedation Score \> 4 will be targeted. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
41443393|NCT06412861|DRUG|Fentanyl|1 mcg/kg fentanyl + 1 mg/kg propofol will be administered. Ramsay Sedation Score will be targeted to be \> 4. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
41443394|NCT05569629|PROCEDURE|Bronchial washing before endobronchial biopsy and brushing|Bronchial washing: adding bronchial washing once to the standard endoscopic sampling sequence (endobronchial biopsy and brushing first, followed by bronchial washing once) in the experimental arm
41101365|NCT04097886|OTHER|Morning Exercise|moderate intensity exercise (70% VO2 max) each morning for 5 days
41101366|NCT04097886|OTHER|Evening Exercise|moderate intensity exercise (70% VO2 max) each evening for 5 days
41101367|NCT04175886|DRUG|Tofacitinib|Patients will be treated with tofacitinib
41101368|NCT05468333|OTHER|Cigarette trial|Per NIH Program Official, this is not an ACT and thus full protocol info is not required at this time (and would be detrimental to the study if details were disclosed during recruitment).
41101369|NCT04265378|DEVICE|anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
41101370|NCT04265378|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
41443395|NCT01424124|DRUG|YHD001 dose level 1|Tablet, three times daily / 8 weeks
41443396|NCT01424124|DRUG|YHD001 dose level 2|Tablet, three times daily / 8 weeks
41443397|NCT01424124|DRUG|Singulair|Tablet, one times daily / 8 weeks
41101371|NCT05602155|PROCEDURE|Group 1|Even numbered patients will partial weight bearing after treatment,
41101372|NCT05602155|PROCEDURE|Group 2|patients with odd numbers will walk with full weight bearing after treatment
41443398|NCT01424124|DRUG|Placebo|Tablet, one times daily / 7 days
41443399|NCT05148273|BEHAVIORAL|telenursing|7-24 counseling and daily treatment protocol reminders will be given to the intervention group.
41443400|NCT03115957|OTHER|Parenteral Nutrition|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
41443401|NCT06562816|DRUG|Trypsin-Chymotrypsin|100000 IU
41443402|NCT06562816|DRUG|Naproxen Sodium 550mg|550mg
41443403|NCT01200810|OTHER|placebo|Given orally
41443404|NCT01200810|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
41443405|NCT01200810|DRUG|bicalutamide|Given orally
41443406|NCT06628141|OTHER|Nutritional support tool|Nutritional support tool
41443407|NCT06553235|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a multi-component intervention consisting of sleep restriction, stimulus control therapy, relaxation therapy, cognitive therapy, and sleep hygiene education
41101373|NCT01483287|DIETARY_SUPPLEMENT|Alpha-Galactosidase|"The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.~No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time)."
41101374|NCT00793806|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
41101375|NCT00944801|DRUG|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
41101376|NCT04977960|DRUG|Potassium Canrenoate|potassium canrenoate for 7 days in addition to maximal medical treatment
41101377|NCT05381662|BIOLOGICAL|CD19 CAR-T cells and CD19 positive feeder T cells|Detailed Description: Patients were divided into two groups, group 1 and group 2, and each group was enrolled in 5 patients. Group 1 patients did not receive any pretreatment, and group 2 patients received pretreatment with cyclophosphamide and fludarabine prior to reinfusion. Then Patients were given Chimeric Antigen Receptor T-Cell ( CAR-T) and CD19-positive T cells.
41101378|NCT05408455|OTHER|EMST150 (Expiratory muscle training)|Respiratory exercise device (Expiratory muscle trainer) developed for the expiratory muscles, and resistant expiratory muscle training were applied. Threshold loading was applied to the cases at approximately 30% of the respiratory muscle strength values measured in the 1st week. In respiratory muscle training, the pressure value was increased according to the tolerance of the patient and training was given at a pressure value between 50-75%. The subjects were asked to do 10 vigorous expirations at the adjusted pressure value by doing normal inspiration for expiratory muscle training in a comfortable sitting position. This program was applied in 3 sets in the same way for approximately 30 minutes. It was continued 3 days a week for 8 weeks
41101379|NCT05408455|OTHER|Sham EMST150 (Expiratory muscle training)|The subjects were asked to perform normal inspiration and then exhale 10 times for expiratory muscle training without threshold loading. This program was applied in 3 sets in the same way for approximately 30 minutes. It will continue 3 days a week for 8 weeks
41101380|NCT03429855|OTHER|trunk training|Bobath based trunk training
41101381|NCT03429855|OTHER|physiotherapy|conventional physiotherapy
41101382|NCT05227469|BEHAVIORAL|myofunctional therapy|In order to confirm that the exercises are done for a sufficient time and are done correctly, the researcher will take video recordings from the participants and examine these recordings every other day. Respondents will be contacted when errors are detected.
41101383|NCT05187767|DIAGNOSTIC_TEST|cf DNA and ct DNA|Quantification of the circulating free DNA and the presence of targeted circulating tumor DNA
41101384|NCT00475813|DRUG|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
41101385|NCT05590312|OTHER|general anesthesia|All patients will undergo general anesthesia. Group D will receive fresh gas flow of 1 l/min and Group Y will receive fresh gas flow of 4 l/min.
41101386|NCT04033237|OTHER|Very low nicotine content cigarettes|Cigarettes containing 0.4 mg nicotine/g tobacco
41101387|NCT03211325|PROCEDURE|Biopsy|
41101388|NCT00159796|DRUG|Asenapine|Asenapine, 3 weeks
41101389|NCT00159796|DRUG|Olanzapine|Olanzapine, 3 weeks
41101390|NCT00159796|DRUG|Placebo|placebo, 3 weeks
41101391|NCT01227642|OTHER|An ultrasound-based technique to identify prostate cancer|The technique uses current ultrasound equipment already in use for prostate brachytherapy guidance.By extracting and processing the radiofrequency signal obtained from the ultrasound transducer in ways not done to create the standard B-mode ultrasound image, areas of cancer can be identified and displayed overlying the standard B-mode ultrasound image. Comparing the results with this technique to the results of prostate biopsies demonstrates a high degree of accuracy with the area under the receiver-operator characteristic curve of 0.87, a result superior to any other imaging methods.
41101392|NCT01227642|OTHER|pre-implant transrectal ultrasound images and planning|an ultrasound-based technique to identify cancer-containing areas within the prostate.
41101393|NCT01227642|OTHER|ultrasound-based cancer-specific images|ultrasound-based cancer-specific images of the prostate prior to the brachytherapy and use them to direct the dosimetry planning
41101394|NCT01673113|DEVICE|Zeltiq CoolSculpting device|"This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the love handles."
41101395|NCT03080792|BEHAVIORAL|Experimental: moderate to high-intensity exercise|2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)
41101396|NCT01774994|OTHER|stable isotope infusion for measurement of metabolism|
41101397|NCT05933655|BEHAVIORAL|Peer Coach|Peer coaching session to support shared decision making among patient with limited health literacy.
41101398|NCT05187351|PROCEDURE|Percutaneous coronary intervention of the native coronary artery with Synergy|This is a registry study that will enroll patients with a 50-99% de novo SVG lesion SVG lesion and treated with percutaneous coronary intervention of the corresponding native coronary artery using a SYNERGY stent.
41101399|NCT01750554|OTHER|intermediate-acting digital nerve block|non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
41101400|NCT06191406|DIAGNOSTIC_TEST|6 minute walk test|Test for physical functions and cognitive functions
41101401|NCT04395755|BEHAVIORAL|Generalized Anxiety Disorder-7 (GAD-7)|The GAD-7 is useful in primary care and mental health settings as a screening tool and symptom severity measure for the four most common anxiety disorders.
41101402|NCT04395755|BEHAVIORAL|Patient Health Questionnaire-9 (PHQ-9)|The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
41101403|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
41101404|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
41101405|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
41101406|NCT04443452|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
41101407|NCT04443452|RADIATION|Radiographic Evaluation|Tibiofemoral and patellofemoral radiographs of the most painful knee will be taken using a standardised protocol (standing posterior-anterior (PA) and skyline views) and will be scored by a single experienced observer in order to generate data for correlation analyses with the primary and secondary outcomes. A Perspex Rosenberg template with lead beads is used for the standing PA view to standardising the degree of knee flexion, foot rotation and magnification. PA radiographs are taken with the participant facing the x-ray tube while standing on the Rosenberg jig and leaning forwards with their thighs touching the anterior aspect of the jig, the x-ray beams passing from the posterior aspect through to the anterior aspect of the knee. Variable jigs are used for the skyline view to obtaining 300 of knee flexion with the participant lying in a reclined supine position on a couch. Grading of radiographs for changes of OA will be based on the Kellgren and Lawrence (K/L) score.
41101408|NCT04443452|PROCEDURE|Ultrasound-guided Aspiration|Ultrasound scanning will be conducted on the most painful knee to identify synovial effusion. During the ultrasound scan, the supra-patellar pouch, medial and lateral recess of the knees will be assessed for synovial thickening, synovial fluid/effusion and for positive power Doppler. An ultrasonic probe will be used to direct ultrasonic waves onto the knee joint during sonography, and a computer converts the signals received so that they can be presented on the screen. During skin application, a sterile probe cover and sterile acoustic gel will be used. Once the best aspiration location is identified and the location of the needle insertion marked, the skin will be prepared with a cleansing agent such as iodine or chlorhexidine. The needle may be introduced into the skin either parallel to the probe or perpendicular to the probe. Once the aspiration is completed, the needle will be removed, the skin cleansed, and a bandage will be applied.
41101409|NCT04443452|DIAGNOSTIC_TEST|Muscle Strength Assessment|Isometric testing will be done at 30 and 60 degrees of flexion as done in the previous study and the participant will be in sitting position with hips and knees strapped to keep the position standardised.
41101410|NCT04443452|DIAGNOSTIC_TEST|Function Assessment (A)|"The participant will start in a seated position. The participant will stand up upon therapist's command, walk 3 meters, turn around, walk back to the chair and sit down. The time will stop when the participant is seated. The subject can use an assistive device. If the assistive device is used, it will be documented.~Important Note: A practice trial will be completed before the timed trial."
41101411|NCT04443452|DIAGNOSTIC_TEST|Function Assessment (B)|The 30-Second Chair Test is administered using a chair. The participant is seated in the middle of the chair with arms crossed at the wrists and held against the chest. The participant will practice a repetition or 2 before completing the test. If a participant must use their arms to complete the test, they are scored 0. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand. While monitoring the participant's performance to ensure proper form, the tester silently counts the completion of each correct stand. The score is the total number of stands within 30 seconds (more than halfway up at the end of 30 seconds counts as a full stand). Incorrectly executed stands are not counted. The 30-second chair stand involves recording the number of stands a person can complete in 30 seconds rather than the amount of time it takes to complete a pre-determined number of repetitions.
41101412|NCT04443452|DIAGNOSTIC_TEST|Balance Assessment|Static balance and postural sway either in the medial-lateral or antero-posterior direction will be assessed using the RS Scan force plate. The participant will be asked to stand on the plate looking straight forward for 30 seconds in two conditions: first with their eyes open and then with eyes closed. Medial-lateral, antero-posterior and total sway will be recorded.
41101413|NCT04409119|DEVICE|HIS/LBB pacing|3830 lead to HIS or LBB
41101414|NCT04409119|DEVICE|LV pacing|LV lead in a CS branch
41101415|NCT03425604|PROCEDURE|Intrauterine insemination|
41101416|NCT05048186|BEHAVIORAL|Attention Deficit Hyperactivity Disorder Treatment Decision Aid|The parent pre-visit cards from the Cincinnati Children's Hospital's Attention Deficit Hyperactivity Disorder (ADHD) Treatment for School Age Children Decision Aid were used in this study. The 6 pre-visit cards provide an overview of ADHD treatment options, the respective benefits and downsides of each option, and questions to elicit goals/preferences. The four different treatment options presented were: (1) watchful waiting, (2) behavioral treatment, (3) medication treatment, and (4) combined treatment (behavioral and medication together).
41443408|NCT06553235|BEHAVIORAL|Sleep hygiene education|- Sleep hygiene education includes information on lifestyle factors (diet, exercise, substance use) and environmental variables (noise, light, temperature) affecting sleep quality.
41101417|NCT03181724|BEHAVIORAL|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
41101418|NCT05447013|BIOLOGICAL|Coronavirus-2-specific T cells|Coronavirus-2-specific T cells ex vivo expanded from selected COVID-19 recovered donors
41101419|NCT05447013|OTHER|standard of care (SOC)|standard of care (SOC)
41101420|NCT00076986|DRUG|IL13-PE38QQR|
41101421|NCT00076986|PROCEDURE|surgery and catheter placement (2 procedures)|
41101422|NCT00076986|DRUG|prolifespan 20 with carmustine implant (GLIADEL® Wafer)|
41101423|NCT00076986|PROCEDURE|surgery and wafer placement (1 procedure)|
41101424|NCT00782639|DRUG|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
41101425|NCT00782639|DRUG|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
41101426|NCT05293301|DEVICE|Use of Periodontal Endoscope (Perioscopy®) to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using a Periodontal Endoscope or Perioscopy® for enhanced visualization, on teeth in one half of the mouth
41101427|NCT05293301|DEVICE|Use of traditional loupes to enhance magnification to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using tradional loupes for enhanced visualization on teeth, in the other half of the mouth
41101428|NCT04731610|OTHER|Radiotherapy|postoperative radiotherapy after complete resection of thymoma
41101429|NCT04731610|OTHER|Surveillance after resection|Surveillance after tumour resection
41101430|NCT04806919|DRUG|Progesteron TID|increasing the dose
41101431|NCT06492889|DRUG|Levonorgestrel|Participants in the levonorgestrel plus mifepristone group will receive one tablet of 1.5 mg levonorgestrel
41101432|NCT06492889|DRUG|Mifepristone|Participants in both groups will receive one tablet of 200 mg mifepristone
41101433|NCT04439513|DEVICE|Hemostasis|Compression device to achieve hemostasis.
40925116|NCT03997227|PROCEDURE|Erector spinae Block|After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
41101434|NCT06022536|DRUG|SSS40|Subjects injected with SSS40
41101435|NCT06022536|DRUG|Placebo|Subjects injected with Placebo
41101436|NCT01191788|BEHAVIORAL|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
41101437|NCT01191788|BEHAVIORAL|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
41101438|NCT06305988|DEVICE|Transcranial direct current stimulation|The anode patch is placed in Fz, and the cathode patch is placed on right cheek, powered by direct current with a current of 1.5mA. Subjects in the placebo comparator group will receive sham tDCS for 1 week, which mimics the tDCS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs. The anode patch is placed at Fz, and the cathode patch is positioned on the right cheek, to maintain the blinding of the intervention.
40925117|NCT00854412|OTHER|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
41101439|NCT00589212|DEVICE|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
41101440|NCT04885595|PROCEDURE|Forceps biopsy and cryobiopsy|Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.
41443409|NCT04543357|OTHER|Blood Draw|Blood Samples for NAb and ADA to AAV9
40925118|NCT01931215|OTHER|spinal anesthesia with intrathecal morphine|in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
40925119|NCT01931215|OTHER|TAP-block with ropivacaine and clonidine|
40925120|NCT06074731|DIAGNOSTIC_TEST|SS-OCT system Plex Elite 9000|We will use a commercially available SS-OCT system (Plex Elite 9000; Carl Zeiss Meditec).
40925121|NCT04136444|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
40925122|NCT05273502|BEHAVIORAL|Citizen Science intervention|Intervention generated by a participatory research process (co-creation) in the elderly population living in rural areas to co-create solutions to improve their lifestyles, quality of life and health.
40925123|NCT03657771|OTHER|DED|DED: Diet eliminating dairy
41101441|NCT05742984|DRUG|Linaprazan Glurate 25 mg|The participating subjects will receive 25 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.
41101442|NCT05742984|DRUG|Linaprazan Glurate 50 mg|The participating subjects will receive 50 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.
41101443|NCT05742984|DRUG|Linaprazan Glurate 75 mg|The participating subjects will receive 75 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.
41101444|NCT05115890|OTHER|Exercise training|Patients with HFpEF will undergo 8 weeks of exercise training.
41101445|NCT05604274|OTHER|App to monitor stool consistency and symptoms|App to monitor stool consistency and symptoms
41101446|NCT02453724|DEVICE|Observation for safety|The investigators will perform the routine lung exam used in emergency department evaluations for shortness of breath in patients scheduled for computed tomography. The investigators will observe if there are any parenchymal changes noted on the chest tomography scan.
41101447|NCT06628375|OTHER|Consultation visit (Visit 1)|"During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the diagnosis of hypospadias, as a part of routine care. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty and then, another sample in a 5 ml EDTA tube will be taken for DNA collection."
41101448|NCT06628375|OTHER|Consultation visit (Visit 1)|"During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the absence of hypospadias. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty."
41101449|NCT03817736|PROCEDURE|TACE|Procedure of TACE will be standardized.
41101450|NCT03817736|RADIATION|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
41101451|NCT03817736|DRUG|Immune Checkpoint Inhibitor|An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons.
41101452|NCT05386758|DRUG|Molnupiravir|Four 200 mg capsules administered orally as a single dose
41101453|NCT01025583|DIETARY_SUPPLEMENT|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
41101454|NCT01025583|DIETARY_SUPPLEMENT|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
41101455|NCT05407519|DRUG|Tislelizumab + Sitravatinib|Drug: Tislelizumab Tislelizumab 200mg IV q3w Other Names: BGB-A317, Immunotherapy, Anti-PD-1 antibody Drug: Sitravatinib Sitravatinib 100mg PO qd Other Name: tyrosine kinase inhibitor, TKI
41101456|NCT05674617|BEHAVIORAL|Written Exposure Therapy|WET will be conducted in accordance with the Written Exposure Therapy for PTSD: A Brief Treatment Approach for Mental Health Professionals Manual and the VA evidence-based practice (EBP) rollout training.
41101457|NCT05674617|BEHAVIORAL|PTSD Education|"The 5-session PTSD psychoeducation and skills protocol we will be utilizing for our PTSD education control condition was developed by PTSD clinical team (PCT) clinicians at the Washington DC VA Medical Center as a group protocol for Veterans admitted to the PCT and who were on the waitlist for individual therapy with an EBP for PTSD. The PTSD 101 protocol consists of psychoeducation on topics related to PTSD symptoms and an introduction to PTSD-related coping skills. Its duration and structure will be similar to WET (5 weekly individual 50-minute sessions). To parallel the time an attention given in individual WET sessions more closely, participants will quietly review any written materials or videos that are a part of the manualized curriculum for 30 minutes of the session, bookended by a 10-minute check-in with their provider on symptoms and introduction to new materials at the start of session and another 10-minute debrief of reviewed materials at the end of session."
41443410|NCT01902394|OTHER|Whole grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
41443411|NCT01902394|OTHER|Refined grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
41443412|NCT01020474|DRUG|placebo|matching placebo capsules twice daily.
40925124|NCT03657771|OTHER|FREE|FREE: Diet eliminating dairy and food additives
40925125|NCT00335270|DRUG|fos-amprenavir calcium, ritonavir|
41101458|NCT00669461|DRUG|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
41101459|NCT05495646|PROCEDURE|Central catheter insertion|The data will be obtained through the review of the medical records and the clinical follow-up of each patient to evaluate the technique of inserting the device, the possible risk factors of catheter-related infection, its clinical manifestations and the data microbiological.
41101460|NCT06184451|OTHER|Therapeutic exercise|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
41101461|NCT06184451|DEVICE|Transcutaneous electrical nerve stimulation|"TENS will be applied with a portable device, Neurodyn Portable System from Ibramed, while carrying out the entire therapeutic exercise program. The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. The application time will be proportional to the time of the exercise session, approximately 60 minutes. The researcher will evaluate the need to adjust the current intensity through the pulse amplitude regularly so that the stimulus does not accommodate."
41101462|NCT06184451|DEVICE|Placebo transcutaneous electrical nerve stimulation|"The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this."
41443413|NCT01020474|DRUG|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
41443414|NCT00161850|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
41443415|NCT02225405|DRUG|Cisplatin|Given IV
41443416|NCT02225405|DRUG|Docetaxel|Given IV
40925126|NCT00335270|DRUG|abacavir/lamivudine as Epzicom|
40925127|NCT05594615|DRUG|EDP-235|Subjects will receive EDP-235 once daily on Days 5-15
40925128|NCT05594615|DRUG|Midazolam|Subjects will receive midazolam once daily on Days 1 and 12
40925129|NCT05594615|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Days 2 and 13
40925130|NCT05594615|DRUG|Caffeine|Subjects will receive caffeine once daily on Days 1 and 12
40925131|NCT06437431|DRUG|glenzocimab|Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total dose of 1g of glenzocimab as an IV infusion over 6 hours, with 1/4 of the dose administered by a 15-minutes bolus and 3/4 of the dose administered by 5h45minutes continuous infusion.
40925132|NCT06437431|DRUG|placebo|Placebo of glenzocimab is 0.9% NaCl for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo should be administered concomitantly for eligible patients. The administration scheme will be the same as in the experimental arm.
40925133|NCT04772638|BEHAVIORAL|PLAY|This intervention focuses on promoting physical activity in preschoolers and the adults (parents and teachers) in their lives. It consists of 1) Teacher training 2) Activity trackers for children, teachers and parents and 3) text messaging with content and individualized goal setting.
40925134|NCT04772638|OTHER|Wait list control|not an active intervention
40925135|NCT06240364|DIETARY_SUPPLEMENT|Saffron extract (Crocus sativus)|Daily intake of one tablet for 84 days.
40925136|NCT06240364|DIETARY_SUPPLEMENT|Placebo|Daily intake of one tablet for 84 days.
40925137|NCT04276727|DRUG|MINT study IMP|Application of gel for 6 weeks.
40925138|NCT06436664|OTHER|Tooth brushing|Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.
40925139|NCT00973297|OTHER|Multidisciplinary falls prevention|Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
40925140|NCT04418401|DRUG|Donafenib and anti-PD-1 antibody|Donafenib was taken orally twice daily, and anti-PD-1 antibody was applied biweekly.
40925141|NCT02635932|DEVICE|Day Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
40925142|NCT02635932|DEVICE|Night Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
40925143|NCT00672204|BIOLOGICAL|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
41101463|NCT06103734|COMBINATION_PRODUCT|Zavegepant 10 mg|4 doses of zavegpant 10 mg intranasal spray device
41443417|NCT02225405|OTHER|Laboratory Biomarker Analysis|Correlative studies
41443418|NCT02225405|DRUG|Nintedanib|Given PO
41443419|NCT01901263|BEHAVIORAL|patients with alzheimer's disease|the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
41101464|NCT06103734|COMBINATION_PRODUCT|Placebo - Control 1|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
41101465|NCT06103734|COMBINATION_PRODUCT|Placebo - Control 2|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
41101466|NCT05241795|OTHER|Knee then Ankle rehabilitation protocol|"Patients will start with knee exercise program that includes~* Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~* Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~* Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~* Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction.~Then, Patients will start ankle exercises program that includes:~* Standing calf raises~* Foot lift~* Ankle eversion exercises~* Ankle Plantarflexion exercises"
41101467|NCT05241795|OTHER|Ankle then Knee rehabilitation protocol|"Patients will start ankle exercises program that includes:~* Standing calf raises~* Foot lift~* Ankle eversion exercises~* Ankle Plantarflexion exercises~Then, Patients will start with knee exercise program that includes~* Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~* Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~* Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~* Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction."
41101468|NCT00555867|DRUG|Anastrozole|oral
41101469|NCT03677206|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
41101470|NCT03677206|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.
41101471|NCT00198172|DRUG|Cisplatin plus Epirubicin|
41101472|NCT00062062|DRUG|carboplatin|
41101473|NCT00062062|DRUG|gefitinib|
41101474|NCT00062062|DRUG|paclitaxel|
40925144|NCT00672204|DRUG|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
40925145|NCT00672204|DRUG|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
40925146|NCT00672204|DRUG|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
40925147|NCT00724321|DRUG|iloprost|A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
40925148|NCT02923921|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus FOLFOX
40925149|NCT02923921|DRUG|FOLFOX|FOLFOX Alone
40925150|NCT04434170|DRUG|Sacubitril-Valsartan|outpatients who start treatment with sacubitril/valsartan according to guidelines will andergo cardiopulmonary exercise testing evaluation
40925151|NCT02644681|PROCEDURE|Aortic Aneurysm, Thoracic surgery|
40925152|NCT03746288|DRUG|CAN008|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
40925153|NCT05950243|BEHAVIORAL|Questionnaire|Questionnaire survey for data collection
40925154|NCT00545285|PROCEDURE|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
40925155|NCT00205907|BIOLOGICAL|BLVR Hydrogel|10 mL BLVR Hydrogel
40925156|NCT04090775|DRUG|Opdivo Injectable Product|"Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected."
40925157|NCT04090775|DRUG|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected."
40925158|NCT04090775|DRUG|Cytoxan|"Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again."
40925159|NCT04090775|PROCEDURE|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
40925160|NCT02896322|RADIATION|Partial breast irradiation with cyberknife|
40925161|NCT02728973|OTHER|ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
40925162|NCT01086839|DRUG|sodium chloride 6%|"* one ampoule sodium chloride 6% per day~* inhalation use~* for 28 days"
40925163|NCT01086839|DRUG|sodium chloride 0,9%|"* one ampoule sodium chloride 0,9% per day~* inhalation use~* for 28 days"
40925164|NCT00002167|DRUG|Tin ethyl etiopurpurin|
40925165|NCT03127982|BEHAVIORAL|Unified Protocol|The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
40925166|NCT04057989|DRUG|ketamine|
40925167|NCT05120921|OTHER|Osteopathic Manual Treatment|includes touch, joint manipulations, stretching and massage
40925168|NCT05120921|OTHER|Self-management|Providing rehabilitative exercises to patients to do at home
40925169|NCT05120921|OTHER|Reassurance|Reassuring patients on their symptoms, diagnosis and prognosis.
40925170|NCT05120921|OTHER|Biopsychosocial management|Giving a central place to the patient in the decision-making to help them to get back to valued activities.
40925171|NCT03874260|DRUG|Fenofibrate|statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
40925172|NCT00146159|DRUG|Mitoxantrone|dosage
41101475|NCT02304822|DRUG|Multiple-dose of Ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
41101476|NCT02304822|DRUG|Single-dose of Ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.
41101477|NCT02304822|DRUG|Zero-dose of Ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
41101478|NCT06351280|OTHER|Standardised Physiotherapy Plan|"Single session of coached deep breathing and coughing exercises. 10 supervised slow flow deep breaths to total lung capacity with a 3-5 second end inspiratory hold completed with 2 end inspiratory sniffs. 2-3 supported coughs or huffs. Repeated for another set. Patients instructed to perform independently hourly. Assisted ambulation according to the following protocol:~* Stage 1 of 2 minutes.~* Stage 2 of 0-1 minute.~* Stage 3 of 1 - 3 minutes.~* Stage 4 of 3 - 6 minutes.~* Stage 5 of 6 - 10 minutes.~* Stage 6 of 10 - 15 minutes.~* Stage 7 \> 15 minutes. Total session time is the accumulative work time."
41101479|NCT00637676|PROCEDURE|VATS, Talc-Pleurodesis, tunneled pleural drainage|poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
41101480|NCT00637676|PROCEDURE|VATS, Talc-pleurodesis|poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
41101481|NCT06426303|DRUG|Naltrexone|12-week randomized double blinded placebo-controlled drug trial titrating drug/placebo dose after 1 week.
41101482|NCT00727584|RADIATION|radiation therapy|Patients undergo external beam radiotherapy
41101483|NCT06092931|DRUG|DC-806|Oral tablets
41101484|NCT06092931|DRUG|Midazolam|Oral syrup
40925173|NCT04391985|DRUG|SOF plus (OBV/PTV/r) plus RBV|They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.
40925174|NCT06361342|BEHAVIORAL|General decrease in smartphone use|Subjects will decrease their time on smartphone in general.
40925175|NCT06361342|BEHAVIORAL|Avoiding Social Media Apps|Subjects will avoid use of social media apps on the smartphone which includes Twitter, Facebook, Tik Tok, Instagram, and Pinterest.
40925176|NCT00923949|DRUG|Pioglitazone|45 mg tablet daily by mouth for six weeks
40925177|NCT04954248|DIAGNOSTIC_TEST|Injected radiotracer with PET Insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
40925178|NCT00222131|DRUG|Esomeprazole|Esomeprazole 40 mg QD
40925179|NCT00222131|OTHER|Placebo|Placebo
40925180|NCT02753088|DRUG|BCD-063|
40925181|NCT02753088|DRUG|Copaxone-Teva|
40925182|NCT02753088|DRUG|Placebo|
40925183|NCT02336126|BEHAVIORAL|Biopsychological intervention|
40925184|NCT06235255|BEHAVIORAL|Guided Imagery|The participant will complete the Guided Imagery Intervention for 21 consecutive days.
40925185|NCT06235255|BEHAVIORAL|Cognitive Power Intervention|The investigator with the subject uses the power profile generated by the PKPCT to generate goals that will positively affect functional health.
40925186|NCT06235255|BEHAVIORAL|Combined Guided Imagery and Cognitive Power Intervention|This intervention is a combination of the Guided Imagery Intervention in tandem with the Cognitive Power Intervention
41101485|NCT06092931|DRUG|Repaglinide|Oral tablets
41101486|NCT06092931|DRUG|Digoxin|Oral tablets
41101487|NCT06092931|DRUG|Rosuvastatin|Oral tablets
41443420|NCT03827707|BEHAVIORAL|Noise|Noise applied via headphones during 60 min after meal ingestion
40925187|NCT03712423|DRUG|Cripec Docetaxel|89 Zirconium Cripec Docetaxel PET
40925188|NCT03613272|PROCEDURE|Subxiphoid approach extended thymectomy by VATS|Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum
40925189|NCT03613272|PROCEDURE|Intercostal approach extended thymectomy by VATS|Extended thymectomy performed through the traditional intercostal VATS approach
40925190|NCT01465685|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
40925191|NCT01465685|DRUG|Methylphenidate|1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
40925192|NCT01465685|DRUG|Placebo|capsules identical to MDMA or methylphenidate
40925193|NCT06309550|DIAGNOSTIC_TEST|exercise test|exercise test
40925194|NCT01984762|PROCEDURE|Roux-en-Y gastric bypass|RYGBP=Roux-en-Y gastric bypass
40925195|NCT01984762|PROCEDURE|sleeve gastrectomy|SG = sleeve gastrectomy
40925196|NCT00886652|OTHER|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
40925197|NCT00811213|DEVICE|SleepStyle 200 Auto Series with SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
40925198|NCT00811213|DEVICE|SleepStyle 200 Auto Series with out SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
40925199|NCT05484687|DRUG|Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation|Administer 1.5 mg/kg lidocaine
41101488|NCT03704311|PROCEDURE|Muscle biopsy|Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).
41101489|NCT04272073|OTHER|High-Protein Mediterranean Diet|As in arm/group descriptions
41101490|NCT04272073|OTHER|Resistance Exercise|As in arm/group descriptions
41101491|NCT04272073|OTHER|Standard Dietary Advice|As in arm/group descriptions
41101492|NCT04272073|OTHER|Standard Cardiac Rehabilitation Exercise|As in arm/group descriptions
41101493|NCT02186405|DRUG|LEVOTHYROXINE|administration of levothyroxine
41443421|NCT03827707|BEHAVIORAL|Silence|Headphones without sound applied during 60 min after meal ingestion
41101494|NCT00946114|DRUG|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
41101495|NCT00946114|DRUG|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
41101496|NCT03012919|OTHER|active decision support system|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
41101497|NCT04621682|OTHER|Non technical skills and checklist training in simulation|using structured debrifing, in three random medical simulation crises, training in non-technical skills will be carried out
41101498|NCT04621682|OTHER|Checklist training simulation|using structured debrifing, in three random medical simulation crises, training in checklist will be carried out
41101499|NCT05523258|BEHAVIORAL|Computerized cognition training|The researchers distribute tablet computers for the patients. The patients in this group receive cognitive function training under the guidance of a full-time cognitive function trainer. The training time is about 45-60 minutes every time, and the frequency is twice a day until the operation. After the operation, cognitive function training should be started as soon as possible when the patient meets the following conditions including Glasgow score ≥ 12, no mechanical ventilation and no sedative drugs. The training intensity is the same as that before operation, generally starting from the 2nd to 3rd day after operation and continuing to discharge or the 7th day after operation.
41101500|NCT05523258|BEHAVIORAL|Basic training based on tablet computer|The researchers distribute the same tablet computer to the patients. The patients in this group receive basic training under the guidance of a full-time cognitive function trainer. The training duration is the same as that of the test group.
41101501|NCT02742142|OTHER|water as placebo|topical application of water as a placebo in the control arm
41101502|NCT02742142|DRUG|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
41101503|NCT04582357|BEHAVIORAL|Physical activity program|The physical activity program is a suite of several exercises which intend to improve muscular mass of targeted muscles.
41101504|NCT06027112|OTHER|musculoskeletal injuries|This research will be conducted to identify the factors that increase the risk of musculoskeletal injuries in university students,
41443422|NCT03577938|DRUG|Chinese herbal medicine|One dosage of CHM includes Artemisiacapillaris Thunb (30g), Salvia miltiorrhiza Bge (30g), Rhizoma Atractylodis Macroce- phalae (30g), Rubia cordifolia L (30g), Sieyesbeckiaorientalis L (30g). Paeoniae Radix Rubra (60g), Gardenia jasminoides Ellis (9g), Hedyotis diffusa Willd (30g) and Bletilla striata (15g) are involved for excess syndrome, and Astragalus membranaceus (30g), Radix Pseudostellariae (15g), Radix Aconiti Lateralis Praeparata (10g), Galli Gigeriae Endothelium Corneum (20g), Polygonum cuspidatum Sieb.et Zucc (15g) are involved for deficiency syndrome.
41443423|NCT03577938|OTHER|Control (blank)|SMT therapy includes a high-calorie diet; nucleoside analogues for HBV DNA-positive patients; sodium restriction, diuretics and paracentesis combined with albumin infusion for ascites; lactulose and L-ornithine aspartate and lactulose for HE and hyper-ammonia; hemostatic treatment for gastrointestinal hemorrhage; antibiotics for infections and renal replacement for HRS and uremic symptoms.
41443424|NCT00881751|BIOLOGICAL|bevacizumab|Given IV
41101505|NCT01545674|PROCEDURE|Blood Draw|Blood will be drawn from the mother and father
41101506|NCT05929911|BEHAVIORAL|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in the ability to reflect and affective regulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
41101507|NCT05090384|DRUG|Prednisone|Prednisone starting dose of 0.5 mg/kg; for patients who respond clinically and continue to have low biomarkers will be tapered rapidly; those that are not clinically responding or whose biomarkers increase will be treated per their treating physicians plan or by standard of care
41101508|NCT04455009|DIETARY_SUPPLEMENT|Fitness Drink Formula|Single drink provided following baseline assessments
41101509|NCT04075357|OTHER|Amniotic membrane transplantation|Amniotic membrane was located over median nerve during surgery of CTS, prior of closing.
40925200|NCT03209674|PROCEDURE|Cardiothoracic surgery|Cardiac or thoracic procedure
40925201|NCT04518995|DRUG|CTP-543 matching placebo|Administered as tablets.
40925202|NCT04518995|DRUG|CTP-543|Administered as tablets.
41101510|NCT02648425|DRUG|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
41101511|NCT02648425|DRUG|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
41443425|NCT00881751|DRUG|erlotinib hydrochloride|Given orally
41443426|NCT00881751|DRUG|sorafenib tosylate|Given orally
41443427|NCT06374134|BEHAVIORAL|Community Engagement Practice|Community engagement includes pre- and post-approval clinical trials that partnered and engaged with diverse public and patient communities; trusted community leaders; local advocacy groups; faith-based and civic organizations; community influencers; community health and government health communities.
41101512|NCT02648425|DRUG|cisplatin + 5-fluorouracil (or+ Leucovorin)|"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."
41101513|NCT04238234|DEVICE|IVC Ultrasonography|Ultrasound measurements will be performed using a curved transducer set to abdominal mode (1-5 MHz; Acuson x300; Siemens Healthcare, Seoul, Korea). IVC variation will be assessed using ultrasound in the long-axis (sagittal) view. IVC diameter will be measured 1 cm distal to its junction with hepatic vein either by 2-D or M modes via a subcostal approach according to the methodology described by the American Society of Echocardiography . A two-dimensional image of the IVC as it enters the right atrium will be first obtained.
41101514|NCT04238234|DEVICE|Plethysmographic variability index (PVI) and perfusion index readings (PI)|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA).~PVI (%) is a measure of the dynamic change in PI that occurs during one or more complete respiratory cycles, calculated as:~PVI= \[(PImax-PImin)/PImax\] x100"
41101515|NCT00633412|DRUG|Esomeprazole|20mg oral daily
41101516|NCT00633412|DRUG|Ranitidine|150mg oral twice daily
41101517|NCT00633412|DRUG|Esomeprazole|40mg oral tablet daily
41101518|NCT02794948|OTHER|Chinese medicine granules (HuYang Yang Kun Formula)|Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province
41101519|NCT02794948|DIETARY_SUPPLEMENT|dehydroepiandrosterone|The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province.
41101520|NCT01585038|DRUG|Efavirenz|600mg orally every evening
41101521|NCT01585038|DRUG|Rilpivirine|25mg orally once daily
41101522|NCT04133974|BEHAVIORAL|methadone induced memory retrieval-extinction procedure|Drug memory is not invariably stable and can be induced transiently labile again by drug-related cues or drug itself, which is termed as 'reconsolidation'. Previously we and other groups have demonstrated that extinction coincided with reconsolidation weakened the drug memory and decreased drug craving and relapse. In the present study, we tried to interfere the methadone-induced heroin addiction memory reconsolidation by extinction given at different times following methadone administration.
41101523|NCT03603418|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone is a synthetic glucocorticoid that is commonly used in human medical practice as potent anti-inflammatory, immunosuppressive and analgesic agent.
41101524|NCT03603418|OTHER|Distilled water|Distilled water
41101525|NCT04402320|DRUG|Midazolam|reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use
41101526|NCT04402320|DEVICE|ventilator|reconnected to mechanical ventilation before extubation for one hour with sedation
41101527|NCT01985399|BEHAVIORAL|Neuropsychological testing|Neuropsychological testing
41101528|NCT04194502|DIAGNOSTIC_TEST|Transesophageal echocardiogram (TEE)|All patients enrolled in the study will undergo a pre-operative research TEE and an intra-operative clinical TEE.
41101529|NCT00002937|DRUG|paclitaxel|
41101530|NCT00002937|DRUG|valspodar|
41101531|NCT06555471|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1
41101532|NCT06555471|DRUG|S-1|po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；\>1.8m2 60mg/time)
41101533|NCT06555471|DRUG|Capecitabine|1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.
41101534|NCT06555471|RADIATION|Extraperitoneal radiation therapy|once a day, five times a week, at a dose of 1.8-2 Gy/f, for a total of 45-50.4 Gy. Radiation therapy starts from the first cycle of Sintilimab Injection combined with chemotherapy
41101535|NCT06219603|OTHER|survey|questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases
41101536|NCT03921684|DRUG|Capecitabine|Capecitabine 825 mg/m2 orally twice-daily, 5 days a week for a total of 28 days, given with radiation therapy
41101537|NCT03921684|RADIATION|Radiation therapy|1.8 Gy/day, 5 days a week for a total of 28 days, given with Capecitabine
41101538|NCT03921684|DRUG|mFOLFOX6|oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab
41101539|NCT03921684|DRUG|Nivolumab|Nivolumab 240mg IV, day 1 of each treatment cycle, every two weeks, given with mFOLFOX6
41101540|NCT02997618|BEHAVIORAL|Community based exercise programme|20 week community (home or gym based) exercise programme
41101541|NCT02997618|OTHER|Control|Usual care consisting of advice.
41443428|NCT06374134|BEHAVIORAL|Patient-Centric Protocol Element|Patient-centric clinical trial designs include those that solicited patient, investigative site and community input into protocol design and clinical trial feasibility; offered solutions that improved patient participation convenience and access; and that more fully and effectively communicated clinical trial knowledge to diverse public and patient communities, health care providers and community influencers.
40925203|NCT04518995|DRUG|CTP-543|Administered as tablets.
41443429|NCT04534790|RADIATION|Low Dose Radiotherapy|anti-inflammatory effect with low-dose radiation to the lungs
41443430|NCT04468126|OTHER|Standard oxygen|Standard low flow oxygen therapy through facemask or non-rebreathing mask at least 10 L/min.
40925204|NCT01403948|DRUG|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
41101542|NCT05616559|COMBINATION_PRODUCT|Treatment Package for First-Episode Depression|The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
41101543|NCT04147416|DRUG|HSK3486 0.1-0.2 /0.3 mg / kg group|Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
41101544|NCT04147416|DRUG|Propofol 0.5-1.0/1.5 mg/kg group|Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
41101545|NCT04092985|DEVICE|iECG recording|iECG tracings will be recorded simultaneously, starting and ending at the same time as the standard 12-lead ECG, using the built-in sensors of a smart watch (Apple Watch Series 4) with the ECG application
41101546|NCT06352294|OTHER|Core stability training|Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult
41101547|NCT06352294|OTHER|Core stability training and myofascial relase|Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult. In addition, myofascial relaxation will be applied with roller bar along the superficial back line.
41101548|NCT03691961|OTHER|Hair sampling|After 4 months of treatment, a strand of hair from the vertex posterior region of the scalp about the width of a thin pencil and with a length equal to or greater than 3 cm will be cut.
41101549|NCT03691961|DIAGNOSTIC_TEST|Hair's drug concentrations|The hair's concentrations of budesonide/formoterol is analysed with mass spectrometry.
41101550|NCT06047262|DRUG|Dapansutrile|Patients receive investigational product.
41101551|NCT06047262|DRUG|Placebo|Patients receive placebo.
41101552|NCT05586204|BEHAVIORAL|Eligibility reminder|Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
41101553|NCT05586204|BEHAVIORAL|Link to a narrow set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
41101554|NCT05586204|BEHAVIORAL|Link to a broad set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find a wide set of local pharmacies that carry the bivalent booster).
41101555|NCT05586204|BEHAVIORAL|Doctors' recommendation and value of vaccine|The reminder will contain information about the value of the bivalent booster and doctors' recommendation to get it
41101556|NCT06629909|DRUG|Secretome|3 ml Injection of secretome for 8 times two weeks apart
41101557|NCT05826834|DEVICE|ball-rolling (Myostorm ball)|the intervention group
40925205|NCT05015413|DEVICE|Shockwave|Shock wave master 500 Germany
41101558|NCT01376141|DRUG|Sumatriptan|
41101559|NCT05450029|DRUG|Sintilimab|6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
41101560|NCT02167243|BEHAVIORAL|Reinforcement for BG testing|Subjects will receive reinforcement for BG tests. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
41101561|NCT02167243|OTHER|Standard of care|Subjects receive standard of care
41101562|NCT06096428|DEVICE|Pulsed-field ablation|Pulsed-field ablation will be done using pentaspline catheter (Farawave, Boston Scientific) and pulsed-field energy generator. The goal will be achieve of electrical isolation of pulmonary veins.
41101563|NCT06096428|DEVICE|Radiofrequency ablation|Pulmonary vein isolation will be done using radiofrequency catheter (Qdot, Biosense-Webster) and generator of radiofrequency energy (nGEN, Biosense-Webster).
41101564|NCT01861678|PROCEDURE|High tie of IMA|Conventional technique
41101565|NCT01861678|PROCEDURE|Low tie of IMA|Technique for preserving left colic arterial perfusion
41101566|NCT06343584|OTHER|Study will conducted over a six-month period using a quasi-experimental Pre-test/Post-test design using Stamm's (2009) ProQOL Scale.|Group 1 will receive a list of suggested tools used to decrease the amount of smartphone interruptions after business hours (Appendix B) and Group 2 will receive a work-issued smartphone with instructions for use (Appendix C). Both groups will use a pre-post test format designed to compare the outcomes between the two groups. Post-study analysis will compare pre- and post-tests within each group and will compare Group 1 and Group 2 post-intervention outcomes.
41101567|NCT02165059|PROCEDURE|Surgical Full Thickness Biopsy|Eligible subjects will undergo a surgical full thickness biopsy of the stomach and/or proximal jejunum as part of their planned surgery.
41101568|NCT05043987|DRUG|CPO102|Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
41101569|NCT02118935|OTHER|Previously marketed cow's mlik-based infant formula|
41101570|NCT02118935|OTHER|Marketed cow's milk-based infant formula with prebiotics|
41101571|NCT06609356|PROCEDURE|Study Visit 1|Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. The study will randomize participants to first receive a five-hour intravenous insulin infusion to achieve normal plasma insulin concentrations (Eu-Ins) or higher plasma insulin concentrations (Hi-Ins)
40925206|NCT03255070|DRUG|ARX788|An antibody drug conjugate
41101572|NCT06609356|DRUG|Placebo|"* T1DM participants in the Hi-Ins study will receive an oral placebo. During the Eu-Ins study they will receive an SGLT2i.~* CGK-MODY participants and healthy volunteers will receive placebo in both studies."
41101573|NCT06609356|PROCEDURE|Study Visit 2|Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. Insulin levels infused during the five-hour insulin infusion will be opposite of the first visit.
41101574|NCT06609356|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|Concurrent with starting the five-hour infusion, T1DM participants in the Eu-Ins study will receive an SGLT2i dose (empagliflozin 25 mg).
41101575|NCT02458534|OTHER|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
41101576|NCT02458534|OTHER|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
41101577|NCT02458534|OTHER|macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
41101578|NCT00261547|DRUG|Rituximab|All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
41101579|NCT06328946|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
41101580|NCT06328946|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
41101581|NCT06328946|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
41101582|NCT01234532|DRUG|entinostat|orally
41101583|NCT01234532|DRUG|anastrozole|Given PO
41101584|NCT01234532|OTHER|diagnostic laboratory biomarker analysis|"Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
41101585|NCT01234532|PROCEDURE|therapeutic conventional surgery|Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
41101586|NCT06113939|DEVICE|airway clearance|mechanical suctioning of airway secretions
41101587|NCT05406180|BIOLOGICAL|VaxigripTetra inj.|Suspension for injection in a pre-filled syringe Injection intramuscular
41101588|NCT02799212|DRUG|somatostatin infusion|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.
41101589|NCT02799212|DRUG|placebo infusion|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
41101590|NCT04002128|OTHER|Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.|Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
41101591|NCT01909232|DEVICE|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
41101592|NCT01909232|DEVICE|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
41101593|NCT05829317|DRUG|Magnesium sulfate|Intravenous Magnesium sulfate
41101594|NCT05829317|DRUG|Placebo|0.9% NaCl
41101595|NCT04637750|BEHAVIORAL|Educational intervention|The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e. gradual step down administration to avoid paradoxical effect).
41101596|NCT03706963|OTHER|Phone Call|-phone call 7 days (+/- 2 days) into preoperative period
41101597|NCT01249300|OTHER|No intervention|No intervention
41101598|NCT05092906|OTHER|LP with complementary hypnoanalgesia|The lumbar puncture technique will be identical to that of the group standard of care. Hypnosis will be performed by a health professional trained in this practice, in addition to the standard analgesic management.
41101599|NCT05092906|OTHER|LP with standard of care|"The LP will be carried out according to the usual techniques without hypnosis.~Standard analgesic treatments will be used (except contraindications):~* EMLA (Lidocain+Prilocain) Cream/Patch~* Local anesthesia with lidocain chlorhydrate monohydrate 1% injectable~* Nitrous oxide"
41101600|NCT03034915|DRUG|UMEC/VI 62.5/25 mcg via ELLIPTA|ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
41101601|NCT03034915|DRUG|UMEC 62.5 mcg via ELLIPTA|The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
41101602|NCT03034915|DRUG|Salmeterol 50 mcg via DISKUS|The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
41101603|NCT03034915|DRUG|Placebo via ELLIPTA|Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
41101604|NCT03034915|DRUG|Placebo via DISKUS|Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
41101605|NCT01913340|DRUG|Erythropoietin|1000 U/kg/dose IV x 5 doses
41101606|NCT01913340|DRUG|Normal saline|placebo: NS IV x 5 doses
41101607|NCT01266044|PROCEDURE|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
41101608|NCT01266044|PROCEDURE|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
41101609|NCT01266044|OTHER|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
41101610|NCT01266044|OTHER|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
41101611|NCT01729819|DRUG|Tolterodine tartrate extended release capsules|
41101612|NCT01729819|DRUG|Desmopressin orally disintegrating tablets|
41101613|NCT01729819|DRUG|Placebo orally disintegrating tablets|
41101614|NCT03809299|OTHER|Ad libitum meal timing|Research participants will eat meals provided by the study throughout the day, ad libitum
41101615|NCT03809299|OTHER|Twice a day meals|Research participants will eat meals provided by the study at two intervals during the day, and fast in between.
41101616|NCT00845611|BIOLOGICAL|peptide vaccine|peptides emulsified with Montanide ISA51
41101617|NCT00470743|DRUG|Ibuprofen|
41101618|NCT00470743|DRUG|Indomethacin|
41443431|NCT04468126|OTHER|High-flow nasal oxygen therapy|Humidified and heated oxygen with a gas flow at least 50 l/min through nasal cannula and inspired fraction of oxygen adjusted in order to maintain a SpO2 between 92 and 96%
41443432|NCT04167267|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
41443433|NCT04167267|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
41443434|NCT06127667|BEHAVIORAL|aerobic exercise|use of single bout of aerobic exercise
41443435|NCT04999501|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
41443436|NCT00681798|DRUG|Vandetanib|100mg/300mg
41443437|NCT02070783|DRUG|ARA290|
41443438|NCT02070783|DRUG|Placebo|
41101619|NCT05599399|DIETARY_SUPPLEMENT|Gum acacia|25 grams of gum acacia powder is administered on daily-basis
41101620|NCT01447914|DRUG|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
41101621|NCT01447914|OTHER|Diagnostic laboratory biomarker analysis|Correlative studies
41101622|NCT01447914|OTHER|Questionnaire administration|Ancillary studies
41101623|NCT01447914|PROCEDURE|Quality-of-life assessment|Ancillary studies
41101624|NCT03645850|DEVICE|Vismed gel Multi 0.3% eye drops|Ophthalmic use. Vismed gel Multi 0.3% eye drops. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
41101625|NCT03645850|DEVICE|Vismed Multi 0.18% eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
41101626|NCT02396979|DRUG|Methadone|
41101627|NCT02396979|BEHAVIORAL|Holistic Health Recovery Program|
41101628|NCT05218408|BIOLOGICAL|CYNK-001 systemic and Intra cavity administration|"Phase 1 Lymphodepletion Days -5,-4 and -3 Cyclophosphamide 900 mg/m2, Fludarabine 30 mg/m2 and Mesna per SOC~IL 2 at 6M IU subcutaneous administration:~For IV cycle ( cycle1) rhIL2 will be administered on Days 1,3,5,8,9,11 and 15 . On days 1, 8 and 15 rhIL-2 will be administered 1 to 3 hours prior to CYNK-001 infusions For IC cycles rhIL2 will be administered 1 to 3 hours prior to each CYNK-001 IC dose.~CYNK-001 : for IV at 2.4 x10\^9 or 3.6 x10\^9 cells Days 1,8 and 15~Tumor resection will take place 7 to 14 day follow by first IC cycle ( Cycle 2) at 100 Million cells or 200 Million cells~IC cycles 3,4,5 once a week for three weeks , 28 days cycle at100 Million cells or 200 Million cells only for Phase 1 cohort 4 and Phase 2a"
41443439|NCT01531894|DRUG|GSK2110183 (afuresertib)|Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.
41443440|NCT01671696|OTHER|Cardiac MRI|Cardiac MRI
41443441|NCT01910753|PROCEDURE|APA|A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
41443442|NCT05191550|BEHAVIORAL|Virtual reality brain tumor simulation|"Task: Complete removal of a simulated tumour - distinguishable by colour and haptic properties - with minimal bleeding and damage to surrounding healthy brain using two surgical instruments (Cavitron Ultrasonic Aspirator and Bipolar pincers) of the NeuroVR (CAE Healthcare) surgical simulator.~Intervention: A single 28-minute simulation session, including six virtual subpial tumour resection attempts. Five simple practice scenarios (3 minutes per task) and one complex realistic scenario (13 minutes). Pre- and post-questionnaires to obtain participant demographics and assess face and content validity of the simulated tasks."
41443443|NCT03298880|DEVICE|Supine VM VAD|Valsalva strain delivered using VAD
41443444|NCT03298880|DEVICE|Supine VAD manometer|supine Valsalva strain delivered using manometer
41443445|NCT03298880|OTHER|Modified VM VAD|modified VM using VAD
41443446|NCT03298880|OTHER|Modified VM Manonmeter|Postural modified position VM using manometer
41101629|NCT03245541|DRUG|Durvalumab|Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q28 days up to 1 year or until progression (11 doses), unacceptable toxicity or other reason. If a patient undergoes resection, they will resume durvalumab once appropriately healed from surgery (approximately 4-8 weeks) at discretion of treating medical oncologist.
41101630|NCT03245541|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|SABR delivered as 6.6 Gy/fraction x 5 fractions given within two weeks will be administered weekdays and will begin D8.
41101631|NCT00876044|DRUG|aflibercept (AVE0005)|Intravenous route
41101632|NCT00876044|DRUG|placebo|Intravenous route
41101633|NCT04604873|OTHER|Hospital day care follow-up|Regular follow up every month in hospital day care
41101634|NCT04689321|OTHER|No intervention|This is not an interventional study.
41101635|NCT01751724|DRUG|Caffeine citrate|"Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
41101636|NCT01751724|OTHER|Normal saline|"Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
41101637|NCT06630299|DRUG|ISL/LEN|Tablet administered orally
41101638|NCT06630299|DRUG|Antiretroviral Combinations|2 or 3 antiretrovirals (ARVs) administered as defined by the investigator, according to the prescribing information.
41101639|NCT02593565|OTHER|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
41101640|NCT03495284|DIETARY_SUPPLEMENT|Potato-based side dish|Daily consumption of a potato-based side dish equivalent to one medium size potato for 4 weeks
41101641|NCT03495284|DIETARY_SUPPLEMENT|Refined grain-based|Daily consumption of an isocaloric refined grain-based side dish for 4 weeks
41101642|NCT04090190|DRUG|Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine|Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
41101643|NCT05100329|DRUG|Mitoxantrone Hydrochloride Liposome injection|20 mg/m\^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
41101644|NCT06430125|DRUG|Nicorandil 10 MG Oral Tablet|Nicorandil 10 MG oral tablet twice daily
41101645|NCT05825235|DRUG|Pramipexole|6 months of treatment with add-on Pramipexole
41101646|NCT00691951|DRUG|budesonide and budesonide/formoterol|
41101647|NCT05155371|OTHER|Titration of Optimal Positive End-expiratory Pressure|Titration of Optimal Positive End-expiratory Pressure with two different methods
41101648|NCT05591079|DRUG|CS0159 (Linafexor)|Oral QD
41101649|NCT03275896|OTHER|Descemet Membrane Transplantation|The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
41101650|NCT01912001|OTHER|Telephone follow-up|
41443447|NCT05004116|DRUG|Repotrectinib|TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).
41443448|NCT05004116|DRUG|Irinotecan and temozolomide|Irinotecan and temozolomide will be given as per institutional standard.
41101651|NCT01912001|OTHER|Sympton Assessment|
41443449|NCT02470247|OTHER|Remote Ischemic Preconditioning (RIPC)|"RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
40925207|NCT06300593|DIAGNOSTIC_TEST|Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in the four study arms
41101652|NCT06514105|OTHER|Physiotherapy program|All patients participating in the study will be included in the physiotherapy program. Physiotherapy program consist of hot-pack (for 15 minutes), ultrasound (Continuous ultrasound, for 5 minutes, 1-MHZ 1.5W/cm2, a 5-cm ultrasound head on the subacromial region),TENS (for 20 minutes with the BTL 4000 combined device) and exercise program (Stretching exercises for the rotator cuff, rhomboid muscles, levator scapula, serratus anterior and pectoaral muscles and strengthening the muscles around the shoulder with a resistance exercise band selected in a color appropriate to the patient's strength).
41101653|NCT06514105|OTHER|High intensity laser|High intensity laser will be applied using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area by making circular movements from the center to the outside for 100 seconds at a power of 10W and a dose of 10 J/cm2 (analgesic effect). The last 5 sessions will be applied to the painful area with linear movements at 4W power and 100 J/cm2 dose (biostimulation effect) for 10 minutes and 25 seconds.
41101654|NCT06514105|OTHER|Sham high intensity laser|In sham application, the patient will be positioned on the treatment stretcher and the device will be turned on. The guide light of the high-intensity laser device, which gives the same color as the laser light, will be applied to the subacromial region in circular movements from outside to inside and from inside to outside.
41101655|NCT01693965|OTHER|sputum samples|
41101656|NCT05711095|DIETARY_SUPPLEMENT|Fortified plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
41101657|NCT05711095|DIETARY_SUPPLEMENT|Plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
41101658|NCT05711095|DIETARY_SUPPLEMENT|Whey protein|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
41101659|NCT02064569|GENETIC|GS010|
41101660|NCT02048709|DRUG|GDC-0919|Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
41101661|NCT03518112|BIOLOGICAL|Blinatumomab|Given IV
41101662|NCT03518112|DRUG|Cyclophosphamide|Given IV
41101663|NCT03518112|DRUG|Cytarabine|Given IT or IV
41101664|NCT03518112|DRUG|Dexamethasone|PO or IV
41101665|NCT03518112|BIOLOGICAL|Filgrastim|Given SC
41101666|NCT03518112|OTHER|Laboratory Biomarker Analysis|Correlative studies
41101667|NCT03518112|DRUG|Leucovorin Calcium|Given IV
41443450|NCT02470247|OTHER|SHAM Remote Ischemic Preconditioning (SHAM RIPC)|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
41443451|NCT01191996|BIOLOGICAL|MIS416|MIS416 intravenously every week
41101668|NCT03518112|DRUG|Mercaptopurine|Given PO
41101669|NCT03518112|DRUG|Methotrexate|Given IT or IV
41101670|NCT03518112|BIOLOGICAL|Pegfilgrastim|Given SC
41101671|NCT03518112|BIOLOGICAL|Rituximab|Given IV
41101672|NCT03518112|DRUG|Vincristine Sulfate|Given IV
41101673|NCT04666337|PROCEDURE|ultrasound-guided supraclavicular brachial plexus blockade|Ultrasound-guided supraclavicular brachial plexus block was done using an ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe. The brachial plexus and its relation to the surrounding structures were viewed while the patient was supine and the head turned 45° to the contralateral side. In the supraclavicular fossa, the probe was placed in the coronal plane to visualize the subclavian artery and the brachial plexus in a transverse sectional view. After skin sterilization and local anesthetic administration, an insulated needle was then introduced lateral to the ultrasound probe and parallel to the long axis of the probe. Once the needle penetrated the brachial plexus cluster, the local anesthetic mixture was injected incrementally after negative aspiration for blood or air just next to the artery, then the needle was repositioned to inject on the upper pole of the artery.
41101674|NCT00921739|RADIATION|Esophageal sparing IMRT|6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
41101675|NCT03103412|DRUG|TD-3504|TD-3504
41101676|NCT03103412|DRUG|15N2-tofacitinib|15N2-tofacitinib
41101677|NCT03103412|DRUG|Placebo|Placebo
41101678|NCT03138473|DIAGNOSTIC_TEST|Residual SYNTAX Score|"The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.~The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, creatinine clearance (CrCl) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of CrCl below 60 ml/min/1.73 m2 (1 point for CrCl between 59 and 50, 2 points for CrCl between 49 and 40 and 3 points for CrCl between 39 and 30 ml/min/1.73 m2). The CrCl is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score."
41101679|NCT03138473|DIAGNOSTIC_TEST|SYNTAX Revascularization Index|The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-\[rSS/bSS\]) ×100.
41101680|NCT04204837|DRUG|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
41101681|NCT04204837|DRUG|Nivolumab plus Relatlimab|Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
41101682|NCT04142788|DRUG|Patiromer|Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
41101683|NCT00296426|PROCEDURE|New technology - PAML|
41101684|NCT05356403|DRUG|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
41101685|NCT05356403|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
41101686|NCT04451889|DEVICE|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
41101687|NCT03641092|BEHAVIORAL|CenteringParenting Intervention|The CenteringParenting(CP) intervention includes group well child care visits during the first 24 months of life. Participants receive a journal with child safety, health and development information. The groups are co-led by a practitioner and support staff member. This bundled intervention supports healthy parent-child interactions and early learning through education and experiential learning within the well-child visit.
41101688|NCT03641092|BEHAVIORAL|Routine Well Child Care|The Comparison Clinical Sites will receive the Routine Well Child Care standard individual clinical care. This clinic will receive delayed training in the CenteringParenting(CP) intervention approximately 3 months after the completion of recruitment at their study site \[when recruited families will be ineligible for CenteringParenting groups that will start in control sites\]. They will receive anticipatory guidance and handouts that are standard for the clinic.
41101689|NCT03059264|OTHER|Natural history|Longitudinal disease progression
41101690|NCT05333887|BEHAVIORAL|PFC+|Therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support. Emphasis throughout the program is placed on parents' connection and engagement with the material and therapist.
41101691|NCT06214221|DEVICE|Signos System|The intervention involves the use of the Signos System, a combination of a proprietary software application with a continuous glucose monitor (CGM), to manage weight in overweight and obese adults.
41101692|NCT06214221|OTHER|Standard Lifestyle Education|"In the Standard Lifestyle Education arm, participants receive conventional advice on diet and exercise, focusing on general healthy lifestyle habits to manage weight."
41101693|NCT06052176|DRUG|Albumin Infusion|Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
41101694|NCT05493462|DRUG|Human FGF-1|Intranasal administration of human FGF-1
41101695|NCT04026620|BEHAVIORAL|Informational Pamphlet|The control group will be provided with two (2) informational pamphlets (and have it read to those who are of lower literacy). Pamphlets contain information about the harmful effects of drinking alcohol during pregnancy and the harmful effects of alcohol on the unborn baby.
41101696|NCT04026620|BEHAVIORAL|Brief Motivational Enhancement Therapy (MET) Session|The case control trial/efficacy study will provide a one-session MET session in Afrikaans (the predominant language of the region). The face-to-face session will provide information to help people and pregnant women who want to change their drinking behavior, become 'dry' and stay motivated to change their drinking behaviors. Sessions will be approximately one (1) hour and 30 minutes.
41101697|NCT01958541|BEHAVIORAL|Sleep Intervention I|Insomnia-focused behavioral treatment (4 sessions).
41101698|NCT01958541|BEHAVIORAL|Sleep Intervention II|Insomnia-focused behavioral treatment (4 sessions).
41101699|NCT03503630|DRUG|COMPOUND 2055269|COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
41101700|NCT03503630|RADIATION|Radiation Therapy|Radiotherapy 25 Gy to be given on Days 1-5
41101701|NCT03503630|DRUG|mFOLFOX|Given every 2 weeks for 6 cycles
41101702|NCT03503630|PROCEDURE|Total Mesorectal Excision|Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
41101703|NCT01414231|DRUG|Cytarabine|Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
41101704|NCT01513642|BEHAVIORAL|Breath Stacking|To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
41101705|NCT00587288|BIOLOGICAL|Reslizumab|
41101706|NCT00587288|OTHER|Saline|
41101707|NCT03583021|DRUG|Sugammadex Injectable Product|Sugammadex of 3 mg/kg is injected.
40925208|NCT06300593|DIAGNOSTIC_TEST|Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to test the above correlations in the four study arms
40925209|NCT05461378|DRUG|Evusheld|Participants who have received or plan to receive Evusheld.
41101708|NCT03583021|DRUG|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
41101709|NCT04163224|DEVICE|RibFix Advantage|Class II device in the United States; consists of bridges (with locking posts) and locking caps for the thoracoscopic fixation and stabilization of ribs. These implants are manufactured from commercially pure titanium and titanium alloys. When fully assembled, the bridge plate is placed on the underside of the rib (pleural cortex); the threaded locking posts extend through pre-drilled holes in the rib, and the locking caps are fixed to the locking post on the anterior (cutaneous) side of the rib. The combined threaded locking post and cap provides for fixation of the bridge and stabilization of the fracture.
41101710|NCT05222750|OTHER|Pre-COVID-19|Pre-COVID-19
41101711|NCT05222750|OTHER|COVID-19|COVID-19
41101712|NCT05222750|OTHER|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out
41101713|NCT03317535|PROCEDURE|General anesthesia|Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
41101714|NCT03317535|PROCEDURE|Local anesthesia/concious sedation|Patients will be injected with propofol and remifentanil.
41101715|NCT03317535|PROCEDURE|Spontaneous breath|Patients will be kept spontaneous breath.
41101716|NCT03317535|PROCEDURE|Controlled ventilation|Patient will be kept with controlled ventilation.
41101717|NCT02575235|DRUG|Cetylpyridinium Chloride (CPC)|Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.
41101718|NCT02575235|DRUG|placebo|Control group takes the placebo for the same period.
41101719|NCT03460327|DRUG|Candesartan|Patients are tested for their normal prescription candesartan medication
41101720|NCT01242150|DEVICE|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow \>40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
41101721|NCT01242150|DEVICE|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
41101722|NCT02633189|DRUG|Erlotinib|given orally 150 mg daily
41101723|NCT02633189|DRUG|Bevacizumab|15 mg/kg intravenously every 21 days.
41101724|NCT01512966|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
41101725|NCT01300832|PROCEDURE|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
41101726|NCT02009358|OTHER|mental health promotion|
41101727|NCT00781690|DEVICE|Evodial hemodialysers and Evodia blood lines|Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
41101728|NCT01253499|DRUG|TRx0037|75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
41101729|NCT03357341|DEVICE|Mobile spirometer|Mobile spirometer will be used to measure FEV1 values weekly.
41101730|NCT03357341|DEVICE|Device sensor|Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.
41101731|NCT03357341|DRUG|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
41101732|NCT03357341|DEVICE|Activity monitor|Subjects will be required to wear activity monitors daily to record their physical activity.
41101733|NCT03357341|OTHER|electronic diary card|Electronic diary card will be completed daily by subjects in COPD cohort.
41101734|NCT03357341|OTHER|CAT|Subjects will be required to complete CAT monthly.
41101735|NCT03357341|OTHER|ACT|Subjects will be required to complete ACT monthly.
41101736|NCT00887640|DRUG|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
41101737|NCT00887640|DRUG|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
41101738|NCT04767230|OTHER|Dietary Intervention|A heart-healthy diet + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil in adjunct to medical treatment for 3 months
41101739|NCT00557804|DEVICE|MUSE clinical system|non-invasive external monitoring device
41101740|NCT05298111|OTHER|Formulation 3|Respondents were consumed 36 g of Formulation 3 containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
41101741|NCT05298111|OTHER|Control|Respondents were consumed 4.5 g of control containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
40925210|NCT02721771|PROCEDURE|Ultrasound examination|echocardiographic diastology and bilateral B-line pattern will be assessed. Optic nerve sheath diameter will be assessed.
40925211|NCT00108875|BIOLOGICAL|Survivin peptide vaccine|
40925212|NCT05187273|BEHAVIORAL|Elastance Group|Fluids are given based on dynamic elastane value
41101742|NCT06631560|DIAGNOSTIC_TEST|ELISA testing|Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
41101743|NCT02235857|DEVICE|LIPOSORBER® LA-15 System|LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
41101744|NCT01187576|BEHAVIORAL|Multi-professional team intervention with PAR, lifestyle brochure|Multi-professional team intervention with PAR, lifestyle brochure
41101745|NCT01187576|BEHAVIORAL|Ordinary recommendations on health behaviours, lifestyle brochure|Ordinary recommendations on health behaviours, lifestyle brochure
41101746|NCT05919108|PROCEDURE|Endocrine Therapy|Undergo endocrine therapy
41101747|NCT05919108|PROCEDURE|Biopsy of breast|Undergo breast biopsy
41101748|NCT05919108|DRUG|Neratinib|Taken by mouth
41101749|NCT05919108|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41101750|NCT05919108|PROCEDURE|Mammogram|Undergo Mammogram
41101751|NCT05919108|PROCEDURE|Magnetic Resonance Imaging|Undergo breast Magnetic Resonance Imaging
41101752|NCT05919108|PROCEDURE|Breast Surgery|Undergo Breast Surgery
41101753|NCT05919108|PROCEDURE|Ultrasound|Undergo Ultrasound
41101754|NCT03636451|DRUG|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
40925213|NCT04595994|DRUG|Selinexor|For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).
40925214|NCT05536128|DRUG|Olaparib|Olaparib tablet 300 mg taken orally twice daily Olaparib 500 mg on Days 1, 15, 29, and every 4 weeks thereafter The treatment will continue till disease progression or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met.
40925215|NCT05536128|DRUG|Fulvestrant|Fulvestrant 500 mg on Days 1, 15, 29, and every 4 weeks thereafter
41101755|NCT03636451|DRUG|20cc 1% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
41101756|NCT01225939|DRUG|AZD8329|tablet
41101757|NCT01225939|DRUG|AZD8329|Solution
41101758|NCT00922675|PROCEDURE|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
41101759|NCT00922675|PROCEDURE|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
41101760|NCT02795650|DRUG|Personalised treatment|Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
41101761|NCT02795650|DRUG|Treatment chosen per investigator´s judge|Investigators are allowed to chose what they consider the best standard treatment option for their patients.
41101762|NCT04729296|DRUG|Golimumab|For participants ≥45 kg, 50 mg of golimumab will be administered subcutaneously For participants \<45 kg, the dose of golimumab is 30 mg/m2 to maximum of 50 mg
40925216|NCT01518738|BEHAVIORAL|breath attention training|4 week training
41101763|NCT04729296|DRUG|Placebo|Inactive Drug
41101764|NCT05402228|DIAGNOSTIC_TEST|temporomandbular joint disorders|no intervention
41101765|NCT00059917|DRUG|polyglutamate camptothecin|
41101766|NCT00771849|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
41101767|NCT00771849|BIOLOGICAL|Haemophilus Influenzae Type b (Hib) vaccine|0.5 mL, Intramuscular
41101768|NCT01854437|DRUG|Mg Oxide|250 mg orally for 4 weeks
41101769|NCT06013241|DRUG|Brensocatib|Film-coated tablet.
41101770|NCT06013241|DRUG|Placebo|Film-coated tablet.
41101771|NCT06013241|DRUG|Mometasone furoate nasal spray (MFNS)|Nasal spray suspension.
41101772|NCT05583292|OTHER|ASA-PS|The American Society of Anesthesiologists classification of physical status (ASA PS) is a scale consisting of 6 classes showing the preoperative comorbidity of the patient.
41101773|NCT05583292|OTHER|SORT|Surgical outcome risk tool (SORT) is a scale used to estimate patient preoperative mortality/ morbidity, measured from sortsurgery.com.
41101774|NCT05583292|OTHER|Sarcopenia|Sarcopenia represents a loss of muscle strength and mass in older individuals and people who have tumors. Sarcopenia score is valuable in predicting preoperative mortality/ morbidity
41101775|NCT00064571|PROCEDURE|vocal fold medialization|
41101776|NCT00064571|PROCEDURE|vocal fold reinnervation|
41101777|NCT01177852|DRUG|diphenhydramine + dropropizine + pseudoephedrine|"Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml"
41101778|NCT01177852|DRUG|Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).|"Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml"
41101779|NCT02664337|OTHER|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
41101780|NCT02664337|OTHER|Standard treatment information|Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
41101781|NCT04769609|DEVICE|bioresorbable membrane|reconstructive surgical treatment of peri-implant bone defects
41101782|NCT05518487|BIOLOGICAL|Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine|0.5 mL per dose of the Sanofi-GSK COVID-19 Vaccine will be administered intramuscularly in the deltoid muscle of the upper arm
40925217|NCT01518738|BEHAVIORAL|working memory attention training|4 week training
40925218|NCT02876250|DRUG|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
40925219|NCT02876250|DRUG|Placebo|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
40925220|NCT03940183|DRUG|Trelagliptin Succinate|the experimental group will use trelagliptin succinate 100 mg for 24weeks
41101783|NCT02205086|OTHER|Diagnosis|"Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software."
41101784|NCT06421688|DRUG|Ascorbic acid|After participants underwent induction of anesthesia, Ascorbic acid (Vitamin C Injection) was administered at a dosage of 50 mg/kg, diluted to 50 ml using saline, with a total amount not exceeding 4 g; pumping was performed using a micro pump at a rate of 25 ml/h.
41101785|NCT06421688|DRUG|Saline|After participants underwent induction of anesthesia, 50 ml of saline was used and pumped using a micro pump at a rate of 25 ml/h.
41101786|NCT01548391|DRUG|HX-1171|20mg, 200mg, 500mg
41101787|NCT00470626|DEVICE|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
41101788|NCT03100162|DIETARY_SUPPLEMENT|Probiotic|
41101789|NCT03100162|DIETARY_SUPPLEMENT|Placebo|
41101790|NCT02294929|PROCEDURE|Atrial fibrillation ablation|Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
41101791|NCT02783157|DEVICE|Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)|Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.
41101792|NCT02783157|DEVICE|Sham LLVNS|A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
41101793|NCT06245109|DRUG|Duloxetine|60 mg, oral
41101794|NCT06245109|DRUG|Celecoxib|200 mg, oral
41101795|NCT06245109|DRUG|Placebo|Matching placebo, oral
41101796|NCT03114020|DRUG|Hyaluronic Acid Inhalation Solution|twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
41101797|NCT03114020|DRUG|Placebo Inhalation Solution|Twice a day 3 ml of placebo inhalation solution
41101798|NCT01194778|DIETARY_SUPPLEMENT|placebo|1 placebo sachet per day containing only sucrose during 12 weeks
41101799|NCT01194778|DIETARY_SUPPLEMENT|vitamin K1|15 µg vitamin K1 per day during 12 weeks
41101800|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|15 µg vitamin K2 per day during 12 weeks
41101801|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|30 µg vitamin K2 per day during 12 weeks
41101802|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|45 µg vitamin K2 per day during 12 weeks
41101803|NCT06629740|DEVICE|Measurements with a eHealth system|The eHealth system Previct Drugs is a CE marked medical device intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. Previct Drugs consists of a mobile phone application used to perform self-administered eye-scanning, a web-based careportal used by the caregiver, a database for storage, handling, and analysis of reported data, and an admin portal for the manufacturer to register and administer customers. In this study, Previct Drugs will be used by healthy volunteers for performing measurements before and after intake of a commonly used medicine to simulate drug intake.
41101804|NCT06027151|DRUG|1ml of 1% metronidazole gel|1ml of 1% metronidazole gel subgingivally at baseline visit
41101805|NCT06027151|DRUG|1ml of 2% minocycline gel|1ml of 2% minocycline gel sub gingivally at baseline visit
41101806|NCT06027151|DRUG|1ml of combination of 1% metronidazole gel and 2% minocycline|1ml of the combination of 1% metronidazole gel and 2% minocycline subgingivally at baseline visit
41101807|NCT05948917|BEHAVIORAL|Mind-Body Skills Groups|The mind-body skills groups consist of supportive small group sessions with about 8-10 participants per group. Participants of these groups learn and practice mind-body techniques including: meditation, self-expression through drawings, autogenics and biofeedback, guided imagery, body awareness, and genograms.
41101808|NCT04442984|DRUG|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
41101809|NCT04442984|DRUG|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
41101810|NCT04442984|DRUG|5-FU|d1-2 5-FU 2200 mg/m² every two weeks
41101811|NCT04442984|DRUG|5-FU|d1 5-FU 250 mg/m² every two weeks
41101812|NCT04442984|DRUG|Leucovorin|d1 Leucovorin 400 mg every two weeks
41101813|NCT04442984|DRUG|5-FU|d1 5-FU 400 mg/m² every two weeks
41101814|NCT04442984|DRUG|5-FU|d1-2 5-FU 2400 mg/m² every two weeks
41101815|NCT01944410|BIOLOGICAL|PRP injection|injection of PRP to traumatic bone cyst defect
41101816|NCT02276508|DRUG|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
41101817|NCT00181909|BEHAVIORAL|Smoking cessation counseling delivered by telephone|
41101818|NCT06137846|DEVICE|Air-Polish|Dental implant will be cleaned with an airpolishing device
41101819|NCT06137846|DEVICE|Ultrasonic|Dental implant will be cleaned with an ultrasonic device with a plastic tip
41101820|NCT06454773|DIETARY_SUPPLEMENT|NCT/NFT|extract from black pepper and hemp hull
41101821|NCT04446689|BEHAVIORAL|Biofeedback|This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph.
41101822|NCT06620302|BIOLOGICAL|Bcl-XL Proteolysis Targeting Chimera DT2216|Given IV
41101823|NCT06620302|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41101824|NCT06620302|DRUG|Irinotecan (drug)|Given IV
41101825|NCT03213470|OTHER|magnetic resonance imaging|
41101826|NCT04392349|DEVICE|Haag-Streit EYESTAR 900|The EYESTAR 900 is a new device developed by HAAG-STREIT AG which utilises Optical Coherence Tomography (OCT) for quantitative measurements of the geometry of the eye. As a successor to the LENSTAR 900, it represents the most recent in a series of successful biometry devices.
41101827|NCT04392349|DEVICE|Tomey CASIA 2|The CASIA2 is a testing application for Cataract / Glaucoma / Cornea Surgery already established on the market. It is a representative device for measurement of anterior and posterior corneal curvature (anterior and posterior corneal topography) by optical coherence tomography, and for measurement of crystalline lens tilt by optical coherence tomography.
41101828|NCT04392349|DEVICE|Oculus PENTACAM HR|The Pentacam HR is a high-resolution rotating Scheimpflug camera system for anterior segment analysis already established on the market. It is used as representative device for advanced anterior segment analysis such as anterior and posterior corneal topography and corneal pachymetry.
41101829|NCT04392349|DEVICE|Zeiss ATLAS 9000|ATLAS is a corneal topography system used as representative device for measurement of anterior corneal curvature (anterior corneal topography).
41101830|NCT00923676|DRUG|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
41101831|NCT00923676|DRUG|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
41101832|NCT00923676|DRUG|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
41101833|NCT06628401|BEHAVIORAL|Educational information (Control)|Information packs will be developed for participants outlining the importance of a control group in research studies to maximise compliance. Participants will receive a £10 gift voucher weekly that they can spend at selected retailers of their choosing.
41101834|NCT06628401|BEHAVIORAL|Educational information (Increasing F&V intake)|Information packs will be developed to support participants in increasing their intake of whole fruits and vegetables, excluding fruit juice. The information packs will be developed using published guidance from the UK government, expert panels, and regulatory bodies. The packs will be co-developed with the public to ensure the guidance is appropriate for its target audience. Participants will also receive a £10 supermarket voucher weekly to purchase fruit and vegetables.
41101835|NCT06628401|BEHAVIORAL|Educational information (Increasing F&V intake + Juice)|Information packs will be developed to support participants in increasing their intake of whole fruits and vegetables, including fruit juice. The information packs will be developed using published guidance from the UK government, expert panels, and regulatory bodies. The packs will be co-developed with the public to ensure the guidance is appropriate for its target audience. Participants will also receive a £10 supermarket voucher weekly to purchase fruit and vegetables.
41101836|NCT02524444|DRUG|Mefloquine|Tabs Mefloquine 250mg
41101837|NCT02524444|DRUG|Sulphadoxine-Pyrimethamine|Sulphadoxine 500mg , Pyrimethamine 25mg
41101838|NCT03208270|DRUG|Antithrombin supplementation|antithrombin concentrate will be supplemented to maintain a functional antithrombin level between 80%-120%
41101839|NCT03208270|DRUG|No antithrombin supplementation|"supplementation of antithrombin will not be provided unless heparin resistance occurs"
41101840|NCT05462925|DEVICE|Functional electrical stimulation therapy.|Functional electrical stimulation therapy will be delivered using the MyndMove system (MyndTec, Inc., Mississauga, Canada).
41101841|NCT05890521|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell)|"Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person.~Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person."
41101842|NCT05370144|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiation 23 Gy in 5 fractions with a simultaneous integrated boost of 26 Gy in 5 fractions to the gross tumor volume (GTV) given concurrently over 1 week during week 3 of chemotherapy.
41101843|NCT04373187|DRUG|CC-93538|one injection of 2mL
41101844|NCT04373187|DRUG|CC-93538|two injections of 1.2mL
41101845|NCT01606384|DRUG|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
41101846|NCT01606384|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
41101847|NCT01935258|OTHER|Psychosomatic therapy|Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
41101848|NCT01935258|OTHER|care as usual|usual care of the general practitioner
41101849|NCT03828162|DRUG|Anticoagulants|
41101850|NCT05825170|DEVICE|FASY L|Subjects will receive FASY L in lips at level of their scar.
41101851|NCT01793272|OTHER|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
41101852|NCT04564391|DIETARY_SUPPLEMENT|protein supplement|protein supplement, daily 60 g of protein, 3 weeks of intervention; blinded to patients
41101853|NCT04564391|DIETARY_SUPPLEMENT|placebo supplement|Placebo supplement, daily intake of placebo, 3 weeks of intervention; blinded to patients
41101854|NCT05289830|DRUG|Escitalopram|Participants will receive Escitalopram 2 weeks: 10 mg/day (1 capsule) 8 weeks: 20 mg/day (2 capsules) 2 weeks: 10 mg/day (1 capsule)
41101855|NCT05289830|OTHER|Placebo|Participants will receive placebo supplements 2 weeks: 1 capsule 8 weeks: 2 capsules 2 weeks: 1 capsule
41101856|NCT00325858|DRUG|Tramadol HCl ER|
41101857|NCT05701462|DIAGNOSTIC_TEST|biopsy under sonographic gidance|pleural biopsy under sonographic guidance
41101858|NCT04628442|PROCEDURE|Sinonasal Debridement Procedure|This is a medical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
41101859|NCT04628442|PROCEDURE|Nasal Polyp Removal|This is a surgical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
41101860|NCT04628442|PROCEDURE|Biopsy|A biopsy is optional and will remove a sample of inferior turbinate tissue from the nasal passage. It will be performed during a nasal polyp removal surgery already scheduled for patient care.
41101861|NCT05880316|BEHAVIORAL|Intermittent Fasting|3:4 regime
41133272|NCT01681654|BEHAVIORAL|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
41101862|NCT06412406|PROCEDURE|External Oblique Intercostal (EOI) block|EOI block technique A linear ultrasound transducer placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, The transducer was then rotated so the cranial end was directed slightly medially and the caudal end laterally to produce a paramedian sagittal oblique view with a short-axis view of the ribs, The following structures were identified, from superficial to deep: subcutaneous tissue, external oblique muscle, intercostal muscles between ribs, pleura, and lung. The skin entry point for the injection was cranial to the sixth rib level just medial to the anterior axillary line, with ultrasound opaque needle advanced in plane from a superomedial-to-inferolateral direction, through the external oblique muscle hydrodissecting the tissue plane between the sixth and seventh ribs, and then the needle was directed caudally toward the eighth rib. and inject 20 ml volume of (0.25 % bupivacaine).
41101863|NCT06412406|PROCEDURE|Transversus abdominis plane (TAP) block|"TAP block technique:~abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest (18) . Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. and ingect 20 ml volume of (0.25 % bupivacaine). If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study."
41101864|NCT06059820|OTHER|rehabilitation treatment|3-month immobilization period, hyperextension braces for specific fractures, therapeutic exercises, and gradual activity restoration.
41101865|NCT06059820|PROCEDURE|Spine fusion|Pedicle screw fixation or fusion; anterior plate fusion
41101866|NCT04180267|DEVICE|Low-magnitude High-frequency Vibration|35Hz, 0.3g, 20min/day, at least 3 times/week
41101867|NCT02452294|DRUG|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
41101868|NCT06629935|PROCEDURE|orthognathic surgery|Le Fort I surgery
41101869|NCT00329979|BEHAVIORAL|vascular access site|Randomized vascular access site
41101870|NCT03370055|DEVICE|LeucoPatch®|LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood
41101871|NCT03370055|OTHER|Control,|Usual wound care in a specialized clinic
41101872|NCT03162887|OTHER|Educational Intervention|Receive a research team member-led breast cancer and mammogram educational module
41101873|NCT03162887|OTHER|Counseling|Undergo a web-based decision counseling session
41101874|NCT03162887|OTHER|Informational Intervention|"Receive a next steps document"
41101875|NCT05939557|PROCEDURE|Jones technique|is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction)
41101876|NCT05939557|DEVICE|Kinesiotape|KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports
41101877|NCT05689268|DIAGNOSTIC_TEST|EUS-PPG and HVPG|"EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed."
41101878|NCT00762619|DRUG|Fluoride|Brush twice daily
41101879|NCT00762619|DRUG|Triclosan, fluoride|Brush twice daily
41101880|NCT00422201|DRUG|Mifepristone|Singe dose
41101881|NCT04903028|DEVICE|Sham rTMS|Two electrodes on the scalp will be connected to transcutaneous electrical nerve stimulation.
41101882|NCT04903028|DEVICE|Active rTMS 10 Hz DLPFC|10 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left dorsolateral prefrontal cortex (DLPFC).
41101883|NCT06628973|BEHAVIORAL|Social prescribing|The intervention consists of SP, wherein patients identified as having significant SDOH-related vulnerabilities on the SPARK questionnaire or during an interview will have a consultation with a LW who will provide them with social prescriptions. LWs are individuals who LINK individuals with social needs to existing community supports and services within the community
41101884|NCT03141658|DRUG|TS-134|Multiple dose titrations from 10 mg to 20 mg once daily for 6 days
41101885|NCT03141658|DRUG|TS-134|Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
41101886|NCT03141658|DRUG|Placebo|Multiple doses of placebo once daily for 6 days
41101887|NCT03141658|OTHER|Ketamine|0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
41101888|NCT00956449|BIOLOGICAL|Seasonal Influenza Vaccine|1 dose of Influenza Vaccine Surface Antigen, Inactivated
41101889|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|40 mg, QD
41101890|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|80 mg, QD
41101891|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|160 mg, QD
41101892|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|240 mg, QD
41101893|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|320 mg, QD
41101894|NCT02141347|DRUG|Tremelimumab|Tremelimumab administered intravenously
41101895|NCT02141347|DRUG|MEDI4736|MEDI4736 administered intravenously.
41101896|NCT05702294|DEVICE|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the control arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
41101897|NCT05702294|DEVICE|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the Lower Urinary Tract Symptoms ( LUTS) arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
41101898|NCT02351180|DRUG|Inhaled beclomethasone|Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
41101899|NCT02351180|DRUG|Placebo|Placebo will serve as a control treatment
41101900|NCT01365403|DRUG|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
41101901|NCT01365403|DRUG|carbamazepine|multiple oral doses, Days 1-24 of study period 2
41101902|NCT05021419|OTHER|Streamlined protocol|A streamlined drug protocol for optimizing heart failure medication
41101903|NCT05021419|OTHER|Standard Protocol|Current standard optimization protocol as per NICE and ESC
41101904|NCT02839330|BIOLOGICAL|aH5N1c|Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).
40925221|NCT03940183|DRUG|Placebo Oral Tablet|the placebo Comparator groups use placebo oral tablet for 24weeks
41101905|NCT02839330|BIOLOGICAL|Placebo|Placebo: Saline injection
41101906|NCT04747457|DEVICE|Research FibroScan|"After having obtained the patient's Informed Consent Form signature, the following 3 examinations will be done:~1. Standard examination \[Reference CE-marked FibroScan\]: the operator will need to find an optimal measurement area, and perform 10 valid measurements.~2. Standard examination \[Research FibroScan\]: the operator must take 15 valid measurements at the same measurement point as the one used for the examination with the Reference FibroScan.~3. Exploratory examination \[Research FibroScan\]: the operator needs to perform15 invalid measurements to acquire data in non-optimal regions of measurement (lungs, vessels, intestines, ribs, edges of the liver)."
41101907|NCT05644652|OTHER|designed physical therapy program|"it will be applied for for 60 min weekly for 3 successive months in the form of three sets of exercises (20 minutes each) as follows:~* Flexibility exercises to restore joint mobility of soft tissues.~* Static and dynamic balance exercises~* Functional strengthening exercises.~* Functional gait training."
41101908|NCT05644652|OTHER|Nordic walking|it will be conducted according to the guidelines of the International Nordic Walking Federation
41101909|NCT06632002|OTHER|DSF1|220 mL
41101910|NCT06632002|OTHER|DSF2|220 mL
41101911|NCT06632002|OTHER|Standard of Care (SOC)|Standard of care
41101912|NCT03640273|DRUG|Prapchompoothaweep remedy|Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.
41101913|NCT03640273|DRUG|Loratadine 10 Mg|Take Loratadine 10 mg once a day before meals.
41101914|NCT05462821|DEVICE|Eye Patch|adhesive patch to cover eye
41101915|NCT06479018|BIOLOGICAL|Blood sampling|Venous blood sampling will be carried out for each patient included in the study.
41101916|NCT06479018|BIOLOGICAL|Liquid bubble sampling|Liquid bubble sampling will be carried out for each patients with Bullous Pemphigoid included in the study.
41101917|NCT06479018|PROCEDURE|Cutaneous biopsy|At least the first cutaneous biopsy will be carried out for each patients with Bullous Pemphigoid included in the study.
41101918|NCT01872819|OTHER|antitumor drug screening assay|Undergo high throughput drug sensitivity assay
41101919|NCT01872819|DRUG|chemotherapy|Patients receive 1 of 160 possible interventions
41101920|NCT01872819|BIOLOGICAL|biological therapy|Patients receive 1 of 160 possible interventions
41101921|NCT00436137|BEHAVIORAL|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
41443452|NCT05187065|OTHER|The mobile-based education and exercise program|Starting from the preoperative period, mobile-based patient education, progressive relaxation exercise and knee exercise program will be applied to the patient as a whole. Mobile-based education will include pre-operative and discharge education. The patient will be given a progressive relaxation exercise with the support of the mobile application and the exercises included in the knee exercise program that should be done after the surgery will be shown. Progressive relaxation exercises will be applied twice a day in the afternoon and evening. Postoperative knee exercises will be performed 3 to 5 times a day, depending on the type of exercise. These exercises will be continued regularly for up to 4 weeks after discharge.
41101922|NCT04187157|DEVICE|Blue-light filtering intraocular lens|Bilateral implantation of blue light-blocking intraocular lens
41101923|NCT04187157|DEVICE|Conventional intraocular lens|Bilateral implantation of conventional intraocular lens
41101924|NCT00851942|DRUG|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
41101925|NCT04923139|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Dosage at the discretion of the treating physician
41101926|NCT06134999|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
41101927|NCT06134999|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
41101928|NCT05671198|DIAGNOSTIC_TEST|Ultrasound of the diaphragm|"Sonographic parameters of the diaphragm:~* Thickening Fraction (TF); (Diaphragm thickness end-inspiration- Diaphragm thickness end-expiration) / Diaphragm thickness end-expiration. (continuous variable).~* Diaphragm end-expiratory thickness: Diaphragm thickness at end-expiration (continuous variable)~* Diaphragm excursion (DE): diaphragm inspiratory amplitude during deep breathing (continuous variable)."
41101929|NCT03935308|RADIATION|MR guided Linear Accelerator|The aim is to perform treatment planning to compute the highest feasible simultaneous boosting dose to the intraprostatic lesion while respecting normal tissue dose constraints. Patients will be treated with MR-guided localization and adaptive planning techniques.
41101930|NCT05266144|PROCEDURE|radiofrequency ablation|Bilateral pulmonary vein isolation, a kind of radiofrequency ablation, is performed in atrial fibrillation patients for atrial arrhythmia therapy.
41101931|NCT03460210|DRUG|Atomoxetine|Patients are tested for their normal prescription atomoxetine medication
41101932|NCT04547348|DRUG|Denosumab Injection|Injections made subcutaneously per standard description
41443453|NCT00489177|DEVICE|A|QuickOpt intra-cardiac electrogram optimization
41101933|NCT04836624|DEVICE|Co-designing of personalised aids of daily living|"In the initial session the researcher will work with the participants to identify challenges in daily living for the device to overcome.~In between sessions the researcher will design and manufacture different solutions which will then be sent out for the participant to trial. The participant will then meet with the researcher to and feedback on the device provided. Feedback from the user is used to alter and improve the design of the device; new device(s) are then , enabling the design to be adapted to the participants needs. The process of design changes and feedback forms an iterative loop. This is expected to continue for 4-5 appointments over a period of serveral months until a final design is agreed upon.~After the device is issue, both qualitative and quantitative outcome measures are provided to participants to complete, including questionnaires and semi-structured interviews. ."
41101934|NCT05634317|BEHAVIORAL|Smartphone delivered Behavioral activation|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 Review the present use of time and use the monitoring form~Session 2 Brain-storm pleasant events and schedule pleasant activities~Session 3 Review scheduling of events and discuss how to improve~Session 4 Review modifications and consolidate gains on scheduling~Session 5 Review present social support and explore new sources of support~Session 6 Examine communication skills and explore new options~Session 7 Review new communications and discuss how to improve~Session 8 Review modification and consolidate gains on support"
41101935|NCT05634317|BEHAVIORAL|Smartphone delivered Mindfulness|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 The Raisin exercise (eating meditation) and12-min body scan~Session 2 Exercises on thoughts and feelings 12-min body scan~Session 3 Exercises focusing on unpleasant experiences, practicing seeing and hearing , sitting meditation, 3-min breathing space, and mindful stretching and breath meditation~Session 4 Practicing seeing and hearing, mindful communication, 3-min breathing space, and sitting meditation~Session 5 Mindful walking, 3-min breathing space, and sitting meditation~Session 6 Sitting meditation, exercises on thoughts and alternative viewpoints, and 3-min breathing space (responsive)~Session 7 Sitting meditation, activity and mood exercise, identifying habitual emotional reactions to difficulties, and 3-min breathing space (responsive)~Session 8 12-min body scan, exercise on looking forward, and exercise on preparing for the future"
41101936|NCT03822351|DRUG|Durvalumab + Oleclumab|Durvalumab + Oleclumab
41101937|NCT03822351|DRUG|Durvalumab|Durvalumab
41101938|NCT03822351|DRUG|Durvalumab + Monalizumab|Durvalumab + Monalizumab
41101939|NCT05302843|DRUG|BPI-28592|Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
41101940|NCT02192034|BEHAVIORAL|Navigation|
41101941|NCT04594330|DRUG|virgin coconut oil (VCO)|15 mL of VCO twice a day for 14 days
41101942|NCT04594330|OTHER|placebo|15 mL of placebo twice a day for 14 days
41101943|NCT00079664|BEHAVIORAL|Tai Chi|
41101944|NCT00580437|PROCEDURE|Dobutamine Stress Echocardiogram|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
41101945|NCT05506709|DEVICE|Seawater nasal spray|Subjects will use the nasal spray (moderately hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and calcium) at least once and up to 6 times as necessary per day during the 14-day test period. Each application is composed of two irrigating sprays per nostril for a total of 4 sprays per application.
41101946|NCT04553302|OTHER|This study does not contain any intervention.|This study does not contain any intervention.
41101947|NCT03161691|PROCEDURE|Percutaneous treatment of ischemic stroke|An additional C-arm CT imaging scan will be done during neurovascular treatment to evaluate perfusion and collateral vessels in ischemic stroke patients.
41101948|NCT00061672|DRUG|ABT-510 - Thrombospondin-1 Mimetic|
41101949|NCT01236989|PROCEDURE|anatomical liver resection|anatomical liver resection by means of IOUS-finger compression
41101950|NCT01236989|PROCEDURE|Non-anatomical liver resection|non-anatomical liver resection
41101951|NCT04604054|DRUG|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
41101952|NCT04604054|DRUG|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
41443454|NCT00489177|DEVICE|B|Single optimization in initial month post-implant
41101953|NCT04591301|DRUG|HEC113995 PA•H2O tablets|Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
41101954|NCT04591301|DRUG|Placebo tablets|Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
41101955|NCT03526835|DRUG|MCLA-158|full-length IgG1 bispecific antibody targeting EGFR and LGR5
41101956|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + Pembrolizumab|MCLA-158 in combination with pembrolizumab (non-IMP) will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.
41101957|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + FOLFIRI|MCLA-158 in combination with FOLFIRI (non-IMPs) will be explored first in mCRC patients in the 2L setting.
41101958|NCT00798772|DIETARY_SUPPLEMENT|Micronutrients and antioxidants|8 capsules twice daily for two years
41101959|NCT00798772|DIETARY_SUPPLEMENT|Multivitamins and minerals|8 capsules twice daily for two years
41101960|NCT03613129|DRUG|CT38|Infusion
41101961|NCT02584153|DRUG|Fibrin Sealant|TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)
41443455|NCT02411903|DRUG|atorvastatin and clopidogrel|Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
41443456|NCT02411903|DRUG|rosuvastatin and clopidogrel|Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
41101962|NCT02584153|DRUG|Silver Microparticles|Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
41101963|NCT04511650|DRUG|Razuprotafib Subcutaneous Solution|Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
41101964|NCT04511650|DRUG|Placebo Subcutaneous Solution|Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
41101965|NCT00029523|DRUG|Intrathecal (injected into the spinal fluid) DepoCyt|
41101966|NCT00029523|DRUG|Intrathecal methotrexate|
41101967|NCT00029523|DRUG|Intrathecal cytarabine (also known as ara-C)|
41101968|NCT00197015|BIOLOGICAL|Havrix®|2 doses administered intramuscularly
41101969|NCT00197015|BIOLOGICAL|M-M-R®II|1 dose administered subcutaneously
41101970|NCT00197015|BIOLOGICAL|VARIVAX®|1 dose administered subcutaneously
41101971|NCT04399525|DRUG|Desloratadine Single Dose|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
41101972|NCT04399525|DRUG|Levocetirizine Single Dose|Levocetirizine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
41101973|NCT04399525|DRUG|Desloratadine Fourfold Dose|Desloratadine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively
41101974|NCT04399525|DRUG|Levocetirizine Fourfold Dose|Levocetirizine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively.
41101975|NCT00343824|PROCEDURE|aquacel AG hydrofiber versus acticoat burn dressing|Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
41101976|NCT02799095|DRUG|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
41101977|NCT02799095|DRUG|ALKS 4230 + pembrolizumab|IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
41101978|NCT03802786|DRUG|Imeglimin|Single administration dose of imeglimin
41101979|NCT04760301|DRUG|local tranexamic acid injection|local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
41101980|NCT04760301|OTHER|local normal saline injection to cervix|local normal saline injection to the cervix- 20 ml saline
41101981|NCT04760301|DRUG|IV 1 g tranexamic acid|IV 1 g tranexamic acid diluted in 100 ml saline
41101982|NCT04760301|OTHER|IV 1 g normal saline|IV 100 ml normal saline
41101983|NCT05318950|BEHAVIORAL|E-learning|8 lessons about nutrition and lifestyle
41101984|NCT05318950|DIETARY_SUPPLEMENT|Diet|Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
41101985|NCT04096144|DRUG|Neuromuscular Blocking Agents|Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
41101986|NCT05046158|DEVICE|Transforming Powder Dressing|Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.
41101987|NCT05046158|OTHER|Standard of care topical wound agents and dressings|Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.
41101988|NCT02877199|OTHER|Triple therapy|Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
41101989|NCT02966743|DRUG|Midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
41101990|NCT02966743|DRUG|Dexmedetomidine|administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
41101991|NCT01954940|DEVICE|Whole Body Vibration Therapy|
41101992|NCT06155253|PROCEDURE|Erector spinae plane block|"ESP block is a paraspinal fascial plane block that involves injection of local anesthetic underneath the anterior fascia of the erector spinae muscles.~Local anaesthetic mixture (lignocaine 2% with adrenaline, bupivacaine 0.25%) will be delivered with insulated needle in bolus(es) to above-mentioned levels (L1 in 1ESP group, T12 \& L1 in 2ESP group)"
41101993|NCT01494662|DRUG|HKI-272|240 mg orally, once daily
41101994|NCT01494662|PROCEDURE|Surgical Resection|Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
41101995|NCT01494662|DRUG|Capecitabine|750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
41101996|NCT01494662|DRUG|HKI-272|160 mg orally, once daily
41101997|NCT01494662|DRUG|Ado-Trastuzumab Emtansine|3.6 mg/kg IV every 3 weeks
41101998|NCT02305485|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
41101999|NCT02305485|DEVICE|XIENCE PRIME EECSS|Subjects receiving XIENCE PRIME EECSS
41102000|NCT00432029|PROCEDURE|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
41102001|NCT00432029|DEVICE|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
41102002|NCT00711646|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
41102003|NCT00711646|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
41102004|NCT00223054|DRUG|tacrolimus|retrospective analyze of drug levels in comparison to polymorphism
41102005|NCT00223054|DRUG|sirolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
41102006|NCT00223054|DRUG|everolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
41102007|NCT00223054|DRUG|cyclosporin A|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
41102008|NCT01784146|OTHER|Oxygen|"For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen."
41102009|NCT01784146|OTHER|Heliox|"For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al."
41102010|NCT01784146|OTHER|PEEP|PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
41102011|NCT00513734|OTHER|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
41102012|NCT00513734|OTHER|Lacrilube ointment|lubricant put into eye (inferior formix)
41102013|NCT05313191|RADIATION|Pencil Beam Scanning Proton Therapy|Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
41102014|NCT06063330|COMBINATION_PRODUCT|RQ-001|"Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator. Drug Product RQ-001 has been developed with an Aptar Bidose liquid nasal spray unit device (BDSI V3) capable of intranasally delivering a 200 uL total volume of drug product (specifically, 100 uL per nare, which delivers a 200 uL of total volume). The combination product comprises the drug constituent (RQ-01) and the assembly of commercially available, off-the-shelf device components.~Study staff will be responsible for assembling the drug product RQ-001 and subjects will self-administer under the supervision of study staff in the clinic."
41102015|NCT06063330|OTHER|Placebo|Matching placebo will be manufactured just as RQ-01 drug substance, with the active ingredient addition step omitted. Placebo will appear similar to RQ-01 drug substance as a clear to hazy, colorless to yellowish liquid. Matching placebo will be administered the same way as RQ-01
41102016|NCT02242929|DRUG|Imiquimod 5% cream with prior curettage|
41102017|NCT02242929|PROCEDURE|Standard surgical excision|
41102018|NCT03658499|BEHAVIORAL|two day skills group plus treatment adjuncts|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will be provided with the treatment adjuncts.
41102019|NCT03658499|BEHAVIORAL|two day skills group control group|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will not be provided with the treatment adjuncts and will serve as the control group
41102020|NCT04009070|DEVICE|Acupuncture Pres Needle: 0.22x1.5 mm needle|Acupunctur group; Acupunctur preoperatively 24 hours before bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the tuberocyte tibia). The tape (Needle Press) will remain for 24 hours after surgery.
41102021|NCT05206890|DRUG|fluzoparib monotherapy or combination therapy|patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
41102022|NCT00427557|DRUG|Fludarabine|30 mg/m\^2 by vein for 4 Days (Day -10 through Day -7).
41102023|NCT00427557|DRUG|Melphalan|140 mg/m\^2 by vein for 1 Day (Day -7).
41102024|NCT00427557|PROCEDURE|Umbilical Cord Blood|1 UCB Unit by vein on Day -5.
41102025|NCT00427557|DRUG|Rituximab|375 mg/m\^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).
41102026|NCT00427557|OTHER|Peripheral Blood Stem Cell Infusion|Infusion of blood stem cells on Day 0.
41102027|NCT03014596|OTHER|Assert|The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
41102028|NCT00968240|DRUG|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.~Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."
41102029|NCT03408860|OTHER|Countering Emotional Behaviors Module from Unified Protocol|This is a 4-week behavioral treatment that teaches patients to counter problematic emotional avoidance by approaching behaviors and situations that may bring up strong emotions in the short-term, but prevent interfering emotional difficulties in the long-term.
41102030|NCT00045916|PROCEDURE|High dosage electroconvulsive therapy|Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
41102031|NCT00045916|DRUG|Nortriptyline|Participants will receive nortriptyline.
41102032|NCT00045916|DRUG|Venlafaxine|Participants will receive venlafaxine.
41102033|NCT00045916|DRUG|Lithium|Participants will receive lithium.
41102034|NCT00045916|PROCEDURE|Low dosage electroconvulsive therapy|Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
41102035|NCT01877616|OTHER|diagnostic test|Polysomnography
41102036|NCT01877616|OTHER|Diagnostic test|overnight polysomnography
41102037|NCT03163953|BEHAVIORAL|TPAG with long break|PA coaching based on Thai Physical Activity Guideline (TPAG) and long break or break 15 minutes for every 2 hours (TPAG with LB)
41102038|NCT03163953|BEHAVIORAL|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
41102039|NCT03163953|OTHER|Control|No intervention
41102040|NCT02460484|BIOLOGICAL|Autologous Cord Blood Infusion|Intravenous infusion
41102041|NCT01981356|BEHAVIORAL|Acceptance and Commitment Therapy|"The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life."
41102042|NCT01981356|OTHER|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
41102043|NCT06551922|COMBINATION_PRODUCT|Instrumental Soft Tissue Mobilization Technique with Conservative Treatment|"TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes will be positioned.~Frequency: 3 times per week. Duration: 90 seconds- 2 minutes on each muscle (Purbia, 2023). Technique: A therapist uses Ergon tools to apply gentle pressure and strokes along the targeted muscles and fascial tissues. Different IASTM techniques, like stroking, raking, and hooking, address specific tissue restrictions. The therapist should continue the IASTM technique for 5-10 minutes, or until the stiffness in the knee is reduced (Mubashar et al., 2022; Purbia, 2023).~Conservative Treatment: Stretching exercises for the hamstrings and quadriceps to improve flexibility and reduce tension. Affected iliotibialband. Hold for 30 seconds. Uncross your legs and stand up straight again. Repeat four more times (Mubashar et al., 2022)."
41102044|NCT06551922|COMBINATION_PRODUCT|Conservative Treatment|"TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes will be positioned.~Stretching exercises with hold for 30 seconds. Uncross your legs and stand up straight again (Mubashar et al., 2022).~Quadriceps Strengthening: Perform exercises like straight leg raises, seated leg press and squats to strengthen (Lim \& Al-Dadah, 2022).~Hamstring Strengthening: Include exercises like leg curls to strengthen the hamstring muscles (Lim \& Al-Dadah, 2022).~Calf Strengthening: Perform calf raises to strengthen the calf muscles (Lim \& Al-Dadah, 2022).~Balance Exercises: Incorporate balance exercises like single-leg stands on a foam pad (Lim \& Al-Dadah, 2022).~Ice Therapy: Apply ice packs to the affected knee for 15-20 minutes (Lim \& Al-Dadah, 2022)."
41102045|NCT00698802|DRUG|EX1000|Treat-to-target titration scheme, s.c. injection
41102046|NCT00698802|DRUG|biphasic human insulin|Treat-to-target titration scheme, s.c. injection
41102047|NCT02785978|DRUG|Levodopa acute challenge|"Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring"
41102048|NCT02785978|OTHER|Controlled environment tests (series of tasks of everyday life)|"Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)"
41102049|NCT02785978|OTHER|Standardized scales: MDS-UPDRS (Part II to IV) and RDRS|"Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS"
41102050|NCT02785978|DEVICE|ActiMyo recording|Continuous activity recording with ActiMyo during the 2 weeks of study participation
41102051|NCT02785978|OTHER|Diary completion|Daily patient logbook completion during the 2 weeks of study participation
41102052|NCT02741167|PROCEDURE|CRS and HIPEC|During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
41102053|NCT03426696|BEHAVIORAL|psychological condition|Graves ́ ophthalmopathy quality of life questionnaire, Symptom checklist 90(SLC-90), Hamilton anxiety scale(HAMA), Somatic self-rating scale(SSS), MATRICS Consensus Cognitive Battery (MCCB), Hamilton depression scale(HAMD)
41102054|NCT01407601|DIETARY_SUPPLEMENT|daily supplementation of MK-7 over 6 weeks|once daily intake of MK-7 prior to dialysis over 6 weeks
41102055|NCT04631549|DRUG|SHR3680|SHR3680, PO, single dose
41102056|NCT05655442|PROCEDURE|early APM|early APM within 3 and 6 month knee pain symptoms
41102057|NCT05655442|PROCEDURE|delayed APM|delayed APM within 6 and 12 month knee pain symptoms
41102058|NCT00057382|DRUG|T138067 intravenous|
41102059|NCT00057382|DRUG|doxorubicin intravenous|
41102060|NCT01738867|DRUG|GSK1521498|White HPMC capsule containing 10 mg of GSK1521498
41102061|NCT01738867|DRUG|Naltrexone (NTX)|Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
41102062|NCT01738867|DRUG|Placebo|Matching placebo capsules to GSK1521498 or NTX
41102063|NCT02834143|OTHER|No intervention|The is no intervention. This study is a descriptive one
41102064|NCT03610997|PROCEDURE|Photorefractive keratectomy|
41133273|NCT01681654|BEHAVIORAL|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
41443457|NCT02243579|OTHER|Laboratory Biomarker Analysis|Correlative studies
41443458|NCT02243579|BIOLOGICAL|Pembrolizumab|Given IV
41102065|NCT04424407|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist once a week for six weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
41102066|NCT03568799|RADIATION|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
41102067|NCT04417270|DEVICE|Freestyle Libre 14 day CGM system|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
41102068|NCT04417270|DEVICE|Accuchek Inform II platform|The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care. Wireless meter quickly transfers data. The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
41102069|NCT03724838|DRUG|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day
41102070|NCT03724838|DRUG|Sildenafil Citrate|Patients will take Sildenafil Citrate 40mg every 8 hours
41102071|NCT03724838|DRUG|Placebo to Esomeprazole|Patients will take inert tablets similar in appearance, color, and consistency to esomeprazole single dose of 40 mg orally once a day
41102072|NCT03724838|DRUG|Placebo to Sildenafil Citrate|Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
41102073|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 1|Each subject will use this product during one of the five treatment periods in the crossover study design.
41102074|NCT06140745|DRUG|1100 ppm NaF Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
41102075|NCT06140745|DRUG|1500 ppm NaMFP Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
41102076|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 2|Each subject will use this product during one of the five treatment periods in the crossover study design.
41102077|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 3|Each subject will use this product during one of the five treatment periods in the crossover study design.
41102078|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Relative Risk|Risk of T2D is presented in comparison to the rest of the Singapore population in a scale 1-10. Suggestions on different lifestyle changes and its potential to reduce the individual's relative risk is presented for user to observe impact of preventative behaviours.
41102079|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Metabolic Age|Risk of T2D is presented as an age, compared to their chronological age as a proxy for their current health status. Suggestions on different lifestyle changes and its potential to reduce the individual's metabolic age is presented for user to observe impact of preventative behaviours.
41102080|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Traffic Light|Risk of T2D is presented as either High (Red) or Low (Green). Generic tips on how to reduce risk of diabetes are included. This imitates the tool that is currently available for residents of Singapore to use to assess their risk of T2D.
41102081|NCT03176030|DIETARY_SUPPLEMENT|Fortified Foods|The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
41102082|NCT01405924|DRUG|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
41102083|NCT01405924|DRUG|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
41102084|NCT01405924|DRUG|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
41102085|NCT01405924|DRUG|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
41102086|NCT02841891|DEVICE|Sylys® Surgical Sealant|Standard Stapled Anastomosis Colectomy Procedure with the addition of Sylys® Surgical Sealant
41102087|NCT02841891|PROCEDURE|Stapled Anastomosis Colectomy Procedure|Standard Stapled Anastomosis Colectomy Procedure without the addition of Sylys® Surgical Sealant
41102088|NCT05528536|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|A two-hour ACT will focus on enhancing participant's psychological flexibility towards pain. All sessions will be delivered face-to-face within their local community centre.
41443459|NCT05136196|PROCEDURE|Biopsy|Undergo tumor biopsies
41102089|NCT05528536|OTHER|Art|To be comparable with the experimental group, the Art session will be a two-hour long session which aims to share different art techniques, without any active components. All sessions will be delivered face-to-face within their local community centre.
41102090|NCT05528536|OTHER|Exercise|An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.
41102091|NCT05528536|OTHER|Treatment as usual|treatment as usual within their community centres
41102092|NCT00009984|DRUG|fludarabine phosphate|Given IV
41102093|NCT00009984|DRUG|thalidomide|Given orally
41102094|NCT02611232|DRUG|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
41102095|NCT02611232|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
41102096|NCT02576340|DRUG|otilonium bromide|otilonium bromide was administered before the procedure
41102097|NCT05838664|DRUG|No OAC|AF Patient who were not exposed to oral anticoagulation
41102098|NCT05838664|DRUG|VKA|AF patients who received VKA
41102099|NCT05838664|DRUG|apixaban|AF patients who received apixaban
41102100|NCT05838664|DRUG|rivaroxaban|AF patients who received rivaroxaban
41102101|NCT05838664|DRUG|dabigatran|AF patients who received dabigatran
41102102|NCT04538248|OTHER|Combined rehabilitation during hemodialysis|Combined rehabilitation during hemodialysis
41102103|NCT01278433|BIOLOGICAL|IMOVAX Polio™: Inactivated Poliomyelitis Vaccine|0.5 mL, Intramuscular
41102104|NCT05607953|DRUG|SD-101|SD-101 doses are administered via PRVI using the PEDD method of administration
41102105|NCT05607953|BIOLOGICAL|anti-PD-1|In the Phase 1b, anti-PD-1 will be administered together with SD-101
41102106|NCT03701230|OTHER|low temperature rota-flush solution|Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
41102107|NCT05026034|DEVICE|non-invasive Cardiopulmonary Management (CPM) wearable device|non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure
41102108|NCT00891618|OTHER|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
41102109|NCT05903482|OTHER|None - observational|Observational
41102110|NCT02390258|DRUG|10mg XEN-D0103|
41102111|NCT02390258|DRUG|Placebo|
41102112|NCT02390258|DRUG|30mg XEN-D0103|
41102113|NCT02390258|DRUG|60mg XEN-D0103|
41102114|NCT02390258|DRUG|120mg XEN-D0103|
41102115|NCT02390258|DRUG|200mg XEN-D0103|
41102116|NCT02390258|DRUG|150mg XEN-D0103|
41102117|NCT00449813|DRUG|Pantoprazole|40 mg Pantoprazole
41102118|NCT04310579|DRUG|Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) and placebo IV 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day."
41102119|NCT04310579|DRUG|Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
41102120|NCT02885051|PROCEDURE|Recording of skin conductance and heart rate variability.|When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
41102121|NCT02646670|DRUG|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
41102122|NCT02646670|DRUG|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
41102123|NCT02646670|DRUG|Ranibizumab and Aflibercept|- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
41102124|NCT02646670|DRUG|Aflibercept and ranibizumab|- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
41102125|NCT06187480|PROCEDURE|total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)|The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.
41102126|NCT03254394|DRUG|Lidocaine Hydrochloride|"Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study."
41102127|NCT03254394|DRUG|Placebo|Dextrose 5% in water will be administered as active comparator.
41102128|NCT03254394|DRUG|FOLFOX regimen|"Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
41102129|NCT00206024|DRUG|Esomeprazole magnesium (Nexium)|
41102130|NCT03692520|BIOLOGICAL|SCT200|Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
41102131|NCT02957292|DRUG|Levonorgestrel (13,5 mg) intrauterine device|
41102132|NCT02957292|DEVICE|Cooper (380mm2) intrauterine device|
41102133|NCT01516788|OTHER|Phototesting|Single MED dose on Day 2
41102134|NCT05660395|DRUG|Loncastuximab Tesirine|Intravenous (IV) Infusion
41102135|NCT01805349|RADIATION|Hand X-rays|Hand X-rays to assess the digital arthrosis
41102136|NCT04835038|DRUG|Sodium Bicarbonate Ringer's Injection|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
41102137|NCT04835038|DRUG|Sodium Lactated Ringer's Injection|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
41102138|NCT04312776|OTHER|none intervention|
41102139|NCT02882048|PROCEDURE|NADA Protocol|NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.
41102140|NCT02882048|OTHER|Medication management|Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
41102141|NCT03230591|OTHER|Echocardiography|LV vortex flow in Echocardiography
41102142|NCT02364518|PROCEDURE|Snoreplasty|The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
41102143|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
41102144|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
41102145|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
41102146|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
41102147|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
41102148|NCT01596725|BIOLOGICAL|Saline Placebo|Placebo; intramuscular, deltoid, Day 0 and Day 21
41102149|NCT00371566|DRUG|Lapatinib oral tablets|
41102150|NCT00371566|DRUG|Placebo|
41102151|NCT06126536|PROCEDURE|Crestal Maxillary Sinus Floor Elevation using Osseodensification|Patients will be prepared for surgery with local anesthesia and thorough oral cavity disinfection. A full thickness crestal incision will be made slightly towards the palate to enhance the possibility of achieving primary wound closure. A conservative flap will be raised, extending slightly beyond the alveolar crest, to minimize flap-related issues. After preparing the osteotomy site using Densah burs and elevating the sinus to the desired height, the implant will be inserted into the osteotomy site.
41102152|NCT06126536|PROCEDURE|Lateral Maxillary Sinus Floor Elevation|A crestal incision with an anterior vertical releasing incision exposes the sinus's lateral wall. A mucoperiosteal flap is carefully reflected, revealing the sinus. A bony window is created using a Piezoelectric device, and after elevation, the sinus floor is carefully lifted with various curettes. Implant osteotomies follow standard placement protocol, with precautions against sinus membrane perforation. Nanobone is used as graft material, mixed with saline and gently packed into the sinus. A resorbable membrane is placed on the window's outer surface, secured with circumferential resorbable sutures, and the flap is sutured for closure.
41102153|NCT03132324|DRUG|INCB059872|INCB059872 tablets
41102154|NCT01014858|DRUG|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
41102155|NCT02160106|DRUG|TEW-7197|Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
41102156|NCT02601053|OTHER|Dull movie|A dull movie (duration approximately 90 minutes)
41102157|NCT02601053|OTHER|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
41102158|NCT02601053|OTHER|Heart rate measurement|Heart rate measurement using a actiheart device
41102159|NCT02387749|GENETIC|mesenchymal stem cells|collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
41102160|NCT00530335|DRUG|Atomoxetine|40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
41102161|NCT05372094|DEVICE|Phonak Hearing Aid|Commercially available hearing aid with various noise reduction strengths
41102162|NCT02074956|BIOLOGICAL|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
41102163|NCT02074956|BIOLOGICAL|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
41102164|NCT05481502|PROCEDURE|Tumor biopsy|3 biopsies will be collected: at baseline, at day+15 and optionally at relapse
41102165|NCT05481502|PROCEDURE|Blood sample|7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse
41102166|NCT05481502|PROCEDURE|Bone marrow sample|If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled
41102167|NCT02047851|OTHER|Acupuncture|Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
41102168|NCT00744250|DRUG|Pancrelipase|PANCRECARB MS-16
41102169|NCT03753152|DEVICE|experimental|Neuramis® Deep Lidocaine
41102170|NCT03753152|DEVICE|comparator|YVOIRE® Volume Plus
41102171|NCT02085356|BEHAVIORAL|Protect your family|"Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)"
41102172|NCT00914823|DRUG|kisspeptin 112-121|One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121
41102173|NCT00914823|DRUG|GnRH|One or more IV doses of GnRH, and/or SC administration of GnRH
41102174|NCT04277689|PROCEDURE|Brain signal data collection|Collection of speech related electrophysiological data at the time of DBS.
41102175|NCT02008734|DRUG|PD0332991|
41102176|NCT05174286|BEHAVIORAL|SBIRT|"SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~The investigators will utilize the Culturally-adapted Alive! Program - a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control."
41102177|NCT05174286|BEHAVIORAL|Referral as Usual (RAU)|Referral as Usual will involve distributing CRC health educational materials (e.g. NCI or CDC brochures that include new guidelines) and contact information for screening service providers in our target community.
41102178|NCT00217711|DRUG|Capecitabine|capecitabine
41102179|NCT00217711|DRUG|irinotecan hydrochloride|irinotecan hydrochloride
41102180|NCT00217711|DRUG|oxaliplatin|oxaliplatin
41102181|NCT02117843|DEVICE|AVI® Arsenic trioxide drug eluting stent|AVI® Arsenic trioxide drug eluting stent
41102182|NCT06424977|DEVICE|Biomarker Targeted Stimulation (BTS)|Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence.
41102183|NCT02903836|DRUG|Nafithromycin 800 mg 3 days|
41102184|NCT02903836|DRUG|Nafithromycin 800 mg 5 days|
41102185|NCT02903836|DRUG|Moxifloxacin 400 mg|
41102186|NCT00890786|DRUG|Temozolomide|"High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5."
41102187|NCT00890786|DRUG|Bevacizumab|"High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days)."
41443460|NCT05136196|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41102188|NCT00890786|DRUG|Irinotecan|"High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days)."
41102189|NCT01664104|DRUG|Tocilizumab|Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
41102190|NCT04588285|DRUG|Ambroxol|Oral ambroxol medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
41443461|NCT05136196|DRUG|Cabozantinib S-malate|Given PO
41443462|NCT05136196|PROCEDURE|Computed Tomography|Undergo CT scans
41443463|NCT05136196|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
41443464|NCT05136196|BIOLOGICAL|Nivolumab|Given IV
41443465|NCT04581304|DEVICE|Geistlich Bio-Oss® Collagen|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation.
41443466|NCT04581304|DEVICE|Geistlich Bio-Oss® Granules|Geistlich Bio-Oss® Granules is intended to be used for filling bone defects and for bone augmentation.
41443467|NCT01340495|RADIATION|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
41443468|NCT05829824|BEHAVIORAL|CareConnect|A combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR)
41443469|NCT05829824|OTHER|AutoReach|Phone call / SMS Text
41443470|NCT05829824|PROCEDURE|Biospecimen samples|Optional saliva sample
41102191|NCT04588285|DRUG|Placebo|Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
41102192|NCT06414382|OTHER|Tape-stripping|22mm tapes x 40 will be attached and removed to skin of all for limbs (tape stripping). On left arm and leg skin will also be subject to micro needling.
41102193|NCT01989637|DIETARY_SUPPLEMENT|Strawberry Meal|High-fat meal (50 g total fat) with 40 g freeze dried strawberry powder
41102194|NCT01989637|DIETARY_SUPPLEMENT|Control Meal|High-fat meal (50 g total fat) with a matched placebo powder containing no strawberry bioactives
41102195|NCT05754281|DEVICE|2nd Gen LabPatch Glucose Sensing System|"I. The 2nd Gen LabPatch chip which lies in the center of a clasp unit. The chip measures approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact~II. A LabPatch clasp device~III. A wire that connects the clasp unit to a Windows tablet which will communicate with the clasp via an application. Each data point will be viewed on the tablet and the application will also have some limited graphing capabilities to view trends of previous measurements"
41102196|NCT02967016|BEHAVIORAL|Actigraph|following delivery a ActiGraph will be offered to patients to track their steps
41102197|NCT03140176|DRUG|Sunitinib|Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.
41102198|NCT00950404|DRUG|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
41102199|NCT00950404|DRUG|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
41102200|NCT00950404|DRUG|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
41102201|NCT00950404|DRUG|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
41102202|NCT03126084|DRUG|Acetaminophen|1000 mg of intravenous acetaminophen will be administered twice a day
41102203|NCT03126084|DRUG|0.25% Bupivacaine|20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.
41102204|NCT03126084|DRUG|0.5% Bupivacaine+Glucose|15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle
41102205|NCT03126084|DRUG|Tramadol HCl|50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
41102206|NCT03126084|PROCEDURE|Inguinal Hernia Repair|Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques
41102207|NCT03126084|DRUG|0.25% Bupivacaine|10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
41102208|NCT04276987|BIOLOGICAL|MSCs-derived exosomes|5 times aerosol inhalation of MSCs-derived exosomes (2.0\*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
41102209|NCT03860220|DRUG|NEWSTATIN TS|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks
41102210|NCT03860220|DRUG|CADUET|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks
41102211|NCT03594331|DRUG|Low-dose PvP001|Low-dose PvP001
41102212|NCT03594331|DRUG|Medium-dose PvP001|Medium-dose PvP001
41102213|NCT03594331|DRUG|High-dose PvP001|High-dose PvP001
41102214|NCT03594331|DRUG|Placebo|100 mL liquid with no drug
41102215|NCT01469949|OTHER|Watching or imagining movement|Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
41102216|NCT02774252|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - Y49-103)
41102217|NCT02785744|OTHER|Gaucher disease DNA mutation analysis|
41102218|NCT00751491|DRUG|Adenosin|Intracoronary Adenosin 50 microg;
41102219|NCT00751491|OTHER|placebo|no intervention
41102220|NCT00751491|DRUG|Clopidogrel|Clopidogrel 300/600 mg
41102221|NCT03018119|OTHER|Survey|
41102222|NCT06394791|DRUG|Tislelizumab + IL-2 Combined with Capox|Tislelizumab + IL-2 Combined with Capox
41102223|NCT02265731|DRUG|azacitadine|75 mg/m2 by IV infusion or subcutaneous dosing
41102224|NCT02265731|DRUG|venetoclax|Step-up doses of venetoclax to the designated cohort dose
41102225|NCT02265731|DRUG|rituximab / IDEC-C2B8|375 mg/m2 on Week 6
41102226|NCT02265731|DRUG|rituximab / IDEC-C2B8|500 mg/m2 Week 10 Day 1 and thereafter
41102227|NCT03789799|OTHER|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
41102228|NCT03789799|OTHER|Placebo|Placebo vaginal capsule, composition: Sodium Hyaluronate, Aloe Barbadensis Extract
41102229|NCT06189105|OTHER|miss alice face it you love me serum|Facial serum with niacinamide, plant-based collagen and peptides will be applied by each participant to the treatment site according to randomization protocol every evening
41102230|NCT06189105|OTHER|No treatment (usual skincare rutine)|No treatment (usual skincare rutine)
41102231|NCT00378677|DRUG|Cyclosporine A dry powder inhalation (Drug)|
41102232|NCT06492356|DEVICE|Tripolar radiofrequency therapy|Twenty patients underwent weekly TriPollar RF treatment, using a new RF technology with three or more electrodes. Glycerin was applied to the treatment area before and after each session, with the procedure lasting 15 minutes. The technology uses a sequence of electrical modulation to prevent overheating and requires no active cooling of the electrodes or skin.
41102233|NCT06492356|DRUG|medical treatment|Twenty patients will receive medical treatment by dermatologist.
41102234|NCT01228851|OTHER|Balance Training|Group balance training sessions three times a week for 8 weeks
41102235|NCT00006391|DRUG|oxaliplatin|
41102236|NCT00006391|DRUG|topotecan hydrochloride|
41102237|NCT00371020|DRUG|low molecular weight heparin, 5-FU|
41102238|NCT05771090|DEVICE|Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
41102239|NCT03158948|DRUG|Nangibotide 0.3 mg/kg|Formulated LR12 peptide
41102240|NCT03158948|DRUG|Placebo|placebo
41102241|NCT03158948|DRUG|Nangibotide 1 mg/kg|Formulated LR12 peptide
41102242|NCT03158948|DRUG|Nangibotide 3 mg/kg|Formulated LR12 peptide
41102243|NCT03810482|DEVICE|Pedometer|A pedometer will be worn by the patient at home for days 1 to 14 and 60 to 74.
41102244|NCT03810482|OTHER|6 minute walking test|Performed according to current recommendations during routine visits (baseline and \~90 days for the purposes of this study).
41102245|NCT03232684|DIAGNOSTIC_TEST|Rapid on-site evaluation|On-site (endoscopy suite) evaluation, by a pathologist or a pulmonologist, of specimens retrieved from intrathoracic lymph nodes during EBUS-TBNA
41102246|NCT03662399|DEVICE|Insoles|Orthotic Insoles
41102247|NCT03662399|OTHER|Standard shoe|Standard shoe
41102248|NCT04859595|OTHER|Telephone follow-up|"Monthly follow-up by telephone from M1 to M6. The interview will unroll in 2 stages, a first stage of discussion during which the speech therapist will take news of the patient. The second, more formal phase will be the opportunity to collect the data necessary for the validation of the primary and secondary outcomes. To do this, the speech therapist will use the Functional Oral Intake Scale (FOIS) score, the DHI and an interview grid.~The interview will be conducted using an interview sheet previously written by the project team. The following elements will be discussed: the description of oral food intakes (TIMES), the perceived swallowing handicap (DHI), the instructions related to the diet and their daily application, ongoing rehabilitation follow-ups, notable events as well, then his emotional and psychological experience in relation to the disorder."
41102249|NCT04990791|DRUG|Aspirin 75mg|Aspirin 75mg OD for 14 days
41102250|NCT04990791|DRUG|Aspirin 20mg|Aspirin 20mg BD for 14 days
41102251|NCT04990791|DRUG|Rivaroxaban 2.5 mg|Rivaroxaban 2.5mg BD
41102252|NCT02873884|BEHAVIORAL|Case-management|
41443471|NCT00829309|DRUG|Pravastatin|80 mg Tablet
41102253|NCT04206046|PROCEDURE|Spinal anaesthesia|Patients will receive a spinal anaesthetic
41102254|NCT04206046|PROCEDURE|General anaesthesia|patients will receive a general anaesthetic and a femoral nerve block
41102255|NCT01142713|RADIATION|Patient Position During Radiotherapy|Two simulations, one in the supine position on a flat table and another in the prone position on belly board
41102256|NCT00683735|DRUG|Sitagliptin|100 mg once daily in the morning
41102257|NCT00683735|DRUG|Metformin|up to 2000 mg/day
41102258|NCT00683735|DRUG|Placebo|500mg 1-0-0-0
41102259|NCT00683735|DRUG|Placebo|100mg 1-0-0-0
41102260|NCT01167426|DRUG|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
41102261|NCT01167426|DRUG|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
41102262|NCT05025124|DEVICE|Entia Liberty|Home monitoring system
41102263|NCT00684528|DRUG|Metformin 1500 mg daily|500 mg thrice daily
41102264|NCT00684528|DRUG|Metformin + Janufer (Janumet)|Titration up to 1500/150 mg daily
41102265|NCT02271607|DEVICE|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
41102266|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~* 14mg/ms day +1 and +8~* 10mg/ms day +1 and +8~* 8mg/ms day +1 and +8~CHOEP-21~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
41102267|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles~* Romidepsin dose according to phase I iv day +1 and +8~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
41102268|NCT06343558|OTHER|Questionnaires, clinical scales and instrumental tests|Questionnaires, clinical scales and instrumental tests to collect a wide range of balance and gait measures.
41102269|NCT00635895|OTHER|Manual Lymph Drainage Therapy and Connective Tissue Massage|The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
41102270|NCT04312568|DRUG|Fadanafil|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
41102271|NCT04312568|DRUG|Placebo|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
41102272|NCT02414919|DRUG|Mirena (Levonorgestrel IUS, BAY86-5028)|Levonorgestrel-releasing intrauterine device 20 mcg/day
41102273|NCT02414919|DRUG|ParaGard|Copper T380A
41102274|NCT02414919|DRUG|Implanon/Nexplanon|Etonorgestrel contraceptive implant
41102275|NCT04543513|OTHER|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
41102276|NCT01609894|DIETARY_SUPPLEMENT|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
41443472|NCT00829309|DRUG|Pravastatin|80 mg Tablets
41102277|NCT01609894|DIETARY_SUPPLEMENT|Routine fortification of breast milk|Infants will be fed routine fortified breast milk.
41102278|NCT04290585|OTHER|Questionnaire Administration|Ancillary studies
41102279|NCT04290585|BEHAVIORAL|Telephone-Based Intervention|Receive text message reminders
41102280|NCT04385342|DRUG|FSH|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
41102281|NCT04385342|DRUG|HP-hMG|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
41102282|NCT04855188|DEVICE|YVOIRE Y-Solution 540|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
41102283|NCT04855188|DEVICE|YVOIRE volume plus|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
41102284|NCT02046616|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered subcutaneously QW.
41102285|NCT02046616|DRUG|Methotrexate|Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
41102286|NCT02046616|DRUG|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
41102287|NCT03098030|BIOLOGICAL|Dinutuximab|Dinutuximab injection, for intravenous (IV) use
41102288|NCT03098030|DRUG|Irinotecan|Irinotecan injection, IV infusion
41102289|NCT03098030|DRUG|Topotecan|Topotecan for injection
41102290|NCT00207844|DRUG|Selenium as sodium selenite|
41102291|NCT04416139|BIOLOGICAL|Infusion IV of Mesenchymal Stem cells|Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose
41102292|NCT02426320|OTHER|Sedation Interruption Protocol|
41102293|NCT02426320|OTHER|Standard Sedation Protocol|
41102294|NCT03755440|DRUG|PD-1 antibody (SHR-1210)|PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
41102295|NCT05765851|DRUG|DS-1103a|One IV infusion Q3W on Day 1 of each 21-day cycle
41102296|NCT05765851|DRUG|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
41102297|NCT04153344|OTHER|Electro-oculogram|Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.
41102298|NCT04153344|OTHER|Full-field electroretinogram|Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).
41102299|NCT00469300|DRUG|Iontophoretic delivery of acyclovir|
41102300|NCT00271765|DRUG|INO-1001|
41102301|NCT00117364|DRUG|SACCHACHITIN patch|
41102302|NCT02414906|OTHER|Goal-directed therapy|Goal-directed therapy with fluids and dobutamine
41102303|NCT04482348|OTHER|Explanation|Explanation provided to patients for more pain than expected
41102304|NCT01646502|BIOLOGICAL|Esp protein|
41102305|NCT01646502|OTHER|Standard wound care|
41102306|NCT02784704|DRUG|Eravacycline|
41102307|NCT02784704|DRUG|Meropenem|
41102308|NCT02784704|DRUG|Placebo|
41102309|NCT00773019|DEVICE|Refills (SynchroMed® II Programmable Drug Infusion Pump)|Refill information at 1, 6, and 12 months post-implant, as well as any additional refills required from implant through end of study. Amount removed from the pump (taken from syringe), Amount placed in the pump (from syringe),Pump predicted amount remaining in the pump.
41102310|NCT05391724|DRUG|CMX001|single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
41102311|NCT05886335|DRUG|Cyclophosphamide|Time of administration
41102312|NCT04766437|DRUG|Prasugrel 10mg|Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg prasugrel at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
41102313|NCT04766437|DRUG|Ticagrelor 90mg|Twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
41102314|NCT03377855|OTHER|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
41102315|NCT01606995|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
41102316|NCT06067230|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
41102317|NCT02951117|DRUG|Venetoclax|Tablet
41102318|NCT02951117|DRUG|ABBV-838|Intravenous infusion
41102319|NCT02951117|DRUG|Dexamethasone|Tablet or intravenous infusion
41102320|NCT04241653|PROCEDURE|Pressure Support Ventilation|Ventilator will be adjusted to administer pressure at 10 cmH2O.
41102321|NCT04241653|PROCEDURE|Unparalyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography.
41102322|NCT04241653|PROCEDURE|Paralyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography. Also, neuromuscular blockade will be achieved.
41102323|NCT04241653|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation; its size is chosen according to the body weight of the child.
41102324|NCT04241653|DRUG|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% will be titrated to achieve adequate depth of anesthesia to maintain immobilization of the eye.
41102325|NCT00004192|BIOLOGICAL|filgrastim|
41102326|NCT00004192|BIOLOGICAL|pegfilgrastim|
41102327|NCT00004192|DRUG|cisplatin|
41102328|NCT00004192|DRUG|cytarabine|
41102329|NCT00004192|DRUG|etoposide|
41102330|NCT00004192|DRUG|methylprednisolone|
41102331|NCT01409512|PROCEDURE|ECG recording|At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
41102332|NCT01424579|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
41102333|NCT01424579|OTHER|Placebo Diactuaneous Fibrolysis|Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
41102334|NCT01424579|OTHER|Protocolized physiotherapeutic Treatment|Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
41102335|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
41102336|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
41102337|NCT01320709|DRUG|Placebo|Single dose of placebo (i.e., 4 placebo capsules)
41102338|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
41102339|NCT04838210|BEHAVIORAL|EleVATE Group Care|10-session (2 hours per session) group prenatal care model following the prenatal visit schedule recommended by ACOG. In addition to pregnancy and infant-care related content, the EleVATE GC curriculum includes behavioral health strategies that can be used to manage depression and labor pain and navigate the daily frustrations and stress of life. Groups are facilitated by an obstetric clinician.
41102340|NCT04838210|BEHAVIORAL|Individual Prenatal Care|The dominant model of prenatal care in the United States, consisting of one-on-one encounters between a patient and obstetric clinician. Patients are seen for 10-15 mins every 4 weeks until 28 weeks gestation, every 2 weeks until 37 weeks or more by provider discretion), and weekly until delivery. Visits focus on routine screening tests and prenatal care.
41102341|NCT05843656|OTHER|Non-invasive brain stimulation|based on sleep-physiology (slow-wave and spindles)
41102342|NCT00757718|DEVICE|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
41102343|NCT00757718|DEVICE|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
41102344|NCT03939572|BEHAVIORAL|Accurate step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.
41102345|NCT03939572|BEHAVIORAL|Deflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count deflated by 40% (i.e., their step count multiplied by 0.6).
41102346|NCT03939572|BEHAVIORAL|Inflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count inflated by 40% (i.e., their step count multiplied by 1.4).
41102347|NCT03939572|BEHAVIORAL|Accurate feedback + mindset intervention|"After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.~Additionally, participants in this arm will receive a meta-mindset intervention in the first weekly survey on day 7, which consists of a series of videos and reflection exercises to teach participants about the power of mindsets and encourage them to choose adaptive mindsets that will benefit their health. There are also short booster reflection exercises in all subsequent daily and weekly surveys, reinforcing the message about adaptive mindsets."
41102348|NCT02856711|BEHAVIORAL|Trauma-informed group|"The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood."
41102349|NCT04716933|BIOLOGICAL|Pembrolizumab|IV infusion Q3W
41102350|NCT04716933|DRUG|Carboplatin|IV infusion Q3W
41102351|NCT04716933|DRUG|Cisplatin|IV infusion Q3W
41102352|NCT04716933|DRUG|Pemetrexed|IV infusion Q3W
41102353|NCT04716933|DRUG|Lenvatinib|Oral capsule once daily
41102354|NCT04716933|DRUG|Placebo matching lenvatinib|Oral capsule once daily
41443473|NCT05947591|BEHAVIORAL|foot posture index|the tendency to foot pronation in healthy subjects will be compared during one hour of walking versus one hour of running in subjects who usually run.
41443474|NCT05405881|OTHER|Proprioception measurement tool|No intervention, as it is a psychometric properties study
41102355|NCT00225719|DRUG|rHDL|
41102356|NCT06458127|OTHER|Tele-palliative care visit|Participants will meet with a specialty palliative care clinician for a video-consultation once a month, and complete three tele-PC consultations in total over a three-to-four-month period. They will also complete self-report assessments at baseline and immediately after the last PC intervention visit, approximately 3-4 months after enrolment.
41102357|NCT03997006|DRUG|IV Aminophylline|IV Aminophylline (100 mg/8h)
41102358|NCT03997006|DRUG|IV Neostigmine Methylsulfate + Atropine Sulphate|IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h
41102359|NCT01245439|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
41102360|NCT00869037|DRUG|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
41102361|NCT00869037|DRUG|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
41102362|NCT04856228|DIAGNOSTIC_TEST|diagnostic posterior interosseous nerve lidocaine injection|ultrasound guided posterior interosseous nerve and lateral epicondyle 1 ml 2% lidocaine injection
41102363|NCT04088188|DRUG|Cisplatin|Given IV
41102364|NCT04088188|DRUG|Gemcitabine|Given IV
41102365|NCT04088188|DRUG|Ivosidenib|Given PO
41102366|NCT04088188|DRUG|Pemigatinib|Given PO
41102367|NCT00697229|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 or 3 doses
41102368|NCT00697229|BIOLOGICAL|HBV-MPL vaccine|Intramuscular injection, 1 or 3 doses
41102369|NCT02784327|DRUG|PRF110|
41102370|NCT03096184|DRUG|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
41102371|NCT03096184|DRUG|Tegafur Gimeracil Oteracil Potassium Capsules|50mg bid p.o. every day for 14 days as a cycle
41102372|NCT02718118|DEVICE|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
41102373|NCT02718118|DEVICE|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
41102374|NCT01188252|DRUG|Roniciclib (BAY1000394)|Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
41102375|NCT05819450|PROCEDURE|Volumetric rejuvenation|Volumetric Rejuvenation with FDA-approved fillers on the skin of the dorsal hands
41102376|NCT06037135|DRUG|dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery. The research nurse, who did not participate in the study other than the management and preparation of the study medication, prepared 50mL of 0.9% normal saline for the control group and a mixture of dexmedetomidine 2 mL and 0.9% normal saline 48 mL (at a concentration of 4 μg/mL) for the dexmedetomidine group.
41102377|NCT06037135|DRUG|0.9% normal saline|In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
41102378|NCT02104609|DRUG|Levonorgestrel 1.5mg by mouth once|Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
41102379|NCT00837616|DRUG|17 B estradiol orally|Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
41102380|NCT00837616|DRUG|17 B estradiol|Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
41102381|NCT04826055|OTHER|biliary limb as fixed length|n all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
41102382|NCT04826055|OTHER|biliary limb as a percentage from small intestine length|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
41102383|NCT00516711|DRUG|Sevoflurane|
41102384|NCT00440284|DRUG|conventional vs. flexible, intensive insulin therapy|
41102385|NCT05931107|OTHER|Stress ball practice group (Stress ball squeezing)|The stress ball is made of round, colorful, high-quality silicone. A stress ball of medium hardness and 6 cm in diameter (suitable for adult use) will be used in the research. When it is loosened, it returns to its original state. In the experimental group, the patients are required to squeeze the ball once after counting to three, inhale each time they squeeze the ball, exhale when they loosen their grip, and focus only on the ball. The experimental group has to squeeze the stress ball for 10-15 minutes every day for 4 weeks.
41102386|NCT05612659|PROCEDURE|Transcranial Electrical stimulation|Noninvasive electrical stimulation of lateral frontal cortex.
41102387|NCT05612659|PROCEDURE|Transcutaneous direct current stimulation|Noninvasive electrical stimulation of the T10 spinal column.
41102388|NCT03269019|DIAGNOSTIC_TEST|HIT with thrombosis|Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.
41102389|NCT00370448|BEHAVIORAL|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
41102390|NCT02667730|DRUG|Acetaminophen|Acetaminophen 500 mg four times daily for 7 days
41102391|NCT02667730|DRUG|Naproxen|naproxen 500mg twice daily for 7 days
41102392|NCT02667730|DRUG|Celecoxib|celecoxib 100mg twice daily
41102393|NCT02667730|OTHER|physiotherapy only|physiotherapy only (no drug)
41102394|NCT03720613|DRUG|Naldemedine|0.2 mg tablet once a day at any time with or without food
41102395|NCT03720613|DRUG|Lubiprostone|0.024 mg twice a day \[adjust dose based on liver function\]
41102396|NCT03720613|DRUG|Naloxegol|25 mg tablet once a day in morning, 1 hour before or 2 hours after food
41102397|NCT02144350|PROCEDURE|Hyperbaric oxygen|patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.
41102398|NCT02144350|PROCEDURE|Sham Hyperbaric Air|Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
41102399|NCT05961670|DEVICE|Neer Infrared Spectroscopy|Premature infants will be studied with brain and lung NIRS before and after surfactant administration
41102400|NCT00099515|DRUG|LY041001 (HIIP)|Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
41102401|NCT00099515|DRUG|LY041001 (HIIP)|Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
41102402|NCT01624636|DRUG|Placebo|
41102403|NCT01624636|DRUG|LFG316|
41102404|NCT01624636|DRUG|LFG316|
41102405|NCT04319796|OTHER|Data set as defined by the ERN Research Workgroup of the European Commission|"The ERN-RND registry will be restricted to the minimum data set as defined by the ERN Research Workgroup of the European Commission. This includes the following data:~* Name of specialist center~* Pseudonym:~* Date of birth: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of birth~* Sex~* Date of death: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of death~* Age of onset~* Orphacode for specific rare disease: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=DE~* Online Mendelian Inheritance in Man (OMIM) code as defined for genetic diseases: https://www.omim.org/~* Human Phenotype Ontology (HPO) terms for key features: https://hpo.jax.org/app/~* Agreement to be contacted for research purposes: Yes/No~* Biological samples (Yes / No)~* Link to a biobank (Link / No)~* Classification of disability (Disease group specific score)"
41102406|NCT01391442|BIOLOGICAL|blood and urine samples|58 ml of blood 120 ml of urine
41102407|NCT01391442|GENETIC|blood sample|11 ml of blood
41102408|NCT01391442|OTHER|cardiovascular assessment|echography, echodoppler, measure of blood pressure...
41102409|NCT01391442|OTHER|Stanislas ancillary study : MRI examination with GRICS technique|
41102410|NCT04087044|DEVICE|Computerized Rotational Head Impulse Test ( crHIT)-Vertical|"1. Oculo-Motility and Positional Testing,~2. Caloric Testing"
41102411|NCT03545217|BEHAVIORAL|Lifestyle Intervention|a 6-month intensive lifestyle intervention program led by a multidisciplinary team of diabetes nurses and dieticians, and a follow up at 12 months for these participants. This will be a group-based activity adapted from the Diabetes Prevention Program -Thailand project
41102412|NCT04622527|OTHER|Random assigned paradigm viewing order|Participants experience the paradigm in a random order
41102413|NCT03470987|PROCEDURE|Phase I Periodontal therapy|Oral hygiene instuction, scaling and root planning
41102414|NCT03470987|DIETARY_SUPPLEMENT|Metabolic control|Calorie restricted diet
41102415|NCT01043471|OTHER|Chewing gum|Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.
41102416|NCT01043471|OTHER|Water|Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
41102417|NCT02485834|PROCEDURE|FDG-PET|
41102418|NCT02485834|PROCEDURE|surgery|
41102419|NCT02485834|DRUG|5-FU|200 mg/m\^2/day IV
41102420|NCT02485834|DRUG|capecitabine|oral 800 mg/m\^2 BID
41102421|NCT02485834|DRUG|docetaxel|30 mg/m\^2 IV
41102422|NCT02485834|DRUG|Irinotecan|50 mg/m\^2 IV
41102423|NCT02485834|RADIATION|3D-CRT|
41102424|NCT02485834|RADIATION|IMRT|
41102425|NCT00938340|DIETARY_SUPPLEMENT|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
41102426|NCT00938340|DIETARY_SUPPLEMENT|Walnut Oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
41102427|NCT00938340|DIETARY_SUPPLEMENT|Walnut Skins|Separated, ground walnut skins incorporated into inert food carrier
41102428|NCT00938340|DIETARY_SUPPLEMENT|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
41102429|NCT05541263|BEHAVIORAL|Mindfulness Based Stress Reduction|The intervention used is an MBSR training which is based on the Mindfulness-Based Stress Reduction programme as developed by Kabat-Zinn (1982). The training consists of 8 weekly sessions lasting 2,5 hours. A silent day of approximately 6 hours is also included, as well as daily home practice assignments of about 45 minutes. During the training participants will learn to focus their attention in the present moment in an accepting and non-judgemental way, rather than ruminating about past and future experiences. The training includes formal exercises during which participants will practice the body scan, sitting meditation, walking meditation and mindful movement. Informal exercises are also included, such as performing a daily activity with full attention to the present experience. The training is led by qualified teachers meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (www.vmbn.nl)
41102430|NCT06015594|DRUG|Metformin|Patients treated with metformin
41102431|NCT01103219|DIETARY_SUPPLEMENT|Nutrition|The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
41102432|NCT06166719|OTHER|No intervention|No intervention
41102433|NCT00425503|DRUG|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
41102434|NCT03360396|DEVICE|Endobronchial Coils|Endobronchial Coil implants
41102435|NCT00541697|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
41102436|NCT00541697|DRUG|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
41102437|NCT02491736|DRUG|Ketoprofen|2.5% ketoprofen gel
41102438|NCT02491736|OTHER|Placebo|Placebo gel
41102439|NCT01159158|DRUG|Nateglinide|Nateglinide Tablets 120 mg
41102440|NCT04406168|PROCEDURE|urinary diversion|follow up outcomes of urinary diversion
41102441|NCT01061229|DRUG|Homeopathic drug C12|Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
41102442|NCT01061229|OTHER|Placebo|Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
41102443|NCT03738137|DEVICE|Narotrend|Narcotrend motoring
41102444|NCT03738137|DEVICE|BIS|Bispectral index monitoring
41102445|NCT03738137|DRUG|Sufentanil|sufentanil is applied.
41102446|NCT03738137|DRUG|Lidocaine|Topical Anesthesia
41102447|NCT03738137|DRUG|Midazolam|midazolam is applied.
41102448|NCT06063356|PROCEDURE|Intra-articular and extra-articular Dextrose Prolotherapy injection|In the prolotherapy group, 28 patients will receive intra-articular 5 cc 25% dextrose solution (4 cc 30% dextrose + 1 cc saline) and extra-articular 10 cc 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) in 3 sessions.Extra-articular Injection: Using a sterile syringe with a 27 gauge needle tip (Dental), the points previously found and marked with US (medial collateral ligament, lateral collateral ligament, patellar ligament and adhesion sites of coronary ligaments; pes anserine and superior patellar regions) perpendicular to the surface, using peppering technique, a total of 10 cc of 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) will be injected in small volumes (0.5cc-1cc) at each point.Injection applications will be done at weeks 0 - 3 - 6.
41102449|NCT06063356|PROCEDURE|Intra-articular and extra-articular Saline injection|In the saline group, 28 patients are planned to receive 3 sessions of intra-articular 5 cc saline and extra-articular 10 cc lidocaine-serum physiologic solution (5 cc saline + 5 cc 1% lidocaine).Injection applications will be done at weeks 0 - 3 - 6.
41102450|NCT02338739|BEHAVIORAL|REC; Outreach if Failure|Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
41102451|NCT02338739|BEHAVIORAL|REC; SMS + Voucher if Failure|Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
41102452|NCT02338739|BEHAVIORAL|REC; Navigator if Failure|REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
41102453|NCT02338739|BEHAVIORAL|SMS; Outreach if Failure|SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
41102454|NCT02338739|BEHAVIORAL|SMS; Outreach if Failure; Stop SMS if Success|SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
41102455|NCT02338739|BEHAVIORAL|SMS; SMS+Voucher if Failure|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
41102456|NCT02338739|BEHAVIORAL|SMS; SMS+Voucher if Failure; Stop SMS if Success|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
40925222|NCT05704127|OTHER|Intelligent Moxibustion Robot|The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
41102457|NCT02338739|BEHAVIORAL|SMS; Navigator if Failure|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
41102458|NCT02338739|BEHAVIORAL|SMS; Navigator if Failure; Stop SMS if Success|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
41102459|NCT02338739|BEHAVIORAL|Voucher; Outreach if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
41102460|NCT02338739|BEHAVIORAL|Voucher; Outreach if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
41102461|NCT02338739|BEHAVIORAL|Voucher; SMS+Voucher if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
41102462|NCT02338739|BEHAVIORAL|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
41102463|NCT02338739|BEHAVIORAL|Voucher; Navigator if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
41443475|NCT05499897|PROCEDURE|ultrasoud guided interscalene block|Open shoulder surgery by ultrasound guided peripherel block. Observation effect of this peripheral block on immunity and wound healing
41102464|NCT02338739|BEHAVIORAL|Voucher; Navigator if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
41102465|NCT03896828|DIETARY_SUPPLEMENT|Mixed-macronutrient meal|"Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be \~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches."
41102466|NCT00506519|DRUG|Antithrombin alfa (INN name)|
41102467|NCT00506519|DRUG|Control (Standard treatment)|
41102468|NCT05779514|DRUG|Mirabegron|Health Volunteers ：Mirabegron p.o. 28 days 100mg qd./ Tumor patients ：Mirabegron p.o. 28 days 100 mg qd or 200 mg qd.
41102469|NCT02013037|DRUG|Eculizumab|"At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit."
41102470|NCT04018118|BIOLOGICAL|Biological sample|Additional blood samples for biobanking
41102471|NCT04875858|DRUG|ProDiax-23 (PPSV23)|diabetic old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed) and healthy old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed)
41102472|NCT00984282|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
41102473|NCT00984282|DRUG|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
41102474|NCT00941031|DRUG|AIN457|
41102475|NCT00941031|DRUG|AIN457A|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9"
41102476|NCT00941031|DRUG|AIN457A|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5"
41102477|NCT00941031|DRUG|Placebo|"Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9"
41102478|NCT04262414|DEVICE|Functional Electrical Stimulation|"The device used was a prototype closed-loop FES system to improve standing balance by activating the ankle plantar flexors and dorsiflexors (i.e. A-FES system). As a closed-loop system, the body's position and velocity are continually monitored, and the level of stimulation adjusted accordingly on a moment-to-moment basis. This differs from currently available FES units, which do not monitor body movement and therefore, provide a constant level of stimulation unless manually adjusted by the user/PT. The control strategy used in the A-FES system mimics the physiological control system in able-bodied people, meaning it has the potential to re-educate normal movement patterns."
41102479|NCT06087432|OTHER|Rocabado's 6x6 Exercises|Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique.
41102480|NCT06087432|OTHER|PNF Exercises|Proprioceptive neuromuscular facilitation (PNF) exercises will be applied to the neck and jaw with rhythmic stabilization (RS) and combined isotonic contraction (CIC) techniques. The RS protocol consists of alternating isometric contractions for 10 seconds and does not involve movement. The KIK technique involves combined concentric, isometric and eccentric contraction of the agonist muscle without rest, with each contraction lasting 5 seconds. KIK exercises consist of 5-15 repetitions per set, depending on the individual's tolerance. Between sets, a 30-second rest will be included. First, the RS protocol will be applied and after a 2-minute rest interval, the exercise will continue with the KIK protocol applications. The expected duration of exercise exercises is 30 minutes. Maximum performance will be requested from the individual in all repetitions and the necessary verbal commands will be given for appropriate movement.
41102481|NCT02716909|DEVICE|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
41102482|NCT05566847|OTHER|Physician Education|The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.
41102483|NCT05566847|OTHER|Accountable Population Manager outreach|Patients will be referred to an Accountable Population Manager (APM) for proactive outreach, including supporting medication adherence and educational and overall support for T2D management. An APM is a non-physician clinician (for example, a clinical pharmacist) supporting diabetes management.
41102484|NCT00578617|DRUG|Rate Control|Metoprolol 50-100mg
41102485|NCT00578617|DEVICE|Ablation Therapy|
41102486|NCT00578617|DRUG|Rate Control|Atenolol 50-100mg,
41102487|NCT00578617|DRUG|Rate control|Propranolol 40-80mg
41102488|NCT00578617|DRUG|Rate control|Acebutolol 200mg
41102489|NCT00578617|DRUG|Rate control|Carvedilol 6.25mg
41102490|NCT00578617|DRUG|Rate Control|Diltiazem 180-240mg
41102491|NCT00578617|DRUG|Rate Control|Verapamil 180-240mg
41102492|NCT00578617|DRUG|Rate Control|Digoxin 0.125mg
41102493|NCT00578617|DRUG|Rhythm Control|Propafenone 450mg
41102494|NCT00578617|DRUG|Rhythm control|Flecainide 200mg
41102495|NCT00578617|DRUG|Rhythm control|Sotalol 240mg
41102496|NCT00578617|DRUG|Rhythm control|Dofetilide 500mcg
41102497|NCT00578617|DRUG|Rhythm control|Amiodarone 200mg
41102498|NCT00578617|DRUG|Rhythm control|Quinidine 600-900mg
41102499|NCT01325870|DEVICE|ACD-CPR|
41102500|NCT01325870|DEVICE|ITPR|standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)
41102501|NCT01325870|PROCEDURE|S-CPR|standard manual CPR
41102502|NCT01325870|DEVICE|Impedance Threshold Device (ITD)|
41102503|NCT02888431|DEVICE|bedside point-of-care device|A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
41102504|NCT05954507|DIAGNOSTIC_TEST|PET/MRI|PET/MRI is a new-generation hybrid camera capable of simultaneously performing FDG positron emission tomography and gadolinium-injected MRI. PET/MRI could be a relevant prognostic marker of progression, and could significantly improve diagnostic performance in patients with suspected cardiac sarcoidosis.
41102505|NCT00731380|DRUG|ABI-007|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
41102506|NCT05550922|BEHAVIORAL|Healthcare Transition-Based Education|The goal is for asthmatic adolescents to take responsibility for their own disease, be prepared for transition to adult pulmonology services, increase their self-efficacy, and gain management skills as a result of health care transition education.
41102507|NCT04890821|DEVICE|CI Percutaneous Ring Annuloplasty System|Percutaneous transcatheter implant and adjustment of the CI ring annuloplasty system.
41102508|NCT06146985|COMBINATION_PRODUCT|20 mg Famitinib & 1200 mg Adebrelimab|Famitinib is a novel multi-targeted tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. Adebrelizumab is a humanised immunoglobulin G4 (IgG4) monoclonal antibody that binds specifically to human PD-L1
41102509|NCT02915055|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
41102510|NCT02915055|DRUG|standard oxycodone/acetaminophen|
41102511|NCT01921140|DRUG|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
41102512|NCT01921140|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
41102513|NCT01921140|OTHER|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
41102514|NCT01921140|OTHER|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
41102515|NCT00031343|DRUG|highly active antiretroviral therapy (HAART)|
41102516|NCT01670019|DRUG|Asenapine 5-20 mg daily|5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
41102517|NCT01670019|DRUG|Placebo 1-4 tablets daily|One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
41102518|NCT00692562|PROCEDURE|simultaneous islet-kidney transplantation|
41102519|NCT01360190|DRUG|fluoxetine|fluoxetine 20 mg. daily
41102520|NCT01720446|DRUG|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
41102521|NCT01720446|DRUG|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
41102522|NCT01720446|DRUG|placebo|Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
41102523|NCT01700790|DRUG|Lopinavir/ritonavir and ritonavir|Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
41102524|NCT06202118|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
41102525|NCT04860154|DRUG|Hematoporphyrin|Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or bald metal stents will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
41102526|NCT03807102|BIOLOGICAL|Tumor Vaccine|NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
41102527|NCT00523731|PROCEDURE|Angiogenic Cell Precursors (ACPs) or Vescell TM|
41102528|NCT00685893|BEHAVIORAL|Education|We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.
41102529|NCT00685893|BEHAVIORAL|Local Champions|We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.
41102530|NCT00685893|BEHAVIORAL|Institution Feedback|We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.
41102531|NCT00685893|BEHAVIORAL|Academic Detailing|Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.
41102532|NCT00685893|BEHAVIORAL|Institutional Forms|We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
41102533|NCT02156635|DEVICE|Transcranial direct current stimulation|
41102534|NCT02156635|BEHAVIORAL|Constraint-Induced Movement Therapy|
41102535|NCT02156635|OTHER|Placebo|
41102536|NCT00502593|BIOLOGICAL|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
41102537|NCT00502593|BIOLOGICAL|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
41102538|NCT03872297|DIETARY_SUPPLEMENT|Placebo supplement|"Consumption of a non active food complement during 3 months.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
41102539|NCT03872297|DIETARY_SUPPLEMENT|Naticol supplement|"Consumption of the active food complement during 3 months containing Naticol.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
41102540|NCT06214468|COMBINATION_PRODUCT|Acetaminophen and Nicotinamide Riboside|Collection of urine at different time intervals following ingestion of Tylenol plus Nicotinamide Riboside
41102541|NCT06214468|DRUG|Acetaminophen|Collection of urine at different time intervals following ingestion of Tylenol only
41102542|NCT03593291|DIAGNOSTIC_TEST|Anti Xa|Levels of Anti Xa measure
41102543|NCT03608670|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
41102544|NCT02594215|DRUG|MK-7075 (miransertib)|MK-7075 or miransertib (formerly ARQ 092) is small molecule that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of miransertib in Proteus syndrome.
41102545|NCT04025606|DRUG|Thoracic epidural|Standard thoracic epidural (needle inserted into the space between the covering of spinal cord and the cord itself) preoperatively. Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively. Thereafter reduction by 30 % every four hours.
41102546|NCT04025606|DRUG|Paravertebral block|Paravertebral block containing 5 ml bupivacaine 5 mg/ ml (optionally 10 ml bupivacaine 2,5 mg/ ml). In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.
41102547|NCT02605434|DRUG|Accordion Pill™ Carbidopa/Levodopa|AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
41102548|NCT02605434|DRUG|Sinemet®|Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
41102549|NCT02605434|DRUG|Placebo -AP-CD/LD|Placebo for AP-CD/LD capsule
41102550|NCT02605434|DRUG|Placebo- Sinemet|Placebo for Sinemet tables
41102551|NCT05014555|BIOLOGICAL|COVID-19 Vaccine|Three-dose mRNA COVID-19 vaccine per standard of care
41102552|NCT04742751|DRUG|Metformin|To begin week 12 for participants who remain prediabetic after 12 week lifestyle run-in. Dosage and Route of Administration: 500 mg dose/ day to be taken orally, increased to 1000 mg dose/ day at week 14 through week 24. The dose should be taken immediately following the evening meal and at approximately the same time daily
41102553|NCT04742751|BEHAVIORAL|Digital Intervention|"Lifestyle Change Digital Intervention - This is a digital platform that will include a core curriculum focused on diet, exercise, and behavioral strategies for goal setting and self-monitoring to improve diet including a weight loss On Day 1, participants will begin their digital lifestyle intervention using their smart-phone application with their lifestyle coach and peer group.~On day 14, participants will be contacted by phone (+/- 4 days, day 10 to 18) and adherence assessed using virtual pill counts via phone calls.~At weeks 4, 8, 16 and 20 a phone-based pill count for adherence and adverse event symptom log will be completed and study medication dispensed.~At week 12 (interim assessment) and 24 (study-end), the participant will return to St. Jude Children's Research Hospital (SJCRH) for an in-person assessment.~The digital lifestyle change program will complete at week 24."
41102554|NCT06309342|OTHER|PREVFUNKTION|Functional profile and advice concerning cardiovascular fitness level, strength, mobility, balance and posture. Motivational interview and support in goalsetting to make lifestyle changes.
41102555|NCT06309342|OTHER|Control|Physical activity measured with accelerometers. Functional examination. Medical examination and advice concerning weight measures, blood pressure and standard blood tests.
41102556|NCT05325944|BEHAVIORAL|Self-guided digital intervention for NSSI|"Psychoeducational content, skill-based practice, and daily ecological momentary assessments will be delivered over an 8-week period.~Psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies."
41102557|NCT05325944|BEHAVIORAL|Digital intervention for NSSI with coaching|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies. Human coaching will be used to support intervention use and engagement twice per week via text, call or email.
41102558|NCT05325944|BEHAVIORAL|Active control|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies.
41102559|NCT01123928|BEHAVIORAL|Video and counseling for cataract patients|Intervention includes: (1) a 5-10 min video consisting of testimony from a previous cataract patient and a doctor; (2) a 10-15 min pre-operative counseling session with a trained nurse, and (3) a 5 min post-operative counseling session with a trained nurse.
41102560|NCT06293365|BIOLOGICAL|VAY736 1ml PFS|Solution for injection.
41102561|NCT06293365|BIOLOGICAL|VAY736 2 ml PFS|Solution for injection
41102562|NCT06293365|BIOLOGICAL|VAY736 2ml AI|Solution for injection.
41102563|NCT00089258|BIOLOGICAL|beta-glucan|
41102564|NCT00089258|BIOLOGICAL|monoclonal antibody 3F8|
41102565|NCT00089258|BIOLOGICAL|sargramostim|
41102566|NCT00089258|DRUG|isotretinoin|
41102567|NCT01521585|DRUG|SEN0014196|50 mg oral once daily tablet
41102568|NCT01521585|DRUG|SEN0014196|200 mg oral once daily tablet
41102569|NCT01521585|DRUG|Placebo|oral once daily tablet
41102570|NCT05825079|BEHAVIORAL|Weight-Bearing Feedback|Feedback on how much weight patients are exerting on their crutch/injured lower extremity (measured via Smart Crutch Tip) will be delivered to their mobile phones.
41102571|NCT05825079|DEVICE|Smart Crutch Tip|The device is attached to the crutch and measures how much weight-bearing load is exerted onto its axis. The device is capable of transmitting this data into the patient and physicians' user interface.
41102572|NCT01678196|BEHAVIORAL|VA-CRAFT|VA-CRAFT is an on-line training program that teaches family members how to communicate and interact with Veterans to promote their engagement in needed mental health services for PTSD or Alcohol Use Disorders. 12 on-line sessions.
41102573|NCT01678196|OTHER|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
41102574|NCT02993471|DRUG|Drug Cocktail|Administered orally
41102575|NCT02993471|DRUG|Ixekizumab|Administered SC
41102576|NCT05836935|RADIATION|Multislice CT scan of the paranasal sinuses.|MSCT scan using GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) , Toshiba Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Or Canon Aquilion Prime SP 160 -multidetector- row CT scanner (Canon Medical Systems, Tochigi, Japan) Thin slice Axial scans will be taken at 0.625-1.0 mm slice thickness, commencing from the hard palate till above the end of frontal sinuses, coronal and sagittal multiplanar reconstruction images will be obtained.
41102577|NCT05836935|RADIATION|MRI examination of the paranasal sinuses|MRI imaging using Philips Achieva 1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea 1.5T MRI device (Siemens Healthineers, Germany) for suspected intracranial and orbital complications.
41102578|NCT00391547|DRUG|Frio Oral Rinse|
41102579|NCT02793297|OTHER|refined wheat crisp bread|Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
41102580|NCT02793297|OTHER|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
41102581|NCT02793297|OTHER|unfermented rye crisp bread|Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
41102582|NCT00413868|PROCEDURE|LASIK|
41102583|NCT00413868|PROCEDURE|PRK|
41102584|NCT00413868|BEHAVIORAL|Small target contrast sensitivity and disability glare|
41102585|NCT06058182|DIAGNOSTIC_TEST|blood draws|Pre-procedure, post-procedure (12-24 h), 6-month, and 12-month blood draws
41102586|NCT04074902|DEVICE|Ultrasonography|Mindray dp1100 plus.
41102587|NCT00409058|BEHAVIORAL|Teen Online Problem Solving|We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
41102588|NCT01123083|BIOLOGICAL|Otelixizumab|infusion
41102589|NCT01123083|BIOLOGICAL|Placebo|Infusion
41102590|NCT00414206|DRUG|Mecamylamine|
41102591|NCT00414206|DRUG|Placebo|
41102592|NCT05225935|DEVICE|image-guided VT ablation strategy|Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
41102593|NCT05225935|DEVICE|conventional VT ablation strategy|Catheter ablation will be performed using conventional mapping techniques to identify targets. The ablation strategy will be left to the local investigator's decision, based on the clinical scenario and operator's habits.
41102594|NCT00759837|DRUG|Bosutinib|
41102595|NCT01105572|DEVICE|Intel Health Guide|An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.
41102596|NCT01105572|OTHER|Case Management|Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
41102597|NCT00002290|DRUG|Zidovudine|
41102598|NCT00002290|DRUG|Acyclovir|
41102599|NCT05566587|OTHER|Mediteranean to Western to Mediteranean Diet|week 2-3 : Switching between Mediterranean diet and Western diet week 4-5 : Switching between Western diet and Mediterranean diet week 6-7 : Switching between Mediterranean diet and Western diet
41102600|NCT05566587|OTHER|Western to Mediteranean to Western Diet|week 2-3 : Switching between Western diet and Mediterranean diet week 4-5 : Switching between Mediterranean diet and Western diet week 6-7 : Switching between Western diet and Mediterranean diet
41102601|NCT06375356|BEHAVIORAL|Resistance Training|Strength exercises (3-4 sets each exercise) videos delivered electronically, participant self-tracks and self-progresses based on effort reported.
41102602|NCT01923857|DRUG|Androxal 25 mg|
41102603|NCT02893228|PROCEDURE|Saline|At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
41102604|NCT02893228|DRUG|Levobupivacaine|the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
41102605|NCT05917249|DEVICE|Capacitive-Resistive Noninvasive Radiofrequency|The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).
41102606|NCT00424762|DRUG|rosiglitazone|6 months of treatment of blinded study drug
41102607|NCT00424762|DRUG|placebo|blinded treatment with matching placebo
41102608|NCT00461799|DRUG|orlistat|
41102609|NCT02580812|OTHER|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
41102610|NCT05969730|DRUG|Baricitinib 4 MG|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, baricitinib 4-mg daily plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm A). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
41102611|NCT05969730|DRUG|Azathioprine 1.5-2.5 mg/kg|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, azathioprine 1.5-2.5 mg/kg plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm B). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
41102612|NCT00545324|DRUG|MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks|
41102613|NCT00545324|DRUG|Comparator: Fluticasone / Duration of Treatment: 6 Weeks|
41102614|NCT03720522|PROCEDURE|Short cardiovascular MRI (CMR)|A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
41102615|NCT03720522|PROCEDURE|Adenosine-perfusion cardiovascular MRI (CMR)|An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
41102616|NCT03720522|PROCEDURE|Blood draw|"The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months."
41102617|NCT03720522|PROCEDURE|Urine (collection over 24h)|"The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months"
41102618|NCT02454205|DRUG|Linezolid|600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
41102619|NCT02454205|DRUG|Bedaquiline|400mg po daily for 2 weeks, followed by 200mg three times per week .
41102620|NCT02454205|DRUG|Levofloxacin|750mg (\<50kg) 1000mg (\>50kg)
41102621|NCT02454205|DRUG|Pyrazinamide|1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
41102622|NCT02454205|DRUG|Isoniazid|high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
41102623|NCT02454205|DRUG|Ethionamide|15mg/kg (max 900mg)
41102624|NCT02454205|DRUG|Terizidone|750mg (40-70kg) 750-1000mg (71-90kg)
41102625|NCT02454205|DRUG|Moxifloxacin|400mg po daily.
41102626|NCT02454205|DRUG|Kanamycin|500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
41102627|NCT03052946|PROCEDURE|Bulking agent|Filling bulking agent in the anal canal
41102628|NCT03052946|PROCEDURE|Endoanal electrostimulation|The technique used will be with a frequency of 30 to 40 Hz with pulse width of 200 ms with maximum intensity of 800mAmp and duration of 30 minutes
41102629|NCT02925052|DEVICE|Gastric Tube Guide|
41102630|NCT02925052|DEVICE|Conventional placement|
41102631|NCT05512819|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
41102632|NCT05512819|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
41102633|NCT05555108|BEHAVIORAL|ACTCOM-I Intervention|ACTCOM-I s an individual treatment protocol based on Acceptance and Commitment Therapy (ACT) with targeted behavioral components for insomnia treatment and a specific focus on selfcompassion as a protector for sleep disturbance.
41102634|NCT05555108|BEHAVIORAL|Standard CBT-I Intervention|Standard CBT-I treatment for chronic insomnia. Treatment protocol adapted from Morin's protocol (1993)
41102635|NCT00111020|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
41102636|NCT04601467|DRUG|AZD5718|Oral dose of AZD5718 (tablet) once daily for 12 months
41102637|NCT04601467|DRUG|Placebo|Oral dose of matching placebo (tablet) once daily for 12 months
41102638|NCT05112250|DEVICE|Percutaneous Coronary Intervention|Intravascular lithotripsy (IVL)
41102639|NCT02653079|OTHER|Blood Draw and Questionaire|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
41102640|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
41102641|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
41102642|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
41102643|NCT00973141|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
41102644|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
41102645|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
41102646|NCT02319785|BEHAVIORAL|RAT-NMES|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive neuromuscular electrical stimulation (NMES) concurrently with RAT.
41102647|NCT02319785|BEHAVIORAL|RAT-MT|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive mirror therapy instead of functional activities training after RAT.
41102648|NCT02319785|BEHAVIORAL|Mirror therapy|This protocol includes mirror therapy and functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
41102649|NCT02319785|BEHAVIORAL|Unilateral RAT|"This protocol includes warm-up, unilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, InMotion Isokinetic Testing and Evaluation System."
41102650|NCT02319785|BEHAVIORAL|Bilateral RAT|"This protocol includes warm-up, bilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany)."
41102651|NCT02319785|BEHAVIORAL|Conventional rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RAT and MT groups.
41102652|NCT02430532|DRUG|dimethyl fumarate|capsule
41102653|NCT02430532|OTHER|Placebo|matched placebo capsule
41102654|NCT06030908|PROCEDURE|Reconstruction of Achilles tendon insertion|knotless double-row anchor fixation of the achilles tendon insertion
41102655|NCT01080599|PROCEDURE|obturator nerve block|
41102656|NCT04491942|DRUG|Cisplatin|Given IV
41102657|NCT04491942|DRUG|Elimusertib|Given PO
41102658|NCT04491942|DRUG|Gemcitabine Hydrochloride|Given IV
41102659|NCT02920359|DRUG|LEUPRORELIN ACETATE|
41102660|NCT02943993|DRUG|Edoxaban|Prescribed according to approved label
41102661|NCT00004367|PROCEDURE|Clinical vestibular tests|
41102662|NCT02526680|DEVICE|OrCam|The OrCam low vision aid, camera attached to glasses, used by 27 glaucoma subjects for 1 month.
41102663|NCT00042588|DRUG|Recombinant Chimeric Monoclonal Antibody|
41102664|NCT03181464|DRUG|Lidocaine 4%|lidocaine solution
41102665|NCT03181464|DRUG|Placebo|saline .9% injection
41102666|NCT03532178|DRUG|"Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline"|"The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period."
41102667|NCT03532178|DRUG|"Group B. Muscle relaxant #2: succinylcholine +saline; Muscle relaxant #1: rocuronium + sugammadex;"|"The participants will be randomized to start with Muscle relaxant #2 in the first study treatment, and will switch to Muscle relaxant #1 in the second study treatment period."
41102668|NCT00470106|BEHAVIORAL|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
41102669|NCT00470106|BEHAVIORAL|Social Cognitive skills training|Group training on emotion perception, social perception, and understanding others' mental states.
41102670|NCT00470106|BEHAVIORAL|hybrid intervention|A combination of the two groups listed above.
41102671|NCT00470106|BEHAVIORAL|skills training|Skills training in how to identify symptoms of illness and medication side effects.
41102672|NCT02028637|OTHER|TLRs|Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
41102673|NCT00641381|DRUG|carmustine|150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
41102674|NCT00641381|DRUG|cyclophosphamide|100 mg/kg on day -2 prior to stem cell reinfusion
41102675|NCT00641381|DRUG|etoposide|60 mg/kg on day -4 prior to stem cell reinfusion
41102676|NCT00641381|OTHER|pharmacological study|Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
41102677|NCT00641381|PROCEDURE|autologous hematopoietic stem cell transplantation|Reinfusion of autologous stem cells
41102678|NCT00641381|PROCEDURE|peripheral blood stem cell transplantation|Reinfusion of autologous stem cells
41102679|NCT05263791|DEVICE|Airmod|Both of the respiratory rate monitor (including experimental and reference device) are installed on the enrolled patients. The practitioners can clearly read the result of both devices.
41102680|NCT03425162|DRUG|Morphine Sulfate|patient-controlled analgesia (PCA) morphine
41102681|NCT03425162|PROCEDURE|Group P|Group P:patient-controlled analgesia (PCA) morphine
41102682|NCT03425162|PROCEDURE|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 Bupivacaine
41102683|NCT01180621|BIOLOGICAL|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
41102684|NCT03367494|DIAGNOSTIC_TEST|Measurement of Sweat Chloride and Sweat Bromide|Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
41443476|NCT05499897|PROCEDURE|general anesthesia|Open shoulder surgery by general anesthesia. Observation effect of this peripheral block on immunity and wound healing
41102685|NCT04966572|DEVICE|Presurgical vacuum formed nasoalveolar molding aligners|at first visit, the infants will receive this appliance which is a maxillary vacuum plate incorporated with palatal screw, the infant's parents will be instructed to activate the screw and apply horizontal tap which will be placed at the base of nose in order to approximate lip segments and to change tape daily. After that, The infants will be recalled one week after the first visit to add the nasal stents into the appliance.
41102686|NCT04966572|DEVICE|Conventional Grayson acrylic formed nasoalveolar molding appliances|"at first visit, the infants will receive this appliance which is a maxillary acrylic plate without adding taping, the infants will be recalled bi weekly for activating the appliance.~When the cleft alveolar gap is reduced to 6mm or less, a pair of nasal stents will be added to mold the nasal cartilage. the infants will be followed up for 4-6 months."
41102687|NCT06106087|OTHER|Mixed methods quality improvement intervention|Quality improvement training for frontline PCH staff
41102688|NCT01235949|BIOLOGICAL|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
41102689|NCT01235949|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses
41102690|NCT01235949|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
41443477|NCT05744232|BEHAVIORAL|Low calorie total diet replacement|"Summary~1. Weeks 1-12: TDR phase~2. Weeks 13-14: Food reintroduction phase I~3. Weeks 15-16: Food reintroduction phase II~4. Weeks 17 till 20: Food reintroduction phase III~5. Weeks 21 till 24: Maintenance phase"
41443478|NCT05744232|OTHER|Usual care|Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded.
41102691|NCT01235949|DRUG|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
41102692|NCT01235949|DRUG|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
41102693|NCT00540813|DEVICE|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
41443479|NCT04848987|PROCEDURE|Etching|Etching enamel surface using phosphoric acid
41102694|NCT02107014|DRUG|Low Dose Naltrexone|Naltrexone 4.5 mg p.o. nocte
41102695|NCT00387465|DRUG|Azacitidine 30mg/m2|Azacitidine 30mg/m2 subcutaneously (SQ)
41102696|NCT00387465|DRUG|Entinostat|7mg by mouth (PO) on days 3 and 10 of each cycle
41102697|NCT00387465|DRUG|Azacitidine 40mg/m2|Azacitidine 40mg/m2 SQ
41102698|NCT03543839|BIOLOGICAL|Belimumab|Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years
41102699|NCT03543839|BIOLOGICAL|Belimumab/Placebo|Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.
41102700|NCT03543839|OTHER|Placebo|Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years
41102701|NCT06234280|DEVICE|Implantation of Eluvia stent|Implantation of Eluvia stent
41102702|NCT06249841|DEVICE|1.1mm flexible Cryoprobe SU|Six tissue samples retrieved by standard biopsy forceps and three samples by cryobiopsy (randomized sequence)
41102703|NCT00763282|BEHAVIORAL|Self Management (SM)|Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
41102704|NCT00763282|BEHAVIORAL|Motivational Interviewing (MI)|Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures.
41102705|NCT00763282|BEHAVIORAL|Education (ED)|The ED intervention differs only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
41443480|NCT03686540|PROCEDURE|ExtraCorporeal Membrane Oxygenation (ECMO)|The objective of this study is to determine the average cost of stay of a patient supported by ExtraCorporeal Membrane Oxygenation from the point of view of the hospital facility, during the hospitalization in which the ECMO was implanted.
41443481|NCT05164354|OTHER|Aromatherapy|Aromatherapy: It will be applied to each child three times, three days in a row. Each application will be 20 minutes. The application time will be decided together with the patient. At the end of the three-day practice.
41102706|NCT02480335|DRUG|bosentan|62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
41102707|NCT03045692|DIAGNOSTIC_TEST|kidney function assessment by 4 hour creatinine clearance|4 hour creatinine clearance is used to decide colistin maintenance dosage.
41102708|NCT03045692|DIAGNOSTIC_TEST|kidney function assessment by creatinine based eGFR|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
41102709|NCT00608907|DRUG|bortezomib|1.3 mg/m\^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
41102710|NCT00608907|DRUG|bortezomib, rifampicin|bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
41102711|NCT00608907|DRUG|bortezomib, dexamethasone|bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
41102712|NCT01265758|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
41102713|NCT02181348|DRUG|Vitamin E|dl-alpha tocopheryl acetate 400 mg once daily for 3 months
41102714|NCT02181348|DRUG|placebo (edible oil)|
41102715|NCT02599844|DRUG|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
41102716|NCT02599844|PROCEDURE|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
41102717|NCT02599844|PROCEDURE|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
41102718|NCT02599844|PROCEDURE|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
41102719|NCT02599844|DRUG|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
41102720|NCT05996757|PROCEDURE|Wet clothing removal|The participants in the intervention group will have their clothing removed prior to insulation.
41102721|NCT06169904|DRUG|Cisplatin injection|We observed the UC patients from Zhongshan Hospital receiving or not receiving adjuvant cisplatin-based chemotherapy after radical cystectomy.
41102722|NCT02282527|BIOLOGICAL|Liquid Alpha₁-PI|Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
41102723|NCT02282527|BIOLOGICAL|Prolastin-C|Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
41102724|NCT05139264|OTHER|Observational|Observation of diet, physical activity, sleep and interstitial glucose
41102725|NCT00159354|DRUG|predisolone|
41102726|NCT03646370|DRUG|Tenofovir Alafenamide|Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
41102727|NCT05768932|DRUG|BAL0891|BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
41102728|NCT05768932|COMBINATION_PRODUCT|Carboplatin|Carboplatin is an Antineoplastic agent
41102729|NCT05768932|COMBINATION_PRODUCT|Paclitaxel|Paclitaxel is a natural product with antitumor activity
41102730|NCT01881919|DIETARY_SUPPLEMENT|Treatment|Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
41102731|NCT01881919|DIETARY_SUPPLEMENT|Control|Address: Fagron GmbH\&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
41102732|NCT06423313|PROCEDURE|maintenance of anesthesia|Types used to maintain anesthesia
41102733|NCT05901558|BEHAVIORAL|Strategies for Toddler ASD with Remote-therapy (STAR)|The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities
41102734|NCT05901558|BEHAVIORAL|Community intervention|Regular community intervention
41102735|NCT01211665|DRUG|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
41102736|NCT01211665|DRUG|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
41102737|NCT01549652|DRUG|Ondansetron|Ondansetron 8 mg oral tablet
41102738|NCT01549652|DRUG|Placebo|Placebo to Match Ondansetron
41102739|NCT01549652|DRUG|Morphine|Sustained release oral morphine, beginning at 30 mg/d, titrated up by 15 mg/d every 2 days until adequate analgesia is achieved
41102740|NCT01549652|DRUG|Naloxone 0.4 mg/70 kg|Naloxone 0.4 mg/70 kg intravenous
41102741|NCT01549652|DRUG|Naloxone 0.8 mg/70 kg|Naloxone 0.8 mg/70 kg intravenous
41102742|NCT03818659|OTHER|Self-Guided M.A.P. BP Improvement Program|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
41102743|NCT03818659|OTHER|Full Support M.A.P. BP Improvement Program|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
41102744|NCT00357396|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
41102745|NCT00357396|DRUG|busulfan|
41102746|NCT00357396|DRUG|melphalan|
41102747|NCT00357396|DRUG|thiotepa|
41102748|NCT00357396|PROCEDURE|allogeneic bone marrow transplantation|
41102749|NCT00357396|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41102750|NCT00357396|PROCEDURE|peripheral blood stem cell transplantation|
41102751|NCT04882722|OTHER|Questionnaire|Self-questionnaire reported before the first PPFR session and after the last session
41102752|NCT00140881|DRUG|MK0476; montelukast sodium|
41102753|NCT00140881|DRUG|Comparator: placebo|
41102754|NCT02454543|PROCEDURE|Radical prostatectomy|Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
41102755|NCT02454543|DRUG|Best systemic therapy|"For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist."
41102756|NCT04994743|DRUG|CORT113176|CORT113176 lipid capsule formulation for oral administration
41102757|NCT04994743|DRUG|Placebo matching CORT113176|Placebo matching CORT113176 lipid capsule formulation for oral administration
41102758|NCT02793427|BIOLOGICAL|blood sample collection|
41102759|NCT04008420|OTHER|monitoring of the oxygen reserve index|The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
41102760|NCT03438487|BIOLOGICAL|Flucelvax Trivalent Influenza Vaccine|"Flucelvax is a cell culture seasonal trivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage or B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
41102761|NCT03438487|BIOLOGICAL|Flucelvax Quadrivalent Influenza Vaccine|"Flucelvax Quadrivalent is a cell culture seasonal quadrivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage, 4) B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
41102762|NCT00154648|PROCEDURE|CE-MRA|
41102763|NCT03870191|OTHER|Injection of either twin block or trigger point injection.|Study participants will be randomized into either group and will receive the intervention.
41102764|NCT00877422|DIETARY_SUPPLEMENT|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
41102765|NCT04825652|DRUG|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles.
41102766|NCT04825652|DRUG|PSMA-11|Patients will receive a dose of gallium (68Ga) gozetotide that is 1.8-2.2 MBq/kg of body weight (0.049-0.059 mCi/kg), with a minimum dose of 111 MBq (3mCi) up to a maximum dose of 259 MBq (7 mCi).
41102767|NCT06489860|DRUG|HIV|"Directions: For adults and for Children 1-12 years old. Indication: Anti-AIDS Drug. Ingredient: Organic Rice 91% and Honey 9% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date."
41102768|NCT06489860|DRUG|Neoplasms|"Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Rice 90% and Honey 10% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date."
41102769|NCT00466076|DRUG|Copaxone (Glatiramer acetate)|
41102770|NCT05708066|OTHER|Lavender Aromatherapy|"Participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations.~After the lavender patch has been in place for 5 minutes, the same VAS anxiety questionnaire will be provided"
41102771|NCT05708066|OTHER|Non-scented Tab|A non-scented tab will be placed on the participant's chest, according to manufacturer recommendations. Participants in this group will only receive the initial VAS anxiety questionnaire.
41102772|NCT02373228|OTHER|Audio signal processing (applied offline before playback)|
41102773|NCT01573858|OTHER|Acupuncture treatment 1|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
41102774|NCT01573858|OTHER|Acupuncture treatment 2|Needles will be inserted to a depth of \<5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
41102775|NCT01573858|OTHER|CC|CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
41102776|NCT01573858|OTHER|CC placebo|CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
41102777|NCT01833507|BEHAVIORAL|Self-Exercise|Behavioral Goal Setting
41102778|NCT01833507|BEHAVIORAL|Usual Care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics. Participants will subsequently be given entry into the active intervention at the 2-month check.
41102779|NCT04898322|DRUG|SY-005|2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
41102780|NCT04898322|DRUG|SY-005|5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
41102781|NCT04898322|DRUG|SY-005|10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
41102782|NCT04898322|DRUG|Placebo|Placebo
41102783|NCT00722215|DRUG|BQ-123 (selective endothelin A receptor antagonist)|Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
41102784|NCT00722215|DRUG|0.9 % saline|Single 15ml 0.9% saline infused for 15 mins as placebo control
41102785|NCT00722215|DRUG|Nifedipine|Single dose of nifedipine 10 mg given orally as active control
41102786|NCT04687553|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs)
41102787|NCT06055114|DIAGNOSTIC_TEST|Microscopic examination of vaginal discharge|Using gram-stained smears to detect vaginal secretions, and then the concentration and diversity of bacterial flora are observed using a microscope.
41102788|NCT05356819|DEVICE|Smart Capnography™, Microstream®|patients monitored by capnograph
41102789|NCT06239948|OTHER|With Music|each subject was placed in a TMS laboratory with music for 20 minutes
41102790|NCT06239948|OTHER|Without Music|each subject was placed in a TMS laboratory without music for 20 minutes
41102791|NCT06070207|PROCEDURE|TEP group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
41102792|NCT06070207|PROCEDURE|eTEP group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
41102793|NCT01712594|DEVICE|Closed Loop Procedure (Medtronic)|The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
41102794|NCT01105884|PROCEDURE|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
41102795|NCT01105884|PROCEDURE|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
41102796|NCT01105884|PROCEDURE|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
41102797|NCT01105884|PROCEDURE|Hydrogel|All the subjects in this group will be treated with Hydrogel
41102798|NCT01105884|PROCEDURE|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
41102799|NCT01221142|DEVICE|"Cincinnati Sub-Zero, Blanketrol III"|
41102800|NCT04726813|BEHAVIORAL|MyADHD|The main goals of the intervention are to help participants with better functioning in daily life; offer strategies that will lead to stress reduction and reduce inattention and improve quality of life.The intervention includes: a short introductory chapter (open to everyone), followed by a start module (goal setting), followed by 6 different themed optional modules. Module content is based on GMT, DBT and CBT techniques and is tailored towards key concerns and difficulties experienced adults with ADHD as informed by previous research (focus-groups, lived experience groups) and experiences from group GMT and DBT.
41102801|NCT04726813|BEHAVIORAL|Psychoeducation|Participants in the control condition will be assigned to psychoeducation modules (see Table 2) and will receive restricted access to the platform. They can contact or be contacted if their symptoms levels increases.
41102802|NCT02994654|DEVICE|ReCell|"The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded."
41102803|NCT01596751|DRUG|PLX3397|Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
41102804|NCT01596751|DRUG|Eribulin|Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
41102805|NCT00686517|BIOLOGICAL|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
41102806|NCT00686517|DRUG|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
41102807|NCT02313441|OTHER|Remote Ischemic Pre-Conditioning|The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
41102808|NCT04201327|BEHAVIORAL|Project Jumpstart|PrEP focused intervention to improve PrEP related health outcomes
41102809|NCT03178994|DRUG|2% ketoconazole cream|2% ketoconazole cream applies twice daily
41102810|NCT03178994|DRUG|Hydrophilic Cream|Hydrophilic cream (in-house preparation) applies twice daily
41102811|NCT02918071|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
41102812|NCT05305989|DRUG|Belumosudil 200 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
41102813|NCT05305989|DRUG|Belumosudil 200 mg BID|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
41102814|NCT05305989|DRUG|Belumosudil 400 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
41102815|NCT01315899|DRUG|ORM-12471 30mg|Given as a single dose once during the crossover study as per Williams design
41102816|NCT01315899|DRUG|ORM-12471|Given as a single dose once during the study as per Williams crossover design
41102817|NCT01315899|DRUG|placebo|Given once as a single dose during the study as per Williams crossover design
41102818|NCT00497562|DRUG|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
41102819|NCT00497562|DRUG|amitriptyline, fluoxetine and tramadol alone (control group)|
41102820|NCT01927965|DRUG|Minnelide™ 001|Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
41102821|NCT00364286|DRUG|Dasatinib (BMS-354825)|50mg Orally twice daily
41102822|NCT00137605|BIOLOGICAL|Pneumovax|
41102823|NCT00137605|BIOLOGICAL|Prevnar|
41102824|NCT02813486|BIOLOGICAL|Biological: GC3111 vaccine|0.5mL, Intramuscular
41102825|NCT02813486|BIOLOGICAL|Biological: Boostrix® vaccine|0.5mL, Intramuscular
41102826|NCT04840862|DRUG|Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]|Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.
41102827|NCT04840862|DRUG|Rifabutin 300mg|After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.
41102828|NCT02808442|BIOLOGICAL|UCART19|
41102829|NCT00098280|DRUG|Eculizumab|
41102830|NCT01303835|DRUG|LDN|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
41102831|NCT01303835|DRUG|Placebo|Randomized patients received placebo to be taken every night before bed.
41102832|NCT00939991|DRUG|Vorinostst/Bevacizumab/Temozolomide|Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
41102833|NCT00608933|OTHER|educational intervention|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
41102834|NCT00608933|OTHER|questionnaire administration|Patients complete questionnaires
41102835|NCT00731211|DRUG|Pazopanib|800 mg of pazopanib orally each day continuously
41102836|NCT06390891|OTHER|Persons with pancreatic resection in a hospital with at least 50 pancreatic resections annually (observational),|Persons that have undergone a pancreatic resection at a hospital with at least 50 pancreatic resections annually (observational)
41102837|NCT06390891|OTHER|Persons with pancreatic resection in a hospital not performing at least 50 pancreatic resections annually (observational),|Persons that have undergone a pancreatic resection at a hospital with not at least 50 pancreatic resections annually (observational)
41102838|NCT00927823|DRUG|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
41102839|NCT00578435|PROCEDURE|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
41102840|NCT01886014|DRUG|Oxytocin|
41102841|NCT01886014|OTHER|placebo|
41102842|NCT01317134|DEVICE|EndoPAT measurement|EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
41102843|NCT01317134|BIOLOGICAL|Blood Test|It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
41102844|NCT04707417|OTHER|Home care|Advanced home care
41102845|NCT05460806|OTHER|Aerobic Exercise|Participants assigned to aerobic exercise training will walk on a treadmill (RodbyTM, RL 1600E, Enhorna, Sweden) for 40 minutes at an intensity of 60-75% of maximum heart rate (220-age formula) three times per week for 8 weeks. The heart rate of the participants will be measured with an electric heart rate monitor throughout the session.
41102846|NCT00424320|DRUG|Sodium bicarbonate|
41102847|NCT06031350|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optovue, Inc., Fremont, CA, USA
41102848|NCT02586454|PROCEDURE|Transmuscular quadratus lumborum block|
41443482|NCT05164354|OTHER|music concert|Music Concert: In this study, a music (lullaby, classical music) to be preferred by the patient or family Children are played for 20 minutes once a day. (morning or afternoon) for three days to help the child sleep. The volume of the music being played will be preserved. Aromatherapy: To be applied each child three times for three consecutive days. Each one The application will take 20 minutes. It will be time to implement The decision is made with the patient. Finally The patient's sleep quality will increase in three days of application. measured by actigraphy.
41443483|NCT03551418|BEHAVIORAL|Watching a video|Watching a video of an adult with DS washing his hands
41443484|NCT05457920|BEHAVIORAL|continuous treatment|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFN α-2b 180μg once a week, or every 8 weeks of injection, 4 weeks off, periodically, the total treatment course does not exceed 96 weeks.
41443485|NCT05457920|BEHAVIORAL|pulse therapy|pulse therapy
41102849|NCT02586454|DRUG|morphine|
41102850|NCT02586454|DRUG|ropivacaine|
41102851|NCT05070104|DRUG|CPI-613|250-1000mg/m2 -14 day cycle
41102852|NCT05070104|DRUG|modified FFX|Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle
41102853|NCT05070104|DRUG|Bevacizumab|5mg/kg IV
41102854|NCT00163085|DRUG|NR2B NMDA Antagonist CP-101,606 (traxoprodil)|
41102855|NCT00853827|DRUG|Placebo|Placebo
41102856|NCT00853827|DRUG|Aliskiren|300 mg
41102857|NCT04702503|DRUG|WP1220|Topical administration 2x daily for 84 consecutive days
41102858|NCT03710564|BIOLOGICAL|Brolucizumab|6 mg/0.05mL solution for intravitreal injection
41102859|NCT03710564|BIOLOGICAL|Aflibercept|2 mg/0.05mL solution for intravitreal injection
41102860|NCT02987543|DRUG|olaparib|300 mg (2x 150 mg tablets) twice daily
41102861|NCT02987543|DRUG|enzalutamide|160 mg (4 x 40 mg capsules) once daily
41102862|NCT02987543|DRUG|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
41102863|NCT02987543|DRUG|abiraterone acetate|1,000 mg (2 x 500 mg tablets) once daily
41102864|NCT02987543|DRUG|enzalutamide|160 mg (4 x 40 mg tablets) once daily
41102865|NCT02989961|OTHER|Resticutis|Autologous, Activated-Platelets type of Preparation
41102866|NCT02989961|OTHER|Platelet-Poor Plasma (PPP)|A preparation of low platelet plasma obtained by a high-speed centrifugation step.
41102867|NCT05245851|DEVICE|Opportunistic screening for low BMD|"Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements:~* This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA \[investigational testing authorization\] from Health Canada, to screen for low bone mineral density (low BMD).~* This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate.~The radiologist can choose to include this as an incidental finding in their report to the referring physician."
41102868|NCT04767035|DRUG|midazolam / ketamine sublingual tablet|sublingual tablet
41102869|NCT01916889|OTHER|RACY test|
41102870|NCT04087746|DRUG|Aflibercept|Intra-vitreal injection of AVEGF AFLIBERCEPT in group I
41102871|NCT04087746|DRUG|Ranibizumab|Intra-vitreal injection of AVEGF Ranibizumab in group 2
41102872|NCT04270175|DRUG|Daratumumab SC|Given as 1800mg via injection
41102873|NCT04270175|DRUG|Pomalidomide|Given as 4mg oral capsule
41102874|NCT04270175|DRUG|Dexamethasone|Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.
41102875|NCT01701713|DEVICE|DKI ED2011|
41102876|NCT01701713|DEVICE|Sham-TDCS|
41102877|NCT00361517|BEHAVIORAL|Galactomannan antigen monitoring, Aspergillus PCR|There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
41102878|NCT00361517|OTHER|blood draws|Blood is drawn for monitoring of Galactomannan antigen in the blood
41102879|NCT00361517|OTHER|blood draws for GM monitoring|blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
41102880|NCT00361517|DRUG|Amphotericin-B deoxycholate|1-1.5mg/kg, i.v, once a day
41102881|NCT00361517|OTHER|blood test|Blood will be tested twice a week for the presence of Galactomannan.
41102882|NCT00361517|OTHER|Blood test|Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
41102883|NCT01087619|PROCEDURE|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
41102884|NCT04720781|DRUG|Vonoprazan|Vonoprazan (20mg/day) is prescribed for 4 weeks.
41102885|NCT04720781|DRUG|Esomeprazole|esomeprazole (20mg/day)
41102886|NCT05396976|BEHAVIORAL|Yoga and Muscle Relaxation Exercise Practices|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
41102887|NCT00315055|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
41102888|NCT00315055|BIOLOGICAL|DTaP-IPV//PRP~T combined|0.5 mL, IM
41102889|NCT00315055|BIOLOGICAL|Hepatitis B vaccine|0.5 mL, IM
41102890|NCT01524536|DRUG|prednisone|Glucocorticoids (GC) are considered the first- line therapy for hypereosinophilic syndrome.
41102891|NCT01539655|DRUG|vandetanib|Oral tablets, 300 mg, single dose
41102892|NCT01539655|DRUG|omeprazole|Oral capsules, 40 mg, multiple doses
41102893|NCT01539655|DRUG|ranitidine|Oral tables, 150 mg, multiple doses
41102894|NCT00999492|DEVICE|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
41102895|NCT03511885|OTHER|There is no intervention|
41102896|NCT01971892|OTHER|Non Invasive ventilation (facial mask and NIV ventilator)|Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option
41102897|NCT01971892|OTHER|Standard oxygen therapy with facial mask|facial Venturi mask
41102898|NCT06067178|BEHAVIORAL|Health Dialogue Intervention|"1. Lifestyle assessment: All participants fill out a questionnaire to assess behavioral risk factors for CVD and undergo blood tests for cholesterol and blood glucose.~2. Lifestyle health dialogue: When presenting in person at the primary care center, blood pressure, BMI, and waist-hip ratio will be measured. The results from the questionnaire, blood tests, blood pressure, and body measurements will be summarized using a visual tool, in which risk factors are graded into risk levels to estimate CVD risk. The visual tool will then be used in the health dialogue to discuss risk factors. The health dialogue is conducted by a licensed healthcare professional who has been trained in the methodology. The dialogue will be conducted in a person-centered manner and will aim to motivate and support lifestyle behavior changes when needed. If necessary, medical treatment will be provided according to existing guidelines."
41102899|NCT06067178|OTHER|Opportunistic Screening|"1. Risk factor assessment: Opportunistic screening entails screening for risk factors (blood pressure, BMI, blood tests for cholesterol and blood glucose, and smoking) among patients visiting the primary care center for another reason. Screening is conducted by a healthcare professional at which the patient has an appointment.~2. Detected risk factors for CVD are treated according to the existing care programs and guidelines at the primary care center, which should always include lifestyle advice as the first intervention and medication if hypertension is established. In this intervention, there is a more limited assessment of behavioral risk factors; that is, patients are asked about smoking, but assessment of diet, physical activity, or alcohol consumption is not included in the opportunistic screening."
41102900|NCT06441656|PROCEDURE|Vitrectomy with ILM flap|In both groups, a single-layer ILM temporal flap of approximately 2 times the size of the optic disc was fashioned using an ILM forceps temporal to the macula. The nasal edge of the flap was not detached from the temporal MH edge. The flap was reflected nasally to cover the MH
41102901|NCT04770935|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form:solution for injection Route of administration: intravenous injection
41102902|NCT03161392|DIAGNOSTIC_TEST|Follow-up|"Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years."
41102903|NCT03161392|DIAGNOSTIC_TEST|Ultrasound-guided percutaneous biopsy|"Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed."
41102904|NCT02885350|DRUG|Spinal analgesia for labour pain|Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
41102905|NCT02885350|DRUG|Epidural analgesia for labour pain|Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
41102906|NCT02245854|DEVICE|Exacto™|Cold snare polypectomy
41102907|NCT04622150|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE is comprised of a series of up to four treatment modules whose inclusion is determined based upon an individuals reasons for nonadherence (adherence barriers).The standardized modules are Psychoeducation, Modified Motivational Interviewing, Communication with Providers, Medication Routines. CAE participants will have a core series of approximately four sessions spaced about one week apart over a period of 4-6 weeks, and one booster in-person session 4 weeks after the completion of the four core sessions (total of approximately 5 sessions). Sessions 2-4 will be delivered remotely by the study interventionist. All participants will have the first session in-person. The final booster session will be conducted at the sites and will review all previously introduced materials. There will be a follow-up phone call with the study interventionist that will occur in the four-week time period between completion of four CAE core sessions and prior to initiation of the booster CAE session.
41102908|NCT04622150|BEHAVIORAL|Enhanced Treatment as Usual (eTAU)|eTAU participants will receive monthly text messages (or phone calls for participants who prefer not to receive texts) to refill medications, fill eCAPs and brief general adherence promotion messages during the follow-up period.
41102909|NCT04227990|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
41102910|NCT04227990|DRUG|Pegfilgrastim|Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
41102911|NCT04227990|DRUG|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
41102912|NCT05725018|BIOLOGICAL|EB-101 Surgical application of RDEB wounds|"EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7~Other Names:~• LZRSE-Col7A1 Engineered Autologous Epidermal Sheets \[LEAES\]"
41102913|NCT05147506|DEVICE|CNRM DTx|A mobile application intervention adapted from the CBT for Depression and CBT for TBI manuals.
41102914|NCT05147506|OTHER|Psychoeducation Comparison|A mobile application that consists of psychoeducational material regarding depression and brain injury.
41102915|NCT06250270|DIETARY_SUPPLEMENT|protein or placebo|casein protein (30g) or placebo (maltodextrin, 30g)
41102916|NCT00191035|DRUG|Atomoxetine|
41102917|NCT03673709|BEHAVIORAL|Antenatal Care|Women in group care bypass the waiting room and have a 2-hour visit with the same provider with a group of 8-12 women at a similar stage of pregnancy. Women assess their own blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
41102918|NCT01111903|DRUG|Lenalidomide|Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
41102919|NCT05237804|OTHER|Patient component|Video, booklet, website
41102920|NCT05237804|OTHER|Organisational component|Coronarography, CT-scan, anesthesia...
41102921|NCT03718793|DIAGNOSTIC_TEST|Peripheral exhaled nitric oxide|Small airway inflammation and dysfunction will be measured using the above mentioned tests.
41102922|NCT00001994|DRUG|Atovaquone|
41102923|NCT03748433|DEVICE|Dexcom G6 CGM|Commercially available Dexcom G6 Continuous Glucose Monitoring
41102924|NCT03748433|DEVICE|Tandem t:slim X2 Insulin Pump|sensor augmented insulin pump with predictive low glucose suspend
41102925|NCT02884583|OTHER|Pulmonary function test|Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
41102926|NCT01830842|DRUG|Nicotine polacrilex|nonsmokers will be measured following nicotine administration
41102927|NCT01830842|DRUG|Placebo|nonsmokers will be measured following placebo administration
41102928|NCT01830842|OTHER|satiety|smokers will be measured in a smoking satiated condition
41102929|NCT01830842|OTHER|abstinence|smokers will be measured following 24-hours of smoking abstinence
41102930|NCT03189134|DRUG|Fluorescite|Dilute fluorescite will be applied to cardiac tissue prior to imaging
41102931|NCT03189134|DEVICE|Cellvizio 100 Series System with Confocal Miniprobes|Microscopy system will image cardiac tissue.
41102932|NCT06027307|DRUG|Enavogliflozin|All study patients will receive enavogliflozin in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
41102933|NCT06027307|DRUG|Placebo|All study patients will receive placebo in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
40925223|NCT05704127|OTHER|Artificial moxibustion|The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
41102934|NCT01651949|BIOLOGICAL|9vHPV Vaccine|9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
41102935|NCT01230346|OTHER|questionnaire administration|Ancillary studies
41102936|NCT01230346|OTHER|survey administration|Ancillary studies
41102937|NCT01230346|OTHER|counseling intervention|Telephone intervention
41102938|NCT01230346|OTHER|educational intervention|Telephone intervention
41102939|NCT03869918|OTHER|Exercise Program|Exercise at home or through a class as chosen by the subject.
41102940|NCT04008797|DRUG|E7386|E7386 dosing.
41102941|NCT04008797|DRUG|Lenvatinib|Lenvatinib, capsules, orally.
41102942|NCT04008797|DRUG|Doxorubicin|Doxorubicin dosing.
41102943|NCT04008797|DRUG|Paclitaxel|Paclitaxel dosing.
41102944|NCT05140564|BEHAVIORAL|STEADY intervention|STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
41102945|NCT05997199|DIETARY_SUPPLEMENT|Vitamin D replacement|Group 1 with vitamin D deficiency will be getting a standart vitamin D replacement of 50.000 IU/week for 8 weeks.
41102946|NCT04850482|OTHER|MyJourney|MyJourney is an online self-help interactive program based on Contextual Cognitive Behavioural Therapy.
41102947|NCT01057758|DRUG|SIMVASTATIN|Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
41102948|NCT01057758|DRUG|PLACEBO|Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
41102949|NCT03171896|OTHER|clown|A medical clown will be offerred to the parturient and will spend time with her during labor as long as she will want it
41102950|NCT03171896|OTHER|Sham|No clown will be present in the room during labor
41102951|NCT01428349|OTHER|Cognitive Remediation|Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
41102952|NCT01428349|OTHER|Cognitive Remediation|Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
41102953|NCT06555523|OTHER|Ultrasound guided injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The linear probe (PLT-704SBT, 7.5 MHz) of the ultrasound device will be kept parallel to the trapezoidal fibers on the marked trigger point and the dental-tipped needle will be directed to the targeted point in plane with real-time imaging
41102954|NCT06555523|OTHER|Blinded injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The needle will be directed to the most sensitive point and advanced until it will be reached the trigger point.
41102955|NCT04857346|DRUG|Indocyanine green|Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.
41102956|NCT02657629|OTHER|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
41102957|NCT02657629|OTHER|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
41102958|NCT01196988|BIOLOGICAL|Influenza vaccine GSK2321138A|intramuscular injections
41102959|NCT01196988|BIOLOGICAL|FluarixTM|intramuscular injections
41102960|NCT01196988|BIOLOGICAL|Influenza vaccine GSK2604409A|intramuscular injections
41102961|NCT05218837|OTHER|Vaginal birth|Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.
41102962|NCT02960542|BEHAVIORAL|HELP Prevent Cancer Intervention|This Behavioral: Lifestyle Weigh Loss Intervention involves a dietary weight-loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight-loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight-loss of .3 kg/week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 minutes/week.
41102963|NCT03252106|PROCEDURE|Contour augmentation with implant placement|Contour augmentation with implant placement
41102964|NCT03165149|DRUG|group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
40925224|NCT00634738|PROCEDURE|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
40925225|NCT06189235|OTHER|Biofeedback training|The target of additional biofeedback training is to provide hints which are related to the essential aspects during hand therapy such as the stress on the tissue and the distance of tendon gliding.
40925226|NCT01779219|DEVICE|iMRI-guided brain tumour biopsy|The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.
41102965|NCT03165149|DRUG|group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
41102966|NCT03165149|DRUG|group (c)|patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
41102967|NCT00496379|DRUG|ZK219477|Given intravenously over approximately 30 minutes once every 3 weeks
41102968|NCT00768131|DRUG|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
41102969|NCT00768131|DRUG|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
41102970|NCT00768131|DRUG|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
41102971|NCT04761562|DRUG|Platelet- and extracellular vesicle-rich plasma|PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.
41443486|NCT04925791|DIAGNOSTIC_TEST|standardized pre-conditioning treatment|3 rounds of 5 minutes of full occlusion alternating with 5 minutes of reperfusion while seated.
41102972|NCT04761562|PROCEDURE|Control group|Edges of the tympanic membrane perforation will be refreshed and the tympanomeatal flap raised. Under the tympanic membrane perforation, a guide (fascia of the temporalis muscle, perichondrium, cartilage or fat) will be placed. An absorbent gelatin sponge will be placed under the guide and on the outer surface of the reconstructed tympanic membrane.
41102973|NCT04619303|DRUG|Dexamethasone intravitreal implant|Intravitreal injection of 0.7mg dexamethasone implant
41102974|NCT04619303|DRUG|Bevacizumab Injectable Product|Invtravitreal injection of 1.25mg/0.05mL bevacizumab
41102975|NCT02962674|DEVICE|prostaFix System|
41102976|NCT02545751|RADIATION|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
41102977|NCT02545751|DRUG|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
41102978|NCT02723929|DEVICE|active low-intensity transcranial electrical stimulation/active transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes."
41102979|NCT02723929|DEVICE|Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes."
41102980|NCT05613257|DEVICE|Distal targeting jig|Patients in this arm will have an assistive targeting device used for interlocking screw placement. The targeting device is attached to the nail proximally or distally (for antegrade or retrograde nailing, respectively) to guide screw placement through the other end of the intramedullary device.
41102981|NCT05613257|PROCEDURE|Free-hand/perfect circles technique|"Patients in this arm will have no assistive targeting device use and the surgeon will use a free-hand technique for the placement of interlocking screws. With this technique, fluoroscopic images are taken such that the interlocking holes of the intramedullary device are perfect circles and indicate that a screw introduced in the same plane that the fluoroscopic image was taken would seat perpendicularly to the intramedullary device. This is the most commonly employed technique for interlocking screw placement through intramedullary devices."
41102982|NCT01191463|OTHER|Mung Bean Meal|50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
41102983|NCT01191463|OTHER|Guava|A fresh Guava fruit will be provided raw (approx 100g fresh weight)
41102984|NCT02796976|OTHER|Training or control condition|Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
41102985|NCT02875665|DEVICE|geko(TM) device|The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
41102986|NCT01549496|DRUG|Amlodipine|amlodipine 2.5 mg QD
41102987|NCT01549496|DRUG|Diltiazem|diltiazem 120 mg qd
41102988|NCT03308461|DRUG|Fecal Microbiota suspension|The prepared microbiota suspension was infused into mid-gut.
41102989|NCT01276990|DRUG|BI 224436|Oral drinking solution
41443487|NCT04925791|DIAGNOSTIC_TEST|Partial occlusion|3 rounds of 5 minutes of partial occlusion alternating with 5 minutes of reperfusion while seated.
41443488|NCT03680053|DRUG|Duphaston|Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.
41443489|NCT03680053|DRUG|Cetrorelix|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
41102990|NCT01276990|DRUG|BI 224436|Oral drinking solution
41102991|NCT01276990|DRUG|BI 224436|Oral drinking solution
41102992|NCT01276990|DRUG|BI 224436|Oral drinking solution
41102993|NCT01276990|DRUG|BI 224436|Oral drinking solution
41102994|NCT01276990|DRUG|BI 224436|Oral drinking solution
41102995|NCT01276990|DRUG|BI 224436|Oral drinking solution
41102996|NCT01276990|DRUG|BI 224436|Oral drinking solution
41102997|NCT01276990|DRUG|BI 224436|Oral drinking solution
41102998|NCT01276990|DRUG|Placebo|Oral drinking solution
41102999|NCT05753644|PROCEDURE|stellate ganglion blocks|At the level between C6 and C7, a 25-gauge needle is inserted laterally, and the needle tip is placed posterior to the carotid artery and anterior to the longus colli muscle using an in-plane approach.
41103000|NCT05753644|DRUG|Ropivacaine|5 mL of 0.5% ropivacaine injected in the plane of the right stellate ganglion
41103001|NCT05753644|DRUG|Sham treatment|5 mL of saline injected in the plane of the right stellate ganglion
41103002|NCT02116855|OTHER|according to the efficacy of AJBRs|
41103003|NCT01040741|OTHER|Non-intervention observational study|Non-intervention observational study
41103004|NCT01499108|DRUG|liraglutide|Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
41103005|NCT00984087|DEVICE|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
41103006|NCT00595218|BEHAVIORAL|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
41443490|NCT00604474|DEVICE|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
41443491|NCT04116957|DEVICE|RTLS current tag|Validate location system performance against manual observation of nursing activity
41443492|NCT04116957|DEVICE|RTLS tag revised|Test a next-generation RTLS tag for healthcare process validation
41103007|NCT00595218|OTHER|Patient Preference Results|Knowledge of Patient Preference Results
41103008|NCT05324631|DRUG|SHR0302|SHR0302, oral, once daily
41103009|NCT05324631|DRUG|SHR0302 placebo|SHR0302 placebo, oral, once daily
41103010|NCT02400151|DRUG|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
41103011|NCT02400151|DRUG|Placebo|Patients randomized to this group will receive placebo for 90 days.
41103012|NCT02400151|OTHER|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
41103013|NCT02400151|OTHER|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
41103014|NCT05253339|PROCEDURE|target-controlled infusion (one of the administration methods)|a method of administering cefoxitin while maintaining a constant target concentration.
41103015|NCT05253339|PROCEDURE|Standard administration method|Standard method of administering cefoxitin in the current clinical setting
41103016|NCT05638204|BEHAVIORAL|Suicidal Crisis Intervention (SCI)|This study's experimental condition consisted of the Suicidal Crisis Intervention (SCI), developed by the Flemish Centre of Expertise of Suicide prevention. The SCI aims to provide tools for dealing with future suicidal crises for people after a suicidal crisis or suicide attempt. The intervention attempts to provide insight into the suicidal crisis by giving suicidality meaning within the life history. It aims to increase motivation for specialized care and therefore facilitate continuity of care. In addition, the method also wants to involve the close relative(s) of the suicidal person in the treatment. The SCI offers care providers a clear structure and handles to do this within a short period of time (4 sessions). Within the SCI are a number of crucial elements: the therapeutic relationship, involving loved ones, person-centred care, the Integrated Explanatory Model for Suicidal Behavior (Van Heeringen, 2007), the safety plan (Stanley \& Brown, 2012) and continuity of care.
41103017|NCT01168011|DRUG|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day for 21 days of 21-day cycles. Treatment may continue until progression.
41103018|NCT06156306|BEHAVIORAL|CBT-I|The CBT-I intervention will cover sleep education, stimulus control, sleep restriction, cognitive therapy and relaxation training.
41103019|NCT06156306|BEHAVIORAL|CBT-I combined ACT|In addition to the standard CBT-I components, mindfulness, thought diary, and other ACT components will be taught in the group.
41103020|NCT01830166|RADIATION|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
41103021|NCT03841019|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of MST in four weeks (three sessions per week)
41103022|NCT03841019|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of ECT in four weeks (three sessions per week)
41103023|NCT00092599|DRUG|MK0653, ezetimibe|
41103024|NCT00092599|DRUG|Comparator: ezetimibe, placebo|
41103025|NCT01505101|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
41103026|NCT01505101|BEHAVIORAL|Conventional Support Group (SG)|The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
41103027|NCT03461991|DEVICE|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
41103028|NCT04611360|OTHER|Anodal Transcranial Direct Current Stimulation Group|"Experimental group were received anodal transcranial direct current stimulation and conventional training exercises for 3 days a weeks for 6 consecutive weeks on alternate days.~Anodal tDCS were given through:~i. Anodal electrode:It has been placed over primary motor cortex(ipsilesional) ii. Cathodal electrode: It has been above contralateral eye. iii. Intensity: 2mA iv Density: 0.07C/cm2 iv. Duration:20 min vi Rectangular electrodes(25cm2 ) inserted in saline soaked sponge used"
41103029|NCT04611360|OTHER|Conventional Training Exercises Group|Conventional physical exercises were given for 3 days a week on alternate days upto 6 weeks. It includes: progressive Conventional Training Exercises : From Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk.
41103030|NCT03801551|DIAGNOSTIC_TEST|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
41103031|NCT06350045|COMBINATION_PRODUCT|PCNL|percutaneous nephrolithotomy
41103032|NCT05376930|DRUG|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
41103033|NCT03058783|DRUG|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
41103034|NCT03058783|DRUG|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
41103035|NCT02076919|DRUG|LHA510 Ophthalmic Suspension|Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
41103036|NCT02076919|DRUG|LHA510 Vehicle|Inactive ingredients used for masking purposes
41103037|NCT03861169|DEVICE|Transluminal viscoelastic delivery and trabeculotomy|Ab-interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System
41103038|NCT00432458|DRUG|Thalidomide|200 mg orally on days 1-28 of 28 day cycle
41103039|NCT00432458|DRUG|zoledronic acid|4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
41103040|NCT05171998|PROCEDURE|venous blood sample|Phlebotomy procedure for a venous blood draw.
41103041|NCT06278064|OTHER|Gastric Cancer|Patients diagnosed with gastric cancer, including early stage gastric and advanced gastric cancer
41103042|NCT06278064|OTHER|Esophagus Cancer|Patients diagnosed with esophagus cancer, including early esophagus gastric and advanced esophagus cancer
41103043|NCT04884737|OTHER|Mepilex Border Flex® (MBF) dressing|A new dressing technology (Mepilex Border Flex® (MBF)) provides increased conformability of the dressing to the skin with the ability of the dressing to move in all directions (e.g., 360-degree flexibility) with even slight body movements. Limited data exists on use of silicone foam dressings with all direction flexibility during prone surgical procedures.
41103044|NCT02768272|DEVICE|PCEA vs PIEB|We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor
41103045|NCT02768272|PROCEDURE|Epidural vs CSE|We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
41103046|NCT03533556|DIETARY_SUPPLEMENT|L-theanine|Oral administration of 2.5 mg/kg body weight of L-theanine dissolved in 100 ml of water
41103047|NCT03533556|DIETARY_SUPPLEMENT|Caffeine|Oral administration of 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
41103048|NCT03533556|DIETARY_SUPPLEMENT|L-theanine-Caffeine Combination|Oral administration of a combination of 2.5 mg/kg body weight of L-theanine and 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
41103049|NCT03533556|OTHER|Placebo|Oral administration of 100 ml of water
41103050|NCT01967654|OTHER|Technical Assistance, training and clinical reminders|
41103051|NCT01967654|OTHER|Referral to Community Health Worker|
41103052|NCT05068167|DIAGNOSTIC_TEST|Kidney function test|Creatinine twice the baseline and urine output of fewer than 0.5 ml/kg per hour for 12 hours
41103053|NCT00338858|OTHER|walking and balance performance evaluation|
41103054|NCT00338858|PROCEDURE|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
41103055|NCT00415558|DEVICE|Microwave Ablation System|
41103056|NCT03784963|DRUG|Omega 3 fatty acids|Patients will receive 4 grams fish oil once daily
41103057|NCT03784963|OTHER|Placebo|Standard of care
41103058|NCT05783960|OTHER|administration questionary|Questionnaire will be compared to 24h sodium and potassium urinary excretion (reference). A Bayesian network and a multiple regression will be used to validate the questionary
41103059|NCT01358916|OTHER|Mailing of antibiotic therapy guidelines to the sentinel physicians|Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
41103060|NCT02486588|OTHER|Messaging|See detailed study description for overview of the different messaging interventions in this study
41103061|NCT02486588|OTHER|Financial incentives|See detailed study description for overview of the different financial incentive-based interventions in this study
40925227|NCT01779219|DEVICE|Stereotactic frameless brain tumour biopsy|The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
41103062|NCT02013986|DRUG|etomidate|0.3mg/kg IV only once during induction of general anesthesia
41103063|NCT02013986|DRUG|midazolam|midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
41103064|NCT02013986|DRUG|propofol|2mg/kg IV only once during induction of general anesthesia
41103065|NCT02176096|DIETARY_SUPPLEMENT|Glycosade|
41103066|NCT04894318|BEHAVIORAL|Low-fat and low-cholesterol diet|Low-fat (\<30% of total energy) and low-cholesterol (\<200mg/day) diet total of 12 weeks
41103067|NCT03679962|BEHAVIORAL|Triple Chronotherapy|"Day 0: One night of total sleep deprivation. The first 24 hours are spent with 1:1 nursing care for provision of comfort measures to stimulate wakefulness and to encourage completion of the intervention.~Day 1-4: Sleep phase advancement Day 1: Sleep from 6 PM to 1 AM Day 2: Sleep from 8 PM to 3 AM Day 3: Sleep from 10 PM and 5 AM Day 4: Awaken at 5 AM; discharge following light therapy~On days 1-4 patients will receive bright light therapy at 7am to 7:30am using a 10,000 Verilux light box. At discharge patients will be given a light box, strongly advised to continue the maintenance sleep schedule and bright light therapy at 7am daily for 30 minutes. Patients will be scheduled for follow-up appointments at 1-week, 1-month and 2-month following discharge."
41103068|NCT03679962|BEHAVIORAL|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
41103069|NCT01070251|BEHAVIORAL|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
41103070|NCT01070251|BEHAVIORAL|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
41103071|NCT03837769|DEVICE|Aktiia OBPM PulseWatch wrist device|The optical signals at the wrist are recorded non-invasively. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
40925228|NCT02436980|DRUG|Tramadol|GROUP T
40925229|NCT02436980|DRUG|Midazolam|GROUP M
41103072|NCT06452355|DEVICE|KOKO Device|The intrauterine rolling drain is extended into the uterus, where low pressure vacuum is applied to the uterus through the fabric intrauterine rolling drain. The KOKO™ device utilizes this vacuum to remove excess blood and compress the uterus reducing further blood loss.
41103073|NCT06317688|DIETARY_SUPPLEMENT|Extra-Virgin Coconut Oil|Active ingredients act as a destructor of bacteria, viruses and fungus
41443493|NCT01466166|BIOLOGICAL|Pegloticase|Pegloticase 8 mg intravenous every 2 weeks
41443494|NCT02160015|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41443495|NCT02160015|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41103074|NCT04140097|OTHER|Prospective monitoring of a large variety of parameters|Patients will be recruited during an inpatient pulmonary rehabilitation program. This setting offers a unique opportunity to study the phenomenon of an acute exacerbation of the Chronic Obstructive Pulmonary Disease prior to the first visible clinical sign and further on to have a follow up of the underlying mechanisms. All COPD patients that are referred to the reference center for a rehabilitation program will be included after providing written informed consent. Prospectively, a wide range of measurements will be collected. If a patient develops an acute exacerbation there will be a comprehensive diagnostic assessment to differentiate between pulmonary, cardiac or cardio-pulmonary reasons for the exacerbation. The clinical diagnosis of an AECOPD will be made by a pulmonologist according to criteria of international guidelines within the first 24h of clinical symptoms suggestive of an exacerbation.
41103075|NCT02565056|OTHER|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
41103076|NCT02261688|DIETARY_SUPPLEMENT|Low salt diet|Low salt diet, 10mmoL of sodium per day, for 6 days
41103077|NCT02261688|DIETARY_SUPPLEMENT|Low salt diet + IV normal saline|Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
41103078|NCT02261688|DIETARY_SUPPLEMENT|Liberal salt diet|Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
40925230|NCT03149848|DRUG|Cabotegravir|It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
41103079|NCT00006369|DRUG|ERA-923|
41103080|NCT03557788|DRUG|Rifaximin Oral Tablet|PO 550mg TDS for 2 weeks
41103081|NCT05795946|DIETARY_SUPPLEMENT|Whole food-based B and D vitamins|Looking at whole food-based B and D vitamins to reduce TMAO levels and if this can modulate gut diversity
41103082|NCT02168335|OTHER|OrasaltsTM|OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice
41103083|NCT02168335|OTHER|Sea salt|Unmedicated sea salt
41103084|NCT02909699|OTHER|Observation|In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
40925231|NCT03149848|DRUG|Rifabutin|It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
40925232|NCT04395950|DRUG|PF-05221304|PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)
40925233|NCT04395950|DRUG|Placebo|Placebo two tablets daily in the morning for 6 weeks
40925234|NCT03893890|BIOLOGICAL|Previously Treated with EN3835|No treatment to be administered - Observational only
40925235|NCT00340574|DRUG|AMA1-C1/Alhydrogel + CpG 7909|
40925236|NCT00322621|DRUG|Duloxetine|
40925237|NCT04839575|DRUG|Latiglutenase|Administered orally (daily)
40925238|NCT04839575|DRUG|Placebo|Administered orally (daily)
40925239|NCT04987944|DRUG|Zavegepant|150 mg BID
40925240|NCT04987944|DRUG|Placebo|Placebo matching active drug
41103085|NCT01419717|DRUG|Denosumab|Administered by subcutaneous injection every 4 weeks (Q4W)
41103086|NCT00608348|PROCEDURE|Hyperinsulinemic glucose clamp procedures|2 hours of either euglycemic or hypoglycemic glucose clamping
41103087|NCT00608348|PROCEDURE|moderate exercise|90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
41103088|NCT04565522|OTHER|Prospective observation|Prospective observation until one year follow-up
41103089|NCT04811079|OTHER|419 nm Spectacle Filter|TEST
41103090|NCT04811079|OTHER|437 nm Spectacle Filter|TEST
41103091|NCT04811079|OTHER|456 nm Spectacle Filter|TEST
41103092|NCT04811079|OTHER|476 nm Spectacle Filter|TEST
41103093|NCT04811079|OTHER|373 nm Spectacle Filter|CONTROL
41103094|NCT00301990|BIOLOGICAL|aldesleukin|
41103095|NCT00301990|BIOLOGICAL|bevacizumab|
41103096|NCT01267838|PROCEDURE|PCI|PCI of bifurcation lesions with double stenting
41103097|NCT03833102|OTHER|biological analysis|ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
41103098|NCT01153750|DRUG|Glivec|
41103099|NCT02556034|OTHER|Disease evaluation.|Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
41103100|NCT05122312|DRUG|Olinanoseal|it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.
40925241|NCT03457441|OTHER|Standards vision tests|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
40925242|NCT03457441|DEVICE|OdySight medical application assessment|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
40925243|NCT05861622|OTHER|Moisturizer|The test product is a novel moisturizer, that contains active ingredients, including rambutan extract, niacinamide, and glycoin.
40925244|NCT02574572|BIOLOGICAL|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
41103101|NCT05122312|DRUG|Curodont D'senz|This agent contains p 11-4 peptide in addition to fluoride
41103102|NCT01680276|BEHAVIORAL|PBS based staff training|"Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219"
41443496|NCT02160015|PROCEDURE|Computed Tomography|Undergo CT
41103103|NCT01680276|OTHER|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
41103104|NCT05993949|DRUG|Dasatinib|3 pulses of oral dasatinib (100 mg daily) beginning on Day 4 (+up to 2 days) for 3 days (with 4 days off), repeated weekly. The weekly 3-day pulse schedule of dasatinib may continue for up to 3 months in subjects who continue to meet the dasatinib eligibility criteria and who do not meet off treatment/off study criteria
41103105|NCT04346524|OTHER|sampling of microbiome|women will sample from vagina, feces, and saliva during pregnancy
41103106|NCT04425434|OTHER|OBSERVATIONAL|We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.
41103107|NCT05998005|BEHAVIORAL|First Face Training Program|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
41103108|NCT06469892|OTHER|Detect the expression level of miR-185 in salivary and plasma exosomes.|"Participants were instructed to refrain from eating, drinking, brushing their teeth, rinsing their mouth, or taking medications for one hour before saliva collection. They were then asked to bend over, lower their head, open their mouth, and allow saliva to flow naturally without chewing or spitting. Using a specialized container, 2 mL of unstimulated saliva was collected.~Participants fasted overnight before blood collection. Researchers used plasma tubes containing anticoagulant (EDTA) to obtain venous blood (4-5 mL) from the participants\&#39; upper arm. Subsequently, the blood was gently inverted to ensure optimal contact with the anticoagulant before centrifugation at 2000 rpm and 4°C for 10 minutes. Following centrifugation, the supernatant was extracted."
41103109|NCT06258980|DRUG|Proph7|Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females
41103110|NCT03036735|DEVICE|steroid eluting spacer|The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer.
41103111|NCT04361487|DEVICE|NOVOSTITCH PRO Meniscal Repair System|Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO
41103112|NCT05822609|DRUG|Semaglutide|1.0 mg
41103113|NCT05822609|OTHER|Placebo|Placebo
41103114|NCT00094809|DRUG|Placebo|Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
41103115|NCT00094809|DRUG|Pegfilgrastim|Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
41103116|NCT06421090|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation，Intervention group25Hz，Control group1Hz
41103117|NCT00531518|DRUG|aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Oral, daily, generally at lower than manufacturer's recommendations
41103118|NCT00531518|BEHAVIORAL|Psychoeducational multifamily group treatment|Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
41103119|NCT00531518|BEHAVIORAL|Supported employment and education|Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
41103120|NCT06345612|BEHAVIORAL|hypoxia|eccentric training program conducted within normobaric hypoxic chamber
41103121|NCT06345612|BEHAVIORAL|normoxia|eccentric training program conducted within normoxic conditions
41103122|NCT06345612|DIETARY_SUPPLEMENT|creatine supplementation|5g of creatine per day
41103123|NCT06345612|DIETARY_SUPPLEMENT|no creatine supplementation|no creatine supplementation
41103124|NCT02614118|DRUG|Ketorolac tromethamine|10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
41103125|NCT02614118|DRUG|Acetaminophen|1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
41103126|NCT02614118|DRUG|Placebo|placebo 45 minutes before root canal treatment
41103127|NCT04118699|DRUG|Rifaximin oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks
41103128|NCT04118699|DRUG|Placebo oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks
41103129|NCT01556256|OTHER|Caregiver-Related Intervention or Procedure|Undergo TMV+P
41103130|NCT01556256|PROCEDURE|Music Therapy|Undergo TMV
41103131|NCT01556256|PROCEDURE|Music Therapy|Undergo TMV+P
41103132|NCT01556256|OTHER|Quality-of-Life Assessment|Ancillary studies
41103133|NCT01556256|OTHER|Questionnaire Administration|Ancillary studies
41103134|NCT06138548|DEVICE|Ossiofiber® Trimmable Fixation Nail|OSSIOfiber® Trimmable Fixation Nails are equally strong in the initial stability and fixation strength - and superior in rotational resistance to traditional metal cannulated headless compression screws.\*
41103135|NCT03068611|BEHAVIORAL|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
41103136|NCT03068611|BEHAVIORAL|Alcohol-focused Web-Based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
41103137|NCT04102449|DRUG|Apremilast|Single arm receiving Apremilast and ultrasound examinations
41103138|NCT00588965|DRUG|Placebo|Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
41103139|NCT00588965|DRUG|Propranolol LA|Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
41133274|NCT03944200|DRUG|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
41103140|NCT05455346|DIAGNOSTIC_TEST|Ultrasound imaging|"Ultrasound B-mode images will be unilaterally collected from the biceps femoris muscle of the dominant limb for each participant using a commercial ultrasound system and linear array transducer. Standardized image locations will correspond to 33%, 50%, and 67% of the thigh length from the ischial tuberosity.~Three repeat longitudinal extended-field-of-view images of the entire biceps femoris muscle will be collected for offline analysis for fascicle length, muscle thickness, and pennation angle. Transverse extended-field-of-view images will be captured at the proximal, mid-belly, and distal locations to determine regional anatomical cross-sectional area of the biceps femoris long head muscle.~To determine changes in tissue stiffness via ultrasound shear wave speed, the same transducer will be placed in the same locations in a longitudinal view. Shear wave maps will be generated by the ultrasound system and shear wave speed measures extracted from the middle of the map."
41103141|NCT05455346|OTHER|Hamstring Eccentric Strength Testing|"Prior to each test, participants will perform a standardized 5-minute general warm-up followed by a task-specific warm-up including 3 sets of submaximal trials. Load increases (5-20%) will be added for each RDL 3-repetition maximum trial attempt until the participant cannot complete 3 repetitions through the full range of motion using proper technique. A 3-minute rest will be administered between all warm-up and testing sets to allow for full recovery.~Participants will kneel on a commercial device used to assess maximum eccentric knee flexor strength via uniaxial load cells with their ankles secured into fixed hooks. Participants will slowly lower their torso to the ground with arms crossed across their chest and without bending at the hips or spine. The maximal test will consist of 1 set of 3 maximal repetitions. If participants can control lower themselves to the ground, then they will hold barbell plates (5-10 lb increments) across their chest while performing the NHE."
41103142|NCT05455346|OTHER|Maximal 60 m Sprint|Following a standardized warm-up, inertial measurement units (IMUs) will be placed on the sternum, sacrum, and bilaterally on the thighs, legs, and foot. Each participant will perform a total of 3 maximal 60 m sprints from a standing position with 1.5-3 min rest in between each trial to minimize the effects of fatigue.
41103143|NCT05455346|OTHER|Romanian Deadlift|The RDL intervention will be performed twice per week for 6 weeks. Participants will hinge at the hips lowering the bar to just below their patella before reversing the movement. The RDL will be performed with a 6 second eccentric component and returning to the start position with a maximal concentric hip extension.
41103144|NCT05455346|OTHER|Nordic hamstring exercise|The NHE will be performed twice per week for 6 weeks. Participants will be instructed to maintain their ankles in a dorsiflexed position, lower themselves as close to the ground as possible at a constant and controlled speed while maintaining a neutral position of the hips and trunk, and to cross their arms in front of their chest.
41103145|NCT02916719|DEVICE|MRI|MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
41103146|NCT03862833|DRUG|IL2|"Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40"
41103147|NCT03862833|DRUG|Zoledronic Acid|4 mg at day +15 post graft
41103148|NCT03094104|OTHER|News items with spin|Interpretation of news items with spin
41103149|NCT03094104|OTHER|News items without spin|Interpretation of news items without spin
41103150|NCT02391246|OTHER|Positron Emission Tomography Imaging|Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
41103151|NCT00208767|DRUG|Valsartan|Valsartan was titrated to a target dose of 320 mg orally daily
41103152|NCT00208767|DRUG|Placebo|A matched placebo pill will be given orally daily.
41103153|NCT02162667|DRUG|Trastuzumab|Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
41103154|NCT05381701|PROCEDURE|Lung Ultrasound Score|Measuring the atelectasis area by ultrasound guidance from 12 different regions of the lung
41103155|NCT03476109|DRUG|Randomisation to omalizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
41103156|NCT03476109|DRUG|Randomisation to mepolizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
41103157|NCT05489406|DRUG|DTG DT (6 x 5 mg)|DTG 5mg dispersible tablet
41103158|NCT05489406|DRUG|F/TAF TOS (3 x 60/7.5 mg)|60/7.5 mg TOS emtricitabine/TAF
41103159|NCT00010946|PROCEDURE|Acupuncture|
41103160|NCT05597943|BEHAVIORAL|Malama App|The Malama smartphone application is a gestational diabetes management app that syncs directly with commercially-available glucometers via Bluetooth, enabling both automatic blood glucose logging and providing interactive diet management/diet education tools. We aim to perform a pilot study assessing the impact of the Malama smartphone application on perinatal and postpartum outcomes in patients with GDM.
41103161|NCT02563704|DRUG|Artesunate|
41103162|NCT02563704|DRUG|Quinine|
40925245|NCT01915329|DEVICE|RSS (repetitive sensory stimulation)|"RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.~In case of the sham-stimulation no pulses are transmitted."
40925246|NCT01915329|DEVICE|SHAM-RSS|The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
40925247|NCT03643536|OTHER|12-WPEP|The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends
40925248|NCT03216928|DIAGNOSTIC_TEST|Blood test|
41103163|NCT02321306|DRUG|LUM001|LUM001 administered orally once each day.
41103164|NCT05621811|DRUG|Naronapride|Naronapride is a 5HT-4 agonist
41103165|NCT05621811|DRUG|Placebo|Placebo
41103166|NCT00367055|DRUG|rosiglitazone-metformin|
41103167|NCT00367055|DRUG|Metformin|
41103168|NCT00367055|DRUG|metformin+ gliclazide|
41103169|NCT05998668|OTHER|Genital hygiene training|In the first meeting with the women, 2 sessions of 45 minutes with a 10-minute break were held in the counselling rooms of the relevant family health centers. Two weeks after these sessions, a 45-minute session was held in order to reinforce the training with the same method.
41103170|NCT02501772|DEVICE|acupressure by ankle band|
41103171|NCT04722094|DIAGNOSTIC_TEST|Full periodontal chart|A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
41103172|NCT04722094|OTHER|Saliva sampling|Saliva samples for miRNAs detection will be taken before starting the visit.
41103173|NCT01803646|DRUG|AM-101|AM-101 gel for intratympanic injection
41103174|NCT01803646|DRUG|Placebo|Placebo gel for intratympanic injection
41103175|NCT04164524|DRUG|Gentamycin|Gentamycin 160 mg spray applied over the mesh
41103176|NCT00140673|BIOLOGICAL|Rotavirus|
41103177|NCT04300816|BEHAVIORAL|CBT for Uncertainty Tolerance|"Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis."
41103178|NCT04300816|BEHAVIORAL|Traditional CBT|Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.
41103179|NCT06359054|DIAGNOSTIC_TEST|18F FDG PET/CT|"18F-FDG PET/CT Imaging: Preparation: Participants will be instructed to fast for at least 6 hours before the procedure to ensure low insulin levels and high FDG uptake by cancer cells.~Radiopharmaceutical Administration: Each participant will receive an intravenous injection of 18F-FDG, dosed at approximately 5.2 MBq/kg (0.14 mCi/kg) of body weight.~Imaging Protocol: After the injection, participants will rest in a quiet and dimly lit room for approximately 60 minutes to allow for optimal distribution and uptake of 18F-FDG by the tissues. Subsequently, they will be positioned on the PET/CT scanner bed, and imaging will be performed from the vertex to the proximal thighs. The scan will include a low-dose CT for attenuation correction followed by PET imaging, with the acquisition time adjusted based on the specific protocol (typically 2-3 minutes per bed position)."
41103180|NCT06359054|DIAGNOSTIC_TEST|68Ga DOTATATE PET/CT|"68Ga-DOTATATE PET/CT Imaging: Preparation: No specific fasting is required for 68Ga-DOTATATE PET/CT. However, participants may be advised to hydrate well before the procedure.~Radiopharmaceutical Administration: Participants will receive an intravenous injection of 68Ga-DOTATATE, dosed at approximately 2.2 MBq/kg (0.06 mCi/kg) of body weight.~Imaging Protocol: Similar to the 18F-FDG protocol, after receiving 68Ga-DOTATATE, participants will wait for about 60 minutes to allow for sufficient uptake of the tracer. They will then undergo PET/CT scanning in a supine position, covering the same body regions as the FDG scan. A low-dose CT scan will be conducted first for attenuation correction, followed by the PET scan, with acquisition parameters tailored to the optimal detection of somatostatin receptor expression."
41103181|NCT03973424|BEHAVIORAL|Simple|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, use a simplified form of tracking only high-calorie, high-fat foods in the study smartphone app, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
41103182|NCT03973424|BEHAVIORAL|Standard|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, track calorie intake, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
41103183|NCT03861767|DRUG|Metformin ER|tablet
41103184|NCT03861767|DRUG|Placebo|Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
41103185|NCT00707590|DRUG|BMS-767778 or Placebo|
41103186|NCT04428320|PROCEDURE|Pelvic floor injection|Injection of 10 cc of bupivacaine
41103187|NCT02934035|DRUG|Antidepressant|
41103188|NCT02945267|DRUG|Nimotuzumab plus S1|Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
41103189|NCT02945267|DRUG|Placebo plus S1|Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
40752101|NCT05675085|DIAGNOSTIC_TEST|Personalized screening protocol|"At the first screening round (recruitment) all participating women had the same tests;~* Two-view tomosynthesis of both breasts~* Calculation of volumetric breast density (VBD)~* Calculation of lifetime risk (LTR) using the Tyrer-Cuzick model~At subsequent rounds:~1. Women with non-dense breasts and low breast cancer risk are re-screened only with DBT every 2 years;~2. Women with dense breasts and low breast cancer risk are re-screened with DBT+US every 2 years;~3. Women with non-dense breasts and intermediate breast cancer risk are re-screened only with DBT every year;~4. Women with dense breasts and intermediate breast cancer risk are re-screened with DBT+US every year;~5. Women at high risk of breast cancer associated with a family history of breast cancer (w/wo hereditary factors) undergo DBT and MRI every year."
41103190|NCT05693155|BEHAVIORAL|Voluntary self-exclusion from gambling ('Spelpaus')|Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')
41103191|NCT03360552|OTHER|Multidimensional fragility index questionnaire RAI-Home Care|Questionnaire for assessing deficits in Alzheimer's disease
41103192|NCT03360552|OTHER|Usual care|Usual clinical evaluation
41103193|NCT02952950|OTHER|Oralstimulation|The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
41103194|NCT00339469|DIETARY_SUPPLEMENT|LIFE|We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
41103195|NCT03255772|DIAGNOSTIC_TEST|Magnetocardiography|Study subjects will be placed within a magnetic shielding apparatus. Noninvasive sensors placed over the subject's torso will acquire magnetic field fluctuations generated by cardiac activity, which will then be analyzed for evidence of myocardial ischemia.
41103196|NCT01167036|DEVICE|FascialEdge instrument|Stroking massage to patient tolerance over the muscle
41103197|NCT01167036|OTHER|Placebo electric point stimulation|Detuned electric point stimulation over the involved muscle
41103198|NCT02860260|BIOLOGICAL|Blood samples|
41103199|NCT02860260|OTHER|Cerebral MRI|
41103200|NCT00695006|OTHER|Sham Traction|Traction \<5lbs
41103201|NCT00695006|OTHER|Traction|Standard supine intermittent traction
41103202|NCT02906306|BEHAVIORAL|Individual Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
41103203|NCT02906306|BEHAVIORAL|Group Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
41103204|NCT05235789|OTHER|Rational-Emotive-Behavioral Therapy|"The structure of the REBT sessions includes the following points:~1. Determine specific goals that explain what the participant want to achieve through the content of the session.~2. Explain the level of skills to be achieved in each session.~3. Development of the session, reminder of the previous session, review of homework (from the second session to the 8th). Irrational beliefs and disruptive thoughts will be worked on together with the participant in order to achieve an improvement in their emotional state. Key messages with healthier alternatives that make your daily life easier.~4. Establishing homework. Using the REBT Toolbox with Key Messages.~5. Individual psychosocial work will be recorded in the computerized medical history."
41103205|NCT05235789|OTHER|Control Group usual care|In the control group, for each center , the depression is treated as usual with the conventional treatment, according to national and international guidelines.
41103206|NCT03640455|DEVICE|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; placebo (dummy stimulation), according to the patient's randomization arm.
41103207|NCT03640455|DEVICE|Anodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in anodal polarity, according to the patient's randomization arm.
41103208|NCT03640455|DEVICE|Cathodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in cathodal polarity, according to the patient's randomization arm.
41103209|NCT03639441|PROCEDURE|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
41103210|NCT03639441|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
41103211|NCT02200952|DRUG|recombinant LH|recombinant LH twice/day for 10 days from pick up
41103212|NCT03693755|PROCEDURE|In-plane Group|Placement of femoral nerve catheter under ultrasound control
41103213|NCT03693755|PROCEDURE|Out-of-plane Group|Placement of femoral nerve catheter under ultrasound control
41103214|NCT03652207|OTHER|isomaltulose (Palatinose(TM)|isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
41103215|NCT03652207|OTHER|Sucrose|sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
41103216|NCT00432653|DRUG|rituximab|
41103217|NCT02765373|DRUG|Exemestane|
40925249|NCT02989987|BEHAVIORAL|Narrative Exposure Therapy|
40925250|NCT02989987|BEHAVIORAL|Social Support|A local counselors provides social support on demand.
40925251|NCT01402427|DRUG|Verapamil|Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
40925252|NCT01402427|DRUG|Placebo|Intraarterial administration of 10 mL saline.
41103218|NCT02765373|DRUG|Letrozole|
41103219|NCT02765373|DRUG|Anastrozole|
41103220|NCT00639366|BIOLOGICAL|trastuzumab|
41103221|NCT00639366|DRUG|chemotherapy|
41103222|NCT00639366|RADIATION|radiation therapy|
41103223|NCT01724788|DRUG|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
41103224|NCT01724788|DRUG|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
41103225|NCT02678104|PROCEDURE|Tooth extraction|Tooth removal
41103226|NCT02678104|DRUG|Chlorhexidine mouth wash|Chlorhexidine mouth wash
41103227|NCT02678104|DRUG|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
41103228|NCT04465578|PROCEDURE|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
41103229|NCT04465578|PROCEDURE|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
41103230|NCT04471467|PROCEDURE|Fixed tracheal tube|Tracheal tube fixation is determined by the surgeon according to the needs of the operation and is an independent process. Our research simply installed a monitoring device between the tube and the nose. The tube fixation takes place whether the observation of pressures is agreed to or not, as per standard protocol.
41103231|NCT00957658|DEVICE|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
41103232|NCT00015990|DRUG|thalidomide|Given orally
41103233|NCT00015990|OTHER|laboratory biomarker analysis|Correlative studies
41103234|NCT02873676|BEHAVIORAL|nutritional intervention|The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
41103235|NCT02873676|BEHAVIORAL|resistance training program|The training program involve warm-up exercise, muscle strength training and relaxing
41103236|NCT02873676|BEHAVIORAL|lifestyle modification project|Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
41103237|NCT02873676|BEHAVIORAL|control|The intervention involve dietary pattern modification and protein intake standardization
41103238|NCT04973852|DEVICE|Ekso|Exoskeleton walking
40925253|NCT04048733|DEVICE|patchy-type wireless 12-lead ECG|Perform 12-lead ECG using patchy-type wireless 12-lead ECG. This device automatically record 12-lead ECG in every 15 minutes by its algorithm.
41103239|NCT03838796|DRUG|lenvatinib|for patients \<60kg, lenvatinib 8mg bid po for patients \>60kg, lenvatinib 12mg bid po
41103240|NCT03838796|PROCEDURE|TACE|The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.
41103241|NCT03055767|DRUG|OnabotulinumtoxinA|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
41103242|NCT03055767|OTHER|Placebo (Saline)|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
41103243|NCT03265717|BIOLOGICAL|INVAC-1|Patients are treated by INVAC-1 for 6 cycles at 4-week intervals
41103244|NCT02341924|OTHER|Portfolio of functional foods|
41103245|NCT02341924|OTHER|Control foods|
41103246|NCT04472806|DRUG|Toripalimab|"Toripalimab, humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.~Toripalimab treatment after chemotherapy in combination with Endostar, 240 mg, Q3W, up to 2 years."
41103247|NCT04472806|DRUG|chemotherapy in combination with Endostar|chemotherapy+ Endostar
41103248|NCT03308487|DIETARY_SUPPLEMENT|vitamin D3 (1000 IU)|
41103249|NCT03308487|DIETARY_SUPPLEMENT|Vitamin D3 (2000 IU)|
41103250|NCT00141830|DRUG|Methotrexate plus ERB-041 for 12 weeks|
41103251|NCT00141830|DRUG|Placebo for 12 weeks|
41103252|NCT03025464|DEVICE|Obstructive Sleep Apnea Screening Device|Assessment of ability of device to detect apneas and hypopneas to screen for OSA
41103253|NCT00478855|DRUG|Tazocin (Piperacillin/Tazobactem)|
41103254|NCT00942149|DRUG|Daptomycin|single dose of 6 mg/kg of daptomycin
41103255|NCT06123585|OTHER|Invisalign® SmileView™|Pretreatment smiles were captured using the Invisalign® SmileView™ to simulate their new smiles before treatment was started.
41103256|NCT06123585|OTHER|Invisalign aligners|Patients were then treated using upper and lower Invisalign aligners with average treatment time of 12±3 months.
41103257|NCT04653350|OTHER|High Intensity Exercises|Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
41103258|NCT04653350|OTHER|General Exercises|Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training \& balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months
41103259|NCT03631563|DRUG|Immunosuppressive Agent|ATG-Fresenius versus ATG
41133275|NCT03944200|DRUG|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
41443497|NCT02160015|PROCEDURE|Electrocardiogram|Undergo ECG
41443498|NCT02160015|DRUG|Ibrutinib|Given PO
41443499|NCT02160015|DRUG|Lenalidomide|Given PO
40925254|NCT03907618|DIAGNOSTIC_TEST|ovarian reserve|To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.
40925255|NCT02102256|DEVICE|Auditory Brainstem Implant|
40925256|NCT05985460|DEVICE|Intervention: motion-sensor video game|The experimental arm is a 1-2 mins motion-sensoring video game, which can accommodate 1-4 individuals, engaging their entire bodies in the physical motions involved. It aims to increase PA intention by increasing their motivation, as well as personal and family well-being by increasing the interaction with family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
40925257|NCT05985460|DEVICE|Placebo: mobile APP game (without motion-sensoring)|The placebo arm is a 1-2 mins mobile app game, which allows 1-4 participants to play together with a duration of 1-2 minutes. It aims to increase participants' family and personal well-being by increasing the interaction of family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
40925258|NCT04857229|DEVICE|Histolog Scanner|Confocal Microscope
40925259|NCT00373438|PROCEDURE|Fetoscopic tracheal balloon occlusion|Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
40925260|NCT03131401|DIAGNOSTIC_TEST|Diagnosis of lymphatic filariasis|Field validation of the diagnostic performance of diagnostic tests for infection with W. bancrofti.
40925261|NCT03131401|DIAGNOSTIC_TEST|Diagnosis of lymphatic Filariasis and onchocerciasis|Field validation of the diagnostic performance of diagnostic tests for infection with both W. bancrofti and O. volvulus.
40925262|NCT03131401|DIAGNOSTIC_TEST|DEC Patch|Field validation of the diagnostic performance of diagnostic tests for infection with O. volvulus.
40925263|NCT02810353|DEVICE|Differential rapid maxillary expansion|Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
40925264|NCT02810353|DEVICE|Conventional rapid maxillary expansion|Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
40925265|NCT02095496|DEVICE|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
40925266|NCT02095496|DEVICE|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
40925267|NCT00395343|DRUG|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
40925268|NCT00395343|DRUG|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
40925269|NCT00771589|DEVICE|Active Knee Prosthesis|Motorized External Knee Prosthesis for above knee amputees.
40925270|NCT05065554|DRUG|Acalabrutinib|Dose per protocol, oral twice daily per cycle
40925271|NCT05065554|DRUG|Rituximab|Premedications (including acetaminophen, an antihistamine, and a steroid) will be given per institutional guideline Dosage determined per protocol and cycle timepoint, Route IV or SQ per protocol and cycle timepoint, schedule per protocol and cycle timepoint
40925272|NCT02834845|DRUG|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance
40925273|NCT02834845|DRUG|Desflurane|Desflurane %6-8 for general anesthesia maintenance
40925274|NCT05277337|BIOLOGICAL|Alluzience|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
40925275|NCT05277337|BIOLOGICAL|powder BoNT-A (BOTOX/Vistabel)|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
40925276|NCT01770444|OTHER|Low-dose Cardiac CT protocol|"A cardiac CT protocol modified for reduction of radiation exposure~1. Prospective gating~2. Range: dedicated imaging (below carina to heart base)"
40925277|NCT01770444|OTHER|Conventional cardiac CT protocol|"Conventional CCTA protocol~1. Retrospective gating with tube current modulation~2. Range: dedicated imaging (below carina to heart base)"
40925278|NCT03452475|DRUG|Arterolane-piperaquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
40925279|NCT03452475|DRUG|Arterolane-piperaquine+mefloquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
40925280|NCT03452475|DRUG|Artemether-lumefantrine|Artemether-lumefantrine tablets (20 mg/120 mg)
40925281|NCT02483871|DRUG|Rosuvastatin|
40925282|NCT01564056|DRUG|HORMONOTHERAPY|"Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
41443500|NCT02160015|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41443501|NCT02160015|BIOLOGICAL|Rituximab|Given IV
41103260|NCT01156116|DEVICE|CPAP mask|"The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~________________________________________"
41103261|NCT01156116|DRUG|Placebo|oral placebo tablet
41103262|NCT00551772|DRUG|SB-742457|
41103263|NCT00345202|DRUG|HMG-CoA reductase inhibition (atorvastatin)|
41103264|NCT02580448|DRUG|Seviteronel|Seviteronel given daily with evening meal in 28 day cycles
41103265|NCT06116058|OTHER|Experimental: Group A: integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition in addition to conventional treatment,INIT which included IC, SCS, and MET for the low back region for the quadratus lumborum( QL) and erector spinae (ES) muscles
41103266|NCT06116058|OTHER|Experimental: Group B :Instrument assissted soft tissue mobilization|IASTM performed on lumbar posterior muscle erector spinae (iliocostalis, longissimus), and quadratus lumborum(QL) The IASTM treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers being treated with the instrument at a 45° angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45° angle for an additional 20-seconds, resulting in a total treatment time of approximately 40 seconds.
41103267|NCT06116058|OTHER|control group C conventional physical therapy|. The control group will applied general exercise. General exercise were applied with stretching exercises and stationary bicycling for 10-15 minutes14, 15) . Three sets of fifteen repetitions will performed, with rest times of 1 minute between sets during 4 weeks.
41103268|NCT06266858|OTHER|rehydration|The fasting patients in anaesthetised receive saline rehydration to maintain central venous pressure of 6-8 cmH2O when undergoing UCG.
41103269|NCT06266858|DIAGNOSTIC_TEST|UCG|UCG is the most common imaging modality to assess the mitral regurgitation in clinical and also is the primary modality recommended by guidelines. At the beginning of the study, the fasting patients receive UCG in the different situation such as pre-anaesthetic, post-anaesthetic and post-rehydration.
41103270|NCT06266858|DIAGNOSTIC_TEST|CMR|CMR may be more accurate than UCG in assessing MR severity. In another time, the patients receive CMR.
41103271|NCT06266858|OTHER|fasting|At the beginning of the study, the patients need to fast when receive UCG.
41103272|NCT00683410|BIOLOGICAL|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
41103273|NCT03018041|DRUG|Omacor|"As described in Arms."
41103274|NCT03018041|DRUG|Placebo Oral Capsule|"As described in Arms."
41103275|NCT01833832|DRUG|Cisplatin|Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
41103276|NCT01833832|PROCEDURE|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.
41103277|NCT01833832|DRUG|sodium thiosulfate|sodium thiosulfate will be given to limit the toxicity of cisplatin
41103278|NCT05242926|DRUG|ModraDoc006/r|One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
41103279|NCT04555265|DEVICE|Radiofrequency ablation or microwave ablation|Hepatocellular carcinoma treated by either radiofrequency ablation or microwave ablation
41103280|NCT03926819|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
41103281|NCT02786771|DEVICE|Spire|
41103282|NCT02786771|DEVICE|Muse headband|
41103283|NCT02686554|OTHER|Neuropsychological assessment|The patients perform tests to assess their cognitive abilities
41103284|NCT06121596|BEHAVIORAL|Breathing Exercise|A breathing exercise is a relaxation technique (or therapy) to increase relaxation (induces a relaxation response) and decrease stress (reduces a stress response).
41103285|NCT04364789|DRUG|TT-00920|Tablets
41103286|NCT04364789|DRUG|Placebos|Tablets
41103287|NCT02466048|PROCEDURE|Spinal Fusion|Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.
41103288|NCT02466048|DEVICE|SurgiFill™|SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
41103289|NCT01499134|DRUG|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
41103290|NCT01499134|DRUG|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
41103291|NCT01034943|PROCEDURE|External fixation|Operation with external fixation and optional addition of k-wire
41103292|NCT01034943|PROCEDURE|Volar plate|Operation with a Synthes volar two column plate (TCP)
40752102|NCT00422461|DRUG|placebo|placebo, oral, tablets, once daily, for 28 days
40752103|NCT00422461|DRUG|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
40752104|NCT00422461|DRUG|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
41103293|NCT04658342|DIAGNOSTIC_TEST|Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM)|"The Videofluoroscopic Imaging (VFSS) is done by inserting a small catheter into the nose and down the throat. The catheter is approximately .4 millimeters in diameter. A trained speech-language pathologist will insert the catheter after applying numbing medicine, or topical anesthetic, inside the nose.~The high-resolution manometry (HRM) is a swallowing pressure test done at the same time as the VFSS. The HRM will measure how strong the throat muscle squeeze the liquids and foods that a person swallows.~The VFSS and HRM will occur about one month after surgery and three months after the completion of the radiation treatment."
41103294|NCT03761784|DRUG|S6G5T-3|Once a day topical cream
41103295|NCT03761784|DRUG|S6G5T-8|Once a day topical cream
41103296|NCT00221078|DEVICE|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
41103297|NCT05999864|OTHER|Rehabilitation|Proprioceptive neuromuscular facilitation exercise will be given to the study group as previously described (Gstoettner et al., 2011). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.
41103298|NCT05356923|RADIATION|68Gallium FAPI PET/MR scan|68Gallium FAPI PET/MR scan
41103299|NCT04138771|DEVICE|An artificial intelligence system for postoperative management of cataract patients|This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
41103300|NCT05565196|BEHAVIORAL|Birth companions|The intervention will have the following components: 1) Orient facilities and providers to benefits of BC; 2) Develop/update formal standard operating procedures (SOP) for implementing BC and develop plans to implement SOP; 3) Assess data required for implementation and an audit and feedback cycle for tracking coverage; 4) Assess and carry out modest structural changes in facilities to facilitate BC; 5) Use human centered design to develop materials/resources and a means to distinguish/recognize the BC, taking into account common barriers and misconceptions; 6) Prepare providers to integrate BC into care team; 7) Orient ANC clients to BC rationale and selection; 8) Prepare BCs to support women; 9) Iterate model and track intervention/policies.
41103301|NCT01282437|RADIATION|Prophylactic Cranial Irradiation|"* 18 fractions of 2Gy~* 12 fractions of 2.5Gy~* 10 fractions of 3 Gy"
41103302|NCT06029842|OTHER|Collaborative approach of clinical pharmacist with physicians in a medical center|For those who allocated to the intervention group, the clinical pharmacist interviewed them at each monthly visit about 30 minutes before seeing physicians, the clinical pharmacist identified treatment related problems, provided medication counseling, answered questions asked by patients or physicians, encouraged compliance, offered instructions on self-monitoring of blood pressure and glucose levels, distributed educational materials about diabetes and emphasis was made on optimizing adherence to pharmacological and non- pharmacological therapy. the pharmacist interventions on treatment related problems (TRPs) and proposed patient care plans were discussed with treatng physicians who decided to accept or reject them.
41103303|NCT02163915|DRUG|TAK-137|TAK-137 tablets
41103304|NCT02163915|DRUG|TAK-137 Placebo|TAK-137 placebo-matching tablets
41103305|NCT02404064|DRUG|cefamezin 1g IV|perioperative antibiotics (Cefamizin 1g IV; )
41103306|NCT02404064|DRUG|metronidazole 500 mg IV|perioperative antibiotics (metronidazole 500 mg IV )
41443502|NCT04521218|OTHER|Thrust Joint Manipulation|"Experimental group included TJM, Cervical hot pack, strengthening exercises and home plan; 3 sessions of manipulation per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold."
40752105|NCT00422461|DRUG|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
40752106|NCT04695626|PROCEDURE|The combination of bone marrow stimulation and modified suture bridge(Greenhouse tec)|According to the anteroposterior diameter of the injury, single or double high braided thread were used to suture the tendon in a modified Mason Allen way without knotting. Bone marrow stimulation was carried out in the footprint area of rotator cuff. A 2.0 mm diameter cone was created with a depth of 1 cm and a spacing of 5 mm. Six to eight holes were made due to the diameter of the tear of rotator cuff until blood and fat droplets exudate. Then the threads were passed through the locking eyelet of the lateral row anchor. After tightening the threads, the anchor was screwed in at the distal part of the gteater tuberosity. With this new technique, the rotator cuff was repaired by one lateral row anchor without medial row knotting.
41103307|NCT02404064|DRUG|Placebo|No perioperative antibiotics
41103308|NCT06175923|BIOLOGICAL|Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care|When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.
41103309|NCT04954040|DRUG|Hydroxychloroquine Pill + Azithromycin Pill|"Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.~1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0"
41103310|NCT04954040|DRUG|SOC|Acetaminophen or Metamizole. Antitussives if needed.
41103311|NCT04333329|DEVICE|NEUROLITH|transcranial pulse stimulation (TPS)
41103312|NCT02846194|BEHAVIORAL|brief guided imagery|
41103313|NCT02631499|PROCEDURE|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
41103314|NCT02631499|DRUG|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
41103315|NCT02631499|DRUG|lipiodol|lipiodol is a kind of embolization material used in TACE
41103316|NCT05098340|GENETIC|Quantitative Real-time polymerase chain reaction|Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).
41103317|NCT03505099|BIOLOGICAL|onasemnogene abeparvovec-xioi|A non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
41103318|NCT03942042|DRUG|Ixekizumab|Administered SC
41103319|NCT03762330|BEHAVIORAL|COPD structured self-management plan.|Education plan , including knowledge of the disease, healthy life habits, correct use of inhalers, skills to control symptoms and strategies to face the disease and exacerbations
41103320|NCT03578523|OTHER|3 Tesla multiparametric MR|Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.
41103321|NCT03578523|OTHER|renal histopathology scoring|Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)
41103322|NCT03578523|BIOLOGICAL|Blood and urine sampling|"Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis"
41103323|NCT03578523|BIOLOGICAL|Iohexol clearance test|Iohexol clearance to measure GFR within 1 week of the scan session
41103324|NCT00480519|PROCEDURE|Meatotomy|
41103325|NCT01152190|DRUG|Tadalafil|Administered orally, once daily for 8 weeks
41103326|NCT01152190|DRUG|Placebo|Administered orally, once daily for 8 weeks
41103327|NCT03635112|DRUG|Placebo|Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
41103328|NCT03635112|DRUG|TD-1473|TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
41103329|NCT02205762|DRUG|Prednisone|Stratum I
41103330|NCT02205762|DRUG|Vinblastine|Stratum I
41103331|NCT02205762|DRUG|mercaptopurine|Stratum I
41103332|NCT02205762|DRUG|INDOMETHACIN|Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
41103333|NCT02205762|DRUG|Methotrexate|fixed dose weekly orally for total treatment duration of 24 months.
41103334|NCT02205762|DRUG|Cytosine Arabinoside|
41103335|NCT02205762|DRUG|2-chlorodeoxyadenosine|
41103336|NCT02205762|PROCEDURE|hematopoietic stem cell transplantation (RIC-HSCT)|
41103337|NCT02205762|BIOLOGICAL|Intravenous immunoglobulin|
41103338|NCT01472536|BEHAVIORAL|Sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
41103339|NCT04940676|DRUG|Huzhangxiefei Decoction|Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
41103340|NCT04940676|DRUG|10% Huzhangxiefei Decoction|10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
41103341|NCT02684565|DIETARY_SUPPLEMENT|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
41103342|NCT02684565|DIETARY_SUPPLEMENT|BCAA Low Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
41103343|NCT00299702|DRUG|Abilify|10-30 mg once daily for 104 weeks
41103344|NCT00299702|DRUG|Risperidal Consta|25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
41103345|NCT00549536|DIETARY_SUPPLEMENT|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
41103346|NCT03525041|PROCEDURE|CABG|CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.
41103347|NCT03525041|PROCEDURE|mitral valve annuloplasty|Surgical techniques for mitral valve annuloplasty may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation.
41103348|NCT02592954|DRUG|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
41103349|NCT02592954|DRUG|Jojoba oil (placebo)|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
41103350|NCT02721225|DIETARY_SUPPLEMENT|Fructooligosaccharide|"A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
41103351|NCT02721225|DIETARY_SUPPLEMENT|Pocari-Sweat|Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
41103352|NCT01949909|BIOLOGICAL|CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
41103353|NCT01949909|BIOLOGICAL|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
41103354|NCT01949909|BIOLOGICAL|TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
41103355|NCT01949909|BIOLOGICAL|TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
41103356|NCT01949909|BIOLOGICAL|TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
41103357|NCT01949909|BIOLOGICAL|TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
41103358|NCT01949909|BIOLOGICAL|TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
41103359|NCT03237936|DRUG|1mg/mL ciclosporin|IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
41103360|NCT05191251|DIAGNOSTIC_TEST|HEMSTOP questionnaire|A HEMSTOP questionnaire is obtained during the anesthesia consultation.
41103361|NCT05285514|DIAGNOSTIC_TEST|Comparison of macro- and microcirculatory parameters|"Microcirculation examination using sublingual videomicroscopy, tissue O2 saturation (StO2) by NIRS and transcutaneous CO2 pressure (tcpCO2) monitoring, in conjunction with macrocirculatory parameters measures including cardiac output, arterial pressure and pulsed O2 saturation, in order to establish the relationship between the macrocirculatory changes in blood pressure and cardiac output and the microcirculatory flow and capillary density during vasoactive agent use. . Participants receive interventions as part of routine medical care to restore Cerebral Perfusion pressure (CPP) to appropriate levels (60-70 mmHg)"
41103362|NCT02375516|BEHAVIORAL|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
41103363|NCT00000871|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
41103364|NCT00000871|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
41103365|NCT00000871|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
41103366|NCT00000871|BIOLOGICAL|rgp120/HIV-1 SF-2|
41103367|NCT02512042|DRUG|Test-Brinzolamide 1% Ophthalmic suspension|
41103368|NCT02512042|DRUG|Reference-Brinzolamide 1% Ophthalmic suspension|
41103369|NCT05485129|DEVICE|BIORICS|Wearing BIORICS in their ear and perform mental arrhythmic test, relaxation exercises and Stroop test
41103370|NCT03663101|DRUG|Lidocaine|0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
41103371|NCT03663101|BIOLOGICAL|Botulinum toxin type A|0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
41103372|NCT03663101|DRUG|Placebo|Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
41103373|NCT03663101|DRUG|Placebo|Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
41103374|NCT03897309|BIOLOGICAL|VXA-G1.1-NN|Monovalent GI.1 tableted vaccine
41103375|NCT03897309|BIOLOGICAL|VXA-G2.4-NS|Monovalent GII.4 tableted vaccine
41103376|NCT03897309|BIOLOGICAL|Placebo Tablets|Tablets matching in number and appearance to active vaccine doses
41103377|NCT01406028|BEHAVIORAL|Phone calls|Phone calls to offer emotional support
41103378|NCT00988286|PROCEDURE|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
41103379|NCT04621708|DEVICE|Repetitive transcranial magnetic stimulation|Left DLPFC iTBS rTMS
41103380|NCT00697411|OTHER|Syndrome cause identification|
41103381|NCT04268563|DRUG|placebo|Oral rehydration solution
41103382|NCT04268563|DRUG|metformin|metformin tablet
41103383|NCT04268563|DRUG|Sitagliptin|Sitagliptin tablet
41103384|NCT04268563|DRUG|Sitagliptin/metformin|Sitagliptin/metformin tablet
41103385|NCT05701592|PROCEDURE|DB-PCLR|DB-PCLR with reconstruction of both PCL bundles: anterolateral and posteromedial bundle will be performed.
41103386|NCT06628713|DRUG|Sebetralstat|Oral Plasma Kallikrein Inhibator
41103387|NCT00219687|OTHER|dispatcher-assisted CPR with compressions & ventilations|Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest
41103388|NCT00219687|OTHER|dispatcher-assisted CPR instructions with compressions only|Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
41103389|NCT03906630|DIAGNOSTIC_TEST|Telehealth clinical exam|This is a pseudo telehealth clinical exam for patients presenting with shoulder pain
41103390|NCT03906630|DIAGNOSTIC_TEST|Standard clinical exam|This is a standard in-person clinical exam for patients presenting with shoulder pain
41103391|NCT02377505|DEVICE|On-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is on"
41103392|NCT02377505|DEVICE|Off-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is off"
41103393|NCT05076656|DIETARY_SUPPLEMENT|Lactobacillus fermentum D3|Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.
41103394|NCT05076656|BIOLOGICAL|Fecal microbiota transplant (FMT)|Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.
41103395|NCT05076656|DRUG|Placebo|Placebo in a white, gelatin capsule (orally), with powder milk
41103396|NCT02098902|BEHAVIORAL|Smart Moms Intervention|Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
41103397|NCT05052736|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 20 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
41103401|NCT00752817|OTHER|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
41103402|NCT00752817|OTHER|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
41103403|NCT02980380|OTHER|Non-invasive brain computer interface|"The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication."
41103404|NCT06435338|BEHAVIORAL|Patient decision aid|The patient decision aid for HPV vaccination among mid-adults, named HPV Decide. It is delivered online on a website.
41103405|NCT06435338|BEHAVIORAL|Control|Vaccine information sheet on HPV vaccination. Attention control condition.
41103406|NCT02595398|DRUG|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 µL), administered as a single injection at 2 timepoints
41103407|NCT02595398|DRUG|Sham Procedure|Sham procedure administered at 2 timepoints
41103408|NCT00186420|DRUG|Taxotere|
41103409|NCT04056923|PROCEDURE|3D-printing guided|3D printed navigational template guided
41103410|NCT04056923|PROCEDURE|CT-guided|CT-guided
41103411|NCT04056923|DRUG|Indocyanine Green|The results are shown by comparison of different colors.
41103412|NCT04056923|DRUG|Methylene blue|The results are shown by comparison of different colors.
41103413|NCT04056923|PROCEDURE|Preoperative|Preoperative localization.
41103414|NCT04056923|PROCEDURE|Intraoperative|Intraoperative localization.
41103415|NCT06261333|OTHER|Questionnaires|No Intervention
41103416|NCT01282840|DRUG|Tolterodine SR|Tolterodine SR 4 mg qd
41103417|NCT00183638|BEHAVIORAL|Internet-based tailored prevention messages|Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
41103418|NCT00183638|BEHAVIORAL|Non-tailored messages|The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
41103419|NCT05380583|BEHAVIORAL|CRAFT-EP|CRAFT-EP is a behavioral intervention delivered via telehealth with the option for one in-person session (when local guidelines allow in-person care without masks). The coaching session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, problem solving, and planning next steps. The intervention is designed for families of individuals experiencing psychosis and substance use who are enrolled or seeking enrollment in early psychosis outpatient services. Participants will be asked to complete assessments at pre-, mid- (approximately week 4), post-intervention, and a follow-up assessment approximately 12 weeks post-intervention.
40925283|NCT01564056|DRUG|CHEMOTHERAPY then HORMONOTHERAPY|"CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~* Docetaxel 75 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~* Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin \[Myocet®\]+ cyclophosphamide)~* Myocet® 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
41103420|NCT05380583|BEHAVIORAL|TAU|Participants may continue to receive their ongoing treatment, if any, which may include psychosocial and/or pharmacological interventions.
41103421|NCT04376814|DRUG|Favipiravir|Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days
41103422|NCT04376814|DRUG|Hydroxychloroquine|200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.
41103423|NCT04376814|DRUG|Lopinavir / Ritonavir|Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.
41103424|NCT02772653|OTHER|Blood Lactate|Analyzed at the 1rst, 8th and 24th hour from hospital admission
41103425|NCT02772653|OTHER|Blood Base Excess|Analyzed at the 1rst, 8th and 24th hour from hospital admission
41103426|NCT02772653|OTHER|Blood B-type Natriuretic Peptide|Analyzed at the 1rst, 8th and 24th hour from hospital admission
41103427|NCT02772653|OTHER|Blood Thromboelastometry (ROTEM)|Analyzed at the 1rst, 8th and 24th hour from hospital admission
41103428|NCT02772653|OTHER|Near-infrared spectroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
41103429|NCT02772653|OTHER|Sublingual videomicroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
41103430|NCT00929591|DRUG|cyclophosphamide|
41103431|NCT00929591|DRUG|doxorubicin hydrochloride|
41103432|NCT00929591|DRUG|endocrine therapy|
40925284|NCT04783688|OTHER|Full Face Snorkel Mask (FFSM)|A mask used for snorkeling that covers the entire face, as opposed to a conventional snorkel, which is held in the mouth only.
41103433|NCT00929591|DRUG|endocrine-modulating drug therapy|
41103434|NCT00929591|DRUG|fluorouracil|
41103435|NCT00929591|DRUG|tamoxifen citrate|
41103436|NCT00929591|RADIATION|brachytherapy|
41103437|NCT00929591|RADIATION|low-LET electron therapy|
41103438|NCT00929591|RADIATION|low-LET photon therapy|
41103439|NCT00929591|RADIATION|radiation therapy|
41103440|NCT02589210|OTHER|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
41103441|NCT05901519|DRUG|Prednisone|Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
41103442|NCT02199145|PROCEDURE|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
41103443|NCT03183024|BIOLOGICAL|benralizumab|open-label treatment
41103444|NCT03183024|BIOLOGICAL|placebo|sterile water to mimic benralizumab
41103445|NCT01859312|DRUG|Hydrocortisone (Solucortef)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.
41103446|NCT01859312|DEVICE|Insulin pump (Medtronic)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA)
41103447|NCT06502769|BEHAVIORAL|Therapeutic Exercise|A therapeutic exercise program will be carried out
41103448|NCT06502769|BEHAVIORAL|Pain Neurophysiology Education|A PNE program will be carried out
41103449|NCT04240730|PROCEDURE|Transvaginal natural orifice endoscopic surgery for endometrial cancer staging|Cases of extreme obese patients with early stage endometrial cancer who underwent v-NOTES
41103450|NCT02680756|DRUG|Ferric Maltol|
41103451|NCT02680756|DRUG|Ferric Carboxy Maltose|
41103452|NCT04517331|PROCEDURE|Thoracic paravertebral block-single injection|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
41103453|NCT04517331|PROCEDURE|Thoracic paravertebral block-double injection|The blocks were performed at both T2-T3 and T4-T5 levels bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
41103454|NCT04034758|PROCEDURE|Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)|heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
41103455|NCT04034758|PROCEDURE|placebo capsule|Oral administration of 30 placebo capsule containing edible pigmented starch
41103456|NCT04860258|BIOLOGICAL|CVnCoV Vaccine|Intramuscular (IM) injection in the deltoid area, preferably in the non-dominant arm.
41103457|NCT02454244|BEHAVIORAL|ART with Mindfulness|"1. Introduction of ART with Mindfulness. Visualization of 100% recovery~2. Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation~3. The ART. Breaking the negative thoughts related to the illness. Walking meditation~4. Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation~5. Mindfulness and self-compassion. Kindly awareness meditation~6. The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation~7. Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities~8. Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values~9. The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self~10. Return to regular life. Mindfulness practice"
41103458|NCT02454244|BEHAVIORAL|Mindfulness Compassion|"1. Introduction.Definition of Compassion~2. Self-Esteemed and Compassion~3. Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions~4. Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability~5. Love,affection and self-compassion.How participants connect with the suffering of others~6. Equanimity~7. Forgiveness~8. Interdependence. Gratitude.Affection to unknown people~9. Developing affection and empathy.Empathy and burn out~10. Review of the practices and meditations"
41103459|NCT02454244|BEHAVIORAL|Relaxation|10 sessions based on relaxation techniques as active comparator intervention
41103460|NCT00123747|PROCEDURE|Positron Emission Tomography (PET) scan Imaging|
41103461|NCT05759585|BEHAVIORAL|person-centered lifestyle intervention|Lifestyle intervention is a combined approach that encourages individuals to change their lifestyles by increasing participation in meaningful readings. This program aims to facilitate the individual's self-development of healthy routines and habits; It includes techniques such as patient education, occupational self-analysis, problem-solving, motivation generation, and implementation of behaviors to prevent and manage disease-related symptoms.
41103462|NCT02161653|DRUG|Prednisone plus Metadoxine|
41103463|NCT02161653|DRUG|Pentoxifylline plus Metadoxine|
41103464|NCT02246816|DRUG|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
41103465|NCT01552304|OTHER|Oxygen therapy|Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
41103466|NCT01552304|OTHER|Control group|
41103467|NCT06145256|DEVICE|MRI brain, MSCT brain, Transcranial Ultrasound|MRI, MSCT and transcranial Ultrasound are an important diagnostic modalities in the assessment of severity and outcome of HIE
41103468|NCT03107286|DRUG|Tc-99M-MAG3|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
41103469|NCT03107286|OTHER|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
41103470|NCT06086899|PROCEDURE|Cervical motion style acupuncture treatment(Trapezius, Rhomboid, Scalene)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
41103471|NCT06086899|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
41443503|NCT04521218|OTHER|Reverse Sustained Natural apophyseal glides|"Control group included Moist Hot Pack (Cervical contour- 8.25 x 10 x 2) for 10 Mins, Reverse SNAGS (10 Repetitions holding for 10 sec in each glide with a rest time of 30 seconds in between), Strengthening exercise and home plan. 3 sessions of mobilization per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold"
41103472|NCT01428895|PROCEDURE|Surgery Alone|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
41103473|NCT01428895|OTHER|Combined Surgery and Radiation therapy|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
41443504|NCT06563336|OTHER|EMG-driven hand robot training|"Robot rehabilitation program was applied with Hand of Hope®(Rehab-Robotics Company, Hong Kong), and EMG-driven exoskeleton. The biggest advantage of this system is that it measures the residual muscle activity values with surface EMG(sEMG) sensors. The residual muscles activity is used by giving feedback to the patient.~This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick."
41103474|NCT05937906|DRUG|Phase I - Mirdametinib - Level 1|Mirdametinib 4 mg twice/day for 7 days per cycle
41103475|NCT05937906|DRUG|Phase II - Mirdametinib|For phase 2 : Randomisation with 2 arm : Standard arm and experimental arm
41103476|NCT05937906|DRUG|Phase I - Mirdametinib - Level 2|Mirdametinib 4 mg twice/day for 14 days per cycle
41103477|NCT05937906|DRUG|Phase I - Mirdametinib - Level 3|Mirdametinib 6 mg twice/day for 7 days per cycle
41103478|NCT05937906|DRUG|Phase I - Mirdametinib - Level 4|Mirdametinib 6 mg twice/day for 14 days per cycle
41103479|NCT04245319|DRUG|Acitretin|The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed
41103480|NCT04245319|OTHER|Narrow band ultraviolet B|Patients receive nbUVB session 3 times per week
41103481|NCT05227066|OTHER|adding lower extremity weights|All children in the two groups received physical therapy protocol for 30 minutes in addition to half kg of sandbags weights attached for each leg
41443505|NCT06563336|OTHER|conventional occupational training|This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick.
41443506|NCT04631562|DRUG|ALXN1820 SC|ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
41103482|NCT05227066|OTHER|traditional physical therapy group|traditional physical therapy group
41103483|NCT04420195|DRUG|Extended-Release Tacrolimus|Envarsus XR is an FDA-approved drug for the prophylaxis of organ rejection in de novo kidney transplant patients or in kidney transplant patients converted from IR tacrolimus when used with other immunosuppressants. Envarsus XR is a novel extended-release formulation of tacrolimus created using MeltDose technology. Envarsus XR is available in tablet form. It is available in 0.75, 1, and 4 mg tablets.
41103484|NCT04420195|DRUG|Immediate-Release Tacrolimus|Historical cohort of 20 subjects who will be maintained on IR tacrolimus following transplant. Dosing will be converted on an individual basis (Capsules: 0.5 mg, 1 mg and 5 mg or Injection: 5 mg) . All patients will be initiated on IR tacrolimus either under the tongue (sublingual) or as a solution given through a tube placed through the nose into the stomach, which is standard of care for all lung transplant recipients.
41103485|NCT02434718|DRUG|Aducanumab|As described in the treatment arm
41103486|NCT02434718|DRUG|Placebo|IV administration of 0.9% sodium chloride
41103487|NCT02709616|BIOLOGICAL|Personalized cellular vaccine|Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
41103488|NCT03703479|OTHER|autologous blood clot made from the patient own clot without any additive|advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
41103489|NCT03675139|DRUG|Medroxyprogesterone Acetate|At a dosage of 10mg/day
41103490|NCT03675139|DRUG|Dydrogesterone 10 MG|At a dosage of 20 mg/day
41103491|NCT01311180|DRUG|Sensoril®|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
41103492|NCT01311180|DRUG|Placebo|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
41103493|NCT00276250|DRUG|Efalizumab|Efalizumab was a medication approved for use in psoriasis which was being explored to determine efficacy with immunosuppression following organ transplantation. Efalizumab was administered subcutaneously on a weekly basis. Upon efalizumab being withdrawn from the US market, the protocol was amended to alter the immunosuppressive regimen to abatacept for the study participants.
41103494|NCT00276250|DRUG|Abatacept|Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.
41103495|NCT00276250|DRUG|Belatacept|Belatacept is a medication to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens. Belatacept is administered intravenously. The protocol for this study was amended to substitute belatacept for abatacept for all newly enrolling participants (current participants remained on abatacept).
41103496|NCT00117871|DRUG|Resiquimod|
41103497|NCT05093712|OTHER|Educational Intervention|Watch educational video
41103498|NCT05093712|OTHER|Survey Administration|Complete surveys
41103499|NCT05716373|BEHAVIORAL|pain|reiki
41103500|NCT01466881|DRUG|Alisertib|Given PO
41103501|NCT01466881|OTHER|Laboratory Biomarker Analysis|Correlative studies
41103502|NCT01466881|OTHER|Pharmacological Study|Correlative studies
41103503|NCT06133452|PROCEDURE|skin reducing mastectomy|"The goal of mastectomy skin reducing is to create a breast reconstruction that appears natural and aesthetically harmonious by minimizing excess skin. Excess skin can be removed in two main ways: as a conventional ellipse around the nipple-areola complex or, preferably, as part of an inverted T-shaped incision, commonly used in reduction mammoplasty. This procedure adheres to oncological principles of skin-conserving mastectomy and also incorporates a lower dermal flap, used to create a dermo-muscular pocket that reinforces the coverage of the prosthetic implant.~This technique allows complete detachment of the pectoral muscle at the bottom while ensuring full coverage of the prosthetic implant with a dermo-muscular layer. By increasing the implant pocket and providing an additional tissue layer at the bottom of the breast, this technique can reduce the risk of complications and improve aesthetic outcomes."
41103504|NCT00819884|DRUG|AZD1656|Oral suspension
41103505|NCT00966199|DRUG|anti-hypertensive medication|8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
41103506|NCT00732368|DRUG|Mometasone furoate|Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
41103507|NCT03234816|DRUG|Norepinephrine 0.05 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
41103508|NCT03234816|DRUG|Norepinephrine 0.1 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
41103509|NCT03234816|DRUG|Norepinephrine 0.15 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
41103510|NCT03234816|DRUG|Bupivacaine|10 mg Bupivacaine intra-thecal for spinal anesthesia
41103511|NCT04814940|OTHER|MENOPUR Cohort|"Non-interventional~All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study take place."
41103512|NCT02287649|OTHER|blood sample|
41103513|NCT01496209|BIOLOGICAL|Endomyocardial injections of allogeneic Human CSps|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
41103514|NCT01496209|BIOLOGICAL|Endomyocardial injections of vehicle only.|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
41103515|NCT02509780|OTHER|Vichy|Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
41443507|NCT04631562|DRUG|ALXN1820 IV|ALXN1820 IV (450 mg) will be administered as an IV infusion.
41103516|NCT01130064|BIOLOGICAL|QAX576|every 3 weeks via intravenous infusion
40925285|NCT05424432|DRUG|Neoadjuvant Chemotherapy|Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)
41103517|NCT01130064|DRUG|Placebo|every 3 weeks via intravenous infusion
41103518|NCT00233740|DEVICE|OPTEASE Vena Cava Filter|
41103519|NCT04324242|OTHER|abdominal hallowing maneuver|abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO
41103520|NCT00514332|PROCEDURE|stent|stent placement for colorectal cancer obstruction
41103521|NCT05309980|OTHER|standard of care|retrospective study : standard of care
41443508|NCT04631562|DRUG|Placebo SC|Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
41103522|NCT01137292|DRUG|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (\<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
41103523|NCT05787730|DEVICE|Transobturator tape|
41103524|NCT05490654|PROCEDURE|Abdominal Massage|Abdominal Massage delivered by manual method or by Mowoot device
41103525|NCT04935749|DEVICE|Ultra wide-field retinal imaging|Diabetic patients will be imaged with an ultra wide-field retinal imaging device (Optos, California). Patients will be imaged either with or without mydriasis.
41103526|NCT05178758|DEVICE|Virtual Reality (VR)|Patients in the intervention (VR) group will receive a series of occupational and physical therapy rehabilitation training using the VR system. All training is consists of daily activities oriented by an occupational therapist, including grasp, grip, pinch, gross, and finger-hand coordination movement. Each training will take around 1 hour for one session per day 5 times per week over a maximum of 4 weeks. The training presented a one-on-one that allowed interaction between instructor (or VR system) and participant.
41103527|NCT03412942|DEVICE|FISH SP|The device will be used to close the femoral artery after angiogram and/or endovascular procedure.
41103528|NCT03992495|OTHER|Exercise|All participants will be exposed to aerobic/strengthening exercises
41103529|NCT06289348|BEHAVIORAL|socio-psychological questionnaire|ton collecte socio-demographic variable
41443509|NCT04631562|DRUG|Placebo IV|Placebo IV will be administered as an IV infusion.
41443510|NCT02892747|BEHAVIORAL|Educational Program|
41103530|NCT06289348|BEHAVIORAL|revised event impact scale (IER-S)|22 items assessed on a scale of frequency from 0 (not at all) to 4 (extremely)
41103531|NCT06289348|OTHER|Non directive interview|composed of a very broad opening sentence to encourage the parents' discourse
41103532|NCT06289348|OTHER|Stern interview|54 questions to investigate the impact of the announcement and the parenthood construction
41103533|NCT06289348|OTHER|semi-directive interview|to propose ideas for improving and harmonizing practices
41103534|NCT02021760|PROCEDURE|Primary Percutaneous Coronary Intervention|Primary Percutanous Coronary Intervention is performed in both Groups.
41103535|NCT03883438|PROCEDURE|Modified coronally advanced flap and acellular dermal matrix graft|Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I\&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
41103536|NCT02404233|DRUG|darunavir/cobicistat|Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food
41103537|NCT02404233|DRUG|rilpivirine|Rilpivirine tablet 25 mg once daily taken with food
41103538|NCT03737175|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting
41103539|NCT03737175|PROCEDURE|Carotid Endarterectomy|Carotid Endarterectomy
41103540|NCT00516503|DRUG|baclofen/amitriptyline/ketamine gel|Applied topically
41103541|NCT00516503|OTHER|placebo|Applied topically
41103542|NCT05912751|OTHER|Exercise Then Foam Roll|Participants in AB will perform the experimental (exercise) intervention first and the control (foam rolling) intervention second.
41103543|NCT05912751|OTHER|Foam Roll Then Exercise|Participants in BA will perform the control (foam rolling) intervention first and the experimental (exercise) intervention second.
41103544|NCT00128596|DRUG|arsenic trioxide|
41103545|NCT03960619|BEHAVIORAL|coping skills training|We aim to test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. We propose a novel intervention protocol that uses a hybrid in-person and mHealth intervention delivery model.
41103546|NCT03643042|OTHER|Transfusion|Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
41103547|NCT01144182|BEHAVIORAL|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
41103548|NCT03683628|PROCEDURE|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
41103549|NCT03683628|DRUG|No PB-MNC therapy|Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
41103550|NCT00208507|DEVICE|28 mm ceramic head on ceramic acetabular liner.|Total hip replacement with 28 mm ceramic head on ceramic liner articulation
41103551|NCT00208507|DEVICE|28 mm ceramic head on polyethylene liner|Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
41103552|NCT06523855|PROCEDURE|bilateral alveolar cleft grafting using iliac crest particulate and microplate fixation|bilateral alveolar cleft grafting using particulate iliac crest graft accompanied with fixation of graft and premaxilla using microplate
41103553|NCT05223192|BEHAVIORAL|Music Therapy Entrainment with Ocean Disc Intervention|The studied intervention regards live entrainment with the ocean disc. Entrainment involves the use of an external stimulus, in the case of this study, an ocean disc instrument. Motion of the disc creates sounds in synchrony with the breathing of the infant and then in turn can control and influence the infant's regulation of the breath.
41103554|NCT04304534|DRUG|BAY2433334|Tablet, taken orally once a day.
41103555|NCT04304534|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
41103556|NCT01979913|DRUG|Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis|
41103557|NCT02935218|BEHAVIORAL|Parenting Skills for Mothers with BPD|The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
41103558|NCT02286999|DRUG|B. infantis|Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
41103559|NCT02286999|DRUG|Placebo|
41103560|NCT04465487|DRUG|REGN6569|Administered by intravenous (IV) infusion
41103561|NCT04465487|DRUG|Cemiplimab|Administered by IV infusion
41103562|NCT04259632|BEHAVIORAL|Time Restricted Eating (TRE)|daily eating window restricted to 8 hours
41103563|NCT04259632|BEHAVIORAL|Caloric Restriction (CR)|15% daily caloric deficient
41103564|NCT00220350|DRUG|leuprolide acetate|
41103565|NCT03646331|DRUG|Imeglimin Reference product|Reference product
41103566|NCT03646331|DRUG|Imeglimin|Test product (new formulation tablet)
40925286|NCT05424432|DRUG|Neoadjuvant Toripalimab|Toripalimab 240mg every 3 weeks for two cycles (D2,D23)
41103567|NCT03682328|PROCEDURE|vertebroplasty|Cement augmentation of the vertebral body
41103568|NCT03682328|PROCEDURE|kyphoplaty|Cement augmentation of the vertebral body
41103569|NCT05593952|OTHER|Dual task|exercise with dual task + usual treatment
41103570|NCT05593952|OTHER|Single task|exercise without dual task + usual treatment.
41103571|NCT03761966|OTHER|Pregnant women|
41103572|NCT00356317|BEHAVIORAL|Culturally informed therapy for schizophrenia (CIT-S)|This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
41103573|NCT00356317|BEHAVIORAL|Psychoeducation treatment as usual|This family therapy consists of three weekly sessions focusing on education about schizophrenia.
41103574|NCT00304980|DRUG|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
41103575|NCT05539248|DRUG|CAN106 20 mg/kg|"Induction and maintenance dosing for cohort 1:~12 mg/kg on Day 1, 16 mg/kg on Day 8, and 20 mg/kg on Day 15 and every 4 weeks thereafter;"
41103576|NCT05539248|DRUG|CAN106 40 mg/kg|"Induction and maintenance dosing for cohort 2:~30 mg/kg on Day 1, and 40mg/kg on Day 8 and every 4 weeks thereafter；"
41103577|NCT05539248|DRUG|CAN106 80 mg/kg|"Induction and maintenance dosing for cohort 3:~60 mg/kg on day 1, and 80 mg/kg on day 15 and every 8 weeks thereafter."
41103578|NCT02072213|DRUG|GL2702 GLARS-NF1|0.4mg once a day
41103579|NCT02072213|DRUG|Omix Ocas|0.4mg once a day
41103580|NCT00090298|DRUG|MK0653A, ezetimibe (+) simvastatin|
41103581|NCT00090298|DRUG|Comparator: Rosuvastatin|
41103582|NCT00882882|DRUG|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
41103583|NCT00882882|DRUG|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
41103584|NCT00882882|DRUG|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
41103585|NCT00882882|DRUG|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
41103586|NCT01221337|OTHER|heparin free haemodialysis|"Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH)."
41103587|NCT01402271|DRUG|carboplatin|
41103588|NCT01402271|DRUG|paclitaxel|
41103589|NCT01402271|DRUG|pazopanib hydrochloride|
41103590|NCT01402271|OTHER|laboratory biomarker analysis|
41103591|NCT01402271|OTHER|pharmacological study|
41103592|NCT03223090|BEHAVIORAL|Tool-use|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
41103593|NCT03223090|BEHAVIORAL|Hand|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
41103594|NCT02817217|DRUG|SP2086|SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
41103595|NCT02817217|DRUG|Valsartan|SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
41103596|NCT04469218|DEVICE|SafeBreak Vascular|SafeBreak Vascular is a breakaway connector that screws into peripheral IV lines using luer connectors on each end. The device is designed to separate when a harmful force is placed on an IV line. Upon separation, valves on each side of the device close. On the patient side of the device, the valve closes to prevent the loss of blood and on the IV pump side of the device, the valve closes to stop the flow of medication. The valve closing on the IV pump side of the line causes the pump's occlusion alarm to sound and notify nurses that the IV needs attention. The nurse is able to throw away the separated SafeBreak Vascular, install a new SafeBreak, and restart the patient's infusion without the negative cascade of events that can occur when a peripheral IV fails.
41103597|NCT03353116|PROCEDURE|the mandible first|the mandible osteotomy is going to be done and fixed first
41103598|NCT03353116|PROCEDURE|the maxilla first|the maxilla osteotomy is going to be done and fixed first
41103599|NCT06020651|DIAGNOSTIC_TEST|Arterial Doppler for Flow Mediated Reserve measurement|Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs
41103600|NCT00392418|DRUG|Multiple micronutrient supplement (iron)|
41103601|NCT05641662|OTHER|Heart Farming|Heart Farming is a mobile game. which can be played indoors and outdoors and stimulates players to be physically active. The game is built around a theme (farming) and users are challenged to collect products by being active. The phone will register movements and convert them into points and fruits and vegetables. For the basic playing only 10 minutes walking a day with the game is possible and is rewarded. For players who want more challenge and level of trading products and collecting products in groups is added. The game is adaptable to different levels of mobility and players can invite others to play with them. Players can see their own game results, progression, and active time.
41103602|NCT01393912|DRUG|Crenolanib|Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
41103603|NCT04667065|OTHER|Physical activity|Physical activity with the remotely guidance of physical activity teachers
41103604|NCT01930019|DRUG|Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)|
41103605|NCT05337657|DRUG|GB491+Letrozole|Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
41103606|NCT03396835|DEVICE|INVSENSOR00009|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
41103607|NCT04048304|DRUG|duration of standard antibiotic therapy|antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
41103608|NCT05968352|DEVICE|Sacral Anterior Root Stimulation (SARS)|Comparison of High frequency versus low frequency stimulation
41103609|NCT03001986|BIOLOGICAL|inactivated EV71 vaccine (KMB-17 cells)|Receiving 2 doses of the EV71 inactivated vaccine at an interval of 1 month.
41103610|NCT03540628|DIETARY_SUPPLEMENT|Thiamine and Vitamin C|Supplementary vitamins for the patient in septic shock
41103611|NCT04844957|DRUG|Vitamin D|Clinical Study
41103612|NCT04844957|DEVICE|Full automatic chemiluminescence measuring instrument|Chemiluminescence immunoassay
41103613|NCT05038969|DRUG|Stomopral|1 capsule contains 40 mg Esomeprazole
41103614|NCT05038969|DRUG|Nexium|1 capsule contains 40 mg Esomeprazole
41103615|NCT05420168|OTHER|Automatic tool to identify inappropriate antibiotic prescriptions|The system will identify inappropriate antibiotic prescriptions.
41103616|NCT04251143|PROCEDURE|corneal cross-linking|UV-A Irradiation and riboflavin
41103617|NCT04251143|DIAGNOSTIC_TEST|corneal topography and tomography|Detailed Information about corneal tomography is used for diagnosis
41103618|NCT00825435|PROCEDURE|Coronary CT Angiogram|Coronary CT Angiogram
41103619|NCT00677248|DRUG|Ezetimibe and placebo|Placebo or three different doses of eprotirome added to ezetimibe treatment
41103620|NCT00677248|DRUG|Eprotirome and ezetimibe|Placebo or three different doses of eprotirome added to ezetimibe treatment
41103621|NCT02057718|DRUG|LUM001 (Maralixibat)|LUM001 also known as Maralixibat (MRX) oral dose up to twice a day (BID).
41103622|NCT06185192|DIETARY_SUPPLEMENT|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
41103623|NCT04590794|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activator Receptor|Participants will undergo sampling of peripheral venous blood, immediately after admission. Blood samples drawn from all patients and EDTA plasma will be stored at -80° C until later measurement. Plasma suPAR levels will be determined using the suPARnostic® ELISA assay (ViroGates, Denmark), which is based on a simplified double monoclonal antibody sandwich ELISA assay whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti-suPAR pre-coated micro wells. The recombinant suPAR standards of the kit are calibrated against healthy human blood donor samples. suPAR concentrations are determined as ng/mL plasma.
41103624|NCT04727723|DRUG|Lutathera®|Treatment with Lutathera® will be independent from participation in this observational study and must not be initiated for the purpose of participating in this study. The decision to treat patients with Lutathera® will occur before patients are enrolled in the study.
41103625|NCT03843463|DRUG|Escitalopram 10mg|Escitalopram tablet
41103626|NCT03843463|DRUG|Placebo|Sugar pill manufactured to mimic escitalopram 10 mg tablet
41103627|NCT03843463|BEHAVIORAL|Computer-delivered naming treatment|15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
41103628|NCT03353467|PROCEDURE|Endoscopic surgery|Endoscopic nasopharyngectomy included endoscopic resection, with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
41103629|NCT03353467|RADIATION|Intensity-modulated radiotherapy|All of the patients were received irradiation by IMRT. The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements reports 50 and 62.
41103630|NCT05190913|OTHER|Instrumental perineal massage|In the active phase of labor, perineal massage will be performed with an instrument twice with an interval of one hour.
41103631|NCT05190913|OTHER|manual perineal massage|In the active phase of labor, manual perineal massage is performed twice an hour apart.
41103632|NCT04073914|BEHAVIORAL|Type 1 Teamwork Program|Psychoeducational web program
41103633|NCT01724255|OTHER|questionnaire|
41103634|NCT02628691|OTHER|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
41103635|NCT06022042|DEVICE|On1 two-stage abutment and one-stage abutment|the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.
41103636|NCT04179227|OTHER|Questionnaire Administration|Ancillary studies
41103637|NCT04179227|OTHER|Survey Administration|Ancillary studies
41103638|NCT05956600|DRUG|Amisulpride 50 MG|Amisulpride 50 mg titrated to dose range of 50 to 1200 mg
41103639|NCT04242732|DIAGNOSTIC_TEST|CT scan of the knee under weight-bearing with the Cone Beam Computed Tomography (CBCT) scanner system.|The patient will be evaluated under weight-bearing, with knee flexed at 30 ° and therefore with contracted thigh muscles. The measurement and maintenance of the 30 ° of flexion will be controlled by a goniometer applied laterally to the knee and fixed by means of an elastic band.
41103640|NCT04242732|DIAGNOSTIC_TEST|Conventional CT scan|The patient will be evaluated in supine position, with the muscles relaxed and the knee in full extension by conventional CT scan
41103641|NCT04308746|BEHAVIORAL|Online Individualistic Prime (statement writing)|Participants write 3 statements each about (1) themselves, (2) why they are not like others, and (3) why it is beneficial to stand out from others
41103642|NCT04308746|BEHAVIORAL|Online Collectivistic Prime (statement writing)|Participants think about a social group and write 3 statements each about (1) their social group, (2) why they are like others, and (3) why it is beneficial to blend in with others
41103643|NCT01023490|DRUG|Vitamin D|34,5000 IU vitamin D per week
41103644|NCT01023490|DRUG|Placebo|Placebo
41103645|NCT04639349|BEHAVIORAL|exercise group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
41103646|NCT04639349|OTHER|control group|the control group will not be trained
41103647|NCT03985917|OTHER|Singing Group Intervention Program|Each session will start with (1) relaxation, vocal warm-up and breething exercises; (2) vocal technique training; (3) memorization and interpretation of music and lyrics; (4) session breaks of 20 minutes for socialization; (5) preparation of a final choir show; (6) vocal tuning tests.
41103648|NCT03985917|OTHER|Alternative Social and Leisure Activities|Day care centers provide social and leisure activities opportunities for older adults. The control group is free to enroll in these activities.
41103649|NCT00396058|DRUG|Methylphenidate|
41103650|NCT00741988|DRUG|Ixabepilone|ixabepilone 30 mg/m2
41103651|NCT00741988|DRUG|Carboplatin|carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
41103652|NCT00741988|DRUG|Bevacizumab|bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
41103653|NCT01616654|DRUG|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
41103654|NCT01616654|DRUG|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
41103655|NCT01616654|DRUG|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
41103656|NCT01616654|DRUG|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
41103657|NCT01616654|DRUG|Vehicle cream|Vehicle cream applied once daily
41103658|NCT02669524|DRUG|LY2409021|
41103659|NCT02669524|DRUG|LY2409021 placebo|
41103660|NCT02669524|PROCEDURE|OGTT|
41103661|NCT02669524|PROCEDURE|IIGI|
41103662|NCT02669524|PROCEDURE|Standardised liquid meal|
41103663|NCT05844748|OTHER|diabetes education with motivational interview technique|Techniques such as developing empathy, developing disengagement, turning with resistance, supporting self-efficacy, avoiding advice, a simple decision, importance-trust scale, open-ended questions, reflection and segmentation in motivational interviews.
41103664|NCT04603014|COMBINATION_PRODUCT|Interdialytic peritoneal ultrafiltration with 10% dextrose solution|Interdialytic peritoneal ultrafiltration with incremental doses of a 10% dextrose solution, after hemodialysis twice weekly for three consecutive weeks
41103665|NCT00651378|DRUG|Rosuvastatin|oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
41103666|NCT00651378|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
41103667|NCT00651378|DRUG|Double Atorvastatin|oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
41103668|NCT03045900|OTHER|Shaded bulk-fill resin composite|Dental bulk-fill resin composite with shades A1, A2, A3
41103669|NCT00315120|PROCEDURE|A. Active OMT and active UST|Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
41103670|NCT00315120|PROCEDURE|B. Sham OMT and active UST|Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
41103671|NCT00315120|PROCEDURE|C. Active OMT and sham UST|Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
41103672|NCT00315120|PROCEDURE|D. Sham OMT and sham UST|Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
41103673|NCT06118229|DEVICE|Wearable smart devices and PROs|Patients wearing wearable smart devices to monitor physiological data while regularly utilizing PROs to report subjective assessments of their own health status.
41103674|NCT00139737|DRUG|Ziprasidone|20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.
41103675|NCT03168191|DRUG|Nicotine|Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
41103676|NCT03168191|OTHER|Experimental Flavor|Experimental fruit flavored e-cigarette for lab session
41103677|NCT03168191|OTHER|Menthol Flavor|Menthol flavored e-cigarette for lab session
41103678|NCT05154942|DEVICE|DOXO+electroacupuncture|DOXO+electroacupuncture
41103679|NCT05689216|BEHAVIORAL|Awake timed prone and repositioning|"Patients were instructed to adopt a timed prone and repositioning strategy with 4 sessions for four consecutive days.~Session 1, lying on the belly; Session 2, lying on the right side; Session 3, sitting up; Session 4, lying on the left side; then back to session 1 (30 minutes to two hours for each session). The daily duration of timed prone and repositioning is strongly recommended for 8-10 hours."
41103680|NCT04103671|PROCEDURE|Prompt panretinal photocoagulation|Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation
41103681|NCT04103671|PROCEDURE|25G Pars-plana vitrectomy|Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.
41103682|NCT05280964|BEHAVIORAL|Better Together Physician Coaching|6 month, online group coaching program
41103683|NCT01779882|DRUG|Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
41103684|NCT01779882|DRUG|Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
41103685|NCT03317639|BEHAVIORAL|Behaviour Change Wheel model guided intervention|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
41103686|NCT02000999|OTHER|brushing of bile duct strictures for cytology|
41103687|NCT03148990|BIOLOGICAL|Measles and Rubella vaccine|Administration of the experimental vaccine (MR).
41103688|NCT03148990|BIOLOGICAL|Measles, Mumps and Rubella vaccine|Administration of the comparator vaccine (MMR).
41103689|NCT00386204|DEVICE|Q-switched Ruby Laser|
41103690|NCT03707678|DRUG|GSK2245035|GSK2245035 will be administered weekly once as a nasal spray solution with dosing strength of 10 ng per actuation. GSK2245035 will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
41103691|NCT03707678|DRUG|Placebo|Placebo will be administered weekly once as a nasal spray solution. Placebo will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
41103692|NCT03707678|DRUG|FP-DPI|FP will be administered using Diskus inhaler with dosing strengths of 500, 250, 100, 50 µg twice daily per actuation.
41103693|NCT03707678|DRUG|Albuterol/Salbutamol|Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.
41103694|NCT03707678|OTHER|eDairy|Subjects will record all the alerts indicative of worsening of asthma in eDairy.
41103695|NCT03707678|OTHER|ACQ-6|ACQ-6 will include six questions which enquire about the frequency and/or severity of symptoms. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/limitation) scale.
41103696|NCT03785782|DEVICE|Ultrasound|Breast ultrasound
41103697|NCT04178343|RADIATION|tomotherapy|"1. the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases;~2. WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.~d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF)."
41103698|NCT01367912|DRUG|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
41103699|NCT01367912|DRUG|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
41103700|NCT03586596|BEHAVIORAL|The Decídetext program|Decídetext participants will be directed to the tablet-based software. Participants will receive an interactive education session that will lead them through language-appropriate, culturally-relevant information about stopping smoking, collection of basic smoking history data, and choices/plans about preparing to quit. Quit plans include: 1) choice of quit date, 2) NRT preference, 3) plan to remove smoking cues, 4) identification of trigger situations and 5) choice of suggested coping strategies. Participant data and choices are used to generate a printed 1-page individualized treatment plan. Tablet components, assessment items, audio narrative, brief multimedia instructional video clips, and the printed treatment plan have been developed to address low-literacy levels.
41103701|NCT03586596|BEHAVIORAL|Standard Care Control|Educational Material provided as of suggested by American Cancer Society and, the National Cancer Institute
41103702|NCT01535989|DRUG|Inotuzumab Ozogamicin|starting dose 0.8 mg/m2, d1 administration, q4wks
41103703|NCT01535989|DRUG|Temsirolimus|starting dose of 15mg, weekly administration, q4ws
41103704|NCT00145535|DEVICE|SOLX Titanium Sapphire Laser (TiSaLT)|Spot laser treatment, \~50 spots over 180°
41103705|NCT00145535|DEVICE|Argon Laser Trabeculoplasty (ALT)|Spot laser treatment, \~50 spots over 180°
41103706|NCT00328055|BEHAVIORAL|AD-Easy (Advance Directive-Easy)|
41103707|NCT00328055|BEHAVIORAL|AD-Standard (Advance Directive-Standard)|
41103708|NCT01022489|DEVICE|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
41103709|NCT01022489|DEVICE|Placebo (sham coil) treatment|Sham coil treatment
41103710|NCT01405235|DRUG|Paclitaxel|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
41103711|NCT01405235|DRUG|Cisplatin/Paclitaxel|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
41103712|NCT04729244|DRUG|CBD|Hemp Oil
41103713|NCT01846169|BEHAVIORAL|Food deliveries|Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
41103714|NCT05479539|BEHAVIORAL|Action observation therapy|Participants will watch 12-minute video-clips followed by 8 minutes of motor imagery. Video-clips observation and imagination will be focused un shoulder tasks occuring on the three planes of motion.
41103715|NCT00100984|DRUG|FUZEON [enfuvirtide]|
41103716|NCT03582956|PROCEDURE|Euglycemic hyperinsulinemic clamp with tracer enhancement|To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
41103717|NCT03582956|PROCEDURE|Euglycemic hyperinsulinemic clamp with tracer enhancement|A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
41103718|NCT03248011|OTHER|Stretching|Lower extremity flexibility exercises will be performed
41103719|NCT03248011|OTHER|Strengthening|Eccentric hamstring strengthening exercises will be performed
41103720|NCT03248011|OTHER|Neuromuscular|Dynamic lower extremity balance and movement control exercises will be performed
41103721|NCT03038503|DRUG|Methylene Blue|after defined refractory shock (need NE\>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr\*4 hr (intervention add on to standard care)
41103722|NCT03038503|DRUG|Terlipressin|after defined refractory shock (need NE\>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
41103723|NCT04575155|BEHAVIORAL|TEAM Strategy|"1. Pharmacists will have read/write EHR access with established Epic security points~2. Pharmacists will initiate medication reconciliation activities by calling the patient for a Comprehensive Medication Review. Pharmacists will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.~3. At 6 month if poor adherence is determined, the pharmacist will initiate Therapy Management Review which is a call from the pharmacist to the patient specifically about the medication(s) for which they have poor adherence. If necessary, the pharmacist will create notes and send an in-basket message to the prescriber.~4. The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit."
41103724|NCT00591838|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
41103725|NCT05678491|OTHER|Endoscopic mucosal band ligation|The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
41103726|NCT04397172|PROCEDURE|Study Arm|"First inpatient examination (within 24 hours after admission to ICU):~* Clinical examination~* Laboratory tests, Biobanking, Mitochondrial function testing~* Neurophysiological examination (MVRC recording)~Follow-up inpatient examinations (day 2, 5 and 10 after admission):~* Clinical examination~* Laboratory tests, Biobanking, Mitochondrial functions testing~* Neurophysiological examination (MVRC recording)~* Day 10 only: Extended neurophysiological examination according to diagnostic criteria~* Day 10 only: Grading of muscle strength (Medical Research Council (MRC) system)~Follow-up outpatient examination (after discharge from intensive care):~* Clinical examination~* Grading of muscle strength (MRC)~* Modified Rankin Scale (mRS)~* Barthel Scale~* Questionnaires (Short Form (36) Health Survey, Essener Questionnaire for Coping with a Disease and Beck's Depression Inventory II)"
41443511|NCT02553564|OTHER|Checklist driven clinical encounter after hospital discharge|"Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:~1. The participants's hospital course will be reviewed and their clinical recovery and stability assessed.~2. Determination of the participants's estimated dry weight (EDW).~3. The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.~4. Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.~5. Write new dialysis orders.~6. Dialysis Access- review access and determine any changes required in treatment"
41443512|NCT02977221|PROCEDURE|Piezosurgery|The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
41443513|NCT05824481|DRUG|Cadonilimab|Injectable solution
41103727|NCT05603650|OTHER|Lumineux Oral Essentials rinse|mouthrinse
41103728|NCT05603650|OTHER|Listerine rinse|mouthrinse
41443514|NCT05824481|DRUG|Lenvatinib|Capsule
41443515|NCT04732325|DEVICE|Spinal cord stimulation|Researchers will program the spinal cord stimulation (SCS) system to deliver, according to the randomization status of the participant, burst, kHz, tonic, and sham stimulation.
41443516|NCT01246258|OTHER|Vestibular evoked myogenic potentials (VEMPs)|Standard test of balance function
41443517|NCT01246258|OTHER|Utricular centrifugation test|Standard test of balance function
41443518|NCT04303884|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab administration at a fix dose of 200 mg every 3 weeks
41103729|NCT01191619|PROCEDURE|McIvor retractor|The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
41103730|NCT05990517|BIOLOGICAL|YD01-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
41103731|NCT01457560|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
41103732|NCT01457560|BIOLOGICAL|OPV|One dose administered orally
41103733|NCT06259448|OTHER|urine self-sampling|urine self-sampling
41103734|NCT00619645|DRUG|busulfan|
41103735|NCT00619645|DRUG|cyclosporine|
41103736|NCT00619645|DRUG|fludarabine phosphate|
40925287|NCT05424432|RADIATION|Short Course Neoadjuvant Radiotherapy|30 Gy in 12 fractions, 1 fraction per day, 5 days per week, D3-D18
41103737|NCT00619645|DRUG|mycophenolate mofetil|
41103738|NCT00619645|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41103739|NCT00619645|PROCEDURE|peripheral blood stem cell transplantation|
41103740|NCT02212717|PROCEDURE|EUS-guided gallbladder drainage (EGBD)|The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.
41103741|NCT02212717|PROCEDURE|Percutaneous cholecystostomy (PC)|Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
41103742|NCT02955498|DRUG|Sevikar tab. 10/40mg|Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
41103743|NCT02955498|DRUG|Lodivikar tab. 5/40mg|Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
41103744|NCT04705857|COMBINATION_PRODUCT|"Histograft, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene"|gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 μg per 1.0 g of the OCP scaffold
41103745|NCT02106442|DRUG|Sodium risedronate|Sodium risedronate tablets
41103746|NCT04768920|BEHAVIORAL|MI-CBT Teletx|"Participants will first receive a 20-45 min phone or video session focused on raising participants' motivation to engage in treatment activities and psychoeducation material about substance use (i.e. engagement session) including possible discussion about risks of substance use, value of alternative healthier activities, and the community and crisis resources pamphlet. The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 \~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc)"
41103747|NCT03279666|OTHER|Tenaculum replacement|Tenaculum replacement during colposcopic biopsy
41103748|NCT05392179|DRUG|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
41103749|NCT05392179|DRUG|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
41103750|NCT06555224|DEVICE|Systane Hydration MDPF eye drops|Systane Hydration MDPF eye drops 4x daily for 3 months additional to routine medication after cataract surgery
41103751|NCT02551354|DEVICE|Portable video pupillometer|Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
41103752|NCT02638415|PROCEDURE|HVPG-guided therapy|"Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.~Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.~Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails."
41103753|NCT02638415|OTHER|routine therapy|Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
41103754|NCT02638415|DRUG|Carvedilol|Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
41103755|NCT03844854|OTHER|Stabilization occlusal splint and manual therapy|Providing stabilization occlusal splint and manual therapy
41103756|NCT04263545|BEHAVIORAL|Group session with smoking cessation counsellor|Group session with smoking cessation counsellor
41103757|NCT04263545|BEHAVIORAL|Standard Care|standard care arm will receive very brief advice (VBA) and signposting to local organisations to support a quit.
41103758|NCT05663619|DEVICE|Virtual Reality Distraction during dental treatment of children.|One of the behavior management techniques used with children in dental clinics to allow for delivering quality dental treatment is the use of Virtual Reality distraction (VRD). Virtual reality distraction immerses the patient in an environment generated by a computer and works by simulating as many senses as possible: vision, hearing, and touch. In dentistry, VRD has exhibited great results in reducing anxiety and fear among children and adolescents compared to those who received no intervention or more conventional BMTs. VRD may allow the dentist to provide more efficient dental treatments, ranging from simple anesthesia to more advanced forms of dental treatment
41443519|NCT00131391|DRUG|Comparator: taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.
41443520|NCT00131391|DRUG|Comparator: placebo|Placebo capsule once daily . 52 week treatment period.
41443521|NCT00599079|DRUG|Azithromycin|Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
41103759|NCT05663619|OTHER|Control: watching cartoon on screen as distraction during dental treatment of children.|"The American Academy of Pediatric Dentistry (AAPD) recommends a series of non-pharmacological behavior management techniques for managing children during dental care including distraction. Distraction is defined by AAPD as the technique of diverting the patient's attention from what may be perceived as an unpleasant procedure. It is widely used as it provides an effective and relaxing experience during treatment."
41103760|NCT01738802|DIETARY_SUPPLEMENT|Anti-oxidant and micronutrient|This group will be randomized to take the anti-oxidant and micronutrient supplement.
41103761|NCT01738802|DRUG|Placebo|This group will take a placebo.
41103762|NCT05550662|DRUG|129Xenon|There is no study medication evaluated. As part of the MRI, participants will inhale hyperpolarized 129Xe gas at a dose of up to 1/6th of total lung capacity (TLC) (lung volume), mixed with nitrogen to a total volume of 1.5 L. The polarized 129Xe will be inhaled in a single breath-hold. This is intended to fill the lungs gas, allowing for lung MRI.
41103763|NCT04927143|DEVICE|App-Based Contingency Management|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
41103764|NCT04927143|BEHAVIORAL|Sham Control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
41103765|NCT02644239|DIETARY_SUPPLEMENT|ketogenic diet|Ketogenic diet with high fat (90%)
41103766|NCT03255018|BIOLOGICAL|Pembrolizumab|Administered intravenously (IV) at a fixed dose of 200 mg every 3 weeks until disease progression or unacceptable toxicity; treatment may continue indefinitely if clinical benefit with options for treatment interruption if responding disease and re-treatment upon relapse.
41103767|NCT05984641|DEVICE|CONAN® Proctological Cream|The active treatment samples used for the duration of the study were allocated at the site involved and consisted in 30 g tubes with an endorectal applicator, identified by the batch number, expiry date and information on the study on dedicated labels. The treatment of patients randomized to Group A consisted in applying the local treatment (1 application 3 times/day) for 30 days. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
41103768|NCT05513300|OTHER|Exercise intervention|12 weeks of exercise training, 3 times per week, \~1h long
41103769|NCT06413940|BEHAVIORAL|Myofunctional Therapy|Oropharyngeal and tongue exercises : strengthening upper airway muscle 20 minutes
41103770|NCT06413940|BEHAVIORAL|Inspiratory Muscle Training|Respiratory muscle strengthening:inspiratory muscle strengthening by resistive loading of 50% maximum inspiratory pressure.
41103771|NCT06413940|BEHAVIORAL|Aerobic Exercise|Exercise intensity :40%-60% HRmax , 3-5 days/week
41103772|NCT02819336|DEVICE|Electroacupuncture (EA)|"The EA group will receive the verum therapies using the following procedures.~1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, CV6 and bilateral points of SP11 and SP6.~3. The verum acupunctures are inserted on each acupoint inside the installed guide-tube. (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Republic of Korea)~4. After de qi response is elicited, the electrical stimulation is presented for 20 minutes by middle frequency (30 Hz). (STN-111, Stratek, Republic of Korea)~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
41103773|NCT02819336|DEVICE|Sham electroacupuncture|"1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, and CV6 unilaterally \& SP11 and SP6 bilaterally.~3. The non-penetrating sham acupunctures are implemented on each acupoint inside the installed guide-tube.~4. The electrical stimulation is presented for 20 minutes by middle frequency (30 Hz), (STN-111, Stratek, Republic of Korea) even though the electrical stimulation is not delivered through the skin because the needles are not penetrated through the skin.~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
41103774|NCT01952795|BEHAVIORAL|Diet and exercise|Total caloric intake aimed at maintaining a diet with\> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
41103775|NCT05824377|OTHER|Continuous Feeds|Continuous feeds will be delivered via an indwelling nasogastric/orogastric tube with a continuous infusion pump.
41103776|NCT05824377|OTHER|Intermittent Bolus Feeds|Intermittent bolus feedings will be given by gravity every 3 hours over 15- 30 minutes.
41103777|NCT05547750|DRUG|Vitamin K2|Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.
41103778|NCT05547750|DRUG|Placebo|Similar-looking placebo tablets
41133276|NCT00110669|DRUG|Prednisone|"Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding."
41443522|NCT05410002|DIETARY_SUPPLEMENT|Dietary Supplement: N-111|Dietary supplement N-111
41443523|NCT05410002|OTHER|Placebo|Dietary placebo
41443524|NCT06558162|BEHAVIORAL|Mindfetalness|"They will be instructed to lie on their left side and focus on the fetal movements for 15 minutes every day while the foetus is awake. They will also be instructed to monitor the character, strength and frequency of fetal movements (not to count them) and to seek medical advice if they feel any change in this pattern.~After two weeks, the pregnant women will be invited back to the organisation for a follow-up interview to check whether they have performed the practice and recorded correctly. An interview will be conducted again after four weeks."
41103779|NCT00728637|BEHAVIORAL|Family Passport to Heart Health Program|Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
41103780|NCT00728637|BEHAVIORAL|General Educational Materials|Participants in the control group received an educational brochure about heart health at the baseline study visit.
41103781|NCT04960176|PROCEDURE|Acupuncture|Acupuncture will be applied by using 0,25x25mm needles.
41103782|NCT04960176|PROCEDURE|Non-invasive Sham Acupuncture|Non-invasive sham acupuncture will be applied by using blunted 0,25x25mm needles.
41103783|NCT00614406|DRUG|Celebrex|One 400mg tablet daily.
41103784|NCT00614406|DRUG|Placebo|One tablet daily.
41103785|NCT01838824|BEHAVIORAL|Speed of Processing Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
41103786|NCT03890640|PROCEDURE|Ultrasound-guided TECI|When performing an ultrasound-guided thoracic epidural catheter insertion (TECI), an 18-gauge Tuohy needle will be used for interlaminar epidural access. All procedures will be performed with a paramedian approach under ultrasound-guidance and using the loss of resistance technique with saline. If the needle is deemed to be in the epidural space when the loss of resistance occurred, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
41103787|NCT04236128|OTHER|Mobile App|"The app will be provided to patients in hospital on post-operative day 3. On the day of discharge, the patient will be emailed a Daily Health Check and receive subsequent Daily Health Check emails on Day 1-14, 21 and 30 days following discharge. The Daily Health Check is a tailored questionnaire to elicit their symptoms and status of post-operative recovery. After the patient has completed the Daily Health Check, a Daily Health Check Summary is emailed to the patient that summarizes their responses and provides appropriate action recommendations based on their responses ranging from: (i) suggestions for educational modules, (ii) expect a call from your health care team in the next 24 hours, (iii) call your surgeon's office today or (iv) go to the nearest emergency room. The patient's Daily Health Check responses are displayed in real time on a secure website that automatically red flags extreme responses to alert the health care team to contact the patient by telephone."
41103788|NCT01648140|DRUG|GSK2336805 40 mg|20 mg tablet, round, 10-mm diameter, white to off-white, no markings
41103789|NCT01648140|DRUG|GSK2336805 60 mg|30 mg tablet, round, 10-mm diameter, white to off-white, no markings
41103790|NCT01648140|DRUG|Pegylated interferon alpha-2a|180 microgram per 0.5 mL prefilled syringe for single use
41103791|NCT01648140|DRUG|Ribavirin|"200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side"
41103792|NCT01648140|DRUG|Telaprevir|375 mg film-coated tablet
41103793|NCT06465667|BEHAVIORAL|Dashboard|The Dashboard intervention, representing current standard of care, will consist of a standard e-mail message with a link to the dashboard and text explanation. No performance data will be included in the e-mail, and links will not be monitored for clickthrough with repeat e-mail.
41103794|NCT06465667|BEHAVIORAL|Precision Feedback Push|"The experimental intervention, precision feedback e-mail messaging, will consist of an e-mail with a link to the dashboard along with tailored information about a participant's performance in the quality process measure of interest. For example, e-mail subject lines may read You have room for improvement in stent omission, accompanied by a visual display in the body of the e-mail showing a participant's performance relative to a top performing peer. The behavior change intervention delivery component will also involve modifications to existing procedures. Namely, performance feedback will be reported directly in the e-mail as either plain text, or an embedded or attached image with graphed data."
41103795|NCT03321955|DRUG|Ziconotide 100 MCG(microgram)/ML Intrathecal Solution|Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.
41103796|NCT03321955|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,
41103797|NCT03321955|DIAGNOSTIC_TEST|Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor|Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
41103798|NCT00533234|DEVICE|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
41103799|NCT02959957|DRUG|Temocillin|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
41103800|NCT02959957|DRUG|Cefotaxime|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
41103801|NCT00803933|DRUG|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
41103802|NCT00803933|DRUG|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
41103803|NCT04246697|DRUG|Tylenol|Used for both arms, scheduled
41103804|NCT04246697|DRUG|Oxycodone|Used for both arms PRN
41103805|NCT04246697|DRUG|Morphine|Used for both arms PRN
41103806|NCT04246697|DRUG|Gabapentin|Used for Arm B
41103807|NCT04246697|DRUG|toradol|Used for Arm B
41103808|NCT04246697|DRUG|Bupivacaine|Used for Arm B - anesthesia block
41103809|NCT00370799|DRUG|Caudal epidural injection|group 1: Caudal epidural injection local anesthetics only
41103810|NCT00370799|DRUG|Caudal Epidural Injection with generic Celestone|Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
41103811|NCT00370799|DRUG|Caudal Epidural Injection with Celestone|Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
41103812|NCT00370799|DRUG|Caudal Epidural Injection with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
41103813|NCT01923948|DRUG|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
41103814|NCT01923948|DRUG|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
41103815|NCT05939648|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
41103816|NCT05939648|OTHER|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
41103817|NCT00762463|DRUG|Celecoxib|capsule, 200 mg QD, 6-12 weeks
41103818|NCT00762463|DRUG|Diclofenac SR|tablet, 75 mg QD,6-12 weeks
41103819|NCT04586036|OTHER|ankle joint brace 1|The influence of ankle joint brace 1 on gait biomechanics
41103820|NCT04586036|OTHER|ankle joint brace 2|The influence of ankle joint brace 2 on gait biomechanics
41103821|NCT04586036|OTHER|ankle joint brace 3|The influence of ankle joint brace 3 on gait biomechanics
41103822|NCT04586036|OTHER|ankle joint brace 4|The influence of ankle joint brace 4 on gait biomechanics
41103823|NCT04586036|OTHER|ankle joint brace 5|The influence of ankle joint brace 5 on gait biomechanics
41103824|NCT06028113|BEHAVIORAL|THRIVE 2.0|Overview of content and strategies: 1) Education on stage of development specific to infant feeding, sleep and infant regulation, attunement to cues; 2) Attunement to cues: reinforcing and modeling accurate discernment \& responsiveness to cues; 3) Infant Soothing and Regulation: Coaching alternative strategies for soothing that feeding for non-hungry, fussy infants; 4) Routines \& Strategies: Promoting developmental activities during wake windows and longer consolidated sleep at night as the infant grows.
41103825|NCT02063607|BIOLOGICAL|Peginterferon lambda|
41103826|NCT01726023|DRUG|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
41103827|NCT01726023|DRUG|metronidazole|Metronidazole 500mg/100ml solution for infusion
41103828|NCT01726023|DRUG|Meropenem|Meropenem powder for solution for infusion 1000mg
41103829|NCT06082076|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
41103830|NCT06082076|DRUG|Ketamine|Patient will will receive ketamine 0.5 mg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
41103831|NCT06082076|DRUG|Meperidine|If the tested drug hasn't stopped shivering patient will receive 0.25 mg/kg meperidine
41103832|NCT03203018|BEHAVIORAL|Interactive workshop based on community specific needs|"Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results."
41103833|NCT05421988|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.
41103834|NCT02729272|PROCEDURE|Laparoscopic colpotomy by ultrasonic ESD|In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
41103835|NCT02729272|PROCEDURE|Laparoscopic colpotomy by monopolar ESD|In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
41103836|NCT02729272|DEVICE|Monopolar ESD|
41103837|NCT02729272|DEVICE|Ultrasonic ESD|
41103838|NCT03994146|DRUG|Remifentanil|"Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
41103839|NCT03994146|DRUG|Sodium Chloride 9mg/mL|"Syringe containing 40 ml of Sodium Chloride 9 mg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
41103840|NCT03875248|DEVICE|Blood pressure measurement|Measure optically the blood pressure through the use of a smartphone
41103841|NCT01364519|DRUG|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
41103842|NCT01364519|DRUG|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
41103843|NCT04081506|OTHER|Individualized perfusion targets|Targeting +/-5mmHg of the optimal mean arterial pressure
41103844|NCT00680472|DRUG|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
41103845|NCT00680472|OTHER|Placebo Patch|Treatment with Placebo Patch
41103846|NCT04814043|DRUG|PD-1 inhibitor|systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
41103847|NCT05054062|DIAGNOSTIC_TEST|Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
41103848|NCT01145885|DRUG|BI 6727|PLK-1 inhibitor
41103849|NCT04656002|DRUG|Vactosertib|Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
41103850|NCT01359371|BEHAVIORAL|Peer telephone cessation counseling|For Veterans who received the inpatient Tobacco Tactics intervention, trained volunteers initiated follow-up telephone cessation counseling at 2, 14, 21 and 60 days after in-patient discharge; three attempts were made per time point.
41133277|NCT01160354|DRUG|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
41103851|NCT04097626|OTHER|nutrition education|The experimental group will receive nutrition education once during the study. It will occur at the beginning of the second week. This will consist of a 30-minute interactive lecture and a 15-minute question-and-answer session. The information covered will be basic nutrition principles for good health and to support regular exercise.
41103852|NCT04097626|OTHER|no nutrition education|This group will not receive nutrition education.
41103853|NCT04800224|DRUG|Standardized Brazilian Green Propolis Extract|900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
41103854|NCT04800224|DRUG|Placebo|900mg/day of Placebo for 10 days.
41103855|NCT02592837|DEVICE|Flexible 19G EBUS-TBNA needle|
41103856|NCT02592837|DEVICE|21G EBUS-TBNA needle|
41103857|NCT03250104|OTHER|Infection Control|The infection control bundle will include staff training, hand hygiene programs, disinfection measures, and contact isolation. Physicians will be discouraged to prescribe proton pump inhibitors (PPIs) where not explicitly needed. The intervention bundle will be defined based on current literature. For implementation, the investigator will adapt the bundle to specific local needs, discuss with the responsible department heads and ward staff, perform training and disseminate standards of care.
41103858|NCT03250104|OTHER|Antibiotic Stewardship|"Antibiotic stewards will develop local standards of procedure based on the provided training and guidelines. They will then train the responsible staff and disseminate guidelines as best suited for the local work environment, e.g. as pocket cards, posters, or electronically. Point-prevalence investigations and antibiotic visits will assure adherence to guidelines."
41103859|NCT02865733|DRUG|Remodulin|After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
41103860|NCT02865733|DRUG|distilled water|After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
41103861|NCT06346769|OTHER|Polyethylene Fiber|In the restoration of the endodontically treated posterior teeth, polyethylene fiber was placed in different directions ('O' shape, mesiodistal I shape, buccolingual I shape) according to the amount of remaining tooth tissue and cavity preparation.
41103862|NCT04861610|BEHAVIORAL|Brief mindfulness based program|An intervention promotes the acceptance and emotion regulation in caregiving for frail older adults
41103863|NCT04861610|BEHAVIORAL|Psychoeducation|An intervention promotes the coping and problem solving in caregiving for the frail older adults
41103864|NCT00006413|PROCEDURE|Stem cell transplantation|
41103865|NCT04965467|DIAGNOSTIC_TEST|Screening for Fabry disease|A questionnaire specifically designed to assess Fabry disease-associated phenotypes in infancy, childhood and adolescence: pain in the hands and feet, angiokeratomas, hypohidrosis, corneal whorls, unexplained renal failure, unexplained hypertrophic myocardiopathy and unexplained early onset stroke. The questionnaire consisted mainly of quantitative, closed questions with pre- defined response options.The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). In females plasma Gb3, globotriaosyl- sphingosine (lyso-Gb3) will be measured for screening.
41103866|NCT06229717|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
41103867|NCT06229717|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
41103868|NCT06229717|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
41103869|NCT06229717|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
41103870|NCT06229717|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
41443525|NCT06558162|BEHAVIORAL|Sadovsky|"They will be asked to continue this procedure every morning, noon or evening for one month (depending on the movements of the pregnant woman and her baby, the time will be left to the pregnant woman, but it should be at the same time every day). Since the aim of the study is to increase maternal awareness rather than to determine fetal well-being, mothers will be asked to count at least 10 movements based on the count to ten and Sadovsky method, and will be asked to record the start and completion time of the movements each time. A follow-up will be made after two weeks and a final follow-up will be made after one month"
41443526|NCT01444053|DEVICE|No Intervention|No Intervention
41103871|NCT04867954|OTHER|Ensure Plus®|In-between two MRI exams, patients will ingest a standardized meal of two cans (16oz) of Ensure Plus® (Abbott Laboratories), providing a 700cal meal (13g protein, 11g fat, 50g carbohydrates), proven to elicit a strong hyperemic splanchnic response.
41103872|NCT04867954|OTHER|Pre-clinical validation contrast enhanced MRI|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
41103873|NCT04867954|OTHER|Clinical validation MRI|"Participants will be screened for any previous reactions to Ferumoxytol or GBCAs and dosing will be consistent with standard of care.~Participants will then undergo a research MRI lasting approximately 1.5 hours.~* All participants will be positioned in the MRI scanner for the initial scanning session (30 min) during which a 3/4 of the full dose of gadolinium based contrast agent (GBCA) or the total dose of Ferumoxytol will be administered.~* The first 50 participants will be removed from the scanner bore, repositioned, and scanned for an additional 15 minutes (repeatability testing).~* All participants will then be removed from the scanner and asked to consume 16 ounces of Ensure Plus®. After 20 minutes, they will be repositioned in the scanner for an additional scanning session (15 minutes) during which, the remaining 1/4 dose of GBCA will be administered, if required."
41103874|NCT04867954|OTHER|Pre-clinical validation contrast enhanced MRI + fasting|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1.5 hours. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
41103875|NCT04784013|PROCEDURE|Conventional CLOSE-guided pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.
41103876|NCT04784013|PROCEDURE|High power short duration pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.
41103877|NCT01532232|DRUG|placebo|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
41103878|NCT01532232|DRUG|varenicline|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
41103879|NCT06463119|OTHER|Collection of data in a registry|The aim of this observational project is to document the immunogenicity and reactogenicity of vaccines given to immunocompromised patients and collect it in a registry.
41103880|NCT02072226|DRUG|Alteplase|Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
41103881|NCT02072226|DRUG|Alteplase Placebo|Single dose of alteplase placebo will be administered as IV injection.
41103882|NCT02072226|DRUG|Aspirin|Single dose of aspirin will be administered at 325 mg orally.
41103883|NCT02072226|DRUG|Aspirin Placebo|Single dose of aspirin placebo will be administered orally.
41103884|NCT02200341|BEHAVIORAL|MBCT|
41103885|NCT02200341|BEHAVIORAL|PRT-PsyEd|
41103886|NCT05738226|DEVICE|EpiCare@Home, wearable multimodal seizure monitoring system|"Two wearable devices (Byteflies Sensor Dots) will be used. One Sensor Dot will be placed in the neck with a skin adhesive and will be connected to EEG electrodes placed behind each ear. The second Sensor Dot will be placed on the chest with an adhesive ECG electrode (i.e., a cardiac patch)."
41103887|NCT04358328|OTHER|Comprehensive geriatric assessment (CGA) and care|Comprehensive geriatric assessment and care including geriatric-, nursing-, physiotherapist-, and dietician assessments followed by appropriate interventions.
41103888|NCT04358328|OTHER|Standard care|Standard pre-, peri- and post operative care.
41103889|NCT04278820|DRUG|TQA3526|Tablet(s) administered orally once daily
41103890|NCT04278820|DRUG|Placebo to match TQA3526|Tablet(s) administered orally once daily
41103891|NCT03061474|DRUG|Nicotinamide|Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
41103892|NCT03061474|DRUG|Placebo Comparator|Oral Tablet
41103893|NCT02791750|OTHER|questionnary of quality of life|
41103894|NCT00295867|DRUG|Zoledronic Acid|Zoledronic acid is a new, highly potent, heterocyclic nitrogen-containing third generation bisphosphonate that has demonstrated 40- to 850- fold greater potency than pamidronate in preclinical models of bone resorption. The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway
41103895|NCT03008018|DRUG|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
41103896|NCT01181089|BIOLOGICAL|Placebo|
41103897|NCT01181089|BIOLOGICAL|Baminercept|
41103898|NCT04220359|DEVICE|non-invasive monitoring|Prospective monitoring with retrospective big-data analysis
41103899|NCT01158196|DEVICE|infra-red diode laser|"laser treatment of scar after keloid excision~laser treatment of surgery scar"
41103900|NCT04408287|OTHER|WebEx Physical Activity Program|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
41103901|NCT02276131|DEVICE|Vigilant Diabetes Management Application|Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
41103902|NCT00202358|DRUG|atenolol|
41103903|NCT00202358|DRUG|placebo|
41103904|NCT04950855|DIAGNOSTIC_TEST|Optical Coherence Tomography,Optical Coherence Tomography Angiography(Topcon)|Optical coherence tomography optical coherence tomography angiography
41103905|NCT05139095|DRUG|Camrelizumab plus apatinib CohortA|Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\] every 2 weeks. For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO. The observation period is 14 days.
41103906|NCT05139095|DRUG|Camrelizumab plus apatinib Cohort B|Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy. The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\]; or EMA/EP \[etoposide, methotrexate and actinomycin-D/etoposide, cisplatin\]; or FAEV \[floxuridine, actinomycin-D, etoposide, vincristine\]). The observation period is 21 days.
41103907|NCT05038072|DRUG|suprachoroidal injection of Triamcinolone Acetonide.|4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).
41103908|NCT00365027|PROCEDURE|Delayed embryo transfer|
41103909|NCT00545376|PROCEDURE|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
41103910|NCT00545376|PROCEDURE|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
41103911|NCT00545376|OTHER|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
41103912|NCT01396291|DRUG|asenapine|asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
41103913|NCT01396291|DRUG|placebo|asenapine-matched placebo, sublingual tablets, BID
41103914|NCT00522756|DRUG|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
41103915|NCT00522756|DRUG|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
41103916|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
41103917|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
41103918|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
41103919|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
41103920|NCT01372163|DRUG|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
41103921|NCT01372163|DRUG|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
41103922|NCT01372163|DRUG|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
41103923|NCT02611414|DEVICE|anodal tDCS|tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
41103924|NCT02611414|DEVICE|Sham tDCS|tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
41103925|NCT03155490|BEHAVIORAL|Leadership training|Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
41103926|NCT00281918|DRUG|Rituximab|Intravenous repeating dose
41103927|NCT00281918|DRUG|Cyclophosphamide|Intravenous repeating dose
41103928|NCT00281918|DRUG|Fludarabine Phosphate|Intravenous repeating dose
41103929|NCT05252624|DRUG|placebo|Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
41103930|NCT05252624|DRUG|Henagliflozin 5Mg Tab|Single oral tablet
41103931|NCT05857306|DIETARY_SUPPLEMENT|Olvanil|"Nutritional recommendation along with 4 mg Olvanil (1 capsule daily)~Subects within the Intervention group will be provided with a nutritional recommendation along with Olvanil capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 4 mg Olvanil and 255 mg soy lecithin as excipient"
41103932|NCT05857306|DIETARY_SUPPLEMENT|Placebo|"Nutritional recommendation along with 255 mg soy lecithin (1 capsule daily)~Subects within the placebo group will be provided with a nutritional recommendation along with placebo capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 255 mg soy lecithin"
41103933|NCT05357365|OTHER|questionnaire survey|Questionnaire survey about occupational, mental, physical factors on one's health.
41103934|NCT02485626|PROCEDURE|2D tissue doppler echocardiography|
41103935|NCT01908634|DIETARY_SUPPLEMENT|Milk-based Strawberry Beverage without meal|
41103936|NCT01908634|DIETARY_SUPPLEMENT|Water-Based Strawberry Beverage without meal|
41103937|NCT01908634|DIETARY_SUPPLEMENT|Milk-based strawberry Beverage with meal|
41103938|NCT01908634|DIETARY_SUPPLEMENT|Water-Based strawberry Beverage with meal|
41103939|NCT05699213|DIAGNOSTIC_TEST|Lung MRI|MRI of the lung
41103940|NCT05699213|DIAGNOSTIC_TEST|Blood Draw|Blood Draw
41103941|NCT06554431|BEHAVIORAL|Self-Driven Repetitive Artmaking|Three (3) art kits which all use repetitive artmaking processes (e.g., materials for mandalas, stamp making kit, weaving kit)
41103942|NCT03437642|BEHAVIORAL|Short Term Psychotherapy|Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs
41103943|NCT00162071|DRUG|apadenoson|
41103944|NCT04016818|DRUG|18F-FDG|Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.
41103945|NCT04016818|DEVICE|Breast-dedicated PET camera|Breast-dedicated PET camera designed by Stanford satellite radiochemistry facility
41103946|NCT05950113|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
41103947|NCT05950113|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
41103948|NCT05950113|PROCEDURE|Computed Tomography|Undergo PET/CT
41103949|NCT05950113|DRUG|Cyclophosphamide|Receive IV
41103950|NCT05950113|PROCEDURE|Echocardiography|Undergo ECHO
41103951|NCT05950113|DRUG|Fludarabine|Receive IV
41103952|NCT05950113|OTHER|Fludeoxyglucose F-18|Receive IV
41103953|NCT05950113|OTHER|Immunotherapy|Receive CART-BCMA/CS1 cells IV
41103954|NCT05950113|PROCEDURE|Leukapheresis|Undergo leukapheresis
41103955|NCT05950113|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41103956|NCT05950113|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41103957|NCT03703440|OTHER|Active arm|≥3 group education sessions in addition to usual diabetes care, every 3 months for 12 months
41103958|NCT03703440|OTHER|Control arm|Usual diabetes care, every 3-month for 12 months
41103959|NCT05823181|DEVICE|laparoscopy|laparoscopic exploration of common bile duct
41103960|NCT05054400|DRUG|F18 Fluciclovine|Given by IV
41103961|NCT05054400|OTHER|Standard of Care|Standard of care
41103962|NCT02389192|DRUG|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
41103963|NCT06321809|BEHAVIORAL|intensive lifestyle|INTENSIVE LIFESTYLE INTERVENTIONS
41103964|NCT04461236|DIETARY_SUPPLEMENT|Oral Supplement|Supplement provided in capsules. Half the capsules to be taken with lunch and the other half with dinner. All supplements are commercially available.
41103965|NCT04461236|DIETARY_SUPPLEMENT|Placebo|Placebo
41103966|NCT01801930|DRUG|OCV-103 and OCV-104|0.3 mg of each
41103967|NCT01801930|DRUG|OCV-103 and OCV-104|1 mg of each
41103968|NCT01801930|DRUG|OCV-103 and OCV-104|3 mg of each
41103969|NCT01801930|DRUG|OCV-103 and OCV-104|6 mg of each
41103970|NCT00612586|DRUG|Enzastaurin|1125 milligram (mg) loading dose, then 250 mg twice daily, oral up to 1 year (yr) or until progressive disease
41103971|NCT00612586|DRUG|Placebo|oral, daily (up to 1 yr or until progressive disease)
41103972|NCT00612586|DRUG|Leucovorin (LV)|400 milligram per meter squared (mg/m\^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
41103973|NCT00612586|DRUG|5-fluorouracil (5-FU)|400 mg/m\^2 bolus then 2400 mg/m\^2 IV over 46 hours, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
41103974|NCT00612586|DRUG|Bevacizumab (Bev)|5 milligram per kilogram (mg/kg) IV, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
41103975|NCT00956982|DRUG|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing \< 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
41103976|NCT00394069|DRUG|MK-0476, montelukast sodium|Duration of Treatment: 14 Days
41103977|NCT06249789|PROCEDURE|Spinal Anesthesia|Participants in this arm will receive single-shot spinal anesthesia with 12-15 mg of either 0.05% or 0.75% bupivacaine (iso or hyperbaric) once before surgery. Additionally, they will undergo an ultrasound-guided nerve block called the Fascia Iliaca Compartment Block (FICB ) in combination with spinal anesthesia.
41103978|NCT06249789|PROCEDURE|General Anesthesia|Participants in this group will be given a combination of general anesthesia and a nerve block. General anesthesia involves the use of a sedative called propofol, along with devices to ensure that the airway remains open during the procedure. Additionally, they will undergo an ultrasound-guided nerve block known as the Fascia Iliaca Compartment Block (FICB) in combination with spinal anesthesia.
41103979|NCT06185400|DRUG|Disitamab Vedotin|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC
41103980|NCT06185400|DRUG|third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression
41103981|NCT06185400|DRUG|pyrotinib|RC48+pyrotinib after EGFR-TKIs progression
41103982|NCT03603717|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention will consist of a standard, structured, multi-component intervention for insomnia that includes sleep education, sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
41103983|NCT03603717|BEHAVIORAL|Sleep Hygiene|The intervention will include basic psychoeducation about sleep, discussion of sleep hygiene factors that disrupt and improve sleep, setting sleep hygiene goals, and developing action steps to achieve those goals.
41103984|NCT02357784|DEVICE|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
41103985|NCT01845896|BEHAVIORAL|Training|
41103986|NCT01735240|DRUG|AZD5069|AZD5069 15 mg (3x5 mg capsules) single administration
41103987|NCT01735240|DRUG|Ketoconazole|Ketoconazole 400 mg (2x200 mg tablets)
41103988|NCT03068637|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
41103989|NCT06051500|BEHAVIORAL|Nostril focus followed by belly focus|Focused breathing on the nostrils followed by focus breathing on the belly.
41103990|NCT06051500|BEHAVIORAL|Belly focus followed by nostril focus|Focused breathing on the bellyfollowed by focus breathing on the nostrils.
41103991|NCT01128530|DRUG|JNJ-32729463|250 mg tablet twice daily
41103992|NCT01128530|DRUG|linezolid|600 mg tablet twice daily
41103993|NCT01128530|DRUG|JNJ-32729463 placebo|1 placebo tablet twice daily
41103994|NCT01128530|DRUG|linezolid placebo|1 placebo tablet, twice daily
41103995|NCT04709744|DRUG|Vitamin D|Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
41103996|NCT04709744|DIAGNOSTIC_TEST|ELISA|Measure vitamin D level
41103997|NCT00982033|DRUG|aliskiren|aliskiren 300mg qd versus placebo for 24 weeks.
41103998|NCT00982033|DRUG|placebo|placebo qd for 24 weeks
41103999|NCT01645917|DEVICE|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
41104000|NCT00307307|DRUG|Niacin/simvastatin compared to simvastatin alone at 2 doses|
41104001|NCT01603810|OTHER|OCT|Optical coherence tomography of periocular basal cell carcinoma
41104002|NCT01285258|PROCEDURE|hysterectomy|excluding the uterus with saving ovaries
41104003|NCT01400750|DRUG|oral ciprofloxacin plus inhaled colistin|oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
41104004|NCT01400750|DRUG|TOBI|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
41133278|NCT01160354|DRUG|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
41133279|NCT01787032|DRUG|BI 113608|tablet
41133280|NCT01787032|DRUG|BI 113608|tablet
41104005|NCT04376385|BEHAVIORAL|GROw: An Internet based Self Applied Treatment Program for Prolonged Grief Disorder (PGD)|"It is a self-applied treatment through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is 8-10 weeks. A support call will be made a week (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided.~Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
41104006|NCT03854006|PROCEDURE|Cryoballoon pulmonary vein isolation|During cryoballoon pulmonary vein isolation, under local anaesthesia, diagnostic catheters are placed in the coronary sinus. The cryoballoon is advanced to the left atrium via a steerable sheath after single transseptal puncture and inflated at the PV(pulmonary vein) ostia. A spiral mapping catheter is advanced through the balloon inner lumen and positioned in the PV at the closest achievable proximity to the cryoballoon in order to record real-time PV potentials during PV isolation. During PV isolation the potentials from the PV are recorded. The TTI is defined as the time of the last recording of a PV potential before sustained isolation. Isolation of all PVs is reassessed at the end of the procedure by documentation of entrance- and exit-block.
41104007|NCT02503202|BIOLOGICAL|V920 Consistency Lot A|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
41104008|NCT02503202|BIOLOGICAL|V920 Consistency Lot B|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
41104009|NCT02503202|BIOLOGICAL|V920 Consistency Lot C|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
41104010|NCT02503202|BIOLOGICAL|V920 High-dose Lot|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection
41104011|NCT02503202|BIOLOGICAL|Placebo to V920|Sodium chloride 0.9%, sterile solution for intramuscular injection
41104012|NCT03914170|DRUG|Folfirinox + cetuximab|Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
41104013|NCT01353092|DEVICE|Re5 Pulsating ElectroMagnetic Fields|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
41104014|NCT01353092|DEVICE|Re5 Pulsating ElectroMagnetic Fields (PEMF)|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
41104015|NCT06368609|DIAGNOSTIC_TEST|IgG RDT|Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
41104016|NCT06368609|DIAGNOSTIC_TEST|IgG4 RDT|Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
41104017|NCT04602936|DRUG|Solriamfetol|Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.
41104018|NCT04602936|DRUG|Placebo|"A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a sugar pill)."
41104019|NCT05577611|COMBINATION_PRODUCT|Basic chemotherapy + UCB transplantation|"The basic chemotherapy regimen was the same as that of the control group~UCB micro transplantation scheme:~Aza 100mg, 75mg/m2/d, IVGTT, D-10 to D-4~Ara-C 1000mg/m2/q12h, IVGTT, D-3 to D-2~Single non consanguineous umbilical cord blood (NC \> 1.5 \* 10 \^ 7 / kg), IVGTT, D0~Bone marrow aspiration smear, MRD and bone marrow chimerism were detected on D14, d30 and D60 after transplantation."
41104020|NCT04411446|DRUG|Vitamin D|5 capsules of 100.000 UI Vitamin D orally given all at once. One dose.
41104021|NCT04411446|DRUG|Placebo|5 capsules of containing placebo orally given all at once. One dose.
41104022|NCT04891887|BEHAVIORAL|Health education program|"Seven face to face sessions and group discussion health education sessions. Two prepared booklets were distributed to all attendants titled Diabetes mellitus and how to control its complications and Mild cognitive impairment and how to prevent it.~Lab results were discussed individually with each participant to discuss his adherence to the lifestyle modification program.~Clinical follow-up and management with endocrinology and neurology specialists. Individualized Medical Nutrition. Participants were then counselled on healthy eating habits.~Individualized biweekly follow-up scheme through mobile phone. A WhatsApp group was created for all participants to contact the research team whenever they have any inquiry concerning life style modifications. Through this group, 12 HE audio electronic messages were shared with participants.~Final reassessment of clinical status and laboratory profile was carried out with participants who continued till the end of the study."
41104023|NCT00028093|DRUG|Peginterferon alfa-2a with Ribavirin|Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients \<75 kg and 1200 mg daily for patients \>=75 kg) for 48 weeks
41104024|NCT00028093|DRUG|Peginterferon alfa-2a|Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
41104025|NCT01066741|DRUG|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
41104026|NCT01066741|DRUG|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
41104027|NCT01141933|OTHER|Cognitive-existential intervention|Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.
41104028|NCT01141933|OTHER|Usual care|This group receive the usual treatment only.
41104029|NCT01644162|DEVICE|iVAPS ventilation|3 months of ventilation on iVAPS mode
41104030|NCT06554067|DEVICE|Active transcranial direct current stimulation|Ten minutes of active transcranial direct current stimulation
41104031|NCT06554067|DEVICE|Active vagus nerve stimulation|Ten minutes of active vagus nerve stimulation
41104032|NCT06554067|OTHER|Sham transcranial direct current stimulation|Ten minutes of sham tDCS
41104033|NCT06554067|OTHER|Sham vagus nerve stimulation|Ten minutes of sham VNS
41104034|NCT00017004|RADIATION|External Beam Radiation Therapy|Undergo radiation
41104035|NCT00017004|DRUG|Cisplatin|Given IV
41104036|NCT00017004|RADIATION|Internal Radiation Therapy|Undergo radiation
41104037|NCT00017004|BIOLOGICAL|Epoetin Alfa|Given SC
41104038|NCT04577170|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.
41104039|NCT03030924|DEVICE|Solace|Noninvasive physiologic monitor
41104040|NCT02864095|DRUG|Tranexamic acid (TXA)|IV and topical administration
41104041|NCT02864095|DRUG|Epinephrine|
41104042|NCT05658198|BEHAVIORAL|Counseling|Patients who first decline HPV vaccination receive a 3-5 minute counseling session on HPV and the benefits of the vaccine.
41104043|NCT03178396|DIETARY_SUPPLEMENT|melatonin|controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
41104044|NCT03297749|OTHER|Observational study (no intervention)|No interventions
41104045|NCT01363362|PROCEDURE|Selective Laser Trabeculoplasty|360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
41104046|NCT02465086|OTHER|Training of linguistic recursion|Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
41104047|NCT03589651|DRUG|Retifanlimab|"Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1."
41104048|NCT03589651|DRUG|Epacadostat|"Part 1: Epacadostat at the protocol-defined starting dose administered orally twice daily, with dose escalation to determine the maximum tolerated dose.~Part 2: Epacadostat at the recommended dose from Part 1."
41104049|NCT03589651|DRUG|INCB050465|Part 1: INCB050465 at the protocol-defined starting dose administered orally once daily, with dose escalation to determine the maximum tolerated dose. Part 2: INCB050465 at the recommended dose from Part 1.
41104050|NCT04830722|DEVICE|Sculptra Aesthetic|One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume
41104051|NCT05747313|DRUG|Chidamide|"Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal."
41104052|NCT00882635|DRUG|enoxaparin|"Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance \< 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency"
41104053|NCT00882635|DRUG|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
41104054|NCT05301400|DEVICE|Bti Unit|Comparison with or without the device
41104055|NCT04188028|DRUG|Dextromethorphan 5 MG|dextromethorphan 5 mg po
41104056|NCT04188028|DRUG|Paroxetine 10Mg Tablet|Paroxetine 10 mg po
41104057|NCT04188028|DRUG|Paroxetine 20Mg Tablet|Paroxetine 20 mg po
41104058|NCT04282980|DRUG|DCC-2618|Oral kinase inhibitor
41104059|NCT06486818|PROCEDURE|Ablation of idiopathic monomorphic PVCs|3D carto ablation of idiopathic monomorphic PVCs
41104060|NCT02049866|DRUG|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
41104061|NCT00699686|DRUG|Glargine|Daily bedtime subcutaneous insulin Glargine in individualized doses.
41104062|NCT00699686|DRUG|Detemir|Daily bedtime subcutaneous insulin Detemir in individualized doses.
41104063|NCT01756417|DRUG|Metformin|One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
41104064|NCT01756417|DRUG|Canagliflozin (JNJ-28431754)|Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
41104065|NCT02191852|DRUG|Seresis®|
41104066|NCT04643405|DRUG|APG-1387 for Injection|APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.
41104067|NCT04643405|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
41104068|NCT04643405|DRUG|Nab paclitaxel|Nab-Paclitaxel 125mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
41104069|NCT05082649|OTHER|Face to Face Exercise|Face to face (in clinic) progressive spinal stabilization exercises.
41104070|NCT05082649|OTHER|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
41104071|NCT06162728|DRUG|Briquilimab|Subcutaneous Administration
41104072|NCT06162728|OTHER|Placebo|Placebo Comparator
41104073|NCT00553189|DRUG|ABT-888|
41104074|NCT00553189|DRUG|Topotecan|
41104075|NCT03328117|DRUG|Imatinib|Over-encapsulated 100 mg imatinib mesilate tablets
41104076|NCT03328117|DRUG|Placebo oral capsule|Matching placebo oral capsule
41104077|NCT00961636|DRUG|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
41104078|NCT00961636|DRUG|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
41104079|NCT00961636|DRUG|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
41104080|NCT00961636|DRUG|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
41104081|NCT03910543|DRUG|Tofacitinib 5 mg twice daily|Tofacitinib will be administered at a dose of 5 mg twice daily
41104082|NCT04178941|BEHAVIORAL|Audit and Feedback|The audit and feedback intervention includes providing each hospital's own continuous pulse oximetry use data back to them on a weekly basis for review and action.
41104083|NCT04178941|BEHAVIORAL|Educational outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
41104084|NCT05889286|DRUG|[F-18]MHF|Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) \[F-18\]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of \[F-18\]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
41104085|NCT05424159|RADIATION|Carbon ion radiotherapy|Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
41104086|NCT04041999|BEHAVIORAL|Daily Cognition Training Program|"Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc."
41104087|NCT03231436|DRUG|Fixed dose of 12.5mg bupivacaine|Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section
41104088|NCT03231436|DRUG|Height-adjusted dose of bupivacaine|Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
41104089|NCT03977116|DRUG|SLGT2|These patients will receive SLGT2 therapy after catheter ablation.
41104090|NCT03977116|DRUG|Placebo|These patients will receive placebo therapy after catheter ablation.
41104091|NCT01025206|BIOLOGICAL|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
41104092|NCT03405389|PROCEDURE|MatrixWAVE MMF System|Standard of care treatment of the injury and use of the MatrixWAVE MMF system to establish occlusion
41104093|NCT05100472|BIOLOGICAL|Androgen deprivation therapy (ADT)|ADT will include bicalutamide 50 mg PO daily started 1-2 weeks before leuprolide 22.5mg IM or SQ delivered every 3 months x 2. Bicalutamide will be continued through radiation and then discontinued on the day of the last fraction. Leuprolide can be given at different doses, but must be given for a total planned duration of 6 months.
41104094|NCT05100472|RADIATION|Brachytherapy|After approximately 3 months (+/- 1 month) of neoadjuvant ADT, patients will undergo general anesthesia for outpatient transperineal high dose rate (HDR) interstitial prostate brachytherapy implant.
41104095|NCT05100472|RADIATION|Hypofractionated pelvic External beam radiation|Patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
41133281|NCT01787032|DRUG|BI 113608|tablet
41133282|NCT01787032|DRUG|Ketoconazole|tablet
41133283|NCT01787032|DRUG|Voriconazole|tablet
41104096|NCT04539951|DRUG|Sertraline 200 milligram(mg)|All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
41104097|NCT04539951|DRUG|Sertraline 300 milligram(mg)|In experimental phase II, the patients in this group will remain on sertraline (higher dosage): where sertraline 200mg has been tolerated, dosage will be increased by 50mg fortnightly to a maximal dose of 300mg/d or to the maximum tolerable dose (less than 300mg/d).
41104098|NCT04539951|DRUG|Fluvoxamine|Fluvoxamine will be initiated at a dose of 50mg/d, increasing quickly to a maximal dose of 300mg/d or the maximum tolerated dose by week 4.
41104099|NCT04539951|DRUG|Venlafaxine|venlafaxine will be initiated at 75mg/d, increasingly weekly by 75mg/day, to a maximal dose of 300 mg/d or the maximum tolerated dose.
41104100|NCT04539951|DRUG|Augment with Memantine|Sertraline will be augmented with memantine initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d (10mg twice daily) or the maximum tolerated dose
41104101|NCT04539951|DRUG|Augment with Aripiprazole|Sertraline will be augmented with aripiprazole, initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d or the maximum tolerated dose
41104102|NCT05644080|RADIATION|177Lu-PSMA I&T|Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
41104103|NCT00939848|DRUG|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
41104104|NCT00939848|DRUG|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
41104105|NCT00939848|DRUG|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
41104106|NCT00939848|DRUG|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
41104107|NCT00939848|DRUG|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
41104108|NCT00939848|DRUG|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
41104109|NCT06360042|DRUG|Adebrelimab plus Apatinib|Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily
41104110|NCT06360042|DRUG|Adebrelimab plus Bevacizumab|Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks
41104111|NCT06360042|DRUG|Camrelizumab plus Apatinib|camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily
41104112|NCT06348186|OTHER|Guidebook|Folder that will be given to the participant to carry out 5 minutes of intervention daily
41104113|NCT06348186|OTHER|Guidebook and Myofascial Reorganization® (RMF).|The intervention will be carried out once a week for 30 minutes for 6 weeks. It will include passive, active-assisted moments (with and without load). In addition to a folder that will be given to the participant to carry out 5 minutes of intervention daily.
41104114|NCT02780245|DRUG|Tranexamic Acid|At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
41104115|NCT02780245|PROCEDURE|Intraoperative Uterine Cooling|Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
41104116|NCT06116812|OTHER|the laughter yoga group|"They will gather in five-person chemotherapy rooms, and laughter therapy will be applied to the women in the application group while they are receiving chemotherapy. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again."
41104117|NCT06116812|OTHER|the mindfulness based stress reduction group|"Mindfulnes therapy will be applied to the women in the application group while they are receiving chemotherapy, in five-person chemotherapy rooms. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again."
41104118|NCT04680702|DIAGNOSTIC_TEST|Sims Score|Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity
41104119|NCT00426036|DRUG|Licarbazepine|
41104120|NCT01992354|DEVICE|PET MR Device|GE PET/MRI system
41104121|NCT03874455|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
41104122|NCT01092806|DRUG|Tacrolimus|Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
41104123|NCT05388344|OTHER|Booklet reading|Submission of the questionnaire before and after booklet reading
41104124|NCT04943380|DIAGNOSTIC_TEST|Cxbladder|The Cxbladder Detect test, developed by Pacific Edge Ltd (O'Sullivan 2012; Holyoake 2008; National Health Committee 2015b) is a molecular diagnostic test, which consists of five mRNA transcripts measured in a small volume of urine.
41104125|NCT02642419|DRUG|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|"* Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~* Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~  * Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~ * Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~ * Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
41104126|NCT02642419|DRUG|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
41104127|NCT01649635|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
41104128|NCT01649635|DRUG|Prednisone|Pharmaceutical form: tablet Route of administration: oral
41104129|NCT01649635|DRUG|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
41104130|NCT01649635|DRUG|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
41104131|NCT05703204|DRUG|QLF32101|The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
41104132|NCT02492464|DIETARY_SUPPLEMENT|Red yeast rice|1 capsule to be taken before to sleep, each day, for 6 months
41104133|NCT02492464|DIETARY_SUPPLEMENT|Placebo|
41104134|NCT02488174|OTHER|PROOFcheck|
41104135|NCT02488174|OTHER|Standard Care|
41104136|NCT00646451|DRUG|pregabalin (Lyrica)|75 mg bid to 300 mg bid based on per subject tolerability
41104137|NCT00646451|DRUG|placebo|up to 4 capsules bid as tolerated
41104138|NCT00195078|DRUG|ZD1839 (IRESSA)|
41104139|NCT00195078|DRUG|Cisplatin|
41104140|NCT00195078|PROCEDURE|Radiation Therapy|
41104141|NCT03109704|PROCEDURE|Supine upper thoracic spine thrust manipulation|The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
41104142|NCT03109704|PROCEDURE|Seated upper thoracic spine thrust manipulation|The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
41104143|NCT03109704|PROCEDURE|Sham manipulation|"The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust."
41104144|NCT02600442|OTHER|non interventional study|
41104145|NCT01006551|DRUG|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
41104146|NCT04509713|BEHAVIORAL|Collection of odour samples|Samples of breath odours will be passively collected while participants wear the mask while breathing naturally, for at least 3 h. Skin odours will be passively collected by participants wearing the shirt and nylon socks for at least 12 h.
41104147|NCT03121963|DRUG|Oxycodone|oxycodone tablet
41104148|NCT03121963|DRUG|Acetaminophen|acetaminophen tablet
41104149|NCT03121963|DRUG|Gabapentin|gabapentin tablet
41104150|NCT03121963|DRUG|Celecoxib|celecoxib tablet
41104151|NCT03121963|DRUG|Hydrocodone-Acetaminophen|hydrocodone 5 mg/acetaminophen 325 mg tablet
41104152|NCT04683159|DRUG|Brimonidine Tartrate 0.15% Oph Soln|1 drop of brimonidine 0.15% (\~0.05mL) 15 minutes prior to surgery
41104153|NCT04683159|DRUG|Brimonidine Tartrate 0.025% Oph Soln|1 drop of brimonidine 0.025% (\~0.05mL) 15 minutes prior to surgery
41104154|NCT00919763|DRUG|CD2027 Ointment 3 mcg/g, twice daily|Topical Ointment
41104155|NCT00919763|DRUG|Vehicle Ointment, twice daily|Topical Ointment
41104156|NCT01615835|OTHER|EnSite NavX System|EnSite NavX system is a 3D Mapping system
41104157|NCT03851237|DRUG|64Cu-DOTA-ECLIi|-The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
41104158|NCT03851237|DEVICE|PET/CT|-Standard of care
41104159|NCT04423484|OTHER|Data collection|Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
41104160|NCT04232592|BIOLOGICAL|Inject a solution of stem cell preparation|The control group was injected with a solution of stem cell preparation
41104161|NCT04232592|BIOLOGICAL|Inject stem cells|Three dose groups were designed: low dose group, medium dose group and high dose group.
41104162|NCT04300933|BEHAVIORAL|Electroencephalogram-based neurofeedback|In this project, SCD participants will receive electroencephalogram-based neurofeedback therapy, once a day, for 5 days. Then, the investigators will compare their memory changes between baseline and post-therapy visits.
41104163|NCT01145456|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
41104164|NCT01145456|DRUG|gemcitabine hydrochloride|Given IV
41104165|NCT01145456|OTHER|pharmacological study|Correlative studies
41104166|NCT01145456|OTHER|laboratory biomarker analysis|Correlative studies
41104167|NCT04333589|DRUG|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
41104168|NCT05837468|BEHAVIORAL|BETTERapp|The BETTER app offers a 'tailor-made' lifestyle programme including the option of personal coaching for a duration of 6 weeks. The BETTER app is an automated and digitised lifestyle programme based on the previously developed and evaluated BETTER programme.
41104169|NCT00380705|DRUG|MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks|
41104170|NCT02634216|DIETARY_SUPPLEMENT|Capros|250 mg BID
41104171|NCT06315400|DRUG|Ingavirin®|60 mg/day for 5 days
41104172|NCT06315400|DRUG|Placebo|1 capsule/day for 5 days
41443527|NCT04403672|DEVICE|performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection|"IEDCR uses many different kits for COVID-19 detection. These kits include, (1) A\*Star Fortitute Kit 2 for COVID-19 detection (Singapure), (2) Sansure Biotec Limited (China), (3) ModularDx Kit (TIB Molecular Biology, Germany, and (4) DaAn Kit (China). Among these 2 kits, A\*Star Fortitude Kit 2 has been known as the best kit in IEDCR depending on its performance because it rarely generates false positive or false negative results.~A\*Star Fortitude Kit 2 is used for confirmation of any discordant results for other kits in IEDCR. That is, IEDCR uses A\*Star Fortitude Kit for COVID detection as the Gold Standard. In our case, this is the main reason for the selection of this kit in order to compare the performances of RealDetect™ COVID-19 RT-PCR kit."
41443528|NCT04215718|PROCEDURE|fistulotomy and marsupialization|the anal fistula was laid open and the the wound edges was marsupialized using vicryle 3\\0 sutures
41104173|NCT00333541|BEHAVIORAL|Using internet/E-mail for follow-up|follow-up via email link to survey
41104174|NCT03728738|PROCEDURE|Head of Bed Positioning|The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
41104175|NCT00877435|BEHAVIORAL|Cognitive behavioral therapy (CBT)|
41104176|NCT03970590|BEHAVIORAL|CTC Intervention|"An integrated peer narrative-based intervention (VIEW \> SELECT \> GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran\] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
41104177|NCT03970590|BEHAVIORAL|Control|6-month HTN management assessment text messages without narrative component
41104178|NCT05292638|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
41443529|NCT04215718|PROCEDURE|fistulectomy and wound closure|anal fistula was excised with both openings and the wound was closed
41104179|NCT05292638|DRUG|Botox®|Intramuscular injection Botox®
41104180|NCT03121950|OTHER|Dance|The primary intervention is a dance class
41104181|NCT03121950|OTHER|Music|the secondary intervention is listening to live music
41104182|NCT03612791|DRUG|Atezolizumab|atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles.
41104183|NCT03612791|RADIATION|Radiotherapy|"* Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~* Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~* Total duration of RT (including brachytherapy) should be ≤ 55 days."
41104184|NCT03612791|DRUG|Cisplatin|"* Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5).~* Not administered: during the interval between EBRT and brachytherapy, or during brachytherapy, or if radiotherapy is interrupted."
41104185|NCT01413594|BEHAVIORAL|HABIT|90 hours of bimanual training over 3 weeks in a day camp environment
41104186|NCT00241540|DRUG|Esomeprazole|
41104187|NCT02702921|DEVICE|Surgeon's 'standard of care' stapler|
41104188|NCT02702921|DEVICE|Ethicon Powered Vascular Stapler|
41104189|NCT02534441|OTHER|Skin patch test|
41104190|NCT03261596|DRUG|Mebendazole|Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
41104191|NCT06269536|OTHER|HRV biofeedback|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
41104192|NCT01137266|DEVICE|TENS|TENS
41104193|NCT03889678|DIAGNOSTIC_TEST|Color flow doppler|Color flow doppler proximal to vein insertion site to document flow
41104194|NCT02182414|DRUG|BI 207127 NA (TF-I)|200 mg tablet
41104195|NCT02182414|DRUG|BI 207127 NA (TF-II)|400 mg tablet
41104196|NCT02182414|DRUG|BI 207127 NA delayed release|400 mg tablet
41104197|NCT02182414|DRUG|BI 207127 NA extended release (10% HPMC)|400 mg tablet
41443530|NCT05726383|DRUG|Iscador*P|Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
41443531|NCT05420896|OTHER|Manual Therapy|Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
41443532|NCT00003980|DRUG|BIBX 1382|
41443533|NCT02006212|PROCEDURE|If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period|
41443534|NCT06452472|DEVICE|I-LIMB|Use of a multi-grip myoelectric hand prosthesis (I-LIMB after using a standard myoelectric prosthesis)
41443535|NCT00859534|DRUG|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
41104198|NCT02182414|DRUG|BI 207127 NA extended release (15% PEO)|400 mg tablet
41104199|NCT02182414|DRUG|BI 207127 NA extended release (20% HPMC)|400 mg tablet
41104200|NCT03787875|PROCEDURE|periodontal treatment|In the study group, periodontal scaling and root planning treatment of the 4 quadrants was performed for two consecutive weeks without the use of antiseptics or antibiotics, and the patients were instructed in oral hygiene, including both brushing techniques and proximal hygiene.
41104201|NCT06537544|OTHER|Comprehensive Rehabilitation Program|Pelvic Floor Muscle Strengthening Exercises Core Strengthening Exercises Breathing Exercises Patient education about bladder diary Postural education
41104202|NCT06537544|OTHER|Conventional Pelvic Floor Training|Kegels exercises in different body positions
41104203|NCT01227707|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
41104204|NCT01227707|DRUG|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
41104205|NCT01227707|RADIATION|Radiation therapy|Total dose of 45 Gy over 38 days
41104206|NCT01227707|PROCEDURE|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
41104207|NCT01227707|DRUG|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
41104208|NCT01227707|DRUG|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
41104209|NCT01227707|DRUG|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
41104210|NCT06069986|PROCEDURE|coronary artery bypass graft CABG|comparison between onpump and off pump CABG
41104211|NCT02197299|DIETARY_SUPPLEMENT|L-carnitine|
41104212|NCT02197299|DIETARY_SUPPLEMENT|Placebo|
41104213|NCT03829410|DRUG|Onvansertib|Onvansertib orally.
41104214|NCT03829410|BIOLOGICAL|Bevacizumab|Bevacizumab intravenously.
41104215|NCT03829410|DRUG|FOLFIRI|FOLFIRI intravenously.
41104216|NCT03925194|DRUG|Anakinra|Application of Anakinra once daily for 28 days
41104217|NCT00242190|DRUG|oxaliplatin|
41104218|NCT00242190|DRUG|gemcitabine|
41104219|NCT00242190|PROCEDURE|radiation therapy|
41104220|NCT02722356|DRUG|Oxytocin|Oxytocin administered per oxytocin group or standard practice group (see above)
41104221|NCT04490148|DEVICE|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
41104222|NCT04490148|DEVICE|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
41104223|NCT04490148|BEHAVIORAL|Nurse Respiratory Health Coaching (NRHC)|"Nurse Respiratory Health Coaching - The NRHC intervention follows the teamlet model described by Bennett et al. \[Bennett2010\], made up of the research coordinator who performs respiratory testing, and the nurse practitioner who coaches using the GROW (goals, realities, options, wrap-up) model."
41104224|NCT00092716|DRUG|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
41104225|NCT00092716|DRUG|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
41104226|NCT01352507|DRUG|Tadalafil|Administered Orally
41104227|NCT01352507|DRUG|Sildenafil|Administered Orally
41443536|NCT02697747|OTHER|Education|Educational intervention in the use of ultrasound to identify landmarks
41443537|NCT05167487|DRUG|Cisplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
41443538|NCT05167487|DRUG|Carboplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
41443539|NCT04797663|DEVICE|Nd-YAG laser|laser hair removal device
41443540|NCT04797663|DRUG|TCA 20%|chemical peel
41443541|NCT05382715|DRUG|Ozanimod|Specified Dose on Specified Days
41443542|NCT02656186|DIETARY_SUPPLEMENT|Pre-intervention|First 2-weeks : keeping routine dietary habit
41443543|NCT02656186|DIETARY_SUPPLEMENT|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
41443544|NCT02907983|DRUG|Stellate Ganglion Block Injection with Bupivicaine|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
41443545|NCT02907983|DRUG|Saline injection|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
41443546|NCT04576234|DIETARY_SUPPLEMENT|entral feeding|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest)
41443547|NCT03370263|DRUG|Benlysta|Benlysta will be administered intravenously or subcutaneously.
41443548|NCT04632550|PROCEDURE|Circumferential pulmonary vein isolation(CPVI) group|"1. PVI(pulmonary vein isolation) will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Evaluation of procedure time, radiofrequency ablation time~4. Evaluation of the complication after the procedure.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
41443549|NCT04632550|PROCEDURE|Posterior box isolation(POBI) group|"1. PVI will be performed using a radiofrequency catheter~2. Additional POBI(Posterior box isolation) is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
41443550|NCT04632550|PROCEDURE|POBI+Anterior linear ablation(AL) group|"1. PVI, POBI will be performed using a radiofrequency catheter~2. Additional AL(anterior linear) ablation is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
41443551|NCT04032418|BIOLOGICAL|Pembrolizumab|Given IV
41443552|NCT00859872|DRUG|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
41443553|NCT00859872|DRUG|haloperidol|haloperidol IM injection (5-20mg/d)
41443554|NCT06560463|DEVICE|Access to Dexcom G7 CGM Data|Eligible patients will undergo Continuous Glucose Monitoring using the Dexcom G7
41443555|NCT00840866|DRUG|cefprozil|500 mg Tablet
41443556|NCT00840866|DRUG|Cefzil®|500 mg Tablet
41443557|NCT02960295|DEVICE|1-Self-monitoring of blood glucose|"Self-monitoring of blood glucose 4 times daily: fasting and 1-hour after each meal. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Intervention: At every office visit and at every telephone (virtual) visit the patient's physician will review glucose results and make adjustments in diet, activity, or medication to bring glucose into desired range."
41443558|NCT02960295|DEVICE|2-Self-weighing|Self-weighing on electronic scale at least once a week. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Consultation with the nutritionist will be obtained for women gaining in excess of or less than that indicated for her pre-pregnancy BMI, per Institute of Medicine (IOM) standards.
41443559|NCT02960295|DEVICE|3-Self-checking of blood pressure|Self-checking of blood pressure at least weekly with sphygmomanometer. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Patients with elevated blood pressure will be requested to come to Obstetrics Triage immediately for further assessment.
41443560|NCT02960295|DEVICE|4-Checking fetal heart rate|Patient will record her fetus' heart rate with a Doppler device at least once weekly. The patient will immediately report to Labor and Delivery for any fetal heart rate below 100 beats per minute or greater than 160 beats per minute over a 10 minute observation period.Those reporting a fetal heart rate outside of the normal range will be requested to come to ObstetricTriage for further assessment.
41443561|NCT02960295|PROCEDURE|5-Visits with caregivers|Telephone visits will alternate with in-office visits.Those failing to keep appointments will be contacted and reappointed at a mutually convenient time.
41443562|NCT02157974|DRUG|Byetta 5Mcg Pen Injection|10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola
41443563|NCT02647463|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|
41443564|NCT04435197|DRUG|Pembrolizumab Injection|Pre-operative Pembrolizumab+chemoradiotherapy
41104228|NCT05163756|DRUG|DW1903|q.d. PO, DW1903 + Placebo of DW1903-R1
41104229|NCT05163756|DRUG|DW1903-R1|q.d. PO, Placebo of DW1903 + DW1903-R1
41104230|NCT04370782|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
41104231|NCT04370782|DRUG|Azithromycin|Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
41104232|NCT04370782|DRUG|Zinc Sulfate|Zinc sulfate 220mg once daily for 5 days
41104233|NCT04370782|DRUG|Doxycycline|Doxycycline 200 mg once daily for 5 days
41443565|NCT01956591|DRUG|Oxybutynin|All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
41443566|NCT03625115|BEHAVIORAL|Family Navigator (FN)|The intervention will be a modified Patient Navigator model, that we will refer to as a Family Navigator (FN) model, that will engage, inform, and assist participating parents to follow-through with the process of EI referrals and services. Eligible children randomized to the intervention arm will be provided with services from a FN. The FN will maintain contact with the family, the child's primary care provider, and Early Intervention staff, if applicable, throughout the duration of the study.
41443567|NCT04050709|BIOLOGICAL|PD-L1 t-haNK|PD-L1 t-haNK Suspension for Infusion
41443568|NCT04690985|BEHAVIORAL|Dietary behaviour change|The intervention consists of dietary guidance and behaviour change techniques, which will last for 15 weeks. The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive the dietary behaviour change guidance in 6 times face-to-face meetings and weekly telephone calls. They will also be asked to take daily food diary.
41443569|NCT04690985|OTHER|Social contact|The control group will not be required any dietary changes. The investigator will contact with the control group with the same frequency and numbers of experimental group. But the chat topic will not be related to sarcopenic obesity or dietary guidance.
41443570|NCT03047343|OTHER|Retrospective data extraction in medical files|Retrospective data extraction in medical files
41443571|NCT06558617|DIAGNOSTIC_TEST|SARC-F Questionnaire|The SARC-F scale consists of five components: strength, walking assistance, rising from a chair, stair climbing, and falls. These elements were selected to reflect changes in health status related to the effects of sarcopenia. Scores on the SARC-F scale range from 0 to 10, composed of five domains, assesses strength, walking assistance, raising from a chair, stair climbing and falls. Each domain score ranges from 0-2. A SARC-F score of ≥4 was considered abnormal. The Thai-version SARC-F questionnaire has been validated in Thai older adults.
41443572|NCT06558617|DIAGNOSTIC_TEST|Calf Circumference Measurement|Calf circumference was measured using a nonelastic tape measure while the participant was standing with relaxed legs. The tape was placed snugly and flat around the widest part of the calf, parallel to the floor. According to the AWGS 2019 criteria, calf circumferences were considered abnormal if they were less than 34 cm for males and less than 33 cm for females.
41443573|NCT06558617|DIAGNOSTIC_TEST|SARC-CalF Questionnaire|This questionnaire integrates the SARC-F and calf circumference as a trigger for case finding. If the calf circumference is below the cut-off value, 10 points are added to the SARC-F score for evaluation. The SARC-CalF score ranges from 0 to 20, with a score of ≥11 considered abnormal for sarcopenia screening.
41443574|NCT04188392|DRUG|Pimavanserin|pimavanserin tablet
41443575|NCT00911274|DRUG|Mycophenolate Mofetil|250 mg Capsule
41443576|NCT00911274|DRUG|CellCept®|250 mg Capsule
41443577|NCT03162315|PROCEDURE|Freeze all|
41443578|NCT03264339|BEHAVIORAL|Small Step Program|The Small Step intervention program has three alternating treatment foci (Hand use, Mobility, Communication) divided into five different steps, each lasting for 6 weeks (in total 30 weeks).
41443579|NCT00905658|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
41443580|NCT00905658|PROCEDURE|standard follow-up care|Patients undergo standard monitoring
41443581|NCT06307639|DIAGNOSTIC_TEST|Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).|Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).
41443582|NCT03874143|OTHER|mHealth Intervention for Quality of Care|Does use of a specially equipped smartphone make a difference in the diagnosis and treatment by RCom of malaria, pneumonia and diarrhea in children aged 2 to 59 months
41443583|NCT00777972|DRUG|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
40752107|NCT04621760|BEHAVIORAL|HIV Prevention Decision Support Tool (DST)|The tool is founded on principles of decision-science and developed in a systematic manner including pilot testing. The tool will present HIV prevention information through a tablet in the clinical setting. The decision support tool will address barriers to PrEP delivery, including 1) limited client knowledge about PrEP, 2) limited time to educate patients in busy clinics, 3) women's lack of knowledge of their own HIV vulnerability, and 4) hesitancy of women to initiate discussions about PrEP with providers due to judgmental attitudes and stigma. Also, the tool emphasizes the highly variable and individual nature of baseline risk.
41443584|NCT02302079|DRUG|ASP8232|oral capsule
41443585|NCT02302079|DRUG|ranibizumab|intravitreal (IVT) injection
41443586|NCT02302079|DRUG|Placebo|oral capsule
40752108|NCT04621760|BEHAVIORAL|Standard Counseling|Participants in this arm will receive usual care.
40752109|NCT00985790|BIOLOGICAL|Influenza vaccine GSK2321138A|Intramuscular injection
40752110|NCT00985790|BIOLOGICAL|Fluarix™|Intramuscular injection
40752111|NCT01229111|DRUG|cediranib maleate|Given PO
41443587|NCT02302079|OTHER|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
40752112|NCT01229111|DRUG|oxaliplatin|Given IV
41443588|NCT06111248|OTHER|Training|Staff training on the use of surgical plethysmographic index (SPI) state entropy (SE) and train-of-four (TOF) intraoperative monitors and AoA software.
41443589|NCT00395694|DRUG|lamictal|anti-epileptic drug
41443590|NCT04523168|DEVICE|The Neovasc Reducer™ System|A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.
41443591|NCT00875524|BIOLOGICAL|CYD dengue vaccine serotypes (1, 2, 3, 4).|0.5 mL, Subcutaneous
41443592|NCT00875524|BIOLOGICAL|Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide|Each at 0.5 mL, Subcutaneous, respectively
41104234|NCT04176458|DEVICE|Methacetin Breath Test (MBT)|The hypothesis is that MBT CPDR 20 in the Fontan patient is abnormal as a result of alterations in liver perfusion, liver cell metabolic capability and transhepatic resistance secondary to hemodynamics unique to the Fontan as well as end-organ liver damage. Due to lack of robust biomarkers or other risk stratification schemes, we aim to determine whether there is prognostic value in hepatic MBT CPDR 20 in the Fontan patient.
41104235|NCT04993963|OTHER|Cycle Ergometery Training (Prehabilitation)|Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion \<13 on Borg scale 20-30 min/session/day (intermittent of exercise 2-3 mint, followed by 1-2 min of active recovery) Cool down (5 minutes) AROM +Body stretch
41104236|NCT04993963|OTHER|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
41104237|NCT01193153|DRUG|Placebo|monthly by i.m. injection for 15 months
41104238|NCT01193153|DRUG|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
41104239|NCT04991974|BEHAVIORAL|Patient Navigation|A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).
41104240|NCT04991974|DRUG|Buprenorphine|"Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study).~Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community."
41104241|NCT05079061|DRUG|Misoprostol|sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
41104242|NCT03782558|PROCEDURE|Surgical transection of transverse ligament|Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
41104243|NCT05765591|OTHER|Balneotherapy and aquatic exercises|Information has already been included in arm/group descriptions
41104244|NCT04162366|DRUG|Aprocitentan 25 mg|Tablet, oral use once daily
41104245|NCT04162366|DRUG|Placebo|Matching placebo tablet, oral use once daily
41104246|NCT05575895|DIETARY_SUPPLEMENT|Ingestion of the energy drink (Red Bull®)|Ingestion of 250 ml of the energy drink (Red Bull®)
41104247|NCT05575895|DIETARY_SUPPLEMENT|Ingestion of mineral water|Ingestion of 250 ml of mineral water (Minalba®)
41104248|NCT05339971|OTHER|block perforation|The bone block used for lateral bone augmentation will be perforated several times.
41104249|NCT04586712|DRUG|Active CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 2000mg/30mL (high).
41104250|NCT04586712|DRUG|Vehicle Control (Placebo)|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
41104251|NCT04369534|DRUG|Clopidogrel|Adjusting clopidogrel dosage according to platelet reactivity results during 12 months after PCI
41104252|NCT04369534|DRUG|Ticagrelor|Administration of standard dose of ticagrelor during 12 months after PCI
41104253|NCT00930813|DEVICE|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
41104254|NCT00930813|DEVICE|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
41104255|NCT04808635|OTHER|no intervention, this is a cross sectional questionnaire based study.|no intervention, this is an observational cross sectional study
41104256|NCT03069781|DRUG|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of Estrance
41104257|NCT03069781|DRUG|Polycose|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
41104258|NCT00906035|DRUG|Dipyridamole 200mg and Aspirin 25mg bid:|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
41104259|NCT00906035|DRUG|Dipyridamole 200 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
41104260|NCT00906035|DRUG|Aspirin 25 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
41104261|NCT05165030|GENETIC|Blood Sample|clinical-radiological evaluation, genetic analysis by whole exome sequencing and constitution of a bio-collection
41104262|NCT01085279|DEVICE|Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)|1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
41104263|NCT01085279|DRUG|Modified Kligman's formula (Triple topical therapy)|Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
41104264|NCT00325923|BEHAVIORAL|Decision aid|
41104265|NCT03563391|OTHER|New Infant Formula|New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.
41104266|NCT05022342|OTHER|alpelisib plus fulvestrant|Prospective observational study. There is no treatment allocation. Patients administered alpelisib plus fulvestrant, that have started before inclusion of the patient into the study will be enrolled.
41104267|NCT02944955|DRUG|BLEX 404 Oral Liquid|"BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks."
41104268|NCT04795089|PROCEDURE|Shunt surgery|Patients are evaluated before and after shunt surgery which is a standard intervention in the clinical practice. HI do not undergo intervention.
41104269|NCT01063023|DRUG|Ortho Tri-Cyclen®|Tablets, Oral, 1 Tablet, once daily
41104270|NCT01063023|DRUG|BMS-650032|Tablets, Oral, 600 mg, BID
41104271|NCT05304663|DRUG|Onfekafusp alfa|Patients will be treated with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26
40752113|NCT01229111|DRUG|leucovorin calcium|Given IV
41104272|NCT05304663|DRUG|Lomustine|"Arm 1: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (60 mg/m2 and 75 mg/m2) on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Arm 2: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (90 mg/m2 and 110 mg/m2) on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles."
41104273|NCT03143192|COMBINATION_PRODUCT|Micropulse Laser|Aflibercept injection with Micropulse laser.
41104274|NCT03143192|DEVICE|Sham Laser|Aflibercept injection with Sham Laser
41104275|NCT04286165|OTHER|Brief Peer Supported webSTAIR|The BPS webSTAIR program is an online platform where individuals are taught skills in emotion regulation. In this program they will learn how to recognize the emotions they are feeling by assessing their own body language, being attentive to their thought processes, and attempting to replace negative behaviors with positive. Throughout the platform they will engage in written exercises to help them solidify the lessons with their own life experiencing. They will also have the support of peers throughout the program to help them when they need clarification or having a difficult time applying the lesson(s).
41104276|NCT00909363|DRUG|Promacta|"WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests.~they will also have diagnostic blood testing prior to initiating treatment"
41104277|NCT00909363|DIAGNOSTIC_TEST|blood drawing in patients with WAS|blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
41104278|NCT00909363|DIAGNOSTIC_TEST|blood drawing in healthy controls|blood will be drawn once in healthy children as controls for platelet parameters
41104279|NCT04479540|RADIATION|Angiography scanner|systematic thoracic angiography scanner to diagnose pulmonary embolism and additional blood sample (hemostasis exploration)
41104280|NCT00480805|DRUG|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
41104281|NCT00480805|DRUG|Comparator : ramipril /Duration of Treatment : 8 Weeks|
41104282|NCT00518362|DRUG|TW|TW,120 mg/d
41104283|NCT06165926|DRUG|15% hypertonic dextrose|"The solution is prepared with 3 ml of 50% Dextrose, 1 ml of 2% xylocaine, and 6 ml of normal saline.~The ultrasound-guided injection of 15% hypertonic dextrose is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with hypertonic dextrose is performed at the fourth weeks. A total of 2 sessions of hypertonic dextrose injections are performed."
41104284|NCT06165926|DRUG|Normal saline|The solution is prepared with 1 ml of 2% xylocaine + 9 ml of normal saline. The ultrasound-guided injection of Normal saline(0.9%) is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with Normal saline is performed at the fourth weeks. A total of 2 sessions of Normal saline injections are performed.
41104285|NCT06165926|OTHER|physical therapy|Under the guidance and supervision of a physical therapist, the patient undergoes physical therapy sessions twice a week for a total duration of 8 weeks. Each session lasts approximately 30 minutes and includes joint activities, stretching, and muscle-strengthening exercises.
41104286|NCT05444179|BEHAVIORAL|Mommies can Eat & Exercise with No Stress (MomEENS)|This intervention involving behaviour modification, incorporates nutrition and physical activity modification. The intervention encourages participants to consume a healthy diet and active lifestyle during postpartum period. For nutrition modification, a general advice on healthy nutrition were given and several nutrients are highlighted which evidenced can reduce postpartum depression. While for physical activity, the mothers are encouraged to do exercise, targeting aerobic, flexibility, and strength type of exercise. The exercise protocol is progressive. During the first month, the participants will be advised to conduct flexibility and strength exercises for 8 repetitions (1 set), at least 3 days per week for both aerobic and flexibility exercise. While during the second month, participants are asked to increase repetitions and frequency of exercises, up to 16 repetitions (2 set) for each flexibility exercise, and conduct exercise at least 5 days per week.
41104287|NCT05341518|PROCEDURE|Subscapularis repair|To complete reverse total shoulder arthroplasty, the surgeon must cut through the subscapularis muscle. In this arm of the study, the muscle will be repaired, rather than left to heal itself.
41104288|NCT03746418|DRUG|Ultrasound Guided Bilateral single shot Erector Spinae Plane Block|Under aseptic technique and after skin infiltration with 3 ml of 2% lidocaine, a 22G, 50-mm, insulated facet type needle (visioplex® - vygon - France) was introduced in plane in a cephalad to caudad direction until (L3) transverse process was hit \[figure1(A)(B)(C)\] and the needle was slightly withdrawn. The confirmation of the correct position of the needle tip was done by injecting 0.5-1 ml of LA. Once confirmed, 20 ml of the drug was administered under vision after confirming negative aspiration of blood. LA distribution was observed in both cranial and caudal directions. This was repeated on the other side also. Twenty minutes later, sensory loss to cold was evident between (T10-T 12) and (L5-S1) vertebral level of the posterior dermatomes and dermatomes of the anterior roots of the spinal nerves (lumbar plexus, upper leg) on both sides without hemodynamic changes. Motor function of the legs was evaluated with a Bromage (0-3) score.
41104289|NCT02057354|BEHAVIORAL|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
41104290|NCT02057354|BEHAVIORAL|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
41104291|NCT05579886|DEVICE|Control Lens|Daily disposable multifocal soft lens with 2 add design (2ADD) for 2 weeks
40752114|NCT01229111|DRUG|fluorouracil|Given IV
40752115|NCT01146444|OTHER|UV A and B irradiation|UV irradiation
40752116|NCT06243926|OTHER|Sperm selection for ICSI|Sperm selection for ICSI is a critical step to ensure the use of viable and healthy sperm for fertilization in vitro. The goal is to choose a sperm that has the best chance of resulting in a successful pregnancy.
41443593|NCT00663663|BEHAVIORAL|Telephone-Delivered Intervention 1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
41443594|NCT00663663|BEHAVIORAL|Telephone-Delivered Intervention 2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
41443595|NCT00905606|DRUG|Topiramate Tablets|
41443596|NCT00905606|DRUG|Topamax® Tablets|
41443597|NCT03520972|DRUG|PB-119 75ug|60 eligible patients will be included in this group
41443598|NCT03520972|DRUG|PB-119 150ug|60 eligible patients will be included in this group
41104292|NCT05579886|DEVICE|Test Lens|Daily disposable multifocal soft lens with 3 add design (3ADD) for 2 weeks
41104293|NCT01181375|OTHER|Tumour Biopsies and Blood Sampling|Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
41104294|NCT04454892|OTHER|Amyotrophic lateral sclerosis|AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3
41104295|NCT04431934|DIETARY_SUPPLEMENT|PROBIOTIC|"Participants assigned to the probiotic arm will receive 2 sachets of Vivomixx® dissolved in 50 L of warm water (according to the manufacturer indications) every 12 h orally or through a nasogastric tube (in this case the tube will be flushed with 50 mL of water after the administration). The probiotic will be started 24 h after the last dose of NAA and will be administered for 14 consecutive days. Each sachet of Vivomixx® contains a combination of 4 Lactobacillus (L. paracasei 24733, L. acidophilus 24735, L. delbrueckii ssp bulgaricus 24734, L. plantarum 24730), 3 Bifidobacteria (B. brief 24732, B. longum 24736, B. infantis 24737), and Streptococcus thermophilus 24731 at a concentration of 450 billion (45x1010) live lyophilized bacteria per sachet."
41104296|NCT04431934|DIETARY_SUPPLEMENT|FMT REGIMEN|The FMT preparation will be administered as 2 doses, once a week, of 14-17 capsules per dose. Each dose (14-17 capsules) will contain the fecal microbiota equivalent to 50 gr of stools from a healthy donor. If the patient is carrying a nasogastric tube, the content of capsules will be decapsulized (\~27 gr of powder), diluted in 50 mL of water and passed through it, followed by the administration of 50 mL of water to flush the tube. The first dose will be administered 24 h after the last dose of NAA and the second dose one week later. Whenever possible, the two doses of FMT will be originated from the same donor. According to our data done by flow cytometry and bacterial culture in three replicates, each absorbate capsule contains approximately 1.12x1010 live bacteria.
41104297|NCT05035654|DRUG|LYR-220 Design 1|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
41104298|NCT05035654|DRUG|LYR-220 Design 2|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
41104299|NCT05035654|DRUG|Bilateral sham procedure control|Bilateral sham procedure control
41104300|NCT05073718|DRUG|Low-dose acetylsalicylic acid|In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.
41104301|NCT05073718|DRUG|Placebo|Placebo
41104302|NCT06080373|BEHAVIORAL|PROBECO|"Spanish participants in the active control group will undergo the PROBECO program, designed by the Spanish Penitentiary Agency for various violent crimes. It aims to eradicate criminal behavior, reduce recidivism, and teach social skills. It has four phases.~German participants will be placed in social therapeutic facilities for compulsory psychotherapy focused on relapse prevention."
41104303|NCT06080373|BEHAVIORAL|Formulation-based cognitive behavioral therapy|"The CBT program includes these core modules:~A. ADHD Psychoeducation: Provides information on ADHD characteristics, neurobiology, treatments, and their efficacy. Shared with a significant other if available.~B. Planning Skills and Distraction Management: Teaches time management, task prioritization, and distraction control techniques.~C. Cognitive Restructuring: Based on Ellis' Rational Behavioral Emotive Therapy, it helps participants identify and modify irrational thoughts for better emotional regulation.~D. Maintenance of Treatment Gains: Reviews progress, identifies risk factors, and develops action plans for post-treatment challenges."
41443599|NCT03520972|DRUG|PB-119 200ug|60 eligible patients will be included in this group
41443600|NCT03520972|DRUG|placebo|60 eligible patients will be included in this group
41443601|NCT02334722|DRUG|Levetiracetam|
41443602|NCT03531021|BEHAVIORAL|Heart healthy intervention|Intervention consists of educational modules, goal setting and brainstorming around strategies and barriers, and a series of heart healthy challenges such as walking a certain number of steps or eating healthy foods a certain number of times in a week.
41443603|NCT03146156|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.
40925288|NCT05424783|OTHER|Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate|The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.
41443604|NCT03692663|DRUG|TABP EIC|A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
40925289|NCT00443196|PROCEDURE|MiCK Assay|Physician determined treatment
41104304|NCT02388139|PROCEDURE|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
41104305|NCT02388139|PROCEDURE|coronarography|
41104306|NCT02388139|PROCEDURE|coronary angioplasty|
41104307|NCT02388139|PROCEDURE|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
41104308|NCT02388139|PROCEDURE|body composition monitoring|using Fresenius device
41104309|NCT05001906|BEHAVIORAL|Exercise group|The exercise program comprises static and dynamic breathing exercises, muscle stretching exercises and muscle strength exercises, exercises to strengthen the abdominal wall muscles, exercises to strengthen the thigh muscles - quadriceps femoris (lat. musculus quadriceps femoris), to strengthen gluteal muscles, exercises to increase pelvic mobility, exercise to improve circulation, as well as pelvic floor muscle training with relaxation techniques.
41104310|NCT01926002|DRUG|Low-Dose MK-8351|Single administration of low-dose MK-8351.
41104311|NCT01926002|DRUG|High-Dose MK-8351|High-Dose MK-8351 administered as a single inhaled dose.
41104312|NCT01926002|DRUG|Placebo to MK-8351|Single-Dose Matching placebo to high-dose or low-dose MK-8351.
41104313|NCT05478772|DRUG|CTP-543|12 mg on Day 1 and Day 7
41104314|NCT05478772|DRUG|Fluconazole|200 mg once daily on Days 3 through to Day 8
41104315|NCT06200636|DEVICE|Use of the PELSA System for dISF extraction|Dermal interstitial fluid will be extracted using the investigational device, for further analysis.
41104316|NCT05542953|DRUG|[18F]APN-1607|In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
41104317|NCT00462410|OTHER|counseling intervention|
41104318|NCT00462410|PROCEDURE|psychosocial assessment and care|
41104319|NCT00135135|DRUG|Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid|See Detailed Description.
41104320|NCT00135135|PROCEDURE|Radiation therapy, Surgery, Peripheral Stem cell transplant|See Detailed Description.
41104321|NCT05756998|DEVICE|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) (classic technique)|During CS , placement of CuT380 IUD at the top of the uterine fundus with ring forceps or manually; before closing the uterine incision, the strings were placed in the lower uterine segment. If the cervix was closed, dilatation from above with ring forceps or manually. Strings passed through the cervix with ring forceps, then checking that IUD remains at the fundus of the uterus prior to closing the uterine incision. The surgeon took a good care not to include IUD strings within the sutures. Six weeks postpartum; Patients will be questioned for any symptoms of complications or side effects. Pelvic examination (per speculum) and transvaginal ultrasound will be performed. Patient satisfaction will be assessed: pain using (VAS score), missed threads.
41104322|NCT05756998|DEVICE|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) ( New technique)|During CS, the plunger will be removed, the introducer remains in place and the arms of the IUD were released to be in a transverse position. The introducer will be inserted in the cervical canal through the uterine incision, threads might be shortened if needed or if couldn't be advanced into the cervical canal, The introducer containing the IUD will be then pushed upwards , towards the uterine fundus.The IUD will be placed at the uterine fundus and the IUD will be stabilized at its fundal position by grasping the fundus between the thumb anteriorly and the other fingers posteriorly. The uterine incision was closed while the introducer is in situ , then the introducer will be removed vaginally at the end of CS. Six weeks postpartum; Patients will be followed as in the classic technique group.
41104323|NCT05756998|PROCEDURE|cesarian section|Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment \& the fetus is extracted , followed by the placenta \& membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis \& closure of the abdomen in layers .
41104324|NCT03168204|BEHAVIORAL|Tailored care and support|Offering tailored care and support whereby the competences, strengths and resources of the older person are taken into account.The intervention will be an enhancement of usual care and will depend on the availability of the municipality, and could be formal (i.e., home care) or informal (e.g. activities of an older adult's association).
41104325|NCT03904199|DRUG|Insulin|Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
41104326|NCT06141980|DRUG|DWP16001 0.3 mg|DWP16001 0.3mg, Tablets, Orally, Once daily
41104327|NCT01792830|DRUG|Metformin|"Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c \< 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin."
41104328|NCT01792830|DRUG|Glargine insulin|"Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.~Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.~Patients with an HbA1c \> 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose."
41443605|NCT03692663|BIOLOGICAL|Cyclophosphamide|Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
41104329|NCT01792830|DRUG|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
41104330|NCT06335836|BEHAVIORAL|social isolation|social isolation (0≤LSNS-6≤12)
41104331|NCT03911245|OTHER|Retrospective study. Analyze of data in medical records|Retrospective study. Analyze of data in medical records
40925290|NCT05510271|OTHER|White Noise|"Orhan OSMAN's song Don't Let Your Baby Cry-2 from the Kolik album was used."
41104332|NCT01544569|GENETIC|DNA analysis|
41443606|NCT03692663|BIOLOGICAL|fludarabine|Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
41443607|NCT03227835|OTHER|intravascular iodinated contrast material administration|Evaluation of the consequences of the protocol change to not giving prophylaxis to patients with an eGFR \>29mL/min/1.73m2
41443608|NCT03856580|BEHAVIORAL|Alternative long-acting PrEP injection strategies|"Participants in the two intervention groups will complete injection procedures (e.g., self-injection, injection by healthcare providers at drop-in clinics) to determine if this could facilitate improved adherence to an inert version of long-acting cabotegravir injections"
41443609|NCT03856580|BEHAVIORAL|mHealth adherence app|"Participants in the two experimental arms will be given a smartphone application, designed to facilitate adherence (this app will be developed during earlier phases of the study using in-depth interviews and design session groups)"
41443610|NCT05260697|OTHER|sexual counselling with plissit model|sexual counselling
41104333|NCT01544569|GENETIC|fluorescence in situ hybridization|
41104334|NCT01544569|GENETIC|gene expression analysis|
41104335|NCT01544569|GENETIC|gene mapping|
41104336|NCT01544569|GENETIC|microarray analysis|
41104337|NCT01544569|GENETIC|polymerase chain reaction|
41104338|NCT01544569|GENETIC|protein expression analysis|
41104339|NCT01544569|OTHER|laboratory biomarker analysis|
41443611|NCT05363059|DRUG|Hypoglycemic drugs|drug
41443612|NCT05363059|PROCEDURE|Bariatric surgery|surgery
41104340|NCT01544569|OTHER|medical chart review|
40925291|NCT05510271|OTHER|Yakson Touch|In order to transfer the Ki energy to the baby, he took a deep breath and gathered the universal energy in his palms, intending the baby's well-being and healing. The researcher applied the Yakson touch by covering the abdomen and chest of the newborn with his right hand (dominant hand) while the newborn was in the supine position, and supported the baby's back and hips with his left hand.
41104341|NCT05853224|DEVICE|Crosslinked Hyaluronic Acid (CLHA) Hydrogel with and without Lidocaine|The injection should be performed at variable depth of the skin (dermal or subdermal), depending on the area to be treated and on the product variants, in accordance to the IFU of the IPs
41104342|NCT01740570|DRUG|Cabazitaxel|"Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.~Phase II: Maximum tolerated dose from Phase I."
40925292|NCT03487601|OTHER|transcranial direct current stimulation|Active treatment will consist of a mild electrical current (2mA) administered via saline-soaked sponge electrodes placed along the intact scalp for 30 minutes a day for five days.
41104343|NCT06553573|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Parasternal Block and Recto-Intercostal Fascial Plane Block:Superficial PSB is performed bilaterally with the patient in the supine position using a high-frequency linear USG probe. The probe is inserted longitudinally 2cm lateral to the sternal border to visualize the T2T4 intercostal space and identify the pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is administered between the pectoralis major and intercostal muscle. Additionally, a Recto-Intercostal Fascial Plane Block is performed bilaterally with a high-frequency linear USG probe. The probe is inserted 2-3cm lateral to the xiphoid to visualize the rectus abdominis muscle and the 6th-7th cartilages. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique, and 1-2ml of saline is injected. After spreading to the target plane is observed, 20ml of 0.25% bupivacaine is administered.
41133284|NCT04348669|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2 times/week for 6-weeks. The yoga sessions will be delivered one-on-one. The sessions will include 5-7 minutes of breathing exercises, 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
41133285|NCT03805243|DEVICE|test of sensors for somnonaute device|test of sensors
41443613|NCT03070119|DRUG|Tofersen|Participants will receive a loading dose regimen followed by maintenance dosing.
41443614|NCT00304538|DRUG|very low dose (VLD) glucagon|
41443615|NCT06559085|PROCEDURE|Laproscopic posterior mesh rectopexy (Wells or LPMR)|After complete rectal mobilization, a mesh is inserted between the sacrum and the posterior rectum, sutured into the rectum, and fixed to the promontory. The mortality rates ranged from 0% to 1.2%, and recurrence rates ranged from 0% to 11% There was an overall improvement in continence (74%-100%), with conflicting results regarding constipation. New-onset constipation in 5% to 44% of patients was reported
41443616|NCT06559085|PROCEDURE|Laparoscopic lateral mesh rectopexy (Orr-Loygue)|This procedure involves complete mobilization of the rectum with two mesh strips sutured laterally to the rectal wall on both sides, and they were suspended to the promontory. There are several studies on this procedure using a laparoscopic approach. Lechaux et al. performed laparoscopic Orr-Loygue rectopexy in 35 patients. Incontinence improved in 27% of patients, and constipation improved in 19% but worsened in 27%. The recurrence rate was 3% (1/35) after a mean follow-up of 36 months. A study on 46 patients with laparoscopic Orr-Loygue procedure with posterior mobilization found a significant reduction in incontinence score after 1 year, but there were no changes in the use of laxatives. The recurrence rate was 4% after a median follow-up of 1.5 years
41443617|NCT05457452|DEVICE|Knee Brace|Installation of an angle-adjustable knee brace, used after ACL reconstruction performed by an orthopedic specialist or orthopedic PPDS with the first week the angle locked at 00, in the second week the angle 0-900, in the third week the angle 0-1200, and the fourth week the angle of flexion full. Braces are used except for physical therapy according to the rehabilitation protocol in the first week.
41133286|NCT03805243|DEVICE|test of sensors for uronaute device|test of sensors
41133287|NCT03805243|DEVICE|test of sensors for toconaute device|test of sensors
41133288|NCT03805243|DEVICE|test of sensors for neuronaute device|test of sensors
41104344|NCT06553573|OTHER|Parasternal Block and Erector Spinae Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2cm lateral to the sternal border to identify the T2T4 intercostal space, pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is applied between the pectoralis major and intercostal muscle. Additionally, an erector spinae plane block is performed with a high-frequency USG probe. Erector spinae plane block is performed under general anesthesia, in the lateral position, under USG guidance, after sterilization, by inserting a needle between the deep surface of the erector spinae muscle and the transverse process with an in-plane approach in the craniocaudal direction. If no air or blood is seen in the aspiration, a 2mL serum test dose is applied to this area and a total of 20mL of 0.25% bupivacaine is injected bilaterally to perform an erector spinae plane block.
41104345|NCT04117451|OTHER|Propolis|Investigating the impact of propolis mouthwash on oral and cardiovascular health
41104346|NCT01649791|DRUG|lenalidomide|Given orally
41104347|NCT01649791|OTHER|laboratory biomarker analysis|Correlative study
41104348|NCT01649791|PROCEDURE|lymph node biopsy|Correlative study
41104349|NCT01649791|PROCEDURE|bone marrow aspiration|Correlative study
41104350|NCT01649791|OTHER|pharmacological study|Correlative study
41104351|NCT01649791|OTHER|flow cytometry|Correlative study
41104352|NCT02892162|PROCEDURE|Additional LAAW linear ablation|Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
41104353|NCT04355130|DIETARY_SUPPLEMENT|Iron, vitamin B12 and acid folic supplementation|Vitamin and iron supplementation is administered one-two weeks before donation, and consist of iron supplementation (i.v. infusion of 20 mg/Kg ferric carboxymaltose in saline 100 ml), s.c. injection of 1 mg of vitamin B12 and acid folic 5 mg/die per os until day +15 post BM donation. BM collection is carried out by the transplant team and a maximal dose of 20-22 ml/Kg of the donor body weight is collected under general anesthesia (induction with fentanyl 1-3 mcg/Kg, Propofol 2-3 mg/Kg, rocuronium 0,6 mg/Kg and mantenaince with sevoflurane 0,8 MAC). Noninvasive cardiac output, blood pressure and hemoglobin monitoring are carried out during the entire procedure and in in the recovery room using the ClearSight™ system (Edwards Clinical) and the Radical Pulse co oxymeter (Masimo). After discharge from the hospital, donors will be revaluated on day + 7 after BM collection, and blood tests will be repeated in outpatient setting.
41104354|NCT00234442|DRUG|Iressa (Gefitinib)|
41104355|NCT02219919|OTHER|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
41104356|NCT02219919|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
41104357|NCT03991949|OTHER|Experimental Infant Formula|Formula fed Ad libitum
41104358|NCT00500500|DRUG|EGb 761® (Tanakan®)|
41104359|NCT02927132|BEHAVIORAL|Expressive Writing|Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
41104360|NCT02927132|BEHAVIORAL|Personalized Normative Feedback|"PNF approaches use information designed to correct normative misperceptions to reduce heavy drinking. Three pieces of information are necessary when providing personalized normative feedback: information about a student's own drinking, information about the student's perceptions of others' drinking, and information about others' actual drinking. The presentation of this information is designed to change students' perceptions of normal drinking by exposing their misperceptions of the norm as well as by comparing their behavior with normal behavior."
41104361|NCT03119363|DEVICE|AYO light glasses (Experimental)|The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.
41104362|NCT03119363|DEVICE|AYO light glasses (Comparator)|The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
41104363|NCT02787694|OTHER|Factor Targeted Walking Training|Individuals walk on a treadmill for 30 minutes while exposed to either endurance, balance, challenge, strength, or speed focused approaches
41104364|NCT02787694|DEVICE|treadmill|
41104365|NCT01062880|BEHAVIORAL|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
40925293|NCT03487601|OTHER|sham transcranial direct current stimulation|Sham stimulation will involve brief delivery of current in a manner that does not result in changes in neuronal firing patterns, but that is perceived as active treatment by participants.
41133289|NCT03805243|DEVICE|test of sensors for cardioskin device|test of sensors
41104366|NCT00694681|BEHAVIORAL|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
41104367|NCT05216419|DRUG|Cholecalciferol|"Since the concentration of D-mac 30,000 IU in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.~In the case of the control group, there is no drug to be taken."
41104368|NCT01137799|DRUG|JNJ-39393406|50mg nanosuspension (sort of liquid formulation) once daily (single dose)
41104369|NCT01137799|DRUG|placebo|Once daily (single dose)
41104370|NCT01137799|DRUG|JNJ-39393406|200mg nanosuspension (sort of liquid formulation) once daily (single dose)
41104371|NCT01137799|DRUG|JNJ-39393406|100mg nanosuspension (sort of liquid formulation) once daily (single dose)
41104372|NCT01137799|DRUG|JNJ-39393406|10mg nanosuspension (sort of liquid formulation) once daily (single dose)
41104373|NCT01137799|DRUG|JNJ-39393406|30mg nanosuspension (sort of liquid formulation) once daily (single dose)
41104374|NCT03255642|DRUG|Melatonin 2mg|4 weeks of 2mg prolonged release melatonin (Circadin)
41104375|NCT03255642|DRUG|ClonazePAM 0.5 MG|4 weeks of 0.5mg clonazepam (Rivotril)
41104376|NCT02619266|OTHER|Acupuncture|Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
41104377|NCT02619266|OTHER|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
41104378|NCT02619266|DRUG|Megestrol Acetate|Megestrol Acetate 160mg tablet
41104379|NCT02619266|DRUG|Placebo(Megestrol Acetate)|Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
41104380|NCT04767828|DRUG|PYRROTINI|CAPECITABINE: 800 mg/m2 twice daily, taken orally within 30 minutes after meal (one in the morning and one in the evening, 12 hours apart, equal to a daily dose of 1600 mg/m2, with one dose in the morning and one dose in the morning) .
41104381|NCT04767828|RADIATION|Brain radiation therapy|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition.
41104382|NCT04590924|PROCEDURE|Hip arthroscopy|Patients that had hip arthroscopic surgery 5 years ago will be invited for 5 year follow up. The surgical procedures consisted of femoral osteoplasty, labral refixation and acetabular osteoplasty
41104383|NCT00290849|DRUG|Bivalirudin|
41104384|NCT03939819|DEVICE|ViSiGi® 3D suction calibration device|ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
41104385|NCT03939819|DEVICE|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope is an illuminated optical, slender and tubular instrument (a type of borescope) used in esophagogastroduodenoscopy.
41104386|NCT01134562|DRUG|Placebo|Single IV injection.
41104387|NCT01134562|DRUG|Etelcalcetide|Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
41104388|NCT03003988|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate (6.0 g) + dextrose (0.5 g)
41104389|NCT03003988|DIETARY_SUPPLEMENT|Creatine nitrate|Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
41104390|NCT03003988|DIETARY_SUPPLEMENT|Placebo|Placebo (6.5 g dextrose)
41104391|NCT04554823|BEHAVIORAL|Health Education|Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression
41104392|NCT04554823|BEHAVIORAL|Physical Exercise|Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
41104393|NCT03489265|DRUG|Eluxadoline 100 mg|100 mg capsule-shaped tablet by mouth taken twice per day
41104394|NCT03489265|OTHER|Placebo|Matching capsule-shaped placebo tablets taken by mouth twice per day
41104395|NCT02834182|BEHAVIORAL|IRMf|
41104396|NCT02834182|BEHAVIORAL|Mini International Neuropsychiatric Interview|
41104397|NCT02834182|BEHAVIORAL|Positive And Negative Syndrom Scale|
41104398|NCT02834182|BEHAVIORAL|Young Mania Rating Scale|
41104399|NCT02834182|BEHAVIORAL|Hamilton Depression Scale|
41104400|NCT06405555|DRUG|Midodrine Oral Tablet|Exposure to up to 5 days of midodrine (or until hospital discharge) in hospital at escalating doses with the following protocol: 2.5 mg po TID x 1 day, 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, 10 mg po TID x 2 days.
41104401|NCT01677104|DRUG|GLP-1|GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
41104402|NCT01677104|DRUG|Placebo|
41104403|NCT04245501|OTHER|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related. Youth receive feedback aimed to reduce interpretation bias.
41104404|NCT04245501|OTHER|Interpretation Control Condition (ICC)|"Computerized control condition in which youth see word-sentence pairs personalized to their anxiety symptoms. Youth indicate whether these are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
41104405|NCT03621761|BEHAVIORAL|Telephone-based Cognitive Behavioral Therapy|"Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue."
41104406|NCT03621761|DRUG|Modafinil|Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).
41104407|NCT01316978|DRUG|Ibuprofen|A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
41104408|NCT01316978|DRUG|Ibuprofen|A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
41104409|NCT01316978|DRUG|Ibuprofen|A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
41104410|NCT00044928|DRUG|Piperacillin/Tazobactam|
41104411|NCT01021865|DRUG|Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere|"GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump"
41104412|NCT03478501|BEHAVIORAL|Decision Aid|This intervention is a tablet based Lethal Means Decision Aid with proposed use to augment lethal means counseling in emergency departments for patients at risk of suicide.
41104413|NCT00241930|BEHAVIORAL|Integrating drug treatment into HIV services|
41104414|NCT04915599|DEVICE|Cooral® mouth cooling device (MCD)|Cooral® mouth cooling device (MCD) to prevent oral mucositis (QM) in patients undergoing radiation therapy for head and neck malignancies
41104415|NCT04058743|DEVICE|TKA with nickel free components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
41104416|NCT04058743|DEVICE|TKA with standard cobalt chromium components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
41104417|NCT01025869|DEVICE|Cinatra™ Corolimus Eluting Coronary Stent System|Stent implantation
41104418|NCT01071967|OTHER|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
41104419|NCT04765163|DEVICE|Intelligent Operating Handle|Intelligent Operating Handle
41104420|NCT00762606|PROCEDURE|Phacoemulsification cataract extraction surgery|Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
41104421|NCT00762606|PROCEDURE|Small incision cataract surgery|Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
41104422|NCT03311958|DRUG|Nivolumab, IV, 240 mg|Patients would be given an infusion of 240 mg nivolumab over 30 min
41104423|NCT04617717|PROCEDURE|Invasive cardiac electrophysiological study and ablation therapy|Invasive cardiac electrophysiological study with cathecholamine provocation and pacing procedures, as well as standard 3D mapping and PVC ablation
41104424|NCT04617717|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Standard ergometer bicycle test
41104425|NCT04617717|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with cine-imaging and late-gadolinium enhancement
41104426|NCT04617717|DIAGNOSTIC_TEST|Holter monitoring|24h 5 lead or 12 lead ECG recording
41104427|NCT04617717|DIAGNOSTIC_TEST|Transthoracic echocardiography|2D echocardiography
41104428|NCT04617717|DIAGNOSTIC_TEST|Coronary angiography|Conventional invasive coronary angiography or CT angiography as indicated
41104429|NCT05578352|OTHER|Add oral hyppoglycemia drug|Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose
40752117|NCT04249739|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda ™ (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
40752118|NCT01867554|GENETIC|gene analysis|gene analysis
41104430|NCT05578352|OTHER|Add GLP-1 receptor agonist|Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose
41104431|NCT05578352|OTHER|Change insulin|Change premix insulin to long-acting insulin
41104432|NCT06262919|DRUG|Tafinlar/Mekinist|There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.
41104433|NCT02837497|OTHER|ICU-RESUS CPR Improvement Bundle|"1. Point-of-care CPR training~2. Post-cardiac arrest educational debriefings"
41104434|NCT00309452|BEHAVIORAL|Cognitive Behavioral Group Therapy|once per week
41104435|NCT00309452|BEHAVIORAL|Cognitive remediation|as needed
41104436|NCT00309452|DRUG|Medications|Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
41104437|NCT00309452|BEHAVIORAL|MFG|Multi-Family psychoeducation Group based on the model published by McFarlane et al.
41104438|NCT00309452|BEHAVIORAL|Assertive case management|Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.
41104439|NCT00309452|OTHER|Treatment as Usual in the community|Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
41104440|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day"
41443618|NCT06225531|OTHER|Autobiographical Memory Based Intervention|"The intervention involves 6 sessions of therapeutic input based around autobiographical memories. Memory based activities will broadly follow the 5 stages outlines in the broad-minded affective coping (BMAC) procedure, but with a focus on specific memories. It will follow the following structure:~Session 1 - Introduction and Familiarisation Session 2 - Neutral Memories Session 3 - Positive Memories Session 4 - Memories of Moves Away from Suicidality Session 5 - Practice of Preferred Memory (from Sessions 2-4) Session 6 - Continued Practice and Post-Intervention Planning"
41104441|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day"
41104442|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day"
41104443|NCT06321913|DRUG|IBI343 combined with IBI308|IBI343 Specifications: 100 mg/bottle Approval method: TBD Q3W intravenous infusion (IV) sintilimab Specifications: 100mg (10ml)/bottle Afghan way: 200 mg Q3W IV infusion
41104444|NCT02618317|DRUG|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
41104445|NCT02618317|DRUG|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
41104446|NCT02618317|DRUG|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
41104447|NCT06026358|DRUG|Tirbanibulin|subjects receive 2,5 mgTirbanibulin in 250 mg ointment with daily administration of one single sachet on the left hand and 250mg ointment placebo on the right hand for 5 d in a single-blinded manner.
41104448|NCT02850055|OTHER|Conventional Physiotherapy|"1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home."
41104449|NCT02850055|OTHER|Specific Manual Therapy|"1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home.~4. Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles."
41104450|NCT00730002|PROCEDURE|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
41104451|NCT00730002|PROCEDURE|Magnetic resonance imaging|MR spectroscopy
41104452|NCT00730002|PROCEDURE|MRA|MRA of the brain
41104453|NCT00730002|PROCEDURE|MRA|
41443619|NCT05679024|DRUG|Apixaban 2.5 milligram Oral Tablet|Oral Tablet
41443620|NCT01685762|DRUG|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
40752119|NCT04772430|RADIATION|snow globe|"Control group; The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure.~Experimental group; The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure."
41104454|NCT00730002|PROCEDURE|diffusion Imaging|MRA of the Brain
41104455|NCT00730002|PROCEDURE|perfusion imaging.|MRA of the brain
41133290|NCT00071799|DRUG|Azacitidine|Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
41443621|NCT01199718|DRUG|CX-4945|CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
41443622|NCT05457985|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.
41443623|NCT05457985|BEHAVIORAL|Full Prolonged Exposure|Treatment will follow the standardized PE manual. Participants will have 60 minute sessions once a week for eight weeks During these sessions, participants will practice in vivo, imaginal, and emotional exposure as well as continue these exposure exercises every day at home.
41443624|NCT05457985|BEHAVIORAL|Clinician Supported PTSD Coach App|This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.
41443625|NCT02703194|DRUG|Prednisone|Prednisone:A starting dose of 0. 5-0. 8mg/(kg\*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.
41443626|NCT02703194|DRUG|Leflunomide|Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
41443627|NCT02530333|OTHER|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
41443628|NCT06491797|BEHAVIORAL|Immediate reactivation|Our intervention will be booster measure of the existing PTP elements that will be designed for each unit that has been randomized to the immediate intervention group. The booster will consist in a reactivation through audit and feedback of 2-3 elements of the PTP program. The selection of the elements to boost will be done locally in each unit through a coordinated discussion between representants of the PTP organization and representants of the unit's medical and nursing professionals. This will create an adaptable intervention that will feature selected standards among the list of 36 existing standards. The boost will be performed over 3 months
41443629|NCT02226250|DIETARY_SUPPLEMENT|3 Placebo Beverages|Sugar beverage 2 hr before meal, with meal and 2 hr after meal
41443630|NCT06302335|DRUG|Povidone-iodine|Application of Povidone-iodine to the surgical wound of patients submitted to colorectal resections.
41443631|NCT06302335|DRUG|Saline solution|Application of saline solution to the surgical wound of patients submitted to colorectal resections.
41443632|NCT01334307|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx)|Lung Volume Reduction Coil (LVRC)
41104456|NCT02780947|PROCEDURE|Ventricular tachycardia substrate ablation|"Study protocol~1. Baseline programmed ventricular stimulation performed from the LV~2. High density endocardial LV mapping using CARTO® 3 System~3. Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~4. Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation."
41443633|NCT01334307|DEVICE|Control|Standard of Care
41443634|NCT00798603|BIOLOGICAL|bevacizumab|
41104457|NCT01817036|DIETARY_SUPPLEMENT|Placebo|placebo
41104458|NCT01817036|DIETARY_SUPPLEMENT|Vitamin D|400 IU vitamin D per pill
41104459|NCT01789489|DEVICE|Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)|
41104460|NCT00092833|DRUG|Comparator: ezetimibe|Ezetimibe (MK0653) 10 mg once daily for 3 years.
41104461|NCT05482854|OTHER|Analytical Treatment Interruption (ATI)|"Analytical Interruption of Treatment for 24-48 weeks~ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria"
41104462|NCT01495195|DRUG|High-dose donepezil|Donepezil titrated to 22.5 mg daily
41104463|NCT01495195|DRUG|Low-dose donepezil|Donepezil titrated to 10 mg daily
41104464|NCT01495195|DRUG|Selegiline|Transdermal selegiline, 6 mg daily
41443635|NCT00798603|DRUG|carboplatin|
41443636|NCT00798603|DRUG|pemetrexed disodium|
41443637|NCT03311061|OTHER|DREAMS Curriculum|Teen Pregnancy Prevention Curriculum as described in arm/group description.
41104465|NCT01495195|DRUG|Placebo|microcrystalline cellulose
41104466|NCT02762318|OTHER|Samples With DNA|"After consenting, all subjects have to undergo the following procedures:~Up to 25 ml of blood will be withdrawn. If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside of the cheek to obtain saliva.~A questionnaire will be used to collect information about individual A routine physical exam will be performed. The subject's medical record will be reviewed To well document some of the specific phenotypes and conditions, physicians might take photographs of the affected body area.~For secondary subjects (relatives or family members), normal examination and routine lab tests/ imagining will be done if needed as per the related standard care."
41133447|NCT02515123|DEVICE|Sham E-Motion System|The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
41133448|NCT00275444|DRUG|Tipranavir|
41443638|NCT06559670|OTHER|Blood sampling|- Collection and analysis of blood samples
41443639|NCT00097734|DRUG|ertapenem|
41443640|NCT00235352|DRUG|CX516 (Ampakine)|
41443641|NCT03932058|DRUG|Chemotherapy|all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
41443642|NCT00468455|PROCEDURE|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
41104467|NCT03533036|DEVICE|applied VR headset|Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D\&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
41443643|NCT00975754|DRUG|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
41104468|NCT02130128|DEVICE|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
41104469|NCT00065052|BEHAVIORAL|Behavior modification|
41104470|NCT00538213|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
41104471|NCT00538213|BIOLOGICAL|GSK Bio's Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
41104472|NCT01586780|DIETARY_SUPPLEMENT|Protein drink|Test drink providing 9g protein
41104473|NCT01586780|DIETARY_SUPPLEMENT|Reference meal|Control meal
41104474|NCT05272046|PROCEDURE|Per-oral Endoscopic Myotomy|Therapeutic endoscopy procedure by means of electrocautery surgical tools for treatment of various esophageal conditions such as achalasia or spastic esophageal disorders.
41104475|NCT05272046|DEVICE|Speedboat (Bipolar electrocautery knife)|Use of Creo Medical's Speedboat RS2 knife and generator in performing the POEM procedure for patients presenting with an esophageal motility disorder.
41104476|NCT03354169|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
41104477|NCT05130060|BIOLOGICAL|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Given SC
41104478|NCT05130060|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
41104479|NCT02488317|OTHER|Decision Aid|Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
41443644|NCT00975754|DRUG|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
41104480|NCT05252871|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
41104481|NCT01821586|OTHER|Modified ORS-1|
41443645|NCT00975754|DRUG|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
41443646|NCT00975754|DRUG|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
41104482|NCT01821586|OTHER|Modified ORS-2 (ReSoMal)|
41104483|NCT01821586|OTHER|Modified ORS-3 (Benefibre)|
41104484|NCT05998096|DIETARY_SUPPLEMENT|Caffeine-Based Energy Drink|Caffeine-based energy drink containing 200 mg caffeine
41104485|NCT05998096|DIETARY_SUPPLEMENT|Placebo|Placebo void of all active ingredients
41104486|NCT05061342|OTHER|No experimental interventions 1. Observation; 2. Anticancer treatments, including surgery, systemic therapy, radiotherapy, Chinese traditional medicine, or palliative/supportive care.|Any anticancer or palliative care
41104487|NCT02717299|DEVICE|Verasense|Verasense will collect balancing data on all patients in this trial.
41104488|NCT03175913|DEVICE|vapocoolant spray|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was sprayed using an vapocoolant spray for 10-sec from a distance of 30 cm
41443647|NCT01090791|DEVICE|Flotrac/Vigileo third generation software|Measurement of stroke volume according to the arterial pressure waveform
41104489|NCT03175913|DRUG|local infiltration|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine
41104490|NCT04658615|PROCEDURE|Non-surgical periodontal therapy|A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia
41443648|NCT01090791|DEVICE|Transthoracic echocardiography|Measurement of stroke volume according to the aortic time-velocity integral
41104491|NCT01768676|DRUG|avanafil|100 mg
41104492|NCT01768676|DRUG|Placebo|
41104493|NCT04089046|BEHAVIORAL|TEAM-UP for Teens|TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
41443649|NCT05108948|BEHAVIORAL|Quality of life questionnaires|Oswestry Disability Index Scoliosis Research Society-22R Short Form 36 Health Survey Questionnaire Tobacco, Alcohol, Prescription medication, and other Substance use Core Outcome Measures Index : back and neck
41443650|NCT05108948|PROCEDURE|Radiography|Spinal radiography : full, face, profile
41443651|NCT00398983|DRUG|Decitabine|20 mg/m\^2 IV over 1 hour daily for 5 days
41104494|NCT04089046|BEHAVIORAL|Enhanced Care (EC)|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
41104495|NCT06381492|DEVICE|MRI|MRI using DTI technology
41104496|NCT06381492|DEVICE|Ultrasound (US)|Standard US
41104497|NCT03180905|DEVICE|ImPACT Online/Paper Pencil Tests|Compare ImPACT Online versus Paper and Pencil Neurocognitive Tests
41104498|NCT03180905|DEVICE|ImPACT Online|ImPACT Online will be administered at 2 time points.
41104499|NCT05246956|OTHER|Intradialytic exercise|Intradialytic exercise group
41104500|NCT03656016|DEVICE|Magnetic Resonance Imaging|Phase contrast magnetic resonance imaging technique
41104501|NCT02183246|DRUG|Porfiromycin|
41104502|NCT02183246|DRUG|Placebo|
41104503|NCT02183246|RADIATION|Radiotherapy|
41104504|NCT02925195|DIETARY_SUPPLEMENT|Vitamin D3|cholecalciferol (vitamin D3) 2000 IU capsules daily
41104505|NCT02925195|DRUG|Placebo|
41104506|NCT03108196|PROCEDURE|sigmoid|The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
41104507|NCT03108196|PROCEDURE|ileal|The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
41104508|NCT02770430|BIOLOGICAL|mesenchymal stem cells|MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg
41104509|NCT02770430|DRUG|conventional treatment|"1. Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~2. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
40752120|NCT03426488|BEHAVIORAL|VIP - Västerbotten Intervention Programme|Intervention on CVD (cardiovascular disease) and diabetes
41104510|NCT00269399|DRUG|Rifaximin (Xifaxan)|
41104511|NCT00269399|DRUG|Vancomycin|
41104512|NCT02716649|OTHER|No intervention|
41104513|NCT00612391|PROCEDURE|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
41104514|NCT00612391|PROCEDURE|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
41104515|NCT00397358|DRUG|Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution|
41104516|NCT05987540|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device.
41104517|NCT04447768|DRUG|Obinutuzumab|"Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg"
41104518|NCT04447768|DRUG|Venetoclax|"Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily"
40752121|NCT06493565|DEVICE|Routine endoscopic anastomosis inspection|"The routine care pathway for early detection of anastomotic leakage includes:~* C-reactive protein guided imaging~* Rectoscopy of the anastomosis three to six days after surgery~* Rectoscopy of the anastomosis two to three weeks after surgery"
41104519|NCT00029926|DRUG|2-deoxy-2 [F-18] fluoro-2-d-glucose|
41104520|NCT03643029|DEVICE|Video-laryngoscopy following SAD insertion|Following insertion of a supraglottic airway device (SAD), the placement and performance tests are carried out. If the tests are successful, a video-laryngoscopy will be performed to confirm the placement of the SAD in the hypopharynx.
41104521|NCT03936829|DRUG|Cyclophosphamide|Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
41104522|NCT05951218|OTHER|inhibition technique|Inhibition treatment consists of applying progressive pressure with the finger until resistance is felt. The patient should feel discomfort but not pain. They should stop when they consider that the trigger point has been sufficiently relaxed. All the techniques should last less than 5 minutes. Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator
41104523|NCT05951218|OTHER|placebo|"The osteopath will perform a light touch on 4 areas for 30 seconds each time. The trigger point area must be lightly touched, followed by the upper part of the pectoralis major, the elbow and finally the anterior part of the opposite glenohumeral region.~Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator with a palpatory pressure measurement tool. A proposition of 1N will be proposed to have a very light touch, without activating the C-tactile sensors."
41104524|NCT04035512|OTHER|Expressive writing|"The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004."
41104525|NCT02952053|DEVICE|MTrP Group|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
41104526|NCT02952053|DEVICE|TB Group|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
41104527|NCT00628940|RADIATION|PET images with 18F-fluoromethylcholine|sequential PET images with 18F-fluoromethylcholine
41104528|NCT02937792|DRUG|intrathecal 15 mg bupivacaine|spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
41104529|NCT02742896|OTHER|Erectile dysfunction|"The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.~The changes of cognitive function by using validated assessment form-The Montreal Cognitive assessment (MoCA) 1 year after conversion to sinus rhythm."
41104530|NCT05773612|OTHER|Rock Steady Boxing Class|Rock Steady Boxing is a non-contact fitness program designed specifically for people with Parkinson's Disease.
41104531|NCT01717794|PROCEDURE|Thunderbeat technology|
41104532|NCT01717794|PROCEDURE|Standard bipolar electrosurgery|
41104533|NCT02470936|BEHAVIORAL|Lifestyle intervention|Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
41104534|NCT03888755|DRUG|Icatibant|Participants will receive icatibant 30 mg SC injection in the abdominal area.
41104535|NCT02555631|BEHAVIORAL|lifestyle|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
41104536|NCT04076202|DEVICE|Cementless Vanguard DD RP|Patients treated with the Cementless Vanguard DD RP knee implant
41104537|NCT03042520|OTHER|Observation only|
41104538|NCT04648436|OTHER|Early neurosurgical hematoma evacuation|Early neurosurgical hematoma evacuation (preferably within 2 hours)
41104539|NCT04648436|OTHER|Conservative treatment (best medical management)|Conservative treatment (best medical management) on the ICU or ward
41104540|NCT04983745|DRUG|Combination drug|niraparib and dostarlimab combination
41104541|NCT06435260|DRUG|Camrelizumab+chemotherapy|"Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy:~AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles.~Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles."
41104542|NCT06435260|RADIATION|hypofractionated radiotherapy|Hypofractionated radiotherapy: pGTV:40Gy/5F, PTV≥25Gy/5F.
41104543|NCT01884389|OTHER|Patient Navigation|Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
40752122|NCT00930176|BIOLOGICAL|Human Coagulation FACTOR X|Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
41104544|NCT04249388|OTHER|No Intervention, just observation|No Intervention, just observation
41104545|NCT03234621|OTHER|ventilator setting during one-lung ventilation|providing various tidal volumes according to the groups with constant PEEP
41104546|NCT00434018|BEHAVIORAL|Wheelchair Skills Training|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
41104547|NCT00434018|BEHAVIORAL|Basic Health Education|Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
41104548|NCT01942967|OTHER|Echocardiography|"Measurement of:~* Left ventricular output (LVO).~* Right ventricular output (RVO).~* Assessment of the Mesenteric Artery Flow."
41104549|NCT01942967|OTHER|Near Infrared Spectroscopy Monitoring|Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
41104550|NCT02637908|BEHAVIORAL|Mindfulness training|6-weeks of group-based mindfulness training for parents
41104551|NCT00597350|DIETARY_SUPPLEMENT|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
41104552|NCT05679830|DRUG|Cannabidiol|Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
41133449|NCT01595269|OTHER|eHealth education|In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
41104553|NCT02309580|DRUG|Ibrutinib|Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
41104554|NCT04555954|OTHER|surveys and questionnaires|The study practised the physical activity levels of healthy adults aged 18-65 years in Turkey during the novel type of coronavirus pandemic by the International Physical Activity Questionnaires-Short Form (IPAQ-SF). Communication with the participants of the study was conducted via online survey software (Google Forms) and social media communication application (WhatsApp).
41104555|NCT00197236|BIOLOGICAL|Havrix™|2 intramuscular injections, 6 months apart
41104556|NCT00197236|BIOLOGICAL|Infanrix™|1 intramuscular injection
41104557|NCT00197236|BIOLOGICAL|ActHIB™|1 intramuscular injection
41104558|NCT03006341|DRUG|Dabigatran etexilate|observed upto 12 months
41104559|NCT03006341|DRUG|Warfarin|Observed upto 12 months
41104560|NCT01876511|DRUG|MK-3475|MK-3475 10 mg/kg every 14 days
41104561|NCT02722668|DRUG|Fludarabine|Both Arms: 30 mg/m\^2 IV over 1 hour Day -6 to Day -2
41104562|NCT02722668|DRUG|Cyclophosphamide|Arm 1: 50 mg/kg IV over 2 hours Day -6
41104563|NCT02722668|DRUG|MMF|"Both Arms:~Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning Day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute graft versus host disease (GVHD). (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, do not stop MMF."
41104564|NCT02722668|DRUG|Sirolimus|"Both Arms:~Adult Dosing: Sirolimus will be administered starting at Day -3 with 8-12 mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines. In the absence of acute GVHD sirolimus may be tapered starting at Day +100 and eliminated by Day +180 post-transplantation.~Pediatric Dosing: Sirolimus will be administered starting on Day -3 with an oral loading dose of 10 mg followed by maintenance dosing of 2.5 mg/m\^2/day (Maximum total daily dose of 4mg) as per institutional guidelines. Target serum concentration goals are 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines."
41104565|NCT02722668|RADIATION|TBI|Both Arms: 200 cGy on Day -1
41104566|NCT02722668|BIOLOGICAL|Umbilical cord blood cell infusion|Both Arms: Day 0
41104567|NCT02722668|BIOLOGICAL|ATG|Arm 2: 15 mg/kg IV every 12 hours Day -6 to Day -4
41104568|NCT00610688|DRUG|Prenatal Vitamin|Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
41104569|NCT00610688|DRUG|Cholecalciferol (Vitamin D3)|Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
41104570|NCT00610688|DRUG|Cholecalciferol (Vitamin D3)|Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
41104571|NCT00244855|OTHER|pharmacological study|Correlative studies
41104572|NCT00244855|BIOLOGICAL|rituximab|Given IV
41104573|NCT00244855|DRUG|dexamethasone|Given IV
41104574|NCT00244855|OTHER|laboratory biomarker analysis|Correlative studies
41104575|NCT00464672|BIOLOGICAL|Influenza virus vaccine|Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
41104576|NCT00464672|BIOLOGICAL|Comparator influenza vaccine|Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
41104577|NCT00978237|DRUG|EFV|one pill QD VO.
41104578|NCT00978237|DRUG|LPV/r|2 pills QD VO
41104579|NCT04270604|OTHER|Biological sample collection|Biological sample collection for biobanking and research
41104580|NCT05498337|OTHER|calcium hydroxide|Dental pulp medicament material
41104581|NCT05498337|OTHER|MTA|Dental pulp medicament material
41104582|NCT05498337|DEVICE|Diode Laser|Device used in pulp therapy
41104583|NCT03045419|PROCEDURE|gadoxetic acid-enhanced liver MRI|liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
41443652|NCT05672784|PROCEDURE|GNB plus standard analgesia|When patients are in supine position with a pillow under the popliteal fossa, we will target points next to superior medial, superior lateral, and inferior medial genicular arteries to block the superior medial, superior lateral, and inferior medial branches of genicular nerve. For identification, we will use color Doppler near the periosteal areas (the junctions of the epicondyle with the shafts of the femur and tibia, accordingly). using a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) positioned parallel to the shaft of the long bones in the legs, the needle will be inserted ( in plane technique in the long-axis view) and a 2.5 mL of bupivacaine (5%) will be injected at each target points.standard analgesia will be given post-operativelly (paracetamol 1 gm/ three times a daily and meloxicam (15 mg)once a day)
41104584|NCT02809300|BIOLOGICAL|blood collection|
41104585|NCT03709693|DEVICE|SternaLock Blu|Sternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.
41104586|NCT00908947|DEVICE|PTA followed by placement of LifeStent® Vascular Stent|PTA followed by placement of LifeStent® Vascular Stent
41104587|NCT04301687|PROCEDURE|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
41104588|NCT04301687|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
41104589|NCT00335023|OTHER|Red blood cell transfusion|At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
41104590|NCT00466414|DEVICE|Polycaprolactone Scaffold|
41104591|NCT06552390|PROCEDURE|Cardiac Rehabilitation|"HRN4HTx is a phase 1 rehabilitation intervention protocol for post-heart transplant focused on the physical exercise component, and an educational plan regarding risk factors and safety criteria. The intervention protocol and its assessments are implemented by the team's rehabilitation nurses, always safeguarding the protective isolation required for these patients. The physical training protocol is divided into five stages of progressive levels of intervention. The protocol was defined following FITT parameters, international recommendations, and an integrated teaching program aimed at the therapeutic regimen exercise area. The frequency of intervention sessions is 7 days a week, twice a day (average of 13 sessions per week) throughout the hospitalization.~The intensity was defined according to Borg's modified scale of subjective perception of exertion (SPE), which must be maintained at less than 5."
41104592|NCT04448418|OTHER|web based survey|Assess specific health care needs for the transpopulation during the COVID-19 outbreack using a newly created questionnaire and some validated questionnaries (Impact of Event Scale-Revised, BECK Depression Inventory and the Self-rated Health SF-12)
41104593|NCT02260310|OTHER|Weizhong and Huantiao|
41104594|NCT02260310|OTHER|A-shi point|
41104595|NCT02559258|DRUG|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
41104596|NCT02559258|DRUG|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
41104597|NCT02559258|DRUG|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
41104598|NCT02559258|DRUG|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
41104599|NCT02559258|DRUG|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
41104600|NCT02606409|DRUG|Dexmedetomidine|Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
41104601|NCT02606409|DRUG|Propofol|Propofol sedation at a starting dose of 10-70 µg/kg/hour.
41104602|NCT03651713|BEHAVIORAL|GLU+EX|Subjects will complete 45 minutes of recumbent cycling at 60-65% of age-predicted maximal heart rate five times over seven days while ingesting a 75g glucose beverage three times daily.
41104603|NCT03651713|DIETARY_SUPPLEMENT|GLU|Subjects will consume a 75g glucose beverage three times daily over a seven-day period.
41104604|NCT05042193|OTHER|SARS-CoV-2|Observational
41104605|NCT02621593|DEVICE|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
41104606|NCT01161719|BEHAVIORAL|parent training|Behavioral management skill training
41104607|NCT04374708|DIAGNOSTIC_TEST|fMRI|fMRI: body morph test and neurocognitive testing
41104608|NCT03355495|PROCEDURE|Colonoscopy - Position Change|Colonoscopy is the gold standard for detecting precancerous lesions. We are proposing that changing positions will provide better visualization for detecting such lesions. We will test our intervention of patients positioned in the Right Lateral Decubitus Position to the gold standard of Left Lateral Decubitus Positioning, hypothesizing better visualization in the right lateral decubitus position.
41104609|NCT04910932|OTHER|Breathing Exercises|Breathing exercises including diaphragmatic breathing, thoracic expansion and breathing control exercises
41104610|NCT04910932|OTHER|Information on COVID-19|"Information about COVID-19 based on the advices in COVID-19 advice for the public section of World Health Organization website."
41104611|NCT04941924|PROCEDURE|Intraductal Radio-Frequency Ablation|"The electrode employed in this study is the STARmed ELRA™ (Endo Luminal Radiofrequency Ablation) electrode; this is a CE marked device. The selected electrode will be connected to the VIVA™ Combo generator (also a CE marked device) and advanced over the guide wire.~The power of the generator should be set at either 7 or 10 W depending on the electrode used per manufacturer instructions. An ablation should then be applied at a temperature of 70 to 80℃ for 2 minutes. For longer length strictures or stent occlusions, the RFA probe is withdrawn from proximal to distal in a step by step fashion in respect to the access method used."
41133450|NCT05364840|DRUG|STI-1558|Orally available protease inhibitor capsule
41104612|NCT04941924|DEVICE|Biliary Stent Placement|Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.
41104613|NCT05349097|DRUG|SAD IMG-004 30mg|Each participant will be randomized to receive a single oral dose of 30mg IMG-004
41104614|NCT05349097|DRUG|SAD IMG-004 100mg|Each participant will be randomized to receive a single oral dose of 100mg IMG-004
41104615|NCT05349097|DRUG|SAD IMG-004 200mg|Each participant will be randomized to receive a single oral dose of 200mg IMG-004
41104616|NCT05349097|DRUG|SAD IMG-004 400mg|Each participant will be randomized to receive a single oral dose of 400mg IMG-004
41104617|NCT05349097|DRUG|SAD IMG-004 600mg|Each participant will be randomized to receive a single oral dose of 600mg IMG-004
41104618|NCT05349097|DRUG|SAD Placebo 30mg|Each participant will be randomized to receive a single oral dose of 30mg matching placebo
41104619|NCT05349097|DRUG|SAD Placebo 100mg|Each participant will be randomized to receive a single oral dose of 100mg matching placebo
41104620|NCT05349097|DRUG|SAD Placebo 200mg|Each participant will be randomized to receive a single oral dose of 200mg matching placebo
41104621|NCT05349097|DRUG|SAD Placebo 400mg|Each participant will be randomized to receive a single oral dose of 400mg matching placebo
41104622|NCT05349097|DRUG|SAD Placebo 600mg|Each participant will be randomized to receive a single oral dose of 600mg matching placebo
41104623|NCT05349097|DRUG|MAD IMG-004 50mg|Each participant will be randomized to receive daily oral dose of 50mg IMG-004 for 10 days
41104624|NCT05349097|DRUG|MAD Placebo 50mg|Each participant will be randomized to receive daily oral dose of 50mg matching placebo for 10 days
41104625|NCT05349097|DRUG|MAD IMG-004 150mg|Each participant will be randomized to receive daily oral dose of 150mg IMG-004 for 10 days
41104626|NCT05349097|DRUG|MAD Placebo 150mg|Each participant will be randomized to receive daily oral dose of 150mg matching placebo for 10 days
41104627|NCT05349097|DRUG|MAD IMG-004 300mg|Each participant will be randomized to receive daily oral dose of 300mg IMG-004 for 10 days
41104628|NCT05349097|DRUG|MAD Placebo 300mg|Each participant will be randomized to receive daily oral dose of 300mg matching placebo for 10 days
41104629|NCT05349097|DRUG|FE IMG-004 150mg|A single dose of IMG-004 at 150 mg dose level will be administered to the participants in fed and fasted states
41104630|NCT00243399|DRUG|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
41104631|NCT05971355|DEVICE|LimpiAD cream 2,5% plus|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
41133451|NCT05364840|DRUG|Placebo|Placebo product capsule
41104632|NCT05971355|OTHER|Vehicle|"Vehicle of LimpiAD cream 2.5 % plus which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus cream but without the HAc-40 component."
41104633|NCT05971355|OTHER|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
41104634|NCT03972813|BEHAVIORAL|Broadened information about cancers|Caregivers receive information that HPV causes more than just cervical cancer.
41104635|NCT03972813|BEHAVIORAL|Information about STDs|Caregivers learn that HPV is an STD.
41104636|NCT03972813|BEHAVIORAL|Information about infectious disease|Caregivers learn that HPV is infectious (but information that it is an STD is omitted).
41104637|NCT03972813|BEHAVIORAL|Recommendation for children 12 years old|Caregivers are prompted to get their child vaccinated when the child is 12 years old.
41104638|NCT03972813|BEHAVIORAL|Recommendation for children 18 years old|Caregivers are prompted to get their child vaccinated when the child is 18 years old.
41104639|NCT03972813|BEHAVIORAL|Standard age information|Caregivers are given information about when the HPV vaccination can be given in China, but no additional recommendations.
41104640|NCT03972813|BEHAVIORAL|Cervical cancer|Caregivers are told that HPV causes cervical cancer.
41104641|NCT03972813|BEHAVIORAL|Blank information about communicability|Caregivers are not given any information on how HPV is spread.
41104642|NCT06416202|DEVICE|Advanced hybrid closed loop insulin pump|All groups will receive comprehensive diabetes education and extensive carbohydrate counting training. Continuous glucose monitoring (CGM) will be conducted using the Guardian 4 sensor or Dexcom G6 for the intervention group depending on the type of pump used. fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
41104643|NCT06416202|OTHER|Open Loop Insulin Delivery system|the control group will continue using their current CGM device. Data on glycemic control, hypoglycemic events, and patient satisfaction will be collected before and throughout Ramadan. Additionally, fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
41104644|NCT04059237|BEHAVIORAL|Web based decision aid intervention|Decision aid tool (website) to assist young adult female cancer survivors in making decisions and preparing for family-building after cancer.
41104645|NCT02655380|DRUG|Ketamine 1|Anesthesia induction is performed with 1 mg ketamine.
41104646|NCT02655380|DRUG|Ketamine 2|Anesthesia induction is performed with 2 mg ketamine.
41104647|NCT02655380|DRUG|Remifentanil|After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
41104648|NCT03319589|DIETARY_SUPPLEMENT|Supplement|locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
41104649|NCT04285762|OTHER|LVEEA|lymphaticovenous end-to-end
41104650|NCT04285762|OTHER|LVESA|lymphaticovenous end-to-side
41104651|NCT04285762|OTHER|LVSEA|lymphaticovenous side-to-end
41104652|NCT05671094|BEHAVIORAL|Prehabilitation|Physical, mental, stress reducing and dietary prehabilitation programme, 4 to 2 weeks before surgery
41104653|NCT06031194|OTHER|Non-Interventional Study|Non-interventional study
41104654|NCT04282304|BEHAVIORAL|Preoperative usual care|"Usual care during the preoperative preparation for bariatric surgery consists of:~* Endocrinologist work-up and follow-up, with at least 2 consultations;~* Dietary advice, provided during the endocrine consultation or dietician consultation~* Psychological counselling with the patient's usual psychiatrist (at least 2 consultations~* Physical activity and nutrition are encouraged, but entrusted to the patient's freedom of choice. Weight loss, or at least, weight stabilization, is recommended before the surgery, without initiating a specific behavioural procedure."
41104655|NCT04282304|BEHAVIORAL|Preoperative intensive behavioral lifestyle intervention|"The intensive behavioral lifestyle intervention program takes place over 4 weeks of 5 days. It includes:~* Rehabilitation to physical exercise every morning~* Therapeutic cooking sessions; during these sessions, the patients prepare the day's meals under the supervision of a nutritionist~* Psychological counselling~* One swimming session per week~* One relaxation session~* Regular physical activity (aerobics, work-up)~* Individual entertainment with the physiotherapist physician and discussion groups~* Weight, BMI and waist circumference control at the end of each week."
41104656|NCT00003604|BIOLOGICAL|aldesleukin|
41104657|NCT05818306|DRUG|BL-001|Live biological product BL-001
41104658|NCT05818306|DRUG|Placebo|Placebo
41104659|NCT05719818|DRUG|biphosphonates|Initiation of bisphosphonate therapy
41104660|NCT05719818|PROCEDURE|Dental care|Surgical dental care
41104661|NCT03241654|PROCEDURE|flow trigger|The flow trigger will be adjust during the pressure assist ventilation.
41104662|NCT02306564|DRUG|Cabergoline|given to patients at high risk for OHSS
41133452|NCT00362219|OTHER|Placebo|Gel with no active ingredient.
41104663|NCT05292599|OTHER|Experimental|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
41104664|NCT05292599|OTHER|Control|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
41104665|NCT04461418|DRUG|Glucocorticoid therapy|The study intervention is defined as treatment with either prednisone or dexamethasone as palliative therapy for the control of neurological symptoms; patients with symptomatic brain metastases with a requirement for glucocorticoid therapy will be treated with an available, standard-of-care immune checkpoint inhibitor regimen.
41104666|NCT04178109|DRUG|Dexketoprofen/tramadol (27mg/75mg)|Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h
41104667|NCT04178109|DRUG|Tramadol hydrochloride|Patients in group B received IV tramadol 75mg every 8h
41104668|NCT04178109|DRUG|Paracetamol|Patients in group B received IV paracetamol 1g every 8h
41104669|NCT04178109|DRUG|Ropivacaine Hydrochloride 7.5 MG/ML|300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients
41104670|NCT04178109|DRUG|Levobupivacaine Hydrochloride|10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia
41104671|NCT05722340|PROCEDURE|Non-intubated video-assisted thoracic surgery (NIVATS) for lung biopsy|An epidural anaesthesia associated with mild sedation requiring no ventilation is used.
41104672|NCT05722340|PROCEDURE|Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS) for lung biopsy|Uses a traditional deep anaesthesia and one-lung ventilation
41104673|NCT06183918|DRUG|Tranexamic acid|"1. Group: Gauze soaked with 1000 mg TXA-topical~2. Group: Gauze soaked with 500 mg TXA + 5 cc saline -topical The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration."
41104674|NCT06183918|OTHER|Saline|3. Group: Gauze soaked with 10 cc of saline-topical. The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration.
41104675|NCT04650048|DEVICE|Active HD-tDCS|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
41104676|NCT04650048|DEVICE|Sham HD-tDCS|"Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.~This sham-configuration is intended to mimic the sensory experience of active HD-tDCS."
41104677|NCT00272935|DRUG|Cenestin 0.3 mg Tablets|1 tablet daily
41104678|NCT00272935|OTHER|Placebo|1 tablet daily
41104679|NCT03636919|OTHER|e-BOOK|Patients will filled an e (carnet) included the questionnaire includes the Control of Allergic Rhinitis and Asthma Test (CARAT)
41104680|NCT03611530|DEVICE|Coqun® ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Coqun® ophthalmic solution
41104681|NCT03611530|OTHER|Placebo ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Placebo ophthalmic solution
41104682|NCT01272648|BEHAVIORAL|RePCa A|"Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises"
41104683|NCT04167917|DRUG|NTX-301|oral hypomethylating agent
41104684|NCT00608673|DRUG|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
41104685|NCT00608673|DRUG|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
41104686|NCT04148937|DRUG|LY3475070|Administered orally
41104687|NCT04148937|DRUG|Pembrolizumab|Administered IV
41104688|NCT02939469|OTHER|Physiologic maneuvers|"Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch"
41104689|NCT04853017|DRUG|ELI-002 2P|Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
41104690|NCT05230641|OTHER|No intervention|This is a prospective observational study
41104691|NCT03684096|DIETARY_SUPPLEMENT|non-estrogenic pollen extract PCC-100|non-estrogenic pollen extract PCC-100
41104692|NCT03684096|OTHER|placebo|placebo -non-estrogenic pollen extract PCC-100
41104693|NCT02925000|DRUG|TLC178|TLC178
41104694|NCT02167646|PROCEDURE|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
41104695|NCT03946813|OTHER|Autologous PRP preparation|For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide
40752123|NCT05161156|COMBINATION_PRODUCT|Test Product (tiotropium bromide inhalation powder)|A single dose of test product
41104696|NCT00132717|DRUG|MK0653A (ezetimibe [+] simvastatin)|
40752124|NCT05161156|COMBINATION_PRODUCT|18 mcg of Spiriva (Reference Product)|A single dose of reference product (Spiriva)
41104697|NCT00132717|DRUG|Comparator: atorvastatin|
41104698|NCT00132717|DRUG|Comparator: fluvastatin|
41104699|NCT00132717|DRUG|Comparator: lovastatin|
41104700|NCT00132717|DRUG|Comparator: pravastatin|
41104701|NCT00132717|DRUG|Comparator: rosuvastatin|
41104702|NCT00132717|DRUG|Comparator: simvastatin|
41104703|NCT04008394|GENETIC|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
41104704|NCT00896948|GENETIC|Southern blotting|
41104705|NCT00896948|GENETIC|TdT-mediated dUTP nick end labeling assay|
41104706|NCT00896948|GENETIC|gene expression analysis|
41104707|NCT00896948|GENETIC|protein expression analysis|
41104708|NCT00896948|OTHER|flow cytometry|
41104709|NCT00896948|OTHER|fluorescent antibody technique|
41104710|NCT00896948|OTHER|immunoenzyme technique|
41104711|NCT00896948|OTHER|immunohistochemistry staining method|
41104712|NCT00896948|OTHER|immunologic technique|
41104713|NCT04744779|BEHAVIORAL|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
40752125|NCT05161156|COMBINATION_PRODUCT|Placebo|A single dose of placebo
41104714|NCT01122420|OTHER|Goal-Setting Tool|Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal
41104715|NCT01122420|OTHER|Health Web Sites|Access to publicly available health-related web sites
41104716|NCT00440973|DRUG|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
41104717|NCT00440973|DRUG|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T \& B lymphocyte proliferation
41104718|NCT05455424|DRUG|Niraparib Oral Product|Niraparib (\[3S\]-3-\[4-\[7-(aminocarbonyl)-2H-indazol-2-yl\] phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, and highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate. Niraparib will be supplied in bottles containing 72 capsules of 100 mg. The capsules should be swallowed whole with water. The capsules should not be chewed or crushed and can be taken without regard to meals.
41104719|NCT05455424|OTHER|Active Symptom Control|ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.
40752126|NCT02417480|BEHAVIORAL|Vegan diet|Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
41104720|NCT05826678|DEVICE|Continuous Glucose Monitor|The Clinical Diabetes Educator (CDE) will follow up with the participants at Month 1 after the baseline study visit, at the study midpoint (Month 3), and at the end of the study (Month 6) to check CGM usage, including timely calibration and change adherence. At the end of the study, participants will be invited to complete a survey and participate in virtual interviews to assess changes in their health behaviors and the acceptability of CGM devices.
41104721|NCT05826678|BEHAVIORAL|Finger stick glucose monitoring|Participants will adhere to the standard care protocol and continue self-monitoring of blood glucose through fingersticks as per usual practice\[46\]. The Clinical Diabetes Educator (CDE) will monitor and provide follow-up to the control group participants as per the same schedule followed for the intervention group.
41104722|NCT05298046|DRUG|Experimental: TAVO101|TAVO101 single ascending dose IV infusion.
41104723|NCT05298046|OTHER|Other: Placebo|Placebo single ascending dose IV infusion.
41104724|NCT04933136|DEVICE|Terry2 Band|Hemostasis protocol following radial or cubital approach catheterization using the dual artery hemostasis device Terry2Band.
41104725|NCT05395949|DRUG|conservative treatment|Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
41104726|NCT06261450|DRUG|CBD Oral Solution (eCBD system Target)|Participants receive orally 6 ml of CBD Oral Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD) followed by 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution 3 weeks later.
41104727|NCT06261450|DRUG|Placebo|Participants receive orally 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution followed by 6 ml of Oral CBD Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD)
41104728|NCT03502317|BEHAVIORAL|Physical Prehabilitation|Physical prehabilitation will comprise a personalized, home-based exercise program designed to meet the Cancer Care Ontario Exercise Guidelines for Cancer Survivors. A Registered Kinesiologist (RKin) will complete a baseline physical assessment and prescribe an individualized multi-modal exercise program consisting of 4-5 days of 30+ minutes of aerobic exercise (brisk walking or equivalent to target heart rate of 40-60% of max) and 2-3 days of moderate intensity resistance training of major muscle groups (8-10 repetitions). Participants will be provided with a Fitbit with a heart rate monitor, resistance bands, and a stability ball. Patients will be required to wear their Fitbit and record the number of steps at the end of each day from randomization to 90 days post-surgery.
40752127|NCT02417480|BEHAVIORAL|Follow habitual, usual diet|Participants will be asked to consume their habitual, usual diet.
40752128|NCT02716142|DRUG|rectal misoprostol|patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
41133453|NCT00362219|DRUG|Morphine - .25 mg|gel with 0.25 mg morphine per 100cm2 square of wound.
41133454|NCT00362219|DRUG|Morphine|Gel with 0.75 mg morphine per 100cm2 square of wound.
41133455|NCT00362219|DRUG|Morphine|Gel with 1.25 mg morphine per 100cm2 square of wound.
41104729|NCT03502317|BEHAVIORAL|Psychological Prehabilitation|Psychological prehabilitation will consist of one in-person coaching session of a 'mindfulness' informed intervention conducted by a specially trained RKin. The 40 minute coaching session will include a guided mindfulness session and debriefing. Participants will be asked to practice for 20 minutes twice a day. The patients will be given access to an audio file that will walk them through the 20 minute sessions.
41443653|NCT05672784|PROCEDURE|GNB plus IPACK block plus standard analgesia|IPACK block will be done when the patients in supine position with the knee flexed in 45 degree. using a low frequency transducer at a depth of 3.5-4 cm positioned transversely, 2-3 cm above the patella and over the medial aspect of the knee, we will identify the distal part of the shaft of the femur and the popliteal artery with sliding the transducer proximally and distally (If the two femoral condyles appear first, proximal sliding of the probe, so the humps of the femoral condyles will disappeared and the flat metaphysis will appeared). With advancement of the needle in plane toward the space between the popliteal artery and the femur, 15 ml of bupivacaine 0.5% will be injected. The genicular nerve block will be done as in group G and standard analgesia will be given post-operative as in group G
41443654|NCT05672784|DRUG|standard analgesia (paracetamol and meloxicam)|(paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.
41104730|NCT02961179|BEHAVIORAL|Increased dairy product|
41104731|NCT02961179|BEHAVIORAL|Dietary counselling|
41104732|NCT03987451|DRUG|Semaglutide|Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks
41443655|NCT05685498|BEHAVIORAL|Peer-led HIV self-testing among male fisherfolk in Uganda|This behavioral intervention is centered on the distribution of HIV self-test kits to men through their respective peer-leaders. The investigators have identified up to 18 social network groups; each group is represented by 1-2 peer-leaders who were selected during community engagement meetings. Peer-leaders have received a 3-day training in the HIV self-testing processes, communication skills, existing referral mechanisms, and basic counseling skills. After the training, each peer-leader nominated up to 20 male members (15+ years) from within their social networks who were screened for study eligibility. Eligible male social network members were administered a baseline interview and requested to go to their peer-leaders to obtain their HIV self-test kits.
41443656|NCT03303781|OTHER|Cardiac Rehabilitation|phase II center-based cardiac rehabilitation
41443657|NCT05064891|PROCEDURE|Ultrasound guided injection|Subdeltoid bursa injection, suprascapular nerve block, or posterior glenohumeral joint injection. The participants should only receive one type of the injection mentioned above.
41443658|NCT06561061|DRUG|zinc sulfate|Dispersible (20 mg) tablet
41443659|NCT06561061|DRUG|Placebo|Dispersible tablet
41443660|NCT06626724|PROCEDURE|Liver transplantation|Liver transplantation for patients with hepatocellular carcinoma.
41443661|NCT05598658|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
41443662|NCT05598658|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
41443663|NCT06552780|DEVICE|TENs , ultrasound therapy|effect of high intensity laser versus ischemic compression on myofascial trigger points in the upper trapezius
41443664|NCT06560749|OTHER|Physical Exercise|Measure the impact of physical exercise in the cognition of pacients diagnosed with Bipolar Disorder
41443665|NCT00829790|DRUG|Doxycycline Monohydrate|25 mg 5mL oral dose
41104733|NCT03987451|DRUG|Placebo (semaglutide)|Semaglutide placebo s.c. given once-weekly for 48 weeks
41104734|NCT00666939|DRUG|Gabapentin|Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
41104735|NCT00666939|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
41104736|NCT00666939|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
41443666|NCT00829790|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
41443667|NCT02086474|DRUG|Hyaluronan|Intra-articular injection
41443668|NCT02086474|DRUG|Bupivacaine|Extra-capsular injection
40752129|NCT02716142|DRUG|sublingual misoprostol|patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
41104737|NCT01586299|DRUG|Ibuprofen|10 mg/kg every 8 hours until 24 hours after resolution of fever
41104738|NCT01586299|DRUG|Acetaminophen|15 mg/kg every 6 hours until 24 hours after resolution of fever
41104739|NCT06279819|DIETARY_SUPPLEMENT|gut microbiota-targeted dietary intervention|"The dietary intervention used the dietary intervention plan constructed in Phase 2, on the basis of which each study participant's individual dietary habits, food preferences and economic level were taken into account.~The dietary intervention was delivered by sending fresh ingredients. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings.~Ingredients will be delivered three times a week for a 12-week intervention period. The initial food items to be sent include: 90g of fish rich in omega-3 fatty acids; 300g of vegetables and/or legumes, and 200g of fruits; 30g of nuts; and a cup of probiotic yogurt.~Guided dietary follow-up was conducted through video viewing and WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance by sending videos every two weeks."
41104740|NCT03650322|BEHAVIORAL|Yoga|12 weeks, total of 150 minutes of exercise per week.
41104741|NCT03650322|BEHAVIORAL|Stretching and Toning|12 weeks, total of 150 minutes of exercise per week.
41104742|NCT03650322|BEHAVIORAL|Aerobic Walking|12 weeks, total of 150 minutes of exercise per week.
41104743|NCT03895788|DRUG|niraparib|Niraparib will be administered as a flat-fixed dose (100mg or 200 mg, daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
41104744|NCT03895788|DRUG|Brivanib|Brivanib will be administered as a flat-fixed dose (200mg, 400 mg, or 600 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area.
41104745|NCT06553989|OTHER|osteopatic visceral mobilization|a combination of breathing and visceral mobilizations
41104746|NCT04021381|DIETARY_SUPPLEMENT|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
41104747|NCT04021381|DIETARY_SUPPLEMENT|Placebo|Patient are treated with placebo 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
41104748|NCT03557658|DRUG|Bexagliflozin|Single oral dose of bexagliflozin tablet, 20 mg
41104749|NCT03906734|PROCEDURE|Septal myectomy|Transaortic septal myectomy
41104750|NCT03906734|PROCEDURE|alfieri stich|Transaortic Mitral valve repair using alfieri technique
41104751|NCT03906734|PROCEDURE|Subvalvular intervention|Transaortic Mitral valve subvalvular intervention including anterior mitral leaflet secondary cord cutting, papillary muscle release
41104752|NCT01887041|PROCEDURE|Stent|Endoscopically inserted biliary tract drainage
41104753|NCT01887041|PROCEDURE|Biliodigestive anastomosis|Biliodigestive anastomosis
41104754|NCT06163586|OTHER|Neonatal Touch and Massage Therapy|Structured touch and massage therapy performed by certified providers.
41104755|NCT02425254|DRUG|Intravenous paracetamol|1000mg intravenous solution for infusion
41104756|NCT02425254|DRUG|Intravenous saline 0.9%|0.9% sodium chloride in order to ensure double-blinding
41104757|NCT03080038|OTHER|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
41104758|NCT01715909|DRUG|Oseltamivir|Participants will receive standard dose (30 to 75 milligrams \[mg\]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for \</= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (\>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
41104759|NCT06555731|GENETIC|Ultra rapid genome sequencing|DNA extraction from blood sample and whole genome sequencing
41104760|NCT05811728|RADIATION|Low level laser therapy|The low-level laser applied will be a Diode laser\* emitting infrared radiation at a wavelength of 980 nm, in a continuous mode. On the experimental side, subjects will receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter, till the termination of the study period (3 months).
41104761|NCT05811728|OTHER|without beam emission|The laser tip will be held passively on the control side without beam emission, providing a placebo effect.
41104762|NCT01977612|DEVICE|4-0 monofilament suture|Skin closure using 4-0 monofilament suture
41104763|NCT01977612|DEVICE|Stainless steel staples|Skin closure using stainless steel staples.
41104764|NCT05928364|PROCEDURE|Buccal mucosa for proximal ureter stricture|Patients with inclusion criteria of uretral stricture will be treated with open uretroplasty with buccal graft and omental wrapping
41104765|NCT04366882|PROCEDURE|CT-scan with minimal invasive autopsy|CT-guided biopsies will be performed directly following the diagnostic CT-scan. Biopsies will be taken from heart, liver, lungs, spleen, kidneys and abdominal fat according to a standard operation procedure. Biopsies will be taken for further histological examination and storage in the biobank. Of the lung, additional samples will be taken for microbiological examination. Additional samples will be taken in case of (focal) abnormalities on CT-imaging. In case of pleural, cardiac or abdominal fluid, this will be aspirated for further cytological, biochemical and microbiological examination. Finally, 15 cc blood will be drawn from the heart.
41104766|NCT02824367|BEHAVIORAL|Completion of scales evaluation|Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
41104767|NCT01934829|DRUG|urea-based cream|"urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator."
41104768|NCT02215044|DRUG|BI 2536, intravenous|
41104769|NCT02215044|DRUG|Gemcitabine, intravenous|
41133456|NCT02099188|DRUG|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
41104770|NCT00711542|BIOLOGICAL|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
41104771|NCT00711542|BIOLOGICAL|placebo medium|intracoronary infusion of placebo medium
41104772|NCT03433950|OTHER|No Intervention|Observational
41104773|NCT01514903|DRUG|HIP0908|SINGLE DOSE , CROSS OVER
41104774|NCT01514903|DRUG|viagra|single dose, cross over
41104775|NCT06431035|DIETARY_SUPPLEMENT|caffeine|The participants chewed either caffeine gum (5 mg/kg for 10 minutes per chew) or a placebo (10 minutes per chew, using regular gum).
41104776|NCT04475224|DRUG|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
41104777|NCT01149681|DRUG|APLIDIN (plitidepsin)|"Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles."
41104778|NCT03771846|DRUG|irinotecan, oxaliplatin , fluorouracil, and leucovorin|administration of irinotecan, oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
41104779|NCT03771846|DRUG|gemcitabine and oxaliplatin|administration of gemcitabine and oxaliplatin via vein
41104780|NCT00579202|DEVICE|Gambro HD-C4 Small Dialyzer|Involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy.
41104781|NCT03702543|BEHAVIORAL|SymTrend, Inc.|Use of SymTrend and Apple Health apps with feedback and strategies provided.
41104782|NCT05359224|DRUG|Prasugrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given prasugrel 5mg once. And aspirin 100mg and prasugrel 5mg will be maintained for 30 days.
41104783|NCT05359224|DRUG|Clopidogrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given pletaal 100mg once. And aspirin 100mg and clopidogrel 75mg mg will be maintained for 30 days.
41104784|NCT05095558|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
41104785|NCT01043549|DEVICE|rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
41104786|NCT01043549|DEVICE|Sham rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
41104787|NCT02931123|DRUG|lattulose and rifaximine|
41104788|NCT00837499|BEHAVIORAL|Questionnaire|Interview and survey during visit or by phone, 30 - 40 minutes.
41104789|NCT02929511|PROCEDURE|Reciprocating single-file system|The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
41104790|NCT02929511|PROCEDURE|Rotational single-file system.|The device is moving in continuous rotational. It is a single-fie endodontic file.
41104791|NCT02929511|PROCEDURE|Active comparator Protaper multi-file system|
41104792|NCT01550978|DEVICE|AnapnoGuard 100 System|AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
41104793|NCT00600457|DEVICE|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
41104794|NCT04348331|DIAGNOSTIC_TEST|Dual echo MRI sequence|new MRI sequences for imaging of joints
41104795|NCT02317016|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
41104796|NCT02317016|DRUG|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
41104797|NCT02317016|DRUG|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
41104798|NCT02317016|PROCEDURE|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
41104799|NCT02317016|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
41104800|NCT05126719|DRUG|MRG003|Administered intravenously
41104801|NCT05126719|DRUG|Capecitabine tablets|Administered peros
41104802|NCT05126719|DRUG|Docetaxel injection|Administered intravenously
41104803|NCT04703699|DEVICE|Myval Transcatheter Heart Valve Series|Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.
41104804|NCT02114749|DEVICE|a set of wearable respiration and cardiac monitoring devices|feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
41104805|NCT01192542|DEVICE|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
41104806|NCT01192542|DEVICE|enfilcon A lens|Marketed silicone hydrogel contact lens
41104807|NCT01190150|DRUG|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
41133457|NCT02099188|DRUG|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
41133458|NCT02099188|DRUG|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
41104808|NCT05452980|PROCEDURE|reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
41104809|NCT05452980|PROCEDURE|sleeve gastrectomy|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
41104810|NCT06000618|DEVICE|Intrapulmonary Percussive ventilator|The volunteers will undergo three minutes low frequency and high frequency intrapulmonary percussive treatments.
41104811|NCT02175212|DRUG|Short term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months"
41104812|NCT02175212|DRUG|Long term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
41104813|NCT02175212|RADIATION|Short term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
41104814|NCT02175212|RADIATION|Long term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
41104815|NCT00004560|DEVICE|defibrillator|
41104816|NCT01322958|DEVICE|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
41104817|NCT06443320|DEVICE|videodrama sessions|Patients will benefit from videodrama sessions, one per week for 9 sessions
41104818|NCT02770196|BEHAVIORAL|CO-CSA plus Nutrition Education|Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
41104819|NCT03573258|DIETARY_SUPPLEMENT|Fiber or Placebo (depending on the randomization)|ingestion of dietary fibers prior to meal intake
41104820|NCT04173572|BEHAVIORAL|PACE-Life|PACE-Life Groups will occur twice per week for 15 minutes in the first two weeks, progressing to 30-minute walking sessions over the course of the intervention without changes in frequency. The intensity of virtual walks will increase throughout this intervention in a stepwise fashion to create an exercise dose response to maximize impact on CRF.
41443669|NCT05464394|DRUG|Tranexamic Acid Injection [Cyklokapron]|A set dose of 1500 mg will be used, based on the study population with morbid obesity. It will be administered intravenous dissolved in 100 ml sodium chloride 0.9% in a time frame of 15-30 minutes, with a maximum of 100 mg/min.
41104821|NCT04173572|BEHAVIORAL|Exercise Intervention|Data from Fitbit devices will be synced and accessed through Fitbit.com. Participants will be provided account information to view data but will be asked not to change any of the settings as the investigators will be using data for tracking steps/day and minutes spent walking.
41104822|NCT02904707|OTHER|Questionary EQ-5D|In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
41104823|NCT06475170|PROCEDURE|proximal gastrectomy combined with 'λ+α' double-tract anastomosis|"1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. The jejunum is dissected 30 cm from the flexor ligament and the distal jejunum is lifted in an anterior colonic direction to the esophageal dissection.~4. Esophagojejunal anastomosis at 16 cm from the distal jejunal stump；~5. Residual gastrojejunostomy at 8 cm from the distal jejunal stump；"
41104824|NCT01695317|DRUG|Acetyl-L-carnitine|Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
41104825|NCT00023218|DRUG|Lopinavir/Ritonavir|
41104826|NCT00023218|DRUG|Efavirenz|
41104827|NCT00518557|PROCEDURE|Transcatheter Arterial Chemoembolization|The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
41104828|NCT01848548|PROCEDURE|Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
41104829|NCT01838200|BIOLOGICAL|Bacillus Calmette-Guérin (BCG) vaccine|BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.
41104830|NCT01838200|DRUG|Ipilimumab|Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.
41104831|NCT01838200|DRUG|Isoniazid|Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.
41104832|NCT02064660|DEVICE|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
41104833|NCT00913913|BIOLOGICAL|DC vaccine|DC Vaccine therapy 10E7 intranodally every cycle
41443670|NCT05464394|DRUG|Sodium chloride 0.9%|100 ml sodium chloride 0.9% will be administered in a time frame of 15-30 minutes
41104834|NCT00913913|DRUG|Bevacizumab|Bevacizumab 10mg/kg iv every 2 weeks
41104835|NCT00913913|BIOLOGICAL|IL-2|IL-2 18 MiU/m2 CI 5 days
41104836|NCT00913913|BIOLOGICAL|IFN|IFN 6 MiU subc TIW
41104837|NCT05860140|OTHER|Education video|Six minutes long education video focusing on protein and energy meals
41104838|NCT04886180|DEVICE|Oxiris membrane|Hemofiltration treatment with Oxiris membrane connected to the ECLS circuit for 24 hours.
41104839|NCT04886180|DEVICE|Prismaflex membrane|Treatment by hemofiltration with PrismaFlex ST150 membrane connected to the ECLS circuit for 24 hours.
41443671|NCT04857008|DEVICE|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
41104840|NCT04886180|BIOLOGICAL|Blood tests|Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement
41443672|NCT02828033|DRUG|Rilonacept|All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
41443673|NCT03238183|DRUG|dextrose|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
41443674|NCT03238183|DEVICE|hyaluronic acid|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
41104841|NCT01345604|PROCEDURE|transcruciate injection of 20cc of normal saline|Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
41443675|NCT05935631|DIETARY_SUPPLEMENT|Salt with folic acid and iodine|Assess serum and RBC folate levels in women at baseline and 1 month after ingesting salt with folic acid
41443676|NCT02061553|BEHAVIORAL|Motivation|Control condition in which participants receive a single session with education on the importance of self-confidence and motivation, followed by 8 weeks of daily SMS messages with self-selected motivational statements.
41104842|NCT01345604|PROCEDURE|transcruciate injection of 20 cc of 0.5% Ropivacaine|Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
41104843|NCT06425237|OTHER|music therapy|standard patient care in interventional radiology associated with a well-being atmosphere with the implementation of music therapy (soothing sound environment) in the preparation box and in the examination room.
41104844|NCT06425237|OTHER|aromatherapy|standard patient care in interventional radiology associated with a well being atmosphere with the implementation of aromatherapy (essential oil of Ylang Ylang) in the preparation box and in the examination room.
41104845|NCT00662636|DRUG|dasatinib|Given orally
40925294|NCT03911687|BEHAVIORAL|CONCERN CDS system notification|"The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months"
41104846|NCT00662636|DRUG|lapatinib ditosylate|Given orally
40752130|NCT04093882|DIAGNOSTIC_TEST|Contrast agent enhanced MRI using Gadovist|By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
40752131|NCT05738252|DIAGNOSTIC_TEST|Clinical Frailty Scale|A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician
40752132|NCT05738252|DIAGNOSTIC_TEST|Frailty Phenotype|Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
40925295|NCT04564638|DRUG|Corticosteroid|
41104847|NCT00662636|OTHER|pharmacological study|Correlative study (cohort II only)
41104848|NCT00662636|OTHER|laboratory biomarker analysis|Correlative study (cohort II only)
41104849|NCT03082430|BIOLOGICAL|autologous PRP.|one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
41104850|NCT00243256|DRUG|Cholecalciferol|
41104851|NCT03531853|DEVICE|hand-held swept source optical coherence tomography|images the eye
41104852|NCT04135209|DIAGNOSTIC_TEST|Optical coherence tomography angiography OCTA|Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA
41104853|NCT03244436|PROCEDURE|Surgery following catheterization|Emergency surgery following pediatric cardiac catheterization
41104854|NCT06357169|DEVICE|Venus Glow|two treatments over a one week period. At the first visit they will complete an initial questionnaire regarding current scalp care practices, skin type, and hair type. An initial baseline scalp swab and HairMetrix photography in the two swab sites will be taken at the beginning of this visit. Treatment with the Venus Glow™ device will also occur. To treat, the scalp will be divided into four quadrants. Swab samples will be collected at the first baseline and concurrent treatment session, second treatment session and 3-6 days after the last treatment when participants have returned to their usual cleansing routine.
41104855|NCT00013650|DRUG|Cyclophosphamate|
41104856|NCT02876471|OTHER|CPAP|OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
41443677|NCT02061553|BEHAVIORAL|Intention|Implementation intentions are created collaboratively by participants and therapists in a single 2-hour session that uses principles of brief BA (the planning of rewarding activities). BA-based implementation intentions will then be delivered daily by text for 8 weeks.
41443678|NCT02061553|BEHAVIORAL|BA-Tech|Participants undergo a total of 8 sessions with a therapist. During these sessions, participants learn about the principles of BA (the translation of important life values into the planning of rewarding activities that support those values). The participants' values are explored and an activity schedule is created collaboratively by participants and therapists based on those values. Reminders to complete the scheduled activities will then be delivered by text once the schedule is made. Participants in this arm will also be monitoring their daily activities (and rating them based on enjoyment and perceived achievement) using a cell phone application.
41443679|NCT02640235|DEVICE|CELSTAT|
41443680|NCT02640235|DEVICE|Surgicel Original|
41443681|NCT05251727|DRUG|thrombomodulin alfa|Weight based dose of reconstituted treatment
41443682|NCT05251727|DRUG|Placebo|Weight based dose of reconstituted treatment
41104857|NCT00109967|BIOLOGICAL|rituximab|375 mg/m\^2 Given IV
41104858|NCT00109967|DRUG|temsirolimus|25 mg given IV
41104859|NCT04095403|OTHER|Tarp Assisted Cooling|Body cooling utilizing a tarp and water
41104860|NCT04095403|OTHER|passive cooling|Supine rest.
41104861|NCT05582317|DRUG|Biodentine|Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide
41104862|NCT05582317|DRUG|Simvastatin|3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
41443683|NCT01714895|OTHER|High insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
41443684|NCT01714895|OTHER|Low insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
41443685|NCT00109265|DRUG|Erlotinib HCl (OSI-774)|
41443686|NCT02463786|OTHER|No intervention|No intervention
41443687|NCT06039306|DIETARY_SUPPLEMENT|Immunonutrition oral nutrition supplementation|Participant will prescribed with 2 servings of immunonutrition supplement 5 days before surgery and 7 days after surgery
41443688|NCT04499664|DEVICE|Monitoring of the autonomic nervous system|Monitoring of the autonomic nervous system using E-patch, LiDCO and Root-Massimo.
41443689|NCT00835588|DRUG|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
41443690|NCT00835588|DRUG|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
41443691|NCT01344863|DRUG|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
41443692|NCT01344863|DRUG|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
41443693|NCT05630586|DRUG|Semaglutide|Subcutaneous Semaglutide, 0.5 mg weekly for 4 weeks. First dose given at inclusion.
41104863|NCT05001919|PROCEDURE|GTR|intrabony defects treated by surgery and bone graft +collagen membrane
41104864|NCT05001919|PROCEDURE|concentrated growth factor|intrabony defects treated by surgery and bone graft +concenrated growth factor membrane
41104865|NCT03338218|DRUG|Volulyte 6%|Solution for infusion
41104866|NCT03338218|DRUG|Ionolyte|Solution for infusion
41104867|NCT06238154|DRUG|Flurbiprofen|The efficacy of two different forms and amounts of active ingredient (100mg tablet vs 25% oral spray) on postoperative pain of different flurbiprofen
41104868|NCT04066738|DIAGNOSTIC_TEST|Cardiac MRI with gadolinium contrast|Imaging of left ventricular scar and coronary sinus venous system
41104869|NCT04066738|DIAGNOSTIC_TEST|3D reconstruction and location of coronary sinus venous system relative to myocardial scar|Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar
41443694|NCT05630586|OTHER|Standard care|Treatment according to Danish national clinical guidelines on stroke treatment, including reperfusion therapy if eligible.
41443695|NCT05505747|DRUG|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
41443696|NCT05505747|DRUG|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
41104870|NCT04066738|DIAGNOSTIC_TEST|Acute haemodynamic measurements during CRT implant|Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
41104871|NCT01451814|BEHAVIORAL|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
41104872|NCT01451814|DRUG|Nicotine polacrilex|8 weeks of nicotine patch
41104873|NCT01451814|BEHAVIORAL|Relaxation training|Instructions in progressive muscle relaxation
41104874|NCT01451814|BEHAVIORAL|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
41104875|NCT00627874|DEVICE|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
41104876|NCT05633199|OTHER|cytoreductive surgery|Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.
41104877|NCT03244787|BEHAVIORAL|patient navigation|Current standard of care is for PNs to work with patients from health centers who are referred by providers. Intervention patients will appear on a PN list without any referral by providers. Control high risk patients will proceed normally and will be eligible to transfer to a PN list after the 6-month study period.
41104878|NCT00143689|DRUG|lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine|See Detailed Description.
41104879|NCT04386733|OTHER|no intervention, it was an observational study which looked at the reasons for surgical cancellations|the investigators observed how many patients had their surgeries cancelled and analysed the reasons of these cancellations
41443697|NCT04450069|COMBINATION_PRODUCT|CLBR001 and SWI019|Investigational immunotherapy for B cell malignancies
41443698|NCT01627158|DRUG|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
41443699|NCT01627158|DRUG|Symbicort Turbuhaler|Symbicort Turbuhaler
41443700|NCT01627158|DRUG|Charcoal and Budesonide/formoterol Easyhaler|Charcoal and Budesonide/formoterol Easyhaler
41104880|NCT00000634|DRUG|Nevirapine|
41443701|NCT01627158|DRUG|Charcoal and Symbicort Turbuhaler|Charcoal and Symbicort Turbuhaler
41443702|NCT03197818|DRUG|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
41104881|NCT01499654|DRUG|Half-dose of the Tc99-m sestamibi (Cardiolite)|Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
41104882|NCT02987335|DRUG|Pancreatic Clamp|We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.
41104883|NCT04709796|DRUG|EmbryoGlue®, Vitrolife|The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent.
41104884|NCT04709796|DRUG|Conventional Transfer|The control arm is the conventional embryo transfer without Embryo glue medium
41104885|NCT02931851|OTHER|ICU Families Website|Professionally developed website for relatives of ICU patients
41104886|NCT02931851|OTHER|Placebo|Standard Information provided online
41443703|NCT03197818|DRUG|160 µg budesonide + 4.5 µg formoterol fumarate|Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
41104887|NCT02806518|PROCEDURE|DIRT|An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
41104888|NCT01544140|DRUG|Midazolam|Oral syrup 7.5 mg, single dose
41104889|NCT01544140|DRUG|vandetanib|Oral tablets, 800 mg, single dose
41104890|NCT06245629|DRUG|Bortezomib-bendamustine-melphalan|The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.
41104891|NCT03899818|DEVICE|drug-eluting balloon|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)
41104892|NCT03899818|DEVICE|drug-eluting stent|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
41104893|NCT06165172|DEVICE|MyoRegulator®|Study participants will receive treatment using the MyoRegulator® device 3 times a week for 2 x 30 minutes per session. The first week of treatment will be followed by a 1-week rest period with no treatments. Treatment sessions will then resume for 4 consecutive weeks, 3 times per week. A follow-up visit will be scheduled 4 weeks after the last treatment session.
41104894|NCT00104754|DRUG|liposomal SN-38|
41104895|NCT00415272|BEHAVIORAL|Pulmonary Rehabilitation|
41104896|NCT02280655|BIOLOGICAL|Storage-aged red blood cells (saRBCs) units|Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
41104897|NCT02280655|BIOLOGICAL|Fresh red blood cells units|Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
41104898|NCT03665701|PROCEDURE|Blood Sampling|Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.
41104899|NCT05315336|DRUG|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
41104900|NCT03413319|DRUG|ABBV-8E12|Solution for infusion
41104901|NCT01858285|GENETIC|Exome and/or whole genome sequencing|
41104902|NCT01020838|DRUG|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
41104903|NCT04448717|DIAGNOSTIC_TEST|COVID-19 Antibody testing|COVID-19 Antibody testing in venous blood and/or saliva samples.
41104904|NCT02211898|DRUG|BNS003|
41104905|NCT00324506|DRUG|Mycophenolate Mofetil (CellCept)|
41104906|NCT05813899|DIETARY_SUPPLEMENT|PS23 heat-treated|PS23 heat-treated, 2 caps daily use
41104907|NCT04963621|BEHAVIORAL|Child-Adolescent Emotion and Stress Intervention Program|Intervention programs include Emotion and Stress Intervention for children with emotional and stress problems
41104908|NCT02081898|DIETARY_SUPPLEMENT|LCD|approximate 100 kcal/d caloric deficit
41104909|NCT02520570|DRUG|ulinastatin|We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
41104910|NCT05127551|DEVICE|iStent Infinite|Implantation of the iStent Infinite
41104911|NCT05127551|DEVICE|Competitor Device|Implantation of competitor device
41104912|NCT01183533|DRUG|Alteplase (iv t-PA)|0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.
41104913|NCT00906620|OTHER|QPR: question, persuade and refer (SEYLE)|"The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
41104914|NCT04644185|DRUG|SCTA01|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
41104915|NCT04644185|OTHER|Placebo|all SCTA01 excipients without active component+best supportive care
41104916|NCT01465243|DRUG|Icotinib|125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
41104917|NCT05330546|PROCEDURE|Densah burs|using Densah burs to prepare implant osteotomy
41104918|NCT05330546|PROCEDURE|Ridge expansion screws|using Ridge expansion screws to prepare implant osteotomy
41104919|NCT03259932|OTHER|no physical activity|no physical activity
41104920|NCT03259932|OTHER|physical activity|Rehabilitation program will start 4 weeks after discharge from acute care (S4), for a duration of 8 weeks (3 sessions / week). Physical training will include aerobic exercises 30-60 minutes at 50-80% of HRmax, associated with muscle building exercises in circuit training (20 min), and balance and flexibility exercises.
41104921|NCT02305082|OTHER|Fast-track group|Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
41104922|NCT01831791|DRUG|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
41104923|NCT01199237|DRUG|Sevoflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
41104924|NCT01199237|DRUG|Desflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
41104925|NCT01199237|DRUG|Rocuronium|
41104926|NCT01199237|DRUG|Neostigmine|
41104927|NCT01199237|DRUG|Glycopyrrolate|
41104928|NCT06505824|DRUG|BL-M14D1|Administration by intravenous infusion for a cycle of 3 weeks.
41104929|NCT05817409|DRUG|Intrathecal Baclofen Pump|intrathecal baclofen treatment
41133459|NCT02099188|DRUG|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
41133460|NCT02099188|DRUG|Adriamycin|20 mg/m2/day - Powder for solution for infusion
41133461|NCT02099188|DRUG|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
41133462|NCT02099188|DRUG|Leucovorin|250 mg/m2/day - Powder for solution for infusion
40752133|NCT01706380|BEHAVIORAL|Interactive voice response with personal feedback|Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.
41104930|NCT02703727|BEHAVIORAL|Extended polymedication check|"Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
41104931|NCT02397317|RADIATION|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
41104932|NCT03038399|DRUG|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 months.
41104933|NCT03038399|DRUG|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 months.
41104934|NCT03038399|DRUG|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 months.
41104935|NCT03038399|DRUG|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 months.
41104936|NCT02250716|PROCEDURE|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
41104937|NCT05165849|DRUG|GFS101A|GFS101A will be administrated intravenously Q3W.
41104938|NCT05165849|DRUG|Toripalimab|Toripalimab with fixed dose of 240 mg Q3W administered intravenously.
41104939|NCT03469154|OTHER|Dyad training method|The training model for paediatric basic life support for laypersons involves a course based on pairs training together guided by instructional videos and with hands-on practice on resuscitation manikins.
41104940|NCT03469154|OTHER|Instructor led training method|The training model for paediatric basic life support for laypersons involves a course led by an instructor including hands-on practice on resuscitation manikins.
41104941|NCT04329663|DEVICE|Indonesian computer-based game prototype|In order to improve the ADHD clinical symptoms and executive function of the player, this game should has challenge similar to memory game which is the player was given object to be memorized and then match the object in accordance to the task given inside the game. With some difficulty leves, this game was tried to trigger players in terms of accuracy and quickness in completing the mission.
41104942|NCT01936753|BEHAVIORAL|Trained Mentor Mother and Supervisor|Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
41104943|NCT00345852|PROCEDURE|Fetoscopic Selective Laser Photocoagulation|
41104944|NCT04038229|OTHER|Enhanced recovery pathway|The applied protocol include psychological screening for yellow flags, preoperative gabapentin, peroperative multimodal preemptive management and postoperative holistic evaluation short -and long term
41104945|NCT05386446|DRUG|Interferon gamma human recombinant (IFN-G)|nasal form
41104946|NCT05785494|OTHER|Narstaende.se|Web-site with supportive information, videos and chat forum targeting family caregivers of patients with life-threatening illness.
41104947|NCT05323682|OTHER|Individualized physical exercise program|An individualized physical exercise program was programmed, monitored remotely by e-mail or the use of an activity wristband
41104948|NCT05323682|OTHER|NO Individualized physical exercise program|Usual medication
41104949|NCT05451017|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition|a single dose of 1 mg AEF0117 in fed condition
41104950|NCT05451017|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition|a single dose of 1 mg AEF0117 in fasting condition
41104951|NCT04572217|DRUG|Topiramate|Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
41104952|NCT04572217|DRUG|Phentermine|Phentermine (starting dose 8 mg, max dose 16 mg)
41104953|NCT05237258|BEHAVIORAL|Specialty Palliative Care|Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
41104954|NCT05237258|BEHAVIORAL|Primary Palliative Care|Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.
41104955|NCT03087539|BIOLOGICAL|Abciximab|
41104956|NCT03087539|BIOLOGICAL|Placebo|
41104957|NCT01517542|OTHER|Nutritional Counseling|2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
40752134|NCT01706380|BEHAVIORAL|Interactive voice response without personal feedback|Control condition. Identical follow-up but without personal feedback.
41104958|NCT02662530|DRUG|Botulinum Toxin Type A|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
41104959|NCT00711919|DRUG|Pitavastatin|"comparison of different target levels of lipid lowering using Pitavastatin~Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months."
41104960|NCT00711919|DRUG|Pitavastatin|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
41104961|NCT02135341|DRUG|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
41104962|NCT02135341|DRUG|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
41104963|NCT00921076|BEHAVIORAL|Gait Analysis|A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.
41104964|NCT05183906|DIAGNOSTIC_TEST|Next generation sequencing|Evaluation of microbiological culturing versus next generation sequencing for ribosomal DNA
41104965|NCT01581736|DRUG|U100 Humulin|Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
41104966|NCT01581736|OTHER|Exercise|Single episode of exercise riding a stationary bike.
41104967|NCT06057220|OTHER|No intervention sample collection only|No intervention
41104968|NCT00829751|DEVICE|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
41104969|NCT00829751|DEVICE|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
41104970|NCT00954707|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
41104971|NCT00954707|DRUG|Placebo & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
41104972|NCT05701111|BEHAVIORAL|Start with the Heart Students|The Start with the Heart curriculum includes psychoeducation, lessons, and activities, on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition to promote well-being. The curriculum will be taught in the classroom to students for 15-20 min per day for 6-8 weeks.
41104973|NCT05701111|BEHAVIORAL|Start with the Heart Teachers|Pure Edge Inc will train teachers to deliver the Start with the Heart curriculum. The training emphasizes the neuroscience of stress and educator self-care. The teachers will implement the training in their respective classrooms for 6-8 weeks.
41104974|NCT05701111|BEHAVIORAL|Cue Centered Therapy Counselors|The Early Life Stress and Resilience Program team members will train school counselors on Cue-Centered Therapy through self-paced online modules, virtual and in-person live training, and office hours as needed. Counselors will implement the intervention with eligible students for 15-18 weeks.
41104975|NCT05701111|BEHAVIORAL|Cue Centered Therapy Students|Students who report a threshold of PTSD symptoms will be offered participation in Cue-Centered Therapy with their school counselors. They will have one-on-one therapy that targets trauma experiences through cognitive behavioral tools, narrative therapy, exposure therapy, psychoeducation, and more. Their caregivers will be involved as needed. They will enroll in treatment for 15-18 weeks.
41104976|NCT05701111|GENETIC|iSWAB-DNA|Eligible students will give DNA buccal swabs at 2-3 time points for later analysis of genetic markers.
41104977|NCT01228513|DRUG|ZK245186|Daily topical application
41104978|NCT01228513|DRUG|Placebo (vehicle without active ingredient)|Daily topical application
41104979|NCT01507948|BEHAVIORAL|Prolonged exposure|PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
41104980|NCT06256211|DRUG|Paracetamol|"All cases will be randomized simply by opaque closed envelop and treated with either rectal or intravenous paracetamol according to the following doses.~* Rectal dose~  * Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.11~ * The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total).11~* Intravenous dose~  * Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).12~ * After the 3-day follow up echocardiogram will be done.12 This will be the end of randomization for the purpose of the study."
41104981|NCT00127829|DRUG|Gefitinib|Oral tablet
41104982|NCT06010888|DRUG|Fruquintinib+mFOLFOX6/FOLFIRI|Fruquintinib: 4mg po qd, d1-d21, q4w with mFOLFOX6/FOLFIRI (standard)
41104983|NCT03122704|PROCEDURE|GBS screening|Vaginal and anal swabs of patients will be screened for GBS screening
41104984|NCT05452993|DEVICE|Analysed Retinophotography|taking 2 retinophotographs per eye, and then analysed by AI software to detect Diabetic retinopathy
41104985|NCT00073138|DRUG|ABT-751|
41104986|NCT03076736|BEHAVIORAL|Singing group + resource pack|SPA is a community-based, 10 weekly singing group. Each SPA session comprises 30 minutes of settling in/wrap-up and departure, and 60 minutes of group singing. Sessions will be led by a community music leader, co-facilitated by a person with aphasia, and involve the group singing from a songbook. Musical accompaniment will be provided by the facilitator(s). Small percussion instruments will be available for participants, enabling involvement of those with limited singing ability. Intervention content integrates the Information-Motivation-Behavioural (IMB) skills model of health behaviour change to support individuals in developing the social skills and confidence needed to improve psychosocial outcomes. Participants will also receive the resource pack.
41104987|NCT03076736|BEHAVIORAL|Resource pack|Resource pack with information on living with aphasia and local community activities.
41104988|NCT00241423|DRUG|exenatide|subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
41104989|NCT00241423|DRUG|Placebo|subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
41104990|NCT04322643|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV over 30 minutes every 3 weeks
41104991|NCT04322643|DRUG|Atezolizumab|Atezolizumab 1200 mg IV over 60 minutes every 3 weeks. (if first dose is tolerated, all subsequent infusions may be delivered over 30 minutes)
41104992|NCT04322643|DRUG|Durvalumab|Durvalumab 10 mg/kg IV over 60 minutes every 2 weeks.
41104993|NCT04322643|DRUG|Nivolumab|Nivolumab 480mg IV over 30 minutes every 4 weeks
40752135|NCT05073510|DEVICE|BVE|Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)
41104994|NCT04322643|DRUG|Avelumab|Avelumab 800 mg IV over 60 minutes every 2 weeks
41104995|NCT05924074|BIOLOGICAL|Biological sampling|The procedure will consist of an additional bone marrow sample and blood sample
41104996|NCT01967407|PROCEDURE|Irreversible Electroporation (IRE)|Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.
41104997|NCT04486729|OTHER|High PEEP with end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system with end inspiratory pause addition in volumen control ventilation
41104998|NCT04486729|OTHER|Low PEEP - FiO2 high|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 96-98%
41104999|NCT04486729|OTHER|High PEEP without end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system without end inspiratory pause addition in volumen control ventilation
41105000|NCT04486729|OTHER|Low PEEP - FiO2 low|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 88-92%
41105001|NCT04538820|DRUG|Dexamethasone 4 mg IV-control|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.
41105002|NCT04538820|DRUG|Dexamethasone 4 mg IV|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
41105003|NCT04538820|DRUG|Dexamethasone 8 mg IV|dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
41105004|NCT02754011|DRUG|Combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
41105005|NCT04715373|PROCEDURE|LISA|LISA administered in the DR after initial resuscitation or in the NICU after stepwise escalation of CPAP based on FiO2 ≥0.3. While maintaining infant on CPAP with binasal prongs/small nasal mask, a thin catheter (Hobart method) is inserted below the vocal cord using direct laryngoscopy. Poractant alfa (200mg/kg) is administered slowly over 2-3 minutes. Catheter is then withdrawn and infant is maintained on CPAP
41105006|NCT03709446|DRUG|Leflunomide|Single agent leflunomide
41105007|NCT03764943|DIETARY_SUPPLEMENT|Impact Advanced Recovery|immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
41105008|NCT02170636|DRUG|BIBR 1048 MS Capsule E|50 mg BIBR 1048 MS
41105009|NCT02170636|DRUG|BIBR 1048 MS Capsule F|50 mg BIBR 1048 MS
41105010|NCT02170636|DRUG|BIBR 1048 MS Capsule G|50 mg BIBR 1048 MS
41105011|NCT02170636|DRUG|BIBR 1048 MS Tablet H|50 mg BIBR 1048 MS
41105012|NCT02170636|DRUG|BIBR 1048 MS Drinking solution|50 mg BIBR 1048 MS tartaric acid solution
41105013|NCT02170636|DRUG|Pantoprazole|40 mg Pantoprazole
41105014|NCT05086809|DEVICE|Device A|Participant wear Device A and evaluate the performance of the device.
41105015|NCT05086809|DEVICE|Device B|Participant wear Device B and evaluate the performance of the device.
41105016|NCT01570751|DRUG|insulin degludec|Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.
41105017|NCT01570751|DRUG|insulin glargine|Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
41105018|NCT02049697|DRUG|14C-JNJ-39823277|Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
41105019|NCT04172948|DEVICE|Oculus go headset/virtual reality headset|10 minute virtual reality tutorial on diaphragmatic breathing, a game in practicing diaphragmatic breathing, and two scenarios in which the patient can also practice diaphragmatic breathing.
41105020|NCT04172948|BEHAVIORAL|Diaphragmatic breathing|10 minute tutorial on diaphragmatic breathing by a medical professional.
41105021|NCT06235606|DRUG|Bupivacaine Liposome 13.3 Milligrams/Milliliter [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
41105022|NCT06235606|DRUG|Dexmedetomidine 0.5milligram (50micrograms)|Dexmedetomidine is a full α₂ adrenergic receptor agonist roughly eight times more selective for the α₂ receptor than clonidine.
41105023|NCT00487578|DRUG|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
41105024|NCT05104905|DRUG|bexmarilimab|A single neoadjuvant dose will be administered prior to surgery.
41105025|NCT01679262|DEVICE|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
40752136|NCT03951415|DRUG|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
40752137|NCT05866328|OTHER|Cognitive Rehabilitation and Individual Placement and Support|Cognitive Rehabilitation and Individual Placement and Support
40752138|NCT01239745|DRUG|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
40752139|NCT00705276|DRUG|Lactic acid (Dermacyd Femina Delicata)|
41105026|NCT05027087|DIETARY_SUPPLEMENT|Blueberry gummy|Gummy bear containing blueberry powder
41105027|NCT05027087|DIETARY_SUPPLEMENT|Placebo gummy|Gummy bear with no active ingredients
41105028|NCT01606553|DEVICE|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
41105029|NCT01606553|DEVICE|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
41105030|NCT03720990|DRUG|Cholic Acid|Participants will be treated with cholic acid for 8 weeks
41105031|NCT04546997|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)
41105032|NCT06249204|BEHAVIORAL|Coaching Group|Over a six-month coaching program period, staff members from care communities work with a coach to assess their current level of adoption of Dementia Care Practice Recommendations (DCPR) (published recommendations by Alzheimer's Association) and prioritize areas of need /focus. Teams meet with the coach virtually or in person for 1 hour each month during the six months. Through an action planning and implementation process, care communities are guided to make organization-wide, measurable changes in the areas of (1) policies and procedures, (2) education and training, and/or (3) care practices to increase and maintain person-centered care practices as outlined in the DCPR. Coaches provide ongoing support to the care community through telephone and email support between meetings.
41105033|NCT04983537|DRUG|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
41105034|NCT03395353|DRUG|Duloxetine Hydrochloride|Administered orally
41105035|NCT02355535|DRUG|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
41105036|NCT02906878|PROCEDURE|Platelets transfusion|Prophylactic platelet transfusion in thrombocytopenic patients for the placement of a central venous catheter
41105037|NCT00681252|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
41105038|NCT04116515|BEHAVIORAL|Xbox / active video games|The investigators would expect children to play active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
41105039|NCT04116515|BEHAVIORAL|Animated cartoon narratives|The investigators would expect the animated cartoon narratives to motivate children to play more active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
41105040|NCT04116515|BEHAVIORAL|Standard clinical care|Each clinic will provide standard clinical care to the participants.
41105041|NCT02940561|DRUG|Methotrexate - Amneal|"Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below"
41105042|NCT02940561|DRUG|Methotrexate - DAVA|Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
41105043|NCT05355415|DEVICE|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
41105044|NCT02734056|OTHER|Music|Listening to music that the patient likes
41105045|NCT02734056|OTHER|Control|Control
41105046|NCT01942083|DRUG|OPB-111077|
41105047|NCT05453864|BEHAVIORAL|CMAP Plus TFCBT|This will include 8 individual sessions of CMAP Plus TFCBT delivered by a trained therapist over a period of 12 weeks. Each session will last between 45 to 60 minutes.
41105048|NCT06392009|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
41105049|NCT02138331|BIOLOGICAL|MSC exosomes.|Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
41105050|NCT00573339|OTHER|Cardiac MRI|up to 3 Cardiac MRI scans per participant in 1-4 months
41105051|NCT05541393|BEHAVIORAL|Active Intervention Group|The intervention will involve meetings with the church health ministers to discuss COVID-19 vaccines and booster shots.
41105052|NCT01260298|DEVICE|MC1 Ultrasonic Device|Ultrasonic and zonal massage device.
41105053|NCT04283825|BEHAVIORAL|Psychological and physical rehabilitation based humanistic care|This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.
41105054|NCT02999048|DRUG|Panax Notoginseng Saponins|Panax Notoginseng Saponins integrated with conventional therapy
41105055|NCT03986424|DRUG|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
41105056|NCT03986424|DRUG|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg to be taken orally, twice daily
41105057|NCT05039606|DRUG|Nedaplatin|Nedaplatin is a second-generation platinum-like derivative, which is a cell cycle non-specific drug, with a mechanism of action and efficacy similar to cisplatin, and a wide anti-cancer spectrum
41105058|NCT05039606|DRUG|Cisplatin|Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug
41105059|NCT06097429|DIAGNOSTIC_TEST|blood sample for platelet aggregation|evaluate platelet aggregation using light-transmission aggregometry and adenosine diphosphate (ADP)
41105060|NCT05576051|OTHER|patterns of use of combination therapy and monotherapy|
41105061|NCT06156319|OTHER|No intervention|No intervention
41105062|NCT03917706|OTHER|Questionnaire|Patients will be contacted by phone in order to fill in a questionnaire regarding their quality of life.
41105063|NCT01105143|BEHAVIORAL|multimodal lifestyle intervention|multimodal lifestyle intervention will be performed to reduce body weight
41105064|NCT01105143|BEHAVIORAL|placebo|no intervention, only follow up
41105065|NCT01941277|BEHAVIORAL|Current Recommendations Exercise Group|
41105066|NCT01941277|BEHAVIORAL|Intensive Exercise Group|
41105067|NCT02178540|DRUG|Placebo|one dose (4 capsules) of placebo
41105068|NCT02178540|DEVICE|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
41105069|NCT01612754|BEHAVIORAL|Noise reduction work place rules|"Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.~Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones."
41105070|NCT01612754|BEHAVIORAL|Presence of an examiner in the concerned theatre|Research Clerk present in theatre, writes on note pad.
41105071|NCT01558921|OTHER|M1 scheme|short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX
41105072|NCT01558921|OTHER|standard long course chemoradiotherapy|long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
41105073|NCT03515720|PROCEDURE|Prolotherapy|It consists of injecting 5% dextrose in sterile aqueous solution without the use of lidocaine in a subcutaneous nerve to inhibit neurogenic inflammation and the release of substance P and CGRP, decreasing neurogenic inflammation.
41105074|NCT06441279|PROCEDURE|intra-articular injection with Platelet lysate (PL).|2 ml of Platelet lysate will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly
41105075|NCT06441279|PROCEDURE|intra-articular injection with Hyaluronic Acid.|2 ml of Hyaluronic Acid will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly.
41105076|NCT04842604|DRUG|Glasdegib|25 mg or 100 mg tablet
41105077|NCT04842604|DRUG|Azacitidine|100 mg/vial powder for 25 mg/mL suspension for injection
41105078|NCT01711047|PROCEDURE|Radiofrequency catheter Ablation|In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
41105079|NCT01711047|PROCEDURE|Radiofrequency catheter ablation|In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
41105080|NCT06125106|DRUG|Blinatumomab|Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
41105081|NCT05679037|OTHER|Placebo|Inactive capsules
41105082|NCT05679037|DRUG|Alpha Lipoic Acid 600 MG Oral Capsule|Universal antioxidant
41105083|NCT01315886|DRUG|SL fentanyl|SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
41105084|NCT00168662|BIOLOGICAL|Measles and inactivated polio vaccine|
41105085|NCT00562679|OTHER|There is no intervention|
41105086|NCT03899480|BIOLOGICAL|Haploidentical Natural Killer (NK) Cells|infusion with N-803 activated NK cells
41105087|NCT04922658|DRUG|Surufatinib|Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
41105088|NCT04922658|DRUG|Surufatinib Plus Vinorelbine|Surufatinib, 250mg, qd, po; Plus Vinorelbine, 20 mg, every 2 days; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
41105089|NCT00667745|DRUG|Lithium Carbonate|Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
41105090|NCT00667745|DRUG|Optimized Treatment (OPT)|The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
41105091|NCT00755118|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
41105092|NCT00755118|DRUG|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
41105093|NCT00755118|DRUG|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
41105094|NCT00755118|DRUG|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
40752140|NCT05544955|DIETARY_SUPPLEMENT|isolate whey protein prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
41105095|NCT00755118|DRUG|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
41105096|NCT00755118|DRUG|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
41105097|NCT00385801|DRUG|Risperidone|
41105098|NCT00385801|DRUG|Placebo|
41105099|NCT03143309|BEHAVIORAL|Intervention|Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.
41105100|NCT03143309|OTHER|Control|Non-health related messages delivered via WhatsApp 2-3 times per week.
41105101|NCT01377519|PROCEDURE|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
41105102|NCT01377519|PROCEDURE|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
41105103|NCT01740817|DRUG|Intralipid 20%|30 ml/h for 48 h
41105104|NCT01740817|DRUG|Saline|30 ml/h for 48 h
41105105|NCT00019669|BIOLOGICAL|aldesleukin|
41105106|NCT00019669|BIOLOGICAL|fowlpox virus vaccine vector|
41105107|NCT00019669|BIOLOGICAL|gp100 antigen|
41105108|NCT01927835|BIOLOGICAL|DNA-HIV-PT123 vaccine|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM
41105109|NCT01927835|BIOLOGICAL|NYVAC-HIV-PT1 vaccine|≥ 5x10\^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10\^8 PFU/ml; administered IM
41105110|NCT01927835|BIOLOGICAL|NYVAC-HIV-PT4 vaccine|≥ 5x10\^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10\^7 PFU/ml; administered IM
41105111|NCT01927835|BIOLOGICAL|AIDSVAX B/E vaccine|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM
41105112|NCT01927835|BIOLOGICAL|Placebo for DNA/NYVAC/AIDSVAX|Sodium Chloride for injection, 0.9%; administered IM
41105113|NCT03800667|DRUG|Ascorbic Acid 1000 MG|1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
41105114|NCT06553807|OTHER|The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes.|The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes. Pre-test and post-test will be applied to the participants after 4 weeks. Follow-up test data will be collected from the intervention and control groups after 3 months.
41105115|NCT01819038|PROCEDURE|continuous renal replacement therapy|
41105116|NCT02857491|DRUG|ranibizumab|intravitreal injection of 0.5 mg ranibizumab before vitrectomy
41105117|NCT02857491|DRUG|sham|sham intravitreal injection before vitrectomy
41105118|NCT02857491|PROCEDURE|pars plana vitrectomy|surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
41105119|NCT04473638|PROCEDURE|Arthroscopic Deltoid Repair|. A 4.5 mm arthroscopic set was used to clean the joint and assess medial and associated injuries. After deltoid injury confirmation through the method already mentioned, the medial gutter was prepared. The ideal positioning for the bone anchor in the medial malleolus followed Vega's recommendations and was located in the inferolateral quadrant created by the intersection of two lines: (1) tibia-talar joint line and (2) tangent line to the medial malleolus joint surface.(14). Sutures were passed respecting the safe zone illustrated by Acevedo at al, at the area between the posterior tibial tendon and the saphenous vein (16-25mm) (15). Sutures were passed but not tightened.
41105120|NCT00408928|DRUG|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
41105121|NCT00604006|DRUG|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
41105122|NCT00604006|DRUG|Placebo|Placebo (lactose in capsules for blinding) once daily
41105123|NCT03140579|OTHER|APRV|Airway pressure release ventilation is a method of inverse ventilation, where high levels of positive end expiratory pressure are maintained to optimise oxygenation with brief releases of pressure to allow ventilation and release carbon dioxide. It is an approved and frequently used method of ventilation.
41105124|NCT04178395|DEVICE|bihemispheric transcranial direct stimulation|"tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA)."
41105125|NCT04615299|DEVICE|Auricular acupuncture|Auricular or Battlefield acupuncture is an auricular therapy which has been in existence for centuries, with roots tied to Eastern Asian medicine.
41105126|NCT00932022|DRUG|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
41105127|NCT00932022|OTHER|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
41105128|NCT01981330|BIOLOGICAL|aMSC|aMSC injected into the vocal fold of the patient
41105129|NCT01981330|BIOLOGICAL|aMSC+hyaluronan gel|aMSC+ hyaluronan gel is injected into the patients vocal fold
41105130|NCT03369587|BEHAVIORAL|Handwriting Practice|Self-directed home handwriting practice daily for 6 weeks
41105131|NCT03551132|OTHER|Exercise test|Fat mass, Functional autonomy, muscular strength, quality of life questionnaire
41105132|NCT01477619|DRUG|Tasimelteon|20mg single dose on Day 1
41105133|NCT05904535|OTHER|Cerbrospinal fluid sampling.|Routine sampling of cerebrospinal fluid from the proximal external ventricular drain port.
41105134|NCT06432569|DIETARY_SUPPLEMENT|ButirBioma + PeaBioma|randomized in a 1:1 ratio to treatment Butir+Pea or treatment with Placebo for six weeks. After the first treatment period, there is a 14-day washout period.
41105135|NCT06432569|DIETARY_SUPPLEMENT|Placebo|Placebo( 3+3 cps/die)
41105136|NCT05936892|OTHER|upper extremity aerobic training|upper extremity aerobic training \& baseline treatment will be given. Overall session time will be 40-45 minutes
41105137|NCT05936892|OTHER|upper extremity resistance training|upper extremity resistance training Overall session time will be 40-45 minutes
41105138|NCT05113355|DRUG|Chidamide|30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.
41105139|NCT05113355|DRUG|Sintilimab|200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.
41105140|NCT00234377|DRUG|Seroquel SR|
41105141|NCT02797249|DRUG|Aspirin|Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
41105142|NCT02797249|OTHER|Blank|Routine examination during pregnancy.
41105143|NCT04575285|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|EEG measures brain activity by recording the spontaneous brain electrical activity and evoked responses non-invasively from the scalp. Reusable Tangle Free 10mm EEG Cup Electrodes will be placed on the subject's scalp using the 10-20 system montage.
41105144|NCT05358197|OTHER|yoga|laughter yoga
41105145|NCT02087306|DRUG|Brincidofovir|BCV administered twice weekly, dose depending on weight.
41105146|NCT05060679|OTHER|Supportive therapy at the ICU|Non-septic ICU patients received adequate supportive treatment (fluid resuscitation, respiratory, anticoagulation, antimicrobial and vasopressor therapy along with sedation, ulcer prophylaxis and nutrition. Blood sampling for non-septic patients were the first (T1) and third (T3) postoperative morning at the ICU. Besides, 23 healthy outpatients were documented without sepsis or sepsis-related organ dysfuntion as a control group.
41105147|NCT05060679|OTHER|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis and nutrition. Blood samples were collected at the ICU from this patient group at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
41105148|NCT05060679|OTHER|Sepsis-related organ dysfunction therapy|Patient management of sepsis and sepsis-related organ dysfunction followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis, nutrition and renal replacement therapy (if needed). In this patient group, blood sampling was performed at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
41105149|NCT03881358|DEVICE|ortho-k lenses and thinner spectacles|Conventinally designed (Emerald) ortho-k lenses (target for -4.00D) and thinner specs during day time
41105150|NCT03881358|DEVICE|newly designed ortho-k lenses|Newly designed (Topaz) ortho-k lenses for high myopia (target for full correction)
41105151|NCT04652817|DEVICE|MMI-22-04-2019|A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.
41105152|NCT01379287|DRUG|Iso-Fludelone|Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
41105153|NCT03705819|DRUG|[11C]-NOP46|Subjects will receive a microdose (≤10 µg) of \[11C\]-NOP46.
41105154|NCT03705819|RADIATION|PET/CT scan|After subjects receive a microdose of \[11C\]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.
41105155|NCT01803516|BEHAVIORAL|questionnaires|This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
41105156|NCT06106659|DEVICE|Mini Midline|"The tube was placed in the upper arm in the test group and in the forearm in the control group. The veins were selected according to anatomical criteria (vein diameter and depth), and the puncture site was protected with a sterile cavity towel. The cannulation nurse wore sterile gloves and injected local anesthesia (1 mL of lidocaine) before venipuncture. Venipuncture was always performed using real-time ultrasound-guided visualization of the vein-guiding needle using an out-of-plane approach, and once the tip of the needle was visualized within the vein and the blood flowed back through the needle, a guidewire was introduced and the needle was removed. After the needle is removed, the cannula is advanced into the vein, the guidewire is removed, and the cannula is attached to an extension cord closed with a needleless connector."
40752141|NCT05544955|DIETARY_SUPPLEMENT|isolate whey protein 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
41105157|NCT03285685|DEVICE|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area
41105158|NCT03285685|DEVICE|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.
41105159|NCT03285685|DEVICE|sham tDCS|The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
41105160|NCT00319085|PROCEDURE|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
40752142|NCT06291207|DRUG|AD-224A|PO, Once daily, 8weeks
40752143|NCT06291207|DRUG|AD-224B|PO, Once daily, 8weeks
40752144|NCT06291207|DRUG|AD-224C|PO, Once daily, 8weeks
40752145|NCT06291207|DRUG|Placebo of AD-224A|PO, Once daily, 8weeks
40752146|NCT06291207|DRUG|Placebo of AD-224B|PO, Once daily, 8weeks
40752147|NCT06291207|DRUG|Placebo of AD-224C|PO, Once daily, 8weeks
40752148|NCT03969758|DRUG|Ciprofloxacin|will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
41105161|NCT02272400|OTHER|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
41105162|NCT06039852|OTHER|Novel Postural Management Night-time Intervention|"Essential elements and components of PMN-TI:~* Safe and comfortable position to enable sleep~* Positioning to enable UAD overnight~* Quiet breathing unobstructed by base of tongue (i.e. stertor), vocal cords (i.e. stridor) or pooled secretions~* Postural support in lying to achieve comfort, promote symmetry of posture and maximum loadbearing~* Stomach contents reduced or emptied overnight to minimize reflux and associated aspiration risk."
41105163|NCT03328949|DEVICE|IVL Coronary Lithotripsy System|The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).
41105164|NCT03787706|OTHER|Dry Needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
41105165|NCT03787706|OTHER|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
41105166|NCT05273281|PROCEDURE|Transabdominal plane block|Peripheral nerve block
41105167|NCT05273281|PROCEDURE|Quadratus lumborum block|Peripheral nerve block
41105168|NCT06345534|DEVICE|Questionnaire|"Patients will be asked to complete questionnaires at different times (before, during and after radiation) to evaluate which schedule gives the fewest side effects and the best quality of life.~The basic questionnaire and questionnaire about early side effects will be completed weekly up to 6 weeks after radiotherapy. The questionnaire about late side effects will be completed: after 6 months, 1 year, 2 years, 3 years, 4 years and 5 years."
41105169|NCT02321748|DRUG|Montelukast|
41105170|NCT02321748|DRUG|ASP2151|
41105171|NCT05848323|BEHAVIORAL|4-week Relaxation Training|A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, b) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, autogenic relaxation, and guided imagery, and c) goal setting and problem-solving barriers focused on integrating relaxation practices into daily routine.
41105172|NCT05848323|BEHAVIORAL|4-week Behavioral Activation|A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
41105173|NCT05848323|BEHAVIORAL|4-week Cognitive Therapy|A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, b) labeling thoughts as helpful, unhelpful, or neutral, c) using distraction to cope with unhelpful thoughts, d) challenging and changing unhelpful thoughts, e) problem solving barriers to coping with or changing unhelpful thoughts.
41105174|NCT00471029|DRUG|esomeprazole|
41105175|NCT06331754|OTHER|Technology-enabled blood pressure management|The intervention will consist of a technology-enabled remote hypertension management program.
41105176|NCT05623384|PROCEDURE|Stellate ganglion block|A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.（lidocaine 80mg；Physiological saline 1ml）
41105177|NCT05623384|PROCEDURE|Facial and glossopharyngeal nerve blocks|The operator touches the position of the mastoid process and needles vertically at the front of the mastoid process directly below the external auditory canal. When the surface of the mastoid is touched, the needle is adjusted to pass through the front of the mastoid and then slowly needled for about 1 cm, and when the patient develops swelling and pain, 3 ml of the drug is injected. then the needle is slowly needled backward for about 1 cm, and when the patient develops swelling and pain, 2 ml of the drug is injected. （mecobalamin injection 1mg；lidocaine 20mg； dexamethasone 10mg ；Physiological saline 2ml）
41105178|NCT05623384|DRUG|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
40752149|NCT03969758|DRUG|Cefixime|will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
40752150|NCT04212065|DRUG|buprenorphine|To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
40752151|NCT04697992|DRUG|vitamin c 20%|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
41105179|NCT05159128|DRUG|JNJ-75105186|JNJ-75105186 will be administered orally in Part 1 and 2.
41105180|NCT05159128|OTHER|Placebo|Matching placebo to JNJ-75105186 will be administered orally in Parts 1 and 2.
41105181|NCT00744393|DRUG|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
41105182|NCT00744393|DRUG|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
41105183|NCT03426280|DEVICE|Apple Watch Series 1|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
41105184|NCT05426863|BEHAVIORAL|DeVI|A multi-component intervention is devised from the components of PM+ developed by WHO incorporating the components of violence prevention. The intervention is anticipated to provide behavioral skills to the participants in the intervention arm which will enhance their coping skills with past experiences of violence, stress management skills, problem-solving skills and safety planning skills. Further, they will be shared the best practices and lessons learned which will aid in danger assessments and prevention of future violence. The intervention will be given to intervention arm in 5 different sessions, one in each week. The 1st session of the intervention is about understanding the multi-component intervention. The 2nd session is identifying and managing problem, 3rd session is about stress management, followed by development of safety plan in 4th session and last session is about promotion of social support.
41105185|NCT05983484|DEVICE|Skiin Underwear|All participants enrolled will wear simultaneously the PocketECG (Standard Holter) and the Skiin Underwear Chestband (wearable textile). Each participant will wear both systems for the duration prescribed by their physician (1 to 14 days).
41105186|NCT03125382|DEVICE|Carelink System|Patients start to perform device data transmission through Carelink system
41105187|NCT03125382|DEVICE|In office standard visit|Patients start or maintain in office standard visits
41105188|NCT03316794|DRUG|SC-005|intravenous
41105189|NCT06182319|DRUG|Gastrografin|Administration of WSC (Gastrografin) 2 hours after placement of NGT.
41105190|NCT06182319|DRUG|Saline|Administration of Saline 2 hours after placement of NGT.
41443704|NCT02161445|DEVICE|the acoustic cardiographic parameters were calculated|STIs were measured using simultaneous recording of the electrocardiogram and acoustic cardiography signals using an analogic numeric system (Biopac Systems, Goleta, CA). A3-minute acoustic cardiographic tracing for all patients was obtained and stored electronically. We measured the electromechanical activation time (EMAT) which is the time between the initial deflection of the electrocardiographic Q wave and the first phonocardiographic complex corresponding to the first heart sound (S1). The left ventricle ejection time (LVET) defined as the interval between the peak components from the S1 and S2 complexes was measured on the same cardiac cycles. All studies were performed in patients in a semi-recumbent position with head at 30 degrees position. For each patient, the acoustic cardiographic parameters were calculated from a 10-second free of artifact recording of data averaging 8 to 12 beats measurements.
41105191|NCT06182319|PROCEDURE|SBO Treatment Without NG Tubes|Patients who decline to have NG tubes placed will be enrolled and followed with the same outcomes protocol as the other patients in the trial
41105192|NCT03310996|OTHER|Transcranial direct current stimulation|tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
41105193|NCT05714735|RADIATION|Cerebral Venography|Cerebral Venography Observation by DSA examinations
41105194|NCT06252506|DRUG|N,N-dimethyltryptamine (DMT) + harmine|DMT and harmine are the two most abundant chemicals in the Amazonian hallucinogenic plant brew, Ayahuasca, which is used traditionally in spiritual and healing ceremonies. An oral formulation of these two substances will be tested against placebo in the context of an FDG-PET scan.
40752152|NCT04697992|DRUG|Tranexamic acid 5mg/ml|one eye was treated with tranexamin acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling)
40752153|NCT00062959|BEHAVIORAL|Going Places: School program to prevent problem behavior|
41105195|NCT06252506|DRUG|Placebo|Placebo will be administered on one of the study days to compare the effects of DMT and harmine with the effects a placebo administration.
41105196|NCT02306343|DEVICE|InsuPad|The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
41105197|NCT05856708|OTHER|DISEASE|
41105198|NCT04921423|BEHAVIORAL|Situational simulation teaching|The intervention included communication theory and skills, aging trend and knowledge, teaching plans for elderly nursing, activities for the elderly and visual experience, application and debriefing of empathy.
41105199|NCT04524832|DRUG|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks
41105200|NCT02188758|OTHER|Adults - CFPE Treatment|Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
40752154|NCT04062604|OTHER|surgery|surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
40752155|NCT04091308|OTHER|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
40752156|NCT04091308|OTHER|Usual Care with Protein Supplementation|The intake of protein supplementation (ARLA PROTINO) will be consumed by participants in the form of protein-enriched yogurts for easy consumption two times daily, with each bottle containing 14 g of protein.
41105201|NCT04548011|OTHER|Acupuncture|The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).
41105202|NCT05061524|DRUG|YH35324|Subcutaneous injection of YH35324
41105203|NCT05061524|DRUG|Placebo|Subcutaneous injection of None of active ingredient
41105204|NCT05061524|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
41105205|NCT00622830|DRUG|SB-480848 (Darapladib)|
41105206|NCT02675920|DRUG|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
41105207|NCT04074148|BEHAVIORAL|Diabetes Prevention Education Program|An educational lifestyle modification program, offering 4 sessions of 30 minutes theory and 30 minutes practice each, total duration 6 months
41105208|NCT04074148|BEHAVIORAL|Diabetes Prevention Education brochure|An educational lifestyle modification brochure
41105209|NCT04868799|BIOLOGICAL|Mass spectrometry|Characterization of the proteomic and phosphoproteomic landscape using mass spectrometry
41105210|NCT01229839|OTHER|Embolization|embolization with lipiodol and polyvinyl alcohol particles (PVA)
41105211|NCT01229839|OTHER|Infusion of anticancer agent|infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water
41105212|NCT01229839|OTHER|Infusion of mixture of anticancer agent and lipiodol|infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
41105213|NCT02247063|DEVICE|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|HD-tDCS is a non-invasive brain neuromodulatory method for M1 that involves sending a weak electrical current into your brain.
41105214|NCT05837390|DEVICE|Cervical stiffness assessment|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
41105215|NCT05837390|OTHER|Cervical length measurement|Cervical length measurement will be obtained via transvaginal ultrasound using a GE Voluson E10 ultrasound machine and 7.5MHz transvaginal probe. All measurements will be performed with the woman in a supine position with an empty bladder in the sagittal plane measuring from the internal to external cervical OS. The full length of the cervical canal will be visualized with the closed portion of cervix remaining being measured. Three measurements are taken with the shortest being documented as the final assessment.
41105216|NCT05837390|OTHER|Fetal fibronectin|Vaginal swab collection. The specimen will be obtained from the posterior fornix over 10 seconds using the polyester tipped swab provided in the Hologic specimen collection kit. This sample will be then be stored frozen and processed using the Rapid fFN 10Q System (HOLOGIC, Marlborough, MA, USA) within 3 months.
41105217|NCT04128423|BIOLOGICAL|AMV564|AMV564 will be administered daily
41105218|NCT02988596|OTHER|Multidimensional Active Rehabilitation|Participants will be asked to complete activities aimed at: stabilization of symptoms, impairment reduction, activity integration, recovery acceleration and sport specific application during a 20 minute session at least 4 times a week. Activities will be selected by the supervising clinician with respect to the specific impairment presentation of each participant. Session logs will be completed by each clinician and will include the following information: initial symptom checklist, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
41105219|NCT02988596|OTHER|Enhanced Graded Exertion|Participants will be asked to use their symptoms to guide their activity from the time of their injury until they are asymptomatic. Once they are asymptomatic they will begin the graded exertion (Zurich/Berlin Protocol). During this time clinicians will complete session logs that include the following information: initial symptom checklist, phase of graded return to play progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
41105220|NCT03639324|DRUG|Dose combination 1-1|100 mg QD of idelalisib + 100 mg QD of venetoclax
41105221|NCT03639324|DRUG|dose combination 1-2|100 mg QD of idelalisib + 200 mg QD of venetoclax
41105222|NCT03639324|DRUG|Dose combination 1-3|100 mg BID of idelalisib + 200 mg QD of venetoclax
41105223|NCT03639324|DRUG|dose combination 1-4|150 mg BID of idelalisib + 200 mg QD of venetoclax
41105224|NCT03639324|DRUG|Sub-Trial: Dose combination 2-1|100 mg BID of idelalisib + 100 mg QD of venetoclax
41105225|NCT03639324|DRUG|Sub-Trial: Dose combination 2-2|150 mg BID of idelalisib + 100 mg QD of venetoclax
41105226|NCT04704102|BEHAVIORAL|Muscle energy technique (MET)|A manual therapy technique that uses the gentle muscle contractions of the patient to relax and lengthen muscles and normalize joint motion.
41105227|NCT04704102|BEHAVIORAL|Strain-counterstrain (SCS)|"It's also called the positional release technique, a manual therapy technique that passively positions the hypertonic (spasmed) muscles and dysfunctional joints in positions of shortened or comfort."
41105228|NCT04704102|BEHAVIORAL|sham SCS|SCS intervention that position with opposite site limb and direction, and with modified method as consider the easiness of a practitioner to press the tender points
41105229|NCT04586231|DRUG|Belzutifan|Immediate-release 40 mg tablet
41105230|NCT04586231|DRUG|Lenvatinib|Capsule available in 4 mg and 10 mg dosages
41105231|NCT04586231|DRUG|Cabozantinib|Tablet available in 20 mg, 40 mg and 60 mg dosages
41105232|NCT00937846|DRUG|GSK1034702|Single oral 5 mg dose in liquid formulation
41105233|NCT06533878|DRUG|HY-209|Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg
41105234|NCT06533878|DRUG|HY-209 placebo|Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg
41105235|NCT00431808|BIOLOGICAL|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
41105236|NCT00431808|BIOLOGICAL|AMA1|50 micrograms of AMA1
41105237|NCT02209740|OTHER|Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
41443705|NCT03563872|OTHER|Intervention|Enhancements to team-based care include clinical decision support and improved protocols for telehealth prescribing.
41443706|NCT03563872|OTHER|Active Comparator|Usual, team-based care
41443707|NCT05901090|OTHER|M-TAPA block|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose was applied to the contralateral side for each group of M-TAPA patients.
41443708|NCT05901090|OTHER|TAP block|After the necessary sterilization conditions were established, the linear ultrasound probe was sterilely coated and placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum were identified. As the tip of the 80 mm sonovisible needle passed through the muscular layers and fascia, a fascial click was felt and the needle was advanced with ultrasound in a controlled manner. After receiving the second click sensation (passage of the fascia of the internal oblique muscle), the location of the needle was fixed and frequently aspirated and applied to the plane so that 20 ml of 0.25% bupivacaine was applied to each side. (40 ml in total)
41443709|NCT05615909|RADIATION|Online MR-guided radiotherapy|Online adaptive MR-guided radiotherapy in the Unity MR-linac for localized intermediate risk prostate cancer (60 Gy/20 fx) or low-volume metastatic prostate cancer (36 Gy/6 fx).
41443710|NCT05615909|RADIATION|CT-guided radiotherapy|CT-guided radiotherapy in linear accelerators for patients with high-risk prostate cancer (78 Gy/39 fx), intermediate risk prostata cancer (60 Gy/20 Fx) or having salvage radiotherapy (70 Gy/35 fx)
41443711|NCT00804856|DRUG|Volasertib|Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
41443712|NCT00804856|DRUG|Cytarabine|Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
41443713|NCT02842853|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
41443714|NCT02842853|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
41443715|NCT05240417|PROCEDURE|"Pontic-shield technique"|A 1mm thick fragment of the vestibular aspect of the root will remain after extraction (partial extraction)
41443716|NCT05240417|PROCEDURE|Alveolar ridge preservation|Particulate deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction
41443717|NCT06560970|BEHAVIORAL|COPPEhR Intervention|Participants will receive access to the COPPEhR system which will provide social support and engagement among older adults diagnosed with HIV.
41443718|NCT06560970|BEHAVIORAL|Device-only Control Condition|Participants will have access to a device only without the COPPEhR system.
41443719|NCT06560723|DIAGNOSTIC_TEST|Quality of life test|The results of the various quality-of-life scores used to compile the study statistics (ADL, iADL, MMS, GDS, MNA, EPICES, SPPB, SF-36) will be provided to the doctor, but without any specific comments or recommendations, and then presented to the patient. Number of emergency room visits and hospitalization days, drug untake evalautions and thepareutic compliance (GIRERD score) will be also collected.
41443720|NCT00745420|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|"The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~* Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively~* Fludarabine: 30 mg/m\^2/day IV on Days -8 through -4~* Melphalan: 140 mg/m\^2 IV on Day -3~* Rest on Days -2 and -1~* Transplant occurs on Day 0~* GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD"
41443721|NCT06180980|DRUG|Pirtobrutinib|Administered orally.
41443722|NCT05977049|BEHAVIORAL|Takotsubo Support Group|Participants will undergo virtual group therapy/education. Participants will meet once every other week (at minimum), for 1 - 1.5 hours (on average). The frequency and/or length of the support group sessions may be adjusted according to participants' needs.
41105238|NCT03669562|DRUG|Alprostadil Liposome for Injection|intravenous infusion Alprostadil Liposome
41105239|NCT03669562|DRUG|Placebo|intravenous infusion liposome control
41105240|NCT00355914|PROCEDURE|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
41105241|NCT01520350|DRUG|Low dose Adjunctive Aripiprazole|low-dose 2-5mg/d for 8 weeks
41105242|NCT01520350|DRUG|placebo|Placebo
41105243|NCT03502733|PROCEDURE|Biopsy|Undergo tumor biopsy
41105244|NCT03502733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41105245|NCT03502733|PROCEDURE|Computed Tomography|Undergo CT scan
41105246|NCT03502733|DRUG|Copanlisib|Given IV
41105247|NCT03502733|PROCEDURE|Echocardiography|Undergo ECHO
41105248|NCT03502733|BIOLOGICAL|Ipilimumab|Given IV
41105249|NCT03502733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41105250|NCT03502733|BIOLOGICAL|Nivolumab|Given IV
41105251|NCT00434278|DRUG|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
41105252|NCT00434278|DRUG|placebo|2.5 mg inhalation dose twice daily for 14±2 days
41443723|NCT03979768|OTHER|Diabetes risk assessment service in Norwegian community pharmacies|Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
41443724|NCT01844050|DRUG|Chinese herbal medicine|According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
41105253|NCT02009735|DEVICE|virosensor|"virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
41105254|NCT01792648|OTHER|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
41443725|NCT01844050|DRUG|Placebo|
41443726|NCT03850795|DRUG|HC-1119|oral once daily 80 mg
41443727|NCT03850795|DRUG|Enzalutamide|oral once daily 160 mg
41443728|NCT04351425|DEVICE|Weaning to crib|We weaned the infants into two groups. Group A, 1.6 kg
41105255|NCT01792648|OTHER|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
41105256|NCT01792648|OTHER|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
41105257|NCT00816829|DRUG|Placebo|Fenofibrate-matching placebo tablet
41105258|NCT00816829|DRUG|Fenofibrate|145 mg NanoCrystal tablet
41105259|NCT04908982|DRUG|Aspirin 81mg|81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.
41105260|NCT03709719|DRUG|Blinatumomab Injection|Blinatumomab 28 μg/day : D1 to D28
41105261|NCT05066113|DEVICE|Radiofrequency-Based treatment|"RF-based treatments use electrothermolysis to deliver heat energy to targeted structures in the skin, such as hair follicles or glands by the use of insulated needles. The investigators will use radio frequency based treatment on a pre-selected skin area (about 3cm x 3cm or 1 ¼ x 1 ¼ inches in size) on either your left or right underarm that is eligible for assessment, study treatment, and biopsy.~Participants will receive clinical assessments, photography, questionnaires, up to 3 treatments of RF-based selective electrothermolysis to pre-selected areas of the axillary skin, up to 2 4-mm skin biopsies for up to 5 study visits."
41105262|NCT01192633|DRUG|GVP|"Drug: gemcitabine, vincristine,cisplatin~cisplatin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 vincristine 1.4mg/m2(less than 2 mg), iv, D1 repeat every 3 weeks"
41443729|NCT04351425|DEVICE|Weaning from incubator|We weaned the infants into two groups. group B, 1.4 kg
41443730|NCT02537093|BEHAVIORAL|Psychiatric Consultation|
41105263|NCT05407142|BIOLOGICAL|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|"Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml).~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml."
41105264|NCT05407142|OTHER|The data from volunteers from the control group|Official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals.
41105265|NCT01343173|DRUG|Imatinib stop|To stop imatinib after inclusion.
41105266|NCT00155558|DRUG|5-Fluorouracil, Leucovorin|
41105267|NCT02674750|DRUG|CUDC-907|
41105268|NCT04673851|DEVICE|Horyzons USA|Participants will be oriented to the site (online platform) and how to use it. The site includes curated therapeutic content surrounding issues such as generalized anxiety, social anxiety, social functioning, depression, and distress tolerance. The site also includes a social media function, in which participants and peer support specialists can post text, images, and videos. The site is monitored by graduate students and trained clinicians.
41105269|NCT00878722|DRUG|PXD101|
41105270|NCT00878722|DRUG|idarubicin|
41443731|NCT02376114|DRUG|Ginkgo biloba|The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
41105271|NCT06279429|DIETARY_SUPPLEMENT|Sideral® Sucrosomial Iron|Sucrosomial Iron 30mg
41105272|NCT06279429|DIETARY_SUPPLEMENT|Iron chewable tablet|Iron chewable tablet 100mg
41105273|NCT05171218|BEHAVIORAL|Music & Auditory Beat Stimulation|Listening to calm music and auditory beat stimulation Participants listened to calm music with theta auditory beat stimulation for 24 minutes
41105274|NCT05171218|BEHAVIORAL|Music Alone|Listening to calm music Participants listened to calm music for 24 minutes
41443732|NCT02376114|DRUG|Placebo to Ginkgo biloba|
41105275|NCT05171218|BEHAVIORAL|Auditory Beat Stimulation|Listening to theta auditory beat stimulation Participants listened to theta auditory beat stimulation for 24 minutes
41105276|NCT05171218|BEHAVIORAL|Pink Noise|Listening to pink noise Participants listened to pink noise for 24 minutes
41105277|NCT05725668|BEHAVIORAL|dual-task tai ji quan|dual-task tai ji quan training
41105278|NCT05725668|BEHAVIORAL|standard tai ji quan|standard tai ji quan training
41105279|NCT05725668|BEHAVIORAL|stretching|stretching exercise
41443733|NCT02671435|DRUG|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
41443734|NCT02671435|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
41443735|NCT02671435|DRUG|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
41443736|NCT02671435|DRUG|mFOLFOX6|Participants will receive IV infusion of mFOLFOX as stated in arm description.
41443737|NCT02671435|DRUG|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
41443738|NCT03140631|DRUG|Protamine Sulfate|Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects.
41443739|NCT05228691|OTHER|Evaluation and Education|A functional physical evaluation will be carried out and they will be informed about the characteristics of their symptoms. After the evaluation, they will be taught a guideline of exercises and recommendations.
41105280|NCT00480012|DEVICE|rTMS|repetitive transcranial meagnetic stimulation of the brain
41105281|NCT01689519|DRUG|Placebo|Placebo supplied as tablets
41105282|NCT01689519|DRUG|Vemurafenib|Vemurafenib supplied as tablets
41105283|NCT01689519|DRUG|Cobimetinib|Cobimetinib supplied as tablets
41105284|NCT02378116|PROCEDURE|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
41105285|NCT03376399|OTHER|Gastroparesis Cardinal Symptom Index Questionnaire|Patients with an established diagnosis of Diabetic Gastroparesis that are interested in a sleeve gastrectomy for weight loss will be asked to participate in the registry. Once the consent process is complete the patient will be asked to complete the Gastroparesis Cardinal Symptom Index Questionnaire prior to weight loss surgery and 30 days, 3 months, 6 months and 12 months after surgery.
41105286|NCT04731051|DRUG|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
41443740|NCT00316277|BEHAVIORAL|Standard Medical Management (SMM) of Prescription Opiate Abuse|Standard Medical Management in Phase 1 will consist of one hour-long initial visit; one individual 15-20 minute visit later in Week 1; one individual 15-20 minute visit per week through the end of Week 4; one 15-20 minute SMM visit at Week 6 and at Week 8. And in Phase 2, one 30-60 minute initial visit; one 15-20 minute follow-up visit later in Week 1; one individual session (15-20 minutes) per week through Week 12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
41443741|NCT00316277|BEHAVIORAL|Enhanced Medical Management (EMM) of Prescription Opiate Abuse|Enhanced Medical Management in Phase 1 will consist of SMM plus two individual sessions with a counselor per week (45 minutes each) through Weeks 1-4, and one 45-minute counseling visit at Week 6 and at Week 8. And in Phase 2, EMM will consist of the SMM plus two individual sessions with a counselor per week (45 minutes each) during Weeks 1-6 and one individual session with a counselor per week (45 minutes each) during Weeks 7-12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
41443742|NCT04642820|DRUG|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
41443743|NCT04642820|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
41443744|NCT01970566|OTHER|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
41443745|NCT01970566|OTHER|Behavioral|Intense Exercise/Moderate Calorie Restriction
41443746|NCT01970566|OTHER|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
41443747|NCT01970566|OTHER|Behavioral|Intense Exercise/Moderate Calorie Restriction
41443748|NCT04961190|BEHAVIORAL|Prolonged Exposure Therapy|A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
41443749|NCT04961190|DRUG|Pharmacotherapy with paroxetine or venlafaxine XR|Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
41443750|NCT04965454|COMBINATION_PRODUCT|Fluorine-18 fluorocholine|18F-fluorocholine is a radiopharmaceutical imaging agent intended for use only with positron emission tomography (PET) imaging. PET with in-line computed tomography imaging of the torso will be performed following intravenous administration of a single unit dose of this investigational new drug.
41443751|NCT06223191|OTHER|Brief Negotiated Interview|"The BNI is a specialized brief intervention for the medical setting, has foundations in motivational interviewing techniques. The BNI helps health care providers explore health behavior change with patients in a respectful, non-judgmental way within a finite time period. The BNI is in the form of an algorithm, or script, that guides providers through the health intervention with carefully phrased key questions and responses, all at the providers' fingertips"
41443752|NCT06223191|OTHER|Narrative Interview|The Narrative Interview is a therapeutic approach that aims to motivate the individual's conscious and transformative knowledge, skills, and capabilities. This interview is based on the technical components of narrative therapy, where the patient narrates their story, using externalizing language and considering social and political aspects related to the issue. It will focus on exploring past and present feelings, thoughts, and actions.
41105287|NCT04731051|DRUG|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
41105288|NCT02687646|DRUG|Adult Allogeneic Mesenchymal cells from adipose tissue.|"Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg"
41105289|NCT04330950|OTHER|Neurocognitive tests|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
41105290|NCT00872417|DRUG|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
41105291|NCT00872417|DRUG|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
41105292|NCT05609448|PROCEDURE|MRI-guided radioembolization|Catheter placement will be performed using fluoroscopy, after which patients are transferred to the MRI scanner, where holmium microspheres are administered based on MRI dosimetry. Thereby, patients get a personalized dose administration.
41443753|NCT03638063|DIAGNOSTIC_TEST|Adenosine Triphosphate|Adenosine Triphosphate aerosol
41443754|NCT03638063|DIAGNOSTIC_TEST|capsaicin|capsaicin aerosol
41443755|NCT05234567|BIOLOGICAL|Asfotase Alfa|All participants will receive asfotase alfa subcutaneously per standard of care. Unless otherwise specified per the Physician's standard of care, participants aged \< 2 years are recommended for a clinic visit approximately every 3 months after Enrollment until 2 years of age, after which they should have a clinic visit approximately every 6 months. Participants should be followed for 5 years, as possible.
41443756|NCT05866588|BEHAVIORAL|Physical, psychological and spiritual nursing care (Nursing Therapeutics)|"1. Follow-up: To make a presentation about the physiological and psychological changes during pregnancy. do dream work~2. Follow-up: Providing education and counseling for childbirth.~3. Follow-up: Training and role rehearsal on mother-infant interaction, breastfeeding and infant care.~4. Follow-up: To provide counseling on the issues needed with the approaching of the birth.~5. Follow-up: Teaching about conscious parenting and mother-infant, father-infant interaction.~6. Tracking. To provide education, counseling and social support on the other roles of the mother in life such as wife role, working woman role, social role.~7. Follow-up: To evaluate the transition to motherhood.~8. Follow-up: To evaluate the outcomes of transition to motherhood and adjustment to motherhood according to expected completion time."
41443757|NCT04560335|BEHAVIORAL|Coach to FIt|"CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about~15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly."
41443758|NCT04560335|BEHAVIORAL|Treatment as Usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
41443759|NCT02818218|PROCEDURE|Liver Transplant|liver transplant recipient surgery
41443760|NCT05816564|BEHAVIORAL|Attention Bias Modification (ABM) for depression|"Both groups will be asked to engage in mindfulness activities but only one group will receive the train-positive ABM task. The control group will receive a sham task that is not programmed to train attention towards positive stimuli."
41443761|NCT05816564|BEHAVIORAL|Sham Attention Bias Modification (ABM)|The sham intervention will be given to the control group (but they will still receive mindfulness exercises).
41443762|NCT06626529|BEHAVIORAL|Guided mindfulness meditation|Watching a video of a guided mindfulness meditation include paying attention to the breath, promoting natural breathing without force; body scan, directing awareness from the head down to the toes, allowing tension to release in each area. The intervention emphasizes observing sensations without judgment, fostering a state of relaxed awareness.
41443763|NCT06626529|BEHAVIORAL|Scenery video|Watching a ten-minute video of calming music and images
41443764|NCT04531605|BEHAVIORAL|YBank program|Adolescents participated in a 12-week peer-led life skills trainings at clinics and received financial incentives via mobile money upon clinic attendance and demonstration of suppressed viral load.
41443765|NCT06486623|DRUG|Black chokeberry extract in capsules with 18% standardization of the anthocyanins content|"Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan."
41443766|NCT06486623|DRUG|Chokeberry fiber in capsules|"Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan."
41443767|NCT05074472|DRUG|ZB131|ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.
41443768|NCT03844334|DEVICE|WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured or unruptured intracranial aneurysms.
40752157|NCT04091308|OTHER|Individualized Physical Exercise Training with Protein Supplementation|Besides getting prescribed individualized physical exercise training programs, this group will consume protein supplementation (ARLA PROTINO) in form of protein enriched yogurts for easy consumption, two times daily, with each bottle containing 14 g of protein.
41443769|NCT04206358|BIOLOGICAL|OrienX010 combination with JS001|"OrienX010 Produced by Oriengene Biotechnology Co., Ltd. Strength: 1.0 mL/vial. Label claim: Titer 8.0 × 10\^7Pfu/mL, NMT 1 × 10 particles11VP/mL.~JS001 Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package."
41443770|NCT02399423|BEHAVIORAL|Weight gain|Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day
41443771|NCT02399423|BEHAVIORAL|Weight loss|Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
41443772|NCT06560294|DRUG|Micronized purified flavonoid fraction (Daflon ®)|Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.
41443773|NCT06560294|OTHER|Glue embolization|Patients will receive transcatheter glue embolization.
41443774|NCT01631331|DRUG|vismodegib|Given PO
41443775|NCT01631331|PROCEDURE|Mohs surgery|Undergo Mohs surgery
41443776|NCT04584294|BEHAVIORAL|MyPath Web-Based Informational and Decision Support Tool|"The MyPath Decision Support Tool includes the following sections and features:~* Questions to capture reproductive goals and orientations towards a potential pregnancy~* Education modules about the menstrual cycle, fertility, and prepregnancy health with the opportunity to flag topics that are relevant and of interest to the patient~* A contraceptive decision module that provides education, elicits patient preferences about different aspects of contraception, and suggests methods most appropriate based on the patient's preferences~* A feature for adding free-text questions that patients may have for their provider~* An email with a summary page that the patient can bring to a visit to guide discussions with primary care providers about reproductive needs"
41443777|NCT03853616|BIOLOGICAL|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
41443778|NCT00836056|DRUG|Clindamycin 300 mg capsule|1 x 300 mg
41443779|NCT00836056|DRUG|Cleocin HCl 300 mg capsules|1 x 300 mg
41443780|NCT02286050|OTHER|CF Nursing Program|
41443781|NCT02561520|BIOLOGICAL|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
41443782|NCT02561520|BIOLOGICAL|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
41443783|NCT03548363|DIETARY_SUPPLEMENT|Gingest powdered extract obtained from Ginger rhizomes|"Description: Powdered extract obtained from Ginger rhizomes. Botanical name: Zingiber officinale Roscoe Plant part used: Dried rhyzome Extraction solvent: CO2 Extract Ratio 45-60 / 1 100mg of extract are equivalent to an average of 4400 mg of dry ginger rhizomes~Composition: Natural extract, Calcium Hydroxide, Polysorbate 80, De-oiled soya lecithin, Calcium silicate"
41105293|NCT03318536|DRUG|Granisetron Hydrochloride|Patients received Granisetron.
41105294|NCT03318536|DRUG|No Granisetron|Patients who did not receive Granisetron.
41443784|NCT03548363|DIETARY_SUPPLEMENT|Placebo|200 mg/d maltodextrin
41443785|NCT00829452|DRUG|Ramipril 10 mg capsule|1 x 10 mg
41105295|NCT00831415|DRUG|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
41105296|NCT05179837|DEVICE|Optical coherence tomography probe|The OCT probe is attached to an approximately 3-meter wire that is attached to the OCT fiber probe system setup. This setup consists of a power supply unit, and a control platform that controls fiber probe rotation and retraction. The OCT probe will be advanced through the colonoscope instrument channel
41105297|NCT01048788|DRUG|OPC-41061|OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
41443786|NCT00829452|DRUG|Altace® 10 mg capsule|1 x 10 mg
41443787|NCT03911583|BEHAVIORAL|Control Group (CG)|The control group does not receive these notifications (PUSH)
41443788|NCT03911583|BEHAVIORAL|Moderate physical activity group (MPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
41105298|NCT00413179|DRUG|Metformin|
41105299|NCT00413179|DRUG|Clomiphene citrate|
41443789|NCT03911583|BEHAVIORAL|Intense physical activity group (IPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
41443790|NCT05355441|DRUG|Paracetamol|Routine clinical practice treatments recommended by the medical team involved
41443791|NCT05355441|DRUG|Ibuprofen 600 mg|Routine clinical practice treatments recommended by the medical team involved
41105300|NCT00413179|DRUG|Placebo|
41443792|NCT05355441|DRUG|Tramadol|Routine clinical practice treatments recommended by the medical team involved
41443793|NCT05355441|DRUG|Morphine|Routine clinical practice treatments recommended by the medical team involved
40752158|NCT01694394|DEVICE|Implantable Cardiac Monitor (Confirm ICM model 2102)|Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.
41105301|NCT00227682|DIETARY_SUPPLEMENT|ascorbic acid|
41105302|NCT00227682|DRUG|arsenic trioxide|
41105303|NCT00227682|DRUG|dexamethasone|
41105304|NCT00227682|DRUG|thalidomide|
41105305|NCT02546219|OTHER|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
41105306|NCT05796440|DRUG|LUM-201|Administered orally once daily
41105307|NCT05161507|PROCEDURE|Magseed|Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.
41443794|NCT03082872|DEVICE|Cemented K-wire|Fracture of proximal phalanx was treated with Cemented K-wire.
41443795|NCT03082872|DEVICE|Transfixion Pinning|Fracture of proximal phalanx was treated with transfixion pinning.
41443796|NCT03044210|OTHER|Metabolic evaluation|"* diet assessment~* biological evaluation~* clinical evaluation~* metabolic evaluation (calorimetry)"
41443797|NCT06559033|BIOLOGICAL|Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS|Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.
41443798|NCT03575650|OTHER|Cardiac imaging modalities|Repeat cardiac echocardiographies, MRI-scans and CT-scans for early subclinical biomarker assessments in breast cancer patients treated with chemotherapy and radiotherapy
41443799|NCT06242145|DRUG|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
41105308|NCT05161507|PROCEDURE|Magtrace|Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.
41105309|NCT05161507|PROCEDURE|Axillary lymph node metastasis - needle biopsy|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.
41105310|NCT06313138|OTHER|The Individual and Family Enhancement Program|The program is a group-based intervention which will be developed by the researcher based on the Individual and Family Self-Management Theory (IFSMT) (self-management skills) and the principle of Medagogy (PITS model: Pathophysiology, Indications, Treatments, Specifies) to improve patients' and their families' understanding of disease-related information and self-management skills consisting of goal setting and action plan, self-monitoring, solving problems and decision-making, and emotional control.
41105311|NCT06112717|OTHER|Supportive-Educative Nursing Care|Adolescents in the intervention group were received Supportive-Educative Nursing Care based on Orem's Self Care Deficit Nursing Theory
41105312|NCT02816632|OTHER|mRI|Neural bases of feedbacks' influence on decision making processes
41105313|NCT02816632|OTHER|Effect of Galvanic Vestibular Stimulation on decision making processes|Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
41105314|NCT00931593|DEVICE|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|"Visit V0 (day 0 - 2 to 14 days):~* Subject selection~* Obtaining of written informed consent~Visit V1 (day 0):~* Fasting subject~* Randomization to determine the examination order~* Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)~Visit V2 (day 0 + 1 day): Phone contact~Visit V3 (day 0 + 2 to 7 days):~* Same as V1~Visit V4 (V3 + 1 day): Phone contact and end of the study"
41105315|NCT00182936|BEHAVIORAL|Delirium Abatement Program|
41105316|NCT02422121|DRUG|RNS60|
41105317|NCT02422121|DRUG|Placebo|
41105318|NCT00697814|DRUG|Clomiphene citrate|Clomiphene 50 mg/day for 12 weeks
41105319|NCT02156687|DEVICE|Y mesh|Y mesh
41105320|NCT02156687|DEVICE|Dual flat mesh|Dual flat mesh
41105321|NCT04878328|BEHAVIORAL|Onsite Point-of-care|Guided by Social Cognitive Theory, O-PoC will employ CHWs with lived experience of incarceration to provide: 1) COVID-19 education; 2) SARS-CoV-2 testing with Cepheid XpertXpress PCR tests at Fortune facilities; 3) Needs assessments and facilitated access to masks and hygiene supplies; 4) Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters, or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5) Supportive counseling.
41105322|NCT01460342|DRUG|Tadalafil|5 mg (2 x 2.5-mg tablets), given once daily as oral tablet
41105323|NCT01460342|DRUG|Placebo|2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
41105324|NCT01976910|DRUG|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
41105325|NCT05534100|DEVICE|Biostrap EVO Wristband|Participants in both groups will wear the Biostrap wearable device
41105326|NCT00166192|PROCEDURE|Jessner's solution chemical peel|
41105327|NCT00166192|PROCEDURE|Trichloroacetic acid chemical peel|
41105328|NCT02175043|PROCEDURE|atrial electrogram and liner ablation|"1. The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~2. The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation"
41105329|NCT01813825|OTHER|Registry|
41105330|NCT02947568|OTHER|non-interventional study|
41105331|NCT05876130|RADIATION|POHIM_EM|hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)
41105332|NCT05949554|OTHER|Ketamine infusion|"Continuous measurement of burst suppression (BS) (%) and 95% spectral frequency front (SEF95) on frontal EEG Sedline® Masimo Corporation, USA).~EEG recording will start 10 minutes before the beginning of infusion until the total amount of 10 milligrams of Ketamine has been infused.~The duration varies depending on patient's weight.~Each patient will receive a dose of 0,5 mg/kg over a period of time of 2 or 4 hours."
41105333|NCT03976336|DIETARY_SUPPLEMENT|Berberine|500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
41105334|NCT03976336|OTHER|Identical Placebo|500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
41105335|NCT02520856|OTHER|blood sample|
41105336|NCT02699801|DRUG|propofol|propofol for post-sternal closure sedation
41105337|NCT02699801|DRUG|Dexmedetomidine|dexmedetomidine for post-sternal closure sedation
41105338|NCT00157014|DRUG|Tacrolimus|Oral
41105339|NCT00157014|DRUG|Cyclosporine|Oral
41105340|NCT00157014|DRUG|Mycophenolate mofetil|Intravenous and Oral
41105341|NCT00157014|DRUG|Methylprednisolone|Intravenous
41105342|NCT00157014|DRUG|Prednisone|Oral
41105343|NCT00810550|OTHER|Carotid ultrasound|Measurement of intima-media thickness
41105344|NCT02749045|RADIATION|SPECT imaging|myocardial perfusion imaging
41105345|NCT04094155|DIAGNOSTIC_TEST|retinal vascular analysis|Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
41105346|NCT03400462|DRUG|NSAID|Nimesulide has anti-inflammatory and analgesic properties. Like other NSAIDs it inhibits the action of COX . If prostaglandins can not be further synthesized, so there is no factor able to excite local nociceptors. According to t must be taken regularly for a minimum 2 weeks to achieve appropriate blood concentration.
41105347|NCT03400462|DEVICE|oral appliance|The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.
41270715|NCT03983499|BEHAVIORAL|Special Intervention|The components of the Special Intervention (SI) integrated design are: 1) Co-location of the clinical team; 2) Shared medical plan; 3) Clinical visits with a medical provider for management of chronic medical conditions; 4) Visits with behavioral health provider for management of psychosocial chronic conditions; 5) Care coordination; 6) Six group-health education classes and two booster sessions led by a promotora. Participants in the SI arm meet with the integrated care team in the context of a regular medical visit primarily to focus on clinical/biological aspects of the chronic medical conditions (diabetes, dyslipidemia, hypertension, obesity, etc.)
41443800|NCT06242145|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
41443801|NCT04825847|DEVICE|BIS monitor|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
41443802|NCT04825847|OTHER|Control group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at \[0.8-1.2\] MAC.
41443803|NCT06559878|DIAGNOSTIC_TEST|13C-α-Ketoisocaproic Acid Breath Test|13C-α-Ketoisocaproic acid with L-Leucine soluted in citric acid drink. The solution is administered orally during metabolic visits (3.-5.).
41443804|NCT06559878|DIETARY_SUPPLEMENT|Ethanol|6% ethanol soluted in normal saline is given intravenously during one metabolic visit.
41443805|NCT06559878|DIETARY_SUPPLEMENT|Lipid Emulsion|Lipid emulsion, heparin and normal saline are given intravenously during one metabolic visit.
41443806|NCT06559878|OTHER|Normal Saline|Normal saline is given intravenously during one metabolic visit.
41443807|NCT05806853|DRUG|68Ga-PSMA|Glu-NH-CO-NH-Lys-(Ahx)-\[68Ga(HBED-CC)\] (68Ga-PSMA)
41443808|NCT05806853|DRUG|68Ga-RM2|Bombesin receptor antagonist (68Ga-RM2)
41443809|NCT02589301|BIOLOGICAL|Pegfilgrastim|
41443810|NCT00028951|DRUG|fibrin sealant|
41443811|NCT00028951|PROCEDURE|surgical wound closure|
41443812|NCT05104866|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
41443813|NCT05104866|DRUG|Capecitabine|Tablet. Oral route of administration. Active comparator
41443814|NCT05104866|DRUG|Gemcitabine|IV Infusion. Active comparator
41105348|NCT03400462|OTHER|dry needling|Equipment: acupuncture needle 0,6\*13 e.g. Dragon Medical Device, Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd)
41270716|NCT05264220|BEHAVIORAL|ACT Matrix|Participants will receive a 4 session psychological intervention based on the ACT Matrix
41443815|NCT05104866|DRUG|Eribulin|IV Infusion. Active comparator
41443816|NCT05104866|DRUG|Vinorelbine|IV Infusion. Active comparator
41443817|NCT03069183|DRUG|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
41443818|NCT03069183|DRUG|Normal saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
41443819|NCT00374231|DRUG|tacrolimus|Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
41443820|NCT00374231|DRUG|mycophenolate mofetil|Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
41443821|NCT00374231|DRUG|Prednisone|Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
41443822|NCT00001835|DRUG|Oxaliplatin|
41443823|NCT00006376|DRUG|chemotherapy|
41443824|NCT00006376|DRUG|tipifarnib|
41443825|NCT05657860|DRUG|Guanfacine Extended Release|Initial dose for all participants will be 1mg per day. If the medication is well tolerated, the dose can be raised to 2 mg until day 28 and increased to 3 mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed., the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8 timepoint, the study will be unblinded.and subjects will continue treatment for 8 weeks.
41443826|NCT05657860|OTHER|Placebo|Placebo will be administered concurrently with GXR during trials.
41443827|NCT04728542|DEVICE|ORIGIN PS System|70 surgeries with the ORIGIN PS System
41443828|NCT04728542|DEVICE|VANGUARD PS System|70 surgeries with the VANGUARD System
41443829|NCT06560853|OTHER|Comprehensive School Health Programme|"Combination intervention which consists of:~* Upgrading sanitation facilities and constructing a 'health room' in the school~* Health teacher training: 5-10 teachers per school are recruited and trained for two weeks to become School Health Workers (SHWs) by Healthy Learners~* The SHWs: (1) deliver education on health and good sanitation and hygiene (2) coordinate with local clinics to deliver preventive care (e.g. school deworming and vitamin A supplementation); (3) assess sick students in the health room with a tablet-based clinical decision support system (CDSS); (4) treat sick students in the health room for some conditions (malaria, diarrhoea, schistosomiasis, pneumonia, conjunctivitis) or (5) refer to the health facility for treatment; (6) monitor absence of learners~* Referral: learners referred by SHWs are given a referral form by the SHW, which contains information about symptoms and suggested diagnosis by the CDSS. The learners are prioritised in the local clinic."
41443830|NCT06560853|OTHER|Deworming and vitamin A supplementation delivery|Schools implement the government policy of distributing deworming drugs and vitamin A supplementation to learners twice a year. Additional support from Healthy Learners ensures reliable delivery.
41443831|NCT05878964|OTHER|EQ-5D-5L questionnaire|Quality of life evaluation questionnaire
41443832|NCT05878964|OTHER|FACT-G (Functional Assessment of Cancer Therapy - General)|Quality of life evaluation questionnaire
41443833|NCT05878964|OTHER|FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)|Self reported evaluation of cutaneous toxicity questionnaire.
41443834|NCT01074203|DRUG|Nitazoxanide|"Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.~Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery \>12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses~All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given."
41443835|NCT04244097|DRUG|Bupivacaine Hydrochloride|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
41443836|NCT04244097|DRUG|Neostigmine|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
41443837|NCT02777372|DRUG|Sertraline|Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine luteinizing hormone (LH) Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.
41443838|NCT06064968|OTHER|Intermittent bladder catheterization|Intermittent bladder catheterization will be taught and performed by intervention group twice daily.
41443839|NCT02230605|OTHER|Mini-Mental State Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
41443840|NCT02230605|OTHER|Self-Administered Gerocognitive Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
41443841|NCT02230605|OTHER|Geriatric Depression Scale|To be completed at the Screening Visit and at POD 90
41443842|NCT02230605|OTHER|Charlson Comorbidity Index|To be completed at the Screening Visit and at POD 90
41443843|NCT02230605|OTHER|Short Form 36 Health Survey|To be completed at the Screening Visit
41443844|NCT02230605|OTHER|Confusion Assessment Method|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
41443845|NCT02230605|OTHER|Memorial Delirium Assessment Scale|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
41443846|NCT02230605|OTHER|Postoperative Quality of Recovery Scale|To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
41443847|NCT03650985|PROCEDURE|Fetoscope technique|Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.
41443848|NCT01654458|BEHAVIORAL|GyneGals Support Group|12-week online (i.e. Internet-based), professionally-facilitated support group
41443849|NCT02259244|BEHAVIORAL|Weight reduction program|
41270717|NCT00379327|PROCEDURE|Acupuncture|Acupuncture administered in last three weeks of pregnancy
41270718|NCT00379327|DEVICE|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
41443850|NCT04889586|DEVICE|EMG-biofeedback armband (REMO)|After clinical evaluation, the subjects execute an instrumental test. By wearing EMG-biofeedback device (REMO), the subjects have to perform 10 different hand gestures: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The muscle activations (EMG signals) during the execution of each movements, are recorded for 3 seconds.
41443851|NCT02464657|DRUG|Nivolumab|"Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
41443852|NCT02464657|DRUG|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
40752159|NCT05424809|BEHAVIORAL|Shared decision-making model|"The model is based on a person-centred care process, where an exchange of information is carried out between the health professional and the patient to make the best decision that is consistent with the person's values and preferences.~A six-stage process constitutes the model: 1) Identificacion of the decision point, 2) design of a specific patient decision aid, 3) identification of possible barriers and ways to overcome them, 4) training for professionals, 5) 3-steps implementation of shared decision-making in clinical practice, 6) evaluation"
41270719|NCT03499431|DEVICE|Endovascular Thoracoabdominal Aneurysm Repair|Standard of care, treatment of thoracoabdominal aneurysms using endovascular techiniques.
41270720|NCT03741361|OTHER|anxiety and depression|Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
41443853|NCT02464657|DRUG|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
41443854|NCT02464657|DRUG|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
41105349|NCT02493933|DRUG|Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine|
41443855|NCT02464657|DRUG|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
41105350|NCT03211637|COMBINATION_PRODUCT|Wounds Protocol|Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
41105351|NCT00154791|DRUG|oxaliplatin|
41105352|NCT00154791|DRUG|gemcitabine|
41105353|NCT00154791|DRUG|5-FU/LV|
41105354|NCT04505813|BIOLOGICAL|NEXI-002 T Cells|The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.
41105355|NCT03698396|BIOLOGICAL|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
41105356|NCT01842724|PROCEDURE|Motec total wrist arthroplasty|
41105357|NCT01842724|PROCEDURE|Remotion total wrist arthroplasty|
41105358|NCT05307666|OTHER|Medication minimization|During the medication minimization visit, and any necessary follow-up visits, patients and providers work together to gradually minimize medication dosages (e.g. reducing 1/4 or 1/2 dose at a time) using the following approach: 1) Medications Treating Symptoms: Find the minimum dose that controls the symptom, 2) Drugs that Lower Blood Pressure: Reduce dosages until systolic BP is in the upper 10mmHg of the target range (e.g. target 130 - 140 mmHg), 3) Drugs That Lower Blood Sugar: Reduce dosages until HbA1c is in the upper 5% of the target range (e.g. target 7.5 - 8.0%).
41105359|NCT04132440|OTHER|Interview|Complete interview
41443856|NCT04738539|DRUG|Contrast Enhanced Voiding Urosonography with Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
41105360|NCT04132440|OTHER|Questionnaire Administration|Complete questionnaire
41105361|NCT02545062|OTHER|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
41105362|NCT04957654|OTHER|VST with collagen plug soaked in blood|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with collagen plug soaked in blood
41105363|NCT04957654|OTHER|VST with Allograft Demineralized bone matrix Grafton|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with Allograft Demineralized bone matrix Grafton
41105364|NCT04957654|OTHER|VST with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles
41105365|NCT01713530|DRUG|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
41105366|NCT01713530|DRUG|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
41105367|NCT01713530|DRUG|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
41105368|NCT05626504|DEVICE|Pipeline Embolization Device with Vantage Technology|Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.
41105369|NCT01913119|DRUG|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
41105370|NCT00145041|DRUG|Vincristine Sulfate Liposomes Injection|Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
41105371|NCT03425890|BEHAVIORAL|SURE program|SURE program is a self-exercise program which aims to empower people with stroke and their caregivers to increase early UL practice outside therapy
41105372|NCT00817817|DEVICE|MF|One evening dose of dry powder inhaled MF 400 μg (Multidose device).
41105373|NCT00817817|DEVICE|MF|One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
41105374|NCT03426683|OTHER|Intestinal Microbiota Transplantation|the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized IMT three times or traditional medicine and would be followed up for at least 3 year.
41105375|NCT01273844|DRUG|Bortezomib|Bortezomib
41105376|NCT00502372|DIETARY_SUPPLEMENT|Nutritional Supplement/Amino acids and HMB|Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
41105377|NCT00502372|DIETARY_SUPPLEMENT|Juven|comparison of Juven with arginine only product in wound healing
41270721|NCT05887999|DRUG|LY3532226|Administered subcutaneously (SC).
41270722|NCT05887999|DRUG|Placebo|Administered SC.
41443857|NCT04738539|DIAGNOSTIC_TEST|Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
41443858|NCT06559618|DRUG|Phage Therapy|A 20 mL sterile solution containing one to three individual phage drug substances (TPC) with total strength (potency) 3 x 10\^8 plaque-forming units (PFU), will be administered intravesicularly twice a day (one instillation in the morning and one in the evening \[at least six hours apart\], respectively) for 7 days. The selection of individual phages to include in the TPC are personalized/customized for each participant per phage susceptibility testing to the participant's urinary E. coli (testing is conducted by TAILФR Service Center). Each dose of TPC will be followed with a 10 mL flush of sterile 0.9% saline solution.
41270723|NCT00877344|PROCEDURE|Immediate insertion|Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
41105382|NCT03150563|OTHER|Passive static stretch|Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.
41105383|NCT04260750|BEHAVIORAL|Internet-administered Cognitive behavioral therapy (ICBT)|"The intervention consists of fifteen modules, each having a specific focus on a problem (e.g. comorbid worry alongside the depression) or containing a specific strategy or element (e.g. behavioral activation).~The fifteen modules are:~Introduction/Psychoeducation about depression, Behavioral activation 1, Behavioral activation 2, Cognitive restructuring, Acceptance, Psychoeducation about emotions, Anxiety and exposure, Comorbid social anxiety, Comorbid worrying and generalized anxiety, Comorbid panic disorder, Sleep problems, Perfectionism, Stress management, Relaxation, and Relapse prevention.~The first and last module are assigned to all participants. The rest is picked either by the participants themselves or by the therapist conducting the intake interview."
41105384|NCT05114044|OTHER|Core stability training|The core stability training were performed 5 days a week for 15 min over a period of 3 weeks. The conventional therapy were performed 5 days a week for 30 min (remaining time of each session) over a period of 3 weeks. Duration of each session was 45 min.
41105385|NCT05114044|OTHER|Conventional therapy|The conventional therapy were performed 5 days a week for 45 min over a period of 3 weeks. Duration of each session was 45 min
41105386|NCT04297982|OTHER|Mandala Activity|Mandala is a method of expressing one's feelings and thoughts. The person draws and paints the paper in a round shape.
41105387|NCT04297982|OTHER|Routine nursing care|Interventions routinely implemented by nurses in the clinic
41443859|NCT06559618|OTHER|Placebo|Sterile 0.9% saline solution also 20 mL, followed with a 10 mL flush of the same solution.
41105388|NCT04666818|DEVICE|Use of Flash Glucose Monitoring|Participants in the intervention group were advised to monitor glucose levels by means of flash glucose system.
41105389|NCT03775551|BEHAVIORAL|Improvement cycle|at least 6 workshops (sessions) will be held with the members of the care system, in order to identify opportunities for improvement oriented to the design and application of an innovative intervention based on best practices.
41105390|NCT05527236|OTHER|Breathing Exercise|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the breathing exercise group was made breathing exercises again. As soon as the virtual reality glasses and breathing exercise device were removed, VAS was applied. In order to evaluate the second and third stages of labor, the birth evaluation section of the labor observation form was filled out. Satisfaction with birth was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.
41105391|NCT05527236|OTHER|Virtual Reality|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm) the virtual reality group watched a 10-minute video with virtual reality glasses. Once the virtual reality glasses were removed from experimental groups Visual Analogue Scale was applied. Birth satisfaction was evaluated with the Birth Satisfaction Scale within the first 4 hours after the delivery was completed.
41105392|NCT00248391|BEHAVIORAL|upright feeding|
41105393|NCT01421654|DEVICE|S9 Elite with Acclimate|S9 Elite Flow Generator with Acclimate feature activated
41105394|NCT01421654|DEVICE|S9 Elite|S9 Elite Flow Generator
41105395|NCT00285688|PROCEDURE|gastroscopic examination|gastroscopic examination for tissue biopsy and real time PCR for gene study
41105396|NCT00003435|BIOLOGICAL|anti-thymocyte globulin|
41105397|NCT00003435|DRUG|melphalan|
41105398|NCT00003435|PROCEDURE|antiviral therapy|
41105399|NCT00003435|PROCEDURE|bone marrow ablation with stem cell support|
41105400|NCT00003435|PROCEDURE|peripheral blood stem cell transplantation|
41270724|NCT00877344|PROCEDURE|Interval insertion|Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
41443860|NCT04862767|DRUG|TASO-001((TGF-β2 targeting anti-sense oligonucleotide)|96 hour continuous infusion
41443861|NCT04862767|COMBINATION_PRODUCT|Aldesleukin|SC, Bid
41443862|NCT02974621|BIOLOGICAL|Bevacizumab|Given IV
41443863|NCT02974621|DRUG|Cediranib|Given PO
41443864|NCT02974621|DRUG|Cediranib Maleate|Given PO
41443865|NCT02974621|DRUG|Olaparib|Given PO
41105401|NCT00003435|PROCEDURE|umbilical cord blood transplantation|
41105402|NCT00003435|RADIATION|radiation therapy|
41105403|NCT02667535|DRUG|Isosorbide Mononitrate|"Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days."
41105404|NCT02787109|BIOLOGICAL|CTH522-CAF01|CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
41105405|NCT02787109|BIOLOGICAL|CTH522-Al(OH)3|CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
41105406|NCT02787109|BIOLOGICAL|Placebo|Saline
41105407|NCT05213715|OTHER|assessment|assessment of upper extremity functions, somatosensorial functions and proprioseption of upper extremity
41443866|NCT04292873|OTHER|Vitamin D supplement|Enteral supplement of 569,600 IU vitamin D
41105408|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
41443867|NCT02817867|DEVICE|tDCS|Transcranial direct current stimulation (tDCS)
41105409|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
41105410|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
41105411|NCT00755781|DRUG|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
41105412|NCT00630513|DRUG|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
41105413|NCT00630513|DRUG|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
41105414|NCT02054299|DRUG|Drug application Amitriptyline|Amitriptyline: 25 mg, single oral application
41105415|NCT02054299|DRUG|Drug application Desvenlafaxine|Desvenlafaxine: 50 mg, single oral application
41105416|NCT02054299|DRUG|Drug application Sumatriptan|Sumatriptan: 50 mg, single oral application
41105417|NCT02054299|DRUG|Drug application Proguanil|Proguanil: 200mg, single oral application
41105418|NCT02054299|DRUG|Drug application Fenoterol|Fenoterol: 180 mcg, single intravenous application
41105419|NCT02054299|DRUG|Drug application Thiamine|Thiamine: 200mg, single oral application
41105420|NCT04243304|OTHER|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
41443868|NCT02817867|DEVICE|TMS|Transcranial magnetic stimulation
41270725|NCT05946967|OTHER|Biofeedback with TENS|Constipation patients will be given biofeedback treatment along with transcutaneous electrical stimulation (TENS) of posterior tibial nerve
41270726|NCT05946967|OTHER|Biofeedback only|Constipation patients will be given biofeedback treatment only
41270727|NCT02661594|DRUG|APD421 5 mg|Therapeutic dose of amisulpride
41270728|NCT02661594|DRUG|APD421 40 mg|Supra-therapeutic dose of amisulpride
41105421|NCT04243304|OTHER|18F-PE2I PET-MR|Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
41105422|NCT02155686|DEVICE|Biosensors|Device: Biometric sensors; Home automation; telecare
41105423|NCT02155686|DEVICE|Home automation|
41105424|NCT01387113|OTHER|Computed tomography perfusion imaging|As per standard of care at CPMC
41105425|NCT00199589|DRUG|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
41105426|NCT02050724|DRUG|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
41105427|NCT02050724|DEVICE|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
41105428|NCT02050724|DEVICE|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
41105429|NCT04174495|DIAGNOSTIC_TEST|DXA and CT-scan|DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
41105430|NCT00564967|BEHAVIORAL|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
41105431|NCT00564967|BEHAVIORAL|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
41270729|NCT02661594|DRUG|Moxifloxacin|Positive control for assay sensitivity
41270730|NCT02661594|DRUG|Placebo|Placebo comparator to establish baseline for calculating change in QTcF
41270731|NCT01939379|DRUG|Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.|
41270732|NCT01939379|DRUG|For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.|
41443869|NCT02817867|DEVICE|tDCS + TMS|Association between tDCS and TMS.
41443870|NCT06614725|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly on Day 1 to participants in OA-RSV and Adults-AIR-RSV groups.
41105432|NCT02026219|DRUG|Clopidogrel|Clopidogrel 600mg loading
41105433|NCT02026219|DRUG|Ticagrelor|Ticagrelor 180mg loading
41105434|NCT00789919|PROCEDURE|Delivery of infant|Vaginal delivery or cesarean section, whichever is indicated
41105435|NCT01215019|DRUG|Mannitol|20% Mannitol, 1-5 doses as needed to control ICP
41105436|NCT01215019|DRUG|NaCl|3% sodium chloride injection, 1-5 doses, as needed to control ICP
41105437|NCT01559506|DEVICE|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
41105438|NCT05616104|DEVICE|FLEX Vessel Prep System|"The FLEX Vessel Prep System to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion.~Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding Instructions for Use. Once advanced into the lesion, the balloon should be inflated according to the site's standard of care."
41105439|NCT00481234|DEVICE|Heart Rate Variability analysis|
41105440|NCT00470938|DEVICE|SpineForce Reactive Neuromuscular Trainer|
41105441|NCT04163471|DEVICE|Radial artery mechanical compression for hemostasis|Transradial hemostasis following arterial catheterization procedures
41105442|NCT02521116|OTHER|Dynamic Vessel Analyzer|
41105443|NCT02521116|OTHER|Oxymap T1|
41105444|NCT00444613|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
41105445|NCT00444613|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
41105446|NCT00444613|DRUG|Placebo|Intramuscular injection, placebo twice a week for 3.5 years.
41105447|NCT05663918|BEHAVIORAL|Self- determined Intensity Interval Training|Individuals will participate in 3 sessions of Self Determined Intensity Interval training, using a cycle ergometer, for 4 weeks.Ratings of Perceived exertion (RPE) will be measured using a Borg's 6-20 scale. (44). Users will be asked to exercise on a stationary bike at an intensity whereby there RPE is challenging. The cycling protocol includes five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery (cycling at a slow pace to bring the individuals heart rate down). Participants will also perform a 3-minute warm-up and a 2-minute cool-down for a total exercise duration of 17.5 minutes
41105448|NCT06341491|BEHAVIORAL|Pé-de-Meia Program|"The Pé-de-Meia Program was established by the Brazilian Federal Government with the aim of encouraging the retention of low-income students in high school by providing maintenance scholarships and savings opportunities. To be eligible for the program, a young person must: Be properly enrolled in a regular public high school course, be between 14 to 24 years old, come from a low-income family, and be registered in the Bolsa Família Program. The Program offers four types of incentives:~An enrollment grant registered at the beginning of the academic year, paid once a year in the amount of 200 BRL.~A minimum school attendance of 80% of the total class hours, paid in nine installments throughout the year at 200 BRL each.~Proven participation in the National High School Exam (ENEM), paid once to the student enrolled in the third year of high school, in the amount of 200 BRL.~Completion of the high school academic years, paid in a single installment of 1,000 BRL."
41105449|NCT02496793|BEHAVIORAL|Peer-facilitated community support group|Support groups were composed of up to 20 women from community. Peer facilitator facilitated a total of 6 groups of a maximum of 20 women each. Women were exposed to 8 two hour sessions. Facilitators gave activities in support of MCH/PMTCT. Group met twice a month for four months. The support group meetings took place in the community at a convenient location for those attending (e.g. village meeting point, churches, schools or individual households). With local support through community leaders, the intervention involved trained peer facilitators working with pregnant and post-partum women to form ANC and PNC support groups through which they will present information on general maternal and child health and PMTCT specific topics using participatory learning and problem-solving approaches.
41105450|NCT00217672|BIOLOGICAL|bevacizumab|Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
41105451|NCT00217672|DRUG|Docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
41105452|NCT06093113|BEHAVIORAL|Alba - Youth in grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains five main sections: Learning, Self-assessment, Manage symptoms, Find support and a Personal space.
41105453|NCT06093113|BEHAVIORAL|Control website|The website will contain information about grief and grief reactions similar to some of the information given in the app.
41105454|NCT02747732|DRUG|Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
41270733|NCT03160729|DRUG|Dexamethasone|pre-operative, single-shot injection
41443871|NCT06614725|COMBINATION_PRODUCT|Placebo|1 dose of placebo (saline solution) administered intramuscularly on Day 1 to participants in OA-Placebo and Adults-AIR-Placebo groups.
41443872|NCT00545792|DRUG|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
41443873|NCT02849496|DRUG|Atezolizumab|Given IV
41105455|NCT02983370|PROCEDURE|Minicraniotomy|The surgical method for the implantation of the intracortical microelectrodes is straightforward and follows the standard neurosurgical procedures. Briefly, after the scalp is prepped with an antiseptic, a small skin incision is made. Then the skin and muscles are lifted off from the bone and folded back. Next, one small burr hole or a minicraniotomy of approximately 1.5 cm is made in the skull. This is a minimally invasive procedure that allows an easy access to the brain and is a standard procedure widely used in neurosurgery.
41105456|NCT06044545|DIAGNOSTIC_TEST|Web Based Pregnancy Preparation Education Structured According to the Health Promotion Model Knowledge Attitude and Health Behaviors|"With this research, according to the health promotion model for the care that should be taken during the preconceptional period (pre-pregnancy) of women who are not yet pregnant, who will marry soon and who are considering pregnancy.~It is thought that they will gain knowledge, increase their awareness and develop positive health behaviors with the web-based pregnancy preparation training. In data collection; Introductory Characteristics Form, Preconceptional Knowledge and Attitudes Scale, Preconception Health Behaviours Scale will be used."
41270734|NCT04226313|DIAGNOSTIC_TEST|Self-sampling by Evalyn Brush|Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
41105457|NCT01615432|DEVICE|V-PAP III ventilator|
41443874|NCT02849496|PROCEDURE|Biopsy|Undergo a biopsy
41443875|NCT02849496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41443876|NCT02849496|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41443877|NCT02849496|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41443878|NCT02849496|PROCEDURE|Bone Scan|Undergo a bone scan
41443879|NCT02849496|PROCEDURE|Computed Tomography|Undergo a CT scan
41443880|NCT02849496|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41443881|NCT02849496|DRUG|Olaparib|Given PO
41443882|NCT02849496|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
41443883|NCT02849496|OTHER|Questionnaire Administration|Ancillary studies
41443884|NCT02849496|PROCEDURE|X-Ray Imaging|Undergo an x-ray
41443885|NCT02974556|PROCEDURE|Standard surgical treatment|Standard surgical treatment (open or laparoscopic techniques) containing at least 12 lymph-nodes for accurate pN staging.
41105458|NCT01615432|DEVICE|Stellar 150 ventilator|
41270735|NCT04226313|DIAGNOSTIC_TEST|Self sampling by Evalyn Brush home or in GP´s clinic|Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush
41443886|NCT02974556|PROCEDURE|Proactive management|Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. After positioning three in- and outflow catheters HIPEC perfusion starts with a minimum of 2 L isotonic dialysis fluid at a flow-rate of 1-2 l min and an inflow temperature of 42-43° C with a total of 30 minutes perfusion time. Before the beginning of HIPEC 5-fluouracil and leucovorin will be administrated intravenously to potentiate oxaliplatin activity.
41443887|NCT02974556|DRUG|Standard adjuvant systemic chemotherapy|Adjuvant systemic chemotherapy (according CAPOX or FOLFOX regimens for a total of 6 months) will be reserved in patients with pT3 tumors with poor prognostic factors, in patients with pT4 tumors and when lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT every six months for the first 24 months and later every year for the next three years in both study arms.
41443888|NCT03847688|DEVICE|Transcranial Magnetic Stimulation|Patient receive Transcranial Magnetic Stimulation for treatment resistant depression as part of their routine care.
41443889|NCT01124175|DRUG|Losartan|100 mg Tablets
41443890|NCT01124175|DRUG|Cozaar®|100 mg Tablets
41443891|NCT06360887|PROCEDURE|Conservative|Conservative treatment
41443892|NCT06360887|PROCEDURE|ORIF|Open surgery
41443893|NCT06360887|PROCEDURE|CRPP|Minimal invasive surgery
41443894|NCT05163743|DIETARY_SUPPLEMENT|Low Calorie Ketogenic Diet|The very low-carbohydrate diet will be hypo caloric and aim to provide less than 50 g of carbohydrates per day. the participants will be counseled to choose vegetarian and healthy sources of fat and protein and to avoid trans fat. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
41443895|NCT01058668|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
41443896|NCT01058668|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
41105459|NCT01615432|DEVICE|BiPAP vision ventilator|
41105460|NCT01615432|DEVICE|V60 ventilator|
41105461|NCT04441593|BEHAVIORAL|Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP)|Videoconferencing intervention to reduce alcohol use and chronic pain interference and severity
41105462|NCT04441593|BEHAVIORAL|Treatment as Usual|Psychoeducation and Information about Treatment Resources
41105463|NCT02071979|DEVICE|Autologous PRP Gel|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then activated (by mixing with thrombin and calcium chloride) and sprayed directly on the area to be treated.
41270736|NCT02345798|PROCEDURE|Standard Follow-Up Care|Undergo usual care
41270737|NCT02345798|OTHER|Caregiver-Related Intervention or Procedure|Undergo video-assisted intervention
41270738|NCT02345798|OTHER|Educational Intervention|Undergo video-assisted intervention
41270739|NCT02345798|OTHER|Quality-of-Life Assessment|Undergo quality of life assessment
41443897|NCT03835117|DRUG|Wide-spectrum nutritional supplement|Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
41443898|NCT03835117|OTHER|Placebo|Inactive placebo comparator
41443899|NCT06421935|DRUG|M9466|Participants will be administered M9466 orally.
40752160|NCT00120874|BEHAVIORAL|Individualized management of AD including caregiver training|Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
41105464|NCT02071979|DEVICE|Autologous PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then drawn into multiple small syringes and injected directly into the wound bed or the skin surrounding it.
41105465|NCT02071979|DEVICE|Autologous PRP Gel plus PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and PRP from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then divided into equal parts and half is drawn into multiple small syringes and injected directly into the skin surrounding the wound bed, half is activated (by mixing with thrombin and calcium chloride) and sprayed the wound bed.
41105466|NCT02071979|PROCEDURE|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
41105467|NCT04608955|DRUG|WX-081|WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
41105468|NCT04608955|DRUG|Bedaquiline|This licensed drug will be used in arm F as positive comparator.
41105469|NCT04608955|DRUG|Standard treatment|Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
41105470|NCT04608955|DRUG|Multi-drug background treatment (MBT)|MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
41105471|NCT02039713|DEVICE|DeSyne drug eluting stent group|
41105472|NCT03099824|DRUG|GC4711 Oral Capsule G-101|82 mg (1 capsule)
41105473|NCT03099824|DRUG|IV GC4419|GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
41105474|NCT03099824|DRUG|GC4711 Oral Capsule G-101|164 mg (2 capsules)
41105475|NCT03099824|DRUG|GC4711 Oral Capsule G-101|246 mg (3 capsules)
41105476|NCT03099824|DRUG|GC4711 Oral Capsule G-111|175 mg (1 capsule)
41105477|NCT03099824|DRUG|GC4711 Oral Capsule G-112|145 mg (1 capsule)
41105478|NCT03099824|DRUG|GC4711 Oral Capsule G-119|233 mg (1 capsule)
41105479|NCT03099824|DRUG|GC4711 Oral Capsule G-125|233 mg (1 capsule)
41105480|NCT03099824|DRUG|IV GC4711|GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
41105481|NCT06001372|DRUG|Ketamine|"Ketamine, 0.5-1.2mg/kg, administered intramuscularly~* Doses can range 0.5-1.2 mg/kg. Starting dose for all participants will be 0.5mg/kg.~* Dose can be titrated up to maximum of 1.2 mg/kg or titrated down to 0.5 mg/kg based on response and clinical judgement.~* Dose will be administered by injecting into large muscle mass (eg, deltoid, gluteal muscle, thigh)"
41105482|NCT03949335|DEVICE|IOL Model ZFR00V|Bilateral implantation with Investigational IOL Model ZFR00V
41105483|NCT03949335|DEVICE|IOL Model ZCB00|Bilateral Implantation with control IOL Model ZCB00
41105484|NCT05192863|OTHER|No Intervention|This is a non-interventional study.
41105485|NCT03999554|BIOLOGICAL|LD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
41105486|NCT03999554|BIOLOGICAL|MD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
41105487|NCT03999554|BIOLOGICAL|HD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
41105488|NCT03999554|BIOLOGICAL|LD Bris10 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.
41105489|NCT03999554|OTHER|Placebo|This group will receive saline placebo administered intranasally.
41105490|NCT04286256|BEHAVIORAL|Motivational Interviewing|Participants/caregivers will receive several telephone-based and in-person motivational interviewing sessions along with specific oral health recommendations.
41105491|NCT04776993|DRUG|Methimazole|Methimazole for 72 weeks
41105492|NCT04776993|PROCEDURE|Radioiodine or thyroidectomy|Treatment with radioiodine or with thyroidectomy
41105493|NCT02777099|PROCEDURE|remote ischemic postconditioning|Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.
41105494|NCT02777099|PROCEDURE|sham remote ischemic postconditioning|Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.
41105495|NCT03184558|DRUG|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor.
41105496|NCT05322824|DRUG|standard medical treatment|standard medical treatment
41105497|NCT05322824|PROCEDURE|Interventional stenting|Interventional stenting
41105498|NCT05593042|BIOLOGICAL|CoronaVac®|The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.
41105499|NCT05593042|BIOLOGICAL|Omicron Vaccine|"An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant."
41105500|NCT05593042|BIOLOGICAL|Trivalent Vaccine|"An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant)."
41105501|NCT05945875|DRUG|Panitumumab-IRDye800|Given by IV
41105502|NCT05945875|OTHER|Indium In 111 Panitumumab|Given by IV
41105503|NCT05945875|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Single Photon Emission Computed Tomography
41105504|NCT05945875|PROCEDURE|Computed Tomography|Undergo Computed Tomography
41105505|NCT05945875|PROCEDURE|Resection|Undergo standard of care surgical resection
41270740|NCT02345798|OTHER|Questionnaire Administration|Undergo questionnaire administration
41443900|NCT06421935|DRUG|Tuvusertib|Participants will be administered Tuvusertib orally.
41443901|NCT03873272|DEVICE|Cryotherapy|Study subjects will wear NatraCure flexible socks on bilateral hands and feet. The sock will act as a mitten and covers the entire hand until past the wrist. There are 2 gel packs inserted into the sock, to provide cooling to the dorsal and frontal aspect of the hand. For the feet, the sock will cover the entire foot until above the ankle. Garments will be refrigerated for at least 3 hours at -25 to -30 Celsius prior to use. With each infusion, patients will wear the frozen garments on their hands and feet for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion. Two sets of socks will be used during each session for 45-60 minutes each to maintain a consistently low temperatures of the extremities.
41105506|NCT05945875|PROCEDURE|Fluorescence Imaging|Undergo standard of care fluorescence imaging
40752161|NCT00120874|DRUG|Memantine|Patients receive 10 milligrams of memantine twice daily.
41105507|NCT02907593|DRUG|Budesonide in Calfactant|Budesonide in Calfactant
41105508|NCT02438124|BEHAVIORAL|Neuropsychological evaluation|The subjects are submitted in one hearing stimulus while they realize a walking test
41105509|NCT04067960|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
41105510|NCT04067960|OTHER|Genetic Testing|Undergo pharmacogenomics testing
41105511|NCT04067960|OTHER|Quality-of-Life Assessment|Ancillary studies
41105512|NCT04067960|OTHER|Questionnaire Administration|Ancillary studies
41105513|NCT00917358|DRUG|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
41105514|NCT06544382|OTHER|The Long COVID Rehabilitation Intervention|The intervention is a structured rehabilitation intervention with a duration of minimum 3 months comprising 4-12 individual sessions and 1-4 group-based courses delivered by physiotherapists and occupational therapists.
41105515|NCT06544382|OTHER|Usual care|A less structured rehabilitation programme comprising individual session with a few group options with patients with long COVID or mixed diagnoses.
41105516|NCT03629119|DIETARY_SUPPLEMENT|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
41105517|NCT03967925|DRUG|Belimumab|Sub-cutaneous injection
41105518|NCT03967925|DRUG|Rituximab|IV infusion 1g x 2
41105519|NCT03967925|DRUG|Prednisolone|20mg prednisolone tapering dose
41105520|NCT05602857|OTHER|Balance Training|"The BT program has multiple difficulty levels, and each child will progress at an individual pace tailored to their balance skills. Training sessions will emphasize top-down control of balance and contain a combination of dynamic and static balance exercises. Children and their parents will receive written step-by-step instructions, with photos, verbal and/or video instructions on their private OneDrive folder.~To monitor compliance, whether the exercises were done properly, and evaluate a child's progress, the parent/guardian will film the sessions, and upload the video to OneDrive, so we can score the child's performance and provide them with a progress tracking chart.~Every child will be given the equipment needed to do the balance exercises: two wooden beams that will make a 12-foot balance beam, four small wooden cubes that will raise the balance beam 5 inches off the ground, a wobble board, a hopscotch mat, one roll of painter's tape, one measuring tape, a bell, a small book."
41270741|NCT00963326|OTHER|laboratory biomarker analysis|
41270742|NCT02427113|OTHER|Sound Oasis Vibrating Chair|Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
41270743|NCT02427113|OTHER|Self-Select Music|The self-select music of the participants will be applied for managing the painful symptoms of TMD
41270744|NCT05230498|DEVICE|anatomy-based fitting then default fitting|Cochlear implant with anatomy-based fitting then default fitting
41270745|NCT05230498|DEVICE|default fitting then anatomy-based fitting|Cochlear implant with anatomy-based fitting then default fitting
41270746|NCT06110650|DRUG|Surufatinib|Surufatinib 300mg orally, once a day, every 21 days for one cycle, treatment until disease progression or intolerance
41270747|NCT05971797|BEHAVIORAL|REBT|During REBT in patients with osteoarthritis and concomitant diseases with diagnosed depression or anxiety before arthroplasty the patients learn how to manage their irrational or unhealthy emotions, thoughts, and behaviors.
41443902|NCT03873272|DEVICE|Compression Therapy|Study participants will wear Sigvaris Secure Arm Sleeves and Gloves on bilateral upper extremities. The sleeves and gloves provide 20-30mmHg of compression. Subjects will wear Sigvaris CompreFlex Lite compression garments on the lower extremities which includes a transition liner with a compressive foot, providing 20-30mmHg of compression on the lower leg and 15mmHg on the toes and feet. AccuTabs will be placed along the CompreFlex Lite to easily and accurately set the compression level at 20-30mmHg. With each chemotherapy infusion, patients will wear the sleeves/gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
41443903|NCT03873272|DEVICE|Loose glove/sock|Study participants will wear a non-compressive sleeve and loosely fitting glove on bilateral arms and hands. They will also wear a non-compressive Sigvaris Basic Liner with the CompreFlex Lite loosely applied over it. The investigators will verify that no compression is applied via using an interface pressure sensor (PicoPress). The maximum level of allowed pressure for garments will be 3mmHg. If the pressure reading is greater than 3mmHg, then a larger garment size will be used. Measurements with the pressure sensor will be repeated as needed to ensure a low pressure level of less than 3mmHg. With each chemotherapy infusion, patients will wear the gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
41443904|NCT00000925|DRUG|Optimune oral nutritional supplement|
41443905|NCT06025110|BIOLOGICAL|TCD601|Investigational Product
41270748|NCT01009528|DEVICE|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
41270749|NCT06391645|DRUG|Nerve Growth Factor|intravenously injection
41443906|NCT06025110|OTHER|Placebo|Comparator
41443907|NCT03012529|DRUG|Rifampin|Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
41270750|NCT05303129|BIOLOGICAL|Blood sampling|Blood sampling for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts )
41105521|NCT05602857|OTHER|Music Training|"Children assigned to MT will be asked what kind of music and what performers they like best, and what songs they like most. After those open-ended questions, they will be asked about specific songs, guided somewhat by the child's previous answers, and will watch short excerpts from music videos to see which the child would like to listen to and watch during Week 1 of the MT program. This is all to guide the selection of music videos the child will enjoy and might give some thought to.~They will receive 10 music videos per week, through the child's private OneDrive folder, from which they can choose 4 to watch every session. Children will be instructed to not do anything else, but simply watch the videos or listen with their eyes closed.~To monitor compliance, and to check if the child was paying attention to the music videos or just having them play in the background while doing something else, the parent/guardian will film the MT sessions, and upload the video to OneDrive."
41105522|NCT03154944|DEVICE|Ostomy device 1|This device consists of a known adhesive and a new top film
41105523|NCT03154944|DEVICE|Ostomy device 2|This device consists of a new adhesive and a known top film
41105524|NCT03154944|DEVICE|Ostomy device 3|This device consists of a known adhesive and a new top film
41105525|NCT01570660|DRUG|Pioglitazone|12 weeks of pioglitazone treatment
41105526|NCT01455051|DRUG|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
41443908|NCT03012529|DRUG|Riboflavin Placebo|A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
41105527|NCT03996746|DIAGNOSTIC_TEST|No intervention|No intervention
41270751|NCT01967290|DEVICE|Vibratory feedback and 3D movement analysis|Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.
41270752|NCT01967290|DEVICE|Only 3D movement analysis|Hand-to-mouth task performed under 3D continuous movement analysis only
41270753|NCT01994083|DRUG|Placebo|Administered orally
41270754|NCT01994083|DRUG|IX-01|Administered orally
41270755|NCT03614936|OTHER|Geriatric Screening Test G8|Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).
41270756|NCT03614936|OTHER|Geriatric fragility test GERICO|"GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:~* the socio-cultural evaluation scale,~* the ADL autonomy questionnaire,~* assessment of locomotor disorders,~* nutritional assessment,~* the MMSE Cognitive Function Evaluation Questionnaire,~* the GDS-4 mood rating scale,~* the comorbidity assessment test (Charlson Index)"
41443909|NCT03724695|OTHER|Clinician nudge or opt out approach for AHCAH liaison visit|"This study is a nudge or opt-out approach of an AHCAH liaison visit to eligible seriously ill HF patients prior to hospital discharge to discuss the AHCAH program and to subsequently facilitate enrolling them in the AHCAH program if they are amenable, compared to the opt-in approach (usual care)."
41443910|NCT02222818|DEVICE|Conducted AF Response (CAFR)|The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
41443911|NCT02222818|DEVICE|Conducted AF Response Plus (CAFRPlus)|The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
41443912|NCT03998150|PROCEDURE|Holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Asclepion MultiPulse HoPlus 110W and Lumenis pulse 100W and 120W)
41443913|NCT03998150|PROCEDURE|Bipolar plasma kinetic enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using bipolar plasma kinetic energy (KLS Martin Maxium or Covidien Force Triad)
41270757|NCT04143633|OTHER|Low FODMAP diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
41270758|NCT04143633|OTHER|Standard diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
41270759|NCT06325514|DIAGNOSTIC_TEST|Artificial intelligence based program|the AI based program is based on image analysis
41443914|NCT02291796|DRUG|Bezafibrate|Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration \>500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
41443915|NCT02281084|DRUG|Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
41443916|NCT02281084|DRUG|Durvalumab|Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.
41443917|NCT01503957|DEVICE|Nasya|Thixotropic nasal spray suspension, 2 sprays in each nostril
41443918|NCT01503957|DEVICE|Saline solution|Nasal spray, 2 sprays in each nostril
41105528|NCT05262803|GENETIC|CYP2C19*2/*3|"* Non-carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with clopidogrel and ASA~* Carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with prasugrel (or ticagrelor) and ASA"
41443919|NCT00789386|DRUG|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
41443920|NCT00789386|DRUG|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
41270760|NCT03556215|DEVICE|Eustachian tube dilatation device|Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
41270761|NCT03556215|PROCEDURE|Myringotomy|Myringotomy will be performed using a standard procedure.
40925296|NCT01610375|OTHER|Telephone Follow-up|This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
41105529|NCT05262803|OTHER|Shorter DAPT duration|Duration of DAPT is shortened to 3 months
41105530|NCT02117401|DRUG|mivacurium chloride|intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
41105531|NCT02117401|DRUG|midazolam|"Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
41270762|NCT00723957|DRUG|Ixabepilone, 32 mg/m^2|Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2
41270763|NCT00723957|DRUG|Paclitaxel, 200 mg/m^2|IV solutions, paclitaxel, 200 mg/m\^2
41270764|NCT00723957|DRUG|Carboplatin (area under the concentration curve [AUC] 6)|Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
41270765|NCT03347149|DEVICE|Alarm Advisor Software|Providing advice on alarm limits as part of routine medical care
41105532|NCT02117401|DRUG|ketamine|"mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
41270766|NCT04088448|DRUG|Placebo oral tablet|Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
41443921|NCT03799835|DRUG|BCG|Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®
41443922|NCT03799835|DRUG|Atezolizumab|IV perfusion
41443923|NCT00218257|DRUG|Progesterone|200mg progesterone twice daily
41443924|NCT00218257|OTHER|Placebo|placebo
41443925|NCT04732117|DRUG|Secukinumab|Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, and 3, followed by administration every 4 weeks starting at Week 4.
41443926|NCT04732117|DRUG|Placebo|Placebo 150 mg s.c.at BSL, Weeks 1, 2 and 3, followed by administration every 4 weeks starting at Week 4.
41443927|NCT03108911|OTHER|Best Practice|Receive standard diet
41443928|NCT03108911|PROCEDURE|Biospecimen Collection|Provide stool sample
41443929|NCT03108911|OTHER|Dietary Intervention|Receive GFD
41443930|NCT03108911|OTHER|Laboratory Biomarker Analysis|Correlative studies
41443931|NCT00006051|DRUG|cisplatin|
41443932|NCT00006051|DRUG|fluorouracil|
41443933|NCT00006051|RADIATION|radiation therapy|
41443934|NCT06562166|RADIATION|online adaptive radiotherapy|Patients in ART group received daily online adaptive radiotherapy with a prescription dose of 50.4Gy/28f.
41270767|NCT04088448|DRUG|Metformin|Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
41105533|NCT02117401|DRUG|propofol|Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
41105534|NCT02117401|DRUG|Remifentanil|Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
41105535|NCT01976754|DRUG|Dexmedetomidine|Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
41105536|NCT00590369|DEVICE|KCI -VAC|Negative pressure wound therapy device
41270768|NCT04796402|BIOLOGICAL|Bamlanivimab|700 mg/20mL IV over at least one hour OD
41443935|NCT01090687|RADIATION|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
41443936|NCT01090687|DEVICE|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
40925297|NCT06203951|DIAGNOSTIC_TEST|Xpert® CT/NG and TV testing|Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment. Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment. Participants assigned to receive Xpert® testing will be counseled on CT/NG/TV testing, including the benefits of testing even in the absence of symptoms to detect asymptomatic infections (as informed by pilot evaluation). If a client accepts Xpert® testing, she will be instructed by the study nurse on how to self-collect a vaginal swab.
41105537|NCT00590369|DEVICE|Versatile One (EZCare)|Negative pressure wound therapy device
40925298|NCT01029405|DRUG|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
40925299|NCT01029405|DRUG|Placebo|Ointment B Vehicle applied once or twice daily
40925300|NCT05955976|OTHER|BIOPSY|biopsy
40925301|NCT02242591|DRUG|Ropivacaine 7,5 mg/ml|
40925302|NCT02242591|DRUG|Saline|
40925303|NCT00000481|BEHAVIORAL|diet, fat-restricted|
40925304|NCT04363398|OTHER|Comprehensive Follow-up|Trained research staff members will provide weekly support to coaches on the NMT warm-up.
40925305|NCT04363398|OTHER|Standard Follow-up|Research staff will monitor teams weekly, however no additional support for warm-up will be provided.
41105538|NCT03961152|BEHAVIORAL|PainCoach app|In response to the patient's input of the pain experienced (no pain, bearable pain, unbearable pain, or untenable pain), the app gave advice on pain medication use, exercises/rest and when to call the clinic from day 1 until day 14 after surgery.
41105539|NCT04371536|DRUG|Ferrous Sulfate|Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.
41105540|NCT04371536|BEHAVIORAL|IRONCHILD|"Delivery of the intervention at each visit should take 15 minutes or less.~* Baseline visit (Session 1) content will be viewed~* At 1-month follow-up visit, additional (Session 2) content will be viewed~* At 3-month final visit, patients will view final (Session 3) content"
41270769|NCT04796402|OTHER|Standard of Care|Standard of care includes primary care and specialist care as indicated by the patient's primary care provider
41270770|NCT00195130|BEHAVIORAL|There are no interventions in this study|
41270771|NCT00956930|RADIATION|yttrium Y 90 glass microspheres|Patients undergo radioembolization.
41270772|NCT00956930|DRUG|Doxorubicin|75mg fixed dose
41443937|NCT00709254|DRUG|i.v. fentanyl|single dose, 200 ug
41443938|NCT00709254|DRUG|3 mL AeroLEF (500 µg/1 mL)|A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
41443939|NCT00709254|DRUG|3 mL AeroLEF (500 µg/1 mL)|A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
41443940|NCT05269849|DRUG|Sirolimus|Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
41443941|NCT03932045|DEVICE|SYB Filler (SF-01)|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
41443942|NCT03932045|DEVICE|Ellansé M|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
41443943|NCT06330142|OTHER|Participation in 10 horse-assisted therapy sessions|supporting children and teenagers undergoing radiotherapy with a horse-assisted therapy approach
41443944|NCT04194801|DRUG|Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 400 mg Fisogatinib (BLU-554) once daily (QD), in combination with 1200mg fixed dose Sugemalimab (CS1001) once every 3 weeks (Q3W). Every 21 days (3 weeks) will be considered as one cycle.
41443945|NCT04194801|DRUG|Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
41443946|NCT04194801|DRUG|Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase II: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
41443947|NCT03961828|DRUG|Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]|The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
41270773|NCT03638492|PROCEDURE|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
41443948|NCT00838279|DRUG|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
40752162|NCT01769872|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
40752163|NCT02571855|DRUG|ACT-541468 (hydrochloride salt)|Hard-gelatin capsules (strength: 5 mg and 25 mg)
41105541|NCT04137874|DIAGNOSTIC_TEST|eSTROKE model|The eSTROKE model includes an electronic learning module, a full day course with practical teaching of National Institute of Health Stroke Scale and a mobile application which will be used for communication with in-hospital stroke physician
41105542|NCT04137874|OTHER|Control|Conventional prehospital care
41105543|NCT02212535|DRUG|Plerixafor|0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
41105544|NCT06020131|PROCEDURE|Thoracic Mobility Rehabilitation|Thoracic mobility exercises: Thoracic extension on foam roller, Sidelying thoracic rotation, Quadruped thoracic rotation, Squat with extension and rotation ( 10 reps x 3 set - 2 times x wk - 8 wk)
41105545|NCT06020131|PROCEDURE|Lumbopelvic Stability Rehabilitation|Lumbopelvic Stabilization Exercises : Bridge with alternate leg, Single leg bridge, Four point kneeling with arm and leg extension, Side plank on front arm with knee flexed (right, left), Sitting on a Swiss Ball and hip flexion (10 reps x 3 set - 2times/wk - 8 wk)
41105546|NCT06020131|PROCEDURE|Ankle Strengthening Home Exercises|Ankle Strengthening exercises with resistive band (dorsiflexion, plantarflexion, inversion, eversion) (10 reps x 3 set - 3 times/wk)
41105547|NCT02030028|DRUG|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
41105548|NCT02061332|BIOLOGICAL|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
41105549|NCT01450072|DEVICE|Selective Venography followed by therapeutic balloon angioplasty|Venography followed by therapeutic balloon angioplasty
41105550|NCT01450072|OTHER|Control arm|Venography and sham angioplasty
41105551|NCT02108743|DRUG|Albuterol.|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
41105552|NCT02108743|DRUG|Normal saline placebo|Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
41105553|NCT02685280|DEVICE|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
41105554|NCT01065636|BEHAVIORAL|Diet + Resistance Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.
41105555|NCT01065636|BEHAVIORAL|Diet + Aerobic Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks
41105556|NCT01065636|BEHAVIORAL|Diet + Resistance/Aerobic Exercise|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
41105557|NCT04139538|PROCEDURE|orthodontic treatment|Malocclusion will be treated with orthodontic appliances (fixed or removable)
41105558|NCT04880733|PROCEDURE|Acupuncture for pain management|A manualized acupuncture protocol will be performed by a licensed acupuncturist in the patient's emergency department room.
41105559|NCT04880733|OTHER|Usual care for pain management|Patient will receive usual care for pain management.
41105560|NCT05536219|DIAGNOSTIC_TEST|Serum anti-IFN-I antibodies|Anti-IFN-I autoantibodies presence will be assessed through serological methods (ThermoFisher Kit)
41105561|NCT03107962|DRUG|Pembrolizumab (PD-1 Blocking Antibody)|pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
41270774|NCT03638492|PROCEDURE|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
41270775|NCT02874911|OTHER|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
41270776|NCT00433888|DRUG|R744|100μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
41105562|NCT02655367|OTHER|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
41270777|NCT00433888|DRUG|R744|150μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
41270778|NCT06500663|OTHER|haemodialysis|haemodialysis effect on thyroid function
41105563|NCT02655367|OTHER|Milled oats|Test meal consisting of 264g porridge made with milled oats
41270779|NCT00424398|DRUG|Bepreve|sterile ophthalmic solution
41270780|NCT00424398|DRUG|Placebo|sterile ophthalmic solution
41443949|NCT00838279|DRUG|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
41443950|NCT06443151|PROCEDURE|Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid)|The brachial artery in the non-dominant arm will be catheterized to infuse endothelium-dependent vasodilator acetylcholine, endothelium-independent vasodilator nitroprusside, and antioxidant ascorbic acid at concentrations to have isolated effect in the forearm.
41443951|NCT06443151|PROCEDURE|venous occlusion plethysmography|Whole forearm blood flow will be measured by mercury-strain gauge while venous occlusion is applied to the forearm and hand by rapid-cuff inflation to sub-arterial pressures. Changes in whole forearm blood flow with be measured at baseline, endothelial agonists, and removal of oxidative stress via acorbic acid.
41443952|NCT06443151|DRUG|Acetylcholine|Endothelium-dependent vasodilation will then be assessed by changes in FBF in response to intra-arterial infusions of the endothelial agonist acetylcholine infused at rates of 4.0, 8.0, 16.0 μg/100 mL of forearm tissue/min to generate a dose-response curve.
41443953|NCT06443151|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation will be assessed by changes in forearm blood flow in response to intra-arterial infusions of sodium nitroprusside at 1.0, 2.0, 4.0 μg/100 mL forearm tissue/min.
41443954|NCT06443151|DRUG|Ascorbic acid|Ascorbic acid will be infused at a constant rate (12 mg/100 mL tissue/min) and maintained at the same rate while the acetylcholine and sodium nitroprusside dose-response curves are repeated.
41443955|NCT06443151|PROCEDURE|venous phlebotomy|Venous blood samples will be collected to measure baseline cardiometabolic characteristics and isolate endothelial cell microvesicles for characterizations and in vitro experiments.
41443956|NCT06124638|DIAGNOSTIC_TEST|Panbio™ COVID-19/Flu A&B Panel|The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users.
41443957|NCT00849823|BEHAVIORAL|Male Sexual Health Program|"An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex."
41105564|NCT06232629|DEVICE|TUS Active|Bilateral GPis will be sonicated using NeuroFUS device for either two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and with 30 W/cm2 Isppa
41105565|NCT06232629|DEVICE|TUS Sham|"Passive sham: Bilateral GPis will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 0 W/cm2 Isppa~Active sham: Bilateral occipital cortices will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 30 W/cm2 Isppa"
41105566|NCT06423742|DEVICE|Transcranial direct current stimulation|The device used for tDCS in this study was DC-Stimulator Plus (NeuroConn GmbH, Ilmenau, Germany). The localization of stimulation area (DLPFC) was determined according to the 10/20 EEG system. Non-conducting, elastic head strap was placed around the head to prevent displacement during stimulation. The recording electrode covered with 5 x 7 cm sized traditional rectangular sponge was soaked with 6-7 mL of 0.9% NaCl saline solution per side and placed on the F3 (anode, left frontal) and F4 (cathode, right frontal) EEG location. Subjects were given 2 mA stimulation intensity for 20 min per session including fade-in and fade-out times for 20 seconds each. Interval between each session was 20 min. Sham procedure has been adopted a Fade In of current, Short Stimulation, Fade Out (FISSFO) protocol that consist of initial ramp up for 20 seconds, 2 mA stimulation for 40 seconds, and 20 seconds for ramp down. To check to impendence, brief current of 110 µA over 15ms every 550ms was delivered.
41270781|NCT00424398|DRUG|Bepotastine Besilate|sterile ophthalmic solution
41270782|NCT03018548|OTHER|blood draw|subjects will have blood drawn done. This blood will then be exposed to blasting with CO2 cartridge
41443958|NCT00849823|BEHAVIORAL|Focus on the Future Program|A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
41443959|NCT05469997|BEHAVIORAL|Mediterranean-Ketogenic Diet|In the MeDi-KD group, the participants will adhere to a modified Mediterranean-ketogenic diet. The ketogenic component of the diet will require limiting the intake of carbohydrates to about 10% of all calories consumed in a day, while obtaining most of the energy from healthy fats, mostly from plant-based sources (\~70-75% of your daily caloric intake) and lean proteins (\~15-20% of your daily caloric intake). The ketogenic ratio (the ratio of fat to carbohydrates) will be gradually increased during the first week from 1:1 to 3:1. The Mediterranean component of the diet will encourage the participants to consume more green leafy vegetables, nuts, and olive oil, while limiting the consumption of processed or fried food, red meat, full-fat dairy, and sweets.
41443960|NCT05469997|DIETARY_SUPPLEMENT|Mediterranean diet supplemented with medium-chain triglyceride oil|"The participants will adhere to the Mediterranean diet. In addition, they will be asked to take two daily doses of medium-chain triglyceride oil (MCT oil).~The MCT oil supplement (Nutiva MCT oil, Nutiva Inc.) is approved by Health Canada (NPN: 80086912) and will be used according to its approved condition of use (i.e., source of medium-chain fatty acids which supports energy production in the body at a cellular level \[ATP\]). Each serving of this product provides 130 Calories from MCTs (14 g) with a C8-C10 ratio of 60:40. Nutiva MCT oil can be mixed into any beverage of choice, but cannot be used for cooking.~participants will start the intervention by taking 5 mL of MCT oil twice daily for the first day to acclimate their bodies to the supplement and gradually increase the dose to 14 g BID by the end of week 1. The participants may be asked to increase the dose to 20 mL of MCT twice daily if tolerability remains positive."
41443961|NCT06563505|DRUG|Mosunetuzumab|Given by IV
41443962|NCT06563505|DRUG|Zanubrutinib|Given by IV
41105567|NCT03774914|DRUG|Alemtuzumab (GZ402673)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
41105568|NCT05586230|DRUG|Pretomanid|Administered orally based on participant's weight
41105569|NCT05586230|DRUG|Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB|Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.
41105570|NCT04726046|DRUG|Cefotetan|Cefotetan (as Disodium) 1 GM Injection before surgery
41105571|NCT04744519|OTHER|Collect data|- Controlled ovarian stimulation with GnRH antagonists effected to the patients in order to get their eggs through follicular puncture, which will be trigger by GnRH analogue. The eggs will be isolated and processed according to the standard protocol.
41105572|NCT04072822|DRUG|Anakinra and Zinc|Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.
41105573|NCT04072822|DRUG|Prednisone|Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.
41105574|NCT04072822|DRUG|Placebos|Matching placebo
41443963|NCT04367766|PROCEDURE|Prosthetically driven implant placement|Insertion of an osseointegrated implant into the bone of anterior maxilla/mandible, following the right prosthetic plan
41443964|NCT06627218|DRUG|Prothrombin Complex Concentrate|Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
41105575|NCT04117191|DIETARY_SUPPLEMENT|Doctor's Best L-Tryptophan|2g tryptophan loading once
41105576|NCT02533206|PROCEDURE|Endoscopic Polypectomy Performed in Clinic|Endoscopic polypectomy performed in clinic under local and topical anesthesia
41443965|NCT05800457|PROCEDURE|Partial synovectomy|Patients in the intervention group will undergo partial synovectomy during total knee replacement surgery
41443966|NCT03734861|DEVICE|BreatheSmart System|"* BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders~* HeroTracker sensor that counts dosage and monitors real-time medication adherence~* CoheroConnect provider portal that allows the Investigator to monitor adherence"
41270783|NCT04760002|DEVICE|NightOwl|The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
41105577|NCT02533206|PROCEDURE|Functional Endoscopic Sinus Surgery (FESS)|Functional Endoscopic Sinus Surgery
41105578|NCT05725889|DEVICE|recation time test|visual-finger tapping and auditory reaction time tests
41105579|NCT01406262|BIOLOGICAL|Albiglutide|once weekly subcutaneous injection
41443967|NCT03734861|OTHER|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
41443968|NCT03031184|DRUG|Mirtazapine|
41443969|NCT03031184|OTHER|Placebo|
41443970|NCT04343794|DEVICE|BIOVITALS|Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
41443971|NCT04841096|DRUG|A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
41105580|NCT01406262|DRUG|Moxifloxacin|oral tablet
41105581|NCT05603767|OTHER|RMT+ VR|(RMT+ VR). The responsive music therapy session combined with virtual reality involves four stages: a) Background settings; b) VR video and music selection; c) Listening experience and VR; and e) Return to alert status. The therapist will help the patient to select the video to be used for the experience. Utilizing the application created by the research team, the patient will be provided with four possible scenarios. As for the music, patients are asked to choose music that relaxes them the most. Chosen music can be instrumental music (guitar, electric piano or violin) or sung music with harmonic accompaniment (piano or guitar). In both cases the music will be played live.
41105582|NCT04218669|PROCEDURE|Roux-en-Y Hepaticojejunostomy|The common hepatic duct was cut and the duodenal side is closed by suture. The small intestine was cut off 15 cm below the ligament of Treitz. The distal end was lifted, and a 1-2 cm incision was made at the jejunal wall 4-5 cm from the jejunal stump. The anastomosis is used a 5-0 PSD Ⅱ suture, with double needles, inside-out in the jejunum and outside-in in the hepatic duct. One side of needles was used to continuely penetrate and suture the whole layer of the posterior-lateral wall of the jejunum, the posterior-lateral wall of the biliary duct, and the other side of needles was used to continuely stuere the anterior part of the anastomosis. Mucosa-to-mucosa contact should be ensured with every stitch.The anastomotic stomas were then checked for leakage. Enteric-enteric anastomosis was performed 60 cm below the site of the hepatojejunal anastomosis.
41105583|NCT04218669|PROCEDURE|T-tube drainage|The T-tube was placed for biliary drainage and the common bile duct was intermittently sutured with 4-0 vicryl sutures.
40752164|NCT02571855|DRUG|ACT-541468 (free base)|Soft capsules (strength: 25 mg)
40752165|NCT02571855|DRUG|Placebo|Placebo capsules matching the ACT-541468 formulations
41270784|NCT06138145|OTHER|Video|Different videos were shown for Arms B and C. No Video was shown for Group A or D.
41443972|NCT04841096|DRUG|B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
41443973|NCT04841096|DRUG|(A2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
41443974|NCT04841096|DRUG|(B2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
41270785|NCT06138145|BEHAVIORAL|Survey|Survey about participant's demographics, information source trust, and clinical trials knowledge. Also includes question about whether the participant is interested in enrolling in the Pediatric Trials Notification System.
41270786|NCT00887861|DRUG|Investigational new drug, company code: BGG492|
41270787|NCT00887861|DRUG|Placebo|
41270788|NCT00037648|DRUG|Anakinra|anakinra
41270789|NCT00037648|DRUG|Placebo|placebo
41270790|NCT02633540|RADIATION|IMRT Radiation|Radiation to Larynx
41270791|NCT00600171|DRUG|GW642444M|GW642444M
41270792|NCT00600171|DRUG|Placebo|Placebo mulit-dose dry powder inhaler
41270793|NCT03646448|BEHAVIORAL|Motivational Interviewing|Up to three counseling sessions on telephone based on Motivational Interviewing and elements of Cognitive Behavioral Therapy. Counselings are within 12 weeks after the baseline diagnostic interview and follow the stepped care approach.
41270794|NCT01838044|DRUG|pregabalin and celecoxib|"During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
41270795|NCT01838044|DRUG|Placebo and celecoxib|"Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
41105584|NCT06552494|OTHER|L-mHealth program|The intervention group receiving the L-mHealth program plus care as usual. Data will be collected at baseline (T0), 1 months (T1) and 3 months (T2) after the intervention.
41105585|NCT02716324|BEHAVIORAL|Care Manager CM)|The CM was an individual responsible for communicating and coordinating ADHD care. The CM established rapport with families and communicated with them every 3 months or more frequently if needed to assess treatment use, identify new concerns, and help problem-solve. The CM also communicated with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
41105586|NCT02716324|OTHER|ADHD Portal|The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
41105587|NCT02767219|DRUG|bevacizumab|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
41105588|NCT02767219|DRUG|5-fluorouracil|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
41105589|NCT02767219|DRUG|Dexamethasone|Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
41270796|NCT05407987|DRUG|Ferric derisomaltose|Ferric Derisomaltose is a solution based iron supplement provided in 100 mg elemental iron/mL. Patients randomized to Iron Therapy Arm will with a bodyweight \<50kg will receive 500mg of Ferric Derisomaltose, and patients with a bodyweight \>50kg will receive 1000mg of Ferric Derisomaltose, to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg. Patients will receive a single infusion between 21 and 90 days preceding surgical intervention.
41270797|NCT05407987|DRUG|Placebo|Patients randomized to the Placebo arm will receive 100mg of normal saline over 1 hour.
41270798|NCT05829681|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants will receive a 5-day course of 10x daily rTMS, with sessions delivered hourly. Each session will deliver up to 1800 pulses of theta-burst stimulation per target.
41443975|NCT01978730|DRUG|high dose group of SaiLuoTong capsule|high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
41443976|NCT01978730|DRUG|low dose group of SaiLuoTong|low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
41443977|NCT01978730|DRUG|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
41270799|NCT04294485|BEHAVIORAL|Physical therapy|Electrostimulation combined with exercise
41270800|NCT00907075|BEHAVIORAL|NES With Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.
41443978|NCT04398056|DRUG|Chemotherapy plus radiotherapy and Toripalimab|"1. Chemotherapy:~   The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h and an intravenous administration of 100 mg/m2 cisplatin on day 1 for a maximum of six cycles.~2. Radiotherapy, intensity-modulated radiation therapy (IMRT), PTVnx:66-70Gy/30-33F; PTVnd:66～70Gy/30～33F; PTV1:60～64Gy/30～33F; PTV2:50～54Gy/30～33F, 5 fractions per week, for 6 weeks~3. Toripalimab 240mg every three weeks (Q3W) began on the first day of radiotherapy until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
41443979|NCT04820829|OTHER|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
41443980|NCT04820829|OTHER|Moderate RM, Moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
41443981|NCT04820829|OTHER|Low RM, High NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
41443982|NCT01948258|DEVICE|Clearblue Advanced Fertility Monitor|Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting
41443983|NCT00420303|DRUG|Etanercept|50 mg injection once weekly
41443984|NCT00420303|OTHER|Placebo|placebo
41443985|NCT05093205|DRUG|PF-06882961|Tablets
41443986|NCT05093205|DRUG|Atorvastatin|Tablets
41270801|NCT00907075|BEHAVIORAL|NES Without Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement.
41443987|NCT05093205|DRUG|Midazolam|Syrup
41443988|NCT05093205|DRUG|Levonorgestrel & Ethinyl Estradiol|Tablet
41443989|NCT02322983|BEHAVIORAL|Control of Stress|To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
41443990|NCT00130377|BIOLOGICAL|cell therapy|autologous or allogeneic cells
41443991|NCT04026815|OTHER|medical history, blood and urine tests|The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.
40752166|NCT03750227|PROCEDURE|Conventional Surgery|Undergo surgery
40752167|NCT03750227|OTHER|Quality-of-Life Assessment|Ancillary studies
40752168|NCT03750227|OTHER|Questionnaire Administration|Ancillary studies
41270802|NCT01934504|PROCEDURE|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
41270803|NCT02800460|PROCEDURE|fMRI-3T|fMRI-3T will be performed during the visit 1: day of anesthesia consultation (this fMRI-3T will last approximately one hour)
41443992|NCT03702608|COMBINATION_PRODUCT|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - (PBMA) and CarboSil®~* Ridaforolimus drug"
41443993|NCT03364192|BEHAVIORAL|Whole Health Coaching|Veterans Health Administration variation of integrative health coaching.
41443994|NCT05830084|DRUG|regorafenib tablet|"Regorafenib will be escalated/de-escalated, starting at DL0:~* DL1: 82 mg/m\^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~* DL0 (starting dose): 66 mg/m\^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~* DL-1: 50 mg/m\^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)"
41443995|NCT05305248|DRUG|Remimazolam|After spinal anesthesia, 5 mg of remimazolam is injected by intravenous route for 1 minute to induce sedation. To maintain sedation, remimazolam is continuously infused at a rate within the range of 0.1 mg/kg/h to 1 mg/kg/h.
41443996|NCT05305248|DRUG|Dexmedetomidine|After performing spinal anesthesia, dexmedetomidine is injected at a loading dose of 1 mcg/kg for 10 minutes to induce sedation. Thereafter, to maintain sedation, Dexmedetomidine is continuously infused at a rate within the range of 0.2 to 0.7 mcg/kg/h.
41443997|NCT00275366|DEVICE|Robotic Therapy|
41443998|NCT02670447|PROCEDURE|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
41443999|NCT04651335|DEVICE|afferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The concentric direction moves the ball from the left to the center of the body.
41444000|NCT04651335|DEVICE|efferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The efferent direction moves from the center to the right.
41444001|NCT06192160|DRUG|Isoniazid|INH 300 mg will be administered as one tablet orally once daily.
41444002|NCT06192160|DRUG|Rifampicin|RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
41444003|NCT06192160|DRUG|Pyrazinamide|PZA will be administered as 500 mg tablets, based on weight, orally once daily.
41444004|NCT06192160|DRUG|Ethambutol|EMB will be administered as 400 mg tablets, based on weight, orally once daily.
41444005|NCT06192160|DRUG|Bedaquiline|BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
41444006|NCT06192160|DRUG|Pretomanid|Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
41444007|NCT06192160|DRUG|Linezolid|LZD 600 mg will be administered as one 600 mg tablet orally once daily.
41444008|NCT06192160|DRUG|TBI-223|TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.
41105590|NCT05544578|BEHAVIORAL|Nurses Taking On Readiness Measures (N- TORM)|The intervention group will be educated about household emergency preparedness via a presentation and the Korean version of a New York City community-specific booklet called Ready New York: My Emergency Plan (NYC Emergency Management, 2022). The intervention will begin with instructing the participant to start the booklet during class 1 and completing it for homework. The class content will complement the booklet and the K-HEPI. The booklet includes preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. During class 2, study personnel will check for completion of the booklets, answer any questions that the participants may have about the evacuation and communication plans and disaster kits, and facilitate group discussion to foster social support from other community members.
41105591|NCT00048828|DRUG|Olanzapine|Participants will receive olanzapine for 12 weeks.
41105592|NCT00048828|DRUG|Clozapine|Participants will receive 12 weeks of clozapine.
41105593|NCT04963049|OTHER|Protocol with Mask|Look at differences in group with facemask and no mask
41270804|NCT00136864|PROCEDURE|PET Diagnostic Imaging|Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
41444009|NCT06192160|DRUG|Sutezolid|SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.
41444010|NCT06192160|DRUG|TBI-223|TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.
41444011|NCT06192160|DRUG|Sutezolid|SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.
41444012|NCT03681470|DRUG|Aczone Gel|Aczone Gel 7.5%
41444013|NCT00740103|DRUG|Semapimod|60 mg IV x 3 days q 6 - 8 weeks
41444014|NCT06152458|DRUG|Vitamin C|Patients in the intervention group (G1) (n=23) received the combined vitamin therapy: IV vitamin C (1.5 g every 6 hours administered as an infusion over 30 to 60 minutes and mixed in a 100- mL solution of normal saline), hydrocortisone (100 mg in bolus-100 mg in perfusor up to 60 min (200mg 24h),), and thiamine (200 mg every 12 hours administered as an infusion over 30 to 60 minutes and mixed in a 100-mL solution of normal saline) for 3 days.
41444015|NCT05305092|DEVICE|PET/MRI, psychobehavioral tests and questionnaires, serum biomarkers and stool sample|Neuroimaging data were collected by integrated PET/MRI machine, and collected the psychobehavioral data, the serum and stool samples of participants.
40752169|NCT03750227|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
41444016|NCT03406156|DRUG|Obinutuzumab|Administered via intravenous infusion
41444017|NCT03406156|DRUG|Bendamustine|Administered via intravenous infusion
41444018|NCT03406156|DRUG|Venetoclax|The venetoclax dose was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg. Venetoclax was continued for a total duration of up to 53 weeks, including the 5-week ramp-up schedule. Participants were instructed to take venetoclax tablets with a meal and water at approximately the same time each day. Venetoclax tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
41444019|NCT05472350|DRUG|Breztri Aerosphere|Breztri Aerosphere is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).
41444020|NCT05472350|OTHER|Placebo|placebo is 0.9% normal saline
41444021|NCT00571064|DRUG|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
41444022|NCT05597982|OTHER|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
41444023|NCT05597982|OTHER|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
41444024|NCT03748381|PROCEDURE|Cataract surgery|During cataract surgery patients will be implanted with the AT Zeiss Lisa tri in one eye and the Rayner trifocal in the contralateral eye
41444025|NCT01490567|DRUG|Donepezil|5 mg/day
41444026|NCT01490567|DRUG|placebo|placebo 5mg/d
41444027|NCT00883233|DRUG|Adapalene BPO Gel standard daily overnight application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
41444028|NCT00883233|DRUG|Adapalene-BPO 3-hour daily application before bedtime|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
41444029|NCT00883233|DRUG|Adapalene-BPO Gel every other day application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
41444030|NCT00883233|DRUG|Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
41444031|NCT03053362|DRUG|Vortioxetine|Observing change in cognition using THINC-it tool in patients with MDD.
41270805|NCT06278688|DIETARY_SUPPLEMENT|Precision probiotics|The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/) The individual gut microbiota will determine the supplement and composition of probiotics.
41270806|NCT04058587|DRUG|Simmitinib|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
41270807|NCT03091023|PROCEDURE|Endometrial Biopsy and endometrial fluid collection|
41270808|NCT01439438|DRUG|Topiramate coated tablet|Test formulation
41270809|NCT01439438|DRUG|Topamax® coated tablet|Reference formulation
41270810|NCT06001567|DRUG|Avatrombopag|Avatrombopag (platelet count \[PLT\] \<40×10\^9/L, 60mg P.O. QD; PLT of 40-75×10\^9/L, 40mg P.O. QD) will be administered to the patients and last 5-10 days. When the PLT reaches ≥100×10\^9/L, the treatment will be discontinued.
41270811|NCT01633957|OTHER|Genotype-based Warfarin Initiation model|Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.
41270812|NCT01633957|OTHER|clinical factor-based warfarin initiation model|Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
41270813|NCT05489081|BEHAVIORAL|Positive Behavior Management Toolkit|The Positive Behavior Management Toolkit, or the implementation strategy resource package, is a set of resources provided to teachers in the intervention group that aims to support their use of positive behavior management practices in the classroom, particularly with students with hyperactive, inattentive, or impulsive behaviors.
41444032|NCT03053362|OTHER|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
41105594|NCT04544761|OTHER|Structured Interview|Structured interview with research staff about your experience living with spinal cord injury
41105595|NCT02054455|DIETARY_SUPPLEMENT|Lactobacillus paracasei F19|25x10E9 live bacterial cells for 3 days/week for 6 months
41105596|NCT02054455|DIETARY_SUPPLEMENT|Placebo|Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
41105597|NCT06556069|OTHER|Peer-Support Enhanced Agitation Code Team (PACT)|"PACT will address systems challenges experienced by staff, safety threats to ED patients with mental illness and substance use disorders, and known structural biases against marginalized individuals during decisions in use of restraints for behavioral crises in the ED.~The PACT intervention includes a peer support service component to deliver patient-centered, trauma-informed, culturally sensitive care to patients presenting with behavioral complaints in the ED and experiencing distress."
41105598|NCT03414710|BEHAVIORAL|Health education booklet plus video plus brief counseling|Participants in the intervention group will receive a health education booklet, watch a 10-minute video and receive counseling provided by the clinicians
41105599|NCT03414710|BEHAVIORAL|Health education booklet only|Participants in the intervention group will only receive a health education booklet
40752170|NCT01086475|DRUG|D-cycloserine|50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
40752171|NCT01086475|DRUG|Placebo|Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
41105600|NCT02712411|DRUG|HCP1303|
41105601|NCT02712411|DRUG|HGP1201|
41105602|NCT02712411|DRUG|HIP1402|
41105603|NCT05963308|BEHAVIORAL|Healthy Minds|"The group intervention (approximately 5 participants per group, 8 groups) is facilitated by two clinicians and consists of 8 sessions (one per week for 8 weeks), with each session focusing on a specific aspect of the return-to-work process from a cognitive-behavioral perspective:~Week1: Coping with work stress at work W2 and W3: Recognizing and modifying my dysfunctional beliefs linked to work W4: Overcoming obstacles linked to work functioning and maintaining work W5: To put in place needed work accommodations with the support of the immediate supervisor W6: My strengths and competencies related to work W7: Accepting criticism and asserting myself appropriately W7: My strengths and related skills W8: My best coping strategies for work Both intervention and control participants receive their standard individualized care from their clinician. However, for the experimental participants, the Healthy Minds intervention is an added component to their regular care."
41105604|NCT02886741|OTHER|Quality Improvement Campaign|"How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty."
41105605|NCT04077437|BEHAVIORAL|Therapy|Standardized non-directive therapy performed by therapist team.
41105606|NCT04077437|DRUG|Midomafetamine|Administration of 80 to 120 mg MDMA during three sessions of MDMA-assisted psychotherapy, followed by a supplemental half-dose of 40 or 60 mg MDMA offered 1.5 to 2 hrs after the initial dose, respectively.
41444033|NCT01300676|DRUG|Tualang honey|"This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia."
41444034|NCT00229021|DRUG|doripenum|
41444035|NCT03125447|OTHER|speed and accuracy answer to visual stimuli|A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
41270814|NCT04833803|BEHAVIORAL|eBLISS|a novel instrument -Eating Behaviour Lapse Inventory Survey Singapore (eBLISS)- will be developed
41270815|NCT02692625|DIETARY_SUPPLEMENT|(L. reuteri Prodentis®).|The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
41270816|NCT02692625|DIETARY_SUPPLEMENT|Placebo lozenges|The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
41270817|NCT05051956|DRUG|Palbociclib 125mg and Ribociclib 600 mg|Administration of Palbociclib or Ribociclib
41270818|NCT01225341|DRUG|onabotulinumtoxinA|Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
41270819|NCT01225341|OTHER|Bacteriostatic normal saline|Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
40925306|NCT02545543|BIOLOGICAL|Seqirus QIV|"Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
41105607|NCT04077437|DRUG|Placebo|Administration of placebo with therapy during three experimental sessions
41105608|NCT04002973|DEVICE|INVSENSOR00037|Noninvasive regional oximeter.
41105609|NCT01230619|DRUG|RV568|RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
41105610|NCT01230619|DRUG|Placebo|Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
41105611|NCT04980261|PROCEDURE|ORIF + autograft|Patients will undergo a standard open reduction internal fixation (ORIF) procedure with autograft implantation (from the iliac crest).
41105612|NCT04980261|PROCEDURE|ORIF + FD BHA/Secretome|Patients will undergo an ORIF procedure and subsequently receive freeze-dried bovine hydroxyapatite/secretome composite implantation.
41105613|NCT04635488|PROCEDURE|lateral lymph node dissection|All participted would receive lateral lymph node dissection for rectal cancer.
41270820|NCT00167479|DRUG|risperidone (Risperdal)|
41270821|NCT01472484|OTHER|586/8x87 white|2 x 50 g
41270822|NCT01472484|OTHER|586/8x87 brown|2 x 50 g
41270823|NCT01472484|OTHER|BAT 881|2 x 50 g
41270824|NCT01472484|OTHER|586/8|2 x 50 g
41270825|NCT04795479|DRUG|Relacorilant|Relacorilant 400 mg (therapeutic dose) or 800 mg (supra-therapeutic dose) capsule by mouth once daily
41270826|NCT04795479|DRUG|Placebo to relacorilant|Placebo to relacorilant capsule by mouth once daily
41270827|NCT04795479|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet by mouth
41270828|NCT02747784|BEHAVIORAL|Cognitive training program RehaCom®|Cognitive training program RehaCom®
41270829|NCT04013126|DIAGNOSTIC_TEST|• Endothelial function using ENDOPAT system|All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.
41444036|NCT03089515|OTHER|Cardio-Pulmonary Exercise Testing (CPET)|This test helps determine if the decreased tolerance to exercise or shortness of breath with activity a patient is experiencing is caused by a cardiac disease, versus a pulmonary disease.
41444037|NCT03348553|DIETARY_SUPPLEMENT|control group|no supplements given for 16 weeks, after 4 week washout of all supplements and dietetic products
41444038|NCT03348553|DIETARY_SUPPLEMENT|Omega2|2 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
41444039|NCT03348553|DIETARY_SUPPLEMENT|Omega4|4 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
41105614|NCT02491723|DRUG|Azithromycin|Patients with bronchiectasis treated with Azithromycin for three to five days.
41105615|NCT00579189|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
41105616|NCT00579189|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
41105617|NCT00579189|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
41105618|NCT01322919|PROCEDURE|Supracor|"All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision."
41105619|NCT01909336|DRUG|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
41105620|NCT01909336|DRUG|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
41105621|NCT01909336|DRUG|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
41105622|NCT01412034|DRUG|CER-001|Biweekly infusion
41105623|NCT06138158|PROCEDURE|Exercise and Education Group|Physical exercise and pain education
41105624|NCT01252316|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. The subject's will undergo training in-hospital then they will be encouraged to take the kit home with them to practice CPR with their family members and friends.
41105625|NCT01252316|OTHER|Implementation of an In-Hospital CPR Training Model|UPHS Nurses and Volunteers will be trained in our in-hospital CPR Training Model using VSI Kits, and encouraged to implement the training program in their respective hospitals.
41105626|NCT01169363|GENETIC|proteomic profiling|
41105627|NCT01169363|OTHER|flow cytometry|
41105628|NCT01169363|OTHER|laboratory biomarker analysis|
41105629|NCT05257733|OTHER|None, pure observationnal study|pure observationnal study
41105630|NCT05629364|DRUG|KIO-101|Randomized, Controlled
41105631|NCT06081231|DEVICE|open-source APS;|a continuous glucose monitoring system, an insulin pump, and an intelligent algorithm.
41105632|NCT03179787|DRUG|Aripiprazole oral product|oral administration of aripiprazole
41105633|NCT02215278|DIETARY_SUPPLEMENT|10 x 55 g/ bean per arm|
41105634|NCT04135378|DRUG|ascorbic acid|Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation
41105635|NCT04135378|OTHER|placebo|:- included 30 students given placebo for one week before presentation.
41105636|NCT04761237|DRUG|Goal-directed fluid therapy (GDET)|Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV \< 13%.The infusion was stopped when the SVV \< 10%.If the increase of SV was less than 10% or CI \< 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
41105637|NCT04270734|PROCEDURE|EEG|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed
41105638|NCT04270734|PROCEDURE|NIRS|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed
41105639|NCT06401018|PROCEDURE|No noise cancellation and no music playing|In this group of patients, no apparatus was used to prevent noise in the environment, and they were not exposed to any music in the environment.
41105640|NCT06401018|PROCEDURE|Noise cancelled but not allowed to listen to music|In this group of patients, only noise cancelling was performed during the operation, but no music was played in the environment.
41105641|NCT06401018|PROCEDURE|Music is played but noise is not cancelled|In this group of patients, ambient noise cancelling was not applied and music, which has been proven to reduce anxiety in studies, was played during surgery.
41105642|NCT01377623|DRUG|Dexmedetomidine group|Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
41105643|NCT01377623|DRUG|Placebo group|Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
41105644|NCT05731648|DEVICE|Intrathecal balofen pump|Management of spasticity
41105645|NCT00059241|BEHAVIORAL|Parent-child communication education|
41105646|NCT00059241|BEHAVIORAL|Service learning|
41105647|NCT00059241|BEHAVIORAL|Classroom health curriculum|
41105648|NCT03692949|DRUG|LY3451838|One dose administered (IV)
41105649|NCT03692949|DRUG|Placebo|Administered IV
41105650|NCT03692949|DRUG|Placebo|Administered SC
41105651|NCT03692949|DRUG|LY3451838|One dose administered SC
41444040|NCT03348553|DIETARY_SUPPLEMENT|Omega2+OGV|2 capsules of JP+® Omega/d plus 2 capsules each of an encapsulated fruit, vegetable and berry-juice concentrate (6 capsules) for 16 weeks, after 4 week washout of all supplements and dietetic products
41105652|NCT02560818|OTHER|collection of a blood sample and breast and ovarian tissue|a blood sample and a breast and ovarian tissue sample will be collected in healthy women during their surgery (breast or ovarian surgery according to selection group :A, B or C)
41105653|NCT02560818|OTHER|use of a previous blood collection for patients|
41105654|NCT04415333|DRUG|Sodium Butyrate 5 mmol|Enema-based delivery of 5 mmol butyrate in 0.9% saline, (60 mL total)
41105655|NCT04415333|DRUG|Sodium Butyrate 80 mmol|Enema-based delivery of 80 mmol butyrate in 0.9% saline, (60 mL total)
41105656|NCT02639429|DRUG|Vaginal Misoprostol|
41105657|NCT02639429|DEVICE|Foley Balloon + Vaginal Misoprostol|
41105658|NCT02010619|BEHAVIORAL|Cognitive behavior therapy|
41105659|NCT02010619|BEHAVIORAL|Supportive therapy|
41105660|NCT02918968|DRUG|Enzalutamide|Oral Capsule
41105661|NCT02918968|DRUG|Flutamide|Oral tablet
41105662|NCT02918968|OTHER|Androgen deprivation therapy|All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
41105663|NCT00032799|DRUG|natalizumab|
41105664|NCT03923725|DRUG|Artemether-lumefantrine+ Amodiaquine (AL+AQ)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
41105665|NCT03923725|DRUG|Artemether-lumefantrine + placebo (AL+PBO)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
41105666|NCT03923725|DRUG|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately.~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
41105667|NCT03923725|DRUG|Artesunate-mefloquine+placebo (AS-MQ+PBO)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
41105668|NCT02310295|DEVICE|Laser|focal macular laser therapy
41105669|NCT02310295|DRUG|Bevacizumab|Intravitreal injection of Bevacizumab
41105670|NCT02310295|DRUG|Triamcinolone Acetonide|Intravitreal injection of Triamcinolone Acetonide
41105671|NCT00853424|PROCEDURE|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
41105672|NCT00853424|OTHER|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
41270830|NCT03670459|OTHER|Cawthorne Cooksey exercises|Eye movements and head movements
41270831|NCT03670459|OTHER|Vestibular habituation exercises|Move from a sitting position to flat on the back
41270832|NCT03670459|OTHER|Balance exercises|Weight Shift Forward and Back
41270833|NCT02016014|DEVICE|Smartphone with APP|Smartphone with APP (EVIDENT) for 3 months
41270834|NCT02016014|BEHAVIORAL|Counseling on lifestyles|Counseling on physical activity and mediterranean diet
41270835|NCT03125603|OTHER|Consultation of the patient's medical files at the hospital|Gradation of the adverse events according to CTCAE scale 4.03 (June 2010).
41105673|NCT04534712|DIAGNOSTIC_TEST|LYMPHOCYTE MONOCYTE RATIO|Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
41105674|NCT02118506|OTHER|Physical practice|"The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
41270836|NCT03048955|DEVICE|Superion® IDS|Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
41270837|NCT03048955|PROCEDURE|Direct decompression Surgery|A surgical procedure - the control
41270838|NCT01061281|DEVICE|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
41270839|NCT01061281|DEVICE|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
41270840|NCT03514589|DRUG|nasal Tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
41105675|NCT02118506|OTHER|Mental and physical practice|"The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
41105676|NCT02771418|DRUG|Propofol|Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention
41105677|NCT02771418|DRUG|Sevoflurane|Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
41270841|NCT03514589|DRUG|IV tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
41270842|NCT04561349|OTHER|Task oriented training|Task oriented training consisted of different functional tasks for lower limbs to improve balance and walk. Each task was given 5 minutes Tasks were progressed according to each child's performance. These progressions included increase of repetitions, speed and switching between the tasks. One hour practice of these tasks was advised for home plan
41270843|NCT04561349|OTHER|Conventional rehabilitation treatment|"Conventional rehabilitation treatment includes mat activities and ROM of all limbs, Lower limb strengthening and stretching, walking, cycling.~Each exercise was performed for 5 minutes. One hour practice of above exercises and thermotherapy for the spastic muscles advised for 10 minutes once a day at home was advised."
41270844|NCT03561402|DRUG|Teriflunomide|Each patient will receive 1 tablet (14 mg) on a daily basis.
41270845|NCT06400992|DEVICE|Cochlear implant processor Sky CITM M90 (CI-5295)|"The Sky CI available to included patients (no procedures added) offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician"
41444041|NCT03394235|DEVICE|Long-pulsed, 1064nm Nd-YAG laser|This long-pulsed Nd-YAG laser is commonly used for laser hair removal and vascular lesions, but in this study it is used to reduce the size of the hair shaft at the occipital area.
41444042|NCT05214794|DRUG|nemolizumab|nemolizumab will be administered subcutaneous injection
40925307|NCT02545543|BIOLOGICAL|Comparator QIV|"The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
40925308|NCT03571945|DEVICE|Bi-spectral Index (BIS QUATRO REF #186-0106)|GA will be monitored and controlled with Bi-spectral index (BIS).
40925309|NCT03571945|DEVICE|End tidal anaesthesia gas concentration (ETAG)|GA will be monitored and controlled with end-tidal anaesthesia gas concentration
40925310|NCT01986777|DRUG|lisdexamfetamine|
40925311|NCT01986777|DRUG|Placebo|The placebo capsules will be filled with lactose.
40925312|NCT01517360|DRUG|Oxytocin|Oxytocin 40 IU, intranasal inhalation
40925313|NCT01517360|OTHER|Placebo|Placebo, matched to Oxytocin, intranasal inhalation
40925314|NCT01517360|BEHAVIORAL|Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
40925315|NCT00830076|DRUG|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
40925316|NCT00830076|DRUG|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
40925317|NCT00830076|DRUG|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
41105678|NCT02771418|PROCEDURE|Elective carotid endarterectomy|
41105679|NCT03794193|PROCEDURE|Radical resection of colon cancer|The patients with colon cancer will receive radical surgery. Adjuvant chemotherapy will be given according to the results of postoperative histological results.
41105680|NCT02823106|DRUG|Verapamil and Citicoline|Single dosing strategy will be used.
41105681|NCT02823106|OTHER|Placebo|Single matching dosing strategy will be used.
41105682|NCT02709863|DRUG|Sevoflurane|1-1.5 MAC, inhalation route, during operation
41105683|NCT02709863|DRUG|Desflurane|1-1.5 MAC, inhalation route, during operation
41105684|NCT02709863|DRUG|Propofol|6-10 mg/kg/h, iv infusion, during operation
41105685|NCT04588337|DRUG|rhTNK-tPA|Thrombolysis
41105686|NCT03094767|OTHER|Cardiovascular Rehabilitation|Aerobic and anaerobic exercises performed for 12 weeks, 3x/week, of 60 minutes each.
41105687|NCT03094767|OTHER|Initial and Final assessment|Measuring blood preassure, heart rate, Borg scale, respiratory rate, oxygen saturation and HbA1C in the first day of assessment and after 12 weeks.
41105688|NCT01568749|DRUG|Paracetamol|Paracetamol
41444043|NCT01735994|BEHAVIORAL|Healthy Weight|Eating Disorder Prevention Program for Athletes
41444044|NCT01735994|OTHER|Brochure|Brochure on the Female athlete triad
41444045|NCT00830258|DRUG|Pravastatin sodium 80 mg tablets|1 x 80 mg
41444046|NCT00830258|DRUG|Pravachol® 80 mg tablets|1 x 80 mg
41105689|NCT01568749|DRUG|Paracetamol formulation 1|Paracetamol
41105690|NCT01568749|DRUG|Paracetamol Formulation 2|Paracetamol
41105691|NCT01568749|DRUG|Paracetamol formulation 3|Paracetamol
41105692|NCT01568749|DRUG|Paracetamol formulation 4|paracetamol
41105693|NCT06111690|PROCEDURE|Blood Flow Restriction Training (BFRT)|Participants will be performing low-resistance exercise with (BFRT). Intervention will start at least seven days after initial evaluation, so it does not influence measures of real-time physical activity. We will use a log to register exercise completion and to record bilateral knee pain before, during and after each intervention session
41105694|NCT02860884|PROCEDURE|liver biopsy|
41105695|NCT02860884|OTHER|infrared spectroscopy|
41270846|NCT06400992|DEVICE|Hearing Aid, including sound processor Phonak: Sky Link M90|"The device is fitting and programmed for home especially for the purpose research at inclusion. The Clinical map parameters will be verified according to clinical routine.~The Sky Link offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician"
41270847|NCT06400992|DIAGNOSTIC_TEST|French simplified matrix test (FraSimat)|The FraSimat speech in noise test will be tested, 6 months before inclusion in the three different fitting configurations: omni, AS clinic, AS Target. The speech will be presented from the front, noise from 180°. Noise will be presented at a fixed level of 65 dB SPL while the speech signal will be adapted to find the 50% speech reception threshold (SRT).
41270848|NCT06400992|BEHAVIORAL|Audiologist Fitting Questionnaire|After the fitting of Hearing Aid at inclusion, the audiologist will complete a questionnaire describing the fitting and justifying fitting decisions and will collect the demographic information
41270849|NCT06400992|BEHAVIORAL|Patient Satisfaction Questionnaire|The patient will be giving a Patient satisfaction Questionnaire, with questions regarding device and accessory use. The audiologist will go over the instructions for filling out the questionnaire at inclusion. Patients will be asked to complete the questionnaire and return it at the next visit, 6 months after inclusion.
41270850|NCT06400992|BEHAVIORAL|AutoSens Feedback Discussion Form|6 months after inclusion and fitting, the audiologist discusses the use of AS clinic with the subject and completes the AS questionnaire (questionnaire on the experience of using the processor in different listening situations).
41270851|NCT03766243|BEHAVIORAL|Brochure and DVD plus nursing training|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD.~The experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. For both groups an information brochure and an audio-visual DVD were developed specifically for the study. The audio-visual DVD is available on the IDI-IRCCS institutional website."
41444047|NCT02902211|DEVICE|Ankle foot orthosis|Patients will wear an ankle foot orthosis at all times except when he/she is sleeping or bathing for three months.
41444048|NCT02902211|OTHER|Control/standard of care|Patients will carry out with typical activities suggested by their physician for three months.
41444049|NCT04029480|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, 1 tablet QD
41444050|NCT04029480|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg, oral, 1 tablet QD
41444051|NCT04029480|DRUG|Placebo to ertugliflozin 15 mg|Placebo to ertugliflozin 15 mg, oral, 1 tablet QD
41444052|NCT04029480|DRUG|Placebo to ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg, oral, 1 tablet QD
41444053|NCT04029480|BIOLOGICAL|Insulin|The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.
41444054|NCT04029480|DRUG|Metformin|Participants will receive stable dose of background metformin.
41444055|NCT04347018|DEVICE|BRIUS|This is a device that is designed based on movements planned virtually on a computer program. Then all the planned movements are embedded into the wire causing the wire to have the necessary bends to move every tooth into its pre-planned final position. This causes the pre-activated wire to consistently express a low force over a long period of time onto all the teeth. This allows the teeth to move into the final position and treatment progresses towards completion
41105696|NCT04518566|BEHAVIORAL|Nudges|Behavioral nudges will be delivered to patients' FitBit device through adaptive intervention platform via notification syncing. To ensure the delivered nudges are timely and personalized, predictive nudges will be developed based on patterns in patients' sociodemographic, clinical and baseline activity tracking. These nudges will be sent automatically to patients upon specific triggers. The nudges will also be assessed for its effectiveness in behavior change. For example, a predictive nudge to encourage patients to take a short walk after detecting long periods of sedentary time will be assessed for its effects by step counts data after delivery of nudge. An iterative approach will be used to generate an effective set of nudges and its most appropriate delivery times for specific activity patterns.
41105697|NCT00493792|DEVICE|Stryker X3 Crosslink Polyethylene|Highly cross-linked polyethylene (HXLPE).
41105698|NCT00493792|DEVICE|N2Vac Polyethylene|Ultra-high-molecular-weight polyethylene (UHMWPE).
41444056|NCT04447313|OTHER|Survey Administration|Ancillary studies
41105699|NCT02114840|PROCEDURE|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
41105700|NCT02114840|PROCEDURE|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
41105701|NCT02114840|PROCEDURE|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
41105702|NCT01159249|DRUG|Vildagliptin|
41444057|NCT04447313|BEHAVIORAL|Telephone-Based Intervention|Receive ACT telephone coaching
41270852|NCT03766243|BEHAVIORAL|Brochure and DVD only|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD."
41270853|NCT02581995|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
41270854|NCT04658069|OTHER|no specific interventions|no specific interventions
41270855|NCT02150031|DRUG|0.2% Chlorhexidine|mouthwash with 10 ml for 1 minute
41270856|NCT02150031|DRUG|1% Chlorhexidine|subgingival irrigation
41444058|NCT04447313|BEHAVIORAL|Telephone-Based Intervention|Receive SBT telephone coaching
41444059|NCT00088829|DRUG|paclitaxel|subjects will receive paclitaxel neoadjuvantly
41444060|NCT00088829|GENETIC|microarray analysis|subjects will have a biopsy to collect tissue for gene microarray analysis
41444061|NCT00088829|PROCEDURE|biopsy|All subjects will have a biopsy to collect tissue
41444062|NCT00088829|PROCEDURE|neoadjuvant therapy|paclitaxel is given neoadjuvantly
41444063|NCT00088829|DRUG|Paclitaxel|All patients will receive paclitaxel neoadjuvantly
41444064|NCT01585792|DRUG|TAK-875|
41444065|NCT01585792|DRUG|TAK-875|
41444066|NCT01585792|DRUG|Glimepiride|
41444067|NCT01585792|DRUG|Placebo|
41444068|NCT04018768|OTHER|ibuprofen 600 mg|MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.
41444069|NCT04018768|OTHER|Oxycodone/acetaminophen (Percocet) 5 mg/325|MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
41444070|NCT06558942|DEVICE|incisional negative pressure wound technology|Negative pressure device used directly on closed or sutured incisions
41444071|NCT06560125|OTHER|Standard care|Treatment appropriate for wound condition
41105703|NCT01919697|DRUG|Plecanatide|
41105704|NCT00365638|DRUG|simvastatin|
41105705|NCT03829267|BEHAVIORAL|eFIT Intervention|eFIT: social network accountability partners, a psychosocial intervention to increase physical activity in persons with multiple sclerosis
41105706|NCT03829267|BEHAVIORAL|eJournal Intervention|1-hour online each week engaged in an active journaling activity
41105707|NCT03829267|BEHAVIORAL|Treatment as usual|Participants in this condition will complete baseline and follow-up surveys with the same frequency as the active treatment groups, but will receive neither eFIT nor eJournal.
41105708|NCT02174562|BEHAVIORAL|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
41105709|NCT02174562|BEHAVIORAL|Enhanced Usual Care|Usual care enhanced with education and attention
41105710|NCT04280913|OTHER|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19.
41270857|NCT02150031|DRUG|1% Chlorhexidine|supragingival irrigation
41444072|NCT02794584|DRUG|sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
41444073|NCT02794584|PROCEDURE|Hybrid closure|Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.
41444074|NCT02794584|PROCEDURE|Control|Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
41444075|NCT06457308|BIOLOGICAL|Physical training of agility|A grouped training for older adults in the community. The training classed lasted for 12 weeks, one session a week for 120 mins, and are under instructed by a trained experienced sport instructor. Use rope ladders and cones to perform multiple tasks of direction changes, acceleration and deceleration of footsteps, hand and foot coordination and spatial orientation training,
41444076|NCT06457308|BIOLOGICAL|Physical training of resistance|A grouped training for older adults in the community. The training classed lasted for 12 weeks, one session a week for 120 mins, and are under instructed by a trained experienced sport instructor. Resistance training for upper and lower limb muscles and core muscles, including squats, use of elastic bands, and simple bars
41444077|NCT05146076|OTHER|home-based physical training|home-based physical training minimum 150 min./week with telemonitoring
41444078|NCT05146076|OTHER|institutional physical training|institutional physical training supervised by physiotherapist 2-3 times 60 min./week
41105711|NCT05880732|DRUG|Magnesium Sulfate|Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.
41105712|NCT05880732|DRUG|normal saline isotonic solution|only 250 ml of normal saline isotonic solution 30 minutes before induction,
41270858|NCT02150031|PROCEDURE|Blood extraction|Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
41270859|NCT02150031|DRUG|Lidocaine plus adrenaline|local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
41105713|NCT05677269|PROCEDURE|Laparoscopic excision of endometriosis, including colorectal endometriosis|Laparoscopic resection of deep endometriosis, including colorectal endometriosis, in a (candidate) level 2 centre of expertise. Complete resection can exist of either 'shaving' of the nodule from the bowel (leaving the lumen closed), discoid excision or segmental resection, depending on the nodule size and extent of disease.
41105714|NCT05677269|PROCEDURE|In vitro fertilisation or intracytoplasmic sperm injection|IVF/ICSI treatment trajectory (maximum of 3 cycles), according to the local protocol. Preferably preceded by 3 months downregulation with either Gonadotrophin-releasing hormone (GnRH) analogue or oral contraceptive pill. One IVF/ICSI cycle is defined as the transfer of all the embryos created after one follicle puncture until pregnancy confirmation or failure of the last embryo transfer.
41105715|NCT03086512|DEVICE|Acutrak 2® - 7.5 Screw|"The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S."
41105716|NCT03086512|DEVICE|Synthes® 7.3 Cannulated Screw|The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
41105717|NCT02714127|OTHER|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
41105718|NCT02714127|OTHER|Cervicovaginal lavage fluid collection|During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
41105719|NCT05236491|BIOLOGICAL|COVID-19 vaccine|Participants are to receive a booster dose of a COVID-19 vaccine.
41105720|NCT04874571|OTHER|Muscle Energy Technique group|In addition to the home exercise program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the MET(Musculer Energy Technique) group.
41105721|NCT02678624|OTHER|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
41105722|NCT02930590|OTHER|Alternating low pressure mattress with air loss function|IsoAir, Stryker, USA
41105723|NCT02930590|OTHER|Gel mattress|IsoGel, Stryker, USA
41105724|NCT02930590|OTHER|Basic foam|Standard hospital mattress
41105725|NCT02950194|PROCEDURE|PPAWI|One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
41270860|NCT02150031|PROCEDURE|Tooth extraction|dental extraction
41270861|NCT03631576|BIOLOGICAL|CD123/CLL1 CAR-T Cells|CD123/CLL1 CAR-T Cell Therapy
41270862|NCT06257914|DIAGNOSTIC_TEST|Catquest-9SF|Measurement of self-assessed visual function with Catquest-9SF, measurement of ocular aberrations with iTrace (Tracey Technologies), and straylight measurements with C-Quant (Oculus)
41270863|NCT06486831|OTHER|Squeeze the stress ball.|The child and parents will be taken to the procedure room for the casting procedure. The plastering process in children takes an average of 10-15 minutes. In the experimental group, the stress ball selected by the child will be started 1-2 minutes before the casting process and will be watched for an average of 10 minutes. If the procedure is prolonged, the time for squeezing and playing with the stress ball will be extended.
41270864|NCT03137979|BIOLOGICAL|GMSCs and collagen scaffolds|Patients in this group were given GMSCs and collagen scaffolds.
41105726|NCT05019729|DRUG|VRC-MALMAB0114-00-AB|VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.
41105727|NCT05019729|OTHER|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum
41105728|NCT02139449|PROCEDURE|ICD/CRT|cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
41270865|NCT03137979|BIOLOGICAL|Collagen scaffolds|Patients in this group were given collagen scaffolds.
41270866|NCT03137979|PROCEDURE|Open flap debridement|The patients in this group will only receive the treatment of open flap debridement.
41270867|NCT01390792|DRUG|Zanamivir hydrate|
41270868|NCT03780998|DRUG|Life7|Life7 will used on the perianal skin with finger tips
41270869|NCT06030427|BEHAVIORAL|Behavioral Dietary Intervention|Participate in weight management program
41270870|NCT06030427|OTHER|Educational Intervention|Receive patient education handouts
41270871|NCT06030427|OTHER|Health Promotion and Education|View behavioral educational PowerPoint presentation
41270872|NCT06030427|OTHER|Internet-Based Intervention|Complete virtual behavioral weight management with an integrated mindfulness component program
41270873|NCT06030427|OTHER|Interview|Ancillary studies
41270874|NCT06030427|OTHER|Medical Device Usage and Evaluation|Wear Fitbit
41270875|NCT06030427|BEHAVIORAL|Mindfulness Relaxation|Complete mindfulness components
41270876|NCT06030427|OTHER|Physical Performance Testing|Ancillary studies
40925318|NCT00830076|DRUG|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
40925319|NCT02811627|DRUG|Memantine|Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.
40925320|NCT02811627|DEVICE|Magnetic Resonance Imaging|The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
41105729|NCT03489317|DRUG|Metformin|Participants with high glucose levels will usually be prescribed Metformin 250 mg three times daily. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
41105730|NCT03489317|BEHAVIORAL|lifestyle modification|Participants with metabolic syndrome will be offered advice on modifying their diets and exercise regimes. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
41105731|NCT03489317|DRUG|Simvastatin 10mg|Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
41270877|NCT06030427|OTHER|Questionnaire Administration|Ancillary studies
41270878|NCT05387356|OTHER|prone position|thirty-one patients who had a positive test result for SARS-CoV-2 RNA through nasopharyngeal swab and underwent three subsequent prone positions for 16 hours will be enrolled the study. Medical datas of the patients will be obtained from patients' files which are strictly filled during pandemic. Prone position indication of intensive care unit (ICU) is in case of severe ARDS with PaO2/FiO2 \<150 despite a PEEP \>10 cmH2O.
41270879|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 10 mg at 1 dose every 8 weeks
41270880|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 5 mg at 1 dose every 8 weeks
41270881|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 2.5 mg at 1 dose every 8 weeks
41270882|NCT00733902|BIOLOGICAL|Placebo|IV placebo to match tanezumab at 1 dose every 8 weeks
41270883|NCT01110187|DRUG|lacosamide|200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
41270884|NCT01110187|DRUG|Fosphenytoin|20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
41270885|NCT04879797|OTHER|Implementation of Maternal Safety Bundles|In the second phase, implementation of the bundles will take place. During this phase investigators will conduct quarterly surveys with the health facilities to measure implementation progress, including an index of evidence-based practices. Investigators will conduct surveys with postpartum women to measure their patient experience. Surveys will be conducted using RedCap software. Participants will be given the opportunity to complete the survey online or if they prefer, a research assistant can call them to conduct the survey over the phone. Data on SMM will be collected through PELL
41270886|NCT04879797|OTHER|Doula Services|Investigators are evaluating doula services that are offered by two doula organizations at three hospitals.
41270887|NCT02890719|DRUG|Grazoprevir 100 mg/day|Grazoprevir 100 mg/ day 12 weeks
41270888|NCT02890719|DRUG|Elbasvir 50 mg/d|Elbasvir 50 mg/day 12 weeks
41270889|NCT02890719|DRUG|Grazoprevir 100 mg/day|Grazoprevir 100 mg/day 16 weeks
41270890|NCT02890719|DRUG|Elbasvir 50 mg/day|Elbasvir 50 mg/d 16 weeks
41270891|NCT02890719|DRUG|Ribavirin 1200 mg/day|Ribavirin 1200 mg/day 16 weeks
41270892|NCT04472728|DRUG|BIO101|BIO101 capsules
41270893|NCT04472728|DRUG|Placebo|placebo capsules
41270894|NCT02489539|DEVICE|GORE® EXCLUDER® Conformable AAA Endoprosthesis|Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
41270895|NCT02652039|OTHER|Questionnaires|Questionnaires
41270896|NCT01530139|BEHAVIORAL|Level 1|Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
41270897|NCT01530139|BEHAVIORAL|Level 2|Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
41270898|NCT01530139|BEHAVIORAL|Level 3|Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
41270899|NCT01530139|BEHAVIORAL|Level 0|Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
41270900|NCT00888355|DRUG|losartan potassium|losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
41270901|NCT00888355|DRUG|Comparator: placebo|placebo to losartan tablet q.a.m. , for 12 weeks
41270902|NCT00929955|DRUG|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
41270903|NCT00929955|DRUG|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
41270904|NCT00929955|DRUG|Placebo|Placebo added to TAU
41270905|NCT02342834|DIETARY_SUPPLEMENT|Small mixed protein and lipid meal|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
41270906|NCT03683602|OTHER|PNF group|PNF is used in treatment of musculoskeletal pain of cervical and lumbar spine. Proprioceptive neuromuscular facilitation is a rehabilitation concept widely used by physiotherapists in many countries, in which stimulation of central nervous system is to achieve the highest possible functional level
41270907|NCT03683602|OTHER|manual therapy group|"Manual therapy is used for an assessment and treatment of joint and soft tissues.~The basic therapeutic tool is mobilisation. In the study joint mobilisation according to Kaltenborn-Evjenth Manual Therapy was used. The joint were mobilised with low velocity passive movements in the whole or end range. Spinal manipulation wasn't used. Liter Exelby reports that manual therapy with joints mobilisation was quite effective in improvement of functional movements and decreasing of pain."
41270908|NCT06072014|OTHER|Virtual reality|A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia
41270909|NCT04474730|DEVICE|BMT Physical Activity app|This app sends reminders to patients, collect activity data from Apple Watch, and allow patients to submit symptoms.
41270910|NCT04474730|OTHER|Watch Only|A locked Apple Watch will be used to collect physical activity data from the Watch Only patients.
41270911|NCT04947293|OTHER|Physical activity|Both groups will practice a physical activity adapted to their motor skills. They will have two group sessions (maximum 5 people per group) in a face-to-face setting, and one independent session at home supported by a video, each week. These programs last 12 weeks, and will be supervised by the same person, a physiotherapist.
41270912|NCT01058603|OTHER|- Conventional culture medium for IVF|Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen
41270913|NCT01058603|OTHER|- Endocell®|Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
41270914|NCT00864760|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
40925321|NCT06154278|DRUG|Imdusiran (AB-729)|60mg subcutaneously, every 8 weeks, for a total of 4 doses
41444079|NCT04571684|OTHER|HITSystem 2.1|HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.
41270915|NCT00864760|DRUG|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
41270916|NCT05241158|BEHAVIORAL|Counselling with visual aid|patients were counselled about the procedure, complications and the post-procedure recovery phase and shown a 5 minutes animated video of the gastroscopy or colonoscopy procedure
41270917|NCT05241158|BEHAVIORAL|Counselling|Patients counselled about the procedure, complications and the post-procedure recovery phase
41270918|NCT04566484|DRUG|BBV87 Chikungunya vaccine|BBV87 Chikungunya vaccine is a whole virus inactivated vaccine formulated with 0.25 mg aluminum (as aluminum hydroxide) per single human dose.
41270919|NCT04566484|DRUG|Normal Saline|Normal saline is the placebo
41270920|NCT00138021|DEVICE|Computerized cognitive training program|"The cognitive training model used in the McGurk et al. (2005) study is referred to as the Thinking Skills for Work program. The program is a manualized, remediative and compensatory training intervention that is integrated with SE services. The program includes a cognitive trainer, a structured training manual (McGurk \& Mueser, unpublished training manual) and a computer-based cognitive training program (described below)."
41270921|NCT05257512|DRUG|SY-3505|The third-generation ALK TKI
41270922|NCT00838591|DRUG|MN-221|Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
41270923|NCT00838591|DRUG|Placebo|
41270924|NCT02318784|DRUG|Carfilzomib|
40925322|NCT03928093|DRUG|Pregabalin|Pregabalin /placebo capsules will be taken by mouth and will be prescribed for the study participants in the doses, depending on their weight and treatment phase: Participant \< 25 kg at baseline will start with 50 mg per day, increasing the dose by 50 mg each week until their maximum dose 200 mg per day; Participants who are greater than or equal to 25 kg at baseline will start with 100 mg per day, increasing their dose by 50 mg each week until their target dose 300 mg per day is achieved. The study medication will be taken twice per day.The dose will be weaned down every 1-2 days by 25 mg in the last two weeks of each treatment period.
41270925|NCT02870725|BEHAVIORAL|CBT Individual Psychotherapy|The 4-session CBT treatment will include receipt of a manualized cognitive behavioral intervention, delivered individually, to treat the depression symptoms (e.g. cognitive restructuring, behavioral activation) and teach adaptive coping strategies to manage their depression. Ideally, the intervention will also positively affect their chronic headaches (i.e. reduction of headache frequency, severity and level of disability). Each session is approximately 60 minutes with specific, reflective and guided activities related to a specific module within the intervention.
41270926|NCT01841632|DRUG|MultiStem|
41105732|NCT03489317|DRUG|Amlodipine 5mg|Participants with high blood pressure could be prescribed antihypertensive medicine such as Amlodipine. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
41105733|NCT04034901|DEVICE|Monitoring of cardiorespiratory parameters with BORA Band|"The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements :~* Activity~* Step count~* Heart rate~* Respiratory rate~* Skin temperature~* SpO2"
41105734|NCT00652119|DRUG|Paclitaxel|Cycle 1 = 60 mg/m\^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m\^2 IP weekly over 1 hour x 3 weeks of each cycle.
41105735|NCT00652119|DRUG|Carboplatin|Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.
41105736|NCT00652119|DRUG|Avastin|Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.
41105737|NCT03284411|DEVICE|Spinal Cord Stimulation|Programming
41105738|NCT02736799|DEVICE|Sham vibrating capsule|Sham device without vibration
41105739|NCT02736799|DEVICE|Vibrant Capsule (1 vibration)|1 vibration/min
41105740|NCT02736799|DEVICE|Vibrant Capsule (3 vibration)|3 vibration/min
41105741|NCT02736799|DEVICE|Vibrant Capsule (5 vibration)|5 vibration/min
41105742|NCT05380505|BEHAVIORAL|Racially Congruent Ads|Facebook food ads that are racially congruent.
41105743|NCT05380505|BEHAVIORAL|Racially Incongruent Ads|Facebook food ads that are racially incongruent.
41270927|NCT04651634|DRUG|MIT-001 plus CCRT|MIT-001 IV-infusion plus CCRT
41270928|NCT02996812|DRUG|Exendin (9-39)|
41270929|NCT03870841|DRUG|PC945|PC945, nebulized
41444080|NCT05276635|BEHAVIORAL|The Sleep Hygiene Education (SHE)|Patients were randomized into two equal groups of 30 participants each. One group received a Sleep Hygiene Education (SHE) intervention
41444081|NCT05276635|BEHAVIORAL|Emotional Freedom Techniques (EFT)|30 participants had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I).
41444082|NCT03923192|DEVICE|Vistacam|device for early proximal caries detection
41444083|NCT03923192|RADIATION|Bitewing radiograph|radiograph for proximal caries detection
41105744|NCT03013348|DEVICE|Brain Sentinel's sEMG Post-processing algorithm|Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography \[EEG\] recordings) that are pathognomonic for PNES activity.
41105745|NCT00395018|DRUG|entecavir|Tablets, Oral, 1 mg, once daily, up to 72 weeks
41105746|NCT01762241|BEHAVIORAL|Home based training using the Xbox Kinect system|Home based training 3 times a week for 12 weeks using the Xbox Kinect system
41105747|NCT05531799|PROCEDURE|OPTIMIZATION PHASE|"The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could~- identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and"
41105748|NCT04479254|DIETARY_SUPPLEMENT|Enteral Nutrients ( Nutren Optimum, Nutren Diabetes, Novasource Renal ), Parenteral Nutrient ( Smofkabiven)|Enteral nutrition feeding formula is used in powder form and will be reconstituted by attending nurses, Continuous feeding is commonly used which will be prescribed by the attending clinicians, Energy and protein intake from EN will be estimated by multiplying the volume of feed given to energy (kcal) and protein (g) in 1 ml of standard dilution, and for Standard PN product, energy and protein intake will also be calculated based on the volume infused.
41105749|NCT04416971|PROCEDURE|AVF puncture|For patients with mature/immature AVF on HD initiation, AVF puncture will be conducted.
41105750|NCT06252727|DRUG|Aminolevulinic Acid|Given PO
41444084|NCT01360333|OTHER|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
41105751|NCT02703740|DEVICE|Hyaluronic acid dermal filler with lidocaine 0.3%|injection in labial fold of a dermal filler
41105752|NCT06112119|DEVICE|MSCT|Using Semi-automatic MSCT Volumetry in assessment of brain atrophy associated with septic ICU patients
41105753|NCT00253058|DRUG|Cetirizine Dry Syrup|
41105754|NCT03967795|DRUG|N2-L-Alanyl-L-Glutamine (Substance)|20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
41105755|NCT03083405|DRUG|Opipramol|The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
41105756|NCT02615912|OTHER|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%|
41105757|NCT02615912|OTHER|Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%|
41105758|NCT02615912|OTHER|Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%|
41105759|NCT02615912|OTHER|Silwet* DA-63 (Momentive) 1.5%|
41105760|NCT02615912|OTHER|Sodium lauryl sulfate (Sigma Aldrich) 1.0%|
41105761|NCT02615912|OTHER|Water (control)|
41105762|NCT03824899|DIAGNOSTIC_TEST|Blood concentration check|Blood concentration check：the plasma concentration of SN-38 was detected by HPLC (high-performance liquid chromatography) at 1.5 h and 49.0 h after CPT-11 infusion
41105763|NCT04670419|OTHER|Viral clade|Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection
41270930|NCT04092842|DEVICE|Silicone prosthesis|Silicone prosthesis
41270931|NCT04092842|PROCEDURE|Usual practice|Usual surgery
41105764|NCT04536441|BEHAVIORAL|Ultra Brief Online Mindfulness-based Intervention|We adapted and contextualized the original RAIN protocol to local pandemic-induced lockdown situation, with short journaling prompts that engage participants in self-reflection. Journaling is known to be a creative way to engage people in a therapeutic activity which promotes self-awareness (Utley \& Garza, 2011). Creating a visual narration of thoughts, feelings and experiences help individuals make internal experiences more tangible and manageable, especially during these uncertain times.
41105765|NCT04536441|BEHAVIORAL|Control|The control group participants were asked to report preventive measures that they have taken to prevent COVID-19, ways that they obtained Movement Control Order news, and things that they wished to do once the Movement Control Order is lifted.
41105766|NCT04369807|DIAGNOSTIC_TEST|Outpatient MRI|"Participation in the study includes up to 3 visits to a partnering imaging facility - this will include measurement of height and weight (to calculate BMI), blood pressure measurement, 3 sets of blood tests, 3 Questionnaires and 3 MRI tests.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications."
41105767|NCT03393117|DRUG|Liposomal Bupivacaine|20mL vial of Liposomal Bupivacaine (266 mg). The infiltration technique for Liposomal Bupivacaine will be 80mL injected into either hemi-abdomen as a transversus abdominous plane (TAP) block via ultrasound guidance. The other 80mL will be utilized in the operative breast for the field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks.
41444085|NCT05916131|BEHAVIORAL|Basic Education|2-week text message intervention for providing knowledge about hypoglycemia management and prevention.
41444086|NCT05916131|BEHAVIORAL|Hypoglycemia Symptom Detection Training|10-week text message intervention for providing training on skills of detecting hypoglycemia symptoms.
41270932|NCT06329934|BEHAVIORAL|Establishment of a hierarchical monitoring and management team|To be specific, the head nurse served as the team leader to conduct comprehensive macro supervision; moreover, there were 3 responsible team leaders and 6 responsible nurses, all of whom had rich clinical nursing experience and solid theoretical knowledge of pressure injury. Consequently, a joint-action mechanism of the head nurse - responsible team leader - responsible nurses was developed to facilitate the unification of the training of nursing content, precautions, etc.
41270933|NCT06329934|BEHAVIORAL|Assessment of pressure injury|Based on the postoperative coma of patients, the Braden assessment scale was applied to effectively evaluate patients from six dimensions of sensory perception, moisture, activity mode, mobility, nutrition, friction, and shear. The total score was 23 points. Patients scoring 13\~14 points were evaluated by Braden once per week; and those scoring ≤12 points were evaluated at a frequency of 3d/ time.
41270934|NCT06329934|BEHAVIORAL|Communication|Through intensive face-to-face communication with family members, timely information on the surgical effect, mechanism of pressure injury, preventive measures, and clinical manifestations through intuitive methods such as PPT and video, family members were taught with basic knowledge of pressure injury, and guided to inform medical staff in a timely manner when patients had symptoms of pressure ulcer. Simultaneously, by case sharing and positive suggestions, family members were supported to alleviate their concerns and improve their coordination with treatment
41270935|NCT06329934|BEHAVIORAL|Intervention for pressure ulcer|For patients with a Braden score of \>14 points, attention should be paid to keeping skin dry and clean, regularly changing bed sheets and bedding (once per day). Patients with Braden score of 13-14 points should be provided with sponge mattresses, increased times of turning over once per 2 hours, and soft pillows or foam dressings at the site of occipital protuberance to relieve pressure and prevent pressure injury. For patients with Braden score ≤12 points, medical staff should repeatedly emphasize to their families the harm of pressure injury to postoperative recovery.
41270936|NCT06329934|BEHAVIORAL|Rehabilitation training|After regaining consciousness with stable vital signs, patients received rehabilitation training following the principle of association of activity and inertia in a regular order. Patients were guided to perform upper limb movements, joint flexion, lower limb flexion and extension, as well as daily training such as washing face, rinsing mouth, and dressing at a frequency of 3\~4 times/d. Moreover, patients were advised to minimize violent behaviors such as laughing and talking loudly
41270937|NCT06329934|BEHAVIORAL|introduction of the current patient's condition to family members|timely introduction of the current patient's condition to family members to alleviate their concerns
41444087|NCT05916131|BEHAVIORAL|Education Plus|10-week text message intervention for helping people consider how they think of hypoglycemia.
41444088|NCT03861247|DRUG|Phosphate-binder intervention|Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
41105768|NCT03393117|DRUG|Bupivacaine|20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.
41105769|NCT03393117|DRUG|Patient-Controlled Analgesia Pump|The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.
41105770|NCT03393117|DRUG|Oral Narcotic|Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
41105771|NCT02590913|DIETARY_SUPPLEMENT|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
41105772|NCT02590913|DIETARY_SUPPLEMENT|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
41270938|NCT06329934|BEHAVIORAL|maintaining appropriate temperature and humidity in the ward|maintaining appropriate temperature (20 ℃\~22 ℃) and humidity (60.0%\~70.0%) in the ward
41444089|NCT03861247|DIETARY_SUPPLEMENT|Phosphorus-restricted dietary intervention|Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary
41105773|NCT04905316|DRUG|Canakinumab|Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
41105774|NCT04905316|DRUG|Durvalumab|Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.
41105775|NCT04905316|RADIATION|Radiation therapy|Radiation therapy will be performed with external beam ionizing radiation as per standard of care in accordance with institutional practice. Intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist. Patients will be simulated in the treatment position with standard immobilization techniques for thoracic radiotherapy. The prescription dose will be 60 Gy (±10%) in 2Gy fractions to fields encompassing gross tumor and lymph nodes, as per institutional guidelines. The dose must satisfy institutional guidelines and minimize risk to adjacent organs at risk.
41105776|NCT04905316|DRUG|Chemotherapy|Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
41105777|NCT00541606|OTHER|Pharmacist collaboration in diabetes care|Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.
41105778|NCT00541606|OTHER|Usual care|Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
41105779|NCT02206386|OTHER|MHTraining-Net|See Arm Description for more details.
41105780|NCT02206386|OTHER|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
41105781|NCT01778712|BEHAVIORAL|Multi-level intervention|The development of a lifestyle program intended to intervene on the individual, social network and community over two years
41105782|NCT03092557|OTHER|Determination of local pleural strain|For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
41105783|NCT01109095|BIOLOGICAL|HER.CAR CMV-specific CTLs|"HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:~* 1 x 10\^6/m\^2~* 3 x 10\^6/m\^2~* 1 x 10\^7/m\^2~* 3 x 10\^7/m\^2~* 1 x 10\^8/m\^2"
41105784|NCT03192046|DEVICE|Carbon Fiber Ankle Foot Orthosis (AFO)|Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
41105785|NCT03192046|OTHER|Standardized walking/exercise program|standardized walking/exercise program without any brace or AFO
41105786|NCT01186848|DEVICE|Combination treatment|The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
41105787|NCT01186848|DEVICE|1550-nm erbium-doped fractionated laser|Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
41105788|NCT02727764|GENETIC|ART-I02|Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint
41105789|NCT05079269|OTHER|Crystalloid Solutions|As above
41105790|NCT02278848|OTHER|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
41105791|NCT04030559|DRUG|Niraparib|Given PO
41105792|NCT04030559|DRUG|Niraparib Tosylate Monohydrate|Given PO
41105793|NCT04030559|PROCEDURE|Radical Prostatectomy|Undergo standard of care surgery
41105794|NCT02650596|DRUG|GLP-1|Liraglutide were taken daily for 3 months
41105795|NCT02650596|DRUG|Placebo|Placebo were taken daily for 3 months
41444090|NCT01400984|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
41444091|NCT03668015|OTHER|Xylitol then Sorbitol gum|Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
41444092|NCT03668015|OTHER|Sorbitol then Xylitol gum|Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
41444093|NCT03037671|DEVICE|Continuous Glucose Monitor (CGM)|Participants will wear the continuous glucose monitor (GCM) device during the peri-HSCT period for the duration of their initial hospital admission. No intervention based on results.
41444094|NCT02610647|DRUG|Wrist anesthesia|Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
41444095|NCT02610647|OTHER|Blinding mask|Patients will don a mask that prevents them from seeing during the tapping test.
41444096|NCT02610647|OTHER|Anti-noise helmet|Patients will don a helmet that prevents them from hearing during the tapping test.
41444097|NCT02610647|OTHER|Tapping test|"Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail."
41444098|NCT06601894|DIAGNOSTIC_TEST|Platelets count|the study include will take medical investigation data for all sickle cell patients.
41444099|NCT04904575|PROCEDURE|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml."
41444100|NCT04904575|PROCEDURE|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%."
41444101|NCT02067611|DRUG|X0002|Parallel Assignment
41444102|NCT02067611|DRUG|Placebo|Parallel Assignment
41444103|NCT04807426|OTHER|Multi Sensory stimulation exercises|Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity is added by increasing speed of task performance. Conservative Management:Passive stretching exercises for paretic upper extremity muscles .Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.
41444104|NCT04807426|OTHER|Task Oriented Exercises|"Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
41270939|NCT06329934|BEHAVIORAL|careful observation of vital signs in patients|careful observation of vital signs such as heart rate, blood oxygen saturation, and blood pressure in patients
41105796|NCT05407480|OTHER|Observational|Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome
41444105|NCT04807426|OTHER|Task-oriented exercises and Multisensory stimulation Exercises|"Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
41444106|NCT03891784|DRUG|Abemaciclib|Given PO
41444107|NCT03706833|DEVICE|Edwards PASCAL System|Transcatheter mitral valve repair with the Edwards PASCAL System
41444108|NCT03706833|DEVICE|Abbott Mitraclip System|Transcatheter mitral valve repair with the Abbott Mitraclip System
41444109|NCT02777580|DRUG|Tenecteplase|Half dose Tenecteplase
41270940|NCT05707572|DRUG|methylprednisolone|a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
41105797|NCT00959920|PROCEDURE|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
41444110|NCT02777580|DRUG|Clopidogrel|300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.
41105798|NCT00959920|PROCEDURE|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
41105799|NCT00851240|DRUG|BTT-1023|intravenous
41105800|NCT00851240|DRUG|Placebo|Intravenous
41105801|NCT01233154|DIETARY_SUPPLEMENT|probiotic|
41105802|NCT01233154|DIETARY_SUPPLEMENT|probiotic|
41105803|NCT03558204|PROCEDURE|Denervation of the thumb CMC joint|Removal/disconnection of the nerve branches to the joint from their attachments to the joint
41105804|NCT03558204|PROCEDURE|trapeziectomy with ligament reconstruction (LRTI)|excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
41105805|NCT06555809|DRUG|Artesunate Injection|Additional blood sample will be collected when other standard of care blood specimens are collected during the 2-day period after the start of intravenous artesunate treatment.
41105806|NCT06018194|DEVICE|ElucidVivo|Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
41105807|NCT00380627|DRUG|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
41105808|NCT00067639|DRUG|Pegfilgrastim (Neulasta)|12 mg single injection of pegfilgrastim under the skin prior to apheresis.
41105809|NCT00067639|PROCEDURE|Apheresis|Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
41105810|NCT03835572|OTHER|CircaHealth: a course on circadian rhythms and health|Participants will receive videos, behavioral modification checklists, and quizzes every week for six weeks.
41105811|NCT03835572|OTHER|Sleep hygiene materials|Participants in the control group will receive weekly materials from the National Sleep Foundation and American Academy of Sleep Medicine on sleep hygiene
41105812|NCT03990272|DRUG|AIT drops|once a day
41105813|NCT03990272|DRUG|placebo drops|once a day
41105814|NCT01988233|BEHAVIORAL|BAILAMOS© Dance Program|
41105815|NCT01988233|BEHAVIORAL|Health Education Control Group|
41105816|NCT00751036|DRUG|Nilotinib|Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
41105817|NCT00751036|DRUG|Imatinib|Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
41105818|NCT06320119|OTHER|PDO Group|Patients in the intervention gruop with set a personalized outcome within a usual asthma review consultation
41105819|NCT02478853|OTHER|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
41105820|NCT00603538|DRUG|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
41105821|NCT03145935|DIAGNOSTIC_TEST|Abdominal compression (AC)|An echocardiography with stroke volume measurement coupled with an abdominal compression will be performed before and after ta diuretics induced diuresis of 10ml/kg in pediatric patients hospitalized in a pediatric intensive care unit (PICU) diagnosed with fluid overload
41105822|NCT03145935|DIAGNOSTIC_TEST|blood sample|proteinemia and hematocrit will be measured before and after a diuretics induced diuresis of 10ml/kg
41105823|NCT04472871|DEVICE|Left atrial appendage closure|The left atrial appendage (LAA) is a small, ear-shaped sac in the muscle wall of the left atrium (top left chamber of the heart). It is unclear what function, if any, the LAA performs. In patients with heart failure and atrial fibrillation, reduced left atrial appendage (LAA) emptying velocities leads to LAA thrombus formation therefor a higher rate of stroke and embolism are observed even on oral anticoagulants. FDA approved devices for left atrial appendage closure will be used under guidance of angiography and trans-esophageal echo with highly efficient and trained personnel.
40752172|NCT06040450|OTHER|Questionnaire survey|On outdoor sports practice activity, barriers to practice, impacts on well-being.
41270941|NCT05707572|PROCEDURE|manual manipulation|The lesser MTPJs of the affected foot will be manually manipulated using a high velocity, low amplitude thrust technique.
41270942|NCT01727960|BEHAVIORAL|Education and posture correction|a lecture concerning the fine posture for health and exercises
41444111|NCT02777580|PROCEDURE|Coronary angiography|Coronary angiography followed by PCI or CABG if required, rescue PCI if required
40752173|NCT00907868|RADIATION|partial breast irradiation|Patients undergo radiation tumor bed boost
40752174|NCT00907868|RADIATION|whole breast irradiation|Patients undergo whole breast irradiation
40752175|NCT00375310|DRUG|Gemcitabine, Sorafenib|"Gemcitabine is given IV~Sorafenib is given orally of varying doses:~1. Sorafenib 200 mg po qd ( during combination therapy)~2. Sorafenib 400 mg po qd ( during combination therapy)~3. Sorafenib 400 mg po bid ( during combination therapy)"
40752176|NCT00375310|PROCEDURE|Radiotherapy|1.8 Gy CTV daily for 5 weeks
40752177|NCT00151463|DRUG|sildenafil citrate|
40752178|NCT00362609|DRUG|pantoprazole|
41105824|NCT02458599|DIETARY_SUPPLEMENT|Test product|Whey protein hydrolysate (20 g)
41105825|NCT02458599|DIETARY_SUPPLEMENT|Reference product 1|Iso-energetic carbohydrate (20 g)
41105826|NCT02458599|DIETARY_SUPPLEMENT|Reference product 2|Negligible energy placebo (20 g)
41270943|NCT01355289|DRUG|Avatrombopag|
41105827|NCT04313452|OTHER|the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged|to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
41105828|NCT00820079|DRUG|ADX10059|oral administration
41105829|NCT00820079|DRUG|ADX10059 Matching Placebo|oral administration
41105830|NCT05528380|BEHAVIORAL|LPA + Fitbit Intervention|Participants will receive a Fitbit to track activity levels and participate in a 6-session lifestyle physical activity intervention over the course of 12 weeks. The intervention consists of 20-25 minute phone or video-delivered session to: (a) review PA progress and re-evaluate current step-count goals, (b) problem-solve barriers to incorporating PA into their daily lives, (c) address difficulties utilizing the Fitbit, (d) encourage the use of bouts of PA as a coping strategy, and e) engage the participant in brief discussions focused on increasing and maintaining PA.
41105831|NCT03807557|OTHER|Robotic Constraint-induced movement therapy|"i.Robotic repetitive task-specific training followed by task-oriented practice: during each session, participants first receive 60 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 30 minutes of functional practice using shaping technique.~ii.Restraint of the unaffected limb: Patients will wear a mitt to restrict the unaffected hand during training at clinic for 0.5 hours of functional practice each session, 3 sessions per week for 8 weeks.~iii. Transfer package: The transfer package aims at transferring the therapy gains to the participant's real world by use of a set of behavioral techniques. This is intended to have the participant responsible for adhering to the treatment requirements and encourage active engagement in the functional practice outside of the clinic setting. The participants will be given appropriated home assignment practicing daily activities outside of the clinic."
41105832|NCT03807557|OTHER|conventional UE rehabilitation training|focusing on UE training and including neuro-developmental techniques(Bobath, 1990), trunk-arm control (ie, practice UE tasks during standing), weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
41105833|NCT00374699|DRUG|Velcade|
41105834|NCT02092844|BEHAVIORAL|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
41105835|NCT04089618|BEHAVIORAL|MBLM|Complex 8 week Mind-Body program.
41105836|NCT04431206|DRUG|Oxytocin|Oxytocin administered by IV infusion
41105837|NCT01709266|DIETARY_SUPPLEMENT|Probiotics|
41105838|NCT01709266|DIETARY_SUPPLEMENT|Placebo|
41105839|NCT04765943|DEVICE|Implantable Loop Recorder implant|Patients will be undergone to an Implantable Loop Recorder implant and monitored for the next 6 months.They will then undergo a cardiac MRI and an ICD will be implanted according to clinical practice guidelines. A minimum follow-up of 2 years is scheduled.
41105840|NCT04330469|PROCEDURE|Periodontal therapy|"Treatment will be performed by a periodontist.~1. Intensive removal of subgingival and supragingival calculus and plaque biofilm by scaling, root-planing and polishing. The procedures will be carried out with the use of hand scalers and a piezoelectric ultrasonic scaler with universal tips. Disclosing solution will be used to visualize the plaque for the clinician.~2. One to four sessions of subgingival scaling and root planing by quadrant, under local anesthesia as may be deemed necessary during the study period.~3. Subgingival irrigation using an antiseptic mouth rinse (chlorhexidine 0.12%).~4. Polishing of the coronal and radicular surfaces of the teeth."
41105841|NCT04330469|PROCEDURE|Oral hygiene advice|Oral hygiene advised by Periodontist
41105842|NCT05095675|BEHAVIORAL|psychological questionnaires|Participants have to fulfill psychological questionnaires in different time points during medical oncological treatment
41444112|NCT02777580|PROCEDURE|Primary PCI|Primary PCI accoring to local standards
41444113|NCT06196554|DRUG|Oxaliplatin|"According to the first-line drugs provided by the NCCN guidelines, the concentration of each drug was added to the organoid culture medium after setting 5-6 concentration gradients according to literature reports. Chemo-sensitive and drug-resistant.~Construction of gastric cancer organoid T cell co-culture system to screen sensitive immunotherapy drugs."
41444114|NCT03273153|DRUG|Cobimetinib|Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
41270944|NCT01355289|DRUG|Placebo|
41444115|NCT03273153|DRUG|Atezolizumab|Atezolizumab 840 mg as IV infusion once in every 2 weeks.
41444116|NCT03273153|DRUG|Pembrolizumab|Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
41444117|NCT05976815|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Apart from the neoadjuvant chemotherapy treatment (standard of care), participants allocated to the experimental group will additionally participate in a supervised physical exercise program that comprises 3 weekly sessions during the months that the patient is undergoing chemotherapy treatment. Each 75-minute session will comprise a 10-minute warm up, 30 minutes of strength training involving exercise for the major muscle groups, 30 minutes of aerobic training at 40-89% of heart rate reserve and a 5-minute cool down.
41444118|NCT02211924|DRUG|BI 44847|
41444119|NCT02211924|DRUG|Placebo|
41444120|NCT00298961|DEVICE|Videoconference equipment FALCON/IP|
40752179|NCT05823077|OTHER|Bergamot|The affected knee will be massaged with Bergamot oil for 4 weeks, 2 sessions per week.
40752180|NCT05823077|OTHER|Placebo|The affected knee will be massaged with sweet almond oil for 4 weeks, 2 sessions per week.
40752181|NCT01060969|DRUG|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
40752182|NCT01060969|DRUG|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
40925323|NCT00748020|PROCEDURE|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
40925324|NCT00748020|PROCEDURE|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
40925325|NCT03679442|DRUG|N-acetylcysteine|Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
41444121|NCT02226432|PROCEDURE|- Postoperative Antagonistic Peripheral Magnetic Stimulation|"Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~* Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~* Comparision of both groups will be statistified"
41444122|NCT02226432|DEVICE|Selective Peripheral Magnetic Stimulation|"Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)"
41444123|NCT02226432|OTHER|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
41444124|NCT04150029|DRUG|MBG453|Solution for intravenous infusion
41444125|NCT04150029|DRUG|Venetoclax|Tablet for oral administration
41444126|NCT04150029|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
41444127|NCT06559280|DRUG|esketamine|During the operation, 0.25mg/kg esketamine was induced, and 1mg/kg esketamine was added to the postoperative analgesia pump
41444128|NCT01165047|DRUG|Nitric Oxide|Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
41444129|NCT06380023|DEVICE|Enclosure barrier|Surgical mask \& Enclosure tent compared with open suction
41444130|NCT03745963|BEHAVIORAL|Skin-to-skin contact|Infants allocated to the SSC arm will be placed in upright, ventral SSC position (holding of a diaper clad baby on the bare chest of a mother) for a minimum of 15 minutes prior to data collection.
41444131|NCT03745963|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance.
41444132|NCT02680444|BEHAVIORAL|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
41444133|NCT02680444|BEHAVIORAL|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
41444134|NCT02680444|BEHAVIORAL|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
41444135|NCT02577458|DRUG|CM082|CM082 tablets taken orally once a day on 28-day cycles
41444136|NCT02577458|DRUG|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
41444137|NCT02885285|BEHAVIORAL|Spinning Class|Spinning Class twice a week for six weeks.
41444138|NCT02885285|BEHAVIORAL|Yoga Class|Yoga Class twice a week for six weeks.
41444139|NCT02885285|BEHAVIORAL|Dance Class|Dance Class twice a week for six weeks.
41444140|NCT02885285|OTHER|No Exercise Class|No exercise class. Subject will continue regular activities for six weeks.
41444141|NCT02641444|PROCEDURE|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
41444142|NCT02641444|PROCEDURE|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
41444143|NCT02641444|PROCEDURE|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
41444144|NCT02753179|OTHER|Head Impulse Tests|Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
41444145|NCT02753179|OTHER|Dynamic visual acuity Test (DVAT)|Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
41444146|NCT02753179|OTHER|VEMPs & VEMPo|VEMPs \& VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
41444147|NCT02753179|OTHER|Dizziness Handicap Inventory|Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
41444148|NCT02753179|OTHER|Oscillopsia severity questionnaire|Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
41444149|NCT04345653|DRUG|Hydroxychloroquine Sulfate (HCQ)|Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.
41444150|NCT04921956|DRUG|Concizumab|Injected under the skin (subcutaneous, sc) once daily, individual dose adjustment.
40925326|NCT00948467|DRUG|TAK-733|"The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days."
41444151|NCT02987153|RADIATION|Kypho-IORT|The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
41444152|NCT03251807|DEVICE|Twin-block|Functional treatment will be achieved using the Twinblock appliance
41444153|NCT03251807|OTHER|LIPUS (Low-intensity pulsed ultrasound)|Functional treatment will be combined with LIPUS (Low-intensity pulsed ultrasound )
41444154|NCT04437199|DRUG|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)"
41444155|NCT04437199|DRUG|Placebo|Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.
41444156|NCT04207437|DEVICE|Vibration therapy|vibration therapy using hand held vibration device
41444157|NCT00471133|BIOLOGICAL|Xenogeneic Tyrosinase DNA Vaccine|
41444158|NCT00471133|DEVICE|TriGrid Delivery System for Intramuscular Electroporation|
41444159|NCT01316055|DRUG|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
41444160|NCT06414200|OTHER|multidisciplinary structured tailored made nutritional advice|The goal is a structured follow-up after discharge. Parents need to fill in questionnaires about eating behavior en feeding difficulties about their child. They also need to fill in a questionnaire about their stress. Together with their nutritional intake (3-days food diary) and growth a tailor-made nutritional plan is made. All the information I showed in a dashboard and discussed it with their dietitian. Who discusses this information in a multi-disciplinary team (pediatrician, psychologist and if needed a speech therapist).
41444161|NCT00938509|DRUG|ibuprofen suppositories|5-10 mg/kg/day-suppositories
40752183|NCT06130904|BEHAVIORAL|Academic detailing|"Eligible dentists/oral surgeons will have one visit (30 minutes or less) at the dentist's office. During the initial visit, the detailers will discuss the evidence against routine opioid prescribing to adolescents and young adults for most common surgeries performed by dentists and oral surgeons, the harms of dental opioid exposure in adolescents and young adults, and the benefits and feasibility of relying on non-opioids as a first line option for routine dental procedures among adolescents and young adults. A survey will be completed to assess the satisfaction regarding the intervention. A professionally designed packet of information on reducing use of opioids for routine procedures will also be given.~There may also be a second optional follow-up visit conducted virtually for any participants that wish to discuss further with the detailer. The second visit may occur any time between the initial visit and March 31, 2024."
41105843|NCT01156935|OTHER|Laugh Yoga|1 hour including laugh, respiratory exercises and guided imagination by a group instructor specialized in laugh yoga
41105844|NCT04267250|DRUG|PF-06700841|60 mg by mouth (PO) once daily (QD).
41105845|NCT04267250|DRUG|Ethinyl estradiol (EE) and levonorgestrel (LN)|Oral tablet containing 30 mcg EE and 150 mcg LN.
41105846|NCT03705299|DEVICE|Non-Invasive CVP vs Standard CVP|
41105847|NCT04361253|BIOLOGICAL|High-Titer COVID-19 Convalescent Plasma (HT-CCP)|250mL HT-CCP x2 doses given sequentially.
41105848|NCT04361253|BIOLOGICAL|Standard Plasma (FFP)|250mL FFP or FP24 x2 doses given sequentially.
41105849|NCT01205750|OTHER|Glucose clamp|450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
41105850|NCT03575819|DRUG|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
41105851|NCT03694678|BEHAVIORAL|Recovering Together|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc) within 2 in person sessions at hospitalization and 4 live video sessions after discharge. Both patient and caregiver will participate in all sessions
41105852|NCT01138215|BIOLOGICAL|VZV vaccination|Dose : 0.5 ml Route : subcutaneous injection (SC)
41444162|NCT05163847|BIOLOGICAL|Cam2020 M2SR H3N2 influenza vaccine|Administered intranasally on Day 1
41444163|NCT05163847|BIOLOGICAL|Fluzone HD IIV|Administered intramuscularly on Day 1
41444164|NCT05163847|OTHER|IN Placebo|Administered intranasally on Day 1
41444165|NCT05163847|OTHER|IM Placebo|Administered intramuscularly on Day 1
41444166|NCT05835349|DEVICE|transcatheter pulmonary valve implantation (TPVI)|A stent-mounted valve is introduced over a guidewire and positioned in the RVOT, followed by balloon inflation to deploy the valve.
41444167|NCT01065610|DRUG|Oxytocin|
40752184|NCT03544164|OTHER|Manual Ventilation|Manual ventilation via endotracheal tube using adult manual resuscitation device
41105853|NCT02967237|DRUG|insulin glargine (U300)|Pharmaceutical form: solution Route of administration: subcutaneous
41105854|NCT06530875|BEHAVIORAL|training on hesitations regarding childhood vaccinations|Training will be given to expectant mothers on childhood vaccination hesitations
41105855|NCT04559243|DIAGNOSTIC_TEST|Transthoracic Echocardiography|After the surgey, the tests data will be collected during 8 visits when the subjects go back to the hospital.
41105856|NCT02889341|DIETARY_SUPPLEMENT|DHA|
41105857|NCT02889341|OTHER|Placebo|
41105858|NCT04208802|OTHER|Use of fluoridated toothpaste|Use of fluoridated toothpaste
41105859|NCT04208802|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
41105860|NCT04208802|OTHER|Wearing of an intraoral device with resin samples|Wearing of an intraoral device with resin samples
41105861|NCT04463524|DEVICE|Personal ECG digital sensor|Patients in test group will receive personal ECG sensor and in control gropu will not.
41444168|NCT01065610|DRUG|Placebo|
41444169|NCT05005026|OTHER|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
41444170|NCT05005026|OTHER|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
41444171|NCT05722184|DIAGNOSTIC_TEST|BactInsight blood culture system|A battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth, in combination with optimized blood culture bottles.
41105862|NCT00268606|BEHAVIORAL|cognitive-behavioral therapy|
41105863|NCT00280033|BIOLOGICAL|Aluminum hydroxide|Provided in vials that contain 0.8 mL volume per vial.
41105864|NCT00280033|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (Chiron)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.
41444172|NCT01470976|OTHER|Goal-directed Resuscitation Therapy (GDT)|"* A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.~* The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.~* When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%."
41444173|NCT01470976|OTHER|Standard protocol|The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
41105865|NCT00280033|BIOLOGICAL|MF-59|Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.
41105866|NCT00280033|DRUG|Placebo|Saline placebo.
41105867|NCT02713048|OTHER|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
41105868|NCT05714358|BEHAVIORAL|Education|"* The patients were given face-to-face training on nutrition, physical activity and drug use in chronic renal failure .~* After the training, the biochemical parameters of the patients were followed for 6 months.~* In this process, the questions asked by the patients in order not to hinder their right to receive information were answered."
41105869|NCT05027906|DRUG|AT-1501|Investigative Arm
41105870|NCT05015868|DIAGNOSTIC_TEST|Standard of care|"Enrollment of patients afferent to our Center with cryptogenic drug-resistant epilepsy with onset in pediatric age, subject to informed consent;~* acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data (previous negative brain magnetic resonance imaging);~* execution of a complete neuropsychological assessment for the classification of cognitive aspects and evaluation of executive functions;~* execution of genetic tests through Next generation sequencing epilepsies panel or exome sequencing"
41105871|NCT05015868|DIAGNOSTIC_TEST|Functional magnetic resonance imaging-Electroencephalogram combined analysis|"A functional brain magnetic resonance imaging is executed analysing blood oxygenation level dependent signal.~During the functional recording, a contemporary electroencephalogram is registered in order to analyse the space-time relationship between the epileptic discharges and the bold abnormalities."
41105872|NCT05015868|DIAGNOSTIC_TEST|High density- electroencephalogram or 7 Tesla magnetic resonance imaging|"In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:~* execution of High Density-electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;~* 7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone (PI, italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition."
41105873|NCT04624204|BIOLOGICAL|Pembrolizumab 200 mg|Pembrolizumab 200 mg Q3W
41105874|NCT04624204|BIOLOGICAL|Pembrolizumab 400 mg|Pembrolizumab 400 mg Q6W
41105875|NCT04624204|DRUG|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q3W
41105876|NCT04624204|DRUG|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q6W
41105877|NCT04624204|DRUG|Olaparib 300 mg BID|Olaparib 300 mg twice daily (BID)
41105878|NCT04624204|DRUG|Olaparib matching placebo|Olaparib matching placebo BID
41105879|NCT04624204|DRUG|Etoposide 100 mg/m^2|Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3
41105880|NCT04624204|DRUG|Platinum, investigator's choice|Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle
41105881|NCT04624204|RADIATION|Standard Thoracic Radiotherapy|Standard Thoracic Radiotherapy
41105882|NCT04624204|RADIATION|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
41444174|NCT02832921|BEHAVIORAL|cognitive training by virtual reality|
41444175|NCT02832921|BEHAVIORAL|watching a scientific TV documentary|
41444176|NCT02832921|DEVICE|treadmill|"VR cognitive training will be augmented by walking on a treadmill, since it is well established that dual tasking-i.e. performing the VR-based cognitive effort together with a motor task, even as simple as walking on a treadmill-places greater demand on cognitive resources than a single task."
41444177|NCT02937259|OTHER|Patient self-admission to inpatient treatment|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
41444178|NCT00270634|DRUG|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
40752185|NCT05635864|PROCEDURE|Catheter ablation|Catheter ablation of atrial tachyarrhythmia (atrial fibrillation, atrial flutter)
41105883|NCT05990569|OTHER|Ultrasound guided Pudendal nerve block|Ultrasound guided bilateral pudendal nerve block
41105884|NCT05506098|OTHER|no intervention|no intervention
41105885|NCT03278288|DEVICE|WellWe-Intervention group|Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
41105886|NCT00423254|BIOLOGICAL|PSMA/PRAME|Low dose
41444179|NCT00270634|DRUG|tacrolimus|tacrolimus 0.05 mg/kg po BID
41105887|NCT00423254|BIOLOGICAL|PSMA/PRAME|high dose
41105888|NCT06374667|PROCEDURE|Y-3 ICO injection|Patients included will be given skull outer plate drilling surgery and Y-3 ICO injection under local anesthesia and sedation. The injection will be given for 3 consecutive days.
41105889|NCT06374667|DRUG|Y-3 intravenous injection|Patients included will be given Y-3 intravenous injection for 7 consecutive days.
41105890|NCT06374667|OTHER|Conventional treatment|standard treatment and management according to related guidelines during the entire treatment period
41105891|NCT03014050|DEVICE|e-Tapper TT-R1|"The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere."
41105892|NCT02970708|DEVICE|EFG group|88 anisometropic amblyopia will be recruited to receive Eyetronix Flicker Glasses treatment.
41105893|NCT02970708|DEVICE|Patching group|88 anisometropic amblyopia will be recruited to receive patching treatment.
41105894|NCT04979052|DRUG|Interferon Gamma-1B|100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
41105895|NCT00324038|DRUG|Buprenorphine|buprenorphine transdermal system 5, 10 and 20 mg
41105896|NCT00324038|DRUG|Codeine paracetamol|combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
41105897|NCT05463354|BIOLOGICAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
41105898|NCT05463354|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
41105899|NCT00005113|DRUG|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
41105900|NCT00005113|DRUG|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
41105901|NCT00005113|DRUG|Tacrolimus|dosage is in oral form titrated to target trough level
41444180|NCT03609203|OTHER|10 Weeks of Strength Trailing|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
41444181|NCT03609203|OTHER|Group Nutrition Discussion: week 1, week 5 and week 10|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
41105902|NCT05997654|DEVICE|MEDGEL ANTIAGE|The MEDGEL ANTIAGE is a medical grade silicone plate, biocompatible.
41105903|NCT00000919|DRUG|Indinavir sulfate|
41444182|NCT00688571|DEVICE|Melody Transcatheter Pulmonary Valve|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
41444183|NCT01208935|DRUG|Nicotine Patch|
41444184|NCT01208935|DRUG|Nicotine Gum|
41444185|NCT05535868|OTHER|SPN3 innoculation|Healthy adult participants aged 18-50 (inclusive) will be inoculated with pure culture of well-characterised, fully sequenced amoxicillin-sensitive SPN3. They will be observed for safety and development of pneumococcal colonisation
41444186|NCT00881569|DRUG|CS-7017|CS-7017 administered orally, twice daily continuously for 6 weeks
41105904|NCT00000919|DRUG|Lamivudine/Zidovudine|
41105905|NCT00000919|DRUG|Ritonavir|
41105906|NCT00000919|DRUG|Hydroxyurea|
41105907|NCT00000919|DRUG|Abacavir sulfate|
41105908|NCT00000919|DRUG|Amprenavir|
41105909|NCT00000919|DRUG|Nelfinavir mesylate|
41105910|NCT00000919|DRUG|Efavirenz|
41105911|NCT00000919|DRUG|Lamivudine|
41105912|NCT00000919|DRUG|Stavudine|
41105913|NCT00000919|DRUG|Zidovudine|
41105914|NCT00000919|DRUG|Didanosine|
41105915|NCT04753463|OTHER|Survey|The on-line questionnaire which assess the subjective feelings of residents of pandemic impact on ophthalmology training programs
41105916|NCT00770965|BIOLOGICAL|AIN457|
41105917|NCT00770965|BIOLOGICAL|Placebo|
41105918|NCT05015517|PROCEDURE|Erector spinae plain block|Patients will be placed in the lateral position.Ultrasonography will be performed by an experienced anesthetist.The 4th lumbar vertebral level will be determined using the conventional method (imaginary line between two iliac crests). The low frequency convex probe (2-5MHz) will then be placed at the mid-vertebral line in the sagittal plane. It will be shifted from the midline, 3.5-4 cm lateral to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-plane technique a 22G/80-mm block needle will be advanced until it reaches the transverse process. After negative aspiration, 0.5-1 ml of the prepared local anaesthetic solution (20 ml bupivacaine 0.5%, 10 ml lidocaine 2%) and 10 ml normal saline will be administered for hydrodissection to confirm correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when injecting local anesthesia
41133291|NCT00071799|OTHER|Physician Choice|"Physician Choice was one of three options:~* Best supportive care (BSC) alone,~* Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or~* Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).~All three options included best supportive care"
41133292|NCT03044457|PROCEDURE|TKA|"femoral and tibial positioning using the reversed gap technique"
41444187|NCT06602544|DEVICE|Robotic Apparel|A robotic apparel system is a portable, lightweight textile-based wearable robot that is worn around the waist and thighs. The apparel provides assistive flexion moment about the hip joint during the swing phase of gait by spooling in a cable that connects the thigh wraps to the front of the waist belt. Inertial measurement units embedded in the thigh wraps are used to control the timing of the robotic apparel assistance. Robotic apparel assistance magnitude is delivered as a small percentage of the bodyweight of the wearer.
41444188|NCT06520904|DRUG|PCSK9 inhibitor|PCSK9 inhibitors combined with moderate-intensity statin therapy
41444189|NCT06520904|DRUG|Statin|Intensive statin therapy
41444190|NCT03136627|DRUG|Tivozanib|Tivozanib (AV-951): Phase 1b study and Phase 2a study: Subjects will receive 1 dose of tivozanib daily for 21 days followed by a 7 day rest period (1 cycle = 4 weeks).
41444191|NCT03136627|DRUG|Nivolumab|Nivolumab: Phase 1b study and Phase 2a study: All subjects will receive IV nivolumab 240 mg every 2 weeks administered over 1 hour.
41444192|NCT05497960|BEHAVIORAL|Vivo workout|2 days a week for 12 weeks of a live, interactive virtual strength training program. Each class is 45 minutes long and lead by a certified trainer.
41444193|NCT05336643|DEVICE|Radiofluorescence|Assessment of pelvic sidewall with Firefly and Sensei
41444194|NCT06390163|OTHER|Sensory-Motor Integration Training|An exercise chain consisting of motor tasks, sensory stimuli and cognitive tasks will be created. Each session will include at least 3 motor tasks, 3 sensory stimuli and 3 cognitive tasks selected according to the patient's condition.
41444195|NCT06562426|BEHAVIORAL|Descriptive group on vitamin D awareness|300 mothers of under-five children will be recruited in the descriptive study to assess their awareness about vitamin D and observe children for their health status outcome. Three tools will be used which are; sociodemographic characteristics of children and their mothers, Mothers' Awareness of Vitamin D Structured Interview Schedule, and Health Status Outcomes of Under- Five Years Children. Permission to conduct the study will be obtained from the administrative authorities of the settings after an explanation of the aim of the study. Each mother will be interviewed individually to obtain characteristics of mothers and their children, as well as knowledge and performance regarding Vitamin D. Each child will be observed for the manifestation of vitamin D deficiency and to measure their weight and height.
41444196|NCT04309968|DRUG|Drug: SYHA1801|Drug: SYHA1801 administered orally
41444197|NCT00840203|DRUG|Rowasa® 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
41444198|NCT00840203|DRUG|Mesalamine 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
41444199|NCT05025085|DRUG|AGEN1777|An immunoglobulin gamma (IgG1) antibody
41444200|NCT05025085|DRUG|a PD-1 inhibitor|Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody
41444201|NCT00243425|PROCEDURE|Standard Quality Improvement|
41444202|NCT00243425|PROCEDURE|Patient-centered Intervention|
41444203|NCT04143516|DIAGNOSTIC_TEST|[18-F]- FDG - PET|Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion
41133293|NCT03244800|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously once daily for 49 days.
41444204|NCT04143516|PROCEDURE|Tumor ablation (TA)|Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.
41444205|NCT04143516|DIAGNOSTIC_TEST|PET/CT Scan|Eligible patients will undergo PET/CT -guided tumor ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of tumor ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.
41444206|NCT03786172|BEHAVIORAL|Smoking cessation Intervention|"* A 10 to 15 minute standardised counseling session performed peri-operatively by an ENT resident, and based on the 5 As motivational interviewing model (Ask, Advise, Assess, Assist, Arrange)~* A motivational gadget distributed to the patients~* Nicotine replacement therapy (NRT), consisting of nicotine transdermal patches for 8 weeks, offered to the patients"
41133294|NCT03244800|DRUG|Placebo|Placebo will be administered subcutaneously once daily for 49 days.
41444207|NCT03786172|BEHAVIORAL|Usual care|A 10-second brief advice to quit smoking, performed peri-operatively by an ENT resident
41444208|NCT02771353|RADIATION|WT_vDIBH|
41133295|NCT01903109|DRUG|Cevimeline|
41133296|NCT05116709|DRUG|BAT6005 injection|Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.
41444209|NCT02771353|RADIATION|VMAT_FB|
41444210|NCT02718326|DRUG|Intravitreal aflibercept injection [IAI]|
41444211|NCT02718326|DRUG|Sham|
41444212|NCT05054777|PROCEDURE|oncoplastic breast-conserving surgery|The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques
41444213|NCT05054777|PROCEDURE|conventional breast-conserving surgery|conventional breast-conserving surgery without any oncoplastic operations
41444214|NCT03328026|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM inoculation intradermally at 4 sites.
41444215|NCT03328026|DRUG|Low dose cyclophosphamide|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
41444216|NCT03328026|DRUG|Interferon Inoculation|Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.
41444217|NCT03328026|DRUG|retifanlimab|retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
41444218|NCT01009229|DIETARY_SUPPLEMENT|Low and high salt diets|High salt diet: 150mmol/d Low salt diet: 30mmol/d
41444219|NCT06557239|DRUG|Lysergic Acid Diethylamide (LSD)|one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department
41444220|NCT06562868|OTHER|Bulk-fill Composite Resin|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
41444221|NCT06562868|OTHER|Traditional Posterior Composite Resin|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
41105919|NCT05015517|PROCEDURE|Fascia Iliaca block|"Patients will be placed in supine position. Ultrasonography will be performed by an experienced anesthetist using ultrasound device equipped with a low frequency (2-5 MHz) convex probe and an echogenic 21 G/ 10 cm needle will be used.~The probe will be placed in the inguinal crease. Scan will be started laterally from the femoral artery and nerve in the inguinal crease to identify the Sartorius muscle. The muscle will then be traced until its origin at the anterior superior iliac spine is identified and the shadow of the bony of iliac crest \& iliacus muscle will be seen. Injection will be performed at the plane deep to the fascia iliaca and above the lateral part of the iliacus muscle. After negative aspiration, the prepared local anaesthetic solution (15 ml bupivacaine 0.5%, 15 ml normal saline) will be injected incrementally, aspirating every 5 ml."
41105920|NCT04162119|BIOLOGICAL|BCMA-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.
41105921|NCT05535530|DEVICE|Active PSIO|new designed active orthopedic appliance will be used. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
41105922|NCT04012853|DEVICE|transcranial direct current stimulation|Treatment group will receive 20 minutes of tDCS stimulation at 2.0 mA administered daily for five days per week and a total of 4 weeks. During the 20minute treatment session, both treatment and sham groups will complete mindfulness meditation via VA health system approved program (Mindfulness Coach).
41105923|NCT00812136|BEHAVIORAL|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
41105924|NCT03479736|DRUG|Oral Fluoroquinolones (FQ)|Participants will not receive any intervention as a part of this study. The FQ include all oral forms of FQ (24-hours extended release tablets, extended release tablets, oral solution, oral suspension, oral tablet, pack). The drugs included are ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin.
41105925|NCT03479736|DRUG|Other Antibiotics|Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
41105926|NCT03479736|OTHER|Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure|Febrile illness not treated with antibiotics is defined as: concurrent diagnoses of viral disease with concurrent fever, and no concurrent prescription for any antibiotic during the 60-day period before and after the first date of viral disease diagnosis; or a diagnosis of influenza with no concurrent inpatient admission during the 60-day period pre- or post-influenza diagnosis, and no prescription for any antibiotics during the 60-day period pre- or post-influenza diagnosis.
41105927|NCT02882230|DRUG|prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir|chemical dosage ARV
41105928|NCT00478335|DRUG|sildenafil|25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
41105929|NCT00478335|DRUG|calcitonin|one nasal spray daily for 4 days
41105930|NCT00478335|DRUG|hydrochlorothiazide/amiloride|25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
41105931|NCT00478335|DRUG|indomethacin|50 mg QD or 50 mg BID x 8 days depending on subject weight
41105932|NCT00478335|DRUG|Placebo for sildenafil|one tablet daily for 4 days
41105933|NCT00478335|DRUG|placebo for calcitonin|one nasal spray daily
41105934|NCT01990937|DRUG|Oral midazolam|5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
41444222|NCT06562868|OTHER|High-filler Flowable Composite|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
41444223|NCT01608360|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
41105935|NCT03014830|DRUG|Alirocumab|150 mg SQ every 2 weeks
41105936|NCT03014830|DRUG|Placebos|Placebo injections SQ every 2 weeks
41105937|NCT04274543|DEVICE|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the meniscal lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
41105938|NCT04274543|DRUG|Normal Saline|"Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small tunnels are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions."
41105939|NCT02314117|DRUG|Ramucirumab|Administered IV
41105940|NCT02314117|DRUG|Capecitabine|Administered orally
41105941|NCT02314117|DRUG|Cisplatin|Administered IV
41444224|NCT01608360|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
41444225|NCT00080951|DRUG|fluorouracil|
41444226|NCT00080951|DRUG|irinotecan hydrochloride|
41444227|NCT00080951|DRUG|leucovorin calcium|
41444228|NCT00080951|DRUG|oxaliplatin|
41444229|NCT05234788|PROCEDURE|Transfemoral Renal Denervation|Radiofrequency renal denervation using the Iberis Renal Denervation System treated via femoral artery access
41444230|NCT05234788|PROCEDURE|Transradial Renal Denervation|Radiofrequency renal denervation using the Iberis Renal Denervation System treated via radial artery access
41444231|NCT06485700|OTHER|Peer Delivery of Medications|Door-to-door peer delivery of medications within patients' communities will be implemented.
41105942|NCT02314117|DRUG|Placebo|Administered IV
41105943|NCT02314117|DRUG|Fluorouracil|Administered IV
41105944|NCT03814395|OTHER|No intervention|This is an observational study without any intervention
41105945|NCT03614611|DEVICE|Contiform pessary|"Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)"
41105946|NCT01638884|BEHAVIORAL|Memory assessment|Neuropsychological tests including clinical and original tests to compare differences between each populations
41105947|NCT01638884|OTHER|Structural MRI|to compare differences between each populations
41105948|NCT01638884|OTHER|Functional MRI|to compare differences between each populations
41105949|NCT01638884|OTHER|Virtual reality / Memory assessment|to compare differences between each populations
41105950|NCT04344613|DEVICE|ABODpoct device|The device has been developed by a consortium including the Université Libre de Bruxelles, research centers (SIRRIS, CER), a private company (CISEO), and the spin-off Antigon S.A..The device includes a reader and a disposable disk (ABOD disk) for testing one patient et a blood bag. Four blood drops from the patient are deposited on one side of the disk and 4 blood drops from the blood bag one the other side. The disk correctly filled is inserted in the reader and after 2 minutes the result is displayed on the screen as a message GO or No GO. In case of incompatibility or any other problem a red Stop message will appear on the screen.
41105951|NCT06116162|DEVICE|SVF-gel Filling and CO2 fractional laser|"SVF-gel preparation and filling:The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. Then the lipoaspirate was centrifuged at 1200g for 3 minutes to obtain Coleman fat in the middle layer. The Coleman fat was then transferred between two syringes until the Coleman fat converted into a uniform emulsion, and then processed by centrifugation at 2000g for 3 min. Finally, the remaining substance under the oil layer was SVF gel. We used a 22G sharp-tip injector to inject the SVF-gel into the dermis of acne scars, and the injected materials were diffusely distributed.~CO2 fractional laser treatment: After local anesthesia, Acupulse device (LUMENIS, US) was used to perform CO2 fractional laser. The laser was operated in DeepFX mode under the parameters of 20-25 MJ energy intensity, 5% coverage. Superficial mode under the parameters of 80-120 MJ energy intensity, 40-60% coverage."
41105952|NCT02052648|DRUG|Indoximod|
41105953|NCT02052648|DRUG|Temozolomide|
41105954|NCT02052648|DRUG|Bevacizumab|
41105955|NCT02052648|RADIATION|Stereotactic Radiation|
41105956|NCT04689568|BEHAVIORAL|Moodkit|"MoodKit is divided into four main sections: Activities, Thoughts, Mood and Journal. In the Thoughts section, the user is asked to briefly describe stressful situations and their reactions to the event and is later educated on a number of thought distortions. In the Mood section, the user is asked to give an overall rating of mood, which can be done several times per day. In the Journal section, the user can write freestanding journal entries. Additional areas of advice and goal setting are contained in a section called Thrive Tips."
41105957|NCT04689568|BEHAVIORAL|Moodgym|The program consists of five modules each taking 20- to 40-minutes to complete, which are completed in a prescribed order.
41105958|NCT04689568|BEHAVIORAL|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey.
41105959|NCT06552884|BEHAVIORAL|(Maternity Identity Development Training)|Monitoring the Effect of the Education Given to Parents According to Maternal Role Ability Theory on Maternal Role Mother-Baby and Father-Infant Attachment
41105960|NCT00078533|BIOLOGICAL|CMV CTL infusion|Three dose levels will be explored. The lowest dose level will be 1x10\^7cells/m2 and the highest will be 1x10\^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
41444232|NCT06485700|OTHER|Health Information Technology (HIT) Platform|The HIT platform provides: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) medication refill tracking to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data.
41444233|NCT05831449|DRUG|Local anesthetic injection of CPL-01|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
41105961|NCT03829254|DRUG|NUC-7738|NUC-7738
41105962|NCT03829254|DRUG|Pembrolizumab|Pembrolizumab
41105963|NCT06206330|OTHER|Platelet rich plasma|After application of platelet rich plasma after surgery, the patients have examined for infection, hematoma, pain, recurrence and the time of epithelialization of the wound.
41105964|NCT01891968|DRUG|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
41105965|NCT06134466|DIETARY_SUPPLEMENT|Liquid Extensively hydrolyzed cow's milk protein infant formula|Liquid Investigational Formula (Extensively hydrolyzed cow's milk protein infant formula) 2.8 g protein/100 kcal
41105966|NCT03015974|DRUG|Corticosteroid|
41105967|NCT03015974|DRUG|Cyclophosphamide|
41105968|NCT03015974|DRUG|Mycophenolate mofetil|
41105969|NCT03015974|DRUG|Dipyridamole|
41105970|NCT03015974|DRUG|ACE Inhibitor or Angiotensin receptor antagonist|
41105971|NCT02488980|DRUG|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
41105972|NCT02488980|DRUG|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
41105973|NCT02488980|DRUG|Placebo|Placebo for three days followed by placebo once a week for 24 weeks
41105974|NCT04352452|PROCEDURE|laparoscopic surgery|differences in musculoskeletal and cognitive stress
41105975|NCT06174337|BEHAVIORAL|Use of Video Connection with Family via Robot|A remote family member is able to connect via video with a nursing home resident.
41105976|NCT01967186|PROCEDURE|Intraportal islet transplantation|
41105977|NCT01967186|PROCEDURE|Intramuscular islet transplantation|
41105978|NCT01967186|PROCEDURE|Intramuscular transpl with stemcells|
41444234|NCT05831449|DRUG|Naropin, 0.5% Injectable Solution|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
41444235|NCT05831449|DRUG|Placebo|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
41105979|NCT01967186|PROCEDURE|Kidney transplantation|All patients will undergo kidney transplantation regardless of arm
41105980|NCT02783755|BEHAVIORAL|Device: smartphone|Coping Skills Training for pain will be delivered to participants using video-conferencing
41105981|NCT02044523|DEVICE|Transient elastography, acoustic radiation force impulse, magnetic resonance elastography|Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
41105982|NCT00819819|DIETARY_SUPPLEMENT|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
41105983|NCT00819819|DIETARY_SUPPLEMENT|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
41105984|NCT05737095|PROCEDURE|Pulmonary ultrasound|Within 6 hours of admission to Neonatal Pediatrics and Intensive Care
41105985|NCT03390569|BEHAVIORAL|Exercise|The patients meet with a registered physiotherapist and receive individualized exercise programs starting the second week of treatment, and continuing up to 3 months later.
41105986|NCT03709628|DRUG|EB8018 (First-in-class FimH blocker)|"Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker~• In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13."
41105987|NCT02303444|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study.
41105988|NCT02303444|DRUG|Other Multikinase inhibitors|Patients can get MKIs at any time during study.
41105989|NCT03588845|OTHER|Treatment Protocol|Protocol treatment sites will be expected to see the patient within a pre-specified window of time. The doctors at that site will apply the treatment algorithm and will make decisions about response to treatment based on the algorithm and on specific patient answers to questionnaires. The treatment protocol will only be made available to IRBs, not to any site personnel before randomization. This was derived from a survey of rheumatologists in many countries and gastroenterologists, mostly in North America, who were asked multiple questions about how they would treat and follow up patients with suspected SIBO. Successful treatment is a response on GSS of no diarrhea plus a total GSS of \< 5.
41105990|NCT03588845|OTHER|Standard of Care|Physicians randomly assigned to standard of care will also be informed of their patients who met eligibility criteria. They will not be aware of the detailed treatment protocol but will be informed of which medications are in the protocol eg antibiotics, prokinetics etc. They will be free to contact the patients at their convenience and to treat them in any way they deem suitable, preferably using these medications but at doses and frequencies according to their own wishes.
41105991|NCT02881125|DRUG|Nortriptyline Hydrochloride|Given PO
41105992|NCT02881125|DRUG|Paclitaxel|Given IV
41105993|NCT04052919|OTHER|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
41105994|NCT03103971|BIOLOGICAL|Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Given IV
41105995|NCT03103971|DRUG|Cyclophosphamide|Given IV
41444236|NCT00006682|DRUG|docetaxel|Docetaxel 70mg/m2 on day 1 of every 21-day cycle
41105996|NCT03103971|DRUG|Fludarabine|Given IV
41105997|NCT03103971|OTHER|Laboratory Biomarker Analysis|Correlative studies
41444237|NCT00006682|DRUG|vinorelbine ditartrate|Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle
41444238|NCT05943665|DRUG|MDMA|medication and therapy combined
41444239|NCT06559020|BEHAVIORAL|Kangroo mother care|Kangaroo Mother Care (KMC) involves continuous skin-to-skin contact between the mother (or another family member) and the infant, aimed at promoting thermal regulation, breastfeeding, and bonding. In this study, KMC was initiated in the hospital and continued at home for a minimum of 8 hours daily.
41444240|NCT03831256|DIAGNOSTIC_TEST|Traditional integrated prenatal screening|biochemical prenatal screening with or without nuchal translucency by US
41444241|NCT03831256|DIAGNOSTIC_TEST|Second-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS after a positive traditional prenatal screen
41444242|NCT03831256|DIAGNOSTIC_TEST|First-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS at first trimester
41444243|NCT03831256|DIAGNOSTIC_TEST|Invasive prenatal testing for fetal aneuploidy|amniocentesis or chorionic villi sampling (CVS)
40752186|NCT04849052|BEHAVIORAL|MASTERY|In MASTERY, participants will have interactive, two-way text message 'sessions' (5-10 minutes of two-way text communication with an automated text-message program) once weekly for 12 weeks. Furthermore, study trainers will conduct 4 brief calls with participants (Weeks 1, 4, 7, and 12) to introduce the program, assess progress, answer questions, and provide support.
40752187|NCT04849052|BEHAVIORAL|Attentional Control|Participants in the control condition will also receive text messages once per week. To ensure time matching, the program will have 4 phone check-ins (on physical activity) as in MASTERY.
41444244|NCT00503789|PROCEDURE|fecal bacteria analysis|ad lib feeding
41444245|NCT03393754|BIOLOGICAL|Hepatitis B Vaccination|Prophylactic Hepatitis B Vaccination
41444246|NCT01710748|DEVICE|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
41444247|NCT01710748|DEVICE|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
41105998|NCT03103971|PROCEDURE|Leukapheresis|Undergo leukapheresis
41105999|NCT03103971|OTHER|Pharmacological Study|Correlative studies
41106000|NCT00382161|DRUG|Fluvastatin-sodium|
41106001|NCT02488252|DRUG|Semi-individualised Chinese Medicine treatment|"A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb"
41106002|NCT02488252|DRUG|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
41106003|NCT06438406|DEVICE|Orthotic devices and therapeutic exercise (Group A)|Group A consisting of patients who were prescribed orthoses, to use gradually, and a 20-session rehabilitation programme, based on the Back School method
41106004|NCT06438406|DEVICE|Orthotic devices (Group B)|Group B consisting of patients who were only prescribed orthoses for the lower limbs
41106005|NCT00698191|BIOLOGICAL|Allogeneic MSC (AlloMSC)|"Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight"
41106006|NCT02002819|DRUG|levetiracetam|
41106007|NCT03109886|DRUG|Milciclib maleate|100 mg/day once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.
41106008|NCT05922215|OTHER|Dynamic Balance training|The Experimental group will be given the Baseline treatment comprising of Stretching \& Static balance training (i.e. heel and toe raises, alternate rising of the left and right foot above the floor and tandem standing.) alongside Dynamic Balance training which will include (weight shifting forward, backward, sideward, and diagonally with eyes opened and eyes closed, walking toe-to-heel barefoot, side walking, reverse walking and one-foot jumps), and Progressive activity training (such as stepping over/on obstacles, throwing and catching a ball, and kicking a ball.) for 40 minutes per day, twice each week for 8 weeks.
41106009|NCT05922215|OTHER|Static balance training|The Control group will continue their regular school schedule, which will include participation in physical education activities at the same frequency. Along with that Baseline treatment including Static balance training (i.e. alternate rising of the left and right foot above the floor and tandem standing.) only, at the same intervals and for the same length of time as the intervention group, with the exception of additional Dynamic balance training and progressive activity training.
41106010|NCT04552886|BIOLOGICAL|TH-1 Dendritic Cell Immunotherapy|Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.
41106011|NCT05458141|BEHAVIORAL|FYA-003|FYA-003: It is a gamified health education module for children aimed at promoting healthy nutrition, physical activity, health hygiene, and infectious diseases risk reduction within the clinically proven app fooya!
41106012|NCT00907218|DRUG|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
41106013|NCT05639023|OTHER|Manipulation Techniques|Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week.
41106014|NCT05639023|OTHER|Physiotherapy Scoliosis-Specific Exercise|Subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
41444248|NCT03614039|DIETARY_SUPPLEMENT|"Symbiter Forte"|"Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)"
41444249|NCT03614039|DIETARY_SUPPLEMENT|Placebo|
41444250|NCT04221113|PROCEDURE|physiotherapy|Two protocols have been described for physiotherapy of post extensor tendon injuries. one is immobilization till 3 weeks and than gradual increase in active motion of hand. The second protocol is early active motion. this would be done under senior physiotherapist.
41444251|NCT02748707|DRUG|Arm1|Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
41444252|NCT02748707|DRUG|Arm 2|Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
41444253|NCT02748707|DRUG|Arm 3|Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
41444254|NCT02748707|OTHER|Arm 4|Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
41444255|NCT01867658|DEVICE|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
41106015|NCT01370707|DRUG|Metformin|1000\~1500mg/day, 24weeks
41106016|NCT01370707|DRUG|CJ-30001/CJ-30002|0.6/1500mg\~0.9/1500mg/day, 24weeks
41106017|NCT00479141|BEHAVIORAL|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
41106018|NCT00479141|BEHAVIORAL|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
41106019|NCT00708032|DEVICE|spectacles|habitual spectacles
41106020|NCT00708032|DEVICE|narafilcon A soft contact lenses|narafilcon A daily disposable contact lenses
41106021|NCT03872869|OTHER|Hip school or Tai CHi for arthritis|Eighty-nine individuals were randomized to one of the three intervention groups 30 individuals to Tai Chi,30 individuals to Hip School and 29 individuals to the control group
41106022|NCT05879588|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
41106023|NCT05879588|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 3 days of debonding
40925327|NCT02065427|BEHAVIORAL|Social Support|a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
41106024|NCT01037530|DRUG|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
41106025|NCT02706067|DRUG|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent \[%\] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
41106026|NCT00908336|DRUG|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
41106027|NCT00908336|DRUG|Erlotinib|150 mg/day po daily
41106028|NCT01228448|PROCEDURE|PET scan|In-Room PET scan
41106029|NCT06202599|DRUG|Fruquintinib|For patients with pulmonary metastasis only, we mostly gave them fruquintinib with 7 mg in adults and 3-5 mg in children (\<10 years) orally per day (5 days on and 2 days off). If patients were extrapulmonary metastasis, we usually used combinations with metronomic chemotherapy (2/3 or 3/5 or even 1/2 of the usual dose) or immunotherapy.
41106030|NCT05906225|PROCEDURE|EEG guided anesthesia|Monitoring of electroencephalogram via Sedline probe by MASIMO corporation. Adjust concentration of inhalational sevoflurane during anesthesia, according to component of slow\&delta wave and alpha wave, so that slow/delta oscillation (with or without alpha oscillation) is maintained.
41106031|NCT05906225|PROCEDURE|Conventional anesthesia|Adjust concentration of inhalational sevoflurane during anesthesia, according to vital signs, so that mean blood pressure and heart rate are maintained between 80% and 120% of baseline values measured at ward before anesthesia.
41106032|NCT01326715|DRUG|Mangafodipir (Teslascan)|gadolinium enhancement on contrast enhanced brain MRI.
41106033|NCT03441360|DRUG|Eribulin mesylate|Intravenous infusion
41106034|NCT02931656|OTHER|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
41444256|NCT03347487|PROCEDURE|Deep brain stimuation system implantation|All subjects will receive bilateral surgical implantation of DBS system.The Medtronic DBS 3389 electrode is utilized in this study. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller.
41106035|NCT02171663|DRUG|BIBW 2992|
41106036|NCT05356312|BIOLOGICAL|Vaccination|Personalized neoantigen vaccination
41106037|NCT01326130|BEHAVIORAL|Chronic care management 1-6|1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
41106038|NCT02087644|BIOLOGICAL|CYT003|Injections
41106039|NCT02087644|BIOLOGICAL|Placebo|Injections
41270945|NCT01355289|DRUG|Pegylated interferon (PEG-IFN)|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
41270946|NCT01355289|DRUG|Telaprevir|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
41106040|NCT06461637|BEHAVIORAL|Stepped Care Mental Health for Foreign Domestic Helpers (SCMH-FDH)|The SCMH-FDH intervention consists of 4 steps. Step 1 involves a self-help intervention (through 12 mental health booklets) delivered in 6 sessions and an online peer support group. Those who did not respond to Step 1 will be referred to Step 2 (group-based resilience workshop). The intervention will be also be delivered in 6 weekly sessions lasting 1-1.5-hours. Those who did not respond to Step 2 will be referred to Step 3 (guided self-help cognitive behavioral therapy, CBT) with guidance from a trained therapist. Self-help materials will be provided. The sessions are spread out over six weeks, with each sessions lasting 30-45 minutes. Those who did not respond to Step 3 will be referred to Step 4 (high intensity interventions provided by mental health professionals). Stepping up is determined by the IAPT-minimum data set. If assessment scores after previous treatment exceeds the defined threshold (PHQ-9 ≥ 10 or GAD-7 ≥ 8), then participants need to step up to the next intervention.
41106041|NCT05923008|DRUG|IBI130|Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
41106042|NCT04208243|BEHAVIORAL|Creative Arts Therapy|"The intervention will consist of approximately weekly CAT in the infusion center during cancer therapy. The interventionist is a Master's prepared, licensed dance/movement therapist who is experienced in music and art therapies as well. The CAT includes dance/movement such as playing with a parachute, simple yoga breathing and postures, and work with physioballs. The music includes singing, listening to music, and playing instruments. The art consists of drawing, finger painting, working with clay. The CAT may occur in individual sessions in private infusion rooms, or in groups in the middle of the infusion center. The CAT is not only a distraction, but also a therapeutic process addressing the stressors of cancer and its treatment. The dose of CAT will be recorded (number and type of sessions) and will be factored into the analysis."
41106043|NCT02116543|DRUG|TD-6450|
41106044|NCT02116543|DRUG|Placebo|
41106045|NCT00024531|DRUG|Atorvastatin calcium|
41106046|NCT03031262|DRUG|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
41106047|NCT03031262|DRUG|Chidamide|Chidamide at a dose of 20mg/d twice a week for 3 months.
41106048|NCT03885596|DRUG|CA-008|Drug: CA-008 4.2 mg reconstituted in saline
41106049|NCT03885596|DRUG|Ketorolac|30 mg IV at the onset of anesthesia
41106050|NCT03885596|DRUG|Acetaminophen IV|1 g at the onset of anesthesia
41444257|NCT03540758|DRUG|Diazoxide|"Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study."
41444258|NCT03540758|DRUG|Nicotinic acid|T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.
41444259|NCT03540758|DRUG|Placebo|"Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study."
41444260|NCT06558929|BEHAVIORAL|Occupational Therapy|Participants will redesign their daily routine (particularly the sleep-wake rhythm) with support from occupational therapists and an online health management platform.
41444261|NCT06558929|OTHER|Conventional Treatment|Participants will receive conventional treatment and education on sleep hygiene.
41444262|NCT05668689|OTHER|Preliminary testing|The pilot test will be administered by local investigators via a computer-based application to 35-50 trainees and consultants. The cohorts will include an equal number of trainees and consultants of varying experience, based on the new RCOA curriculum and the extent of their regional experience (stage 1 (CT1-3); stage 2 (ST4-5); stage 3 (ST6-7); stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The pilot test will contain short video clips and images of ultrasound guided regional anaesthesia with questions in a constructed response question (CRQ) format to identify relevant structures, anatomy and clinical knowledge.
41444263|NCT05668689|OTHER|Psychometric main study testing (Phase 5)|The main study assessment tool will be administered to trainees of all levels and consultants, aiming to recruit an equal number across different stages of the RCoA curriculum and of varying regional anaesthesia experience (stage 1; stage 2; stage 3; stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The exam will consist of constructed response questions (CRQs), which will require the participant to write free-text responses to questions, in line with RCoA examinations.
41444264|NCT01434953|BEHAVIORAL|Labeled prehypertension|A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
41444265|NCT01434953|BEHAVIORAL|Unlabeled prehypertension|"A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed."
41444266|NCT01746550|DEVICE|MD-12-001 Stent|MD-12-001 is a self-expanding nitinol stent
41444267|NCT06321653|RADIATION|Hypofractionated radiotherapy scheme|Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed
41106051|NCT03885596|DRUG|Fentanyl|100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
41106052|NCT03885596|DRUG|Bupivacaine Hydrochloride|0.25% 30 mL (75 mg) prior to surgery
41106053|NCT03885596|DRUG|Lidocaine HCl|1.5% 12 mL at the end of surgery
41106054|NCT03885596|DRUG|Celecoxib|200 mg PO bid each day postoperative
41106055|NCT03885596|DRUG|Acetaminophen Oral|1 g postoperative
41444268|NCT06562387|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation is one of the most studied techniques in noninvasive neuromodulation. With a very good safety profile and low cost, it has been widely used to modulate cognition and behavior in both experimental and clinical settings. A growing body of literature, including randomized controlled trials, reports the clinical benefits of tDCS for many psychiatric symptoms, such as depression, anxiety, psychosis, addiction, and cognitive functions. tDCS has considerable potential as a treatment due to its relative cost, portability, safety, and ease of use compared to other neuromodulation methods. Early studies evaluated the effects of tDCS on the motor cortex; however, more recent research has also focused on its effects on the dorsolateral prefrontal cortex (DLPFC), in particular for treating psychiatric disorders and modulating cognitive performance.
41106056|NCT03885596|DRUG|Lidocaine Hydrochloride|2% 15 mL at the end of surgery
41106057|NCT03885596|DRUG|Exparel|Bupivacaine liposome injection suspension
41106058|NCT04265703|PROCEDURE|Internal jugular vein catheterization|Catheterization of internal jugular vein with real-time (in-plane) method, with neutral neck position. Standard aseptic technique.
41106059|NCT04265703|PROCEDURE|Subclavian vein catheterization|Catheterization of subclavian/axillary vein with infra-clavicular approach with real-time (in-plane) method, without shoulder retraction. Standard aseptic technique.
41106060|NCT04265703|PROCEDURE|Innominate vein catheterization|Catheterization of innominate vein with supra-clavicular approach with real-time (in-plane) method, with neutral shoulder position and no shoulder retraction. Standard aseptic technique.
41106061|NCT02467296|OTHER|Dietary plan with controlled amount of Sodium|Dietary plan with 1.5 gr vs 3 gr of Sodium
41106062|NCT00764920|DEVICE|non-invasive imaging modalities for assessment of skin|skin imaging
41106063|NCT04151550|DEVICE|Bilateral Laser Scleral Microporation procedure|"Device: Laser Scleral Microporation~Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern."
41106064|NCT00939042|PROCEDURE|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
41106065|NCT00939042|PROCEDURE|BMNC therapy|Injection of BMNC after common PCI
41106066|NCT06134804|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
41106067|NCT06134804|BIOLOGICAL|Placebo|Placebo will be administered as an IM injection.
41106068|NCT06134804|BIOLOGICAL|HD quadrivalent influenza vaccine|HD quadrivalent influenza vaccine will be administered as IM injection.
41106069|NCT03258619|BIOLOGICAL|Aldosterone / renin dosage|Plasma levels of aldosterone and renin
41106070|NCT03258619|BIOLOGICAL|Natriuresis|natriuresis levels
41106071|NCT05591001|DRUG|ketamine and dexmeditomidine combination|Dexmedetomidine( 0.4 -0.6 μg/.kg /.hr)) ketamine,( 1 -2m/.kg/.hr) infusion
41106072|NCT05591001|DRUG|Propofol|propofol (100 ug /kg/min) infusion
41106073|NCT05737238|BEHAVIORAL|Intervention during phase B: Compensatory brain game supporting Goal Management Training intervention|The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently at their own home. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
41106074|NCT00957229|DRUG|GDC-0449|capsule, 150 mg, one pill daily, 18 months
41106075|NCT03172533|DRUG|ethinyl estradiol 0.03mg and dienogest 2 mg (combination)|approved oral contraceptive (Germany): Maxim
41106076|NCT03172533|DRUG|Placebo oral capsule|placebo
41106077|NCT01050569|DRUG|Nicotine Patch|21 mg
41106078|NCT01050569|OTHER|VLNC Cigarette|Cigarette where the tobacco contains \<0.1 mg of nicotine yield.
41106079|NCT01050569|OTHER|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing \<0.1 mg nicotine yield.
41106080|NCT03677999|DIAGNOSTIC_TEST|MEGA-PRESS sequence Magnetic Resonance Spectroscopy|MRS protocols and novel MRI methods that allow detection and quantification of 2 hydroxyglutarates (2HG) as well as the physiologic consequences of 2HG accumulation.
41106081|NCT05453955|DRUG|Propofol|Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
41106082|NCT05453955|DRUG|Remimazolam Besylate|Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
41106083|NCT00798122|PROCEDURE|Intravascular ultrasound|intravascular ultrasound
41106084|NCT00798122|PROCEDURE|MRI|cardiac MRI
41106085|NCT01767259|DRUG|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
41106086|NCT01767259|DRUG|Valsartan|Valsartan alone
41106087|NCT01767259|DRUG|Hydrochlorothiazide|Hydrochlorothiazide alone
41106088|NCT01694628|BEHAVIORAL|CLIMB (COPD Lifestyle, Mood, and Behavior)|Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
41106089|NCT06555198|BEHAVIORAL|Foot(at)Work intervention|Foot(at)Work intervention is targeted for nurses working in clinical settings to promote their competence in lower extremity health self-care.
41270947|NCT01355289|DRUG|Ribavirin|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
41106090|NCT05381571|OTHER|Motivating reminiscence physical therapy|The jDome BikeAround system involves participants using a stationary bike while their selected location is displayed in front of them on a domed projector screen using Google Street View. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
41106091|NCT06427252|DRUG|HIPEC|In the experimental group, HIPEC treatment (paclitaxel, 3000 ml of physiological saline at 43°C for 60 min) was performed on the first day after the first exploratory laparotomy and on the third day after the radical surgery for a total of 2-3 times (total amount of paclitaxel was 175 mg/m2 ), with an interval of not more than 72 h. Intravenous systemic therapy was started 3 weeks after the completion of HIPEC treatment. systemic therapy.
41106092|NCT06427252|DRUG|Systemic therapy|"1. Tirilizumab: 200 mg, i.v., D1, Q3W;~2. oxaliplatin: 130mg/m2, i.v., D1, Q3W;~3. Herceptin: a tri-weekly dosing regimen with an initial loading dose of 8 mg/kg followed by 6 mg/kg Q3W.~4. Tegeo: Oral administration: 40 mg per dose for BSA \<1.25, 50 mg per dose for BSA 1.25 to 1.5, and 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle D1-D14, Q3W;"
41106093|NCT03598972|OTHER|intervention|elementary analysis
41106094|NCT03591809|OTHER|combined exercise training|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
41106095|NCT00300040|DRUG|Hemoglobin glutamer 250 - bovine|intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
41106096|NCT00300040|DRUG|6% Hydroxyethylstarch|250ml for intravenous infusion
41106097|NCT03731936|OTHER|No intervention|No intervention
41106098|NCT00738075|DEVICE|Auditory cue|When device recognizes automatically freezing episode it will generate auditory cue
41106099|NCT02559518|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
41106100|NCT02559518|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
41106101|NCT02559518|DEVICE|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
41106102|NCT02559518|DEVICE|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
41106103|NCT02559518|DEVICE|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
41106104|NCT02559518|DEVICE|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
41106105|NCT02559518|DEVICE|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
41106106|NCT05967338|DEVICE|using McGrath Video Laryngoscope|glottis visualization in indirect and direct lifting methods by using McGrath Video Laryngoscope
41106107|NCT03936348|DEVICE|Exercise training program with and without FB|"Participants carried out a supervised RP for 8 weeks, 3 days per week. The training sessions lasted 60 minutes and included a warning up phase, the main phase and a recovery phase. After each session, Borg's perceived exertion was measured. The Rehabilitation Program (RP) included aerobic exercise on cycle ergometer and on treadmill (progressing since 10' to 30' and since 40 to 75% of the reserve heart rate (RHR) or 6-7 score based on Borg's perceived exertion), strengthening of lower and upper limb muscles groups, breathing exercises (pursed lip breathing, diaphragmatic and abdominal breathing and diaphragmatic mobility) and finally stretching exercises.~In the FB group, for restricted nasal breathing, at the beginning of the training program, the small size device was used (4 mm). The size of the device was progressively increasing according to the patient adaptation to the 5 or 6 mm device, depending on the score on Borg's perceived exertion scale."
41106108|NCT00337818|BIOLOGICAL|Cervarix™|Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
41106109|NCT03128658|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)
41106110|NCT03128658|DIAGNOSTIC_TEST|Computational model|The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
41270948|NCT05437887|DIETARY_SUPPLEMENT|Fucoidan|All patients consumed fucoidan.
41270949|NCT03244358|DRUG|Epalrestat|Epalrestat 50mg tid added to standard chemotherapy treatment
41106111|NCT05975788|DRUG|Staphylococcus and Neisseria Tablets|Staphylococcus and Neisseria tablets is used as an adjuvant treatment drug for respiratory disease in acute attack period, such as chronic tracheitis, bronchitis and various types of colds. It has been proved to effectively shorten the course of disease. In this study, Staphylococcus and Neisseria tablets will be administered with 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months according to clinicians.
41106112|NCT01810263|DIETARY_SUPPLEMENT|high protein supplement|Dietary Supplement: high protein supplement
41106113|NCT02866214|DRUG|Febuxostat|Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session
41106114|NCT02866214|DRUG|Placebo|"Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.~same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) ."
41106115|NCT03425630|DIETARY_SUPPLEMENT|Argicolina|8 weeks
41106116|NCT03425630|DIETARY_SUPPLEMENT|Normolip|8 weeks
41106117|NCT06248788|DEVICE|PoC Device|PoC Device for Testing Salivary IgA
41106118|NCT02018224|PROCEDURE|End-to-end suturation without augmentation|End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
41106119|NCT02018224|PROCEDURE|End-to-end suturation with augmentation.|End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
41106120|NCT03478696|DRUG|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
41106121|NCT03478696|DRUG|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
41106122|NCT03478696|DRUG|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
41106123|NCT03478696|DRUG|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
41106124|NCT03478696|DRUG|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
41106125|NCT03478696|DRUG|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
41106126|NCT03478696|DRUG|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
41106127|NCT03478696|DEVICE|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
41106128|NCT03478696|DEVICE|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
41106129|NCT03478696|DEVICE|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
41106130|NCT04691973|BEHAVIORAL|Health and lifestyle tool|Health and lifestyle tool used online
41106131|NCT04691973|OTHER|Usual care|Usual care at ordinary healthcare provider
41106132|NCT02525510|OTHER|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.OPO's protocol
41106133|NCT02525510|OTHER|Pump Eligible - Hypothermia and Pump Right Kidney|"Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.~Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation."
41106134|NCT02525510|OTHER|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
41106135|NCT02525510|OTHER|Not Pump Eligible - Normothermia|"Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.~Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol"
41106136|NCT02525510|OTHER|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
41106137|NCT05864482|OTHER|Psychosocial nursing intervention|The sessions were planned to be at least 45 minutes in a time suitable for the groups, with the bed curtains drawn if possible. Session 1: The purpose of this session; Brief CIS information will be provided. Session 2: The session starts with mood control of individuals. It is discussed whether they have experienced an event that occupies their minds and is likely to affect their illness. Session 3: It starts with mood control of individuals. They are asked if there is anything from the places where the guests are. Cognitive reviews are reviewed. It aims to describe recent stressful observations, negative automatic outcome descriptions, and evaluation of such experiences. 4.Session: The session starts with the mood control of the patient. It is discussed whether the patient has experienced an event that occupies his mind. Continuous analysis of negative thoughts and review of cognitive techniques and coping mechanisms are provided.
41106138|NCT03745118|DEVICE|EpiTel EpiLog|Plastic pad that is about the size of a house key, and will be adhered to your scalp with gel
41106139|NCT03745118|DEVICE|Byte Flies Sensor Dots|Plastic pads that will be adhered to your chest area
41106140|NCT03745118|DEVICE|Empatica E4|wearable seizure detection wristband
41106141|NCT03745118|DEVICE|Biovotion Everion|wearable seizure detection device armband that is attached to upper arm
41106142|NCT03745118|DEVICE|GeneActiv|wearable seizure detection watch
41106143|NCT00148434|BEHAVIORAL|Patient-held guideline for hypertension|
41106144|NCT01295918|DIETARY_SUPPLEMENT|L reuteri in children on antibiotics|Each patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.
41106145|NCT00221637|DRUG|Sodium Valproate|
41106146|NCT06553222|BIOLOGICAL|Putty bone - Tricalcium phosphate with Collagen gel|Minimally invasive debridement periodontal flap and Bone graft placement to augment the lost alveolar bone
41444269|NCT06562387|OTHER|cognitive stimulation|This brain stimulation program is based on cognitive reserve and neuronal plasticity to improve mental performance through online games. The activities presented in this tool combine different therapeutic exercises, rehabilitation and learning techniques aimed at retraining and improving the skills most needed by each person. The intervention battery has multi-disciplinary tasks organized in a systematic and strategic way. To make these materials accessible, they are presented in the form of simple games that can be easily practiced through any computer or device. These cognitive stimulation tools are aimed at both healthy subjects and people concerned about their brain health, or patients with some kind of injury or decline in the central nervous system.
41106147|NCT02886897|BIOLOGICAL|D-CIK and anti-PD-1 antibody|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
41106148|NCT04687085|OTHER|10 minute mindful meditation recording|10 minute mindful meditation recording
41106149|NCT04107805|DRUG|BI 1323495|Tablet
41106150|NCT04107805|DRUG|Placebo|Tablet
41106151|NCT04107805|DRUG|Midazolam|Oral administration
41106152|NCT05427058|PROCEDURE|Superior Hypogastric Plexus Block|this procedure uses a transdiscal approach at the level of the L5-S1 vertebrae by injecting 5 ml of 1% lidocaine + 10 ml of 96% alcohol and confirmed by C-arm.
41106153|NCT05427058|PROCEDURE|Ganglion Impar Block|this procedure uses a trans-sacrococcygeal approach by injecting 4 ml of 1% lidocaine + 6 ml of 96% alcohol and confirmed by C-arm.
41106154|NCT03275077|DEVICE|Thromboelastography|A viscoelastic test of coagulation
41106155|NCT01345838|PROCEDURE|labrum|Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
41106156|NCT04741971|DIETARY_SUPPLEMENT|Probiotics group|Will give Probiotics with Vitamin D3 one drop per day for 90 days
41106157|NCT04741971|DIETARY_SUPPLEMENT|Non-probiotics group|Will give Vitamin D3 five drops per day for 90 days
41106158|NCT01291290|PROCEDURE|Platelet|2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.
41106159|NCT00060099|BIOLOGICAL|HspE7|
41106160|NCT05903963|DRUG|Midazolam|midazolam infusion by 0.03-0.3mg/kg in increments of 1-2.5mg followed by Maintenance dose: 0.03-0.2mg/kg/hour for midazolam.
41106161|NCT05903963|DRUG|dexmedetomidine|dexmedetomidine infusion 1 µg/kg dexmedetomidine for 10 minutes followed by a continuous IV infusion at 0.2-0.3 µg/kg/hour .
41106162|NCT01335542|PROCEDURE|Peri-Articular Injection|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), dexamethasone (6mg) Anesthetic:: Combined Spinal-Epidural with 0.5% bupivacaine. IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Postoperative pain management: hydromorphone/bupivacaine PCEA (4/4/10/20, initially). Meloxicam (7.5 or 15mg), Oxycodone/Acetaminophen (5/325 3hr PRN)
41106163|NCT01335542|PROCEDURE|Epidural Pathway (PCEA+FNB)|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), extended release oxycodone (10mg or 20mg), dexamethasone (6mg), clonidine patch (100 mcg/24 hr) Anesthetic: Spinal with 0.5% bupivacaine, IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Post-operative analgesia:Prilosec (20mg), Meloxicam (7.5mg or 15 mg PO), extended release oxycodone (10mg or 20mg), Oxycodone (5mg q 3 hr PRN), Acetaminophen (1000mg), ketorolac 15mg IV
41106164|NCT02909049|DRUG|MIDAZOLAM|Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
41106165|NCT02909049|DRUG|MEPIVACAÍNE|Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
41106166|NCT02909049|DRUG|FENTANILE|Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
41106167|NCT02909049|DRUG|KETAMINE|Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
41106168|NCT02331043|DIETARY_SUPPLEMENT|Plant stanol ester|
41106169|NCT02331043|DIETARY_SUPPLEMENT|Placebo|
41106170|NCT05509842|DEVICE|rTMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be used to apply rTMS to targeted locations marked on the structural MRI using a frameless infrared stereotactic neuronavigation system (Brainsight, Rogue Research).
41106171|NCT00105794|PROCEDURE|Psychiatric Advance Directives intervention|
41106172|NCT06405867|PROCEDURE|delayed cord clamping (> 60 sec)|In the DCC group, cord pulse was checked without allowing clamping. Waited until the cord pulse stopped. It was wrapped in a sterile and warm cloth and dried. The cord was clamped when the pulse stopped. The cord clamping time was noted on the case report form. In DCC, the baby was placed on the mother's legs in cesarean section (C/S) births and on the mother's mons pubis region in normal vaginal births. The baby was administered a routine delivery room neonatal resuscitation program (NRP) by the pediatrician. After cord clamping, the baby was handed over to the pediatric team.
41106173|NCT00075972|BEHAVIORAL|Mood Tolearance|
41106174|NCT00075972|BEHAVIORAL|Mood Management|
41106175|NCT00075972|DRUG|Nicotine Replacement therapy|
41106176|NCT03590288|PROCEDURE|Transjugular intrahepatic portosystemic shunt|"Covered stents will be used, that will be dilated to 8 mm. The aim will be to reduce the portacaval pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of portacaval pressure gradient will be done immediate after TIPS, then repeated 1-3 days and at 1 month after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected."
41270950|NCT05683756|BEHAVIORAL|Brief Parent Behavioral Intervention|PBI administered in pediatric primary care by an embedded therapist.
41270951|NCT05683756|BEHAVIORAL|Sleep-Focused Parent Behavioral Intervention|SF-PBI administered in pediatric primary care by an embedded therapist.
41270952|NCT00175981|DRUG|sildenafil, fluvoxamine|
41444270|NCT06562387|DEVICE|sham transcranial direct current stimulation|Regarding the simulated condition or sham, the equipment has the option inside to program it. It gives the options: Active / sham protocol, by default: ON - enables active stimulation and OFF - enables sham stimulation. The devices will be programmed, such that a few seconds of stimulation are administered at the beginning and end of the programmed time period to mimic the cutaneous perceptions (itching, tingling) that tend to be reported within the first few moments of stimulator on, without being able to modify cortical excitability.
41444271|NCT01371435|DRUG|Paroxetine|
41106177|NCT03487042|DRUG|Bimatoprost 0.03% ophthalmic solution|"Each patient will be subjected to the following:~One side will be treated by narrow band ultraviolet rays B sessions twice weekly for 3 months + topical bimatoprost 0.03% solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays B sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months.~Patients' Evaluation:~The recruited patients will be subjected to:~A) Full history taking. B) General clinical examination. C) Dermatological examination of the skin lesions. D) Vitiligo area scoring index score will be calculated for each patient E) Clinical photographs will be taken at baseline, after each month during treatment and after the end of treatment by 3 months.~F) A skin biopsy from the treated lesions for histochemical examination. F) Dermoscopic evaluation of the treated sites every 2 weeks."
41106178|NCT06129370|DEVICE|Standard practice|Lexicomp and manual calculator
41106179|NCT06129370|DEVICE|Medication dosing software|Medication dosing software
41106180|NCT00161447|DRUG|Acyline|Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
41106181|NCT00161447|DRUG|Testosterone Gel|Testosterone Gel (10 g daily
41106182|NCT00161447|DRUG|Depo-Medroxyprogesterone|DMPA (injected into muscle) Day 0 \& month 3
41106183|NCT01346930|DRUG|Macitentan|10 mg, tablet, once daily
41106184|NCT00395434|DRUG|Combretastatin A4 Phosphate (CA4P)|
41106185|NCT00395434|DRUG|Bevacizumab (Avastin)|
41106186|NCT01219218|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
41106187|NCT00628719|DRUG|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
41444272|NCT03049631|DIETARY_SUPPLEMENT|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
41444273|NCT03049631|DIETARY_SUPPLEMENT|Raspberry|Red raspberries (1 cup equivalent)
41444274|NCT01098591|OTHER|cell therapy|
41444275|NCT01946477|DRUG|Pomalidomide|
41106188|NCT00628719|DRUG|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
41106189|NCT03334019|OTHER|blood test|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
41106190|NCT01541358|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
41106191|NCT01541358|PROCEDURE|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
41106192|NCT05586113|DRUG|10-day Tegoprazan bismuth-containing quadruple therapy|10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
41106193|NCT01367548|DRUG|IV Methylnaltrexone (MNTX)|
41106194|NCT01367548|DRUG|Placebo|
41444276|NCT01946477|DRUG|Dexamethasone|
41444277|NCT01946477|DRUG|Daratumumab|
41444278|NCT00741780|DRUG|Placebo|
41444279|NCT00741780|DRUG|plerixafor|
41444280|NCT00741780|DRUG|granulocyte colony-stimulating factor (G-CSF)|
41444281|NCT00345696|DRUG|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
41444282|NCT00345696|DRUG|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
41106195|NCT06556134|DRUG|Intravenous Iron Sucrose|Intravenous iron-hydroxide sucrose complex administered in a dose of 100 mg, diluted in 250 mL of normal saline, and infused weekly for a period of 3 months
41106196|NCT06556134|DRUG|Oral Iron|One oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid
41106197|NCT05112718|BIOLOGICAL|Platelet Rich Plasma Injections|"PRP injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 PRP injections at 4-6-week intervals. Xylocaine gel 2% is applied to the distal anterior vaginal wall 20 minutes before injections."
41106198|NCT05112718|OTHER|Normal Saline Injections|"Normal saline injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 injections at 4-6-week intervals."
41106199|NCT00114699|DRUG|CCR5mAb004|
41106200|NCT01850017|DRUG|Dexmedetomidine|In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
41106201|NCT05676736|OTHER|No intervention|No intervention to be done for the group
41270953|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
41270954|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
41270955|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
41444283|NCT00345696|DRUG|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
41444284|NCT00030186|DRUG|CEP-701 60mg|60mg orally 2 times a day for 28 days
41444285|NCT00030186|DRUG|Cep-701 80mg|80mg 2 times a day, dependent upon response to cycle 1
41444286|NCT00030186|DRUG|Cep-701 40mg|40mg 2 times a day, dependent upon response to cycle 1
41444287|NCT00271492|DRUG|Atrasentan|1 10mg capsule to be taken daily for 6 month study period.
41444288|NCT00271492|DRUG|Atrasentan|1 10mg capsule per day for the 6 month study period.
41106202|NCT02540551|PROCEDURE|Injection of radioactive tracer combined with Patent Blue|Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
41106203|NCT04364269|DRUG|VIT-2763 once a day (QD)|Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
41106204|NCT04364269|DRUG|VIT-2763 twice a day (BID)|Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
41106205|NCT04364269|DRUG|Placebo|Participants will receive hard capsules of Placebo, twice a day.
41106206|NCT01971788|DEVICE|Optical Coherence Tomography of the infarct related artery|
41106207|NCT05573854|DIETARY_SUPPLEMENT|Gastric emptying after an oral supplement containing carbohydrates and whey protein|Ingestion of an oral supplement containing carbohydrates and whey protein
41106208|NCT05573854|DIETARY_SUPPLEMENT|Overnight Fast|Residual Gastric Volume assessed by MRI after overnight fast (8h)
41106209|NCT04570956|DRUG|Tamoxifen|Oral Tamoxifen 10 mg/day
41106210|NCT04570956|DRUG|Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day|Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
41106211|NCT04570956|DRUG|Placebo|placebo pill or placebo gel
41106212|NCT04570956|OTHER|Questionnaire Administration|Ancillary studies
41106213|NCT00329732|DRUG|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
41106214|NCT00329732|DRUG|Saline placebo|matching volume of saline (placebo)
41106215|NCT05125367|PROCEDURE|coronary stent implantation|coronary stent implantation using everolimus-eluting balloon expandable stents
41106216|NCT05125367|PROCEDURE|bypass grafting|coronary artery bypass graft
41106217|NCT03680391|PROCEDURE|Cesarean section|"Both groups cesarean section will be held with the same technique:~* spinal anethesia~* pfennenstiel imcision~* lower segment cesarean section~* suturing uterus in two layers while exterionezed~* gentle manibulation~* no towels in gutters will be used"
41106218|NCT00606580|DRUG|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
41106219|NCT00606580|DRUG|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
41106220|NCT00606580|DRUG|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
41106221|NCT03478956|DRUG|Etrolizumab|Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.
41106222|NCT03103295|BIOLOGICAL|3D-Tissue Engineered Bone Equivalent|Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
41106223|NCT00223548|DRUG|sodium 2-mercaptoethane sulfonate|
41106224|NCT02667249|OTHER|clinical pathway|implementation of a standardized clinical pathway
41106225|NCT00127179|DRUG|MK0906, finasteride / Duration of Treatment: 48 weeks|
41106226|NCT00127179|DRUG|Comparator: placebo / Duration of Treatment: 48 weeks|
41106227|NCT00305695|OTHER|Laboratory Biomarker Analysis|Correlative studies
41106228|NCT00305695|DRUG|Zoledronic Acid|Given IV
41106229|NCT03618849|DEVICE|tDCS|Real and sham tDCS/Mozart piano sonata (K.448)
41106230|NCT02372019|BEHAVIORAL|CBM With Active Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 10 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the memory reconsolidation window that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting."
41106231|NCT02372019|BEHAVIORAL|CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the memory reconsolidation window that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control."
41106232|NCT02372019|BEHAVIORAL|Inert CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the memory reconsolidation window that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions."
41106233|NCT04466904|DRUG|IBI362|Administrated by subcutaneous injection
41106234|NCT04466904|DRUG|Placebo|Administrated by subcutaneous injection
41106235|NCT04466904|DRUG|Dulaglutide|Administrated by subcutaneous injection
41106236|NCT03673943|DRUG|64Cu-DOTATATE|Detection of somatostatin positive lesions in NET
41270956|NCT04907851|BIOLOGICAL|Denosumab|Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
41444289|NCT00271492|DRUG|atrasentan|One 10 mg capsule per day for 6 month study period
41444290|NCT05589753|OTHER|Hyperoxia|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure.
41106237|NCT05561803|RADIATION|Photobiomodulation Therapy|Focal low-level laser therapy, Red Laser (wavelength 633 nm to 685 nm), or Infrared Laser Laser (wavelength 780 nm to 830 nm), with a low-intensity laser equipment of 100 mW and a cross-sectional area of the device beam of 0.0434 cm². The parameters are 1 to 3 J per point, with equidistant points of 1.5 to 2 cm, covering the entire length of the open lesion. Therapy is carried out every 48 hours until the total wound healing, regardless of the number of sessions required.
41106238|NCT02050308|OTHER|Internet-All Nations Breath of Life (I-ANBL)|"* Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session~* Weekly procedures will follow the same format as for the first session"
41106239|NCT02050308|OTHER|Honoring the Gift of Heart Health|"These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities."
41106240|NCT02050308|DRUG|Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®|Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
41106241|NCT01810250|DEVICE|Endurant Stent Graft|
41106242|NCT03097016|DRUG|CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
41106243|NCT02241668|PROCEDURE|PET Scan|FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.
41106244|NCT02241668|DRUG|3'-Deoxy-3'-18f-Fluorothymidine|3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
41106245|NCT00328523|DRUG|MK-0653, ezetimibe|
41106246|NCT00328523|DRUG|Duration of Treatment: 3 months|
41106247|NCT04882449|DEVICE|Bodyport Scale|The Bodyport scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
41106248|NCT00377455|DRUG|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
41106249|NCT00377455|DRUG|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
41106250|NCT04911049|DIAGNOSTIC_TEST|Blood Pressure measurement|Blood Pressure measurement
41106251|NCT05571358|DEVICE|Virtual Reality (Nature Trek)|"At the end of each session, participants will experience an immersive virtual landscape displayed by Nature Trek VR software (httpp://naturetreksvr.com/). First, participants will be placed in a sit down position and guided for their breathing control during 5 minutes (meditation Lotus option). After that, they will be encouraged to freely move around a relaxing virtual environment during 15 minutes taking special attention to soothing sounds of nature. The themes environment will be selected based on the preferences of the participants.~At the beginning of the study, advice is given on general care, in physical activity and issues concerning drug intake. Patients are advised to refrain from any other specific training during the intervention period. Any deviations from the adherence and practice of the VRi are recorded daily, noting any adverse incidents."
41106252|NCT01975311|OTHER|Lumbopelvic Manipulation|High-velocity low-amplitude non-specific lumbopelvic thrust manipulation
41106253|NCT01975311|OTHER|Passive lumbar spine flexion and extension|Passive lumbar spine flexion and extension without reaching the physiological end feel for 1 min from a side lying position.
41106254|NCT01819493|BEHAVIORAL|Lifestyle Intervention|Family-based group lifestyle intervention
41106255|NCT01819493|BEHAVIORAL|Standard Family-Based intervention|Comparison intervention
41106256|NCT06005220|OTHER|SBD121|Medical Food
41106257|NCT06005220|OTHER|Placebo|Placebo
41106258|NCT01765686|DEVICE|Harmonic Scalpel (Ethicon Endo-Surgery, USA)|
41106259|NCT01765686|DEVICE|Ligasure Small Jaw (Covidien, USA)|
41444291|NCT05589753|DRUG|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 6 days. On the final 4 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
41444292|NCT03256695|DRUG|Albuterol sulfate (ABS)|ABS will be administered via eMDPI as per the dose and schedule specified in the arm.
41106260|NCT04658849|DRUG|Pioglitazone 30 Mg Oral Tablet|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
41106261|NCT04658849|DRUG|Pioglitazone placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
41106262|NCT02404337|DRUG|Betaine|
41106263|NCT02628093|DEVICE|THUNDERBEAT|Tissue dissection and vessels ligation
41106264|NCT02628093|DEVICE|LIGASURE|Tissue dissection and vessels ligation
41106265|NCT05847842|PROCEDURE|Anterior quadratus lumborum block|20 mL of 0.25% bupivacaine will be given
41444293|NCT04786496|BEHAVIORAL|ITP+SA Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults. It includes two components: a self-affirmation (SA) activity and an ITP intervention. The SA component includes a list of values so that they could choose the three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component resembled the intervention developed by David S. Yeager and colleagues and it was adapted to first year university students. It consisted of three parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled pathways in the brain that have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by second year university students to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative (self-persuasive writing exercise).
41444294|NCT04786496|BEHAVIORAL|ITP Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes the ITP component described above for the ITP+SA Wise intervention.
41444295|NCT04786496|BEHAVIORAL|Control condition|The control intervention was designed to have a similar structure than the experimental interventions, including also reading and writing tasks, but that they were not in any way related to the contents of the experimental interventions. In particular, participants were asked to read an article about the fire that took place in the Notre Dame cathedral in Paris that had been recently published in a newspaper. Starting from the accident of the Notre Dame cathedral, the article focuses on reflecting on the problem of heritage conservation and analyzing the situation of other important cathedrals. After reading the article, the participants were asked to write a few lines evaluating in their opinion the importance of the conservation of historical buildings such as those mentioned and how much of the public economic budget should be used for heritage conservation.
41444296|NCT06562621|BIOLOGICAL|ON-01|ON-01 consists of a yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5-FC) to the anticancer drug 5-FU in cells that have been infected by ON-01.
41444297|NCT06562621|DRUG|ONF|ONF is an extended-release formulation of flucytosine.
41444298|NCT06501222|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
41444299|NCT02866357|OTHER|No intervention|Just collection of nasopharyngeal aspirate for assessment
41444300|NCT06135051|DEVICE|Diadem prototype|The device delivers low-intensity ultrasonic waves into specific brain targets.
41444301|NCT00858754|DRUG|methylnaltrexone|
41444302|NCT00858754|DRUG|placebo|
41444303|NCT03537482|DRUG|APG-2575|APG-2575 will be administered as an oral tablet
41444304|NCT00309881|BIOLOGICAL|rituximab|
41444305|NCT00309881|DRUG|cyclophosphamide|
41444306|NCT00309881|DRUG|doxorubicin hydrochloride|
41444307|NCT00309881|DRUG|prednisone|
41444308|NCT00309881|DRUG|vincristine sulfate|
41106266|NCT05847842|PROCEDURE|Transversus abdominis plane block|20 mL of 0.25% bupivacaine will be given
41106267|NCT05847842|PROCEDURE|Local infiltration|20 mL of 0.25% bupivacaine will be given
41106268|NCT02289625|OTHER|Exercise Training|six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
41106269|NCT00201695|DRUG|Doxil®|40 mg/m2 IV day 1
41444309|NCT06177418|PROCEDURE|Transumbilical laparoscopic appendectomy + Glove finger technique|Ssince the appendix becomes infected when it is removed from the umbilicus, the infected appendix contacts the edge of the incision during release, thus contaminating the incision and causing postoperative wound infection. Additionally, in the experimental, to prevent this wound infection, after the appendix is taken out through the umbilical incision, the appendix is placed inside the glove finger, thus preventing the appendix from touching the wound during its release. This reduces wound infection in the postoperative period.
41444310|NCT06177418|PROCEDURE|Standard transumbilical laparoscopic appendectomy|Standart transumbilical laparoscopic appendectomy
41106270|NCT00201695|DRUG|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
41106271|NCT00201695|DRUG|Dexamethasone|40 mg PO days 1-4
41106272|NCT00201695|DRUG|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
41106273|NCT02864628|BIOLOGICAL|MVA-BN-RSV|MVA-mBN294B
41106274|NCT02864628|OTHER|Placebo|Tris Buffered Saline
41106275|NCT06140680|BEHAVIORAL|LifelongU|"The LifelongU intervention is an abbreviation name from LifelongU: Cultivating Physical Literacy for University \& Beyond. LifelongU is a unique and coined term that symbolizes the program's commitment to promoting physical literacy as a lifelong journey. It combines the words Lifelong and University to represent an intervention that focuses on physical literacy development not only during the university years but also throughout a person's entire life. The name is designed to convey the idea that physical literacy is an asset that will benefit individuals in all aspects of life, even after they leave the university."
41106276|NCT06140680|BEHAVIORAL|Physical education|The control group received 12-week traditional physical education lesson as usual.
41106277|NCT02045719|DRUG|uncaria tomentosa (cat´s claw)|
41106278|NCT06556186|PROCEDURE|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
41106279|NCT06556186|DRUG|Bromocriptin 2.5mg, 2-3 times a day|Bromocriptin 2.5mg, 2-3 times a day
41106280|NCT05035927|DRUG|TRYP-0082|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
41106281|NCT05035927|BEHAVIORAL|Psychotherapy|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
41106282|NCT02361437|DIETARY_SUPPLEMENT|Vasculera|Vasculera 630 mg b.i.d.
41106283|NCT00002932|DRUG|cisplatin|
41106284|NCT00002932|RADIATION|radiation therapy|
41106285|NCT05733936|OTHER|rehabilitation protocol|rehabilitation protocols after ACLR have been described, aiming to improve muscle strength and knee stability through muscle strengthening exercises in addition to exercises to improve joint proprioception
41106286|NCT00623506|DRUG|Pregnenolone|"Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)"
40925328|NCT06492837|DRUG|Mosunetuzumab in combination with Zanubrutinib|Combinations of Mosunetuzumab and Zanubrutinib as salvage strategy in patients with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
41106287|NCT00623506|DRUG|Placebo|"Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)"
41106288|NCT03415048|OTHER|No Intervention|
41106289|NCT06083467|DIAGNOSTIC_TEST|Amyloid PET scan|Positron Emission Tomography (PET) scan using either Florbetaben F18 or 11C-PiB radiotracer
41106290|NCT06083467|DIAGNOSTIC_TEST|Brain MRI Scan|MRI scan of the brain
41106291|NCT06083467|BEHAVIORAL|Neurologic exam|Neurologic exam and assessments, including video interview
41106292|NCT04696341|PROCEDURE|Matrix Rhythm Therapy|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.Five sessions of MRT (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy to Matrix Rhythm Group. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 min (15 min for right and left sides each) according to the instructions of the technique developer.
41106293|NCT04696341|PROCEDURE|Control|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.
41106294|NCT04897737|BEHAVIORAL|HIVST and enhanced adherence biofeedback|"The intervention includes the provision of an OraQuick HIV self-test (HIVST) for the woman and one test for each of her reported sex partners, along with instructions on how to use and interpret the results. Women were asked to report back within one month if their partner was able to test via a SMS, WhatsApp or by bringing in the test to confirm that he had tested.~Women then received adherence based feedback following the urine lateral flow assay (that measures recent tenofovir use in past 48 hours). Study counsellors requested that women provide a urine sample that was tested using the UrSure/Orasure test that provides feedback on the result in 2-3 minutes. Counselors provided counseling based on the results including how to improve daily adherence (for women without tenofovir present in their urine) and importance of condom use."
41106295|NCT04897737|DIAGNOSTIC_TEST|Orasure/UrSure test|See above
41106296|NCT05398965|DRUG|Eucalyptus Oil|The Eucalyptus Oil pack contains Oleum Eucalyptus citriodora, Oleum Eucalyptus globulus, and Peppermint oil, given 4 times daily for 45 minutes each frequency, applied to the mask.
41106297|NCT05398965|DRUG|Standard COVID medication|This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day, zinc 20 mg a day, tablet of complex vitamin B, and other symptomatic treatments.
41106298|NCT05652322|DRUG|Furosemide Pill 150% equivalent iv dose|change from intravenous to oral furosemide
41106299|NCT05652322|DRUG|Furosemide Pill 200% equivalent iv dose|change from intravenous to oral furosemide
41106300|NCT05652322|DRUG|Furosemide Injection|change from intravenous to oral furosemide
41106301|NCT05279092|DRUG|Bupivacaine-Liposomal Bupivacaine|Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block
41106302|NCT05279092|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
41106303|NCT05514444|BIOLOGICAL|MK-4464|MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.
41106304|NCT05514444|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered as an IV infusion every three weeks.
41106305|NCT05514444|DRUG|89Zr-MK-4464|89ZR-MK-4464 administered as an IV infusion on C1D1.
41270957|NCT04907851|BIOLOGICAL|pembrolizumab|Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks
40925329|NCT06103331|OTHER|Invasive Fungal disease surveillance|Management of invasive fungal infection according to pathogen identification and susceptibility report.
41270958|NCT05868785|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 pm
41106306|NCT05416450|DEVICE|intravaginal electrical stimulation added to bladder training|BT was given as a home program. After information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply and self-motivating. In the third stage, a timed voiding program was started; a timed voiding and increasing the time between urination considering the voiding diary. IVES was applied in addition to BT in both groups. It was performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with a vaginal probe; three days a week, a total of 24 sessions for 8 weeks. Every session lasted 20 minutes. The stimulation parameters were a 10 Hz of frequency, a 5-10 s of work-rest cycle duration and, a 100 ms of pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100 mA.
41106307|NCT06457568|DIAGNOSTIC_TEST|Blood pressure measurement|The blood pressure measurement was taken simultaneously by two observers using mercury sphygmomanometer and by a supervisor using the tested device, CONTEC08C.
41106308|NCT04347135|DRUG|F-18 FES|F-18 FES PET/MRI for detection of endometriosis.
41106309|NCT00454792|OTHER|Exercise|Back exercise: At home every day. In groups once a week. Duration 10 weeks.
41106310|NCT00454792|OTHER|Restitution|Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
41106311|NCT03145337|BIOLOGICAL|FlexHD ADM (Cohort A)|Tissue assisted breast reconstruction with FlexHD pliable perforated ADM
41106312|NCT03145337|BIOLOGICAL|AlloDerm RTU ADM (Cohort B)|Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM
41106313|NCT06027372|DEVICE|"LARGAN ECG Holter"|"wear LARGAN ECG Holter during sleep once after completion of pulmonary function test"
41106314|NCT04340154|BIOLOGICAL|chimeric antigen receptor T cell|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given twice（anti-CD19 CAR-T first, then anti-CD22 CAR-T). All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
41106315|NCT03055416|OTHER|Mobile Men App Prototype|Testing of app functionality
41106316|NCT02515682|DIETARY_SUPPLEMENT|High equol group|Participants will be give natural S-equol 20mg/d for 24 weeks.
41106317|NCT02515682|DIETARY_SUPPLEMENT|Low equol group|Participants will be give natural S-equol 10mg/d for 24 weeks.
41106318|NCT02515682|DIETARY_SUPPLEMENT|Placebo|Participants will be give placebo for 24 weeks.
41106319|NCT04439799|DRUG|Testosterone Cypionate 200 Mg/ML|Participants in this group will receive intramuscular testosterone cypionate injections of 1 cc (200mg) once every 14 days for four months.
41106320|NCT04439799|DRUG|Intranasal Testosterone|Participant in this group will receive Intranasal testosterone administered using a multi-dose dispenser, as two or three daily doses (5.5 mg per nostril, 11.0 mg single dose) for 4 consecutive months,
41106321|NCT02129933|DRUG|Bevacizumab-IRDye800CW|"Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.~\* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)"
41106322|NCT02129933|DEVICE|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
41106323|NCT06555276|DEVICE|Disposable endoscope linear cutting stapler and components|to use the study device for excision, transection and anastomosis of lung, bronchial tissue, stomach and intestine in open or endoscopic surgery.
41106324|NCT05882578|OTHER|Oncological physical exercise intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
41106325|NCT05882578|OTHER|Active Physical Activities intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
41106326|NCT02733250|BIOLOGICAL|Pembrolizumab|200mg IV Day 1 of each 21 cycles
41106327|NCT02733250|DRUG|Nab-Paclitaxel|100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
41106328|NCT05593822|PROCEDURE|primary percutaneous intervention|percutaneous catheterization through peripheral arteries to coronary arteries
41444311|NCT01519258|OTHER|Pressure Support ventilation|Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
41106329|NCT03163186|PROCEDURE|Transarterial embolization|Transarterial hepatic embolization of liver cancer
41444312|NCT01519258|DEVICE|NAVA|Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
41444313|NCT05984303|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
41444314|NCT04440436|DRUG|IM19 CAR-T Cells|"IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days"
41106330|NCT00839046|BEHAVIORAL|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
41106331|NCT00839046|OTHER|Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
41106332|NCT00839046|OTHER|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
41106333|NCT05515042|DRUG|Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)|As included in arm/group descriptions
41106334|NCT06122896|OTHER|Screening Blood Tests|Carbohydrate antigen (CA) 19-9, Hemoglobin A1C (HbA1c), and Fasting blood glucose (FBG) per standard-of-care.
41106335|NCT06122896|DIAGNOSTIC_TEST|Endoscopic Ultrasound|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
41106336|NCT06122896|COMBINATION_PRODUCT|Magnetic Resonance Imaging|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
41106337|NCT06122896|COMBINATION_PRODUCT|Magnetic Resonance Cholangiopancreatography|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
41106338|NCT04835987|DIAGNOSTIC_TEST|Holter ECG|Measurement of the modification of the sympathomimetic balance
41106339|NCT04835987|BEHAVIORAL|Questionary|Lifestyle questionary (time spent in front of television, physical activity)
41106340|NCT04835987|DIAGNOSTIC_TEST|Pupillometry|Monitoring of nociception and autonomic nervous system by pupillometry in intraoperative.
41106341|NCT02753413|BIOLOGICAL|RSV vaccine GSK3003891A|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
41106342|NCT02753413|BIOLOGICAL|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
41106343|NCT02391207|PROCEDURE|Hepatic vein-sparing hepatectomy|HV detachment, partial resection and section on the basis of HV-CLM relationship
41106344|NCT02982213|OTHER|Companion Present|A companion will be present during the epidural catheter placement.
41106345|NCT01955668|DRUG|Administration of AZD6738|An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially
41106346|NCT03187782|DIAGNOSTIC_TEST|ANSWatch|
41106347|NCT05257785|BEHAVIORAL|Lymfit exercise intervention|Participants randomized to this arm will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed. Participants will be followed-up at 6 months and 12 months.
41106348|NCT05257785|BEHAVIORAL|Waitlist control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
41106349|NCT01289119|DRUG|Alogliptin|Alogliptin tablets
41106350|NCT01289119|DRUG|Placebo to alogliptin|Alogliptin placebo-matching tablets.
41106351|NCT01289119|DRUG|Metformin|Stable metformin dose
41106352|NCT01289119|DRUG|Pioglitazone|Stable pioglitazone dose
41106353|NCT00391833|DRUG|Panax Ginseng|
41133297|NCT03656198|BIOLOGICAL|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).
41133298|NCT03656198|DRUG|Sterile Water Injection|The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
41444315|NCT05770648|DEVICE|Transcatheter Annuloplasty|Under the guidance of ultrasound, the transcatheter tricuspid ring forming system accurately reaches the designated position of the tricuspid valve region through the jugular vein and superior vena cava approach. The expanded tricuspid ring tissue is clammed together with the clamping parts and anchor parts, and the circumference of the tricuspid ring is reduced, thus reducing the area of the opening of the tricuspid valve that cannot be closed originally, and achieving the purpose of minimally invasive treatment of tricuspid regurgitation.
41444316|NCT05770648|OTHER|The guidelines guide medication|The guidelines guide medication
41444317|NCT03262103|BIOLOGICAL|Intratumoral (IT) Poly ICLC 0.5 mg|0.5 mg IT once/week (week 1)
41444318|NCT03262103|BIOLOGICAL|Intratumoral (IT) Poly ICLC 1.0 mg|1.0 mg IT once/week (week 1)
41444319|NCT03262103|BIOLOGICAL|Intramuscular (IM) Poly ICLC|1 mg IM twice weekly (weeks 3-6)
41444320|NCT03262103|PROCEDURE|Radical Prostatectomy|as per standard care
41444321|NCT03725969|DIETARY_SUPPLEMENT|Camel milk|Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions
41106354|NCT03990220|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus yoba 2012|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug."
41106355|NCT06127888|OTHER|Interviews|Semi-structured interviews
41106356|NCT06127888|OTHER|Surveys|Estructured survey
41106357|NCT06148948|DRUG|BI 1584862|BI 1584862
41106358|NCT06148948|DRUG|Placebo|Placebo matching BI 1584862
41106359|NCT01182116|PROCEDURE|J Pouch|Comparing J pouch, side to end coloanal surgery
41106360|NCT04584450|OTHER|Questionnaire|data collection using questionnaire
41106361|NCT00520208|DRUG|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
41106362|NCT05483335|OTHER|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
41106363|NCT06553391|DRUG|The tetralogy of medication regimen|"During the rewarming process, the study group received an injection of 0.15g amiodarone via the extracorporeal circulation oxygenator. After heart re-beating：~1. If the heart rate is ≥70 beats per minute without specific therapy and in sinus rhythm or atrioventricular junctional rhythm, no special treatment is required. If the heart rate \<70 beats/min, intravenous injection of isoproterenol 2 ug may be administered.~2. In cases where there is sinus rhythm or atrioventricular junctional rhythm with a heart rate \<70 beats/min and perfusion pressure \<60mmHg, intravenous injection of ephedrine 10 mg + aminophylline 0.15 g should be given.~3. For patients with atrioventricular junctional rhythm or sinus rhythm and a heart rate \<70 beats/min but perfusion pressure ≥60mmHg, intravenous injections of aminophylline (0.15g) and ephedrine (10 mg) .~4. In cases where there is atrial fibrillation (AF), and the heart rate is ≥70 beats/min without special treatment."
41106364|NCT02881749|RADIATION|Total skin electron beam therapy (TSEBT)|"TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy."
41106365|NCT02881749|DRUG|mechlorethamine gel 0.016%|The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
41106366|NCT00075491|DRUG|fenretinide|Given orally
41106367|NCT00075491|PROCEDURE|therapeutic conventional surgery|Undergo surgery
41106368|NCT00075491|OTHER|pharmacological study|Correlative studies
41106369|NCT00075491|OTHER|laboratory biomarker analysis|Correlative studies
41106370|NCT02796092|DEVICE|Fibered platinum coils|
41106371|NCT02796092|DEVICE|Vascular plugs|
41106372|NCT05172154|DIAGNOSTIC_TEST|GlowTest COVID-19 Antigen Home Test Kit|The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection
41106373|NCT00238212|DRUG|sorafenib tosylate|Given orally
41106374|NCT00238212|OTHER|laboratory biomarker analysis|Correlative studies
41106375|NCT03861741|GENETIC|WES|A peripheral venous blood sample will be processed internally, and externally subjected to WES. Only genetic material from relatives of probands in which a mutation has been identified will be sequenced.
41106376|NCT03861741|DIAGNOSTIC_TEST|MRI|A MRI of the thoracic aorta will be performed in all relatives able to attend the Glenfield Hospital and who have no contra-indications to this imaging modality; pulse-wave velocity will be recorded.
41106377|NCT03861741|DIAGNOSTIC_TEST|TTE|TTE screening will be performed by a trained physiologist. Aortic diameter will be measured from the parasternal long-axis view at the sinuses of Valsalva and at the widest level of the ascending aorta. All measurements will be made in end-diastole.
41106378|NCT03861741|OTHER|Questionnaire|Acceptability questionnaires will be submitted to assess a baseline score of depression/anxiety that will be compared with a follow up value at three months
41106379|NCT03994055|OTHER|Omega-3 fatty acids|Diet will include foods rich in omega-3 fatty acids.
41106380|NCT03994055|OTHER|Antioxidants|Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.
41106381|NCT03994055|OTHER|Soluble fiber|Diet will include foods rich in soluble fiber.
41106382|NCT03994055|OTHER|Probiotics|Diet will include foods rich in probiotics.
41444322|NCT03725969|DIETARY_SUPPLEMENT|Cow milk|Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
41106383|NCT03994055|OTHER|Lactose restriction|Diet will be restricted to 5g lactose/day
41106384|NCT03994055|OTHER|Fiber restriction|Diet will be restricted to 20g fiber/day
41106385|NCT03994055|OTHER|Fat restriction|Diet will be restricted to 20% total energy intake
41270959|NCT05868785|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 am
41444323|NCT00838188|OTHER|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
41444324|NCT02889380|DRUG|No Intervention|This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
41444325|NCT05213286|DIAGNOSTIC_TEST|Application of ZAQ and RAADS-R-DK|Test of the questionnaires in each of the three groups.
41444326|NCT01877317|DEVICE|SelfFit adjusted hearing device|Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
41106386|NCT03522519|BEHAVIORAL|Real world performance of physical activity and arm use|Patients will be assessed by using movement sensors and standard clinical assessments
41106387|NCT01006746|OTHER|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
41106388|NCT05572801|DIAGNOSTIC_TEST|AMR B: HPV positive ctDNA guided imaging in follow-up|Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure
41106389|NCT00042224|PROCEDURE|Electroconvulsive Therapy (ECT)|ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
41106390|NCT00042224|DRUG|Clozapine|Patients with psychotic symptoms will receive clozapine
41106391|NCT04028635|BEHAVIORAL|Cognitive-behavioral therapy plus VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions.
41106392|NCT04028635|BEHAVIORAL|Cognitive behavioral therapy|Usual CBT
41106393|NCT05804604|PROCEDURE|Surgical treatment of proximal femur fracture and blood sample test|Open reduction of femoral neck or pertrochanteric fracture with hemi/total hip arthroplasty or gamma nail. Analysis of serum concentration of: SHBG, CTX - I, CK-MB
41106394|NCT05804604|PROCEDURE|Blood sample test|Analysis of serum concentration of: SHBG, CTX - I, CK-MB
41106395|NCT00596648|DRUG|XL184|Capsules administered orally daily
41106396|NCT00596648|DRUG|erlotinib|Tablets administered orally daily.
41106397|NCT04407325|DEVICE|electronic nose device|electronic nose device will be tested as a triage instrument for tuberculosis in a high risk population
41106398|NCT04407325|DEVICE|dig chest Xray with automated readings|software for tuberculosis detection on digital Chest Xray providing a probability score from 0-100
41106399|NCT00203580|DRUG|Tinzaparin sodium|
41106400|NCT03451435|DRUG|N acetyl cysteine|N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
41106401|NCT01685606|BIOLOGICAL|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
41106402|NCT04727424|DIETARY_SUPPLEMENT|Spirulin Platensis|Two tablets every 12 hours since randomization through day 09 following randomization
41106403|NCT04727424|DRUG|Budesonide Powder|"One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 09."
41106404|NCT04727424|DRUG|Fluoxetine 20 MG|"Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07."
41106405|NCT04727424|DRUG|Placebo|"Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)~PLUS~Placebo Inhalation Therapy:~One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm)~OR~Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)"
41106406|NCT05045703|DIETARY_SUPPLEMENT|Vitamin A palmitate|Vitamin A palmitate, 15,000 IU daily for 4 months
41106407|NCT00552097|DRUG|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
41106408|NCT00552097|DRUG|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
41270960|NCT01627145|DRUG|Solifenacin|Solifenacin 5 mg qd,
41444327|NCT05086835|OTHER|Working Memory Task|A smartphone-based visual-spatial working memory task that will be optimized in the Stage 1A phase of this study.
41444328|NCT05086835|OTHER|Visual Search Task|A smartphone-based visual search task that will be optimized in the Stage 1A phase of this study.
41444329|NCT03604198|DRUG|relacorilant|CORT125134 is supplied as capsules for oral dosing.
41444330|NCT01116739|DEVICE|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
41444331|NCT01116739|BEHAVIORAL|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
41106409|NCT05076318|OTHER|Aminoacid, alanine-infusion|During 3 hours, patient will receive alanine-infusion, while amino-acid and urea will be monitored by blood samples.
41106410|NCT00202969|DRUG|S-1|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
41106411|NCT00202969|DRUG|S-1 plus CDDP|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
41106412|NCT00202969|DRUG|5-FU plus CDDP|5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
41106413|NCT01081340|BEHAVIORAL|Social network building intervention|Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
41106414|NCT01081340|BEHAVIORAL|Home visit|Three home visits during third trimester and three during postpartum period until 6 months postpartum
41106415|NCT00964366|DRUG|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
41106416|NCT00964366|DRUG|Dapsone gel|Twice-daily applications of dapsone gel
40925330|NCT03657303|DEVICE|Magnetic resonance imaging (MRI)|Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
41106417|NCT04340284|BIOLOGICAL|autologous adipose tissue derived stromal vascular fraction (SVF)|"liquid and solid portion of lipo-aspirate after non enzymatic processing yields SVF.~This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ ,~, the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC, 20%), plus a wide number of CD34+ hematopoietic cells (40%)."
41106418|NCT06107738|DRUG|Iberdomide|Iberdomide 1.0mg daily for days 1-21 of a 28-day cycle, an increase to 1.3 mg daily on Day 1-21 of a 28-day cycle is allowed at cycle 4 or higher if the 1.0 mg dose was well tolerated.
41106419|NCT06107738|DRUG|Daratumumab/rHuPH20 Co-formulation|"Daratumumab/rHuPH20 will be dosed as follows:~* Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22 (28-day cycle; cycles 1-2)~* Daratumumab/rHuPH20 1800 mg SC days 1, 15 (28-day cycle; cycles 3-6)~* Daratumumab/rHuPH20 1800 mg SC day 1 (28-day cycle; cycles 7-26)"
41106420|NCT05907551|OTHER|Questionnaires|25-items questionnaire
41106421|NCT04752735|OTHER|endovascular treatment|all enrolled patients must receive endovascular treatment.
41106422|NCT05506943|DRUG|CTX-009|IV infusion on day 1 and 14 of every 28 day cycle
41106423|NCT05506943|DRUG|Paclitaxel|IV infusion on day 1, 8, and 15 of every 28 day cycle
41106424|NCT01087684|PROCEDURE|Argon laser trabeculoplasty|Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
41106425|NCT01087684|PROCEDURE|Selective laser trabeculoplasty|Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
40925331|NCT05790161|DRUG|Caffeine|2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)
41106426|NCT01572337|PROCEDURE|Non-invasive ventilation|Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
41106427|NCT01572337|OTHER|Standard care|
41106428|NCT06084117|OTHER|HFNO|Respiratory support with HFNO (as opposed to NIV, as per standard of care)
41106429|NCT06084117|OTHER|NIV|Respiratory support with Non-invasive ventilation, standard of care
41106430|NCT02531568|DRUG|Warfarin|
41106431|NCT02531568|DRUG|MT-3995|
41106432|NCT05664100|DRUG|FX-345|Single intratympanic injection of FX-345
41106433|NCT05664100|DRUG|Placebo|Single intratympanic injection of placebo
41106434|NCT05969236|DRUG|MDI-1228_mesylate Ophthalmic Solution|"MDI-1228_mesylate Ophthalmic Solution includes 2 strengths:~* 0.1% (0.4 mL \[0.4 mg\] free base)~* 0.3% (0.4 mL \[1.2 mg\] free base)"
41444332|NCT01116739|OTHER|Dental services delivered by the Indian Health Service.|
40925332|NCT05036473|DRUG|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
40925333|NCT05036473|DRUG|Placebo|placebo tablets-matching the active groups.
40925334|NCT01643031|DRUG|Ticagrelor|Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
41106435|NCT05969236|DRUG|Placebo|The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228_mesylate is absent.
41106436|NCT02313090|OTHER|Welltang|The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
41106437|NCT00943605|DEVICE|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
41444333|NCT05218668|DRUG|Fasudil (WP-0512)|Oral fasudil up to 180 mg/day
41444334|NCT05218668|DRUG|Fasudil (WP-0512)|Oral fasudil up to 300 mg/day
41444335|NCT05750849|PROCEDURE|BLOOD COLLECTION FOR P4 DETERMINATION|Serum progesterone levels on the pregnancy test day
41444336|NCT03059979|DRUG|Methylprednisolone|methylprednisolone 1000 mg dissolved in 100 cc of NaCl 0.9%, by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
41444337|NCT03059979|OTHER|sodium chloride|100 cc of NaCl 0,9% , administered by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
41444338|NCT06152081|DEVICE|LumiCare rinse|The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. Lumicare rinse will be applied onto the test areas for 30 seconds and the excess removed using a saliva ejector. The sites will then be rinsed with plain water for 10 seconds and excess will be removed using high volume suction. A blue curing light will then be held 1-2 inches from the test surfaces while the examiner assesses the surfaces for the presence or absence of fluorescent illumination.
41444339|NCT06152081|DEVICE|QLF Inspektor Pro Imaging|The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. The QLF device will be positioned over the tooth surface to be tested and an image will be taken. The images will be stored automatically and assessed by the examiners for the presence of green fluorescence using the QA2 program (Version 1.25, Inspektor Research systems BV, Amsterdam, The Netherlands) . The trend in green fluorescence will also be calculated using this software algorithm.
41444340|NCT01049334|DRUG|Placebo|Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
41444341|NCT01049334|DRUG|Flurbiprofen|Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
41444342|NCT03276559|BEHAVIORAL|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
41444343|NCT03276559|OTHER|Enhanced Usual Care|Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
41444344|NCT06559345|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
41444345|NCT06559345|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
41444346|NCT06559345|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
41106438|NCT00943605|DEVICE|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
41444347|NCT01966484|DRUG|Succinylcholine|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
41444348|NCT01966484|DRUG|Mivacurium|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
41106439|NCT01899872|BEHAVIORAL|Resistance exercise session|Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
41106440|NCT01899872|BEHAVIORAL|Aerobic exercise session|Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
41444349|NCT01319162|OTHER|Weight reduction regimen|The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (\<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
41444350|NCT03781622|DEVICE|WOLF Thrombectomy Device|Mechanical thrombectomy for the neurovasculature
41444351|NCT01528696|DEVICE|Silverlon|"Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum."
41106441|NCT06358066|DRUG|self assembling peptide p11-4 with fluoride|"Self-assembling peptide (P11-4) fluoride plus will be applied according to the manufacturer's instructions by pushing the two cylinders together and will left for 5 min till the tooth surface appears dry to insure its diffusion~The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment"
41106442|NCT06358066|DRUG|5% sodium fluoride varnish|Fluoride varnish will be applied under manufacturer instructions by applying thin layer of varnish with a brush in strokes The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment
41106443|NCT03657017|DIAGNOSTIC_TEST|PET/MR|Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.
41106444|NCT03448757|OTHER|measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure|"This study aims to create a method for non-invasive diagnosis of biofeedback effect exposure to LEEF modulated to specific frequencies in individuals exposed to hepatocellular carcinoma -specific frequencies in increasing sequential manner, frequency to frequency in patients with advanced hepatocellular carcinoma and healthy individuals.~Patients with advanced hepatocellular carcinoma will be exposed to specific LEEF-modulated frequencies (3 to 10 Hz difference) to identify the optimal frequency associated with greater response to the biofeedback effect in patients with advanced hepatocellular carcinoma."
41444352|NCT01528696|DEVICE|Standard Dressing|Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
41444353|NCT04300946|DEVICE|TMS targeted on the cerebellum|Impact on EEG performance (preparation wave in temporal tasks) of cerebellar stimulation by MSD in healthy subjects. The contrast between the post-stimulation effects of verrum stimulation and placebo stimulation will indicate the magnitude of the effect and will allow us to optimize the type of protocol that may be useful in schizophrenia.
41444354|NCT05458583|PROCEDURE|Baseline periodontal measurements (T0)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the bonding session.
41444355|NCT05458583|PROCEDURE|Periodontal measurements (T1)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 6 months after bonding.
41106445|NCT05237219|PROCEDURE|Passive heating|Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
41106446|NCT05237219|PROCEDURE|Thermoneutral|Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
41106447|NCT05739929|DRUG|Colchicine 0.5 MG Oral Tablet|0.5 mg colchicine tablets twice daily.
41106448|NCT05739929|DRUG|Placebo|Placebo tablets twice daily
41106449|NCT00530842|DRUG|Tiotropium plus Salmeterol|
41106450|NCT00530842|DRUG|Fluticasone/Salmeterol|
41106451|NCT00057850|DRUG|cisplatin|
41106452|NCT00057850|DRUG|ixabepilone|
41444356|NCT05458583|PROCEDURE|Periodontal measurements (T2)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 12 months after bonding.
41444357|NCT05458583|PROCEDURE|Retainer failure rates|A retainer with at least one composite pad detachment was considered to be a failure during 1-year follow-up.
41444358|NCT04819243|DRUG|Pabociclib, Endocrine, Talazoparib, Atezolizumab|"* Palbociclib 125mg~* AI~* GnRH agonist~* Talazoparib~* Atezolizumab"
41444359|NCT04819243|DRUG|Pabociclib, Endocrine, Talazoparib,|"* Palbociclib 125mg~* AI~* GnRH agonist~* Talazoparib"
41444360|NCT06377410|DRUG|Syrup Prospan|Participant with stable COPD who received Syrup prospan for 1 month
41444361|NCT06377410|DRUG|N-Acetylcysteine|Participant with stable COPD who received N-Acetylcysteine for 1 month
41444362|NCT06560801|DRUG|Dapagliflozin 10mg Tab|Randomization will take place at visit 1 to either the group receiving standard care and dapagliflozin or standard care only.
41444363|NCT01438593|PROCEDURE|Intercerebral implantation of allogenic CD34+ stem cell|Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
41444364|NCT01441297|DRUG|BIBF 1120|BIBF 1120 200mg bid, PO, daily until PD
41444365|NCT01851772|DEVICE|Treatment with Electronic Brachytherapy|
41444366|NCT05849662|DRUG|Trametinib|"PO or NG QD Days 1-28~For patients age \< 6 years: 0.032 mg/kg/day at max dose = 2mg/day~For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day"
41444367|NCT05849662|DRUG|Azacitidine|"IV over 30 minutes Days 1-5~Age \< 1 year or weight \<10kg:~2.5 mg/kg/day~Age ≥ 1 year and weight ≥ 10kg:~75 mg/m2/day"
41106453|NCT02939495|DRUG|Dapoxetine/Sildenafil 30/50 mg film coated tablet|1 tablet before sexual intercourse
41106457|NCT00018525|PROCEDURE|Lung Volume Reduction Surgery|
41106458|NCT01989910|DRUG|Raltegravir|Raltegravir 400mg oral twice daily
41106459|NCT01989910|DRUG|Efavirenz|Efavirenz 600mg oral at bedtime
41106460|NCT05451199|DRUG|ICP-488|ICP-488 will be administered as tablet
41444368|NCT05849662|DRUG|Fludarabine|"IV over 30 minutes Days 6-10~30 mg/m2/day (1mg/kg if \<12 kg)"
41106461|NCT05451199|DRUG|Placebo|Matching placebo will be administered as tablet
41106462|NCT04990219|DRUG|Lu AG06466|Lu AG06466 - capsule
41106463|NCT04990219|DRUG|Placebo|Placebo - capsule
41106464|NCT04588480|BIOLOGICAL|BNT162b2|BNT162b2 (intramuscular injection)
41106465|NCT04588480|OTHER|Placebo|Placebo (intramuscular injection)
41106466|NCT04009356|PROCEDURE|bariatric surgical procedures|gastric bypass, sleeve, banding,biliopancreatic diversion
41106467|NCT04842669|OTHER|low level laser therapy|Endo-laser 422 with interchangeable laser probes will be used for the purpose. It is a 2-channel unit and is software operated. For treatment of small surfaces with mono laser there are diodes of 25, 100 and 500 milliWatt.Frequency will be adjusted to 500 Hz, dose 0.1/cm2 with time duration of 1-5 minutes.
41444369|NCT05849662|DRUG|Cytarabine|"IV over 3 hours Days 6-10~2000 mg/m2/day (67mg/kg if \<12 kg)"
41444370|NCT06563479|DIAGNOSTIC_TEST|FMISO-PET Scan|Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days\* after start of radiation is allowed.
41444371|NCT06563479|COMBINATION_PRODUCT|Chemoradiation|30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)
41444372|NCT06563479|COMBINATION_PRODUCT|Chemoradiation|70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)
41444373|NCT06563479|OTHER|Assessments|EQ-5D-5L (5 questions); 2. MDADI-HN (total of 20 questions); 3. COST-FACIT (total of 12 questions).
41444374|NCT01417663|DRUG|Alt-711|Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
41444375|NCT01417663|BEHAVIORAL|Physical exercise training|Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
41444376|NCT04274374|DIETARY_SUPPLEMENT|Gluten-Free Diet|Dietary supplement without gluten
41444377|NCT04274374|DIETARY_SUPPLEMENT|Gluten Diet|Dietary supplement with gluten
41444378|NCT03446768|OTHER|Peer support|Access to educational and informational support by a trained peer coach
41106468|NCT04842669|OTHER|Conservative treatment|(Topical ibuprofen gel) for muscle soreness will be provided
41106469|NCT00018226|BEHAVIORAL|Case Management|
41106470|NCT01830010|DRUG|Study Part 1: KRP203|All subjects will receive KRP203 for 111 days
41444379|NCT03446768|OTHER|Online platform|An online platform that provides educational, informational and access to several therapeutic device metrics
41444380|NCT03446768|OTHER|Respiratory Therapist support|Limited medical support provided by trained Respiratory Therapists.
41444381|NCT00835432|DEVICE|Ossix|Test group
41444382|NCT00835432|DEVICE|Biogide|controls
41444383|NCT04131842|OTHER|External focus of attention visual feedback|Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.
41444384|NCT04131842|OTHER|External focus of attention auditory feedback|Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.
41444385|NCT04131842|OTHER|Internal focus of attention video feedback|Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.
41444386|NCT04131842|OTHER|No feedback|Patients will receive no feedback during the impairment-based rehabilitation program.
41444387|NCT05295550|OTHER|Realibility|measurement of the thoracic kyphosis with flexicurve and Smartphone inclinometer app
41106471|NCT01830010|DRUG|Study Part 2: KRP203 lower dose|
41106472|NCT01830010|DRUG|Study Part 2: KRP203 higher dose|
41106473|NCT06028451|OTHER|Record the information data|Record the information data
41106474|NCT00597519|DRUG|Fludarabine, Cyclophosphamide|"Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery."
41106475|NCT00597519|PROCEDURE|Transplantation|The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
41106476|NCT01564199|DRUG|salmeterol / fluticasone propionate|100/1000 μg oral capsule
41106477|NCT04279171|DIAGNOSTIC_TEST|Greyson NDE scale|Questionnaire to detect occurence of NDE. A NDE is identified if score \> or = 7/32
41106478|NCT04279171|DIAGNOSTIC_TEST|DES dissociation scale|Screening for dissociative symptoms
41444388|NCT03785301|DEVICE|Freestyle Libre Flash Glucose Monitoring|Freestyle Libre Flash Glucose Monitoring will be used in diabetic patients once a month for therr months to monitor glucose level. Patients could scan the sensor to get the glucose level at any time as they want. They could alter thier diet and exercise according to the glucose levels. Patients will be required to keep track of food and exercise during wearing FGM sensor. Physicians would adjust patients' medication according their glucose profile provided by FGM, A1c, and diet and exercise every month.
41444389|NCT00840476|DRUG|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fasting
41444390|NCT00840476|DRUG|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fasting
41444391|NCT02339558|OTHER|Laboratory Biomarker Analysis|Correlative studies
41444392|NCT02339558|BIOLOGICAL|Nivolumab|Given IV
41444393|NCT06056414|OTHER|Energy Resonance by Cutaneous Stimulation|Energy Resonance by Cutaneous Stimulation session
41444394|NCT04673721|DIETARY_SUPPLEMENT|Fortified eggs|Average 12 eggs consumed per week
41444395|NCT04673721|BEHAVIORAL|Intermittent fasting|16-hour fast and then an 8-hour nutritional window with aim for energy needs to be consumed during an 8 hour eating window (e.g., 11 am - 7 pm) with fasting for 16 hours (e.g., 7 pm - 11 am the next day).
41444396|NCT04673721|DIETARY_SUPPLEMENT|Non-egg supplemented|2 or less eggs consumed per week
41444397|NCT04673721|BEHAVIORAL|Usual care diet|Consistency with current diet without consideration of intermittent fasting
41444398|NCT03506672|OTHER|Approach based on the meanings of vocal behaviours|Systematic problem-solving approach involving reflecting, deciding, planning and acting together (family and formal caregivers to reduce vocal behaviours and to increase everyone's well-being.
41444399|NCT03506672|OTHER|Usual practices|Usual practices of formal caregivers regarding vocal behaviours
41106479|NCT04279171|DIAGNOSTIC_TEST|WHOQOL-SRPB|WHOQOL-SRPB is an instrument developed to evaluate how spirituality, religiosity and personal beliefs (SRPB) are related to quality of life in health and health care.
41106480|NCT04279171|DIAGNOSTIC_TEST|cerebral magnetic resonance imaging|Types of images to be acquired: T1, T2, Diffusion Weighted Imaging-DWI, Fluid Attenuated Inversion Recovery and spectroscopy
41106481|NCT04672590|OTHER|Primary exposure is hypoxia (no intervention)|The primary exposure, hypoxia, will be defined as severe, non-severe or none for each participant, based on pre-defined criteria.
41106482|NCT00678795|DRUG|Sativex®|"Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours"
41106483|NCT00678795|DRUG|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
41106484|NCT03958500|PROCEDURE|Indocyanine green fluorescent angiography intraluminally and intraperitoneally|The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis
41106485|NCT00192400|BIOLOGICAL|CAIV-T|
41106486|NCT05404893|DIAGNOSTIC_TEST|Fecal calprotectin measurement|Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.
41106487|NCT01802866|DRUG|ACU-4429|Take orally once daily for 24 months
41444400|NCT06560697|RADIATION|SABR VS Intracavitary 3D Brachytherapy|Arm 1 will be the experimental arm and will consist of patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy. Arm 2 will be the control arm that will consist of patients with CC clinical stages IB3-IIIC1 and will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.
41106488|NCT01802866|DRUG|Placebo|Take orally once daily for 24 months
41106489|NCT05214287|DRUG|Hypoxic Gas Mixture|Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
41106490|NCT02707913|DRUG|BF-Amlodipine Tablet 10mg|BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
41106491|NCT02707913|DRUG|Norvasc Tablet 10mg|Norvasc Tablet 10mg will be used as a comparator drug for the BE study
41106492|NCT04645394|DIETARY_SUPPLEMENT|Aronia melanocarpa|Administered once (acute study)
41106493|NCT04645394|DIETARY_SUPPLEMENT|Fermented Aronia Melanocarpa high dose|Administered once (acute study)
41106494|NCT04645394|DIETARY_SUPPLEMENT|Fermented Aronia Melanocarpa low dose|Administered once (acute study)
41106495|NCT04645394|DIETARY_SUPPLEMENT|Placebo|Administered once (acute study)
41106496|NCT05329454|DRUG|Ibuprofen Tablets|"Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses.~Treatment B:~One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing)."
41106497|NCT00215345|DRUG|Taxotere|
41106498|NCT00215345|DRUG|Celecoxib|
41106499|NCT06348849|DEVICE|Low-level laser therapy|Wavelength 980nm (SmartM, Lasotronix, Poland)
41106500|NCT06348849|DRUG|Nanosilver fluoride|Optimized synthesis of Nanosilver Fluoride
41106501|NCT04551781|DRUG|20 Mg Prednisone for 14 days|20 Mg Prednisone for 14 days
41106502|NCT04551781|DRUG|control|symptomatic ttt
41106503|NCT00138138|DRUG|Ritalin|
41106504|NCT02060019|DRUG|administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.|
41106505|NCT01727128|DRUG|BKM120|
41106506|NCT05010304|DRUG|Amoxicillin|Two-dose amoxicillin challenge
41106507|NCT04928053|GENETIC|ocytocine dosage and genetic analyse|All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment
41106508|NCT02852863|OTHER|Gum|Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
41106509|NCT02248025|OTHER|Observational study: No special intervention will be made.|No special intervention will be made, only data will be collected before, and after a passive leg raising and a fluid challenge decided and performed by the attending physician.
41106510|NCT00415389|BEHAVIORAL|interactive educational program|2-session interactive stroke educational program
41106511|NCT00415389|BEHAVIORAL|usual medical care|standard educational materials and usual care
41106512|NCT00092898|DRUG|MK0653, ezetimibe|
41106513|NCT00092898|DRUG|Comparator: placebo|
41106514|NCT03915769|DRUG|Ozanimod|Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5
41106515|NCT03915769|OTHER|Placebo|The placebo is a capsule that contains no study medication but looks exactly like the study medication capsule.
41106516|NCT00002819|DRUG|carboplatin|
41106517|NCT00002819|DRUG|cyclophosphamide|
41106518|NCT00002819|DRUG|mitoxantrone hydrochloride|
41106519|NCT00002819|DRUG|paclitaxel|
41106520|NCT00002819|PROCEDURE|autologous bone marrow transplantation|
41106521|NCT00002819|PROCEDURE|peripheral blood stem cell transplantation|
41106522|NCT00130819|BEHAVIORAL|Clinic-based substance abuse treatment with buprenorphine|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
41106523|NCT00130819|BEHAVIORAL|Case management and referred substance abuse treatment|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
41106524|NCT02217644|DRUG|BI 653048 H3PO4 solution|
41106525|NCT02217644|DRUG|BI 653048 H3PO4 low dose capsule|
41106526|NCT02217644|DRUG|BI 653048 H3PO4 high dose capsule|
41106527|NCT02217644|DRUG|Placebo|
41106528|NCT03823911|DRUG|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|All approved direct-acting antivirals for hepatitis C will be used as the intervention.
41106529|NCT03823911|PROCEDURE|Cardiac MRI|Cardiac MRI to assess for myocardial function and fibrosis
41106530|NCT04347499|OTHER|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
41106531|NCT03185819|DRUG|Intranasal Placebo|Participants will receive placebo as intranasal dose to match intranasal esketamine.
41106532|NCT03185819|DRUG|Midazolam Placebo Solution|Participants will receive placebo as oral dose to match midazolam drug.
41106533|NCT03185819|DRUG|Midazolam|Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
41106534|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 28 mg as intranasal solution.
41106535|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 56 mg as intranasal solution.
41106536|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 84 mg as intranasal solution.
41106537|NCT03265210|BEHAVIORAL|RELIEF|A 9-week behavioral intervention for primary care designed to reduce depression and pain-related disability.
41106538|NCT03963128|DIETARY_SUPPLEMENT|Supplementation Vitamin D3|Supplementation of vitamin D3 at a dose of 50.000 IU administered every two months (equivalent of 800 IU per day)
41106539|NCT03963128|DIETARY_SUPPLEMENT|Placebo|Placebo administred every two months
41106540|NCT01018524|PROCEDURE|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
41106541|NCT01094041|OTHER|Gluten free diet|A 4-week gluten free diet provided
41106542|NCT01094041|OTHER|Gluten rich diet|A 4-week gluten rich diet is provided
41106543|NCT05907720|BEHAVIORAL|Human-centered design prototype solutions for vulnerable pregnant women|The intervention package will include various social and behavior change programs derived from a human-centered design approach. The intervention will be tailored to vulnerable pregnant women's needs and contexts. It may include but is not limited to health communication campaigns, including radio and print media.
41106544|NCT02673788|OTHER|observation without intervention in this follow up study|observation without intervention in this follow up study
41106545|NCT03417492|DRUG|Sildenafil Citrate|Three 20 mg capsules for the single dose studies. For the 5-week treatment phase, subjects will be assigned to a titration of doses for the 5 week duration of the study. Subjects will be instructed to take 20mg twice per day for 3 days, then 40mg twice per day for 3 days, and then 80mg twice per day for 4 weeks.
41444401|NCT04215705|PROCEDURE|Quadratus block versus peritubal local infiltration|Quadratus lumborum block III versus peritubal local infiltration in patients undergoing Percutaneous Nephrolithotomy operation
41106546|NCT03068468|DRUG|BIIB092|BIIB092 intravenous infusion on specified days
41106547|NCT03068468|DRUG|Placebo|Placebo intravenous infusion on specified days
41106548|NCT02179281|DEVICE|Medtronic MiniMed™ 640G system|The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
41106549|NCT03302741|DRUG|Botulinum neurotoxin (BTX)|Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
41106550|NCT03302741|OTHER|Physical Therapy|Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
41106551|NCT03302741|DEVICE|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.
41106552|NCT03302741|DEVICE|3-dimensional innervation zone (3DIZ) guided injection|Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
41106553|NCT01145248|DEVICE|double-balloon enteroscopy forceps biopsy|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
41106554|NCT01145248|DEVICE|Transpapillary brush cytology|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
41106555|NCT05907850|DRUG|Riboflavin|Commercially available source of riboflavin capsules
41106556|NCT05907850|DRUG|Placebo|Placebo capsule compounded to be similar in appearance to the active intervention
41106557|NCT05784688|DRUG|TU2218 + Pembrolizumab|TU2218: Orally administered Pembrolizumab: Intravenously administered
41106558|NCT00227032|DRUG|erlotinib hydrochloride|"300 mg, per day for subjects taking EIAEDs~150 mg, per day for those NOT taking EIAEDs"
41106559|NCT05163418|DEVICE|Foot orthosis for flat feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
41106560|NCT05163418|DEVICE|Foot orthoses for high arches feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
41106561|NCT01949740|OTHER|questionnaire administration|Ancillary studies
41106562|NCT01949740|PROCEDURE|quality-of-life assessment|Ancillary studies
41106563|NCT05033509|OTHER|supervision the Kidney fonction on ECMO|patients who benefited from ECMO, and presented an acute kidney injury afterwards
41106564|NCT00796068|DRUG|Cyclosporine|Given IV or PO
41106565|NCT00796068|DRUG|Fludarabine Phosphate|Given IV
41106566|NCT00796068|OTHER|Laboratory Biomarker Analysis|Correlative studies
41106567|NCT00796068|DRUG|Mycophenolate Mofetil|Given IV
41106568|NCT00796068|RADIATION|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
41106569|NCT00796068|DRUG|Treosulfan|Given IV
41444402|NCT04631393|DRUG|Propofol Alfentanil|Propofol and Alfentanil are self-administered by the participant.
41444403|NCT00989950|DRUG|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
41106570|NCT00796068|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
41106571|NCT05315180|DRUG|BPI-421286|Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation
41106572|NCT03439904|OTHER|Pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
41106573|NCT00640029|PROCEDURE|Arthrodesis|"* posterior,~* anterior,~* circumference approach"
41106574|NCT00640029|DEVICE|Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)|"* SYNTHES : PRODISC-C® , PRODISC-L®~* LDR : Mobi-C®, Mobidisc®~* MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~* SCIENT'X : DISCOCERV®"
41106575|NCT00296907|BEHAVIORAL|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
41106576|NCT00590603|DRUG|Arsenic Trioxide, Ascorbic Acid and Bortezomib|"Phase I/Cohort I~Loading:~1. Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~2. Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~1. ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~2. Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~3. Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I."
41106577|NCT06552676|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomy is a widely used technique in intensive care. It involves creating a passage between the tracheal lumen and the outside, through which a cannula is placed.
41106578|NCT02572219|DIETARY_SUPPLEMENT|Nutraceutical compound|
41444404|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
41444405|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
41444406|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
41444407|NCT03804749|DRUG|suramin sodium|The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
41444408|NCT03804749|OTHER|placebo|Placebo is 0.9% sodium chloride injection.
41444409|NCT06407700|PROCEDURE|Brugger's exercise.|Participant was in a high sitting position. An elastic resistance band was be wrapped on each hand of the participant leaving the palm open and instructed to abduct and extend of thumb along with fingers, followed by wrist extension and forearm supination, the participant were instructed to perform scapular retraction with chin tucked in ,shoulder external rotation, elbow extension, shoulder abduction, and extension. Intervention was started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time was 30 seconds, 4 sets 12 times repetitions.
41444410|NCT06407700|PROCEDURE|Kendall Exercise.|Kendall exercises with the frequency 5 sets of consisting of 12 repetitions of postures, each taking 30 seconds,3 times a week for total of 6 weeks.
41106579|NCT02572219|DIETARY_SUPPLEMENT|Placebo|
41106580|NCT03806751|DRUG|[O-15]Water|All study participants with undergo brain imaging with \[O-15\]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
41106581|NCT03806751|DRUG|Acetazolamide|The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
41106582|NCT02675491|DRUG|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
41133299|NCT04942184|BEHAVIORAL|Memory strategies in Arm 1|Memory strategies will consist of daily at-home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. At the start of week 1 participants will be taught the memory strategies to use while completing the daily memory tasks. In week 1 and 2, subjects will be reminded daily to use the memory strategies. At the start of week 3, subjects will be advised to use the memory strategies however they will not be given daily reminders.
41270961|NCT06251011|BEHAVIORAL|Exercise training|"1. Physical therapy training via video call~2. An advise and a leaflet for cardiopulmonary rehabilitation"
41106583|NCT03319017|PROCEDURE|Multiple-trauma patients|"The blood samples of the patients who agreed on this research are obtained in order to check their inflammatory response factor, and then their medical records are checked to find their initial ABGA result, lactate, C-reactive protein(CRP) known as initial inflammatory response, and procalcitonin.~A patient's whole blood is collected in the tube with ethylene diaminetetracetic acid (EDTA) treatment. A modified method of Boyum's technique is applied so as to separate polymorphonuclear neutrophils. The separated polymorphonuclear neutrophils is collected so as to check apoptosis. And then, in the separated plasma, interleukin(IL)-6 and tumor necrosis factor(TNF)-α are measured, and its correlation with oxygen saturation will be analyzed."
41106584|NCT05255718|DIETARY_SUPPLEMENT|Aronia juice|Once daily dose of 100 mL of aronia juice
41106585|NCT05255718|OTHER|Placebo|Once daily dose of 100 mL of placebo juice containing no polyphenols and matched to experimental Aronia juice in color, taste, and macronutrient content
41106586|NCT01209546|OTHER|control group|In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
41106587|NCT01209546|OTHER|Flutter group|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).
41106588|NCT01209546|OTHER|PEP group|Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).
41106589|NCT01209546|OTHER|Group Sham|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
41106590|NCT03131206|DRUG|Alectinib|"* Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days."
41106591|NCT01986686|PROCEDURE|Colon resection|Elective robotic/laparoscopic/open colon resection for diverticular disease.
41444411|NCT06055764|DEVICE|PET/CT|"Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room.~Procedure:~All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital.~PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images."
41444412|NCT01527006|DRUG|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
41444413|NCT06441591|DRUG|Vinpocetine|Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel
41444414|NCT06441591|DRUG|Standard Therapy|Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
41106592|NCT03197337|PROCEDURE|Pressure-test|Pressure will be applied to the posterior fornix using a speculum.
41106593|NCT02773160|OTHER|Sensor-based postural feedback|Motion tracking sensors will provide feedback to subjects during the learning phase of a motor control task
41106594|NCT02773160|OTHER|Mirror feedback|Subjects will receive feedback from a mirror during the learning phase of a motor control task
41106595|NCT02773160|OTHER|Control group|Subjects will receive no feedback during the learning phase of a motor control task
41106596|NCT00921830|DRUG|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
41106597|NCT01639638|DRUG|PROAPOPTOTIC PEPTIDE CIGB 300|CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
41106598|NCT05831007|GENETIC|LX102-C01 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX102-C01 at Day 0 in the trial.
41106599|NCT03991481|BIOLOGICAL|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
41106600|NCT03991481|BIOLOGICAL|Liquid-stored platelets|Liquid-stored platelets as per standard practice
41106601|NCT04612894|DRUG|Camrelizumab and Apatinib|All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
41106602|NCT04612894|PROCEDURE|surgery|Perform surgery if operable after neoadjuvant therapy
41106603|NCT04612894|PROCEDURE|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
41106604|NCT01212757|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
41106605|NCT01212757|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
41106606|NCT01212757|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
41106607|NCT01212757|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
41106608|NCT04155151|OTHER|6 minute walk test|A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
41270962|NCT03869814|OTHER|Blood Draw|Blood Draw
41444415|NCT06441591|OTHER|Placebo|Starch-filled capsules, matching those of the intervention
41444416|NCT06562452|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|fter the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. Digital model were obtained at five time points: before tooth extraction (T0) and in the fourth week (T1), eighth week (T2), twelfth week (T3), sixteenth week (T4) from the beginning of distalization.
41106609|NCT00756743|DRUG|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
41106610|NCT00756743|DRUG|Placebo|Placebo capsules q12 hours for 10 days
41106611|NCT02824159|OTHER|Blood samples for pharmacokinetics exploration|6 blood sample at regular intervals
41106612|NCT02824159|OTHER|Imagery|Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
41106613|NCT02824159|OTHER|Quality of life scale|Quality of life will be evaluated with questionaries 5 times during the study
41106614|NCT02824159|OTHER|Detection of adverse events|The detection will be assessed using the AMA (assistance des malades ambulatoires) system
41106615|NCT02824159|GENETIC|Saliva samples|Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
41444417|NCT00418145|DRUG|megadose oral methylprednisolone|1400 mg qd/5 days
41444418|NCT00418145|DRUG|IV methylprednisolone|1000 mg/qd/5 days
41444419|NCT06103058|OTHER|Cross sectional|Cross sectional
41444420|NCT06410144|BEHAVIORAL|CKD-EDU|Subjects in the intervention group will receive 1) a video and paper decision aid , and 2) coaching from a palliative care clinician. The visits will be aimed to support patients with kidney therapy decision making.
41444421|NCT06410144|BEHAVIORAL|Usual Care|Subjects in the Control Group will receive the usual care from their nephrologist and a dialysis educator.
41444422|NCT05401734|DEVICE|Observation and follow up measurement|"The measured variables include:~Questionnaires~* Health related quality of life (Health Related Quality of Life Questionnaire)~* Physical activity level (Physical Activity Scale for Persons with Impairments and Disabilities)~* Walking ability (Walking Index for Spinal Cord Injury)~* Independence in activities of daily living (SCIM III Questionnaire)~* Pain (International SCI Pain Basic Data Set)~* Resilience (Resilience Scale)~* Bowel and bladder function (Neurogenic Bowel Dysfunction score, International Consultation on Incontinence Modular Questionnaire - Lower Urinary Tract Symptoms)~Measurements:~* Muscular strength and joint ROM (Manual Muscle Testing)~* Spasticity (Modified Ashworth Scale)~* Walking parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed)~* Cardiovascular response (blood pressure, heart frequency, blood lactate concentration and Borg RPE score)"
41444423|NCT01798264|DRUG|ITCA 650 (exenatide in DUROS)|
41444424|NCT02624297|OTHER|Aerobic exercise training|The patients will be submitted to four months of aerobic exercise training, three time a week.
41444425|NCT04277403|RADIATION|Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.
41444426|NCT04277403|RADIATION|Single session or hypofractionated stereotactic radiosurgery|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.
41444427|NCT03003091|OTHER|Needs-based patient education|
41444428|NCT03003091|OTHER|Traditional patient education|
41444429|NCT00604162|DEVICE|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
41444430|NCT00604162|PROCEDURE|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
41444431|NCT05452785|DRUG|DFD-29 (Minocycline) Fasting|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
41106616|NCT02824159|GENETIC|Blood sample|A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
41106617|NCT02824159|OTHER|Biological statement|"The following parameters will be assessed :~* Complete blood count~* Hemoglobin~* Hepatic enzymes~* Creatinine clearance~* Lactate dehydrogenase rate~* Total bilirubin rate~* Cluster of differentiation 4 T lymphocytes rate~* Total gamma-globulins rate"
41106618|NCT02824159|OTHER|Clinical examination|"The clinical examination are composed by :~* Weigh, Height and body mass index measurement~* Clinical state of patient during examination~* Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~* Presence of B symptomatology~* Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
41106619|NCT00786448|DRUG|Darifenacin, Emselex (BAY79-4998)|Patients from routine practice
41106620|NCT03584646|DEVICE|Nokia GO Wearable StepTracker|All participants will be provided with a Nokia GO step tracker to monitor daily step counts. The device is not subject to FDA regulation.
41106621|NCT03584646|OTHER|Medication Reminder|Medication reminders are sent to participants in Arm 2 on a daily basis.
41106622|NCT03584646|OTHER|Weekly Check-in appointment with study team or provider|Virtual meeting or telephone call between participants and study team to assess study involvement, adherence to procedures, and following of medical care recommendations.
41106623|NCT01844141|DRUG|70% alcohol|After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
41106624|NCT01844141|DRUG|70% alcohol - 0.5% clorhexidine|In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
41106625|NCT04861012|DEVICE|Ultrasound|All subjects initially will be subjected to abdominal ultrasound, and if fatty liver is detected fibroscan will be done
41106626|NCT00572000|BIOLOGICAL|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
41444432|NCT05452785|DRUG|DFD-29 (Minocycline) Fed|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
41444433|NCT05452785|DRUG|Solodyn (Minocycline) Fasting|In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
41444434|NCT02926677|BEHAVIORAL|Cue-Centered Treatment (CCT)|Identify stress reactions and develop coping skills to deal with them independently. Helps address ongoing traumatic stressors.
41444435|NCT02926677|BEHAVIORAL|Trauma-Focused CBT (TF-CBT)|Identifies negative cognitive/emotional patterns and helps re-frame them. Uses active support from guardians and focuses on emotional and cognitive conditioning. Focuses on discrete past incidents.
41444436|NCT02926677|BEHAVIORAL|Treatment as Usual|The control group. The standard treatment utilized at Stanford Youth Solutions
41444437|NCT02926677|DEVICE|NIRScout|The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.
41444438|NCT01995227|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine
41444439|NCT01995227|BIOLOGICAL|CRCL|Personalized anti-cancer vaccine
41444440|NCT01995227|BIOLOGICAL|AlloStim|ID injections IV infusion
41444441|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
41444442|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
41444443|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
41444444|NCT04965935|DRUG|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
41444445|NCT04965935|DRUG|Placebo Matching Dapagliflozin Oral Tablet|Placebo will be administered for 12 weeks.
41444446|NCT00029263|DRUG|herbals|
41444447|NCT03316963|DRUG|Neostigmine Methylsulfate|After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using five 1 mL syringes filled with 0.5 mL neostigmine each. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
41444448|NCT06066749|OTHER|NIOSH certified N95 personal face covering (mask)|During the this final exposure session, participants will be randomly assigned to wear an N95 respirator (3M cat. #: 9205+). Participants will be instructed on how to wear the mask to ensure a proper fit before entering the chamber.
41444449|NCT06066749|OTHER|Surgical Mask|During the this final exposure session, participants will be randomly assigned to wear an ear loop style surgical mask. Participants will be instructed on how to wear the mask to ensure a proper fit before entering the chamber.
41444450|NCT06563297|DRUG|Alfentanil|We first start with alfentanil 100 ng/ml, and use the up and down method as adjust 25 ng/ml of concentration of alfentanil each time. An SPI higher than 80 and hyperdynamics (the increased HR and MBP up 20% of baseline or HR\>100bpm and ABP\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 25 ng/ml at the next patient; an SPI lower than 80 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 25 ng/ml during skull pin fixation. If the analgesia is inadequate, increase alfentanil concentration will be prescribed. On the other hand, if analgesia is adequate, however hyperdynamics was noted, beta blocker or calcium channel blocker will be prescribed. If hypotension (ABP\<90/50 mmHg) or bradycardia (HR\<50 bpm) occur, we first stop alfentanil infusion and treated with ephedrine or atropine, respectively.
41444451|NCT04906772|DRUG|Dexmedetomidine|participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
41444452|NCT04906772|DRUG|Propofol|participants received loading of ketamine 1 mg/kg and propofol 1mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
41444453|NCT05465863|BIOLOGICAL|SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)|When permitted by local guidelines, children and adolescents who were over 12 years old were notified of vaccine eligibility and encouraged to schedule an appointment
41106627|NCT02196818|DEVICE|Mpact Acetabular Shell|Total Hip Replacement
41270963|NCT00430807|DRUG|hydroxychloroquine/placebo|
41444454|NCT03611608|DRUG|LY3316531|Administered IV
41444455|NCT03611608|DRUG|Placebo|Administered IV
41444456|NCT00127153|BIOLOGICAL|V110, pneumococcal vaccine polyvalent|
41106628|NCT03561610|DIETARY_SUPPLEMENT|sip feed|normal oral Nutrition + sip feed (Fresubin2.0®; covers individual energy and nutrient demands; high in protein)
41106629|NCT03561610|DIETARY_SUPPLEMENT|gumdrops|normal oral Nutrition + gumdrops (Nutrimed®; covers individual energy and nutrient demands; high in protein)
41106630|NCT01844544|OTHER|inspection of medical records|
41270964|NCT03244059|BIOLOGICAL|Belimumab|Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.
41270965|NCT03244059|DRUG|Placebo|An identically appearing placebo infusion.
41270966|NCT04937699|DRUG|Standard-DAPT of Ticagrelor plus aspirin|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months
41444457|NCT05277896|DRUG|Ketamine|Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation
41106631|NCT05826275|DRUG|TGN-S11|Small Molecule
41106632|NCT05826275|DRUG|Pembrolizumab|PD-1 checkpoint blockade
41444458|NCT05277896|DRUG|Etomidate|Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation
41444459|NCT04551066|DRUG|parsaclisib|parsaclisib will be administered QD orally
41444460|NCT04551066|DRUG|ruxolitinib|ruxolitinib will be administered BID orally
41444461|NCT04551066|DRUG|placebo|placebo will be administered QD orally
41444462|NCT02209194|DEVICE|E-liac Stent Graft System|Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
41106633|NCT02435199|DRUG|EMA401 600mg|
41106634|NCT02435199|DRUG|Placebo|
41106635|NCT01492387|OTHER|Discontinuation of antibiotic therapy|Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
41106636|NCT00811057|DRUG|1 Magnesium Sulfate|Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
41106637|NCT00811057|DRUG|Nifedipine|Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
41106638|NCT00811057|DRUG|Indomethacin|Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
41106639|NCT04107129|PROCEDURE|Endometrial Biopsy|An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers
41106640|NCT04107129|OTHER|Euploid embryo transfer|Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.
41106641|NCT04107129|DIAGNOSTIC_TEST|Blood sample|Estradiol and Progesterone levels in the blood will be checked
41106642|NCT00002415|DRUG|Tenofovir disoproxil fumarate|
41444463|NCT06559566|PROCEDURE|USG|The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
41444464|NCT06559566|PROCEDURE|BCT|The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
41444465|NCT02267187|PROCEDURE|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
41444466|NCT02267187|DRUG|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
41444467|NCT02267187|DEVICE|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
41444468|NCT02267187|OTHER|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
41444469|NCT05758415|DRUG|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
41106643|NCT03009513|DRUG|Teneligliptin+Glimepiride|
41106644|NCT01630564|BIOLOGICAL|Aldesleukin|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
41106645|NCT01630564|PROCEDURE|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
41106646|NCT01630564|BIOLOGICAL|Umbilical Cord Blood-Derived Lymphocyte Therapy|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
41106647|NCT00027820|DRUG|Fludarabine Phosphate|Given IV
41106648|NCT00027820|RADIATION|Total-Body Irradiation|Undergo TBI
41444470|NCT05758415|DRUG|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
41444471|NCT04154592|OTHER|Humeral Head Depressor Muscle Co-Activation Training- Experimental Group|In addition to the conservative treatment, humeral head depressor muscle co-activation training will be applied for 14 weeks. Participants in the coactivation group will perform the glenohumeral exercises while recruiting the pectoralis major, latissimus dorsi, and teres major muscles. To achieve this, voluntary recruitment of the pectoralis major, latissimus dorsi, and teres major will be taught prior to the demonstration of the glenohumeral exercises using visual feedback provided by EMG Biofeedback. When recruitment is correctly executed (50% of the maximum voluntary contraction signal), it should be maintained while performing the glenohumeral exercises. This will be confirmed by visualizing EMG signals during the exercise training session. During each appointment with the therapist, participants will be evaluated on their capacity to achieve the exercises while performing co-activation.
41106649|NCT00027820|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
41106650|NCT00027820|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
41106651|NCT00027820|DRUG|Cyclosporine|Given PO
41106652|NCT00027820|DRUG|Mycophenolate Mofetil|Given PO
41106653|NCT01557998|BEHAVIORAL|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
41106654|NCT01557998|DRUG|HCV+PWID|Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.
41106655|NCT01557998|BEHAVIORAL|Control - No intervention|
41444472|NCT04154592|OTHER|Control Group|"The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., \& Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).~Individuals in the control group will use shoulder straps for 6 weeks after arthroscopic shoulder surgery. These patients will be referred to physiotherapy clinics 6th week. Patients between 6 and 20 weeks (a total of 14 weeks) will be admitted to the rehabilitation program according to the guideline mentioned above."
41444473|NCT01262001|DRUG|FG-3019|Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
41444474|NCT01262001|DRUG|FG-3019|Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
41444475|NCT04975035|DRUG|Zolodine|Collect 200 patients who meet the criteria into the group. After enrollment, according to the principle of cross dressing change, the attending physician can decide the dressing change method according to the patient's condition, individual condition and other factors; within 2-4 weeks, the original antipsychotics should be gradually stopped, and Zoladine capsules will be gradually added to the target The dose is 120-160mg/d, orally 1-2 times a day, with meals.
41444476|NCT00834873|DRUG|Carvedilol 25 mg tablets|1 x 25 mg
41444477|NCT00834873|DRUG|COREG® 25 mg tablets|1 x 25 mg
41444478|NCT06559111|DEVICE|2-week casting followed by 4-week bracing|Participants in the bracing group had a cast for 2 weeks after the surgery followed by ankle brace for 4 weeks.
41444479|NCT06559111|DEVICE|6-week casting|Participants in the casting group had a cast for 6 weeks after the surgery.
41444480|NCT05800262|BEHAVIORAL|Dynamic stability exercises|A dynamic stability exercise program for daily home-exercise was applied during five physiotherapist led sessions distributed over seven weeks.
41106656|NCT04841733|OTHER|Foam Roller (FR)|Foam Roller (FR): participants will follow the Foam Roller protocol using a polyvinylchloride pipe roller (10.3-cm diameter, 0.3-cm thickness surrounded by a 1,5-cm thickness neoprene foam). They will begin with the Foam Roller at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth along it as smoothly as possible at a cadence of 1 second superior and 1 second inferior as determined with the metronome. Foam Roller will be performed for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.
41106657|NCT04841733|OTHER|Stretching (STR)|Stretching (STR): participants will perform 8-min of static stretching, involving 3 bilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.
41106658|NCT04841733|OTHER|Cold-Water Immersion (CWI)|Cold-Water Immersion (CWI): will be the last strategy used. Participants will immerse their lower body to the level of the hips for 10 minutes in cold water (10° C).
41133300|NCT04942184|DEVICE|Electroencephalogram (EEG) headset in Arm 1|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
41444481|NCT04499677|DRUG|Favipiravir|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
41444482|NCT04499677|DRUG|Lopinavir/ Ritonavir|Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
41444483|NCT04499677|OTHER|Favipiravir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
41444484|NCT04499677|OTHER|Lopinavir/ Ritonavir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
41444485|NCT06469671|DEVICE|The system based on real - time artificial intelligence - assisted for colonoscopy|"Russian medical decision support system based on artificial intelligence ArtInCol"
41444486|NCT06313034|BEHAVIORAL|Breastfeeding education based on motivational interviewing technique|"Breastfeeding education based on motivational interviewing technique; Breast milk properties, benefits to mother and baby, breastfeeding positions, the relationship between breastfeeding and attachment, signs of hunger in the newborn, Breastfeeding frequency, duration and termination, Breast milk expressing methods, Expressions showing that the newborn has enough milk, Breast milk storage will cover the topics. These topics will be given based on motivational interviewing technique.~According to the motivational interviewing technique, the mother's intention, importance and confidence-sufficiency regarding breastfeeding will be determined and firstly, an agenda will be created on issues related to breastfeeding with the mother. Each session will be conducted by following the open-ended questioning, verification, reflective listening and summarizing approaches of the motivational interviewing technique."
41444487|NCT05279742|DRUG|MANP|Single subcutaneous injection 5 µg/Kg
41444488|NCT05279742|DRUG|Sacubitril/Valsartan|Oral single dose 97/103 mg
41444489|NCT05279742|DRUG|Oral Placebo|Oral single dose that contains no active ingredient
41444490|NCT05279742|DRUG|Injection Placebo|Single subcutaneous injection that contains no active ingredient
41444491|NCT05543135|DIAGNOSTIC_TEST|basic audiological evaluation|pure tone audiometry\&immitancemetry
41444492|NCT05146492|PROCEDURE|MRI|MRI with gadolinium contrast media injection
41444493|NCT02033902|DRUG|Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
41444494|NCT02962752|DIETARY_SUPPLEMENT|Blackadder Juice|
41444495|NCT02962752|OTHER|Placebo|
41444496|NCT06267625|OTHER|Physical Evaluations of individuals|Participants will be evaluated on posture, cough strength, functional mobility and hand grip strength.They will be asked to answer the Standardized Mini Mental Test, Modified Medical Research Council Scale, Physical Activity Scale for the Elderly, Berg Balance Scale. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
41444497|NCT00663481|DRUG|CoFactor|
41444498|NCT00663481|DRUG|Leucovorin|
41444499|NCT06619483|DRUG|BAY3018250 Dose 1|Single dose
41444500|NCT06619483|DRUG|Placebo|Matching placebo to BAY3018250
41444501|NCT06619483|DRUG|BAY3018250 Dose 2|Single dose
41444502|NCT00000159|DRUG|Sorbinil|
41444503|NCT04603482|BEHAVIORAL|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
41444504|NCT04603482|BEHAVIORAL|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
41444505|NCT04603482|BEHAVIORAL|Diversional Activites|An audiovisual format presenting 12 activities for adults including but not limited; crossword puzzles, reading, gardening, exercise, cooking/baking, board games, learning a new language, social activities, online games, etc.
41444506|NCT00811655|PROCEDURE|therapeutic conventional surgery|Surgery of a single brain metastasis.
41444507|NCT00811655|RADIATION|stereotactic radiosurgery|Pre-operative single fraction SRS
41444508|NCT06545890|DRUG|Ketamine|continous infusion during surgery
41444509|NCT06545890|DRUG|Dexmedetomidine|continous infusion during surgery
41444510|NCT06562010|BEHAVIORAL|iCT-SAD-PK|The intervention arm will receive a Pakistani version of Internet-delivered Cognitive Therapy for Social Anxiety Disorder (iCT-SAD), assessing its effectiveness in reducing social anxiety symptoms among Pakistani individuals. This will involve culturally tailored online therapy modules, therapist support, and regular progress assessments.
41444511|NCT03730272|DRUG|analgesic drugs and methods|the patient will receive analgesic treatment at the discretion of the physician in charge
41444512|NCT04976634|DRUG|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
41444513|NCT04976634|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
41444514|NCT04976634|DRUG|Lenvatinib|Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
41444515|NCT03948503|PROCEDURE|Mulligan concept|Mobilization with movement during an active dorsi-flexion of the ankle
41444516|NCT03948503|PROCEDURE|Placebo|Sham mobilization with movement during an active dorsi-flexion of the ankle
41444517|NCT05369884|DRUG|WPQW granule|WPQW granule, 2 sachets / time, 3 times / day.
41444518|NCT05369884|DRUG|WPQW granule simulant|WPQW granule simulant, 2 sachets / time, 3 times / day.
41444519|NCT00958334|DRUG|Proellex®|25 mg daily (two 12.5 mg capsules)
41444520|NCT00091195|DRUG|romidepsin|
41444521|NCT04988594|DIETARY_SUPPLEMENT|Lactobacillus acidophilus 207, Bifidobacterium lactis B420/205|Cultures containing 3.7 × 10 \^ 9 CFU/mg
41444522|NCT04988594|DIETARY_SUPPLEMENT|Lactobacillus bulgaricus and Streptococcus thermophillus|Cultures containing 3.7 × 10 \^ 6 CFU/mg
41444523|NCT04988594|DIETARY_SUPPLEMENT|No culture|No probiotic cultures
41444524|NCT02087553|BIOLOGICAL|Transfusion of red blood cells|(non-experimental) PRBC transfusion
41444525|NCT02087553|BIOLOGICAL|Infusion of albumin/saline|(non-experimental) albumin/saline infusion
41444526|NCT05590039|DEVICE|MyEllevate Procedure|"The defined study area will be identified and may be marked with a surgical marker.~A local tumescent anesthetic, such as lidocaine, will be injected to the area prior to the procedure. The MyEllevate® device will be used in accordance with the Instructions for Use (IFU) manual for soft tissue approximation and elevation of sub dermis and underlying muscle of the submentum and jawline."
41444527|NCT06623643|DIAGNOSTIC_TEST|The investigation of melatonin and cortisol levels in the saliva|In the related study, patient data from individuals who visited the Oral and Maxillofacial Radiology clinic at Van Yüzüncü Yıl University Faculty of Dentistry with complaints of bruxism will be used. The diagnosis of bruxism will be made based on clinical data. Diagnoses will be made by Dr. Sema KAYA using clinical findings such as patient history used for the current diagnosis of bruxism, tooth wear, tooth mobility, pain in the temporomandibular joint (TMJ), headaches, pain in the chewing muscles, hypertrophy, and a feeling of fatigue. Before taking the saliva samples, patients will be asked to rinse their mouths with sterile water, and then they will be asked to spit into sterile plastic containers. After approximately 3 mL of saliva is collected, it will be transferred to appropriate Eppendorf tubes and stored at -80°C. Melatonin and cortisol levels will later be analyzed using the enzyme-linked immunosorbent assay (ELISA) method.
41444528|NCT03820427|DIAGNOSTIC_TEST|impulse oscillometry|impulse oscillometry
41444529|NCT03820427|DIAGNOSTIC_TEST|multiple breath washout test|multiple breath washout test
41444530|NCT03820427|DIAGNOSTIC_TEST|body plethysmography|body plethysmography
41444531|NCT05845723|DRUG|tocilizumab|Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
41444532|NCT05845723|DRUG|tofacitinib|Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.
41444533|NCT05845723|DRUG|cyclophosphamide|Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
41444534|NCT04972565|BEHAVIORAL|Usual Care plus Inspiratory Muscle Training (IMT)|Participants will receive usual care and will also be provided with a personalized prescription for an IMT program for 8 weeks. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session), 5 days per week in their home environment. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
41444535|NCT00868660|DRUG|ZP1848|sc. bolus
41444536|NCT06558812|DEVICE|prefabricated space maintainer|"i. Prefabricated band will be selected for the abutment tooth by measuring the mesiodistal diameter of the abutment tooth with a caliper and will be adjusted with the internal diameter of the prefabricated band.~ii. The loop will be selected based on the available mesiodistal space and buccolingual width of the abutment tooth, excessive length with be cut by cutting plier and will then place inside the band's tube by using a HOWE pliers.~iii. Cotton roll isolation will use, then will be cemented with glass ionomer,"
41444537|NCT06558812|DEVICE|conventional space maintainer|"i. A full arch Impressions will be taken with alginate material. ii. Impressions will be poured up using dental stone within 30 min of the impression taking.~iii. The children will be given an appointment for space maintainer insertion. iv. In the second visit , Cotton roll isolation will use, cementation will be performed with glass ionomer ."
41444538|NCT05606458|BEHAVIORAL|İntervention Group|Before the procedure, the baby was started to be breastfed (1st stimulus). The mother supported her baby's back and bottom with one hand. He started to touch by positioning the thumb of the other hand to prevent the baby's nose from being blocked, and the other fingers of the same hand to touch the baby's face (2nd stimulus). The mother started to talk to her baby with a gentle tone of voice, sometimes using sentences (lullaby, song, etc.) that she wanted to increase the volume of her voice (3rd stimulus). The mother was in the baby's sight (4th stimulus). Clothes were removed as much as possible for the smell of the mother's skin (5th stimulus). The baby's foot in the mother's arms was warmed in the nurse's hand for a minute. The area was determined, and the baby's heel was wiped with 70% alcohol. It was expected to dry. Heel piercing was performed while the stimuli continued. Heel blood was taken. When the evaluation period is complete, the process is over.
41444539|NCT06560762|DRUG|STM01|Neonatal mesenchymal stem cells (nMSCs),
41444540|NCT02534272|OTHER|Stool sampling and sequencing of gut microbiota.|
41444541|NCT04908735|DRUG|Ruxolitinib|Participants will receive ruxolitinib orally twice daily for 24 weeks.
41444542|NCT02997345|OTHER|There is no intervention associated with this study.|There is no intervention associated with this study.
41444543|NCT00829764|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
41444544|NCT00829764|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
41444545|NCT03469843|OTHER|Non intervention|patients without intervention
41444546|NCT04574219|OTHER|Use of Facetime with child and parents during induction|Families will be able to use Facetime with their child when the child is taken to the operating room
41106659|NCT02861937|PROCEDURE|non surgical periodontal therapy|and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
41106660|NCT03142646|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
41106661|NCT04837313|PROCEDURE|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
41106662|NCT04354610|PROCEDURE|Biological samples specific to research|Blood samples, saliva collection, and urine collection to carry out biomarker assays and for the constitution of a biological collection.
41106663|NCT04354610|PROCEDURE|Clinical examination|Clinical examination
41106664|NCT04354610|PROCEDURE|Telephone follow-up|Telephone follow-up at 3 months after discharge from hospital
41444547|NCT01255085|DIETARY_SUPPLEMENT|yellow pea protein|Served in a tomato soup
41106665|NCT00320502|DRUG|BXT-51072|
41106666|NCT01912703|OTHER|Telephone interview|Subjects with incomplete data will be asked to complete a telephone interview
41106667|NCT03525119|BIOLOGICAL|TDV|TDV SC injection
41106668|NCT03525119|BIOLOGICAL|HAV Vaccine|HAV Vaccine IM injection.
41106669|NCT03525119|BIOLOGICAL|TDV Placebo|Placebo-matching (normal saline (0.9% NaCl) SC injection.
41106670|NCT03525119|BIOLOGICAL|HAV Vaccine Placebo|Placebo-matching (normal saline (0.9% NaCl) IM injection.
41106671|NCT02942290|DRUG|Azacitidine|Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 \& Days 1-2 of Week 2 of 28 day cycle.
41106672|NCT02942290|DRUG|Venetoclax|Oral; Tablet
41106673|NCT01843491|BIOLOGICAL|Ad-PfCA|Vaccine
41106674|NCT06477302|BEHAVIORAL|Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer (STA-RR-LC)|Patients will be given a measurement instrument to determine the level of therapeutic adherence.
41106675|NCT04327063|DRUG|Saline|Injection of the solution of Saline not exceeding 30 mL of maximal volume.
41106676|NCT04327063|DRUG|Ropivacaine|Dilution of Ropivacaine 7.5 mg/ml to 5 mg/ml not to exceed 3 mg/kg of maximal dose and 30 ml of maximal volume
41106677|NCT00807430|DEVICE|Grindcare (Active)|Active treatment
41106678|NCT00807430|DEVICE|Grindcare (Placebo - the device is not activated)|Placebo treatment
41106679|NCT02871999|DEVICE|Acupuncture therapy|
41444548|NCT01255085|DIETARY_SUPPLEMENT|yellow pea fiber|Served in a tomato soup
41106680|NCT02871999|PROCEDURE|Laparoscopic Surgery|
41106681|NCT00518726|BIOLOGICAL|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
41106682|NCT05004272|PROCEDURE|Massage|20-minute manual full-body massage
41106683|NCT05004272|PROCEDURE|Gymnastics|20-minute moderate body workout
41106684|NCT05004272|OTHER|Lecture|20-minute lecture on medicinal herbs
41106685|NCT02120313|OTHER|inpatient rehabilitation|
41106686|NCT02120313|OTHER|outpatient rehabilitation|
41106687|NCT05112354|DRUG|systemic and intratympanic injection of steoid|"-If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator."
41106688|NCT01450124|DRUG|Boswellic acids (BOSWELAN)|8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
41106689|NCT01038349|OTHER|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
41106690|NCT02968472|GENETIC|prophylactic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
41106691|NCT04473586|DEVICE|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
41106692|NCT04021615|OTHER|Comprehensive physical therapy rehabilitation program combined with inspiratory muscle training|A threshold inspiratory muscle trainer will be connected to the artificial airway with 15 mm and 22 mm adaptors. Training bouts consist of three to five sets of six repetitions breathing through the trainer. Training will be conducted with the patient in bed with an approximately 30° head-up tilt and with intensity about 40 %- 50 % of maximal inspiratory pressure. Patients will be returned to mechanical ventilation for rest between training sets as needed. Three to five sets of six training breaths will be completed for a total of 18 to 30 training breaths per session. Following each training set, the patient indicated a rating of perceived inspiratory exertion on modified Borg scale . The study group will also receive comprehensive rehabilitation program consist of upper-extremity exercises, lower extremity exercises, pedaling exercises, trunk control exercises and bedside functional training
41106693|NCT04021615|OTHER|Traditional chest physical therapy rehabilitation program combined with inspiratory muscle training|The same inspiratory muscle training for the study group combined with the traditional physical therapy program consist of positioning , modified postural drainage , percussion , vibration.
41106694|NCT04680741|BEHAVIORAL|Addiction Pilot App behavior tracking|a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.
41106695|NCT05708014|BEHAVIORAL|Intervention LuvHub|From day 1 to day 487 (i.e., entire 16-month duration, post baseline) of the trial, participants randomized to the intervention arm will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
41106696|NCT05708014|BEHAVIORAL|Waitlist Control LuvHub|From day 243 to day 487 (i.e., starting after 8-month assessment) of the trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
41106697|NCT04832542|OTHER|outpatient follow-up|The patients were evaluated every six months in order to assess the incidence of traumatic syncope recurrence during follow-up after implantable loop recorder implantation.
41106698|NCT02618278|OTHER|Physiotherapy|The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
41106699|NCT06081829|DRUG|Ivosidenib|Subjects will take 2 tablets (500 mg total) orally once daily.
41106700|NCT05582057|BEHAVIORAL|Strengths to Grow: Preteen|An online, strength based parenting program for parents of preteens (aged 9-14).
41106701|NCT00001886|PROCEDURE|Real time 3-dimensional stress echocardiography|
41106702|NCT00111722|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment -1day|
41106703|NCT00111722|DRUG|Comparator: placebo / Duration of Treatment - 1 day|
41106704|NCT01215695|DEVICE|aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)|The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
41106705|NCT01215695|DEVICE|Control|pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
41270967|NCT04937699|DRUG|Sequential monotherapy of Ticagrelor and clopidogrel|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.
40925335|NCT01643031|DRUG|Continued clopidogrel|Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
41444549|NCT01255085|DIETARY_SUPPLEMENT|Control Tomato Soup|Served in a tomato soup
40925336|NCT00977847|OTHER|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
41444550|NCT04732065|DRUG|ONC206|Given orally (PO)
41444551|NCT04732065|RADIATION|Standard of Care Radiation Therapy|Undergo RT
41444552|NCT04732065|PROCEDURE|Optional Proton (1H) MR spectroscopy (MRS)|Optional imaging procedure
41444553|NCT03972306|DRUG|Ocrelizumab|Administered by subcutaneous Injection
41444554|NCT03972306|DRUG|Ocrelizumab|Administered by Intravenous (IV) Injection
41444555|NCT03972306|DRUG|rHuPH20|Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
41444556|NCT02809196|BEHAVIORAL|1: Tailored SMS program implicating friend and mother|
41444557|NCT02809196|BEHAVIORAL|2: Standardized SMS program implicating friend and mother|
41444558|NCT02809196|BEHAVIORAL|3: Tailored SMS program implicating friend, not mother|
41444559|NCT02809196|BEHAVIORAL|4: Standardized SMS program implicating friend, not mother|
41444560|NCT02809196|BEHAVIORAL|5: Tailored SMS program implicating mother, not friend|
41444561|NCT02809196|BEHAVIORAL|6: Standardized SMS program implicating mother, not friend|
41444562|NCT02809196|BEHAVIORAL|7: Tailored SMS program not implicating mother or friend|
41444563|NCT02809196|BEHAVIORAL|8: Standardized SMS program not implicating mother or friend|
41444564|NCT02809196|BEHAVIORAL|9: No SMS program|
41444565|NCT05506956|DRUG|Flotetuzumab|Patients enrolled on dose level 1 (DL1) will receive flotetuzumab by continuous infusion using multi-step lead-in dosing, and then 500 ng/kg/day on days 7-28. After one cycle, all patients will undergo a bone marrow biopsy to assess response including assessment of minimal residual disease (MRD). Patients who fail to achieve a CR, CRi, CRh (complete remission with partial hematologic recovery), or MLFS may continue with subsequent induction cycles as a continuous infusion up to a total of five cycles. If there is evidence of response (CR, CRi, CRh, or MLFS) and the toxicities of treatment are acceptable, patients will be eligible for two consolidation cycles. Additional bone marrow biopsies for response assessment will be performed after the second cycle. If there is a need to de-escalate dosing based on toxicity, then patients will be enrolled on DL-1 using multi-step lead-in dosing, and then 300 ng/kg/day on days 5-28 of the first cycle and days 1-28 of subsequent cycles.
41444566|NCT05257564|DEVICE|Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)|Fingerstick capillary blood will be collected according to each manufacturer's Instructions for use. The fingerstick capillary blood samples will be used immediately on the point-of-care assays. The venous blood will be collected in specific tubes for plasma (GLU), for whole blood (HbA1c) and for serum (CREP, CHOL). Plasma will be separated by centrifugation at the PHC facility and health post and aliquots will be prepared. Serum will be left to clot prior to centrifugation and serum aliquots will be prepared at the PHC facility and health post. The samples will be stored until transfer to the BPKIHS reference lab.
41444567|NCT05146336|DEVICE|CytoSorb|Sorbent hemoperfusion system
41444568|NCT03591458|DRUG|Amitriptyline|Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.
41444569|NCT03591458|DRUG|Placebo|Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
41444570|NCT00932477|DRUG|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
41444571|NCT00932477|DRUG|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
41444572|NCT00932477|DRUG|Glycerin and Polysorbate 80 based artificial tear|1 to 2 drops into each eye three times per day
41444573|NCT01634139|DRUG|Tiotropium low dose QD|2 actuations once daily in the evening
41444574|NCT01634139|DRUG|Tiotropium high dose QD|2 actuations once daily in the evening
41444575|NCT01634139|DRUG|Placebo|2 actuations once daily in the evening
41444576|NCT02319655|PROCEDURE|Air tamponade|Air tamponade
41444577|NCT02319655|PROCEDURE|Balanced salt solution filling|BSS filling
41444578|NCT01328652|DRUG|dexlansoprazole|dexlansoprazole 60 mg once daily for 3 months
41444579|NCT06561425|GENETIC|GLPG5101|Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy
41444580|NCT01899755|DRUG|GSK2800528, solution for injection|Drug will be administered at 3 different dose levels by subcutaneous injection.
41444581|NCT01899755|DRUG|Placebo (0.9% w/v Sodium Chloride), solution for injection|Subcutaneous injection of. 0.8 mL solution will be administered
41444582|NCT01899755|DRUG|Adalimumab, solution for injection|Subcutaneous injection of 0.8 mL solution will be administered (40mg)
41444583|NCT01148186|BEHAVIORAL|knowledge transfer tool|knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
40925337|NCT02831907|PROCEDURE|Cardiac surgery|All cardiac surgery procedures with the use of cardiopulmonary bypass
40925338|NCT02866955|DRUG|Estramustine|140mg/4 caps/day
40925339|NCT02866955|DRUG|Tamoxifen|20mg/day
41444584|NCT06563115|DRUG|(PEG)-BHD1028 Single Ascending Dose|4, 8, 16, 32, and 64 μg/Kg
41444585|NCT06563115|DRUG|(PEG)-BHD1028 Multiple Ascending Dose|8, 16, and 32 μg/Kg
41444586|NCT06563115|OTHER|Placebo|Diluent
41444587|NCT04067752|OTHER|high dialysate sodium concentration (138 mEq/L)|high dialysate sodium concentration (138 mEq/L)
41444588|NCT04067752|OTHER|Low dialysate sodium concentration|low dialysate sodium concentration (132 mEq/L)
41444589|NCT05770388|DEVICE|App Take Care of Your Mood|The app provides psychoeducational information, contains several thematic modules (mindfulness, emotional regulation, healthy lifestyle habits, safety plan for crisis management, among others), allows mood monitoring, contains motivational messages and videos aimed at promoting help-seeking in mental health, and information on available support services.
41444590|NCT05770388|BEHAVIORAL|Reminder messages and counseling|Participants receive reminder messages (by email and chat) encouraging them to use the app and to request a counseling session (via phone call, videoconference or chat) with a clinical psychologist if they think it is necessary.
41444591|NCT03016858|PROCEDURE|Thoracoscopic Bullectomy Surgery|undergoing the Thoracoscopic Bullectomy Surgery
41444592|NCT04016415|BEHAVIORAL|Mindfulness Based Stress Reduction|Subjects randomized to Mindfulness-Based Stress Reduction (MBSR) will receive the 8-week University of Massachusetts Authorized MBSR curriculum followed by monthly mindfulness boosters in Months 3 to 6. The University of Massachusetts MBSR curriculum was selected for the intervention, as it is the most standardized and researched mindfulness program that has been shown to reduce psychological distress in various patient populations.
41444593|NCT04016415|BEHAVIORAL|Stress Management Education|Subjects randomized to Stress Management Education (SME) will receive health education on nutrition (adapted for the type 2 diabetes population), exercise as gentle stretching to match yoga in MBSR, and other general health topics that may be relevant to the type 2 diabetes population such as sleep, time management, etc. Stress Management Education does not have any mindfulness in it. Stress Management Education was specifically created as a control condition for MBSR studies so it matches MBSR for time, social support, homework, etc.
41444594|NCT02875392|OTHER|275mg Oligo Fucoidan + 275mg HS Fucoxanthin|Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
41444595|NCT02875392|OTHER|placebo pills|taking placebo pills as if patients are under treatment.
41444596|NCT02625974|DRUG|Nifurtimox (Lampit, BAYA2502)|"For pediatric participants with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.~For pediatric participants with body weight \> 40 kg: 8 - 10 mg/kg/day in three divided doses.~60 days or 30 days of nifurtimox treatment"
41444597|NCT02625974|DRUG|Placebo|Matching placebo
41444598|NCT03997019|PROCEDURE|opioid analgesia|opioid analgesia will be used with general anaesthesia
41444599|NCT03997019|PROCEDURE|ESP block|ultrasound guided ESP Block before anaesthesia induction
41444600|NCT03975075|BEHAVIORAL|Psychophysiological monitoring|30 minutes of one channel (ECG) physiological monitoring with Mindfield eSense Pulse.
41444601|NCT03975075|BEHAVIORAL|Biofeedback training|Traditional resonance frequency training with the Mindfield eSense Pulse smartphone application. Using visual feedback of real time parameters of HRV and the use of controlled breathing, participants are trained to reach a relaxed state.
41444602|NCT05657587|DEVICE|SPRINT PNS|Each subject will have 2 leads placed for 60 days. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
41444603|NCT04926818|DRUG|Fingolimod|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
41444604|NCT04926818|DRUG|Ofatumumab|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
41444605|NCT04926818|DRUG|Siponimod|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
41444606|NCT04926818|OTHER|Fingolimod placebo|Fingolimod matching placebo capsule
41444607|NCT04926818|OTHER|Siponimod placebo|Siponimod matching placebo tablet
41444608|NCT04926818|OTHER|Ofatumumab placebo|Ofatumumab matching placebo autoinjector
41444609|NCT01693523|DRUG|Minocycline|100 mg by mouth two times a day (200 mg/day).
41444610|NCT01693523|OTHER|Placebo|Matching placebo capsules by mouth twice a day.
41270968|NCT01328587|DRUG|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
41444611|NCT01693523|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
41444612|NCT05288686|PROCEDURE|sentinel lymph node biopsy procedure|Patient received respective tracer injection and sentinel lymph node biopsy was performed in the operation theatre with the corresponding device.
41444613|NCT05344092|BEHAVIORAL|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period
41270969|NCT01562028|DRUG|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
41444614|NCT01650194|DRUG|enzalutamide|Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
41444615|NCT01650194|DRUG|abiraterone acetate|Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
41444616|NCT01650194|DRUG|prednisone|Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
41444617|NCT04896580|BEHAVIORAL|Nature based exercise|Participants will engage in three months of moderate intensity PA, consisting of three 50-minute walking sessions per week (5-minute warm-up, 40 minute walk, 5 minute cool-down and stretch) with an exercise physiologist for 12 weeks.
41444618|NCT02464254|BEHAVIORAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
41444619|NCT02464254|BEHAVIORAL|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
41444620|NCT03542669|DRUG|6B11-OCIK Injection|Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.
41444621|NCT03542669|DRUG|Doxorubicin|Subjects will be adminitered 4\~6 cycles of chemotherapy (Doxorubicin, 30 mg/m\^2 IV on Day 1 of every cycle)
41444622|NCT01277276|DEVICE|Diffuse optical spectroscopy and Near infrared spectroscopy|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
40925340|NCT00391183|PROCEDURE|Biliary stenting|ERCP and stenting
41270970|NCT01562028|DRUG|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
41444623|NCT01897207|BIOLOGICAL|Dendritic cell application|S.C. injection of peptide pulsed autologous dendritic cells
41444624|NCT03405688|PROCEDURE|Blood sampling|Extra blood samples taken for laboratory analysis
41444625|NCT06251180|DRUG|Rocbrutinib|orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
41444626|NCT06251180|BIOLOGICAL|Rituximab|375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
41444627|NCT06251180|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
41444628|NCT06251180|DRUG|doxorubicin|50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
41444629|NCT06251180|DRUG|Vincristin|1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
41444630|NCT06251180|DRUG|Prednisone|100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
41444631|NCT04365387|DRUG|Nemolizumab|Nemolizumab will be administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.
41106706|NCT05344300|OTHER|Temperature-measurement in lungs under sauna bath|Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.
41106707|NCT04694248|DRUG|Rivaroxaban|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
41106708|NCT04694248|DRUG|Aspirin|For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
41106709|NCT00684034|OTHER|Sampling of blood|A sampling of blood will be made
41106710|NCT00684034|OTHER|Sampling of blood|A sampling of bood will be made before the dialysis
41106711|NCT00684034|OTHER|Sampling of blood|A sampling of blood will be made.
41106712|NCT03324152|OTHER|High-intensity interval training (HIIT) - myositis|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
41444632|NCT04365387|DRUG|Placebo|Placebo will be administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
41444633|NCT02025010|DRUG|abiraterone acetate|Abiraterone acetate is a selective and irreversible inhibitor of CYP17 which has demonstrated clinical efficacy in patients with CRPC. Currently, AA is administered with concomitant prednisone.
41444634|NCT04966741|DRUG|Setmelanotide|SC injection once daily.
41444635|NCT05880056|DRUG|Nerkardou (5 mg) & (10 mg)|Bisoprolol oral dissolved film ODF(5 mg): equivalent to 5 mg of bisoprolol fumarate Bisoprolol oral dissolved film ODF (10 mg): equivalent to 10 mg of bisoprolol fumarate.
41444636|NCT03158727|BIOLOGICAL|Cx611|Two intravenous infusions, one on day 1 and another one on day 3.
41444637|NCT03158727|OTHER|Placebo|Two intravenous infusions, one on day 1 and another one on day 3.
41106713|NCT03324152|OTHER|Standard low-intensity home exercise|12 weeks of 5 days/week low-intensity resistance home exercise in combination with outdoor walks of 20 minutes.
41106714|NCT03324152|OTHER|High-intensity interval training (HIIT) - healthy|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
41106715|NCT03691428|BEHAVIORAL|Wish Outcome Obstacle Plan|"1. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if \[specified obstacle - when I feel impatient\], then I will \[specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly\] plan."
41444638|NCT01937143|BEHAVIORAL|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
41444639|NCT01937143|BEHAVIORAL|High intensity intervention|Pamphlet and video with information about pain management during immunizations at birth of a newborn infant
41444640|NCT01937143|BEHAVIORAL|Control|General information about infant immunizations at birth of a newborn infant
41444641|NCT00507117|DRUG|Lunesta|Lunesta 3mg prior to PSG
41444642|NCT00507117|DRUG|Placebo control|matching placebo
41106716|NCT04318717|DRUG|Pembrolizumab|Pembrolizumab is commercially available
41444643|NCT06382636|BEHAVIORAL|Standard Care|This group will utilize standard care with respect to healthcare provider practices.
41444644|NCT06382636|BEHAVIORAL|Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot|This group will be exposed to the AI enabled healthcare chatbot.
41444645|NCT05747196|DEVICE|WhiteSwell eLym System|The WhiteSwell eLym™ System is designed to treat congestion in Acute Decompensated Heart Failure (ADHF) patients. The device comprises two endovascular components, a Catheter and a Sheath, that are used in combination with a Console. The device is designed to create a low-pressure zone at the Thoracic Duct Outflow which is located adjacent to the venous angle (junction of the left subclavian vein and left internal jugular vein). This low-pressure region facilitates movement of fluid (lymph) from the interstitial compartment through the lymphatic system and the Thoracic Duct and into the intravascular space, while removal of fluids from the intravascular space is enabled using diuretic therapy. The treatment duration will be up to 72 hours.
41444646|NCT02623647|RADIATION|stereotactic body radiotherapy SBRT|40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
41444647|NCT03904381|DRUG|5-fluorouracil|5-fluorouracil subconjunctival injections were a first-choice therapy for bleb failure and were administered according to predetermined criteria.
41106717|NCT04318717|RADIATION|Hypofractionated radiation therapy|It is preferred to leave at least 48 hours between fractions. Daily imaging to verify accurate set-up is mandatory.
41106718|NCT02399696|BEHAVIORAL|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
41270971|NCT01795651|PROCEDURE|identification of take-home message of lecture|
41444648|NCT03904381|PROCEDURE|Transconjunctival needling|Transconjunctival needling was administered according to predetermined criteria.
41106719|NCT02399696|BEHAVIORAL|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
41106720|NCT03887546|DEVICE|Inspiratory muscle trainer|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
41106721|NCT03887546|PROCEDURE|Respiratory exercise|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
41106722|NCT01662180|DRUG|Follicle Stimulating Hormone|All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
41106723|NCT02528591|DEVICE|oscillometric device (Arteriograph®, Medexpert)|Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).
41106724|NCT00079482|DRUG|CEP-701|
41106725|NCT00079482|DRUG|high-dose cytarabine|Chemotherapy
41444649|NCT03904381|PROCEDURE|Transconjunctival revision|Transconjunctival revision was administered according to predetermined criteria.
41444650|NCT05140759|DEVICE|automated continual water removal system|The device removes excess fluids in heart failure patients with diuretic resistance
41444651|NCT05550064|OTHER|Structured contraceptive counseling|"1. Educational video - healthcare providers (Medical doctors and nurse-midwives)present available contraceptives that could be used after delivery, with emphasis on effectiveness, how they should be used, mechanism of action and health benefits.~2. The four key questions are to be asked to all pregnant women to make them reflect on factors that highly affects choice of contraceptives.~3. A tiered effectiveness chart will be used to visualize the effectiveness of different contraceptives, and guide the prospective user in her choice depending on the answers to the key questions~4. The box of contraceptive models are used for the prospective user to inspect, hold, feel the different contraceptives, as this has been shown to decrease fear regarding specific methods."
41444652|NCT05562778|OTHER|Chatbot|A chatbot is a software program designed to simulate human conversation, typically via text. Chatbots utilize natural language processing to gather patient data, anticipate questions, and predict responses. In this study, the Chatbot will simulate a text-like conversation with patients via a smartphone and use this platform to deal with the time-consuming nature of family history collection. The chatbots can then triage the collected family history against medical guidelines to determine which patients warrant genetic testing. For those patients meeting criteria for genetic testing, the chatbot can offer pre-test education and assist physicians with ordering genetic testing for interested patients meeting high-risk criteria.
41444653|NCT04456881|OTHER|Patients with patellar dislocation undergo patellar femoral medial reconstruction|Arthroscopic double-beam anatomical reconstruction of medial patellofemoral ligament
41444654|NCT04363359|BIOLOGICAL|0.5ml Quadrivalent influenza vaccine|The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
41444655|NCT04363359|BIOLOGICAL|0.25ml Quadrivalent influenza vaccine|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
41444656|NCT04363359|BIOLOGICAL|0.25ml Trivalent influenza vaccine(B/V)|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Victoria strains
41106726|NCT00079482|DRUG|Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)|Chemotherapy
41106727|NCT02082405|DRUG|bortezomib|Given SC or IV
41444657|NCT04363359|BIOLOGICAL|0.25ml Trivalent influenza vaccine(B/Y)|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Yamagata strains
41444658|NCT06165354|DRUG|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 20 mL-bottle.
41106728|NCT02082405|DRUG|cyclophosphamide|Given PO
41106729|NCT02082405|DRUG|dexamethasone|Given PO
41106730|NCT02082405|OTHER|laboratory biomarker analysis|Optional correlative studies
41270972|NCT01036399|DRUG|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
40925341|NCT05378698|DRUG|Application of Tralokinumab|2 Arms 20 patients 5 healthy controls
41106731|NCT02082405|OTHER|quality-of-life assessment|Ancillary studies
41106732|NCT02853474|BEHAVIORAL|Early Palliative Care visit|"A PC visit is a visit done by a PC physician. Any kind of visits done by other professionals IS NOT a PC visit.~Five PC visits are scheduled in this arm."
41106733|NCT02853474|OTHER|EORTC-QLQ-C30 questionnaire|The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.
41106734|NCT02853474|OTHER|HADS score|The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
41106735|NCT00185016|BEHAVIORAL|a training to improve recognition of partner abuse.|
41106736|NCT00486759|DRUG|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
41270973|NCT04274322|OTHER|Nutrition support|Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement
41270974|NCT02412865|BEHAVIORAL|Quit4Baby|
40925342|NCT06220890|PROCEDURE|Tooth preparation in Class IV lesions with 2mm bevel|Class IV cavity with 2 mm bevel will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
41444659|NCT06165354|COMBINATION_PRODUCT|LiveSpo X-secret|"In Vietnam, LiveSpo X-SECRET is manufactured as two product lines: (1) Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam and ISO 13485:2016 (Certificate No YT117-19) and (2) comestic (Product declaration No.14981/22/CBMP-HA) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam (Certificate No 118/CNĐĐKSXMP. Both product lines have the same probiotic composition.~The cosmetic type was used for the clinical trial conducted at Hanoi OGH. The Class-A medical device type was used for the clinical trial conducted at Bac Ninh CDC."
41444660|NCT04630431|OTHER|Best Practice|Undergo standard of care follow-up
41444661|NCT04630431|OTHER|Educational Intervention|Undergo clinical trial education via a video and educational booklet
41444662|NCT04630431|OTHER|Electronic Health Record Review|Review of medical record
41444663|NCT04630431|BEHAVIORAL|Patient Navigation|Undergo clinical trial navigation
41444664|NCT04630431|OTHER|Questionnaire Administration|Complete questionnaire
41444665|NCT05379647|DRUG|QN-019a|Experimental Interventional Therapy
41444666|NCT05379647|DRUG|Rituximab|Monoclonal Antibody
41444667|NCT05379647|DRUG|Cyclophosphamid|Lympho-conditioning Agent
41444668|NCT05379647|DRUG|Fludarabine|Lympho-conditioning Agent
41444669|NCT05379647|DRUG|VP-16|Lympho-conditioning Agent
40925343|NCT06220890|PROCEDURE|Tooth preparation in Class IV lesions with 2mm stair-step chamfer|Class IV cavity with 2 mm stair step chamfer will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
41106737|NCT00486759|DRUG|Rituximab|Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
41106738|NCT00486759|DRUG|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
41106739|NCT00486759|DRUG|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
40925344|NCT00272714|DRUG|Afimoxifene (0.057%) in hydroalcoholic gel|
40925345|NCT05168501|OTHER|Rebreathing procedure|Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.
41106740|NCT05712018|DRUG|Hydroxyethyl starch coload - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
41106741|NCT05712018|DRUG|Hydroxyethyl starch coload - 5 ml/kg|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
41270975|NCT02412865|BEHAVIORAL|Text4Baby|
41270976|NCT02210780|DRUG|Dupilumab|Administered via subcutaneous injection.
41444670|NCT01718873|DRUG|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
41444671|NCT01718873|DRUG|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
41444672|NCT01718873|DRUG|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
41444673|NCT01718873|DRUG|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
41444674|NCT01718873|DRUG|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
41444675|NCT02684747|OTHER|Autologous Transfusion|Participants will receive autologous transfusion on Day 21
41444676|NCT02684747|OTHER|Control - Normal Saline (Placebo)|Participants will receive saline on Day 21
41444677|NCT06561074|DRUG|Decitabine|Given by vein
41444678|NCT06561074|DRUG|Venetoclax|Given by mouth
41444679|NCT06561074|DRUG|Calaspargase pegol-mknl|Given by vein
41444680|NCT06265727|DRUG|CRB-701|Nectin-4 targeted Antibody Drug Conjugate (ADC)
41444681|NCT06115291|OTHER|Smell Test|Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.
41444682|NCT00833209|PROCEDURE|PET (withdrawal)|3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
41444683|NCT00833209|PROCEDURE|Imaging|2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
41444684|NCT00833209|PROCEDURE|Imaging|1 MRI ; Iowa Gambling Task test and questionnaires.
41444685|NCT04362085|DRUG|Therapeutic Anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
41444686|NCT05504902|DEVICE|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with Advanced stage Parkinson's disease
41444687|NCT05036707|DEVICE|Xenodiagnosis Ticks|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors.
41444688|NCT05036707|PROCEDURE|skin biopsy|2-3 mm skin punch biopsies will be performed.
41444689|NCT05036707|PROCEDURE|blood draw|Peripheral blood draws will be performed.
41444690|NCT00834405|DRUG|ARAVA® 20 mg tablets|1 x 20 mg, single-dose non-fasting
41444691|NCT00834405|DRUG|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose non-fasting
41444692|NCT06559631|BEHAVIORAL|Indigenously Adapted CRA|Treatment group will receive psychotherapy based on CRA which is an evidence based approach. This adapted version of CRA also consists emotional management, behavioral interventions, drug addiction treatment and islamically integrated psychotherapy for drug addiction and comorbid mental disorders.
41444693|NCT03572868|OTHER|Evaluation of the long term neurodevelopmental outcome|Evaluation of the long-term neurodevelopmental outcome of newborns who have an isolated transverse cerebellar diameter \< 5th centile during the second or the third trimester of pregnancy.
41444694|NCT04255563|DEVICE|DCB treatment|DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.
41444695|NCT05418647|OTHER|high dialysate Na|high dialysate sodium (Na = 141 mmol/L) for 8 weeks
41444696|NCT05418647|OTHER|low dialysate Na|low dialysate sodium (Na = 136 mmol/L) for 8 weeks
41444697|NCT05925010|DIETARY_SUPPLEMENT|Supplementation with soluble fibre from guar (Optifibre©)|10g of soluble fibre from guar in the form of Optifibre© (dietary food for special medical purposes) is added to the standardized meal (Resource cereal porridge©).
41444698|NCT02108535|DRUG|Nanocrystalline silver|Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.
41444699|NCT02108535|DRUG|Silver Sulfadiazine|This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
41444700|NCT03781102|BEHAVIORAL|16-Week Diabetes Prevention Program for Mothers and Children|The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
41444701|NCT05510908|OTHER|Non-Interventional|Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
41444702|NCT05510908|OTHER|Non-Interventional Follow-up|Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
41444703|NCT06559241|DEVICE|14-day remote ischemic conditioning|RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 14 days post-thrombectomy.
41444704|NCT06559241|DEVICE|30-day remote ischemic conditioning|RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 30 days post-thrombectomy.
41444705|NCT06559241|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy procedures are performed according to the guidelines to recanalize the occluded large vessel safely.
41106742|NCT05712018|DRUG|Hydroxyethyl starch coload - 10 ml/kg|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
41106743|NCT03742102|DRUG|Durvalumab|Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
41444706|NCT06559241|DRUG|Best medical management|Best medical management is prescribed at the discretion of the treating physicians according to the guidelines.
41444707|NCT02121067|DRUG|Levonorgestrel Intrauterine System (LNG-IUS)|The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
41444708|NCT05406050|DRUG|reference eldecalcitol soft capsule|0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan
41444709|NCT05406050|DRUG|test eldecalcitol soft capsule|0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
41444710|NCT01440803|DRUG|Teriparatide|Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.
41106744|NCT03742102|DRUG|Capivasertib|Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
41106745|NCT03742102|DRUG|Oleclumab|Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
41106746|NCT03742102|DRUG|Paclitaxel|Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
41106747|NCT03742102|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
41106748|NCT03742102|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
41106749|NCT03458546|DRUG|Roflumilast|All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
41106750|NCT01368406|BEHAVIORAL|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
41106751|NCT00995150|DRUG|LNG20|levonorgestrel-releasing intrauterine system for contraception
41106752|NCT00995150|DRUG|Mirena|Mirena intrauterine system
41106753|NCT04674332|DRUG|Long acting insulin|long acting insulin analogue once daily at bed time
41106754|NCT04674332|DRUG|multiple dose regimen|intermediate and short acting insulin
41106755|NCT02251613|DRUG|Olopatadine HCl ophthalmic solution, 0.1%|
41106756|NCT02251613|DRUG|Epinastine HCl ophthalmic solution, 0.05%|
41106757|NCT03516604|DRUG|PF-04995274|PF-04995274 tablets
41106758|NCT03516604|DRUG|Citalopram|Citalopram capsule
41106759|NCT03516604|DRUG|Placebo Oral Tablet|Placebo tablet, identical to PF-04995274 tablet
41106760|NCT03516604|DRUG|Placebo oral capsule|Placebo capsule, identical to citalopram capsule
41106761|NCT05826704|DIETARY_SUPPLEMENT|Probiotics|Participants will be taking 2 capsule a day for 6 weeks
41106762|NCT02787369|DRUG|ACY-1215|
41106763|NCT02787369|DRUG|Ibrutinib|
41106764|NCT02787369|DRUG|Idelalisib|
41106765|NCT00001934|DRUG|Zenapax|
41106766|NCT03510091|BEHAVIORAL|Counseling|A video will be shown to parents of patients ages 9-18 that review HPV transmission, relation to cancer, role of immunization, myths, side effects, series timing and need for completion. All parents or legal guardians of patients will be given the option to proceed with HPV vaccination, decline, or discuss further with their provider
41444711|NCT01440803|DRUG|Saline Placebo|Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
41106767|NCT03910517|OTHER|No intervention|No intervention
41106768|NCT01320280|DRUG|BIBW 2992 (Afatinib)|50 mg BIBW 2992 (Afatinib) tablets daily continuously
41106769|NCT04267744|OTHER|Myia Health® remote patient monitoring unblinded treatment arm|"After consenting to the study, the Myia in-home suite of devices will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Device: Myia Health platform and in-home suite of devices®:~Emfit Ballistocardiograph® Withings Connected Scale® VitalScout (VivaLink) ECG Accelerometer® Omron Blood Pressure Monitor® (Sphygmomanometer) Cradlepoint - Hotspot / Adaptor® (LTE Connection) Samsung Galaxy Tab A 8.0® (User Interface)"
41106770|NCT00223119|DEVICE|Absorbable Sutures|
41106771|NCT04224181|RADIATION|Cardiac PET|A scan examining blood flow to the heart
41106772|NCT04224181|RADIATION|99mTc-tilmanocept SPECT/CT|A scan to look at inflammation in the arteries
41106773|NCT04224181|RADIATION|Contrast Enhanced Coronary and Aortic Computed Tomography Angiography|A scan of the heart and surrounding blood vessels
41106774|NCT05826951|DRUG|Alcohol|Alcohol (0.8g/kg)
41106775|NCT05826951|DRUG|Placebo|Placebo
41106776|NCT05046132|DRUG|Setmelanotide|Administered once daily via SC injection.
41106777|NCT05046132|DRUG|Moxifloxacin|Moxifloxacin capsules via oral administration.
41106778|NCT05046132|DRUG|Oral Placebo|Placebo capsules via oral administration.
41106779|NCT05046132|DRUG|SC Placebo|Placebo via SC injection.
41106780|NCT01523249|DEVICE|Lumbar 3D ultrasound scanning and palpation (Ultrasonix )|Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
41106781|NCT01935869|DRUG|LEO 90100|
41106782|NCT01935869|DRUG|Vehicle|
41106783|NCT01935869|DRUG|Petrolatum ointment|
41106784|NCT03357549|OTHER|Brief Motivational Intervention|The Brief Motivational Intervention is an intervention that use strategies are typical of patient-centered interventions. These strategies will help the interviewer to listen, to elicit important information, and to build rapport with the patient and should be used throughout the intervention. The four strategies are Open-Ended Questions, Affirmations, Reflections and Summaries. The objective of de BMI is to increase the client motivation to adopt healthy initiatives, and to increase their self-efficacy to reach their own objectives.
41106785|NCT03357549|OTHER|Breastfeeding education|It's a common educational intervention about breastfeeding. The women will receive the information by a leaflet with information about breastfeeding and community resources and they will receive verbal information during 20-30 minutes to resolve their doubts.
41106786|NCT03706261|DRUG|18F-MK-6240|Administration of 5 mCi of 18F-MK-6240 for tau PET.
41106787|NCT03706261|DRUG|18F-Florbetaben|Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.
41106788|NCT01876654|DEVICE|TruMatch® patient specific cutting guide|
41106789|NCT00162331|DRUG|Technetium Tc99m Sestamibi|
41106790|NCT02079324|BIOLOGICAL|GX-051|intratumoral injection
41106791|NCT02919176|DRUG|Mirabegron|Mirabegron 50 mg/day
41106792|NCT02919176|DRUG|Pioglitazone|Pioglitazone 30 mg/day
41106793|NCT02919176|DRUG|Mirabegron and Pioglitazone|Mirabegron 50 mg/day and Pioglitazone 30 mg/day
41106794|NCT02177318|DRUG|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
41270977|NCT02210780|DRUG|Placebo|An inactive substance containing no medicine administered via subcutaneous injection.
41270978|NCT03217851|DIAGNOSTIC_TEST|Blood Collection|blood smear and/or rapid diagnostic
41270979|NCT03217851|DIAGNOSTIC_TEST|Dried Blood Spot|Dried Blood Spot on filter paper
41270980|NCT00269763|DRUG|Fentanyl Transdermal Therapeutic System (TTS)|
41444712|NCT01007994|DRUG|New Medication: Enalapril, Isradipine, Propranolol|"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril \< 40 kg starting dose 2.5 mg titrate to 5 mg \> 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine \< 40 kg 2.5 mg \> 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol \<40 kg starting dose 10 mg titrate to 20 mg \>40 kg starting dose 20 mg titrate to 40 mg"
41444713|NCT00178802|OTHER|thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)|"5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days~Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour~Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily~Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol"
41444714|NCT05323916|BEHAVIORAL|"Neuroproprioceptive facilitation, inhibition"|"Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of neuroproprioceptive facilitation, inhibition physical therapy."
41444715|NCT05323916|BEHAVIORAL|Technology based physical therapy|Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of technology based physical therapy.
41444716|NCT05323916|BEHAVIORAL|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|Participants will undergo a four hour a day for three weeks of effectively managed comprehensive intensive rehabilitation implementing the recommendations of the World Health Organization.
41444717|NCT05323916|BEHAVIORAL|Standard care|Participants will undergo standardly provided care including face to face physiotherapy (bed mobility, transfers, gait, therapeutic exercises, positioning, education).
41444718|NCT03978442|BEHAVIORAL|Smoking Cessation Cognitive Behavioral Therapy (CBT)|12 sessions of cognitive behavioral therapy for smoking cessation, designed to help participants prepare for quitting smoking, make a quit attempt, and stay quit from smoking.
41444719|NCT03978442|DRUG|Bupropion|All medically eligible participants will be prescribed bupropion to begin 7 days before the quit date and continued through 12 weeks post-quit. Participants will be scheduled to begin at 150mg/day of bupropion for at least 3 days before titrating up to 300mg/day dose of bupropion.
41444720|NCT03978442|BEHAVIORAL|Cognitive Processing Therapy|12 sessions of CPT, which is a well-established trauma-focused psychotherapy for PTSD that has demonstrated efficacy and effectiveness in Veterans.
41444721|NCT03978442|BEHAVIORAL|Smoking Abstinence Reinforcement Therapy|Monetary reinforcement for smoking abstinence that is bioverified by breath carbon monoxide and saliva samples.
41444722|NCT03978442|BEHAVIORAL|Yoked Contingency Management|Participants in the yoked control will receive the monetary reinforcement of their yoked participant regardless of smoking abstinence or session attendance.
41444723|NCT00841698|DRUG|Paroxetine HCl|40 mg Film-Coated Tablet
41444724|NCT00841698|DRUG|Paxil®|40 mg Film-Coated Tablet
41444725|NCT05674240|DEVICE|Intrathecal Targeted Drug Delivery|Intrathecal drug delivery systems (IDDs) deliver small doses of analgesics directly to the spinal cord.
41444726|NCT05674240|COMBINATION_PRODUCT|Conservative medical management|Including physical therapy, oral or transdermal medications and injections
41444727|NCT04784338|BEHAVIORAL|Virtual shared medical visit|a shared medical visit done by zoom in a group, 1.5 hours
41444728|NCT04784338|BEHAVIORAL|Nutritional classes|A cooking class done by the teaching kitchen demonstrating cooking skills
41444729|NCT05058430|DEVICE|Electrical salivary stimulator system assigned to subjects with xerostomia|SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
41444730|NCT05058430|DEVICE|No Electrical salivary stimulator system assigned to subjects without xerostomia|SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
41444731|NCT05329961|DRUG|Gardasil9|The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP. The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.
41444732|NCT04675372|DRUG|Dexmedetomidine|Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
41444733|NCT04675372|DRUG|Midazolam|Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam
41106795|NCT01595321|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) 200 mg/m\^2 administered one day prior to GVAX (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
41106796|NCT01595321|BIOLOGICAL|GVAX Pancreas Vaccine|GVAX administered one day after Cy (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
41106797|NCT01595321|RADIATION|Stereotactic Body Radiation|"Cohort 1 and 2: SBRT (6.6 Gy per day, 33 Gy total dose) will be administered over 5 days within 6-10 weeks of pancreas surgery (Whipple).~Cohort 3: SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first dose of CY/GVAX."
41444734|NCT04888039|OTHER|quality of life questionnaires (EORTC QLQ-C30 ; EORTC QLQMY20 ; EQ-5D-5L ; Cohen's stress scale)|"Excepted the delivery of quality of life questionnaires (a maximum of 5 times during the course of treatment) specific to this study, only the data available during the course of patient care will be collected.~The quality of life questionnaires and the perceived stress questionnaire will be given to patients :~* At diagnosis (before starting 1st line of treatment),~* after the induction phase (before autologous transplantation for patients who will be transplanted),~* after the consolidation phase,~* after the maintenance phase : 1 year and 2 years after the start of the maintenance."
41444735|NCT06057727|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming appointment and encouraging the patient to ask their provider about receiving the vaccine.
41444736|NCT06057727|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
41444737|NCT06057727|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention.
41444738|NCT06057727|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
41444739|NCT00211263|BEHAVIORAL|Enhanced Clinical Intervention|
41444740|NCT00211263|DRUG|mood stabilizer|
41444741|NCT01728181|DRUG|Tivozanib|The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
41270981|NCT01652924|DEVICE|Mechanical ventilation with facial mask|This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
41444742|NCT01728181|DRUG|Erlotinib|150 mg/day for 28 day cycle. No rest period.
41444743|NCT01728181|OTHER|Standard of Care treatment|This treatment will be determined by the study doctor and is considered standard of care.
41444744|NCT06350955|DRUG|Iron isomaltoside|single dose of 500 mg iron isomaltoside
41444745|NCT06350955|DRUG|Iron Carboxymaltose|single dose of 500 mg ferric carboxymaltose
41444746|NCT01180322|DRUG|Cytarabine|"Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)~Consolidation therapy:~Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).~Elderly patients (\>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2)."
41444747|NCT01180322|DRUG|Idarubicin|"First induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (\>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.~Arm B:~12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (\>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.~Second induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)~Arm B:~12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups)."
41444748|NCT01180322|DRUG|Etoposide|"Induction therapy:~Arm A, C, D:~100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (\>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.~Arm B:~100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (\>65 yrs) patients only two doses of etoposide are foreseen on days 6+8."
41444749|NCT01180322|DRUG|Azacitidine|"Induction therapy:~Arm B and C:~100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Arm D:~100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Maintenance therapy:~Arm B, C, D:~50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)"
41444750|NCT01180322|DRUG|Lenograstim|"Consolidation therapy:~subcutaneously daily beginning on day 10 until neutrophil count \> 0.5 x 109/l."
41444751|NCT00028587|DRUG|bortezomib|Given IV
41444752|NCT00028587|DRUG|paclitaxel|Given IV
41444753|NCT00028587|DRUG|carboplatin|Given IV
41444754|NCT00028587|OTHER|laboratory biomarker analysis|Optional correlative studies
41444755|NCT06558955|BEHAVIORAL|Technology-enabled anticipatory guidance and peer support|The intervention includes 4 online sessions led by an oral health therapist (OHT) or dentist, as well as push notifications and information delivered to participants via a mobile/web app.
41444756|NCT06558955|BEHAVIORAL|Conventional health education|Participants on this arm will receive conventional child oral health education materials at 4 time points.
41444757|NCT02412553|OTHER|Specific carbohydrate diet|
41444758|NCT02412553|OTHER|Elemental diet|
41444759|NCT05502679|OTHER|Weight bearing as tolerated|Bearing weight on lower limb extremity
41444760|NCT05502679|OTHER|Pragmatic Exercise protocol|Designed exercise prescriptions according to the patients' needs
41444761|NCT00819169|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
41444762|NCT00819169|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
41444763|NCT03202459|DRUG|Group A - gabapentin 600 mg|The patient will receive oral 600 mg gabapentin 2 h before surgery
41106798|NCT01595321|DRUG|FOLFIRINOX|"FOLFIRINOX is given over six 28-day cycles, starting at least 1 weeks after SBRT.~FOLFIRINOX consists of the following drugs given IV on days 1 and 15 of each cycle:~Oxaliplatin (85 mg/m\^2), Irinotecan (180 mg/m\^2), Leucovorin (400 mg/m\^2), Fluorouracil (400 mg/m\^2 bolus followed by 2,400 mg/m\^2 continuous infusion over 46-48 hours);~modified FOLFIRINOX consists of the same regimen described above but without the 400 mg/m\^2 Fluorouracil bolus."
41444764|NCT03202459|DRUG|Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
41444765|NCT03202459|DRUG|Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
41444766|NCT03275363|DIAGNOSTIC_TEST|Neurocognitive battery|"Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).~NACC: Story recall, Benson's complex figure copy, colour trail test (black \& white), verbal fluency, digit forward and backward span."
41444767|NCT03275363|DIAGNOSTIC_TEST|MRI|MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
41444768|NCT03275363|BIOLOGICAL|Blood tests|Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
41444769|NCT03275363|DIAGNOSTIC_TEST|EEG with event-related potential (ERP)|128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
41106799|NCT00798096|DRUG|Fostamatinib Disodium|200 mg PO BID
41444770|NCT03275363|DIAGNOSTIC_TEST|Amyloid PET CT|F18 Flutametamol PET CT for selected patients
41444771|NCT04733183|DRUG|Dacarbazine|Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
41444772|NCT04733183|DRUG|onfekafusp alfa|L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
41444773|NCT04509453|DEVICE|McGRATH laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using McGRATH video layngoscopy
41106800|NCT02984124|BEHAVIORAL|Informed Assent Discussion|"Participants randomized to the intervention arm will participate in a discussion about CPR with a study doctor that follows these steps:~1. Patient's values and preferences for therapies and outcomes elicited from patient and family; overall therapeutic goals formulated~2. Description of CPR and dying process provided~3. Personalized explanation provided about probable lack of achieving any reasonable therapeutic goal with CPR (i.e. why s/he is a poor candidate for CPR due to underlying illness)~4. Patient and family informed that due to severe underlying illness and high likelihood that CPR will be burdensome/harmful and will not provide benefit, CPR will not be offered unless they disagree (except in rare circumstance where overall therapeutic goals from step 1 are to preserve life regardless of quality of that life) Assessment of patient's and family's understanding of issues discussed; patients may actively disagree and request CPR be performed, but CPR not explicitly offered"
41106801|NCT02984124|BEHAVIORAL|Usual Care with Attention Control|Participants who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
41106802|NCT04063826|DEVICE|PET MRI|All participants will have a liver scan
41444774|NCT04509453|DEVICE|Macintosh laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using classic Macintosh video layngoscopy
41444775|NCT03264521|OTHER|Surveys|Web surveys about experiences with chronic low back pain, demographics, coding qualitative text.
41444776|NCT04489719|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41444777|NCT04489719|OTHER|Questionnaire Administration|Ancillary studies
41106803|NCT02466672|OTHER|none - observational only|
41106804|NCT06236516|RADIATION|One fraction stereotactic body radiotherapy|Radiotherapy will consist of one-fraction SBRT using the Ethos linear accelerator and online adaptive treatment planning system.
41106805|NCT06236516|DEVICE|HyperSight|HyperSight is a novel on-board imaging platform equipped with rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for both simulation and treatment.
41106806|NCT06236516|DEVICE|Ethos|Ethos is a unique ring-gantry CT-guided linear accelerator notable for having a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
41106807|NCT00117988|DRUG|tanespimycin|
41106808|NCT05219617|DRUG|Carisbamate|"Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\])."
41444778|NCT04489719|DRUG|Radium Ra 223 Dichloride|Given IV
41444779|NCT03379883|PROCEDURE|Pulsed radiofrequency (P-RF)|"Intra articular RF~Insertion of the RF cannula within the joint. The recommended parameters are a pulse width of 20 msec and a rate of 2 Hz at 42°C for 10min.~Genicular nerve RF ablation.~The RF probe will be placed. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of \< 0.6 V"
41444780|NCT03379883|PROCEDURE|Platelet rich plasma (PRP)|Under ultrasound guidance while the patients in a sitting position. In total, 3 to 8 mL of PRP will be injected via the inta-articular route
41444781|NCT03961230|DRUG|Jueyin granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
41444782|NCT03961230|DRUG|Jueyin Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
41444783|NCT02914990|DRUG|BPI-15086|BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
41444784|NCT00233415|DEVICE|Stereotactic Radiosurgery (Cyberknife)|
41444785|NCT02327559|BEHAVIORAL|Mind in Labor (MIL): Working with Pain in Childbirth|The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.
41444786|NCT02327559|BEHAVIORAL|Treatment as usual (TAU)|"The treatment as usual TAU active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis)."
41444787|NCT03378492|DEVICE|Ultrasound Guided Epidural|Sterile ultrasound gel will be applied to the patient's back and the sterile device will be used to image the lumbar vertebrae in the area of the palpation-derived location. When the device is placed above the vertebral interspace, the 3D image mode will identify the spine midline and the depth from the skin to the epidural space. A single 3D ultrasound video loop of the vertebral interspace will be saved to confirm correct landmark identification. After identification of the vertebral interspace, the skin will be marked with a marking utensil or physical indentation at the point of needle entry indicated by the device. The epidural needle will then be placed in the same fashion as in the standard procedure group. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance.
41444788|NCT03378492|PROCEDURE|Standard Epidural|The point of needle entry will be located using the landmarks technique. The specific level of epidural placement will be determined on a per-patient basis at the anesthesiologist's discretion. The spine midline will also be palpated to determine the approximate location of an interlaminar space. The needle will then be inserted at the appropriate location determined by the landmarks technique, and successful epidural placement will be confirmed by observation of loss of resistance and follow-up confirmation of analgesia. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance. The epidural catheter will be inserted and the procedure will continue according to the standard of care.
41444789|NCT01724515|OTHER|Lipid infusion and muscle biopsies|Subjects will undergo a baseline muscle biopsy, a lipid infusion for 5 hours (60 ml/hr), and a muscle biopsy after the lipid infusion.
41444790|NCT06540716|DEVICE|Inspire System|Hypoglossal nerve stimulation therapy will be activated at approximately 1 month post-implant.
41444791|NCT04630795|DEVICE|ViscoTurf insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest.
41444792|NCT04630795|DEVICE|Control insole|Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
41444793|NCT01756326|DRUG|PREOB® Implantation|
41444794|NCT01756326|PROCEDURE|Bone Autograft|
41444795|NCT06548789|DIETARY_SUPPLEMENT|Prebiotic Xnack Packouts|Prebiotic snack packouts (distributed every two weeks) and diet counseling to support increased consumption of prebiotic foods which provide dietary fiber, plant-based protein and other nutrients selectively fermented by the microbiome (e.g., pulses and legumes).
41444796|NCT02982577|DRUG|Pilocarpine|Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
41444797|NCT02982577|OTHER|Spray without Pilocarpine|Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
41444798|NCT05270499|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention will be conducted in this study.
41106809|NCT04352582|OTHER|Survey|Survey
41106810|NCT00006450|DRUG|Phenylbutyrate|
41106811|NCT06425068|DEVICE|Exposure of the patient to a novel air mattress.|"see information provided in the Arms section (experimental)"
41444799|NCT05301881|PROCEDURE|Surgery|resection of the oligometastatic lesion(s)
41106812|NCT06425068|DEVICE|Exposure of the patient to a conventional foam mattress.|"see information provided in the Arms section (active comparator)"
41106813|NCT02253719|PROCEDURE|cryotherapy, further biopsy, LEEP, surgery as indicated|These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
41106814|NCT03311568|DEVICE|ultrasound for microcirculatory assessment|"Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface."
41106815|NCT02162420|DRUG|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
41106816|NCT02162420|DRUG|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
41106817|NCT02162420|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
41106818|NCT02162420|RADIATION|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
41106819|NCT02162420|BIOLOGICAL|Stem Cell Transplant|Stem cell transplant on day 0.
41106820|NCT02162420|DRUG|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
41106821|NCT00765492|DRUG|AZD8529|oral
41106822|NCT00765492|DRUG|Placebo|oral
41106823|NCT04505943|DRUG|Isonicotinic Acid Hydrazide|2 vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
41444800|NCT05301881|RADIATION|Radiotherapy|radiation of the oligometastatic lesion(s)
41444801|NCT05301881|OTHER|Radiofrequent ablation|radiofrequent ablation of the oligometastatic lesion(s)
41444802|NCT06613100|DRUG|Xaluritamig|Intravenous (IV) infusion
41444803|NCT04501003|DEVICE|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm. The cavity was widened to be triangular and symmetrical. Both tubal ostium surgeries were clearly observed at the end of the surgery. All patients were discharged on the day of surgery and no hormonal therapy and intrauterine balloon was applied after surgery. Approximately 3 months after the hysteroscopic T-shaped operation, an office hysteroscopy operation was planned to control patients in the secretory phase, to perform uterine cavity and post-operative fly control and to receive post-operative control endometrial biopsy specimens.
41444804|NCT05464563|DEVICE|Electroencephalogram|An electroencephalogram is recorded during a task of rest then self-compassion and then empathy.
41106824|NCT04505943|DRUG|dinoprostine|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
41106825|NCT04505943|DRUG|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion
41106826|NCT00722670|BEHAVIORAL|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
41444805|NCT02911792|DRUG|Dapagliflozin|SGLT2 inhibitor
41106827|NCT00722670|BEHAVIORAL|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
41106828|NCT02266641|BEHAVIORAL|nutrition counseling|Pregnancy diet (include one-carbon nutrients)
41106829|NCT02266641|DIETARY_SUPPLEMENT|multivitamin supplement|
41444806|NCT02911792|DRUG|Metformin|Oral diabetes medicine that helps control blood sugar levels.
41444807|NCT02911792|DRUG|Glipizide 5 MG|Oral diabetes medicine that helps control blood sugar levels.
41444808|NCT03292458|DRUG|Sodium Oxybate|Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.
41444809|NCT06483646|OTHER|Gaseous sampling:|the subject is asked to aspirate the gaseous contents of his oral cavity using a 1ml plastic syringe.
41444810|NCT06558994|PROCEDURE|Transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis|Half of the patients will undergo transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis.
41444811|NCT06558994|PROCEDURE|Ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis|Half of the patients will undergo ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
41444812|NCT06308484|DEVICE|Transcutaneous vagus nerve stimulation|Patients that are enrolled in a MBRP program will be subjected to weekly tVNS stimulation during a 30-minute audio guided mindfulness exercise.
41444813|NCT06308484|DEVICE|Closed-loop AM-tACS|Patients that are enrolled in a MBRP program will be subjected to weekly CLAM-tACS stimulation during a 30-minute audio guided mindfulness exercise.
41444814|NCT00585286|DEVICE|10,600 nm fractional carbon dioxide laser system|1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2
41444815|NCT00378963|DEVICE|ProAdjuster|
41444816|NCT00440934|DEVICE|Amplitude-modulated electromagnetic fields|
41444817|NCT06512909|OTHER|Virtual Reality Glasses Application|A video containing relaxing nature images will be shown to a group via VR. Intramuscular injection will begin three minutes after the individual starts watching the video, and the procedure will be performed while continuing to watch the video.
41444818|NCT06512909|OTHER|Stress Ball Application|One group will be given a stress ball in the hand on the side where the intramuscular injection will be administered. Three minutes after the individual starts squeezing the ball, intramuscular injection will begin and the procedure will be performed while squeezing the ball.
41444819|NCT05074576|OTHER|Mulligan group|"Ultrasound (8minutes, 1.5 w/cm2, pulsed), conventional transcutaneous electrical nerve stimulation (TENS) (20 minutes, 60-120 Hz frequency) and hot pack application (20 minutes) and interferential current (100 rpm) as electrotherapy agents. In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied. Mobilization is performed by giving 15-20 seconds rest between 3 sets of 4-5 repetations.~Patients were treated in a sitting position. SNAG technique was applied by the physiotherapist at each on spinal level. Active movement with using passive manual force in the direction of translation or rotation was applied to the cervical vertebrae. At the end range of the joint, overpressure was applied by the patient himself"
41444820|NCT05074576|OTHER|Control group|Electroterapy agents are applied in the same conditions with Mulligan Group. Active neck, shoulder and thoracic region exercises for correction postural misalignment are performed in both groups. All exercises were done in 3 sets of 10 repetitions. Stretching exercises of upper part of Trapezius, sternocleidomastoideus and pectoral muscles are done with 10 repetitions and for 15-30 seconds.
41106830|NCT00509769|DRUG|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
41106831|NCT02888002|BEHAVIORAL|Guide to better alcohol habits|A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
41106832|NCT05982353|DEVICE|PTFE application|Polytetrafluoroethylene membrane used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
41106833|NCT05982353|DEVICE|Gelatin sponge|gelatin sponge used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
41106834|NCT04680871|DEVICE|In-Ear Sensor|The device will passively monitor participants' biometrics
41106835|NCT05674370|DEVICE|GRIP Electronic Diagnostic Chip|Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab
41106836|NCT05674370|DIAGNOSTIC_TEST|Laboratory-based nucleic acid amplification tests (NAATs)|Polymerase Chain Reaction (PCR) analysis for detection of viruses (e.g., Roche cobas SARS-CoV-2 or influenza A/B) from nasal swab
41444821|NCT05344053|OTHER|Community-based precise management|The community-based precise management is a modified management strategy beyond the traditional standard community-based care under the hierarchical medical system of China. In the intervention arm, the community doctors receive training to improve their skills on coronary artery disease management. Patients will be under management for 1 year according to the strategies of community-based precise management and rehabilitation model.
41444822|NCT05344053|OTHER|Standard community-based management|The standard community-based management is the usual community-based care under the hierarchical medical system of China. In this arm, the community doctors will not receive any training on precise management strategies to improve their skills on coronary artery disease management, and patients will be under usual care for 1 year.
41444823|NCT01197391|BIOLOGICAL|REGN728|2 Subcutaneous Cohorts (dose 1, 2)
41444824|NCT06558500|PROCEDURE|Uterocervical angle|"With the patient in the lithotomy position and empty bladder, care was taken to avoid applying pressure to the cervix with the transvaginal probe. The cervix was aligned in the midline, and the endocervical canal was visualized throughout its length.During cervical measurement, care was taken to ensure that the internal os, external os, and entire endocervical canal were visible in the same image. With the endocervical canal, external os, and internal os linearly displayed on the screen, the angle between the endocervical canal, anterior and posterior uterine segment was measured using the ultrasound's angle measurement feature.For the measurement of the uterocervical angle, the first line of the angle was defined along the endocervical canal used for measuring cervical length, and the second line was drawn from the internal os along the anterior uterine segment for a minimum of two centimeters. The angle between these two lines was recorded as the uterocervical angle in the form."
41444825|NCT04211779|DEVICE|Real tDCS|Real tDCS (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The active session of tDCS will consist in applying anodal stimulation over left M1 (C3 according to the 10-20 international EEG placement) and the cathodal stimulation over right supraorbital area (Fp2 according to the 10-20 international EEG placement), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp.
41444826|NCT04211779|DEVICE|Sham tDCS|Sham current (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
41444827|NCT04211779|OTHER|Exercise|The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
41444828|NCT04776447|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02"
41444829|NCT04776447|DRUG|Placlitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
41444830|NCT04776447|DRUG|Atezolizumab|"Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions."
41444831|NCT03448263|PROCEDURE|Balanced Force technique|Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth
41444832|NCT03448263|PROCEDURE|WaveOne technique|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
41444833|NCT03448263|PROCEDURE|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
41444834|NCT01034358|BIOLOGICAL|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
41444835|NCT03499873|DRUG|Nepafenac 0.3% Oph Susp|Nepafenac 0.3% Ophthalmic suspension (experimental product)
41444836|NCT03499873|DRUG|Placebos|Placebo
41444837|NCT03499873|DRUG|Nepafenac 0.3% Oph Susp (reference)|Nepafenac 0.3% Ophthalmic suspension (Innovator)
41444838|NCT04097561|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
41444839|NCT02132663|OTHER|Control: Marketed routine infant formula|
41444840|NCT02132663|OTHER|An investigational infant formula containing an alternate source of DHA|
41106837|NCT03554902|PROCEDURE|Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
41106838|NCT00915330|PROCEDURE|Rapid on-site cytopathologic evaluation (ROSE)|ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
41106839|NCT00915330|PROCEDURE|TBNA|transbronchial needle aspiration
41133301|NCT04942184|OTHER|Tablet in Arm 1|A computer tablet will be provided to each participant that will have daily reminders about the memory strategies during week 1 and 2, while no reminders will be present in week 3 and 4. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
41444841|NCT05844605|PROCEDURE|Non-invasive neuromodulation (TMS and/or tDCS)|Non-invasive neuromodulation (TMS and/or tDCS) coupled with intensive behavioural training (neurorehabilitation and/or cognitive rehabilitation)
41444842|NCT04811235|DEVICE|Near Infra-Red Spectroscopy (NIRS) Sensor|The NIRS sensor is laid on top of the dura, at the site of the SCI, and emits near-infrared light signals into the cord to measure tissue oxygenation and tissue hemodynamics in real-time.
41444843|NCT02220985|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
41444844|NCT02220985|DRUG|Cyclophosphamide|Given IV
41444845|NCT02220985|DRUG|Fludarabine Phosphate|Given IV
41106840|NCT04806256|BEHAVIORAL|Clinical Decision Support System|This project is based on the artificial intelligence (AI) algorithm to screen the effective methods of traditional Chinese medicine intervention for dry eye and its applicable conditions, and optimize the traditional Chinese medicine intervention plan for dry eye through the evaluation of evidence-based medicine and expert consensus, and construct the traditional Chinese medicine intervention Clinical Decision Support Systems (CDSS) for dry eye. At the same time, the CDSS is provided to clinicians for their selection.
41106841|NCT04806256|OTHER|Routine intervention|The routine intervention without CDSS is also the clinically common intervention at present.
41444846|NCT02220985|OTHER|Laboratory Biomarker Analysis|Correlative studies
41444847|NCT02220985|DRUG|Methotrexate|Given IV
41444848|NCT02220985|DRUG|Mycophenolate Mofetil|Given IV and PO
41444849|NCT02220985|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
41444850|NCT02220985|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with CD45RA-depleted cells
41444851|NCT02220985|DRUG|Tacrolimus|Given IV or PO
41444852|NCT02220985|DRUG|Thiotepa|Given IV
41444853|NCT02220985|RADIATION|Total-Body Irradiation|Undergo TBI
41444854|NCT05850676|DIAGNOSTIC_TEST|Sleep study|Participants will spend two nights in the Penn Sleep Center
41106842|NCT00758602|DRUG|mycophenolate mofetil|0.75-1 g PO BID from Day 0 through Month 12
41444855|NCT03016650|DRUG|Acetaminophen|Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
41444856|NCT03016650|DRUG|Ibuprofen|Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
41444857|NCT06562114|DRUG|TML-6 Granules|Administered orally
41444858|NCT06562114|DRUG|Placebo|Administered orally
41106843|NCT00758602|DRUG|tacrolimus, standard dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
41444859|NCT01293097|DRUG|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
41444860|NCT01293097|DRUG|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
41444861|NCT03942770|BEHAVIORAL|Contingency Management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
41444862|NCT03942770|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
41444863|NCT04873063|DRUG|Beclomethasone dipropionate|BDP 3 mg bid (R product) BDP 6 mg qd (T product)
41444864|NCT04042233|DRUG|Experimental Intraosseous vancomycin 500mg in 250 mL NS|500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.
41444865|NCT04042233|DRUG|Standard IV administration of vancomycin|IV antibiotics (cefepime \& vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).
41444866|NCT01165450|DRUG|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
41444867|NCT01165450|DRUG|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
41444868|NCT03131895|DRUG|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
41444869|NCT03131895|DRUG|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
41444870|NCT03131895|DRUG|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
41444871|NCT03131895|DRUG|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
41444872|NCT05616728|DRUG|EDP-235|capsule
41106844|NCT00758602|DRUG|tacrolimus, low dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.
41106845|NCT00758602|DRUG|corticosteroids|According to center's practice
41444873|NCT05616728|DRUG|Placebo|capsule
41106846|NCT02370563|DRUG|18F-FSPG|18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
41106847|NCT03418324|DRUG|TRC105|Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks
41444874|NCT06216964|DIAGNOSTIC_TEST|Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) NAAT(s)|Test every week after the start of treatment, until NAAT negativation and up to a maximum of 4 weeks
41444875|NCT06081153|DRUG|Evolocumab|See arm description.
41444876|NCT06081153|DRUG|Placebo|See arm description.
41444877|NCT01528462|OTHER|Expedited Treatment of Sleep Disorders|Patients in this arm will undergo an expedited polysomnogram (if clinically necessary) and early treatment of any sleep disorders. Sleep-related disorders will be managed with the currently recommended therapies; patients with obstructive sleep apnea will be treated with positional therapy, continuous positive airway pressure (CPAP), etc., and those with restless legs syndrome will be treated with standard treatments such as iron, or dopaminergic agonists. Patients will also be counselled on improving their sleep hygiene and adjusting the timing of their medication administration to optimize efficacy. Furthermore, patients will receive information handouts.
41444878|NCT03581097|OTHER|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of Intra-Venous Regional Anesthesia (IVRA)
41444879|NCT06627699|DEVICE|Total Knee Arthroplasty|Post-Market Surveillance of the Freedom Total Knee System for Primary TKA
41444880|NCT05645120|OTHER|Education|All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.
41444881|NCT04246476|BEHAVIORAL|Mentally singing|All participants (people with PD and age-matched controls) sing their song in their head and match their footfalls or finger tapping to the beat.
41444882|NCT04246476|BEHAVIORAL|Listening to music|All participants (people with PD and age-matched controls) listen to their song and match their footfalls or finger tapping to the beat.
41444883|NCT00761813|DEVICE|Open reduction internal fixation (ORIF) with single sliding hip screw|The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
41444884|NCT00761813|DEVICE|ORIF with multiple cancellous screws|ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
41444885|NCT01304823|DIETARY_SUPPLEMENT|lactisole|flavoring agent/sweet taste antagonist
41444886|NCT01304823|OTHER|mixed liquid meal|Ensure Plus
41444887|NCT03919058|OTHER|Baseline activity (control regime)|This is a baseline measurement of physical activity during which subjects will be instructed not to change activity patterns during four days and to note all activities they perform.
41106848|NCT03418324|DRUG|Abiraterone|Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.
41106849|NCT03418324|DRUG|Enzalutamide|Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.
41106850|NCT02459899|DRUG|Placebo|Placebo, once daily, before the first meal of the day
41444888|NCT03919058|OTHER|Increased sitting time (sit regime)|Participants have to spend 14h of their day sitting, 1h walking and 1h standing, for four consecutive days. According to the compendium of Ainsworth et al. (2011), this corresponds with a daily workload of activities (DWA) of 27 metabolic equivalents (MET's) per day.
41444889|NCT03919058|OTHER|Non-exercise physical activity (sit less regime)|Each day (4 days in total) will consist of 3h walking, 4h standing and 9h sitting. These time frames are chosen to result in a comparable DWA increase as the exercise regime compared to the sit regime (+7 MET's)27. The additional 2h of walking and 3h of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of \> 1h. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h (e.g. walking during shopping and work related walking in an office).
41444890|NCT03919058|OTHER|Structured exercise (exercise regime)|One hour of sitting in the sit regime will be replaced with 1 training session (1h) on a cycle ergometer in the research center. The remaining hours of each day (4 days in total) have to be spent as follows: 13h sitting, 1h walking and 1h standing for daily care. The intensity of the training session (50-60% of Wmax) results in a DWA of 34.5 MET's according to the compendium of physical activities. Duration of training sessions will be adapted individually with ActivPAL data of the sit less and sit regime to identically match DWA increase between the sit less and exercise regime, compared to the sitting regime.
41444891|NCT03834376|DRUG|Pimodivir|Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram \[mg\]) over a time period of 5 days.
41444892|NCT01527890|DRUG|Fentanyl|intravenous patient-controlled analgesia
41106851|NCT02459899|DRUG|Sotagliflozin|Sotagliflozin,once daily, before the first meal of the day
41444893|NCT06433258|BEHAVIORAL|Enhanced TSSC curriculum|In addition to the original TSSC curriculum participants will also be educated with the enhanced curriculum which includes components related to alcohol and social determinants of health needs) to promote cancer prevention through healthy lifestyles.
41444894|NCT06433258|BEHAVIORAL|Original TSSC curriculum|Participants will be educated with evidence-based modules focused on topics such as introduction to TSSC, physical activity, fruit and vegetable consumption, reduce sugar intake, diabetes, portion control, cancer, and high blood pressure.These modules are provided by community health workers who have been trained in the contents of the modules, as well as motivational interviewing techniques for delivering the modules.
41444895|NCT03615573|OTHER|Quality of Life Surveys|Patients with breast cancer diagnosis complete questionnaires over 20-30 minutes at baseline and at 3, 6, and 12 months after enrollment.
41444896|NCT02627963|DRUG|Tivozanib hydrochloride|Tivozanib hydrochloride
41444897|NCT02627963|DRUG|Sorafenib|Sorafenib
41444898|NCT01642277|DRUG|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
41444899|NCT03487081|BEHAVIORAL|Social regulation|Participants will be instructed to help another person think about their negative events differently using an emotion regulation strategy called reappraisal.
41444900|NCT03487081|BEHAVIORAL|Self regulation|Participants will be instructed to think about their negative events by reframing the meaning of the event. This is a typical strategy in emotion regulation research known as reappraisal.
41106852|NCT03356665|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT)|The 4 rapid diagnostic tests (RDT) will be carried out on fresh blood from clinical suspects. Only those subjects that are positive in at least 1 RDT will 1) undergo tests on DBS (immune trypanolysis, ELISA and DNA detection); 2) undergo parasitological confirmation (reference standard) at inclusion.
41270982|NCT01652924|DEVICE|Manual ventilation with facial mask|"This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.~The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist."
41270983|NCT00749190|DRUG|BI 10773|
41270984|NCT00749190|DRUG|placebo|
41270985|NCT00749190|DRUG|sitagliptin|
41270986|NCT00460382|DRUG|raltegravir potassium|400 mg twice a day
41270987|NCT00460382|DRUG|darunavir/ritonavir|2 pills of 300 mg twice a day
41270988|NCT00460382|DRUG|etravirine|2 pills of 100 mg twice a day
41270989|NCT00460382|DRUG|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
41270990|NCT03705390|DRUG|ILB|Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks
41270991|NCT04513470|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
41270992|NCT00997971|OTHER|Modilac Rose 1|Infant formula used for non-breastfed children
41270993|NCT02368470|DRUG|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
41270994|NCT02368470|DRUG|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
41270995|NCT01241500|DRUG|ON 01910.Na|The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
41270996|NCT04730895|DRUG|Oral 13 cis retinoic acid|Dose of 0.5 mg/kg/day in 2 divided doses orally for 14 days
41270997|NCT04730895|DRUG|Aerosolized 13 cis retinoic acid|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day
41270998|NCT04730895|COMBINATION_PRODUCT|13 cis retinoic acid doses orally in combination with spike protein based vaccine|Dose of 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
41444901|NCT03647293|PROCEDURE|Ultrasound Guided Central Catheter Insertion|
41444902|NCT03647293|PROCEDURE|Peripherally Inserted Central Catheter|
41444903|NCT02149420|DRUG|VAY736|
41444904|NCT02149420|DRUG|Placebo|
41444905|NCT02921893|DRUG|Dexamethasone|Given PO
41444906|NCT02921893|DRUG|Ixazomib Citrate|Given PO
41444907|NCT02921893|DRUG|Lenalidomide|Given PO
41444908|NCT02921893|OTHER|Questionnaire Administration|Ancillary studies
41106853|NCT03356665|DIAGNOSTIC_TEST|Serological and molecular tests on DBS|Serological and molecular reference tests on dried blood spots (DBS) are carried out on RDT positive clinical suspects, which also undergo parasitological examination at inclusion (reference standard). If at least one of the serological or molecular reference tests on dried blood spots is positive, parasitological examination is repeated 3 and 6 months after inclusion. The combined results of parasitological examinations (at inclusion and if applicable at 3 and 6 months) serve as reference standard
41106854|NCT00578656|DIETARY_SUPPLEMENT|Baked Milk|Extensively heated milk
41106855|NCT02148133|DRUG|Eltrombopag 12.5 mg|White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
41106856|NCT02148133|DRUG|Eltrombopag 25 mg|White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
41106857|NCT03734536|DEVICE|REGENETEN™ Bioinductive Implant|The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.
41106858|NCT03734536|DEVICE|Arthroscopic repair of the high-grade (>50%) partialthickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
41106859|NCT05565391|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
41106860|NCT05565391|DRUG|Standard of care|Standard of care
41106861|NCT06152484|OTHER|Pentacam, Corvis ST and CASIA2|morphological and biomechanical parameters of corneal were obtain by CASIA2, Pentacam and Corvis ST
41106862|NCT05384392|OTHER|Recorded interview|A recorded clinical interview, transcribed verbatim and blinded analyzed
41106863|NCT05384392|OTHER|Clinical scales|Answering to clinical scales : PANSS (Positive and Negative Syndrome Scale); BPRS (Brief Psychiatric Rating Scale); CDSS (Calgary Depression Scale for Schizophrenia); MADRS (Montgomery-Åsberg Depression Rating Scale); Altman; YMRS (Young Mania Rating Scale); GAF (Global Assessment of Functioning); SF-36 (36-Item Short Form Survey); CGI-S (Clinical Global Impression Scale) et CGI-I (CGI-Improvement)
41106864|NCT05384392|BIOLOGICAL|Blood sample|Blood collection of inflammatory markers (IL-1, sIL-2R, IL-4, IL-6, IL-8 and TNF levels) and 2 EDTA tubes and 2 dry tubes for biological collection (plasma bank and serum bank). This blood sample will be taken during routine sampling.
41106865|NCT05384392|OTHER|MRI scans of the brain|The MRI scans of the brain will be performed. This exam is performed in routine care in the context of this pathology
41106866|NCT06227286|DEVICE|EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, initiates with 0.030MPa.
41106867|NCT06227286|DEVICE|Sham-EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, constant to 75 mmHg.
41106868|NCT00001575|BIOLOGICAL|Y-90 Humanized Anti-Tac|10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
41106869|NCT00001575|DRUG|Calcium-DTPA|Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
41106870|NCT01672840|DIETARY_SUPPLEMENT|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
41106871|NCT01672840|DIETARY_SUPPLEMENT|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
41106872|NCT04126239|OTHER|Online survey - questionnaire|Online survey - questionnaire
41106873|NCT00983164|DIETARY_SUPPLEMENT|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
41106874|NCT01521013|BEHAVIORAL|Supported self-care|"Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).~Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook."
41106875|NCT01521013|BEHAVIORAL|Unsupported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
41106876|NCT03119636|BIOLOGICAL|NPC transplantation|The cells are stereotactically implanted in the striatum.
41106877|NCT03119636|DRUG|Levodopa|Levodopa is used depending on the patient's condition
41106878|NCT06074380|DRUG|MIST surfactant|Surfactant will be given via MIST while neonate is on CPAP
41106879|NCT00525850|OTHER|high fat diet|high saturated fat no starch diet
41106880|NCT00525850|OTHER|low saturated fat diet|low calorie low saturated fat low trans fat high fiber diet
41106881|NCT02299336|DRUG|Aflibercept|pro re nata (PRN)
41270999|NCT04730895|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
41271000|NCT04730895|BIOLOGICAL|Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Dose of 5-7.5x10\^10vp of spike protein based vaccine such as ChAdOx1 nCoV-19 in deltoid of non-dominant arm, 28 days apart
41271001|NCT04743050|DRUG|Fatty Acids, Unsaturated|All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
41271002|NCT04743050|DIAGNOSTIC_TEST|Diagnostic Tests|All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
41271003|NCT01128985|DRUG|Canagliflozin 50 mg|50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
41444909|NCT06334991|BIOLOGICAL|CD19 t-haNK|"CD19t-haNK erived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).~Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM."
41444910|NCT05055063|DRUG|Belantamab mafodotin|by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
41444911|NCT01885117|BIOLOGICAL|TIVf|Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
41444912|NCT06242613|PROCEDURE|Robot-Assisted Gastrectomy|Gastrectomy performed with a robotic system.
41444913|NCT06242613|PROCEDURE|Laparoscopic Gastrectomy|Gastrectomy performed with conventional laparoscopic approach.
41444914|NCT03716466|OTHER|Endotracheal intubation|Subjects will receive prophylactic endotracheal intubation for upper gastrointestinal endoscopy procedure
41444915|NCT03716466|OTHER|No airway intervention|Subjects without prophylactic endotracheal intubation during upper gastrointestinal endoscopy procedure
41444916|NCT00836472|DRUG|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
41444917|NCT00836472|DRUG|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
41444918|NCT03118557|OTHER|Pilates pelvic floor strengthening|Pilates pelvic floor strengthening.
41444919|NCT04134910|PROCEDURE|Physical Therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
41106882|NCT02299336|PROCEDURE|Focal Laser|Focal laser administered based on pre-specified criteria
41106883|NCT06553794|OTHER|Gastroscopy with duodenal mucosal tissue biopsies|"Subjects will undergo a standardized heavy water dosing protocol for 2 days (1 loading day, 1 maintenance day) and consume a standardized diet for 2 days. On the experimental test day, a gastroscopy with collection of duodenal mucosa tissue samples will be performed."
41106884|NCT06368804|DRUG|Antibiotic monotherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
41444920|NCT05529576|DRUG|Omega 3 fatty acid|Omega-3 fatty acids complementation according to the patient's CRP level
41444921|NCT04451746|DRUG|Combined Oral Contraceptive|The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
41444922|NCT05571462|OTHER|Activity monitor group|No intervention will be applied. All included patients will be monitored with body-worn physical activity monitors during two periods.
41444923|NCT04275479|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|This is a two step process. Subjects will be asked to fast overnight,(no food and only water to drink for at least 8 hours). Then when subjects arrive for the visit,participants will have blood drawn and be asked to drink a sugary liquid. One hour later, another blood sample will be drawn and after two hours a final blood sample will be drawn.
41444924|NCT04275479|OTHER|Modified Oral Glucose Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). There will be no blood drawn during this test, participant will be asked to drink a sugary liquid and to remaining fasting (water only) for the two hour after finishing the drink.
41444925|NCT04275479|OTHER|Modified Mixed Meal Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). The participant will be given a meal supplement to drink in place of breakfast, for example Boost Plus. The participant will be asked to drink the meal supplement and to remaining fasting (water only) for the next two hours.
41444926|NCT04275479|DEVICE|Continuous Glucose Monitor|The participant will be provided a CGM device to wear for 10 days during the study period. The CGM will be blinded (meaning that the participant will not be able to see the results).
41444927|NCT04275479|OTHER|Food Diary|The participant will be asked to maintain a detailed food diary for 3 days during the 10 day study period.
41444928|NCT04275479|OTHER|Medical History Questionnaires|The participant will be asked to provide detailed medical history
41106885|NCT06368804|DRUG|Antibiotic bitherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
41444929|NCT04870606|DRUG|Proxalutamide (GT0918)|Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
41271004|NCT01128985|DRUG|Canagliflozin 100 mg|100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
41444930|NCT04870606|DRUG|Placebo|Placebo+Standard of care determined by PI and local regulatory
41444931|NCT04199741|DRUG|89Zr-DFO-SC16.56|Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.
41444932|NCT04199741|DRUG|SC16.56, Phase I, Cohort 2|7.5mg
41444933|NCT04199741|DRUG|SC16.56, Phase I, Cohort 3|22.5mg
41444934|NCT04199741|DRUG|SC16.56, Phase II|Dose for Phase II will be determined by results from Phase I.
41444935|NCT05900713|OTHER|dynamic neuromuscular stabilization training|DNS methods demonstrated efficacy in improving global trunk stabilizing patterns with noted gains in extremity movement and strength
41444936|NCT05900713|OTHER|balance exercises plus diaphragmatic breathing|The balance exercises is balance exercises while standing and walking The patient assume a semi-Fowler's position and perform diaphragmatic breathing.
41444937|NCT01310257|OTHER|Questionnaires|Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
41444938|NCT02036788|OTHER|Occlusion test|Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.
41444939|NCT02036788|OTHER|Thoraco-abdominal compressions|Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
41106886|NCT02892968|PROCEDURE|Fascia-Iliaca Block(FIB)|The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
41444940|NCT05592574|OTHER|Blood sample|Blood samples required to performe IL-17 Dosage
41444941|NCT00239382|DRUG|Meloxicam ampoule|
41444942|NCT00239382|DRUG|Meloxicam tablet|
41106887|NCT02892968|PROCEDURE|Femoral Nerve Block(FNB)|The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
41106888|NCT00420316|BIOLOGICAL|Rotarix (primary vaccination study)|GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.
41106889|NCT00420316|BIOLOGICAL|Placebo (primary vaccination study)|Two liquid oral doses of placebo
41106890|NCT06479668|BEHAVIORAL|Trier Social Stress Task|Specify details not covered in associated Arm Description.
41106891|NCT04925492|RADIATION|Positron Emission Tomography|An imaging method that uses radiotracers to view changes in the metabolic process.
41106892|NCT04925492|DRUG|Cu-64]-LLP2A|A radioactive tracer used in PET imaging.
41106893|NCT06223529|BEHAVIORAL|Therapeutic Instrumental Music Performance|Exercises using musical instruments to improve hemiparetic hand and arm function
41106894|NCT00316836|PROCEDURE|mammography|
41106895|NCT00723450|DRUG|lamictal|Flexible Dosing
41106896|NCT01131494|OTHER|Motor exercises for swallowing, breathing and phonation|This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
41106897|NCT06553833|BIOLOGICAL|Allogeneic transfusion|Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
41106898|NCT06553833|OTHER|Patient Blood Management|PBM is a strategy to manage the participants own blood. Its focus is on anemia, bleeding and coagulation management (using predominantly pharmaceutical and technological means).
41106899|NCT00031512|OTHER|Placebo|Placebo.
41106900|NCT00031512|DRUG|Pleconaril|5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
41106901|NCT06553287|DRUG|LNK01004 ointment 0.3%|LNK01004 ointment 0.3% for topical application
41106902|NCT06553287|DRUG|LNK01004 ointment 1.0%|LNK01004 ointment 1.0% for topical application
41106903|NCT06553287|DRUG|LNK01004 ointment 1.5%|LNK01004 ointment 1.5% for topical application
41106904|NCT06553287|DRUG|Vehicle BID|Inactive vehicle matched to LNK01004 ointment for topical application.
41106905|NCT01981850|BIOLOGICAL|RO7490677|IV infusion
41106906|NCT01981850|DRUG|Ruxolitinib|IV infusion
41106907|NCT00665379|OTHER|Regular Compression therapy (Trico bandages)|Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
41106908|NCT00665379|OTHER|New Compression therapy (C2L bandages)|Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
41106909|NCT03674190|PROCEDURE|Anterior Lumbar Interbody Fusion|Anterior Lumbar Fusion(ALIF)
41444943|NCT01548586|DEVICE|Eldith DC stimulator ( Magstim Company Ltd. UK)|Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
41444944|NCT01449981|BEHAVIORAL|Integrated Twelve-Step Facilitation|The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
41444945|NCT01449981|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
41444946|NCT04467151|DRUG|anti-SARS-CoV-2 plasma|Administration of anti-SARS-CoV-2 convalescent plasma
41444947|NCT04467151|OTHER|Placebo|Administration of placebo (albumin 5%)
41444948|NCT01942239|DEVICE|real time continuous glucose monitoring|
41444949|NCT04739358|DRUG|Tepotinib|Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
41444950|NCT01326494|DRUG|Arm 1 Oral Cortico Steroids|"Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )"
41444951|NCT06560827|BIOLOGICAL|CT011 CAR-GPC3 T Cells Injection|The dose selection for this trial was mainly based on the preliminary safety and efficacy results of CT011-HCC-01 trial in subjects with advanced HCC, in which 3 and 5 subjects in the 2.5 × 108 cell and 5.0 × 108 cell dose groups, respectively, completed a single infusion of CT011. The results showed that the two dose groups of CT011 were generally well tolerated in HCC subjects who failed to standard treatment, with controllable safety, and showed preliminary anti-tumor efficacy.
41444952|NCT00041392|DRUG|Magnesium|100 mg/kg
41444953|NCT00041392|DRUG|0.9% saline|Placebo
41444954|NCT06541327|DRUG|Chimeric Antigen Receptor|CAR-T
41444955|NCT04236596|DEVICE|Participants received a Neurostimulator, which was used to map the pudendal nerve|Participants in study received neurostimulator at their pudendal nerve as part of their normal clinical care. This neurostimulator was used to map the nerve.
41444956|NCT05476588|OTHER|Screening|Screening and validation of assessment tool translated into Spanish
41444957|NCT02511535|BIOLOGICAL|TBE booster vaccination|
41444958|NCT06235723|DEVICE|Virtual Reality|Virtual Reality was used before and during punctures. For every observation patients underwent either port puncture or peripheral venous puncture. One examination was carried out according to the Standard-of-Care. The other one was carried out with the additional use of VR. Participants watched a passive distraction video.
41444959|NCT00151229|OTHER|target blood pressure|
41444960|NCT04747535|DEVICE|Auto-CPAP|AIrSense 10, Auto-CPAP, Minimum pressure 5 cm water, maximum pressure 10 cm water
41444961|NCT04747535|DEVICE|CPAP since before|A CPAP the patient uses since before because of previously diagnosed obstructive sleep apnea
41106910|NCT03674190|PROCEDURE|Total Disc Replacement|Total Disc Replacement
41106911|NCT00511160|PROCEDURE|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
41106912|NCT00511160|PROCEDURE|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
41106913|NCT05386680|GENETIC|OAV101|Intrathecal administration of OAV101 at a dose of 1.2 x 10\^14 vector genomes, one time dose
41106914|NCT05861388|PROCEDURE|implant placement|2 implants were placed at position of lower 2nd premolar and 2nd molar
41444962|NCT02765724|DRUG|Pacritinib|Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration
41444963|NCT05977686|DEVICE|Masimo Root Radical 7 Pulse CO-Oximeter|The Masimo device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value.
41444964|NCT05977686|DEVICE|HemoCue Hb 801|The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement.
41444965|NCT04510597|PROCEDURE|Cytoreductive Nephrectomy|Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization
41444966|NCT04510597|DRUG|Active Comparator|"Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
41444967|NCT04717960|PROCEDURE|nasal submucosal injection of platelet rich plasma|"* The selected region will be inﬁltrated with a cold saline solution with addition of 1 mL of adrenaline and 25 mL of 2% lignocaine per 500 mL saline.~* Platelet-rich plasma is prepared by drawing 10 mL of blood sample from the patient.~* The blood will be centrifuged at 1530 g for 10 min to obtain platelet-poor plasma.~* This will again centrifuged at 2720 g for 10 min to get platelet-rich plasma.~* Approximately 1 mL of platelet-rich plasma will be obtained from 10 mL blood. Usually amount of about 3ml is needed to be injected in each nostril at the affected sites of inferior and middle turbinates, septum and floor of the nose. Platelet rich plasma injected into the affected area after degranulating the platelet by adding 0.5 mL of calcium chloride.~  * Injection interval of 2 weeks (up to total 3 consecutive injections).~ * Follow-up duration: 4 months"
41106915|NCT03781336|BEHAVIORAL|Mindfulness-based self care|Experimental: an abridged mindfulness-based program that is incorporated into the work day, which consists of five weekly 1.5 hour sessions.
41106916|NCT03646006|DRUG|Bupivacaine|10 mL (5mg/mL)
41106917|NCT03646006|DRUG|Placebo|10 mL normal saline
41106918|NCT03298919|BEHAVIORAL|Exercise Video Games|12 weeks laboratory based exercise videogames
41106919|NCT03298919|BEHAVIORAL|Aerobic Exercise|Stationary bike and/or treadmill walking for 12 weeks
41106920|NCT03298919|BEHAVIORAL|Home exercise videogames|videogame console and active videogames
41106921|NCT03298919|BEHAVIORAL|Home Standard Exercise|Personalized physical activity promotion materials
41106922|NCT01414842|DEVICE|Automated sodium profiling in endogenous hemodiafiltration|Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
41106923|NCT01414842|DEVICE|Standard sodium dialysate|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
41106924|NCT03649165|DRUG|Treatment A|During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
41106925|NCT03649165|DRUG|Treatment B|During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
41106926|NCT03649165|DRUG|Treatment C|During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
41106927|NCT03649165|DRUG|Treatment D|During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
41106928|NCT03649165|DRUG|Acetaminophen|Participants will receive a single 500mg dose of acetaminophen at the same time.
41106929|NCT01393119|DRUG|GTx-758|3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist
41106930|NCT04018508|OTHER|Massage|Massage intervention including effleurage, petrissage and energy work/Reiki at a pressure of 2 or less (Walton Pressure Scale)
41106931|NCT05990933|DRUG|Adrenaline|Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
41106932|NCT05334758|DEVICE|Bio-Self COVID-19 Antigen Home Test|At home COVID-19 antigen test kit
41106933|NCT05334758|DEVICE|Standard of Care COVID-19 Test|Standard of care
41106934|NCT05334758|DIAGNOSTIC_TEST|RT-PCR Test|High Sensitivity RT-PCR COVID-19 Test
41106935|NCT00920244|PROCEDURE|Cardiopulmonary resuscitation (CPR)|CPR is performed according to international and national guidelines on all patients.
41106936|NCT00920244|DRUG|Epinephrine|According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
41106937|NCT00920244|DRUG|Atropine|According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency \< 60 beat/min.
41106938|NCT00920244|DRUG|Amiodarone|According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.
41106939|NCT00920244|DEVICE|External defibrillator|According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.
41106940|NCT03812354|OTHER|THRIVE 4L/kg/min|High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
41106941|NCT03812354|OTHER|THRIVE 2L/kg/min|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
41106942|NCT03624413|BEHAVIORAL|Social Media Intervention|The social media intervention is a behavioral intervention developed by the study investigators and is delivered via mobile phones. The intervention uses the Social-ecological Model of Adolescent and Young Adult Readiness to Transition (SMART) model, highlighting modifiable targets of intervention that can be addressed through a social media platform. The SMART model incorporates modifiable factors such as knowledge, skills/self-efficacy, relationships and social support that can be targets of interventions to improve transition care. The SMART model emphasizes eight modifiable factors, three key stakeholders (adolescents, caregivers, and clinicians) and their interconnected relationship in influencing successful transition to adult care. The intervention is designed to overcome barriers and enhance facilitators to transitioning care among adolescents living with HIV who are transitioning to adult care in South Africa.
41106943|NCT03624413|OTHER|Standard of Care|Standard of care transition from pediatric to adult care for HIV.
41106944|NCT06249295|OTHER|oral cryotherapy|The experimental group used drinking water from a water dispenser with regular filter replacement and maintenance, plus a 2x5x7 cm (50 ml) ice lolly module to make ice lollies, and then intervened in the post-surgical period using oral cold therapy (ice lolly in the mouth)
41106945|NCT05136443|DRUG|loteprednol etabonate 0.25% ophthalmic suspension|tapering dose
41271005|NCT01128985|DRUG|Canagliflozin 300 mg|300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
41271006|NCT01128985|DRUG|Placebo|matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
41106946|NCT02678091|DEVICE|Ultrasound exam with Doppler|Ultrasound exam of the orbit
41271007|NCT00666744|OTHER|Family Mediated Exercise Therapy|35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
41444968|NCT02248051|DRUG|CXA-10|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
41444969|NCT03016806|RADIATION|Total Body Irradiation 1200 cGy|Total Body Irradiation 1200 cGy in 8 fractions
41106947|NCT01418391|PROCEDURE|Transversus Abdominis Plane block|"TAP BLOCK:~dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12\~18 hours upon to the regional anesthetics choose"
41106948|NCT02845050|DRUG|Vinflunine|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
41106949|NCT02845050|DRUG|Cisplatin|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
41106950|NCT02845050|PROCEDURE|Radical cystectomy|max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
41106951|NCT01597154|BEHAVIORAL|Lifestyle Counselling|Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
41106952|NCT04436055|OTHER|No Intervention will be used|Since this is an observational study, there are no interventions.
41106953|NCT06466564|DEVICE|Nufairy® Coil embolization system for intracranial aneurysm|Nufairy® Coil embolization system for intracranial aneurysm
41106954|NCT03230396|DIETARY_SUPPLEMENT|Vitamingum Sport|Vitamin -supplemented chewing gum
41106955|NCT03230396|DIETARY_SUPPLEMENT|Vitamingum Immunity|Vitamin -supplemented chewing gum
41106956|NCT03230396|DIETARY_SUPPLEMENT|Placebo|Control chewing gum. No vitamin content.
41106957|NCT05300399|DEVICE|mHealth app|The local healthcare providers will be assigned to an intervention group receiving the mHealth app to be used in their daily practices or a control group.
41106958|NCT01818401|DEVICE|the prosthesis GMK ® without the ancillary MyKnee ® LBS|
41106959|NCT01818401|DEVICE|Matched patient cutting blocks MyKnee ® LBS|
41106960|NCT05582187|DRUG|Fosmanogepix|a single dose of fosmanogepix administered by mouth under fasted conditions
41106961|NCT02225600|DRUG|40 IU Intranasal Oxytocin|40 IU intranasal oxytocin
41106962|NCT02225600|DRUG|Placebo|Intranasal Placebo
41106963|NCT02225600|DRUG|24 IU intranasal Oxytocin|
41106964|NCT02558218|DRUG|Systane Ultra|Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
41106965|NCT02558218|DRUG|tobradex quid (Standard)|Standard medication (tobradex quid for 20 days)
41106966|NCT01189006|DRUG|Dextromethorphan|Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
41106967|NCT05671484|OTHER|Transversalis Fascial Plane Block|Patients will receive ultrasound-guided transversalis fascial plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
41106968|NCT05671484|OTHER|Quadratus Lumborum Plane Block|Patients will receive ultrasound-guided quadratus lumborum plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
41106969|NCT00309088|DRUG|tacrolimus|oral
41106970|NCT00309088|DRUG|placebo|oral
41444970|NCT03016806|RADIATION|Total Body Irradiation 200 cGy|Total Body Irradiation 200 cGy in one fraction
41444971|NCT03016806|DRUG|Cyclophosphamide|50 mg/kg or 60 mg/kg
41444972|NCT03016806|DRUG|Mesna|50 mg/kg or 60 mg/kg plus 10% loading dose
41444973|NCT03016806|PROCEDURE|Cord Blood Infusion|Intravenous infusion of cord blood stem cells
41444974|NCT03016806|DRUG|Busulfan|0.8 mg/kg x 16 doses
41106971|NCT05691660|DRUG|TAS3731 Dose1|Oral administration,1 day,QD
41106972|NCT05691660|DRUG|TAS3731 Dose2|Oral administration,7 days,QD
41106973|NCT05691660|DRUG|TAS3731 Dose3|Oral administration,7 days,BID
41106974|NCT05691660|DRUG|Placebo|Oral administration, 1 day,QD
41106975|NCT05691660|DRUG|Placebo|Oral administration, 7 days,QD
41106976|NCT05691660|DRUG|Placebo|Oral administration, 7 days,BID
41106977|NCT04593719|OTHER|Experiment|The main components of the Lactation Management Model; breastfeeding training in the prenatal period (from the 30th week of pregnancy), early postpartum period (first 48 hours) skin to skin contact, early breastfeeding, relaxation using a dreaming technique, warm application to the breast, breast massage and for the first 48 hours after postpartum 6 months of continuous support (face to face, by phone, via social media).
41106978|NCT04351113|DIETARY_SUPPLEMENT|MITO-AO|Participants will receive 160 mg with breakfast on day 1 of bed rest and 40 mg with breakfast on days 2-5.
41106979|NCT04351113|DIETARY_SUPPLEMENT|PB-125|Participants will receive 100 mg on days 1-5 of bed rest.
41444975|NCT03016806|DRUG|Fludarabine|30 mg/m2/day x 5 or 40 mg/m2/day x 5
41444976|NCT03016806|DRUG|Melphalan|140 mg/m2
41444977|NCT00187928|DRUG|Topiramate|
41106980|NCT04351113|OTHER|Placebo|Participants will receive Placebo on days 1-5 of bed rest.
41106981|NCT04351113|OTHER|Passive Leg Movement (PLM)|Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.
41106982|NCT04351113|OTHER|Plantar flexion|Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.
41444978|NCT05037318|BEHAVIORAL|Stress arousal reappraisal|Participants will watch a video explaining that stress arousal is not harmful but rather functional and adaptive for performance in stressful situations.
41444979|NCT05037318|BEHAVIORAL|Worked examples|The worked example will be in form of brief video sequences showing a physician (played by an actor) delivering the bad diagnosis of lung cancer to an SP following the SPIKES protocol.
41444980|NCT06559410|OTHER|Electroencephalogram (EEG), CT Brain, Echocardiogram|analyze the etiology, electroencephalographic (EEG) findings, neuroimaging, and neurological sequalae of newborns with congenital heart disease who were presented with seizures
41444981|NCT06352775|DIETARY_SUPPLEMENT|Calcium Carbonate|We will be using it in routes and doses consistent with its approved uses. Per the drug label information for Calcium Carbonate USP 500 mg found in the US National Library of Medicine, adults may take 2-4 tablets as symptoms occur and if pregnant to not exceed 10 tablets in 24 hours. Therefore, using a dosing of 500mg every 4 hours will be well below that guidance. When both cervical ripening has been completed and the oxytocin administration begins, the calcium carbonate treatment group will be given calcium carbonate 500mg every 4 hours (not to exceed 10 tablets in 24 hours) until they deliver.
41106983|NCT04351113|OTHER|Isometric knee extensor test|Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.
41444982|NCT05756634|BEHAVIORAL|Care Coordination after Preterm Birth (CCAPB)|For participants randomized to CCAPB, the care coordinator will follow a manualized intervention to support care planning, health care access, and wellbeing. Contact with participants will be initiated as soon as possible after enrollment, and will continue until six months after enrollment.
41106984|NCT04351113|OTHER|Bed rest|Participants will undergo 5 days bed rest after 5 day baseline assessments
41444983|NCT05956925|BEHAVIORAL|Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.|The investigators showed participants how to use the Health Mate app, upload Withings BP cuff readings, upload historical data to the cloud, read trend lines in their record, rank their daily motivational level, and answer a brief short message service (SMS) question about whether the participants completed the behavioral change task encouraged by the daily message. A one-page instruction sheet with the research team's contact information was provided. Participants were instructed to take their BP daily, before their first meal and encouraged to avoid prior alcohol and caffeine intake as well as physical activity. The participants were instructed to rate their motivational level as low, moderate, or high via SMS when transmitting their BP value. Their level will trigger the appropriate behavioral change SMS prompt.
41444984|NCT06374264|DEVICE|MR-C-014|Use of device 3 times per week (for 30 minutes) for 8 weeks - for a total of 24 sessions.
41444985|NCT05746104|DRUG|Administration of Indocyanine Green (ICG) and Visualization of Tumor|A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
41444986|NCT02465125|BIOLOGICAL|red blood cell transfusion|
41444987|NCT03625973|BEHAVIORAL|3D-RT|Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy
41444988|NCT03625973|BEHAVIORAL|RT-Verbal|Verbal cues will be used as stimuli in Reminiscence Therapy
41444989|NCT05846022|OTHER|Dry Needling|This dry needling study involves bilaterally insertion of a fine sterile needle into upper trapezius muscle fibers using a clean needling technique.
41444990|NCT05846022|OTHER|Sham Needle|"Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube."
41444991|NCT06223516|DRUG|Subcutaneous (SC) ABBV-383|SC Injection
41444992|NCT06223516|DRUG|Intravenous (IV) ABBV-383|IV Infusion
41444993|NCT04378621|DRUG|TNF-α inhibitor OR JAK inhibitor|Pharmacological anti-rheumatic treatment
41444994|NCT04378621|OTHER|Hand training|Physical hand training 10 min twice daily while on stable treatment
41444995|NCT05748561|DRUG|Recombinant human erythropoietin 4,000 UI and 2,000 UI|Intravenous recombinant human erythropoietin (10,000 IU every 24 hours for 5 days)
41444996|NCT05748561|DRUG|Methylprednisolone succinate 500 mg|Intravenous Methylprednisolone succinate (1 g daily for 5 days)
41444997|NCT06618092|DEVICE|Relisten|Patients will be attended using Relisten
41444998|NCT03827356|DEVICE|Inspiratory muscle trainer (IMT)|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
41106985|NCT03641950|DRUG|Botulinum toxin type A|Recommended initial dose to be intra-muscularly injected to the medial and contralateral pretarsal orbicularis oculi of the upper eyelid and the contralateral pretarsal orbicularis oculi of the lower eyelid is 1.25-2.5U (0.05ml \~ 0.1ml per site).
41106986|NCT05576844|BEHAVIORAL|8-week interpersonal and social rhythm intervention|The development of the intervention strategies are based on social rhythm theory, interpersonal and social rhythm therapy, and previous research results, and the intervention aims to improve sleep by stabilizing participants' social rhythm and increasing the amount of interpersonal communication.
41444999|NCT05351957|PROCEDURE|Dry needling|Only dry needling of the lower limbs will performed in all patients with acupunture needling
41445000|NCT05747625|BIOLOGICAL|Panitumumab|Given IV
41445001|NCT05747625|DRUG|Zirconium Zr 89 Panitumumab|Given IV
41445002|NCT05747625|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41445003|NCT05747625|PROCEDURE|Computed Tomography|Undergo PET/CT
41445004|NCT05747625|OTHER|Electronic Health Record Review|Ancillary studies
41445005|NCT04567303|DRUG|Zifibancimig|"Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant."
41445006|NCT04567303|DRUG|Ranibizumab|Participants will receive ranibizumab 100 mg/mL through the PD implant
41445007|NCT04567303|DEVICE|Port Delivery Platform|Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
41445008|NCT01409499|PROCEDURE|hepatic resection|palliative hepatectomy followed by sorafenib
41445009|NCT01409499|PROCEDURE|transcatheter hepatic arterial chemoembolization|TACE followed by sorafenib
41106987|NCT05576844|OTHER|Usual care|Control group participants received usual care, including daily disease management and routine drug guidance.
41106988|NCT04143919|DIAGNOSTIC_TEST|NYHA assessment|The New York Heart Association (NYHA) functional classification of HF
41445010|NCT01409499|DRUG|sorafenib|sorafenib monotherapy, 400mg Bid, continuously
41445011|NCT04442503|DRUG|SAGE-217|SAGE-217 oral capsules.
41445012|NCT04442503|DRUG|Placebo|SAGE-217 matched-placebo oral capsules.
41445013|NCT00907907|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil Tablet 500 mg
41445014|NCT00907907|DRUG|CellCept® Tablets|CellCept® Tablets, 500 mg
41445015|NCT06560710|OTHER|vitrectimy|Clinical characteristics and surgical outcomes
41445016|NCT00107991|DRUG|etanercept|etanercept 50 mg/week subcutaneous injection
41445017|NCT04532684|DRUG|Duloxetine|
41445018|NCT04532684|DRUG|Pregabalin|
41445019|NCT01924377|PROCEDURE|standard circumferential pulmonary vein isolation by radiofrequency ablation catheter|To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance \>5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
41445020|NCT01924377|PROCEDURE|CPVI + rotors' identification and ablation|In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
41445021|NCT02224586|DEVICE|light treatment|clinical routine treatment according to the doctor's advice
41445022|NCT05383794|OTHER|Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
41445023|NCT00310271|BIOLOGICAL|pPJV7630 with pPJV2012 administered by PMED|
41445024|NCT03687762|BEHAVIORAL|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
41445025|NCT03687762|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
41445026|NCT03687762|BEHAVIORAL|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
41445027|NCT03274492|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
41445028|NCT03274492|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
41445029|NCT03274492|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
41445030|NCT03274492|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
41106989|NCT04143919|PROCEDURE|Serum NT-proBNP concentration|Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
41106990|NCT04143919|DIAGNOSTIC_TEST|Transthoracic Ecocardiogram|Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
41106991|NCT02785718|OTHER|Global Haemostasis assays|
41271008|NCT03216993|OTHER|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
41106992|NCT00307450|DRUG|Levetiracetam|up to 200 mg per day in two dosages per day.
41106993|NCT00215306|DEVICE|CHARITÉ Artificial Disc|
41106994|NCT00215306|DEVICE|Anterior Interbody Fusion with BAK Cage|
41445031|NCT03274492|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
41445032|NCT03274492|DRUG|Vincristine Placebo|Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
41445033|NCT03274492|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
41445034|NCT03274492|DRUG|Polatuzumab vedotin Placebo|Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
41445035|NCT00840216|DRUG|Clarithromycin ER 500 mg tablets|1 x 500 mg
41445036|NCT00840216|DRUG|BIAXIN® XL 500 mg tablets|1 x 500 mg
41445037|NCT03106415|DRUG|Binimetinib|Given PO
41445038|NCT03106415|OTHER|Laboratory Biomarker Analysis|Correlative studies
41106995|NCT05574530|DIETARY_SUPPLEMENT|Colon-delivered multivitamin supplement|6-week intervention of one dietary supplement a day, containing vitamin B2 (10mg), vitamin B3 (4mg), vitamin B6 (1.4mg), vitamin B9 (400μg), vitamin C (200mg) and vitamin D3 (15ug).
41445039|NCT03106415|BIOLOGICAL|Pembrolizumab|Given IV
41445040|NCT00402103|DRUG|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
41445041|NCT00402103|DRUG|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
41445042|NCT00402103|DRUG|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
41106996|NCT05574530|DIETARY_SUPPLEMENT|Placebo supplement|6-week intervention of one dietary supplement a day, containing 200 mg of microcrystalline cellulose.
41106997|NCT04854993|DRUG|Sugammadex 6 mg/kg|i.v. injection of an increased (by 50%) dose of sugammadex to reverse dNMB
41445043|NCT06172283|OTHER|Intermittent Fasting|Dietary intervention
41445044|NCT02216981|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|
41106998|NCT04854993|DRUG|Sugammadex 4 mg/kg|i.v. injection of a standard dose of sugammadex to reverse dNMB
41106999|NCT04089488|OTHER|Medical Chart Review|Correlative studies
41107000|NCT04089488|OTHER|Survey Administration|Respond to surveys
41445045|NCT06524479|PROCEDURE|SEEG recording and CCEP|This study aims to utilize the clinical, imaging, and electrophysiological data of patients with drug-resistant epilepsy. By Performing CCEP detection at specific targets during both wakefulness and sleep and analyzing its electrophysiological characteristics, the study will compare the functional properties of white matter fibers during wakefulness and sleep.
41445046|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 80mg|Metacavir Enteric-coated Capsules 80mg
41445047|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 160mg|Metacavir Enteric-coated Capsules 160mg
41445048|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 320mg|Metacavir Enteric-coated Capsules 320mg
41445049|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 240mg|Metacavir Enteric-coated Capsules Placebo 240mg
41445050|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 160mg|Metacavir Enteric-coated Capsules Placebo 160mg
41445051|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 320mg|Metacavir Enteric-coated Capsules Placebo 320mg
41445052|NCT02965859|DRUG|Adefovir Dipivoxil Capsule10mg|Adefovir Dipivoxil Capsule10mg
41445053|NCT02965859|DRUG|Adefovir Dipivoxil Capsule Placebo 10mg|Adefovir Dipivoxil Capsule Placebo 10mg
41445054|NCT06244043|OTHER|Initial Coaching Call|Participant will receive initial coaching call with a team member. This coaching call will either be interventional (i.e., include content intended to prompt their adherence and benefit from the HMP app) or informational (i.e., include content intended to control for the time and attention of attending a coaching session, but not intended to provide specific benefits).
41445055|NCT06244043|OTHER|Email Support|Email-based support throughout study period
41445056|NCT06244043|OTHER|Text Messages|All participants with receive text messages encouraging them to engage in the practices taught in the app.
41445057|NCT06446479|DRUG|Dronabinol Pill|Dronabinol 20 mg
41445058|NCT06446479|DRUG|Placebo|placebo
41445059|NCT00429286|BEHAVIORAL|Problem Solving Training|A systematic cognitive-behavioral intervention teaching problem solving skills for addressing functional impairment related to breast cancer and its treatment.
41445060|NCT06094933|BEHAVIORAL|Mobile Anger Reduction Intervention (MARI)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will download the MARI app and be instructed to complete at least 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
41107001|NCT03937843|DRUG|Carboplatin|Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
41107002|NCT03937843|DRUG|Cisplatin|"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
41107003|NCT03937843|DRUG|Etoposide|"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
41107004|NCT01598948|DRUG|mipomersen|mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
41107005|NCT06391619|OTHER|No intervention|Study is observational
41107006|NCT01118338|DEVICE|Redesigned Purevision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
41107007|NCT01118338|DEVICE|PureVision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
41445061|NCT06094933|BEHAVIORAL|Health Education Condition (HED)|This is a mobile application that delivers videos with psychoeducation about healthy habits and selfcare for general wellness. Participants will download the HED app and be instructed to use it at least 5 times a week for a period of 4 weeks.
41445062|NCT05625412|DRUG|BMS-986360|Specified dose on specified days
41445063|NCT05625412|DRUG|Docetaxel|Specified dose on specified days
41445064|NCT05625412|DRUG|Nivolumab|Specified dose on specified days
41445065|NCT05625412|DRUG|Capecitabine|Specified dose on specified days
41445066|NCT00802763|DEVICE|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
41445067|NCT05572281|DRUG|Tasimelteon Oral Capsule|No additional information
41445068|NCT05572281|DRUG|Tasimelteon Oral Suspension|No additional information
41445069|NCT06559735|DEVICE|CereVu Device|Observational, non-invasive measurements
41445070|NCT04519879|OTHER|Clinical Observation|Undergo clinical observation
41445071|NCT04519879|OTHER|Patient Observation|Undergo active surveillance
41445072|NCT04519879|OTHER|Questionnaire Administration|Ancillary studies
41445073|NCT04519879|DRUG|White Button Mushroom Extract|Given PO
41445074|NCT00966485|DRUG|80 mg ASA dosing|
41445075|NCT00966485|DRUG|500 mg ASA dosing|
41445076|NCT05637125|OTHER|aerobic exercise for upper limb|aerobic exercise for upper limb in the form of arm ergometer 3 session/week for 12 weeks. Patient started with warming up for 5 minutes in form of stretching. Patients used arm ergometer without resistance for upper limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion, after 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
41445077|NCT05637125|OTHER|aerobic exercise for lower limb|received aerobic exercise for lower limb in the form of cycling 3session/week for 12 weeks. Patient started with warming up for 5 minutes. Patients used bicycle for lower limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion. After 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
41445078|NCT05450653|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the delivery Microcatheter (BALTACCI-BDPE100)|A Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus with severe congenital diaphragmatic hernia (o/e LHR \<25% with liver up) during the FETO procedure between gestational age 27 weeks 0 days and 29 weeks and 6 days. The fetal tracheal balloon will be removed at between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
41445079|NCT03307577|DRUG|UHE-101 Cream|Topical cream containing investigational drug at a concentration of 1%
41445080|NCT03307577|OTHER|Vehicle Cream|Topical cream containing no drug (i.e., placebo)
41445081|NCT00059332|DRUG|Magnesium Sulfate|Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
41445082|NCT00059332|DRUG|Normal Saline|Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
41445083|NCT03934476|BEHAVIORAL|Ketogenic diet|The study subjects randomized for this intervention will observe the ketogenic diet, as prescribed by the protocol.
41445084|NCT03934476|BEHAVIORAL|Exercise HIIT|The study subjects randomized for this intervention will observe the HIIT exercise programme, as prescribed by the protocol.
41445085|NCT04656353|BEHAVIORAL|Intervention Arm|Participants randomized to the Intervention Arm will be provided with the website link to the online self-help program and a questionnaire and a distress survey. They will be asked to use the website within two weeks and then to complete these documents after using it and mail them back in a self-addressed stamped envelope. Same documents will be administered at the 3-month follow-up period, and the participant will be given two weeks to complete and return it in a self-addressed stamped envelope. Additionally, participants will also be asked in the 3-month follow-up questionnaire if they are interested in attending a focus group to elaborate on their experience with the psychosocial self-help program. Those who have expressed an interest will be contacted. The focus groups will last about 1-1.5 hours and consist of 3-4 participants. Focus groups will be audio-taped and conducted in either English or Chinese.
41445086|NCT04656353|BEHAVIORAL|Control Group|Participants randomized to the Control group will receive standard care (no intervention). They will be used as a baseline to compare groups and assess the effect of the intervention (i.e., the online psychosocial program). At the two weeks following randomization (T1) and the 3-month follow-up periods (T2), they will be asked to complete the questionnaire and distress survey and return them in a self-addressed stamped envelope. Participants will be given two weeks to complete the questionnaire and distress survey. The same documents will be administered at the 3-month follow-up period (T2). Once the 3-month follow-up is completed, each participant will be provided with the website link to view the self-help program.
41107008|NCT02824094|DRUG|crizotinib|Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule
41445087|NCT03890796|BEHAVIORAL|Activity Scheduling|AS is strategy for behavioral activation that has also been used with success in people with dementia, after the training of their caregivers. A certified occupational therapist will train up the caregivers of dementia in conducting AS activities for participants in experimental group
41445088|NCT03890796|BEHAVIORAL|Educational|A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
41445089|NCT05367986|DEVICE|electro-acupuncture|"Electro-acupuncture was given at the Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) acupoints, twice a day for 30 minutes, and for 5 days in total.~1. Acupoints were selected as follows. (1) Zusanli (ST36) belongs to zuyangming stomach meridian. It is located on the anterolateral part of the lower leg 3 inches (4 horizontal fingers) below the eye of the external knee between the fibula and the tibia, and a horizontal finger (middle finger) width from the front edge of the tibia. (2) Guan yuan (CV4) is located 3 inches below the umbilicus, on the midline of the abdomen. (3) Qihai (CV6) is located 1.5 inches below the umbilicus on the midline.~2. Acupuncture and electro-acupuncture methods were performed as follows. Participants were in the supine position, and needles was inserted in the skin . After the participant has acid, numbness, swelling, pain or other feelings, the electro-acupuncture device was connect to the acupuncture needle, the frequency was set to continuous wave."
41445090|NCT03600883|DRUG|sotorasib|Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation
41445091|NCT03600883|DRUG|Anti PD-1/L1|Administered as an intravenous (IV) infusion
41445092|NCT03600883|DRUG|Midazolam|Administered as an oral hydrochloride (HCI) syrup
41445093|NCT06559475|PROCEDURE|Super-Bore 8F Thrombosis Aspiration Catheter treatment group|For the subjects randomized to the Super-Bore 8F Thrombosis Aspiration Catheter treatment group, Mechanical thrombectomy will be performed using a Super-Bore 8F Thrombosis Aspiration Catheter.
41445094|NCT06559475|PROCEDURE|Conventional thrombectomy device treatment group|For the subjects randomized to the conventional thrombectomy device treatment group, mechanical thrombectomy will be performed using a commonly used thrombectomy devices in clinic, except for Super-Bore 8F Thrombosis Aspiration Catheter.
41107009|NCT03570827|DRUG|Androgen Suppression|Given androgen suppression therapy
41107010|NCT03570827|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
41107011|NCT03570827|OTHER|Quality-of-Life Assessment|Ancillary studies
41107012|NCT03570827|OTHER|Questionnaire Administration|Ancillary studies
41107013|NCT03835390|BEHAVIORAL|SIMDiscovery|The SIMDiscovery program consists of nine stations that were designed to mirror the different stages of the perioperative process. The stations mirror the different stages of the surgical process and provide patients and their families with education regarding what they can anticipate during each aspect of the intervention.
41107014|NCT02248480|DRUG|Duloxetine|Administered orally
41107015|NCT02248480|DRUG|Placebo|Administered orally
41107016|NCT02328352|PROCEDURE|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
41271009|NCT03216993|OTHER|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
41271010|NCT02318056|OTHER|Aquacel® Ag Burn Glove|burn dressing
41271011|NCT02318056|OTHER|Mepilex® Transfer Ag|burn dressing
41271012|NCT02318056|DRUG|antibiotic|antibiotic burn dressing
41271013|NCT03633279|DRUG|Branched chain amino acid|Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
41271014|NCT03633279|DRUG|Placebo|an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
41271015|NCT01191814|PROCEDURE|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
41271016|NCT01191814|PROCEDURE|Plastic stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
41445095|NCT04461964|DEVICE|Machine-vision Image Guided Surgery (MvIGS) spine navigation system.|"The intended use of the MvIGS navigation system is to provide high quality intraoperative imaging with no radiation exposure. Use of the proprietary integrated surgical light with embedded tracking technology and Flash™ registration allows for continuous and direct visualization of the surgical field. The MvIGS system is exempt from IDE regulations as the device cleared Premarket Notification FDA-510(k) (K162375). The device includes:~* A single mobile cart with a boom arm and an integrated surgical light with embedded tracking technology (P/N 10-0001);~* Proprietary imaging software (P/N 60-0007); and,~* Kit of tacked surgical instruments including a spine reference clamp, awl tip, pedicle probe (P/N 11-0006)."
41445096|NCT04887415|BEHAVIORAL|Respiratory Strength Training (RST) Program|Participants will complete RST exercises 5 days per week by performing 5 sets of 5 repetitions of both expiratory and inspiratory muscle strength training (a total of 50 repetitions per day). Trainer devices will be calibrated to 50% of participants' maximum expiratory pressure (MEP) and maximum inspiratory pressure (MIP) as determined via respiratory assessment prior to and during the RST program.
41445097|NCT06558695|DRUG|Sevoflurane|Sevoflurane was managed for maintenance of the general anestesia during spinal surgeries
41445098|NCT06558695|DRUG|TIVA|TIVA was managed for maintenance of the general anesthesia during spinal surgeries
41107017|NCT02328352|PROCEDURE|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
41107018|NCT02328352|PROCEDURE|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
41445099|NCT00216242|BIOLOGICAL|Influenza virus vaccine (Fluviral)|
41107019|NCT02328352|PROCEDURE|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
41107020|NCT05920798|PROCEDURE|Biopsy|Undergo biopsy
41107021|NCT05920798|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41445100|NCT00216242|BIOLOGICAL|Saline placebo|
41445101|NCT03986294|DRUG|S1 + Nal-IRI|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.
41445102|NCT03986294|DRUG|Nal-IRI+Leucovorin+5-FU|Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
41445103|NCT04205123|GENETIC|sickle cell syndrome|"Academic Study prospective multicenter observational factors responsible for nephropathy in patients with sickle cell disease followed by Belgium and the Nord-Pas -De- Calais Region and creating a biobank of blood and urine.~In the population of patients with SCD followed in all participating centres.~Know the prevalence of nephropathy and the relationship between it with their some of their genotypic mutations and clinical phenotype promoting mutated hemoglobin polymerization.~Determine the behaviour of dense cells in the basal state and in a hypeosmolaire environment~Determine the place of the erythrocyte microparticles as a biomarker of sickle cell nephropathy~Studying genes known as risk factor for proteinuria~Create a BioBank of samples of sickle cell patients in clinically stable condition for other research purposes."
41445104|NCT00274781|DRUG|arsenic trioxide|Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
41445105|NCT00274781|DRUG|gemtuzumab ozogamicin|Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
41445106|NCT05187923|DIAGNOSTIC_TEST|Artificial Intelligence Algorithm|Different machine learning and deep learning computer aided strategies for model construction and validation.
41445107|NCT02584907|OTHER|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
41445108|NCT03592420|BEHAVIORAL|Interdisciplinary multicomponent interventions|
41445109|NCT03592420|BEHAVIORAL|Usual care|standard care
41445110|NCT01625715|DRUG|Ketotifen|titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
41445111|NCT06308861|DRUG|Single administration Amg dose Group|Orally, Amg tablet single administration
41445112|NCT06308861|DRUG|Single administration Bmg dose Group|Orally, Bmg tablet single administration
41107022|NCT05920798|PROCEDURE|Computed Tomography|Undergo CT
41445113|NCT06308861|DRUG|Single administration Cmg dose Group|Orally, Cmg tablet single administration
41445114|NCT06308861|DRUG|Single administration Dmg dose Group|Orally, Dmg tablet single administration
41445115|NCT06308861|DRUG|Single administration Emg dose Group|Orally, Emg tablet single administration
41445116|NCT06308861|DRUG|Single administration Amg dose Group-Placebo|Orally, Placebo Amg tablet, single administration
41107023|NCT05920798|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41107024|NCT05920798|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
41107025|NCT05920798|BIOLOGICAL|Pembrolizumab|Given IV
41107026|NCT05920798|PROCEDURE|Pheresis|Undergo apheresis
41445117|NCT06308861|DRUG|Single administration Bmg dose Group-Placebo|Orally, Placebo Bmg tablet, single administration
41445118|NCT06308861|DRUG|Single administration Cmg dose Group-Placebo|Orally, Placebo Cmg tablet, single administration
41445119|NCT06308861|DRUG|Single administration Dmg dose Group-Placebo|Orally, Placebo Dmg tablet, single administration
41445120|NCT06308861|DRUG|Single administration Emg dose Group-Placebo|Orally, Placebo Emg tablet, single administration
41107027|NCT06184854|OTHER|3D-Enhanced Training Models|3D-enhanced Jenga polo model for task 1 and 3D-enhanced suturing model for task 2
41107028|NCT06184854|OTHER|Standard 3D LapPass Training Models|Standard 3D LapPass polo model for task 1 and standard 3D LapPass model for task 2
41445121|NCT06308861|DRUG|Multiple administration Amg dose group|Orally, Amg 1 tablet, once a day for 3 days, multiple administration
41445122|NCT06308861|DRUG|Multiple administration Bmg dose group|Orally, Bmg 1 tablet, once a day for 3 days, multiple administration
41445123|NCT06308861|DRUG|Multiple administration Cmg dose group|Orally, Cmg 1 tablet, once a day for 3 days, multiple administration
41445124|NCT06308861|DRUG|Multiple administration Dmg dose group|Orally, Dmg 1 tablet, once a day for 3 days, multiple administration
41445125|NCT06308861|DRUG|Multiple administration Emg dose group|Orally, Emg 1 tablet, once a day for 3 days, multiple administration
41445126|NCT06308861|DRUG|Multiple administration Amg dose group - Placebo|Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration
41445127|NCT06308861|DRUG|Multiple administration Bmg dose group - Placebo|Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration
40925346|NCT04796987|DIAGNOSTIC_TEST|Convolutional Neural Network|Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.
40925347|NCT03739788|DRUG|BMS-986165|Oral administration of tablet and 15-minute intravenous BMS-986165 solution for infusion
40925348|NCT04144127|BEHAVIORAL|Soccer|"* Soccer drills and other fitness routines (two 1-hour sessions per week)~* In person education in Life's Simple 7 to help improve life through Lifestyle changes: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure."
40925349|NCT05872854|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment
40925350|NCT05872854|OTHER|Visible Light|After application of HyBryte (0.25% hypericin ointment), participants will be placed in a light booth containing fluorescent light bulbs to activate the HyBryte.
41107029|NCT05359913|BEHAVIORAL|Cervical cancer podcast for African American women|"The video podcast will deliver cervical cancer prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
41107030|NCT04256876|DEVICE|TTNS|See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
41107031|NCT04256876|DEVICE|TTNS Sham|See section 'arms'
41107032|NCT05127499|OTHER|progressive relaxation exercises|progressive relaxation exercises will do
41107033|NCT02770248|DRUG|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
41107034|NCT02770248|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
41107035|NCT06409988|OTHER|Safe discharge|There was no specific intervention, we only aimed to see if those admitted patients could have been safely dicharged from the emergency department.
41107036|NCT01607619|DIETARY_SUPPLEMENT|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
41107037|NCT04156724|DEVICE|Helmet vetilation|We will apply non-invasive positive pressure ventilation via a helmet as interface
41107038|NCT00015236|BEHAVIORAL|Amantadine|
41107039|NCT02321813|BEHAVIORAL|quality of life pathway|Quality of life measurement, diagnosis and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
41107040|NCT02321813|OTHER|placebo control|Quality of life measurement
41107041|NCT02840994|BIOLOGICAL|CV301|
41107042|NCT02840994|BIOLOGICAL|Pembrolizumab|
41107043|NCT02840994|BIOLOGICAL|Nivolumab|
41107044|NCT05112861|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
41107045|NCT02501733|DEVICE|Medacta GMK Sphere® Medial Knee Prosthesis|"There is no consensus within the Arthroplasty community as to whether a traditional post and cam-style Posterior Stabilized total knee device is superior to a medial-pivot, more congruent device. However, the majority of surgeons seem to prefer the former, though there is a minority that uses the latter device with great success.~To date, there have been few prospective trials directly comparing these devices, and none with the latest generation of Total Knee Arthroplasty implants. Almost all such studies have been retrospective and/or utilizing older generation devices."
41107046|NCT04744428|BEHAVIORAL|Autism Parent Navigators|The Autism Parent Navigator program consists of six sessions delivered to parents in the home, supporting adjustment to ASD, accessing services, and coparenting support.
41107047|NCT04744428|BEHAVIORAL|Peer mentoring|Six in-home or telephone sessions, depending on family uptake, providing non-manualized general support as usual from parent peer mentors regarding adjustment to ASD.
41445128|NCT06308861|DRUG|Multiple administration Cmg dose group - Placebo|Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration
41445129|NCT06308861|DRUG|Multiple administration Dmg dose group - Placebo|Orally, Placebo Dmg 1 tablet, once a day for 3 days, multiple administration
41445130|NCT06308861|DRUG|Multiple administration Emg dose group - Placebo|Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration
41445131|NCT06544941|DEVICE|Smart Bassinet|The SNOO will respond to a crying or fussing infant in order to soothe and calm it down.
41445132|NCT06544941|DEVICE|HALO|The HALO is a commercially available bassinet
41445133|NCT00455312|DRUG|Campath 1H|10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
41445134|NCT00455312|DRUG|Cyclophosphamide|7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
41445135|NCT00455312|DRUG|Fludarabine|6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
41445136|NCT00455312|PROCEDURE|Total Body Irradiation|1 day before the transplant one dose (200 cGy) of total body irradiation is given
41445137|NCT00455312|PROCEDURE|Stem Cell Transplantation|Infusion of stem cells on Day 0.
41445138|NCT00455312|DRUG|antithymocyte globulin|ATG (rabbit) 3 mg/kg for 3 days.
41445139|NCT00455312|DRUG|Methylprednisolone|2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
41445140|NCT06561893|DIETARY_SUPPLEMENT|Broccoli sprouts extract supplementation|Intake of broccoli sprouts extract supplement (Brand: Source Naturals, Scotts Valley, CA 95066 - USA) in an acute dose (84 umol of glucoraphanin) before and after 2 weeks of probiotic or placebo supplementation, to assess sulforaphane bioavailability measured in urine metabolites
41271017|NCT02279316|DRUG|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
41445141|NCT05117489|DRUG|Miricorilant 150 mg|Miricorilant 150 mg for oral dosing
41445142|NCT05117489|DRUG|Miricorilant 100 mg|Miricorilant 100 mg for oral dosing
41445143|NCT05117489|DRUG|Miricorilant 50 mg|Miricorilant 50 mg for oral dosing
41445144|NCT05117489|DRUG|Miricorilant 10 mg|Miricorilant 10 mg for oral dosing.
41445145|NCT00091377|DRUG|cisplatin|IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
41445146|NCT00091377|DRUG|paclitaxel|IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
41445147|NCT00091377|DRUG|phenoxodiol|IV 3 mg/kg
41445148|NCT05491187|DRUG|0.5% bupivacaine heavy|Spinal anesthesia with 0.5% bupivacaine heavy at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
41445149|NCT05491187|DRUG|0.5% bupivacaine heavy with fentanyl|Spinal anesthesia with 0.5% bupivacaine heavy with fentanyl at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
41445150|NCT01726933|DRUG|LAS41008|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
41445151|NCT01726933|DRUG|LASW1835|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
41445152|NCT01726933|DRUG|Placebo|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
41445153|NCT04284787|DRUG|Azacitidine|Given IV or SC
41445154|NCT04284787|PROCEDURE|Biopsy|Undergo biopsy
41445155|NCT04284787|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
41445156|NCT04284787|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41445157|NCT04284787|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41445158|NCT04284787|BIOLOGICAL|Pembrolizumab|Given IV
41445159|NCT04284787|DRUG|Venetoclax|Given PO
41445160|NCT05745363|DRUG|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor
41445161|NCT03035643|DEVICE|AMDS|The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
40925351|NCT02601807|DEVICE|ActiPatch (active)|Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.
41445162|NCT02045667|DRUG|Mexiletine|"Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy."
41445163|NCT02045667|DRUG|Placebo|Placebo tablets do not contain any active medicinal component.
40925352|NCT02601807|DEVICE|ActiPatch (placebo)|Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
40925353|NCT06299254|OTHER|Placebo-Natural History|"Half of the participants will receive a placebo (i.e., motivational/verbal) cue before and after an experimental session in which they will perform several lifts.~Half of the participants will receive no placebo before and after an experimental session in which they will perform several lifts."
40925354|NCT02718170|PROCEDURE|Buried Intramedullary K-wire Fixation|
40925355|NCT02718170|PROCEDURE|Plate and Screw Fixation|
40925356|NCT03714269|OTHER|measurement evaluated with an isokinetic dynamometer|measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer
40925357|NCT03714269|OTHER|measurement evaluated with an 2D ultrasound|"* simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~* recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction."
40925358|NCT03714269|OTHER|assessment of the level of discomfort|visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
40925359|NCT00509262|DRUG|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
40925360|NCT00509262|DRUG|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
40925361|NCT00509262|DRUG|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
40925362|NCT00509262|DRUG|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
40925363|NCT00879008|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
40925364|NCT02451371|DEVICE|tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
40925365|NCT00851968|PROCEDURE|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
40925366|NCT00851968|PROCEDURE|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
40925367|NCT00851968|PROCEDURE|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
41107048|NCT02128789|OTHER|Elder Tree website|Elder Tree is a private, secure information, support and communication website developed for this study.
41107049|NCT04090762|BEHAVIORAL|Conditional cash transfer|Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.
41107050|NCT04090762|BEHAVIORAL|Risk information provision|Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.
41107051|NCT06360016|BEHAVIORAL|Recreation Activity Program|Students in the study group were subjected to a 24-session RAP, including entertaining games. This program was conducted by the first-name researcher, who had completed their undergraduate education in preschool education and was supported by the second and third-named researchers as assistant instructors. The 24-session program, which included rhythm, balance, and patience acquisition games, was planned according to a game theory model that primarily aimed to entertain children. The program, aimed at developing children's self-regulation skills based on fundamental reflections of the model, would consist of simple rule-based entertaining games. Before the program's application, researchers provided information about the research and program to the experimental group, and verbal consent was obtained.
41107052|NCT00112983|BIOLOGICAL|eculizumab|
41107053|NCT06549933|OTHER|Criostymulation|"Method: Cryosauna. Temperature: -160°C. Duration: 5 days. Session Timing: 9:00 a.m.~Session Length: 3 minutes per day"
41107054|NCT00878462|DRUG|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
41107055|NCT00878462|DRUG|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
41107056|NCT00878462|DRUG|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
41107057|NCT02327104|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
41445164|NCT05582915|DIAGNOSTIC_TEST|Blood sampling|4 ml of blood will be collected into EDTA tube for proteomic analysis at visit 0 and visit 1
41107058|NCT02327104|OTHER|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
41107059|NCT05851768|DRUG|Bupivacaine|Bupivacaine 0.25%
41445165|NCT01333826|BEHAVIORAL|Zomba Cash Transfer Program|Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
40925368|NCT03865797|OTHER|Experimental|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.The intervention will be done before the training session.
40925369|NCT03865797|OTHER|Control active|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The objective of the application of these exercises is to increase the control of the Core, and therefore improve the stability both central and of members. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises (13) will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.
40925370|NCT04133922|DRUG|GLP-1|glucagon-like peptide 1
40925371|NCT04133922|DRUG|Insulin|we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp
40925372|NCT04133922|DRUG|Dextrose 20 % in Water|We are using Dextrose to maintain Euglycemia during the insulin clamp
40925373|NCT01030666|DRUG|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
40925374|NCT01030666|DRUG|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
41107060|NCT05851768|DRUG|Bupivacaine + Magnesium|Bupivacaine 0.25% + Magnesium
41107061|NCT05851768|DRUG|Bupivacaine + Dexmedetomidine|Bupivacaine 0.25% + Dexmedetomidine
41107062|NCT03684265|DRUG|Meloxicam Capsule (Test)|single dose
41107063|NCT03684265|DRUG|Meloxicam Tablet (Reference)|single dose
41107064|NCT01910636|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
41107065|NCT01910636|DRUG|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
41107066|NCT00298649|BEHAVIORAL|Lay Health Advisor|
41107067|NCT05723991|DRUG|Disitamab Vedotin and Gemcitabine|Disitamab Vedotin (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every two weeks. After completing 3 cycles of neoadjuvant combined therapy, imaging evaluation was performed. If the tumor is T0, radical surgery for bladder cancer was performed; Otherwise, perform radical surgery for bladder cancer after completing 1-3 cycles of treatment (total cystectomy+standard/extended lymph node dissection)
41107068|NCT04574024|DRUG|NBT-NM108 (60 g/day)|Patients will receive NBT-NM108 at 60 g/day.
41107069|NCT04574024|OTHER|NBT-NM108 (0 g/day)|Patients will receive NBT-NM108 at 0 g/day.
41107070|NCT03768856|RADIATION|Temporally Feathered Radiation Therapy (TFRT)|Up to 5 different plans are created and delivered on a daily basis Monday-Friday for 7 weeks. The treating physician designates up to 5 organs at risk (OARs) to be feathered based on the proximity to the target. The daily prescription dose delivered to the Planning Target Volumes (PTV) is not changed.
41107071|NCT00132119|DRUG|nalmefene HCl|Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
41107072|NCT00132119|OTHER|Placebo|Placebo tablet
41107073|NCT02375581|DRUG|Icotinib|125mg, Po, TID during RT
41107074|NCT02375581|RADIATION|Thoracic radiotherapy|involved-Field irradiaton without elective nodal irradiation
41107075|NCT06145854|DRUG|Cabotegravir Injection [Apretude]|Apretude for PrEP
41107076|NCT00479206|DRUG|Artesunate|
41107077|NCT04481386|DEVICE|Vitargus, BFC-1401|A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.
41107078|NCT05646745|PROCEDURE|Autologous Transobturator Fascia Lata Sling|"Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip."
41107079|NCT03009006|DRUG|Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
41107080|NCT03009006|DRUG|Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
41107081|NCT03993392|DRUG|TM buprenorphine|4mg TM buprenorphine, investigator choice as to brand
41107082|NCT03993392|DRUG|SUBLOCADE|300mg subcutaneous injection
41445166|NCT03025984|BEHAVIORAL|Texting|patient adherence to her recommended care regimen after intervention of a text message reminder and education system
41445167|NCT06524219|PROCEDURE|unilateral intrafascial resection|Conducting unilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
41445168|NCT06524219|PROCEDURE|bilateral intrafascial resection|Conducting bilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
41445169|NCT06524219|PROCEDURE|bilateral extrafascial resection|Conducting bilateral extrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
41445170|NCT01463579|OTHER|Exercise Programme|"Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.~At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home."
41445171|NCT01463579|OTHER|Standard Care|Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
41445172|NCT00006256|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.
41445173|NCT00006256|PROCEDURE|adjuvant therapy|doxorubicin and cyclophosphamide adjuvant regimen
41445174|NCT00006256|RADIATION|radiation therapy|Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.
41445175|NCT01655654|BEHAVIORAL|Physical activity|This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
41107083|NCT02674451|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
41107084|NCT06025019|BEHAVIORAL|parent-based Electronic Health intervention|"The eHealth intervention comprises 12 modules on three interaction modules related to physical activity, dietary behavior, and sleep. The intervention groups will be invited to a WeChat group. A 3-minute video (made on the TikTok APP) will be sent to each WeChat group. Based upon the social media studies recommendation, five to nine members in a group will produce the desirable group interactive effect. Therefore, the present study allocates eight parents to one WeChat group. In total, there will be 26 groups (206 parents) according to the sample size calculation. Consistent with Social Cognitive THeory, the content of each module will follow the four steps: 1. Attention (Read educational material and watch TikTok/Douyin video (less than 3 minutes). 2.Retention (parental interaction). 3.Reproduction (Set goals and conduct behaviors). 4.Motivation (feedback and making changes)."
41107085|NCT06281704|BIOLOGICAL|AK101 IV|AK101 will be administered intravenously.
41445176|NCT01655654|BEHAVIORAL|Dietary|Make at least one positive dietary change including or similar to a DASH diet snack substitution.
41445177|NCT01655654|OTHER|Primary care provider visit|Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
41445178|NCT03569059|DEVICE|Early Robotic/VR Therapy (EVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 5-30 days post stroke.
41445179|NCT03569059|BEHAVIORAL|Dose-Matched Usual Physical Therapy Care|Subjects will perform state-of-art usual physical/occupational care and 10 days of one additional hour of state-of-art usual inpatient and/or outpatient physical therapy/occupational therapy.
41445180|NCT03569059|DEVICE|Delayed Robotic/VR Therapy (DVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 31-60 days post stroke.
41107086|NCT06281704|BIOLOGICAL|AK101 SC|AK101 will be administered subcutaneously.
41107087|NCT06281704|BIOLOGICAL|Placebo|Placebo will be administered subcutaneously or intravenously.
41445181|NCT03352362|DRUG|ibuprofen (caldolor 10 mg / kg)|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
41445182|NCT03352362|DRUG|propacetamol (denogan 30 mg / kg)|Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
41445183|NCT03352362|DRUG|ibuprofen + propacetamol|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
41445184|NCT05609981|OTHER|Clinical medication review focused on deprescribing|"A pharmacist-led intervention consisting of a clinical medication review with the focus on deprescribing in older patients using multidose drug dispensing (MDD) systems.~Pharmacist are trained in deprescribing and a developed toolbox to support the intervention is provided"
41445185|NCT00841542|DRUG|Amlodipine Besylate|10 mg Tablet
41445186|NCT00841542|DRUG|Norvasc®|10 mg Tablet
40925375|NCT01030666|PROCEDURE|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
41107088|NCT06281704|BIOLOGICAL|AK101 IV/AK101 SC|AK101 will be administered as intravenous infusion at Week8, then subcutaneously every 8 weeks thereafter .
41107089|NCT01326988|PROCEDURE|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
41107090|NCT06053242|DRUG|CELZ-201-DDT|Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
41445187|NCT02157051|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
41445188|NCT02157051|OTHER|Laboratory Biomarker Analysis|Correlative studies
41445189|NCT04954573|RADIATION|infrared-A (wIRA)|Local-water filtered infrared-A (wIRA) irradiation
41445190|NCT06243796|PROCEDURE|Flap fixation technique|After complete the modified radical mastectomy procedure, the researcher will use absorbable sutures (vicryl), multiple alternating stitched 2.5 cm apart between the subcutaneous of the flap and underlying muscle
41445191|NCT01844843|DEVICE|TCD-10023 drug eluting stent|Implantation of new drug eluting stent in coronary artery lesions
41271018|NCT02279316|OTHER|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
41445192|NCT00768963|DRUG|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
41107091|NCT06053242|OTHER|Placebo|Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
41107092|NCT02135458|OTHER|Telemonitoring|
41107093|NCT02135458|OTHER|Conventional care|
41445193|NCT00768963|DRUG|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
41445194|NCT05438940|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
41445195|NCT05438940|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth
41445196|NCT05438940|BEHAVIORAL|Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
40925376|NCT01030666|BIOLOGICAL|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
41107094|NCT06294704|OTHER|bariatric surgery|Having undergone bariatric surgery and on a closed-loop insulin pump after bariatric surgery
41107095|NCT03035045|DRUG|Paracetamol|
41107096|NCT03035045|DRUG|Placebo Oral Tablet|
41107097|NCT03827512|OTHER|Doppler arterial waveforms analysis|terminology used when describing arterial Doppler waveforms
41107098|NCT00127647|DRUG|montelukast sodium|montelukast sodium; 5 mg, 10 mg QD 2-weeks.
41445197|NCT03923374|DRUG|Subutex / Buprenorphine|Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.
41445198|NCT03923374|DIAGNOSTIC_TEST|Fetal & Neonatal MRI|Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.
41445199|NCT03923374|DIAGNOSTIC_TEST|DNA/Genetic/Pharmacokenetic Blood Draws|Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.
41445200|NCT05985343|DRUG|Neostigmine / Glycopyrrolate|Patients will receive standard of care for reversal of neuromuscular blockade
41445201|NCT05985343|DRUG|Sugammadex|Patients will receive sugammadex for reversal of neuromuscular blockade
41445202|NCT02254005|DRUG|bivatuzumab mertansine|
41107099|NCT00127647|DRUG|Comparator: pranlukast|Pranlukast 225 mg BID 2-weeks.
41107100|NCT03101618|OTHER|Animal allergy|Allergic symptom occurs during exposure to laboratory or pet animal
41107101|NCT03101618|OTHER|Non-animal allergy|Allergic symptom does not occur during exposure to laboratory or pet animal
41107102|NCT06437834|OTHER|Information Sheet|Information sheet describing the importance of vaccines and preventive care as well as contact information for patient navigators.
41107103|NCT06437834|OTHER|High-touch connect|Engagement with a patient navigator.
41107104|NCT06409637|DRUG|FOLFOX4 regimen|FOLFOX4 regimen: Oxaliplatin 85mg/m2 intravenous infusion over 2 hours on Day 1; Leucovorin 400mg/m2 intravenous infusion over 2 hours on Days 1-2; 5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours. Each cycle lasts for 4 weeks, repeated every 4 weeks for a total of 6-8 cycles.
40925377|NCT01030666|DRUG|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
40925378|NCT01030666|DRUG|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
41445203|NCT05725928|BEHAVIORAL|Mobility technician|Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.
41445204|NCT03936101|DIAGNOSTIC_TEST|Prenatal Genomic Sequencing|Whole genome sequencing (which initially will be masked and reported as exome only)
41445205|NCT04660747|DRUG|Oral anticoagulant|Direct oral anticoagulants or vitamin K antagonists. Please note that the study is fully observational. The choice of anticoagulant type and duration of treatment are left at the discretion of the treating physicians and patients. No treatment, intervention, or examinations are imposed on patients in the context of this study.
40925379|NCT01030666|DRUG|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
40925380|NCT03044574|DEVICE|SCD|Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
40925381|NCT03044574|DEVICE|GCS|Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
40925382|NCT03044574|DRUG|LMWH|LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
40925383|NCT00003388|BIOLOGICAL|filgrastim|
40925384|NCT00003388|DRUG|cyclophosphamide|
40925385|NCT00003388|DRUG|cytarabine|
40925386|NCT00003388|DRUG|methotrexate|
40925387|NCT00003388|DRUG|pegylated liposomal doxorubicin hydrochloride|
40925388|NCT00003388|DRUG|prednisone|
40925389|NCT00003388|DRUG|vincristine sulfate|
40925390|NCT00003388|RADIATION|radiation therapy|
40925391|NCT02920853|BEHAVIORAL|Biofeedback Training (BT-CPR)|Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
40925392|NCT02920853|BEHAVIORAL|Biofeedback Training|Participants will receive biofeedback training to reduce arousal and pain
40925393|NCT01302132|DRUG|ASP1941|Oral solution
40925394|NCT02437227|DRUG|CCT3833|CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
40925395|NCT00420641|DRUG|GSK372475|GSK372475 1.0-1.5 mg/day
40925396|NCT00420641|DRUG|Paroxetine|Paroxetine 20-30 mg/day
40925397|NCT00420641|OTHER|Placebo|Placebo to Match
40925398|NCT04111562|PROCEDURE|Cranioplasty|Bone grafts
40925399|NCT02338908|OTHER|exercise program|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
41271019|NCT02279316|OTHER|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
41271020|NCT03094130|OTHER|News items with spin|Interpretation of news items with spin
41271021|NCT03094130|OTHER|News items without spin|Interpretation of news items without spin
41271022|NCT03269981|RADIATION|Whole breast irradiation|Radiotherapy to the whole breast alone.
41271023|NCT03269981|RADIATION|Whole breast and nodal irradiation|Radiotherapy to the whole breast and regional lymph nodes.
41271024|NCT04297943|DEVICE|Orthosis fabrication|see summary
41271025|NCT04297943|DEVICE|Thermal Sensor Monitoring of Orthosis Use|see summary
41271026|NCT04297943|DIAGNOSTIC_TEST|4D CT Scan|see summary
41271027|NCT01485978|DRUG|Ramipril|Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
41271028|NCT01485978|DRUG|placebo to ramipril|Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
41271029|NCT01485978|DRUG|Ramipril|Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
41271030|NCT02734173|DRUG|ABT450r-ABT267-ABT333 +/- Ribavirin|12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
41271031|NCT06033729|DRUG|Remifentanil TCI|REMI-TCI administration begun 5 minutes before the procedure, starting from an initial target at the effect site of 1 ng/ml and gradually increasing by 0.5 ng/ml until reaching an adequate level of sedation (Ramsey score between 2-3).
41271032|NCT06033729|DRUG|Midazolam injection|Bolus administration of midazolam (1-2 mg)and/or until a Ramsey score 2-3 was reached
41271033|NCT06033729|DRUG|Fentanyl|Bolus adminitration of fentanyl (50-100 mcg) until a Ramsey score 2-3 was reached
41271034|NCT06033729|DRUG|Propofol|Bolus adminitration of propofol until a Ramsey score 2-3 was reached
41445206|NCT06393387|DRUG|DTG/3TC versus BIC/F/TAF|A new-user, active comparator, retrospective cohort study design will be employed using inverse probability of treatment weighting to adjust for measured confounders. This study will be conducted as a retrospective chart review and the organization's electronic health record (EHR) will be utilized. Subjects identified as having previously been or currently receiving DTG/3TC or BIC/F/TAF will be assessed for eligibility based on inclusion/exclusion criteria. Subject eligibility will be confirmed by the Principal Investigator (PI).
41445207|NCT00004933|DRUG|hydroxyurea|0.5 to 5 grams PO per day
41107105|NCT06409637|DRUG|lenvatinib|Lenvatinib: For patients with a body weight \<60 kg, the recommended daily dose of lenvatinib is 8 mg (2 capsules of 4 mg each), once daily; for patients with a body weight ≥60 kg, the recommended daily dose of lenvatinib is 12 mg (3 capsules of 4 mg each), once daily. Treatment should be continued until disease progression, intolerable adverse effects, or the end of the study.
41445208|NCT00004933|DRUG|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
41445209|NCT04854798|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
40925400|NCT02338908|OTHER|TrP-DN|In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
40925401|NCT00484185|DRUG|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
40925402|NCT03131830|OTHER|Online-based questionnaire|Participants receive a web-link to a questionnaire, which is active for 3 months
40925403|NCT04874051|DEVICE|Experimental Group|The experimental treatment will be provided by means of the OAK system. This device consists of 1 cabinet with 2 independent balance boards, 2 monitors (one for the physiotherapist and one for the patient) and 3 wireless IMUs (one for the left lower limb, one for the right lower limb and one for the trunk). The 2 balance boards provide body weight transfer exercises, while the wireless motion sensors provide one leg stance exercises or trunk exercises in a virtual environment.
40925404|NCT04874051|OTHER|Control Group|The Control Group will perform conventional balance exercises similar to the exercises provided with the OAK system.
40925405|NCT03994029|DIETARY_SUPPLEMENT|Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness|Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness
40925406|NCT02891785|BEHAVIORAL|ANtiPain|After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
40925407|NCT02787239|DRUG|HLX01|
40925408|NCT02787239|DRUG|Rituximab|
40925409|NCT02787239|DRUG|CHOP|
40925410|NCT04357288|OTHER|Patient Decision Aid|The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.
41107106|NCT00223314|BEHAVIORAL|HIV, STD, Pregnancy Prevention Curriculum|The curriculum is designed to change students' knowledge, perceptions of norms, beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors related to HIV. The curriculum included use of facilitators for selected lessons such as role playing. Intervention strategies included demonstrations of skills by role playing, use of role model stories, and other experiential learning techniques. The curriculum was delivered during the school days by facilitators (project staff) who received intensive training prior to implementation and coaching and support during implementation.
41107107|NCT03624166|DRUG|Ketamine|patients will receive sub- anesthetic dose of ketamine 0.5 mg/kg in 3 ml of isotonic saline after spinal anesthesia
41107108|NCT03624166|DRUG|isotonic saline|patients will receive 3 ml of isotonic saline after spinal anesthesia
41107109|NCT00585455|DRUG|sertraline|open label 25-50 mg daily as tolerated
41107110|NCT04429230|DEVICE|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline soaked (0.9% NaCl) surface sponge electrodes. Anodal stimulation will be given to brain area based on qEEG findings
41107111|NCT04429230|DEVICE|Sham Transcranial pulsed current stimulation (tPCS)|Electrode placement will be the same as active stimulation but the electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
41107112|NCT05250141|DRUG|Levodopa 250mg and Carbidopa 25mg Test Drug tablet|Investigational Medicinal Product
41107113|NCT05250141|DRUG|Levodopa 250mg and Carbidopa 25mg Referent Product tablet|Sinemet (Savio Industrial S.R.L, Brazil)
41107114|NCT02807558|DRUG|Tamibarotene|Administered as oral tablets
41107115|NCT02807558|DRUG|Azacitidine|Administered via intravenous (IV) or subcutaneous (SC) infusion
41107116|NCT02807558|DRUG|Daratumumab|Administered via IV infusion
41107117|NCT01927952|PROCEDURE|Kirschner wire|Surgical fixation utiliziing Kirschner wire
41107118|NCT01927952|PROCEDURE|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
41107119|NCT01927952|PROCEDURE|Stryker Smart-Toe Implant|surgical fixation utilizing the Stryker Smart-Toe Implant
41107120|NCT00740155|BIOLOGICAL|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)
41445210|NCT00462345|DRUG|rituximab|1000 mg i.v. on Days 1 and 15
41445211|NCT00462345|DRUG|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
41445212|NCT00462345|DRUG|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
41107121|NCT00740155|BIOLOGICAL|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)
41107122|NCT00740155|BIOLOGICAL|Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
41107123|NCT00740155|BIOLOGICAL|Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
41107124|NCT00740155|BIOLOGICAL|JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
41107125|NCT04114383|OTHER|D3-Creatine|30mg D3-Creatine to measure muscle mass
41107126|NCT04114383|OTHER|Deuterium Oxide|D2O provided to measure muscle protein synthesis
41107127|NCT04114383|OTHER|D3-3-methylhistidine|D3-3-methylhistidine is provided to measure muscle protein breakdown
41107128|NCT00839540|DRUG|micafungin|100 mg qd by slow IV infusion for 24 h
41107129|NCT00839540|DRUG|Micafungin|200 mg qd by slow IV infusion for 24 h
41107130|NCT00839540|DRUG|Caspofungin|70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
41107131|NCT05744206|OTHER|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
41107132|NCT01183780|BIOLOGICAL|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
41107133|NCT01183780|BIOLOGICAL|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
41107134|NCT01183780|DRUG|Irinotecan|180 milligrams/square meter (mg/m\^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
41107135|NCT01183780|DRUG|Folinic Acid|400 mg/m\^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
41107136|NCT01183780|DRUG|5-Fluorouracil|400 mg/m\^2 bolus immediately followed by 2400 mg/m\^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
41107137|NCT04998799|BEHAVIORAL|Current clinical practices of participating physicians|Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge
41107138|NCT01231113|DRUG|artesunate-amodiaquine|The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
41107139|NCT01231113|DRUG|Dihydroartemisinin-piperaquine|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
41107140|NCT05553613|DRUG|Ticagrelor 90 MG Oral Tablet|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
41107141|NCT05553613|DRUG|Clopidogrel tablet|efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke and possible adverse effects.
41107142|NCT05442463|DRUG|Captopril Tablets|Captorpril challenge to each participant
41107143|NCT01196429|DRUG|Carboplatin|Given IV
41107144|NCT01196429|DRUG|Docetaxel|Given IV
41107145|NCT01196429|OTHER|Laboratory Biomarker Analysis|Correlative studies
41107146|NCT01196429|DRUG|Paclitaxel|Given IV
41107147|NCT01196429|DRUG|Temsirolimus|Given IV
41107148|NCT05005819|DRUG|[18F] APN-1607|Subjects will undergo PET imaging using \[18F\]APN-1607.
41107149|NCT01697319|DRUG|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
41107150|NCT02590042|BIOLOGICAL|ADSC-SVF-002|"ADSC-SVF with the following identity:~Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10\^6 cells/g of liposuctioned (hydrated fat)"
41107151|NCT03795428|DRUG|Pemziviptadil (PB1046) Injection|Once-weekly subcutaneous injection
41107152|NCT01560949|DRUG|Oxaliplatin|75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
41107153|NCT01560949|DRUG|Irinotecan|150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
41107154|NCT01560949|DRUG|5-FU|2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
41107155|NCT01560949|DRUG|Gemcitabine|350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).
41107156|NCT01560949|RADIATION|Radiation Therapy|External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
41107157|NCT01174199|DRUG|vorinostat|Given orally
41107158|NCT01174199|DRUG|temsirolimus|Given IV
41107159|NCT01174199|OTHER|laboratory biomarker analysis|Correlative study
41107160|NCT01174199|PROCEDURE|positron emission tomography/computed tomography|PET scan
41107161|NCT03450278|PROCEDURE|micro-osteoperforation|Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
41107162|NCT00880906|PROCEDURE|Esophageal dilation|The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
41107163|NCT00880906|DRUG|Steroid and Proton Pump Inhibitor Therapy|
41107164|NCT04159636|OTHER|Carbohydrate beverage|The participants in this group are allowed to drink carbohydrate until 2 hours before surgery
41107165|NCT06401174|BEHAVIORAL|Delivery of patient navigation|Clinics will receive educational materials and access a referral order for patient navigation. Iterative strategies will be used to increase CRC screening
41445213|NCT00462345|DIETARY_SUPPLEMENT|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
41445214|NCT03081403|DEVICE|Quantitative Sensory Testing|Study of detection thresholds of vibration, cold and pain related to the heat in the dominant hand of the subjects through the QST.
41445215|NCT03639077|DEVICE|Allograft bone alone|The subject will receive an allograft as graft material of choice for sinus augmentation
41445216|NCT03639077|DEVICE|Allograft and xenograft mixture|The subjects will receive a mixture of allograft and anorganic bovine bone xenograft as graft material of choice for sinus augmentation
41445217|NCT06507176|PROCEDURE|flexible ureteroscopic lithotripsy|This group of patients underwent flexible ureteroscopic lithotripsy.
40752188|NCT04250389|OTHER|Hemodynamic assessment (micro and macrocirculatory)|"Each of the variable related to macro- and microcirculatory will be evaluated before and one hour after start of MB infusion.~Macrocirculatory parameters will include :~* Mean, systolic, diastolic arterial, heart rate (HR)~* Cardiac output (CO), sequential vascular response (SVR) and stroke volume (obtained with transthoracic echocardiography or transpulmonary thermodilution catheter if available).~* A passive leg raising (PLR) test will be performed before and one hour after MB infusion. Patients will be classified as fluid responder if they had a CO of at least 10% after PLR.~Microcirculatory parameters will include :~* Cutaneous and gingival refill time~* Tissue oxygen saturation combined with vascular occlusion test (VOT)~* Video microscopy measurements of the sublingual microcirculation~* Metabolic variables: Arterial blood gases including arterial lactate and central venous blood gases."
41445218|NCT06507176|PROCEDURE|percutaneous nephrolithotomy|This group of patients underwent percutaneous nephrolithotomy.
41445219|NCT02698579|GENETIC|No interventional drug product utilized in this follow-up study|"Participants received a single IV infusion of Lenti-D Drug Product (also known as elivaldogene autotemcel or eli-cel) in either parent Study ALD-102 or ALD-104.~The objectives of this long-term follow-up study are to assess long-term safety and efficacy following completion of participation in parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant are conducted in this study."
41445220|NCT03706794|BEHAVIORAL|Clinical Decision Support Tool|Tailored education provided via a smartphone application.
41445221|NCT03706794|BEHAVIORAL|Headache Education|Non-tailored education provided via a smartphone application.
41445222|NCT05619692|DRUG|SAGE-718|Softgel lipid capsules.
41445223|NCT05619692|DRUG|SAGE-718-matching Placebo|Softgel lipid capsules.
41445224|NCT03134664|PROCEDURE|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
41445225|NCT03134664|PROCEDURE|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
41445226|NCT02572713|PROCEDURE|Biofluid samplings|Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
41445227|NCT02572713|PROCEDURE|Tissue samplings|Tissue samplings (skin, colon, submandibular gland)
41445228|NCT02572713|DRUG|DaTSCAN™|
41445229|NCT04882150|DRUG|BMS-986196|Specified dose on specified days
41445230|NCT04882150|OTHER|Placebo|Specified dose on specified days
41445231|NCT00919737|DRUG|NPC-08|Polifeprosan 20 with Carmustine 3.85%
41107166|NCT02704819|OTHER|Decision Support System (DSS)|"The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:~1. Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.~2. Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own."
41445232|NCT06338748|DEVICE|Continuous glucose monitor (CGM) Dexcom G7 used in blinded mode|Dexcom G7 used in blinded mode
41445233|NCT04456972|DIAGNOSTIC_TEST|One arm only|Samples of plasma to analyze ctDNA
41445234|NCT04995783|DIAGNOSTIC_TEST|Coral FRS test|A novel clinical test to predict autoimmune medication response
41107167|NCT02704819|OTHER|Specialist Audiovestibular Consultation|"After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor."
41107168|NCT02704819|OTHER|DSS Customised Vestibular Physiotherapy|"Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.~1. Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.~2. Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement."
41107169|NCT02704819|OTHER|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
41107170|NCT02704819|OTHER|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
41107171|NCT05290818|DEVICE|MAKO™ Partial Knee Arthroplasty|The robotic-arm will be used to position a partial knee arthroplasty.
41445235|NCT00629122|DRUG|Tacrolimus (Arm B)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
41445236|NCT00629122|DRUG|Clotrimazole Troche|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
40752189|NCT04151641|DIETARY_SUPPLEMENT|MNGDPF|Standardized mangosteen extract in dry powder form
41445237|NCT00629122|DRUG|Tacrolimus (Arm A)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
40752190|NCT04151641|DIETARY_SUPPLEMENT|MNGEF|Standardized mangosteen extract in encapsulated form
40752191|NCT04403893|OTHER|HANARO biliary stent placement|HANARO biliary stent placement
41107172|NCT05290818|DEVICE|Triathlon (Stryker) Total Knee Arthroplasty|Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert.
41445238|NCT00629122|DRUG|Nystatin Suspension|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
41445239|NCT01283503|DRUG|BKM120|
41445240|NCT03714594|DRUG|Dapagliflozin 10mg|Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.\[
41445241|NCT03714594|DRUG|Saxagliptin 5mg|Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
41445242|NCT03714594|DRUG|Saxagliptin 5mg + Dapagliflozin 10 mg|Please see Intervention 1 and 2
41445243|NCT05954494|BIOLOGICAL|BPAN Patients|Patients, children or adults with a neurological impairment (epilepsy, dystonia, cognitive impairment...) related to a pathogenic variant of the WDR45 gene
41445244|NCT05166109|DRUG|Vamorolone|Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
41445245|NCT05166109|DRUG|Placebo|Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
41445246|NCT05362292|DRUG|Tolterodine Tartrate ER|Anticholinergic
41445247|NCT05362292|DRUG|Mirabegron|Beta-3-adrenergic agonist
41445248|NCT05362292|DRUG|Placebo|matching placebo pill
40752192|NCT00581789|DRUG|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
40752193|NCT00714272|DEVICE|Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1|6 treatments. One per week during the first six consecutive weeks.
41107173|NCT05379881|BEHAVIORAL|Common Elements Toolbox (COMET)|COMET is an unguided single-session intervention (SSI) combining elements of cognitive-behavioral therapy (CBT) and positive psychology.
41107174|NCT06552533|OTHER|Resistance Exercises with Plyometric exercises|"We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions.~Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane).After resistance training the athletes will go for plyometric exercises and will follow the following guidelines.Tubing Exercises,Plyometric Ankle Jumps Ankle Circles"
41107175|NCT06552533|OTHER|Resistance Exercises without Plyometric exercises|We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane). While controlling the time that a maximal contraction will be maintained, the therapist will assure that the targeted musculature will being maximally loaded
41107176|NCT02883088|PROCEDURE|Frequency Domain - Optical Coherence Tomography (FD-OCT)|FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
41107177|NCT05735444|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) is one of the standard medical treatments for patients with OSAS. The mechanism of CPAP probably involves maintenance of a positive pharyngeal transmural pressure so that the intraluminal pressure exceeds the surrounding pressure. CPAP also increases end-expiratory lung volume, which stabilises the upper airway through caudal traction.
41107178|NCT00696618|DRUG|Fleet Enema|hyper-osmolar preparation
40752194|NCT00714272|DEVICE|Treatment with a sham device, EXcorLab box 1.2|6 sham treatments. One treatment per week during the first six consecutive weeks.
41107179|NCT00696618|DRUG|tap water enema|hypo-osmolar preparation
41107180|NCT00696618|DRUG|Normosol-R enema|iso-osmolar preparation
41107181|NCT05318573|DRUG|Pembrolizumab|Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832
41271035|NCT01212445|DRUG|PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)|13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
41271036|NCT06343090|DRUG|CD19 CAR T-cell|Murine-derived CD19 CAR T cells
41271037|NCT06343090|DRUG|CD22 CAR T cells|humanized CD22 CAR T cells
41271038|NCT06343090|PROCEDURE|hematopoietic stem-cell transplantation|allo-HSCT
41271039|NCT01941589|DRUG|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
41271040|NCT01941589|DRUG|corticosteroids only|IV corticosteroids only
41271041|NCT02590029|BEHAVIORAL|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
41271042|NCT02590029|BEHAVIORAL|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
41271043|NCT02590029|BEHAVIORAL|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
41271044|NCT01271140|DRUG|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
41271045|NCT04756414|BEHAVIORAL|Exposure based face-to-face Cognitive Behavior Group Therapy|See under detailed description
41271046|NCT01954823|DEVICE|e-diary|"The e-diary can collect data on:~* Medical data: information on diseases, treatments and attending physicians~* Diary: daily report of drugs intake, symptoms and their intensity and additional relevant data~* Reminders: the application can send reminders on drug intake or medical appointments to cellular phones or emails~* Reports: textual and graphical reports of the data in the diary can be created"
41271047|NCT02093611|DIETARY_SUPPLEMENT|Placebo|
41271048|NCT02093611|DIETARY_SUPPLEMENT|ATP|400 mg of ATP
41271049|NCT01892488|DRUG|Sultamicillin|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD."
41445249|NCT04737603|DRUG|ED-Initiated treatment with buprenorphine / naloxone|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores \>=8. Participants who weigh \> 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh \<= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
41445250|NCT04200274|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
41445251|NCT05150041|DEVICE|Guardian connect|"* Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
41445252|NCT05150041|DEVICE|iPro2|"* Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
41445253|NCT05133440|DRUG|Radium dichloride|Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.
41445254|NCT05133440|DIAGNOSTIC_TEST|PET Scan|For both arms, the NaF PET will be used to identify discrete osseous lesions which will become index lesions for the study. The simulation scan (either baseline or after 2 cycles of Ra-223) will be used to generate a suitable SBRT radiation plan, per standard practice. If the index lesions are no longer visible after two cycles of Ra-223, we still intend to consolidate the area with radiation. If the lesions are initially radio-occult on the CT and only visible on the NaF PET, we will fuse the pre-treatment NaF PET/CT to the simulation CT after 2 cycles of Ra-223 to delineate the SBRT treatment volumes.
41445255|NCT04380181|DRUG|dobu|Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass
41445256|NCT04849390|DRUG|ESO-101|Daily administration in the evening at bedtime for 28 days
41445257|NCT04849390|DRUG|Placebo|Daily administration in the evening at bedtime for 28 days
41445258|NCT04053153|DEVICE|Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)|exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
41445259|NCT04704323|DRUG|CAP-100|CAP-100 (humanized antibody against C-C-chemokine receptor 7 \[CCR\]7)
41445260|NCT02937948|OTHER|Adaptative treatment plan|"Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder."
41445261|NCT02937948|RADIATION|External radiotherapy|At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
41445262|NCT02055547|DRUG|MK-8521 35μg|Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)
41445263|NCT02055547|DRUG|MK-8521 100μg|Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)
41445264|NCT02055547|DRUG|MK-8521 125μg|Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)
41445265|NCT02055547|DRUG|MK-8521 150μg|Single dose 150μg SC injection in a treatment period (Part 1, Panel B)
41445266|NCT02055547|DRUG|MK-8521 175μg|Single dose 175μg SC injection in a treatment period (Part 1, Panel B)
41445267|NCT02055547|DRUG|MK-8521 200μg|Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)
41445268|NCT02055547|DRUG|MK-8521 300μg|Single dose 300μg SC injection in a treatment period (Part 1, Panel A)
41445269|NCT02055547|DRUG|MK-8521 50/72μg|MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)
41445270|NCT02055547|DRUG|MK-8521 72/125μg|MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)
41445271|NCT02055547|DRUG|MK-8521 100/150μg|MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)
41445272|NCT02055547|DRUG|MK-8521 125/150μg|MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)
41445273|NCT02055547|DRUG|Placebo|Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
41445274|NCT03285594|DRUG|Sotagliflozin|"Pharmaceutical form: Tablet~Route of administration: Oral"
41445275|NCT03285594|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
41445276|NCT03285594|DRUG|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
41445277|NCT03285594|DRUG|Oral Antidiabetes Drugs (OADs)|OADs (including metformin) as prescribed by the investigator as per local labeling.
41445278|NCT05261399|DRUG|Savolitinib|300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
41445279|NCT05261399|DRUG|Osimertinib|"80 mg osimertinib~(1 × 80 mg tablet once daily) Administrative route : oral"
41445280|NCT05261399|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) Administrative route : IV infusion
41445281|NCT05261399|DRUG|Cisplatin|Cisplatin (75 mg/m2) or Administrative route : IV infusion
41445282|NCT05261399|DRUG|Carboplatin|Carboplatin (AUC5) Administrative route : IV infusion
41445283|NCT00222118|BEHAVIORAL|labor/birth preparation classes|prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks
41107182|NCT05318573|DRUG|FF-10832|Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
41445284|NCT00222118|OTHER|intervention|prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum
41445285|NCT00222118|OTHER|usual care|no intervention
41445286|NCT00606281|DRUG|Aripiprazole|oral, 24mg/day
41445287|NCT00606281|DRUG|placebo|oral, 0mg(4tablets)/day
41445288|NCT00746421|DRUG|Quetiapine XR|oral doses, 200 mg, 300 mg, 400 mg
41445289|NCT00746421|DRUG|Placebo|200mg, 300mg or 400mg
41445290|NCT06561490|RADIATION|sonographic assesment of placental thickness and volume|sonographic assesment of placental thickness and volume
41445291|NCT06628219|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
41445292|NCT01711632|DRUG|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
40752195|NCT05655572|OTHER|Action Observation Theraoy|After initial baseline assessment patients allocated in AOT group will undergo treatment protocol of 6 weeks having 4 stages of duration 1.5 weeks each performed 3 days per week. . Assessment will be perform at baseline after 2, 4 and 6 weeks
40752196|NCT05655572|OTHER|Functional Training|after baseline assessment participants including in this group will perform the tasks for 6 weeks (3 days per week) s and after that again assessment will be made for examining the improvements.Assessment will be perform at baseline after 2 ,4 and 6 weeks
40752197|NCT00901563|DRUG|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
41445293|NCT06562322|DEVICE|Placebo|Participants will be received placebo PBMT on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
41445294|NCT06562322|DEVICE|300 J|Participants will be received PBMT at 300 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
41445295|NCT06562322|DEVICE|600 J|Participants will be received PBMT at 600 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
41445296|NCT06562322|DEVICE|1260 J|Participants will be received PBMT at 1260 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
41445297|NCT04254133|BEHAVIORAL|Questionnaire|Complete questionnaire
41445298|NCT04254133|PROCEDURE|Biospecimen Collection|Provide saliva samples
41445299|NCT04254133|DIAGNOSTIC_TEST|Genetic Testing|Undergo genetic testing
41107183|NCT04476095|DEVICE|Active PBMT|Active PBMT will be applied using a device with 152 emitters (wavelength - 808 nm; dose - 3000 J; treatment time - 600 s), in the low back region.
41107184|NCT04476095|DEVICE|Placebo PBMT|The placebo PBMT will be applied using the same device as that of active PBMT but without any emission of therapeutic dose. Moreover, the irradiated site and the irradiation time were the same as that of active PBMT. Patients received a total dose of 0 J in the placebo mode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
41107185|NCT03181958|DEVICE|NHFOV|Nasal high frequency oscillation ventilation (NHFOV) is used as the noninvasive supporting mode after extubation.
41107186|NCT03181958|DEVICE|NCPAP|Nasal continuous positive airway pressure(NCPAP) is used as the noninvasive supporting mode after extubation.
41107187|NCT03181958|DEVICE|NIPPV|Nasal intermittent positive pressure ventilation(NIPPV) is used as the noninvasive supporting mode after extubation.
41107188|NCT04619914|DRUG|Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt|CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-\[p-(2-chloro-1,2-diphenylvinyl)phenoxy\] triethylamine citrate (1:1)
41107189|NCT04619914|DRUG|letrozole (Femara; Novartis pharma AG, Basle, Switzerland)|Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
41107190|NCT04265625|DEVICE|endoscopic guidance|Percutaneous tracheotomy performed by endoscopic guidance
41107191|NCT02710149|BIOLOGICAL|Anti-CD20-CAR-transduced T cells|Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
41107192|NCT03394027|DRUG|ONC201|625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
41107193|NCT02535624|PROCEDURE|PACKING|By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
41107194|NCT02535624|PROCEDURE|ANGIO|Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
41107195|NCT02410538|OTHER|"list of FAQ"|
41107196|NCT02834871|DEVICE|Electromyogram|
41445300|NCT04254133|OTHER|Genetic Counseling|Undergo counseling
41445301|NCT04254133|OTHER|Laboratory Biomarker Analysis|Correlative Studies
41445302|NCT00829894|DRUG|Risperidone|1 mg Tablet
40752198|NCT00901563|OTHER|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
41107197|NCT01360840|DRUG|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent \[%\] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
41107198|NCT01360840|DRUG|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
41107199|NCT01360840|OTHER|Placebo|Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
41107200|NCT01360840|OTHER|Standard of Care (SoC)|All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
41107201|NCT04168619|DRUG|Discontinue methotrexate|According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
41107202|NCT04168619|OTHER|Medication depends on clinical judgement|Once discontinued methotrexate, based on subject's clinical condition and prescribe alternative treatment
41445303|NCT00829894|DRUG|Risperidone|1 mg Tablet
41107203|NCT04039971|PROCEDURE|ACL Reconstruction|Surgical techniques
41107204|NCT00680537|PROCEDURE|Exercises|Completion of a series of shoulder exercises for 6 weeks post device implant
41271050|NCT01892488|DRUG|Placebo|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD"
41445304|NCT02854800|DRUG|varenicline|Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
41445305|NCT02649647|PROCEDURE|Conventional resection|The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
41445306|NCT02649647|PROCEDURE|Proximally extended resection|The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
41445307|NCT06452251|DIAGNOSTIC_TEST|OPG, OC, RANKL, IL-10, IL-1β, Ca, TNF-α and Caspase-1 ELISA|The levels of OPG, OC, RANKL, IL10, IL1β, Ca, TNF-α and Caspase1 in bone and PICF of patients with or without Vitamin D sufficiency were measured by ELISA.
41107205|NCT00633854|PROCEDURE|Ultrasound examination|Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
41107206|NCT05207137|BEHAVIORAL|Telephone call about vaccination|Participants receive phone call from their family physician, where they are invited to ask questions about the COVID-19 vaccine.
41107207|NCT01955694|DRUG|BAY94-8862|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
41107208|NCT01955694|DRUG|Eplerenone|INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
41107209|NCT01955694|DRUG|Placebo|matching placebo
41107210|NCT01069341|DRUG|Ranibizumab|Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
41107211|NCT00174434|DRUG|SU011248|SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
41107212|NCT00174434|DRUG|Paclitaxel|Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
41107213|NCT00844571|OTHER|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
41107214|NCT04881136|DEVICE|Reveal LINQ™|The physical device is the Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data that will be used for gait analysis.
41107215|NCT03617406|DIAGNOSTIC_TEST|Volume Challenge|Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE
41107216|NCT02385669|DRUG|Ipilimumab|Checkpoint blockade inhibitor
41107217|NCT02385669|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
41107218|NCT00855153|OTHER|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
41107219|NCT00855153|DRUG|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
41107220|NCT04298606|OTHER|Quality-of-Life Assessment|Ancillary studies
41107221|NCT04298606|OTHER|Questionnaire Administration|Ancillary studies
41107222|NCT04298606|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
41107223|NCT01623349|DRUG|BKM120 and Olaparib|Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
41107224|NCT01623349|DRUG|BYL719 and Olaparib|Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
41107225|NCT03052361|DRUG|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage.
41107226|NCT03052361|DRUG|Placebos|similar looking and tasting liquid placebo
41107227|NCT03168646|PROCEDURE|wafer procedure|wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
41107228|NCT03168646|PROCEDURE|arthroscopy and ulnar shortening osteotomy|wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
41107229|NCT05457478|OTHER|Medical Device Qardio® smart scale Usage and Evaluation|Weight monitored using a Qardio® smart scale
41107230|NCT05457478|OTHER|Questionnaire Administration|Ancillary studies
41107231|NCT00559949|OTHER|Laboratory Biomarker Analysis|Correlative studies
41107232|NCT00559949|DRUG|Selumetinib|Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.
41107233|NCT01467700|DRUG|Ramelteon SL|Ramelteon SL tablets
41107234|NCT01467700|DRUG|Placebo|Ramelteon placebo-matching tablets
41107235|NCT02008253|PROCEDURE|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
41107236|NCT01604447|PROCEDURE|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
41445308|NCT06452251|DIAGNOSTIC_TEST|Resonance Frequency Analysis|Implant stability was measured by a device (Penguin RFA, Integration Diagnostics, Sweden) based on Resonance Frequency Analysis (RFA) and categorized by Implant Stability Quotient (ISQ) scale.
41107237|NCT01604447|PROCEDURE|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
41107238|NCT05977933|DEVICE|Shape II CPET|Submaximal Cardiopulmonary exercise test equipment
41107239|NCT02624219|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
41107240|NCT02624219|DRUG|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
41107241|NCT02624219|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
41107242|NCT05585567|BIOLOGICAL|V-01/V-01-B5|Contains 10μg of V-01 and 10μg of V-01-B5
41445309|NCT06452251|DIAGNOSTIC_TEST|Periodontal clinical examination|Clinical periodontal indices including plaque index (PI) (Silness and Löe 1964), gingival index (GI) (Löe 1967), probing depth (PD), and bleeding on probing (BOP) (Ainamo and Bay 1975) were recorded using a Williams periodontal probe. The BOP percentage (%) was calculated by dividing the number of bleeding sites by the total number of sites examined.
41107243|NCT05585567|BIOLOGICAL|V-01-351/V-01-B5|Contains 10μg of V-01-351 and 10μg of V-01-B5
41107244|NCT05585567|BIOLOGICAL|V-01|Contains 10μg of V-01
41107245|NCT00568542|DRUG|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
41107246|NCT00568542|DRUG|placebo|35 I.E. kg body weight placebo to erythropoetin beta
41107247|NCT06548880|OTHER|Structured exercise program|The intervention applied in this research has an online exercise training conducting with a structured exercise program including different types of exercise which are range of motion, stretching and low intensity aerobic exercises. The exercise program continued with sessions each lasting 60 minutes, once a week for 10 weeks.
41107248|NCT00202748|BEHAVIORAL|Increase in activity to control weight|
41107249|NCT00202748|BEHAVIORAL|Increase in activity to control weight.|
41107250|NCT00762099|DRUG|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
41107251|NCT00762099|DRUG|Placebo|Placebo/sugar tabs will look identical to active drug.
41445310|NCT06452251|PROCEDURE|Dental implant placement and bone sample collection|All patients were received by a single examiner a bone level implant (standard type and Sandblasted, Large-grit, Acid-etched surface) (Implant Swiss, Yverdon, Switzerland).
41107252|NCT02421081|PROCEDURE|vessel microsurgery|That is a surgery ro repair artery laceration.
41107253|NCT02421081|PROCEDURE|tendon repair|That is a surgery ro repair tendon cut.
41107254|NCT02421081|PROCEDURE|nerve microsurgery|That is a surgery ro repair median/ ulnar/ radial nerve cut.
41107255|NCT00924534|DRUG|Placebo|Placebo
41107256|NCT00924534|DRUG|SLV337|SLV337 400 mg/day
41107257|NCT00924534|DRUG|SLV337|SLV337 800 mg/day
41107258|NCT00924534|DRUG|SLV337|SLV337 1400 mg/day
41107259|NCT02833272|BEHAVIORAL|EMPOWER Educational Brochure|The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
41107260|NCT00261053|DRUG|i.v. recombinant human C1 inhibitor|
41107261|NCT03245593|OTHER|Shared-decision making process|Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available
41107262|NCT03245593|OTHER|standard care|Care of patients according to standard practice of managing patients with bipolar disorder
41107263|NCT02371135|GENETIC|colonic biopsies|
41107264|NCT02371135|GENETIC|questionnaires|
41107265|NCT06479733|PROCEDURE|buccal pedicle flap|For the first group (buccal pedicle flap group), outlining the full-thickness palatal flap 1 mm greater than the diameter of the underlying cover screw will be done, making a partial incision at the hinge portion of the created mini-pedicle flap to facilitate buccal rolling, de-epithelializing the mini-pedicle flap, then two small vertical incisions will be performed similarly mesial and distal to the screw border as wide as possible preserving the papilla and extending labially to include all the keratinized mucosa, elevating a full-thickness flap, then rolling of the pedicle flap into the created buccal pouch. The flap will be then sutured all around in place using a 5/0 vicryl suture
41107266|NCT06479733|PROCEDURE|connective tissue graft|For the second group (free CTG group), masticatory mucosa on the palate between palatal raphae and maxillary posterior teeth is the most common location for the donor site for free CTG. It will be obtained by harvesting and de-epithelializing FGG asbeing a CTG derived from de-epithelialization of FGG mainly composed of lamina propria. Then the donor site will be covered by gel foam , sutured and protected.
41107267|NCT06479733|PROCEDURE|acellular dermal matrix|"* For the third group (ADM group) , The matrix will be trimmed so that it is gently adapted to the artificial envelope created on the buccal aspect of the ridge.The matrix will be trimmed and beveled to make its adaptation into the artificial envelope easier. Before placement, matrix will be hydrated for 10 minutes in fresh human blood collected after flap elevation in each patient.~* For both second and third groups, graft will be carefully positioned under the buccal pouch, sutured to it, light pressure will be applied over the inserted graft with moist gauze for 10 minutes to minimize blood clot and dead space formation between the graft and the underlying bone."
41107268|NCT06479733|PROCEDURE|control group|only placement of dental implant without soft tissue augmentation
41107269|NCT04681768|DRUG|Abemaciclib|Abemaciclib tablets 150 mg, 100 mg, 50 mg as clinical routine: 150 mg twice daily per os, in-label administration in combination with endocrine therapy (aromatase inhibitor or Fulvestrant)
41107270|NCT01320436|DIETARY_SUPPLEMENT|Curcumin|3 capsules (820 mg containig 500 mg curcumin each) twice daily.
41107271|NCT01320436|DRUG|5-aminosalicylic acid|The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
41107272|NCT00982618|DRUG|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
41107273|NCT00982618|PROCEDURE|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
41107274|NCT00982618|DRUG|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
41107275|NCT00563537|RADIATION|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
41107276|NCT05928819|PROCEDURE|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.
41107277|NCT06375824|DRUG|Bufei Recipe|Bufei Recipe: Roasted Astragalus, Codonopsis pilosula, Walnut kernels, Sichuan Fritillaria, Angelica sinensis, Stir fried Purple Su Zi, Honey Baibu, Roasted Purple Aster, etc. Take 1 dose daily, 5 days a week.
41107278|NCT06375824|DRUG|Bufei Recipe placebo|The placebo was prepared using 5% of the drug, with color, odor, taste, appearance, and weight similar to the experimental group drug, and packaging consistent with the experimental group drug.
41107279|NCT04849416|DRUG|LOXO-305|Administered orally.
41107280|NCT02498158|DEVICE|MRI scans|"20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:~1. anatomical scan according to standard protocol~2. functional scan according to the standard protocol of rest-state fMRI.~scans of 10 healthy subjects will be taken from existing scans at the imaging department."
41107281|NCT02029664|DEVICE|Visual distortion increment based on the gait pattern|
41107282|NCT05672446|OTHER|simulation with standardized child patient|49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients. In the simulation, a school-aged child was used as the standard patient.
41107283|NCT04316234|OTHER|Passive vape|On days with passive vape, 2-3 vapers in an adjacent chamber were vaping by turn, and vape was passed on to the exposure chamber continuously .
41107284|NCT00284973|BIOLOGICAL|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
41107285|NCT05566418|OTHER|mulligan mobilization|Mulligan mobilization belt will be wrapped around the subject's proximal forearm, close to the elbow joint line, and then wrapped around the therapist's shoulder. This will be done with the therapist's other hand on the distal humerus. The belt will give the subject's forearm a 10-to 15-second lateral glide.
41107286|NCT05566418|OTHER|myofascial release|Myofascial release will be performed on the patient, commencing at the common extensor origin and progressing all the way to the extensor retinaculum in the wrist. The periosteum will be engaged with the fingertips, with contact progressing inferiorly to the common extensor tendon and then to the wrist's extensor retinaculum
41107287|NCT01420718|DRUG|MTA|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
41107288|NCT01420718|DRUG|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
41107289|NCT03931044|PROCEDURE|Image-Guided Robotic Gastrectomy|The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.
41107290|NCT05726292|DRUG|Relacorilant|Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is being used in this study as an experimental drug combined with other treatments for prostate cancer.
41107291|NCT05726292|DRUG|Enzalutamide|Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer.
41107292|NCT05726292|OTHER|Placebo (Sugar Pill)|This would be a sugar pill consisting of 2 softgels. This is not an experimental drug or treatment.
41445311|NCT06452251|PROCEDURE|Gingival Crevicular Fluid Sampling|One month after the healing caps were inserted, peri-implant crevicular fluid (PISF) samples were collected from 6 different sides of each implant. Before sampling, the area was isolated and dried, and paper strips were gently kept in periimplant sulcus for 30 seconds. Strips with blood or saliva contamination were discarded. PISF volumes of each strip were measured by a device (Periotron 8,010, Oraflow Inc, USA). Strips were then pooled, and inserted into tubes. PISF was recovered from paper strips through agitation in phosphate buffer saline (50 mM Tris-HCl, 5 mM CaCl2, 0.2 M NaCl,pH 7.5). All samples were stored at -80C until the day of analysis.
41445312|NCT06161571|DRUG|Efruxifermin|Administered by subcutaneous (SC) injection
41445313|NCT06161571|DRUG|Placebo|Administered by SC injection
41445314|NCT06267703|OTHER|Metabolomic profiling|Metabolomic profiling using serum samples was performed based on Nightingale Blood Biomarker Analysis platform; Proteomic profiling will be performed by both Scanning SWATH and OLINK® Explore 384 Oncology panel.
41445315|NCT00644137|DRUG|pregabalin|Help stop smoking
41445316|NCT00644137|OTHER|cigarettes|help stop smoking with study medication
41445317|NCT06410638|DIAGNOSTIC_TEST|Six Minute Walking Test|It is applied in a 30 m long corridor in an indoor environment, and the distance walked by the patient in a six-minute period, oxygen saturation, heart rate, and change in dyspnea are recorded. For this, before starting the test, oxygen saturation, heart rate, arterial blood pressure and dyspnea level according to the Borg scale are recorded. The same parameters are measured again at the end of the test. The feature of this test is that the person walks at his own pace, stopping when necessary and allowing the use of oxygen. It is an exercise test that is easy to perform and well tolerated.
41445318|NCT06410638|DIAGNOSTIC_TEST|Shuttle walking test|Shuttle walking test at increasing speed is an exercise test in which walk between two cones 10 m apart at an increasing speed throughout the test and each 10-meter journey between the two cones is counted as a shuttle.
41445319|NCT01997983|DEVICE|TC-3 Gel mixed with Botox (BTX)|TC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
41445320|NCT00906477|PROCEDURE|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
41445321|NCT02375477|OTHER|Educational Intervention|Given educational presentation
41445322|NCT00104910|RADIATION|Internal Radiation Therapy|
41445323|NCT00104910|RADIATION|3-Dimensional Conformal Radiation Therapy|
41445324|NCT00104910|BIOLOGICAL|Cetuximab|Given IV
41445325|NCT00104910|DRUG|Cisplatin|Given IV
41107293|NCT05726292|OTHER|Androgen Deprivation Therapy|"All participants in this study, who meet the requirements to participate, will get Androgen Deprivation Therapy (ADT; a form of hormone therapy) continuously before their radical prostatectomy surgery. As part of this study, ADT consists of one injection every 1-3 months. In this study, ADT is a gonadotropin releasing hormone (GnRH) agonists or antagonist; the choice of which brand of ADT to use is up to your treating physician. GnRH agonists and antagonists are drugs that lower the production of androgens (male hormones) in your body. Prostate cancer cells usually require androgens, such as testosterone, to grow.~Androgen Deprivation Therapy (ADT) has been approved by United Stated Food and Drug Administration (US FDA) to treat patients with prostate cancer but is not approved to treat patients prior to prostatectomy."
41107294|NCT05726292|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is surgery to remove the entire prostate gland and surrounding lymph nodes to treat men with localized prostate cancer.
41107295|NCT00138606|DRUG|vildagliptin|
41107296|NCT03328273|DRUG|Ceralasertib|An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
41107297|NCT03328273|DRUG|Acalabrutinib|An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
41107298|NCT04900142|PROCEDURE|Micropulsed laser trabeculoplasty|Trabeculoplasty
41107299|NCT04561037|DEVICE|Pulsed Electromagnetic Field therapy (PEMFT)|PEMFT was connected to electrical mains supplying 220v. Pair of applicators sized 16x10x3 cm was adjust to be over TMJ, on both sides of the face; the appliance was adjusted to the frequency of 50 HZ and intensity of 90 Gauss. Twelve PEMF treatment sessions of 30 min duration were provided 3 times per week TMJ mobilization techniques and isometric exercises against resistance for muscles of mastication
41107300|NCT04561037|OTHER|TMJ physical therapy program|TMJ manual physical therapy program (mobilization and gentle isometric exercises) for 30, 3 times a week, for 4 weeks.
41107301|NCT06165185|OTHER|Water|Please see the associated arm description
41107302|NCT06165185|OTHER|Coffee|Please see the associated arm description
41107303|NCT06165185|OTHER|Control|Please see the associated arm description
41107304|NCT02513238|DRUG|Mesenchymal stem cell|Stemcells injected into submandibularis
41107305|NCT02513238|DRUG|Isotonic NaCl|
41107306|NCT06327919|DIETARY_SUPPLEMENT|Probiotic supplement|multi-strain probiotics were used in this study. Each probiotic capsule contains Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus reuteri, Lactobacillus rhamnosus, magnesium stearate and maltodextrin. 1.8 × 109 CFU / capsule. 2 capsules per day, for 12 weeks
41107307|NCT06327919|OTHER|Placebo supplement|The placebo capsule contains 300 mg of starch. 2 capsules per day, for 12 weeks
41107308|NCT03360422|OTHER|Survey|Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
41107309|NCT03360422|OTHER|Focus Group|After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
41107310|NCT03360422|OTHER|Usability study|After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
41107311|NCT06553248|DRUG|GZR4|Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks
41107312|NCT06553248|DRUG|Insulin Degludec|Administered once daily subcutaneously (s.c., under the skin) for 6 weeks
41107313|NCT00607503|DRUG|Terbutaline|"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
41107314|NCT00810680|DRUG|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
41107315|NCT00660478|DEVICE|Endeavor|Comparison of two different drug eluting coronary stents
41107316|NCT00660478|DEVICE|Cypher Select|Comparison of two different drug eluting coronary stents
41107317|NCT03244696|BEHAVIORAL|Step Tracking|The step tracking intervention is designed to increase physical activity through the use of self-monitoring and brief motivational materials. The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
41271051|NCT01498133|PROCEDURE|skin-to skin contact|Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
40925411|NCT04357288|OTHER|Encounter Decision Aid|The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.
40925412|NCT02363023|PROCEDURE|Collect tracheal and pulmonary secretions|Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
40925413|NCT02057588|PROCEDURE|LV pacing site|Patient will be paced in VVI mode from Left ventricle specific position for a short period of time per position in order to cover spontaneous ventricular activity
40925414|NCT04552145|PROCEDURE|surgery|standard decompression surgery
40925415|NCT04552145|BEHAVIORAL|Physiotherapy|3 month physical therapy treatment including home activity based on a well defined program and 4 to 6 visits at physical therapy intervention center.
40925416|NCT02077621|DRUG|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
40925417|NCT02077621|DRUG|Placebo|500 mL normal saline
40925418|NCT01374035|OTHER|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
40925419|NCT01073501|DRUG|Pregabalin|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
40925420|NCT01073501|DRUG|Placebo|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
40925421|NCT05979545|DIAGNOSTIC_TEST|Rapid Diagnostics|Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.
40925422|NCT03254459|DRUG|Buprenorphine Sublingual Spray|0.5 mg Sublingual Spray
40925423|NCT03254459|DRUG|Morphine|4 mg Intravenous Injection
40925424|NCT03254459|DRUG|Oxycodone Hydrochloride|10 mg tablet
40925425|NCT03254459|DRUG|Zofran|4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
40925426|NCT05262348|DEVICE|adaptive DBS delivered through AlphaDBS IPG System|"The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive real-time fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable."
41107318|NCT03244696|BEHAVIORAL|Water Tracking|The water tracking intervention is designed to increase water intake, to a healthy level, through the use of self-monitoring and brief motivational materials.The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
41107319|NCT04421391|DIETARY_SUPPLEMENT|QuadraMune(TM)|QuadraMune(TM) is a commercially available nutritional supplement
41107320|NCT02065050|OTHER|team-based care|Patients in the eDMS arm are called at least every month for their diabetes treatment.
41107321|NCT05434650|DEVICE|electrophysiology study and ablation with an Abbott Ablation Catheter|During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat
41107322|NCT00845832|DRUG|Placebo|iv on days 1 and 15 (Parts 1 and 2)
41107323|NCT00845832|DRUG|rituximab [MabThera/Rituxan]|0.5g iv on days 1 and 15 (Parts 1 and 2)
41107324|NCT00845832|DRUG|tocilizumab [RoActemra/Actemra]|2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
41445326|NCT05954741|OTHER|Motor rehabilitation alone|Participants will undergo motor training consisting of a walking session (20 minutes), balance exercises, postural control exercises, proprioceptive exercises, joint mobilization exercises, and muscle strengthening exercises for a total of 25 minutes. A muscle relaxation session will follow (45 minutes).
40925427|NCT05262348|DEVICE|conventional DBS delivered through AlphaDBS IPG System|The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
40925428|NCT03815578|OTHER|Clinical examination|"* Number of painful joints,~* Number of swollen joints,~* Patient Global assessment VAS (0 - 100)~* and Physician Global assessment VAS (0 - 100)"
40925429|NCT03815578|OTHER|Pain assessment|"* Pressure Pain Thresholds (PPTs),~* Mechanical Temporal Summation (MTS)~* and Diffuse Noxious Inhibitory Control (DNIC)"
40925430|NCT03815578|OTHER|blood sample|18 ml whole blood for ELISA analysis and miRNAs detection
41107325|NCT06287229|DRUG|Blinatumomab|Given by Infusion
41107326|NCT06287229|DRUG|Inotuzumab Ozogamicin|Given by IV
41107327|NCT06287229|DRUG|Hyper-CVAD|Given by IV Participants younger than 60 years of age, you will receive hyper-CVAD.
41107328|NCT06287229|DRUG|Mini-hyper-CVD|Given by IV Participants 60 years of age or older, you will receive mini-hyper-CVD
41107329|NCT00168467|DRUG|Ramipril|
41107330|NCT01566513|BEHAVIORAL|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
41107331|NCT01566513|BEHAVIORAL|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
41107332|NCT01566513|BEHAVIORAL|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
41107333|NCT04154137|OTHER|Questionnaire|Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
41107334|NCT00605033|DRUG|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
41107335|NCT00605033|DRUG|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
41107336|NCT02428088|DRUG|Dasotraline|Dasotraline 2 mg once daily
41107337|NCT02428088|DRUG|Dasotraline|Dasotraline 4 mg once daily
41107338|NCT02428088|DRUG|Placebo Comparator|Placebo once daily
41107339|NCT02131324|DRUG|DFD06 Cream|
41107340|NCT02131324|DRUG|Clobetasol Propionate Cream 0.05%|
41107341|NCT02508896|BIOLOGICAL|AFFITOPE® AT04A+adjuvant|subcutaneous injection
41107342|NCT02508896|BIOLOGICAL|AFFITOPE® AT06A+adjuvant|subcutaneous injection
41107343|NCT02508896|BIOLOGICAL|Adjuvant without active component|subcutaneous injection
41107344|NCT01649180|DRUG|Axitinib|Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
41107345|NCT05032937|DRUG|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
41107346|NCT05538455|DEVICE|PC4L solutions|Two different versions of the PC4L system will be tested. A fully equipped version and a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). 25% of participants will use the full system, the remaining 75% will use the cloud-based system. As part of the decision support system, the PC4L platform includes a recommendation component. This component collects information from different sources available (directly from sensors, cognitive games, questionnaires, and the multimodal fusion engine), and under clinical and professional guidance, after evaluating the potential improvement or worsening of patients' conditions, issues personalized recommendations to address identified problems. The recommendations relate to the following areas: physical activities; sleep; cognitive; nutrition. These recommendations will generally be sent to the PC4L application on the patients' smartphone, where they will appear as pop-up notifications.
41445327|NCT05954741|OTHER|Motor rehabilitation and Cognitive rehabilitation (paper-based)|Group 2 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a standard cognitive intervention, with the execution of cognitive exercises in the domains of attention, memory, executive function, visuo-spatial abilities, space-time orientation, by paper-pencil support (45 minutes per day).
41445328|NCT05954741|OTHER|Motor rehabilitation and cognitive rehabilitation (digital-based)|Group 3 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a digital cognitive intervention, with the execution of cognitive exercises on attention, memory, executive functions, visual-spatial ability, space-time orientation, employing device support (tablet) with interactive exercises presented by specific software (VRRS Home tablet Khymeia Srl) (45 minutes).
41445329|NCT02180321|DRUG|Tranexamic Acid|10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
41107347|NCT04247204|BIOLOGICAL|Platelet-rich plasma intrauterine infusion|For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.
41107348|NCT04747392|BIOLOGICAL|SAL001|administrated once by subcutaneous injection
41107349|NCT04747392|BIOLOGICAL|FORSTEO|administrated once by subcutaneous injection
41107350|NCT04467788|OTHER|Computer-aided sessions|Changing participants' KAP of ergonomics in dentistry
41107351|NCT04467788|OTHER|Clinical simulation sessions|Changing participants' KAP of ergonomics in dentistry
41107352|NCT01169311|DEVICE|Hemorrhoidopexy|
41271052|NCT01049776|DRUG|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
41445330|NCT02180321|DRUG|normal saline|10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
41107353|NCT06467279|DEVICE|Target Controlled İnfusion|TCI (Target-Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
40925431|NCT03815578|OTHER|Patient Reported Outcomes|"* Health Assessment Questionnaire (HAQ),~* Rheumatoid Arthritis Impact of Disease score (RAID),~* Daily joint pain intensity VAS (0-100),~* Hospital Anxiety and Depression scale~* and Coping Strategy Questionnaire."
40925432|NCT05885178|PROCEDURE|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
40925433|NCT03635580|OTHER|Negative control|Untreated-control group
41107354|NCT06467279|DRUG|Inhalation anesthetic|In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
41107355|NCT03118804|DIAGNOSTIC_TEST|Assessment of Lung Tidal Distribution With EIT|Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
41107356|NCT05944822|OTHER|pro-inflammatory cytokines|compare the levels of pro-inflammatory cytokines in patients with Essure® contraceptive implants and in control patients with endometriosis or adenomyosis.
41107357|NCT06460948|DRUG|Norethindrone Acetate-Ethinyl Estradiol|Estrogen-progestin will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and healthy control cohort.
41107358|NCT03280017|DRUG|Ketamine|intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
41107359|NCT03280017|DRUG|Normal saline|normal saline infusion
41107360|NCT03915613|DRUG|Humulin R|"The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
41107361|NCT03915613|DRUG|Diluent|"The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
41107362|NCT06462963|RADIATION|single-fraction SBRT|Single-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers a high dose of radiation in a single treatment session to a targeted area, often used for treating small, well-defined tumors. This approach minimizes exposure to surrounding healthy tissues while effectively treating the tumor.
41107363|NCT06462963|RADIATION|multiple-fraction SBRT|Multiple-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers high doses of radiation over several treatment sessions to a targeted area, typically used for treating small, well-defined tumors. This method helps to further protect surrounding healthy tissues by spreading the total radiation dose over multiple sessions.
41107364|NCT01291004|DRUG|Desogestrel/ethinyl estradiol and ethinyl estradiol|Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
41107365|NCT01291004|DRUG|28-day drospirenone oral contraceptive|Drospirenone/ethinyl estradiol 0.3/0.02 mg
41107366|NCT01291004|DRUG|28-day levonorgestrel oral contraceptive|Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
41107367|NCT05543837|DRUG|Capsaicin|Patients will receive a fixed dose of capsaicin
41107368|NCT01494246|OTHER|electronic mail|Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
41107369|NCT04410055|BEHAVIORAL|Sitting|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
41107370|NCT04410055|BEHAVIORAL|Static standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
41107371|NCT04410055|BEHAVIORAL|Dynamic standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
41107372|NCT05047341|DRUG|SHR0302、[14C]SHR0302|8 mg SHR0302/ 80 µCi \[14C\]SHR0302, once, D1
41107373|NCT02326649|DEVICE|Physioflow|impedance cardiography instrument that measures cardiac output non-invasively
41107374|NCT05566080|PROCEDURE|Carotid endarterectomy|Patients who have a significant carotid stenosis and who undergo surgical carotid endarterectomy
41107375|NCT01194258|DRUG|Insulin lispro|
41107376|NCT01194258|DRUG|Insulin aspart|
41107377|NCT01194258|DRUG|Recombinant human hyaluronidase PH20|
41107378|NCT01194258|DRUG|Insulin glulisine|
41107379|NCT01194258|DRUG|Insulin glargine|
41107380|NCT01918163|DIETARY_SUPPLEMENT|Pomegranate pills|
41107381|NCT04302155|OTHER|balance-specific -games focusing on dynamic aspects of COP on Wii fit system.|"The participants were randomly assigned into two groups interventional and control. Total 18 minutes session was given to both groups wii fit group and traditional balance training group. All participants were given 3 sessions per week for 6.~Total 48 participants were initially accessed initially for eligibility , 13 participants were excluded because of having good balance and good balance age score on Wii fit assessment, 35 participants were recruited for balance training. These participants were randomly divided into Wii fit and traditional training group through sealed enveloped method 18 participants was recruited in Wii fit group and 17 in traditional balance training group. 3 participants drop out from Wii fit group and 2 from traditional balance training group.~Some examples include catching apples in a basket ,moving a golf ball around barriers towards a hole , popping rising balloons/bubbles and air hockey ."
41107382|NCT04302155|OTHER|mini trampoline and inflatable discs group|"High skipping and landing on a limb every time (2 repeats of 45 s each leg).Standing on one leg and try to catch the ball thrown at them in various directions by the researcher (2 repeats of 45 s each leg) Exercises in inFlated rubber hemisphere attached toa rigid platform (BOSU)~1. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance (2 repeats of 45 s each leg).~2. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance, while lifting the non-support leg forward and backward (2 repeats of 45 s each leg).~3. Standing on BOSU flat hard surface with both legs, in an attempt to maintain balance (3 minutes on both legs).~4. Standing on BOSUs flat hard surface with both feet, in an attempt to maintain balance, while trying to catch the ball thrown at them by the experimenter in various directions (3 minutes on both leg)"
41107383|NCT05969665|DEVICE|Fitbit Inspire 2|A smartwatch (Fitbit Inspire 2) with its respective app will be worn by the patients in the intervention group for 3 months.
41107384|NCT05969665|DEVICE|Abbott Freestyle Libre 3|A continuous glucose measuring device (Abbott Freestyle Libre 3) with its respective app will be worn by the patients in the intervention group for 3 months.
41107385|NCT00862680|PROCEDURE|4-Dimensional Computed Tomography|Undergo 4D PET/CT
41107386|NCT00862680|PROCEDURE|4D PET Scan|Undergo 4D PET/CT scan
41107387|NCT01703130|PROCEDURE|Dose of of ropivacaine 0.75% used in block procedure|
41107388|NCT01890889|DIETARY_SUPPLEMENT|Ad-Chol-Pre|
41107389|NCT01890889|DIETARY_SUPPLEMENT|Half-dose Ad-Chol-Pre|
41107390|NCT01890889|OTHER|Defatted egg yolk without the active ingredient of the other two interventions|
41107391|NCT00100100|DRUG|Modafinil|
41107392|NCT01130818|DRUG|GLPG0492|single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
41107393|NCT01130818|DRUG|placebo|single dose, oral solution
41107394|NCT01130818|DRUG|GLPG0492|single dose, solid formulation, 50 mg (2\*25 mg/capsule), fasting
41107395|NCT01130818|DRUG|GLPG0492|single dose, solid formulation, 50 mg (2\*25 mg/capsule), after high fat breakfast
41107396|NCT00662324|BEHAVIORAL|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.~The focus group to last from 60 to 90 minutes."
41107397|NCT00662324|BEHAVIORAL|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.~We expect the focus group to last from 60 to 90 minutes."
41107398|NCT00662324|BEHAVIORAL|focus groups|"MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.~Expect the focus group to last from 60 to 90 minutes."
41107399|NCT00354640|DRUG|anastrozole|1 milligram tablet PO QD for 14 days
41107400|NCT00354640|DRUG|simvastatin|40 milligram tablet PO QD for 14 days
41107401|NCT00354640|OTHER|pharmacological study|laboratory analysis
41107402|NCT00354640|PROCEDURE|adjuvant therapy|laboratory analysis
41107403|NCT03192319|BIOLOGICAL|Zostavax|Zostavax will be administrated by subcutaneous injection
41445331|NCT00586989|PROCEDURE|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
41445332|NCT06128863|DRUG|Pembrolizumab, Eftilagimod alpha|Eftilagimod alpha 20 mg s.c. every 2 weeks (5 doses), Pembrolizumab 200 mg i.v. every 3 weeks (3 cycles), Radiotherapy 50 Gy (25 x 2 Gy)
41107404|NCT03930823|OTHER|Interview|One to one interview
41107405|NCT05802264|COMBINATION_PRODUCT|ABCI|Subjects will receive ABCI via oral inhalation
41107406|NCT05802264|COMBINATION_PRODUCT|Placebo|Subjects will receive ABCI via oral inhalation
41107407|NCT05311319|DRUG|HAIC+TQB2450+Anlotinib|HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
41107408|NCT00344019|DRUG|Placebo Oral Tablet|placebo pre-PCI for ACS
41445333|NCT06558721|OTHER|Conventional rehabilitation|Lower extremity conventional rehabilitation in stroke patients
41445334|NCT06558721|OTHER|Mirror therapy|Mirror therapy of the lower extremity in stroke patients
41445335|NCT06558721|DEVICE|Bicycle ergometer with functional electric stimulation|Bicycle ergometer with functional electric stimulation therapy of the lower extremity in stroke patients
41445336|NCT04865003|OTHER|treatment of infection|
41445337|NCT03689595|OTHER|Sample of Blood|Collection of blood sample from participants
41107409|NCT00344019|DRUG|Atorvastatin 80mg|atorvastatin 80 mg pre-angio/PCI
41107410|NCT00344019|OTHER|Screening|Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
41107411|NCT00548119|BIOLOGICAL|NeoCart|autologous tissue implant
41107412|NCT00548119|PROCEDURE|microfracture|microfracture
41107413|NCT00001318|DRUG|interferon gamma|
41107414|NCT02794350|DEVICE|Cochlear implant|
41107415|NCT04630912|OTHER|Acceptance and Commitment Therapy|There is no specific protocol for ACT with dementia, therefore a published ACT protocol, 'Better Living with Illness' (Brassington et al., 2016), will be used flexibly to guide the intervention.
41107416|NCT03646279|DEVICE|Calibrace|The CALIBRACE is a new product designed to improve posture using a front-to-back tensioning system that lifts shoulders up and back.
41107417|NCT00927667|PROCEDURE|No Drug|Patients have received primary FVIII prophylaxis (started \< 2 years of age)
41107418|NCT00927667|PROCEDURE|No Drug|Patients have received secondary FVIII prophylaxis (started 2 - \< 6 years of age)
41445338|NCT06110689|OTHER|VU-AMS device|Patients will wear the VU-AMS monitor prior to MRI.
41445339|NCT05763537|BEHAVIORAL|Standard Doula Care Plus PMAD Intervention|Doulas trained in the DONA training, and the PMAD-focused training will provide care to perinatal people.
41445340|NCT05763537|BEHAVIORAL|Standard Doula Care|Doulas trained in the DONA training will provide care to perinatal people.
41445341|NCT00819754|DRUG|IXO regimen + bevacizumab|"Phase I study - identifies the safety of IXO with bevacizumab and recommended phase II dose~Phase II study - assesses efficacy and safety of IXO with bevacizumab"
41445342|NCT05891522|PROCEDURE|portable scanner|performing a portable cranial scanner on cerebro-injured intensive care patients
41445343|NCT05891522|PROCEDURE|fixed scanner|performing a conventional fixed cranial scanner on cerebro-injured intensive care patients
40925434|NCT05537870|BEHAVIORAL|cancer nurse navigator care|oncology case manager care combined with cancer nurse navigator care
40925435|NCT05537870|BEHAVIORAL|case manager care|case manager care (usual care)
40925436|NCT03561532|OTHER|Fecal microbiota transplantation (FMT)|FMT administered into the cecum of the patient in colonoscopy.
40925437|NCT03561532|OTHER|Placebo|Autologous FMT (fecal suspension made of patients own feces) administered into the cecum of the patient in colonoscopy.
40925438|NCT02880085|DRUG|Local anesthetic|local injection
41107419|NCT00927667|PROCEDURE|No Drug|Patients have received secondary FVIII prophylaxis (started 6 - \< 12 years of age)
41107420|NCT00927667|PROCEDURE|No Drug|Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)
41107421|NCT00927667|PROCEDURE|No Drug|Patients have received on-demand therapy
41107422|NCT00597103|OTHER|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
41107423|NCT00597103|OTHER|Sleep Assessment Testing|"Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously"
41107424|NCT00597103|OTHER|Periodic Leg Movement Syndrome Assessment|"Subjects will wear and Actiwatch on both legs for three consecutive nights."
41107425|NCT06552364|DRUG|LABA+LAMA|1 dose per day (AM)
41107426|NCT06552364|DRUG|LABA+LAMA+ICS|1 dose per day (AM)
41107427|NCT06552364|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control
41107428|NCT06552364|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
41107429|NCT01390402|DRUG|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
41107430|NCT01390402|DRUG|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
41445344|NCT05053854|DRUG|Talazoparib|During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks
41445345|NCT05954650|BEHAVIORAL|Rehabilitation|Physical therapy and multisensory stimulation adjusted to the needs of each patient.
41107431|NCT01390402|PROCEDURE|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
41107432|NCT01390402|DRUG|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
41107433|NCT01390402|DRUG|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
41107434|NCT01390402|PROCEDURE|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
41107435|NCT01390402|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
41107436|NCT01390402|DRUG|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
41107437|NCT01390402|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
41107438|NCT01460290|DRUG|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
41107439|NCT04598919|DRUG|Saracatinab|125 mg once daily by mouth for 24 weeks
41107440|NCT04598919|DRUG|Placebo|once daily by mouth for 24 weeks
41107441|NCT00540202|DRUG|artemether-lumefantrine|Tablets taken twice daily for 3 days according to weight based guidelines.
41107442|NCT00540202|DRUG|Oral quinine|Quinine tablets given at 10mg/kg 8 hourly for 7 days
41107443|NCT05154955|DRUG|10XB-101 Solution for Injection|One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.
41107444|NCT05154955|DRUG|10XB-101 Vehicle Solution for Injection|This is the placebo control
41107445|NCT00770978|DRUG|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
41107446|NCT00770978|DRUG|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
41107447|NCT01726530|DRUG|transdermal fentanyl patch (50 mcg/hour)|
41107448|NCT01726530|DRUG|Placebo|
41107449|NCT04760119|PROCEDURE|Vein bypass surgery first strategy|Vein bypass will be performed with standart anaesthetic and surgical techniques using reversed great saphenous vein conduit. Location of proximal and distal anastomosis will be recorded. Post surgery completion angiography imaging will be performed.
41107450|NCT04760119|PROCEDURE|Endovascular treatment first (drug coated balloon angioplasty) strategy|Endovascular treatment using drug-coated balloons will be performed under local anaesthetic via common femoral artery. Final angiography imaging will be demonstrated.
41107451|NCT00238446|DRUG|EC-MPS|
41107452|NCT02247258|DRUG|Azathioprine|See arm/group descriptions
41107453|NCT02247258|DRUG|Azathioprine in case of endoscopic recurrence|See arm/group descriptions
41107454|NCT02247258|PROCEDURE|Ileocolonoscopy|See arm/group descriptions
41107455|NCT02247258|PROCEDURE|Small bowel follow trough|See arm/group descriptions
41107456|NCT04531488|PROCEDURE|Powered Mobility Training Simulator|Two groups of participants- 18 in each- were provided with either a simulator or powered wheelchair. Both groups were tested at baseline for powered mobility level. Both groups the practiced at home or school for 12 weeks, 4 times a week for at least 20 minutes. Both groups returned and underwent another evaluation to assess powered mobility level after 12 weeks of practice.
41107457|NCT04531488|OTHER|Training with Powered Wheel Chair|Training with Powered Wheel Chair
41107458|NCT05875155|DIAGNOSTIC_TEST|Infectious Disease Labwork|Infectious disease labs will be drawn and resulted.
41107459|NCT05875155|DIAGNOSTIC_TEST|Fertility-Based Labwork|Other labwork to understand fertility may be drawn.
41107460|NCT05987969|OTHER|"Alena mobile application"|This mobile application primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.
41107461|NCT06301035|DEVICE|Asymmetric High flow nasal cannula|"* Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary."
41107462|NCT06301035|DEVICE|Standard(symmetric) High flow nasal cannula|"* Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary."
41107463|NCT03465007|DRUG|Hydrocortisone|we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.
41107464|NCT03465007|DRUG|Normal saline|we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
41107465|NCT00055432|DRUG|Gemzar and Alimta|
41107466|NCT01814644|BEHAVIORAL|TRIMM Intervention|Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
41107467|NCT01814644|BEHAVIORAL|Standard Care|Individual assessment, lifestyle counseling
41107468|NCT00299741|DRUG|Sunitinib|Sunitinib 50 mg daily, 4/2 schedule
41107469|NCT00208078|DEVICE|pressure support ventilator|Non invasive ventilation 4h/d 5 days a week
41107470|NCT03813706|PROCEDURE|lymph node dissection|The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
41107471|NCT05377346|OTHER|Placement of the i-gel|The lubricated i-gel is inserted into the mouth and introduced along the hard palate with a continuous and gentle push until resistance was felt in the hypopharynx.
41107472|NCT03551067|DRUG|Dexmedetomidine|Dexmedetomidine mixed with juice was given to the child orally preoperatively.
41107473|NCT03551067|COMBINATION_PRODUCT|Midazolam/Ketamine|Midazolam/Ketamine was mixed with juice and given to the child orally preoperatively
41107474|NCT04948593|PROCEDURE|Native kidney biopsy|
41107475|NCT02960139|DEVICE|Test- Treatment with Sylys Surgical Sealan|Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
41107476|NCT04191434|DRUG|Flamboyant 125/12|Flamboyant 125/12 capsule
41107477|NCT04191434|DRUG|Budesonide/formoterol 200/6|Budesonid/formoterol 200/6 capsule
41107478|NCT04191434|OTHER|Flamboyant 125/12 Placebo|Flamboyant 125/12 Placebo capsule
41107479|NCT04191434|OTHER|Budesonide/formoterol 200/6 placebo|Budesonid/formoterol 200/6 Placebo capsule
40925439|NCT03483129|BEHAVIORAL|Consultation|15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.
40925440|NCT05884801|DRUG|QLS1103|Oral dose
41107480|NCT03203356|DRUG|growth hormone|Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
41133302|NCT04942184|BEHAVIORAL|Memory strategies in Arm 2|Memory strategies will consist of daily at home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. During weeks 1 and 2, participants will be completing the memory tasks without being instructed to use any specific strategy. At the end of week 2 subjects will be taught the memory strategies and during week 3 and 4, they will be reminded daily to use the memory strategies while completing the memory tasks.
41107481|NCT05139732|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
41107482|NCT01641913|OTHER|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
41107483|NCT02012166|DRUG|MK-0893 10 mg|MK-0893 10 mg administered orally in 240 mL of water
40925441|NCT02763943|BEHAVIORAL|Pharmacist-led, technology enabled education intervention|Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.
40925442|NCT02361476|DRUG|Clonidine|Injection - during surgery
41107484|NCT02012166|DRUG|MK-0893 40 mg|MK-0893 40 mg administered orally in 240 mL of water
40925443|NCT02361476|DRUG|Placebo|Injection - during surgery
40925444|NCT05088473|OTHER|Biological collection|Collection of cerebrospinal fluid kappa and lambda free light chains and indexes
41107485|NCT02012166|DRUG|MK-0893 200 mg|MK-0893 200 mg administered orally in 240 mL of water
40925445|NCT01698710|DRUG|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
41107486|NCT02012166|DRUG|MK-0893 1000 mg|MK-0893 1000 mg administered orally in 240 mL of water
41107487|NCT02012166|DRUG|Placebo|Placebo administered orally in 240 mL of water
41107488|NCT02012166|BIOLOGICAL|Sandostatine®|Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.
41107489|NCT02012166|BIOLOGICAL|Insulin|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.
41107490|NCT02012166|BIOLOGICAL|Glucagon|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
41107491|NCT04851730|PROCEDURE|Orthopedic Physical Therapy Intervention|"First, a deep slow breathing protocol is intended to increase the expansion of the pelvic floor, utilizing the relationship between the diaphragm and the pelvic floor, resulting in a gentle stretching of the pelvic floor.~Next, abdominal soft tissue mobilization, or scar mobilization of the lumbopelvic abdominal area will take place.~Next, manual therapy to the thoracic or lumbar spine or the hips will be performed based on the impairments found in the orthopedic evaluation.~The participant will be given a home exercise program to support breath training, and manual therapy. During the initiation of the second visit each participant will watch a standardized pain education video on the tablet, Understanding pain in less than 5 minutes and what to do about it The above plan of care will be completed 2 times/week for 4 weeks for a total of 8 visits."
41107492|NCT04851730|DEVICE|Dry Needling|"Third, the investigator will dry needle appropriate muscles. Dry needling treatment technique will include insertion of a sterile, disposable, solid filament needle into the muscle belly in the area palpated as listed below. A 0.30 × 0.50mm, or specified size below, stainless steel Seirin J-type or Myotech needle will be used (Dommerholt 2011). Clean technique will be employed throughout the treatment procedure which includes hand washing, clean latex-free glove use, and skin-surface preparation with an alcohol swab ( Baima \& Isaac 2008). Each muscle will receive a maximal number of 2 insertions and each insertion consists of up to 5 seconds of a pistoning (in and out motion) technique in an attempt to elicit a local twitch response. Standard protocol for each muscle will be established prior to beginning data collection.~Details about the dry needling protocol can be found in Appendix L."
41107493|NCT06178354|PROCEDURE|Cryosurgery|Undergo focal cryotherapy ablation
41107494|NCT06178354|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo high intensity frequency ultrasound ablation
41107495|NCT06178354|OTHER|Survey Administration|Ancillary studies
40925446|NCT05520710|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
41445346|NCT00573443|DRUG|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
41445347|NCT00573443|DRUG|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
41445348|NCT00573443|DRUG|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
41445349|NCT01763177|OTHER|Oxygen|Oxygen mask 40% 8 LPM for 30 minutes
41445350|NCT06586112|DRUG|ESK-001|ESK-001
40925447|NCT05520710|OTHER|Education|Educational materials, designed to help people with traumatic brain injury manage their everyday cognitive challenges will be provided through Zoom video conferencing software.
40925448|NCT06411171|DRUG|Pembrolizumab plus chemotherapy (FLOT)|The experimental group was treated with pembrolizumab combined with FLOT, and the control group was treated with FLOT chemotherapy alone
40925449|NCT04995523|DRUG|AZD2936|Anti-TIGIT/Anti-PD-1 Bispecific Antibody
41107496|NCT04788433|DIAGNOSTIC_TEST|glycomic analysis|Analysis of glycans on plasma samples
41107497|NCT04788433|OTHER|Phone interview|patients are followed up by phone up to 1 year
41107498|NCT04296513|DIAGNOSTIC_TEST|High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by
41107499|NCT04296513|DIAGNOSTIC_TEST|High-definition magnification with digital chromoendoscopy.|Subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
41107500|NCT05053009|DRUG|Brufen Retard|800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
41107501|NCT00547118|DRUG|Rimonabant|One 20 mg tablet given 1 time per day for 112 days.
41107502|NCT00547118|DRUG|Placebo|One placebo tablet given 1 time per day for 112 days.
41445351|NCT06586112|DRUG|Apremilast|Apremilast
41445352|NCT06586112|DRUG|Placebo|Placebo
41445353|NCT04715646|DRUG|Brivaracetam|"Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses.~Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral~Oral solution Concentration: 10 mg/ml Route of administration: oral"
41445354|NCT02388971|DRUG|MLN1202|MLN1202 solution
41445355|NCT02388971|DRUG|Placebo|MLN1202 placebo-matching solution
41445356|NCT03114748|OTHER|EEG|
41107503|NCT05926180|DRUG|DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)|Patients will receive single oral doses of probe drugs alone and after at least 27 days of treatment with DZD9008, 300 mg, once daily, until a treatment discontinuation criterion is met. Each patient will receive a single oral dose of DZD9008 on Day 7, and DZD9008 once daily for 27 days from Day 9 to Day 35. Patients will also receive a single oral dose of 2 mg midazolam on Day 1 and Day 32, and oral dose of 10 mg rosuvastatin and 0.25 mg digoxin cocktail on Day 2, Day 7 and Day 33.
41107504|NCT03206554|DRUG|Ropivacaine|Large volume local anaesthetic intraarticularly
41107505|NCT03206554|OTHER|Saline|sham injection
41445357|NCT03114748|OTHER|DBS switched OFF and ON|
41271053|NCT06125860|DIETARY_SUPPLEMENT|Targeted BEP based on baseline nutritional status|In Arm 2 (targeted BEP based on baseline nutritional status), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm.
41271054|NCT06125860|DIETARY_SUPPLEMENT|Targeted BEP based on baseline nutritional status and monthly GWG monitoring|In Arm 3 (targeted BEP based on baseline nutritional status and monthly GWG monitoring), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm; participants with an inadequate GWG at a monthly follow-up visit will receive additional BEP supplements.
40925450|NCT03956719|DRUG|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device.
40925451|NCT03956719|PROCEDURE|abdominal liposuction|50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells
41271055|NCT06125860|DIETARY_SUPPLEMENT|Universal BEP|In Arm 4 (universal BEP), all participants will receive BEP supplements from baseline through the end of pregnancy.
41271056|NCT05204563|DRUG|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection
41271057|NCT05204563|DRUG|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25 g for Injection
41107506|NCT01505946|OTHER|TGA (Thrombin generation Assay)|"TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period"
41107507|NCT02662855|OTHER|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
41107508|NCT02662855|DRUG|Favipiravir|oral administration of Favipiravir tablets
41107509|NCT06485427|PROCEDURE|Selective Intra-arterial Cooling Infusion (IA-SCI)|"Pre-recanalization: During the procedure, the micro-catheter is advanced over a micro-guide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4 ℃) is infused intro into the ischemic territory at a rate of 10 mL/min via the micro-catheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~Post-recanalization: After recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL/min for 10 min, repeated twice with a 10-minute interval between infusions."
41107510|NCT00238316|DRUG|letrozole|2.5 mg PO daily for 1 year
41107511|NCT00238316|OTHER|Placebo|2.5 mg PO daily for one 1 year
41107512|NCT03073499|PROCEDURE|Oncological Home Hospitalization|
41107513|NCT02887768|DEVICE|Epicardial Infarct Repair with CorMatrix-ECM|CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
40925452|NCT01247805|DRUG|sildenafil citrate|Single oral dose of 1 x 20 mg IR oral tablet.
41107514|NCT02887768|PROCEDURE|Coronary Artery Bypass Grafting Surgery|All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
41107515|NCT03857334|BIOLOGICAL|Injection of autologous platelet rich plasma|
41107516|NCT03857334|DRUG|Injection of cortivazol : Altim®|Corticosteroids
41107517|NCT06347952|PROCEDURE|Use of Acoustic and color imaging doppler during surgery for breast cancer|The intervention (post pilot study) is to systematically record the effect of routine use of acoustic as well as color imaging doppler during mammoplasty for breast cancer (for both the therapeutic and symmetrising breast reduction).
41107518|NCT06343103|OTHER|Workers exposed|Workers exposed to cytotoxic agents
41107519|NCT06343103|OTHER|Workers not exposed|Workers not exposed to cytotoxic agents
41107520|NCT04542369|DRUG|Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)|Inductive/neoadjuvant therapy: Tislelizumab + EP Maintenance/adjuvant therapy: Tislelizumab + EP
41107521|NCT02261467|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
41107522|NCT02261467|DRUG|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
41107523|NCT04157530|DEVICE|wang-bu-liu-xing|wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
41107524|NCT04157530|DEVICE|acupuncture|acupuncture applied to Qingming and Qiuhou with Der-qi
41107525|NCT04157530|DEVICE|Electroacupuncture|acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi, the frequencies of stimulus were 6 Hz, the intensity of stimulus was minimal visible muscle twitch
41107526|NCT03514251|PROCEDURE|The suture marks the location of the parathyroid gland|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker. Vascular protection.
41107527|NCT02727972|BEHAVIORAL|Cognitive Testing|Verbal assessments as well as computer testing.
41107528|NCT02727972|OTHER|MRI|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. MR acquisition will be a Sag 3D magnetization-prepared rapid gradient-echo (MPRAGE) sequence with 3.34 ms echo time, 2,500 ms repetition time, 1,000 ms inversion time, 7 degree flip angle, and 180 Hz/pixel bandwidth. The image dimensions will be 256 x 256 x 176 and pixel size 0.98 x 0.98 x 1.0 mm. Resting state MRIs will also be obtained as follows: We will be doing 2 six minute scans with subjects in the scanner, eyes open, fixating a cross. TR = 3 secs 45 slices x 3 mm slice thickness = 13.5 cm. In plane resolution = 3 x 3 mm, slice acquisition order = ascending.
41107529|NCT02727972|RADIATION|PET|High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or HR+ will be used to image subjects. Vital signs (blood pressure, pulse, respiration) will be obtained before and after radiotracer administration. An antecubital venous catheter will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter will be inserted by an experienced physician before the PET scan. At the beginning of each scan, the subject's head will be immobilized and a 6 minute transmission scan using an orbiting 137Cs (HRRT) or 68GE (HR+) point-source is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of FPEB or ABP688.
41107530|NCT00016913|DRUG|carboplatin|AUC=6 week one of each 4 week cycle
40925453|NCT01247805|DRUG|Sildenafil citrate|single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.
41107531|NCT00016913|DRUG|estramustine|2 tablets tid PO 5 of 7 days per week each 4 week cycle
41107532|NCT00016913|DRUG|paclitaxel|80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
41107533|NCT00016913|RADIATION|radiation therapy|77.4 Gy in 1.8 Gy fractions
41107534|NCT00016913|DRUG|leuprolide or goserelin acetate|7.5 mg IM injection once every 4 weeks for 6 months
41107535|NCT04558437|OTHER|Questionnaire|"Questionnaire at M0 M3 M6:~PCL-5 (Post-Traumatic Stress Disorder Checklist Scale, version DSM-5) HAD (Hospital Anxiety and Depression Scale) SDS (Sheehan Disability Scales)"
41107536|NCT00198848|DRUG|Iron-folic acid supplement|
41107537|NCT00009646|DRUG|indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
41107538|NCT00009646|DRUG|Indomethacin|0.1 mg per kilogram of body weight
41107539|NCT00009646|DRUG|Placebo|0.1 mg per kilogram of body weight
41107540|NCT01552018|DRUG|Saxagliptin|Saxagliptin 5 mg, 1 tablet per day for 3 months
41107541|NCT01552018|DRUG|Placebo|Placebo, 1 tablet per day for 3 months.
41107542|NCT00961142|DRUG|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
41107543|NCT03795558|DRUG|Etelcalcetide|Up-Titration
41107544|NCT02709343|DRUG|Bone-marrow derived MSCs|Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells
41271058|NCT00294125|DRUG|Flavocoxid|Daily flavocoxid for 12 weeks
41271059|NCT00294125|DRUG|Placebo|Daily placebo for 12 weeks
41107545|NCT02709343|DRUG|Placebo|Placebo product visually very similar to mesenchymal stromal cells
41107546|NCT06343896|OTHER|monitorization reliability|evaluation of the use of the integral pulmonary index in the child patient group
41107547|NCT04743128|BEHAVIORAL|Exercise|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
41107548|NCT00392678|DRUG|Salsalate|Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
41107549|NCT00392678|DRUG|Placebo|Placebo to Salsalate
41107550|NCT02482233|BEHAVIORAL|ENDD (NJOY)|As described above.
41107551|NCT02482233|DRUG|NRT (NicoDerm CQ)|As described above.
41107552|NCT02482233|BEHAVIORAL|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
41107553|NCT02482233|BEHAVIORAL|brief advice|"Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
41107554|NCT02482233|BEHAVIORAL|brochure|"A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf"
41107555|NCT02457702|OTHER|Orally administered labeled glycerol|Oral administration of labeled glycerol
41107556|NCT00105820|PROCEDURE|System level depression care quality improvement|
41271060|NCT04301427|OTHER|Bone mineral density|Bone mineral density will be measured twice in all included patients.
41445358|NCT02287961|PROCEDURE|Standard proctologic examination|(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
41445359|NCT02287961|PROCEDURE|High resolution anoscopy|at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
41445360|NCT02287961|PROCEDURE|Biopsy(ies) during High Resolution Anoscopy|only if lesion suggestive of AIN detected during High Resolution Anoscopy
41445361|NCT02287961|PROCEDURE|High Resolution Anoscopy biannually|Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
41445362|NCT01613872|OTHER|Mindfulness Based Stress Reduction|An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
41445363|NCT04626596|COMBINATION_PRODUCT|Radiopaque Etonogestrel (ENG) Implant|68 mg subdermal implant
40925454|NCT01247805|DRUG|sildenafil citrate|single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
40925455|NCT05738343|OTHER|dieta mediterranea|nutritional education or Mediterranean food scheme
41445364|NCT06559358|DEVICE|electrical stimulation|A two-channel portable electrical stimulation unit (BTL-4620, Czech Republic).
41445365|NCT04939571|OTHER|Registry of preterm born infants with treatment-requiring ROP|All prematurely born infants who develop treatment requiring ROP and are treated (independent of the kind of treatment modality) at a center that participates in the registry are eligible for database entry.
40925456|NCT06009185|DRUG|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.
41445366|NCT04908007|OTHER|Qualitative analysis for professionals|"3 individual interviews with the different categories of professionals most involved during the crisis in each university hospital. In the first phase, the points of improvement identified will be analyzed In the second phase, good practices and innovations will be analyzed. For these first two phases, the duration of one hour was chosen because it is difficult to mobilize the professionals for longer. Individual interviews are preferred, but group interviews are possible with no more than three people so that everyone can express himself or herself. Finally, individual interviews of 15 to 30 minutes will be conducted with some of the people interviewed previously in order to identify the costs of the dysfunctions or problems encountered during the crisis.~Questionnaires with establishments associated with the crisis management, the ARS AuRA and France Assos Santé AuRA.~Analysis of evidence documents in the university hospitals"
41107557|NCT06223009|DRUG|cNP8|cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.
41107558|NCT06223009|OTHER|Placebo|Subjects not randomized to cNP8 will receive a single 30 minute IV infusion of placebo.
41445367|NCT04908007|OTHER|Quantitative analysis for Professionals|"A self-assessment of the three phases of the crisis management process (preparation, crisis management, crisis recovery) will be carried out in the participating establishments using the WHO grid with the target persons identified within the establishments.~This step will use the crisis response assessment tool developed by the WHO following the H1N1 pandemic in 2011. This grid will be adapted beforehand to the COVID-19 situation and to the local organization by the study's scientific committee. The dimensions investigated will be : Command and control, Communication, Safety and security, Triage, Surge capacity, Continuity of essential services; Human resources, Logistics and supply management, Post-disaster recovery.~The grids will be sent to the 4 university hospitals to be filled in with the target audience recommended by the WHO methodological guide.~The results of this self-assessment will be linked to and interpreted with the results of the interviews in phase 1."
41445368|NCT04908007|OTHER|Quantitative analysis for Patients|"A questionnaire of patients' perceptions on the same perimeter (crisis and post-crisis management, from the point of view of points of improvement and good practices) will be constructed and sent by the management of the establishments to all patients hospitalized for 48 hours or more during the first wave and who have left their email address (methods similar to the e-satis survey). The online questionnaire survey is preferred in order to get away from the emotion and for feasibility reasons. This patient experience questionnaire adapted to COVID will be co-constructed with expert/partner patients and user associations.~Four dimensions will be investigated : The perception of the quality of the information received by the patient, The nature of the information on the specific health protection protocol from which the patient benefited, The patient's consideration of the overall context, during and after, The effects of the health context on the overall management of the patient"
41445369|NCT04908007|OTHER|Tools development|"Development of tools to prepare for situations of uncertainty : In the third phase of the project, design thinking workshops will be organized (within the HCL) to develop training (in the form of simulation) in order to appropriate virtuous practices in situations of uncertainty. The purpose of these training sessions will be to improve the institution's ability to learn in a situation of uncertainty and thus to develop its reliability.~The aim of these workshops is to provide tools for raising awareness of situations of uncertainty to all hospital staff."
41445370|NCT03037554|DEVICE|Sleepwear with Lateralized Thermal Characteristics|Subjects will wear sleepwear constructed with insulating fabric on one side and conductive fabric on the other side, arranged bilaterally.
41445371|NCT03037554|DEVICE|Sham-Lateralized Sleepwear|Subjects will wear sleepwear constructed with two insulating fabrics arranged bilaterally.
41445372|NCT04935554|OTHER|Person centred care|physical activity, nutrition, motivation, health competence, psychosocial.
41445373|NCT01837914|PROCEDURE|Maxillary expansion|
41445374|NCT01837914|PROCEDURE|Adenotonsillectomy|
41445375|NCT05526183|BIOLOGICAL|Adeno-viral vector vaccine|The vaccine will be injected intramuscularly, as two doses 28 days apart. Two different dosages will be given to volunteers (low dose: 5x1010 and high dose: 1x1011)
41445376|NCT05445180|BEHAVIORAL|Contingency management|Contingency management will be used to encourage abstinence
41445377|NCT06559813|BEHAVIORAL|Step-by-step: A cognitive behavioral parent program with role-plays in virtual reality|A parent training program based on social learning theory and cognitive behavioral therapy (CBT), incorporating virtual reality for training in brief role plays. The program includes similar strategies as other common CBT-parent training programs for parents of children with behavior problems, with the difference that virtual reality is used as an additional way to practice skills.
41445378|NCT04514757|DEVICE|active tVNS|20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
41445379|NCT04514757|DEVICE|sham tVNS|Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.
41445380|NCT03992404|DRUG|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
41445381|NCT03992404|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
41445382|NCT04222790|DRUG|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).
41445383|NCT04222790|OTHER|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
41445384|NCT05952544|DRUG|essential amino acids and keto-analogues supplementation|very low protein diet plus essential amino acids and keto-analogues supplementation
41445385|NCT05952544|OTHER|low protein diet|patients were on low protein diet only
41445386|NCT05802784|PROCEDURE|Hysteroscopic septoplasty with scissors|In hysteroscopic septoplasty with scissors arm, incision of the septum was done by continuous flow hysteroscopy and scissors using saline as distension media.
41107559|NCT05241119|PROCEDURE|SLNB|undergo fluorescence SLNB.
41107560|NCT05241119|PROCEDURE|pALND|undergo low axillary lymph node dissection with ICBN as the boundary
41107561|NCT05241119|PROCEDURE|ALND|undergo ALND
41107562|NCT04124068|OTHER|Hydrogen peroxide teeth whitening gel|Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
41107563|NCT04124068|DEVICE|GLO Brilliant Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
41107564|NCT04124068|DEVICE|GLO Lit Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
41107565|NCT04124068|DEVICE|GLO Science Professional Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
41107566|NCT00130637|DRUG|Daclizumab|
41107567|NCT05102266|DRUG|BR1016C|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
41107568|NCT05102266|DRUG|BR1016D|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
41107569|NCT01392872|OTHER|Neuropsychological assessment|This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
41445387|NCT05802784|PROCEDURE|Hysteroscopic septoplasty with resectoscope|In hysteroscopic septoplasty with resectoscope arm, incision of the septum was done by 26 Fr monopolar resectoscope with collin's knife using glycine1.5% as distension media.
41445388|NCT06505187|DRUG|Celecoxib|200mg every 12 hours
41445389|NCT06505187|DRUG|Tylenol|650mg q6h
41445390|NCT06505187|DRUG|Oxycodone|5mg every 6 hours as needed
41445391|NCT06505187|DRUG|placebo|every 12 hours
41107570|NCT03419156|OTHER|Text Message Arm Intervention|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
41445392|NCT03425344|DIAGNOSTIC_TEST|Diagnostic|No traditionally intervention will be given but participants will be exposed to shoulder- MRI, ultrasound and sonoelastography..
41445393|NCT04200586|DRUG|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.
41107571|NCT05620303|OTHER|Exercise|Parents/guardians will receive three different contents weekly (i.e., infographics, video recipes, information pills, or videos) each week related to 24-h movement behaviors (i.e., PA, sedentary behavior, sleep duration) or Mediterranean Diet for 36 weeks.
41107572|NCT02281318|BIOLOGICAL|Mepolizumab|Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
41107573|NCT02281318|DRUG|Placebo|Sterile 0.9% sodium chloride solution
41107574|NCT02281318|DRUG|SOC|Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
41107575|NCT01463046|DRUG|Panobinostat|"Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8"
41107576|NCT01463046|DRUG|Cytarabine|"Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9."
41107577|NCT01463046|DRUG|Daunorubicin|"Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5."
41107578|NCT04969172|DRUG|Exosomes overexpressing CD24|The suggested therapeutic agent here is based on an existing therapeutic platform that uses exosomes that were engineered to overexpress CD24 that can directly suppress the cytokine storm. The exosomes will be isolated and purified from human embryonic kidney T-REx™-293 cells that constitutively express high levels of human CD24.
41107579|NCT02607384|BEHAVIORAL|Eyeglass wearing|Children found to require eyeglasses will be given two pairs free of charge
41107580|NCT02607384|BEHAVIORAL|Orthoptic exercises|Children found to have convergence insufficiency will be prescribed orthoptic exercises
41107581|NCT02607384|OTHER|Specialist referral|Children found to any other eye condition will be referred to a pediatric eye care specialist
41107582|NCT05351372|RADIATION|Ultra-low dose protocol|
41107583|NCT05351372|RADIATION|Standard dose protocol|
41107584|NCT03302546|PROCEDURE|Incremental hemodialysis|Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week
41107585|NCT03302546|PROCEDURE|Conventional hemodialysis|Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
41107586|NCT05937919|DRUG|Intravenous injection of 68Ga-PMD22|68Ga-PMD22 were intravenous injected into the patients before PET/CT scans
41107587|NCT04565691|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment that is accepted to cause bacteremia in about 40% of the cases.
41107588|NCT02633358|DEVICE|Therapeutic hypothermia group|Therapeutic hypothermia
41107589|NCT00092755|DRUG|MK0663, etoricoxib|
41107590|NCT00092755|DRUG|Comparators: ibuprofen and placebo|
41107591|NCT00303836|DRUG|cyclophosphamide|Given IV
41107592|NCT00303836|DRUG|fludarabine phosphate|Given IV
41107593|NCT00303836|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
41107594|NCT00303836|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
41107595|NCT00303836|BIOLOGICAL|gp100 antigen|Given SC
41107596|NCT00303836|BIOLOGICAL|MART-1 antigen|Given SC
41107597|NCT00303836|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
41107598|NCT00303836|BIOLOGICAL|filgrastim|Given SC
41107599|NCT00303836|BIOLOGICAL|aldesleukin|Given IV
41107600|NCT04645069|BIOLOGICAL|ADG126 Mono|ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.
41107601|NCT04645069|BIOLOGICAL|ADG126-anti PD1|ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion
41107602|NCT04645069|BIOLOGICAL|ADG126-ADG106|ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion
41107603|NCT02900326|OTHER|Endurance exercise training|In each group, there will be a comparison of aerobic capacity, quality of life (with questionnaires), functional cerebral measurements (fRMI), and telomerase activity between before and after the 8 weeks program
41107604|NCT02900326|OTHER|Mindfulness-based-stress-reduction|
41107605|NCT02900326|OTHER|Both interventions together|
41107606|NCT02900326|OTHER|Vo2max measurements|
41107607|NCT02900326|GENETIC|Telomerase activity on a blood sample|
41107608|NCT02900326|OTHER|Quality of life (questionnaires)|
41107609|NCT02900326|OTHER|Cerebral IRMf|
41107610|NCT00979537|DRUG|Nisoldipine Extended-release Tablets, 40 mg|
41107611|NCT00979537|DRUG|Sular Tablets, 40 mg|
41107612|NCT03941912|DEVICE|Erchonia EVRL|Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.
41107613|NCT05859542|DEVICE|Videolaryngoscope first|started the session with 3 intubations using the videolaryngoscope
40925457|NCT06190054|DEVICE|MERAMIRT|"MERAMIRT®, a class IIa medical device, is indicated for hydration and lubrication of the ocular surface under conditions of eye disorders caused by environmental, visual and mechanical stress, also due to asthenopia and accommodation effort. The main component of MERAMIRT® are Hydroxypropyl-methylcellulose (HPMC 0.3%) and Inositol (0.1%).~HPMC has the property of moisturizing and lubricating the eye. Inositol is used with an antioxidant role"
41107614|NCT05859542|DEVICE|Direct laryngoscope first|started the session with 3 intubations using the Direct laryngoscope
41107615|NCT01630772|OTHER|Physical therapy|Physical therapy in women with preeclampsia during the hospitalization
41107616|NCT01630772|OTHER|No physical therapy|Comparison of maternal and fetal hemodynamics in women with preeclampsia who underwent physical therapy and who did not have physical therapy
41107617|NCT00521937|OTHER|Dermagen®|Weekly topical applications
41107618|NCT05677178|OTHER|observational|This study is an observational study without any intervention.
41107619|NCT03582618|DRUG|Sorafenib|Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period
41107620|NCT03582618|DRUG|CVM-1118|CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle
41107621|NCT05262270|DRUG|Extended-Release Naltrexone|XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.
41107622|NCT05262270|DRUG|Extended Release Buprenorphine|Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen. Option for 100mg at Weeks 3 and 6 (if needed to alleviate side effects).
41107623|NCT05262270|DRUG|Placebo (PLB) Injectable matched to XR-NTX|3 doses of intramuscular injections (Week 0, 3, 6)
41107624|NCT05262270|DRUG|Placebo (PLB) Injectable matched to XR-BUP|2 doses of subcutaneous injections (Week 0, 4)
41107625|NCT05014516|DRUG|129Xenon gas|Observational
41107626|NCT02390544|DRUG|Melphalan|Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
41107627|NCT03465345|DRUG|Metformin|Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
41107628|NCT03465345|DRUG|Oligomeric Procyanidin Complex|OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
41107629|NCT02804516|BEHAVIORAL|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
41107630|NCT02804516|BEHAVIORAL|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
41107631|NCT04379349|BEHAVIORAL|SMS text messaging - interactive check-in|Interactive SMS text message check-ins delivered once weekly to participants.
41107632|NCT04379349|BEHAVIORAL|SMS text messaging - inactive control|Minimally interactive SMS text message delivered once weekly to participants.
41107633|NCT04866823|BEHAVIORAL|Medically Tailored Meals|Participants will receive weekly meals (20 per week) prepared by a local community kitchen and catering group. Each week, 10 dinners and 10 lunches will be delivered to the participant's home with instructions for storage, re-heating, recipes, and nutritional information.
41107634|NCT03398837|DRUG|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
41107635|NCT03398837|DRUG|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
41107636|NCT03398837|OTHER|Placebo oral capsule|Subjects will receive placebo twice daily.
41107637|NCT04204720|DEVICE|needle (Chiba)|intravascular injection using chiba needle during caudal epidural block
41107638|NCT04204720|DEVICE|needle (Whitacre)|intravascular injection using whitacre needle during caudal epidural block
41107639|NCT05074615|OTHER|Cranio-Cervical Flexion Training|"Participants of this group will receive conventional training along with Cranio-cervical flexion training:~* The pressure cuff is placed behind the neck just next to the occiput and inflated up to a baseline pressure of 20 mmHg. The patient is asked to perform Cranio-Cervical Flexion (CCF) to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the patient is instructed to maintain the contraction for 10 sec for 10 repetitions with brief rest periods between each contraction i.e., 3-5 seconds. Once a set of 10 repetitions of 10 sec is achieved at one target level, the exercise is progressed to train at the next target level up to the final target level at 30 mmHg.~Conventional therapy will be given along with home plan. Exercise protocol will consist of 30 minutes. Exercise will have total 3 sessions/week for 3 weeks."
41107640|NCT05074615|OTHER|Conventional Therapy|"Participants of this group will receive only conventional therapy and home plan will be given which includes;~* Hot pack placed on the posterior neck for 15 minutes.~* Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~* Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~* Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~* Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks"
41107641|NCT03145246|PROCEDURE|regeneration treated teeth loss|number of regeneration treated teeth loss
41107642|NCT03145246|PROCEDURE|regenerated treated teeth with clinical attachment loss|regenerated treated teeth with clinical attachment loss ≥ 2 mm
41107643|NCT04408274|BEHAVIORAL|Emotional Processing Training|
41107644|NCT04408274|BEHAVIORAL|Placebo Control|
41107645|NCT00922207|DRUG|Adefovir|From week -4 to week 2
41107646|NCT00922207|DRUG|Entecavir|From week -4 to week 2
41107647|NCT00922207|DRUG|Placebo|From week -4 to week 2
41107648|NCT00922207|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
41107649|NCT01424332|DRUG|Darexaban|oral
41107650|NCT01424332|DRUG|Acetyl Salicylic Acid (ASA)|oral
41107651|NCT05245825|OTHER|Flaxseed|A total of 30 g of ground flaxseed per day divided into two portions of 15 grams each, subjects will be asked to take 15 g in the morning and 15 g in the night dissolved in 400 ml of water. They will receive a dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates.
41107652|NCT05245825|OTHER|Dietary plan|Dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates, controlled consumption of alpha-linolenic acid (no more than 6.8 g/day, the amount provided by 30 g of flaxseed).
41107653|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
41107654|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
41107655|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
41107656|NCT00981630|BIOLOGICAL|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
41107657|NCT02523651|GENETIC|DPSC injection|A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
41107658|NCT02523651|OTHER|Placebo|A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
41107659|NCT00273949|DRUG|lactulose|
41271061|NCT00670787|DRUG|Combination pill of losartan and hydrochlorothiazide|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
41107660|NCT03749590|DRUG|Magnesium Sulfate|Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
41107661|NCT03749590|DRUG|Placebo (NaCl 0,9%)|Patients receive 2 infusions (10 ml NaCl 0.9% added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
40752199|NCT03733483|BEHAVIORAL|Sleep Deprivation|Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
40752200|NCT03808909|OTHER|Continuous Labor Support|Participants in the intervention condition will be assigned a doula who is a lay person trained to provide emotional and practical support to individuals throughout labor and delivery.
41107662|NCT05345561|OTHER|Clinical data collection|Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.
41107663|NCT00601848|DRUG|chemotherapy|
41107664|NCT00601848|DRUG|porfimer sodium|
41107665|NCT00601848|OTHER|immunohistochemistry staining method|
41107666|NCT00601848|OTHER|laboratory biomarker analysis|
41107667|NCT00601848|PROCEDURE|spectroscopy|
41107668|NCT00601848|PROCEDURE|therapeutic conventional surgery|
41107669|NCT00873691|DEVICE|ICD|Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
41107670|NCT02599818|BEHAVIORAL|NavSTAR|Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
41107671|NCT01669148|DEVICE|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
41107672|NCT01669148|DEVICE|Conventional|conventional (2D) imaging (standard mammography)
41107673|NCT00158028|DRUG|Risperidone|The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.
41107674|NCT00158028|DRUG|Placebo|placebo match in identical tablets
41107675|NCT01002768|DRUG|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
41107676|NCT01002768|DRUG|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
40752201|NCT04143438|PROCEDURE|EOS 3D imaging protocol pre- and post-surgery|Patients will undergo a EOS 3D Imaging protocol before and 6 months after undergoing patello-femoral surgery. This protocol is already used routinely in the hospital before every patello-femoral surgery.
41107677|NCT02537522|DEVICE|Contact Lenses with 8.5 BC|Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.
41107678|NCT02537522|DEVICE|Contact Lenses with 9.0 BC|Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
41107679|NCT03665090|BEHAVIORAL|Diabetic eye disease screening|Community-based, prospective cohort study from three consecutive years (2016 to 2018) to determine the prevalence and impact of diabetic eye disease, especially diabetic retinopathy (DR), in adults with diabetes living in Shanghai.
41107680|NCT06399692|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
41107681|NCT06399692|PROCEDURE|Percutaneous coronary intervention (PCI)|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
41107682|NCT00800163|OTHER|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
41107683|NCT00544440|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
41107684|NCT00544440|DRUG|Prednisone|Prednisone 5 mg tablet taken orally twice daily
41107685|NCT03444506|DRUG|Molo 1 (also referred as GSP 301-2 NS)|
41107686|NCT03444506|DRUG|Molo 2 (also referred as GSP 301-1 NS)|
41107687|NCT03444506|DRUG|Placebo nasal spray|
41107688|NCT03444506|DRUG|DYMISTA nasal spray|
41107689|NCT03444506|DRUG|PATANASE nasal spray|
41107690|NCT02533635|DIETARY_SUPPLEMENT|A Master Ganoderma Detox Tea|A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
41107691|NCT03629730|BEHAVIORAL|Coordination training|The intervention will consist of 8 weeks of exercises to decrease the variability of participants' body and gait coordination. The intervention will consist of 1 training session /week in the Mobility Research Laboratory and 4 days of home-based training. In each session participants will perform 6 trials of 4 body coordination exercises and 1 gait exercise. In the intervention sessions participants will perform interlimb coordination exercises, synchronizing body segments with auditory metronome tones. Participants also will perform a gait exercise by synchronizing steps with an auditory metronome during walking. The metronome will assist participants to retrain their movement timing to decrease coordination variability.
41107692|NCT06456762|BEHAVIORAL|iPEACE: Intervention for Parent Education about Care after the ED|Automated texting intervention for parents to increase engagement in their child's outpatient mental health treatment over an 8-week period.
41107693|NCT06456762|BEHAVIORAL|Text Messaging Reminders Only|Weekly automated text reminders to instruct parents to make an appointment with their child's outpatient mental health provider over an 8-week period.
41107694|NCT02561923|DRUG|Rivaroxaban|A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
41107695|NCT02561923|DRUG|Tranexamic acid|1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.
41107696|NCT02561923|DRUG|Kcentra, a 4-factor PCC|Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 \[international units\] IU/min) on Day 4.
41445394|NCT01058213|BEHAVIORAL|Resistance training|Supervised training will be performed on a cable exercise system (Body Solid, Forest Park, IL) using six exercises that involve concentric and eccentric muscle actions: leg press, knee flexion, knee extension, calf raise, hip adduction, hip abduction. Subjects will perform the lower extremity exercises under the direct supervision of an exercise specialist three times per week. Subjects will perform 2 sets of 8-10 repetitions at 70% of their maximum strength for 2 weeks, then will perform 2 sets of 8-10 repetitions at 80% of their maximal strength for 2 weeks, and for the next 4 weeks they will perform 3 sets of 8-10 repetitions at 80% of their maximal strength. Sets will be separated by at least a 2-3 minute rest period for multiple-joint exercises and at least 1-2 minutes for single-joint exercises. A moderate velocity of muscle contraction (\~1-2 seconds for concentric and eccentric contraction) will be used.
40752202|NCT02868710|OTHER|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)
40752203|NCT00936039|BEHAVIORAL|unloading|2 weeks of unloading of a single leg
41107697|NCT02561923|DRUG|Saline|Saline \[Kcentra saline control or TXA saline control\] on Day 4.
41107698|NCT00269516|DRUG|pardoprunox|fixed dose 6 mg
41107699|NCT00269516|DRUG|Pardoprunox|fixed dose 12 mg
41107700|NCT00269516|DRUG|Pardoprunox|12-42mg
41107701|NCT00269516|DRUG|Placebo|Placebo
41133303|NCT04942184|DEVICE|Electroencephalogram (EEG) headset in Arm 2|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
40752204|NCT05448027|DEVICE|Low intensity laser therapy|It will be applied for Group (A), by a pulsed diode low intensity laser device (Endolaser 422 Cp 400, Enraf - nonius apparatus) (Enraf, Rootterdam, Netherlands). with a wave length of 905 nm, mean power output of 400 mWatt, frequency of 10000 Hz and dose of 300 J/cm² . Laser probe will be applied perpendicularly and directly with an irradiation time of 30 sec for each point
41445395|NCT01058213|BEHAVIORAL|Aerobic training|Cycle ergometry training will be performed in the lab on a stationary cycle ergometer, calibrated with a 4 kg weight (Monark 828E, Varberg, Sweden). Initial work rate will be 50% of peak work rate (PWR) as tolerated and will be evaluated weekly with progressive increases targeted to achieve the highest work rate tolerated for 3-5 minutes{: wks 1-2 50% PWR, wks 3-4 60% PWR, wks 5-6 70% PWR, wks 7-8 80% PWR}. An interval training protocol will be used with subjects performing four work sets of five minutes duration separated by rest intervals of unloaded cycling lasting 2-4 minutes.
41445396|NCT01863745|DRUG|nilotinib|Nilotinib was administered daily as hard gelatin capsules for oral use. The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
41445397|NCT03110627|DEVICE|VDD ICD (experimental group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
41445398|NCT03110627|DEVICE|Single chamber VVI ICD (control group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
41445399|NCT01554007|OTHER|Observation study|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
41107702|NCT05619107|DEVICE|Active Transauricular nerve stimulation|The first allocated intervention will be undertaken for 30 minutes. The electrode placement and stimulation parameters are described in the arm/group section. After the 30-minute intervention, day 1 of the protocol will be complete. The investigator will remain present in the room with the participant to ensure compliance and adherence to the protocol. The allocated intervention will then be repeated by the participant at a similar time of day for 7 consecutive days. The investigator will arrange video-calls with the participant whilst off-site to ensure ongoing compliance and adherence to the protocol. On the seventh day, participants return to the clinical research facility to take the final first allocated intervention. A 14-day rest period will follow. Then the participants will perform the same 7-day protocol for the opposite intervention to their first treatment allocation.
41107703|NCT05619107|DEVICE|Sham transauricular nerve stimulation|Protocol as for active but sham ear leads are applied, unable to deliver current.
41107704|NCT01534910|DRUG|aged garlic extract|2400 mg a day
41107705|NCT01534910|DRUG|placebo|placebo
41107706|NCT02111148|PROCEDURE|Urea and creatinine|the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
41107707|NCT02111148|PROCEDURE|Nitrazine|Nitrazine detection in vaginal wash
41107708|NCT02111148|DRUG|5ml saline|the vagina will be washed with 5ml saline and vaginal wash will be collected.
41107709|NCT00039455|BIOLOGICAL|trastuzumab|Given IV
41107710|NCT00039455|DRUG|alvocidib|Given IV
41107711|NCT00039455|OTHER|laboratory biomarker analysis|Correlative studies
41107712|NCT00039455|OTHER|pharmacological study|Correlative studies
41107713|NCT01319435|PROCEDURE|Collection of biological samples|"Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces"
41107714|NCT00732381|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
41107715|NCT00732381|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
41445400|NCT03579615|DEVICE|FIASP + closed loop device|Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
41445401|NCT03579615|DEVICE|Insulin aspart (standard of care insulin) + closed loop device|Participants will be advised to maintain their usual insulin 24 hours prior to admission.
41445402|NCT05877261|DEVICE|Cementless Total Knee Replacement|Artificial knee implant inserted by cementless fixation.
41107716|NCT02401633|PROCEDURE|CO-CPR|CPR provided by bystander with chest-compressions only
41107717|NCT02401633|PROCEDURE|S-CPR|CPR with Chest Compressions and Rescue Breaths in a ratio of 30:2
41107718|NCT06073158|PROCEDURE|Esophageal biopsy collection during anastomosis|During the anastomosis, the surgeon will collect an esophageal mucosa biopsy
41107719|NCT05503212|OTHER|Conservative treatment (CT)|Best medical treatment without intravenous thrombolysis nor endovascular thrombectomy
41107720|NCT05503212|OTHER|Intravenous thrombolysis (IVT)|Best medical treatment with intravenous thrombolysis but without endovascular thrombectomy
41107721|NCT05503212|OTHER|Endovascular thrombectomy (EVT) ± intravenous thrombolysis (IVT)|Best medical treatment with endovascular thrombectomy with or without intravenous thrombolysis
41107722|NCT05418387|BEHAVIORAL|Social Support Network Intervention|The navigator will provide basic patient navigation services and Supportive Health Education to the patient/caregiver dyads in the patient's preferred language using the Support Network Workbook. The intervention will consist of 7 telephone sessions. There will be 2 sessions in the first month and one session per month after the first month (6 months total). Coaching and guiding techniques rather than lectures will be used applying dyads' specific social support network information. Each session will be about 30 minutes long.
41107723|NCT05418387|BEHAVIORAL|Control (Patient Navigation Service)|The patient navigator will provide basic patient navigation services consisting of health care barriers/social needs assessment, referral to social workers (if eligible) and support groups for patients and caregivers, and transportation assistance without Supportive Health Education. Patient/caregiver dyads in the control group will be contacted at 3- and 6-months post-enrollment and asked about their experience receiving treatment, any challenges they encountered or are currently facing, and the care support they received from family members, friends, CHWs, and health care providers.
41107724|NCT00003656|BIOLOGICAL|recombinant interferon alfa|
41107725|NCT00003656|DRUG|tretinoin liposome|
41107726|NCT04876573|DRUG|Cyproheptadine Hydrochloride 4 MG|"Phase 1: Cyproheptadine 4 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~Phase 2: Cyproheptadine 8 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~The dose will be adjusted according to the renal function."
41107727|NCT01948804|DRUG|GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)|
41107728|NCT01948804|DRUG|microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)|
41107729|NCT01948804|DRUG|Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)|
41107730|NCT01948804|DRUG|GnRH antagonist protocol (Cetrotide, Serono)|
41107731|NCT05027178|OTHER|Chiropractic Care|Chiropractic care on stroke participants
41107732|NCT03547752|OTHER|observed action and motor imaginery|Observation of a video of neck movement and imagination of the same observed movement, feeling the realization of the movement but not developing it.
41107733|NCT02854319|DEVICE|LOTUS Edge Valve System|Transcatheter Aortic Valve Implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
41107734|NCT00002810|BIOLOGICAL|filgrastim|
41107735|NCT00002810|DRUG|melphalan|
41107736|NCT00002810|PROCEDURE|bone marrow ablation with stem cell support|
41107737|NCT00002810|PROCEDURE|peripheral blood stem cell transplantation|
41107738|NCT04246619|DRUG|Pregabalin|"Pregabalin Krka (pregabalin) hard capsules of different strenghts: 25 mg, 75 mg, 150 mg, 300 mg.~Duration: 12 weeks"
41107739|NCT04246619|DRUG|Duloxetine|"Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg.~Duration: 12 weeks"
41107740|NCT06553560|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2 cm lateral to the sternal border to visualize the T2-T4 intercostal space and to identify the pectoralis major muscle, intercostal muscle, and pleura. 10 ml of 0.25% bupivacaine local anesthetic is administered between the pectoralis major and intercostal muscle using an in-plane approach with a 100 mm needle. In addition, a Recto-Intercostal Fascial Plane Block is performed with a high-frequency linear USG probe. The probe is placed 2-3 cm lateral to the xiphoid so that the rectus abdominis muscle and 6-7th cartilages are visualized. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique and 1-2 ml of saline is injected. After observing the spread to the target plane, 20 ml of 0.25% bupivacaine is applied. The same process is repeated bilaterally.
41107741|NCT00670020|PROCEDURE|supplemental perioperative oxygen|increased perioperative oxygen verses non-interventional oxygen
41107742|NCT02458911|DEVICE|Paclitaxel-eluting balloon|
41107743|NCT06226636|OTHER|salt|After ≥8 hr overnight fasting, participants will be required to ingest 780 mg of sodium (2 g salt) and BP measured every 10 minutes for 2 hours to determine IPROS. For SSBP, Participants are put on low salt (50 mmol Na/day) followed by seven days of high salt diet (250 mmol Na/day). Participants' mean arterial pressure (MAP) difference between low- and high-salt diet will be used to define salt sensitivity (MAP≥8 mmHg) and salt resistance (MAP≤5 mmHg).
41107744|NCT04176367|DRUG|Nicergoline from China|This is the test arm of China local manufactured Nicergoline
41107745|NCT04176367|DRUG|Nicergoline from Italy|This is the reference arm of Italy originator Nicergoline.
41107746|NCT03050788|DEVICE|Smartphone confocal microscopy|Imaging of skin lesion using the smartphone confocal microscopy
41107747|NCT05922124|DRUG|Cefiderocol|Test drug regimen
41107748|NCT05922124|DRUG|Ampicillin-sulbactam|Synergistic combination
41107749|NCT05922124|DRUG|Colistin|Historical comparator
41107750|NCT05922124|DRUG|Meropenem|Historical comparator synergistic combination
41107751|NCT01219699|DRUG|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
41107752|NCT01219699|DRUG|Fulvestrant|"In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.~Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection"
41445403|NCT01923545|DRUG|PEG-G-CSF|Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
41445404|NCT01923545|DRUG|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 1 cycle
41107753|NCT00161018|DRUG|Quetiapine, Risperidone, Fluphenazine|
41445405|NCT06559202|DIAGNOSTIC_TEST|chest and abdominoplevic CT|chest and abdominopelvic computed tomography on the same day for health screening purposes
41107754|NCT03439124|DRUG|ceftobiprole medocaril|"Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole).~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment."
41107755|NCT03439124|DRUG|IV standard-of-care cephalosporin|"Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days.~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.~At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
41107756|NCT00014599|DRUG|paclitaxel|
41107757|NCT00980135|DEVICE|Sinecort cream|Application over 29 days
41107758|NCT00980135|DRUG|Hydrocortison cream|Application over 29 days
41107759|NCT00980135|OTHER|Untreated skin|
41107760|NCT06260696|OTHER|No treatment is given|No treatment is given
41107761|NCT01591616|DRUG|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
41107762|NCT06554548|DRUG|HS-10518|Treatment A: Single oral dose of HS-10518 160 mg tablet under fasted conditions Treatment B: Single oral dose of HS-10518 160 mg tablet after a high-fat meal
41107763|NCT01027299|DEVICE|Biventricular pacing|Optimised temporary biventricular pacing.
41107764|NCT02045836|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
41107765|NCT02045836|BIOLOGICAL|Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™|One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
41107766|NCT05005065|DRUG|IN-C005 X mg|Oral capsule
41107767|NCT05005065|DRUG|IN-A001 Y mg|Oral tablet
41107768|NCT05005065|DRUG|IN-C005 Y mg|Oral capsule
41107769|NCT05005065|DRUG|IN-C005 Z mg|Oral capsule
41107770|NCT01491399|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
41107771|NCT01491399|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
41107772|NCT02660645|DRUG|Hexaminolevulinate hydrochloride (HCL)|Instillation in bladder
41107773|NCT02660645|DEVICE|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
41107774|NCT00243854|DRUG|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
41107775|NCT01240941|DRUG|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
41107776|NCT01240941|DRUG|Exemestane|25 mg orally daily
41107777|NCT01240941|DRUG|Goserelin|3.6 mg orally monthly
41107778|NCT06554262|OTHER|No intervention|No intervention was involved in this study
41107779|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
41107780|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
41107781|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
41107782|NCT00444431|PROCEDURE|Pyeloplasty|
41107783|NCT06410963|BEHAVIORAL|Reactivate|The study period is 84 days (12 weeks). Depending on the length of the baseline period (randomly assigned to be 7, 14 or 21 days), the treatment period varies between 63-77 days and contains 6-11 sessions. The intervention consists of 2-4 educational sessions in pain mechanisms and fear avoidance and 4-9 sessions of individually tailored intervention with graded exposure and reactivation to avoided physical activities. Intervention will take place from one time per week to one time every two weeks, 30-60 minutes per session. Number of treatment sessions will depend on when the individual participants' goals are considered reached. If necessary, given the participants consent, their legal guardians will be invited to attend the sessions.
41107784|NCT04289610|DEVICE|Transcutaneous pulse radiofrequency therapy|Transcutaneous pulse radiofrequency therapy (TCPRF) is a painless and outpatient physiotherapy modality
41107785|NCT02000817|BIOLOGICAL|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
41107786|NCT02000817|BIOLOGICAL|Placebo|Placebo is available 0.9% w/v sodium chloride
41107787|NCT03690037|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
41107788|NCT03690037|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid: Tranexamic Acid 500mg Tablets
41107789|NCT00333060|DRUG|OT-551 ophthalmic solution|
41107790|NCT06554886|DEVICE|Cryoneurolysis|Cryoneurolysis
41107791|NCT02516644|BEHAVIORAL|Virtual Reality|12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
41107792|NCT02516644|BEHAVIORAL|Conventional Therapy|12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
41107793|NCT02538263|DEVICE|Volume-targeted noninvasive ventilation|
41107794|NCT05923762|BEHAVIORAL|OHRQoL|"Oral health-related quality of life will be measured by the Oral Impact on Daily Performance (OIDP)"
40925458|NCT06470568|BEHAVIORAL|Progressive Resistance exercise training|"The training sessions will begin with a 5-minute warm-up on a cycle ergometer and global movements involving the upper limbs. Following this, participants will perform one additional warm-up set, followed by four regular sets on both the leg press and leg extension machines. Upper body exercises will then be conducted on the chest press, pull-up, and horizontal rowing machines, with each exercise comprising 2 sets.~To conclude each session, there will be a 5-minute cooldown period involving global muscle stretching exercises. During the initial 6-week period, the workload will progressively increase from 60% to 80% of 1RM (10 repetitions per set). Subsequently, the 1RM will be reassessed to adjust workloads (maintaining 60%-80%) for the subsequent 6-week period. Compliance for per-protocol analysis will require participants to complete at least 80% of the training sessions (i.e., a minimum of 29 out of 36 sessions)."
40925459|NCT04835831|OTHER|adapted physical activity + Dietetic advice|adapted physical activity during 24 weeks
40925460|NCT05575921|DIAGNOSTIC_TEST|Polysomnography|Children underwent at-home polysomnography in routine clinical practice. The exam is interpreted in 2 ways by the physician with sleep stages (PSG) and without sleep stages (PG). The data are retrospectively collected from the patient's recording
40925461|NCT06334406|OTHER|Biological samples|"Blood samples will be collected at baseline, after the diagnostic TURBT, and D15 after the end of treatment in each cohort.~Tumor tissues will be collected at baseline for three patients."
40925462|NCT00128505|DRUG|Mifepristone|
40925463|NCT05035810|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
40925464|NCT05035810|DRUG|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
40925465|NCT05035810|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
41107795|NCT04083833|DRUG|Tetrodotoxin|A single TTX dose in a dose ascending study
41107796|NCT04083833|DRUG|Placebos|matching placebo comparator
41107797|NCT04675944|DRUG|BIA 5-1058|200 mg (2 x 100 mg tablets), oral route
40752205|NCT05448027|DEVICE|High intensity laser therapy|It will be applied for Group (B), by pulsed high intensity laser therapy with pulsed Nd:YAG laser produced by HIRO 3.0 devices (ASA, Arcugnano, Vicenza , Italy). The high intensity laser therapy apparatus used postulates (Nd:YAG), with pulsed emission of wave length ( 1064nm ), very high power peaks (3kW), high intensity obtained (up to 15,000 W/cm2), high level of fluency/energy density (510-1,780 mJ/cm), very short pulse duration (120-150 μs), low frequency (10-40 Hz), duty cycle of about 0.1 % and total energy of 880 J
40752206|NCT02609906|DEVICE|PhilosTM with augmentation (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)."
40752207|NCT02609906|DEVICE|MultiLoc®-Nail (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes)."
40752208|NCT04462250|DEVICE|Prescription Opioid Management App|Smartphone application that provides education and reinforcement of safe opioid use, storage, and disposal
40752209|NCT03049800|DEVICE|Magnetic Resonance Imaging|Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.
40752210|NCT00874809|DEVICE|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
40752211|NCT02102737|DRUG|6-DIG|injection of 6-DIG
40752212|NCT02102737|PROCEDURE|clamp|hyperinsulinemic euglycemic clamp
40752213|NCT02738697|DRUG|Adjuvant chemotherapy|8\~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
40752214|NCT02738697|PROCEDURE|Follow-up|Patients received just follow-up instead of adjuvant chemotherapy
40752215|NCT02126202|PROCEDURE|Coronary angiography and revascularization if feasible|Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
40752216|NCT00283569|OTHER|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
41107798|NCT04675944|DRUG|treprostinil|1 mg (1 extended-release tablet), oral route
41107799|NCT01511471|DRUG|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
41107800|NCT02485041|DRUG|Dapoxetine 30mg|Tablet, Orally administered
41107801|NCT02485041|DRUG|Mirodenafil 100mg|Table, Orally administered
41107802|NCT04781595|DIETARY_SUPPLEMENT|Watermelon|A single dose of watermelon powder containing 3g of L-citrulline
41445406|NCT06562179|DEVICE|da Vinci SP® Single-Port Robotic Surgical System|The da Vinci SP® Surgical System is designed to enable the performance of surgical procedures using a minimally invasive single-port approach. The system consists of a Surgeon Console, a Vision Cart, and a Patient Cart and is used with a camera, instruments, and accessories.
41107803|NCT04781595|DIETARY_SUPPLEMENT|Beetroot|A single dose of beetroot powder containing 8 mmol of nitrate
41107804|NCT04781595|DIETARY_SUPPLEMENT|Watermelon + beetroot|A single dose of watermelon and beetroot powder containing 3g of L-citrulline and 8 mmol of nitrate
41107805|NCT04781595|DIETARY_SUPPLEMENT|Placebo|A single dose of maltodextrin
41107806|NCT04910919|DIETARY_SUPPLEMENT|Honey|Participants 51 - 100 will receive the standard of care treatment as usual plus 1 tsp of honey with every dose of acetaminophen.
41107807|NCT04910919|OTHER|Standard of Care|The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
41107808|NCT02572141|DRUG|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
41107809|NCT02572141|DRUG|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens|Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
40752217|NCT00559117|DRUG|VB-111|A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
40752218|NCT00167947|DRUG|Cyclosporine|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
40752219|NCT00167947|DRUG|Steroids|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
41107810|NCT00750750|DRUG|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
41271062|NCT00943683|DRUG|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
41445407|NCT04629326|OTHER|68Ga-WL12 PET/CT|WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning
41107811|NCT00750750|DRUG|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
41107812|NCT00750750|DRUG|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
41107813|NCT00750750|DRUG|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
41107814|NCT02187900|DRUG|Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)|The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
41107815|NCT02187900|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
41107816|NCT05257798|DRUG|IFN-β inhibitor treatment|PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
41107817|NCT05257798|OTHER|Placebo|Placebo for PF-06823859, 0 mg/mL solution for injection
40925466|NCT05035810|DRUG|Procedure: Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
41107818|NCT06345560|DRUG|Drospirenone|4 mg tablet once daily
41107819|NCT04455399|DEVICE|Intravitreal injection guide (Malosa)|A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion
41107820|NCT04455399|DEVICE|Dual Blade Eyelid Speculum|A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.
41107821|NCT04106141|OTHER|6 weeks changing of archwire|changing the archwire after 6 weeks instead of 4 weeks
41107822|NCT04106141|OTHER|4 weeks changing of archwire|changing the archwire every 4 weeks
41107823|NCT05769517|DIAGNOSTIC_TEST|Germinal BRCA|We will conduct a multicenter prospective observational study aimed at automatically implementing the predictive model and collecting US images of healthy ovaries from patients tested for germline BRCA pathogenetic variants according to current indications.
41107824|NCT05216653|DRUG|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
41107825|NCT05216653|DRUG|Oxaliplatin|130mg/m2，ivgtt，d1
41107826|NCT05216653|DRUG|Capecitabine|1000mg/m2，po，bid，d1-14
41107827|NCT05216653|RADIATION|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
41107828|NCT05216653|PROCEDURE|TME surgery, total mesorectal excision|The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient.
41107829|NCT06554951|OTHER|Patients who are candidates for CAR-T cell therapy for hematologic malignancy|This study will include patients who undergo CAR-T cell infusion at participating centers during the 18-month duration of the enrollment period. A total of 100 patients are expected to be enrolled, including 80 patients for the prospective part and 20 for the retrospective part.
41445408|NCT05752721|BEHAVIORAL|Transition to Online Ordering|The intervention food pantry will transition to online ordering at least once.
41445409|NCT05600907|BIOLOGICAL|JSP191|A monoclonal antibody that targets human CD117
41107830|NCT02899286|BIOLOGICAL|PEG-BCT-100|PEGylated recombinant human arginase
41107831|NCT03206671|DRUG|Rituximab window|Rituximab window (375 mg/m²)
41107832|NCT03206671|DRUG|Additional doses of Rituximab|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
41107833|NCT03206671|DRUG|Cyclophosphamide|see detailed protocol description
41107834|NCT03206671|DRUG|Cytarabine|see detailed protocol description
41107835|NCT03206671|DRUG|Dexamethasone|see detailed protocol description
41107836|NCT03206671|DRUG|Doxorubicin hydrochloride|see detailed protocol description
41107837|NCT03206671|DRUG|Vindesine Sulfate|see detailed protocol description
41107838|NCT03206671|DRUG|Etoposide|see detailed protocol description
41445410|NCT04985435|DRUG|Filgotinib|200 mg tablet once daily or 100 mg once daily
41445411|NCT04985435|DRUG|Anti-Tumor Necrosis Factor Alpha Drug (Product)|Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
41107839|NCT03206671|DRUG|Ifosfamide|see detailed protocol description
41107840|NCT03206671|DRUG|Methotrexate|see detailed protocol description
41107841|NCT03206671|DRUG|Prednisolone|see detailed protocol description
41107842|NCT03206671|DRUG|Vincristine|see detailed protocol description
41107843|NCT02981186|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
41107844|NCT02981186|DEVICE|IOL implantation comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
41107845|NCT04302519|BIOLOGICAL|Dental pulp mesenchymal stem cells|On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.
41107846|NCT01549730|PROCEDURE|18F-Fluoroazomycin Arabinoside (18F-FAZA)|A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
41107847|NCT00974025|DIETARY_SUPPLEMENT|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
41107848|NCT00974025|DIETARY_SUPPLEMENT|Placebo|Placebo will be administered twice daily for four weeks
41107849|NCT04628026|DRUG|Venetoclax|Venetoclax will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
41107850|NCT04628026|DRUG|Placebo|Placebo will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
41107851|NCT04628026|COMBINATION_PRODUCT|Standard chemotherapy|"Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6, and daunorubicin 60 mg/m2 IV (days 1-3). Patients \>60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6 without daunorubicin.~Consolidation chemotherapy option 1 consists of one cycle of mitoxantrone (10mg/m2 IV) and etoposide (100mg/m2 IV) (ME) days 1-5 (patients ≤60 yrs) or days 1-3 (patients \>60 yrs). Consolidation chemotherapy option 2 consists of intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are \>60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients \>60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment."
41107852|NCT04628026|OTHER|Autologous stem cell transplantation|Busulfan/Cyclophosphamide will be administered as conditioning regime. Patients may proceed to autologous HCT when they have reached CR/CRi/MLFS after at least two cycles of chemotherapy and performance status permits continuation with high-dose chemotherapy. Venetoclax will not be added to or given after the conditioning regimen.
41107853|NCT04628026|OTHER|Allogeneic stem cell transplantation|Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
41271063|NCT00943683|DRUG|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
40925467|NCT04105478|PROCEDURE|Shoulder arthroplasty|Patients suffering from severe glenohumeral osteoarthritis are treated surgically by a total shoulder arthroplasty
41107854|NCT03245060|BEHAVIORAL|Adapted Solution Focused Brief Therapy|Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
41107855|NCT02602743|DRUG|Remifentanyl|0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
41107856|NCT02602743|DRUG|Propofol|1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
41107857|NCT02602743|DRUG|Ketamine|2 mg/kg ketamine will be administered for induction in 1 minute.
40925468|NCT02524613|OTHER|Pelvis CT scan|
41107858|NCT02203630|DRUG|Phenylephrine|Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
40752220|NCT00167947|DRUG|Rapamune (Sirolimus)|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
40925469|NCT05870982|BEHAVIORAL|Early TRE|Participants will be instructed to eat only during an 8-hour window starting 1-2 hours after waking.
40925470|NCT05870982|BEHAVIORAL|Late TRE|Participants will be instructed to eat only during an 8-hour window starting 5-6 hours after waking.
40925471|NCT05870982|BEHAVIORAL|DCR|Participants will be instructed to reduce caloric intake by 25%.
41107859|NCT02203630|DRUG|Norepinephrine|Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
41107860|NCT04378062|PROCEDURE|Digital nerve procedure|The type of procedure performed on the digital nerve at the time of amputation
40925472|NCT03494491|DIETARY_SUPPLEMENT|Chitin-glucan|Second test day (D2), subjects will received 4.5g of chitine-glucan
40925473|NCT03494491|DIETARY_SUPPLEMENT|Maltodextrin|First test day (D0), subjects will received 4.5g of maltodextrin.
40925474|NCT03467152|DRUG|Irsenontrine|Oral hypromellose capsules.
41107861|NCT05645432|DRUG|Brexanolone|Brexanolone IV infusion
41107862|NCT04367376|OTHER|mobilization|central postroanterion mobilization on the most painful vertebral level at the lumbar spine
41107863|NCT04367376|OTHER|manual therapy|manual therapy
41107864|NCT04367376|OTHER|instrumental manual therapy|instrumental manual therapy
41271064|NCT03492593|OTHER|lycopene|A tomato oleoresin containing lycopene
41271065|NCT03492593|OTHER|beta-carotene|13C beta-carotene
41271066|NCT03492593|OTHER|control|emulsified liquid meal alone
41271067|NCT00360347|DRUG|C.E.R.A.|
41445412|NCT04985435|BEHAVIORAL|50 patients will have a Free Choice between Filgotinib and anti TNF|50 patients will be given the opportunity to choose between either TNFi (etanercept 50 mg SC once a week or adalimumab 40 mg SC once every two weeks) or filgotinib, an oral JAKi, 200 mg once a day while another group of 50 patients will be randomized to the same treatment arms.
41445413|NCT05630235|DRUG|CBD/CBD-A|Participants will be administered a one-time dose of 217.7 mg of CBD/CBD-A orally.
41445414|NCT05630235|OTHER|Placebo|The placebo equivalent of the CBD/CBD-A dose administered orally.
41445415|NCT03783897|DRUG|EDP-305|Subjects will receive EDP-305 on on Days 11 through 21 of cycle 3
41445416|NCT03783897|DRUG|Oral Contraceptive|Subjects will receive active Oral Contraceptive on Days 1-21 and inert OC on Days 22-28 of cycles 1, 2 and 3
41445417|NCT06562400|DIETARY_SUPPLEMENT|Palmitoyl ethanolamide|PEA supplementation (600mg twice a day for three months)
41445418|NCT06562400|BEHAVIORAL|Ketogenic diet|Diet characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates
41445419|NCT05143047|BEHAVIORAL|Medication counseling|"Participants will receive a customized written medication instruction sheet which includes a picture of an oral dosing syringe indicating the patient's dose as well as a chart showing medication name, dose, route, frequency, duration, next dose due, side effects, and storage information. In addition, participants will be shown how to draw up their child's dose using an oral syringe and then will be asked to practice this task (show-back). Teach-back will be used to ensure participant's understanding of medication details."
41445420|NCT03363464|DRUG|Empagliflozin|Empagliflozin
41445421|NCT03363464|DRUG|DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor
41445422|NCT03363464|DRUG|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist
41445423|NCT05422521|OTHER|blood samples and 18FDG PET-CT exams|"* 18 FDG PET scanner at inclusion and post CART-cells treatment ( 1, 3, 6, 9 and 12 month)~* blood collection at inclusion and post CART-cells treatment (7 days, 1 month and 3 month)"
41445424|NCT06310291|BIOLOGICAL|VTP-1000|Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component
41445425|NCT06310291|OTHER|Matched Placebo|Intramuscular (IM) injection comprised of saline solution
41445426|NCT05754203|RADIATION|Super-hyperfractionation Pulse Radiotherapy|Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy \* 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
41445427|NCT02528279|DRUG|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
41445428|NCT00852696|DRUG|Solifenacin|Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
41445429|NCT00852696|OTHER|Placebo|Take orally once daily for 9 weeks.
41445430|NCT01370369|DRUG|Testosterone gel (FE 99903)|
41445431|NCT06493019|DRUG|Pembrolizumab|Chemoradiation Pembrolizumab 200mg IV
41445432|NCT06493019|DRUG|Paclitaxel|Paclitaxel 50 mg/m\^2 IV
41445433|NCT06493019|DRUG|Carboplatin|Carboplatin AUC 2 IV
41445434|NCT06493019|RADIATION|Radiation|Delivered as per institutional standards
41445435|NCT06493019|DRUG|Pembrolizumab|Maintenance Pembrolizumab 400mg IV
40752221|NCT02027571|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( \> 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
41445436|NCT06321016|OTHER|Physical exercise program|At least two sessions a week for a 6-month supervised and individualized physical exercise program that will have two phases: one that will be carried out in person in the hospital environment taking advantage of medical visits, and a second phase that will allow the patient to carry out the exercise sessions from home with live virtual supervision.
41445437|NCT06321016|OTHER|Type of the physical exercise program|Two types of intervention are proposed depending on the age of the patients: Exercise intervention for adolescents (12 to 18 years): training will be based on strength training (2 - 3 sets of 8 - 12 repetitions) with elastic bands, weights, weights, medicine balls or body weight and aerobic work on a stationary bike, treadmill or other aerobic exercises. Sessions will last about 30-60 minutes (depending on the patient's situation). Exercise intervention for children (4 to 11 years old): The aim will be to work on basic motor skills through play, thus trying to avoid the delay in motor development, and to indirectly work on their physical condition to better cope with the effects of the treatments. Music, games that require movement and materials such as balls, hoops, etc., will be used to motivate the child to move while enjoying themselves. This will be done in sessions of 20 - 40 minutes.
41445438|NCT03701594|OTHER|Yoga-based physical therapy group|All yoga-based sessions will be led by the same therapist to maximize between-session consistency. A trained researcher will also be present to provide additional cueing to subjects when required. The basic elements of the postures are similar to that of traditional physical therapy balance exercises. Cues will be provided throughout to pair appropriate breath cycles with appropriate postures consistent with a standard, able-bodied yoga program. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
41445439|NCT03701594|OTHER|Seated Rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
40752222|NCT01341548|DRUG|Civamide nasal solution 0.01%|20ug/dose, BID for 7 days 0.1 ml to each nostril
40752223|NCT03708770|DEVICE|everlinQ endoAVF System|
40925475|NCT03467152|DRUG|Placebo|Oral hypromellose capsules.
41107865|NCT04908371|PROCEDURE|Selective Trunk Block|"It is one type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 20ml) injected at the trunks of the brachial plexus in order to produce the anesthesia of the whole upper extremity of the patients scheduled for upper limb surgery. SeTB will be performed as a two-injection technique. One at the side of the neck (interscalene groove) of the affected upper limb, injections will be made near the superior trunk (5mL) and follow by redirection of the needle under ultrasound guidance to inject the LA to middle trunk (5mL). Then the second skin puncture will be made near the upper part mid-collar bone (supraclavicular fossa) to inject the LA to the inferior trunk (10mL)."
41107866|NCT04908371|PROCEDURE|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)|"It is another type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 30ml) injected at the interscalene groove and supraclavicular fossa, so two-injection technique will be adopted. The first skin puncture will be near the side of the neck (interscalene groove) of the affected upper limb (15mL) and then the second skin puncture will also be made near the upper mid-collar bone (supraclavicular fossa) to inject 15mL of LA."
40925476|NCT02009384|DRUG|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
41107867|NCT02499471|OTHER|Levothyroxine therapy (137.75 ± 23.75 μg/day)|This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
41107868|NCT00831272|DRUG|naltrexone|50mg/day
41107869|NCT00831272|DRUG|Placebo|Placebo
41271068|NCT02190734|OTHER|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
41271069|NCT02190734|OTHER|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
41445440|NCT03701594|OTHER|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
41445441|NCT02816450|BEHAVIORAL|Water Intake|
41445442|NCT05735145|DRUG|paclitaxel combined with platinum|Adjuvant chemotherapy with paclitaxel combined with platinum
41445443|NCT04481958|BEHAVIORAL|I-PROTECT|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application (the I-PROTECT GO), including modules tailored for coaches, players, club administrators, and caregivers, respectively. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Due to pandemic restrictions, the mobile application could not be finalized, and only the module for coaches was available.
41445444|NCT01366781|OTHER|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
41107870|NCT02228408|DRUG|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Target Dose:~Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35 mg-3x/day ISD/HY 40 mg/75 mg-3x/day~Dose Titration:~ISD/HY will be administered at a starting dose ISD/HY 10 mg/10-3x/day and titrated to ISD/HY 20 mg/35 mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects."
41107871|NCT02228408|DRUG|Placebo|Placebo titration will mimic titration of active study arm
41107872|NCT00481390|PROCEDURE|Cheek cells sample|Cheek cells sample
41107873|NCT00481390|PROCEDURE|Blood sample|Blood sample
41107874|NCT03101436|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil and Red Wine|"Phase I: Extra VIrgin Olive Oil 80 grams per day (1 month)~Washout Period: 15 days~Phase II: Red Wine (270 ml per day) (1 month)"
41107875|NCT04158999|DEVICE|milk analyzer|Human Milk Sample
41107876|NCT04158999|BEHAVIORAL|Mother's nutrition values|evaluation of nutritional elements of maternal onset with Bebis Program
41107877|NCT01351272|DRUG|Methylphenidate, non-retard|Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
41107878|NCT01351272|DRUG|Placebo|
41107879|NCT04875130|DIAGNOSTIC_TEST|blood samples|Taking blood samples (plasma, serum) and measure the level of Adrenomedullin
41107880|NCT04848649|OTHER|Study arm|Questionnaires, blood sample, skin (for psoriasis patients) or digestive (for IBD patients) biopsy and swab testing
41445445|NCT03853005|OTHER|HVHDF|Patients will receive HVHDF treatment for 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 70 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours.
41133304|NCT04942184|OTHER|Tablet in Arm 2|A computer tablet will be provided to each participant. During week 3 and 4, the tablet will present daily reminders to use memory strategies while completing the memory tasks. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
41271070|NCT02190734|OTHER|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
41445446|NCT03853005|OTHER|controlled|Patients will receive the usual care
40752224|NCT05112068|OTHER|traditional skin care method|Skin and hair care for critically ill patients will be carried out using traditional means: clean warm water, cotton diapers and napkins, liquid soap, 0.02% aqueous chlorhexidine solution, and regular shampoo.
41445447|NCT06331715|DRUG|Palbociclib 125mg|Pharmacokinetic parameters AUC and Cmax will be evaluated to establish bioequivalence betweeen the Test and Reference products
40925477|NCT05427877|DEVICE|Heating device (Heatwave Technology)|Heating devices will be applied to the trunk and extremities of the body during the first study visit. During each heating cycle, the temperature will increase quickly from room temperature to a high of 45C and then cycle back down. Each heating cycle is 30 minutes with a 3 minute cool down period where no heat is applied. The maximum temperature used in this study is 45 degrees C (113 degrees F). There will be a total of 3 heating cycles at the visit.
40925478|NCT01268579|DRUG|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
41133305|NCT04996225|OTHER|Aerobics exercises, Balance exercises|Aerobic exercise, or endurance exercise, is a subdivision of physical exercise that improves cardiovascular and respiratory health. Additionally, it is generally assumed to increase well-being and reduce negative mood states such as anxiety and depression.
41445448|NCT06560086|DRUG|Ketoconazole|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 10-6 mol/L ketoconazole, which is the injectable solution powder. Ketoconazole is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
41445449|NCT06560086|DRUG|Luteinizing Hormone|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 1 IU/mL luteinizing hormone, which is the injectable solution powder. Luteinizing hormone is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
41445450|NCT01876667|OTHER|Intervention (CPCRS) Group|CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.
41445451|NCT01876667|OTHER|Placebo|Usual Care
41445452|NCT06289738|OTHER|ICF|Matching the answers given to the question set consisting of 6 open-ended questions with ICF
41445453|NCT04226248|DRUG|Rivastigmine Transdermal System|Rivastigmine Trandermal Patches applied once a day for up to 12 months
41445454|NCT04226248|OTHER|Placebo Transdermal System|Placebo Trandermal Patches applied once a day for up to 12 months
41445455|NCT02183311|DRUG|BI 1356 BS - single rising dose|
41445456|NCT02183311|DRUG|BI 1356 BS - multiple rising dose|
41445457|NCT02183311|DRUG|Placebo|
41445458|NCT02158494|DEVICE|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
41445459|NCT02158494|DEVICE|Sham Device|The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
41445460|NCT02890069|BIOLOGICAL|PDR001|anti-PD1 antibody
40752225|NCT05112068|OTHER|method using specialized gloves|"Specialized hygienic gloves soaked in a washing lotion Aqua Total Hygiene (Cleanis, France) for skin care and Aqua Shampoo (Cleanis, France) for hair care will be used.~According to the manufacturer's recommendation, six hygienic gloves should be used for one skin care procedure, and two gloves should be used for hair care. The care method used in the experimental group will not require additional rinsing and drying."
40925479|NCT04307615|COMBINATION_PRODUCT|Oxygen + continuous positive airway pressure (CPAP)|Oxygen-driven CPAP (7,5 cmH2O): 20 min treatment followed by 10 min rest and assessment
40925480|NCT04307615|DRUG|Oxygen|Oxygen: 20 min treatment followed by 10 min rest and assessment
41133306|NCT02441569|BEHAVIORAL|Common factors engagement training for provider|Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
41445461|NCT02890069|DRUG|LCL161|
41445462|NCT02890069|DRUG|Everolimus|
41445463|NCT02890069|DRUG|Panobinostat|
41445464|NCT02890069|DRUG|QBM076|
41445465|NCT02890069|DRUG|HDM201|
41445466|NCT04937062|DRUG|Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]|"Glycerol phenylbutyrate (trade name Ravicti) is an FDA-approved medication used for urea cycle disorders in children and adults. We will titrate to a goal dose of 1.2 mL/m2 (12.4 g/m2) in three equally divided doses given enterally (i.e., by mouth or by g-tube).~The dosing is consistent with the dosing guidelines in the FDA approved Medication Guide (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf)."
41445467|NCT01502254|OTHER|audio recorded information|Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
41445468|NCT01019421|DRUG|Lu AE58054|Add-on treatment to donepezil
41445469|NCT01019421|DRUG|Placebo|Add-on treatment to donepezil
41445470|NCT02259972|DRUG|BI 113823 solution|
41445471|NCT02259972|DRUG|BI 113823 tablet|
41445472|NCT02259972|DRUG|Placebo|
41445473|NCT02259972|OTHER|High fat, high calorie breakfast|only for dose group 5
41445474|NCT02580279|DRUG|EGCG|
41445475|NCT02580279|DRUG|placebo|
41445476|NCT05884957|DIAGNOSTIC_TEST|Nitric oxide synthase gene|Biochemical assessment of serum nitric oxide level pre and post 5 mg tadalafil therapy in diabetic patients with erectile dysfunction and in normal healthy controls.
41445477|NCT01354626|OTHER|dietary protein|in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
41445478|NCT01354626|OTHER|low-protein|The control group will get a diet which is according to healthy eating guidelines.
41445479|NCT03641222|DEVICE|Acupuncture|Traditional Chinese Medicine (TCM) Acupuncture
41445480|NCT05032807|DRUG|Standard formulation|Cannabidiol 1000mg standard formulation, single dose, oral
41445481|NCT05032807|DRUG|Novel formulation|Cannabidiol 1000mg with lipid matrix, single dose, oral
41445482|NCT05957146|DEVICE|Routine hemodialysis|"* Dialyzers: Cordiax FX80 dialyzers; membrane material HelixonePlus (polysulfone); (Fresenius Medical Care Bad Homburg, Germany)~* Dialysis machines: Baxter Gambro AK 98 (Gambro Lundia AB, Lund, Sweden; part of Baxter Healthcare Corporation)~* Needles for vascular access: Nipro SafeTouch dialysis cath 1.6x25 mm (16G) or 1.9x25 mm (15G); or Nipro SafeTouch Tulip needles (15G; all Nipro Medical Europe Mechelen, Belgium)~* Ultrapure dialysis fluids (less than 0.1 colony forming units/ml, less than 0.03 endotoxin units/ml) will be mixed with AC-F 219/1 or 213/4 liquid acid concentrates and BiBag dry bicarbonate concentrate. Hence, the electrolyte composition of the dialysis fluid will be: Na 138-142 mmol/L; K 2.0-3.0 mmol/L; HCO3 26-35 mmol/L; Ca 1.25-1.50 mmol/L; Mg 0.5 mmol/L; Cl 108.5-109 mmol/L; glucose 5.6 mmol/L; acetate 3 mmol/L. Dialysate flow rate will be 500 mL/min.~* Anticoagulation: nadroparin."
41445483|NCT04390256|OTHER|Clove water extract|natural product
41445484|NCT04390256|OTHER|Carbopol|Bioadhesive polymer
41445485|NCT04390256|OTHER|Carboxymethyle cellulose|Bioadhesive polymer
41445486|NCT04921696|OTHER|RBC transfusion|RBC was transfused to the infants.
41445487|NCT04921696|OTHER|no-RBC transfusion|RBC was not transfused to the infants.
41445488|NCT05598320|DRUG|TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP
41445489|NCT05598320|DRUG|Placebo for TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP
41445490|NCT00202462|DRUG|Testosterone gel|Testosterone gel 7.5 gm qd
41445491|NCT00694187|DRUG|Zaleplon|
41445492|NCT05250323|OTHER|observational tests in face-to-face visit|All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment
41445493|NCT05003232|DEVICE|Near-infrared spectroscopy (NIRS) and ICM+|The intervention group will be given continuous NIRS and invasive blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP. Then the goal of blood pressure (within 5 mmHg of CPPopt) will be maintained as the target of blood pressure management for the intervention group during ICU stay.
41445494|NCT06194877|DRUG|BGB-3245|Oral capsule
41445495|NCT06194877|DRUG|Panitumumab|Intravenous (IV) infusion via an infusion pump
41445496|NCT01930903|DEVICE|Pantera Lux Drug Eluting Balloon|All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.
41445497|NCT01066858|DRUG|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
41445498|NCT04512235|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
41445499|NCT04512235|OTHER|Placebo|Commercially available 0.9% Normal Saline will be used as the placebo.
41445500|NCT04512235|DRUG|cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen|According to institutional standard of care.
41445501|NCT04079296|BIOLOGICAL|ASP7517|Intravenous (IV)
41445502|NCT06627140|DIAGNOSTIC_TEST|Diagnostic procedures|Self- and parent-report on behavioral/emotional symptoms and assessment of cognitive functioning
41445503|NCT06394973|DRUG|T4090 0.2%|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
41445504|NCT06394973|DRUG|T4090 0.3%|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
41445505|NCT06394973|DRUG|Rhopressa®|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
41445506|NCT03589313|DRUG|GLPG3067 single dose|GLPG3067 film coated tablets provided at Day 1.
41445507|NCT04968405|DEVICE|Catalyst CSR Total Shoulder System|The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.
41271071|NCT05376917|DEVICE|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50D on the dominated eye
41445508|NCT02364713|BIOLOGICAL|Bevacizumab|Given IV
41445509|NCT02364713|DRUG|Gemcitabine Hydrochloride|Given IV
41445510|NCT02364713|OTHER|Laboratory Biomarker Analysis|Correlative studies
41445511|NCT02364713|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
40752226|NCT03437733|DEVICE|Radiofrequency Ablation|RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter
40752227|NCT04193215|BIOLOGICAL|V114|IM injection
40752228|NCT04193215|OTHER|Pediatric vaccines|Standard of care vaccines administered according to the local recommended schedule.
41107881|NCT06264648|OTHER|Pressure sensitivity education|Therapists were asked to apply pressure to the scale with estimated weights of 0.5 kg, 1 kg, 2 kg and 4 kg. In each measurement, the value shown on the scale was recorded without being shown to the participant.After the measurements, the participants were made to experiment when the digital screen can be seen, in order to teach the physiotherapists how much pressure they applied to reach the target weight. Participants were given a total of 10 minutes for the trials. Then, the digital screen was hidden again, and the therapist was asked to apply 0.5 kg, 1 kg, 2 kg and 4 kg weight in a randomized order and maintain this pressure for 5 seconds. The weight fixed by the therapist for 5 seconds was noted by the researcher; the participant was not informed about the values on the digital screen.
41107882|NCT05762419|DRUG|Etoposide; Oral, 50 Mg|Subjects will receive focused ultrasound sonication followed by once daily oral etoposide (50mg/m\^2/dose). Oral etoposide will be taken every day for 21 days, followed by one week of rest. For the first cycle, etoposide will be administered immediately following confirming of the blood brain barrier opening through contrast magnetic resonance imaging (MRI) which will occur within 4 hours of the focused ultrasound procedure. For subsequent cycles, etoposide will be administered immediately following the focused ultrasound procedure. Subjects may continue for a maximum of 4 cycles.
41107883|NCT05762419|DEVICE|Focused ultrasound with neuro-navigator-controlled sonication|Focused ultrasound sonication will be performed a maximum of three times a week for two weeks with two weeks of rest.
41107884|NCT03521037|DRUG|Rucaparib camsylate|In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
41107885|NCT04392713|DRUG|Ivermectin 6 MG Oral Tablet (2 tablets)|12 mg single dose of Ivermectin will be given to intervention arm
41107886|NCT01595854|DRUG|dabigatran etexilate|medium dose dabigatran
41107887|NCT01595854|DRUG|Ticagrelor|high dose ticagrelor
41107888|NCT01595854|DRUG|Ticagrelor|high dose ticagrelor
41107889|NCT01595854|DRUG|dabigatran etexilate|low dose dabigatran
41107890|NCT01595854|DRUG|dabigatran etexilate|medium dose dabigatran
41107891|NCT01835899|DRUG|Placebo|Placebo to BI 1015550
41107892|NCT01835899|DRUG|BI 1015550|medium dose 1 powder for oral solution
41107893|NCT01835899|DRUG|BI 1015550|medium dose 2 powder for oral solution
41445512|NCT02364713|DRUG|Paclitaxel|Given IV
41445513|NCT02364713|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
41107894|NCT01835899|DRUG|BI1015550|low dose 2 powder for oral solution
41107895|NCT01835899|DRUG|BI 1015550|low dose 1 powder for oral solution
41107896|NCT03504072|DRUG|Tofacitinib 5 mg,|tofacitinib 5 mg 12 hourly daily for 9 months
41107897|NCT03504072|DRUG|Etanercept|Etanercept 50 mg sc every 7 days interval in 1st month, every 15 days interval in 2nd month and then every 21 days interval from 3rd month onward upto 9 months
41107898|NCT02886754|BEHAVIORAL|Proficiency-based progression|Use of validated metrics and performance benchmarks to simulation training
41107899|NCT02886754|BEHAVIORAL|National e-learning programme only|National e-learning programme (COMPASS)
41107900|NCT02886754|BEHAVIORAL|Standard simulation|Paper based simulation cases
41107901|NCT03197246|DEVICE|IVECG|Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.
41107902|NCT03197246|DEVICE|Chest X-ray|Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
41107903|NCT01243619|DRUG|3'-deoxy-3'-(18) F-fluorothymidine|Radio-tracer for tumor imaging
41107904|NCT02740530|DEVICE|Magstim® Rapid 2 machine|See Arms description
41107905|NCT06554197|DIAGNOSTIC_TEST|CMV/EBV-CMI|The CMV/EBV-CMI is tested before conditioning regimen and 30 days, 45 days, 60 days, 90 days, 120 days, 180 days after transplantation.
41107906|NCT05132686|BEHAVIORAL|IER+MED|Over a 6 month period follow a euenergetic Mediterranean diet 5 days per week and a 20% energy restriction over 2 contiguous days as a 70% energy restriction using the same macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
41107907|NCT05132686|BEHAVIORAL|MED/DER|Over a 6 month period follow a Mediterranean diet 7 days per week with a 20% energy restriction 7 days a week using the macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
41107908|NCT02886793|DRUG|fludeoxyglucose|
41107909|NCT00271700|BEHAVIORAL|Order Set, Education, Feedback|
41107910|NCT01829386|OTHER|MRI scans with non heme iron levels|"MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.~Each MRI will take up to 1 hour to complete and will be done on day 3, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research."
41107911|NCT05602909|DEVICE|Guided biaxial alveolar distraction device|A crestal incision will be done, a surgical guide will be placed to assist the correct position of osteotomy, an Extraosseous alveolar distractor will be placed on the ridge to mark screw sites and then will be removed, A distractor will be stabilized to the basal segment with a monocortical screw.
41107912|NCT04610008|OTHER|No intervention. Purely observation|Retrospective image analysis of the shape of the optic nerve head in both groups
41445514|NCT02364713|OTHER|Quality-of-Life Assessment|Ancillary studies
41107913|NCT03180450|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
41107914|NCT03180450|DRUG|conventional treatment|The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
41133307|NCT02441569|BEHAVIORAL|Standard pediatric advice for childhood anxiety|Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
41445515|NCT02364713|DRUG|Topotecan Hydrochloride|Given IV
41445516|NCT06558916|DRUG|Dexketoprofen Trometamol|
41271072|NCT05376917|DEVICE|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
41445517|NCT06558916|DRUG|Meperidine Injectable Solution|
41445518|NCT06558916|DRUG|Paracetamol|
41133308|NCT04148170|PROCEDURE|Endodiathermy Probe and Intubation Versus Intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
40752229|NCT04202211|BIOLOGICAL|FMT oral|lyophilized FMT given orally (10 capsules) twice weekly for total of 8 weeks
41133309|NCT02798900|OTHER|Functional task-training|The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.
41271073|NCT05376917|DEVICE|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
41445519|NCT06558916|DRUG|Fentanyl|Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.
40752230|NCT04202211|BIOLOGICAL|FMT enema|lyophilized FMT given via enema (1) twice weekly for total of 8 weeks
40752231|NCT04202211|OTHER|Placebo oral|placebo given orally (10 capsules) twice weekly for total of 8 weeks
40752232|NCT04202211|OTHER|Placebo enema|placebo given via enema (1) twice weekly for total of 8 weeks
40752233|NCT00047268|DRUG|cytarabine|
40925481|NCT03282331|PROCEDURE|Standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
40925482|NCT03282331|PROCEDURE|High flow nasal oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
40925483|NCT03282331|PROCEDURE|noninvasive ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
40925484|NCT01429909|DEVICE|MAGNETOM Avanto (MRI device)|The primary purpose is to optimize the fMRI by a quantitative measurement of the T2\* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2\*.
40925485|NCT02618356|DRUG|Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage \<1.25 m2 80 mg/d~* 1.25m2 - \<1.5 m2 100 mg/d~* 1.5 m2 120 mg/d"
40925486|NCT01409343|DRUG|TrasGEX™|Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
40925487|NCT04316702|DEVICE|Hyperbaric oxygen therapy (HBOT) treatment|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
40925488|NCT04316702|DRUG|Cymbalta / Lyrica - Drug treatment|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning).
41107915|NCT05647070|PROCEDURE|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, \~1 cm× \~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
41107916|NCT03311113|OTHER|Drug adherence questionnaire|Adherence to oral antibiotic therapy will be assessed by means of a questionnaire adapted from the French standardized self-assessment questionnaire of Girerd et al. This questionnaire has six questions, each question being associated with a score. Patient's drug adherence is classified into three groups based on the total score: of high, moderate and poor adherence. The questionnaire will be carried by a phone call to the patient.
41107917|NCT02156050|DEVICE|two sessions of 4 hours Phototherapy treatment|two sessions of 4 hours Phototherapy treatment
41107918|NCT01596504|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection self-administered with a pen-like injector (OptiClik®).~Route of administration: subcutaneous"
41107919|NCT01596504|DRUG|Liraglutide|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
41107920|NCT01596504|DRUG|Insulin Glargine|Doses to be adjusted to maintain a fasting self-measured plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)
41107921|NCT01596504|DRUG|Metformin|If previously taken metformin to be continued at stable dose throughout the study
41107922|NCT04801329|DRUG|Vyndamax (tafamidis 61mg)|As prescribed in real world practice
41107923|NCT02245334|DRUG|Povidone-Iodine|1 pill per biopsy
41107924|NCT01610479|DRUG|TAS-114 + S-1|
41107925|NCT00246012|DRUG|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
41107926|NCT00246012|DRUG|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
40752234|NCT00047268|DRUG|mercaptopurine|
40752235|NCT00047268|OTHER|laboratory biomarker analysis|
40752236|NCT00047268|PROCEDURE|allogeneic bone marrow transplantation|
40752237|NCT00047268|PROCEDURE|biopsy|
40752238|NCT00047268|PROCEDURE|peripheral blood stem cell transplantation|
40752239|NCT05338580|DRUG|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
40925489|NCT01765309|PROCEDURE|Bilateral mastectomy with reconstruction|In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
40925490|NCT05824143|DRUG|Darigabat|Oral tablet
40925491|NCT05824143|DRUG|Carbamazepine|Oral tablets
41107927|NCT00246012|DRUG|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
41107928|NCT05125133|OTHER|ITENs + ITWS|A dual active ingredient (dual AI) Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification.
41107929|NCT03630224|DRUG|Plasmalyte Viaflo|Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
41107930|NCT03630224|DRUG|NaCl 0.9%|Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
41107931|NCT05162144|PROCEDURE|Proximal Medial Gastrocnemius Recession|Patients will be operated with PMGR as described by Barouk. No additional procedures will be performed. The surgery will be performed with the patients in a prone position under local anaesthetics. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied. Patients will be instructed to continue the stretching exercises and fully weight-bear from the first postoperative day. If needed, the patients will be allowed to use crutches during the first 2 weeks after surgery. Sutures are removed 2-3 weeks after surgery.
41107932|NCT04617652|DRUG|Magnesium sulfate|Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.
41107933|NCT04617652|DRUG|Normal saline|Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
41107934|NCT04930393|PROCEDURE|Nerve Block - either PECS II or axillary ring|In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis
41107935|NCT05415761|BEHAVIORAL|iCanQuit|iCanQuit is a smoking cessation smart phone application that uses acceptance and commitment therapy (ACT) approach, a cognitive behavioral treatment
41107936|NCT05415761|BEHAVIORAL|iCanQuit+Motiv8|iCanQuit + Motiv8 is a integrated version of iCanQuit (Cognitive Behavioral Therapy smoking cessation therapy application) with Motiv8 (a contingency management program that rewards decreased smoking determined by measuring CO levels of participant)
41107937|NCT05415761|BEHAVIORAL|Florida quit line|An evidence-based, existing smoking cessation healthcare option recommended by the U.S. clinical practice that connects active smokers to trained quit coaches via referral by their providers.
41107938|NCT03510949|DEVICE|Nasopharyngeal airway or laryngeal mask airway|Comparing the incidence of postoperative soar throat with the use of nasopharyngeal airway versus laryngeal mask airway
41107939|NCT04217330|BEHAVIORAL|Choice of home-based or centre-based pulmonary rehabilitation|Participants will be offered the choice of HomeBase, a home-based pulmonary rehabilitation program, or the traditional centre-based pulmonary rehabilitation program.
41107940|NCT04217330|BEHAVIORAL|Centre-based pulmonary rehabilitation|Participants will be offered a traditional centre-based pulmonary rehabilitation program
41107941|NCT03556137|DRUG|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
41107942|NCT00567515|DEVICE|AtriCure LAA Exclusion System|Placement of clip of LAA.
41107943|NCT00783354|DRUG|desloratadine|"Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (Placebo) in case of symptoms for 2 months."
41107944|NCT00783354|DRUG|desloratadine|"Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (desloratadine 5 mg) in case of symptoms for 2 months."
41107945|NCT01490580|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
41107946|NCT01490580|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
41107947|NCT02918786|DEVICE|Nasal high-flow|After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.
41107948|NCT02918786|DEVICE|CPAP|After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
41107949|NCT02842424|DRUG|Ramipril|Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
41107950|NCT04671641|DEVICE|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
41107951|NCT05843136|OTHER|physiotherapy treatment|this is an interventional study of the use of 3 physiotherapy treatment techniques in order to evaluate the effectiveness of interferential current in relieving chronic low back pain
41133310|NCT02798900|DEVICE|Therapeutic Ultrasound|Therapeutic pulsed ultrasound will be applied prior to functional task-training with an intensity of 2.2 W/cm2, frequency of 1 MHz and application time of 4 minutes on the anterior, medial and lateral hip area.
41133311|NCT03744026|DEVICE|SonoCloud-9|Escalating numbers of ultrasound beams at constant acoustic pressure
41133312|NCT03744026|DRUG|Carboplatin|Dose of carboplatin infusion is AUC4-6
41133313|NCT02255474|DEVICE|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
41445520|NCT03538327|DRUG|Silybin|After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
41445521|NCT05217108|DEVICE|FitBit|All participants in each study group will receive a Fitbit. Participants will be asked to wear a Fitbit every day for 8 weeks to record the number of steps you take
41445522|NCT04652856|DEVICE|Electrical Brain Stimulation|Electrical Brain Stimulation (EBS) will be used to disrupt local neural activity in inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of EBS will be examined on attention and eye movement behavior, and all participants will receive both EBS and sham electrical brain stimulation.
41445523|NCT04652856|DEVICE|Sham Electrical Brain Stimulation|Sham electrical brain stimulation (SEBS) will be applied to inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of SEBS will be examined on attention and eye movement behavior, and all participants will receive both SEBS and EBS.
41445524|NCT02466451|OTHER|Questionnaires|"For not collaborative patients, under the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).~For collaborative patients, over the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )~* Spirometry~* 6-minutes walk test (WT 6')~* Prick tests~* Children Quality of life questionnaire (KINDL questionnaire)~* Psychological test (Raven Matrices)~* Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)"
41445525|NCT02554890|DRUG|sacubitril/valsartan (LCZ696)|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
41445526|NCT02554890|DRUG|Enalapril|Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
41445527|NCT02554890|DRUG|sacubitril/valsartan (LCZ696) matching placebo|matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
41445528|NCT02554890|DRUG|enalapril matching placebo|enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
41445529|NCT03787758|DRUG|SAGE-718|SAGE-718
41445530|NCT06218524|DRUG|Haloperidol Tablets|Haloperidol tablet 6mg, Oral, Triple/Day
41445531|NCT06218524|DRUG|Temozolomide|Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days
41445532|NCT04993274|DIAGNOSTIC_TEST|PASS-MS|protocol using short motor tasks performed by the subject and recorded by a depth camera, motion analysis by visuo-perceptive computing
41445533|NCT01717339|OTHER|Sleep Study|
41445534|NCT06562517|OTHER|Digital training module|The intervention is a 24/7 accessible educational website for pediatric oncology nurses, based on the EONS Cancer Nursing Education Framework. It features five validated training modules, enhanced with visual and auditory materials such as videos and infographics. Nurses will receive login credentials, allowing them to access the platform and participate in the training. Each module ends with a 20-question test, requiring a score of 60 to advance. A support line enables nurses to ask questions directly to researchers. Successful completion of each module earns a certificate. The website will be piloted with 15 nurses, and feedback will be used to refine its design and content.
41445535|NCT05215483|BEHAVIORAL|Customised testing advice|Customised advice: With Corona related symptoms, get tested at a test facility. If this isn't possible, use a Lateral Flow test.
41445536|NCT05215483|BEHAVIORAL|Regular testing advice|"Government guideline testing advice: With Corona related symptoms, get tested at a test facility."
41445537|NCT05215483|BEHAVIORAL|LFT available|LFT availability: Enough lateral flow tests available at home
41445538|NCT05215483|BEHAVIORAL|No LFT available|LFT availability: No lateral flow tests available at home
41445539|NCT03850522|BIOLOGICAL|PD-L1 peptide|PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
41445540|NCT05041855|BEHAVIORAL|The Healthy Living Program/La Vida Saludable|A whole-family group childhood obesity intervention delivered at community recreation centers
41445541|NCT05041855|BEHAVIORAL|Recommended Treatment of Obesity in Primary Care|A healthy lifestyle counseling protocol that enhances usual primary care
41133314|NCT02255474|DEVICE|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
41107952|NCT03961633|BEHAVIORAL|AWARE intervention|"will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the Study Description - Detailed Description section.~Participants will fill out forms that detail their therapeutic goals (commitments) and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes."
41107953|NCT03610958|DEVICE|Epitomee Device|A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
41107954|NCT02083991|DRUG|Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon|
41107955|NCT01998555|OTHER|CBT|
41107956|NCT02026258|PROCEDURE|Piezotome-Corticision|Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
41107957|NCT02026258|DEVICE|Orthodontics|Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
41107958|NCT04097418|BEHAVIORAL|Aerobic training compared to conventional motor training|"Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks."
41107959|NCT02792374|OTHER|Psychological Measurement|Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
41107960|NCT06186739|BEHAVIORAL|home-based motor rehabilitation training participated by caregivers|The knowledge provider was a multi-disciplinary home-based rehabilitation nursing team, which is composed of advanced practice nurse (APN) who engaged in professional rehabilitation of stroke, neurologists, rehabilitation doctors and physical therapists. Among them, APN mainly carry out and supervise family rehabilitation education and all members are collectively responsible for the adjustment and optimization of the program content. After the assessment is completed, the patient's current functional status will be confirmed. based on this, team members recommend home-exercise items that match the patient's motor function state . In this intervention programme, the content of the intervention was developed based on the recommendations of internationally published guidelines related to the rehabilitation of ischemic patients, with some adjustments to consider the cultural appropriateness of implementation in China.
41445542|NCT03850938|DEVICE|Conventional Kyphoplasty|The cement is injected into the cavity created by PKP. The diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones.
41445543|NCT03850938|DEVICE|Kyphoplasty with Rotary Cutter|The rotary cutter is applied before cement injection to destroy the structure around the cavity created by inflated balloon. Then, the rotary cutter will make the bone cement to support a wider range and to blend with the surrounding cancellous bones more densely.
41107961|NCT06186739|BEHAVIORAL|routine self-care|the patients in this group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.
41445544|NCT03208374|BEHAVIORAL|Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire|Participants will be asked how often on average over the year prior to their most recent diagnosis they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g. heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.
41107962|NCT02267980|DRUG|Sevoflurane|Inhalation anesthetic agent
41107963|NCT02267980|DRUG|Ketamine|Intravenous anesthetic agent
41107964|NCT02267980|DRUG|Saline|Isotonic solution for placebo group
41107965|NCT03193619|DEVICE|PTA (UltraScore Focused Force PTA Balloon)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated."
41107966|NCT04879563|OTHER|ASCAPE-based follow-up strategy|"Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions depending on the type of QoL issue that needs to be tackled.~The ASCAPE-based follow-up strategy includes follow-up through validated QoL questionnaires, wearables for capturing active monitoring data, and mobile apps for answering the questionnaires and capturing potential health-related issues."
41107967|NCT03312335|DRUG|Low-dose Aldesleukin (Proleukin®)|Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.
41107968|NCT06070688|DIAGNOSTIC_TEST|MeMed BV® biomarker test|one purple top tube of whole blood (2-3 cc) to be used for the MeMed Key® device processing without the need for centrifuge. The MeMed BV® test takes approximately 15 minutes to process and result. After, the sample has been processed and the MeMed BV® test has resulted, the sample of blood will be discarded for each patient enrolled in the study.
41107969|NCT06070688|DIAGNOSTIC_TEST|Usual care|Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.
41107970|NCT02401919|BEHAVIORAL|Tell-us Card|Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
41107971|NCT03313128|OTHER|Sanitation|Improved sanitation facility
41107972|NCT03804086|PROCEDURE|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement|"will treated with OFD +A- PRF+ nano-crystalline hydroxyapatite bone substitute,10 mL of blood will be drawn from only patient assigned to the intervention group by vein puncture of the antecubital vein and is collected in sterile glass test tube, without any anticoagulant.~* The blood will be quickly collected, and the tube will immediately centrifuge at 1500 rpm for14 min at room temperature.~* After centrifugation, the A-PRF clot will be removed from the tube using sterile tweezers and placed on sterile woven gauze. Membrane will prepared by compressing clots between two pieces of woven gauze."
41107973|NCT03804086|PROCEDURE|Open flap debridement|a periodontal access flap will be initiated by intrasulcular incisions on the buccal and lingual aspects. The incisions will be carried as far interproximally as possible to preserve the entire Interdental papillae and to achieve primary wound closure.
41107974|NCT01948999|PROCEDURE|ECT|Electroconvulsive Therapy inclusive anesthesia and concomitant muscular paralysis
41107975|NCT01948999|PROCEDURE|SHAM ECT|Anesthesia and concomitant muscular paralysis
41107976|NCT01948999|DRUG|Anesthesia|Temporary induced state of analgesia
41107977|NCT01029717|DEVICE|Standard polyurethane Central Venous Catheter|Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.
41107978|NCT01029717|DEVICE|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
41107979|NCT01029717|DEVICE|Heparin bonded polyurethane CVC|Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
41107980|NCT04314830|DEVICE|Gait training with perturbations|Changes in speed of one of the belt of the split belt treadmill during swing phase
41445545|NCT03208374|BEHAVIORAL|Current Exercise Behavior Questions: International Physical Activity Questionnaire Short Form (IPAQ SF)|The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
41445546|NCT06561269|PROCEDURE|Multifidus plane block|"Using the in-plane technique,The fascial plane between the multifidus muscle and the median sacral crests of S2 and S3, will be injected by bupivacaine."
41445547|NCT06561269|PROCEDURE|caudal block|"The ultrasound transducer will first be placed transversely at the midline to obtain the transverse view of sacral hiatus. At this level, the ultrasound transducer is rotated 90 degrees to obtain the longitudinal view of sacral hiatus. The block needle is inserted using the in-plane technique."
41445548|NCT05014958|OTHER|Exercise training on whole body vibration|Participants will be included in the 6-week exercise training on whole body vibration
41107981|NCT04314830|DEVICE|Gait training without perturbation|Walking on a treadmill with steady belt speed
41107982|NCT05696977|DRUG|Cyclosporine Capsule|Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile
41107983|NCT05607108|DRUG|ZEN003694|ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle
41107984|NCT01832506|DRUG|MSC2156119J|Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
41107985|NCT06044740|DRUG|Sevoflurane|After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration is reached. During the two drug conditions, subjects will first receive low-dose sevoflurane (0.4% corresponding to 0.2 Minimum Alveolar Concentration) and then a higher dose sevoflurane condition (0.8% corresponding to 0.4 Minimum Alveolar Concentration).
41107986|NCT06044740|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
41107987|NCT05263960|DRUG|CM350_group 1|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 5ug of CM350 on the first day of first cycle (C1D1), 5ug on C1D8, 5ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
41107988|NCT05263960|DRUG|CM350_group 2|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 15ug of CM350 on the first day of first cycle (C1D1), 15ug on C1D8, 15ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
41107989|NCT05263960|DRUG|CM350_group 3|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 45ug on C1D8, 45ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
41107990|NCT05263960|DRUG|CM350_group 4|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 135ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
41133315|NCT02255474|DEVICE|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
41271074|NCT05376917|DEVICE|Zeiss AT Lara / Zeiss AT Lara|Micromonovision with refractive target of -0.75D on the non-dominant eye
41107991|NCT05263960|DRUG|CM350_group 5a|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 270ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
41107992|NCT05263960|DRUG|CM350_group 5b|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 135ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
41107993|NCT05263960|DRUG|CM350_group 6a|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
41107994|NCT05263960|DRUG|CM350_group 6b|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 270ug on C1D8, 270ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
41107995|NCT05263960|DRUG|CM350_group 7|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
41107996|NCT05263960|DRUG|CM350_group 8|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 405ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
41107997|NCT05263960|DRUG|CM350_MTD level|CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
41107998|NCT05263960|DRUG|CM350_MTD-1 level|CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
41107999|NCT05035199|BEHAVIORAL|Spiritual Distress and Resources Questionnaire (SDRQ)|The SDRQ is a validated self-rating instrument to assess spiritual distress and resources. It focuses on beliefs, attitudes, experiences and practices of various kinds (every day and extraordinary), as well as on (dis-)connectedness. It consists of 22 items covering three subscales: spiritual resources, spiritual distress, and spiritual coping (Peng-Keller et. al., 2020, submitted). We constructed five additional questions to find out more why patients want to include spiritual aspects in their treatment.
41108000|NCT02916836|OTHER|therapeutic drug conciliation sheet (TDC)|Use of therapeutic drug conciliation sheet (TDC)
41108001|NCT02916836|OTHER|No Use of therapeutic drug conciliation sheet (TDC)|
41108002|NCT03743246|DRUG|JCAR017|JCAR017
41108003|NCT03743246|DRUG|Lymphodepleting|Lymphodepleting
41108004|NCT03743246|DRUG|Fludarabine|Fludarabine
41108005|NCT03743246|DRUG|Cyclophosphamide|Cyclophosphamide
41108006|NCT03747354|DIAGNOSTIC_TEST|blood samples|blood samples
41108007|NCT03897348|DRUG|Placebo|Oral medication
41108008|NCT03897348|DRUG|Lacosamide 100 mg|Oral medication
41108009|NCT03897348|DRUG|Lacosamide 200 mg|Oral medication
41108010|NCT02596035|DRUG|Nivolumab|
41108011|NCT05254730|DEVICE|macro-micro tetrodes for intracranial recording|novel design of tetrode micro electrodes within the standard macro intracranial electrodes used clinically for identification of the epileptogenic zone
41108012|NCT03219645|DRUG|Ginkgo Diterpene Lactone Meglumine Injection|The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.
41108013|NCT03219645|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
41108014|NCT00332436|DRUG|brimonidine/timolol fixed combination|
41108015|NCT04629118|DEVICE|Selution SLR™ 018 Drug Eluting Balloon|Target lesion will be pre-dilated with high pressure non-compliant balloon, then treated with SELUTION SLR™ 018 DEB Balloon.
41108016|NCT03156712|DIETARY_SUPPLEMENT|Ferrous sulfate|The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
41108017|NCT06111937|OTHER|after ultrasound gastric assessment to ensure gastric empty, painless colonoscopy was performed within 2 hours|Patients received gastric ultrasound examination every 15 minutes 2 or 4 hours immediately after taking the last dose of MgSO4 solution in group A or B respectively.
41108018|NCT00457691|DRUG|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
41108019|NCT00457691|DRUG|irinotecan|180mg/m2 iv day 1 every 14 days
41108020|NCT00457691|DRUG|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
41108021|NCT00457691|DRUG|sunitinib|37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
41108022|NCT00457691|DRUG|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
41108023|NCT00457691|DRUG|irinotecan|180mg/m2 iv day 1 every 14 days
41108024|NCT00457691|DRUG|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
41108025|NCT00457691|DRUG|placebo|37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
41108026|NCT05647980|OTHER|TACTIC|Participants execute the three steps of TACTIC Participants fill in questionnaires Participants take laboratory and biometric tests to measure their cardiovascular risk
41108027|NCT05695833|DEVICE|Radiofrequency|Device emitting electric waves generating heat
41108028|NCT00362206|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 20mg
41108029|NCT00362206|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
41108030|NCT00362206|DRUG|Pravastatin|Pravastatin 40 mg
41108031|NCT04616053|BEHAVIORAL|IMPACT intervention|A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist ...). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology ...) and/or collective care (for example : patient education, physical activity, relaxation ...). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
41108032|NCT02318381|PROCEDURE|Dissection of the superior transverse scapular ligament|After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
41108033|NCT03698708|BEHAVIORAL|CARES Intervention|A group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.
41445549|NCT03749187|DRUG|PARP Inhibitor BGB-290|Given PO
41108034|NCT03235349|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
41108035|NCT00000251|DRUG|30% N2O|
41108036|NCT00000251|DRUG|0.2% isoflurane|
41108037|NCT00000251|DRUG|0.4% isoflurane|
41108038|NCT00000251|OTHER|100% oxygen|Placebo
41108039|NCT06452446|DRUG|Selinexor|Selinexor is an oral therapy that is FDA approved for multiple myeloma and diffuse large B-cell lymphoma that have returned after prior therapy. Side effects like nausea, vomiting, and fatigue can affect how long a patient is able to continue taking Selinexor, which could mean that treatment might stop sooner.
41108040|NCT03463135|DRUG|Glucopyranosyl Lipid A (GLA)|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
41108041|NCT03463135|DRUG|Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Pharmaceutical form:Solution Route of administration: Sublingual
41108042|NCT03463135|DRUG|Placebo for GLA|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
41108043|NCT03463135|DRUG|Placebo for SLIT PE|Pharmaceutical form:Solution Route of administration: Sublingual
41108044|NCT05925972|PROCEDURE|Plane block|Plane block application in laparoscopic hysterectomies
41108045|NCT05558020|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise (CLE), incremental exercise protocol|The incremental work rate exercise test will be performed using a cycle-ergometer. The exercise protocol is initiated by a five-minute warm-up at 50 Watts (W). Subsequently, they will complete a stepwise protocol, which will begin at 100 W and increase by 2 W every 6th second, until exhaustion or until the patient is unable to continue exercise, for any reason.
41445550|NCT03749187|DRUG|Temozolomide|Given PO
41445551|NCT02369822|DIETARY_SUPPLEMENT|Vitamin C|those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
41445552|NCT03319108|OTHER|Exercise|Pulmonary Rehabilitation Program for 8 weeks
41445553|NCT00070148|DRUG|Megestrol Acetate|Megace by mouth for 12 weeks
41445554|NCT00070148|DRUG|Oxandrolone 20 mg|20 mg/day for 3 months (12 weeks)
41445555|NCT06268665|DRUG|Tart Cherry Juice|Given PO
41108046|NCT05558020|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise (CLE), continuous work rate protocol|"Within two weeks the participants will perform an additional CLE-test at various intensities. The new exercise protocol is designed to induce EILO at different exercise intensities. Using the participants' individually calculated exercise capacity, three different workloads (70 %, 80 % and 90 %) will be calculated.~The exercise protocol will be initiated with a five-minute warm-up at 50 W, then the workload will increase to the watt equivalent to 70 % of the participant's maximal exercise capacity. This workload will be fixed for ten minutes and only terminated if the participant feels the need to stop due to exhaustion or breathing difficulties. Next, the participant will have a five-minute resting phase with a set workload of 50 W. This protocol will be repeated at a workload equivalent to 80 % and 90 %"
41108047|NCT05857319|BEHAVIORAL|Nutritional Psycho-Behavioral Reeducation Program|"The RNPC Program is based on a clinical protocol in three successive phases:~1. A weight loss phase during which food intake is restricted to 800-1000 kcal per day, with a nutrient distribution of 60% protein, 25% carbohydrates and 15% lipids. Patients eat two meals a day consisting of meat/fish/eggs/shellfish and vegetables, supplemented by products enriched in proteins, vitamins and minerals, and depleted in carbohydrates and lipids.~2. A stabilization phase specifically established for each patient according to their weight loss and their daily caloric needs, allowing them to gradually return to a balanced diet, with a nutrient distribution of 25% protein, 45% carbohydrates and 30% lipids. During this phase, the consumption of meal supplements gradually decreases.~3. A phase of return to dietary balance, unlimited in time, based on the precepts of the Mediterranean diet.~Each patient is followed every 14 days by a dietitian during the entire program."
41108048|NCT04572672|OTHER|Non-pharmacologic treatment; Pursed-Lip Breathing Combined with Number Counting|"Pursed-lip breathing and number counting one and two during inspiration, and then number counting, one, two, three, and four during exhalation. The nurse advised the patient to continue pursed-lip breathing with number counting for the first 15 minutes (min) of each hour to prevent the patient from being exhausted, total study time was 3 hours, or until the patient was discharged from the ER, or was withdrawn from the study."
41108049|NCT04867291|DIETARY_SUPPLEMENT|Pizza|Portion equivalent to 200 µg of iodine (half a pizza), consumed with \~450mL of water.
41108050|NCT04867291|DIETARY_SUPPLEMENT|Seaweed Sheets|Portion equivalent to 200 µg of iodine (\~10g), consumed with two slices of white bread and \~450mL of water.
41108051|NCT04867291|DIETARY_SUPPLEMENT|Seaweed Powder|Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and \~450mL of water.
41108052|NCT04867291|DIETARY_SUPPLEMENT|Potassium iodide|Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and \~450mL of water.
41108053|NCT06216301|DEVICE|NovoTTF-200T|"The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death.~Drug: Pembrolizumab. Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.~Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer."
41108054|NCT06216301|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
41108055|NCT06216301|DRUG|Platinum based chemotherapy|Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer
41108056|NCT01247337|DRUG|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
41108057|NCT01247337|DRUG|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
41108058|NCT00174317|DRUG|Celecoxib|
41108059|NCT00174317|DRUG|Diclofenac|
41108060|NCT04935489|DEVICE|Intermittent Theta Burst Stimulation (form of repetitive transcranial magnetic stimulation) given in an accelerated form|The intervention is used regularly for patients with treatment resistant depression, however, in this trial it will be given multiple times per day and over less days than the usual protocol
41108061|NCT00435799|PROCEDURE|corneal cross-linking (CCL)|
41108062|NCT00435799|DRUG|Riboflavin/dextran eyedrops|
41108063|NCT00435799|DEVICE|UV-X system|
41108064|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
41108065|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft. The injectable PRF will be added to the particulate demineralized dentin graft forming sticky demineralized tooth graft then inserted in the extraction socket and covered then suturing
41108066|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
41108067|NCT00002436|DRUG|Lamivudine|
41108068|NCT00002436|DRUG|Zidovudine|
41108069|NCT00002436|DRUG|Zalcitabine|
41108070|NCT06013878|OTHER|Transfer Training with clinician|Participants will undergo transfer training with a clinician who is an expert on assisted transfer techniques if they are found to have skill deficits during the study. After training, a transfer assessment will be conducted to examine if the transfer skills of the caregiver have improved
41108071|NCT02954848|DRUG|Placebo|TAK-438 placebo-matching tablets
41108072|NCT02954848|DRUG|TAK-438 10 mg|TAK-438 tablets
41108073|NCT02623868|DRUG|CKD-519 50mg 2Tabs.|after taking Standard meal, CKD-519 50mg 2Tabs. administration.
41108074|NCT02623868|DRUG|CKD-519 100mg 1Tab.|after taking Standard meal, CKD-519 100mg 1Tab. administration.
41108075|NCT02623868|DRUG|CKD-519 100mg 1Cap.|after taking Standard meal, CKD-519 100mg 1Cap. administration.
41133316|NCT03878966|DEVICE|Inserting polymer free drug eluting stent in the coronary arteries|• Early invasive strategy with percutaneous coronary intervention will be done for the patients presenting with NST ACS who meet the inclusion criteria using Polymer-free drug eluting stents instead of the polymer-permanent drug eluting stents .
41108076|NCT06002360|BEHAVIORAL|Reach Out and Read|Families will be provided with a book and ROR programming from trained study team members (either the principal investigator or a research assistant, both of whom are ROR trained). ROR programming will include discussion of current reading practices, anticipatory guidance on the importance and benefits of reading, modeling of active reading, discussion of how to incorporate reading into a daily routine and answering any questions parents/caregivers may have.
41108077|NCT00005786|DRUG|arsenic trioxide|Given IV
41108078|NCT00005786|OTHER|laboratory biomarker analysis|Correlative studies
41108079|NCT02204618|DEVICE|cochlear implantation|
41108080|NCT02204618|OTHER|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
41108081|NCT02979899|BIOLOGICAL|TRC105|TRC105 antibody
41108082|NCT02979899|DRUG|Votrient|pazopanib
41108083|NCT03552913|PROCEDURE|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery
41108084|NCT03552913|PROCEDURE|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery
41108085|NCT03552913|PROCEDURE|No specific program toward improving practices|No specific program toward improving practices
41108086|NCT04333758|DEVICE|Jintronix Virtual Reality Telerehabilitation System|"System consists of an internet-based rehabilitation software linked to a Microsoft Kinect camera for motion detection.~Study team therapist prescribed a list of guided exercises and therapeutic activities (games) for training of whole body, lower and upper extremities. These can be done in sitting or standing, depending on individual participant's capacity.~Telemonitoring is done by study team therapist during each of the training day (Mondays-Fridays) of the home-based training phase. Training performance results are reviewed and training games are adjusted or changed to optimise home training."
41108087|NCT00509535|DRUG|vitreoscilla filiformis cream|
41108088|NCT03329144|BEHAVIORAL|Cognitive Behavioural Therapy|The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
41108089|NCT00506181|DRUG|probiotic mixture|"Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day."
41108090|NCT00506181|DRUG|Placebo|
41108091|NCT03897413|DRUG|S-888711|Administered orally as three 0.25 mg tablets
41108092|NCT03897413|DIETARY_SUPPLEMENT|Calcium Antacid|Calcium carbonate 4000 mg chewable tablets
41108093|NCT03884855|OTHER|Classical Cardiac Rehabilitation|Patients benefit from classical cardiac rehabilitation during 3 months.
41108094|NCT03884855|OTHER|Karate rehabilitation|Patients benefit from cardiac rehabilitation with traditional karate during 3 months. Patients will have four 60-minute group sessions four times a week, during which they will have 45-minute individual exercises and 15-minute pairs of exercises. The course of the sessions has been protocolised.
41108095|NCT00631579|DRUG|Rasburicase (SR29142)|
41108096|NCT06552702|OTHER|There is no intervention|There is no intervention.
41108097|NCT00630188|OTHER|You Decide|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
41108098|NCT00630188|OTHER|Reducing Your Risks in the Crash|Publicly available video on highway safety and reducing individual risks in a crash
41108099|NCT05297448|DRUG|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
41108100|NCT05297448|DRUG|Placebo|Placebo Twice Daily
41108101|NCT01771666|DEVICE|SPY Elite Imaging|A camera that is directed into the axillary cavity to try to capture an image of the tumor site labeled with Indocyanine green before and after excising sentinel nodes
41108102|NCT01771666|DRUG|Indocyanine Green|"started at 1mg /mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
41108103|NCT01771666|DRUG|Isosulfan blue|"3 to 5 mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
41108104|NCT01771666|DRUG|99technetium-sulfur colloid radiolabel|
41108105|NCT02274896|DEVICE|PD Catheter group|PD catheter
41108106|NCT06068699|OTHER|Postcard|Participants received a postcard asking them to address non-adherence to remote monitoring.
41108107|NCT01970748|DRUG|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
41108108|NCT01970748|PROCEDURE|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
41108109|NCT02032719|BEHAVIORAL|smartphone-assisted health coaching|smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
41108110|NCT02032719|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
41108111|NCT00714558|DRUG|Fentanyl citrate; Naltrexone; Naloxone|
41108112|NCT00866554|DRUG|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
41108113|NCT00866554|DRUG|administration of Bicalutamide, Dutasteride and Tamoxifen|"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
41108114|NCT01492218|DRUG|biphasic human insulin 30|Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
41108115|NCT06333132|BEHAVIORAL|Weight loss-induced Diabetes Remission|Patients will undergo a dietary intervention plus drugs (if needed) with the purpose to obtain a 10% (or at least 10 kg) body weight reduction to achieve diabetes remission
41108116|NCT02997280|DRUG|Ruxolitinib Oral Tablet|"Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight \> 40 kg, 0.08 mg/kg bid for children with body weight \< 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications."
41108117|NCT02682446|DRUG|H pylori eradication|The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen \[lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week\]
41108118|NCT01233713|PROCEDURE|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
41108119|NCT01233713|PROCEDURE|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering proximal ileostomy, followed by a stoma reversal operation.
41108120|NCT05745376|BEHAVIORAL|Farm to ECE programming|Students and parents at this center will receive program elements described in arm descriptions.
41108121|NCT02001623|DRUG|Tisotumab Vedotin (HuMax-TF-ADC)|
41108122|NCT04465734|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
41445556|NCT03110991|BEHAVIORAL|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
41445557|NCT03110991|BEHAVIORAL|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
41445558|NCT06181422|DRUG|Metformin|metformin 500 mg
41445559|NCT06181422|DRUG|Lactoferrin|lactoferrin 100 mg
41445560|NCT04560738|DRUG|[14C]-CC-92480|Oral
41445561|NCT05600322|DRUG|Hexaminolevulinate Hydrochloride|Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
41445562|NCT05600322|DEVICE|Richard Wolf Photodynamic Diagnostic Equipment (PDD) system|Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
41445563|NCT05985486|BEHAVIORAL|Diet|A reduced calorie diet which uses frozen meals purchased at the store and focuses on increasing fruits and vegetables associated with brain health.
41445564|NCT05985486|BEHAVIORAL|Health Education|Monthly health education sessions delivered remotely.
41445565|NCT06242912|BEHAVIORAL|QOL - quality of life|QOL assessments using EQ5D (Euroqol 5 dimension) +/- ESAS (Edmonton Symptom Assessment Scale) +/- CPC (Canadian Problem Checklist) every 4-8 weeks +/- 2 weeks
41445566|NCT06242912|DIAGNOSTIC_TEST|Radiographic or laboratory evaluation|Radiographic or laboratory evaluation every 12 weeks +/- 2 weeks
41445567|NCT04247243|DEVICE|Rapid testing|Abbott ID NOW Strep A testing
41445568|NCT04247243|DIAGNOSTIC_TEST|Reference testing|Culture-based testing
41445569|NCT02134821|PROCEDURE|Surgery for lumbar spinal stenosis|decompression with or without fusion for lumbar spinal stenosis
41445570|NCT04204395|DEVICE|Peanut Ball|The participants in the experimental group will use the peanut ball at least every 2 hours, 30-minute usage for each time. More frequency will be available. Then, the participants will stop using the peanut ball when cervical os is dilated and effaced, may be ready to push.
41445571|NCT00887419|BEHAVIORAL|Coping Skills Training|Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.
41445572|NCT00887419|BEHAVIORAL|Education|Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
41445573|NCT03199963|DRUG|4-OH tamoxifen|4-Hydroxytamoxifen (afimoxifene) gel
41445574|NCT03199963|DRUG|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
41445575|NCT05850728|DRUG|TLC-ART|TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension
41445576|NCT01149733|DRUG|Tamsulosin|Test 0.4 mg Capsule
41445577|NCT01149733|DRUG|Tamsulosin|Reference Listed 0.4 Capsule
41445578|NCT01229800|DRUG|Polyethylene glycol|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
41445579|NCT01229800|DRUG|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
41445580|NCT04002947|DRUG|DA-EPOCH|Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.
41445581|NCT04002947|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for 6 cycles.
41108123|NCT04465734|DRUG|HLX04|HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
41108124|NCT04465734|DRUG|Sorafenib|Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
41108125|NCT05100199|DRUG|OnabotulinumtoxinA X|Injection
41108126|NCT05100199|DRUG|Placebo|Injection
41108127|NCT06465680|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver push notifications. The notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of five therapeutic approaches: 1) CBT-Behavioral, 2) CBT-Cognitive, 3) Distanced Self-Talk, 4) Mindfulness, 5) Motivational Interviewing.
41108128|NCT02517307|DRUG|Intralipid/Heparin|Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
41108129|NCT02517307|DRUG|Glycerol/Saline|Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
41108130|NCT02517307|DRUG|Hyperinsulinemic euglycemic clamp|Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
41108131|NCT05774119|OTHER|breakfast with coffee|breakfast with coffee with 6 mg/caffeine/kg body weight
41108132|NCT05774119|OTHER|breakfast with water|breakfast with 250 mL of water
41108133|NCT03615248|DEVICE|BreatheSuite|"BreatheSuite (patent pending) is a device and mobile application developed by Mr. Brett Vokey, an engineering student at Memorial University of Newfoundland. BreatheSuite has been recognized by numerous provincial competitions, featured at the Eastern Health Innovation Showcase, and was recently selected as a finalist for the New York Health Innovation Challenge.~This device attaches to metered dose inhalers and it can determine if:~1. the dose was given,~2. the metered dose inhaler was properly shaken,~3. the metered dose inhaler is properly aligned,~4. the flow of medication is appropriate and~5. there is no accidental exhalation into the inhaler."
41108134|NCT04123132|OTHER|Kinesiophobia|The presence of kinesiofobia in patients with metabolic syndrome
41108135|NCT02020824|BEHAVIORAL|Exposure to anxiogenous environments|"The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms Exposure to anxiogenous environments (with or without control)."
41108136|NCT02020824|OTHER|Imagery with functional MRI initial|Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
41108137|NCT02020824|OTHER|Imagery with PET-scanner initial|Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
41108138|NCT02020824|OTHER|Imagery with functional MRI final|Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
41108139|NCT02020824|OTHER|Imagery with PET-scanner final|Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
41108140|NCT05875285|OTHER|Iontophoresis with methotrexate|"The methotrexate iontophoresis group the patient's hands are placed in direct contact with the conductive electrodes.~The patient will receive full explanation to the purpose of the treatment, the therapeutic and physiological benefits of this method of treatment. Before starting the treatment, all the previous measurements of each patient in this group is taken for a comparison.~Every patient will receive 12 sessions 3times/week every session consist of 30 minutes application of methotrexate iontophoresis using continuous direct current, the patient should feel mild tingling sensation (not painful), the polarity should be reversed halftime of treatment session, as the anodal current is more effective."
41108141|NCT05875285|OTHER|Iontophoresis with coal tar ointement|For coal tar ointement group the ointement is putted direct on the skin after describing the instruction and method of application and time of application and do alarm instead not to forget.
41108142|NCT01693614|DRUG|Buparlisib|100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
41108143|NCT01133132|BEHAVIORAL|Survivorship CHESS|Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
41108144|NCT01133132|OTHER|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
41108145|NCT00476060|PROCEDURE|Autologous mesenchymal stem cell transplantation|Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
41108146|NCT01115049|DRUG|chlorobutanol, hexetidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
41108147|NCT01115049|DRUG|Chlorhexidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
41108148|NCT02971930|BIOLOGICAL|BAY94-9027|Intravenous infusion of BAY94-9027
41108149|NCT06176716|DRUG|ET-26|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
41108150|NCT01834703|PROCEDURE|UAE|The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
41108151|NCT01834703|PROCEDURE|HIFU|Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
41108152|NCT06182462|DEVICE|Virtual Reality Distraction|"The experimental group will receive a VR video game called DREAM DENTAL designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. The VR video game aims at reducing anxiety in children aged 6 to 17 years old by means of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant or resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded."
41108153|NCT06182462|DEVICE|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes viewing cartoons on a muted mounted television set and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia, according to the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose to do so.
41445582|NCT04002947|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m2 IV, Vincristine 1.4 mg/m2 (2 mg cap) IV are administered on Day 1 of each 21-day cycle for 6 cycles. Prednisone 40 mg/m2 PO is administered daily on Days 1-5 of each cycle.
41445583|NCT04002947|DRUG|Acalabrutinib|Acalabrutinib is administered orally at 100 mg twice a day for 14 days during the window period. During combination therapy, acalabrutinib is administered 100 mg twice daily for the first 10 days for 6 cycles.
41445584|NCT04550702|DRUG|Mirabegron 25mg|Mirabegron 25 mg per day
41445585|NCT06274762|OTHER|Training and BSE application on a model|A breast cancer awareness training designed according to the headings of sensitivity, seriousness, benefit, obstacle perception, health motivation and self-efficacy, which are the steps of the health belief model, followed by applied BSE on a model.
41445586|NCT04290858|DRUG|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
41445587|NCT06560671|OTHER|novel type of health education|animation video based health education
41445588|NCT01239862|OTHER|Autologous cell transplantation|Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
41445589|NCT00242554|DRUG|Zoledronic acid|
41108154|NCT03037502|BEHAVIORAL|Tailor Made: Solutions for your health (A su Medida: Soluciones para su salud)|Assess the effectiveness of a person-specific, randomized controlled pilot weight loss study of 80 African American and 40 Latino men; to compare changes in chronic disease risk behaviors (e.g., diet and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., social support, autonomous motivation) between data collected at baseline and at 3-months.
41108155|NCT03199235|DEVICE|Lucky Iron Fish|200g iron ingot that is placed in boiling water for 10+ minutes, and then removed. The water is then used to eating and drinking.
41108156|NCT03199235|OTHER|enhanced standard of care|parents of subjects are provided oral iron supplementation per usual clinical care at clinic and followed for their anemia in addition to study visits
41108157|NCT01254019|DRUG|GSK2402968 6mg/kg/week|subcutaneous
41108158|NCT01685788|OTHER|No intervention|
41108159|NCT00109785|PROCEDURE|positron emission tomography|
41108160|NCT00109785|RADIATION|fludeoxyglucose F 18|
41108161|NCT00109785|RADIATION|iodine I 124 iododeoxyuridine|
41108162|NCT03423394|BEHAVIORAL|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment. The first MET session intervention will involve a counselor using motivational interviewing (MI) strategies to establish an empathic therapeutic relationship and focus learning about the PTSD symptoms the participant is experiencing and exploring ambivalence about seeking treatment services. MET sessions 2 and 3 will focus on identifying and responding to risk factors for dropping out of treatment (increases in ambivalence, avoidance behavior, concerns about stigma, life chaos), identifying and responding to barriers to participant's active engagement in treatment, and facilitating enrollment in alternate therapeutic resources if necessary.
41108163|NCT03423394|BEHAVIORAL|Treatment as Usual|TAU will include a written referral list comprised of PTSD resources including information on in-person treatments, self-help, web-based and bibliotherapy options. At the completion of the study, participants in the TAU condition will be offered the MET intervention.
41108164|NCT02296619|PROCEDURE|TAP block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
41108165|NCT02296619|PROCEDURE|Control|A sham band-aid will be applied to the abdomen of subjects
41108166|NCT00814346|DRUG|EGb761®|Four weeks for AD patients, 18 months for MC and CNE patients
41108167|NCT00814346|DRUG|Placebo|Placebo 1 tablet BID
41108168|NCT00000313|DRUG|Fenfluramine|
41108169|NCT05571436|BEHAVIORAL|iCan Diabetes Self-management and Prevention Support Group|"Participants will be asked to attend six weekly sessions and complete pre-and post-assessments with an optional focus group.~The intervention will cover the following topics: 1) Yes, iCan! - Affirmations and Empowerment, 2) The Language of Diabetes - Diabetes Synopsis, 3) Diabetes and Me - Management Strategies, 4) Extraordinary Health - Dream Team, 5) Food for Thought - Food Conscious, and 6) Discussion - Stories/Goals.~Each session is composed of a Check-in, Affirmation/Empowerment Activity, Short Presentation, Q\&A and Discussion, Goal setting, and Testing Healthy Snacks."
41133317|NCT05270460|DRUG|PCS12852|PCS12852 oral tablet administered once daily
41108170|NCT04243213|OTHER|Vibration Plate|Vibration at 15° tilt, which means the patients partly use their own body weight (resistive vibration exercise).
41108171|NCT04243213|OTHER|Tilt at 15°|To compare if a possible effect derives from the vibration or the tilting only, a second group was added who will only receive 10 min of 15° tilt without the vibration.
41108172|NCT04243213|OTHER|Standard hospital mobilization|early mobilization of patients 24h post surgery, done routinely, and physiotherapy this is done routinely in all patients
41108173|NCT02107378|BIOLOGICAL|DCVAC/OvCa|DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin
41108174|NCT02107378|DRUG|Standard of Care (Paclitaxel or topotecan or doxorubicin)|Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
41108175|NCT00517933|DRUG|Sildenafil Citrate|Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
41108176|NCT00517933|OTHER|Placebo|Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
41108177|NCT00091624|DRUG|CC-5013|
41108178|NCT00779545|DRUG|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
41108179|NCT00779545|DRUG|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
41108180|NCT00779545|DRUG|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
41108181|NCT00779545|DRUG|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
41108182|NCT00779545|DRUG|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
41108183|NCT00779545|DRUG|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
41108184|NCT00780663|DRUG|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
41108185|NCT02026076|OTHER|mechanical lumbar traction|15 minutes at up to 50% body weight lumbar traction in supine hooklying with split table open
41108186|NCT05338996|BEHAVIORAL|iENGAGE for PrEP|This intervention originally developed for people living with HIV (PLWH), is designed to promote engagement, retention, and adherence to treatment by addressing the social determinants of health that often act as barrier to remaining in care and achieving viral suppression. Based on our experience with this intervention we believe that it is well suited to similarly promote engagement, retention, and utilization of PrEP care among our proposed target population of WOC by a) removing barriers to care and b) addressing unmet needs by providing c) point-to-point linkage to care services delivered by multi-disciplinary teams of individuals within or outside of the health facility, and d) the use of telehealth visits to facilitate engagement in care and improve health visit attendance. The original iENGAGE is a 4-session, in-clinic behavioral intervention.
41108187|NCT02230358|PROCEDURE|Regional anesthesia|Regional anesthesia
41108188|NCT02230358|PROCEDURE|General anesthesia|General anesthesia
41108189|NCT02230358|DEVICE|Transcranial Doppler ultrasonography|6x for 4 hours
41108190|NCT02230358|PROCEDURE|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
41108191|NCT02230358|PROCEDURE|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
41108192|NCT02230358|PROCEDURE|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
41108193|NCT02230358|BEHAVIORAL|Neurological Control|perioperative, 2-3 days, as done in clinical routine
41108194|NCT02230358|BEHAVIORAL|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
41108195|NCT02230358|DEVICE|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
41108196|NCT05270551|PROCEDURE|ACL Reconstruction|All participants will do ACL reconstruction with and without Augmentation and will receive Accelerated rehabilitation program
41108197|NCT01788930|DEVICE|CPAP|
41108198|NCT04851561|DIAGNOSTIC_TEST|Cardiopulmonary stress test (CPET)|Cardiopulmonary stress test will be conducted under the guidance of sports and exercise physicians and nursing staff. Electrocardiogram, spirometry, blood pressure and gas exchange measuring will be assessed at rest. The participants will then undergo CPET according to a modified Astrand treadmill test protocol. The test will be terminated at maximal exercise or upon the appearance of limiting symptoms. Continuous electrocardiogram and repeated blood pressure measuring will be conducted at the recovery phase. Post-exercise spirometry will also be assessed.
41108199|NCT01569919|BIOLOGICAL|TroVax®|Dose of 1 x 10\^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
41108200|NCT01569919|DRUG|Pemetrexed|500 mg/m\^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
41108201|NCT01569919|DRUG|Cisplatin|75mg/m\^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
41108202|NCT01569919|DIETARY_SUPPLEMENT|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
41108203|NCT01569919|DIETARY_SUPPLEMENT|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
41108204|NCT01569919|DRUG|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
41108205|NCT06226714|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
41108206|NCT06226714|BIOLOGICAL|MPSV4|1 dose of MSPV4 on Day 0
41108207|NCT00092664|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks|
41108208|NCT00235040|BEHAVIORAL|Smart Form|Computer Decision Support System
41108209|NCT03624140|DEVICE|blood measurement|Hemoglobin measurement
41108210|NCT03624140|DEVICE|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
41108211|NCT03624140|DEVICE|hemoCue|non invasive method of hemoglobin measurement
41108212|NCT04291586|OTHER|Virtual reality|Virtual Reality Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
41133318|NCT05270460|DRUG|Placebo|Placebo comparator oral tablet administered once daily
41108213|NCT04291586|OTHER|Paper and Pencil|Paper and Pencil Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
41108214|NCT06331871|PROCEDURE|Ultrasound Guied Percutaneus Electrical Nerve Stimulation (US-PENS) and Manual physiotherapy protocol based on available evidence.|Intervention performed by needling in the vicinity of the peripheral nerves of the shoulder under ultrasound-guided control.
41133319|NCT02987218|DRUG|Propofol|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
41108215|NCT06331871|PROCEDURE|Manual physiotherapy protocol based on available evidence.|Physiotherapy treatment based on the best scientific evidence available, based on manual therapy and passive and active kinesitherapy
41445590|NCT04820309|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
41108216|NCT04931446|PROCEDURE|Biopsy/surgical tissue and peripheral blood|Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens
41108217|NCT02909751|DRUG|Epirubicin 90 mg/m2 iv|Max. 3 months
41108218|NCT02909751|DRUG|Cyclophosphamide 600 mg/m2 iv|Max. 3 months
41108219|NCT02909751|DRUG|Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Max. 3 months
41108220|NCT02909751|DRUG|Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Max. 3 months.
41108221|NCT02909751|DRUG|Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Max. 3 months
41108222|NCT02909751|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily|Max. 6 months
41108223|NCT05752552|DRUG|DO-2|Deuterated MET kinase inhibitor
41108224|NCT00411996|DRUG|indinavir/ritonavir|IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
41108225|NCT00074633|BEHAVIORAL|Health at Every Size (HAES)|
41108226|NCT00074633|BEHAVIORAL|Diet (Traditional, moderate energy restriction)|
41108227|NCT01377259|OTHER|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
41108228|NCT00801983|DEVICE|Alternative Keyboard|Subjects use either a typical or alternative keyboard
41108229|NCT00596167|DRUG|Intravenous antibiotics|Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
41108230|NCT02582437|OTHER|History for opioid use|
41108231|NCT00761930|DRUG|Fluoride|Brush twice daily
41108232|NCT00761930|DRUG|Triclosan and fluoride|Brush twice daily
41108233|NCT00761930|DRUG|Herbal Ingredient and fluoride|Brush twice daily
41108234|NCT01291563|DRUG|Moxifloxacin|1 capsule of moxifloxacin (400 mg/capsule) on Day 2
41108235|NCT01291563|DRUG|TMC207|8 tablets of TMC207 (100 mg/tablet) on Day 1
41108236|NCT01291563|DRUG|TMC207 placebo|8 tablets of TMC207 placebo on Day 1
41108237|NCT01291563|DRUG|Moxifloxacin placebo|1 capsule of moxifloxacin placebo on Day 2
41108238|NCT04483063|DRUG|2% chlorhexidine gluconate skin cleanser|2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery
41108239|NCT00819442|PROCEDURE|cardiobiopsy|5 samples will be taken from right ventricle by Cordis bioptome
41108240|NCT05697718|BIOLOGICAL|MSC|a single injection dose i.v.
41108241|NCT06556173|DRUG|VTX3232|Dose A
41108242|NCT00430300|DRUG|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
41108243|NCT00430300|DRUG|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
41108244|NCT00156117|DRUG|asenapine|5 mg BID or 10mg BID
41108245|NCT00156117|DRUG|Placebo|Placebo
41108246|NCT00156117|DRUG|olanzapine|olanzapine 15 mg QD
41133320|NCT02987218|DRUG|Desflurane|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
41133321|NCT05153681|OTHER|Peloid Therapy|Peloid therapy; A total of 10 sessions were applied for 30 minutes by heating the proximal part of the sole of the foot, including the heel part, at a temperature of 45 degrees. Kinesioband application: One strip is prepared as a rake with a length of about 25 cm, and the other strip is prepared as an I tape with a length of about 20 cm. The ankle is in a neutral position of 90 degrees. Lymphatic and mechanical correction technique is applied. Afterwards, the band is activated.
41108247|NCT05430880|DIAGNOSTIC_TEST|impact of fluid challenge on the cardiac index and CO2 respiratory parameters analysis (VCO2, EtCO2)|"Preliminary daily data will record: demographic, ventilatory (tidal volume, FiO2, positive expiratory pressure, compliance, respiratory rate, I/E ratio) and biological parameters (fibrinogen, CRP, leukocytes count, PaO2, PvO2, PaCO2, PvCO2, CO2gap, arterial lactate, ScvO2, platelets count)~1. st step CO2 record (between Time-6minutes and T0; T0 corresponding to fluid challenge) VCO2 and EtCO2 (End-tidal CO2) automated measurement by Hamilton module. Average VCO2 obtained before fluid challenge.~   CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli.~2. nd step: Crystalloid (ringer lactate) filling 500mL in 5 minutes~3. rd step CO2 record (between T+5min and Time+11minutes): VCO2 and EtCO2: automated measurement by Hamilton module. Average VCO2 obtained after fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli"
41108248|NCT06227091|DIETARY_SUPPLEMENT|Beetroot juice|acute dose of beetroot juice
41108249|NCT06227091|DIETARY_SUPPLEMENT|Placebo|depleted nitrate beetroot juice
41108250|NCT04630080|DEVICE|Scalp cooling|Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
41108251|NCT01606163|BIOLOGICAL|GC1102|"1. Description: GC1102 IV bolus injection during 10\~ 30 seconds.~2. Amount: group1-3ml, group2-5ml, group3-8ml~3. Subject number: group1-8, group2-8, group3-8~4. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
41108252|NCT01606163|OTHER|JW normal saline|"1. Description: Normal saline IV bolus injection through 10\~ 30 seconds.~   * Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~2. Subject number: 9~3. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
41108253|NCT01546155|RADIATION|PET imaging|Up to a 120 minute PET scan using \[11C\]diprenorphine as the radiotracer
41108254|NCT06131047|OTHER|High intensity Traditional Resistance Traning without Blood Flow Restriction|Group A will undergo Traditional Resistance training without blood flow Restriction. A 30-minute progressive, weight training program will be initiated 8 weeks after the ACL-reconstruction and will be conducted subsequent to the individual based program. The resistance (training loads) will be increased when the individual could do more repetitions than the number specified in the weight training protocol. The exercises will be performed at a slow speed to ensure full control of the movement
41108255|NCT06131047|OTHER|High intensity Traditional Resistance Traning with Blood Flow Restriction|Group B will recieve low-load blood flow restriction (LL-BFR) training using external loads of 20-40% 1RM has been suggested as an alternative to traditional strength rehabilitation. Minimum of 2 -3 sets and maximum total 5 sets,20-30 repetitions of each exercise with 30 to 60 seconds rest period and 2-3 times per weekly for 4-6 weeks to During LL-BFR training, a pressurized cuff is applied to the proximal thigh that oc¬cludes venous outflow while maintaining arterial in¬flow. The combination of venous occlusion and resis¬tance training is believed to induce muscle hypertrophy secondary to elevated systematic hormone production, cell swelling, production of reactive oxygen species, intramus¬cular anabolic signaling and fast-twitch fiber recruit¬ment
41108256|NCT05685173|DRUG|Odronextamab|Odronextamab will be administered by IV infusion
41108257|NCT05685173|DRUG|REGN5837|REGN5837 will be administered by IV infusion
41108258|NCT02812459|OTHER|Kinesio taping|Kinesio taping is a new taping modality which act diminishing pain.
41108259|NCT02812459|OTHER|Electrical Stimulation|Electrical stimulation therapy is a electrical current that allow patients diminish pain.
41108260|NCT05874986|OTHER|Resistance training|12-week resistance training intervention
41108261|NCT01181180|DIETARY_SUPPLEMENT|water consumption|The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
40752240|NCT06235970|DEVICE|Transcranial electrical stimulation (tES) including SHAM|Transcranial electrical stimulation, known as tES, refers to a family of devices that utilize low-cost technologies and involve low-intensity currents which are safe for humans, and carry minimal risk of side effects or adverse events. Conventional approaches, which utilize fixed direct currents (tDCS) or alternating currents at a fixed oscillatory frequency (tACS), have been widely used as both a basic research tool and as a clinical intervention. In the current project, we use a custom-built device that enables near real-time current modulation triggered digitally, via software control, to allow for stimulation protocols guided by whole-brain individualized neural modeling.
41271075|NCT03669705|PROCEDURE|Omitting axillary surgery in early breast cancer|Before the Sentinel Node era all invasive breast cancer was recommended to have axillary dissection but after the introduction of national breast cancer screening this guideline statement was challenged by this national Swedish cohort.
40752241|NCT03502772|OTHER|Pilates exercises|Clinical Pilates training program will be given one session in a week for 8 weeks plus two days home exercise program. Group exercise sessions will be performed. The sessions will be supervised by a physiotherapist who is certified.
41108262|NCT01885845|DEVICE|Excellent BRASSS-V Drape™.|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
41108263|NCT01885845|OTHER|Indirect weight assesment of blood loss|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
41108264|NCT00355940|DEVICE|Technological Methods|"Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.~In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images"
41108265|NCT00355940|DEVICE|Regular Fluoroscopy|Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
41108266|NCT01656096|DEVICE|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|
41108267|NCT01656096|OTHER|Sham procedure|
41108268|NCT04998318|DEVICE|Pocket Colposcope|Both arms will receive treatment in order to prevent cervical cancer. However, the intervention using the pocket colposcope device will be used on half the enrolled subjects.
41108269|NCT04998318|PROCEDURE|Standard of Care Colposcopy|VIA and VILI as previously described,
41108270|NCT04050631|BEHAVIORAL|maternal arrest simulation on L&D floor|AFE on L\&D
41108271|NCT06037187|DIAGNOSTIC_TEST|Blood Draw|Standard coagulation assays (aPTT, INR, ACT), viscoelastic coagulation profiles (rotational thromboelastometry (ROTEM)/thromboelastography (TEG), tPA-challenged ROTEM/TEG), and molecular profiling
41108272|NCT05790096|BIOLOGICAL|Granulokine|Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
41108273|NCT05790096|BIOLOGICAL|Filgrastine|Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
41108274|NCT00197886|DRUG|Changing dose of norepinephrine and blood pressure|
41108275|NCT04302844|BEHAVIORAL|Imago Relationship Therapy|Imago relationship therapy (IRT) involves learning the Imago dialogue process, which helps couples understand more clearly why they and their partners react as they do. Couples practice communicating in a manner that helps them move from reactivity and blame to understanding and empathy. The dialogue is used to transform conflicts into opportunities for healing and growth, and to connect more deeply and effectively with one another. Specific topics of therapy are determined by the couple's needs and goals. In general, the therapist helps them use the Imago dialogue to promote understanding, heal painful emotions, and make requests of one another to change behaviors. In effort to minimize risk of exposure to the virus that causes COVID-19, since the spring of 2020, therapy sessions will be conducted via telehealth, with a HIPAA-compliant audio/visual platform, and with couples at home or in another private place during the therapy sessions and the therapist in his or her office.
41271076|NCT03396328|BEHAVIORAL|conventional low salt education|conventional low salt education
41108276|NCT04302844|BEHAVIORAL|Waitlist with Bibliotherapy followed by Workshop|"Participants assigned to this group will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read, with exercises to practice, during that time. After 12 weeks and the 12-week assessment has been completed, couples will attend an educational workshop that provides the principles and communication skills of Imago Relationship Therapy, typically in a weekend format that is usually about 18-20 hours. The workshops, called Getting the Love You Want (GTLYW), are led by certified and experienced Imago workshop presenters, and are attended by a group of couples. The workshop includes presentations, discussions, and practice of communication exercises. Participation in the workshops will also be virtual or via telehealth, as described above."
41108277|NCT01671124|OTHER|Soline capsule|
41108278|NCT00588419|BEHAVIORAL|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
41108279|NCT04397198|DIAGNOSTIC_TEST|Speckle Tracking echocardiography|"Diagnostic tests:~Speckle Tracking echocardiography with analyzing the myocardial strain, myocardial velocities, 128-multislice CCTA with the evaluation of the Calcium Scoring (total and local) , identifying the coronary stenosis, evaluation of the plaque vulnerability degree, assess polar maps of the myocardium.~MRI for the evaluation of the percentage of myocardial scar, also the percentage of the viable myocardial tissue using contrast late enhancement sequences, measuring myocardial fibrosis using Q-mass software.~Diagnostic tests:~Laboratory assessment for the evaluation of the level of hs-CRP and myocardial necrosis biomarkers"
41108280|NCT02015741|DEVICE|EEG monitoring with Bispectral Index and NeuroSENSE|
41108281|NCT02015741|BEHAVIORAL|Clinical observation|Patients will be observed during awake periods and during natural sleep.
41108282|NCT01063036|DRUG|Entecavir|Tablets, Oral, 1 mg, once daily, 96 weeks
41108283|NCT01063036|DRUG|Tenofovir|Tablets, Oral, 300 mg, once daily, 96 weeks
41108284|NCT00207532|DRUG|folic acid|
41108285|NCT05390099|DRUG|Moringa oleifera leaf|Moringa toothpaste
41108286|NCT01740063|DRUG|DAS181-F02 formulation|
41108287|NCT01740063|DRUG|DAS181-F04 formulation|
41108288|NCT01740063|DRUG|Placebo|
41108289|NCT02734628|DRUG|Dexpanthenol (Bepanthen® Wund- und Heilsalbe, BAY81-2996)|30 g of 5% of the active ingredient dexpanthenol plus other ingredients as ointment
41108290|NCT02734628|DRUG|Placebo|Placebo to Bepanthen® ointment without active ingredient dexpanthenol
41108291|NCT04275817|OTHER|Data collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
41445591|NCT04343196|RADIATION|Diagnostic Angiography (DSA or DVA based on randomization result)|After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool
41445592|NCT06138821|DEVICE|ESG + lifestyle modification|Endoscopic sleeve gastroplasty - an endoscopic weight loss procedure where an endoscopic suturing device is utilized to reduce the size of the stomach by 70%.
41445593|NCT06138821|BEHAVIORAL|Lifestyle modification|Lifestyle modification program consisting of diet and exercise therapy
41445594|NCT06561971|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
41445595|NCT03801980|DRUG|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
41445596|NCT03801980|DRUG|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
41445597|NCT05334875|DIAGNOSTIC_TEST|Electroretinogram (ERG)|Applying electrodes to assess retinal function
41445598|NCT05334875|DIAGNOSTIC_TEST|Visual evoked potential (VEP)|Applying electrodes to assess visual pathway function
41445599|NCT01470560|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
41445600|NCT01470560|BEHAVIORAL|Sham Yoga Group|Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
41445601|NCT01842750|DEVICE|Endorectal Balloon insertion|
41445602|NCT03750903|BEHAVIORAL|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
41445603|NCT03750903|BEHAVIORAL|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
41445604|NCT06293586|PROCEDURE|peribulbar block|"Peribulbar block using a two-injection technique was performed by a second anesthetist under sterile conditions and before the application of surgical drapes. LAM was injected both infratemporal and superonasally using a 26-G needle, in contrast to the single infratemporal injection approach.~Gentle digital oculopression was performed for 5 minutes"
41108292|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
41108293|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
41108294|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
41108295|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
41108296|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
41108297|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
41108298|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
41108299|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
41108300|NCT04347954|DRUG|Povidone-Iodine 2%|Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day
40752242|NCT03502772|OTHER|Home exercise program|written exercises that matched the aims of the Pilates exercises, 3 times per week for 8 weeks. These exercises reflect routine clinical practice (flexibility, strength, and balance exercises).
40925492|NCT04348968|DEVICE|Total hip arthroplasty|"The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.~In this study, the acetabular component is the Zimmer Maxera Cup, which is a monoblock construct consisting of a pre-assembled shell and liner. The ceramic liner articulates with a ceramic femoral head for a ceramic-on-ceramic large diameter head articulation. The Maxera Cup is intended for single use only and is designed for reconstruction of the hip joint for conditions described in the inclusion and exclusion section of this protocol."
40925493|NCT02093351|DRUG|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
40925494|NCT02093351|DRUG|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
40925495|NCT02093351|DRUG|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
41108301|NCT04347954|DRUG|Povidone-Iodine 0.5%|Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day
41108302|NCT04347954|DRUG|Isotonic saline 0.9%|Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day
41108303|NCT04430426|OTHER|Controlled Diet|Participants will consume a controlled low oxalate diet for five days.
41108304|NCT04430426|OTHER|Glycolate Administration|Participants will come to the UAB Clinical Research Unit (CRU) and be administered a glycolate load via intravenous (IV) catheter.
41108305|NCT02500654|DEVICE|Emdogain®|Surgery and Emdogain®
41108306|NCT02500654|DEVICE|Surgery alone|Surgery alone
41108307|NCT04013971|OTHER|AGRF Biofeedback Game|During the AGRF biofeedback game participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game for 4 minutes.
41108308|NCT04013971|OTHER|Traditional Biofeedback Interface|"For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes."
41108309|NCT04013971|OTHER|Control Condition|Participants will complete a control walk with out feedback.
41108310|NCT04013971|OTHER|Optional Game with VR|During the optional AGRF biofeedback game with virtual reality (VR) participants will walk on a split-belt treadmill with a head-mounted VR display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game with VR for 4 minutes.
41108311|NCT03653013|BEHAVIORAL|Usual standard of care|Participants will receive treatment and diabetes management as usual standard of care from their diabetes care team. They will also complete as part of the study visit: a pediatric quality of life scale(PedsQL,GenericScale and Diabetes Module) and diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study.
40752243|NCT01795339|DRUG|AZD3293|Oral solution
40752244|NCT01795339|DRUG|Placebo|Oral solution
40752245|NCT04539431|GENETIC|validation of new technologies|Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity
40752246|NCT03428269|OTHER|simulation by gaming (LabForGames Warning)|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
40752247|NCT03428269|OTHER|traditional education|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
40925496|NCT02093351|DRUG|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
40925497|NCT02093351|PROCEDURE|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
40925498|NCT03866395|DRUG|Ivabradine|Ivabradine 5 mg twice a day
40752248|NCT04296682|PROCEDURE|Alveolar Ridge Preservation With Gingival Graft|Closure of the alveolus with the placement of a free gingival tissue graft removed from the individual palate.
40752249|NCT04595578|DEVICE|Cerebellar repetitive transcranial magnetic stimulation|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
41108312|NCT03653013|BEHAVIORAL|Neuropsychological Consultation|Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL,Generic Scale and Diabetes Module),diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
40925499|NCT00222716|BEHAVIORAL|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
41108313|NCT00571818|PROCEDURE|Oral glucose tolerance test|test done over 2 hours
41108314|NCT00571818|PROCEDURE|IV Glucose Tolerance Test|Done over 4 hours
41108315|NCT03546608|DRUG|Tepotinib|Participants received a single oral dose of tepotinib in Part 1.
41108316|NCT05473871|BEHAVIORAL|Faith in Action|"Interpersonal level: Group exercise classes offered 6 days/week (walking, cardio dance, strength training), Kickoff event~Individual level: Motivational Interviewing calls every 6 months, Health handouts on 14 topics distributed at PA classes"
41108317|NCT05473871|BEHAVIORAL|Faith in Action+|Standard Faith in Action Intervention plus: 1) Health Behavior Change Workshop for FBO leaders; 2) Targeted Messaging; and 3) Empowerment Training for Promotoras
41108318|NCT05473871|BEHAVIORAL|Faith in Action++|Enhanced Condition plus: 1) Foster community collaborations and 2) Provide maintenance support
41108319|NCT03020108|OTHER|Blood sample|2 cc blood samples will be drawn from antecubital vein
41108320|NCT00373555|PROCEDURE|Bronchoscopy|
41108321|NCT02779608|DRUG|intraperitoneal docetaxel|One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
41108322|NCT02779608|DRUG|oral S-1|40mg/m² twice daily on day 1-14 every 3 weeks
41108323|NCT01321411|OTHER|Near Infrared Spectroscopy|"Healthy Volunteers:~Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.~Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV."
41108324|NCT01321411|OTHER|Near Infrared Spectroscopy|"Clinical Volunteers:~Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.~Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB."
41108325|NCT03140735|OTHER|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
41108326|NCT03140735|OTHER|Control group without heart disease|Control group without heart disease
41108327|NCT00542087|DRUG|MK0663, etoricoxib / Duration of Treatment: 6 Weeks|
41108328|NCT00542087|DRUG|Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks|
41108329|NCT05193318|DRUG|Ketamine-assisted psychotherapy|Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
41108330|NCT05875350|PROCEDURE|Intraligamental local anesthetic injection|The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)
41108331|NCT03285191|OTHER|Numerical rating scale|Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
41108332|NCT03285191|OTHER|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
41108333|NCT00092027|DRUG|MK0217, alendronate sodium/Duration of Treatment: 6 months|
41108334|NCT00092027|DRUG|Comparator: placebo / Duration of Treatment: 6 months|
41108335|NCT05200247|DRUG|spesolimab|solution for infusion
41108336|NCT02178917|OTHER|Neurofeedback therapy|
41108337|NCT02178917|OTHER|No neurofeedback therapy|
41108338|NCT02485379|PROCEDURE|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
41108339|NCT03956641|OTHER|Adaptated Physical Activity|Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)
41108340|NCT02981706|PROCEDURE|Arteriovenous Fistula (AVF)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.
41108341|NCT02981706|PROCEDURE|Arteriovenous Graft (AVG)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
41108342|NCT01070888|DRUG|Budesonide/Formoterol|Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
41108343|NCT01070888|DRUG|Budesonide|Budesonide 180mcg, 2 puffs twice daily for 2 weeks
41108344|NCT04477538|OTHER|Post-mastectomy breast reconstruction physical well-being survey|-The survey will ascertain: function status (BREAST Q - Physical Well Being Module and PROMIS upper extremity function), former interaction with physical or occupational therapy, amount of narcotics taken weekly due to chest/neck/breast pain, amount of Tylenol or similar anti-inflammatories taken weekly due to chest/neck/breast pain, and amount of muscle relaxants taken weekly due to chest/neck/breast pain.
41108345|NCT00979056|DRUG|Rifaximin|400 mg per day, oral use, maximum duration 28 days
41108346|NCT00979056|DRUG|Lactose|Coated Tablet, Oral Use
41108347|NCT06351787|BEHAVIORAL|Resting and movement-based focused awareness meditations|Resting and movement-based focused awareness meditations
41108348|NCT04872829|DEVICE|cataract surgery|"All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D."
41108349|NCT04009226|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
41108350|NCT03546634|BIOLOGICAL|Sabin IPV|We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.
41108351|NCT05590650|DRUG|SZKJT(San-Zhong-Kui-Jian-Tang)|The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.
41108352|NCT04948151|DRUG|Sildenafil|Patients will apply 2-gram applications up to 9 times per month.
41108353|NCT04948151|DRUG|Placebo|Patients will apply 2-gram applications up to 9 times per month
41108354|NCT03728595|DIAGNOSTIC_TEST|Venepuncture|A blood sample will be taken for serum bicarbonate
41445605|NCT06293586|PROCEDURE|sub-tenon block|Children in the sub-Tenon group received a sub-Tenon block. Sub-Tenon's anesthesia was performed with 0.5% bupivacaine (0.08 ml/kg), bearing in mind not to exceed the maximum dose. Under sterile conditions, a 19- gauge curved blunt metallic cannula (25 mm) was inserted into sub-Tenon's space and the local anesthetic was injected by the ophthalmologist after the application of surgical drapes.
41108355|NCT03728595|DIAGNOSTIC_TEST|Spirometry|All patients who have not had a spirometry in the 12 months prior to the HAST will undergo one on the day of the HAST.
41108356|NCT03728595|DIAGNOSTIC_TEST|Hypoxic altitude simulation test (HAST)|HAST will be performed as per clinical team request. No changes to this intervention will be made for research purposes.
41108357|NCT00877513|BEHAVIORAL|Smoking cessation|Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
41108358|NCT02560519|DRUG|Albumin solution|"Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.~During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy.The volume replacement therapy is not determined but will be based on the clinical decision."
41108359|NCT02560519|DRUG|Ringers acetate solution|"The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.~During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not determined but will be based on the clinical decision."
41108360|NCT04024631|OTHER|75g glucose beverage (Glucola, Trutol, or similar brand)|Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
41108361|NCT04024631|OTHER|DXA, whole body|Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
41108362|NCT00140972|DRUG|MK0663; etoricoxib / Duration of Treatment:4 Weeks|
41108363|NCT00140972|DRUG|Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks|
41108364|NCT03566186|OTHER|Phototherapy|Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.
41445606|NCT06293586|DRUG|Paracetamol|Children in the control group received IV paracetamol (15 mg/kg) after induction of anesthesia before any surgical intervention.
41445607|NCT04296994|BIOLOGICAL|QL1706|QL1706（PSB205） is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
41445608|NCT06626932|RADIATION|18 FDG (Fludeoxyglucose 18F)|18-f FDG
41445609|NCT01073657|OTHER|Supported Education|Rehabilitation counseling using peers to achieve educational goals
41445610|NCT01073657|OTHER|General Peer Support|Matched peer support for any personal goal other than education
41445611|NCT00444353|DEVICE|DL6049 (injectable poly-L-lactic acid)|
41445612|NCT06563024|DEVICE|18F-FET PET/CT|The enrolled patients receive the 18F-FET PET/CT.
41445613|NCT02010463|OTHER|Exercise|
41445614|NCT02412085|DRUG|Golimumab|"Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)~Maintenance regimen:~* body weight \< 80kg: 50 mg every 4 weeks~* body weight ≥ 80 kg: 100 mg every 4 weeks"
40752250|NCT03114644|OTHER|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
40752251|NCT05130021|DRUG|MAX-40279-01|MAX-40279-01 50mg/70mg
40925500|NCT05934669|DRUG|Intranasal Midazolam|Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.
41108365|NCT03566186|OTHER|Placebo|The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).
41108366|NCT03566186|OTHER|Passive recovery|Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
41445615|NCT04784663|BEHAVIORAL|Messaging|Four brief video messages, each approximately 1.5 minutes in length, focused on facilitating treatment seeking by addressing barriers and improving attitudes. Intervention delivered to participant by study mobile app downloaded to participants' own smartphone.
41445616|NCT04784663|OTHER|Wait list control|one push notification each week thanking individuals for participation, informing them that they will receive messages in the near future or reminding them of the length of the study.
41445617|NCT06356766|OTHER|Telerehabilitation|Modified Duran Protocol via Telerehabilitation
41445618|NCT06356766|OTHER|Face-to-face rehabilitation|Modified Duran Protocol
41445619|NCT01450189|BEHAVIORAL|Standard HIV prevention messages|A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
40752252|NCT05130021|DRUG|regorafenib|regorafenib
40752253|NCT04954443|PROCEDURE|Removing urinary catheter|Removing urinary catheter after vaginal surgery of pelvic organ prolapse
40752254|NCT04132466|DEVICE|Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system|defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator
40752255|NCT00271570|DRUG|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
40752256|NCT00271570|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
40752257|NCT01667614|DRUG|spironolacone 25 mg tablets added to losartan|spironolactone 25 mg once daily added to losartan
40752258|NCT04046575|RADIATION|Intensity Modulated Radiation Therapy|-15 fractions of treatment
40752259|NCT04046575|DRUG|Carboplatin|Begins on day 1 of radiotherapy
40752260|NCT04046575|OTHER|MD Anderson Symptom Inventory (MDASI)-Plus module|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
41108367|NCT06549517|BEHAVIORAL|Cognitive training|MTT24.5 consists in the learning of 40 new datas or knowledges, along 24.5 hours distributted on classes or sessions, during which an average of 3.5 new pieces of knowledge are taught and reinforced through training. Participants are trained using 4 techniques assigned to each new piece of information from a total of 100 available techniques. These techniques include the use of non-dominant skills, literacy in Braille for sighted individuals, and performing 5 actions simultaneously. Each technique is designed to aid in the memorization and learning of new knowledge
40925501|NCT05934669|DRUG|Intranasal Dexmedetomidine|See above
41445620|NCT01450189|BEHAVIORAL|BI: Information-Motivation-Behavioral Skills Model|The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
41445621|NCT01450189|DRUG|Raltegravir|raltegravir (400 mg) administered orally twice daily for 12 weeks
40925502|NCT05934669|DRUG|Intranasal Ketamine|See above
40925503|NCT01768884|DRUG|Nitric Oxide|
41108368|NCT01373346|PROCEDURE|Long limb Roux-en Y reconstruction|After radical gastrectomy, the gastrointestinal tract was reconstructed by Roux-en-Y gastrojejunostomy or esophagojejunostomy. The jejunum was divided at approximately 100-120 cm distal to the ligament of Treitz and the distal limb of the jejunum was then anastomosed along the proximal gastric greater curvature or esophagus. The jejuno-jejunostomy was performed approximately 100 to 120 cm distal from the gastrojejunal or esophagojejunal anastomosis
41108369|NCT01221779|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
41108370|NCT01221779|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
41445622|NCT01450189|DRUG|emtricitabine/tenofovir disoproxil fumarate|emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
40752261|NCT04046575|OTHER|EuroQol (EQ-5D)|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
40925504|NCT01768884|DRUG|Placebo|
40925505|NCT04420078|PROCEDURE|Catheter Ablation|Ventricular fibrillation substrate
41445623|NCT03905980|PROCEDURE|vaginal delivery|pregnancy ended by vaginal delivery
41445624|NCT03905980|PROCEDURE|Cesarean section|pregnancy ended by cesarean delivery
41445625|NCT01462708|DRUG|[18F]MK-9470|Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not \>10% of 10 mCi limit)of \[18F\]MK-9470, followed by PET imaging.
41108371|NCT05675956|DEVICE|Experimental group with 100% intensity setting on Apollo Neuro device|The group will have the device set to 100% intensity at one of their two experimental visits.
41108372|NCT05675956|DEVICE|Active Comparator group with 10% intensity setting on the Apollo Neuro device|The group will have the device set to 10% intensity at one of their two experimental visits.
41108373|NCT04421365|DEVICE|neurofeedback brain-computer interface (BCI)|The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.
41108374|NCT05247034|DIETARY_SUPPLEMENT|Cocoa|Each capsule of cocoa powder contains 12.5 mg of flavonoids, providing a total of 50 mg per day.
41108375|NCT05247034|OTHER|Placebo|Each capsule contains 500 mg of methylcellulose
41108376|NCT03814668|DIETARY_SUPPLEMENT|Probiotic|Intake of probiotic
41108377|NCT03814668|DIETARY_SUPPLEMENT|Lactase|Intake of lactase
41108378|NCT03814668|OTHER|Placebo|Intake of placebo
41108379|NCT01795144|DRUG|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
41108380|NCT01795144|DRUG|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
41108381|NCT00189202|DRUG|Sirolimus|Thymoglobulin induction, sirolimus and no maintenance corticosteroid
41108382|NCT03506373|DRUG|Ibrutinib|Given PO
41108383|NCT03506373|DRUG|Ixazomib Citrate|Given PO
41108384|NCT03506373|OTHER|Laboratory Biomarker Analysis|Correlative studies
41108385|NCT03506373|OTHER|Pharmacodynamic Study|Correlative studies
41108386|NCT03506373|OTHER|Pharmacokinetic Study|Correlative studies
41108387|NCT00099619|DRUG|exenatide/insulin glargine|Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels
41108388|NCT00099619|DRUG|insulin glargine/exenatide|Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
41108389|NCT02145182|DRUG|Eculizumab|Eculizumab is a complement component 5 inhibitor.
41108390|NCT02145182|DRUG|Placebo|0.9% sodium chloride
41108391|NCT02813252|GENETIC|JCAR015|No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
41445626|NCT00649987|DRUG|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
41108392|NCT04589000|OTHER|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
41108393|NCT05823350|OTHER|Abdominal massage|Abdominal massage after colonoscopy
41108394|NCT01870479|OTHER|Live music|
41108395|NCT01870479|OTHER|Taped music|
41108396|NCT02403323|DRUG|Etrolizumab|105 mg etrolizumab subcutaneous administration once every 4 weeks
41108397|NCT00680342|DRUG|Silymarin|700mg dose (5 pills, three times daily) for 24-week treatment period
41445627|NCT00649987|DRUG|VoSpire® ER Tablets 8 mg|8mg, single dose fed
41445628|NCT00526188|DRUG|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
41445629|NCT02781883|DRUG|BP1001 in combination with Ventoclax plus decitabine|BP1001 in combination with Ventoclax plus decitabine
41108398|NCT00680342|DRUG|Silymarin|420mg dose (5 pills, three times daily) for 24-week treatment period
41108399|NCT00680342|OTHER|Placebo|Placebo (5 pills, three times daily) for 24-week treatment period
41108400|NCT03443037|DRUG|amantadine sulphate|
41108401|NCT05949125|OTHER|Cyclophosphamide (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
41445630|NCT02781883|DRUG|BP1001 plus decitabine|BP1001 plus decitabine in ventoclax intolerant or resistant subjects
41108402|NCT05949125|OTHER|Fludarabine (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
41445631|NCT02795572|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 2000 IU oral once daily
41445632|NCT02795572|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6 100 mg oral once daily
41445633|NCT02795572|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 100 mcg oral once daily
41445634|NCT02795572|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
41445635|NCT02938351|BEHAVIORAL|Collaborative care|Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
41445636|NCT05775718|DRUG|Zoster Vaccine Recombinant|Injection
41445637|NCT00354835|DRUG|Cyclophosphamide|Given IV
41445638|NCT00354835|BIOLOGICAL|Dactinomycin|Given IV
41445639|NCT00354835|DRUG|Irinotecan Hydrochloride|Given IV
41445640|NCT00354835|OTHER|Laboratory Biomarker Analysis|Correlative studies
41445641|NCT00354835|OTHER|Questionnaire Administration|Ancillary studies
41445642|NCT00354835|RADIATION|Radiation Therapy|Undergo radiotherapy
41445643|NCT00354835|DRUG|Vincristine Sulfate|Given IV
41108403|NCT05949125|DRUG|R-TM123|Intravenous infusion over 20 days
41445644|NCT06558656|DRUG|NTQ5082 capsule|"Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle.~Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle."
41108404|NCT05949125|DRUG|Allo-RevCAR01-T|A single dose of Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1. Allo-RevCAR01-T will not be administered again within this study.
41108405|NCT01026636|DRUG|Ceftobiprole|
41108406|NCT01301196|BEHAVIORAL|Educational workshop|3h attendance at educational workshop plus self-monitoring
41108407|NCT03026036|RADIATION|PET Scan with Raclopride|A subsample (21 per group) will complete the PET imaging.
41108408|NCT03753594|DEVICE|tissue oxygenation saturation|tissue oxygenation saturation
41445645|NCT06627725|BEHAVIORAL|Patient-Family Communication|Patient-Family Communication
41108409|NCT06553014|OTHER|Endovascular Plug Embolization|Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome
41108410|NCT03273348|PROCEDURE|Oncoplastic breast surgery|, Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
41445646|NCT05997108|DIAGNOSTIC_TEST|CBC|Platelet and red blood cell volume indices
41108411|NCT03978533|BEHAVIORAL|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
41108412|NCT04994054|DIETARY_SUPPLEMENT|silkworms (Bombyx mori L.) pupae extracts group|silkworms (Bombyx mori L.) pupae extracts 2,400 mg/day for 12 weeks
41108413|NCT04994054|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,400 mg/day for 12 weeks
41108414|NCT01198340|PROCEDURE|PC-FNB with basal administration of local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.
41108415|NCT01198340|PROCEDURE|PC-FNB without basal local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
41108416|NCT03382080|OTHER|Dream School Program|The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
41108417|NCT03382080|OTHER|Mental Health Support Team|"MHST is also a whole school project but aimed at specific students at risk of dropping out. It is a systematisation of the student services through~1. Co-location of services and staff working in services~2. One open door to increase accessibility to the services and staff for students~3. Focus on the transition from lower to upper secondary school~4. Close follow-up of students at risk to ensure tailored help to each student~5. Early intervention and follow up when students starts being absent from school This work demands cross- and multidisciplinary collaborations within the MHST, between MHST and school leadership, and between lower and upper secondary schools."
41271077|NCT03396328|BEHAVIORAL|Intensive low salt dietary education by smartphone application|Participants are provided with information on food and recipe, which allows them to record daily meals in their applications. Through the mobile application, the participants receive information on daily salt intake. Based on this information, the clinical nutritionist coach sets a goal for low salt diet and provides feedback to the patients through the mobile application. The clinical nutritionist coach checks the activity of the user more than twice a week and sends in-app messages to maintain compliance.
41445647|NCT05411913|DRUG|GoodFOR Pain|GoodFOR Pain is a FDA registered topical analgesic.
41445648|NCT05411913|DRUG|Icy Hot|a FDA OTC registered topical analgesic.
41445649|NCT05411913|DRUG|Tiger Balm|a FDA OTC registered topical analgesic
41445650|NCT05411913|DRUG|Bengay|a FDA OTC registered topical analgesic.
41445651|NCT05411913|DRUG|CBD Clinic Muscle and Joint Pain Relief Ointment|a non FDA registered topical analgesic.
41445652|NCT05411913|DRUG|CBD FX CBD Muscle and Joint Cream: Cooling Formula|a non FDA registered topical analgesic.
41445653|NCT05411913|DRUG|Essential Wholesale Muscle Gel|a non FDA registered topical analgesic.
41445654|NCT05411913|DRUG|Extract Labs Muscle Cream|a non FDA registered topical analgesic.
41445655|NCT05226533|DRUG|DWRX2003|Intramuscular injection of DWRX2003
41445656|NCT05226533|DRUG|Placebo|Intramuscular injection of placebo
41445657|NCT04994847|DRUG|Amyloid and Tau PET|NAV4694 and MK6240 PET scans completed every two years
41445658|NCT02030223|PROCEDURE|Transversus abdominis plane block|ultrasound guided transversus abdominis plane block
41445659|NCT04057287|OTHER|No intervention|No intervention
41445660|NCT06420687|DEVICE|Clinically prescribed prosthesis|Clinically prescribed prosthesis:
41445661|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + 1-DOF|1-DOF wrist rotation and1-DOF hand
41445662|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + Wrist flexion +1-DOF|2-DOF wrist (rotation and flexion) and 1-DOF hand
40752262|NCT04046575|OTHER|SF-12|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
40752263|NCT04046575|OTHER|MOS Social Support Measure|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
41108418|NCT00987961|BEHAVIORAL|Linkage|This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
41445663|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + Multi DOF hand|1-DOF wrist rotation and multi-DOF hand
41445664|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + wrist flexion + Multi DOF hand|2-DOF wrist (rotation and flexion) and multi-DOF hand
40752264|NCT04046575|OTHER|CES-D|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
40752265|NCT04046575|PROCEDURE|Blood for ctDNA (optional)|-Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up
41445665|NCT06585787|DRUG|KarXT|Specified dose on specified days
41445666|NCT06585787|DRUG|Placebo|Specified dose on specified days
41108419|NCT00573833|OTHER|questionnaire administration|
41108420|NCT00573833|PROCEDURE|quality-of-life assessment|
41108421|NCT00573833|RADIATION|brachytherapy|
41108422|NCT03312309|PROCEDURE|personal embryo transfer|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
41108423|NCT00768651|DRUG|Pantoprazole|Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
41108424|NCT00768651|DRUG|Sitagliptin|Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
41108425|NCT03574844|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae, dose 500|Experimental arm
41108426|NCT03574844|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae, dose 1000|Experimental arm
41108427|NCT03574844|DIETARY_SUPPLEMENT|Placebo|Placebo comparator arm
41108428|NCT04988048|BIOLOGICAL|COVID-19 vaccines|"Gam-COVID-Vac Gamaleya National Center for Epidemiology and Microbiology - Russia. Non-replicative viral vector. Multi-dose vial (5 doses in 3 mL) Single-dose vial (1 dose in 0.5 mL). Intramuscular T° less than -18 ° C~BBIBP-CorV Beijing Institute of Biological Products - People's Republic of China. Inactivated viruses. Single-dose vials (1 dose in 0.5 mL) or multi-dose vial (2 doses per vial). Intramuscular T° 2 to 8 ° C~ChAdOx1 nCoV-19 vaccine AZD1222 AstraZeneca-Oxford - United Kingdom. Non-replicative viral vector. Multi-dose vial (10 doses in 5 mL). Intramuscular T°: 2 to 8 ° C~mRNA-1273 or Spikevax Moderna Switzerland GmbH and the National Institute of Allergy and Infectious Diseases (NIAID) of the United States. mRNA. Multi-dose vial (maximum 15 doses per 0.5ml vial). Intramuscular. T°-15 ° to -50 °"
41108429|NCT02692742|DRUG|Myelo001|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
41108430|NCT02692742|DRUG|Placebo|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
40752266|NCT04046575|PROCEDURE|Blood for SCCA|-Collected at pre-treatment, completion of therapy, and 6 month follow-up
40752267|NCT04046575|DRUG|Paclitaxel|Begins on day 1 of radiotherapy
40752268|NCT02373163|DRUG|Hydrochlorothiazide|Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
40752269|NCT02373163|DRUG|Amlodipine|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
41108431|NCT04154241|DIAGNOSTIC_TEST|PET/MR scan|"The PET will be performed with (68Ga)-labeled somatostatin analogue since it was proven to be superior to other NET PET tracers in terms of lesion detection and sensitivity \[11\] \[12\]. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, diffusion-weighted images with multiple b values and apparent diffusion coefficient (ADC) maps.~All images will be analyzed with big data tools such as radiomics and texture analysis in order to integrate all image parameters and different contrasts into individual tumor status. Then, accuracy, sensitivity and specificity will be evaluated by correlation of this data collection and analysis method with histological biomarkers (for example, Ki67 level) and treatment results."
41108432|NCT06493214|BEHAVIORAL|Physical activity|Participants will be asked to complete three eight-minute InPACT at Home exercise videos per day, five days a week, for 12 weeks.
41108433|NCT02639013|PROCEDURE|transducer technique|the nurses will receive the intervention ( the transducer method) to measure intraabdominal pressure intraabdominal hypertension and how to measure intraabdominal pressure in the third section
41108434|NCT06121830|DRUG|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 4 weeks
41108435|NCT06121830|DRUG|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 4 weeks
41108436|NCT06121830|DRUG|Placebo|Placebo, tablet, orally, once daily for up to 4 weeks
41108437|NCT05603520|OTHER|Collection of Clinical Data|prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms
41108438|NCT04580199|PROCEDURE|thyroidectomy|to excise the thyroid gland
41108439|NCT05522699|BEHAVIORAL|Cough suppressive therapy|"The cough suppressive therapy based on the treatment regime Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough (PSALTI) developed by S. Chamberlain et al (Thorax. 2017 Feb;72(2):129-136)."
41108440|NCT05522699|BEHAVIORAL|General healthy lifestyle instructions|The general healthy lifestyle instructions are based on the recommendations from the The Public Health Agency of Sweden.
41108441|NCT06248359|DRUG|L-Arginine hydrochloride|Postoperative administration of L-Arginine hydrochloride before incidence of CS-AKI
41108442|NCT00336232|DRUG|Vitamin K|phylloquinone (vitamin K1) 500 mcg daily in third month
41108443|NCT01335932|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
41108444|NCT01335932|DRUG|Placebo|"For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications."
41108445|NCT04040530|PROCEDURE|CT-guided cryoablation|Percutaneous computed tomography guided cryoablation with the patient in sedation or general anaesthesia.
41108446|NCT04040530|PROCEDURE|Partial nephrectomy|Surgical removal of the renal cancer, leaving the healthy renal tissue. Surgery is either done laparoscopically, robot-assisted laparoscopically or as an open surgery. The patient is under general anaesthesia.
41108447|NCT05510544|DRUG|Plerixafor,G-CSF|"G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8.~Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours."
41108448|NCT04581824|DRUG|Dostarlimab|Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
41108449|NCT04581824|DRUG|Pembrolizumab|Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
41108450|NCT04581824|DRUG|Chemotherapy|"Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision."
41108451|NCT00209443|DRUG|Gadodiamide Injection|
41108452|NCT06465563|DRUG|SHR-8068|SHR-8068
41108453|NCT06465563|DRUG|Adebrelimab|Adebrelimab
41108454|NCT06465563|DRUG|Cisplatin|Cisplatin
41108455|NCT06465563|DRUG|Gemcitabine|Gemcitabine
41108456|NCT06372912|PROCEDURE|Sleeve gastrectomy, Roux-en-Y gastric bypass, mini-gastric bypass, SADIS, intragastric balloon insertion, and gastric band placement are bariatric surgeries.|Sleeve gastrectomy: reduces stomach size. Roux-en-Y gastric bypass: limits calorie absorption. Mini gastric bypass: achieves weight loss with fewer incisions. SADIS: combines sleeve gastrectomy with small bowel bypass. Intragastric balloon: reduces stomach volume. Gastric banding: restricts food intake.
40752270|NCT02373163|DRUG|Telmisartan|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
41108457|NCT00652301|DRUG|ezetimibe|ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
41108458|NCT00652301|DRUG|Comparator: Placebo (unspecified)|matching placebo tablet. Duration of Treatment 31 Weeks.
41108459|NCT00652301|DRUG|simvastatin|simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
41108460|NCT06554080|PROCEDURE|Platform-switched implant placement|NobelParallel or NobelActive implants placed
41108461|NCT06554080|PROCEDURE|Platform-matched implant placement|Nobel Brånemark, NobelSpeedy Groovy implants placed
41108462|NCT05156450|DRUG|TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone|Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
41108463|NCT04620018|DRUG|Amoxicillin|Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.
41108464|NCT03896841|OTHER|Observation|Ocular Findings Observations
41108465|NCT01979354|DRUG|Spinal morphine|0.15 mg spinal morphine
41108466|NCT00460785|DRUG|Opioid|
41108467|NCT04060537|OTHER|Laboratory analysis of samples|RNA sequencing, immunohistochemistry, immunofluorescence, and cytometry of tumour tissues
41108468|NCT04060537|OTHER|Application of machine learning|Using machine learning to interrogate data generated from analysis of Renal Cell Cancer tumours using RNA sequencing, immunohistochemistry, immunofluorescence, cytometry, and MRI imaging of tumours.
41108469|NCT02523391|DRUG|TA-8995|Capsule
40752271|NCT03217188|RADIATION|conventionally fractionated full dose re-irradiation|re-irradiation \[60-70 Gy (RBE) in 2 Gy (RBE) fractions
40752272|NCT03217188|RADIATION|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break \[+/- 2 weeks\], repeated up to 4 cycles)."
41108470|NCT02523391|DRUG|TA-8995|Tablet
41108471|NCT05859971|DRUG|SLN mapping using technetium-99m +/- isosulfan blue dye|The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.
41108472|NCT05859971|DEVICE|SLN mapping with ICG fluorescence using the Asimov Platform|2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.
41108473|NCT00815750|OTHER|Information Gathering|An information gathering phase leading to development of a new decision aid.
41108474|NCT00815750|OTHER|Decision Aid|To test the newly developed decision aid.
41108475|NCT02487316|DRUG|crizotinib|crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
41108476|NCT06009419|OTHER|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given a dual task program in addition to the program given to the control group.
41108477|NCT04577625|DIETARY_SUPPLEMENT|Lactobacillus reuteri (L. reuteri)|L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
41108478|NCT04077151|BEHAVIORAL|PrEP Demonstration Project|In phase 2, a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth will be developed by incorporates the PK data from phase 1 and data gathered from focus groups and in-depth interviews with young transgender women and transgender men. During phase 3, this intervention will be given to the experimental arm and tested versus a standard-of-care control group.
41108479|NCT02414204|DRUG|Sildenafil|Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
41108480|NCT02414204|OTHER|Placebo|Placebo will be over encapsulated to identical to drug comparison
41108481|NCT03768843|PROCEDURE|Harms technique|Atlantoaxial fusion
41108482|NCT05638620|DRUG|stellate ganglion block with 0.5% bupivacaine|"The stellate ganglion block is being done on both sides of the neck. The stellate ganglion block will be performed on the right side at the first visit. The procedure will be repeated on the left side one week after the first injection.~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. Similar to a phase 1 clinical trial, the main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms. As a general rule, phase 1 studies require a low number of patients, typically 12-20 subjects. There is considerable uncertainty regarding long COVID as a disease state, so data from even small numbers of patients in a well-designed clinical trial will make steps towards reducing that uncertainty."
41108483|NCT05968833|BEHAVIORAL|iParent2Parent Program|iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric kidney transplant recipients who are trained to offer vital peer support and mentorship.
41108484|NCT00456274|PROCEDURE|Frequent baseline blood sampling|3 ml of blood sampled every 10 minutes for a total of 8-12 hours
41108485|NCT04456348|OTHER|there is no intervention|There is no intervention
41108486|NCT04178291|DEVICE|Ultrasonic scaler and Gracey currettes|Full mouth subgingival debridement using ultrasonic scaler and Gracey currettes
41108487|NCT04178291|DEVICE|Air polishing with erythritol powder|Air flow PLUS
41108488|NCT02751580|OTHER|Telemedicine|Attend a virtual visit via the JeffConnect telehealth app
40752273|NCT01777529|BIOLOGICAL|MMR Vaccine|Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
41108489|NCT02751580|OTHER|Questionnaire Administration|Ancillary studies
41108490|NCT04158154|OTHER|Evidence-based fixed-dose combination protocol based treatment|The intervention has been adapted based on a local needs' assessment including exploration of health care workers and patient's knowledge, attitudes, and behaviors related to HTN, causes, consequences, and treatment. Implementation pathways have been developed with particular attention to overcoming modifiable barriers to HTN treatment and control across capability, intentional, and system domains using CFIR. Sites will randomly be assigned to receive either: Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 2 separate pills); Step 3 amlodipine 10 mg + losartan 100 mg (as 4 separate pills); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo) or Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 1 single pill combo); Step 3 amlodipine 10 mg + losartan 100 mg (as 2 single pill combo); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo).
40752274|NCT06478940|DRUG|3 mixtatin pulpotomy|pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin
41108491|NCT01437358|OTHER|Epidural analgesia|The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
41108492|NCT04812938|DIAGNOSTIC_TEST|Patients with Ovarian cancer and pap test available|Define the possibility to detect through the pap test the presence of ovarian cancer cells in vaginal smear in patients with no evidence of ginecological malignancies.
41108493|NCT02469467|DIETARY_SUPPLEMENT|VS-505|VS-505 is orally administered with meal for 8 weeks
41108494|NCT01491698|PROCEDURE|Roux-en-Y pouch reconstruction (RYP)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
41108495|NCT01491698|PROCEDURE|conventional Roux-en-Y reconstruction (RYC)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
41108496|NCT00250562|DRUG|valsartan plus hydrochlorothiazide|
40752275|NCT06478940|DRUG|MTA pulpotomy|pulp treatment with applying MTA
40752276|NCT02731859|DEVICE|Insertion of EndoBarrier for approximately one year|Insertion of EndoBarrier for approximately one year then explantation and follow-up
40752277|NCT06024161|OTHER|Weight gain|≥5% weight gain
40752278|NCT06024161|OTHER|Weight loss|≥5% weight loss after arthroplasty
40752279|NCT06024161|OTHER|Weight unchanged|\<5% weight change after arthroplasty
41108497|NCT06059001|DRUG|OMO-103|Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion
41108498|NCT06059001|DRUG|Nab-Paclitaxel|IV infusion - Standard of Care
41108499|NCT06059001|DRUG|Gemcitabine|IV infusion - Standard of Care
41108500|NCT00237107|PROCEDURE|Curretage|
41108501|NCT00709644|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid.|
41108502|NCT03058991|BEHAVIORAL|Distress Tolerance Intervention|See arm/group description.
41108503|NCT03058991|BEHAVIORAL|Working Memory Intervention|See arm/group description.
41108504|NCT03058991|BEHAVIORAL|Control Informational Intervention|See arm/group description.
41108505|NCT02573818|DEVICE|SEDASYS System|propofol sedation with the SEDASYS System
41108506|NCT04986683|DIAGNOSTIC_TEST|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate the presence, type, and severity of brain abnormalities in enrolled subjects.
41108507|NCT04986683|BEHAVIORAL|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language, and other neurocognitive functions potentially affected by drug-resistant epilepsy.
41108508|NCT04292093|BEHAVIORAL|Home rehabilitation training|The rehabilitation training will be provided via Lumosity platform. Participants will be asked to play computer video-games aimed at strengthening specific sub-functions pertaining to the macro area of executive functions for 30 minutes a day, 5 days a week, for a total of 8 weeks. Specifically, 20 games out of a total of 64 available games provided by the platform have been selected. The selected games are aimed at training 4 cognitive skills: memory, attention, cognitive flexibility and problem solving. In particular, 5 different games were chosen for each cognitive ability.
41108509|NCT04292093|BEHAVIORAL|Home control activity|The control group will watch a series of animated / TV shows suitable for the sample age, again for 30 minutes a day, 5 days a week, for 8 weeks. The videos will be provided by the experimenter and participants will watch them on their personal computer. At the end of each videos, participants will answer a series of multiple-choice questions aimed at evaluating the attention deployed to the content of the videos.
41108510|NCT01426750|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
41108511|NCT00802490|DEVICE|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
41108512|NCT00802490|DEVICE|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
41108513|NCT06357819|DEVICE|INSTI HCV Self Test|Each participant was provided with contrived INSTI membrane units by the study observer, in random order, and was asked to interpret the results using the INSTI HCV ST Instructions for Use.
41108514|NCT02552186|OTHER|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
41108515|NCT06466902|OTHER|Quality assessment of D2 lymphadenectomy using the PhotoNode Score|"During the surgical procedure, a set of 5 high quality laparoscopic intraoperative images of the surgical field will be put on record. Photographs will be taken at the end of the lymphadenectomy phase, before the reconstructive phase begins.~Three surgeons will review the images. Quality of D2 lymphadenectomy will be assessed independently rating eight node stations (1, 5, 6, 7, 8a, 9, 11p and 12a), based upon the evaluation of the 5 images. Each node station will be given a score from 0 to 3, corresponding to a judgment of Unevaluable (0), Poor (1), Doubtful (2) or Excellent (3) lymphadenectomy respectively, in that specific node station.~A total score for each patient will be independently obtained from each reviewer ranging from a minimum of 7 (poor lymphadenectomy) to a maximum of 24 (excellent lymphadenectomy). The PNS for each patient will originate from the average score among the three reviewers."
41108516|NCT02488200|OTHER|No intervention|No intervention
41108517|NCT01897233|DRUG|Lumacaftor|
41108518|NCT01897233|DRUG|Ivacaftor|
41108519|NCT04852146|PROCEDURE|Electronic feedback|Feedbacks have been identified as one of the most effective interventions to improve practices and organisations in health care institutions. It is also a tool for facilitating and coordinating practice registers, improving the contribution of data producers and the quality of data.
41108520|NCT04178954|DIAGNOSTIC_TEST|semen fluid analysis|semen fluid analysis
41108521|NCT00155363|DEVICE|conventional artificial kidney (AK) vs. high flux AK|
41108522|NCT01486550|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg minimum
41108523|NCT01486550|DRUG|Sodium Chloride 9mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
41108524|NCT02685033|DRUG|Dalbavancin|
41108525|NCT02685033|DRUG|Comparator|
41108526|NCT00947596|DRUG|atropine sulfate|dry powder for inhalation
41108527|NCT00947596|DRUG|atropine sulfate|intramuscular injection
41108528|NCT05647044|DEVICE|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
41108529|NCT05647044|DEVICE|placebo intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
41108530|NCT05966779|OTHER|modified CDT physical therapy protocol, based on Godoy's Method|modified CDT physical therapy protocol
41108531|NCT01241292|BIOLOGICAL|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
41108532|NCT01241292|BIOLOGICAL|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
41108533|NCT01114945|DEVICE|McGrath|Intubation with the McGrath device
41108534|NCT01114945|DEVICE|GlideScope|Intubation with the GlideScope device
41108535|NCT01114945|DEVICE|Direct Macintosh Laryngoscopy|Intubation with Direct Macintosh Laryngoscope
41108536|NCT01114945|DEVICE|Video-Mac|Intubation with the Video-Mac device
41108537|NCT05493124|DRUG|Manpixiao|A traditional Chinese medicine composition
41108538|NCT05493124|DRUG|Active comparator|Other drugs that may have therapeutic effects
41108539|NCT04852432|DEVICE|high flow nasal cannula|The heated air is administered at a rate of 2L/kg/min using an Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand). Inhalation oxygen concentration starts with 50%.
41108540|NCT04852432|DEVICE|nasal prong|Oxygen is administered via nasal prong
41108541|NCT05271188|PROCEDURE|Infiltration of local anaesthetic between popliteal artery and posterior knee capsule|Adductor canal block (ACB) is a popular peripheral nerve block that has been shown to decrease pain significantly and thereby opioid consumption with minimal effect on quadriceps function \[8\]. Though ACB provides analgesia to the peripatellar and intra-articular aspect of knee joint, it does not relieve posterior knee pain which is moderate to severe in intensity \[9, 10\]. The recent technique of an ultrasound (US)-guided local anesthetic infiltration of the interspace between popliteal artery and the capsule of posterior knee (IPACK) has shown to provide significant posterior knee analgesia without affecting the common peroneal nerve (CPN) \[11\]. We postulated that IPACK will provide better pain relief and improve knee function in the immediate postoperative period compared to ACB
41108542|NCT02156609|DEVICE|Percutaneous ventricular support with the HeartMate PHP|The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
41108543|NCT02955524|DRUG|Tetracaine 0.5%|One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
41108544|NCT02955524|DRUG|Lidocaine hydrochloride ophthalmic gel 3.5%|1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
41108545|NCT05274217|BEHAVIORAL|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
41108546|NCT03002844|DRUG|EGFR-TK Inhibitor|EGFR-TKI (gefitinib 250mg per day)
41108547|NCT03002844|DRUG|EGFR-TKI|EGFR-TKI (gefitinib 250mg per day)
41108548|NCT03002844|DRUG|EGFR-TKI and Chemotherapy|pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
41108549|NCT04033432|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
41108550|NCT03769233|BEHAVIORAL|Mindfulness-based Intervention|MBI will be delivered in group format, 90 minutes per week, for 5 consecutive weeks with 6-15 participants per group.
41108551|NCT02336776|OTHER|Functional electrical stimulation|"Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.~Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session."
41108552|NCT00003880|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
41108553|NCT00003880|DRUG|carboplatin|
41108554|NCT00003880|DRUG|paclitaxel|
41108555|NCT00402155|BEHAVIORAL|Stress on visual discomfort|Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
41108556|NCT02511197|DRUG|68Ga-NOTA-PRGD2|68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans
41108557|NCT02511197|DEVICE|PET/CT|
41108558|NCT04470258|OTHER|ELMO PROJECT AT COVID-19: STUDY IN HUMANS|The Elmo system will be applied to 10 patients with hypoxemic respiratory failure by COVID-19 and its effectiveness will be assessed by analyzing the physiological variables and the patient's comfort, as well as their clinical outcomes (need for tracheal intubation) and recovery time. Hypoxemic respiratory failure and need for O2.
41108559|NCT04470258|DEVICE|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY|After testing for the following requirements: offering CPAP, ensuring the maintenance of alveolar ventilation without CO2 rebreathing, monitoring intra-ELMO pressure, minimizing adverse effects of the system such as noise, face temperature, airway dryness and comfort global; tests will be carried out on healthy volunteers using prototypes of the Elmo system and assessing whether their effectiveness in providing positive airway pressure and their usability from the perspective of their primary users (doctor, physiotherapist and nurses) and the volunteer's comfort . With this, realistic simulations will be carried out, centered on the evaluation based on heuristic principles.
41108560|NCT01001078|DEVICE|I-Gel supraglottic airway device|2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.
41108561|NCT01001078|DEVICE|LMA Supreme supraglottic airway device|In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
41108562|NCT01001078|DEVICE|Standard endotracheal tube|In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted
41108563|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 28 days
41108564|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 14 days
41108565|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
41108566|NCT02732678|DRUG|PROPRANOLOL|
41108567|NCT05911750|DIAGNOSTIC_TEST|Anal pap smear and oral swab for cytology and HPV testing|Anal and oral swab sampling for HPV detection (polymerase chain reaction) and cytology
41108568|NCT00382135|DRUG|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
41108569|NCT00382135|DRUG|placebo|Placebo tablet taken by mouth once a day for 40 weeks
41108570|NCT03644329|OTHER|Control group|The volunteers will not performed the interventions.
41108571|NCT03644329|OTHER|Lower-load resistance training (LL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
41108572|NCT03644329|OTHER|Higher-load resistance training (HL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
41108573|NCT03644329|OTHER|Higher-volume resistance training (HV)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
41108574|NCT02104765|DRUG|LY2951742|Administered subcutaneously.
41108575|NCT02104765|DRUG|Placebo|Administered subcutaneously.
41108576|NCT06189391|DRUG|CN201|"In fixed dosing group, patients will be administered with CN201 by intravenous infusion on Day 1 of each week for 3 consecutive weeks, followed by 1 week off for 4 weeks as a treatment cycle.~Patients in step-up dosing group will be administered with CN201 by intravenous infusion on Day 1 of each week for 3 consecutive weeks (without treatment off week). Patients who complete 4 treatment cycles and remain in complete response (CR) or partial response (PR) may also be considered by the investigator for 2-weekly dosing (Q2W, window: -3 days, 4 weeks in a treatment cycle), which allows further comparative observation of the long-term efficacy and safety of Q2W. Treatment will be continued untill confirmed disease progression, intolerable toxicity, withdrawal of consent, patient being lost to follow-up, receipt of other antitumor therapy, death or study termination by sponsor, whichever occurs earlier, or up to 12 months in the absence of disease progression."
41108577|NCT04304859|DIAGNOSTIC_TEST|BASIC|Validation
41108578|NCT04688268|DRUG|deep neuromuscular blockade|Train of Four=0/4, Post tetanic count 1-2
41108579|NCT05924438|DRUG|Delstrigo|Treatment Group 1 Participants will receive Doravirine, as part of a fixed-dose oral combination with lamivudine and tenofovir disoproxil fumarate (DOR/3TC/TDF, Delstrigo)tablets which are to be administered orally and once daily.
41108580|NCT05924438|DRUG|KOCITAF|Treatment Group 2 Participants will receive dolutegravir, as part of a fixed-dose oral combination with tenofovir alafenamide plus emtricitabine (DTG/TAF/FTC, KOCITAF) tablets which are to be administered orally and once daily.
41108581|NCT00082810|DRUG|fulvestrant|Given intramuscularly
41108582|NCT00082810|DRUG|tipifarnib|Given IV
41108583|NCT00369733|DRUG|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
41108584|NCT02232178|DRUG|2 100mg Xaracoll implants|
41108585|NCT02232178|DRUG|3 100mg Xaracoll implants|
41108586|NCT02232178|DRUG|150mg Bupivacaine HCl injection|
41108587|NCT06356116|OTHER|Usual care|"During hospitalization, physical therapist visits the patient once or twice on day one or two post-operative (treatments including bedside standing, ambulation, stepping, active-assisted range of motion exercises).~Educational material will be given at discharge from hospital."
41108588|NCT06356116|OTHER|Accelerated rehabilitation|"Physical therapist visits 5 times during hospitalization, including~1. Pre-operatively: instruction regarding range of motion exercises, use of assistive device.~2. Post-operative day zero: bedside standing, ambulation, stepping, active-assisted range of motion exercises.~3. Post-operative day one: visit #1 continuing the day-zero exercises;~4. Post-operative day one: visit #2 mini-squat against wall; stair negotiation training (1/2 flight).~5. Post-operative day two: continuing the day-zero exercises; stair negotiation (1 flight); discharge from hospital in the afternoon.~After discharge from hospital: post-operative day three \~ week 4: telerehabilitation"
41108589|NCT06518187|OTHER|Assessing the impact of three different catheter advancement techniques on needle tip movement during intravenous insertion|Each participant will perform 3 simulated IV catheter insertions using each of the specified techniques. Participants will use the instrumented 16ga IV catheter to insert into the peripheral vascular access simulator. Needle tip movement (from intent of catheter advancement to 5mm of advancement off the needle) will be measured with 0.2mm accuracy using the electromagnetic tracking technology of the simulator. Data collected will include needle movement after simulated vein punction and during initial catheter advancement off the needle (in mm) which will be recorded within the simulation program and output as a de-identified Excel file
41108590|NCT05676190|COMBINATION_PRODUCT|CIK combined with chemotherapy group|Combination of chemotherapy and autologous cytokine induced killer cells
41108591|NCT05676190|COMBINATION_PRODUCT|CIK combined immunotherapy group|Combination of immunotherapy and autologous cytokine induced killer cells
41108592|NCT05676190|COMBINATION_PRODUCT|CIK combined targeted therapy group|Combination of targeted therapy and autologous cytokine induced killer cells
41108593|NCT05676190|COMBINATION_PRODUCT|CIK in combination with other therapies|CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)
41108594|NCT04514419|DRUG|HS627|Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).
41108595|NCT04514419|DRUG|Pertuzumab|Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).
41108596|NCT02551055|DRUG|MLN1117|MLN1117 Tablets
41108597|NCT02551055|DRUG|TAK-659|TAK-659 Tablets
41108598|NCT02551055|DRUG|Alisertib|Alisertib Tablets
41108599|NCT02551055|DRUG|Paclitaxel|Paclitaxel intravenous infusion
41108600|NCT02551055|DRUG|Docetaxel|Docetaxel intravenous infusion
41108601|NCT01340079|BEHAVIORAL|virtual world|health education using virtual world Second Life
41108602|NCT01340079|BEHAVIORAL|face to face|health education delivered in face to face groups
41108603|NCT02867566|DRUG|IBI301 plus CHOP|Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
41108604|NCT02867566|DRUG|Rituximab plus CHOP|Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
41108605|NCT02618239|DIETARY_SUPPLEMENT|Bimuno Galacto-oligo-saccharide|
41108606|NCT05037344|BEHAVIORAL|Cognitive-behavioral psychotherapy|The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
41108607|NCT03062137|DIAGNOSTIC_TEST|blood gas sampling|
41108608|NCT00618540|BIOLOGICAL|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
41108609|NCT00618540|DRUG|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age \<12 months)
41108610|NCT00618540|DRUG|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age \<12 months)
41108611|NCT00618540|PROCEDURE|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
41108612|NCT01233050|DRUG|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
41108613|NCT01233050|DRUG|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
41108614|NCT03280836|BEHAVIORAL|Exercise|"All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.~The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max."
41108615|NCT05587309|DRUG|BLI5100|Orally via tablet
41108616|NCT05587309|DRUG|PPI Control|Orally via tablet
41108617|NCT06440824|DRUG|Romiplostim N01|2.0 µg/kg, subcutaneous injection, once a week, up to a maximum of 8 weeks. Stop medication when platelet count increases by 50 × 109/L or more compared to before medication
41108618|NCT06440824|DRUG|Recombinant Human Thrombopoietin|30000 U/d, subcutaneously injected once a day, for a maximum of 8 weeks. Medication should be stopped when platelets increase by 50 × 109/L or more compared to before medication
41108619|NCT02665130|OTHER|Tai-chi plus Indacaterol|Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
41108620|NCT02665130|OTHER|Pulmonary rehabilitation plus Indacaterol|Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
41108621|NCT04213599|DIAGNOSTIC_TEST|Coronary intervention|Patients with STEMI undergo coronary intervention
41108622|NCT06113406|BEHAVIORAL|Classroom Training|Active Comparator
41108623|NCT06113406|BEHAVIORAL|Virtual Reality Training|Experimental
41108624|NCT01641172|PROCEDURE|Dexa scan|"the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year."
41108625|NCT01641172|PROCEDURE|audiogram|"the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year."
41108626|NCT01641172|PROCEDURE|measurement of heart rate variability and baroreflex sensitivity|"the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year."
41108627|NCT01641172|PROCEDURE|Glucose tolerance assessment|"Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year."
41108628|NCT01641172|DIETARY_SUPPLEMENT|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
40752280|NCT02226783|DRUG|AZD1722 salt tablet|AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
40752281|NCT02226783|DRUG|AZD1722 free base tablet|AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
41108629|NCT01641172|BEHAVIORAL|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
41445667|NCT06598332|DRUG|5-Azacytidine|"Patients will be treated with 5 azacytidine at a dose of 32 mg/m2 SQ or IV. The investigators aim to start AZA on Day 1 of steroids but it can be started up to 72 hours after steroids are started . Patients will be premedicated with antiemetics.~Patients must receive steroids at a minimum dose of prednisone 2 mg/kg/day PO (or methylprednisolone 1.6 mg/kg/day IV) divided into 1-2 daily doses as therapy for acute GVHD. For patients that weigh over 100 kg, maximal starting dose of prednisone will be 200 mg (or methylprednisolone-equivalent).~Steroid Taper for responding patients (Prednisone/Methylprednisolone) Days 1-5 2 mg/kg/day (taper cannot start until 3 days after enrollment) Days 6-10 1.5 mg/kg/day Day 11-15 1.0 mg/kg/day Days 16-20 0.5 mg/kg/day Days 21-28\* 0.25 mg/kg/day Days 29-56 Gradual further taper with a goal of reaching \< 0.2 mg/kg/day of prednisone (or \< 0.16 mg/kg/day of methylprednisolone) by Day 56."
41445668|NCT00294047|BIOLOGICAL|Cervarix|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
41445669|NCT00294047|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
41445670|NCT03679598|DRUG|Alvelestat (MPH966)|Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.
41445671|NCT03679598|OTHER|Placebo|Placebo is a pill or tablet that does not contain any study drug.
41445672|NCT01116362|PROCEDURE|primary repair|during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
41445673|NCT01116362|PROCEDURE|secondary repair|after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
41445674|NCT01851135|OTHER|Neuropsychological examination and quality of life measures|
41445675|NCT01880853|OTHER|mammography|participants were screened by mammography alone every year
41445676|NCT01880853|OTHER|ultrasound|participants were screened by ultrasound alone every year
41445677|NCT01880853|OTHER|mammography and ultrasound|Participants were screened by both mammography and ultrasound every year
41445678|NCT02362464|BIOLOGICAL|Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine|dose of 20 x 10\^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally at weeks 3, 6, 9, 12, 15 and 24.
41445679|NCT01111045|DRUG|Bone morphogenetic protein 7|Comparison of different doses of the drug via single intraarticular knee injection
41445680|NCT01111045|DRUG|Placebo|Placebo
41445681|NCT02632864|RADIATION|Proton arm|Proton beam therapy
41445682|NCT06361407|BEHAVIORAL|Illusion task|The task is the illusion already described in the arm description. All participants will additionally benefit from a short neuropsychological evaluation exploring attention (CPT-AX) and semantic knowledge (fNART) and a clinical evaluation exploring the sense of self (EASE).
41108630|NCT01641172|BEHAVIORAL|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
41108631|NCT01738308|PROCEDURE|Healing Touch|"When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
41108632|NCT01738308|PROCEDURE|Healing Touch Sham Treatment|"The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside"
41108633|NCT02954016|DEVICE|ePass|Subject is implanted with the device for up to 3 years.
41108634|NCT05429424|OTHER|Verum acupuncture group|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
41108635|NCT05429424|OTHER|Sham control group I|The needle does not penetrate the skin and retract in the handle while the acupuncturist needling into the skin. The participants easily believe their intervention owing to the sensation of needling into the skin that the device mimics. The needles were fixed with a plastic ring and micropore on the body of the participants without manipulation.
41108636|NCT05429424|OTHER|Sham control group II|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
41108637|NCT01664871|DEVICE|DIammine SIlver Fluoride|Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
41108638|NCT05154799|BEHAVIORAL|Proprioception and tactile localization with manual or ocular response and/or free hand grasp|"In the first part of the study, the subject must designate a target in 2 ways: manual pointing or ocular saccadic response.~In the second part of the study the subject will have to reach and grasp a rectangular block of wood placed on the table at a distance of 35 cm. He will have to catch the wooden block, lift it a few centimeters and put it back on the table. Tool use and control phases: the subject grasps the wooden block with a tool or without the tool but with a weighted bracelet loading his wrist by the same amount as the tool."
41108639|NCT02066441|DIETARY_SUPPLEMENT|Bio-D-Mulsion Forte®|According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570
41108640|NCT02066441|OTHER|Placebo|
41108641|NCT01461213|DRUG|rAAV2.REP1|Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
41108642|NCT02698891|DRUG|Paclitaxel|
41108643|NCT02698891|DRUG|Neulasta|
41108644|NCT05672797|OTHER|Wellth app|The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.
41108645|NCT05672797|BEHAVIORAL|Habit training|"Participants in treatment groups 1 and 2 will be asked to identify an existing routine behavior that will act as a cue for their daily pill-taking behavior to. However, only participants in treatment group 2 will have to submit visual evidence of their cue to the Wellth app in addition to photos of their medication in order to receive credit for the medication check-in (i.e., financial incentives conditional on using their cue)."
41108646|NCT05639699|OTHER|motivational interview|Quitting smoking with motivational interviewing
41108647|NCT06281431|PROCEDURE|Echogenic nerve block needle|A 22G 8-cm echogenic nerve block needle (LEAPMED, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The spread of the medication will be assessed through short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the incidence of punctures, and any associated complications are all meticulously appraised.
41108648|NCT06281431|PROCEDURE|Non-echogenic nerve block needle|A 22G 8-cm thin wall low bottom nerve block needle (KDL, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The distribution of the medication will be assessed using short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the number of punctures, and any associated complications are all meticulously appraised.
41108649|NCT01188629|BEHAVIORAL|Safety Training|IT intervention focuses on safety in the home.
41108650|NCT01188629|BEHAVIORAL|Personal Health Partner and Counseling (PHP+C)|The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
41108651|NCT04533139|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens"
41108652|NCT03721432|DRUG|Pregabalin 150mg|pregabalin 150 mg capsules (Lyrica®,Pfizer) given 60 minutes prior to epidural anesthesia
41108653|NCT03721432|DRUG|Placebo oral capsule|Placebo oral capsule given 60 minutes prior to epidural anesthesia
41108654|NCT02462369|DRUG|Saxagliptin|
41108655|NCT02462369|DRUG|glimepiride|
41108656|NCT04362215|DIAGNOSTIC_TEST|Subjective accomodation amplitude measurement|ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))
41108657|NCT04642794|OTHER|observational study|patients admitted for AP with portosplenomesenteric vein thrombosis.
41108658|NCT05723510|DRUG|Tegoprazan 50mg|Oral administration of one tablet of tegoprazan 50 mg once daily
41108659|NCT05723510|DRUG|Edoxaban 60mg|Oral administration of one tablet of edoxaban 60 mg once daily
41108660|NCT05723510|DRUG|Apixaban 5mg|Oral administration of one tablet of apixaban 5 mg twice daily
41108661|NCT05723510|DRUG|Rivaroxaban 20mg|Oral administration of one tablet of rivaroxaban 20 mg once daily
41108662|NCT01382342|DRUG|Rasagiline|1 mg daily
41108663|NCT01382342|DRUG|Placebo|1 mg daily
41108664|NCT05347199|DRUG|Amisulpride Pill|Two single low doses amisulpride (100 mg); orally
41108665|NCT05347199|DRUG|Placebo|two doses, orally
41108666|NCT03320096|DEVICE|Microfocused ultrasound with visualization|Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3\*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
41108667|NCT04242264|OTHER|Placebo|0.9% Sterile Normal Saline, USP
41108668|NCT04242264|BIOLOGICAL|Shigella sonnei strain 53G|1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
41108669|NCT04242264|BIOLOGICAL|WRSs2|10\^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
41108670|NCT04696250|DRUG|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
41108671|NCT00768664|DRUG|PF-00299804|45 mg by continuous oral dosing
41108672|NCT04586686|PROCEDURE|Ovarian biopsy via laparoscopy|A laparoscopy will be performed to achieve an ovarian cortical biopsy of one of both ovaries. Approximately twenty % of the ovarian volume as initially measured on the baseline ultrasound at the first visit will be removed to be processed in the lab for cortex freezing. The laparoscopic procedure in order to take the ovarian cortex biopsy will be standardised as much as possible. The technique developed by ProFam will be followed and adapted if needed by the surgeon's discretion. A three to four port laparoscopy will be used. The ovarian cortex biopsy will be taken using a curved scissor. Bipolar or unipolar cauterisation will be avoided as much as possible. If necessary for approximation or for hemostatic reasons, the ovarian edges can be stitched or Surgicel ® Absorbable Hemostat can be used.
41108673|NCT04586686|PROCEDURE|Transvaginal oocyte retrieval|After ovarian stimulation, a transvaginal oocyte retrieval will be performed either under local or general anaesthetics (patient's choice). The oocyte yield between the biopsied and non-biopsied ovary will be evaluated.
41108674|NCT00130013|DRUG|Oral Amoxicillin|
41133322|NCT03927651|DRUG|ICG|Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
41133323|NCT00091689|DRUG|852A|
41133324|NCT02992652|DRUG|Allopurinol|600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
41133325|NCT03615352|PROCEDURE|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
41133326|NCT03615352|PROCEDURE|ovarian cyst aspiration and coagulation|laparoscopic ovarian cyst aspiration and coagulation in endometrioma
41133327|NCT03856619|DRUG|TERIFLUNOMIDE HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
41133328|NCT03336892|BEHAVIORAL|Mental Health Care Coordination|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
41108675|NCT06556251|DEVICE|PIPPEP App|"Digital platform with psichoeducative content in infographics, animated and testimonial videos about:~* psychotic and comorbid symptoms, substance use, available treatments, healthy lifestyle habits, social and health emergency resources and outpatient clinics for young people.~* Regular self-completed questionnaires to measure alarm symptoms, side effects of pharmacological treatment, emotional state, and treatment adherence. There will be a feedback for patients in the form of graphs of the evolution of the different types of questionnaires.~* A bidirectional messaging service with the professional reference team, allowing better accessibility in non-urgent cases.~* A gamification system to encourage use of the application, which includes points, rewards, a leaderboard and mini-games.~* A folder where patients can keep documents they find useful (personal reports, relapse prevention plan, crisis plan)."
41108676|NCT03993613|BIOLOGICAL|human apotransferrin|Intravenous infusions
41108677|NCT05323838|BEHAVIORAL|Subjective quality of live|The groups fill out scientifically validated questionnaires to know the differences in perceived stress, anxiety, quality of life, depression, quality of sleep, pain, fatigue, and impact of the disease on daily life.
41108678|NCT05323838|PROCEDURE|Blood extraction|Blood collection by qualified personnel.
41108679|NCT05323838|BEHAVIORAL|Accelerometry|To know the objective differences between physical activity/sedentary lifestyle, caloric expenditure and quality of sleep, we used the accelerometry technique
41108680|NCT05323838|DIETARY_SUPPLEMENT|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
41108681|NCT01456819|BIOLOGICAL|Mononuclear and mesenchymal stem cells|Intramuscular administration into the ischemic limb
41108682|NCT01456819|BIOLOGICAL|Mononuclear cells|Intramuscular administration into the ischemic limb
41108683|NCT01354769|DEVICE|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
41108684|NCT03908424|OTHER|Epidural Blood patch.|"An epidural blood patch is a surgical procedure that uses autologous blood in order to close one or many holes in the dura mater of the spinal cord, usually as a result of a previous lumbar puncture. A small amount of the patient's blood is injected into the epidural space near the site of the original puncture; the resulting blood clot then patches the meningeal leak. An epidural needle is inserted into the epidural space at the site of the cerebrospinal fluid leak and blood is injected. The clotting factors of the blood close the hole in the dura."
40752282|NCT02226783|DRUG|AZD1722 free base tablet + Omeprazole|AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
40752283|NCT01215240|DEVICE|Peritoneal dialysis|Prophylactic peritoneal dialysis
41108685|NCT03485859|DEVICE|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
41108686|NCT03485859|DEVICE|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
41108687|NCT01785004|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol), 2000 IU per day|cholecalciferol
41108688|NCT01785004|DRUG|omega-3 fatty acids (fish oil)|
41108689|NCT05273242|DRUG|Artesunate Injection|"* Artesunate: 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours and thereafter every 24 hours; IV injection; duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria.~* Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.~* Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies."
41108690|NCT00644709|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
41108691|NCT03200587|DRUG|Avelumab|Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
41108692|NCT03200587|DRUG|Cabozantinib|Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
41108693|NCT03988036|DRUG|Pembrolizumab|Intravenous infusion; 200 mg; every 3 weeks
41108694|NCT03988036|DRUG|Trastuzumab Biosimilar ABP 980|Intravenous infusion; 8 mg/kg loading dose, thereafter 6 mg/kg; every 3 weeks
41108695|NCT03988036|DRUG|Pertuzumab|Intravenous infusion; 840 mg/kg loading dose, thereafter 420 mg/kg; every 3 weeks
41108696|NCT02652936|DRUG|AF-130|AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
41108697|NCT02652936|DRUG|Placebo comparator|AF-130 matching placebo capsule
41108698|NCT01777893|BEHAVIORAL|High protein/ high intensity physical activity (HP-HI)|Participants follow a high protein diet and a high intensity physical activity intervention
41108699|NCT01777893|BEHAVIORAL|High protein / moderate intensity physical activity (HP-MI)|Participants follow a high protein diet and moderate intensity physical activity intervention
41108700|NCT01777893|BEHAVIORAL|Moderate protein/ high intensity physical activity (MP-HI)|Participants follow a moderate protein diet and a high intensity physical activity intervention
41108701|NCT01777893|BEHAVIORAL|Moderate protein/ moderate intensity physical activity (MP-MI)|Participants follow a moderate protein diet and moderate intensity physical activity intervention
41108702|NCT03967886|DRUG|YYD601 20mg|Patients should take drugs an hour before breakfast.
41108703|NCT03967886|DRUG|Nexium 20mg|Patients should take drugs an hour before breakfast.
41108704|NCT03967886|DRUG|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
41108705|NCT03312439|BEHAVIORAL|Given advice|Based on results of testing the participants will be give advice with the general aim to decrease the future risk of non-communicable disease by increasing physical activity,
41108706|NCT02012543|DIETARY_SUPPLEMENT|Agar jelly|
41108707|NCT02001714|BEHAVIORAL|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
41108708|NCT03906942|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content in the form of 152 BET I CAN challenges \[1\]. Behavior challenges are intended to increase a participant's capabilities to set a goal and to create positive habits. Emotion challenges are intended to increase a participant's capabilities to cope with negative emotions and to cultivate positive emotions. Thought challenges are intended to increase a participant's capabilities to challenge negative assumptions and to create a new narrative for their life. Interaction challenges are intended to increase a participant's capabilities to communicate and connect with others. Context challenges are intended to increase a participant's capabilities to read cues and to change cues in the environment. Awareness challenges are intended to increase a participant's capabilities to know herself/himself and to know the issue. Next steps challenges are intended to increase a participant's capabilities to make a plan and to stick with a plan.
41108709|NCT05496816|DIAGNOSTIC_TEST|CAC in septic patients|"Data collected included demographic parameters, comorbidities, vasopressors requirement, laboratory findings, in-hospital mortality scoring and diagnostic colagulation scores. Demographic parameters were taken on the day of admission, all other variables were taken on the day of admission to the ICU and on the day of initiation of invasive mechanical ventilation or on the day of discharge from the ICU.~Demographic parameters included age and sex of the patient, followed by comorbidities which was marked with Yes or No on the day of admission in the ICU. Mortality was assessed according to the qSOFA score and vasopressor requirements on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge. Laboratory analysis included analysis of platelets, neutrophils, lymphocytes, PCT, CRP, fibrinogen, D-dimer on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge."
41108710|NCT03505619|BEHAVIORAL|ASSIST 1.0|10 weeks intervention applying a person-centred approach by using goal setting and smart products.
41108711|NCT00476333|DEVICE|APOS biomechanical gait system|
41108712|NCT04184804|BEHAVIORAL|Behavioral Intervention|"The intervention package will be consisted of:~1. Introduction of organic fruits and vegetables (by replacing the conventional ones) in school lunch menus~2. Signs in school areas about organic fruits and vegetables~3. Workshops and interactive games for children~4. Seminars for parents"
41108713|NCT02433795|DRUG|bendamustine plus rituximab|Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
41108714|NCT04476745|DIETARY_SUPPLEMENT|Vitamin D3|Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks
41108715|NCT05505279|DEVICE|THRIVE (High Flow Nasal Cannula)|2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen
41108716|NCT02894151|DRUG|Depot medroxyprogesterone acetate|
41108717|NCT02894151|DEVICE|LNG-IUS|
41108718|NCT06552962|DEVICE|Whole body vibration|The aim of this study is to reveal the effect of exercises performed with WBV on the myofascial tissue of the lumbar region and the tone of superficial back muscles, as well as to investigate the effects on pain, function, muscle strength, balance, proprioception and endurance parameters, compared to the exercise-only group.
41108719|NCT06552962|BEHAVIORAL|lumbar stabilization exercises|The control group will undergo lumbar stabilization exercises twice a week for 6 weeks.
41108720|NCT02668263|PROCEDURE|Surgery alone|Surgery
41108721|NCT02668263|PROCEDURE|Surgery and Drain(s)|Drains inserted as per standard practice
41108722|NCT02668263|PROCEDURE|Surgery and Quilting Sutures|Quilting sutures to mastectomy flaps
41108723|NCT04189107|DRUG|Dexamethasone|High-dose dexamethasone peroperative and postoperative on day 2 and 4
41108724|NCT04189107|DRUG|Placebo|low dose dexamethasone peroperative and placebo postoperatively on day 2 and 4
41108725|NCT03083119|DRUG|Xuesaitong soft capsule|Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.
41108726|NCT03083119|DRUG|Placebo oral capsule|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
41108727|NCT06533527|DRUG|Semaglutide|GLP1 medication
41108728|NCT06533527|DRUG|Tirzepatide|GLP1/GIP medication
41108729|NCT06533527|DRUG|Liraglutide|GLP1 medication
41108730|NCT06533527|DRUG|Dulaglutide|GLP1 Medication
41108731|NCT00188461|DEVICE|CT Thorax|
41108732|NCT03253913|DRUG|Sirolimus|Patients will have been on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.
41108733|NCT03253913|DRUG|Resveratrol|Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.
41108734|NCT05110391|DRUG|Hormonal Therapy Agent|Consecutive patients with NOA and hypogonadism (defined by baseline total testosterone levels equal or below 350 ng/dL) subjected to microdissection testicular sperm extraction who received or not pre-sperm retrieval gonadotropin therapy.
41108735|NCT01114919|BEHAVIORAL|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
41108736|NCT01114919|BEHAVIORAL|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
41108737|NCT02964195|DRUG|Rifaximin|ALFA WASSERMANN S.p.A.
41108738|NCT05097469|DEVICE|Carbon dioxide laser|3 consecutive sessions of carbon dioxide laser treatment
41108739|NCT05097469|DEVICE|Sham laser treatment|3 consecutive sessions of sham laser treatment
41108740|NCT05991986|OTHER|somatic cell collection|One or more types of somatic cells will be collected from every participant by collecting approximately 100\~500 ml of midstream urine, 20\~30 ml of peripheral blood, skin biopsies (3mm), conjunctiva biopsies (5mm×5mm), etc.
41108741|NCT06278025|DIAGNOSTIC_TEST|assessment|"DCF Muscle Strength Evaluation~DCF muscle strength was determined using the 5-step Craniocervical Flexion Test (CCFT) performed with a Chattanooga Stabilizer ™ Pressure Biofeedback Unit which was developed by Jull et al. \[33, 34\]. The CCFT is based on the craniocervical flexion movement, which is provided by DCF muscle contraction. The CCFT includes 5 pressure increments starting with 20mmHg.Activation score ranges from 0 to 10. The performance index is determined by both the highest pressure level and the number of repetitions.~Evaluation of the DCF Endurance The DCF endurance test, which is a valid and reliable method, was used to measure DCF muscle endurance \[36\]. Conducted in supine, endurance is measured by calculating the time (in seconds) an individual can raise their head at minimal flexion angle."
41108742|NCT06199648|OTHER|web-based documentation and advice|Caregivers will be supported with a web-based documentation and advice system for home care for elderly people
41108743|NCT02243813|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
41108744|NCT02696707|PROCEDURE|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
41108745|NCT02696707|PROCEDURE|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
41108746|NCT00647530|BIOLOGICAL|panitumumab|
41108747|NCT00647530|DRUG|capecitabine|
41108748|NCT00647530|DRUG|fluorouracil|
41108749|NCT00647530|DRUG|oxaliplatin|
41108750|NCT06273891|DRUG|Erythromycin|"Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
41108751|NCT06273891|DRUG|Azithromycin|"Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
41108752|NCT00664911|OTHER|chemotherapy|
41108753|NCT02057692|DRUG|LUM001|LUM001 administered orally
41108754|NCT02057692|DRUG|Placebo|Placebo administered orally
41108755|NCT01510041|OTHER|Inspiratory muscle training|A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free
41108756|NCT01510041|OTHER|Respiratory exercise|Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
40925506|NCT00843778|BIOLOGICAL|Certolizumab Pegol|"200 mg every two weeks~Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 \[NCT00674362\], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks."
41108757|NCT01576133|BEHAVIORAL|CAPABLE|Occupational therapy visits plus nursing visits plus handyman repair
41108758|NCT01576133|BEHAVIORAL|Attention visits|Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
41108759|NCT03183999|DIETARY_SUPPLEMENT|fermented ginseng (GINST)|Intervention group should take fermented ginseng (GINST) capsule 3 times a day, 2 capsules at one time for 12 weeks
41108760|NCT03183999|DIETARY_SUPPLEMENT|Placebo|Control group should take placebo capsule 3 times a day, 2 capsules at one time for 12 weeks
41108761|NCT00172185|DRUG|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
41108762|NCT00172185|DRUG|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
41108763|NCT00327665|BIOLOGICAL|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
40925507|NCT05423353|DEVICE|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
41108764|NCT00327665|BIOLOGICAL|Pneumo 23™|Single-dose intramuscular injection.
41108765|NCT00327665|BIOLOGICAL|Placebo|1 intramuscular injection.
41108766|NCT00327665|BIOLOGICAL|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
41108767|NCT02383108|DRUG|DTG +DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
41108768|NCT02383108|DRUG|SOC|Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
41108769|NCT01958099|BEHAVIORAL|Education|
41108770|NCT01099891|DRUG|rhEGF|rhEGF 50 μg/ml, spray type, twice a day
41108771|NCT01099891|DRUG|Placebo|Placebo, Spray type, Twice a day
41108772|NCT00165451|DRUG|Thalidomide|Oral administration once daily at night starting at 3mg/Kg for 6 months.
41108773|NCT00165451|DRUG|Celecoxib|Oral administration twice daily starting at 100mg/dose for 6 months.
41108774|NCT00165451|DRUG|Etoposide|Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.
41108775|NCT00165451|DRUG|Cyclophosphamide|Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
41108776|NCT05389462|DRUG|ADCT-601|Intravenous (IV) infusion
40925508|NCT05423353|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
40925509|NCT05027295|DRUG|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of continuous UVA light for 7.5 minutes.
40925510|NCT05027295|DRUG|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of pulsed UVA light for 15 minutes
41108777|NCT05389462|DRUG|Gemcitabine|Intravenous (IV) infusion
41108778|NCT01277445|DIETARY_SUPPLEMENT|Prebiotic|Inulin-fructan 15mg/day for 28days
41108779|NCT01277445|DIETARY_SUPPLEMENT|Prebiotic|Daily consumption of 15g inulin-fructan for 28 days
41108780|NCT03329742|OTHER|Low protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
41108781|NCT03329742|OTHER|Control protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
41108782|NCT00570869|OTHER|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
41108783|NCT04511130|DRUG|MT-401|MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.
41108784|NCT05158361|OTHER|Acupuncture|Participants will receive acupuncture, three times per week for eight weeks. The selected acupoints include bilateral BL33, BL35, SP6, and ST36. All acupoints areas have been sterilized before acupuncture. For BL33, a needle (Ф0.40×100mm) will be inserted with an angle of 60° in an inferomedial direction at a depth of 90-100mm. For BL35, the same needle will be inserted with a direction to the ischial rectal fossa at a depth of 60-70 mm deep. For SP6 and ST36, needles (Ф0.30×50mm) will be directly inserted at a depth of 25-30 mm deep. After the needles are inserted, a portable electro-acupuncture machine will be connected to the handles of needles located in BL33 and BL35 to provide the electrical stimulation for 30 minutes with a disperse-dense wave (4/20Hz). All current intensities will be as high as can be tolerated.
41108785|NCT05158361|OTHER|Sham acupuncture|The sham acupoints will be located at 20 mm outward to BL33, BL35, SP6, and ST36, and the needless will be inserted with a depth of 2 mm. The BL33 and BL35 will not receive any electrical stimulation, though the handles of needles will be connected to the same machine as the acupuncture group, and the parameter setting and course are also the same.
41108786|NCT05640791|DRUG|Cisplatin|25mg/m2；d1, 8, 21 d cycle
41108787|NCT05640791|DRUG|Gemcitabine|1000mg/m2；d1, 8, 21 d cycle
41108788|NCT05640791|DRUG|Nab-paclitaxel|100mg/m2；d1, 8, 21 d cycle
41108789|NCT05640791|DRUG|Durvalumab|1000mg；d1, 21 d cycle
41108790|NCT00541749|DRUG|rhuMAb IFNalpha|Intravenous repeating dose
41108791|NCT03391635|DEVICE|Electroacupuncture|Participants will receive electroacupuncture at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
41108792|NCT03391635|DEVICE|TranscutaneousElectricNerveStimulation|Participants will receive transcutaneous electric nerve stimulation at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
40925511|NCT04308733|DEVICE|Anodal tDCS|patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
40925512|NCT00448396|DRUG|Patupilone|
40925513|NCT06221657|DRUG|Vemlidy|1 tablet once a day, oral administration
40925514|NCT06221657|DRUG|Virreal|1 tablet once a day, oral administration
41108793|NCT04132518|DEVICE|Sculptra|Initial injection and optional 3 injections with Sculptra in Midface.
41108794|NCT03324035|DRUG|Amitriptyline|Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
41108795|NCT03324035|DRUG|Placebo oral capsule|Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
41108796|NCT03324035|DRUG|Tramadol|"Administer to both arms on as needed scheme, to a maximum of 150mg/day."
41108797|NCT06076382|PROCEDURE|endoscopic ultrasound guided colorectal ESD surgery|The experimental group first underwent endoscopic ultrasound examination, with a small ultrasound probe inserted into the intestinal cavity through the biopsy port. After water injection, the lesion was scanned and (1) the direction of gravity was determined. (2) fibrosis/infiltration under the mucosa, and the fibrosis was divided into F0 (no fibrosis), F1 (cold fibrosis), or F2 (severe fibrosis). (3) The lesion was divided into nine compartments. Mark submucosal fibrosis/infiltration sites, according to nine compartments. (4) Based on the results of endoscopic ultrasound scanning of the lesion, the surgeon draw up surgical approach and perform injection and dissection.
41108798|NCT06076382|PROCEDURE|the traditional colorectal ESD surgery|The control group underwent injection and dissection directly.
41108799|NCT00620217|GENETIC|intramyocardial injection of VEGF-A165/bFGF:placebo plasmid|The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
41108800|NCT04048018|DIAGNOSTIC_TEST|Blood draw and IGRA test|One to two blood samples will be obtained from participants in all arms in order to conduct testing.
41108801|NCT02201173|BEHAVIORAL|Locomotor Training|Progressive retraining in functional skills including balance, transfers, activities of daily living and ambulation. Compliance to eliminate or minimize lower limb orthotics is also expected to optimize sensory input to the spinal cord and promote optimal recovery. Intensive therapy occurs in all three environments 5 times/ week for 90 minutes
41108802|NCT02960269|OTHER|interprofessional back pain assessment|team assessment and education with urban physical therapist and rural nurse practitioner via telehealth
41108803|NCT03608618|BIOLOGICAL|MCY-M11|Intraperitoneal administration
41108804|NCT03608618|DRUG|Cyclophosphamide|Intravenous administration for preconditioning
41108805|NCT05943652|DIAGNOSTIC_TEST|Neurological examination|A neurological examination following a protocol to detect positive signs of functional neurological disorders.
41108806|NCT05943652|DIAGNOSTIC_TEST|Anamnesis|"A standardized question about the patient´s history. The response time is measured.~Question: Could you tell me about the problems with the movement disorder you are experiencing?"
41108807|NCT05943652|DIAGNOSTIC_TEST|Neuropsychological testing|"Neuropsychological cognitive testing including:~* Montreal Cognitive Assessment (MOCA)~* Rey-Osterrieth Complex Figure Test (ROCFT)~* Wechsler Memory Scale IV~* Comprehensive Trail Making Test (CTMT)~* semantic and phonematic fluency tests"
41108808|NCT05943652|DIAGNOSTIC_TEST|Questionnaires|"* Short Form 36 (SF 36)~* Somatic Symptom Disorder - B Criteria Scale (SSD 12)~* Patient Health Questionnaire 9 (PHQ 9)~* Patient Health Questionnaire 15 (PHQ 15)~* Generalized Anxiety Disorder 7 (GAD 7)~* Fatigue Severity Scale (FSS)~* Psychosomatic Competence Inventory (PSCI)~* Work Ability Index (WAI)~* Level of Personality Functioning Scale~* Toronto Alexithymia Scale~* Levels of Emotional Awareness Scale (short version)~* Certainty About Mental States Questionnaire~* Somatosensoric Amplification Scale~* Personality Inventory for DSM-5 short version (PID5BF+M)~* Childhood Trauma Questionnaire~* European Quality of Life 5 Dimensions 5 Level Version (EQ5D5L)"
41108809|NCT05943652|DIAGNOSTIC_TEST|Tremor recording|Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)
41108810|NCT00775242|DRUG|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
41108811|NCT00775242|DRUG|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
41108812|NCT03502278|BEHAVIORAL|Islamic Trauma Healing|A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles
41108813|NCT00000878|DRUG|Lamivudine|
41108814|NCT00000878|DRUG|Stavudine|
41108815|NCT00000878|DRUG|Zidovudine|
40925515|NCT02879045|OTHER|Elasticity Belly® oil|We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
40925516|NCT02880696|BEHAVIORAL|Regular stimulation sequence|Vibrotactile stimulation of the right hand with regular intervals and random omissions
40925517|NCT02880696|BEHAVIORAL|Random stimulation sequence|Vibrotactile stimulation of the right hand with random intervals and random omissions
41108816|NCT00842257|DRUG|panitumumab|Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
40925518|NCT02880696|DEVICE|DCS|Near-infrared imaging of the neurovascular response in the left somatosensory cortex
41108817|NCT02418806|BEHAVIORAL|Psychotherapy groups|
40925519|NCT02747303|PROCEDURE|Stereotactic Radiosurgery|The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
41108818|NCT02418806|BEHAVIORAL|Self-help groups|
41108819|NCT00383188|DRUG|placebo|Capsule, once daily (QD) for 12 weeks
41108820|NCT00383188|DRUG|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
41108821|NCT00383188|DRUG|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
41108822|NCT00383188|DRUG|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
41108823|NCT00383188|DRUG|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
41108824|NCT04602052|PROCEDURE|Dilation and evacuation|Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
41108825|NCT02698007|DEVICE|Laryngeal Mask Airway (LMA)|Fiberoptic bronchoscopy with the use of LMA
41108826|NCT03582410|PROCEDURE|laparoscopic sacral colpopexy with absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture
41108827|NCT03582410|PROCEDURE|laparoscopic sacral colpopexy with non absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture
41108828|NCT00107835|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
41108829|NCT02311972|DEVICE|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|
41108830|NCT02311972|DEVICE|Standard of care feeding tube|
41108831|NCT01204528|DRUG|Zemplar|Vitamin D receptor activator (VDRA)
41108832|NCT00367692|DRUG|PSI-697|
41108833|NCT02497092|OTHER|Technique of injection|
41108834|NCT03775369|OTHER|endurance training|physical activity and exercising (PAE)
41108835|NCT03775369|OTHER|social support and counseling|social support and counseling
41108836|NCT03775369|OTHER|resistance training|physical activity and exercising (PAE)
41108837|NCT05617586|OTHER|In-depth parental interview|A semi-structurerd interview will be conducted of parents with a child diagnosed with DCD. The interview will be audio-recorderded. The audiofile will be transcribed ad-verbatim and analyzed using narrative analysis methods.
41108838|NCT05617586|OTHER|Developmental Coordination Disorder Questionnaire (DCD-Q)|Parents will be asked to complete the DCD-Q. This will help us describe the sample.
41108839|NCT00003717|DRUG|estramustine phosphate sodium|
41108840|NCT00003717|DRUG|paclitaxel|
41108841|NCT00816049|DRUG|6MPindividualized|Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
41108842|NCT00816049|DRUG|6MPfixed|Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
41108843|NCT00044148|DRUG|LY333531|
41108844|NCT03693742|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT scan|"Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes."
41108845|NCT03693742|OTHER|Placebo drink|Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.
41108846|NCT03693742|OTHER|MSG drink|Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
41108847|NCT04650841|DRUG|Placebo Cream with Naloxone|Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
41271078|NCT04233489|BEHAVIORAL|Family Nurture Intervention (FNI)|"FNI is a family based intervention that facilitates and strengthens the mother-infant emotional connection through a structured guided interaction by a physician.~The mother is asked to sit with her baby in her arms so that they are face-to-face, and when the baby becomes restless, the physician will coach the mom to bring the baby back to a calm state. The mother will also be encouraged to verbalize her feelings to her baby. Mother-infant emotional connection is known to affect various developmental processes and improve overall health. FNI was previously shown to be efficacious in improving several long-term health outcomes in preterm infants in the neonatal intensive care unit (NICU)."
40925520|NCT03515954|PROCEDURE|Treatment of diffuse ocular surface squamous neoplasia|Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.
40925521|NCT03231683|DRUG|Esketamine|intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model
40925522|NCT03231683|DRUG|Saline|intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
41108848|NCT04650841|DRUG|Control Cream with Naloxone|Participants will be informed that the spray is saline.
41108849|NCT04650841|DRUG|Placebo Cream with Saline|Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
41108850|NCT04650841|DRUG|Control Cream with Saline|Participants will be informed that the spray is saline.
41108851|NCT01456078|DRUG|177Lu-DOTA-TATE|"177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy."
41108852|NCT03794180|DRUG|TJ003234|Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
40925523|NCT03231683|DRUG|Remifentanil|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
40925524|NCT03231683|DRUG|Propofol|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
40925525|NCT04293744|DEVICE|Colloid priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
40925526|NCT04293744|DEVICE|Standard priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
40925527|NCT02000908|DEVICE|photobiomodulation|The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.
40925528|NCT02000908|OTHER|Sham treatment|All patients in sham treatment arm cross over to laser therapy followed by physiotherapy
41108853|NCT03794180|DRUG|Placebo|Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
40925529|NCT02000908|OTHER|Physiotherapy|Chiropractic massage and lymphedema treatment
40925530|NCT01037621|DRUG|Valacyclovir|Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
40925531|NCT00722371|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
40925532|NCT00722371|DRUG|Pioglitazone hydrochloride|Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
40925533|NCT00722371|DRUG|Matching placebo to sitagliptin|Matching placebo to sitagliptin orally once daily for 54 weeks.
40925534|NCT00722371|DRUG|Matching placebo to pioglitazone|Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
40925535|NCT00722371|DRUG|Metformin|Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
40925536|NCT01005121|DRUG|colchicine|2mg, per-os, once daily for six months
40925537|NCT04061993|PROCEDURE|Strength and Sensory-Motor Training|Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).
40925538|NCT04061993|PROCEDURE|Current Standard Physiotherapy|Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
40925539|NCT03387384|OTHER|Non-interventional study|Non-interventional study
40925540|NCT04591860|DEVICE|Laparoscopic or robot-assisted hiatal closure (sutures only vs. absorbable mesh vs. pledgeted sutures) and fundoplication according to Toupet|Patients are scheduled to undergo laparoscopic or robot-assisted surgery for a large symptomatic hiatal hernia.The hiatal closure will be done with sutures, pledgeted sutures or absorbable mesh (Phasix™ST mesh). After cruroplasty a fundoplication according to Toupet will be done additionally.
41108854|NCT04789798|DEVICE|TeleDiab (Telemedicine)|"TeleDiab program components consist of:~1. Electronic transmission of capillary blood glucose measurement results~2. Electronic transmission of blood pressure measurements~3. Synchronized video-conferencing, secure messaging~4. Access to clinical data from patient files when necessary~5. Reminding of routine follow-up tests and examinations~6. Providing web-based educational materials to patients."
41108855|NCT04789798|OTHER|Usual care|Usual diabetes care, as provided by primary care providers
41108856|NCT03321344|DEVICE|Focused Ultrasound Thermal ablation|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
41108857|NCT06450977|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
41108858|NCT06450977|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
41108859|NCT04250285|OTHER|descriptive method|After obtaining relevant permissions from the university and organization of education and selecting participants, the study was explained for students and their satisfaction obtained. Then questionnaires were given to participants. To observe ethical considerations, questionnaires were anonymous and has been confided that the participants' responses was maintained in the study and is not given anyone
41108860|NCT04487236|DRUG|ZN-A-1041 50mg BID|Orally 21days for one cycle
41108861|NCT04487236|DRUG|ZN-A-1041 100mg BID|Orally 21days for one cycle
41108862|NCT04487236|DRUG|ZN-A-1041 200mg BID|Orally 21days for one cycle
41108863|NCT04487236|DRUG|ZN-A-1041 400mg BID|Orally 21days for one cycle
41108864|NCT04487236|DRUG|ZN-A-1041 600mg BID|Orally 21days for one cycle
41108865|NCT04487236|DRUG|ZN-A-1041 800mg BID|Orally 21days for one cycle
41108866|NCT04487236|DRUG|ZN-A-1041 1000mg BID|Orally 21days for one cycle
41108867|NCT04487236|DRUG|ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
41108868|NCT04487236|DRUG|ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
40925541|NCT02571907|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation.
40925542|NCT02571907|DEVICE|Atrium iCAST™|Implantation of Atrium iCAST
40925543|NCT02571907|DEVICE|Zenith® Flex AAA Endovascular Graft|Implantation of the Zenith Flex Endovascular Graft
40925544|NCT01024621|DEVICE|Endomicroscope|Pentax EC3870K, Tokyo, Japan
40925545|NCT01024621|DEVICE|Standard endoscopy|Pentax EG-2931 gastroscope
40925546|NCT04585503|DEVICE|Electrode implantation|The intervention consist in implanting 6 electrodes in subdural or intra cortical position and monitor the central nervous system activity. This monitoring will be additional to the usual monitoring.
40925547|NCT01605578|PROCEDURE|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
41108869|NCT04487236|DRUG|ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
41108870|NCT04487236|DRUG|ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle|Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
41108871|NCT04209049|DRUG|NNC0174-0833|A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
41108872|NCT04061902|OTHER|Participation with enhanced patient perioperative information|Improved information and dialogue about the care goals in the fast track protocol.
41108873|NCT05502458|DRUG|Desﬂurane|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h. In the general anesthesia group with desflurane (group D), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane. The analgesic and muscle relaxant regimens were the same in both groups except for sedative drugs. All patients were treated with no medication before operation, and the operation was completed under endotracheal intubation and general anesthesia. The amount of propofol or desflurane was adjusted according to BIS or MAC values and hemodynamic changes during operation. Add 10mg of rocuronium every half hour. Vasoactive drugs can be used to maintain hemodynamic stability during the operation, and corresponding records should be made
41108874|NCT05502458|DRUG|Propofol|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h.
41108875|NCT05989412|OTHER|Patient health questionnaire-9 via the Your Research application|Both intervention arms will have 4-weekly screening with either lenient follow-up or screening with stricter follow-up for a time period of one year. Data will be collected via an app designed by Your Research which runs on Microsoft Azure server, as the primary of participants' response collection. A dedicated backup system will serve as a secondary data collection.
41108876|NCT01597752|BIOLOGICAL|Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control|Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
41108877|NCT03900637|DRUG|Leuprorelin acetate|In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)
41108878|NCT03900637|DRUG|Letrozole|2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)
41108879|NCT03900637|GENETIC|MammaPrint|In this study, patients with MammaPrint test is performed, neoadjuvant chemotherapy is conducted to genomic High Risk patients, and neoadjuvant endocrine therapy is conducted to Low Risk patients.
41108880|NCT05400707|DIAGNOSTIC_TEST|Assessment of vital signs|heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
41108881|NCT05400707|DIAGNOSTIC_TEST|Assessment of patient mobility at presentation|Patients are asked how they assess their own mobility: - Stable walking without aids or limited mobility with aids (walking aid, wheelchair, lying down).
41108882|NCT05400707|DIAGNOSTIC_TEST|Assessment of level of consciousness by AVPUC scale|Assessment of level of consciousness by AVPUC scale (alert, new confusion, verbal, pain, unresponsive, new confusion)
41108883|NCT05400707|DIAGNOSTIC_TEST|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 37 symptoms
41108884|NCT05400707|DIAGNOSTIC_TEST|Assessment of what matters most in patients of 65 years and older|"Patients over the age of 65 are asked the following: generally asked: what matters most to you at the moment? and why is that important for you?."
41108885|NCT05400707|DIAGNOSTIC_TEST|Assessment of Decision-making in senior physicians|Questionnaire consisting of 10 questions about the decision-making processes in the emergency department and the factors that form the basis of their decisions regarding the diagnosis, treatment, and disposition of the patient.
41108886|NCT05400707|DIAGNOSTIC_TEST|Pain Numeric Rating Scale (NRS)|"The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain ('0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine))"
41108887|NCT05400707|DIAGNOSTIC_TEST|Clinical Frailty Scale (CFS)|The CFS is a commonly used score to assess frailty. It was developed within the Canadian Study of Health and Aging and consists of a 9-level ordinal scale ranging from very fit (score 1) to living with very severe frailty (score 8), and score 9 reserved for those who are terminally ill.
41108888|NCT03121131|OTHER|Clinical Exam Findings|Findings found on clinical exam of a patient the radiologist will be reading CT scans of.
41108889|NCT03121131|OTHER|Inaccurate Clinical Exam Findings|Inaccurate findings are given to the radiologists
41108890|NCT03121131|OTHER|No clinical exam findings|No clinical exam findings are given to the radiologists
41108891|NCT04519671|DRUG|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)
41108892|NCT04519671|OTHER|Placebo|Normal saline
41108893|NCT04128436|OTHER|Taking blood samples for analyzing progesterone levels|As part of standard in vitro fertilization treatment, Crinone gel will be used starting the next morning following the oocyte pick-up (OPU) as a luteal phase support. On the trigger day, on the day OPU+2/3 (early luteal phase) and on the embryo transfer day (OPU+5, mid luteal phase) blood samples will be taken from patients for evaluating the progesterone levels. Blood samples will be collected at the 6th hour following the morning dose of vaginal progesterone gel. No other intervention will be done to the patients.
41108894|NCT00480766|DRUG|MK0217/Duration of Treatment : 12 Months|
41108895|NCT02952768|BEHAVIORAL|ultrasound training|Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
41108896|NCT02787161|DEVICE|Hemodiafiltration|High volume online HDF
41108897|NCT02787161|DEVICE|Hemodialysis|High-flux HD
41271079|NCT05676710|DRUG|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
41271080|NCT03622281|OTHER|quality improvement intervention using artificial intelligence|Colonoscopists received performance measure monitoring and feedback
41108898|NCT03665298|BEHAVIORAL|Smartphone Application|App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
41108899|NCT05662891|OTHER|Blood Flow Restriction|After randomization, a cuff was placed proximal to one lower extremity. Blood flow was restricted from 60% of the arterial occlusion pressure. The other extremity was determined as the control group. 3x5 nordic hamstring exercises were performed. Surface emg was measured for hamstring muscles during exercise.
41108900|NCT05081310|DEVICE|superior vena cava isolation|SVC isolation by the means of cryoballoon
41108901|NCT05081310|DEVICE|pulmonary vein isolation|conventional pulmonary vein isolation by the means of cryoballoon
41108902|NCT02957539|BEHAVIORAL|Financial rewards|Veterans in the financial reward arm receive all of the services of the usual care arm, plus rewards that are earned in two ways: an assured portion, and a random portion. For the assured reward, they will receive compensation at the end of each month (defined as a four week period) that they are at or below their target weight. For the random portion, each week that a participant is at or below their target weight, the patient is entered into a drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning. Over the 17-32 week period, Veterans in this group will receive token incentives for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters their weight into the portal, s/he will have a 1-in-8 chance to earn the token incentive, such as a t-shirt or movie ticket. The participant will receive reminder text messages.
41108903|NCT02957539|BEHAVIORAL|Non-Financial rewards|Procedures for the non-financial rewards arm are identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each weekly random drawing will be for 20 points. Veterans will choose non-financial rewards associated with the number of points they earn.
41108904|NCT01405872|OTHER|AVONEX PEN|Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
41108905|NCT03368833|DIAGNOSTIC_TEST|Electrocardiogram|12-lead ECG will be obtained after induction and at 5, 10, 20, 30, and 60 minutes after the caudal epidural block.
41108906|NCT00206258|DRUG|Pramlintide and glucagon|
41108907|NCT05688761|DRUG|Proton pump inhibitor|Long-term use of medications, particularly proton pump inhibitors
41108908|NCT04672772|DRUG|Cetuximab|Weekly cetuximab at starting dose, that could be switched to biweekly
41108909|NCT04672772|DRUG|Paclitaxel|Paclitaxel at starting dose of 80 mg/m2
41108910|NCT04848441|OTHER|The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1|The purpose of the study is to compare the effects of BNT162b2, mRNA-1273 and ChAdOx1 with respect to incident COVID-19 infection of different severities.
41108911|NCT06367517|DRUG|Tocilizumab|Tocilizumab administrated at a dose of 8 mg/kg, given once every four weeks
41108912|NCT04870060|DRUG|Curcumin Lozenges|Curcumin lozenges - 4 lozenges to be chewed BD. Each lozenge contained 100 mg of curcumin and the formulation was Solid Lipid Curcumin Particle (SLCP)
41108913|NCT03684213|DRUG|Control (Norepinephrine)|This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
40752284|NCT01217138|DEVICE|Epinephrine autoinjector|We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
40752285|NCT06433544|OTHER|6-week online mindfulness course|The experimental group received a 6-week online mindfulness course, once a week for 90 minutes each session.
41108914|NCT03684213|DRUG|Norepinephrine + Ascorbic Acid|This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.
41108915|NCT03684213|DRUG|Norepinephrine + L-NAME|This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.
41108916|NCT03684213|DRUG|Norepinephrine + L-NAME + Ascorbic Acid|This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.
41108917|NCT03404154|DIAGNOSTIC_TEST|3D ultrasound|it describes the diagnostic test which is 3D us to diagnose the cause of postmenopausal bleeding
41108918|NCT03404154|PROCEDURE|Dilatation and curretage|it describes the surgical maneuver that will be made to diagnose cause of bleeding
41108919|NCT00346593|DEVICE|Silicone hydrogel contact lens|
41108920|NCT04183959|DEVICE|video stylet|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
40752286|NCT02577380|BEHAVIORAL|IPV/GBV HTC|Participants will be interviewed after receiving their services.
40752287|NCT00001857|DRUG|BG9588|
40752288|NCT03640026|DRUG|Tacrolimus|Tacrolimus will be initiated at 0.1 mg/kg/day in two separate 12-hour oral doses (capsules) for 14 days.
40752289|NCT03436420|DRUG|Gemcabene|Participants will take 300 milligrams (mg) of gemcabene, once per day for 12 weeks.
41108921|NCT04183959|DEVICE|fiberoptic|intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
41108922|NCT02806869|DRUG|Single dose of ibuprofen (800 mg tablet)|
41108923|NCT02806869|DIETARY_SUPPLEMENT|Pulmocare, two 8.0 oz (236.6 mL) cans|
41108924|NCT05037032|DRUG|Naltrexone Pill|50 mg PO one-time only
41108925|NCT05037032|DRUG|Placebo|Matching placebo for naltrexone
41108926|NCT04618458|BEHAVIORAL|Power to Prevent|Lifestyle diabetes prevention intervention based on the National Diabetes Prevention Program and tailored for African American families. The intervention will be delivered using telehealth and small group videoconferencing.
41108927|NCT00363116|DRUG|Daclizumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
41108928|NCT02485236|DEVICE|Low flow oxygen via nasal cannula|In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of \> 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
41108929|NCT02485236|DEVICE|Humidified Nasal High Flow Therapy|Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen \> 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
41108930|NCT01353170|OTHER|Dialysate calcium concentration|Calcium dialysate concentrations: 1.25, 1.35 and 1.5 mmol/l
41108931|NCT01834248|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC and ID
41108932|NCT01834248|DRUG|Decitabine|Given IV
41108933|NCT01834248|OTHER|Laboratory Biomarker Analysis|Correlative studies
41108934|NCT01834248|DRUG|Poly ICLC|Given SC
41108935|NCT04521192|DRUG|Fluzoparib|the first period: test preparation; the second period: reference preparation
41108936|NCT04521192|DRUG|Fluzoparib|the first period: reference preparation the second period: test preparation
41108937|NCT03725371|OTHER|No intervention was administered for the purpose of this study.|No intervention was administered for the purpose of this study. Observations were carried out for all participants.
41108938|NCT00972504|DRUG|GSK835726 10mg|GSK835726 10mg tablet
41108939|NCT00972504|DRUG|GSK1004723 1000mcg|GSK1004723 1000mcg nasal spray solution
41108940|NCT00972504|DRUG|Cetirizine 10mg|Cetirizine 10mg active comparator
41108941|NCT00972504|DRUG|placebo|placebo to match actives
41108942|NCT03958513|DRUG|Bupivacaine|1.5 ml 0.25% bupivacaine for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
40752290|NCT00440739|DRUG|etoricoxib|etoricoxib 120 mg
40752291|NCT00440739|DRUG|flavoxate|flavoxate 200 mg 3 times
41108943|NCT03958513|DRUG|0.9% normal saline|1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
41108944|NCT05537766|BIOLOGICAL|Brexucabtagene Autoleucel|Administered intravenously
41108945|NCT05537766|DRUG|Cyclophosphamide|Administered intravenously
41108946|NCT05537766|DRUG|Fludarabine|Administered intravenously
41108947|NCT02299635|DRUG|PF-03084014|Tablet, 10 mg, twice a day.
41108948|NCT02299635|DRUG|PF-03084014|Tablet, 50 mg, twice a day
41108949|NCT02299635|DRUG|PF-03084014|Tablet, 100 mg, twice a day
41108950|NCT02905968|DEVICE|transanual tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
40752292|NCT00440739|DRUG|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
40752293|NCT00440739|DRUG|placebo|placebo once and placebo 3 times
40752294|NCT03970343|DEVICE|OPTIMIZER Smart System|"Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:~1. Optimizer Smart or Optimizer Smart Mini~2. Vesta Charger or Guardio Charger~3. Two commercially available intravascular leads"
40752295|NCT03531502|PROCEDURE|Ventricular Tachycardia Ablation|Ventricular Tachycardia Ablation
41108951|NCT02724085|DRUG|TP-271|TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
41108952|NCT05817318|DEVICE|Renal Denervation|Arrhythmia burden pre-to-post renal denervation as assessed by an implantable cardiac monitor
41108953|NCT04633980|DRUG|Mixture 3,6% H2 in N2 (96.4%)|Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
41108954|NCT02570295|OTHER|Swiss Army Physical Fitness Training|2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
41108955|NCT05803850|DRUG|HNC1058 Capsules|HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
41108956|NCT04462107|OTHER|Surveys|All participants will complete surveys that range in time from baseline to 3 months post partum.
41271081|NCT03505437|OTHER|Cold water condition|Cold water condition of the SECPT. Participants immerse their hand into ice-cold water (0-3°C). During the SECPT, participants are videotyped and monitored. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders
41271082|NCT03505437|OTHER|Warm water condition|Warm water condition of the SECPT. Participants immerse their hand into warm water (36-37°C). Participants are neither videotyped nor monitored during the whole procedure. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders.
40752296|NCT03531502|OTHER|Standard Medical Therapy|For the antiarrhythmic naïve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.
40752297|NCT03531502|PROCEDURE|Non-Invasive Programmed Stimulation (NIPS)|All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.
40752298|NCT02605616|DRUG|AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
41108957|NCT03342872|BEHAVIORAL|Core Training: FBS System Mapping and MTFS-I Installation|Core Training will be a blended strategy wherein multiple interventions targeting multiple agency roles are combined to help ASU treatment providers increase their FBS quality. Core Training will be conducted with administrators, supervisors, data managers, and clinical staff. It will contain two 3-hour sessions focusing on FBS System Mapping and MTFS-I Installation. FBS System Mapping will focus on process mapping of existing site policies and practices for assessing family functioning at intake, educating families about intervention strategies and activities, including family members in treatment sessions, and hiring and supporting clinicians trained in and routinely delivering FBS. MTFS-Installation will focus on introducing MTFS-I components and integrating principles of DDDM.
41108958|NCT03342872|BEHAVIORAL|Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings|Facilitation will consist of monthly on-site meetings to review progress toward FBS improvements, discuss MTFS-I feedback reports and online resource use, and provide intensive technical assistance for progressing toward site-selected FBS improvement goals. Meetings will involve a subset of site-delegated participants from Core Training sessions to serve as a local change team (quality improvement team). The efficacy of facilitation-guided change teams has been established. Although there are several models for creating change teams, at least three features are common: (1) members represent multiple organizational roles (supervisors, data managers, line staff); (2) focus on data-driven decisions; and (3) use of external expert advisors.
41108959|NCT00909935|DRUG|Dexmedetomidine|Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
41108960|NCT04017169|OTHER|No intervention as observational study|
41108961|NCT05914506|DIAGNOSTIC_TEST|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level
41271083|NCT06464211|BEHAVIORAL|Cognitive Behavioral Model-Based Family Counseling Program|A Cognitive Behavioral Model-Based Family Counseling Program is a therapeutic approach that focuses on identifying and changing negative thought patterns and behaviors within the family unit, using principles of cognitive-behavioral therapy to improve communication, resolve conflicts, and enhance overall family functioning.
41271084|NCT00790517|BEHAVIORAL|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
41445683|NCT06034483|OTHER|Pelvic floor exercise training|"* Pelvic floor muscle contraction will be verified with vaginal palpation and a progressive pelvic floor muscle training program will be given.~* In the pelvic floor muscle training program:~* Fast and slow pelvic floor muscle contractions will be taught,~* Training will begin with 3 sets of exercises per day, exercise compliance of individuals will be monitored in the controls to be made every 2 weeks, and the number of exercise sets will be increased by one set.~* 1 set of exercises: It will include 10 fast + 10 continuous (frequent-(3-10 sec) hold-release) contractions.~* Individuals will be tracked with exercise diaries.~* At the end of the 8th week, post-intervention evaluations will be made again.~* The exercise program will be completed with a total of 6 sets of exercises per day (60 fast and 60 slow per day)."
41445684|NCT06034483|OTHER|Patient/individual education|"In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~* Explaining menopause and menopausal symptoms~* Defining the Genitourinary Syndrome of Menopause (MGS)~* The effect of MGS on sexual function cycle and sexual function,~* Conservative recommendations on MGS management~* Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month."
41445685|NCT04889898|DEVICE|Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone|\[Patients only\] Weekly completion of audio recordings of speech and swallowing performed at home by the subject using the study smartphone application on their personal device.
41271085|NCT06156527|DRUG|Lazertinib|Lazertinib 240mg, QD, daily
41445686|NCT04889898|RADIATION|Modified Barium Swallow Study (MBSS)|\[Patients only\] MBSS is an instrumented evaluation of oropharyngeal swallowing function that is performed using videofluoroscopy.
41445687|NCT04889898|BEHAVIORAL|Speech Intelligibility Test (SIT)|\[Patients only\] The SIT is a standardized test for measuring speech intelligibility.
41445688|NCT04889898|BEHAVIORAL|SIT Scoring|\[Listeners only\] Listeners will judge the intelligibility of speech recordings made by patients in the study.
40752299|NCT02605616|OTHER|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
40752300|NCT06042660|OTHER|the prevalence of comorbid conditions|analysis of history of comorbidities at the time of CML diagnosis
41108962|NCT01425983|DIETARY_SUPPLEMENT|amino acid composition (asn01)|"Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
41108963|NCT01425983|OTHER|Placebo|"Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
41108964|NCT04768361|BEHAVIORAL|Behavioral Activation without Mindfulness|"Behavioral Activation without Mindfulness includes functional analysis as key to defining out-of-session and activation strategies as central to mood change."
41108965|NCT04768361|BEHAVIORAL|Behavioral Activation with Mindfulness|"Behavioral Activation with Mindfulness includes functional analysis as key to defining out-of-session and activation strategies and mindfulness as central to mood change."
41108966|NCT05416671|BEHAVIORAL|guided narrative technique-writing|The experimental group underwent the psychological intervention of guided narrative technique-writing with the theme of teacher criticism for 20 to 30 minutes once a day for three consecutive days.
41108967|NCT04203264|DIAGNOSTIC_TEST|Real-time artificial intelligence identification system|The patients swallowed the MCE with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. The magnetic steering time for passing through the pylorus was not allowed more than 15 min. The real-time auxiliary system implemented real-time processing for the output image of MCE system. Professional operators guarantee the integrity of the examination and the diagnostic results of professional endoscopist was used as the gold standard. The system diagnosis results was recorded at the same time. The sensitivity, delay time, specificity of lesions and anatomical landmarks will be analyzed.
41108968|NCT02473419|DRUG|Vayarin|
41108969|NCT02473419|DRUG|Placebo|
41108970|NCT03750942|DEVICE|Adhesix® monofilament polypropylene mesh (Bard Davol)|The intervention group will receive preventive mesh placement and in the control group no mesh is placed, the stoma is closed according to standard practise.
41108971|NCT05998525|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria and after catheterization will be randomized to receive Dapagliflozin 10 mg every 24 hours and upon dischargetreatment will continue for 12 months
41108972|NCT05998525|DRUG|Placebo|patients who meet the inclusion criteria and after catheterization will be randomized to receive a placebo pill 24 hours and upon discharge treatment will continue for 12 months
41108973|NCT01693419|DRUG|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m² IV on day 1, 8~2. Erlotinib 100 mg/day PO on day 1~3. S-1 60 mg/m²/day PO on day 1-14"
41108974|NCT00325013|DRUG|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
41108975|NCT00964184|DRUG|Metformin|
41108976|NCT00964184|BEHAVIORAL|Lifestyle modification|
41108977|NCT04680260|OTHER|Standard of care|Patients will be offered adjuvant chemotherapy according to standard of care. Follow up will be performed with imaging according to standard guidelines, equal to the experimental arm. Blood samples will be analyzed retrospectively to evaluate the ctDNA status.
41108978|NCT04680260|OTHER|Circulating tumor DNA guided treatment approach|Circulating tumor-marker positivity will lead to escalation with 6 months of intensified chemotherapy consisting of 4 months of FOLFOXIRI followed by 2 months of 5FU monotherapy. Circulating tumor-marker negativity will based on shared decision-making lead to de-escalation i.e. possibilities for observation in patients otherwise eligible for monotherapy or observation/monotherapy in patients, otherwise eligible for combination chemotherapy according to standard of care.
41108979|NCT02023125|DRUG|Alectinib|A single 600-mg oral dose of alectinib will be administered in a fasted or fed condition.
41108980|NCT02023125|DRUG|Esomeprazole|Esomeprazole 40 mg will be administered orally once daily for 6 days prior to alectinib administration.
41108981|NCT02023125|OTHER|High Fat and Calorie Meal|High fat and calorie meal served prior to alectinib administration
41108982|NCT02023125|OTHER|Standard Meal|Standard meal served prior to alectinib administration
41108983|NCT06070324|PROCEDURE|Breast surgery|Any surgery involving incisions made along the nipple areolar complex. These would include transgender mastectomy, cisgender female breast reduction/augmentation/reconstruction, and cisgender male gynecomastia correction.
41271086|NCT06156527|DRUG|Bevacizumab Injectable Product|Bevacizumab: 15mg/kg IV every 3 weeks
41108984|NCT06070324|DEVICE|Suturing of surgical incision|The closing of a surgical incision by using sutures so appose and maintain apposition of two skin edges. Suturing may or may not require knot-tying depending on the material of suture used.
41108985|NCT03162978|OTHER|HIIT + POE|Subjects will participate in high-intensity interval training (HIIT) with an additional treatment component to increase positive outcome expectations (POE) of exercise.
41108986|NCT03162978|OTHER|HIIT only|Subjects will participate in high-intensity interval training (HIIT) only.
41108987|NCT00676533|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
41108988|NCT02572024|DEVICE|BAT|Baroreflex activation therapy device ON
41108989|NCT02572024|OTHER|Placebo|Baroreflex activation therapy device OFF
41108990|NCT01611467|DRUG|CC-223|20 mg oral CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution
41108991|NCT01611467|DRUG|CC-223|20-mg oral CC-223 tablet under fasting or fed conditions
41108992|NCT00389246|BEHAVIORAL|Consultation without genetic information|
41108993|NCT00389246|BEHAVIORAL|Consultation with genetic information|
41108994|NCT04307316|OTHER|ACBT group|"ACBT:~Breathing control 3 to 4 Thoracic Expansion Exercise A: 3 seconds hold B: Chest clapping C: Chest vibration Forced Expiratory Technique Breathing control A: 3 seconds hold B: Chest clapping C: Chest vibration 3 to 4 Thoracic Expansion Exercise Breathing control 1-2 Huff combine with breathing control Huff and cough~Chest Physical Therapy Early mobilization"
41108995|NCT04307316|OTHER|Conventional Physical therapy|Chest percussion, deep breathing, Huff and cough. Early mobilization
41108996|NCT05272124|OTHER|Hip Abductor Strengthening|"Elastic resisted training of Hip Abductors (5-10 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
41108997|NCT05272124|OTHER|Traditional Physical Therapy|"Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
41108998|NCT04742842|BIOLOGICAL|COVIGEN C19 0.8 mg ID or Placebo ID|2 doses of COVIGEN C19 0.8 mg ID or Placebo ID will be given at Day 1 and Day 29.
41108999|NCT04742842|BIOLOGICAL|COVIGEN C19 2.0 mg IM or Placebo IM|2 doses of COVIGEN C19 2.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
41109000|NCT04742842|BIOLOGICAL|COVIGEN C19 4.0 mg IM or Placebo IM|2 doses of COVIGEN C19 4.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
41109001|NCT04742842|BIOLOGICAL|COVIGEN C20 1.0mg vaccine ID|COVIGEN C20 1.0mg ID vaccine will be given at Day 1
41109002|NCT05767099|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
41109003|NCT04671719|BIOLOGICAL|blood sample|blood sample for circulating autotaxin measurement (5ml).
41109004|NCT00319566|DRUG|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
41109005|NCT05557812|DRUG|non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies|non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars
41271087|NCT04874857|OTHER|Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L.|Massage application
41109006|NCT05557812|DRUG|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
41109007|NCT02770599|OTHER|IBD multidisciplinary team model including IBD nurse|IBD multidisciplinary team model including IBD nurse
41109008|NCT05657041|DRUG|Clopidogrel|Body weight adjusted clopidogrel dosing
41109009|NCT05475106|BIOLOGICAL|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks, and every month for 5 months after that.
41109010|NCT05632432|PROCEDURE|Epicardial AAMs-patch transplantation|Perioperative assembly of an AAMs-patch with epicardial transplantation onto the epicardium of the scarred myocardium at the end of CABG surgery
41109011|NCT05632432|DIAGNOSTIC_TEST|RNA-stabilized whole blood sampling|Collection (preoperative and at 6-month-follow-up) of TEMPUS(TM) stabilizing whole blood for epitranscriptomics-oriented measurements
41109012|NCT05632432|DIAGNOSTIC_TEST|Plasma sampling|Collection (preoperative and at 6-month follow-up) of blood-derived both RNA-stabilized and non-stabilized plasma aliquots for epitranscriptomic-oriented and other CVD biomarker oriented measurements, respectively
41109013|NCT05632432|DIAGNOSTIC_TEST|Transthoracic echocardiography|To assess cardiac structure and function both pre- and postoperatively (at both hospital discharge and 3-month follow-up)
41109014|NCT05632432|DIAGNOSTIC_TEST|Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI)|To assess detailed cardiac structure (i.e. interstitial fibrosis) and function both preoperatively and at 6-month follow-up postoperatively.
41109015|NCT05632432|OTHER|Symptom-scaling|Standardised evaluation of IHD and HF-related angina pectoris (CCS) and dyspnea (NYHA) and life quality (RAND36) pre- and postoperatively (at both 3- and 6-month follow-up).
41109016|NCT05632432|OTHER|6-minute walking test (6MWT)|Standardised assessment of physcial capacity pre- and postoperatively (at 6-month follow-up)
41109017|NCT05632432|DIAGNOSTIC_TEST|Blood sampling (NT-proBNP)|Collection of a blood sample measurement of NT-proBNP by an accredited hospital laboratory pre- and postoperatively (at both 3- and 6-month follow-up).
41109018|NCT05632432|DIAGNOSTIC_TEST|Transesophageal echocardiography|Performed by the perfusion-anesthesiologist at the beginning of the CABG surgery to evaluate both LAA and RAA for blood flow velocities, anatomy, possible sludge and thrombus.
41109019|NCT05632432|PROCEDURE|Epicardial collagen-based patch transplantation|Epicardial transplantation of the collaged-based patch material without the AAMs onto the epicardium of the scarred myocardium at the end of CABG surgery.
41109020|NCT02529696|DEVICE|Accelerometer|Measures patient movement
41109021|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: Beef Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
41445689|NCT05084677|COMBINATION_PRODUCT|Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy|Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) concurrent with chemoradiotherapy; 6 cycles of Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) after chemoradiotherapy; Toripalimab 240mg intravenously(IV) every 6 weeks (Q6W) thereafter until the whole treatment period reached one year since the beginning.
41109022|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: whey Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
41109023|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: CHO|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
41109024|NCT01000129|OTHER|Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)|Planning CT scan performed by qualified planning radiographers
41109025|NCT01000129|OTHER|Cone beam CT acquisition|Cone beam CT acquisition performed by therapy radiographers who have training and experience of using cone beam CT.
41109026|NCT04219137|GENETIC|Molecular Profiling|This is a correlative study collecting biosamples to evaluate genomic characteristics and treatment outcomes of gastroesophageal adenocarcinoma.
41109027|NCT00323752|PROCEDURE|rHuEpo|Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.
41109028|NCT00661648|DEVICE|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
41109029|NCT03818178|DIETARY_SUPPLEMENT|Intralipid|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
41109030|NCT03818178|DIETARY_SUPPLEMENT|Palm Oil Emulsion|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
41109031|NCT03818178|OTHER|Saline|All participants will serve as their own controls with a saline infusion study day.
41109032|NCT05394896|DEVICE|ACUMEN (Edwards Lifesciences, Irvine, USA)|ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.
41109033|NCT05394896|DEVICE|Invasive Blood Pressure|Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)
41109034|NCT01668212|PROCEDURE|Doppler ultrasound|Doppler Ultrasound
41109035|NCT02533908|DRUG|Fentanyl intranasal|fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
41109036|NCT02533908|DRUG|NaCl 0.9% intranasal|Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
41109037|NCT01671241|DEVICE|Polyethylene wrap|
41109038|NCT01671241|DEVICE|Polyethylene wrap|
41109039|NCT02747563|OTHER|Blood test (PSA)|Measurement of blood PSA levels
41109040|NCT02874430|DRUG|Metformin Hydrochloride|Given orally
41109041|NCT02874430|DRUG|Doxycycline|Given orally
41109042|NCT03819361|DIAGNOSTIC_TEST|pulse-oximetry|Patients with suspected OSA will be monitored with 14 nights of pulse-oximetry prior to the already planned in-hospital single-night sleep study at the University Hospital Zurich
41109043|NCT04481373|BEHAVIORAL|THRIVE|"The ACT components (3-3.5 hours) will focus on clarifying patient values and goals and identifying obstacles that may be getting in the way of living a rich life. Short-and long-term effects of avoidance will be discussed (e.g., avoidance reduces immediate contact with distressing experiences and provides short-term relief but leads to greater dysfunction in long run). Patients will be taught acceptance, mindfulness, and perspective taking to help patient cope with difficult emotions and thoughts that may interfere with living a values-driven life. Individuals will also be encouraged to examine the costs of stigmatization on their life (e.g. avoidance of medical care, sense of isolation).~Education will include medical information about HIV, services available at the clinic, and health needs related to comorbidities. This content to be delivered in 30 minutes."
41109044|NCT04481373|OTHER|Treatment as Usual|Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
41109045|NCT01391130|DRUG|LY2510924|Administered subcutaneously
41109046|NCT01391130|DRUG|Sunitinib|Administered orally
41109047|NCT00255437|DRUG|ferumoxytol or oral iron|
41109048|NCT05584046|OTHER|CDAM|Novel drugs such as Traditional Chinese Medicine (TCM) formula that can suppress inflammation may augment tissue healing and reduce activity-related pain in patients suffering from plantar fasciitis. Our team has experiences of using TCM for the treatment of plantar fasciitis. Based on our previous experience, our group has developed a new proprietary topical TCM herbal formula, CDAM, containing Carthami Flos , Dipsaci Radix , Aconiti Lateralis Radix Praeparata and Herba Menthae for the treatment of plantar fasciitis.
41109049|NCT04288219|DEVICE|Non-Invasive Positive Pressure Ventilation|Continuous positive airway pressure delivered by face mask at 10cmH2O
41109050|NCT04288219|DRUG|Nifedipine|Nifedipine 30mg, Pharmacotherapy
41109051|NCT04288219|OTHER|supplemental oxygen|supplemental oxygen
41109052|NCT05739513|DIAGNOSTIC_TEST|miRNA analysis in plasma|blood sample
41109053|NCT01299753|DRUG|placebo|identically packed placebo
41109054|NCT01299753|DRUG|propranolol|20-40 mg q6-8h
41109055|NCT05422716|DEVICE|Epidural implant stimulation device|Individuals randomized to the Baclofen pump device group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments). The epidural implant group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity.
41109056|NCT05538988|DRUG|Cemiplimab|Cemiplimab is a recombinant human IgG monoclonal antibody known as a programmed cell death 1 (PD-1) immune checkpoint inhibitor. The PD-1 pathway is an immune system checkpoint that may be exploited by tumour cells to escape active T-cell surveillance. Cemiplimab binds to PD-1 on T cells and blocks the interaction with its ligands, PD-L1 and PD-L2. Inhibition of the receptor/ligand signaling restores the anti-tumour immune response
41109057|NCT04027426|BEHAVIORAL|FBT|FBT will receive a family-based, behavioral intervention for childhood obesity, consisting of group meetings once a week for months 1 to 4, twice a month for months 5 to 6, once a month for months 7 to 12, and once every two months for months 13 to 18 (29 sessions). For all meetings, the child and adult caregiver will be weighed and be provided with feedback, homework will be reviewed, and a behavioral lesson will be presented. At the 60-min meetings, the child and adult will attend separate 40 min group meetings, and then for the last 20 min of the meetings they will meet together with an individual therapist to address specific family-issues by developing behavioral action plans. No goals on variety in RED foods will be provided.
41271088|NCT04874857|OTHER|Baby oil|Massage application
41109058|NCT04027426|BEHAVIORAL|FBT+Variety|This condition is FBT with a limited variety prescription. The limited variety prescription reduces the number of different RED foods consumed.
41109059|NCT01966055|DRUG|Solithromycin|
41109060|NCT03617653|DIAGNOSTIC_TEST|Group A|Refer to detailed study Description
41109061|NCT00999843|DRUG|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
41109062|NCT03224299|DRUG|OCT - clear|Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
41109063|NCT03224299|DRUG|OCT- tinted|Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
41109064|NCT03224299|OTHER|ChloraPrep|Active Control: ChloraPrep® - Hi-Lite Orange® applicator
41109065|NCT03224299|OTHER|Saline|Negative Control: sterile 0.9% saline applied with single use applicator
41109066|NCT06398912|OTHER|Music Based Intervention|Measuring how the fundamental frequency of differential music facilitators (mother, father, male and female music therapist) impacts the premature infant brain
41109067|NCT04683263|OTHER|Placebo|topical cream with same composition as Intervention but without active ingredients
41109068|NCT04683263|OTHER|Fisiocrem|a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
41109069|NCT01052454|BEHAVIORAL|Mindfulness-based stress reduction|Participants in the MBSR arm attend eight weekly classes.
41109070|NCT00562913|DRUG|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
41109071|NCT01253226|DRUG|LY2127399 (Tabalumab)|Administered subcutaneously
41109072|NCT01253226|DRUG|Placebo|Administered subcutaneously
41109073|NCT01454661|DIETARY_SUPPLEMENT|LGG|Lactobacillus rhamnosus GG 10E9 cfu / day
41109074|NCT01454661|DIETARY_SUPPLEMENT|LGG+Bb-12|A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
41109075|NCT01454661|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose is used as placebo.
41109076|NCT00442117|DRUG|mometasone furoate dry powder inhaler|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
41109077|NCT00442117|DRUG|Budesonide DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
41109078|NCT01007344|DIETARY_SUPPLEMENT|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
41109079|NCT01007344|DIETARY_SUPPLEMENT|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
41109080|NCT05654012|DEVICE|MRI|Grey Matter Volume (T1) Resting state BOLD
41109081|NCT05654012|DEVICE|Thermal Stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
41109082|NCT05654012|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
41109083|NCT05654012|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 10 or 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
41109084|NCT05654012|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus.
41109085|NCT05654012|BEHAVIORAL|Conditioned pain modulation (CPM) efficiency|The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information.
41109086|NCT05654012|DIAGNOSTIC_TEST|Hormonal assessment|Blood samples will be collected for analyses of sex hormone levels
41109087|NCT05654012|BEHAVIORAL|Migraine-related measures|Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.
41109088|NCT05654012|BEHAVIORAL|Neural assessments|MRI and fMRI scans
41109089|NCT05654012|DIAGNOSTIC_TEST|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-
41109090|NCT00566904|DRUG|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
41109091|NCT00566904|DRUG|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
41109092|NCT00566904|OTHER|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
41271089|NCT04371796|DRUG|Sintilimab injection|Sintilimab injection 200mg, 2cycles of treatment before surgery
41271090|NCT05313438|DEVICE|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
41271091|NCT01089192|DRUG|Metformin|
41445690|NCT05187481|DRUG|Jianpi Huatan dispensing granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
41109093|NCT01337869|PROCEDURE|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
41109094|NCT01337869|PROCEDURE|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
41109095|NCT01312337|DRUG|salvage iressa|Iressa 250mg per day until progression
41109096|NCT01441453|PROCEDURE|FibroScan (Transient Elastography measurement)|Preoperative evaluation of liver stiffness through FibroScan
41109097|NCT00892593|DEVICE|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
41109098|NCT00892593|DEVICE|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
41109099|NCT01847651|PROCEDURE|Vastus Muscle Biopsy|Both Arms, all 3 visits at 0, 4 and 12 weeks
41109100|NCT01847651|DRUG|LOLA or placebo|Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
41109101|NCT01847651|OTHER|Cognitive assessment (PHES)|Both Arms, all 3 visits at 0, 4 and 12 weeks
41109102|NCT01847651|OTHER|Cognitive Assessement (Cogstate)|Both Arms, all 3 visits at 0, 4 and 12 weeks
41109103|NCT01847651|OTHER|blood and urine sampling|Both Arms, all 3 visits at 0, 4 and 12 weeks
41109104|NCT01847651|OTHER|Nutritional assessment|Both Arms, all 3 visits at 0, 4 and 12 weeks
41109105|NCT01847651|OTHER|MRI brain and spectroscopy|Both Arms, all 3 visits at 0, 4 and 12 weeks
41109106|NCT01847651|OTHER|MRI leg cross section|Both Arms, all 3 visits at 0, 4 and 12 weeks
41109107|NCT01847651|OTHER|Functional MRI (working memory and attention tasks)|Both Arms, all 3 visits at 0, 4 and 12 weeks
41109108|NCT01256034|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
41109109|NCT01353963|DRUG|desvenlafaxine succinate|50 mg tablet once daily
41109110|NCT00817830|DRUG|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
41109111|NCT00095004|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
41109112|NCT00095004|DRUG|Comparator: placebo / Duration of Treatment: 1 day|
41109113|NCT01436838|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
41109114|NCT06420713|PROCEDURE|Horizontal Bone Augmentation of Alveolar Ridge|Elevation of the flap in the anterior region of atrophic maxilla to receive particulate autogenous bone mixed with deproteinized bovine bone graft (Group A) or Leukocyte-and-Platelet-Rich Fibrin (L-PRF) mixed with deproteinized bovine bone graft (Group B). In both groups, bone augmentations were covered with a collagen membrane stabilized with pins.
41109115|NCT06420713|PROCEDURE|Groups|"The patients underwent Guided Bone Regeneration (GBR) procedures for the reconstruction of atrophic edentulous alveolar ridges and were divided into two groups according to the proposed treatment:~Group A - GBR using a mixture of particulate autogenous bone graft and deproteinized bovine bone graft (Bio-Oss® Small; Geistlich AG, Wolhusen, Switzerland).~Group B - GBR using a mixture of deproteinized bovine bone graft (Bio-Oss® Small) and L-PRF + Liquid Fibrinogen."
41109116|NCT06420713|PROCEDURE|Dental Implants|"After 8 months of GBR healing, dental implants were placed in the grafted regions using guided surgery techniques.~Cone beam computed tomography (CBCT) scans were performed preoperatively, immediately after the surgical procedure, and after 8 months of follow-up to measure the linear and volumetric changes in the alveolar ridge. At the time of dental implant placement, after an 8-month period following the GBR procedures, bone biopsies were obtained from the grafted area for histological and micro-CT analysis.~The stability of the implants was assessed using resonance frequency analysis in the immediate postoperative period and at 6 months postoperatively.~After the 6-month period following dental implant placement, the patients were cleared for implant-supported prosthetic rehabilitation."
41109117|NCT00846313|OTHER|Individual dietary counseling.|Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
41109118|NCT03699488|BEHAVIORAL|psychotherapy via asynchronous message|Behavioral psychotherapy delivered by asynchronous message using the Talkspace application
41109119|NCT02196051|OTHER|one bout of 45 minutes exercise|45 minutes of exercise on an elliptical exercise machine
41109120|NCT01682200|DRUG|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
41109121|NCT04519450|DEVICE|Mindray TE7 ultrasound machine|The study was performed using a Mindray TE7 ultrasound machine with the depth of the linear probe at 70 mm and gain of 90 dB; settings remained unchanged during the study. Measurements of the right m. sternocleidomastoideus, the right m. trapezius, and the right upper leg were taken, with the final value being the average of three measurements for each. The probe was set at the musculoskeletal ultrasound setting.
41109122|NCT01787994|GENETIC|Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.|
41109123|NCT05387837|DRUG|D-4517.2|D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
41109124|NCT01595906|PROCEDURE|Ventilated Helmet|The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.
41109125|NCT02747602|DRUG|AC-1204|40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
41109126|NCT02747602|DRUG|caprylic triglyceride oil (standard breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
41109127|NCT02747602|DRUG|caprylic triglyceride oil (high fat breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
41109128|NCT04246762|DRUG|Olokizumab|Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)
41109129|NCT04246762|DRUG|Omeprazole|Tablets, 20 mg, oral
41109130|NCT04246762|DRUG|Caffeine|Tablets, 100 mg, oral
41109131|NCT04246762|DRUG|Warfarin+ Vitamin K|Warfarin -Tablets 10 mg (containing 5 mg S-warfarin), oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule, orally.
41109132|NCT04246762|DRUG|Midazolam|Syrup, 2 mg/mL, oral
41109133|NCT02885311|BEHAVIORAL|Motivation Enhancement Therapy|Motivation Enhancement Therapy (MET) similarly allows for goal choice in treatment, and has been shown to be effective in treating a broad spectrum of drinking problems in both abstinent and non-abstinent goal conditions. The unique goals of MET (enhancing intrinsic motivation for change and facilitating development of a self-generated change plan).
41109134|NCT02885311|BEHAVIORAL|Modified Behavioral Self-Control Therapy|Motivational Interviewing was developed to increase self-efficacy and motivation for drinking, and Cognitive Behavioral Therapy allows for individuals to develop strategies for drinking reduction. Both are evidence-based interventions that have been combined in previous studies for drinking reduction in problem drinkers.
41109135|NCT02885311|DRUG|Naltrexone|Participants, who choose medication treatment, will be offered naltrexone (50 mg per day), which is an FDA-Approved medication for alcohol use disorder. According to the package insert for NTX, the medication has been associated with liver toxicity at very high doses (up to 300 mg/day); however, a number of clinical trials and published studies suggest there are few serious adverse effects, including minimal hepatotoxicity, associated with daily dose of 50 mg of naltrexone. Its most common side effects in opioid-free individuals are nausea, vomiting, anxiety, headache, abdominal discomfort, difficulty sleeping, fatigue, irritability, and decreased appetite. A rare serious adverse effect may include minimal liver toxicity, but is more likely to occur at very high doses (300 mg/day).
41109136|NCT02885311|BEHAVIORAL|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
41109137|NCT02885311|OTHER|Referral to specialty substance use disorder treatment|Participants who present with complex drinking concerns will be referred to specialty substance use disorder treatment. This treatment will be provided in a separate treatment facility that focuses on substance use disorders and will potentially provide a combination of medication management and individual/group behavioral treatment for substance use disorders.
41109138|NCT04136496|DEVICE|Black-Eye Ink|There are two proposed studies utilizing the Ink during differing timepoints.Both will identify patients with breast cancer, with a biopsied metastatic axillary lymph node(LN) with a tissue marker clip placed, as is current practice. In Study A, 0.5mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy. In Study B, 0.5mL of Black Eye Ink will be placed before neoadjuvant therapy. In both studies, the LN containing the tissue marker clip will be the one to have the radioactive seed and Ink inserted. The seed will still be inserted, in the event the dye is not well-visualized. In both studies, the surgeon will attempt to find the LN by direct visualization and then confirm the appropriate LN has been removed by using the Gamma probe and intra-operative radiographs. If the seed is not within the tattooed node, the LN containing the seed will also be removed. All lymph nodes injected with Ink will be removed by the surgeon;no Ink-injected node remains in body.
41109139|NCT05028712|BEHAVIORAL|Visual Information Training|Participants in this arm will receive training to improve the use of residual vision to enhance functional performance.
41109140|NCT05028712|BEHAVIORAL|Multimodal training|Participants in this arm will receive training in integrating input from different senses to enhance functional performance.
41109141|NCT03462199|DIETARY_SUPPLEMENT|Actazin (green kiwi powder) High Dose|Participants will consume 4 capsules (600 mg green kiwi powder) daily for 28-days
41109142|NCT03462199|DIETARY_SUPPLEMENT|Actazin (green kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg green kiwi powder) daily for 28-days
41109143|NCT03462199|DIETARY_SUPPLEMENT|Control Formula (Actazin green kiwi powder + PreticX prebiotic)|Participants will consume 4 capsules (150 mg green kiwi powder + 250 mg PreticX prebiotic) daily for 28-days
41109144|NCT03462199|DIETARY_SUPPLEMENT|Livaux (gold kiwi powder) High Dose|Participants will consume 4 capsules (600 mg gold kiwi powder) daily for 28-days
41109145|NCT03462199|DIETARY_SUPPLEMENT|Livaux (gold kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg gold kiwi powder) daily for 28-days
41109146|NCT03462199|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|Participants will consume 4 capsules containing no active ingredients daily for 28-days
41109147|NCT00487305|BIOLOGICAL|Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells|Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
41109148|NCT01482013|DRUG|HPP854|Oral, once a day for 28 days.
41109149|NCT01482013|DRUG|Placebo|Oral, once a day for 28 days.
41109150|NCT03780816|OTHER|Observation of provider-patient interactions and interviews|Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.
41109151|NCT01010919|DIETARY_SUPPLEMENT|Chicory root extract|
41109152|NCT00194623|DRUG|Botulinum Toxin A (Botox)|
41109153|NCT02355158|DRUG|clonidine hydrochloride topical gel, 0.1%|
41109154|NCT02873754|BEHAVIORAL|Cognitive Behavioral Counseling|Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
41109155|NCT02873754|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
41109156|NCT02873754|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
41109157|NCT02873754|DRUG|Transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
41109158|NCT02873754|DRUG|Nicotine polacrilex|Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
41109159|NCT02873754|DRUG|Nicotine lozenge|Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
41109160|NCT04911842|DEVICE|HydroMID|Hydrophilic biomaterial
41109161|NCT04911842|DEVICE|TPU|Thermoplastic polyurethane
41109162|NCT00001182|PROCEDURE|current standard of care treatments|
41109163|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|5mg/day
41109164|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|10mg/day
41109165|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|25mg/day
41109166|NCT00288691|DRUG|Placebo|Placebo
41109167|NCT03008915|DRUG|Aspirin|81mg aspirin taken once per day in the morning
41109168|NCT03008915|DRUG|Placebo|placebo taken once per day in the morning
41109169|NCT03008915|OTHER|Withdrawal from alpha1 antitrypsin replacement therapy|After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.
41109170|NCT00873899|DEVICE|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
41109171|NCT05862363|DIETARY_SUPPLEMENT|Microbiota-directed balanced energy protein (MD-BEP)|Prototypes for nutritional interventions that are composed of locally available, affordable, culturally acceptable complementary foods commonly consumed in Bangladesh have recently been developed.
41271092|NCT03083717|DIAGNOSTIC_TEST|Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)|2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.
41271093|NCT02956811|DRUG|Dapagliflozin|SGLT2 inhibitor
41445691|NCT05187481|DRUG|Placebo granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
41445692|NCT01499602|DRUG|LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland|Initial release rate of 20µg Levonorgestrel per day for one year follow up.
41109172|NCT05862363|DIETARY_SUPPLEMENT|Ready-to-use supplementary food-balanced energy protein (RUSF-BEP)|RUSF-BEP is composed of rice, lentil, sugar, soybean oil, and skimmed milk powder mixed with vitamin-mineral premix. MD-BEP is composed of chickpea flour, peanut flour, soy flour, green banana pulp, sugar, soybean oil, and vitamin-mineral premix. The results from previous studies support the notion that repair of impaired gut microbial community development could represent a new therapeutic concept for restoring healthy growth. RUSF-BEP will be given to one arm of low-BMI women of reproductive age and low-BMI pregnant women.
41109173|NCT05862363|PROCEDURE|Esophagogastroduodenoscopy (EGD)|Aim 1A consists of performing EGD to women with low-BMI and normal BMI women with function dyspepsia. In order to enroll 30 participants with normal duodenal mucosal histology, we are planning to perform EGD on 100 healthy women (BMI 20-24.9 kg/m2) of childbearing age who have been referred for evaluation of functional dyspepsia. Undernourished low-BMI (\<18.5kg/m2; 18-35 years) women of childbearing age will be enrolled from Bauniabadh and adjacent slum area of Mirpur, Dhaka and EGD will be performed among 60 women. A total of 6-8 biopsy samples from SI and a dry duodenal aspirate will be collected for biopsy, histochemical and immunocytochemical analysis.
41109174|NCT05862363|BEHAVIORAL|Counselling and follow-up|Normal BMI pregnant women will be counseled and followed up as per standard guidelines and will be provided routine antenatal care.
41109175|NCT05268042|OTHER|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
41109176|NCT05268042|OTHER|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
41109177|NCT06513546|DRUG|PLL001 or placebo daily subcutaneous injections|PLL001 consists of the combination of 4 drug substances (DS) each being a linear poly-lysine flexible backbone with an average length of 70 L-lysines linked with 10% of conjugated side chains all being small chain fatty acids (SCFAs) (acetate, butyrate, lactate and propionate). The remaining 90% of the lysine residues are present as bromide salt. PLL001 DP is presented as 20 mL vials containing 16 mL of a sterilised solution for SC injection with the following formula (5× concentration)
41109178|NCT01909778|DRUG|BI 201335|single oral doses
41109179|NCT05456386|BEHAVIORAL|The Circadian Rhythm Approach to Weight Loss (CRAWL)|The Circadian Rhythm Approach to Weight Loss (CRAWL) is a behavioral intervention that is designed to provide support for behavioral change to improve sleep and feeding parameters that will lead to sustainable weight loss.
41109180|NCT05126329|DRUG|amcenestrant|tablet for oral use
41271094|NCT02956811|DRUG|Placebo|Matching Placebo
41109181|NCT01490112|DRUG|insulin aspart|Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
41109182|NCT01456936|DRUG|Placebo|Triple dummy placebo for each treatment arm
41109183|NCT01456936|DRUG|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
41109184|NCT01456936|DRUG|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
40752301|NCT03307070|BEHAVIORAL|Cognitive Behavioral Therapy for individuals with TBI|Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.
40752302|NCT03307070|OTHER|Waitlist Control|Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
40752303|NCT04449809|BEHAVIORAL|Exercise program|3x per week group monitored group exercise sessions
40752304|NCT02062684|DRUG|Blisibimod|
41109185|NCT01456936|DRUG|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
41109186|NCT03432780|DRUG|Docetaxel|
41109187|NCT03432780|BIOLOGICAL|Hormone and radiation therapy|
41109188|NCT03432780|RADIATION|Radiation therapy|
41109189|NCT00005840|DRUG|Paclitaxel|Given IV
41109190|NCT00005840|DRUG|Cisplatin|Given IV
41109191|NCT00005840|RADIATION|Radiation Therapy|Undergo whole abdominal radiation therapy
41109192|NCT04164563|DEVICE|Even-Up|Orthotic shoe lift worn on contralateral foot to increase leg length
41109193|NCT05535491|OTHER|Educational and Research Hospital|breathing exercise
41109194|NCT04701294|DEVICE|Giomer Beautifil flow plusF03 Shofu-Japan|A pair of permanent first molars will be used for each participant homologs The operator will apply in the upper / lower first molars the sealant material in the order assigned according to the previous randomization. For the intervention group, they will be sealed based on a fluid resin with s-prg glass ionomer filling (Giomer F03 Beautiful -Shofu) in association with a bottle of adhesive (Single Bond) . The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
41109195|NCT04701294|DEVICE|Tetric N flow ivoclar vivadent-Germany|And on the contralateral side (control) the first upper / lower molars will be sealed will be sealed with a fluid resin compound (Tetric N-Flow ivoclar vivadent) in association with a bottle of adhesive (Single Bond). Both materials have a similar color. The operator and the child will not be informed about the brand of the material used. The assistant will collect the data in the file. The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
41109196|NCT04039984|DEVICE|Prime Cup|Patients in this group will have the Prime cementless acetabular cup used during surgery.
41109197|NCT00431431|DRUG|tibolone|2 years treatment with tibolone (1.25 mg Org OD-14)
41109198|NCT00431431|DRUG|raloxifen|2 years treatment with raloxifene (60 mg)
41109199|NCT01443117|BIOLOGICAL|PPV-23 Vaccine|Administered as a 0.5 mL IM dose
41109200|NCT01443117|BIOLOGICAL|PCV-13 Vaccine|Administered as a 0.5 mL IM dose
41109201|NCT01443117|BIOLOGICAL|Placebo Vaccine|Administered as a 0.5 mL IM dose
41109202|NCT04141917|COMBINATION_PRODUCT|Point-of-care molecular testing and treatment of influenza|Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged \<12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.
41109203|NCT05288348|DRUG|Sufentanil 30 MCG Sublingual Tablet|30 microgram sublingual tablet administered using sublingual applicator
41109204|NCT05288348|DRUG|standard care pain treatment|standard care pain treatment given in Emergency Department
41109205|NCT02664194|DEVICE|Proteus® Cooling System|Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.
41109206|NCT02664194|PROCEDURE|Primary Percutaneous Coronary Intervention|Primary percutaneous coronary intervention
41109207|NCT01750307|DIETARY_SUPPLEMENT|Experimental fatty acid supplementation|4 x capsules per day. Daily dose: 1584mg EFA
41109208|NCT01750307|DIETARY_SUPPLEMENT|Placebo comparator: MCT oil softgel|4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
41109209|NCT03420209|BEHAVIORAL|Group applying PNF technique|
41109210|NCT04368858|DIAGNOSTIC_TEST|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.|In the Mobility Exploration Unit of the University Hospital of Clermont-Ferrand, patients with chronic illnesses undergo a complete assessment of their physical capacities as well as their nutritional status. For the purpose of this protocol, patients will have to perform 2 functional tests, namely the TM6 and the TUG, while being equipped with inertial sensor units (mTUG® and mGAIT®). The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter.
41109211|NCT05788146|OTHER|Cognitive Behavioural Therapy|A psychological intervention used to target depression
41109212|NCT03202849|DIETARY_SUPPLEMENT|Vitamin D and A|A single dose of Vitamin A and Vitamin D will be given.
41109213|NCT03202849|DIETARY_SUPPLEMENT|Vitamin D and Placebo|A single dose of Vitamin D plus a placebo will be given.
41109214|NCT03719391|OTHER|Virginia Tobacco flavored JUUL 5% ENDS|Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).
41109215|NCT03719391|OTHER|Cool Mint flavored JUUL 5% ENDS|Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).
41109216|NCT03719391|OTHER|Mango flavored JUUL 5% ENDS|Treatment with Mango flavored JUUL 5% ENDS (10 puffs).
41109217|NCT03719391|OTHER|Creme Brulee flavored JUUL 5% ENDS|Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).
41109218|NCT03719391|OTHER|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).
41109219|NCT03719391|OTHER|Nicorette White Ice Mint 4mg nicotine polacrilex gum|Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)
41109220|NCT03719391|OTHER|Usual Brand combustible cigarette|Treatment with usual brand cigarette (10 puffs).
41109221|NCT05042076|DRUG|BK-specific T cells from Donor Lymphocytes|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis, enriched for BK-specific CD4+ and CD8+ T cells~Suspension of BK-specific T cells in approximately 7 mL (5-10 mL range for volume of IMP) of 0.9% NaCl with 2.5% HSA at a cell dose of: ≥ 300 and ≤ 5,000 BK virus-specific CD3+ T cells/kg body weight (BW).~IV bolus injection; IV push of IMP over approximately 2-4 minutes, resulting in an infusion rate of approximately 3 mL/min."
41109222|NCT01190007|DRUG|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
41109223|NCT03289611|BIOLOGICAL|sFlt-1 / PlGF ratio|"* Ambulatory management if sFlt-1 / PlGF ratio is below 38~* usual management if sFlt-1/PlGF is between 38 and 85.~* If the ratio is \> 85, monitoring will be intensified and patient hospitalization will be continued"
41109224|NCT05864586|BEHAVIORAL|Vaping study EC A|Vaping two puffs using the study EC device
41109225|NCT05864586|BEHAVIORAL|Vaping study EC B|Vaping two puffs using the study EC device
41109226|NCT05864586|BEHAVIORAL|Vaping study EC C|Vaping two puffs using the study EC device
41109227|NCT05864586|BEHAVIORAL|Vaping study EC D|Vaping two puffs using the study EC device
41109228|NCT05864586|BEHAVIORAL|Vaping study EC E|Vaping two puffs using the study EC device
41109229|NCT05864586|BEHAVIORAL|Vaping study EC F|Vaping two puffs using the study EC device
41109230|NCT05864586|BEHAVIORAL|Vaping study EC G|Vaping two puffs using the study EC device
41109231|NCT05864586|BEHAVIORAL|Vaping study EC H|Vaping two puffs using the study EC device
41109232|NCT05864586|BEHAVIORAL|Vaping study EC I|Vaping two puffs using the study EC device
41109233|NCT05864586|BEHAVIORAL|Vaping study EC J|Vaping two puffs using the study EC device
41109234|NCT00199342|DRUG|KW-2871|potentially therapeutic monoclonal antibody for the treatment of advanced stage four melanoma
41109235|NCT04606069|DRUG|Regadenoson|Regadenoson will be given intravenously as 5 ug/kg (up to 400 mg/patient) loading dose over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
41445693|NCT01499602|DRUG|Norethisterone Acetate tablets|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
40752305|NCT02062684|DRUG|Placebo|
40752306|NCT01935154|DRUG|Vx-001|
40752307|NCT01935154|DRUG|Placebo|
40752308|NCT00358800|DEVICE|REMStar Auto with C-Flex|
41109236|NCT04606069|OTHER|Placebo Control|The same volume of saline will be given intravenously for 6 and half hours.
41109237|NCT04381494|DEVICE|Multiparametric Mobile Technology|Using a spirometer, an armband, and a tablet to collect data.
41109238|NCT02169154|DRUG|1% Diclofenac Sodium|1% diclofenac sodium
41109239|NCT02169154|DRUG|3% Menthol|3% Menthol
41109240|NCT02169154|DRUG|0.09% Menthol|0.09% Menthol
41109241|NCT02169154|DRUG|0.2% Sodium Lauryl Sulfate|0.2% Sodium Lauryl Sulfate
41109242|NCT02169154|DRUG|0.9% Saline|0.9% Saline
41109243|NCT03870854|PROCEDURE|PEFA VT ablation technique|Catheter ablation guided by PEFA technique
41109244|NCT05165888|BEHAVIORAL|Communication and Bias Mitigation Training|Training to improve communication skills and reduce the effect of racial bias on clinician communication behavior
41109245|NCT05165888|BEHAVIORAL|Communication skills training|Training to improve communication skills between physicians and caregivers.
41109246|NCT00504114|PROCEDURE|ACL Reconstruction Surgery|
41109247|NCT00504114|PROCEDURE|Cartilage Resurfacing Surgery|
41109248|NCT00504114|PROCEDURE|Total Knee Replacement|
41109249|NCT00420654|DRUG|Growth Hormone|1.25 mg, 6 months
41109250|NCT00420654|DRUG|Placebo|Equivalent to 1.25 mg, 6 months
41109251|NCT00420654|OTHER|Healthy controls|Healthy controls
41109252|NCT00130780|DRUG|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
41109253|NCT00130780|DRUG|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
41109254|NCT04567888|BEHAVIORAL|Happify Teens|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
41109255|NCT01230840|DIETARY_SUPPLEMENT|wheat dextrin|5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
41109256|NCT01230840|DIETARY_SUPPLEMENT|placebo|cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
41109257|NCT05622188|OTHER|Elevated ambient heat|Temporary exposure to increased ambient temperature +10°C (the effect of the intervention is fully and spontaneously reversible)
41109258|NCT05622188|OTHER|Elevated relative humidity|Temporary exposure to increased ambient relative humidity +40% (max. 90%) (the effect of the intervention is fully and spontaneously reversible)
41109259|NCT05622188|OTHER|Exertion|Temporary exertion on an ergometer (1W/kg body weight) (the effect of the intervention is fully and spontaneously reversible)
41109260|NCT03920215|DRUG|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray
41109261|NCT03920215|DRUG|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray
41109262|NCT03920215|DRUG|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray
41109263|NCT03920215|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
41109264|NCT05092412|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
41109265|NCT05092412|DRUG|Durvalumab|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy.
41109266|NCT05092412|DRUG|Etoposide, and cisplatin/carboplatin|Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator.
41109267|NCT04635358|BEHAVIORAL|Hypnosis|Setting up hypnosis sessions
41109268|NCT04635358|BEHAVIORAL|Psychological support|Setting up psychological support
41109269|NCT04635358|BEHAVIORAL|Nutrional support|Setting up nutritional support
41109270|NCT01597258|DRUG|Crizotinib (Xalkori)|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
41271095|NCT06544278|DIETARY_SUPPLEMENT|probiotic product|During the experiment, subjects take one sachet probiotic product daily. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
41445694|NCT05867017|OTHER|Measure of physiologic parameters|Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
41445695|NCT00817440|OTHER|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
41271096|NCT06544278|DIETARY_SUPPLEMENT|Maltodextrin|During the experiment, subjects take one sachet maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
41445696|NCT00817440|OTHER|Fasting|3 days of fasting and then the same as arm 1
40752309|NCT03012945|DRUG|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia. General anesthesia is performed as that in the general anesthesia group. Epidural anesthesia is performed with ropivacaine. Epidural analgesia is performed with a mixture of ropivacaine and sufentanil.
40752310|NCT03012945|DRUG|General anesthesia|General anesthesia and postoperative intravenous analgesia. General anesthesia is performed with propofol induction and propofol and/or sevoflurane maintenance. Intravenous analgesia is performed with morphine.
40752311|NCT00609973|DRUG|Ciprofloxacin|Ciprofloxacin 500 mg oral bid for 6 months
40752312|NCT00609973|DRUG|Placebo|Placebo bid for 6 months
40752313|NCT00618566|BEHAVIORAL|WPD and Depression Treatment Group|Intervention selected will depend on Phase I data analysis.
40752314|NCT05235256|PROCEDURE|bilateral sphenopalatine ganglion block|peripheral n block
40752315|NCT05235256|PROCEDURE|bilateral greater occipital nerve block|bilateral greater occipital nerve block
40752316|NCT05235256|DRUG|lidocaine plus dexamethasone|lidocaine plus dexamethasone
40752317|NCT04235062|DRUG|Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution|A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
41109271|NCT04589130|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).~Participants randomized to the control arm for the first 6 months will crossover and be administered 4 Contrave tablets a day during the second 6 months (2 tablets taken twice a day). All participants will be in the treatment group (Contrave) during the second 6 month phase of the study."
41109272|NCT04589130|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day (2 tablets, taken twice a day) during the first 6 months of the study. These participants will crossover to treatment with Contrave for the second 6 months of the study.
41109273|NCT06476002|OTHER|Questionnaire|Completion of translated VPAQscreen, VPAQdesc, VPAQcope and VPAQpartner questionnaires by patients, followed by assessment of comprehension of the various items.
41445697|NCT02354560|DRUG|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
41445698|NCT01673685|DEVICE|Portable Oxygen|
41109274|NCT05230875|BEHAVIORAL|self-administered questionnaire|"All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program.~A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program."
41109275|NCT02666742|DRUG|DOAC|DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
41109276|NCT02666742|DRUG|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
41109277|NCT02614560|DRUG|Fludarabine|30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)
41109278|NCT02614560|DRUG|Melphalan|Melphalan 140 mg/m2 intravenously, 2 days before the transplant
41109279|NCT02614560|DRUG|vadastuximab talirine|Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant
41109280|NCT02614560|DRUG|vadastuximab talirine|Post-allo (after stem cell transplant) given on Day 1 of each cycle
41109281|NCT03834753|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
41109282|NCT03834753|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
41109283|NCT02975934|DRUG|Rucaparib|Rucaparib will be administered daily.
41109284|NCT02975934|DRUG|Abiraterone acetate or Enzalutamide or Docetaxel|Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
41109285|NCT03600935|OTHER|Vancouver Clinical Pathway|Vancouver Clinical Pathway
41109286|NCT02517411|OTHER|Standard care|The standard care of stable COPD is based on long-acting bronchodilators (LABD).
41109287|NCT02517411|OTHER|Physiotherapy added to standard care|The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
41109288|NCT04756050|DRUG|Bupivacaine HCl 0.5% Injectable Solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
41271097|NCT01838135|DEVICE|WheelSeeU Training Program|WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
41271098|NCT03538028|BIOLOGICAL|INCAGN02385|INCAGN02385 administered as an intravenous infusion over 30 minutes.
41109289|NCT04756050|DRUG|Prilocaine HCl % 2 injectable solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
41109290|NCT04756050|DRUG|adrenaline amp 0.5mg|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
40925548|NCT04918056|DIAGNOSTIC_TEST|Hematological Analysis and Genetical Analysis|"Hematological Analysis: Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio-Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).~Genetical Analysis: Genomic DNA was extracted from peripheral blood (PB) by using a standard phenol/chloroform method. The genotypes of samples are analyzed by NGS assay."
40925549|NCT06177574|DRUG|BIC/FTC/TAF|TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
41109291|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block Corner pocket approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance. Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
41109292|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block Corner pocket + intracluster approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance .10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
41109293|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block multi approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
41109294|NCT04756050|PROCEDURE|diagraphma muscle evaluation with ultrasound|"All patients will be evaluated with USG in a head-up position facing the side to be operated before and 30 minutes after the block is performed.~The probe will be placed perpendicular to the chest wall, in the eighth or ninth intercostal space, between the anterior axillary and midaxillary lines, 0.5 to 2 cm below the costophrenic sinus."
41109295|NCT01335165|DRUG|ALXN1102|Single Ascending Dose IV
41109296|NCT01335165|DRUG|ALXN1103|Single Ascending Dose IV or SC
41109297|NCT03848234|DRUG|Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
41109298|NCT03848234|DEVICE|Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
41109299|NCT03070938|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
41109300|NCT01638949|BEHAVIORAL|Memory assessment|Neuropsycological tests including clinical and original tests to compare differences between each populations.
41109301|NCT01638949|BIOLOGICAL|Circulating biomarkers measure|ELISA tests from blood samples to compare differences between each populations.
41109302|NCT01638949|GENETIC|ApoE4|Evaluation of apolipoprotein E polymorphism as a risk factor.
41109303|NCT01638949|OTHER|Brain imaging examination MRI and PET examinations|Structural and functional MRI FDG-PET to compare differences between each populations.
41109304|NCT04531137|DIETARY_SUPPLEMENT|CLA-fortified milk powder|3.4 gram of CLA-fortified milk powder one a day for 12 weeks
41109305|NCT04531137|OTHER|Placebo|Placebo milk powder one a day for 12 weeks
41109306|NCT04531137|OTHER|Nutrition Counseling|Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
41109307|NCT06374732|BEHAVIORAL|High-intensity interval training|The experimental group will perform 6-to-10-minute of high-intensity interval training at the beginning of their physical education lessons or physical activity lessons.
41109308|NCT06374732|BEHAVIORAL|Control group|The control group will maintain their normal behaviour, including regular physical education lessons and physical activity lessons.
41109309|NCT02263508|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec administered by intratumoral injection
41109310|NCT02263508|DRUG|Pembrolizumab|Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.
41109311|NCT02263508|DRUG|Placebo|Administered by intratumoral injection
41109312|NCT02446223|DRUG|Inggenol Mebutate 0.015%|
41109313|NCT01170299|DIETARY_SUPPLEMENT|dietary intervention|
41109314|NCT01170299|OTHER|laboratory biomarker analysis|
41109315|NCT01170299|PROCEDURE|gastrointestinal complications management/prevention|
41109316|NCT01170299|PROCEDURE|management of therapy complications|
41109317|NCT01170299|RADIATION|selective external radiation therapy|
41109318|NCT06259058|DRUG|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14-day cycle
41109319|NCT06259058|DRUG|Oxaliplatin|60 mg/m² on Day 1 of a 14-day cycle
41109320|NCT06259058|DRUG|5-Fluorouracil|2400 mg/m² continuous IV infusion in 46 h
41109321|NCT06259058|DRUG|Leucovorin|400 mg/m² on Day 1 of a 14-day cycle
41109322|NCT06259058|RADIATION|SBRT|30Gy/5Fx
40925550|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
41133463|NCT02099188|RADIATION|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
41109323|NCT04643236|BEHAVIORAL|Periodontal health education session|This session comprised of a condensed version of motivational interviewing and a periodontal education view/point. First, patients were analysed in terms of expectations from periodontal treatment/oral hygiene practice, knowledge about periodontal diseases and its consequences, daily oral hygiene routine, awareness of the current periodontal status and the main reasons for not doing proper brushing and interproximal cleaning. The same researcher who did not included in the clinic process informed the patients about how periodontal diseases develops, its aetiology, symptoms, consequences and the relationship with the important systemic disorders verbally and via brochure as well. The importance of the patients' own efforts about daily cleaning of the mouth were emphasized. Finally oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
41109324|NCT04643236|BEHAVIORAL|Oral hygiene motivation session|Standard oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
41109325|NCT04379713|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
41109326|NCT04379713|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
41109327|NCT00868192|DRUG|Pemetrexed|
41109328|NCT00868192|DRUG|Bevacizumab|
41109329|NCT03215251|OTHER|Intervention bundle|Assessment of the patient's mouth and lips determined, to check any stickiness or dryness in the mouth or around lips or split skin at the corners of the mouth or cracked lips. Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered for in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
40925551|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
41109330|NCT01852019|DRUG|Cangrelor|Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8
40925552|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
41109331|NCT01852019|DRUG|Prasugrel|"Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8."
41109332|NCT06002542|BEHAVIORAL|Information provided|get information at every stage of care in emergency room
41109333|NCT06002542|BEHAVIORAL|Control|Information is only provided when participants request it.
41109334|NCT02470949|BEHAVIORAL|Low Social Status|The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
41109335|NCT02470949|BEHAVIORAL|High Social Status|The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
41109336|NCT01080872|DEVICE|CFR|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
41109337|NCT00258895|BIOLOGICAL|DAPTACEL®: DTaP|0.5 mL, Intramuscular
41109338|NCT00258895|BIOLOGICAL|DAPTACEL®: DTaP|0.5 mL, Intramuscular
40925553|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
41109339|NCT02845856|DRUG|Cetuximab|400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
41109340|NCT02845856|BIOLOGICAL|NK immunotherapy|For each procedure, 10 billion cells will be infused in 4 times
40925554|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
41109341|NCT00025987|DEVICE|Head and Neck Cooling System|
41109342|NCT00025987|DEVICE|Thermometer Pill|
41109343|NCT02447263|PROCEDURE|interventional therapy|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
41109344|NCT03808883|BEHAVIORAL|TGNC Directed Advocacy Meetings|Series of 18 meetings with TGNC cohort, including 3 facilitated dialogues with the healthcare participants, to articulate barriers to access and to enter into dialogue with medical providers and staff.
41109345|NCT03808883|BEHAVIORAL|Facilitated Dialogues between TGNC Cohort and Healthcare Participants|Healthcare Participants attend a facilitated dialogue with the TGNC cohort. 3 total facilitated dialogues were held, but each healthcare participant attends only 1 session.
41109346|NCT02891525|DIETARY_SUPPLEMENT|50g glucose|
41109347|NCT02891525|DIETARY_SUPPLEMENT|25g fructose|
41109348|NCT02891525|DIETARY_SUPPLEMENT|220mg acesulfame-K|
41109349|NCT02891525|DIETARY_SUPPLEMENT|250mL tap water|
41109350|NCT04603625|OTHER|postural management|postural management in sitting position
41109351|NCT02950558|DRUG|Ropivacaine|Single injection of ropivacaine immediately prior to surgery.
41109352|NCT02950558|PROCEDURE|Nerve block|insertion of catheter to deliver continuous 5 day popliteal sciatic nerve block using a disposable ambulatory pain pump.
41109353|NCT04704037|OTHER|Guideline implementation tool|Family physicians will receive a tailored letter with their patient's mental health screening test results and associated mental health treatment recommendations from the Ontario Neurotrauma Foundation guidelines, as well as a list of mental health treatment resources. In addition, the patient will receive a written information package about mental health problems after mTBI and treatment options to discuss with their family physician.
40925555|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
40925556|NCT01227629|DRUG|warfarin|comparator
41271099|NCT05086679|DEVICE|Compression Stockings with 25-30 mm Hg pressure|The group will have compression stockings with 25-30 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
40925557|NCT01227629|DRUG|dabigatran without ASA|dose comparison
40925558|NCT01227629|DRUG|dabigatran without ASA|dose comparison
40925559|NCT01227629|DRUG|dabigatran without ASA|dose comparison
40925560|NCT06356428|OTHER|Physcian Attitudes toward Cardiac Rehabilitation and Referral Scale-Revised (PACRR-R)|The PACRR comprises 20 items and 1 open ended item to assess physicians' attitudes and beliefs about CR and referral (includes instructions for scale completion to respondents). Response options were 1 = strongly disagree, 2 = agree, 3 = neutral, 4 = agree, and 5 = strongly agree. Five (5) items are reverse-scored to mitigate acquiescence bias (denoted with \*), such that higher scores reflect more positive atti- tudes toward CR and referral. A mean score is computed for the total (where at least 80% of items were completed; i.e., 15/19) scale and subscales.
41109354|NCT04704037|OTHER|Generic information about concussion management|Family physicians will receive a generic letter drawing their attention to Canadian clinical practice guidelines for mild Traumatic Brain Injury (developed by the Ontario Neurotrauma Foundation). Patients will receive instructions about how to access generic education materials about mTBI (from concussion.vch.ca/), which they should have received anyway as part of usual care.
41109355|NCT04440124|OTHER|Incremental shuttle walk test|All patients were reviewed by a physiotherapist during their pre-assessment clinic one week prior to surgery to complete an incremental shuttle walk test (ISWT). The ISWT was completed according to a standardised protocol and involved patients walking around 2 cones set up 9 metres apart. Patients were asked to cover the distance between the cones in time to auditory cues. Oxygen levels and heart rate were recorded during the assessment with the use of a portable pulse oximeter. The test was stopped when patients could no longer keep pace with the auditory cues or were too breathless to continue. The total distance mobilised was recorded.
41109356|NCT04956146|DRUG|Fruquintinib，Sintilimab，Pemetrexed，Carboplatin|Fruquintinib,fruquintinib at the dose determined in phase safety lead-in,5mg-intermittent (2 weeks on/ 1 week off) ，po，every 3 weeks(q3w) ; Sintilimab at the dose 200mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=4\~5，iv，d1；given every 3 weeks (q3w); Maintenance treatment：After 4\~6 cycles of carboplatin treatment, Sintilimab 200mg, iv, d1, q3w；Fruquintinib RP2D intermittent(2 weeks on/1 weeks off), po，q3w； pemetrexed 500mg/m2, d1,iv, q3w until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
41109357|NCT01799148|OTHER|Particulate air pollutants|We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
41109358|NCT02101190|DRUG|BIA 9-1067|Opicapone, OPC
41109359|NCT02457507|DIETARY_SUPPLEMENT|Vitamin B12|2 tablets
41109360|NCT02457507|DIETARY_SUPPLEMENT|Placebo|2 tablets
41109361|NCT05967819|BEHAVIORAL|Exercise Stress|Increased exercise volume
41109362|NCT05967819|BEHAVIORAL|Psychosocial Stress|cognitive tasks
41109363|NCT03533491|BEHAVIORAL|Rewire App|A prototype Rewire app will be designed and created; the first four modules will be evaluated by 60 high-risk adolescents. The teens are asked to complete each module and spend a few minutes each day for two weeks using the practice exercises.
40925561|NCT05024292|PROCEDURE|rapid local ischemic postconditioning (RL-IPostC)|with 5 circules of balloon inflations in the ipsilateral internal carotid artery, each circulation includes inflation lasting 15 seconds followed by 15 seconds of deflation
41109364|NCT02928757|OTHER|Complex care clinic as part of the CCKO initiative|"The CCKO intervention involves intensive care coordination, defined as: deliberate organization of patient care activities between two or more participants (including the patient) involved in a patient's care to facilitate the appropriate delivery of health care services. Organizing care involves marshaling of personnel and other resources needed to carry out all required patient care activities and is often managed by the exchange of information among participants responsible for different aspects of care. Within CCKO, intensive care coordination will specifically include: 1) the tailored, family/health care provider co-creation and regular updating of care coordination plans for each child which will be 2) facilitated and accounted for by key workers partnering with families."
41109365|NCT00158054|BEHAVIORAL|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
41109366|NCT00158054|BEHAVIORAL|Referred depression care|Physician notified of depression symptoms, usual care followed.
41109367|NCT05147389|DIAGNOSTIC_TEST|AI model classification|AIWorks is an artificial intelligence model for real-time cholangioscopic detection of neoplastic and non-neoplastic bile duct lesions. It allows you to choose using a video file or a USB camera input as the detection source. Once the input source has been selected, the software performs real-time detection by surrounding the area of interest (i.e., the area with malignancy features) inside a bounding box. All detections made are displayed on the right side of the screen and can also be reviewed afterwards.
41133329|NCT05351294|OTHER|Questionnaires|"All patients in Arm 2 will be seen and treated by one of three ROs with an interest in participating in this study, who will be trained by the PI to perform these visits reproducibly and with rigor. These will all be regular ROs, who like most ROs administer a mix of curative and PRT in their clinical practice; like most cancer centers, there are no ROs who formally subspecialize in PRT at our institution. Notably, patients in Arm 1 (control arm) will always have standard-of-care RO referral available for consideration of PRT if needed for symptom relief. However, patients in Arm 1 will be seen by other ROs without any specific training for this study. Any courses of PRT administered in either arm are at the discretion of the treating RO in terms of the timing, dose, fractionation, and treatment technique."
40925562|NCT01406405|PROCEDURE|Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)|Lumbar or cervical fusion
41133330|NCT05351294|COMBINATION_PRODUCT|Early Radiation Oncology Involvement Alongside Standard Oncologic Care|Early Radiation Oncology Involvement Alongside Standard Oncologic Care
41133331|NCT01375699|DRUG|Doxorubicin|As prescribed by treating provider.
41133332|NCT01375699|DRUG|Sildenafil|Given PO, by mouth
41109368|NCT05147389|DIAGNOSTIC_TEST|DSOC endoscopist experts' classification|"Six endoscopists with high DSOC expertise will observe and classify a set of videos among neoplastic or non-neoplastic bile duct lesions following a Bernoulli distribution; blinded to clinical records and should have never attended said patients.~Gastroenterologists from each center, with non-DSOC responsibility, will select DSOC videos and corresponding baseline data. DSOC videos and data will be gathered in one set. Each video represents a full DSOC for a single patient. The patient will be the unit of this study.~The neoplastic bile duct criteria are in accordance with the Robles-Medranda et al and the Mendoza classifications (ie. Irregular mucosa surface, Tortuous and dilated vascularity, Irregular nodulations, Polyps, Ulceration, Honeycomb pattern, etc.). The experts will assess neoplastic bile duct by presence or absence of disaggregated criteria. Likewise, by Boolean logical operators, the statistical software will compute disaggregated answers."
41109369|NCT04432688|DRUG|Lurasidone HCl|This is a non-interventional, observational study
41109370|NCT05300919|OTHER|Measurement based care|Measurement-based care based on arm.
41109371|NCT02298140|OTHER|SMS reminders|Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
41109372|NCT01196936|DRUG|Tamoxifen Citrate|5 mg PO Daily
41109373|NCT01196936|DRUG|Placebo|1 tablet daily
41109374|NCT01196936|PROCEDURE|Digital mammography|Correlative studies
41109375|NCT01196936|OTHER|immunohistochemistry staining method|Correlative Studies
41109376|NCT01196936|OTHER|pharmacological study|Correlative Studies
41109377|NCT01196936|OTHER|laboratory biomarker analysis|Correlative Studies
40752318|NCT04235062|DRUG|Intravenous Bolus Furosemide|Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
40752319|NCT03977610|DRUG|Ga-68 PSMA ligand|For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.
40752320|NCT00394472|DRUG|AZD3355|
41109378|NCT01196936|GENETIC|protein expression analysis|correlative studies
41109379|NCT01196936|OTHER|pharmacogenomic studies|correlative studies
41109380|NCT01196936|OTHER|questionnaire administration|Ancillary studies
41109381|NCT01196936|PROCEDURE|Fine needle aspiration|
41109382|NCT01196936|OTHER|Quality of Life Assessment|Ancillary Studies
41109383|NCT04736849|DEVICE|Percutaneous epidural and dorsal root stimulation|"Abbott percutaneous trial lead for dorsal root ganglion neurostimulation (Model MN10350)~Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
41109384|NCT04955119|DIAGNOSTIC_TEST|Fusion imaging contrast-enhanced ultrasound|"Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
41109385|NCT06041893|DRUG|ATG-LDPTCy|antithymocyte globulin with low dose post-transplant cyclophosphamide
41133333|NCT00981552|RADIATION|IMRT planning|
40925563|NCT01067924|BEHAVIORAL|Motivational interviewing|Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
40925564|NCT01213667|DRUG|Ranibizumab|upload (three monthly injections), re-treatment as needed
41271100|NCT05086679|DEVICE|Compression stockings with up to <=10 mm Hg pressure|The group will have compression stockings with up to 10 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
41133334|NCT00981552|RADIATION|4-Field Radiation Planning|
41109386|NCT04925739|OTHER|Self-questionnaire on the comfort and general appreciation of a nasal mask|Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use
41109387|NCT04925739|OTHER|Self-questionnaire on the appearance of CPAP side effects related to the mask|Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use
40752321|NCT04594083|DEVICE|Palm Stimulator|The Palm Stimulator, developed by the present researchers for the first time, is 1.6 cm in diameter, 4 cm in length, and has a cylindrical, non-slippery structure for an easy grip to ensure maximum contact with the palm The Palm Stimulator consists of blunt protrusions that will provide a tactile stimulus on the palm. The blunt protrusions do not penetrate into the skin. The simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
41109388|NCT04925739|OTHER|Self-questionnaire on the patient's appreciation of the mask headgear,|Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.
41109389|NCT04925739|OTHER|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.
41133335|NCT05622097|OTHER|0.9% Saline warmed to 37 degrees Celsius|0.9% Saline warmed to 37 degrees Celsius
40925565|NCT03302364|DRUG|Risperidone|patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
41109390|NCT04925739|OTHER|Self-questionnaire Epworth on the daytime sleepiness|"Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion.~To study the parameters of the CPAP treatment."
41109391|NCT04925739|OTHER|To study the CPAP compliance|To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.
41133336|NCT05622097|OTHER|0.9% Saline warmed to 24 degrees Celsius|0.9% Saline warmed to 24 degrees Celsius
41109392|NCT04925739|OTHER|To study the unintentional leakage|To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.
41109393|NCT04925739|OTHER|To study the therapeutic pressures of CPAP|To collect the therapeutic pressures of CPAP, during the 30 days of treatment.
41109394|NCT00126308|DEVICE|poly-L-lactic acid|immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
41109395|NCT00126308|DEVICE|poly-L-lactic acid|delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
41109396|NCT03034681|OTHER|Physiotherapy technique: TENS|
41109397|NCT03034681|OTHER|Physiotherapy technique: Vojta Therapy|
41445699|NCT06533345|BEHAVIORAL|Behavior Change Coaching|Done by Dr. Hollingsworth or students via consultations with participants. Participant's health behavior aspirations or target outcomes will be clarified, informed by the participant's interactions with other MERCI providers. Behaviors that move the participant towards their aspirations/outcomes will be explored to find target behaviors that the participant is motivated and able to do. Target behaviors and supporting habits will be designed into the participant's existing routine. The Fogg Behavior Model will be used 1) to find the participant's primary motivation for engaging in target behaviors and 2) to make target behaviors easier to do. Implementation intentions - When/then or If/then plans - will be used to form habits and promote behavior engagement. Adopting a growth mindset will also be discussed. Subsequent consultations will focus on troubleshooting, iterative improvements, and incorporation of new aspirations/outcomes, target behaviors, and supporting habits.
41109398|NCT05262478|DEVICE|Alpha-D CDP|Alpha-D cervical disc prosthesis was developed jointly by the Spine Center of Koç University Faculty of Medicine and Toledo University Bioengineering Department. It was designed as a single unit to ensure user-friendly administration for surgeons, and it was designed and manufactured to reproduce the movements of the normal cervical movement segment.
41109399|NCT01112644|DRUG|Oxycodone naloxone prolonged release tablets (OXN PR)|Different daily doses; intake every 12 hours
41109400|NCT01112644|OTHER|Placebo (PLA)|Different daily doses; intake every 12 hours
41109401|NCT02627183|PROCEDURE|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
41109402|NCT02627183|BEHAVIORAL|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
41109403|NCT01424540|DRUG|GSK2336805 150mg|Single Dose
41109404|NCT01424540|OTHER|Placebo|Single Dose
41109405|NCT01239563|DRUG|antithymocyte globulin|Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose
41109406|NCT01239563|DRUG|Basiliximab|Intravenous 20mg, day 0\&4
41109407|NCT00480662|DRUG|alendronate|Duration of Treatment : 6 Months
41109408|NCT05802602|DEVICE|Porcine Collagen Membrane|Atraumatic tooth extraction with porcine collagen membrane placement
41109409|NCT05802602|DEVICE|Bovine Collagen Dressing|Atraumatic tooth extraction with bovine collagen dressing placement
41109410|NCT00190216|DEVICE|Magnetic stimulator|
41109411|NCT02749578|DRUG|Atorvastatin|
41109412|NCT02749578|DRUG|MGL-3196|
41109413|NCT03802266|DEVICE|Electromagnetic Navigation guided transthoracic needle aspiration|Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
41109414|NCT03802266|DEVICE|CT-guided Transthoracic Needle Aspiration|Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
41109415|NCT06015542|DRUG|Elranatamab|Elranatamab will be administered as monotherapy for six cycles of 28 days. Elranatamab 76 mg will be administered QW with a 2-step-up priming dose regimen administered during the first week (12 mg D1 and 32 mg D4).
41109416|NCT04956224|BIOLOGICAL|VLA2001|"whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide (Wuhan strain)~2 vaccinations 28 days apart~Booster Vaccination on Visit B1"
41109417|NCT05835219|DRUG|REBYOTA™|REBYOTA™ is administered in the rectum
41271101|NCT05086679|BEHAVIORAL|Lifestyle modification|All patients will receive standard treatment of VVS despite their randomization(drink 2-3 liters of fluids, consume 10 grams 120 mmol/day of sodium chloride, and practice counter-pressure maneuvers (squatting, leg crossing, handgrip, and arm-tensing))
41271102|NCT04992416|PROCEDURE|immediate implant placement with ATBG and SMV|immediate implant placement using ATBG as a graft material, with SMV
41271103|NCT04992416|PROCEDURE|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without SMV
41271104|NCT04210726|DRUG|25% Hypertonic Saline Bath|25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%).
41271105|NCT04210726|OTHER|0.9% Isotonic Saline Bath|0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%).
41445700|NCT06533345|BEHAVIORAL|Nutrition|Nutrition: The nutrition intervention will be conducted as a 12-week protocol with assessment points at baseline, 1 month, and 3 months. Following consent, eligible participants will work through a self-taught educational module detailing the anti-inflammatory dietary program. Once the module is completed, participants will be scheduled for one-on-one counseling sessions with a Registered Dietitian or a supervised Dietetic Intern or Medical Student on the research team to receive personalized guidance on implementation of the dietary intervention. A dietary recall will be conducted via the automated self-administered dietary assessment tool (ASA24®), which takes about 20 minutes to complete. This survey will be conducted on two non-consecutive days at each timepoint (baseline, 1 month, and 3 months).
41445701|NCT06533345|OTHER|Autonomic Recalibration|Participant will be outfitted with the Empatica wrist sensor. An initial history to rule out pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance. The pattern of sympathetic dominance is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. Day 2 is the same until the initial history and r/o. Here, the history is from the previous day, asking about perception of pain, sleep, digestion, or other pertinent issues brought up on the first visit. Treatment proceeds same as Day 1. Any emotional tags to trigger points are identified and acknowledged. Subjects may be scheduled for follow-up visits if their pain persists.
41109418|NCT03368937|DEVICE|Tandem t:slim X2 with Control-IQ Technology|Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
41109419|NCT00078572|DRUG|capecitabine|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
41109420|NCT00078572|DRUG|lapatinib (GW572016)|Lapatinib 1250 mg orally once daily
41109421|NCT04194749|OTHER|Digital Media Based Physical Therapy|This intervention is a modified post immobilization protocol. This will include giving the patients a USB drive loaded with a 12 week therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health \& Science University website.
41109422|NCT04194749|OTHER|Traditional Physical Therapy|This intervention is a 12 week therapist supervised clinic-based therapy protocol.
41109423|NCT02732314|DRUG|Investigational OTC Cream|
41109424|NCT02732314|OTHER|Cosmetic Eczema Cream|
41109425|NCT02732314|DRUG|0.05% Desonide Cream|
41109426|NCT02732314|OTHER|Placebo Cream|
41109427|NCT06257693|DRUG|enzalutamide|Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy
41109428|NCT01556971|DRUG|Botox|Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
41109429|NCT01556971|DRUG|Saline Solution|29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
41109430|NCT03615924|DRUG|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~* \>48 kg: Ticagrelor 45 mg, twice a day."
41109431|NCT03615924|DRUG|Placebo|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~* \>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
41109432|NCT06354738|PROCEDURE|total hysterectomy with bilateral salpingo-oophorectomy, lymph node staging and comprehensive peritoneal staging|"Surgical treatment will consist of total hysterectomy with bilateral salpingo-oophorectomy according to international guidelines.~In low- and intermediate-risk EC patients, staging will include a sentinel lymph node (SLN) procedure. In high intermediate-risk and high-risk EC patients, lymph node staging will involve SLN procedure and/or pelvic and para-aortic lymph node dissection (LND), depending on the local protocol.~The Study-related procedures include infracolic omentectomy or two separate omental representative biopsies, biopsies of all suspicious lesions as well as six peritoneal sites (bladder, pouch of Douglas, bilateral paracolic gutter and bilateral diaphragm).~Stage IV patients will be treated according to European guidelines. When feasible, full surgical intervention (i.e. debulking) is recommended. If this cannot be achieved, a radiologic and/or histologic confirmation of tumor spread beyond the uterus will be accepted."
41109433|NCT06556160|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests to search synaptopathie. During the surgery, stimuli are delivered."
41109434|NCT05649878|DRUG|Evaluation of bioavailability of methylprednisolone succinate administered intravenously|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intravenously. The nominal doses were similar, volunteers were randomly assigned to receive a single dose of MEP by IV bolus of 1.5 mL. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
41109435|NCT05649878|DRUG|Evaluation of bioavailability of methylprednisolone succinate administered intranasally|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intranasally. Volunteers were randomly assigned to receive a single dose of MEP intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
41109436|NCT04408937|DRUG|triopifexor|Tropifexor as a dry blend in hard gelatin capsules for oral administration
41109437|NCT04408937|DRUG|Placebo|Placebo capsules for oral administration
41109438|NCT06158048|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
40752322|NCT04594083|DEVICE|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
41109439|NCT06158048|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
41109440|NCT02961127|OTHER|Venous blood was collected|Venous blood was collected by standard vein puncture in fasting condition
41445702|NCT06533345|PROCEDURE|Dry Needling|An initial history to document a chief complaint relevant to pain is conducted and to identify and potential contraindications (infection of overlying skin, patient on anticoagulation drugs, 1st trimester of pregnancy, etc.) A physical exam is performed to identify the trigger points causing pain. The subject is educated about the risks/benefits/indications and alternative treatments. The subject is also educated about dry needling aftercare. The skin over the trigger points is cleaned with 70% isopropyl alcohol. The pertinent trigger points are treated with dry needling (95% of time), direct inhibition (2 - 3% of time) or injection of 1% lidocaine in a fan-like fashion (1 - 2 % of the time). Subject is assessed for any bleeding. An office note, including a procedure note, is documented in the subject's record. Subject is scheduled for additional follow-up meeting.
41109441|NCT04821336|OTHER|Metabolites dosage|"On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand.~The investigators will compare the rate of deregulation between sane and malignant ones."
41109442|NCT02947217|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
41109443|NCT02947217|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
41445703|NCT06533345|OTHER|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment: After inform and consent process, the subject will enter patient room and meet with Dr. Hayes, who will conduct a brief history of patient pain, injuries, and procedures. Subjects will be asked to wear, or change into, athletic shorts or a tank top or loose-fitting T-shirt to facilitate treatment. Subject will undergo a brief somatic dysfunction screen, which involves light tough and manipulation. Once Hayes has diagnosed potential dysfunctions, he will proceed with osteopathic manipulative treatment. Treatment will last anywhere from 15 minutes to 1 hour. At the end of the treatment, subjects will be scheduled for a follow-up visit.
41445704|NCT06533345|BEHAVIORAL|Counseling Psychology|Psychoeducation Workshop and Counseling: The psychoeducational group intervention will be done according to the standardized Empowered Relief (Darnall et al., 2024) protocol. Empowered Relief is a single-session, 2-hour group workshop (online or in person) that teaches participants pain neuroscience education, mindfulness principles, and cognitive-behavioral skills. During the program, participants will complete a personalized plan to work toward pain relief. This program requires a certified instructor; Marilyn Cornish (Co-I), a licensed psychologist, is certified. After completion, participants can attend up to 4 individual counseling sessions with a counseling psychology doctoral student (supervised by Marilyn Cornish). Sessions will be approximately 50-60 minutes and will occur every other week. Specific in-session interventions will be tailored to the participant's unique needs but will focus on participants' pain relief plan and overall psychological wellbeing of participants.
41445705|NCT06533345|OTHER|Multiple Treatments|"Subjects receiving multiple treatment interventions over the same period of time.~Example: A subject joins the Osteopathic Manipulative Treatment group and meets with Dr. Hayes for treatment visits. At the same time, they are meeting with Dr. Kirby in a separate visit (or at the same time, if scheduling allows) to discuss Nutrition. Any subjects who were in multiple/overlapping treatment groups will fit this description."
41109444|NCT00494442|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
41109445|NCT00494442|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
41109446|NCT03257813|DRUG|PRO-122|1 drop every 12 hours for 30 days of alternating treatment with 30 days
41109447|NCT03257813|DRUG|Krytantek Ofteno®|1 drop every 12 hours for 30 days of alternating treatment with 30 days
41109448|NCT01306513|BIOLOGICAL|autologous bone marrow derived mesenchymal stromal cells|Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
40925566|NCT03997045|BEHAVIORAL|Supervised physical exercise program|Supervised physical conditioning program of two 60-minutes sessions per week during pregnancy, developed from gestational week 20 to 38. Each session consists of 25-30 minutes of cardiovascular exercise,15 minutes of strengthening exercises, 5 minutes of coordination and balance exercises and 10 minutes of pelvic floor muscles training.
40925567|NCT01407653|PROCEDURE|Virtual reality|3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
40925568|NCT01407653|PROCEDURE|Usual care|Classical care
40925569|NCT03468569|OTHER|Functional Movement Screen|
41109449|NCT06316206|DRUG|Ethinylestradiol/Dienogest 0.03mg/2mg|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
41109450|NCT02899000|DRUG|Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel|Topical acne therapy
41109451|NCT02899000|DRUG|Oral doxycycline hyclate|Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)
40925570|NCT02412514|BIOLOGICAL|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
41133337|NCT01976507|DRUG|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
40752323|NCT04267328|PROCEDURE|Elective Orthopedic Surgery|Patients having knee (unilateral primary osteoarthritis or bilateral primary osteoarthritis) surgery, hip (unilateral primary osteoarthritis or bilateral primary osteoarthritis) or shoulder (primary osteoarthritis) elective surgery.
40925571|NCT02412514|BIOLOGICAL|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
40925572|NCT02412514|BIOLOGICAL|IPV|IPV administered at 6 weeks of age
41133338|NCT01100151|DRUG|RDC-1036 (ALKS 37)|Capsules for oral administration
41133339|NCT01100151|DRUG|Placebo|Capsules for oral administration
41109452|NCT02422095|PROCEDURE|Endoscopy-based (EUS-guided) interventions for pancreatic fluid collections|Data included are patient demographics, symptoms, disease severity, procedural indications, details of the pancreatic fluid collection on cross-sectional imaging/EUS, review of laboratory results/imaging, details of interventions, clinical response to intervention, adverse events from interventions and pancreatitis/pancreatic fluid collections, response to treatment including any recurrent hospital admissions, recurrence of pancreatic fluid collections, need for repeat interventions, details of pancreatic duct integrity (e.g. presence of disconnected pancreatic duct syndrome), and clinical status at follow-up.
41109453|NCT02422095|PROCEDURE|EUS of pancreatic cysts|Data included are patient demographics (age, gender, race), symptoms at presentation, imaging modality performed to detect the cyst, cyst features on EUS, technical details of EUS-guided sampling, results of cyst fluid analysis, final diagnosis, any follow up and repeat examinations and details of any treatment performed.
41109454|NCT06518798|BEHAVIORAL|Fasting Mimicking Diet|Participants will be instructed to follow their usual diet except for 5 days when they eat the foods in the FMD kit. The FMD consists of a blend of 100% plant based nutrients generally regarded as safe. One FMD kit provides for the replacement of the normal diet with plant products for five consecutive days. The formulation of these products was based on studies carried out at the Longevity Institute of the University of Southern California, led by Dr. Valter Longo and his collaborators over several decades of research.
41109455|NCT00968448|BEHAVIORAL|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
41109456|NCT00968448|BEHAVIORAL|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
41109457|NCT05310136|BEHAVIORAL|BBTi|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi, sleep diaries, and adherence record. In the end of weeks 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
41109458|NCT04405063|DEVICE|Paclitaxel Coated PTCA Balloon Catheter|Drug coated balloon
41109459|NCT01863004|DRUG|Bortezomib|
41109460|NCT02881944|BEHAVIORAL|Low FODMAP Diet|Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
41109461|NCT02881944|BEHAVIORAL|High FODMAP Diet|Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
41109462|NCT04637152|DRUG|Sacubitril-Valsartan|Use of sacubitril/valsartan after suspension of ACE inhibitors or ARBs.
40752324|NCT01903200|DRUG|FK949E|Oral
40752325|NCT02326246|OTHER|multi-parametic MRI|
41109463|NCT00754936|DRUG|Escitalopram|20 mg by mouth daily
41109464|NCT04700930|OTHER|CBD-Cigarettes|CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
41109465|NCT00001637|PROCEDURE|Blood cell transplantation|
41445706|NCT00996684|DRUG|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
41109466|NCT00628862|DRUG|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
41109467|NCT00628862|DRUG|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
41109468|NCT00628862|DRUG|Turbuhaler® placebo|placebo inhaled twice daily
41445707|NCT00996684|DRUG|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
41445708|NCT05713058|BEHAVIORAL|eTRC diet|12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) focusing on the distribution of macronutrients within the day so as to avoid carbohydrate consumption after lunch
41109469|NCT01505881|DRUG|dabigatran etexilate low dose|active treatment (low)
41109470|NCT01505881|DRUG|warfarin 5mg|comparator warfarin
41109471|NCT01505881|DRUG|dabigatran etexilate intermediate dose|active treatment (medium)
41109472|NCT01505881|DRUG|warfarin 1mg|comparator warfarin
41109473|NCT01505881|DRUG|dabigatran etexilate high dose|active treatment (high)
41109474|NCT01505881|DRUG|warfarin 3mg|comparator warfarin
41109475|NCT04678830|DRUG|Placebos|Placebos
41109476|NCT04678830|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
41109477|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection (high dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
41109478|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection (low dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
41109479|NCT04846491|DRUG|TDF|Patients will take TDF orally for the first 48 weeks, and then one can choose to continue the single-TDF treatment up to 144 weeks, or may choose to change to receive peginterferon alfa-2b combined TDF therapy for the later 96 weeks, peginterferon alfa-2b will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 weeks a cycle. And then followed for 24 weeks after treatment.
41109480|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
41109481|NCT05865314|OTHER|Optimisation of nutrition therapy coupled with early mobilisation|"Optimisation of nutrition therapy coupled with early mobilisation with:~* Optimisation of nutrition therapy during ICU stay~* Optimisation of physiotherapy during ICU stay~* Better communication and closer collaboration between physiotherapy and nutrition teams.~* Optimisation of continuity of the care."
41109482|NCT05865314|OTHER|Standard care|Patients will receive nutritional therapy and mobilisation according to local standard procedures.
41109483|NCT00765934|DRUG|Rapydan|lidocaine / tetracaine 70/70 mg patch
41109484|NCT02275325|OTHER|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
40752326|NCT03508453|BIOLOGICAL|IC14|Monoclonal antibody against CD14
41109485|NCT06048991|DIAGNOSTIC_TEST|Thermographic assessment|Patients will undergo a termographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
41109486|NCT00390728|DRUG|Insulin Glargine|
41109487|NCT05573711|OTHER|assessments|Assessments, no specific intervention
41109488|NCT00128193|BIOLOGICAL|Tuberculin, Purified Protein Derivative|A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose
41109489|NCT00128193|OTHER|MLSA-LAM|Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
41109490|NCT00128193|OTHER|MLCwA|Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
41109491|NCT00128193|BIOLOGICAL|Tuberculin, Purified Protein Derivative|Licensed TB reagent, 100 microliters, 5 TU dose.
41109492|NCT00128193|OTHER|Placebo|Saline (NaCl) serves as a diluent control in Stage A and B only.
41109493|NCT03043638|PROCEDURE|CAF+ADM+PRP|CAF+ADM+PRP group treated with coronally advanced flap technique including ADM placement, In CAF+ADM+PRP group, ADM was hydrated in the platelet-poor plasma (PPP) and the PRP was applied to surgical sites prior to final suturing.
41109494|NCT03043638|PROCEDURE|CAF+ADM|CAF+ADM group treated with coronally advanced flap technique including ADM placement without PRP application
41445709|NCT05713058|BEHAVIORAL|Control diet|12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) without any recommendations on the distribution of macronutrients within the day
41445710|NCT00829712|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
41109495|NCT05679713|DIAGNOSTIC_TEST|Comprehensive risk assessment algorithm|Risk assessment algorithm including clinical and patient-centered information and a novel RNA-based biomarkers using next-generation sequencing technology.
41109496|NCT03703219|OTHER|Mothers Touch Program|Combination of diet, massage, body binding methods along with 40 days of rest following the traditional way of delivering
41109497|NCT03483519|OTHER|Rehabilitation|Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
41109498|NCT03483519|OTHER|Standard of Care|Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.
41109499|NCT00326924|BIOLOGICAL|Transfusion|PRBC blood transfusions.
41109500|NCT05076435|DRUG|Isotonic crystalloids|"Types of fluids in both intervention groups:~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy."
41109501|NCT01251354|DRUG|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
41109502|NCT05818904|OTHER|Physical Therapy|All arthrosis participants will be treated as the traditional methods using physical therapy.
41109503|NCT01370694|DRUG|MK-8808|
41109504|NCT01370694|DRUG|cyclophosphamide|
41109505|NCT01370694|DRUG|vincristine|
41109506|NCT01370694|DRUG|prednisolone|
41445711|NCT00829712|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
41445712|NCT00320034|DRUG|R-albuterol, S-albuterol|
41445713|NCT06469645|DRUG|Empagliflozin 10 MG|Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day on top of their regular medications.
41109507|NCT00970307|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, three doses
41109508|NCT00970307|BIOLOGICAL|10-valent pneumococcal vaccine (GSK 1024850A)|Intramuscular, three doses
41109509|NCT00970307|BIOLOGICAL|Infanrix hexa™|Intramuscular, three doses
41109510|NCT00970307|BIOLOGICAL|Menjugate®|Intramuscular, two doses
41109511|NCT05903833|DRUG|Pembrolizumab|400 mg Q6W
41109512|NCT05903833|DRUG|Lenvatinib|20 mg QD
41109513|NCT01025843|DRUG|MK-5478|In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
41109514|NCT01025843|DRUG|Comparator: Candesartan cilexetil|Single dose administration of candesartan, 32 mg oral tablet
41109515|NCT01025843|DRUG|Comparator: Pbo|Placebo
41109516|NCT00484575|DRUG|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
41109517|NCT00484575|DRUG|propofol|propofol given intravenously for sedation in control group
41109518|NCT06223113|DEVICE|EyenableTM PA60AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® EyenableTM PA60AS1 IOL in the eye capsule.
41109519|NCT04560855|DEVICE|Connected devices measurements|The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.
41109520|NCT05097781|DRUG|PD-1 blocking antibody|All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
41109521|NCT04576858|DIAGNOSTIC_TEST|Circulating tumor DNA|Measurement of circulating tumor DNA from plasma over a period of 2 years.
41109522|NCT00521833|PROCEDURE|phacoemulsification and intraocular lens implantation|clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
41109523|NCT05647967|DIAGNOSTIC_TEST|Ultrasound|Each patient underwent ultrasound after admission of ICU.
41109524|NCT03969472|DRUG|probiotics|apply probiotic after operation
41109525|NCT03969472|DEVICE|Electrophysiologic Therapy|Pelvic floor electrophysiological therapy is used after surgery
41109526|NCT05758727|OTHER|Exercise intervention|The exercise programme is progressive and has three levels. Each bout of exercise and Tai-chi snacking consists of 5 exercises. Each exercise is performed for one minute with one minute rest in between. For exercise snacking movements (including leg exercise, shoulder exercise, single leg exercise, arm exercise, and ankle exercise), participants are encouraged to complete as many repetitions as possible of that exercise in that minute. For Tai-chi snacking movements (including single leg squat, trunk rotation, single leg stand, hip and knee exercise, and ankle mobility exercise), participants are encouraged to complete repetitions of each exercise at a self-selected pace that is comfortable for them to maintain for the full minute, with the aim being to complete the movements as accurately and smoothly as possible (based on correct posture and proper alignment).
41109527|NCT02504619|BIOLOGICAL|CordIn|CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
41109528|NCT01957319|DRUG|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg|
41445714|NCT04005690|DRUG|Cobimetinib|Given PO
41109529|NCT01957319|DRUG|sugar pill|
41109530|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
41133340|NCT03802994|DRUG|23 valent pneumococcal polysaccharide vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 23 different pneumococcal serotypes. Only group 5 will potentially receive this as an intervention.
41109531|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS (sham device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
41109532|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS (COVID active device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
41109533|NCT04043364|BEHAVIORAL|LIVE|Learning, Innovation, Volunteers and Empowerment
41109534|NCT04879082|OTHER|Professional course, occupational exposures|"The data collected are the following variables: age, sex, diploma, professional course coded in CITP (International Standard Classification of Professions) and NAF (French Nomenclature of Activities), occupational exposures, smoking, risk factors non-professionals, clinical elements of ILD and elements relating to an occupational disease certificate. This database is anonymized.~The precise diagnosis of ILD is retained during the multidisiciplinary meeting.~Occupational exposures are assessed in specialized consultation :~* a first professional interview phase: The professional history is traced, listing the training courses followed and the trades carried out. The questioning is precise and focuses on the different tasks performed, and the products used.~* a second step, where a questionnaire is completed by the doctor: A list of specific substances is offered to the patient, who responds whether or not he thinks he has been exposed to them in his professional past."
41109535|NCT06297135|BEHAVIORAL|Behavioral Parent Training|Teaches parents antecedent- and reinforcement-based behavior management techniques and provide support to manage their stress
41109536|NCT05830136|DRUG|sodium bicarbonate Ringer's solution|Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.
40752327|NCT03508453|OTHER|Placebo|sterile normal saline for injection prepared to be identical to study drug
41445715|NCT04005690|DRUG|Olaparib|Given PO
41109537|NCT04321642|DRUG|Entonox|Entonox gas with mouth piece
41109538|NCT04321642|DRUG|Not receive Entonox|Not receive any gas
41109539|NCT05016713|COMBINATION_PRODUCT|Chlorhexidine mouthwash|"Chlorhexidine mouthwash is added to the oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.~If any participant shows any signs of CHX hypersensitivity, the intervention will be discontinued."
41109540|NCT05016713|DEVICE|Interdental brush|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
41109541|NCT05016713|OTHER|Fluoride-based toothpaste|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
41109542|NCT00372450|PROCEDURE|management of therapy complications|
41109543|NCT00372450|PROCEDURE|quality-of-life assessment|
41109544|NCT00258635|BIOLOGICAL|RagweedMATAMPL|
41109545|NCT06429852|BEHAVIORAL|The DeST-ACT Trauma-Focused Acceptance and Commitment Therapy Program|The Trauma-focused psychosocial intervention program consists of 4 sessions online therapy.
41109546|NCT00843193|DRUG|INTRAVENOUS GSK679586|GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
41109547|NCT00843193|DRUG|INTRAVENOUS PLACEBO|Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
41109548|NCT00843193|DRUG|FLUTICASONE PROPIONATE|Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
41109549|NCT04372394|DRUG|surufatinib|Surufatinib: 300 mg as a single dose on Days 1 and 8 with or without food
41109550|NCT05482399|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
41109551|NCT05650268|DRUG|Vitamin D3|Receiving 576000 international units in single oral dose of liquid vitamin D 3\~7 days prior to the surgery.
41109552|NCT05650268|OTHER|95% MCT|95% MCT supplement 3-7 day before surgery
40925573|NCT04705844|DRUG|Adalimumab|adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)
41109553|NCT01013441|BIOLOGICAL|Infusion of CD3/CD28 stimulated T cells|Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
41109554|NCT04152616|OTHER|Instrumental evaluation of posture|"After a time of installation of the Optitrack® device's and two accelerometers (one placed on the subject's trunk facing the sternum fixed with a headband and the second at the level of the head also held with a headband), the subject will perform an evaluation of the balance sitting on the sensor pad; the movements of the head and trunk will be analyzed by the Optitrack® device and by the two accelerometers.~The subject will perform 4 30-second tests, two with eyes open and two with eyes closed. A rest period may be taken between each assessment depending on the subject.~During these evaluations, a physiotherapist will be present to avoid the risk of falling.~After a rest period of 30 minutes, a new assessment of the sitting posture will be carried out to assess the reproducibility of the tools (sensor pad, accelerometers, Optitrack®)."
41109555|NCT02411942|DRUG|Adapalene Gel 0.3%|Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days
41109556|NCT02411942|DRUG|Differin®|Differin® applied to the entire face once daily for 84 consecutive days
41109557|NCT02411942|DRUG|Placebo|Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
41445716|NCT04005690|DRUG|Onvansertib|Given PO
41445717|NCT04005690|DRUG|Azenosertib|Given PO
41445718|NCT04005690|DRUG|Saruparib|Given PO
41109558|NCT03196167|DRUG|Sugammadex|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
41109559|NCT03196167|OTHER|Placebo|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
41109560|NCT04325048|DEVICE|Cordio App|Adult patients positive to COVID-19 virus will record several predefined sentences via a smartphone / tablet and will answer questions via the app
41109561|NCT00929721|PROCEDURE|Blood draw|culture for Streptococcus pneumoniae Frequency-1
41109562|NCT00929721|PROCEDURE|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
41109563|NCT00929721|PROCEDURE|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
41109564|NCT00929721|PROCEDURE|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
41109565|NCT00929721|PROCEDURE|sputum|culture for Streptococcus pneumoniae Frequency-1
41109566|NCT01376336|DEVICE|Safe storage device|This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
41109567|NCT04658212|PROCEDURE|3D LCBDE|three-dimensional (3D) video system for LCBDE (laparoscopic cholecystectomy and laparoscopic common bile duct exploration )
41109568|NCT04658212|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
41109569|NCT02931435|PROCEDURE|Nerve Block with Radiofrequency Ablation|Ablation of the genicular nerves of the knee by radiofrequency
41109570|NCT02931435|PROCEDURE|Nerve Block with Sham Radiofrequency Ablation|Genicular radiofrequency of the knee without neurotomy
41109571|NCT01072357|DRUG|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
41109572|NCT01072357|DRUG|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
41109573|NCT01043263|DRUG|EN3324 (axomadol)|twice daily dosing
41109574|NCT01043263|DRUG|Placebo|twice daily dosing
41109575|NCT01752465|BEHAVIORAL|Health Coaching|Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
41109576|NCT01752465|BEHAVIORAL|Standard care|Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
41109577|NCT04660214|DEVICE|septotomy|endoscopic diverticulotomy
41445719|NCT04005690|BIOLOGICAL|Tremelimumab|Given IV
41109578|NCT03899675|DIETARY_SUPPLEMENT|Placebo|On the first day of collection, the volunteers will not take placebo intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of placebo and will be advised to consume 1 hour before the procedure.
41109579|NCT03899675|OTHER|Caffeine|On the first day of collection, the volunteers will not take caffeine intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of caffeine and will be advised to consume 1 hour before the procedure.
41109580|NCT06556199|DRUG|Selinexor|Selinexor dose escalation: 40,60,80mg respectively every week, and dose expansion at the RP2D of Selinexor,every 3 weeks for 6 cycles.
41109581|NCT06556199|DRUG|Temozolomide|Temozolomide 150mg/m2 po d1-5 every 3 weeks for 6 cycles.
41109582|NCT06556199|DRUG|Anti-PD-1 monoclonal antibody|The dose of anti-PD-1 monoclonal antibody is fixed dose 200 mg intravenously every 3 weeks until until disease progression or recurrence, intolerance of toxicity, death, loss of follow-up, withdrawal of notification (whatever happened first).
41445720|NCT06628336|DEVICE|HARMONY EVOLUTION|It is planned to include consecutive eligible subjects which will be treated with the HARMONY EVOLUTION devices.
40925574|NCT04705844|DRUG|Placebo|placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)
41109583|NCT01045655|BEHAVIORAL|MOMCare|8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
41109584|NCT01121549|DRUG|Aromasin|25 mg daily continuously
41109585|NCT06315049|OTHER|Music therapy|Music therapy sessions to reduce anxiety
41109586|NCT00391755|DRUG|ramelteon|"1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary"
41109587|NCT04778917|DRUG|Low-Molecular-Weight Heparins Calcium Injection|We use different dose of low-molecular-weight heparins calcium injection to different interventions
41109588|NCT01964469|BEHAVIORAL|mobile & web-based action plan|Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application
41109589|NCT02312336|OTHER|Cohort A - Room temperature coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
41109590|NCT02312336|OTHER|Cohort B - Cooled coronary perfusate|"Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).~The research intervention is the infusion of Hartmans solution cooled to 15 degrees."
41109591|NCT01075217|DRUG|iopamidol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
41109592|NCT01075217|DRUG|iodixanol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
41109593|NCT00002995|BIOLOGICAL|dactinomycin|
41109594|NCT00002995|BIOLOGICAL|filgrastim|
41109595|NCT00002995|BIOLOGICAL|sargramostim|
41109596|NCT00002995|DRUG|cyclophosphamide|
41109597|NCT00002995|DRUG|vincristine sulfate|
41109598|NCT00002995|RADIATION|radiation therapy|
41109599|NCT05305235|DEVICE|RISE Guide|Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress.
41109600|NCT05305235|DEVICE|Relaxation Control|Guides users through relaxation techniques.
41109601|NCT03921450|DEVICE|1 Hz rTMS|1 Hz stimulation at 110% of resting motor threshold over supplementary motor area
41109602|NCT03921450|DEVICE|iTBS|50 Hz theta burst stimulation at 80% of resting motor threshold over supplementary motor area
41109603|NCT03921450|DRUG|Placebo|1 Hz stimulation with the placebo TMS coil without any magnetic emission
41109604|NCT04008836|DEVICE|T-PLUS Meter|Blood Glucose Monitoring System (BGMS)
41109605|NCT05121506|COMBINATION_PRODUCT|CBD and THC with GT4 technology|A single topical dose of CBD and THC will be administered with GT4 technology. The material will be provided in a single use pre-filled syringe.
41109606|NCT04438668|DEVICE|Centaflow and Standard Care|The intervention is screening methods
41109607|NCT04438668|DIAGNOSTIC_TEST|Standard Care|The intervention is screening methods
41109608|NCT03092713|BEHAVIORAL|Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.
41109609|NCT03092713|BEHAVIORAL|Control Group|The Control Group receives usual assessment and treatment at Oslo University Hospital.
41109610|NCT05023512|BEHAVIORAL|Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health|Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.
41109611|NCT01064804|DRUG|PF-04191834|PF-04191834. 100mg Immediate Release Tablets or oral suspension
41109612|NCT03445130|OTHER|Lavandula Angustifolia oil (LO)|two drops on the inside of an oxygen face mask for 15 minutes.
41109613|NCT03445130|OTHER|Michelia Alba Leaf oil (MA)|two drops on the inside of an oxygen face mask for 15 minutes.
41109614|NCT03445130|OTHER|Almond oil (AO)|two drops on the inside of an oxygen face mask for 15 minutes.
41109615|NCT03445130|OTHER|Water|two drops on the inside of an oxygen face mask for 15 minutes.
41109616|NCT02371746|DRUG|ENV515-3 Travoprost XR|
41109617|NCT02371746|DRUG|ENV515-1 Travoprost XR|
41109618|NCT02371746|DRUG|ENV515-3-2 Travoprost XR|
41109619|NCT03900819|OTHER|dexterity measurement|4 non-invasive tests will be performed
41109620|NCT04962074|DEVICE|Microfluidic sperm sorting chip|Fertile Ultimate® (Koek Biotechnology, Turkey) microfluidic sperm sorting chips
41109621|NCT04962074|DEVICE|Density gradient|Density gradient centrifugation
41109622|NCT01145170|RADIATION|Radiotherapy|Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
41109623|NCT01145170|BIOLOGICAL|Nimotuzumab|The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
41109624|NCT06060002|PROCEDURE|Group A - Stent exchange if cholecystectomy dated beyond 3 months|Stent removal and cholangiogram and stone clearance (if recurrent stone/s is/are found). Stent exchange if cholecystectomy dated beyond 3 months
41109625|NCT06060002|DIAGNOSTIC_TEST|Group B - Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months|Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months to see recurrence of CDL. ERC and stone clearance (if recurrent stone/s found on EUS/MRCP/USG abdomen)
41109626|NCT04503356|PROCEDURE|OMNI as a standalone procedure|It uses a single, self-sealing clear corneal incision with ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System as a standalone procedure.
41109627|NCT04503356|PROCEDURE|OMNI combined with cataract surgery|Phacoemulsification with intraocular lens implantation is performed. Then, ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System.
41109628|NCT02608528|RADIATION|[18F]fluoroglucose(FDG)|
41109629|NCT04554628|DIAGNOSTIC_TEST|ELISA test in urine|enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
41109630|NCT04241224|DEVICE|Atherectomy|Endovascular treatment of peripheral arterial disease
41109631|NCT02949583|DRUG|Punica granatum Linn.|Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
41109632|NCT02949583|DRUG|chlorhexidine|standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
41109633|NCT00297674|DRUG|Intravenous Clarithromycin|
41109634|NCT00130741|DRUG|CHT - herbal therapy|
41109635|NCT00586586|BEHAVIORAL|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
41109636|NCT01985906|PROCEDURE|Multiple overlapping uncovered stents|Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents
41109637|NCT01985906|DEVICE|Uncovered stents|The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.
41109638|NCT02052219|DRUG|Blisibimod|Blisibimod administered subcutaneously
41109639|NCT02052219|DRUG|Placebo|Placebo administered subcutaneously
41109640|NCT02331004|OTHER|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
41109641|NCT02331004|OTHER|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
41109642|NCT03272113|BEHAVIORAL|SKIP-IT|A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
41109643|NCT03697616|DEVICE|Ridge augmentation with sticky bone and GBR|"* Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~* Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~* Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~* For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~* Periosteal releasing incision will be done to provide flap advancement for tension free closure~* Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures"
41109644|NCT01500395|PROCEDURE|Hybrid operation|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
41109645|NCT04538755|DRUG|Placebo oral capsule|Placebo before sleep
41109646|NCT04538755|DRUG|DAW2020 oral capsule|DAW2020 34 mg 4 h before sleep, single night administration
41109647|NCT04720014|BEHAVIORAL|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~1. an understanding of stress physiology and the physiology of the relaxation response;~2. a regular practice of eliciting the relaxation response; and~3. cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
41109648|NCT05677438|DRUG|CKD-498 dose#1|oral, once daily, 24 weeks
41109649|NCT05677438|DRUG|CKD-498 dose#2|oral, once daily, 24 weeks
41109650|NCT05677438|DRUG|CKD-498 dose#3|oral, once daily, 24 weeks
41109651|NCT05677438|DRUG|Placebo of CKD-498 dose#1|oral, once daily, 24 weeks
41109652|NCT05677438|DRUG|Placebo of CKD-498 dose#2|oral, once daily, 24 weeks
41109653|NCT05677438|DRUG|Placebo of CKD-498 dose#3|oral, once daily, 24 weeks
41109654|NCT05112146|DIETARY_SUPPLEMENT|Whey protein isolate|Oral administration
41109655|NCT05112146|DIETARY_SUPPLEMENT|Whey protein microgel|Oral administration
41109656|NCT05112146|DIETARY_SUPPLEMENT|Water|Oral administration
41109657|NCT04047784|DEVICE|Endobronchial ultrasound (EBUS)|"An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow.~Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion. At the completion of the imaging the EBUS bronchoscope will be withdrawn."
41109658|NCT03671525|DRUG|Nimodipine|Subject will receive two 30mg capsules of nimodipine during study visit.
41109659|NCT03671525|DRUG|Placebo oral capsule|Two coconut oil capsules that mimic the size and color of the nimodipine capsules
41109660|NCT04169399|DRUG|Toripalimab|240mg intravenously every 3 weeks
41109661|NCT04169399|RADIATION|Stereotactic body radiotherapy|Radiotherapy dose was 36 \~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
41109662|NCT04442919|DRUG|Ticagrelor followed with Methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
41109663|NCT04442919|DRUG|Ticagrelor followed with Morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
41109664|NCT04442919|DRUG|Ticagrelor alone|patients who received ticagrelor without any analgesia due to unstable angina
41109665|NCT04710017|DRUG|Tranexamic acid|will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.
41109666|NCT04710017|DRUG|Medroxyprogesterone Acetate 150 MG/ML|will be given MPA at 150 mg once intramuscular injection
41109667|NCT03213249|OTHER|Normal saline|Intraoperative pocket irrigation with normal saline
41109668|NCT03213249|DRUG|Cefazolin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
41109669|NCT03213249|PROCEDURE|Skin biopsy|Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.
41109670|NCT03213249|PROCEDURE|Bilateral skin- or nipple-sparing mastectomies|Standard of care
41109671|NCT03213249|DEVICE|Tissue expander|Standard of care
41109672|NCT03213249|DEVICE|Breast implant|"* Standard of care~* Either breast implant or autologous flap"
41109673|NCT03213249|PROCEDURE|Autologous flap|"* Standard of care~* Either breast implant or autologous flap"
41109674|NCT03213249|OTHER|Acellular dermal matrix sling|Standard of care
41109675|NCT03213249|DRUG|Gentamicin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
41109676|NCT03213249|DRUG|Bacitracin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
41109677|NCT01886430|OTHER|Functional electrical stimulation|Functional electrical stimulation for 10 days
41109678|NCT01886430|OTHER|Placebo electrical stimulation|Placebo electrical stimulation for 10 days
41109679|NCT04301986|DEVICE|Cytosponge|In a seated position, subjects will swallow the Cytosponge capsule with 150-250 mL of water. Seven minutes and 30 seconds to ten minutes after ingestion, the sponge is then withdrawn by gentle traction on the suture. After retrieval, the string is cut and the retrieved foam sphere containing the cytological specimen is immersed in fixative and stored refrigerated (1° to 12°C \[34° to 54°F\]).
41109680|NCT04301986|DEVICE|Transnasal Endoscopy (TNE)|In an upright position, the scope will be inserted via the nares to examine the posterior pharynx, esophagus and proximal stomach with the transnasal endoscopy approach. The scope will be withdrawn from the nares following completion of the exam.
41109681|NCT04301986|DEVICE|Esophagogastroduodenoscopy|Laying on the subjects' left side, the flexible endoscope is inserted through the mouth to allow visualization of the esophageal mucosa from the upper esophageal sphincter all the way to the esophagogastric junction (EGJ).
41109682|NCT00880048|DRUG|orvepitant|neurokinin-1 antagonist
41109683|NCT00880048|OTHER|Placebo|Placebo to match orvepitant 30 mg and 60 mg
41109684|NCT03123172|DIAGNOSTIC_TEST|arterial and central venous blood gases|withdrawal of arterial and central venous blood gases to measure Co2 gap
41109685|NCT00534937|PROCEDURE|Compression wrapping|Short-stretch compression wrap will be applied at least once a week.
41109686|NCT00534937|PROCEDURE|Flexitouch compression pump|In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
41109687|NCT00920881|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|Subjects wore 2 Navigator sensors for approximately 122 hours. Subjects and clinical staff were masked to continuous glucose data. During the time the subjects wore the continuous sensor, they were instructed to continue with their current diabetes management plan. Subjects stayed at the clinic for approximately 50 hours during the study period. While in the clinic, venous blood samples were collected every 15 minutes to determine whole blood reference glucose concentrations using the Yellow Springs Instrument. Subjects were also asked to obtain up to 50 FreeStyle finger blood glucose measurements using the system in the Navigator receiver for comparative analysis and system calibration. This was not a treatment study.
41109688|NCT04164680|DIAGNOSTIC_TEST|Multimodal Neuroimaging|fludeoxyglucose (FDG-)PET/MR imaging
41109689|NCT06015581|BEHAVIORAL|Workforce Development: Tailored Motivational Interviewing and Technical Assistance|TMI training includes an initial 12 hour virtual workshop, standard patient interaction with feedback, group coaching, and a final standard patient interaction and feedback. TMI relies on experiential activities developed by the network while minimizing didactic presentations. Stigma-reducing communication is emphasized by practicing autonomy supportive and empathic statements and improving cultural humility practices. Role plays map on to the Mystery Shopper domains focusing on risk reduction counseling and PrEP referral. TA addresses factors in the EPIS framework.
41271106|NCT02300649|DRUG|Dexmedetomidine, Transesophageal echocardiography(TEE)|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
41271107|NCT02300649|DRUG|Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.|
41109690|NCT06015581|BEHAVIORAL|Quality Management, Mystery Shopper Feedback|Mystery shoppers visit each agency two times per quarter to systematically examine testing clinics' environmental characteristics and their experiences with clinic staff (e.g., quality of testing session, safer sex discussions, perceived provider competency, PrEP discussions and referral). The investigator team meets with each agency once per quarter to review the data and provide technical assistance.
41109691|NCT05302414|OTHER|board game-based teamwork training|Using board game-based learning to develop resuscitation teamwork competency in PGY doctors and nurses.
41109692|NCT05302414|BEHAVIORAL|simulation-based teamwork training|Using board simulation-based learning to develop resuscitation teamwork competency in PGY doctors and nurses.
41109693|NCT05302414|OTHER|lecture-based teamwork training|Using board lecture-based learning to develop resuscitation teamwork competency in PGY doctors and nurses.
41109694|NCT04664049|DIETARY_SUPPLEMENT|NRICM101|"Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
41109695|NCT04753099|BEHAVIORAL|occupation-based coaching|"Occupation based coaching is an intervention proven to be an effective intervention in family-centered practice. OBC is a strength-based approach that emphases collaboration with clients in goals setting and attainment to increase overall health and quality of life. Clients are the central focus of the intervention and generate their own strategies to address goals as part of the coaching process. In their role as coach, the therapists employ techniques such as reflective questioning and comments to support clients in identifying existing routines and rituals that impact goal attainment and to increase knowledge and access to resources that can promote improved caregiver quality of life after a child's diagnoses with T1D. Occupation based coaching can be divided into the following steps: (1) setting goals, (2) exploring options, (3) planning action, (4) carrying out the plan, (5) checking performance, and (6) generalizing(Little et al., 2018, p.2)."
41109696|NCT04498754|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|8 sessions of treatment for insomnia.
41109697|NCT04498754|BEHAVIORAL|Weekly phone contacts|Weekly calls to monitor insomnia symptoms.
41109698|NCT04258358|OTHER|CASCADE ways of working|Technology, learning and development resources and nursing and therapeutic care are the key drivers for the CASCADE ways of working promoting community integrated dementia care and support to optimise safety and independence for people living with dementia.
41109699|NCT00868569|PROCEDURE|TACE + folfox 4|"tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4"
41109700|NCT00868569|PROCEDURE|TAC + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4"
41109701|NCT06419933|OTHER|The SuperKids Program|The SuperKids program will be administered following the manual of the intervention by a trained therapist, as described in the section of intervention/ treatment
41109702|NCT05211063|DIETARY_SUPPLEMENT|Saffron extract (Crocus sativus)|Daily intake of one tablet for 42 days.
41109703|NCT05211063|DIETARY_SUPPLEMENT|Placebo|Daily intake of one tablet for 42 days.
41133341|NCT03802994|BIOLOGICAL|13 valent conjugated pneumococcal vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 13 different pneumococcal serotypes conjugated to CRM197. Only group 5 will receive this as an intervention. In all other groups Prevnar 13 will be given as standard of care.
40925575|NCT05798468|OTHER|Augmented reality|The intervention will be carried out in the Physiotherapy Degree of the Universities of Malaga and Cadiz. It will consist of the use of software and a platform that works with augmented reality. Previously a study of the demographic variable of the population that conforms the study will be carried out. During the intervention, teaching will be carried out with the support and enhancement of the use of augmented reality through Zapworks and Aumentaty. A study and analysis of the variables of the qualifications and usability of the study population will be carried out. For the qualification variable, the academic performance of the students will be taken into account and for the usability variable, the System Usability Scale will be used. Subsequently, an analysis and interpretation will be carried out to assess the correlation between both variables.
40925576|NCT05798468|OTHER|Control group|Traditional education will be carried out
40925577|NCT00595374|DRUG|insulin detemir|
41109704|NCT04023916|DRUG|Sintilimab-R-CHOP|"Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m\^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable."
41109705|NCT04126330|DIETARY_SUPPLEMENT|Probiotic, Omega-3, Vitamin D supplement|"The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards)."
41109706|NCT04126330|DIETARY_SUPPLEMENT|Placebo|Placebo generated for probiotic and omega-3/vitamin D supplements
41109707|NCT02878915|DEVICE|Ultrasound guided femoral puncture|
40925578|NCT00595374|DRUG|insulin NPH|
40925579|NCT00595374|DRUG|insulin aspart|
40925580|NCT04111978|DRUG|Letrozole 2.5mg|Aromatase inhibitor
41109708|NCT00038714|DRUG|SGN-00101|
41109709|NCT05463549|OTHER|Informative video|An informative instructional film regarding the amniocentesis procedure including answers to frequently asked questions.
41109710|NCT04676568|PROCEDURE|Extravesical VVF repair|Both standard transvesical and extravesical approach for VVF repair will be utilised
41109711|NCT03758950|DRUG|Placebo|Once daily inhaled placebo for 48 weeks
41109712|NCT03758950|DRUG|Mometasone|Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
41109713|NCT04306354|DRUG|Oxytocin nasal spray|Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
41109714|NCT04306354|DRUG|placebo nasal spray|Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
41109715|NCT04459988|DRUG|Ocrelizumab|Description Needed
41109716|NCT00258037|BEHAVIORAL|Pelvic Floor Muscle training|
41109717|NCT02212054|BEHAVIORAL|conservative|anal dilatation; colonic lavage; oral probiotic
41109718|NCT02212054|PROCEDURE|operative|one stage pull through radical colectomy
41109719|NCT00660439|BEHAVIORAL|Narrative Exposure Therapy|"Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist."
40925581|NCT04111978|OTHER|Placebo|Placebo tablet of Femara
41109720|NCT04459819|OTHER|Respiratory physiotherapy|"Respiratory physiotherapy consists of:~* early mobilization (passive and active mobilization, muscle-strengthening exercises, mobilization out of bed, standing, walking, ADL)~* patients positioning~* non-invasive mechanical ventilation / CPAP~* tracheostomy management~* invasive mechanical ventilation weaning~* airway clearance~* oxygen titration"
41109721|NCT02740686|OTHER|Sample collection|Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.
40925582|NCT04571528|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
40925583|NCT04571528|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
41109722|NCT02955069|DRUG|PDR001|PDR001 was administered at a dose of 400 mg via intravenous infusion once every 4 weeks (Q4W). PDR001 was administered on Day 1 of every cycle. Each cycle was 28 days.
41109723|NCT01140113|PROCEDURE|Modified Ultrafiltration|After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
41109724|NCT03597841|DRUG|Combination therapy|Patients who are given combination therapy will be allocated to this group.
41109725|NCT01687452|BIOLOGICAL|Blood samples|
41109726|NCT05498363|BIOLOGICAL|Bacteriophage therapy|Difficult-to-treat bacterial infections were treated with bacteriophages (selected from a collection of 25 individual bacteriophages and 6 bacteriophage cocktails), which were shown to target the patient's infecting bacterial strain (in vitro)
40925584|NCT04571528|BEHAVIORAL|TAU + Physiotherapy part of VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients: - Pain neuroscience education (30 min.) - Physical exercise(30 min.) - Treatment as Usual (TAU). Standard pharmacological treatment usually provided to patients with fibromyalgia.
41109727|NCT00000635|DRUG|Trifluridine|
41109728|NCT00000635|DRUG|Bacitracin zinc/Polymyxin B sulfate|
41109729|NCT03070483|DRUG|Cholecalciferol|5000 IU cholecalciferol with 1000 mg calcium citrate daily
41109730|NCT00793754|DRUG|Aspirin|100 mg / day for 8 weeks
41109731|NCT00793754|DRUG|Atorvastatin|40 mg / day for 8 weeks
40752328|NCT05440929|BEHAVIORAL|Clinician Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
41445721|NCT04927013|BEHAVIORAL|Message-based Outreach Intervention for Survivors|The Georgia Cancer Registry will mail the initial recruitment containing messages intended to persuade the survivor to visit the study website as well as a unique login to access the website. In addition to the components of the standard website, an expanded website for the Message-based group will include Guidance for Talking with Close Relatives about Their Cancer Risk, and the request to enumerate each close relative and choose from a menu of options about how the survivor would prefer for their relatives to be contacted. Survivors also can select the option that they prefer a relative not be contacted. In this case, no invitation letter will be generated for these relatives. Survivors who provide mobile phone numbers will receive two SMS thanking them for accessing the website, and encouraging them to revisit the website to review information and contact relatives. The messages will occur at 3-week intervals over a 6-week time period.
41109732|NCT00793754|DRUG|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
41109733|NCT03895034|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
41109734|NCT04191265|DIAGNOSTIC_TEST|serum tropinin, serum CKmb|early detection of myocardial injury, allowing application of acute cardiac shock and cardiogenic shock
41109735|NCT02641990|DRUG|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
41445722|NCT04927013|BEHAVIORAL|Standard Outreach for Survivors|The Georgia Cancer Registry will mail survivors an introductory letter modeled on the Registry's general outreach letters that will include log in information. Survivors will have access to a condensed version of the website that includes Information about Ovarian Cancer, Information about Who in Your Family is at Increased Risk, and the offer of Free Genetic Counseling with the option to schedule an appointment.
41109736|NCT02641990|DRUG|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
41109737|NCT00143936|BEHAVIORAL|Low- Carbohydrate -Atkins Diet|Low Carbohydrate Diet
40752329|NCT02544815|DRUG|Digoxin|Digoxin 0.25 mg pills
40752330|NCT02544815|DRUG|Placebo|Placebo pills
41109738|NCT00143936|BEHAVIORAL|Low Calorie Diet|Maintain a low calorie diet
41109739|NCT00857142|DRUG|oxymorphone hydrochloride|
41109740|NCT00857142|DRUG|Opana|
41109741|NCT00828672|DRUG|Oxaliplatin|Administered on days 15,22,29,36 en 43; 50 mg/m2
41109742|NCT00828672|DRUG|Bevacizumab|Administered on days 1,15,29 and 43 ; 5mg/kg
41109743|NCT00828672|DRUG|Capecitabine|825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
41109744|NCT00828672|RADIATION|radiotherapy|Total dose 45Gy
41109745|NCT03119558|DRUG|18F-Florbetaben (Neuraceq®) PET/MRI|Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
41109746|NCT01122368|DRUG|micafungin|IV
41109747|NCT01122368|DRUG|placebo|IV
41109748|NCT06326437|OTHER|6-week dyadic intervention|Comprising 1 session with 60-90min, followed by 5 weekly internet-based sessions.
41109749|NCT01930045|DRUG|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
41109750|NCT01930045|DRUG|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
41109751|NCT03935048|DIETARY_SUPPLEMENT|Higher protein, low glycemic load diet|"All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided."
41109752|NCT05936671|PROCEDURE|EEG-and-ANI-guided anesthesia|During anesthetic maintenance, sevoflurane concentration will be titrated according to EEG monitoring. Sevoflurane concentration will be titrated to maintain intraoperative Patient state index (PSi) ≥ 35 and to avoid burst suppression. Intraoperative target-controlled infusion of remifentanil will be titrated to maintain intraoperative ANI between 50 and 70.
41109753|NCT05936671|PROCEDURE|standard anesthesia|During anesthetic maintenance, the attending anesthesiologists will provide a routine standard care for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the sevoflurane concentration and remifentanil infusion rates.
41109754|NCT05936671|DRUG|Sevoflurane and remifentanil|For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.
41109755|NCT05936671|DEVICE|EEG and ANI|EEG monitoring using SEDline (Masimo, Irvine, California, USA) and Analgesia Nociception Index (ANI; MetroDoloris Medical Systems, Lille, France) monitoring will be performed.
41109756|NCT03015454|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
41109757|NCT03015454|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
41109758|NCT00745446|PROCEDURE|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
41109759|NCT05348226|DIAGNOSTIC_TEST|Additional Cardiac Magnetic Resonance Scan|Standard of care medical treatment with sacubitril/valsartan (Entresto). Additional Cardiac Magnetic Resonance Imaging (CMR) Scan after 4-6 months of treatment.
40925585|NCT01700439|DEVICE|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
40925586|NCT05279391|DRUG|Dexamethasone|Dexamethasone 6-8 mg once daily
41109760|NCT03121586|DRUG|Pimavanserin|Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
41109761|NCT02519452|DRUG|Daratumumab Subcutaneous (SC) Administration|Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
41271108|NCT04752202|BEHAVIORAL|Individually balanced elimination/reducing diets|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced elimination/reducing diets, in accordance with the previously performed food sensitivity tests for 6 months. Laboratory tests for type III food sensitivity in the IgG1-3 class using the ELISA method were performed in an accredited medical laboratory. Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
40925587|NCT05279391|DRUG|Low molecular weight heparin|Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
41109762|NCT02519452|DRUG|Recombinant Human Hyaluronidase [rHuPH20]) SC Administration|Participants will receive Recombinant Human Hyaluronidase \[rHuPH20\]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
41109763|NCT04599582|DEVICE|Hip Arthroplasty|Patients are operated with hip replacement.
40752331|NCT00785447|OTHER|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
40752332|NCT02157337|DRUG|Atorvastatin|80 mg (PO) once daily for 6 days
40752333|NCT02157337|DRUG|placebo|80 mg (PO) once daily for 6 days
40752334|NCT02455856|DRUG|JNJ-42847922|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter \[mL\] oral solution on Day 1 and Day 6.
40752335|NCT02455856|DRUG|Itraconazole|Participants will receive single dose of itraconazole as 200 mg (2\*100 mg capsule) from Day 2 to Day 6.
40925588|NCT05279391|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
41109764|NCT01555684|PROCEDURE|percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency|percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
41109765|NCT03597100|DEVICE|Cala TWO|Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
41109766|NCT03920371|OTHER|gamma camera imaging|Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, additional research gamma camera imaging is carried out
41109767|NCT03419325|GENETIC|CYP2C19 test|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
41109768|NCT03419325|DIAGNOSTIC_TEST|P2RY12 assay|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
41109769|NCT05018754|DEVICE|TREATMENT OF ORAL MUCOSITIS USING PLATELET-RICH-FIBRIN (PRF)|All patients were affected by oral mucositis (9 RIOM, 6 chemotherapy-related oral mucositis). They were treated with almost 2 different systemic therapies before and during platelets gel applications. Median of time before the lesions were treated with platelets gel were 7 days. Lesions affected buccal mucosa, tongue, labial commissure and lower lip. Preliminar parameters were the microbiological contamination of lesions and presence of pain. Patients refer spontaneous widespread pain worsened by swallowing and feeding. Response to treatment has been evaluated in relation to the reduction of lesions dimensions, to the involution of pain and presence of granulation tissue after every application of platelet gel.
41109770|NCT01533519|DRUG|Neuropeptide Y|Intranasal administration will be administered with a nasal drug delivery device.
41109771|NCT01026233|DRUG|brentuximab vedotin|1.8 mg/kg IV every 21 days
41109772|NCT04533464|BIOLOGICAL|MultiStem|Intravenous Infusion
41109773|NCT04533464|BIOLOGICAL|Placebo|Intravenous Infusion
41109774|NCT05380869|DIAGNOSTIC_TEST|Point-of-care Test|to test Point-of-care procalcitonin in suspected pneumonia
40752336|NCT04336800|DEVICE|LiverMultiscan|The LiverMultiscan is a quick 15 min, contrast free scan that non-invasively provides three metrics of liver health namely liver fat, iron and fibro-inflammation
40752337|NCT01084863|DRUG|CT-P6|CT-P6: administered every 3 weeks
40752338|NCT01084863|DRUG|Herceptin|Herceptin: administered every 3 weeks
40925589|NCT05279391|DRUG|Tocilizumab|IV administration of Tocilizumab as a single dose of 8mg/kg
40925590|NCT05279391|DRUG|Baricitinib|4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to \<60 ml/min/1.73 m2)
41109775|NCT03097744|DEVICE|Ceterix NovoStitch|The device allows the physician to place a circumferential compression stitch around meniscal tears. This stitch is placed by passing suture from the tibial side to the femoral side of the meniscus and across the tear. This allows compression across the entire tear surface.
41109776|NCT03949348|PROCEDURE|Mid-urethral sling placement using autologous rectus fascia|Mid-urethral sling placement using autologous rectus fascia
41109777|NCT03949348|PROCEDURE|Mid-urethral sling placement using synthetic mesh|Mid-urethral sling placement using synthetic mesh
41109778|NCT03301454|DRUG|pursuit of chemotherapy|Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
41109779|NCT01946035|DRUG|Doxazosin XL|
40752339|NCT01084863|DRUG|Paclitaxel|Paclitaxel: administered every 3 weeks
41109780|NCT01946035|OTHER|Placebo|
41109781|NCT01125306|DEVICE|Xal-Ease|Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
41109782|NCT04668742|DEVICE|DYNAtraq|Tracheostomy alignment with DYNAtraq
41109783|NCT03012230|OTHER|Laboratory Biomarker Analysis|Correlative studies
41109784|NCT03012230|BIOLOGICAL|Pembrolizumab|Given IV
41109785|NCT03012230|DRUG|Ruxolitinib Phosphate|Given PO
41109786|NCT02020616|DRUG|LY3053102|Administered SC
41109787|NCT02020616|DRUG|Exenatide ER|Administered SC
41109788|NCT02020616|DRUG|Placebo|Administered SC
41109789|NCT02020616|DRUG|Metformin|Administered orally (PO)
41109790|NCT02571387|BEHAVIORAL|Mindfulness-based intervention|
40752340|NCT01732523|DIAGNOSTIC_TEST|Contrast enhanced carotid ultrasound|
40752341|NCT00003501|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41109791|NCT02571387|BEHAVIORAL|Sham meditation|
41109792|NCT04570631|DRUG|Eftozanermin alfa|Intravenous (IV) infusion
41109793|NCT04570631|DRUG|Bortezomib|Intravenous (IV) or Subcutaneous (SC) injection
40752342|NCT02902315|OTHER|Cryotherapy|The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
40752343|NCT02902315|OTHER|Vitamins C and E|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection.
40752344|NCT02902315|OTHER|Vitamins C and E associated with cryotherapy|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection. The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
41109794|NCT04570631|DRUG|Dexamethasone|Oral Tablet
41109795|NCT02894463|OTHER|questionnaire|
41109796|NCT02427698|PROCEDURE|cyrolipolysis (CoolSculpting device)|Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.
41109797|NCT02427698|PROCEDURE|subcision|The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
41109798|NCT03772379|DEVICE|tooth borne hyrax expander|ready made four stainless steel bands will be supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax,.The appliance will be activated one quarter turn per day untill reaching maximum amount of lateral expansion of the jack screw. the patients will be recalled twice per week to evaluate the progress of treatment.
41109799|NCT03772379|PROCEDURE|microosteoperforation|"ready made four stainless steel bands supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax.No activation will be provided to the hyrax expander before the micro-osteoperforation is performed.~Microosteoperforation will applied bilaterally on the buccal surface between the roots of teeth at the level of mucoginival junction, starting from the distal of canine till the distal of the first permanent molar using a small sized surgical bur mounted on a hand piece ."
41109800|NCT02533713|DEVICE|Exoskeleton assisted gait training|Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
41109801|NCT00560014|DIETARY_SUPPLEMENT|Arginine and canola oil|Canola oil 1 tablespoon BID Arginine 9.0grams BID
41109802|NCT00560014|DIETARY_SUPPLEMENT|Coromega and Arginine|Arginine 9.0 grams BID Coromega dose based on weight
41109803|NCT04299230|DEVICE|Cortium C3|
41109804|NCT00271167|DRUG|INO-1001|
40752345|NCT02902315|OTHER|Placebo|The volunteers from placebo exercise session will receive two pills (containing wheat flour) and the remaining procedures were conserved.
40752346|NCT00924482|DEVICE|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery|Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
41109805|NCT02929485|DRUG|Tolcapone|Tolcapone 200mg (single dose) administered at study visit
41109806|NCT02929485|DRUG|Placebo|Placebo (200mg) administered at study visit
41109807|NCT02929485|DRUG|Bromocriptine|Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
41109808|NCT05670951|DRUG|ELGN-2112|Human insulin \[rDNA\]
41109809|NCT05670951|DRUG|Placebo|Placebo
41109810|NCT01442935|DRUG|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
41109811|NCT01442935|DRUG|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
41109812|NCT01442935|DRUG|5-FU|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
41109813|NCT01442935|DRUG|Irinotecan|180mg/m² over 90 mn every 2 weeks up to progression or toxicity
41109814|NCT01442935|DRUG|Irinotecan|150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
41109815|NCT01442935|DRUG|Bevacizumab|5mg/kg over 90 mn every 2 weeks up to progression or toxicity
41109816|NCT01442935|DRUG|Cetuximab|500mg/m² over 90 mn every 2 weeks up to progression or toxicity
41109817|NCT01886625|PROCEDURE|unilateral single-port VATS sympathicotomy|
41109818|NCT00910754|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
41109819|NCT00910754|DRUG|Prednisone|Prednisone 5 mg tablets administered orally twice daily.
41109820|NCT03959241|PROCEDURE|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
40925591|NCT05279391|DRUG|Dornase Alfa Inhalant Product|Inh. 2,500 U/twice daily, for up to 14 days.
41453306|NCT01350986|BEHAVIORAL|Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual Treatment program for children with hyperactive and oppositional problem behavior (THOP) (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006)."
40752347|NCT06274437|DRUG|BND-35|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
40925592|NCT05324488|OTHER|No intervention|In this registry no intervention is carried out
40925593|NCT02878356|BEHAVIORAL|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
40925594|NCT02878356|BEHAVIORAL|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
40752348|NCT06274437|DRUG|Nivolumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
40752349|NCT06274437|DRUG|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
40925595|NCT02878356|BEHAVIORAL|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
40925596|NCT00134420|DRUG|Nutropin AQ|Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
40925597|NCT00134420|PROCEDURE|Arginine and Clonidine Stimulation Testing|This testing was done to determine growth hormone status prior to starting treatment.
41109821|NCT03959241|DRUG|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
41109822|NCT03959241|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
40925598|NCT00134420|PROCEDURE|Growth Factors Laboratory Testing|This involved assessment of growth factors such as IGF#1 before treatment was initiated.
40925599|NCT00134420|PROCEDURE|Neuropsychological Testing|This testing was done prior to treatment and at the end of treatment.
41109823|NCT03959241|PROCEDURE|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
41109824|NCT03959241|DRUG|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
41109825|NCT03959241|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
40925600|NCT00681356|DRUG|4975, 15 and 5 mg|Direct instillation into the surgical site
40925601|NCT00681356|DRUG|Placebo Comparator|Direct instillation into the surgical site
40925602|NCT00681356|DRUG|4975 - 5 mg|Direct instillation into the surgical site
40925603|NCT00254579|DRUG|CP-675,206|15 mg/kg Q12W dosing regimen
40925604|NCT05446831|DRUG|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily. The decision to initiate rescue therapy was made after assessment of the extent of bleeding, patient preferences, lifestyle and activity, the complications of specific therapies, comorbidities that predisposed patients to bleeding and the tolerance of side effects. If a platelet count over 300,000/μL was observed for two consecutive tests at least 2 weeks apart, baricitinib treatment was interrupted.
40925605|NCT00668356|DRUG|didanosine|28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
40925606|NCT00668356|DRUG|didanosine|28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
40752350|NCT05163405|DRUG|Bortezomib|Self-administration of subcutaneously Velcade.
40925607|NCT00794898|BIOLOGICAL|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
40925608|NCT05095532|BIOLOGICAL|Bone marrow-derived mesenchymal stem cells|MSC transplantation
40925609|NCT05095532|OTHER|Placebo|Standard of Care
40925610|NCT04929717|OTHER|Breastfeeding education and counseling|Breastfeeding education was applied for four weeks.
40925611|NCT04929717|OTHER|Routine postpartum breastfeeding training included in the hospital procedure|The routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures.
40925612|NCT01004198|DRUG|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
40925613|NCT01004198|DRUG|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
40925614|NCT01004198|DRUG|Ringers Lactate solution|Ringers Lactate solution for Injection
40925615|NCT05736029|OTHER|blood, stool and tissue samples collection|blood, stool and tissue samples collection before and during the treatment, as applicable
40925616|NCT05905614|DRUG|SPH4336 Tablets|Open-label SPH4336 Tablets ：Administered by oral
40752351|NCT03416933|OTHER|Blood sampling|2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.
40752352|NCT00284648|PROCEDURE|Surgical repair Achilles tendon rupture|
40925617|NCT03986931|OTHER|Experimental: Pharmacist-Bidirectional Texting Group|The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.
41109826|NCT03959241|DRUG|Cyclophosphamide|Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if actual body weight (ABW) \< IBW, use ABW\] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
40752353|NCT00284648|PROCEDURE|Non-surgical repair Achilles tendon rupture|
40752354|NCT04557137|DRUG|Somatostatin analog|120 mg ipstyl every 28 days
41109827|NCT05232630|DRUG|Fenfluramine|"Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day \[or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP\]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks."
41109828|NCT04327882|DIAGNOSTIC_TEST|Point-of-care ultrasound|performance of a POCUS: lung and cardiac ultrasound mainly
40752355|NCT04066244|DRUG|BLZ945|Investigational drug
40752356|NCT06243159|GENETIC|JY231|Infusion of JY231 Injection by dose of 1-10×10\^6 TU/kg、 1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
40752357|NCT02175758|DRUG|SOF|SOF administered orally once daily
41109829|NCT03002246|OTHER|Ultrasound Examination|Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.
41109830|NCT05787964|PROCEDURE|Biological sample collection|Whole blood (blood draw/phlebotomy) will be obtained to proceed with immunologic analysis of samples. Collection of biologic samples will occur up to 12 months.
41109831|NCT06465498|PROCEDURE|LUS decongestive strategy|LUS results are documented in the electronic case report form (eCRF) and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
41109832|NCT06465498|PROCEDURE|PE decongestive strategy|PE results are documented in the eCRF and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
40752358|NCT02175758|DRUG|RBV|RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
40752359|NCT03174275|DRUG|Durvalumab|Subjects will receive durvalumab, 750 mg every 2 weeks by IV infusion over approximately 1 hour (± 5 minutes).
40752360|NCT03174275|DRUG|Carboplatin|Carboplatin is commercially available and approved by the US FDA for use in patients with ovarian cancer.
40752361|NCT03174275|DRUG|Nab-paclitaxel|Nab-paclitaxel is commercially available and approved by the US Food and Drug Administration (FDA) for use in patients with metastatic breast cancer, metastatic pancreatic cancer, and for the treatment of locally advanced or metastatic NSCLC.
40752362|NCT03174275|DRUG|Cisplatin|Cisplatin is commercially available and approved by the US Food and Drug Administration (FDA) for the treatment of advanced bladder, ovarian and testicular cancer. It has been widely studied in a variety of solid tumor types.
40752363|NCT03174275|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
40752364|NCT03174275|RADIATION|IMRT|"involved field radiation will refer to areas demonstrated to harbor disease on pathology, and not elective areas"
40925618|NCT03986931|OTHER|Active Comparator: Control Group|This group will receive bidirectional texting, but no pharmacist monitoring.
40752365|NCT05847335|BEHAVIORAL|Survey work|Childhood Trauma scale, Personality Beliefs questionnaire, Emotional Intelligence scale
40925619|NCT00253708|PROCEDURE|management of therapy complications|
40925620|NCT00253708|PROCEDURE|massage therapy|
40925621|NCT00253708|PROCEDURE|pain therapy|
41109833|NCT04710225|PROCEDURE|Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting|"Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= \[SBP+10\]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure."
41109834|NCT04148417|DEVICE|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure
41109835|NCT05145517|DEVICE|Open repair|Open repair of the aorta and peripheral arteries
40925622|NCT00253708|PROCEDURE|psychosocial assessment and care|
40925623|NCT00253708|PROCEDURE|quality-of-life assessment|
40925624|NCT05541588|PROCEDURE|peripheral nerve block|ultrasound guided nerve block
41109836|NCT02715258|DRUG|Bexagliflozin|tablets containing 20 mg bexagliflozin
41109837|NCT02715258|DRUG|Placebo|tablets matching the appearance of bexagliflozin tablets
41109838|NCT04915885|OTHER|Routine care|Routine contraceptive counseling and routine method availability
40752366|NCT01307618|BIOLOGICAL|NA17.A2 Peptide Vaccine|Given SC or ID
40925625|NCT06086015|DEVICE|transcranial alternating current stimulation (tACS)|2mA tACS over right hemisphere, at positions F4, P4, T8 (10-10 convention)
41109839|NCT04915885|OTHER|Package of contraceptive counseling interventions|The implementation package will be co-designed by providers and clients during the formative and research design phases
41109840|NCT04915885|OTHER|Expanded methods|Expanded range of contraceptive methods as recommended by national policies
41109841|NCT03496649|DRUG|Dysport 500 Unit Powder for Injection|Dysport administered by intramuscular injection
41109842|NCT00295074|PROCEDURE|neuropsychologic testing|
41109843|NCT01056835|DRUG|prostaglandin I2 analogue|
41109844|NCT00844636|DEVICE|Sharp needle|
41109845|NCT00844636|DEVICE|Blunt needles|
41109846|NCT03337568|PROCEDURE|allogeneic hematopoietic cell transplantation|perform allogeneic hematopoietic cell transplantation (HCT) using conditioning regimen of busulfan, fludarabine, and antithymocyte globulin
41109847|NCT05401227|DRUG|Ketamine|Ketamine during an MRI
41109848|NCT05401227|DRUG|Ts-134|4 days of TS-134 20 mg
41109849|NCT05401227|DRUG|Placebo|4 days of placebo TS-134
41109850|NCT05819541|DRUG|Montelukast Oral Granules|Oral montelukast granules, USP powder, or crushed tablets at weight-based doses between 2 mg/kg and 3 mg/kg to a maximum of 180 mg.
41109851|NCT05819541|DRUG|Albuterol|Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer
41109852|NCT05819541|DRUG|Corticosteroid|Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
41109853|NCT00688519|DRUG|U0267|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
41109854|NCT00688519|DRUG|Vehicle|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
41109855|NCT06555848|DEVICE|CERAMENT G|CERAMENT G is intended for use as a bone void filler as an adjunct to systemic antibiotic therapy and surgical debridement (standard treatment approach to a bone infection) as part of the surgical treatment of osteomyelitis. By eluting gentamicin, CERAMENT G can reduce the recurrence of chronic osteomyelitis from gentamicin-sensitive microorganisms in order to protect bone healing.
41109856|NCT01377129|PROCEDURE|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
41109857|NCT01377129|PROCEDURE|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
41109858|NCT03335969|DEVICE|colon irrigation|Study is to compare bowel movement patterns before and after colon irrigation.
41109859|NCT06553521|OTHER|MyHEARTSMAP Youth Self-assessment Tool (At Admission)|MyHEARTSMAP is a validated self-assessment tool for pediatric populations, demonstrating high sensitivity and specificity for identifying psychosocial concerns. Adapted from HEARTSMAP, it allows self- and proxy-reporting across 10 well-being domains, providing personalized recommendations. Currently, the clinician-reported HEARTSMAP is the standard of care at BC Children's Hospital ED for the initial assessment of youth with primary psychiatric concerns
41109860|NCT01689272|PROCEDURE|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
41109861|NCT02863380|PROCEDURE|Functional magnetic resonance imaging used to individualize rTMS protocol|Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
41109862|NCT02863380|DEVICE|Individualized rTMS (transcranial magnetic stimulation)|
41109863|NCT02863380|DEVICE|Classical rTMS (transcranial magnetic stimulation)|
41109864|NCT02863380|DEVICE|Classical tDCS (transcranial direct current stimulation)|
41109865|NCT04932707|OTHER|sub-occipital muscle inhibition technique|this technique will be conducted from a supine lying position. The therapist stretches the suboccipital, placing the hands beneath the patient's head applying pressure up and backward, pressure was maintained till tissue relaxation occurred flexes the head of the patient to get the chin to the manibiurim sternm.
40752367|NCT01307618|BIOLOGICAL|Recombinant MAGE-3.1 Antigen|Given SC or ID
41109866|NCT04932707|OTHER|Neurodynamic mobilization|Patient in a comfortable short sitting position at the edge of the bed with the trunk in an military straight position then ask the patient to slump; flex her neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot.
41109867|NCT04932707|OTHER|control (passive stretch exercises)|The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side
41109868|NCT06296056|BIOLOGICAL|Combi|Biological immune cell therapy
41109869|NCT00436644|DRUG|Lapatinib|1250 mg orally days 1 -28.
41109870|NCT00436644|DRUG|Topotecan|3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 \& 15.
41109871|NCT05596630|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiotherapy for small intrahepatic recurrent HCC. Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
41109872|NCT04010448|BIOLOGICAL|TV P2-VP8|90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57
41109873|NCT04010448|BIOLOGICAL|Rotarix|Rotarix® PO plus IM placebo administered on study days 1, 29 and 57
41109874|NCT04340362|DRUG|VX-147|Tablets for oral administration.
41109875|NCT04964479|DRUG|TQB2450 injection|1200mg injection once every 3 week
41109876|NCT04964479|DRUG|Anlotinib Hydrochloride Capsules|12mg capsule once daily
41109877|NCT04964479|DRUG|Pembrolizumab injection|200mg injection once every 3 week
41109878|NCT04964479|DRUG|Placebo|Placebo capsule once daily
41109879|NCT04136639|OTHER|Miswak|sticks
41109880|NCT04136639|OTHER|Grape Seed Extract Mouthwash|Mouthwash
41109881|NCT04136639|OTHER|fluoride|mouthwash
41109882|NCT01667354|BEHAVIORAL|Academic Detailing|"The intervention design is based on academic detailing, an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations."
41109883|NCT03799380|DIETARY_SUPPLEMENT|Gatorade G2|Gatorade (G2), 20 oz. bottle, daily through the entire course of radiation therapy (approximately 5-7 weeks)
41109884|NCT03799380|DIETARY_SUPPLEMENT|Standard of care nutritional support|Standard of care nutritional support
41109885|NCT00920725|DRUG|Insulin (Aspart Insulin [Novolog], Regular Insulin)|"Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous"
41109886|NCT02346006|BEHAVIORAL|More physical activity.|Subjects receiving more physical activity in school.
41109887|NCT02276820|BIOLOGICAL|Viralym-A|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
41109888|NCT02878330|DRUG|MEDI8897|A single IM dose of 50 mg on Day 1 of the study.
41109889|NCT02878330|DRUG|Placebo|A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
41109890|NCT00319436|BEHAVIORAL|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
41109891|NCT00319436|BEHAVIORAL|Standard Parent Education for Substance Using Mothers|This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
41109892|NCT02332369|DEVICE|Capsular Tension Ring|
40752368|NCT01307618|BIOLOGICAL|Recombinant Interleukin-12|Given SC or ID
40752369|NCT01307618|BIOLOGICAL|MART-1 Antigen|Given SC or ID
40752370|NCT01307618|OTHER|Laboratory Biomarker Analysis|Correlative studies
41109893|NCT00739102|DEVICE|S.M.A.R.T. ® Stent|The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
41109894|NCT00868595|BIOLOGICAL|BPX-101|Vaccine
41109895|NCT00868595|DRUG|AP1903|Activating agent, infusion
41109896|NCT01750463|OTHER|Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor|Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
41445723|NCT04927013|BEHAVIORAL|Message-based Outreach Intervention for Close Relatives|Relatives will receive a unique website login linked to the survivor that enables access to the website. The website content will be identical to the survivor content with the exception of the addition of the Breast Cancer Genetics Referral Screening Tool (B-RST) risk assessment tool. This brief risk assessment is a validated screening tools that is clinically useful for estimating the probability of breast cancer (BRCA1/2) gene mutation and identifying women for referral to genetic counseling. Although all 1st or 2nd degree relatives of ovarian cancer survivors will screen positive on B-RST, asking relatives to complete the screener aims to raise their awareness of the factors that contribute to hereditary risk of ovarian cancer and will reinforce the salience of seeking genetic counseling. Additionally, relatives for who provide cell phone numbers will receive 3 SMS reminders over 9 weeks.
41109897|NCT01750463|OTHER|Standard Laboratory Blood Draw and Hemoglobin Analysis|Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
41109898|NCT05390736|BEHAVIORAL|Gait and balance assessment|Patients are given Time Up and Go (TUG) tests, 30-second chair test, and 4-stage balance test (side-by-side, instep, tandem, and one foot).
41109899|NCT05390736|BEHAVIORAL|Medication review|Patients' medication history in the EHR is assessed for polypharmacy (using 5 or more medications concurrently) and use of medication in the following classes: tricyclic antidepressants, antihistamines, antiemetics, antipsychotics, antispasmotics, muscle relaxants, benzodiazepines, hypnotics, and opioids. The CRN confirms prescriptions with the patient. The CRN reports the medication risk in her provider report and provides medication management educational materials to the patient. At the patient's upcoming primary care visit, providers evaluated whether the medications associated with increased fall risk could be adjusted.
41109900|NCT05390736|BEHAVIORAL|Comorbidity review|The clinical research nurse reviews the patient's EHR problem list for diagnoses of comorbidities associated with increased fall risk including: cognition problems, Parkinson's disease, cardiac issues, depression, or incontinence. Comorbidities are shared with providers in the recommendation statement.
41109901|NCT05390736|BEHAVIORAL|Fall history|The CRN asks how many times the patient had fallen in the past 12 months, whether those with falls sought medical attention, and if they experienced blackouts, loss of consciousness, or a broken/fractured bone(s) resulting from a fall. Fall history information is added to the provider report to increase the salience of fall prevention information.
41109902|NCT05390736|BEHAVIORAL|Assessment of feet/footwear|The CRN observes or asks about the patient's current footwear, asks about foot pain or loss of sensation, and notes a diabetes diagnosis when applicable. Patient reports of foot pain, loss of sensation or diabetes result in a CRN note to the provider to examine the patient's feet and the potential need for a referral to podiatry. The CRN also reviewed a safe footwear handout with all patients regardless of their responses and emailed it to patients with other patient information following the call.
41109903|NCT05390736|BEHAVIORAL|Assessment of visual acuity|The CRN projects a Banner eye chart on Zoom for the patient to read with their contacts or glasses from five feet away for both eyes together and each eye individually. Phone patients are asked to self-report any vision problems. If either the video screening or patient self-report indicated any vision problems, the CRN notes the result and recommendation for eye care referral for the patient's provider to review and order.
41445724|NCT04927013|BEHAVIORAL|Standard Outreach for Close Relatives|The invitation letter shared by the survivor will provide a unique login code for each relative to visit the standard website with sections specifically for relatives that include information about genetic risk, the value of completing an online short validated risk screener, and the offer of free genetic counseling with the option to schedule an appointment.
41445725|NCT03507491|DRUG|Gemcitabine|Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).
41109904|NCT05390736|BEHAVIORAL|Home safety risk assessment|"The CRN reviews the CDC brochure Check for Safety: A Home Fall Prevention Checklist for Older Adults with each patient. Check for Safety asks 17 questions about the home's floors, stairs and steps, kitchen, bathrooms, and bedrooms and suggests ideas for removing or reducing fall hazards. The CRN communicates home safety risks and a recommendation for occupational therapy to the provider for indicated patients."
41109905|NCT05390736|BEHAVIORAL|Vitamin D Deficiency|The CRN asks the patient if they usually take a Vitamin D supplement with their other medications. If the patient does not take a Vitamin D supplement, the CRN recommends the provider check Vitamin D levels and consider supplementation if Vitamin D levels are less than 20 ng/mL.
41109906|NCT02526641|PROCEDURE|Functional Hepatic Nitrogen Clearance (FHNC)|
41109907|NCT02526641|PROCEDURE|Galactose Elimination Capacity (GEC)|
41109908|NCT02526641|PROCEDURE|Liver vein catheterization|
41109909|NCT05499637|DRUG|[68Ga]Ga-PentixaFor PET/CT|\[68Ga\]Ga-PentixaFor PET/CT
41109910|NCT03876457|DEVICE|Endovascular Thrombectomy|Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.
41109911|NCT03876457|OTHER|Medical Management|Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
41109912|NCT02612818|DEVICE|Coelioscopy|
41109913|NCT00234091|DRUG|Abacavir|8 mg/kg (up to 300 mg/dose) take orally twice daily
41109914|NCT00234091|DRUG|Efavirenz|200 to 600 mg taken orally once daily
41109915|NCT00234091|DRUG|Lamivudine|4 mg/kg (up to 150 mg/dose) taken orally twice daily
41109916|NCT00234091|DRUG|Lopinavir/Ritonavir|230 mg/57.5 mg/m\^2 body surface area taken orally twice daily with food
41109917|NCT00234091|DRUG|Nelfinavir|45-55 mg/kg taken orally twice daily with food
41109918|NCT00234091|DRUG|Nevirapine|120 mg/m\^2 once daily for first 14 days, tehn 200 mg/m\^2 (up to 400 mg/day) twice daily
41109919|NCT00234091|DRUG|Zidovudine|180-240 mg/m\^2 every 12 hours (up to 300 mg/dose)
41109920|NCT01116180|DRUG|Angiotensin II receptor antagonists (Candesartan)|Seven days of treatment with Candesartan 32 mg, capsules.
41109921|NCT01116180|DRUG|Placebo|Placebo Capsule matching the active comparator. Given for 7 days once daily.
41109922|NCT03601351|OTHER|ELISA for MOR-1 expression|To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.
41109923|NCT01559519|DRUG|Albumin|albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
41109924|NCT01808495|DRUG|Mitomycin C|
41109925|NCT04143555|PROCEDURE|endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy|Indocyanine green was injected under endoscope within 24 hours before operation. Four points(0.5ml/point,1.25mg/ml) were evenly injected in four quadrants at the edge of the tumor. The injection method was direct submucosal injection and 0.5ml saline + 0.5ml indocyanine green solution + 0.5ml saline (sandwich method). The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. The effect was divided into grade0 and Grade1. Grade1: The imaging of the tumor and the corresponding lymphatic drainage area in the injection area both were ideal. Grade 0: not up to grade 1, classified into tumor body and drainage area without imaging, only tumor body imaging, and even though tumor body and regional lymph drainage area imaging, the contrast agent in the gastric wall was too diffuse or even overflowing, which seriously interfered with the observation of lymph drainage area imaging.
41271109|NCT04752202|BEHAVIORAL|Individually balanced reducing diets (without elimination)|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced reducing diets (without elimination) for 6 months.Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
41109926|NCT00199108|DRUG|Depocyt|
41109927|NCT00199108|DRUG|Dexamethasone|
41109928|NCT05185830|OTHER|Interactive robots|Children will mobilize with the interactive robot when control group will mobilize with nurse.
41109929|NCT00860717|PROCEDURE|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
41109930|NCT00860717|RADIATION|Low level laser therapy (LLLT)|"The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact."
41109931|NCT01566708|BEHAVIORAL|Neuro-Music Therapy immediately|20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
41109932|NCT01566708|BEHAVIORAL|Neuro-Music Therapy after waiting time|20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.
41109933|NCT01566708|BEHAVIORAL|Music-therapeutical stress management coaching|20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
41109934|NCT00401323|DRUG|docetaxel (XRP6976)|
41109935|NCT00401323|DRUG|cisplatin|
41109936|NCT00401323|DRUG|5-fluorouracil (5-FU)|
41109937|NCT01959412|DRUG|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
41109938|NCT01959412|DRUG|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
41109939|NCT01959412|DRUG|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
41109940|NCT01959412|DRUG|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
41109941|NCT01959412|DRUG|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
41109942|NCT01959412|DRUG|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
41109943|NCT02980718|BEHAVIORAL|intensive olfactory training|
41109944|NCT02980718|BEHAVIORAL|ordinary olfactory training|
41109945|NCT03008499|BIOLOGICAL|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
41109946|NCT02444013|DRUG|Folic acid|
41109947|NCT02444013|DRUG|Placebo|
41109948|NCT04424836|DEVICE|high flow nasal cannula device|device is supplying oxygen with heated and humidified air in a high flow rate
41109949|NCT04308473|OTHER|Ultra-processed Food Meal|An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.
41445726|NCT03507491|DRUG|Nab-paclitaxel|Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
41109950|NCT04308473|OTHER|Whole Food Meal|A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.
41109951|NCT06245200|OTHER|UNIPDES - Internet Based Intervention - GUIDED|The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones). Participants in this arm will receive weekly feedback from counselors through the web software used.
41109952|NCT06245200|OTHER|UNIPDES - Internet Based Intervention - UNGUIDED|The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones).
41109953|NCT00855465|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
41109954|NCT00855465|DRUG|Placebo|Matching Placebo tid orally for 16 weeks
41109955|NCT02888457|OTHER|Nasopharyngeal sampling with a swab|
41109956|NCT01245452|DRUG|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
41109957|NCT01245452|DRUG|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
40752371|NCT06432465|DEVICE|tDCS|The anode will be placed over the right DLPFC (F4 on the EEG 10-20 system) and the cathode over the left DLPFC65 (F3) using 25cm2 sponges at an intensity of 2mA. Stimulation will be delivered via two saline-soaked surface sponge electrodes and a battery-driven, constant current stimulator (NeuroConn DC Stimulator Plus). This device includes a study mode, in which subject-specific codes are entered to deliver active or sham stimulation, keeping the administrator blinded. Sham stimulation will use a method in which stimulation will be ramped up and back down over a 30-second period at the beginning and end of sham tDCS.
41109958|NCT05686434|DRUG|Osimertinib|This is a prospective, open, single-center, single-arm phase II clinical study with EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
41109959|NCT05393180|DEVICE|Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF|"Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. This will be done endocardially using an irrigated endocardial ablation catheter.~Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation. ."
41109960|NCT02031471|DRUG|tocilizumab|Fixed dose of 162 mg subcutaneously weekly
41109961|NCT05481333|DRUG|REGN7999|Ascending IV or SC dose administered per protocol
41109962|NCT05481333|DRUG|Placebo|Ascending IV or SC dose administered per protocol
41109963|NCT05214235|DRUG|Hypoglycemic Drugs|Patients were divided into metformin group and sitagliptin group according to the type of hypoglycemic drugs they took.
41109964|NCT05576181|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B-ALL.
41109965|NCT05576181|DRUG|Fludarabine Oral Tablet|Fludarabine is used for lymphodepletion.
41109966|NCT05576181|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
41109967|NCT05576181|DRUG|VP-16|VP-16 is used for lymphodepletion.
41109968|NCT05576181|PROCEDURE|HSCT|Hematological stem cell transplantation
41109969|NCT00515450|BIOLOGICAL|GB-0998 (Intravenous immunoglobulin)|
41109970|NCT00515450|PROCEDURE|Plasmapheresis|
41109971|NCT01086917|BIOLOGICAL|PfSPZ Challenge|each volunteer to receive a single dose
41109972|NCT04323358|DIAGNOSTIC_TEST|Biometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
41109973|NCT04323358|DIAGNOSTIC_TEST|Keratometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
41109974|NCT04069182|BEHAVIORAL|Behavioral Activation Therapy|Behavioral Activation Therapy (BAT) has its origins in Cognitive Behavioral Therapy. In BAT, the patient monitors his emotions and daily activities, as a behavioral element. It seeks to increase the number of pleasant activities and increase interactions with the environment. The BAT considers positive reinforcement as the main intervention strategy. The treatment focuses on helping patients to systematically increase contact with their life's reward sources and solve their problems through procedures that focus on activation and on processes that inhibit it such as escape, avoidance behaviors and ruminant thoughts. It is a brief treatment consisting of 10 to 12 sessions spaced weekly (one hour per session), the first sessions are an explanation of the treatment and depression. Subsequent sessions are based on a collaborative work where the therapist and the patient work together to find activities that are according to the needs of the patient.
41109975|NCT05635604|DRUG|Eptinezumab|Eptinezumab or ALD403 is a humanized anti-calcitonin gene-related peptide IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). It selectively binds human CGRP ligand to prevent activation of the CGRP receptor and blocks its binding to the receptor for the prevention of migraine.
41109976|NCT05635604|DRUG|PACAP-38|PACAP-38 is a naturally occurring peptide diffusely expressed throughout the body. The Danish Headache Center has used infusion of PACAP-38 for several years and the first time in 2007 where infusion of PACAP-38 triggered headaches and migraines in migraine patients.
41109977|NCT02139748|PROCEDURE|Dental Implant & ADM|A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
41109978|NCT02139748|PROCEDURE|Dental Implant & ADM & bone xenograft|A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
41109979|NCT05871346|BEHAVIORAL|Complementary feeding counseling|Complementary Feeding Counseling to Improve Appropriate Complementary Feeding Practices and Reduce Child Undernutrition
41109980|NCT05327829|COMBINATION_PRODUCT|External non-invasive stimulation|The participants are randomized into the block design of sham or tACS/tnVNS during the first three appointments or the last three appointments. Eye tracking will be used to test the predominant focus of decisions during the gaze phase on costs or difficulty levels during the COGED. The study is investigating the use of neuromodulation after TBI for improved cognitive function.
41109981|NCT05327829|BEHAVIORAL|COGED|The COGED task consists of the classic N-back task of working memory-based decision making, followed by a valuation phase. The N-back phase of the task allows calculation of cognitive performance of a working memory task. During valuation, participants receive titrating offers of differing amounts of money to perform different difficulty levels of the N-back. The result is an effort discounting curve used to measure the individual effort cost. Effort discounting curves show the perceived cognitive effort required to complete each level of the task relative to another (typically the 1-back).
41109982|NCT04998903|PROCEDURE|Fiberoptic Bronchoscopy|Fiberoptic bronchoscopy done under conscious sedation
40925626|NCT01471431|OTHER|spontaneous breathing trial|"The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).~During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia \<100 for \>15 seconds or oxygen saturation by pulse oximetry \<85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met."
40925627|NCT03819907|COMBINATION_PRODUCT|Audiovisual Guided Relaxation|Five-minute guided relaxation delivered via a computer screen and speakers
40752372|NCT04162314|DRUG|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
40752373|NCT04162314|DRUG|Placebos|Placebos
40752374|NCT03444688|OTHER|Conventional Gait Training|Subjects allocated to the CT group will first perform active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. They will then perform conventional gait and balance therapy based on the proprioceptive neuromuscular facilitation (PNF) concept for 15 minutes. They will be given a 5 minutes rest. Finally, the CT subjects will undergo the over-ground gait training with or without aid or orthoses and with manual assistance from senior physiotherapist for 15 minutes, depending on the individual subject's abilities.
40752375|NCT03444688|DEVICE|Gait rehabilitation with walker|For WT group, subjects will first go through active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. The main therapy consists of 2 parts with 5 minutes rest in between. During part 1, subjects will be trained on the robotic walker with the help of active body weight support (BWS) and functional electrical stimulation (FES) for 15 minutes with pelvic motion support function and lateral balance function being continuously provided. During part 2, subjects will also receive resistance/assistance forces on top of the BWS and FES training for 15 minutes.
41109983|NCT03081949|DRUG|Oral Sodium Selenite 200 µg/day for 3 months|PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
41109984|NCT00092014|DRUG|Alendronate|Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
41109985|NCT00092014|DRUG|Risedronate 35 mg|Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
40752376|NCT02472951|OTHER|Low carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%"
40752377|NCT02472951|OTHER|Standard carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%"
40925628|NCT03819907|COMBINATION_PRODUCT|Virtual Reality Guided Relaxation|Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.
41109986|NCT00092014|DIETARY_SUPPLEMENT|Elemental Calcium|Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
41109987|NCT00092014|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
41109988|NCT00092014|DRUG|Risendronate placebo|Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
41109989|NCT00092014|DRUG|Alendronate placebo|Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
41109990|NCT00437346|PROCEDURE|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
41109991|NCT00437346|DRUG|Lanzo Melt|30mg, od, 1/2 h before meal
41109992|NCT00437346|DRUG|Lanzo Melt|30mg, od, 1/2 h before meal
41109993|NCT03160781|BIOLOGICAL|Platelet Rich Plasma|Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
41109994|NCT00604019|DRUG|Dopamine|Dopamine 5-20 mcg/kg/min to pre-determined max of 20
41109995|NCT00604019|DRUG|Norepinephrine|Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
41109996|NCT05061953|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
40925629|NCT03343418|DRUG|Desmopressin|Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.
41109997|NCT01091454|DRUG|brostallicin|Given IV
41109998|NCT01091454|DRUG|cisplatin|Given IV
41109999|NCT02939378|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
41110000|NCT02939378|DIETARY_SUPPLEMENT|Standard diet|Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
41110001|NCT02854761|DRUG|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
41110002|NCT00422019|DRUG|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
41110003|NCT00422019|DRUG|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
41110004|NCT04679519|OTHER|Drop Jumps|Perform 100 drop jumps from 40 cm height. The protocol is divided into 5 sets of 20 repetitions. Between each repetition participants get 10 seconds, and between each set 2 minutes rest. Stand on the box, drop of the box and land with feet shoulder width apart. Then immediately bend knee to approx 45 degrees and jump straight up. Throughout each jump hands are placed on hips and should not move.
41110005|NCT04210765|DRUG|Clomiphene Citrate|Clomiphene citrate used in incremental doses in nonresponsive cases.
41110006|NCT06233812|PROCEDURE|Simple interrupted suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
41110007|NCT06233812|PROCEDURE|Running suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
41110008|NCT00719017|PROCEDURE|Upper vaginectomy|Laparoscopic surgery with upper vaginectomy
41110009|NCT00719017|RADIATION|Post-operative brachytherapy|Laparoscopic surgery followed by brachytherapy
41110010|NCT00719017|PROCEDURE|Standard procedures|Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
41110011|NCT05058469|DEVICE|Tracheotomy|Tracheotomy in patients +/- antiplatelet therapy
41110012|NCT02959658|DRUG|Dimethyl fumarate|
41110013|NCT02959658|DRUG|Placebo|Manufactured to mimic Dimethyl Fumarate capsules
41110014|NCT03368378|PROCEDURE|Early DVC ligation|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
41110015|NCT01510912|DRUG|Diclofenac|35 mg bid or tid Capsules
41110016|NCT04402957|DRUG|LSALT peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
41110017|NCT04402957|DRUG|Placebo|0.9% saline solution
41110018|NCT02308137|DRUG|Domperidone|Simon-2-stage design for domperidone futility
41110019|NCT06512649|BEHAVIORAL|Early intervention|90-minute parent-coaching session once a week for 6 months with an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention. The intervention is individualized and tailored to each child's needs and identifies with caregivers the ways to embody objectives in daily life.
41110020|NCT06512649|BEHAVIORAL|Active monitoring|90-minute session once a month for 6 months. Sessions will be performed by an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention.
41445727|NCT01826838|DRUG|Dasatinib|"1.1 Primary Objective 1.1.1 To evaluate the maximum tolerated dose and dose limiting toxicities of dasatinib, up to a dose of 100mg/day, with concurrent standard radiation and hormone therapy for patients with intermediate and high risk prostate cancer.~1.2 Secondary Objective: 1.2.1 To determine the time to progression and overall survival for patients who are diagnosed with Intermediate and High Risk Prostate Cancer and were treated with dasatinib."
41110021|NCT02213107|DRUG|Enzalutamide and Dutasteride or finasteride|"Use of either two oral drugs together~1. Enzalutamide by mouth daily and dutasteride by mouth daily or~2. Enzalutamide by mouth daily and finasteride by mouth daily"
41110022|NCT04779333|BEHAVIORAL|LEAP|LEAP will be delivered through the typical 9 weekly BMT group sessions lasting 90 minutes. Plus wrist worn activity tracker \& facebook group.
41110023|NCT04779333|BEHAVIORAL|Standard BMT|Weekly BMT groups sessions which follow the Barkley curriculum
41110024|NCT02771171|RADIATION|CT Scan|CT imaging
41110025|NCT02890368|DRUG|TTI-621 Monotherapy|"TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages."
41110026|NCT02890368|DRUG|TTI-621 + PD-1/PD-L1 Inhibitor|TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
41445728|NCT06114836|DRUG|Omeprazole|Omeprazole will be the PPI prescribed for 4 weeks.
41445729|NCT06114836|OTHER|AR formula|Added rice formula will be ordered for 4 weeks.
41445730|NCT00860938|DRUG|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
41445731|NCT02581553|DRUG|lesinurad/allopurinol 200/300 FDC tablets|
41110027|NCT02890368|DRUG|TTI-621 + pegylated interferon-α2a|TTI-621 will be given in combination with pegylated interferon-α2a. Subjects in this cohort must have a cancer diagnosis for which pegylated interferon-α2a is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
41445732|NCT02581553|DRUG|lesinurad 200 mg|
41445733|NCT02581553|DRUG|allopurinol 300 mg|
41445734|NCT02581553|DRUG|lesinurad/allopurinol 200/200 FDC tablets|
41445735|NCT02581553|DRUG|allopurinol 200 mg|
41110028|NCT02890368|OTHER|TTI-621 + T-Vec|TTI-621 will be given in combination with talimogene laherparepvec (T-Vec). Subjects in this cohort must have unresectable melanoma.
41110029|NCT02890368|OTHER|TTI-621 + radiation|TTI-621 will be given following radiation to the target plasmacytoma. Subjects in this cohort must have relapsed multiple myeloma with bony or soft tissue plasmacytoma(s).
41110030|NCT05657795|DEVICE|Closed-loop automated oxygen control (Oxygenie, SLE6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
41110031|NCT05312866|PROCEDURE|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
41110032|NCT05312866|PROCEDURE|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
41110033|NCT02602106|BEHAVIORAL|Aquatic activities intervention|Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
41110034|NCT04567407|DRUG|Bilateral erector spinae blocks using ropivacaine|Bilateral chest wall nerve blocks using ropivacaine.
41110035|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 12 μg|CVGBM will be administered as an IM injection.
41110036|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 25 μg|CVGBM will be administered as an IM injection.
41110037|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 50 μg|CVGBM will be administered as an IM injection.
41110038|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 100 μg|CVGBM will be administered as an IM injection.
41110039|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine RDE 100 μg|CVGBM will be administered as an IM injection.
41110040|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 6 μg|CVGBM will be administered as an IM injection.
41110041|NCT00952718|OTHER|Inspiratory muscle training|A pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) was used for the inspiratory muscle training program. The individualized training program was started at an intensity of 30% MIP, which was increased by 2 cmH2O each week, but the maximal intensity did not exceed 50% of MIP. Patients were encouraged to perform IMT for 30 minutes per day, at least 5 days a week for 8 weeks.
41110042|NCT01130558|OTHER|Diabetes Management|Using electronic insulin order template for basal-bolus insulin and education
41110043|NCT02035735|PROCEDURE|WL and NBI|For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
41110044|NCT04838886|OTHER|Telerehabilitation-based Pilates Exercise|The group that will receive telerehabilitation-based pilates training via telerehabilitation
41110045|NCT00143234|DRUG|Amlodipine/atorvastatin single pill|
41110046|NCT06051786|DRUG|azelastine/fluticasone 137/50 mcg nasal spray|AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. AFC is administered intranasally and is used to treat Allergic Rhinitis (AR).
41110047|NCT06051786|DRUG|Dymista™|Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
41110048|NCT01282944|BEHAVIORAL|Financial Incentive|Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.
41110049|NCT01282944|BEHAVIORAL|Peer Network|Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
41110050|NCT05501548|DRUG|Olaparib|Olaparib 300mg by mouth twice daily
41110051|NCT05501548|DIETARY_SUPPLEMENT|Vitamin C|Ascorbic acid 1g/kg administered intravenously twice weekly
41110052|NCT02888249|OTHER|Altered composition cigarette|This double-blind study will systematically determine the abuse liability of altered composition cigarettes using a behavioral economics abuse-liability approach. Altered composition cigarettes (e.g., cigarettes differing in casings, sugars, tar levels, moisture) may result in decreased intake and decreased dependence, although critical questions remain regarding the abuse-liability of altered composition cigarettes, whether exposure to these cigarettes reduces use, and whether altered composition cigarettes will substitute for standard cigarettes. The addictive effects and abuse liability of altered composition cigarettes, therefore, are not well understood, and will be tested in this study.
41110053|NCT00993850|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
41110054|NCT00993850|OTHER|Bipolar education|Psychoeducation
41110055|NCT00532220|DRUG|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
41110056|NCT00532220|DRUG|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
41110057|NCT03148496|DEVICE|Biologic Mesh|Biologic mesh placed during surgery
41110058|NCT03148496|PROCEDURE|Small Bites|0.5 cm x 0.5 cm sutures used
41110059|NCT03148496|PROCEDURE|Large Bites|1.0 x 1.0 sutures used
41110060|NCT03702673|DRUG|K-877 CR Tablet A|K-877 Controlled Release Tablet A
41110061|NCT03702673|DRUG|K-877 CR Tablet B|K-877 Controlled Release Tablet B
41110062|NCT03702673|DRUG|K-877 CR Tablet E|K-877 Controlled Release Tablet E
41110063|NCT03702673|DRUG|K-877 IR Tablet|K-877 Immediate Release Tablet
41110064|NCT01640821|BEHAVIORAL|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
41110065|NCT01585558|DRUG|Ospemifene (Dose 1)|
41110066|NCT01585558|DRUG|Ospemifene (Dose 2)|
41110067|NCT01585558|DRUG|Placebo|
41110068|NCT00506727|DRUG|Mixed amphetamine salts (ADDERALL XR)|
41110069|NCT00506727|DRUG|Atomoxetine hydrochloride|
41110070|NCT01168154|DIETARY_SUPPLEMENT|Lactobacillus Reuterii|Lactobacillus Reuterii 10000000000 CFU per day
41110071|NCT01168154|DIETARY_SUPPLEMENT|placebo|placebo
41110072|NCT00753168|DRUG|OT-730 ophthalmic solution|one eye drop twice daily
41110073|NCT00753168|DRUG|timolol maleate ophthalmic solution|one eye drop twice daily
41445736|NCT05625178|DEVICE|Transcutaneous vagus nerve stimulation|tVNS will be performed by the application of an auricular electrode placed at the cymba concha of the left ear. The auricular electrode containing the anode will be applied with a conductive gel without prior disinfection. Once the electrode fits the cymba concha comfortably, the participant will lie down or take a position that is comfortable for them. Once in position, investigators initiate tVNS for 60 minutes with a below-discomfort-threshold intensity with 25 Hz and pulse width 250 uS. The electrical parameters will be modified accordingly to keep the below-discomfort threshold during the intervention.
41445737|NCT04547192|OTHER|Improving initial care of the injured|Improvement in Care Processes
41445738|NCT01855685|GENETIC|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
41445739|NCT01207479|DEVICE|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
41445740|NCT00443391|DRUG|ABT-089|Open label study, subjects will take up to 80mg daily for 24 months.
41110074|NCT00753168|DRUG|OT-730 placebo|one eye drop twice daily
41110075|NCT00383513|BIOLOGICAL|Epratuzumab|360 mg/m\^2 four consecutive 12-week maintenance cycles beginning with 2 consecutive weekly administrations each lasting ≤ 1 hour
41110076|NCT06555627|BEHAVIORAL|High Protein Breakfast|For 5 days children will receive a high protein breakfast comprised of baked items (i.e. waffles with syrup) and Greek yogurt. The high protein meal will aim for 40% protein, 40% carbohydrates, and 20% fat. Meals will be served with a cup of water.
41110077|NCT06555627|BEHAVIORAL|Morning Exercise|Exercise Intervention. For 5 days, a 30-min physical activity bout including a 5-minute warm up and cool down will be provided to participants in this group. The aim is for students to achieve an average heart rate above 150 for the session, not including warm up or cool down. To monitor intensity, the participant will wear heart rate monitors around their chest and waist-worn accelerometers.
41445741|NCT03078608|BEHAVIORAL|Mindfulness meditation program (administered via mobile app)|Mobile app-based/online mindfulness meditation program
41445742|NCT03078608|BEHAVIORAL|Progressive muscle relaxation (via mobile app)|Mobile app-based/online progressive muscle relaxation program
41445743|NCT06627777|BEHAVIORAL|Laboratory tasks in early adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
41445744|NCT03325062|BEHAVIORAL|Control|The contemporary progressive rehabilitation program consists of progressive resistive exercise to key lower extremity muscle groups, knee range of motion exercise, weight-bearing exercise, as well as education on symptom management strategies.
41110078|NCT06555627|BEHAVIORAL|High Carb Breakfast|For 5 days children will receive a high carb breakfast that will be comprised of 15% protein, 65% carbohydrates and 20% fat. Total energy content, fat, sugar, fiber, energy density, are similar between the breakfast meals.
41110079|NCT02220491|RADIATION|Single-fraction radiotherapy|Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
41110080|NCT02220491|RADIATION|Whole-brain radiotherapy|Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
41110081|NCT02163954|DRUG|Ticagrelor|After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
41110082|NCT02163954|DRUG|Clopidogrel|After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
41110083|NCT04628572|DRUG|Ceftazidime-avibactam|Non-Interventional Study
41110084|NCT01328418|PROCEDURE|Lengthening over nail|External fixator is used to lengthen either the femur or the tibia over an intramedullary nail
41110085|NCT05307614|DRUG|Moksi® 400mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
41110086|NCT05307614|DRUG|Drug: Avelox® 400Mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
41110087|NCT04484480|PROCEDURE|Balance training|Proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
41110088|NCT04842682|BIOLOGICAL|Solo 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
41445745|NCT03325062|BEHAVIORAL|Experimental: MOVE|The MOVE program emphasizes movement pattern retraining in conjunction with contemporary rehabilitation. More specifically, the MOVE program promotes symmetry in functional knee motion and loading without postural compensation. Intervention uses pressure-sensing shoe insoles to deliver real-time visual biofeedback during activity performance.
41110089|NCT04842682|BIOLOGICAL|Solo 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
41110090|NCT04842682|BIOLOGICAL|Solo 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
41110091|NCT04842682|BIOLOGICAL|Combi 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
41110092|NCT04842682|BIOLOGICAL|Combi 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
41110093|NCT04842682|BIOLOGICAL|Combi 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
41110094|NCT00519129|DEVICE|3D-imager|3D-imager vs fluoroscopy during coloscopy
41110095|NCT02762006|DRUG|Durvalumab|Durvalumab is a programmed cell death ligand-1 monoclonal antibody which has demonstrated anti-tumor efficacy renal cell carcinoma and other malignancies via activation of the immune system.
41110096|NCT02762006|DRUG|Tremelimumab|Tremelimumab is a CTLA-4 monoclonal antibody.
41110097|NCT03091712|DEVICE|Glooko Mobile Insulin Dosing System(MIDS)|Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management
41110098|NCT01340261|BEHAVIORAL|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
41110099|NCT01940003|OTHER|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
41110100|NCT00793286|PROCEDURE|Mesh fixation by staples|Mesh fixation by staples
41110101|NCT00793286|PROCEDURE|Mesh fixation by glue|Mesh fixation by glue
41110102|NCT05041491|BEHAVIORAL|BREAK|The BREAK intervention is a physical activity regimen.
41110103|NCT05041491|BEHAVIORAL|ONE|The ONE intervention is a physical activity regimen.
41110104|NCT04428658|BEHAVIORAL|Supplemental video visits|Receiving home-based video visits with a pediatric endocrinologist monthly as a supplement to regular diabetes clinic visits.
41110105|NCT04428658|BEHAVIORAL|Standard of Care|Usual quarterly visits with the UCD Pediatric Diabetes Clinic.
41110106|NCT04428658|BEHAVIORAL|Supplemental remote monitoring|Receiving remote glucose monitoring with monthly outreach from a pediatric endocrinologist as a supplement to regular diabetes clinic visits.
41110107|NCT02674646|RADIATION|Radiotherapy|Radiation as indicated by the cancer diagnosis
41110108|NCT02674646|DEVICE|Needle Acupuncture|Needle Acupuncture according to Traditional Chinese Medicine (TCM)
41110109|NCT02712658|DRUG|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
41110110|NCT02712658|DRUG|Placebo|
41110111|NCT06282744|OTHER|Outpatient physical therapy improvement in movement assessment log|The Outpatient Physical Therapy Improvement in Movement Assessment Log (OPTIMAL) is an instrument that measures difficulty and self-confidence in performing 22 movements that a patient needs to accomplish in order to do various functional activities.
41110112|NCT01511172|DRUG|liraglutide|Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
41110113|NCT01511172|DRUG|metformin|1000 mg daily, administered orally
41110114|NCT01511172|DRUG|placebo|Metformin placebo administered orally. 1000 mg daily
41110115|NCT01511172|DRUG|placebo|NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
41110116|NCT01511172|DRUG|glimepiride|Individually adjusted dose, administered orally
41110117|NCT01285830|DIETARY_SUPPLEMENT|Lactobacillus reuteri|The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)
41110118|NCT01285830|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
41110119|NCT01212991|DRUG|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
41110120|NCT01212991|DRUG|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
41271110|NCT05564559|OTHER|multifamily group psychoeducation|The intervention involves 8 weeks of multifamily psychoeducation for families. Duration of sessions: 75 minutes on average Context: First session: psychoeducation on substance-abuse disorders; second session; effects of addiction on the family; third session; illness management; fourth session; supporting recovery; fifth session; improving stress coping skills/stress management; sixth session; developing problem-solving skills; seventh session; strengthening the family; eighth session; working with stigma Preferred approach: face-to-face, multi-family Approach: Psychoeducation
41271111|NCT04109599|BEHAVIORAL|PlaySmart|Participants played the developed PlaySmart game over the course of a week.
41110121|NCT05470894|BIOLOGICAL|Approved COVID-19 vaccine|Vaccination for COVI9-19
41110122|NCT04391283|DRUG|Osimertinib|The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity according to the prescription information and clinical practice. It can be taken with or without food at the same time each day.
41110123|NCT05417542|OTHER|EEG|EEG recording during prematurity or around term
41110124|NCT05417542|OTHER|NIRS|NIRS recording during prematurity or around term
41110125|NCT02091336|DRUG|Metformin|patients treatment
41110126|NCT02091336|DRUG|Glyburide|patients treatment
41110127|NCT05303155|DIAGNOSTIC_TEST|16S rRNA sequencing|Fecal microbiome analysis using 16S rRNA sequencing
41110128|NCT04714450|BEHAVIORAL|Experimental: MMST+|The format of the MMST will remain the same; however, the white noise, images and math task will be modified to mitigate habituation effects.
41110129|NCT05399394|DRUG|Chemotherapy|The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.
41271112|NCT04109599|BEHAVIORAL|PlaySmart Storyline|Participants played through one PlaySmart Storyline during one 1-1.5 hour session.
41110130|NCT05399394|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by the Clinical Target Volume (CTV) with a safety margin to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied through cone-beam computed tomography systems (CBCT) for all patients to evaluate the precision of the set-up.
41110131|NCT05022251|PROCEDURE|Lumbar discectomy|surgically removing a hernia
41110132|NCT04042519|DIAGNOSTIC_TEST|Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.|This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.
41110133|NCT04042519|DIAGNOSTIC_TEST|Agilent 1290 Infinity LC system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection.|We used the Agilent 1290 Infinity LC system mass spectrometer to analyze and detect metabolite peaks of patients according to retention time and mass/charge ratio after preliminary experiments and derivatization.
41110134|NCT04042519|DIAGNOSTIC_TEST|Routine blood test|Blood routine test results include CRP, PCT, white blood cell count, red blood cell count, neutrophil percentage, eosinophil, basophil, et al.
41110135|NCT04132024|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
41110136|NCT05146817|OTHER|Oral care|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine . Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
41110137|NCT04365400|DRUG|DS102|DS102 Epeleuton capsules
41110138|NCT04365400|DRUG|Placebo|Placebo capsules
41110139|NCT05380791|OTHER|Follow-up visits|Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations
41110140|NCT06425419|DRUG|Topotecan|20 micrograms of intravitreal topotecan given in a 1 cc tuberculin syringe at a concentration of 20 mcg/20mcL.
41110141|NCT00971022|BEHAVIORAL|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
41110142|NCT00971022|BEHAVIORAL|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
41110143|NCT04190342|OTHER|control group|A booklet on the self-management of cancer symptoms. After the pilot RCT is completed, if the participants allocated to the control group are interested in practising tai chi, the intervention will be provided
41110144|NCT04190342|BEHAVIORAL|tai chi group|Around 60 minutes practising easy tai chi movements/postures twice per week
41110145|NCT02184325|DRUG|Kiddi® Pharmaton Fizz, effervescent tablets|
41110146|NCT02184325|DRUG|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
41110147|NCT02184325|DRUG|Comparator product|active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
41271113|NCT04109599|BEHAVIORAL|Play Smart Mini-Game|Participants played through all levels of the PlaySmart Risk Sense mini-game during one 1-1.5 hour session.
41271114|NCT02494570|DRUG|nab-Sirolimus|Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.
41110148|NCT03483662|BEHAVIORAL|Multicomponent Intervention|The core component of the intervention is protocol-based treatment using the SPRINT BP management algorithm. The following implementation strategies are adaptable components that will be modified to fit specific federally-qualified health center (FQHC) settings: dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
41110149|NCT03483662|BEHAVIORAL|Enhanced Usual Care|The investigators will provide an up-to-date clinical guideline for hypertension management to providers. A webinar education session on the new American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and findings from the SPRINT trial will be conducted. Otherwise, the investigators will not conduct any active intervention and all control clinics will follow their routine clinic practice in the management of hypertensive patients
41110150|NCT01696578|BEHAVIORAL|BF-CBT and group physiotherapy|Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
41110151|NCT01983306|DRUG|SP-333 1 mg|Tablet
41110152|NCT01983306|DRUG|SP-333 3 mg|Tablet
41110153|NCT01983306|DRUG|SP-333 6 mg|Tablet
41110154|NCT01983306|DRUG|Placebo|Tablet
41110155|NCT05603338|PROCEDURE|LSG with omental band|LSG with omental band
41110156|NCT05603338|PROCEDURE|LSG|just to do sleeve gastrectomy
41110157|NCT06345417|OTHER|Patient Blood Management (PBM)|PBM is a strategy to manage the participant's own blood. Its focus is on anemia, bleeding and coagulation management.
41110158|NCT06345417|BIOLOGICAL|Allogeneic transfusion|Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
41110159|NCT03071848|OTHER|No Intervention|This was an observational study.
41110160|NCT05593146|BEHAVIORAL|modified anteversion angle placement(( α-15°)±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis pre- designed anteversion angle is assembled for reconstruction after tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
41445746|NCT02825160|DRUG|Ventavis (Iloprost, BAYQ6256)|The treatment of Ventavis should comply with the local product information
41110161|NCT05593146|BEHAVIORAL|conventional anteversion angle placement ( α±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis with predesigned anteversion angle is assembled for reconstruction following tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
41110162|NCT05026086|OTHER|pressure biofeedback|10 patients will be treated with isometric exercises and pressure biofeedback.
41110163|NCT05026086|OTHER|isometric exercises|10 patients will be treated with isometric exercises
41110164|NCT02698241|DEVICE|Diagnostic & Medication Management|Single Arm Study. Subjects will be managed using integrated diagnostics.
41110165|NCT01733238|DRUG|PNT2258|
41110166|NCT04877834|DRUG|Dexlansoprazole|Dexlansoprazole capsule prepared by SAMI Pharmaceuticals will be administered to this arm.
41110167|NCT04877834|DRUG|Dexlansoprazole|Dexlansoprazole capsule prepared by Takeda Pharmaceutical Company will be administered to this arm.
41110168|NCT02570191|DRUG|Peginterferon alfa-2a|180 uG in 0.5 mL solution administered once weekly for 48 weeks
41110169|NCT02778958|DRUG|paracetamol|"iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
41110170|NCT02778958|DRUG|ibuprofen|"iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
41110171|NCT02491749|PROCEDURE|Ultra Fast-Track Anesthesia|early extubation at the end or within one hour post operatively
41445747|NCT03811158|DEVICE|HHHFNC|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
41110172|NCT04628650|DEVICE|Digital Pain-Management Tool|Self management digital tool for chronic pain
41271115|NCT00365755|DRUG|carboplatin|
41271116|NCT00365755|DRUG|cisplatin|
41271117|NCT00365755|DRUG|cyclophosphamide|
41271118|NCT00365755|DRUG|etoposide|
41271119|NCT00365755|DRUG|melphalan|
41271120|NCT00365755|DRUG|vincristine sulfate|
41271121|NCT00365755|PROCEDURE|autologous bone marrow transplantation|
41271122|NCT00365755|PROCEDURE|conventional surgery|
41110173|NCT05119023|BEHAVIORAL|Observational Learning|All participants will complete a computer-based serial response time task intended to measure observational (implicit) learning ability. In this task, participants look at a dot move from one of 4 positions on a computer screen. Unbeknownst to participants, dot movement followed a 12-movement pattern for most experimental blocks. Eye-tracking data is collected and eye fixations within regions of interest trigger trial advancement. Learning ability is evaluated as a comparison of saccadic response times during sequenced trials relative to pseudorandomized trials.
41110174|NCT05119023|BEHAVIORAL|Rule-based Learning|All participants will complete a computer-based rule-based learning task intended to measure rule-based (explicit) learning ability. In this task, participants look at sequences of geometric shapes on a computer screen. Through visuals and verbal instruction, they are taught 5 rules that govern sequences. After learning rules, participants are asked to judge via button press whether novel sequences adhere to rules or not.
41110175|NCT03522558|BEHAVIORAL|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
41110176|NCT03522558|BEHAVIORAL|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
41110177|NCT01033058|DRUG|atorvastatin|80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI
41110178|NCT01033058|DRUG|atorvastatin|No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
41110179|NCT00468910|DRUG|acetylsalicylic acid|Given orally
41110180|NCT00468910|DRUG|placebo|Given orally
41271123|NCT03036878|OTHER|ReNu|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
41271124|NCT00586365|DRUG|Naproxen|500 mg Naproxen twice a day for two weeks
41110181|NCT00468910|OTHER|laboratory biomarker analysis|Correlative study
41110182|NCT02214693|DRUG|DA-1229|
41110183|NCT02916758|OTHER|Let's Go Community Mobility Program|Four week multi-modal education and experiential program to improve community mobilty
41110184|NCT05679154|BEHAVIORAL|Team-focused Implementation|CACs randomized to the experimental condition (n = 2) will participate in team-focused implementation. They will receive team development interventions (e.g., goal-setting exercise, training in communication skills) integrated with standard CPM-PTS training and technical assistance strategies.
41110185|NCT05679154|BEHAVIORAL|Standard Implementation|CACs randomized to the comparison condition (n = 2) will receive standard training and technical assistance strategies to support CPM-PTS implementation. They will receive CPM-PTS materials (e.g., manual, REDCap surveys, referral protocols), an interactive training, and six months of technical assistance.
41110186|NCT00233519|DRUG|SomatoKine/IPLEX|"Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.~Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection."
41110187|NCT01953757|OTHER|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
41110188|NCT01953757|DIETARY_SUPPLEMENT|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
41445748|NCT03811158|DEVICE|UHFOM|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
41445749|NCT01261039|RADIATION|UV radiation|Subjects in both groups will be exposed to light in a solar bed for approximately 10 minutes (depending on Fitzpatrick skin type test) on the first day, but only one of the solar beds wields ultraviolet rays. The other has a filter, which filters out the ultraviolet rays.
41445750|NCT00198835|BEHAVIORAL|Maternal nutrition and infant feeding advice|
41445751|NCT05189106|DRUG|Baricitinib|Each participant will be treated with open-label baricitinib for 24 weeks. Participants will receive 2 mg baricitinib by mouth daily for the first 8 weeks and 4 mg baricitinib by mouth daily for the remaining 16 weeks.
40925630|NCT03343418|DRUG|Placebo|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
40925631|NCT01704612|DRUG|ropivacaine|patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
41445752|NCT03867838|DEVICE|compliant support|Participants will be given compliant arm support and their reachable workspace measured
41445753|NCT04511845|DRUG|SPYK04|SPYK04 capsule
41445754|NCT02343926|DRUG|GEMIGLIPTIN LS15-0444|"Pharmaceutical form:tablet~Route of administration: oral"
41445755|NCT02343926|DRUG|vildagliptin|"Pharmaceutical form:tablet~Route of administration: oral"
41110189|NCT00860353|DRUG|AZD2551|Single dose of oral solution.
41110190|NCT00860353|DRUG|Placebo|Single dose of oral solution
41110191|NCT02774538|OTHER|Agreement between oral and cervical HPV infection|"A total of 165 women will have a Pap test and an oral brushing performed on the day of inclusion. Risk factors for oral HPV infection will be defined using a self-administered survey summarizing the demographics and sexual behaviors.~A second oral brushing up to 18 months will be performed during a standard follow-up visit."
41110192|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours
41110193|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours
41110194|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours every 8 hours
41445756|NCT02343926|DRUG|metformin|"Pharmaceutical form:tablet~Route of administration: oral"
40752378|NCT03934879|BEHAVIORAL|FitClub|Participants will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
40752379|NCT03934879|OTHER|Regular School Activities|Students will participate in regular school activities.
40925632|NCT00571402|BEHAVIORAL|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
40925633|NCT00571402|BEHAVIORAL|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
40925634|NCT04652414|DRUG|Prednisone|Prednisone 50mg will be administered enterally for 7 days.
40925635|NCT04652414|DRUG|Placebo|This is a matching placebo to prednisone.
40925636|NCT00645710|DRUG|gemcitabine hydrochloride|Given IV
40925637|NCT00645710|DRUG|floxuridine|Given via hepatic arterial infusion
40925638|NCT00645710|GENETIC|proteomic profiling|Correlative studies
40925639|NCT00645710|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
40925640|NCT00645710|OTHER|liquid chromatography|Correlative studies
40925641|NCT00645710|RADIATION|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Given IV
40925642|NCT00645710|OTHER|laboratory biomarker analysis|Correlative studies
40925643|NCT00645710|OTHER|mass spectrometry|Correlative studies
40925644|NCT00645710|OTHER|pharmacological study|Correlative studies
40925645|NCT05094544|RADIATION|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
40925646|NCT03051620|DRUG|Discontinue alendronate|136 patients with osteoporosis stopping treatment with alendronate.
40925647|NCT06165458|OTHER|6% hydrogen peroxide gel + violet LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by violet LED
40925648|NCT06165458|OTHER|6% hydrogen peroxide gel + blue LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by blue LED
40925649|NCT06165458|OTHER|35% hydrogen peroxide gel + violet LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by violet LED
41110195|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours every 8 hours
40925650|NCT06165458|OTHER|35% hydrogen peroxide gel + blue LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by blue LED
40925651|NCT04280770|PROCEDURE|23 PARS PLANA VITRECTOMY|We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
40925652|NCT01659801|DEVICE|BunnyLens TR|BunnyLens TR IOL is an Aspheric Toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism.
40925653|NCT00427180|DEVICE|Retinal Implant System (IRIS)|AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina
41110196|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.
41110197|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
41271125|NCT02303054|PROCEDURE|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
41445757|NCT03927300|DEVICE|Telemonitoring Software|Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.
41445758|NCT01937234|DRUG|Metoclopramide|"Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses."
40925654|NCT03689907|OTHER|Chimerism Evaluation|Blood collection for chimerism evaluation will be performed on days +14/15-post transplant and +30-post transplant for each study participant.
40925655|NCT06363305|DIETARY_SUPPLEMENT|Dietary capsules|Daily doses of dietary capsaicin or placebo in capsule form
40925656|NCT05981976|BIOLOGICAL|Abatacept|Specified dose on specified days
40925657|NCT03271983|DRUG|Metronidazole gel 1|RLD gel
40925658|NCT03271983|DRUG|Metronidazole gel 2|generic gel
40925659|NCT03271983|DRUG|Metronidazole cream|generic cream
40925660|NCT00918060|DRUG|Camella sinensis gel|clinical effect of locally-delivered gel between Camella sinensis and placebo
41110198|NCT05905913|DRUG|Meropenem|Meropenem will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
41110199|NCT05905913|DRUG|Meropenem-placebo|Meropenem-placebo will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
41110200|NCT05921526|DIAGNOSTIC_TEST|Point-of-care lung ultrasound|Participants assigned to the intervention group will receive POCLUS which will be performed by one of the trained pediatricians. The procedure involves 12 views: two anterior views, two lateral views and two posterior views on both chest walls
41110201|NCT05921526|DIAGNOSTIC_TEST|Chest X-ray (digital images)|Participants assigned to the chest X--ray group will be sent to the Radiology department to get a CXR (digital) which will be performed by radio technicians like in routine care. Anteroposterior and/or posteroanterior chest images will be obtained. Reading/ reporting of the digital images will be done by both the radiologist and the enrolling pediatrician. The image/ clinical expert review panels (IERP/ CERP) will also have access to the images for review.
41110202|NCT04989725|OTHER|Standard arm|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
41110203|NCT04989725|RADIATION|Experimental arm|SABR to all oligoprogressive lesions + continuation of current systemic therapy
41110204|NCT01948648|DRUG|Colesevelam|Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.
41110205|NCT01948648|DIETARY_SUPPLEMENT|Fish Oil|In softgel form, contains 660mg EPA and 330mg DHA. Participant consume 1 softgel per day during treatment session.
41110206|NCT01948648|DRUG|Combination of fish oil and colesevelam|combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.
41110207|NCT01036113|DRUG|EZN-2208|EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
41110208|NCT00293293|OTHER|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
41110209|NCT00293293|OTHER|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
41110210|NCT00293293|OTHER|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
41110211|NCT00293293|DRUG|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
41110212|NCT00328393|DRUG|Pioglitazone|45 mg 8 weeks
41110213|NCT00328393|DRUG|Placebo|Placebo
41110214|NCT00903266|BEHAVIORAL|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
41110215|NCT00903266|BEHAVIORAL|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
41110216|NCT04456543|PROCEDURE|pressure monitoring|garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg.
41110217|NCT00294905|BEHAVIORAL|Implementation of a combined smoking cessation strategy|
41110218|NCT05661162|DEVICE|CR 500™ SINGLE-DOSE GEL|CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility
41110219|NCT01018212|OTHER|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.~The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application."
41110220|NCT01097343|DRUG|clopidogrel 75 mg|75 mg once daily
40752380|NCT03008330|BIOLOGICAL|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
40752381|NCT01117350|DRUG|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
41110221|NCT01097343|DRUG|Clopidogrel 150 mg|clopidogrel 150 mg
41445759|NCT01937234|DRUG|Placebo|"Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.~Maximum of 3 doses."
40752382|NCT01117350|DRUG|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
41110222|NCT01941563|DRUG|Condoliase|1.25U, intradiscal injection, one time
41110223|NCT01941563|DRUG|placebo|
41110224|NCT01771588|DIETARY_SUPPLEMENT|Human milk fortifier|
41110225|NCT02212522|OTHER|Collect of environmental data on T1D patients before diagnosis|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
41110226|NCT02212522|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
41110227|NCT02212522|OTHER|Collect of clinical data on the disease and its evolution|Collect of clinical data on the disease and its evolution every 6 months after enrollment
41110228|NCT02212522|OTHER|Collect of environmental data on French controls (age-matched for T1D patients)|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
41110229|NCT02212522|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
41110230|NCT02040935|DRUG|Trastuzumab|600 mg SC Q3W by SID
41110231|NCT02950896|OTHER|observational fetal heart rate monitoring|Patients will have fetal heart rate monitoring
41110232|NCT02953080|OTHER|Call for life mHealth adherence support|Daily/ weekly pill reminder support Health Info-tips Appointment visit reminders Self-reported symptom support
41110233|NCT00653341|DRUG|insulin glargine|
41110234|NCT00653341|DRUG|NPH human insulin|
41445760|NCT05127057|OTHER|PRIME Parkinson Care|A novel model of care
41110235|NCT04128839|DIETARY_SUPPLEMENT|Aronia berry juice|A juice blend of three different cultivars was used: Viking, MacKenzie and Autumn Magic. Raw juice was heat pasteurized before provided to participants. Participants consumed 100 mL of juice per day.
41110236|NCT04128839|OTHER|Sham comparator|The placebo was flavor, color, and carbohydrate-matched to aronia juice. The placebo consisted of 28.8 g black cherry Koolaid mix (no sugar added), 128.5 g sorbitol, 74.5 g glucose, 77.9 g fructose, 4 oz lemon juice, 16 drops of blue food coloring, and enough water to create 1 L of solution. Participants consumed 100 mL of juice per day.
41110237|NCT03998280|DEVICE|Assessment|Neck proprioception and postural stability
41110238|NCT01609517|DRUG|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
41110239|NCT04228536|PROCEDURE|Totally ExtraPeritoneal (TEP) repair|
41110240|NCT04228536|PROCEDURE|TransAbdominal PrePeritoneal (TAPP) repair|
41110241|NCT04228536|PROCEDURE|Open anterior mesh repair (OAM)|
41110242|NCT04228536|PROCEDURE|Combined Anterior and Posterior technique (CAP)|
41110243|NCT04228536|PROCEDURE|Open PrePeritoneal Mesh technique (OPPM)|
41110244|NCT04228536|PROCEDURE|Sutured Repair|
41110245|NCT02590952|DRUG|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
41110246|NCT02474147|OTHER|Processed meat hamburger|MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)
41110247|NCT02474147|OTHER|Vegan sandwich|Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)
41110248|NCT00947986|OTHER|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
41445761|NCT05127057|OTHER|Usual Care|Usual NHS Care
41445762|NCT01326663|DRUG|Medication Trial|
41445763|NCT02042859|DEVICE|Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer|
41445764|NCT04906070|DEVICE|HB-001|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
41445765|NCT06074328|DEVICE|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset as a form of neurorehabilitation in patients who suffer a traumatic brain injury.
41445766|NCT00835484|DRUG|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose fasting
41445767|NCT00835484|DRUG|OMNICEF® 300 mg|1 x 300 mg, single-dose fasting
41445768|NCT04802655|OTHER|Video-game based exercise - Exergame|Selected Kinect compatible video games from Microsoft Xbox one will be applied in this group. Four video games will be selected for a session (each game will last 10 mins). Video games are active video games which participants have to use their body parts in order to control games.
41445769|NCT04802655|OTHER|Activity Based Exercise Group (AG)|Task-oriented exercises to be performed in standing and sitting positions, including upper extremity and trunk, will be applied to the activity-based exercise group in addition to routine NDT training. Examples for activities; stepping and putting stickers on the wall, treading the play dough placed on a step board within one leg stance; reach-grasp activities progressively from sitting to standing, throwing and catching balls on a balance board.
41445770|NCT03098901|DIAGNOSTIC_TEST|Tc99m-labeled pyrophosphate scan|Intravenous injection of Tc99m-labeled pyrophosphate with consecutive whole body scan using gamma ray scanner for assessment of radioactive uptake in the heart. The results of the scan will be evaluated by a specialist in the field. The uptake will be graded using Perugini scale (0- no uptake, 1- uptake in heart less intense than in bones, 2-uptake in heart as intense as in bones, 3-uptake in heart more intense than in bones).
41445771|NCT03849547|OTHER|App Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Guidance through smartphone application as home program."
41445772|NCT03849547|OTHER|Home Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Follow the usual home program provided in clinics."
41445773|NCT06559722|DRUG|Insulin Degludec/liraglutide Injection|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
41445774|NCT06559722|DRUG|XULTOPHY®|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
41445775|NCT00840281|DRUG|Cefzil® 500 mg tablets|1 x 500 mg, single-dose fasting
41445776|NCT00840281|DRUG|Cefprozil 500 mg Tablets|1 x 500 mg, single-dose fasting
41445777|NCT03893123|OTHER|Observational study, prostate cancer is outcome of interest|Observational study
41445778|NCT03505151|DRUG|BI 409306 (C-13/N-15)|i.v solution
41445779|NCT03505151|DRUG|BI 409306|Film-coated tablet
41445780|NCT01717352|BEHAVIORAL|Weight Loss Education|
41445781|NCT01717352|BEHAVIORAL|Sleep and Eating Routine|
41445782|NCT05931458|PROCEDURE|Appendectomy|Laparoscopic appendectomy is a relatively simple surgical procedure that can be performedby most surgeons, either on an outpatient basis or with a single-night hospital stay. The laparoscopic approach is now the recommended option due to faster recovery times and fewer wound complications.
41445783|NCT05931458|DRUG|Infliximab|Administration of Infliximab (Anti-TNF-a biologic drug)
41445784|NCT04009499|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
41445785|NCT01076491|DRUG|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
41445786|NCT02120872|DRUG|Platelet rich fibrin and simvastatin|Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.
41445787|NCT02120872|BIOLOGICAL|Platelet rich fibrin|Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.
41445788|NCT02120872|PROCEDURE|Open Flap Debridement alone|Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.
41445789|NCT05190068|DRUG|HMPL-760|HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
41445790|NCT06627868|DIETARY_SUPPLEMENT|NAD+ precursor|NAD+ precursor supplementation (Nicotinamide, Nicotinamide Riboside, or Nicotinamide Mononucleotide)
41445791|NCT06627868|OTHER|Placebo|Oral placebo daily intake for 6 months
41445792|NCT00387933|DRUG|hydroxyurea|
41445793|NCT00387933|DRUG|imatinib mesylate|
41445794|NCT00387933|DRUG|vatalanib|
41445795|NCT00772603|DRUG|Placebo|Non-active tablet identical to study drug tablets
41445796|NCT00772603|DRUG|2400mg SPN-804|tablets containing 600mg OXC XR, identical to non-active tablets
41445797|NCT00772603|DRUG|1200mg SPN-804|two active tablets and two non-active tablets, all identical
41445798|NCT03429582|DEVICE|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
41445799|NCT03429582|DEVICE|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
41445800|NCT03429582|DEVICE|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
41445801|NCT05843864|DEVICE|Photobiomodulation Therapy with Standard Physical Therapy|Photobiomodulation Therapy (PBMT) will be provided by a trained individual in addition to standard physical therapy. Treatment will be delivered for approximately 10-16 minutes. Participants will then be instructed to rest for 5 minutes after the treatment.
41445802|NCT05843864|OTHER|Sham Photobiomodulation Therapy with Standard Physical Therapy|Sham Photobiomodulation Therapy (PBMT) will be provided by a trained to the some location and with the same contact time and frequency as the active intervention (PBMT) in addition to standard physical therapy. Participants will then be instructed to rest for 5 minutes after the treatment.
41445803|NCT05413096|COMBINATION_PRODUCT|Combination of diclofenac potassium and propolis|Patients will be divided into two groups: the first one will be treated with a combination of diclofenac 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel and the second one is placebo group. Participants will be allocated randomly. The patients will be asked to apply gel 2 times per day. The patients will be instructed, not to eat or drink for 1 h after application of the gel
41445804|NCT05413096|OTHER|placebo|placebo
41110249|NCT05350267|BEHAVIORAL|HALO|"Health and Lifestyle Behaviors in Offspring, or HALO is designed for mothers who recently had bariatric surgery who have a school-aged child. HALO focuses on providing each mother with education and parenting strategies to improve her child's healthy lifestyle behaviors, such as her child's eating and physical activity, while she is engaged in her own lifestyle behavior change after bariatric surgery."
41110250|NCT05350267|BEHAVIORAL|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
41110251|NCT00148291|DRUG|Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.|
41110252|NCT00726999|DRUG|Gabapentin|oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
41110253|NCT00726999|DRUG|Placebo|
41110254|NCT00726999|DRUG|Morphine|Administered as needed
41110255|NCT04286529|DRUG|Calcitriol capsules|0.25micrograms, taken daily for eight weeks, orally
41110256|NCT04286529|DRUG|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
41110257|NCT01970618|DRUG|RV1162 single dose|Safety and tolerability of single escalating doses
41445805|NCT05745038|BEHAVIORAL|SONATA|The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.
41445806|NCT06449066|OTHER|Non applicable|Non applicable (data collection)
41445807|NCT06550661|BEHAVIORAL|Ba duan jin|a kind of exercise
41445808|NCT01325909|BEHAVIORAL|Exercise programme|
41445809|NCT02348463|DRUG|Clindamycin-2-phosphate|how many women will deliver before the 37th week of gestation
41445810|NCT01782053|BEHAVIORAL|Picture warning|Warning contains picture proposed for each text statement by FDA
41445811|NCT01782053|BEHAVIORAL|Control|
41445812|NCT01134549|DRUG|Etelcalcetide|Administered as a single intravenous (IV) injection
41445813|NCT01134549|DRUG|Placebo|Administered as a single intravenous (IV) injection
41445814|NCT03423654|OTHER|Spatial Training|Spatial Training using a 5x5 grid
41445815|NCT03423654|OTHER|Letter number matching|Letter number matching
41445816|NCT04518072|OTHER|Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)|assessed biomarker in clinical samples
41445817|NCT03633721|DRUG|Cannabis|7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
41445818|NCT03633721|OTHER|Placebo|0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
41445819|NCT06559748|DEVICE|transcranial magnetic thetaburst stimulation （TBS）|TBS group: iTBS was administered to stimulate RMFC, 80-100% RMT, 10 times a course, twice a day, for a total of 5 days; Conventional drugs group: pantoprazole 40 mg orally once a day; itopride 50 mg orally three times a day; treatment for 4 weeks. （Standard medication regimen）
41445820|NCT05629728|BEHAVIORAL|Tai Chi exercise|Sun-style Tai Chi (21 forms)
41445821|NCT04330534|DRUG|BCX9930|BCX9930 capsules for oral administration
41445822|NCT04330534|DRUG|Placebo|placebo to match BCX9930 capsules for oral administration
41445823|NCT06627686|DIAGNOSTIC_TEST|Air way occlusion pressure|Predictive Value of Airway Occlusion Pressure, Maximal Inspiratory Pressure and Their Ratio for Successful Extubation in Patients with Traumatic Brain Injury
41445824|NCT06472167|BEHAVIORAL|Breathing exercises|Breathing exercises as diaphragmatic breathing exercises and pursued lip breathing and incentive spirometry
41445825|NCT00672984|DRUG|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
41445826|NCT00672984|DRUG|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
41445827|NCT00672984|DRUG|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
41445828|NCT02317263|DRUG|testosterone|
41445829|NCT02317263|DRUG|placebo gel|
41445830|NCT03193021|DEVICE|Cardiva Mid-Bore VVCS|The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.
41110258|NCT01970618|DRUG|RV1162 matching placebo single dose|Safety and tolerability of single escalating doses
41110259|NCT01970618|DRUG|RV1162: 7 day repeat dose|Safety and tolerability of a repeat dose
41110260|NCT01970618|DRUG|RV1162 matching placebo: 7 day repeat dose|Safety and tolerability of a repeat dose
41110261|NCT01970618|DRUG|RV1162: 14 day repeat dose|Safety and tolerability of repeat escalating doses
41110262|NCT01970618|DRUG|RV1162 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
41110263|NCT02021799|DIETARY_SUPPLEMENT|Moringa and Lactobacillus rhamnosus GR-1|
41110264|NCT05752006|OTHER|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
40752383|NCT01117350|DRUG|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
41110265|NCT00179335|PROCEDURE|Blood drawing to determine drug levels|
40752384|NCT03286803|BIOLOGICAL|Inactivated Poliovirus vaccine|we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine
41110266|NCT03279718|PROCEDURE|Periodontal Treatment|Scaling and root planing
41445831|NCT03193021|OTHER|Manual compression|Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.
41110267|NCT05608369|DRUG|Cisplatin|Cisplatin100 mg/m2 every 3 weeks or 40 mg/m2 weekly
41110268|NCT05608369|RADIATION|Radiation therapy|Radiation therapy (70 Gy) for total of 7 weeks
40752385|NCT01665105|DEVICE|acupuncture|electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
41110269|NCT05608369|DRUG|Vorinostat|Pre-treatment; 300 mg every other day and ends with the dose closest to the last fraction of radiation (total of 8 weeks)
41110270|NCT00886145|DEVICE|Vibration: Right Leg and No Vibration: Left Leg.|"Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.~No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month."
41110271|NCT06225388|OTHER|Compression socks|A pair of socks corresponding to the intervention allocated will be given to the participant, by an investigator who will not participate in the evaluation, in a dark plastic bag to avoid any visual influence. We will adopt strategies to prevent information about the socks from influencing the participants' behaviour: (1) the compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
41110272|NCT06225388|OTHER|Placebo socks|The compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
41110273|NCT05761834|OTHER|Sample blood and 2D-echocardiography with Doppler|Investigate whether patients with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells.
41110274|NCT00956306|DRUG|Udenafil|100mg Single Oral Dose of Udenafil
41110275|NCT01184235|DRUG|Pharmacological Intervention|This study will include those anticipating or receiving any pharmacological intervention
41110276|NCT06555354|DIAGNOSTIC_TEST|miRNA targeted analysis on breast cancer tissues|Total RNA is extracted from tissue sample and selected miRNA quantified by PCR based relative quantification method (QPCR) with a standard curve.
41110277|NCT06555354|DIAGNOSTIC_TEST|miRNA targeted analysis on plasma samples|miRNAs extracted from plasma samples are analysed by QPCR and/or ddPCR .
41110278|NCT06555354|DIAGNOSTIC_TEST|miRNA profiling of breast cancer tissues|Selected samples from the retrospective cohort are profiled for miRNA expression by using GeneChip® miRNA 4.0 Array.
41110279|NCT00781196|DRUG|folic acid|capsule 0.5 mg once a day
41110280|NCT00781196|DRUG|placebo|capsule, once a day
41110281|NCT03085316|DEVICE|Investigational device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
41110282|NCT04755530|DIETARY_SUPPLEMENT|Regular whole milk|400 g/day of regular whole milk
41110283|NCT04755530|DIETARY_SUPPLEMENT|Yogurt with live bacteria|400 g/day of yogurt with live bacteria
41110284|NCT04755530|DIETARY_SUPPLEMENT|Yogurt with inactivated bacteria|400 g/day of yogurt with inactivated bacteria
41110285|NCT04755530|DIETARY_SUPPLEMENT|Acidified whole milk|400 g/day of yogurt with acidified whole milk
41110286|NCT01513135|BIOLOGICAL|Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
41110287|NCT01513135|BIOLOGICAL|Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
41110288|NCT04541706|DRUG|Lorlatinib|Lorlatinib will be supplied for oral administration as 25 mg tablets. The recommended dosage of lorlatinib is 100 mg orally once daily.
40752386|NCT04163770|DEVICE|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
40752387|NCT04163770|DEVICE|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
41110289|NCT00537563|DRUG|Telithromycin|
41110290|NCT00490685|DRUG|Sorafenib (BAY-43-9006)|
41110291|NCT00003900|DRUG|docetaxel|
41110292|NCT00003900|DRUG|irinotecan hydrochloride|
41110293|NCT02897622|OTHER|Case management|Case management by Eira unit
41110294|NCT05250336|OTHER|Observational Study|Assessment of Prognostic and Predictive value of Tumor-Infiltrating Lymphocytes and Programmed cell Death - Ligand 1 in Breast cancer
41110295|NCT03884244|OTHER|chewing gum|The group who take chewing gum after operation
41110296|NCT01194154|DRUG|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
41110297|NCT01194154|DRUG|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
41110298|NCT03967717|OTHER|Characterization of parameters of medical history, examination and diagnostics.|Patients receive standard of care diuretics. The study only collects data to characterize parameters of medical history, examination and diagnostics.
41445832|NCT01637376|DRUG|Temoporfin|A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
41445833|NCT06563193|DIAGNOSTIC_TEST|NERVE GROWTH FACTOR|urinary neurotrophins
40752388|NCT03864549|DIETARY_SUPPLEMENT|Femina II|2 capsules per day until delivery
40752389|NCT03864549|OTHER|Placebo|2 capsules per day until delivery
41110299|NCT06037824|OTHER|cryotherapy|"cryotherapy was added to rehabilitation\*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~\* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
41110300|NCT00649935|DRUG|Azithromycin Tablets 600 mg|600mg, single dose fed
40752390|NCT03845868|OTHER|Dietary and environmental exposure (Observational study)|
41110301|NCT00649935|DRUG|Zithromax® Tablets 600 mg|600mg, single dose fed
41110302|NCT01269736|BEHAVIORAL|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
41110303|NCT06240663|BEHAVIORAL|Exercise|Both groups complete the exercise intervention identically, but one is in the fasted state and one is in the fed state.
41110304|NCT03534869|PROCEDURE|Ear acupuncture|French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point.
41110305|NCT03534869|DRUG|Analgesics|Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
41110306|NCT00211913|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single IM dose totalling 200 mcg of conjugate
41110307|NCT00211913|BIOLOGICAL|placebo|single IM dose
40752391|NCT01629862|DEVICE|Continuous positive airway pressure|CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
40752392|NCT01629862|DEVICE|Sham continuous positive airway pressure|CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
41110308|NCT03207568|DEVICE|Thoracic Endovascular Aortic Repair (TEVAR)|thoracic endovascular repair (TEVAR) with a thoracic stent-graft
41110309|NCT03738111|DRUG|TG02 Citrate|TG02 citrate capsules
41110310|NCT02279017|BEHAVIORAL|mHealth Texting for Weight Loss|
41110311|NCT05488366|DRUG|Pembrolizumab|Given IV
41110312|NCT05488366|RADIATION|Radiation therapy|Single target will be selected by the treating radiation oncologist. A lesion causing symptoms or expected to become symptomatic will be favored for target selection.
41110313|NCT03726268|DRUG|Methadone|"Dose is 0.15-0.3 mg/kg IV methadone HCl given intraoperatively and in the immediate post-operative period. Intraoperative methadone doses are 15 mg in short-stay, anticipated next-day discharge patients (10 mg if ≤55kg), and 10 mg in same-day surgery patients."
41110314|NCT03726268|DRUG|Fentanyl|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
41110315|NCT03726268|DRUG|Hydromorphone|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
41110316|NCT03726268|DRUG|Morphine|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
41110317|NCT03726268|DRUG|Sufentanil|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
41110318|NCT03812003|DRUG|Remifentanil|remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
41110319|NCT01943799|BIOLOGICAL|GS-4774|Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
41110320|NCT01943799|DRUG|OAV Regimen|Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
41110321|NCT06444386|DEVICE|MPP + SyncAV|Cardiac resynchronization therapy (CRT) features of MultiPoint Pacing (MPP) and SyncAV (dynamic atrioventricular delay programming) enabled.
41110322|NCT02403219|DRUG|Botulinum toxin type A injection|Injection of botulinum toxin type A
41110323|NCT02403219|OTHER|Saline solution injection|Injection of saline solution
41110324|NCT03987763|DRUG|IDP-122 Lotion|Topical
40752393|NCT05363085|OTHER|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during mechanical ventilation and during specific respiratory manoeuvres. No intervention is planned.
41110325|NCT01563991|PROCEDURE|Normal fluid volume|Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total
41110326|NCT01563991|PROCEDURE|Reduced fluid volume|Subject receives 80 cc/ hr LR during the peri-operative period
41110327|NCT02053363|DRUG|Tranexamic Acid (Cyklokapron)|
41110328|NCT03302819|DIAGNOSTIC_TEST|MARIA scan|The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.
41110329|NCT00362726|DRUG|Rosiglitazone maleate|Tablets, Oral, RGZ 4 mg, once daily, 1 day.
41110330|NCT00362726|DRUG|Atazanavir Sulphate|Capsules, Oral, ATV 400 mg, once daily, 5 days.
41110331|NCT00362726|DRUG|Atazanavir Sulphate + Rosiglitazone maleate|Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.
41110332|NCT00362726|DRUG|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.
40752394|NCT00293982|BEHAVIORAL|Physician knowledge of parental expectations for the visit|
41110333|NCT00362726|DRUG|Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate|Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
41110334|NCT04946045|OTHER|Sensorimotor Interventions (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking)|"Sensorimotor interventions were applied to in preterm infants between 30-33 weeks of age for 10 days. After that, preterms were included in the Six-phase feeding progression protocol."
41110335|NCT04878081|BEHAVIORAL|hot flush|"Hot Flash Diaries to record the change of daily hot flush symptoms for 30 days. The Hot Flash Related Daily Interference Scale to record how much did hot flush effect daily life.~The Kupperman menopausal index to evaluate the severity of menopausal symptoms. The Pittsburgh Sleep Quality Index to evaluate sleep disorder. Wireless temperature monitor to record hot flush and body temperature during sleeping.~Classify patients' traditional Chinese constitution by using Physical classification and judgment self-test table."
40752395|NCT01283425|DEVICE|InsuPatch|Heaters for single use and a permanent control unit.
40752396|NCT04692688|DRUG|APX3330|APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
40752397|NCT04692688|DRUG|Placebo|Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
41110336|NCT01740310|BEHAVIORAL|Maternal Vaccine Education|It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
41110337|NCT04968119|OTHER|Exercise Intervention|Participate in telehealth exercise sessions
41110338|NCT04968119|OTHER|Quality-of-Life Assessment|Ancillary studies
41110339|NCT04968119|OTHER|Questionnaire Administration|Ancillary studies
41110340|NCT02562911|PROCEDURE|Data collection|"* Clinical examination~* Complete pelvic ultrasound abdominal ultrasound~* Bone age: X-ray~* biological examination~* Lung function assessed by the Maximum Volume Expired~* Brasfield radiological score (if available)"
41110341|NCT01393353|OTHER|Cognitive Training|
41110342|NCT01393353|OTHER|computer game|
41110343|NCT05093218|DIETARY_SUPPLEMENT|branch chain amino acid|• Branch chain amino acid at a dose of approxiametely 0.35g/kg will be supplemented in two divided doses group for a period of 12 weeks.For the sake of administration, it will be prescribed as per the following weight band categories: \<5kg 2 gm 5-10kg 4 gm 10-20kg 8 gm 20-40kg 12 gm 40-60kg 24 gm
40752398|NCT06328621|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40752399|NCT06328621|PROCEDURE|Computed Tomography|Undergo low-dose CT
40752400|NCT06328621|OTHER|Electronic Health Record Review|Review of medical records
40752401|NCT06328621|OTHER|Survey Administration|Complete survey
40752402|NCT04885010|DIETARY_SUPPLEMENT|probiotics|participants will be given probiotics twice a day for 15 days
41110344|NCT05093218|OTHER|placebo|Placebo will have the similar colour, taste and consistency. Both groups will be given the same dose.
41110345|NCT00590668|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Measurement of peak diastolic flow velocity
41110346|NCT06112704|DRUG|HS-20093|Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
41110347|NCT06245746|BIOLOGICAL|umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)|UCMSC-Exo will be infused intravenously.
41110348|NCT04803630|OTHER|Quality-of-Life Assessment|Ancillary studies
41110349|NCT04803630|OTHER|Questionnaire Administration|Ancillary studies
41110350|NCT04803630|PROCEDURE|Thermotherapy|Undergo thermal therapy
41110351|NCT03766711|OTHER|Physical Therapy|Repetitive bimanual task training for upper limb motor function recovery.
40752403|NCT04885010|DIETARY_SUPPLEMENT|placebo|participants will be given a placebo twice a day for 15 days
40752404|NCT05359757|OTHER|Effect of Naturalistic Teaching Strategies in Children with autism spectrum disorder|"In this group, the patients will be provided with both the naturalistic therapeutic techniques the PECS Therapy.~A baseline of the kids in this group will be made using the portage guide and PECS~* Incidental teaching trial, natural language paradigm, and time delay concepts will be incorporated in the therapy sessions and communication using picture cards will be made.~* 40 minutes session will be conducted in which 20 minutes session will be for naturalistic teaching techniques and 20 minutes will be for PECS.~* This will be followed for 30 sessions"
40752405|NCT05359757|OTHER|PECS Therapy only|"A baseline will be developed using the portage guide and PECS.~* Communication strategies using the PECS picture cards will be made~* 30 minutes session will be conducted~* This will be followed for 30 sessions"
40752406|NCT01762462|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
40752407|NCT05220995|GENETIC|protocol|ovarian stimulation protocols on euploid rates were compared.
40752408|NCT03142204|DRUG|[18F]F-AraG|Single dose IV injection of \[18F\]F-AraG for each imaging day.
41110352|NCT04775290|BEHAVIORAL|Yoga lessons|2 weekly yoga classes during the 5 weeks of radiotherapy
41110353|NCT03346018|DIAGNOSTIC_TEST|Analysis of aqueous humor and plasma samples|"The collected samples will be analyzed as follow:~1. Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~2. Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~3. Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~4. Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants."
41110354|NCT03825133|PROCEDURE|Bone Marrow Aspirate Concentrate|Bone marrow ( 100 ml) is aspirated from proximal tibia, concentrated in Arthrex Angel Centrifuge, and after concentration 6 ml of BMAC is injected in the knee
41110355|NCT03825133|PROCEDURE|Leukocyte Rich Platelet Rich Plasma|Blood sample is taken ( 100 ml), centrifuged in Arthrex Angel Centrifuge and after double spinning process about 6 ml of PRP is injected in the knee
40752409|NCT04832971|DRUG|ARO-ANG3|ARO-ANG3 Injection
40752410|NCT04832971|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl)
41110356|NCT03825133|DRUG|Hyaluronic Acid|Three injections of Cartinorm (1% Sodium Hyaluronat (20mg/2 ml) by Goodwill Pharma) is injected in the knee weekly
41110357|NCT03349736|OTHER|Pelvic Floor Muscle Training|All the women will receive information and instruction/guidance exercise individually and in groups on PFMT on the first day of their visit. Following this, the women are advised to perform daily PFMT at home which includes 10 sec hold X 10 times X 3 sets. Women will record their home PFMT using an exercise diary. During the follow-up, women will attend the PFMT in a group or individual led by a Physiotherapists (to motivate and to ensure women are performing the PFMT correctly). Exercise diary will be collected in every follow up so that the information is retained even if the women discontinued or deviate from intervention protocols.
41110358|NCT05222087|RADIATION|Radiotherapy|35Gy/5# Central 40Gy/5# Large Tumours \>5cm (non-central) 36Gy/12# or 40Gy/15# Ultracentral lesions 50Gy/5# Peripheral Tumours ≤5cm
41110359|NCT05222087|DRUG|SoC systemic therapy|Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
41110360|NCT00576888|OTHER|no intervention|no intervention - observational only
41110361|NCT02655835|BEHAVIORAL|Internet Mindfulness Meditation|
41110362|NCT02655835|BEHAVIORAL|Access|
41110363|NCT05593159|OTHER|Dentin Conditioning|After washing and drying -but not desiccating- Dentin Conditioner 20% (GC, Japan) will be applied using a cotton pellet for 20 seconds then rinsed thoroughly and gently dried
41110364|NCT05593159|OTHER|RM-GIC|RM-GIC (Fuji II LC) will be applied in \<2mm incremental layers afterword light-cured for 10 sec (1,000 mW/cm2) per increment to fill the cavity.
41110365|NCT05593159|OTHER|1-step adhesive|A universal adhesive system (Tetric® N-Bond Universal) will be applied on both enamel and dentin and gently scraped for 20 sec, then dispersed with oil-free gentle air stream, then light-cured for 10 sec (1,000 mW/cm2).
41110366|NCT05593159|OTHER|Cention N|The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)
41110367|NCT05593159|OTHER|Dentin roughness|Using a round carbide bur size 14/16, (H1SEM.204.014 VPE5 or H1SEM.204.016 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece. (No bevel preparation will be made)
41110368|NCT05593159|OTHER|Gingival retentive groove preparation|Using size-010 round carbide bur (H1SEM.205.010 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece.
40752411|NCT05414942|BEHAVIORAL|Opioid Reduction Program|Subjects will engage in a brief, educational session which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
40752412|NCT00409227|DRUG|Alpha blocker-alfuzosin|P.O. alfuzosin 10 mg once a day
40752413|NCT00409227|DRUG|placebo|placebo once a day for 3 months or stone free
41110369|NCT00346151|DRUG|Belatacept|10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks
41110370|NCT00346151|DRUG|Sirolimus|4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year
41110371|NCT00346151|DRUG|Anti-thymocyte globulin|1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.
41110372|NCT00346151|DRUG|methylprednisolone|500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
41110373|NCT00232635|DRUG|A-60444|
41110374|NCT00136058|PROCEDURE|bone densitometry (DEXA)|
41110375|NCT00136058|DRUG|alendronate or risedronate|
41110376|NCT00046995|DRUG|carboplatin|
40752414|NCT03281720|PROCEDURE|TAD|the same intervention as listed in the arm description
41110377|NCT00046995|DRUG|fluorouracil|
41110378|NCT00046995|DRUG|leucovorin calcium|
41110379|NCT00046995|PROCEDURE|adjuvant therapy|
40752415|NCT02609451|PROCEDURE|Ileostomy closure|Ileostomy closure at a different time point
40752416|NCT00005596|DRUG|cyclophosphamide|
40752417|NCT00005596|DRUG|cytarabine|
40752418|NCT00005596|DRUG|daunorubicin hydrochloride|30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
40752419|NCT00005596|DRUG|dexamethasone|6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
40752420|NCT00005596|DRUG|leucovorin calcium|5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
41110380|NCT06427486|OTHER|Parents Telecoaching Intervention|- Synchronous (Zoom platform) and Asynchronous coaching sessions for parents of children with autism.
41110381|NCT05330143|DRUG|ASC22 1mg/kg|ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.
41110382|NCT05330143|DRUG|ASC22 2.5mg/kg|ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.
41110383|NCT05330143|DRUG|Antiretroviral Therapy|standard antiretroviral therapy including Integrase inhibitors (INSTIs)
41110384|NCT05330143|DRUG|Placebo|0.9% saline vials administered subcutaneously once 4 week.
41110385|NCT00687622|DRUG|GSK1120212|Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
41110386|NCT05667480|BEHAVIORAL|VR-based script training|The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.
40925661|NCT04139746|PROCEDURE|Scleral Buckling|Limbal 360 degrees peritomy of the conjunctiva was performed and the four recti muscles were isolated with 4 silk threads 4-0. A width-2 mm silicone encircling band was placed and sutured with 5-0 mersilene on the 4 quadrants of the sclera. Anterior chamber paracentesis was performed, draining about 0.3 mL of aqueous humour, and a buckle (220, 501, 506, or 516; Mira, Waltham, MA, USA) was sutured over the break. In all cases, the drainage puncture was executed at a distance of 11 mm from the limbus, in the area of greatest amount of subretinal fluid. Soon after the drainage puncture, a balanced salt solution (BSS) injection was performed in order to compensate the escape of the subretinal fluid.
41110387|NCT05667480|BEHAVIORAL|Conventional script training|The flow of training is identical to the VR condition, except that photos depicting the scenarios and pre-recorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.
41110388|NCT05815342|DEVICE|Omnipod 5 Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
40752421|NCT00005596|DRUG|mercaptopurine|50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC \> 500/μL and platelets \> 75,000/uL
41110389|NCT03326648|OTHER|Strength training|Heavy load strength training performed twice a week for 10 weeks.
41110390|NCT03326648|DIETARY_SUPPLEMENT|Protein supplementation|Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
41110391|NCT05790616|PROCEDURE|Arterial blood draw|"For the IN(Fast-Sitting) arm arterial blood will be collected to derive Gold-standard SaO2 reference values."
41110392|NCT05790616|OTHER|Oxygen reduction|Volunteers undergo an ambient oxygen decrease from 21% to 10%
41110393|NCT00903019|BEHAVIORAL|Tele-Problem-Solving Therapy|Six sessions of tele-PST
41110394|NCT00903019|BEHAVIORAL|In-Person PST|Six sessions of in person PST
41110395|NCT00903019|BEHAVIORAL|Attention control|Six weekly telephone calls
41110396|NCT02006940|DEVICE|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
41110397|NCT01277796|DEVICE|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
41110398|NCT05308004|OTHER|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering
41110399|NCT02476890|DRUG|Gefapixant 100 mg|Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
41110400|NCT02476890|DRUG|Placebo|Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
41110401|NCT01705249|DRUG|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
40752422|NCT00005596|DRUG|methotrexate|"IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22."
41110402|NCT03060642|DEVICE|Tethered capsule sponge|Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
41110403|NCT03060642|DEVICE|Electronic nose device|Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
41110404|NCT03773861|OTHER|errors made in one BLS session|BLS instructors have to oversee a standardized BLS training session, where standardized errors are made by trained volunteers.
41110405|NCT02239796|DEVICE|NeuroTrac continence stimulators|"Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators."
41110406|NCT02239796|DEVICE|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
41110407|NCT04433429|DIETARY_SUPPLEMENT|Liposcudil Plus|
41110408|NCT01587755|OTHER|TTOP|Patient is taken care of in an intensified, optimised manner
41110409|NCT01587755|OTHER|non-TTOP|Standard medical care
41110410|NCT03413748|PROCEDURE|Elective Cesarean Section|lower segment cesarean section
41110411|NCT03413748|OTHER|Peritoneal irrigation|Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline
41110412|NCT01025999|OTHER|No intervention|
41110413|NCT01623336|DRUG|BIP 48 (Peginterferon alfa 2b 48kDA)|BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
41110414|NCT01623336|DRUG|Peginterferon alfa 2a 40kDA|Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
41110415|NCT01623336|DRUG|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
41110416|NCT02524288|DRUG|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
41110417|NCT03773120|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
41110418|NCT01378065|DEVICE|Restorelle Direct Fix A&P|Restorelle Direct Fix A\&P is a permanently implantable synthetic mesh for reconstruction of the pelvic floor secondary to the prolapse or protrusion of the pelvic organs into or out of the vaginal canal.
41110419|NCT00001063|DRUG|Stavudine|
41110420|NCT00001063|DRUG|Zidovudine|
41110421|NCT00001063|DRUG|Didanosine|
41110422|NCT02508844|DIETARY_SUPPLEMENT|Vivomixx®|probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
41110423|NCT02508844|DIETARY_SUPPLEMENT|Placebo|Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
41110424|NCT03400969|DEVICE|Glycerol 17%|Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist.
41110425|NCT03400969|DEVICE|Aequasyal (OGT)|Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist.
41110426|NCT03400969|DEVICE|Salient (new product)|Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist.
41110427|NCT00242853|PROCEDURE|Power doppler ultrasonography|
41110428|NCT00242853|PROCEDURE|High frequency ultrasonography|
41110429|NCT00242853|PROCEDURE|Exhaled nitric oxide assessment|
41110430|NCT04266080|OTHER|Fitbit Inspire HR|assessing step counts
41110431|NCT04266080|OTHER|Questionaires|Patient-Reported Outcomes Measurement Information System (PROMIS)
40752423|NCT00005596|DRUG|pegaspargase|2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; \> or = 1 day after the IT MTX
40752424|NCT00005596|DRUG|thioguanine|60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC \> or = 500/ul and platelets \> or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
40752425|NCT00005596|DRUG|vincristine sulfate|1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
40752426|NCT02622022|DRUG|Morphine hydrochloride|
41110432|NCT04181307|BEHAVIORAL|BE-EHR module|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
41110433|NCT00541125|BIOLOGICAL|bevacizumab|
41110434|NCT00541125|BIOLOGICAL|filgrastim|
41110435|NCT00541125|DRUG|fluorouracil|
41110436|NCT00541125|DRUG|irinotecan hydrochloride|
41110437|NCT00541125|DRUG|leucovorin calcium|
41110438|NCT01234844|BEHAVIORAL|care of guinea pigs|twice weekly sessions of care with guinea pigs
41110439|NCT01234844|BEHAVIORAL|guinea pigs|"twice weekly pet therapy and twice weekly usual  occupational therapy"
41110440|NCT04866069|BIOLOGICAL|SARS-CoV-2 vaccine|Adjuvanted inactivated vaccine
41110441|NCT04866069|BIOLOGICAL|Placebo|0.9% NaCl
41110442|NCT00398606|DRUG|MK0217, alendronate sodium / Duration of Treatment : 2 Years|
41110443|NCT00398606|DRUG|Comparator : calcium carbonate /Duration of Treatment : 2 Years|
41110444|NCT06241235|DRUG|ZG005 Powder for Injection|ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
41110445|NCT06241235|DRUG|Paclitaxel|IV infusion
41110446|NCT06241235|BIOLOGICAL|Bevacizumab|IV infusion
41110447|NCT06241235|DRUG|Cisplatin|IV infusion
41110448|NCT06241235|DRUG|Carboplatin|IV infusion
41110449|NCT04233931|BEHAVIORAL|PrEP medication adherence mobile app|Participants use a PrEP medication adherence mobile app for six weeks.
41110450|NCT06038032|BEHAVIORAL|Digital wellness platform|A digital wellness platform based on preventive self-care that contains tools to monitor nutrition, physical activity, and mental wellbeing will be accessed daily for 24 weeks.
41110451|NCT06038032|BEHAVIORAL|Online healthcare professional support|Individual and group sessions with a registered dietitian, an exercise professional, and a mental health therapist for 16 weeks.
41110452|NCT00050375|DRUG|oregovomab|
41110453|NCT04873336|DEVICE|Intellivent ASV|A closed loop mechanical ventilation mode that adjusts oxygenization and ventilation automatically
41110454|NCT00479648|BIOLOGICAL|CSL412|
41110455|NCT00479648|BIOLOGICAL|Inactivated trivalent influenza vaccine|
41110456|NCT05022147|DEVICE|High-Frequency-Only Stimulation|Control condition, constant high-frequency DBS stimulation (130Hz)
41110457|NCT05022147|DEVICE|Low-Frequency-Only Stimulation|Experimental condition, constant low-frequency DBS stimulation (60 Hz)
41110458|NCT05022147|DEVICE|Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 10 seconds for low, respectively.
41110459|NCT05022147|DEVICE|Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 50 seconds for low, respectively.
41110460|NCT05022147|DEVICE|Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 50 seconds for low, respectively.
41110461|NCT05022147|DEVICE|Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 10 seconds for low, respectively.
41110462|NCT05022147|DRUG|OFF Dopaminergic Medication|All six device interventions will be performed in medication OFF state
41110463|NCT05022147|DRUG|ON Dopaminergic Medication|All six device interventions will be performed in medication ON state
41110464|NCT04988841|DRUG|MaaT013|study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
41110465|NCT04988841|DRUG|Ipilimumab|Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)
41110466|NCT04988841|DRUG|Nivolumab|AntiPD1 ( immunothérapy)
41110467|NCT04988841|DRUG|MoviPrep|Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
41110468|NCT04988841|DRUG|Normacol|hypertonic enema solution
41110469|NCT04988841|DRUG|Placebo of Maat013|expérimental drug placebo of MaaT013
41110470|NCT02195713|DEVICE|Accuryn|Accuryn is a novel electronic urine output monitor
41110471|NCT02888080|DRUG|ACZ885|ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
41110472|NCT02888080|DRUG|Placebo|Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
41110473|NCT00000699|DRUG|Inosine pranobex|
41110474|NCT00000699|DRUG|Ribavirin|
41110475|NCT02008019|DRUG|Everolimus 2.5 mg/day|Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
41110476|NCT02008019|DRUG|Everolimus 10 mg/day|Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
41110477|NCT01365208|DRUG|Chemotherapy|platinum-based chemotherapy
41110478|NCT01039142|DRUG|Acitretin|capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
41110479|NCT05239299|OTHER|No intervention, observational study|Focus Group
41110480|NCT04141943|OTHER|Virtual reality|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality.
41110481|NCT05061641|DRUG|Progesterone|The delivery outcomes of the three groups were compared, including the rate of premature delivery (\<37 weeks of gestation), the rate of early premature delivery (\<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (\<37 weeks), neonatal perinatal mortality and morbidity.
41110482|NCT06212167|BEHAVIORAL|Nursing Interventions for Stroke Patient Care|In the first phase of the research, the relatives of the patients who are in the hospital every day for a week during the routine and discharge process will be included in a training program. These trainings will be explained didactically to the caregiver at the bedside by the research supervisor and the intensive care nurse, the practices will be demonstrated with demonstrations, and the caregiver will be asked to apply them themselves. Then, the researchers will call the caregivers and make an appointment for an online meeting twice a week (7 weeks - 14 times). During these meetings, the training the caregivers need will be explained again and any questions they have will be answered. The researcher will also conduct motivational interviews with the caregivers.
41110483|NCT00794118|OTHER|As per clinical practice|As per clinical practice
41110484|NCT06513806|DRUG|Granisetron 1 Mg/mL Intravenous Solution|will receive granisetron 3 mg iv bolus
41110485|NCT06513806|DRUG|Pethidin|will receive pethidine 25 mg iv bolus
40752427|NCT02622022|OTHER|Placebo|
41110486|NCT04415086|BIOLOGICAL|convalescent plasma|The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
41110487|NCT03890016|DIAGNOSTIC_TEST|20'Whole Blood ClottingTest (WBCT)|"1ml of blood drawn from snake bite victims in clean glass test tubes of 1 cm diameter Kept undisturbed for a period of 20 minutes (measured by a stop watch). At the end of 20 minutes the tube is tilted to see if the blood has clotted or not.~If a well formed clot is not formed, the test is recorded as 'abnormal'.~If the clot seems well formed, it is further observed for a period of 30 minutes to look for dissolution of the formed clot and would be termed clot lysis. Clot lysis indicates an unstable clot."
41110488|NCT03890016|DIAGNOSTIC_TEST|Modified Lee and White (MLW) Method Clotting Time|"The blood collected in three additional test tubes would be utilised for MLW.~The three test tubes would be kept on a rack at ambient temperature.~The blood sample would be drawn in a 5cc syringe and 1 ml would be added in the three test tubes consecutively.~The test tube would be left undisturbed for 5 minutes, after that the first tube would be tilted approximately to check for clot formation every 30 seconds while the other tubes are left undisturbed.~After the blood in the first tube has clotted, the time would be noted and the second tube would be tilted every 30 seconds and examined.~Following its clotting, the third tube would be examined. The time at which the third tube is recorded as the CT value.~Once clotted, then the sample in the all three test tube would be assessed at 20 minute and 30 min to look for breakup or lysis of the clot."
41110489|NCT05612048|OTHER|Survey|This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.
41110490|NCT05612048|OTHER|Intra-oral camera|Intraoral pictures of molars and incisors in 13 key regions
41110491|NCT05612048|OTHER|Optional Salvia sample|Cohort 1 only. Participant is responsible for collecting and bringing the salvia sample to clinic.
41110492|NCT03601780|DRUG|local wound infiltration plus usual care|local wound infiltration plus usual care
41110493|NCT03601780|DRUG|usual care only|usual care only
41110494|NCT02539212|DEVICE|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
41110495|NCT02539212|DEVICE|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
41110496|NCT03491696|DRUG|Metyrapone|Association of Selective Serotonin Reuptake Inhibitor or Serotonin and Norepinephrine Reuptake Inhibitor and METYRAPONE. Duration of the association : 28 days.
41110497|NCT01698255|BEHAVIORAL|ENGAGE|
41110498|NCT01698255|BEHAVIORAL|Standard of Care Psychotherapy|
41110499|NCT04864925|DRUG|Colgate Total Clean Mint|2 minutes of whole mouth toothbrushing
41110500|NCT04864925|DRUG|Tom's Botanically Bright Peppermint|2 minutes of whole mouth toothbrushing
41110501|NCT03804918|OTHER|VitalTips mobile application|VitalTips is a mobile learning application with learning on breaking bad news. Participants were expected to spend at least three hours using the mobile learning resource, ensuring that the time did not impact on their clinical and academic commitments.
41110502|NCT03522467|DRUG|MRCP001|MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
41110503|NCT04723706|DIAGNOSTIC_TEST|COVID-19 serology IgG|patients with SCT or CART who decide to get their vaccines we will measure response by therapy by measuring COVID-19 serology IgG at the following schedule: Baseline +5 days after vaccination; 1 month +/- 10 days (after the first dose), 2 months +/- 10 days (after the 2nd dose), 3 months +/- 10 days, 6 months +/- 10 days and 12 months +/- 10 days
41110504|NCT02825225|OTHER|20 core-biopsy fragments|Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.
41110505|NCT02825225|PROCEDURE|Base and apex local anesthesia|Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.
41110506|NCT03856541|DRUG|SHR-A1403|SHR-A1403 is a humanized anti C-Met immunoglobulin G2 (IgG2) monoclonal antibody conjugated with microtubule inhibitor. SHR-A1403 is provided as the lyophilized powder,40 mg/vial.SHR-A1403 was given intravenously per 3 weeks at the day 1.Intravenous infusion over 30 min
41110507|NCT01161563|DRUG|Triptorelin pamoate|Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
41110508|NCT01161563|DRUG|Leuprolide acetate|Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
41110509|NCT04962906|DRUG|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.
41110510|NCT02434107|PROCEDURE|Completion Lymphadenectomy|
41110511|NCT02434107|PROCEDURE|Clinical Monitoring (Palpation and node ultrasound)|
41271126|NCT00673595|DRUG|Varenicline|"Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day."
41110512|NCT02441036|DEVICE|Ultherapy Treatment|Focused ultrasound energy delivered below the surface of the skin.
41110513|NCT00491517|DRUG|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
41110514|NCT00491517|DRUG|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
41110515|NCT03572023|OTHER|Integrative characterization of MINOCA patients|"Characterization of MINOCA patients will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
41110516|NCT03572023|OTHER|Characterization of MI patients with coronary obstruction|"Characterization of patients with myocardial infarction and obstructive atherosclerosis will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
41110517|NCT05295134|DIETARY_SUPPLEMENT|Placebo|Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
41110518|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (225,000 FIP lipase units per day)|Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
41110519|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (450,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
41110520|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (675,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
41110521|NCT01815450|DRUG|BLI1100|BLI1100 topical cream
41110522|NCT01815450|DRUG|BLI1100 - modified formulation|BLI1100 topical cream
41110523|NCT01815450|DRUG|Placebo|Placebo topical cream
41110524|NCT00688948|DRUG|Alfuzosin|Alfuzosin 10 mg once daily po for 12 weeks
41271127|NCT00673595|DRUG|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
40752428|NCT03654079|OTHER|Simulation|Participants assigned to the intervention group will participate in the following simulations: 1) the process that may occur if a baby has a significant drop in heart rate during labor, 2) the process of moving from the labor bed to the transport stretcher and on to the operating room in the event that a woman needs a cesarean delivery, 3) the pushing process after a woman becomes completely dilated
40752429|NCT01778985|DRUG|Premarin|
40752430|NCT01778985|OTHER|Placebo|
41110525|NCT04658030|DEVICE|VR 360 video surgery preparation|Preparing children on the surgery by a virtual reality 360 degrees video tour from the pediatric ward to the surgery room. In this video all information is given necessary for the surgery. This takes a maximum of 30 minutes and will be performed 1 time.
41110526|NCT04658030|OTHER|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
41110527|NCT00822055|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
41110528|NCT00822055|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
41110529|NCT00822055|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
41110530|NCT00822055|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
41110531|NCT04759066|DEVICE|HEALiX|HEALiX is a non-restraint patient safety device
41110532|NCT02329457|BIOLOGICAL|Zostavax|varicella zoster vaccine
41110533|NCT02329457|BIOLOGICAL|Normal Saline|normal saline placebo vaccine
41110534|NCT04121858|OTHER|Brain Safe App|The Brain Safe app includes the medication list, a personalized risk calculator, multimedia educational content, and a conversation starter/doctor's report.
41110535|NCT04121858|OTHER|Attention Control App|The attention control app, called Med Safe, includes only the medication list feature.
41110536|NCT00414648|DRUG|Sirolimus|A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.
41110537|NCT00414648|DRUG|Placebo|A placebo dose of 2 tablets per day for 1 year.
41110538|NCT01984086|DRUG|Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
41110539|NCT01984086|DRUG|Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
41110540|NCT01984086|DRUG|Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
41110541|NCT01984086|DRUG|Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
41110542|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister|Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
41110543|NCT01984086|DRUG|Salbutamol MDI 100mcg|Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
41110544|NCT01984086|DRUG|Salbutamol Sulphate UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
41110545|NCT01984086|DRUG|Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
41110546|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister without activated charcoal|Formulation will be determined depending on the outcome of Part A.
41110547|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister with activated charcoal|Formulation will be determined depending on the outcome of Part A.
41110548|NCT01984086|DRUG|Salbutamol MDI 100mcg without activated charcoal|Formulation will be determined depending on the outcome of Part A.
41110549|NCT01984086|DRUG|Salbutamol MDI 100mcg with activated charcoal|Formulation will be determined depending on the outcome of Part A.
41110550|NCT03371966|DIETARY_SUPPLEMENT|High Nitrate Beetroot Juice|High nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of low nitrate beetroot juice.
41110551|NCT03371966|DIETARY_SUPPLEMENT|Low Nitrate Beetroot Juice|Low nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of high nitrate beetroot juice..
40752431|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
41110552|NCT00001304|DRUG|Synthetic Human Parathyroid Hormone 1-34|twice daily subcutaneous injections
41110553|NCT00001304|DRUG|Calcitriol & Calcium|Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
40752432|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
40752433|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
41110554|NCT04353037|DRUG|Group 1 HCQ|Enrolled participants randomized in Group 1 receive the HCQ drug
41110555|NCT04353037|DRUG|Group 2 Placebo|Enrolled participants randomized in Group 2 will receive a placebo drug
41110556|NCT03753841|OTHER|Adjustment of oral diet|Adjustment of oral diet based on findings in fiberendoscopic evaluation of swallowing (FEES)
41110557|NCT03703518|OTHER|Mixed reality|"This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
41110558|NCT03703518|OTHER|Conventional exercise group|This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
41110559|NCT04385355|DEVICE|Conventional transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
41110560|NCT04385355|DEVICE|Narrow transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
41110561|NCT05190419|DRUG|Orismilast modified release tablets|Orismilast modified release is a next generation phosphodiesterase-4 (PDE4) inhibitor with high selectivity for the PDE4 subtypes linked to inflammation.
41110562|NCT05190419|DRUG|Placebo|Matching placebo tablets
41110563|NCT02118077|BIOLOGICAL|G17DT|
41110564|NCT02897219|DRUG|ipragliflozin|Oral administration once daily
41110565|NCT02897219|DRUG|Placebo|Oral administration once daily
41110566|NCT02897219|OTHER|Insulin Therapy|Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
41110567|NCT04551794|BEHAVIORAL|Selfapy with therapeutic guidance|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences with a therapeutic guide.
40752434|NCT00709800|BIOLOGICAL|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
41110568|NCT04551794|BEHAVIORAL|Selfapy with additional peer support|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
41110569|NCT06170593|DRUG|Triamcinolone Injection|0.1mL of triamcinolone 1% solution per lesion
41110570|NCT01714193|DRUG|Oral contraceptive|One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
41110571|NCT01714193|DRUG|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
41110572|NCT03580798|PROCEDURE|Delayed graft|8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.
41110573|NCT03580798|PROCEDURE|Simultaneous graft|At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
41110574|NCT05019417|DRUG|Glycerol Phenylbutyrate 1100 MG/ML|Daily adminisitraion of the study drug (three times a day) in escalting dose over 4 months
41110575|NCT00007956|BIOLOGICAL|monoclonal antibody mono-dgA-RFB4|
40752435|NCT00709800|BIOLOGICAL|PBS|IM, 1 mL, 2 injections, 0 and 21 days
40752436|NCT02344095|DRUG|weekly paclitaxel|Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
40752437|NCT02344095|DRUG|weekly cisplatin|Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
41110576|NCT01552980|DRUG|S-1 and Oxaliplatin|"Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;~Efficacy will be evaluated every three cycles."
41110577|NCT05181254|BEHAVIORAL|health dialogue|The visual health assessment formulary is based on detailed questions about food, physical activity, heredity, smoking, alcohol, stress and mental illness and measurements such as BMI, blood pressure and blood fats. Patients fill in a web-based questionnaire resulting in a visual colorful scale showing a risk assessment (Figure 1). The Health Dialogue is a prognostic tool that provides an estimate of the increase in risk with current lifestyle habits. The use has shown improvement of lifestyle habits such as smoking cessation, lower intake of fat and higher physical activity level as well as reduced mortality in a long-term follow-up.
41110578|NCT01672619|PROCEDURE|dynamic craniotomy|Surgical technique of craniotomy spiral without detachment of dura mater
41110579|NCT03179969|OTHER|paravalvular leak|Observational study on patients with paravalvular leak
41110580|NCT00777816|DRUG|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
41110581|NCT00777816|DRUG|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
41110582|NCT01637662|DRUG|Natriuretic peptides|I.V. infusion between 0.2-3 microgram over 20 minutes
41110583|NCT02620410|DEVICE|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
41110584|NCT05216692|PROCEDURE|La Tour Hospital Foot Strengthening Protocol|"First exercise : NMES forward lean doming. Doming exercise assisted by NMES placed on the IFM. 8 sec of contraction (6 sec rest) moving the trunk forward. 12 repetitions, 3 sets. Progressive increase of the intensity of NEMS during 4 weeks and increase of body load while decreasing the number of repetitions.~Second exercise : MTP joint flexion. Isometric MTP joint flexion contractions. 4 contractions of 5 sec (10 sec rest), 3 sets. Progressive increase of the number of MVIC during 4 weeks and of increase body load while keeping the same intensity.~Third exercise : Foot-ankle rebound. Multiple jumps with only plantar flexion. Keeping the knee stiff and straight and pushing off the ground with only ankle and MTP plantar flexion by a forefoot contact with the ground. 10 seconds of jump (1 min of rest) during 5 sets. Progressive increase of body load while keeping the same intensity."
41271128|NCT05078489|OTHER|Action-observation therapy|Action observation therapy involves the observation and perception of human movement performed by others. The observation of actions performed by others activates in the perceiver the same neural structures responsible for the actual execution of those same actions.
41271129|NCT05078489|OTHER|Placebo|Participants will watch a natural landscape without any human.
41271130|NCT02091180|DRUG|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
41271131|NCT02091180|DRUG|Control|Saline infusion
41271132|NCT00000927|DRUG|BufferGel|
40752438|NCT02344095|DEVICE|oncothermia|"Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W."
41110585|NCT05216692|PROCEDURE|Standard Literature Foot Strengthening Protocol|"During the 1st week, the participants will perform the Short foot exercise (SFE) during 3 series of 10 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 2nd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 3rd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing bipedal position. 1 minute of rest will be give between series.~During the 4th week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing unipedal position. 1 minute of rest will be give between series.~The progression of the exercise during the protocol will be based on passing from a sitting position to a unipedal standing position."
41110586|NCT01305434|DIETARY_SUPPLEMENT|Mulberry leaf extract effect on post prandial blood glucose|"Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.~Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications."
40752439|NCT06262373|DIAGNOSTIC_TEST|Ultrasound|Ultrasound based observational study
40752440|NCT02203786|DRUG|Haloperidol|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol."
41110587|NCT02041104|DIETARY_SUPPLEMENT|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
41110588|NCT02041104|DIETARY_SUPPLEMENT|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
41110589|NCT02376517|BEHAVIORAL|Educational program|The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
41110590|NCT03594396|DRUG|Olaparib|Olaparib 300mg bid will be given on days 1-28 days without rest.
41110591|NCT03594396|DRUG|Durvalumab|A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
41110592|NCT02427269|OTHER|Specimen Collection|"* 1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection~* Up to 10 research-specific biopsies obtained from the esophagus during the routine care EGD.~* Four biopsies will be taken from the midpoint of the current BE (or midpoint of previous BE if the patient has already received ablation for previous BE),~* Two biopsies from normal squamous epithelium, and~* One biopsy from each area of esophageal nodularity seen during the procedure~* Pathology slides from routine care biopsies taken during the enrollment procedure, as well as retrospective pathology slides from routine care biopsies taken prior to enrollment on the study.~* Up to 4 cytology brushes during the procedure."
41110593|NCT02886858|DEVICE|Device : Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
41110594|NCT02886858|DEVICE|Device : sham Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
41110595|NCT00457769|DRUG|Donepezil and self-generated memory training|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
41110596|NCT00457769|DRUG|Donepezil and experimenter-administered memory training|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
41110597|NCT05685095|BEHAVIORAL|Physical training|Supervised gait training program 3 times a week, 12 weeks
41110598|NCT01091298|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)|Single dose (0.5 mL) of the vaccine administered orally
41110599|NCT01091298|OTHER|Placebo|Single dose (0.5 mL) of the placebo administered orally
41110600|NCT05345119|DRUG|Sirolimus|2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
41110601|NCT05345119|DRUG|Methylprednisolone|500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
41110602|NCT04783454|OTHER|Exercise program|educational video on training program design and healthy lifestyle 24 training sessions (12 on cardiovascular endurance training, 12 on mobility and strength)
41110603|NCT05485402|DIETARY_SUPPLEMENT|Refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
41110604|NCT05485402|DIETARY_SUPPLEMENT|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
41110605|NCT05485402|DIETARY_SUPPLEMENT|Maltodextrin|The dosage will be 7,5 g/day of maltodextrin.
41110606|NCT05485402|DIETARY_SUPPLEMENT|Prebiotic (FOS and inulin)|The dosage will be 7,5 g/day of prebiotic supplement (FOS and inulin).
41110607|NCT05485402|OTHER|Nutritional and physical activity recommendations|The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine) and vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions dedicated to the development of motor strength.
41110608|NCT00376519|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
41110609|NCT00376519|DRUG|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of \>200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
41110610|NCT00376519|DRUG|fludarabine phosphate|Fludarabine 25 mg/m\^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
41110611|NCT00376519|DRUG|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
40752441|NCT02203786|DRUG|Fluphenazine|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine."
41110612|NCT00376519|PROCEDURE|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10\^6/kg, 0.3 x 10\^6/kg, 1 x 10\^6/kg and 3 x 10\^6/kg weight (determined on the day prior to administration of the preparative therapy).
41110613|NCT00376519|PROCEDURE|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
41110614|NCT00376519|RADIATION|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
41110615|NCT03343938|OTHER|Embryo handling in a closed station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
41110616|NCT01305291|OTHER|placebo|
41110617|NCT01305291|DIETARY_SUPPLEMENT|digestion-resistant maltodextrin|
41110618|NCT04771234|BEHAVIORAL|Digital self-guided CBT-i|A brief version of CBT-i consisting of brief psychoeducation, and the core components sleep restricion and stimulus control, where sleep restriction is based on a simplified sleep diary.
41110619|NCT05632731|PROCEDURE|double cleavage-stage or single blastocyst stage embryos transfer|Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.
41110620|NCT03206736|OTHER|Loop DS surgery|these patients will receive a loop DS bariatric procedure
41110621|NCT00318019|DIETARY_SUPPLEMENT|OPC Factor(TM)|Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
41110622|NCT00318019|OTHER|Placebo|Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
41110623|NCT05925686|DRUG|Tramadol.|Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers.
41110624|NCT02969863|DEVICE|Bihormonal Bionic Pancreas|Participants will wear a Bionic Pancreas that uses glucagon and insulin (bihormonal) to automate their glucose control based on continuous glucose monitor readings.
41110625|NCT02969863|DEVICE|Insulin Only Bionic Pancreas|Participants will wear a Bionic Pancreas that uses just insulin (insulin-only) to automate their glucose control based on continuous glucose monitor readings.
41110626|NCT02969863|OTHER|Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
41110627|NCT02969863|OTHER|Not Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity only, not hypoglycemia.
41110628|NCT00003292|DRUG|ifosfamide|
41110629|NCT02910388|DEVICE|LLETZ with colposcopy|Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue
41110630|NCT02910388|OTHER|LLETZ without colposcopy|Loop procedure without using a colposcope
41110631|NCT04656886|DRUG|Intravenous Infusion|
41110632|NCT00814047|DRUG|Yohimbine hydrochloride|
41110633|NCT04352803|BIOLOGICAL|Autologous Adipose MSC's|Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV
41110634|NCT00318253|PROCEDURE|cranberry juice|
41110635|NCT03621917|DEVICE|Near-infrared spectroscopy reading|Non-invasive readings will be taken from forehead with near-infrared spectroscopy
41110636|NCT01281813|DRUG|Darunavir|Participants will receive darunavir (per parent study) as oral suspension.
41110637|NCT01281813|DRUG|Ritonavir|Participants will receive ritonavir (per parent study) as oral solution/suspension.
41271133|NCT02519114|PROCEDURE|Donor Bone Marrow stem cell transplantation|KIR-mismatched haploidentical Bone Marrow stem cell transplantation
41110638|NCT05261568|BEHAVIORAL|PROGRESSIVE RELAXATION EXERCISE|Progressive relaxation exercise will be done for 6 weeks by watching the animation video in the mobile application program.
41110639|NCT05519813|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
41110640|NCT05519813|DRUG|Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
41110641|NCT02823548|DRUG|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
41110642|NCT02823548|DRUG|Placebo|Placebo
41110643|NCT06089694|DEVICE|Enabling Sensor Research Holter Mode feature|The Sensor Research Holter Mode feature within the Crome and Cobalt ICD and CRT-D devices will be enabled for a short period of time at the In-clinic Testing Visit to allow for desired data collection.
41110644|NCT03208101|BIOLOGICAL|DTP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
41110645|NCT03208101|BIOLOGICAL|DTP-HepB-Hib vaccine & IPV|Pentavalent vaccine (DTP-HepB-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b vaccine)+ IPV(Inactivated poliovirus vaccine)
41110646|NCT03612882|OTHER|Online questionnaire|Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
41110647|NCT00360451|BEHAVIORAL|Adolescent only Penn Resiliency Program (Adolescent PRP)|In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
41110648|NCT00360451|BEHAVIORAL|Parent Penn Resiliency Program (Parent PRP)|Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
41110649|NCT03973944|DEVICE|Cardiac resynchronization therapy|Atrio-biventricular pacing to shorten the prolonged PR interval
41271134|NCT05576207|DIETARY_SUPPLEMENT|Balanced energy and protein supplement for pregnant women|A fortified balanced energy and protein supplement providing both macro and micronutrients recommended for use during pregnancy in undernourished contexts.
41110650|NCT00736853|DRUG|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
41110651|NCT00736853|DRUG|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose \[number of tablets\] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
41110652|NCT00736853|DRUG|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
41110653|NCT06390943|OTHER|Facility-based feeding support package plus (FB-FSP+)|Package of materials to support facility-based feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
41110654|NCT06390943|OTHER|Transition-to-home feeding support package plus (TTH-FSP+)|Package of materials to support transition-to-home feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
41110655|NCT04133740|DRUG|Oxygen|Liberal versus conservative oxygen therapy.
41110656|NCT00903227|DRUG|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
41110657|NCT00903227|DRUG|Placebo|1 puff of inhaled Placebo twice a day
41110658|NCT00903227|DRUG|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
41110659|NCT00903227|DRUG|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
41110660|NCT00903227|DRUG|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
41110661|NCT01320657|DEVICE|Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket|"Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks."
41110662|NCT04330768|PROCEDURE|PRF pulp capping|PRF is injected in the site of exposure
41110663|NCT04330768|PROCEDURE|MTA pulp capping|conventional pulp capping procedure
41110664|NCT02378337|OTHER|Image quantify|Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
40947771|NCT05815173|DRUG|Ladarixin|"Ladarixin dose will be escalated as follows in Phase I: 3 patients will receive a starting dose of 200mg. If 2 or more patients experience a DLT at the lowest dose, the study will stop. If 0 out of 3 patients experience a DLT within 28 days, the next 3 patients will receive 300mg. If 1 out of 3 patients experiences a DLT, 3 more patients will be added to the 200 mg dose. If no more patients experience a DLT at 200mg, the next 3 patients will receive 300mg. If 2 of 6 patients receiving 200mg experience a DLT, the study will stop. If 2 or more patients experience DLTs, the maximum tolerated dose (MTD) will be the previous dose level. The same process will be repeated at each dose level. There will be 6 patients enrolled at MTD level for a maximum of 12 patients in the phase I cohort. Ladarixin will be administered as a twice-daily dose over a 21 day treatment cycle.~In Phase II, ladarixin will be administered twice-daily at the recommended phase II dose over 21-day cycles."
41110665|NCT03895268|DEVICE|ALiA Analyser|NPS specimens shall be tested with the investigational device
41110666|NCT03895268|DEVICE|Influenza A+B Test Kit|NPS specimens shall be tested with the investigational device
41110667|NCT02298751|BEHAVIORAL|Cue Exposure Treatment|
41110668|NCT01203618|DRUG|Farletuzumab|Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.
41110669|NCT06375655|BEHAVIORAL|Team2BF|Team2BF includes 3-4 breastfeeding-supportive messages per time interval, sent weekly from 28 weeks gestation through delivery, daily through 2 weeks postpartum, weekly from 2 to 10 weeks, and then monthly to one year. Other maternal health topics are not addressed.
41110670|NCT06375655|BEHAVIORAL|Bright By Text|Bright By Text sends 2-4 messages per week from the first trimester through and beyond one year postpartum about a wide range of maternal and child health topics as outlined on their website; 8 messages are specifically about breastfeeding.
41110671|NCT00116623|DRUG|Indomethacin|
41110672|NCT00116623|DRUG|Magnesium sulfate|
41110673|NCT06230679|DEVICE|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
41110674|NCT06230679|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
41110675|NCT01316263|BIOLOGICAL|Olaratumab|Administered IV
41110676|NCT02787941|BEHAVIORAL|Pharmacist-delivered multifaceted intervention|"First counselling: A pharmacist performs a 30-minute in-person counselling within 1 week before discharge including: (1) assessment and giving advice on basic knowledge of acute coronary syndrome: definition, risk factors, possible cardiac events, and prevention; (2) assessment of past experiences of using medications, encouragement and tailored advice; (3) providing support with pill organiser and drug information leaflet; (4) teaching back and correcting misunderstanding.~Second counselling: A pharmacist performs a 30-minute telephone counselling within 1 week after discharge including: (1) assessment of general and medication-related issues patients concerning; (2) encouragement and tailored advice; (3) teaching back and correcting misunderstanding."
41110677|NCT02891278|DRUG|Sertraline|"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM."
41110678|NCT02891278|DRUG|Cytosine arabinoside|"Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours)."
41110679|NCT02891278|PROCEDURE|allogeneic stem cell transplantation|Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
41110680|NCT03408925|OTHER|Exercise program|The orienteerers are asked to perform specific exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function. Each second week the exercises' difficulty level is increased.
41110681|NCT05996588|DRUG|Propofol 1 % Injectable Suspension|Propofol 1 % Injectable Suspension at a rate of 50 microgram/kg/min intravenously
41110682|NCT05996588|DRUG|Sevoflurane|Sevoflurane inhalation anaesthetic at a concentration of 4-5% to achieve a MAC of 0.25
41110683|NCT00309595|DEVICE|stent|Cordis SMART™ Nitinol Stent System
41110684|NCT00309595|DEVICE|balloon|balloon angioplasty
41110685|NCT04951518|OTHER|VAN Stroke Scale|V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients
41110686|NCT05300035|DRUG|Recombinant human monoclonal antibody (bNAbs)|"1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria."
41110687|NCT05300035|DRUG|Placebo|"1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria."
41110688|NCT00463788|DRUG|cetuximab, cisplatin|"Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m\^2) followed by weekly doses of 250 mg/m\^2. All doses will be given by intravenous (IV) infusion.~Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent."
41110689|NCT00463788|DRUG|cisplatin|"Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.~Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent."
41271135|NCT05576207|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement for pregnant women|"Prenatal supplements containing vitamins and minerals - also called multiple micronutrient supplements will be used in the control group."
41110690|NCT05460936|OTHER|Lower Extremity Functional Training|motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps
41110691|NCT05460936|OTHER|conventional physical therapy|Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
41110692|NCT03829917|DRUG|Miltefosine and Paromomycin|28 days of miltefosine plus 28 days of Paromomycin cream
41110693|NCT03829917|DRUG|miltefosine|28 days of miltefosine
41110694|NCT03829917|DRUG|paromomycin|28 days of paromomycin creaam
41110695|NCT02925351|PROCEDURE|Computed Tomography|Undergo PET/CT scan
41445834|NCT04376190|RADIATION|low level laser therapy|In the laser group, patients received LLLT from a semiconductor Gallium Aluminum Arsenide diode laser (SMARTMPRO, LASOTRONIX, Poland) with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. Laser was applied (Fig.2) at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points.
41110696|NCT02925351|RADIATION|Fluorine F 18 Clofarabine|Given IV
41110697|NCT02925351|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
41110698|NCT00943735|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
41110699|NCT00943735|BEHAVIORAL|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
41110700|NCT05001750|DRUG|long term prophylactic antibiotics (Nafcillin or Doxycycline)|VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
41110701|NCT01240837|OTHER|Arenga Pinnata Sugar|50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
41110702|NCT01240837|OTHER|Glucose|50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
41445835|NCT00500201|DRUG|SB- 773812 60 mg|SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
41445836|NCT00500201|DRUG|SB- 773812 120 mg|SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
41445837|NCT00500201|DRUG|Placebo|Placebo tablets will be administered orally by subjects.
41445838|NCT03332732|DRUG|VNRX-5133|β-lactamase inhibitor
41110703|NCT01240837|OTHER|Sucrose|50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
41110704|NCT01065220|DRUG|Testolactone undecanoate|4ml i.m.
41110705|NCT01065220|DRUG|Lynestrenol|2/day
41110706|NCT01065220|DRUG|Cyproterone Acetate|50mg per day
41110707|NCT01065220|DRUG|Estradiol|100 microgram TTS twice a week
41110708|NCT01065220|DRUG|5-alpha reductase inhibitor|1mg daily
41110709|NCT05590273|BEHAVIORAL|CALM Therapy|"The CALM intervention includes 3 to 6 individual therapy Zoom teletherapy sessions, each approximately 50-60 minutes in length biweekly, delivered over 3 months. Participants (caregivers) will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy (baseline) and immediately after the program (post-intervention)~In addition, after each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components.~Lastly, participants will complete an exit interview immediately following the end of the intervention."
41110710|NCT00748410|DRUG|SB-656933|7 days repeat dose
41445839|NCT03332732|DRUG|VNRX-5022|Approved β-lactam antibiotic
41445840|NCT03332732|DRUG|Metronidazole|Approved antibiotic and antiprotozoal medication
41445841|NCT03332732|DRUG|Placebo|Placebo (matching VNRX-5133 + VNRX-5022)
41445842|NCT04222023|DRUG|Intravenous immunoglobulins (IVIG)|"Experimental group: administration of a single dose of IVIG at:~* Day 10+/- 4 days~* Day 41 +/- 7 days~* Day 62 +/- 7 days The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day."
41445843|NCT06488157|OTHER|I-HoME|Video visits with a nurse practitioner for up to six visits every 2 weeks to address symptom management and care needs
41445844|NCT00346385|DRUG|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
41445845|NCT04522258|DIETARY_SUPPLEMENT|Dietary fiber|Fermentable cereal bran
40947772|NCT05384860|DEVICE|Auricular Trauma Protocol (ATP) Acupuncture|Small filiform (needle) like needles use low frequency electrostimulation at eight ear points for 60 minutes while patient is sedated during surgery. All other aspects of the surgical procedure will go as planned according to the hospital's standard of care.
41445846|NCT04522258|DIETARY_SUPPLEMENT|Placebo|Refined cereal flour
41445847|NCT06352645|DEVICE|Bixdo Ultra Compact Water Flosser|Use of water flosser, in addition to standard tooth brushing, twice a day for 8 weeks.
41445848|NCT06352645|DEVICE|Manual toothbrush|For those in the control group, they will be asked to use only the study-provided manual toothbrush, twice a day for 8 weeks.
41110711|NCT00958386|DRUG|Panitumumab+irinotecan|"Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.~Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.~Each treatment cycle will have a duration of 14 days."
41110712|NCT01951508|DRUG|Methylphenidate|60mg per os, single dose
41110713|NCT01951508|DRUG|Modafinil|600mg per os, single dose
41110714|NCT01951508|DRUG|MDMA|125mg per os, single dose
41110715|NCT01951508|DRUG|Placebo|per os
41445849|NCT06555913|OTHER|Maitland Mobilization|"MM applies a passive oscillatory technique, classified from Grade I-IV with respect to intensity, to the shoulder in order to treat pain and stiffness.~Grade I refers to an intensity of small amplitude that is applied at the beginning of the joint ROM, where there is no loading on connective tissue; it is often used in cases of severe pain"
41445850|NCT06555913|OTHER|Scapular Stabilization|"Scapular stabilization exercises are thought to have an important role in improving pain and dysfunction in the shoulder. The concept that an unstable~scapula is associated with pathology and dysfunction of the shoulder is well accepted. The predominant theory emphasizes that for optimal function of the glenohumeral joint, the scapula must provide a stable base upon which upper extremity tasks are completed. Impaired scapular stability increases the risk for pathologies such as impingement or rotator cuff tears"
41445851|NCT06555913|OTHER|Traditional Physical Therapy|ROM exercises, stretching exercises and strengthening exercises for shoulder muscles
41445852|NCT04793971|PROCEDURE|percutaneous paratenon release|percutaneous paratenon release for chronic midportion Achilles tendinopathy
41445853|NCT06223139|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength will be measured by 3 efforts.
41445854|NCT02714465|OTHER|hyperbaric oxygen therapy|hyperbaric oxygen therapy
41445855|NCT06556017|DIAGNOSTIC_TEST|Diagnosis of SSI|Comparison of the manual system and ChatGPT for SSI diagnosis in colorectal surgery procedures enrolled in the SSI surveillance programme.
41445856|NCT04021563|DRUG|SR419|Ascending single and multiple doses of SR419 orally
41445857|NCT04021563|DRUG|Placebo|Ascending single and multiple doses of placebo orally
41445858|NCT01983969|DRUG|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
41445859|NCT01983969|DRUG|Vorinostat|1000 mg by vein on Day -11 through Day -2.
41445860|NCT01983969|DRUG|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
41445861|NCT01983969|DRUG|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
41445862|NCT01983969|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
41445863|NCT01983969|DRUG|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
41445864|NCT01983969|OTHER|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
41445865|NCT01983969|DRUG|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
40947773|NCT05384860|OTHER|No Acupuncture Group|This involves not receiving the acupuncture treatment and surgery going entirely as normal according to the hospital's standard of care.
41110716|NCT01287286|DIETARY_SUPPLEMENT|AC-Can|Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
41110717|NCT01287286|DIETARY_SUPPLEMENT|placebo|Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
41110718|NCT06089954|OTHER|private web-portal eHealth disclosure of genetic results|The intervention involves delivering actionable genetic research results to participants via a secure, private web-portal.
41445866|NCT01983969|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
41445867|NCT01983969|DRUG|Rituximab|375 mg/m2 by vein on Days -9.
41445868|NCT00903877|DRUG|T3|Patients receive T3 in a dose of 25mcg and 50mcg
41445869|NCT05049746|OTHER|Discussion|Participate in discussion
41445870|NCT05049746|OTHER|Interview|Participate in interview
41445871|NCT05049746|OTHER|Questionnaire Administration|Complete questionnaire
41445872|NCT06380816|DRUG|UCB4594|Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).
41445873|NCT00501735|DRUG|Forodesine 200 mg|2 x 100mg tablets once daily
40947774|NCT03202888|BEHAVIORAL|Intervention|QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
41110719|NCT06089954|OTHER|eHealth education intervention (web or chatbot)|The intervention involves pre-disclosure education via an eHealth intervention (web or chatbot). The intervention will review the types of actionable results being returned, the method of return, the differences between research and clinical testing, the need for confirmation testing and the benefits, risks and limitations of receiving actionable genetic research results and study steps and procedures.
40752442|NCT02203786|DRUG|Dexedrine|"Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine."
41110720|NCT02814643|DRUG|Benralizumab|Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
41110721|NCT02814643|DRUG|Benralizumab Placebo|Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
40752443|NCT02203786|DRUG|Placebo|"Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1."
41110722|NCT02814643|DRUG|Seasonal influenza virus vaccine|Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
41110723|NCT03488056|OTHER|ICCMS|"The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment~-Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.~After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The treatment is divided into Non-Operative Care and Tooth-Preserving Operative Care (restorations with minimal intervention to preserve maximum dental structure).~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
41445874|NCT01242098|DRUG|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
41445875|NCT01242098|DRUG|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
40752444|NCT02203786|BEHAVIORAL|Slot Machine|15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
41110724|NCT03488056|OTHER|SESC standard care|Standard care related to: Caries Diagnosis, operative and non-operative treatments, Indication of recall interval according to the dentist opinion
41110725|NCT02205307|DEVICE|PINPOINT|
41110726|NCT02205307|DEVICE|SPY Elite|
41110727|NCT04891458|DRUG|Patients received lighter sedation with propofol after spinal anesthesia.|MOAA/S 0-2.
41110728|NCT04891458|DRUG|Patients received heavier sedation with propofol after spinal anesthesia|MOAA/S 3-5.
41110729|NCT04891458|DRUG|Patients received lighter sedation with dexmedetomidine after spinal anesthesia|MOAA/S 0-2.
41110730|NCT04891458|DRUG|Patients received heavier sedation with dexmedetomidine after spinal anesthesia.|MOAA/S 3-5.
41110731|NCT05589506|DEVICE|Removable partial denture PEEK|A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.
41110732|NCT02240550|DEVICE|ProFlor Hernia Repair System|The 3-D hernia mesh will be used in the repair of your inguinal hernia.
41110733|NCT02240550|DEVICE|Lichtenstein hernia repair|The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
41110734|NCT02138006|DRUG|Intensive insulin treatment|Mealtime insulin (Actrapid) Basal insulin (Monotard)
41110735|NCT02138006|DRUG|Standard insulin treatment|Insulin Mixtard
41110736|NCT01820195|DRUG|Oral N-Acetyl Cystein|Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
41110737|NCT01820195|DRUG|IV N-Acetyl Cystein|Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
41110738|NCT01820195|DRUG|Placebo group|The patients in this group will be received both oral placebo and IV placebo
41110739|NCT00414999|DRUG|TG100801|
41110740|NCT04612348|DIAGNOSTIC_TEST|Ultrasound|Point of care ultrasound to measure gastric contents.
41110741|NCT01573130|BEHAVIORAL|Physical exercise program|An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
41110742|NCT04847219|DEVICE|Professional flash glucose mornitoring|Subjects will use Professional flash glucose mornitoring once a month for 3 months.
41110743|NCT04847219|DEVICE|Personal flash glucose mornitoring|Subjects will use Personal flash glucose mornitoring once a month for 3 months.
41110744|NCT03812978|OTHER|Smart phone application|Smart phone application including exercise videos, push notifications for exercise, questions and answers, exercise diary.
41110745|NCT01787760|DEVICE|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
41110746|NCT01787760|DEVICE|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
41110747|NCT01787760|DEVICE|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
41110748|NCT02068430|DRUG|Riboflavin 0.1%|After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
40947775|NCT06218212|DIETARY_SUPPLEMENT|Renastart formula|"* Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company.~* Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water.~* Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet.~* Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio.~* Readjusting dosage ratio according to serum electrolytes levels especially potassium."
41110749|NCT02068430|OTHER|UV-X™ Illumination System|When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
41110750|NCT05635162|DRUG|Zanubrutinib|Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
41110751|NCT05635162|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous (IV)\* on day 1 (+/-3 days) of each 28-day cycle
41445876|NCT01882686|OTHER|Classification Based Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
41445877|NCT03596567|DRUG|Glasdegib single 100 mg dose in normal healthy subjects|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
40752445|NCT02958527|DRUG|venlafaxine|The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.
40752446|NCT05221229|DRUG|Liraglutide plus upstream risk factors modification advice and consultation|Patients will be on treatment with daily injections of Liraglutide for a total of 65 weeks. During initial consultation for AF ablation, patients' BMI, risk factors status and baseline blood tests were performed and reviewed. Then the patients were discussed and encouraged to achieve optimal goal of risk factors modifications by non pharmacological and pharmacological measures.
40752447|NCT05651737|BEHAVIORAL|Sui App (SRK)|"The Sui app contains the following chapters:~6 well-being chapters on: stress, sleep, resources throughout the day, chronic pain, emotion regulation, audio exercises 9 Swiss-specific information chapters on: housing, health (two sub-chapters), finances, asylum process, residence status, social integration, occupational integration, family reunification"
41110752|NCT03737240|DRUG|IDegLira|Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
41110753|NCT03737240|DRUG|Insulin Degludec (U-100)|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.
41110754|NCT03737240|DRUG|Insulin Aspart|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
40947776|NCT06218212|DRUG|calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.|calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
40947777|NCT05586646|DIETARY_SUPPLEMENT|alanyl-glutamine|Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
41110755|NCT00476255|BEHAVIORAL|Enhanced Standard Care (ESC)|Reading material
41110756|NCT00476255|BEHAVIORAL|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
40947778|NCT00017017|DRUG|paclitaxel poliglumex|
40947779|NCT04361825|DRUG|Durvalumab|Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects \> 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 1 and 7. One cycle is consisted of 28 days.
40925662|NCT04139746|PROCEDURE|Drainage-Injection-Pneumoretinopexy|According to the location of the sub-retinal fluid, a quadrant-flap of conjunctiva was opened. Indirect ophthalmoscopy evaluation was also used intraoperatively to localize the break and the subretinal fluid drainage site: in this area a vicryl 6-0 thread was passed through the sclera, about 9-10 mm posteriorly from the limbus, to facilitate the surgical maneuvers. The drainage puncture was performed 11 mm posteriorly from the limbus, having attention not to perform it directly above the site of the retinal break. In detail, a 2 mm radial sclera incision was created with a 15° disposable knife. The incision was cautiously deepened down to the choroid, which was finally perforated by a lachrymal dilator having a blunt tip. Soon after beginning the subretinal fluid drainage, an injection of BSS was performed in the opposite quadrant of the sclera (4 mm from the limbus) in order to allow an optimal spillage of the subretinal fluid and to flatten the retina.
41110757|NCT04238000|DEVICE|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
41110758|NCT04613024|DRUG|Topamax|Experiment randomized group will be prescribed Topamax before and after surgery with follow up at regular interval
41110759|NCT04613024|DRUG|Gabapentin|Control group will be prescribed gabapentin after surgery with follow up at regular interval
41110760|NCT04407780|OTHER|No interventions are planned|Non applicable
41110761|NCT00928213|DRUG|Progesterone|40 units daily admission
41110762|NCT00928213|DRUG|Low molecular weight Heparin|40-80 mg/day
41110763|NCT00928213|DRUG|No Drug|no treatment
41445878|NCT03596567|DRUG|Glasdegib single 100 mg dose in moderate renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
41445879|NCT03596567|DRUG|Glasdegib single 100 mg dose in severe renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
41445880|NCT02826694|GENETIC|Well infant, whole exome sequencing|Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.
41110764|NCT01956669|DRUG|Pazopanib|Pazopanib was supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension was a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
41110765|NCT03416842|DEVICE|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
41110766|NCT05570019|PROCEDURE|Revascularization|Open surgery (arterial endarterectomy with or without bypass surgery) and/or angioplasty (with or without stent placement)
41110767|NCT03919864|BEHAVIORAL|CONNECT Intervention|Participants will be included in a multi-component e-tool with brief educational videos, an assessment of multidimensional supportive care needs, a tailored resource list and an optional automated referral to a caregiver navigator. Two weeks after baseline participants will receive re-education and an optional referral.
41110768|NCT03919864|BEHAVIORAL|CONTROL Group|Participants will receive a generic printed list of hospital, community, and national supportive care resources.
41110769|NCT01830946|OTHER|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
41110770|NCT01830946|OTHER|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
40925663|NCT02027129|OTHER|High Frequency Oscillation|Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
41110771|NCT01830946|OTHER|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
41110772|NCT02083029|PROCEDURE|Simulated dive reflex|All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
41110773|NCT06376513|OTHER|Evaluation|Evaluation of the manipulation abilities of patients with penile prostheses Evaluation of the rigidity of erections with penile prosthesis, the patient and partner's sexual satisfaction, the satisfaction related to pump manipulation
41110774|NCT04045106|OTHER|Proprioceptive Neuromuscular Facilitation Patterns|The participants were asked to sit on a chair, the therapist performed the pattern of movement himself then passively applied the pattern on the participant then asked the participant to perform the pattern, and the therapist observed and corrected the movement if it was done improperly.Then participants were told that the therapist will resist their movement, they were also told to keep breathing normally and to report any discomfort and/or pain.After mastering the pattern,the therapist placed one hand on the participant's mandibular and the other hand approximately between parietal and occipital bones to apply resistance through out the ROM, each pattern performed for 3 sets of 10 repetitions with 1-2-minute rest between sets.
41110775|NCT04045106|OTHER|Proprioceptive Neuromuscular Facilitation stretching|was done for 6 repetitions with hold for 6 seconds in position of stretch and sub maximal isometric contraction for 6 seconds, 1-2-minute rest was given before changing the target muscle group
41110776|NCT04045106|OTHER|Passive range of motion|ineffective passive ROM for 10 repetitions for flexion, extension, right and left side bending and right and left rotation, it was done from neutral position to the limit of motion without causing any stretch to the muscle.
41110777|NCT05274334|OTHER|Assessment of de novo lipogenesis non-invasively in exhaled breath|"1. Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements.~2. They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish.~3. Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water.~4. Participants execute several exhalation sets over time.~5. Participants consume 300g of 'Excellence Joghurt Nature gezuckert.~6. Participants execute several exhalation sets over time.~7. After around 4.5hours with regular exhalation sets taking place, the trial is concluded."
40925664|NCT03418103|DEVICE|Thermal imaging analysis of participant position in a hospital bed|The SAFE sensor system will use thermal imaging to detect and identify a participant's position relative to the edges of the hospital bed. If a dangerous position is identified, an alarm notification will be sent to the ward staff to allow them to take pre-emptive action to prevent the participant's situation from evolving into a fall event.
41110778|NCT04014933|DIAGNOSTIC_TEST|LASER SPECKLE FLOWGRAPHY|Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region
41110779|NCT04020718|BEHAVIORAL|Brief telephone advice plus tailored text messages|All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.
41110780|NCT04020718|DRUG|Mailed nicotine replacement therapy|Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
41110781|NCT04020718|BEHAVIORAL|Proactive telephone coaching|Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
41110782|NCT01965119|DRUG|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
41110783|NCT06126783|DRUG|IBI311|The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
41110784|NCT02412748|BEHAVIORAL|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
41110785|NCT02412748|BEHAVIORAL|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
41110786|NCT04645550|DRUG|Apixaban|From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.
41110787|NCT04645550|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.
41110788|NCT04645550|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.
41110789|NCT04645550|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
41110790|NCT04645550|DRUG|Low molecular weight heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
41110791|NCT02536430|DRUG|Ketorolac Tromethamine|One group received a buccal infiltration of Ketorolac Tromethamine
41110792|NCT02536430|DRUG|Placebo|buccal infiltration of Normal Saline.
41110793|NCT03319706|DRUG|Torrent's Olmesartan Medoxomil Tablets 40 mg|
41110794|NCT03319706|DRUG|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
41110795|NCT01083342|DRUG|MTX, MVD, VIA|MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
41110796|NCT06552325|BEHAVIORAL|Single Session Narrative Therapy|The proposed single session narrative therapy intervention has been widely implemented in walk-in therapy clinics in Ontario Province, Canada. In these clinics, 60-minute psychotherapy sessions, informed by narrative therapy, are available on a walk-in basis. The therapist collaborates with a patient to co-develop a useful and meaningful focus for the session and then engages the patient in conversation that is respectful but shifts their way of thinking about the presenting problem. The therapist highlights and documents the patient's values and skills and works with the patient to create an action plan. If the therapist identifies additional treatment needs, the patient is offered an external referral to specialty mental health services.
41110797|NCT05697081|OTHER|Medical doctors infected with COVID-19|web-based survey
41110798|NCT05605834|OTHER|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray with reservoir|"Patients will be randomly divided into two groups. Alginate impressions of maxillary dental arches of patients will be taken to obtain casts and produce the customized trays.~Reservoirs 1 mm thick will be created on the facial surfaces of anterior teeth, including the first premolars in the arches, applying a light-cured resin on the casts. The resin layer thickness will be standardized using a thickness gauge (1.5 mm thickness). Then, customized trays will be fabricated with 0.9-mm-thick vinyl acetate sheets using the thermoforming process. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the patients' mouth."
41110799|NCT05605834|OTHER|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray without reservoir.|Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9-mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
41110800|NCT03255096|DRUG|RO6870810|RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
41110801|NCT03255096|DRUG|Venetoclax|Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
41110802|NCT03255096|DRUG|Rituximab|Rituximab intravenously (IV) at dose of 375 mg/m\^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
40752448|NCT01851304|DIETARY_SUPPLEMENT|Satiety of breads|One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
41445881|NCT02826694|GENETIC|Diagnosed, whole exome sequencing|In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
41445882|NCT06093932|DRUG|Songling Xuemaikang Capsules|3 capsules at a time, three times a day, duration: 12 weeks
41445883|NCT06093932|BEHAVIORAL|Lifestyle intervention|everyday, duration: 12 weeks
41110803|NCT04507945|DRUG|Nutritional Therapy, Metabolic Disorder, Regular|According to the result reported by Byrne, Wilmore, etc. in 1992 \~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.
41110804|NCT00270803|DRUG|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
41110805|NCT05684042|OTHER|Data analysis: Accuracy measurement of the classifications of the distal radius fracture in the fracture database.|An expert panel (3 in-house experienced specialists) carries out a new fracture classification based on the anonymous radiological images in the interface of the REDCap fracture database. The degree of discrepancy between the expert panel and the database in fracture classifications is analyzed. By evaluating the extracted data, it is analyzed how valid the quality of the collected fracture classifications are, which the medical staff carry out in everyday clinical practice.
41445884|NCT06093932|DRUG|Placebo|3 capsules at a time, three times a day, duration: 12 weeks
41445885|NCT01860638|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
41110806|NCT02042898|OTHER|Restrictive Transfusion Strategy|
41110807|NCT02042898|OTHER|Liberal transfusion strategy|
41110808|NCT06332404|DEVICE|Hypoglossal nerve stimulation Inspire system (Inspire Medical Systems Inc., USA)|Hypoglossal nerve stimulation therapy
41110809|NCT00035841|DRUG|TLK286|
41445886|NCT01860638|DRUG|Lomustine|Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.
41445887|NCT01860638|DRUG|Placebo|Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
41445888|NCT01860638|RADIATION|Radiotherapy|Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
41445889|NCT01860638|DRUG|Temozolomide|Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
41445890|NCT01860638|DRUG|SOC Agent|The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
41445891|NCT05797207|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
41445892|NCT05797207|PROCEDURE|Colonoscopy|Colonoscopy procedure
41445893|NCT06258746|DRUG|[14C]HSK31679|A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.
41445894|NCT01977521|DEVICE|Eldith DC Stimulator stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.
41445895|NCT01977521|DEVICE|Eldith DC Stimulator sham stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
41445896|NCT05512650|DEVICE|Virtual Reality Meditation|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
40925665|NCT04316910|DRUG|General anesthetic|General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.
41110810|NCT00212784|DRUG|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
41445897|NCT05512650|DEVICE|Non-VR Meditation|Participants will engage and follow along with a 10-20 minute guided meditation on a computer screen placed before them. The meditation program may include simulated movement visuals, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
41445898|NCT04056338|OTHER|No intervention|No intervention.
41445899|NCT04964440|DEVICE|Pure-EP|Advanced Signal Acquisition and Processing
41445900|NCT01991548|DEVICE|MiniMed® 640G Insulin Pump and Guardian® Link Transmitter|
41110811|NCT00212784|DRUG|olanzapine|Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
41110812|NCT01061424|BEHAVIORAL|community health worker|community health worker provides home visits for education
41110813|NCT01061424|BEHAVIORAL|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
41110814|NCT00839241|DEVICE|Bellovac ABT|Bellovac ABT (autologous blood)
41445901|NCT00840879|DRUG|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fed
41445902|NCT00840879|DRUG|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fed
41445903|NCT00025935|DRUG|Lithium|
41445904|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
40925666|NCT01220544|BIOLOGICAL|Haploidentical transplantation with donor NK cells|Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain \> 8 x 10e6 CD34+ cells/kg and \< 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
41110815|NCT00839241|PROCEDURE|Allogenic Blood Transfusion|"Transfusion of allogenic (bank) blood."
41110816|NCT00405951|DRUG|Obatoclax mesylate 250 ml|
41110817|NCT00405951|DRUG|Docetaxel|
41445905|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
41445906|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
41110818|NCT06164327|DRUG|BEBT-908 for Injection|BEBT-908 for Injection,dosage of administration:15mg/m\^2 or 22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
41110819|NCT06164327|DRUG|Rituximab Injection|Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle.
41110820|NCT06164327|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
41110821|NCT06164327|DRUG|Oxaliplatin Injection|Oxaliplatin Injection，dosage of administration:100mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
41110822|NCT06164327|DRUG|Etoposide Injection|Etoposide Injection,dosage of administration:100mg/m\^2，frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle,and 21 days as a cycle.
41110823|NCT06164327|DRUG|Ifosfamide for Injection|Ifosfamide for Injection,dosage of administration:5000mg/m\^2,24 hours of continuous intravenous drip，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
41110824|NCT06164327|DRUG|Carboplatin Injection|Carboplatin Injection，dosage of administration:based on AUC=5, single dose ≤800 mg，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
41445907|NCT06210984|DRUG|Low caffeine dose|2 mg/kg dose of caffeine in pill form
41445908|NCT06210984|DRUG|Moderate caffeine dose|5 mg/kg dose of caffeine in pill form
41110825|NCT00232895|DRUG|lipuro propofol|
41110826|NCT00232895|DRUG|standard formulation propofol|
41110827|NCT03236064|DRUG|Polyethylene Glycols|Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
41110828|NCT03003637|DRUG|Nivolumab|Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
41110829|NCT03003637|DRUG|Ipilimumab|Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
41110830|NCT05608343|DRUG|Difamilast|Off-white ointment containing active ingredient, petrolatum and other ingredients
41445909|NCT06210984|DRUG|Placebo|5 mg/kg dose of maltodextrin in pill form
41445910|NCT03559569|BIOLOGICAL|Biological samples will be done to evaluate the endothelial and leukocyte senescence.|Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
41445911|NCT06571747|BEHAVIORAL|Cardiovascular-Focused Nudge Communication|Intervention arms will receive a behavioral economic rooted nudge communication highlighting the potential cardiovascular benefits of vaccination.
41445912|NCT04374630|DRUG|Paclitaxel|Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.
41110831|NCT05608343|DRUG|Placebo|Matching Difamilast (Study drug) ointment without active ingradient
41110832|NCT04617353|PROCEDURE|NO-based treatment of sterno-mediastinitis|"Preparation of a postoperative wound in case of infectious complications. A mandatory sampling material for culture and antibiotic sensitivity is collected before and after the air plasma flow treatment.~Direct effect of the air-plasma flow on the entire wound surface in sterilization mode with an exposure of 2-3 minutes for each surgical wound, until the level of bacterial contamination decreases to 10-5 and below.~The technique of using air-plasma flow when closing a wound after preventing infectious complications in it.~In the postoperative period, daily air-plasma flow treatment in sterilization mode along the suture line for 3 minutes. Penetrating drainage NO supply in the biological stimulation mode daily for 10 days, with an exposure of 1-2 minutes up to 10 days, with a volume of up to 2 liters per minute.~Collecting wound culture from the drainage containers on 1-3-7-12 days to detect pathogens and the bacterial number."
41110833|NCT04617353|PROCEDURE|Treatment of sterno-mediastinitis|patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage
41110834|NCT04634617|OTHER|Questionnaire Administration|Complete questionnaires
41110835|NCT04502511|DIAGNOSTIC_TEST|Standard diagnosis test|Care as usual
41110836|NCT02173444|OTHER|Blood test|
41110837|NCT04456218|DEVICE|NCKU-scope-01 (a custom-made biliary endoscope system)|The NCKU-scope-01 is a custom-made endoscope system for this study and it will be applied to help biliary disorders diagnosis
41110838|NCT01392313|DIETARY_SUPPLEMENT|Carnitine|Carnitine Ingestion
41110839|NCT01392313|DIETARY_SUPPLEMENT|Placebo|Carnitine placebo
41110840|NCT02329132|DRUG|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
41110841|NCT01607372|DRUG|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
41110842|NCT01607372|DEVICE|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
41110843|NCT01607372|OTHER|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
41445913|NCT04374630|DRUG|Afuresertib|"Each afuresertib 50 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 50 mg of afuresertib (free base).~Each afuresertib 75 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 75 mg of afuresertib (free base)"
40925667|NCT03381729|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
41110844|NCT05563246|DRUG|LY3473329|Administered orally
41110845|NCT05563246|DRUG|Placebo|Administered orally
41110846|NCT00657943|DRUG|metformin|metformin tablets 2 g x 2
41110847|NCT00657943|DRUG|insulin detemir|insulin as requested
41110848|NCT00657943|DRUG|insulin aspart + insulin aspart protamin|insulin as requested
41110849|NCT00657943|DRUG|Insulin aspart|insulin as requested
41110850|NCT02872753|BIOLOGICAL|ACP|Autologous Conditioned Plasma will be obtained directly in the operatory room from the peripheral venous blood of the patient, and injected intra-articularly at the end of arthroscopic meniscectomy
41110851|NCT02872753|OTHER|Standard Meniscectomy|Patients will receive standard arthroscopic meniscectomy
41110852|NCT01901510|DRUG|Chromoendoscopy (Indigo Carmine)|Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
41110853|NCT01901510|OTHER|Control|The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
41445914|NCT04168398|DRUG|Combination drug|Anticoagulation
41445915|NCT05245500|DRUG|MRTX1719|"MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days"
41110854|NCT01111526|DRUG|Panobinostat (LBH589)|"Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.~DL -1: 1.25 mg/m\^2 IV; DL 1: 2.5 mg/m\^2 IV; DL 2: 5 mg/m\^2 IV; DL 3: 7.5 mg/m\^2 IV; DL 4: 10 mg/m\^2 IV.~Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.~DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.~Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks."
41110855|NCT04300426|DRUG|"ACHIM as solute (10^9 intestinal microbes/ml)"|Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
41110856|NCT04747756|OTHER|Virtual Village|The purpose of this study is to create a virtual village for people aging with HIV, and to pilot test the virtual village intervention as a final step.
41110857|NCT00590707|DEVICE|Deeper sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.
41110858|NCT00590707|DEVICE|Moderate sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
41271136|NCT01133340|RADIATION|Radiation|No treatment intervention is planned. Patients will be scanned and treated as per department standards. The patient will have MRI at the time of their standard plan. They will then have clips inserted to mark the tumor after the standard scan is performed. The MRI and additional imaging with clips in place will be processed by 3 investigators who will contour based on the experimental image and compare this with the standard treated plan. Comparison of volumes in a blinded manner between investigators will also occur. The patients treatment will not be affected by the MRI or clip placement.
41271137|NCT01322906|OTHER|Group 1|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
40925668|NCT01215916|DRUG|LY573636|"Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid \[350 micrograms (µg) to 1000 µg orally, daily\], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone \[4 milligrams (mg) orally, twice daily or equivalent\]."
40925669|NCT01215916|DRUG|Pemetrexed|"375 to 500 milligrams per square meter (mg/m\^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent)."
40925670|NCT06055738|DRUG|Zimberelimab|240mg,d1,iv,Q21D
41110859|NCT03635294|OTHER|Blood sample|combining genomics, transcriptomics, metabolomics and morphological analyses performed on induced pluripotent stem cell (iPSC)-derived neural cells
41110860|NCT02105064|DEVICE|Active rTMS|rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
41110861|NCT02105064|DEVICE|SHAM rTMS|Sham rTMS, without brain stimulation
41110862|NCT05118581|DEVICE|ultrasound guided vascular access|Arterial or venous catheterization guided by ultrasound
41110863|NCT02086370|PROCEDURE|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
41110864|NCT02086370|PROCEDURE|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
41110865|NCT01712113|DRUG|Irbesartan|
41110866|NCT01712113|DRUG|Avapro|
41445916|NCT02173834|OTHER|18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan|
40925671|NCT06055738|DRUG|Albumin-bound Paclitaxel|260mg/m2,d1,iv,Q21D
40925672|NCT06055738|DRUG|Cisplatin|75mg/m2,d1,iv,Q21D
41110867|NCT05486260|DIETARY_SUPPLEMENT|DMB lowest dose|Intake of 150 mg of DMB
41110868|NCT05486260|DIETARY_SUPPLEMENT|DMB highest dose|Intake of 300 mg of DMB
41110869|NCT05486260|DIETARY_SUPPLEMENT|Strawberry lyophilisate|Intake of 300 mg of strawberry lyophilisate
41110870|NCT03689699|DRUG|Nivolumab|A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
41110871|NCT03689699|DRUG|Degarelix|Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
41271138|NCT01322906|OTHER|Group 2|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
41271139|NCT01322906|OTHER|Group 3|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
40925673|NCT04125264|DEVICE|Intense Therapeutic Ultrasound|Application of 1000 pulses, until 5000 joules (5 joules per pulse), during approximately 15 minutes, with the possibility of 5 minutes rest, depending on the tolerance of the patient.
40925674|NCT02842554|OTHER|EPT|
41110872|NCT03689699|DRUG|BMS-986253|BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
41110873|NCT06542133|DEVICE|AVEIR remote care system|In-clinic or an at-home system designed to support remote follow up in Aveir leadless pacemaker patients
41110874|NCT05739474|BIOLOGICAL|Influenza vaccine [inactivated]|solution for intramuscular injection, 1 dose (0.5 mL)
41110875|NCT05739474|BIOLOGICAL|Influenza vaccine [inactivated]|suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
41110876|NCT02914951|BEHAVIORAL|Cognitive-Behavioral Therapy|CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.
40925675|NCT02842554|DRUG|Drug Placebo Administration|
41110877|NCT02914951|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
41110878|NCT00920257|DRUG|GSK2141795|GSK2141795 is an oral AKT inhibitor.
41110879|NCT01568918|DRUG|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
41110880|NCT01568918|OTHER|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
40925676|NCT02842554|OTHER|C|No Intervention
41110881|NCT01235884|DIETARY_SUPPLEMENT|Lactobacillus reuteri|1000000000 CFU per day (5 drops) for 28 days
41110882|NCT01235884|DIETARY_SUPPLEMENT|Placebo|5 drops daily for 28 days
41110883|NCT05283616|DRUG|Pegfilgrastim|Pegfilgrastim 3mg per chemotherapy cycle
41110884|NCT05741996|BEHAVIORAL|Taping|Taping types and brace acute effects for knee osteoartritis
41110885|NCT01826695|OTHER|Neurodynamic technique group|"Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.~The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks."
41110886|NCT01826695|OTHER|Placebo group|Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
41110887|NCT05093478|DRUG|Intranasal capsaicin|Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.
41110888|NCT05093478|DRUG|topical lidocaine|The nose will be pre-treated with topical lidocaine 15 minutes before each application
41110889|NCT04557488|OTHER|Music therapy|Each session will follow a similar structure with a hello song, musical activities, and a goodbye song. The musical activities will vary in each session and will be mixed in later sessions to revisit and practice social skills
41110890|NCT04557488|BEHAVIORAL|Behavioral-based social skill training|Each intervention session will follow a standard structure of opening greetings, social activities according to the theme of the session, and a closing activity. The activities and games will vary in each session and will be mixed in later session to revisit and practice social skills.
41110891|NCT03016455|OTHER|Presence of DSA w/ cAMR|
41110892|NCT03016455|OTHER|Presence of DSA w/o cAMR|
41110893|NCT03016455|OTHER|No DSA No cAMR|
41110894|NCT02630719|DRUG|Timolol eye drops|eye drops
41110895|NCT02630719|DRUG|Artificial tears|Placebo drop
41110896|NCT00533013|OTHER|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
41110897|NCT00533013|OTHER|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
41110898|NCT05857436|OTHER|apical periodontitis|Of these patients, 60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study
41110899|NCT06513442|OTHER|Trabecular bone score software|To assess the clinical utility of trabecular bone score (TBS) on fracture risk prediction including the new version (TBS V4) and future TBS versions at the spine and hip.
41110900|NCT00079183|DRUG|sirolimus|Given PO
41110901|NCT02805439|DRUG|S47445 15mg|One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
41110902|NCT02805439|DRUG|S47445 50mg|One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
41110903|NCT02805439|DRUG|Placebo|One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
41110904|NCT03471611|DRUG|Autologous CD34+ Cells|The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min
41110905|NCT03471611|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5mg/kg twice daily
41110906|NCT05581654|PROCEDURE|Salpingectomy|Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
41110907|NCT05196438|OTHER|Collecting statistics about congenital heart patterns and investigations done and interventions done to them|Collecting statistics about congenital heart patterns and investigations done and treatment given or interventions e.g. catheterization or surgical operations done to them
41110908|NCT05383313|DRUG|Psilocybin|Effect of psilocybin on treatment-resistant depression
41110909|NCT05383313|DRUG|Ketamine Hydrochloride|Effect of ketamine on treatment-resistant depression
41110910|NCT05383313|DRUG|Midazolam Ph. Eur 9.0|Effect of midazolam on treatment-resistant depression
41110911|NCT00938535|BEHAVIORAL|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
41110912|NCT02491554|DEVICE|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
41445917|NCT02316223|BEHAVIORAL|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
41110913|NCT02491554|DEVICE|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
41445918|NCT01876992|DRUG|Metformin|
41445919|NCT05803135|DRUG|Iguratimod combined with Tofacitinib;|Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily); Placebo of Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily)
41445920|NCT06055686|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test|Electrical stimulation test measures sensory/motor responses
41110914|NCT04273412|BEHAVIORAL|moderate-intensity lifestyle intervention|standardized 12- week program and would be delivered in 4 sessions (2 individual, 2 telephonic). This lifestyle modification program is a combination of diet therapy (optimum calorie), increased daily physical activity and behavioral modification (self-monitoring, stimulus control, motivational interviewing)
41110915|NCT02110056|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
41110916|NCT02110056|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
41110917|NCT06175572|DEVICE|coronary physiological indices|coronary physiological indices
41110918|NCT05339763|RADIATION|chemoradiotherapy|exposure of patients with rectal cancer to radiotherapy and assessment of their bowel function after surgery
41110919|NCT06467253|DEVICE|1. rTMS + CS|"In the first phase each participant will receive 15 sessions of rTMS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of rTMS and 1 session of CS per week for 12 weeks. Each session will consist of 10 trains of 10 stimuli, at a 5-Hz frequency and a stimulation intensity of 120% of the resting motor threshold.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The rTMS condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS."
41110920|NCT06467253|DEVICE|2. rTMS Sham + CS|"In the first phase each participant will receive 15 sessions of rTMS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham rTMS and 1 session of CS per week for 12 weeks.~In total, each participant will receive 27 sessions of Sham rTMS and 21 sessions of CS.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The sham condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS."
41110921|NCT06467253|DEVICE|3. tDCS + CS|"In the first phase each participant will receive 15 sessions of tDCS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of tDCS and 1 session of CS per week for 12 weeks. Each session will consist of the delivery of a weak direct current of 2mA for 30 minutes.~tDCS will be administered by the Sooma tDCS stimulator. The tDCS condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of tCDS and 21 sessions of CS."
41110922|NCT06467253|DEVICE|4. tDCS Sham + CS|"In the first phase each participant will receive 15 sessions of tDCS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham tDCS and 1 session of CS per week for 12 weeks.~tDCS will be administered by the Sooma tDCS stimulator. The sham condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of Sham tDCS and 21 sessions of CS."
41110923|NCT06237868|DEVICE|rTMS Active|The participants undergo Active rTMS, approximately 10-15 min and then complete tasks and questionnaires.
41110924|NCT06237868|DEVICE|rTMS Sham|The participants undergo Sham rTMS, approximately 10-15 min and then complete tasks and questionnaires.
41110925|NCT02128607|DEVICE|SNAG|sustained natural apophyseal glide: SNAG / Mulligan technique
41110926|NCT02128607|DEVICE|Sham|
41110927|NCT04353830|DRUG|IBI939|Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
41110928|NCT04353830|DRUG|IBI939+ Sintilimab|"IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
41110929|NCT04353830|DRUG|IBI939+ Sintilimab|"IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
40752449|NCT01851304|DIETARY_SUPPLEMENT|Satiety of puddings|One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
41110930|NCT03141333|BEHAVIORAL|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
40752450|NCT03512886|OTHER|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
40752451|NCT03512886|OTHER|Single task training|An exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
40752452|NCT00625729|BIOLOGICAL|aldesleukin|Day 0-14, 10 million international units, 3 times per week for 6 doses
40752453|NCT00625729|BIOLOGICAL|allogeneic natural killer cells|Day 0 infusion of cells (1.5-8 x 10\^7 cells/kg).
40752454|NCT00625729|BIOLOGICAL|rituximab|Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m\^2
41110931|NCT00746330|DRUG|Mometasone furoate/formoterol fumarate (MFF)|Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
41110932|NCT00746330|DRUG|Formoterol fumarate 12 μg pMDI (F12M)|Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
41110933|NCT00746330|DRUG|Formoterol fumarate 12 μg DPI (F12D)|Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
41110934|NCT00746330|DRUG|Placebo to F12D|Placebo to formoterol fumarate DPI delivered via DPI
41110935|NCT00746330|DRUG|Placebo to F12M/MFF|Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
41110936|NCT04805073|DRUG|Promethazine|1cc 25mg/ml Promethazine (study medication)
41110937|NCT04805073|DRUG|Placebo|1cc 0.9% Sodium Chloride (placebo)
41110938|NCT00102063|DRUG|Aripiprazole tablet, 10 mg|Aripiprazole tablet 10 mg po qd x 42 days
41110939|NCT00102063|DRUG|Aripiprazole tablet, 30 mg|Aripiprazole tablet 30 mg po qd x 42 days
41110940|NCT00102063|DRUG|Placebo tablet|Placebo tablet po qd x 42 days
41110941|NCT06302491|DRUG|AND017 capsules|Administer AND017 capsules once per day (QD)
41110942|NCT06302491|DRUG|AND017 Placebo|Administer AND017 matching placebo capsules once per day (QD)
41110943|NCT06009120|OTHER|Education|The education program emphasized the characteristics of the oral stage, positive traits that can be acquired when the baby's needs are met during this stage, negative traits that may develop in the baby when their needs are not met, and the relationship between the oral stage and breastfeeding.
41110944|NCT00979563|DRUG|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
41110945|NCT01828320|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy|
41110946|NCT01828320|BEHAVIORAL|Psychoeducation|
41110947|NCT03201562|DRUG|Aceclidine+tropicamide combination|Ophthalmic Solution
41110948|NCT03201562|DRUG|Aceclidine|Ophthalmic Solution
41110949|NCT03201562|DRUG|Vehicle|Ophthalmic Solution
41110950|NCT03484585|DRUG|Rogaratinib (BAY1163877)|Single dose, intake orally, 200 mg
41110951|NCT05244486|DEVICE|RestoreX 1-6 months (randomized phase)|Study participants are recommended utilize the device for 30-60 minutes, 5-7 days a week starting at 1 month post-prostatectomy and continuing until 6 months.
41110952|NCT05244486|DEVICE|RestoreX 6-9 months (open label phase)|Both the treatment and control arms will be allowed to use the therapy from 6-9 months post-prostatectomy (open label phase). Only straight traction will be used (no counterbending).
41110953|NCT06555991|OTHER|SIRSI and TSK-SI|The SIRSI and TSK-SI as well as the WOSI and RTS-, Clinical- and Demographic Information are gathered. The SIRSI and TSK-SI are re-administered one week later
41110954|NCT03546907|DRUG|SAR440340|Pharmaceutical form: Solution for injection; Route of administration: SC
41110955|NCT03546907|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: SC
41110956|NCT03546907|DRUG|Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
41110957|NCT03546907|DRUG|Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
41110958|NCT03546907|DRUG|Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
41110959|NCT03546907|DRUG|Any short-acting β agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
41110960|NCT00293865|PROCEDURE|sentinel node|detection of the sentinel node in breast cancer
41110961|NCT00293865|PROCEDURE|GAS|
41110962|NCT03770507|OTHER|Exercise Training|Comparison of stationary bike and treadmill exercise among adolescents and adults
41445921|NCT06627829|DEVICE|Surgically facilitated orthodontics therapy (SFOT) using allograft|Participants will receive Surgically facilitated orthodontics therapy (SFOT) along with bone grafting using particulate allograft and collagen membrane, prior to orthodontics treatment.
41110963|NCT02987530|DRUG|Dolutegravir|Oral use, 50mg/day
41110964|NCT02987530|DRUG|Darunavir-cobicistat|Oral use, 800-150mg/day
41110965|NCT02987530|DRUG|Emtricitabine-Tenofovir|Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
41110966|NCT03599453|PROCEDURE|Biopsy|Undergo Biopsy
41110967|NCT03599453|PROCEDURE|Chemokine Modulation Therapy|Undergo chemokine modulation therapy
41110968|NCT03599453|DRUG|Celecoxib|Given by mouth
41110969|NCT03599453|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given intravenously
41110970|NCT03599453|DRUG|Rintatolimod|Given intravenously
41110971|NCT03599453|BIOLOGICAL|Pembrolizumab|Given intravenously
41110972|NCT04356612|OTHER|Chart Review|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
41110973|NCT00587925|OTHER|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
41110974|NCT06109831|DRUG|SHR-1918|SHR-1918
41110975|NCT06109831|DRUG|SHR-1918 placebo|SHR-1918 placebo
41110976|NCT01807663|DEVICE|healthy volonteers|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
41110977|NCT01807663|DEVICE|Free breath monitoring|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
41110978|NCT02894749|RADIATION|3D rotational angiography (3DRA)|3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
41110979|NCT05774717|DRUG|Tranexamic acid|1 gram IV (intravenous) tranexamic acid administered in the operating room just prior to starting the case (10 minutes), at time that routine preoperative antibiotic is given.
41110981|NCT00148369|DRUG|Safety observation|Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
41110982|NCT03731312|OTHER|No intervention|This is an observational study and no interventions will be administered.
41110983|NCT02644174|PROCEDURE|Bariatric Surgery|
41110984|NCT04533659|BEHAVIORAL|ADA-based nutrition education with digital self-monitoring|Diabetes nutrition education developed by the American Diabetes Association with digital self-monitoring for diet and physical activity
41110985|NCT04533659|BEHAVIORAL|Personalized Behavioral Nutrition (PBN) intervention group|Personalized behavioral nutrition intervention consisting of digital self-monitoring for diet and physical activity, personalized nutrition change goal and recommendation, and diabetes nutrition education developed by ADA
41110986|NCT00118066|DIETARY_SUPPLEMENT|calcitriol|Given orally
41110987|NCT00118066|PROCEDURE|observation|No initial intervention
41110988|NCT03922867|BEHAVIORAL|CBT|A web-based educational platform to deliver cognitive behavioral therapy (CBT) for insomnia
41110989|NCT00134511|DRUG|Torcetrapib/atorvastatin|
41110990|NCT02462551|DEVICE|Focal Electrically Administered Seizure Therapy|A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.
41110991|NCT02888808|OTHER|Gastroscopy|Upper gastrointestinal endoscopy procedure
41110992|NCT04800016|DEVICE|AcrySof IQ Vivity Extended Vision IOL|UV and blue-light filtering extended depth of focus foldable IOL intended to provide a full range of vision from distance to functional near.
41110993|NCT04800016|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ Vivity Extended Vision IOL
41110994|NCT02542852|DRUG|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
41110995|NCT00193518|DRUG|Arsenic Trioxide|
40925677|NCT04517357|DRUG|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
40752455|NCT00625729|DRUG|cyclophosphamide|60 mg/kg intravenous (IV) on Day -5.
40925678|NCT04517357|DRUG|Fluzoparib|Fluzoparib monotherapy
41110996|NCT04651244|DIAGNOSTIC_TEST|MRI|Gold standard for identifying inflammatory changes in patients with acute pyelonephritis
41110997|NCT04651244|DIAGNOSTIC_TEST|Ultrasound performed by a radiologist|US performed by a radiologist including standard grayscale evaluation of the kidneys, Doppler US and contrast enhanced US (CEUS).
41110998|NCT04651244|DIAGNOSTIC_TEST|Point of care ultrasound|Point of care US by a study assistant with basic ultrasound skills and training to access the presence or absence of hydronephrosis. If hydronephrosis is present it will be graded into one of four categories.
41110999|NCT04484402|BIOLOGICAL|mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution
41111000|NCT04484402|BIOLOGICAL|limbal stem cells|Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution
41111001|NCT04484402|OTHER|standard treatment|Standard treatment according to the Clinical protocols
41111002|NCT03305003|OTHER|Spiral notebook|
41111003|NCT03305003|OTHER|Mobile application|
41111004|NCT02777632|PROCEDURE|Living donor liver transplantation|
41111005|NCT01189513|DRUG|SCH 900105|10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
41111006|NCT05664880|DRUG|Paricalcitol|2 MCG Oral Capsule
41111007|NCT05664880|DRUG|Placebo|Matching capsule to 2 MCG Paricalcitol Oral Capsule
41111008|NCT00758433|DRUG|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
41111009|NCT00758433|DRUG|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
41111010|NCT00758433|DRUG|Placebo patch|Placebo patch q.d. 24 hours for 7 days
41111011|NCT00588666|DRUG|Bevacizumab|
41111012|NCT00588666|DRUG|Carboplatin|
41111013|NCT00588666|DRUG|Gemcitabine|
41111014|NCT02297880|OTHER|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners
41111015|NCT02297880|OTHER|Still water|Still water (no flavour)
41111016|NCT00000760|DRUG|Ro 24-7429|
41445922|NCT06627829|DEVICE|Surgically facilitated orthodontics therapy (SFOT) using xenograft|Participants will receive SFOT using particulate xenograft and collagen membrane, prior to orthodontics treatment.
41445923|NCT06627829|DEVICE|Usual care|Participants will have conventional orthodontics treatment with Invisalign aligners, without any surgical intervention
41445924|NCT05920447|DEVICE|LMA|Monitor the ventilatory parameter and incidence of complications
41111017|NCT00000760|DRUG|Zidovudine|
41111018|NCT00000760|DRUG|Didanosine|
41445925|NCT03690960|PROCEDURE|electrospun TAP nanofibers|electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material
41111019|NCT01787240|DRUG|Escitalopram 10mg|
41111020|NCT01787240|DRUG|Placebo|
41111021|NCT02785380|PROCEDURE|laparoscopic surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
40752456|NCT00625729|DRUG|fludarabine phosphate|Day -6 through day -2, 25 mg/m\^2 intravenous (IV)
40752457|NCT00930332|DRUG|methadone hydrochloride|"Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)"
40752458|NCT00930332|OTHER|questionnaire administration|within 48 hours of registration
40752459|NCT00930332|PROCEDURE|management of therapy complications|if required
41445926|NCT03690960|PROCEDURE|modified TAP paste|modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
41111022|NCT02785380|PROCEDURE|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
41111023|NCT04510454|DIAGNOSTIC_TEST|Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
41111024|NCT02587130|DRUG|Ketamine|ketamine administered in bolus by subcutaneous injection
40925679|NCT04517357|DRUG|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
40925680|NCT02009605|DRUG|Icotinib|125mg, oral administration, three times per day.
41111025|NCT01126307|DRUG|Verapamil|80 mg tid
41111026|NCT01126307|DRUG|placebo|placebo tid
41111027|NCT01523158|BIOLOGICAL|Allergovit grass or birch|subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
41111028|NCT02274493|DEVICE|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
41111029|NCT02274493|PROCEDURE|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
41111030|NCT02274493|PROCEDURE|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
41111031|NCT02274493|BEHAVIORAL|Questionnaires|Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.
41111032|NCT00190619|DRUG|Duloxetine|
41111033|NCT00190619|DRUG|Placebo|
41111034|NCT04431388|DEVICE|ultrasound device|We performe a differnt analgesic techniques to know if some of then are better
41111035|NCT04431388|DRUG|Levobupivacaine|using the same AL
41111036|NCT02847117|OTHER|Mastiha|The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
41111037|NCT01141322|DRUG|Ursodeoxycholic Acid|ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
41445927|NCT05825716|OTHER|Ifaa Basic|"* PSNP Systems: (1) Provision of food aid commodities (wheat, oil, and pulse) per the PSNP transfer schedule for 3-6 months; 2) Food System Taskforce (FSTF) capacity building, and 3) private sector engagement~* Health and Nutrition: 1) Government of Ethiopia (GoE) basic health extension program; 2) GoE supportive supervision coaching; 3) GoE-led community social behavior change (SBC) sessions; and 4) Community Management of Acute Malnutrition (CMAM) Programming.~* Water and Sanitation: 1) Water infrastructure development; 2) improved governance via water, sanitation and hygiene (WASH) committees; and 3) water source monitoring.~* Natural Resource Management: 1) Public works projects; 2) community training in planning and sustaining community assets; 3) Implementation of the environment and social management framework; 4) enhance participation of watershed committees"
41445928|NCT05825716|BEHAVIORAL|Ifaa Enhanced|"* PSNP Systems: 1) establishment and training of Community Technical Coordinating Forum; 2) Case management capacity building; and 3) private sector construction of infrastructure~* Health and Nutrition:1) the Care Group Model approach; 2) home garden promotion; 3) the nutrition budget calculator; and 4) labor and time-saving technologies.~* Community-level interventions are 1) adolescent nutrition school clubs; 2) religious leader mobilization and training vulnerable groups; 3) audio toolkit against harmful traditional practice; 4) enhanced SBC tools for health/nutrition promotion; 5) additional health extension programs~* Water and Sanitation: 1) Community Led Total Sanitation and Hygiene; 2) WASH systems assessments and strengthening; 3) Ensuring water quality and safety via routine monitoring; 4) Private sector engagement of WASH-related businesses;"
41445929|NCT05825716|OTHER|Ifaa Enhanced + Livelihoods|"* Additional resources provided to the groups, including 1) Engagement of Private Service Providers to enable access to sustainable credit and larger loans; 2) Financial Education using an expanded 'Smart Skills' curriculum focusing on savings, smart borrowing and effective financial management; and 3) Life Skills Training for Youth.~* Additional supports include: 1) Seven Steps of Marketing Training; 2) Climate Smart Agriculture to reduce water needs and increase soil health and vegetation coverage; 3) Producers Groups and linkages to markets/suppliers/buyers; Selected financial institutions will be provided with a credit guarantee fund and capacity-building support to help facilitate loans. Private sector value chain assessment and financing. Additional private sector engagement and linkage facilitation."
41111038|NCT01141322|DRUG|Placebo|The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
41111039|NCT05319288|DEVICE|Acupuncture|In DPOG, motion style acupuncture would be used; in LPMG, Traditional Chinese Medicine acupuncture is used.
41111040|NCT05754918|DEVICE|TnoFs then TFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without fine structure coding then with fine structure coding
41111041|NCT05754918|DEVICE|TFS then TnoFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with fine structure coding then without fine structure coding
41111042|NCT02847312|OTHER|High avenanthramide, phenolic acid|High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
41111043|NCT02847312|OTHER|Low avenanthramide, medium phenolic acid|Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
41111044|NCT02847312|OTHER|Control|Control are matched with energy and insoluable fibre.
41111045|NCT04940117|DIETARY_SUPPLEMENT|Eefooton oral solution|Check eGFR value, liver and kidney function every month
41111046|NCT00861458|DRUG|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
41271140|NCT05368090|PROCEDURE|EUS-RFA of left adrenal tumour in PA with AVS-verified left lateralisation|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
41111047|NCT03885817|BEHAVIORAL|Exercise training and nutritional guide|30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.
41111048|NCT03885817|OTHER|Standard follow-up care|standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.
41111049|NCT05943171|DEVICE|Cognitive Behavioral Therapy|All participants will receive Cognitive Behavioral Therapy. They will be randomized to either Digital RITch®CBT or Standard CBT
41111050|NCT03470142|PROCEDURE|traditional laparoscopy-assisted surgery|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
41111051|NCT03470142|PROCEDURE|total laparoscopic surgery with no incision (natural orifice transluminal endoscopic surgery, NOSES)|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice (anal).
41111052|NCT00043264|DRUG|Rifampin|
41111053|NCT00043264|DRUG|Azithromycin|
41111054|NCT05128019|BEHAVIORAL|ICIT|Patients in the intervention group will receive a number of consultations with their GP based on the ICIT
41111055|NCT04554082|PROCEDURE|laparoscopic sleeve gastrectomy|bariatric surgery to loss weight
41111056|NCT04120051|DIETARY_SUPPLEMENT|Fermented canola-seaweed|A daily sachet with 5 gram FCS-granulate for 6 weeks
41111057|NCT04120051|OTHER|Placebo|A daily sachet with 5 gram rye cereal for 6 weeks
41111058|NCT01802632|DRUG|AZD9291|Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
41111059|NCT05426057|BEHAVIORAL|eHealth Familias Unidas Mental Health|eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.
41111060|NCT00164333|BEHAVIORAL|TAP: Treatment Advocacy Program|
41111061|NCT05238194|OTHER|The Psychological Effects of The Covid-19 Pandemic Process|Investigation of The Psychological Effects of The Covid-19 Pandemic Process on The Health Staff Workıng in The Filation Team
41111062|NCT01807858|DIETARY_SUPPLEMENT|Bifidobacterium lactis|5 billion active Bifidobacterium lactis
41111063|NCT01807858|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus İnülin|5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given
41111064|NCT01807858|OTHER|Maltodextrin|Maltodextrin
41111065|NCT01807858|DIETARY_SUPPLEMENT|İnulin|900 mg inulin per day will be given
41111066|NCT06555757|OTHER|Height, weight, and BMI|Height, weight measurement and BMI calculation
41111067|NCT06555757|OTHER|Medical history|Brief medical history including medications/allergies and heart failure related healthcare utilisation over previous 12 months
41111068|NCT06555757|OTHER|Physical examination|Brief physical examination
41111069|NCT06555757|DIAGNOSTIC_TEST|Venous blood samples|Venous blood samples, to include WCC, HB, CRP and NTproBNP
41111070|NCT06555757|OTHER|Resting vital signs|HR, BP, RR, oxygen saturations on air)
41111071|NCT06555757|DIAGNOSTIC_TEST|Transthoracic echocardiogram|LVEF, IVC collapsibility, LV filling pressure, PA pressure
41111072|NCT06555757|OTHER|Sound recordings|Sound recordings (voice/cough/chest) recorded with the in-built microphone in a smartphone
41111073|NCT06555757|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound
41111074|NCT06555757|OTHER|KCCQ questionnaire|Kansas City Cardiomyopathy Questionnaire
41111075|NCT06555757|OTHER|ASCEND-HF score|An in-hospital congestion score which risk stratifies patients admitted with worsening heart failure, developed for the Acute study of clinical effectiveness of Nesiritide in decompensated heart failure trial
41111076|NCT06555757|OTHER|Composite Everest congestion score|A shortened version of the original 18-point score from the EVEREST trial
41111077|NCT06555757|DIAGNOSTIC_TEST|Bio impedance and total body water measurement|Bio impedance and total body water measurement using TANITA device
41111078|NCT04991233|PROCEDURE|Endoscopic surgery|The endoscopic surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
41111079|NCT04991233|PROCEDURE|Suboccipital craniotomy surgery|The suboccipital craniotomy surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
41111080|NCT05581745|PROCEDURE|Blood group A2 donor to blood group O recipient lung transplant surgery|Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant
41111081|NCT02485444|DRUG|Oxytocin|20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
41111082|NCT00269880|DRUG|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
41111083|NCT00269880|DRUG|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
41111084|NCT00269880|DRUG|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
41111085|NCT04201249|DRUG|Piroxicam, lidocaine|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
41111086|NCT04201249|DEVICE|Mesotherapy without drug administration|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
41445930|NCT02175095|DRUG|Regorafenib|Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
41111087|NCT04801836|DRUG|Estetrol monohydrate 15 mg|One Estetrol monohydrate (E4) 15 mg tablet once per day
41111088|NCT04801836|DRUG|Placebo|One placebo tablet once per day
41111089|NCT00765973|DRUG|Topotecan Liposomes Injection (TLI)|TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
41111090|NCT00765973|DRUG|Topotecan Liposomes Injection (TLI)|TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
41111091|NCT02884544|DRUG|HLD100|Treatment
41111092|NCT03109795|DRUG|Clonidine Pill|sympathetic nerve activity blockade
41111093|NCT03109795|DRUG|Hydrochlorothiazide|Blood pressure-lowering control condition
41111094|NCT01764451|DRUG|Simvastatin|
41111095|NCT04926571|DRUG|Dexamethasone Oral|New users of Dexamethasone
41111096|NCT00969371|DEVICE|posterior chamber IOL implantation|
41111097|NCT00969371|DEVICE|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
40925681|NCT00128323|DRUG|Gentian violet 1% solution|
40925682|NCT00128323|DRUG|Gentian violet 0.00165% solution|
40925683|NCT00128323|DRUG|Nystatin solution|
41111098|NCT03703037|DIAGNOSTIC_TEST|Ultrasound and Doppler ultrasound|Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.
41111099|NCT02393001|OTHER|Dermatology patients|Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.
41111100|NCT02393001|OTHER|Dermatology patients|Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.
41111101|NCT02393001|OTHER|Dermatology patients|This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.
41111102|NCT02393001|OTHER|Dermatology patients|Cleanse an area of unafflicted (control) skin with an alcohol swab.
41111103|NCT04952129|DRUG|Selenomethionine|Seleno-amino acid
41111104|NCT04952129|DRUG|Methylselenocysteine|Seleno-amino acid
41111105|NCT00662480|PROCEDURE|Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm|Invited to vascular screening
41111106|NCT05393336|OTHER|V-sitting posture stabilization|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the V-sitting exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
41111107|NCT05393336|OTHER|Modified clamshell exercises|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the modified clamshell exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
41111108|NCT02427633|OTHER|Educational Intervention UKRC 1997|Educational poster intervention indicating the modified UKRC 1997 recovery position
40752460|NCT02021604|DRUG|Fluorodopa F 18|A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
40752461|NCT02912520|DRUG|Anti-Bacterial Agents|administration of any antibiotic substance(s) over the course of 2 weeks
40752462|NCT00385229|DRUG|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
40752463|NCT03855371|DRUG|Decitabine|20mg/m2/d, intravenously, d1-d5, q4w
41111109|NCT02427633|OTHER|Educational Intervention UKRC 2010|Educational poster intervention indicating the modified UKRC 2010 recovery position
41111110|NCT02631148|DRUG|Melatonin|2mg controlled release melatonin tablet
41111111|NCT02631148|DRUG|Placebo|placebo tablet identical to circadin
41111112|NCT05452681|OTHER|Educational Intervention|Receive Y-AMBIENT
41111113|NCT05452681|OTHER|Quality-of-Life Assessment|Ancillary studies
41111114|NCT05452681|OTHER|Questionnaire Administration|Ancillary studies
41111115|NCT05452681|OTHER|Control Intervention|Receive cookbook and socialization calls
41111116|NCT03636867|OTHER|data and specimen collection|to identify laboratory, cellular and molecular determinants of clinical success after treatment, several clinical information and specimens will be collected by Authors from each patient
41111117|NCT00740415|BIOLOGICAL|rituximab|Rituximab, 375 mg/m2 Intraveinous
41111118|NCT00740415|DRUG|bortezomib|-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
41111119|NCT00740415|DRUG|dexamethasone|day - Dexamethasone, 40 mg Intraveinous
41111120|NCT00740415|DRUG|Bendamustine|-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
41111121|NCT03816124|PROCEDURE|radiofrequency ablation|radiofrequency ablation of the genicular nerves
41111122|NCT02033018|DRUG|Aflibercept Injection|Aflibercept intravitreal injection
41111123|NCT02984319|DIETARY_SUPPLEMENT|Cherry versus placebo concentrate|Acute cherry concentrate
41111124|NCT04628286|OTHER|Sham Laser|Sham Laser in plantar fascia
41111125|NCT04628286|OTHER|Myofascial Induction|Myofascial Induction in plantar fascia
41111126|NCT01474707|BEHAVIORAL|Group one|Group 1 will view the knowledge-based video only
41111127|NCT01474707|BEHAVIORAL|Group two|Group two will view the motivational video only
41111128|NCT01474707|BEHAVIORAL|Group three|Group three will view both knowledge-based and motivational videos
41111129|NCT01474707|BEHAVIORAL|Group four|Group four will view the printed educational pamphlet and will not view either video
41111130|NCT06216730|PROCEDURE|Endoscopic papillectomy|"patients undergoing endoscopic papillectomy will be included and treated according to the study algorithm.~* A papillary adenoma (abnormal tissue growth/ tumour at junction of bile duct \& intestines) will be removed completely by cutting \& removing abnormal tissue growth using a flexible tube containing a camera through the mouth.~* After the procedure you will be admitted in the hospital for at least 24 hours for observation,~* You will be asked to use medications which decrease acid production (PPIs- proton pump inhibitors) in stomach for 2 weeks to decrease the risk of bleeding."
41111131|NCT02347436|PROCEDURE|24-hr ambulatory blood pressure measurement|
41111132|NCT06072105|OTHER|Telemedicine visits|Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations
41111133|NCT06072105|OTHER|Multidisciplinary, personalized symptomatic treatment|Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
41111134|NCT00718406|DRUG|Metoprolol|
41111135|NCT00718406|DRUG|metoprolol plus morphine|
41111136|NCT02801071|DRUG|15g L-citrulline daily p.o.|
41111137|NCT02801071|DRUG|Placebo|
41111138|NCT03040661|PROCEDURE|Ablation for atrial fibrillation.|Ablation for atrial fibrillation.
41111139|NCT00028769|DRUG|bicalutamide|
41445931|NCT02175095|DIAGNOSTIC_TEST|[18F]FLT-PET|\[18F\]FLT-PET scans before and on 21st day from the administration of regorafenib.
41111140|NCT00028769|DRUG|estramustine|
41111141|NCT00028769|DRUG|etoposide|
41111142|NCT00028769|DRUG|flutamide|
41111143|NCT00028769|DRUG|goserelin|
41111144|NCT00028769|DRUG|leuprolide|
41111145|NCT00028769|DRUG|nilutamide|
41111146|NCT00028769|DRUG|paclitaxel|
41111147|NCT05790928|DEVICE|Lotrafilcon A spherical contact lenses|CE-marked silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia) in persons with minimal astigmatism that does not interfere with visual acuity
41111148|NCT06355388|DEVICE|Active tVNS|"As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus, and a 10-minute stimulation will be initiated with a pulse width of 200 μs, a frequency of 30 Hz, and an intensity of one mA lower than the patient's sensitivity threshold.~As fort he mid-term phase, a device will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session."
41445932|NCT02175095|DIAGNOSTIC_TEST|[18F]FDG-PET|\[18F\]FDG-PET will be performed before treatment and at 21 days after treatment.
41445933|NCT03007524|DRUG|High dose Rosuvastatin|20mg/d qN, at least 6 months
41111149|NCT06355388|DEVICE|Sham tVNS|"As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus for 10-minute but no current will be delivered.~As fort he mid-term phase, a device (configured to withhold power delivery) will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session."
41111150|NCT05692947|DEVICE|Core body temperature device|This study is to verify the claims of CORE™ body temperature system to estimate core body temperature from skin temperature and heart rate during exercise under varying environmental conditions. Subjects will ingest a temperature sensing pill and be outfitted with skin temperature sensors, a chest strap heart rate monitor, and the CORE and CaleraResearch devices. Athletes will run or cycle in hot/dry and hot/humid conditions for 45 minutes at an absolute workload of 60% VO2 Max/Peak.
41111151|NCT04704739|DRUG|GLPG1205 film-coated tablets|Single oral dose of GLPG1205
41111152|NCT04704739|DRUG|[14C]-GLPG1205 solution for infusion|A 15-minute IV infusion of \[14C\]-GLPG1205
41111153|NCT04704739|DRUG|GLPG1205 capsules|Single oral dose of GLPG1205 as solid formulation
41111154|NCT04097210|DIAGNOSTIC_TEST|POC|
41111155|NCT04795050|BEHAVIORAL|Project POWER|Diabetes health promotion/cardiovascular disease risk reduction educational curriculum
41445934|NCT03007524|DRUG|Low dose Rosuvastatin|10mg/d qN, at least 6 months
40752464|NCT03855371|DRUG|Arsenic Trioxide|0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
41111156|NCT03815396|DRUG|INBRX-101/rhAAT-Fc|INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).
41111157|NCT06409949|DIAGNOSTIC_TEST|Walking assessment|"Participating patients will undergo the following evaluations at baseline and after six months of treatment with MitoQ or placebo:~Assessment of walking impairment: Evaluation of treadmill maximum walking distances, six-minute walking distance, and daily physical activity (average steps taken daily)"
41111158|NCT06409949|OTHER|QOL Survey|Assessment of quality of life: Survey of Quality of life with the Walking Impairment Questionnaire and Short Form 36
41111159|NCT06409949|DIAGNOSTIC_TEST|Ankle pressure at rest and after stress|Assessment of leg hemodynamics: Evaluation of post-occlusive ankle pressure and ankle/brachial index
41111160|NCT06409949|DIAGNOSTIC_TEST|Muscle Oxygen|Evaluation of calf muscle heme oxygen saturation
41111161|NCT06409949|DIAGNOSTIC_TEST|Serum MitoQ Level|Evaluation of serum concentrations of MitoQ
41111162|NCT06409949|PROCEDURE|Needle Biopsy|Needle biopsy of the calf muscle
41111163|NCT01131624|DRUG|ferrous sulphate|200 mg iron per day in a convenient dosage schedule.
41111164|NCT01131624|DRUG|Ferinject|1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
40925684|NCT00005866|DRUG|busulfan|arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4
41111165|NCT04812951|DRUG|CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion|one cyclosporine 0.1% eye drop twice a day for 30 preoperative days
41111166|NCT04812951|DEVICE|cationorm eye drops|one cationorm eye drop twice a day for 30 preoperative days
41111167|NCT01293604|OTHER|Daily ingestion of whole grain barley and oats|Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
41111168|NCT04670159|BEHAVIORAL|Online Education|Online ergonomics, exercise and physical activity training will be provided 3 times a week for 6 weeks. The trainings it is planned to be made with a video-based online platform called Edpuzzle. With the online classroom created, the student education will be provided. A total of 18 training videos will be prepared, each video is 6-10 minutes. After the training there will be an individual motivational interview with the students in the this group with the zoom application. With motivational interview solutions by revealing the willingness, obstacles and indecision of the student to transfer the learned information to his daily life will be recommended.
41453307|NCT01350986|BEHAVIORAL|Non-Directive Self-Help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on Parent effectiveness training (Gordon, 1970) and Teaching children self-discipline at home and at school (Gordon, 1989)."
41111169|NCT04670159|BEHAVIORAL|Information With Brochure|An e-brochure will be prepared for students in this group to provide information on ergonomics, physical activity and exercise. and the e-brochure will be sent to the students via e-mail after the initial evaluation.
41111170|NCT05984784|DRUG|Placebo|Drug: Placebo Intravenous Infusion
41453308|NCT00064324|DRUG|perifosine|Given orally
41111171|NCT05984784|DRUG|IMG-007|Drug: IMG-007 Intravenous Infusion
41111172|NCT04408898|GENETIC|ADP-A2M4 in combination with pembrolizumab.|Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced cells by a single intravenous infusion Repeat doses of pembrolizumab every 3 weeks. Dose: 200mg
41111173|NCT03107403|BEHAVIORAL|web form|The scale assessing the bereavement process is the one reported in Teissier 2010
41111174|NCT06234644|OTHER|Standardized Walking Obstacle Course (SWOC)|The Standardized Walking Obstacle Course (SWOC) is a test that allows interaction of a child with environmental demands and obstructions while examining differences in functional ambulation performances. The Group A (experimental group) will receive the treatment with Standardized walking obstacle course (SWOC), the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of SWOC training and 5 minutes of cool down period.
41111175|NCT06234644|OTHER|Conventional Gait Training|Conventional gait training protocol including walking on a treadmill, parallel bar walk, seated marching. The Group B (Control group) will receive the treatment with conventional Gait training, the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of Conventional gait training and 5 minutes of cool down period.
41111176|NCT01522092|DRUG|escitalopram|5mg-20mg, tablet, od, 12 months
41111177|NCT01806454|DRUG|calcium|
41111178|NCT05572216|PROCEDURE|Robot assisted partial nephrectomy with 3D image guidance|patient have a partial nephrectomy for renal complex tumor
41111179|NCT01434134|DRUG|Metoprolol|Tablet, target dose 100 mg once daily
41111180|NCT01434134|DRUG|Placebo|Tablet, target dose 100 mg once daily
41111181|NCT01434134|DRUG|Candesartan|Tablet, target dose 32 mg once daily
41111182|NCT01434134|DRUG|Placebo|Tablet, 32 mg once daily
41111183|NCT00929617|BEHAVIORAL|Experimental 1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
41111184|NCT00929617|OTHER|Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
41111185|NCT02519699|DRUG|norepinephrine|Increase in mean arterial pressure using norepinephrine
41111186|NCT02227771|DEVICE|Percutaneous coronary intervention|
41111187|NCT02032329|DEVICE|FastFES|Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
41111188|NCT04109534|DIAGNOSTIC_TEST|Bronchial allergen provocation (BAP)|Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc... until the FEV1 decreases 20% below the initial FEV1-value
41111189|NCT04109534|DIAGNOSTIC_TEST|Nasal provocation test (NPT)|Dermatophagoides farina will be administered in both nostrils
41111190|NCT04109534|DIAGNOSTIC_TEST|Methacholine test|Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value
41111191|NCT04109534|DIAGNOSTIC_TEST|Peak nasal expiratory flow (PNIF)|Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
41111192|NCT05824442|BIOLOGICAL|Blood sample for multiplex QPCR technique|Blood sampling specifically for qPCR Echino at inclusion and one year after
41111193|NCT01124188|DRUG|Higher-dose venlafaxine|Dosing of venlafaxine will range from 187.5-300 mg/day.
41111194|NCT01124188|BEHAVIORAL|Supportive management|Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
41111195|NCT01124188|BEHAVIORAL|Problem Solving Therapy for Depression and Pain|PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
41111196|NCT05211544|OTHER|physical therapy modalities and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.
41453309|NCT00064324|OTHER|laboratory biomarker analysis|Correlative studies
41453310|NCT00064324|OTHER|pharmacological study|Correlative studies
41111197|NCT05211544|OTHER|kinesio taping and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week
41111198|NCT05211544|OTHER|exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
41111199|NCT01444235|DRUG|Custodiol-N|Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
41111200|NCT01444235|DRUG|Custodiol|Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
41111201|NCT02846480|OTHER|physical therapy|"Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.~Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises."
41111202|NCT02846480|OTHER|surgical treatment|Surgical correction of POP.
41111203|NCT02846480|OTHER|behavior therapy|At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
41453311|NCT02893163|BEHAVIORAL|CHANGE Intervention|Canadian Health Advanced by Nutrition and Graded Exercise Protocol
41453312|NCT02893163|OTHER|Usual Care|Usual Care by Family Doctor
41111204|NCT05831917|RADIATION|Radiotherapy|"Radiotherapy: All patients were treated with Unity MRI Linac intensity modulated radiation therapy, daily imaging of MRI-IGRT and online target delineation, redesign, and total radiation dose: GTV 70Gy/33f, GTVLN 70Gy/33f, CTV 60Gy/33f, CTVLN 54Gy/33f, 5 days per week. Dose limit: The average dose to the upper, middle, and lower pharyngeal constrictor muscles is ≤ 40-50Gy, with oropharyngeal cancer requiring an average dose to the upper, middle, and lower pharyngeal constrictor muscles to be ≤ 50Gy and ≤ 20Gy; Lower pharyngeal cancer requires an average dose of ≤ 40Gy for the upper and middle pharyngeal constrictor muscles, and ≤ 50Gy for the lower pharyngeal constrictor muscles.~chemotherapy: cisplatin 75mg/m2, 21 days per cycle, a total of 3 cycles."
41111205|NCT00703625|DRUG|Temsirolimus|
41111206|NCT00703625|DRUG|Docetaxel|
41111207|NCT02311907|DRUG|Carboplatin|Given IV, over 30 minutes per planned chemotherapy regimen
41111208|NCT02311907|DRUG|Glutathione|Given IV, over 15 minutes, immediately before chemotherapy administration
41111209|NCT02311907|OTHER|Laboratory Biomarker Analysis|Correlative studies
41111210|NCT02311907|DRUG|Paclitaxel|Given IV, over 1 or 3 hours, per planned chemotherapy regimen
41111211|NCT02311907|OTHER|Placebo|Given IV
41111212|NCT02311907|OTHER|Quality-of-Life Assessment|Ancillary studies
41111213|NCT00036036|DRUG|CP-461|
41111214|NCT01716858|DIETARY_SUPPLEMENT|Sulforaphane-rich Broccoli Sprout Extract|
41111215|NCT02008084|DRUG|TRIA-662|Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
41111216|NCT02008084|DRUG|Placebo|Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
41111217|NCT05056051|DEVICE|WATS-3D tissue sampling prior to forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells.
41111218|NCT05056051|DEVICE|WATS-3D tissue sampling following forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells. This will be done after forceps biopsies in this arm.
41111219|NCT00362869|DRUG|Levofloxacin|Administered at a dose of 500 mg once a day for 3 days
41111220|NCT00362869|DRUG|Placebo|Sodium bicarbonate solution
41111221|NCT00362869|BIOLOGICAL|Enteroaggregative E. coli (EAEC)|Dosages: 1X10\^9, 5X10\^9, 1X10\^10, and 5X10\^10 cfu; given in a sodium bicarbonate solution
41111222|NCT00486330|DRUG|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
41111223|NCT06554158|RADIATION|Radiation Therapy|De-escalation of Adjuvant Radiotherapy
41111224|NCT01550666|BEHAVIORAL|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
41111225|NCT06535958|BEHAVIORAL|OHI|All patients (test and control) will be instructed to brush the implants twice daily to remove supragingival biofilms with a low-abrasive dentifrice and to use specific cylindrical or conical brushes in the interproximal area. Patients will be indicated to brush under, around, and in the peri-implant crevice circumferentially. In those cases with no access for proper OHI, prosthesis will be modified.The interproximal brush device used will be chosen for the patient individually, according to the interproximal space available, the thicker brush that can be used comfortably will be the selected one. It will be previously tested on the patient and its use will be taught, patients should demonstrate proficiency
41111226|NCT06535958|PROCEDURE|OHI+PMPR|Supra- and sub-gingival debridement of the implant surface, the implant neck, and the abutment will be carried out by means of a combination of ultrasonics with a plastic tip and plastic curettes . Finally, the prosthetic components will be polished with a rubber cup
40752465|NCT04784780|DRUG|Elobixibat 10mg|Patients with chronic constipation are administered Elobixibat 10mg for 12 weeks
40752466|NCT04784780|DRUG|Placebo|Patients with chronic constipation are administered placebo for 12 weeks
41111227|NCT06313125|OTHER|3-dimensional foot-ankle extension exercises|In three-dimensional foot-ankle extension exercises, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
40925685|NCT00005866|DRUG|cyclophosphamide|arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
41111228|NCT06313125|OTHER|Clam exercise|In three-dimensional foot-ankle extension exercises and clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
41111229|NCT06313125|OTHER|Short-foot exercise|In clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
41111230|NCT06259669|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
41111231|NCT05956626|GENETIC|OCU410ST|Subretinal Administration of OCU410ST
41111232|NCT02965248|DRUG|Standard adjuvant systemic chemotherapy|"Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles."
41111233|NCT02965248|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed|Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.
41453313|NCT05281354|OTHER|Multimodal intervention|Treatment to normalise resting energy expenditure according to the observed abnormalities such as anti-inflammatory treatment with Omega 3 in the case of systemic inflammation, treatment with a non-specific beta-blocker such as propanolol in the case of activation of the beta-adrenergic system, appropriate physical activity in the case of sarcopenia, or nutritional support aimed at re-establishing the balance of calorie and protein intake and expenditure, or a combination of these actions
40925686|NCT00005866|DRUG|cyclosporine|both arms per published schedule
40925687|NCT00005866|DRUG|methotrexate|GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
40925688|NCT00005866|PROCEDURE|allogeneic bone marrow transplantation|day 0
40925689|NCT00005866|RADIATION|radiation therapy|both arms: 1200 cGy total dose (6 x 200 fractions)
40925690|NCT00280111|BIOLOGICAL|116E AGMK|Single dose of 116E 10\^5 FFu
41111234|NCT02965248|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin|Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.
41111235|NCT00001384|DRUG|Adriamycin|
41111236|NCT00001384|DRUG|cyclophosphamide|
41111237|NCT00001384|DRUG|G-CSF|
41111238|NCT00001384|DRUG|paclitaxel|
41111239|NCT06376357|OTHER|Foot Massage with roller|The intervention group is expected to apply roller massage to the soles of both feet in a sitting position on a chair (8 hours apart at 08.00, 16.00, 24.00 hours) every day for 6 weeks, 3x5 minutes a day. Video recording will be used as a reminder in the application.
41111240|NCT03201224|DEVICE|"After Group"|
41111241|NCT00666094|BEHAVIORAL|Endurance training|supervised endurance training. Three sessions per week in three months.
41111242|NCT00666094|BEHAVIORAL|strength training|Supervised strength training. Three sessions per week in three months.
41111243|NCT01490086|DRUG|RP5063|daily
41111244|NCT01490086|DRUG|placebo|daily
41111245|NCT01490086|DRUG|RP5063|daily
41111246|NCT01490086|DRUG|RP5063|daily
41111247|NCT01490086|DRUG|aripiprazole|daily
41111248|NCT04215406|OTHER|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.
40752467|NCT04858529|DRUG|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)
41111249|NCT03760419|BEHAVIORAL|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
41111250|NCT06297070|BEHAVIORAL|Whole Health Lifestyle Care for Reproductive Well-being pilot program|The program consists of an individual Integrative Health and Medicine (IHM) consultation with a CWH IHM provider, 4 Shared Medical Appointments (SMA), and 4 individual Health and Wellness Coaching (HWC) sessions. The SMA sessions occur at the UH CWH Beachwood office conference and movement rooms. The HWC sessions are virtual. The consultations are either virtual or in person at UH CWH Beachwood.
41111251|NCT05097924|OTHER|NAN Supreme HypoAllergenic Starter Infant Formula in ready-to-feed format|Post-market observational study with formula feeding administered via standard of care
41111252|NCT06028984|DEVICE|Intervention app|An app-based intervention for depression
40752468|NCT04858529|DRUG|investigator-selected taxane/trastuzumab/pertuzumab (THP)|investigator-selected taxane/trastuzumab/pertuzumab (THP)
40752469|NCT03656575|BIOLOGICAL|synovial fluid biomarker concentrations|Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
40752470|NCT04682964|DRUG|Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.|Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.
41111253|NCT06028984|OTHER|Control app|An app with non-therapeutic content
41111254|NCT05543915|DEVICE|Active tDCS|The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.
41111255|NCT00153309|BEHAVIORAL|People with Arthritis Can Exercise|
41111256|NCT01125761|DRUG|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
41111257|NCT01125761|DRUG|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
41111258|NCT05763290|OTHER|Affective Response to Exercise|Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.
41111259|NCT00664430|DRUG|Calcitriol|Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
40752471|NCT04626778|DRUG|Peroxyl Mouthwash|Mouthwash
40752472|NCT04626778|DRUG|Placebo Mouthwash|Mouthwash
40925691|NCT00280111|DRUG|I321|Single dose of I321 10\^5 FFu
41111260|NCT00664430|DRUG|Paricalcitol|Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
41111261|NCT02202499|DRUG|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
41111262|NCT02202499|OTHER|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
41111263|NCT02202499|OTHER|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
41111264|NCT02957981|BEHAVIORAL|Web-based Counseling|The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
41111265|NCT02957981|BEHAVIORAL|Standard Care|Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
41111266|NCT04668391|PROCEDURE|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament|Bilateral single-injection 20 ml 0.56% ropivacaine. Intravenous analgesia was started postoperatively and consisted of 1ug/ml sufentanil，2 ml/h with a 5-minute lockout period, a limited 12 ml/h dose.
41111267|NCT04668391|PROCEDURE|Thoracic epidural analgesia|A thoracic epidural at the level of T7-10. Epidural infusion was started postoperatively and consisted of sufentanil (0.6ug/mL) and ropivacaine（0.2%） at 3ml/h.
41453314|NCT06430632|DEVICE|Robotic Gait Training|Participants will complete standing and walking activities while wearing a robotic exoskeleton. Participants will also be asked to complete questionnaires about their walking and function.
41111268|NCT01629186|OTHER|NPO with Nose-close and Abdomen-compression|Infants with body weight (BW) \<5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) \<80 beats/min or oxygen saturation (SpO2) \<85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
41445935|NCT06187142|BEHAVIORAL|Initial phase: Personalized Chat Support (PCS)|Participants will receive three months of personalized chat support through WeChat. A total of 24 pre-set messages will be sent with the schedule of 3 times a week for 2 weeks, twice a week for the next 8 weeks and once a week for the last 2 weeks. These messages cover generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and hazards of smoking for chronic diseases experienced by different participants. Counsellors will respond to the participants' messages instantly. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PCS (subgroup PCS-1). Incomplete responders (smokers) will be randomly assigned to continue PCS (subgroup PCS-2) or receive PCS and MOS (subgroup PCS-3).
40925692|NCT00280111|DRUG|Placebo|1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
40925693|NCT02350751|DRUG|MEDI8852|
40925694|NCT02350751|DRUG|Placebo|
40925695|NCT05832554|DEVICE|nasal airway|nasopharyngeal airway
40925696|NCT05832554|DEVICE|oral airway|oropharyngeal airway
40925697|NCT04631094|OTHER|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the serrated ball during the blood draw.
41111269|NCT01911169|DRUG|Cholecalciferol|5,000 International units versus 400 international units as an active comparator
41111270|NCT05618236|DRUG|Group N; neostigmine+atropine|"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."
41111271|NCT05618236|DRUG|GROUP S; decurarized with sugammadex.|"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."
41111272|NCT02616861|DRUG|IW-1973|IW-1973 Tablet
41111273|NCT02616861|DRUG|Matching Placebo Tablet|Matching placebo tablet
41111274|NCT00332644|DRUG|nicotine patch|used according to FDA package label
41111275|NCT00332644|DRUG|nicotine lozenge|used according to FDA-approved package directions
41111276|NCT00332644|DRUG|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
41111277|NCT00332644|DRUG|bupropion|dosage according to FDA-approved instructions
41111278|NCT00332644|DRUG|bupropion + lozenge|dosage according to FDA approved standard instructions
41111279|NCT00332644|DRUG|placebo|dosage same as active drug conditions
41111280|NCT01148719|OTHER|Index group|Diagnostic triage strategy includes; electrocardiography, echocardiography, spirometry and blood testing
41111281|NCT05250895|OTHER|18F-Fluoromisonidazole|Given IV
41111282|NCT05250895|PROCEDURE|Biopsy|Undergo biopsy
41111283|NCT05250895|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
41111284|NCT05250895|PROCEDURE|Positron Emission Tomography|Undergo PET
41111285|NCT06554912|PROCEDURE|Lymphatic Decompression|"Patients will be prepared according to standard procedures Clinical examinations, para-clinical assessment and biological tests Patient will be set in angiography room and local anesthesia at the puncture area (femoral vein or brachial vein).~Obtain access to the femoral vein per standard procedures (option for brachial access depending on anatomy based on pre-operative CT, per physician discretion) After setting introducer sheath, catheterism of cardiac cavity will be performed for assess the following standard hemodynamic measures Catheterism of thoracic duct through the subclavian vein will be performed under fluoro guidance and phlebography using contrast Measure TD and central venous pressures Deploy stent under fluoro guidance Standard vascular stent deployed in subclavian vein and into lymphovenous junction Evaluate the procedure with standard phlebography and hemodynamic measures Remove catheters, and temporary compression as standard venous procedures"
41111286|NCT06375668|DIETARY_SUPPLEMENT|Probiotic|The patients who give their consent to take part in this study, will receive one time per day for a period of 12 month a capsule containing ten billions of Lactobacillus plantarum (LP 140 NORDBIOTIC™) and Lactobacillus paracasei (LPC 100 NORDBIOTIC™).
41111287|NCT06375668|OTHER|Placebo|The patients who give their consent to take part in this study, will receive one time per day for a period of 12 months a capsule containing maltodextrin.
41111288|NCT06030713|DRUG|Cefazolin|Cord clamping before or after antibiotic (cefazolin) prophylaxis
41111289|NCT01883908|DEVICE|Acupuncture with Seirin® needles|Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
41111290|NCT01883908|OTHER|Usual medical care|usual medical care such as viscous Lidocaine for relief of pain
41111291|NCT00774436|PROCEDURE|focal cryotherapy|Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
41111292|NCT04689425|DRUG|Umbilical cord blood mononuclear cell gel（MNC）|Local wound treatment by combination of PRP and MNC, once;
41111293|NCT04689425|DRUG|The platelet rich plasma（PRP）|Local wound treatment by PRP alone, once.
41111294|NCT05674357|BEHAVIORAL|Individualized Evidence-Based Therapy in Cancer (Patients)|"The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient and referring problem.~* Cognitive Behavioral Therapy (CBT)~* Acceptance Commitment Therapy (ACT)~* Mindfulness-Based Cognitive Therapy (MBCT)~* Mindfulness-Based Stress Reduction (MBSR)~* Meaning-Centered Psychotherapy (MCP)~* Cognitive Behavioral Therapy for Insomnia (CBT-I)~* CBT for pain~* CBT for fatigue~* CBT for nausea"
41111295|NCT05674357|BEHAVIORAL|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|Enrolled therapist participants will receive training in evidence-based therapies and deliver therapy to patient participants.
41441058|NCT04925453|COMBINATION_PRODUCT|active tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
41445936|NCT06187142|BEHAVIORAL|Second phase: Multi-component Optional Support (MOS)|For incomplete responders (subgroup PCS-3) randomized to MOS, the available intervention options include phone counseling, family/peer support group and financial incentive for nicotine replacement therapy. Participants will be guided by cessation counsellors at 1-month follow-up to choose any combination of MOS based on their prefer choice or combination of MOS. If MOS participants cannot be followed up at 1-month, they will continue PCS by default.
41453315|NCT06430632|OTHER|Usual Care Gait Training|Participants will complete standing and walking activities such as body weight-supported treadmill training and conventional overground walking. Participants will also be asked to complete questionnaires about their walking and function.
41453316|NCT00893945|DRUG|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
41111296|NCT04455516|PROCEDURE|Meniscus repair; partial meniscectomy|69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.
41111297|NCT04215471|DRUG|PD-L1 Antibody SHR-1316|Neoadjuvant therapy with immunoreagent (PD-L1 antibody SHR-1316) for resectable oesophageal squamous cell carcinoma
41111298|NCT01157182|DRUG|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
41111299|NCT01157182|DRUG|Activella®|1/0.5 mg Tablets
41111300|NCT04448158|DIAGNOSTIC_TEST|Genotypic Resistance Test|"A Genotypic Resistance Test by Sanger sequencing will be done after the period of virological suppression.~* If M184V is still present no additional test will be performed.~* If M184V is absent, we will go back in the previous samples (one per year) to determine the time point where the mutation has been cleared by sanger and UDS sequencing."
41111301|NCT00867191|DRUG|Placebo|Placebo, 1 tablet daily, per os., 15 days
41111302|NCT00867191|DRUG|Desloratadine|Desloratadine, one 5 mg tablet daily, per os, 15 days
41111303|NCT01305733|DRUG|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
41111304|NCT01305733|OTHER|saline injection|saline
41111305|NCT00809120|DEVICE|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
41111306|NCT03336450|DRUG|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
41111307|NCT03336450|DRUG|MHOS/SHP615|MHOS/SHP615
41111308|NCT00492791|DEVICE|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
41111309|NCT03506646|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
41111310|NCT00349583|DRUG|Topical Cyclosporine, Tears|
41111311|NCT05853978|DRUG|BSS Plus|BSS PLUS® Sterile Intraocular Irrigating Solution (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)
41111312|NCT05853978|DRUG|BSS|BSS® Sterile Irrigating Solution (balanced salt solution)
41111313|NCT00281996|DRUG|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
41111314|NCT00281996|DRUG|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
41111315|NCT05561452|OTHER|Single PRP Injection|"In single-PRP injection group, 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
41453317|NCT00893945|DRUG|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
40752473|NCT04129801|OTHER|Isokinetic Dynamometer|Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.
40925698|NCT04631094|OTHER|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the serrated ball during the blood draw.
41445937|NCT06187142|BEHAVIORAL|Initial phase: Group Chat Support (GCS)|Participant will receive three months of group chat support through WeChat. In this group, participants can send 'No Smoking' and the smart quit-smoking assistant will record it. A smoking cessation clinic doctor in the group will respond to participants' questions about smoking cessation. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive GCS (subgroup GCS-1). Incomplete responders (smokers) will be randomly assigned to continue GCS (subgroup GCS-2) or receive GCS and PCS (subgroup GCS-3).
41445938|NCT06187142|BEHAVIORAL|Second phase: Personalized Chat Support (PCS)|For incomplete responders (subgroup GCS-3) randomized to PCS, participants will receive the same intervention as Group PCS delivered at the initial stage. Participants will receive two months of personalized messages through WeChat. Please refer to Intervention Group 'Initial phase: Personalized Chat Support (PCS) for details.
41445939|NCT06187142|BEHAVIORAL|5A's / 5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
41445940|NCT06187142|BEHAVIORAL|health warning leaflet|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
41445941|NCT06187142|BEHAVIORAL|Self-help booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
41445942|NCT03612960|DRUG|Very low nicotine content cigarettes|Very low nicotine content cigarettes
41445943|NCT03612960|DRUG|Normal nicotine content cigarettes|Normal nicotine content cigarettes
41445944|NCT02559843|DIETARY_SUPPLEMENT|pomegranate juice|
41445945|NCT02559843|BEHAVIORAL|lifestyle modification|
41445946|NCT06559644|BIOLOGICAL|Hema-NeoTIL01|Patients will receive intravenous infusion of Hema-NeoTIL01, which is a highly specific tumor infiltrating lymphocyte (TIL) product derived from patients' bone marrow or peripheral blood, expanded ex vivo through antigen presentation.
41445947|NCT00431041|DRUG|solifenacin|Oral
41445948|NCT00431041|DRUG|oxybutynin immediate release|Oral
41445949|NCT01957059|DRUG|Regimen Selection Phase Group 2|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg"
41445950|NCT01957059|DRUG|Regimen Selection Phase Group 3|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg"
41445951|NCT01957059|DRUG|Treatment Phase Group 4|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
41445952|NCT01957059|DRUG|Regimen Selection Phase Group 1 (COMPLETED)|All doses of BMN053 have been administered as subcutaneous injections.
41445953|NCT01957059|DRUG|Dosing Extension|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
41445954|NCT05387603|DRUG|177Lu-DOTATOC|"The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing."
41445955|NCT05387603|DRUG|Capecitabine|Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
41445956|NCT02011945|DRUG|Dasatinib|
41445957|NCT02011945|DRUG|Nivolumab|
41445958|NCT03797248|COMBINATION_PRODUCT|Chinese herbal medicine|All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
41445959|NCT01539239|DEVICE|Hydrus Aqueous Implant|The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
41445960|NCT01539239|PROCEDURE|Cataract surgery|A monofocal intraocular lens (IOL) placed during the cataract surgery.
41445961|NCT02588781|DRUG|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
41445962|NCT05387408|BEHAVIORAL|Best Practice Health and Employment Opioid-related Policies|The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
41445963|NCT05594095|DRUG|PIK3CA inhibitor|PIK3CA inhibitor
41445964|NCT05594095|DRUG|AKT inhibitor|AKT inhibitor
41445965|NCT05594095|DRUG|Carrelizumab|Pd-1 mab
41445966|NCT05594095|DRUG|Famitinib|VEGFR inhibitor
41445967|NCT05594095|DRUG|Fluzoparib|PARP inhibitor
41445968|NCT05594095|DRUG|Dalpiciclib|CDK4/6 inhibitor
41445969|NCT05594095|DRUG|SHR-A1811|HER2 ADC
41445970|NCT05594095|DRUG|Everolimus|mTOR inhibior
41445971|NCT05594095|DRUG|Aromatase Inhibitors or Fulvestrant|Letrozole/Anastrozole/Exemestane or Fulvestrant
41445972|NCT05594095|DRUG|Goserelin|For premenopause
41445973|NCT05594095|DRUG|TPC|Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
40925699|NCT04631094|OTHER|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the smooth ball during the blood draw.
41111316|NCT05561452|OTHER|Multiple PRP Injections|"In multiple-PRP injection group, two PRP injections will be performed with an interval of 3 weeks. 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained is planned to be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
40925700|NCT04631094|OTHER|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the smooth ball during the blood draw.
40925701|NCT01890720|DEVICE|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
41111317|NCT05561452|OTHER|Placebo Injection|"In placebo-injection group,10 ml of venous blood will be taken and after the same waiting time 4 ml of 0.9% saline will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
41133464|NCT02099188|RADIATION|Radiotherapy - Patients not needing ENI|"1. Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
40752474|NCT04129801|OTHER|Bioimpedance|Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
40752475|NCT03854981|BEHAVIORAL|Exercise|Subjects will be asked to exercise 5 days/week in addition to receiving standard care before bariatric surgery.
40752476|NCT03854981|PROCEDURE|Standard Care|Standard preoperative care of bariatric surgery
40925702|NCT01890720|OTHER|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
40925703|NCT01038869|DRUG|Azelaic acid|Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
40752477|NCT00370136|DRUG|ultrasound contrast|
40752478|NCT00156130|RADIATION|Conventional radiotherapy schedule|50 Gy in 25 fractions over 35 days
40925704|NCT00918996|PROCEDURE|Omission of Bladder Flap Creation|Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
40925705|NCT00645255|DRUG|placebo|placebo one capsule daily
41111318|NCT04051255|DRUG|full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
41111319|NCT05480358|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet ProlonADTM|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
41111320|NCT00298597|DRUG|granulocyte - colony stimulating factor (G-CSF)|
41111321|NCT00298597|DRUG|erythropoetin (EPO)|
41111322|NCT01663519|OTHER|Custom made insoles 35 shore|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
41111323|NCT01663519|OTHER|Prefabricated insoles|Prefabricated insoles
41111324|NCT01663519|OTHER|55 shore Custom made insole|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
41111325|NCT05975983|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
40925706|NCT00645255|DRUG|sibutramine or placebo|one capsule daily
40925707|NCT00686634|DRUG|Sitagliptin|Sitagliptin 100 mg by mouth once daily
41445974|NCT05594095|DRUG|Sorafenib|RTK Inhibitor
40925708|NCT04138979|DRUG|cyclophosphamide|First use of chemotherapy after breast cancer
40925709|NCT03154229|OTHER|Smartphone-based decision-support|WHO guidelines have been adapted from paper onto a smartphone referred to as a Rehydration Calculator
40925710|NCT03154229|OTHER|Paper-based decision-support|WHO guidelines presented on paper
40925711|NCT03154229|OTHER|Pre-Assessment of practices|Observation of baseline clinical practice.
41111326|NCT05975983|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
41111327|NCT00967512|DRUG|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
41111328|NCT00967512|DRUG|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
41111329|NCT00967512|DRUG|idarubicin, cytarabine|idarubicin, cytarabine
41111330|NCT04911439|OTHER|Low Arousal|This group will see affective images of the International Affective Picture System with low arousal level
41111331|NCT04911439|OTHER|Medium arousal|This group will see affective images of the International Affective Picture System with medium arousal level
41445975|NCT05594095|DRUG|Apatinib|Apatinib 250mg po qd
41445976|NCT05594095|DRUG|SHR-A1921|TROP2 ADC
41445977|NCT05594095|DRUG|SHR-A2102|NECTIN4 ADC
41445978|NCT05594095|DRUG|SHR-A2009|HER3 ADC
41445979|NCT05594095|DRUG|SHR-1167|PARP1i
41445980|NCT05594095|DRUG|SHR-6209|CDK4i
41445981|NCT05594095|DRUG|bevacizumab|bevacizumab
41445982|NCT01023334|PROCEDURE|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
41445983|NCT01023334|PROCEDURE|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
41445984|NCT06561607|DRUG|TQB2102 for Injection|TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.
41445985|NCT06561607|DRUG|Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)|"Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs for treatment.~* Capecitabine: 1000-1250 mg/m2 twice daily, administered consecutively on day 1-14, 21 days as a treatment cycle.~* Paclitaxel: 175 mg/m2, IV infusion, administered Day1 per cycle, 21 days as a treatment cycle. OR 80 mg/m2 by IV infusion administered weekly.~* Albumin Paclitaxel: 260 mg/m2, IV infusion, administered every cycle of Day1 for 21 days as a treatment cycle. 100 mg/m2 or 125 mg/m2, IV infusion, administered every cycle of Day 1 and Day 8 for 21 days as a treatment cycle; or Day 1, Day 8, and Day 15 administered every cycle for 28 days as a treatment cycle."
41445986|NCT03469401|OTHER|Intervention|Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
41445987|NCT04924075|DRUG|Belzutifan|Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
41445988|NCT05238428|BEHAVIORAL|Trust boost|The investigators adapt the wording of the vaccination invitation to foster trust and increase vaccination acceptance.
41445989|NCT04292548|DIAGNOSTIC_TEST|taking saliva samples to determine TAS, TOS and LL-37|
41445990|NCT05826119|DRUG|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
41445991|NCT05826119|DRUG|Placebo|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
40752479|NCT00156130|RADIATION|Accelarated radiotherapy schedule|42.5 Gy in 16 fractions over 22 days
40925712|NCT01337999|OTHER|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
41111332|NCT04911439|OTHER|High arousal|This group will see affective images of the International Affective Picture System with high arousal level
41111333|NCT05499351|BIOLOGICAL|Adult group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
41111334|NCT05499351|BIOLOGICAL|Elderly group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
41111335|NCT05499351|BIOLOGICAL|Adult group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
41111336|NCT05499351|BIOLOGICAL|Elderly group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
41111337|NCT04574635|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41111338|NCT00092937|DRUG|Busulfan|
41111339|NCT00002555|DRUG|cisplatin|
41111340|NCT00002555|RADIATION|low-LET cobalt-60 gamma ray therapy|
41111341|NCT00002555|RADIATION|low-LET electron therapy|
41111342|NCT00002555|RADIATION|low-LET photon therapy|
40752480|NCT02217553|DRUG|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
40925713|NCT04872270|PROCEDURE|Total Shoulder Arthroplasty|Participant will have total shoulder replacement
40925714|NCT04872270|DRUG|Caffeine Pill|2 week supply of 1000 mg caffeine given postoperatively as part of the pain regimen
41111343|NCT02073123|DRUG|Indoximod|"Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~* If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~* If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~* If \> 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~* If \>1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If \>1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1"
41111344|NCT02073123|DRUG|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
41111345|NCT02073123|DRUG|Nivolumab|Nivolumab administered intravenously at 240 mg every 2 weeks.
41111346|NCT02073123|DRUG|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
40752481|NCT02325453|PROCEDURE|Robotic Surgery|Surgical procedure performed with a robotic system.
40752482|NCT02325453|PROCEDURE|Laparoscopic Surgery|Surgical procedure performed with laparoscopic techniques.
40752483|NCT02325453|PROCEDURE|Open Surgery|Traditional approach for gastric cancer.
40925715|NCT04872270|DRUG|Percocet 10Mg-325Mg Tablet|given postoperatively as standard post-op pain management
40752484|NCT06391515|DIAGNOSTIC_TEST|Blood sample, CRF, thyroid ultrasound|Five visits were planned: at diagnosis (V0) and after 1, 3, 6 and 12 months (V1, V2, V3 and V4, respectively). At each visit, subjects were evaluated with anamnesis, physical examination, thyroid US and blood tests.
40752485|NCT00377806|DRUG|Diclofenac gel|
40752486|NCT02182453|DRUG|BI 10773 - single rising dose|
40752487|NCT02182453|DRUG|Placebo|
40752488|NCT00354211|DEVICE|minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)|
40752489|NCT06156267|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody.
41111347|NCT02835768|OTHER|Internet-based injury prevention program|"An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum."
41111348|NCT04892290|OTHER|Conservative Treatment for Postdural Puncture Headache|The patients in Group C were given continuous bed rest in the supine position, 3000 mL daily hydration, 6 mg kg-1 aminophylline , 2 g day-1 paracetamol and 65 mg day-1 caffeine as conservative treatment. Topical SGB was applied to patients in Group SGB in addition to conservative treatment.
41111349|NCT00545077|DRUG|Letrozole|
41111350|NCT00545077|DRUG|Bevacizumab|
41111351|NCT00545077|DRUG|Fulvestrant|
41111352|NCT06167265|DRUG|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
41111353|NCT06167265|DRUG|PMR Tablet 145 mg|Single oral dose (total daily dose of 290 mg)
41111354|NCT04942249|OTHER|No intervention|No intervention
41111355|NCT05467800|DRUG|Canakinumab|Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles.
41111356|NCT04010955|DRUG|Edoxaban Monotherapy|when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
41111357|NCT03259919|DRUG|Metformin|Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
41111358|NCT03259919|DRUG|Placebo|Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
40752490|NCT06156267|DRUG|mRNA tumor vaccines|neoantigen personalized mRNA vaccines
40925716|NCT04872270|DRUG|Zofran 4Mg Tablet|given postoperatively as standard post-op management
41111359|NCT00889694|DRUG|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
41111360|NCT00889694|DRUG|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
41111361|NCT00889694|DRUG|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
41111362|NCT02937831|BIOLOGICAL|RIXUBIS|
41111363|NCT01800513|PROCEDURE|Endometrial Biopsy|
41111364|NCT01800513|PROCEDURE|Sham Procedure|
41111365|NCT03823196|DIETARY_SUPPLEMENT|Verum900|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 900 mg for 16 weeks
41111366|NCT03823196|DIETARY_SUPPLEMENT|Verum1800|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 1800 mg for 16 weeks
41111367|NCT02620761|DRUG|Fenoldopam|Randomized to receive Fenoldopam or 0.9%NS
41111368|NCT02620761|DRUG|0.9%NS|Randomized to receive Fenoldopam or 0.9%NS
41445992|NCT06603103|PROCEDURE|SPHERIKA prosthesis|total knee arthroplasty with kinematic alignement with SPHERIKA prosthesis
41111369|NCT03954015|DIAGNOSTIC_TEST|Contrast Enhanced imaging|Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.
41111370|NCT03954015|DRUG|Lumason|FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
41111371|NCT00993369|OTHER|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
41111372|NCT00475501|DRUG|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
41111373|NCT00475501|DRUG|Finasteride|5 mg, oral, once/day, for 52 weeks
41111374|NCT00475501|OTHER|Placebo|Placebo
41111375|NCT05862454|DRUG|Magnesium|Magnesium injection therapy
41111376|NCT02419261|DRUG|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
41111377|NCT02419261|PROCEDURE|Arthroscopic surgical repair of the anterior cruciate ligament|
41111378|NCT02578108|PROCEDURE|genicular nerve diagnostic block with lidocaine (local anesthetic)|sensory denervation of the knee joint
41111379|NCT02578108|PROCEDURE|genicular nerve radiofrequency ablation|Ablation of the genicular nerves of the knee by radiofrequency energy
41111380|NCT02423135|BIOLOGICAL|Autologous blood transfusion|Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
41111381|NCT00786942|PROCEDURE|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
41111382|NCT00786942|PROCEDURE|higi tibial osteotomy|the gap of the tibia is unfilled
41111383|NCT03922412|PROCEDURE|PLANTAR BLOCK|"1. Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of mepivacain 1% (200mg)~2. Plantar block 10 minutes later : patient in supine position. Medial midfoot injection of 5 ml of the mixture labelled  BLOC PLANTAIRE  containing 5 ml of Ropivacaine 0,5% (25mg) with 0,5 ml dexaméthasone (2mg)~3. Distal deep fibular block : patient in supine position, injection around the dorsal foot artery of 2 ml of the mixture labelled  BLOC FIBULAIRE  containing 2 ml of Ropivacaine 0,5% (10mg)."
41111384|NCT03922412|PROCEDURE|Sciatic popliteal block|"1-Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of ropivacaine 0,5% (100mg) with 2mg (0,5 ml) of dexamethasone"
41111385|NCT01548846|RADIATION|Tomotherapy|Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT
41111386|NCT03903900|BEHAVIORAL|Lifestyle-oriented Occupational Therapy added to current treatment of chronic non-malignant pain|The participants are recruited from the outpatient cohort admitted at The Multidisciplinary Pain Center (MPC) at Naestved Hospital (Zealand Region, Denmark). The participants receive both, the current treatment based on Cognitive Behavioural Therapy (CBT) and delivered by physicians, nurses, physical therapists and a social worker as usual care, and a lifestyle-oriented Occupational Therapy intervention. The Occupational Therapy intervention targets meaningful daily occupations, physical activity, and eating habits and routines. The intervention is delivered by graduated occupational therapists once á week during the 15 weeks after the initial 5-weeks compulsory psychoeducation course at the MPC. The intervention contains in-person contacts with OTs every other week (e.g. two 1-hour individual sessions at the hospital and/ or at-home and five 2-hours group sessions) and seven phone consultations in the opposite weeks.
40752491|NCT01554852|DRUG|Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
41111387|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
41111388|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
41111389|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
41111390|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
41111391|NCT01583712|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
41445993|NCT06603103|PROCEDURE|ORIGIN prosthesis|total knee arthroplasty with kinematic alignement with ORIGIN prosthesis
41111392|NCT01583712|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
41111393|NCT01801410|DEVICE|Foley Catheter|Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
41111394|NCT01801410|DRUG|Misoprostol|25mcg every 2 hours for maximum of 12 doses
41111395|NCT00419094|DRUG|Keppra XR|Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
41111396|NCT00419094|DRUG|Keppra XR|Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
41111397|NCT01872403|DRUG|nanoparticle albumin-bound paclitaxel/carboplatin|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
41111398|NCT00101010|BIOLOGICAL|Filgrastim|5 mcg/kg, SC daily, start 24 hours after chemotherapy
41111399|NCT00101010|BIOLOGICAL|Pegfilgrastim|6 mg SC one time (24 hours after chemotherapy)
41111400|NCT00101010|BIOLOGICAL|Rituximab|375 mg/m\^2 intravenous piggy back (IVPB) on day 1, administered 1st
41111401|NCT00101010|DRUG|Cyclophosphamide|750 mg/m\^2 IVPB on day 1
41111402|NCT00101010|DRUG|Pegylated liposomal doxorubicin hydrochloride|40 mg/m\^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
41445994|NCT03768635|OTHER|necrotizing external otitis|description of necrotizing external otitis
41445995|NCT01857947|OTHER|AECOPD Mr proADM|
41445996|NCT01359696|DRUG|GDC-0425|Oral escalating dose
41111403|NCT00101010|DRUG|Prednisone|40 mg/m\^2 oral days 1 - 5.
41111404|NCT00101010|DRUG|Vincristine Sulfate|2 mg IV, day 1
41111405|NCT00922649|DEVICE|Insulin Pump therapy|Initiation of Insulin pump therapy in patients on \>2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
41111406|NCT03542630|DIAGNOSTIC_TEST|salivary MMP8 test|All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response
41111407|NCT03542630|OTHER|periodontal examination|Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.
41111408|NCT03542630|OTHER|blood tests|All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.
41111409|NCT01717677|PROCEDURE|radical prostatectomy|
41111410|NCT01717677|RADIATION|percutaneous radiation therapy|
41111411|NCT01717677|RADIATION|permanent seed implantation|
41111412|NCT01717677|PROCEDURE|Active Surveillance|
41111413|NCT02304913|OTHER|Hypoglossal acupuncture|
41111414|NCT02304913|OTHER|Sham acupuncture|
41111415|NCT02304913|BEHAVIORAL|Dietary recommendations|
41111416|NCT02770495|OTHER|blood sample|
41111417|NCT06312943|OTHER|Collection of joint fluid or tissue sample|During a puncture or joint surgery planned as part of the routine care of the patient, a part of the joint fluid or tissue sample will be collected in order to carry out the analyzes planned for the research.
41111418|NCT04756323|BIOLOGICAL|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
41111419|NCT04756323|BIOLOGICAL|high dosage inactivated SARS-CoV-2 vaccine|high dosage
41111420|NCT04756323|BIOLOGICAL|Placebo|placebo
41111421|NCT00771446|BIOLOGICAL|ELAD plus standard of care treatment|ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
41111422|NCT00771446|OTHER|Standard of care treatment|Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
41111423|NCT04009642|OTHER|Surely observational based on disease state|Metabolism in T2DM vs non diabetic
41111424|NCT06228846|DRUG|YY001|Oral
41445997|NCT01359696|DRUG|gemcitabine|Intravenous repeating dose
41445998|NCT04972578|DEVICE|Suture Button vs Screw Fixation|Syndesmotic fixation utilizing suture button fixation versus Screw Fixation (placing one or two screws across the syndesmosis)
41445999|NCT02709018|DRUG|losartan|Angiotensin receptor blocker (ARB)
41446000|NCT02709018|DRUG|Placebo|Placebo
41453318|NCT00893945|DRUG|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
41453319|NCT04121507|DRUG|High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)|High-dose therapy (HDT) prior to alloSCT will consist of FTC
41111425|NCT02616835|DEVICE|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
41111426|NCT02616835|DEVICE|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
41111427|NCT01205620|DEVICE|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
41111428|NCT01205620|OTHER|No intervention|No intervention will be performed in the control group
41111429|NCT01113333|DRUG|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
41111430|NCT01113333|DRUG|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
41111431|NCT02828423|PROCEDURE|EMD|Regenerative surgery with EMD
41111432|NCT02828423|PROCEDURE|BC|Regenerative surgery with BC
41111433|NCT05705700|DRUG|Dutasteride|High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression
41111434|NCT05705700|DRUG|Abiraterone|1000 mg PO daily
41111435|NCT02221219|DRUG|Indomethacin|indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
41111436|NCT02221219|PROCEDURE|delay in umbilical cord clamp at birth|provision of a \~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
41111437|NCT02221219|DRUG|placebo infusion|saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
41111438|NCT02221219|PROCEDURE|immediate cord clamp at birth|no delay in umbilical cord clamp; \<10sec (recorded in delivery note)
41111439|NCT05865379|DEVICE|BUFY01 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
41111440|NCT05865379|DEVICE|SVS20 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
41111441|NCT02158481|DIETARY_SUPPLEMENT|A capsule containing both polyphenols and carotenoids|
41111442|NCT02158481|DIETARY_SUPPLEMENT|Placebo intervention|Placebo intervention
41111443|NCT05216120|DRUG|Pemigatinib 4.5 MG|"Pemigatinib 4.5 mg tablets taken 3 times per day \[daily dose of 13.5 mg (3 tablets)\] for 14 consecutive days followed by 7 days off medication in 21-day cycles~Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food."
41111444|NCT01987154|OTHER|Marketed cow milk-based premature infant formula|
41111445|NCT01987154|OTHER|Marketed extensively hydrolyzed casein infant formula|
41111446|NCT03774459|DRUG|High dose ANAVEX2-73|Active oral capsule
41453320|NCT04121507|PROCEDURE|Bone marrow histology|Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved
41453321|NCT04121507|DIAGNOSTIC_TEST|clinical and laboratory parameters|During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.
40752492|NCT01554852|DRUG|Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
41111447|NCT03774459|DRUG|Mid dose ANAVEX2-73|Active oral capsule
41111448|NCT03774459|DRUG|Placebo oral capsule|Placebo oral capsule
41111449|NCT06203054|DEVICE|Penditure™ LAA Exclusion System|Exclusion of the left atrial appendage using the Penditure™ LAA Exclusion System in subjects undergoing concomitant cardiac surgery.
41111450|NCT01035658|DRUG|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
41111451|NCT01035658|DRUG|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
41111452|NCT00444990|DEVICE|Magnetic Flex Pad|
41111453|NCT02032849|PROCEDURE|Manual air-impingement operation|A method which we invented to clear subglottic secretion
41111454|NCT02032849|DEVICE|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
41111455|NCT01162876|DRUG|saxaglipitin|oral administration of 5 mg tablet before breakfast for 14 consecutive days
41111456|NCT04396730|DRUG|Cannabidiol Oil|400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.
41111457|NCT04396730|DRUG|Placebo|Placebo will be administered daily along with oral contraceptives daily for 24 days.
41111458|NCT04396730|DRUG|Combined oral contraceptive pill|All participants will receive oral contraceptives
41111459|NCT05503446|OTHER|Peanut in common foods or supermarket-sourced cow's milk (CM)|Participants will be given a set dose of peanut (e.g. peanut-containing cereal, whole peanuts) or cow's milk to take on a daily basis, as per protocol
41111460|NCT05078424|BEHAVIORAL|Cognitive Behavioural Therapy|CBT is a well-established, evidence-based intervention frequently used for easing depressive and anxiety symptoms. The intervention will be delivered for 6-7 sessions, each session lasts for 1.5 hours, in the format of a group for a period of 6-7 weeks by frontline social or youth workers trained by professional CBT clinicians. Core treatment components include mood monitoring, emotion education, behavioural activation, emotion cycle/ ABC model, identification of automatic thoughts, and cognitive restructuring. It is designed to improve youths' abilities/ skills in handling their moods to have better emotional management.
41111461|NCT01366664|DRUG|Treatment sequence 2|Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days)
41111462|NCT01366664|DRUG|Treatment sequence 1|Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days)
41111463|NCT03229707|DEVICE|Digital photography using software Photoshop|"When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).~* Images are then opened into Photoshop.~* The INFO panel must be open.~* Click on the small eyedropper in the Info panel window and click on ''Lab Color.~* Place the mouse over the center of the tooth to be measured for L value.~* Click on the HSB Color option, which stands for hue, saturation, and brightness."
41111464|NCT03229707|DEVICE|Vita 3D master shade guide|Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
41111465|NCT02093533|DRUG|Eculizumab|
41111466|NCT04569318|DEVICE|Treatment Beam|One of the subject's eyes will be treated with the 415 nm treatment beam (20mW) up to 8 times for 15 minutes.
41111467|NCT02375048|RADIATION|Hypofractionated WBI|Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
41111468|NCT02375048|RADIATION|Accelerated Partial Breast Irradiation|APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
41111469|NCT01483248|BIOLOGICAL|conventional therapy plus MenSC transplantation|"patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.~MenSCs transplantation: taken i.v., twice per week, at a dose of 1\*10E6 MSC/kg body for 2 weeks."
41111470|NCT01483248|DRUG|Conventional therapy plus placebo treatment|25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
41111471|NCT01465724|PROCEDURE|Renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
41111472|NCT01783977|BIOLOGICAL|DNA-HIV-PT123 vaccine|DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
41111473|NCT01783977|BIOLOGICAL|NYVAC-HIV-PT1 vaccine|NYVAC-HIV-PT1 at greater than or equal to 5x10\^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10\^8 PFU/ml; administered as 1 mL IM in participant's deltoid
41111474|NCT01783977|BIOLOGICAL|NYVAC-HIV-PT4 vaccine|NYVAC-HIV-PT4 at greater than or equal to 5x10\^6 PFU/ml for a planned maximum dose of 1.1x10\^7 PFU/ml; administered as 1 mL IM in participant's deltoid
41111475|NCT01783977|BIOLOGICAL|Placebo for DNA-HIV-PT123 vaccine|Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
41111476|NCT01783977|BIOLOGICAL|Placebo for NYVAC-HIV-PT1 vaccine|Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
41111477|NCT01783977|BIOLOGICAL|Placebo for NYVAC-HIV-PT4 vaccine|Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
41111478|NCT01794936|DEVICE|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
41111479|NCT05209880|BEHAVIORAL|ED GOAL|The emergency department clinician-led, behavioral intervention (ED GOAL) is designed to engage seriously ill yet clinically stable older adults in the emergency department to address their values and preferences towards end-of-life care with their outpatient clinicians. The intervention consists of an interview to discuss participants' values and preferences for end-of-life care. The participants will receive coaching on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and outpatient clinicians. The participants' outpatient clinicians will also receive a summary of what participants disclosed via email or mailed letter.
41111480|NCT02957812|DEVICE|Custom-made Foot Orthotics (CFO)|Provides longitudinal arch support
41111481|NCT03789786|DIAGNOSTIC_TEST|Gait and Motion Analysis|Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
41446001|NCT02878018|DRUG|Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula|Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
41446002|NCT02878018|DRUG|angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant|prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
41446003|NCT06559553|DRUG|Selinexor+pegaspargase+dexamethasone|Nuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.
41111482|NCT03789786|DIAGNOSTIC_TEST|Gross Motor Function Measure (GMFM)|Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping
41111483|NCT03789786|BEHAVIORAL|Surveys|Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history
41111484|NCT02994719|DRUG|Anti-Parkinson medication|During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
41111485|NCT02994719|DEVICE|Deep Brain Stimulation|During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.
41111486|NCT04528264|DEVICE|Intraoperative ultrasound guided|Samsung Mysono U6 machine with LN 15 linear (https://www.samsunghealthcare.com/en/products/UltrasoundSystem/MySono%20U6/General%20Imaging/transducers) probe capable of Musculoskeletal imaging will be used for visualization and location of fracture after which elevation and reduction of fracture will be attempted. The ultrasound probe will be used as described by McCann. Radiographic continuity of periosteal shadow without any step will be taken as end point for reduction and the procedure will be terminated.
41111487|NCT04528264|OTHER|Conventional blind reduction technique|Conventional blind reduction technique
41111488|NCT03598478|BEHAVIORAL|TC-MPT|Participants will receive two levels of training within each 90-minute session over a 12-week period: (1) TC training and (2) MPT. The TC training protocol consists of five basic TC movements. After receiving TC training, the participants in this group will take a 5-minute break and then receive MPT. During MPT, the participants will contract their major postural muscles bilaterally as fast as possible against a resistance equivalent to 70% of one repetition maximum.
41111489|NCT03598478|BEHAVIORAL|TC|Children in the TC group will skip the MPT session and practice TC movements repeatedly for 90 minutes. The exercise progression pattern in the TC-alone group will be the same as that in the TC-MPT group.
40925717|NCT03584373|DRUG|Ketorolac Oral Tablet [Toradol]|Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
40925718|NCT03584373|DRUG|Acetaminophen|Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
41111490|NCT03598478|BEHAVIORAL|MPT|Those children in the MPT group will perform strengthening exercises repeatedly for 90 minutes, with a short 5-minute break between the three sets of exercises if necessary. The exercise progression pattern in the MPT-alone group will be the same as that in the TC-MPT group.
41111491|NCT00624312|DRUG|Procrit|"10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit"
41111492|NCT00624312|DRUG|Placebo|"10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo"
41111493|NCT00168922|DRUG|Bendamustin/Ribomustin|
41111494|NCT04635267|OTHER|Prone position in patients with ARDS|Transpulmonary thermodilution, arterial blood gas and recruitment/inflation calculation will be made every 8 hours: at baseline (just before prone position), after eight hours of prone position, after 16 hours of prone position (end of prone position), after 24 hours ( 8 hours after the end of prone position).
40752493|NCT01554852|DRUG|Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1 \& 2, 8 \& 9, 15 \& 16 - carfilzomib 20\*/36 mg/m2\*\* IV (\*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; \*\*carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 \& 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
40752494|NCT01554852|DRUG|Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
40925719|NCT03584373|DRUG|Oxycodone Acetaminophen|Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
41111495|NCT03943459|DRUG|Quercetin|Quercetin 250 mg BID
41111496|NCT01980641|BEHAVIORAL|Educational intervention|All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.
41111497|NCT01980641|DEVICE|Smartphone-based application|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
41111498|NCT02866435|DRUG|Insulin|In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
40925720|NCT05542745|DEVICE|palatal and buccal retraction|comparison
40925721|NCT00667173|DRUG|IDP-115|Topical application for 12 weeks
40925722|NCT00667173|DRUG|Vehicle|Topical application for 12 weeks
40925723|NCT00667173|DRUG|Vehicle|Topical application for 12 weeks
40925724|NCT00123890|DRUG|GW873140|
40925725|NCT06271473|PROCEDURE|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
41111499|NCT02866435|DRUG|Glucose|Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
41111500|NCT02866435|DRUG|Potassium phosphate|Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
41111501|NCT02852681|DRUG|15 mg E4/3 mg DRSP|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
41111502|NCT00901069|DRUG|Azacitidine with rituximab, vincristine, and cyclophosphamide|Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2\^ Azacitidine 50 mg/m2\^ Azacitidine 75 mg/m2\^ Azacitidine 100 mg/m2\^
41111503|NCT06000072|OTHER|Core Exercise Program|Core exercises
41111504|NCT05206630|OTHER|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
41111505|NCT04807322|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|Implantation of a Reverse Total Shoulder Arthroplasty
41111506|NCT04868656|OTHER|Implementation Strategy: Foundational Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We propose that low intensity implementation support that promotes adapting STRIDE for context and provides tools for ongoing STRIDE evaluation (defined as foundational support), will be sufficient for some but not all hospitals to successfully incorporate STRIDE into routine practice.
41111507|NCT04868656|OTHER|Implementation Strategy: Enhanced Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We posit that monitoring hospitals' progress and adding, for hospitals with low adoption, higher intensity strategies (defined as Enhanced Support) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
41111508|NCT00035542|DRUG|Glucovance (metformin HCl/glyburide)|
41111509|NCT00035542|DRUG|metformin HCl|
41111510|NCT00035542|DRUG|glyburide|
41111511|NCT00296751|PROCEDURE|ECG recording|
41111512|NCT00296751|PROCEDURE|Epidural catheter insertion|
41111513|NCT00296751|DRUG|Intravenous meperidine injection|
41111514|NCT00296751|DRUG|Epidural Bupivacaine and fentanyl injection|
41111515|NCT00510601|DEVICE|Kaneka Liposorber|LDL-apheresis on a bi-weekly basis
41111516|NCT01885806|DEVICE|Magnetic Stimulator Magstim Rapid 2|All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
41111517|NCT01885806|DEVICE|Sham Magnetic Stimulator|"This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.~Total of session: 10"
41111518|NCT03996083|OTHER|Multicomponent exercise intervention|"Strength exercises were focused on lower limb strengthening. Individual bilateral intensities were calculated to estimate one repetition maximum (1-RM) for the leg and arm. This test was performed on the 2nd and 7th weeks of the intervention. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. No external loads were applied to the rest of the exercises due to their complex execution technique and subsequent risk of adverse events. In these cases, training progression was achieved through volume (number of repetitions) and execution velocity increments.~Balance exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention."
41111519|NCT03996083|OTHER|Walking intervention|"To comply with the walking goals, walking distance was calculated based on each participant´s performance on the 6-minute walking test and using a rule of thumb. Therefore, every participant had an itinerary to follow to comply with the minimum walking time each week. Distance rather than time was used with participants for practical reasons and the inability of most of them to measure time. Moreover, time and distance were individually adapted according to each participant´s performance on the previous week.~To ensure that participants complied with the walking goals, each of them (if they were cognitively able) was given a record sheet in which they had to write down their everyday walking routines. In addition, the caregivers were also informed about the walking routines and ensured that those participants who needed close supervision had someone to walk with and filled the sheet of those that were unable to do so."
41111520|NCT00410124|DRUG|RAD001|The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
41111521|NCT00410124|DRUG|Placebo|
41111522|NCT05722106|BEHAVIORAL|Persuasive Appeal|Persuasive appeals were manipulated using promotional flyers ostensibly distributed by the Public Health Agency of Canada.
40925726|NCT05319873|DRUG|Carboplatin|Given IV
40925727|NCT05319873|DRUG|Docetaxel|Given IV
40925728|NCT05319873|DRUG|Fulvestrant|Given SC
40925729|NCT05319873|BIOLOGICAL|Pertuzumab|Given IV
40925730|NCT05319873|OTHER|Quality-of-Life Assessment|Ancillary Studies
40925731|NCT05319873|DRUG|Ribociclib|Given PO
40925732|NCT05319873|BIOLOGICAL|Trastuzumab|Given IV
40925733|NCT05319873|DRUG|Tucatinib|Given PO
40925734|NCT02805270|OTHER|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
41111523|NCT01036412|DRUG|1% Chlorhexidine Gluconate Gel|Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
41111524|NCT01036412|BEHAVIORAL|Surveys|M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
41111525|NCT01685528|BEHAVIORAL|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
41111526|NCT04485156|DRUG|High-dose rifampicin|30mg/kg
41111527|NCT04485156|DRUG|Isoniazid|300mg
41111528|NCT04485156|DRUG|Pyrazinamide|20-30mg/kg
41111529|NCT04485156|DRUG|Ethambutol|15-20mg/kg
41111530|NCT04485156|DRUG|Rifampicin|10mg/kg
41111531|NCT00228007|DRUG|Antidepressant Medication|
41111532|NCT02061930|PROCEDURE|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
41111533|NCT02798718|DIETARY_SUPPLEMENT|full-fat milk|intake 250ml full-fat milk per day, do not intake any other dairy products
41111534|NCT03631537|OTHER|NST group|Nutrition-support-team based intervention on nutrition, including dietary supplement, parenteral nutrient solutions and patient education
41111535|NCT03151590|BEHAVIORAL|exercise training|
41111536|NCT01551433|DEVICE|wireless pulse oximeter (Wipox)|In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
41111537|NCT01038011|DRUG|drug treatment|
41111538|NCT01018836|DRUG|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
41446004|NCT05442086|BEHAVIORAL|Music and Theta Auditory Beat Stimulation|Participants will listen to calm music with theta auditory beat stimulation for 24 minutes
41446005|NCT05442086|BEHAVIORAL|Pink Noise (control)|Participants will listen to pink noise for 24 minutes
41111539|NCT01018836|RADIATION|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
41446006|NCT01026402|DRUG|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
41111540|NCT00841633|DRUG|Induced hypertension with norepinephrine|Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
41111541|NCT03229044|GENETIC|Tetranectin|Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
41111542|NCT06336486|DEVICE|intermittent pneumatic compression +pregabalin group|The investigators divided the patients into two equal groups , some of the patients were given an intermittent pneumatic compression program at a pressure of 35 mmhg for 30 min to the lower extremity for 10 days of extreme alternation in our clinic and pregabalin treatment was continued.
41111543|NCT06336486|OTHER|pregabalin group|only pregabalin treatment was continued.
41111544|NCT00282971|DRUG|Inhaled Insulin (Exubera)|Addition of inhaled insulin to pre-existing oral diabetes therapy.
41111545|NCT00282971|OTHER|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
41111546|NCT02076451|DRUG|DS-8273a|DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
41111547|NCT01101152|DRUG|Desvenlafaxine succinate|"Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day"
41111548|NCT05721612|OTHER|Flapless transcrestal sinus lift approach with TPRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the TPRF as a sole grafting material.
41111549|NCT05721612|OTHER|Flapless transcrestal sinus lift approach with PRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the PRF as a sole grafting material.
41111550|NCT03777696|DRUG|Misoprostol|400 μg of buccal misoprostol
41111551|NCT03777696|DRUG|TA|1 gm of tranexamic acid in 100 ml saline iv
41111552|NCT03777696|DRUG|placebo to misoprostol|placebo tablets to misoprostol buccal
41111553|NCT03777696|DRUG|placebo to TA|110 ml saline iv
41111554|NCT00732953|DEVICE|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
41111555|NCT00732953|DEVICE|Genous stent implantation|Genous stent implantation
41111556|NCT04480827|DRUG|Aramchol free acid tablet 600mg, single dose|Aramchol free acid tablet 600mg, single dose
41111557|NCT04480827|DRUG|Aramchol free acid tablet 300mg, bid|Aramchol acid tablet 300mg, bid for 12 days
41111558|NCT05221736|PROCEDURE|Ultrasound-Guided Ethanol Sclerotherapy (UGES)|Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) \& surgical excision in management of warthin tumor of parotid gland.
41111559|NCT00001354|DRUG|Interleukin-2/Zidovudine (AZT)|
41111560|NCT05781555|DEVICE|Experimental: DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. The study objectives are to collect data on the general safety and efficacy of DaRT among patients who do not fit the entry criteria of existing investigational trials.
41111561|NCT02940704|PROCEDURE|Reciproc|"* Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~* There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~* Reciproc file selection: R40 (40/0.06) is to be used."
41111562|NCT02940704|PROCEDURE|One Shape|"* Coronal preflaring will be performed using Gates Glidden drill.~* Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~* For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used."
41111563|NCT02498769|DRUG|Botulinum Toxin Type A|The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
41111564|NCT02498769|DRUG|Placebo|
41111565|NCT06392633|PROCEDURE|spastic hand sugery|Deformity correction can be performed with single event multilevel surgery, using a combination of soft tissue releases and lengthening, tendon transfers and joint stabilization procedures. In addition, selective and supraselective neurectomies can also be performed.
41446007|NCT05571592|DRUG|Cannabidiol|Oral Capsule Formulation of CBD dissolved in a self-emulsifying drug technology called nanodomains, encapsulated within 1-ml softgel capsules, with a CBD purity ≥98%. Imported from Ananda Scientific
41446008|NCT05571592|DRUG|Placebo|"Drug: Placebo~Placebo softgel capsule formulation."
41111566|NCT06392633|DRUG|Botulinum Toxin A|Treatment consists of periodic injections of the toxin into the spastic muscles. It causes reversible chemical denervation by preventing the release of acetylcholine vesicles at the neuromuscular junctions of the affected muscles.
41111567|NCT03456336|OTHER|Active Treatment|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other. If the infant receives both, it will be considered a protocol violation.
41111568|NCT03456336|OTHER|Expectant Management|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
41111569|NCT05059730|OTHER|Zero Degrees Cold Environment|Participants will be exposed to zero degrees celsius environment.
41111570|NCT05059730|OTHER|Eight Degrees Cold Environment|Participants will be exposed to eight degrees celsius environment.
41111571|NCT05059730|OTHER|Ten Degrees Cold Environment|Participants will be exposed to Ten degrees celsius environment.
41111572|NCT05059730|OTHER|40 degrees Hot Environment|Participants will be exposed to 40 degrees celsius hot environment.
41111573|NCT02839369|OTHER|walking under varies conditions|The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
41446009|NCT05464836|DRUG|CB-103|Given by PO
41446010|NCT05464836|DRUG|Venetoclax|Given by PO
41446011|NCT05888311|DEVICE|Liquid bandage|Liquid elastic collodion- and benzethonium chloride-based topical solution
41446012|NCT01349218|OTHER|Blood sample drawn from a vein|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis.
41446013|NCT01349218|OTHER|Blood sample drawn from a heel stick|A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
41111574|NCT02839369|OTHER|walking under varies conditions|walking on electronic walkway under different conditions
41111575|NCT04074577|DIAGNOSTIC_TEST|Standard technique First|colonoscopy without automated polyp detection software
41111576|NCT04074577|DIAGNOSTIC_TEST|combination technique First|automated polyp detection software
41111577|NCT01883492|DEVICE|Femoral Stem|JMDN classification/Class III device
41111578|NCT01883492|DEVICE|Acetabular Cup|JMDN classification: Class III device
41111579|NCT01883492|DEVICE|Acetabular Liner|JMDN classification: Class III device
41111580|NCT01760837|OTHER|Baked milk products to cow's milk allergic patients|
41111581|NCT00509639|DRUG|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
41111582|NCT03578640|DRUG|Elbasvir, Grazoprevir 50-100Mg Oral Tablet|Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
41111583|NCT01801293|DRUG|GS-5806|
41111584|NCT04177017|BEHAVIORAL|Mindfulness-based intervention|"The behavioral intervention was carried out once a week during 60 minutes from May to November, and included mindfulness-based practices sought to foster self-awareness, and dyadic activities sought to awakening subtle perception of the other.~Group activities, which entailed more than two participants, were also conducted to foster empathic collaboration and prosocialness. Diverse collaborative games were carried out in which mutual help was needed for achieving shared goals in an amusing way .~Perspective-taking was encouraged within the group, by sharing each participant's experience, which included expressing how each child had felt (i.e., if neglected, ignored or cared for) and whether they had enjoyed helping their peers or no."
41111585|NCT01184508|DRUG|Placebo|Administered orally, once daily, for 12 weeks
41111586|NCT01184508|DRUG|LY2300559|300 milligrams (mg) administered orally, once daily, for 12 weeks
41111587|NCT02631343|BEHAVIORAL|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
41111588|NCT02631343|OTHER|Essential newborn care|
41111589|NCT04573803|DRUG|Phenytoin Sodium|Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
41111590|NCT04573803|DRUG|Levetiracetam|Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.
41111591|NCT03457246|OTHER|D-Pigment rich texture|
41111592|NCT03457246|OTHER|Hydrance optimale riche|
41111593|NCT00829348|OTHER|No intervention|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
41111594|NCT00829348|BEHAVIORAL|Short Message Service (SMS)|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
41111595|NCT04835870|DRUG|Zanubrutinib|Zanubrutinib-160mg bid PO d0-d20(1-21d)
41111596|NCT04835870|DRUG|Rituximab|Rituximab-375 mg/m2 i.v d0 (/21d)
41111597|NCT04835870|DRUG|Cyclophosphamide|Cyclophosphamide-750 mg/m2 i.v d1 (/21d)
41111598|NCT04835870|DRUG|Doxorubicin|Doxorubicin-50 mg/m2 i.v d1 (/21d)
41111599|NCT04835870|DRUG|Vincristine|Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)
41111600|NCT04835870|DRUG|Prednisone|Prednisone-100 mg p.o d1-d5 (/21d)
41111601|NCT01063517|DRUG|olaparib|100mg BID oral tablet continuous
41111602|NCT01063517|DRUG|paclitaxel|iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
41111603|NCT01063517|DRUG|Placebo|100mg BID oral tablet to match olaparib tablet
41111604|NCT05505799|OTHER|Intubation Checklist|A preprocedure checklist will be made available to clinicians, and they will be educated on proper use of the checklist
41111605|NCT05505799|OTHER|Standard Care|Clinicians will intubate as per their usual practice
41111606|NCT06530264|OTHER|DCR|6. An H shaped incision at the postero-inferior lacrimal sac is made, with a long anterior flap and shorter posterior flap. Similarly an H shaped incision at the nasal mucosa is made. The posterior flap of lacrimal sac is sutured with posterior flap of nasal mucosa in interrupted fashion using 6-0 vicryl sutures in Group A, while in Group B the posterior flap is trimmed without suturing.
41111607|NCT05168553|OTHER|Revascualrization|Regain pulp vascularity for mature permenant teeth
41111608|NCT05168553|OTHER|Conventional endodontic treatment|Root canal treatment of permenant mature teeth with mechanical preparation and cleaning followed by canal obturation by inert material ( gutta percha)
41111609|NCT04423328|BEHAVIORAL|acupressure|self-acupressure
41111610|NCT06466980|OTHER|Ventilator associated event|Measure of incidence of Ventilator associated event
41111611|NCT02537769|DEVICE|Left ventricular assist device (LVAD)|Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
41111612|NCT02537769|PROCEDURE|Tricuspid Valve Repair (TVR)|Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
41111613|NCT02943629|DEVICE|Apneic oxygenation: Eight minute|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
41111614|NCT02943629|DEVICE|Without apneic oxygenation|A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
41111615|NCT02943629|DEVICE|Apneic oxygenation: five minutes|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
41111616|NCT03984617|OTHER|Emergency visit in a French tertiary Maternity hospital (Maternity of Nancy)|total number of visits (hospitalizations and consultations)
41111617|NCT00527540|DRUG|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
41111618|NCT06304636|DRUG|Descartes-15|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
41111619|NCT04566042|BEHAVIORAL|Acceptance and commitment therapy video game|The intervention is a videogame which teaches the participant about acceptance and commitment therapy.
41111620|NCT04920617|DRUG|DPX-Survivac|SC injection on D7 and D28, then every 8 weeks
41111621|NCT04920617|DRUG|Pembrolizumab|IV infusion every 3 weeks
41111622|NCT04920617|DRUG|CPA|50 mg twice daily, week on then week off
41111623|NCT05307991|DRUG|PrEP|HIV pre-exposure prophylaxis (or PrEP) will include the Malawi-approved PrEP regimen at time of study enrollment. At time of submission, the only Malawi-approved regimen includes Tenofovir/emtricitabine (TDF/FTC) containing 300 mg of TDF and 200 mg of FTC. If additional PrEP regimens become available in Malawi during the study recruitment or follow-up, participants will be able to choose from any regimen that they are eligible to receive per Malawi PrEP guidelines.
41111624|NCT05307991|DEVICE|STI testing|Urine specimens will be tested for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) using GeneXpert® (Cepheid, Sunnyvale, CA) Xpert® CT/GC platform and cartridge and syphilis RPR titer (BD Macro-VUE™, Becton, Dickinson and Company, Franklin Lakes, NJ \[FDA approved\]) with confirmatory Treponema pallidum particle agglutination (TP-PA) (Serodia Fujirebio Inc, Malvern, PA \[CE mark\]) if RPR is positive.
41111625|NCT05307991|BEHAVIORAL|Assisted partner notification|"Participants will be asked to provide the name and locator information for all sexual partners in the preceding 6 months. Participants will be asked to refer sexual partners to the clinic and will be provided with cards to distribute to partners. Each card will request that the recipient report to the STI clinic with the card and will contain a linking number that links them back to the index participant.~Sexual Partner Tracing: In accordance with the contract referral approach, if the named partners do not present to an STI clinic within 7-14 days, community outreach workers will contact the partners and counsel them to visit the clinic. Contact may be made through telephone, text message, or in person, as needed and will not disclose the name or identify of the index patient."
41111626|NCT05307991|DIAGNOSTIC_TEST|Acute HIV testing|Persons initiating or re-initiating PrEP will also be screened for acute HIV infection (AHI) using Abbott RealTime HIV-1 Assay (Abbott Laboratories, Chicago, IL) or Xpert® HIV-1 Viral Load (GeneXpert, Cepheid, Sunnyvale, CA).
41111627|NCT01183871|PROCEDURE|Monitoring of cerebral oxygenation|The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
41111628|NCT03668288|OTHER|Data record and questionnaires passation|Data record and questionnaires passation (SF36)
41111629|NCT03571191|DRUG|Denosumab|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
41111630|NCT03818204|DEVICE|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).
40925735|NCT03719534|PROCEDURE|haplo-HCT|HCT will be performed with a haploidentical donor
40925736|NCT03719534|PROCEDURE|haplo-cord HCT|Haploidentical donor HCT will be performed with coinfusion of unrelated cord blood unit
41111631|NCT05001945|DRUG|MLS-101 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
41111632|NCT05001945|OTHER|Placebo (Part I)|Placebo tablet(s) by mouth once or twice daily.
41111633|NCT05001945|OTHER|Placebo (Part II)|Placebo tablet(s) by mouth once daily.
41111634|NCT05001945|DRUG|MLS-101 (Part II)|MLS-101 tablet(s) by mouth once daily.
41111635|NCT02393716|DEVICE|Endurant Evo AAA Stent Graft System|
41111636|NCT02393716|PROCEDURE|Endovascular aneurysm repair (EVAR)|
41111637|NCT01679951|DRUG|Placebo|Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
41111638|NCT01679951|DRUG|JNJ-38518168 (3 mg)|Type=exact number, unit=mg, number=3, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
41111639|NCT01679951|DRUG|JNJ-38518168 (10 mg)|Type=exact number, unit=mg, number=10, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
41111640|NCT01679951|DRUG|JNJ-38518168 (30 mg)|Type=exact number, unit=mg, number=30, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
41446014|NCT05243251|DRUG|Olanzapine 5 MG|, Olanzapine (OLZ) is an atypical antipsychotic agent that blocks multiple neurotransmitters: dopamine at D1, D2, D3 and D4 brain receptors, serotonin at 5-HT2a , 5-HT2c, 5-HT3, and 5-HT6receptors, catecholamines at alpha 1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors is suggested to have a valuable role in CAC
41446015|NCT05243251|DRUG|Placebo|Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug
41446016|NCT05487625|BEHAVIORAL|High-ventilated cigarette alone|High-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
40925737|NCT00023127|PROCEDURE|Integrated Pest Management|
40925738|NCT02188901|OTHER|Sonazoid-enhanced ultrasonography|Sonazoid (perflubutane) \[GE healthcare\]
40925739|NCT03869801|PROCEDURE|erector spinae plane block|Ultrasound-guided bilateral Erector spinae plane (ESP) block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
40925740|NCT03869801|PROCEDURE|quadratus lumborum block|Ultrasound-guided bilateral Quadratus lumborum (QLB) type 2 block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
41111641|NCT01679951|DRUG|Methotrexate|Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
41111642|NCT02208258|DEVICE|Consure 120 Stool Management System|Novel device designed to manage fecal incontinence in hospitalized bedridden patients with liquid to semi-formed stool.
41111643|NCT05949749|DIAGNOSTIC_TEST|Epitope exploration|Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.
41111644|NCT05727202|DIAGNOSTIC_TEST|The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel|A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).
41111645|NCT03951207|DRUG|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
41446017|NCT05487625|BEHAVIORAL|Low-ventilated cigarette alone|Low-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
41446018|NCT05487625|BEHAVIORAL|High- and low-ventilated cigarette with high-ventilated cigarettes increasing in price|High- and low ventilated cigarettes are available in the Experimental Tobacco Marketplace with high-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
41453322|NCT04121507|DIAGNOSTIC_TEST|PET-CT or CT|Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.
40925741|NCT04569071|DEVICE|Sinovation Laser Ablation System|In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.
40925742|NCT03865888|DRUG|Cyclosporins|Cyclosporins eye drops to be administered in dry eyes
40925743|NCT03865888|DRUG|Tacrolimus|Tacrolimus eye drops to be administered in dry eyes
40925744|NCT06270758|DIAGNOSTIC_TEST|CT scan at the femur|Additional CT scan which is not part of the standard clinical path
40925745|NCT03330392|DIETARY_SUPPLEMENT|AGP|take two tablets per day (500 mg/day) for 8 weeks
40925746|NCT03330392|DIETARY_SUPPLEMENT|Placebo|take two tablets per day (500 mg/day) for 8 weeks
40925747|NCT00830908|DEVICE|HairMax LaserComb|LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
40925748|NCT04656899|BEHAVIORAL|Reminders messages to improve adherence.|"If the participant does not take their medicine at the correct time, a light on the smart pill cap begins to flash. If the bottle is not opened within 20 minutes, the Pillsy application sends an SMS text reminder to the participant's phone. If the bottle is not opened within 60 minutes, the participant receives an automated phone call. The participant may also receive brief motivational phrases or craving surveys that can be tailored to participant needs and preferences. Also, based on pre-populated and adjustable craving and withdrawal levels, the participants' provider could be contacted automatically based on the thresholds being crossed. Pillsy also includes a Pillsy Helpers feature in which the patient can name friends and family members who will also receive a text message notification one hour after a missed dose."
40925749|NCT04294264|DRUG|Oxaliplatin|Given IV
40925750|NCT04294264|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
40925751|NCT05806827|DIAGNOSTIC_TEST|Virological screening|The preoperative viral screening protocol will start with a self-assessment questionnaire that will be provided to all the enrolled patients, where they will be asked to indicate previously SARS-CoV-2, HPV, EBV, CMV infections. Collection of peripheral blood mononuclear cells (PBMCs) from blood samples and serum specimens for the virological screening (HPV, EBV, CMV, SARS-CoV-2). Preoperative MoCA assessment, follow-up 5 days, 3 months and 6 months after the surgery.
40925752|NCT04313647|BIOLOGICAL|1X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)
40925753|NCT04313647|BIOLOGICAL|2X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)
40925754|NCT04313647|BIOLOGICAL|4X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)
41111646|NCT03951207|DRUG|Rosuampin 20/5mg|Rosuampin 20/5mg qd for 8 weeks
41111647|NCT03951207|DRUG|Amlodipine/Atorvastatin 5/20mg|Amlodipine/Atorvastatin 5/20mg qd for 8 weeks
41111648|NCT03923491|BEHAVIORAL|Healthy Feeding, Healthy Eating|Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers
40925755|NCT04313647|BIOLOGICAL|6X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)
40925756|NCT04313647|BIOLOGICAL|8X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)
40925757|NCT04405232|OTHER|Non-interventional|Observational study
40925758|NCT05181280|OTHER|Intervention Group|"Exposure session will consist of 15 social media ideal body message posts."
40925759|NCT05181280|OTHER|Control Group|Exposure will consist of 15 social media posts on infant feeding tips.
40925760|NCT06455267|DIETARY_SUPPLEMENT|Now Foods L-Ornithine Capsules|L-ornithine is an amino acid that helps the liver clear toxic ammonia and plays an important role in liver protection and treatment of hepatic encephalopathy. Now Foods L-ornithine capsules are an ornithine supplement containing 500mg of L-ornithine per capsule. Patients in the L-ornithine supplementation group take ornithine capsules orally twice a day, three capsules each time, for 8 weeks.
40925761|NCT01607203|DRUG|Decapeptyl Daily|Decapeptyl 0.2 mg SC once 1day
40925762|NCT01607203|DRUG|pregnyl|5000 IU SC
41446019|NCT05487625|BEHAVIORAL|Low- and high-ventilated cigarette with high-ventilated cigarettes increasing in price|Low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with low-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
41446020|NCT05487625|BEHAVIORAL|Usual, high- and low-ventilated cigarette with usual cigarettes increasing in price.|Usual cigarette, low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with usual cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
41111649|NCT03923491|BEHAVIORAL|Reading Readiness|Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
40925763|NCT01606657|PROCEDURE|Irrigation|The patient will receive irrigation as a part of their wound care
40925764|NCT01606657|OTHER|No Irrigation|The patient will not receive irrigation as part of their wound care
41111650|NCT05054764|DEVICE|Promus PREMIER BTK DES|Collect one year data of the Promus PREMIER BTK drug eluting stent in CLTI patients
41111651|NCT01526642|DEVICE|Non Invasive Ventilation|NIV during night
41111652|NCT01386138|BEHAVIORAL|Psycho-education|Receive RBT education and peer-support in a group format.
41111653|NCT01386138|BEHAVIORAL|Experimental|Receive RBT education and a pro-active counseling method
41111654|NCT04594759|DRUG|Isotretinoin|Participants will be getting isotretinoin (1-1.5 mg/kg/week)
41446021|NCT01369368|DRUG|Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.|Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
40752495|NCT01554852|DRUG|Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
40925765|NCT04218565|BIOLOGICAL|Golimumab (GOL)|Patients with refractory BD associated uveitis will receive Golimumab therapy, the efficacy and corticosteroids-sparing effects will be evaluated.
40925766|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean protein concentrate|Protein concentrate treatment
40925767|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean protein isolate|Protein isolate treatment
41111655|NCT05981534|DRUG|Vitamin D|4000IU/day vitamin D supplement will be used for 6 months
41111656|NCT05981534|DRUG|Placebo|Placebo will be used for 6 months
41111657|NCT03356444|DRUG|Abiraterone Acetate|Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
41111658|NCT03356444|DRUG|Docetaxel|"Docetaxel: intravenously, 75 mg/m\^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment"
41111659|NCT00551876|DRUG|MK0653, ezetimibe / Duration of Treatment: 30 Weeks|
41111660|NCT00551876|DRUG|Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks|
41111661|NCT03853655|RADIATION|Post-operative adjuvant radiotherapy|"Conventional treatment planning, as well as intensity-modulated radiation therapy (IMRT) planning, would be allowed on the study with patients being stratified on the RT technique.~Treatment would be delivered on telecobalt unit (gamma-rays/linear accelerator (6MV photons). All fields would be treated daily.~Phase I: 46 Gray(Gy) in 23 fractions over 4.5 weeks Phase II: 14Gray in 7 fractions over 1.5 weeks~For IMRT, inverse planning would be done on a commercial TPS configured to deliver IMRT using 6MV photons. Patients shall be treated using the simultaneous integrated boost (SIB) technique with 5 fractions being delivered every week."
41111662|NCT02969954|OTHER|Self-efficacy for diabetes management|Participants at both sites will watch a 12 minute video featuring the digital stories on diabetes. Following the video, participants will engage in a brief facilitated discussion regarding motivations and barriers to diabetes management, led by a trained Spanish-speaking facilitator.
41111663|NCT04108754|OTHER|microangiopathic burden|to determine the value of the global microangiopathic burden on the prediction of early stroke risk in a homogeneous cohort of TIA.
41111664|NCT03579368|DEVICE|Symfony implantation|Bilateral Symfony IOL Implantation
41111665|NCT05700513|COMBINATION_PRODUCT|Capsules containing the combination products|Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac
41111666|NCT05700513|DRUG|Placebo capsules|Placebo capsules containing maltodextrin
41111667|NCT00711958|DRUG|HX575, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
41111668|NCT00711958|DRUG|ERYPO®, Janssen-Cilag, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
41111669|NCT02511639|DRUG|Everolimus|Everolimus is formulated as tablets of 10 mg strength for oral administration.
41111670|NCT02511639|DRUG|Aromatase Inhibitors|Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
41111671|NCT04367415|DIAGNOSTIC_TEST|Darwish test for a free endometrial cavity|Darwish test (Office hysteroscopic bubble suction and tubal peristalsis). If the uterine cavity is normal the patient will be allocated as group A
41111672|NCT04367415|DIAGNOSTIC_TEST|Darwish test for an endometrial cavity with endometrial polyps|Darwish test (Office hysteroscopic bubble suction and tubal peristalsis).If there is one or more polyp(s) the patient will be allocated as group B.
41111673|NCT02577419|OTHER|Target Fortification|
41111674|NCT02577419|OTHER|Higher Initial Concentration|
41111675|NCT02577419|OTHER|Portagen Formula|
41111676|NCT04537065|OTHER|cycloplegic refraction|"Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek)."
41111677|NCT01336439|DRUG|Botulinum toxin type A (Meditoxin®)|"In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography."
41111678|NCT01132794|DRUG|Intranasal dexmedetomidine|1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
41111679|NCT01132794|DRUG|Placebo|Intranasal nasal saline
41446022|NCT05493735|DRUG|Lidocaine Hcl 2% Jelly|Participants in the experimental arm will undergo pessary removal and reinsertion after the application of lidocaine topical gel.
41111680|NCT03427255|BEHAVIORAL|CBT group treatment-plus|The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
40925768|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean starch|Starch treatment
40925769|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean flour|Flour treatment
41111681|NCT03427255|OTHER|Waiting-list control condition|Waiting-list control condition during length of active treatment (6 months).
41111682|NCT02786602|GENETIC|pyrosequencing|
41446023|NCT05493735|DRUG|Placebo Jelly|Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
41111683|NCT05402735|DIAGNOSTIC_TEST|Serum uric acid level|Serum uric acid level
41111684|NCT02582710|DIETARY_SUPPLEMENT|VASCAZEN|6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy
41111685|NCT02582710|DIETARY_SUPPLEMENT|PLACEBO|6 weeks treatment with a placebo before the carotid endarterectomy
41446024|NCT04114890|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
41111686|NCT04045977|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
41111687|NCT04045977|DEVICE|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
41111688|NCT04045977|BEHAVIORAL|Standard therapeutic support|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
41111689|NCT05173324|BIOLOGICAL|HPV vaccine|Licensed HPV vaccines (bivalent, quadrivalent, or nonvalent) available in the country of the study site
41111690|NCT05173324|DIAGNOSTIC_TEST|HPV testing|HPV testing with partial genotyping of HPV16/18 (and/or 45) to be used as a primary cervical screening test for all participants regardless of the study arm
41111691|NCT05173324|BIOLOGICAL|HAV vaccine|Hepatitis A virus (HAV) vaccine to be offered as a placebo
41111692|NCT00346333|DRUG|Lutein|12mg/d
41111693|NCT00346333|DIETARY_SUPPLEMENT|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
41111694|NCT00226148|PROCEDURE|Use of a membrane to cover bonedefects around implant|
41111695|NCT00226148|DEVICE|Use of bonechips to fill up defects around implant|
41111696|NCT00226148|PROCEDURE|Use of membrane and bonechips to manage defects|
40925770|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with no faba bean fraction|Control treatment
41111697|NCT02749318|GENETIC|IL-1 genetic test for risk of severe periodontitis|DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
41111698|NCT01387334|BEHAVIORAL|Resistance Exercise Training Program With Rubber Bands|Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
41111699|NCT05356572|DEVICE|Investigational Skin Preparation Device|Removal of hyperkeratotic skin with Investigational Skin Preparation Device
41111700|NCT05356572|DEVICE|GMDN 47102 / Electrode Skin Abrasive Pad|Removal of hyperkeratotic skin with Abrasive Pad for Skin Preparation
41446025|NCT05755438|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).
41446026|NCT05755438|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle controlled period (DBVC).
41446027|NCT06561477|OTHER|Intensive care cirrhosis outcome (ICCO) score|ICCO score will be calculated for the participants to use it as a predictor for mortality and ICU outcome The ICCO score is 0.3707 + (0.0773 x bilirubin (mg/dl)) - (0.00849 x cholesterol (mg/dl)) -(0.0155 x creatinine clearance (ml/min)) + (0.1351 x lactate (mmol/l))
40925771|NCT00179491|BEHAVIORAL|Intercessory Prayer|14 days of intercessory prayer from 3 sites
40925772|NCT02762227|DEVICE|Abdominal high resolution CT|CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
41111701|NCT05356572|DEVICE|UMDNS 13-230 / Biopsy punch (Dermal Curette)|Removal of hyperkeratotic skin with Disposable Dermal Curette
41111702|NCT05454163|OTHER|SNOT 22 questionnaire|22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
41111703|NCT01628237|DEVICE|comparison of spinal cord stimulation|
41111704|NCT03737682|DIAGNOSTIC_TEST|ENzyme linked immunity-sorbet assays|Hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels
41111705|NCT04665661|BEHAVIORAL|High-intensity aerobic training|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
41453323|NCT00948480|BIOLOGICAL|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
41453324|NCT00948480|DRUG|GM-CSF|500 mcg
41111706|NCT04665661|BEHAVIORAL|Wait-list control|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
41111707|NCT05434611|DIAGNOSTIC_TEST|S100A12|The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
41111708|NCT03030248|DRUG|Vancomycin Oral Capsule|We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.
41111709|NCT03030248|DRUG|Placebo Oral Capsule|A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD\&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
41111710|NCT03837028|OTHER|FSFI|Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
41111711|NCT01385891|DRUG|Clofarabine VP 16 ciclophospahamide|Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
41111712|NCT03078634|OTHER|Multi-disciplinary clinic model|Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.
41111713|NCT03078634|OTHER|Standard outpatient care|Standard care provided in outpatient clinics staffed by GI doctors only
41111714|NCT03830658|BEHAVIORAL|Structured Intervention on Self-care with AVF (SISC-AVF)|"Theoretical Part: structured intervention involved an educational group session with the purpose of teaching patients how to identify situations that can compromise AVF working. Each presentation allowed a maximum of eight patients and took 30 minutes. Each presentation was assessed in the end by asking participants to identify the signs and symptoms of infection, thrombosis and steal syndrome and to describe the care to be taken during dialysis and in the period outside dialysis.~Practical Part: started a week after the theoretical part, lasting for two weeks, and was given to each participant in an appropriate room at the beginning of the HD treatment. Interactive training sessions were conducted using an informal approach with the objective of developing skills of inspection and palpation of the AVF arm. Inspection had the purpose of enabling participants to identify situations that could compromise the working of the AVF. Each patient was given two 15-minute sessions."
41111715|NCT04128319|DRUG|T-Guard|Patients will receive 4 doses of T-Guard treatment, administered intravenously as four 4-hour infusions at least two calendar days (no less than 40 hours) apart. Each dose consists of 4 mg/m\^2 Body Surface Area (BSA).
41111716|NCT04707729|DIAGNOSTIC_TEST|ROX index algorithm|"The thresholds of the ROX index for intubation are the following:~* After 2 hours of HFNC: ROX \<2.85.~* After 4 and 6 hours of HFNC: ROX \<3.47~* After 8, 10 and 12 hours of HFNC: ROX \<3.85 If the ROX index is between the abovementioned thresholds and 4.88, the NHF support will be also increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done and the ROX index will be recalculated after 30 minutes of full NHF support. The ROX index will be recalculated in 30 minutes: 1) if the ΔROX is \<0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 20 minutes; and 3) if the ΔROX is \>0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration."
41111717|NCT00464399|DRUG|everolimus|
41111718|NCT04000269|DEVICE|Soterix MxN Neuromodulation device|Up to 2 mA stimulation to primary motor cortex for 10 sessions at 20min per session
41111719|NCT04000269|DEVICE|Sham Stimulation|Uses slight stimulation initially then turns of and provides no stimulation after a few seconds.
41111720|NCT00006276|DRUG|Micellar Paclitaxel|
41111721|NCT02449863|OTHER|Lung ultrasound|Lung ultrasound performed to newborns with respiratory distress
41111722|NCT02129049|OTHER|educational intervention|Participate in the Enhancing Connections Telephone Program
41111723|NCT02129049|BEHAVIORAL|telephone-based intervention|Participate in the Enhancing Connections Telephone Program
41111724|NCT02129049|OTHER|questionnaire administration|Ancillary studies
41111725|NCT03587363|DRUG|Erdafitinib|Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.
41111726|NCT00574743|DRUG|Enteric-coated Mycophenolate Sodium|
41111727|NCT05641311|DRUG|ALXN1840|Tablet for oral use.
41111728|NCT04868188|OTHER|5 blood samples|5 blood samples across 3 occasions/sampling windows (Day 1-4, Day 6-9 and Day 11-14) to determine plasma concentrations of voriconazole
41111729|NCT04868188|GENETIC|Determination of CYP2C19 genotype|A single buccal swab to determine the CYP2C19 genotype will be undertaken during the course of ICU stay.
41111730|NCT03023280|PROCEDURE|Radiofrequency ablation|
41111731|NCT02431663|DRUG|Ketamine|Intravenous administration in continuous
41111732|NCT04871750|DIETARY_SUPPLEMENT|Soy protein|Daily consumption for 24 weeks
41453325|NCT05668650|DRUG|Pembrolizumab|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
40925773|NCT02762227|DEVICE|Contrast-enhanced ultrasonography (CEUS)|CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
41111733|NCT04871750|DIETARY_SUPPLEMENT|Casein protein|Daily consumption for 24 weeks
41111734|NCT02874326|DRUG|Octreotide LAR|
41111735|NCT01700400|DRUG|Everolimus|
41111736|NCT01700400|DRUG|Pemetrexed|
41111737|NCT01700400|DRUG|Carboplatin|
41111738|NCT01700400|DRUG|Bevacizumab|
41111739|NCT06077019|DRUG|Vilanterol and Fluticasone Furoate|Participants inhale 25 µg vilanterol + fluticasone furoate daily
41111740|NCT06077019|DRUG|Indacaterol and Mometasone Furoate|Participants inhale 125 µg indacaterol + mometasone furoate daily
41111741|NCT06077019|DRUG|Placebo|Participants inhale placebo daily
41111742|NCT00281489|DEVICE|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
41111743|NCT00281489|BEHAVIORAL|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
41111744|NCT01924975|PROCEDURE|Saphenous vein cannulation|Intravenous cannulation to saphenous vein
41111745|NCT01924975|DEVICE|ultrasound with a linear transducer (L15-7io)|Portable, bed-side ultrasound to detect saphenous vein
41111746|NCT01924975|DEVICE|A 22 or 24 G intravenous catheter|
41111747|NCT05266599|OTHER|MTA Fillapex root canal sealer|Root canal treatments were performed with MTA Fillapex
41111748|NCT05266599|OTHER|AH Plus root canal sealer|Root canal treatments were performed with AH plus
41111749|NCT03419208|OTHER|SPIN-HAND Program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
41111750|NCT02613676|DEVICE|Transcutaneous bilirubin screening|Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
41111751|NCT02613676|OTHER|Standard care (Visual inspection)|Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
40752496|NCT01554852|DRUG|Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Days 1, 4, 8 \& 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 \& 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
40925774|NCT02762227|PROCEDURE|Cholecystectomy|Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
40925775|NCT00736515|DRUG|Gliclazide MR and Insulin Glargine Injection|Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
41111752|NCT04913779|DRUG|Anti-SARS-CoV-2|Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)
41111753|NCT04913779|DRUG|Placebo|Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
41111754|NCT05360043|DEVICE|laser treatment|All subjects were treated with a 1565-nm NAFL on their left faces for one pass, A 34-40 mJ per microbeam laser was used, and density was 250-300 microbeam per cm2. Their right faces were treated with a 1064-nm LPNY for one pass. We used a spot size of 10 mm in diameter, an energy density of 45-50 J/cm2, pulse width of 300 microseconds, and a repetition rate of 2 Hz. 1064-nm LPNY was equipped with a dynamic cooling device (DCD), the parameter was set as 40/20/0 ms. A total of 5 treatments were carried out at 2-week intervals, and one follow-up session at two months after last treatment. Before each treatment, subjects were asked to wash their face with clean water, and no topical lotion was applied. For post-treatment care, all subjects were advised to use their own moisturizing cream and avoid sun exposure.
41111755|NCT02534350|DRUG|Presatovir|Tablets administered orally or via nasogastric (NG) tube once daily
41111756|NCT02534350|DRUG|Placebo|Tablets administered orally or via NG tube once daily
41111757|NCT01942707|PROCEDURE|abdominoplasty with Scarpa's Fascia|During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.
41111758|NCT01942707|PROCEDURE|Abdominoplasty without Scarpa´s Facia|During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
41111759|NCT04707430|OTHER|blood progesterone test|progesterone levels on blood sample
41111760|NCT01418118|DRUG|Epinephrine|0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
41111761|NCT01418118|DRUG|Norepinephrine|Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
41111762|NCT01418118|DRUG|Dobutamine|Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
41111763|NCT01418118|DRUG|Dopexamine|Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
40925776|NCT00736515|DRUG|Biosynthetic Human Insulin Injection|Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
41111764|NCT04120597|DRUG|Zishen Qingre Lishi Huayu Granules|The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu（Anemarrhena asphodeloides Bge.）, Shengdi（Rehmannia glutinosa Libosch.）, Maidong（Ophio pogon japonicus (L.f) KerGawl.） , Bixie（Dioscorea septemloma Thunb.）, Huanglian（Coptis chinensis Franch.）, Zhuling（Polyporus umbellatus（Pers.）Fries）, Xuanshen（Scrophularia ningpoensis Hemsl.）, Zelan（Lycopus lucidus Turcz. Var. Hirtus Regel）, Danshen（Salvia miltiorrhiza Beg.）， Gancao（Glycyrrhiza uralensis Fisch.）. Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
40925777|NCT01449643|DEVICE|Threshold|
41111765|NCT04120597|DRUG|Placebo|"The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months."
41111766|NCT06454734|DEVICE|Extracorporeal shock wave therapy by radial device|Patients will receive treatment by extracorporeal shock waves therapy (ESWT).
41111767|NCT06454734|DEVICE|Placebo extracorporeal shock wave therapy by radial device|Patients will receive treatment sham extracorporeal shock waves.
41111768|NCT06454734|OTHER|DLT|Patients will receive treatment with decongestive lymphatic therapy (DLT: manual lymphatic drainage, compression)
40752497|NCT01554852|DRUG|Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
40925778|NCT01449643|DEVICE|Sham Threshold|
41111769|NCT03983889|DRUG|Midazolam|Midazolam is used as a common medication for sedation in all groups.
41111770|NCT03983889|DRUG|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
41111771|NCT03983889|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
41111772|NCT03983889|DRUG|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
41111773|NCT03983889|DRUG|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
41111774|NCT05135013|DRUG|Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol|"History of hormonal use as follows:~1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)~2. Duration of hormonal use~3. Type of hormonal drug used: dose, hormone type, route of administration"
41111775|NCT06064357|OTHER|Transverese friction massage and tissue floss technique|"Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf of both lower limbs. TFM on each group of muscle for 30 seconds, 3 sets with 10 seconds rest interval.4 session / week for 6 weeks.~Tissue floss band will be applied on Rectus femoris, hip adductors, calf and hamstring of both lower limbs. Floss band will be wrap around the particular group of muscle from distal to proximal direction with 25 % stretch and 50% overlap and then 10 Reps of rom will be performed the rest interval is 2 mint. 4 sessions / week for 6 weeks.~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf (10 repetitions with at least 8 seconds hold) 4 times / week for 6 weeks."
41111776|NCT00753012|DRUG|Lisdexamfetamine|Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
41111777|NCT04305574|BEHAVIORAL|Use of social media during COVID-19|Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
41111778|NCT04063410|PROCEDURE|Angiography|Undergo standard of care CTA
41111779|NCT04063410|PROCEDURE|MRI-Based Angiogram|Undergo pPCA
41111780|NCT04063410|OTHER|Quality-of-Life Assessment|Ancillary studies
41111781|NCT00161733|DRUG|Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)|
41111782|NCT00161733|DRUG|TISSEEL VH fibrin sealant|
41111783|NCT04881318|OTHER|Waist-High Compression Tights|Waist-high compression tights providing 15-40 mmHg of pressure.
41111784|NCT04881318|OTHER|Abdominal Compression Garments|Abdominal compression garment compressing the abdomen, buttocks, and upper thighs.
40752498|NCT01554852|DRUG|Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 \& 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
40925779|NCT01397097|DRUG|LNG-IUS (BAY 86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
41111785|NCT04881318|DRUG|Medications that modulate heart rate and blood pressure|Medications that modulate heart rate and blood pressure that participants regularly take. These medications include beta-blockers, midodrine, ivabradine and stimulants.
41111786|NCT04493242|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
41111787|NCT04493242|OTHER|Intravenous normal saline|Placebo
41111788|NCT05153551|OTHER|Play-based assessment (RITA-T)|"The RITA-T is a play-based assessment that involves nine different activities that can be done safely with a child seated in the exam room. After scoring the RITA-T, the PEARS PCP will immediately provide feedback to the parent regarding results and next steps.~In addition, parents will complete certain assessments/surveys during the study to evaluate the program."
41111789|NCT02830750|PROCEDURE|Ablation|
41111790|NCT04504916|DRUG|Zilovertamab vedotin|Intravenous infusion
41111791|NCT04973735|DRUG|LY-CovMab|single IV infusion
41111792|NCT02200159|DRUG|Sedation with dexmedetomidine|
41111793|NCT00129948|DRUG|Troxatyl™ (troxacitabine)|
41111794|NCT01102049|DIETARY_SUPPLEMENT|fish, beef, fruit|
41111795|NCT03444649|DRUG|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Idarubicin and Cytarabine)
41111796|NCT03444649|DRUG|Idarubicin|Standard chemotherapy d1-d3 cycle 1
41111797|NCT03444649|DRUG|Cytarabine|Standard chemotherapy d1-d7 cycle 1 and 2
41111798|NCT03444649|DRUG|Daunorubicin|Standard chemotherapy d1-3 cycle 2
41111799|NCT03053388|DRUG|Nitric Oxide|Nitric Oxide given via inhalation in cycles
41111800|NCT03053388|OTHER|Supportive treatment|Supportive treatment (including oxygen)
41446028|NCT06283147|BEHAVIORAL|Risk assessment and Management Programme - Knee Osteoarthritis|"(i) Arthritis education: Topics will cover the 21 key messages identified in International Consensus List of Essential Statements for Osteoarthritis What Do People With Knee or Hip Osteoarthritis Need to Know~(ii) Structured land-based exercise: We have selected strengthening, flexibility training (stretching), and aerobic exercise as our key components because they are most applicable in primary care settings.~(iii) Weight Management: Weight management will be offered for participants with a BMI ≥ 23 kg/m2.~(iv) Counselling support for psychosocial health: counselling support will be provided for those with mild to moderate anxiety and depression, insomnia and loneliness identified in the risk assessment.~(v) Dietary advice: Online dietary education for musculoskeletal health (with reference to local context) will be provided. The dietitian will also provide support regarding specific dietary advice on weight management."
41111801|NCT00182845|DRUG|Donepezil|
41111802|NCT00588809|DRUG|selumetinib|Given PO
41111803|NCT02278393|OTHER|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
41446029|NCT05001958|BEHAVIORAL|Action observation|Participants will view a video of a task performed by a non-disabled actor and then the participants perform the task from the video with their weaker arm \& hand.
41446030|NCT00513253|DRUG|lapatinib|
40925780|NCT01397097|DRUG|68 mg etonorgestrel implant for subdermal use (Nexplanon)|Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
40925781|NCT00603642|DRUG|Placebo|Subcutaneously administered, once a week, for 12 weeks
41111804|NCT02278393|OTHER|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
41111805|NCT05977634|BEHAVIORAL|Bladder training|Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom
41111806|NCT05977634|DEVICE|Transcutaneous tibial nerve stimulation|A combined electrotherapy device capable of applying transcutaneous electrical nerve stimulation will be used. Each session will take 30 minutes. Patient will visit the hospital twice a week for 6 weeks. An electrical current of 0-50 amperes with a frequency of 20 herz, and a duration of 200 micro seconds will be applied using 50x50 mm surface electordes. The aim is to create a tingling sensation without causing any pain on the tibial nerve, at the ankle level.
41111807|NCT02044588|BIOLOGICAL|HBsAg positive kidney allograft donor|
41111808|NCT02754479|DEVICE|Nd:YAG laser|Treatment of lower extremity spider veins
41111809|NCT00002472|DRUG|cisplatin|
41111810|NCT00002472|DRUG|etoposide|
41111811|NCT00002472|PROCEDURE|conventional surgery|
41111812|NCT00002472|PROCEDURE|neoadjuvant therapy|
41111813|NCT00002472|RADIATION|radiation therapy|
41111814|NCT05368025|DEVICE|Mobili-T/Noona|Use of two mobile health systems over a period of 6 months
41111815|NCT06400446|OTHER|Standard care|The babies in this group will receive the standard care of the unit. The vital signs and pain scores of the babies will be recorded before the mother's visit for seven days. The vital signs and pain scores of the infants who received the standard care of the unit during one hour, which is the time of the mother's visit, will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
41111816|NCT06400446|OTHER|Kangaroo care|Kangaroo care will be applied to the experimental group for seven days. Kangaroo care will be started for the babies in the intervention group when the baby is extubated, when the baby starts oral feeding and when the chest incision is closed. Consistent with previous research, mothers will provide skin-to-skin contact for at least 1 hour per day for seven days, starting immediately after feeding. The vital signs and pain scores of the babies will be recorded during the kangaroo care of the mother for seven days. During the kangaroo care, vital signs and pain scores of the infants will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
41111817|NCT01443416|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
41111818|NCT01443416|BIOLOGICAL|10-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
41111819|NCT02993510|PROCEDURE|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
41111820|NCT02993510|DEVICE|Chondro-Gide sutured|Implantation of Chondro-Gide membrane using atraumatic sutures following microfracture via mini-arthrotomy
41111821|NCT02993510|DEVICE|Chondro-Gide glued|Implantation of Chondro-Gide membrane using Fibrin glue following microfracture via mini-arthrotomy
41111822|NCT05148780|DIAGNOSTIC_TEST|Nasal Swab Sample|Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.
41111823|NCT05126004|DRUG|Azacitidine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
40925782|NCT00603642|DRUG|AMG 531|Subcutaneously administered, once a week, for 12 weeks
40925783|NCT01328444|DRUG|GSK 573719 +GW642444 125/25|125mcg/ 25mcg
41111824|NCT05126004|DRUG|N Acetyl L Cysteine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
41111825|NCT01278888|PROCEDURE|Anterolateral thoracotomy|Standard anterolateral thoracotomy
41111826|NCT01278888|PROCEDURE|Posterolateral thoracotomy|Standard muscle sparing posterolateral thoracotomy
41111827|NCT01278888|PROCEDURE|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
41111828|NCT01278888|PROCEDURE|Anterolateral Thoracotomy|Standard anterolateral thoracotomy
41111829|NCT05133063|BEHAVIORAL|Gratitude letter|"Participants are given the following instructions:~Think of someone in your life who you feel like you have never fully or properly thanked for something meaningful or important that they did for you. . . . In the space provided below, please write a note to this person that describes why you feel like you never properly thanked them and letting them know why you feel thankful for something important that they did for you. Though this letter will not actually be sent to this person and is simply an exercise for you, please use this as an opportunity to really explore those feelings surrounding how you feel about what they have done for you and write honestly and openly from your heart. You have ten minutes."
40925784|NCT01328444|DRUG|GSK573719 + GW642444 62.5/25|62.5mcg/25mcg
40925785|NCT01328444|DRUG|GSK 573719 125|125mcg
40925786|NCT01328444|DRUG|GSK 573719 62.5|62.5mcg
41111830|NCT05133063|BEHAVIORAL|Control intervention|"Participants receive the following instructions:~Think of the room you are in.... In the space below, please provide a description of the room you are in. Try to focus on the specific elements in the room, the colours of the wall or objects in the room. Use this writing session as an opportunity to paint a detailed picture of this room and include as much specific information as you can. You have ten minutes."
41111831|NCT02896699|BEHAVIORAL|PrEP Intervention Group|
41111832|NCT02896699|OTHER|Control Group|
41111833|NCT05898152|OTHER|Data collection|A collection about patient's data demographic, neurologic and gynecologic follow-up and satisfaction will be review by questionnaire. And a calendar of epileptic seizures will be completed by patients on 4 months
41111834|NCT00546871|DRUG|Immune Globulin Intravenous (Human), 10%|Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
41111835|NCT00665444|DRUG|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
41111836|NCT03316482|DRUG|Leuplin DPS 11.25mg|Leuplin DPS 11.25mg s.c. every 12 weeks
41111837|NCT01382030|DRUG|EIA chemotherapy|ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1
41111838|NCT02469337|DRUG|Dichloroacetate|Dichloroacetate, an analog of acetic acid has been shown to increase the activation of PDC by inhibiting PDK4 in humans. This drug is expected to shift the metabolism of pyruvate from glycolysis and towards oxidative pathway in the mitochondria
41111839|NCT02469337|DIETARY_SUPPLEMENT|Carbohydrate drinks|preoperative carbohydrate drinks
41111840|NCT02469337|BEHAVIORAL|Moderate intensity exercise|30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate
41111841|NCT00976625|PROCEDURE|Aortic Valve Replacement|Surgical valve replacement of the aorta
41111842|NCT02474394|DEVICE|Mcgrath|The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
41111843|NCT02474394|DEVICE|Macintosh|The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
41111844|NCT02707224|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
41111845|NCT02707224|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
41111846|NCT02707224|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
41111847|NCT01015404|DRUG|Trafermin|Administered to the bone defect during flap operation
41111848|NCT01087762|BIOLOGICAL|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
41446031|NCT04407403|BEHAVIORAL|Tai Chi tailored for lowering blood pressure (PRESSURE)|PRESSURE Tai Chi routine consisted of eight forms following Yang style. PRESSURE was tailored for the targeted health outcome of BP in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored PRESSURE to emphasize slow, deep breathing and relaxation by utilizing Tai Chi movements that: 1) were slow and smooth; 2) without break or pause; and 3) had minimal muscular force and exertion. Investigators included the following eight forms in PRESSURE: 1) Begin Tai Ji Quan; 2) Part the Horse's Mane; 3) Brush Knee and Push; 4) Cloud Hands; 5) Open and Close; 6) Part the Grass; 7) Single Whip; and 8) Finish Tai Ji Quan.
41111849|NCT01087762|BIOLOGICAL|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
41111850|NCT01087762|OTHER|Placebo|Matching Placebo to CZP injection.
40925787|NCT01328444|DRUG|GW642444 25|25mcg
40925788|NCT01328444|DRUG|Plb|Comparator
41111851|NCT05237921|BEHAVIORAL|Combined Exercise and Dietary Intervention (CEDI)|"Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status.~Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Forticare®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake."
41111852|NCT05237921|BEHAVIORAL|Standard Care|Standard Care
41111853|NCT04655131|DIETARY_SUPPLEMENT|Whey protein isolate|Commercially available, FDA approved whey protein isolate for dietary supplementation
41111854|NCT03988569|OTHER|audiovisual decision aid|Will view AVDA and then have opportunity for questions with physician before signing consent forms
41111855|NCT06457971|DEVICE|Robotic Ventral Hernia Repair|The AnovoTM Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS with graspers and electrosurgery devices for endoscopic manipulation of tissue including grasping, blunt dissection, approximation, and electrosurgery, during single site, laparoscopic surgical procedures. The AnovoTM System's articulated robotic arms allow the surgeon to access and reach different structures in the pelvic and abdominal cavity. Closing the fascial defect robotically is easier from a technical standpoint than attempting it with classical laparoscopic instruments
41111856|NCT05116839|DEVICE|the first 15 minutes with pressure support ventilation|PSV pressure support ventilation:triggered by minute volume \< 3 Liter ,with no frequency
41111857|NCT05116839|DEVICE|the following 15 minutes ventilation will be changed to continous positive air way pressureCPAP mode|continous positive air way pressure CPAP mode at 10 cm H2o .
41111858|NCT05116839|DEVICE|i gel air way|supraglottic air way device
41111859|NCT03387319|BEHAVIORAL|Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
41111860|NCT03387319|BEHAVIORAL|Non-Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
41111861|NCT00552552|BEHAVIORAL|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
41111862|NCT00552552|BEHAVIORAL|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
41133342|NCT03802994|OTHER|Peripheral blood sample|Peripheral blood samples (30-60 mL) will be collected at day 0 (pre-immune), day 7, and day 30 (4 weeks post-PPV23) for groups 1-4 and at days 366, 373 and 396 for group 5. In addition, day 5, and 10 blood samples will be obtained from a limited (n=10) number of elderly RT participants to determine the optimal time point for circulation of PPS-specific B cells. Yearly blood samples will be obtained thereafter for serum antibody and OPA analyses to test longevity of antibody and OPA responses. Samples obtained from days 0, 30 and yearly samples will be used for antibody titers and opsonophagocytic assays. Samples from day 0 (day of vaccination with PCV13) and day 7 will be used for flow cytometric analysis.
41111863|NCT05985824|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
41111864|NCT01290224|OTHER|scrambler therapy|Undergo MC5-A therapy
41111865|NCT01290224|PROCEDURE|sham intervention|Undergo sham procedure
41111866|NCT01290224|OTHER|questionnaire administration|Ancillary studies
41111867|NCT01159704|BEHAVIORAL|Peer Education Model|The peer education intervention will be delivered by trained outreach workers in a group format with 8-10 indexes over five sessions spanning three weeks. The sessions will focus on knowledge of HIV transmission, self-efficacy and skills-building regarding HIV risk reduction, with an emphasis on the dissemination of such information and skills to network members.
41111868|NCT01159704|BEHAVIORAL|HIV Counseling and Education Model|"The C \& E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
41111869|NCT01188499|DRUG|Birinapant|
41111870|NCT00887835|DEVICE|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
41111871|NCT02748265|DRUG|Inhaled Epoprostenol and phenylephrine|After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
41111872|NCT02748265|DRUG|Sevoflurane|Volatile maintenance anesthesia
40752499|NCT01554852|DRUG|High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)|High dose melphalan therapy and autologous stem cell transplant to be given as per local practice
40752500|NCT05922735|BEHAVIORAL|Questionnaire|Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox
41111873|NCT02748265|DRUG|Propofol|Intravenous maintenance anesthesia
41111874|NCT06373744|DRUG|cyclophosphamide , methotrexate , vinorelbine ,capecitabine|The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
41111875|NCT03414736|DRUG|SAR425899|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
41111876|NCT03763721|DEVICE|intraoperative optical coherence tomography (iOCT)|"The OCT technology is fully integrated in a conventional ophthalmic surgical microscope (Zeiss LUMERA 700 platform). The OCT consists of A-scans (length/thickness) and B-scans (X-Y plane) to create the three dimensional image. Alternatively C-scans (3D cube scans) are available. All scans are non-invasive. The surgeon can continue surgery whilst using the iOCT and view a live image projected in the binocular or on the external screen and the video stream can be recorded as well.~The iOCT features are controlled using the foot paddle and the images are recorded on device. Investigations will be performed in a standardized matter: iOCT imagery and cube-scans after graft insertion, air injection, and the end of surgery."
41111877|NCT00597038|DRUG|Dasatinib and Dacarbazine (DTIC)|"Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m\^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m\^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m\^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m\^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m\^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m\^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m\^2."
41111878|NCT04558112|DRUG|L-DOPA|two gel capsules with 100mg L-DOPA (with 25 mg carbidopa to inhibit peripheral decarboxylase)
41111879|NCT04558112|DRUG|Placebo|two gel capsules of placebo
41111880|NCT03776890|BEHAVIORAL|DeStress for Health Program|The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
41111881|NCT05575869|OTHER|(online) PRONEtect educational material|This is a website containing educational material like short simulation videos on how to turn a patient from supine-to-prone and prone-to-supine positioning, how to protect the skin from incontinence, or before securing endotracheal-/nasogastric tubes, how to reposition the patient to prevent pressure injuries, a full protocol regarding prone positioning etc.
41111882|NCT05575869|OTHER|Classic (normal) one hour lesson/lecture|As per normal, a classroom lecture given by the nursing school by one of the nursing school lecturers.
41111883|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml|0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
41111884|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml|0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
41111885|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml|0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
41111886|NCT04297917|BIOLOGICAL|ChAdOx1-HBV|chimpanzee adenovirus-vectored hepatitis B virus vaccine
41111887|NCT02808338|DEVICE|Philips BiPAP AutoSV Advanced System One|Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
41111888|NCT02808338|DEVICE|Modified Philips BiPAP ASV|This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
41111889|NCT02808338|DEVICE|ResMed S7 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
41111890|NCT02808338|DEVICE|ResMed S9 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
40925789|NCT00428584|DRUG|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
41111891|NCT05159297|OTHER|Reference values|Normative reference values of coordination tests will be obtained
41111892|NCT00933088|OTHER|questionnaires|"The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.~Mothers will be asked to complete data form."
41111893|NCT00176371|BEHAVIORAL|physical exercise|
41111894|NCT00971711|BIOLOGICAL|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
41111895|NCT05607186|RADIATION|neoadjuvant long course chemoradiotherapy|neoadjuvant long course chemoradiotherapy consist of radiosensitizing 5FU or capecitabine and 50.4 Gy in 28 fractions over 5 weeks
41111896|NCT06028282|RADIATION|SPECT|SPECT of thyroid traced with I-131
41111897|NCT03728036|BEHAVIORAL|conventional rehabilitation|The investigated cohort will be exposed to 'standard care' including conventional rehabilitation therapy.
41111898|NCT02009839|BEHAVIORAL|Meeky Mouse program|
41111899|NCT02009839|OTHER|Computer Games|
41111900|NCT02695290|DRUG|Afatinib|
41111901|NCT05117372|OTHER|treatment with immunotherapy and diffuse infiltrative lung disease|Patients treated with with immunotherapy and developing diffuse infiltrative lung disease
41111902|NCT05117372|OTHER|Patients requiring carcinologic lobectomy|Patients requiring carcinologic lobectomy
41111903|NCT03781206|DEVICE|PICO™ 7|PICO™ system (Smith\&Nephew Healthcare, Hull, UK) is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips.
41111904|NCT02168751|DRUG|propofol|
41111905|NCT02168751|DRUG|Sevoflurane|
41111906|NCT04189900|DRUG|Triptorelin|Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
41111907|NCT05095051|DEVICE|Paxman Cryocompression System (PCCS)|"Establishing optimal temperature and pressure for limb cryocompression therapy. Healthy subjects will undergo 3 hours of limb cryocompression.~The cryocompression device used in this study consists of a control unit, and limb wraps. The control unit contains the coolant reservoir and pump to circulate the coolant and air for compression. It is able to thermoregulate (control the temperature of the circulating coolant) and offer cyclic air pressure in the wraps. The wraps cover the limbs from the elbow/knee to the fingers/toes."
41111908|NCT05095051|DEVICE|Paxman Cryocompression System (PCCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Limb cryocompression sessions comprised of a pre-cooling period (up to one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, limb cryocompression will be administered for no longer than four hours."
41111909|NCT05039723|DRUG|Radiesse, Xeomin, Belotero|Rejuvenation with Radiesse, Xeomin, Belotero
41111910|NCT05340244|DEVICE|Investigational ultrasound exam|"Eligible subjects will be enrolled into the study and positioned for their ultrasound exam. Standard clinical practice procedures will be followed using the standard of care device at the site to complete the clinically indicated exams.~After the clinically indicated exam, portions of the TTE and/or TEE exam will be repeated with the investigational ultrasound device."
41111911|NCT00475319|DRUG|placebo|comparison of different dosages of drug
41111912|NCT00475319|DRUG|1% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
41111913|NCT00475319|DRUG|2% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
41111914|NCT02599935|DIETARY_SUPPLEMENT|Hypercaloric beverages|Nutritional supplement: Hypercaloric beverages
41111915|NCT02599935|OTHER|standard treatment|No other than standard treatment
41111916|NCT02599935|OTHER|educational structured counseling|Nutritional counseling leaded to patient and caregivers
41111917|NCT00057837|BIOLOGICAL|G-CSF|G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery \> 10,000 dL.
41111918|NCT00057837|DRUG|Cisplatin|Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
41111919|NCT00057837|DRUG|Etoposide|Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
41111920|NCT00057837|DRUG|Irinotecan|50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
41111921|NCT00057837|DRUG|Topotecan|Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
41111922|NCT03629444|RADIATION|ct scan|all patients will be subjected to CT scan and anthroprometric measurments
41111923|NCT05964231|DIETARY_SUPPLEMENT|Heat-treated PS23|Lactobacillus paracasei PS23 heat-treated, 2caps daily use
41111924|NCT05964231|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, 2caps daily use
41111925|NCT03244579|BEHAVIORAL|Dietary Intervention|Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.
41111926|NCT05983107|DRUG|Everolimus|Everolimus combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
41111927|NCT05983107|DRUG|Chidamide|Chidamide combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
41111928|NCT05983107|DRUG|Endocrine therapy|Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.
41111929|NCT05983107|DRUG|Ovarian function suppression(OFS)|Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.
40925790|NCT00428584|DRUG|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
41111930|NCT05773326|DRUG|Temsirolimus|TORISEL® (temsirolimus) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
41111931|NCT04298788|OTHER|Blue dishware|blue dishware is used for plates and bowls
41111932|NCT01980069|DRUG|Sugammadex|In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.
41111933|NCT01980069|DRUG|Neostigmine|In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
41111934|NCT00367991|DRUG|Recombinant human erythropoietin alfa (drug)|200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
41111935|NCT00367991|DRUG|Placebo|Normal saline to match active drug (rHuEpo)
41111936|NCT01165658|RADIATION|Proton Therapy|The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
41111937|NCT00666276|DRUG|linezolid (Zyvox)|"Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration."
41111938|NCT01688089|DRUG|ODM103|
41111939|NCT01688089|DRUG|Placebo|
41111940|NCT01688089|DRUG|Entacapone|
41111941|NCT01688089|DRUG|Levodopa/carbidopa|
41111942|NCT02081274|PROCEDURE|Surgery for congenital heart disease|
40925791|NCT05421884|BEHAVIORAL|5 Love Languages|Emotional support will be given through utilizing the patient/partners specific Love Language (physical touch, words of affirmation, gifts, quality time, and acts of service).
41111943|NCT06386562|BEHAVIORAL|Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program|The internet-based parenting support program is based on social learning theory. A foundation is the Family Check-up program (FCU), which includes approaches from motivational interviewing (MI). The parenting support is also based on similar CBT-parenting strategies as in other evaluated face-to-face CBT-parenting support programs (e.g., Comet) as well as internet-based programs (e.g., iComet; ParentWeb).
41111944|NCT06386562|BEHAVIORAL|Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program with additional parental support|The internet-based parenting program includes the same contents and chat-function as in the other condition. The focus for the digital/phone meetings is to explore potential questions, problem-solve around potential challenges, and motivate parents to practice strategies and complete modules.
41111945|NCT05814211|DEVICE|Investigational device - newly developed intermittent catheter|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
41111946|NCT05814211|DEVICE|Comparator device #1 - SpeediCath Eve|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
41111947|NCT05814211|DEVICE|Comparator device #2 - SpeediCath Compact Plus Female|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
41111948|NCT06017167|DRUG|Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .|compare antiemetic effects between dexmedetomidine and ondansetron in the first group versus dexamethasone and ondansetron in the second group
41111949|NCT06017167|DRUG|Ondansetron 4mg + dexamethasone 8mg + normal saline.|Group II: Ondansetron 4mg + dexamethasone 8mg + normal saline.
41111950|NCT00881842|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
41111951|NCT06354283|BEHAVIORAL|Progressive Muscle Relaxation Exercises|Progressive muscle relaxation techniques were explained to the women from the couples assigned to the Intervention Group by a researcher. In addition to relaxation exercises, deep breathing movements were also explained to the women and progressive muscle relaxation exercises and breathing exercises were performed together. The importance of the exercises and how to do them were explained to the women by the researcher for about 30 minutes and then demonstrated practically for 30 minutes. Each progressive muscle relaxation exercise session lasted approximately 20-25 minutes. The women in the intervention group continued the exercises at home three times a week for four weeks.
41111952|NCT04709055|OTHER|Co-management|Personalized and intensive geriatric peri-operative care
41111953|NCT04709055|OTHER|Usual care|Pre-operative and post-operative geriatric care as per usual practice
41111954|NCT02830152|DEVICE|LAAO|The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.
41111955|NCT02830152|DRUG|Medical Therapy|Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
41111956|NCT06241989|OTHER|health education supported by motivational interviewing|The intervention group will receive health education supported by motivational interviewing consisting of 6 sessions. Within the scope of the intervention, the first two sessions will be health education and the last four sessions will be motivational interviewing.
41111957|NCT04501276|DRUG|ADG116|For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
41111958|NCT04501276|DRUG|ADG106|For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
41111959|NCT04501276|DRUG|anti PD1 drug|For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
41111960|NCT01348191|PROCEDURE|Myometrial biopsy|At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
40925792|NCT04958395|DIAGNOSTIC_TEST|FFR and d-FFR|Measure FFR and d-FFR
41111961|NCT06385886|BEHAVIORAL|Linkage Coordinator|The Linkage Coordinator (LC) will be the initial contact with unaffiliated SCD patients to establish a relationship, champion preventative services, and support them in engaging with an SCD specialist by helping patients address barriers to care. Study staff will provide initial and ongoing training to the LC to ensure they have adequate support to effectively engage with patients.
41111962|NCT03329066|BEHAVIORAL|MAST - Managing Asthma & Sleep in Teens|This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.
41111963|NCT03329066|BEHAVIORAL|ASMA - Asthma Self-Management for Adol|This behavioral intervention focuses only on asthma care.
41111964|NCT03329066|BEHAVIORAL|Information & Referral Control Group|Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
41111965|NCT03727854|DIETARY_SUPPLEMENT|Premeal protein enriched bar|Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).
41111966|NCT03727854|BEHAVIORAL|Dietary modification|Subjects in this group will follow diabetes diet education.
41111967|NCT00940992|DRUG|DER 45 EV|Topical application to face for 12 weeks
41111968|NCT00940992|DRUG|Vehicle|Topical application to face for 12 weeks
41111969|NCT04225780|DRUG|Low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10\^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group, or ganciclovir group. Low-dose IL-2 is defined as 1 million IU per day subcutaneously.
41111970|NCT04580303|DRUG|collagenase clostridium histolyticum|Delivered via uniform grid injection techniques.
40925793|NCT01449942|BIOLOGICAL|DNAzyme targeting EBV-LMP1 (DZ1)|"DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
41111971|NCT02061228|DEVICE|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
41111972|NCT01441934|DRUG|Sildenafil citrate|sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
41111973|NCT01441934|DRUG|Sugar pills|placebo t.i.d.
41111974|NCT02378714|DRUG|Varenicline|Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
41111975|NCT02378714|BEHAVIORAL|BASC|"The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions."
41133343|NCT03848975|OTHER|Simulation training for ECV|Intervention for the ECV group is a ECV simulation training. The group will have theoretical courses and five simulation sessions with four ECV simulation on a model (i.e., a total of 20 ECV), associated with clinical practice in the delivery room.
41111976|NCT02378714|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
41111977|NCT05188781|DRUG|Pembrolizumab combined Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
41111978|NCT04195516|OTHER|web based training,individual counseling, using reminders|"Health Promotion Model based Health Promotion Program will be applied to the experimental group. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.~Within the context of the Web Based Health Promotion Program, 8 weeks of training to improve healthy eating and physical activity behaviors, individual counseling will be given.~Colorful picture reminders will be sent to the experimental group through Whatsapp groups.~At the end of the intervention, cognitive and physical measurements of the students will be done at 1st, 3rd and 6th months."
41111979|NCT02067026|DIETARY_SUPPLEMENT|Aleurone|
41111980|NCT02067026|DIETARY_SUPPLEMENT|Placebo|
41111981|NCT05184946|DRUG|Camrelizumab Combined with SOX|Administer camrelizumab and SOX regimen in the adjuvant treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma
41111982|NCT03199781|DEVICE|Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics|Patients will be treated with motorized mechanical massage with the Dermothonus Slim® electromedical equipment (Ibramed- Brazilian Industry of Electrical Equipment) associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
41111983|NCT00834834|DRUG|Fluoxetine|Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
41111984|NCT00834834|BEHAVIORAL|DBT|One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
41111985|NCT00834834|DRUG|Citalopram|Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
40925794|NCT01449942|OTHER|Saline|"0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
40925795|NCT00181636|DRUG|Galantamine-CR|
40925796|NCT02933671|PROCEDURE|Suprainguinal fascia iliaca (SIFI) block|An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.
40925797|NCT02933671|PROCEDURE|Sham block|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
40925798|NCT02933671|DRUG|Ropivacaine|Local anesthetic (numbing drug)
40925799|NCT02933671|DRUG|Saline|Salt water placebo
41111986|NCT03656094|DRUG|Pembrolizumab plus chemotherapy|Pembrolizumab plus chemotherapy
41111987|NCT03656094|DRUG|Placebo plus chemotherapy|Placebo plus chemotherapy
41111988|NCT02905812|OTHER|RGI & Massage|A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
41111989|NCT02705937|OTHER|Dairy product|Dairy products are given to patients with the instruction to eat as many products as necessary to provide them with some relief (within a limit of 6 per day) for 14 days
41111990|NCT02705937|DEVICE|Aequasyal mouth spray|The mouth spray will be used by patients as needed (according to the package leaflet) for 14 days
41111991|NCT03498170|DRUG|BCT197|Single dose of BCT197
41111992|NCT03498170|DRUG|Itraconazole 200 mg|Single dose of itraconazole
41111993|NCT00717626|DRUG|Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS|Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is \< 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
41111994|NCT01029093|OTHER|no intervention, MRI and motor skill test|Two MR Investigations at two different times
41111995|NCT05417893|DEVICE|MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)|The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.
41111996|NCT01180153|DRUG|S-1 oxaliplatin|S-1 (20mg, 25mg); L-OHP (50 mg)
41111997|NCT05103748|BEHAVIORAL|Traditional vestibular rehabilitation|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target.
41111998|NCT05103748|BEHAVIORAL|Cognitive and vestibular dual task training|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
41111999|NCT03988504|DIAGNOSTIC_TEST|Routine check up including genetic testing|Intervention is a routine check up including preemptive genetic testing
41112000|NCT00004004|DRUG|procarbazine hydrochloride|
41112001|NCT03137966|DRUG|Deferoxamine|Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
41112002|NCT03137966|DRUG|Placebo|Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
41112003|NCT00644475|DRUG|Imidapril|tablets; 5, 10, 15, 20 mg; od; 12 weeks
41112004|NCT00644475|DRUG|Candesartan|tablets; 8, 16, 24, and 32 mg; od; 12 weeks
41112005|NCT02379546|DRUG|Desflurane|Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
41112006|NCT02379546|DEVICE|Bispectral index monitoring|Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
41112007|NCT03123835|PROCEDURE|Endoscopic Intervention|After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
41112008|NCT01296425|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
41112009|NCT04010318|PROCEDURE|Spinal Anesthesia|The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
41112010|NCT04618224|DIAGNOSTIC_TEST|DDART Testing|One randomly selected eye is included for each study participant. Participants respond to the DDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
41112011|NCT04618224|DIAGNOSTIC_TEST|wDDART Testing|One randomly selected eye is included for each study participant. Participants respond to the wDDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
41112012|NCT02452242|DRUG|ABX464|25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
40925800|NCT05535218|DRUG|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|"Neoadjuvant treatment: 10 mg/kg sacituzumab-govitecan IV, on days 1, 8, of each 21 day cycle; Pembrolizumab will be administered in combination with sacituzumab-govitecan on day 1, every 21 days, at the standard dose of 200 mg intravenously. A total of 4 cycles is planned before surgery.~After surgery patients will receive additional 13 cycles of pembrolizumab at the standard dose, every 3 weeks, accounting for a total of 17 cycles of perioperative pembrolizumab (neoadjuvant + adjuvant)."
41112013|NCT02452242|OTHER|Placebo|1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
41112014|NCT05633368|OTHER|Questionnaires|"Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~* Patient Health Questionnaire (PHQ-9)~* Clinical Global Impression (CGI)~* Scaling question regarding depressive symptomatology"
41112015|NCT05241847|BEHAVIORAL|PeLTQL delivery via electronic means|Delivery of PeLTQL scoring information to clinicians via electronic means.
41112016|NCT00866866|DRUG|N-Acetyl Cysteine|600 mg PO BID
41112017|NCT00866866|DRUG|Placebo|1 tab PO BID
41112018|NCT00255281|DRUG|AZD7009, no generic name available|
41112019|NCT00870207|BEHAVIORAL|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
41112020|NCT02932709|BEHAVIORAL|suicide attempt|suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
41112021|NCT02194933|DRUG|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
41112022|NCT02135172|BEHAVIORAL|Sitting|
40925801|NCT05292547|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS using Magventure TMS system is delivered at the dorsolateral prefrontal cortex of consented subjects according to 3 different stimulation schedules.
41112023|NCT02135172|BEHAVIORAL|Standing|
41112024|NCT02135172|BEHAVIORAL|Walking|
41112025|NCT04906278|DEVICE|Foley catheter balloon|A Cusco speculum will be placed and a 16F Foley catheter will be inserted into the cervix using ring forceps. Then the balloon will be inflated with 40 ml of saline and it will be pulled out to ensure the balloon covered the internal os of the cervix
41112026|NCT04906278|PROCEDURE|Amniotomy|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip. Care should be taken to protect maternal vaginal tissues from the forceps. Once the forceps reach the amniotic sac, the tip is pushed up against the sac with the index or middle finger of the internal hand to pierce the membranes. The nature of amniotic fluid will be checked.
41112027|NCT04906278|DRUG|Oxytocin|The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.
41112028|NCT05134025|OTHER|Pump settings|Alteration in the pump setting prior to exercise commencement
41112029|NCT02949206|DRUG|JNJ-64179375|During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
41112030|NCT02949206|DRUG|Placebo|Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
41112031|NCT02949206|DRUG|4 Factor Prothrombin Complex Concentrate (PCC)|Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
41112032|NCT01222910|DRUG|Valacyclovir hydrochloride|
40925802|NCT02919384|OTHER|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
40925803|NCT00002642|DRUG|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
40925804|NCT00002642|DRUG|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
41112033|NCT03291470|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1
41112034|NCT03291470|BIOLOGICAL|Placebo Control|2 mL normal saline intraarticular injection
41112035|NCT01288326|DRUG|liraglutide|Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
41112036|NCT01175317|PROCEDURE|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
40925805|NCT00002642|PROCEDURE|conventional surgery|surgery some time between weeks 9 and 12
40925806|NCT00002642|RADIATION|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
41112037|NCT01175317|OTHER|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
40925807|NCT05456282|DEVICE|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
41112038|NCT03907098|DRUG|Endostar|an anti-angiogenesis drug
41112039|NCT03907098|DRUG|Chemotherapy|Physician's choice
41112040|NCT04757103|PROCEDURE|Resection of the retrorectal tumor|Surgical resection of the retrorectal mass
41112041|NCT03400124|PROCEDURE|ISBCS|The intervention group will undergo cataract surgery in both eyes on the same day (ISBCS)
41112042|NCT03400124|PROCEDURE|DSBCS|The usual care / control group will undergo cataract surgery in both eyes on separate days, with a time period of at least two weeks between surgeries.
41112043|NCT02553460|DRUG|ITMHA|Given intrathecally (IT).
41112044|NCT02553460|DRUG|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
41112045|NCT02553460|DRUG|Mitoxantrone|Given IV.
41112046|NCT02553460|DRUG|Pegaspargase|Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
41112047|NCT02553460|DRUG|Asparaginase Erwinia Chrysanthemi|Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
41112048|NCT02553460|DRUG|Bortezomib|Given IV.
41112049|NCT02553460|DRUG|Vorinostat|Taken PO or NG.
41112050|NCT02553460|DRUG|Cyclophosphamide|Given IV.
41112051|NCT02553460|DRUG|Mercaptopurine|Given PO or NG.
40752503|NCT00884065|OTHER|Diacutaneous Fibrolysis|The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
40752504|NCT00884065|OTHER|Diacutaneous Fibrolysis (placebo)|The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
41112052|NCT02553460|DRUG|Methotrexate|Given IV, IM or PO.
41112053|NCT02553460|DRUG|Leucovorin Calcium|Leucovorin rescue PO or IV.
41112054|NCT02553460|DRUG|Cytarabine|Given IV.
41112055|NCT02553460|DRUG|Etoposide|Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
41112056|NCT02553460|DRUG|Vincristine|Given IV.
41112057|NCT01495936|PROCEDURE|RM + Positive End Expiratory Pressure|A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.
41112058|NCT01495936|PROCEDURE|Continuous Positive Airway Pressure|Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
41112059|NCT00001524|DRUG|Thalidomide|
41112060|NCT00478738|DRUG|GSK961081|
41112061|NCT00004878|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40752505|NCT00928005|BEHAVIORAL|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
40752506|NCT00928005|BEHAVIORAL|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
40752507|NCT00496327|BIOLOGICAL|Varicella Virus Vaccine Live (Oka-Merck)|VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
40752508|NCT03978208|DRUG|ATB-346 low dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
40752509|NCT03978208|OTHER|Placebo|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
41112062|NCT00004878|DRUG|cytarabine|
41112063|NCT00004878|DRUG|fludarabine phosphate|
41112064|NCT00004878|DRUG|idarubicin|
41112065|NCT00004878|DRUG|methotrexate|
41112066|NCT00004878|DRUG|tacrolimus|
41112067|NCT00004878|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
41112068|NCT00004878|PROCEDURE|peripheral blood stem cell transplantation|
41112069|NCT04250194|DEVICE|CT-Guided Biopsy|Images will be generated by a CT scanner to accurately insert a needle into the lung nodule allowing a sample to be removed for testing
41112070|NCT04250194|DEVICE|Navigation bronchoscopy|A virtual three-dimensional map of the lung will be generated enabling the physician to perform an anatomically precise biopsy
41112071|NCT03694288|PROCEDURE|Implant removal|Surgical Implant removal
41112072|NCT00012506|DRUG|TNFR:Fc|
41112073|NCT00918957|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
41112074|NCT00918957|DRUG|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
41112075|NCT02010138|PROCEDURE|small-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.
41112076|NCT02010138|PROCEDURE|large-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
41112077|NCT04302805|DRUG|Privigen|Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.
41112078|NCT04302805|DRUG|Thymoglobulin|All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
41112079|NCT04302805|OTHER|Plasma Exchange|All patient will undergo Plasma Exchange before transplantation.
41112080|NCT03625765|DEVICE|SmartGoggles|the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.
41112081|NCT05651399|DRUG|Remimazolam|Patients receive remimazolam at a rate of 1 mg/kg/hr. When a patient's MOAA/S reaches 3 or less, the rate of remomazolam is maintained at a rate between 0.3 mg/kr/hr and 1.0 mg/kg/hr until the end of surgery.
41112082|NCT05651399|DRUG|Propofol|Patients are administered propofol with an effect-site concentration of 1.0 mcg/mL to 2.5 mcg/mL by target controlled infusion.
41112083|NCT03902236|OTHER|Reaction Time and Postural Control|Reaction Time and Postural Control: With ''Fitlight TrainerTM'', 6 light emitting diode (LED) lights placed at certain points on the wall are randomly lit and expected to deactivate them as fast as possible. In the protocol, the leds will be placed according to the physical structure of the person, and the scores of 29 LED's will be kept in seconds. The scores will be compared cystic fibrosis, bronchiectasis and healthy groups.
41112084|NCT03902236|OTHER|Muscle oxygenation|Muscle oxygenation will be assessed with wearable lactate threshold predicting device in cystic fibrosis, bronchiectasis and healthy groups.
41112085|NCT03902236|OTHER|Exercise capacity|Exercise capacity will be assessed with incremental shuttle walk test in cystic fibrosis, bronchiectasis and healthy groups.The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases.The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends The number of shuttles is recorded. Each shuttle represents a distance of ten metres
41112086|NCT03902236|OTHER|Balance|Balance will be assessed with functional reach test in cystic fibrosis, bronchiectasis and healthy groups Functional Reach measures the maximum distance a person can reach forward, the distance of the person standing at the edge of the wall with a 90-degree shoulder flexion and the maximum distance to the front of the thumb will be noted.
41112087|NCT04045886|BEHAVIORAL|Online Educational Modules (Videos)|5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.
41112088|NCT03209037|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
41112089|NCT05719038|DIAGNOSTIC_TEST|observational study|observational study
41112090|NCT00629941|DRUG|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
41112091|NCT02731339|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
41112092|NCT02731339|BEHAVIORAL|Low back pain intensity measurement|Low back pain intensity of the patients was questioned by Visual Analogue Scale
41112093|NCT02731339|BEHAVIORAL|Urogenital symptoms measurement|The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
41112094|NCT02731339|BEHAVIORAL|Disability caused by low back pain|Disability caused by low back pain was assessed with the Oswestry Disability Index
41112095|NCT02577198|OTHER|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
41112096|NCT05007678|DRUG|leflunomide|leflunomide administered orally; daily loading dose of 100mg for 3 days, followed by a daily maintenance dose 10-20mg daily, to a total course of 10 days
41112097|NCT00413595|OTHER|No intervention|Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
41112098|NCT06103669|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
41112099|NCT05830604|PROCEDURE|Occlusal Splint Treatment- Non Invasive treatment|Each patient in the study had temporomandibular disorder. The first-line routine treatment of this disease is an occlusal splint. This treatment was applied to each patient. Surgical intervention was not performed.
41112100|NCT02827617|DRUG|Ibrutinib|Treatment with ibrutinib 420 mg quaque die in the clinical practice
41112101|NCT00411099|DRUG|agomelatine|
41112102|NCT00411099|DRUG|placebo|
41112103|NCT01283750|BEHAVIORAL|care coordination|dementia-related care coordination
41112104|NCT02010372|OTHER|Reminder Recall Report|Practices (administrators) that are randomized to this intervention will receive training in how to run reminder recall reports for patients due to receive any dose of HPV vaccine. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
41112105|NCT02010372|OTHER|Audit-Feedback/Immunization Forecasting Reports|Practices (administrators) that are randomized to this intervention will receive training in how to run audit-feedback/immunization forecasting reports for patients due to receive any dose of HPV vaccine and to determine the % of patients in their practice who have received at least one dose of HPV vaccine within the study period. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
41112106|NCT06406972|OTHER|Brief Admission by self-referral (BA)|Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.
41112107|NCT00384436|DRUG|escitalopram|
41112108|NCT03799536|DRUG|Sotalol|Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
41112109|NCT03799536|DRUG|Sotalex|Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH \& Co. KGaA, Germany
41112110|NCT04217850|OTHER|250 kcal Dietary Energy Restriction|The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).
41112111|NCT04217850|OTHER|Aerobic Exercise|Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
41112112|NCT02425111|DRUG|Vedolizumab|Vedolizumab intravenous injection
41112113|NCT04405713|PROCEDURE|from the onset of symptoms within the first 3 days|ELC within 3 days of onset of ACC
41112114|NCT04405713|PROCEDURE|: from the onset of symptoms within the 4-7 days|ELC 4-7days of onset of ACC
41112115|NCT04405713|PROCEDURE|from the onset of symptoms beyond 7 days|ELC after 7days of onset of ACC
41112116|NCT03127358|DEVICE|AiCure|Smartphone App
41112117|NCT03127358|DEVICE|AiCure with gamification|Smartphone App with gaming.
41112118|NCT01562925|DIETARY_SUPPLEMENT|Red wine|Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
41112119|NCT01562925|DIETARY_SUPPLEMENT|White wine|White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
41112120|NCT01562925|DIETARY_SUPPLEMENT|Beer|Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
41112121|NCT01063686|DEVICE|insemination cervical cap|Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
41112122|NCT00240916|BIOLOGICAL|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
41112123|NCT00240916|BIOLOGICAL|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
41112124|NCT03840486|DEVICE|Non-rebreather mask (NRBM)|The non-rebreather mask (NRBM) will be used to assist in the delivery of oxygen. Participants will be placed on NRBM at different flow rates (15 LPM, 35 LPM, or Flush rate at 55 LPM).
41112125|NCT03840486|DEVICE|Non-invasive ventilator mask (NIV)|The NIV is a non-invasive face (nasal) mask for oxygen delivery. Participants will receive oxygen at 50% FiO2 for 3 minutes, 75% FiO2 for 3 minutes or 100% FiO2 for 3 minutes each.
41112126|NCT03840486|DEVICE|Nasal cannula EtO2 sensor|The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.
41112127|NCT03840486|DRUG|Oxygen (NRBM)|Oxygen will be delivered via the NRBM. Participants will receive oxygen at different flow rates (15 LPM, 35 LPM, or flush rate at 55 LPM).
41112128|NCT03840486|DRUG|Oxygen (NIV)|Oxygen will be delivered via the NIV mask. Participants will receive oxygen at 50% FiO2, 75% FiO2 or 100% FiO2 for 3 minutes each.
41133344|NCT03848975|OTHER|Simulation training for VE|Intervention for the VE group is a simulation training. The group will have theoretical courses and five simulation sessions with four VE simulation on a model (i.e., a total of 20 VE), associated with clinical practice in the delivery room. The investigators will us Kiwi® Omni Cup Vacuum Delivery System, as this is the vacuum system chosen for clinical practice in our obstetric service.
41133345|NCT01121965|PROCEDURE|Pars plana vitrectomy with ILM peeling|Pars plana vitrectomy with ILM peeling
40752510|NCT03978208|DRUG|ATB-346 mid-dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
41112129|NCT04104698|DIAGNOSTIC_TEST|Quantitative EEG|"1. Both groups will undergo evaluation of depression severity using Beck Depression Inventory Scale-II (Arabic Version)~2. Both groups will be assessed for psychological \& cognitive contributes respectively using:~   A. Connor and Davidson Scale for resilience (Arabic Version) B. The scale of Islamic Religiosity Attitude (SIRA)~3. Both groups will do Quantitative EEG (qEEG) to detect electrical, functional and brain mapping changes {Using Neurovirtual BW III, Florida, USA)~4. The quantitative analysis of EEG will focus on the following functions:~Histogram, Topography, Spectrum Analysis, Spectral Differences, Propagation, Positional Diagram, Medium Amplitude, Ranges of Absolute Frequencies, Ranges of Relative Frequencies, CSA, Spectrum, and CSA Compressed."
41112130|NCT03231722|DRUG|Panitumumab|6 mg/kg iv over 60 minutes, day 1
41112131|NCT03231722|DRUG|Irinotecan|150 mg/sqm iv over 60 minutes day 1
41112132|NCT03231722|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
41112133|NCT03231722|DRUG|l-leucovorin|200 mg/sqm iv over 2 hours
41112134|NCT03231722|DRUG|5-fluorouracil|400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
41112135|NCT01125319|OTHER|blood sample|
41112136|NCT05209386|BEHAVIORAL|Dimension-Based Statistical Learning|"Each participant will complete self-paced blocks of stimuli that will first establish a baseline for neural activity and behavioral responses with clear speech, and will then record responses for experimentally manipulated blocks to introduce 1) speech-in-noise and 2) a Canonical-Reverse block to model an accent. Auditory stimuli will be adjusted to a comfortable level for each participant as determined by a calibration process completed by the participant. Each block involves listening to sound via earphones and making a categorical decision between initial consonants (/b/ or /p/) by tapping a button to indicate the word heard by the participant."
40752511|NCT03978208|DRUG|ATB-346 standard dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
41112137|NCT03699293|DRUG|celecoxib 200mg capsule|celecoxib 200mg twice a day for 4 weeks
41112138|NCT03699293|DRUG|naproxen sodium 550mg tablet|naproxen sodium 550mg twice a day for 4 weeks
41112139|NCT03699293|DRUG|Aspirin 81mg tablet|81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
41112140|NCT01725854|BEHAVIORAL|Relaxation Response training|Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
41112141|NCT04375449|DIETARY_SUPPLEMENT|Pep2dia|what is the effect of Pep2dia on postprandial glycemia after a meal rich in carbohydrates (75g)
41112142|NCT04375449|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin
41112143|NCT02764307|DEVICE|Constant jet nebulizer|A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
41112144|NCT02764307|DEVICE|Breath enhanced nebulizer|A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
41112145|NCT02764307|DEVICE|Manual-actuated nebulizer|A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
41112146|NCT02764307|DEVICE|Breath-actuated nebulizer|A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
41112147|NCT03696966|DIETARY_SUPPLEMENT|Portion-Controlled Meals|Increase dietary structure using portion-controlled meals (PCM)
41112148|NCT03696966|BEHAVIORAL|Low-Calorie Diet|Restrict calorie intake daily
41112149|NCT03696966|BEHAVIORAL|Intermittent Very-Low Calorie Diet|Severely restrict calorie intake intermittently
41112150|NCT02319122|OTHER|High Intensity Interval Training|See arm description
41112151|NCT02319122|OTHER|Progressive Resistance Training|See arm description
41112152|NCT03359460|DRUG|Ibrutinib|Given PO
41112153|NCT03359460|DRUG|Lenalidomide|Given PO
41112154|NCT06214117|DRUG|Remimazolam|Anesthesia induction:intravenous Fentanyl 2-3 μg/kg, remimazolam 0.3-0.5 mg/kg and Rocuronium 0.6mg/kg; Maintenance of anesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h), and remifentanil will administer at an initial infusion rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
41112155|NCT06214117|DRUG|Sevoflurane|Anesthesia induction: Anesthesia will induce with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min, and then intravenous fentanyl (2-3 μg/kg) and rocuronium (0.6 mg/kg); Maintenance of anaesthesia: Anesthesia depth will maintain at 1-1.5 minimum alveolar concentration (MAC), and remifentanil was infuse at an initial rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
41112156|NCT04749017|DIETARY_SUPPLEMENT|Experimental product consumption|Consumption of the experimental product 2 capsules daily, morning and evening (450 mg each capsule) for 60 days
41112157|NCT04749017|OTHER|Control product consumption|Consumption of control product of identical appearance 2 capsules daily for 60 days, morning and evening
41112158|NCT03932188|BEHAVIORAL|Mental Health Assessments and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
41112159|NCT03932188|DEVICE|MRI scan|Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
41112160|NCT02341625|DRUG|BMS-986148|
41112161|NCT02341625|BIOLOGICAL|Nivolumab|
41112162|NCT00535977|DIETARY_SUPPLEMENT|Broccoli|400g ITC-enriched broccoli per week for 12 months
41112163|NCT00535977|DIETARY_SUPPLEMENT|Peas|400g frozen garden peas per week for 12 months
40925808|NCT05456282|DEVICE|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
40925809|NCT01150669|OTHER|laboratory biomarker analysis|Samples are analyzed in laboratory studies
41112164|NCT06188611|DRUG|Huazhi Rougan Granule Placebo granule|Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule
41112165|NCT01811407|BEHAVIORAL|Precommitment announcement|
41112166|NCT01811407|BEHAVIORAL|Results announcement|
41112167|NCT01811407|BEHAVIORAL|Walking program|
41112168|NCT06511817|OTHER|No intervention will be performed|No intervention will be performed
41112169|NCT05756010|DEVICE|EMG|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises
41112170|NCT00959946|DRUG|Bosutinib|Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
41112171|NCT00959946|DRUG|Capecitabine|Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
41112172|NCT00565110|BEHAVIORAL|ADAPt-C intervention|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
41112173|NCT04827654|DIETARY_SUPPLEMENT|Weekly produce box and gift card|Weekly box of produce (5-10 lbs) and $10.00 gift card to a local grocery store to purchase preferred produce. If progress on self-goals completed, an additional $10.00 card provided, weekly, for 3 weeks.
41112174|NCT01849055|DRUG|Placebo|Administered orally
41112175|NCT01849055|DRUG|LY3023703|Administered orally
41112176|NCT01849055|DRUG|Celecoxib|Administered orally
41112177|NCT01402830|OTHER|Visual analogue scales (EVAs)|This scale measures the pain intensity.
41112178|NCT03375255|DRUG|SRP-5051|Single dose of SRP-5051 administered as an intravenous (IV) infusion.
41112179|NCT06375291|OTHER|splint /steroid injection/both|pregnant women treated in pain department by splint /steroid injection/both
41112180|NCT03730922|PROCEDURE|Delayed-immediate reconstruction|Skin sparing mastectomy and reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix. Final reconstruction with any reconstructive procedure 6-12 months after completion of chemotherapy and RT.
41112181|NCT03730922|PROCEDURE|Delayed reconstruction|Total mastectomy and delayed reconstruction:with any reconstructive procedure 6-12 months after completion of PMRT
41112182|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 1.1 Usage|Participants will use their Radicle Relief Active Study Product 1.1 as directed for a period of 6 weeks.
41112183|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 1.2 Usage|Participants will use their Radicle Relief Active Study Product 1.2 as directed for a period of 6 weeks.
41112184|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
41112185|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 2.1 Usage|Participants will use their Radicle Relief Active Study Product 2.1 as directed for a period of 6 weeks.
41112186|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
41112187|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
41112188|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.1 Usage|Participants will use their Radicle Relief Active Study Product 3.1 as directed for a period of 6 weeks.
41112189|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.2 Usage|Participants will use their Radicle Relief Active Study Product 3.2 as directed for a period of 6 weeks.
41453326|NCT05668650|DRUG|Pembrolizumab biosimilar|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
41453327|NCT05579262|DIETARY_SUPPLEMENT|Beetroot juice|Single-centre, two-arm study involving 16 weeks of beetroot juice supplementation
40925810|NCT01440543|PROCEDURE|Water immersion insertion AND CO2 insufflation|"* room temperature water infused by water pump into the colon just to facilitate scope insertion~* CO2 insufflation by CO2 insufflation system during colonoscope withdrawal and mucosal inspection"
40925811|NCT01440543|PROCEDURE|Water immersion insertion|"* room temperature water infused by water pump into the colon just to facilitate scope insertion~* standard room air insufflation during colonoscope withdrawal and mucosal inspection"
41112190|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.3 Usage|Participants will use their Radicle Relief Active Study Product 3.3 as directed for a period of 6 weeks.
41112191|NCT04292054|DRUG|active intervention|The antibiotic prophylaxis will be cefazolin 2 g, or piperacilline-tazobactam 4 g, powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
41112192|NCT04292054|OTHER|placebo intervention|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
41112193|NCT06555146|DRUG|Semaglutide, 0.5 mg/mL|1 subcutaneous injection on baseline day
41112194|NCT06555146|DRUG|Placebo, Saline|1 subcutaneous injection on baseline day
41112195|NCT01471392|DEVICE|STD Diagnostic Kit (Identigene)|The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
41112196|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions at sea|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) at sea Standard pharmacological treatment usually provided to patients with fibromyalgia."
41112197|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions in nature|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) in nature Standard pharmacological treatment usually provided to patients with fibromyalgia."
41112198|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
41112199|NCT06071624|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
41112200|NCT00984737|DRUG|Insulin|"Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.~Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection."
41112201|NCT01270633|DEVICE|PriMatrix|Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
41112202|NCT01270633|OTHER|Standard of Care|Following sharp debridement, moist wound therapy
41112203|NCT06136897|PROCEDURE|Biopsy|Undergo biopsy
41112204|NCT06136897|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41112205|NCT06136897|PROCEDURE|Echocardiography|Undergo ECHO
41112206|NCT06136897|BIOLOGICAL|Pertuzumab|Given IV
41112207|NCT06136897|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
41112208|NCT06136897|BIOLOGICAL|Trastuzumab|Given IV
41112209|NCT04414683|PROCEDURE|staging surgery|laparoscopic or laparotomic staging surgery
40752512|NCT01851226|PROCEDURE|Hands-on ERCP training.|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
40925812|NCT01440543|PROCEDURE|CO2 insufflation|- CO2 insufflation by CO2 insufflation system during both colonoscope insertion and withdrawal
40925813|NCT04665869|BEHAVIORAL|Combined balance and brisk walking training|6-months of combined balance and brisk walking training
41112210|NCT04933123|DEVICE|indirect restorative treatement with a glass ceramic|Inlays and onlays of glass ceramic for molars and premolars are adhesively luted.
41112211|NCT02457117|RADIATION|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Five fraction radiation therapy to the lumpectomy cavity
41112212|NCT05605444|OTHER|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
41112213|NCT06178822|OTHER|No intervention|There is no intervention
41112214|NCT00837746|DRUG|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
41112215|NCT00130117|DRUG|r-metHuLeptin|Starting dose: 0.08mg/kg once daily Subcutaneous injection.
41112216|NCT00130117|DRUG|Oral Contraceptive Pills (OCPs)|Sprintec taken orally once daily.
41112217|NCT00130117|OTHER|Placebo|placebo (no active medication)
41112218|NCT01576484|DRUG|Alirocumab|Alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
41453328|NCT02075385|PROCEDURE|pre, during and pos-treatment swallowing exercises|Speech pathology therapy
40925814|NCT04665869|BEHAVIORAL|Flexibility and strengthening exercise|6-months of flexibility and strengthening exercise
41112219|NCT01576484|DRUG|Placebo Matched to Alirocumab|Placebo matched to alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
41112220|NCT04332666|DRUG|Angiotensin 1-7|endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%
41112221|NCT04332666|DRUG|Placebos|infusion of NaCl 0.9% without diluted peptide in it
41112222|NCT00637234|DRUG|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
41112223|NCT00637234|DRUG|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
41112224|NCT02554240|DRUG|DA-5202 20mg|once a week, intra-articular injection, for 3 weeks
41112225|NCT02554240|DRUG|DA-5202 10mg|once a week, intra-articular injection, for 3 weeks
41112226|NCT02554240|DRUG|Na Hyaluronate 20mg|once a week, intra-articular injection, for 3 weeks
41112227|NCT06319586|PROCEDURE|Radial Forearm Flap|"* Elevate the flap from ulnar to radial side toward the FCR~* Elevate flap from radial to ulnar side to the brachioradialis tendon. Ligate and divide the radial artery and venae comitantes distally.~* incise the skin over the cephalic vein proximally to the cubital fossa. Identify the venous branching pattern and perforating vein.~* Elevate the skin and subcutaneous paddles proximally off of the FCR and brachioradialis.~* Define the venous anatomy at the cubital fossa. In most cases, the median basilic vein and continuation of the median vein contribution to the cephalic vein can be harvested proximal to the perforating vein. This anatomy allows two large veins to be harvested that drain both the deep and superficial systems. Occasionally, one large vein will be identified.~* Closure is performed by harvesting a 0.018-inch skin graft to cover the donor defect. The radial skin edge should be advanced to cover the exposed radial nerve."
41112228|NCT04681079|DRUG|albuterol sulfate (MDI)|albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer
41112229|NCT04681079|DRUG|albuterol sulfate (nebulizer)|albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece
41133346|NCT05722626|PROCEDURE|PRP|2 ml of platelet rich plasma intraarticular injection twice in one week interval
41453329|NCT05472740|DEVICE|TENS 7000|TENS device to be used in both the active and placebo groups
41112230|NCT04676984|OTHER|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
41112231|NCT03855891|DIAGNOSTIC_TEST|blood test|Blood test for spectrum and level of cardiospecific micro-RNA
41112232|NCT03477149|DEVICE|Easyx|Embolization will be done with Easyx liquid agent.
41112233|NCT04781439|PROCEDURE|IV-to-PO conversion of antibiotics|IV-to-PO switching of antibiotics treatment
41112234|NCT00003339|BIOLOGICAL|gp100 antigen|
41112235|NCT00003339|BIOLOGICAL|incomplete Freund's adjuvant|
41112236|NCT00003339|BIOLOGICAL|recombinant interleukin-12|
41112237|NCT00003339|BIOLOGICAL|tyrosinase peptide|
41112238|NCT04301596|OTHER|Collection of data|different set of data will be collected over a 6 months period
41112239|NCT05129124|DEVICE|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings
41112240|NCT05129124|DEVICE|Commercially available Ultra for Astigmatism Contact Lenses|Commercially available Ultra for Astigmatism Contact Lenses at different fittings
41112241|NCT00190931|DRUG|Atomoxetine Hydrochloride|
41112242|NCT00190931|DRUG|placebo|
41112243|NCT04287478|BIOLOGICAL|Bacteriophage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
41112244|NCT05731466|DEVICE|CardioMems HF System|"1. Implantation CardioMems device.~2. Evaluation of right ventricular-arterial coupling during exercise using a hybrid technique of real-time CMR-derived volume measures and CardioMems-derived pulmonary artery pressure measurements."
41112245|NCT04704778|COMBINATION_PRODUCT|Transcutaneus electrostimulation therapies|"Sterile steel acupuncture needles of 0.25x13mm, disposable AcuBEST brand, and portable electro-stimulator equipment KWD- will be used. The superficial area of the skin of the masseter muscle will be cleaned with alcohol.~Two needles will be placed in each masseter muscle, the area to be punctured is the origin of the masseter muscle or superficial area of the mandibular condyle anterior to the atrial tragus approximately 1cm away, insertion of the masseter muscle at the angle of the mandible. The two double alligator cables will be connected to the head of the needles. The positive pole will be connected at the origin of the masseter muscle and the negative pole at the insertion.~The parameters to be used will be are two frequency bands (210Hz-10140Hz.); amplitude 3050 volts, pulse duration: 40100 msec; and the output intensity: 0.70 (for 100Hz). The treatment time will be 20 minutes."
41112246|NCT04704778|COMBINATION_PRODUCT|Percutaneus electrostimulation therapies|"Kendall® MediTrace 100 conductive adhesive ECG electrodes (pediatric) 2.4 cm in diameter, and portable KWD-808 electrostimulator equipment will be used.~The superficial area of the skin will be cleaned, two electrodes will be placed on each muscle (superficial area of the mandibular condyle and at the angle of the jaw). The current leads will then be connected to the KWD-808 electroacupuncturist to the patient.~Current will be transmitted with a square waveform, 210Hz-10140Hz of frequency, 3050 volts of amplitude and 40100 msec pulse time. The treatment time will be 20 minutes."
41112247|NCT04704778|DIAGNOSTIC_TEST|Oclusal splint|"The occlusal splint is worn 24 hours a day, removed for eating and brushing teeth. It is washed with neutral liquid hand soap.~For the preparation, an impression of the maxillary dental arches will be taken with alginate; It is made with acetate .060 and .080.~Relining is done with self-curing acrylic on the occlusal surface of the splint"
41112248|NCT00552942|PROCEDURE|laparoscopic gastric bypass plus omentectomy|
41112249|NCT00716144|DRUG|Talarozole|Oral Capsule Once Daily
41112250|NCT02378155|DEVICE|SenSmart Model X-100, Nonin Medical|Device to measure cerebral tissue oxygen saturation
41112251|NCT03221023|DRUG|Vancomycin Hydrochloride|Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
41112252|NCT03221023|DRUG|Saline Solution|Individuals in the control arm will receive intrawound saline solution
41112253|NCT01711710|DEVICE|Cohesive Gel Breast Implant|"Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction."
40925815|NCT05898269|DIAGNOSTIC_TEST|Trendelenburg maneuver|Bed tilting from the +13° position to the -13° position for 60 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the highest value observed during the maneuver
41112254|NCT02692105|RADIATION|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
41112255|NCT02692105|RADIATION|High Dose Rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
41112256|NCT02139046|DRUG|Febuxostat IR|Febuxostat IR over-encapsulated tablets
41453330|NCT00420095|DRUG|Human insulin 30/70|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
41453331|NCT00420095|DRUG|Insulin lispro low mix|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
41453332|NCT04939558|DEVICE|N-Tidal C handset|Participants are to use the 'N-Tidal C' handset every day for 14 days. This will ideally be two times a day (once in the morning and once in the evening, before using any regular inhalers). Each breath record requires the participant to breathe through the mouthpiece for 75 seconds in a relaxed manner.
41112257|NCT02139046|DRUG|Febuxostat XR|Febuxostat XR over-encapsulated capsules
41112258|NCT02139046|DRUG|Febuxostat placebo|Febuxostat placebo-matching capsules
41112259|NCT02139046|DRUG|Colchicine|Colchicine tablets
41112260|NCT02139046|DRUG|Naproxen|Naproxen tablets
41112261|NCT02139046|DRUG|Lansoprazole|Lansoprazole capsules
41133347|NCT05722626|OTHER|Normal Saline|NaCl 0.9%
41133348|NCT02013115|DRUG|Budesonide|Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
41453333|NCT00156182|DRUG|Asoprisnil|10mg Tablet, oral Daily for 6 months
41112262|NCT03264235|DEVICE|Keeogo|"Keeogo is a computer-controlled lower extremity motorized orthosis worn over the user's hips and legs. The controller box contains sensors that supply information about the kinematics and the kinetics of the user's lower extremities and includes software that recognizes the user's mobility intentions. The system is powered by a lithium-polymer battery. The leg brace assembly is mainly comprised of the actuator, the electronic boards, hip joint, and soft goods (cuffs, belts) for affixing the assembly to the user's legs. The waist belt comes in various sizes adapted to each wearer, and adds additional support of the device on the user.~Keeogo does not initiate any movement but waits for the user's lead. Once the user makes the first move, Keeogo assists according to the activity. The individual must be able to initiate and terminate steps."
41112263|NCT03264235|OTHER|Traditional Stair Training|Individuals will participate in traditional stair training physical therapy for the same duration of time as Group 1.
40925816|NCT05898269|DIAGNOSTIC_TEST|End-expiratory occlusion test (EE OCC)|"End-expiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause"
41112264|NCT00630786|DRUG|Panitumumab|Administered by intravenous infusion
41112265|NCT00630786|DRUG|Conatumumab|Administered by intravenous infusion
41112266|NCT04418323|PROCEDURE|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
41112267|NCT04779892|DRUG|Infliximab|100mg/vial
41112268|NCT01093430|PROCEDURE|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
41112269|NCT01093430|PROCEDURE|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
41112270|NCT05242653|PROCEDURE|pressure by a cotton swab|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with pressure by a cotton swab.
41112271|NCT05242653|PROCEDURE|stromal hydration with the balanced salt solution（BSS）|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with stromal hydration.
41112272|NCT03691922|PROCEDURE|Erector Spinae Plane (ESP) Block|"1. Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~2. PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
41112273|NCT03691922|PROCEDURE|Periarticular Infiltration (PAI)|"1. Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~2. PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
41112274|NCT03519737|DEVICE|tPA in combination with the Sonolysis Headframe (TUS)|tPA: 60 minutes per approved labeling TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
41112275|NCT03519737|DEVICE|tPA in combination with the Sonolysis Headframe (Sham TUS)|tPA per approved labeling Sham (inactive) TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
41112276|NCT02562391|DEVICE|Surgical ablation of the left atrium (PVI+Box lesions)|
41112277|NCT02562391|DEVICE|Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting|
41112278|NCT02576821|OTHER|Neurological examinations|
41112279|NCT02576821|OTHER|Neuropsychological examinations|
41112280|NCT02576821|OTHER|Clinical examinations|
41112281|NCT02576821|RADIATION|MRI 3T|
41112282|NCT02576821|RADIATION|MRI 7T|
41112283|NCT04978935|OTHER|Care protocol|"Before starting the application, the investigator (DS) will fill out the Introductory Characteristics Form of all patients, the Pre-thoracotomy Pulmonary Function Test (PFT) section of the Patient Results Form. The PFT section will be re-evaluated on the 1st, 5th day and on the day of discharge after thoracotomy.~Nursing interventions will be applied to the study group (n=40), starting from the 0th day (the first day spent in the intensive care unit) after the thoracotomy in line with the prepared care protocol application steps until discharge. Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises."
41112284|NCT00561743|DRUG|Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone|
41453334|NCT05204537|PROCEDURE|Lung parenchyma resection|Lung parenchyma removal
40925817|NCT05898269|DIAGNOSTIC_TEST|End-expiratory and end-inspiratory occlusion test (EI OCC)|"End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test)."
41112285|NCT06549582|OTHER|Taohong Tongluo Xiaoban Prescription|"Chinese herbal medicine Taohong Tongluo Xiaoban prescription, which includes Pinelliae Rhizoma, Poria, Bambusae caulis in taenias, Aurantii Fructus Immaturus, Arisaema cum bile, Acori Tatarinowii Rhizoma, Persicae Semen, Carthami Flos, Chuanxiong Rhizoma and Paeoniae Radix Rubra as a once - daily dosage with one administration per dose"
41453335|NCT05204537|PROCEDURE|Empyemectomy|Intrapleural cavity effusion removal, parietal pleura removal.
41453336|NCT03958812|DIAGNOSTIC_TEST|Circulating tumor cells, Volatile organic compounds|Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients
41453337|NCT00479531|DEVICE|AirCast Sequential Compression Device|
41453338|NCT05770011|DEVICE|intraoral scanner of nonsplinted scan bodies|scanning of non splinted scan bodies
41453339|NCT05770011|DEVICE|impression material|conventional recording
41453340|NCT05770011|DEVICE|intraoral scanner of splinted scan bodies|scanning of splinted scan bodies
41112286|NCT06549582|OTHER|Fundamental medical treatment|The specific methods were developed in accordance with the 2010 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. It primarily involves managing risk factors such as hypertension, diabetes, abnormal lipid metabolism, etc., and implementing antithrombotic therapy including antiplatelet agents (aspirin, clopidogrel, dipyridamole, dipyridamole + aspirin, clopidogrel + aspirin, silostazole, triflurosal, etc). For the management of post-stroke mood disorders, cognitive impairments, and spastic paralysis, pharmacological interventions encompass oral administration of anxiolytic or antidepressant agents, anti-dementia medications, as well as muscle relaxants.
41112287|NCT00497991|DRUG|AZD1152|
41112288|NCT02315391|DIETARY_SUPPLEMENT|isolated whey protein|isolated whey protein
41112289|NCT02315391|DIETARY_SUPPLEMENT|micellar whey protein|micellar whey protein
41112290|NCT02315391|DIETARY_SUPPLEMENT|glycine|glycine
41112291|NCT02315391|DIETARY_SUPPLEMENT|citrulline|citrulline
41112292|NCT01220336|BEHAVIORAL|Health coaching by medical assistants in primary care|Patients with uncontrolled diabetes, hypertension, hyperlipidemia will receive health coaching by medical assistants working with primary care providers in the Teamlet Model \[Bodenheimer 2007\] for 12 months.
41112293|NCT00542035|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1, dose 2
41112294|NCT00542035|DRUG|Placebo; oral|dose 1, dose 2
41112295|NCT00542035|DRUG|Placebo; oral|dose 1
41112296|NCT00542035|DRUG|ARRY-371797, p38 inhibitor; oral|dose 2
41112297|NCT03951649|DRUG|Occipital Nerve Block|This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
41112298|NCT05751499|DIAGNOSTIC_TEST|• Blood Markers CRP, TNFα, IL-6, IL-8, IL-1, and IL-1β AND FIBRINOGEN|"* Low Back Outcome Scale~* Center for Epidemiological Studies-Depression Scale (CES-D)~* International Physical Activity Questionnaire~* Roland-Morris Disability Questionnaire~* Force Platform~* Pain Self-Efficacy Questionnaire (PSEQ)~* Numeric Rating Scale~* Job Content Questionnaire~* Pits Burgh Sleep Quality Index (PSQI)~* Orebo Musculoskeletal Pain Screening Questionnaire~* Gait \& Balance App~* Keele STarT Back Screening Tool (SBST)~* Fear-Avoidance Beliefs Questionnaire (FABQ)~* Pain Catastrophizing Scale"
41112299|NCT06301841|OTHER|experimental|"At day 3, clinicians have to consider all the early microbiological results (including the respiratory broad-panel mPCR (Biofire FilmArray Pneumonia plus Panel de Biomérieux) and procalcitonin, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation.~Discontinuation is encouraged in case of no bacteria documentation and a procalcitonin \< 1 ng/L; discontinuation is even encouraged if a viral documentation is concurrently obtained. In case of no bacteria documentation and a procalcitonin \> 1 nd/L, antibiotic continuation is encouraged for additional two days.~In case of bacteria documentation, antibiotic continuation is encouraged, but with narrowing the spectrum as much as possible. The duration of antibiotics is based on a procalcitonin algorithm: procalcitonin \< 0.1 nd/l: discontinuation; 0.1 ng/l \< procalcitonin \< 0.25 ng/l: additional 1 day; procalcitonin \> 0.25 ng/l: additional 2 days."
41112300|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
41112301|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
41112302|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
41112303|NCT01135511|DRUG|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
41112304|NCT01135511|DRUG|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
41112305|NCT04875429|DEVICE|Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2|Endovascular aneurysm repair
41112306|NCT02304952|PROCEDURE|Radiofrequency microtenotomy|For the minimally invasive surgery will Arthrocare Topaz MicroDebrider device be used. A small incision will be made and the tip of the device is placed on surface of the tendon to structure and activated for 0.5 second, at 5 mm distance intervals on the tendon creating a grid-like pattern.
41112307|NCT02304952|OTHER|Eccentric exercise|Eccentric exercise for 3 months. The exercise will be performed once a day with 3 set and 5 reps, women start with 0.5 and men 1.0 kilo with a 10 % increase every week.
41112308|NCT02304952|DEVICE|Arthrocare Topaz MicroDebrider|
41112309|NCT01178632|DRUG|Passiflora|01 tablet Passiflora p.o., b.i.d.
41112310|NCT01178632|DRUG|Valeriana officinalis|Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
41112311|NCT06500962|BEHAVIORAL|Usual Care|Participants will receive a message sent to their electronic health record portal with instructions about how to sign up for a food is medicine program.
41112312|NCT06500962|BEHAVIORAL|Navigation|Participants will receive a weekly phone call from a navigator to promote enrollment in the food is medicine program and address any barriers to participation.
41112313|NCT06500962|BEHAVIORAL|Text Messaging|Participants will receive two text messages per week to promote healthy eating, enrolling in a food is medicine program, and continuing to participate in a food is medicine program.
41112314|NCT04577612|DRUG|CHI-554|hemp-derived CBD in MCT oil
41112315|NCT04705376|DEVICE|Breg Polarcare|The Breg Polarcare device is a type of cryotherapy machine that circulates ice cold water into a patch that can be worn by the patient on their affected joint (e.g., shoulder, knee).
41112316|NCT04705376|DEVICE|Thermazone|ThermaZone is a compact device that uses thermoelectric technology to provide heating and cooling therapy without the use of ice.
41112317|NCT00002450|DRUG|Tenofovir disoproxil fumarate|
41112318|NCT05148897|OTHER|Questionnaire|a self-administered questionnaire. Based on extensive literature review no questionnaire was found that specifically related to knowledge evaluation. The basic theme of the questionnaire was taken from Diabetes Knowledge Questionnaire (DKN), a well validated tool for knowledge assessment among type 1 and type 2 diabetes mellitus patients. Some modifications were made and new questions particularly related to GDM were included.
41112319|NCT03538912|OTHER|Biomarker strategy|EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.
41112320|NCT03538912|OTHER|Routine strategy|EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
41112321|NCT00917241|DRUG|MMI combined with IID|MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
41112322|NCT00917241|DRUG|MMI|MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
41112323|NCT02613364|BEHAVIORAL|Behavioral Intervention|Undergo yoga intervention
41112324|NCT02613364|OTHER|Cognitive Intervention|Undergo CBT-I intervention
41112325|NCT02613364|OTHER|Educational Intervention|Receive health education
41112326|NCT02613364|OTHER|Laboratory Biomarker Analysis|Correlative studies
41112327|NCT02613364|DEVICE|Monitoring Device|Correlative studies
41112328|NCT02613364|OTHER|Quality-of-Life Assessment|Ancillary studies
41112329|NCT05857813|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills (PEERS®)|developed at the University of California, Los Angeles (E. A. Laugeson \& F. Frankel, 2010). This is a parent-assisted, manualized social skills training program that addresses crucial areas of social functioning for adolescents. Psycho-education and cognitive-behavioral therapy techniques are employed to help adolescents develop ecologically valid skills for making and maintaining friendships.
41446032|NCT04407403|BEHAVIORAL|Tai Chi tailored for improving balance (BALANCE)|BALANCE Tai Chi routine consisted of eight forms following Yang style. BALANCE was tailored for the targeted health outcome of balance in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored BALANCE to provide moderate to high levels of challenge to balance control by emphasizing movement principles (e.g., consciously control weight shifting during multi-directional stepping), and integrating Tai Chi movements that: 1) reduced the base of support; 2) moved the center of gravity; and 3) improved lower-extremity strength. Investigators included the following eight forms in BALANCE: 1) Begin Tai Ji Quan; 2) Roll the Ball; 3) Kick with Heel; 4) Repulse the Monkey; 5) Gather the Earth's Qi; 6) White Crane Spread Wing; 7) Fairy Weaves the Shuttle; and 8) Finish Tai Ji Quan.
40925818|NCT05898269|DIAGNOSTIC_TEST|Tidal volume challenge|"Increase in tidal volume set on the ventilator from 6 ml.kg-1 of predicted body weight, to 8 ml.kg-1 for 60 seconds.~Evaluator: difference in the pulse pressure variation measured at 6 ml.kg-1 and at 8 ml.kg-1."
41112330|NCT04091152|OTHER|usability assessment|"Usability of ardoiz will be assesse using a validated usability questionnary"
41112331|NCT03798080|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41112332|NCT03798080|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41112333|NCT03798080|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
41112334|NCT02089698|DEVICE|Mini-flared|Mini-flared Kelman tip
41112335|NCT02089698|DEVICE|Reversed tip|Reversed Kelman tip
41112336|NCT02412774|BEHAVIORAL|DBs at the end of the main meal + Diet|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
41112337|NCT02412774|BEHAVIORAL|Water at the end of the main meal+ Diet|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
41112338|NCT01923012|DRUG|Vitamin K2 (Menaquinone)|
41112339|NCT02599142|DEVICE|Group A: Closed-face shell|As for arm description
41112340|NCT02599142|DEVICE|Group B: Open-face shell|As for arm description
41112341|NCT02562352|OTHER|TAPER program|Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
41112342|NCT03094013|OTHER|Assessment|Assessment
41112343|NCT04829539|BEHAVIORAL|Behavioral Intervention|Receive BBT-CI
41112344|NCT04829539|BEHAVIORAL|Behavioral Intervention|Receive HEAL
41112345|NCT04829539|OTHER|Quality-of-Life Assessment|Ancillary studies
41112346|NCT04829539|OTHER|Questionnaire Administration|Ancillary studies
41112347|NCT02307565|DRUG|Midodrine|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
41112348|NCT02307565|DRUG|Placebo|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
41112349|NCT05641363|DRUG|Ketorolac Tromethamine|ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.
41112350|NCT03292315|DRUG|Semaglutide 1MG Injection [Ozempic]|Once weekly injection of 1mg of Semaglutide.
41112351|NCT03292315|OTHER|No Intervention|No injection will be administered
41446033|NCT03954483|DRUG|Buspirone 10 Mg Oral Tablet|Orally administered prior to experiments.
41112352|NCT01591733|DRUG|FOLFIRINOX|Up to Eight-14 day cycles
41112353|NCT01591733|DRUG|Capecitabine|Orally, for 10 days
41112354|NCT01591733|RADIATION|Short Course Radiation|Five or ten days
41112355|NCT01591733|PROCEDURE|Surgery|1-4 weeks after completion of capecitabine therapy
40925819|NCT05898269|DIAGNOSTIC_TEST|Fluid bolus (reference diagnostic method)|"After the 4 tests, the patient will receive a 500-ml fluid bolus of crystalloids in less than 15 minutes.~Evaluator (reference method): cardiac index measured by transpulmonary thermodilution before and immediately after the fluid bolus. Patients with a relative change in cardiac index \> 15% will be identified as being fluid responders, and the others as non-responders."
41112356|NCT03966508|PROCEDURE|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be 5mA. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
41112357|NCT04275778|DRUG|Plaquenil 200Mg Tablet|Hydroxychloroquine will be taken at a dosage of 400 mg / day until delivery
41112358|NCT04275778|DRUG|Placebo oral tablet|placebo will be taken at a dosage of 400 mg / day until delivery
41112359|NCT01350804|BIOLOGICAL|AIN457|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
41112360|NCT01350804|BIOLOGICAL|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
41112361|NCT01350804|BIOLOGICAL|Abatacept|Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
41112362|NCT04290117|BEHAVIORAL|Acceptance and Commitment Training|During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.
41112363|NCT04290117|BEHAVIORAL|Sleep Hygiene and bright light in the morning|During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
41112364|NCT01321606|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10\^10 organisms
41112365|NCT01321606|DIETARY_SUPPLEMENT|sugar pill (placebo)|Placebo identical to the active product will be given
41112366|NCT03653169|DEVICE|Transcranial Magnetic Stimulation|TMS is a form of noninvasive brain stimulation. An external electromagnetic coil is placed on the head, and a large current is passed through an insulated wire coil held flat on the surface of a subject's scalp in a fraction of a millisecond. This pulse of current induces a weak electrical current within the surface brain cortex. Repetitive trains of TMS pulses (repetitive TMS or rTMS) can transiently modulate corticospinal excitability following the rTMS train. When current is delivered at high frequency (10 Hz), it may simultaneously increase the activity of the brain at this site. In this study, individuals will receive 10 treatments with intermittent theta burst stimulation (twice daily for 5 days).
41112367|NCT04807725|GENETIC|Analysis of genetic polymorphisms|For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab. The genetic analysis will be done with the DNA extraction technique followed by PCR-RFLP techniques (polymerase chain reaction followed by restriction fragment length polymorphism).
41112368|NCT04807725|OTHER|Biochemical analysis|For the biochemical analysis of the inflammatory mediators IL-1beta, TNF-alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.
41446034|NCT03954483|DRUG|Triazolam 0.25 MG Oral Tablet|Orally administered prior to experiments.
41446035|NCT03954483|DRUG|Placebo oral tablet|Orally administered prior to experiments.
41112369|NCT00715494|BEHAVIORAL|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
41112370|NCT01477879|OTHER|Versabase gel with sarracenia purpurea 20% liquid extract|Topical application of gel/plant mix to lesions
41112371|NCT01477879|OTHER|placebo (versabase gel only)|versabase gel only
41112372|NCT04792554|OTHER|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, Brief Psychiatric Rating Scale, NuDESC, 3D-CAM. Blood taking.
41112373|NCT00599716|DRUG|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
41112374|NCT00599716|DRUG|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
41112375|NCT01801449|DRUG|Rilonacept|
41112376|NCT03441763|DEVICE|Emed foot device|foot pressure will be measure by using emed foot pressure system
41112377|NCT03182959|DRUG|Avmacol®|Avmacol® tablets
41112378|NCT01292681|OTHER|Multi-modality imaging|Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
41112379|NCT06554093|DEVICE|Medical Device - PKS|The PKS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw instrumentation in patients undergoing posterior fusion in single or multiple levels.
41112380|NCT01315314|DRUG|Balance, Fresenius Medical Care, Germany|low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
41112381|NCT02140138|BIOLOGICAL|CV9104|
41112382|NCT02140138|DEVICE|needle free injection device (Tropis®)|
41112383|NCT03630939|DRUG|ESR-114|ESR-114 Topical Gel
41112384|NCT03630939|OTHER|Placebo|Placebo Topical Gel
41112385|NCT05486364|DIAGNOSTIC_TEST|Digital Monitoring|Subjects will perform self-measurements with a PPG based smartphone application (FibriCheck™) to monitor for AF recurrence after the PVI procedure. One-minute measurements will be performed twice daily starting one month before the PVI procedure and continue up to 12 months after the procedure.
41446036|NCT00003035|BIOLOGICAL|filgrastim|
41446037|NCT00003035|DRUG|doxorubicin hydrochloride|
41446038|NCT00003035|DRUG|paclitaxel|
41446039|NCT00003035|DRUG|tamoxifen citrate|
41446040|NCT00003035|PROCEDURE|surgical procedure|
41112386|NCT05486364|DIAGNOSTIC_TEST|Standard of care|Subjects will wear a 24-hour holter monitor at 3, 6 and 12 months after the PVI procedure. Additionally, outpatient cardiology clinic visits are organised at 6 weeks, 3 months and 12 months after the PVI procedure (including a 12-lead ECG and cardiologist consultation).
41112387|NCT00558363|DRUG|Avodart|0.5 mg administered orally once daily
41112388|NCT00558363|OTHER|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
41112389|NCT06225882|DRUG|Oxaluria evolution.|To collect real data from the specific French experience by collecting data from patients treated throughout the country and to monitor in particular the evolution of oxaluria before and after treatment.
41112390|NCT04414098|DRUG|INC424 / Ruxolitinib|"1. Ruxolitinib 5 mg orally every 12 hours during 14 days.~2. Total Follow-up time will be of 45 days.~3. The reduction of ruxolitinib dose will be considered in cases of drug-related cytopenias.~4. During hospitalization, clinical and laboratory evolution parameters will be recorded daily in the medical history of the patient and in the data collection table of the study. Upon patient's discharge, a follow-up will be conducted until day +45~5. During hospitalization, adverse events will be monitored daily by means of clinical assessment and laboratory data.~6. After discharge, monitoring of adverse events will continue during the outpatient follow-up.~7. Pro-inflammatory parameters will be assessed at baseline, after one week (day +7) and at the end of treatment (day +14)~8. Ruxolitinib will be associated to the standard of care for COVID-19 of each center.~9. In case of an adverse effect or a need to discontinue the treatment, ruxolitinib should be suspended."
41112391|NCT02104648|OTHER|Placebo RO4602522|Daily oral doses
41112392|NCT02104648|DRUG|RO4602522|Daily oral doses
41112393|NCT02104648|DRUG|RO4602522|Single, oral dose
41112394|NCT02104648|DRUG|moxifloxacin|400 mg oral dose given on Day 1 or 11
41112395|NCT02104648|OTHER|moxifloxacin placebo|Dose given orally on Days 1 and/or 11
41112396|NCT04705623|BEHAVIORAL|Iyengar Yoga|Weekly 90 minute Iyengar Yoga classes taught y a professional instructor. Twice weekly 45 minute self practice of Iyengar Yoga at home by the participants
41112397|NCT06242899|OTHER|Exercise|"Exercise with a cycle ergometer in three phases:~* Warm-up: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.~* Short exercise at moderate intensity for 8, 10 or 15 minutes according to group allocation. The exercise was cycling at 75% HRmax determined with an effort test.~* Cool down: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes."
41112398|NCT05719129|BEHAVIORAL|Date With Destiny (DWD) Seminar|6 days of immersive seminar
41446041|NCT00003035|RADIATION|radiation therapy|
41446042|NCT05019261|OTHER|Multi-component Family Support Intervention|The multi-component intervention is designed to enhance the quality of clinician-family communication and help families manage the emotional and cognitive complexities of surrogate decision-making. It involves: 1) proactive clinician-family meetings; 2) use by surrogates of an interactive web-based tool throughout the ICU stay which is narrated by family members of ICU patients and includes stories and experiences from other families, self-care strategies, brief videos explaining what to expect during family meetings, a question prompt list, an interactive values clarification exercise, and an explanation of different treatment pathways for critically ill patients. 3. Prior to the proactive family meetings, the ICU team is provided with a summary of the family's main questions/concerns, their prognostic expectations, a summary of the patient's values and preferences, and surrogates' current ratings of the extent to which their psychosocial needs are being addressed in the ICU.
41446043|NCT02012335|DRUG|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
41446044|NCT04855279|OTHER|neutral sodium fluoride|Topically applied
41446045|NCT04855279|OTHER|ACP-CCP gel|Topically applied
40752513|NCT01232907|DRUG|L-Carnitine|L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
41112399|NCT00617812|BIOLOGICAL|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
41112400|NCT02616237|BEHAVIORAL|Lifestyle Intervention|East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
41112401|NCT00030888|DRUG|7-hydroxystaurosporine|
41112402|NCT04040413|PROCEDURE|bariatric surgery|All bariatric procedures
41112403|NCT00246714|DRUG|repeated injections of endotoxin during 5 days|
41112404|NCT06006091|DRUG|Letrozole|Different endothelial preparations according to groups, see arm descriptions for details
41112405|NCT02967588|BEHAVIORAL|Intervention group|"All stages of the intervention will take place during hospitalization. Patients will complete a questionnaire about their personal beliefs about medicines. Patients responses to this questionnaire will form the basis of Session 1 where beliefs about medicines will be discussed. Any negative beliefs or concerns will be discussed and beliefs about drug necessity will be encouraged.~Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').~Prior to discharge, patients will complete the beliefs questionnaire again to see if there has been any shift in their beliefs about medications. Patients will also be asked to provide detailed feedback about the study. The investigators want to know whether the intervention setting, timing, content and delivery method seem to be acceptable to patients."
41112406|NCT05727397|DRUG|RC28-E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
40752514|NCT00250575|DRUG|Clozapine|
40925820|NCT04074876|DEVICE|Pulmonary echography|"Pulmonary echography during preoperative evaluation for patients undergoing urgency orthopedic surgery for femur fracture.~Pulmonary ultrasound will evaluate the presence of one of four patterns defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient (2 anterior, 2 lateral and 2 posterior). Each region is defined by axillary lines (anterior and posterior) and then is divided into 2 subregions (superior and inferior), thus defining the 6 fields. For a comprehensive exam, all intercostal spaces in the setting of each field will have to be examined by sliding the probe along them . A score will be used for each field that will have this definition:~* 0: normal pattern (A-lines)~* 1: multiple B lines (at least 3 for field), well defined.~* 2: B lines coalescent~* 3: consolidation of any dimension"
41112407|NCT05727397|DRUG|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
41112408|NCT02589002|OTHER|Sucralose|
41112409|NCT04572191|DIAGNOSTIC_TEST|CERAMIDE LEVEL IN BLOOD|BY ELISA ASSAY TO DETECT CERAMIDE LEVEL IN BLOOD IN ANTERIOR STEMI PATIENTS
41112410|NCT03945942|DEVICE|Near infrared spectroscopy with INVOS device|somatic and cerebral oximetry by INVOS in pediatric liver transplantation
40925821|NCT04081259|DRUG|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
40925822|NCT04582825|OTHER|N/A - Observational Study|N/A - Observational Study
41112411|NCT03945942|DEVICE|Near infrared spectroscopy with Foresight device|somatic and cerebral oximetry with Foresight device in pediatric liver transplantation
41112412|NCT00319397|BEHAVIORAL|Exercise-Training Program|
41112413|NCT04669171|BIOLOGICAL|EO2463|Multiple dose of EO2463
41112414|NCT04669171|DRUG|lenalidomide|D1-21 of 4-weekly cycles
41446046|NCT04855279|OTHER|nano-hydroxyapatite solution|Topically applied
41446047|NCT04855279|OTHER|glycerine|Topically applied
40752515|NCT00743262|DEVICE|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
40752516|NCT00000839|DRUG|Didanosine|
40752517|NCT03476512|OTHER|Adherence Education|Patients were given adherence education to resolve the identified deficits
41112415|NCT04669171|BIOLOGICAL|rituximab|Multiple doses of rituximab
41112416|NCT01325558|BIOLOGICAL|ALT-836 in combination with gemcitabine|Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
41112417|NCT04021667|OTHER|educational intervention|İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
41112418|NCT00977223|DRUG|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
41112419|NCT01839903|OTHER|EDIS|Changes made to EDIS system to improve tracking and treatment of smoking in the ED
41112420|NCT01839903|OTHER|Care as usual|Care as usual in the ED will be tracked
41112421|NCT01228916|BEHAVIORAL|Tobacco Cessation and Secondhand Smoke Reduction|Awareness raising and resources for cessation and secondhand smoke reduction
41112422|NCT02329613|OTHER|Standard evening meals.|Patients will receive usual evening meals.
41112423|NCT02329613|OTHER|Improved evening meal|Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
41112424|NCT04974008|DRUG|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
41112425|NCT00184925|PROCEDURE|Tracheostomy|trachesotomy with subglottic drainage
41112426|NCT00184925|DEVICE|cannula with subglottic drainage|
41112427|NCT02783235|OTHER|cervical cancer screening|for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
41112428|NCT03916835|DEVICE|Pain evaluation ( FLACC scale) before and during the cleaning care with and without music therapy.|"Each child will benefit two cleaning cares during hospitalization. One with music therapy and the other without music therapy.~Every time, the preparation will be the same with an equipment installation in order to keep comparability and blind.~Child will be videotaped without sound during the care. The order of music therapy intervention will be randomized."
41112429|NCT05715151|OTHER|CQI intervention|Activity 1: Reflective sessions and problem prioritisation. Activity 2: PDSA cycles. Activity 3: Group mentoring.
41112430|NCT05715151|OTHER|Audit and Feedback|Audit and Feedback on six key AA indicators, patients reported experience about access and selected AA processes.
41112431|NCT06079840|DEVICE|mindfulness-based stress reduction app|mobile application (app) for caregivers
41112432|NCT00000646|DRUG|Pentoxifylline|
41112433|NCT04065932|DRUG|BMS-986165-01|Participants will receive BMS- 986165 -01 in prototype formulation
41112434|NCT04065932|DRUG|BMS-986165 Tablet|Participants will receive BMS-986165 in tablet form.
41112435|NCT04065932|DRUG|Famotidine|Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
41112436|NCT03614546|RADIATION|SBRT|Stereotactic Body Radiation Therapy (SBRT)
41112437|NCT03614546|RADIATION|IMRT|Intensity-modulated Radiation Therapy (IMRT)
41112438|NCT03614546|PROCEDURE|Hepatectomy|Hepatectomy
41112439|NCT03614546|PROCEDURE|TACE|transarterial chemoembolization (TACE)
41112440|NCT00346684|DRUG|Rituximab|
41112441|NCT04879732|DEVICE|ACTIS|ACTIS Hip stem
41112442|NCT04033042|DEVICE|Prototype 0.5|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
41112443|NCT05881577|OTHER|Observational|Impact of AR on educational outcomes
41133350|NCT04396210|OTHER|Questionnaire|Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
41133351|NCT00266656|DRUG|Humatrope|According to investigator's clinical practice and guided by the approved package insert
41133352|NCT01825850|DRUG|Gemigliptin|
41133353|NCT01825850|DRUG|Irbesartan|
41133354|NCT02564705|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|
41133355|NCT02564705|PROCEDURE|Posterior Fusion|"* Posterolateral Fusion (PLF)~* Posterior Lumbar Interbody Fusion (PLIF)~* Transforaminal Lumbar Interbody Fusion (TLIF)"
41112444|NCT03890263|BEHAVIORAL|Chronic Pain Self-Management Support|"Family physicians and nurse practitioners will participate in an academic detailing session with a pharmacist that focuses on safe, evidence-based opioid deprescribing. The pharmacist will provide pre-visit recommendations for each visit with a person on high doses of opioids. The pharmacist and healthcare providers will develop a patient centered, opioid taper schedule, with follow-up at 2 to 4 week intervals to assess for efficacy and safety.~The self-management intervention will be Chronic Pain Self-management Support with Pain Science Education and Exercise (COMMENCE), which consists of 2 visits per week over 6 weeks. One visit per week is 1.5 hours in a group format. with education about self-management and pain science as well as cognitive behavioural principles. The 2nd visit each week is 30 minutes in a one-to-one format and is individually tailored to support implementation of self-management plans and development of an exercise program."
41112445|NCT04713371|DRUG|Keytruda Injectable Product|"Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected."
41112446|NCT04713371|DRUG|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected."
41112447|NCT04713371|DRUG|Cytoxan|Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.
41112448|NCT04713371|PROCEDURE|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.
41112449|NCT04713371|DRUG|GM-CSF Injectable|Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.
41112450|NCT06024369|DEVICE|CPM Device|Wearable monitor used for 5 minutes per day.
41112451|NCT00444769|DRUG|GW842166|
41112452|NCT02675309|DRUG|MT-8554|
41112453|NCT02675309|DRUG|rosuvastatin|
41112454|NCT02675309|DRUG|simvastatin|
41112455|NCT00617201|DRUG|atomoxetine|Once daily oral dosing
41112456|NCT00617201|DRUG|placebo|Once daily oral dosing - matched placebo
41112457|NCT03330418|BIOLOGICAL|Placebo|Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.
41112458|NCT03330418|BIOLOGICAL|RC18 160 mg|In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.
41112459|NCT00576134|DEVICE|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
41112460|NCT01147341|DRUG|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
41112461|NCT01147341|DRUG|Placebo|prefilled saline syringe
41112462|NCT02472782|DRUG|Teriparatide|The study will include patients from pre-defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
41446048|NCT04965688|DRUG|Drug determined by treating oncologist based on recommendation from systems biology analysis.|All patients will have a biopsy at the beginning of the trial. The biopsy will be sent for DNA sequencing through FoundationOne(clinical test) and RNA profiling at Fulgent(research test) for determination of activation of various oncogenic pathways and phenotypes. The results will be analyzed and a treatment recommendation will be made to the treating physician based on an algorithm.
41112463|NCT02425917|DEVICE|geko|neuromuscular electrostimulator
41112464|NCT02425917|DEVICE|IPC-Calf|IPC used on calf with or without geko
41112465|NCT00891176|BIOLOGICAL|MenitorixTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
41112466|NCT00891176|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
41112467|NCT00891176|BIOLOGICAL|PrevenarTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
41112468|NCT00891176|BIOLOGICAL|MeningitecTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
41112469|NCT00891176|BIOLOGICAL|NeisVac-CTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
41112470|NCT00891176|BIOLOGICAL|InfanrixTM hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
41112471|NCT00891176|BIOLOGICAL|InfanrixTM penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
41112472|NCT00891176|BIOLOGICAL|InfanrixTM IPV/Hib|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
41446049|NCT05110963|BEHAVIORAL|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence
41112473|NCT00891176|BIOLOGICAL|InfanrixTM IPV|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
41112474|NCT03802032|DRUG|Lidocaine Gel|topical lidocaine gel
41112475|NCT03802032|DRUG|KY jelly|topical KY jelly
41112476|NCT03009864|DRUG|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
41112477|NCT03009864|DRUG|Placebos|Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
41112478|NCT05987878|PROCEDURE|single minimal conjunctival incision|A 5-0 PGA traction suture was used near the corneal limbus corresponding to the operated muscle. A 3-4 mm single conjunctival incision posterior and parallel to the insertion in medial, lateral or superior rectus muscle was used. A hang-back recession of the muscle was done using 6-0 PGA suture. The conjunctiva was closed by an 8-0 PGA single stitch with knot burial
41112479|NCT01809392|DRUG|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
41112480|NCT02126878|DRUG|Kenalog|
41112481|NCT03411239|DEVICE|Adult esophageal balloon catheter (obc)|Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
41112482|NCT05226871|DRUG|Palbociclib|oral
41112483|NCT05226871|DRUG|Cetuximab|Intravenous (IV) infusion
41112484|NCT05226871|DRUG|Fulvestrant|Intramuscular (IM)
41112485|NCT05226871|DRUG|Letrozole|oral
41112486|NCT04055766|DEVICE|DeepDoc AI-based Decision Support System|Patients are diagnosed by the DeepDoc within 24 hours of admission.
41112487|NCT03058965|DRUG|[18F]MNI-958|Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
41112488|NCT03058965|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-958.
41112489|NCT03058965|DRUG|DaTscan|DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
41446050|NCT05110963|BEHAVIORAL|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
41112490|NCT02997917|BEHAVIORAL|Education|
41112491|NCT02997917|BEHAVIORAL|Sham|
41446051|NCT05110963|BEHAVIORAL|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
41446052|NCT05124444|GENETIC|High throughput DNA and RNA sequencing|High throughput DNA and RNA sequencing
41446053|NCT03089983|DRUG|Methadone|Participants will receive daily or weekly doses of oral methadone.
41446054|NCT03089983|DRUG|Isoniazid|Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.
41446055|NCT03089983|DRUG|Rifapentine|Participants will be randomized to receive short course INH + RIF as TB treatment in prison for 12 weeks.
41112492|NCT03068858|DIAGNOSTIC_TEST|real-time feedback of SYNTAX score category|
41112493|NCT04838158|DIAGNOSTIC_TEST|Isokinetic measurements|Each patient underwent an isokinetic examination on Biodex System 3 (Biodex Multi-Joint System - Pro, Biodex Medical Systems, Inc. New York, USA). In the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (PT), torque in 30 degree of the knee flexion (T 30 deg.), angle of peak torque (APT) and peak torque hamstring to quadriceps ratio (H/Q ratio).
41112494|NCT01845532|DRUG|TPI|Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25\~0.5% lidocaine, 0.125% bupivacaine)
41112495|NCT01845532|DRUG|EMLA cream|EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)
41112496|NCT06464172|OTHER|Acute Oral gamma-aminobutyric acid (Natural Health Product in Canada)|1800 mg (3 capsules of 600mg) of GABA taken at the research center under the supervision of the research team.
41112497|NCT06464172|OTHER|Acute Placebo|A capsule filled with powdered sugar taken under the supervision of the research team.
41112498|NCT05469802|BIOLOGICAL|Purified Inactivated Zika Virus Vaccine (PIZV)|PIZV vaccine with aluminium hydroxide adjuvant IM injection.
41112499|NCT05469802|OTHER|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
41112500|NCT06513559|DEVICE|Anatomic total shoulder replacement|Humeral head with a metal ball and the glenoid socket with a polyethylene glenoid component.
41112501|NCT06513559|DEVICE|Reverse total shoulder replacement|Polyethylene socket on the humeral side and the glenosphere going on the glenoid side.
41112502|NCT02773017|DRUG|Dexmedetomidine A|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
41112503|NCT02773017|DRUG|Dexmedetomidine B|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
41112504|NCT02773017|DRUG|Dexmedetomidine C|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
41133356|NCT04808024|PROCEDURE|SelfMyofascial Release|Myofascial auto-release consisted of rolling the roller on a group of knee flexors for 3.5 minutes between the sciatic tumor and the knee joint in both directions, omitting the popliteal fossa. Before and after the intervention, sEMG of the biceps and gluteal muscles will be performed.
41112505|NCT03729518|RADIATION|Radiation Therapy (IMRT or IMPT)|"* Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In those patients requiring treatment of the primary site, reduced dose (50 Gy) will be delivered.~* Receipt of concurrent chemotherapy per current guidelines. Chemotherapy may be omitted in patients with focal or microscopic ENE (defined as ≤ 1 mm ENE), at the discretion of the treating Medical Oncologist.~* Blood samples will be obtained at time of enrollment, and at two time points during RT, to quantify circulating HPV DNA and perform immune profiling."
41112506|NCT01592448|BEHAVIORAL|Active Ingredient Icon|"Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen."
41112507|NCT04393246|DRUG|EDP1815|EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
41112508|NCT04393246|DRUG|Dapagliflozin|Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
41112509|NCT04393246|DRUG|Ambrisentan|Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
41112510|NCT04393246|OTHER|Standard of care|Regular standard of care for COVID-19 patients
41112511|NCT00727038|DRUG|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
41112512|NCT00951379|DRUG|Pioglitazone hydrochloride|Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
41112513|NCT00951379|OTHER|placebo|Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
41112514|NCT00951379|OTHER|laboratory biomarker analysis|Correlative studies
41112515|NCT05552508|COMBINATION_PRODUCT|Benralizumab|Participants will receive benralizumab subcutaneously.
41112516|NCT03266302|DEVICE|hemoadsorber for removal of cytokines|Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.
41112517|NCT02425449|DRUG|Succinylcholine|will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
41112518|NCT05598151|DRUG|HM97662|To evaluate the safety, tolerability, preliminary anti-tumor efficacy, PK and PD of HM97662 in solid tumors
41112519|NCT02418013|OTHER|Fresh cord blood(experimental group A)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment."
41112520|NCT02418013|OTHER|Frozen cord blood(experimental group B)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
41112521|NCT02418013|OTHER|Frozen plasma(experimental group C)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
41112522|NCT02418013|OTHER|Placebo group|"A placebo agent is administered through intravenous at CHA clinical trail institute.~It should be certain that when administered, participants are not aware of which treatments are preformed."
41112523|NCT04686942|DIAGNOSTIC_TEST|After sonazoid|0.015ml/mg sonazoid enhanced US to detection of liver metastases.
41112524|NCT06054867|DEVICE|Robotic Waterjet Treatment|"The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System.~During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real-time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan."
41112525|NCT06377111|DIETARY_SUPPLEMENT|C-PAN|C-PAN is an essential nutrient as it is required for the synthesis of CoA, a key cofactor in the tricarboxylic acid cycle and fatty acid metabolism, as well as for the synthesis of acyl carrier protein. Pantothenate appears to be safe in humans with studies describing the administration of doses up to 10 grams per day over prolonged periods of time; hence, no upper limit for tolerability has been established. In this study, oral supplement consisting of 2000 mg daily of C-PAN will be administered to a single cohort of patients.
41133357|NCT01825720|DRUG|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
41133358|NCT01825720|DRUG|normal saline group|same rate of normal saline
41446056|NCT04496349|DRUG|APG-115|QOD, 2 weeks on, 1 week off, in repeated 21-day cycles
41446057|NCT04496349|DRUG|APG-2575|APG-2575 given orally each day in cycle, in repeated 21-day cycles
41446058|NCT00178178|DEVICE|Breg Pain Care 3000 Catheter|Device: Breg Pain Care 3000 Catheter
41446059|NCT00178178|DRUG|Bupivicaine 0.5%|Drug: Bupivicaine 0.5 %
41112526|NCT06377111|BIOLOGICAL|Nivolumab|Nivolumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. Nivolumab 1 mg/kg every 3 weeks for up to 4 cycles (upon patient´s tolerability) followed by maintenance Nivolumab 3 mg/kg (or fixed dose 240 mg) every 2 weeks or Nivolumab 6 mg/kg (or fixed dose 480 mg) every 4 weeks.
40752518|NCT05655897|DEVICE|GeminiOne Transcatheter Valve Edge-to-Edge Repair System|The transcatheter valve clamp system consists of a valve clamp, an adjustable bend mid-tube, and a manipulated inner tube. The adjustable bend introducer catheter consists of an adjustable bend outer tube and dilator. The valve clip is composed of nickel-titanium alloy, cobalt-chromium-nickel-molybdenum-iron alloy, and polyethylene terephthalate material and contains a closure clip, gripping tab, central mechanism, braid, and suture. The adjustable bend guiding catheter is used to provide access to the transcatheter valve clamping system and to reach the designated position. The adjustable curved mid-tube and manipulated inner tube are used to enable the delivery, gripping, and release process of the valve clips within the body.
41112527|NCT06377111|BIOLOGICAL|Ipilimumab|Ipilimumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein CTLA-4 on immune cells called T cells. Ipilimumab 3 mg/kg every 3 weeks for up to 4 cycles.
41112528|NCT03005678|DRUG|Denosumab|active treatment group
41112529|NCT03005678|DRUG|Alendronate|comparator
41112530|NCT06441539|DEVICE|Bingo® Paclitaxel coated balloon|Treat the main vessel and side branch of bifurcation lesion with drug-eluting balloon
41112531|NCT06441539|DEVICE|Xience® Alpine Everolimus Eluting Coronary Stent System|Treat the main vessel of bifurcation lesion with drug-eluting stent, and treat the side branch with uncoated balloon or drug-eluting stent
41112532|NCT06291233|BEHAVIORAL|Virtual Interview Training (VIT)|Teachers will administer the intervention (Virtual Interview Training) with the student participants. University of Michigan research staff will train all teachers (including sites in California) and will provide support as necessary throughout the intervention delivery process. Surveys will be captures several times throughout delivery as delivery is expected to be anywhere between 4 to 6 weeks long.
41112533|NCT06291233|BEHAVIORAL|Services-as-usual|Participants will receive services-as-usual at participants school or program for approximately 6 weeks. Those that are in the active control group will receive access to the e-learning content of the Rita/Travis intervention (not the practice interviews) and will be able to review the e-learning content with teacher's supervision. In addition, this group will review a series of video conversations with autistic adults about navigating the pathway to a career. Surveys will be collected at different time points after randomization.
41112534|NCT03396692|PROCEDURE|Intravenous morphine patient-controlled analgesia (PCA)|"Group 1 control:~* Morphine titration at 0.1 mg/kg~* Establishment of PCA morphine:~* concentration 1mg/ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day. Premedication of the patient with Ketamine 0.15 mg/kg and Propofol 0.5 mg /kg"
41112535|NCT03396692|PROCEDURE|Block of the posterior exo-thoracic fascia with Ropivacaine|"Group 2 PEF block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a block of the posterior exo-thoracic fascia (PEF block) at the median level of ribs fractures with ropivacaine 5mg / mL, 3 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of ropivacaine bolus 2mg / ml at 0.1ml/kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia."
41112536|NCT03396692|PROCEDURE|Block of paravertebral space with Ropivacaine|"Group 3 paravertebral block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a paravertebral block (BPV) at the median level of ribs fractures ropivacaine 5mg / mL, (0.3ml / kg) 1.5 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of bolus of ropivacaine 2mg / ml at 0.1ml / kg every 4 hours.~Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.~In the case of failure of initial management with significant pain despite the iterative boli, epidural analgesia is used in recourse."
41112537|NCT05339477|OTHER|Accelerometer measurement|Study personnel will initiate an accelerometer and inform the patient to wear the accelerometer with an elastic belt on their right hip during waking hours for seven consecutive days. Moreover, patients are instructed to register their wear time in an activity diary in paper form. In addition, patients will register their working hours, if relevant. After seven days, patients send back the accelerometer and diary in a pre-paid envelope. The same procedure is repeated at the second follow-up visit at 1 year.
41112538|NCT04296019|DRUG|Fruquintinib|Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
41112539|NCT06513455|DRUG|Irinotecan liposome（40mg/m2）|irinotecan Liposome was administered 40mg/m2, D1，iv. q2w
41112540|NCT06513455|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w
41112541|NCT06513455|DRUG|Gemcitabine|gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w
41112542|NCT06513455|DRUG|Irinotecan Liposome（60mg/m2）|irinotecan Liposome was administered 60mg/m2, D1，iv. q2w
41112543|NCT04587908|DRUG|TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]|・Treatment period：oral administration for 52 weeks, BID after meal
41112544|NCT04587908|DRUG|Placebo [Ambulatory Cohort] only|"* Observation period：oral administration for 2 weeks, BID after meal~* Treatment period：oral administration for 52 weeks, BID after meal"
41112545|NCT02845063|BEHAVIORAL|concentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
41112546|NCT02845063|BEHAVIORAL|eccentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.
41446060|NCT00178178|DRUG|Placebo|Drug: Placebo
41446061|NCT04684186|PROCEDURE|Endovascular fiducial marker insertion|Fiducial markers will be inserted using an endovascular route
41446062|NCT04684186|PROCEDURE|Bronchoscopic fiducial marker insertion|Fiducial markers will be inserted using an endoscopic route
41446063|NCT00951457|DRUG|Bendamustine|
41446064|NCT00951457|DRUG|Alemtuzumab|
41112547|NCT02845063|GENETIC|ACE genotyping|Subjects will be genotyped for the ACE-I/D gene polymorphism.
41112548|NCT02808585|DRUG|PB1046 Injection|Four weekly subcutaneous injections of PB1046.
41112549|NCT02808585|DRUG|Placebo Injection|Four weekly subcutaneous injections of placebo.
41112550|NCT00748150|BIOLOGICAL|Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009|1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
41112551|NCT05247749|DEVICE|CONVIVO Confocal Endomicroscopy System|Confocal Laser Endomicroscopy (CEM) system intended for viewing intra-operative blood flow in the cerebral vascular area. Manufacturer - Zeiss
40925823|NCT04731857|GENETIC|Retrospective data analysis|The outlined evaluation contributes to the improvement of molecular genetic diagnostics in patient care - for example when which diagnostics can be sensibly recommended for patients with which indications or not. Diagnostic gaps can be systematically evaluated and specifically addressed in the future. This potentially affects every examination assignment for current and future patients. In addition, the evaluation of the PRSs for example, can contribute significantly to the timely introduction to routine diagnostics. For familial breast cancer, according to the guidelines, there may be very specific preventive measures. Estimates currently assume up to 5% of patients, which would mean up to 25 cases per year with a potentially adapted management for patients with the question of a tumor disease alone.
40925824|NCT06173310|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
40925825|NCT00410709|DRUG|NatrOVA Creme Rinse (1%)|
40925826|NCT00732836|DRUG|HAI Abraxane|Escalating doses (beginning dose 180 mg/m\^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
40925827|NCT00732836|PROCEDURE|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
40925828|NCT00732836|DRUG|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m\^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
40925829|NCT02663726|OTHER|Yoga|10 weekly 75-min sessions of specialised yoga
40925830|NCT02663726|BEHAVIORAL|Written advice|Written advice about physical activity
40925831|NCT05680116|DEVICE|MYOVOLT (MyovoltTM, Myovolt Limited, Christchurch, New Zealand ) wearable vibration therapy device|Patients will wear Myovolt shoulder device twice a week and each session will continue 30minutes. This therapy will apply during the radiotherapy process. The device will be applied on the bare skin of the shoulder area. The first 10 minutes of the 30 minutes will be intermittent vibration, the other 20 minutes will be done in the sinusoidal vibration program. Both programs will be in the range of 20-100 Hz.
40925832|NCT05680116|OTHER|Home based exercise|Patients will do home based exercise during the radiotherapy process. 5 days a week. 2 sessions a day, each exercise will be 10x2 repetitions
40925833|NCT02454361|DRUG|KBP-7072|KBP-7072
40925834|NCT02454361|DRUG|Placebo|Placebo
40925835|NCT02677311|PROCEDURE|Blood draw|Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
40925836|NCT02677311|PROCEDURE|Pelvic Ultrasound|Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
40925837|NCT02672020|BIOLOGICAL|omics identity card|
40925838|NCT04304547|DRUG|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2|"Subject of sequence A takes IP in the following order:~1. Each tablet of CKD-828 and D097 and D337 be taken at once~2. CKD-348 T1 1 tablet~3. CKD-348 T2 1 tabet"
40925839|NCT04304547|DRUG|CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,|"Subject of sequence B takes IP in the following order:~1. CKD-348 T1 1 tablet~2. CKD-348 T2 1 tablet~3. Each tablet of CKD-828 and D097 and D337 be taken at once"
40925840|NCT04304547|DRUG|CKD-348 T2, CKD-348 T1, CKD-828, D097, D337|"Subject of sequence C takes IP in the following order:~1. CKD-348 T2 1 tablet~2. Each tablet of CKD-828 and D097 and D337 be taken at once~3. CKD-348 T1 1 tablet"
40925841|NCT05357729|DEVICE|MultiSense® remote monitoring|At hospital, the patient will be monitored with conventional monitoring devices as well as the MultiSense® solution (at least one hour with a reference monitor). After hospital discharge, the patients will be remotely monitored by their healthcare professional using the MultiSense® solution.
40925842|NCT02176746|BIOLOGICAL|cancer stem cell vaccine|
41112552|NCT03906968|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
41112553|NCT06194734|DRUG|KC1036|KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle
41112554|NCT06194734|DRUG|Irinotecan|Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks
41112555|NCT06194734|DRUG|Docetaxel|Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks；
41112556|NCT06194734|DRUG|S-1|S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle
41112557|NCT03477695|DEVICE|ambulatory use of the Upright device|Patients will wear the UpRight for a period of two month
41112558|NCT05223205|PROCEDURE|Air|Test if air is sufficient for macular hole closure.
41112559|NCT05223205|PROCEDURE|10% SF6 and 90% air|Test if 10% SF6 and 90% air is sufficient for macular hole closure.
41112560|NCT04266951|BEHAVIORAL|Singstrong:|Group singing and breathing control training
41112561|NCT01287052|DRUG|Nitrous Oxide|Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
41112562|NCT06456970|DEVICE|fibroscan|"Fibroscan examination with controlled attenuation parameterCAP (Echosens FibroScan ® Compact 530) for evaluation of steatosis and its degree (by CAP score) and fibrosis stage by liver stiffness measurement(LSM)"
41112563|NCT01101685|DRUG|Escitalopram|7 days dosing of 10mg per day
41112564|NCT01101685|DRUG|Placebo|7 days dosing at 10mg daily
41112565|NCT04497727|OTHER|Gene Expression|Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination
41112566|NCT03299816|BEHAVIORAL|Coaching DASH group (C-DASH)|Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
41112567|NCT03299816|BEHAVIORAL|Self-Shopping DASH group (S-DASH)|Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
41112568|NCT02158754|DIAGNOSTIC_TEST|Corus CAD (ASGES)|
41112569|NCT01895218|DRUG|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
41112570|NCT01895218|OTHER|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
41112571|NCT00043082|DRUG|carboplatin|intravenous q 4 weeks
41112572|NCT00043082|DRUG|pegylated liposomal doxorubicin hydrochloride|intravenous q 4 weeks
41112573|NCT06201819|DRUG|Liraglutide injection|Liraglutide (GLP-1 analog) injection during 3 months
41112574|NCT02353988|DRUG|Bicalutamide|"Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade \>= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity."
41112575|NCT02353988|OTHER|Physician's Choice|"The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.~The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance."
41112576|NCT02995096|PROCEDURE|Pre-treatment|Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
41112577|NCT02995096|DRUG|Sirolimus based immunosuppression|Immunosuppression regimens containing Sirolimus
41112578|NCT06513936|PROCEDURE|The skin care Bundle|S- Secure device and protect the skin with dressings K- Keep repositioning more frequently than twice daily Inspect the skin under the device more than twice daily N- Nutrition and hydration C- Choose the correct size and type of medical device A- Avoid placing devices over sites of prior or existing pressure injury R- Report MDRPI correctly and immediately E- Educate staff on the correct use of devices and prevention of skin breakdown
40752519|NCT02681432|DRUG|HIPEC|Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
40752520|NCT02681432|PROCEDURE|No HIPEC|Cytoreductive surgery without HIPEC
41112579|NCT06513936|PROCEDURE|Routine care|Routine care delivered in the unit
41112580|NCT00188604|DRUG|sodium selenite|
41112581|NCT00585533|DRUG|Erlotinib (Tarceva)|Erlotinib
41112582|NCT05204615|OTHER|Collection of clinical, psychometric and biometric data|Wearable devices and a mobile app will be used to collect real-time data for 4 weeks to detect physiological and psychological complications based on biometric and psychometric (patient-reported outcomes) information.
41112583|NCT05678972|OTHER|Self-help online mindfulness-based intervention|"This self-help online mindfulness-based intervention is comprised of four weekly modules on education about mindfulness, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and videos are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice.~Participants will be asked to meditate daily and complete a daily log on their mindfulness practice during this 8-week period."
41112584|NCT04382365|OTHER|Sleep Health Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness|Cognitive-Behavioral Treatment for insomnia (CBT-I) is a non-pharmacological intervention that is effective in treating insomnia in older adults, even when present with comorbid medical and psychological conditions.25 CBT-I focuses on the maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems, and typically consists of five primary treatment components: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
41112585|NCT00292383|PROCEDURE|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
41112586|NCT05404906|DRUG|Azacitidine|Given SC
41112587|NCT05404906|DRUG|Venetoclax|Given PO
41112588|NCT05404906|OTHER|Supportive care|Patients will receive disease monitoring and supportive care for any complication.
41112589|NCT05919680|DRUG|NST-6179 Part A|Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
41112590|NCT05919680|DRUG|NST-6179 Part B|Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
41112591|NCT05919680|OTHER|Matched Placebo|Matched placebo for administration in Part A or Part B
41112592|NCT00395603|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
41112593|NCT00395603|DRUG|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
41112594|NCT03484611|DRUG|GnRH antagonist|0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
41112595|NCT03484611|DRUG|Gonadotropins|started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU
41112596|NCT03484611|DRUG|Human chorionic gonadotropin|10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more
41112597|NCT03484611|PROCEDURE|Embryo transfer|0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)
41112598|NCT03484611|DRUG|Progesterone|vaginal prontogest 400 mg twice daily
41112599|NCT02651233|OTHER|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
41112600|NCT05193188|DRUG|Anlotinib hydrochloride|Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
41112601|NCT05193188|DRUG|PD-1 inhibitor|Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
41112602|NCT00864786|DRUG|PF03635659|Inhaled doses of 200 mcgQD
41112603|NCT00864786|DRUG|PF03635659|Inhaled doses of 600 mcg QD
41112604|NCT00864786|DRUG|PF03635659|Inhaled doses of 1000 mcg QD
41112605|NCT00864786|DRUG|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
41112606|NCT00864786|DRUG|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
41112607|NCT02817724|DEVICE|BENECA System|BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
41112608|NCT02817724|OTHER|Supervised-occupational therapy program|It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
41112609|NCT00316316|BEHAVIORAL|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
41112610|NCT00316316|BEHAVIORAL|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
41112611|NCT06553547|DRUG|Tenapanor|Tenapanor 5 mg/mL solution
41112612|NCT06553547|DRUG|Placebo|Matching Placebo solution
41112613|NCT03270358|PROCEDURE|Blood sampling in arterioveinous fistula without stenosis|"Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session"
41112614|NCT03270358|PROCEDURE|Blood sampling in arterioveinous fistula with stenosis|Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
41112615|NCT05839938|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
41112616|NCT05839938|OTHER|Placebo|Placebo
41112617|NCT03934658|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
41112618|NCT03934658|DEVICE|NightWare Therapeutic System in Sham Mode|A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
41112619|NCT06246435|OTHER|moderate aerobic exercise|
41112620|NCT04653935|BEHAVIORAL|Self-management app with all intervention components|A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based.
41112621|NCT04653935|BEHAVIORAL|Self-management app with Information component only|self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only.
41112622|NCT05667454|DRUG|Atropine Ophthalmic 0.05%|Atropine 0.05% sulphate ophthalmic solution
41112623|NCT05667454|DRUG|Atropine Ophthalmic 0.5%|Atropine 0.5% sulphate ophthalmic solution
41112624|NCT06275412|BEHAVIORAL|The 3Ms 2.0 Intervention|The 3Ms is a culturally tailored, mHealth intervention for primary caregivers of Black adolescents with T1D focused on promoting daily parental monitoring of adolescent diabetes care and delivered via an Internet platform, Computer Intervention Authoring System (CIAS). The intervention content is based on the Information-Motivation-Behavioral Skills (IMB) model. Caregivers randomized to The 3Ms receive 3 sessions. The caregiver is guided through each session by an interactive and emotive three-dimensional narrator that reads and speaks aloud. Additional intervention content includes brief videoclips to provide skills demonstrations of supportive parenting practices related to diabetes care and text message reminders. Each session is no more than 20 minutes in length. The intervention is delivered over a three-month window, with the two follow-up sessions available to be accessed by the caregiver at one-month intervals after completion of the initial session.
41133359|NCT05118178|DIAGNOSTIC_TEST|echocardiography, computed tomography|echocardiography - including GLS and MWI computed tomography - with calcium score index
41446065|NCT03504085|OTHER|Yoga: Active Hatha|Classical Hatha yoga with influences from Viniyoga and Iyengar yoga. Both Viniyoga and Iyengar yoga styles emphasize modifications and adaptations including the use of props such as straps and blocks in order to minimize the risk of injury and make the poses accessible to people with health problems and limitations
41446066|NCT03504085|OTHER|Yoga: Restorative|Restorative Yoga is a slow-paced yoga style that emphasizes relaxation and includes very little movement.
41446067|NCT00408018|DRUG|P276-00|Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
41446068|NCT05613972|OTHER|Brief Suicide and Trauma Therapy|12-week trauma therapy
41446069|NCT02566122|OTHER|measurements|
41446070|NCT02818530|DEVICE|IOP by tonometer|Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
41112625|NCT06275412|BEHAVIORAL|Educational Attention Control (EAC)|The EAC intervention consists of three sessions delivered in an mHealth format via the CIAS internet platform over three months, with access for a maximum of six months. EAC provides structured information on topics of interest to caregivers of adolescents with T1D such as travelling with diabetes, or emergency preparedness for persons with diabetes. All participants receive their standard medical care.
41112626|NCT02744521|OTHER|Symptom-based screening intervention|The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
41112627|NCT04997746|BEHAVIORAL|Multiprofessional educational interventions|Preventive educational interventions
41112628|NCT04997746|OTHER|Measurement of anthropometric measurements|Measurement of height (in meters), weight (in kilograms), knee height, arm circumference and calf circumference (in centimeters)
41112629|NCT00305591|DRUG|l-ornithine l-aspartate|
41112630|NCT02613871|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
41112631|NCT06261775|OTHER|Red meat-based meal|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
41112632|NCT06261775|OTHER|Lacto-ovo-vegetarian meal|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
41112633|NCT05304546|DRUG|Pembrolizumab|Solution for IV
41112634|NCT05304546|DRUG|Encorafenib|Oral QD
41112635|NCT05304546|DRUG|Binimetinib|Oral BID
41112636|NCT00166166|DRUG|Tetraethylammonium (TEA)|5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
41112637|NCT00166166|DRUG|L-NG-monomethyl Arginine (L-NMMA)|5 minute intra-arterial infusion of L-NMMA 8 μmol/min
41112638|NCT00166166|DRUG|Bradykinin|Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
41112639|NCT00166166|DRUG|Sodium nitroprusside|Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
41112640|NCT00166166|DRUG|Acetylcholine|Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
41112641|NCT00166166|DRUG|Saline|5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
41112642|NCT00166166|DRUG|Fluconazole|5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
41112643|NCT05131386|DRUG|Trabectedin|ET-743, Yondelis (vials of 1 mg). Route of administration: intravenous infusion
41112644|NCT00711126|DRUG|GW642444|2.5mcg IV
41112645|NCT00711126|DRUG|GW642444|5mcg IV
41112646|NCT00711126|DRUG|GW642444|10mcg IV
41112647|NCT00711126|DRUG|GW642444|100mcg inhaled
41112648|NCT00711126|DRUG|GW642444|20mcg IV
41112649|NCT00711126|DRUG|GW642444|500mcg oral
41112650|NCT05827393|PROCEDURE|muscle transplantation|the resected extra stump of rectus muscle was transplanted to the other horizontal rectus muscle which was recessed by a standard recession technique
41112651|NCT04825184|BEHAVIORAL|Body image chatbot|See arm/group description.
41112652|NCT01764815|DEVICE|directSTN Acute lead connected to external neurostimulator|Test phase will be performed intra-operatively, prior to chronic lead implant
41112653|NCT02098382|DEVICE|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
41112654|NCT05388565|BEHAVIORAL|Domestic Violence Enhanced Perinatal Care Program|Our intervention consists of four major components: a) information about IPV and its effects on maternal and infant health, b) danger assessment, c) options and safety plan, and d) resources.
41112655|NCT05388565|BEHAVIORAL|Standard of Care|Usual perinatal care (e.g., prenatal health education) and a list of resource information (e.g., crisis lines, local IPV and mental health resources)
41112656|NCT00317226|DRUG|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
41112657|NCT01263730|BEHAVIORAL|Tai Chi|Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
41112658|NCT03874650|BEHAVIORAL|Activity Planning Group|Participants in this group will receive 8 1-hour sessions of Behavioural Activation combined with select Goal Management Training strategies over the course of 8 weeks.
41112659|NCT03874650|BEHAVIORAL|Activity Engagement Group|Participants in this group will attend 8 1-hour sessions of various social activities such as board games and puzzles.
41112660|NCT03874650|BEHAVIORAL|Waitlist Group|Participants in this group will continue on their care as usual before being re-randomised into either the Activity Planning Group or Activity Engagement Group after 8 weeks.
41112661|NCT01420393|PROCEDURE|Rhythm control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
41112662|NCT01420393|OTHER|Rate Control|Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR \< 80 bpm and 6-minute walk HR \< 110 bpm.
41112663|NCT01257074|DRUG|Acyclovir 50mg/g|Cream, dose 5 times daily during 5 days
41112664|NCT01257074|DRUG|Penciclovir 10mg/g|Cream, dose 5 times daily during 5 days
41112665|NCT00875160|DRUG|AT2101|225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
41112666|NCT06338241|COMBINATION_PRODUCT|Biphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin|The intervention description for Galibone+ in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. Galibone is indicated to treat segmental and cavity bone loss, aesthetic repairs and bone augmentations (such as inlay or onlay grafts); to fill dental alveolar bone; for the placement of dental implants; for the stabilization of osteotomies and prostheses in dentistry.
41112667|NCT06338241|OTHER|Bovine Hydroxyapatite|The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.
41112668|NCT01567683|DRUG|Imiquimod (topical use)|
41112669|NCT04157855|PROCEDURE|Abdominal Plane Block(s) with depot Steroids|APB Steroids treatment: under real time ultrasound guidance, a 100 mm needle is introduced into the specified plane (subcostal TAP for upper abdomen pain, posterior TAP for lower abdomen pain or TQL for flank and lower abdominal pain). Normal saline (10 ml) is used to open the fascial plane (saline hydrodissection). Then 40 mg of depomedrone diluted in 10 ml of 0.25% levo-bupivacaine is injected into the plane. . A total of 80 mg of depomedrone (steroid) will be used.
41112670|NCT02356549|BEHAVIORAL|EMR Tailoring|Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
41112671|NCT02356549|BEHAVIORAL|Survey Tailoring|Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
41112672|NCT02356549|BEHAVIORAL|Physician Involvement|Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
41112673|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 1|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
41112674|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 2|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.
41112675|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 3|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.
41112676|NCT04432207|DRUG|Atezolizumab|Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
41112677|NCT04432207|DRUG|Standard of care chemotherapy|Chemotherapy to be administered according to the prescribing information.
41112678|NCT01748318|DRUG|New Mexico Honey|Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
41112679|NCT01748318|DRUG|Bactrim DS|Bactrim DS
41112680|NCT00761436|BIOLOGICAL|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
41112681|NCT00344994|DRUG|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
41133360|NCT04388137|OTHER|No intervention.|No intervention.
41133361|NCT00002232|BIOLOGICAL|APL 400-003|
41112682|NCT00598208|DRUG|corifollitropin alfa|On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
41112683|NCT00598208|DRUG|Follitropin beta injection|Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
41112684|NCT00488410|DEVICE|Doppler echocardiography|
41112685|NCT05715957|OTHER|No intervention|No intervention
41112686|NCT05919446|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Each session in the ACT group will include the first hour of ACT intervention followed by 1 hour of back exercise class. The ACT group will be led by a trained ACT counsellor and a trained exercise trainer.
41112687|NCT05919446|BEHAVIORAL|back exercise|The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.
41112688|NCT00638963|DRUG|temozolomide|Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles
41112689|NCT02716220|DEVICE|Percutaneous Coronary Intervention|Implanttaion fo the DREAMS 2G Scaffold
41112690|NCT01259102|DRUG|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
41112691|NCT00687388|DRUG|selective alpha 1-blockers|Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
41112692|NCT00687388|DRUG|celecoxib|200mg daily for 8 weeks
41112693|NCT00687388|DRUG|alpha-blocker and NSAID|amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
41112694|NCT00084903|PROCEDURE|Colposcopic biopsy|Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
41112695|NCT00084903|PROCEDURE|Light-Scattering Spectroscopy|Spectroscopy readings taken in 2 regions of cervix.
41112696|NCT03184623|OTHER|muscle mass measurement|measurement of muscle mass by echocardiography
41112697|NCT05147688|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41112698|NCT03359889|DRUG|PraxbindTM|Drug
41112699|NCT01428297|DRUG|BPR277 ointment (controlled application)|
41112700|NCT01428297|DRUG|Placebo (Vehicle)|
41112701|NCT01428297|DRUG|BPR277 ointment|
41112702|NCT01428297|DRUG|Placebo (Vehicle)|
41112703|NCT01428297|DRUG|BPR277|
41112704|NCT01428297|DRUG|Placebo (Vehicle)|
41112705|NCT03473522|DEVICE|tDCS|Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
41112706|NCT03473522|BEHAVIORAL|Exercise Therapy|Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
41112707|NCT04956679|DIAGNOSTIC_TEST|carbon 13 breath test|Patients with positive Helicobacter pylori infection were determined by carbon 13 breath test ,The diagnosis and treatment of positive patients were followed up without other intervention.
41112708|NCT06231355|DRUG|Performing paravertebral nerve block with lipo-bupivacaine|Paravertebral block is performed using liposomal bupivacaine.
41112709|NCT06231355|DRUG|Performing paravertebral nerve block with bupivacaine|Paravertebral block is performed using bupivacaine.
41112710|NCT00326144|DRUG|Quetiapine fumarate|
41112711|NCT00971906|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant,or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups
41112712|NCT04283552|DEVICE|Dynamic PET/CT Imaging|-Will take approximately 60 minutes
41112713|NCT04911933|BEHAVIORAL|Family Therapy|There will be systemic family psychotherapy sessions every two weeks. Families and individuals who require a more intensive service will be referred to a higher level of care.
41112714|NCT03720210|DEVICE|RFA|Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis
41112715|NCT00959582|PROCEDURE|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
41112716|NCT02694978|DRUG|Ferumoxytol|
41112717|NCT02694978|DRUG|FCM|
41112718|NCT01462058|DIETARY_SUPPLEMENT|Vitamin D3|70µg Vitamin D3, daily, 12 weeks
41112719|NCT01462058|DRUG|Placebo|Placebo, daily, 12 weeks
41112720|NCT04016025|BEHAVIORAL|Adherence to topical standard therapy assessed|Adherence defined as percentage of patients applying at least aimed daily dose
41446071|NCT02818530|DEVICE|Anterior chamber depth measurement by ultrasound|Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
41446072|NCT04304209|DRUG|Oxaliplatin|130mg/m2, d1 q3w, in Capeox regimen (100mg/m2 when used cocurrently with radiotherapy), intravenous infusion
41446073|NCT04304209|DRUG|Capecitabine|1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration
41112721|NCT03707691|BEHAVIORAL|Listening tests. Pitch training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
41112722|NCT03707691|BEHAVIORAL|visuo-spatial training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
41112723|NCT03707691|BEHAVIORAL|EEG/MEG/MRI recordings.|Listening tests. EEG/MEG/MRI recordings
41112724|NCT06339489|DIAGNOSTIC_TEST|Testing the serum levels of bone metabolic markers|Testing serum levels of TRACP-5b and BALP, BMD values of lumbar spine L1-L4, left and right hip, left and right femoral neck et.al.
41112725|NCT00212056|DRUG|ANP(hANP)|0∙025 μg/kg per min for 3 days(intravenous)
41112726|NCT00212056|DRUG|Control|placebo
41112727|NCT05189340|OTHER|Educational Videos|Series of six videos each covering a specific aspect of post-transplant care related to medication use or monitoring
41112728|NCT05072743|DEVICE|Photobiomodulation Therapy|PBMT will be applied to the cervical spine using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
41112729|NCT00092274|DRUG|HuMax-CD20|
41112730|NCT02838199|DEVICE|SAPIEN 3|
41446074|NCT04304209|DRUG|Sintilimab|200mg, d1 q3w, intravenous infusion
41112731|NCT02838199|PROCEDURE|SAVR|
41112732|NCT06040333|OTHER|Exercise|Dynamic Neuromuscular Stabilisation Exercise
41112733|NCT06040333|OTHER|Standard therapy|Patient education, massage, diaphragmatic breathing, kegel exercise
41112734|NCT01521624|DRUG|Metformin|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
41133362|NCT03056066|DEVICE|Plethysmograph|A full Body Plethysmography examination
41446075|NCT04304209|RADIATION|radiotherapy|neoadjuvant radiotherapy with 50Gy to GTV, 45Gy to CTV in 25 fractions.
41446076|NCT04304209|PROCEDURE|total mesorectal excision|total mesorectal excision after neoadjuvant treatment
41446077|NCT04304209|OTHER|Watch and wait|Watch and wait for cCR patients after neoadjuvant treatment
41446078|NCT05957549|OTHER|Speech discrimination|Two different speech sounds are played at the same sound intensity.
41112735|NCT02594735|DRUG|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight \< 50 KG).
41112736|NCT00067353|DRUG|Fluoride varnish|
41112737|NCT03481608|OTHER|Lauric acid (coconut oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.
41112738|NCT03481608|OTHER|No Lauric acid (olive oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.
41112739|NCT02667808|OTHER|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
41112740|NCT02667808|OTHER|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
41112741|NCT04152694|OTHER|Ceftaroline levels in CRRT|Levels of ceftaroline measured in patients receiving CRRT
41112742|NCT00777244|DRUG|MITOTANE|mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
41112743|NCT01714882|BEHAVIORAL|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
41112744|NCT01714882|BEHAVIORAL|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
41112745|NCT00783133|DRUG|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
41112746|NCT00783133|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
41112747|NCT05092139|DEVICE|endovascular treatment|all enrolled patients must receive endovascular treatment
41112748|NCT02704741|DEVICE|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
40752521|NCT03397758|DEVICE|Study population|First, periorbital area was treated with the short needles (exposure time 150ms, power 9W) to tighten the overlying dermis. Then, the fat pocket itself was treated additionally with the long needle (exposure time 400ms, power 9W).
40752522|NCT03315689|DRUG|Vehicle|Vehicle Topical Solution
41112749|NCT03093467|BEHAVIORAL|ASCENSO|Internet-based program: an adjunct support and monitoring system for the treatment of depression.
41112750|NCT03093467|DRUG|Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.|Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
41112751|NCT03093467|BEHAVIORAL|Psychotherapy|Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
41112752|NCT00178399|PROCEDURE|Stereotactic Body Radiation Therapy|
41112753|NCT03903081|DRUG|HEC110114 tablet|administered orally once daily
41112754|NCT03903081|DRUG|Placebo Oral Tablet|Placebo will be administered orally at a dose and frequency matched to HEC110114
41112755|NCT00149864|DRUG|Mycophenolate sodium (enteric coated)|
41112756|NCT02678572|COMBINATION_PRODUCT|Melphalan/HDS|Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)
41112757|NCT03822572|OTHER|endurance exercise|defined exercise program
41112758|NCT03822572|OTHER|control|habitual physical activity before the diagnosis
41112759|NCT05887180|OTHER|PräVaNet-Intervention|interdisciplinary and digitally supported prevention concept
41112760|NCT02950779|OTHER|Handgrip Strength Measurement|
41112761|NCT05064930|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium lactis|The probiotic will be administered orally over a period of 12 weeks.
41112762|NCT05064930|DIETARY_SUPPLEMENT|Probiotic Bacillus coagulans|The probiotic will be administered orally over a period of 12 weeks.
41112763|NCT05064930|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as a placebo will be administered orally over a period of 12 weeks. The taste and appearance of the placebo will be similar to those of the probiotic formulation.
40752523|NCT03315689|DRUG|ATI-50002|ATI-50002 Topical Solution
41112764|NCT06384547|DRUG|VRDN-001 10 mg/kg|5 infusions of VRDN-001 10 mg/kg
41112765|NCT06384547|DRUG|VRDN-001 3 mg/kg|5 infusions of VRDN-001 3 mg/kg
41112766|NCT00036933|BIOLOGICAL|MUC-2-Globo H-KLH conjugate vaccine|
41112767|NCT00036933|BIOLOGICAL|QS21|
41112768|NCT03705442|DIETARY_SUPPLEMENT|Omni-Biotic 10|All patients will have at their disposal current medications for diarrhea based on guidelines, and education regarding side effects and dietary recommendations will be undertaken. One cohort will also ingest a probiotic (OMNi-BiOTiC® 10AAD), while other cohort will take a placebo, same in colour, shape, taste and smell; both medications will be taken 2 per day, every 12 hours, over 84 days (6 chemotherapy cycles every 14 days).
41112769|NCT03705442|DRUG|"loperamide (Seldiar)"|All the patients will have access to standard drugs for diarrhoea
41112770|NCT02671344|OTHER|Determination of gene profiles using arrays semen|Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
41446079|NCT02491099|DRUG|Afatinib|Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
41446080|NCT04096664|DEVICE|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
41446081|NCT02964663|DEVICE|esCCO|comparison of non-invasive monitoring esCCO vs VV on cardiac output measurements
40752524|NCT04555733|DRUG|Lemborexant|Lemborexant oral tablets.
40752525|NCT02440529|BEHAVIORAL|Intervention|Discussion
40752526|NCT02440529|BEHAVIORAL|Verbal Group|Detailed Discussion
41112771|NCT02561949|BEHAVIORAL|YRI|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
41112772|NCT02561949|OTHER|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
41112773|NCT02401646|DIETARY_SUPPLEMENT|Polygoni Multiflori Radix complex extract|Intervention is manufactured by Chun-Ho food
41112774|NCT02401646|DIETARY_SUPPLEMENT|Placebo|The placebo is filled with starch, so does not contain the active ingredient.
41112775|NCT06347640|BIOLOGICAL|induced bleeding|revascularization of tooth is achieved by induced bleeding
41112776|NCT06347640|BIOLOGICAL|plasma rich fibrin|revascularization of tooth is achieved by plasma rich fibrin
41112777|NCT02692417|DEVICE|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
41112778|NCT03407131|PROCEDURE|Joint replacement surgery|Joint replacement surgery is to replace the original joint function, so that the patient can recover the joint function as soon as possible.
41112779|NCT03407131|PROCEDURE|Intramedullary nail fixation|Internal fixation surgery is the stable fixation of fracture, which provides the condition for the restoration of joint function.
41112780|NCT05971563|DIETARY_SUPPLEMENT|Casein|Natural protein
41112781|NCT05971563|DIETARY_SUPPLEMENT|L-amino acids|Synthetic amino acids based protein substitute for Phenylketonuria
41112782|NCT05971563|DIETARY_SUPPLEMENT|CGMP-AA|Glycomacropeptide based protein substitute for Phenylketonuria
41112783|NCT04584099|DEVICE|Radiofrequency device treatment|TempSure firm
41112784|NCT05882266|DIETARY_SUPPLEMENT|Plant Omega|A commercial plant-based omega-3 beverage consumed once daily during breakfast
41112785|NCT05882266|OTHER|Dietary therapy only|Standard dietary therapy
41112786|NCT03958734|OTHER|High-fat meal|Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
41112787|NCT02964429|DEVICE|Diacap Pro High-Flux|During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.
41112788|NCT06231277|DRUG|BH002|Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
41112789|NCT04477330|OTHER|Transcranial direct current stimulation (tDCS)|1 mA tDCS
41112790|NCT04477330|OTHER|Ankle motor training|Visuomotor target tracking task
41112791|NCT04477330|BEHAVIORAL|High intensity interval speed based treadmill training (HIISTT)|Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
41112792|NCT01640678|PROCEDURE|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
41112793|NCT01640678|PROCEDURE|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
41112794|NCT06397105|BEHAVIORAL|Problem Management Plus|"Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy will comprise a digital support program that participants can access via the internet."
41112795|NCT00482378|DRUG|Pamidronate|90 mg by IV monthly.
41112796|NCT00482378|DRUG|Zoledronic acid|4 mg by IV monthly.
41112797|NCT00482378|RADIATION|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
41112798|NCT01241435|DRUG|LY2216684|Administered orally
41112799|NCT05717114|PROCEDURE|Pecs block|(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.
41112800|NCT04125433|BEHAVIORAL|Peer Integrated Care Services|The project employs a two level intervention to include Peer Support Specialist (PSS) and Community Health Advocate (CHA). Contact and engagement with participating members will be through both direct intervention in the emergency department as well as in the community for prevention visits and follow up. Peers and Community Health Advocates will address Behavioral and Social Determinants of Health (SDoH) concerns through a coordinated intervention supported by a common IT Medicaid member tracking platform. This research project will determine the feasibility of deploying a single shared IT platform that will include referral, appointment completion, and intervention outcome data. Project staff will develop a relationship with the members improving member access and engagement with community-based services. The project will determine the impact on total cost of care through redirecting study participants to community resources rather than return visits to the emergency department.
41112801|NCT01856335|OTHER|Patient Education|
41112802|NCT01856335|OTHER|exercise: increase physical activity/goal setting|
41112803|NCT01161498|BIOLOGICAL|Talimogene Laherparepvec|Administered by intratumoral injection
41112804|NCT01161498|RADIATION|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
41446082|NCT03641079|DRUG|Brinjal peel extract containing cream|Brinjal peel extract, white wax, white petrolatum, stearyl alcohol
41112805|NCT01161498|DRUG|Cisplatin|Administered by intravenous infusion
41112806|NCT00702806|DRUG|Org 36286|Intra-abdominal injection of Org 36286
41112807|NCT00702806|DRUG|Puregon®|Subcutaneous Puregon® 150 IU
41112808|NCT00702806|DRUG|Orgalutran®|Subcutaneous Orgalutran® 0.25 mg
41112809|NCT00702806|DRUG|Pregnyl®|Subcutaneous Pregnyl® 10,000 IU
41112810|NCT02055794|PROCEDURE|Suturing of the perineal skin|
41112811|NCT02055794|PROCEDURE|Closing perineal skin with surgical glue|
41112812|NCT02055794|PROCEDURE|No suturing of the perineal skin|
41112813|NCT01638039|OTHER|Laboratory Tests|Stool, blood, urine and saliva samples
41112814|NCT03057639|OTHER|Quality-of-Life Assessment|Ancillary studies
41112815|NCT03057639|OTHER|Questionnaire Administration|Ancillary studies
41112816|NCT01976936|DRUG|Low Dose Lovastatin|80 mg daily for 3 days
41112817|NCT01976936|OTHER|Placebo|Placebo for 3 days
41112818|NCT01976936|DRUG|High Dose Lovastatin|640 mg daily for 3 days
41112819|NCT04647786|DEVICE|Prototype medical device (SEA CtV)|A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.
41112820|NCT05817630|OTHER|Silicone oil Tamponade for Retinal Detachment|eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed
41112821|NCT05254769|DEVICE|Neurofeedback Equipment (Cygnet) by BEE Medic GmbH Technologies, Baden-Wurttemberg, Germany.|The EEG NeuroAmp (Electroencephalogram Amplifier) is a user-friendly high-performance interface between client and clinician computer. It can be used in two different functionalities: In an EEG/ERP (Event related potential) measurement and in an EEG biofeedback (neurofeedback) and/or peripheral biofeedback setting.
41112822|NCT06188377|DEVICE|measured by a impedance analyzer|the healthy chinese neonates will be measured by a impedance analyzer, and will be compared with that of other ethnicity whose data have been reported by literatures.
41112823|NCT01772420|DRUG|Eltrombopag Olamine|Given PO
41112824|NCT01772420|OTHER|Laboratory Biomarker Analysis|Correlative studies
41112825|NCT01772420|DRUG|Lenalidomide|Given PO
41112826|NCT03768869|DRUG|Low Risk: Oupatient Management|Intravenous Levaquin initially, then oral dosing. Patient discharged to go home to finish medication cycle after initial 120 minutes observation. Patients will be evaluated daily in the clinic, and his or her temperature must be taken and recorded four times per day. Blood cultures will be drawn at clinic visits.
41112827|NCT03768869|DRUG|Low Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
41112828|NCT03768869|DRUG|High Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
41112829|NCT06121310|OTHER|Survey|Non interventional. Pediatric anesthesia satisfaction scale validity and reliability is going to investigate by survey analyses
41112830|NCT04184336|OTHER|surveillance|
41112831|NCT06212141|DEVICE|VisCalor Bulk,VOCO,Germany|"It was placed class II restorations.Before applying it, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 15 sec. and Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Then light air pressure will be applied for 5 sec., and then polymerization will be carried out for 10 sec. using LED light.~When it comes to the application of VisCalor , the VisCalor Gun , heating device will be used. A disposable composite capsule will be placed into the device, and it will be heated by selecting program 1 (65°C) for 30 sec. The material will remain hot for 2.5 min.~The nozzle of the capsule on the gun will be directly applied to the deepest part of the cavity, ensuring that the material is placed from bottom to top without exceeding 4 mm. Polymerization will be carried out with LED for 10 sec."
41112832|NCT06212141|DEVICE|Admira Fusion x-tra,VOCO,Germany|"Admira Fusion x-tra composite resin was placed class II restorations. Before applying it an orthophosphoric acid with a concentration of 37% will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 20 sec. And Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec. using LED light with a power of 1200 mW/cm².~Afterwards bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light for 20 seconds."
41133363|NCT02448069|DRUG|Argatroban|All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
41133364|NCT04828096|OTHER|Orthodontic retention|The stability of the mandibular anterior teeth after two resp. 5 years of retention
41133365|NCT06151340|OTHER|Data collection|Data collection
41133366|NCT02551224|OTHER|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
41112833|NCT06212141|DEVICE|Filtek One Bulk,3M,Germany|"Filtek One Bulk composite resin was placed class II restorations. Before applyingthe material, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin, followed by rinsing the cavity with pressurized air and water for 20 sec.Then , adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec using LED light .~Afterwards, bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light at a power of 1200 mW/cm² for 10 sec from all directions, following the manufacturer's recommendations."
41112834|NCT02482519|OTHER|High calorie diet|High calorie diet for 10 days
41112835|NCT02482519|OTHER|Fasting|10 day fast
41112836|NCT05263037|DEVICE|EaseVRx|VR software with interactive content
41112837|NCT05263037|DEVICE|Sham VR|VR with neutral non-interactive content
41112838|NCT02206672|OTHER|Micro reinjection of autologus adipose tissue|
41112839|NCT01692730|BEHAVIORAL|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
41112840|NCT01692730|BEHAVIORAL|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
41112841|NCT03709758|DRUG|Venetoclax|Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die
41112842|NCT03709758|DRUG|Daunorubicin|Chemotherapy is most effective at killing cells that are rapidly dividing.
41112843|NCT03709758|DRUG|Cytarabine|Chemotherapy is most effective at killing cells that are rapidly dividing.
41112844|NCT06449300|OTHER|Resistance exercise-LVT|(low volume training - 3 sessions of 12 exercises per week)
41112845|NCT06449300|OTHER|Resistance exercise-MVT|(moderate volume training - 4 sessions of 12 exercises per week)
41112846|NCT06449300|OTHER|Resistance exercise-HVT|(high volume training - 5 sessions of 12 exercises per week)
41112847|NCT01229358|OTHER|Surgical dressing|Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
41112848|NCT06513234|DRUG|Orelabrutinib and obinutuzumab|Orelabrutinib and obinutuzumab 6cycles ;orelabrutinib 150mg
41112849|NCT02027558|BEHAVIORAL|Insomnia treatment & PAP adherence|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
41112850|NCT02027558|BEHAVIORAL|General sleep education|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
41112851|NCT00361283|DRUG|Atorvastatin|atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
41112852|NCT01779999|OTHER|PICC-carrying patients|Echographic monitoring of patients carrying a peripherally inserted central catheter
41112853|NCT03801499|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
41112854|NCT01786525|BEHAVIORAL|House Calls|60-minute home based educational intervention which will be administered by a health educator
41112855|NCT01786525|BEHAVIORAL|Web-Based Patient-Centered Decision Support Intervention|Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
41112856|NCT04266912|DRUG|Avelumab|Given IV
41112857|NCT04266912|DRUG|Berzosertib|Given IV
41112858|NCT01998711|BEHAVIORAL|Memory group|Five 1-1.5 hour weekly session of memory training
41112859|NCT05384210|DRUG|Milnacipran|Milnacipran will be administered according to the treatment recommendations for fibromyalgia, starting with 50 mg once daily for 1 week then increasing to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 months.
41112860|NCT05384210|DRUG|Gabapentin|Patients will receive gabapentin (1200 mg twice daily) as a monotherapy. Gabapentin will be administered according to the treatment recommendations for FM patients starting with 400 mg 3 times per day, then increasing the dose to 800 mg 3 times per day with a maximum dose of 2400 mg per day according to efficacy and tolerability for 3 months
41112861|NCT05384210|DRUG|Combined gabapentin/milnacipran|Patients will receive combined gabapentin as group B and MLN as group A
41112862|NCT03061552|DIAGNOSTIC_TEST|sonographic measurement of inferior vena cava diameter|pre-dialysis measurement of inferior vena cava diameter using echocardiography
41446083|NCT06253507|BIOLOGICAL|Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47|"Cryopreserved autologous CD34+ cells transduced ex vivo with the pCCLCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use.~The minimum cell dose for infusion is 3 x 10\^6 CD34+/kg, maximum cell dose 30 x 10\^6 CD34+/kg."
40752527|NCT02077712|DRUG|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
41112863|NCT04661410|BEHAVIORAL|Reward Re-Training|A brief, 10-session group-based behavioral treatment that is designed to indirectly change binge eating by directly focusing on building a more rewarding life. RRT hypothesizes that reductions in binge eating will occur as life becomes more rewarding because individuals will no longer need to rely on binge eating as a primary source of momentary reward. RRT notes that in order to live a satisfying life, individuals need to experience an adequate amount of reward in two overlapping yet distinguishable domains: momentary reward (i.e., the active experience of pleasure in the moment) and sustained reward (i.e., a deeper and more long-lasting sense of fulfillment and meaning that arises from building a personally valued life). A key aspect of RRT is an emphasize on building lasting and meaningful social relationships given the clear evidence that social connectedness can enhance both momentary reward and sustained reward.
41112864|NCT04661410|BEHAVIORAL|Supportive Therapy|A brief, 10-session group-based treatment that is designed to instill hope and optimism and to increase social connection and support through a non-directive group leader that allows the patients to determine the focus of each session. The group leader will act as an empathetic provider by using reflective listening, eliciting and validating affect, and offering empathic comments.
41112865|NCT02219178|DRUG|lenalidomide|25mg days 1 - 14 of 21 day schedule
41112866|NCT02219178|DRUG|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
41112867|NCT02219178|DRUG|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
41112868|NCT04189770|DEVICE|Accelerometer|Wear accelerometer
41112869|NCT04189770|OTHER|Ecological Momentary Assessment|Complete EMA questionnaire
41112870|NCT04189770|OTHER|Questionnaire Administration|Complete questionnaire
41112871|NCT04189770|OTHER|Survey Administration|Complete survey
41112872|NCT02843217|BEHAVIORAL|Lifestyle, screening|
41112873|NCT03318484|DRUG|Optimal Medical Care|Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
40947780|NCT05520099|PROCEDURE|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
41112874|NCT03318484|COMBINATION_PRODUCT|Sonodynamic therapy|SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
41446084|NCT05049291|BEHAVIORAL|telehealth advance care planning|An education information sheet containing prognosis and outcomes of acute care and intensive treatments
41446085|NCT03628209|DRUG|Nivolumab|Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
41446086|NCT03628209|DRUG|Azacitidine|Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m\^2. Dose level 3: 75 mg/m\^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
40752528|NCT03556878|BEHAVIORAL|Fitted Transdiagnostic Sleep and Circadian intervention|Fitted TranS-C is an adapted version is designed to improve the fit with community needs and resources.
40752529|NCT00800150|DRUG|fludarabine phosphate|
40752530|NCT00800150|DRUG|melphalan|
40947783|NCT05105230|DIAGNOSTIC_TEST|soluble programmed death 1biomarker|soluble programmed death 1biomarker
40947784|NCT01072669|DRUG|ambrisentan|Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily\[if the lower dose is tolerated\] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
40947785|NCT02001181|DRUG|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
40947786|NCT02001181|DRUG|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
40947787|NCT05147584|DEVICE|Dual fetal oxygen sensors|Placement of both internal and external fetal oxygen sensors
40947788|NCT02186873|DRUG|Placebo|Participants will receive matching placebo.
40947789|NCT02186873|DRUG|Golimumab|Participants will receive 2mg/kg of intravenous infusions of golimumab .
40947790|NCT01042574|DRUG|Clevidipine butyrate|Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.
40947791|NCT04234360|DRUG|5 days of systemic corticotherapy (prednisone)|Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
40947792|NCT04234360|DRUG|5 days of placebo|Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
40947793|NCT03061383|OTHER|8% Arginine based toothpaste|toothpaste
40947794|NCT03061383|OTHER|8% strontium acetate based toothpaste|toothpaste
40947795|NCT03061383|OTHER|placebo|toothpaste
40947796|NCT03090438|PROCEDURE|Varicocele embolization|Ultrasound guided right internal jugular vein access with placement of a vascular sheath. Fluoroscopically guided selective catheterization of the left and right (if bilateral) spermatic veins to the level of the inguinal ligament. Occlusion of the spermatic vein(s) by embolization coils and a sclerosing agent (sodium tetradecyl sulphate 3%).
41112875|NCT05008419|BEHAVIORAL|Narrative discourse treatment|The protocol will incorporate elements from prior treatment studies that showed some promise: 1) hierarchical training, 2) variety of discourse stimuli, 3) development of skills and strategies for discourse processing, 4) structured training prompts, 5) meta-cognitive and meta-linguistic strategies, and 6) integration of learning principles. Novel treatment elements will include: 1) targeting both story content and story organization, 2) use of a discourse model to guide treatment, and 3) functional communication training. Treatment will be delivered twice a week over 8 weeks. There will be four treatment phases: education, story organization, story content, and integration of story organization and content.
41112876|NCT04126109|OTHER|questionaire|A questionaire will be offered to every parents
41112877|NCT06491212|DIAGNOSTIC_TEST|Determination of Foot Deformity Level|One of the methods used in our study to determine the presence and degree of pes planus is the navicular drop test.
41112878|NCT06491212|DIAGNOSTIC_TEST|Foot Function Index|Evaluation of Foot Function
41112879|NCT06491212|DIAGNOSTIC_TEST|UFAA-International Physical Activity Questionnaire|To determination of physical activity level.
41112880|NCT06491212|DIAGNOSTIC_TEST|Diaphragm ultrasound measurements|Rehabilitative ultrasound imaging is a method frequently used by physiotherapists to assess muscle function.
41112881|NCT06491212|DIAGNOSTIC_TEST|NeuruCom Balance Master Balnce and Performans Test|Balance master will be used for postural stability, static and dynamic balance measurements.
41112882|NCT06491212|DIAGNOSTIC_TEST|Plantar Pressure Assessment|When assessing plantar pressure, postural control will be evaluated statically or dynamically, through examination of the behavior of the center of plantar pressure (COP).
41112883|NCT01990924|RADIATION|15 FPS|X-ray pictures
40947797|NCT01902238|PROCEDURE|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
41112884|NCT01990924|RADIATION|7.5 FPS|X-ray pictures
41112885|NCT01334320|PROCEDURE|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
41112886|NCT02633423|PROCEDURE|Use of PEEP before and after CPB|PEEP will be set in order to reach an airway pressure of 5 cmH2O
41112887|NCT02633423|PROCEDURE|No use of PEEP before and after CPB(ZEEP)|No PEEP will be used
41112888|NCT02633423|PROCEDURE|Ventilation with CPAP during CPB|A continuous Positive Airway Pressure (CPAP) will be applied during CPB
41112889|NCT02633423|PROCEDURE|No ventilation during CPB|No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
41112890|NCT01317719|PROCEDURE|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
41112891|NCT04733534|DRUG|Dasatinib plus Quercetin|Dasatinib (100 mg/day) plus Quercetin (500 mg twice daily) on days 1, 2, 3, 30, 31, 32 taken orally under observation of the study nurse.
41112892|NCT04733534|DRUG|Fisetin|Fisetin (20mg/kg/day) on days 1, 2, 30 and 31 taken orally under observation of the study nurse. Fisetin will be dispensed based on weight of 20 mg/kg/day on the four separate days.
41112893|NCT02975310|PROCEDURE|Endoscopic polypectomy in clinic (EPIC)|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
41112894|NCT02975310|PROCEDURE|Endoscopic Sinus Surgery (ESS)|The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
41112895|NCT02975310|OTHER|General Anesthesia|ESS will be performed under general anesthesia in the operating room
41112896|NCT02975310|OTHER|Local and topical anesthesia|EPIC will be performed under topical and local anesthesia in a clinic setting
41112897|NCT01091233|PROCEDURE|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
41112898|NCT03511651|PROCEDURE|PEEP|Two PEEP levels will be used during mechanical ventilation.
41112899|NCT05752136|BIOLOGICAL|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
41112900|NCT00333658|BEHAVIORAL|Goal setting and work feedback group|Goal setting and feedback using WBI
41112901|NCT06397118|BEHAVIORAL|Maternal Nutrition Education|Community Health Worker delivered Maternal Nutrition Education
41112902|NCT06397118|BEHAVIORAL|Standard Care|Standard care in the sickle cell disease (SCD) clinic
40752531|NCT00800150|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
40752532|NCT00800150|RADIATION|intensity-modulated radiation therapy|
40752533|NCT00800150|RADIATION|tomotherapy|
40752534|NCT00800150|RADIATION|total marrow irradiation|
40752535|NCT00800150|RADIATION|total nodal irradiation|
41112903|NCT00310154|DRUG|docetaxel|
40752536|NCT06354543|DEVICE|Cemented joint arthroplasty|Joint replacement with cemented prosthetic components
41112904|NCT00310154|DRUG|gefitinib|
41112905|NCT00310154|OTHER|laboratory biomarker analysis|
41112906|NCT00310154|RADIATION|radiation therapy|
41112907|NCT04810793|DRUG|Amoxicillin , Levofloxacin and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens
41112908|NCT04810793|DRUG|Amoxicillin , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens
41112909|NCT04810793|DRUG|Tetracycline , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
41112910|NCT04810793|DRUG|Amoxicillin,Levofloxacin and Vonoprazan fumarate|Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group
41112911|NCT04810793|DRUG|Amoxicillin,Furazolidone and Vonoprazan fumarate|Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group
41112912|NCT04810793|DRUG|Tetracycline,Furazolidone and Vonoprazan fumarate|Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
41112913|NCT04299984|PROCEDURE|Open Conversion after EVAR|"See Open Conversions group description."
41112914|NCT04299984|PROCEDURE|SemiConversion after EVAR|"See SemiConversions group description."
41112915|NCT05311137|PROCEDURE|Radiofrequency ablation|Combined use of radiofrequency ablation, cryoablation, left bundle branch pacing, and left atrial appendage closure according to the actual situation of the patient.
41112916|NCT03350542|DEVICE|SYNERGY 48 mm|A drug eluting coronary stent system
41112917|NCT06068439|DRUG|Acetylsalicylic Acid|aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
41112918|NCT06068439|DRUG|Placebo|Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
41112919|NCT06142851|OTHER|Data collection|data collection
41112920|NCT02737878|BEHAVIORAL|Aerobic Training|"Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
41112921|NCT02737878|BEHAVIORAL|Resistance Training|"Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
41112922|NCT02737878|BEHAVIORAL|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
41112923|NCT02737878|BEHAVIORAL|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
41112924|NCT00138619|DRUG|vildagliptin|
41112925|NCT02430740|DRUG|recFSH|
41112926|NCT06265636|PROCEDURE|Percutaneous nerve stimulation|Percutaneous nerve stimulation (PENS) involves inserting a dry needling needle through muscle tissue until it reaches a nerve branch. At this point, a bipolar TENS current with different parameters is applied to the needle with the goal of improving the patient's pain perception.
41112927|NCT06265636|OTHER|Manual therapy|Digital pressure techniques in muscle areas with the aim of reducing the perception of stiffness and pain
41112928|NCT06265636|OTHER|exercise|Exercises for improving mandibular mobility, occlusion coordination and regulation of temporomandibular muscle tone
41112929|NCT04956757|OTHER|Exercise Intervention|Scapula retraction exercises at varying shoulder abduction angles will be applied
41112930|NCT06250413|OTHER|FMT|Capsulated oral auto fecal microbiota transplant
41112931|NCT06250413|OTHER|Placebo|Capsulated hot chocolate powder
41112932|NCT06250413|DRUG|Amox Clav|5 day course of Amoxicillin Clavulanic acid given to all participants
41112933|NCT04949607|DIETARY_SUPPLEMENT|Inulin fructooligosaccharide|Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.
41112934|NCT04130165|OTHER|Matched donor human milk|Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
41112935|NCT04818255|BEHAVIORAL|PET Biomarker Disclosure|Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested.
41112936|NCT01458210|DRUG|Ortho-Cyclen|Administered orally
40925843|NCT06149013|DEVICE|MindAhead Active|MindAhead's Active app focuses on increasing meaningful and enjoyable cognitive, physical, and social activities specifically adapted to patients with early cognitive decline (MCI or mild dementia). These techniques include psychoeducation (explaining the rationale, the components of behavioral activation, and protective activities), action planning (selecting activities, goal setting, activity scheduling, graded task assignment, written schedules, and step-by-step sequencing) and action/self-monitoring (assessing execution of and enjoyment in activities, monitor mood and cognitive problems), as well as value-based activation (understanding most important values, selecting activities according to these values). This process aims to enable the users to understand which activities are enjoyable and meaningful to them and how to implement these activities into their daily lives. MindAhead's Active app consists of one to five sessions per week.
40925844|NCT06149013|OTHER|Treatment-as-usual|Depending on patient-specific clinical findings it includes antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins.
40925845|NCT02307253|DEVICE|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)|EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
40925846|NCT01820260|DRUG|Ingenol mebutate gel|
40925847|NCT01820260|DRUG|placebo|
40925848|NCT00243607|OTHER|hydrotherapy according to Kneipp rules|2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
40925849|NCT03699969|RADIATION|Hypofractionated dose escalated VMAT|measure the local control, progression free survival and overall survival
40925850|NCT04674540|OTHER|No Intervention|No Intervention
40925851|NCT04903470|DRUG|Bisacodyl|Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics
40925852|NCT04903470|DRUG|Atropin|Atropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult.
40925853|NCT01233518|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
40925854|NCT03961477|OTHER|Interferential therapy|Exercise therapy
40925855|NCT01666847|PROCEDURE|Milking the umbilical cord before cord clamping|The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
40925856|NCT02610101|OTHER|Traditional SCD Diet|Traditional SCD includes removal of all processed foods as well as all grains, sweetners except for honey and all diary except for yogurt fermented for over 24hrs and some hard cheeses
41112937|NCT01458210|BIOLOGICAL|Dulaglutide|Administered subcutaneously
41112938|NCT06555653|OTHER|Video based multimedia information|The intervention group was shown a 5 minute informational video before amniocentesis including definition of amniocentesis, its indications, the setup of amniocentesis room, the purpose and steps of the procedure, potential complications and how to manage them
41112939|NCT02574026|BEHAVIORAL|Psychomotor tasks|the acquisition of data will be performed in one unique session no drug administration no surgery
41112940|NCT04129658|BEHAVIORAL|Educational outreach visit|Two-four hours of discussion between a cardiologist and the primary care physicians at the PHCC encompassing evidence-based treatment guidelines and counseling upon specific patient cases and their diagnose and treatment for congestive heart failure.
41112941|NCT01104415|DRUG|Telotristat etiprate|Telotristat etiprate capsules orally three times daily.
40925857|NCT02610101|OTHER|Modified SCD Diet|Food components of the traditional SCD with the addition of rice and oats.
40925858|NCT02610101|OTHER|Whole foods diet|A whole foods diet with removal of processed foods. Removal of corn, wheat, sugar and milk are also apart of this dietary regime.
40925859|NCT05347147|DRUG|Presendin|Presendin is supplied as 2 parts, one vial consisting of a drug part (white or greyish white powder in a clear vial) and one pre-filled syringe containing the diluent part (colourless liquid). The drug part is suspended in the diluent part solution and administered SC as a suspension.
40925860|NCT05347147|DRUG|Placebo|Placebo is supplied as 2 parts (visually identical to the Presendin vial and pre-filled diluent syringe). The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent. The drug part is suspended in the diluent part solution and administered SC as a suspension.
40925861|NCT05143788|PROCEDURE|Awake craniotomy|The awake neurosurgical procedure performed on the brain is to provide a real-time neurological functions monitoring in order to preserve the functions of brain to the greatest extent.
40925862|NCT04910308|RADIATION|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
40925863|NCT00562900|PROCEDURE|robotic assisted cholecystectomy|robotic assisted cholecystectomy
40925864|NCT00562900|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
40925865|NCT03445156|BEHAVIORAL|Video game|Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.
40925866|NCT03445156|BEHAVIORAL|Controller|Participants used either a gun-shaped or regular controller to play the violent and nonviolent shooting video games.
40925867|NCT05176457|OTHER|communication tool PICT'REA|"The pictograms communication tool PICT'REA will be available to patients with invasive ventilation systems preventing them from speaking"
40925868|NCT01687556|OTHER|topical EGCG application on acne|two times application of topical EGCG on acne lesion
41112942|NCT00233337|DRUG|Co-artemether|
41112943|NCT06272162|RADIATION|MR guided radiotherapy|5 fractions of 10 Gray MRgRT in addition to standard of care
41446087|NCT03628209|PROCEDURE|Post Treatment Surgery|Resection surgery at end of Cycle 1 treatment, day 28-35.
41112944|NCT05284812|BIOLOGICAL|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
41112945|NCT05284812|BIOLOGICAL|High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive high-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
40925869|NCT04089800|OTHER|Mobile phone based multimedia application|The investigators shall develop a multimedia mobile health application using Java programming language, while the database that hosts multimedia messages shall be developed using SQlite. It shall be an offline (stand-alone) application following user-centered design approaches that involve incorporating input from pregnant women as prospective users. Pregnant women shall be provided with solar chargers to supplement electricity charging. The application has three major functionalities, appointment reminder function, calling function and the multimedia (Video and audio) function.
40925870|NCT03257917|OTHER|Understanding value in Metastatic Breast Cancer|The overall objective of this project is to gain knowledge about out-of-pocket (OOP) expenses and lost opportunity costs among metastatic breast cancer (MBC) patients. To achieve this objective, MBC patients will be asked to participate in a short, 37-question survey asking questions about the financial burden, OOP expenses, and opportunity costs related to their cancer care.
40925871|NCT04877509|BIOLOGICAL|Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization|Micronutrient assays on heparinized plasma.
40925872|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|32 mg
40925873|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|48 mg
40925874|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|64 mg
40925875|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|80mg
40925876|NCT02815826|OTHER|Barefoot training|During 16 weeks, habitual shod runners kept their normal running training routine (wearing shoes), while they were introduced progressively to BF condition. Three training sessions were performed per week. Barefoot training started with 5% and ended with 20% of their WTV being performed without shoes. Soft surfaces (i.e. sand and grass) were adopted in the beginning of training (week 1 to 8). From week 9 to 16, participants mixed soft with harder surfaces, as treadmill and asphalt, to accomplish the training.
40925877|NCT02815826|OTHER|Shod training|Running training planned individually to each runner, according to their physical fitness, and performed with shoes.
41112946|NCT05284812|BIOLOGICAL|High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive high-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
41112947|NCT05284812|BIOLOGICAL|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|Subjects receive Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo injection into the deltoid muscle of the upper arm
41112948|NCT01814033|OTHER|Experimental: LRU Pillow|Foam wedge with a trough for positioning of the lower leg in an elevated position.
41112949|NCT01814033|OTHER|Control Group|Standard bed pillows placed under the lower leg to facilitate elevation
40925878|NCT06471387|BEHAVIORAL|Flexiquit Smoking Cessation Intervention|Participants will enter a 6-week (once weekly) self-delivered computerized intervention program called Flexiquit. Developed and validated by Clinical Psychologists of the Department of Psychology at the University of Cyprus, Flexiquit is an avatar-led app designed to support smoking cessation. It aims to assist with abstinence and monitor participants' progress through personalized modules and assessments.
40925879|NCT02723487|DRUG|Bupivacaine 0.125%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.
40925880|NCT02723487|DRUG|Bupivacaine 0.25%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
40925881|NCT05196711|DRUG|MAX-40070|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days."
41112950|NCT06088225|DEVICE|distance-image screen|Distance-image screen is a screen make each image at distance of 6-meters to reduce the accommodation and convergence for eyes during the reading and learning with screens.
41112951|NCT05372380|DRUG|BR1017-1|Administration to the F/F+AE group: BR1017-1 will be administered 1 tablet QD, five-day repeat dose
41112952|NCT05372380|DRUG|BR1017-2|Administration to the AE group: BR1017-2 will be administered 1 tablet QD, 9-day repeat dose Administration to the F+AE group: BR1017-2 will be administered 1 tablet once QD, 5-day repeat dose.
41112953|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 12.5 mg (titration only)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg
41112954|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg
40752537|NCT06479057|OTHER|Supportive Care Pathway|All pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level.
41112955|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg
41112956|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg, then week 3 to 37.5 mg
41112957|NCT05286762|DRUG|Placebo|Subjects will be randomized at Visit 2 to Placebo
41112958|NCT05817968|DEVICE|intelligent Esophageal Pressure Catheter (iEPC)|"Placement of the iEPC nasogastric catheter with solid state sensor for esophageal manometry.~Comparator: Esophageal balloon catheter (NutriVent)."
41112959|NCT04848233|DIETARY_SUPPLEMENT|Drinks containing 5AA+CrPic and Placebo|Same diet will be repeated for 3 days in a row and the beverage switched every day. 3 periods of 3 days are included in the study.
41112960|NCT06469684|BEHAVIORAL|Health education session|1 hour health education session religious teaching promoting health-seeking behaviour, and question and answer session with healthcare professional.
40752538|NCT00974233|DRUG|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
40752539|NCT00974233|DRUG|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
41112961|NCT05206266|OTHER|Turmeric|Three amounts of dietary turmeric will be tested: 1) turmeric 300 mg/day, 2) turmeric 1 g/day, 3) turmeric 3 g/day.
41112962|NCT05206266|OTHER|Turmeric+Black Pepper|Three amounts of dietary turmeric (300mg/day, 1g/day or 3g/day) with black pepper (300 mg) added to the turmeric.
41112963|NCT01787773|DEVICE|Veniti Inferior Vena Cava Filter|
41112964|NCT05201261|DEVICE|ltrasonic measure|In the right decubitus position, the spine was scanned with an ultrasonic convex array probe. Starting from the sacrum, the length of each vertebral body of the lumbar spine was measured on a para-midsagittal oblique view. The intervertebral space was located and the width of the subarachnoid space was measured on a midsagittal and transverse view.
41112965|NCT03126812|DRUG|Carboplatin|Carboplatin AUC=6
41112966|NCT03126812|DRUG|Paclitaxel|paclitaxel 80 mg/m2
41112967|NCT03126812|DRUG|Pembrolizumab|200 mg flat dose, starting cycle 2
41112968|NCT03498651|BEHAVIORAL|Cognitive Bias Modification - Interpretation training|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.
41112969|NCT03498651|BEHAVIORAL|Coaching|Participants identified as high risk for attrition will receive low-intensity coaching, which includes a mix of brief phone calls, texts, and/or emails with a trained member of the study team to help address challenges with adherence to and application of the training.
41112970|NCT03498651|BEHAVIORAL|Online psychoeducation about anxiety|Participants will review webpages that describe information about symptoms and causes of anxiety, including the nature of biased thinking in anxiety.
41112971|NCT02828254|DRUG|PRI-724|
41112972|NCT03778099|DRUG|Cinnamon Cap 500 MG|The Cinnamomum cassia (C. aromaticum) capsules will be purchase from Spring Valley company (distributed by Wal-Mart Stores, Inc. USA) by the investigator.
41112973|NCT03778099|DRUG|Placebo|450 mg of starch and 50 mg of cinnamon powder
41112974|NCT02550197|BIOLOGICAL|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
41112975|NCT02550197|BIOLOGICAL|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
41112976|NCT00375453|DRUG|SH U04722|
41112977|NCT06360744|BIOLOGICAL|Johnson & Johnson|Vaccination with the Johnson \& Johnson vaccine which is NOT part of the Danish National Government programme
41112978|NCT04693130|BEHAVIORAL|Mindfulness-based prenatal education|Mindfulness-based prenatal education involves mindfulness breathing and other skills with mindfulness meditations.
41112979|NCT04693130|BEHAVIORAL|Hospital-based antenatal care|Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
41112980|NCT03915886|DRUG|JNJ-0440|JNJ-0440 tablets will be administered orally.
41112981|NCT03915886|DRUG|Placebo|Matching placebo tablets will be administered orally.
41112982|NCT01681251|OTHER|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%|"Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.~Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV."
41446088|NCT04709081|DRUG|ACH-0145228|ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.
41112983|NCT01681251|OTHER|Fluid titrated at the discretion of the attending anesthesiologist|In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
41112984|NCT00947453|DRUG|montelukast|montelukast 10 mg once daily for 8 weeks
41112985|NCT02910635|DRUG|Volanesorsen|ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial
41112986|NCT02910635|DRUG|Moxifloxacin|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
41112987|NCT02910635|DRUG|Placebo|
41112988|NCT03814252|DEVICE|MRI-TULSA|"The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)"
41112989|NCT02520908|PROCEDURE|HSCT|Hematopoietic stem cell transplantation
41112990|NCT02520908|OTHER|Standard Care|
41112991|NCT00338299|DRUG|Epoetin alfa|
41112992|NCT01026064|OTHER|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
41112993|NCT01026064|DRUG|Azithromycin|Zithromax (250 mg oral capsule).
41112994|NCT01026064|DRUG|Placebo|Matching placebo
41112995|NCT06555510|OTHER|InBody|Bioelectrical impedance analysis
40925882|NCT05196711|DRUG|Placebo|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo"
40925883|NCT02165839|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBT-I)|
41446089|NCT04709081|DRUG|Midazolam|Midazolam was dosed at 2 mg (1 milliliter \[mL\] of a 2 mg/mL syrup).
40925884|NCT02165839|BEHAVIORAL|Healthy Eating Education Learning (HEAL)|
40925885|NCT01515020|DRUG|vancomycin monotherapy|intravenous therapy by vancomycin
40925886|NCT01515020|DRUG|daptomycin monotherapy|intravenous therapy by daptomycin
41112996|NCT05150613|OTHER|No Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
41446090|NCT04709081|DRUG|Digoxin|Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.
41446091|NCT04709081|DRUG|Itraconazole|Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).
41446092|NCT06562127|BEHAVIORAL|TRAIN-Vets|The TRAIN-Vets intervention entails 6 months of thrice-weekly aquatic-based exercise training at Veterans Affairs Palo Alto Health Care System (VAPAHCS). After completion of the 6-months of exercise training, Veterans in this condition will participate in 2 months of weekly structured on-line cognitive training focused on improvement of executive function and attention based out of the San Francisco Veterans Affairs Health Care System (SFVAHCS). Concurrently, Veterans in TRAIN-Vets will also participate virtually in monthly lifestyle coaching based at SFVAHCS focused on other risk factors and symptoms.
41112997|NCT05150613|OTHER|Surgical Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
41112998|NCT05150613|OTHER|N95 Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
41112999|NCT05068362|DEVICE|Auricular reconstruction|Medpor implant for treatment of microtia
41113000|NCT04193410|BEHAVIORAL|Various health-promoting initiatives|No intervention is allocated in this study other than activities planned by childcare centres in accordance with wishes and needs of childcare centre staff and parents.
41113001|NCT00306449|BEHAVIORAL|Small group seminar-based educational intervention|
41113002|NCT01841437|DEVICE|iStent|
41113003|NCT06010433|DEVICE|CERAMENT G|"* Primary mode of action is to be a resorbable ceramic bone graft substitute intended to fill gaps and voids in the skeleton system to promote bone healing. CERAMENT ™\|G provides a void/gap filler that during the surgical procedure can augment hardware and bone alignments.~* Secondary mode of action is to prevent colonization of Gentamicin sensitive microorganisms in order to protect bone healing."
41113004|NCT04713007|BEHAVIORAL|Quality of Life Ted Talks|There will be 9 training modules released weekly on the tablet. A survey will be required at baseline, each of the 9 weeks and at 3 months.
41113005|NCT04713007|BEHAVIORAL|Quality of Life Supportive Resources|The tablet will be preloaded with cancer information and supportive care resources from the National Cancer Institute. A survey will be required at baseline, each of the 9 weeks and at 3 months.
41113006|NCT04627493|BEHAVIORAL|Online exercise|Participants will participate in an online exercise program on Zoom delivered by Registered Kinesiologists and Physiotherapists three times a week.
41113007|NCT04082273|DEVICE|Femtosecond Laser for Cataract Surgery|Cataract Surgery on study eye according to conventional procedure, with the exception of three steps (Capsulotomy, Lens Fragmentation and Clear Corneal Incisions) which are performed with a Femtosecond Laser in the laser treatment group. Equipment uesd for measurements is the same for both groups and in line with the normal equipment used for the conventional cataract treatment
41113008|NCT04082273|OTHER|Conventional Cataract Surgery|Cataract surgery will be performed conventionally, this means the clear corneal incisions will be performed manually by a blade, the capsulorhexis will be performed manually by a hook, and the lens extraction will be done by phacoemulsification
41113009|NCT05432934|DRUG|Dexamethasone|Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.
41113010|NCT04782817|OTHER|Recommendation for high flow nasal cannula oxygen therapy order set|Participants will be assigned post extubation physician order set which recommends the administration of oxygen therapy via HFNC. HFNC is a heated and humidified system that allows prescribed fraction of inspired oxygen (FIO2) levels to be delivered at very high flow rates.
41113011|NCT04782817|OTHER|Provider choice standard care order set|Participants will receive order set with provider choice of standard care therapy.
41113012|NCT04153435|DRUG|Calcium Chloride|Calcium chloride 5 mmol
41113013|NCT04153435|DRUG|Sodium chloride 0.9%|Placebo
41113014|NCT02323529|DRUG|Nitisinone|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
41113015|NCT03480854|OTHER|Quality Improvement|Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.
41113016|NCT00980330|DRUG|TMC435|One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
41113017|NCT00980330|DRUG|Placebo|One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
41113018|NCT00980330|DRUG|Peg-IFN-alfa-2a (P)|180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
41113019|NCT00980330|DRUG|Ribavirin (R)|1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
41446093|NCT06562127|BEHAVIORAL|Health Education Control|The Health Education Control (HEC) receives mailed educational materials about brain health and healthy lifestyles over 8 months, as well as regular contact with study staff.
41446094|NCT05490095|DRUG|SVG101 (T)|5mg of SVG101
41446095|NCT05490095|DRUG|Afinitor (R)|5mg of Afinitor
41113020|NCT00411138|RADIATION|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
41113021|NCT00411138|DRUG|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
41113022|NCT00411138|DRUG|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
41113023|NCT00411138|DRUG|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
41113024|NCT04313543|DIETARY_SUPPLEMENT|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes. Then, they take 50g of longan syrup in 250 ml of water in 5 minutes
41113025|NCT03429062|OTHER|Personal training exercises|Personal training: strengthening, stretching, endurance, balance Whole body vibration: strengthening, balance, stretching, endurance, balance
41113026|NCT05650125|OTHER|Biosampling|Biosampling of blood/tumour/adjacent normal tissue
40925887|NCT05959642|DEVICE|dentapen|"Experimental: Controlled Flow Delivery Dentapen according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted upper D teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle"
41113027|NCT01557855|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
41113028|NCT06113198|BIOLOGICAL|rMenB+OMV NZ|3 doses of rMenB+OMV NZ vaccine administered intramuscularly on Day 1, Day 61, and any day between Day 241 - Day 391.
41113029|NCT04276402|PROCEDURE|Irradiation of implants with 808nm laser|Irradiation of implants with 808nm laser
41113030|NCT02079155|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
41113031|NCT02079155|PROCEDURE|robot-assisted laparoscopic surgery|Undergo R-LESS RP
41113032|NCT02079155|OTHER|laboratory biomarker analysis|Correlative studies
41113033|NCT02079155|OTHER|quality-of-life assessment|Ancillary studies
41113034|NCT02079155|OTHER|questionnaire administration|Ancillary studies
41113035|NCT03760627|BEHAVIORAL|Refugees Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
41113036|NCT03760627|BEHAVIORAL|Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
41113037|NCT05567822|DRUG|Esmolol Hydrochloride|In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively
41113038|NCT05567822|DRUG|normal saline|In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
41113039|NCT00851708|DRUG|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
41113040|NCT03174054|PROCEDURE|Biopsy|Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.
41113041|NCT02082158|OTHER|Study Procedures|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
41446096|NCT03605342|DRUG|Buprenorphine|Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, which is standard practice.
41446097|NCT03605342|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT-C is a manualized, 12-session 1:1 cognitive therapy that has been designed for patients with PTSD. In this study the sessions will be conducted weekly. CPT-C uses Socratic questioning targeting distorted cognitions such as self-blame, hindsight bias, and other guilt cognitions. CPT-C is focused on the cognitive components of the therapy without exposure.
41113042|NCT04222686|DRUG|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
41113043|NCT04222686|DRUG|Losartan Potassium|100 mg Losartan tablet will be added to the usual treatment for each patient for a period of 08 weeks.
41113044|NCT00345761|DRUG|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
41113045|NCT00345761|DRUG|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
41113046|NCT00345761|DRUG|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
41113047|NCT00002527|DRUG|aspirin|
41113048|NCT00002527|OTHER|placebo|
41113049|NCT01094405|BIOLOGICAL|Recombinant Epstein-Barr Virus (EBV) Vaccine|
41113050|NCT00917865|DRUG|anti [18F]FACBC|Anti\[18F\]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
41113051|NCT05260086|DEVICE|Neuronavigated aiTBS|Accelerated intermittent theta burst stimulation (aiTBS, 4 sessions per day with at least 20 minutes pause between sessions) in the left dorsolateral prefrontal cortex (DLPFC)
41113052|NCT05656846|DEVICE|PulseNmore ES™|The patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team.
41113053|NCT05656846|DEVICE|Standard Ultrasound|These patients will not receive the additional intervention and will use the Standard Ultrasound. A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
41113054|NCT03791892|OTHER|Shoulder mobilization Group|Suprascapular nerve block administered every week to both groups. Joint mobilization (3 sets / 40 seconds hold / 30 seconds interval) Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Strengthening exercises ( 3 sets / 15 reps)
41113055|NCT03791892|OTHER|Conventional Treatment Group|Suprascapular nerve block administered every week to both groups. Daily Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Daily Strengthening exercises ( 3 sets / 15 reps)
41113056|NCT03842488|DRUG|Experimental: RAL QD|Prescription of 2x RAL 600mg (1200MG) once daily
41113057|NCT03842488|DRUG|Active comparator: DRV/cb|Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
41113058|NCT01796782|DRUG|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
41113059|NCT01796782|DRUG|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
41113060|NCT01866566|BIOLOGICAL|HBV-3|Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month
41113061|NCT01866566|BIOLOGICAL|HBV-6|Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month
41113062|NCT01866566|BIOLOGICAL|varicella-3|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month
41113063|NCT01866566|BIOLOGICAL|varicella-6|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
41113064|NCT05473260|OTHER|Control|In-patient care.
41113065|NCT05473260|OTHER|Experimental|Early discharge and outpatient follow-up.
41113066|NCT04563156|DIAGNOSTIC_TEST|Lung Function Test|Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
41113067|NCT04075318|BIOLOGICAL|UB-312|A synthetic peptide-based vaccine
41113068|NCT04075318|BIOLOGICAL|Placebo|Matching placebo
41113069|NCT01039688|DRUG|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 24 months
41113070|NCT01039688|DRUG|CP-690,550|Oral tablets administered at a dose of 10 mg BID for 24 months
41113071|NCT01039688|DRUG|Disease-modifying antirheumatic drug|Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
41113072|NCT05744193|OTHER|Exempt Infant Formula|Liquid human milk fortifier to be added to human milk daily
41113073|NCT03611205|PROCEDURE|Computed Tomography|Undergo dPET/CT
41113074|NCT03611205|PROCEDURE|Positron Emission Tomography|Undergo dPET/CT
41113075|NCT06174662|DEVICE|Music|The patient can decide the music genre (a standard playlist) and receives a noise-cancelling headphone playing the chosen music during mobilization.
41113076|NCT05921708|OTHER|Assessment1|International Physical Activity Questionnaire (IPAQ) (Short)
41113077|NCT05921708|OTHER|Assesment2|Physical Appearance Comparison Scale-Revised (PACS-R)
41113078|NCT05921708|OTHER|Assessment3|Sociocultural Attitudes Towards Appearance Questionnaire -4-Revised (SATAQ-4R)
41113079|NCT05921708|OTHER|Assessment4|Body-Cathexis Scale (BCS)
41113080|NCT05921708|OTHER|Assessment5|Mobile Health, Exercise Preferences and Social Media Questionnaire
41113081|NCT04440046|OTHER|Manual therapy thoracic spine|Manual therapy mobilization directed to the costovertebral joint.
41113082|NCT04440046|OTHER|Manual therapy glenohumeral joint|Manual therapy mobilization directed to the glenohumeral joint.
41113083|NCT04440046|OTHER|Sham thoracic manual therapy|Sham manual therapy directed to the costovertebral joint.
41113084|NCT04440046|OTHER|Sham glenohumeral manual therapy|Sham manual therapy directed to the glenohumeral joint.
41113085|NCT04440046|OTHER|Therapeutic exercise|Therapeutic exercise program consisting on isometric exercise with progressive load.
41113086|NCT03181763|DRUG|Placebo|Placebo given day after startle assessment
41113087|NCT03181763|DRUG|Midomafetamine|Participant will receive 100 mg MDMA one day after startle assessment
41113088|NCT03181763|BEHAVIORAL|Acoustic startle|Startle assessment
41113089|NCT01269749|RADIATION|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
41113090|NCT01269749|DRUG|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
41113091|NCT04460612|DEVICE|Active IR sock|Subjects will be wearing the infrared socks for 60 minutes
41113092|NCT04460612|OTHER|Placebo socks|Placebo Socks will be placed on participants feet first for 60 minute
41113093|NCT02563613|BEHAVIORAL|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
41113094|NCT02563613|BEHAVIORAL|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
41113095|NCT02563613|OTHER|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
41113096|NCT04117724|OTHER|Survey|Patients will be asked to complete a 4 question survey assessing adherence. Follow up via patient's preferred method of contact will be conducted after the patient's intended antibiotic completion date and covariates for antibiotic regimens will be recorded including antibiotic type, number of doses, antibiotic duration, reason for non-adherence, pills remaining, and number of other medications.
41113097|NCT01141010|OTHER|Language|Plain language without psychological intervention
41113098|NCT01141010|OTHER|Language|Psychological linguistic intervention will be given
41113099|NCT00915239|DRUG|Pantoprazole|40 mg pantoprazole once daily for 28 days
41113100|NCT00915239|DRUG|Placebo|identical placebo once daily for 28 days
41113101|NCT01100125|DRUG|sitagliptin|sitagliptin 100mg once daily, orally, for 24 weeks.
41113102|NCT01100125|DRUG|insulin dose increase|insulin dose increase
41113103|NCT03503084|BEHAVIORAL|Classical Yang's TCC exercise|
41113104|NCT05530577|DRUG|Semaglutide|Semaglutide (subcutaneous)
41113105|NCT05530577|DRUG|Sham/placebo|Sham subcutaneous injection
41113106|NCT02120599|DIETARY_SUPPLEMENT|ready-to-use supplementary food|
41113107|NCT02120599|DIETARY_SUPPLEMENT|corn-soy blend|
41113108|NCT02120599|DIETARY_SUPPLEMENT|iron|
41113109|NCT02120599|DIETARY_SUPPLEMENT|folic acid|
41113110|NCT02120599|DIETARY_SUPPLEMENT|UNIMMAP|
41113111|NCT01793662|PROCEDURE|Laparoscopic aortobifemoral bypass|Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
41113112|NCT02817334|DRUG|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
41113113|NCT01884636|DRUG|isavuconazole|oral
41113114|NCT01884636|DRUG|methotrexate|oral
41113115|NCT03147391|DEVICE|LAA closure with LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
41113116|NCT01052233|PROCEDURE|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
41113117|NCT01052233|PROCEDURE|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
41113118|NCT04412018|DRUG|Icosapent ethyl|Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
41113119|NCT05537155|PROCEDURE|Buccal acupuncture in addition to routine care|"Acupuncture will be performed at a depth of 10 mm, with the needle retaining for 20 min, in addition to routine care. Bilateral acupoints include Tou, Shangjing, Jing, Bei, and Sanjiao. Unilateral acupoints is related to surgical sites and include Kuan in hip joint replacement surgery and Xi in knee joint replacement surgery. Patients with agitation will be treated first until agitation is controlled before acupuncture is performed."
41113120|NCT05537155|OTHER|Routine care|Routing care includes the following: (1) remove the precipitating cause and treat the primary disease; and (2) supportive care, including reorientation and cognitive stimulation, sleep enhancement, early mobility and exercise, vision and hearing optimization, family engagement and empowerment, and early oral intake and nutrition.
41113121|NCT02129582|RADIATION|total marrow irradiation|Undergo TMI
41113122|NCT02129582|DRUG|fludarabine phosphate|Given IV
41113123|NCT02129582|DRUG|busulfan|Given IV or PO
41113124|NCT02129582|PROCEDURE|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
41113125|NCT02129582|BIOLOGICAL|anti-thymocyte globulin|Given IV
41113126|NCT02129582|DRUG|tacrolimus|Given IV or PO
41113127|NCT02129582|DRUG|methotrexate|Given IV
41113128|NCT02129582|OTHER|laboratory biomarker analysis|Correlative studies
41113129|NCT03887624|DRUG|Ethosuximide|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
41113130|NCT03887624|DRUG|Placebo|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
41113131|NCT03887624|DRUG|Escitalopram|1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
41113132|NCT05552469|DRUG|DFV890|DFV890 Single Agent
41113133|NCT04360057|OTHER|PMD|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance used on the initial visit.
41113134|NCT04360057|OTHER|PMDPlus|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance on follow up visits
41113135|NCT03857971|DEVICE|Coronary Optical Coherence tomography|Optical coherence tomography imaging is performed of non-obstructive, non-culprit coronary lesions to assess plaque morphology.
41113136|NCT04820439|DRUG|recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|A single intravenous infusion of HS627 420mg
41113137|NCT04820439|DRUG|Perjeta ®|A single intravenous infusion of Perjeta ®420mg
41113138|NCT01296191|DRUG|Moxifloxacin|One drop 4 times daily for 3 days and one drop the day of sample collection
41113139|NCT01296191|DRUG|besifloxacin|One drop 4 times daily for 3 days and one drop on day of sample collection
41113140|NCT04878991|DIAGNOSTIC_TEST|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
40925888|NCT05959642|DEVICE|Traditional metal Syringes|"Active Comparator: Conventional Injection of infiltration upper d a standard technique for the Injection of infiltration upper d will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed to primary molars"
40925889|NCT00737399|BEHAVIORAL|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
41113141|NCT03590080|DRUG|Methylprednisolone|
41113142|NCT04155177|PROCEDURE|training for french ambulatory caesarean section|"The participant will be first invited to consult a theoretical support and a video treating on FAUCS.~After that, he will be asked to be the first assistant, in a FAUCS procedure with one of the two senior surgeons assigned for the study.~In a second step, the trainee will have to perform all the steps of the FAUCS, assisted by one of the two senior surgeons . During each surgery, Operative time will be measured, while an evaluation on four stages according to the Zwisch model of supervision will performed by the senior surgeons .~Once, the two seniors agree on the highest level assessment for the resident, he will be allowed to operate alone FAUCS procedures and will be evaluated by the measurement of operating times, the neonatal outcomes and the occurrence or not of complications.~finally, total number of FAUCS procedures required for each resident in order to master the technique will be determined."
41113143|NCT02170324|DRUG|Exenatide|
41113144|NCT02170324|DRUG|Placebo|
41113145|NCT01191892|DRUG|carboplatin|
40925890|NCT04381988|DRUG|Hydroxychloroquine|400mg daily
40925891|NCT04381988|OTHER|Placebo|400mg daily
41113146|NCT01191892|DRUG|gemcitabine hydrochloride|
41113147|NCT01191892|DRUG|vandetanib|
41113148|NCT01191892|DRUG|Placebo|Placebo of vandetanib tablet
41113149|NCT02994017|OTHER|cardiopulmonary exercise testing|The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
41113150|NCT04520880|DIAGNOSTIC_TEST|Testing procedure for Binding antibodies|Levels of S-specific and N-specific binding antibodies will be measured by enzyme immune-sorbent assay (ELISA). Briefly, a purified, recombinant S or N proteins will be coated into 96-well plates and incubated for 1 hour at room temperature. The plates will be then washed with 1X PBS five times. The unbound regions of the coated S proteins are blocked by 5% non-fat dry milk. After overnight incubation at 4 C. The plates are washed several times with 5X PBS. Patients sera samples are added in duplicate and incubated for 1 hour at room temperature. After several washes. anti-human IgG HRP conjugate is added. After 1-hour incubation at room temperature, the plates are washed with 1X PBS five times 3,3', 5,5' tetramethylbenzidine (TMB) substrate is added to each wells and incubated for 5 minutes. The reaction will be then stopped with 0.2 M sulfuric acid and the absorbance is measured at 450nm.
40925892|NCT04381988|RADIATION|Radiation therapy|Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist.
40925893|NCT04571983|OTHER|Blood Eosinophil counts - comparing historical with stable state|Comparing historical blood eosinophil counts over 24 months to stable state eosinophil count.
41113151|NCT04520880|DIAGNOSTIC_TEST|Neutralizing antibodies|Neutralizing antibodies against the S protein of SARS-CoV-2 are measured by PV microneutralization assay. Briefly, individual plasmids expressing S.fl gene, luciferase genes, and reporter genes are co-transfected into 293T cells to produce luciferase-expressing pseudo-viruses. Then, pseudo-viruses are added at equal volume into 96 well plates and incubated at 37 for 1 hour. Then, the ACE2 expressing 293T cells are added into the 96well pates with 100 ul of patients' sera in duplicates. After, a single round of replication the cells are lysed with lysis buffer. Luciferase activity is measured by the luciferase assay kit. The activity of luciferases is proportional to the number of cells infected. Luciferase activity is then measured by the luminometer device and the neutralization rate is calculated.
41113152|NCT03189316|OTHER|peritoneal fluid and blood sample|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
41113153|NCT05539755|PROCEDURE|Non surgical debridement of peri-implantitis|"The procedure was standardized as follows: the implants' prosthesis was checked for its cleansability, and retrieved when possible. Then, the prosthesis was modified following a previously described elsewhere (de Tapia et al., 2019). After local anaesthesia (articaine 4% and adrenaline 1:100,000), the implant surfaces were cleaned with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the steel alloy H3 dental ultrasonic scaler tip (H3, Satelec Acteon; Olliergues, France), curettage (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) of the bone defect was performed, and glycine air powder applied submucosally (Air-flow® powder subgingival PERIO, EMS; Nyon, France) with an air-flow piezon device (Air-flow master piezon®, EMS, Nyon; France).~Oral hygiene instructions were given and metronidazole 500 mg every 8 h for 7 days was prescribed. Patients were scheduled at 3 months for supragingival plaque control and supragingival debridement, if needed."
41113154|NCT05296811|PROCEDURE|Lateral Arm Free Flap|Primary Reconstruction of intraoral defects by use of Lateral Arm Free Flap.
41113155|NCT05672849|DEVICE|Modified Surgical Instruments/Devices (Sheaths and Irrigator)|Patients who choose to undergo fetoscopic surgery will be offered participation in this study. All patients will undergo a fetoscopic repair of the fetal open neural tube defect with the use of the modified devices in this study.
41113156|NCT05849233|OTHER|no intervention|no intervention
41113157|NCT06237751|DRUG|Sildenafil 100 MG|Sildenafil 100mg orally half an hour before surgery
41113158|NCT01312441|DRUG|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
41113159|NCT01312441|DRUG|Placebo|Placebo by mouth once weekly for 6 months
41113160|NCT05124847|BEHAVIORAL|Standard Care|Participants will receive nutritional education sessions and will be instructed to maintain an intake window of at least 13 hours a day, preferably every day of the week and in any case at least 6 days a week.
41113161|NCT05124847|BEHAVIORAL|Time restricted eating|A personalized progression will be established to progressively reduce the intake window during the first 10 days of intervention. After these first 10 days, the participants will be prescribed to limit food intake to a maximum of 10 hours a day, at least 5 days a week. Participant can freely select the time of day to place the intake window. However, it will be recommended to avoid making the last intake in the 3 hours before going to bed. After 4 weeks of intervention, the dietitian will invite them to reduce the intake window to 9 or 8 hours, if they consider it feasible, maintaining this new intake window during the last 4 weeks of intervention. The intake window can be maintained at 10 hours until the end of the study.
41113162|NCT04992156|DRUG|Palbociclib|Palbociclib 125mg/d
41113163|NCT00947817|OTHER|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
41113164|NCT00634452|BIOLOGICAL|MDX-1401|IV weekly for 4 weeks
41113165|NCT04640259|OTHER|Online Survey|Epidemiological Survey (approx 200 questions)
41113166|NCT01390818|DRUG|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
41113167|NCT01390818|DRUG|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
40925894|NCT04052802|OTHER|Fissure sealing|The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
40925895|NCT02226744|BEHAVIORAL|Focused Breathing|
40925896|NCT04514302|DRUG|Placebo|Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.
41113168|NCT01390818|DRUG|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
41113169|NCT01390818|DRUG|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
41113170|NCT03300037|DEVICE|Kinesthetic stimulation|The kinesthetic actuator is placed on the skin near the ear and emits vibrations.
41113171|NCT00354406|DRUG|abciximab|standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
41446098|NCT03605342|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC will serve as the control group. The current standard of treatment for Veterans entering buprenorphine maintenance is to do drug counseling. Standard counseling is the primary means to achieve goals. IDC uses a semi-structured, time-limited addictions-counseling model in a 1:1 setting. The IDC manual provides an organized, concise version of what is currently practiced by most addiction counselors.
41446099|NCT05748626|DEVICE|Anti-snoring device|For group 1, the study team will aid the subject in molding and preparing the device in the pre-operative area. They will wear the device throughout the entirety of the case.
40925897|NCT04514302|DRUG|Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)|INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.
40925898|NCT02955251|DRUG|ABBV-428|ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
40925899|NCT02955251|DRUG|Nivolumab|Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
40925900|NCT04691700|DRUG|Goreisan|Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics
40925901|NCT04691700|DRUG|Standard Treatment|Standard therapy without Goreisan
40925902|NCT05433623|PROCEDURE|Surgery|It will be documented if the patient underwent surgery for their vascular issue
40925903|NCT00970775|DRUG|AZD2423|oral solution, single dose
40925904|NCT00970775|DRUG|Placebo|oral solution,single dose
40925905|NCT03556488|DIAGNOSTIC_TEST|US air bronchogram score|"On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment."
40925906|NCT02835053|OTHER|Frailty|Participants will be defined as frail based on the Johns Hopkins ACG Frailty Defining Diagnoses Indicator, which will be applied to available health administrative data in the 3 years preceding index hospital admission. If no frailty defining diagnoses are present participants will be defined as not frail
40925907|NCT00709579|DRUG|RV3391A|A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
40925908|NCT00709579|DRUG|Placebo|placebo
40925909|NCT02248688|DEVICE|BeadBlock 300 - 500 Micron|Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
41446100|NCT05748626|PROCEDURE|No anti -snoring device during their procedure.|For group 2 there will be no anti snoring device used during the case.
40925910|NCT02248688|PROCEDURE|Left Gastric Artery Embolization|
40925911|NCT04504058|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
40925912|NCT00407381|DRUG|Ranibizumab|Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
40925913|NCT00407381|PROCEDURE|Laser photocoagulation|Laser photocoagulation in either focal or grid pattern as determined by investigator.
40925914|NCT03768557|DRUG|Minocycline|Minocycline (200mg)
40925915|NCT03768557|OTHER|placebo|Lactose (400mg)
40925916|NCT04837677|DRUG|PRT1419|PRT1419 will be administered by intravenous infusion
41113172|NCT06063733|OTHER|Digital pursed lip breathing intervention|"After registration, participants will watch an educational video on the developed software, covering the definition, benefits, and techniques of pursed lip breathing. Following this, participants will engage in pursed lip breathing interventions, guided by voice and animated instructions from the software. These sessions will occur three times daily (morning, afternoon, and night) for 10 minutes each, lasting for 8 weeks.~After each session, participants can choose to post texts on a peer social forum for peer support. Fellow participants can give 'comments' or 'likes'. The principal researcher will oversee texts, peer comments, removing information containing personal data, medical recommendations, and negative comments.~Additionally, participants can earn health points by performing specific actions (e.g., watching the educational video and practicing pursed lip breathing) on the software, encouraging their participation in related activities."
41113173|NCT04960644|DRUG|MTX|MTX (5-10 mg/day,Dmax 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
41113174|NCT04960644|DRUG|Corticosteroid|corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response
41113175|NCT05347108|PROCEDURE|laser-assisted neural decompression (LAND) procedure|"The LAND procedure is a minimally invasive spinal decompression procedure that uses a focused laser beam to reduce and remove disc herniations that are causing nerve compressions and impingements within the spinal canal. It is performed in an outpatient setting and the patient receives local anesthesia.~The LAND procedure has been performed extensively over the past 2-years on hundreds of patients, so including patients that have previously had the surgery allows for additional data points and improved reporting."
41113176|NCT05375188|DRUG|Dexmedetomidine|DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr
41113177|NCT05375188|DRUG|Normal Saline|DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
41113178|NCT03123198|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a multimodal comprehensive psychosocial treatment.
41113179|NCT00567333|OTHER|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
41113180|NCT00567333|OTHER|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
41113181|NCT05660993|DRUG|Nivolumab|"Drug: Nivolumab Schedule: Nivolumab 3 mg/kg on day 0 of the Nivo-BeGEV or a maximum of 4 cycles Drug: Bendamustine~Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles Other Name: Ribomustin~Drug: Gemcitabine Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles Other Name: Gemzar~Drug: Vinorelbine Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles Other Name: Navelbine"
41113182|NCT01185769|DIETARY_SUPPLEMENT|Tocotrienol|500 mg of tocotrienol will be administered after consumption of high fat diet
41113183|NCT01185769|DIETARY_SUPPLEMENT|Tocotrienol|500 mg of tocotrienol will be administered after consumption of low fat diet
41113184|NCT02779517|OTHER|Mobile Service Robot Survey|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
41113185|NCT02779517|OTHER|Mobile Service Robot Survey for Patients|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact). This survey differs in terms of design questions.
40925917|NCT05449470|DEVICE|CDSS|A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction
41113186|NCT05111483|OTHER|Tupler technique|"The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~1. Repositioning with diastasis rehab splint :~2. Protect the connective tissue~3. Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~4. Diastasis safe exercises program to maintain the gains"
40925918|NCT05449470|DEVICE|Patient Portal|A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.
40925919|NCT04389437|PROCEDURE|Ophthalmological exam|OCT-A and AO
40925920|NCT04389437|PROCEDURE|Blood pressure measurement|Blood pressure measurement before the ophthalmological exam
40925921|NCT00345644|DRUG|risedronate|risedronate sodium 35 mg tablets (once a week dose)
40925922|NCT00345644|DRUG|risedronate placebo|placebo for risedronate tablets (once a week dose)
40925923|NCT01811264|BEHAVIORAL|Patient-Participation Aid|The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
40925924|NCT01028690|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
40925925|NCT01028690|DIETARY_SUPPLEMENT|Placebo|placebo
40925926|NCT03355482|DRUG|Methylprednisolone|160mg IM at baseline
40925927|NCT03355482|DRUG|Placebos|IM saline injection at baseline
40925928|NCT02085642|OTHER|Acupuncture|Single disposal needle to be used, 0.02 mm x 25 mm in length
40925929|NCT02085642|OTHER|Sham needle|Retractable needle with no skin puncture
40925930|NCT04840030|BEHAVIORAL|Multimodal intervention (MM-int)|"1. Cognitive intervention objective: To enhance cognitive functioning and incorporate daily habits and routines that are cognitively stimulating~2. Socio-emotional intervention objective: • Promote socio-emotional skills associated with awareness, communication and regulation of emotions in late life.~3. Nutritional intervention objective: To improve eating habits of participants to be based on the Mediterranean Dietary pattern by an educational program~4. Physical activity intervention objective: To improve aerobic capacity y, decrease the risk of falls, and improve static and dynamic balance.~5. Risk factors and comorbidities monitoring intervention: quarterly scheduled visits for a cardiovascular risk factors check-up and review active medication"
40925931|NCT03680742|DEVICE|Contour Neurovascular System|The Contour Neurovascular System™ is an intrasaccular, self-expanding, embolization device intended for the treatment of unruptured intracranial aneurysms.
40925932|NCT03294577|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
41113187|NCT05111483|OTHER|conventional therapy|"The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~1. Tie a scarf around abdomen while performing exercises~2. Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~3. Respiratory rehabilitation manoeuvre"
41113188|NCT03216538|DRUG|AS101 1% oral solution|0.4 ml daily p.o.
41113189|NCT03216538|DRUG|Placebo|0.4 ml daily p.o.
41113190|NCT02238210|DRUG|Atrovent®|
40752540|NCT00974233|DRUG|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
40752541|NCT05686252|OTHER|Held Position|Change in angle of held position during kangaroo mother care to alternative angle
40925933|NCT03294577|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
40925934|NCT03294577|OTHER|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
40925935|NCT03294577|DRUG|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
40925936|NCT03233880|DRUG|Azithromycin 1gm|Azithromicin 1 gm oral single dose
40925937|NCT03233880|OTHER|PLACEBO|placebo
40925938|NCT03660137|DEVICE|MOLLI Localization|All patients will also be implanted with an additional MOLLI seed using a specialized introducer needle. A specialized MOLLI probe will be used to find the magnetic seed during the lumpectomy surgery.
40925939|NCT04842032|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
40925940|NCT01599364|DRUG|Atazanavir, ritonavir, lamivudine|Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
40925941|NCT02246712|DRUG|Single oral dose of 100 mg racemic tramadol|Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
40925942|NCT02246712|OTHER|CYP2D6 phenotype|"Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato"
40925943|NCT02246712|OTHER|CYP3A phenotype|"A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance."
40925944|NCT02246712|GENETIC|CYP2B6 genotype|The single nucleotide polymorphism 516G\>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
40925945|NCT04564768|BEHAVIORAL|Online Mindfulness-Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
40925946|NCT05429775|DRUG|Budesonide|single dose of 2 mg oral suspension formulation administered orally under fasting conditions
40925947|NCT04613843|OTHER|Water Stirring|Following an active heating protocol, the cooling intervention includes vigorous water stirring throughout cold water immersion.
40925948|NCT04613843|OTHER|No Water Stirring|Following an active heating protocol, the cooling intervention includes no water stirring throughout cold water immersion.
40925949|NCT03896347|OTHER|ViBone®|Viable bone allograft
40925950|NCT03896347|OTHER|Demineralized Bone Matrix|Demineralized Bone Matrix
40925951|NCT03896347|OTHER|Bone Morphogenetic Protein|Bone Morphogenetic Protein
40925952|NCT05247528|DRUG|MANP|Novel designer peptide to represent a pGC-A/cGMP therapeutic
40925953|NCT05247528|DRUG|Placebo|Placebo Comparator
40925954|NCT00591110|BEHAVIORAL|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
40925955|NCT00591110|BEHAVIORAL|Social-contact control|Participants receive an engaging informational session on a non-health related topic
40925956|NCT04108351|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
40925957|NCT04108351|OTHER|Car-following test|Intervention Description: Driving with simulator program for DCV measurement
40925958|NCT04108351|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
40925959|NCT05349253|DIETARY_SUPPLEMENT|Garlic extracts|One intake in total
40925960|NCT05349253|DIETARY_SUPPLEMENT|Placebo|One intake in total
40925961|NCT01027806|DRUG|Montelukast|1 pill per day for 4 months
40925962|NCT01873469|RADIATION|Radiochemotherapy|postoperative radiochemotherapy 60 Gy/ Temozolomide
40925963|NCT05274854|BEHAVIORAL|a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing|Pre consultation interventions consist of one of four intervention a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing
41113191|NCT02471755|DEVICE|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30\*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
41113192|NCT02471755|DEVICE|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
41113193|NCT00034463|DRUG|ALIMTA|
41113194|NCT00034463|DRUG|folic acid|
41113195|NCT00034463|DRUG|multi-vitamins|
41113196|NCT00923871|PROCEDURE|Cone Beam CT|Patients will also have a CBCT scan when they are having their first IMRT treatment.
41113197|NCT01354795|PROCEDURE|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
41113198|NCT01354795|PROCEDURE|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
41113199|NCT05919368|DIETARY_SUPPLEMENT|Yam pill|It consists of sweet potato, white art and ginseng
41113200|NCT00865436|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
41113201|NCT00865436|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
41113202|NCT02474238|DEVICE|The sequential technique|By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
41113203|NCT02474238|DEVICE|The pure Nd:YAG laser technique|By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
40925964|NCT05274854|BEHAVIORAL|a) consultant-led outpatient clinic or b) a integrated care clinic|Consultation intervention consists of one of two interventions a) consultant-led outpatient clinic or b) a integrated care clinic
40925965|NCT01213576|DRUG|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
40925966|NCT01213576|DRUG|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
40925967|NCT01213576|DRUG|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
41113204|NCT00658996|DEVICE|SofLens DD Toric|daily disposable wear contact lens for 2 weeks
41113205|NCT00658996|DEVICE|Ciba Vision Focus Dailies Toric Contact Lens|daily disposable wear contact lens for 2 weeks
41113206|NCT01745016|DIETARY_SUPPLEMENT|Placebo|
41113207|NCT01745016|DIETARY_SUPPLEMENT|Beta-alanine|
40925968|NCT01213576|DRUG|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
41113208|NCT00446550|DRUG|afegostat tartrate|
41113209|NCT04959136|DEVICE|Ambulatory Monitoring Solution|Aim is to evaluate PR; RR; NIBP, cNIBP, SpO2 and arterial blood pressure with investigational Ambulatory Monitoring Solution (AMS)
41113210|NCT04139499|PROCEDURE|Drug-induced sleep endoscopy (DISE)|DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.
41113211|NCT04139499|PROCEDURE|High-resolution manometry (HRM):|After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.
41113212|NCT02080650|DEVICE|Mesenchymal-marker based ferrofluid (c-MET)|
41113213|NCT02080650|DEVICE|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
41113214|NCT06238752|DRUG|Apatinib Combined With Tislelizumab and Chemotherapy|apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks
41113215|NCT04920149|DRUG|Mesalamine|The IMP will be supplied as sachets with slow-releasing granules.
41113216|NCT04920149|DRUG|Placebo|The IMP will be supplied as sachets with slow-releasing granules.
41113217|NCT02449070|DRUG|Nicorandil|4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
41113218|NCT04609618|DEVICE|Appscent Device|computer-controlled, low pressure compressed air based, with disposable odorant capsules solution provided an odor environment at the nose,
41113219|NCT04152421|OTHER|Software use|"The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities."
41113220|NCT00281008|DRUG|ISIS 301012 or Placebo|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
41113221|NCT00281008|DRUG|ISIS 301012 or Placebo|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
40925969|NCT04493528|COMBINATION_PRODUCT|Meso-Jet, 2% lidocaine(xylocaine)|Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.
41113222|NCT00281008|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
41113223|NCT00281008|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
41113224|NCT03007836|BIOLOGICAL|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
41113225|NCT05739903|DRUG|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
41113226|NCT05739903|DRUG|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
41113227|NCT04783610|OTHER|Ethanol|Ethanol will be administered via oral route.
41113228|NCT05379491|DRUG|3 L PEG + linaclotide|Participants take a linaclotide capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another linaclotide capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
41113229|NCT05379491|DRUG|3 L PEG + placebo|Participants take a placebo capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another placebo capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
41113230|NCT04277299|DEVICE|IcorySolution|The ICory-solution programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery. The healthcare professional have received face-to-face training on how to use the BuddyCare dashboard and BuddyCare has been in the hospital in earlier studies.The Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support, games and distraction to children and a virtual tour to the hospital before children´s operation.
41113231|NCT00992238|DRUG|Flavoxate Hydrochloride Tablets, 100mg|
41113232|NCT00992238|DRUG|Urispas® Tablets, 100mg|
41113233|NCT01126112|BIOLOGICAL|Panitumumab|Panitumumab: 6 mg/Kg Q2W
41113234|NCT02529995|DRUG|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
41113235|NCT02529995|DRUG|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
41113236|NCT06545994|OTHER|Observation|It's a observational cohort study and no interventions are performed.
41113237|NCT03401190|DRUG|CM4620 Injectable Emulsion (Low Dose)|CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
41113238|NCT03401190|DRUG|CM4620 Injectable Emulsion (High Dose)|CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
41113239|NCT06050109|DRUG|OFS continues to use group after 5 years use|Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
41113240|NCT06050109|DIAGNOSTIC_TEST|Immunohistochemical detection of HR status|Enrolled patients must be HR-positive premenopausal breast cancer patients
40925970|NCT04493528|COMBINATION_PRODUCT|Needle,2% lidocaine(xylocaine)|Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.
40925971|NCT00642889|DRUG|Safinamide|
40925972|NCT00642889|DRUG|Safinamide|
41113241|NCT06374199|BEHAVIORAL|Med-South Lifestyle Intervention for Pregnancy--Arm 1|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil and nuts
41113242|NCT06374199|BEHAVIORAL|Med-South Lifestyle Intervention for Pregnancy--Arm 2|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil, nuts, and medically tailored meals
41113243|NCT06043128|OTHER|Patients With Stroke With Different Trunk Impact Levels|"Before the study, written and verbal Informed Consent Form will be obtained from all participants who meet the inclusion criteria.Trunk Impairment Scale (TRS) will be used to measure trunk control, which is our independent variable. Scores close to 23 points on the TIS will constitute the group with high trunk control, and those with scores close to 0 will constitute the group with low trunk control. Spasticity of the participants, Modified Tardiue Scale (MTS), cervical proprioceptive awareness cervical joint error test, lower extremity proprioceptive awareness Proprioception test in Technobody Prokin 252 Isokinetic Balance Platform, balance skills Dynamic and static balance in Tecnobody Prokin 252 Isonkinetic Balance Platform will be evaluated by tests. The patients' quality of life will be evaluated with the stroke-specific quality of life scale. All data obtained will be noted on a prepared evaluation form."
41113244|NCT01901276|DRUG|Omeprazole 40 mg bid|As above.
41113245|NCT04091425|DRUG|TAK-925|TAK-925 IV infusion
41113246|NCT04091425|DRUG|Placebo|TAK-925 placebo-matching IV infusion
41113247|NCT00068198|BIOLOGICAL|Dryvax|
41113248|NCT04584489|OTHER|iron stores assessment.|assessment of iron stores by measuring serum ferritin level (mandatory), serum iron and transferrin saturation.
41113249|NCT00835770|DRUG|dimethyl fumarate|BG00012 capsules
41113250|NCT00835770|DRUG|Placebo|Capsules taken to maintain the blind in the 240 mg BID treatment group.
41453341|NCT04668820|DIAGNOSTIC_TEST|video Pediatric Gait, Arms, Legs and Spine (V-pGALS)|The Video-pGALS includes maneuvers from pediatric regional examination of the musculoskeletal system (pREMS) and derived from the pediatric gait arms legs spine examination assessment which is a validated simple basic musculoskeletal (MSK) examination for children. V-pGALS offers a structured approach to a cursory overview MSK exam with a focus on range of movement and symmetry. Utilizing the parent or caregiver to feel the joint in question for obvious warmth/ swelling or to palpate for point of maximal tenderness can add important information.
40925973|NCT00642889|DRUG|Placebo|
40925974|NCT05624710|DRUG|INCB054707|INCB054707 75 mg will be administered orally on Day 1.
40925975|NCT04034953|DIAGNOSTIC_TEST|Faecal Immunochemical Test|Faecal Immunochemical Test detects if there is any hemoglobin presents in stools, so even tiny amount of blood in stool can be found.
40925976|NCT04034953|DIAGNOSTIC_TEST|Prostate-Specific Antigen Test|PSA blood test is used to measure the level of PSA in blood. When the PSA level is higher than normal, it may represent prostate cancer or benign prostate hyperplasia. Patient who have high PSA level should receive additional tests.
40925977|NCT04034953|DIAGNOSTIC_TEST|Mammogram|Each sides of breast will be taken imaging in 2 different views.The breast will be pressed between 2 plastic plates to flatten and spread the breast tissue for clear imaging.
40925978|NCT04315584|PROCEDURE|Positron Emission Tomography|Undergo PET/CT Scans
40925979|NCT04315584|PROCEDURE|Computed Tomography|Undergo PET/CT Scans
40925980|NCT04315584|PROCEDURE|Multiparametric Magnetic Resonance Imaging Scan|Undergo a multiparametric MRI scan
40925981|NCT04315584|RADIATION|Fludeoxyglucose F-18|IV (intravenous) administration of radiotracer
40925982|NCT04315584|RADIATION|fluorine F 18 fluorodopa|IV (intravenous) administration of radiotracer
40925983|NCT03821844|BEHAVIORAL|Music and Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
40925984|NCT04124744|OTHER|Health Champions intervention|Health Champions are trained volunteers who will support service users with their physical health goals over 9 months, meeting once a week
40925985|NCT04124744|OTHER|Control group-treatment as usual|Participants will receive treatment as usual from their Community Mental Health Team
40925986|NCT02032043|DRUG|Annual versus Semiannual Albendazole plus Ivermectin MDA|Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
40925987|NCT05864456|DEVICE|Prizvalve Pro™ transcatheter aortic valve system|Transcatheter Aortic Valve Replacement
40925988|NCT01464957|BEHAVIORAL|Semi-tailored newsletter|Delivered over 3 consecutive years, in the spring
40925989|NCT01335022|BEHAVIORAL|lecture|6 lectures on cardiovascular disease covering obesity, diet \& exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.
40925990|NCT05885308|BEHAVIORAL|Otago|Group training is compared with training performed at participants' homes, using an online film
40925991|NCT05945862|BEHAVIORAL|NUTRIGANDO|Program consisting in nutrition education and physical activity training to promote healthy lifestyles
40925992|NCT05394493|DRUG|avelumab|as provided in real world setting
40925993|NCT05394493|DRUG|axitinib|as provided in real world settings
40925994|NCT00125125|DRUG|Fluvastatin|
40925995|NCT05214053|DEVICE|Cone Beam CT|Each patient will undergo a Cone Beam CT and a MDCT
40947798|NCT03867279|OTHER|Flossing|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground. The subjects included in this group will perform the exercises while a compression band is applied to the ankle.
41113251|NCT03786991|OTHER|No intervention|No intervention
41113252|NCT04893213|OTHER|Manipulation of availability of lower energy meal options|Menus provided differ in % of menu options that are higher vs. lower in energy
41113253|NCT06259474|COMBINATION_PRODUCT|Hypopressive Exercises and (heat therapy, medication, and progressive strength training)|20 subjects combined HE with traditional treatments for LBP (heat therapy, medication, and progressive strength training). Each session consisted of 5 to 10 HEs. Participants were instructed not to hold their breath or perform PFMS contractions during the HEs. Traditional treatment for low back pain typically involved using medications like acetaminophen (0.5-1 g three times daily) and heat therapy, which consisted of using a continuous heat wrap for 2 hours, 3 times per week at 40 °C, one hour before and after the session
41113254|NCT02547922|BIOLOGICAL|Anifrolumab|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
41113255|NCT02547922|DRUG|Placebo|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
41113256|NCT01266265|DRUG|inhaled prostacyclin|Tyvaso
41113257|NCT01266265|DRUG|inhaled prostacyclin|As prescribed by the physician
41113258|NCT01266265|DRUG|prostacyclin|As prescribed by the physician
41113259|NCT01266265|DRUG|subcutaneous and intravenous prostacyclin|As prescribed by physician
41113260|NCT01266265|DRUG|oral ERA|As prescribed by physician
41113261|NCT01266265|DRUG|oral PDE5 inhibitors|As prescribed by physician
41113262|NCT01261234|DRUG|Cilostazol or Non-Cilostazol|Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
41113263|NCT05162755|DRUG|S095029|S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
41113264|NCT05162755|DRUG|S95029 and Sym021|Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
41113265|NCT05162755|DRUG|S095029 and Sym021 and anti-HER2 therapy|Patients will be administered with S095029, Sym021 and anti-HER2 therapy.
41113266|NCT05162755|DRUG|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|Patients will be administered with S095029, Sym021 and futuximab/modotuximab.
41113267|NCT01348880|DRUG|Vardenafil ODT, (Staxyn, BAY38-9456)|Single dose of 10 mg of vardenafil ODT, taken without water
41453342|NCT03599583|BEHAVIORAL|STOP-HPV prompts intervention|This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
41113268|NCT01348880|DRUG|Placebo|Single dose of placebo to match 10 mg vardenafil ODT. taken without water
41113269|NCT03760835|DRUG|Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)|Treatment of congenital adrenal hyperplasia
41113270|NCT03760835|DRUG|Dual release hydrocortisone (plenadren)|Treatment of congenital adrenal hyperplasia
41113271|NCT04687241|DRUG|Almonertinib|The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.
41113272|NCT04687241|DRUG|Placebo Almonertinib|Placebo Almonertinib
41113273|NCT00004266|DRUG|Lisinopril|
41113274|NCT00004266|DRUG|Nifedipine|
41113275|NCT00004266|DRUG|Simvastatin|
41113276|NCT00866203|DRUG|HDS vs ProMECE/CytaBOM|
41113277|NCT03301025|DRUG|Pregabalin|Pregabalin 150 mg capsule, one h preinduction of general anesthesia
41113278|NCT03301025|DRUG|placebo|given a placebo identical capsule once one hour before anesthesia
41113279|NCT03860532|DRUG|HMPL-011 tablets|Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.
41113280|NCT03860532|DRUG|HMPL-011 capsules|Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
41113281|NCT06108271|DEVICE|Triglotix®|The Triglotix® has a biocompatible self-expanding viscoelastic cuff that is located in the supraglottic, glottic and subglottic space. This cuff separates the endotracheal tube from the laryngeal vestibule in the supraglottic space and the vocal cords avoiding direct tissue damage from the plastic components of the tube. The viscoelastic cuff self-expands after the endotracheal tube is in adequate position in the airway. Then it adapts progressively and gradually to the shape of structures it comes in contact with, applying minimal pressure to the surrounding tissue. The ETT-T also has two wire reinforced segments: the first is located outside the mouth to prevent deformation related with kinking, while the second segment is positioned distally along the larynx. The primary purpose of this design is to mitigate torsional, rotational and lateralization forces that the tube may encounter while the patient is intubated.
41113282|NCT06108271|DEVICE|Conventional endotracheal tube|Conventional endotracheal tube that is currently used worldwide
41113283|NCT02139943|DRUG|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
41113284|NCT02139943|DRUG|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
41113285|NCT02139943|DRUG|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
41113286|NCT00080639|OTHER|physiologic testing|
41113287|NCT00080639|PROCEDURE|study of high risk factors|
41113288|NCT00835380|BIOLOGICAL|Hepatitis A Vaccine, Purified Inactivated (VAQTA™)|Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
41113289|NCT00869258|DRUG|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
41113290|NCT00869258|RADIATION|Radiation therapy with gemzar|Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
41113291|NCT05317611|DRUG|Intraperitoneal instillation of ondansetron and bupivacaine|The aim is to detect the effect of intraperitoneal instillation of ondansetron for prevention of postoperative nausea and vomiting
41113292|NCT05317611|DRUG|Intravenous ondansetron and intraperitoneal instillation of bupivacaine|The aim is to detect effect of intravenous ondansetron for prevention of postoperative nausea and vomiting
41113293|NCT05317611|DRUG|Intraperitoneal instillation of bupivacaine|The aim is to detect effect of intraperitoneal instillation of bupivacaine
41113294|NCT03220425|DRUG|Insulin detemir|
41113295|NCT03220425|DRUG|NPH insulin|
41113296|NCT01665092|DRUG|Levo-Carnitine|
40925996|NCT03796520|DIAGNOSTIC_TEST|EpiPick simplified seizure classification algorithm|"EpiPick simplified seizure classification algorithm input:~Grey matter brain lesion Exclusively nocturnal seizures First seizure at age \> 20 years Lip smacking or chewing during seizures Staring with impaired awareness, lasting less than 20s without postictal confusion Sudden irregular jerks, in isolation or brief series, if none of the following applies: Are the jerks consistently in the same limb? When resting in bed when falling asleep? Bilateral tonic-clonic seizures within 1h of awakening or immediately preceded by irregular jerks Any of the following is present: Skin turning pale pre-ictally; Loss of consciousness immediately after urination or defecation; Sudden slump with loss of awareness, lasting less than 10 seconds; Seizure lasting longer than 10 minutes, with eyes closed throughout the seizure; Severe pre-ictal headache; Episodes consisting of falls that occur always after change in posture to the upright position, or coughing or feeling pain."
41113297|NCT01665092|DRUG|placebo|
41113298|NCT04349150|DEVICE|Virtual reality|Intervention consists of providing virtual reality in place of standard sedatives and narcotics for a portion or the duration of the colonoscopy
41113299|NCT06148727|DEVICE|Dental implant placement|Procedure/ surgery: Surgical placement of dental implants, four interforaminal dental implants were placed
41113300|NCT06148727|DEVICE|Bar attachment|Device: attachment, implants were connected to each others by 3 implant assembly in a trapezoidal design implants were loaded after 3 months of osseo-integration Control Group: patients received coventionally constructed heat cured overdenture Study Group: patients received 3d printed overdenture
41113301|NCT05570188|BIOLOGICAL|anti-CD19 UCAR-NK cells|"Enrolled participants are chosen to receive one of three different dose levels of U-CAR-NK cells:~Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg."
41113302|NCT05880472|DEVICE|Intratumoral|Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.
41113303|NCT04461197|DEVICE|customised foot orthoses|The foot orthoses for group A were custom made using phenolic foam molds of the feet. Separated molds were made of both feet for all the participants. . The insole was made based on a positive mold of plaster with 45 Shore cork materials with horizontal thrusts just proximal to the metatarsal heads, with the intention of correcting the pathological subtalar pronation, with a 3mm bilateral raising of the heel and a bilateral latex metatarsal bar.
41113304|NCT04461197|DEVICE|orthotic insole|For group B, a flat insole of polyester resin was made, fitting it to the foot's size.
41113305|NCT01535833|PROCEDURE|Device- Robotic sacral colpopexy|To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
41113306|NCT05960695|OTHER|Stretching|"Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds. The exercises will be done online by the physiotherapist.~The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises."
41113307|NCT05960695|OTHER|Relaxation|Diaphragmatic breathing will be taught as a relaxation exercise. The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises.
41113308|NCT05322837|OTHER|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires related to upper limb function and quality of life will be used
41113309|NCT00988637|DRUG|Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
41113310|NCT00988637|DRUG|Clobex® Spray morning and Vectical™ Ointment evening regimen|Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
41113311|NCT04816487|DRUG|Potassium Iodide or Glutathione|Patient will receive either Glutathione or Potassium iodide
41113312|NCT05702996|DRUG|Eculizumab administration|Patient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab
41113313|NCT05965401|OTHER|Pharmacogenetic-guided dosing|SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
41113314|NCT05965401|OTHER|GLAD-PC guided dosing|SSRI dosing based on GLAD-PC clinical practice guidelines
41113315|NCT03663842|OTHER|Physical therapy treatment|All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
41113316|NCT02616263|OTHER|Foot exercise|
41113317|NCT02616263|OTHER|Shoulder exercise|
41113318|NCT06137365|DRUG|Cannabis|Cannabis gummy product will be prepared using cannabis flower extract.
41113319|NCT06137365|DRUG|Placebo|Placebo gummy product will be prepared using the same ingredients as the cannabis gummy but will not contain active cannabinoids.
41113320|NCT04662840|PROCEDURE|Geniculate artery embolization|Under fluoroscopic guidance and angiographic imaging, a microcatheter is used to select all the arteries feeding the affected knee and Embosphere (100-300um) particles are injected to obtaining pruning of the hypervascular tissues arteries.
41113321|NCT04662840|PROCEDURE|Geniculate nerve ablation|Under fluoroscopic guidance, a Cool-tip RFA ablation needle is advanced such that it touches the femur at the condylar convexity on each side and the tibia at the tibial plateau convexity on the medial side. The ablation is performed to obtain an approximate zone of ablation of 2cm.
41113322|NCT04662840|PROCEDURE|Skin infiltration of local anesthetic at groin and knee|Freezing of the skin will be performed at the groin (as prior to an arterial access for embolization procedure) and at three areas around the knee (as prior to insertion of the ablation needles for nerve ablation procedure).
40925997|NCT03007888|DRUG|Sinemet|Immediate Release Tablet containing carbidopa-levodopa flexible dosing
41113323|NCT03089840|DEVICE|OrganOx metra|Following the routine retrieval procedure at the donor hospital the liver will be flushed with cold preservation solution and prepared for cannulation. The donor organ is then placed on the OrganOx metra device and will be perfused with warmed solution. The OrganOx metra device containing the donor organ is then transported to the recipient transplant centre. The donor liver is then removed from the device and flushed with standard of care preservation solution. Alternatively, where more practical, the livers will be transported to the University of Alberta hospital with ≤ 6 hours of cold storage and then placed on the metra™ for ≥ 4 hours. Implantation and reperfusion of the liver proceed as per the usual practice of the recipient transplant centre.
41113324|NCT04776265|OTHER|Evaluation of therapeutical approach after ASCT|Evaluation of therapeutical approach after ASCT
41113325|NCT01599117|DRUG|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
41113326|NCT01599117|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
41113327|NCT01446068|DIETARY_SUPPLEMENT|High-fat meal|Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
41113328|NCT02108106|DRUG|AG-348|A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
41113329|NCT02108106|DRUG|Placebo|
41113330|NCT06475508|BIOLOGICAL|Complarate®|The investigational drug Complarate® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
41113331|NCT06475508|BIOLOGICAL|Actemra®|The reference drug Actemra® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
41113332|NCT02620618|DRUG|Intravitreal Infliximab|ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
41113333|NCT03851549|DEVICE|New BGMS (US)|New blood glucose monitoring system / In vitro diagnostic device (IVDD)
41113334|NCT00131144|DRUG|Octreotide Acetate in Microspheres 20 mg|
41113335|NCT00131144|DRUG|Octreotide Acetate in Microspheres|
41113336|NCT00131144|DRUG|Placebo|
41113337|NCT01282346|DEVICE|SOLX Gold Shunt|Single use implant
41113338|NCT06006052|COMBINATION_PRODUCT|regeneration technique|clinical procedure of regenerative endodontic as AAE mentioned using different material in each group
41113339|NCT02175784|DRUG|ipragliflozin|oral
41113340|NCT02175784|DRUG|placebo|oral
41113341|NCT01574807|DRUG|mepivacaine + lidocaine followed by lidocaine +lidocaine|1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
41113342|NCT01574807|DRUG|lidocaine + lidocaine followed by mepivacaine + lidocaine|1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
41113343|NCT03150238|OTHER|observation of prognostic factors for relapse|The identification of the most relevant prognostic factors and the definition of their weight in predict the risk of re-intervention will be the basis for the definition of a combined score
41113344|NCT00992173|DRUG|Ultratrace Iobenguane I 131|Subjects will receive an Imaging Dose of 0.1 mCi/kg \[3.7 MBq/kg\] (a minimum dose of 1.0 mCi \[37 MBq\] but not to exceed 5.0 mCi \[185 MBq\]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
40925998|NCT03007888|DRUG|IPX203|Extended Release capsules containing carbidopa-levodopa flexible dosing
40925999|NCT01439815|DRUG|Fluticasone Propionate Nasal Spray|two sprays in each nostril once daily
40926000|NCT01439815|DRUG|Saline Nasal Spray|two sprays in each nostril once daily
40752542|NCT05032105|DEVICE|Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
40926001|NCT05974423|DRUG|Tylenol, Ibuprofen, and Oxycodone|A script for these three medications will be provided
41113345|NCT06007118|RADIATION|APBI|accelerated partial breast irradiation to the surgery bed (5 x 6,0 Gy; in 5 working days)
41113346|NCT06007118|RADIATION|WBI|accelerated whole breast irradiation with the boost to tumor bed (15x 2,67 Gy + 5x 2,0 Gy, every working day)
41113347|NCT02957006|DEVICE|Loop Recorder|Observation of Loop Recorder implanted for clinical reasons
41113348|NCT05949255|DIETARY_SUPPLEMENT|Probiotic|10 subject will receive a probiotic daily for 12 weeks.
41113349|NCT05949255|DIETARY_SUPPLEMENT|Placebo|10 subjects will receive a placebo daily for 12 weeks.
41113350|NCT05296148|DEVICE|Transcatheter Tricuspid Valve Implantation|Implantation of a tricuspid coaptation valve through a transcatheter approach.
41113351|NCT01199705|BIOLOGICAL|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
41113352|NCT04738565|DIETARY_SUPPLEMENT|Probiotic preparation|The mixture of Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908 and Lactobacillus casei ŁOCK 0919 administered once a day at a dose of one billion for 3 months.
41113353|NCT04738565|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture administered once a day for 3 months.
41113354|NCT00878618|DRUG|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
41113355|NCT00878618|DRUG|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
41113356|NCT02971488|OTHER|Screening for HCV in PWID and Linkage-To-Care|"Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population."
41113357|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 1|6Gy x 2 fractions to all sites in 2 weeks
41113358|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 2|6Gy x 3 fractions to all sites in 3 weeks
41113359|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 3|6Gy x 4 fractions to all sites in 4 weeks
41113360|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 4|6Gy x 5 fractions to all sites in 5 weeks
41113361|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - De-escalation Level|6Gy x 1 fraction to all sites in 1 week
41113362|NCT03426228|DIAGNOSTIC_TEST|HbA1C|"After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:~1. At baseline (second day of the menstrual period)~2. Triggering phase (post-egg retrieval procedure)~3. Embryo transfer phase (post-transfer procedure)~4. Week 4 (positive bHCG)~4. Week 8 of pregnancy"
40926002|NCT05974423|DRUG|Tylenol and Ibuprofen only|A script for only these two medications will be provided initially following surgery. Should the patient need stronger medication for adequate pain control, the on-call physician will provide a script for oxycodone
40926003|NCT02603796|OTHER|3D Scan of nares|3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
40926004|NCT01488344|DRUG|triple kinase inhibitor BIBF1120|triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
41113363|NCT02076958|BEHAVIORAL|Community Health Advisor education|
41113364|NCT03336424|DIAGNOSTIC_TEST|Non-invasive investigations|Ultrasound, blood tests, urine analysis and culture, uroflowmetry
41113365|NCT03336424|DIAGNOSTIC_TEST|Invasive investigations|Cystomanometry, pressure flow study, EMG
41113366|NCT02277288|OTHER|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
40926005|NCT05059288|DEVICE|Investigational Non Invasive Ventilation Mask|Oronasal non invasive ventilation mask
41113367|NCT05561036|DRUG|Liposome doxorubicin|Liposome doxorubicin (50mg/m2) or intravenous placebo with a treatment cycle of once every 28 days
40926006|NCT03189498|DRUG|JNJ-64041575|All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250 mg tablets) on Day 1.
40926007|NCT06311799|BEHAVIORAL|WIC Referral|Clinical team will refer study participants to WIC
41113368|NCT05561036|DRUG|Saline Solution|saline solution
41113369|NCT03662048|BEHAVIORAL|Safe|Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
41113370|NCT04080258|OTHER|Osteopathic manipulative therapy (OMTh)|"The Osteopathic Manipulative Therapy includes both evaluation and treatment. The evaluation is semi-structured, two osteopaths will assess the presence of somatic dysfunctions which have to include the hyoid-pharyngeal, laryngeal, temporo-mandibular and lingual areas.~The therapy is based on the treatment of somatic dysfunctions with different approaches that include: the balanced ligamentous tension technique, the myofascial release, the visceral manipulation, and the balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 of evaluation and 30 of treatment."
41113371|NCT04080258|OTHER|Light Touch Therapy (LTT)|The Light Touch Therapy is a sham treatment consistent with the OMTh one during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force.
41113372|NCT06486987|OTHER|Constraint induced movement therapy delivered by televideo|In-home Constraint induced movement therapy delivered by a therapist participating by televideo
41113373|NCT02824939|OTHER|Transversus Abdominis Plane (TAP) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
41113374|NCT02824939|OTHER|Quadratus Lumborum (QL) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
41113375|NCT06393244|BEHAVIORAL|a theory-based home-based multi-component exercise training|The participants in the intervention group will receive a 12-week theory-based home-based MCE program, which consists of three phases: exercise mobilization phase, exercise preparation phase (exercise instructions and exercise plan determination), and home-based autonomous exercise training. Structured guidelines have been developed for the intervention by the research team. This allowed interveners to deliver the intervention in a structured way with the same dosage.
41113376|NCT04257435|BEHAVIORAL|Positive Psychological Group Treatment|Positive psychological group treatment will involve engagement in traditional behavioral health treatment, as well as a group treatment focusing on previously researched exercises that have been demonstrated to relate to reduced depression and increased positive emotionality (Seligman, Rashid, Parks, et al., 2005; Seligman, Rashid, \& Parks, 2006; Rashid, 2015).
41113377|NCT04257435|BEHAVIORAL|Traditional Behavioral Health Treatment|Treatment will include traditional individual behavioral health treatment, involving CBT-based therapeutic interventions for presenting diagnoses (typically depression, anxiety, or PTSD-related symptomatology).
41113378|NCT06167525|DEVICE|Real-time feedback through the device. Bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will be recorded|"During the first stage of the study the device will be set to record cervical spine positioning without bio-feedback signals. This will be used to record duration of time surgeons held maladaptation postures.~The second stage will involve real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for \>1 minute. Response of surgeons to bio-feedback signals will also be recorded.~The Neck Disability index score will be used to assess for neck pain and the functional implications in relation to reported neck pain. This will be completed following study completion."
41113379|NCT02537704|BEHAVIORAL|Group Lifestyle Balance Program|
41113380|NCT02744859|OTHER|Label Condition|Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.
41113381|NCT00230399|DRUG|Celecoxib|
41113382|NCT00230399|DRUG|Capecitabine|
41113383|NCT00230399|DRUG|Irinotecan|
41113384|NCT02726490|DRUG|Glyburide|glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)
41113385|NCT02726490|DRUG|Glucovance|glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
41113386|NCT00812617|DIETARY_SUPPLEMENT|Mineral water (Hita, Oita, Japan)|
41113387|NCT00812617|DIETARY_SUPPLEMENT|Mineral water (Aso-gun, Kumamoto, Japan)|
41113388|NCT01435395|DRUG|Temozolomide, bevacizumab and bortezomib|Escalating temozolomide with standard dose bevacizumab and bortezomib
41113389|NCT00002632|DRUG|paclitaxel|
41113390|NCT02050763|BEHAVIORAL|The SHARE Project|"SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau \& Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska \& DiClemente, 1983; Prochaska \& Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.~We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior."
41113391|NCT00004124|DRUG|bicalutamide|
41113392|NCT00004124|DRUG|goserelin|
40926008|NCT06311799|BEHAVIORAL|RDN Referral|Clinical team will refer study participants to a RDN
41113393|NCT00004124|DRUG|mitoxantrone hydrochloride|
41113394|NCT00004124|DRUG|prednisone|
41113395|NCT02271971|DIETARY_SUPPLEMENT|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
41113396|NCT02271971|DIETARY_SUPPLEMENT|Placebo|A daily placebo capsule during 6 weeks.
41113397|NCT03105219|DRUG|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
41113398|NCT03105219|OTHER|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
41113399|NCT01793441|DRUG|Placebo|Placebo will be administered in different stages of the study for 12 weeks.
41113400|NCT01793441|DRUG|RG7314|RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
41113402|NCT05516641|DIETARY_SUPPLEMENT|Soluble Corn Fiber|once daily additive to diet
41113403|NCT05516641|DIETARY_SUPPLEMENT|Maltodextrin|once daily additive to diet
41113404|NCT02705586|BEHAVIORAL|Mindfulness|Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
41113405|NCT01356758|DRUG|biological treatment|patients treated with anti-psoriatic biological agents
41113406|NCT00626418|DRUG|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
41113407|NCT00626418|DRUG|Placebo|Placebo tablets
40752543|NCT05180656|BEHAVIORAL|Yoga Intervention|The yoga intervention will consist of two 60-minute yoga classes each week, taught by a certified yoga instructor and delivered remotely through videoconferencing. Participants will be asked to participate in the intervention for 8 weeks.
41113408|NCT05979324|DEVICE|ABAStroke Digital Therapeutics|The total time of the study is 30 weeks in total, i.e. 15 weeks of patient recruitment and then a maximum of another 15 weeks until the end of the observation of the last patient. Within 2 weeks from the last patient, the last Monitor's visit will be performed to close the study. The patient will use the ABAStroke application for a maximum of 91 days (the minimum time is 28 days) and standard therapy, including rehabilitation (as recommended by researchers or other physicians rehabilitating a patient after a stroke).
41113409|NCT00739518|PROCEDURE|MRI|Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
41113410|NCT01977638|DRUG|CXD101|Capsules, administered orally
41113411|NCT03385967|DRUG|Dexmedetomidine|Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine
41113412|NCT03385967|DRUG|ropivacaine|Standard of care 0.5%ropivacaine
41113413|NCT00846066|OTHER|Hands on training|Hands on training by a pediatric dentist on preventive oral health
40752544|NCT01396785|DRUG|33525|Daily for 14 days
41113414|NCT00846066|OTHER|Web based training|Web based training alone
41113415|NCT01669382|DEVICE|percutaneous coronary intervention|after the intervention patients are randomized to either Angio Seal or Exo Seal
41113416|NCT02337569|DRUG|NPC-02|
41113417|NCT02337569|DRUG|Placebos|
41113418|NCT00210509|DRUG|almotriptan malate|
41113419|NCT04036630|DEVICE|Transcranial alternating current stimulation (tACS)|"The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition."
41113420|NCT04036630|DEVICE|Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)|"TMS is a technique where a transient magnetic field (or pulse) is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.~MEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple."
41113421|NCT04632368|BEHAVIORAL|Transcendental Meditation|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to HCPs dealing with COVID-19 pandemic
41113422|NCT04424641|BIOLOGICAL|GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.|GEN1044 will be administered intravenously in cycles of 21 days.
41113423|NCT03981042|DEVICE|Monitoring|"After the anesthetic induction with sufentanil, propofol and atracurium, patients will be ventilated with mask until:~- Monitoring group: TOF ratio at the corrugator supercilli will be measured every 15 s after injection of atracurium. When TOF ratio reach 0, laryngoscopy with intubation will be performed"
41113424|NCT03581357|BEHAVIORAL|Mobile Mindfulness Meditation|It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.
41113425|NCT03581357|BEHAVIORAL|Mindfulness Coach|It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.
41113426|NCT04030767|DRUG|Botox Injectable Product|Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
41113427|NCT03854253|PROCEDURE|Long introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-25cm
41113428|NCT03854253|PROCEDURE|Short introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-10cm
41113429|NCT06512714|OTHER|A diagnosis of mycetoma in a medical, radiologic, or laboratory record.|For each patient, data will be extracted for each clinical, laboratory or radiologic visit related to the condition that may meet this study's case definition.
41113430|NCT03752385|BEHAVIORAL|reducing smartphone screen time|"Cutting average smartphone screen time in half. Sleeping without smartphone in bedroom. Establishing a bedtime to stop smartphone screen time."
41113431|NCT02894242|DEVICE|F&P Deimos Nasal Pillows Mask|Investigative Nasal Pillows Mask to be used for OSA therapy
41113432|NCT00636064|DRUG|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
41113433|NCT00636064|DRUG|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
41113434|NCT00636064|OTHER|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
41113435|NCT04745663|DRUG|Povidone-Iodine 0.3%|Low concentration iodine
41113436|NCT04745663|DRUG|Povidone-Iodine 5%|Standard concentration iodine
41113437|NCT01807546|DRUG|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
41113438|NCT06300489|DRUG|irinotecan liposomes+capecitabine|"Radiotherapy：IMRT DT 50Gy/25Fx. Capecitabine: 625mg/m2 bid po d1-5 qw. For patients are double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)，the intial dose of Irinotecan liposomes is 25mg/m2 weekly，for four weeks。 This study stratify cases by the 3+3 rule according to UGT1A1 \* 6 and UGT1A1 \* 28 phenotypes. Three cases were enrolled in each dose group, and if there was no DLT, they were promoted to the next dose group（an increase of 5mg/m2）; If there is 1 case of DLT, 3 cases will be reenrolled in the same dose group. If there is no new occurrence of DLT, it will be promoted to the next dose group. Otherwise, the study will be terminated; If there are 2 cases of DLT, the study will be terminated, and the previous dose group will be the maximum tolerated dose (MTD)."
41453343|NCT02676973|PROCEDURE|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
41113439|NCT02363192|BEHAVIORAL|Pharmacist intervention and pharmacist support|Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
41113440|NCT00181753|DRUG|standard vs. glutamine enteral or parenteral feeding.|Patient in each group will continue on the same diet for \> 3 days before we conduct stable isotope tracer measurements.
41113441|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours of primed constant infusion
41113442|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope study|7 hours of primed constant infusion of stable isotope tracers.
41113443|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours of primed constant stable isotope tracer infusion.
41113444|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours primed constant infusion of stable isotope tracer study
41113445|NCT04783246|BEHAVIORAL|Group Fitness|The group fitness intervention will involve streaming a group fitness class lead by a certified personal trainer. certified personal trainer and include variations of body-weight strength and aerobic exercise activities. Each work out session will be 30 minutes in duration and follow a structure of a warm-up period, alternating strength and aerobic exercises of varying intensity, and a cool-down period. The videos will be streamed to the group by a facilitator over Zoom video conferencing.
41113446|NCT04783246|OTHER|Nutrition education|The nutrition education intervention will involve 45-minute educational sessions involving didactic teaching, interactive goal setting, and a live cooking demonstration. Each session will be taught by a registered dietician who will also be responsible for designing the curriculum schedule.
41113447|NCT04944446|OTHER|Treatment|Myofascial release of various muscle groups Treatment of mobilization of the shoulder joint
41113448|NCT00307463|PROCEDURE|strict volume control policy|strict volume control by UF and dietary salt restriction
41113449|NCT00307463|PROCEDURE|antihypertensive drugs administration|continue antihypertensive medications
41113450|NCT03573999|DRUG|Mannitol|4.6 ml/kg will be administered before dura opening
41113451|NCT03573999|DRUG|NaCl 7.5%|2 ml/kg will be administered before dura opening
41113452|NCT04577014|DRUG|Retifanlimab|"Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)"
41113453|NCT04577014|DRUG|Gemcitabine|"Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
41113454|NCT04577014|DRUG|Docetaxel|"Phase I:~Dose Level 1 - 75 mg/m2 Dose Level 0 - 75 mg/m2 Dose Level -1 - 60 mg/m2 Dose Level -2 - 50 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
41113455|NCT05265559|PROCEDURE|Partial Indirect Restoration|Dental restorative treatment
41113456|NCT02739035|DRUG|Dexamethasone|8 mg of IV dexamethasone immediately before MUA.
41113457|NCT02739035|DRUG|Celecoxib|2 weeks per mouth of celecoxib (200 mg daily)
41113458|NCT04102371|DRUG|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
41113459|NCT04102371|DRUG|Normal Saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
41113460|NCT04102371|DRUG|Plasma-lyte|PL is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide. The pH is 7.4 (6.5 to 8.0).
41113461|NCT03380390|DRUG|Oxymetazoline HCL 1.0% Cream|Oxymetazoline HCl cream 1.0% once daily application
41113462|NCT03380390|DEVICE|Energy-Based Therapy|Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\])
40752545|NCT01396785|DRUG|Placebo|Daily for 14 days
40752546|NCT00502515|DRUG|SSR180575|Oral, once daily dosing
41113463|NCT02964780|PROCEDURE|Gastric bypass surgery|
41113464|NCT02964780|BEHAVIORAL|Conservative weight loss program|
41113465|NCT01094613|DRUG|Delayed Release 6 mercaptopurine|"Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets."
41113466|NCT01094613|DRUG|6 Mercaptopurine|Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
40752547|NCT00502515|DRUG|Placebo|Oral, once daily dosing
40752548|NCT02783937|BIOLOGICAL|Filgrastim|"Each case will have two intervention phases done blindly at random with a wash-out period of 6 months:~Phase A:~Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days.~Phase B:~Injection of saline SC injection twice daily for five consecutive days."
41113467|NCT01719666|PROCEDURE|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
41113468|NCT01719666|PROCEDURE|conventional surgery|conventional surgery: MPFL reconstruction
41113469|NCT06203639|OTHER|UR Caregiver|The UR Caregiver app was informed by previous research and developed in collaboration with caregiver partners. The app utilizes cognitive behavioural principles and is consistent with models of stress and coping. The app consists of seven modules. The app is available on IOS and Googe Play store. In addition to the didactic information provided in the app, worksheets are available in each module to practice the strategy/skill provided.
41113470|NCT06203639|OTHER|CLEAR Dementia Care|A subset of participants will be randomly assigned to use the CLEAR Dementia Care app as part of an active control group. The app consists of features that primarily address care-related needs (as opposed to stress management strategies) allowing for a comparison with the UR Caregiver app. The app was developed by the Northern Health and Social Care Trust (Northern Ireland) and is freely available on both IOS and Google Play stores. The CLEAR Dementia Care app provides users with information about dementia (e.g., the different types of dementia, how dementia affects the brain, and symptoms associated with dementia). The app offers suggestions and alternative approaches to various care-related situations through illustrations/images that caregivers may experience.
41113471|NCT06300996|DEVICE|Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)|Spinal cord stimulation is FDA approved for treatment of pain. We are proposing utilizing the same technology to help restore motor control in people who have declining function due to the progression of SMA. These are 2-4 leads that are FDA-approved.
41113472|NCT05991999|OTHER|Stretching|"Master swimmers will be taught iliopsoas, sternocleidomastoid and pectoralis major stretching exercises as stretching exercises. Participants will stretch daily for 3 repetitions, each stretching for 20 seconds.~Participants will continue their swimming training 2 days a week."
41113473|NCT05991999|OTHER|Training|Participants continued their swimming training 2 days a week.
41113474|NCT01755949|DRUG|Colchicine, 0.6 mg PO BID|Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
41113475|NCT01755949|DRUG|Matching placebo|Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
41113476|NCT03754218|DRUG|Amnion Membrane Powder|This sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.
41113477|NCT03754218|PROCEDURE|SOC Wound Covering|Institutional standard of care wound covering.
41113478|NCT06367816|PROCEDURE|INTELLiVENT|Closed-loop mode of ventilation
41113479|NCT06367816|PROCEDURE|Conventional ventilation|Mode of ventilation
41113480|NCT03749044|OTHER|Patient Educational Tool|This tool is a modified version of the patient educational sheet elaborated and validated by You et al in collaboration with the Preeclampsia Foundation. This patient educational sheet graphically defines preeclampsia and its. A licensing agreement has been obtained from the Preeclampsia Foundation, with the rights to modify the educational tool for this RCT. The SLE-specific educational tool will consist in a sheet displaying the previously developed patient educational form on the recto. However, on the verso of the sheet, SLE-specific information related to the risk of preeclampsia in SLE pregnancies and the estimated efficacy of ASA in reducing preeclampsia risk in women at high risk are displayed.
41113481|NCT00126997|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
41113482|NCT03967626|DEVICE|external cooling with the xxxxx device|external cooling with the xxxxx device
41113483|NCT05790408|DEVICE|Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG)|The Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb during transconjunctival needle revision of trabeculectomy bleb.
41113484|NCT05790408|DEVICE|Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)|The Spectralis Anterior-segment OCT (AS-OCT) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb in the office.
41113485|NCT05845645|DRUG|UCB0599|Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B
41113486|NCT05845645|OTHER|Esomeprazole|Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational medicinal product (NIMP) in this study.
41113487|NCT05845645|OTHER|Placebo|Study participants will receive placebo comparator administered orally in a a pre-specified sequence during the Treatment Period of Part B.
41113488|NCT01199783|DRUG|Daptomycin|Infusion (6 mg/kg/bodyweight) once daily
41113489|NCT01199783|DRUG|Vancomycin|vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
41113490|NCT05752513|PROCEDURE|Late bladder dissection|The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection
41113491|NCT05752513|PROCEDURE|early bladder dissection|The bladder dissection is early as in classic cesarean hysterectomy
41113492|NCT03318406|DEVICE|Bronchoscopic Thermal Vapor Ablation|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
41113493|NCT05520086|DRUG|Single Dose|Single Dose: Administration of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
41113494|NCT05520086|DRUG|Double Dose|Repetead Dose: Administration of 2 doses, separated by 14 days, of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
41113495|NCT03571711|DRUG|Meropenem Injection|Meropenem is administered as prescribed by treating physician
41113496|NCT02566707|DRUG|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
41113497|NCT02566707|DRUG|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
40752549|NCT02783937|DRUG|Saline|Injection of saline SC injection twice daily for five consecutive days
41113498|NCT02566707|DRUG|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
41113499|NCT01755897|PROCEDURE|radical hysterectomy + pelvic lymph node dissection|
41113500|NCT01755897|DRUG|Paclitaxel|135-175 mg/m(2) intravenously (IV) on day 1
41113501|NCT01755897|DRUG|Cisplatin|75 mg/m(2) IV on day 2 and 3
41113502|NCT01755897|DRUG|Cisplatin|35 mg/m(2) IV once a week
41113503|NCT01755897|RADIATION|Pelvic RT|IMRT
41113504|NCT05845528|DEVICE|s-tDCS|- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
41113505|NCT05845528|DEVICE|a- tDCS|- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
41113506|NCT03145480|DRUG|Obinutuzumab|100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
41113507|NCT03145480|DRUG|Ibrutinib|560mg po daily
41113508|NCT03145480|OTHER|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
41113509|NCT05898074|DEVICE|Non-Absorbable Packing (Silastic Splint)|Participant will have silastic splint applied to nasoseptal flap harvest site
41113510|NCT05898074|DEVICE|PuraGel (RADA16) Hydrogel|Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site
41113511|NCT01703897|DEVICE|Manometry and Impedance analysis|
41113512|NCT00393484|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
41113513|NCT00393484|DRUG|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
41113514|NCT00393484|DRUG|Lamivudine|"Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)"
41113515|NCT00393484|DRUG|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
41113516|NCT05870579|DRUG|[68Ga]Ga-NeoB|"\[68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions, at screening.~\[68Ga\]Ga-NeoB will be administered as a single intravenous (i.v.) dose."
41113517|NCT05870579|DRUG|[177Lu]Lu-NeoB|Study participants will receive \[177Lu\]Lu-NeoB once every cycle
41113518|NCT05870579|DRUG|Ribociclib|600 mg once daily (OD) days 1 to 21 every 28 days
41113519|NCT05870579|DRUG|Fulvestrant|500 mg at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and every 28 days thereafter
41113520|NCT05870579|OTHER|Goserelin|For pre/peri-menopausal women only.
41113521|NCT02507336|DRUG|Thalidomide|100-300 mg capsule taken by mouth once daily.
41113522|NCT05991908|DRUG|Fludarabine, busulfan and melphalan|FLudarabine 150mg/m2 + Busulfan 6.4mg.kg + Mel 140mg/m2
41113523|NCT05991908|DRUG|Fludarabine and Busulfan|FLudarabine 150mg/m2 + Busulfan 12.8mg.kg
41113524|NCT01624168|BEHAVIORAL|Anxiety Management Education|written materials on management of anxiety for self-study
41113525|NCT01624168|BEHAVIORAL|10 week tai chi intervention|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
41113526|NCT01624168|BEHAVIORAL|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
41113527|NCT03637231|DIAGNOSTIC_TEST|Ultra low-dose CTAC|All patients undergo two non-contrast enhanced CT scans with standard dose (i.e. 120 kVp), one with 80 kVp and one with 70 kVp.
41113528|NCT01667302|DRUG|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
41113529|NCT03909477|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
41113530|NCT03909477|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
41113531|NCT03909477|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFTs)|Participants will have their lung function evaluated using PFTs
41113532|NCT03909477|DIAGNOSTIC_TEST|Six Minute Walk Test (6MWT)|Participants \>35 years of age will perform the six minute walk test as a measure of exercise capacity
41113533|NCT03909477|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants \<35 will perform cardiopulmonary exercise testing as a measure of exercise capacity
41113534|NCT03909477|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
41113535|NCT03909477|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
41113536|NCT04255888|PROCEDURE|Laterally positioned flap in thick periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
41113537|NCT04255888|PROCEDURE|Laterally positioned flap in thin periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
41113538|NCT06397963|BIOLOGICAL|GT307 injection|GT307 injection to treat solid tumours
41113539|NCT02534311|DRUG|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
41113540|NCT05657496|DRUG|Triamcinolone Acetonide 40 mg/ml Inj, Susp|Prepared in clinic by physician or medical staff
41113541|NCT05657496|BIOLOGICAL|Platelet-rich plasma Inj|Produced from participant's whole blood venous draw of approximately 15 mL. Prepared by centrifuge in clinical office
41113542|NCT01336283|OTHER|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
41113543|NCT01336283|OTHER|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
41113544|NCT01336283|OTHER|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
41113545|NCT03546998|DIAGNOSTIC_TEST|Clinical instrumental examinations|Achalasia patients were periodically submitted to clinical assessment, barium swallow (esophageal diameter and residual barium column were measured), endoscopy. Mucosal esophageal biopsies were taken in order to diagnose dysplasia or epidermoid carcinoma.
41113546|NCT02249988|DRUG|ABX203 therapeutic Hepatitis B vaccine treatment arm|
41113547|NCT02931383|DRUG|Liraglutide 3 mg (Saxenda)|
41113548|NCT02931383|DRUG|Liraglutide 3 mg placebo|
41113549|NCT00012935|BEHAVIORAL|Help with decision making on prostate cancer treatment|
41113550|NCT05999292|DRUG|68Ga-R8760 injection at pre-defined dose levels|PET/CT imaging at predefined timepoints
41113551|NCT05999292|DRUG|68Ga-R8760 injection|PET/CT imaging at a single timepoint
41113552|NCT00390299|BIOLOGICAL|Carcinoembryonic Antigen-Expressing Measles Virus|Given via injection into resection cavity or around tumor bed and/or IT
41113553|NCT00390299|OTHER|Laboratory Biomarker Analysis|Correlative studies
41113554|NCT00390299|PROCEDURE|Therapeutic Conventional Surgery|Undergo en bloc resection
41113555|NCT04065113|PROCEDURE|Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma
41113556|NCT04065113|PROCEDURE|Drainage of Subdural Hematoma|Drainage of subdural hematoma via burrhole or craniotomy
41113557|NCT03182010|DEVICE|Cesarean section incision closure using barbed sutures|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
41113558|NCT03182010|DEVICE|Cesarean section incision closure using conventional sutures|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
41453344|NCT02676973|PROCEDURE|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
41113559|NCT02014766|PROCEDURE|Interscalene block|Ultrasound-guided interscalene block is performed.
41113560|NCT02014766|PROCEDURE|Supraclavicular block|Ultrasound-guided supraclavicular block is performed
41113561|NCT02993588|DRUG|Melatonin|Melatonin 6 mg tablet once daily
41113562|NCT02993588|OTHER|Placebo|one tablet once daily
41113563|NCT05452759|DEVICE|high-flow oxygen therapy device for Severe pneumonia patients with artificial airway|Using NTHF, adjust the MR850 humidifier to invasive automatic gear, the temperature sensor automatically adjusts and maintains the gas temperature at the entrance of the tracheal tube at 37°C according to the feedback temperature, and monitors and maintains SpO2 between 94% and 100%. The monitored pulse oxygen saturation (SpO2) is used to adjust the concentration of the venturi valve and the corresponding oxygen flow rate. At the preset gas flow rate levels of 40L/min, 50L/min and 60L/min, the test pipeline is connected to optimize the breath. The actual gas flow rate value and the gas flow rate loss difference before and after the gas joint (screw joint), and at the corresponding gas flow rate, measure the gas temperature and humidity at the near-patient end of the pipeline.
41113564|NCT05452759|DEVICE|AIRVOTM2 device for Severe pneumonia patients with artificial airway|Use AIRVOTM2 (Fisher \& Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
41453345|NCT02676973|PROCEDURE|Uphold™ LITE|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
41113565|NCT05471414|BEHAVIORAL|Whole-food, Plant-Based Diet|Pre-packaged, plant-based meals (prepared by Plantable) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals using Plantable's assistance.
41113566|NCT05471414|BEHAVIORAL|General Nutritional Counseling|"All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.~Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls."
41113567|NCT00412321|DRUG|CNTO 328|Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6. After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a. Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated. In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
41113568|NCT03824080|DRUG|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
41113569|NCT04028336|OTHER|TITRATION|PEP titration pulmonary opening (PEP-OP) was performed in all patients followed by new LUS and Peso measurement.
41113570|NCT00542113|BEHAVIORAL|DvtProgram ENERGY|11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
41113571|NCT00542113|BEHAVIORAL|DvtProgram ENERGY|6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
41113572|NCT00542113|BEHAVIORAL|DvtProgramENERGY|Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
41113573|NCT02999581|DIETARY_SUPPLEMENT|C4 Extreme, C4 Extreme (without Advantra Z)|
41453346|NCT00548431|DRUG|6-mercaptopurine|Standard dose 25 mg/m\^2/day. Can be increased up to 75 mg/m\^2/day if the myelosuppression is acceptable (ANC\>0.5 T-count \>50)
41113574|NCT05939063|PROCEDURE|LRAMPS|For LRAMPS procedure, Gerota's fascia and perirenal fat capsule are removed, and the procedure is divided into anterior LRAMPS and posterior LRAMPS depending on whether the left adrenal gland is resected. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
41113575|NCT05939063|PROCEDURE|LDP|For LDP procedure, the dissection plane is located behind the fusion fascia. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
41113576|NCT02506257|DRUG|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
41113577|NCT02506257|DRUG|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
41113578|NCT02506257|DRUG|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
41113579|NCT02506257|DRUG|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
41113580|NCT01230047|BEHAVIORAL|Psychoeducational course|Psychoeducational course on mindfulness and lifestyle interventions for depression and anxiety
41113581|NCT01128790|OTHER|Remote ischemic preconditioning|4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
41113582|NCT01128790|OTHER|Sham Control|4 cycles x 5mins blood pressure cuff inflation to 10mmHg
41113583|NCT04358354|DRUG|Irinotecan|Irinotecan 150 mg/m2
41113584|NCT04358354|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2
41113585|NCT04358354|DRUG|5-fluorouracil|5-fluorouracil 400 mg/m2 iv bolus and 2400 mg/m2 civ 46 hours
41113586|NCT00707135|DRUG|Rapamycin|Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
41113587|NCT03702647|DRUG|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
41113588|NCT03702647|DRUG|Normal saline|30mL of normal saline placed in the POEM tunnel
41113589|NCT00014248|DRUG|adenosine triphosphate|
41113590|NCT00014248|PROCEDURE|quality-of-life assessment|
41113591|NCT01790529|PROCEDURE|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)|
41113592|NCT01790529|PROCEDURE|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)|
41113593|NCT00785863|OTHER|Placebo|Placebo IV before placebo infusion
41113594|NCT00785863|DRUG|Remifentanil|placebo IV and remifentanil infusion
41113595|NCT00785863|DRUG|Ketorolac and remifentanil|Ketorolac IV and remifentanil infusion
41113596|NCT00785863|DRUG|Parecoxib and remifentanil|Parecoxib IV and remifentanil infusion
41113597|NCT01736098|OTHER|Energy Flux Exercise Intervention|Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
41113598|NCT03161327|DEVICE|ABI using QuantaFlo™|"Perform Digital ABI:~* Will be performed by the nurse/medical assistant with training to perform this test~* The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement.~* The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes.~* Usually each digit takes about 15 seconds to obtain a waveform~* At the end of 60 seconds, an automated digital ABI will be generated.~Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic.~II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same."
41453347|NCT00731458|DEVICE|Optical coherance tomography ( Cirrus; Stratus)|Non-contact retinal thickness analyzer
41453348|NCT03822130|DRUG|Arterial catheter infusion chemotherapy|Arterial catheter infusion chemotherapy
41113599|NCT02390986|DRUG|LON002|Extension study to provide continuing access to LON002 medication.
41113600|NCT03426839|DIAGNOSTIC_TEST|Coagulation tests|
41113601|NCT05056753|DEVICE|HWBV chair|vibration-actuated, saddle-seat type stool
41113602|NCT02846389|OTHER|Moderate Exercise|Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
41113603|NCT03856099|DRUG|TTAC-0001|"* Investigational product (IP): TTAC-0001~* Treatment groups: 3 dose groups~  * Dose group A : TTAC-0001 16 mg/kg on D1 and D15~ * Dose group B : TTAC-0001 20 mg/kg on D1 and D15~ * Dose group C : TTAC-0001 24 mg/kg on D1 and D15~* Cycle: 4 weeks (28 days per cycle)"
41113604|NCT04263480|DRUG|Carfilzomib + Ibrutinib|"Carfilzomib:~Cycle 1, day 1: 20 mg/m² i.v. Cycle 1, day 8, day 15: 70 mg/m² i.v. Cycle 2 - 12, day 1, day 8, day 15: 70 mg/m² i.v. Cycle 13 - 24, day 1, day 15: 70 mg/m² i.v.~Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
41113605|NCT04263480|DRUG|Ibrutinib|"Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
41113606|NCT04425408|DEVICE|Consecutive trial of two different devices for the treatment of positional sleep apnoea, for 3 nights with each device (positional pillow and vibrating belt).|Patients will be randomly allocated to use either a positional pillow or a vibrating belt for three consecutive nights at home followed by three nights with the other device.
41453349|NCT03822130|DRUG|Sodium Bicarbonate|Arterial catheter infusion Sodium Bicarbonate
41453350|NCT03822130|DRUG|Systemic Chemotherapy|Systemic Chemotherapy
41453351|NCT03822130|DRUG|Oral Chemotherapy|Oral Chemotherapy
41113607|NCT05339893|DEVICE|In Motion Rehabilitation Robot|Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.
40926009|NCT06458075|BEHAVIORAL|CO-LEAD|The investigators will provide clinicians with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill data and the DOSE-Nonadherence-SLE survey, and engage and formulate solutions to adherence barriers together. The study team will provide the clinician intervention training in-person or virtually and will include didactics, demonstration, and practice that include two one-hour sessions one month apart. After training, CO-LEAD clinicians will be encouraged to incorporate the intervention in regular clinic visits with all patients.
41113608|NCT00114244|DRUG|sorafenib tosylate|Given PO
41113609|NCT00114244|DRUG|gemcitabine hydrochloride|Given IV
41113610|NCT00114244|OTHER|laboratory biomarker analysis|Correlative studies
41113611|NCT00427752|PROCEDURE|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
41113612|NCT04505982|OTHER|Data extraction from medical files|Data extraction from medical files
41113613|NCT02492048|DEVICE|Cellutome Epidermal Harvesting System|Cellutome Epidermal Harvesting System
41113614|NCT02492048|PROCEDURE|Split Thickness Skin Graft|Split Thickness Skin Graft
41113615|NCT00159783|DRUG|asenapine|Asenapine, 40 weeks
41113616|NCT00159783|DRUG|Olanzapine|Olanzapine, 40 weeks
41113617|NCT00572078|DRUG|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
41113618|NCT03751150|OTHER|Exercise program|The runners will be asked to perform the training program twice a week. The intervention consist of muscle control and foam rolling exercises for the lower extremities.
41113619|NCT01012388|DEVICE|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
41113620|NCT06139315|DRUG|BI 765845|BI 765845
41113621|NCT06139315|DRUG|Placebo|Placebo
41113622|NCT06124066|DRUG|Mirabegron 50 MG|The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.
41113623|NCT01374893|BEHAVIORAL|Exercise|The intervention group will perform the multi-session per day training program
41113624|NCT01374893|BEHAVIORAL|Control|Usual care
40926010|NCT00782431|BIOLOGICAL|Vero cell derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
40926011|NCT00782431|BIOLOGICAL|Licensed egg-derived, trivalent seasonal influenza vaccine|Single intramuscular injection
40926012|NCT01300533|DRUG|BIND-014|
41113625|NCT00898846|DRUG|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
41113626|NCT04154514|DEVICE|A functional electrical stimulation device for post-stroke rehabilitation|Most of the FDA-approved commercial FES devices deliver therapy that targets specific kinematic impairment in the step cycle (e.g., foot drop). Our device will be unique in that it can stimulate many muscles around multiple joints for a more comprehensive and naturalistic restoration of lower-limb motor functions.
41113627|NCT06271304|DEVICE|Blue blocking eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
41113628|NCT06271304|DEVICE|Low filtration eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
41113629|NCT03152344|PROCEDURE|Timed Up and Go|It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value \>12 seconds).
41113630|NCT04798248|BEHAVIORAL|Momentary Affect Regulation - Safer Sex Intervention (MARSSI)|MARSSI is an individual-level intervention that involves a one-hour manualized session with a sexual reproductive health (SRH) counselor, followed by one-month of daily use of a mobile health app and a final 20-minute booster session with the SRH counselor.
41113631|NCT04798248|BEHAVIORAL|Podcast Health Group|Participants assigned to the Podcast Health Group will listen to \~20 minute podcast episode put out by the Susan G. Komen Foundation about family history of breast cancer; the podcast does not include information related to the outcomes of interest for the study.
41113632|NCT01202955|DRUG|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
41113633|NCT01202955|DRUG|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
41113634|NCT04562636|OTHER|Environmental message|Participants will be randomized to view a set of four messages about the environmental harms of meat production from the Meatless Monday campaign.
40926013|NCT00349700|PROCEDURE|Compression: 2 weeks four layer bandages, then stockings|
40926014|NCT00349700|PROCEDURE|debridement|
40926015|NCT00349700|PROCEDURE|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
40926016|NCT00680719|BEHAVIORAL|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
40926017|NCT00680719|BEHAVIORAL|IBFT|Integrated Behavioral and Family Therapy (IBFT).
40926018|NCT04352153|DRUG|Febuxostat|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
40926019|NCT04352153|DRUG|Uralyt-U|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
40926020|NCT06036602|BIOLOGICAL|cAD3-Sudan Ebolavirus Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
40926021|NCT06036602|OTHER|Placebo|0.9% NaCl solution for injection.
40926022|NCT01993836|DRUG|Total intravenous anesthesia with propofol|
40926023|NCT01993836|DRUG|General anesthesia with isoflurane|
40926024|NCT00813540|BEHAVIORAL|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
40926025|NCT00813540|OTHER|Usual Care|Usual Care
40926026|NCT00493857|DRUG|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
40926027|NCT00493857|DRUG|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
40926028|NCT06370715|DRUG|Insulin Lispro-aabc|Administered SC
40926029|NCT06370715|DRUG|Insulin Glargine|Administered SC
40926030|NCT02192840|PROCEDURE|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
40926031|NCT02266953|BEHAVIORAL|Use of communication tool about diet|The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
40926032|NCT02266953|BEHAVIORAL|Treatment as usual|The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
40926033|NCT05939778|BIOLOGICAL|TH-SC01(Umbilical cord mesenchymal stem cells)|"5+7 principle:~1. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject.~1. If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group.~2. If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step.~2. 7 subjects were included in the second step."
40926034|NCT05895799|OTHER|Tuition from a expert clinical trainer|Each group was initially provided with an online tutorial on the complete physical examination of the cardiovascular system as performed on a standardized patient by the trainer. At the beginning of each session, the trainer performed the examination on a hybrid patient wearing the auscultation vest and provided additional teaching, explanations, and rationale. Following the demonstration, each participant was invited to perform repeated physical examinations in front of their peers with real-time one-to-one feedback from the trainer. After each performance, the participant was encouraged to critique their own performance(s), peers were invited to provide some insights, and the trainer gave some overall feedback. At the end of the session and after each participant had had the opportunity to perform the complete examination at least once, the participants were taken through a range of abnormal signs using the auscultation vest with explanations provided by the trainer.
40926035|NCT02656680|BEHAVIORAL|Continuous Enrollment|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. For this arm, the study team will keep recruitment open for this condition to allow enrollment of new participants through week 8.
40926036|NCT02656680|BEHAVIORAL|Closed Enrollment|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
40926037|NCT04989452|DIAGNOSTIC_TEST|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
41453352|NCT04364763|DRUG|RBT-9 (90 mg)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
41113635|NCT04562636|OTHER|Health message|Participants will be randomized to view a set of four messages about the health harms of meat consumption from the Meatless Monday campaign.
41113636|NCT04562636|OTHER|Neutral Message|Participants will be randomized to view a set of four messages about checking their credit score.
40926038|NCT04140032|BEHAVIORAL|Multi-level preschool obesity control intervention|The multi-level intervention is a preschool-based program that integrates healthy nutrition and physical activity policies and practices into preschool operations via the Sesame Street Healthy Habits for Life curriculum. In addition to the curriculum, the intervention includes coaching sessions to enhance teacher lesson planning to routinely include nutrition and physical activity; as well as assist preschool site directors with implementing policy changes and parent engagement sessions.
40926039|NCT01428947|PROCEDURE|Arterial approach|Randomization to right radial or femoral approach
40926040|NCT04661254|OTHER|Lymphapheresis|- From the blood product of lymphapheresis: Autologous naïve regulatory CD45RA+CD4+CD25+FoxP3+ T lymphocytes (Tregs) selected and amplified ex vivo; obtained by selection and sorting of CD4+CD25 +CD127lowCD45RA+ cells, derived from lymphapheresis and amplified ex vivo for 10 +/- 1 days, under cGMP condition in the presence of IL2 and Rapamycin
40926041|NCT05530018|BEHAVIORAL|Brief contact intervention|The brief contact intervention (BCI) will send out text messages to the participants. The text messages will include caring messages, reminders of appointments, and a link to a web page. The web page is anticipated to include safety planning, volitional helpsheet, and resources information. The text messages are anticipated to send out to the participants on a weekly base for 6 weeks in a row, and then change to monthly reminders. The monthly reminders are anticipated to include caring messages, reminders of appointments, and invitations to encourage the participants to click the previous web links again. The monthly reminders are anticipated to send out to the participants three times in a row. In the final reminder, the participants will be told that this intervention is going to end. In total, the participants will receive 9 texts within 5 months.
40926042|NCT01642875|OTHER|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
40926043|NCT01642875|OTHER|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
40926044|NCT02396160|DIETARY_SUPPLEMENT|Urox|Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
40926045|NCT02396160|OTHER|Placebo|Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
40926046|NCT00411580|BIOLOGICAL|CAD106|
40926047|NCT00411580|DRUG|Placebo|
40926048|NCT03920904|OTHER|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
40926049|NCT02990247|DEVICE|anharmonic morphological analysis of the respiratory signals (AMARS)|
40926050|NCT02310087|DIETARY_SUPPLEMENT|astaxanthin with vitamin E|Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
40926051|NCT02310087|OTHER|Placebo|Four tablets of placebo daily, taken at once. Continuously for three months.
40926052|NCT04183660|DEVICE|MOBYBOX System|extracorporeal cardiopulmonary support
40926053|NCT02296138|DRUG|olodaterol|fixed dose combination
40926054|NCT02296138|DRUG|tiotropium|fixed dose combination
40926055|NCT02296138|DRUG|tiotropium|
40926056|NCT05099224|BEHAVIORAL|Mindfulness meditation|similar to the information included in arm/group descriptions
40926057|NCT04801940|DRUG|Apixaban|Apixaban 2.5mg orally twice daily for 14 days.
40926058|NCT04801940|DRUG|Atorvastatin|Atorvastatin 40mg orally once daily for 12 months.
40926059|NCT04821362|DEVICE|Ultrasound group|In the ultrasound group, the nurses will insert the cannulas to the peripheral veins as horizontally and longitudinally with the linear probe.
40926060|NCT04821362|DEVICE|Near Infrared Device Group|In the near infrared device group, the nurses will insert the cannulas to the peripheral veins with AccuVein AV 400.
40926061|NCT01613170|DRUG|Toviaz|Toviaz 4mg daily
40926062|NCT01613170|DRUG|Premarin|Premarin cream 1 g per vagina twice weekly
40926063|NCT01613170|DRUG|Placebo cream|Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
40926064|NCT00320957|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
40926065|NCT05012670|DRUG|[14C]-Paxalisib Capsule|Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
40926066|NCT05599477|DEVICE|Endoscopic sutured gastroplasty with endomina|"The endomina is is used to perform endoscopic sutured gastroplasty. Two guidewires are introduced via an upper GI endoscopy down to the duodenum. The endomina system is introduced and the endoscope is inserted and fixed to the system. Next a needle preloaded with suture is introduced into the platform. The stomach wall is grasped with a forceps and pulled back. The needle is pushed through the wall, and a first tag is released. The needle is retracted, the first plicature is released and a second plicature is made with the same needle at the opposite wall. Then the pretied knot is grasped and tightened until both plicatures are firmly apposed. The same procedure is repeated along the great curvature from the incisura to the upper body.~The procedure will include the placement of 6-9 sutures. The first suture is done at the level of the incisura, at the lower part of the greater curvature. The following stitches are placed along the body of the stomach"
41113637|NCT02808039|OTHER|Platelet reactivity testing|assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
41113638|NCT00316641|DRUG|Lipid-lowing Tea|
41113639|NCT05105646|PROCEDURE|Knee Arthroplasty, knee revision arthoplasty|Primary knee arthroplasty (e.g., total, unicondylar and patellofemoral)
41113640|NCT04054635|DEVICE|Silver diamine fluoride|Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
41113641|NCT05249036|PROCEDURE|Ultrasound guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using real-time ultrasound guidance
41113642|NCT05249036|PROCEDURE|Palpation guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using palpation technique (standard-of-care)
41113643|NCT01544270|DIETARY_SUPPLEMENT|Yogurt-like snacks|twice a day 120 g for four weeks
41113644|NCT05919017|DRUG|Naltrexone implant|Naltrexone implant
41113645|NCT05919017|DRUG|Placebo|Placebo
41113646|NCT03319680|OTHER|Citrate dialysate|Compare the effect of citrate dialysate with acetate dialysate
41113647|NCT02034968|DRUG|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
41113648|NCT02448446|DRUG|ranibizumab 0.3mg|intravitreally administered
41113649|NCT03491215|DRUG|Ruxolitinib|Ruxolitinib taken orally (5mg tablets) or oral pediatric formulation and dosage based on age group
41113650|NCT01422616|DRUG|Low-dose rtPA|Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus \[maximum bolus dose of 9mg\] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
41113651|NCT01422616|DRUG|Standard-dose rtPA|Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
41113652|NCT01422616|OTHER|Intensive blood pressure (BP) lowering|"Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
41113653|NCT01422616|OTHER|BP management policies|"Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
41113654|NCT01964937|BIOLOGICAL|DNA-HIV-PT123|The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.
41113655|NCT01964937|BIOLOGICAL|NYVAC-HIV-PT1|The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10\^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10\^8 PFU.
41113656|NCT01964937|BIOLOGICAL|NYVAC-HIV-PT4|The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10\^6 PFU IM, for a planned maximum dose of 1.1×10\^7 PFU.
41113657|NCT01964937|BIOLOGICAL|AIDSVAX B/E®|The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.
41113658|NCT01964937|BIOLOGICAL|Placebo vaccine|The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
41113659|NCT03352778|RADIATION|IMRT|66Gy by intensity-modulated radiotherapy
41113660|NCT03352778|RADIATION|2DRT|66Gy by 2-dimensional radiotherapy
41113661|NCT03655938|PROCEDURE|Piezocision combined minimally invasive alveolar bone regeneration|The piezocision surgery was performed two weeks after orthodontic appliance placement. The patients received local anesthesia in mandibular arch and vertical interproximal incisions were made below the interdental papillae in the midline, from the mesial aspect of each canine and in between each of the posterior lower teeth. The periostium was then released in order to create two subperiotal envelopes connecting the vertical incisions together. Thereafter, corticotomies were performed in the region of the incisions with a piezotome (Acteon, Merignac, France) and the envelopes were filled with a beta tricalcium phosphate, a resorbable biomaterial in order to thicken the buccal bone plate. Resorbable 5-0 sutures were used to close the flaps. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
41113662|NCT02315469|OTHER|Comprehensive Geriatric Assessment|Complete pre-operative geriatric assessment
41113663|NCT02315469|OTHER|Questionnaire Administration|Ancillary studies
41113664|NCT00842049|DEVICE|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
41113665|NCT00842049|OTHER|No lumbar drain|No lumbar drain
41113666|NCT02272452|DEVICE|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
41113667|NCT00149838|PROCEDURE|Prefrontal rTMS|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
41113668|NCT00149838|DRUG|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
41113669|NCT00149838|PROCEDURE|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
41113670|NCT00092885|DRUG|MK0476, montelukast sodium|
41113671|NCT00092885|DRUG|Comparator: placebo|
41113672|NCT03233919|DEVICE|comprehensive remote ischaemic conditioning|"comprehensive remote ischaemic conditioning will be induced using an automated RIC device: Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
41113673|NCT06492512|DRUG|daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill daily
41113674|NCT06492512|DRUG|alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill every other day
40926067|NCT03415386|DRUG|Combination of antiplatelet drugs and anticoagulants for at least one month|Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
41113675|NCT01803555|DRUG|Budesonide/Formoterol SPIROMAX®|BF Spiromax will be administered per dose and schedule specified in the arm.
41113676|NCT01803555|DRUG|SYMBICORT® TURBOHALER®|Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
41113677|NCT01803555|DRUG|SYMBICORT placebo|SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
41113678|NCT01803555|DRUG|SPIROMAX Placebo|SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
41113679|NCT05948956|DIETARY_SUPPLEMENT|Ketone Ester Beverage|Participants will consume ketone ester (KE) beverage, consisting of 2 scoops (=25 g C8-KE) of Juvenescence Cognitive Switch ™ and electrolyte solution diluted in water, before each of 5 1-hour sessions of aerobic exercise.
41113680|NCT05948956|DIETARY_SUPPLEMENT|Electrolyte Beverage|Participants will consume an electrolyte solution diluted in water, before each of 5 1-hour sessions of aerobic exercise.
41113681|NCT05948956|BEHAVIORAL|Cycling Intervention|"Five 1-hour sessions of cycling on the ergometer over a 2-week period. Sessions will consist of a 10 min warm up followed by 8 intervals consisting of 3 min fast cycling at 80-90 rpm followed by 2 min of slow cycling at ≤60rpm, followed by a 10-minute cool-down."
41113682|NCT03348371|OTHER|Ethanol|The intervention is two different administrationforms of ethanol, orally and i.v.
41113683|NCT03002805|DRUG|CBT-1®|"CBT-1®, oral, on days 1-7 of each cycle 21-day cycle. Participants will be assigned to dose level of CBT-1®:~Dose level 1 - 50 mg/m2/day Dose level 2 - 100 mg/m2/day Dose level 3 - 150 mg/m2/day Dose level 4 - 200 mg/m2/day Dose level 5 - 250 mg/m2/day Dose level 6 - 300 mg/m2/day doxorubicin, 37.5 mg/m2, IV, on days 5 and 6 of each cycle Study treatment discontinued after 450 mg/m2 lifetime cumulative dose of doxorubicin reached or after 4-5 cycles completed."
41113684|NCT05583110|DRUG|Tucatinib|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
41113685|NCT05583110|DRUG|Trastuzumab|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
41453353|NCT04364763|DRUG|0.9% sodium chloride (normal saline)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
41453354|NCT01051349|BIOLOGICAL|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
41453355|NCT01051349|BIOLOGICAL|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
40926068|NCT00057980|DRUG|celecoxib|
40926069|NCT00057980|DRUG|epirubicin hydrochloride|
40926070|NCT05555173|DEVICE|Buzzy|Buzzy is a small vibrating bee with ice-pack wings.
41113686|NCT05583110|DRUG|Vinorelbine|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
41113687|NCT00131066|OTHER|Follow up from previous treatment with MEDI-507|There will be no investigational drugs administered under this protocol.
41113688|NCT02423291|DRUG|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
41113689|NCT00006327|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
41113690|NCT06131385|DRUG|intravenous thrombolysis|Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.
41113691|NCT05440981|DEVICE|iTind device|Cystoscopy will be performed to assess the anatomy of the bladder and prostate. The iTind device would be inserted under visual guidance into the bladder. The device will then be deployed and under visual guidance, it will be positioned at the prostatic lumen. After confirming the position of the device, cystoscopy will be withdrawn and the position will be finished.
41113692|NCT02354885|DRUG|Tranexamic Acid|Coagulation Management / Efficiency
41113693|NCT04853602|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses. In addition to priming anti-tumor immunity in immune checkpoint inhibitor (ICI)-naïve patients, this could re-sensitize patients with primary or secondary ICI clinical resistance."
41113694|NCT06552260|DRUG|Troriluzole|Tripeptide prodrug of Riluzole, 100 mg capsule, taken orally per protocol.
41113695|NCT04525170|DEVICE|HPT treatment|
41113696|NCT04525170|DEVICE|untreated|
41113697|NCT01694823|DRUG|CS-ACI|"Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）"
41113698|NCT05819099|DIAGNOSTIC_TEST|An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning|This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.
41113699|NCT03957798|BEHAVIORAL|RecoveryWarrior 2.0|"RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer. All games made use of whole-body motion detection and the same voice-recognition feature. Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia. Voice features consisted of recognition of the refusal phrase I'm Clean Players could say or shout I'm Clean in order to gain additional strength for their game play avatar. All game art was created in a hyperrealistic, idealized, heroic style."
41113700|NCT06552624|DRUG|Magaldrate|A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
41113701|NCT06552624|DRUG|Magaldrate|A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
41113702|NCT05552443|DRUG|Hydromorphone 2.5 mcg/kg|2.5 mcg/kg intrathecal
41113703|NCT05552443|DRUG|Hydromorphone 2.75 mcg/kg|2.75 mcg/kg intrathecal
41113704|NCT05552443|DRUG|Hydromorphone 3 mcg/kg|3 mcg/kg intrathecal
41113705|NCT05552443|DRUG|Hydromorphone 3.25 mcg/kg|3.25 mcg/kg intrathecal
41113706|NCT05552443|DRUG|Hydromorphone 3.5 mcg/kg|3.5 mcg/kg intrathecal
41113707|NCT05552443|DRUG|Hydromorphone 4 mcg/kg|4 mcg/kg intrathecal
41113708|NCT05552443|DRUG|Hydromorphone 4.5 mcg/kg|4.5 mcg/kg intrathecal
41113709|NCT05552443|DRUG|Hydromorphone 5 mcg/kg|5 mcg/kg intrathecal
41113710|NCT04102462|DRUG|BI 764198|Capsules
41113711|NCT04102462|DRUG|Matching placebo|Capsules
41113712|NCT00232349|DRUG|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
41113713|NCT02052375|DRUG|ASP2408|subcutaneous injection
41113714|NCT02052375|DRUG|Placebo|subcutaneous injection
41113715|NCT05501249|BEHAVIORAL|Aquatic Integrated Cognitive Motor Training|Aquatic exercise class with focus on cognitive and physical exercise
41113716|NCT00625937|DRUG|cisplatin|
41113717|NCT00625937|DRUG|docetaxel|
41113718|NCT00625937|DRUG|tegafur-gimeracil-oteracil potassium|
41113719|NCT00625937|RADIATION|radiation therapy|
41113720|NCT03101410|BEHAVIORAL|Gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
41113721|NCT03101410|BEHAVIORAL|Gluten free|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
41113722|NCT05892055|OTHER|Procedure|All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.
41113723|NCT05516654|DIAGNOSTIC_TEST|Routine bacteriological cultures|culture of different samples on different culture media as nutrient agar, blood agar, MacConkey agar, EMB agar, TSI
41113724|NCT05516654|DIAGNOSTIC_TEST|Identification of the organism and antibiotic sensitivity will be done by VITEK II|Automated identification of the organism and antibiotic sensitivity will be done by VITEK II
41113725|NCT05516654|DIAGNOSTIC_TEST|Detection of biofilm formation|Detection of Biofilm formation to the collected organism by tissue culture plate method.
41113726|NCT05516654|DIAGNOSTIC_TEST|Molecular detection by PCR|Molecular detection of Type VI Secretion System genes, capsular serotyping( k1, k2), and FimH genes by PCR.
41113727|NCT01852526|DEVICE|Experimental: hybrid system|The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
41113728|NCT01852526|DEVICE|Active Comparator: Plif|monosegmental PLIF
41113729|NCT06242041|DRUG|sodium zirconium cyclic silicate|On the non-dialysis day, the drug was given to patients in the treatment group, four times a week, starting from 5g/day each time, and the blood potassium before dialysis was maintained at 4.0-5.0mmol/L, which could be adjusted at 10g/week each time, and the highest dose could be increased to 80g/ week.
41113730|NCT04064424|OTHER|Prevention video advertisement|Skin Cancer Prevention videos
41113731|NCT04064424|OTHER|Prevention images for advertisement|Skin Cancer Prevention images
41113732|NCT04064424|OTHER|No Advertisement|No skin cancer prevention videos or images were advertised.
41113733|NCT05766969|DRUG|CBD/PEA|A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
41113734|NCT05766969|DRUG|Placebo|An inactive compound.
41113735|NCT06127836|PROCEDURE|ICG guided sentinel lymph node biopsy|The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only. Once the surgeon has identified the SLN in this way, he or she will be unblinded to the results of the lymphoscintigraphy and will use the results of preoperative imaging and an intraoperative gamma counter to confirm the SLNs.
41113736|NCT02957136|DEVICE|Rapid respiratory pathogen nucleic acid amplification test|Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
41113737|NCT06002945|OTHER|Blood sample|Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood
41113738|NCT03091010|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days
41113739|NCT03091010|DRUG|Steroids|Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
41113740|NCT05717751|PROCEDURE|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
41113741|NCT02026778|DRUG|ondansetron|"The ondansetron group is given placebo (pyridoxin) instead of betahistine.~The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
41113742|NCT02026778|DRUG|ondansetron-betahistine|"The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.~The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
41113743|NCT04677322|DRUG|Adult patients diagnosed and treated for high blood pressure|Educational program interventions conducted by primary care staff to encourage adherence to a low-sodium diet consisting of direct action on the patient and provision of educational materials will be assessed. Compliance and follow-up of the low sodium diet will be done by monitoring the sodium in urine in the target population, selected according to the selection criteria described in the protocol.
41113744|NCT02048592|DIETARY_SUPPLEMENT|Impact-Nutridrink|"IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support \|(Nutridrink) for another 8 weeks."
41113745|NCT02048592|DIETARY_SUPPLEMENT|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
41113746|NCT06112977|PROCEDURE|Prepectoral implant-based immediate breast reconstruction|Prepectoral implant based breast reconstruction is an immediate breast reconstruction whereby a fixed volume implant or expander is placed on top of the chest wall muscle (Pectoralis Major) to reconstruct the breast after mastectomy.
41113747|NCT06450730|BEHAVIORAL|Cognitive-Behavioral Therapy: face-to-face + app|"This group will receive three 1-hour face-to-face CBT sessions (1,3,8). Participants will be involved in psychoeducation and practical activities related to psychological variables crucial for the adequate management of the disease (emotion regulation, self-efficacy, psychological flexibility, decision-making, etc.). These activities will include role-playing, discussions, and assignments to highlight the importance of emotions, thoughts, and healthy behaviors in managing diabetes and and their impact on the quality of life.~For the online sessions, an app will be developed to complement the face-to-face intervention. Participants will engage in 5-weeks of exercises with weekly activities related to the intervention content (2,5,6,7). The structure of the activities will mirror that of the face-to-face sessions and will include tasks, self-report instruments, reinforcement and activity monitoring. In addition, the app will incoportate multiple resources (texts, slides, videos)."
41113748|NCT03354039|DRUG|Tamoxifen|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.
41113749|NCT03354039|DRUG|Matching placebo|Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.
41113750|NCT02914522|DRUG|Filgotinib|Tablet(s) administered orally once daily
41113751|NCT02914522|DRUG|PTM filgotinib|Tablet(s) administered orally once daily
41113752|NCT01071993|DRUG|placebo|pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
41113753|NCT01071993|DRUG|atorvastatin|pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
41113754|NCT03587168|OTHER|the timed 360° turn test|Turning ability is assessed by using the timed 360° turn test.
41113755|NCT03587168|OTHER|Berg Balance Scale|Functional balance is assessed by using the Berg Balance Scale.
41113756|NCT03587168|OTHER|Four Square Step Test|The Four Square Step Test measures dynamic balance.
41113757|NCT03587168|OTHER|Functional Reach Test|The Functional Reach Test assesses limits of stability.
41113758|NCT03587168|OTHER|Trunk Impairment Scale|Trunk performance is assessed by using the trunk impairment scale.
41113759|NCT03587168|OTHER|Timed Up and Go Test|Functional mobility is assessed by using the timed up and go test.
41113760|NCT03587168|OTHER|Hoehn and Yahr Scale|Disease stage is assessed by the Hoehn and Yahr Scale.
41113761|NCT03587168|OTHER|Unified Parkinson's Disease Rating Scale|The Unified Parkinson's Disease Rating Scale assesses disease severity.
41113762|NCT03178110|BEHAVIORAL|Physical therapy and dynasplint|Participants will receive a session of 30-45 minutes of manual therapy two times per week, for eight weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased.
41113763|NCT03069313|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
41113764|NCT00696280|BEHAVIORAL|Functional Living Index - Emesis|
41113765|NCT00033163|DRUG|Adefovir dipivoxil|
41113766|NCT00033163|DRUG|Tenofovir disoproxil fumarate|
41113767|NCT04852302|BEHAVIORAL|CALM Therapy|The CALM intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients.
41113768|NCT03404583|BEHAVIORAL|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
41113769|NCT03071653|PROCEDURE|Left Cardiac Sympathetic Denervation (LCSD)|The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
41113770|NCT03071653|OTHER|Optimal Medical Therapy|"All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~1. A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~2. A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~3. A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~4. The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician"
41113771|NCT01944319|DRUG|Routine meropenem therapy|Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
41113772|NCT01944319|DRUG|Meropenem therapy based on a PPK and PD model|Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
41113773|NCT04013646|DRUG|Umbilical cord blood infusion|The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
41113774|NCT04013646|DRUG|Erythropoietin injection|Recombinant human erythropoietin is used and is administered intravenously at a maximum of 5 times at a rate of 500 IU / kg 2 times/week after cord blood peripheral blood infusion, calculated as the dose per body weight. Or subcutaneous administration if intravenous administration is not possible. Store in a sealed container at 2-8 °C in the refrigerator before dosing. Erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
41113775|NCT04013646|DRUG|Placebo umbilical cord blood infusion|Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
41113776|NCT04013646|DRUG|Placebo erythropoietin injection|Placebo erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
41113777|NCT04013646|PROCEDURE|Active rehabilitation|Physical therapy and occupational therapy are performed daily.
41113778|NCT06404710|BEHAVIORAL|Exercise|Participants in this group will be given a gradual muscle relaxation exercise.
41113779|NCT05499559|BEHAVIORAL|Joint Academy digital treatment|The Joint Academy® (www.jointacademy.com) program for people with hand OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons, possibility for a social chat group with other patients and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three months.
41113780|NCT04364594|DIAGNOSTIC_TEST|conjunctival swab|analysis of conjunctival cells (real time PCR) collected by conjunctival swabs in both eyes
41113781|NCT00288392|DRUG|Soluble beta-1,3/1,6-glucan|
41113782|NCT04086966|DRUG|[68Ga]PSMA-PET/MRI or PET/CT|\[68Ga\]PSMA-PET/MRI or PET/CT
41113783|NCT06277401|OTHER|Neuromuscular training for the knee|The exercise programme includes exercises identified in literature to target muscles around the knee.
41113784|NCT06277401|OTHER|High-load strength training for the knee|The exercise programme includes exercises identified in literature to target muscles around the knee.
41113785|NCT04353674|DEVICE|Control group|Patients randomized into this group will receive standard of care for COVID-19 infection
41113786|NCT04353674|DEVICE|SLEDD with a L-MOD|Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
41113787|NCT01907789|OTHER|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
41113788|NCT01907789|PROCEDURE|Prophylactic Salpingectomy with Delayed Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
41113789|NCT01907789|PROCEDURE|Risk-Reducing Salpingo-Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
41113790|NCT01907789|BEHAVIORAL|Questionnaire|"Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery."
41453356|NCT05972590|OTHER|Biological samples collection (blood + feces)|Blood + stools samples will be collected from each volunteer
41453357|NCT01873391|PROCEDURE|Diagnostic hysteroscopy|
41453358|NCT05393401|DEVICE|VOP1k|Photoplethysmographic records
40926071|NCT05895916|BEHAVIORAL|High-volume road cycling|1,144 km of road cycling performed on seven consecutive days with an increase in energy intake to maintain a stable body weight
40926072|NCT00348933|DRUG|Betaine|100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
40926073|NCT00348933|DRUG|Creatine|200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
40926074|NCT00348933|DRUG|Metafolin|0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
40926075|NCT00348933|DRUG|Vitamin B12|1 mg by mouth per day for all weights and ages
40926076|NCT01726660|DEVICE|IMT Robotic Arm therapy|Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
40926077|NCT01811667|DRUG|Sirolimus|
40926078|NCT05631678|DRUG|Rifampicin; ASK120067|Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
40926079|NCT05631678|DRUG|ASK120067;itraconazole|Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
40926080|NCT02194257|DRUG|[14C]-cyclohexane ambroxol oral solution|
40926081|NCT02194257|DRUG|[14C]-benzyl ambroxol oral solution|
40926082|NCT02194257|DRUG|Ambroxol lozenge|
40926083|NCT00476567|OTHER|standard|standard antenatal care
40926084|NCT00476567|BEHAVIORAL|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
41453359|NCT01540344|PROCEDURE|CRS|complete macroscopic cytoreduction (CC-0/1)
40926085|NCT03691740|DEVICE|Ocular light|A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
40926086|NCT06515535|DRUG|Topical tranexamic acid|Topical tranexamic acid will be applied after placental delivery on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%
40926087|NCT06515535|DRUG|Intravenous tranexamic acid|Intravenous tranexamic acid will be given in the form of an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.
40926088|NCT01260675|DRUG|Buprenorphine HCl/Naloxone HCl|
40926089|NCT00252941|DEVICE|Memokath 028SW Urethral Stent|
40926090|NCT00207324|DEVICE|Silver Leaf Dressing|
40926091|NCT03991546|BEHAVIORAL|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot|Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
40926092|NCT00169858|BIOLOGICAL|Engerix-B|10 mkg per dose; 3 doses according to 0, 1, 6 month schedule; booster doses 5, 10 or 15 years post-primary vaccination.
40926093|NCT02969408|DRUG|Albuterol Sulfate|Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
40926094|NCT05946434|OTHER|Kinesio Tape Group|"Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end kinesio taping will be performed at knee joint for inhibition.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28."
40926095|NCT05946434|OTHER|Rigid Tape Group|"Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end rigid tape will be applied on knee joint to provide stability.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28"
40926096|NCT05170776|OTHER|Pilates and postural correction exercise|"ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1 postural correction exercise~1-Strengthening deep cervical flexors 2-Stretching cervical extensors 3- Strengthen shoulder retractors 4-Unilateral and bilateral pectoralis stretch"
41113791|NCT01907789|PROCEDURE|Transvaginal Ultrasound|"Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline."
41113792|NCT01907789|BEHAVIORAL|Phone Call|"Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly."
41113793|NCT01948960|DRUG|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
41113794|NCT03573284|DIAGNOSTIC_TEST|fractional exhaled nitric oxide(FeNO)|FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
41113795|NCT03573284|DIAGNOSTIC_TEST|impulse oscillometry(IOS)|The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
41113796|NCT00570219|DRUG|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
40926097|NCT05170776|OTHER|Pilates exercises|"ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1"
41113797|NCT06318104|DRUG|Tegoprazan|Tegoprazan 50 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
41113798|NCT06318104|DRUG|Esomeprazole 40mg|Esomeprazole 40 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
41113799|NCT04831190|BEHAVIORAL|Tailored Exercise Intervention|The exercise program to be implemented for neuro-oncology patients will combine aerobic, resistance, balance, and flexibility exercises delivered in one-to-one setting (i.e., personal training) twice per week, for 12 weeks. Based on needs and preferences, participants will have the option to join a circuit-type group class once per week in place of one of their personal training sessions. During COVID-19, all sessions will be delivered remotely. If facilities are open and deemed safe for cancer patients, participants will have the option to attend an in-person session, integrated in the community. Whether delivered in-class or remotely, the intervention will follow exercise progression principles (i.e., frequency, intensity, time, type, overload, and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs, with aims of promoting wellness and physical function. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
41113800|NCT00119951|BEHAVIORAL|Participation on the ACOR Listserv|
41113801|NCT03655626|OTHER|Sepsis Watch|The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
41113802|NCT03547479|BEHAVIORAL|VDOT|In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.
41113803|NCT03547479|BEHAVIORAL|VDOT + mobile money|The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
41113804|NCT02245581|PROCEDURE|SVV-guided fluid management|
41113805|NCT02245581|PROCEDURE|CVP-guided fluid management|
41113806|NCT05172752|OTHER|Citizen Scientist Training Program|Citizen Scientist Training Program Participants is a three year training and in-home sampling program for disinfection byproducts. Participants will be trained and assessed based on their experience in the training program.
41113807|NCT05172752|OTHER|Stakeholder Consultation Core Program|Stakeholder Consultation Core Program Participants is a five year assessments where participants will participate in quarterly meetings and deliberative activities related to disinfection byproducts. Participants will be assessed based on their experience in the program.
41113808|NCT03201549|DIETARY_SUPPLEMENT|oral fructose challenge|Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
41113809|NCT05623007|DIETARY_SUPPLEMENT|Probiotics|Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)
41113810|NCT05623007|BEHAVIORAL|Counselling on healthy eating, physical activity, and psychosocial stimulation|Counselling on healthy eating, physical activity, and psychosocial stimulation.
40926098|NCT05170776|OTHER|postural correction exercises|"postural correction exercise in the form of :~1. Strengthening deep cervical flexors through chin tucks,~2. Stretching cervical extensors through a chin drop~3. Strengthen shoulder retractors~4. Unilateral and bilateral pectoralis stretch alternating each two-week period."
40926099|NCT04544215|BIOLOGICAL|Dosage 1 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (8.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
40926100|NCT04544215|BIOLOGICAL|Dosage 2 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (16.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
40926101|NCT04544215|BIOLOGICAL|No MPCs-derived exosomes|No aerosol inhalation of MPCs-derived exosomes
40926102|NCT00499057|RADIATION|interstitial high dose-rate brachytherapy, PBI|Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
40926103|NCT00965965|BEHAVIORAL|New colorectal cancer screening patient education document|The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.
41113811|NCT05623007|DIETARY_SUPPLEMENT|Placebo probiotics|Maltodextrin
41113812|NCT00711217|OTHER|Medical Food|twice daily
41113813|NCT00711217|OTHER|Drink mix calorically similar to experimental product|twice daily
41113814|NCT01301469|DRUG|6% HES 130/0.42 in plasma adapted Ringer's solution|60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)
41113815|NCT01301469|DRUG|6% HES 130/0.4 in a saline solution|60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
40926104|NCT00965965|BEHAVIORAL|Traditional colorectal cancer screening education document|The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
40926105|NCT00608946|DIETARY_SUPPLEMENT|copper|intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
40926106|NCT00608946|DIETARY_SUPPLEMENT|placebo|placebo
40926107|NCT02506985|DRUG|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
40926108|NCT02506985|DRUG|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
40926109|NCT00232869|DEVICE|drug-eluting stent|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
40926110|NCT00232869|DEVICE|bare-metal stent|SMART™ bare-metal stent
40926111|NCT05661747|DEVICE|Vivos Grow/Vivos Way Device|Children already using the device will be monitored to determined whether it improves symptoms of SDB
40926112|NCT03027284|DRUG|Merestinib|Administered orally
40926113|NCT03027284|DRUG|Cisplatin|Administered IV
40926114|NCT03027284|DRUG|Gemcitabine|Administered IV
40926115|NCT04098055|DEVICE|Custom-Made Foot Orthoses|The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.
41113816|NCT01899027|DRUG|Rosuvastatin|Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
41113817|NCT01899027|DRUG|Placebo|Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
41113818|NCT01385384|DEVICE|NeuRx RA/4 diaphragmatic pacemaker|"Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.~The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.~Sites that provide the optimal response (greater region and magnitude) are noted.~Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed."
41113819|NCT02557542|OTHER|One Stop Vein Clinic|Same day diagnosis and treatment
41113820|NCT02557542|DEVICE|Radiofrequency ablation|Venous ablation
41113821|NCT02557542|DEVICE|Endovenous laser ablation|Venous ablation
40926116|NCT04098055|DEVICE|Placebo|The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
40926117|NCT02407652|BEHAVIORAL|Cognitive Control Training|10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
40926118|NCT02407652|BEHAVIORAL|Low Cognitive Load Training|10 low cognitive load sessions, 400 trials each
40926119|NCT02204761|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam re-irradiation therapy
40926120|NCT03603171|DIAGNOSTIC_TEST|DM1-ActivC|A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)
40926121|NCT03603171|DIAGNOSTIC_TEST|R-PAct|A Rasch-built Pompe-specific activity scale.
40926122|NCT03603171|DIAGNOSTIC_TEST|Beck depression inventory|A self-reported depression inventory administered verbally or self administered.
41113822|NCT02557542|DRUG|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
41113823|NCT04663464|COMBINATION_PRODUCT|abaloparatide-sMTS|Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
41113824|NCT04663464|COMBINATION_PRODUCT|abaloparatide-SC|Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen
41113825|NCT02350842|DEVICE|triple-site biventricular pacing with peri-operative echo guidance|placement of the third lead by peri-operative echo guidance.
41113826|NCT02350842|DEVICE|standard biventricular pacing|standard biventricular pacing without optimization by echo guidance
41113827|NCT02013830|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
41113828|NCT02013830|DRUG|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
41113829|NCT03688659|DRUG|Vancomycin and gentamycin|intravenous
41113830|NCT06448598|OTHER|Exercise|The exercise protocol involved twice-weekly sessions, with aerobic exercises performed at 70% of the maximum heart rate achieved during the step test, and resistance exercises at 60% of 1RM. Participants self-selected their exercise timing, either intradialytic (during HDF sessions) or interdialytic (on non-dialysis days). For the intradialytic group, exercise was seamlessly integrated into the HDF session, excluding the initial and final two hours of dialysis.
41113831|NCT00329251|BIOLOGICAL|Hepatitis A|
41113832|NCT00329251|BIOLOGICAL|Hepatitis B|
41113833|NCT00329251|BIOLOGICAL|Influenza|
41113834|NCT00329251|BIOLOGICAL|Pneumococcal|
41113835|NCT00329251|BIOLOGICAL|Tetanus-diphteria|
41113836|NCT00329251|BIOLOGICAL|Varicella|
41113837|NCT00329251|BIOLOGICAL|Measles-Mumps-Rubella|
41113838|NCT03126656|DRUG|Testosterone Undecanoate|just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation
41113839|NCT00097188|DRUG|rituximab|
41113840|NCT00003516|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
41113841|NCT00639002|DRUG|Ruxolitinib 25 mg|Ruxolitinib was supplied as 5 and 25 mg tablets.
41113842|NCT00639002|DRUG|Dexamethasone 40 mg|Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
41113843|NCT04905225|PROCEDURE|Ascending aortic replacement|Surgical access will be performed through a median sternotomy. Ascending aortic repair is performed under conditions of cardiopulmonary bypass (CPB) and MHCA with unilateral ACP via innominate artery with a flow rate of 8-10 ml/kg/min and perfusion pressure of 60-80 mmHg. Once CPB is instituted, the aortic cross-clamp is applied, and the heart is arrested with antegrade cardioplegia. Hemiarch replacement involves resection lesser curve of the aortic arch from the base of the innominate artery (Zone 0) to a point immediately distal to the nadir of the lesser curvature (Zone 3 or Zone 2 if the left subclavian artery was too far).
41113844|NCT03783754|DRUG|telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg|low-dose combination therapy
41113845|NCT03783754|DRUG|Placebo oral capsule|matched placebo
41113846|NCT05355623|PROCEDURE|Vaginal Repair|Vaginal Repair will be done either by application of sterilized (gamma irradiated) amniotic membrane or by Classical repair
41113847|NCT02569866|DRUG|Cephalexin|Capsules containing cephalexin/500mg
41113848|NCT02569866|DRUG|Placebo|Capsules containing placebo/500mg
41113849|NCT01895023|DRUG|Dexmedetomidine|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
41113850|NCT01895023|DRUG|Midazolam|The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
41113851|NCT01895023|DRUG|Saline|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
41113852|NCT00223795|DEVICE|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
41113853|NCT00470899|PROCEDURE|drainage of placenta of fetal blood|
41113854|NCT00003728|DRUG|asparaginase|
41113855|NCT00003728|DRUG|cyclophosphamide|
41113856|NCT00003728|DRUG|cytarabine|
41113857|NCT00003728|DRUG|daunorubicin hydrochloride|
41113858|NCT00003728|DRUG|dexamethasone|
41113859|NCT00003728|DRUG|doxorubicin hydrochloride|
41113860|NCT00003728|DRUG|etoposide|
41113861|NCT00003728|DRUG|leucovorin calcium|
41113862|NCT00003728|DRUG|mercaptopurine|
41113863|NCT00003728|DRUG|methotrexate|
41113864|NCT00003728|DRUG|methylprednisolone|
41113865|NCT00003728|DRUG|mitoxantrone hydrochloride|
41113866|NCT00003728|DRUG|prednisolone|
41113867|NCT00003728|DRUG|therapeutic hydrocortisone|
41113868|NCT00003728|DRUG|thioguanine|
41113869|NCT00003728|DRUG|vincristine sulfate|
41113870|NCT00003728|DRUG|vindesine|
41113871|NCT00003728|PROCEDURE|allogeneic bone marrow transplantation|
41113872|NCT00003728|PROCEDURE|peripheral blood stem cell transplantation|
41113873|NCT02847702|DRUG|VM902A 200-mg Capsules|Taken orally with food twice daily
41113874|NCT02847702|DRUG|VM902A 400-mg Capsules|Taken orally with food twice daily
41113875|NCT02847702|DRUG|Naproxen 500-mg Capsules|Taken orally with food twice daily
41113876|NCT02847702|DRUG|Placebo|Capsules to match VM902A and/or naproxen taken orally with food twice daily
41113877|NCT04148040|PROCEDURE|G-POEM|Per-oral pyloromyotomy (POP), also named as gastric per-oral endoscopic myotomy (G-POEM), for treating infantile hypertrophic pyloric stenosis (IHPS) has the following steps: mucosal incision, creation of submucosal tunnel, full-thickness pyloromyotomy, closure of the mucosal entry.
41113878|NCT01908296|DRUG|FK949E|Oral
41113879|NCT01908296|DRUG|fluvoxamine|Oral
41113880|NCT02838342|DRUG|Metronomic cyclophosphamide|50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance
41113881|NCT02838342|DRUG|Interferon-alpha|3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
41113882|NCT00719459|DRUG|Iron Sucrose|Venofer 20 mg/mL
41113883|NCT00719459|DRUG|Iron Sucrose|Iron sucrose 20 mg/mL
41113884|NCT02258815|DRUG|ch14.18/CHO|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
40926123|NCT03603171|DIAGNOSTIC_TEST|McGill pain questionnaire|The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.
41113885|NCT00296361|DRUG|Tacrolimus|immunosuppression
41113886|NCT02032069|OTHER|no intervention|
41113887|NCT00756730|DRUG|ATV/r|Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
41113888|NCT00756730|DRUG|DRV/r|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
41113889|NCT05187975|PROCEDURE|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Qimen (LR14), Taixi (KI3).~Traditional Chinese medicine:~Chaihushugan Power: Chaihu 12g, Chenpi 12g, Chuanxiong 9g, vinegar Xiangfu 9g, Zhike 9g, Shaoyao 9g, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation:~The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 10Hz.~Standard care:~The same as the standard care group."
41113890|NCT03674047|DRUG|ruxolitinib|Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
41113891|NCT04275193|DRUG|Zishenqing|Zishenqing Granule
41113892|NCT04275193|DRUG|Placebo|Granule manufactured to mimic Zishenqing(containing 10% composition)
41113893|NCT05042024|PROCEDURE|Scaling and root planing|Conventional periodontal therapy, non-surgical periodontal therapy
41113894|NCT05042024|DRUG|Oral L-arginine aspartate administration|The use of L-arginine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
41113895|NCT05042024|DRUG|Oral L-ornithine aspartate administration|The use of L-ornithine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
41113896|NCT00117663|OTHER|temporary discontinuation of hormone therapy for 1 month|temporary discontinuation of hormone replacement therapy for 1 month prior to screening mammogram.
41113897|NCT00117663|OTHER|temporary discontinuation of hormone therapy for 2 months|temporary discontinuation of hormone replacement therapy for 2 months prior to screening mammogram
41113898|NCT06063148|DEVICE|Enrolled Participant|Participant will undergo at most 10 SpO2 measurements paired with at most 10 routine blood gas samples.
41113899|NCT00259961|PROCEDURE|open fundoplication|
41113900|NCT00259961|PROCEDURE|laparoscopic fundopliaction|
41113901|NCT03802318|DRUG|Rabeprazole|Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
41113902|NCT03995446|DEVICE|low-level laser|low level laser emission on specific acupuncture points
41113903|NCT03995446|DEVICE|Sham laser|Sham laser
41113904|NCT06281808|DEVICE|Photon Counting Detector CT|Photon counting detector CT scan with dose arbitrarily reduced compared to EID CT scan (e.g., half the dose of EID CT)
41113905|NCT01591239|BEHAVIORAL|Home-Based Intervention|Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.
41113906|NCT01591239|BEHAVIORAL|Educational Group|Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
41113907|NCT06386627|DIAGNOSTIC_TEST|Stimulus response task|Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.
41113908|NCT06386627|DIAGNOSTIC_TEST|Transcranial magnetic stimulation|Transcranial magnetic stimulation to assess the integrity of corticospinal connections
41113909|NCT05342818|DRUG|Neostigmine|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
41113910|NCT05342818|DRUG|Ondansetron 8mg|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
41113911|NCT05342818|DRUG|Metoclopramide Injection|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
41113912|NCT05342818|OTHER|Enteral feeding nutrition|The type and rate of enteral feeding nutrition will be the same for all patients (180ml/3h). All patients have a 30-degree head-up position
41113913|NCT05342818|OTHER|Sequential Organ Failure Assessment (SOFA) score|SOFA score will be performed on all patients before the beginning of the study
41113914|NCT05756140|OTHER|No intervention|No Control
41113915|NCT01865253|DEVICE|Renal Denervation|Renal Denervation
41113916|NCT04062760|DRUG|Standard diuretic therapy|The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.
40926124|NCT03603171|DIAGNOSTIC_TEST|Brief Pain Inventory Short-Form|A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning
41113917|NCT04062760|DRUG|Early sequential nephron blockade|"After 24-72 hours of an algorithm-based treatment with high-dose intravenous furosemide started at the time of hospital admission, the patients in this arm will be randomized to receiving:~1. oral furosemide in 2 daily divided doses at a dose equivalent to that administered intravenously during the past 24 hours~2. metolazone at a dose based on serum creatinine value~3. acetazolamide at a dose based on serum creatinine value~4. spironolactone or potassium canrenoate (unless serum potassium value is higher than 5 mmol/L); dose will be established based on serum creatinine value"
41113918|NCT02416076|DEVICE|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
41113919|NCT02416076|DEVICE|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
41113920|NCT00092781|DRUG|MK0663, etoricoxib|
41113921|NCT00092781|DRUG|Comparator: celecoxib|
41113922|NCT05593523|DRUG|Indocyanine green (ICG)|ICG is a well, known, FDA-approved dye
41113923|NCT05593523|DEVICE|OnLume|The OnLume Clinical Imaging System (CIS), also known as the Asimov-MSK Imaging System, used in this study is a clinical fluorescence-guided imaging system.
41113924|NCT03883529|OTHER|Writing about and reviewing birth experience|Writing about and reviewing birth experience with a known midwife from antenatal care about 6 weeks post-partum.
41113925|NCT00113971|DRUG|epratuzumab|
41113926|NCT03267966|DIAGNOSTIC_TEST|Leeds Pathology Protocol (LEEPP)|LEEPP includes: 1) multicolor inking; 2) axial slicing; 3) circumferential margin; 4) 1-mm clearance
41113927|NCT05172388|OTHER|Air purifier|Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).
41113928|NCT00590551|OTHER|sling or no sling|Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
40926125|NCT03603171|DIAGNOSTIC_TEST|Fatigue and Daytime Sleepiness Scale|A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.
41113929|NCT03426033|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
41113930|NCT03426033|DRUG|Warfarin|25mg tablet administered orally
41113931|NCT04464421|BEHAVIORAL|Contingency Management (CM)|Participants were able to draw a gift card from a virtual fishbowl when their urine toxicology results are positive for buprenorphine metabolites. Gift card values were $25, $50, or $100.
41113932|NCT04464421|BEHAVIORAL|Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)|Participants had one-on-one sessions with a behavioral interventionist to discuss their goals regarding treatment, how to reach these goals, the importance of substance-free activities, and mindfulness skills.
41113933|NCT04168801|DIETARY_SUPPLEMENT|early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
41113934|NCT03815019|DRUG|Megestrol Acetate|The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable.
41113935|NCT03815019|BEHAVIORAL|iKanEat Behavioral Intervention|"The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating.~Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding."
40926126|NCT03603171|DIAGNOSTIC_TEST|Myotonia Behaviour scale|It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life
41113936|NCT00891930|BIOLOGICAL|Panitumumab|Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
41113937|NCT00891930|BIOLOGICAL|Ganitumab|AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
41113938|NCT00891930|DRUG|Irinotecan|Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
41113939|NCT00981968|DRUG|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
41113940|NCT00981968|DRUG|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
41113941|NCT05082714|DRUG|Tocilizumab|tocilizumab 8mg/kg single infusion (a second infusion within 48 hours can be applied upon clinician's discretion)
41113942|NCT05082714|DRUG|Baricitinib|The baricitinib intervention consists of baricitinib at a dose of 4 mg/day (given daily for up to 14 days or until discharge from hospital, whichever occurred first); however, 2 mg/day will be given if the patient has a baseline eGFR of 30 to less than 60 mL/min/1·73 m2
41113943|NCT05702515|OTHER|Digital ECG Data Collection|synchronized digital data collected from the G4 and ECG machines during the PICC insertion procedure
41113944|NCT00140088|DRUG|ALGRX 3268|
41113945|NCT04689061|DEVICE|Arthrex FastThread Interference Screw|The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping. The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping
41113946|NCT00539799|DRUG|prednisolone|5 - 7.5 mg/day
41113947|NCT00539799|DRUG|Placebo|Matched placebo to prednisolone
41113948|NCT01082809|DRUG|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
41113949|NCT01496521|DRUG|Aspirin|100mg qd for 6 months.
41113950|NCT01496521|DIETARY_SUPPLEMENT|Tea Polyphenols|300mg bid for 6 months.
41113951|NCT01352533|PROCEDURE|Running polypropylene closure|Half of every wound will be closed with Standard of Care running polypropylene sutures
41113952|NCT01352533|PROCEDURE|Tissue Adhesive (Derma-Bond)|Approximately half of wounds will be randomized to be closed with tissue adhesive.
41113953|NCT01352533|PROCEDURE|Subcuticular polyglactin-910 combined with tissue adhesive|Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
41113954|NCT04947072|PROCEDURE|Erector Spinae Plane Block|The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000
41113955|NCT04947072|PROCEDURE|Spinal anesthesia|Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5
41113956|NCT02113072|DRUG|Beclomethasone|The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
41113957|NCT02113072|DRUG|Probiotics|Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
41113958|NCT02113072|DRUG|Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
41113959|NCT03772652|OTHER|Observation|Soft tissue implant measurements
41113960|NCT00074646|DRUG|CC-8490|
41113961|NCT06193005|OTHER|no intervention|no intervention
41113962|NCT05276973|PROCEDURE|Biopsy|Undergo biopsy
41113963|NCT05276973|DRUG|Carboplatin|Given IV
41113964|NCT05276973|DRUG|Ipatasertib|Given PO
41113965|NCT05276973|DRUG|Paclitaxel|Given IV
41113966|NCT01519752|DRUG|Oxiconazole Nitrate Cream 1%|Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
41113967|NCT01519752|DRUG|Oxiconazole Nitrate Cream 1% (Oxistat®)|Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
41113968|NCT01519752|DRUG|Placebo|Placebo applied to affected area once a day for 28 days
41113969|NCT04580771|DRUG|Cisplatin|Given IV
41113970|NCT04580771|BIOLOGICAL|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
41113971|NCT04580771|RADIATION|Radiation Therapy|Undergo radiation therapy
41113972|NCT04618614|DEVICE|HD-tDCS 1 mA to S1|Anodal high definition transcranial direct current stimulation of the right primary somatosensory cortex with an intensity of 1 mA
41113973|NCT04618614|DEVICE|HD-tDCS 1 mA to M1|Anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1 mA
41113974|NCT04618614|DEVICE|Sham control|Sham stimulation of the right primary somatosensory cortex
41113975|NCT02667743|DRUG|Paclitaxel Micelles for Injection|
41113976|NCT02667743|DRUG|Paclitaxel Injection|
41113977|NCT02667743|DRUG|Cisplatin|
41113978|NCT04666857|OTHER|early motor intervention|infants with CHD after open heart surgery will receive early intervention
41113979|NCT03830866|BIOLOGICAL|Durvalumab|IV infusion every 4 weeks
41113980|NCT03830866|DRUG|Cisplatin|Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
41113981|NCT03830866|DRUG|Carboplatin|For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
41113982|NCT03830866|RADIATION|external beam radiation therapy (EBRT) + brachytherapy|Radiation therapy per standard of care
41113983|NCT04688801|DRUG|Chemotherapy Drugs, Cancer|Chemotherapy± Radiotherapy after surgery
41113984|NCT04688801|DRUG|Immunotherapy|Chemotherapy + Immuonotherapy ± Radiotherapy after surgery
41113985|NCT05176964|RADIATION|split-course HFRT|7Gy/F, d7, q3w, 5 cycles
41113986|NCT05176964|DRUG|CAPOX chemotherapy|CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m\^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m\^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
41113987|NCT05176964|DRUG|Tislelizumab|Tislelizumab 200 mg intravenous infusion on day 1 of each 21-day cycle for each of six cycles.
41113988|NCT04181255|DRUG|Curosurf|This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.
41113989|NCT04181255|DRUG|Sham|This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
41113990|NCT00888979|DRUG|Nicotrol Inhaler|10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
41453360|NCT01540344|DRUG|HIPEC|bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
41113991|NCT03385681|OTHER|Tailored Educational Intervention|The intervention will be a one-day seminar for nurses working at the units, with lectures and workshops with main focus on the subjects showing the lowest pediatric pain management competence. In addition, there will be clinical supervision in pediatric postoperative pain management (two or three days per unit). The intervention will be conducted by two experts (nurse and physician) in pediatric postoperative pain management. After the intervention there will be different reminders every week for the first month, and then every month (in different forms) about pediatric pain management during six months of time.
40752550|NCT04281771|PROCEDURE|cardiac MRI|"Patients are studied on a clinical 1.5 Tesla scanner with cardiac radiofrequency receiver coil centered over the heart, and ECG monitoring. The following parameters are assessed:~Functional imaging: ECG-gated cine Steady-state free precession (SSFP) MRI images are obtained during repeated breath holds in long axis and short axis orientations covering the entire left ventricle. Global systolic and diastolic function are assessed, and left ventricular mass is calculated.~Flow imaging: ECG-gated 2D flow measurements are assessed above the prosthetic valve, and at the level of the pulmonary trunk."
40752551|NCT04636944|OTHER|web-based COMPASS intervention|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). COMPASS is tailored to gain an understanding of the difficulties that LTC patients experience and provide information and tools on how to manage these. This qualitative study will explore participants' perspectives on using COMPASS for managing depression and anxiety in heart failure.
41113992|NCT00492271|DRUG|Friulimicin B|Intravenous, once daily, single dose
41113993|NCT03557008|BIOLOGICAL|Rabies Vaccine|A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.
41113994|NCT03557008|DRUG|Metronidazole|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.
41113995|NCT03557008|DRUG|Vancomycin|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.
41113996|NCT03557008|DRUG|Neomycin Sulfate|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
41113997|NCT01919645|OTHER|Combined Training ( Strength + Aerobics)|Strength training performed using workout devices and aerobic training performed using stationary bicycle.
41113998|NCT05000944|OTHER|breakfast omission (BO)|this group will not be provided with a breakfast until lunch time (at 12:30).
41113999|NCT05000944|OTHER|early-morning breakfast consumption (EM-BC)|this group will be provided with an early morning breakfast (at 08:30).
41114000|NCT05000944|OTHER|mid-morning breakfast consumption (MM-BC)|this group will be provided with a mid (late) morning breakfast (at 10:30).
41114001|NCT05905172|DRUG|Hydronidone capsules|After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 5 years.
41114002|NCT05905172|DRUG|The placebo capsules|After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.
41114003|NCT02771899|DEVICE|spineEOS software|During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.
41114004|NCT02771899|DEVICE|EOS|The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
41114005|NCT03474822|BIOLOGICAL|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
41114006|NCT03239899|DRUG|Pembrolizumab|Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
41114007|NCT01624844|OTHER|Geometrical calculation of dural sac volume|Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
41114008|NCT05551065|DEVICE|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) using a hand-held ultrasound (Vscan, GE Healthcare)
41114009|NCT05468398|DEVICE|Soothe VR|The Soothe VR system is manufactured by Applied VR. It is a HIPAA-compliant platform and has been validated by randomized control trials. It has not yet been reviewed by the FDA.
41114010|NCT02711293|OTHER|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count \>350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been \>350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.
41114011|NCT02711293|OTHER|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.
41114012|NCT06322797|DEVICE|rTMS|"Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. First, the resting motor threshold was measured for each patient. At the lowest stimulus output, a stimulus was applied to the M1 cortex of the uninjured hemisphere aiming at the site that caused the largest visible twitch in the participant's thumb. The resting motor threshold was defined as the intensity required to generate a motor-induced potential of \> 50 uV in the contralateral abductor pollicis brevis muscle at least 5 out of 10 times with 30 s of inter-stimulus time interval.~Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min."
41114013|NCT06322797|DEVICE|rTMS|Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. After identifying the brain site that is activated during finger tapping during fMI, Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min. the resting motor threshold was measured for each patient at target brain site.
40926127|NCT03603171|DIAGNOSTIC_TEST|Hand opening time|A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.
41114014|NCT06322797|DEVICE|Sham|In Sound Mode, no actual stimulation is applied, and 20 minutes of treatment is performed like other experimental groups.
41114015|NCT01438086|DRUG|mecasermin|Intracoronary bolus
41114016|NCT01438086|DRUG|mecasermin|Intracoronary bolus
41114017|NCT01438086|DRUG|0.9% sodium chloride injection|Intracoronary bolus
41114018|NCT02632305|DRUG|nab-paclitaxel in combination with gemcitabine + cisplatin|Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
41114019|NCT04706078|DIAGNOSTIC_TEST|The biotype of gingival|The biotype of gingival was also determined by periodontal probe.
41453361|NCT00465218|PROCEDURE|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
41453362|NCT01204138|DRUG|Apremilast|Apremilast 30mg BID
40926128|NCT03603171|DIAGNOSTIC_TEST|Pressure pain threshold|Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value of two measurements will be recorded.
41453363|NCT01204138|DRUG|Placebo|Placebo BID
41453364|NCT00857779|BIOLOGICAL|subcutaneous immunotherapy|7 injections
41453365|NCT02096705|DRUG|Dapagliflozin|Tablet
41453366|NCT02096705|DRUG|Dapagliflozin Placebo|Tablet
40752552|NCT05372939|DRUG|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
41114020|NCT00311363|DRUG|GEn (XP13512)|1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
41114021|NCT00311363|DRUG|GEn (XP13512)|1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
41114022|NCT00311363|DRUG|Placebo|Placebo, orally, once daily for 12 weeks following single blind 24-week phase
41114023|NCT02880241|DRUG|MMV390048|Tablets of 20mg each
41114024|NCT04561544|BEHAVIORAL|Knowing Who You Are (Becoming): Cultural Identity Intervention|8-week cultural identity development program led by Alaska Native Elders
41114025|NCT02016352|BIOLOGICAL|patient CSF extraction with hydrocephalus|CSF extraction
41114026|NCT02016352|BIOLOGICAL|witness CSF extraction|CSF extraction from patient not suffering from hydrocephalus
41114027|NCT04004819|DRUG|Rituximab|A lower dosage of rituximab for HTLV-1-associated myelopathy
41114028|NCT06249776|DEVICE|Supernova revascularization device|Mechanical Thrombectomy
41114029|NCT05150054|DEVICE|CardioFlux|Not an intervention
41114030|NCT02768571|DRUG|Cerebrolysin|Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day \* 21 days with rehabilitation
41114031|NCT02768571|DRUG|Placebo|Placebo- saline 100 ml/day \* 21 days with rehabilitation
41114032|NCT04563559|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.
41114033|NCT04563559|DRUG|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
41114034|NCT04861324|BEHAVIORAL|Dietary Intervention|Increasing fruit and vegetable by two servings a day and at least 30 min a day of postprandial physical activity
41114035|NCT06108778|DEVICE|MRI|Investigations as CT,MRI.serum ammonia and lactate
41114036|NCT00636207|DRUG|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
41114037|NCT00636207|DRUG|Placebo|Placebo dry powder inhaler
41114038|NCT06154239|DEVICE|DAYE Diagnostic Tampon|The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746). The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion.
41114039|NCT06154239|DIAGNOSTIC_TEST|Vaginal self-swab|A vaginal self-swab typically consists of a long, slender, and flexible stick or handle, often made of plastic or a similar material. At one end, there's a soft, absorbent tip made of cotton or synthetic material. This tip is designed to collect a sample from the vaginal walls or cervix.
40752553|NCT05372939|OTHER|Placebo (oral)|Orally administered placebo comparator taken once daily
41114040|NCT06154239|DIAGNOSTIC_TEST|Clinician vaginal swab|A clinician vaginal swab is a medical tool used by healthcare professionals to collect samples from the vaginal canal for diagnostic purposes. It's typically a long, thin, and flexible instrument. At one end, there's a cotton, rayon, or synthetic tip designed to collect cells, discharge, or other materials from the vaginal walls, cervix, or other areas within the vaginal canal.
41114041|NCT00473902|BEHAVIORAL|Training|
41114042|NCT00473902|DRUG|Creatine Monohydrate, Conjugated Linoleic Acid|
41114043|NCT01626612|PROCEDURE|continuation of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
41114044|NCT01626612|PROCEDURE|streamlining of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
41114045|NCT04807556|OTHER|Alusti Test|Physical and psychological functional conditions are key factors in the elderly population
41114046|NCT00085436|BIOLOGICAL|Aldesleukin,|Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
41114047|NCT00085436|BIOLOGICAL|autologous tumor cell vaccine|we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
41114048|NCT00085436|BIOLOGICAL|recombinant interferon alfa|Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
41114049|NCT01531075|BIOLOGICAL|ENGERIX-B (HBV Vaccine)|ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
41114050|NCT01531075|BIOLOGICAL|Sci-B-Vac|Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
41114051|NCT01846936|PROCEDURE|DLT with conventional technique|The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
41114052|NCT01846936|PROCEDURE|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation."
41114053|NCT01846936|PROCEDURE|Disconnection technique|Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
41114054|NCT05251688|OTHER|Cryoanalgesia|"On the first day of the study, the PI met the participants and assessed their level of consciousness using the Modified Glasgow Coma Scale to ensure that they were unconscious and reviewed the medical records to collect their sociodemographic data. After that, the participants received routine care before the arterial puncture. The PI assessed their pain scores during the puncture.~In the second meeting (on the same day or the following day), the PI prepared the ice packs by crushing small pieces of ice and wrapping them in smooth gauze to avoid skin damage and moisture in the puncture area. Before the arterial puncture, the ice pack was applied over the selected puncture site (radial, brachial, or femoral artery) for 5 minutes in addition to the routine care. After removing the ice pack, the nurse palpated the artery, wiped of the residue of ice vapor present on the skin, and took the arterial blood sample. During the puncture, the PI assessed the participants' pain scores."
41114055|NCT00151424|DRUG|asenapine|Asenapine 5-10mgBID
41114056|NCT00151424|DRUG|Placebo|Matched against asenapine and olanzapine
41114057|NCT00151424|DRUG|Olanzapine|10-20 mg QD
41114058|NCT05619861|BIOLOGICAL|CAR-T|Patients will receive CAR-T treatment
41114059|NCT00481182|DRUG|fosamprenavir + ritonavir + methadone|
41114060|NCT05081570|DEVICE|telecare consultation|Two tertiary stroke care consultations will be provided by stroke nurses via telecare in 2 months. Consultation content includes provide education on modifying stroke-specific risk factors, disseminate self-management knowledge, reinforce the importance of medication compliance, revise the blood and investigation results, and co-design and follow-up on mutually agreed rehabilitation goals with the subjects. When necessary, the nurse will also refer the stroke survivors to multidisciplinary team members according to the referral guidelines. The nurse will also encourage the patients' family and/or informal caregivers to participate in the consultations.
41114061|NCT01016522|DIETARY_SUPPLEMENT|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
41114062|NCT05583539|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography is a viscoelastic test that measures the dynamics of blood clotting on whole blood samples.
41114063|NCT04112069|DEVICE|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
41114064|NCT04112069|OTHER|Usual Care|Usual care
40926129|NCT03603171|DIAGNOSTIC_TEST|Manual muscle testing|The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two mesurements is considered. The following muscles were assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and Extensors, digit flexors and extensors and thumb abductors.
41114065|NCT02703714|DRUG|Pembrolizumab|200 mg given intravenously (IV)
41114066|NCT02703714|DRUG|Sargramostim|250 µg given subcutaneously (SC)
41114067|NCT04409912|DEVICE|Sirolimus coated balloon|"Sirolimus has a high transfer rate to the vessel wall and effectively inhibit neointimal hyperplasia in the porcine coronary model. In coronary artery interventions, preliminary clinical studies using sirolimus coated balloon have shown excellent procedural and 6 month patency. The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.~When compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety."
41114068|NCT04409912|DEVICE|Plain balloon|Plain balloon angioplasty is the current standard therapy to treat stenosis in dialysis access. However, the mid and long term patency of plain balloon angioplasty in patients with end stage renal disease is poor. The average primary patency is around 40 to 50 percent at 1 year and multiple repeated angioplasty is required to maintain the patency of the vascular access.
41114069|NCT01561989|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
41114070|NCT01561989|OTHER|questionnaire administration|Ancillary studies
41114071|NCT01561989|BIOLOGICAL|trivalent influenza vaccine|Given IM
41114072|NCT00813904|BIOLOGICAL|rThrombin, 1000 IU/mL|At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
41114073|NCT01482975|OTHER|Tailored computer based intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.
40926130|NCT03603171|DIAGNOSTIC_TEST|Quantitative muscle testing|Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference \> 10% between measurements, a third attempt is performed. The following muscles are assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and extensors and digit flexors.
41114074|NCT01482975|OTHER|Tailored computer intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
41114075|NCT00609310|DIETARY_SUPPLEMENT|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
41114076|NCT03785834|PROCEDURE|Punch Biopsy|The patient will undergo two 6 mm punch biopsies into the affected extremity at the most proximal portion of the redness.
41114077|NCT00235508|DRUG|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
40926131|NCT03603171|DIAGNOSTIC_TEST|Scale for Assessment and Rating of Ataxia|SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.
41114078|NCT05076058|DIETARY_SUPPLEMENT|Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza|"Brand names: BY-HEALTH；~Main contents (per 100g): silibinin 2g, salvianolic acid B 0.72g，Puerarin 0.68g"
41114079|NCT05076058|OTHER|Placebo tablet|"Brand names: BY-HEALTH；~Main contents : starch"
41114080|NCT04114968|OTHER|GP-based screening or HPV self-sampling|Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.
41114081|NCT04186546|DEVICE|Zephyr Valve Procedure|The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
41114082|NCT04722237|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an evidence-based psychological therapy that has been used to improve physical and mental health among adults with health conditions, including cancer (Graham, Gouick, Krahe, \& Gillanders, 2016). It fosters engagement with, rather than avoidance of, painful experiences, to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing problems.
41114083|NCT02439827|BEHAVIORAL|"Fortaleça sua Saúde program"|The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
41114084|NCT02218502|OTHER|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
41114085|NCT02218502|OTHER|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
41114086|NCT02218502|OTHER|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
41114087|NCT02218502|OTHER|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
41114088|NCT00588302|DRUG|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
41114089|NCT02174393|DRUG|Universal Peel|Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
41114090|NCT02174393|PROCEDURE|Microneedling|"Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.~For this protocol, the needle depth will be increased over the 3 sessions:~Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.~Each Session: Microneedling procedure on Day 1, followed by skin care regimen"
40926132|NCT03603171|DIAGNOSTIC_TEST|Berg balance scale|It is a 14 item objective measure designed to assess static balance and fall risk in adult populations
40926133|NCT03603171|DIAGNOSTIC_TEST|Quick motor function test|Assessment of proximal motor function.
41114091|NCT02174393|DRUG|Post-Microneedling Skin Care|"On Day 1 (after Microneedling procedure):~* Gentle Antioxidant Soothing Cleanser daily~* Soothing Recovery Ointment and Sheer Physical Sunscreen~On Day 2-7:~* AM: Physical sheer sunscreen and recovery ointment~* PM: Retinol/Vitamin C in the evening and soothing recovery ointment~On Day 7:~* AM: BD Hydrating Day/Night Cream~* PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)"
40926134|NCT03603171|DIAGNOSTIC_TEST|GSGC|GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.
41114092|NCT02174393|DRUG|Post-Universal Peel Skin Care|"* Gentle Antioxidant Soothing Cleanser daily~* Physical Sunscreen daily~* Soothing recovery ointment fortified with silver only when peeling occurs~* After completely peeling, vitamin c product in the morning and the retinol in the evening"
41114093|NCT03247543|DRUG|Placebo|Placebo was administered once daily
41114094|NCT03247543|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
41114095|NCT03247543|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
41114096|NCT02725086|DRUG|Leucostim®|
41114097|NCT02725086|DRUG|Neupogen®|
41114098|NCT03451799|OTHER|Ketogenic Diet|A 4-month ketogenic diet will be supervised and monitored by the study investigators. Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining metabolic ketosis.
41114099|NCT03451799|RADIATION|Standard-of-care radiation|Patients will receive standard-of-care radiation. Radiation is not protocol directed.
41114100|NCT03451799|DRUG|Standard-of-care Temozolomide|Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
41446101|NCT06377605|PROCEDURE|ESPB|the target vertebral level ( T7 transverse process ) \[8\] in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) \[16\] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected ,
41446102|NCT06377605|PROCEDURE|local anaesthetic infiltration|the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.
41446103|NCT06377605|DRUG|midazolam and lidocaine|midazolam administration intravenous , and 5 cm lidocaine 1% infiltration
41446104|NCT06377605|DRUG|Bupivacain|bupivacaine infiltration
41446105|NCT02028221|DRUG|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
41446106|NCT02028221|DRUG|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
41453367|NCT04821349|DEVICE|Capsule endoscopy|"A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.~Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient."
40926135|NCT03603171|DIAGNOSTIC_TEST|30 seconds sit to stand test|It is a measurement that assesses functional lower extremity strenght in older adults.
40926136|NCT03603171|DIAGNOSTIC_TEST|Functional Index-2|Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.
41114101|NCT03293056|OTHER|High-intensity interval Hydrogynmastics|The HIIH to PSE group during the high intensity (HI) period should remain between 16 to 18 points, while in the moderate intensity (MI) intervals around 11. The dynamic exercises will progression, in the first month will be 1 min of HI and 2 min of MI, in the second month of 1 min of HI and 1 min of MI and in the last month of 1 min of HI and 30 s of MI, until completing 30 min in total.
41114102|NCT03293056|OTHER|Hydrogynmastics Continuous Moderate|For the HCM group the PSE will be around 11 points during the 30 min of moderate continuous exercise. In both groups the form of intensity monitoring that will be through the PSE, in which this scale will be printed in banner form and affixed next to the physical education teacher during the classes.
41114103|NCT00021008|DRUG|picoplatin|
41114104|NCT04446598|DEVICE|non-ablative SMOOTH mode Erbium YAG laser|Erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode
41114105|NCT04446598|DRUG|Tadalafil 5mg|oral tadalafil 5 mg was administered daily over a period of two months
41114106|NCT04651881|DRUG|Reference drug|1 Cap., single oral administration under fed condition
41114107|NCT04651881|DRUG|Test drug 1|1 Tab., single oral administration under fed condition
41114108|NCT04651881|DRUG|Test drug 2|1 Tab., single oral administration under fed condition
41114109|NCT05636332|DIAGNOSTIC_TEST|12 lead Electrocardiogram|12 lead Electrocardiogram
41114110|NCT01518478|DRUG|Fluzone® Intradermal (Sanofi Pasteur Inc.)|"Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus."
41114111|NCT04731948|DIETARY_SUPPLEMENT|Folic Acid|400µg Folic Acid per day for 16 weeks
41114112|NCT04731948|DIETARY_SUPPLEMENT|2 µg Vitamin B12|2 µg Vitamin B12 per day for 16 weeks
41114113|NCT04731948|DIETARY_SUPPLEMENT|10 µg Vitamin B12|10 µg Vitamin B12 per day for 16 weeks
41114114|NCT04731948|DIETARY_SUPPLEMENT|50 µg Vitamin B12|50 µg Vitamin B12 per day for 16 weeks
41114115|NCT04239586|DRUG|Sulfonylurea|Starting treatment with sulfonylurea class of drug
41114116|NCT05549869|DIAGNOSTIC_TEST|serum leptin|Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators
41114117|NCT03868397|DIAGNOSTIC_TEST|Liver MRI|"Liver MRI including 4D flow sequence is performed twice in liver transplantation recipients, before and 1 month-after transplantation.~In donor candidates, liver MRI including 4D flow sequence is performed twice in 1-3 weeks to assess repeatability of the technique."
41114118|NCT03087084|DEVICE|Cardiac Pacing and Impedance Measurement system|Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
41114119|NCT01512810|PROCEDURE|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
41114120|NCT03522337|OTHER|Visual pedagogy (social stories)|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
41114121|NCT03522337|OTHER|Conventional leaflets|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
41114122|NCT01171625|DEVICE|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
41114123|NCT04307407|BEHAVIORAL|Aerobic Exercise|Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm
41114124|NCT00705588|DRUG|Tadalafil|Orally, titrated to maximum 20mg od
41114125|NCT00705588|DRUG|Vardenafil|Orally, titrated to 10 mg bid
41114126|NCT05554614|BEHAVIORAL|BTW app with reward-based feedback|Teen drivers will be notified of their weekly driving performance via a driving safety score with information on the types of high-risk driving behaviors committed as well as progress on maintaining and/or improving weekly safe driving behaviors. Educational materials on different driving situations and scenarios associated with the high-risk driving behaviors (e.g. 90-second videos) will be provided for the driver to review at any point and time. Information on these driving behaviors and the education material will be provided via push notifications from the BTW app. Weekly leader boards will show the driver's driving safety score in comparison to other drivers of the same age. Consistently high driver safety scores in certain driving skill areas (e.g., cornering) and a total overall score above 70% of other users on that skill or total score will unlock gamification-based rewards (e.g., driving safety badges, driving safety score leader board, group challenges with winners).
41114127|NCT05554614|BEHAVIORAL|BTW app with situational supervised driving practice|Teen drivers will be provided bi-weekly push-notifications from the BTW app notifying them of situational supervised driving practice activities that are to be completed during the assigned week. There are 12 situational supervised driving activities and six skill-building driving activities (Table 1). Skill-building sessions are assigned for off weeks during the first half of the six months (weeks 2-12), allowing for skills to be further developed when the situations are encountered for a second time (weeks 15-23). Parents will be prompted to directly log situational supervised and skill-building driving activities in the app after the session within the BTW app to obtain the module completion date and duration time.
41446107|NCT05766553|OTHER|Virtual reality pod|The first two sessions provide guided training in relaxation and mindfulness through immersion in a virtual forest environment for the first session, and in a virtual beach environment for the second. Sessions 3 and 4 present environments with addiction-related stimuli (Cues). The session 3 consists of a walk through the virtual street environment, buying a bottle of water from the store, and then ordering a coffee from a virtual bar. The session 4 takes place in a virtual party environment in an apartment: people smoke and drink alcohol in the living room, the session consists of sitting with them, then going to the kitchen to get a water bottle. Sessions 5 and 6 present stressful environments. Session 5 consists of a virtual parachute jump. The 6th session takes place in a virtual airplane environment, which will encounter turbulence.
41446108|NCT05766553|OTHER|nicotine patches and chewing gum|Participants in this group will be prescribed a Gold Standard smoking cessation treatment with nicotine patches adapted to their consumption and 4mg nicotine chewing gum for a period of 3 months.
41446109|NCT05911711|OTHER|Prognostic factor|normal person (no sepsis group)
41114128|NCT05554614|BEHAVIORAL|Sham BTW app|Teens will be provided links to passive education materials and information on car maintenance every week. They will not be given feedback on their driving performances.
41114129|NCT04975945|DRUG|Ceftriaxone Sodium|Intravenous vs local action
41114130|NCT06555380|BEHAVIORAL|The one-year intervention|A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
41114131|NCT06555380|BEHAVIORAL|The three-year intervention|A multifactorial family-centered lifestyle intervention extending up to three years, with clinical visits at local healthcare centers which included repeatedly visits (up to 8 times / year). The intervention was managed by specialized nurses.
41114132|NCT04339348|DRUG|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus inert placebo cream vaginally at the time of LNG-IUD insertion
41114133|NCT04339348|DRUG|Lidocaine-Prilocaine Topical cream|Lidocaine-Prilocaine cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
41114134|NCT04339348|DRUG|placebo|inert placebo cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
41114135|NCT04014803|DRUG|Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin|"Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~1. Prasugrel plus Aspirin arm~2. Clopidogrel plus Aspirin arm"
41114136|NCT02229019|BEHAVIORAL|Volunteer mealtime assistance|
41114137|NCT05176106|BEHAVIORAL|CHW Incentives Intervention|The intervention comprises of an incentives package provided to VHTs who are active in the intervention-randomized parishes. It will comprise of items that will motivate them and support their work as VHTs in the community.
41114138|NCT00134446|DEVICE|transcranial magnetic stimulation|
41114139|NCT00933400|DIAGNOSTIC_TEST|CT Coronary Angiography (CTCA)|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
41114140|NCT00933400|PROCEDURE|Traditional Strategy|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
41114141|NCT04833855|BIOLOGICAL|Tezepelumab Dose 1|Subcutaneous injection.
41114142|NCT04833855|BIOLOGICAL|Tezepelumab Dose 2|Subcutaneous injection.
41114143|NCT04833855|BIOLOGICAL|Omalizumab|Subcutaneous injection.
41114144|NCT04833855|BIOLOGICAL|Placebo|Subcutaneous injection.
41446110|NCT06272643|DIAGNOSTIC_TEST|IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography)|OCT and IVUS in Patients with LMCA lesion (25-60%)
41446111|NCT06429592|OTHER|education|nursing care practice
41446112|NCT03808519|DIETARY_SUPPLEMENT|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
41114145|NCT02748954|BEHAVIORAL|Thoughts|"Thoughts. Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week."
41114146|NCT02748954|BEHAVIORAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
41446113|NCT03808519|DIETARY_SUPPLEMENT|Placebo|Organic Sunflower Oil 5000mg per day
41446114|NCT00835146|DRUG|Ribavirin 200 mg tablets|1 x 200 mg, single-dose fasting
41446115|NCT00835146|DRUG|COPEGUS™|1 x 200 mg, single-dose fasting
41446116|NCT05513196|PROCEDURE|Erector spinae plane block (ESPB)|Bilateral erector spinae plane block will be performed with 20 mL, 0.25% bupivacaine at T9 level preoperatively.
41446117|NCT03914365|PROCEDURE|Ultrasound-guided pudendal nerve block (PNB) and Ultrasound-guided penile nerve block (DPNB)|Our primary objective is to compare analgesia between the two blocks during and after pediatric circumcisions to minimize post-operative pain.
40752554|NCT05372939|COMBINATION_PRODUCT|Humira (adalimumab)|Humira comparator is administered subcutaneously, on Humira frequency schedule.
40752555|NCT01272856|DRUG|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
41114147|NCT02748954|BEHAVIORAL|Assertiveness.|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict.
41114148|NCT02748954|BEHAVIORAL|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
41114149|NCT02748954|BEHAVIORAL|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
41114150|NCT00005772|DEVICE|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
41114151|NCT00005772|DEVICE|Control|Control group: standard care
41114152|NCT05433935|OTHER|Observation|This is an observational study.
41114153|NCT00889499|DRUG|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
41114154|NCT00889499|DRUG|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
41114155|NCT00889499|DRUG|Placebo|NHCL 0,9%
41114156|NCT00084045|PROCEDURE|Intrapartum HIV counseling/testing|
41114157|NCT00084045|PROCEDURE|Postpartum HIV counseling/testing|
41114158|NCT01396837|DEVICE|RedDress Wound Care System (RD1)|Weekly application. A blood based wound care treatment
41114159|NCT04979988|DRUG|Lortlatinib|as provided in real world practice
41114160|NCT04147910|DRUG|KW-6356|Single oral dose of KW-6356
41446118|NCT04512781|DEVICE|Control Cannula - Prosoft Cannula - Unicorn Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
41446119|NCT04512781|DEVICE|Control Cannula - Unicorn Cannula - Prosoft Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
41446120|NCT06200363|DRUG|T3011|T3011 will be administered intravenously on D1, 4, 8, 11, 15, 18 of each 28-day cycle.
41446121|NCT06200363|DRUG|Regorafenib|Regorafenib will be administered orally once daily for the first 21 days of each 28-day cycle according to NCCN and CSCO guidance.
41446122|NCT01891773|BEHAVIORAL|Inhaled steroids in school.|Morning dose of inhaled steroids given in school by school nurse instead of at home.
41446123|NCT05356481|DEVICE|segmental muscle vibration|Segmental muscle vibration will delivered over the target muscles by means of vibrator with general physical therapy session
41446124|NCT05048667|DEVICE|Shock Wave therapy (SWT)|Each SWT will administer 720 shocks in the treatment arm. Total of 3600 shocks are given over 5 weeks treatment period.
41446125|NCT05048667|DRUG|Platelet Rich Plasma (PRP)|5 mL PRP will be administered via intracavernous injection
41114161|NCT02735291|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
41114162|NCT05700630|BIOLOGICAL|FT538|FT538 is an investigational off-the-shelf cryopreserved NK cell product derived from an iPSC that contains three functional modifications: 1) a novel high affinity, non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface and remains fully functional after NK cell activation, thus augmenting ADCC; 2) an IL-15 receptor fusion that promotes NK cell activity and enhances cell persistence; and 3) the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.
40752556|NCT01391871|DEVICE|OCT|Optical coherence tomography
41114163|NCT05700630|DRUG|Vorinostat|Vorinostat is a histone deacetylase inhibitor (HDACi) that is FDA approved for the treatment of cutaneous T-cell lymphoma and, under investigation in HIV as disruptor of HIV latency.
41114164|NCT01071408|OTHER|Stroke prevention care program|Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
41114165|NCT05559346|OTHER|Diaphragmatic exercises|Diaphragm exercises will be applied to the research group in addition to conventional rehabilitation.The content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control. In addition to conventional rehabilitation, manual diaphragmatic relaxation exercises and diaphragmatic breathing exercises will be applied to the children in the research group two days a week.
41114166|NCT05559346|OTHER|conventional physiotherapy|The control group will only be taken to the conventional rehabilitation program. e content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control.
41114167|NCT05393804|BIOLOGICAL|Ide-cel (bb2121)|Eligible patients will undergo leukapheresis, receive lymphodepleting (LD) chemotherapy followed by infusion of Ide-Cel or Cilta-Cel, and be monitored daily for 14 days, three times a week until day + 30 after CAR T infusion and monthly until 12 months post CAR T infusion.
41114168|NCT03634280|OTHER|Kinesio taping|In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
41114169|NCT00190008|DRUG|piracetam|
41114170|NCT05018325|PROCEDURE|Colonoscopy with 6 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
41114171|NCT05018325|PROCEDURE|Colonoscopy 9 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
41114172|NCT05018325|PROCEDURE|Colonoscopy 12 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
41114173|NCT00833365|DRUG|Ibuprofen|Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
41114174|NCT00833365|DRUG|Ibuprofen|Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
41114175|NCT01430858|DEVICE|Strain Gauge|The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
41114176|NCT01430858|OTHER|Vibration therapy|"Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion \& strain gauge readings will be captured.~Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion \& strain gauge readings will be captured.~Power Plate Pro5 Two amplitude settings will be tested, described as low \& high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion \& strain gauge readings will be captured."
41114177|NCT03670368|BEHAVIORAL|Mentoring|The intervention will include one-on-one mentoring sessions held after school, focusing on coping, social relationships, and healthy lifestyles.
41114178|NCT03670368|BEHAVIORAL|Comparison group - written materials|Written materials from the mentoring sessions will be provided to those in the comparison group
41114179|NCT04801563|OTHER|MDS and AlloHSCT|Allogeneic stem cell transplantation, based on TMLI and followed by infusion of donor regulatory T cells and conventional T cells and purified donor CD34+ hematopoietic stem cells
41114180|NCT04951492|DRUG|Olaparib|Given PO
41114181|NCT06488079|OTHER|Summary Label|The Nutri-Score Front-of-Pack nutritional label
41114182|NCT06488079|OTHER|Nutrient-specific label|The NutrInform Battery Front-of-Pack nutritional label
41114183|NCT06488079|OTHER|No label|Conventional food educational flyer
41114184|NCT02338245|DRUG|ASLAN001|ASLAN001 400mg BID
41114185|NCT02338245|DRUG|Lapatinib|Lapatinib 1250mg QD
41114186|NCT02338245|DRUG|Capecitabine|Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
41114187|NCT00787033|DRUG|PF-04554878|Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
41114188|NCT02400099|DIETARY_SUPPLEMENT|High-protein low calorie diet|
41114189|NCT02400099|DIETARY_SUPPLEMENT|Control low calorie diet|
41114190|NCT02400099|OTHER|Anthropometrical measurements|
41114191|NCT02400099|OTHER|Body composition|
41114192|NCT02400099|OTHER|8-h metabolic profile|
41114193|NCT02400099|OTHER|Liver biopsy|
41114194|NCT05030077|DRUG|Anlotinib|Anlotinib(12mg) oral daily for days 1-14, 21 days per cycle
41114195|NCT05030077|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
41114196|NCT05030077|DRUG|Carboplatin|If the patients can't tolerate cisplatin, they will be treated with carboplatin (AUC 4.5mg/mL·min) IV day 1
41114197|NCT05030077|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
41114198|NCT06207435|BEHAVIORAL|Transportation|Eligible patients are contacted and offered free transportation to and from their upcoming appointment.
41114199|NCT06170450|DEVICE|Cyclic SNM|SNM cycling: 8 hours on, 16 hours off
41114200|NCT06170450|DEVICE|Continuous SNM|Continuous SNM: on continuously, no 'off' period
41114201|NCT05162794|OTHER|Laparoscopy with excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. Then, the relevant tissue will be excised and a histology will be performed.
41114202|NCT05162794|OTHER|Laparoscopy without excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. However, no tissue will be excised and histology will not be performed.
41114203|NCT05162794|OTHER|Medical treatment-as-usual|Patients continue their hormonal and analgesic treatment-as-usual.
41114204|NCT04826445|OTHER|Data collection|Imaging collection
41114205|NCT06354140|DRUG|Tegafur|Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year. Tegafur: body surface area (BSA) \< 1.25m2, use 80mg; 1.25-1.5m2, use 100mg; \> 1.5m2, use 120mg. Treatment for 1 year
41114206|NCT03185780|OTHER|Acupuncture|"Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.~Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.~Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas."
41114207|NCT03686891|OTHER|Skin prick tests with four native legumes|Skin prick tests with four native legumes
41114208|NCT04679571|BIOLOGICAL|Albumin|Patients with serum albumin \<3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin \>3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin \>3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks.
41114209|NCT04679571|DRUG|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year."
41114210|NCT04042129|OTHER|gynecologic operations with urological complications|
41114211|NCT06554860|OTHER|scapular Blackburn stabilization plus exercise|scapular Blackburn stabilization
41114212|NCT06554860|OTHER|PNF plus Exercise|PNF plus Exercise
41114213|NCT06554860|OTHER|exercise only|Exercise only
41114214|NCT01925469|DRUG|Benzocaine|
41114215|NCT01925469|DRUG|Saline spray|A saline spray will be used in the placebo group
41114216|NCT05698069|DIAGNOSTIC_TEST|Pain Modulation Index|A 18 item questionnaire assessing patients' pain characteristics for the detection of disordered pain modulation processes.
41114217|NCT05698069|OTHER|Pain Detect|A questionnaire that was validated for the assessment of neuropathic pain
41114218|NCT05698069|OTHER|Central sensitization inventory|A questionnaire developed for the detection of central sensitization.
41114219|NCT04705922|DRUG|TT-00420 Capsule|TT-00420 capsule formulation, administered orally
41114220|NCT04705922|DRUG|TT-00420 Tablet|TT-00420 tablet formulation, administered orally
41114221|NCT02960659|DRUG|Liraglutide|Liraglutide (6mg/ml, 3ml ) solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6mg, 1.2mg or 1.8mg.
41114222|NCT02960659|DRUG|Metformin|Metformin 500mg oral tablet
41114223|NCT04233632|DEVICE|FC2 Condom|FC2: FC2 is composed of a synthetic nitrile rubber latex and 170mm in length. It has a flexible inner ring as the internal retention mechanism and a circular ring as the outer retention mechanism at the open end of the condom. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is available in clear and other colors/scents. It is manufactured by Female Health Company, USA and has USFDA, World Health Organisation (WHO)/United Nations Populations Fund (UNFPA) and South African Bureau of Standards (SABS) approval
41114224|NCT04233632|DEVICE|Cupid Condom|Cupid is composed of a Natural rubber latex and is 155mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in clear and red color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union (EU) and SABS approval
41114225|NCT04233632|DEVICE|Cupid 2 Condom|Cupid2 is composed of a Natural rubber latex and is 125mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in Clear and purple color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, CE Mark of the EU and SABS approval
41114226|NCT05531032|OTHER|Phone Interview|Phone interview questionnaire
41114227|NCT04236973|DEVICE|Molbio Truenat™ HCV assay (the investigational product)|The Molbio Truenat™ HCV assay (the investigational product) is a quantitative chip-based Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) tests for the detection of HCV genomic RNA from human whole blood, EDTA plasma and serum. The Truenat™ HCV assay runs on the Truelab™ Uno, Truelab™ Duo or Truelab™ Quadro Dx. Results of testing by Truenat™ HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
41114228|NCT04236973|OTHER|Abbott RealTime HCV assay|Plasma specimens will be also tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities. Only the results of Abbott RealTime HCV assay may be used to make clinical decisions.
41114229|NCT00145743|BEHAVIORAL|physio,pain,psychotherapy;social,nutrit.counselling&sports|profile and treatment recommendations based on the profile vs. routine psychooncology
41114230|NCT05488080|BEHAVIORAL|Department-level audit and feedback and electronic health record-embedded clinical decision support|This intervention will provide clinicians with Equity Report Cards and clinician decision support on mitigating disparities in quality of care.
41446126|NCT05048667|OTHER|Sham SWT|Sham Shockwave Therapy will be administered in the sham arm.
41446127|NCT05048667|OTHER|Placebo Saline|5 mL Placebo saline will be administered via intracavernous injection in the sham arm.
40752557|NCT01391871|DEVICE|Transthoracic echocardiography CFR measurement|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
40752558|NCT06016790|GENETIC|cfDNA sequencing|Multi-omics sequencing of cfDNA in peripheral venous blood.
41114231|NCT00648011|DRUG|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
41114232|NCT00648011|DRUG|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fed
41114233|NCT04164056|DEVICE|deep brain stimulation|deep brain stimulation on the hippocampus or the anterior nucleus of the thalamus
41114234|NCT00107796|DRUG|Modafinil|
41114235|NCT01566916|PROCEDURE|Total Hip Arthroplasty|
41114236|NCT03110965|BEHAVIORAL|Yoga poses|Patients are asked to perform one or two yoga poses daily for 4-10 months
41114237|NCT03648762|BEHAVIORAL|Aerobic Exercise Intervention|Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
41114238|NCT03648762|BEHAVIORAL|Combined Aerobic and Strength Exercise Intervention|Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
41114239|NCT03648762|BEHAVIORAL|Inspiratory Muscle Training Exercise Intervention|Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
41114240|NCT00831675|BIOLOGICAL|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
41114241|NCT00831675|BIOLOGICAL|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
41114242|NCT06457178|BEHAVIORAL|Acceptance and Commitment Therapy-Based Intervention for Oncology Patients|An intervention program was prepared for oncology patients aiming to reduce psychological distress and increase participation in normal life.
41114243|NCT06457178|BEHAVIORAL|Psychoeducation for Oncology Patients|A program was prepared to support oncology patients in physical and psychological symptom management.
41114244|NCT05989646|DEVICE|Sacral TENS|Sacral TENS applied two hours daily for 10 weeks
41114245|NCT05448846|PROCEDURE|Enhanced Recovery After Surgery|ERAS protocol includes preoperative counselling, optimization of nutrition, standardized analgesic and anesthetic regimens and early mobilization.
41114246|NCT05448846|BEHAVIORAL|Home-based multicomponent exercise program (EXE)|"Home-based multicomponent exercise program:~A) Strength and balance (20 to 40 minutes, 2 days/week):~* Chair sit to stand exercise \| 1 to 3 sets completing repetitions until rating 5 to 8 in the Rated of Perceived Exertion, 0-10 scale (RPE).~* Seated curl to press exercise \| 1 to 3 sets completing repetitions until rating 5 to 8 RPE.~* Monopodal balance \| 1 to 3 sets with progressive time targets up to 60-second for each leg.~B) Gait (at least 30 minutes at an intensity that allows for comfortable conversation, 2 days/week on separate days from strength and balance exercise)~C) Inspiratory Muscle Training: 30 inspirations at 40% of maximal inspiratory pressure through a Power Breathe device, 2 times per day)"
41114247|NCT04520659|BIOLOGICAL|RSV LID/ΔM2-2/1030s|10\^5 plaque-forming units (PFU); administered as nose drops
41114248|NCT04520659|BIOLOGICAL|Placebo|Administered as nose drops
41114249|NCT06086080|OTHER|Standard care|Bracing and physical therapy
41114250|NCT06086080|OTHER|Taping|The patient is treated with tape in special configuration (McConell modified) for the patella + standard care
41114251|NCT06086080|DEVICE|Sham taping|Taping with no treatment disposition
41114252|NCT01147380|BIOLOGICAL|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
41114253|NCT05273788|DEVICE|2400 ThorS-MagNT Stimulations at 1Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 1 Hz ThorS-MagNT, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
41114254|NCT05273788|DEVICE|2400 ThorS-MagNT Stimulations at 10Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 10Hz ThorS-MagNT involves delivering one train of 100 pulses per minute with 50-second rest intervals over twelve minutes on both right and left sides (total 1200 pulses/side).
41114255|NCT05273788|DEVICE|Sham Stimulations|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. Sham stimulations, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
41114256|NCT05591144|DRUG|Prednisone tablet|The dose selection of oral prednisone is the maximum daily dose based on weight for 4 days, followed by a taper every 2 days, with the maximum duration to 14 days.
41114257|NCT05591144|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extracts are traditional Chinese medicine, which can improve microcirculation and provide good ameliorating effects for the treatment of tinnitus
41114258|NCT00595205|OTHER|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
41114259|NCT04674371|OTHER|central venous catheter insertion|Every operator should perform the CVC Insertion Procedure according to his common clinical practice.
41114260|NCT05434624|DRUG|Midazolam|Before the procedure, all patients were given i.v. 0:02 - 0:04 mg / kg midazolam (zolamide 15 mg / 3 mL, and medications, Turkey) will be administered.
41114261|NCT05434624|DRUG|Propofol|Propofol 0.5 mg/kg bolus dose will be administered to Group II. Maintenance will be provided with 60 mcg/kg/min propofol infusion, and the propofol infusion dose will be increased by 10 mcg/kg/min by titration until the BIS value is 40-60 during the procedure.
41114262|NCT02384070|PROCEDURE|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
41114263|NCT02384070|DRUG|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
41114264|NCT02384070|DRUG|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
41114265|NCT02384070|DRUG|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
41114266|NCT01318655|DRUG|NKTR-118|Tablet, Oral, Once daily
41114267|NCT01318655|DRUG|Placebo|Tablet, Oral, Once daily
41114268|NCT00414544|DEVICE|CosmetaLife|Dermal filler
41114269|NCT00414544|DEVICE|Restylane|Dermal filler
41114270|NCT00002972|DRUG|paclitaxel|
41114271|NCT00731523|DRUG|fingolimod (FTY720)|
41114272|NCT05425433|OTHER|Tailored serial casting intercention|Every participant will undergo 1 week of usual care for the affected joint according to the OT's prescription (static progressive, dynamic or serial static) combined with stretching, moisturizers, pressure therapy, or thermal modalities. After the one week of splinting, if the PROM of the targeted joint does not improve, the participant will start serial casting (Monday to Friday). Patients will have a cast applied on Monday morning and worn for 24hrs/day or for 48hrs according to the OTs and treating physician's decision (rationale documented).The OT will decide how many weeks the participant will be wearing casts and the rationale to stop this treatment will be documented. When the treatment is stopped, patients will be encouraged to wear a maintenance splint for the following 2 weeks.
41114273|NCT01773980|OTHER|Clinic Intervention|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
40752559|NCT00263562|DRUG|Steroid arm|Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
40752560|NCT00263562|OTHER|Placebo|Patients received normal saline in lieu of intravenously-administered methylprednisolone and placebo pills equal in number to the steroid pills received in the steroid arm
40752561|NCT00360100|DRUG|Zmax|
41114274|NCT01773980|OTHER|Patient Intervention|The patient intervention consists of a single 90-minute interactive in-person session.
41114275|NCT00009217|DRUG|Haloperidol-Haloperidol|Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
41114276|NCT00009217|DRUG|Haloperidol-Placebo|Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
41114277|NCT04674436|BEHAVIORAL|Walking|6 minute casual walk
41114278|NCT01343290|DRUG|Canagliflozin|Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
41114279|NCT03617978|PROCEDURE|Hemodynamics parameters|real-time evaluation of cardiac output parameters using the ICON device
41114280|NCT03247023|DEVICE|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
41114281|NCT04583306|OTHER|Raman analysis of saliva, characterization of the Raman database and building of the classification model|Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
41114282|NCT03557411|DRUG|SHR-1210|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
41114283|NCT00695071|DRUG|Itraconazole|Oral
41114284|NCT02999022|DRUG|Lithium Carbonate|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
41114285|NCT02999022|DRUG|Lactose Placebo|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
41114286|NCT03014973|BIOLOGICAL|intra-prostatic concentration of sexual steroids|
41114287|NCT03014973|PROCEDURE|Trans-rectal biopsy|
41114288|NCT03411278|DEVICE|Deep Oscillation (DO)|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2).The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
41114289|NCT02468388|OTHER|maltitol|maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
41114290|NCT02468388|OTHER|xylitol|xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
41114291|NCT02468388|OTHER|gum base|gum base: 99% gum base; two pellets for 10 min five times each day
41114292|NCT02377726|BEHAVIORAL|Alkoholhjälpen counselor support|Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.
41114293|NCT02377726|BEHAVIORAL|eChange Alkoholhjälpen|An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help
41114294|NCT02377726|BEHAVIORAL|Alkoholhjälpen|A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
41114295|NCT05317910|OTHER|MUSIC CARE|"Relaxation-type receptive musical intervention technique. The standardized 20-minute musical sequence is broken down into several phases that gradually lead the patient to relaxation using the new U-Mount technique \[1, 2\] (Figure 1). The effect works by reducing the musical rhythm, orchestral formation, frequencies and volume (the U descending phase). After a maximum relaxation phase (lower part of the U), a re-activating phase (ascending branch of the U) is followed."
41114296|NCT06042439|BEHAVIORAL|6 weeks of exercise training (Pre-training)|handgrip and treadmill walking 4 days per week
41114297|NCT06042439|BEHAVIORAL|6 weeks of exercise training (Post-training)|handgrip and treadmill walking 4 days per week
41114298|NCT04488783|DIETARY_SUPPLEMENT|zinc and ascorbate|oral zinc and ascorbate
41114299|NCT05858073|OTHER|Kinesio Taping|"Standard 5 cm Kinesio Tex will be used. Initially, a Y-strip was paper-off (without tension) from the starting point to the insertion of the supraspinatus, while the participants were reaching with their upper extremities behind their backs and flexing their necks to the contralateral side. Second, an I-strip from the coracoid process will be applied around the posterior deltoid using approximately 50% to 75% downward flexion. Initially, the shoulder will be externally rotated without elevation, and then slightly horizontally adduction and forward elevation as the end of the band is applied without stretching. This I strip is shaped like a Y at the end of the tape.~Finally, a Y-strip will be applied using paper-off tension from the T10-T12 region to the medial border of the scapula to facilitate the lower trapezius muscle. For this technique, the shoulder was adducted horizontally and the middle tail was applied with the hands crossed over the chest."
41114300|NCT05858073|OTHER|Placebo Kinesio Taping|Standard placebo taping will be applied to the placebo Kinesio taping group with a standard 5 cm Kinesio Tex. Two tension-free strips will be applied separately to the acromioclavicular joint and lower trapezius muscle. Suspicious participants will be excluded from the study.
41114301|NCT02711059|PROCEDURE|parathyroidectomy|surgical treatment of hyperparathyroidism
41114302|NCT03695471|BIOLOGICAL|Pembrolizumab|Given IV
41114303|NCT01691963|DEVICE|C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
41114304|NCT00028678|DRUG|dalteparin|
41114305|NCT00028678|RADIATION|radiation therapy|
41114306|NCT01493310|DRUG|mifepristone|"Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)"
41114307|NCT01493310|DRUG|placebo|Given orally
41114308|NCT01493310|DRUG|nab-paclitaxel|"Given by intravenous infusion (IV)~Dose of 80 mg/m2"
41453368|NCT01172249|DRUG|Glucosamine sulfate + chondroitin sulfate - MANTECORP|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
40752562|NCT02473263|DRUG|Ceftriaxone|Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
40752563|NCT02473263|DRUG|Piperacillin tazobactam|Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
41453369|NCT01172249|DRUG|Glucosamine sulfate + chondroitin sulfate - CONDROFLEX|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
40752564|NCT02473263|DRUG|Norepinephrine|Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
40752565|NCT02473263|DRUG|Hydrocortisone|Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
40752566|NCT05039593|OTHER|chlorhexidine|The population of the research is the patients hospitalized in the Internal Medicine intensive care unit of Aydın Adnan Menderes University Practice and Research Hospital between 01.06.2021 and 01.06.2022, and the sample is; Patients who are older than 18 years of age, who are in the first 24 hours of mechanical ventilation, who are 18 years of age and older, and whose relatives have consented.Oral care of the patients will be done with 0.12% chlorhexidine solution, and the frequency of oral care will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses.
40926137|NCT03603171|DIAGNOSTIC_TEST|Six minute walking test|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
40926138|NCT03603171|DIAGNOSTIC_TEST|Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)|A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.
40926139|NCT00849316|DRUG|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
40926140|NCT05402033|BEHAVIORAL|Survey / Interview Group|Patients with any cancer type who are informed that they may be eligible for participation in any phase therapeutic cancer clinical trial by their treating physician (typically a clinical oncologist) will be provided information about the Financial Reimbursement Program. Patients who enroll to therapeutic cancer clinical trial will be eligible for the reimbursement program and offered an opportunity to participate in this study.
40926141|NCT06092047|BIOLOGICAL|UTAA09 cells for infusion|Intravenous injection, dosage:1-10×10\^8 CAR+ γδT cells, Cell concentration: 2×10\^7 cells/mL.
40926142|NCT06092047|DRUG|Fludarabine|30 mg/m\^2/day×4 days
40926143|NCT06092047|DRUG|Cyclophosphamide|1000 mg/m\^2/day×3 days
40926144|NCT00945906|BIOLOGICAL|FXIII Concentrate (Human) (FXIII)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion."
40926145|NCT04158193|OTHER|acupuncture|Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.
40926146|NCT04158193|OTHER|sham acupuncture|"Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks."
40926147|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.1).
40926148|NCT04604132|DRUG|Derazantinib-paclitaxel-ramucirumab combination|"Derazantinib was administered orally at a dose of 200 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
41114309|NCT01464736|OTHER|physical training|For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
41114310|NCT03593213|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily.
41114311|NCT03593213|DRUG|Placebo|Matching placebo capsules, oral administration, once daily.
41114312|NCT01596946|BEHAVIORAL|Contact tracing mode test at clinic|
41114313|NCT01596946|BEHAVIORAL|Self-sampling at home - Sent Test Kit|
41114314|NCT01489982|DEVICE|Light box (Litebook company)|Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
41114315|NCT01489982|BEHAVIORAL|CBT and sleep hygiene|6 weekly sessions totalling 90 minutes
41114316|NCT01489982|DRUG|Doxepin and Zopiclone|Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
41114317|NCT01489982|DEVICE|Light box ( Litebook company)|The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
41114318|NCT01271452|BIOLOGICAL|botulinum toxin type A|20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
41114319|NCT01271452|BIOLOGICAL|botulinum toxin type A|30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
41114320|NCT05702658|BEHAVIORAL|CAPS|Community Autism Peer Support is a one-to-one autistic-delivered peer support, community-based intervention focused on independent living and participation.
41114321|NCT03276104|PROCEDURE|IOL repositioning|Intraocular lens repositioning by scleral suturing
41114322|NCT03276104|PROCEDURE|IOL exchange|Intraocular lens exchange with retropupillary iris-claw lens
41114323|NCT06076980|DRUG|Paracetamol|compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
41114324|NCT06076980|DRUG|Normal saline|as placebo
41114325|NCT00516386|DRUG|RhIGF-1|35-40 mcg/k/dose twice daily SC
41114326|NCT03403998|OTHER|Exercises|The treatment will consist of an 8-week progressive exercise program of neck flexors and extensors exercises supervised by a physical therapist for 30-45 min twice a week per 8 weeks as described in Arm/group descriptions.
41114327|NCT03403998|OTHER|Placebo|The placebo treatment will be for 30-45 min twice a week for 8 weeks, as for the intervention group. ( see details in arm description)
41114328|NCT03930225|BEHAVIORAL|Stigma Directed Psycho-educational Intervention program|psycho-educational intervention with emphasis on Stigma
41114329|NCT02220478|DEVICE|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
41114330|NCT05888584|OTHER|Research readiness tool|Online/paper based tool for use by nurses to aid discussions with lung cancer patients about clinical trials opportunities.
41114331|NCT06518538|DRUG|CPI-613, modified Folfirinox|"* CPI-613, devimistat~* mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan"
41114332|NCT05907473|OTHER|Virtual Reality Therapy|Patients in this group will play balance-based games with the Virtual Reality System.
41114333|NCT05907473|OTHER|Conventional Rehabilitation|In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.
41114334|NCT03394976|DIAGNOSTIC_TEST|No intervention|No intervention
41114335|NCT02728765|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
41114336|NCT05323266|DEVICE|Nasal Continuous Positive Airway Pressure (nCPAP)|The two main interventions in this study were Nasal continuous positive airway pressure (nCPAP) and high-flow nasal cannula (HFNC) in patients with acute stroke. Nasal continuous positive airway pressure (nCPAP) is a way of ventilation completed in a non-invasive ventilator. In this study, the nasal mask is mainly used to replace the traditional oral and nasal mask.
40926149|NCT04604132|DRUG|Derazantinib-paclitaxel-ramucirumab combination|"Derazantinib was administered orally at a dose of 300 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
41114337|NCT05323266|DEVICE|High-Flow Nasal Cannula (HFNC)|The high-flow nasal cannula (HFNC), as another oxygen therapy, is also used as an intervention in this study to study the effect of early prognosis in patients with acute ischemic stroke.
41114338|NCT03929770|PROCEDURE|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
41114339|NCT03929770|PROCEDURE|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
41114340|NCT00767013|OTHER|DSCT, TTE|One assessment each
41114341|NCT02348658|DRUG|TAK-536TCH|TAK-536TCH tablets
41114342|NCT01430611|BIOLOGICAL|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
41114343|NCT01430611|BIOLOGICAL|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
41114344|NCT06444958|DIAGNOSTIC_TEST|observational study without any intervention component.|"extracting and analyzing the following data:~Outpatient department records: Diagnoses, treatments, patient demographics Inpatient admission records: Admission diagnoses, treatments, patient outcomes (discharged, transferred, died) Mortality records: Causes of death for pediatric patients"
41114345|NCT05684094|BEHAVIORAL|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
41114346|NCT05684094|BEHAVIORAL|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
40926150|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 200 mg twice daily as monotherapy in the Substudy 1 (Cohort 1.3).
40926151|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.2).
40926152|NCT03235180|DRUG|Sulfur Hexafluoride|Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.
41114347|NCT04777968|DRUG|Silver diamine fluoride|a layer of 38% SDF solution was topically applied to the cavity using a micro brush, immediately followed by a saturated Potassium Iodide KI solution using a micro brush also, then a creamy white precipitate was immediately formed, KI was applied until the white precipitate turned clear.
41114348|NCT05143658|PROCEDURE|LLS versus LP|Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
41114349|NCT01865149|PROCEDURE|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
41114350|NCT02825485|PROCEDURE|Voiding cystourethrogram|
41114351|NCT01932450|PROCEDURE|renal sympathetic denervation|One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
41114352|NCT01932450|DRUG|antihypertensive drugs|antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
41114353|NCT04880694|DRUG|STC3141|"To receive continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
41114354|NCT04880694|DRUG|STC3141|"To receive continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
41114355|NCT05132348|DIAGNOSTIC_TEST|Immunological markers|Markers of blood samples of patients suffering from osteoporosis will be analyzed
41114356|NCT01415349|DRUG|SSP-002358|1 mg, oral, once
41114357|NCT01415349|DRUG|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
41114358|NCT04712851|BIOLOGICAL|Pembrolizumab|Given IV
41114359|NCT02444130|DEVICE|contact lenses|Presbyopia was compensated with contact lenses by monovision and multifocality.
41114360|NCT00930098|DRUG|clofarabine|
41114361|NCT04390958|DRUG|nab-paclitaxel|125mg/m2 ivgtt d1、d8
41114362|NCT04390958|DRUG|Cisplatin|60mg/m2 ivgtt d1 or d1-2
41114363|NCT04390958|DRUG|Capecitabine|1750mg/m2 po bid d1-14
41114364|NCT06131268|DRUG|Venlafaxine|we will recruit a cohort of 10 MDD patients currently receiving evidence-based treatments for depression (including treatment with an antidepressant drug such as SSRIs/SNRIs) who will be switched to the antidepressant venlafaxine and followed along for 4 weeks (Group 1). The switch from the ongoing treatment to venlafaxine will must be required by therapeutical needs (null or partial response and/or poor tolerability or compliance to ongoing therapy) according to the indications of the principle clinical guidelines for the treatment of MDD and it is independent of the decision of including the patient in the study.
41114365|NCT03276871|PROCEDURE|Telescopic Dissection|Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
41114366|NCT03276871|DEVICE|Balloon Dissection|Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
41114367|NCT02772263|OTHER|CHAP-EMS|The CHAP-EMS program is a low cost community program that is designed to assess community dwelling seniors for lifestyle risk factors that may impact their health and well-being and to provide targeted education to address the pertinent risk factors. Each participant is guided through a structured health-risk assessment focused on diabetes, cardiovascular disease and other potential health issues. The assessment is conducted by a trained paramedic in a common area within the community housing building. Data gathered are used to develop individualized action plans concerning health-risk reduction, to direct participants to local health activities or resources, educate on promoting health and to transmit this information to a participants' family physician.
41114368|NCT03375151|DEVICE|EEG based feedback|Participants will participate in cognitive training sessions. The therapist will use feedback from the EEG analyzed data to direct the cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
41114369|NCT03375151|BEHAVIORAL|Standard practice based feedback|Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.
41114370|NCT03375151|BEHAVIORAL|No feedback|Participants will participate in cognitive training sessions. The therapist will not guide them during the sessions.
41114371|NCT03068078|DIETARY_SUPPLEMENT|Low carbohydrate diet high in monounsaturated fats|Participants will have to change their diet during 6 months
41114372|NCT03010553|PROCEDURE|Detection and resection of sentinel lymph node|
41114373|NCT00964197|DEVICE|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
41114374|NCT04655859|DIAGNOSTIC_TEST|saliva cotton swab|evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group
41114375|NCT05414786|BIOLOGICAL|eOD-GT8 60mer mRNA Vaccine (100µg)|"* 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~* No control group. There is no blinding and no randomization in this open label study"
41114376|NCT02107339|DRUG|Methadone|Methadone 0.2 mg/kg administered at induction of anesthesia
41114377|NCT02107339|DRUG|Hydromorphone|Hydromorphone 2 mg administered at the conclusion of anesthesia
41114378|NCT04516603|DRUG|Fampridine SR|Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
41114379|NCT04516603|DRUG|Placebo|no active component
41114380|NCT01060514|DRUG|Pazopanib|dose escalation, administered orally, daily
41114381|NCT01060514|DRUG|Vinorelbine|dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
41114382|NCT01198275|DRUG|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
41114383|NCT01198275|DRUG|Placebo|1.0 g of olive oil,one capsule twice a day
41114384|NCT01198275|DRUG|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
41114385|NCT01198275|DRUG|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
41114386|NCT04320771|DRUG|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
41114387|NCT04813952|DRUG|Sevoflurane inhalant product|The sevoflurane dose differed in both groups in relation to the fresh gas flow. Since the fresh gas flow is less in group M, the concentration of sevoflurane consumed by the patient at the end of the case will be less.
41114388|NCT01153451|OTHER|Email Notification|BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
41114389|NCT02464852|BEHAVIORAL|Head movements|Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.
41114390|NCT02464852|BEHAVIORAL|Activities of daily living (drinking, washing hand and eating)|Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).
41114391|NCT02464852|DEVICE|Sheffield Support Snood|
41114392|NCT02464852|DEVICE|sEMG|
41114393|NCT06227637|OTHER|Local Muscle Vibration compared to Muscle energy technique in SIJD|Apply Local Muscle Vibration compared to Muscle energy technique on patients with sacroiliac joint dysfunction and note the effect on pain intensity, pain pressure threshold, functional disability, and innominate angle tilt in SIJD.
41114394|NCT01537419|BEHAVIORAL|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
41114395|NCT01537419|BEHAVIORAL|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
41114396|NCT04329364|COMBINATION_PRODUCT|Laser Haemorrhoidoplasty (LAH)|Using a laser diode to cause coagulative necrosis to the haemorrhoidal cushion
40926153|NCT03235180|DEVICE|Ultrasound Elastography|Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
40926154|NCT03235180|DEVICE|Ultrasound Vascularity|Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
41114397|NCT04329364|PROCEDURE|Open milligan-morgan conventional haemorrhoidectomy|conventional excisional haemorrhoidectomy
41114398|NCT01546753|DRUG|Walnut Protein Powder|Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.
41114399|NCT01546753|DRUG|Oat Powder (placebo)|Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.
41114400|NCT01546753|DRUG|Open-label Walnut Protein Powder|Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
41114401|NCT04481074|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed using the tapered flow-resistive loading trainer (POWERbreathe®).
41114402|NCT04949035|DIAGNOSTIC_TEST|Assessment of mental state and quality of life|Patients qualified for rehabilitation will be assessed for stress levels as well as symptoms of anxiety and depression and quality of life before rehabilitation began
41114403|NCT04115683|OTHER|Dual Task Training|45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.
41114404|NCT04115683|OTHER|Single Task Training|45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
41114405|NCT06269822|DIAGNOSTIC_TEST|Sympathetic skin response, heart rate variability test, quantitative EEG|Sympathetic skin test (electrodermal activity) to test for sympathetic function Heart rate variability test to assess cardiovagal function Quantitative EEG to quantitatively assessing the brain function using fast fourier transform technique
41114406|NCT02928874|BEHAVIORAL|% COMPX (low ED vs. high ED preload)|
41114407|NCT02928874|BEHAVIORAL|EAH (low ED vs. high ED snacks)|
41114408|NCT05032638|BEHAVIORAL|Therapist guided training|Therapist guided period delivered virtually (WebEx/Zoom). Participants will be patients associated with NYULH and will have access to Zoom. Each session will last 45 min, and will completed 3x/week by research therapists, who are part of the study.
41114409|NCT05032638|BEHAVIORAL|Upper extremity (UE) Training|The 4-week UE training is completed in the participants home on their own and communication with study staff is virtual. Participants will receive daily communication through the Expiwell app to answer survey questions related to adherence, and safety/adverse events. Participants will also complete weekly check-ins with their research therapist over Zoom to answer questions about difficulties related to UE training activities, refinement of training goals, and to receive feedback on their training performance. Each weekly check-in will be approximately 45 minutes.
41114410|NCT04291729|DRUG|Ganovo+ritonavir+/-Interferon nebulization|Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
41114411|NCT02962141|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|Treatment group
41114412|NCT02962141|DEVICE|Balloon Dilatation Catheter|Control group
41114413|NCT01813812|DRUG|DA-6034|
41114414|NCT01813812|DRUG|Rebamipide 300mg|
41114415|NCT06555588|BEHAVIORAL|ENGAGE|This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is based on an integration of Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) approaches for managing symptoms of pain, fatigue, and distress. Participants are trained in behavioral symptom management skills (e.g., activity pacing, mindfulness) with an emphasis on engaging in highly valued activities.
41114416|NCT06555588|BEHAVIORAL|Supportive Care|This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is designed to provide participants with education, support, and resources for a range of issues relevant to those with advanced cancer (e.g., education on symptoms, body image concerns, and financial concerns).
41114417|NCT06441786|BEHAVIORAL|A metacognitive group therapy of depression and anxiety in youth with autism|"The treatment model is based on Adrian Wells' transdiagnostic A-M-C model and treatment structure described in Wells (2009) Metacognitive therapy for anxiety and depression. The group treatment is delivered in 10 weekly sessions."
41114418|NCT02359188|DEVICE|Transcutaneous vagal nerve stimulation|4 hours of transcutaneous vagal nerve stimulation
41114419|NCT00144144|DRUG|Angiotensin II receptor antagonists, Calcium channel blocker|
41114420|NCT05496907|BEHAVIORAL|Diabetes specialist nurse-led collaborative care intervention|10 sessions with a diabetes nurse to help improve physical and mental health outcomes
41446128|NCT06558240|DEVICE|HERADERM Hydrogel Wound Dressing (Sterile)|HERADERM Hydrogel Wound Dressing (Sterile) is a transparent, composite hydrogel dressing. The outer layer is a waterproof and breathable polyurethane film (PU film), which can prevent external bacterial invasion and reduce the risk of infection. The inner layer is A+ polymer hydrogel, which can keep the wound bed in a moist state and reduce the infiltration problem caused by wound exudate.
41114421|NCT04806958|OTHER|PulsePoint notification|"The PulsePoint interface software monitors each 9-1-1 call on dispatch computers and is automatically triggered by particular conditions including call type (e.g. suspected cardiac arrest) and location type (public location). When triggered, the system pushes location data to all PulsePoint mobile application users within 400 meters of the emergency location.~When a mobile device running the PulsePoint Respond application receives the alert data from the PulsePoint system, the device alarms with auditory, tactile (vibration) and visual stimuli. The application presents a map showing the exact location of the suspected cardiac arrest and the closest public access defibrillator."
40926155|NCT03235180|DEVICE|Magnetic Resonance Enterography (MRE)|Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
41114422|NCT05084612|DEVICE|standard LMA insertion|"Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete~the laryngeal mask will be inserted with using the standard method described by Brain; after lubrication of the posterior aspect of the partially deflated mask, the patient's head will be positioned with head extended at the atlanto-axial joint and flexed at the neck with non-dominant hand. The LMA will be held like a pen and index finger will be placed at the junction of LMA tube and cuff. Index finger will be used to press the LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of the hypopharynx. LMA will then be held with non-dominant hand and index finger will be removed."
41114423|NCT05084612|DEVICE|New technique LMA insertion|Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete LMA will be inserted by a two Person Insertion with lateral rotation Technique; after lubrication of the posterior aspect of the partially deflated mask, the assistant will achieve jaw thrust and mouth opening then LMA will be inserted by the anaesthiologist. LMA will be inserted by holding the mask by index, middle finger and thumb; after insertion of the entire cuff inside the mouth, the LMA will be rotated anticlockwise through 90° (the inner surface of LMA will be directed medially towards the mouth cavity) and advanced through the side of the tongue until resistance felt, then turned back in the hypopharynx.
41114424|NCT03891927|DIETARY_SUPPLEMENT|extra virgin olive oil|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO
41114425|NCT00700336|DRUG|pemetrexed, cisplatin and CBP501|"CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
41114426|NCT00700336|DRUG|pemetrexed and cisplatin|"Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
41446129|NCT04994535|DRUG|OnabotulinumtoxinA|Injection
41446130|NCT04994535|DRUG|Placebo|Saline injection
41114427|NCT00700336|DRUG|pemetrexed, cisplatin and CBP501, dose finding|"Dose level 1: CBP501 16 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Dose level 2: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
41114428|NCT04383730|DRUG|Intravenous sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
41114429|NCT04383730|DRUG|Inhaled sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
41114430|NCT05692908|BIOLOGICAL|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
41114431|NCT02186197|OTHER|Critical Care Ultrasound|A critical care ultrasound exam will be performed on all patients included in this study
41114432|NCT03654235|OTHER|Health Education|6 pain neuroscience education sessions (10 hours) and delivery of printed reinforcement material.
41114433|NCT03654235|OTHER|Physical exercise|Group physical exercise program (18 sessions; 3 sessions/week) leaded by a physiotherapist. It includes exercises to improve strength, coordination, balance and aerobic capacity. Work with double tasks, recreational activities to overcome kinesiophobia and activities to do at home are used in the program.
41114434|NCT03654235|OTHER|Usual care in Primary Care Physiotherapy Units|"Treatment supported by the protocol of primary care of physiotherapy in the health service of Castilla y León that was in force at the time of the intervention.~Patients receive 15 sessions of analgesic electrotherapy, thermotherapy and standardized physical exercise"
41446131|NCT05954559|DRUG|Elucirem (Gadopiclenol)|Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.
41446132|NCT04013217|COMBINATION_PRODUCT|Eribulin ORA|Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK
40926156|NCT03066973|BEHAVIORAL|BREATHING EXERCISE|The intervention group was instructed on breathing exercise according to the established trial protocol.
41114435|NCT06335472|PROCEDURE|3 nerves pulsed radiofrequency with hydrodissection|"Patient will be in a sitting position, targeting the SSN, needle will be pushed towards floor of the suprascapular fossa, SSN is just adjacent to the suprascapular artery.~The axillary nerve, between the deltoid muscle posteriorly, triceps muscle caudally and humerus anteriorly, axillary nerve appears as hyperechoic round in relation to posterior circumflex humeral artery.~Lateral pectoral nerve, middle of coracoid process should be targeted, lie within hyperechoic fascial plane between pectoralis major and pectoralis minor muscle.~hydrodissection, US transducer will be positioned inferior to scapular line , landmarks are contours of glenoid rim and humeral head, needle will be advanced until enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by infusion of up to 40 mL of normal saline, until capsule is adequately distended and resistance felt"
41114436|NCT06335472|PROCEDURE|suprascapular nerve pulsed radiofrequency with hydrodissection|"The patient will be positioned in a sitting position, PRF needle will be pushed forward towards the floor of the suprascapular fossa the SSN will be visualized just adjacent to the suprascapular artery.~hydrodissection will be done under all aseptic measures ,the US transducer will be positioned just inferior to the scapular line , landmarks are contours of posterior glenoid rim and humeral head, needle will be advanced until the needle tip will enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by an infusion of up to 40 mL of normal saline , until the capsule is adequately distended and resistance will be felt."
41114437|NCT01818713|DRUG|2B3-101|50 mg/m2 2B3-101 intravenous 3-weekly administration
41114438|NCT00952263|BIOLOGICAL|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
41114439|NCT02517450|BEHAVIORAL|an adventure-based training programme|The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year
41114440|NCT02517450|OTHER|a placebo control programme|Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
41114441|NCT04271410|BIOLOGICAL|CD19 CAR-T cells|CD19 CAR-T cell therapy
41114442|NCT03908671|BIOLOGICAL|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine
41114443|NCT05132478|OTHER|Emotionally Supportive Video|The video is approximately 6 1/2 minutes in length and portrays an emotionally supportive conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy with the addition of emotionally supportive statements and gestures.
41114444|NCT05132478|OTHER|Standard Video|The video is approximately 5 minutes in length and portrays a standard conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy.
41114445|NCT04378361|DEVICE|endovascular repair|Endovascular repair of complicated acute, subacute or chronic type B aortic dissection with double lumen
41114446|NCT04178239|DIAGNOSTIC_TEST|fMRI, questionnaires, pneumologic diagnostics|fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
41114447|NCT01461655|DRUG|marketed topical retinoid|once daily application, 4 weeks
41114448|NCT01461655|DRUG|marketed topical NSAID|once daily application, 4 weeks
41114449|NCT01461655|DRUG|vehicle gel|once daily application, 4 weeks
41114450|NCT01461655|DRUG|marketed topical retinoid|once daily application, 4 weeks
41114451|NCT05493254|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
41114452|NCT05493254|BEHAVIORAL|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
41114453|NCT05158153|OTHER|ORKID Bundled Intervention|During the 90-day study period, participants will be prescribed outpatient hemodialysis with cooled dialysate (35-36°C), high sodium dialysate (145 mmol/L), a high ultrafiltration hold threshold (systolic blood pressure \> 110 mmHg; ultrafiltration hold threshold will not be applied in participants with baseline systolic blood pressure \< 120 mmHg), and high dose diuretics (160 mg oral furosemide twice daily) to be taken every day at home will also be prescribed. Dialysis will be weaned according to an active weaning protocol.
41114454|NCT05158153|DRUG|Furosemide|160 mg oral furosemide twice daily to be taken every day at home
41114455|NCT00092105|DRUG|MK0476, montelukast sodium|
41114456|NCT00092105|DRUG|Comparator: placebo|
41114457|NCT02971176|RADIATION|Low-dose protocol computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
41114458|NCT02971176|RADIATION|Standard-dose protocol computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
41114459|NCT02502708|DRUG|Indoximod|Indoximod will be administered orally twice daily.
41114460|NCT02502708|DRUG|Temozolomide|Temozolomide will be administered on days 1-5 of every 28 day cycle.
41114461|NCT02502708|RADIATION|Conformal Radiation|Conformal radiation will be administered on days 3-7 of induction cycle.
41114462|NCT02502708|DRUG|Cyclophosphamide|Cyclophosphamide will be administered orally daily.
41114463|NCT02502708|DRUG|Etoposide|Etoposide will be administered orally daily.
41114464|NCT01833364|PROCEDURE|Implantation of the Peripheral Nerve Graft|"The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility."
41114465|NCT00420901|DRUG|sildenafil|
41114466|NCT00749749|DRUG|Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)|The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
41114467|NCT00749749|DRUG|ON-Q PainBuster Post-op Pain relief System|5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL \[900 mg\])
41114468|NCT02540746|BEHAVIORAL|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
41114469|NCT02540746|BEHAVIORAL|Motivational Enhancement|Three week Motivational Enhancement group
41114470|NCT02540746|BEHAVIORAL|Family Skills Training|12-week group-based family skills training using Family Connections model
41114471|NCT03881449|COMBINATION_PRODUCT|ABILIFY MYCITE|Initiation of ABILIFY MYCITE will commence immediately, with subjects wearing the patch and using the smartphone app for a total of 3 months from baseline visit to the 3 month visit. Following the initial 90-days, the physician and patient may determine to use ABILIFY MYCITE anytime during the following 9 months. Following this period (up to 12 months), the subjects will not use ABILIFY MYCITE and return to standard care. A safety follow-up phone call will occur at 2 weeks after the 12 month/early termination (ET) visit. In addition, individuals in the ABILIFY MYCITE arm will evaluate satisfaction with the use of ABILIFY MYCITE.
41114472|NCT03520413|OTHER|PRACTICE-DM|Five-component diabetes intervention: 1) telemonitoring; 2) self-management support; 3) diet/activity support; 4) medication management; and 5) depression support.
41114473|NCT03520413|OTHER|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
41114474|NCT01241916|DEVICE|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
41114475|NCT01241916|DEVICE|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
41114476|NCT00861029|DRUG|Pazopanib|Subjects treated with pazopanib
41114477|NCT00861029|OTHER|Placebo for pazopanib|Control for comparison with pazopanib
41114478|NCT00861029|DRUG|Moxifloxacin|Comparator for pazopanib
41114479|NCT00861029|OTHER|Placebo for moxifloxacin|Placebo for moxifloxacin
41114480|NCT04496362|DRUG|subcutaneous heparin anticoagulation|The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
41114481|NCT01472003|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
41114482|NCT01472003|DRUG|ABT-806i|ABT-806i will be administered by intravenous infusion.
41114483|NCT00888108|DRUG|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
41114484|NCT00888108|DRUG|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
41114485|NCT04828148|BEHAVIORAL|Survey|An online survey made by the authors was used, which is comprised of a total of 48 questions where different types of information are distinguished regarding the participant who is answering it such as age, gender, medical degree, comorbidities if during the pandemic they have been in contact with patients suspected or confirmed of COVID-19 infection if they have been infected by COVID-19 and the outcome of this infection. It also refers to whether they know doctors in the same specialty or others who have died from COVID-19 infection.
41114486|NCT02494999|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
41114487|NCT02494999|BIOLOGICAL|Prevnar 13|0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose
41114488|NCT03567369|DRUG|Dexamethasone|Dexamethasone 4,0 mg/mL
41114489|NCT03567369|DRUG|Traumeel S|Traummel S 2,2 mg/mL
41114490|NCT02398565|OTHER|No intervention|
41114491|NCT03925558|DIETARY_SUPPLEMENT|Probiotics|
41114492|NCT03925558|DIETARY_SUPPLEMENT|Placebo|
41114493|NCT05631210|OTHER|Privacy agreements with pictograms|The intervention consisted of a modified privacy agreement talking about health data. Instead of presenting all of that information through text, the investigators added pictograms that summarized the key points at the beginning.
41114494|NCT02810080|DEVICE|Closed Loop Control Ventilation|Closed loop control ventilation using ZOLL 731 ventilator with physiologic closed-loop control software
41114495|NCT02810080|DEVICE|Manual Control Ventilation|Manual control ventilation using ZOLL 731 ventilator
41114496|NCT01472146|DRUG|Zo-Nantax|"Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg \[loading dose\] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy"
41114497|NCT02228356|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy with either Dynamic Tumor Tracking/Internal Target Volume approach on the Vero machine, and/or Internal Target Volume approach on the Tomotherapy machine.
41114498|NCT04004468|BEHAVIORAL|Resistance Training|Standard barbell resistance training programs
41114499|NCT03396900|DRUG|RhBMP-2 Protein, Recombinant|Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
41114500|NCT03396900|OTHER|Conventional Corticotomy|A conventional PAOO Surgical procedure will be performed for individuals in this arm
41114501|NCT01431586|DRUG|JDtic|"The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.~Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug."
41114502|NCT04561219|DRUG|Nitazoxanide|Nitazoxanide 500mg three times a day for 5 days
41114503|NCT04561219|DRUG|Placebo|Placebo three times a day for 5 days
41114504|NCT05942963|DRUG|Empagliflozin 10 MG|10-25 mg/day
41114505|NCT05942963|DRUG|Pioglitazone 15mg|15-45 mg/day
41114506|NCT05942963|DRUG|Metformin|1000mg-2850mg/ day
41114507|NCT02238483|DRUG|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
41114508|NCT02238483|DRUG|Placebo|Inhaled placebo solution
41114509|NCT03977935|DEVICE|the second-generation MCCG|Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
41114510|NCT03600051|DEVICE|Automated Heart Murmur Detection AI|"Automated AI algorithm-based analysis of digital heart sound recordings to detect pathological heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. Algorithm results for each recording included: AHA classification (I pathologic versus III innocent/no murmur), murmur timing, murmur grade, heart rate and S1/S2 identification."
41114511|NCT02100371|DRUG|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
41114512|NCT03745001|DRUG|EHP-101 Liquid single dose|One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).
41114513|NCT03745001|DRUG|EHP-101 Liquid multiple doses|One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)
41114514|NCT03745001|DRUG|Matching placebo|Oral liquid administration daily
41114515|NCT06400394|DEVICE|Hydrocyn Aqua®|The study solution comes in a liquid form containing hypochlorous acid (HOCl) in a concentration of 0.003%. It is used as a topical agent for wound and peritoneal lavage before wound closure
41114516|NCT06400394|DEVICE|Normal Saline|aqueous solution of electrolytes and other hydrophilic molecules
41114517|NCT00137371|DRUG|PVC (daily for 21 days, 7 days off)|
41114518|NCT00137371|DRUG|PVC (twice weekly)|
41114519|NCT06479187|DRUG|18F-rhPSMA-7.3|radiopharmaceutical targeting PSMA and used to image prostate cancer with PET scan.
41114520|NCT06479187|DEVICE|PET/CT|Diagnostic imaging test
41114521|NCT05988307|DEVICE|Percussion massage gun|Percussion massage gun on hamstrings flexibility in patients with knee Osteoarthritis.
41114522|NCT04834219|PROCEDURE|On-Pump CABG|Patients who have undergone on-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
41114523|NCT04834219|PROCEDURE|Off-Pump CABG|Patients who have undergone off-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
41114524|NCT05729672|BEHAVIORAL|Received the Nightingale in Gen-sEx course|The experimental group (n=75) will participate in the SPOC- based education program, consisting of five online teaching and learning modules over the span of 3 months and two hours of offline classroom.
41114525|NCT06149819|OTHER|Diagnostic and safety of a nursing pathway for the management of non-traumatic chest pain|trained nurses will take in charge non-traumatic chest pain patient according to the standardized algorithm based on the recommendations .
41114526|NCT03003845|OTHER|Questionnaires|QOL and pain questionnaires will be given to patients at 3, 6, and 12 months post surgery
41114527|NCT03003845|OTHER|Collection of Blood samples|Blood for PBLs will be collected at 3, 6, and 12 months post surgery
41114528|NCT04674449|DIAGNOSTIC_TEST|Disclosure of IDP results|The results of the adjunctive IDP performed at time of invasive coronary angiography are made available to the catheter laboratory clinician, to aid in the diagnostic process.
41114529|NCT04674449|OTHER|IDP performed but results not disclosed|The results of the IDP performed at the time of invasive coronary angiography are concealed from the catheter laboratory clinician who will be blinded. The patient is managed according to standard of care.
41114530|NCT06110416|OTHER|nausea relief inhaler|Aromatherapy and essential oils are an alternative method to controlling post-operative nausea and vomiting after post-surgical intervention.
41114531|NCT05734924|DEVICE|low Frequency High Intensity magnetic therapy|low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT
41114532|NCT05007665|BIOLOGICAL|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
41114533|NCT04753580|GENETIC|Stool collection|"The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g."
41114534|NCT00043654|DRUG|Mifepristone|
41114535|NCT02886221|PROCEDURE|Reverdin-Isham Osteotomy|Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
41114536|NCT04566458|OTHER|No intervention|retrospective chart review study
41114537|NCT04958798|BEHAVIORAL|Culturally Centered MOUD Implementation Intervention|Support clinical sites to culturally center the delivery of medications for opioid use disorder through evidence-based implementation strategies tailored to local needs
41114538|NCT03185156|DRUG|Propofol|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
41114539|NCT03185156|DRUG|Normal saline|first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
41114540|NCT03376152|BEHAVIORAL|Electric Kettle Promotion|Provision of free electric kettles and promotional materials/information
41453370|NCT06180395|OTHER|Group 1|"consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
40926157|NCT04623125|BEHAVIORAL|Spaced Retrieval Practice|Online picture-naming training with 60 words which the participant experiences word-retrieval difficulties. Cards are shuffled arranged by the computerized training program.
40926158|NCT01044329|DRUG|Bevacizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
40926159|NCT01044329|DRUG|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
41114541|NCT03789955|PROCEDURE|Fluoroscopic-guided TEB|When performing a fluoroscopic-guided thoracic epidural block (TEB), an 18-gauge Tuohy needle will be used for interlaminar epidural access. If the epidural space was accessed under fluoroscopic guidance and using the loss of resistance technique with air. All procedures will be performed with a paramedian approach under the true AP and lateral view at first, If the interlaminar space is not visible, the CLO view will be used. If the needle is deemed to be in the epidural space when the loss occurred, six fluoroscopic views will be obtained: true AP, CLO at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral. The CLO measured angle will be determined by measuring the angle between the superior lamina and spinous process on the midsagittal plane on thoracic MRI or CT.
41114542|NCT03849495|DRUG|CKD-370|Test drug
41114543|NCT03849495|DRUG|D745|Reference drug
41114544|NCT04410510|DRUG|P2Et (Caesalpinia spinosa extract)|P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
41114545|NCT04410510|OTHER|Placebo|Placebo capsule equivalent to 250mg of excipients of P2Et every 12 hours for 14 days + Standard Care
41114546|NCT01568073|DRUG|BIA 9-1067|5, 25 and 50 mg of BIA 9-1067 (once-daily)
41114547|NCT01568073|DRUG|Entacapone|200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
41114548|NCT01568073|DRUG|Placebo|200 mg
41114549|NCT01568073|DRUG|Levodopa|
41114550|NCT01568073|DRUG|Carbidopa|DOPA decarboxylase inhibitor
41114551|NCT01568073|DRUG|Benserazide|DOPA decarboxylase inhibitor
41114552|NCT06530056|OTHER|Costovertebral Mobilization+Conventional Therapy|"Patient would receive costovertebral mobilization in side lying position for left 10th to 6th, in sitting position for right 10th to 2nd rib and in supine lying position for 1st rib.~Conventional Therapy:~Hot pack 10 mints, Posture corrective exercises, Breathing exercises Frequency; 4 times/week for 3 weeks"
41114553|NCT06530056|OTHER|Conventional Therapy|"Electrotherapy:~• Hot Pack 10 minutes~Posture Corrective Exercises:~* Thoracic Rotation 10 rep/session~* Thoracic extension 10 rep/session~* Scapular retraction 5 rep/session~* Deep neck flexor Isometric 5 rep/session~Deep Breathing Exercises:~• Pursed lip breathing 10 repetition in one session"
41114554|NCT02379299|DEVICE|DiaCon dual-hormone closed-loop glucose control algorithm|Dual-hormone closed-loop glucose control
41114555|NCT02379299|DEVICE|DiaCon single-hormone closed-loop glucose control algorithm|Single-hormone closed-loop glucose control
40926160|NCT00322985|DRUG|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
41114556|NCT00675246|DRUG|Betamethasone|IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
41114557|NCT04878198|BEHAVIORAL|Jogging program|This intervention consists of 50 sessions of morning jogging sessions at moderate intensity level. Each intervention session will be administered by a trained research assistant assisted by student helpers. All the research staff (i.e. student helpers and research assistant) will be required to attend a workshop (see educational plan) to standardize the procedure on implementing the intervention, as well as handling and motivating their ASD partners. Motivation techniques in previous protocol will be used to enhance the compliance rate.
41114558|NCT04878198|DRUG|Melatonin supplement intervention|This intervention is a 10-week melatonin supplement intervention where melatonin supplement will be provided 30 minutes before bedtime.
41114559|NCT05499039|DEVICE|High flow nasal cannula (HFNC)|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C Flow rate 30: 50 L/min. FiO2 will be adjusted to achieve a SpO2 at least 95%"
41114560|NCT05499039|DEVICE|Non-Invasive Mechanical Ventilation (NIV)|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O. Pressure support (PS): 12-20 cmH2O. FiO2 will be adjusted to achieve a SpO2 at least 95% Intervention: Device: non-invasive ventilation"
41114561|NCT04301635|PROCEDURE|Maxillo-mandibular Advancement + Counterclockwise rotation|Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation
41114562|NCT04450199|DRUG|Vitamin D2|Vitamin D tablets
41114563|NCT04450199|OTHER|Placebo|Over encapsulated sugar pills
41114564|NCT01982136|PROCEDURE|end-to-end urethroplasty|
41114565|NCT01982136|PROCEDURE|substitution urethroplasty (buccal mucosa)|
41114566|NCT01982136|PROCEDURE|substitution urethroplasty (pedicled skin flap)|
41114567|NCT01274299|PROCEDURE|Digital camera picture|A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
41114568|NCT00539292|PROCEDURE|Primary placement of a spring-loaded silo|
41114569|NCT00539292|PROCEDURE|Primary Closure|primary closure of abdomen
41114570|NCT01573598|DRUG|Placebo|Matching placebo given orally, once per day
41114571|NCT01573598|DRUG|Vilazodone|Vilazodone, 20 mg per day, oral administration
41114572|NCT01573598|DRUG|Vilazodone|Vilazodone, 40 mg once per day, oral administration
41114573|NCT00971789|RADIATION|fludeoxyglucose F 18|Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.
41114574|NCT00971789|DRUG|sirolimus|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
41114575|NCT00971789|OTHER|Clinical Videography|This examination involves testing of cerebellar function that controls movement, balance, and coordination.
41114576|NCT02600052|OTHER|PNF|RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
41114577|NCT02600052|DEVICE|treadmill|AEROBIC TRAINING
41114578|NCT02267967|DRUG|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
41114579|NCT01151839|PROCEDURE|Esophagectomy|Patient with squamous cell carcinoma of esophagus will be treated with surgery alone
41114580|NCT01151839|PROCEDURE|Neoadjuvant chemoradiation followed by surgery|Patient with squamous cell carcinoma of esophagus will be treated by neoadjuvant chemoradiation followed by surgery
41114581|NCT02561039|DRUG|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
41114582|NCT03915340|DRUG|Propafenone|Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.
41114583|NCT03915340|DRUG|Rytmonorm|Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
41114584|NCT01666704|DRUG|BMS-823778|Capsules, Oral, 2mg, Once daily, 1 year
41114585|NCT01666704|DRUG|BMS-823778|Capsules, Oral, 15mg, Once daily, 1 year
41114586|NCT01666704|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0mg, Once daily, 1 year
41114587|NCT00976937|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
41114588|NCT00976937|DRUG|Lixisenatide Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
41114589|NCT00976937|DEVICE|Pen auto-injector|
41114590|NCT00976937|DRUG|Sitagliptin|Administered orally once a day in the morning with or without food at approximately the same time each day.
41114591|NCT00976937|DRUG|Sitagliptin Placebo|Administered orally once a day in the morning with or without food at approximately the same time each day.
41114592|NCT00976937|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
41114593|NCT01903798|DRUG|Mycophenolate mofetil|Immunosuppressive agent
41114594|NCT01903798|DRUG|Prednisolone|Corticosteroid
41114595|NCT01903798|DRUG|Rilonacept|
41114596|NCT06383117|DIETARY_SUPPLEMENT|Calcium carbonate|2 capsules containing 600 mg of calcium carbonate each
41114597|NCT06383117|DIETARY_SUPPLEMENT|Placebo Control|2 capsules containing methylcellulose
41114598|NCT02769858|DEVICE|Light therapy|Light therapy glasses
41114599|NCT02343211|DRUG|Immunoglobulin|
41114600|NCT02365766|DRUG|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
41114601|NCT02365766|DRUG|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
41114602|NCT02365766|DRUG|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
41114603|NCT02365766|PROCEDURE|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
41114604|NCT01231568|DRUG|Regimen A|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
41114605|NCT01231568|DRUG|Regimen B|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
41114606|NCT01231568|DRUG|Regimen C|Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
41114607|NCT01231568|DRUG|Regimen D|Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
41114608|NCT05709899|OTHER|nerve blocks|Comparison of ultrasound-guided erector spinae plane block and transmuscular quadratus lumborum block for postoperative analgesia in abdominal cancer surgeries.
41114609|NCT05590468|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)
41114610|NCT05590468|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
41114611|NCT01323777|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
41114612|NCT02544152|DRUG|Lubiprostone|8 mcg administered orally twice daily (BID)
41114613|NCT02544152|DRUG|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
41114614|NCT03441204|DRUG|LTOT 24 h/day|LTOT prescribed for 24 h/day.
41114615|NCT03441204|DRUG|LTOT 15h/day|: LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
41114616|NCT03072953|DRUG|APD334|APD334 active treatment
40926161|NCT04664894|DRUG|Sofosbuvir|the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population
41114617|NCT05570435|BIOLOGICAL|Blood collection|Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.
41114618|NCT02202395|DRUG|LTS 0.25mg|use LTS 0.25mg/d
41114619|NCT02202395|DRUG|LTS 0.5mg|use LTS 0.5mg/d
41114620|NCT02202395|DRUG|LTS 1.0mg|use LTS 1.0mg/d
40752567|NCT04315207|BEHAVIORAL|Telephone call|"All patients are informed that they will receive a telephone call between 08 AM and 5 PM on workdays, as soon as the results of invasive workup are available. This is expectedly 3 to 5 days after invasive workup. At the telephone call, patients are free to ask for a later call, to summon relatives, to turn on the loud speaker, and/or ask the physician to call one relative of choice to share the information.~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
40926162|NCT02702297|OTHER|single arm|Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
41114621|NCT02202395|DRUG|Placebo|use placebo once daily
41114622|NCT00162292|DRUG|BMS-582949 and Methotrexate|
41114623|NCT00006446|PROCEDURE|Training in parenting skills and communication|
41114624|NCT00637936|DRUG|Oxygen|Inspiratory fraction during anaesthesia
41114625|NCT04531592|DRUG|Valproic acid|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
41114626|NCT04531592|DRUG|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
41114627|NCT06181318|DIAGNOSTIC_TEST|Multiparametric MRI scan of the liver|MRI scans will be performed at the Champalimaud Foundation using a 1.5T scanner after patients have fasted for 4 hours. Transverse abdominal T1 maps will be acquired to estimate extracellular fluid (which increases in cases of fibrosis and inflammation) and T2\* maps will be acquired to estimate liver iron levels. These quantitative MRI maps will be laid onto the volumetric images of Couinaud segments. Multi-slice quantitative maps will be generated using Liver MultiScan software (Perspectum, UK) with operators blinded to patient status. T1 measurements will be adjusted for the iron level to give iron-corrected T1 maps (cT1). Reference ranges for cT1 have been defined in the general population. PDFF maps of the liver will be calculated using MRI multi-echo and spoiled-gradient-echo acquisition. No intravenous contrast agents will be used in Liver MultiScan maps and the total scan duration will be approximately 30 minutes.
41114628|NCT03364595|PROCEDURE|plate fixation|ORIF of the radial head fracture
41114629|NCT03364595|PROCEDURE|replacement|replacement of the radial head fracture
41114630|NCT01239316|OTHER|Laboratory Biomarker Analysis|Correlative studies
41114631|NCT01239316|OTHER|Pharmacological Study|Correlative studies
40926163|NCT05787990|DIAGNOSTIC_TEST|Diabetes Microvascular Complication Tests|Continuous glucose monitoring using Freestyle Libre Pro, Foot examination with monofilament and neurothesiometer, HbA1c and Urine Microalbumin Creatinine Ratio, Corneal confocal microscopy, Fundal photography, Optical coherence tomography, Optical cohere
40926164|NCT03859973|DRUG|BI 425809|Tablet
40926165|NCT03859973|DRUG|Placebo|Tablet
41114632|NCT01239316|DRUG|Vismodegib|Given PO
41114633|NCT04035291|OTHER|exercise|exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
41114634|NCT02600520|DRUG|SRP with RSV gel LDD|After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
40926166|NCT03693729|DEVICE|HD-tDCS|Participants will complete a metamemory and memory task
40926167|NCT02727231|DEVICE|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
41114635|NCT02600520|DRUG|SRP with ATV gel LDD|After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
41114636|NCT02600520|DRUG|SRP with placebo gel LDD|After SRP, placebo gel was delivered subgingivally into the pocket
41114637|NCT03450096|OTHER|LPB|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
41114638|NCT06267131|DEVICE|Brain Pulse Oximeter|Sensor is placed on the right and/or left forehead and maintained with an elasticized headband. The duration of monitoring will last for approximately 60 minutes per monitoring session to obtain sufficient data. Serial monitoring will occur on three consecutive days.
41114639|NCT04088032|DRUG|Abemaciclib, durvalumab and aromatase inhibitor|Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
41114640|NCT03495713|DRUG|Nivolumab|Nivolumab 3 mg/kg will be administered on day 1 (pre-response assessment week 0) and on day 1 and continued per standard of care and institutional practices. A
41114641|NCT03221478|OTHER|Kinesio Taping placebo and exercises|Kinesio Taping placebo and exercises
41114642|NCT03221478|OTHER|Kinesio Taping with tension and exercises|Kinesio Taping with tension and exercises
41114643|NCT03221478|OTHER|Kinesio Taping with tension|Kinesio Taping with tension
41114644|NCT03085498|OTHER|No intervention|no intervention
41114645|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 1 (nOPV1)|Live attenuated novel poliomyelitis virus type 1 at two different dosages, containing middle-dose (MD) 10\^6.0, or high-dose (HD) 10\^6.5 CCID₅₀/dose
41114646|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 2 (nOPV2)|Live attenuated novel poliomyelitis virus type 2 administered at low-dose (LD) 10\^5.3 and HD 10\^5.6 CCID₅₀/dose.
40752568|NCT04315207|BEHAVIORAL|In-person meeting|"All patients are provided a written and verbal appointment date 5 workdays after invasive workup, and that they will receive a telephone call if 1) results are not available at the time of the meeting, and/or 2) if results need urgent action (such as small-cell lung cancer).~At the in-person meeting, patients are free to invite family and relatives (up to 4 persons, restriction due to space available).~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
40926168|NCT02727231|DEVICE|CSII with CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
40926169|NCT02217072|BEHAVIORAL|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
41114647|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 3 (nOPV3)|Live attenuated novel poliomyelitis virus type 3 at two different dosages, containing MD 10\^6.0, or HD 10\^6.5 CCID₅₀/dose.
41114648|NCT06137664|BIOLOGICAL|Bivalent Oral Poliomyelitis Vaccine (bOPV)|Live attenuated poliomyelitis viruses types 1 and 3 (Sabin strains). Each dose (2 drops = 0.1 mL) contains not less than 10\^6.0 infective units of type 1 and 10\^5.8 of type 3.
41114649|NCT05824546|PROCEDURE|Intervention Arm (uSINE-PAMS-technique)|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be identified by palpation of external landmarks of the patients' iliac crests and spinous process of lumbar vertebrae L3, L4 and L5 and confirmed using uSINE-integrated ultrasound. The angle of needle during needle advancement will also be determined using the uSINE-integrated ultrasound. Markings on the patients' skin surface will be made using PAMS (non-sterile component) to enable relocation of the site and angle of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted with location and angulation according to PAMS (sterile component) guidance.
41114650|NCT04081792|PROCEDURE|Antibiotic therapy|Postoperative randomizations regarding the duration of systemic antibiotics
41114651|NCT00430872|BEHAVIORAL|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
41114652|NCT02889718|DEVICE|CONCERT-CL® station|"During cancer surgery (surgery \> 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~* Port B = open loop: Analgesic~* Port A = closed loop: Hypnotic~* Port C = closed loop: Curare"
41114653|NCT02889718|OTHER|Surgery|Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
41114654|NCT06197217|DRUG|WPV01|Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
41114655|NCT06197217|DRUG|Placebo|Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
41114656|NCT04034745|DRUG|telotristat ethyl|250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
41114657|NCT02387099|DRUG|3 weeks Dose Induction of Everolimus|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
41114658|NCT02387099|DRUG|3 weeks Conventional Everolimus Dosing|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
41114659|NCT02387099|DRUG|Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
41114660|NCT02387099|DRUG|Standard Care after 24 weeks|It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
41114661|NCT02544880|DRUG|Tadalafil|Tadalafil tablets administered by mouth. Dose will be between 10 to 20 mg adjusted depending on patient's body weight. On course 1, Tadalafil will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil will be administered daily for 14 consecutive days. No Tadalafil will be provided on Course 5.
41114662|NCT02544880|BIOLOGICAL|Anti-MUC1 Vaccine|300 uL Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
41114663|NCT02544880|BIOLOGICAL|Anti-Influenza Vaccine|300 uL Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
41114664|NCT02544880|OTHER|Tadalafil Placebo|Placebo tablets mimicking Tadalafil administered by mouth. On course 1, Tadalafil Placebo will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil placebo will be administered daily for 14 consecutive days. No Tadalafil Placebo will be provided on Course 5.
41114665|NCT02544880|OTHER|Anti-MUC1 Vaccine Placebo|Placebo for Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Placebo for Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5..
41114666|NCT02544880|OTHER|Standard of Care Treatment|Treatment according to prescribed standard of care regimen.
41114667|NCT02544880|OTHER|Anti-Influenza Vaccine Placebo|Placebo for Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Placebo for Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
41114668|NCT05569837|OTHER|Regular meal pattern|6 meals every day
41114669|NCT05569837|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
41114670|NCT00396084|DRUG|Gatifloxacin|Gatifloxacin 400 mg/day x 7 days.
41114671|NCT00396084|DRUG|Isoniazid|Isoniazid 300 mg/day x 7 days.
41114672|NCT00396084|DRUG|Levofloxacin|Levofloxacin 1000 mg/day x 7 days.
41114673|NCT00396084|DRUG|Linezolid|Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
41114674|NCT00396084|DRUG|Moxifloxacin|Moxifloxacin 400 mg/day x 7 days.
41114675|NCT06490991|DRUG|HRS-5965 tablets；HRS-5965 capsules|Medication regimen: 1 Drug: HRS-5965 tablets Medication regimen: 2 Drug: HRS-5965 capsules
41114676|NCT04769765|OTHER|Definition of the Individualized Care Pathway|Implementation of an individualized care pathway defined in concertation with a multidisciplinary tele-expertise meeting held every 3 months for one year. These multidisciplinary tele-expertise meetings will be held between each of the normal routine consultations which are part of the normal, basic diabetic program which includes a consultation with a dietitian, monitoring by a state-registered nurse and treatment prescribed by the patient's general practitioner (with or without a consultation with the clinical pharmacist).
41114677|NCT05957900|BEHAVIORAL|Multisensory stimulation module|"* Tactile Stimulation; Gentle stroking massage with moderate pressure, with warm palms for 3 min in a sequence of chest, upper limbs, and lower limbs in supine position.~* Visual Stimulation; Black and white visual stimulation card hung at 8-10 in. from the neonate for 3 min.~* Vestibular Stimulation; neonates placed in a hammock for 3 min.~* Kinesthetic stimulation: It consist of passive exercises (flexion and extension) of upper and lower limbs; one of the hands support the stimulated limb, whereas the other hand will perform the movements for 3 min. in supine position.~* Oral stimulation: the perioral structures will stroke by gently tapping the cheeks, lips and jaw by the index and middle finger for 2 min and stroking the intraoral structures by rubbing the gum and applying downward pressure of the tongue for 2 min. Non-nutritive sucking for 8 minutes.~* Olfactory Stimulation for 3 min. using mother's milk.~* Auditory Stimulation listening to mother's heart beats for 3 min."
41114678|NCT04734730|DRUG|Abiraterone Acetate|Given PO
41114679|NCT04734730|DRUG|Bicalutamide|Given PO
41114680|NCT04734730|DRUG|Degarelix|Given SC
41114681|NCT04734730|DRUG|Goserelin Acetate|Given SC
41114682|NCT04734730|DRUG|Leuprolide Acetate|Given IM
41114683|NCT04734730|DRUG|Prednisone|Given PO
41114684|NCT04734730|OTHER|Questionnaire Administration|Ancillary studies
41114685|NCT04734730|DRUG|Talazoparib|Given PO
41114686|NCT00622219|OTHER|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
41114687|NCT05625282|PROCEDURE|Weil osteotomy|Open, oblique, distal osteotomy of the metatarsal bone, with screw fixation.
41114688|NCT05625282|PROCEDURE|Plantar plate repair|Plantar plate reconstruction at metatarsophalangeal area, using sutures.
41114689|NCT05596994|DEVICE|Lighting Intervention Therapy|The LIT will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The TLI intervention will remain in place and will be delivered to participants for 10 weeks each in a counterbalanced manner. Combining spectrum and light level, LIT will allow the research team to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The research team will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater) and about 50 lux at the eye during the evening hours (CS of less than 0.1) and when the control lighting intervention is used.
40926170|NCT02217072|BEHAVIORAL|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
41114690|NCT05596994|DEVICE|Sham LIT|A placebo comparison lighting intervention will be used. The comparison lighting intervention will remain in place and will be delivered to participants for 10 weeks.
41114691|NCT02878772|DRUG|vinpocetine|30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
41114692|NCT02878772|DRUG|Aspirin|100mg, once daily, oral medication
41114693|NCT01590836|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
41114694|NCT01590836|DRUG|insulin degludec/insulin aspart|Single dose administered subcutaneously (s.c., under the skin).
41114695|NCT05786898|OTHER|NEAR-TSA|"Neuropsychological and Educational Approach of Cognitive Remediation adapted to autism~32 sessions spread over 4 to 8 months (1 session per week for minors, 2 sessions per week for adults), lasting 90 to 120 minutes"
41114696|NCT00573482|BEHAVIORAL|REDE|"The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~* Four group education sessions to introduce the REDE principles of eating;~* Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~* Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~* Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions."
41114697|NCT00573482|BEHAVIORAL|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
41114698|NCT02807467|DRUG|Dexmedetomidine|Continuous infusion of dexmedetomidine between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
41114699|NCT02807467|DRUG|Propofol|Continuous infusion of propofol between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
41114700|NCT04249713|DRUG|Brodalumab|Interleukin 17 Receptor A Antagonist
41114701|NCT02147535|DRUG|Methylphenidate|10 mg as a single dose followed by one blood sample 3 hours post-dose
41114702|NCT03942835|OTHER|experience 1 : Competitive attention test in healthy participants|Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).
41114703|NCT03942835|OTHER|experience 2 : Competitive attention test in patients with ADHD with no treatment|Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.
41114704|NCT03942835|OTHER|experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment|Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
41114705|NCT04411849|OTHER|Best Practice|Receive usual care
40926171|NCT00164944|PROCEDURE|Colonoscopy|To determine the adenomas during colonoscopy
40926172|NCT00164944|PROCEDURE|Colonoscopy|To determine the adenomas during colonoscopy
41114706|NCT04411849|PROCEDURE|HPV Self-Collection|Receive HPV self-testing intervention
40926173|NCT05314764|DRUG|Cefiderocol|Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.
41114707|NCT04411849|OTHER|Informational Intervention|Receive information about cervical cancer
41114708|NCT04411849|BEHAVIORAL|Patient Navigation Program|Receive telephone-based patient navigation
40926174|NCT02047318|DRUG|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
41114709|NCT05353517|DEVICE|Device: focal muscle vibration and theta burst stimulation|non invasive techniques of neuromodulation for inducing plasticity in M1 and spinal cord
41114710|NCT00613782|DRUG|Reandron 1000|1000mg at 0,6,18,30 weeks
41114711|NCT00613782|DRUG|placebo|placebo injection 0,6.18.30 weeks
41114712|NCT01824030|DEVICE|FFR guided PCI|FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
41114713|NCT01824030|DEVICE|OCT guided PCI|OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
41114714|NCT00000493|DRUG|propranolol|
41114715|NCT00000493|DRUG|hyaluronidase|
41114716|NCT01576952|DRUG|ISV-303|Bromfenac in DuraSite
41114717|NCT01576952|OTHER|DuraSite Vehicle|DuraSite Vehicle
41114718|NCT00239083|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
41114719|NCT04813419|DEVICE|1927nm thulium laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. The left face of subjects were treated with fractional 1927nm thulium laser(Lavieen, korea). Parameters were set as stamp mode, a spot size of 5\*5mm, a pulse time of 1000us, an energy intensity of 3645mJ/cm2 and a repetition of 1-3 times. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
41114720|NCT04813419|DEVICE|2940nm Er:YAG laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
41114721|NCT02120911|DRUG|Pertuzumab, trastuzumab|Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
41114722|NCT06499584|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests. During the surgery, stimuli are delivered."
41114723|NCT03933605|DRUG|midazolam and palonosetron group|intravenous midazolam and palonosetron administraion as prevention of postoperative nausea and vomiting
41114724|NCT03933605|DRUG|palonosetron group|intravenous palonosetron administraion as prevention of postoperative nausea and vomiting
41114725|NCT03339258|DRUG|Doxazosin Mesylate, Extended Release|Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
41114726|NCT03339258|DRUG|Placebo|Placebo, or inactive pill.
41114727|NCT06106516|DEVICE|novel vital sign monitor|Devices that are to be introduced into the clinic but where data from clinical relevant conditions such as complications are lacking to assess the validity under clinical conditions
41114728|NCT02399943|DRUG|Trametinib|
41114729|NCT02399943|DRUG|Panitumumab|
41114730|NCT05542862|BIOLOGICAL|SpikoGen vaccine|Recombinant spike protein based Covid-19 vaccine
41114731|NCT01216722|OTHER|Resistance Strengthening Exercise Program|Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
41114732|NCT04583046|DRUG|normal saline inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).
41114733|NCT04583046|DRUG|iloprost inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
41114734|NCT01673555|DRUG|GSK1278863|GSK1278863
41114735|NCT01673555|DRUG|Placebo|Placebo
40752569|NCT05879172|DEVICE|electric tubular anastomotic device|"The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery.~Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment."
40926175|NCT02004288|DIETARY_SUPPLEMENT|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
40926176|NCT00002289|DRUG|Thymopentin|
40926177|NCT03239665|BEHAVIORAL|Pharmacist-led Intervention (PHARM)|60 minute didactic lecture about vaccinations.
41114736|NCT02986269|PROCEDURE|general anesthesia across LMA|general anesthesia across LMA
41114737|NCT02986269|PROCEDURE|Spontaneous breathing(SB)|general anesthesia across LMA under SB without PSV
41114738|NCT02986269|PROCEDURE|Pressure Support Ventilation|general anesthesia across LMA under SB with PSV
41114739|NCT02860286|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
41114740|NCT01269853|DRUG|Bevacizumab|"Experimental portion of this proposal:~This trial will have two experimental arms that will be open labeled and non-randomized.~ARM 1 (If the patient has multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
40752570|NCT05879172|DEVICE|traditional anastomotic device|Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.
40752571|NCT00723944|DEVICE|Osseotite Certain Prevail|Root form titanium dental implant
40752572|NCT00723944|DEVICE|Osseotite Certain|Dental implant without the lateralized design
41114741|NCT01269853|DRUG|Bevacizumab|"ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment~If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle"
41114742|NCT03615417|DEVICE|High Flow Nasal Cannula (HFNC)|"Preoxygenation trough High Flow Nasal Cannula (HFNC) at 100% FiO2, 50 liters/min and closed mouth.~After Rapid Sequence Induction (RSI), maintenance of apnea with HFNC at 100% FiO2, 70 liters/min and jaw thrust.~At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
41114743|NCT03615417|DEVICE|Standard anesthesia FaceMask (FM)|"Preoxygenation trough standard anesthesia FaceMask (FM) at 100% FiO2, 12 liters/min, CPAP 7 cmH2O.~After Rapid Sequence Induction (RSI), maintenance of apnea without mask. At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
41114744|NCT01324453|PROCEDURE|Post Conditioning + Primary PCI|Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
41114745|NCT01324453|PROCEDURE|Standard Primary PCI|Routine Percutaneous Coronary Intervention as clinically indicated.
41114746|NCT03132922|GENETIC|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1
41114747|NCT03132922|RADIATION|Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation|Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells
41114748|NCT06552663|DEVICE|CCTA|Coronary CT angiography
41114749|NCT00668863|DRUG|FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
41114750|NCT00668863|DRUG|Sunitinib|37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
41114751|NCT03221569|DRUG|Intravenous ketamine|0.3mg/kg IVPB over 15 minutes
41114752|NCT03221569|DRUG|Ketorolac|as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
41114753|NCT03221569|DRUG|Normal saline|"Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine."
40752573|NCT05597891|DEVICE|Hēlo PE Thombectomy System|Treatment with the Hēlo PE Thombectomy System for thromboembolectomy
40752574|NCT03701087|DRUG|Vitamin D|2800 IU daily till 26 weeks of pregnancy
40752575|NCT04759170|OTHER|Music therapy|The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby
40752576|NCT00057577|BEHAVIORAL|Cognitive Therapy|CT sessions occur weekly during acute treatment and monthly during continuation. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue CT.
40926178|NCT03239665|BEHAVIORAL|Peer-led Intervention (PEER)|60 minute peer led small group intervention including skits and other educational material
41114754|NCT03221569|DRUG|Normal saline|1ml intravenous push as placebo for double-blinding purposes
41114755|NCT03191981|DRUG|Cyclophosphamide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
41114756|NCT03191981|DRUG|Lenalidomide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
41114757|NCT03191981|DRUG|Pembrolizumab|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
41114758|NCT04065802|RADIATION|Stereotactic Radioablation|External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias
41114759|NCT01947790|DRUG|pioglitazone group|
41114760|NCT01947790|DRUG|Metformin group|
40752577|NCT00057577|DRUG|Medications|Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
41114761|NCT01535144|DEVICE|Fracture compressing screw ZfW 102 Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
41114762|NCT01535144|DEVICE|Fracture compressing screw titanium Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
41114763|NCT00373529|DRUG|clofarabine|"Induction cycle 1: cycle 1 of clofarabine 30 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days."
41114764|NCT02035969|BEHAVIORAL|Enhanced Treatment Support (ETS)|"Peer supporters, who are also caregivers of HIV-infected children, organize peer support group meetings. In the meetings one peer supporter discusses problems related to adherence with caretakers and provides them with information. Another supporter provides children above 3 years of age with age relevant information about their disease and treatment as well as games and play to enhance group bounds. The supporter will also have weekly telephone contact with all caretakers to assess the condition of the child.~For children with poor adherence individual support to caretakers and patients will be arranged to assess the child's condition and reason for poor adherence, in case of complications the supporter gives advice or refers the child for medical checkup."
41114765|NCT03853109|DRUG|AMG 404|AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
41114766|NCT02178020|DEVICE|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
41114767|NCT02178020|DEVICE|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
41114768|NCT05706168|DEVICE|treadmill exercise|Treadmill exercise is a form of aerobic exercise training that involves the use of a treadmill machine in a structured exercise programs.
41114769|NCT05706168|DEVICE|Cycle ergometer exercise|Cycle ergometer exercise is a form of aerobic exercise training that involves the use of a stationery recumbent bike in a structured exercise programs.
41114770|NCT01234610|BEHAVIORAL|Supervised exercise training|Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
41114771|NCT00624026|DRUG|Memantine-HCl|20 mg per day (once daily)
41114772|NCT06245863|DEVICE|Negative pressure and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 milliwatts (mW) per laser. Vacuum therapy: 60 mm suction cup, pulsed mode (MP9, 50 pulsations per minute) and pressure of -150 at -350 mbar. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
40752578|NCT01964560|DRUG|Lacosamide|"Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use"
41114773|NCT06245863|DEVICE|Positive Pressure and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Positive Pressure: Massage with rollers. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
41114774|NCT06245863|DEVICE|Ultrasound and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Ultrasound: 1 megahertz (MHz), continuous mode and 1 milliwatts per square centimeter (mW/cm2). The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
41114775|NCT06245863|DEVICE|Laser|Infrared Laser (808 nm), continuous mode, 100 mW. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
41114776|NCT06245863|DEVICE|Placebo Laser|Laser: off mode. The placebo treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
41114777|NCT02565069|DEVICE|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
41114778|NCT02645149|DRUG|Standard therapy or clinical trial|Patients with BRAF V600 mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
41114779|NCT02645149|DRUG|Matched targeted therapy|Patients with tumour found to be non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for non-V600 BRAF, wildtype and NRAS wildtype melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour on NGS testing.
40926179|NCT05023369|DRUG|Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)|Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)
40752579|NCT01964560|DRUG|Lacosamide|"Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use"
41114780|NCT02645149|DRUG|Trametinib and / or supportive care|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma for whom there is no actionable genetic aberration found on extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
41114781|NCT02645149|DRUG|CDK4/6 and MEK inhibitor|"Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib."
41114782|NCT02645149|DRUG|Compassionate Access Targeted Therapy|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma may have an actionable aberration(s) for which there is no current study-specific drug supply. In this scenario, access will be sought for compassionate use of the off label use of the relevant regulatory approved targeted therapy
41114783|NCT03264261|DEVICE|robotic training|robotic training, 3 times/week for 6 weeks
41114784|NCT03264261|DEVICE|treadmill training|treadmill training only, 3 times/week for 6 weeks
41114785|NCT00681525|DRUG|ABT-335|One ABT-335 135 mg capsule QD for 10 days
41114786|NCT00681525|DRUG|Atorvastatin|One 80 mg tablet of atorvastatin QD for 10 days
41114787|NCT00681525|DRUG|Ezetimibe|One ezetimibe 10 mg tablet QD for 10 days
41114788|NCT06342063|DEVICE|Blood Flow Restriction Therapy|Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is inflated.
41114789|NCT06342063|DEVICE|Blood Flow Restriction Therapy Sham|Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is not inflated.
41114790|NCT00002919|BIOLOGICAL|filgrastim|
41114791|NCT00002919|DRUG|cisplatin|
41114792|NCT00002919|DRUG|doxorubicin hydrochloride|
41114793|NCT00002919|DRUG|methotrexate|
41114794|NCT00002919|DRUG|vinblastine sulfate|
41114795|NCT00002919|PROCEDURE|conventional surgery|
41114796|NCT02902471|OTHER|Forced oscillations measure|
41114797|NCT05774444|DIETARY_SUPPLEMENT|Krill oil|Krill oil will be supplemented to see if they can gain strength and/or muscle mass following supplementation.
41114798|NCT05774444|DIETARY_SUPPLEMENT|Krill protein|Krill protein will be given to the participant following a resistance exercise bout.
41114799|NCT05774444|DIETARY_SUPPLEMENT|Vegetable oil|This will be the control against the Krill oil
41114800|NCT05774444|DIETARY_SUPPLEMENT|Carbohydrate|This will be the control for the Krill protein
41114801|NCT03222323|DRUG|Dexmedetomidine perineurally|Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
41114802|NCT03222323|DRUG|Ropivacaine 5mg/ml|Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
41114803|NCT03222323|DRUG|Ropivacaine 7.5mg/ml|In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
41114804|NCT03222323|DRUG|Dexmedetomidine systemically|Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
41114805|NCT03222323|DRUG|Isotonic saline|placebo (saline) is administered perineurally in all but the perineural group.
41114806|NCT03393377|DRUG|fluvastatin 10 mg and valsartan 20 mg|
41114807|NCT03393377|DRUG|placebo|
41114808|NCT00428519|DRUG|Placebo|Placebo for 14 days
41114809|NCT00428519|DRUG|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
41114810|NCT00428519|DRUG|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
41114811|NCT00592813|BEHAVIORAL|Enhanced Strong for Life|"The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars."
41114812|NCT00592813|BEHAVIORAL|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
41114813|NCT00616733|DRUG|CS-0777 tablets|0.1 mg, once-weekly, for 12 weeks
41114814|NCT00616733|DRUG|CS-0777 tablets|0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
41114815|NCT00616733|DRUG|CS-0777 tablets|0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
40752580|NCT05611424|GENETIC|FT-003|Administered via intraocular injection.
41114816|NCT00192491|BIOLOGICAL|FluMist|Nasal Sprayer of one dosage of FluMist and other experimental
41114817|NCT00192491|BIOLOGICAL|FluMist|Nasal sprayer of FluMist
41114818|NCT00192491|OTHER|Placebo|Nasal Sprayer of Placebo
41114819|NCT03529396|DRUG|Chloroquine|Standard chloroquine (three days)
41114820|NCT03529396|DRUG|Primaquine|Daily Primaquine (0.5 mg of base/kg/day for seven days) starting only at the fifth day post chloroquine initiation.
41114821|NCT03529396|DRUG|Primaquine|Weekly primaquine (0.75 mg of base/kg/week for eight weeks) starting with first dose of chloroquine.
41114822|NCT03529396|DRUG|Chloroquine|Weekly, once a week chloroquine (5 mg of base/kg/week for twelve weeks)
41114823|NCT03529396|DRUG|Primaquine|Standard primaquine (0.5mg of base/kg/day for seven days) concomitant with chloroquine.
41114824|NCT03999866|DEVICE|airtraq|airtraq videolaryngoscope
41114825|NCT03999866|DEVICE|mcgrath mac x-blade|mcgarth mac videolaryngoscope
41114826|NCT03999866|DEVICE|storz c-mac|storz c-mac videolaryngoscope
41114827|NCT03999866|DEVICE|storz d-blade|storz d-blade video laryngoscope
41114828|NCT01981837|DRUG|ALN-TTRSC (revusiran) for subcutaneous administration|
41114829|NCT06101563|PROCEDURE|Early ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 7 days after normalization of inflammatory indices.
41114830|NCT06101563|PROCEDURE|Delayed Ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 2-4 weeks after normalization of inflammatory indices.
41114831|NCT05952206|DEVICE|Angiolite: Sirolimus-eluting stent|The angiolite stent (iVascular, Barcelona, Spain) is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design containing a durable biostable coating composed of three layers - acrylate to ensure adhesion to the metal surface, fluoroacrylate that carries the sirolimus, and a top layer of fluoroacrylate to control drug release.
41114832|NCT05952206|DEVICE|Xience: Sirolimus-eluting stent|The Xience stent family (Abbott vascular, California, United States of America), characterized by an L-605 cobalt-chromium (CoCr) is a thin-strut cobalt-chromium everolimus-eluting stent with an open-cell design containing a nonerodable polymer made of PBMA, a reservoir made of a fluorinated copolymer of vinylidene fluoride and hexafluoropropylene monomers. Xience™ stent family includes XIENCE Skypoint™ and XIENCE Sierra™
41114833|NCT05952206|DRUG|1-month DAPT|"DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month. Then, only the same oral P2Y12 inhibitor (clopidogrel, prasugrel, and ticagrelor) up to 12 months.~The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC"
41114834|NCT05952206|DRUG|12-month DAPT (Standard of care)|DAPT with acetylsalicylic acid and prasugrel or ticagrelor up to 12 months. The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC
41114835|NCT04426045|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.2% will be injected.
41114836|NCT04426045|PROCEDURE|Supra-inguinal fascia iliaca compartment block|"A linear 6-13-MHz ultrasound probe will be placed in the sagittal plane to obtain an image of the anterior superior iliac spine. The fascia iliaca and sartorius, iliopsoas, and oblique internal muscles will be identified by sliding the probe medially. After identifying the bow-tie sign formed by the muscle fascias, a 22-gauge, 80-mm needle will be introduced 1 cm cephalad to the inguinal ligament. Using an in-plane approach, the fascia iliaca will be penetrated and hydrodissected, separating the fascia iliaca from the iliac muscle. A total volume of 30 ml of ropivacaine 0.2% will be injected."
41114837|NCT04232371|PROCEDURE|New Ablation Technique|Patient will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
41114838|NCT04232371|PROCEDURE|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
41114839|NCT00149279|PROCEDURE|Surgery: D2 dissection|
41114840|NCT00149279|PROCEDURE|Surgery: D2+paraaortic dissection|
41114841|NCT04057196|BEHAVIORAL|Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC)|The SST-LC is a brief structured intervention deliverable by video conference. The new SST-LC protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors.
41114842|NCT00117130|DRUG|Aranesp®|
41114843|NCT00404417|DRUG|Botulinum Toxin A / Placebo|Botulinum Toxin A at first injection / Placebo at second injection
41114844|NCT00404417|DRUG|Botulinum Toxin A / Botulinum Toxin A|Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
41114845|NCT00404417|DRUG|Placebo / Botulinum Toxin A|Placebo at first injection / Botulinum Toxin A at second injection
41114846|NCT00404417|DRUG|Placebo / Placebo|Placebo at first injection / Placebo at second injection
41114847|NCT05628493|BEHAVIORAL|Gut microbiota Analysis|fecal samples were collected per patient on days 1,3 and 7 after ICU admission. All eligible patients were given antibiotics therapy, actively control infection source by puncture drainage or surgery if necessary, as well as other supportive therapy to maintain organ function.
41114848|NCT04213053|PROCEDURE|strabismus surgery|Lees screen before and after concomitant strabismus surgery
41114849|NCT01778283|BIOLOGICAL|Acetate-free dialysis solution|the hemodialysis solution that does not contain acetate as buffer
41114850|NCT05622786|OTHER|HIGT - physical rehab|High Intensity Gait Training using treadmill and overhead harness for fall prevention
41114851|NCT05622786|OTHER|Low intensity physical therapy|Low Intensity Gait Activities
41114852|NCT01812148|PROCEDURE|Cytoreductive surgery and HIPEC|Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent
41114853|NCT05662917|BEHAVIORAL|Individual semi-structured interviews|After information and written consent, the investigator will interview the participants through a semi-structured individual interview (conducted by an interview guide). The interview is expected to last 45 minutes (variable depending on the subject). It will be recorded by dictaphone, respecting the anonymity of the participant throughout the interview. The subject's participation will end after the interview.
41114854|NCT00206375|DRUG|Growth hormone|Growth hormone + Synthroid + Lupron
41114855|NCT00206375|DRUG|Growth hormone treatment and puberty|Lupron once a month and growth hormone daily
41114856|NCT00494780|DRUG|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
41114857|NCT00494780|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
41114858|NCT00494780|DRUG|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
41114859|NCT00494780|DRUG|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
41114860|NCT00494780|DRUG|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
41114861|NCT03234088|BEHAVIORAL|Daily weight measured by digital scale and symptom reporting|All subjects will be provided the intervention.
41114862|NCT05491031|OTHER|magnetic resonance spectroscopy|Investigation of the association, in patients with multiple sclerosis, between MRI biomarker data at inclusion and progression of physical disability during follow-up (6, 12, 18 and 24 months) assessed by a composite endpoint EDSS plus (EDSS, 9HPT, T25FW)
41114863|NCT04669249|BEHAVIORAL|PROCare|PROCare is a reward-based digital recovery management platform for individuals receiving medication treatment for opioid use disorder. Patients have the opportunity to earn both non-monetary and monetary incentives via smart debit card for a variety of clinically-indicated behaviors, including taking their medication (buprenorphine) as directed, attending clinic appointments and community-based mutual-help support group meetings, participating in routine outcomes monitoring surveys using validated measures, accessing the curated psychoeducation content library, and engaging in other recovery-oriented activities within the smartphone app.
41114864|NCT00839371|DRUG|Propofol|i.v. propofol titration until adequate depth of sedation
41114865|NCT00839371|DRUG|Midazolam|i.v. midazolam titration until adequate depth of sedation
41114866|NCT00193297|DRUG|Topotecan|
41114867|NCT00193297|DRUG|Paclitaxel|
41114868|NCT00193297|DRUG|Carboplatin|
41114869|NCT05500807|DRUG|Emicizumab|Subcutaneous injection of emicizumab for prophylaxis
41114870|NCT00473811|BEHAVIORAL|Low GI|low-GI education
41114871|NCT00473811|BEHAVIORAL|ADA diet|ADA dietary education
41114872|NCT02867670|DEVICE|Transcranial Magnetic Stimulation|TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
41114873|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 1|Oat based beverage with added different concentration of extracted oat component.
41114874|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 2|Oat based beverage with added different concentration of extracted oat component.
41114875|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 3|Oat based beverage with added different concentration of extracted oat component.
41114876|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 4|Oat based beverage with added different concentration of extracted oat component.
41114877|NCT03830736|COMBINATION_PRODUCT|Control product|Glucose based beverage without added test components is used as control product
41114878|NCT02904759|DRUG|Desmopressin|
41114879|NCT02904759|DRUG|Placebo|
41114880|NCT00869323|BIOLOGICAL|rituximab|375 mg/m\^2 intravenously on Days 1,8, 15 and 22
41114881|NCT00869323|DRUG|bortezomib|1.3 mg/m\^2 intravenous bolus days 1, 8, 15 and 22
41114882|NCT02163876|DRUG|HuCNS-SC cells|surgery arm
41114883|NCT05346978|DIETARY_SUPPLEMENT|Nasturtium (Tropaeolum majus)|Freeze dried nasturtium (Edible flower)
41114884|NCT05346978|DIETARY_SUPPLEMENT|Placebo|collagen colored with green pigment used in the food industry
41114885|NCT04077632|DEVICE|Transcranial direct current stimulation|tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
41114886|NCT05448807|DRUG|OraVerse|Phentolamine mesylate is a vaso-dilator that was used for treating dermal necrosis and severe hypertension cases since 1952. It is alpha-adrenergic antagonist. Oraverse is supplied in a dose equal to the amount of LA taken in adults and children with weights more than 30 kg. While in children less than 30 kg, it is advised to use only half carpule according the manufacturer's instructions.
41114887|NCT00103025|DRUG|Sodium Nitrite|
41114888|NCT00103025|DRUG|Sodium Nitrite Injection|
41453371|NCT06180395|OTHER|Group 2|"consisted of 38 children with CP classified to level IV and V according to GMFCS. then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
41114889|NCT04395235|OTHER|Survey|A multi-item survey was prepared to assess fellow's perception of residency training. The survey was utilized by our group, understanding of patient vascular anatomy, awareness of the changes based on variations, independent decision-making, differential diagnosis, plan on key surgical steps, and preparation for unexpected bleeding. The answers to the questions asked for each case were analyzed to include senior (3 years and over) - junior (1-2 years) residents.Assistants spend 45 minutes in the survey. Data are entered into SPSS 24.0 for statistical analysis. Wilcoxon Signed Ranks Test was used to determine any significant differences in the measurements between the original CT images, 3D rendered images, the 3D model and CT images of the 3D model. Statistical significance was defined as a p value of less than 0.05. Junior assistants stated that they perceived 2D image statistically better than 3D models compared to the senior assistants (Kruskal-Wallis Test).
41114890|NCT04809090|BEHAVIORAL|SMT|Standard 8 SMT (Stress Management Training) psychological interviews.
41114891|NCT04809090|DEVICE|App CA|An APP together a CA (Conversational Agent).
41114892|NCT06325761|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
41114893|NCT06325761|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
41114894|NCT05546359|DRUG|Amisulpride Injection|Dose finding treatment for continuation to phase 3
41114895|NCT05546359|DRUG|Dexamethasone|Standard of care treatment
41114896|NCT05822063|DRUG|Lidocaine topical|lidocaine spray
41114897|NCT05822063|OTHER|cold packs|ice packs
41114898|NCT05822063|DEVICE|flash lights|flash lights by camera
41114899|NCT02302300|DEVICE|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
41114900|NCT02694666|OTHER|Controlled whole-body vibration training|The intervention is an 8-week program
41114901|NCT04735341|DEVICE|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
41114902|NCT05861063|DEVICE|Fractional CO2 laser|All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment
41114903|NCT05861063|DRUG|Dezocine|Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)
41114904|NCT02765438|DEVICE|BOBO|"Each subject will play four games with the BOBO system."
41114905|NCT06323902|PROCEDURE|Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation|In the operating room through pars plana vitrectomy after having completed the complete air exchange, with the help of a Backwash Charles cannula, the PRGF membrane is placed in the macular hole and C3F8 gas is left in the posterior chamber, the first hour in the recumbent position. supine and subsequently face down during the first postoperative week.
41114906|NCT02108236|DEVICE|acupuncture|Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).
41114907|NCT05404958|OTHER|Systems Analysis and Improvement Approach (SAIA)|"What is SAIA? It is a 5-step cycle that is repeated every 4-6 weeks for continuous quality improvement, implemented by Kenyan public health workforce and FP clinic staff, and monitored by Mombasa DOH.~Step 1: Understanding the cascade from FP clinic enrollment to HIV testing to linkage to treatment and prevention services.~Step 2: Use process mapping to identify modifiable bottlenecks. Step 3: Define and implement workflow adaptations to eliminate modifiable bottlenecks.~Step 4: Monitor change in performance. Step 5: Repeat the analysis and improvement cycle (steps 1-4)."
41114908|NCT01996917|DEVICE|Prineo|After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
41114909|NCT06478238|DRUG|calcium folinate|Intravenous infusion and/or oral therapy
41114910|NCT00899899|GENETIC|microarray analysis|
41114911|NCT00899899|GENETIC|reverse transcriptase-polymerase chain reaction|
41114912|NCT00899899|OTHER|laboratory biomarker analysis|
41114913|NCT01013246|OTHER|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
41114914|NCT02858882|OTHER|Screening|Screening of elite swimmers
41114915|NCT03157401|DRUG|intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
41114916|NCT03157401|DRUG|intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
41114917|NCT03157401|DRUG|control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
41114918|NCT03411291|DEVICE|MRI, MR Spectroscopy, MR Perfusion|One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.
41114919|NCT01689844|BEHAVIORAL|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
41114920|NCT01689844|BEHAVIORAL|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
41114921|NCT00012740|BEHAVIORAL|Casefinding and Referral System|
41114922|NCT01638611|DRUG|HIP2B|Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
41114923|NCT01638611|DRUG|Placebo|Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
41114924|NCT06553209|BIOLOGICAL|CM512|CM512 injection
41114925|NCT06553209|DRUG|Placebo|Placebo
41114926|NCT01580293|BIOLOGICAL|BAY94-9027|Intravenous infusion of BAY94-9027
41114927|NCT02731755|OTHER|Oat|The study oat intervention products will consist of 67.7g oatflake and 22.5g oatbran concentrate.
41114928|NCT02731755|OTHER|Control|60g cream of rice
41114929|NCT01985269|OTHER|Home visits|The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
41114930|NCT00600548|DRUG|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
41446133|NCT06559124|OTHER|Traditional Physiotherapy + Sham Kinesiotape|"As exercise training, joint range of motion, flexion and abduction external cycle will be practiced with the gymnasts.~Circumference measurements will be taken for shoulder bone swelling and for atrophy.~Shoulder joint mobilizations will be applied (posterior cutting for flexion limitation, downward shifting and scapular mobilizations for abduction limitation).~Flexion and abduction will be stretched externally. Friction massage will be applied. Strengthening exercises for flexion, abduction and external rotation in the lower and upper segments of the shoulder with dumbbells and theraband, shoulder wheel and finger ladder will be practiced.~Codman exercises and staff exercises will be practiced."
41114931|NCT00600548|DRUG|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
41114932|NCT00600548|DRUG|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
41114933|NCT00600548|DRUG|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
41114934|NCT04009577|DRUG|LEM 5 mg|LEM tablet.
41114935|NCT04009577|DRUG|LEM 10 mg|LEM tablet.
41114936|NCT06491888|DIAGNOSTIC_TEST|Detection of Cervical Lesions by Fluorescence Photoelectric Image|Photoelectric detection was carried out on the subjects of the experimental group.
41114937|NCT06101992|DRUG|Mesoglycan|Mesoglycan capsules 50 mg are composed by heparan sulphate 47.5%, dermathan sulphate 35.5%, chondroitin sulfate 8.5%,slow heparin 8.5%, excipients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine
41114938|NCT06101992|OTHER|Placebo|placebo capsules are composed by lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate
41114939|NCT03863834|DEVICE|InModeRF|InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
41114940|NCT02122445|DEVICE|Cramer Sports Motion Tape|lower body exercises with and without Cramer Sports Motion tape applied to the hip
41114941|NCT00486005|DRUG|Olanzapine Hydrochloride|
41114942|NCT00486005|DRUG|Nizatidine|
41114943|NCT00486005|DRUG|Placebo|
41114944|NCT00145314|DRUG|FLOX (5-fluorouracil/folinic acid/oxaliplatin)|FLOX every 2nd week
41114945|NCT00145314|DRUG|FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|FLOX every 2nd week Cetuximab weekly
41114946|NCT00145314|DRUG|FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab|"FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.~Cetuximab weekly."
41453372|NCT04911218|DEVICE|GlideSheath Slender 5Fr arterial sheath|Placement of GlideSheath Slender 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
41114947|NCT03938428|OTHER|Survey|Patients who are eligible for this study will have been previously identified as part of the PREFACES project. The pharmacist who has conducted the clinical medication review will obtain verbal permission from the patient to be contacted by the research study team. This will be documented on the referral outcome document that is returned to the YAS clinical team. A member of YAS clinical staff from the PREFACES project will forward the name and residential address of patients who have agreed to be contacted to the research paramedic for this study. A covering letter, participant information sheet, questionnaire and consent form, will be posted to potential participants. A stamped addressed envelope will be included to enable return of the completed booklet at no costs to participants.
41114948|NCT01514344|DRUG|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
41114949|NCT01514344|BIOLOGICAL|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
41114950|NCT00530517|DEVICE|Intraject Sumatriptan|needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
41114951|NCT00651105|DRUG|Vildagliptin|
41114952|NCT00651105|DRUG|Placebo|
41114953|NCT02328768|DRUG|Omegaven|
41114954|NCT00739765|BEHAVIORAL|Interpersonal Psychotherapy|14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
41114955|NCT00739765|BEHAVIORAL|Prolonged Exposure Therapy|Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
41114956|NCT00739765|BEHAVIORAL|Relaxation Therapy|Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
41114957|NCT03461575|DRUG|HU007|cyclosporine 0.02%, trehalose 3%
41114958|NCT03461575|DRUG|Restasis|cyclosporine 0.05%
41114959|NCT03461575|DRUG|Moisview|trehalose 3%
41114960|NCT00389012|PROCEDURE|exercise therapy|
41114961|NCT00389012|PROCEDURE|walking rehabilitation|
41453373|NCT04911218|DEVICE|Conventional 5Fr arterial sheath|Placement of conventional 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
41114962|NCT04136470|BIOLOGICAL|Collection of stool, blood (PBMC) and biopsy (FFPE)|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
41114963|NCT05691738|OTHER|Exercise Group|The exercise group will be informed about diabetes and diabetes complications. A total of 16 sessions of 8 weeks, modified otago exercises will be applied individually by the research physiotherapist.Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program).
41114964|NCT05691738|OTHER|Control Group|The control group will be informed about diabetes and diabetes complications. Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program)
41114965|NCT02342119|OTHER|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
41114966|NCT02342119|OTHER|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
41114967|NCT00813449|DRUG|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
41114968|NCT00813449|DRUG|dacarbazine plus placebo (control group)|dacarbazine plus placebo
41114969|NCT03399370|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
41114970|NCT03399370|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
41114971|NCT03462589|DRUG|SY-008|The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
41114972|NCT00908817|DRUG|triamcinolone acetonide|paste applied over tracheal tube for lubrication
41114973|NCT00908817|DRUG|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
41453374|NCT02117830|DRUG|Androxal 25 mg capsules|
41453375|NCT02117830|DRUG|Androxal 250 Capsules|
41453376|NCT02117830|DRUG|Placebo Capsules|
41453377|NCT02117830|DRUG|Moxifloxacin 400 mg|
41114974|NCT02043054|DRUG|Liraglutide|"Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.~* BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or~* BMI \< 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities."
41114975|NCT02043054|DRUG|Sitagliptin|Sitagliptin (Januvia®, Merck \& Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
41114976|NCT04113707|BEHAVIORAL|Motor lab activity|fitness, gross motor, fine motor, and motor coordination activities
41114977|NCT06392451|DIAGNOSTIC_TEST|LIAISON NES FLU A/B, RSV, & COVID-19|The LIAISON® NES FLU A/B, RSV \& COVID-19 real-time (RT) PCR assay is a Point of Care (POC) system that enables the extraction, amplification, detection and differentiation of influenza A, Influenza B, respiratory syncytial virus (RSV) and SARS-CoV-2 viral RNA from dry nasal swabs (NS). The system consists of the LIAISON® NES FLU A/B, RSV \& COVID-19 cartridge, the LIAISON® NES system (with LIAISON® NES Software), and associated accessories. In the LIAISON® NES FLU A/B, RSV \& COVID-19 cartridge, extraction reagents and lyophilized fluorescent probes are used together with corresponding forward and reverse primers to extract and amplify influenza A, influenza B, RSV, SARS-CoV-2 and internal control RNA targets.
41114978|NCT06392451|DIAGNOSTIC_TEST|LIAISON PLEX Respiratory Flex Assay|"The LIAISON PLEX® (also known as VERIGENE® II) RSP Flex Assay is an automated test for the detection and identification of common viruses and bacteria, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, from upper respiratory specimens. The VERIGENE® II Respiratory Flex (RSP Flex) Assay is performed on the VERIGENE® II System. The VERIGENE® II System is an automated platform that performs sample preparation and is capable of polymerase chain reaction (PCR) for the detection of target-specific nucleic acids. The VERIGENE® II System is a fully automated, bench-top sample-to-answer device. The test reagents are supplied in a single, disposable test cartridge."
41114979|NCT03310112|BEHAVIORAL|4-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
41114980|NCT03310112|BEHAVIORAL|2-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
41114981|NCT06174636|PROCEDURE|Application of abdominal weight|Application of variable weight on the abdomen to reach a 5 mmHg increase in IAP
41114982|NCT01284907|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months
41114983|NCT01284907|DIETARY_SUPPLEMENT|Placebo Drops|
41114984|NCT03410966|PROCEDURE|trans cateheter ablation|All AF patients will receive trans catheter ablation by radiofrequency, to destroy arrhythmic atrial cells, and to isolate arrhythmic atrial firing around pulmonary veins' ostia.
41114985|NCT04889131|BEHAVIORAL|Yoga Program Immediately|free 12 week yoga program, twice a week for 75 minutes each
41114986|NCT04889131|BEHAVIORAL|Wait-Listed Control|assigned to take the Yoga Program in 12-weeks
41114987|NCT04889131|OTHER|Activity Monitor|Garmin VivoSmart activity monitor throughout study
41114988|NCT03837431|DIAGNOSTIC_TEST|Skin slit|Skin slit microscopy, RDT and PCR
41114989|NCT03837431|DIAGNOSTIC_TEST|Dental broach|Dental broach RDT and PCR
41114990|NCT03837431|DIAGNOSTIC_TEST|Tape disc|Tape disc PCR
40752581|NCT03398382|DIETARY_SUPPLEMENT|Magnesium tablet group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-artikain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected, the patient will receive magnesium citrate tablets. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
41114991|NCT04135989|DEVICE|Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.|Implantation of polymer-free, amphilimus-eluting, drug-eluting stents
41114992|NCT04135989|DEVICE|Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.|Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents
41114993|NCT04135989|DRUG|Personalized DAPT duration|Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score
41114994|NCT04135989|DRUG|Standard DAPT duration|Duration of dual antiplatelet therapy for 12 months.
41114995|NCT06326632|OTHER|Constant-load Aerobic Exercise|The CL-AE group received a 12-week aerobic training, three times in addition to the respiratory re-training. the program included a moderate-intensity aerobic training program, with an intensity set at 65% of the maximum age-predicted heart rate for 45 minutes. The training intensity and duration were maintained at the same level throughout the program. The CL-AE program included a warm-up for 5 minutes and a cool-down for 5 minutes
41114996|NCT06326632|OTHER|Graded Aerobic exercise|The G-AE group received a 12-week intensity- and duration-graded aerobic training, three times in addition to the respiratory re-training. The G-AE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The G-AE program also included a warm-up for 5 minutes and a cool-down for 5 minutes.
41114997|NCT06326632|OTHER|Respiratory Re-training|The respiratory re-training lasted for 30 minutes per session and was repeated three times a week for 12 consecutive weeks. The program consisted of diaphragmatic breathing exercises, breath-hold, and breathing control exercises, pursed lip breathing, respiratory muscle strengthening, postural correction exercises, and relaxation techniques.
40752582|NCT03398382|DIETARY_SUPPLEMENT|Placebo tablets group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected , the patient will receive placebo tablets which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
41114998|NCT03347942|BEHAVIORAL|Intervention group|Wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before serving again if he or she feels the need. The intervention time will be monitored by the participants themselves, who will be instructed by the researcher when the methodology to be performed.
41114999|NCT03347942|OTHER|Control group|The control group will also serve the dish of the form, but can serve additional portion without waiting.
41115000|NCT04486222|DEVICE|Repeated Transcranial Magnetic Stimulation|Magstim® Super Rapid² Transcranial Magnetic Stimulation System
41115001|NCT03829813|OTHER|Music therapy|20 to 40 minute music therapy treatment session with a qualified music therapist.
41115002|NCT02095899|DRUG|Rufinamide|2x200mg up to max 2x800mg a day Titration over 20days
41115003|NCT05235698|PROCEDURE|Ophthalmological examinations|Visual acuity, slit lamp examination, eye pressure, retinophotography, indocyanine green retinal angiography, OCT-A( Optical Coherence Tomography- Angiography), adaptive optics, automated visual field
41115004|NCT05235698|PROCEDURE|GlycoCheck|"Evaluation of the glycocalyx of sublingual capillaries with the GlycoCheck :~A sidestream dark field camera, coupled with GlycoCheck™ software is used to visualize the patient's sublingual microvascularization"
41115005|NCT03712930|DRUG|Pamiparib|60 mg orally twice daily (BID)
41115006|NCT01052246|DRUG|Fixed combination of clindamycin 1% + benzoyl peroxide 5%|Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
41115007|NCT01052246|DEVICE|Pulsed dye laser|"Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:~* Wavelength 585 nm~* Energy fluence 3 J/cm2~* Pulse duration 0.35 msec~* Spot size 7 mm"
41115008|NCT01538914|PROCEDURE|paravertebral block|Postoperative pain is controlled with local analgesics via PVB.
40752583|NCT03398382|DIETARY_SUPPLEMENT|Magnesium lozenge group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX..) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive magnesium citrate lozenge.The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate lozenges. 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
41115009|NCT01538914|PROCEDURE|PCA|Postoperative pain is controlled with intravenous PCA.
41115010|NCT01267383|DRUG|Sertraline|Sertraline Hydrochloride Tablets 100 mg
41115011|NCT03532711|DRUG|fluorouracil|chemotherapy treated patients
41115012|NCT06484855|DRUG|IBI355|IBI355 IV. Q4W
41115013|NCT06484855|DRUG|IBI355 placebo|IBI355 placebo IV. Q4W
41115014|NCT02701855|BEHAVIORAL|Cognitive tests|"Cognitive tests include:~* The MMSE (Mini Mental State Examination)~* Free and Cued Selective Recall Reminding Test (FCSRT).~* Executive functions (fluencies, TMT A and B, span).~* Tests of verbal fluency (literal and category)~* Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)~* The Clinical Dementia Rating Scale~* The IADL scale evaluates autonomy.~* Geriatric Depression screening Scale (GDS)"
41115015|NCT02701855|BIOLOGICAL|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
41446134|NCT06559124|OTHER|Kinesiotape with Facilitation Method + Traditional Physiotherapy|Kinesio tape will be applied with 0 tension at the starting point when the arm is in a relaxed position and will be slightly heated. Since the deltoid muscle is a three-headed muscle, it will be applied with 0 tension in the flexed position at the elbow, for the front part, the arm with the elbow in full extension, and for the middle part of the deltoid, the I tape will be applied along the muscle without applying tension.
41115016|NCT02701855|RADIATION|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
41115017|NCT02701855|OTHER|Adaptative optics|"The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging."
41115018|NCT06162858|OTHER|IMU (Inertial Measurement Devices)|Functional placing and reaching of objects of different weights on different heights
41115019|NCT03309488|DIAGNOSTIC_TEST|Oral food challenge|Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.
41115020|NCT01926977|DRUG|Ranibizumab 0.5mg|Patient will receive intravitreal injection of Ranibizumab 0.5mg.
41115021|NCT01926977|DRUG|Aflibercept 2.0mg|Patients will receive intravitreal injection of Aflibercept 2.0mg.
41115022|NCT03948997|RADIATION|Pulsed dye laser (PDL)|Pulsed dye laser (PDL, 595nm) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis
41115023|NCT03460067|RADIATION|Omission of Radiation|No Radiation will be given. 1 year of trastuzumab +/- pertuzumab treatment will be given with 5 years of follow up occurring every 3 months to check for recurrence
41115024|NCT05003570|DRUG|Remifentanil|Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
41115025|NCT05003570|DRUG|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
41115026|NCT04516564|DRUG|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects
41115027|NCT04516564|DRUG|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects
41115028|NCT00356265|DRUG|Procedure: Regional phenylephrine arterial infusion|
41115029|NCT05088629|DIAGNOSTIC_TEST|Clinical Tests|Clinical Tests
41115030|NCT01603784|BEHAVIORAL|Intensive Exercise|"Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at \~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max."
41115031|NCT01603784|BEHAVIORAL|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
41115032|NCT01603784|BEHAVIORAL|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
41115033|NCT01603784|BEHAVIORAL|Health Education|"Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment."
41115034|NCT01199575|DRUG|Revlimid|
41115035|NCT01199575|DRUG|Rituximab|
41115036|NCT00523237|DRUG|Raltegravir|400 mg Twice daily for 24 weeks
41115037|NCT04022616|OTHER|Specimen collection|Specimens are obtained from patients who are being treated for breast malignancies.
41115038|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.
41115039|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.
41115040|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
41446135|NCT06559124|OTHER|Kinesiotape with Inhibition Method + Traditional Physiotherapy|The Y-shaped kinesio tape will be placed on the deltoid muscle with inhibition and mechanical correction technique, and the Y-shaped kinesio tape will be placed on the supraspinatus muscle with inhibition technique, 3 cm below the humerus tuberculum deltoidea without tension. The Y tape will be applied along the outer edge of the anterior deltoid of the forearm with 15-25% light tension, and the posterior arm will be applied along the outer edge of the posterior deltoid with 15-25% light tension up to the lateral acromion. The last 3-5 cm of the tails will be applied to their permanent locations without tension. The shoulder will be held in maximum transverse extension and external rotation for the forearm of the Y support, and in 45 degrees transverse flexion and horizontal adduction for the posterior arm of the Y support. In addition, ultrasound, electrotherapy and cold application will be applied to the participants depending on their tolerance.
41446136|NCT05234463|OTHER|IgAN patients|Adult patients Histologically proven diagnosis of IgA nephropathy Primary and secondary forms of the disease With or without kidney transplantation history Regardless of kidney/graft function Patients followed in the Nephrology Department of Strasbourg University Hospital.
41446137|NCT06545474|DEVICE|bilateral theta burst stimulation|Each stimulation session consists of 600 stimuli applied in bursts of 3 pulses at 50 Hz, with an interstimulus interval of 200 ms. iTBS is administered 20 times for 2 seconds to the left dlPFC, with an intertrain interval of 8 seconds and cTBS continuously for 40 seconds to the right dlPFC in alternating order.
41446138|NCT06545474|DRUG|SSRI treatment|Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.
41446139|NCT00319696|DRUG|Bosentan 62.5 mg|Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
41446140|NCT00319696|DRUG|Bosentan 125 mg|Bosentan 125-mg oral tablets administered b.i.d. (target dose)
41446141|NCT05395052|DRUG|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy
41115041|NCT02700191|DEVICE|uCor|
41115042|NCT02272959|BEHAVIORAL|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
41115043|NCT02272959|BEHAVIORAL|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
41115044|NCT00886951|DRUG|I123MNI388/I123MNI390|Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
41115045|NCT05089097|OTHER|evaluation of delirium with CAM-ICU Score|the CAM-ICU score is an evaluation tool to verify the presence or absence of delirium in a subject
41115046|NCT02711839|DIETARY_SUPPLEMENT|Commercial diabetic formula|The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
41115047|NCT02711839|DIETARY_SUPPLEMENT|White sweet potato formula|The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
41115048|NCT06178978|DEVICE|KalEYEdoscope|"KalEYEdoscope is a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration. In the future, developing such a device for home monitoring of macular degeneration may increase access to timely treatment to prevent vision loss.~This study was conducted at the Kellogg Eye Center in Ann Arbor. Participants in the outpatient setting who agreed to enroll in the study tested the device and provided user feedback via a questionnaire as well as completed questionnaires about their visual function. This study assessed the usability, comfort, duration, ergonomics, and ease of use of the device among AMD patients in a single session."
41115049|NCT03616639|DRUG|Oxycodone|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
41115050|NCT03616639|DRUG|Morphine|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
41115051|NCT01542593|DEVICE|Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR|"During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
41115052|NCT03501173|OTHER|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
41115053|NCT03122574|OTHER|Lavender Aromatherapy|100% pure lavender aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet.
41115054|NCT03122574|OTHER|Jojoba Aromatherapy|100% pure jojoba aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet. This colorless, odorless oil was used as a placebo comparator.
41115055|NCT04874558|DIAGNOSTIC_TEST|Ultra-low dose chest CT|A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.
41115056|NCT05688644|DEVICE|InterStim II|Sacral neuromodulation
41115057|NCT02457845|BIOLOGICAL|G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
41115058|NCT00187941|DRUG|Mycophenolate Mofetil|Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
41446142|NCT05395052|DRUG|Cyclophosphamide|Lympho-conditioning agent
41446143|NCT05395052|DRUG|Fludarabine|Lympho-conditioning agent
41446144|NCT05395052|DRUG|IL-2|For Cohort AA ONLY: To be combined with FT536 at the MTD or MAD
41115059|NCT02806557|DEVICE|Home finger-prick capillary blood count monitoring|A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
41115060|NCT01185782|DRUG|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
41115061|NCT01185782|DRUG|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
41115062|NCT03443453|DRUG|MIV-711|MIV-711 administered as tablets and capsules at four occasions
41115063|NCT06261372|BEHAVIORAL|The mindfulness meditation combined with progressive muscle relaxation training .|The first part is progressive muscle relaxation training. The second part is mindfulness meditation training.
41115064|NCT01892553|DEVICE|tDCS|"Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~* Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~* Cathodal tDCS: Intensity of 1.25 mA during 15 min~* Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)"
41115065|NCT01139398|DIETARY_SUPPLEMENT|Limicol (plant extract)|Artichoke extract, anti-caking agents: dicalcium phosphate, calcium citrate, vegetable magnesium stearate, red yeast rice, microcrystalline cellulose, natural vitamin E, garlic extract, sugar cane policosanols, inositol hexanicotinate, vitamin B3, vitamin B2.
41115066|NCT02502344|BEHAVIORAL|healthy lifestyle|food control and intensive exercise to lose weight
41115067|NCT02502344|DRUG|Metformin|use metformin to reduce insulin resistance
41115068|NCT04614675|PROCEDURE|Distal soft tissue procedure with TALR|TALR group: Transarticular lateral release as the distal soft tissue procedure
41115069|NCT04614675|PROCEDURE|Distal soft tissue procedure with PCLR|PCLR: Percutaneous soft tissue procedures as the distal soft tissue procedure
41115070|NCT01068743|DRUG|saxagliptin|Tablets, Oral, 2.5 mg, once daily, single dose
41115071|NCT01068743|DRUG|metformin|Tablets, Oral, 850 mg, once daily, single dose
41115072|NCT01068743|DRUG|saxagliptin + metformin (FDC tablet)|Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
41115073|NCT03565796|BEHAVIORAL|Personalized active referral plus financial incentive|Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.
41115074|NCT03565796|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
41115075|NCT03565796|BEHAVIORAL|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
41115076|NCT03565796|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
41115077|NCT03565796|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
41115078|NCT03262623|OTHER|Radial nerve block|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
41115079|NCT03262623|OTHER|Placebo|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
41115080|NCT05261815|OTHER|Ultrasound Therapy|Ultrasound Therapy improves the pain management in patients with herniation. It eases down the severity of symptoms as well.
41115081|NCT05261815|OTHER|High Intensity Laser Therapy|Treatment of low disc herniation should be non-surgical, pharmacological and by physical therapy modalities. Laser radiation with high intensity used as a modality called high intensity laser therapy. It is used to relieve the pain by three process; Photo-chemical, Photo-thermal, Photo-mechanical. High Intensity Laser Therapy uses high intensity laser irradiation and low light absorption.
41115082|NCT03339024|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
41115083|NCT03339024|OTHER|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
41115084|NCT00081250|DIETARY_SUPPLEMENT|creatine monohydrate|Given orally
41115085|NCT00081250|OTHER|placebo|Given orally
41115086|NCT00885157|BIOLOGICAL|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.1 mL, intradermal
41115087|NCT00885157|BIOLOGICAL|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.5 mL, Intramuscular
41115088|NCT03493269|DRUG|BAY1834845|Orally administered.
41115089|NCT03493269|OTHER|Matching Placebo|Orally administered.
41115090|NCT03493269|DRUG|Midazolam|Part 1: Orally administered 1mg as a single dose.
41115091|NCT04737681|OTHER|body composition|This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
41115092|NCT03393078|DEVICE|transcranial magnetic stimulation with real coil|TMS with real coil is a noninvasive technique to activate and modify the activity of the neurons
41115093|NCT03393078|DEVICE|transcranial magnetic stimulation with sham coil|TMS with sham coil is a placebo
41115094|NCT05392946|DRUG|Bortezomib|Given SC
41115095|NCT05392946|BIOLOGICAL|Daratumumab|Given SC
41115096|NCT05392946|DRUG|Dexamethasone|Given PO
41446145|NCT05395052|COMBINATION_PRODUCT|Avelumab|Monoclonal antibody
41446146|NCT05395052|COMBINATION_PRODUCT|Pembrolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
41115097|NCT05392946|DRUG|Iberdomide|Given PO
41115098|NCT00548574|DRUG|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
41115099|NCT00548574|DRUG|Mesalazine|
41115100|NCT06081686|DRUG|Phase I:[177Lu]Lu-XT033 Injection|Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of \[177Lu\] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .
41446147|NCT05395052|COMBINATION_PRODUCT|Nivolumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
41115101|NCT06081686|DRUG|Phase II:[177Lu]Lu-XT033 Injection|Patients received \[177Lu\]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
41115102|NCT01032486|DRUG|Rasagiline mesylate|Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
41115103|NCT01645098|DRUG|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
41115104|NCT01645098|DRUG|Dexmedetomidine|0.5 mcg/kg/hr IV
41115105|NCT03601910|DRUG|D308 10mg Tab.|D308 10mg Tab.1T single oral administration under fasting condition
41115106|NCT03601910|DRUG|CKD-380 10mg Tab.|CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
41115107|NCT00495417|BIOLOGICAL|AFFITOPE AD01|s.c. injection
41115108|NCT00495417|BIOLOGICAL|AFFITOPE AD01 adjuvanted|s.c. injection
41115109|NCT05505071|DEVICE|DANTE SPACE sequence|investigational MRI sequence less than 15 minutes
41115110|NCT05426317|OTHER|Blood sample|This study only involves the patient taking 5 additional blood tests (peripheral venipuncture) compared to his usual care, which will be taken when he comes to the hospital. Each sample only requires a blood volume of 5mL (one tube), or a total blood volume of 25mL for the study (one blood test every 3 months for one year).
41115111|NCT04674293|DRUG|Revelisa|Thrombolytic therapy for patients with ischemic stroke
41115112|NCT04979299|OTHER|Wheelchair|Patient will be asked to sit in a wheelchair, and a 5-minute video recording of spontaneous speech capturing the semi-structured iCGI interview is made.
41115113|NCT01359436|DEVICE|Electrosensing antibody probing system (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
40752584|NCT03398382|DIETARY_SUPPLEMENT|Placebo lozenges group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive placebo lozenges which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo lozenges 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
41115114|NCT00703911|DRUG|eptacog alfa (activated)|Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
41446148|NCT05395052|COMBINATION_PRODUCT|Atezolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
41446149|NCT05395052|COMBINATION_PRODUCT|Trastuzumab|Monoclonal antibody
41446150|NCT05395052|COMBINATION_PRODUCT|Cetuximab|Monoclonal antibody
41115115|NCT02797717|RADIATION|Radiotherapy:|"All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not."
41115116|NCT02797717|DRUG|Vincristine|ARM A and ARM B
41115117|NCT02797717|DRUG|Etoposide|ARM B , 100mg/m2/day
41115118|NCT02797717|DRUG|Prednisone|ARM A and ARM B , 40mg/m2/day p.o
40752585|NCT00614341|DEVICE|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
41115119|NCT02797717|DRUG|Doxorubicin|ARM B , 25mg/m2
41115120|NCT02797717|DRUG|Dacarbazine|ARM A and ARM B , 250mg/m2 i.v
41446151|NCT05395052|COMBINATION_PRODUCT|Amivantamab|Monoclonal antibody
41115121|NCT02797717|DRUG|Cyclophosphamide|ARM A and ARM B , 625mg/m2 i.v
41115122|NCT03020745|DRUG|GSK3389404|GSK3389404 is available as Clear colorless to slightly yellow solution for injection.
40752586|NCT03719937|DEVICE|weight on the anterior chest of the patient|The investigators aim at assessing whether and to what extent an artificial increase in chest wall elastance, while the patient is in the supine position, may yield a significant benefit to oxygenation. The increase in chest wall elastance will be will be achieved placing a 100 g/kg weight on the anterior chest wall of the patient while he/she is in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
40752587|NCT02186171|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection once a month.
41115123|NCT03020745|DRUG|Placebo|Placebo is available as a Clear colorless solution.
41115124|NCT02351648|OTHER|a transitional care model|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
41115125|NCT02351648|OTHER|Control|Patients receive usual standard of care from the internal medicine team
41115126|NCT03448653|OTHER|Colonoscopy with NBI|Colonoscopy with NBI
41115127|NCT03399968|DEVICE|ESWT|at low energy, shockwaves are applied non-invasively at the injury level and 5 segments up and down of the spinal cord paravertebrally left and right
41115128|NCT03399968|DEVICE|Placebo ESWT|the ESWT therapy head is positioned at the level of injury and is moved up and down identically as described in the Verum intervention group (ESWT) but without application of shockwaves. The sound which is normally produced by shockwave generation is played by high quality sound recordings in the same amount as in the Verum group
41115129|NCT00445952|OTHER|clinical observation|
41115130|NCT00445952|PROCEDURE|management of therapy complications|
41115131|NCT03168048|OTHER|mobile application|Oncologic therapy support by means of a mobile application
41115132|NCT04767698|DRUG|Belimumab|200 mg SC weekly for 36 months
41115133|NCT04767698|DRUG|Short-course Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)
41115134|NCT04767698|DRUG|Continued Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
40752588|NCT02186171|DRUG|Placebo|Administered by subcutaneous injection once a month.
40752589|NCT03144635|DRUG|Grazoprevir plus Elbasvir|An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
40752590|NCT02588755|PROCEDURE|TACE+Tegafur|Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.
40752591|NCT02588755|PROCEDURE|TACE|TACE alone
40752592|NCT00106535|DRUG|tocilizumab [RoActemra/Actemra]|4 mg/kg or 8 mg/kg IV/month every 4 weeks.
40752593|NCT00106535|DRUG|Placebo|IV/month
41115135|NCT03997682|OTHER|Hands-Up Program|In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
41115136|NCT04820933|DRUG|Doravirine 100 Mg|Doravirine 100 Mg orally dail
41446152|NCT05395052|DRUG|IL-2|For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD
41115137|NCT03621826|OTHER|Questionnaire/Interview|A convenience sample of patients/parents and stakeholders will be asked to participate in a survey and/or interview to evaluate barriers to care in sickle cell.
41115138|NCT04788836|OTHER|Questionnaire (Survey and Food Frequency Questionnaire (FFQ))|Each participant will be asked to fill a web-based questionnaire that captures sociodemographic, lifestyle, physical and mental health information (Survey) and dietary intake patterns (FFQ). This will be done pre-treatment (only for those included pre-treatment), 6 months after the start of obesity treatment, 1 year after the start of the treatment and then yearly until 5 year after the start of the treatment.
41115139|NCT04788836|OTHER|Collection of digital receipts from grocery shopping|"Participants will create their BitsaboutMe-account (GDPR-compliant data sharing platform from Bern, Switzerland) with the help of study team members. Data from digital receipts will be obtained from Migros Cumulus and Coop Supercard via their BitsaboutMe-account. The data collection allow retrospective digital receipts collection for up to 2 years and automatically continuous collection during study duration.~GDPR: General Data Protection Regulation"
41115140|NCT02634970|DRUG|Ranibizumab|0.5 mg, intravitreal injection
41115141|NCT02950948|DRUG|Progesterone|Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.
41115142|NCT02950948|DRUG|Placebo|A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
41115143|NCT04352283|DEVICE|Preprocedural ultrasound exam of lumbar spine|Preprocedural ultrasound exam of lumbar spine used to determinate needle puncture site
41115144|NCT00448721|DRUG|Perifosine|Perifosine will be administered orally at 100mg PO daily with food.
41115145|NCT03950778|DRUG|Human albumin|Patients are divided into 2 groups by envelope randomization. In the treated group, albumin supplementation occurs up to a target of 30 g / l at the end of the test period at a maximum dose of 3 x 100 ml, and no albumin is added above the control value of 20 g / l. Patients with albumin below 20 g / l in the control group are excluded from the study and albumin supplemented. Blood samples are taken directly at the intensive care class, and at the same time on the following days. Urine was collected for 24 hours. The kinetics of the parameters are examined for five days.
41115146|NCT06455241|OTHER|HABIT (Hand Activities Behavior Intervention)|A Novel Occupational Therapy Intervention for Enhancing Daily Hand-Use of the affected upper extremity Among Individuals post Stroke.
41115147|NCT03105505|DRUG|Permethrin 5%|Facial skin application once a night for 3 months.
41115148|NCT03105505|DRUG|Synthomycine 5%|Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
41115149|NCT03105505|DRUG|Fusidic Acid 1% M/R Eye Drops|viscous eye drops application once a night for 3 months.
41115150|NCT03204396|DRUG|Dulaglutide|Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
40926180|NCT06472986|OTHER|Activity-based therapy and transcutaneous spinal cord stimulation|Activity Based Therapy (ABT) is a method of neuro-rehabilitation that incorporates a high intensity, long duration and effortful engagement from the individual receiving therapy, to garner improvements in sensory and motor function. The ABT constitutes 4 types of exercises including: cardio-fitness, resistance, postural/weightbearing and functional exercises. TransCutaneous Spinal Cord Stimulation (TCSCS) stimulates spinal networks in the cervical region to neuro-modulate the descending motor commands/motor intentions from the brain, which control the muscles. In tCSCS, electrical stimulation is delivered at a frequency of 30-50Hz at 500-1000µs between C3-C7. 12 sessions of ABT (4 weeks), followed by 28 sessions of ABT-TCSCS (7 weeks). Each session will last 1 hour and delivered 3 times per week.
41115151|NCT03204396|DRUG|0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])|Application of 0.5 ml normal saline (0.9% sodium chloride \[0.9% NaCl\]) once weekly for 12 weeks
41115152|NCT03658304|DRUG|Mitomycin c|All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
41115153|NCT03165071|DRUG|ACT-132577|Capsule
41446153|NCT04906538|PROCEDURE|all- inside anterior cruciate ligament reconstruction|all- inside anterior cruciate ligament reconstruction with internal suture augmentation technique
40752594|NCT00106535|DRUG|Methotrexate|10-25 mg/week
40752595|NCT00504231|BIOLOGICAL|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
41446154|NCT04392999|DRUG|Intraarticular platelet rich plasma cervical facet injection|Injection of PRP into the cervical facet joints.
40752596|NCT05747547|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) optotypes or Snellen optotype chart.
40752597|NCT05747547|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
40752598|NCT05747547|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
40926181|NCT00941434|DIETARY_SUPPLEMENT|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
41115154|NCT00317902|DRUG|Epoetin alfa|
41115155|NCT01292252|BIOLOGICAL|teriparatide|Teriparatide 20 ug subcutaneous injection daily for 12 weeks
41115156|NCT01292252|BIOLOGICAL|Placebo|Saline solution
41115157|NCT05723133|DEVICE|Electric toothbrush|Patients will receive oral hygiene instructions and an electric toothbrush with or without daily personal feedback using the brushing app (Oral-B app).
41115158|NCT05723133|BEHAVIORAL|Oral hygiene instructions|The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.
41115159|NCT05289466|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
41115160|NCT05289466|PROCEDURE|Oncoplastic partial mastectomy|Breast Conserving Therapy
41115161|NCT04319874|DRUG|Ganoderma lucidum|Participants take ganoderma lucidum spore powder once a day, 1000mg
41115162|NCT04319874|DRUG|Chemotherapy|Subjects are treated with conventional chemotherapy
41115163|NCT04319874|DRUG|Placebos|Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg
41115164|NCT00042198|BEHAVIORAL|Cognitive behavior therapy|Up to 12 weekly, individual, hour-long sessions
41115165|NCT00042198|BEHAVIORAL|Supportive Stress Management|Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
41115166|NCT05948358|OTHER|Menstrual Distress Questionnaire|The Menstrual Distress Questionnaire (MEDI-Q) is a new tool originally developed in Italian that comprehensively evaluates menstrual-related distress.
41115167|NCT04152317|DRUG|Misoprostol 200mcg Tab|In the misoprostol 200mcg group there will be one tablet of 200mcg and three identical tablets in shape, size and color without pharmacological properties. These four tablets will be single dose administered via vaginal route for each participant.
41115168|NCT04152317|DRUG|Misoprostol 800mcg Tab|In the misoprostol 800mcg group there will be four tablets of 200mcg. These four tablets will be single dose administered via vaginal route for each participant.
41115169|NCT06554769|PROCEDURE|non rigid indirect anchorage connection|a nonrigid connection is placed between the miniscrews and the second premolar to prevent mesial tooth movement.
40752599|NCT05747547|DIAGNOSTIC_TEST|Retinal oximetry|Performing of retinal oximetry with an Oxymap T1 instrument (Oxymap ehf.) paired with a Topcon TRC-50DX retinal camera.
41115170|NCT06554769|PROCEDURE|rigid indirect anchorage connection|a rigid connection is placed between the miniscrews and the first molar to prevent mesial tooth movement.
40752600|NCT05747547|DIAGNOSTIC_TEST|Optical coherence tomography and angiography|Performing of optical coherence tomography and angiography with the Spectralis Optical Coherence Tomography Plus (Heidelberg Engineering).
41115171|NCT02420613|RADIATION|Radiation Therapy|Undergo radiation therapy
41115172|NCT02420613|DRUG|Temsirolimus|Given IV
41115173|NCT02420613|DRUG|Vorinostat|Given PO
41115174|NCT00724217|OTHER|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
41115175|NCT00724217|OTHER|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
41115176|NCT04928248|OTHER|Diabetes Dashboard integrated with Disease Manager App|The Diabetes Dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface. The Diabetes Dashboard is integrated within the diabetes module of the EHR-integrated Disease Manager App, which uses key information from the Diabetes Dashboard and provides a link to the Diabetes Dashboard.
41115177|NCT06306378|DIAGNOSTIC_TEST|social memory levels and spindle levels|Take a face recognition memory test, and a car recognition memory test as a control . Then record nighttime EEG recordings after the two tasks and performed subsequent spindle analysis.So conduct the correlation between social memory levels and the level of spindles in the EEG by using machine learning to model.
41115178|NCT02798835|DRUG|Adductor canal block|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
40752601|NCT06310109|OTHER|PICU diary|.The PICU diary is a notebook with lined sheets located at the patient's bedside. In this diary parents, other caregivers, family members, healthcare professionals or other visitors can write thoughts, report events related to the child/adolescent's admission, attach drawings or photographs for the patient or related to the PICU admission.
41115179|NCT02798835|DRUG|Adductor canal block with dexamethasone|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
41115180|NCT02798835|DRUG|Adductor canal catheter|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
41115181|NCT02798835|DRUG|Bupivacaine|Used in spinal anesthetic
41115182|NCT02798835|DRUG|Fentanyl|May or may not be used in spinal anesthetic
41115183|NCT02798835|DRUG|Ropivacaine 0.5% Injectable Solution|Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
41115184|NCT02798835|DRUG|Dexamethasone|To be given intravenously at time of nerve block to one of the study arms.
41446155|NCT04392999|DRUG|Corticosteroid injection|Injection of corticosteroid into the cervical facet joints.
41115185|NCT02496702|DEVICE|Training on Interactive Modulare Tiles|Training with the Interactive Modulare Tiles
41115186|NCT00949975|DRUG|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
41115187|NCT00949975|DRUG|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
41115188|NCT00949975|DRUG|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
41115189|NCT00949975|DRUG|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
41115190|NCT05500378|OTHER|Head extension and rotation movement|Active exercise of the head
41115191|NCT04949581|OTHER|bioelectric therapy|the patient will receive microcurrent therapy from a supine lying position. the negative electrode on the incision area and the positive electrode proximal. the intensity will be less than 20 microamperes and frequency at 20 HZ.
41115192|NCT04949581|OTHER|cardiac rehabilitation program|the patient will receive cardiac rehabilitation program
41115193|NCT04782635|DEVICE|mobile based application|Application basic function would be support and improve nutrition status of children. Personalization of goals and challenges, daily intake of calories, carbohydrates, proteins, fats, minerals and vitamins will be tracked, food logging, food tracking, meal and supplement reminders, recipes, visual cues (remaining calories) will be notified, episodes of vomiting, meals missed, diarrhea, nausea will be recorded , meal planned according to the food preferences of child, food composition table, nutrition blogs and articles
40752602|NCT04055298|DEVICE|SMASS-Triage|SMASS-Triage is a web-based symptom checker developed by In4medicine Ltd. SMASS-Triage is based on a computerized transparent neural network, which was trained with the evidence of more than 1200 studies and the expertise of various panels of specialists in the field of preclinical medical triage. SMASS-Triage provides digitalized questionnaires of 87 frequent reasons of encounters (e.g. fever, cough, abdominal pain) and their associated red flags. The triage-result of SMASS-Triage encompasses the appropriate time-to-treat (T2T) and the adequate point-of-care (PoC).
40926182|NCT05201456|DEVICE|LithoVue Elite System|The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
41115194|NCT04782635|BEHAVIORAL|Pamphlet|A pamphlet which will be provide knowledge to the patients
41115195|NCT03179722|BEHAVIORAL|Medication review|The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
41115196|NCT03179722|BEHAVIORAL|Additional data collection: questionnaires|"Pre-post study design.~At three timepoints, data is collected:~* before the medication review (T-1week)~* during the review (Tweek 3)~* after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management"
41115197|NCT04149548|DIAGNOSTIC_TEST|ultrasound|Obstetric ultrasound to pregnant women
41115198|NCT01909258|OTHER|Goniometric measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured via goniometry.~The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes)."
41115199|NCT01909258|OTHER|Photographic measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using photography.~Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements)."
41446156|NCT06072339|OTHER|Lung Ultrasound for PEEP setting|NIV is started and adjusted by the physiotherapist. For the adjustment of PEEP, the ultrasound probe is placed on the thorax, facing the intercostal space having obtained the highest score during the initial LUS (synonym of the worst pulmonary aeration) and the images observed in real time. PEEP is increased until the physiotherapist cannot see any additional benefit on pulmonary aeration or appearance of a patient discomfort or an increasing of air leaks.
40926183|NCT00540371|OTHER|Port wine stain Birthmark|Port wine stain Birthmark
40926184|NCT04816409|OTHER|conventional therapy|"Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing~- Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,"
40752603|NCT05366842|DRUG|Stravix lyopreserved placental tissue (LPT)|Participants will undergo surgical implantation of Stravix lyopreserved placental tissue (LPT) during a standard of care radical prostatectomy.
40752604|NCT05366842|PROCEDURE|Radical prostatectomy|Standard care (no placement of tissue)
40752605|NCT05737732|DEVICE|Circadian Effective Lighting|Participants will receive lighting with a spectrum of 300K, 500 lux to the eye level between 7:00am and 10:00am in the morning, and hospital lighting (\<100lux) during the afternoon between 10:00am and 6:00pm. In the evening this group of participants will receive lighting with a spectrum of 3000K, \<50lux at eye light level between 6:00PM and bedtime.
41115200|NCT01909258|OTHER|EOS measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using the imaging system EOS.~Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed."
41115201|NCT05110534|BEHAVIORAL|additional oral hygiene appointments|Two additional preventive sessions including oral hygiene instructions one week before the date of the general anaesthesia treatment and at the control visit about a week after the general anaesthesia.
41115202|NCT05716763|DRUG|Tramadol Hydrochloride 5 MG/ML Oral Solution|50mg (10mL) single dose
41115203|NCT05716763|DRUG|Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))|50mg (20 drops) single dose
41115204|NCT03618134|BIOLOGICAL|Durvalumab|Given IV
41115205|NCT03618134|PROCEDURE|Modified Radical Neck Dissection|Undergo modified radical neck dissection
41115206|NCT03618134|OTHER|Quality-of-Life Assessment|Ancillary studies
41115207|NCT03618134|OTHER|Questionnaire Administration|Ancillary studies
41115208|NCT03618134|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41115209|NCT03618134|PROCEDURE|Transoral Robotic Surgery|Undergo TORS
41115210|NCT03618134|BIOLOGICAL|Tremelimumab|Given IV
41115211|NCT00553683|DRUG|cyclophosphamide|
41115212|NCT00553683|DRUG|poly ICLC|
41446157|NCT06072339|PROCEDURE|Non invasive ventilation session|"The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece.~The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above."
40752606|NCT05737732|DEVICE|Circadian Ineffective Lightning (CIL)|Participants will receive lower lighting levels in the morning (lighting with A spectrum of 300k, \<50lux to the eye level between 7:00am and 10:00am) and the same lighting levels throughout the rest of the day.
41115213|NCT00553683|PROCEDURE|hepatic artery embolization|
41115214|NCT00553683|RADIATION|3-dimensional conformal radiation therapy|
41115215|NCT06333717|DIETARY_SUPPLEMENT|Whole grain bread|Consumption of high-fibre bread as a dietary supplementation
41115216|NCT06333717|DIETARY_SUPPLEMENT|Control bread|Consumption of control bread as a dietary supplementation
41115217|NCT03110458|DRUG|SENS-111 100mg|SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
41115218|NCT03110458|DRUG|SENS-111 200mg|SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
40947799|NCT03867279|OTHER|Reeducation exercises|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground.
40947800|NCT00176787|DRUG|Capecitabine|
40947801|NCT00176787|PROCEDURE|Radiation|
40947802|NCT00176787|PROCEDURE|Surgery|
41115219|NCT03110458|DRUG|Placebo Oral Tablet|Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
40752607|NCT04474379|BEHAVIORAL|Strategy Training (Time- and Event- Based)|In time-based training, strategic clock-checking behavior is taught by requiring participants to click a button to reveal the virtual time of day. Event-based training involves implementation intention methods.
40752608|NCT03090035|DRUG|Pegylated Interferon α2|Peg-INF was given in a dose of 180 μg/week
40752609|NCT03090035|DRUG|Ribavirin|ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3
40752610|NCT05565404|BEHAVIORAL|mobile health|Scaling and root planing, interdental brushing demonstration and regular text messages in type 2 embrasure patients.
40947803|NCT03860610|DIAGNOSTIC_TEST|Muscle strength test|Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
40947804|NCT03860610|DIAGNOSTIC_TEST|Dynamic stability test during level and uphill walking|Instrumented gait analysis on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz) and on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany)
41115220|NCT05758597|DRUG|Remazolam besylate|Remazolam benzoate group was given 0.1-1mg/kg/h, and the target RASS score was maintained.
41115221|NCT05758597|DRUG|midazolam|Meanwhile the midazolam group was given 0.05-0.2 mg/kg/h midazolam, and the target RASS score was maintained.
41115222|NCT05870241|OTHER|Ga-As Laser|Patient sits on a chair with back support and the two GA-AS laser ( 5 milli Watts \& 904 nm) probe will be applied one on the shoulder tip for 5 minutes and the other application another 5 minutes will be on the center of deltoid muscle. The main power of the laser switch will be turned on. The duration of the treatment will be 10 minutes.
41115223|NCT05870241|OTHER|Microcurrent Electrical Stimulation|The patient sits on a chair with back support and the two electrodes from Microcurrent 850 unit device will be applied one on the shoulder tip and the other electrode on the center of the deltoid muscle. A wet cloth was placed between the electrode and the patient's skin. An adhesive tape was used to hold the electrode over the treated areas. The main power switch will be turned on. The treatment duration will be for 10 minutes.
41115224|NCT05870241|OTHER|traditional therapy|the patients will receive traditional physical therapy in the form of manual lymphatic drainage , compression bandage, exercise to increase lymphatic drainage, skin care. and ROM exercises to improve shoulder mobility
41115225|NCT05850091|DRUG|Rosuvastatin|Pharmacotherapy for reduction in LDL cholesterol level
41115226|NCT05850091|DRUG|Colchicine|Pharmacotherapy for inflammation inhibition
41115227|NCT05850091|DRUG|Placebo|Capsule with sugar pill that mimics active study drugs
41115228|NCT00643071|DRUG|Tacrolimus|Oral
41446158|NCT06072339|BIOLOGICAL|Arterial blood gas|Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.
40947805|NCT03860610|DIAGNOSTIC_TEST|Postural stability test|The overall stability index (OSI) will be assessed using the Biodex Balance System SD (Biodex Medical Systems, Inc., Shirley, NY, USA) and is determined by the variance in platform displacement from the horizontal plane.
40947806|NCT03860610|DIAGNOSTIC_TEST|EuroQol Group Health questionnaire (EQ-5D-5L)|Overall health will be assessed using the EQ-5D-5L health questionnaire
40947807|NCT03860610|DIAGNOSTIC_TEST|HOOS/ KOOS|Site specific pain and function will be assessed with the Hip Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) depending on the affected joint (hip or knee).
41446159|NCT06072339|OTHER|Interview on pain and comfort|The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).
41446160|NCT03881943|DRUG|Ticagrelor 60 mg|Potent antiplatelet agent, 60mg twice daily for 3 months
41446161|NCT03881943|DRUG|Aspirin 100 MG Oral Tablet, Enteric Coated|antiplatelet agent, 100mg once daily for 3 months
41115229|NCT05849311|DRUG|Envafolimab with new manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
41115230|NCT05849311|DRUG|Envafolimab with old manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
41115231|NCT02541916|OTHER|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy \& LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
41115232|NCT02570711|DRUG|ACP-196|ACP-196 capsule
41115233|NCT02570711|DRUG|Nab-paclitaxel|Nab-paclitaxel infusion
41115234|NCT02570711|DRUG|Gemcitabine|Gemcitabine infusion
41115235|NCT03284086|DIAGNOSTIC_TEST|upper-body double-poling|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
41115236|NCT03284086|DIAGNOSTIC_TEST|arm crank ergometry|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
41115237|NCT06007352|DRUG|Gentamicin|Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy
41115238|NCT06007352|OTHER|Placebo|3 L of NaCl irrigation typically used for ureteroscopy surgery
41115239|NCT01537003|DEVICE|Promogran|Promogran is a collagen/ORC dressing which modulates the wound environment
41115240|NCT01537003|DEVICE|Coban 2 layer|Compression bandage
41115241|NCT01363492|BIOLOGICAL|Replagal (agalsidase alfa)|0.2 mg/kg administered over 40 minutes every other week (EOW)
41115242|NCT06325111|OTHER|Determinants of T1D glycaemic control|DNA genotyping, microbiome, DNA methylation and microRNAs analysis
41115243|NCT00236340|DEVICE|syringe aspiration|
41115244|NCT00236340|DEVICE|Wall suction|
41115245|NCT00566527|BIOLOGICAL|ProQuad® manufactured with recombinant Human Albumin (rHA)|A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
41115246|NCT02789917|OTHER|Dual Therapy|Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
41115247|NCT02789917|OTHER|Triple Therapy|"HAS-BLED-Score \<3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months."
41115248|NCT04001517|DRUG|Neflamapimod|Double-Blind, Placebo-Controlled
41115249|NCT03567798|DIETARY_SUPPLEMENT|UPLAT|Carica papaya leaf Extract + Tinospora cardifolia Extract
40752611|NCT05565404|PROCEDURE|Scaling and root planing+Interdental aid|Scaling and root planing, interdental brushing demonstration in type 2 embrasure patients.
41115250|NCT03567798|OTHER|Placebo|Placebo
41115251|NCT01784653|BEHAVIORAL|iMET|Self-completed, computerized motivational enhancement therapy
41115252|NCT01784653|BEHAVIORAL|MET|Clinician-delivered Motivational Enhancement Therapy
41115253|NCT01296334|DRUG|morphine LO|intravenous infusion, 10 mg, once, 4 hours
41115254|NCT01296334|DRUG|Morphine Hi|intravenous infusion, 20 mg, once, 4 hours
41115255|NCT01296334|DRUG|Buprenorphine LO|intravenous infusion, 0.3 mg, once, 4 hours
41115256|NCT01296334|DRUG|Buprenorphine Hi|intravenous infusion, 0.6 mg, once, 4 hours
41115257|NCT01296334|OTHER|saline|intravenous infusion, 0.9% saline, once, 4 hours
41115258|NCT06386237|OTHER|Dietary intervention: Standardized breakfast with varying amounts of macronutrients (in particular carbohydrate/protein ratios)|Participants receive a standardized meal with one type of macronutrient composition in one experimental session and the other type in a different experimental session a few days apart (within-subjects crossover design; i.e. order counterbalanced)
41115259|NCT01897298|BEHAVIORAL|Urban training|Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
41115260|NCT02754999|DRUG|SANGUINATE™|As needed (PRN) infusions of 500 mL of SANGUINATE
41115261|NCT03419442|DRUG|Xofigo|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection
41115262|NCT03419442|DRUG|Taxotere|Docetaxel injection 75mg/m2 every 3 weeks
41115263|NCT03419442|DRUG|Jevtana|Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks
41115264|NCT00790790|DRUG|Placebo|LY545694 placebo BID po for 5 weeks
41115265|NCT00790790|DRUG|LY545694 49 mg|LY545694 49 mg BID po for 5 weeks.
41115266|NCT00790790|DRUG|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks.
41446162|NCT05643638|BIOLOGICAL|CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)|Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.
41446163|NCT05643638|BIOLOGICAL|Placebo|The placebo product is identical to CYP-001, except that it contains no active agent
41446164|NCT05643638|DRUG|Corticosteroids|All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
41115267|NCT03978468|OTHER|Interagency Collaboration (ICollab)|The intervention has the following components: 1) ICollab Component 1: The Nurse Clinician will review clinic and emergency room (ER) visit notes for clinicians' recommendations and communicate these to the home health nurse (HHN). 2) ICollab Component 2a: The intervention team will meet weekly by phone with HHNs (6 times/ child). The Nurse Clinician will document meeting notes for each child in the ER, communicate this information with the HHN, and share it with the primary care provider (PCP) by routing the note through the ER or faxing the note. 3) ICollab Component 2b: The Nurse Clinician will be available as a resource for the HHN during regular work hours for clinical problem-solving. 4) ICollab Component 2c: the intervention team physician will offer her contact information for clinical problem-solving about the child to the PCP. The Nurse Clinician will communicate with the PCP about the plan developed in the meetings, and changes to plan of care.
41115268|NCT03978468|OTHER|Usual Care|The primary medical team identifies the need for home health nursing services for Children with Medical Complexity(CMC), and the hospital care coordinators help caregivers choose a home health agency. Hospital-based physicians write home health orders that are communicated to the home health agency. The clinic manager of the home health agency uses these orders to develop the home health plan of care, Centers for Medicare \& Medicaid Services(Form CMS-485) and communicates the plan to the agencies' HHNs. PCPs oversee the home health plan of care.
41115269|NCT04320186|BEHAVIORAL|Entertainment education|
41115270|NCT04320186|OTHER|video|video
41115271|NCT04925765|OTHER|Virtual Reality Biofeedback Session|"The Flowly intervention treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain/anxiety/depression."
41115272|NCT00786006|DRUG|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
41115273|NCT00786006|DRUG|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
41115274|NCT01843569|BIOLOGICAL|In Vitro maturation|
41115275|NCT01983371|DRUG|Ferumoxytol|All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
41115276|NCT01983371|OTHER|Magnetic Resonance Imaging|All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
41446165|NCT03368443|BEHAVIORAL|treadmill training and overground gait training|The participants will be randomized into two different groups, and they will receive treadmill and overground gait training in one or two rooms.
41446166|NCT05285865|OTHER|Conventional Treatment|Thrice a day for complete length of stay. This is Conventional treatment The total duration of session will be of 15-20 mins.
41446167|NCT05285865|OTHER|Scapular Mobilization|Thrice a day for complete length of stay including two sets of repetitions with a rest interval of 30 seconds between sets. Grade 1-3 As reported in a study Scapular mobilization (SM) i.e., Scapular superior, inferior glides, upward and downward rotations and scapular distraction, along with Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
41446168|NCT01437761|DEVICE|2008 Sorbent System|2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
41446169|NCT06547164|DRUG|Midazolam|Midazolam will be administered orally.
41446170|NCT06547164|DRUG|Camizestrant|Camizestrant will be administered orally.
41446171|NCT06547164|DRUG|Carbamazepine|Carbamazepine will be administered orally.
41446172|NCT04614155|OTHER|Educational Intervention|Take part in health education session
41446173|NCT04614155|PROCEDURE|HPV Self-Collection|Receive HPV self-collection kit
41446174|NCT04614155|OTHER|Questionnaire Administration|Complete questionnaires
41446175|NCT03525639|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
41446176|NCT06239350|BEHAVIORAL|Counseling|Research staff will provide skills-based counseling at remote weekly visits, starting at Day 0. Counseling sessions will be brief (\~5-10 minutes) and will focus on strategies for preparing for the quit attempt, dealing with triggers, refusal skills, and enhancing motivation.
40752612|NCT02159404|BIOLOGICAL|Immunotherapy|
40752613|NCT03540940|OTHER|PEEP|7cmH2O positive end expiratory pressure
41115277|NCT01839578|DRUG|Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~* 4% trisodium citrate solution~* Calcium chloride solution (100 mmol/L)~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~* Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~* Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~* Blood flow adapted to the acid-base status"
41115278|NCT01839578|DRUG|Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~* Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~* Standard dialysate for CRRT : Prismasol® K2 solution~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of"
41115279|NCT01126918|BEHAVIORAL|Body Project|Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
41115280|NCT00642980|DRUG|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
41115281|NCT00642980|DRUG|Placebo|Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
41115282|NCT00642980|DRUG|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
41115283|NCT01061151|DRUG|Zidovudine (ZDV)|300 mg twice daily
41115284|NCT01061151|DRUG|Nevirapine (NVP): Antepartum Mothers|200 mg at onset of labor
41115285|NCT01061151|DRUG|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail|200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
41115286|NCT01061151|DRUG|Lamivudine-Zidovudine (3TC-ZDV)|150 mg/300 mg twice daily
41115287|NCT01061151|DRUG|Lopinavir-ritonavir (LPV-RTV)|400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
41115288|NCT01061151|DRUG|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|200 mg/300 mg
41115289|NCT01061151|DRUG|Nevirapine (NVP): Infant short-course|Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
41115290|NCT01061151|DRUG|Nevirapine (NVP): Infant extended|Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
41115291|NCT01061151|OTHER|No Intervention|"Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada \[TRV\]) tail."
41115292|NCT01061151|OTHER|Discontinue triple ARVs|ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
41115293|NCT01061151|OTHER|Continue triple ARVs|Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
41446177|NCT06239350|BEHAVIORAL|Contingency management|Contingency management (CM): CM will be provided to all study participants to promote abstinence from all nicotine products. Incentives for abstinence (based on submission of a negative cotinine sample) will be provided on an escalating schedule during treatment (Days 8-84).
41115294|NCT00386516|DRUG|GM-CT-01|GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
41115295|NCT00386516|DRUG|5-Fluorouracil|5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
41115296|NCT05936411|DEVICE|Siemens Quadra PET/CT and [18F]FDG|The Siemens Quadra PET/CT, a clinically approved imaging device, is utilized in conjunction with the radiopharmaceutical tracer \[18F\]FDG in this study. The device allows for the acquisition of emission data across an extended axial field of view (axFOV) of 106 cm, covering an imaging range from the head to the thighs. The device's capabilities are leveraged to perform quantitative functional examinations of an extended axFOV. Subjects are scanned twice within a month for reproducibility standards. Each time, they are injected with 100MBq \[18F\]FDG and examined for 60 minutes in a dynamic scan. The tracer is used to build an atlas of normative glycolytic activities for most organs, excluding the brain. The glycolytic activities are measured as organ-based standardized uptake values. An ultra-low-dose CT scan is acquired to estimate mandatory attenuation correction factors.
41446178|NCT06239350|BEHAVIORAL|Text-based support|All participants will be provided with evidence-based nicotine cessation resources. For those who are vaping nicotine, participants will be provided information for This is Quitting (SMS text-based program). For those who are primarily smoking cigarettes, NCI's QuitSTART (mobile app, web content), as well SmokefreeTXT (SMS-text based program), will be recommended, potentially in addition to This is Quitting for those using multiple products. These resources provide real time monitoring of nicotine use, mood, triggers and lapses.
41446179|NCT03272685|DRUG|Very Low Nicotine Content Cigarettes|0.4 mg nicotine/g tobacco; 9 mg tar
40752614|NCT03540940|OTHER|ZEEP|0 cmH2O positive end expiratory pressure
41115297|NCT05936411|DEVICE|Apple i-Watch|The Apple i-Watch, a wearable smart device, is used to continuously monitor physiological signals from the subjects. These signals include heart rate, steps and distance, calories burned, sleep tracking, blood oxygen saturation (SpO2), electrocardiogram (ECG), and workout tracking. Subjects are required to wear the Apple i-Watch for three months prior to the first PET scan and up to three months after the second PET scan. The data collected from the Apple i-Watch is paired with the FDG-PET image readouts to identify relationships between lifestyle and glucose uptakes during the scan.
41115298|NCT03946046|PROCEDURE|Clinical targeting|The intervention consists of the injection of botulinum toxin A into muscles targeted by a clinical localization method (observation and palpation of target muscles)
41115299|NCT03946046|PROCEDURE|Ultrasonography targeting|The intervention consists of the injection of botulinum toxin A into muscles by ultrason-guided method
41115300|NCT01653834|PROCEDURE|Lymphocyte harvesting & reinfusion|Lymphocytes will be collected and stored approximately one week prior to initiating concurrent radiation therapy (RT) and temozolomide (TMZ). Two lymphocyte collections are allowed. After the patient has completed 6 weeks of RT/TMZ, all of the collected lymphocytes will be re-infused. After lymphocyte re-infusion, Heme-8 and absolute lymphocyte count (ALC) will be checked per standard of care. The absolute increase in ALC as the primary endpoint will be assessed 4 weeks after lymphocyte re-infusion.
41115301|NCT02740595|OTHER|one time exposure to e-cig with nicotine|one time exposure to e-cig vapor with nicotine
41115302|NCT02740595|OTHER|one time exposure to e-cig without nicotine|one time exposure to e-cig without nicotine
41115303|NCT02740595|OTHER|one time exposure to empty e-cig|one time exposure to empty e-cig (sham control
41115304|NCT03692013|DRUG|Losartan|Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
41115305|NCT02887625|DRUG|Pioglitazone plus exenatide|pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
41115306|NCT02887625|DRUG|insulin glargine and insulin aspart|the dose will be escalated to maintain HbA1c \<7.0%
41115307|NCT00030238|DRUG|Calcium supplement|Calcium Carbonate capsules prepared by NIH PDS
41115308|NCT00030238|DRUG|Placebo|Placebo capsules prepared by the NIH PDS to be identical to Calcium Carbonate capsules
41115309|NCT03024606|BEHAVIORAL|text messages focused on smoking cessation and pregnancy|The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
41115310|NCT02976116|DRUG|Fruquintinib|Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
41115311|NCT02976116|DRUG|Gefitinib|Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
41115312|NCT02345018|PROCEDURE|Mechano-chemical ablation|Treatment with mechano-chemical ablation
41115313|NCT04763044|DRUG|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
41115314|NCT04763044|DRUG|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
41115315|NCT04763044|DRUG|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
41115316|NCT04763044|DRUG|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
41115317|NCT04763044|DRUG|1100 ppm SnF2|Each subject will be assigned to this treatment during the fifth period for this crossover study.
41115318|NCT00477776|DRUG|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
41115319|NCT00477776|DRUG|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
41115320|NCT04559659|OTHER|Respiratory muscle strength|Pimax and Pmax will be performed according to the (ATS) and (ERS). A Manovacuometer (Analog M 120, GlobalMed) with a range between 0-120cmH2O will be used. The elderly should undergo forced inspiration after maximal expiration and forced expiration after maximal inspiration through a mouthpiece with a hole to prevent closure of the glottis to evaluate Pimax and Pmax. The elderly should sustain the inspiration for 1 second. Three measurements will be performed, with a one-minute interval between them, with less difference equal to 10% between them, the higher value will be used.
41115321|NCT06238869|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|CCBT (Computerized Cognitive Behavioral Therapy) is a unique approach to improving mental well-being. It utilizes computer-based cognitive and behavioral techniques to induce relaxation and regulate emotional responses by targeting specific brain regions. CCBT offers interactive and personalized interventions, empowering individuals to address mental health challenges like depression and anxiety. Its convenience and accessibility through digital platforms make it a practical choice for enhancing emotional well-being.
41115322|NCT06238869|BEHAVIORAL|Music Therapy|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
41115323|NCT06238869|BEHAVIORAL|Health education|Health education focuses on providing insights into adolescent mental health, offering practical coping strategies and behavior patterns. It emphasizes the crucial link between parental guidance and the well-being of adolescents. By fostering healthier psychological interactions, it cultivates an environment supportive of adolescent mental health, strengthens family support, and promotes comprehensive development in physical, mental, and cognitive aspects.
41115324|NCT00381173|DRUG|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m\^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
41115325|NCT04795544|PROCEDURE|Intracuff pressure measurement|Intracuff pressure is measured by a pressure manometer.
41446180|NCT03272685|DRUG|Normal Nicotine Content Cigarettes|15.8 mg nicotine/g tobacco; 9 mg tar
40752615|NCT04483232|BIOLOGICAL|Ear canal swab|Ear canal swab
41115326|NCT03210129|BEHAVIORAL|Motivational interviewing|"the patients of the motivational interviewing group will receive 12 motivational interviewing sessions within 12 weeks: 2 face-to-face sessions and 10 phone call sessions. The first and the seventh motivational interviewing sessions will be face-to-face sessions. An intervention is considered valid if a minimum of 10 sessions has been completed. The face-to-face motivational interviewing sessions will be administered at the Luxembourg Institute of Health (Strassen, Luxembourg). They generally last up to 30 minutes, while the motivational interviewing phone calls generally last up to 15 minutes. Thereby, patients in the motivational interviewing group will receive a total of approximately 3.5 hours of contact time over a period of 12 weeks.~Motivational interviewing techniques will explore self-assessed confidence, ambivalence, and personal values concerning changes in active lifestyle."
41446181|NCT06275321|OTHER|Synchronous-supervised online home-based group|An online exercise program combining endurance and strength training
41446182|NCT06275321|OTHER|Exercise recommendation group|General recommendation about physical exercise. No supervised
40752616|NCT01158404|DRUG|LY900009 - Dose Escalation Phase (Part A)|"2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
40752617|NCT01158404|DRUG|LY900009 - Dose Confirmation Phase (Part B)|"30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
41446183|NCT06559605|PROCEDURE|zirconia barrier|barrier membrane used for guided bone regeneration and augmentation of ridge defect
41115327|NCT04880434|DRUG|Fludarabine|Administered intravenously
41115328|NCT04880434|DRUG|Cyclophosphamide|Administered intravenously
41115329|NCT04880434|BIOLOGICAL|Brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
41115330|NCT04756245|BEHAVIORAL|Virtual Reality|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within virtual reality software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both virtual reality and real-world physical activities.
41115331|NCT04756245|BEHAVIORAL|Video Conference|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within video conference software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both streaming video and real-world physical activities.
40752618|NCT03150797|DRUG|Melatonin|Melatonin
41115332|NCT03883542|GENETIC|genomic mutations study|"Sequencing of the DNA samples extracted from the subgroups~1. serous BOT tissue,~2. serous BOT tissue with non-invasive implants and~3. serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)"
41115333|NCT00712335|DRUG|Fluticasone Propionate|DPI 250 mcg BID for 3 weeks
41115334|NCT00712335|DRUG|Montelukast|PO 10 mg QHS for 3 weeks
41115335|NCT00712335|DRUG|Salmeterol|DPI 50mg BID for 3 weeks
41115336|NCT05389436|PROCEDURE|Ambulatory care|The surgery is performed in ambulatory setting
41115337|NCT05389436|PROCEDURE|Inpatient care|The surgery is performed during inpatient care
41115338|NCT02695381|DRUG|Etodolac-lidocaine topical patch|Once daily
40752619|NCT03150797|DRUG|Placebo oral capsule|Placebo
40752620|NCT05753969|DEVICE|MT1 Device|Pre-and post-evaluation in MT1 device following stimulant treatment or placebo control
40752621|NCT02027493|DRUG|Reiferon R|subcutaneous injection of 100 μg/m2
40752622|NCT02027493|DRUG|Ribavirin|15 mg/kg daily on two divided doses
40752623|NCT02528305|OTHER|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5\&6, 8 sprints in sessions 7\&8, 9 sprints in sessions 9\&10 and 10 sprints in sessions 11\&12.
41115339|NCT02695381|DRUG|Placebo|Once daily
41115340|NCT04631744|DRUG|Cabozantinib|Subjects will receive cabozantinib orally at a (starting) dose of 40 mg once daily
41115341|NCT04970979|OTHER|survey|questionnaire about the influencing factors of home-based cardiac rehabilitation
41115342|NCT03127995|RADIATION|HYPOFRACTIONATED|40 Gy/ 15 fractions / 3 weeks
41115343|NCT03127995|RADIATION|NORMOFRACTIONATED|50 Gy/ 25 fractions / 5 weeks
41115344|NCT02710708|DRUG|EE20/DRSP (YAZ, BAY86-5300)|YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
40752624|NCT02358395|DRUG|BBI608|Administered continuously twice daily with doses separated by 9-15 hours.
40752625|NCT02358395|DRUG|Sorafenib|Sorafenib 400 mg twice daily (800 mg total daily dose).
40752626|NCT06106373|DEVICE|iotaSOFT Insertion System|robotic assistive technology for cochlear implant electrode insertion
41115345|NCT04780035|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart."
41115346|NCT04780035|OTHER|Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)|The use of placebo: intramuscularly twice, given 21 to 28 days apart at a dose of 0.5 ml
41115347|NCT01331863|PROCEDURE|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
41115348|NCT03328715|DEVICE|intraoperative OCT|before and after surgery intraoperative OCT is performed
41115349|NCT03328715|DEVICE|stand-alone OCT|before and after surgery stand-alone OCT is performed
41115350|NCT03093298|OTHER|Enteroscopy with biopsy sampling and mixed meal test|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
41115351|NCT05173714|BEHAVIORAL|SLIMM|Increase in light walking activity, replacing 1 hour/day of sedentary duration with casual walking duration. Increase in sedentary breaks, from sitting/lying position to standing position, at least once every hour as independent of the total time spent on sedentary activities.
41115352|NCT05173714|BEHAVIORAL|Standard Resistance Training|Participants will be provided a standard resistance training regimen to follow during the course of the study. Participants will not receive individualized instruction, guidance or modification to the resistance training regimen.
41115353|NCT05173714|BEHAVIORAL|Guided Resistance Training|Supervised resistance training sessions are individualized for a low-resistance, high-repetition regimen of lower body major muscle groups with established guidelines. Instructions and resistance training bands will be provided for home use. Study participants will record compliance to the resistance training regimen for further guidance and potential modification.
41115354|NCT05173714|DRUG|Placebo|Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.
41115355|NCT05173714|DRUG|Semaglutide|Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.
41115356|NCT01215344|DRUG|VELCADE|1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle
41115357|NCT01215344|DRUG|Lenalidomide|25 mg by mouth on days 1-4 of each cycle
41115358|NCT01215344|DRUG|Dexamethasone|20 mg the day before and the day after receiving VELCADE
41115359|NCT01215344|DRUG|DVT prophylaxis|At least one asprin 81 mg per day. Other option per physician's choice
41115360|NCT01215344|DRUG|Bisphosphonates|Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
41115361|NCT01215344|DRUG|Liposomal doxorubicin|30 mg/m2 on day 4 of each cycle
41115362|NCT01215344|DRUG|Dexamethasone|40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
41115363|NCT03384069|BEHAVIORAL|Group-based Cognitive Behavioral Therapy (CBT)|The group-based CBT intervention will include twelve 1-hour group sessions held biweekly for six months. Each sixty-minute session will consist of 15 minutes of Alzheimer's disease (AD) prevention education and approximately 45 minutes of CBT presentations/engagement activities. A physician and a Behavioral Interventionist will collaboratively facilitate the group sessions.
41115364|NCT03384069|BEHAVIORAL|Phone-based Cognitive Behavioral Therapy (CBT)|Participants in the phone-based CBT will be asked to reserve a 1-hour period for a phone call from the Behavioral Interventionist biweekly for six months. Text reminders will be sent to the participant's prior the sessions. This intervention will follow the same frequency and format as the group-based CBT and will use an established protocol incorporating the same elements of cognitive behavior change as in the group-based CBT, but without the opportunity for group-interaction.
41115365|NCT06499246|PROCEDURE|Donor Parathyroid|Once a potential donor becomes available, the transplant team will assess if the donor is a match for our study participant using standardized transplantation protocols that include serology blood tests completed in the pre-operative setting. If the donor is a match, the procurement team will procure all parathyroid tissue using standard surgical techniques. The specimen will be kept in organ preservation solution for transport and transported to the operating room. The recipient (study participant) will be admitted to the hospital under and taken to the operating room for the surgical procedure. Once the procurement team arrives with the parathyroid tissue the procedure will be performed under local anesthesia using a well-established technique, for parathyroid auto transplant, of implanting parathyroid tissue in the non-dominant brachioradialis muscle. Immunosuppression medication protocols will be initiated.
41115366|NCT03187860|PROCEDURE|Bronchial Biopsy|Bronchial biopsies will be performed on all subjects.
41115367|NCT03187860|OTHER|ALI culture|Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
41115368|NCT01701453|DRUG|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
41115369|NCT03035123|BEHAVIORAL|Therapeutic education|Interventional arm
41115370|NCT04484415|COMBINATION_PRODUCT|Cevira®|The device is a single-use, disposable, LED-based red light source. The device will automatically switch on the light 5 hours after administration, and provide continuous photoactivation of 125 J/cm2 over 4.6 hours before automatically shutting down.
41115371|NCT04484415|COMBINATION_PRODUCT|Placebo|The placebo device is identical in appearance as the Cevira® device, but does not provide light.
41115372|NCT04773327|OTHER|Mecapegfilgrastim Injection|24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle
41115373|NCT02510534|DRUG|Menopur 150 international units|Menopur 150 international units given x 1 dose
41115374|NCT02510534|DRUG|Endometrin 100 mg|Endometrin 100mg twice daily x 14 days
41115375|NCT00006224|DRUG|gemcitabine hydrochloride|
41115376|NCT05865938|DEVICE|PASCAL vs. MitraClip|"transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device."
41115377|NCT02146716|OTHER|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
41446184|NCT06559605|PROCEDURE|titanium mesh|barrier membrane used for guided bone regeneration
41446185|NCT02394860|OTHER|echo Doppler lower limbs|
40752627|NCT03849456|DRUG|GWP42006|Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
41446186|NCT06449703|DRUG|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.
41115378|NCT05284435|BEHAVIORAL|Cognitive Behavioral Therapy-Email (iCBT-E)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails, therapists will serve to provide encouragement and support as the parent works through the program independently."
41115379|NCT05284435|BEHAVIORAL|Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails and six videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently. Therapists will also assist the parent with any problem-solving as needed."
41115380|NCT01066923|DRUG|Daily aspirin (ASA)|Two weeks 82 mg aspirin taken orally prior to exercise protocol
41115381|NCT01066923|OTHER|Active cooling|Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
41115382|NCT01066923|DRUG|Acute aspirin (ASA)|325 mg chewable aspirin administered immediately following exercise
41115383|NCT01066923|OTHER|Passive cooling|Removing protective garments for passive cooling following exercise
41115384|NCT01066923|DRUG|Daily placebo|Placebo comparator for daily aspirin therapy
41115385|NCT01066923|DRUG|Acute placebo|Placebo comparator for acute aspirin therapy
41115386|NCT03282786|OTHER|carbon dioxide insufflation during colonoscopy|Use of Carbon dioxide instead of air insufflation
41115387|NCT03264846|DIAGNOSTIC_TEST|Collection of Serum and Saliva Samples|Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
41115388|NCT04930718|OTHER|Thumb active Exercises|Active específico exercises; Reeducation program
41115389|NCT00596609|DRUG|Intrathecal Morphine|"* In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~* In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection."
41115390|NCT02152813|BEHAVIORAL|TENS and Task-orientated training|All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
41115391|NCT05384496|DRUG|Nivolumab and/or Ipilimumab|Combination of nivolumab 3mg/kg IV every 3 weeks with ipilimumab 1mg/kg or nivolumab 480mg IV every 4 weeks as monotherapy is considered standard of care for patients with unresectable locally advanced or metastatic mucosal melanoma.
41115392|NCT05384496|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT upon local or oligometastatic progression. The prescribed dose of SBRT will be 30 Gy in 5 fractions.
40752628|NCT04469283|OTHER|caffeine and movement disorders|Caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
41115393|NCT05384496|DRUG|axitinib|5mg twice daily
41115394|NCT05588453|BIOLOGICAL|Natural Killer Cell Therapy|Given UD TGFbi NK cell IV
41115395|NCT05588453|DRUG|Temozolomide|Given PO
41115396|NCT04434586|DEVICE|femoropopliteal revascularization for TASC C or TASC D lesion|Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control
41115397|NCT00099086|DRUG|Bicalutamide|Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
41115398|NCT00099086|DRUG|docetaxel|Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
41115399|NCT00099086|DRUG|GnRh analog|"A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)"
40752629|NCT06075290|BEHAVIORAL|internet plus model|Intelligent transcutaneous bilirubin meter and Internet plus model for neonatal jaundice monitoring at home and remote follow-up
41115400|NCT00099086|RADIATION|radiotherapy|External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
41115401|NCT00010309|BIOLOGICAL|MART-1 antigen|
41115402|NCT00010309|BIOLOGICAL|gp100 antigen|
41115403|NCT02403596|DRUG|Exacyl®|
41115404|NCT02403596|OTHER|Placebo of Exacyl®|
41115405|NCT01972763|DRUG|Ranibizumab|Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.
41115406|NCT04957225|BEHAVIORAL|MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)|Multimodal intensive treatment of aphasia and AOS
41115407|NCT03555214|OTHER|Manual Therapy based on soft tissues|"Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique."
41115408|NCT03555214|OTHER|Control group|"Placebo treatment:~The patient remains supine and the therapist sits on a stool at the bedside with the forearms resting on the couch. Both hands are placed on the posterolateral part of the patient's head and the position is maintained for 10 minutes without exerting any force or movement."
41446187|NCT06449703|DRUG|Xultophy®|Xultophy®
41115409|NCT03555214|OTHER|Manual Therapy based on structural techniques|"Manual Therapy:~1. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~2. Articulation technique of the high cervical spine (C0-C1).~3. Postero-anterior articular technique of C2-C7 in supine position.~4. Postero-anterior articular technique of C2-C7 in prone position.~5. Manipulative technique of the flapper C7-T1.~6. Dorsal spinal manipulative technique (T1-T8).~7. Lumbosacral global manipulative technique."
41115410|NCT03555214|OTHER|Manual Therapy based on soft tissues and structural techniques|"Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique.~6. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~7. Articulation technique of the high cervical spine (C0-C1).~8. Postero-anterior articular technique of C2-C7 in supine position.~9. Postero-anterior articular technique of C2-C7 in prone position.~10. Manipulative technique of the flapper C7-T1.~11. Dorsal spinal manipulative technique (T1-T8).~12. Lumbosacral global manipulative technique."
41115411|NCT03696771|DRUG|NJH395|Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
41115412|NCT02059980|BEHAVIORAL|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
41115413|NCT02059980|BEHAVIORAL|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
41446188|NCT04018404|OTHER|FRI CLINICAL PROGRAM|University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
41446189|NCT02323256|OTHER|Auditory steady-state response ASSR|comparison of ASSR amplitudes in response to amplitude-modulated sounds delivered at different intensities
41446190|NCT02323256|OTHER|Speech-ABR|
41446191|NCT02323256|OTHER|Acoustic Change Complex ACC|comparison of ACC complex in response to changes within speech stimulation
41115414|NCT01962844|DIETARY_SUPPLEMENT|Coconut Oil|Patients were followed for 6 months with dietary treatment. Beginning supplementation with coconut oil extra virgin from the third month of intervention nutrition. Coconut oil was consumed neat or added to fruit.
41115415|NCT01962844|BEHAVIORAL|Diet|Patients were instructed to follow the dietary treatment for 6 months
41115416|NCT01501188|OTHER|Kinesio Taping|The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
41115417|NCT01501188|OTHER|Placebo kinesio taping|Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
41115418|NCT05164341|DRUG|metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
41115419|NCT05164341|DRUG|Placebo|Placebo
41115420|NCT00011531|PROCEDURE|Prevention of Pressure Ulcers|
41115421|NCT01580319|OTHER|physical exercise|150 minutes per week
41115422|NCT05036746|OTHER|No intervention|No intervention
41115423|NCT05447975|OTHER|Tai Chi training|"As for Tai Chi training, standardized Tai Chi was taught by professional Tai Chi coaches from Sino Taiji of Fuxing International in classes: Qishi (Starting Posture), Shangsanbu (Twist Step), Yema Fenzong(Part the Wild Horse's Mane on Both Side), Jingang Daozhui (Buddha's warrior attendant pounds mortar), Shoushi (Closing Posture). Patients participated in this class were trained, twice a week, 60 min per time. PD patients whose attendance rate less than 75% were excluded."
41115424|NCT05573191|DRUG|Lidocaine|The experimental group was injected with lidocaine 1.5mg/kg, and propofol was pumped intravenously at 90s after lidocaine injection.The dose of propofol was further set according to groups. The heart rate, mean arterial pressure, pulse oxygen saturation and NTI values of subjects were recorded in tne basic state,during the 90s after lidocaine administration, 60s after propofol administration and consciousness loss.The control group simply replaced lidocaine with equal volume normal saline
41115425|NCT05573191|DRUG|Normal saline|Normal saline
41115426|NCT02519517|PROCEDURE|Permissive hypercapnia|During one lung ventilation, right ventricular function was assessed by transesophageal echocardiography (TEE) and the effect of increased carbon dioxide pressure was evaluated
41446192|NCT02323256|OTHER|P1-N1-P2 complex and Mismatch Negativity MMN|comparison of amplitudes and latencies of P1-N1-P2 complex and MMN generated in response to the detection of changes in a series of auditory stimulation
40752630|NCT06075290|BEHAVIORAL|control|follow-up by conventional methods; hospital or community follow-up depending on arrangement
41446193|NCT05921981|BEHAVIORAL|Multisensorial Stimulation|Multisensory stimulation in newborns involves the deliberate and simultaneous activation of multiple sensory modalities to provide sensory experiences that promote development and enhance learning. Newborns are naturally inclined to explore and make sense of their environment through their senses, including touch, sight, sound, taste, and smell.
41446194|NCT05921981|BEHAVIORAL|White Noise|White Noise
41446195|NCT04809363|OTHER|CDPATH™|Crohn's disease risk prediction tool.
41446196|NCT04809363|OTHER|Blood Draw|Three blood samples will be drawn.
41446197|NCT06589986|DRUG|RO7790121|RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.
41446198|NCT06589986|DRUG|Placebo|Placebo matching IV RO7790121. Placebo matching SC RO7790121.
41115429|NCT05253664|BEHAVIORAL|Woman-Centered Care Group|Each woman in the experimental group was given woman-centered care as from 2 hours postpartum and this process continued until 24 hours postpartum. Physiological parameters (systolic-diastolic blood pressure, pulse, body temperature) of women assigned either to the experimental group or the control group were measured at 2 hrs postpartum. The State, Trait Anxiety, and Postpartum Comfort Scales were pretested. A dynamic interaction was ensured between the researcher and the women in the experimental group who received woman-centered care. In the processes of determining and meeting the care needs of women in the early postpartum period, both the women and the researcher took equal responsibilities and the common goal of achieving safe results was shared. Clinical guidelines were used while providing woman-centered care.
41115430|NCT01622413|PROCEDURE|joimax TESSYS|Transforaminal Endoscopic Surgery System
41115431|NCT01622413|PROCEDURE|Microdiscectomy|Standard procedure for disc surgery
41115432|NCT05504941|DIAGNOSTIC_TEST|Diagnostic, cerebral Digital Subtraction Angiography (DSA)|The DSA is the goldstandard for the visualization of brain vessels. For performing a diagnostic cerebral DSA, the femoral artery of the patient will be punctured in the groin. Over this arterial access a catheter will be advanced under fluoroscopy guidance to the target vessel in the brain. After navigation to the targeted brain vessel, contrast media will be injected over the catheter into the vessel. The efflux of the contrast media will be monitored and visualized with fluoroscopy. The additional radiation to the patient due to the DSA will be approx. 1.1 mSv. The duration of the DSA will be 15 to 20 minutes.
41115433|NCT03799783|DRUG|dexmedetomidine|To administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
41115434|NCT05981547|DEVICE|Libre 3 continuous glucose monitoring sensor|Libre 3 CGM sensor applied to women prior to their Oral Glucose Tolerance test.
41115435|NCT03293498|BIOLOGICAL|NanoFlu|Vaccine
41115436|NCT03293498|BIOLOGICAL|Fluzone HD - Day 0|Vaccine
41115437|NCT03293498|BIOLOGICAL|Fluzone HD - Day 21|Vaccine
41115438|NCT03293498|OTHER|Saline - Day 21|Placebo
41115439|NCT04141865|DEVICE|Xen|Xen microstent implantation
41115440|NCT04141865|DEVICE|Aqueous shunt|Aqueous shunt implantation
41115441|NCT04128358|DIAGNOSTIC_TEST|Serological assay for blood born viral hepatitis|Qualitative PCR for patients with hepatitis C antibody positive
41115442|NCT04128358|DIAGNOSTIC_TEST|Quantitative microbiological test for HCV|Quantitative PCR in those with proven HCV infection
41115443|NCT04906954|OTHER|NMES|Standardized strength program (75 Hz frequency, 40 cycles). The stimulation intensity will be increased up to the highest tolerated level in order to evoke strong muscle contractions.
41115444|NCT00153569|BIOLOGICAL|Tyrosinase, MAGE-3, GnTV|
41115445|NCT05471635|BIOLOGICAL|COVID-19 Vaccine|All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
41115446|NCT03396848|OTHER|SHAReClinic|Online clinic with educational modules
41115447|NCT03596268|DIAGNOSTIC_TEST|Imaging|3T Prisma MRI
41115448|NCT03596268|DIAGNOSTIC_TEST|Serum Laboratory Tests|Blood (plasma and cellular) will be collected.
41115449|NCT03596268|DIAGNOSTIC_TEST|Lumbar Puncture|CSF will be collected
41115450|NCT05528146|DIETARY_SUPPLEMENT|Psyllium huks|psyllium in 250ml of water
41115451|NCT01028118|OTHER|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
41115452|NCT06383442|OTHER|L-HIIT|the long-interval HIIT group (4 × 4 min Exercise/4 min Rest)
41115453|NCT06383442|OTHER|M-HIIT|the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest)
41115454|NCT01129232|DRUG|GAD-alum|20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
41115455|NCT01129232|OTHER|Placebo|Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
41115456|NCT00364013|DRUG|Panitumumab|Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
41115457|NCT00364013|DRUG|FOLFOX regimen|The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
41115458|NCT01699152|DRUG|TG02 citrate|TG02 citrate capsules
41115459|NCT02962791|PROCEDURE|Cardiac resynchronization therapy implantation|Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure
41115460|NCT02962791|DEVICE|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy with stimulation of 3 ventricular sites
41115461|NCT02962791|DEVICE|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy with stimulation of 2 ventricular sites
41115462|NCT02962791|DEVICE|Echocardiography|Standard Echocardiography will de bone for patient
41115463|NCT05780788|DEVICE|Monitoring Tooth Movement|Monitoring Canine Retraction
41115464|NCT00051272|DRUG|Extended-release Bupropion Hydrochloride|
41115465|NCT01979393|DRUG|Cabozantinib|
41446199|NCT00492076|BIOLOGICAL|Pangramin Plus D. pteronyssinus 100%|"1. Active. Pangramin Plus D. pteronyssinus 100%~2. Placebo. Pangramin Plus placebo"
41115466|NCT01979393|DRUG|Placebo|
41115467|NCT00592241|DEVICE|"Adi Insulin Pump Usability"|no intervention
41115468|NCT02464293|OTHER|Mindfulness-based cognitive therapy|An 8 week course of mindfulness-based cognitive therapy
41115469|NCT01240330|DEVICE|Pneumatic Compression therapy|Subject comparison analysis of femoral venous Peak Flow Velocity at rest and during compression therapy.
41115470|NCT03290248|BIOLOGICAL|B244 suspension|B244 suspension in 30ml/bottle
41115471|NCT03290248|BIOLOGICAL|Vehicle|Vehicle, 30ml/bottle
41115472|NCT05955391|DRUG|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles
41115473|NCT04370418|DRUG|short course chemo-radiation with 5-fluorouracil|neo-adjuvant short course chemo-radiation in locally advanced rectal cancer patients followed by delayed surgery
41115474|NCT02708108|BEHAVIORAL|Dietary Intervention|Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.
41115475|NCT02708108|BEHAVIORAL|Activity and Exercise Intervention|"Beginning at the time of diagnosis, the exercise and activity component uses an activity menu to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy."
41115476|NCT05881317|DEVICE|ArtiAid® Plus Intra-articular Injection|Inject ArtiAid® Plus in the affected joint at weekly interval for 3 weeks
41115477|NCT03751943|DEVICE|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter
41115478|NCT01904071|PROCEDURE|UFNB (Ultrasound guided femoral nerve block)|Ultrasound Guided Femoral Nerve Block
41115479|NCT01904071|PROCEDURE|UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)|
41115480|NCT01904071|DRUG|IVMS (IV Morphine)|Intravenous Morphine
41115481|NCT06155071|OTHER|Plyometric Training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step."
41115482|NCT06155071|OTHER|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats"
41115483|NCT04574349|PROCEDURE|Decompressive craniectomy|Removing part of the skull (bone flap) to lower intracranial pressure
41115484|NCT05184036|DIAGNOSTIC_TEST|Low Vision|"* The application of a questionnaire evaluating the functionality and quality of life and records several of the daily life of Greek LV patients.~* The evaluation of the basic parameters of visual function included in the LIFE4LV platform in order to evaluate the effectiveness of this platform in correlation with the routine ophthalmologic exams.~* The evaluation of existing digital supportive tools for LV and record of the patient's feedback"
41115485|NCT00591500|BEHAVIORAL|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
41115486|NCT00591500|BEHAVIORAL|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
41115487|NCT01294033|OTHER|Fractional inspired oxygen (FiO2) 0.21|
41115488|NCT01294033|OTHER|Fractional inspired oxygen 0.28|Supplemental oxygen
41115489|NCT06199323|BEHAVIORAL|Routine rehabilitation training|"1. Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~2. Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~3. Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~4. Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
41115490|NCT06199323|BEHAVIORAL|Swallowing rehabilitation training|"1. Swallowing-related organ training: including movement training of lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises of vocal cord closure, laryngeal lifting and pharyngeal muscle training. 5-15 minutes/time, 1-2 times/day, 5-7 days/week.~2. Sensory stimulation training: With the self-made popsicle, medical staff slowly and gently stimulated the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface and sublingual area repeatedly. 5-25 minutes/time, 1-3 times/day, 3-7 days/week.~3. Direct training: When the patient's swallowing function improves to a certain extent of which the safety of oral intake can be basically ensured, oral feeding training (direct training) can be attempted gradually.~4. Mendelsohn maneuver: During the Mendelsohn maneuver, the patient consciously prolonged the duration of the muscle contraction in the throat during swallowing.15-30 minutes/time, once per day, 5 days/week."
41115491|NCT06199323|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
41115492|NCT04792905|DEVICE|Cardiologs|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
41115493|NCT00158639|BEHAVIORAL|Home BP;secure messaging;pharmaceutical care;|
41115494|NCT04558424|DIETARY_SUPPLEMENT|zinc gluconate and ascorbic acid|This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
41115495|NCT03250052|DRUG|(fimasartan or linagliptin) x 7days|Part A: fimasartan, Part B: linagliptin
41115496|NCT03250052|DRUG|(fimasartan and linagliptin) x 7days|Part A \& Part B: Co-administration of fimasartan and linagliptin
41115497|NCT05608018|OTHER|Intervention Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with all features turned on.
41115498|NCT05608018|OTHER|Intervention non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with all features turned on.
41115499|NCT05608018|OTHER|Control Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with some features turned off.
41115500|NCT05608018|OTHER|Control non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with some features turned off.
41115501|NCT06312358|BEHAVIORAL|Building Capacity for Infant Achievements in Child Care|All teacher participants will be assigned to the professional development intervention consisting of an interactive workshop and weekly coaching sessions.
41115502|NCT05090930|DEVICE|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated
41115503|NCT05090930|DEVICE|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated
41115504|NCT03185338|BEHAVIORAL|Active commuting to/from school|Active transport to/from school on foot or by bike will be promoted
41115505|NCT03185338|BEHAVIORAL|Active Physical Education lessons|Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
41115506|NCT03185338|BEHAVIORAL|Active school recess|Teachers will design games and activities and will encourage children for being active
41115507|NCT03185338|BEHAVIORAL|Sleep health promotion|This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
41115508|NCT03185338|BEHAVIORAL|School global intervention|A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
41115509|NCT01434862|DRUG|Closed loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
41115510|NCT01434862|DEVICE|Closed loop without pramlintide|This visit will assess how well the closed loop system works without the pramlintide.
41115511|NCT01434862|DRUG|Open loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
41115512|NCT04414904|OTHER|Exposure: Covid-19 infection|Previous history of COVID-19 infection.
41115513|NCT04308330|DRUG|Vorinostat|This is a phase I study of the combination of four drugs: vorinostat, vincristine, irinotecan, and temozolomide. This is called a Phase I study because the goal is to find the highest dose of vorinostat that investigators can give safely when it is used together with the chemotherapy drugs vincristine, irinotecan and temozolomide. Investigators are using vorinostat because it seems to work against cancer in test tubes and animals. It may be most effective when it is given with chemotherapy. The combination of these three agents together has never been given to children. Vincristine, irinotecan, and temozolomide are approved and used for the treatment of other types of cancer in adults and children. Vorinostat is approved and used to treat cancer in adults. The combination of these four drugs together is experimental. Investigators do not know if this combination of medicines will work in people. There is a lot that investigators do not yet know about this combination of medicines.
41115514|NCT00716859|DRUG|Timolol|Timolol 0.5% dosed twice-daily
41115515|NCT00716859|DRUG|latanoprost|Latanoprost 0.005% ophthalmic solution dosed once-daily
41115516|NCT00623792|BEHAVIORAL|Preoperative lifestyle Intervention|"6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery"
41115517|NCT04730713|DEVICE|The morphology and parameters of cranial ultrasound spectrum based on cerebral artery|Subjects who meet the standards will undergo a full-body examination and basic life after entering the ICU Sign evaluation and monitoring, mainly including nervous system specialist physical examination, multi-modal brain function testing, Respiratory system monitoring and management, hemodynamic monitoring, APACHE Ⅱ score, GCS score, and routine general circulation, respiratory management, sedation and analgesia management, temperature management, infiltration Pressure management, lumbar pressure measurement The included subjects were monitored for optic nerve sheath diameter, TCD/TCCD before and after lumbar puncture, and recorded spectrum morphology: normal, high resistance state, ischemic topic, congestion state, spasticity, nail wave/oscillating wave state, S1S2 fusion high point state, and recording at the same time Parameters: systolic flow rate (Vs) Shu Tensile blood flow velocity (Vd), average blood flow velocity (Vm), pulsatility index (PI), impedance Index (RI)
41115518|NCT01326039|DRUG|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
41115519|NCT01326039|DRUG|saline|perineural isotonic saline 20 ml
41115520|NCT03782350|DRUG|Tranexamic Acid Dosage 1|Tranexamic Acid Dosage 1
41115521|NCT03782350|DRUG|Tranexamic Acid Dosage 2|Tranexamic Acid Dosage 2
41115522|NCT06551909|RADIATION|Neoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated Boost|Patients with Glioblastoma will receive neoadjuvant stereotactic radiotherapy to Planning Target Volume (PTV) to 30 Gy in 5 fractions, and a Simultaneous Integrated Boost delivering 35-50 GY to GTV. Patients will be divided into groups of 5 and will receive (in the absence of 2 G4 toxicities per group), the following dose levels: 35-40-42.5-45-47.5 and 50 Gy. Standard Temozolomide chemotherapy will be prescribed after surgery.
41115523|NCT05074069|PROCEDURE|Gynaecological reconstruction|Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation
41115524|NCT05933551|OTHER|Z Technique Training|Training on Z technique will be given on the planned day, time and place. The education is planned to be given at Tarsus University. The training content will be presented to the participants as a powerpoint presentation (30 min), laboratory practice (15 min) and question-answer (15 min).
41115525|NCT01697969|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
41115526|NCT05778591|DRUG|Placebo|Placebo.
41115527|NCT05778591|DRUG|Buprenorphine 0.15 MG [Belbuca]|Buprenorphine
41115528|NCT04382404|DRUG|Sofosbuvir-Velpatasvir Drug Combination|One pill once a day for 12 weeks
41115529|NCT01297101|DRUG|Erlotinib|150mg/qd, on day 15-28 of each 28 day cycle.
41115530|NCT04469855|DRUG|semaglutide|Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.
41115531|NCT04487431|DRUG|BAY1817080|Oral single dose
41115532|NCT04487431|DRUG|[14C]BAY1817080|Oral single dose
41115533|NCT03183518|OTHER|Facial micellar cleanser|Each participant will have the test product applied topically via semi occlusive patch, on-site by a technician.
41115534|NCT03183518|OTHER|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Each participant will have the reference product applied topically via semi occlusive patch, on-site by a technician.
41446200|NCT00714935|BEHAVIORAL|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
41115535|NCT03643939|DEVICE|High Flow Nasal Catheter|"HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2."
41115536|NCT03643939|DEVICE|Noninvasive ventilation|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
41115537|NCT00589667|DRUG|Pemetrexed plus Gemcitabine|"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.~Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.~For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist."
41115538|NCT00200213|BEHAVIORAL|portion or unportioned food|
41115539|NCT03932981|DRUG|Temozolomide|Temozolomide at a monthly standard dose of 150-200 mg/m2/day at day 1 to day 5 for a duration of treatment of 12 months
41115540|NCT02831712|DIETARY_SUPPLEMENT|Ferrous Fumarate|One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
41115541|NCT01517347|DRUG|Interleukin-2|Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
41115542|NCT03997916|DEVICE|Belun Ring|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
41115543|NCT03997916|DIAGNOSTIC_TEST|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
41115544|NCT01721824|BEHAVIORAL|The IPS-MA method|During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
41115545|NCT01304277|BIOLOGICAL|agalsidase alfa|
41115546|NCT03911479|PROCEDURE|Bariatric Surgery|Bariatric Surgery - convencionals Roux-en-Y gastric bypass (RYGB) and vertical gastrectomy (Sleeve; SG)
41115547|NCT02634541|DRUG|Adalimumab|Biologic drug
41115548|NCT02634541|OTHER|PET/CT imaging|PET/CT imaging
41115549|NCT06263673|DRUG|Sitagliptin|100 mg once daily, oral
41115550|NCT06263673|DRUG|Dapagliflozin|10 mg once daily, oral
41115551|NCT06263673|DRUG|Placebo|Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.
41115552|NCT02576613|OTHER|MPP-S|\> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
41115553|NCT02576613|OTHER|TAU|standard medical treatment without structured psychotherapeutic intervention
41115554|NCT04404881|DRUG|Bevacizumab|"* Induction Period (first 3 months of bevacizumab treatment):~  -- Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~* Maintenance Period (second 3 months of bevacizumab treatment):~  * Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
41115555|NCT05437783|DRUG|Azithromycin Dihydrate|exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
41115556|NCT01236001|DRUG|Lacosamide|
41115557|NCT00396851|DRUG|Gurmar|
41115558|NCT00396851|DRUG|Metformin|
41115559|NCT01180192|DRUG|oxygen|either 8 L/minute O2 via face mask for 2 hours
41115560|NCT06307548|DRUG|Aminolevulinic Acid|Given PO
41115561|NCT06307548|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41115562|NCT06307548|PROCEDURE|Computed Tomography|Undergo CT
41115563|NCT06307548|PROCEDURE|Fluorescence-Guided Surgery|Undergo fluorescence-guided surgery
41115564|NCT06307548|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41115565|NCT06307548|DRUG|Photodynamic Therapy|Undergo PDT
41115566|NCT06307548|PROCEDURE|Surgical Procedure|Undergo surgery
41115567|NCT03789578|DRUG|NNC0148-0287sema|Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
41115568|NCT03789578|DRUG|Semaglutide|Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
41115569|NCT03789578|DRUG|NNC0148-0287|Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
41115570|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
41115571|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
41115572|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
41115573|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
41115574|NCT03407846|PROCEDURE|Hystrectomy|Total laparscopic hystrectomy versus total abdominal hystrectomy
41115575|NCT04960072|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
41115576|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
41115577|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
41115578|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
41115579|NCT05468411|OTHER|Oral application of miracle fruit pill|Miracle fruit has a taste modifying function from sourness to sweetness when it is exposed to an acidic environment. To activate the miracle fruit's function, a miracle fruit pill should be orally administered to coat taste buds prior to eating sour food. Thus, participants are instructed to place a miracle fruit pill is on their tongue, and roll the pill around their mouth to allow full contact of the pill with the surface of the oral cavity without chewing until the pill completely dissolved. A miracle fruit pill is administered prior to eating.
41115580|NCT05468411|OTHER|Oral application of sugar candy|To simulate the miracle fruit's function as a placebo, a chewable sugar candy that has a similar appearance to miracle fruit pill is orally administered. The same protocol that is used in miracle fruit intervention is followed in this placebo intervention but with a chewable sugar candy. Participants are instructed to place a sugar candy is on their tongue, and roll the candy around their mouth to allow full contact of the candy with the surface of the oral cavity without chewing until the candy completely dissolved. A sugar candy is administered prior to eating.
41115581|NCT00024141|DRUG|fluorouracil|
41115582|NCT00024141|DRUG|irinotecan hydrochloride|
41115583|NCT05344326|OTHER|Cognitive Analytic Therapy - Guided Self Help (CAT-GSH)|CAT-GSH is a novel intervention designed to help those with depression by focusing on the relationships within their life. GSH is used in step two of IAPT services and is typically six fortnightly sessions where the PWP helps the service user complete the self help manual.
41115584|NCT05167877|OTHER|No intervention will be given to the participants|This is an observational feasibility study with no intervention.
41115585|NCT00391846|DRUG|Captopril|
41115586|NCT00391846|DRUG|Enalapril|
41115587|NCT00391846|DRUG|Lisinopril|
41115588|NCT00391846|DRUG|Ramipril|
41115589|NCT00391846|DRUG|Trandolapril|
41115590|NCT00391846|DRUG|Bisoprolol|
41115591|NCT00391846|DRUG|Carvedilol|
41115592|NCT00391846|DRUG|Metoprolol succinate|
41115593|NCT00391846|DRUG|Candesartan|
41115594|NCT00391846|DRUG|Valsartan|
41115595|NCT00391846|DRUG|Eplerenone|
41115596|NCT00391846|DRUG|Spironolactone|
41115597|NCT00391846|DRUG|Diuretics|
41115598|NCT00391846|DRUG|HF treatment according to Swedish guidelines|
41115599|NCT00391846|PROCEDURE|Blood samples|
41115600|NCT00391846|PROCEDURE|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
41115601|NCT00569049|PROCEDURE|breast tissue, lymph node tissue or blood|Molecular Analyses of samples
41115602|NCT02794194|OTHER|Proprioceptive training on a whole body vibration platform|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
41115603|NCT02794194|OTHER|Proprioceptive training with the BOSU® on the floor|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
41115604|NCT05495477|DEVICE|EIT|Evaluation of ventilation distrinution during deep sedation through EIT
41115605|NCT04191486|DRUG|T-817MA|224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.
41115606|NCT04191486|DRUG|Placebo|Placebo once daily
41115607|NCT04058626|DIAGNOSTIC_TEST|Transcutaneous pressure of oxygen (TcPO2)|Measurements will be taken from the dorsum of the foot using an automated machine equipped with Clark electrodes.
41115608|NCT04058626|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
41115609|NCT04058626|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.
41115610|NCT04058626|DIAGNOSTIC_TEST|Duplex Assist|Continuous Doppler device which gives visual display of arterial spectral waveform at the ankle.
41115611|NCT04058626|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the DPA and PTA.
41115612|NCT01448317|DRUG|Alirocumab (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41115613|NCT01448317|DRUG|Alirocumab (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
41115614|NCT01448317|DRUG|Placebo (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41115615|NCT01448317|DRUG|Placebo (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous"
41115616|NCT04529278|DRUG|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26."
41115617|NCT00089544|DRUG|Dacarbazine|Given IV
41115618|NCT00089544|DRUG|Doxorubicin Hydrochloride|Given IV
41115619|NCT00089544|BIOLOGICAL|Filgrastim|Given subcutaneously
41115620|NCT00089544|DRUG|Ifosfamide|Given IV
41115621|NCT00089544|OTHER|Laboratory Biomarker Analysis|Correlative studies
41115622|NCT00089544|RADIATION|Radiation Therapy|Undergo radiotherapy
41115623|NCT00089544|DRUG|Thalidomide|Given orally
41115624|NCT00089544|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
41115625|NCT02477670|DRUG|AVP-786|
41115626|NCT02477670|DRUG|Placebo|
41115627|NCT01918644|RADIATION|stereotactic body radiation therapy|Undergo SBRT
41115628|NCT01918644|DRUG|capecitabine|Given PO
41115629|NCT01918644|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
41115630|NCT01918644|PROCEDURE|magnetic resonance imaging|Optional correlative studies
41115631|NCT01918644|OTHER|laboratory biomarker analysis|Optional correlative studies
41115632|NCT05664477|DIETARY_SUPPLEMENT|PhytoSERM|PhytoSERM is a dietary supplement containing equal amounts of genistein (16.7 mg ± 10%), daidzein (16.7 mg ± 10%) and S-equol (16.7 mg ± 10%).
41115633|NCT05664477|DRUG|Placebo|Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.
41115634|NCT06172517|OTHER|Orthosis intervention|Clinical feasibility trial with one group using a custom-made foot orthotics prescribed by podiatrists (foot impression, polypropylene orthotics and covering at podiatrists' discretion).
41115635|NCT04540822|OTHER|peripheral venous catheter with compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. Under the catheter-extension tube junction will be inserted a sterile non-woven compress, cut sterilely (3.5x1.5 cm). The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
41115636|NCT04540822|OTHER|peripheral venous catheter without compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. No compresses will be inserted under the catheter-extension tube junction.The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
41446201|NCT00714935|BEHAVIORAL|Coronary Artery Disease Decision Aid|"Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
41115637|NCT05992701|DEVICE|Directional deep brain stimualtion|Directional deep brain stimualtion in the treatment of Parkinson's disease using L305/L306 leads and G107R/G107 implanted pulse generators (Beijing Pins Medical Co.).
41446202|NCT03214588|DRUG|TAK-831|TAK-831 tablets
40752631|NCT05311410|OTHER|Non-bloody dental procedures (control group)|Control group composed of 30 positive patients for SARS-CoV-2, from the same ICU, submitted to non-bloody procedures.
41446203|NCT03214588|DRUG|TAK-831 Placebo|TAK-831 placebo matching tablets
40752632|NCT05311410|PROCEDURE|Bloody dental procedures (study group)|Study group consisting of 30 patients who require open dental treatment and with a positive PCR test for SARS-CoV-2 prior and admitted to the Intensive Care Unit.
40752633|NCT05362136|PROCEDURE|perforation of the sinus floor|perforation of the cortical layer of the sinus floor prior to inserting the augmentation material during sinus floor elevation
41446204|NCT06242028|DRUG|Group P|In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine and 4 mg dexamethasone.
41446205|NCT06242028|DRUG|Group S|In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine. In addition, 4 mg dexamethasone will be administered intravenously.
40752634|NCT05362136|PROCEDURE|no perforation of the sinus floor|standard procedure for sinus floor elevation
41115638|NCT04415528|OTHER|Emotion-Focused Mindfulness Therapy|"EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention."
41115639|NCT02242695|DRUG|Fluomizin vaginal tablets|One vaginal tablet for 6 days and 1 placebo tablet on day 7
41115640|NCT02242695|DRUG|Canesten vaginal tablets|one vaginal tablet for 7 days
41115641|NCT03470662|OTHER|Care bundle|Care bundle
41115642|NCT01320215|PROCEDURE|Robot-assisted promontofixation|Sacrohysteropexy with robotic assistance (da Vinci robot)
41115643|NCT01320215|PROCEDURE|Non-robot assisted promontofixation|Laparoscopic sacrohysteropexy, without robot assistance
41115644|NCT02327611|DRUG|Custodiol|
41115645|NCT02327611|DRUG|Enriched Ringer's lactate solution|
41115646|NCT03734692|DRUG|Rintatolimod|200 mg by IP administration over 1-2 hours
41115647|NCT03734692|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion
41115648|NCT03734692|DRUG|Cisplatin|50mg/m\^2 solution
41115649|NCT03102710|DEVICE|transcranial direct current stimulation (tDCS)|tCDS safely applies a weak electrical current to your scalp using two sponge electrodes that look like flat circular pads. The pads will be held in place on your head with a neoprene cap. The pads will be attached to a generator that will send a weak stimulus to your scalp. This current influences the way that your brain cells work. When the stimulus starts, you might feel a tingling sensation underneath the electrode pads. That sensation is not painful and goes away in seconds.
41115650|NCT03102710|OTHER|Lidocaine cream|Lidocaine cream will be applied on the arm to reduce pain sensitivity (analgesia).
41115651|NCT03102710|OTHER|Capsaicin cream|Capsaicin cream will be applied on the arm to increase pain sensitivity (hyperalgesia).
41115652|NCT03102710|OTHER|Control cream|A neutral cream will be applied on the arm as a control.
41115653|NCT04134143|BIOLOGICAL|ExpressGraft-C9T1 Skin Tissue|A round patch of experimental skin tissue that the doctor applies over the ulcer
41446206|NCT06563258|DEVICE|Biodex Balance Training|"Sixty Subjects of both genders aged 40-60 years old with grade 2 knee osteoarthritis years will diagnosed by orthopedists they will assigned randomly into three groups:~* Group A Will receive WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.~* Group B will receive Biobex training and traditional exercises Total time of training was 10 minutes each set is 3 minutes with 20-second rest intervals~* Group C Patients will receive only traditional exercises, 3 sessions per week for four weeks. a good general guideline is 2-3 sets of 10-15 repetitions for each exercise."
41446207|NCT06563258|DEVICE|A vibration device|WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.
40752635|NCT06254690|DRUG|Pyrotinib dose escalation|Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
41115654|NCT06257888|OTHER|patient navigation|two trained patient navigators will admit breast cancer patients to HCM, navigate them from admission to commencement of first treatment and will collect all pertinent epidemiological data and variables
41115655|NCT04958343|PROCEDURE|pelvic reconstruction|After radical cystectomy, the pelvic reconstruction including the ligation of dorsal vascular complex and posterior reconstruction will be performed on patients.
41115656|NCT06459024|OTHER|Registration into the STREAM platform|All patients fulfilling eligibility criteria will be registered into the STREAM platform. Baseline and follow up information will be recorded for each patient enrolled. Each patient will be followed up according to normal clinical practice up to 4 years.
41115657|NCT04296227|DEVICE|The Vital Detect blood pressure monitor|The end goal is to provide Non-invasive Blood Pressure (NIBP) accuracy data to support validation of the Vital Detect blood pressure monitor.
41115658|NCT01551953|BEHAVIORAL|Tai chi|12 week tai chi class
41115659|NCT01551953|BEHAVIORAL|Mind-body breathing|12 week breathing class
41115660|NCT01551953|BEHAVIORAL|Education|12 week education class
41115661|NCT00176813|DRUG|Gemcitabine|
41115662|NCT00176813|DRUG|Cisplatin|
41115663|NCT00176813|DRUG|Celecoxib|
41115664|NCT00510887|DRUG|Bortezomib|Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
41115665|NCT00510887|DRUG|Rituximab|Rituximab 375 mg/m2 IV on day 1
41115666|NCT00510887|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV on days 1,2,3
41115667|NCT00510887|DRUG|Mitoxantrone|Mitoxantrone 10 mg/m2 IV on day 2
41115668|NCT00510887|DRUG|Dexamethasone|Dexamethasone 20 mg orally on days 1,2,3,4,5
41115669|NCT00857545|OTHER|Laboratory Biomarker Analysis|Correlative studies
41115670|NCT00857545|BIOLOGICAL|Polyvalent Antigen-KLH Conjugate Vaccine|Given SC
41115671|NCT00857545|BIOLOGICAL|Saponin-based Immunoadjuvant OBI-821|Given SC
41115672|NCT00955825|DRUG|300 IR|300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
41115673|NCT00955825|DRUG|Placebo|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
41115674|NCT00632424|DRUG|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
41115675|NCT04048135|DRUG|Pegozafermin|Subcutaneous injection
41115676|NCT04048135|OTHER|Placebo|Subcutaneous injection
41115677|NCT05206617|OTHER|No intervention - pure observational study|No intervention
41115678|NCT00139672|DRUG|PD-217,014|
41115679|NCT04937842|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
41115680|NCT03802708|DIAGNOSTIC_TEST|Metabolomic analysis urine sample|a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
41446208|NCT06563258|OTHER|traditional exercises|"1. Stretch exercises (flexibility exercise) Rectus femoris, Iliotibial band, Hamstring and self-stretch for calf muscle (3sets, each stretch 30 sec hold, between each set 5sec rests).~2. Strengthen exercises(resistance exercise)~   1. Isometric Exercises for quadriceps (10 rep,3sets)~  2. Hip abductors strengthening 45 degree (10 rep,3sets)~  3. Hip extensor strengthening 15 degree (10 rep,3sets)~  4. Straight leg raising 45-70 degree (10 rep,3sets)~  5. Short arc knee extension (10 rep,3sets)"
41115681|NCT05185921|BEHAVIORAL|Trial-based Cognitive therapy|The virtual CBT will be provided by 02 psychotherapists, who will follow a protocol developed for this study. The number of sessions will be eight, which will be held weekly, projecting an intervention time of 2 to 3 months considering the possibility of rescheduling any of the sessions for reasons derived from the participant People with relevant cognitive impairment that prevents them from answering the questionnaire questions or providing informed consent are excluded.
41115682|NCT00596310|OTHER|CT|Screening CT
40752636|NCT06254690|DRUG|Pyrotinib dose normal|Pyrotinib: 400mg per week, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
40752637|NCT05229354|BIOLOGICAL|TV005|The TV005 admixture is comprised of four monovalent dengue vaccine candidates representing each of the four DENV serotypes: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, and rDEN4Δ30.
40926185|NCT04816409|OTHER|Neurodevelopmental therapy|"Starting Posture~* Start and evaluate the supreme effective posture to move from(usually straight)~* Reassemble to mid plane (head/trunk)~* Neutral position of body (47) Identify the Missing Components Detect starting posture and compare to normal.(47)~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.(48) 2. Developmental movement patterns training: Obstacle crawl, hold swing's ropes in kneeling and half kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of~li"
41115683|NCT02033148|DRUG|icotinib hydrochloride|Given PO
41115684|NCT02033148|OTHER|laboratory biomarker analysis|Correlative studies
41115685|NCT02033148|OTHER|pharmacological study|Correlative studies
41115686|NCT05076799|DRUG|100 ml lactulose combined with 1 L PEG|the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
41115687|NCT05076799|DRUG|100 ml lactulose combined with 2 L PEG|the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
41115688|NCT05076799|DRUG|200 ml lactulose|the participants were instructed to consume 200 ml lactulose alone
41115689|NCT05076799|DRUG|3 L Polyethylene glycol solution|the participants were instructed to consume 3000 mL of PEG solution
41115690|NCT03806348|PROCEDURE|Resuturing|Early reconstruction of the perineal body after wound dehiscence within two weeks of delivery.
41115691|NCT00457743|DRUG|Sunitinib malate (SU011248)|SU011248
41115692|NCT01314352|DRUG|Desloratadine|Desloratadine Tablets, 5 mg
41115693|NCT03268577|OTHER|Internet-Based Intervention|Complete ASA24
41115694|NCT03268577|OTHER|Internet-Based Intervention|Complete ACT24 reporting
41115695|NCT03268577|DEVICE|Monitoring Device|Wear accelerometer and inclinometer physical activity monitors
41115696|NCT03268577|OTHER|Questionnaire Administration|Ancillary studies
41446209|NCT06561009|DRUG|Anti-BAFFR CART|Anti-BAFFR CART
41446210|NCT04519515|DEVICE|Allergan Vollure|Injection of Allergan Vollure into Atrophic Scars
41115697|NCT03824262|DEVICE|HICO-VARIOTHERM 550|Warming during perioperative period.
41115698|NCT03824262|DEVICE|Mistral-Air Plus forced air warming device|Warming during perioperative period.
41115699|NCT02738372|OTHER|Diagnosis/Prognosis|The present study will be a 24 months multi-center, triple-blind, prospective, cohort study which will be carried out between April 2016 and March 2018. Subjects diagnosed of rotator cuff (RC) tendinopathy, adhesive capsulitis (AC), glenohumeral instability, SLAP lesion, and/or acromioclavicular pathology and fulfill the inclusion criteria will be asked for participating in our study. Several questionnaires that will test the influence of different biopsychosocial factors and the presence of Central Sensitization will be administrated to these subjects. The outcomes will be assessed at baseline and 5 follow-ups (after 3, 6, 12, 18 and 24 months, t1-t6).
41115700|NCT00897546|OTHER|laboratory biomarker analysis|
41115701|NCT05623163|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (up to 5 sutures) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
41115702|NCT01763970|RADIATION|SBRT|
41115703|NCT06357910|DRUG|HCP2303|Take 1 tablet once per period
41115704|NCT06357910|DRUG|RLD2302|Take 1 tablet once per period
41115705|NCT06357910|DRUG|RLD2102|Take 1 tablet once per period
41115706|NCT03724578|DRUG|Grape Seed Extract mouth wash|participants will use grape seeds extract mouth wash in addition to standard preventive measures
41115707|NCT03724578|DRUG|standard preventive measures|twice daily brushing with fluoride tooth pate and daily flossing
41115708|NCT03724578|DRUG|antimicrobial and fluoride mouth wash|using chlorhexidine and fluoride containing mouth wash
41115709|NCT00004423|DRUG|-aminosalicylic acid|
41115710|NCT02074488|OTHER|Balancing Act exercise curriculum|"Balance improvement exercise curriculum titled Balancing Act"
40752638|NCT05229354|BIOLOGICAL|rDEN2Δ30-7169 attenuated virus strain|based on a cDNA derived DENV-2 virus (strain Tonga/74) in which the 3´ UTR of DENV-2 contains a 30 (nt) deletion (nt 173 - 143) homologous to the ∆30 deletion in the 3´ UTR of rDEN4Δ30 (named Δ30 for consistency). A plasmid was constructed to encode the entire genome of DENV-2 Tonga/74. The cDNA of the 3´ UTR of DENV-2 Tonga/74 was then modified to introduce a 31-nucleotide deletion homologous to the DEN4Δ30 deletion (∆30). Genome-length, capped, RNA transcripts were synthesized from the plasmid p2Δ30-7169 and purified
40752639|NCT01235416|DRUG|AMG 706|In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
41115711|NCT02074488|OTHER|Informational Brochure|Informational Brochure on falls prevention
41115712|NCT03844269|DEVICE|AKL-T01|"AKL-T01 digital treatment is a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty based on the user's ability. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task. Performance on these tasks are assessed in isolation and when performed together to calculate a performance index for each individual user. A personalized multitask treatment regimen is automatically configured and delivered to the user and is optimized adaptively to increase multitask performance. As players proceed through the treatment periodic recalibration occurs to maintain an optimal difficulty level."
40752640|NCT03870971|OTHER|blood glucose measurement|After the patient has performed the manual reading, the investigator or staff member will obtain another capillary blood sample and a reference reading by means of the YSI 2300 Stat plus analyzer will be performed and recorded. If patients need more than one attempt to get a successful blood glucose reading, the number of attempts will be documented. A questionnaire needs to filled by the participant
40752641|NCT00163852|DRUG|Normal saline IV, salt tablets|
40752642|NCT05756309|DEVICE|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
40752643|NCT04787120|DEVICE|SQUIDperi|Liquid embolic delivery syringes and micro-catheter
40752644|NCT04795362|BIOLOGICAL|blood sample|"5 tubes of 1 milliliters (ml) will be sampled on a catheter placed as part of the usual practice every hour for 4 hours (at Time 0, at Time 1 hour, at time 2hours, at Time 3 hours, at time 4 hours) as soon as DCI is suspected.~In the event of a mechanical angioplasty decision, the samples will be continued (Time 0, Time 2 hours, Time 4 hours, Time 6hours, Time 12 hours, Time 24 hours, so 6 samples of 1 ml)."
40752645|NCT04287556|DIAGNOSTIC_TEST|In vitro contracture test (IVCT)|In vitro study of muscle contraction after exposure to different substances (caffeine and halothane).
40752646|NCT04287556|DIAGNOSTIC_TEST|In vitro test of hypermetabolism in B lymphocytes|In vitro study of the activation of lymphocytes B after being incubated with a cocktail of primary antibodies and measuring the acidification in response to the RyR1, 4-CmC agonist, using ryanodine as a positive control.
40752647|NCT04287556|DIAGNOSTIC_TEST|Genetic test|Analysis of genes related to MH (CACNA1S and RYR1).
40752648|NCT04561609|OTHER|Transcutaneous CO2 application|"Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes.~Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only)."
40926186|NCT00130351|DEVICE|formoterol|
40926187|NCT00455832|PROCEDURE|peginterferon alpha and ribavirin|sperm collection
41115713|NCT02511613|DRUG|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution, 0.2% administered BID
41115714|NCT02511613|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution, administered BID
41115715|NCT02511613|DRUG|ranibizumab|ranibizumab intravitreal injection
41446211|NCT01125163|DIETARY_SUPPLEMENT|Iron Supplement|multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120 ml/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted postmenstrual age.
41115716|NCT03688360|BEHAVIORAL|Cognitive Behavioral Therapy|. Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy, formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises.
41115717|NCT05188430|DEVICE|Medical Device (Kaptufat®)|"140 mg chitosan, 460 mg cellulose and 35.384 mg ascorbic acid for 1 tablet~Oral administration: 3 tablets twice a day before the main meals"
41115718|NCT05188430|OTHER|Placebo|Oral administration: 3 tablets twice a day before the main meals
41115719|NCT04201041|PROCEDURE|pudendal nerve pulsed radiofrequency|received pudendal nerve pulsed radiofrequency through trans-vaginal approach or trans-gluteal approach
41115720|NCT02972801|PROCEDURE|Testicular biopsy|Testicular biopsy is performed to obtain testicular tissue for cryopreservation
41115721|NCT04302246|GENETIC|Biological testing on sequential blood sample|Biological characterization of various immune function and blood circulating leukocytes phenotyping before liver transplantation and therafter at day-3, -7, -14 postoperatively and if septic complication occurs.
41115722|NCT02589340|DRUG|Buspirone|
41115723|NCT02589340|DRUG|Placebo|Sugar Pill
41115724|NCT03226899|DRUG|Lesinurad|200 mg oral tablet
41115725|NCT03226899|DRUG|XOI|All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
41115726|NCT03226899|DRUG|Placebo|matching placebo oral tablet
41115727|NCT03226899|DRUG|colchicine|Gout flare prophylaxis: commercially available colchicine is provided through the Month 6 study visit. Actual colchicine dose (0.5 or 0.6 mg qd) and frequency were adjusted based on the local label, subject medical history, and clinical judgement.
41115728|NCT03226899|DRUG|corticosteroids|Gout flare prophylaxis: Participants unable to take colchicine are permitted to take a short course of low-dose oral corticosteroids up to the Month 3 study visit
41115729|NCT01527253|OTHER|Synergistic food basket|A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
41115730|NCT05067621|DRUG|Semaglutide Pen Injector|Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.
41115731|NCT05067621|DRUG|Placebo|Injection pen contains excipients.
40752649|NCT04561609|OTHER|Placebo treatment|Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.
41115732|NCT04337307|BIOLOGICAL|Skin sampling of the hands of the healthcare workers involved in the decontamination of incubators|"Each incubator will be sampled in 5 points before and after decontamination. The healthcare worker that will be involved in the decontamination will also be sampled (skin sample of the hand) before and after decontamination of the incubator.~All the samples will be analyzed for the presence of pathogenic bacteria, using an inoculation on selective agar then an identification of each bacterial colony."
41115733|NCT01317446|DRUG|amine fluoride/stannous fluoride|10 ml qd, oral, topical, 6 months duration
41115734|NCT00939419|OTHER|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
41115735|NCT00939419|OTHER|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
41446212|NCT01125163|DIETARY_SUPPLEMENT|multivitamin|daily oral multivitamin without iron until 36 weeks adjusted postmenstrual age
41446213|NCT01988376|DEVICE|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
41115736|NCT00939419|OTHER|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
41115737|NCT01195883|DRUG|Crystalloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
41115738|NCT01195883|DRUG|Colloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
41115739|NCT02793154|DRUG|Exenatide|Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate \>=6 hours apart)
41115740|NCT02793154|DRUG|Albiglutide|Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
41115741|NCT00345007|PROCEDURE|Scleral buckling|
41115742|NCT00222326|BEHAVIORAL|Pelvic floor muscle training and lifestyle modification|
41115743|NCT04129619|DRUG|ORP-101|Oral tablet
41115744|NCT04129619|DRUG|Placebo|Oral tablet
41115745|NCT01843101|DEVICE|Optical Coherence Tomography|Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
41115746|NCT01485653|DRUG|Mepivacaine|Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
41115747|NCT05528341|BIOLOGICAL|NKG2D-CAR-NK92 cells|NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10\^6-2×10\^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
41115748|NCT03161990|PROCEDURE|Transgluteal approach to the hip joint|Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.
41115749|NCT03161990|PROCEDURE|Posterior approach to the hip joint|Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
41115750|NCT01426269|DRUG|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
41115751|NCT01426269|DRUG|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
41115752|NCT01426269|DRUG|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
41115753|NCT02748590|DEVICE|InterStim II Neurostimulator Model 3058|The neuromodulation will be carried out according to the usual protocol: Hospitalization for the establishment of percutaneous electrode in the operating room under general anesthesia with fluoroscopic control. The pacemaker startup will be performed within 12h after surgery
41115754|NCT01821612|DRUG|oxaliplatin|IV
41115755|NCT01821612|DRUG|irinotecan|IV
41115756|NCT01821612|DRUG|leucovorin|IV
40926188|NCT00327470|DRUG|Pegaptanib Sodium 0.3 mg|Pegaptanib Sodium dosed every 6 weeks in affected eye.
41115757|NCT01821612|DRUG|5-fluorouracil|IV
41115758|NCT01821612|DRUG|capecitabine|PO
41115759|NCT01821612|RADIATION|radiation|
41115760|NCT01821612|PROCEDURE|surgery|
41115761|NCT01821612|DRUG|gemcitabine|IV
41115762|NCT04744402|DRUG|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
41115763|NCT02705183|RADIATION|Radiotherapy|Multifractionated post-operative radiotherapy, several weeks after surgery
41115764|NCT01042639|BEHAVIORAL|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
40752650|NCT04450875|DIETARY_SUPPLEMENT|Experimental group (with diet)|Two nutritionists performed both diet instruction and 24-hour reminder monitoring monthly. At the end of the three-month follow-up, the 24-hour reminder data such as food consumed, daily rations, and the monthly average of milligrams of consumed methionine contained in the food, were recorded in a database for subsequent analysis.
41115765|NCT02618018|PROCEDURE|AT TORBI 709M|Cataract surgery with AT TORBI 709M 4-haptic toric IOL
41115766|NCT01081145|DRUG|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
41115767|NCT01081145|OTHER|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
41115768|NCT04498663|BEHAVIORAL|Emotion- and Relationship-Focused Therapeutic Interview|In this study, the therapeutic interview will be one-session lasting 90 minutes. Participants will explore prior and ongoing stressful life experiences. Participants will be educated about the role of stress in pain and will be encouraged to identify links between stressors, psychological and emotional conflicts related to the stressors, and their pain symptoms. The interview will encourage the experience and expression of previously avoided emotions related to interpersonal stressors.
41115769|NCT02841150|DRUG|IMBRUVICA (Treatment A)|IMBRUVICA (reference treatment), 4\*140 milligram (mg), capsules.
41115770|NCT02841150|DRUG|Ibrutinib (Treatment B)|Ibrutinib (test treatment), 1\*560 mg, tablet.
41115771|NCT06422650|DRUG|Nigella Sativa capsule 500mg|Nigella Sativa capsule 500mg twice daily for 8 weeks
41115772|NCT06422650|DRUG|Placebo|Oral placebo identical to astaxanthin
41115773|NCT04234776|DRUG|Ketamine|(0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole
41115774|NCT04234776|DIAGNOSTIC_TEST|Cognition|Composite tools
41115775|NCT04234776|OTHER|Suicide risk|MADRS (10) and HAM-D (3)
41115776|NCT04234776|OTHER|Depression thoughts|EPD
41115777|NCT04234776|OTHER|Quality of life and disability|Quality of life and disability
41115778|NCT04234776|OTHER|Clinical and epidemiological factors|Variables and categories
41115779|NCT04234776|DEVICE|Safety of ketamine IM|Vital signs
41115780|NCT04234776|OTHER|Tolerability of ketamine IM|UKU-SERS, YOUNG, CADSS and BPRS-12.
41115781|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Iced-Tea (Control)|Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
41115782|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Tea - Vitamin D3|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
41115783|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Tea- Vitamin D3 & Calcium|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
41115784|NCT01109745|OTHER|PELICAN Primary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in primary care. The general practitioner can integrate the information of the Pelican instrument in their consultation and disease management decisions. The general practitioner will be trained and supported to negotiate the child's, and physicians' agendas based on the outcome of the instrument, and discuss possible interventions. All participating children of a GP will be allocated to the same treatment group (i.e., hierarchical or nested design).
41115785|NCT01109745|OTHER|PELICAN Secondary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in secondary care. The nurse can integrate the information of the Pelican instrument in their consultation and disease management decisions. The paediatricians will be trained and supported to negotiate the child's, and nurses' agendas based on the outcome of the instrument, and discuss possible interventions.
40752651|NCT01164605|DRUG|Raltegravir|60 tablets (30-day supply)
40752652|NCT04787458|DEVICE|abdomen binder (Sejung Korea, Seoul, Republic of Korea)|abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea)
41115786|NCT03692117|DEVICE|Extracorporeal Carbon Dioxide Removal|Place a double lumen catheter in jugular vein, drainage the venous blood in vitro tube, after blood-gas exchange and remove CO2, then return back to the Superior vena cava
41115787|NCT04985136|DRUG|camrelizumab；Rivoceranib|Camrelizumab at 200 mg via intravenous administration (IV), once every 2 weeks (Q2W), in combination with 250 mg of rivoceranib mesylate, oral administration, once a day (QD)
41115788|NCT04985136|DRUG|Rivoceranib|Rivoceranib mesylate (750 mg, QD, po)
41115789|NCT04985136|DRUG|Sorafenib|Sorafenib tosylate (400 mg, twice a day (BID), po)
41115790|NCT04985136|DRUG|Regorafenib|Regorafenib (160 mg, administer for 21 days then stop for 7 days, po)
41115791|NCT05857371|PROCEDURE|lipoaspiration|The surgeon will perform lipoaspiration under local anesthesia for the ADSVF production.
41115792|NCT05857371|PROCEDURE|urethrotomy|The urologist will perform an endoscopic urethrotomy (standard care).
41115793|NCT05857371|DRUG|autologous ADSVF administration|ADSVF will be administrated in fibrotic lesion during urethrotomy by the urologist.
41115794|NCT03476746|DRUG|LEO 90100 foam|A foam formulation of the active comparator Dovobet® ointment
41115795|NCT03476746|DRUG|Dovobet® ointment|Ointment formulation containing same active ingredients as LEO 90100 foam
41115796|NCT03400488|DRUG|AZD5718 oral suspension|In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
41115797|NCT03400488|OTHER|Placebo matching AZD5817 oral suspension|In all cohorts, randomized subjects will receive orally placebo matching AZD5718 oral suspension on Day 1 and from Days 3 to 10. On Day 2, no dose will be given.
41446214|NCT01988376|DEVICE|Conventional Pap smear|Conventional Pap smear
41115798|NCT03445598|BEHAVIORAL|Interactive and personalized CCBT|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements along with personalized content and interactive features in the program
41115799|NCT03445598|BEHAVIORAL|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features.
40752653|NCT01558375|DRUG|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
40752654|NCT01558375|DRUG|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
41115800|NCT03445598|OTHER|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
41115801|NCT02541188|GENETIC|Genetic analysis|
41115802|NCT03381651|RADIATION|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
41115803|NCT03381651|RADIATION|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
41115804|NCT03865758|DEVICE|IN2L computer system|Therapists will use the IN2L computer system to choose videos, music, games and exercise specific to the rehabilitation needs and personal preferences of patients.
41115805|NCT02550691|PROCEDURE|blood sampling|A blood sample will be taken on subject carrying specific genotype
41115806|NCT00629850|DEVICE|Powerlung Performer|Inspiratory/Expiratory muscle trainer
41115807|NCT04496050|DRUG|Prostaglandin E1|The same drug will be used. In this study the same patients will be evaluated after the same dose of medication.
41115808|NCT03912961|OTHER|Picture of the retina with a handheld retinal camera|Patient with diabetes will have their undilated and dilated images taken, with the images being centered on the macula and on the optic disc.
41115809|NCT05627336|DIAGNOSTIC_TEST|pregnant women in the 3rd trimester|Pregnant women who are in their third trimester and will give birth in the clinic will form the study group. These pregnant women will be measured by applying a set of questionnaires to measure their fear of childbirth.
41115810|NCT06204055|OTHER|Intramuscular Dry-Needling|It is a minimally invasive procedure where a solid filament needle is inserted deeply into a myofascial trigger point (MTrP) within a muscle in an attempt to abate it and illicit a desired treatment effect.
41115811|NCT03143348|PROCEDURE|Single blood draw|One blood draw of 0.5 ml volume prior to discharge
41115812|NCT03143348|PROCEDURE|Multiple blood draws|Blood draw at 6 peri-operative time points.
41115813|NCT03143348|PROCEDURE|Multiple blood draws|Blood draw at 7 peri-operative time points
41115814|NCT03094663|DRUG|Bupivacaine with epinephrine|bupivacaine 0.5% with epinephrine 30cc
41115815|NCT03094663|DRUG|Methylprednisolone|40 mg/ml, 1 ml
41115816|NCT03094663|DRUG|Cefazolin|500 mg in 10 ml
41115817|NCT03094663|DEVICE|8 MHz. Chiba needle|22G/ 4 inches
41115818|NCT03094663|DRUG|Bupivacaine with Dexamethasone|15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
41115819|NCT03094663|DRUG|Bupivacaine 25cc|25 cc 0.25% bupivacaine
41115820|NCT03094663|DRUG|Bupivacaine 20cc|20cc 0.25% bupivacaine
41115821|NCT03094663|DRUG|Dexamethasone|2 mg IV dexamethasone.
41115822|NCT00447733|BEHAVIORAL|Integrated mental health and substance use treatment|Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
41115823|NCT00447733|BEHAVIORAL|Treatment as usual|Non-standardized psychiatric outpatient treatment
41115824|NCT06235294|DIETARY_SUPPLEMENT|Resveratrol|Daily capsule of 200 mg Polygonum cuspidatum (Solgar®, Dietimport, Lisboa, Portugal) yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene), by morning, every day during the 3 months preceding in vitro fertilization treatment.
41115825|NCT06235294|DIETARY_SUPPLEMENT|Folic acid|Daily capsule of 400 mcg folic acid (Solgar®, Dietimport, Lisboa, Portugal), by morning, every day during the 3 months preceding in vitro fertilization treatment.
41115826|NCT05850026|PROCEDURE|Septal myectomy and mitral valve repair with edge-to-edge technique|Resection of the obstructing part of the interventricular septum and mitral repair using the edge-to-edge technique (suture of leaflets free margins in the regurgitation spot)
41115827|NCT01460563|DRUG|Magnesium Sulfate|MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
41115828|NCT01460563|DRUG|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
40752655|NCT02585492|OTHER|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
40926189|NCT05258370|OTHER|Dosage|Evaluation of circulating C-terminal FGF23 (FGF23Ct) rate, circulating intact FGF23 (FGF23i) rate and Erythropoietin
41115829|NCT01460563|DRUG|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
41115830|NCT01622075|DEVICE|SeQuent® Please|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
41446215|NCT05069688|DRUG|rifampicin|Patients will receive standard TB and HIV treatment, however, for two weeks (study weeks 20-21) the dose of rifampicin will be increased from standard-dose to high-dose to assess pharmacokinetics and safety
41446216|NCT00191815|DRUG|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
41446217|NCT00191815|DRUG|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
41446218|NCT06626971|DRUG|ARA290|4 mg subcutaneous injections of ARA290 over an 84 day period
40752656|NCT02585492|OTHER|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
40752657|NCT00573820|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
40926190|NCT05258370|OTHER|Cardiac echography|12 months after patient enrollment
41115831|NCT01622075|DEVICE|Taxus Liberte|Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
41115832|NCT03178292|DRUG|Levofloxacin|Levofloxacin 500Mg daily for 5 days
41115833|NCT03178292|DRUG|Placebo|Placebo Oral Tablet daily for 5 days
41446219|NCT01367054|DRUG|Metformin|500 mg tablet
41115834|NCT04738903|PROCEDURE|Femtosecond laser assisted LASIK eye surgery|FS-LASIK eye surgery includes corneal flap creation with femtosecond laser using the Femtosecond laser WaveLight FS200 followed by excimer laser vision correction of the patient's refractive error using excimer laser WaveLight EX500.
41115835|NCT02452918|DRUG|Oritavancin|Administered intravenously
41115836|NCT02452918|DRUG|Warfarin|Administered as a concomitant medication at a standard dose and dosing schedule
41115837|NCT06520345|DRUG|177Lu-TLX591|Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart
41115838|NCT06520345|DRUG|Enzalutamide|Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.
41115839|NCT06520345|DRUG|Abiraterone|Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)
41115840|NCT06520345|DRUG|Docetaxel|Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles
41115841|NCT05706480|DIAGNOSTIC_TEST|colored periodontal probes (CPP)|The CPP will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
41115842|NCT05706480|DIAGNOSTIC_TEST|standard periodontal probes (SPP)|The SPP (William's graduated probe) will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
41115843|NCT05706480|DIAGNOSTIC_TEST|transgingival sounding with an endodontic file|the gingival thickness using the transgingival sounding. After application of local anesthesia gel an endodontic file (ISO 20) with a rubber stopper will be inserted perpendicularly into the buccal aspect of the gingiva (1 mm below the gingival margin) until it touches the tooth surface. The insertion depth will be ensured through placing the rubber stopper in contact with the gingiva and fixing its position and the distance between the tip and the rubber stopper will be calibrated using a manual calibration device (endodontic ruler).
41115844|NCT03396146|OTHER|12 ml total blood tubes volume|12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
41115845|NCT03396146|OTHER|Fecal sample|Fecal sample at inclusion
41115846|NCT06034665|OTHER|Exercise|All patients will be included in the exercise program for their symptoms regarding knee osteoarthritis for 15 sessions.
41115847|NCT05630508|BEHAVIORAL|interactive Mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
41115848|NCT05630508|OTHER|Sham|Receiving standard care, LIVEN educational material and access to the application
41115849|NCT02965846|DRUG|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
41115850|NCT02965846|DRUG|Vehicle|1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily.
41115851|NCT00291824|BEHAVIORAL|Cardiovascular risk factors and willingness to change|
41115852|NCT03895346|BEHAVIORAL|Mindfulness|Mindfulness meditation is a technique of sustained attention and focus, involving preventing the mind from wandering from the meditative object (i.e. breath or body sensations)
41115853|NCT03895346|BEHAVIORAL|Brain Games and Puzzles|Intervention will include the instruction and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
41115854|NCT03264755|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation for cortical excitability in smokers and non smokers
41115855|NCT00468702|DEVICE|CoaguChek S|
41115856|NCT05993026|BEHAVIORAL|Mental health course|The student course involves classroom-based teaching of eight lessons over eight weeks. The aim is to strengthen students' faith in their own abilities (self-efficacy) and ability to understand themselves and others (mentalization). In this way, students become better at entering into positive relationships and communities as well as better at handling everyday challenges both academically and socially. The student course includes teaching, exercises and training in simple tools for mastery and mentalization. The student courses in the classes are handled by staff close to the students and are based on both physical and digital material as well as an app for the students. The employees initially participate in a competency development course.
40752658|NCT01818310|BIOLOGICAL|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
40752659|NCT01818310|BIOLOGICAL|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
41115857|NCT04694885|BEHAVIORAL|Structured Hypnotherapy|"The Intervention includes 10 structured hypnotherapy sessions lasting 45 to 60 minutes. During hypnosis, patients reach a trance-like state comparable to a deep relaxation. The therapist guides the patient verbally and also communicates with the patient.~Patients will be supported to use their own imagination without suggesting any imagery. By repeatedly asking what the patient is perceiving, and by verbally repeating what the patient is saying, the therapist can help the patient to go deeper into trance. In these trance states the patient learns to reduce negative side effects of the chemotherapy and increase the quality of life by activating both physical and mental resources using imagination and focusing on positive memories and feelings."
41115858|NCT05578053|DRUG|Dalpiciclib|a new, orally administered, selective CDK4/6 inhibitor
41115859|NCT00583817|DEVICE|Endovascular stent-graft implantation|Endovascular repair of aorta
41115860|NCT03416465|BEHAVIORAL|medical questionnaire|The patient will complete a questionnaire of 10 questions before leaving hospital. This questionnaire concerns the care pathway for hospitalized patients.
41115861|NCT05530499|OTHER|Almond supplementation|Daily consumption of 57g of whole almonds
41115862|NCT05530499|OTHER|Cookie supplementation|Daily consumption of cookie snack calorically equivalent to 57 grams of whole almonds.
41446220|NCT01367054|DRUG|Glifage|500 mg tablet
41446221|NCT01044537|DRUG|Placebo|Placebo to match PF-04937319 will be provided.
41115863|NCT03814265|BEHAVIORAL|Laughter yoga|440/5000 Laughter yoga; It is an exercise program that combines breathing techniques with unconditional laughter. During the sessions, laughter is simulated by hand clapping and warm-up exercises and by eye contact with other members in the group and by playing childish games with group members. Most of the time this simulation turns into genuine and contagious laughter. Laughter yoga is based on the argument that the brain cannot distinguish between real and unreal laugh.
41115864|NCT00214591|DRUG|GALIDA|
41115865|NCT01591304|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
41115866|NCT01502969|BIOLOGICAL|Rotavin-M1|liquid, 10e6ffu/dose, 2 doses, 2 month interval
41115867|NCT01502969|BIOLOGICAL|cell culture medium in absence of virus|Placebo
41115868|NCT05516004|DEVICE|PXL Platinum 330 system|to determine the efficacy of riboflavin solution and UV light to treat cornea thinning conditions
41115869|NCT01906788|DRUG|Artemether Lumefantrine|
40752660|NCT01818310|BIOLOGICAL|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
41115870|NCT01906788|DRUG|Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0|
41115871|NCT01906788|DRUG|Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2|
41115872|NCT06219642|BEHAVIORAL|Mindfulness using virtual reality|"In each session, participants will be led through the following mindfulness script while using the VR device here is an abbreviated version with excerpts:~Look around. Try to bring yourself to the moment you are in. Notice the presence of the scene around you. How does the air feel against your skin? How do your feet feel against the ground? Where are you? What do you see? Do you hear anything? What do you smell? What do you taste? While you stay seated, imagine you are walking. What body sensations are you experiencing? What thoughts are you having? What emotions are you feeling? At the end of the intervention, participants are asked questions like, What did you notice about your thoughts and mood before, during, and after the VR session? Did you notice a change in how your body felt or your emotions? Was there anything difficult or uncomfortable about the experience that you feel comfortable sharing?"
41115873|NCT02873312|DEVICE|StimRouter|"The StimRouter System is a neuromodulation system consisting of the following components and accessories:~* An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~* An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~* A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories."
41115874|NCT05177601|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of mood disorders.
41115875|NCT05177601|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
41115876|NCT05177601|DRUG|D-cycloserine|Daily oral D-cycloserine 100mg during TMS treatments (20 days).
41115877|NCT05177601|DRUG|Placebo oral capsule|Daily oral placebo during the TMS treatments (20 days).
41115878|NCT03100227|OTHER|PET [18F] FDG|Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.
41115879|NCT03100227|OTHER|Anatomical MRI|All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
41115880|NCT00177216|DRUG|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or \>). The dose was decreased to 5 mg if side effects occurred.
41115881|NCT00177216|DRUG|Escitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
41115882|NCT00177216|DRUG|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
41115883|NCT06554041|DEVICE|Dental Crown with Titanium-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
41115884|NCT06554041|DEVICE|Dental Crown with PEEK (Polyetheretherketone)-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
41115885|NCT06554041|DEVICE|Dental Crown with Zirconia-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
41115886|NCT06554041|DEVICE|Dental Crown with Lithium-Disilicate-Abutment (e.max)|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
41115887|NCT04805996|BEHAVIORAL|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|Participants will replace usual foods with the commercially available total diet replacement Modifast (Impolin AB), which is delivered to them during the study period without any cost. Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor and will be advised to measure body weight, fasting blood glucose and blood pressure every morning. The results are registered in the mobile phone application Telia Health Monitoring (Telia Sweden AB) and are wirelessly transmitted to the study team.
41115888|NCT04929587|OTHER|This is a observational research, there is no intervention|This is a observational research, there is no intervention
41115889|NCT03166449|DIETARY_SUPPLEMENT|Neomune|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
41115890|NCT03166449|DIETARY_SUPPLEMENT|Fresubin® HP energy|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
41115891|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 3)|
41115892|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 5)|
41115893|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 5D)|
41115894|NCT01582646|DRUG|Terbutaline sustained release 5 mg|Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
41115895|NCT03675256|BIOLOGICAL|immediate Gardasil 9, delayed MenVeo vaccine|Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine
41115896|NCT03675256|BIOLOGICAL|immediate MenVeo vaccine, delayed Gardasil 9|Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9
41115897|NCT03675256|BIOLOGICAL|immediate Cervarix, delayed MenVeo vaccine|Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine
41115898|NCT00484614|PROCEDURE|Positron Emission Mammography|Molecular Imaging Device
41115899|NCT00484614|PROCEDURE|Magnetic Resonance Imaging|Imaging Device
41115900|NCT03583125|DRUG|EOC317|tablet(s) PO
41115901|NCT06090786|DIAGNOSTIC_TEST|MRD assessment|Bone marrow withdrawal for MRD quantification
41115902|NCT05305846|DEVICE|TENA-PROTO2|During urodynamics, the TENA-PROTO2 will be positioned onto the lower abdomen of patients to collect raw data for the continuous development of the future ultrasound bladder sensor.
41115903|NCT06148298|OTHER|Non-Human Subject Research study.|This is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.
41115904|NCT01149395|DRUG|Dexlansoprazole|Dosage: 30 mg once per day for 4 weeks by mouth
41115905|NCT01400776|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
41115906|NCT01400776|DRUG|Vehicle|Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
41115907|NCT05289349|DRUG|Propofol|Propofol (2 mg/kg) for induction of anesthesia , and ( 6 mg/kg/h) for maintenance of anesthesia
41115908|NCT05289349|DRUG|Sevoflurane|Sevoflurane 1.0-1.5 minimum alveolar concentration (MAC)
41115909|NCT01234116|DRUG|emtricitabine/tenofovir disoproxil fumarate|Each health care worker will receive one of the Treatment Arms for 28 days.
41115910|NCT02561871|BIOLOGICAL|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 in Group 2.
41115911|NCT02561871|BIOLOGICAL|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 85 in Group 2.
41115912|NCT02561871|DRUG|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
41115913|NCT00941655|DRUG|Oxaliplatin|"Oxaliplatin 460 mg/m\^2 diluted in 2.0 L/m\^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m\^2 over 120 minutes,"
41115914|NCT00941655|DRUG|Irinotecan|Irinotecan 165 mg/m\^2 IV over 90 minutes
41115915|NCT00941655|DRUG|5-Fluorouracil|"Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m\^2 continuous intravenous over 48 hours."
41115916|NCT00941655|DRUG|Leucovorin|"surgery and heated intraperitoneal chemotherapy -20 mg/m\^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m\^2 intravenous over 120 minutes."
41115917|NCT00941655|PROCEDURE|Gastrectomy and/or metastasectomy|"Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy."
41115918|NCT02359370|DRUG|Lidocaine|Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
41115919|NCT02359370|DRUG|Magnesium Sulphate|Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
41115920|NCT02455752|PROCEDURE|LE-TME|Retroperitoneal approach for total mesorectal excision
41115921|NCT05544643|DEVICE|Medtronic Extended Mio 30 Infusion Set|Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set
41446222|NCT01044537|DRUG|PF-04937319|The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
41446223|NCT04325321|OTHER|Stress reactivity test|"The protocol consists of Resting Baseline (BL), Emotion Recall (ER), followed by a Recovery Phase (RP). Heart rate and blood pressure are measured at baseline and then every 5 minutes during ER and RP.~Resting Baseline (BL - 10 min). The participant is instructed to rest quietly.~Emotion Recall (ER - 5-10 min). The participant is instructed to think about the incident associated with the onset of their cardiac event and bring to mind details of the incident. When the participants have the incident clearly in mind, they are instructed to relate the incident and their experience out loud; frequent questions to re-elicit the emotion are asked.~Recovery Phase (RP - 20 min). Upon completion of RP, the catheter is removed and participants are de-instrumented. Blood samples for plasma catecholamines, assessments of heart rate variability, and echocardiograms are performed 10-min into BL, 10-min into ER, and 18 minutes into RP."
41446224|NCT02115165|DRUG|Cabazitaxel|On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
41446225|NCT05770076|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotic)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
41115922|NCT00854191|DEVICE|simulator training|4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
41446226|NCT05770076|DIETARY_SUPPLEMENT|Placebo|Placebo
41115923|NCT06075212|DRUG|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
41115924|NCT04436393|DIAGNOSTIC_TEST|Guardant360 test|tumor cfDNA testing
41115925|NCT02860910|BEHAVIORAL|Cognitive Behavioral Group Therapy|
41115926|NCT00214266|DRUG|Campath 1H®, Rituximab, mycophenolate mofetil|Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
41115927|NCT03648346|DRUG|Cohort 1: HL217 Ophathalmic Solution BID|Two drops of 3 mg/mL of the treatment in one eye twice a day
41115928|NCT03648346|DRUG|Cohort 2: HL217 Ophathalmic Solution QID|Two drops of 3 mg/mL of the treatment in one eye 4 times a day
41115929|NCT03648346|DRUG|Placebo|Placebo eye drops
41115930|NCT02683811|BEHAVIORAL|Diario della Salute (DDS-2)|The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
41115931|NCT04305405|DRUG|Benralizumab|Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.
41115932|NCT06554743|BEHAVIORAL|Default Veg|Received a plant-based meal as the default option on the event RSVP form that required participants to pre-select their meal choice
41115933|NCT06554743|BEHAVIORAL|Default Meat|Received a meal with meat as the default option on the event RSVP form that required participants to pre-select their meal choice
41115934|NCT06509841|OTHER|conventional rehabilitation treatment|Adopting conventional rehabilitation training methods for TSCI patients, including: ① posture training; ② Joint rehabilitation training; ③ Breathing training; ④ Muscle strength training, 7 times a week, with continuous treatment for 4 weeks.
41115935|NCT06509841|OTHER|Acupuncture treatment rehabilitation|Routine rehabilitation treatment combined with acupuncture and moxibustion treatment, the acupuncture measures taken are mainly Dumai points. Once a day. 5 times a week, continuous treatment for 4 weeks.
41115936|NCT01180088|PROCEDURE|RIGHT HEPATECTOMY WITH CLASSIC APPROACH|The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
41115937|NCT00520546|OTHER|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|"PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq \[18F\]Fluoroethylcholine chloride (FEC; Eckert \& Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure."
41115938|NCT00520546|OTHER|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
41115939|NCT04934904|DRUG|Ropivacaine injection|On the first day of inclusion, performed T8 bilateral ultrasound-guided erector spinae plane block and indwelling tube will be left + 0.375% ropivacaine 20ml to both sides. Patients will be given injections every 12 h for 7 days.
41115940|NCT03762291|BIOLOGICAL|CVD908ssb-TXSVN|"TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin."
41115941|NCT03953222|DEVICE|Wearable real-time feedback device|The proposed wearable device can provide real-time feedback of primary gait and posture measures through auditory feedback. The feasibility of people with Parkinson's disease (PD) to utilize to feedback to modulate and improve their gait and posture will be investigated. Two types of feedback will be studied: (a) continuous feedback involving sonification of movements to facilitate learning proper movements (such as to take big steps, swing arms, rhythmic walking, maintain upright posture, etc.) and (b) on-demand feedback where the feedback is provided only if necessary to reduce overload of information and prevent developing dependency on the system.
41115942|NCT02944188|PROCEDURE|Laparoscopic right hemicolectomy plus ERAS|patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
41115943|NCT02944188|PROCEDURE|Open right hemicolectomy plus ERAS|patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
41115944|NCT04153058|PROCEDURE|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
41115945|NCT04153058|PROCEDURE|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
41115946|NCT04326192|DEVICE|Research electrode|A second electrode will be placed percutaneously by Tuohy needle in the epidural space at the same time as the SCS trial implant; at lateral T1-2 area randomly assigned to the left or right side of the lateral epidural space, at the time of the procedure. Placement of electrodes is not experimental, but the placement of a second electrode is a research-driven procedure.
41446227|NCT04025021|DIETARY_SUPPLEMENT|Targeted Fortification|The TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day.
41446228|NCT04025021|DEVICE|The Miris Human Milk Analyzer|The Miris human milk analyzer is a mid infrared that reports the amount of energy absorbed at each wavelength. The amount of fat (grams), lactose (grams), total protein (grams), true protein (grams), and energy (kcal) per 100 ml will be reported.
41446229|NCT03426657|COMBINATION_PRODUCT|Durvalumab + Tremelimumab + RT|Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
41446230|NCT05733585|DEVICE|Purabond|hemostatic efficacy of PuraBond
41446231|NCT03808376|DEVICE|Continuous Glucose Monitoring System|The Eversense® 180 CGM System
41115947|NCT01365598|DRUG|Primaquine|Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
41115948|NCT04339855|OTHER|CAD with LCI for colorectal polyp detection|Polyps within fully recorded endoscopy videos with LCI mode, covering the whole spectrum of adenomatous histology, are used to evaluate the efficacy of CAD with LCI for polyp detection.
41115949|NCT03740009|DRUG|Bazedoxifene/Conjugated Estrogen|20 mg bazedoxifene/0.45mg conjugated estrogens tablets
41115950|NCT03114904|OTHER|Variation of Jasinski score between H0 (stop of sedatives) and H6|To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
41115951|NCT06231069|DIETARY_SUPPLEMENT|Multi-nutrient supplement|12 weeks of supplement intake of milk proteins, N-3 PUFAs, creatine, and vitamin D at levels previously shown to augment muscle protein synthesis in young individuals.
41115952|NCT06231069|OTHER|Exercise|12 weeks of short-duration mixed endurance and resistance exercise.
41115953|NCT00726544|DRUG|ARC 1779 Placebo|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.
41115954|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
41115955|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.
41115956|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
41115957|NCT02706717|DRUG|Visbiome Extra Strength|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
41115958|NCT02706717|DRUG|Placebo|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
41115959|NCT00432523|BIOLOGICAL|M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®|
41115960|NCT05533515|DIAGNOSTIC_TEST|CTC Blood Test|We will draw blood to measure the level of Circulating Tumour Cells
41115961|NCT04820361|DRUG|Cannabis sativa L., folium cum flore|Muscle Relaxation
41115962|NCT04820361|DRUG|Placebo|Muscle Relaxation
41115963|NCT02868268|OTHER|Gene panel sequencing of tumor specimens|Archival or biopsied tumor specimens will undergo gene panel sequencing to identify subgroups with targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor associated macrophage infiltration, PD-L1 expression) biomarkers in neuroblastoma. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receipt of clinical report.
41115964|NCT03834792|OTHER|No intervention but exposure|Different sleep disorders will be considered as an exposure. The data elements included in the database: demographics, date of the sleep study, study type, all available polysomnography indices, symptoms, sleep schedule, comorbidities, medications, social history, electrocardiography, positive airway pressure treatment related variables.
41115965|NCT05692778|OTHER|Patients being foot examined by using an eHealth tool|Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool
41115966|NCT05692778|OTHER|Patients being foot examined in traditional manner|Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes
41115967|NCT04048993|OTHER|Biobank development and integrative physiological analysis|Collection of biological samples (blood, urine, interstitial fluid, adipose tissue and muscle) from subjects enrolled in the Section registry, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
41115968|NCT00529659|DRUG|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
41115969|NCT00529659|DRUG|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
41115970|NCT06553365|DRUG|FCN-159|FCN-159 8mg qd po
41115971|NCT02748486|BEHAVIORAL|Metacognitive Training Jumping to Conclusion|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - jumping to conclusion.
41115972|NCT02748486|BEHAVIORAL|Group discussion|Group discussion of current events
41115973|NCT02748486|BEHAVIORAL|Metacognitive Training To Empathize|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - Theory of Mind deficits.
41446232|NCT00106223|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
41115974|NCT05868161|DEVICE|Pounce Thrombectomy System|Non-surgical removal of thrombi and emboli from the peripheral arterial vasculature with the Pounce Thrombectomy System.
41115975|NCT03616535|OTHER|Cognitive training|The investigators will provide participants with tablets to play brain games.
41115976|NCT03616535|OTHER|Exercise training|The investigators will provide participants with foot peddlers.
41446233|NCT00151593|OTHER|Celsior®|Graft preservation solution
41453378|NCT05655169|PROCEDURE|Piezosurgery and GaALAs diode laser|"One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.~After six weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied."
41115977|NCT03616535|OTHER|Combined cognitive and exercise training|The investigators will provide participants with tablets to play brain games for cognitive training and stationary foot peddlers for exercise training.
41115978|NCT05521958|PROCEDURE|Acute injury without compartment syndrome|"Acute tibial shaft or tibial plateau fractures who do not have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
41115979|NCT05521958|PROCEDURE|Acute injury with compartment syndrome|"Acute tibial shaft or tibial plateau fractures who have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
41115980|NCT05521958|PROCEDURE|Exertional compartment syndrome|For patients with exertional compartment syndrome, a muscle biopsy will be obtained from affected extremity.
40752661|NCT01818310|PROCEDURE|Group D: Surgical endovascular treatment with maximum medicamentous treatment|Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
40752662|NCT04909411|OTHER|OPHTHALMOLOGICAL ASSESSMENT|assessment of eye mobility (search for heterophoria or strabismus), visual acuity, visual fields, external structures and funduscopic examination
40752663|NCT04909411|OTHER|NEUROPSYCHOLOGICAL ASSESSMENT|completion of WISC-5, Vineland Adaptive Behavior Scale II and Strengths and Difficulties Questionnaire
40752664|NCT04951063|RADIATION|Hypofractionated radiotherapy|"Split-course adaptive HRT-CHT is administered at the following three dose levels:~1. Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~2. Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~3. Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course."
40752665|NCT04951063|DRUG|Concurrent chemotherapy|weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT
40752666|NCT04951063|DRUG|Consolidation immunotherapy|Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT.
40752667|NCT00324194|DRUG|MGCD0103|MGCD0103 oral dose given 2 times per week.
40752668|NCT01263028|DRUG|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
40752669|NCT05414812|BEHAVIORAL|Multi-component oncofertility care intervention|"The intervention includes:~1. Young breast cancer patients presenting to oncology visits will complete a clinic-based oncofertility needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future, ii) need for contraception, and iii) sexual health/menopause symptoms.~2. A women's health survivorship care plan (SCP) in Spanish and English encompasses content on screening and management strategies for a) fertility concerns/pregnancy health; b) contraception; c) hot flashes and d) sexual health.~3. Oncofertility navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's oncofertility needs, ii) review the women's health SCP, iii) provide support with the goal of engaging in oncofertility care.~4. Oncofertility consultation as indicated via telehealth or in person will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
40752670|NCT06108336|PROCEDURE|TMS during sequence-demanding task|TMS is administered during the execution of sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
40752671|NCT06108336|PROCEDURE|No TMS during sequence-demanding task|TMS is not administered during the execution of sequence-demanding task.
41446234|NCT03246763|BEHAVIORAL|Integrated community-healthcare childhood obesity treatment|"The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
40752672|NCT06108336|PROCEDURE|TMS during non-sequence-demanding task|TMS is administered during the execution of non-sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
40752673|NCT06108336|PROCEDURE|No TMS during non-sequence-demanding task|TMS is not administered during the execution of non-sequence-demanding task
40752674|NCT00657501|DRUG|testosterone gel|once daily transdermal gel, 300 mcg
40752675|NCT00657501|DRUG|placebo gel|once daily transdermal placebo gel
40752676|NCT05553938|DRUG|Empagliflozin 10 mg|Empagliflozin 10mg
40752677|NCT05553938|DRUG|Placebo|Empagliflozin matched placebo tablet
40752678|NCT03112369|BEHAVIORAL|Narrative Exposure Therapy (NET)|An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.
40752679|NCT03112369|BEHAVIORAL|Motivational Interviewing w/Skills Training (MIST)|Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
40752680|NCT03368521|OTHER|Back pain screening test|The care giver use the screening tool in order to score the back patient to three levels of risk. For each level of risk, one suggested type of care is provided; 1) simple advise; 2) physiotherapy; 3) multimodal rehabilitation. highest risk level includes multimodal intervention.
40752681|NCT00989443|DRUG|Cidofovir gel|topical gel applied once a week for 3 weeks
40752682|NCT02800746|DRUG|Ferric carboxymaltose|Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
40752683|NCT02800746|DRUG|Placebo|normal saline 100 ml is intravenously administered on 7-10 day before surgery
40926191|NCT00923988|OTHER|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
40926192|NCT03466593|OTHER|Prehabilitation|Prehabilitation concerning eating, smoking, drinking and physical activity
41115981|NCT05682183|BEHAVIORAL|Multi-domain Psychoeducation Self-management Programme|The MPSP is a 5-weeks psychoeducation programme aimed at improving the biopsychosocial health of people with MDD (PMDD). It will be conducted on every Saturday in the morning, afternoon and evening. Specific time of each session will be further discussed with the centre. Each session will last for approximately 45 minutes to 60 minutes and will be capped at 10 participants. The mode of session will be face-to-face (F2F) session conducted at MindCare.
41115982|NCT05682183|OTHER|Treatment as usual|Care management from assigned care manager
41115983|NCT03366870|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
41115984|NCT03366870|BEHAVIORAL|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform.
41115985|NCT00439569|DRUG|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
41115986|NCT02708927|OTHER|Clinical evaluation|• Clinical assessment : Expanded Disability Status Scale (EDSS), ambulation test. Medications will be recorded.
41115987|NCT02708927|OTHER|Cognitive evaluation|• Neuropsychological, psychological, social and social cognitive evaluation
41115988|NCT03988023|BIOLOGICAL|Ampion|4 mL injection of Ampion
41115989|NCT03988023|DRUG|Saline|Saline solution, 4 mL, single intra-articular injection
41115990|NCT05816486|DIAGNOSTIC_TEST|Immunobiogram|This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.
41115991|NCT00177086|OTHER|Alfuzosin Hydrochloride|One tablet every day for 4 weeks
41115992|NCT04597658|BEHAVIORAL|Bodyweight supported treadmill training (BWSTT)|In the BWSTT group, walking training will be given by asking the patients to walk on the treadmill as fast as they can, without exceeding the medium intensity according to the Borg scale. Bodyweight support will be gradually reduced according to the patient's tolerance.
41115993|NCT04597658|BEHAVIORAL|Conventional rehabilitation|The conventional rehabilitation program includes posture and breathing exercises, lower extremity stretching, active-assistive range of motion and strengthening, balance-coordination exercises, and walking with a physiotherapist on a smooth surface.
41115994|NCT04369495|OTHER|BAFF serum levels|BAFF levels in serum in visit 0,1,2 during induction therapy
41115995|NCT05140434|DIAGNOSTIC_TEST|Exercise test|exercise test on an exercise bike with increasing load
41115996|NCT05140434|DIAGNOSTIC_TEST|Cardiac CT|cardiac CT scan
41115997|NCT01881386|DEVICE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy
41115998|NCT01164098|DRUG|Rituximab|Induction therapy
41115999|NCT01898741|RADIATION|24 Gy in 3 fractions|
41116000|NCT00742300|PROCEDURE|Autologous hematopoietic stem cell transplantation|Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
41116001|NCT04993898|OTHER|Plyometric training with warm up and cool down|These Include Squat to Squat Jump, Lunge to Plyo Lunge, Step Jack to Star Jumps, Plank to Plyo Spider Lunge, Plank to Frogger Frequency = 2 days per week for 2 weeks and then 4 days per week after 2nd week to 4th week Intensity =500 jumps Time = 30 min
41116002|NCT04993898|OTHER|Conventional training with warm up & cool down|These include Squats, Single leg squat, Cork hip lift, Press ups, Normal warm-up time 15 min before game.
41446235|NCT05502380|DRUG|Standard antibiotic prophylaxis|One to three intravenous doses of cefuroxime 1.5 g intravenously; or 3g if obesity; or vancomycin 1 g or clindamycin 600 mg; if allergy. Continuation of eventual current therapeutic antibiotc regimens for any infection
41446236|NCT02651506|PROCEDURE|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
41116003|NCT00823225|PROCEDURE|standard therapy|wound debridement, moist wound dressing
41116004|NCT00823225|DRUG|Urokinase|"Daily infusion up to 21 applications, dose dependent on fibrinogen level:~\> 2,5g/l 1 000 000 IU, \< 2,5g/l 500 000 IU"
41116005|NCT01686906|PROCEDURE|Bowman layer graft implantation|For patients with progressive advanced keratoconus, a mid-stromal manual dissection is made and a donor isolated Bowman layer is positioned into the stromal pocket.
41116006|NCT04898140|DIAGNOSTIC_TEST|SARS-CoV-2 specific IgM and IgG detection|Detection of IgM and IgG antibodies specific to the SARS-CoV-2 antigens in the blood serum using enzyme-linked immunosorbent assay (ELISA).
41116007|NCT04898140|DIAGNOSTIC_TEST|ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins|Detection of peripheral blood T lymphocytes which are activated and secrete interferon gamma (IFNgamma) upon stimulation with peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, or spike glycoprotein S proteins of SARS-CoV-2 coronavirus.
41116008|NCT04898140|DIAGNOSTIC_TEST|Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes|Detection of peripheral blood T-helpers (CD45+CD3+CD4+)\* and cytotoxic T cells (CD45+CD3+CD8+)\* which are activated and secrete IFNgamma and/or interleukin-2 (IL2) upon stimulation with mixture of peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, and spike glycoprotein S proteins of SARS-CoV-2 coronavirus. \* CD, cluster of differentiation
41116009|NCT02892903|DEVICE|Routine Measurement of FFR|FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow \<3 will not be examined but will be 'awarded' an FFR value of 0.5
41116010|NCT00964730|DRUG|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
41116011|NCT00964730|DRUG|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
41116012|NCT00964730|DRUG|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
41116013|NCT05925140|DRUG|Lopinavir / Ritonavir|"Kaletra is a medication that is produced by AbbVie, a pharmaceutical company based in the United States. It is FDA approved for the treatment of HIV-1 infection in adults and pediatric patients. Kaletra contains two active ingredients, lopinavir, and ritonavir, which work together to inhibit the replication of the HIV virus.~Administration dose and duration of treatment: Patients will receive a loading dose (800/200, daily) of lopinavir 400 mg plus ritonavir 100 mg orally every 12 h for 10 days or until discharge, if sooner."
41116014|NCT05925140|DRUG|Remdesivir (RDV)|"Remdesivir is provided by the United States as an FDA-approved drug, an antiviral medication developed by Gilead Sciences, and has been authorized for emergency use and approved for the treatment of COVID-19 in certain countries, including the United States.~Administration dose and duration of treatment: intravenously as a 200-mg loading dose on day 1, followed by a 100-mg once daily on days 2-10 or until hospital discharge or death. Duration is generally 5 days or until hospital discharge, whichever is first, but may extend to up to 10 days based on clinical response: For inpatients not requiring IMV and/or ECMO: 5 days; if clinical improvement is not demonstrated, treatment may be extended up to 10 days total. For inpatients requiring IMV and/or ECMO: 10 days."
41116015|NCT05925140|DRUG|Tocilizumab|"Actemra is an FDA-approved brand name for Tocilizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, an immunosuppressive drug produced by Roche. It belongs to a class of medications known as IL-6 receptor antagonists and is designed to suppress the activity of the immune system. By blocking IL-6 receptor signaling, Actemra helps reduce inflammation and is used in the treatment of various autoimmune conditions and cytokine release syndrome.~Administration dose and duration of treatment: TCZ was administered 8 mg/kg intravenously (800 mg per infusion) as a single 60-minute intravenous infusion for 4 Weeks initially. The second infusion (400 mg) after 24 h may be administered based on clinical response in case of respiratory worsening, or 8 mg/kg at T0 followed by 8 mg/kg after 12 h."
41116016|NCT05925140|OTHER|Corticosteroid Therapy-enhanced Standard Care (CTSC)|(1) Methylprednisone (120mg/24h/IV) followed by 80mg/day (7days), and if necessary, continued with 40mg/day; or a pulse therapy (patient in critical state (360mg/day/IV) for 3 serial days, followed by 80mg/day (7days), and if necessary, continued with a dose of 40mg/day. (2) Standard Care: Normal Saline 0.9% (500cc/24h); vitamins \[D (Oravil, 100.000IU/2ml PO STAT), C (10g/250cc in normal saline, 60drops/min/day), B (BECOZYME, 6 ampoules IV STAT)\]; Omeprazole (RISEK, 40 mg/day IV); Paracetamol (PREFALGAN, 1g IV each 8h 3 times per day), Ketoprofen (PROFENID, 100mg/12h); Ceftriaxone (ROCEPHIN, 2g/day for 3 consecutive days), Doxycycline (VIBRAMYCIN, 100mg/12h PO for 8 days), Ivermectin (12mg/day for a period of 5 days); TOPLEXIL (Syrup, 10cc/each 8h) or SINECOD (Syrup, 15cc/each 8h); ATORVASTATIN (20mg/day); LOVENOX (40mg/12h if \<80kg, or 60mg/12h if \>80kg). Tranquillizers: NORMOCALM (400mg/night), XANAX (10mg/day), SEROQUEL (25mg/night), DEPIA (2mg/day), to be administered orally
41116017|NCT00743444|DRUG|AZD3355|65 mg capsules, oral, 3 single doses
41116018|NCT00743444|DRUG|Placebo|capsules, oral, 3 single doses
41116019|NCT03435770|DEVICE|EUSRA RFA needle|A 19-gauge RFA electrode and a RF generator with a electrode that is needle-shaped and echogenic that allows EUS guided puncture of the target lesion. The active electrode tip is 1 cm in length. During ablation, the RF electrode is cooled and perfused internally with circulating chilled saline solution (0°C) delivered via a pump to maintain a constant temperature. A setting of 50W energy would be used for RFA and the duration of application is 10 seconds. Sequential applications of up to 7 times per session are allowed for complete ablation of the lesions.
41116020|NCT04981015|DIAGNOSTIC_TEST|Three-day bladder diary|A three-day bladder diary for recording voiding-flow pattern of a women
41116021|NCT01038648|DRUG|Sitagliptin|100mg/day
40752684|NCT05202171|OTHER|Cervical Stabilization Exercise|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
40752685|NCT05202171|OTHER|Standard treatment|standard treatment will include preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks
40752686|NCT00392509|PROCEDURE|ALDH-br bone marrow cells vs. mononuclear bone marrow cells|Surgery
40752687|NCT00021359|DRUG|dexamethasone|
40752688|NCT00021359|DRUG|isotretinoin|
40752689|NCT05848232|DEVICE|coraFlex Catheter|The coraFlex catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
40752690|NCT05848232|DEVICE|coraForce Catheter|The coraForce catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
40752691|NCT05848232|DEVICE|coraCross Catheter|The coraCross catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
41116022|NCT01038648|OTHER|life style modification at base line|Advice on physical activity, diet and drug adherence.
41116023|NCT04446078|DEVICE|PEEK- acrylic resin prosthesis supported by 4 dental implants|Patients rehabilitated for edentulism of one or both arches through an implant supported fixed prosthesis
40752692|NCT03995472|DRUG|SHR-1501|Administered subcutaneously
41116024|NCT03626558|OTHER|ultrasound measures|It is three diaphragmatic ultrasounds measures of a duration of twenty minutes each approximately. The diaphragmatic ultrasound is practised by trans-thoracic way and is non-invasive, completely painless and does not require the exposure of patients to radiation.
41116025|NCT03943277|OTHER|No intervention, observational study|No intervention observational study
40752693|NCT03995472|DRUG|SHR-1316|Administered intravenously
41116026|NCT00731185|DRUG|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
41116027|NCT00731185|DRUG|Placebo|
41116028|NCT00411034|DRUG|OROS Hydromorphone HCI|
41446237|NCT02651506|PROCEDURE|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
40752694|NCT06209125|DEVICE|hybrid aesthetic functional appliance|treatment of class II division one malocclusion
41116029|NCT00946842|DRUG|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
41116030|NCT00946842|DRUG|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
41116031|NCT00946842|DRUG|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
41116032|NCT00946842|DRUG|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
41116033|NCT00946842|DRUG|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
41116034|NCT00946842|DRUG|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
41116035|NCT00566514|DIETARY_SUPPLEMENT|D-ribose|5 grams administered orally TID
41116036|NCT00566514|OTHER|dextrose|5 grams orally TID
41116037|NCT01750866|DRUG|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
41116038|NCT01750866|DRUG|Prednisone|Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
41116039|NCT01750866|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
41116040|NCT03460756|DRUG|Ganaxolone|Oral
41116041|NCT03460756|DRUG|Placebo|Oral
41116042|NCT00529516|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
41116043|NCT00529516|BIOLOGICAL|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
41116044|NCT02468297|DEVICE|Electronic Acupunture Shoes|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.~Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy."
41116045|NCT02468297|DRUG|Ibuprofen|Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
41116046|NCT05425199|OTHER|Habituation exercises + vestibular treatment|"Exercises will include Intensity: 10 repetitions of each set Frequency= 3 sessions per week for 6 weeks.~Time= 30 minutes"
41116047|NCT05425199|OTHER|proprioceptive training + vestibular therapy|Exercise protocol will include Time= total session of 30 minutes . Each exercise will be hold for 30 seconds . Frequency= 3 session per week for 6 weeks Intensity= 10 repetitions and 3 sets
40752695|NCT04674904|OTHER|Dry Needling|Dry needling on Upper trapezius, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids for 10 min
40752696|NCT04674904|OTHER|Hot pack , TENS , Stretching|"Treatments are~1. Hot Pack for 15 minutes~2. TENS for 10 minutes~3. Stretching~The third treatment which is Stretching will be given one time on each muscle (tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids) of upper spine"
40752697|NCT00537082|DRUG|FTY720|Administered orally once daily for 6 months
40752698|NCT00537082|DRUG|Placebo|Administered orally once daily for 6 months
40752699|NCT00137280|BEHAVIORAL|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
40752700|NCT00292370|DRUG|Open Label (OL) Paroxetine|Open-label Paroxetine
40752701|NCT00292370|DRUG|Placebo|Double-blind placebo taken with OL paroxetine
40752702|NCT00292370|DRUG|Quetiapine|Double-blind quetiapine taken with OL paroxetine
40752703|NCT00158470|DRUG|efavirenz|
40752704|NCT00158470|DRUG|didanosine|
40752705|NCT00158470|DRUG|lamivudine|
40752706|NCT02123511|DRUG|acetylcysteine|Oral rinse
40752707|NCT02123511|OTHER|placebo|Oral rinse
41116048|NCT05425199|OTHER|conventional vestibular treatment|Epley's Manuever. Frequency= It will be performed once in a week . Time= 10-15 minutes per session
41116049|NCT02290470|DRUG|Olanzapine|"* Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy)."
41116050|NCT02290470|DRUG|Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine|all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
41116051|NCT04014634|DRUG|Methylprednisolone|Single GON injection with methylprednisolone
41116052|NCT04014634|OTHER|Placebo|Single GON-injection with NaCl
41116053|NCT06327386|DIAGNOSTIC_TEST|18F-FAPI#18F-FDG|FAPI and FDG combined with PET/MR imaging in patients with gastric cancer after neoadjuvant therapy
41116054|NCT01291615|DRUG|Gemcitabine|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
41116055|NCT01291615|DRUG|S-1|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
41446238|NCT02429583|DRUG|Recombivax|Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
41116056|NCT03236909|DEVICE|MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System|Subjects will be implanted with the MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System with +FLEX28 or +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO (single-unit) external audio processors.
41116057|NCT04628715|DEVICE|RSA biofeedback|Biofeedback intervention based on breathing at resonance frequency
41116058|NCT00444600|DRUG|Triamcinolone Acetonide + laser|4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
41116059|NCT00444600|DRUG|Ranibizumab + laser|0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
41116060|NCT00444600|DRUG|Sham injection + laser|Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
41446239|NCT02096185|RADIATION|3 dimensional tomosynthesis imaging|Each operative specimen will be imaged twice using each condition
41446240|NCT02096185|RADIATION|2 dimensional digital imaging|
41446241|NCT00665925|DRUG|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day
41116061|NCT00444600|DRUG|Ranibizumab + deferred laser|0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
41116062|NCT02444598|DEVICE|Vaccum Assisted Closure device|Negative-pressure wound therapy
41116063|NCT02444598|PROCEDURE|Conventional wound dressings|Conventional wound dressings
41116064|NCT01968226|DRUG|[F-18] RDG-K5|Up to fifteen (15) subjects with carotid stenosis \>50% who are undergoing planned carotid endarterectomy will be imaged under PET with \[F-18\] RDG-K5
41116065|NCT03429998|DRUG|evolocumab|evolocumab 140 mg/biweekly
41116066|NCT03429998|DRUG|evolocumab and LDL apheresis|evolocumab 140 mg/biweekly LDL-apheresis monthly
41116067|NCT03429998|PROCEDURE|LDL apheresis|LDL apheresis biweekly
41116068|NCT03149991|DRUG|Brexpiprazole|Administration of up to 3mg brexpiprazole
41116069|NCT03149991|DRUG|Ketamine|administration 6 times over two weeks of inhaled ketamine
41116070|NCT03149991|DRUG|Placebo|Administration of placebo which matches brexpiprazole in size and number of tablets per dose
41116071|NCT00160004|BEHAVIORAL|Intensive Controlled Exercise|
41116072|NCT00000338|DRUG|Lisuride|
41116073|NCT04701879|OTHER|Spine decompression with core stability exercises|"* 50 minutes per session~* Decompression with core stability on alternate days for 8 visits."
41116074|NCT04701879|OTHER|Spine decompression|"40 minutes per session~-Decompression therapy on alternate days for 8 visits."
41116075|NCT04835181|BEHAVIORAL|Electroacupuncture combined with umbilical moxibustion|"①Umbilical moxibustion intervention: point selection: Shenque point Operation: Place the aconite cake on the Shenque point, place the Aizhu in the middle of the aconite cake, ignite the Aizhu and apply moxibustion to make the local warm sensation without burning pain, until the skin is flushed.~②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
41116076|NCT04835181|BEHAVIORAL|Electroacupuncture|"②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
41116077|NCT04996264|DRUG|Varespladib Methyl|Varespladib-methyl (LY333013) is an IR, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration. Scaled pediatric doses of varespladib-methyl (LY333013) are supplied as 50 mg IR capsules for oral administration.
41116078|NCT04996264|DRUG|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate."
40752708|NCT02123511|OTHER|quality-of-life assessment|Ancillary studies
41116079|NCT04996264|DRUG|Standard of care (SOC)|SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
41116080|NCT02549170|BIOLOGICAL|HYQVIA|Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
41116081|NCT02549170|BIOLOGICAL|0.25% albumin placebo solution with rHuPH20|Participants will receive placebo solution (0.25% human albumin in Lactated Ringer's solution) and rHuPH20.
41116082|NCT02549170|BIOLOGICAL|IGIV GAMMAGARD LIQUID/KIOVIG|Participants will receive GAMMAGARD LIQUID/KIOVIG
41116083|NCT02549170|BIOLOGICAL|IGIV GAMUNEX®-C|Participants will receive GAMUNEX®-C
41446242|NCT00665925|DRUG|Fostamatinib disodium (R935788)|150 mg tablet, orally, once a day
41446243|NCT00665925|DRUG|Placebo|Placebo, orally, either once a day, or twice a day
40752709|NCT02123511|OTHER|questionnaire administration|Ancillary studies
40752710|NCT01927861|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
41116084|NCT04567043|BEHAVIORAL|MORE+JITAI|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse. JITAI involves stress-triggered reminders to practice mindfulness skills.
41116085|NCT04567043|BEHAVIORAL|Supporive Psychotherapy|A supportive psychotherapy group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
41116086|NCT06505642|DEVICE|needle-based confocal laser endomicroscopy|needle-based confocal laser endomicroscopy at the tip of the TBNA needle for two punctures, combined with confirmatory CBCT spin for tool-in-lesion confirmation
41116087|NCT05317572|DRUG|80 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 80 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
41116088|NCT05317572|DRUG|120 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 120 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
41116089|NCT05317572|DRUG|160 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 160 mcg of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
41116090|NCT05619016|DIAGNOSTIC_TEST|[68Ga]Ga-ABY-025 PET|\[68Ga\]Ga-ABY-025 PET: Each patient in Cohort 1 will be imaged with a PET/CT twice using the radiolabeled investigational product ABY-025 as a tracer. At the time of injection, a 45-minutes long dynamic scan will take place over a pre specified region of interest. Three hours after injection a full body PET scan followed by a CT scan will be performed.
41116091|NCT05619016|DIAGNOSTIC_TEST|Biopsy and analysis of HER2 expression|Biopsy: Within 3 days after the first ABY-025-PET a tissue sample from at least one metastasis \>10 mm available for biopsy, preferably shallow lymph nodes, will be analyzed for HER2 expression through immunohistochemistry- (IHC) and in situ hybridization- (ISH) analysis in patients with GEAC and HER2low mBC.
41116092|NCT04426461|BEHAVIORAL|Behavioral Activation|Behavioral activation will be delivered as a 10-week, manualized, behavioral intervention focused on enhancing engagement in meaningful and reinforcing activities.
41116093|NCT04426461|BEHAVIORAL|Exposure-based therapy|Exposure-based therapy will be delivered as a 10-week, manualized, behavioral intervention focused on decreasing avoidance to allow for inhibitory learning and challenging negative expectations.
41116094|NCT04426461|BEHAVIORAL|Supportive therapy|Supportive therapy will be delivered as a 10-week, manualized intervention focused on encouraging patients to talk openly about their thoughts, emotions, and any past or current concerns.
41116095|NCT03049969|DEVICE|tDCS stimulation|up to 4.0 mA, dorsolateral prefrontal cortex (montage dependent on specific area of deficit) while completing cognitive training tasks
41116096|NCT05233007|PROCEDURE|Minor endoscopic biopsy|As per standard of care
41116097|NCT06188754|BEHAVIORAL|Time restricted eating|Limiting food intake to 10 hours per day
41116098|NCT06188754|BEHAVIORAL|Mediterranean diet|Dietary advice designed to improve consumption of vegetables, fruits, whole grains, and the use of olive oil.
41116099|NCT02202824|OTHER|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
41116100|NCT01691326|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|0.25 mL dose, Intramuscular
41116101|NCT01691326|BIOLOGICAL|Fluzone®; Influenza Virus Vaccine, No Preservative|0.5 mL dose, Intramuscular
41116102|NCT06371196|DRUG|Babaodan Capsule|Babao Dan Capsule (State Drug License: Z10940006) is produced by Xiamen Traditional Chinese Medicine Factory Co., Ltd; Packing specification: 0.3g/capsule, 6 capsules/board×2 boards/small box; Ingredients are in vitro cultivated cowhide, snake gallbladder, antelope horn, pearl, panax ginseng, artificial musk, and so on. Intervention measures are really the original UDCA treatment program based on the addition of eight treasure Dan capsule, 2 capsules / times, tid, oral. Course of treatment: 3 months (based on 30 days/month).
41116103|NCT04019873|DRUG|Dolutegravir (DTG)|DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.
41116104|NCT04019873|DRUG|Lamivudine (3TC)|3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.
41446244|NCT00253305|DRUG|Organogel of naftifine, 2%|
41446245|NCT00253305|DRUG|Organogel of terbinafine, 2%|
40752711|NCT06499220|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulation (SCS) as an aid in the management of chronic, intractable pain of the trunk and/or limbs.
40752712|NCT00400205|DRUG|Docetaxel|Docetaxel 75 mg/m2, intravenous infusion over 1 hour, mixed with normal saline per institutional standard, day 1 and then every 3 weeks.
41116105|NCT04019873|DRUG|Rilpivirine (RPV)|RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
41116106|NCT05929105|PROCEDURE|artificial intelligence (AI)-assisted three-dimensional preoperative planning technology|In the AI planning group, AI was used to assist in the 3D planning to complete the preoperative design. Preoperative planning was performed by two experienced surgeons and without the chief physician to ensure that the results of the preoperative planning did not affect the selection of intraoperative procedures and prosthesis size.
41116107|NCT05929105|OTHER|X-ray film template for 2D planning|A traditional X-ray film template was used to complete the preoperative design in the traditional planning group. The position and size of the prosthesis, the level of femoral neck osteotomy, the length of the LLs and the restoration of eccentricity were estimated by X-ray. A plastic template provided by the manufacturer was used to take the line of the lower edge of the teardrop on both sides as the horizontal reference line, and the acetabular template was placed at 40 abduction on the inner edge of the teardrop so that the lower edge of the acetabular cup was adjacent to the teardrop. An appropriate type of acetabular component was selected to fill the acetabulum and maintain coverage, and the femoral component that best matched the femoral medullary cavity was chosen. The height of the osteotomy was determined, and the planning model was recorded after the surgeons were happy with the placement and outcome.
41116108|NCT02961569|PROCEDURE|sputum collection for acid fast bacilli|spontaneous or post fiberoptic bronchoscopy sputa
41116109|NCT03264443|BEHAVIORAL|Health education|Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.
41116110|NCT03264443|BEHAVIORAL|Combined training|Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
41116111|NCT00855686|DRUG|Memantine|20mg once daily oral dose
40752713|NCT00400205|DRUG|Cisplatin|Cisplatin 100 mg/m2, intravenous infusion over 30 minutes to 3 hours, day 1 and then every 3 weeks.
40752714|NCT00400205|DRUG|5-fluorouracil|5-fluorouracil 1000 mg/m2/day, 24 hour continuous infusion over 4 days, every 3 weeks.
41116112|NCT00855686|DRUG|Placebo|Daily oral dose
41116113|NCT00812877|DRUG|Mineral Trioxide Aggregate|Pulp capping agent, Mineral TrioxideAggregate
41116114|NCT00812877|DRUG|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide
41116115|NCT04433078|DRUG|Doxycycline|100 MG Tablet
41116116|NCT04433078|DRUG|Placebo|Placebo Tablet
41116117|NCT01449422|DEVICE|Dressing|the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
40926193|NCT03466593|OTHER|Routine care|Preoperative information
41116118|NCT01449422|DEVICE|Dressing|the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
41116119|NCT00368186|BIOLOGICAL|Pneumo 23|
41116120|NCT00939978|DRUG|rhEPO|recombinant human erythropoietin(rhEPO)
41116121|NCT03663504|OTHER|No Preparation|No preparation before surgery
41116122|NCT03663504|DRUG|Neomycin and Flagyl|Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery
41116123|NCT03551535|BEHAVIORAL|Monitored, At-Home Exercise Intervention|Patients will be enrolled in the BurnAlong program as well as receive FitBit heart rate + activity monitors to track adherence rates to the prescribed exercise regimen on BurnAlong, with subsequent motivational interventions triggered if compliance varies from prescription
41116124|NCT04431297|OTHER|Mindfulness Rounds|Virtually delivered mindfulness education sessions of 15-30 minutes, two times/week, for four weeks
41116125|NCT05165082|DRUG|Timolol maleate 0.5% ophthalmic solution|Apply on affected finger or toes twice daily for 8 weeks
40752715|NCT02184442|DEVICE|TAVR Implantation with SAPIEN XT|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
40752716|NCT02184442|DEVICE|TAVR Implantation with SAPIEN|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
41116126|NCT05165082|PROCEDURE|Cryotherapy with liquid nitrogen|Conducted on affected finger or toes every other week for four sessions.
41116127|NCT05407571|BEHAVIORAL|Significance of Echogenic Amniotic Fluid on Perinatal Outcome|To estimate the nature of echogenic amniotic fluid.and To overcome unnecessary intervention due to turbid amniotic fluid, assess neonatal outcome and estimate gestational age at time of delivery in patients with echogenic amniotic fluid.
41116128|NCT04141150|DRUG|[18F]APN-1607|In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
41116129|NCT03762213|DEVICE|Oculus GO VR HMD, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
41116130|NCT03762213|DEVICE|iPad, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
41116131|NCT05591040|DEVICE|Biofeedback|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, two surface electrodes will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
41116132|NCT05591040|OTHER|Conventional|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The control group will perform this training for 45 minutes, with a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
41116133|NCT01832480|DRUG|MTZ 500 mg twice daily x 7 days|MTZ 500 mg twice daily x 7 days
41116134|NCT01832480|DRUG|MTZ 2 g|MTZ 2 g
41116135|NCT02804425|OTHER|actor-spectator|"actor-spectator group : actor at least once during the simulation session"
41116136|NCT03607708|OTHER|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
41116137|NCT03607708|OTHER|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
41116138|NCT01061203|DRUG|Grazax|Treatment with 75.000 SQ-T once daily
41116139|NCT01061203|DRUG|Placebo|Tablet with no active grass component.
41116140|NCT05663151|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
41116141|NCT05369507|BEHAVIORAL|Virtual Care Coordination|Participants randomly assigned to the virtual care coordination group will use a mobile app to assist in HCV treatment care coordination.
41116142|NCT00194714|BIOLOGICAL|HER-2/neu Peptide Vaccine|Given ID
41116143|NCT00194714|OTHER|Laboratory Biomarker Analysis|Correlative studies
41116144|NCT06353282|DRUG|MDMA|MDMA will be dosed in pre-filled capsules and administered orally to participants in two fixed doses - an 80mg dose following the fourth session and a 120mg dose following the ninth session of MDMA to each participant. MDMA experimental medication administration session 1 (8 hours); MDMA experimental medication session 2 (8 hours). Participants will be required to remain in the therapy room for the duration of the experimental medication sessions without the youths' parent/guardian present. The parent/guardian will be invited to attend integration sessions and must be available to drop off and pick up the participant.
41116145|NCT06353282|BEHAVIORAL|Psychotherapy|Treatment session order: Four weekly 90-minute experimental medication preparation psychotherapy sessions; four weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session; and Five weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session.
41446246|NCT00253305|DRUG|Organogel of naftifine, 6%|
40752717|NCT05163535|DRUG|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
40752718|NCT05163535|OTHER|ELPIDA®|Elsulfavirine capsules
40752719|NCT02583477|DRUG|MEDI4736 in combination with nab-paclitaxel and gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
40752720|NCT02583477|DRUG|MEDI4736 in combination with AZD5069|MEDI4736 via IV infusion and oral AZD5069
40926194|NCT03466593|OTHER|Extra early mobilization|Mobilization the day of surgery
41116146|NCT00106080|BEHAVIORAL|Audit and Feedback|Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
41116147|NCT02399865|OTHER|Youth Social Behaviour and Network Therapy|"The Y-SBNT will be delivered according to the developed purpose-designed therapy manual. Participants randomised to Y-SBNT will be offered six, 50 minute SBNT sessions for over a maximum period of 12 weeks. Where consent is obtained, sessions will audio-recorded and reviewed by the research team to ensure fidelity with the YSBNT manual and principles of practice.~Using the identification of the social network of the young person conducted in the first session as a platform, subsequent core strategies of the adapted YSBNT approach include motivational techniques, improving communication and coping mechanisms, and crucially given the nature of substance misuse, developing a network-based relapse management plan. Participants will be given the opportunity to invite members of their network to the treatment sessions. The therapeutic approach also has scope to address client-focussed elective areas, for example, educational requirements."
41116148|NCT06440746|DRUG|Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)|Olokizumab is a sterile solution for subcutaneous injection in a 2-mL clear Type I glass vial, containing a target fill volume of 0.5 mL (for withdrawal of no less than 0.4 mL) of olokizumab drug substance at a concentration of 160 milligrams (mg)/mL.
41116149|NCT06440746|DRUG|SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL|Placebo (sodium chloride 0.9 %) does not contain any active pharmaceutical ingredients. Placebo will be supplied in 2-mL, 5-mL, or 10-mL ampoules made of low-density polyethylene or polypropylene.
41116150|NCT03640624|COMBINATION_PRODUCT|Multidisciplinary treatment|"1. Assessment by gynaecologist and dermatologist, resulting in tailored vulvar care, including daily topical lidocaine 5% ointment. Other topical or oral medication, such as oestradiol cream or oral antidepressants will be prescribed on individual basis.~2. Tailored physiotherapy targeting muscular dysfunction, utilizing: Patient education, pelvic floor muscle exercises (contraction and relaxation), EMG-biofeedback. Low frequent electrical stimulation, massage, stretching and myofascial release and trigger point treatment of the pelvic floor. Desensitization exercises (manually or vaginal dilator). Relaxation and body awareness. Minimum one visit per month.~3. Guided imagery sessions, minimum twice a week using a sound track that is developed for vulvodynia patients."
41116151|NCT03640624|COMBINATION_PRODUCT|Treatment as usual|Treatment as usual in accordance with local guidelines by specialist in gynaecology, including a minimum of two visits (when diagnosis is made and after 3 - 6 months)
41116152|NCT02906735|PROCEDURE|Surgery|Implantation of knee joint prosthesis or deviation osteotomies of the knee
41116153|NCT05222399|DRUG|LY3871801|Administered orally.
41116154|NCT02979808|DEVICE|Navina Smart|Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
41116155|NCT02886637|OTHER|None intervention|
41116156|NCT00226538|DRUG|Phenytoin|
41116157|NCT00226538|DRUG|Rifampicin|
41116158|NCT00226538|DRUG|Diclophenac|
40752721|NCT05181631|OTHER|Biobanking|"Collection of blood (One tube of blood 4-5 ml + One EDTA tube of blood 5 ml) will be attempted for each participant at baseline. Availability of these samples will be indicated in the e-CRF.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in CRB of Hospital Avicenne under the responsibility of Pr Marianne ZIOL. "
40926195|NCT03466593|OTHER|Standard mobilization|Mobilization the day after surgery
41116159|NCT00226538|DRUG|Fluconazole|
41116160|NCT05340114|DEVICE|CEREBO®|Near-infrared based point-of-care portable intracranial hematoma detector
41116161|NCT05712941|DRUG|Lerociclib|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice a day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
41133465|NCT02099188|RADIATION|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
41116162|NCT05712941|DRUG|Letrozole 2.5mg|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice daily (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
41116163|NCT05712941|DRUG|Placebo|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
41116164|NCT04395378|DEVICE|Continuous Glucose monitoring DEXCOM G6|Continuous glucose monitoring during flight and normal living life
41116165|NCT05672888|DRUG|Jaktinib|100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.
41116166|NCT05672888|DRUG|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
41116167|NCT00150176|DRUG|Asenapine - Open Label|Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
41116168|NCT00150176|DRUG|Placebo - Double Blind|Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
41116169|NCT00150176|DRUG|Asenapine - Double Blind|Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
41116170|NCT02429570|DRUG|Meclofenamate|
41116171|NCT01186198|DEVICE|MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
41116172|NCT01484353|BEHAVIORAL|Coronary Health Improvement Project Program|The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
40752722|NCT04169412|DIAGNOSTIC_TEST|Blood Collection|Blood Gas Analysis using Stat Profile pHOx® Series (nova biomedical, Waltham, U.S.) and Enzym-linked Immunosorbent Assay (ELISA) using Bio-Rad (Bio-Rad Laboratories, California, U.S.)
40752723|NCT03748212|DRUG|D935 Cap. 1T|single oral administration under fed condition
40752724|NCT03748212|DRUG|CKD-385 Tab. 1T|single oral administration under fed condition
41116173|NCT04746131|DRUG|IMM0306|IMM0306 is an bi-specific antibody
41116174|NCT00506298|DRUG|bezafibrate + diflunisal|bezafibrate + diflunisal
41116175|NCT00506298|DRUG|bezafibrate + placebo|bezafibrate + placebo
41116176|NCT05325853|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
41116177|NCT05325853|DRUG|Proparacaine Ophthalmic|0.5% Proparacaine Hydrochloride
41116178|NCT02167867|DEVICE|Lay End Users|Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.
41116179|NCT02167867|DEVICE|Treatment Subject Group|Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
41116180|NCT05264870|DRUG|Norepinephrine|treatment of postspinal hypotension
41116181|NCT05264870|DRUG|Norepinephrine|treatment of postspinal hypotension
41116182|NCT00005027|DRUG|becatecarin|
41116183|NCT05475405|OTHER|scapulothoracic mobilization|Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula.
41116184|NCT05475405|OTHER|IASTM|"Restrictions and myofascial adhesions should be assessed prior to treatment along both sides using IASTM tool and a lubricant.~Once restrictions are assessed, fanning strokes at 45 degree angles to skin should be applied using the tool. This technique should be performed for 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers for each muscle group in scapulothoracic region. Total time for IASTM application is 10 mints. Upon completing all this patient should be given a home plan consisting of 2 different self-stretches targeting levator scapulae and upper trapezius"
41116185|NCT03087578|OTHER|electroacupncture|Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
41116186|NCT03087578|DRUG|Mirabegron 50 MG [Myrbetriq]|Patients will receive 50 mg of mirabegron daily for 6 weeks.
41116187|NCT00117702|DRUG|Tacrolimus|day 0-100, then taper
41116188|NCT00117702|DRUG|Everolimus|day 0-56
41116189|NCT04404686|DRUG|Indomethacin|Per vagina administration of 100 mg followed by a second 100 mg dosage the following day
41116190|NCT04404686|DRUG|Nifedipine|Per os administration according to current protocol of 20mg each 20 minutes for 1 hour followed by 20 mg q8 for 48 hours.
41116191|NCT04425629|DRUG|casirivimab+imdevimab combination therapy|Administered intravenously (IV) single dose
41116192|NCT00396513|DRUG|Simvastatin|
40752725|NCT05718336|OTHER|Integrated care|multi-discipline care program
41116193|NCT00396513|DRUG|Simvastatin and Metformin|
41116194|NCT00396513|DRUG|Metformin|
41116195|NCT03199209|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about healthy lifestyles
40752726|NCT00826293|PROCEDURE|Stabilization belt|Patients receive true stabilization.
40752727|NCT00826293|PROCEDURE|Stabilization belt|Patients receive sham stabilization.
40752728|NCT04354688|DEVICE|T3 Certain Tapered Implant|Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
41116196|NCT03199209|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about healthy homes
40752729|NCT01467284|BEHAVIORAL|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
41116197|NCT03199209|BEHAVIORAL|Patient Visit|Attend study visit with research staff
41116198|NCT03199209|OTHER|Questionnaire Administration|Ancillary studies
41116199|NCT03199209|OTHER|Text Message|Receive information about healthy lifestyles
41116200|NCT03199209|OTHER|Text Message|Receive texts about healthy homes
41116201|NCT00478478|PROCEDURE|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
41133466|NCT00348361|DRUG|Fluticasone Propionate|
41133467|NCT03261466|DRUG|Bifidobacterium breve BR03 and Bifidobacterium breve B632|
41133468|NCT03261466|DRUG|Placebos|
41133469|NCT06397586|OTHER|Routine volleyball|MOtor imagery
41133470|NCT03584074|DRUG|Pregabalin 75mg|Orally taken twice daily for 8 weeks
41133471|NCT03584074|DRUG|Celebrex 200Mg Capsule|Orally taken once daily for 8 weeks
41446247|NCT00253305|DRUG|Organogel of terbinafine, 6%|
41116202|NCT03677349|PROCEDURE|neurorrhaphy|"During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1."
41116203|NCT01256736|DRUG|Tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
41116204|NCT01256736|DRUG|DMARDs|DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
41116205|NCT05793723|DIAGNOSTIC_TEST|Pulmonary function testing device|Patients will undergo pulmonary function tests with the Exhalyzer D (Ecomedics, Switzerland) device. This device consists of 1) an ultrasonic flow measuring system for measuring flow, volume and molecular mass, 2) a nitrogen washout system to measure functional residual capacity (FRC) and other indices, 3) a carbon dioxide infrared measurement device for monitoring the level of carbon dioxide in exhaled breath.
41116206|NCT06169735|DRUG|Indocyanine green|ICG Administration: All enrolled patients with scheduled thyroidectomy or parathyroidectomy will receive a standard cervical incision that afford access to either side of neck. Following sufficient exposure of thyroid, 25 mg of indocyanine green (ICG), reconstituted in 10 ml of sterile water, will be administered intravenously. A dosage of 1 ml of this solution will be injected into a peripheral IV line, followed by a 5 ml flush of normal saline to ensure the propagation of the dye within the vascular compartment.
41116207|NCT06169735|DEVICE|SPY Portable Handheld Imaging|Fluorescent Imaging: Approximately 30 seconds post-administration, the parathyroid glands are expected to exhibit fluorescence under near-infrared imaging. The emitted fluorescence is anticipated to persist for approximately 20 minutes, allowing ample time for intraoperative evaluation of parathyroid viability and perfusion
41116208|NCT03264742|OTHER|Ghrelin|The patients are assigned within the scope of the admission according to emergency to the treatment and clarification on the Stroke Unit of the KSW. There the patients are enclosed in the study and are examined according to the draught on the Stroke Unit within the scope of the complex treatment. The inclusion of the patients occurs after clarification and in the consent of the patients. In the morning after the admission day the decrease of the first blood test occurs within the scope of the blood sample as a matter of routine to be carried out for the Ghrelinbestimmung. Also 48 H occurs after the first withdrawal and 3 months after the stroke a blood sample to the regulation of Ghrelin.
41116209|NCT05814328|OTHER|Transitional Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
41116210|NCT06196177|DRUG|Levosimontane injection|Levosimendan injection was given once intravenously with a micro-pump: 12.5mg levosimendan injection was diluted with 5% glucose injection to 50ml at the initial pump speed of 2ml/h for 24h.
41116211|NCT04581317|OTHER|meals|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.
41116212|NCT04581317|OTHER|AES 8 basic usage|For the second 6 weeks, participants will continue to have meal deliveries and will now have the AES 8 device which can be used by the cognitively impaired participant and their caregiver. AES 8 devices will be installed in participant's homes by the study team and participants will be given basic instructions on using the device as well as a one-page handout that will include instructions on how to use and maintain privacy with their device. The study staff will continue to call twice a week to ask the 5 questions. At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
41116213|NCT04581317|OTHER|AES 8 advanced usage|In the third 6 weeks, the participants will continue to have meal deliveries and the AES 8 will be upgraded to provide an active intervention by asking the twice a week 5 questions through the device. The questions should be answered by the cognitively impaired older adult using the device, though the caregiver can still use the device for other basic services. The participant will be able to answer the questions verbally or by touch screen options displayed on the device.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
41116214|NCT02658370|DEVICE|animated home-based exercises (Wii-fit)|
41116215|NCT02658370|PROCEDURE|conventional home-based exercise program|
41116216|NCT03806907|RADIATION|Computed tomography lung subtraction iodine mapping|Subtraction of the non-contrast CT from the contrast-enhance CTPA produces the CT-LSIM
41116217|NCT01867632|DEVICE|Acellular Dermal Matrix|
41116218|NCT04530747|DRUG|Metformin + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing metformin extended release (XR). Metformin XR dosing will be 500 mg (1 x 500 mg) every evening (qPM) during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
41116219|NCT04530747|DRUG|Placebo oral capsule + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
41116220|NCT00332917|DRUG|Pardoprunox|12-42 mg
41116221|NCT04257136|DRUG|VBI-S|VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension.
41116222|NCT03559348|DRUG|chemotherapy: TS-1, Leucovorin and Gemcitabine|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
41116223|NCT04275245|DRUG|Meplazumab for Injection|humanized MAb against CD147
41116224|NCT00957411|BIOLOGICAL|cetuximab|Given IV
41116225|NCT00957411|DRUG|cisplatin|Given IV
41116226|NCT03484065|OTHER|Questionnaire quality of life|
41116227|NCT06107582|OTHER|data collection|The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
41116228|NCT00310726|OTHER|abrupt weaning at 4 months|abrupt weaning at 4 months
41116229|NCT00310726|OTHER|Continued exclusive breastfeeding|Continued exclusive breastfeeding
41116230|NCT04217512|DRUG|Pantoprazole low dose|Pantoprazole 0.6 mg/kg
41116231|NCT04217512|DRUG|Pantoprazole high dose|Pantoprazole 1.6 mg\\kg
41116232|NCT04217512|OTHER|Standard hydration|Standard hydration alone
41116233|NCT04217512|DRUG|Cisplatin|Cisplatin
41116234|NCT00483093|DRUG|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
41116235|NCT00483093|DRUG|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
41116236|NCT01677936|OTHER|Raisins|1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm
41116237|NCT01677936|OTHER|Snacks|100 calorie snack packs will be administered to the subjects in the snack group
41116238|NCT03174171|DRUG|Everolimus 0.75 mg|Everolimus 0.75 mg b.i.d. orally for 14 days.
41116239|NCT06376383|PROCEDURE|Tonsillectomy|Standard tonsillectomy
41116240|NCT06376383|PROCEDURE|Tonsillotomy|Tonsillotomy
41116241|NCT06396611|BEHAVIORAL|Exercise Training as Intervention|Supervised Exercise Training as an Intervention using Resistance Training.
41116242|NCT04575740|DEVICE|PAP|Positive airway pressure to treat sleep apnea
41116243|NCT05486897|OTHER|None, pure observational study|None, pure observational study
41116244|NCT03320434|DRUG|PRT-2761 0.5%|Six drops in each eye over a 17 day period.
41116245|NCT03320434|DRUG|PRT-2761 1%|Six drops in each eye over a 17 day period.
41116246|NCT03320434|DRUG|Patanol|Six drops in each eye over a 17 day period.
41116247|NCT03320434|DRUG|Pred-forte|Four drops in each eye over a 3 day period.
41116248|NCT03320434|DRUG|PRT-2761 0%|Six drops in each eye over a 17 day period.
41116249|NCT04610671|DRUG|CG0070|CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with 5% DDM and normal saline.
41116250|NCT04610671|DRUG|Nivolumab|Two neoadjuvant doses of nivolumab 480 mg Q4W (every 4 weeks) for 2 doses (week 2 and 6)
41116251|NCT05944003|PROCEDURE|Resuscitative thoracotomies|Resuscitative thoracotomies is an effective life saving measure in appropriate populations \[1-8\]. Unfortunately, when used outside of these populations the mortality rate is typically more than 90% \[1-8\]. Western Trauma Association and Eastern Association for the Surgery of Trauma have provided guidelines for which trauma patients are a candidate for RT \[1-
41116252|NCT00471627|PROCEDURE|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
41116253|NCT03524534|OTHER|Telephone Call|A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.
41116254|NCT03524534|OTHER|In-Person Primary Care Clinical Follow-Up Visit|This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.
41116255|NCT01547546|DRUG|GDC-0084|Multiple doses
40752730|NCT01467284|BEHAVIORAL|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
40752731|NCT01096186|DRUG|IPX066 95 mg|23.75 - 95 mg CD-LD capsules
40752732|NCT01096186|DRUG|IPX066 145 mg|36.25 - 145 mg CD-LD capsules
41116256|NCT03383146|DRUG|Placebo|Placebo injected subcutaneously twice daily.
41116257|NCT03383146|DRUG|Relamorelin|Relamorelin 10 μg injected subcutaneously twice daily.
41116258|NCT01376089|DRUG|Iodixanol|Iodixanol 320 mg I/mL as a single iv. administration.
40926196|NCT04248959|BEHAVIORAL|Multimodal prehabilitation|"Multimodal Prehabilitation~* Aerobic exercise~  * Home-based, high-intensity interval training (HIIT), 2 days/week~ * Home-based, moderate-intensity continuous training (MICT), 2-3 days/week~* Resistance exercise~  * Home-based, moderate-intensity resistance training, 2-3 d/wk, all major muscle groups (working around tumour-related deficits), 8-10 exercises, 12-15 repetitions, resistance bands and body weight based~* Nutrition~  * Protein intake 1.2-1.5 g/kg body weight/day in compliance with European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines~* Stress management~  * Daily mindfulness practice, 20 min/session, guided by audio file created at Mount Sinai Hospital"
40926197|NCT04184986|DIAGNOSTIC_TEST|dry blood test|screening test for Fabry disease
41116259|NCT01376089|DRUG|Iopamidol|Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
41116260|NCT00441636|DEVICE|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
41116261|NCT06492070|OTHER|Best Practice|Undergo standard of care
41116262|NCT06492070|DRUG|Cilostazol|Given PO
41116263|NCT06492070|DEVICE|Cryocompression Therapy|Undergo cryocompression therapy
41116264|NCT06492070|DRUG|Paclitaxel|Given by infusion
41116265|NCT06492070|OTHER|Quality-of-Life Assessment|Ancillary studies
41116266|NCT00166283|BEHAVIORAL|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
41116267|NCT00166283|BEHAVIORAL|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
41116268|NCT04821219|OTHER|Treatment prediction PDT platform|PDT will be generated and response to various chemotherapies and radiation will be investigated. Actionable targets will be identified and response to the target drug will be assessed and compared to the conventional treatment options.
40752733|NCT01096186|DRUG|IPX066 195 mg|48.75 - 195 mg CD-LD capsules
40752734|NCT01096186|DRUG|IPX066 245 mg|61.25 - 245 mg CD-LD capsules
40752735|NCT03012152|PROCEDURE|Standard conservative breast surgery|
41116269|NCT05924958|DRUG|Eprolidone|This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
41116270|NCT02886286|DRUG|Bupivacaine|Patient-activated intrathecal bolus for incident pain
41116271|NCT02886286|DRUG|Opioid|Patient-activated intrathecal bolus for incident pain
41116272|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Aloe Vera with Crocus (saffron)|Dietary Supplement:Aloe Vera with Crocus (saffron) with 1L of Aloe Vera with Crocus (saffron) 1 glass bottle per 15 days
40752736|NCT03012152|PROCEDURE|Oncoplastic breast surgery|
40752737|NCT05386836|DEVICE|Pulse oximeter validation population|Evaluation of the SpO2 accuracy performance of the Sunrise Sensor 2 placed at the tip of the chin during non-motion conditions over the range of 70-100% by comparison to SaO2 values determined from arterial blood sample specimen analyzed by a CO-oximeter.
40752738|NCT03017755|OTHER|Survey for Patients Treated for Scoliosis and ther Families|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and ther Families
40752739|NCT00801268|DRUG|tripterygium wilfordii|TW，60mg/d
40752740|NCT00801268|DRUG|Emodin|100mg/d
40752741|NCT04040673|PROCEDURE|thyroid lobectomy|routine surgical removal of thyroid for biopsy
40752742|NCT04040673|DEVICE|Raman spectroscopy probe measurement|The measurement of Raman spectra from the excised tissue
40752743|NCT01399086|DRUG|Fulvestrant|250mg on d1,15,29 or 250mg on d1 q28days
40752744|NCT04849000|DRUG|SHR-1209|SHR-1209
40752745|NCT04849000|DRUG|SHR-1209 Placebo|SHR-1209 Placebo
40752746|NCT00908388|DEVICE|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
40752747|NCT03987880|PROCEDURE|4.0 mm treatment|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.
40752748|NCT03987880|PROCEDURE|3.5 mm treatment|PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
40752749|NCT00529581|DRUG|C105|
41116273|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Aloe Vera (simple)|Dietary Supplement:Aloe Vera (simple)with 1L of Aloe Vera 1 glass bottle per 15 days
41116274|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Mediterranean Diet|Dietary Supplement:Mediterranean dietary protocol Intervention:mediterranean diet
41116275|NCT06209476|DIAGNOSTIC_TEST|Experimental|Eligible subjects with sphere component of the subjective spherocylindrical refraction between +1.50 to -6.00D (inclusive) and 2.00D or less astigmatism in the right eye will be unilaterally measured with the WAM-5500 autorefractor by 3 testers.
41116276|NCT06047522|DEVICE|Casque Lumeen|Participants will take part in virtual reality sessions via headset. They will benefit from a before/after evaluation, and a 3-week intervention where they will have 1 virtual reality session per week.
41116277|NCT02685488|DEVICE|Transcranial Ultrasound Power|Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
41116278|NCT02685488|DEVICE|Transcranial Ultrasound Sham|"Transcranial ultrasound will be used without power for a sham condition."
41116279|NCT02301208|DRUG|Nedaplatin|Nedaplatin combine with IMRT
41116280|NCT02301208|DRUG|Cisplatin|Cisplatin combine with IMRT
41116281|NCT02935998|DRUG|Ziprasidone|During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score\>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
41116282|NCT01926678|OTHER|Swedish massage therapy|
41116283|NCT01926678|OTHER|Light touch therapy|
40752750|NCT01603251|DRUG|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
40752751|NCT01603251|DRUG|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
41116284|NCT05817370|BEHAVIORAL|Enhanced Training on screening and treatment of HSIL (e-STH)|Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
41116285|NCT03746665|BIOLOGICAL|meningococcal serogroup A conjugate vaccine|Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.
41116286|NCT04825366|DEVICE|Continuous glucose monitoring device|Participants will have to wear their continuous glucose monitoring device throughout the study.
41116287|NCT04825366|OTHER|Gold method|The Gold method will be used to assess impaired awareness of hypoglycemia
41446248|NCT03049748|DEVICE|Mobile phone app (VAD Care App)|"VAD Care App is a novel self-management tool being tested for patients with implantable LVADs. The app has daily push notifications (alerts), cues for daily self-management tasks, two-way communication using text messages and videoconferencing (virtual clinic), and links to LVAD self-management skills and videos easily accessible for self-management skill review."
40752752|NCT01603251|DRUG|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
40752753|NCT05610839|BEHAVIORAL|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
40926198|NCT05334056|DRUG|Cocaine Nasal|2 ml of 4% cocaine given as a nasal spray immediately prior to nasal intubation
40752754|NCT03638167|BIOLOGICAL|EGFR806-specific chimeric antigen receptor (CAR) T cell|Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
41116288|NCT04825366|OTHER|Clarke questionnaire|The Clarke questionnaire will be used to assess impaired awarness of hypoglycemia
41446249|NCT03049748|OTHER|Usual LVAD Care|Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.
41446250|NCT06146374|OTHER|Placebo for SLV213|Microcrystalline cellulose in a size 1 orange hard gelatin capsule.
41116289|NCT04825366|OTHER|Edinburgh Hypoglycemia Symptom Scale|The Edinburgh Hypoglycemia Symptom Scale will be used to assess symptoms of hypoglycemia
41116290|NCT04825366|OTHER|BAPAD questionnaire|The BArriers to Physical Activity in type 1 Diabetes (BAPAD) questionnaire will be used to assess barriers of physical activity
41116291|NCT04825366|OTHER|Hypoglycemia Fear Survey II|The Hypoglycemia Fear Survey II will be used to assess fear of hypoglycemia
41116292|NCT04825366|OTHER|Physical activity questionnaire|The International Physical Activity Questionnaire will be used to assess physical activity practice
41116293|NCT04825366|OTHER|Well-being|The WHO-5 well-being index will be used to assess well-being.
41116294|NCT04825366|OTHER|Treatment satisfaction|The Diabetes Treatment Satisfaction Questionnaire will be used to assess treatment satisfaction.
41116295|NCT04825366|OTHER|Hypoglycemia diary|Participants will be asked to record in a diary treatments for hypoglycemic events
41116296|NCT04825366|DEVICE|Piezo RxD|Participants will be asked to wear a pedometer throughout the study
41116297|NCT04825366|DEVICE|Heart rate monitor|During training sessions, participants will be asked to wear a heart rate monitor
41116298|NCT04825366|OTHER|Exercise diary|Before each training session, participants will be asked to note in a diary their glucose levels, if they have taken a snack or not and if insulin was administered. After each training session, participants will be asked to note that same information. In addition, they will be asked to note their bedtime blood glucose, if they have taken a bedtime snack and if adjustment to insulin doses was made.
41116299|NCT00703950|PROCEDURE|cup feeding|Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
41116300|NCT00703950|PROCEDURE|bottle feeding|bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
41116301|NCT01471145|DRUG|Naltrexone|naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
40752755|NCT04501575|OTHER|Osteopathic Consultation|A consultation including case history taking, physical assessment, osteopathic manual treatment, exercise prescription, and postural advice.
41116302|NCT01909167|BEHAVIORAL|Online Cognitive Behavioral Therapy (CBT)|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
41116303|NCT01909167|OTHER|Treatment as usual|Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
41116304|NCT02749968|DRUG|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
41116305|NCT02749968|DRUG|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
41116306|NCT03592069|DRUG|10 day concomitant regimen|10 Day Concomitant Hp therapy Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid
41116307|NCT03592069|DRUG|14 day hybrid regimen|14 Day Hybrid Hp therapy Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days.
40752756|NCT04501575|OTHER|Sham Osteopathic Consultation|A sham treatment using light touch on bony structures, no diagnosis, advise or prescriptions
40752757|NCT01411371|PROCEDURE|Catheter ablation of persistent atrial fibrillation|Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).
40926199|NCT00388427|DRUG|Dasatinib (BMS-354825)|100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
40926200|NCT00388427|DRUG|Cetuximab (Erbitux, C225)|Loading dose of IV 400 mg/m\^2 on Day 1 of Cycle 1; IV 250 mg/m\^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
40926201|NCT04137107|DRUG|Oxaliplatin|Given standard of care oxaliplatin
41116308|NCT02502396|OTHER|Retrospective Chart Review|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
41116309|NCT01070069|DEVICE|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
41116310|NCT01070069|DEVICE|SEVAR (IntuiTrak)|Standard vascular exposure for access prior to EVAR
40752758|NCT01411371|DRUG|Medical treatment alone|Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
40752759|NCT03565588|BEHAVIORAL|Education session with fixed incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants assigned to receive fixed incentives will receive payment through mobile payments. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
40926202|NCT04137107|DRUG|Duloxetine Hydrochloride|Given PO
41116311|NCT01070069|DEVICE|PEVAR (Prostar XL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
40926203|NCT04137107|DRUG|Duloxetine|Given PO
40926204|NCT04137107|OTHER|Quality-of-Life Assessment|Ancillary studies
41116312|NCT02115139|DRUG|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
41116313|NCT06335654|DIAGNOSTIC_TEST|artificial intelligence system|The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. After endocytoscopic observation, the artificial intelligence system will be open and display the predictive result. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue. After endocytoscopic observation, the artificial intelligence system will be open again and display the predictive result.
41116314|NCT03156595|BEHAVIORAL|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
41116315|NCT03156595|BEHAVIORAL|Hypnosis sessions|Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
41116316|NCT03901937|DRUG|ω-3 polyunsaturated fatty acid|CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).
41116317|NCT03901937|PROCEDURE|Intestinal surgery for Crohn's Disease|Patients receive bowel resection due to complications of Crohn's Disease
41116318|NCT00944372|DRUG|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
41116319|NCT00393848|DRUG|Essential amino acid supplement|15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
41116320|NCT00393848|DRUG|Ketoconazole|200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
41446251|NCT06146374|DRUG|SLV213|SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
41446252|NCT01958450|PROCEDURE|Er:YAG laser|acne scar treatment using Er:YAG laser
40926205|NCT04137107|OTHER|Questionnaire Administration|Ancillary studies
40926206|NCT04137107|OTHER|Placebo|Given PO
41116321|NCT00393848|DRUG|Placebo|Placebo for Ketoconazole
41116322|NCT04961749|OTHER|Whole body vibration training|Whole-body vibration training applies a vibration stimulus to an individual as they are standing on a side-alternating platform. The vibration creates small muscle contractions in the lower extremity musculature which has been shown to improve function and ambulatory function.
41116323|NCT01859416|DIETARY_SUPPLEMENT|Oral nutritional supplement|
41116324|NCT04218266|DRUG|BAY2433334|Tablet, taken orally once a day.
41116325|NCT04218266|DRUG|Apixaban|Capsule, taken orally twice a day.
41116326|NCT04218266|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
41116327|NCT04218266|OTHER|Apixaban matching placebo|Capsule, taken orally twice a day.
41116328|NCT02703701|BEHAVIORAL|Physician at triage|A physician embedded at triage
41116329|NCT02703701|OTHER|Usual Care|No physician at triage
41116330|NCT01613274|OTHER|gum chewing|gum chewing three times a day for up to 20 minutes
41116331|NCT01613274|OTHER|no gum chewing|no gum chewing
41116332|NCT06331611|DEVICE|TOF monitoring|Reversal with Sugammadex will be based on TOF monitoring
41116333|NCT03195426|PROCEDURE|distal nerves blocks group|"* ICB: US probe will be placed just below clavicle inferior to site of needle entry. Following identification of axillary artery and cords, the needle will be advanced posterior to axillary artery. 20 cc of Ropivacaine 0.375% will then be deposited in a U-shaped distribution posterior and to each side of the axillary artery.~* SSNB will be performed by locating the brachial plexus and the departure of the suprascapular nerve from the superior trunk under the inferior belly of the omohyoid muscle by sliding the transducer distally and then injecting 5 mL of ropivacaine 0.375%.~* SCNB will be performed injecting 5 mL of ropivacaine 0.375% in the intermuscular plane between the sternocleidomastoid and scalene muscles using a lateral to medial in-plane technique."
41446253|NCT01958450|PROCEDURE|Bipolar radiofrequency with diode laser|acne scar treatment with bipolar radiofrequency combined with diode laser
41116334|NCT03195426|PROCEDURE|Diaphragmatic function assessment|"Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.~This a pain free and safe procedure, that we usually perform in patients at risk of respiratory failure."
41116335|NCT00536341|DRUG|lenalidomide|2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6
41116336|NCT00536341|DRUG|Rituximab|375 mg/m2 Cycle 1 (split over Day 1 \& Day 2); 500 mg/m2 Day 1 of Cycles 2-6
41116337|NCT00536341|DRUG|Fludarabine|25 mg/m2 on Days 1, 2, and 3
41116338|NCT03635151|BEHAVIORAL|Telephone Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide that we developed and 8 weekly calls from a nurse. The nurse will call again a month later. The TASK III nurse will help you assess your needs and concerns, build your skills as a caregiver, and refer you to community resources.
41116339|NCT03635151|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure and 8 weekly calls from a nurse. The nurse will call again a month later. The ISR nurse will provide information, support, and referral to community resources.
41116340|NCT02070666|BEHAVIORAL|Protective mechanical ventilation|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~* Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure \< 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~* Fraction of inspired oxygen inspired oxygen fraction (FiO2) \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cmH2O"
41116341|NCT02070666|BEHAVIORAL|Control group|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~* Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~  · FiO2 \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cm H2O."
41116342|NCT02070666|OTHER|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
41116343|NCT00910767|DEVICE|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
41116344|NCT00910767|DEVICE|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
41116345|NCT04861532|DIAGNOSTIC_TEST|Imaging|MRI scanning using new protocols
41116346|NCT02368171|OTHER|measure exhaled carbon monoxide and nitric oxide|
41116347|NCT03381781|DRUG|Decitabine|20mg/m\^2,d1-5,ivgtt,28days as a duration
41116348|NCT03381781|DRUG|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
41116349|NCT03381781|DRUG|Cytarabine|15mg/m\^2,hypodermic injection,q12h,d1-7
41116350|NCT06106555|BEHAVIORAL|Dialectibal Behaviour Therapy|Standard Dialectical Behaviour Therapy of up to 12 months as described Professor Linehan
41116351|NCT03086161|BEHAVIORAL|Interpersonal Psychotherapy|Six individual 1-hour sessions delivered over the course of pregnancy to address interpersonal problems areas that may lead to emotional eating, physical inactivity, and increased stress during pregnancy, which are drivers of excess weight gain in pregnancy
41116352|NCT03086161|BEHAVIORAL|Treatment-as-usual|Routine prenatal care as part of multidisciplinary adolescent pregnancy clinic, including medical (ob/gyn), nutrition, and social work
41116353|NCT03516435|DEVICE|Parasacral transcutaneous electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Parasacral transcutaneous electrical stimulation：Clinic using 2 superficial 3.5 cm electrodes placed on each side of S3 and S4.
41116354|NCT03516435|DEVICE|Intravaginal electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Intravaginal electrical stimulation：The electrode plug for vaginal plug was cylinder-formed with ring-formed placed into vaginal.
41116355|NCT03553212|RADIATION|tomotherapy|20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
41116356|NCT04423146|OTHER|The evocation of reproducible motor evoked potential according to the different BIS levels|The evocation of reproducible motor evoked potential and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
41116357|NCT01432613|PROCEDURE|MRI-oriented muscle biopsy|Orientation of muscle biopsy according to the MRI results
41116358|NCT03565939|BIOLOGICAL|Trichuris suis ova|Eggs from the pig whipworm
41116359|NCT03565939|BIOLOGICAL|Placebo|Solution without TSO
41116360|NCT03802149|DRUG|Ulipristal Acetate|90mg Ulipristal Acetate 18-24-hours prior to dilation and evacuation
41116361|NCT05184361|BEHAVIORAL|Intermittent energy restriction (IER)|"Both groups will be accompanied by a registered dietitian in order to provide an individual and personalized diet plan that will suppress the respective daily requirements for each phase. Macronutrient distribution will be the following: 35% protein, 35% carbohydrate and 30% fat.~Daily energy requirements (DER) will be calculated by multiplying measured RMR (through indirect calorimetry) by physical activity level (PAL), assessed by accelerometry.~In order to achieve a neutral EB, 100% of their daily energy requirements (DER) will be prescribed for each participant. For both groups, an energy restriction of 33% of one's DER will be created. The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.~The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks."
41116362|NCT05184361|BEHAVIORAL|Continuous energy restriction (CER)|A dietary plan comprising 67% of DER will be prescribed to the CER group. Participants will be asked to follow this plan in a total of 16-weeks, without interruptions.
41116363|NCT04616911|PROCEDURE|Rerouting seton|Excision of superficial fistula tract and placment of seton with rerouting of the fistula tract around the internal anal sphincter
41116364|NCT04616911|PROCEDURE|LIFT|Ligation of the intersphincteric fistula tract
41116365|NCT02988037|BEHAVIORAL|A-DBT-A|Adapted Dialectical Behaviour Therapy for Adolescents
41116366|NCT04042545|DRUG|PPP001|1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device
41116367|NCT04042545|DRUG|Placebo|1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
41116368|NCT01828775|OTHER|palliative care|Receive early PCI
41116369|NCT01828775|OTHER|palliative care|Receive delayed PCI
41116370|NCT01828775|PROCEDURE|quality-of-life assessment|Ancillary studies
41116371|NCT01828775|OTHER|survey administration|Ancillary studies
41116372|NCT01394510|DRUG|N-acetylcysteine|600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
41116373|NCT05215925|DRUG|HLX07+carboplatin+pemetrexed|HLX07 1500mg q3w+carboplatin+pemetrexed
41116374|NCT05215925|DRUG|HLX07+docetaxel|HLX07 1500mg q3w+docetaxel
41116375|NCT05215925|DRUG|HLX07|HLX07 1500mg q3w
41116376|NCT04575493|DIETARY_SUPPLEMENT|Crano-cure|Research literatures have revealed that Tribulus terrestris (Gokhro), Vaccinium macrocarpon (karonda), Cuminum cyminum (Zeera sufaid), Rheum emodi (Revand chini) and Piper cubeba (Kabab chini) are important therapeutic plants. Many pharmacological researches have been done on these plants. For instance, antioxidant, antiseptic, anti-microbial, anti-bacterial, anticancer etc. In the above claims and facts, the study is conducted to formulate and evaluate the polyherbal capsule and to find out the most effective combination having anti-bacterial activity.
41116377|NCT04575493|DRUG|Ciprofloxacin 500 mg|Being a standard drug as antibiotic and will be used in Control group.
41116378|NCT00727922|DRUG|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
40752760|NCT03565588|BEHAVIORAL|Education session with lottery incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants will participate in a lottery with prizes equivalent in expected value to the fixed incentives. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
41116379|NCT04593810|PROCEDURE|INTELLiVENT-ASV|INTELLiVENT-ASV is activated as soon possible. The sensors for ETCO2 and SpO2 are connected and activated. Patient's gender and height are set on the ventilator and patient condition is chosen if applicable.
41116380|NCT04593810|PROCEDURE|CONVENTIONAL VENTILATION|Conventional ventilation consists of VCV or PCV and PSV, depending on patient's activity. None of the semi or fully automated modes of ventilation is allowed at any time.
41116381|NCT00401206|DRUG|dexmedetomidine|
41116382|NCT02456506|RADIATION|Hyperfractionated IMRT|
41116383|NCT02456506|RADIATION|Conventional Fraction IMRT|
41116384|NCT05263336|DRUG|Verdye Green|intraoperative iv application of indocyanic green for visualisation of blood supply to the anastomosis after rectal cancer recection
41116385|NCT03164408|PROCEDURE|Orthopaedic Implant Removal|
41116386|NCT06107894|BIOLOGICAL|Tumor-infiltrating lymphocytes|After NMA Lymphodepletion, autologous TILs will be intravenous infused into patients.
41116387|NCT06107894|DRUG|IL-2|IL-2 will be subcutaneous administrated for 14 days following TILs infusion.
41116388|NCT01958866|DRUG|Tinospora Crispa-extract Product|
41116389|NCT01958866|DRUG|Acetaminophen|
41116390|NCT01958866|OTHER|Placebo|
41116391|NCT06150287|OTHER|Florajen Digestion|Florajen Digestion is a probiotics. One probiotics capsule contains 15 billion Colony Forming Unit (CFU) of live microorganisms. No live microorganisms are present in the placebo capsules.
41116392|NCT02807493|DEVICE|Occlusal Support Device|Bite plate
41116393|NCT02807493|OTHER|Control|Control group
41116394|NCT05972915|DIAGNOSTIC_TEST|Separation sign|The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta.
41116395|NCT03434652|DEVICE|Percutaneous neurostimulation|Auricular percutaneous neurostimulation
41116396|NCT04906161|DIAGNOSTIC_TEST|Vitamin D and calcium levels|Mini VIDAS® compact multiparametric immunoanalyzer for vitamin D analysis (BIOMERIEUX- France)
41116397|NCT05815797|DRUG|SDD formula|SDD formula consists of 23 herbal medicines
41116398|NCT05815797|DRUG|Placebo|Placebo
41116399|NCT02512965|RADIATION|20 Gy in 5 fractions|
41116400|NCT02512965|RADIATION|Conventional SBRT: 24 Gy in 2 fractions|
41116401|NCT03200626|PROCEDURE|Autologous hematopoietic cell transplant|Autologous hematopoietic cell transplant
41116402|NCT01000480|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
41116403|NCT01000480|DRUG|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
41116404|NCT01000480|RADIATION|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
41116405|NCT00457275|DRUG|MK0653, ezetimibe / Duration of Treatment: 4 Weeks|
41116406|NCT01499771|DRUG|Atorvastatin|80 Mg tablets
41116407|NCT01760564|DRUG|Miglustat|miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
41116408|NCT05000216|BIOLOGICAL|Moderna mRNA-1273|Administration: One dose administered intramuscularly.
41116409|NCT05000216|BIOLOGICAL|BNT162b2|Administration: One dose administered intramuscularly.
41116410|NCT05000216|BIOLOGICAL|Ad26.COV2.S|Administration: One dose administered intramuscularly.
41116411|NCT05000216|DRUG|Continue IS (MMF or MPA)|Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
41116412|NCT05000216|DRUG|Continue IS (MTX)|Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
41116413|NCT05000216|BIOLOGICAL|Continue IS (B cell depletion therapy)|Participants will continue to take their prescribed immunosuppressive (IS) medications without alterations in schedule and dosing.
41116414|NCT05000216|BIOLOGICAL|Monovalent [B.1.351] CoV2 preS dTM-AS03|One dose administered intramuscularly
41116415|NCT05000216|DRUG|Withhold IS (MMF or MPA)|Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
40752761|NCT02245386|RADIATION|transperineal pelvic floor ultrasound|"Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
41116416|NCT05000216|DRUG|Withhold IS (MTX)|Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
41116417|NCT05000216|DRUG|Withhold IS (B cell depletion therapy)|Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.
41116418|NCT05000216|BIOLOGICAL|Moderna mRNA-1273, Bivalent|Administration: One dose administered intramuscularly.
41116419|NCT05000216|BIOLOGICAL|BNT162b2, Bivalent|Administration: One dose administered intramuscularly.
41116420|NCT01351493|DRUG|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
41116421|NCT01351493|DRUG|placebo|placebo Gel, once or twice per day, 12weeks
41116422|NCT03314675|DEVICE|BIOTRONIK CRT-D|Pre-specified follow-up and measurements
41116423|NCT00812526|PROCEDURE|Suction cup application|
41116424|NCT00812526|PROCEDURE|Squatting|
41116425|NCT00559286|DRUG|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
41116426|NCT03135184|DEVICE|HDL Therapeutics PDS-2 System|Delipidation of plasma HDL to reduce coronary atheroma
41116427|NCT00366873|PROCEDURE|Calcium absorption|formula with or without prebiotics
41116428|NCT00507689|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
41116429|NCT00507689|DRUG|Hepatitis B Immunoglobulin (HBIg)|HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
41116430|NCT02244060|OTHER|Priming effect from vignette|In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
41116431|NCT02761239|DEVICE|The NIM 3.0 Nerve Monitoring System|Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
41116432|NCT01044303|DRUG|Myfortic Escalation|Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
41116433|NCT03540381|OTHER|neoatherosclerosis|
41116434|NCT05095246|BIOLOGICAL|KB407 (Nebulization)|Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
41116435|NCT04075942|PROCEDURE|Atrophic Anterior Maxillary Ridges|Use of modified cortical shell technique grafted with customized Xenograft bone shell
41116436|NCT04722588|OTHER|Introducing clinical pharmacists to the interdisciplinary ED team.|There will be two shifts, one shift from 08.00 - 15.00 and one from 12.00 - 19.00. Consequently, the hours of the day when the majority of patients arrives, are covered and the pharmacist capacity is doubled during the busiest time of the day. Early mornings are normally relatively slowed paced and the pharmacist may use this time to follow up on patients admitted during the night (from 19.00 - 08.00), in particularly those who have been admitted to wards without an assigned pharmacist.
41116437|NCT05586711|DRUG|vaginal estradiol 10 μg|Vagifem® (estradiol), vaginal tablets
41116438|NCT05586711|DRUG|vaginal DHEA 6.5 mg|Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
41116439|NCT01599104|DRUG|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
41116440|NCT01599104|DRUG|Olmesartan|Olmesartan 20 mg capsule one daily
41116441|NCT01599104|DRUG|Placebo|Placebo to LCZ696 or Olmesartan
41116442|NCT02755181|BEHAVIORAL|Experimental|with functional imaging and behavioural measurements at baseline and 4 weeks
41116443|NCT03989986|BEHAVIORAL|iPeer2Peer Mentorship|Mentors and participants can have up to ten Skype calls over the course of 15 weeks.
41116444|NCT01210820|DEVICE|iFS™ Femtosecond Laser System|intrastromal arcuate cuts made with iFS™ femtosecond laser
41116445|NCT04227288|DRUG|Enstilar Foam|Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.
41116446|NCT00540748|DRUG|oxytocin|5 U i.v. during surgical abortion
41116447|NCT03621696|DRUG|Cisplatin|-100 mg/m\^2 intravenous push bolus (IVPB)
41116448|NCT03621696|RADIATION|Intensity modulated radiation therapy|-IMRT or IMPT can be used
41116449|NCT03621696|RADIATION|Intensity modulated proton therapy|-IMRT or IMPT can be used
41116450|NCT03621696|PROCEDURE|Surgery|-Standard of care
41116451|NCT03621696|OTHER|FACT-H&N|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
41116452|NCT03621696|OTHER|MD Anderson Dysphagia Inventory|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
41116453|NCT03621696|OTHER|University of Michigan Xerostomia Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
41116454|NCT03621696|OTHER|Scale of Subjective Total Taste Acuity|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
41116455|NCT03621696|OTHER|Neck Dissection Impairment Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
41116456|NCT04010006|PROCEDURE|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
41116457|NCT04010006|PROCEDURE|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
41116458|NCT06145984|BEHAVIORAL|Mindfulness|Participants receive a two-hour professional training to get familiar with the basic techniques of mindfulness. The training is given by a mindfulness professional and consists of psycho-education, instructions for mindfulness and guided practice. It focuses mainly on attending to stimuli such as breathing, external sounds or bodily sensations and becoming aware of where one's attention is. After the professional training, participants receive instructions about the audio application with which participants continue performing short exercises using the learned technique every day guided by an application on their smartphone customized for this research. Specifically, participants perform one short exercise (10 min) per day for in total six days. The exercises that are being performed are: attention to breathing part 1, attention to breathing part 2, attention to sounds, attention to bodily sensations, attention to thoughts, attention to emotions and feelings.
41116459|NCT06145984|BEHAVIORAL|Positive Fantasizing|"In a two-hour training session by a professional trainer, participants get familiar with the positive fantasizing technique. Participants receive psycho-education about the role of dysfunctional beliefs. The positive fantasizing technique starts with identifying dysfunctional beliefs and schema and subsequently fantasize about a positive fantasy belief. Participants are guided by the professional using imagery and experiencing thoughts and feelings that would be elicited when using their fantasy belief as if in an ideal world. After using imagery techniques, participants are asked, with help of the professional, to reflect on their experience during the fantasizing exercise and to think of how they could implement this fantasy belief more in their daily life, by adapting their fantasy belief into a more practical belief. After the training, participants are asked to perform one exercise per day using the fantasizing technique using a mobile application for six days in total."
41116460|NCT00251576|DRUG|A-Phase: tirofiban; Z-Phase simvastatin|
41116461|NCT00251576|DRUG|Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|
40752762|NCT05951842|DRUG|anesthetic method|Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.
41116462|NCT00251576|DRUG|Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|
41116463|NCT00251576|DRUG|Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|
41116464|NCT00251576|DRUG|Duration of Treatment: Z-Phase, 2 years.|
41116465|NCT06554327|DEVICE|Multiplex PCR|In the intervention group (Multiplex PCR performed and results communicated to the clinician), bronchoalveolar lavage will be examined directly after Gram staining by the laboratory, followed by quantitative culture. A multiplex PCR will be performed.
41453379|NCT05655169|PROCEDURE|Piezosurgery|One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.
41116466|NCT01012453|BEHAVIORAL|A randomised clinical trial of the effect of classification and individual counselling|The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.
41116467|NCT03610815|BEHAVIORAL|Screening, Brief Intervention, Referral to Treatment|Screening, Brief Intervention, Referral to Treatment
41116468|NCT03954301|DIAGNOSTIC_TEST|Anthropometric measures|Q, valgity angle, subtalar joint, medial longitudinal arch and hallux valgus angles were measured with a goniometer. The height from the ground of the navicula was calculated by caliper, using the Navicular drop test. Metatarsal width was also calculated with this device. Medial longitudinal arch angle, metatarsal width and nacivular drop tests were performed under weight-bearing and non-weight-bearing conditions.
41116469|NCT06112899|BEHAVIORAL|Nordic Hamstring Exercise|The NHE, also referred to as the nordic curl, is designed to improve eccentric strength of the hamstring muscles. Individuals start in a kneeling position, with the torso from the knees upward held rigid and straight. The training partner ensures that the individual's feet are in contact with the ground throughout the exercise by applying pressure to the player's heels/lower legs. The individual then lowers his upper body to the ground, as slowly as possible to maximize loading in the eccentric phase. Hands and arms are used to break his forward fall and to push him back up after the chest has touched the ground, to minimize loading in the concentric phase.The exercise protocol is planned as 5 sets of 8 repetitions and 2 minutes of rest between each set.
41116470|NCT04910555|OTHER|strong desire to void - cognitive task|Strong desire to void - cognitive task (verbal fluency)
41453380|NCT05655169|OTHER|Fixed orthodontic appliance|"After the levelling and alignment phase is completed, the rectangular stainless steel archwires (0.019 × 0.025) will be inserted, then after two weeks, the en masse retraction will be started via closed nickel-titanium coil springs applying 250 g of force per side."
40752763|NCT00118859|BEHAVIORAL|Integrative care for low back pain|
40752764|NCT00118859|BEHAVIORAL|Conventional treatment for low back pain|
40926207|NCT05721807|OTHER|functional magnetic stimulation|"When applying functional magnetic stimulation, the stress urinary incontinence program P2 stress was chosen. The first 20 min. current frequency was 35 Hz, modulation - rising amplitude (from 0 to maximum per second), total wave duration 12 s. active time 6 s., pause time 6 s. After 20 min. current frequency changed to 5 Hz, modulation and wave remained the same. After 2 min. current frequency changed to 35 Hz, modulation - amplitude, one-sided sinusoidal, wave remained the same. The total duration of the procedure was 30 min. A magnetic spring is installed at the bottom of the chair. During the treatment, each subject was instructed to sit on a chair so that the perineum was centered on the spring and that the subjects felt the contraction of the muscles. The intensity of the magnetic field was adjusted so as to feel comfortable during the study procedure (Vadalà et al., 2017)."
41116471|NCT02415140|OTHER|Rate of depression|
41116472|NCT00480077|DEVICE|Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )|OptiVol® Fluid status Monitoring with Cardiac Compass
41116473|NCT00422617|DRUG|Alefacept (Amevive)|
41116474|NCT02192606|DEVICE|Storz 3D Laparoscopy System|The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
41116475|NCT02192606|DEVICE|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
41116476|NCT02071836|BEHAVIORAL|Right Turns web application|
41116477|NCT02071836|BEHAVIORAL|Treatment as usual|
41116478|NCT00551980|BEHAVIORAL|Cognitive, Relaxation, Exercise Therapy|The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
41116479|NCT02861066|BEHAVIORAL|Mindfulness-based Intervention|MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
41116480|NCT01373398|DRUG|EO9(Apaziquone)|immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
41116481|NCT04882072|DRUG|Ustekinumab|Participants will receive IV infusion and SC injection of ustekinumab.
41116482|NCT04882072|OTHER|Placebo|Participants will receive IV infusion and SC injection of matching placebo.
41116483|NCT04882072|DRUG|Glucorticoid Taper Regimen|Glucocorticoid will be administered orally.
41116484|NCT00431704|DRUG|vinorelbine|25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients
41116485|NCT00431704|DRUG|carboplatin|AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
41116486|NCT00431704|DRUG|trastuzumab|8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
41116487|NCT03875963|OTHER|Antibiotic loaded bone filler|Defect management by placement of antibiotic loaded Stimulan as a bone void filler \[calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin\].
41116488|NCT04567355|BEHAVIORAL|Migraine Manager|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
41116489|NCT00826852|DRUG|docetaxel and carboplatin|weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
41116490|NCT03297346|OTHER|Cardiac imaging and circulating biomarkers|Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
41116491|NCT02271789|OTHER|problematic tooth|problematic tooth
41116492|NCT02624141|DRUG|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
41116493|NCT04107402|OTHER|Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay|Blood sample Urine Sample Pulmonary, hepatic and cardiac tissue from biopsy and autopsy
41116494|NCT05652933|DIAGNOSTIC_TEST|Software for identifying vessel occlusion, infarct volume and penumbra|Assessment of the AI tool software
41116495|NCT02577835|DEVICE|Ambulatory blood pressure monitoring|Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
41116496|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation|
41116497|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation|
41116498|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation|
41116499|NCT02206269|DEVICE|Alair System|The Alair system is used for doing bronchial thermoplasty.
41116500|NCT01764464|DRUG|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
41116501|NCT01764464|DRUG|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
41116502|NCT03238313|BEHAVIORAL|Plan A|
41116503|NCT03238313|BEHAVIORAL|Toxic Life Cycle of a Cigarette|Video
41116504|NCT00970359|BIOLOGICAL|AZD6244|"Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process."
41116505|NCT06210334|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d3, q3w
41116506|NCT06210334|DRUG|Lenvatinib|Lenvatinib 8mg (\<60kg) or 12mg (≥60kg), po, qd
41446254|NCT03990662|OTHER|Physiotherapy - Manual Therapy|Participants will receive four sessions of manual therapy applied to craniomandibular structures over four weeks. The application of manual therapy aims to decrease pain by treating masticatory muscle trigger points, muscle tightness, and restricted temporomandibular joint movements. Several techniques will be considered, including ventral and caudal anterior glide temporomandibular joint mobilisation, soft tissue interventions for the management of trigger points in masticatory muscles and myofascial induction therapy applied to craniomandibular structures. The structures targeted in the treatment sessions will be the temporomandibular joint, temporal muscles, masseter muscles, medial and lateral pterygoid muscles and suprahyoid muscles.
41446255|NCT04118335|OTHER|Black Mulberry Syrup|The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
40752765|NCT04783727|DIAGNOSTIC_TEST|Individualised treatment duration based on RNA transcriptomic model|Anti-MDR-TB treatment with standard drugs and individual treatment duration guided by the RNA transcriptomic model; may be shorter or longer than standard WHO-recommended treatment duration of 20 months.
40752766|NCT00002482|BIOLOGICAL|antibody therapy|
40752767|NCT00002482|BIOLOGICAL|biological therapy|
40752768|NCT00002482|BIOLOGICAL|muromonab-CD3|
41116507|NCT04517136|BEHAVIORAL|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
41116508|NCT04517136|BIOLOGICAL|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: Dehydroepiandrosterone (DHEA), cortisol and chromogranin A levels
41116509|NCT04517136|DEVICE|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
41116510|NCT04517136|BEHAVIORAL|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
41116511|NCT00194974|DRUG|methyldopa|
41116512|NCT00194974|DRUG|labetalol|
41116513|NCT00194974|DRUG|nifedipine|
41116514|NCT00194974|DRUG|clonidine|
41116515|NCT02662894|DRUG|Valsartan 160mg + Rosuvastatin 20mg|1 tablet, oral, a day
41116516|NCT02662894|DRUG|Valsartan 320mg + Rosuvastatin 20mg|1 tablet, oral, a day
41116517|NCT02662894|DRUG|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
41116518|NCT02662894|DRUG|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
41116519|NCT04381273|OTHER|No intervention|questionnaire-based assessment
40752769|NCT00002482|DRUG|cyclophosphamide|
40752770|NCT04432298|DRUG|Pamrevlumab|Sterile liquid for injection
40752771|NCT04432298|DRUG|Placebo|Sterile liquid for injection
41116520|NCT02945098|OTHER|Kinesio Taping|Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
41116521|NCT02945098|OTHER|Placebo Kinesio Taping|Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
41116522|NCT03664401|DEVICE|Kerecis Oral™|
41116523|NCT03664401|OTHER|Free Gingival Graft|A free gingival autograft from patient palate placed and secured on wound bed
40752772|NCT05125939|OTHER|Comparison of ADR|The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
41116524|NCT02933944|BIOLOGICAL|TG02-treatment|
40752773|NCT00013299|DEVICE|Prevention of Diabetic Ulcers|
40752774|NCT01113814|DEVICE|FibroScan|
40752775|NCT01113814|DEVICE|Acoustic Radiation Force Impulse (ARFI)- Imaging|
41116525|NCT02933944|DRUG|Pembrolizumab|
41116526|NCT00432588|DRUG|misoprostol|
41116527|NCT00432588|DRUG|dinoprostone|
41116528|NCT04226664|PROCEDURE|Bariatric surgery|Although there may be slight variation by centre, Gastric Bypass generally involves creation of a 30-50 cc stomach pouch, which is anastamosed with a Roux limb of jejunum 75-100 cm in length and a biliary limb of 20-30 cm in length. The operation creates a small gastric pouch, with nutrients bypassing the duodenum and proximal jejunum. Sleeve Gastrectomy involves decreasing the size of the stomach to approximately 15% of its original size by resecting a large portion of the stomach along the greater curvature.
41116529|NCT02047981|DRUG|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
41116530|NCT02047981|DRUG|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
41116531|NCT03452189|DRUG|Vancomycin|Oral vancomycin 250mg capsules
41116532|NCT03452189|OTHER|Placebo|"Placebo Pills distributed by Research Pharmacy labeled placebo."
41116533|NCT04484935|DRUG|Nirsevimab|Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
41116534|NCT01959126|BEHAVIORAL|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
41116535|NCT03733522|PROCEDURE|Rubber dam isolation|Local anesthesia, use of dental clamp and rubber dam, followed by restoration using universal adhesive system and bulkfill composite restoration
41116536|NCT03733522|PROCEDURE|Relative isolation|No local anesthesia, use of cotton rollers and saliva ejector, followed by restoration using universal adhesive system and bulkfill composite restoration
41446256|NCT01137591|DRUG|APAP and NAC combination|APAP 650mg and NAC 600mg combination oral tablet administered once
41446257|NCT01137591|DRUG|APAP and Placebo|APAP 650mg and Placebo combination oral tablet administered once
40752776|NCT00443287|DRUG|ataciguat (HMR1766)|oral administration
40752777|NCT00443287|DRUG|placebo|oral administration
40752778|NCT00443287|DRUG|cilostazol|oral administration
40752779|NCT06500221|BEHAVIORAL|incentive spirometry|The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
40752780|NCT03206385|RADIATION|Radiation treatment|50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.
41116537|NCT04962282|OTHER|Follow-up by telephone|Studies have shown that the compliance of patients at 8-12 weeks reaches a peak, so this time node is the most suitable time node to investigate compliance. Telephone follow-up is irreplaceable convenience, so the telephone follow-up survey of patient compliance with exercise prescriptions is The most feasible method The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.
41116538|NCT06176924|DEVICE|tDCS|tDCS (2mA, 20 min anode placed on DLFPC of left side and cathode on supraorbital cortex of right side) along with relaxation technique.
40752781|NCT03206385|RADIATION|CK Boost Pelvis|Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR
40752782|NCT02173366|BEHAVIORAL|Change Club Intervention|
40752783|NCT05145439|DEVICE|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf.
40752784|NCT03796975|DRUG|Combination of Pioglitazone and Metformin Tablets|15mg/500mg, oral, 2/day
40752785|NCT03796975|DRUG|Metformin Hydrochloride Tablets|Oral metformin 850mg, 2/day in the control group
40752786|NCT05162391|BEHAVIORAL|Contingency Management|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
40752787|NCT03460964|DEVICE|Adhesive glucose sensor|"Will assess sensor's performance by comparing readings from an adhesive glucose sensor with those from a glucometer.~pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat"
40752788|NCT03460964|DRUG|Pilocarpine|Pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat; will apply a minimum of 2 doses to each participant.
40752789|NCT06096948|DEVICE|NEXPOWDER-ENDOHS|Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
40752790|NCT03760640|DRUG|LY900014|Administered SC
40752791|NCT03760640|DRUG|Insulin Lispro|Administered SC
40752792|NCT03837535|PROCEDURE|Surgery|Neuro, Lung/thorax, GI, Gynecologic, Urologic, Orthopedic, Vascular surgery
40752793|NCT02105857|OTHER|grade A+ knee mobilization|grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
40752794|NCT03073057|DRUG|Budesonide/formoterol|2 inhalations as a single dose
41116539|NCT06176924|OTHER|Relaxation technique|Relaxation technique
40752795|NCT03073057|OTHER|Charcoal|
41116540|NCT05836285|OTHER|ARRC|Eligible for ARRC and managed in ARRC unit
40752796|NCT03073057|DRUG|Symbicort Turbuhaler|2 inhalations as a single dose
40752797|NCT00098761|DRUG|laromustine|This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.
41116541|NCT05836285|OTHER|Usual Care|Eligible for ARRC but managed elsewhere as no ARRC bed available
41116542|NCT01059877|DEVICE|1072nm infrared Photobiomodulation|1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.
41116543|NCT01059877|DEVICE|Photobiomodulation SIMULATED|Device mounted and procedure followed but with no stimulation.
40752798|NCT05463666|OTHER|Rheumatoid arthritis|A diagnosis of rheumatoid arthritis.
40752799|NCT05595395|DRUG|Enteral Dose Form|"In this intervention arm, fluid substitution is primarily done via enteral administration. The used substance for enteral fluid administered is going to be tap water. Intravenous fluid of choice is going to be Elomel isoton."
40752800|NCT05595395|DRUG|Intravenous Infusion|"In this intervention arm, fluid substitution is primarily done via intravenous administration. The used substance for intravenous fluid administered is going to be Elomel isoton."
40752801|NCT03197272|PROCEDURE|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
41116544|NCT01331330|DEVICE|Deep Brain Stimulation|Normal DBS Programming
41116545|NCT01331330|DEVICE|Deep Brain Stimulation|Low Programming
41453381|NCT01228539|BEHAVIORAL|TARGET (Trauma Affect Regulation)|TARGET teaches a skill sequence for affect regulation and social/interpersonal information processing.
41116546|NCT06436144|DRUG|Osimertinib|Etoposide Soft Capsules Dosage：25mg/tablet, 2 tablets/time, taken continuously for 21 days, and stopped for one week. Osimertinib Dosage：80mg/tablet, 1 tablet/time, QD, taken for two cycles.
41116547|NCT00106054|DRUG|Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.|
41116548|NCT00955695|DRUG|erlotinib hydrochloride|
41116549|NCT00955695|DRUG|gefitinib|
41116550|NCT00955695|OTHER|questionnaire administration|
41116551|NCT00955695|PROCEDURE|quality-of-life assessment|
41116552|NCT00955695|RADIATION|whole-brain radiation therapy|
41116553|NCT06255795|DRUG|chidamide, anti-PD1 antibody, and pegaspargase|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, anti-PD1 antibody 200mg intravenously on day 2, chidamide 30mg biw orally, every 21 days.
41446258|NCT02825680|OTHER|Enhanced NCP Support|NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
41446259|NCT02825680|OTHER|LEAP|The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model for Improvement, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool.
41446260|NCT05620823|DRUG|Povorcitinib|Oral; Tablet
40752802|NCT03211832|OTHER|Dissemination of public health knowledge|Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
40752803|NCT02913859|RADIATION|Radiotherapy to the pelvis|Radiotherapy to the pelvis and prostate
41116554|NCT06255795|DRUG|DDGP|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, cisplatin 20mg/m2 intravenously on days 1 through 4, dexamethasone 15mg/m2 intravenously on days 1 through 5, gemcitabine 800mg/m2 on day 1 and day 8, every 21 days.
41116555|NCT02864238|OTHER|electronic milestone pathway|an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
41116556|NCT05369169|BEHAVIORAL|Resonance breathing|Participants will synchronize their breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
41446261|NCT05620823|DRUG|Placebo|Oral; Tablet
41446262|NCT06263478|DRUG|INCA034176|IV infusion
41446263|NCT00835705|DRUG|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
41446264|NCT00835705|DRUG|Augmentin®|400 mg-57 mg chewable tablet
41446265|NCT05315791|PROCEDURE|different methods for maxillary sinus floor elevation|a: 0\~3mm+ground into pieces; b: 0\~3mm+replace the bone; c: 0\~3mm+turn inward to hold up the membrane; d: 3\~5mm+ground into pieces; e: 3\~5mm+replace the bone; f: 3\~5mm+turn inward to hold up the membrane
41446266|NCT03037398|DEVICE|Vercise Deep Brain Stimulation System|
41116557|NCT05369169|BEHAVIORAL|Low demand cognitive task|Different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles
41116558|NCT04492631|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5|Sachets containing Streptococcus salivarius DB-B5 will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks. The participants will consume 10 billion colony forming units (CFU) per day.
41116559|NCT04492631|OTHER|Placebo|Sachets containing a placebo (probiotic carrier) will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks.
41116560|NCT04303156|DRUG|Islatravir|Single oral dose of 60 mg Islatravir administered in capsule form
41116561|NCT04297371|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
41116562|NCT00705328|BEHAVIORAL|Primary Health Care Model (PRMHLTH)|Primary health care service delivery
41116563|NCT00705328|BEHAVIORAL|Recreation Coordination Model (REC)|Recreation coordination service delivery
41116564|NCT00705328|BEHAVIORAL|Comprehensive Model (COMP)|a comprehensive service delivery model consisting of PRMHLTH plus REC.
41116565|NCT03641703|BIOLOGICAL|FLT180a|FLT180a is a replication-incompetent adeno-associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
41116566|NCT06213324|DRUG|Ketamine|0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously
41116567|NCT06213324|DRUG|Placebo|Normal saline delivered intravenously
41116568|NCT00643929|DRUG|Eltrombopag|Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
41116569|NCT01641198|DEVICE|Configuration 1|B placed at sites 2 and 5, SW placed at sites 1 and 4, SC placed at site 3
41116570|NCT01641198|DEVICE|Configuration 2|B placed at site 3, SW placed at sites 2 and 5, SC placed at sites 1 and 4
41116571|NCT01641198|DEVICE|Configuration 3|B placed at sites 1 and 4, SW placed at site 3, SC placed at sites 2 and 5
41116572|NCT01465516|DRUG|Boceprevir|"Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).~Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results"
41116573|NCT04306718|PROCEDURE|membrane peeling|ERM and ILM are peeled routinely during surgery
41116574|NCT04962477|OTHER|Nasal brush sampling|Nasal brush samples will be collected from the inferior turbinate using standardized techniques after local anesthetic application. After clearing the mucus from the nasal cavity by asking the patient to blow their nostrils twice followed by local anesthetic spray application, nasal brush samples will be collected from the inferior turbinate of each nostril with dedicated soft cytology brushes and pooled together for molecular biological experiments. Simultaneously, 10 mL of peripheral blood will be collected for immunophenotyping.
41116575|NCT05420090|BEHAVIORAL|Banana arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied.Food consumption frequency and food-based follow-up will be carried out.Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
41116576|NCT05420090|BEHAVIORAL|Milk arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. Food consumption frequency and food-based follow-up will be carried out. Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
41116577|NCT05420090|BEHAVIORAL|No intervention|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. The frequency of food consumption will be taken from the participants each week.Participants are expected not to make any changes in their diet. As in other groups, the frequency of food consumption will be taken from the participants every week in this group. In order to observe the possible changes in the experimental arms, the individuals in the control arm will be asked not to consume bananas and whole milk after 16:00 and they will be informed about this.
41116578|NCT02500264|DEVICE|TENS|
41116579|NCT04329130|DRUG|Chidamide, Lenalidomide|All patients enrolled in the study will accept Chidamide combination with lenalidomide regimen.
41116580|NCT01599897|BIOLOGICAL|ID93 + GLA-SE|ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
41116581|NCT01599897|BIOLOGICAL|ID93 alone|ID93 antigen alone. 3 injections and Days 0, 28, and 56.
41116582|NCT01373697|DRUG|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
41116583|NCT01373697|DRUG|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
41116584|NCT00561886|DRUG|Formoterol|One inhalation of 24µg Formoterol
41116585|NCT05287282|OTHER|TECAR application|Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow
41116586|NCT06464198|PROCEDURE|simultaneous postoperative radiochemotherapy|The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated.
41116587|NCT00413257|DRUG|Nefopam|0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
41446267|NCT03045198|DRUG|Azithromycin|
41446268|NCT06626555|DRUG|Letermovir|Letermovir 480mg PO once daily
41446269|NCT00840840|DRUG|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
40752804|NCT02913859|DRUG|Hormonal therapy (LHRH agonist and/or antiandrogens)|life-long hormonal therapy (LHRH agonist and/or antiandrogens)
40752805|NCT03406052|BEHAVIORAL|Smartphone-Assisted MB-CBT|Experimental subjects will receive a mindfulness-based CBT online software program workbook (in collaboration with Nex J Systems, Inc.) accessible online. Exposure to and interaction with the online workbook is combined with health coaching (duration of 24 total hours) primarily delivered in phone and software interactions. In addition, each participant will be given a Fitbit-HR Charge, a wearable bracelet that assesses physical steps and 24 hour heart rate in 5 second (averaged) durations (with related access to software that permits daily tracking).
41116588|NCT00413257|DRUG|néfopam|bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
41116589|NCT00413257|DRUG|Placebo comparator|bolus NaCl during 10 min at the end of surgery and during postoperative H48
41116590|NCT00366171|DRUG|Bifeprunox|
41116591|NCT05344014|PROCEDURE|Photobiomodulation|In experimental groups, before topical anesthesia, PBMT was applied by utilizing a diode laser (EpiX; Biolase technology, inc., USA) with a continuous wavelength of 940 nm on a 400-μm fiber with only biostimulation properties. In accordance with the recommendations of the device's manufacturer, it was applied using circular motions in a manner as slowly as possible (an average of 33-36 circular movements in 60 s)
41116592|NCT05344014|PROCEDURE|Placebo|In the control group (placebo), the laser probe was directed to the mucosa for (buccal and palatal area), but not activated, and the sound of the laser device previously recorded on the mobile telephone was played for the same time of experimental group in order to provide similar conditions
41116593|NCT05744258|DEVICE|Bio-electrical impedance analysis|"Bio-electrical Impedance Analysis will be performed by trained personnel. BIA will be performed after fasting for at least 6 hours. Subjects should refrain from intensive physical activity the day be-fore the measurement. For women, measurements will be performed outside menstruating periods. Subjects will lay down on an examination couch with bare feet. Any jewelry will be removed.~Reactance and resistance will be obtained. Phase angle will be calculated according to the formula:~PhA (°) = (reactance/ resistance° x (180°/π). Body composition, including muscle mass and percentage body fat will be calculated."
41116594|NCT05335798|DEVICE|Bodyweight augment system|Motorized cables will be providing downward force on the participant's pelvis
41116595|NCT05335798|DEVICE|Smart insole|Insole provided auditory feedback when heel strike or toe-off events happen
41116596|NCT00989937|DRUG|Oxytocin|20 IU BID or 40 IU BID
41116597|NCT00989937|DRUG|Placebo|20 IU BID or 40 IU BID
41116598|NCT03906435|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.
41116599|NCT01713946|DRUG|RAD001|Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
41116600|NCT01713946|DRUG|Placebo|Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
41116601|NCT01713946|DRUG|Antiepileptic drug (1 to 3 only)|no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
41116602|NCT01713946|DRUG|open label RAD001 (only used for post-extension phase)|everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
41116603|NCT03522454|DIETARY_SUPPLEMENT|Protein-rich oral nutritional supplement|Ready-to-drink beverage containing 20 g protein and 1.5 g hydroxymethylbutyrate (HMB) per serving, consumed twice daily.
40752806|NCT05280314|DRUG|IO102-IO103|IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
41116604|NCT03522454|BEHAVIORAL|Home-based supervised exercise program|WEBB (Weight-bearing Exercise for Better Balance) program combining walking and weight-bearing exercises to build strength and balance, administered by a trained therapist at the participant's home.
41116605|NCT02344355|DRUG|Temozolomide|"oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days."
41116606|NCT02344355|RADIATION|radiation therapy|Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
41446270|NCT00840840|DRUG|Augmentin ES-600™|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
41446271|NCT01159145|DRUG|D961H|Oral, capsule
41446272|NCT01159145|DRUG|Omeprazole|Oral, tablet
41446273|NCT06628063|OTHER|ultrasound evaluation|Ultrasound scan of fetus in second and third trimestrers
41446274|NCT04723693|OTHER|Qualitative Interview|A single one hour semi structured qualitative interview
40752807|NCT05280314|DRUG|Pembrolizumab KEYTRUDA®|Pembrolizumab KEYTRUDA® administered intravenously
40752808|NCT02037984|BIOLOGICAL|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.
40752809|NCT02037984|BIOLOGICAL|V114 1x:1x:1x|V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).
41116607|NCT02344355|DRUG|Ascorbic Acid|"Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide."
41116608|NCT04901936|DRUG|Pegcetacoplan|Complement (C3) inhibitor
41116609|NCT02092519|DEVICE|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport
41116610|NCT02092519|DEVICE|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport
41116611|NCT01493778|DRUG|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
41116612|NCT03961906|BEHAVIORAL|physiotherapy|Will receive two trainings. First training in week one after baseline assessment for three consecutive days 60 min twice daily by trained physiotherapists and in week three further two days with 60min once daily.
41116613|NCT00005137|OTHER|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
41116614|NCT06014775|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
41116615|NCT05283447|OTHER|Osteopathic Medicine|The clinical protocol subject to analysis for the intervention group consists of manual approach techniques for the myofascial and viscerofascial structures of the anterior face of the neck, maneuvers for the mediastinal region, techniques for normalizing the tone of the thoracic diaphragm and its pillars, on the peritoneal ligaments, and caudal traction of the stomach for manual correction of hiatal hernia.
41116616|NCT05283447|OTHER|Control|The physiotherapeutic treatment on the control group consists of an approach to the lumbopelvic joint restrictions and a massage on the inframesocolic abdominal region with minimal pressure, which does not affect the activity and position of the stomach.
41116617|NCT03737591|DIAGNOSTIC_TEST|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy
41116618|NCT00566124|DRUG|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
41116619|NCT00566124|DRUG|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
41116620|NCT00566124|DRUG|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
41116621|NCT04811950|DEVICE|Emerald|Complete blood countdevice
41116622|NCT04384250|DIAGNOSTIC_TEST|Whole Exome Sequencing|Genetic study of patients
41116623|NCT03022123|DRUG|PL-doxorubicin and epirubicin|PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
41116624|NCT03639350|BEHAVIORAL|IER+MED group|Follow a Mediterranean diet 5 days per week and follow intermittent energy restriction 2 days per week.
40752810|NCT02037984|BIOLOGICAL|V114 2x:2x:2x|V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
40752811|NCT02037984|BIOLOGICAL|V114 2x:1x:2x|V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
40752812|NCT02037984|BIOLOGICAL|V114 1x:1x:2x|V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
41116625|NCT03639350|BEHAVIORAL|DASH group|Follow the distribution of macronutrients and food groups prescribed by the DASH diet 7 days per week.
41116626|NCT03194958|BEHAVIORAL|Specialized Quitline|Very low-income smokers are different from other smokers in important ways not always addressed by standard quitline services. The research team and Alere staff has created custom protocols, scripts, prompts and other content to maximize intervention relevance and acceptability to very low-income smokers. Research Implementation Unit (RIU) coaches who will be delivering the Specialized Quitline services have received training from clinical quitline staff, the research team and 2-1-1 staff who have extensive experience with the target population. Focus areas for training and distinctive content and protocol for the Specialized Quitline include: health literacy, abstract vs. concrete language, lived experience, resource constraints, future orientation, getting cigarettes, living situation, phone/internet access.
41133367|NCT06389266|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of rTMS with functional magnetic resonance imaging allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.
41116627|NCT03194958|BEHAVIORAL|Basic Needs Navigator|Navigators will: (1) identify and assess smokers' needs, including the reasons they called 2-1-1; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help smokers access available resources by scheduling appointments and provide appointment reminders; (8) prepare smokers to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.
41116628|NCT03861364|DRUG|Propofol|2,4 mg/kg
41116629|NCT03861364|DRUG|Propofol|1,4 mg/kg
41116630|NCT02317965|OTHER|Maternal Blood Draw|Maternal Blood Draw
41116631|NCT05150067|OTHER|A Blended Learning Programme|A blended learning programme with face-to-face training and an online module on handover practice
41116632|NCT05150067|OTHER|Waitlist control group|The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed
41116633|NCT00534183|DRUG|Olanzapine|Olanzapine in dose range of 10-20mg
41116634|NCT00534183|DRUG|Risperidone|Risperidone 1-6mg
41116635|NCT00534183|DRUG|Haloperidol|Haloperidol 10-20mg
41116636|NCT04631003|DIAGNOSTIC_TEST|dynamic functional testing|First, with an arthroCT of the wrist by intraarticular injection of contrast agent, a possible scaphulonary band lesion is detected. The surgeon does not yet know the findings of the possible ligament injury at this time, but he can assess the fracture in the CT. Subsequently, a dynamic functional test of the scapholunary distance is carried out intraoperatively under investigation with the modified Watson test before and after performing the osteosynthesis. For this purpose, the wrist is intraoperatively brought under pull on the thumb from a radial abduction into an ulnarabduction. In the presence of a scapholunary instability, a change in the distance of the scapholunary joint gap is shown here under illumination. Now the surgeon receives the finding of the Arthro-CT regarding an existing ligament injury. If necessary, this is treated in the same anaesthetic with a band seam and ossary transfixation.
41116637|NCT05920746|OTHER|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 10-20 Hz, type of impulse: bipolar, rectangular pulse
41116638|NCT05904925|OTHER|Pilates exercises|Sessions will last 60 minutes: five minutes for warming up, 50 minutes for the practice of Pilates exercises, and five minutes for relaxing with the Swiss ball. The exercise protocol will be divided into three gestational phases, covering the entire gestational period, with different and specific objectives for each phase. In all phases, the exercises will be classified into three levels of difficulty: basic, intermediate, and advanced, according to the evolution of each pregnant woman throughout the practice of Pilates. Modifications will be allowed to facilitate or hinder the execution of the movement. The exercises will be performed in one or two sets of seven to 10 repetitions. The number of series, repetitions and exercises and interval time between them, as well as the level of difficulty of the exercises, will be gradually adjusted. The intensity of the exercises will vary between light and moderate and will be controlled by the Borg scale.
41116639|NCT04528706|DRUG|MIN-102|Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.
41116640|NCT05004935|DIETARY_SUPPLEMENT|beetroot juice|single intake of beetroot juice containing 800mg nitrates
41116641|NCT05004935|OTHER|nitrate|single intake of 800mg nitrates
41116642|NCT06554418|BEHAVIORAL|Communities Care|Communities Care is a violence prevention program targeting social norms and behavioral change
41116643|NCT01689090|OTHER|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
41116644|NCT01689090|OTHER|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
41116645|NCT01689090|OTHER|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
41116646|NCT01816958|OTHER|co-administration of TMS and infused ketamine|co-administration of TMS and infused ketamine
41116647|NCT06394271|DEVICE|EVAR|Catheter based insertion of aortic endograft via iliac or femoral arteries
41116648|NCT05081713|BEHAVIORAL|high-intensity training focused on stepping in variable contexts|Approximately 10 weeks (\~30 sessions) of high-intensity training
41116649|NCT04618757|BEHAVIORAL|Hedonic Reward|A reimbursement credit for hedonic expenses worth up to $50 will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
41116650|NCT04618757|BEHAVIORAL|Cash Reward|A reimbursement credit for $50 in cash will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
41116651|NCT04618757|DEVICE|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
41116652|NCT00656721|DEVICE|Flutter Valve|"Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.~In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done."
41116653|NCT02528188|DRUG|NSAID|Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
41116654|NCT02528188|BIOLOGICAL|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
41116655|NCT02528188|BIOLOGICAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
41116656|NCT06019299|BEHAVIORAL|Mindfulness Practice|Participants were instructed to practice mindfulness daily using their instructed approaches for a period of 4 weeks.
41116657|NCT05896319|DEVICE|Hyaluronic acid gel|"Post-operative application of Hyaluronic acid gel 3 times per day (8 hours distance between each application) for 7 days after oral hygiene and without swallowing, eating or drinking for one hour after the application, as follows: wash your hands thoroughly before each application, apply a layer of gel on the injured mucosa, massage with a finger in order to facilitate spreading of the product over the treated area."
41116658|NCT05032794|OTHER|Unrestricted diet before colonoscopy|Free diet, without restrictions
41116659|NCT05032794|OTHER|1-day low residue diet|To follow a diet low in residues / fiber. the day before the colonoscopy.
41116660|NCT05032794|DRUG|Bisacodyl 5 MG|If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
41116661|NCT02092077|DRUG|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
41116662|NCT02092077|DRUG|somatropin|Dose may be adjusted as required
41116663|NCT05052450|OTHER|Observational|Patients data were collected throughout the following time
41116664|NCT05350527|OTHER|Consultation of a Web Platform|Patients willing to participate in this research and randomized in the experimental arm will benefit, in addition to standard preoperative medical information, an access to the EDOP internet platform via personalized and secure access codes. They will be able to watch an explanatory video about breast surgery and find all the essential, practical and useful information about their intervention and the postoperative effects for the duration of their follow-up.
41116665|NCT01595061|DRUG|Cisplatin|Given IV
41116666|NCT01595061|DRUG|Gemcitabine Hydrochloride|Given IV
41116667|NCT01595061|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41116668|NCT01595061|PROCEDURE|Therapeutic Conventional Surgery|Undergo local core biopsy or surgical excision
41116669|NCT04065334|BEHAVIORAL|High dose training|4 x 4 minutes of high intensity workload on treadmill and 4 repetitions x 4 sets of high intensity workload in hack squat
41116670|NCT04065334|BEHAVIORAL|low dose training|1 x 4 minutes of high intensity workload on treadmill and 2 repetitions x 4 sets of high intensity workload in hack squat
41116671|NCT02988817|BIOLOGICAL|Enapotamab vedotin (HuMax-AXL-ADC)|Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.
41116672|NCT00982098|PROCEDURE|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
41446275|NCT06479096|OTHER|Brush / Espresso Mild Prototype|Subjects will brush and rinse with their assigned mouthwash twice daily.
41116673|NCT02709304|DRUG|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
41116674|NCT02709304|DRUG|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
41116675|NCT04901312|BEHAVIORAL|Adolescent Community Reinforcement Approach|The Adolescent Community Reinforcement Approach (A-CRA) is a developmentally-appropriate behavioral treatment for youth and young adults ages 12 to 24 years old with substance use disorders. A-CRA seeks to increase the family, social, and educational/vocational reinforces to support recovery. This intervention has been implemented in outpatient, intensive outpatient, and residential treatment settings. A-CRA includes guidelines for three types of sessions: individuals alone, parents/caregivers alone, and individuals and parents/caregivers together. According to the individual's needs and self-assessment of happiness in multiple life areas, clinicians choose from a variety of A-CRA procedures that address, for example, problem-solving skills to cope with day-to-day stressors, communication skills, and active participation in positive social and recreational activities with the goal of improving life satisfaction and eliminating alcohol and substance use problems.
41116676|NCT04901312|BEHAVIORAL|Assertive Continuing Care|Assertive Continuing Care (ACC) uses Community Reinforcement Approach (CRA) procedures, home visits, and case management for individuals following an initial substance use treatment episode. It stresses rapid initiation of services after discharge from residential, intensive outpatient, or regular outpatient treatment in order to promote recovery and prevent relapse.
41116677|NCT04901312|BEHAVIORAL|Trauma Affect Regulation Guide for Education and Therapy|Trauma Affect Regulation: Guide for Education and Therapy is a psychosocial intervention for traumatized adolescents, adults, and families, and for workforce and organizational responses to secondary/vicarious traumatization. T4, the 4-session version, provides education about the impact of complex traumatic stress on the brain's stress response system, and strengths-based practical skills for re-setting the trauma-related alarm/survival reactions that occur in complex PTSD.
41116678|NCT04901312|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is a collaborative, person-centered form of guiding to elicit and strengthen motivation for change.
41116679|NCT04901312|OTHER|Opioid Education Workbook|A digital workbook designed to be completed on a computer in about 2 hours. Topics include opioid use, opioid use disorder, and prevention and treatment of opioid overdose.
41116680|NCT05547607|DIAGNOSTIC_TEST|advanced cardiac imaging|In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).
41116681|NCT04151407|DRUG|Drug 601|Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
41116682|NCT02882698|BEHAVIORAL|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
41116683|NCT02882698|BEHAVIORAL|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
41116684|NCT02882698|BEHAVIORAL|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
41116685|NCT02882698|BEHAVIORAL|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
41116686|NCT01304342|DRUG|Remifentanil|1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
41116687|NCT01304342|DRUG|Fentanyl|Intranasal fentanyl 200 micrograms 5 min before the ERCP
41116688|NCT01304342|DRUG|Normal saline|Normal saline intravenously and intranasally
41116689|NCT02861846|BIOLOGICAL|profile of CSF biomarkers of AD|dosage of biomarker of AD
41116690|NCT06147167|DEVICE|individualized intermittent theta burst sitmulation (iTBS)|Participants undergo daily sessions of individualized intermittent theta-burst stimulation (iTBS) administered with the MagStim stimulator (Rapid2, MagStim, Whiteland, United States). The intervention spans five days a week and extends over a three-week period. In this group, participants receive a personalized iTBS protocol comprising three pulses of stimulation delivered at 50 Hz, repeated every 200 ms. The stimulation frequency is tailored based on the electroencephalogram (EEG) results and is administered every 10 seconds, with a total duration of 190 seconds. The treatment is administered once a day for five days a week and continues for three weeks, with an immediate cessation in case of any discomfort. This study design ensures a meticulous and tailored approach to iTBS administration.
41116691|NCT06147167|DEVICE|standard iTBS|The MagStim stimulator (Rapid2, MagStim, Whiteland, United States) was employed in the current study. The intermittent theta-burst stimulation (iTBS) protocol utilized three pulses of stimulation delivered at a frequency of 50 Hz, with a repetition rate of every 200 ms. These pulses were organized into 2-second trains, repeated every 10 seconds, resulting in a cumulative duration of 190 seconds (equivalent to a total of 600 pulses). Notably, the administration of the treatment ceased promptly in the event of any participant discomfort.
40926208|NCT05721807|OTHER|pelvic floor muscle training program|The program consisted of two parts. From procedures 1 to 6, 6 exercises were performed, after 6 times the exercises were adjusted, and from procedures 7 to 12, another 5 exercises were performed. The program consists of breathing, pelvic floor muscle strength, endurance, speed training exercises and exercises to strengthen the thighs, buttocks, deep back and deep abdominal muscles. Exercises were performed in 2 sets of 10 repetitions at an intensity from various positions: lying on the back, side, sitting, quadruped (Oliveira et al., 2017; Walton et al., 2019).
41116692|NCT06147167|DEVICE|sham stimulation|The device and protocol are identical to the standard iTBS, with the only difference being the orientation of the coil, which is perpendicular to the scalp.
41116693|NCT04014114|OTHER|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
41116694|NCT02759913|PROCEDURE|Lumbar puncture|Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
41116695|NCT02147054|DRUG|Rocuronium|
41116696|NCT02147054|DRUG|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
41116697|NCT04900636|DEVICE|Telemedicine Arm|Patients with DM1 ≥ 18 years of age, users of closed loop hybrid systems, assigned to a follow-up program using a telemedicine platform combined with face-to-face visits according to protocol.
40752813|NCT02037984|BIOLOGICAL|V114 0.5x:0.5x:2x|V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
41116698|NCT02728349|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
41116699|NCT00893425|DRUG|ramipril|
41116700|NCT01130727|OTHER|green tea extract|1.21g of green tea extract (965 mg of flavonols)
41116701|NCT01130727|OTHER|cocoa extract rich in polyphenols|2.14 g of cocoa extract rich in polyphenols equivalent to 965 mg of polyphenols
40752814|NCT05938010|DEVICE|Dailies Total1® contact lenses for astigmatism (T30fA)|Dailies Total1® contact lenses for astigmatism (T30fA)
40752815|NCT05670340|DEVICE|Switched Prosthetic Profile|The implant will be rehabilitated with a switched emergence profile
41116702|NCT01130727|OTHER|placebo|placebo
40752816|NCT05670340|DEVICE|Matched Prosthetic Profile|The implant will be rehabilitated with a matched emergence profile
40752817|NCT02845596|DRUG|cyclosporine|cyclosporine
40926209|NCT02763592|DRUG|Lidocaine|The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery
41116703|NCT01130727|OTHER|low polyphenol cocoa extract|placebo
41116704|NCT04219930|DIAGNOSTIC_TEST|Expression of nucleotide protein -3|Expression of nucleotide protein -3 will be measured in serum by ELISA
41116705|NCT03399916|BEHAVIORAL|Prompt sent|
41116706|NCT04836806|DRUG|Cetirizine and Famotidine|Participants will take 10 milligrams (mg) of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
41116707|NCT04836806|DRUG|Placebo|Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
41116708|NCT04797416|DEVICE|FGM infiltration 1 hour group|The sensor is activated immediately after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
41116709|NCT04797416|DEVICE|FGM infiltration 6-hour group|Reactivate the sensor 5 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
41116710|NCT04797416|DEVICE|FGM infiltration 12-hour group|Reactivate the sensor 11 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
41116711|NCT02568683|DRUG|Entospletinib|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
41116712|NCT02568683|DRUG|Vincristine|VCR administered intravenously
41116713|NCT06006806|RADIATION|Pencil Beam Scanning Proton Therapy|"Part of the normal proton therapy process is to have a CT scan (called a CT simulation) performed that is used to create a proton treatment plan. A proton treatment plan is a computer model of the proton beam that is used to calculate where the protons will go inside the body. During the treatment planning process, the clinical team works to find the best possible placement of the protons. This study uses a process called Spot Delete to keep protons from stopping in the skin, which is believed to be related to skin reddening. Spot Delete is a software application that was developed at the Thompson Proton Center and is used in the treatment planning process."
41116714|NCT06193850|OTHER|Observation during time|Evaluation through clinical investigation and questionnaires useful for evaluating the patient's psycho-physical conditions
41116715|NCT04804046|DIETARY_SUPPLEMENT|Synbiotic|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with three Bifidobacterium spp. (3x10\^9 CFU) plus three dietary fibers (24 g fiber) daily for six months.
41116716|NCT04804046|OTHER|Digestible Maltodextrin|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with Maltodextrin daily for six months.
40752818|NCT02845596|PROCEDURE|Matched Unrelated Donor Hematopoietic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
40752819|NCT02845596|DRUG|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
41116717|NCT02514278|DRUG|Neoadjuvant chemotherapy Folfirinox, 4 cycles|"* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~* 5FU: 2400 mg/m2"
41116718|NCT02514278|RADIATION|50 Gy, 2 Gy/session; 25 fractions|Radiochemotherapy 5 weeks
41116719|NCT02514278|PROCEDURE|Local excision in good responders|"If local excision:~* Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~* Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1."
41116720|NCT02514278|PROCEDURE|Rectal excision in bad responders|
41116721|NCT02514278|DRUG|Capecitabine|1600 mg/m2 daily 5 days/7
41116722|NCT03508310|OTHER|Taking Care of Me Video|The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
41116723|NCT01304849|DRUG|Escalated BEACOPP|"Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm"
41116724|NCT00306397|DRUG|Rapamycin|Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
41116725|NCT06553911|OTHER|Artificial Intelligence-based medical imaging interpretation|In the AI interpretation group, using clinical information, imaging data, and corresponding etiological results of the study participants, an AI diagnostic tool is established to specifically recognize patients' chest medical imaging and construct corresponding diagnostic conclusions.
41116726|NCT05949242|DEVICE|OMNI canaloplasty|OMNI device is used to catheterize Schlemm's canal for 180 degrees and perform canaloplasty. Viscoelastic is eluded upon retraction of the catheter performing viscodilation of the canal
41116727|NCT05949242|DEVICE|Hydrus microstent|Hydrus stent is introduced into Schlemm's canal to scaffold open the canal
41116728|NCT01257555|DEVICE|Photopneumatic therapy|Use of intense pulsed light (photo) in combination with vacuum technology (pneumatic) to treat mild to moderate acne.
41116729|NCT04191954|DRUG|Fasudil eye drops (concentration 0.5 percent)|receive Fasudil eye drops (concentration 0.5 percent) twice daily
41116730|NCT04191954|DRUG|receive artificial tears drop|receive artificial tears drop with the same frequency
41116731|NCT00334594|DRUG|Cisplatin|Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days
41116732|NCT00334594|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days
41116733|NCT00334594|PROCEDURE|Therapeutic conventional surgery|Extrapleural pneumonectomy
41116734|NCT00334594|RADIATION|Radiotherapy|CTV1 will receive 45 or 46 Gy. CTV2 will be treated up to a total dose of 55,9 to 56,2 Gy.
40752820|NCT02845596|DRUG|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
40752821|NCT02845596|DRUG|methotrexate|methotrexate
41116735|NCT05871450|BEHAVIORAL|Inclusive events|Inclusive events such as inclusive sport festivals, citizen festivals or working groups at school are organized
41116736|NCT05253612|DIAGNOSTIC_TEST|Analog testing conducted by a trained test leader using, ISPOCD test battery|Cognitive function will be measured by using the International Study Group of Postoperative Cognitive Dysfunction (ISPOCD) analog test battery v
41116737|NCT05253612|DIAGNOSTIC_TEST|self-administered Mindmore digital cognitive screening battery|Cognitive function will be measured by using the Mindmores digital test battery
41116738|NCT00477308|PROCEDURE|salvage therapy|
41116739|NCT01211093|PROCEDURE|High frequency whole body vibration|1 single session (10 minutes) of whole body vibration therapy at 30 Hz
41116740|NCT01211093|PROCEDURE|Low frequency whole body vibration|1 single session of whole body vibration therapy at 20 Hz
41116741|NCT01211093|PROCEDURE|control|1 single session of standing on the vibration platform, with no vibration signals delivered.
41116742|NCT00425152|DRUG|fluorouracil|
41116743|NCT00425152|DRUG|leucovorin calcium|
40752822|NCT02845596|DRUG|fludarabine|fludarabine
41116744|NCT00425152|DRUG|levamisole hydrochloride|
41116745|NCT01612169|BEHAVIORAL|Patient Navigation (PN) Group|The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
41116746|NCT01612169|BEHAVIORAL|Patient Navigator Plus Contingency Management (PN+CM) Group|Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
41116747|NCT03843021|OTHER|VAD Infection Prevention Survey|Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.
41116748|NCT04366908|DRUG|BAT + Calcifediol|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule"
41116749|NCT04366908|DRUG|BAT|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
41116750|NCT00676234|DRUG|epoetinum|Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
41116751|NCT03772457|DRUG|Rivaroxaban|new oral anticoagulant molecules which is the selective factor Xa inhibitor
41116752|NCT01742481|BEHAVIORAL|Education and empowerment|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
41116753|NCT00568854|BIOLOGICAL|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
41446276|NCT06479096|OTHER|Brush / Espresso Intense Prototype|Subjects will brush and rinse with their assigned mouthwash twice daily.
40752823|NCT02845596|DRUG|cyclophosphamide|cyclophosphamide
40752824|NCT02845596|RADIATION|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
40752825|NCT02845596|PROCEDURE|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
41116754|NCT05511428|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
41116755|NCT05511428|OTHER|Questionnaire Administration|Ancillary studies
41116756|NCT05511428|OTHER|Quality-of-Life Assessment|Ancillary studies
41116757|NCT05511428|OTHER|Interview|Ancillary studies
41116758|NCT02640781|PROCEDURE|self-expandable metal stent insertion(covered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
41116759|NCT02640781|PROCEDURE|self-expandable metal stent insertion(uncovered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
41116760|NCT04529382|DIAGNOSTIC_TEST|Cognitive testing (Bayley III, WPPSI III and WISC V)|Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.
41116761|NCT02283242|DRUG|Galantamine|Oral use for 12 weeks
41116762|NCT02283242|DRUG|Placebo (for galantamine)|Oral use for 12 weeks
41116763|NCT00003432|BIOLOGICAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
41133368|NCT05768282|DRUG|Oral prednisolone (30mg/day) for 28 days|Oral prednisolone was started at a dose of 30 mg/day on the third day after RFA, and continued for 4 weeks.
41446277|NCT06479096|OTHER|Brush / Fresh Breath Oral Rinse|Subjects will brush and rinse with their assigned mouthwash twice daily.
41446278|NCT06479096|OTHER|Brush / Hydroalcohol|Subjects will brush and rinse with their assigned mouthwash twice daily.
41453382|NCT01228539|BEHAVIORAL|Prolonged Exposure|Cognitive behavior therapy with trauma memory exposure
41116764|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning|"Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
41116765|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae|"Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets."
41116766|NCT00922220|OTHER|stationary bike|Participants rode a stationary bike for five minutes
41116767|NCT00922220|OTHER|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
41116768|NCT00922220|OTHER|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
41116769|NCT04444258|OTHER|Application of computer aided virtual reality glasses|Experimental I Group: After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
40752826|NCT04236466|DEVICE|hyrax appliance|Hyrax will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines.
41116770|NCT04444258|OTHER|Teaching fetal development theoretically|Control Group: FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
41116771|NCT03920566|OTHER|Anti-Xa level|Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment
40752827|NCT04236466|DEVICE|haas appliance|Haas will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines. Acrylic part will be added on palate
41116772|NCT06299293|OTHER|Facial Emotion Recognition Test|In this test, the ability to detect and recognize facial expressions of fear or anger will be investigated.
41116773|NCT01917097|DRUG|Dexmedetomidine|
41116774|NCT01563354|DRUG|Pasireotide LAR|60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1
41116775|NCT01563354|DRUG|Everolimus|10 mg tables administered orally once a day
41116776|NCT01563354|DRUG|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
41116777|NCT04593914|DEVICE|Cavilon Advanced Skin Protectant|"3M™ Cavilon™ Advanced Skin Protectant is a polymeric-cyanoacrylate solution intended for the protection of intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier. It is elastomeric, adhering to the contours of the skin and providing a uniform film. The film is transparent and possesses good oxygen and moisture vapor permeability.~The polymer-cyanoacrylate is dispersed in a non-stinging solvent. The film is colorless, non-cytotoxic and has a low dermatitis potential. The film adheres to dry, moist or wet skin surfaces and remains intact during conditions of continuous or repeated exposure to moisture or caustic irritants. It will wear off the skin and does not require removal."
41116778|NCT01731041|DRUG|Ticagrelor 180mg|Patients will receive 180 mg of ticagrelor
41116779|NCT01731041|DRUG|Ticagrelor 90mg|Patients will receive 90 mg of ticagrelor
41116780|NCT02344498|DRUG|Tenofovir disoproxil|
41116781|NCT05142878|DEVICE|Ultracore Repose® mattress|Residents will be placed on the Ultracore Repose® mattress during 14 days
41116782|NCT06484504|DIETARY_SUPPLEMENT|Kombucha beverage|After 4-weeks of consuming a beige diet (i.e. low-fiber, low polyphenol diet), 20 subjects (kombucha group) will consume one bottle (two servings) of kombucha daily for 4 weeks and 10 subjects (control group) will not change their dietary habits
41116783|NCT04783012|PROCEDURE|Catheter removal|Catheter management strategy after surgery
41116784|NCT03769571|BEHAVIORAL|Parental coaching program at ESDM (P-ESDM)|It will have a duration of 7 months (with an inclusion period of 1 year). Parents will come to the hospital with their child once every 15 days for one-hour parental coaching sessions on the ESDM method. Home video sessions will also be performed by parents once every 15 days. Each parent will have a Certified therapist referral to the practice of ESDM and the program is framed by a certified therapist and trained in ESDM parental coaching.
41116785|NCT05125029|DRUG|Botulinum toxin|Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum that prevents the release of the neurotransmitter acetylcholine from the neuromuscular junction, thereby preventing muscular contraction. Eligible subjects will be randomized 1:1:1 into three different groups: 1) placebo 2) 10 Units of BT injected per digit and 3) 20 units of BT injected per digit.
41116786|NCT03284905|DIETARY_SUPPLEMENT|Probiotic supplement|Capsule containing freeze dried probiotic bacteria together with maize starch
41116787|NCT03284905|DIETARY_SUPPLEMENT|Placebo supplement|Capsule containing maize starch
41116788|NCT04468698|OTHER|Peritoneum insufflation|Before surgery pneumoperitoneum is established by insufflating gas into the abdomen. Intraabdominal pressure (IAP) is set to 15 mmHg for initial abdominal stretching and then decreased in a stepwise manner down until 8 mmHg.
41116789|NCT02789215|BEHAVIORAL|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|
41116790|NCT00988975|PROCEDURE|Insertion of pelvicol graft|Pelvicol graft
41116791|NCT03379935|PROCEDURE|Type of radial head arthroplasty|Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.
41116792|NCT02220816|BEHAVIORAL|Competitive training|30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
41116793|NCT02220816|BEHAVIORAL|Non-Competitive Training|30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
41116794|NCT04585412|DRUG|Palonosetron|Pharmacokinetic study under fasting conditions
41116795|NCT03038217|DRUG|Capecitabine +/- Oxaliplatin|Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.
41116796|NCT03038217|PROCEDURE|local resection|Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma
41116797|NCT03038217|PROCEDURE|radical resection|Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma
41116798|NCT03038217|OTHER|No adjuvant chemotherapy|Patients in Non-ACT group will not undergo postoperative adjuvant chemotherapy.
41116799|NCT03050814|DRUG|Avelumab|10 mg/kg intravenous (IV) over 30-60 min on Day 1
41116800|NCT03050814|BIOLOGICAL|Ad-CEA vaccine|Subcutaneous injection in the thigh prior to Avelumab on Day 1 of cycles 1, 2 3, 5, 7, 9; every 6 cycles thereafter.
41116801|NCT03050814|DRUG|Bevacizumab|5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
41116802|NCT03050814|DRUG|5-Fluorouracil (FU)|400mg/m\^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.
41116803|NCT03050814|DRUG|Leucovorin|400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
41116804|NCT03050814|DRUG|Oxaliplatin|85mg/m\^2 (Arm A) or 68mg/m\^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
41116805|NCT03050814|DRUG|Capecitabine|625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.
41116806|NCT03050814|DRUG|5-Fluorouracil (FU)|2400 mg/m\^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.
41116807|NCT01047852|PROCEDURE|Noninvasive ventilation|NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
41116808|NCT00459758|DEVICE|Hans unit|
41116809|NCT06203197|OTHER|Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)|intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS).
41116810|NCT03939195|OTHER|Follow-up|4 follow-up visits with OCT Angiography and Structural OCT B
41116811|NCT04724018|DRUG|Sacituzumab Govitecan (SG)|Intravenous infusion
41116812|NCT04724018|DRUG|Enfortumab vedotin-ejfv (EV)|Intravenous infusion
40752828|NCT01200134|OTHER|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
40752829|NCT04225520|DEVICE|Cardiac resynchronization therapy ON|Implantation of a CRT device. Bi-ventricular pacing will be turned ON.
40752830|NCT04225520|DEVICE|Cardiac resynchronization therapy OFF|Implantation of a CRT device. Bi-ventricular pacing will be turned OFF.
40752831|NCT01928576|DRUG|Azacitidine|
41116813|NCT05390749|DRUG|Orelabrutinib|Orelabrutinib will be given as 150mg orally d1-d21 for 6 cycles,every 21 days for 1 cycle.
41116814|NCT05390749|DRUG|Pomalidomide|Pomalidomide will be given as 4mg d1-d14 for 4 cycles,every 21 days for 1 cycle.
41116815|NCT05390749|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
41116816|NCT05390749|DRUG|Methotrexate|methotrexate 3.5g/m2 civ d1/cycle5-6
41116817|NCT02014142|DRUG|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
41116818|NCT03062332|GENETIC|Faecal genome|Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
41116819|NCT03560934|DRUG|Dronabinol|Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.
41116820|NCT02515838|DRUG|Sevuparin|The Drug Product sevuparin solution for IV infusion
41116821|NCT02515838|OTHER|Placebo|Placebo for IV infusion
41116822|NCT06399029|DRUG|Ruxolitinib Topical Cream|Ruxolitinib cream will be applied topically twice daily on up to 20% of the body surface over 12 weeks in patients with lichenoid skin toxicity under anti PD1 treatment.
41116823|NCT06327685|DRUG|Avapritinib|Avapritinib is an oral tyrosine kinase inhibitor.
41116824|NCT06327685|DRUG|Decitabine|Decitabine is a nucleoside metabolic inhibitor given intravenously.
41116825|NCT06327685|COMBINATION_PRODUCT|Decitabine/Cedazuridine|Decitabine/Cedazuridine is a combination medicine given orally.
41116826|NCT03295747|DRUG|Peppermint oil|Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.
41116827|NCT02753192|OTHER|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.
41116828|NCT02064959|DEVICE|Temperature management Zoll Intravascular Temperature Management device|
41116829|NCT05544721|DRUG|Ropivacaine|0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
41116830|NCT06460688|OTHER|Mother Rehabilitative Aid Education Program|Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. A class will be organized to educate Mothers/ Caregivers through PPT presentation, video and pictures. This class will contain 3 domains (Counseling, Educating, Practicing). Feedback will be taken on daily basis through video recordings. Mothers will take part in treatment session, 45 minutes for 5 days a week for 8 weeks.
41116831|NCT06460688|OTHER|Neuro physical Therapy|Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. for 45 minutes, 5 days a week for 8 weeks. Participants in group B will not be educated about treatment plan. Routine home plan was given in this group once in a week, for 8 weeks.
41116832|NCT02622984|BEHAVIORAL|RBIRT|Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.
41116833|NCT02622984|BEHAVIORAL|SBIRT|"Face to face standard intervention considered treatment as usual."
41116834|NCT01063140|BIOLOGICAL|Rabies Vaccine (RabAvert)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
41116835|NCT01063140|BIOLOGICAL|Rabies Vaccine (Imovax)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
41116836|NCT00423098|DRUG|Mycophenolate sodium|Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
41116837|NCT00423098|DRUG|Prednisone|Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
41116838|NCT00423098|DRUG|Methylprednisolone|All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
41116839|NCT02238418|DRUG|Cholecalciferol vial (100 000 UI)|"VISIT 1:~Patient \> 60 kg and initial 25OHD serum concentration \< 25nmol/L : prescription of 4 vials to be taken every 2 weeks between 25 and 50 nmol/L: prescription of 3 vials to be taken every 2 weeks between 50 and 75 nmol/L: prescription of 2 vials to be taken every 2 weeks Patient between 20 and 60 kg and initial 25OHD serum concentration \< 25nmol/L: prescription of 2 vials to be taken every month between 25 and 50 nmol/L: prescription of 2 vials to be taken every 6 weeks between 50 and 75 nmol/L: prescription of 1 single vial Patient \< 20 kg and initial 25OHD serum concentration \< 75 nmol/L: prescription of 1 single vial~A local lab will performed urinary dosage of calciuria and creatininuria:~* at days 0, 1, 2, 3, 4 and 7 after the first intake of a 25OHD vial~* at days 0, 2 and 4 after other intakes (when applicable)~VISIT 2:~25OHD serum concentration will then be dosed at month 2 after visit 1"
40752832|NCT01928576|DRUG|Entinostat|
41116840|NCT03302429|OTHER|PRF/ BCP|Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)
41116841|NCT03302429|OTHER|Autogenous bone graft|Bone obtained from the same individual who receiving the graft
41116842|NCT05372588|DRUG|NVX-CoV2515|Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
41116843|NCT05372588|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
41116844|NCT05372588|DRUG|NVX-CoV2373 + NVX-CoV2515|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
41116845|NCT05372588|DRUG|NVX-CoV2540|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
40752833|NCT01928576|DRUG|Nivolumab|
40752834|NCT01928576|DRUG|CC-486 300|
40752835|NCT03611465|OTHER|Pace-mapping|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
41116846|NCT05372588|DRUG|NVX-CoV2373 + NVX-CoV2540|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
40752836|NCT03611465|OTHER|Standard pace-mapping examination|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
41116847|NCT03535558|DRUG|Fluoroquinolone (FQ)|Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
41116848|NCT03535558|DRUG|Azithromycin (AZ)|Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
41116849|NCT03535558|DRUG|Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination|Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.
41116850|NCT02951013|OTHER|restrictive transfusion|Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL
41116851|NCT02951013|OTHER|liberal transfusion|
41116852|NCT03696862|PROCEDURE|free gingival graft|Use of free gingival graft to seal the socket after flapless atraumatic tooth extraction is performed, implant placement and filling the socket with bone graft.
41116853|NCT01118377|DRUG|Capecitabine|Capecitabine was supplied as film-coated tablets.
40752837|NCT01496859|DEVICE|Placement and use of Baska mask|use of a supraglottic airway device as a standard part of a general anaesthetic
41116854|NCT01118377|RADIATION|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
41116855|NCT00086892|BIOLOGICAL|cetuximab|
41116856|NCT00086892|DRUG|carboplatin|
41116857|NCT04003805|DRUG|Standardized Research E-cigarette (SREC)|The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (\~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
41116858|NCT04003805|DRUG|Nicotine Mini-Lozenge|We will use commercially available nicotine mini-lozenges containing 2 or 4 mg nicotine/lozenge (Nicorette, manufactured by GlaxoSmithKline). Dose will be determined per instructions on the package (e.g, if smoking within 30 minutes upon awakening, then 4 mg dose will be prescribed).
41116859|NCT01404182|BIOLOGICAL|Vaccination with Fluval AB influenza vaccine|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
41116860|NCT04272645|DRUG|Abemaciclib 200 MG|200 MG orally BID Days 1-21
41116861|NCT04272645|DRUG|Atezolizumab 1200 MG in 20 ML Injection|1200 mg IV on Day 1 of 21-day cycle
41116862|NCT04272645|DRUG|Abemaciclib 150 MG|150 MG orally BID Days 1-21
41116863|NCT02689180|DRUG|Placebo|Replacement of furosemide by placebo
41116864|NCT02689180|DRUG|Furosemide|Maintenance of furosemide on usual doses
41116865|NCT06412445|PROCEDURE|Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair applying tissue glue for mesh fixation|The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving applying tissue glue for mesh fixation. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
41116866|NCT06412445|PROCEDURE|Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair using self-fixating mesh|The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving the adherence of grips to tissue using self-fixating mesh. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
41116867|NCT00997386|DRUG|busulfan, and melphalan, and alemtuzumab|"intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1."
41116868|NCT02655458|DRUG|Elotuzumab|"The following must also be administered before any elotuzumab:~Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po)."
41116869|NCT02655458|DRUG|Lenalidomide|On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
41133369|NCT05728684|BIOLOGICAL|CM310|CM310 Injection
41133370|NCT05561491|BIOLOGICAL|ONCOS-102|Oncolytic virus
41133371|NCT05561491|BIOLOGICAL|Balstilimab|Anti PD-1
41133372|NCT00800176|DRUG|Placebo|po daily for 12 weeks
41133373|NCT00800176|DRUG|RO4998452|2.5mg po daily for 12 weeks
41116870|NCT02655458|OTHER|autologous PBMC reconstitution|Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.
41116871|NCT02655458|OTHER|ASCT|"Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are harvested, stored and then returned to the body (engrafted). To be done as part of standard of care."
41116872|NCT00118768|DRUG|valopicitabine|
41116873|NCT00118768|DRUG|Pegylated Interferon Alfa|
40752838|NCT05186298|DEVICE|AcrySof® IQ PanOptix®|The AcrySof IQ PanOptix® (Alcon) mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL
41116874|NCT04668170|BIOLOGICAL|Blood collection on admission and longitudinally|Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
41116875|NCT04668170|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|Samples already collected on consultation (D0) and 14 days later
41116876|NCT03876210|COMBINATION_PRODUCT|PK101|PK101-001 + PK101-002 (combination)
41116877|NCT03876210|DRUG|PK101-001, PK101-002|coadministration
41116878|NCT02815566|DRUG|tenofovir-alafenamide-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
41116879|NCT02815566|DRUG|tenofovir-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
41116880|NCT05886491|DRUG|GDX012|GDX012 suspension for IV infusion.
41116881|NCT05886491|DRUG|Chemotherapy Agents|Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.
41116882|NCT04830501|DRUG|TT-00434|Once daily \[QD\], 28 days/cycle.
41116883|NCT01914913|BIOLOGICAL|BMMNCs|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
41116884|NCT01735019|DRUG|Administration of remifentanil with TCI system|A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
41116885|NCT00622531|DEVICE|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
41116886|NCT00622531|OTHER|hidden BNP value|no intervention
41116887|NCT01681381|DEVICE|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
41116888|NCT01681381|DEVICE|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
41116889|NCT03623997|OTHER|Iron stable isotope labeled iron(II) sulfate|Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia
41116890|NCT00065260|DRUG|Campath-1H|Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
41116891|NCT00065260|DRUG|r-ATG|Rabbit ATG 3.5mg/kg/day for consecutive 5 days
41116892|NCT00065260|DRUG|CsA|CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
41116893|NCT05485389|OTHER|simulation based learning|An educational methodology that aims to improve participants' attitudes towards the elderly and their perception of individualized care.
41116894|NCT01538719|DRUG|Rilonacept|Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
41116895|NCT01538719|OTHER|Placebo|Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks
41116896|NCT00427323|PROCEDURE|light exposure|
41116897|NCT00827346|DRUG|Clopidogrel|600 mg now
41116898|NCT00827346|DRUG|Clopidogrel|600 mg now and 600 mg in 3 hours
41116899|NCT00827346|DRUG|Clopidogrel|900 mg now
41116900|NCT00827346|DRUG|Clopidogrel|600 mg now and 300 mg in 3 hours
41116901|NCT05316220|DRUG|Mesalamine|Oral Capsules
41116902|NCT05316220|DRUG|Placebo|Oral Capsule
41116903|NCT03381820|OTHER|instrumental folk music|The music was composed and edited by a professor of Folk Musical Department, Faculty of Arts, Khon Kaen University. There were total of 6 songs, 32-minute length. The music was slow-instrumental, 60-80 beats per minute and ranged between 40-60 decibel levels.
41116904|NCT00664404|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
41116905|NCT05006092|DEVICE|ENDOMIND|CADe system for Polyp detection
41116906|NCT03950869|BEHAVIORAL|Positive Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase positive expectations.
41116907|NCT03950869|BEHAVIORAL|Negative Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase negative expectations.
41116908|NCT00319306|DRUG|Budesonide/formoterol|
41116909|NCT00319306|DEVICE|Symbicort® Turbohaler®|
41116910|NCT04725305|DEVICE|BiZact|It has been described as describes a bipolar device that continuously measures impedance of clamped tissue, adjusting energy levels in real time and automatically stopping energy delivery when a seal is established. Their literature suggests the device permanently seals vessels up to 3mm with less thermal damage, resulting in less intraoperative blood loss, more efficient procedures, and possibly less pain
40926210|NCT02763592|OTHER|placebo plaster|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
41116911|NCT04725305|PROCEDURE|Standard of care|This method would involve removal of tonsils using electrocautery technique
41116912|NCT03615495|DEVICE|Flourish Pediatric Esphogeal Atresia device|The Flourish Pediatric Esophageal Atresia device consists of an esophageal catheter and a gastric catheter. Both catheters are equipped with an inner magnet catheter. When the esophageal and gastric catheters are aligned tip to tip, the magnets attract.
41116913|NCT00697489|PROCEDURE|correction of POP plus preventive continence procedure|
41116914|NCT00697489|PROCEDURE|POP surgery followed by eventual incontinence procedure|
41116915|NCT02645006|BEHAVIORAL|3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
41116916|NCT02645006|BEHAVIORAL|1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
41116917|NCT04454151|DRUG|Azithromycin Tablets|given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
41116918|NCT04237155|OTHER|Questionnaire|Subjects will complete a verbal material scoring questionnaire
41116919|NCT04237155|OTHER|Cognitive tests|Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference
41116920|NCT01532310|DRUG|belimumab|Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
41116921|NCT01869543|OTHER|Stand Alone Air Cleaner|This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
41116922|NCT01869543|OTHER|HVAC Modification|This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.
41116923|NCT02743078|DRUG|Bevacizumab|10 mg/kg every 2 weeks intravenously over 30 minutes.
41116924|NCT02743078|DEVICE|TTFields Therapy|Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.
41116925|NCT00006517|DEVICE|bright light box|10,000 lux bright light therapy
41116926|NCT00006517|DEVICE|dawn simulator|gradual rise in bedroom illumination prior to wake-up
40926211|NCT00423787|BIOLOGICAL|Ragweed MATA MPL|"4 injections of increasing dose strength:~1. 300 SU/0.5 ml~2. 700 SU/0.5 ml~3. 2000 SU/0.5 ml~4. 6000 SU/0.5 ml"
41116927|NCT00006517|DEVICE|high-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
41116928|NCT00006517|DEVICE|low-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
41116929|NCT00006517|DEVICE|dawn light pulse|rectangular light pulse matched for lux.time of dawn simulation delivered prior towake-up
41116930|NCT02869022|DRUG|Custodiol-N|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
41133374|NCT00800176|DRUG|RO4998452|5mg po daily for 12 weeks
40926212|NCT02739633|DRUG|Genexol-PM|125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
41116931|NCT02869022|DRUG|Custodiol|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
41116932|NCT02869022|PROCEDURE|organ perfusion for heart transplantation|
41116933|NCT05082935|BEHAVIORAL|Phase II Promotores de Salud|Community partners (e.g., Mexican Consulate) select events for testing and use their usual outreach methods to attract participants to the site and their event. Then, at the community partner's event, the research team holds COVID-19 testing events and the Promotores de Salud health behavior intervention is delivered by bilingual research staff. The health behavior intervention includes: 1) psychoeducation to promote hand-washing, social distancing, mask wearing if unvaccinated, and continued testing to mitigate the spread of COVID-19 and psychoeducation to address vaccine hesitancy; 2) information support and service navigation to address logistical challenges associated with testing and vaccination (e.g., scheduling health care visits, transportation, language barriers); 3) motivational interviewing to explore personal, social, and behavioral barriers to testing and vaccination, and to discuss available resources.
41116934|NCT05082935|BEHAVIORAL|Phase I Promotores de Salud Outreach|Testing events re-occur every two weeks at the same location and time, based on census density on Latinx individuals for site selection. Outreach conducted by promotores occurs to increase attendance at the testing events. Outreach is culturally responsive (e.g., culturally tailored radio announcements, social media posts, community canvassing, referral by community leaders).
41116935|NCT05208554|BEHAVIORAL|Integrated health counseling and step prescription|8 weekly dyad-based sessions with a health counselor to train couples in the use of communal coping strategies to support one another in achieving physical activity goals plus individualized step prescription based on remotely-monitored Fitbit-derived step counts the week prior
41116936|NCT01530698|BIOLOGICAL|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
41116937|NCT01530698|BIOLOGICAL|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
41116938|NCT05721924|PROCEDURE|Pericapsular nerve group (PENG) block|In PENG group, the patient will be given PENG block 30mls of 0.2% ropivacaine
41116939|NCT05721924|PROCEDURE|Supra-inguinal fascia iliaca compartment (S-FICB) block|Patients in group B (S-FICB group) will be supra-inguinal fascia iliaca compartment block 30mls of 0.2% ropivacaine
41116940|NCT04167163|DRUG|Abaloparatide|18 month ABL treatment
41116941|NCT01860612|DEVICE|Artificial Iris (CustomFlex)|
41116942|NCT03967704|PROCEDURE|Life quality evaluation|As part of this research, 2 additional consultations at 12 months and 24 months will be carried out by one of the rheumatologists in the department. At the consultation 12 months after his inclusion, the patient will have a clinical examination, a quality of life questionnaire to complete and additional images (x-rays). For the 24-month consultation, the patient will have a clinical examination, a quality of life questionnaire to complete and the patient may have an additional X-ray of the spine if there is height loss \> 2 cm and/or pain.
41116943|NCT02240446|DEVICE|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
41116944|NCT02240446|DEVICE|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
41116945|NCT03547791|DRUG|Betamethason Sodium Phosphate|The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.
41116946|NCT03547791|DRUG|Normal saline|Intramuscular injection of normal saline 3ml twice 24hours apart
41116947|NCT05765370|PROCEDURE|Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 25mg/dL≤ LDL-C\<70mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
41133375|NCT00800176|DRUG|RO4998452|10mg po daily for 12 weeks
41133376|NCT00800176|DRUG|RO4998452|20mg po daily for 12 weeks
41133377|NCT00800176|DRUG|RO4998452|40mg po daily for 12 weeks
41133378|NCT01212822|BIOLOGICAL|bevacizumab|Given IV
41133379|NCT01212822|DRUG|oxaliplatin|Given IV
41133380|NCT01212822|DRUG|leucovorin calcium|Given IV
41133381|NCT01212822|DRUG|fluorouracil|Given IV
40752839|NCT05186298|DEVICE|Synergy®|The TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing far vision comparable to an aspheric monofocal IOL. Compared to an aspheric monofocal IOL, the lens provides significantly improved intermediate and near vision, including in low-light conditions.
40926213|NCT02739633|DRUG|Gemcitabine|1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
41116948|NCT05765370|PROCEDURE|Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 70mg/dL≤ LDL-C\<100mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
41116949|NCT00199966|DRUG|Divalproex sodium extended release|
41116950|NCT05834842|BEHAVIORAL|Unisalud|"The UNISALUD intervention will be made up of 42 videos, made using the visual collage technique, where illustration, video fragments and visual interactions are mixed and in some there will be a presenter to achieve captivating visual material. to the participant. Likewise, it will be accompanied by digital infographics that will help reinforce the information proposed by the intervention."
41116951|NCT03784768|OTHER|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
41116952|NCT03784768|OTHER|Control Group|Patients in control group will be received 60-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
41116953|NCT05218733|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive bilateral ultrasound-guided ESPB by the an experienced anesthetist in US regional blocks, with each block 20 mL of bupivacaine 0.25%
41116954|NCT05218733|DRUG|Intra thecal morphine.|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive intra thecal morphine with spinal needle 25G, 3 ml containing 300 ug preservative free morphine
41116955|NCT05218733|DRUG|General anesthesia using intravenous fentanyl (1µgm/kg)|Patients will receive general anesthesia using intravenous fentanyl (1µgm/kg)
41116956|NCT00818805|DRUG|Olopatadine 0.1%|one drop in one eye
41116957|NCT00818805|DRUG|Tranilast 0.5%|one drop in one eye
41116958|NCT00818805|DRUG|Placebo (Olopatadine)|one drop in contralateral eye
41116959|NCT00818805|DRUG|Placebo (Tranilast)|one drop in contralateral eye
41116960|NCT02384577|DRUG|Budesonide, Formoterol Fumarate Dihydrate|
41116961|NCT05993351|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|All participants will have 3 MRI scanning sessions to track brain health over time following the same protocol each time. The MRI sessions will occur acutely (\<2 weeks post-concussion), 3-months and 6-months post-concussion. A series of MRI scans will be acquired including T1, T2, T2-FLAIR, SWI, ASL, rsfMRI, and DTI scans to characterize structural, microstructural, functional and tissue perfusion changes within the brain over time.
41116962|NCT05993351|DIAGNOSTIC_TEST|Urine and saliva samples|At each study visit all participants will be asked to provide small urine and saliva samples for a metabolomic analysis using a high throughput multi-segment injection-capillary electrophoresis-mass spectrometry technology. This will allow for rapid non-targeted analysis of polar/hydrophilic metabolites, as well as non-polar/ionic lipids with stringent quality control.
41116963|NCT05993351|BEHAVIORAL|Questionnaires|The Post-Concussion Symptom Scale (PCSS) and the Depression Anxiety Stress Scale (DASS-42) will be used to assess the self-reported presence and severity of known concussion-related symptoms.
41116964|NCT03996863|DEVICE|Otoband|Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
41116965|NCT03996863|DEVICE|Placebo device|Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
41116966|NCT02874118|BEHAVIORAL|Fried scale for frailty assessement|
41116967|NCT05086159|BEHAVIORAL|Pain Neuroscience Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1: the nervous system is like an alarm to protect.~Session 2: common ways the nervous system becomes sensitive.~Session 3: importance of gradual conditioning and neuroplasticity.~Session 4: common ways to decrease nervous system sensitivity."
41133382|NCT01212822|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
41133383|NCT01212822|OTHER|laboratory biomarker analysis|Correlative studies
41133384|NCT02824198|BIOLOGICAL|CYD Dengue Vaccine (5 dose formulation)|0.5 mL, Subcutaneous
41133385|NCT02824198|BIOLOGICAL|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
41133386|NCT02588443|DRUG|RO70097890|
41453383|NCT05921812|DIAGNOSTIC_TEST|real time pcr|evaluate the expression of certain circulating microRNAs by real time pcr
41453384|NCT01023113|PROCEDURE|PASCAL laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
41453385|NCT01023113|PROCEDURE|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
40926214|NCT01120067|BEHAVIORAL|Intensive Treatment|Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
40926215|NCT01120067|BEHAVIORAL|Treatment as Usual|Treatment as Usual.
40926216|NCT02153879|DRUG|Fenofibrate|fenofibrate 145/day for 12 weeks
40926217|NCT02153879|DRUG|Niacin plus laropiprant|Niacin 2 g/day plus Laropiprant for 12 weeks
41116968|NCT05086159|BEHAVIORAL|Exercise|"The exercise protocol for each group will be identical and modeled after the Back to Fitness program. This program will consist of a 5-10-minute cardiovascular warm-up of walking in place or riding an exercise bike. Next is a 15-minute circuit consisting of 10 different general exercises for 1-minute each. Finally, a 5-minute cool down will consist of light stretching and trunk range of motion exercises. Each exercise will be tailored as easy, medium, or hard depending on the individual patient's tolerance. This program has been shown to be equally as effective as motor control exercises for long-term outcomes in patients with non-specific LBP."
40752840|NCT05186298|PROCEDURE|Cataract Surgery|IOL implantation will be performed
40752841|NCT03950388|BEHAVIORAL|Intervention|Wards randomly assigned to receive the intervention will have a Band 8a Psychologist based on the ward for 0.5FTE for 7 months. During this time, all patients will be involved with the proposed stepped model of care intervention at one of three levels. The level the patient receives will be decided by the multidisciplinary ward team. At Step one, all patients will have a psychological formulation developed by the psychologist in conjunction with the patient or members of the ward team. At Step 2, all qualified nurses will be trained and supervised to deliver guided self-help material of psychological interventions targeting key problem areas for patients. At Step 3, patients will be offered up to 16, one-to-one therapy sessions with the psychologist.
40752842|NCT02266862|RADIATION|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
40752843|NCT04771871|DRUG|Epirubicin|Epirubicin is an antitumor antibiotics with good activity on breast cancer. It has less cardiotoxic effect than doxorubicin
41116969|NCT05086159|BEHAVIORAL|Traditional Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1 will include a basic overview of the anatomy of the spine.~Session 2 will discuss an overview of stress symptoms to include hypervigilance, avoidance, and re-experiencing.~Session 3 will cover common recommendations delivered in stress education: the do's and don'ts of stress management.~Session 4: review and mindfulness."
40752844|NCT04771871|DRUG|Cyclophosphamide|Cyclophosphamide is a cytoxic drug indicated for the treatment of many malignancies including breast cancer
40752845|NCT04771871|DRUG|Paclitaxel|Paclitaxel is a taxane chemotherapy agent indicated for the treatment of many cancers including breast cancer. It can be used alone or in combination with other drugs
41116970|NCT04226703|DIAGNOSTIC_TEST|Ultrasonographic upper airway measurements|"Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge root.~Indirect Laryngoscopy: Grading of laryngoscopic view (I=Visible anterior commissure and vocal cords, II= visible posterior part of vocal cords and posterior commissure, III= Visible posterior commissure and epiglottis, IV= Visible only epiglottis tip and posterior pharyngeal wall)"
41116971|NCT05981157|DRUG|Anrotinib plus Tirelizumab|Subjects receive Anrotinib, 10mg, QD and Tirelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
41116972|NCT03260647|OTHER|Management algorithm for Malignant Bowel Obstruction|a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
41116973|NCT04310072|DEVICE|Neuromuscular electrical stimulation|NMES therapy induces visible rhythmic and repeated muscle contractions without volitional effort from the patient by applying electrodes to the thigh and/or calf muscles.
41133387|NCT02588443|DRUG|nab-paclitaxel|
41133388|NCT02588443|DRUG|gemcitabine|
41453386|NCT03257254|DRUG|Varithena|Administration procedures and volume are per standard of care, full prescribing information, and instructions for use.
40752846|NCT04771871|DRUG|Carboplatin|Carboplatin is a platinum compound indicated for the treatment of many types of malignancies including breast cancer
41133389|NCT03999788|PROCEDURE|lumbar puncture and blood withdrawal|lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening
41453387|NCT00180401|BEHAVIORAL|CRT-P and CRT-D devices|
41453388|NCT04224753|DEVICE|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest. INVSENSOR00027 detects falls for each subject.
40752847|NCT06105463|OTHER|Strength training sessions and High-interval intensity training sessions|"During strength training sessions, participants will perform 4 lower limb exercises, including bilateral leg press, unilateral leg extension, unilateral hip extension, and bilateral seated calf raise on conventional weight machines. The intensity of the session will be 70-75% of 1-RM, 4 sets, 10 repetitions (1-2 RIR) and 120 seconds rest between sets.~During High-interval intensity training (HIIT) sessions, participants will perform 10 minutes of warm-up at 50% of peak power + 20 minutes of HIIT consisting of 30 seconds at 90% of peak power followed by 30 seconds of rest + 10 minutes of cool-down at 35-40% of peak power in cycloergometer."
40752848|NCT00055965|DRUG|carboplatin|
41116974|NCT05702775|PROCEDURE|Endoscopic treatment group (EUS-GBD group|The placement of a endoscopic drain performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy. Subsequently, the interior of the gallbladder will be irrigated with saline solution until the vesicular content comes out.
41116975|NCT02986906|DRUG|5% dextrose|Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
41116976|NCT02986906|DRUG|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
41116977|NCT02986906|DEVICE|Ultrasound|The ultrasound was used for injection guidance
41116978|NCT01013012|DRUG|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
41116979|NCT01013012|DRUG|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
41116980|NCT04210505|DRUG|Povidone-Iodine Topical Ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.
41116981|NCT04210505|OTHER|Standard Care|Control group will receive standard care as provided by the dialysis center
41116982|NCT04207294|OTHER|Pork arm|The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
41116983|NCT04207294|OTHER|Chicken arm|The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
41116984|NCT01533870|DRUG|NKTR-118|Oral 25 mg
41116985|NCT01533870|DRUG|Rifampin|Oral 600 mg
41116986|NCT01359592|BIOLOGICAL|rituximab|
41116987|NCT01359592|DRUG|cyclophosphamide|
41116988|NCT01359592|DRUG|doxorubicin hydrochloride|
41116989|NCT01359592|DRUG|prednisone|
41116990|NCT01359592|DRUG|vincristine sulfate|
41116991|NCT01359592|OTHER|R-CHOP regimen|
40752849|NCT00055965|DRUG|cisplatin|
40752850|NCT00055965|DRUG|gemcitabine hydrochloride|
40752851|NCT00000538|BEHAVIORAL|diet, fat-restricted|
41446279|NCT06558786|OTHER|EORTC QLQ-C30 questionnaire|"The EORTC QLQ-C30 has 30 items arranged into 9 scales and 6 single items. The scales are divided into 5 function scales (physical, role, cognitive, emotional, and social function), 3 symptom scales (fatigue, pain, and nausea or vomiting), and 1 global health status/quality-of-life scale. The 6 single items address specific symptoms (dyspnea, appetite loss, insomnia, constipation, and diarrhea) and the financial impact of the disease. Each item has 4 response alternatives: (1) not at all, (2) a little, (3) quite a bit, and (4) very much, except for the global health status/quality-of-life scale, which has response options ranging from (1) very poor to (7) excellent. For analysis, all questionnaire responses will be transformed into scores on a linear scale of 0 to 100 in accordance with the EORTC scoring manual. Mean scores with standard deviations will be calculated, with a higher score indicating a better health-related quality of life."
41453389|NCT00627731|DRUG|methylprednisolone sodium succinate (mPSL)|mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
41453390|NCT00627731|DRUG|prednisolone (PSL)|PSL 40 mg per day for 10 days
40752852|NCT01392495|DRUG|Imatinib|200 mg or 400 mg qd
40752853|NCT00971503|PROCEDURE|autologous bone marrow implantation|Filgrastim treatment before bone marrow aspiration that will then be implanted via pancreatic artery
41116992|NCT01359592|OTHER|laboratory biomarker analysis|
41116993|NCT01359592|RADIATION|fludeoxyglucose F 18|
41116994|NCT01359592|RADIATION|selective external radiation therapy|
41116995|NCT01359592|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
41116996|NCT05984836|BEHAVIORAL|Implement health education|"Implement health education class for the rural mothers in the for of one session will take about 30 minutes and it will include the following:~First aid (fracture, burn, bleeding, injuries and food poising). Critique malpractice for injuries management behavior at home.~About 10 mothers will be included in the session. Each session will take 30 minutes (in the family health center), to cover all theoretical contents.~The researcher will use different teaching methods as demonstration and discussion, learning aids as handout, video and pictures."
41116997|NCT02203760|DRUG|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
41116998|NCT02203760|DRUG|Pazopanib|Pazopanib 800 mg orally once daily
41116999|NCT05796739|DIAGNOSTIC_TEST|Non-invasive stress test|Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging
41117000|NCT05796739|DIAGNOSTIC_TEST|Medical treatment without further testing|Optimal medical treatment for primary prevention.
41117001|NCT04287114|BEHAVIORAL|Acute exercise|Acute exercise with different exercise intensities
41117002|NCT03294499|OTHER|Questionnaire|Patients will be asked to complete one off questionnaire.
41117003|NCT04738058|DRUG|Bovine Lactoferrin Supplement|Bovine lactoferrin or placebo will be given to both arms with each feed for 30 days or till discharge from NICU the Lactoferrin dose 100mg/day Then determin is effect by serum zonulin level
41117004|NCT04738058|DRUG|placebo|placebo
41117005|NCT03430414|DIAGNOSTIC_TEST|Transcriptome Analysis|Transcriptome Analysis of Formalin Fixed Paraffin Embedded biopsies
41117006|NCT03674814|DRUG|Enzalutamide|Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
41117007|NCT03674814|DRUG|Relacorilant|Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
41117008|NCT04056611|DRUG|JNJ-53718678 250 mg|JNJ-53718678 250 mg will be administered orally.
41117009|NCT04056611|DRUG|Placebo|Matching placebo will be administered orally.
41117010|NCT04056611|DRUG|JNJ-53718678 125 mg|JNJ-53718678 125 mg will be administered orally.
41117011|NCT00226772|DRUG|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
41117012|NCT00226772|DRUG|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
41117013|NCT05025995|BEHAVIORAL|Serious health game|Serious health game
41117014|NCT05908942|DEVICE|Nerve ablation|radiofrequency and phenol ablation of the genicular nerves will be performed
41117015|NCT05072171|PROCEDURE|Inguinal hernia repair with dynamic prosthesis|Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H\&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.
41117016|NCT06109220|BEHAVIORAL|Stromal vascular fraction,SVF|SVF was injected into the knee cavity
41117017|NCT05631405|DRUG|Dexamethasone|Patients treated with dexamethasone
41117018|NCT05631405|DRUG|Placebo|Patients treated with placebo
41117019|NCT04867902|BEHAVIORAL|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
41117020|NCT03098810|DRUG|Zinc sulphate|Oral syrup zinc sulphate
41117021|NCT03098810|OTHER|Placebo|Oral syrup placebo
41117022|NCT05878158|DRUG|Simvastatin|pulpotomy of immature permanent teeth
41117023|NCT03547804|DRUG|Apatinib|500 mg qd/250mg
41117024|NCT03547804|DRUG|chemotherapy|Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
41117025|NCT03586817|DRUG|Palonosetron|75 mcg during the anesthesia
41117026|NCT03586817|DRUG|Fosaprepitant|150 mg during the anesthesia
41117027|NCT02396602|BEHAVIORAL|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
41117028|NCT02840422|DEVICE|ARTHRUM H 2%|ARTHRUM H 2%
41117029|NCT03357289|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
41117030|NCT00436072|DRUG|ZD6474|Orally on a daily basis
41117031|NCT00436072|DRUG|Cetuximab|Infusion once weekly
41117032|NCT00436072|DRUG|Irinotecan|Infusion once the safe dose of ZD6474 and cetuximab is established
41117033|NCT02108210|DRUG|Anakinra|
41117034|NCT02108210|DRUG|Placebo|
41117035|NCT06362278|OTHER|multi-omics studies|15cc peripheral venous blood will be collected for multi-omics studies, including whole-exome study, transcriptomics \& metabolomics studies.
41117036|NCT04794959|DIAGNOSTIC_TEST|Dual-energy CT|CMI patients planned for endovascular stent placement will be contacted and informed about this study prior to their procedure. If they wish to take part in the study, then a date for a pre-operative DECT scan will be arranged. Before scanning the patient will be given a standardized calorie dense drink (Nutridrink). This will take place one week prior to their surgical procedure. Following the surgical procedure, the patient will undergo another DECT scan before discharge.
41117037|NCT04894565|PROCEDURE|rehabilitation|physical therapy 24 hrs after surgery
41117038|NCT01336946|BEHAVIORAL|Psycho educational and behavioural group sessions|10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
41117039|NCT01336946|BEHAVIORAL|Walking session|A weekly supervised walking session (30 minutes) in a 10-week period.
41117040|NCT01368016|DRUG|Nicotine|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
41117041|NCT01368016|DRUG|Nicotine|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
40752854|NCT00971503|OTHER|Saline injection|Injection of saline solution for 5 days
41117042|NCT03819816|OTHER|DEA-App|"The intervention (DEA) group will receive the newly developed app. DEA will consist of three simultaneous modules that provide multidimensional support for informal caregivers aiming to reduce the caregiver burden:~1. Information module~   The information module consists of general information on the disease and the care of people suffering from dementia.~2. Activity module~   The activity module suggests individualized activities and physical fitness exercises by a self-learning algorithm, which supports the caregiver to deliver more targeted and easier care.~3. Communication module~If two or more persons are caring for one person with dementia, the communication module provides a networking possibility."
41117043|NCT03819816|OTHER|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
41117044|NCT02903615|OTHER|Novel diet|Novel diet to optimise glucose levels and minimise systemic inflammation: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
41117045|NCT02903615|OTHER|Standard diet|Standard diabetes diet recommendations
41117046|NCT04391101|DRUG|Convalescent plasma|400-500ml convalescent plasma
41117047|NCT01361945|DRUG|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
41117048|NCT00595790|BIOLOGICAL|IC51|
41117049|NCT06187246|BEHAVIORAL|Avatar-based intervention|"Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective.~It was delivered via a metaverse: Second Life."
41117050|NCT06187246|OTHER|Individual informative talks|Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
41117051|NCT02994173|DRUG|Oxycodone|Current clinical practice, used as a control in this study
41117052|NCT02994173|DRUG|S-Ketamine 0.25|dosage
41117053|NCT02994173|DRUG|S-Ketamine 0.5|dosage
41117054|NCT02994173|DRUG|S-Ketamine 0.75|dosage
41117055|NCT06190522|DIAGNOSTIC_TEST|Emergency physician clinical ultrasound|Clinical ultrasound by emergency doctor consisting in obtaining frontal sections of the 2 kidneys and a transverse section of the bladder
40752855|NCT04981756|OTHER|observation|This observational study does not have any intervention.
41117056|NCT04377698|BIOLOGICAL|Platelet Rich Fibrin|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
41117057|NCT04377698|BIOLOGICAL|FDBA|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
41117058|NCT00838253|DRUG|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
41117059|NCT00838253|DRUG|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
41117060|NCT00838253|DRUG|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
41117061|NCT00838253|DRUG|Placebo|Placebo continuous i.v. infusion for 24 hours
41117062|NCT00879060|DRUG|Spironolactone|spironolactone 50mg daily
41117063|NCT00879060|DRUG|Placebo|inactive placebo pill daily
41117064|NCT00476346|DIETARY_SUPPLEMENT|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
41117065|NCT00738023|DRUG|Rosiglitazone|Diabetic subjects will be receive rosiglitazone for 6 weeks
41117066|NCT00738023|DRUG|Normal saline 0.9%|Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
41117067|NCT00738023|DRUG|Intralipid 20%|Intralipid 20% at 40ml/hr intravenously for 48 hours
41117068|NCT02380209|OTHER|CEST MRI|CEST MRI will be performed on patients prior to surgical resection of their tumor
41117069|NCT04324333|BEHAVIORAL|Digital wearable system|Owlytics Healthcare's system is dedicated to improving the lives of all seniors by using the predictive power of data analytics.
41117070|NCT05632471|BEHAVIORAL|"web-based I know digital games training for intervation grup"|"I know digital games training consisting of 10 web-based videos"
41117071|NCT05632471|OTHER|The control group was not trained|The control group was not trained
41117072|NCT06242782|PROCEDURE|VRA + d-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced d-PTFE membrane
41117073|NCT06242782|PROCEDURE|VRA + e-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced e-PTFE membrane
41117074|NCT06242782|PROCEDURE|VRA + customised Ti-mesh|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + 3D printed Titanium mesh
41117075|NCT06242782|PROCEDURE|VRA + RPM|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Reinforced PTFE mesh
41117076|NCT04843306|BEHAVIORAL|Biofeedback|Relaxation coaching will be used in this study.
41117077|NCT04843306|BEHAVIORAL|Active Breathing Control Technique|Active breathing control (ABC) requires patients to reproducibly perform multiple deep-inspiratory breath holds during treatment.
40752856|NCT03114397|DEVICE|transcranial direct current stimulation - active|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes.
40752857|NCT03114397|DEVICE|transcranial direct current stimulation - sham|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes. The sham intervention consists of 30 seconds of stimulation at the beginning and the end of the 20minutes of intervention.
40752858|NCT00215553|DRUG|A.1 Lucinactant|3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
41117078|NCT01563380|BIOLOGICAL|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
41117079|NCT04944407|PROCEDURE|LHP|A skin microincision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe (1.85 mm of diameter) was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions), 8 watt per 3 seconds each, of approximately 24 Joule using a 1470-nm diode laser generator (LEONARDO® DUAL 45 Biolitec® Jena, Germany) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
41117080|NCT04944407|PROCEDURE|MM|The hemorrhoidectomy was performed by radiofrequency (LigaSure TM Small Jaw® Covidien®, Colorado, USA) or ultrasound (Focus® Ultracision® harmonic scalpel; Ethicon Endo-Surgery®, Inc., Cincinnati, Ohio). The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
41117081|NCT02372253|DRUG|Verapamil|
41117082|NCT02372253|DRUG|Placebo|
40752859|NCT00215553|OTHER|B.3 SoC|Standard ARDS management and ICU care
40752860|NCT00215553|DRUG|A.2 Lucinactant|3 30 mL aliquots at a concentration of 10 mg/mL each
41117083|NCT03768310|BIOLOGICAL|CD19.CAR-multiVST for Group A|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.
41117084|NCT03768310|BIOLOGICAL|CD19.CAR-multiVST for Group B|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the bone marrow transplant. A time period of 6 weeks will constitute the time for clinical safety monitoring. If patients with relapse after transplant or those with evidence of disease before bone marrow transplant have at least a partial response to the treatment or have stable disease, they will be eligible to receive up to 6 additional doses of T cells separated by a minimum of four weeks. Patients are eligible to receive additional doses only after they have completed the initial 6-week clinical safety monitoring period.
41117085|NCT01306864|DEVICE|Hemospray Kit|Hemostasis of Arterial GI Bleeding
41117086|NCT03506880|BEHAVIORAL|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
41117087|NCT03506880|BEHAVIORAL|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
40752861|NCT00215553|DRUG|A.3 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
40752862|NCT00215553|DRUG|A.4 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
41117088|NCT02235272|DRUG|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
41117089|NCT02235272|DRUG|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
41117090|NCT05500664|DRUG|Lavender Oil|three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
41117091|NCT01399671|OTHER|vestibular stimulation|vestibular stimulation
41117092|NCT05789771|DRUG|Abemaciclib|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
41117093|NCT05789771|DRUG|Abemaciclib|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
41117094|NCT05789771|DRUG|Abemaciclib|Abemaciclib 200 mg orally every 12 hours
40752863|NCT00215553|DRUG|B.1 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
41117095|NCT01064817|DRUG|PRM-151|PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
41117096|NCT01064817|DRUG|Placebo|Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
41117097|NCT04895475|BEHAVIORAL|SARS-CoV-2 vaccine|Baseline demographics, baseline breast milk samples, and blood collection will be obtained at the initial visit. Serial collections of breastmilk and blood as well as weekly self-administered monthly surveys will occur
41117098|NCT05817097|DRUG|Dipeptidyl peptidase-4 inhibitor|The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
41453391|NCT04898998|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Surgical patients under general anesthesia were recruited from a medical center. Each patient was randomly assigned to the experimental group (TENS) or control group (routine care).
41453392|NCT04898998|OTHER|routine care|routine care
40752864|NCT00215553|DRUG|B.2 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
40752865|NCT04134312|BIOLOGICAL|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
40752866|NCT05080543|DRUG|Albumin 20% and terlipressin|Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
40752867|NCT01801605|PROCEDURE|rTMS|Active session with stimulation and placebo session with fictive stimulation
40752868|NCT00884000|DRUG|Genotropin|
41117099|NCT05942768|DRUG|regorafenib plus anti-PD-1 antibodies|The patients were treated orally with regorafenib (80 mg once daily for 21 days on/7 days off, over a 28-day cycle), combined with 1 of the 5 anti-PD-1 antibodies (i.e., nivolumab, pembrolizumab, camrelizumab, sintilimab, or toripalimab). The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks
41117100|NCT00718939|DEVICE|Rheos Baroreflex Activation Therapy System|The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
41117101|NCT03100513|DRUG|Lactulose|(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
41117102|NCT03100513|DRUG|Polyethylene Glycol|PEG as single dose of (3sachets if patient \<75Kg over 3 hours or 4 sachets if patient \>75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
41117103|NCT02780440|BEHAVIORAL|Traditional Home Based Exercise Program|Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.
41117104|NCT02780440|BEHAVIORAL|Unimanual Home Based Mirror Therapy Program|The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.
41117105|NCT02780440|BEHAVIORAL|Bimanual Home Based Mirror Therapy Program|The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
41117106|NCT03133117|RADIATION|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)
41117107|NCT01723410|BEHAVIORAL|Writing about people|Subjects will be asked to write about other people in their lives once a week for 6-weeks.
41117108|NCT01723410|OTHER|Writing about places, objects|
41117109|NCT00523146|DRUG|Kanion Capsule|
41117110|NCT00780299|DEVICE|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
41117111|NCT00780299|PROCEDURE|CVVH|hemofiltration intermittent dialysis
41117112|NCT00064012|DRUG|bortezomib|
40752869|NCT00884000|DRUG|Zomacton|
40926218|NCT02958683|OTHER|Chest wall motion analysis|Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
41117113|NCT00064012|DRUG|docetaxel|
41453393|NCT02230930|DRUG|Apomorphine 0.25% (2.5mg/ml)|Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).
41453394|NCT02230930|DEVICE|Massage with a spiky ball|Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.
41117114|NCT03400254|DRUG|Hydroxychloroquine (HCQ)|All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).
41117115|NCT03400254|DRUG|Gedatolisib|"Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC \>1.0 x 109/L and platelet count \> 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to \<grade 1 then any further treatment with GED should be stopped."
41117116|NCT00768235|OTHER|yoga practice|The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
41117117|NCT05446363|DEVICE|Medimonitor|A digital solution consisting of web based portal gathering data from mobile fundus camera and intraocular tonometer provided to the physicians located remotely to the University hospital that provides consults and analyses of on-site gathered data.
41117118|NCT03039361|BEHAVIORAL|Equine Assisted Psychotherapy|Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
41117119|NCT01426178|DEVICE|Neurally Adjusted Ventilatory Assist in Non Invasive Ventilation (Device)|"After written information and consent, patients are randomised in two groups: NAVA first or PSV first.~They receive a NAVA catheter, which has exactly the same appearance as a standard naso-gastric catheter."
41117120|NCT01839981|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
41117121|NCT04778124|PROCEDURE|Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)|All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.
41117122|NCT04778124|PROCEDURE|Excision of thrombosed hemorrhoid / Hemorrhoidectomy /|One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.
41117123|NCT00003005|DRUG|Cordycepin|"Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2"
41117124|NCT00003005|DRUG|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
41117125|NCT06338618|PROCEDURE|liver treatment protocol|The liver treatment protocol consists of performing twelve visceral manual techniques in an approximate time of 30 minutes twice a week for 4 weeks
41117126|NCT02020252|BEHAVIORAL|Testing an interactive technology in a diverse health literary population|Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. We tested an interactive technology designed for patients with diverse health literacy skills aimed at improving patient receptiveness, willingness, knowledge, self-efficacy and positive attitudes regarding clinical trials.
41117127|NCT05997966|OTHER|Progresive Resistance Exercises|At the beginning of the study, there will be a home visit (week 0) where the exercises will be taught. Exercise brochures explaining the exercises in written and visual form will also be given to each participant during the first and subsequent home visits. After the first home visit, individuals will be asked to keep an exercise diary prepared by the physiotherapist in order to control the exercises, the occurrence of side effects and dependence on the treatment, and information will be obtained from the individuals by phone calls every week. Two more home visits will take place in weeks 5 and 9 to further the IDE program. Apart from these visits and phone calls, the participant will be allowed to call the physiotherapist if needed. In the exercise group, the 12-week home-based IDE program will be applied 2 sets/day for 3 days/week (on non-consecutive days).
41117128|NCT05997966|OTHER|No intervation|After a general education about osteoarthritis in the control group, 30 minutes of walking will be requested twice a week, and no other intervention will be made.
41117129|NCT04122937|PROCEDURE|Cytoreductive surgery|Partial removal of peritoneal tissue involved by neoplastic invasion
41117130|NCT06553261|PROCEDURE|suturing of leak, lavage, drainage|Operative suturing of the leak, lavage, drainage within a revision surgery.
41117131|NCT06553261|PROCEDURE|Formation of a new anasthomosis|Operative resection of the old leaking anastomosis and formation of a new one.
41117132|NCT06553261|PROCEDURE|Fecal diversion|Formation of a deviating stoma.
41117133|NCT04478851|BEHAVIORAL|Group Exercise Classes|The exercise program to be implemented for rural cancer survivors will combine aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format, twice weekly for a 12-week period. If public health restrictions require closure of fitness facilities due to COVID-19, the program will be delivered online. If facilities are open, the sessions will be integrated in the community, delivered in-person. Whether delivered in-class or remotely, the program follows exercise progression principles (ie, frequency, intensity, time, type, overload and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
41117134|NCT02613546|BEHAVIORAL|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~1. evaluation session;~2. sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
41117135|NCT02613546|BEHAVIORAL|Control therapy|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
41117136|NCT04056039|DRUG|Atorvastatin|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
41117137|NCT04056039|DRUG|Colchicine|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
41117138|NCT04481672|DRUG|Magnesium Sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
41117139|NCT03648814|PROCEDURE|Intracameral injection|A/C injection of 1.25 mg/0.05 mL bevacizumab
41117140|NCT03648814|PROCEDURE|Intravitreal injection|Vitreous injection of 1.25 mg/0.05 mL bevacizumab
41117141|NCT06131892|OTHER|Defibrillation|Defibrillation
41117142|NCT03083197|DRUG|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
41117143|NCT03083197|DRUG|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
41117144|NCT03083197|DRUG|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
41117145|NCT01347125|DEVICE|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
41117146|NCT04358549|DRUG|Favipiravir|Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets
41117147|NCT04358549|OTHER|Standard of Care|Standard of Care for individual study site as determined by each hospital's protocol
41117148|NCT05971680|DRUG|VITAMIN B1 500mg|VITAMIN B1 (High Potency) 500mg tab every day for 3 months
41117149|NCT05971680|DEVICE|intra-uterine contraceptive device|intra-uterine contraceptive device
41117150|NCT02284555|DRUG|Mupirocin|Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
41117151|NCT03418805|DRUG|Advil Ibuprofen table 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
41117152|NCT03418805|DRUG|Motrin IB Ibuprofen Tablets 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
41117153|NCT03418805|DRUG|Ibuprofen CR Tablets 600 mg|"Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively"
41117154|NCT05153135|DRUG|Ribociclib|Participants who initiated CDK4/6i therapy
41117155|NCT05153135|DRUG|Palbociclib|Participants who initiated CDK4/6i therapy
41117156|NCT05153135|DRUG|Abemaciclib|Participants who initiated CDK4/6i therapy
41117157|NCT06103630|OTHER|Oropharyngeal Exercises|Oropharyngeal Exercises
41117158|NCT06103630|OTHER|Mandibular advancement device|Mandibular advancement device
41117159|NCT00773708|DRUG|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
41117160|NCT03316521|DRUG|AMY-101|AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
41117161|NCT02613806|DRUG|Dexmeditomidine|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
41117162|NCT02613806|DRUG|normal saline|Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
41117163|NCT03881488|DRUG|CTX-471|IV infusion every 2 weeks
41117164|NCT03881488|DRUG|Pembrolizumab (KEYTRUDA®)|IV infusion every 6 weeks
41117165|NCT02889237|DIETARY_SUPPLEMENT|Calcium|Immediate administration of daily calcium supplementation for 12 weeks
41117166|NCT02889237|DIETARY_SUPPLEMENT|Calcium + low dose vitamin D|Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks
41117167|NCT02889237|DIETARY_SUPPLEMENT|Calcium + high dose vitamin D|Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
41117168|NCT05658341|BEHAVIORAL|ADA|"The 12-weeks program will include one-hour in adapted physical activity (APA), and a discussion on relaxation techniques and the undertaking of deep breathing exercises (making them APA+ sessions). A series of minute for nutrition short information sheets will be distributed at the end of each session.~Two workshops on living better after breast cancer will also be offered: one on general mobility and the other on daily nutrition.~Moreover, women will be asked to set personal challenges as a method of motivational reinforcement, and will also be called for motivational check-ins at least 3 times. Follow-up calls will allow for further individualization, motivation, and the reception of participants' concerns or remarks.~Further, participants in the intervention group will have access to a dedicated internet space containing several documents and videos on topics of concern to patients during the post-treatment phase."
41117169|NCT05658341|BEHAVIORAL|Usual Care|"Participants in the control group will be offered weekly APA sessions for 12 weeks, these sessions are based on current practices within the Siel Bleu organization. Sessions' content is adapted to people who have been treated for (all types) cancer and are based on current recommendations.~These sessions are commonly organized by Siel Bleu in hospitals, community groups or local committees of the national league against cancer organization."
41453395|NCT02230930|DRUG|Hydrocortisone cream 1%|Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
41117170|NCT03286244|DRUG|CM082 plus paclitaxel|"CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles."
41117171|NCT00360698|DRUG|Insulin Glargine|One daily injection at bedtime
41117172|NCT00360698|DRUG|Glimepiride|At same dosage as during the run-in period
41117173|NCT00360698|DRUG|Insulin Glulisine|One bolus given before the main meal
41117174|NCT00360698|DRUG|Metformin|At same dosage as during the run-in period
41117175|NCT01277614|BEHAVIORAL|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
41446280|NCT06558786|OTHER|QLQ-OGS25 questionnaire|The QLQ-OGS25 is specific for esophageal, GEJ, or gastric cancer and consists of a symptom scale only. The QLQ-OGS25 has 6 scales: dysphagia, eating restrictions, reflux, odynophagia, pain, and anxiety. Scales have good reliability (α range, 0.67-0.87), and they distinguish between tumor sites and disease stage. The response format is a 4-point Likert scale. Responses to the questionnaires will be transformed into a scale of 0 to 100 using the EORTC guidelines, with a higher score indicating a deterioration of symptoms.
41446281|NCT06455449|COMBINATION_PRODUCT|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
41117176|NCT05685030|DIETARY_SUPPLEMENT|Placebo|product vehicle (sunflower oil)
41117177|NCT05685030|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri CCT 7862|Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ day.
41117178|NCT05685030|DIETARY_SUPPLEMENT|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day
41117179|NCT01062087|DRUG|Bupivacaine, Lidocaine|Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
41117180|NCT01379014|BEHAVIORAL|Decision Aid Tool|A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances
41117181|NCT01379014|OTHER|Treatment as Usual|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
41117182|NCT00848627|OTHER|Specimen and questionnaires only|Specimen and questionnaires only
41117183|NCT00459446|DRUG|MS-325 Injection (Gadofosveset Trisodium)|
41117184|NCT01525446|RADIATION|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of \> 3 cm)
41117185|NCT03938246|DRUG|TVB-2640|Oral dose, tablet, daily dosing
41117186|NCT03938246|OTHER|Placebo|Oral dose, tablet, daily dosing
41117187|NCT04912791|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
41117188|NCT00841035|DRUG|erlotinib|Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
41446282|NCT06455449|OTHER|Placebo|Matched placebo delivered subcutaneously, once weekly for 52 weeks
41117189|NCT03389191|DRUG|Acyclovir|
41117190|NCT04988568|OTHER|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where patients will be interviewed.
41117191|NCT00994097|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
41117192|NCT00994097|DRUG|Cisplatin|Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
41117193|NCT00994097|DRUG|Gemcitabine|Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
41117194|NCT00994097|DRUG|Pemetrexed|Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
41117195|NCT01395758|DRUG|ARQ 197 plus erlotinib|Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.
41117196|NCT01395758|DRUG|Pemetrexed, docetaxel or gemcitabine|Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.
41117197|NCT02167906|OTHER|arterial stiffness measurement|
41117198|NCT01060137|DRUG|fentanyl matrix|Fentanyl transdermal patch 12 - 25mcg/hr
40752870|NCT02610257|DEVICE|Mechanical stimulus (vibration) applied on the forearm|"Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports."
41117199|NCT05573334|DEVICE|BioNourish|"BioNourish is a 510k-cleared class II medical device that has been on the market for over two years. It is a vaginal moisturizing gel that is designed with pH, osmolality, and lactic acid levels that match those observed in healthy vaginas. It does not have an active ingredient, but only provides moisture in a formula that is matched for physicochemical characteristics to healthy vaginal fluid."
40752871|NCT04387214|OTHER|survey|online survey
41446283|NCT06455449|COMBINATION_PRODUCT|Anifrolumab (unblinded, open label)|At Week 52, all study participants on anifrolumab or placebo will receive open label anifrolumab once weekly for an additional 52 weeks
41117200|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - single intravenous dose|A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
41117201|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous low dose|A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
41117202|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous medium dose|A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
41117203|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous high dose|A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
41117204|NCT03870607|DIETARY_SUPPLEMENT|prebiotics in combination with probiotics|Administration of prebiotics in combination with probiotics before the start of Ch-RT
41117205|NCT02817984|BIOLOGICAL|Acellular Adipose Tissue (AAT)|The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
41446284|NCT03843190|BEHAVIORAL|Take of Pounds Sensibly (TOPS)|Dietician-facilitated classes
41117206|NCT06555770|BEHAVIORAL|müzik müdahalesi|One group of patients will be listening to music for 15 minutes during the surgery, while the other group will be applied a stress ball.
41117207|NCT05386498|PROCEDURE|precured composite insert technique|After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
41117208|NCT05386498|PROCEDURE|Contact making instrument|"a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact."
41117209|NCT05386498|PROCEDURE|Incremental composite layering technique|Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
41117210|NCT02971085|PROCEDURE|Active surveillance|Active surveillance cohorts are routinely performed the systematic biopsy ≥ 12 cores by TRUS-guided or MR-TRUS fusion according to the protocol based by time path as 1, 2, 4, 7, 10 years and subsequently every 5 years following initial TRUS biopsy.
41117211|NCT03996278|OTHER|Grafalon|None interventional study but there are two groups
41117212|NCT05973812|DIETARY_SUPPLEMENT|Infant formula supplemented with Bifidobacterium breve PS1|Feeding with an infant formula containing 7 log10 cfu of the strain per gram of formula.
41117213|NCT05973812|DIETARY_SUPPLEMENT|Infant formula NOT supplemented with Bifidobacterium breve PS1|Feeding with the same infant formula but without supplementation with the B. breve strain
41117214|NCT05332366|DRUG|Delgocitinib cream|Cream for topical application
41117215|NCT05332366|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
41446285|NCT03843190|OTHER|Waitlist Control|At end of study, offered peer-led classes to attend.
41453396|NCT02230930|DRUG|Subcutaneous hydrocortisone 10mg|Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
41117216|NCT06430346|BEHAVIORAL|Exercise|Physical activity and resistance training
40752872|NCT02355470|BEHAVIORAL|GIFTSS|Universal education and brief counseling regarding sexual violence
41117217|NCT05181592|DRUG|Luspatercept|Once 1.75 mg/kg on Day 1 of each 21-day cycle for 24 weeks (9 cycles)
41117218|NCT04093908|OTHER|Prediction of motor outcome after STN DBS based on preoperative variables|Generating individual probabilities for motor response based on preoperative variables
41117219|NCT04682483|DRUG|Vasopressor|The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
41117220|NCT04682483|DRUG|Inotrope|Inotropes include dobutamine and milrinone.
41117221|NCT04682483|DEVICE|Acute Mechanical Circulatory Support Devices|Acute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.
41117222|NCT02462499|DRUG|Inspra (eplerenone)|
41117223|NCT05657730|DIETARY_SUPPLEMENT|Water Kefir beverage|Participants will consume the water kefir beverage for two weeks.
41117224|NCT02582086|OTHER|BOR15001L7|Active cream with 5% 15019L0
41117225|NCT02582086|OTHER|Placebo|Placebo Cream with 0% 15019L0
41117226|NCT02726828|DRUG|intrathecal morphine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
41117227|NCT02726828|DRUG|intrathecal ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
41117228|NCT02726828|DRUG|intrathecal morphine + ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
41117229|NCT01831284|PROCEDURE|Sigmoidoscopy with biopsy|Sigmoidoscopy with biopsy
41117230|NCT01888848|DIETARY_SUPPLEMENT|Freeze-dried Blueberry|12g freeze-dried blueberry (powder), twice daily with water, for 90 days
41117231|NCT01888848|DIETARY_SUPPLEMENT|Blueberry Placebo|12g blue, blueberry-flavored powder, twice daily with water, for 90 days
41117232|NCT00485940|DRUG|Prucalopride|2 mg o.d.
41117233|NCT00485940|OTHER|Placebo|Placebo o.d.
41117234|NCT00485940|DRUG|Prucalopride|4 mg o.d.
41117235|NCT01954407|BEHAVIORAL|Smoking-Related Messages|
41117236|NCT06555159|BEHAVIORAL|Physical exercise prescription: Continuous aerobic training (jogging, swimming, static cycling)|Aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate. (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload
41117237|NCT06555159|BEHAVIORAL|Control group: Continuous aerobic physical exercise|Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax, keeping this intensity for the 8 week intervention period.
41446286|NCT05398809|DRUG|Ruxolitinib|Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
40752873|NCT02355470|BEHAVIORAL|Brief alcohol use intervention|Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
41117238|NCT04367272|PROCEDURE|First Arthroplasty|First Knee
41117239|NCT04367272|PROCEDURE|Second Arthroplasty|Second Knee
40752874|NCT00086125|DRUG|ridaforolimus|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
41117240|NCT02615210|DEVICE|SOC-directed biopsies using the SpyGlass System|The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
41117241|NCT05283395|DRUG|Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution|Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
41117242|NCT04399148|DRUG|Desloratadine 5 mg|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
41117243|NCT04399148|DRUG|Aprepitant 125 mg|Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
41117244|NCT04399148|DRUG|Ketotifen 1 MG|Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
41117245|NCT00001992|BIOLOGICAL|rgp120/HIV-1IIIB|
41117246|NCT06555718|BEHAVIORAL|The Peer Support Program|Implementation of the research; Peer support programme for the intervention group will be carried out for 10 weeks in accordance with the peer guide-client implementation plan. Standard follow-up and training programme will be applied to the control group in accordance with the procedures of the institution.
41117247|NCT06555718|BEHAVIORAL|Standart care|The standard care provided by the institution will continue.
41117248|NCT05985512|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia is the main therapy for the patients. Medications include sedative-hypnotics and antidepressants with a sedative effect.
41117249|NCT02509585|DRUG|Tc99m tilmanocept|A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
41453397|NCT05086653|PROCEDURE|Surgery|Sutured by Prolene 3-0 with two layers of pledge
40752875|NCT00829478|BEHAVIORAL|Decision Aid for Atrial Fibrillation|Single contact educational session
40752876|NCT00829478|OTHER|Usual Care|Usual Care
40752877|NCT04331171|DEVICE|Web application users|questionnaire of comorbidity and symptoms completed by the patient on his smartphone
40752878|NCT02978508|DRUG|Permethrin Cream, 5%|Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
41117250|NCT01117519|DRUG|Infusion Therapy|Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
40752879|NCT02978508|DRUG|Elimite|Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
41117251|NCT03801967|DRUG|AZD9977|Randomized participants will receive oral dose of AZD9977.
41117252|NCT03801967|DRUG|Placebo|Randomized participants will receive oral dose of matching placebo.
41117253|NCT00710515|DRUG|AZD6244|75mg
41117254|NCT03737097|OTHER|Online Spaced Education|Investigators created a set of fall prevention strategies for multiple sclerosis patients into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), spaced education has been shown in randomized trials to improve knowledge acquisition, boosts learning retention for up to two years, and durably improves changes in behavior.
41117255|NCT03737097|OTHER|Brochure Education|The investigators translated and validated the Minimizing Your Risk of Falls A GUIDE FOR PEOPLE WITH MS brochure developed by the National Multiple Sclerosis Society. The control cohort will receive the main education model for patients that has been used in the past few years.
41117256|NCT02578615|OTHER|physiotherapy|physiotherapeutic intervention according to the principles of the Spiraldynamik® concept
41117257|NCT00687167|DRUG|Zonisamide 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
41117258|NCT00687167|DRUG|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
41117259|NCT03472807|OTHER|Collection of blood sample or saliva|at Inclusion
41117260|NCT03472807|OTHER|Collection of a tumor sample taken before the participation of the patient in study|at Inclusion
41117261|NCT03472807|OTHER|Collection of blood sample if tumor sample is not available|at Inclusion
41117262|NCT01595334|DRUG|Cetrorelix|Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (\>4.5 mIU/ml) in the study arm
41117263|NCT01595334|DRUG|Luprolide Acetate|Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
41117264|NCT04433572|DRUG|Temsirolimus|0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
41117265|NCT04433572|DRUG|Saline placebo|Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
41117266|NCT02006017|OTHER|Evidence summary alone plus a recommendation|
41117267|NCT02006017|OTHER|Evidence summary alone|
41117268|NCT01767714|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
41117269|NCT01767714|DRUG|Plerixafor|0.24 mg/kg/day subcutaneous injection
41117270|NCT01767714|DRUG|Placebo|0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
41117271|NCT03009305|OTHER|Lower body negative pressure|Model of hypovolemia: Lower body negative pressure down to -80 mmHg (maximum).
41117272|NCT03009305|DEVICE|Continuous positive airway pressure|CPAP of 0, 5 and 10 cm water (H2O).
41117273|NCT03009305|DEVICE|Positive expiratory pressure|PEP of 0, 5 and 10 cm H2O.
41117274|NCT00257283|DRUG|Omega-3-acid ethyl esters 90|
40752880|NCT02176525|DRUG|BI 207127 NA|
40752881|NCT02176525|DRUG|Placebo|
40752882|NCT02781194|DEVICE|3M™ Bair Hugger™|forced-air warming blanket
40752883|NCT02781194|DEVICE|F&P HumiGard™ Surgical Humidification System|warmed, humidified insufflation
40752884|NCT03975114|DRUG|Chemotherapy|Any approved first line chemotherapy regimen at Investigators' choice
41117275|NCT05300061|BEHAVIORAL|Personal Values Intervention|A 15 minute personal values intervention. Aim is to help participants clarify their own values around flying and promote committed action towards airplanes.
41117276|NCT05300061|BEHAVIORAL|Prosocial Values Intervention|A 15 minute prosocial values intervention. Aim is to help participants clarify their prosocial values around flying and promote committed action towards airplanes.
41446287|NCT05005728|COMBINATION_PRODUCT|vudalimab + carboplatin + cabazitaxel|Vudalimab IV, carboplatin IV, cabazitaxel IV
41446288|NCT05005728|COMBINATION_PRODUCT|vudalimab + olaparib|Vudalimab IV, olaparib oral
41117277|NCT03082846|RADIATION|hypofractionated radiation|The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
41117278|NCT03082846|DRUG|Temozolomide chemotherapy|Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
41117279|NCT04719377|DEVICE|catheter placement|catheter placement
41117280|NCT01875744|DRUG|Polyethylene glycol 4000|
41117281|NCT02342210|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
41117282|NCT05263115|OTHER|Resistance Exercise intervention|12-week progressive resistance exercise intervention
41117283|NCT05263115|OTHER|Functional stair climbing and stepping-based exercise intervention|12-week progressive stair climbing and stepping-based exercise intervention
41117284|NCT06131359|DIAGNOSTIC_TEST|Fine wire EMG and Force Frame muscle strength testing|Insertion of fine wires for EMG study of tibialis posterior and assessment of muscle strength using a force frame
41117285|NCT01598636|PROCEDURE|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
41117286|NCT03265886|DRUG|Warm bupivacaine at (37°c)|Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.
41117287|NCT03265886|DRUG|Bupivacaine at operating room temperature (23°c)|Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
41117288|NCT05214924|BIOLOGICAL|Injectable platelet-rich fibrin|Intra-articular injection of injectable platelet-rich fibrin into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
41117289|NCT05214924|BIOLOGICAL|Platelet-rich plasma|Intra-articular injection of platelet-rich plasma into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
41117290|NCT01215552|DRUG|HT-0712|A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
41117291|NCT01645423|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
40752885|NCT03975114|DRUG|Durvalumab|Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal
41117292|NCT06233500|PROCEDURE|pars plana vitrectomy|"All eyes in this study will be subjected to pars plana vitrectomy procedure with these main steps:~* 23 G trocar system will be used~* Posterior vitreous detachment will be induced with the aid of triamcinolone acetate injection, and core vitrectomy will be done~* Brilliant blue stain will be injected, and ILM forceps will be used for ILM peeling~Patients will be divided then into two groups:~Group A: Only wide ILM peeling up to the arcades well be done Group B: ILM peeling with flap well be done~* Shaving of the vitreous base, and then fluid air exchange~* SF 6 gas tamponade will be used"
41117293|NCT01219205|PROCEDURE|intravitreal bevacizumab|Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
41117294|NCT01551407|DRUG|Hexvix|50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
41117295|NCT01655888|DRUG|Tremelimumab|Tremelimumab is administered as endovenous infusion
41117296|NCT02750072|PROCEDURE|Infrapatellar Approach|Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
41117297|NCT02750072|PROCEDURE|Suprapatellar Approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
41117298|NCT02751138|PROCEDURE|Surgery|Tumor resection
41117299|NCT00513526|BIOLOGICAL|Gardasil|week 0, 8, 24, 128
41117300|NCT00677391|DRUG|Sibutramine|Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
41117301|NCT00677391|DRUG|Placebo|Capsules, once daily
40752886|NCT03975114|DRUG|Tremelimumab|Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)
40752887|NCT00686218|DRUG|imatinib mesylate|Given orally
41446289|NCT05005728|BIOLOGICAL|vudalimab monotherapy|Vudalimab IV
41446290|NCT05005728|COMBINATION_PRODUCT|vudalimab + docetaxel|Vudalimab IV, docetaxel IV
40752888|NCT00686218|DRUG|panobinostat|Given orally
40752889|NCT00686218|GENETIC|polymerase chain reaction|Testing
40752890|NCT00686218|GENETIC|protein expression analysis|Testing
40752891|NCT00686218|GENETIC|western blotting|Testing
40752892|NCT00686218|OTHER|flow cytometry|Testing
40752893|NCT00686218|OTHER|laboratory biomarker analysis|Testing
41117302|NCT05565859|BEHAVIORAL|Planetary Health Plate signage|A Planetary Health Plate graphic was developed based on the healthy reference diet proposed by the Eat Lancet Commission. The graphic was designed to capture the food groups and proportions of food groups promoted by the Planetary Health diet.
41117303|NCT03189329|DRUG|2% lidocaine hydrochloride|Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
41117304|NCT03189329|DRUG|0.5% levobupivacaine|and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
41117305|NCT00661778|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
41117306|NCT00661778|DRUG|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
41117307|NCT00661778|DRUG|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
41117308|NCT00851669|BEHAVIORAL|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
41117309|NCT00851669|BEHAVIORAL|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
41117310|NCT01803139|DEVICE|Adjuvant breast radiotherapy|Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
41117311|NCT05658406|DRUG|Ringer's Lactate|infusion of 15 mL/kg/hour Ringer's lactate intraoperative
41117312|NCT05658406|DRUG|Ringer's Lactate|infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
40752894|NCT00686218|OTHER|pharmacological study|Testing
40752895|NCT03995082|OTHER|Patient Reported Outcome Measure Survey result feedback|Patients will receive a graph of their results from the PROM survey each time they complete a survey
40752896|NCT02496429|DEVICE|BrownieForSymphony use|Professional will use the BrownieForSymphony Pumpset in their daily work. hospitalized lactating woman will pump with the BrownieForSymphony Pumpset
40752897|NCT04690647|OTHER|Opioid and non opioid postoperative analgesia.|Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
40752898|NCT04690647|OTHER|Fascia iliaca compartment block|Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.
40752899|NCT04690647|DRUG|Dexamethasone|Dexamethasone will be administered preoperatively in a dose of 0,1 mg/kg.
41117313|NCT05658406|DRUG|Ringer's Lactate|infusion of 6 mL/kg/hour Ringer's lactate intraoperative .
41117314|NCT05658406|DRUG|normal Saline|standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
41117315|NCT01077934|DEVICE|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
41117316|NCT03671213|DEVICE|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
41117317|NCT02320123|BEHAVIORAL|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
41117318|NCT04487600|OTHER|Active voiding trial|
41117319|NCT03410446|DRUG|Ketamine Hydrochloride|Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.
41117320|NCT00502736|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3
41117321|NCT03411369|DIETARY_SUPPLEMENT|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|The treatment will consist of taking 2 sachets / day for the first two weeks, and then continuing with 1 sachet/day for the next month.
40752900|NCT01383824|DEVICE|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
41117322|NCT03411369|OTHER|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
41117323|NCT00188136|DRUG|Melphalan, ATG, Fludarabine|allo Tx during aplasia
41117324|NCT00534300|DRUG|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
41117325|NCT00534300|DRUG|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
41117326|NCT00006035|BIOLOGICAL|bleomycin sulfate|
41117327|NCT00006035|DRUG|electroporation therapy|
41117328|NCT03646435|DEVICE|Fitbit Charge 2|The Fitbit Charge 2 is the electronic wearable chosen for this pilot study. This particular Fitbit is capable of measuring patient heart rate, sleep and physical activity. The data collected will then be analyzed with respect to the outcomes of this study. To determine the accuracy of the Fitbit, data collected will be compared to the nurses' standard patient assessment (for HR and physical activity) and to patient responses on the Richards-Campbell Sleep Questionnaire (for sleep).
41117329|NCT00247208|DEVICE|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
40752901|NCT04941911|DRUG|Octreotide Acetate|Octreotide syringes will contain 50ml of octreotide acetate at 20mcg/ml in 0.9% w/v sodium chloride in water.
41117330|NCT00247208|DEVICE|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
41117331|NCT02244411|BEHAVIORAL|individual diet & physical activity counselor and website through Healthways at Hopkins|Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.
41117332|NCT02244411|BEHAVIORAL|self directed weight loss|Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.
40752902|NCT04941911|OTHER|Placebo|Sodium chloride 0.9% w/v
41117333|NCT02244411|BEHAVIORAL|questionnaires|Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.
41117334|NCT02244411|OTHER|fasting blood draw, measurement of height, weight and waist circumference, and blood pressure|During three time periods, at baseline and at 12 and 24 months.
41117335|NCT05031390|PROCEDURE|Physiotherapist-led training|Patients will undergo a 12-week physiotherapist-led training program consisting of 8 supervised sessions and home-based training in between
41117336|NCT00861510|DRUG|ON01910 Na|
41117337|NCT00019747|DRUG|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
40752903|NCT02301429|DEVICE|Model 20105|implant and follow-up of study device
40752904|NCT00067873|BEHAVIORAL|Diet|
40752905|NCT00067873|BEHAVIORAL|Aerobic exercise|
40752906|NCT00067873|BEHAVIORAL|Resistance exercise|
40752907|NCT05960123|PROCEDURE|Tubularized Incised Plate (TIP) urethroplasty|tubularization of urethral plate with or without spongioplasty
41117338|NCT00019747|PROCEDURE|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
41117339|NCT00019747|OTHER|Placebo|oral placebo once daily
41117340|NCT05318885|OTHER|A Randomized Controlled Study|For forward-leaning position, the child is first placed on a suitable chair with a soft pillow on their knees. The child will remain in the same position for the duration of the nebulization, and the pillow provides support, ensuring the child does not get tired. The child leans forward at an angle of 45°, places their arms on the pillow as shown in the figure and holds their head upright with their eyes facing forward (slight hyperextension). The upright head position of the child prevents spillage of the liquid medicine from the nebulizer chamber.
41117341|NCT02918279|DRUG|Liraglutide|Administered once daily subcutaneously (s.c., under the skin)
41117342|NCT02918279|DRUG|Placebo|Administered once daily subcutaneously (s.c., under the skin)
41117343|NCT03816228|DRUG|F 18 T807 Flortaucipir|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
41117344|NCT05930561|BIOLOGICAL|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.
41117345|NCT05930561|BIOLOGICAL|Aflibercept IVT|Commercially available Active Comparator
41117346|NCT01041417|DRUG|Granulocyte-Macrophage Stimulating Factor (GM-CSF)|500 micrograms of GM-CSF
41117347|NCT01041417|DRUG|Placebo|Saline injection
41117348|NCT00995306|DRUG|Civamide (Zucapsaicin)|"Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks"
41117349|NCT04363996|OTHER|New Bioactive Restorative Material|Filling material
41117350|NCT04581850|BEHAVIORAL|Sleep recording|Sleep is recorded at home during 7 nights in a row using a connected headband. The participant also has to fill in a sleep agenda every day.
41117351|NCT04581850|BEHAVIORAL|Cognitive tasks|Working memory and inhibition capacity is assessed during computer-based tasks (2-back and Go/No-Go tasks) at enrollment and 1 month after enrollment.
41117352|NCT04581850|OTHER|Questionnaires|"The participant has to fill in several questionnaires at enrollment and 1 month after enrollment in order to assess:~* PTSD severity~* chronotype~* Sleep quality~* Daytime sleepiness~* Mood state~* Depression~* Mental disorders and their consequences"
41117353|NCT00025324|BIOLOGICAL|filgrastim|
41117354|NCT00025324|DRUG|carboplatin|
41117355|NCT00025324|DRUG|cyclophosphamide|
41117356|NCT00025324|DRUG|etoposide|
41117357|NCT00025324|DRUG|thiotepa|
41117358|NCT00025324|PROCEDURE|autologous bone marrow transplantation|
41117359|NCT00025324|PROCEDURE|bone marrow ablation with stem cell support|
41117360|NCT00025324|PROCEDURE|conventional surgery|
41117361|NCT00025324|PROCEDURE|peripheral blood stem cell transplantation|
41117362|NCT00025324|RADIATION|radiation therapy|
41117363|NCT05458817|OTHER|digital platform|Patients in the digital group complete the tests in the patient's mobile application and/or in the Internet-based research environment of the Institute of Psychology of the University of Tartu kaemus.psych.ut.ee. Patients and specialists of the control group fill in the tests and the satisfaction questionnaire in the kaemus.psych.ut.ee environment.
41117364|NCT02339779|PROCEDURE|autologous fat transfer|"Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~1. First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~2. Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~3. Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast."
41117365|NCT02339779|PROCEDURE|breast implant|"Implant-based reconstruction typically will occur as follows:~1. During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~2. The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~3. When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)"
40752908|NCT00656812|DRUG|Rituximab|375 mg/m2 on day 1 of a 21-day treatment cycle
40752909|NCT00656812|DRUG|2-CdA|0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
41117366|NCT03923946|BEHAVIORAL|Compassion focused therapy|Compassionate Imagery intervention based on compassionate imagery exercises in The Compassionate Mind Workbook by Irons and Beaumont, 2017
41117367|NCT01372761|DRUG|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
41117368|NCT01372761|DRUG|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
41446291|NCT05005728|COMBINATION_PRODUCT|vudalimab + cabazitaxel or docetaxel|Vudalimab IV, cabazitaxel or docetaxel IV
41117369|NCT05457127|DEVICE|Automatic Positive Airway Pressure (APAP)|"If eligible, participants will be given a clinical Automatic Positive Airway Pressure (APAP) device for up to 3 months, while they are waiting for their clinical evaluation from a sleep physician. The APAP device will we will be using is the ResMed Airsense 11 Autoset. APAP is a smart positive airway pressure (PAP) device, where the pressure changes as needed to provide optimal pressure to splint the upper airway. Dr. Lee and Dr. Schmickl will oversee management of the device.~During the first month of APAP use, individuals will participate in weekly phone calls or in-person visits to ensure optimal adherence and troubleshoot any issues (improper mask fitting, discomfort, etc) that may arise."
41117370|NCT03718598|BEHAVIORAL|Tendon and Nerve Gliding Exercises|Tendon and Nerve Gliding Exercises: The tendon slip exercises used in this study were performed in five different positions, namely flexion, flat, hook, punch, table top and flat punch positions. Nerve-gliding exercises were performed by moving the fingers and wrists in six different positions, focusing on the median nerve consisting of all the disease grip, finger lengthening, wrist extension, thumb extension, forearm supination and gentle gentle gait. Instructions were given to make 10 sets of exercises in 3 sets, written and verbal, in order to have e exercises for all patient's tendons and nerves shifting exercises. Brochures were also provided explaining the exercises.
41117371|NCT00501618|DRUG|Fazaclo|single-arm
41117372|NCT00224601|PROCEDURE|Colonoscopy with chromoscopy|
41117373|NCT05075694|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch performed in line with the Therapeutic Touch Practice Procedure included the following steps: centering, assessing, rebalancing, reassessing, reexamining, grounding, and closure.
41117374|NCT05075694|OTHER|Sham Therapeutic Touch|The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with STTPP. The practice was implemented by not centering or intending to help to heal, by moving at a longer distance, and by imitating the TT practice protocol visually.
41117375|NCT01271517|DRUG|NPH insulin|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
41446292|NCT04159285|BEHAVIORAL|EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients|Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.
40752910|NCT05956457|BEHAVIORAL|Digital Health Coaching Program|Digital health intervention consisting of weekly calls from a Health Advisor to a participant, accompanied by delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
40752911|NCT05956457|DEVICE|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
41117376|NCT01271517|DRUG|Glargine|Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
41117377|NCT01271517|DRUG|Detemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
41446293|NCT04159285|OTHER|Treatment as usual|Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
41446294|NCT02013882|PROCEDURE|1-1-12 wash-in|wash-in phase during start of low flow anesthesia
40752912|NCT04088357|DRUG|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
41117378|NCT04457752|BIOLOGICAL|Dual Layer Amniotic Membrane (DLAM). Artacent®|"Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers."
41117379|NCT04641741|DRUG|Mepolizumab 100 MG|Discovery of predictive/prognostic biomarkers of response to mepolizumab using flow cytometry, transcriptomic, and proteomic technologies.
41117380|NCT06353165|DRUG|Stannous fluoride toothpaste|product containing 0.45% stannous fluoride
41117381|NCT06353165|DRUG|Colgate Dental Cream|product containing 0.76% sodium monofluorophosphate
41117382|NCT00371085|BEHAVIORAL|education|Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
41117383|NCT00212745|BEHAVIORAL|Andrews/Reiter behavioral treatment for epilepsy|The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
41117384|NCT00461747|DRUG|VBMCP/VBAD/Velcade|"VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20."
41117385|NCT00461747|DRUG|Thalidomide/Dexamethasone|"Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity \< grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
41117386|NCT00461747|DRUG|Velcade/Thalidomide/Dexamethasone|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is \< grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days"
41117387|NCT05278871|DEVICE|Constructive Shearwave Interference (CSI)|handheld ultrasound
41117388|NCT05316246|DRUG|Brentuximab Vedotin in Combination with Tislelizumab|Brentuximab vedotin will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a dose of 1.8 mg/kg. Tislelizumab will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a fixed dose of 200 mg. The rationale of fixed dose of Tislelizumab is according to the drug description, which is based on previous I/II phase clinical trial results of Tislelizumab. The time interval between administration of tislelizumab and brentuximab vedotin should be not less than 2 hours, and thereafter, the dosing cycle of tislelizumab is synchronized with that of brentuximab vedotin.
41117389|NCT01268813|OTHER|Breath analysis and blood analysis|Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
41117390|NCT03603184|DRUG|Atezolizumab|Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
41117391|NCT03603184|DRUG|Placebos|Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
41117392|NCT03603184|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.
41117393|NCT03603184|DRUG|Carboplatin|Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.
41117394|NCT05726604|OTHER|Respiratory gating|10 minutes breathing motion monitoring during an additional CT scan to establish a more accurate cardiac and LAD dosimetry compared to reality
41117395|NCT02968225|BEHAVIORAL|Computer Game|The game involves viewing subtle nonverbal behaviors of game characters for the purpose of executing their own goal-directed behavior in the game related to solving various crimes. The learning involves interpreting nonverbal cues on the animated characters, such as pointing, head turns, eye gaze cues.
41117396|NCT00795054|OTHER|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
41117397|NCT00989183|OTHER|Women undergoing a bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma|Women undergoing an elective bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma Age range 21-55 years old
41117398|NCT03981822|COMBINATION_PRODUCT|VP-102 and applicator|In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.
41117399|NCT03981822|COMBINATION_PRODUCT|Placebo|The placebo single-use applicator contains the same formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin
41117400|NCT06554756|OTHER|Saliva, serum and GCF sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Gingival crevicular fluid (GCF) samples were taken from the vestibular, mesial, and distal surfaces of a single-rooted tooth with standard paper strips (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, GCF and serum were then stored at -80 °C until analysis.
41117401|NCT05783726|OTHER|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
41117402|NCT05783726|BEHAVIORAL|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
41117403|NCT05783726|BEHAVIORAL|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
41117404|NCT05783726|BEHAVIORAL|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
41117405|NCT00880477|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
41117406|NCT00880477|BIOLOGICAL|DTPa-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
41117407|NCT00880477|BIOLOGICAL|EngerixTM-B|The vaccine was administered according to a 2-dose schedule at 1½ and 6 months of age with booster at 15-18 months of age.
41117408|NCT03385824|BEHAVIORAL|Self-Advocacy for Independent Life (SAIL)|SAIL program is based on an interactive workshop model. In -person sessions will focus on: enhancement of self-efficacy beliefs; enhancement of knowledge of TBI self-advocacy information; group process to instill hope and universality; and practice of self-advocacy behaviors in a supportive neuro-rehabilitation structured group environment.
41117409|NCT03947086|DEVICE|Transcranial Direct Current Stimulation (TDCS)- Active|A constant current stimulator (TCT Research Limited) will be used using electrodes of 5 × 5 cm2 embedded in saline (0.9 % NaCl) and application of 1.5 mA current for 20 minutes for 5 consecutive days. The cathode will be positioned in the right supra-orbital region, and while the anode will have the following provision in the left dorsolateral prefrontal cortex (F3).
41117410|NCT03947086|DEVICE|Transcranial Direct Current Stimulation (TDCS)- Sham|The protocol for participants receiving simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing.
41117411|NCT03947086|BEHAVIORAL|Cognitive Training|"Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, \& Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao \& Maurer, 2009; Dillon, Kannan, Dean, Spelke, \& Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved."
41117412|NCT01939171|DRUG|Thymoglobulin|
40752913|NCT04088357|DRUG|Topical Vehicle Gel|TolaSure Vehicle Gel is applied topically to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
40752914|NCT03374904|BEHAVIORAL|Video Feedback|first, a play interaction between the child and caregiver is recorded (5 to 10 minutes), then the therapist and caregivers watch together a selected part of the video (1 to 2 minutes) and provide feedback with a six step protocol.
40752915|NCT03374904|BEHAVIORAL|Control Group|Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
41117413|NCT05126121|DRUG|three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol|Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
41117414|NCT04380155|OTHER|Exercise|Moderate intensity cycling trials of different duration (30, 60 and 120 min)
41117415|NCT00761709|DRUG|AL-39256 Ophthalmic Suspension, 1%|
41117416|NCT00761709|DRUG|Latanoprost Ophthalmic Solution, 0.005%|
40752916|NCT03765021|DRUG|Tranexamic Acid|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
41117417|NCT00761709|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
41117418|NCT04470401|DRUG|AbobotulinumtoxinA|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
41117419|NCT04470401|DRUG|Saline|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
40752917|NCT03765021|DEVICE|Fractional CO2 laser|The other side of the face will be randomly assigned to low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
41117420|NCT05767294|OTHER|Observation|clinical manifestation (body temperature, fever days before admission, cough, red throat/sore throat, runny nose, shortness of breath, wheezing, vomiting), physical signs (auscultation of lungs, X-ray results), length of stay, therapeutic measures (oxygen therapy, ICU admission, antibiotic therapy, etc.)
41117421|NCT00832325|BEHAVIORAL|interview|The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.
41117422|NCT00832325|BEHAVIORAL|Focus groups|The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.
41117423|NCT00832325|BEHAVIORAL|Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
41117424|NCT04068207|DRUG|Minocycline|Tab. Minocycline 100mg po per day for 12 months
41117425|NCT02383472|DEVICE|MedX Health Console model 1100|"All treatments will be administered using the MedX Health Console model 1100. These units were cleared by the FDA as non-significant risk in 2003 and approved for home treatment use in 2005 for temporary increase in local blood flow circulation . . . for temporary relief of minor muscle and joint aches. Cluster heads are 2 inches in diameter. Each contains 9 red (633nm wavelength) diodes and 52 near infrared (870 nm wavelength) diodes. LED cluster heads would be applied to the frontal, parietal and temporal areas, as well as the mid sagittal suture line"
41117426|NCT02383472|DEVICE|MedX Health Console model 1100-placebo|The placebo machine is identical in appearance as the treatment machine; It vibrates, warms, and does everything the treatment machine does except it does not have LED lights on the marker, therefore it cannot emit light. Subjects enrolled in the placebo group will be on the same schedule as the treatment group. They will have two, 10 minute treatments, three times a week totaling 18 visits. The placebo allows the researchers to isolate the effect of the study treatment. If patient's in the LED treatment group fare significantly better than those in the placebo treatment group, the study helps support the conclusion that the LED therapy is effective.
41117427|NCT01371968|DRUG|alfentanil|Alfentanil is administered intravenously at the end of surgery.
41117428|NCT02186769|DRUG|Risperdal® Consta®|
41117429|NCT02186769|DRUG|LY03004|
41117430|NCT05094050|DRUG|ABBV-951|Continuous Subcutaneous Infusion (CSCI)
41117431|NCT05234983|BEHAVIORAL|LifeFirst SWASTH brief advice intervention|This intervention will support tobacco cessation among patients of high-reach, low-resource community healthcare settings in Mumbai (TB clinics, dental practices, and NGO-run health centers). The intervention will also use technology to build the capacity of practitioners in these settings to use evidence-based practices in their work and allow them to network and exchange best practices with one another.
41117432|NCT02154217|DRUG|Bimatoprost|
41117433|NCT02154217|DRUG|Latanoprost/Timolol|
41117434|NCT00687011|DRUG|Palonosetron and Dexamethasone|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
41117435|NCT02747381|DIETARY_SUPPLEMENT|Alfacalcidol|1-alpha hydroxy cholecalciferol 1 mcg
41117436|NCT02265276|DRUG|Saroglitazar|Tab Saroglitazar 4 mg oral daily for 24 weeks
41117437|NCT02265276|DRUG|Pioglitazone|Tab Pioglitazone 30 mg oral daily for 24 weeks
41117438|NCT02362035|DRUG|Acalabrutinib|Orally Administered (PO)
41117439|NCT02362035|DRUG|Pembrolizumab|Intravenous Administered (IV)
41117440|NCT00937183|BIOLOGICAL|autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|
41117441|NCT00937183|BIOLOGICAL|autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|
41117442|NCT00937183|BIOLOGICAL|autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine|
41117443|NCT00064714|DRUG|AC2993 (exenatide)|Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
41117444|NCT00064714|DRUG|daclizumab (immunosuppressive)|2 mg/kg intravenously infused over 30 minutes every month for 12 months
41117445|NCT05640154|BEHAVIORAL|educational program|The nursing educational program will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).
41117446|NCT06266780|BEHAVIORAL|PROMPTS Enhanced Family Planning Counselling|Based on a targeted human-centered-design process with pregnant and early postpartum mothers, the intervention consists of informative messages, counselling and reminders regarding postpartum family planning and birth spacing, leveraging an existing mobile health platform (PROMPTS) for intervention delivery and Jacaranda's established partnership with the Kenyan Ministry of Health, county health offices and public maternity hospitals method options. The intervention includes several features: activation of family planning discussions between pregnant and postpartum women and their health care providers, information provision, method selection support to help women choose their preferred method, and reminders to follow-up. The key feature is to help women make an informed plan about family planning in the prenatal or early postpartum period and follow through with this plan.
41117447|NCT02784132|OTHER|Video diversion|The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.
41117448|NCT03419013|OTHER|New adhesive strip|This strip is made of a newly developed adhesive
41117449|NCT01733095|DRUG|ambrisentan|Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
41117450|NCT02466516|DRUG|SEL|SEL tablet administered orally once daily
41117451|NCT02466516|BIOLOGICAL|SIM|Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
41117452|NCT02299375|DRUG|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
41117453|NCT02299375|DRUG|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
41117454|NCT02299375|DRUG|Salbutamol MDI|Salbutamol MDI will be provided as a rescue medication.
41117455|NCT03570957|DRUG|MT-2990|MT-2990 solution for injection in vial
41117456|NCT03570957|DRUG|Placebo|Placebo solution for injection in vial
41117457|NCT04854863|DIAGNOSTIC_TEST|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
41117458|NCT02849535|BEHAVIORAL|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
41117459|NCT01697059|DRUG|Piperacillin + Amoxicillin|
41117460|NCT01090544|DEVICE|Nasal Insufflation|Breathing therapy
41117461|NCT01086163|DRUG|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
41117462|NCT05622396|PROCEDURE|Mindfulness Based Stress Reduction|Inspired by the standard Mindfulness Based Stress Reductio program, the study MAdaPARK is a 8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews carried out as part of the M-PARK study,as well as the reflections of the working group specially set up for this purpose. Several areas of adaptation have been identified: shorter mediations, a break time during the sessions, more times for exchanges, a more developed practice in movement, and finally, more important work based on self-esteem and self-compassion.
41117463|NCT06437600|PROCEDURE|Immediate angioplasty|See arm/group descriptions.
41117464|NCT00904852|DRUG|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
41117465|NCT03378141|BEHAVIORAL|Maternal Nutrition Behavior change|Counseling and community mobilization
41117466|NCT02190578|DEVICE|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
41117467|NCT05834946|OTHER|Megagen implant placement|Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface
41117468|NCT05834946|OTHER|Biomate-Swiss implant|Biomate-Swiss implant with precision dimension laser (PDL) surface
41117469|NCT05119010|DIETARY_SUPPLEMENT|Continuous ketogenic diet|ARM A : continuous ketogenic diet
41117470|NCT05119010|DIETARY_SUPPLEMENT|Discontinuous ketogenic diet|ARM B : discontinuous ketogenic diet
41117471|NCT05119010|DIETARY_SUPPLEMENT|beta-hydroxybutyrate (BHB) supplementation|ARM C : BHB supplementation
41117472|NCT05732649|BEHAVIORAL|Auditory neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound.
41117473|NCT05732649|BEHAVIORAL|Tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of tactile stimulation (i.e., electrical or vibrotactile stimulators applied on both hands and feet).
41117474|NCT05732649|BEHAVIORAL|Auditory and tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound and tactile stimulation.
41117475|NCT05732649|BEHAVIORAL|Neurofeedback|Participants train to decrease the intensity of a sensory stimulation (defined in Experiment 1) that is coupled with the network interaction at a specific brain region.
41117476|NCT05579106|DEVICE|Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel|"The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient.~These parameters are:~* Temperature~* Galvanic skin response~* Accelerometer~* Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude)~All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement."
41117477|NCT05579106|DEVICE|Bispectral index (BIS)|The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.
41117478|NCT05579106|OTHER|Questionnaire perception of the nurse on pain patient|The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.
41117479|NCT00739141|DRUG|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
41117480|NCT03956004|OTHER|OM1 Dell Shared Decision Making Tool|Decision aid meant to improve shared decision making among patients and providers.
41117481|NCT03956004|OTHER|Education material from OM1 Dell Shared Decision Making Tool|Investigator-written educational material and quiz to test knowledge of osteoarthritis and treatment options.
41117482|NCT02256254|DRUG|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
41117483|NCT02256254|DRUG|Placebo|2 placebo capsules every evening for 14 days
41117484|NCT01706354|PROCEDURE|Local Anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
41117485|NCT01706354|PROCEDURE|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
41117486|NCT02202772|DRUG|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
41117487|NCT02202772|DRUG|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
41117488|NCT02202772|DRUG|Cisplatin|Intravesical installation of Cisplatin for 2hours
41117489|NCT05105126|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"The anodal electrode will be placed over F3 using the international 10-20 EEG electrode placement system to target the left dorsolateral prefrontal cortex (DLPFC).~The cathode electrode will be placed on the right dorsolateral prefrontal cortex.~40 stimulation sessions will be completed (20 active, 20 sham), each lasting 20 minutes per session at 1.0mA."
41117490|NCT05105126|DEVICE|Sham tDCS|Sham tDCS
41117491|NCT04110223|GENETIC|next generation sequence|targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.
41117492|NCT00160914|BEHAVIORAL|Identification/management of childhood obesity (behavior)|In this project, we plan to conduct a national survey of pediatricians to assess common strategies for identification and management of childhood obesity, along with pediatricians' attitudes and beliefs about childhood obesity.
41117493|NCT05968859|BEHAVIORAL|Aerobic Training|Aerobic training will be conducted at 30 minutes 3 times a week using brisk walking with target heart rates goals based on percentage of peak HR reserve (HRR= peak-rest HR) during baseline exercise right heart catheterization (RHC). The target HR will progress over the study period from 50% to 70% of peak HR reserve added to resting HR using the standard Karvonen formula (Goal HR = rest HR + target % of HRR). HR will be monitored using Fitbits to guide training intensity with raw data analyzed using the Fitabase platform to monitor compliance
41117494|NCT05968859|BEHAVIORAL|Leg Training|Leg training will be performed using assigned ankle weights to perform knee extension while seated. Initial weight assignment will be guided by a protocol driven in-person exercise tolerance test using varying weights to identify the optimal initial and target training weight for each patient based on the 10 repetition maximum weight identified during this test. Leg training weight will begin at 40% of the baseline 10-repetition maximum weight for weeks 1-4 during which time patients will be required to complete 3 sets of 10 repetitions (30 repetitions total) on 3 days per week. For weeks 4-8, 55% of the initial 10-repetition maximum weight will be used for 4 sets of 10 repetitions (40 repetitions total). For weeks 8-12, 70% of the initial 10-repetition maximum weight will be used for 5 sets of 10 repetitions (50 repetitions total).
41117495|NCT05639777|DRUG|Dexmedetomidine group|That will receive intranasal dexmedetomidine (1.5mcg/kg)
41117496|NCT05639777|OTHER|control group|That will receive the same volume of 2 ml of intranasal normal saline
41117497|NCT00477035|DRUG|CIK cells|2x10e8 cells/kg
41446295|NCT03986034|DRUG|During Venetoclax|Patients with CLL/SLL will enroll on the study. Subjects will be treated at the NIH Clinical Center for the duration of the ramp-up phase of venetoclax. After the ramp-up phase is complete, subjects will be transitioned to the care of their local hematologist/oncologist and receive venetoclax monotherapy or in combination with other agent(s) at the discretion of the treating oncologist. Subjects will have the option to follow-up at the NIH every 6 months (from initiation of venetoclax) and at (suspected) progression.
41446296|NCT02483195|DRUG|5% Minoxidil|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
41446297|NCT02483195|DRUG|200mg Spironolactone|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
41446298|NCT02483195|DRUG|5mg Finasteride|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
41117498|NCT00477035|DRUG|etoposide|60 mg/kg
41117499|NCT00477035|DRUG|bcnu|15 mg/kg
41117500|NCT00477035|DRUG|cyclophosphamide|100 mg/kg
41117501|NCT00477035|DRUG|gemcitabine|1250 mg/m2
41117502|NCT00477035|DRUG|vinorelbine|30 mg/m2
41117503|NCT00477035|DRUG|melphalan|200 mg/m2
41117504|NCT04562259|RADIATION|Verification of Kimmerle's anomaly by x-ray methods of research|In patients with Kimmerle's anomaly, using computed tomography of the brain with the capture of the upper cervical spine and cervical spine, it is planned to determine at what age this pathology is more common, localization of the anomaly (right, left), complete or incomplete form of the anomaly.
41117505|NCT00131638|DRUG|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
41117506|NCT00131638|DRUG|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
41117507|NCT02355197|DRUG|L-ascorbic acid|1 gram L-ascorbic acid (vitamin C .....) per day from the time of diagnosis until the time of delivery
41117508|NCT04271449|DEVICE|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
41117509|NCT04271449|BEHAVIORAL|Virtual reality device|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
41117510|NCT04271449|DEVICE|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be either the cerebellum or the primary motor cortex, but the stimulation will be turned off after 15 seconds to insure a sham condition.~Prismatic googles will also be used in the same way in all groups during prism exposure."
41117511|NCT02802995|DRUG|PRP/thrombin mixture|Mixture of platelet rich plasma and thrombin applied topically on the wound surface
41117512|NCT02983617|DRUG|Tirabrutinib|Administered orally once daily
41117513|NCT02983617|DRUG|Entospletinib|Administered orally once daily
41117514|NCT02983617|DRUG|Obinutuzumab|Administered intravenously
41117515|NCT05215340|DRUG|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
41117516|NCT05215340|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
41117517|NCT00126646|DRUG|BL22 immunotoxin|
41117518|NCT00126646|PROCEDURE|antibody-drug conjugate therapy|
41117519|NCT00126646|PROCEDURE|immunotoxin therapy|
41117520|NCT06499714|OTHER|Exposure to 3600 m|Participants will travel to and stay for 2 days at an altitude of 3600 m.
41117521|NCT01925339|DEVICE|Test (immediate restoration)|Test (immediate restoration)
41117522|NCT01925339|DEVICE|Control: delayed restoration|Control: delayed restoration
41117523|NCT05893459|BEHAVIORAL|Debrief|Post-Stressor Discussion with a Friend
41117524|NCT01495663|DRUG|I-131-CLR1404|"Description:~* Dosimetry: IV, 5 mCi, single dose, 6-day duration~* Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year"
41117525|NCT00048217|DRUG|T-1249|
41117526|NCT04828642|DIETARY_SUPPLEMENT|Vitamin C and vitamin E|1000 mg 235 mg
41117527|NCT04828642|DIETARY_SUPPLEMENT|Placebo|Placebo
41117528|NCT03544515|DEVICE|Er,Cr:YSGG laser|Application of Er,Cr:YSGG in peri-implantitis cases as a coadjutant has shown reduction in the pocket depths and bleeding on probing
41117529|NCT03544515|PROCEDURE|Scaling|Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)
41117530|NCT03544515|DEVICE|Inactive Er,Cr:YSGG|Er,Cr:YSGG laser (inactive form - sham procedure) applied to the surface of the implant
41117531|NCT02781623|PROCEDURE|MRI|
41117532|NCT00455494|DRUG|AQ-13|
41117533|NCT00554736|BIOLOGICAL|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
41117534|NCT03848910|DEVICE|Investigational device - Sound Processor|"At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator."
41117535|NCT00919685|BIOLOGICAL|blood sample|from rest of blood sample collected for other measurements
41446299|NCT02483195|OTHER|Placebo|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
41446300|NCT04987554|DIETARY_SUPPLEMENT|glycophosphopeptical AM3|3 g/day of AM3
41446301|NCT04987554|OTHER|Placebo|3 g/day of placebo
41446302|NCT05394714|BIOLOGICAL|Magicell-NK contains NK cells suspended in 100 mL normal saline|Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled
41446303|NCT06214507|OTHER|No intervention|No intervention
41117536|NCT05051449|DRUG|Ketamine Hydrochloride|Ketamine will be administered by a nurse in a 2-week treatment phase, during which participants will receive six IV infusions of 0.5 mg/kg (over 40-50 minutes) ketamine three times per week. Infusion days for patients will be on Mondays, Wednesdays, and Fridays, +/- 1 day. Ketamine infusions will take place at the UMB General Clinical Research Center (GCRC). The GCRC nurse will deliver ketamine within a private exam room. The infusions will last 40-50 min, and the participant will be observed by the GCRC clinical staff for 2 hours post-infusion. Vital signs will be monitored throughout the treatment; specifically, blood pressure, pulse ox and heart rate will be checked prior to treatment, q20 minutes during infusion, and q30-60 minutes after infusion for up to three hours.
41117537|NCT03960398|DRUG|Iatrogenic disease impact on emergency consultations|Determination of the proportion of emergency consultations linked to iatrogenic diseases
41117538|NCT05228054|PROCEDURE|laser procedure|In modified litothomy position patients with hemorrhoidal deasease will be treated with transcutaneous laser 1940nm 3watt in impulse regimen
41117539|NCT05228054|PROCEDURE|sclerotherapy|In modified litothomy position patients with hemorrhoidal deasease will be treated with sclerotherapy with Aethoxysklerol
41117540|NCT00006431|BIOLOGICAL|DC RCC-RNA|
41117541|NCT03811587|OTHER|Fasting Mimicking diet|The fasting mimicking diet is though to activate the metabolism as fasting would do, although the diet does include several meals a day and more calories than conventional fasting diets.
41117542|NCT04957069|PROCEDURE|fixation|double row fixation with 3-4 wire anchors
41117543|NCT04957069|PROCEDURE|primary repair|end-to-end repair
41117544|NCT05049434|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
41117545|NCT05049434|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
41117546|NCT05910749|DEVICE|QEEG-Guided sLoreta Neurofeedback Training|The team will produce a neurofeedback (NFB) protocol based on QEEG sLORETA Brodmann Voxel evaluation of brain deviated/dysregulated areas. Subsequent 12 to15 sessions of individualized NFB protocol will be conducted using BrainAvatar software to normalize these regions. The NFB session will display the cortical surface and subsurface networks being trained in a live fashion. Patients will be seated on a comfortable chair in a dimly lit room and, wearing a 19-channel EEG-cap connected to an EEG amplifier, they will receive auditory and visual feedback when they meet Brodmann Voxels Z-Scores inside of +/-1.5 standard deviations (SD) on each electrode training site. Thresholds for the feedback will be first set a +/-2 SD and brought down to +/-1.5 SD throughout the sessions (subject performance dependent). Patients are encouraged to relax, hear the sounds, and watch a feedback game.
41117547|NCT05220215|OTHER|Nordic Hamstring Exercise|To perform Nordic Hamstring Exercise, the subject was in kneeling position on the mat, arms by the side or in front of the chest, knee in 90-degree flexion and ankles well stabilized with the help of a therapist which is positioned behind the subject. Then subject was asked to lean forward by using the hamstring muscles by extending while trying to resist the forward fall, he should lean forward from the knee and not from the hip. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and them repeat the procedure again.
41117548|NCT05220215|OTHER|Hamstring Curl with Resistance band|"Traditional Hamstring Curl by using Resistance band.~Resistance Band: Thera-band Green, 4.6 kg resistance at 100% elongation"
41117549|NCT03674034|OTHER|CTscan and MRI images|CTscan and MRI images segmented according to procedures previously developed by GRAMFC
41117550|NCT05203861|BEHAVIORAL|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
41117551|NCT05203861|BEHAVIORAL|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
41117552|NCT05684354|OTHER|Patient Reported Outcomes (PROs)|"The day before or the morning before surgery, the patient filled the first QoR-15 scale alone or could be helped by one of the investigators in case of questions or difficulties.~The second QoR-15 scale was distributed the day before or the day of discharge from the hospital"
41117553|NCT00975039|DRUG|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
40752918|NCT05192083|BEHAVIORAL|Self-management and Support|A smartphone-based self-management support programme includes a 30-min face-to-face or online session at baseline, 3 phone calls and 2-month mobile messages
40752919|NCT03384485|DIAGNOSTIC_TEST|antiphospholipid syndrome|blood test for enzyme test,plasma and Lys-3-3 plasma
41117554|NCT05004597|OTHER|three dimensional photography using a 3dMDHead System (3dMD, Atlanta, GA, USA)|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months.
40752920|NCT05812599|OTHER|Educational Module|The COVID Test Learning Module will present four multi-part character scenarios that someone might experience when considering testing for COVID-19. Participants will answer questions about the character's behavior. Accurate guidelines will be provided in response to each scenario to educate participants about what to do in nuanced COVID testing decision-making situations.
40752921|NCT04534725|DRUG|Interferon alfa|intranasal spray
41117555|NCT01634893|DRUG|Sorafenib combined with Hydroxychloroquine|"dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
40752922|NCT04534725|DRUG|Selinexor|oral tablet
41117556|NCT05119764|PROCEDURE|Manual Lymphatic Drainage|"Manual Lymphatic Drainage is a form of physical therapy with the primary goal of accelerating lymphatic drainage.~In this study, the manual lymphatic drainage is applied by experienced physical therapists 5 days in a row for 30 minutes each; after and/or before the surgery."
40752923|NCT04534725|DRUG|Lenzilumab|intravenous infusion
40752924|NCT05706675|PROCEDURE|Non surgical periodontal therapy|Manual root planning+Ultrasonic subgingival debridement
40752925|NCT04492293|DRUG|ICP-192|ICP-192 is a white, round, uncoated table
41117557|NCT04072653|PROCEDURE|SLNB is spared|SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)
41117558|NCT02917343|BEHAVIORAL|mirror therapy and repetitive task training|
41117559|NCT03684044|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
41117560|NCT03684044|OTHER|Placebo|Participants will receive matching placebo on Days 1, 4 and 7.
40752926|NCT00638079|DRUG|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
40752927|NCT00638079|DRUG|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
40752928|NCT03066557|PROCEDURE|TACE and Apatinib|TACE and Apatinib 250mg po qd
41117561|NCT00220272|DRUG|SR57667B|
41117562|NCT03344536|DRUG|Fulvestrant|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter.
41117563|NCT03344536|DRUG|Debio 1347|Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated.
41117564|NCT05800639|PROCEDURE|Ophthalmic surgery|Ophthalmic surgery will be performed as standard practice of our institution.
41117565|NCT05800639|PROCEDURE|General anesthesia|General anesthesia will be performed as standard practice of our institution.
41117566|NCT00978172|DRUG|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
40752929|NCT03066557|PROCEDURE|TACE|TACE
40752930|NCT05800847|DRUG|Gabapentin|Gabapentin will be administered for 2 days at 100 mg q8h for titration to avoid side effects. The next 12 days, gabapentin will be taken at 300 mg q8h.
40752931|NCT05800847|DRUG|Placebo|Placebo will follow the same dosing pattern as gabapentin to allow for blinding. Placebo will be encapsulated with a gelatin capsule to mimic the look of gabapentin.
40752932|NCT00311168|DEVICE|Intervention/treatment|"Device: VIP On~Device: VIP Off"
40752933|NCT03800628|OTHER|qualitative study|semi-structured interviews
40752934|NCT01161121|DRUG|adenosine|Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
41117567|NCT00903539|DEVICE|SecurAcath Securement System|Subcutaneous catheter securement system
41117568|NCT04114422|OTHER|Seven-day preoperative exercise training program|The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
41117569|NCT02036307|DIETARY_SUPPLEMENT|DHA-enriched|DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
41117570|NCT02036307|DIETARY_SUPPLEMENT|EPA-enriched|EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
41117571|NCT00713063|BEHAVIORAL|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
41117572|NCT00713063|BEHAVIORAL|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
41117573|NCT03145649|OTHER|Dietary therapy or insulin injection|
41117574|NCT03133039|PROCEDURE|surgery, bioabsorbable screw|In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
41117575|NCT00616668|DEVICE|Air- Limb|
41117576|NCT05083702|PROCEDURE|Fluoroscopy-guided superior hypogastric plexus block transdiscal approach|Patient lies prone, L5-S1 interspace identified under fluoroscopy, the skin is prepared and sterile drapes are placed after local anesthetic infiltration of the skin the subcutaneous tissue with 2% lidocaine a 20 guage, 15 cm needle with short bevel is inserted at the center of L5- S1 interlaminar space under anteroposterior fluoroscopic vision. The needle is then advanced toward the intervertebral disc. After confirmation, the needle is advanced through the intervertebral disc until it exists at its anterior surface confirmed by administration of 4 ml of soluble contrast media in both lateral and anteroposterior fluoroscopic view. Neurolysis is performed with 8 ml 8 % phenol solution. After neurolysis, 0.5 ml of saline is given to avoid the deposition of phenol within the intervertebral disc material. While withdrawing, the needle cephazoline 50 mg in 1 ml is injected into the disc.
41117577|NCT05083702|PROCEDURE|ultrasound-guided superior hypogastric plexus block|Patients are placed in the supine position and after sterilization, the low-frequency curved probe is used in the longitudinal axis to visualize the aortic bifurcation and is identified using a longitudinal Ultra-Sound (Phillips Healthcare, Andover, Massachusetts, US). Next, the probe is placed deeply transverse till aorta end and bifurcation seen of iliac vessels once seen we enter out of plane and inject.as it lies in front the vertebral body of the L5 vertebra. Local infiltration with 1% lidocaine is obtained at port of entry 1-1.5 inches below the umbilicus. A 15-cm, 22-G Chiba needle is inserted (out-of-plane) and advanced by avoiding vascular structures until contact with the L5-body. The needle will be withdrawan the 1-2 mm and inject 8 ml 8% phenol in saline. Finally, 0.5 ml of lidocaine is injected during Chiba needle removal
41117578|NCT03386539|DRUG|Everolimus|Everolimus tablet
41117579|NCT03386539|DRUG|Tacrolimus|Tacrolimus capsule or liquid suspension
41117580|NCT03386539|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil capsule or liquid suspension
41117581|NCT05932082|PROCEDURE|myomectomy or not|The study group receive myomectomy, while the control group don't receive myomectomy.
41117582|NCT05967533|DRUG|Fermented Wheat Germ Extract|Given PO
41117583|NCT02872675|DIETARY_SUPPLEMENT|HOST-DM059|"Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases."
41117584|NCT02872675|DIETARY_SUPPLEMENT|Maltodextrin|Placebo Comparator: Maltodextrin.
41117585|NCT05481463|DRUG|Surufatinib|surufatinib,250mg, qd, po, 28 days for a cycle
40752935|NCT01161121|DRUG|regadenoson|Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
40752936|NCT03511066|DRUG|CT-P27 90 mg/kg|Influenza A treatment drug.
40752937|NCT03511066|DRUG|CT-P27 45 mg/kg|Influenza A treatment drug.
40752938|NCT03511066|DRUG|Placebo|Placebo.
40752939|NCT04743895|DEVICE|Stainless Steel Wire Cerclage|Wire cerclage used to close sternum after cardiothoracic surgery.
40752940|NCT01435980|PROCEDURE|Gastric Bypass|basal treatment and Gastric Bypass
40752941|NCT01435980|DRUG|Exenatide|basal treatment and Exenatide
41117586|NCT05481463|DRUG|TAS-102|TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle
41117587|NCT05592925|DIAGNOSTIC_TEST|coagulation-related factors|We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.
41117588|NCT04167020|DEVICE|High definition surface electromyography (HD-sEMG)|HD-sEMG data will be collected by Mobita 32® (TMSi) device
41117589|NCT04987021|DEVICE|Cochlear Implant (CI)-CI500 series, CI600 series or Freedom series cochlear implants|The Remote Assist (RA) System is intended to support clinicians to conduct a remote programming session with their CI recipients.
40752942|NCT03169972|BIOLOGICAL|ADYNOVATE|Antihemophilic Factor (Recombinant), PEGylated
40752943|NCT04875273|DEVICE|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine
40752944|NCT04875273|DEVICE|Kinesiology Tape application|Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine
41117590|NCT06045845|DIETARY_SUPPLEMENT|Beet Juice|70 milliliter (70mL) standard Beet Juice (Beet It Sport Shot) consumed 2.5 hours before exercise test
41117591|NCT06045845|DIETARY_SUPPLEMENT|Placebo|70mL placebo Beet Juice (Beet It Sport Shot with nitrate removed) consumed 2.5 hours before exercise test
41117592|NCT04882553|PROCEDURE|Diaphragmatic echography|Echography of the diaphragm at the zone of apposition. End-inspiratory and/or end-expiratory thickness of the diaphragm will be measured in M-mode.
41117593|NCT04882553|PROCEDURE|Measurement of esophageal pressure|Pressure will be measured in the lower third of the esophagus using an esophageal balloon and pressure transducer.
41117594|NCT04882553|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
41117595|NCT05826860|BEHAVIORAL|Mindfulness Practice|Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.
41117596|NCT05826860|BEHAVIORAL|Storytelling Workshop|Participants attend 2 (90 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.
41117597|NCT06177106|OTHER|Solar Simulated Light|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
41117598|NCT00001277|DRUG|68Ga-Dotatate|68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
41117599|NCT00001277|DRUG|18F-DOPA|18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
41117600|NCT03098368|DRUG|Rotigotine|
41117601|NCT03098368|DRUG|Placebo|Placebo of rotigotine patch
41117602|NCT00388661|DRUG|Melatonin tablet 3 mg once daily|Melatonin tablet 3 mg once daily
41117603|NCT00388661|DRUG|Placebo comparator|Placebo comparator
41117604|NCT04426890|BIOLOGICAL|CT-P39|Prefilled syringe (PFS) of 1 mL solution
41117605|NCT04426890|BIOLOGICAL|EU-approved Xolair|Prefilled syringe (PFS) of 1 mL solution
41117606|NCT04854395|DRUG|Marcain 5 mg/ml|Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
41117607|NCT01227278|OTHER|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
41117608|NCT01227278|BIOLOGICAL|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
41117609|NCT05429034|BEHAVIORAL|MIST paradigm|Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.
41117610|NCT05429034|BEHAVIORAL|Sham paradigm|Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
41117611|NCT05459233|PROCEDURE|Doppler-echocardiography|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements. Balloon post-dilation with a non-compliant balloon will be performed in the presence of a residual mean gradient ≥20 mmHg as assessed by Doppler-echocardiography.
41117612|NCT05459233|PROCEDURE|Invasive hemodynamic measurements|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording). Balloon post-dilation will be performed with a non-compliant balloon in the presence of a mean residual gradient ≥20 mmHg as assessed by hemodynamic measurements.
41117613|NCT05278494|DRUG|Dextromethorphan Hydrobromide|PO
41117614|NCT05278494|DRUG|Placebo|PO
41117615|NCT03872362|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
41117616|NCT02742519|DRUG|ivacaftor|
41117617|NCT02742519|DRUG|Placebo|
41117618|NCT03062813|DRUG|Tacrolimus &entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
41117619|NCT03062813|DRUG|placebo & entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
41117620|NCT04247074|BIOLOGICAL|botulinum toxin neuromodulator|QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL
41117621|NCT04247074|BIOLOGICAL|Placebo|Placebo will be injected into either the LCL, GL, or both the LCL and GL
41117622|NCT00542789|DRUG|Esomeprazole|20mg once daily oral
41117623|NCT00542789|DRUG|Placebo|once daily oral
41117624|NCT04616963|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.
41117625|NCT04616963|DRUG|Emtricitabine Tenofovir Alafenamide 200/25 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
41117626|NCT01367483|DRUG|IV methylnaltrexone (MNTX)|
40926219|NCT05420753|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation|During a TIPS procedure, the interventional radiologist, with the help of x-ray and ultrasound guidance, makes a channel through the liver to connect the portal vein (the vein that carries blood from the digestive organs to the liver) to one of the hepatic vein (three veins that carry blood away from the liver back to the heart) using a special type of needle. The interventional radiologist then replaces the needle with a wire and catheter, and a small tubular device called a stent graft is placed in this channel to keep the pathway open between the two blood vessels.
41117627|NCT04038814|PROCEDURE|Routine prevention of VAP|Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) \< 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax
41117628|NCT04038814|PROCEDURE|Modified prevention of VAP|"3 modifications of the routine bundle in the prevention of VAP:~* Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~* Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~* Automatic continuous subglottic secretion drainage"
41117629|NCT02840006|PROCEDURE|General anesthesia only|Induction drugs: Citrate of fentanyl, atracurium, etomidate
41117630|NCT02840006|PROCEDURE|General anesthesia and Spinal anesthesia|Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
41117631|NCT06015399|PROCEDURE|Implementation of closed insufflation technique during segmentectomy|After the identification the targeted segmental bronchus during the operation,ligating the proximal end of the targeted bronchus. Put the vessel separation forceps in the distal bronchial space to avoid the accidental damage of the vessels. Use a 50ml syringe to inject air into the distal bronchus (about 100ml is expected) until the intersegmental plane is satisfactory. Divide the target bronchus using the cutting and closing device.
41117632|NCT06015399|PROCEDURE|Implementation of dilatation and collapse technique during segmentectomy|Divide the target bronchus using the cutting and closing device. Ask the anesthesiologist to inflate the lung completely from pure oxygen to the affected side and then change to single lung ventilation. Wait for the intersegmental plane to appear(usually about 15 minutes).
41117633|NCT05032261|DRUG|Circulatory shock with norepinephrine in ICU|Circulatory shock with norepinephrine in ICU
41117634|NCT02367924|DRUG|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
41117635|NCT05395546|OTHER|dCBT-I|"1. Complete the evaluation of various scales and record a 7-day sleep diary before entering the group~2. Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor~3. Scale assessment needs to be completed at the end of treatment~4. One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation"
41117636|NCT04144595|DIAGNOSTIC_TEST|2 hour 75 g Oral glucose tolerance test|In pregnant women between 24 and 34 weeks of gestational age, plasma glucose was recorded after an overnight fast. Following consumption of 75 g glucose in 200 mL water over 10 min, the equivalent 1 hour and 2 hour values was recorded
41117637|NCT02278627|OTHER|manual lymphatic drainage|
41117638|NCT06223048|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
41117639|NCT01278394|DRUG|AN2690 Solution, 5.0%|Once daily application for 360 days
41117640|NCT05215561|OTHER|Cosentyx|There is no treatment allocation. Patients administered Cosentyx by prescription that have started before inclusion of the patient into the study will be enrolled.
41117641|NCT03658408|DRUG|4-aminopyridine|Oral tablet of 2.5 mg given 4 times a day
41117642|NCT03658408|DRUG|placebo|2.5 mg sugar pill given orally 4 times a day
41117643|NCT01853410|DEVICE|gekoTM|
41117644|NCT01759771|DRUG|Vitamin D3|4,000 IU of VD3 for at least one year
41117645|NCT01759771|DRUG|Placebo|Placebo for at least one year
41117646|NCT03340857|OTHER|Intelligent electric bicycle (VELIS) sessions|Oncology patients will participate in intelligent electric bicycle (VELIS) sessions twice a week for 6 weeks after their release from a rehabilitation and recuperative care facility
41117647|NCT04307199|PROCEDURE|Amniotic membrane sweep|Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.
41117648|NCT04834648|BEHAVIORAL|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
41117649|NCT00479635|DRUG|TPI 287|160 mg/m2 every three weeks for six cycles
41117650|NCT00479635|DRUG|TPI 287|160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
41446304|NCT03649581|OTHER|compare the two groups of schizophrenic patients|"Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia)."
40926220|NCT00139867|DRUG|PARCOPA|
40926221|NCT04729400|DEVICE|Vacuum Myofascial Therapy device|Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
41117651|NCT00855400|PROCEDURE|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
41117652|NCT00855400|PROCEDURE|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
41117653|NCT03496103|BIOLOGICAL|ragweed pollen|three hours ragweed pollen in a allergen exposure chamber
41117654|NCT00694447|PROCEDURE|Acupuncture|
41117655|NCT00002964|DRUG|porfimer sodium|
41117656|NCT00002964|OTHER|fluorophotometry|
41117657|NCT02990234|PROCEDURE|Capsular Repair|
41117658|NCT02990234|PROCEDURE|No Capsular Repair|
41117659|NCT05910918|BEHAVIORAL|Intensive Care Nurses' Training Package|For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
41117660|NCT02296463|BIOLOGICAL|RSV F Vaccine with adjuvant (0.5mL injection)|
41117661|NCT02296463|BIOLOGICAL|RSV F Vaccine (0.5mL injection)|
41117662|NCT02296463|BIOLOGICAL|Hepatitis A Vaccine (0.5mL injection)|
41117663|NCT02296463|BIOLOGICAL|Placebo (0.5mL injection)|
41117664|NCT06075472|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) is a therapeutic technique which involves specific training of respiratory muscles to yield improvements in inspiratory muscle strength and respiratory function.
41117665|NCT06075472|OTHER|Balance Exercises|Balance exercises involve functional movements at the individual's maximum level of independence.
41117666|NCT06177444|DRUG|Antibiotic|Postoperative antibiotic treatment
41117667|NCT03409263|OTHER|Observational study|Not applicable (observational registry study)
41117668|NCT05865145|DEVICE|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be adjusted for High or Low interval intensity training.
41117669|NCT02060955|BIOLOGICAL|ALECSAT|The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
41117670|NCT02060955|DRUG|Bevacizumab/Irinotecan|Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
41117671|NCT01137708|DRUG|ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
41117672|NCT01137708|DRUG|CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
41117673|NCT02537483|DRUG|IDP-120 Gel|Investigational Product: IDP-120 Gel
41117674|NCT02537483|DRUG|IDP-120 Component A|Comparator Product: IDP-120 Component A
41117675|NCT02537483|DRUG|IDP-120 Component B|Comparator Product: IDP-120 Component B
41117676|NCT02537483|DRUG|IDP-120 Vehicle Gel|Comparator Product: IDP-120 Vehicle Lotion
41117677|NCT01120418|DRUG|Besifloxacin Ophthalmic Suspension 0.6%|administered 3 times a day for 5 days to one eye.
41117678|NCT04196504|DEVICE|Echocardiograghy, ECG|transthoracic echocariography, 12 lead ECG
41117679|NCT06155877|BEHAVIORAL|Activité Vaccins et Vaccination - LAMAP|Two activities created by the La Main a la Pate foundation
41446305|NCT03649581|OTHER|compare the two groups of schizophrenic patients versus volunteers|compare the results of the schizophrenic patient group with healthy volunteers
41117680|NCT06155877|BEHAVIORAL|Kidivax Chatbot|A chatbot created by our team to answer the most common questions about vaccination, based on a literature review and on focus groups.
41117681|NCT01104675|DRUG|ENMD-2076|275 mg (or 250 mg for BSA \< 1.65) per day in oral capsules in 28 day continuous cycles
41117682|NCT02306577|DRUG|STRIBILD|Taking oral 1 STRIBILD tablet once a day for 48 weeks
41117683|NCT06255262|DRUG|Surufatinib|"(1) Safety introduction phase (6 cases): 250mg, oral, QD,after one cycle of combined treatment, the occurrence of DLT was evaluated: 1) If ≤1person occurs, continue the dose expansion study at that dose level. 2)In the event of DLT\> 1, then the dose of surufatinib was adjusted to 200mg，oral，QD,until disease progression or intolerance of toxicity.~(2) Dose expansion phase (24 cases): RP2D, oral, QD,until disease progression or intolerance of toxicity."
41117684|NCT06255262|DRUG|Durvalumab|1500mg, Q4W.iv.every 28 days; until disease progression or intolerance of toxicity.
41117685|NCT03113266|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
41117686|NCT01837472|DRUG|Probiotic|Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
41117687|NCT01837472|DRUG|Placebo|Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
41117688|NCT00171184|DRUG|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
41117689|NCT00171184|DRUG|Placebo|Placebo tablet once daily with sham titration
41117690|NCT03830086|DRUG|Midazolam|Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
41117691|NCT03830086|DRUG|Sufentanil|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
41117692|NCT03830086|DRUG|Propofol|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
41117693|NCT03830086|DRUG|Rocuronium|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
41117694|NCT03830086|DRUG|Sevoflurane|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
41117695|NCT03830086|DRUG|Bupivacaine|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
41117696|NCT02995655|DRUG|CX-01|CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
41117697|NCT02995655|DRUG|Azacitidine|Azacitidine at a dose of 75mg/m\^2 on Days 1-7 of each 28-day cycle.
41117698|NCT02995655|PROCEDURE|Bone marrow biopsy|-Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
41117699|NCT02995655|PROCEDURE|Peripheral blood draw|-Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
41117700|NCT03968354|BIOLOGICAL|"Collection of additional blood tubes; Biobanking (plasma, liver tissue)."|"* Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research"
41117701|NCT05762159|OTHER|data collected|"data collected:~* Morphological data of the patients~* Data of the erector block realization~* Pupillometric data :the variation of the pupil size on stimulation (in percentage of the base diameter)"
41117702|NCT00979992|OTHER|Laboratory Biomarker Analysis|Correlative studies
41117703|NCT00979992|DRUG|Sunitinib Malate|Given PO
41117704|NCT05218044|PROCEDURE|Cryoablation|The cryoprobe tip will be inserted into the breast and directed under ultrasound guidance to the location where the ultrasound visible marker is located. Next, the cryoprobe will be used to freeze a 4 X 3 X 3 cm diameter area of DCIS using two separate 10-minute freeze cycles separated by a single 10-minute thaw cycle. The cryoprobe will remain in place the entire time. After the second freeze, the cryoprobe will be withdrawn from the breast and a bandage will be applied to the skin.
41117705|NCT05603013|DRUG|Vinorelbine|Vinorelbine Tartrate Oral
41117706|NCT05603013|RADIATION|Radiotherapy|hypofractionated radiotherapy
41117707|NCT05603013|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection
41117708|NCT05603013|DRUG|GM-CSF|GM-CSF subcutaneous injection
41117709|NCT05603013|DRUG|IL-2|IL-2 subcutaneous injection
41117710|NCT05918614|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
41117711|NCT05918614|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
41117712|NCT03924882|DRUG|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
41117713|NCT03931265|DIAGNOSTIC_TEST|ketohexokinase|Check the isoforms of ketohexokinase in the specimen of endometrial cancer
40926222|NCT04729400|OTHER|physical therapy program|The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
40926223|NCT04729400|PROCEDURE|Therapeutic Percutaneous Electrolysis|Therapeutic Percutaneous Electrolysis
41117714|NCT02036424|DRUG|Ozurdex|intravitreal steroid
41117715|NCT02036424|DRUG|Bevacizumab|antiVEGF
41117716|NCT06552728|OTHER|Energy Healing|EH derives from the theory that by using the body's biological energy, there can be a therapeutic effect that guides the patient towards a homeostatic state. Preliminary data in chronic pain patients, suggests that EH, delivered by an experienced practitioner, is able to reduce self-reported pain symptoms within minutes. Effects lasting for weeks to months have also been anecdotally reported. For patients with pain, this can result in a reduction of symptoms. Participants will also be presented with sham EH as a control.
41117717|NCT04971447|DRUG|gender affirming hormonal treatment in transgender men|testosterone enanthate
41117718|NCT04971447|DRUG|gender affirming hormonal treatment in transgender women|GnRH agonists + estrogen
41117719|NCT05308381|BEHAVIORAL|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
41117720|NCT05308381|BEHAVIORAL|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
41117721|NCT05308381|BEHAVIORAL|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
41117722|NCT05264012|PROCEDURE|Neurosurgery|Neurosurgery
41117723|NCT02434744|DRUG|KD026|Dosed in combination
41117724|NCT02434744|DRUG|Placebo|Dosed in combination
41117725|NCT02434744|DRUG|Metformin|Drug prescribed by each subject's prescribing physician
41117726|NCT00547469|DRUG|DDP733|
41117727|NCT05866536|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
41117728|NCT05866536|BIOLOGICAL|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
41117729|NCT04548024|DEVICE|Short term monitoring|By using the Biobeat monitoring device, we will monitor CHF patients during an outpatient visit and during treatment with diuretics.
41117730|NCT01845259|DRUG|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
41117731|NCT01845259|DRUG|Liraglutide Placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
41117732|NCT01758328|DRUG|busulfan|
41117733|NCT01758328|DRUG|melphalan|
41117734|NCT01758328|DRUG|fludarabine|
41117735|NCT01758328|BIOLOGICAL|anti-thymocyte globulin (ATG)|
40752945|NCT05311982|DEVICE|DLPFC-R (F4) TDCS|direct current brain stimulation- The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A), combined tDCS in DLPFC-L (F3) and DLPFC-R (F4) simultaneously (Block B) or sham-tDCS (Block C) with equal electrode configuration guaranteed blindness. After the procedures, each participant received the following intervention in the order ABC, BCA or CAB with a period of 1 week between each one. Each block took 3 weeks, organized into: 1) Assessment; 2) Application of stimulation; 3) Reassessment and washout week. Adding 1 more week of final evaluation, the study totaled the period of 10 weeks. During this period, patients were instructed to continue their behavioral/educational treatment and medication routines.
40752946|NCT05311982|DEVICE|DLPFC-L (F3) and DLPFC-R (F4) TDCS|DLPFC-L (F3) and DLPFC-R (F4) (Bock B)
40752947|NCT05311982|DEVICE|sham-tDCS|sham-tDCS (Block C) with equal electrode configuration guaranteed blindness
40752948|NCT01681303|DRUG|AST-120|
41117736|NCT01758328|PROCEDURE|a T cell depleted stem cell transplant|
41117737|NCT04260906|DEVICE|Vagus nerve stimulator|Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears (Figure 1). The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
41117738|NCT04260906|OTHER|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
41117739|NCT03656406|BEHAVIORAL|Lateral decubitus positioning|After the DLT intubation, the patient is placed in lateral decubitus position
41117740|NCT03656406|DEVICE|Cuff-manometer|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning.
40752949|NCT01230814|DRUG|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole \& Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
41117741|NCT04512651|OTHER|Tibiotarsal Thrust Manipulation|The dancers were positioned in dorsal decubitus position with the heel outside the stretcher. The osteopath positioned in a lateral feint, inflected knees and forearms in the same plane as the participant's leg. With the internal hand slipped the pinky finger on the medial edge of the foot to the talus neck, the other fingers on the dorsum of the foot and the thumbs controlling the first metatarsus. The position of the talus in relation to the tibia was corrected, initially by placing the foot in eversion and then in dorsal flexion. The osteopath left the body weight behind, causing a traction in the joint. The thrust consisted of a impulse of high speed and low amplitude impulse in a caudal direction, closing the elbows20. The technique was performed until the obtainment (achieved) the joint noise only in the restricted foot, and only one service was performed. After one week, a reassessment of the painful sensation after the dance was performed.
41117742|NCT04512651|OTHER|Simulation Tibiotarsal Thrust Manipulation|Simulation of the technique Tibiotarsal Thrust Manipulation, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
40752950|NCT01230814|DRUG|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
41117743|NCT01123408|DRUG|Clozapine|500 mg/day
41117744|NCT01123408|DRUG|Olanzapine|20 mg/day
41117745|NCT01123408|DRUG|Haloperidol|20 mg/day
41117746|NCT01032798|DRUG|mepivacaine|One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
41117747|NCT01231802|DRUG|Eniluracil|Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, \& 15
41117748|NCT01231802|DRUG|5-Fluorouracil|5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, \& 16
41117749|NCT01231802|DRUG|Leucovorin|Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, \& 17
41117750|NCT01231802|DRUG|Capecitabine|Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
41117751|NCT01662336|DRUG|Lopinavir / ritonavir|Prescribed according to the product monograph and physician's discretion.
41117752|NCT01662336|BEHAVIORAL|Kaletra Adherence Support Assistance Program|A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.
41117753|NCT01407198|DRUG|Nilotinib|Orally, daily 200 - 400 mg BID
41117754|NCT01407198|RADIATION|Radiation therapy|External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.
41117755|NCT01684150|DRUG|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
41117756|NCT00721565|BEHAVIORAL|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
41117757|NCT04252586|DRUG|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
41117758|NCT02089217|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy
41117759|NCT02089217|DEVICE|Carotid Stenting (CAS)|Carotid stenting
41117760|NCT02089217|OTHER|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
41117761|NCT02089217|OTHER|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
41117762|NCT06373549|PROCEDURE|Patients with coronary artery bypass surgery routine procedural administration of cardioplegia solutions|To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
41117763|NCT06373549|PROCEDURE|Patients who underwent heart valve surgery without coronary artery disease routine procedural administration of cardioplegia solutions|To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
41117764|NCT05763524|PROCEDURE|Adrenalectomy with or without lymphadenectomy|Regarding lymphadenectomy extent, it will be described as locoregional or systematic depending on availability of data in the Eurocrine database.
41117765|NCT03202199|DEVICE|PET/MRI|2 PET/MRI examinations
41117766|NCT04297306|BEHAVIORAL|Exercise Prescription|Standardised Exercise Prescription.
41117767|NCT04297306|DEVICE|Exercise Prescription and Virtual Reality Exercise Gaming support|Standardised Exercise Prescription with the additional support of Virtual Reality Promoted Exercise Games.
41117768|NCT02768467|PROCEDURE|Tissue Matrix Graft Placement|Subject will receive a covering for the wound post buccal mucosa removal.
41117769|NCT02768467|PROCEDURE|No Stitches|Subject will not receive stitches post buccal mucosa removal.
41117770|NCT02118675|OTHER|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements. Your BMI will be calculated from these measurements.
40752951|NCT01864096|DRUG|Metformin|One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.
41117771|NCT02118675|OTHER|Body Composition and Circumference measurements|This test is to measure the amount of water in your body. After a fasting urine sample is collected, you will drink a glass of water that has been enriched with an atom called a stable isotope (deuterium). After you drink this non-radioactive heavy water, you will provide urine samples several times over the next 4 hours.
41117772|NCT02118675|OTHER|Whole Body DXA scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. You will be carefully positioned on the table, and your legs will be placed together using two Velcro straps. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes approximately ten minutes.
41117773|NCT02118675|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will repeat this procedure on three different BIA systems.
41117774|NCT02118675|OTHER|BodPod|This test will estimate the amount of fat mass and fat free mass in your body. You will be required to change into a swimsuit and swim cap that we will provide for this procedure. If your swimsuit meets the necessary criteria, you can bring and wear it for the procedure, or PBRC will provide one for you. You will step onto a scale for a quick weight measurement. Next, you will sit inside of the system like you are sitting in a chair. The door of the system will be closed, but you will have a window so that you can see outside of the system while the measurements are completed. The test will be completed in about 15 minutes.
40752952|NCT01864096|DRUG|Placebo|One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
40752953|NCT06549764|BEHAVIORAL|Youth Aware of Mental Health|Help-seeking and literacy increasing intervention
40752954|NCT02307500|DRUG|Regorafenib|oral therapy
41117775|NCT02118675|OTHER|Circumferences|This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
41117776|NCT02118675|OTHER|Ultrasound|An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.
40752955|NCT03556280|DEVICE|GammaSense Stimulation System (Active Settings)|Proprietary auditory and visual sensory stimulation device.
41117777|NCT06335576|OTHER|This study is a single-arm and observational study with no intervention.|This study is a single-arm and observational study with no intervention.
41117778|NCT01128075|DEVICE|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
41117779|NCT01128075|DEVICE|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
41117780|NCT04377815|OTHER|General Public cohort|No intervention is being tested
41117781|NCT01823536|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
41117782|NCT05075213|BEHAVIORAL|contingency management (deposit contract)|Participants will deposit $30 of their own money to play QuitBet. Participants will submit a CO test once per day between the hours of noon and 11:59pm. Participants whose CO test is 6ppm or lower (indicating no smoking) on at least 24 of 26 days between day 3-28 of the game will be declared winners and split the pot of deposited money. Participants who submit at least 21 CO tests, regardless of the result, will be entered into a raffle to win a prize worth $75.
41117783|NCT05075213|BEHAVIORAL|leaderboard and social feed|Participants will have access to a discussion board on which participants can post and respond to messages to each other. Also, a game host will post educational information about smoking cessation and serve as a discussion moderator.
41117784|NCT05075213|BEHAVIORAL|smoking cessation resource list|Participants will have access to a list of smoking cessation resources
41117785|NCT01480505|PROCEDURE|Pars plana vitrectomy with gas tamponade|"A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.~Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment."
41117786|NCT05518253|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
41117787|NCT05518253|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
41117788|NCT05162586|DRUG|Enpatoran low dose|Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
41117789|NCT05162586|DRUG|Enpatoran medium dose|Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
41117790|NCT05162586|DRUG|Enpatoran high dose|Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
41117791|NCT05162586|DRUG|Placebo|Participants will receive placebo matched to Enpatoran up to 24 weeks.
41117792|NCT05689125|DEVICE|Railroaded bougie|Residents expose the glottis by a video laryngoscope and place the tip of bougie through the vocal cords. Then, an assistant loads an endotracheal tube on the free end of the bougie. Residents advance the endotracheal tube over the bougie and withdraw the bougie.
41117793|NCT05689125|DEVICE|Preloaded bougie|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation using a bougie with a preloaded endotracheal tube while an assistant secures the free end of the bougie. Residents withdraw the bougie when the endotracheal tube reaches an appropriate depth.
41117794|NCT05689125|DEVICE|Stylet|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation with the assistance of a stylet. An assistant withdraws the stylet when the tip of the endotracheal tube passes through the vocal cords. Then residents place the endotracheal tube to an appropriate depth.
41117795|NCT06166225|BEHAVIORAL|Internet-based weight loss program|12-month, automated and behaviorally-based, Internet-delivered weight loss and weight loss maintenance program
41117796|NCT06166225|BEHAVIORAL|Yoga|9-month Iyengar yoga program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12, and self-guided yoga practice recommendations.
41117797|NCT06166225|BEHAVIORAL|Health and Wellness|9-month health and wellness program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12.
41117798|NCT03873337|BEHAVIORAL|Persistence Targeted Smoking Cessation in SMI (PTSC-S)|All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth
41117799|NCT03873337|DRUG|Nicotine patch|All participants will receive 10 weeks of nicotine patch
41117800|NCT05756504|DRUG|Ketorolac|Injection ketorolac 30 mg IV x TDS will be given to each patient in each group.
41117801|NCT05756504|DRUG|Tramadol|Injection Tramadol 25-50 mg IV x TDs wil be given to each patient in this group. Maximum dose will be 400 mg/ day
41117802|NCT02657200|OTHER|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
41117803|NCT03285386|BEHAVIORAL|Priming exercise|"All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions."
40752956|NCT03556280|DEVICE|GammaSense Stimulation System (Sham Settings)|Proprietary auditory and visual sensory stimulation device.
41117804|NCT03285386|BEHAVIORAL|Control Exercise|All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
41117805|NCT01830738|PROCEDURE|Single-port, peri-umbilical hysterectomy|Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
41117806|NCT01830738|PROCEDURE|Multi-port hysterectomy|Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
41117807|NCT01214824|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
41117808|NCT01388777|DEVICE|Visica 2™ Treatment System|The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
41117809|NCT01388777|PROCEDURE|Cryoablation|Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
41117810|NCT01388777|PROCEDURE|Surgical Resection|Complete surgical resection of the primary tumor following cryoablation therapy.
41117811|NCT00522782|DRUG|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
41117812|NCT00522782|DEVICE|Nitric Oxide Analyzer|Niox NO analyzer
41117813|NCT05701397|DIAGNOSTIC_TEST|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin cardiac amyloidsis
41117814|NCT02800434|PROCEDURE|hand allograft|
41117815|NCT02700958|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
41117816|NCT02700958|PROCEDURE|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
41117817|NCT03204968|DEVICE|Vagus nerve stimulation|transcutaneous Intermittent stimulation of the vagus nerve using neurostimulator V (Ducest®, Germany)
41117818|NCT03833648|OTHER|UControl Pain App with Education|The intervention will include educational information on pain management, e.g., using acetaminophen and NSAIDs to manage pain, as well as information on addiction and safe storage of medications.
41117819|NCT06012331|PROCEDURE|concentrated growth factors in open apex|"Dry canals with paper points. A 10 ml of venous blood will be collected and transferred to sterile tubes without anticoagulant solutions by a trained nurse. The tubes will be centrifuged machine using a one-step centrifugation protocol at variable rpm, after centrifugation, four layers will be obtained: the first layer at the top is serum, second layer is the fibrin buffy coat, the third layer is the liquid phase containing growth factors, The concentrated growth factor was separated from the red blood cells and serum using sterile scissors.~CGF will be packed into canal to the full working length using sterile pluggers.~The coronal level of the CGF gel is near the cervical area above cementoenamel junction and white MTA placed as capping material after CGF, then GIC and composite restoration"
41117820|NCT06012331|PROCEDURE|Blood Clot (BC)|"1. Create bleeding into the canal by over-instrumenting (induce by rotating a pre-curved K-file at 2 mm past the apical foramen with the goal of having the entire canal filled with blood to CEJ level)~2. Stop bleeding at a level that allows for 3-4 mm of restorative material.~3. Then white MTA as a coronal plug material be followed by GIC, then composite restoration."
41117821|NCT00802464|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
41117822|NCT00802464|BIOLOGICAL|Placebo|2 vaccinations at Months 0 and 2 with placebo
41117823|NCT00983593|BEHAVIORAL|Mind-Body Bridging|16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
41117824|NCT02622672|DIETARY_SUPPLEMENT|water-soluble ubiquinol|100 mg/d
41117825|NCT02622672|DIETARY_SUPPLEMENT|Placebo|glycerin.soy-lecithin, and water
41117826|NCT00835952|DRUG|ATX-101|ATX-101 single doses
41117827|NCT00549848|DRUG|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
41117828|NCT00549848|DRUG|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
41117829|NCT03751891|DEVICE|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
41117830|NCT03751891|DEVICE|HearingAid_A|HearingAid_A is the most recent Receiver-in-the-canal Hearing aid from manufacturer_A which will be fitted to the participants individual Hearing loss.
41117831|NCT03751891|DEVICE|HearingAid_B|HearingAid_B is the most recent Receiver-in-the-canal Hearing aid from manufacturer_B which will be fitted to the participants individual Hearing loss.
41117832|NCT02057939|DRUG|enzalutamide|160 mg orally once daily for six months
41117833|NCT02057939|DRUG|Androgen Deprivation|Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
41117834|NCT02057939|RADIATION|Radiation Therapy|Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
41117835|NCT03160599|OTHER|ketogenic diet|The treatment is mainly restricted calorie ketogenic diet. KD will consist of 4:1-1:1\[fat\]:\[protein+carbohydrate\].Carbohydrate is limited to 10-30 g / day.
41117836|NCT02810184|RADIATION|cone-beam computed tomography (CBCT)|additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
41117837|NCT04064086|OTHER|Comprehensive Pre-ESRD Patient Education (CPE)|Structured education session/s
41117838|NCT04064086|OTHER|Provision of the freely available resources for Kidney Disease Education|freely available resources
41117839|NCT01043458|DRUG|ABT-126|ABT-126 Low Dose \& ABT-126 High Dose
41117840|NCT01043458|DRUG|Placebo for ABT-126|Matching Placebo for Arms 1 \& 2
41117841|NCT02414412|DIETARY_SUPPLEMENT|Ulmus macrocarpa water extract|
41117842|NCT02209415|BEHAVIORAL|standard follow-up|Outpatient clinic visits
41117843|NCT02209415|PROCEDURE|PET/CT and EUS|PET/CT and EUS
41117844|NCT02921399|OTHER|eradication timing|patients who underwent ESD for gastric neoplasms were randomized to receive early (3-5 days) or late (8-9 weeks) H. pylori eradication therapy after ESD.
41117845|NCT01257932|DEVICE|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
41117846|NCT00237770|DRUG|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
41117847|NCT00237770|PROCEDURE|Head-up Tilt maneuver|Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
41117848|NCT03947684|DEVICE|Transcranial Magnetic Stimulation Device|The TMS device electrically stimulates the intended parts of the brain. In this study, the investigator plan to target the part of the brain cortex that is responsible for the voluntary motion of the leg muscles, whose functions are under investigation.
41117849|NCT01443845|DRUG|Roflumilast|Roflumilast 500 µg, oral administration, once per day
41117850|NCT01443845|DRUG|Placebo|Dose-matched placebo, oral administration, once per day.
41117851|NCT02412683|OTHER|oxaliplatin|
41117852|NCT04346732|OTHER|Vapocoolant spray|Vapocoolant spray
41117853|NCT04781881|DRUG|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
41117854|NCT01122901|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
41117855|NCT01122901|PROCEDURE|therapeutic conventional surgery|Undergo surgery
41117856|NCT01122901|OTHER|pharmacological study|Correlative studies
41117857|NCT01122901|OTHER|laboratory biomarker analysis|Correlative studies
41117858|NCT05186714|BEHAVIORAL|Tai Chi versus wellness education|12 weeks of Tai Chi (2x/week) or a wellness education (2x/week)
41117859|NCT04802369|DIAGNOSTIC_TEST|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.
41117860|NCT03619616|DRUG|ZSP1603 7.5 mg|ZSP1603 capsule administered orally once daily under fasted condition.
41117861|NCT03619616|DRUG|ZSP1603 12.5 mg|ZSP1603 capsule administered orally once daily in the fasting state.
41117862|NCT03619616|DRUG|Placebo 12.5mg|Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.
41117863|NCT03619616|DRUG|ZSP1603 25 mg|ZSP1603 capsule administered orally once daily under fasted condition.
41117864|NCT03619616|DRUG|Placebo 25mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
41117865|NCT03619616|DRUG|ZSP1603 50 mg|ZSP1603 capsule administered orally once daily under fasted state.
41117866|NCT03619616|DRUG|Placebo 50mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
41117867|NCT00337545|DRUG|RAD001|
41117868|NCT05710575|BIOLOGICAL|probiotic|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
41117869|NCT05710575|OTHER|placebo|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
41117870|NCT00751075|DRUG|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
41117871|NCT00751075|DRUG|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
40752957|NCT00337961|PROCEDURE|Optic Nerve Sheath Fenestration|
40752958|NCT01062295|DEVICE|Siesta-System|
41117872|NCT00751075|DRUG|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
41117873|NCT00751075|DRUG|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
41117874|NCT02794480|DEVICE|ELLIPTA DPI|It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)
41117875|NCT02794480|DEVICE|GSK MDI|It is the placebo inhaler with clear liquid containing propellant (1,1,1, 2- Tetrafluoroethane). It is given as oral inhalation (Inhalation Aerosol).
41117876|NCT02794480|DEVICE|AZ MDI|It is the placebo inhaler with clear liquid. It is given as oral inhalation (Inhalation Aerosol).
40752959|NCT01062295|DEVICE|Standard headrest|
40752960|NCT01578720|DRUG|EYLEA (Aflibercept) intravitreal injection|Intravitreal Injection once every 8 weeks with 3 initial monthly doses
41117877|NCT03281382|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-hIL12|Oncolytic adenovirus expressing two suicide genes and human IL-12
41117878|NCT01667796|DIETARY_SUPPLEMENT|Vitamin D3|
41117879|NCT06315777|GENETIC|cumulus cell oocytes complex (COC) among women with poor ovarian reserve|level of expression of Gremlin-1 (GREM1), Hyaluronic acid synthetase-2 (HAS2), and Prostaglandin-endoperoxide synthase-2 (PTGS2) in cumulus cell oocytes complex (COC) among women with poor ovarian reserve were analyzed
41117880|NCT03561064|BEHAVIORAL|CBT-I|Eligible participants will receive CBT-I by a licensed clinical psychologist.
41117881|NCT01388881|OTHER|Music Education|"The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the classical elements/music."
41117882|NCT06451185|OTHER|A haemostatic mineral powder product.|The intervention is the addition of an approved and commercially available haemostatic powder product which is indicated for the temporary external control of bleeding. Recommended application is at central venous catheter insertion, prior to the site being covered with a transparent dressing. Comprising a hydrophilic polymer and potassium ferrate, once in contact with protein-rich body fluids, the mechanism of action of the powder is to dehydrate and to absorb exudate. This simultaneously forms a low pH seal barrier which is hostile to microbial penetration while also purporting to help maintain clean and dry environment beneath transparent site dressings.
41117883|NCT04583514|BEHAVIORAL|Control|Weight-stable Control group
41117884|NCT04583514|BEHAVIORAL|Overfeeding|30% Overfeeding group
41117885|NCT02773303|DEVICE|Mente Autism™|A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
41117886|NCT02773303|DEVICE|Sham|a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
41117887|NCT05899452|BEHAVIORAL|Bubble blowing (active)|Bubble blowing as a method of active distraction during painful procedure (insertion of an IV cannula)
41117888|NCT05899452|BEHAVIORAL|Video distraction (passive)|Video on a tablet computer as a method of passive distraction during painful procedure (insertion of an IV cannula)
41117889|NCT06020963|PROCEDURE|Low Intensity Shockwave Therapy (LiSWT)|Low Intensity Shockwave Therapy (LiSWT) has been used for many years. Its mechanism is to use shock wave energy to promote angiogenesis to achieve the functions of tissue repair and cell regeneration.
41117890|NCT06020963|DRUG|Tamsulosin|Tamsulosin is a selective alpha-1 blocker, its main function is to relax the smooth muscles of the base of the prostate, urethra, and bladder, and improve lower urinary tract symptoms.
40752961|NCT01395602|DRUG|Cabergoline|cabergoline 0.5 mg twice weekly
41117891|NCT04933890|DEVICE|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
41117892|NCT04479969|BEHAVIORAL|Video Chat|Video chat with health coach using a computer tablet.
41117893|NCT04711213|DRUG|Dexamethasone Dose 1|Dexamethasone ophthalmic suspension dose 1
41117894|NCT04711213|DRUG|Dexamethasone Dose 2|Dexamethasone ophthalmic suspension dose 2
41117895|NCT04711213|DRUG|Placebo Dose 1|Placebo suspension dose 1
41117896|NCT04711213|DRUG|Placebo Dose 2|Placebo suspension dose 2
41117897|NCT00035971|DRUG|raloxifene HCI and alendronate Na|
41117898|NCT04225949|OTHER|survey 1|survey with one version of depiction
41117899|NCT04225949|OTHER|survey 2|survey with one version of depiction
41117900|NCT04838496|DRUG|FOLFOXIRI Protocol|"FOLFOXIRI consists of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil and is administered every 2 weeks:~Dosing:~* Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA, followed by:~* Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV~* Day 3-14: rest days.~Both regimen are initially administered for four cycles. In case of responsive or stable disease, a 5th and 6th cycle of FOLFOXIRI will be administered.~In case of unacceptable toxicity, the aforementioned dosages can be reduced or one or more chemotherapeutical agents can be omitted at discretion of the medical oncologist and will be noted in the patient's medical file. At discretion of the medical oncologist, a start dosage of 75% of the advised dosage could be considered in patients above 70 years of age."
40752962|NCT01395602|OTHER|placebo|1 pill twice weekly
40752963|NCT04846478|DRUG|Talazoparib|capsule, taken by mouth, once a day
40752964|NCT04846478|DRUG|Tazemetostat|orally as a tablet twice daily.
40752965|NCT00445120|DRUG|Lactobacillus Rhamnosus GG|patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
40752966|NCT00445120|DRUG|placebo (sugar)|Placebo will be administered to patients once daily for six months
41117901|NCT00666068|OTHER|corticotropin releasing hormone (CRH)|50 µg injected at 2200, 2300, 0000, and 0100
41117902|NCT00666068|OTHER|Placebo|injected at 2200, 2300, 0000, and 0100
41117903|NCT00666068|OTHER|Placebo|injected at 2200, 2300, 0000, and 0100
41117904|NCT01285635|DRUG|AT-101|Pulse Dose: AT-101 dose of 40 mg b.i.d. on days 1-3 Metronomic Dose: AT-101, 20 mg daily, days 1-14
41117905|NCT01285635|DRUG|Docetaxel|Docetaxel 75 mg/m2 on Cycle Day 1
41117906|NCT03366701|OTHER|Rehabilitation|The intervention (routine care) correspond to five weeks rehabilitation program
41117907|NCT05677061|DEVICE|Dynamic Hip Screw with HA-coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with hydroxyapatite coating on the screw thread was used to fix the fracture
41117908|NCT05677061|DEVICE|Dynamic Hip Screw without coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with no coating on the screw thread was used to fix the fracture
41117909|NCT04732338|OTHER|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic practitioners use a wide variety of therapeutic manual techniques to improve physiological function and help restore homeostasis in the body. There is a structural assessment is to identify possible abnormalities of tissue texture. Areas of asymmetry and misalignment of bony landmarks are also evaluated, along with the quality of motion, balance, and organization. These asymmetries, also known as somatic dysfunctions, are then treated by a variety of manual treatments, administered by osteopaths.
41117910|NCT00003868|DRUG|cyclophosphamide|
41117911|NCT00003868|DRUG|methotrexate|
41117912|NCT00003868|PROCEDURE|allogeneic bone marrow transplantation|
41117913|NCT00003868|PROCEDURE|peripheral blood stem cell transplantation|
41117914|NCT00003868|RADIATION|iodine I 131 monoclonal antibody BC8|
41117915|NCT00003868|RADIATION|radiation therapy|
41117916|NCT01663584|PROCEDURE|Blood draw|
41117917|NCT00781378|DRUG|rt-PA|rt-PA 100 mg continuous intravenous infusion for 2 hours
41117918|NCT00781378|DRUG|rt-PA|rt-PA 50 mg continuous intravenous infusion for 2 hours
41117919|NCT05382104|DRUG|Maribavir|Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.
40926224|NCT04729400|PROCEDURE|ultrasound pulsatil therapy (US) and massage|ultrasound pulsatil therapy (US) and massage
40926225|NCT03620656|DIAGNOSTIC_TEST|FibriCheck|Photoplethysmography-based smartphone or smartwatch sensor to assess cardiac rhythm
41117920|NCT00038506|DRUG|abacavir/lamivudine/zidovudine|
40752967|NCT01631929|OTHER|One bag|Infusion of dextrose and electrolytes using one bag
41117921|NCT00038506|DRUG|tenofovir|
41117922|NCT00857649|DRUG|Memantine|20 mg Oral Tablets Once Daily
41117923|NCT00857649|DRUG|Placebo|Oral Tablets Once Daily
40752968|NCT01631929|OTHER|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
41117924|NCT03482011|DRUG|Mirikizumab|Administered SC
41117925|NCT03482011|DRUG|Placebo|Administered SC
41117926|NCT01369498|DRUG|Simtuzumab|Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks
41117927|NCT01369498|DRUG|Ruxolitinib|In Stage 2, participants will be on a stable dose of ruxolitinib
41117928|NCT00465192|DRUG|estradiol, 10 mcg|
41117929|NCT00465192|DRUG|estradiol, 25 mcg|
41117930|NCT00465192|DRUG|placebo|
41117931|NCT00003375|DRUG|lomustine|
41117932|NCT00003375|DRUG|procarbazine hydrochloride|
40926226|NCT03400956|DRUG|Vilaprisan (BAY1002670)|Orally, coated tablet 2 mg, once daily
40926227|NCT03400956|DRUG|Placebo|Orally, coated tablet, once daily
40926228|NCT00940472|DRUG|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
41117933|NCT00003375|DRUG|vincristine sulfate|
41117934|NCT00003375|RADIATION|radiation therapy|
41117935|NCT05598580|DRUG|Lenalidomide|Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy.
41117936|NCT05598580|DRUG|Adenosylmethionine|Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
41117937|NCT04280497|DRUG|Administration procedures|"Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off."
40926229|NCT00940472|DRUG|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
40926230|NCT02671916|BEHAVIORAL|questionnaire|Investigation on all study patients, no Intervention, no groups
41117938|NCT04526834|DRUG|CD30.CAR-T|"Bendamustine and Fludarabine (3 days)~Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)"
41117939|NCT06522295|DEVICE|ultrasonography|Ultrasonographic Measurement of Optic Nerve Sheath Diameter
41117940|NCT03146065|BIOLOGICAL|PF-06730512|Comparison of different dosages of PF-06730512 to Placebo
41117941|NCT03146065|DRUG|Placebo|Comparison of Placebo to different doses of PF-06730512
41117942|NCT05459259|OTHER|Interviews and Delphi Survey|no intervention delivered
41117943|NCT02658240|DRUG|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
41117944|NCT02658240|DRUG|Epinephrine|0.5 mg epinephrine
41117945|NCT00502229|DRUG|Clomiphene citrate, metformin, highly purified urinary FSH|
41117946|NCT04435236|PROCEDURE|Cervical ESP block|Cervical ESP block will be performed as described by Elsharkawy at al. (7). ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
41117947|NCT04162444|DIAGNOSTIC_TEST|Physical examination|A physical examination is a routine screening procedure used to investigate a patient's symptoms or complaints. It consists of a series of questions regarding patient medical history followed by an examination of the symptoms to determine the correct diagnosis and treatment plan.
41117948|NCT04162444|DIAGNOSTIC_TEST|The Ross Classification for Heart Failure in Children|The assessment is performed by pediatric cardiologist according to the classic Ross scale. One of the 4 classes of chronic heart failure is registered.
41117949|NCT04162444|DIAGNOSTIC_TEST|The Aristotle score|Surgical risks will be assessed by the ARISTOTLE score developed specially for the task. The calculation will be performed online, available from http://www.aristotleinstitute.org.
41117950|NCT04162444|OTHER|Assessment of administered specific therapy|"The data will be registered as groups of administered medicines:~* Antiplatelet agents~* Loop diuretics~* Potassium-sparing diuretics~* Angiotensin-converting enzyme inhibitors"
41117951|NCT04162444|DIAGNOSTIC_TEST|Multispiral computed tomography/3D echocardiography|"All patients enrolled in the study should be routinely examined with multispiral computed tomography (MS-CT) or 3D-echo before surgery and 3 years later. As a result, a 3D aortic root reconstruction will be made to assess its size and anatomy and subsequently build a 3D soft model for surgery imitation.~At the study onset, we plan to perform MS-CT, then 3D-echo. If the correlation resulting from 3D-echo and the actual sizes will be high, the isolated 3D-echo will be preferred in the future.~If none of the methods is available, the patients will not be enrolled in the study.~The following data will be registered for further analysis:~* Perimeter of the aortic valve~* Diameter of the aortic valve at sinuses level~* Height of the aortic sinuses~* Morphology of the aortic valve"
41117952|NCT04162444|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography|"Transthoracic echocardiography is carried out at baseline, at discharge and then annually. It is performed in order to assess the contractile function of the heart and hemodynamic characteristics of the aortic valve and its autopericardium graft.~Transesophageal echocardiography is carried out directly after the withdrawal of the artificial circulation when performing augmentation of the aortic valve with autopericardium in order to asses hemodynamic characteristics of the aortic neo-valve."
41117953|NCT04162444|DIAGNOSTIC_TEST|12-lead electrocardiogram|"Registering 12-lead electrocardiogram (ECG) is used as a tool for assessment of the regularity of the heart rhythm as well as screening and predictive tool for assessment of fibrosis and hypertrophy processes in the myocardium. The following data will be registered:~* Heart rate~* Sinus rhythm (yes/no)~* Positive R wave in leads V5-6~* Angle α less than 0~* Presence/absence of abnormal Q wave~* Presence/absence of ST-segment depression in precordial leads"
41117954|NCT06100458|OTHER|Skin and leakage protocol|The skin and leakage protocol have been developed by the sponsor with the aim to offer a tool that can aid care providers in identifying problems in continence care and follow up the effect of any care interventions to remedy these problems. The protocol is a digital diary tool that tracks both the instances of urine leaking out of an absorbing incontinence product onto clothes and bedsheets, and any apparent skin changes in the area covered by the product. The protocol is in clinical use at the care homes were the subjects are residing.
41117955|NCT06244615|DEVICE|Verum (WO 6607)|Mouth and throat rinse and gargle solution
41117956|NCT06244615|DEVICE|Placebo (WO 6608)|Mouth and throat rinse and gargle solution
41117957|NCT01620684|DRUG|metyrapone|Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
41117958|NCT01620684|DRUG|placebo|placebo capsules
41117959|NCT02539108|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)
41117960|NCT02539108|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2015 2016 formulation)
41117961|NCT01997944|BIOLOGICAL|Human Serum ALbumin/interferon alpha2a|600,750 or 900 mcg dosing every 2 weeks
40752969|NCT00159874|DRUG|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight \>20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight \>45 kg: 80 mg 3 times a day (tid)
41117962|NCT01997944|BIOLOGICAL|Pegasys|180 mcg dosing every week
41117963|NCT04279548|DEVICE|Deep Brain Stimulation|Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS
41117964|NCT01611831|BEHAVIORAL|ACT in group|A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
41117965|NCT01611831|BEHAVIORAL|Improved treatment as usual by General Practitioners|General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
41117966|NCT05863481|PROCEDURE|Laparoscopic cerclage placement|The surgical method of the laparoscopic cerclage procedure at Aarhus University Hospital previous described in a paper by Riiskjaer et al (DOI: 10.1111/aogs.12001)
40752970|NCT00159874|DRUG|Sildenafil citrate|Oral,10 mg 3 times a day (tid), only subjects with body weight \>20 kg
41117967|NCT00716924|DRUG|Clopidogrel|300 mg
41117968|NCT00716924|DRUG|Clopidogrel|600 mg
41446306|NCT06042166|BEHAVIORAL|Connecting and Reflecting Experience (CARE) Program|The intervention consists of a 12-session mentalizing-focused parenting group, which will involve weekly one-hour telehealth therapy sessions with up to 7 postpartum parents per group and 1 to 2 facilitators. CARE is a therapy focused on parents' reflective capacity, or the ability to consider how our own and our children's thoughts, feelings, intentions, and other mental states shape behavior and parent-child relationships.
40752971|NCT00159874|DRUG|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight \>20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight \>45 kg: 40 mg 3 times a day (tid)
41117969|NCT00568659|PROCEDURE|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
40752972|NCT02923622|OTHER|Traditional Chinese medicine herbals|TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
41446307|NCT03684538|OTHER|Probiotics|Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)
41117970|NCT03957213|DEVICE|Acute Intermittent Hypoxia|Acute intermittent hypoxia is a safe, non-invasive technique. All sessions will be monitored by research study staff trained in delivering acute intermittent hypoxia. Hypoxic intervals will be delivered with a commercially available sports performance hypoxicator. A unit capable of delivering a fraction of inspired oxygen ranging from 21%-9% will be used. Air will be delivered into a mask that will be secured comfortably over the subject's nose and mouth. Intervention sessions will occur for 10 days over a 2 week period.
41117971|NCT03957213|BEHAVIORAL|Computerized Cognitive Training|60 minutes of Double Decision cognitive training for 10 days over a 2 week period.
41117972|NCT04954196|DRUG|Amlodipine 5mg|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive,HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative,HRT will be stopped gradually~Amlodipine administration: On the day of the first monitoring Dm (corresponding to D13 D16 of the cycle), a single per os dose of amlodipine 5 mg is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.The treatment will be maintained until the pregnancy test is performed then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
41117973|NCT04954196|DRUG|Placebo|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
41117974|NCT01900834|OTHER|No treatment given|The participants will not receive any treatment
41117975|NCT02095171|DRUG|PRX002|
41117976|NCT02095171|OTHER|Placebo|
41117977|NCT05928637|DRUG|D745, D759, D150|QD, PO for 5 days
41117978|NCT06290297|DEVICE|Telerehabilitation VRRS|Telerehabilitation programs delivered at home, aiming to improve cognitive, motor and/or speech-language skills, through VRRS - Khymeia or Niurion devices. Such technologies are equipped with a wide library of activities to be performed also with the use of peripheral sensors. A one-shot assessment is also proposed to children admitted to institutes adhering to the project in order to understand the feasibility of the use of such devices. Ad hoc feasibility questionnaire are administered at the end of the one shot session and after the home training to the main stakeholders (children, families, clinicians)
41117979|NCT03370796|OTHER|Reminiscence Therapy Program|The Reminiscence Therapy program is composed of: (i) main strand lasting 7 weeks, with sessions twice a week (total of 14 sessions); (ii) maintenance strand, which runs for 7 weeks, once a week (total of 7 sessions). The duration for each session will be 60 minutes.
41117980|NCT01134237|DRUG|urokinase|intrapleural urokinase injection
41117981|NCT01134237|DRUG|placebo|Normal saline as a placebo for control arm
41117982|NCT02708069|OTHER|e-Unstuck|An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.
41117983|NCT02708069|OTHER|Unstuck and On Target|An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
41117984|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine the presence of sepsis|Standard laboratory biochemical methods will be used to determine sepsis diagnosis accord-ing to SEPSIS 3 (1). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
41117985|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine the presence of sepsis and acute kidney injury|Standard laboratory biochemical methods will be used to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to Guidelines Kidney Disease Improving Global Outcomes (KDIGO) 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
41117986|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine miRNA and biochemical parameters|Laboratory examination will be performed to determine miRNA and biochemical parameters.
41117987|NCT02633267|BEHAVIORAL|Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)|Teaches thought restructuring and exposure therapy to socially anxious job seekers delivered by vocational service professionals
41117988|NCT02633267|BEHAVIORAL|Usual Vocational Services|Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
41117989|NCT00488657|DEVICE|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
41117990|NCT06335446|OTHER|Novel mapping algorithm|Signals will be collected during the catheter ablation. These signals STAR maps will be created post procedure and these will be compared to the conventional maps used during the atrial tachycardia ablation. This will be used to validate the STAR maps created.
41117991|NCT00000152|DRUG|Aspirin|
41117992|NCT00000152|DRUG|Beta-Carotene|
41117993|NCT03106142|PROCEDURE|Academic detailing visit arm|General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
41117994|NCT04982445|DRUG|CABENUVA|CABENUVA will be administered IM at infusion centers/ASAs
41117995|NCT05290168|DIAGNOSTIC_TEST|abdominal Doppler|"1. Inferior vena cava diameter and distensibility~2. Hepatic vein Doppler~3. Portal vein Doppler~4. Splenic artery and vein Doppler~5. Renal artery and vein Doppler"
41117996|NCT02803801|BEHAVIORAL|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
41117997|NCT03697538|PROCEDURE|Nerve Block for pain control post-revision total knee arthroplasty|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
41117998|NCT04428736|BEHAVIORAL|Disclosure Toolkit|"Participants will receive a Disclosure Toolkit consisting of a family letter, gene information chatbot, and informational website to aid in communicating their genetic test results with at-risk relatives."
41117999|NCT06168578|DEVICE|ultrasound|Optic nerve diameter will be measured by ultrasound at certain stages of the operation in Group I (ARM-) and Group II (ARM+)
41118000|NCT04035668|DRUG|Remibrutinib|Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.
41118001|NCT04035668|DRUG|Placebo|Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
41118002|NCT03593733|OTHER|Photobiomodulation Therapy|Photobiomodulation Therapy
41118003|NCT03593733|OTHER|Cold Water Immersion|Cold Water Immersion
41118004|NCT01366677|BEHAVIORAL|Yoga Intervention|Three yoga classes per week for 8 weeks.
41118005|NCT02759588|BIOLOGICAL|GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab|GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.
41118006|NCT05882617|OTHER|implants supported overdentures|implant supported and retained with different number of implants retained by ball attachments
40752973|NCT02923622|OTHER|Integrated traditional Chinese and Western medicine|TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
40752974|NCT02923622|OTHER|Western medicine|Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
41118007|NCT06006611|DRUG|Azvudine|Received antiviral treatment with azvudine
41118008|NCT04771780|DRUG|KHK7791|oral administration
41118009|NCT03573063|OTHER|Androgen metabolism after starvation|"The 20 women will all undergo the same process of starvation for 48 hours. During this time three blood samples and three 24-hours urine samples will be collected. At baseline, the investigators will draw blood, perform a pregnancy test and collect the 24 hours urine as well as a spot urine.~Then the 48 hours starvation starts and two blood and two 24 hours urine samples and spot urines will be collected after 24 and 48 hours in the morning. After the third visit the study is completed for the participant."
41118010|NCT06552819|OTHER|No intervention|No intervention
41118011|NCT06277037|OTHER|Non-interventional|This is a rollover study
41118012|NCT05210257|OTHER|Conventional physiotherapy|Group 1 was given conventinal physiotherapy Physiotherapy agents; 5 min ultrasound 1.5 watts/cm2 20 min conventional TENS 20 min heat agent application (hot pack) Exercise program; Stretching and relaxation exercises, Neck strengthening exercises that include concentric and isometric contractions Posture exercises 3 sets per day, 1 in the hospital with 10 repetitions
41118013|NCT05210257|OTHER|Neuroscience education|"Conventional physiotherapy program and The neuroscience education trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions.~In sessions ; neurons and nerve conduction in the session, the formation process of pain, peripheral neuropathic pain, pain spread during the session, neuroplasticity, peripheral and central sensitization, hyperalgesia and allodynia, acute-chronic pain, The effects of stress, fear, anxiety, false thoughts and beliefs about pain and other psychosocial factors on the pain process and determining possible psychosocial factors in the patient during the session, Strategies for controlling the pain process and coping with psychosocial factors in the session will be completed by explaining the effect mechanisms of exercise on pain."
41118014|NCT03017183|PROCEDURE|EBUS-TBNA|Endobronchial ultrasound guided transbronchial needle aspiration
41118015|NCT03017183|PROCEDURE|Endobronchial forceps biopsy|Conventional endobronchial forceps biopsy
41118016|NCT01970891|DEVICE|neuromuscular stimulation device|Effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait amelioration.
41118017|NCT02756377|DRUG|cetylpyridinium chloride mouthwash|cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
41118018|NCT02756377|DRUG|Chlorhexidine mouthwash|Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
41118019|NCT03372473|DRUG|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg, one dose per day
41118020|NCT03372473|DRUG|Montelukast|Montelukast 5mg
40926231|NCT03257709|PROCEDURE|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
40926232|NCT03257709|PROCEDURE|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
40752975|NCT04356703|OTHER|Neuropsicomotor developmental test|Children will be evaluated trough Bayley III and PEDI scale. They also will be examined by pediatrician, neurosurgeon, orthopedics and phisiatry
41118021|NCT02570568|DEVICE|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
41118022|NCT02570568|DEVICE|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
41118023|NCT02570568|PROCEDURE|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
41118024|NCT00899015|OTHER|pharmacological study|
41118025|NCT05989035|PROCEDURE|Abdominal subcutaneous adipose tissue biopsy|"Fatty tissue biopsy- Participant will be placed in a supine position with arms placed at side while abdominal skin is marked with a skin marker and cleansed with chlorhexidine. Afterwards, the abdominal fatty tissue biopsy will be performed.~Collect fatty tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that fatty tissue in the laboratory."
41118026|NCT02584829|DRUG|Avelumab|Given IV
41118027|NCT02584829|OTHER|Laboratory Biomarker Analysis|Correlative studies
41118028|NCT02584829|BIOLOGICAL|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
41118029|NCT02584829|RADIATION|Radiation Therapy|Undergo radiation therapy
41118030|NCT02584829|BIOLOGICAL|Recombinant Interferon Beta|Given via intra-tumor injection
41118031|NCT05033314|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10mg PO daily as thromboprophylaxis
41118032|NCT05033314|DRUG|Placebo|matching placebo daily
41118033|NCT05152992|BEHAVIORAL|Viewing visual stimuli and electrical stimulation of the brain|View emotionally evocative videos and undergo stimulation of brain regions involved in emotion. In a 20-minute block (5 total blocks), eighteen 30-second movie clips will be used to elicit different categories of emotions (sadness, fear, disgust, awe, affection, and amusement). Additionally, each hub of the emotion network will be stimulated to identify areas that generate similar emotional states as those elicited by the videos. Each stimulation trial consists of 3 minutes of 1-3 mA, 50 Hz, 100 us pulse-width stimulation.
41118034|NCT00761605|DRUG|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
41118035|NCT04293705|DEVICE|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
41118036|NCT01227876|DRUG|Ster|prednisolone 1% ophthalmic suspension
41118037|NCT01227876|DRUG|Pred Fort|prednisolone 1% ophthalmic suspension
41118038|NCT03780686|DRUG|Norepinephrine, dopamine|drugs to decrease bleeding
41118039|NCT02147678|DRUG|Etomidate|
41118040|NCT02147678|DRUG|Propofol|
41118041|NCT02147678|DRUG|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2\~0.4 μg/kg/min.
41446308|NCT03684538|OTHER|Zinc|Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
41118042|NCT02147678|DRUG|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
41118043|NCT05855655|BEHAVIORAL|Mindfulness-Based Queer Resilience (MBQR)|"This work aims to develop an internet-delivered MBI to address minority stress and its negative HIV-related health consequences experienced by young men who have sex with men (YMSM). This aim will examine the feasibility and acceptability of the internet-delivered mindfulness-based intervention (iMBI), called Mindfulness-based Queer Resilience (MBQR), for HIV prevention. The study will enroll and randomize a sample of 60 distressed, high-risk YMSM into one of two groups: MBQR intervention (n=30) or active control condition (n=30)."
41118044|NCT02218060|PROCEDURE|Coronary CT angiography on SOMATOM Force|Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
41118045|NCT02218060|PROCEDURE|Previous coronary CT angiography on 2nd generation CT scanner|Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
41118046|NCT00653276|DRUG|ezetimibe|ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
41118047|NCT00653276|DRUG|Comparator: cyclosporine|single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
41118048|NCT01922830|DIETARY_SUPPLEMENT|Bio-25 (Supherb)|The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.
41118049|NCT01922830|DIETARY_SUPPLEMENT|Placebo (for Bio-25, Supherb)|A pill manufactured to mimic Bio-25 (Supherb) pill
41446309|NCT03684538|OTHER|Probiotics & Zinc|Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
40752976|NCT01512173|DRUG|propranolol gel|Topical administration twice daily
40752977|NCT01512173|DRUG|Placebo|Topical administration twice daily
40752978|NCT01981993|BIOLOGICAL|Urinary proteomic analysis|
41118050|NCT05028959|OTHER|Multidisciplinary monitoring of healthy women|Multidisciplinary monitoring
41118051|NCT05327959|DEVICE|Clavicle open reduction and internal fixation|Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System
41446310|NCT03684538|OTHER|Standard care|initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
41446311|NCT02512900|DRUG|MEDI9929, 140 mg|On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
41446312|NCT05608642|OTHER|Intravenous hydration|500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.
41118052|NCT05806255|DEVICE|The RELIEF App|"RELIEF is a virtual app designed for the remote self-reporting of symptoms in patients with palliative care needs. The patient/caregiver securely logs into the site and self-reports symptoms, distress, and pain using the validated clinical tools ESAS-r, Distress Thermometer (DT), and Brief Pain Inventory (BPI) currently in daily use by healthcare providers across Canada.~This data is reported to the healthcare providers via RELIEF. Any increases in symptom burden, distress, or pain are flagged for clinical review as RELIEF alerts. Healthcare providers received alerts via secure email for any sudden changes in symptom status, or if the patient's symptoms, distress, or pain severity increases by set amounts over a period of time. Following review of the RELIEF alert by the healthcare providers, patients receive (1) earlier intervention; (2) mobilization of auxiliary services; and (3) recommendation for urgent clinic/home visit or emergency department visit."
41118053|NCT06498544|OTHER|Exposure to 3600 m|Participants will travel to and stay for 2 nights at an altitude of 3600 m.
41118054|NCT00214240|DRUG|CMV Immune globulin|CMV IvIg 150mg/kg x 6 doses
41118055|NCT00328731|PROCEDURE|Procedure|
41118056|NCT02274142|PROCEDURE|Restoration with hand-mixed material|restoration with hand-mixed glass ionomer cement
41118057|NCT02274142|PROCEDURE|Restoration with Encapsulated material|restoration with encapsulated ionomer cement
41118058|NCT02274142|DEVICE|Encapsulated glass ionomer cement (EQUIA - GC Corp).|
41118059|NCT02274142|DEVICE|powder-liquid glass ionomer cement (Fuji IX - GC Corp)|
41118060|NCT01066026|PROCEDURE|hyaluronic acid with metallic cannula or standard needle.|"The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~* In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~* In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula."
41118061|NCT01066026|DRUG|Hyaluronic acid injected with the new tool.|hyaluronic acid with metallic cannula.
41118062|NCT01301716|DRUG|GDC-0980|Oral escalating dose
41118063|NCT01301716|DRUG|bevacizumab|Intravenous repeating dose
41118064|NCT01301716|DRUG|carboplatin|Intravenous repeating dose
41118065|NCT01301716|DRUG|cisplatin|intravenous repeating dose
41118066|NCT01301716|DRUG|paclitaxel|Intravenous repeating dose
41118067|NCT01301716|DRUG|pemetrexed|intravenous repeating dose
41118068|NCT02270645|DEVICE|595/1064 multiplex laser|595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.
41118069|NCT00096967|DRUG|Avastin (bevacizumab)|
41118070|NCT00174382|DRUG|Donepezil|donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
41118071|NCT00925899|DRUG|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
41118072|NCT00925899|DRUG|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
41118073|NCT00000217|DRUG|Carbamazepine|
41118074|NCT02550067|DRUG|DMPA|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
41118075|NCT02550067|DRUG|LNG|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
41118076|NCT02550067|DRUG|Copper IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
41118077|NCT06478992|PROCEDURE|A:hysteroscopic suture fixation of Mirena|A(the thickness of the thickest uterine myometrium ≥30mm ):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
41118078|NCT06478992|PROCEDURE|A: simple Mirena placement under hysteroscopy|A(the thickness of the thickest uterine myometrium ≥30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
41118079|NCT06478992|PROCEDURE|B: hysteroscopic suture fixation of Mirena|B(the thickness of the thickest uterine myometrium\<30mm):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
41118080|NCT06478992|PROCEDURE|B：simple Mirena placement under hysteroscopy|B(the thickness of the thickest uterine myometrium\<30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
41118081|NCT06232577|DRUG|Hydrocodone|Given by PO
41118082|NCT06232577|DRUG|Tramadol|Given by PO
41118083|NCT06232577|DRUG|Oxycodone|Given by PO
41118084|NCT04747743|OTHER|a self structured questionnaire|A self structured questionnaire to assess knowledge of skeletal muscle use in dental practice
41118085|NCT02974634|OTHER|Ostomy self management training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
41118086|NCT04327167|BEHAVIORAL|Video and questionnaire|Potential donors would be shown a video and asked to complete a questionnaire to capture change in attitude towards donation.
41118087|NCT06408493|BEHAVIORAL|MYCardio-PEER|MYCardio-PEER participants will attend an 8-weeks intervention program delivered over the social networking application. Bite-sized videos and infographic posters on healthy diet and lifestyle for primary prevention of CVD will be delivered weekly, supplemented by interactive peer-group activities to encourage behavior change.
40752979|NCT05569889|PROCEDURE|Anterior Cruciate Ligament reconstruction (ACLR)|A comparison between the two groups were done regarding the three following stages: (a) the preparation time of the trolley, which is the time taken by the CNOR to recover from the reserves all the single-packed sterile instruments (SPSI) necessary for the intervention or to recover the CST (b) the opening time of the instruments by the circulating nurse who opens the packages and gives them to the surgical nurse while respecting the sterility of the items, and by the surgical nurse who prepares the table for the intervention, and (c) the sorting time of the waste between plastic and paper at the end of the intervention.
41118088|NCT05241041|BEHAVIORAL|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
41118089|NCT05241041|DEVICE|auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously.
41118090|NCT05241041|DEVICE|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
41118091|NCT05848531|DRUG|Clonidine|Comparing Clonidine with Morphine PCIA for the treatment of Vaso-Occlusive crisis in Sickle Cell disease patient
41118092|NCT02477605|DEVICE|CONSTELLATION® 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.
41118093|NCT02477605|DEVICE|CONSTELLATION® 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
41118094|NCT02477605|PROCEDURE|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
41118095|NCT00071253|DRUG|Divalproex Sodium (Delayed-Release Tablets)|
41118096|NCT00071253|DRUG|Divalproex Sodium (Extended-Release Tablets)|
41118097|NCT00071253|DRUG|Olanzapine|
41118098|NCT04333355|BIOLOGICAL|Convalescent Plasma|Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.
41118099|NCT04816799|BEHAVIORAL|Startle Adjuvant Rehabilitation Therapy (START)|Exposure to loud acoustic stimulus during training of motor task (in this case speech).
41118100|NCT04243980|DEVICE|Short anatomical femoral stem in THR|Patients with osteoarthritis after total hip arthroplasty
41118101|NCT00001730|DRUG|Thyrogen|
41118102|NCT02694835|DEVICE|Delefilcon A contact lenses with UV Absorber|
41118103|NCT02694835|DEVICE|Delefilcon A contact lenses|
41118104|NCT01820182|DEVICE|capsule endoscopies|Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
41446313|NCT05608642|OTHER|Intravenous prednisolone|The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.
40926233|NCT01141062|DEVICE|Philips MR-guided HIFU|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
41118105|NCT03475524|DRUG|MetFORMIN 1000 Mg Oral Tablet|oral tablet 1ooomg systemic metformin will be given to group
41118106|NCT03475524|DRUG|Placebos|oral placebos will be given to control beside trichloracetic acid peeling
41118107|NCT03475524|DRUG|Trichloroacetic Acid Peeling|Trichloroacetic acid peeling to the three groups
41118108|NCT03475524|DRUG|MetFORMIN 500 Mg Oral Tablet|oral tablet 500 mg
41118109|NCT00459745|DRUG|Pravafen|
41118110|NCT00459745|DRUG|Pravastatin|
41118111|NCT00459745|DRUG|Fenofibrate|
41118112|NCT00846326|DRUG|oxymetazoline-fluticasone propionate|Oxymetazoline 0.05% w/v Fluticasone propionate 0.05% w/w 2 squirts in each nostril twice daily
41118113|NCT00846326|DRUG|Oxymetazoline|oxymetazoline 0.05% w/v and placebo nasal spray 2 squirts in each nostril twice daily
41118114|NCT02983669|DIETARY_SUPPLEMENT|Thyme|Thyme capsule 350 mg twice daily
41118115|NCT02983669|OTHER|Placebo|Placebo capsule 350 mg twice daily
41118116|NCT03837886|DIETARY_SUPPLEMENT|Sodium bicarbonate|The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.
41118117|NCT03837886|DIETARY_SUPPLEMENT|Calcium carbonate|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
41118118|NCT04456725|BEHAVIORAL|Intensive management|The intervention group will be assigned to a partnership of one nurse practitioner and one medical assistant who will manage them intensively, with the support of the study team.
41118119|NCT04456725|BEHAVIORAL|Control|Usual care
41118120|NCT03817060|PROCEDURE|cryopreservation of embryos at cleavage stage|cryopreservation of embryos at cleavage stage (day 3) of embryo development
41118121|NCT03817060|PROCEDURE|cryopreservation of embryos at blastocyst stage|cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development
41118122|NCT05496777|PROCEDURE|Home-based prehabilitation program|The home-based prehabilitation program will consist of a four-week program, where patients are expected to perform a high-intensity interval training on a home-trainer combined with functional mobility training three times a week. The program is partly supervised by a trained physiotherapist.
41118123|NCT04225403|BEHAVIORAL|Telephone-based motivational interviewing for smoking cessation|"The motivational brief intervention is known by the acronym 5 R and lasts about 5-10 minutes. It is an approach based on the principles of motivational interviewing and develops the intervention in five short steps:~* Relevance. Help patients identify why personal reasons may be relevant to quitting smoking.~* Risks. Help identify what negative consequences tobacco use has.~* Rewards. Help identify potential benefits of quitting smoking.~* Resistors. Help patients identify barriers to smoking cessation, which can often include fear of withdrawal symptoms, failure, wainweight, face social situations, etc.~* Repeat. Repeat the intervention at 3 months if you do not advance at the stage of change."
41446314|NCT05608642|OTHER|Intravenous lidocaine|The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.
41118124|NCT05781347|PROCEDURE|Radiofrequency Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under general anesthesia which uses radiofrequency (RF) energy delivered to the lower esophageal sphincter and cardia.
41118125|NCT05781347|DEVICE|Stretta|Stretta is a FDA approved device for the management of GERD.
41118126|NCT02847780|DEVICE|Active Comparator :C-Mac Videolaryngoscope|Real time assessment of Glottic aperture at the time of extubation by videolaryngoscope
41118127|NCT02847780|DEVICE|Experimental: Airway ultrasound,|Airway ultrasound using portable ultrasound machine to assess vocal cords movement.
41118128|NCT06186492|DRUG|WVE-006|RNA editing oligonucleotide
41118129|NCT06114602|BEHAVIORAL|E-Mail Reminder|Patients who have an appointment (either face-to-face or teleconsultation) scheduled with a doctor at the Hospital receive an e-mail at the time of their request as well as 14 days and 48 hours prior to the appointment, reminding them of the appointment time and the place where they have to go. In addition, a button has been added to the e-mail so that the patient can click on it and cancel it directly in a simple way.
41118130|NCT05234853|DRUG|PUR001|Monoclonal antibody
41118131|NCT00147485|DRUG|AG-024322|
41118132|NCT01606124|DRUG|defined green tea catechin extract|Given PO
41118133|NCT01606124|OTHER|placebo|Given PO
41118134|NCT01606124|OTHER|questionnaire administration|Ancillary studies
41118135|NCT01606124|OTHER|laboratory biomarker analysis|Correlative studies
41118136|NCT02778828|DRUG|Linezolid|adjustment of Linezolid of based on the AUC/MIC and % T\> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently performed in case of too low residual or toxicity.
41118137|NCT05001529|BIOLOGICAL|anti IL5 receptor antibodies|Subjects with severe uncontrolled asthma will be assigned to treatment with Omalizumab (anti Ig E antibodies) or Mepolizumab (anti IL-5 antibodies) according to medical advice and standardized protocols for asthma treatment.
41118138|NCT02612844|DRUG|NNC0143-0406|Subject will receive one single dose only Subcutanesously (s.c., under the skin)
41118139|NCT02612844|DRUG|insulin aspart|Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
41118140|NCT04760834|OTHER|Questionnaire|Complete a questionnaire to look for signs of concussion in the past. The questions also seek to collect data on participants' knowledge, concussion management and potential confounding factors
41118141|NCT01408849|DRUG|Maytenus ilicifolia leaves infusion|2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
41118142|NCT01408849|DRUG|Omeprazole|Standard therapy
41118143|NCT02234739|DRUG|Voriconazole|2-week long intravenous instillation of voriconazole
41118144|NCT00253110|DRUG|risperidone|
41118145|NCT00253110|DRUG|haloperidol|
41118146|NCT01198028|DRUG|Erlotinib|Given PO
41118147|NCT06075069|DEVICE|Feeding appliance|A preliminary alginate impression was made using wax stock tray to get a preliminary cast and construct a self-cure acrylic custom-made tray. A Medium viscosity rubber base impression material was used for making final impression which in turn will be poured to obtain a master cast. On this master cast, a feeding appliance will be constructed. Readymade facebow with two straight side length of hard, rounded, of 2mm diameter, 15cm length Nickel-Chrome wire with omega loops (at the end of the wire) was used to form extra-oral wings to be used as a retentive aid to maintain the prosthesis in situ. The appliance was fabricated in clear acrylic resin then finished and polished. A small piece of cold cure acrylic resin was added and adapted to the omega loops and manipulated to follow the checks contour.
41118148|NCT05183490|DRUG|Rapidly generated virus specific T (R-MVST) cells|"The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~* (-1A) 0.25x10\^6 R-MVST TNC/kg~* (1A) 0.5x10\^6 R-MVST TNC/kg~* (2A) 1x10\^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~* (-1B) 1x10\^6 R-MVST TNC/kg~* (1B) 2x10\^6 R-MVST TNC/kg~* (2B) 4x10\^6 R-MVST TNC/kg"
41118149|NCT02906891|DEVICE|Vigilant Diabetes Management Application|The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
41118150|NCT03051165|DEVICE|Hypoglossal Nerve Stimulation Treatment Withdrawal|After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
41118151|NCT02496975|DRUG|Cyclosporine A|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
41118152|NCT02496975|OTHER|Placebo|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
41118153|NCT02301442|BEHAVIORAL|Exercise + behaviour change intervention|In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.
41118154|NCT02301442|BEHAVIORAL|Exercise + control education|The control group will receive exercise and education components. The exercise intervention includes aerobic \& strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers \& exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
41118155|NCT04614636|DRUG|FT538|Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
41118156|NCT04614636|DRUG|Cyclophosphamide|Lympho-conditioning Agent
41118157|NCT04614636|DRUG|Fludarabine|Lympho-conditioning Agent
41118158|NCT04614636|DRUG|Daratumumab|Monoclonal Antibody, CD38, Anti-CD38
41118159|NCT04614636|DRUG|Elotuzumab|Monoclonal Antibody
41118160|NCT03432403|DEVICE|Ambu LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
41118161|NCT03432403|DEVICE|Gastro LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
41118162|NCT05464316|DEVICE|Adjustable Transobturator Male System|The ATOMS sling was developed in 2008 by Agency for Medical Innovations GmbH in Austria. It is a self-anchoring adjustable system which supports the bulbar urethra dorsally and uses the trans obturator approach. This device gained its fame in the male sling scene by being adjustable, which theoretically makes it more efficacious than its competitors.
41118163|NCT05464316|DEVICE|Artificial Urinary Sphincter|"The AMS800™, which is by far the most frequently implanted AUS, was first marketed in 1983 and was developed by America Medical Holdings in Minnesota. Today, the AUS has been given the title gold standard for surgical treatment for PPI. This device is an inflatable cuff which wraps around the urethra to supply circumferential pressure. It has a control pump, which is found in the scrotum and is operated by the patient. The patient can void simply by squeezing the pump, which brings the fluid from the cuff to a reservoir and release the pressure around the urethra. The cuff is then automatically refilled with fluid within a couple of minutes to close back the sphincter."
41118164|NCT06300424|DRUG|almonertinib|110mg qd
41118165|NCT06300424|DRUG|Carboplatin|AUC 5, d1 every 3 weeks
41118166|NCT06300424|DRUG|Nab paclitaxel|135 mg/m2, d1,d8 every 3 weeks
41118167|NCT01346982|DRUG|Silimarine|darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
41118168|NCT01082289|DRUG|Lurasidone|
41118169|NCT05103423|DRUG|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
41118170|NCT05103423|DRUG|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
41118171|NCT05103423|DRUG|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
41118172|NCT00238836|BEHAVIORAL|Self-management of chronic illness|
41118173|NCT01457612|DIETARY_SUPPLEMENT|Strawberry|20g twice per day (BID) in beverage
41118174|NCT01457612|DIETARY_SUPPLEMENT|Placebo1|Placebo Beverage 1 without fiber
41118175|NCT01457612|DIETARY_SUPPLEMENT|Placebo2|Placebo Beverage 2 with Fiber
41118176|NCT00718848|PROCEDURE|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
41118177|NCT00718848|PROCEDURE|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
41118178|NCT02410018|DEVICE|OCL 503 (uterine artery embolization)|Transcatheter embolization of the uterine artery(ies) using an embolic agent.
41118179|NCT00847834|DRUG|Irbesartan 150mg / Hydrochlorothiazide 12.5mg|Once a day
41118180|NCT00847834|DRUG|Irbesartan 150mg|Once a day
41118181|NCT02273986|DRUG|Digoxin|
41118182|NCT02273986|DRUG|K-877|
41118183|NCT00117936|COMBINATION_PRODUCT|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose|Up to ten intramyocardial injections of low dose FGF 1-141, via a NOGA Injection Catheter, single cath lab session
41118184|NCT00117936|COMBINATION_PRODUCT|Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose|Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session
41118185|NCT00117936|COMBINATION_PRODUCT|Placebo|Up to ten intramyocardial injections of placebo via a NOGA Injection Catheter, single cath lab session
41118186|NCT02722551|DEVICE|Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve|Replacement of the mitral valve through a transcatheter approach
41118187|NCT01763086|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10\^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
41118188|NCT00239434|DRUG|tiotropium inhalation powder capsule|
41118189|NCT00239434|DRUG|ipratropium bromide Metered Dose Inhaler|
41118190|NCT00328835|PROCEDURE|Brief Elevation of IOP|
41118191|NCT04310358|OTHER|4 short PLMs group 1|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 1 (pre-test), Test 2 (immediate post-test), Test 1 (remote post-test)
41118192|NCT04310358|OTHER|4 short PLMs group 2|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 2 (pre-test), Test 1 (immediate post-test), Test 2 (remote post-test)
41118193|NCT05089526|DRUG|ketamine-lidocaine-dexmedetomidine|"In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
40926234|NCT04492215|BEHAVIORAL|Interaction between patient and trained general practitioners in motivational interviewing|Impact of the medical interview on the patient
41118194|NCT05089526|DRUG|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
41118195|NCT03759743|DIETARY_SUPPLEMENT|LMT1-48|capsules containing Probiotics
41118196|NCT03759743|DIETARY_SUPPLEMENT|Placebo|capsules that did not contain any probiotics
41118197|NCT05303753|OTHER|fermented dairy protein with prebiotic fiber|During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
41118198|NCT06038799|BEHAVIORAL|Caregiver Skills Training (CST)|The investigators are comparing the relative efficacy of CST between a CST group led by clinicians trained and supervised remotely versus a group led by clinicians trained an supervised face-to-face.
41118199|NCT04974450|DIETARY_SUPPLEMENT|Trigona honey|composition : vitamin C 0.15%, Protein 1.32%, lipid 0.23%, carbohydrate 64.12%, beta carotene 10.61 ppm, Calcium 273,23, magnesium 338.94, zinc 12.49 ppm, and acidity 5.76. Total polyphenol 133.52 ppm, total flavonoid 159.62 ppm. This liquid has a sour profile
41118200|NCT04974450|DIETARY_SUPPLEMENT|control|Artificial honey with fructose, Glucose, pure honey (2,271%), citric acid, and lime extract (0,076%).
41118201|NCT02479906|DEVICE|Deep TMS System|Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
41118202|NCT02479906|DEVICE|Sham Treatment|Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
41118203|NCT01950780|DRUG|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
41118204|NCT05060614|PROCEDURE|Hip fracture surgery|Hip fracture surgery
40926235|NCT00957125|DRUG|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
41118205|NCT04739527|BIOLOGICAL|DCP-001|allogeneic dendritic cell vaccine
41118206|NCT02059044|OTHER|ISTOP-ADE|Interactive Voice Response System + Pharmacist
41118207|NCT00757133|PROCEDURE|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
41118208|NCT00757133|PROCEDURE|Laparotomy closure with mesh augmentation|"Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias"
41118209|NCT06196788|DRUG|Gemcitabine|1000 mg per square meter
41118210|NCT06196788|DRUG|Nab paclitaxel|120 mg per square meter of body-surface area
41118211|NCT04652583|DEVICE|Earstim - Active Stimulation|Intramuscular stimulation
41118212|NCT04652583|DEVICE|Earstim - Sham Stimulation|Sham stimulation
41118213|NCT00224445|DRUG|Truvada|Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
41118214|NCT00224445|DRUG|Atazanavir|Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
41118215|NCT00224445|DRUG|Ritonavir|Ritonavir 100 mg capsule administered orally QD
41118216|NCT02940951|OTHER|QPSS|Home care providers use the QPSS that includes standardized instruments for assessing patient and family caregiver quality of life in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.
41118217|NCT02940951|OTHER|Usual care|Home healthcare services provided by nurses and, where applicable, multi-professional teams.
41118218|NCT03074331|DRUG|SOF/VEL|400/100 mg FDC tablet(s) administered orally once daily
41118219|NCT05862610|DRUG|Trilaciclib plus chemotherapy|Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
41118220|NCT05862610|DRUG|Chemotherapy|epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
41118221|NCT04223297|PROCEDURE|lung ultrasound|"The lung ultrasound will be performed by following the  Blue protocol "
41118222|NCT03921580|OTHER|Control Canned Tuna|210 g/day
41118223|NCT03921580|OTHER|Enriched Canned Tuna Variety 1|210 g/day
41118224|NCT03921580|OTHER|Enriched Canned Tuna Variety 2|210 g/day
41118225|NCT04261465|DRUG|Olaparib|PARP INHIBITOR
41118226|NCT04261465|DRUG|Paclitaxel|Chemotherapy
41118227|NCT04261465|DRUG|Carboplatin|Chemotherapy
41118228|NCT00646035|DRUG|paricalcitol capsules|baseline iPTH/60
41118229|NCT02161783|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
41118230|NCT02161783|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
41118231|NCT02161783|RADIATION|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
41118232|NCT02161783|BIOLOGICAL|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
41118233|NCT00620997|DRUG|Proparacaine drops 0.05%|topical, 0.05% drops, PRN continuously for up to 7 days
40926236|NCT00957125|DRUG|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
40926237|NCT00957125|DRUG|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
40926238|NCT05587465|DEVICE|Lobster Device|The intervention is performed percutaneously using the dedicated instrument set.
40926239|NCT03952390|OTHER|control|
40926240|NCT03952390|OTHER|sepsis|
41118234|NCT00620997|DRUG|saline drops|saline drops continuously PRN for up to 7 days
41118235|NCT05511766|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
41118236|NCT05511766|DRUG|Atorvastatin 20mg|is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties
41118237|NCT05511766|DRUG|Placebo|not containing drugs
41118238|NCT02009813|PROCEDURE|Hyperbaric Oxygen Therapy|Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
41118239|NCT00946582|BEHAVIORAL|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
41118240|NCT01726842|DEVICE|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
41118241|NCT02083575|DRUG|Vitamin C, Defriprone, deferisarox|adjuvant vitamin c with iron chelator.
41118242|NCT02083575|DRUG|deferiprone , deferesarox|iron chelator
41118243|NCT05579899|DRUG|EVO101|Topical Cream
41118244|NCT05178225|DIETARY_SUPPLEMENT|ubiquinol (reduced coenzyme Q10)|supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg. one morning after breakfast, and second dose after dinner.
41118245|NCT05178225|OTHER|mountain spa rehabilitation|special spa rehabilitation in the mountain High Tatras; Functional capacity of the lungs (6MWT) at before and after 16-18 days of rehabilitation, Borg scale for dyspnea and oxygen saturation SpO2 (%) were monitored.
41118246|NCT05178225|DIAGNOSTIC_TEST|2x14 ml of peripheral blood collected in a tube with anticoagulant|2x14 ml of peripheral blood collected in a tube with anticoagulant
41118247|NCT00418496|DRUG|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
41118248|NCT00418496|DRUG|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
41118249|NCT05079646|OTHER|class 1 and class 2 cavity preparation and restored with contemporary materials|class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
41118250|NCT01873313|DRUG|Ropivacaine|
41118251|NCT02781766|OTHER|Thrombin generation measurement.|
41118252|NCT03462823|DEVICE|Osteoconductive scaffold-hamstring tendon composite repair|The device under study is a composite bone substitute composed of a natural mineral matrix of bovine origin, reinforced with biodegradable synthetic polymers and natural collagen derivatives of bovine origin (smartbone, IBI S.A., Switzerland).
41118253|NCT03462823|DEVICE|Hamstring tendon-only repair|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
41118254|NCT04006717|DEVICE|Low Level Laser therapy|Diode laser (EPIC™ BIOLASE) with wavelength 940nm
41118255|NCT04006717|PROCEDURE|Intra canal Cryotherapy|Irrigation with cold saline 2-4 C
41118256|NCT01860820|DEVICE|Geko device|
41118257|NCT02191319|DRUG|Viramune®|
41118258|NCT03900442|DRUG|PTX-100|Doses of 500 to 2000 mg/m2 will be administered.
41118259|NCT04970342|DRUG|Placebo (Lactose) Capsule|Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose
41118260|NCT04970342|DRUG|0.75 mg Alprazolam Capsule|Single dose on one of the three study visits, orally administered 40 minutes prior to cannabis dose
41118261|NCT04970342|DRUG|Cannabis (6.18% THC / <0.025% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (6.18% THC / \<0.025% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose on one of the three study visits.
41118262|NCT04970342|DRUG|Cannabis (0%/ THC / 0% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (0% THC / 0% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose at two of the three study visits.
41118263|NCT01875848|DRUG|buprenorphine/naloxone|partial opioid agonist
41118264|NCT01875848|DRUG|opioid dose escalation|up to 25% increase in patient's current opioid dose
41118265|NCT02486835|DEVICE|Cough syrup for adults and children|Dosage is 5 ml three times a day for 4 nights, 3 days
41118266|NCT02486835|DEVICE|Placebo|Dosage is 5 ml three times a day for 4 nights, 3 days
41118267|NCT05868772|DEVICE|Active Sentry Handpiece|With low IOP settings
41118268|NCT05868772|DEVICE|Ozil Handpiece|With high IOP settings.
41118269|NCT00807937|DRUG|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
41118270|NCT00807937|DRUG|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
41118271|NCT00807937|DRUG|Lorazepam|4 tablets and 1 capsule taken twice a day for 28 days
41118272|NCT00807937|DRUG|Placebo|4 tablets and 1 capsule taken twice a day for 28 days
41118273|NCT04531917|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) teaches patients about complex pain mechanisms known to be of importance in pain following breast cancer such as malfunctioning of the endogenous analgesic system and pain memories.
41118274|NCT04531917|OTHER|Behavioural Graded Activity|"Patients in the experimental group will receive a behavioural treatment integrated within the concepts of operant conditioning. The purpose of Behavioural Graded Activity (BGA) is to increase the level of physical activity in the patient's daily lives in a time-contingent manner. On top of that, a healthy behaviour will be positively reinforced to consequently create a withdrawal of the attention towards pain behaviour, which is seen as an unreliable alarm sign in chronic pain patients. The implementation of BGA after PNE is described in the guideline reported by the International Association for the Study of Pain."
41446315|NCT04061746|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Patients in Group A will receive a single MSCs infusion
41446316|NCT04061746|OTHER|Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)|Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)
41118275|NCT04531917|OTHER|Usual care|The content of the leaflet has a biomedical approach in explaining pain and providing information on the different pain medication classes. This leaflet is mostly available in waiting rooms of oncology centres and units of the Flemish part of Belgium.
41118276|NCT02012569|DRUG|TT-173|Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
41118277|NCT02012569|DRUG|Placebo|
41118278|NCT04743310|DRUG|tozuleristide|tozuleristide 24 or 36 mg administered intravenously 1-24 hours prior to surgery
41118279|NCT04743310|DEVICE|Canvas imaging system|imaging device attached to surgical microscope
41118280|NCT04743310|PROCEDURE|Surgical resection of tumor|Standard of care surgical resection of tumor
41118281|NCT02214160|DRUG|UX007|Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
41118282|NCT03067116|DIAGNOSTIC_TEST|Posturography Evaluation|Posturography testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, with eyes open or closed
41118283|NCT03067116|DIAGNOSTIC_TEST|Anthropometrics|measurement of height, minimum stance width (feet together or as close as they can be), circumference of the torso at the breast level, of the abdomen, of the hip, and of each thigh, and supine fundal height
41118284|NCT03067116|DIAGNOSTIC_TEST|Vitals|measurement (bilateral and seated/standing if applicable) of temperature, respiration rate, heart rate, blood pressure, pulse oxygenation and heart rate variability
41118285|NCT03067116|OTHER|Health and daily activity questionnaires|one time general health questionnaire as well as session questionnaires asking the subjects if they have fallen since their last testing session and how comfortable they are in doing daily activities
41118286|NCT03858868|BEHAVIORAL|Church and park-based intervention|Multiple components involving motivational messages and concrete opportunities for physical activity at the church and the local park.
41118287|NCT03858868|BEHAVIORAL|Standard health education on physical activity|Participants will receive publicly available brochures, tip sheets, etc. about physical activity
41118288|NCT05157724|PROCEDURE|PLASMA|"The aim is to remove the prostatic adenoma by enucleation, i.e. to pass through the plane between the adenoma and the prostatic capsule, as opposed to resection, which also consists of removing the adenoma, but by making small cuts in the prostatic tissue, without necessarily reaching this anatomical plane between the adenoma and the capsule. This means removing less adenoma and therefore increasing the risk of adenomatous regrowth in the long term or obtaining worse results than enucleation in the short to medium term.~The other advantage of using this approach is that it reduces intra- and post-operative bleeding and does not require the systematic discontinuation of anti-aggregating or anticoagulant treatments prior to the operation. The field of indications is thus potentially enlarged."
41118289|NCT01189331|DEVICE|CT coronary angiography and computational fluid dynamics|Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
41118290|NCT01740531|BIOLOGICAL|S-303 Treated Red Blood Cells (RBCs)|
41118291|NCT01740531|BIOLOGICAL|Conventional, untreated Red Blood Cells|
41118292|NCT02296424|DRUG|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
41118293|NCT05463432|DRUG|HR19024|Intravenous infusion
41118294|NCT01224015|DRUG|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
41118295|NCT01224015|BIOLOGICAL|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
41118296|NCT01224015|BIOLOGICAL|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
41118297|NCT04358939|OTHER|Prone decubitus|According to the tolerance, the objective is to spend as much time as possible, up to 16 hours and beyond in prone position every 24 hours. At least two sessions of at least 30 minutes each must be performed daily.
41118298|NCT01771731|DRUG|Cannabis|
41118299|NCT06217692|OTHER|nutrition education|nutrition education
41118300|NCT01000597|DRUG|fluticasone furoate|"Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).~A single intravenous dose of 250mcg FF given over 20 minutes (Day 1)."
41118301|NCT02082548|OTHER|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
41118302|NCT04479865|DRUG|Aricept 5mg Tablet|1 tablet once daily
41118303|NCT04479865|DRUG|Aricept 10mg Tablet|1 tablet once daily
41118304|NCT04479865|DRUG|DA-5207 150mg|1 patch once weekly
41118305|NCT04479865|DRUG|DA-5207 170mg|1 patch once weekly
41118306|NCT04373590|BEHAVIORAL|Decision aid|The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.
41118307|NCT05362110|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
41118308|NCT05362110|DRUG|RLD2002|Take it once daily for 8 weeks orally.
41118309|NCT05362110|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
41118310|NCT05362110|DRUG|HPP2004|Placebo drug. Take it once daily for 8 weeks orally.
41118311|NCT00332813|BEHAVIORAL|HIV Risk Behavior Intervention|
41118312|NCT00067691|PROCEDURE|Acupuncture|
41118313|NCT02665988|DEVICE|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
41118314|NCT02665988|DEVICE|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
41118315|NCT06314763|DRUG|Rivaroxaban 20mg|Single dose on day 1 and day 16
41118316|NCT06314763|DRUG|Sotorasib 960mg|Daily dose from day 3 till day 16
41118317|NCT01098344|DRUG|Notch signaling pathway inhibitor MK0752|
41118318|NCT01098344|DRUG|gemcitabine hydrochloride|
41118319|NCT01098344|OTHER|imaging biomarker analysis|
41118320|NCT01098344|OTHER|laboratory biomarker analysis|
41118321|NCT01098344|OTHER|pharmacological study|
41118322|NCT01912131|BEHAVIORAL|single pilot interview|Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
41118323|NCT01912131|BEHAVIORAL|goals-of-care (GOC) video|Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
41118324|NCT01912131|BEHAVIORAL|goals-of-care (GOC) video and narrative question|subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry \& Behavioral Sciences,
41118325|NCT01912131|BEHAVIORAL|usual care|Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
41118326|NCT01912131|BEHAVIORAL|Part 2|Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
41118327|NCT04336059|PROCEDURE|pericapsular nerve group block|"The regional block will be performed with the patient in the supine position under complete sterile technique. A low frequency curvilinear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliacspine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminance(IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will observed.~A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly after local infiltration of the site of the block with 3 ml lidocaine 2%. Following negative aspiration,the normal saline solution will injected in 5-mL increments while observing for adequate fluid spread in this plane."
41118328|NCT05844449|DRUG|VNZ/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
41118329|NCT04559555|DRUG|Nilotinib|The compassionate use dose of nilotinib is 400 mg orally twice daily and should not be taken with food
41118330|NCT03882502|OTHER|anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation|anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
41118331|NCT06196099|DEVICE|Blood Flow Restriction|The study participants were instructed to rest quietly in a seated position for 10 minutes. During the last 3 minutes of the resting period, upper arm blood pressure was measured twice using an automatic blood pressure monitor (BP170, InBody, Korea). The blood flow restriction cuffs (BFR Therapy Cuff, BFR Therapy Co., USA) - measuring 5cm in width and 60cm in length - were applied to the upper third of the thigh on both legs. To maintain consistency in measurements, the distance from the proximal part of the kneecap to the distal edge of the cuff was measured. A Capillary Reaction Time (CRT) test was used to assess the appropriateness of the cuff pressure; this involved applying thumb pressure to the quadriceps muscle after cuff application and timing how long it took for the skin color to return to normal.
41118332|NCT06196099|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation (NMES) was applied five times a week for one week using a four-channel stimulator (Compex Physio, Chattanooga, Switzerland). The stimulation protocol was set to a frequency of 35Hz, with electrodes attached to the vastus lateralis and vastus medialis muscles. The therapist adjusted the intensity and alternating output of the electrodes selectively to facilitate the squat exercises required during the intervention. During the stimulation period, participants were engaged in a squat exercise program, with the total duration of stimulation being 10 minutes.
41118333|NCT06196099|BEHAVIORAL|Squat exercise|In this study, the squat exercise was performed in four sets. Participants were instructed to position their feet shoulder-width apart and educated to squat in such a way that their knees did not extend beyond their toes. To ensure consistency in performing the squat at the same angle, a mark was made on the wall at the pelvic height during a 90° squat. This allowed participants to perform squats at the same height. The exercise was conducted under the guidance of a physical therapist with five years of clinical experience.
41118334|NCT05075083|BIOLOGICAL|Inactivated COVID-19 vaccine|receive two doses inactivated COVID-19 vaccine with the interval of 21 days
41118335|NCT06449170|OTHER|Mango Ataulfo|In this intervention, subjects consumed 150g of mango Ataulfo plus 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage has the purpose of providing energy intake and limiting the noise that the control beverage may contribute to the metabolomic profile in urine and serum.
41118336|NCT06449170|OTHER|Avocado Hass|In this intervention, subjects consumed 120g of avocado hass plus 150 ml of a control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolomic profile in urine and serum.
41118337|NCT06449170|OTHER|Nopal|In this intervention, subjects consumed 300g of cooked nopal and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
41118338|NCT06449170|OTHER|3 corn tortilla|In this intervention, subjects consumed 3 corn tortillas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
41118339|NCT06449170|OTHER|Guava|In this intervention, subjects consumed 3 guavas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
41118340|NCT06449170|OTHER|Amaranth|In this intervention, subjects consumed 1/2 cup of amaranth and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
41118341|NCT06449170|DIETARY_SUPPLEMENT|Control Beverage (Supportan Drink ® Capuccino)|In this intervention, subjects consumed 290ml of Supportan Drink ® Capuccino to act as a control for the metabolomic profiling in urine and serum.
41118342|NCT04600440|BIOLOGICAL|Convalescent plasma|Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
41118343|NCT04049435|DEVICE|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
41118344|NCT01279798|BIOLOGICAL|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
41118345|NCT02308319|DRUG|Tenofovir disoproxil fumarate|300mg q.d. per oral
41118346|NCT02313363|DEVICE|patient-centered smartphone-based diabetes care system|patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
41118347|NCT03425734|DRUG|Dexmedetomidine|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
41118348|NCT03658460|OTHER|DNA sequencing|Targeted next generation sequencing and gene expression analysis with focus on immuno-oncology signatures
41118349|NCT01620034|RADIATION|Stereotactic Body Radiotherapy|Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
41118350|NCT00617331|BIOLOGICAL|Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine|Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
41118351|NCT04380467|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|(aviticol) 5x 20,000unit capsules administered monthly over 20 weeks
41118352|NCT03438032|DIAGNOSTIC_TEST|Bronchoscopy with lavage|During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.
41118353|NCT02301559|BEHAVIORAL|Pilates exercises|Pilates exercises with emphasis on pelvic region
41118354|NCT03419572|OTHER|Data collection|Only available evaluations as decided by the investigator based on local clinical practice will be collected.
41118355|NCT03114267|OTHER|Comparison of the prevalences of the parvovirus genome|Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature
41118356|NCT00002270|DRUG|Interferon alfa-2b|
41118357|NCT00002270|DRUG|Zidovudine|
41446317|NCT06093984|PROCEDURE|duostim vs. two antagonist ovarian stimulations|Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group. In the duostim group, all of the embryos are frozen. Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.
41118358|NCT03973892|DIAGNOSTIC_TEST|Cere|Magnetic Rseonance imaging for brain tumour follow-up
41118359|NCT04527822|OTHER|Nurse led discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
41118360|NCT03922061|BIOLOGICAL|dmLT|double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)
41118361|NCT03922061|BIOLOGICAL|fIPV|fractional-dose inactived polio vaccine
41118362|NCT00191412|DRUG|Pemetrexed|
41118363|NCT02961010|BEHAVIORAL|Keeping Safe|A whole school Preventative Education programme
41118364|NCT05074836|DIETARY_SUPPLEMENT|Formula milk|"Brand name: Yili (QQ star formula milk);~Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;~Dosage: 195ml\*2/d;~Intervention duration: 12 months"
41118365|NCT05074836|DIETARY_SUPPLEMENT|Regular milk|"Brand name: Yili；~Type: regular milk (pure milk);~Dosage: 195ml\*2/d;~Intervention duration: 12 months"
41118366|NCT05074836|OTHER|Control foods|"Brand: N/A;~Food type: grain foods (e.g., bread);~Dosage: 20-40g \* 2/d grain foods~Intervention duration: 12 months"
41118367|NCT02150967|DRUG|BGJ398 (infigratinib)|Capsule for oral use
41118368|NCT00519389|BIOLOGICAL|H5N1 VLP Vaccine|Two doses - Day 0 \& Day 28
41118369|NCT00519389|BIOLOGICAL|Placebo|Two doses - Day 0 \& Day 28
41118370|NCT04094532|DRUG|Bupivacaine|Ultrasound guided 20 ml % 0.250 bupivacaine injection to transverse thoracic muscle plane bilaterally
41118371|NCT04094532|DRUG|Saline|Ultrasound guided 20 ml % 0.9 saline injection to transverse thoracic muscle plane bilaterally
41118372|NCT05520294|OTHER|High-performance liquid chromatography-tandem mass spectrometry assays|Paraffin blocks will be requested for slide creation, and at least 12 mL of whole blood will be collected in 2 green top tubes, centrifuged, and plasma transferred for storage at -80 C until further processing
41118373|NCT01827345|DIETARY_SUPPLEMENT|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
41446318|NCT05860777|OTHER|Complexity score and implementation|AI machine learning model to identify patients with complex care needs and implementation with active reaching out to clinicians to offer interpreter services
41118374|NCT03339115|DEVICE|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
41118375|NCT01600729|DRUG|No Intervention|No intervention.
41118376|NCT04996680|DEVICE|Blood Flow Restriction (by using smart-cuff pro devices, acting as pressurized tourniquet) combined low load strengh training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with optimal pressurized blood flow restriction
41118377|NCT04996680|OTHER|Standardised low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises
41118378|NCT04996680|DEVICE|Sham-BFR (by using smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with blood flow restriction, but pressurized so the occlusion cuff has no significant effect on the lower limb blood flow.
41118379|NCT03221777|DIAGNOSTIC_TEST|14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)|The ZIO XT Patch (http://www.irhythmtech.com/zio-solution/zio-patch/) is an ultra-portable wearable adhesive patch monitor that provides continuous single-lead ECG recording for up to 14 days. It has been cleared by the FDA for arrhythmia detection and is in current clinical use in the U.S.\[87\]. It will be used in this study under an investigational testing authorization by Health Canada. The ZIO XT Patch is a single-use device worn over the left pectoral region with a skin adhesive (Figure 4). Its small, lightweight, water-resistant, patch-based design has advantages for patients compared with traditional ECG screening methods (e.g. Holter, event loop recorders, mobile outpatient telemetry systems), which are all more cumbersome and require detachable wired leads, two or more removable skin contact electrodes, plus separate recording units (+/- smartphone attachment).
41118380|NCT02788604|OTHER|Summary of psychosocial risk factors|The treatment team will receive a psychosocial risk summary shortly following diagnosis based on parent report.
40752980|NCT06314035|OTHER|COPD Patient Decision Aid|Participants in this group will receive two 60-minute intervention sessions in one month. The COPD PDA consists of three main parts: The first component, clinical counselling, guides the participants in reviewing the common EOL scenarios. The second component, an evidence-based decision aid, is presented as an option grid in a booklet and a video to provide information about outcome probabilities of various treatment options and survival estimates in a balanced and unbiased manner. The information is presented in plain language for laypersons. The third component, decision coaching, introduces the concept of ACP and guides deliberation through value clarification.
40926241|NCT04415970|OTHER|Flotation therapy sensory deprivation tank|Participants will float for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with sleep pod every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short safety questionnaire and an anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
40926242|NCT04415970|OTHER|Sleep Pod|Participants will utilize the sleep pod for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with float every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
41118381|NCT02788604|OTHER|Control|The treatment team will NOT receive a psychosocial risk summary shortly following diagnosis based on parent report.
41118382|NCT03757572|OTHER|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Alginate dressings with silver and high-G cellulose will be applied to the wound. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials, will be also placed.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
41118383|NCT03757572|OTHER|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Simple gauze dressings will be applied to the wound.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
41446319|NCT02167659|DEVICE|23-32 mmHg compression sleeve with gauntlet|A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and \<10% above pre-surgical baseline.
41118384|NCT03704727|DIETARY_SUPPLEMENT|Probiotic|Probiotics (beneficial microorganisms) VSL#3 is a probiotic formula containing a mixture of 9x10\^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10\^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10\^10 CFU/g Streptococcus thermophilus
41118385|NCT06459063|DRUG|Allocetra - Safety run-in phase|Intra-articular injection of Allocetra performed once on Day 1 of the study at different doses.
41118386|NCT06459063|OTHER|Placebo|Intra-articular injection of placebo solution containing all excipients except for the Allocetra cells.
41118387|NCT06459063|DRUG|Allocetra - Randomization phase|Intra-articular injection of selected dose of Allocetra based on the safety run-in, performed on Day 1 of the study.
41118388|NCT05378828|DEVICE|Using anti-collision Sensors on electric wheelchairs|use of anti-collision sensors on the electric wheelchair during 3 weeks
41118389|NCT05378828|OTHER|Use of an electric wheelchair without sensors|Use of an electric wheelchair without sensors for 3 weeks before using anti-collision sensors then during 3 weeks after using the anti-collision sensors.
41118390|NCT00682708|DIETARY_SUPPLEMENT|PlumpyNut|
41118391|NCT00682708|DIETARY_SUPPLEMENT|PlumpyDoz|
41118392|NCT03899324|DRUG|Bumetanide white, oblong, scored tablet|Bumetanide with a titration period
41118393|NCT03899324|DRUG|Placebo white, oblong, scored tablet|placebo intake identically to group 1
41118394|NCT03238391|PROCEDURE|Ischemic preconditioning|It is mentioned before in arm/group descriptions
41118395|NCT02863900|OTHER|cohort of BC of each subtypes|
41118396|NCT00309907|BIOLOGICAL|etanercept|Given IV and subcutaneously
41118397|NCT00309907|DRUG|methylprednisolone|Given IV and orally
41118398|NCT04212195|GENETIC|Next generation sequencing|Saliva samples
40926243|NCT04095585|GENETIC|chromosomal microarray analysis (CMA) and whole exome sequencing (WES)|"The investigator evaluated the following hypotheses:~i) atypically large 7q11.23 deletions including additional genes; ii) rare pathogenic variants in genes located within the deletion, in particular GTF2I iii) additional pathogenic copy number variants (CNVs) or rare intragenic pathogenic variants located in other chromosomal regions with various inheritance patterns (autosomal recessive, X-linked, de novo autosomal dominant); given the small number of patients recruited, we focused on rare exonic variants considered to be pathogenic according to the criteria of the American College of Medical Genetics and Genomics (ACMG)"
40926244|NCT04868630|DEVICE|Pulsewave Health Monitor (PAD-2A) Device|This is an observational study of the average breathing rate measurement of a non-invasive wrist cuff device. The purpose of this study is to calibrate the average breathing rate measurement of the Pulsewave Health Monitor (PAD-2A) wrist cuff device with the breathing rate measurement of a standard clinical capnography device. Additionally, we will also compare the average breathing rate measurement of the capnography device with other standard clinical respiratory devices (i.e. nasal pressure transducer, thermistor, and respiratory inductance plethysmography (RIP) belts of the chest and abdomen).
40926245|NCT06388044|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is a third-wave cognitive behavioral therapy. ACT aims to increase psychological flexibility through six core processes: acceptance, cognitive defusion, present-moment awareness, self as context, values, and committed action.
41118399|NCT04212195|DIAGNOSTIC_TEST|Imaging and fluid biomarkers|Magnetic resonance imaging of the brain and urine, blood and cerebrospinal fluid sampling
41118400|NCT06031012|DRUG|glutamine combined with thalidomide|Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.
41118401|NCT06031012|DRUG|glutamine alone|Patients received glutamine alone from the beginning of radiotherapy to one week after radiotherapy.
41118402|NCT01177696|BEHAVIORAL|Psychotherapeutic intervention|A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
41118403|NCT01102231|DRUG|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
41118404|NCT01102231|DRUG|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
41118405|NCT01102231|RADIATION|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
41118406|NCT04806529|DRUG|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
41118407|NCT04806529|DRUG|Comparator|Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
41118408|NCT02675088|RADIATION|high-dose TRT|every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f
41118409|NCT02675088|RADIATION|standard-dose TRT|every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
41118410|NCT05876143|DEVICE|Unicompartmental knee arthroplasty|"Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state."
41118411|NCT02217904|DRUG|1 mg islatravir|Single oral dose of 1 mg islatravir administered following ≥8 hour fast
41118412|NCT02217904|DRUG|2 mg islatravir|Single oral dose of 2 mg islatravir administered following ≥8 hour fast
41118413|NCT02217904|DRUG|10 mg islatravir|Single oral dose of 10 mg islatravir administered following ≥8 hour fast
41118414|NCT02217904|DRUG|30 mg islatravir|Single oral dose of 30 mg islatravir administered following ≥8 hour fast
41118415|NCT02217904|DRUG|0.5 mg islatravir|Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast
41446320|NCT04877522|DRUG|Asciminib single agent|Taken orally, twice daily (BID) or once daily (QD), in fasting state
41446321|NCT04877522|DRUG|Imatinib|Taken orally, once daily, in the morning with low-fat meal
41446322|NCT04877522|DRUG|Nilotinib|Taken orally, twice daily, on an empty stomach
41446323|NCT04877522|DRUG|Bosutinib|Taken orally, once daily, with food
41446324|NCT04877522|DRUG|Dasatinib|Taken orally, once daily in a fasted state, 1 or 2 hours before a meal
41118416|NCT02217904|DRUG|0.25 mg islatravir|Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
41118417|NCT03803605|BIOLOGICAL|VRC07-523LS|VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)
41118418|NCT03803605|DRUG|Vorinostat (VOR)|Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)
41118419|NCT00111709|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment -1 day|
41118420|NCT00111709|DRUG|Comparator: placebo / Duration of Treatment - 1 day|
41118421|NCT01475123|DRUG|Nicorandil|15mg per day
41118422|NCT00012454|DRUG|E-Selectin nasal spray|
41118423|NCT04992364|OTHER|Burnout and Clinical performances questionnaires|Subjects were given questionnaires to assess burnout score and clinical performances
41118424|NCT01281163|DRUG|Akt Inhibitor MK2206|Given PO
41446325|NCT00833300|DRUG|Haloperidol|"* 2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician."
41118425|NCT01281163|OTHER|Laboratory Biomarker Analysis|Correlative studies
41118426|NCT01281163|DRUG|Lapatinib Ditosylate|Given PO
41118427|NCT01281163|OTHER|Pharmacogenomic Study|Correlative studies
40926246|NCT02342093|DRUG|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
40926247|NCT02342093|DRUG|20EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
40926248|NCT05207189|BIOLOGICAL|UVT|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
40926249|NCT04397770|DRUG|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
40926250|NCT04397770|DRUG|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
41118428|NCT01281163|OTHER|Pharmacological Study|Correlative studies
41118429|NCT04666506|OTHER|Virtual reality|"The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog)."
41118430|NCT04625257|OTHER|Saliva based assay: crude RNA extraction|Crude RNA extraction to inactivate the virus and stabilize the RNA for transport at room temperature. Validation of the crude RNA extraction from saliva in combination with NGS diagnostics and LAMP assays and point of care test (POCT) for rapid detection of viral antigens on patients' samples.
41118431|NCT04625257|OTHER|Validation of the NGS method|Compare the results obtained with the next-generation sequencing (NGS) method to the nasopharyngeal swabs analysed in a FAMH certified lab.
41118432|NCT04625257|OTHER|Validation of the LAMP assays|The RNA will be analyzed onsite using the loop mediated amplification (LAMP) assay.
40926251|NCT04397770|DRUG|Temozolomide Injection|Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
40926252|NCT03660670|BEHAVIORAL|ONCORAL therapeutic education|Multidisciplinary program that includes informative cessions with a hospital pharmacist about the anticancer drug: information is given to the patients on adverse events and their managements, optimizing drug dosage plans. Moreover, information is shared with town partners: doctor, pharmacists, and nurses.
41118433|NCT04625257|OTHER|Validation of the POCT Antigen and Antibody tests|Rapid point of care tests (POCT) detecting viral protein antigens (Ag) and antibodies (Ab) on patients' samples. POCT are often employed in low income countries, but for COVID-19 they are not yet characterized. Their performance is to be characterized that they can be used as a safe guard if the lab diagnostics fail.
41118434|NCT03697655|DRUG|Daratumumab 20 MG/ML [Darzalex]|Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
41118435|NCT01377428|DRUG|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
41118436|NCT01377428|DRUG|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
41118437|NCT03995498|OTHER|Physical activity|Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.
41118438|NCT03995498|OTHER|FreeStyle Libre|Glucose levels will be measured by the FreeStyle Libre
41118439|NCT03995498|OTHER|SenseWear Armband|Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.
41118440|NCT01711905|DIETARY_SUPPLEMENT|Vitamin D3|daily dosage of 20 µg Vitamin D3 for 12 weeks
41118441|NCT01499992|PROCEDURE|Standard physical therapy program PLUS aquatic physical therapy|2. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
41118442|NCT01499992|OTHER|standard care|Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
41118443|NCT05515900|DIETARY_SUPPLEMENT|Sodium|Daily sodium supplementation of 2000 mg.
41118444|NCT05515900|DIETARY_SUPPLEMENT|HMB|Daily HMB supplementation of 3 g.
41118445|NCT05515900|OTHER|Placebo|Placebo pills that will be identical to sodium or HMB supplementations
41118446|NCT02190643|BEHAVIORAL|Cessation counseling with adherence focus|
41118447|NCT02190643|BEHAVIORAL|Cessation counseling without adherence focus|
40752981|NCT06314035|OTHER|General Health Coaching Intervention|The participants in the control group will receive two 60-minute health coaching sessions developed by the PI for another project as an attention placebo control. Trained research personnel will use the same amount of interaction time and similar formats to avoid threats to the study's internal validity. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes. The trained research personnel will give the guidebook consisting of general self-management advice to participants in this group.
40752982|NCT02072993|DRUG|AZD1979|Single dose, oral solution administration
40926253|NCT03660670|BEHAVIORAL|Standard of care|In the group of standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessments.
40926254|NCT06521879|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v probiotic support|Addition of Lactobacillus plantarum 299v (L. plantarum 299v) probiotic supplementation to iron replacement therapy.
40926255|NCT06478628|BEHAVIORAL|Inpatient rehabilitation|Inpatient multimodal rehabilitation in specialist health care
41118448|NCT04491032|PROCEDURE|Caudal anesthesia|Caudal epidural injection will be performed after induction of general anesthesia.
41118449|NCT02709655|DRUG|Vortioxetine 10 mg/day|"10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
41118450|NCT02709655|DRUG|Vortioxetine 20 mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
41118451|NCT02709655|DRUG|Fluoxetine 20mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"
41118452|NCT02709655|OTHER|Placebo|Encapsulated tablet, orally
41118453|NCT01708499|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
41118454|NCT04916145|DEVICE|SAT-008|SAT-008 is a digital device containing several types of activities related to the immune function of adults.
41118455|NCT00156741|DEVICE|Vitatron C50 D Model C50A2 of Vitatron C60 DR model C60A2|
41118456|NCT00156741|PROCEDURE|Required pacemaker setting|
41118457|NCT00593866|RADIATION|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
41118458|NCT00593866|DRUG|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
41118459|NCT04189744|DRUG|IPTp-sulphadoxine-pyrimethamine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-DP plus MTZ to assess whether DP is superior to SP in preventing adverse birth outcomes. This intervention arm will also be compared to the IPTp-SP plus MTZ placebo arm to assess whether the combination of MTZ with IPTp-SP is superior to IPTp-SP alone in reducing adverse pregnancy outcomes.
41118460|NCT04189744|DRUG|IPTp-dihydroartemisinin-piperaquine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-SP plus MTZ to assess whether DP is superior to SP in in reducing adverse pregnancy outcomes.
41118461|NCT04189744|DRUG|IPTp-sulphadoxine-pyrimethamine|The World Health Organization (WHO) recommends providing intermittent preventive treatment (IPTp) using sulphadoxine-pyrimethamine (SP) to pregnant women during the second and third trimesters of pregnancy to clear placental infection.
41118462|NCT05580380|OTHER|Limited Relationship|In this group, participants will share information regarding their low back pain history to a clinician who is not providing eye-contact, has farther physical distance, and is not directly facing the participant. The clinician will not provide verbal affirmations or ask clarifying questions about the patient's low back pain history. Instead, more time will be spent on completion of documentation.
41118463|NCT05580380|OTHER|Enhanced Relationship|A condition in which the clinician is providing enhanced relatedness with consistent eye contact, closer physical distance, facing the patient, and providing non-verbal affirmations (i.e. nodding, smiling), as the participant shares their low back pain history. The clinician will provide empathic verbal affirmations and will ask clarifying questions about the patient's low back pain history.
40752983|NCT02072993|DRUG|Placebo to match|Single dose, oral solution administration
41118464|NCT03565523|OTHER|Beetroot|Containing 385 mg nitrate
41118465|NCT03565523|OTHER|Placebo beverage|\<0.1 mmol nitrate in sucrose solution with beet coloring
41118466|NCT03882554|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
41118467|NCT00766298|BEHAVIORAL|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
41118468|NCT00766298|BEHAVIORAL|Weight Loss|The reduction of kcal/day through implementation of low fat diet
41118469|NCT00766298|BEHAVIORAL|Exercise and weight loss|"Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet."
41118470|NCT02720965|OTHER|Remote-controlled perineural local anesthetics delivery|Remote-controlled perineural local anesthetics delivery
40926256|NCT06478628|BEHAVIORAL|Outpatient day rehabilitation|Multimodal rehabilitation in specialist health care with program lasting whole work days
40926257|NCT04891393|DIETARY_SUPPLEMENT|Coffee|"Starbucks brand Via instant coffee. (Caffeine Content: 3 mg / kg)"
41118471|NCT04591067|OTHER|Testing of physical capacity|"This cross-sectional study will involve evaluation of physical capacity by assessment of:~1. Gait function~2. Muscle activity during walking~3. Endurance during walking~4. Hip muscle strength~5. Hip range of motion~6. Hip and muscle-tendon-related groin pain~7. Hip and groin related patient-reported outcome measures (PROMs)"
41118472|NCT02834598|DEVICE|high-density electroencephalography|Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
41118473|NCT00701896|DRUG|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
41118474|NCT00701896|DRUG|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
41118475|NCT00701896|OTHER|Biological Control|No treatment intervention only information and procedures.
41118476|NCT00701896|BEHAVIORAL|Motivational Interview|60 minute one-on-one Interview
41118477|NCT02981888|RADIATION|X-Ray|X-ray of the abdomen will be performed to assess colonic transit
41118478|NCT04562844|OTHER|sociale cognition|several social cognition test
41118479|NCT02153541|DRUG|Antipyrine-benzocaine otic solution|Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
41118480|NCT02153541|OTHER|Glycerin with Oxyquinoline Sulfate|50% of participants will receive the glycerin with oxyquinoline sulfate. These participants will be randomly selected and unaware that they are receiving the placebo and are expected to have no change in usage of rescue inhalers.
41118481|NCT02731885|DRUG|ABX464 Single dose|Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
41118482|NCT02731885|DRUG|ABX464 Repeated dose|Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
41118483|NCT05747495|OTHER|Online training in CPR-AED|"The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link \[https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/\]."
41118484|NCT03811574|DRUG|Semaglutide|Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
41118485|NCT03811574|DRUG|Placebo (semaglutide)|Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
41118486|NCT00049790|DRUG|recombinant human Angiostatin protein|
41118487|NCT00049790|DRUG|paclitaxel|
41118488|NCT00049790|DRUG|carboplatin|
41118489|NCT00016471|PROCEDURE|Audiogram|
41118490|NCT00016471|PROCEDURE|Electroretinogram|
41118491|NCT03982303|DRUG|Hemay102|Hemay102 was administered through i.v. infusion for 4hrs.
41118492|NCT06364839|OTHER||
41118493|NCT04528472|OTHER|Acupuncture Treatment|stimulate acupoints to accelerate recovery
40752984|NCT03246594|DEVICE|Placement of oesophageal probe for temperature measurement|The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
41118494|NCT04528472|OTHER|Regular Treatment|Oral Medicine and Rehabilitation Treatment
41118495|NCT05475041|PROCEDURE|Major liver resection|Major liver resection (3 or more contiguous segments)
41118496|NCT05475041|PROCEDURE|Technically major liver resection|Minor liver resection (\<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)
41118497|NCT02972944|PROCEDURE|Laparoscopic cholecystectomy|
41118498|NCT02972944|PROCEDURE|Non-operative treatment|
41118499|NCT04425668|BEHAVIORAL|Academic detailing (AD)|In addition to continuing educational (CE) videos this group will receive up to two personalized, one-on-one, education sessions from an academic detailer. The sessions will last between 15-30 minutes. Each AD visit will consist of: an introduction, a brief needs assessment, key educational messages, a discussion of challenges the provider faces, and giving the provider leave-behind educational materials. The AD visit key educational messages are specific recommendations for opioid-prescribing practice change. When appropriate the detailer will suggest a phone call with Dr. Romesh Nalliah to discuss specific dentistry questions. There may also be a second AD visit if agreed upon by the dentist.
41118500|NCT04425668|OTHER|Continuing educational|"Dentists enrolled in the CE program will serve as the control group. They will have access to the 3 hours of CE content online similar to the AD group; however, they will not receive academic detailing or the opportunity to connect via phone with Dr. Nalliah.~In this group, if the dentists have content-specific questions after participating in the CE program, they may contact MichiganOPENdental@umich.edu for responses appropriately directed to Dr. Nalliah."
41118501|NCT00734240|DRUG|ISIS 353512|50 mg via 2 hour IV infusion, single dose
41118502|NCT00734240|DRUG|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
41118503|NCT00734240|DRUG|ISIS 353512|50 mg via SC injection, single dose
41118504|NCT00734240|DRUG|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
41118505|NCT00734240|DRUG|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
41118506|NCT00734240|DRUG|ISIS 353512|100 mg via 2 hour IV infusion, single dose
41118507|NCT00734240|DRUG|ISIS 353512|200 mg via 2 hour IV infusion, single dose
41118508|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection, single dose
41118509|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection, single-dose
41118510|NCT00734240|DRUG|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
41118511|NCT00734240|DRUG|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
41118512|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
41118513|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
41118514|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
40926258|NCT04891393|DIETARY_SUPPLEMENT|Decaffeinated coffee|"Starbucks brand Via instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)"
40926259|NCT05758701|COMBINATION_PRODUCT|Iodinated Contrast Agent (Omnipaque)|Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.
41118515|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
41118516|NCT00734240|DRUG|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
41118517|NCT04728906|DEVICE|Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells|heart patch is seeded with patient's cardiomyocytes (taken from patient's heart waste tissue when undergoing bypass surgery) and stock amnion epithelial stem cells (HLA-DR negative to eliminate risk of rejection)
41118518|NCT03125863|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
41118519|NCT00394615|PROCEDURE|Metabolic Imaging|
41118520|NCT03424499|PROCEDURE|Single-use catheter|Each urethral catheterization will be done with a new sterile catheter in a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
41118521|NCT03424499|PROCEDURE|Reused catheter|Each catheter is programmed to last 1 week. Evaluation will last a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). after catheterization. Each catheter was programmed to last a week. Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
40752985|NCT03246594|DEVICE|Power limitation of RF generator|no probe utilized; Limit the RF Generator Output to 25W
40752986|NCT05948982|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion, once every 4 weeks for a total of 3 infusions. All subjects received experimental drugs and conventional treatment during the study period.
41118522|NCT03424499|DIAGNOSTIC_TEST|Urine culture|A midstream urine sample will be obtained using sterile catheterization for urine culture performed by health provider. Urine cultures will be done in days 0, 7, 14, 28, 42 and 56.
40752987|NCT04928404|PROCEDURE|tongue base suspension using barbed suture|all patients will undergo multi-level surgeries .Therefor, Anterolateral advancement pharyngeoplasty (ALA) or Barbed Reposition Pharyngoplasty (BRP) will be applied to improve retro-palatal obstruction and tongue base suspension using barbed suture for retro-lingual obstruction.
40752988|NCT03182556|BEHAVIORAL|Electromyography-Biofeedback (EMG-BFB) training|The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.
41118523|NCT05692024|DRUG|Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.|Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.
40926260|NCT05758701|DEVICE|Dual Energy CT|Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
40926261|NCT04982601|OTHER|Yoga Exercises|Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises.
41118524|NCT05692024|DRUG|Placebo|Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.
41118525|NCT00490802|DRUG|Oxytocin|Intranasal Oxytocin
41118526|NCT00490802|DRUG|Placebo|Placebo Comparator
41118527|NCT00465816|BIOLOGICAL|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
41118528|NCT00465816|BIOLOGICAL|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
41118529|NCT01867216|DRUG|Placebo|Administered orally as capsules
41118530|NCT01867216|DRUG|LY2922470|Administered orally as capsules
41446326|NCT00833300|DRUG|Olanzapine|"* 2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician."
41446327|NCT06555458|DRUG|Dexmedetomidine|Patient group to be given dexmedetomidine
41446328|NCT06555458|DRUG|Saline|Patient group to be given salin
40752989|NCT03182556|BEHAVIORAL|Aquatic exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
41118531|NCT04460313|OTHER|nasopharyngeal sample|Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.
41118532|NCT04460313|OTHER|Stools collection or anorectal swab samples|For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
41118533|NCT01721434|DRUG|Levosimendan|
41118534|NCT01721434|DRUG|Placebo|Similar coloured placebo
41446329|NCT06560879|BIOLOGICAL|Lactobacillus casei|Lacticaseibacillus casei is a species of Gram-positive anaerobic bacteria found in the intestine and mouth of humans. This lactic acid-producing bacterium is used in the dairy industry in the production of probiotic foods.
41118535|NCT04026594|OTHER|Mindfulness Based Stress Reduction|"MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
41118536|NCT04026594|OTHER|Relaxation group|control group
41118537|NCT02525796|DRUG|eplerenone|eplerenone, titrated up to a maximum of 50mg BID
41118538|NCT02525796|DRUG|amiloride|amiloride, titrated up to a maximum of 10mg BID
41118539|NCT02525796|DRUG|Placebo|
41118540|NCT02525796|DRUG|Cinacalcet|Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
41118541|NCT01069471|BIOLOGICAL|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
41118542|NCT05033938|PROCEDURE|Early Mobilization Protocol|Subjects will be placed in a bulky soft dressing immediately after surgery. They will be made non-weight bearing, but active and passive motion of digits, forearm, elbow, and shoulder will be allowed with light functional tasks permitted as tolerated. Wrist motion within the soft dressing will be permitted as tolerated by patient. On postoperative day 3, patients will be advised to remove the dressing at home and begin home hand/wrist therapy. They will use a removable Velcro wrist splint for nighttime wear and strenuous activity. This splint can be removed during normal activities of daily living and therapy.
41118543|NCT05033938|PROCEDURE|Late Mobilization Protocol|Subjects will be placed in a plaster volar resting splint. They will be made non-weight bearing, with use of digits for light functional tasks permitted. They will be given home exercises for their fingers but will not yet resume wrist motion
41118544|NCT00293358|DRUG|carboplatin|
41118545|NCT00293358|DRUG|cisplatin|
41118546|NCT00293358|DRUG|etoposide phosphate|
41118547|NCT00293358|DRUG|ifosfamide|
41118548|NCT00293358|PROCEDURE|adjuvant therapy|
41118549|NCT00293358|PROCEDURE|conventional surgery|
41118550|NCT00293358|PROCEDURE|neoadjuvant therapy|
41446330|NCT06560879|BIOLOGICAL|Lactobacillus rhamnosus|A live form of a bacterium that makes lactic acid (a substance derived from milk sugars and also made by the body). Lactobacillus rhamnosus GG is given to help with digestion and normal bowel function. In addition, it may help maintain a healthy gastrointestinal tract. It is being studied for the prevention of infections in patients who received donor stem cell transplants and for other conditions.
41446331|NCT06560879|BIOLOGICAL|Bifidobacterium bifidum|B. bifidum is an essential bacteria found in the human intestine. When it is low or absent all together in the human intestine, it is an indication of being in an unhealthy state. Intestinal flora can be improved if someone takes oral B. bifidum. Also, oral B. bifidum is used for other things such as therapy for enteric and hepatic disorders, for activating the immune response, and for preventing some cancers
41118551|NCT00293358|RADIATION|radiation therapy|
41118552|NCT01124734|DRUG|Interleukin-2|Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg
41118553|NCT01124734|DRUG|Temozolomide|Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
41118554|NCT05875883|PROCEDURE|Neck ultrasound|The investigators will scan patients' necks with an ultrasound and look for anatomical landmarks to identify the phrenic nerve
41118555|NCT01048931|PROCEDURE|single-port LAVH|single-port LAVH
41118556|NCT02539225|DRUG|Ramucirumab|Administered IV
41118557|NCT02539225|DRUG|Placebo|Administered IV
41118558|NCT02539225|DRUG|S-1|Administered PO
41118559|NCT02539225|DRUG|Oxaliplatin|Administered IV
41118560|NCT02539225|DRUG|Paclitaxel|Administered IV
41118561|NCT06081530|DRUG|BI 3802876|BI 3802876
41118562|NCT06081530|DRUG|Placebo matching BI 3802876|Placebo matching BI 3802876
41118563|NCT02165761|DEVICE|GORE® Hybrid Vascular Graft|
41118564|NCT02165761|DEVICE|Non-heparin bonded synthetic graft|
41118565|NCT03010813|PROCEDURE|Robotic single port surgery and NOTES|Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
41118566|NCT00552201|DRUG|Tacrolimus|Administration Twice a day after adjustment to blood level
41118567|NCT03983681|BEHAVIORAL|Strategy-Based Training to Enhance Memory (STEM)|Protocol designed to improve memory functioning in individuals with neurological injuries administered for 4 weeks (8 training sessions).
41118568|NCT03983681|BEHAVIORAL|Placebo control exercises|Placebo control memory exercises will be administered for 4 weeks (8 training sessions).
40752990|NCT06502080|RADIATION|Consolidative radiotherapy|Consolidative radiotherapy: total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
41118569|NCT03425552|DRUG|Paliperidone|Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)
41118570|NCT03425552|DRUG|Paliperidone|Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension
41118571|NCT02058875|DRUG|Myfortic®|
41118572|NCT02058875|DRUG|Neoral®|
41118573|NCT02058875|DRUG|Cellcept®|
41118574|NCT02058875|DRUG|Prednisone|
41446332|NCT06560879|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production.The most common form is used in vitamin supplements or tablets
41118575|NCT02541565|DRUG|Cyclophosphamide|Given IV
41118576|NCT02541565|DRUG|Doxorubicin Hydrochloride|Given IV
41446333|NCT06300216|DRUG|Octreotide microspheres|20mg/30mg Q4W
41118577|NCT02541565|OTHER|Laboratory Biomarker Analysis|Correlative studies
41118578|NCT02541565|BIOLOGICAL|Pembrolizumab|Given IV
41118579|NCT02541565|DRUG|Prednisone|Given PO
41118580|NCT02541565|BIOLOGICAL|Rituximab|Given IV
41118581|NCT02541565|DRUG|Vincristine Sulfate|Given IV
41118582|NCT01116596|DRUG|Paracetamol|determine, in subjects aged over 70 years, the blood concentration of glutathione (GSH) and urinary loss of cysteine in the detoxification of paracetamol, when taking paracetamol treatment repeated.
41118583|NCT04018924|DEVICE|Illumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)|Debridement and Dressing or compressive dressing if needed
41118584|NCT03690596|OTHER|NRT + QuitBuddy|QuitBuddy treatment app and 1 month supply of 4 mg nicotine lozenge
41446334|NCT05199064|OTHER|Ultrasound guided greater occipital nerve (GON) radiofrequency|After identifying the GON with ultrasound guidance, a catheter needle (22-gauge 5 cm 5 mm active tip hybrid electrode) is inserted with an in-plane technique from lateral to medial.After visualizing the electrode tip placed close to the right or left GON, a sensory stimulation test is performed using an RF generator (URF-3AP Diros Tecnology Inc.). After the patient reports dysesthesia and a tingling sensation at the occipital area with less than 0.2 V, the PRF treatment is administered at 5 Hz and 5 milliseconds pulsed width for 360 seconds at 45 V under the constraint that the temperature of the electrode tips does not exceed 42°C
41446335|NCT06555640|DRUG|DR10624 Injection|Drug: DR10624 injection
41446336|NCT06555640|DRUG|Placebo|Drug: placebo
41446337|NCT06558968|OTHER|aesthetic functional space maintainers|evaluate the use of Polyetheretherketone 'PEEK' and monolithic zirconia 'Bruxzir' as esthetic functional band and loop space maintainers.
41118585|NCT03690596|OTHER|NRT + QuitBuddy-Recall|QuitBuddy-Recall treatment app and 1 month supply of 4 mg nicotine lozenge
40752991|NCT06502080|DRUG|Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab|Standard-of-care systemic therapy as decided by the treating medical oncologist: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
41118586|NCT03690596|OTHER|Treatment as Usual|1 month supply of 4 mg nicotine lozenge
41118587|NCT03608475|OTHER|Limited Ultrasound Imaging|Ultrasound imaging will not be performed at the 2, 5 and 8 week clinic visits
41118588|NCT03608475|OTHER|Standard Ultrasound Imaging|Ultrasound imaging will be performed at all clinic visits
41446338|NCT02507063|PROCEDURE|ultrasound|Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
41446339|NCT05235854|DRUG|Injection of corticosteroids (Diprostène®)|Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.
41446340|NCT00241982|DRUG|long-circulating liposomal prednisolone|
41118589|NCT02014129|DRUG|LY2835219|Administered orally
41118590|NCT02647268|DRUG|Oxytocin|Oxytocin, 10-5M solution
41118591|NCT02647268|DRUG|Magnesium Sulphate|Magnesium sulphate, 3.5mM solution
41118592|NCT06014216|OTHER|Flavoured ice lollies (popsicles)|Blackcurrant flavoured ice popsicles, 105ml volume.
41118593|NCT06014216|OTHER|Water|Water from tap, one cup given by recovery nurses.
41118594|NCT02297061|BIOLOGICAL|Thrombelastography analysis (TEG)|TEG analysis is performed on admission
41118595|NCT04564196|PROCEDURE|Breath Sample|breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
40752992|NCT04140903|DRUG|Early transition to oral antibiotics|Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
41118596|NCT02986412|OTHER|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
41118597|NCT06143371|BIOLOGICAL|CAN10|Single dose intravenous or Multiple doses subcutaneously
41118598|NCT06143371|BIOLOGICAL|CAN10 - Placebo|Single dose intravenous or Multiple doses subcutaneously
41118599|NCT05724420|BEHAVIORAL|STRIVE course delivery|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session..
41118600|NCT02120222|DRUG|selinexor|Given PO
41118601|NCT02120222|OTHER|Correlative studies|Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
41118602|NCT00708188|DEVICE|Multidetector raw CT|Multidetector raw CT
41118603|NCT05368831|DRUG|NST-1024|Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
41118604|NCT04856982|DRUG|Tofersen|Administered as specified in the treatment arm
41118605|NCT04856982|DRUG|Placebo|Administered as specified in the treatment arm
41118606|NCT02490254|OTHER|Surveillance card|
41118607|NCT04329793|DEVICE|Assisted gait training with Walkbot System|The experimental group will receive at least 3 treatment sessions per week consisting of 40 minutes in robot-assisted gait training with Walkbot System in addition to their usual Physical therapy sessions. In total, the number of Walkbot sessions will be 20, in uninterrupted weeks.
41118608|NCT04329793|OTHER|Physical Therapy|The control group will receive their usual Physical therapy sessions during 6 weeks.
41118609|NCT02178423|PROCEDURE|Ultrasound for diagnosis of CVC position in children|Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
41118610|NCT06512545|OTHER|second allogeneic stem cell transplantation|"1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 )/cyclophosphamide (1g/m2/day, days -5 to -4)/rabbit antithymocyte globulin (1.5mg/kg/day, days -4 to -2)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg, +1d, +8d, +15d)"
41118611|NCT04808778|DRUG|Hydroxyurea therapy per standard care|Moderate-dose of 20mg/kg/day
41118612|NCT02234778|DEVICE|TGI SVF material via intramuscular injection|Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
41118613|NCT01039948|BIOLOGICAL|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
41118614|NCT01039948|DRUG|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
41118615|NCT03446859|OTHER|TENS|"First, there was explanation of the overall test procedure. The subject was placed in supine lying in a comfortable position.A pair of electrodes (inactive electrodes) was placed a little below the umbilicus (Right and Left) and the other pair (active electrode) along the inguinal region at the level of pubic symphysis (Right and Left) according to (Akinbo et al 2000).~The TENS equipment was switched on and the intensity was set at a level tolerable by each participant's. The treatment period lasted for 30 minutes for each treatment sessions and the procedure was carried out once a day on the 1st, 3rd and 5th days (Akinbo et.al 2000). Pain intensity was measured pre treatment and post treatment each day of treatment using the visual analogue scale (VAS)."
41118616|NCT03104387|OTHER|Electric train|Exposure to air with low level of ultrafine particles (Electric train)
41118617|NCT03104387|OTHER|Diesel train|Exposure to air with high level of ultrafine particles (Diesel train)
41118618|NCT06435637|DIETARY_SUPPLEMENT|Collagen protein|Ingestion of 40, 20, 20 and 20 gram of collagen protein right after and every 2 hours after a bout of exercise
41118619|NCT06435637|BEHAVIORAL|Resistance exercise|A single resistance exercise session of the leg press and leg extension exercise
41118620|NCT03014947|DRUG|MSB11022|Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
41118621|NCT03014947|DRUG|US-licensed Humira|Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
41118622|NCT03014947|DRUG|EU-approved Humira|Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
41118623|NCT02621086|DIETARY_SUPPLEMENT|Cellodextrin|Gastrointestinal tolerability of single ascending doses of Cellodextrins
41118624|NCT01574794|OTHER|Muscle strengthening exercises|The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
41118625|NCT01574794|OTHER|Muscle stretching exercise|The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
40752993|NCT04140903|DRUG|Standard treatment of intravenous antibiotics|Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
40752994|NCT03385642|DEVICE|ChondroMimetic|ChondroMimetic is a single-use, biphasic implant that serves as an osteochondral scaffold for the repair of cartilage defects in the knee
41118626|NCT06168149|DIAGNOSTIC_TEST|fetal lung elastography measurement|"Elastography measurements are planned to be performed as in the studies Feasibility of two-dimensional ultrasound shear wave elastography of human fetal lungs and liver: A pilot study and Feasibility of 2-D ultrasound shear wave elastography of fetal lungs in case of threatened preterm labour: a study protocol in the literature examples section of the file."
41118627|NCT03611972|DIETARY_SUPPLEMENT|Sugar-sweetened beverage|Sugar-sweetened koolaid-flavored water.
40752995|NCT06355921|PROCEDURE|radiofrequency ablation|"Anesthesia: Local (Novocaine, Lidocaine, Bupivacaine) Access: transcutaneous Navigation under CT control Cannulas are used: 22G 100 and 150 mm, the size of the electrode corresponds to the size of the cannula The starting power is 20W followed by steps of 10W every 2 minutes until the maximum power is reached, the maximum power is 60W.~In order to prevent infectious complications, two-day antibiotic prophylaxis of Cefazolin (1g) is carried out 3 times a day In order to prevent skin burns with superficially located DFS, the skin is cooled during the procedure."
40752996|NCT01953276|DEVICE|Serial Electrocardiograms|All participants will have serial electrocardiograms performed.
40752997|NCT04813874|DRUG|Nitrous Oxide|Nitrous Oxide Inhalational Agent
40752998|NCT04813874|PROCEDURE|Neuraxial analgesia|Epidural Labor Analgesia Placement
40752999|NCT04557761|DEVICE|microMend®|microMend® is a novel wound closure device that consists of arrays of tiny staples, known as Microstaples, which are attached to a backing material that is the size and shape of a butterfly closure. The Microstaples enable secure attachment of the device to the skin, allowing for the safe closure of wounds associated with surgery and traumatic injuries, such as lacerations. microMend is listed with the FDA and is available for sale in the United States.
41118628|NCT04598321|DRUG|Talazoparib Oral Capsule|An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.
41118629|NCT00891436|DRUG|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
41118630|NCT00891436|DRUG|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
41118631|NCT01291446|DIETARY_SUPPLEMENT|High flatulogenic diet|During 3-days subjects will consume a diet with high content of fermentable residues
41118632|NCT00484913|PROCEDURE|abdominal hot compress|
41446341|NCT04835363|OTHER|Early Occupational Therapy intervention|four-week OT intervention program with the support of the main caregiver in patients who have suffered a stroke with the aim of improving the functional result and facilitating the return home by providing knowledge to the caregiver about specific care and neurorehabilitation.
41446342|NCT06027528|PROCEDURE|dentin graft mixed with autologous fibrin glue|extracted tooth will be grinded into small particles to form dentin graft that will be mixed with autologous fibrin glue to be grafted in the extracted socket using centrifuge
41446343|NCT06027528|PROCEDURE|dentin graft|extracted tooth will be grafted in the socket
40753000|NCT04557761|DEVICE|Closure with Sutures|The Subject's laceration will be closed with sutures per regular institutional policies and procedures.
40753001|NCT04739774|DRUG|CHF6001 DPI|Single dose of CHF6001
40753002|NCT04739774|DRUG|Itraconazole|Repeated doses of oral Itraconazole
40753003|NCT00676962|BEHAVIORAL|External facilitation|Study facilitator meets regularly with therapists to aid implementation of CBT
41118633|NCT00073684|BEHAVIORAL|Trauma focused cognitive behavioral therapy (TF-CBT)|This study aims to: (1) examine the differential effects of CBT with and without trauma narrative interventions; (2) examine the comparative efficacy of brief and extended (8 vs. 16 sessions) individual CBT; (3) make developmental comparisons between 4-7 year olds and 8-11 year olds as to the appropriateness and therapeutic necessity of exposure interventions and longer treatment; and (4) identify child and parent factors that may significantly mediate the relationships between treatment conditions and outcomes. The findings of this study will help establish clinical as well as developmental markers for the early identification of sexually abused children who may require more focused (i.e., including trauma narrative) and/or longer treatment to achieve optimal outcomes.
41118634|NCT00073684|BEHAVIORAL|Brief abuse-focused treatment|Participants will receive 8 sessions of TF-CBT with abuse-focused treatment.
41118635|NCT00073684|BEHAVIORAL|Brief coping skills treatment|Participants will receive 8 sessions of TF-CBT with brief coping skills treatment.
41118636|NCT00073684|BEHAVIORAL|Extended abuse-focused treatment|Participants will receive 16 sessions of TF-CBT with extended abuse-focused treatment.
40753004|NCT06539663|COMBINATION_PRODUCT|OmniLenz®|OmniLenz® applied for 1 week in all patients after development of corneal perforation
41118637|NCT00073684|BEHAVIORAL|Extended coping skills treatment|Participants will receive 16 sessions of TF-CBT with extended coping skills treatment.
41118638|NCT03999671|OTHER|Educational|Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.
41118639|NCT03999671|OTHER|Maneuver control|Verify that the control and intervention group developed the assigned activities in each case.
41118640|NCT00382681|DEVICE|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
41118641|NCT00382681|DEVICE|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
41118642|NCT01416558|DRUG|Nab-Paclitaxel|"Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks~Given until progression, unacceptable toxicity, patient's request or withdrawal from Study"
41118643|NCT02455297|DRUG|Copanlisib (BAY80-6946)|Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.
41118644|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
41118645|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
41118646|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
41118647|NCT04218110|DRUG|Prevantics 3.15 % / 70 % Swabstick|Application of antiseptic drug to the inguinal area of the subjects
41118648|NCT03427216|DRUG|Baclofen/diazepam|Vaginal suppository placed once daily, patients will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weekly
41118649|NCT03427216|DRUG|Vaginal placebo|Vaginal suppository placed once daily, patient will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weeky.
41118650|NCT03260010|DRUG|Fosfomycin|Infectofos 5 g
41118651|NCT02701257|DEVICE|iPhone bionic pancreas|An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps
41118652|NCT02701257|DEVICE|iLet bionic pancreas|An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.
41118653|NCT02701257|DRUG|Xeris Xerisol glucagon|A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
41118654|NCT02701257|DRUG|Lilly glucagon|An aqueous formulation of human glucagon with limited stability that must be changed daily
41118655|NCT02701257|DEVICE|iLet infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
40753005|NCT06466772|BEHAVIORAL|Hyper-personalized feedback (HPF intervention)|For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.
40753006|NCT06466772|BEHAVIORAL|Targeted auditory stimulation during sleep (TASS verum intervention)|The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands
40753007|NCT06466772|BEHAVIORAL|Control targeted auditory stimulation during sleep (TASS sham intervention)|Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
40753008|NCT01300065|DEVICE|Experimental- Soflens|A new pair of lenses will be worn each day while the subject is in the study
40753009|NCT01300065|DEVICE|Marketed - Soflens|A new pair of lenses will be worn each day while the subject is in the study.
41118656|NCT02701257|DEVICE|Contact Detach infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
40753010|NCT00441935|DEVICE|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
41118657|NCT00771160|DRUG|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
41118658|NCT05623553|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
41118659|NCT05319457|OTHER|The radon app|Participants will be asked to use the radon app.
41118660|NCT05319457|OTHER|Print brochure|Participants will receive print brochures.
41118661|NCT05289258|BEHAVIORAL|Neuropsychological treatment|combination of the programs tested by (Von Ah et al. 2012). These programs are, on the one hand, a cognitive training adapted from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) (Jobe et al., 2001) and, on the other, a processing speed training using the Insight program (from Posit Science) (Mahncke et al., 2006). The first consists of teaching patients memorization techniques, and the second consists of a series of exercises on information processing of varying difficulty. These exercises automatically adjust your difficulty to maintain an 85% rate of return. Treatment is carried out in groups of 10 cancer survivors. It consists of 10 weekly sessions of 2 hours each (the first hour for memory training and the second for processing speed exercises). In order to improve the adherence to treatment of the participants, emails and telephone text messages will be sent with reminders of appointments and tasks to be performed.
41118662|NCT05289258|BEHAVIORAL|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED). Therefore, it focuses on the adaptive value of emotions and promotes tolerance to intense emotions as well as the identification and modification of dysfunctional emotional regulation strategies. Patients receive 10 group therapy sessions (3-5 cancer survivors per group) with all PU modules (Barlow et al., 2011). The Spanish version of the therapist's guide and the patient's workbook are used (Barlow et al., 2015). All patients receive the workbook to help them read the contents of each session, do the recommended exercises between sessions, and to help them once the treatment is finished. The treatment lasts 10 weeks (one session a week). As in the previous intervention group, emails and telephone text messages will be used with reminders of appointments and tasks to be carried out.
41118663|NCT05289258|BEHAVIORAL|Waitlist group|The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
41118664|NCT02398617|OTHER|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
41118665|NCT00538122|DEVICE|24 Holter Monitor Recording|"All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects."
41118666|NCT04257409|OTHER|Physical intervention by exercise|12 week lasting exercise intervention
41118667|NCT00906529|DRUG|Levemir (Detemir) and Novolog (Aspart) Insulin|Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
41118668|NCT02163252|BEHAVIORAL|Standard|
41118669|NCT02163252|BEHAVIORAL|Early Intervention|
41118670|NCT03009136|DRUG|SCRT|composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
41118671|NCT03009136|DRUG|Placebos|is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
41118672|NCT00006368|RADIATION|yttrium Y 90-edotreotide|
41118673|NCT00242359|DRUG|omalizumab|
41118674|NCT05908799|DRUG|Pembrolizumab + Pemetrexed-Platinum|Medication records in EHR database used to define exposure group
40753011|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program|We will modify the CI speech processor program to reduce interaural loudness and pitch mismatches.
41118675|NCT05908799|DRUG|Pemetrexed-Platinum|Medication records in EHR database used to define comparator group
41118676|NCT03045354|OTHER|Mashed potatoes|Isocaloric (450 kcal) breakfast treatments of eggs with a side of mashed potatoes
41118677|NCT03045354|OTHER|Traditional breakfast|Isocaloric (450 kcal) control breakfast treatments of cereal, milk, toast and jam
41118678|NCT03045354|OTHER|Breakfast skipping|No breakfast
41118679|NCT03045354|OTHER|French fries|Isocaloric (450 kcal) breakfast treatments of eggs with a side of French fries
41118680|NCT03045354|OTHER|Beans|Isocaloric (450 kcal) breakfast treatments of eggs with a side of beans
41118681|NCT02639910|BIOLOGICAL|Tafasitamab|tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion
41118682|NCT02639910|DRUG|Idelalisib|idelalisib dose: 150 mg twice daily orally
41118683|NCT02639910|DRUG|Venetoclax|venetoclax dose: 400 mg once daily orally
41118684|NCT00210691|DRUG|Risperidone|
41118685|NCT04597203|DEVICE|755-nm picosecond alexandrite laser with topical 2% hydroquinone|treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone
41118686|NCT04597203|DRUG|topical 2% hydroquinone|treatment one side of the face with topical 2% hydroquinone
41118687|NCT00011986|DRUG|Paclitaxel|Given IV
41118688|NCT00011986|DRUG|Carboplatin|Given IV
41118689|NCT00011986|DRUG|Gemcitabine Hydrochloride|Given IV
41118690|NCT00011986|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|
41118691|NCT00011986|DRUG|Topotecan Hydrochloride|Given IV
41118692|NCT00011986|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41118693|NCT01760109|DRUG|Piperacillin Sodium and Sulbactam Sodium|1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
41118694|NCT02650791|DRUG|Tranexamic Acid|
41446344|NCT05402137|BEHAVIORAL|Weight stigma intervention|Those undergoing the weight stigma manipulation will be exposed to an interaction partner (a trained confederate) who will endorse anti-fat attitudes. The purpose of this interaction is to examine the causal effects of weight stigma on eating behaviors, physical activity, and sleep.
41118695|NCT03703336|BIOLOGICAL|ROTAVIN (liquid formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 plaque forming units (PFU) of strain G1P\[8\] per dose of 2 mL.
41118696|NCT03703336|BIOLOGICAL|ROTAVIN-M1 (frozen formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 PFU of strain G1P\[8\] per dose of 2 mL.
41118697|NCT05709431|OTHER|Questionnaire CIQoL-35|The Cochlear Implant - Quality of Life (CIQoL) PROM is a quality-of-life assessment questionnaire for adults with cochlear implants (1-7). The CIQoL responds to an important need for a questionnaire that captures the benefits of cochlear implantation as perceived by patients and that can be used in clinical practice. The CIQoL is available in two lengths: 35 questions (CIQoL-35) and 10 questions (CIQoL-10). The CIQoL-35 has interesting measurement properties including good construct validity, convergent validity, and test-retest reliability.
41118698|NCT03767907|BEHAVIORAL|Computer-based Training for Cognitive Behavioural Therapy|Interactive content organized into seven modules, illustrating real-life scenarios associated with common risky situations, which illustrate the application of targeted skills and strategies
41118699|NCT03767907|BEHAVIORAL|Treatment As Usual|Treatment as usual will include standard psychosocial care determined to be appropriate or necessary, on an individual patient basis.
41118700|NCT00929760|BEHAVIORAL|specialised renal care|"* Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~* Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG."
41446345|NCT04370509|DRUG|Axitinib (VEGF-TKI)|Given PO
41118701|NCT01115959|DRUG|valproic acid|treatment of 1 month dosage of 400 mg BID
41118702|NCT01115959|DRUG|placebo bid|
41118703|NCT05383859|BEHAVIORAL|Intervention|"1. Dietary and/ or physical activity: face to face plus written material (at baseline)~2. 3 months later: motivational phone call."
41118704|NCT05506436|DEVICE|Evident 3|It consists of brief 5-minute counselling on general physical activity recommendations and explaining the plate method for a balanced diet. Also, it includes the Evident 3 application, which is a daily dietary log that provides information on calories and diet composition and shows a reminder of the 10000 steps/day.
41118705|NCT05506436|OTHER|Implementation strategy|"Four sessions have been designed to obtain the implementation strategy:~First session: Presentation of the Evident 3 application and its results in clinical trials. Training in the use of the application and identification of possible areas for improvement.~Second session: Presentation of evidence-based practices on the management of obesity in Primary Care. Consensus selection of those related to health promotion and mHealth. Sharing of possible lines of improvement of the care offered in the practice.~Third session (optional): Intervention on those components (coherence, cognitive participation, collective action and reflective follow-up) of the NOMAD questionnaire, if very low scores are obtained.~Fourth session: Brainstorming on possible strategies for the implementation of the Evident 3 intervention. Analysis and evaluation of these strategies and determination of a common strategy for their implementation."
41118706|NCT06514027|DRUG|BEBT-109 Capsules|BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.
41118707|NCT06514027|DRUG|Pemetrexed Disodium for Injection|Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.
41118708|NCT06514027|DRUG|Carboplatin Injection|Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
41118709|NCT06514027|DRUG|Cisplatin Injection|Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
41446346|NCT04370509|PROCEDURE|Cytoreductive Nephrectomy (CN)|Undergo CN
41446347|NCT04370509|PROCEDURE|Metastasectomy (MET)|Undergo MET
41446348|NCT04370509|BIOLOGICAL|Pembrolizumab|Given IV
41446349|NCT05778630|OTHER|Focus group meetings|Focus group meetings with different experts in the domain of CPCs (health care professionals) and/or parents or family members of a child with CPC. Focus group meetings will be facilitated by one or two study investigators. Group discussions will be audio-recorded.
41446350|NCT05778630|OTHER|Individual interviews|Individual qualitative interviews (semi-directive), conducted by one or two study facilitators.
41118710|NCT01504659|DRUG|Ketamine hydrochloride injection|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.
41118711|NCT01504659|DRUG|Flat tonic water (e.g., Canada Dry Tonic Water)|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
41118712|NCT03596853|OTHER|Progressive mobilization|"Will be applied once a day, 5x/ week, performed into 4 levels: N1 (bridge and rolling for both sides); N2 (transfer training from lying down to sitting on both sides); N3 (sit and stand up from a chair); N4 (running training). According to their functional level, patients will perform, once a day, 8 sets of each movement, alternating 20 seconds of execution with 10 seconds of rest. Patients will be stimulated constantly to perform the movements with the highest possible speed.~If the patient performs adequately within of your level functional level, can will progress in level, if can not progress, there will be an increase in training volume within the level itself. Adequate performance within the functional level means that the patient is able to complete more than eight sets of exercise and does not present increased sensation of pain, present sensation of perceived exertion within the safety limit of the protocol (Borg ≤ 6)."
40926262|NCT04879524|PROCEDURE|Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|"The intervention is an injection of 200 units of Botulinum toxin type A in to the puborectalis muscle under ultrasound guidance.~In the prone position, the puborectalis muscle will be identified below the coccyx using ultrasound. After skin preparation using 70% Isopropyl Alcohol Pad, and up to 5ml of local anaesthetic (1% lidocaine), an electromyography (EMG) needle will be inserted and the puborectalis muscle stimulated using a current to confirm correct needle position. 200 units of BTXA (Botox, Allergan, Ireland) prepared in 2 ml of saline solution and drawn up using a 2ml syringe. 1ml (100 units) of BTXA solution is injected through the EMG needle into the puborectalis muscle to each side of the midline, achieving a total of 200 units. The needle is withdrawn, and the procedure is complete."
40926263|NCT04045509|DEVICE|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
41118713|NCT03596853|OTHER|Usual Care|This group will receive standard usual, which will be monitored, but not protocolised.
41118714|NCT00648349|DRUG|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
41118715|NCT00648349|DRUG|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
41118716|NCT02407834|OTHER|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
41118717|NCT02407834|OTHER|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
41118718|NCT02407834|OTHER|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
41118719|NCT02407834|OTHER|S4|Immersion in Saline solution for 20 minutes, during 7 days.
41118720|NCT00969137|DRUG|saline|intravenous saline
41118721|NCT00969137|DRUG|Nicotine|Intravenous nicotine
41118722|NCT03995992|BEHAVIORAL|sport|10 days of sport (diving or multisport), once training per day
40926264|NCT04045509|DEVICE|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
41118723|NCT02738840|PROCEDURE|MRI scan|MRI scan
41118724|NCT02155010|DRUG|Dexmedetomidine|Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
41118725|NCT02155010|DRUG|Dexmedetomidine with heavy bupivacaine|Dexmedetomidine infusion after IT of heavy bupivacaine
41118726|NCT00006330|DRUG|Digoxin|
41118727|NCT00006330|DRUG|Hawthorn|
41118728|NCT04875624|DIAGNOSTIC_TEST|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status. Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
41118729|NCT04581733|DRUG|MT1621|All patients will receive MT1621 up to a target dose of 400 mg/kg/day each dC and dT, as tolerated.
41118730|NCT01815008|DRUG|Clopidogrel|Clopidogrel 75 mg daily
41118731|NCT01815008|DRUG|Aspirin|Aspirin 81 mg daily
41118732|NCT05673252|DIAGNOSTIC_TEST|Venous blood sample|Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
41118733|NCT05673252|PROCEDURE|biopsy|histopathology findings
41118734|NCT00098553|DRUG|everolimus|
41118735|NCT05725135|DRUG|Propofol|Propofol total intravenous anesthesia (TIVA) will be used for induction and maintenance of anesthesia. Propofol will be delivered using automated closed-loop anesthesia delivery system.
41118736|NCT03402633|OTHER|Examination of leukotrichia in vitiligo patients|Examination of leukotrichia will be enhanced by wood's light and dermoscopy for better enhancing of the lesions and good magnification
41118737|NCT04356430|DRUG|Abiraterone Acetate|1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy
41118738|NCT04356430|DRUG|Prednisone|5 mg oral low dose prednisone, once daily
41118739|NCT04356430|DRUG|Goserelin 10.8 mg|10.8 mg goserelin hypodermic once per 12 weeks
41271141|NCT05368090|PROCEDURE|"EUS-RFA of left adrenal tumour in PA, debulking group"|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
41446351|NCT04584749|DRUG|Lidocaine Iv|"2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine ."
41118740|NCT05563740|OTHER|Psychosocial|Daily telephone calls with two sessions of Brief Interventions for alcohol
41446352|NCT00031434|DRUG|Valganciclovir|Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
40753012|NCT01065766|DRUG|Sitagliptin/metformin|Sitagliptin/metformin 50/500 mg, 50/850 mg, or 50/1000 mg tablet administered twice daily with meals.
40753013|NCT01184118|DRUG|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
40753014|NCT01496443|DRUG|TAK-875 and Glimepiride|
41118741|NCT02976532|OTHER|Electromagnetic tracking unit in femoral derotation surgery|Use of the electromagnetic tracking system during the surgical procedure in addition to the normal measurement with goniometer, the different devices listed are combined to form the EMT system unit
41118742|NCT00120367|DRUG|Enfuvirtide|
41118743|NCT00120367|DRUG|Tenofovir-Emtricitabine|
41118744|NCT03332758|PROCEDURE|Pars plana vitrectomy|Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.
40926265|NCT04045509|DEVICE|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
41118745|NCT03332758|PROCEDURE|External drainage|Standard of care treatment for retinal detachment.
40753015|NCT06291961|GENETIC|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
40753016|NCT02636036|BIOLOGICAL|enadenotucirev|
40753017|NCT02636036|BIOLOGICAL|nivolumab|
40753018|NCT05020119|DRUG|Neoantigen-expanded cell therapy.|Infusion of personalized neoantigen-expanded T (CIK) cells
41118746|NCT04734132|DIETARY_SUPPLEMENT|Moringa|Leaves of Moringa oleifera from an organic Iberian peninsula cultivar. A single lot was prepared from the same crop. Leaves were dried and ground and encapsulated as a organic dietary supplement. No other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
41118747|NCT04734132|DIETARY_SUPPLEMENT|Placebo|Placebo capsules were indistinguishable from the experimental capsules in material and color (opaque white). Same number of capsules were consumed as in the experimental arm and no other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
41118748|NCT02692469|PROCEDURE|Duodenal Switch|Bariatric procedure
41118749|NCT02692469|PROCEDURE|Duodenal-ileal Bypass with Sleeve Gastrectomy|Bariatric procedure
41118750|NCT04077164|OTHER|No intervention, observational only.|No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
41118751|NCT04718688|OTHER|CO-OP rehabilitation|"The intervention was included within the child's conventional rehabilitation program.~In the CO-OP original protocol, the child sets 3 goals. Here, we concentrated on two rather than three goals, as addressing three occupations per session seemed too ambitious given the children's cognitive profile (the third goal served as control goal).~We chose to increase the number of sessions to 14 (two sessions per week for seven weeks, vs ten in the original protocol).~The global strategy was taught to the child at the first session. The following sessions consisted of an iterative process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the children were experiencing when performing the self-selected tasks. In addition, homework was assigned to encourage the application and practice. Parents were invited to attend the sessions if it was possible for them."
41118752|NCT04676334|DRUG|Rucaparib|Rucaparib will be administered daily.
41118753|NCT00779636|DRUG|Desloratadine|Desloratadine 10 mg daily x 28 days
41118754|NCT00779636|DRUG|Placebo|Placebo daily x 28 days
41446353|NCT00031434|DRUG|Ganciclovir|Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
41446354|NCT00001035|DRUG|Interferon alfa-2b|
41446355|NCT00001035|DRUG|Zidovudine|
41446356|NCT00001035|DRUG|Zalcitabine|
41446357|NCT00001035|DRUG|Didanosine|
41271142|NCT05368090|PROCEDURE|EUS-RFA of left adrenal tumour in MACS with AVS-verified left lateralisation|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
41118755|NCT01736215|DRUG|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
41118756|NCT03720236|PROCEDURE|Implant bed preparation protocol|This is the first surgical phase, we prepare the implant bed by using different increasing size drills.
41446358|NCT06628050|DEVICE|ORIGIN® PS Modular devices|Consecutive eligible subjects have been included which have been treated with the ORIGIN® PS Modular devices.
41446359|NCT06338826|DRUG|TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI|"The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from~* NNRTI = efavirenz, rilpivirine, etravirine, doravirine~* PI/r = atazanavir/r ou darunavir/r~* INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir"
40753019|NCT05900310|DIAGNOSTIC_TEST|Core Cognitive Evaluation (CCE)|The Linus Health Core Cognitive Evaluation (CCE) is an easy-to-use but powerful tool to augment and facilitate cognitive health assessment during a patient's visit to their PCP. As a digital assessment solution, the CCE combines objective insights into cognitive ability with patient-reported insights to detect early signs of cognitive impairment and reveal specific modifiable risk factors earlier than the existing status quo assessments. The CCE is an FDA-listed Class II 510k exempt software as a medical device. The CCE has two components: The Digital Clock and Recall (DCR™) test and the Life and Health Questionnaire (LHQ).
40753020|NCT02916914|OTHER|Q2 feeding|Infants are going to be fed every 2 hours
40753021|NCT02663570|DRUG|Melatonin|
40753022|NCT00562861|DRUG|citalopram + mood stabilizer|Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
41118757|NCT03720236|PROCEDURE|Implant loading|This is the second phase, based on prosthetic procedures, to design the crown over the dental implant
41118758|NCT00296036|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Given orally
41118759|NCT00296036|DRUG|urea/lactic acid-based topical cream|Applied topically
41118760|NCT00296036|OTHER|placebo|Given orally or applied topically
41118761|NCT05293548|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) in the deltoid muscle of the upper arm
41118762|NCT05293548|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Biological/Vaccine: Inactivated COVID-19 vaccine (Vero cells) Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
41118763|NCT02058017|DRUG|OPB-51602|
41118764|NCT06446726|DRUG|Tislelizumab|Patients will undergo two cycles of immunotherapy, each cycle lasting 21 days. Day 3 and Day 24: Tislelizumab, fixed dose of 200 mg
41118765|NCT06446726|RADIATION|Low-dose radiotherapy|Patients will undergo two cycles of low-dose radiotherapy. Day 1/2 and Day 22/23: Low-dose radiotherapy (8 Gy/4f)
41118766|NCT06446726|DRUG|Nab-paclitaxel|Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Nab-paclitaxel 260 mg/m2
41118767|NCT06446726|DRUG|Cisplatin|Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Cisplatin 75 mg/m2.
41118768|NCT00739739|DRUG|PD 0299685 at 15mg BID|5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
41118769|NCT00739739|DRUG|PD 0299685 at 30mg BID|10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
41118770|NCT00739739|DRUG|placebo for PD 0299685|Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
41118771|NCT00924807|DRUG|Leuprolide acetate, Bicalutamide, Sorafenib|Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
41118772|NCT00035828|DRUG|ABX-IL8|
41118773|NCT01887600|DRUG|Roxadustat|Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
41118774|NCT01887600|DRUG|Placebo|Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
41271143|NCT05368090|PROCEDURE|"EUS-RFA of left adrenal tumour in MACS with bilateral overproduction, debulking group"|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
41271144|NCT01253603|DRUG|QAW039 capsules once daily for 28 days|
41271145|NCT01253603|DRUG|Placebo to QAW039 capsules once daily for 28 days|
41271146|NCT01253603|DRUG|Fluticasone propionate inhaler twice daily for 28 days|
41271147|NCT03058484|BEHAVIORAL|Community Health Worker intervention|The intervention included four integrated components: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
41271148|NCT00828451|BIOLOGICAL|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
41271149|NCT00428402|BEHAVIORAL|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
41271150|NCT01865292|DRUG|insulin degludec|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
41271151|NCT01865292|DRUG|insulin glargine|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
41271152|NCT01564706|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
41271153|NCT06382090|OTHER|Laughter yoga|This practice, which includes deep breathing exercises and laughter exercises, takes approximately 45 minutes. The sessions will be conducted by the principal investigator.
41271154|NCT04662034|DEVICE|CMIC|The C-MIC System consists of three implantable parts: a transvenous and an epicardial lead which are both connected to an implanted power source, and an external programing device. The patch lead is placed over the free wall of the left ventricle and fixated with sutures. When lead placement is achieved, the leads are then tunneled subcutaneously to the infraclavicular region and connected to the power source.
41271155|NCT04662034|DRUG|Standard of Care (SOC)|Patients receive optimal SOC based defined in pertinent guideline and at the discretion of the investigator
41271156|NCT04924127|DIAGNOSTIC_TEST|Detection of IDH and TERT mutation|Detection of IDH and TERT mutation using frozen glioma tissues
41271157|NCT03619915|DIAGNOSTIC_TEST|Spirometry|The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres
41271158|NCT03619915|OTHER|Functional Independence Measure|Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.
41271159|NCT06379334|DIAGNOSTIC_TEST|Urine test|Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.
41271160|NCT00766792|PROCEDURE|Nocturnal dialysis|Switch to nocturnal dialysis (3 times 480 min/week)
41271161|NCT00766792|PROCEDURE|Standard dialysis|Standard dialysis (3 times 240-270 min/week)
41271162|NCT03990129|DRUG|Metamizole|One week treatment with metamizole (500 mg tablets, 2-2-2)
41271163|NCT01624194|DRUG|Oxytocin nasal spray|24IU BID (3 x 0.1 mL \[4IU\] sprays per nostril twice daily for 4-weeks.
41271164|NCT01624194|DRUG|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
41271165|NCT04436302|DEVICE|Exergame device|motor-cognitive training
41271166|NCT02867631|BEHAVIORAL|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
41271167|NCT00898092|GENETIC|microarray analysis|
41271168|NCT00898092|GENETIC|molecular genetic technique|
41271169|NCT00898092|GENETIC|mutation analysis|
41271170|NCT00898092|GENETIC|polymerase chain reaction|
41271171|NCT00898092|GENETIC|reverse transcriptase-polymerase chain reaction|
41271172|NCT00898092|OTHER|diagnostic laboratory biomarker analysis|
41271173|NCT02510807|OTHER|Pedometer|The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
41271174|NCT00255073|DRUG|baclofen|
41271175|NCT05559879|DRUG|Cabo + Dostarlimab|Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment
41271176|NCT01445171|DEVICE|Aortic Valve Replacement with EDWARDS INTUITY Valve System|Aortic Valve bioprosthesis
41271177|NCT05304364|COMBINATION_PRODUCT|Combination Product: Naltrexone|Naltrexone Implant
41271178|NCT00001325|DRUG|18 FDG|
41271179|NCT04919629|BIOLOGICAL|Bevacizumab|Given IV
41271180|NCT04919629|PROCEDURE|Biopsy|Undergo tumor biopsy
41271181|NCT04919629|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41271182|NCT04919629|DRUG|Pegcetacoplan|Given IV and SC
41118775|NCT00816751|PROCEDURE|Paracervical block|The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
41118776|NCT00816751|PROCEDURE|Intracervical|The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
40926266|NCT03195400|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
40926267|NCT03195400|DIAGNOSTIC_TEST|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
40926268|NCT03195400|DIAGNOSTIC_TEST|Isoglycemic Intravenous Glucose Test|Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.
40926269|NCT03195400|DIAGNOSTIC_TEST|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
41118777|NCT00816751|DRUG|Buffered Lidocaine, vasopressin, sodium bicarbonate|The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
41118778|NCT00304135|DRUG|cisplatin|
41118779|NCT00304135|DRUG|gemcitabine hydrochloride|
41118780|NCT00304135|DRUG|oxaliplatin|
41118781|NCT02725762|DEVICE|LT-300 Active (PBM)|
41118782|NCT02725762|DEVICE|LT-300 Inactive (Sham)|
41118783|NCT03315884|PROCEDURE|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)|"Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used."
41271183|NCT04919629|BIOLOGICAL|Pembrolizumab|Given IV
41271184|NCT04919629|OTHER|Questionnaire Administration|Ancillary studies
41271185|NCT00759603|DRUG|Lenalidomide|Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
41271186|NCT00759603|DRUG|Rituximab|Dose of 375 mg/m\^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
40926270|NCT05783427|OTHER|liberal hydration|evaluate the effect of 'Sip Til Send' on overall gastric volume pregnant women undergoing elective caesarean delivery
40926271|NCT02058524|BIOLOGICAL|fecal microbiota transplantation|
40926272|NCT02104388|DRUG|SJP-0035 Ophthalmic Solution|
40926273|NCT02104388|DRUG|Vehicle of SJP-0035 Ophthalmic Solution|
40926274|NCT04468399|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
40926275|NCT04468399|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
40926276|NCT01517971|OTHER|laboratory biomarker analysis|Correlative studies
40926277|NCT06164821|DRUG|luspatercept|Adult patients with TD thalassemia were given luspatercept subcutaneous injection.
40926278|NCT04403009|OTHER|no intervention|no intervention
40926279|NCT01482390|DRUG|Ribavirin|Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.
40926280|NCT01482390|DRUG|Mericitabine|Participants will receive mericitabine 1000 mg orally twice daily.
40926281|NCT01482390|DRUG|Peginterferon Alfa-2a|Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.
40926282|NCT01482390|DRUG|Placebo|Participants will receive placebo matching to mericitabine orally twice daily.
40926283|NCT01482390|DRUG|Telaprevir|Participants will receive telaprevir 750 mg orally three times daily.
40926284|NCT04860908|OTHER|no intervention, observation only|no intervention, observation only
40926285|NCT03457779|DIETARY_SUPPLEMENT|Glucose|"The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of \[1,2-13C\] glucose as an IV"
41118784|NCT03315884|PROCEDURE|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch|Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
41118785|NCT00704184|DRUG|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
41118786|NCT00704184|DRUG|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
41118787|NCT00704184|DRUG|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
41118788|NCT00704184|DRUG|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
41118789|NCT03071185|PROCEDURE|femoral nerve block, common peroneal nerve block|For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.
41118790|NCT05102409|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed once
41118791|NCT05102409|DRUG|Xiidra® (5% lifitegrast ophthalmic solution)|Xiidra® (5% lifitegrast ophthalmic solution) dosed once
41118792|NCT02607670|DRUG|TAT4 Gel|
41118793|NCT02607670|DRUG|Matching placebo|
41118794|NCT04191096|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
41118795|NCT04191096|DRUG|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
41118796|NCT04191096|DRUG|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
41118797|NCT04191096|OTHER|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
41118798|NCT00142558|DRUG|MK0663; etoricoxib / Duration of Treatment: 5 Days|
41118799|NCT00142558|DRUG|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
41118800|NCT03248271|DRUG|Insulin Lispro|Insulin
41118801|NCT05291104|DIETARY_SUPPLEMENT|Folic acid, choline chloride|In this study, we divide intervention group into two groups which received folic acid (FA) or choline chloride (CC) supplement. Each subgroups contain 20 subjects, including 10 men and women. According to Recommended Daily Nutrient Allowance, FA recommended intake is 400 ug / day and choline recommended intake in men and women is 450 and 390 mg / day. From phase 1 to phase 3 stage, for every 10 days, subjects are given 2-fold, 4-fold and 8-fold recommended intake dose of FA or CC. All supplement solve in 240 ml cranberry juice.
41118802|NCT01061671|DRUG|simvastatin|40 mgms of simvastatin daily
41118803|NCT01061671|DRUG|Placebo|Matched placebo pill daily
41118804|NCT02769468|OTHER|The Back|
41118805|NCT02769468|OTHER|Chest|
41118806|NCT02769468|OTHER|Left Axilla|
41118807|NCT01528306|BIOLOGICAL|HP802-247|"Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each"
41118808|NCT01528306|OTHER|Placebo|"Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each"
41118809|NCT05826379|BEHAVIORAL|Adaptive Daily Goal Setting|Daily step goals displayed by the study application
41118810|NCT05826379|BEHAVIORAL|Interim Goal Prompt|Short-term step goals
41118811|NCT05625334|DRUG|ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
41118812|NCT05625334|DRUG|non-enteric-coated chewable aspirin|Orally administered
41118813|NCT03084744|BEHAVIORAL|Schema therapy|Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.
41118814|NCT03084744|BEHAVIORAL|Active monitoring|Active tele-monitoring by clinical psychologists.
41118815|NCT01184664|DRUG|Nicotine Patch|Varenicline + nicotine patch
41118816|NCT01184664|DRUG|Placebo|Varenicline + placebo patch
41118817|NCT01184664|DRUG|Varenicline|All participants will receive a standard dose of varenicline (12 weeks).
41118818|NCT04169698|DRUG|Denosumab 60 mg/ml [Prolia]|full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand
41118819|NCT04169698|DRUG|Alendronate 70Mg Tab|Bisphosphonates
41118820|NCT06011109|DRUG|APG-157|The participants will receive APG-157 daily; and continue to receive Bevacizumab as standard of care.
41118821|NCT03482804|OTHER|Questionnaires|"Parents will be interviewed before being seen in consultation in the emergency room. The reason for consultation will not be taken into account, the only criterion being the age of the child. There will be no sign in the waiting room, the study will be proposed to them by the principal investigator.~The questionnaires will be collected on live paper. The answers will be transferred in a second time on an Excel database protected by a password."
41118822|NCT05958654|BEHAVIORAL|Detection of Elder mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool|DETECT-RPC is an elder mistreatment (EM) screening tool designed for medics who respond to older adults' homes and will be adapted for home-based primary care (HBPC). The DETECT-RPC tool is designed to (1) be brief, (2) be based on the clinician's direct observations of the older adult and the older adult's physical and social environment, (3) provide reporting guidance, and (4) be integrated into their existing procedures and medical charting software.
41118823|NCT01444417|DRUG|Romiplostim|The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.
41118824|NCT01444417|DRUG|Placebo|Matching placebo administered by subcutaneous injection
41118825|NCT04490252|DIETARY_SUPPLEMENT|Fasting mimetic diet|Fasting mimetic diet for 5 days, another cycle after 25 days
41118826|NCT00551577|PROCEDURE|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
40753023|NCT00562861|DRUG|placebo + mood stabilizer|This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
41118827|NCT00551577|PROCEDURE|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
41118828|NCT04277715|BEHAVIORAL|Parent training|Parents will learn evidence-based techniques for increasing support and decreasing accommodation of children's chronic symptoms.
41118829|NCT01610297|DRUG|ICL670|Oral dose of ICL670 at 10 mg/kg daily
41118830|NCT01982890|OTHER|Control|No intervention as this group is simply followed prospectively.
41118831|NCT03731377|DRUG|Crystalloid Solutions|Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.
41118832|NCT06261996|DRUG|Fospropofol|Fospropofol is administered after admission to the room at a pumping rate of 1 mg/kg/h.
41118833|NCT00405535|DRUG|glycine|
41118834|NCT00405535|OTHER|placebo|
41118835|NCT00575523|DRUG|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
41118836|NCT00575523|DRUG|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
41118837|NCT03926884|DIETARY_SUPPLEMENT|Three-seeds mixture|mixture of white mustard seeds, radish seeds and beefsteak plant (Korean perilla, a species of Perilla in the mint family, widely cultivated and edible for humans; a daily food for Korean people; many Japanese people drink as tea) seeds
41118838|NCT03926884|DIETARY_SUPPLEMENT|Control|warm water with negligible amount of the three-seeds mixture
41118839|NCT00936507|OTHER|Energy Density/Portion Size|
41118840|NCT00482729|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
41118841|NCT00482729|DRUG|metformin|metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
41118842|NCT05887063|OTHER|Dementia Awareness Course UK|An online course delivered to a small group of informal caregivers in between 3 and 4 hours. The course is made up of three modules: what is dementia, positive engagement and caring for someone with dementia. The course is delivered by one facilitator and includes teaching, discussions and activities.
41118843|NCT00094575|PROCEDURE|Endovascular Repair|Endovascular Repair
41118844|NCT00094575|PROCEDURE|Standard Open Repair|Standard Open Repair
41118845|NCT03047746|DEVICE|CliniMACs|Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
41118846|NCT05740657|DRUG|Fentanyl|The drugs were administered in the course of a surgery or for pain management.
41118847|NCT05377151|OTHER|Mobile application|"Nutrition intervention using either mHealth interventions or conventional methods will be carried out among pregnant women).~Subjects will be allocated into three groups, namely, two interventions group which are:~Group 1: mHealth intervention group (98 subjects)~Group 2: mHealth intervention group + dietitian consultation (98 subjects)~Group 3: control group (98 subjects)"
41118848|NCT02271854|DRUG|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
41118849|NCT02271854|DRUG|Placebo|Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
41118850|NCT03332992|BEHAVIORAL|Viral changes|Telephone script language provided pre-questions regarding the fact that influenza viruses change each year
40753024|NCT02127515|PROCEDURE|Non Invasive Prenatal Testing|
40753025|NCT02127515|PROCEDURE|Invasive Prenatal Testing|
41118851|NCT03332992|BEHAVIORAL|Protect others|Telephone script language provided pre-questions emphasizing the need to protect vulnerable others
41118852|NCT03332992|BEHAVIORAL|General intentions|Question language asking about general interest in getting influenza vaccination
41118853|NCT03332992|BEHAVIORAL|Behavioral intentions|Question language asking individual to make specific plans to be vaccinated
41271187|NCT05957705|PROCEDURE|Maxilar Sinus augmentation|The patients will be submitted to bilateral sinus augmentation using two different techniques to provide enough bone tissue for dental implants placement.
41271188|NCT05957705|PROCEDURE|Dental implant placement using guided surgery|After 4 months of sinus augmentation, patients will be prepared to receive dental implants for oral rehabilitation. Performed by guided surgery the implants will be placed at the best location for the rehabilitation and at the place were the sinus lighting were performed.
41271189|NCT01541293|DRUG|Lidocaine|100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
41271190|NCT01541293|DRUG|Normal Saline|5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
41271191|NCT02313740|BIOLOGICAL|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
41271192|NCT03224286|DEVICE|Pressure sensitive mat|Infant placed on pressure sensitive mat and has physiological parameters recorded.
41271193|NCT00439855|DRUG|Enoxaparin i.v.|
41271194|NCT00439855|DRUG|unfractionated heparin|
41271195|NCT06351202|OTHER|Abdominal massage|An abdominal massage for premature babies lasts 10 minutes. Our abdominal massage techniques is described in our protocole and will be adapted according to the term of the child.
41271196|NCT06130332|DRUG|PD-1 with chemotherapy|"Tirellizumab+Carboplatin+albumin-bound paclitaxel:2 courses Tirellizumab,+Carboplatin+albumin-bound paclitaxel Tirellizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor"
41271197|NCT06130332|PROCEDURE|upright surgery|"Surgery：Primary resection，excision with the safe margin 1.0-1.5cm away from the original tumor~selective neck dissection:I II III region neck dissection"
41271198|NCT06171802|DRUG|Empagliflozin|10 mg empagliflozin daily for six months
41271199|NCT06171802|DRUG|Placebo|Placebo capsule once daily for six months
41271200|NCT02617914|PROCEDURE|individualized PEEP treatment, Invasive mechanical ventilation, ECMO,|
41271201|NCT00193830|PROCEDURE|HIgh Dose Rate Vs Low DOse Rate Brachytherapy|
41271202|NCT05173129|DIAGNOSTIC_TEST|Posture Analysis|Posture analysis and assessment of mechanical properties of posture muscles
41271203|NCT04268134|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplement|4 capsules taken by mouth each day for 24 weeks (starting at the week 12 visit).
40753026|NCT04626531|OTHER|Web-Based Education|Participants in the intervention group had unlimited access to the Web site, free of charge. The Web site was designed to run on personal computers and smartphones.
41271204|NCT01006343|OTHER|Higher Protein (HP)|
41271205|NCT01006343|OTHER|Lower Protein (LP)|
41271206|NCT03545464|DRUG|Placebo Oral Tablet|Placebo of cortancyl Oral Tablet 20mg
41271207|NCT03545464|DRUG|Cortancyl Oral Tablet|Cortancyl oral Tablet 20 mg
41271208|NCT03545464|DRUG|Levocetirizine Oral Tablet|Levocetirizine Oral Tablet 5 mg
41271209|NCT00870337|DRUG|everolimus|
41271210|NCT04219436|PROCEDURE|esthetic crown leghthening|two different suturing technique used for flap closure after esthetic crown lengthening
41271211|NCT05657184|DRUG|REGEND001|Transplantation of REGEND001 for dose escalation.
41271212|NCT03252782|DEVICE|Herbst Appliance|Acrylic Splint Herbst Appliance
41271213|NCT03252782|DEVICE|Distal Jet Appliance|Anterior Median Palate Implant Borne Distal Jet Appliance
40753027|NCT04626531|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
41271214|NCT01361711|BIOLOGICAL|alemtuzumab|Given SC
41271215|NCT01361711|BIOLOGICAL|ofatumumab|Given IV
41271216|NCT01361711|PROCEDURE|biopsy|Correlative studies
41271217|NCT03445702|DRUG|Metformin|Metformin 1000mg once
41271218|NCT03445702|DRUG|Placebo|Sugar pill manufactured to mimic metformin 1000mg
41271219|NCT06078657|DRUG|IBI110+Sintilimab|"IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.~Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years."
41271220|NCT03200951|DRUG|Bolus group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
41271221|NCT03200951|DRUG|Infusion group for epidural block|Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
41271222|NCT06142084|DIETARY_SUPPLEMENT|Oat Protein, low bioavailability|Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).
41271223|NCT06142084|DIETARY_SUPPLEMENT|Oat Protein, high bioavailability|Participants will consume a protein meal consisting of heated oat protein concentrate (amount based on body weight, 0.3g of protein/kg bodyweight).
41271224|NCT06142084|DIETARY_SUPPLEMENT|Pea Protein, low bioavailability|Participants will consume a protein meal consisting of cooked whole yellow peas (amount based on body weight, 0.3g of protein/kg bodyweight).
41271225|NCT06142084|DIETARY_SUPPLEMENT|Pea Protein, high bioavailability|Participants will consume a protein meal consisting of heated pea protein isolate (amount based on body weight, 0.3g of protein/kg bodyweight).
41271226|NCT06142084|DIETARY_SUPPLEMENT|Protein-free meal|Participants will consume a protein-free meal to correct analyses for endogenous protein losses.
41271227|NCT01111604|BIOLOGICAL|Ramucirumab|8 mg/kg IV Q2W
41271228|NCT01111604|BIOLOGICAL|Icrucumab|15 mg/kg IV Q2W
41271229|NCT01111604|DRUG|mFOLFOX-6|"Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W"
40926286|NCT03748615|DEVICE|Computer Guided ridge splitting in posterior mandible|"The computer guided ridge splitting for patients with atrophic posterior mandible and with residual bone width at least 3 to 5mm of residual ridge.~The selected patients will be informed of the nature of the research work and informed consent will be signed.~Radiographic examination included preoperative digital panoramic radiograph with 1:1 magnification for each patient as a primary survey to obtain an approximation of the available bone height and detect the presence of remaining roots and localized pathosis.~Computer surgical guides are fabricated for partially edentulous patients using teeth and tissue as support for the guide.~The same surgeon performed all surgeries. All surgical procedures were performed under strict aseptic conditions, all patients received nerve block local anesthesia (Articaine 4% 1:100 000 epinephrine).~A crestal incision is made using No. 15 blade extending over the posterior mandible using computer guided surgical stent.~no flap elevation ."
40926287|NCT03203278|BEHAVIORAL|Web-based exercise programme|Aerobic, resistance and balance exercises
41271230|NCT01113320|DRUG|Placebo|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
41271231|NCT01113320|DRUG|Safinamide|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
41271232|NCT01998542|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine with AlloStim(TM) and CRCL
41271233|NCT01998542|BIOLOGICAL|CRCL|autologous tumor-derived chaperone protein mixture
41271234|NCT01998542|BIOLOGICAL|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
41271235|NCT04093596|GENETIC|ALLO-715|ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA
41271236|NCT04093596|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
41271237|NCT04093596|DRUG|Fludarabine|Chemotherapy for lymphodepletion
41271238|NCT04093596|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
41271239|NCT04093596|DRUG|Nirogacestat|a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.
41271240|NCT06222424|OTHER|outpatient prescription issues|Evaluation of utility will involve describing all Emergency Medicine Pharmacist (EMP)-written prescriptions pursuant to resolution of prescription issues realized after discharge
41271241|NCT04006184|OTHER|Chart review|Retrospective review of medical records at a single site with six physicians
41271242|NCT01835184|DRUG|cabozantinib-s-malate|Given PO
41271243|NCT01835184|DRUG|vemurafenib|Given PO
41271244|NCT01835184|OTHER|laboratory biomarker analysis|Correlative studies
41271245|NCT01835184|OTHER|pharmacological study|Correlative studies
41271246|NCT05397314|DIETARY_SUPPLEMENT|Punalpin|
41271247|NCT05397314|OTHER|Placebo|
41271248|NCT00368706|DRUG|solifenacin succinate|Oral
41271249|NCT00368706|DRUG|tolterodine|oral
41271250|NCT03275909|BEHAVIORAL|Integrated Psychological Therapy|The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
41271251|NCT00712348|DRUG|Taliglucerase alfa|Intravenous infusion every 2 weeks
41271252|NCT02822456|PROCEDURE|VFSS|VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube
41271253|NCT06277973|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention is based on EMDR therapy for PTSD treatment. Participants will answer demographic questions, choose a primary distress source and watch a therapist-guided video (male or female, based on participant choice) that will instruct them through the 'Butterfly Hug' method (tapping alternately on both sides of the body) while hearing positive statements from the therapists on the chosen distress source. Before and after each video participants will rate their distress level on a scale between 0 and 10 and they can view up to 8 videos per session. The system will monitor distress levels, and if it detects a sustained deterioration, it will end the intervention. At the end of the intervention, participants will be given information about possible reactions to it and how to deal with them, they will be encouraged to use the technique whenever necessary, and they will be informed of relevant support lines that they can contact if needed.
41271254|NCT06458192|BEHAVIORAL|Adaptive Messaging Intervention|The intervention delivers 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. The intervention will apply reinforcement learning to select daily messaging styles to maximize user engagement.
41271255|NCT06458192|BEHAVIORAL|Non-Adaptive Messaging Intervention|The intervention involves 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. Daily messaging styles will be randomly selected.
41271256|NCT06458192|BEHAVIORAL|Psychoeducation-Only Control|An active control which will deliver psychoeducational content via clickable URLs over 8 weeks.
41271257|NCT02080052|DEVICE|Robot-assisted prostate biopsy|
41271258|NCT00078364|PROCEDURE|MRI|
41271259|NCT00108329|BEHAVIORAL|Weight Loss|
40753028|NCT04516200|DEVICE|transcranial direct current stimulation and traditional physical therapy program|Transcranial stimulation will be applied only for the study group.
40753029|NCT04516200|OTHER|designed physical therapy program|sensory training and balance training
41271260|NCT01784796|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
41271261|NCT01784796|BEHAVIORAL|Health Education Program|8 week Health Education Program
41271262|NCT01053910|DRUG|Ramipril|tablet of Ramipril once daily
41271263|NCT00222911|DEVICE|dorsiflexion night splint|
41271264|NCT00222911|DEVICE|medial arch support|
41271265|NCT00891735|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
41271266|NCT01973257|PROCEDURE|imaging diagnostics|
41271267|NCT00175305|DRUG|Sandostatin LAR|
41271268|NCT02975830|RADIATION|Three dimensional CT based images|Right bronchial angle, left bronchial angle
41271269|NCT03228368|DRUG|Atezolizumab (MPDL3280A)|anti-programmed death-ligand 1 (PD-L1) antibody
41271270|NCT04379752|DEVICE|Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment|Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area
41271271|NCT02005822|DRUG|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
41271272|NCT05307458|DRUG|Buprenorphine/naloxone|Participants will receive gradually increasing doses of buprenorphine while tapering down on their methadone dose.
41271273|NCT00787436|DRUG|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
41271274|NCT01766648|DEVICE|Far Cortical locking screw fixation|Standard screw fixation
41271275|NCT01766648|DEVICE|Standard screw fixation|
41271276|NCT03762304|OTHER|Household blood pressure screening with care encouragement|"During the household survey visit, survey enumerators collected two measurements of the respondent's blood pressure. If either of the measurements exceeded 140 mmHg systolic or 90 mmHg diastolic, enumerators told participants: Your blood pressure readings are higher than normal. High blood pressure is dangerous because it makes the heart work too hard. High blood pressure increases the risk of heart disease and stroke. High blood pressure can also cause other problems, such as heart failure, kidney disease, and blindness. You can control high blood pressure by taking action. Then the enumerators recommend that an individual seek medical care within 2 months."
41271277|NCT00057707|DRUG|Modafinil|Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)
41271278|NCT00057707|PROCEDURE|Functional MRI|
41271279|NCT00057707|PROCEDURE|Neuropsychological Testing|
41271280|NCT04492904|OTHER|Home-use Test and Follow-up Questionnaire|Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
41271281|NCT00499109|DRUG|Docetaxel|"GD Group: 40 mg/m\^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m\^2 on day 1~DV Group: 50 mg/m\^2 on days 1 and 15, every 28 days"
41271282|NCT00499109|DRUG|Vinorelbine|DV Group: 35 mg/m\^2 on days 1 and 15
41271283|NCT00499109|DRUG|Carboplatin|"GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
41271284|NCT00499109|DRUG|Gemcitabine|"GCb Group: 1,250 mg/m\^2 on days 1 and 8~GD Group: 1,250 mg/m\^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
41271285|NCT04460430|DRUG|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
41271286|NCT02598830|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
41271287|NCT02598830|DIETARY_SUPPLEMENT|Placebo|Olive oil, encapsuled
41271288|NCT02065544|BEHAVIORAL|behavioral weight loss and exercise|Weight loss and exercise counseling
41271289|NCT03453892|DRUG|Nivolumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
41271290|NCT03453892|DRUG|Pembrolizumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
41271291|NCT03453892|RADIATION|Radiotherapy|The normal clinical treatment-plan of the underlying disease remains unchanged.
41271292|NCT03453892|DRUG|Ipilimumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
41271293|NCT00733525|BEHAVIORAL|Cognitive Behavioral Therapy|Therapy focusing on skills needed to alter eating patterns
41271294|NCT00733525|DRUG|Fluoxetine|20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
41271295|NCT00733525|BEHAVIORAL|Guided Self-Help|Manual designed to impart teachings of cognitive behavioral therapy
41271296|NCT05334329|BIOLOGICAL|Antineoplastic Immune Cell|Given COH06 IV
41271297|NCT05334329|BIOLOGICAL|Atezolizumab|Given IV
41271298|NCT05334329|PROCEDURE|Biospecimen Collection|Correlative studies
41271299|NCT05334329|DRUG|Cyclophosphamide|Given IV
41271300|NCT05334329|DRUG|Fludarabine|Given IV
41446360|NCT06338826|DRUG|Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)|dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
41118854|NCT03332992|BEHAVIORAL|Accountability|Question language asking individual whether their care team can learn about their vaccination intentions
41118855|NCT04187664|BEHAVIORAL|Postoperative Monitoring|Nursing and medical staff will monitor patients vital signs and clinical deterioration triggers twice as often as in previous ward care.
41271301|NCT04288024|BEHAVIORAL|Weight-shifting training|"Postural task: Participants are standing with their weak side on the force plate. During the task, they wight-shift from side to side ranging from 10 to 90 percent of their body weight.~Suprapostural task: Participants hold a tray with their arms beside the body, 90 degrees of elbow flexion. They rotate the tray left and right for 45 degrees respectively.~During their task, participants should weight-shift and rotate the tray at the same time."
41271302|NCT05422976|DEVICE|EVI-01|High molecular weight Hyaluronic Acid
41118856|NCT04187664|DIAGNOSTIC_TEST|High-sensitivity cardiac troponin testing|High-risk patients will have their high-sensitivity cardiac troponin tested preoperatively and daily for the first 48h postoperatively
41118857|NCT01703923|DRUG|FP01|
41118858|NCT01703923|DRUG|placebo|
41118859|NCT02326987|DRUG|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
41118860|NCT02326987|DRUG|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
41118861|NCT05263609|DRUG|Axitinib|If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
41118862|NCT05263609|DRUG|Pembrolizumab|If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
41118863|NCT02621632|DEVICE|(Socknleg)To done of a novel compression system|To done a novel compression system.
41118864|NCT01112670|DRUG|Sitagliptin|sitagliptin 100 mg x 1 dose
41118865|NCT01112670|DRUG|atorvastatin|atorvastatin 40 mg x 5 doses
41118866|NCT01047241|DRUG|Intranasal sufentanil/ketamine|Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
41118867|NCT05973578|RADIATION|Stereotactic radiotherapy|Single-session high dose stereotactic radiotherapy
41118868|NCT04244214|OTHER|More Stamina|More Stamina is a gamified task organization tool designed to help persons with MS manage their energy, to minimize the impact of fatigue in their day to day life.
41271303|NCT06054217|DRUG|Vehicle of TP-03|The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
41271304|NCT06321692|OTHER|Evaluation of blood levels of biomarkers of cardiac damage|Evaluation of ultra-sensitive troponin I, BNP, NT-proBNP, and ST2 in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome
41271305|NCT03528525|OTHER||observation
41271306|NCT04574726|OTHER|static balance|30-second right and left unipodal static balance test
41271307|NCT04574726|OTHER|dynamic balance|"for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~* 180° elevation of the arms~* lowering of the arms on the side of the single-legged support to the horizontal position~* 180° horizontal translation of the arms~* return from the horizontal to the starting point"
41271308|NCT01055509|BEHAVIORAL|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
41271309|NCT01277640|DRUG|dapivirine|"* dosage form: gel 0.05%~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
41271310|NCT01277640|DRUG|matched placebo|"* dosage form: gel, no api~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
41271311|NCT01277640|DRUG|universal placebo|"* dosage form: gel, HEC-based~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
41118869|NCT04825028|DEVICE|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
41118870|NCT06417346|PROCEDURE|Laparoscopic TEP Repair|Laparoscopic TEP Repair performed
41118871|NCT06417346|PROCEDURE|Open Technique (Lichtenstein)|Open Technique (Lichtenstein) performed
41118872|NCT05653583|DEVICE|Wrist Device|peripheral nerve stimulation via wrist-worn device
41118873|NCT05653583|DEVICE|Ear Device|peripheral nerve stimulation via ear-worn device
41118874|NCT05653583|DEVICE|Sham Device|Wrist-worn device that does not actually deliver stimulation
41118875|NCT00879463|PROCEDURE|Brain tissue oxygen saturation monitoring|Brain tissue oxygen saturation monitoring with infrared spectrophotoscopy
41118876|NCT00879463|PROCEDURE|Transfusion according to the anesthesiologist's judgement|Transfusion if hemoglobin is between 5.5-7 mg/dl
41118877|NCT00000924|DRUG|Ritonavir|
41118878|NCT00000924|DRUG|Nelfinavir mesylate|
41118879|NCT00000924|DRUG|Nevirapine|
41118880|NCT00000924|DRUG|Stavudine|
41118881|NCT00000924|DRUG|Didanosine|
41118882|NCT03963336|DRUG|LMWH|Subcutaneous LMWH 1mg/kg/day for 2 weeks
41118883|NCT03963336|DRUG|acetazolamide|Carbonic anhydrase inhibitor 1-2g/day for 6 months
41271312|NCT04085887|DRUG|Panitumumab-IRDye800|Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).
41271313|NCT04085887|DEVICE|Pinpoint-IR9000 endoscopic/handheld device|"Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
41271314|NCT04085887|DEVICE|Explorer Air camera|"Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
41271315|NCT04085887|DEVICE|PDE-NEO-II|"Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
41271316|NCT04574843|PROCEDURE|Embolization of MMA|embolization of MMA with one of following liquid embolic agents (Onyx-Squid-Phil)
41271317|NCT04153084|DRUG|Polyethylene Glycol 4000 with electrolytes|The high volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
41271318|NCT04153084|DRUG|PEG-3350 with electrolytes|The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
41271319|NCT04153084|DRUG|Sodium picosulfate|"The Sodium picosulfate will be administered the day before the procedure at different doses depending on the patient´s age:~* From 1 to 2 years old: ¼ sachet reconstituted in ¼ glass of water/juice in the afternoon (15:00 h) and ¼ sachet reconstituted in ¼ glass of water/juice 6 hours later (21:00 h)~* From 2 to 4 years old: ½ sachet in ½ glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* From 4 to 9 years old: 1 sachet in 1 glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* Of 9 years old and older: 1 sachet in the afternoon and 1 sachet at night."
41118884|NCT05133375|PROCEDURE|Tracheal Intubation|Before reporting to Operation theatre, a detailed pre anesthesia assessment was done in all patients, all necessary laboratory investigations were collected. On OT table pulse and systolic blood pressure was checked by non-invasive method. 18G cannula was passed and ECG was attached. A pillow was placed under the head to obtain classical sniffing position for intubation. All the patients were pre medicated with injection midazolam 0.08mg/kg, injection nalbuphine 0.1 mg/kg, injection dexamethasone 0.08mg/kg and injection metoclopramide 0.1 mg/kg. Pre oxygenation was done with 100% oxygen for 3 mins. Induction was done with injection propofol2 mg/kg, muscle relaxation achieved with injection atracurium 0.5mg/kg. Laryngoscopy was started after 3 minutes by a qualified anesthetist. Pulse and systolic blood pressure was recorded by non-invasive measures before laryngoscopy and at 30 seconds, 2 and 3 minutes after intubation.
41118885|NCT00772044|DEVICE|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
41118886|NCT00772044|DEVICE|Sham Device|Sham device will be applied
41118887|NCT03110549|DRUG|TMB-607|
41118888|NCT03110549|DRUG|Placebo|
41118889|NCT05284136|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet (CDED)|16-week course of CDED+Partial Enteral Nutrition. During the first 6 weeks (phase 1 of CDED), patients will be prescribed the CDED and oral Modulen 1 liter (1000kcal) daily. Between week 6 and 16 (phase 2 of CDED), patients will be prescribed CDED and oral Modulen (500 mL).
41271320|NCT04698876|PROCEDURE|Self-tonometry by means of ICareHOME|Outpatient measurement of intraocular pressure at home
41271321|NCT04698876|PROCEDURE|Intraocular measurement by means of rebound tonometry or Goldmann applanation tonometry|Stationary measurement of intraocular pressure in a clinic
41271322|NCT04698876|PROCEDURE|Blood pressure|Blood pressure measurement for 24 h
41271323|NCT01413893|DRUG|linifanib|QD daily
41271324|NCT02421198|BEHAVIORAL|YMCA Family Diabetes Prevention Program (YFDPP)|12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
40753030|NCT02370693|DRUG|Bortezomib|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
40753031|NCT02370693|DRUG|Placebo|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
41118890|NCT05284136|DRUG|Oral prednisolone|oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
41118891|NCT02389777|BIOLOGICAL|ST266 immediate|ST266 will be applied immediately to the UV light burn wound topically by spray twice per day
41118892|NCT02389777|BIOLOGICAL|ST266 delayed|ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
41118893|NCT03675581|DRUG|Microgynon|fixed sequence trial
41118894|NCT03675581|DRUG|Nintedanib|fixed sequence trial
41271325|NCT02717156|PROCEDURE|Computed Tomography|Correlative studies
41271326|NCT02717156|OTHER|Laboratory Biomarker Analysis|Correlative studies
41271327|NCT02717156|BIOLOGICAL|Pembrolizumab|Given IV
41271328|NCT02717156|PROCEDURE|Positron Emission Tomography|Correlative studies
41271329|NCT02717156|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
41271330|NCT04000646|OTHER|standard care|standard care non-pharmacologic interventions during anesthesia induction
41271331|NCT04000646|OTHER|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
41118895|NCT04434677|RADIATION|Hypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
40753032|NCT02370693|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
41271332|NCT01145560|DRUG|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
41271333|NCT01145560|DRUG|Placebo|Placebo
40753033|NCT01784536|DRUG|Single-Dose IV Oritavancin Diphosphate|Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
40753034|NCT00365820|DRUG|Tegaserod|
40753035|NCT00374985|DRUG|Docetaxel, Oxaliplatin|weekly doses
40753036|NCT00374985|PROCEDURE|Radiotherapy|regular fractions
41118896|NCT04434677|RADIATION|ultraHypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
41118897|NCT05016830|DEVICE|Bilateral transcranial direct current stimulation|A direct current is applied with two electrodes (cathode and anode) in specific parts of the skull. In this case the anode was over the occipital area to target the amblyopic cortex, while the cathode was over the contralateral side, targeting the fellow cortex.
41118898|NCT05951309|DRUG|inofolic combi|The patients in this group were given inofolic combi once a day for 12-16 weeks
41118899|NCT05951309|DRUG|Glucophage 500Mg Tablet|The patients in this group were given glucophage three times a day for 12-16 weeks
41118900|NCT05582044|OTHER|Lower-body Negative Pressure (-25 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
41118901|NCT05582044|OTHER|Lower-body Negative Pressure (-15 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.
41118902|NCT05582044|OTHER|Lower-body Neutral Pressure (0 mmHg)|In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
41118903|NCT06001190|DIETARY_SUPPLEMENT|probiotic:Lactobacillus crispatus|We seek to observe that probiotic supplement(arm A) can improve vagina microbiome distribution by comapred to placebo group(arm B) in our study.
41118904|NCT05820269|BEHAVIORAL|parents-child psychotherapy|filling out questionnaires during psychotherapy consultations
41118905|NCT03876249|OTHER|exposure to RSV|No intervention will be given, children naturally exposed to RSV in their early life
41118906|NCT00744224|DRUG|Placebo|Single dose of placebo with saline infusion
41118907|NCT00744224|DRUG|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
41118908|NCT00744224|DRUG|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
41118909|NCT03242148|DEVICE|Toffee Nasal Pillows Mask|Participants will be placed on this intervention for a total 14 ± 5 days from Visit 2. Participants will be using the Toffee nasal pillows mask during this treatment arm.
41118910|NCT05731999|DEVICE|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
41118911|NCT05543057|RADIATION|3DCRT|Three-dimensional conformal radiotherapy (3DCRT)
41118912|NCT03107806|DEVICE|OptiScanner®|"1. Glucose monitoring by OptiScanner® for 48 h~2. Glucose lowering intervention (insulin) guided by OptiScanner®"
41118913|NCT01197807|PROCEDURE|Bulb Suctioning|Bulb suctioning of the mouth then the nose immediately following delivery
41118914|NCT01197807|PROCEDURE|Wiping|Gentle wiping of mouth then nose with a soft cloth immediately following delivery
41118915|NCT00634621|DRUG|Hexaminolevulinate (Hexvix)|Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
41118916|NCT00130546|DEVICE|Paclitaxel-eluting TAXUS(TM)|TAXUS(TM) Paclitaxel-eluting stent
41118917|NCT00130546|DEVICE|Sirolimus eluting Cypher Select(TM)|Sirolimus eluting Cypher Select(TM) stent
41118918|NCT01470040|DRUG|discontinuation of aspirin therapy|discontinuation of aspirin therapy
41118919|NCT01470040|DRUG|continuation of aspirin therapy|continuation of pre-injury low dose aspirin therapy as per previous medical indication
41118920|NCT05157022|DEVICE|ESWT|Extracorporeal Shock-wave Therapy
41118921|NCT03667911|OTHER|virtual reality videos|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
41271334|NCT02104063|PROCEDURE|MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
41271335|NCT06003062|DRUG|Narcissus Tazetta Bulb Extract and Novel Hemp Extract|Topical nightly application of phytonutraceutical
41271336|NCT01676038|PROCEDURE|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
41271337|NCT01676038|PROCEDURE|Conventional Total Knee Arthroplasty|Conventional technique.
40753037|NCT05243316|PROCEDURE|Clamping|There will be a randomized selection of patients who will have a clamping of the chest tube 6 hours prior to chest tube removal.
40753038|NCT05243316|PROCEDURE|Non Clampling|There will be a randomized selection of patients who wont have chest tube clamping 6 hours prior to chest tube removal.
41271338|NCT04970329|DRUG|Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,|Drugs will be given to two group and third group will kept on placebo.
41118922|NCT00803387|DRUG|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
41118923|NCT02304055|DRUG|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
41118924|NCT02304055|DRUG|Oxytocin|100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
41118925|NCT04761146|RADIATION|DaRT Diffusing Alpha-emitters Radiation Therapy|DaRT is a brachytherapy treatment comprising stainless-steel 316LVM wires coated with radium-224 (Alpha DaRT seeds). The radioactive seeds are inserted directly into the tumour on the perineum and will be removed after 14 days.
41118926|NCT03836378|PROCEDURE|BioXclude™|The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
41118927|NCT00215397|DRUG|Formoterol Fumarate|
41118928|NCT03086863|DEVICE|electroacupuncture|All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
41118929|NCT03086863|DEVICE|sham electroacupuncture|We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
41118930|NCT01542229|BEHAVIORAL|Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU)|12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual
41118931|NCT01542229|BEHAVIORAL|Treatment As Usual (TAU)|Treatment as usual (TAU) will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
41118932|NCT06445257|DRUG|zanubrutinib 160 mg BID orally|The ZRMT induction and maintenance regimen
41118933|NCT01668940|OTHER|Lillipops Iced Soothies (4 flavours)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
41271339|NCT00978302|DRUG|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
41118934|NCT01668940|OTHER|Mr. Freeze Freezies|There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
41271340|NCT00978302|DRUG|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
41271341|NCT00978302|DRUG|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
41271342|NCT00978302|DRUG|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
41271343|NCT00978302|DRUG|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
41271344|NCT00978302|DRUG|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
41446361|NCT05383911|BEHAVIORAL|SCD Shared Decision-Making Toolkit for AYAs - including VR|The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including virtual reality, online (videos, animations, articles), and print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
41271345|NCT00978302|DRUG|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
41271346|NCT00507325|PROCEDURE|Blood Sample|Blood samples will be collected.
41271347|NCT00507325|PROCEDURE|Tumor Sample|Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
40753039|NCT02277860|BEHAVIORAL|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
41118935|NCT01668940|OTHER|Lillipop Iced Soothies (Ginger flavour)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
41118936|NCT01426295|DEVICE|Caphosol|"The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)~The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.~Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.~The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC\> 500/mm3), and / or mucositis grade 0."
41118937|NCT01426295|DRUG|Bicarbonate de sodium|"Treatment of the early start on the day of conditioning and stop when the ANC\> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.~Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®."
41118938|NCT02743195|DIETARY_SUPPLEMENT|Polyphenol/prebiotic blend|
41118939|NCT02722473|BIOLOGICAL|"NSE dosage hypothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.
41118940|NCT02722473|BIOLOGICAL|"NSE dosage normothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
41118941|NCT03279861|DRUG|Entresto|First line therapy in Entresto arm
41118942|NCT03279861|DRUG|Valsartan|"First line therapy in usual meds arm"
41118943|NCT05993507|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, scalable intervention that is developed by World Health Organization for communities exposed to adversity. PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session 5. Facilitators will receive weekly supervisions by PM+ supervisors.
41118944|NCT05303415|OTHER|Neuromodulation with low-intensity focused ultrasound|Application of LIFU to induce temporary neuromodulation, effects tested with resting state and heat evoked (QST) fMRI signals
41118945|NCT05048914|DRUG|Ibuprofen|treatment of acute migraine attack
41118946|NCT06103149|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
41118947|NCT05081999|OTHER|Medical Assessment|medical hx, events inquiry, adherence to treatment arm periodically over 4 years
41118948|NCT05081999|OTHER|Quality of Life Assessment|online questionnaires periodically over 4 years, including SAQ, EQ-5D-5L, IIEF-5 (males) or FSFI (females)
41118949|NCT04206098|OTHER|Factors associated with Hospital admission for an Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)|Develop a descriptive predictive model fo factors that influence clinical characteristic of patients that require hospital admission
41118950|NCT04348617|OTHER|Moderate exercise|50 minutes of moderate exercise on treadmill
41118951|NCT04348617|OTHER|Rest|50 minutes of rest or sedentary activity
41118952|NCT05424796|COMBINATION_PRODUCT|Physiological saline|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, hemostasis was achieved by checking the saline soaked cotton pellet.
41118953|NCT05424796|COMBINATION_PRODUCT|Hemostasis and cavity disinfection with NaOCl|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices.
41118954|NCT05424796|DEVICE|Hemostasis and cavity disinfection with KTP laser|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy).
41118955|NCT01024881|PROCEDURE|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
40753040|NCT05202431|BEHAVIORAL|Treatment adherence|The patients were reminded to take drug by patient training, telephone follow-up, and daily sms. It was determined that the effect of the training and telephone follow-up provided to the TB patients and contacts on the treatment adherence.
40926288|NCT01510288|DRUG|GVAX and ipilimumab|All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
41118956|NCT01024881|PROCEDURE|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
40926289|NCT03234881|BEHAVIORAL|MOVE!|Participants randomized to the MOVE!(or TeleMOVE!) arm only. MOVE! is 16 weeks of 60-minute weekly groups that are led by a physical therapist, dietician, and/or clinical health psychologist. Clinicians utilize materials available online and encourage the use, but do not require or provide food diaries. TeleMOVE! is a 90-day program utilizing technology to provide home-based messaging focusing on health education and as needed clinician contact. \*TeleMOVE! was added as an option since many in-person MOVE! programs were on pause due to the pandemic.
41118957|NCT00184041|DRUG|Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine|Induction I/II, consolidation I/II/III/IV and Maintenance
41118958|NCT06307223|DRUG|30% supramolecular salicylic acid|The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.
41271348|NCT04240587|DEVICE|TrueTear™ intranasal neurostimulator (ITN)|"The ITN delivers small electrical currents to the inner cavity of the nose, gently activating nerves that stimulate the body's natural tear production system. Those in the ITN active arm will receive the active tips which contain the current from the base to the nasociliary nerve. Those in the ITN sham arm will receive tips without the current."
41271349|NCT02319369|DRUG|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg
41118959|NCT06307223|DRUG|supramolecular active zinc|The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.
41118960|NCT00610649|DRUG|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
41118961|NCT00610649|DRUG|Placebo|Orally administered matching placebo capsules.
41118962|NCT02947958|OTHER|Teleconsultation|Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
41118963|NCT02947958|OTHER|Hospital (control)|The patient will keep his usual care at the tertiary care.
41271350|NCT02319369|DRUG|AZA|AZA will be administered at 75 mg/m\^2 subcutaneously or intravenously
41446362|NCT05383911|BEHAVIORAL|SCD Shared Decision-Making Toolkit for AYAs - without VR|The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including online videos, animations, and articles as well as print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
41118964|NCT03990649|DRUG|Soticlestat|Soticlestat tablets
41118965|NCT03990649|DRUG|Placebo|Soticlestat matching placebo tablets
41271351|NCT02319369|DRUG|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 mg, 80 mg, and/or 100 mg milademetan may be utilized.
41271352|NCT00728429|BEHAVIORAL|exercise intervention|24 week program of exercise
41271353|NCT06393283|BEHAVIORAL|Diaphragm Training|Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
41271354|NCT05844917|DEVICE|ultrasound|Ultrasound detection of subclinical arthritis among Patients With SLE
41271355|NCT00559091|DRUG|ribavirin|Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
41271356|NCT04480151|OTHER|standard of care|retrospective study: standard of care
41271357|NCT02495337|OTHER|Tissue Collection|
41271358|NCT05447702|DRUG|Camrelizumab|Intravenous (IV) infusion
41271359|NCT05447702|DRUG|Apatinib|po.
41271360|NCT05447702|DRUG|Nab-paclitaxel|IV infusion.
41271361|NCT05447702|DRUG|Epirubicin|IV infusion.
41118966|NCT05640869|BEHAVIORAL|Modified Diabetes Prevention Program Curriculum|The modified DPP curriculum will be an exact copy of the current DPP curriculum except that references to the prevention of diabetes will be modified to prevention of health outcomes associated with overweight/obesity and/or management of overweight/obesity.
41118967|NCT04960098|PROCEDURE|arthroplasty|patient with hip and knee osteoarthritis underwent hip and knee arthroplasty
41118968|NCT04421261|DEVICE|Air-Q Self Pressurized Airway Device with Blocker|used in low risk adult females undergoing elective surgeries
41118969|NCT04421261|DEVICE|Proseal Laryngeal Mask Airway|used in low risk adult female patients undergoing elective surgeries
41118970|NCT02162446|DRUG|satoreotide trizoxetan|
41446363|NCT04703504|OTHER|Multiple intervention program|Support for patient follow-up assisted by a computer program
41118971|NCT00125645|DRUG|Irbesartan Oral Tablet|
41118972|NCT03817476|DRUG|BI 425809 (Treatment T1)|Intended commercial formulation tablet from batch 1 (iCF1)
41118973|NCT03817476|DRUG|BI 425809 (Treatment T2)|Intended commercial formulation tablet from batch 2 (iCF2)
41118974|NCT03817476|DRUG|BI 425809 (Treatment R)|Trial formulation 2 tablet (TF2)
41118975|NCT01875250|BIOLOGICAL|PROSTVAC-F (Fowlpox)/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
41271362|NCT05447702|DRUG|Cyclophosphamide|IV infusion.
41271363|NCT06544109|DRUG|venetoclax|patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax
41118976|NCT01875250|BIOLOGICAL|PROSTVAC-V (Vaccinia)/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
41271364|NCT01264939|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
41271365|NCT01264939|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
41271366|NCT01264939|DRUG|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
41271367|NCT01264939|DRUG|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
41271368|NCT02928952|BEHAVIORAL|Mind-STRIDE|Mindful Stress Reduction in Diabetes Education- mindfulness training with home practice will be introduced as part of diabetes education
41271369|NCT02543242|DEVICE|InToneTM (InControl Medical, LLC) - Medical Device|
41118977|NCT01875250|DRUG|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
41118978|NCT02575560|OTHER|history data|history data of PFS after 1st line or second line theray
41271370|NCT01956006|DRUG|Milrinone|Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
41271371|NCT05258461|OTHER|use of a smartphone app for adverse event management|At their enrollment, patients will receive detailed introduction and adequate assistance on the use of the smartphone app. The smartphone app will offer proper advice for adverse event management based on calculated results by artificial intelligence on the innovative app, which was developed by YL et al. It was specifically intended for risk prediction, early prevention, as well as management of symptoms and concerns during adjuvant chemotherapy in the treatment of breast cancer. The app consisted of 4 modules: (1) Module 1: clinical data collection. (2) Module 2: risk evaluation for 12 common adverse events during breast cancer chemotherapy. (3) Module 3: personalized prophylaxis based on predicted risks of adverse events. (4) Module 4: Q\&A platform.
41271372|NCT05258461|OTHER|conventional adverse event management|Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience. For example, colony-stimulating factors and antibiotics may be used for febrile neutropenia, loperamide (or diphenoxylate plus atropine) as prophylaxis for diarrhea, together with eating low-lactose and low-fat frequent small meals. 5-hydroxytryptamine 3 receptor antagonist, neurokinin 1 receptor antagonist, and/or dexamethasone would be prescribed for patients at high risks of vomiting.
40753041|NCT02659228|DEVICE|EEG recording|EEG recording with anesthetic (DIPRIVAN)
40753042|NCT02659228|DRUG|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
41118979|NCT06012071|DEVICE|Zirconia dental implants|Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.
41118980|NCT00821184|DRUG|Vesicare (solifenacin)|5mg po qd
41118981|NCT00821184|BEHAVIORAL|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
41271373|NCT06488300|DRUG|Ribavirin|"Oral ribavirin 400 to 1000mg three times a day for 5 days. Each tablet contains 200mg, The total daily dosage in adults is weight dependent as outlined below;~* 40-59.9kg = 1200mg/day~* 60-79.9kg = 1800mg/day~* 80-99.9kg = 2400mg/day~* ≥100kg = 3000mg/day"
41271374|NCT06488300|DRUG|Molnupiravir|Oral molnupiravir 800mg BD for 5 days
41271375|NCT06488300|DRUG|Favipiravir|Oral favipiravir 1800mg BD on Day 0, and 800mg BD for a further 4 days
41271376|NCT04890873|DRUG|ERX1000|ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension
41271377|NCT04890873|DRUG|Placebo|A suspension containing magnesium hydroxide carbonate in polysorbate
41118982|NCT00686504|DRUG|AZD2066|single dose of oral dose, 3 times per subject
41118983|NCT00686504|DRUG|radioligand [11C] AZ12713580|single dose of iv administered 4 times per subject (3 times together with AZD2066)
41118984|NCT02904642|BEHAVIORAL|SMS reminder|Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age
41118985|NCT02904642|BEHAVIORAL|Unconditional Incentive|A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
41118986|NCT04521530|OTHER|immediate functional implant loading|Patients will undergo implant placement and a minimum of 35 Ncm reading with the graded torque wrench. Temporary crowns in functional occlusion were cemented.
41118987|NCT04521530|OTHER|immediate non functional implant loading|implant will be placed into the site following the manufacturer's protocol making sure to have a minimum of 35 Newton centimeter reading with the degraded torque wrench. Non-functional temporary crowns were cemented.
41271378|NCT03580330|OTHER|mHealth intervention|Individual in the intervention group receive a weekly educational health SMS for the intervention period of 1 year. SMS content covered different health themes providing health information on lifestyle, dietary habits, body weight, smoking, medications, importance of compliance, as well as symptoms and self-management of HTN and diabetes. Community individuals who were diagnosed and were receiving necessary care previous to the investigator's intervention were sent weekly informative health SMS, as well as customized SMSs reminders to follow up on their scheduled medical appointments (eg, to check their HbA1c levels and have their annual foot or eye exams).
41271379|NCT01499290|DRUG|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
41271380|NCT01499290|DRUG|Metronidazole|500 mg of Metronidazole
41271381|NCT01499290|DRUG|Meropenem|1 gram of Meropenem
41118988|NCT01993160|DRUG|Fluorocholine (18F-FCH) Injection|Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
41118989|NCT01993160|RADIATION|PET scan|A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
41118990|NCT01993160|RADIATION|Whole body MRI|A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
41118991|NCT00648726|DRUG|cefuroxime plus erythromycin|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
41118992|NCT00648726|DRUG|azithromycin (Zithromax)|intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
41118993|NCT00648726|DRUG|cefuroxime|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
41118994|NCT01628419|BEHAVIORAL|Health intervention|"physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.~Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects."
41118995|NCT05583253|PROCEDURE|Vitrectomy|Small gauge pars-plana vitrectomy for management of retinal detachment.
41118996|NCT00818454|DRUG|Combivent CFC MDI|
41271382|NCT01577862|DRUG|Colistin|2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
41271383|NCT01577862|DRUG|Rifampicin|600 mg every 12 hours intravenously
41118997|NCT00818454|DRUG|Albuterol HFA MDI|
41118998|NCT00818454|DRUG|Respimat Combivent|
41271384|NCT06290440|OTHER|Telepharmacy-led counselling|The counselling process will be delivered as follows: (1) researchers assist patients in signing up and using the telepharmacy application; (2) researchers send the counselling information from the telepharmacy application to the patient's account (the information will be provided as leaflets and 3-5-minute videos to improve the accessibility); (3) the integrated chatbot system forwards any additional questions or concerns of the patients to the counselling pharmacists; and (4) the pharmacists directly address the patient's questions or concerns through phone calls within the shortest possible timeframe.
40753043|NCT00384150|DRUG|galiximab in combination with rituximab|galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.
40753044|NCT00492674|DEVICE|APOS biomechanical gait system|
40753045|NCT00492674|PROCEDURE|Physical Therapy|
41118999|NCT06092697|OTHER|3D printed PEEK restorations|Indirect dental restoration
41119000|NCT05344924|DRUG|TACE+penpulimab+anlotinib vs. penpulimab+anlotinib|Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
41119001|NCT06033118|DRUG|gemcitabine ,oxaliplatin,anlotinib,Sintilimab|Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
41271385|NCT06290440|OTHER|Pharmacist-led counselling|Pharmacists will counsel the patients on how to use their OAC. Each counselling section will take approximately 7-15 minutes, depending on the patient's questions or concerns. The counselling contents have already been compiled and validated by NDGD Hospital to ensure rationale and simplicity for every patient. Counselling pharmacists have received specialised training in drug information and patient communication so intervention delivery will be consistent across different pharmacists.
41271386|NCT00768222|DEVICE|silk suture|skin closure
41271387|NCT00768222|DEVICE|VICRYL* Plus suture|skin closure
41271388|NCT04550026|OTHER|HTP inhalation|Sham inhalation for 30 minutes
41271389|NCT06129890|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - M1/DLPFC|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of M1 then rTMS of DLPFC.
41271390|NCT06129890|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - DLPFC/M1|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of DLPFC then rTMS of M1.
41271391|NCT02119520|DRUG|Platelet rich fibrin +Atorvastatin|
41271392|NCT02119520|DRUG|Platelet rich fibrin|
41271393|NCT02119520|PROCEDURE|open flap debridement|
41271394|NCT04825548|OTHER|No intervention|Examination of patients with previous DVT
41271395|NCT02031094|OTHER|Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure|Observational methods of measuring resting energy expenditure
41119002|NCT04750044|OTHER|early refeeding|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
41119003|NCT04750044|OTHER|delayed refeeding|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
41119004|NCT03743506|DIAGNOSTIC_TEST|With feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.
41119005|NCT03743506|DIAGNOSTIC_TEST|Without feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
41119006|NCT05948644|DRUG|TPN171H|TPN171H 2.5mg TPN171H 5mg TPN171H 10mg
41119007|NCT04723394|DRUG|AZD7442|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
41271396|NCT05462184|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
41271397|NCT05462184|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|
41271398|NCT05330026|COMBINATION_PRODUCT|Diaphragm´s study during yoga breathing|Study and compare the activation of the diaphragm during different breaths: rest, ujjayi and pursed lips
41271399|NCT03931655|DIAGNOSTIC_TEST|Spectroscopic photoacoustic imaging|Spectroscopic photoacoustic imaging uses a laser that is pulsed for a nanosecond, applying laser light to the patient's skin. Hemoglobin and melanin absorb the laser's energy and convert it to heat, which rapidly expands local tissue and produces a broadband ultrasound wave and is detected with a clinical ultrasound transducer. Because the signal is proportional to the optical absorption in tissue, high resolution images of the lymph nodes can be acquired from the detected ultrasound waves, and can be used to measure saturated oxygen in the nodes.
41271400|NCT03732547|DRUG|PD-1 mAb|Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.
41271401|NCT03732547|DRUG|PolyIC|Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
40753046|NCT05528666|OTHER|High Efficacy Therapy (HET)|HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.
41119008|NCT04723394|DRUG|Placebo|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
41271402|NCT01621932|PROCEDURE|Direct anterior approach with capsulectomy|Direct anterior approach with capsulectomy
41271403|NCT01621932|PROCEDURE|Direct anterior approach without capsulectomy|Direct anterior approach without capsulectomy
41271404|NCT05563493|OTHER|Treatment group, Chair-Based Exercise Training|"The weights of the elastic bands to be used in the exercises will be determined by the physiotherapist according to the abilities and development of the participants.~The intensity of the exercise will be adjusted according to the dyspnea or fatigue patients feel according to the Modified Borg Scale.~During the exercises, heart rate and oxygen saturation will be measured with a pulse oximeter, and blood pressure will be measured with a sphygmomanometer.~Chair-based exercise training will be applied to the patients every day they are hospitalized."
41271405|NCT05563493|OTHER|Control group, Breathing exercise|Breathing exercise will be applied to the patients every day they are hospitalized.
41119009|NCT05678023|OTHER|Effect on contrast media depending on the time of its administratsion|CM is a common practice when it comes to the management of small bowel obstruction. However there is no consensus as when it should be administered
41271406|NCT00538642|DRUG|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
41271407|NCT01986530|DIETARY_SUPPLEMENT|Boost|After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion
40753047|NCT05528666|OTHER|Non High Efficacy Therapy (Non-HET)|Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
40926290|NCT03234881|BEHAVIORAL|MOVE!+CBT|Participants randomized to the MOVE!+CBT arm will attend the 16 weeks of 60-minute weekly MOVE! or 90-days of the TeleMOVE! Treatment groups, along with up to 10 clinician-led individual sessions over a 3-month period. Participants will also be given a patient treatment manual to read at home, food diaries that will be expected to be completed on a daily basis, and gradually increase daily physical activity.
40926291|NCT00473122|PROCEDURE|Delayed-Immediate Breast Reconstruction|Immediate reconstruction surgery if no XRT required; or reconstruction surgery delayed until XRT complete.
41119010|NCT00376363|DEVICE|Ahmed implant|placement of glaucoma drainage device to control intraocular pressure
41119011|NCT00376363|DEVICE|Baerveldt implant|placement of glaucoma drainage device to control intraocular press
41119012|NCT06379711|DEVICE|Transcutaneous Spinal Cord Stimulation (tSCS)|Transcutaneous spinal cord stimulation (tSCS) will be delivered via a non-invasive central nervous system stimulator TESCoN or SCONE (SpineX Inc., CA - experimental type II medical devices) through self-adhesive electrode(s) placed on the skin between spinous processes over the midline of the vertebral column as the cathode(s) and two rectangular electrodes placed symmetrically on the skin over the iliac crests as anodes. Stimulation will be applied at various waveforms and frequencies (ranging between 1Hz and 90Hz) with and without a carrier frequency. Current amplitude will start at 10mA and proceed incrementally until tolerable or responses plateau. If spasticity occurs or is uncomfortable, the current will be decreased. Specific areas for electrode placement will be examined and prepared to reduce skin impedance. tSCS will be delivered under the supervision of a physician (Dr. Krassioukov/Dr. Berger) by trained doctoral/post-doctoral trainees.
41119013|NCT06320912|DEVICE|The intraparenchymal portal vein covered stent|The intraparenchymal portal vein covered stent, produced by Shanghai Shenqi Medical Technology Co., Ltd., is used for a transjugular approach. It establishes an artificial shunt between the hepatic vein and the main branches of the portal vein within the liver. This helps in reducing portal venous pressure and alleviating or improving the symptoms of portal hypertension and its complications, such as variceal bleeding, gastropathy, refractory ascites, and/or hepatic hydrothorax.
41119014|NCT06320912|DEVICE|TIPS Covered Stent System GORE|The GORE® VIATORR® Transjugular Intrahepatic Portosystemic Shunt (TIPS) Covered Stent consists of an implantable covered stent and a percutaneous delivery catheter.
41119015|NCT02685189|OTHER|Previous exposure to stannsoporfin|No intervention in this protocol
41119016|NCT06218303|BIOLOGICAL|MUC1 Peptide Vaccine|MUC1, a therapeutic vaccine, is a transmembrane glycoprotein and a member of the mucin family of molecules.
41119017|NCT06218303|DRUG|Hiltonol®|A synthetic dsRNA viral mimic and host-defense activator, mimics nature by combining the essential elements of human immunity.
41119018|NCT06218303|DRUG|Aromatase Inhibitor|A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
41119019|NCT02759016|DRUG|BI 836826|
41119020|NCT02759016|DRUG|Ibrutinib|Standard of Care
41119021|NCT02178098|DRUG|ETC-1002|ETC-1002 capsules taken once daily
41119022|NCT02178098|DRUG|Placebo|Placebo capsules taken once daily
40753048|NCT06354842|DIAGNOSTIC_TEST|pilocarpine iontopheresis|Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry
40753049|NCT05822271|PROCEDURE|Orthognathic Surgery|Type of surgery performed to correct skeletal malocclusions
40753050|NCT03724227|DRUG|ACE-011|ACE-011 will be administered subcutaneous injection
40926292|NCT01634256|DIETARY_SUPPLEMENT|Placebo|Placebo(3.0g/day)
40926293|NCT01634256|DIETARY_SUPPLEMENT|Fermented turmeric|Fermented turmeric(3.0g/day)
40753051|NCT02758080|OTHER|Matching on the basis of molecular analysis|
40753052|NCT02758080|OTHER|Matching on the basis of physician's choice|
40926294|NCT03923803|DIAGNOSTIC_TEST|C- reactive protein|the measurement will be done by chemileumeniscence
40926295|NCT03923803|DIAGNOSTIC_TEST|Pro calcitonin|the measurement will be done by chemileumeniscence
40926296|NCT04883723|DEVICE|Shotblocker|Shotblocker is a small, flat, horseshoe-shaped plastic tool that can be used to reduce pain due to intramuscular injection, suitable for all age groups, without drug properties. It is used by keeping it on the skin surface during injection and has no side effects. Shotblocker has short, non-pointed blunt protrusions on one side that connect with the skin, there is a hole in the middle of the vehicle to expose the injection site. The protruding surface of the vehicle is placed in the area to be applied just before injection. The protrusions on the surface of the Shotblocker do not pierce the skin and provide a warning for the Door Control Theory, which is thought to exist regarding pain
41119023|NCT02568644|DIETARY_SUPPLEMENT|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols).
41119024|NCT02568644|OTHER|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
41119025|NCT02568644|DRUG|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
41119026|NCT03778645|PROCEDURE|Adrenal Venous Sampling|Adrenal Venous Sampling via an Antecubital Approach
41119027|NCT03032224|PROCEDURE|Resection of the esophagus and the gastroesophageal junction|
41119028|NCT02444416|PROCEDURE|blood sample|
41119029|NCT00392054|PROCEDURE|Pulmonary Vein Isolation performed by Catheter Ablation|Ablation will be done to achieve entrance block into all pulmonary veins.
41119030|NCT00392054|DRUG|Conventional Antiarrhythmic Drug Therapy|Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
41119031|NCT00006505|DRUG|Islet Transplantation|Islet cell transplantation. This study will test whether a new islet transplant procedure will enable patients with type 1 diabetes mellitus to stop insulin therapy
41119032|NCT04853706|DIAGNOSTIC_TEST|3d cam|The 3D-CAM is a short interview that uses verbal responses and allows completion of the Confusion Assessment Method (CAM) diagnostic algorithm
41119033|NCT04853706|DIAGNOSTIC_TEST|DSM 5|The DSM-5 is the gold standard for diagnosing delirium. But proper use requires professional psychiatric background and training.
41271408|NCT01986530|OTHER|Aerobic exercise|After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise
41271409|NCT02252367|DRUG|Tadalafil|Tadalafil 5 mg once daily for 12 weeks.
41271410|NCT02252367|OTHER|Placebo|Placebo tablet once daily for 12 weeks.
41271411|NCT01642212|DRUG|Oral Budesonide Suspension (MB-9)|OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
41271412|NCT01642212|DRUG|Placebo|
41271413|NCT03931018|OTHER|Alcohol|Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.
41271414|NCT06055166|DRUG|Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))|Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles
41271415|NCT00806221|DRUG|emollient (Cetaphil cream)|Cetaphil cream applied daily from birth
41271416|NCT00650611|DRUG|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
41271417|NCT00650611|DRUG|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
41271418|NCT03759158|DRUG|N-Acetyl Cysteine|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
41119034|NCT05628792|DIAGNOSTIC_TEST|CT|Ultra High Resolution CT scan
41119035|NCT01387906|DRUG|topical bimatoprost|topical bimatoprost will be applied one drop to each eyebrow each night.
41119036|NCT01251224|OTHER|Integrated Pest Management|The IPM intervention will include professional mouse abatement, two HEPA filters, targeted cleaning, education about IPM, and allergen-proof mattress and pillow encasements. The intervention will be delivered at baseline to the IPM Group, and then repeated if recurrent or persistent mouse infestation is present.
41119037|NCT01251224|OTHER|Education|This group will receive education about mouse IPM.
41271419|NCT03759158|DRUG|Placebo Oral Tablet|Placebo Oral Tablet twice daily.
41271420|NCT02272192|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is a comprehensive developmental and behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures based in applied behavioral analysis to deliver this content. The teaching format focuses on trained therapists delivering the intervention 1:1 by engaging reciprocally with children in typical toddler activities involving play or daily routines, adding additional structure for children who need it to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches.
41119038|NCT06513117|BEHAVIORAL|Behaviour change|healthy conversations to support behaviour change
41271421|NCT02272192|BEHAVIORAL|Early Intensive Behavioral Intervention (EIBI)|EIBI is a one-to-one instructional approach based in applied behavior analysis used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Trial by trial data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
41119039|NCT06513117|BEHAVIORAL|Dietary support|Guidance on healthy eating
41119040|NCT06513117|BEHAVIORAL|Breathing pattern retraining|guidance on breathing pattern in exercise
41119041|NCT06513117|BEHAVIORAL|Exercise training|Exercise intervention prescribed to participant fitness level
41271422|NCT04416022|DIAGNOSTIC_TEST|Ultrasound examination|Women that are planned for labour induction, will undergo a routine ultrasound examination prior to the initiation of the induction process.
41271423|NCT06353672|DEVICE|Robotic liver resection|Liver resection using Da Vinci robotic system
41119042|NCT01084031|DRUG|propofol|intravenous propofol with sevoflurane inhalation induction
40753053|NCT01573793|BEHAVIORAL|Parenting Education|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
40753054|NCT01573793|BEHAVIORAL|Control Group - Safety Materials|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
41119043|NCT03751449|OTHER|Educational Intervention|Receive nutrition education
41119044|NCT03751449|BEHAVIORAL|Exercise Intervention|Complete home-based aerobic and resistance exercise program
41119045|NCT03751449|OTHER|Quality-of-Life Assessment|Ancillary studies
41119046|NCT03751449|OTHER|Questionnaire Administration|Ancillary studies
41119047|NCT02489617|OTHER|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
41119048|NCT04542733|DRUG|Everolimus|Everolimus will be given with tacrolimus.
41119049|NCT04542733|DRUG|reduced dose tacrolimus|Reduced dose tacrolimus will be given with or without leflunomide
41119050|NCT04165967|DRUG|Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2|"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.~Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing). Actual body weight will be used in calculating the dose of interleukin-2.~Starting Day 14: Nivolumab application 240 mg i.v. over 30 minutes ever 2 weeks with a maximum to 2 years, or until disease progression or inacceptable toxicity."
41271424|NCT03893045|DRUG|ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution
41271425|NCT03893045|DRUG|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
41271426|NCT05962008|DIETARY_SUPPLEMENT|DHAPS® product|Take 4 capsules per day after breakfast with warm water.
41271427|NCT05962008|DIETARY_SUPPLEMENT|BioPS® product|Take 4 capsules per day after breakfast with warm water.
41271428|NCT05962008|DIETARY_SUPPLEMENT|Placebo|Take 4 capsules per day after breakfast with warm water.
41271429|NCT03443167|BEHAVIORAL|Training on emergency telephone numbers and mnemonics|"The intervention will consist in carrying out an initial theoretical training on how to act in case of attending an emergency, with graphic support of slides (power-point) during 5 minutes, followed by a practical part with the projection of the video of a song and with a role play activity for 15 minutes, to remember the helpline number for emergencies (112) and relate it to the mnemonic mouth-nose-eyes. At the beginning and at the end of the theoretical-practical activity, the evaluation questionnaires will be administered to each one of the students."
41271430|NCT03443167|BEHAVIORAL|Sham generic formation on the cardiopulmonary arrest.|The sham intervention for the control group will consist in providing a generic formation on the cardiopulmonary arrest, with graphic support of slides (power-point) during 10 minutes, without specifying the telephone number of assistance for emergencies or the mnemonics mouth-nose-eyes. At the beginning and at the end of the theoretical activity, the evaluation questionnaires will be administered to each one of the students.
41271431|NCT00898547|OTHER|immunoenzyme technique|
41119051|NCT00269789|DRUG|Ritalin|
40926297|NCT04883723|OTHER|Manual Pressure|The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated. There are many studies in the literature that prove the effectiveness of this method.
41271432|NCT00898547|OTHER|laboratory biomarker analysis|
41271433|NCT02204904|GENETIC|Allo-HSCT|Allogeneic Hematopoietic Stem Cell Transplantation
41271434|NCT06030934|DRUG|envafolimab and lenvatinib combined with paclitaxel-albumin|envafolimab: 200mg d1,15 s.c. Q4W; lenvatinib: 8mg (\<60kg) or 12mg (≥60kg) p.o. Q.d.; paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
41271435|NCT05543590|DRUG|Plasmapheresis|5 sessions of plasma exchanges
41119052|NCT00269789|DRUG|OROS Methylphenidate HCl|
41119053|NCT00269789|DRUG|Placebo|
41119054|NCT01130467|DRUG|methylphenidate|IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
41119055|NCT01130467|DRUG|Atomoxetine|Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
41119056|NCT01130467|BEHAVIORAL|behavioral modification|Parenting and teaching skill education
41119057|NCT06397144|DRUG|Paxlovid|Reference 1
41119058|NCT06397144|DRUG|Paxlovid|Reference 2
41271436|NCT05543590|OTHER|Blood collection|Blood collection to assess biological markers at baseline, M3 and M12
41271437|NCT05543590|OTHER|Stool samples|Stool samples will be collected from participants at baseline,M3 and M12
41271438|NCT05543590|OTHER|PET scan|PET scan at baseline and M6
41271439|NCT05543590|OTHER|Cycle ergometer stress test|Cycle ergometer stress test at M6
40753055|NCT00325585|BEHAVIORAL|Couples HIV counseling and testing|
40753056|NCT00325585|BEHAVIORAL|Women's relationship-focused HIV counseling and testing|
41119059|NCT06397144|DRUG|Nirmatrelvir/ritonavir|Test 1
41119060|NCT06397144|DRUG|Nirmatrelvir/ritonavir|Test 2
41271440|NCT05543590|OTHER|Questionnaires at baseline|Questionnaires at baseline, M3 and M6
41271441|NCT05543590|OTHER|Medical consultations|Medical consultations
41271442|NCT00624234|BEHAVIORAL|Tutoring Program I|Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
40753057|NCT04116697|OTHER|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.
41119061|NCT05350475|RADIATION|Proton therapy|Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.
41271443|NCT00624234|BEHAVIORAL|Tutoring Program II|Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
41271444|NCT05760716|OTHER|practicing prone position|Wash your hands. Prepare the materials. Before starting the procedure, inform the patient and explain the procedure. Ensure patient privacy. Raise the guardrail opposite the work area. Take the proper posture. Pay attention to body mechanics. Lay the patient on their back in the middle of the bed. Place a pillow under the patient's head to cover their shoulders. Extend arms to side of body with elbows slightly bent inward (flexion). Place a pillow under your arms. Place roller in palm. Place a thin pillow or a thinly folded towel/sheet under the waist. Place a thin towel under the knees. Support the bottom of the ankles with a pillow. Support the soles of the feet with a foot board. Raise the guardrail on the working side. Inform the patient that they can stay in this position for a maximum of 2 hours.
41271445|NCT06316479|DEVICE|PTMC Dermal Filler|A total of 120 subjects will receive treatment with PTMC Dermal Filler. The volume of filler injected will vary depending on the severity of the nasolabial fold. Injections will be administered by the investigator at the beginning of the study, with the injection technique, plane, and volume recorded. Touch-up treatments are permitted at the 1-month follow-up visit, if necessary.
41271446|NCT03325764|OTHER|functional assessment|assessment of functional capacity, habitual physical, cardiorespiratory fitness, muscle power and postural stability and gait parameters
41119062|NCT05350475|RADIATION|Photon therapy|Patients in the photon arm will receive standard treatment with photon therapy.
41271447|NCT00615537|PROCEDURE|Laser Ablation of Thyroid Nodule|Laser ablation using a laser generator, disposable fiberoptic laser fiber, cooling catheter and pump, will be performed under conscious sedation. Ultrasound will be used to localize masses. Local anesthesia will be administered both intradermally and subcutaneously. The laser applicator will be placed into the mass and laser energy will be delivered at 15W for 30-120 seconds. Real-time ultrasound monitoring of the ablation front will be used to ensure complete treatment of the target lesion. In larger masses applicators may be placed of the applicator into multiple locations. The number of locations will be determined by the treatment team, and based on lesion morphology, size, location, and accessibility.
41271448|NCT04002167|BEHAVIORAL|Neurofeedback|The Neurofeedback group will receive the proposed intervention which integrates computerized working memory training with neuromonitoring and neurofeedback.
41271449|NCT04002167|BEHAVIORAL|Cognitive training|The Cognitive training group will receive computerized working memory training with performance feedback.
41271450|NCT05850741|DEVICE|Cardiokit|The CardioKit prototype used in the study can monitor cyclical heart-beat motion, cyclical respiratory motion and non-cyclical heart position changes while the patient is lying in supine position.
41271451|NCT01306760|DRUG|Ketamine|Ketamine used as the anaesthetic during ECT.
41271452|NCT01306760|DRUG|Propofol|The standard anaesthetic used for ECT.
41271453|NCT02312973|DRUG|Molidustat(BAY85-3934)|Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
41271454|NCT02312973|DRUG|Molidustat(BAY85-3934)|One single oral dose of 75 mg molidustat in healthy subjects
41271455|NCT02314793|DRUG|ASP2205|oral
41271456|NCT02314793|DRUG|Placebo|oral
41119063|NCT02318901|DRUG|Pembrolizumab|
41119064|NCT02318901|DRUG|Trastuzumab|
41119065|NCT02318901|DRUG|ado-trastuzumab emtansine|
41119066|NCT02318901|DRUG|Cetuximab|
41119067|NCT01222039|OTHER|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
41271457|NCT01569633|DRUG|Metclopramide|Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
40926298|NCT05069701|DIAGNOSTIC_TEST|SVV test|SVV test will be done with virtual reality glasses.
41119068|NCT01222039|OTHER|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
41271458|NCT01569633|DRUG|Erythromycin|Dose of erythromycin is 1 miligram per kilogram every eight hours
40753058|NCT04116697|OTHER|Aromatherapy|Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
40753059|NCT02238327|PROCEDURE|blood draw|Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
40926299|NCT01659554|DRUG|Cisplatin|Cisplatin (75 mg/m2) prepared in 2L normal saline.
40926300|NCT01659554|DRUG|Doxorubicin|Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
41271459|NCT01569633|DRUG|placebo|The dose of sugar water is 1 ml per 8 hours.
41119069|NCT00360386|DRUG|Clopidogrel|
41119070|NCT05036408|OTHER|Behavioral, Psychological or Informational Intervention|Participate in group psychological intervention
41119071|NCT05036408|OTHER|Educational Intervention|Attend educational session
41119072|NCT05036408|PROCEDURE|Manipulative and Body-Based Intervention Procedure|Undergo osteopathic manual treatments
41119073|NCT05036408|BEHAVIORAL|Occupational Therapy|Participate in occupational therapy
41119074|NCT05036408|OTHER|Physical Activity|Participate in physical activity
41119075|NCT05036408|PROCEDURE|Physical Therapy|Participate in physical therapy
41119076|NCT05036408|OTHER|Questionnaire Administration|Ancillary studies
41119077|NCT03109223|OTHER|sole source nutrition|Infant formula
41119078|NCT00186186|DRUG|Depakote ER|Depakote ER
41119079|NCT03237416|DRUG|Dabigatran etexilate|In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
41119080|NCT03237416|DRUG|Midazolam|In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast
41119081|NCT03237416|DRUG|BAY1841788 (darolutamide)|In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
41119082|NCT02001818|DRUG|Nilotinib, Pegylated interferon alpha-2b, Imatinib|All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
41119083|NCT04459169|PROCEDURE|diagnostic algorithm|Cardiac amyloidosis diagnosed according to Gillmore's algorithm
41271460|NCT00640094|DRUG|melatonin|Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
41271461|NCT02619422|OTHER|Intensive cardiac rehabilitation program in less time|2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
41271462|NCT00746174|DRUG|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
41271463|NCT00746174|DRUG|Placebo|Placebo 1 tablet PO daily for 16 weeks
41271464|NCT05394415|DRUG|Tislelizumab|The 1st and 2nd doses were administered concurrently with TP regimen chemotherapy, 200 mg each, on D1 and D22 by intravenous infusion. In patients with successful conversion therapy, one dose of 200 mg on D60, was administered sequentially at the time before surgery after radiation therapy, and two doses of immunotherapy, on D150 and 171, were administered 8 weeks after surgery in concurrent with the 3rd and 4th cycles of chemotherapy as adjuvant therapy; in patients with failed conversion, two doses of chemotherapy combined with tislelizumab, on D60 and D81, were administered 2 weeks after the completion of radiation therapy.
41271465|NCT05394415|DRUG|Paclitaxel|A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1 and D22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150, 171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, on D60, 81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
41271466|NCT05394415|DRUG|Carboplatin|A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1, 22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150,171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, D60,81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
41119084|NCT05629182|OTHER|No intervention applied - Observational study only|Observational study only. Video footage is used to review all 64 matches in the football tournament.
41119085|NCT04968756|DEVICE|Selective retina therapy SPECTRALIS CENTAURUS device|Microsecond laser microsurgery by using the SPECTRALIS CENTAURUS device
41119086|NCT03278769|PROCEDURE|Lung protective ventilator settings|Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
41271467|NCT05394415|RADIATION|Radiotherapy|Radiotherapy was scheduled to be given on D1 of the 2nd cycle of chemotherapy. The primary lesions and/or lymph nodes in the operation area would be radiated in 2 stages. A dose of 30Gy/12F would be given in the first stage. When 12 Fractions were given, our MDT team would evaluate the regression of the lesions according to CT and MR results. If surgery is feasible, radiotherapy would be stopped for the primary lesions and lymph nodes in the operation area; if not resectable, the 2nd stage of radiotherapy would be given with a dose of 15Gy/6F, totaling to 45Gy/18F to the ESCC lesions. Radiotherapy for all lymph nodes outside the operation area was with DT of 45Gy/18F. All radiotherapy in this study was scheduled to be 2.5Gy/F, 1F/d, 5F/w. The preoperative radiotherapy target area was outlined by the consensus of the thoracic surgeon and radiotherapist.
41271468|NCT01559909|DEVICE|Vacuum assisted socket technology (Harmony System, Otto Bock Healthcare)|The brim height of the socket will be systematically reduced
41271469|NCT04718896|DRUG|bimekizumab|Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
41271470|NCT01946178|DEVICE|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
40753060|NCT02238327|PROCEDURE|questionnaires|The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
40926301|NCT05098977|PROCEDURE|Heart rate variability measurement|HRV will be measured at the moment of patients' admission to the cardiac catheterization laboratory on the top of therapy guided by European guidelines. Both, time- and frequency-domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio) of the HRV will be obtained using a validated medical device during 5-minute segments before and after revascularization of the culprit artery. In addition, HRV will be evaluated in ambulatory setting, at 1 month and at 6 months after the index event. Obtained interbeat interval data will be further analysed using a dedicated software in order to derive specified HRV parameters.
41119087|NCT00693121|DRUG|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
41119088|NCT00693121|DRUG|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
41119089|NCT06383793|PROCEDURE|overlap|Π
41119090|NCT00211419|DRUG|Anecortave Acetate 15 mg|
41119091|NCT00211419|DRUG|Triamcinolone Acetate 4 mg|
41119092|NCT00211419|PROCEDURE|Photodynamic Therapy with Verteporfin|
41119093|NCT00211419|PROCEDURE|Thermal Laser|
41271471|NCT00610636|PROCEDURE|Hepatic resection|Hepatic resection
41271472|NCT01678976|DRUG|BIA 2-093|Tablets containing BIA 2-093 in doses of 300 and 600 mg
41271473|NCT01678976|DRUG|Oxcarbazepine|Tablets containing 300 mg and 600 mg of Trileptal®
41271474|NCT01849757|OTHER|prime crystalloid|used for priming the CPB circuit
41119094|NCT01029587|DRUG|Eculizumab|Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
40753061|NCT02238327|PROCEDURE|Lung function testing|The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
40926302|NCT05098977|PROCEDURE|Percutaneous coronary intervention|Coronary angiography and PCI will be performed using femoral or radial approach after local anesthetic infiltration with Lidocaine and arterial sheath placement. Following the culprit lesion detection and guidewire placement, thromboaspiration and glycoprotein IIb/IIIa inhibitors will be left to the operator decision. Also, the choice of coronary stenting technique and stent sizing will be performed according to the operator experience. Antiplatelet and anticoagulant drugs will be administered in concordance with latest European guidelines.
40926303|NCT00753090|DEVICE|Vanguard™ Deep Dish Rotating Platform Knee|Vanguard™ Deep Dish Rotating Platform Knee
41119095|NCT06433713|DRUG|Lidocaine IV|They received IV infusion of 2 mg/kg per hour of lidocaine starting with skin incision, which was maintained until skin closure. This was done using a syringe pump with the calculated amount of lidocaine added to 50 ml of normal saline infused at a rate of 50 ml/hr.
40753062|NCT02238327|PROCEDURE|Six-Minute walk test|Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to \<88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
40753063|NCT02238327|RADIATION|Quantitative CT scans|Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
40753064|NCT02238327|PROCEDURE|Nasal secretion and cell collection|Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
40753065|NCT02238327|PROCEDURE|Echocardiogram|The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
41119096|NCT06433713|DRUG|Placebo|0.9% normal saline infusion
41119097|NCT01801514|DEVICE|Computed Tomography scan|Routine Computed Tomography scan
41119098|NCT02125695|PROCEDURE|Skin Taping|Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)
41119099|NCT02125695|PROCEDURE|Blood Sampling|Sampling for biomarker and basic research in CLE and AD
40926304|NCT00753090|DEVICE|Vanguard™ Cruciate Retaining Knee|Vanguard™ Cruciate Retaining Knee
40926305|NCT03206788|DRUG|Losartan|25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
40926306|NCT03206788|DRUG|placebo|Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
41119100|NCT02125695|PROCEDURE|Skin Biopsy|As described in the treatment arm
41119101|NCT03432858|DRUG|Vancomycin|Vancomycin - 1-gram dosing
41119102|NCT03432858|DRUG|Cefazolin|2-gram dosing for patients \<120 kg 3-gram dosing for patients 120 kg or greater
41119103|NCT03432858|DRUG|Saline Solution|Placebo
40926307|NCT06252077|DIETARY_SUPPLEMENT|very low ketogenic diet|1 month of active phase of very low ketogenic diet
40926308|NCT00592774|DRUG|E2007 (perampanel)|2 mg titrated up to 8 mg maximum; taken once daily.
40926309|NCT00592774|DRUG|Placebo|2 mg titrated up to 8 mg maximum; taken once daily.
41119104|NCT00203372|DRUG|Bevacizumab 7.5 and TAC|Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
41119105|NCT00203372|DRUG|Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
41119106|NCT00203372|DRUG|Bevacizumab 15 and TAC|one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
41119107|NCT00203372|DRUG|Placebo 15 and TAC|one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
41271475|NCT01849757|OTHER|Human Albumin|Used as a constituent for priming the CPB circuit
41271476|NCT01849757|OTHER|Voluven|Used as a constituent for priming the CPB circuit
41271477|NCT01154608|DRUG|Creon|
41271478|NCT01154608|OTHER|No enzyme therapy|Current enzyme therapy of the patient is stopped during 7 days
41271479|NCT02280850|DRUG|Guanxin Shutong Capsule|3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
41271480|NCT02280850|DRUG|Placebo Capsule|3 capsules three times a day; Duration: 4 weeks.
41119108|NCT04760938|BEHAVIORAL|Outdoor Behavioral Healthcare (OBH)|Participants in this intervention will participate in one of 7 programs that have been accredited by the Outdoor Behavioral Healthcare Council that specializes in 13-17 year old adolescents experiencing behavioral healthcare issues. Each program works in a unique wilderness setting in various United States National Forests and Parks (e.g., Washington, Oregon, New Mexico, Wisconsin, Utah). The average length of stay in an OBH wilderness program is 90 days, which is a total standard care time of 1,056 hours. All of the OBH programs have been accredited by the Association for Experiential Education Accreditation for Outdoor Behavioral Healthcare programs.
41271481|NCT02280850|DRUG|nitroglycerine|"Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts."
41271482|NCT04752761|BEHAVIORAL|Extrambulatory digital PROMs detection|An alternative PROMs evaluation method will be used in which the questionnaire will be administered to the patient digitally (Google Forms) in an outpatient environment
41271483|NCT01597947|DRUG|ACHN-975|Intravenous single dose
41271484|NCT01597947|DRUG|placebo|Intravenous single dose
41271485|NCT05735054|PROCEDURE|endoscopic thyroidectomy|the patients who underwent endoscopic transaxillary thyroidectomy
41271486|NCT02235649|BEHAVIORAL|Social Cognition therapy ( Psychological Therapy)|
41271487|NCT01429571|OTHER|No intervention|No intervention
41271488|NCT02246361|PROCEDURE|Patient Information Leaflet (PIL)|Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
41271489|NCT05699655|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
41271490|NCT05699655|DRUG|apatinib|Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks
41271491|NCT05699655|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
41271492|NCT05699655|DRUG|S-1|Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
41271493|NCT02246972|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
41271494|NCT04902235|DRUG|Experimental: CRH administration|CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
41271495|NCT04902235|DRUG|Control: Placebo administration|Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
41271496|NCT00666562|DIETARY_SUPPLEMENT|Defined Green Tea Catechin Extract|Given orally
41271497|NCT00666562|OTHER|Laboratory Biomarker Analysis|Correlative studies
41271498|NCT00666562|OTHER|Pharmacological Study|Correlative studies
40753066|NCT05737498|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation was applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode was placed over the contralateral supraorbital area for 20 min, on alternate days for 2 weeks 6 sessions with working memory training task. the anode (positive) and the cathode (negative). To reduce resistance and minimize discomfort during application (the electrodes were covered in 35 cm2, saline-soaked sponges
41271499|NCT00666562|DRUG|Placebo|Given orally
41271500|NCT00666562|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41271501|NCT02893267|DEVICE|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
40926310|NCT00400296|DRUG|RG547|Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
40926311|NCT03511898|DRUG|THR-149 dose level 1|single intravitreal injection of THR-149 dose level 1
41271502|NCT02893267|OTHER|Physical Therapy|Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
41271503|NCT02893267|OTHER|Sham-PT|Participants randomized to sham-PT will receive 8 60-minute sessions with therapists with the goal of controlling for the effect of regular contact with a therapist and study staff in a therapeutic environment. Participants will undergo a hands-on evaluation and re-evaluation before and after treatment. Therapists will provide sham ultrasound therapy and light application of inert gel to the shoulder for 10 minutes, Pre-Gait Training or Gait training, Exercise therapy, and relaxation therapy.
41271504|NCT02893267|DEVICE|Sham-PNS|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source.The stimulator will appear to function as normal though will not deliver electrical current to the electrode. The subjects will be prescribed 6 hours of sham-stimulation per day for 3 weeks.
41271505|NCT05873712|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41271506|NCT05873712|PROCEDURE|Bone Marrow Biopsy|Undergo BM biopsy
41271507|NCT05873712|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
41271508|NCT05873712|DRUG|Cyclophosphamide|Given IV
41271509|NCT05873712|DRUG|Fludarabine|Given IV
41271510|NCT05873712|PROCEDURE|Leukapheresis|Given IV
41271511|NCT05873712|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
41271512|NCT05873712|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
41271513|NCT05873712|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41271514|NCT05873712|DRUG|Zanubrutinib|Given PO
41271515|NCT06273995|OTHER|Behavioral Activation|All participants will undergo behavioral activation treatment for 8-10 weeks
41271516|NCT00730340|PROCEDURE|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
41271517|NCT00730340|PROCEDURE|Tonsillectomy with open fossa|SOP for a tonsillectomy.
41119109|NCT04760938|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The 12-week treatment period will consist of 15 90-minute sessions that will be administered individually. Homework (including reading assignments) are given to encourage your child to practice the techniques learned during the weekly sessions. The total standard of care time for CBT is 22.5 hours of direct treatment hours not including time spent on homework over these twelve weeks. Those therapists that are selected to deliver treatment for the CBT group will be certified by a nationally recognized CBT organization and licensed to work as a therapist in the state where they are providing treatment. Therapy will be delivered in an outpatient setting or through Telehealth.
41119110|NCT04600752|DRUG|Augmentin (ES)-600|Augmentin ES will be administered as reconstituted oral suspension containing Amoxicillin and Potassium Clavulanate 600 mg/42.9 mg per 5 milliliters.
41119111|NCT00819325|DRUG|pioglitazone|pioglitazone 30mg p.o. once a day for 6 months
41119112|NCT00819325|DRUG|oral hypoglycemic agents|sulfonylurea or metformin
41119113|NCT00110864|DRUG|PN2034|
41119114|NCT00110864|DRUG|Insulin|
41119115|NCT00592410|DRUG|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
41119116|NCT05374889|OTHER|Open Kinetic Chain Proprioception Exercises|basketball-specific target shooting in open kinetic chain
41119117|NCT04093895|DRUG|PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) administration
41119118|NCT00155415|BEHAVIORAL|Different timing of taking polyethylene glycol(PEG)|
41119119|NCT00799552|DRUG|RX-10045|RX-10045 eye drop
41271518|NCT03932526|DRUG|Vinorelbine + placebo|Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.
41271519|NCT03932526|DRUG|Vinorelbine + Apatinib|Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
41271520|NCT05617560|OTHER|Telemedical care|Telemedical care will be provided to all participants after stationary hospital stay. This care will be in form of telephone consultations and / or videocall consultations with a medical physician. Depending on the individual medical history and the planned aftercare and procedure of the participants it will comprise of one or more such telephone consultations.
41271521|NCT02906800|DRUG|Digoxin|The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
41271522|NCT00559338|DRUG|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
41271523|NCT00559338|DRUG|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
41119120|NCT00799552|DRUG|Placebo|Placebo eye drop
41119121|NCT00378222|PROCEDURE|Autologous Stem Cell Transplantation|
40926312|NCT03511898|DRUG|THR-149 dose level 2|single intravitreal injection of THR-149 dose level 2
40926313|NCT03511898|DRUG|THR-149 dose level 3|single intravitreal injection of THR-149 dose level 3
41119122|NCT00322920|DRUG|Topotecan|
41119123|NCT00322920|DRUG|Cisplatin|
41119124|NCT03850613|BEHAVIORAL|E-painting mobile app|The subjects can use the newly developed mobile app to draw their own pictures at the time convenient to them.
41119125|NCT00002842|DRUG|floxuridine|Starting dose of 0.2 mg/kg/day for 14 consecutive days.
41119126|NCT00002842|DRUG|fluorouracil|300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
41119127|NCT00002842|DRUG|leucovorin calcium|500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
41119128|NCT00002842|PROCEDURE|adjuvant therapy|Chemotherapy given after hepatic resection
41119129|NCT00002842|PROCEDURE|conventional surgery|Hepatic resection
41119130|NCT05670834|GENETIC|genotyping assay by real-time PCR|genotyping assay of MMP-2 gene with the real-time polymerase chain reaction
41119131|NCT05670834|DIAGNOSTIC_TEST|ELISA|. IL-6 level in serum will be analyzed by ELISA assay kit.
41119132|NCT05810194|DEVICE|StrataXRT|StrataXRT® is a TGA-approved silicone-based topical preparation. StrataXRT is a self-drying, non-sticky, transparent, silicone gel formulation and when used as directed, dries to form an inert, thin, flexible wound dressing with a protective layer that is gas permeable and waterproof. It is the only self-drying topical silicone gel indicated for the use on radiation dermatitis, which hydrates and protects compromised skin areas and open wounds from chemical and microbial invasion. StrataXRT helps create an optimal wound healing environment which leads to faster re-epithelialization and a reduced inflammatory response. The product can be applied to fresh incisions and excisions, open wounds and compromised skin surfaces.
41119133|NCT05810194|DRUG|Calendula|Calendula creams are over-the-counter (OTC) skin care ointments that are non-greasy, non-sticky, and quickly absorbed by the skin. Calendula is a topical agent derived from a plant of the marigold family Calendula Officinalis and is used in cuts, scrapes, chafing and minor burns. Containing numerous polyphenolic antioxidants, calendula has been studied in both the laboratory and clinical setting for the use in treating and preventing radiation induced skin toxicity.
41119134|NCT05810194|DRUG|Aquaphor|Aquaphor, containing 41 percent petrolatum (or petroleum jelly), temporarily protects minor cuts, scrapes, and burns; Aquaphor protects and helps relieve chapped or cracked skin and lips, as well as helps protecting from the drying effects of wind and cold weather.
41119135|NCT02630823|DRUG|MK-3475|
41119136|NCT02630823|PROCEDURE|Surgical resection (standard of care)|
41119137|NCT02630823|DRUG|Paclitaxel (standard of care)|
41119138|NCT02630823|DRUG|Carboplatin (standard of care)|
41119139|NCT02630823|RADIATION|Radiation (standard of care)|
41119140|NCT02630823|PROCEDURE|Endometrial biopsy|
40753067|NCT02333968|BEHAVIORAL|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
41119141|NCT02630823|PROCEDURE|Peripheral blood draw|
41119142|NCT06515951|DIAGNOSTIC_TEST|STANDING algorithm|The STANDING algorithm is composed by four steps. The first phase consists in evaluating the presence of spontaneous nystagmus at rest for at least five minutes with and without Frenzel goggles in order to assess if a acute vestibular syndrome is present. If there is not a spontaneous nystagmus, then positional maneuvers (Pagnini-Mc Cure and Dix-Hallpike) have to be performed. Otherwise if spontaneous nystagmus is observed, its feature are fundamental to diagnose a central vertigo. If nystagmus characteristics suggest a peripheral form, the head impulse test is performed by instructing the patient to keep eyes on a fixed target and then turned the head quickly. An abnormal response is typical of vestibular neuritis. In any cases after the described maneuvers, the patient must be evaluated when standing up and walking: if this turn out to be impossibile, the test is indicative of central nervous system disease.
41119143|NCT03427632|DRUG|Bone Cements|patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
41119144|NCT01275105|DRUG|Vehicle|one drop in each eye at designated visits
41119145|NCT01275105|DRUG|Brimonidine Tartrate 0.01%|one drop in each eye at designated visits
41119146|NCT01275105|DRUG|Brimonidine Tartrate 0.025%|one drop in each eye at designated visits
41119147|NCT01275105|DRUG|Oxymetazoline HCl 0.025%|one drop in each eye at designated visits
41119148|NCT00241241|DRUG|pegylated interferon-alfa 2a|
41119149|NCT02881203|DEVICE|Breathe Well|Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.
41119150|NCT02881203|DEVICE|RPM|Varian Real-time Position Management (RPM) system
41119151|NCT03849352|BEHAVIORAL|Lifestyle changes with the support of health technology|Written instructions will be provided to participants, to include how to download supportive apps on smartphones. Participants will be asked to complete a 3 day food diary using an online platform (MyFood24) prior to attending a face to face consultation which will reinforce the participant's responsibilities. Participants will be assisted to set specific diet and lifestyle goals. 3 fortnightly follow ups will be arranged via 15 minute telephone consultations, three 24 hour dietary diaries will be completed via MyFood24 prior to each fortnightly digital consultation. Participants will be asked to measure their daily activity via a pedometer on their smart phones. Participants will be asked to complete the Godin leisure time questionnaire to assess changes in leisure time exercise.
40753068|NCT00069329|DRUG|anakinra|daily injection of subcutaneous injection
41119152|NCT05489536|BEHAVIORAL|A web/smartphone-based lifestyle program package|"There are two platforms for the lifestyle program, namely Health and Nutrition Education (HNE) website and HNE app. The participants are requested to download and register on the HNE website and the HNE app. The HNE app is Android and IOS compatible. Both the HNE website and app are designed to support self-directed learning and independently monitor their GWG and dietary intake during pregnancy. Both the HNE website and app will be passcode protected throughout the study period such that access is restricted to only participants in the intervention group.~The web/smartphone-based lifestyle program package consists of:~I. Health and Nutrition Education (HNE) resources II. Gestational Weight Gain (GWG) monitoring III. Dietary intake monitoring"
41119153|NCT00173524|BEHAVIORAL|PharmacoEconomic Assessment|Collecting PE data.
41119154|NCT00886756|DRUG|AZD8529|Oral
41119155|NCT00886756|DRUG|Placebo|Oral
41119156|NCT01806116|DRUG|decitabine|
41119157|NCT03792204|DIAGNOSTIC_TEST|Wearing-off 9 questionnaire|The participants would receive appropriate anti-PD medical treatments according to the patients' need during the investigation.The anti -PD treatment would not be changed in the population of the participants.
41119158|NCT00678912|DEVICE|Smartcare/PS|computer-driven protocol that adjusts pressure support level in pressure support mode to patient respiratory status
41119159|NCT03695536|BEHAVIORAL|ultrasound use during resuscitation|ultrasound use during resuscitation
40753069|NCT01282554|DEVICE|electrostimulation program (Rehab 400)|"electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months.~Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity.~Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months."
41119160|NCT04508972|DEVICE|Alexa Amazon|To test the use of the Amazon Alexa device as a tool to conduct screening of employees and patients at the point of entry into the Heart Failure (HF) Clinic of the McGill University Health Center.
41119161|NCT01505712|GENETIC|gene expression analysis|
41119162|NCT01505712|OTHER|laboratory biomarker analysis|
41119163|NCT04967742|BIOLOGICAL|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
41119164|NCT01507038|DRUG|YH14617|1mg once weekly
41119165|NCT01507038|DRUG|YH14617|1.6mg once weekly
41119166|NCT01507038|DRUG|YH14617|2mg once biweekly
41119167|NCT01507038|DRUG|Placebo|Once weekly
41119168|NCT05391464|PROCEDURE|Peripheral Nerve Block|Utilized preoperatively with sedation during surgery, or postoperatively for additional anesthesia after GA.
41119169|NCT00788853|OTHER|No treatment given|No treatment is given
41119170|NCT02727296|DRUG|sevoflurane|General anesthesia with sevoflurane
41119171|NCT02727296|DRUG|propofol|General anesthesia with propofol
41119172|NCT02467946|DRUG|Adcetris-Levact|Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
41119173|NCT05829525|OTHER|Evaluation of sleep quality, sleep duration, heart rate and step count|Evaluation of sleep quality with the Pittsburgh Sleep Quality Index Evaluation of sleep duration, heart rate, and step count with the Fitbit® Inspire 2 (Fitbit, Inc., San Francisco, California, USA) Evaluation of quality of life with the Nottingham Health Profile
41119174|NCT05461417|DEVICE|D-SAD|Patients equipped with Panthera D-SAD® orthosis will be recruited.
41119175|NCT01885793|DEVICE|Cuffed endotracheal tube|Intubation with a cuffed endotracheal tube (ETT).
41119176|NCT01832467|DRUG|cetuximab-containing chemotherapy|
41119177|NCT05155917|DRUG|Insulin Glargine 300 UNT/ML [Toujeo]|insulin glargine sc (0.25 U/kg body weight)
40753070|NCT01442285|BEHAVIORAL|personalized, motivational messages|A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
40753071|NCT03156452|DRUG|Mycophenolate Mofetil|500 mg and 250mg tablets for oral administration
40753072|NCT03156452|DRUG|Prednisolone|5mg tablets for oral administration
41119178|NCT03023800|PROCEDURE|Macular buckling|Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
41119179|NCT03023800|PROCEDURE|Vitrectomy|Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia
41119180|NCT03452085|DEVICE|artificial saliva spray (AS)|cross over design
41119181|NCT03452085|OTHER|maritime throat spray (TT)|cross over design
41119182|NCT01499199|DRUG|Dolutegravir|50mg Once Daily
41119183|NCT04238429|DRUG|Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate|Use the toothpaste to brush teeth twice a day for 8 weeks
41119184|NCT04238429|DRUG|Control toothpaste|Use the toothpaste to brush teeth twice a day for 8 weeks
41119185|NCT04667780|DRUG|Colchicine|Colchicine tablet 0.5 mg
41119186|NCT04667780|DRUG|Standard COVID-19 care|As per the hospital guidelines
41119187|NCT00686855|DRUG|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
41119188|NCT00686855|DRUG|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
41119189|NCT01254188|DRUG|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
41119190|NCT04281576|DEVICE|NovoTTF-100L(P)|Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
41119191|NCT04281576|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 intravenous infusion will be administered once every 3 weeks
41119192|NCT04281576|DRUG|Capecitabine|Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
41119193|NCT04281576|DRUG|Trastuzumab|Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
41119194|NCT04571606|PROCEDURE|Single injection peripheral nerve block with liposomal bupivacaine (Exparel)|10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine
41119195|NCT04571606|PROCEDURE|Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump|20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours
41119196|NCT03430258|DEVICE|high-flow nasal cannula|high flow of air with supplemental oxygen was delivered by an Optiflow cannula interface using an AIRVO 2 blower humidifier
40753073|NCT04057638|PROCEDURE|Combined Craniomaxillofacial and Upper Extremity Allotransplantation|Combined Craniomaxillofacial and Upper Extremity Allotransplantation
40753074|NCT00896233|PROCEDURE|MRE|"Part 1: Participants will have a screening visit, followed \~1 month later by two imaging visits over \~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed \~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans."
41119197|NCT03430258|DEVICE|Conventional oxygen therapy|Conventional oxygen therapy
41119198|NCT05579054|DIAGNOSTIC_TEST|Foot Posture Index (FPI-6)|FPI-6 is a valid and reliable assessment tool for pediatrics in which 6 items are scored separately for the right and left feet while the patient was in an upright position in a relaxed posture with their body-weight evenly distributed on the both feet. Each item is scored as -2, -1, 0, 1, 2 and the assessment categorized as follows: 0 to +5 normal; +6 to +9 pronated; 10+ higly pronated; -1 to -4 supianted; and -5 to -12 higly supinated.
41119199|NCT02336386|DRUG|CDD|Chemotherapy
41119200|NCT02336386|DRUG|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
41119201|NCT04082611|BEHAVIORAL|Data-Driven Clinical Recommendations|Data-driven clinical recommendations. Participants will receive routine care with data-driven, personalized, multi-modal clinical recommendations by a study physician based on study assessments and clinical lab values and be monitored and re-assessed for a period of 12 months.
41119202|NCT04082611|BEHAVIORAL|Coached Data-Driven Clinical Recommendations|Data-driven multi-modal lifestyle intervention with coaching. Participants will receive coached routine care with data-driven, personalized, multimodal recommendations. MMIC participants will receive an intensive multi-modal intervention with health coaching, support and resources to carry out these recommendations. This additional intervention services include: 13 personal, data-driven brain health coaching sessions (with an RDN), 7 personal dietary counseling sessions (with an RDN), 33 group-based cognitive and physical exercise classes (CogFit) with a certified personal trainer and a computer-based neurocognitive program at home and be monitored and re-assessed for a period of 12 months.
41119203|NCT04426500|DRUG|Bupivacain|Direct injection of 0.25% bupivacaine into surgical wounds
41119204|NCT04426500|DRUG|Ultrasound-guided transversus abdominus plane block|bilateral TAP using ultrasound guidance in prostatectomies
41119205|NCT04426500|DRUG|Laparoscopic-guided transversus abdominus plane block|bilateral TAP using laparoscopic guidance in prostatectomies
41119206|NCT04055246|DIETARY_SUPPLEMENT|Inulin|9 grams of food grade inulin added to custom made fiber bars.
41119207|NCT04055246|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|9 grams of food grade maltodextrin - replaces inulin in fiber bars.
41119208|NCT06162897|BEHAVIORAL|Dyadic Case Management|Subjects enrolled in the intervention arm will be offered focused case management centered around goal setting and future orientation. Subjects will be assigned two case managers to support their goals.
41119209|NCT06516250|OTHER|Virtual serious game GEMAS|Implement and evaluate a virtual serious game designed to improve the learning and retention of clinical knowledge in medicine and nursing students and residents through the simulation of clinical cases in a hospital emergency environment.
41119210|NCT03437850|OTHER|Usual care|Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts
41119211|NCT02882035|OTHER|OFA|
41119212|NCT01866969|OTHER|questionnaire administration|Ancillary studies
41119213|NCT01866969|PROCEDURE|quality-of-life assessment|Ancillary studies
41119214|NCT06152939|OTHER|Primary percutaneous coronary intervention or thrombolytic therapy|Primary percutaneous coronary intervention or thrombolytic therapy
41446364|NCT05861258|DRUG|Minocycline|Patients with M. avium complex pulmonary disease will receive 200 mg of minocycline for 5 days before starting rifampicin and after 1 month (±1 week) of receiving rifampicin. Antimycobacterial drugs other than rifampicin can be started prior to or simultaneous with the first minocycline dosing period as part of standard care. At day 5 of both minocycline dosing periods, blood will be sampled for minocycline plasma concentration measurements at T = 0, 1, 2, 3, 4, 6, 8 and 24 hours.
40753075|NCT00370604|DEVICE|19g Tuohy-type epidural needle, 23g catheter|Patients in the experimental group will receive a 23g 90cm adult length epidural catheter placed via a 19g Tuohy epidural needle (SIMS Portex, Hythe, UK). The 19g Tuohy needle is a standard 3½ inch length.
40753076|NCT00370604|DEVICE|=> 18g Tuohy-type needle|Patients in the control arm will receive a traditional large gauge (16g, 17g or 18g Tuohy or Hustead) epidural needle and a traditional epidural catheter. Two control needles and two control catheters will be designated apriori by each institution for use in the study.
40753077|NCT04677036|OTHER|No intervention is given|No intervention given
40753078|NCT01663805|DRUG|Everolimus|Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
40753079|NCT00096408|PROCEDURE|Total Abdominal Hysterectomy|For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.
41119215|NCT01957124|PROCEDURE|PRF (Platelet-Rich Fibrin)|
41119216|NCT06523868|OTHER|GRAIL Galleri|A multi-cancer early detection (MCED) blood test.
41119217|NCT05199142|DRUG|SDI-118|SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.
41119218|NCT05199142|DRUG|Placebo|The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
41119219|NCT01615393|DRUG|ribavirin [Copegus]|Single oral dose of 400 mg tablets
41119220|NCT01615393|DRUG|ribavirin [Vilona]|Single oral dose of a 400 mg capsule
41119221|NCT00411151|DRUG|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
41119222|NCT05202912|DRUG|IDX-1197(After a meal)|randomized, open-label, single-dose, 2-period, 2-sequence crossover study in healthy male Korean and Caucasian volunteers
41119223|NCT05202912|DRUG|IDX-1197(fasting)|open-label, single-dose study in Chinese male volunteers
41119224|NCT03245580|DIAGNOSTIC_TEST|Core Liver Biopsy|Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
41271524|NCT01972321|OTHER|Technology supported supervision|"CHWs will be provided with mobile phones and solar chargers to carry out the following:~1. Establish closed user groups (CUGs) to enable two-way communication between CHWs and their supervisors free of charge to the users.~2. Data submission through mobile phones 2.1. receive motivational performance related feedback provided in response. 2.2. Automated messages to supervisors which 2.2.1. Flags problems and strengths/successes identified in CHWs data 2.2.2. Alerting supervisors as to which CHWs require targeted supervision. 2.3. CHWs data summarised in a user friendly format and made accessible to district statisticians~3. Monthly motivational short message service (SMS) messages provided to CHWs that are locally relevant to CHW work and that are designed to impact positively on CHW performance."
41271525|NCT01972321|BEHAVIORAL|Community supported supervision|CHWs will facilitate the clubs using a learning, planning and action cycle. Club members will rank child health challenges faced by their community using picture cards and decide which one to focus on for each cycle. They will discuss solutions, which include supporting CHWs services, and take actions to meet challenges. They will also promote group decision-making and ownership and through this process gain tangible results. Solutions to health challenges developed by club members are a key focus of the village health club approach. Village Health Clubs are based on 5 guiding principles: clubs are open to all, village owned, intended to support CHW work, strength based, and fun and focused.
41271526|NCT01972321|OTHER|Integrated community case management|Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.
41271527|NCT05872048|DEVICE|periodontal distractor|custom made device from hyrex screw
41119225|NCT03489915|DEVICE|OCT|Assessment of macular edema secondary to retinal vein occlusion usin optical coherence tomography and its correlation with visual acuity
41119226|NCT03097770|BIOLOGICAL|anti-CD19/20-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
41119227|NCT02931175|DRUG|ACTH gel|Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
41119228|NCT03832894|DRUG|Estradiol Valerate|Oestradiol supplementation starting from day of trigger through out the luteal phase
41119229|NCT03669913|OTHER|Lessons on comprehensive sexuality education|Provision of 11 standardized lessons on comprehensive sexuality education based on international guidance on sexuality education by UNESCO
41271528|NCT01147809|DRUG|Eltrombopag olamine|thrombopoietin receptor agonist
41271529|NCT01147809|OTHER|Placebo|Placebo tablets with no active pharmaceutical ingredient
41119230|NCT05517564|DRUG|GM-60106|The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
41119231|NCT05517564|OTHER|Placebo|Placebo-to-match GM-60106 capsules
41119232|NCT05142202|RADIATION|Breast Irradiation after Breast-Conserving Surgery|All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.
41119233|NCT00390793|DRUG|Cyclophosphamide|Given IV
41119234|NCT00390793|DRUG|Cytarabine|Given IV or IT
41119235|NCT00390793|DRUG|Dasatinib|Given PO
41119236|NCT00390793|DRUG|Dexamethasone|Given IV or PO
40753080|NCT00096408|PROCEDURE|Total Laparoscopic Hysterectomy|The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
41119237|NCT00390793|DRUG|Doxorubicin|Given IV
41119238|NCT00390793|DRUG|Methotrexate|Given IV or IT
41119239|NCT00390793|DRUG|Prednisone|Given PO
41119240|NCT00390793|DRUG|Vincristine|Given IV
41119241|NCT00557206|DRUG|Oxaliplatin and Docetaxel|"Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days."
41119242|NCT01381471|DRUG|fluticasone propionate/salmeterol xinafoate combination|fluticasone propionate/salmeterol xinafoate combination
41119243|NCT00317486|DRUG|bosentan|
41119244|NCT00726596|DRUG|hydroxychloroquine|Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
41119245|NCT05597280|DRUG|BE-PEP Bedaquiline|bedaquiline
41119246|NCT05597280|DRUG|SDR-PEP Rifampicin|SDR-PEP: rifampicin
41119247|NCT05597280|DRUG|BE-PEP Rifampicin|BE-PEP rifampicin
41119248|NCT04508348|OTHER|Human Milk|Exclusive Human Milk diet
41119249|NCT04508348|OTHER|Standard of Care|This diet will include mother's milk and/or formula
41119250|NCT02952209|DEVICE|Xenograft|
41119251|NCT01275287|DRUG|Standard of care treatment|"induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m\^2 for patients \> than 70 or with estimated Glomerular Filtration Rate (eGFR) \< 20 ml/min) to be titrated up to 1 gm/m\^2 depending on the 2 week white blood count (WBC) nadir \> 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .~For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study."
41119252|NCT01275287|DRUG|eculizumab|In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
41119253|NCT05521061|DIETARY_SUPPLEMENT|2-fucosyllactose|Volunteers will be visited to provide the investigational product/placebo to the diets of the patients included in the study for 3 months, and the use of the investigational product/placebo will be monitored. Parents will be trained by their fellows to provide synthetic breast milk oligosaccharides/placebo, the products to be used in the study will be provided by the scholars on a weekly basis, and their daily intake and possible problems will be monitored through weekly interviews. In this study, it is planned to supplement the diet of the placebo group with 1.5 g/day maltodextrins to approximately half of the diet and to supplement the other half with 3 g/day maltodextrins, after the group was randomized within itself. Effects of these doses on metabolic control are not expected. Maltodextrine is in powder form, its dosage of up to 3 g/day has a negligible effect on blood glucose, it has a neutral taste, it is cheap and easy to find, and it is safe and ineffective.
41119254|NCT02197975|DRUG|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
41119255|NCT02197975|DRUG|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
41119256|NCT02197975|DRUG|Placebo MDI|Placebo MDI. Administered as 2 inhalations
41119257|NCT02178111|OTHER|Never perform episiotomy|In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
41119258|NCT02178111|PROCEDURE|episiotomy|
41119259|NCT03631953|DRUG|Trametinib|Trametinib administered at a fixed dose (1.5 mg daily)
41119260|NCT03631953|DRUG|Alpelisib|A panel of 3 doses of ALPELISIB could be tested
41119261|NCT03631953|BIOLOGICAL|Blood sample|Therapeutic biomarkers
41119262|NCT03631953|DEVICE|MRI|A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
41119263|NCT00933426|DRUG|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
41119264|NCT00933426|DRUG|Paclitaxel|50 mg/m\^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
41119265|NCT04143204|OTHER|Oral nutritional intake|The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
41119266|NCT05510895|DRUG|Binimetinib|Triplet combination administered neoadjuvant and adjuvant, depending on TRG
41119267|NCT05773313|BEHAVIORAL|The Open Table|An organization that connects community volunteers to individuals in need to help overcome life's challenges.
41119268|NCT05261997|PROCEDURE|extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct|In addition to drug administrated in the control group, patients in this group would be treated with ESWL and endoscopic drainage of the main pancreatic duct.
41119269|NCT05261997|DRUG|pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)|Patients will receive drugs to control pancreatic insufficiency
41119270|NCT04676321|OTHER|Patient pathway|Investigation on the appropriateness and quality of NSCLC care among participating sites
41119271|NCT02578589|PROCEDURE|Plica resection vs conservative treatment|Plica resection vs conservative treatment
41119272|NCT02275377|OTHER|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
41271530|NCT04256967|OTHER|Body and health focused study environment|Students are exposed to lectures, literature, co-students, contexts that provide body and lifestyle awareness beyond the existing exposure of the society in general
41271531|NCT02732067|OTHER|anesthesia related deaths|number of anesthetized patients who died in the perioperative period inside the hospital
41271532|NCT05674448|BIOLOGICAL|HH-003 20mg/kg|HH-003 20mg/kg Q2W intravenously for 24 weeks
41271533|NCT05674448|BIOLOGICAL|HH-003 3mg/kg|HH-003 3mg/kg Q2W intravenously for 24 weeks
41271534|NCT05527951|OTHER|eMBC|The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
40753081|NCT02405858|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
40753082|NCT02405858|DRUG|Prednisolone|Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
40753083|NCT00126737|OTHER|Weight Control Nutritional Program|a week of food diary and information about dietary fat intake and proper proportions of vegetables.
41271535|NCT05527951|OTHER|standard MBC|The control intervention group will implement standard MBC using paper and pencil questionnaires.
41271536|NCT00211406|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
41271537|NCT06258642|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, Q2W, iv
41271538|NCT06258642|DRUG|Anlotinib|12 mg, qd, po for 2 consecutive weeks and then discontinued for 1 week.
41271539|NCT00904787|DRUG|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
41271540|NCT04647110|DRUG|crizotinib|as provided in real world practice
41271541|NCT04647110|DRUG|alectinib|as provided in real world practice
41271542|NCT04647110|DRUG|brigatinib|as provided in real world practice
41271543|NCT04647110|DRUG|ceritinib|as provided in real world practice
41271544|NCT04647110|DRUG|lorlatinib|as provided in real world practice
41271545|NCT00603239|DRUG|exenatide|subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
41271546|NCT00603239|DRUG|placebo|subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
41271547|NCT06117189|OTHER|Questionnaire|Oral Health Impact Daily Life questionnaire including 7 domains (eating, speaking, appearance, social, psychological, health, and finance) and 16 questions regarding perceived intensity
41271548|NCT04529291|OTHER|Group with walking disorder|During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital. Additional home visits, corresponding to intervention, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team.
41271549|NCT04529291|OTHER|Group without walking disorder|"During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital.~Additional home visits, corresponding to interventions, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team."
41271550|NCT00349128|DRUG|fenofibrate and metformin combination (drug)|
41271551|NCT02968355|OTHER|Observational study|Observational study
41271552|NCT04047888|OTHER|Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message|60 minute educational message at each visit
41271553|NCT04047888|OTHER|Non nutrition-based educational message|No nutrition-based education on infant feeding and practices
41271554|NCT01323296|OTHER|Ferumoxytol|One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
41271555|NCT02583984|PROCEDURE|Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic surgery with lung resection, such as lobectomy, segmentectomy
41271556|NCT02583984|PROCEDURE|Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic surgery without lung resection, such as esophageal surgery, mediastinal surgery
41271557|NCT00928070|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg
41271558|NCT00928070|DRUG|Placebo|Placebo sham 4 mg and 8 mg
41271559|NCT01822561|DRUG|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
41271560|NCT03485989|OTHER|Hazelnuts|Dry roasted, individually packaged hazelnuts provided from the Hazelnuts Marketing Board of Oregon
41271561|NCT03611699|DRUG|Umeclidinium / Vilanterol Dry Powder Inhaler|umeclidinium/vilanterol dry powder inhaler
41271562|NCT03611699|DRUG|Placebo|Placebo inhaler
41271563|NCT04525703|BEHAVIORAL|Pathways for Parents after Incarceration|The Pathways for Parents after Incarceration program uses eight key lessons, including topics on effective listening, speaking, and problem-solving skills, lessons on emotion regulation, and issues surrounding family engagement. The program (both classroom and therapeutic peer support) will be offered virtually and weekly for 8 continuous weeks.
41271564|NCT04839861|BEHAVIORAL|Mightier Family Games|Mightier Family Games includes five offline card games that can be played by two or more people. During card game play, one player wears the Mightier heart rate monitor, and can see a representation of their heart rate on a separate screen within the Mightier app. Each game includes elements that are tied to heart rate.
41271565|NCT04839861|BEHAVIORAL|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own."
41271566|NCT00834054|PROCEDURE|Double-lung transplantation|Double-lung transplanted patients
41271567|NCT00277758|BIOLOGICAL|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
41271568|NCT00277758|DRUG|Ribavirin|Ribavirin @ 800 mg daily (\< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (\> 85 kg)
41271569|NCT00277758|BIOLOGICAL|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
41271570|NCT00277758|BIOLOGICAL|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
41271571|NCT00277758|DRUG|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight \<65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight \>85 kg.
41271572|NCT02229773|DRUG|BIBB 1464 MS low dose|
41271573|NCT02229773|DRUG|Placebo|
41271574|NCT02229773|DRUG|Pravastatin|
41271575|NCT02229773|DRUG|BIBB 1464 MS medium dose|
41271576|NCT02229773|DRUG|BIBB 1464 MS high dose|
41271577|NCT00441688|DRUG|GI265235|
41271578|NCT01412879|BIOLOGICAL|rituximab|Given IV
41271579|NCT01412879|DRUG|bendamustine hydrochloride|Given IV
41271580|NCT01412879|DRUG|cyclophosphamide|Given IV
41119273|NCT02275377|OTHER|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
41119274|NCT05757388|DRUG|Parecoxib + paracetamol|Administers after induction of anesthesia.
41119275|NCT05757388|DRUG|Normal saline|Administers after induction of anesthesia.
41119276|NCT02597751|BEHAVIORAL|Cognitive Orientation to Occupational Performance (CO-OP)|"CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
41119277|NCT05193695|OTHER|Treadmill exercise|the patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002)
41119278|NCT03388281|OTHER|No intervention, retrospective analysis only.|No intervention, retrospective analysis only.
41119279|NCT03303651|PROCEDURE|Opioid administration in intervention groups|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.
41119280|NCT03303651|PROCEDURE|Opioid administration in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by clinical signs in the control group.
41119281|NCT03426878|OTHER|Modified genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive modified genetic counseling to help them understand the results.
41119282|NCT03426878|OTHER|Traditional genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive traditional genetic counseling to help them understand the results.
41119283|NCT04290013|DRUG|norethisterone acetate|norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.
41119284|NCT04290013|DRUG|tranexamic acid tablets|tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
41271581|NCT01412879|DRUG|cytarabine|Given IV
41271582|NCT01412879|DRUG|dexamethasone|Given PO or IV
41271583|NCT01412879|DRUG|doxorubicin hydrochloride|Given IV
41271584|NCT01412879|DRUG|leucovorin calcium|Given PO or IV
41271585|NCT01412879|DRUG|methotrexate|Given IV
41271586|NCT01412879|DRUG|vincristine sulfate|Given IV
41271587|NCT01575613|DRUG|Artemether-lumefantrine combination|Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
40753084|NCT00126737|OTHER|Home-based exercise program|24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.
41119285|NCT01234363|DEVICE|Magnetic Resonance Elastography, and Supersonic Shear Imaging|Magnetic Resonance Elastography, and Supersonic Shear Imaging
41119286|NCT01166152|BEHAVIORAL|social skills training|meeting once a week or biweekly to play together using toys, games, and physical exercises.
41119287|NCT00314860|DRUG|ropinirole Extended Release (XR)|
41119288|NCT03681522|PROCEDURE|Pelvic plexus block|Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
41271588|NCT01575613|BIOLOGICAL|Bacillus thuringiensis|Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
41271589|NCT01575613|BIOLOGICAL|Long lasting insecticide treated net (LLINs)|Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
41271590|NCT01575613|BIOLOGICAL|Indoor Residual Spraying (IRS)|6-monthly IRS with deltamethrin in all households malaria hotspots.
41271591|NCT06368726|DEVICE|tDCS or Transcranial Direct Current Stimulation|We use weak currents applied over the child's scalp over 30 minutes twice a week during 100 days
41271592|NCT06368726|DRUG|Risperidone|Risperidone Risperidone according to child's weighs
41271593|NCT06134297|DEVICE|Cycle ergometer|The Aerobic Exercise Group will perform a cycle ergometer for 15 consecutive minutes with a load adjusted to maintain heart rate (HR) between 65-75% of the maximum HR predicted for age (HRmax = 200-age). Peripheral oxygen saturation will be controlled and, upon a sustained drop (\> 2 minutes after load reduction) below 90%, the session will be interrupted. The subjective feeling of tiredness in the legs and shortness of breath will be constantly monitored and if values equal to or greater than 8 (0-10) occur, the exercise will be stopped.
41271594|NCT06134297|DEVICE|Strength Training - elastic band and shin guards|The Anaerobic Exercise Group will perform muscular strength training using maximum strength, where the contraction time should not exceed 20 seconds. For the upper limbs, the overload used will be through the use of an elastic band, with guidance for the patient to perform the shoulder external rotation exercise, elbow flexion exercises and open row rowing exercise. For the lower limbs, bridge movements, lunges and sit-up exercises will be performed with a maximum of 15 repetitions, and overload with ankle weights or dumbbells can be used in addition to body weight. The muscle contraction should lead the patient to a state of muscular fatigue and if the objective is not achieved, the exercise will be adapted to require greater strength from the patient so that he or she can reach maximum strength.
41119289|NCT03681522|PROCEDURE|Periprostatic nerve block|Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
41271595|NCT06134297|DEVICE|Cycle ergometer, elastic band and shin guards|Mixed Exercise Group will perform the exercises by alternating between aerobic and anaerobic overload, in a 1:1 ratio until the end of the physical rehabilitation program, following exactly the same protocols described previously (alternating one session of the aerobic protocol and in the following session the anaerobic protocol).
41271596|NCT06035822|OTHER|Debriefing with TeamGAINS|The IG debriefings were conducted by the research teacher, who is trained in clinical simulation methodology, is a clinical simulation instructor, and is trained in the use of the TeamGAINS tool, using this tool as a debriefing script, in accordance with the objectives Clinical Simulation Scenario
41271597|NCT00887952|PROCEDURE|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
41271598|NCT00887952|PROCEDURE|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
41119290|NCT03681054|OTHER|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
41119291|NCT03681054|OTHER|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 50 E%; fat 30 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
41119292|NCT04978051|DRUG|Firazyr|Icatibant 10 MG/ML Prefilled Syringe
41119293|NCT04978051|OTHER|SoC|The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
41119294|NCT02073578|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
41119295|NCT04891835|OTHER|Data extraction from medical files|Data extraction from medical files
41119296|NCT02365779|PROCEDURE|bilateral laparoscopic salpingectomy|Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
40753085|NCT04942509|BEHAVIORAL|Coloring as a brief mindfulness-based intervention|Participants watched an instructional video on mindful coloring at the beginning of the intervention and colored mindfully for at least 5 days or 100 minutes in total during a 10-day period. The intervention included a coloring booklet that contained mandala patterns for coloring.
41119297|NCT02365779|DEVICE|endomicroscopy Cellvizio® system|
41119298|NCT00824135|DRUG|Clofarabine|"One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous"
41119299|NCT00824135|PROCEDURE|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
41119300|NCT00824135|OTHER|OKT3|"Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3"
41119301|NCT00824135|DRUG|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
41119302|NCT00824135|DRUG|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
41119303|NCT00824135|DRUG|Mycophenolate mofetil|"Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)"
41119304|NCT00824135|DRUG|Rituximab|375 mg/m2 intravenous for 1 dose total
41271599|NCT06067854|PROCEDURE|the standard procedure - without regional anaesthesia|the standard procedure - without regional anaesthesia
41271600|NCT06067854|PROCEDURE|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon
41271601|NCT05897814|OTHER|Location of the epidural analgesia catheter|Research of the location of the epidural analgesia catheter using M-mode and color Doppler (cD) ultrasonography.
41271602|NCT00316823|GENETIC|gene expression analysis|
41271603|NCT00316823|GENETIC|polymerase chain reaction|
41271604|NCT00316823|GENETIC|reverse transcriptase-polymerase chain reaction|
41271605|NCT00316823|OTHER|diagnostic laboratory biomarker analysis|
40753086|NCT01658735|DEVICE|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
41119305|NCT00824135|OTHER|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
41271606|NCT00316823|OTHER|immunohistochemistry staining method|
41271607|NCT00316823|PROCEDURE|needle biopsy|
41271608|NCT03501862|BEHAVIORAL|Mindfulness-based cognitive therapy (psychosis)|A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills
41271609|NCT03501862|BEHAVIORAL|Psychoeducation (psychosis)|A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
41271610|NCT05205590|OTHER|Non|Non
41271611|NCT01283737|DEVICE|DBX Putty|OCD of the knee will be treated with DBX Putty
41271612|NCT01283737|PROCEDURE|Mosaicplasty|Mosaicplasty procedure performed to treat OCD of the knee
41271613|NCT03502187|BEHAVIORAL|Progressive Exercise Plan|The goal of PEP is to reduce back pain, disability, and improve trunk flexibility, strength and endurance through controlled, gradual, progressive back exercises. PEP teaches muscle strengthening exercises and self-management strategies to promote back fitness. PEP sessions provide a standardized self-management framework for performing the exercises at home. PEP is performed every other day/week for about \~1 hour over a period of 9 weeks. PEP consists of 3 sequential phases with each phase lasting 3 weeks. Exercises become progressively more difficult and intense, focusing on back stretching and strengthening that progressively load and unload the lumbar spine by means of flexion/extension exercises. The PEP group will perform 31 exercise sessions for 60 minutes on alternating days.
41271614|NCT03502187|DEVICE|NeuromuscularElectricalStimulation(NMES)|The NMES treatment group will receive a portable battery-operated device, Recovery Back (Neurotech®, Minnetonka, MN) with a 2-garment site-specific system: back \& abdomen. NMES muscle contractions will be elicited by an electrical impulse generated by the Recovery Back system. The device delivers a pre-set program of NMES using a symmetrical biphasic square pulse waveform. (Moore SR, Shurman J, 1997) The garments are light-weight, breathable fabric that wraps around the waist with precise placements for the reusable electrodes. The controller uses a rechargeable battery with charger supplied. The NMES protocol consists of 30-minutes of NMES stimulation alternating between the abdominal and lumbar site over 9-weeks (one day Back training, next day Abdominal training).
41271615|NCT03502187|BEHAVIORAL|Primary Care Management (PCM)|All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.
41271616|NCT03812406|PROCEDURE|French Abulatory Cesrean Section|A cesarean section performed according to the FAUCS technique
41271617|NCT03812406|PROCEDURE|Misgav-Ladach|A cesarean section performed according to the Misgav Ladach technique
41271618|NCT04598542|DRUG|Lorecivivint (LOR)|0.07 mg
41271619|NCT04598542|DRUG|Triamcinolone acetonide (TA)|40 mg
41271620|NCT02714179|DRUG|Paracetamol was given intravenously in both group at different times|
41271621|NCT03892421|DRUG|Rituximab|Rituximab 375 mg/m²
41271622|NCT03892421|DRUG|Carboplatin|Carboplatin AUC5
41446365|NCT06459258|OTHER|Motion-triggered NMES training protocol|Experimental group subjects undergo a motion-triggered NMES shoulder strengthening training program (3x/week, 30 minutes for 6 weeks) using the Shoulder Pacemaker (NCS Lab Srl, Modena, Italy), a motion activated stimulation device to strengthen muscular disbalances. This is accomplished through varying neuromuscular electrical stimulation intensity based on the angle of motion of the arm producing subtetanic contraction and provoking supraspinal neural adaptations. Electrode placement: electrode 1, inferior to the scapular spine (infraspinatus, teres minor, + posterior deltoid); electrode 2, medial to the medial scapula border (lower trapezius + rhomboids) . Sets x repetitions: 3x20 Levels: Level 1-3; Exercise 1: L1: Supported row, L2: Front raises in 45°, L3 Front raises (thumbs up) Exercise 2: L1: Resisted front raises, L2: Crossbody resisted raises, L3: Crossbody; forehand swing; Exercise 3: L1: Rear dealt fly, L2: Single arm resisted row, L3: Underhand volleyball
41446366|NCT06459258|OTHER|Non-Motion-triggered NMES training protocol|Arm Description: Subjects of the control group undergo a conventional standardized strength training program (3x/week, 30 minutes for 6 weeks) with concentric, eccentric, and functional training exercises.
41119306|NCT00010725|DRUG|MAK|
41119307|NCT00010725|DRUG|Vitamin Supplements|
41119308|NCT00422006|PROCEDURE|biopsy of muscle, of liver, and of adipose tissue|biopsy of muscle, of liver, and of adipose tissue
41119309|NCT00422006|PROCEDURE|clamp euglycemic - hyperglycemic|clamp euglycemic-hyperglycemic
41119310|NCT00422006|BEHAVIORAL|diet|diet
41119311|NCT00422006|OTHER|biopsies for biological and genetic analyses|biopsies for biological and genetic analyses
41119312|NCT05445440|DRUG|Methotrexate|Specified dose on specified days
41271623|NCT03892421|DRUG|Cytarabine Injection|Cytarabine 2000 mg/m² qd 2 days
41271624|NCT03892421|DRUG|Dexamethasone|Dexamethasone 40 mg
41271625|NCT03892421|DRUG|Filgrastim 0.3 MG/ML|One subcutaneous injection daily for 5 days
41271626|NCT03948789|PROCEDURE|Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy|Magnetic Resonance Imaging-controlled high-focussed ultrasound
41271627|NCT03948789|PROCEDURE|Myomectomy (laparoscopic or open surgical)|Myomectomy (laparoscopic or open surgical)
41271628|NCT01228747|DRUG|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
41119313|NCT05445440|DRUG|Leucovorin|Specified dose on specified days
41119314|NCT05445440|DRUG|BMS-986371|Specified dose on specified days
41119315|NCT05445440|DRUG|Sulfasalazine|Specified dose on specified days
41119316|NCT06217874|OTHER|Non-Interventional Study|Non-interventional study
41119317|NCT03205436|OTHER|Affinity human amniotic membrane|fresh hypothermically stored human amniotic membrane
41119318|NCT04353102|DRUG|YH002|YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.
41119319|NCT01691690|DRUG|Acetaminophen (paracetamol)|Acetaminophen IV (15 mg/kg).
41119320|NCT01691690|DRUG|Normal Saline Flush|Saline placebo will be infused intraoperatively.
41119321|NCT01691690|DRUG|Midazolam|Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
41119322|NCT01691690|DRUG|Sevoflurane|Sevoflurane for anesthesia induction.
41119323|NCT01691690|DRUG|Nitrous Oxide/Oxygen|Combination of NO2 \& O2 for anesthesia induction.
41119324|NCT01691690|DRUG|Propofol|Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.
41119325|NCT01691690|DRUG|Morphine|Morphine 0.1 mg/kg given prior to intubation.
41119326|NCT01691690|DRUG|Ondansetron|Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.
41119327|NCT01691690|DRUG|Dexamethasone|Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
41119328|NCT02361918|PROCEDURE|Colon surgery|
41119329|NCT02990546|DRUG|midodrine|Midodrine will be given to treatment arm as enteral medication
41119330|NCT02990546|OTHER|Standard of Care|Patients in the control arm will receive standard of care for septic shock
41271629|NCT01228747|DRUG|Placebo|Matching oral placebo tablets twice daily for 28 weeks
41271630|NCT05728814|DRUG|Dostarlimab|"The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles."
41271631|NCT04103866|DEVICE|Juvederm Voluma|Juvederm will be used in various parts of the foot to increase collagen volume and decrease high pressures of stress typically seen as people age. It will serve to promote the following: foot cushioning due to tissue atrophy, increase comfort when walking, decrease gait peak pressures which will decrease stress on bones and soft tissue and heal calluses, skin lesions, etc. It will also decrease the patient need for balancing and offloading by the use of an in-shoe orthotic device that requires a closed shoe system. Many people complain of pain walking barefoot, in high heels and sandals where orthotics are not effective.
41271632|NCT00716976|DRUG|sodium thiosulfate|Given IV
41271633|NCT00716976|PROCEDURE|examination|Patients undergo audiological assessments periodically
41119331|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed drink|Drink containing flaxseed mucilage
41119332|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed drink|Drink containing flaxseed mucilage
41119333|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed tablet|Tablets containing flaxseed mucilage consumed with a control drink
41119334|NCT01238744|DIETARY_SUPPLEMENT|Control drink|Control drink
41119335|NCT03324945|BEHAVIORAL|Neurocognitive assessments|Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
41119336|NCT06550245|OTHER|Infants observing familiar and unfamiliar racial groups|All infants will see videos of people from familiar and unfamiliar racial backgrounds. Depending on the caregiver's race, infants will be assigned to see people who are from the same racial background as their caregiver (i.e., familiar) and people who are not.
41119337|NCT05231408|OTHER|High-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
41119338|NCT05231408|OTHER|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
41119339|NCT03117023|DRUG|dexmedetomidine|sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
41119340|NCT04364451|OTHER|Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Leukaemia During Therapy With L - Asparaginase|Children that meet all the inclusion criteria for this study will be examined and undergo treatment with asparaginase (Experimental group) and will be compared to the corresponding teams of healthy children and children that have ailed and are off chemotherapy for at least 6 months (Control group).
41271634|NCT01781455|DRUG|BBI503|
41271635|NCT03599661|OTHER|Interview|Participants will review a computer prototype of Fertilit-e alpha. Using an interview guide, participants will be asked about issues of content, functionality, and ease of use (i.e., comprehensibility and usability). Interviews will be completed within 45-60 minutes.
41271636|NCT03599661|OTHER|Questionnaire Administration|All participants will complete an interviewer administered screener for health literacy and self-report items for technology use, eHealth literacy, and need for cognition.
41271637|NCT02832089|DRUG|oral carvedilol|oral carvedilol in escalating doses for reducing ventricular rate in AF patients
41271638|NCT02419027|DIETARY_SUPPLEMENT|GI Flora|
41271639|NCT02419027|DIETARY_SUPPLEMENT|Placebo|
41271640|NCT01296048|DEVICE|Comparison test|Scaleman Body Fat Scales, FS-148BW1, accuracy: ±0.1kg and range: 0-180kg.
40926314|NCT03712007|DEVICE|MAMP therapy with MARPE expander|Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.
41119341|NCT05975749|DRUG|Serplulimab|Serplulimab: 4.5mg/Kg on day 1
41446367|NCT03537807|DRUG|Riluzole|For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).
41119342|NCT05975749|DRUG|Trastuzuma|Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1
41119343|NCT05975749|DRUG|Chemotherapy|Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
41119344|NCT01551355|BEHAVIORAL|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
41119345|NCT04995718|OTHER|Intelligent Physical Exercise Training (IPET)|Wind technicians performed 1-hour weekly individualized physical exercise training during working hours. The specific content of the exercise program was based on the specific job exposure profile, the physical capacity profile and the physical health profile of the employee.
41119346|NCT00206986|DRUG|clonidine|Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication
41271641|NCT01151137|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
41271642|NCT01151137|DRUG|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
41446368|NCT05431491|DEVICE|Ultrafiltration|Ultrafiltration through much smaller intravenous cannula than what has previously been used.
41446369|NCT04137835|DEVICE|Showmotion|Each healthy volunteers will wear sensors at the interested joint and do the measurement.
40926315|NCT03712007|DEVICE|MAMP therapy with Hyrax expander|Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
41119347|NCT00206986|DRUG|clonidine|0.15 mg of clonidine will be administered to 20 healthy male volunteers
41119348|NCT03203538|DEVICE|LED-light, 1000 lux|Full-spectrum light, 1000 lux, 4000 K. Represent a light intensity within acceptable range (light that is not too glary); 4000 K is among the most commonly used indoor light colour temperatures.
41271643|NCT00367211|DRUG|PN 200 tablets (500 mg naproxen and 20 mg omeprazole)|
41271644|NCT00367211|DRUG|Naproxen 500 mg tablets (PN 200 minus omeprazole)|
41271645|NCT04045067|PROCEDURE|Isolation of pulmonary veins|Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
41271646|NCT04045067|PROCEDURE|Ablation by radiofrequency of low-voltage areas|The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
41271647|NCT02945657|DRUG|MM36 topical ointment, 1%|Twice daily application for 28 consecutive days
41446370|NCT06408519|OTHER|Placebo (open-label)|P-Tabletten weiss 10mm (Lichtenstein, Zentiva) pills 3x/day
41271648|NCT05096299|DEVICE|OCS Heart|Transplanted with OCS preserved heart.
41271649|NCT00275561|DRUG|Fluticasone|Aerosolized swallowed fluticasone 880 mg twice a day
41119349|NCT03203538|DEVICE|LED-light, 100 lux|Full-spectrum light, 100 lux, 4000 K. Represent a light intensity within acceptable range (light that provides sufficient eye sight); 4000 K is among the most commonly used indoor light colour temperatures.
41119350|NCT03203538|DEVICE|LED-light, 7000 K|Full-spectrum light, 7000 K, 200 lux. Represent the upper border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
41119351|NCT03203538|DEVICE|LED-light, 2500 K|Full-spectrum light, 2500 K, 200 lux. Represent the lower border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
41119352|NCT03203538|DEVICE|Blue LED-light|Blue light with peak wavelength 455 nm. Known to delay the circadian rhythm, suppress melatonin, and increase alertness.
41119353|NCT03203538|DEVICE|Red LED-light|Red light with peak wavelength 615 nm. Known not to affect the circadian rhythm, melatonin, and alertness.
41119354|NCT03576742|DIAGNOSTIC_TEST|potential biomarkers|facs analysis, microbiome analysis
41119355|NCT04011631|PROCEDURE|Internal defibrillation during cardiac surgery, using the iD-system|When ventricular fibrillation of ventricular tachycardia occurs during surgery, the iD-Paddle will be applied directly to the heart. A maximum of 4 shocks are delivered to the heart to restore normal sinus rhythm. If 4 shocks are not successful standard operating procedure will be enable conform hospital protocol.
41119356|NCT06118827|DRUG|HS-10518|QD, orally for 7 days
41119357|NCT06118827|DRUG|Placebo|QD, orally for 7 days
41119358|NCT04921293|BEHAVIORAL|Ketogenic diet|A diet with \<50gr of carbohydrates per day. Monosaturated fats consumption will encourage over saturated fats
41119359|NCT04921293|DIETARY_SUPPLEMENT|Exogenous ketones|Administration of ketone monoester 25 ml t.i.d
41119360|NCT04921293|BEHAVIORAL|Standard diet + placebo|A standard diet incorporating current recommendations (low in sodium and low in liquids) for heart failure patients.
41119361|NCT06079931|DRUG|Babaodan Capsule|The patient received 66-66Gy/30-33F radiation therapy. During radiation therapy, concurrent chemotherapy includes receiving 45mg/m2 paclitaxel and carboplatin (AUC 2) once a week; From the start of radiation therapy to 2 months after the completion of CCRT, the patient takes 2 capsules of Babaodan orally every day, tid (1.8 g/day), and systemic corticosteroids can be used for acute radiation pneumonia patients with G ≥ 2.
41119362|NCT05874830|OTHER|Fecal microbiota transplant or plasebo through endoscopy|Colonoscopy and gastroscopy
41119363|NCT04441008|DEVICE|Accelerated Intermittent Theta Burst (aiTBS)|High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.
41119364|NCT04441008|DEVICE|Electroconvulsive therapy (ECT)|ECT as per standard clinical care and management.
41119365|NCT01603758|DRUG|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
41119366|NCT03701386|PROCEDURE|cesarean hysterectomy|Elective cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. Delivery will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
41271650|NCT00275561|DRUG|Placebo|Placebo inhaler swallowed twice a day for 6 weeks
41271651|NCT04239417|OTHER|Graduated abdominal strengthening exercises|"1. Exercise mat and inflatable Swiss ball~2. Wall bar, wedges, elastic tubing"
41119367|NCT03701386|PROCEDURE|N&H sandwich technique|In the N\&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade will be performed
41119368|NCT04114786|DEVICE|3D-printed mask|After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment
41119369|NCT04114786|DEVICE|Thermoplastic mask|Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
41271652|NCT04239417|DEVICE|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
41271653|NCT04239417|COMBINATION_PRODUCT|Graduated abdominal strengthening exercises and the Russian current stimulation|Combination between The Russian current and abdominal exercises
41271654|NCT01769937|DRUG|H.P. Acthar Gel|Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
41271655|NCT03152942|DRUG|Progesterone|Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
41271656|NCT03152942|DRUG|Aminophylline|Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
40926316|NCT00731042|DRUG|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
40926317|NCT00731042|DRUG|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
41271657|NCT03709992|DRUG|Trospium Chloride|30 mg of Trospium chloride tablet twice daily
41271658|NCT03709992|DRUG|Tamsulosin|0.4 mg of Tamsulosin tablet once daily
41271659|NCT05448118|DIAGNOSTIC_TEST|Virtual POC Toxicology Test|Providers and patients will use Saliva Toxicology test at the point of care during virtual care visits.
41271660|NCT05685940|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.
41271661|NCT05685940|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
41271662|NCT02370121|DRUG|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
41271663|NCT02370121|DRUG|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
41446371|NCT06408519|DRUG|Ibuprofen 400 mg|Ibuprofen pills 3x/day
41119370|NCT01839526|DRUG|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
41119371|NCT03473340|DRUG|Pirfenidone Capsule|"Dosing:~Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
41271664|NCT03396289|OTHER|Conventional physiotherapy including balance exercises|Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.
41271665|NCT03396289|OTHER|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
41271666|NCT01708031|OTHER|physiological signals|
41119372|NCT03473340|DRUG|Placebo Capsule|"Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
41119373|NCT05992298|OTHER|7 T MRI vs 3 T MRI|Adult healthy and patient volunteers will undergo a ca. 1 hour examination of non-invasive magnetic-resonance imaging at 7T, and, if appropriate, a closely matching examination at 3T as a standard of reference.
41119374|NCT03966846|DIETARY_SUPPLEMENT|Kefir|
41119375|NCT03966846|DIETARY_SUPPLEMENT|Milk|
41119376|NCT03113630|DEVICE|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
41119377|NCT03113630|DEVICE|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
41271667|NCT01427309|BIOLOGICAL|High Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
41271668|NCT01427309|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
41271669|NCT04023084|DRUG|Crisaborole|Crisaborole 2% topical ointment applied twice daily to affected area(s) for 28 days
41271670|NCT01557790|RADIATION|Proton Radiation Therapy|
41271671|NCT03315026|DRUG|Siltuximab|Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 (+/-2) after stem cell infusion.
40753087|NCT01658735|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
41119378|NCT03113630|DEVICE|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
41271672|NCT03315026|BEHAVIORAL|The M.D. Anderson Symptom Inventory (MDASI)|assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).
41271673|NCT00854269|PROCEDURE|surgery|cervical biopsy or specimen of hysterectomy
41271674|NCT00001757|DRUG|Voriconazole|
41271675|NCT02823457|BEHAVIORAL|VBMI|12 week values based motivational interviewing intervention with a licensed psychologist
41271676|NCT03284190|PROCEDURE|Surgery|Surgery
41271677|NCT03609255|BEHAVIORAL|Reducing sedentary behavior|Educational handouts for sedentary behavior and strategies reducing sedentary behavior and weekly videos related to reduced sedentary behavior
41271678|NCT03609255|BEHAVIORAL|Reducing stress|Educational handouts for sedentary behavior and stress management handout and weekly videos related stress management
41271679|NCT03609255|BEHAVIORAL|Control|An educational handout for sedentary behavior and weekly neutral topic videos
40753088|NCT01658735|DEVICE|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
41119379|NCT03113630|DEVICE|Acquisition on TouchScreen Control Group|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
41119380|NCT03113630|DEVICE|Acquisition on Kinect Control Group|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
41119381|NCT03113630|DEVICE|Acquisition on LeapMotion Control Group|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
41119382|NCT00637585|DRUG|Fexofenadine|
41271680|NCT06016816|PROCEDURE|Bilateral endoscopic sphenopalatine ganglion block|After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,
41271681|NCT06016816|PROCEDURE|placebo|Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
41271682|NCT00542711|DRUG|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
41453398|NCT01216020|DRUG|cetuximab|"* Cetuximab is given according to the standard mode of administration: loading dose : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
41119383|NCT02657733|DEVICE|Radical-7|"Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.~Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa)."
41119384|NCT02657733|DEVICE|Nellcor™ Bedside Respiratory Patient Monitoring System|"Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.~Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi)."
41119385|NCT02657733|DEVICE|Capnostream 20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
41119386|NCT04157426|OTHER|Percutaneous electrolysis|Ultrasound-guided percutaneous electrolysis in the active myofascial trigger point of the levator scapulae muscle
41119387|NCT04157426|OTHER|Dry needling|Ultrasound-guided dry needling the active myofascial trigger point of the levator scapulae muscle
41271683|NCT01773655|OTHER|tumor specimens|"All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).~Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome."
41271684|NCT00701493|DRUG|Topiramate oral liquid formulation;Topiramate Sprinkle formulation|
41271685|NCT05451420|DRUG|PegIFN α- 2b|"Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）"
41271686|NCT05238584|PROCEDURE|Partial omentectomy|Partial omentectomy: with preservation of the greater omentum at \>2 cm from the gastroepiploic arcade.
40753089|NCT05129384|DIETARY_SUPPLEMENT|B. infantis EVC001 or Lactose Placebo|Infant probiotic
40753090|NCT03701178|OTHER|BioHPP PEEK|milled BioHPP PEEK in a new material can be used as a dental restoration
41119388|NCT02371512|DEVICE|MitraClip system (Abbott Vascular, Menlo Park, USA)|Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
41119389|NCT02371512|PROCEDURE|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
41271687|NCT00981994|BEHAVIORAL|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
41271688|NCT01157117|BIOLOGICAL|Placebo for omalizumab|Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
41271689|NCT01157117|BIOLOGICAL|Omalizumab|Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
41271690|NCT01157117|DRUG|Milk powder|Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
41271691|NCT00022074|DRUG|gabapentin|
41271692|NCT00022074|PROCEDURE|quality-of-life assessment|
41271693|NCT01287104|BIOLOGICAL|Natural Killer (NK) Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
41271694|NCT01287104|BIOLOGICAL|Stem Cell Infusion|Transplant Day 0: \>4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) \>5000/microliters x2
41119390|NCT03878199|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
40753091|NCT03296345|DRUG|Ketamine|The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).
40753092|NCT05839119|DRUG|Degarelix|initial dose is 240 mg administered as two 120 mg (3 mL) injections (SC), followed by subsequent doses at 80 mg (4 mL) administered as one injection (SC)
41119391|NCT03878199|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
41119392|NCT03878199|DRUG|Ruxolitinib|Given PO
41119393|NCT04525651|DEVICE|Digital Acupuncture Manipulation Therapeutic Instrument|The device is based on the characteristics of traditional acupuncture manipulation of Shanghai School of Traditional Chinese Medicine, and absorbs the information of the techniques of famous experts, modulates the stimulation waveform of the electroacupuncture device by modulating the signal, and realizes the digitization of acupuncture technique information.
41119394|NCT04525651|OTHER|Manual Acupuncture|Manual acupuncture to acheive de qi.
41119395|NCT04525651|OTHER|Sham Acupuncture|Sham acupuncture to avoid de qi.
41119396|NCT00526006|DRUG|esomeprazole|40 mg od for 8 wks
41119397|NCT06175520|BEHAVIORAL|Preconception care (PCC)|The investigators will introduce PCC through the existing public health system. At the community level facility, healthcare providers will screen the women for some specific health problems and provide necessary supplements. Healthcare providers will screen for health problems such as- infectious diseases (e.g., Tuberculosis), Hypertension, Anaemia, Diabetes Mellitus, Thyroid problems, Sexually Transmitted Infection/Reproductive Tract Infection/Urinary Tract Infection, Nutritional status (e.g., Body mass index), Thalassemia symptoms, Thyroid symptoms, severe Dysmenorrhea, Immunization status, and Symptoms of acute Hepatitis B Virus infection, etc. The provider will also consider age, menstrual history, and reproductive history during preconception screening. If the provider finds any abnormality from the screening test which is a risk for a woman to become pregnant and for her newborn; the woman will be provided proper counseling, treatment, and referral to the appropriate facility.
41119398|NCT06057116|OTHER|massage|Massage and acupressure were applied when cervical dilatation was 3-4, 5-7 and 8-10 cm in latent active and transitional phases.
41119399|NCT05622110|PROCEDURE|Adhesive glue closure|Incision closure with adhesive glue
41119400|NCT05622110|PROCEDURE|Subcuticular closure|Incision closure with 3-0 vicryl subcuticular sutures
41119401|NCT04156204|OTHER|Medication Event Monitoring System (MEMS)|AYA kidney recipients will receive a Medication Event Monitoring System (MEMS) via medication bottle and cap system
41119402|NCT04156204|DRUG|Once-Daily Tacrolimus extended release|AYA kidney recipients will receive once daily tacrolimus XR 1-10mg daily
41119403|NCT01367405|PROCEDURE|Surgical decompression|Surgical decompression within 24 hour postinjury
41119404|NCT01367405|PROCEDURE|Conservative treatment|Usual conservative treatment without surgery
40753093|NCT05839119|COMBINATION_PRODUCT|Gemcitabine/Cisplatin|"SOC Neoadjuvant Chemotherapy: Gemcitabine/Cisplatin 21-day cycles (4 cycles total)~* Gemcitabine: 1000 mg/m2 (IV) Days 1 and 8 of each cycle~* Cisplatin: 70 mg/m2 (if borderline renal function: 35 mg/m2) (IV) Day 1 of each cycle (if borderline renal function, days 1 and 8 of each cycle)."
41271695|NCT03035760|DRUG|Oxfendazole|methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
40753094|NCT01713738|DRUG|rituximab|infusion of 4 weekly doses of 375 mg/m2 rituximab
41119405|NCT01159275|DRUG|Generic LPV/r and Aluvia (pharmacokinetics)|Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID
41119406|NCT01159275|DRUG|Aluvia and Generic LPV/r (pharmacokinetics)|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
41119407|NCT06497959|DRUG|SonoVue|Placental contrast ultrasound using SonoVue by maternal intravenous injection
41119408|NCT06239012|DEVICE|Position measurement with BePow|14 measurements taken with the device
41119409|NCT06239012|OTHER|Position measurement with MCPAA scale|MCPAA : measurement of seated postural control in adults in French 12 measurements taken with the goniometer
41119410|NCT00591708|DIETARY_SUPPLEMENT|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
41119411|NCT00591708|DIETARY_SUPPLEMENT|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
41119412|NCT04080336|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
41119413|NCT04080336|DRUG|Misoprostol|1 vaginal tablet of misoprostol (200mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
41119414|NCT04080336|DRUG|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
41119415|NCT05035966|OTHER|Plasma β-amyloid 40 and 42 concentration|Plasma β-amyloid 40 and 42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).
41119416|NCT03516240|OTHER|Biofreeze|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group.
41119417|NCT03516240|OTHER|Placebo|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group. Placebo cream will be blinded to both the experimenter and study participant. It will look and smell the same and will be in the same packaging.
41119418|NCT01534494|DRUG|Psilocybin|two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
41119419|NCT05720455|DRUG|Fexofenadine HCL and pseudoephedrine HCL|Extended-Release Tablets
41119420|NCT02232295|DEVICE|Recognise [TM]|Recognise accurately measures to identify left and right body parts and movements, and to train left/right discrimination as part of a comprehensive GMI rehabilitation process.
41271696|NCT00058461|DRUG|ifosfamide|Given IV
41119421|NCT02232295|DEVICE|Mirror Box|A resource used for many pain and disability states of the hands and feet.
41119422|NCT05977179|OTHER|Dietary intervention to mitigate Post-Acute COVID-19 Syndrome|As it was described in the arm/group descriptions.
41119423|NCT05977179|OTHER|Attention Control|As it was described in the arm/group descriptions.
41119424|NCT01449123|DRUG|Mannitol challenge test & reversibility test|"Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness"
41119425|NCT03608202|BEHAVIORAL|POCUS protocol group|"The findings of multiorgan ultrasound can modify diagnoses and treatments and immediate interventions (eg volume loading with saline solution, pleural or pericardial drainage, initiation of diuretics, increase in positive end expiratory pressure, etc.).~This protocol is performed in the first 24 h of admission to the Intensive Care Unit (ICU) and is repeated at 24 h."
41271697|NCT00058461|DRUG|etoposide|Given IV
41271698|NCT00058461|BIOLOGICAL|rituximab|Given IV
41271699|NCT00058461|DRUG|carboplatin|Given IV
41271700|NCT00058461|BIOLOGICAL|filgrastim|Given SC
41271701|NCT00058461|DRUG|methotrexate|Given IT
41271702|NCT00058461|DRUG|cytarabine|Given IT
41271703|NCT00058461|OTHER|laboratory biomarker analysis|Correlative studies
41271704|NCT00452803|DRUG|chemotherapy|Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
41271705|NCT00452803|DRUG|Concurrent chemoradiation therapy|Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
41119426|NCT03608202|OTHER|Control group|Routine protocol of the treating team is followed
41119427|NCT03101930|DRUG|Liraglutide|subcutaneous liraglutide daily
41119428|NCT03101930|DRUG|Sitagliptin|oral sitagliptin daily
41119429|NCT03101930|OTHER|hypocaloric diet|Reduced calorie intake to achieve weight loss.
41119430|NCT03101930|DRUG|Placebos|Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
41119431|NCT03101930|DRUG|Exendin (9-39)|All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
41271706|NCT00452803|RADIATION|Concurrent chemoradiation therapy|Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
41271707|NCT06047704|OTHER|No intervention|No intervention
41271708|NCT00191854|DRUG|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
41271709|NCT00191854|DRUG|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
41271710|NCT00191854|DRUG|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
41271711|NCT00191854|DRUG|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
41271712|NCT03541473|DIETARY_SUPPLEMENT|Peptamen® 1.5 Vanilla|Nutritionally complete formula with 10g MCT in 250 mL, commercially available
41271713|NCT03541473|DIETARY_SUPPLEMENT|Boost Plus® Vanilla|Product of same nutritional composition but without MCT
41271714|NCT02608632|DEVICE|Renal denervation guided by HFS|
41271715|NCT02608632|DEVICE|Renal denervation as standard procedure|
41271716|NCT04003129|OTHER|questionnaire|"Data will be obtained through a written questionnaire for assessing knowledge, practice and attitude of paediatricians regarding early childhood caries.~Data collected will be saved and tabulated on computer and finally statistically analysed."
41271717|NCT06427447|COMBINATION_PRODUCT|Adjuvant chemoradiotherapy|Upfront chemotherapy (gemcitabine plus capecitabine) followed chemoradiotherapy (radiotherapy with concurrent capecitabine)
41119432|NCT06206824|DRUG|Leucettinib-21|See arm's description.
41119433|NCT02653508|BEHAVIORAL|Diet and Activity|During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.
41271718|NCT06427447|DRUG|Adjuvant chemotherapy|Chemotherapy (gemcitabine plus capecitabine)
41271719|NCT05383235|OTHER|ROUTINE CARE|1. ROUTINE CARE : retrieval of sociodemographic characteristics, medical and psychological assessment, multidisciplinary meeting about the patient
41271720|NCT05383235|DEVICE|Facial emotion stimuli prensentation task with EEG recording and facial emotion recognition task|"2. RUN-IN PERIOD :~* Eligibility criteria will be assessed during the multidisciplinary meeting;~* Study presentation, delivery of the information note and consent form; 3. STUDY:~* Collection of consent form;~* Facial emotion stimuli presentation task with EEG recording and facial emotion recording task;~* Neuropsychological evaluation (TOM-15);~* Scales and questionnaires (TAS-20, PCL-R SV, CECAQ, QCAE);~* Debriefing."
41271721|NCT00686816|DIETARY_SUPPLEMENT|Low calorie diet|low calorie diet
41271722|NCT00686816|DIETARY_SUPPLEMENT|Olestra|low calorie Olestra diet
41271723|NCT03389243|DRUG|Metamizol|in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
41271724|NCT03389243|DRUG|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
41271725|NCT03389243|DRUG|paracetamol and metamizole|in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
41271726|NCT01604746|BIOLOGICAL|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
41271727|NCT05090956|OTHER|mri|
41271728|NCT03068715|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
41271729|NCT03068715|DEVICE|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
41271730|NCT03068715|DEVICE|Open label TBS-DLPFC|"All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
40753095|NCT05335265|OTHER|Treatment training|"Face-to-face:Metered-DoseInhalerTraining gave 3 times on the 1st day, 2 times on the 2nd day, once on the 3rd day.During discharge, inhaler technical evaluation were done according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by using the Patient's Booklet of the Turkish Thoracic Society (TTS).The people who is evaluate the patient's inhaler technique (IT) on the day of discharge was someone different from the health personnel who provided the training. In IT control, the patient's performance was evaluated simultaneously by 2 observers.~Video training:Training gave 3 times on the 1st day, 2 times on the 2nd day,once on the 3rd day.The TTS-Virtual Training Video were used.During discharge,inhaler technical evaluation was done same with face-to-face training.The person who is evaluate the patient's IT was someone different from the training personnel.In IT observation,it was used same method with face-to-face training."
41119434|NCT02653508|BEHAVIORAL|Activity|All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
41119435|NCT01519037|DRUG|Cinacalcet 60 MG|one dose of oral cinacalcet, 60mg
41271731|NCT03668756|PROCEDURE|Computer-Assisted Navigation TKA|TKAs were performed using the image-free CAS navigation system VectorVision
41271732|NCT05002478|OTHER|Prone positioning|Turn patient in prone position after surfactant administration.
41271733|NCT00096161|DRUG|Cyclosporine|Given PO
41271734|NCT00096161|DRUG|Mycophenolate Mofetil|Given PO
41271735|NCT00096161|DRUG|Pentostatin|Given IV
41271736|NCT00096161|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
41271737|NCT02922387|DRUG|Varenicline|Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
41271738|NCT02922387|BEHAVIORAL|Behavioral support|An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
41271739|NCT01099228|OTHER|131-I MIBG and 111-In pentetreotide|Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
41271740|NCT01099228|OTHER|131-I MIBG and In-111 DOTATATE|131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
41271741|NCT02340650|DEVICE|Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope|
41119436|NCT01519037|DRUG|Placebo oral tablet|one tablet of placebo
41271742|NCT00814931|DRUG|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
41271743|NCT00814931|DRUG|Placebo|matching oral liquid suspension placebo twice a day for 8 days
41271744|NCT02485717|DRUG|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
41271745|NCT02485717|OTHER|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
41271746|NCT04548076|OTHER|Block group|Control group
41271747|NCT05424393|DRUG|YISAIPU® ( An etanercept biosimilar)|YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.
41446372|NCT06626841|DIAGNOSTIC_TEST|Pelvic floor muscles contractile capacity and activation|"An initial assessment of the pelvic floor is carried out when athletes arrive at the facility. Participants then complete a FFT workout, which consists of performing as many rounds as possible (AMRAP type) of 20 wallballs, 15 box jumps, and 10 burpees within 15 minutes. These plyometrics and load lifting exercises are chosen to fatigue the PFM and are simple to execute. The pelvic floor assessment is performed again at 3 minutes following the FFT workout.~Measurements of the pelvic floor parameters are conducted by a specialist physiotherapist. The muscle activation and strength of the PFM are obtained using a vaginal dynamometer (i.e. pelvimeter probe fixed at a vertex with two arms that can be separated by up to 25°), connected to the Phenix USB2, Vivaltis (Pelvimètre Phenix, Vivaltis)."
41119437|NCT02559362|BEHAVIORAL|Survey|
41119438|NCT05486052|OTHER|Evaluation of reliability, repeatability and validity of devices among healthy subjects|"Evaluation of reliability, reproducibility and validity of devices among healthy subjects Prior to the study among individuals with neurological disorders, an evaluation of the reliability, repeatability and credibility of the devices to be included in the biofeedback rehabilitation and optical oximetry measurements will be carried out.~The evaluation of the devices will be carried out by two independent researchers twice"
41271748|NCT05424393|DRUG|csDMARDs|csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
41271749|NCT05875545|OTHER|Breathing Exercises|Diaphragmatic breathing exercises with a physiotherapist for 8 weeks, two days a week
41271750|NCT05875545|OTHER|Pelvic Floor Exercises|Pelvic floor exercises with a physiotherapist for 8 weeks, two days a week
41271751|NCT02757547|DEVICE|Transcranial magnetic stimulation - Placebo Arm|Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.
41446373|NCT05404490|DRUG|Bupivacain|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
41119439|NCT05486052|OTHER|Biofeedback method and Health-resort based rehabilitation Health-resort based treatments supplemented with biofeedback training|"The rehabilitation programme will run for 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massages, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.~Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, peat wraps, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy."
41119440|NCT05486052|OTHER|Health-resort based rehabilitation Control group - health-resort based treatments, without biofeedback training.|Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy
41119441|NCT01967836|DEVICE|Glad Press 'n Seal|Application of Glad Press n' Seal product as an IV site dressing protection during subject showering
41119442|NCT04125810|BIOLOGICAL|Probiotic|Probiotic
41119443|NCT04125810|OTHER|Placebo|Placebo
41119444|NCT02176772|OTHER|Stable iron isotopes, non-drug intervention|
41271752|NCT02757547|DEVICE|Transcranial magnetic stimulation - Active Arm|Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.
41271753|NCT03515187|DRUG|0.3% sodium hyaluronate ophthalmic solution|one to two drops in eye, four times per day
41271754|NCT03515187|DRUG|0.1% sodium bromide solution|one to two drops in eye, twice per day
41271755|NCT03515187|OTHER|Meibomian gland massage|Physiotherapy
41271756|NCT03515187|OTHER|Placebo|Vehicle
41271757|NCT02774993|DRUG|Doxycycline|
41271758|NCT02774993|DRUG|placebo|
41271759|NCT01929083|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
41271760|NCT01929083|DRUG|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
41271761|NCT01929083|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
41446374|NCT05404490|DRUG|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
41119445|NCT05738707|BIOLOGICAL|Recombinant protein vaccine and adenovirus vector vaccine|Administer recombinant protein vaccine and adenovirus vector vaccine
41119446|NCT03262935|DRUG|(vic-)trastuzumab duocarmazine|Intravenous SYD985, Q3W
41119447|NCT03262935|DRUG|Physician's choice|See drug label
41119448|NCT00115089|DRUG|R926112|
41119449|NCT00115089|DRUG|Beclomethasone dipropionate|
41119450|NCT05339113|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT|Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval.
41271762|NCT04558502|DRUG|Minocycline hydrochloride capsule|Antibiotic for H. pylori eradication
41271763|NCT04558502|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
41271764|NCT04558502|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
41271765|NCT04558502|DRUG|colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
41271766|NCT04558502|DRUG|esomeprazole|Proton pump inhibitor
41271767|NCT06326944|PROCEDURE|Ultrasound- guided Fascia Transversalis plane block|Ultrasound probe will be placed in a transverse orientation above the iliac crest; and the external oblique, internal oblique (IO), and transversus abdominis TA muscles will be identified and traced posteriorly until first the TA muscle and then the IO muscle tapered into their common aponeurosis, adjacent to the quadratus lumborum muscle. The tip of a 22-gauge 80-mm block needle will be positioned just deep to the TA muscle and its aponeurosis at the point where the TA is tapered off. 0.4 ml/kg bupivacaine 0.25% will be injected into the plane between the TA and underlying transversalis fascia
41271768|NCT06326944|PROCEDURE|Ultrasound-guided Transversus abdominus plane block|the probe will be placed transversely in the mid-axillary line between the iliac crest and the costal margin at the level of the umbilicus. The external oblique, internal oblique and transversus abdominis muscles and their fascias will be visualized. A 22 gauge, 80 mm needle will be introduced anteriorly and in the plane of the ultrasound probe, and on entering the plane between IO and TA, 2 ml of 0.9% saline will be injected to verify the correct position of the needle. Following negative aspiration, 0.4 ml/kg of bupivacaine 0.25% will be injected.
41446375|NCT03586622|DIETARY_SUPPLEMENT|Low FODMAP diet (LFD)|The Low FODMAP diet (LFD) is an acronym for Fermentable Oligo-, Di-, and Monosaccharides And Polyols - all of which are small osmotic active carbohydrates or sugar alcohols that are poorly absorbed in the small intestine and therefore easily fermented by the gut microbiota. The fact that they are fermented rapidly and osmotic active makes them potential and likely candidates for causing luminal distension due to accumulation of gas and water in the intestine.
41271769|NCT06326944|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
41271770|NCT06326944|DRUG|Pethidine|Pethidine IV will be given as rescue analgesia (0.5 mg/kg) if the FLACC pain score was more than 4 , the maximum allowed dose is 1mg/kg every 4 hours.
41271771|NCT06326944|DRUG|Acetaminophen|patients will be given paracetamol (15 mg /kg/8 hrs ).
40926318|NCT06162390|DRUG|Remifentanil|"Following a sequential allocation scheme, the predetermined Ce of remifentanil for each patient will be determined by the Dixon up-and-down method. The Ce of remifentanil for the first patient will be 4.0 ng/ml, and then the remifentanil Ce will be increased or decreased in 0.5 ng/ml increments for subsequent patients depending on the success or failure of intubation.~The Ce of remifentanil to provide acceptable intubation at low dose neuromuscular blockade, the primary outcome, will be determined by obtaining seven crossovers of patients with acceptable intubation/unacceptable intubation and then calculating the mean of the midpoint doses for each independent pair of patients. According to previous studies that estimated EC50 by Dixon's up-and-down method, 6-8 failure/success crossover pairs are required, so this study aims to collect independent data of 7 pairs of intubation acceptable/unacceptable patients."
41119451|NCT00176839|PROCEDURE|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
41119452|NCT00176839|DRUG|Busulfan|Prior to transplantation, subjects will receive BUSULFAN via the central venous line, four times a day for four days (days -7 through -4).
41119453|NCT00176839|DRUG|Cyclophosphamide|Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.
41119454|NCT00176839|DRUG|Melphalan|MELPHALAN will be given via the central venous line for one day, on day -1, prior to stem cell transplantation.
41271772|NCT02605525|BIOLOGICAL|SM101|Human soluble recombinant Fcγ Receptor IIB
41271773|NCT02605525|OTHER|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
41271774|NCT02812199|DEVICE|Composite Removable Sinus Stent|Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.
41271775|NCT02812199|DRUG|adrenaline-lidocaine|adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)
41119455|NCT00176839|DRUG|G-CSF|G-CSF is to be given daily IV beginning on day +1 until ANC 2.5 x 109/L.
41271776|NCT02812199|PROCEDURE|cold saline wash|nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
41271777|NCT03124459|DRUG|ACE-083|Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
41271778|NCT03124459|DRUG|Placebo|Recombinant fusion protein or buffer solution
41271779|NCT00781365|OTHER|Telemonitors and pharmacy management|Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
40926319|NCT04575597|DRUG|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
41119456|NCT00176839|DRUG|ATG|ATG will be administered to umbilical cord blood recipients.
41119457|NCT04438343|OTHER|Impairment-specific and augmented intervention|Balance and lower extremities strength training
41119458|NCT04438343|OTHER|Conventional physical therapy|Trunk and upper extremity training
41271780|NCT03823664|DIAGNOSTIC_TEST|Cardiorespiratory Fitness|Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.
41271781|NCT04970667|DRUG|Flupentixol melitracen tablets|Patients were treated with Flupentixol and melitracen tablets for 12 weeks
41271782|NCT05555550|DRUG|18F-Fluciclovine|18F-Fluciclovine will be injected via IV prior to PET-MRI imaging
41271783|NCT02495779|DRUG|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
41271784|NCT02495779|BEHAVIORAL|CBT-based counseling|Brief CBT-based counseling to promote adherence
41271785|NCT00003803|DRUG|cisplatin|
41271786|NCT00003803|DRUG|gemcitabine hydrochloride|
41271787|NCT00003803|RADIATION|radiation therapy|
41271788|NCT04026568|DRUG|4-Aminopyridine|Single drug test for nerve continuity
41271789|NCT04026568|DRUG|Placebo oral tablet|Placebo arm
41271790|NCT01849926|DRUG|Ibuprofen|
41271791|NCT01849926|DRUG|Mecillinam|
41271792|NCT00748657|BIOLOGICAL|Bevacizumab|Given IV
41271793|NCT00748657|OTHER|Laboratory Biomarker Analysis|Correlative studies
41271794|NCT02779205|PROCEDURE|adipose tissue sample|adipose tissue sample
41271795|NCT03240926|DEVICE|Loop Band|Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
41271796|NCT05405829|OTHER|Health education|theoretical-practical hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
41271797|NCT05114772|DIAGNOSTIC_TEST|Measuring Serum bio-markers|ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha
41271798|NCT05597787|BEHAVIORAL|HIV Connect|online education and clinical skills
41271799|NCT05597787|BEHAVIORAL|Project ECHO for HIV Prevention|education and clinical skills
41271800|NCT05597787|BEHAVIORAL|Project ECHO for HIV Prevention and Stigma Reduction|education, clinical skills and contact
41271801|NCT00582517|DEVICE|Compass Universal Hinge External Fixator|Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
41271802|NCT00582517|PROCEDURE|Non-invasive External Knee Brace|For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
40926320|NCT04575597|DRUG|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
41119459|NCT01323686|OTHER|Imaging guided optimal LV lead placement|"LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.~Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate \<30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used."
41119460|NCT00233038|PROCEDURE|Ethanol injection into a cyst|
41119461|NCT04730362|DEVICE|guedel airway|"Anesthesia will be conducted by induction with 1-2~• Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%. The goal is to maintain the patient spontaneous ventilation throughout the procedure. Monitoring of the patients is done by MRI compatible pulse oximetry for heart rate and oxygen saturation which is connected to MRI control room."
41119462|NCT04730362|DEVICE|supraglottic airway|supraglottic airway
41119463|NCT04730362|DRUG|propofol bolus and then anesthesia sevoflurane|Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%
41119464|NCT04113798|OTHER|Day 1 Assessments|Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)
41119465|NCT04113798|OTHER|Day 2 Fear Learning|Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.
41119466|NCT04113798|OTHER|Day 3 Fear Extinction|Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.
41119467|NCT04113798|BEHAVIORAL|Moderate Intensity Exercise|The moderate-intensity aerobic exercise session will consist of a 5 minute warm-up of light intensity activity (40-60% maximum heart rate; MHR) on a treadmill followed by walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes on Day 3
41271803|NCT00287742|DRUG|risperidone|
41271804|NCT03502122|OTHER|VR rehabilitation for motor function|rehabilitation for motor function
41271805|NCT01710930|OTHER|Study of predictive factors|"Phase 1 : Inclusion of patients (V0) :~In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.~Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.~Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9)."
41271806|NCT01814657|DRUG|Lidocaine hydrochloride (HCl) 1% solution|Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
41271807|NCT01814657|DRUG|Sterile Normal Saline%|Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
41119468|NCT04113798|BEHAVIORAL|Low Intensity Exercise|Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for the full duration of 30 minutes.
41119469|NCT04113798|OTHER|Day 4 Recall of Fear Extinction|During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur \~24 hours following Day 3, and lasts about 30 minutes.
41119470|NCT01611246|DEVICE|Iontophoresis System With Earset|iontophoresis of lidocaine-based solution for numbing tympanic membrane
41271808|NCT03469076|OTHER|YUN ACN Cream|YUN ACN Cream with live probiotic bacteria (min. 10-6 à 10-7 CFU per application) applied twice daily (morning and evening) on the entire face
41271809|NCT00609622|DRUG|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
41271810|NCT00609622|DRUG|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
41271811|NCT00609622|DRUG|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
41271812|NCT00609622|DRUG|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
41271813|NCT00960076|DRUG|Saxagliptin|5mg oral tablet once daily
41271814|NCT00960076|DRUG|Metformin XR|500mg oral tablet once daily
41271815|NCT00960076|DRUG|Metformin XR|750mg, 2 tablets once daily
41271816|NCT00579813|DRUG|Pioglitazone|Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
41271817|NCT04477226|DIAGNOSTIC_TEST|Transvaginal ultrasound scan|Transvaginal ultrasound is done to measure the cervical length, as per Fetal Medicine Foundation guidelines
41271818|NCT05312502|OTHER|Birth Ball|During labour, the pregnant woman was positioned using a birth ball.
41271819|NCT03490487|DRUG|conventional antiepileptic drugs|will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
41271820|NCT03490487|DRUG|oral steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
40926321|NCT05779774|BEHAVIORAL|WayToServe Plus In-service Component|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe training only \[comparison control\] v. WayToServe training plus WayToServe Plus in-service component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe training and WayToServe Plus after baseline in Month 18, stratified by state and location. Remaining premises will receive WayToServe Training Only. All premises will be recruited to have servers complete WayToServe training. Servers in intervention group will be accepted into a Facebook private group after WayToServe training to receive in-service component with \~3 posts per week for 12 months. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
41119471|NCT00925886|PROCEDURE|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
41271821|NCT00623831|BIOLOGICAL|Mixed bacterial vaccine|MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
41271822|NCT02631720|PROCEDURE|Blood Draw|
41119472|NCT02523716|OTHER|Hypoxia|Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).
41119473|NCT02523716|OTHER|Normoxia|Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
41271823|NCT02631720|PROCEDURE|Bronchoscopy|
41271824|NCT01802281|PROCEDURE|Uterosacral ligament suspension|The USLS procedure used in this protocol is a modification of the technique described by Shull.
41119474|NCT00763152|OTHER|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
41119475|NCT03201861|DRUG|Paclitaxel, Cisplatin|weekly paclitaxel and cisplatin
41271825|NCT01802281|PROCEDURE|Uphold® LITE|The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
41271826|NCT01739426|DEVICE|Repair w/LigaSure|Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
41271827|NCT00812669|BIOLOGICAL|pegfilgrastim|
41271828|NCT00812669|BIOLOGICAL|rituximab|
41271829|NCT00812669|DRUG|cyclophosphamide|
41271830|NCT00812669|DRUG|fludarabine phosphate|
41271831|NCT00812669|GENETIC|cytogenetic analysis|
41271832|NCT00812669|GENETIC|fluorescence in situ hybridization|
41271833|NCT00812669|GENETIC|gene expression analysis|
41271834|NCT00812669|GENETIC|mutation analysis|
41271835|NCT00812669|GENETIC|protein expression analysis|
41271836|NCT00812669|OTHER|flow cytometry|
41271837|NCT00812669|OTHER|laboratory biomarker analysis|
41271838|NCT06140771|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
41271839|NCT06140771|DRUG|1.15% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
41271840|NCT06140771|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
41271841|NCT06140771|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
41271842|NCT02131857|BEHAVIORAL|active interventional program based on Mindfulness training|active interventional program based on Mindfulness training
41271843|NCT02151825|DIETARY_SUPPLEMENT|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
41119476|NCT03201861|DRUG|EC to docetaxel or paclitaxel|Standard adjuvant chemotherapy recommended by guideline
41119477|NCT00798642|BEHAVIORAL|Hypnotherapy|8 weeks of gut-directed hypnotherapy
41119478|NCT00798642|BEHAVIORAL|Standard care|8 weeks of standard of care
41119479|NCT00798642|BEHAVIORAL|Mind Body Therapy|8 weeks of mind-body therapy
41119480|NCT01136876|DRUG|Iopamidol|Iopamidol 370, one time administration for percutaneous coronary intervention
41119481|NCT01136876|DRUG|Iodixanol-320|Iodixanol-320 single administration for percutaneous coronary intervention procedure
41119482|NCT01937507|DRUG|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
41119483|NCT02015520|DRUG|Clazakizumab|
41271844|NCT02151825|OTHER|Placebo|3 capsules of Maltodextrin per day
41271845|NCT06295055|PROCEDURE|Ridge augmentation with semi-rigid shell barrier system|The semi-rigid shell, fixed to the outside cortex by tacks, acts as a bone wall. Bone particles are placed in the gap and covered with the semi-resorbable covering membrane, serving as a barrier membrane.
41271846|NCT02472457|OTHER|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
41271847|NCT02472457|OTHER|Free Diet|This diet contains no restrictions.
41119484|NCT02015520|DRUG|Placebo (Matching with Clazakizumab)|
41119485|NCT03433586|DRUG|Aspirin 81 mg|81mg of aspirin to be taken daily for 10-14 days
41119486|NCT03433586|DRUG|Placebo|Placebo pill (visually identical to aspirin pill) to be taken daily for 10-14 days
41271848|NCT02786901|DRUG|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
41271849|NCT02786901|DRUG|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
41271850|NCT02786901|DRUG|Vehicle Gel|Gel
41119487|NCT05572060|DRUG|Metformin|Patient screening will be done using SOFA scoring and NEWS Supplemental oxygen will be supplied. Intubation and mechanical ventilation may be required Venous access will be established.CBC, chemistries, liver function tests,coagulation studies ,Peripheral blood cultures, urinalysis, microbiological cultures from suspected sources (eg, sputum, urine,etc),(ABG) and serum lactate will be obtained Crystalloids will be given at 30 mL/kg, started by one hour and completed within three hours Empiric antibiotic therapy is targeted at the suspected organism(s) In patients with lactic acidosis and severe acidemia, Sodium bicarbonate will be used to maintain the arterial pH above 7.15 In patients having persistent hypoperfusion vasopressors will be added Evaluation of volume status will be done using straight leg raising test and ultrasound guided IVC collapsibility index Plasma rennin, serum lactate and IL6 concentrations will be measured on admission and at one week.
41271851|NCT01361256|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
41453399|NCT01216020|DRUG|cisplatin (associated to radiotherapy)|"* CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
41119488|NCT05572060|OTHER|standardized protocol|standardized protocol
41119489|NCT06048172|BEHAVIORAL|Prolonged Exposure|In the intervention condition, patients are treated directly after the baseline measurement by Prolonged Exposure in 16 hours of individual therapy. The 16 individual therapy sessions will take place in 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapy sessions are videotaped with camera focus on the therapist. Parts of the Prolonged Exposure process (the re-experiencing of the traumatic memory) are recorded on tape, so that the patient can listen to the recording as homework at home. Afterwards, the patients take part in a study diagnostic session.
41119490|NCT03628235|BEHAVIORAL|Online survey|Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions
41119491|NCT02620813|DRUG|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
40753096|NCT01843504|BIOLOGICAL|platelet rich plasma|A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
41119492|NCT02620813|DRUG|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
41119493|NCT00640250|BIOLOGICAL|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
41271852|NCT01361256|DEVICE|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
41271853|NCT00914381|BEHAVIORAL|Behavioral therapy|
40926322|NCT05779774|BEHAVIORAL|WayToServe Training Only|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe Training Only \[comparison control\] v. WayToServe Plus In-service Component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe Traiing Only after baseline in Month 18, stratified by state and location. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
41271854|NCT05645094|DRUG|Envafolimab|Patients will receive single drug therapy of Envafolimab (300mg) once every two weeks. Patients who do not have tumor regression after 3 months of treatment should be judged by the investigator whether to adopt standard chemoradiotherapy plus surgery. Patients with tumor regression should continue to receive Envafolimab therapy until 6 months. For patients who do not reach complete clinical response (cCR) after 6 months of treatment, the investigator shall determine whether to perform standard chemoradiotherapy or radical surgery. For patients who reach cCR, they could receive the observation waiting or local resection which depend on the investigator. Patients should be followed up until reaching cCR or 3 years after surgery.
41271855|NCT01169779|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
41271856|NCT01169779|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
40753097|NCT01843504|OTHER|saline|A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
40753098|NCT01128920|BEHAVIORAL|Skin and Needle Hygiene Intervention|Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices
41271857|NCT01169779|DEVICE|Pen auto-injector|
40753099|NCT01128920|OTHER|No intervention - assessment-only condition|No intervention is assigned in this condition
40753100|NCT03545581|OTHER|Experimental diet Fru rich diet|7 days (day 1 to day 7) with fructose enriched drinks 3x/d. Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
41271858|NCT01169779|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
41271859|NCT01169779|DRUG|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c \<8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c \>=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
41119494|NCT04790604|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
41119495|NCT00024063|DRUG|orantinib|
41119496|NCT05816902|OTHER|The location of the patient's treatment|The location of the patient's treatment
41119497|NCT01844492|BEHAVIORAL|The PARTNER Intervention|The PARTNER intervention (PAiring Re-engineered ICU Teams with Nurse-driven Emotional Support and Relationship-building) consists of: 1) institution of a clinical pathway for family support overseen by ICU staff nurses; 2) advanced communication skills training for ICU staff nurses; 3) a multifaceted strategy to support implementation of the clinical pathway for family support.
41119498|NCT01844492|OTHER|ICU Usual Care Control|The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
41271860|NCT04326530|DEVICE|Pneumopipe® (European patent 12425057.2, Rome, Italy)|Collection of VOCs on a cartridge after that the child has normally breathed in it for 3 min, both at the baseline and at the last visit.
41453400|NCT03447535|OTHER|Semi-directive interview (Kiddy Sads)|semi-directive interview (Kiddy Sads) conducted as part of the care
40753101|NCT03545581|OTHER|Experimental low Fru diet|7 days (day 1 to day 7) with low-fructose diet (\<10g/d). Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
40753102|NCT03607136|OTHER|exercise training|Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
41119499|NCT00435578|DRUG|Glufosfamide|
41119500|NCT00123903|DRUG|metoprolol xl|
41119501|NCT00123903|DRUG|carvedilol MR|
41119502|NCT00123903|DRUG|lisinopril|
41119503|NCT02190981|DEVICE|Ultrasound for Small Bowel Obstruction|Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
41119504|NCT01332058|BEHAVIORAL|Motivational Interviewing|8 possible weeks of motivational interviewing sessions
41119505|NCT06361953|DEVICE|EEG Neurofeedback|neurofeedback training over five weeks, comprising 15 sessions. Each neurofeedback training session lasted 30 minutes.
41119506|NCT04455633|DRUG|LX9211 low dose|11-week assessment period
41119507|NCT04455633|DRUG|LX9211 high dose|11-week assessment period
41119508|NCT04455633|DRUG|LX9211 Placebo|11-week assessment period
41119509|NCT01601041|OTHER|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
41119510|NCT06345586|DRUG|Drospirenone|4 mg tablet once daily
41119511|NCT03796936|BEHAVIORAL|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy|a novel treatment for PTSD combining aspects of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), within the Computer Assisted Rehabilitation Environment (CAREN)
40753103|NCT03080714|DEVICE|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes
41119512|NCT04410458|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
41119513|NCT00433199|DRUG|Testosterone (T) Gel 1.62%|Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
41119514|NCT00433199|DRUG|Placebo|Placebo Control
41119515|NCT00108823|DRUG|Roflumilast|
41119516|NCT06502275|BEHAVIORAL|Mobile Health Management Frailty Care Program|"Through the LINE communication software, participants are provided with exercise and nutrition information three times a week, with a total of 36 messages. As well as 6 podcasts of health information and 6 sports videos in total. At weeks 2, 4, and 6, researchers scheduled 5- to 10-minute telephone consultations. Participants can receive guidance through telephone consultations and carry a Xiaomi sports band wearable device to monitor their exercise."
41119517|NCT03595852|DRUG|Cefazolin|Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
41119518|NCT03595852|DRUG|Placebos|IV normal saline will be given to patients 30-60 minutes prior to incision
41119519|NCT00263952|BIOLOGICAL|bee venom|
41119520|NCT00223535|BEHAVIORAL|Cognitive Remediation|
41271861|NCT04326530|OTHER|Other assessments|"* Spirometry, both at the baseline and at the last visit.~* 24-hour urine collection, both at the baseline and at the last visit."
41119521|NCT00223535|BEHAVIORAL|Social Skills Training|
41271862|NCT01627418|BEHAVIORAL|Energy Voucher|Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
40753104|NCT03080714|DEVICE|3D OCT-1 Maestro|The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
40753105|NCT03480516|DEVICE|SDF|38% silver diamine fluoride solution
41271863|NCT01627418|BEHAVIORAL|No intervention : control arm|Do not receive the money or pamphlet in the initial study year
41271864|NCT01780792|OTHER|Dance Dance Revolution video game play|Individuals play dance dance revolution 3 times a week for 8 weeks
40753106|NCT03480516|DEVICE|Fluoride varnish|5% sodium fluoride varnish
40753107|NCT01282138|DRUG|Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
40753108|NCT01282138|OTHER|Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
41271865|NCT06438328|DIAGNOSTIC_TEST|Left/ Right affected arm|Therapeutic exercises: eccentric and concentric exercises and wrist isometrics 10 repetitions of 3 sets with 10 seconds interval
41271866|NCT06438328|OTHER|Grip strength|assessed by using modified sphygmomanometer in which it first inflated to 100 mmHg with closed valve. The pressure was reduced to 20mmHg and the resisted wrist extension performed at baseline and at the 4th week.
41271867|NCT04770766|OTHER|Non-medical practitioners|All observational research activity in each cohort is related to the exposure of non-medical practitioners in the Emergency Department or Urgent Treatment Centre
40753109|NCT02597361|DRUG|Irbesartan|Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
40753110|NCT02597361|DRUG|Placebo|Placebo o.d. to match 150mg or 300mg irbesartan tablets
40926323|NCT02770209|BIOLOGICAL|biomimetic cartilage matrix + autologous chondrocytes|
41271868|NCT00564993|DRUG|Dobutamin|10\&20 µg/kg/min
41271869|NCT04698928|DEVICE|Theta burst stimulation|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
40753111|NCT03385486|BIOLOGICAL|TBX-3400|Autologous transfusion
41271870|NCT04268030|OTHER|collection of LFPs|collection of local field potentials (LFPs) at rest and during hand opening and closing
41271871|NCT00002309|DRUG|Azithromycin|
41453401|NCT03447535|OTHER|SDQ questionnaires (strenghs and difficulties questionnaire)|SDQ questionnaires (strenghs and difficulties questionnaire) conducted as part of the care
40753112|NCT00485342|DRUG|Peg-interferon alpha 2a and ribavin|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
40753113|NCT00485342|DRUG|ribavirin with adaptation dose|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
40753114|NCT01570907|DRUG|Quetiapine Fumarate|25 mg tablet
40753115|NCT01197105|BIOLOGICAL|Use of natural product (Schinus terebinthifolius)|Mouthwash (0,3125% of schinus terebinthifolius) 10mL per day during 14 days.
40753116|NCT05803343|BEHAVIORAL|Regulating Together-Canine|RT-C is an animal assisted, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. RT-C meets for 1.5 hours, twice weekly for five weeks with concurrent youth and caregiver groups. The children progress through skills including relaxation training, arousal ratings, problem size, mindfulness, problem solving, and cognitive flexibility. The caregivers learn crisis management, reward systems, and coaching strategies for topics taught to the children. Homework is utilized to reinforce use of skills outside the group. The canines are present throughout as both a calming presence and teaching assistant. Children will be able to interact with the dog when practicing relaxation at the beginning of each session and throughout the session. Additionally, the dog will help to emphasize certain curriculum concepts.
40926324|NCT02770209|PROCEDURE|arthroscopic debridement|
40926325|NCT02770209|PROCEDURE|microfracture surgery|
41119522|NCT03914859|BIOLOGICAL|IN VITRO FERTILIZATION|Using exposure biomarker as a reliable means of evaluating gamete quality to estimate the chances of success in in vitro fertilization.
40926326|NCT05045950|DRUG|Memantine -Twice Daily or Extended Release|"Both extended release memantine and twice daily memantine dosing will be allowed.~Twice daily dosing:~The target dose for memantine is 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg each week to a target of 10 mg twice daily (i.e., 5 mg a day on week 1, then 5 mg twice daily (BID) on week 2, then 10 mg in AM plus 5 mg in PM on week 3, followed by 10 mg in AM plus 10 mg in PM by week 4).~Extended Release Memantine:~The target dose for extended release memantine is 28 mg. Dose will be escalated by 7 mg per week to a target of 28 mg daily (i.e., 7 mg a day on week 1, then 14 mg a day on week 2, then 21 mg a day on week 3, followed by 28 mg a day by week 4)."
40926327|NCT05045950|RADIATION|WBRT utilizing the PRDR technique|The total dose of 3000 cGy (30 Gy) will be divided 10 fractions of 300 cGy (3 Gy); each fraction will be delivered as a series of 20 cGy (0.2Gy) pulses separated by 3 min time intervals. 20 cGy / 3 min = 6.67 cGy/min (or 0.0667 Gy/min). Total time is determined by the fractionated series and time intervals, meaning 300cGy/20cGy = 15 division x 3 minutes = 45 minutes. Including time to set up, approximate total time per treatment session will be 60 minutes.
40926328|NCT04748588|DRUG|Anti-SARS-CoV-2 mAb|"Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used."
41119523|NCT02949375|DRUG|Placebo Comparator|Placebo gel capsule to be taken daily for 28 days
41119524|NCT02949375|DRUG|Active Comparator:4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken daily for 28 days
41119525|NCT02949375|DRUG|Active Comparator: 6.0mg GRI-0621|6.0mg GRI-0621 gel capsule to be taken daily for 28 days
41119526|NCT05106075|PROCEDURE|blood sample or joint fluid or gingival exudate|blood sample collected by peripheral blood mobilization joint fluid collected by punction gingival exudate collected with paper strips
41119527|NCT05308056|DEVICE|Depth of anesthesia monitor, SedLine® (Masimo, Irvine, CA, USA)|The device monitors the patient's electroencephalogram using electrodes applied to the forehead.
40753117|NCT05803343|BEHAVIORAL|Regulating Together-Standard|RT-S an established, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
40926329|NCT03515291|BIOLOGICAL|iMP cells|Immunomodulatory progenitor cells
40926330|NCT03515291|OTHER|Control injection|Cell suspension solution
41119528|NCT03465527|DRUG|PrednisoLONE 50 MG|Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
41119529|NCT06077110|OTHER|P-OMICs-flow services|The Service Intervention is the P-OMICs-flow clinic being delivered at The Prince of Wales Hospital. This clinic provides a streamlined, multidisciplinary model to seamlessly integrate research-led precision medicine into the routine oncology setting.
41271872|NCT01665937|DRUG|STA-9090|"IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen."
41453402|NCT05775120|DIAGNOSTIC_TEST|OLGA and H.pylori culture|Upper endoscopy will be performed by endoscopists using modern endoscopes (Fujinon EG-590WR, Olimpus GIF-H190 and others) while patient is sedated. Using sterile biopsy forceps, biopsy specimens will be taken from five areas of the stomach (two biopsy specimens - greater and lesser curvature of the antrum of the stomach; two biopsy specimens - lesser and greater curvature (or anterior and posterior wall) of the body of the stomach and one from the corner of the stomach) for pathology assessment. Pathology assessment of the gastritis stage and degree will be conducted according to the OLGA system developed by the international group of gastroenterologists and pathologists (Atrophy Club).
40926331|NCT04623424|DIAGNOSTIC_TEST|intestinal microbiota|Stoll samples will be tested for different bacteria
41119530|NCT02779062|OTHER|Interview|Interview
41119531|NCT02088424|OTHER|insulin resistance(fasting glucose/fasting insulin)|insulin resistance(fasting glucose/fasting insulin )
41119532|NCT02403024|BEHAVIORAL|InterWalk|Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week
41119533|NCT02403024|BEHAVIORAL|Waiting list control|Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks
41119534|NCT00121329|DRUG|Intrauterine lidocaine infusion 4%|
41119535|NCT00840229|DRUG|Triamcinolone hexacetonide|20 mg
41119536|NCT00840229|DRUG|Triamcinolone hexacetonide|1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
40926332|NCT01624805|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
40926333|NCT01624805|DRUG|Cyclosporine|Given PO
41119537|NCT00746343|BEHAVIORAL|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
41119538|NCT00746343|BEHAVIORAL|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
41119539|NCT01781585|PROCEDURE|hemodialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
41271873|NCT01309737|DRUG|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
41271874|NCT01309737|DRUG|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
41271875|NCT01309737|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
41271876|NCT01309737|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
41271877|NCT00807950|DRUG|Simvastatin|
41271878|NCT02894229|BEHAVIORAL|Mindfulness Based Stress Reduction|A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
41271879|NCT02894229|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) Group|A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
41271880|NCT01021566|DEVICE|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
41271881|NCT01021566|DRUG|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
40926334|NCT01624805|BIOLOGICAL|Filgrastim|Given SC
40926335|NCT01624805|DRUG|Methylprednisolone|Given IV or PO
40926336|NCT01624805|BIOLOGICAL|Pegfilgrastim|Given SC
41119540|NCT04982536|DEVICE|VMCore Biopsy System|Prostate Examine
40926337|NCT00622271|BEHAVIORAL|Group Therapy|Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
41119541|NCT04982536|DEVICE|Standard of Care Biopsy Needle|Prostate Examine
41119542|NCT02618486|PROCEDURE|Non surgical periodontal therapy|NSPT includes oral hygiene education, scaling root planing and mouth wash
41119543|NCT06307301|DRUG|Abatacept Injection [Orencia] and Proleukin (aldesleukin)|Abatacept (Orencia®) and recombinant human IL-2 (aldesleukin). Patients will receive a fixed dose of subcutaneous abatacept (125 mg/mL) at day 1. Two weeks later (day 15), patients will receive the second dose of subcutaneous abatacept (125 mg/mL). In addition, patients will receive subcutaneous IL-2 (1x106units /day) for 5 days (days 15-19). If this treatment regimen is tolerated, patients will receive 28 further similar treatment courses of abatacept and IL-2 every two weeks.
41271882|NCT04301414|DRUG|BMS-986218 and Degarelix|BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.
41271883|NCT04301414|DRUG|Degarelix|Degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy
41271884|NCT01722461|DEVICE|Ulthera System|Focused ultrasound energy delivered below the surface of the skin
41271885|NCT01722461|DEVICE|Sham treatment|Ulthera System delivering no ultrasound energy
41271886|NCT03359902|DEVICE|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width
41271887|NCT03359902|DEVICE|Sham stimulation|Sham stimulation will be performed using electrodes placed on earlobe
41271888|NCT03625388|DRUG|Dasatinib|Film coated tablet contains dasatinib monohydrate
41271889|NCT02655484|DEVICE|"BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）"|See details from arm descriptions.
41271890|NCT02494141|DRUG|Curcumin|Dietary Supplement
41271891|NCT02494141|OTHER|Placebo|
41271892|NCT06322758|OTHER|Tidal volume customization in the acute respiratory distress syndrome|During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target
40926338|NCT01715129|DRUG|Triptorelin Pamoate 11.25mg|
41119544|NCT03855397|OTHER|Microneedle|A microneedle patch (no drug) was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa to access pain, discomfort and safety.
41119545|NCT03855397|OTHER|Hypodermic needle|30 gauge hypodermic needle was inserted in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
41119546|NCT03855397|OTHER|Flat patch|A flat patch was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
41119547|NCT00194896|DRUG|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
41119548|NCT00194896|DRUG|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
41119549|NCT00505323|DEVICE|Implantation of neurostimulators and their auxiliary components|"Implantation neurostimulators and their auxiliary components :~Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482"
41119550|NCT03085394|DRUG|tranexamic acid|Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
41119551|NCT03085394|DRUG|Placebo|Preoperative intravenous administration of 10 ml saline
40926339|NCT02742246|BEHAVIORAL|Individual clinician-provided CBT|Individual clinician-provided CBT
41119552|NCT03113617|PROCEDURE|Computed Tomography|Undergo PET/CT
41119553|NCT03113617|DRUG|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
41119554|NCT03113617|OTHER|Laboratory Biomarker Analysis|Correlative studies
41119555|NCT03113617|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41119556|NCT05498818|DIETARY_SUPPLEMENT|Synaquell|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
40753118|NCT05373966|OTHER|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in the field of robotic RNU. The Delphi questionnaire will be administered via Welphi.com.~In the first survey, panel members will outline the training program for robotic RNU.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
40926340|NCT02742246|BEHAVIORAL|CBT4CBT|CBT computer program assisted therapy
40753119|NCT04560309|DRUG|L-alanyl-L-glutamine dipeptide|Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.
40753120|NCT04560309|DRUG|Placebo|Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.
40753121|NCT03854448|DEVICE|holter monitoring|"Transthoracic Echocardiography (TTE) Left atrial ( LA) volume will be measured using standard apical two- and four-chamber views on the frame just prior to mitral valve opening and as specified by current American Society of Echocardiography guidelines (10) LA volume is indexed to body surface area. Mitral inflow velocity is obtained in the apical four-chamber view by placing a pulsed-Doppler sample volume between the tips of the mitral leaflets. Mitral annular velocity is assessed during the early phase of diastole(e=) using pulsed-wave Doppler sampling of septal mitral annular motion from the four chamber view.~24 to 48 hours Holter monitoring after 1 month after PCI"
40753122|NCT05128344|DRUG|AMZ002 injectable solution, 0.5mg/mL|Injectable solution
40753123|NCT05128344|DRUG|Vigabatrin, oral|Oral administration
40753124|NCT05492682|DRUG|PeptiCRAd-1|All patients will receive 6 doses of PeptiCRAd-1.
41271893|NCT05335889|DEVICE|eButton|The eButton is a wearable camera that takes pictures every 6 seconds of whatever is in front of participants. The recorded data are processed by algorithms to determine food names, volumes, and nutrient value of the consumed food (e.g., grams of carbohydrates). The eButton is a wearable device containing a multicore microprocessor, a rechargeable battery capable of 10-15 hours of continuous operation (upon a flexible choice of battery capacity), a miniSD card for data storage.
41271894|NCT05335889|DEVICE|Continuous Glucose Monitoring (CGM)|The use of this device provides ambulatory glucose profiles, giving graphic and quantitative information on 24-hour glucose patterns. It does not require finger-prick testing for calibration. The system consists of a reader and a sensor (35 mm x 5 mm). The sensor is applied to the back of a person's arm. The sensor automatically measures interstitial glucose at 15-minute intervals during daily activities like work, sleep, eating, and exercise. It is able to store blocks of glucose data for 14 days.
41271895|NCT02905734|DRUG|Nicotine patch|Single administration of an active treatment (nicotine patch)
40753125|NCT05492682|DRUG|Cyclophosphamide|All patients will be pre-treated with one single dose of Cyclophosphamide.
40753126|NCT05492682|DRUG|Pembrolizumab|All patients will receive 6 doses of Pembrolizumab within the study.
40753127|NCT01694771|DRUG|Tiotropium|Marketed dose
40753128|NCT01694771|DRUG|Placebo matching Olodaterol|One dose
40753129|NCT01694771|DRUG|Olodaterol|One dose
40753130|NCT01694771|DRUG|Tiotropium|Marketed dose
40753131|NCT05627661|DEVICE|Biosensor|Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days
40753132|NCT00593645|DRUG|Clofarabine|
41271896|NCT02905734|OTHER|placebo patch|Single administration of a placebo treatment
41271897|NCT04658602|PROCEDURE|Preformed stainless steal crown cemented by glass ionomer lutting cement (Ketac cem,3M Espe)|Covering the affected molar with preformed metal crown cemented by glass ionomer lutting cement
41453403|NCT02368262|OTHER|Questionnaire and micturition and drinking diaries|"Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart"
40753133|NCT00593645|DRUG|Cytarabine|
40753134|NCT00593645|DRUG|Thymoglobulin|
40753135|NCT00593645|PROCEDURE|Stem cell infusion|
40753136|NCT01688401|DRUG|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks."
40753137|NCT04578054|OTHER|Flying transport|Patient care who requires flying transport
40753138|NCT04256031|OTHER|Assessment|The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.
41271898|NCT00544934|DRUG|GLY-230|125, 250 0r 375 mg bid for 14 days
41119557|NCT05498818|DIETARY_SUPPLEMENT|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
41119558|NCT03009994|PROCEDURE|Repair of uterine incision|
41119559|NCT03009994|PROCEDURE|Exteriorization of the uterus|
41271899|NCT00544934|OTHER|Placebo|No drug administered
41271900|NCT05951283|DEVICE|Hybrid Closed Loop Insulin Pump|As above
41271901|NCT01416129|DEVICE|Standard of care socket|Amputees' preferred socket.
41271902|NCT01416129|DEVICE|Prosthetic brimless socket|Study socket
41119560|NCT03009994|PROCEDURE|Non exteriorization of the uterus|
40753139|NCT03221296|BEHAVIORAL|Vestibular Training (Intervention Group)|Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
40753140|NCT01894360|DRUG|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
40753141|NCT04233580|DEVICE|Amnio Excel + weekly|Amnio Excel + weekly
40753142|NCT04233580|DEVICE|Amnio Excel + max every 2 weeks|Amnio Excel + max every 2 weeks
40753143|NCT01104337|DRUG|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
41119561|NCT03930121|OTHER|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)|Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
41119562|NCT00348322|DRUG|Systane Free Lubricant Eye Drops|
41119563|NCT02504086|BEHAVIORAL|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
41119564|NCT03040596|DRUG|Fluticasone propionate|fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks
41119565|NCT03040596|BEHAVIORAL|Standard voice therapy|Standard voice therapy sessions
41119566|NCT02180763|BIOLOGICAL|Gammanorm|Sub-Q IgG
41119567|NCT03565315|BIOLOGICAL|VRC-HIVMAB095-00-AB (10E8VLS)|10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.
41271903|NCT02683369|DIETARY_SUPPLEMENT|Blood Builder®/Iron Response®|"The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~* 15 mg of Vitamin C~* 400 mcg of Folate~* 30 mcg Vitamin of B-12~* 26 mg of Iron~* 125 mg of Beet Root"
41271904|NCT02413203|DRUG|Celecoxib|Blood and urine collections before and 3 hours after celecoxib administration.
41271905|NCT02413203|DRUG|Placebo|Blood and urine collections before and 3 hours after placebo administration.
41271906|NCT04187027|DEVICE|pulsed electromagnetic field therapy device|magnetic field stimulation (MFS) is a novel technique for stimulating the nervous system non-invasively, which can activate deep neural structures via induced electric currents, without pain and discomfort. Also, several clinical trials including placebo-controlled studies have shown that MFS of the pelvic floor and sacral roots is effective for overactive bladder (OAB). MFS induces inhibitory effects on detrusor overactivity in a similar manner to electrical stimulation, with significant clinical advantages. MFS of the sacral nerve roots could be a promising alternative treatment for OAB.
41453404|NCT02368262|PROCEDURE|Uroflowmetry, pelvic floor EMG and bladderscan|Voiding variables, pelvic floor activity during micturition and postmictional residue.
41453405|NCT03784534|OTHER|Imaging|high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan
41119568|NCT03565315|BIOLOGICAL|VRC-HIVMAB075-00-AB (VRC07-523LS)|VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
41119569|NCT01075113|DRUG|sorafenib tosylate|Given orally
41119570|NCT01075113|DRUG|vorinostat|Given orally
41119571|NCT05911581|OTHER|intra-arterial flushing|"The catheter will be flushed to prevent occlusion after radial artery catheterization.~intra-arterial flushing with heparinized fluid kept in room air"
41119572|NCT05911581|OTHER|intra-arterial flushing|Intra-arterial flushing with heparinized fluid at patient body temperature
41119573|NCT04626180|PROCEDURE|Extubation|Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.
41119574|NCT04626180|PROCEDURE|Manual Hyperinflation|Providing a larger tidal volume than baseline tidal volume to the patient and using a tidal volume which is 50% greater than that delivered by the ventilator
41119575|NCT04385056|BIOLOGICAL|MSCTC-0010|MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
41119576|NCT01150383|OTHER|Physical exercise training with supplemental oxygen|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.~After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above)."
41119577|NCT01150383|OTHER|"Physical exercise training with room air supplementation"|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.~After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above)."
41119578|NCT02512341|DEVICE|Computer Aided Auscultation (CAA)|
41119579|NCT01517815|DRUG|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
41119580|NCT01517815|DRUG|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
41119581|NCT06521723|OTHER|Daily acute intermittent hypoxia|Each participant will be exposed to 16 sessions of daily acute intermittent hypoxia via air generators over the span of four weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
41119582|NCT06521723|DEVICE|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
41119583|NCT05965388|DRUG|nucleoside analogues or interferon|ETV、TDF、TAF、TAF、IFN-a-2b
41119584|NCT03480971|DRUG|Tempol|Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.
41119585|NCT03480971|DRUG|Placebo Solution|The placebo contains the same excipients as the active product plus FD\&C Yellow #6 for color matching.
41119586|NCT02699385|OTHER|Oral Rehydration Therapy|Each participants will initiate ORT in the physician's office on Day 1.
41119587|NCT02699385|DRUG|Domperidone|Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
41271907|NCT03189979|BEHAVIORAL|Physical activity and healthy eating intervention|Using a community-based participatory approach, BGC staff and academic researchers developed intervention components informed by formative studies and based on a social ecological theory framework. Components included healthy eating and physical activity policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
41119588|NCT02699385|DRUG|Placebo|Each participants will receive placebo oral suspension thrice daily for up to 7 days.
41119589|NCT02067949|DRUG|Simvastatin|single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
41119590|NCT01228669|DRUG|NNC 0172-0000-2021|Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
41271908|NCT03757884|BEHAVIORAL|Mindfulness breathing exercise|Spire monitor instructed mindfulness breathing
41271909|NCT03757884|BEHAVIORAL|Diagnostic Checklist|Checklist reminder for diagnosis
41271910|NCT03757884|BEHAVIORAL|Noise cancelling headphones|Noise cancelling headphones
41271911|NCT03757884|BEHAVIORAL|Privacy tablescreen|Privacy Tablescreen
41271912|NCT03757884|BEHAVIORAL|Diagnostic assistance application|Diagnostic assistance application
41271913|NCT05684640|DRUG|Rodatristat Ethyl|Tablets, Oral, 600mg, QD
41271914|NCT05684640|DRUG|Placebo|Tablets, Oral, 0mg, BID
41119591|NCT01228669|DRUG|NNC 0172-0000-2021|Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
41119592|NCT01228669|DRUG|placebo|Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
41119593|NCT01989455|DRUG|Deferiprone|"Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"
40753144|NCT01104337|DRUG|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
40753145|NCT01104337|DRUG|Placebo|Treatment consisted of two matching placebo tablets three times a day.
40753146|NCT05461092|DRUG|Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine|Patient receives standard of care anesthesia with TLIP Block of bupivicaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
40753147|NCT05461092|DIAGNOSTIC_TEST|Blood Test|Blood Tests measuring inflammatory markers: IL-10, MCP-1, IL-8, IL-6, TNFa
40753148|NCT05461092|OTHER|3D CAM Delirium Severity Scoring|Questionnaire that will rate each symptom of delirium
41119594|NCT01989455|DRUG|Placebo|Placebo: normal saline solution.
41119595|NCT04146324|DRUG|nivolumab|Administered as adjuvant therapy as per the market authorization in Australia
41119596|NCT00767559|DRUG|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery\*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
41119597|NCT00767559|DRUG|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day\*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
41119598|NCT00767559|DRUG|warfarin|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery."
41119599|NCT03196310|DRUG|Platelet Concentrate|Platelet Rich plasma
41271915|NCT05395676|DEVICE|Exergame home training programme|Each training programme (Xbox or Wii Fit) is aimed at improving the following issues: improper weight shifting and reduced dual tasking. The participants will be guided in the first sessions to familiarize themselves with the exercises. Then, they will be allowed to exercise independently at home. Allowing enough practice time before collecting data helps minimize practice effects. practice effects are confounding factors that can affect the results and make it difficult to identify whether the improvement in outcome is due to the training or not. The duration of the training programme will be approximately 30 minutes. Each game will be played three times (the duration for each game is approximately one minute).
40753149|NCT05461092|OTHER|Generalized Anxiety Disorder 7-item (GAD-7) scale|Questionnaire for screening and severity measurement of generalized anxiety disorder.
40753150|NCT05461092|OTHER|Numerical Rating Score (NRS)|Questionnaire assessing pain intensity
40753151|NCT05461092|OTHER|PROMIS-Pain Interference|Questionnaire measuring the effect of pain on patient physical, emotional, and social functioning.
40753152|NCT05461092|OTHER|Oswestry Disability Index (ODI)|Questionnaire assessing disability and quality of life impairment in adults with lower back pain.
40753153|NCT05461092|OTHER|Saint Louis University Mental Status Examination (SLUMs)|Questionnaire assessing baseline cognition.
40753154|NCT05461092|OTHER|Delirium Rating Scale-Revised-98 (DRS)|16 item clinician rated scale assessing delirium severity.
40753155|NCT05461092|OTHER|Telephone Interview for Cognitive Status - Modified (TICS-M)|Telephone interview questionnaire evaluating patient cognitive status.
41119600|NCT03196310|DRUG|Corticosteroid injection|Kenalog
41119601|NCT03196310|OTHER|Normal Saline|Control Group - Placebo
41119602|NCT05197881|DEVICE|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
41453406|NCT03784534|BEHAVIORAL|Clinical and behavioral testing : Motor recovery progress|NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, test of Ashworth
40753156|NCT05461092|OTHER|Opioid Equivalents measured by Morphine Milligram Equivalents (MME)|The amount of opioids administered will be collected through patient self-report
40753157|NCT05461092|OTHER|Patient Health Questionnaire depression scale (PHQ-8)|Questionnaire used to diagnose and determine the severity measure for depressive disorders.
40753158|NCT05461092|OTHER|Pain Catastrophizing|Scale used to determine pain catastrophizing and it's severity.
40753159|NCT05461092|OTHER|Fear Avoidance Beliefs Questionnaire (FABQ)|Questionnaire used to help predict patients that have a high pain avoidance behavior.
41119603|NCT02740491|OTHER|Remission Consultation|"At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.~If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient."
41119604|NCT06461871|OTHER|BALANCE TRAINING WITH MODERATE INTESITY AEROBIC VERSUS RESISTED TRAINING (RT)|The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP A: Baseline treatment + Moderate intensity aerobic exercises in combination with balance training
41119605|NCT06461871|OTHER|Moderate intensity resistance exercises in combination with balance training|The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP B: Baseline treatment + Moderate intensity resistance exercises in combination with balance training
41119606|NCT00175292|DRUG|Probiotic - VSL#3|
41119607|NCT06407258|BEHAVIORAL|SLEEPAC|"6x individual blended-care counselling sessions:~* 1 x face-to-face kick-off sessions at study site (45 min)~* 1 x try-out exercise sessions at study site (45 min)~* 4 x online face-to-face sessions via zoom (30 min)~* Both the intervention and the waitlist control condition will continue with TAU.~Component 1: CBT-I: Sleep restriction, and cognitive therapy strategies with education about sleep-wake regulation, sleep hygiene, and pre-bedtime counter arousal methods.~Component 2: Circadian treatment: Morning bright light therapy with a gradual advanced sleep schedule and timed morning exercise.~Component 3: Physical activity counselling involves providing personalized guidance and support to individuals to help them adopt and maintain a physically active lifestyle tailored to their preferences and needs."
41119608|NCT00580918|OTHER|functional magnetic resonance imaging fMRI|functional magnetic resonance imaging fMRI
41119609|NCT05769764|OTHER|Archival tissue specimen and immunohistochemistry staining|This is a non-interventional study and no intervention will be administered.
41119610|NCT01170962|DRUG|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
40753160|NCT05461092|OTHER|Opioid Side Effects and Likeability Questionnaire|Survey determining adverse events related to opioid side effects and complications.
41119611|NCT01170962|DRUG|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
41119612|NCT01170962|DRUG|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
41119613|NCT01170962|DRUG|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
41119614|NCT01170962|DRUG|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
41119615|NCT01061034|DRUG|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
41119616|NCT04241354|BIOLOGICAL|Leukocyte-poor platelet rich plasma|Platelet rich plasma was prepared using PurePRP Supra Physiologic Protocol A preparation \[EmCyte Corp. Fort Myers FL\].
41119617|NCT05771350|PROCEDURE|online hemodiafiltration|20 patients on regular hemodialysis received online hemodiafiltration
41119618|NCT05771350|PROCEDURE|high flux hemodialysis|20 patients on regular hemodialysis received high flux hemodialysis
41119619|NCT05771350|PROCEDURE|low flux hemodialysis|20 patients on regular hemodialysis received low flux hemodialysis
41119620|NCT03111537|OTHER|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
41119621|NCT03111537|OTHER|E-Cigarette|Use of E-cigarette: multiple flavors offered.
40753161|NCT05461092|OTHER|Daily Pain Trajectory|Questionnaire assessing pain location, severity, impact to quality of life, and medications used to alleviate.
41119622|NCT03111537|OTHER|Nicotine Gum or Lozenge|Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
41119623|NCT03417869|DEVICE|QuickVue Influenza A+B|Rapid diagnostic test with IVD, QuickVue Influenza A+B
41119624|NCT03953001|DEVICE|Adminstration Technique using Buzzy external distractor|External application of Buzzy distractor during administration of dental anesthetic
41119625|NCT03953001|DRUG|2% Lidocaine with 1:50,000 epinephrine|Local Dental anesthetic infiltration
41119626|NCT03953001|DRUG|Topical Anesthetic|20% Benzocaine gel was applied on the area of infiltration
41119627|NCT03244046|BEHAVIORAL|Psychotherapy|The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.
41453407|NCT03784534|BEHAVIORAL|Clinical and behavioral testing : Motor skills|the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
41453408|NCT02745600|DEVICE|RFA therapy simulator|Computer assisted RFA of liver tumors: Planning, simulation, and follow up,
40753162|NCT05461092|OTHER|Tampa Scale of Kinesiophobia|Questionnaire assessing Kinesiophobia
40753163|NCT05461092|OTHER|Quality of Recovery 15|Questionnaire assessing postoperative quality of recovery
40753164|NCT01812941|OTHER|trauma: blood collection|Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.
41271916|NCT02566720|DRUG|Amantadine|Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
41271917|NCT02566720|PROCEDURE|MRI Tractography Study|Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
41271918|NCT00484315|DEVICE|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent placement
41271919|NCT00484315|DEVICE|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement|TAXUS Express Stent Implant
41271920|NCT01364805|DRUG|Intravenous Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
41119628|NCT03244046|BEHAVIORAL|Physiotherapy|This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
41271921|NCT01364805|DRUG|Gemcitabine|Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
41271922|NCT04762030|DRUG|Durvalumab Anlotinib Carboplatin Nab-paclitaxel|"Neoadjuvant treatment (durvalumab+carboplatin+nab-paclitaxel + anlotinib) will start within 1-3 days from enrollment. 2 cycles will be administered at 21-day (+/- 3 days) intervals (QW3). Then, two cycles of combined durvalumab and anlotinib (QW3) will be administered prior to surgery. Before surgery, a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 5rd-7th week from day 1 cycle 4 of neoadjuvant treatment (day 35-49 after day 1 of cycle 4). Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Twelve cycles of durvalumab adjuvant treatment (Q4W) will be administered."
40753165|NCT01812941|OTHER|healthy volunteers: blood collection|blood collected at designated time intervals
40753166|NCT01812941|OTHER|Burn: blood collection|blood collected at designated time intervals
40753167|NCT03632720|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL
41119629|NCT04917224|RADIATION|Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)|Cohort A will include 30 patients with central tumors; the dose regimen prescribed is 50 Gy (Gray) in 5 fractions with a 40 hour inter-fraction interval.
41119630|NCT04917224|RADIATION|Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)|Cohort B will include 30 patients with ultra-central tumors; the dose regimen prescribed is 60 Gy (Gray) in 8 fractions on consecutive days.
41119631|NCT01411631|DIETARY_SUPPLEMENT|Grape juice polyphenols|Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
41119632|NCT00920738|OTHER|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
41119633|NCT00920738|OTHER|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
41119634|NCT03059394|DEVICE|Non intervention study|Test - Retest of measurements
41119635|NCT00014794|DRUG|15-O labeled water|
41119636|NCT01308567|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
41119637|NCT01308567|DRUG|Docetaxel (XRP6976)|Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
41119638|NCT01308567|DRUG|Prednisone|Pharmaceutical form: Tablet; Route of administration: Oral
41119639|NCT01871324|BEHAVIORAL|Lifestyle counseling|group therapy
41119640|NCT06261710|OTHER|Sonography in labour|Using intrapartum sonography parameters in labour
40753168|NCT03632720|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL
40753169|NCT03632720|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine|Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL
40753170|NCT03632720|BIOLOGICAL|Human rotavirus RIX4414 strain vaccine|Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL
40753171|NCT03632720|BIOLOGICAL|Pneumococcal 13-valent polysaccharide conjugate vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
40753172|NCT03091491|DRUG|Ipilimumab|Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
41119641|NCT02184806|PROCEDURE|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
41119642|NCT02184806|PROCEDURE|heterotopic graft|"1. put under the skin~2. the ovarian fragments can be put under the skin of the abdomen"
41119643|NCT06472453|DEVICE|Allograft/Xenograft|Alveolar ridge preservation of a single extraction socket site with vallomix™ (demineralized cortical bone substitute and Bio-Oss®)
40753173|NCT03091491|DRUG|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
41119644|NCT06472453|DEVICE|Allograft|Alveolar ridge preservation of a single extraction socket site with vallos™ (mineralized cortico-cancellous bone substitute)
41119645|NCT01302236|DRUG|Eplerenone|50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
41119646|NCT03638440|DRUG|Naloxegol|Naloxegol is a PEGylated derivative of the μ-opioid receptor antagonist naloxone
41119647|NCT02226536|BEHAVIORAL|fractioned diet without glucose|Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention
41271923|NCT04742673|DRUG|Guanfacine|Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.
40753174|NCT03380481|OTHER|observational only-no intervention|Observational only and no predesigned interventions in this study.
40753175|NCT03202550|DRUG|Oxycodone and Lorazepam (Active Comparator)|Oxycodone and Lorazepam
40753176|NCT03202550|DRUG|Placebo Comparator|Placebo oral pills
40753177|NCT04920825|DIETARY_SUPPLEMENT|Sacha Inchi Oil softgel supplement|A twice daily supplementation of Sacha Inchi Oil softgel for 12 weeks
40753178|NCT04920825|DIETARY_SUPPLEMENT|Corn oil softgel|A twice daily supplementation of Corn Oil softgel for 12 weeks (Placebo)
41271924|NCT04742673|DRUG|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.
41271925|NCT02674945|DEVICE|Wireless Activity tracker: Fitbit|Patients will wear a Fitbit flex
41271926|NCT02312804|DRUG|BGJ398|BGJ398 will be administered orally once daily on each day of the 21 day cycle.
40753179|NCT03118271|DEVICE|lumbar traction|
40753180|NCT03118271|PROCEDURE|spinal manipulation|
40753181|NCT03118271|PROCEDURE|surgery|
40753182|NCT04380025|DIETARY_SUPPLEMENT|Experimental: Oral Mirtogenol|The experimental arm is Oral Mirtogenol dietary supplement, one capsule daily in addition to bimatoprost ophthalmic drops with primary open angle glaucoma
40753183|NCT04380025|DIETARY_SUPPLEMENT|Placebo of oral Dietary supplement|This is the oral placebo of the supplement (control) un daily capsule in addition to the bimatoprost ophtalmic drops
40926341|NCT05194566|DEVICE|tACS|Neurostimulation will be done using the Neuro Device tCS (Neuro Device tCS), which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.
41119648|NCT06070714|DEVICE|Holmium laser with pulse modulation|The holmium laser with pulse modulation emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed.
41119649|NCT06070714|DEVICE|Thulium fiber laser|The thulium fiber laser has a different wavelength then the holmium laser with pulse modulation and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns.
41119650|NCT03106922|DRUG|PMF104|"Powder for oral solution:~* Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~* Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water"
41271927|NCT02312804|DRUG|Carboplatin|Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
41453409|NCT01187823|DEVICE|Adaptive servo ventilation|Nocturnal use of Adaptive servo ventilation
40753184|NCT01783873|OTHER|standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)|At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
40753185|NCT02327247|DRUG|Felodipine|Extended Release Tablets, 10mg
40753186|NCT02327247|DRUG|PLENDIL®|Extended Release Tablets, 10mg
40753187|NCT02914223|DRUG|Cenerimod|Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
40753188|NCT05697003|DRUG|Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
40753189|NCT05697003|DRUG|ADVAIR DISKUS 100/50|2 inhalations in one study period
40753190|NCT03160807|DRUG|Levofloxacin|Levolet 500 mg OD for 5 days
40753191|NCT03160807|DRUG|Levofloxacin|Levolet 500 OD for 10 days
41119651|NCT03106922|DRUG|Klean-prep|"Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water"
40753194|NCT03784300|DRUG|50 mg PTI-125|PTI-125 50 mg Oral Solution
40753195|NCT03784300|DRUG|100 mg PTI-125|PTI-125 100 mg Oral Solution
40753196|NCT03784300|DRUG|200 mg PTI-125|PTI-125 200 mg Oral Solution
40753197|NCT03118895|DEVICE|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
40753198|NCT01663987|DRUG|tiotropium bromide|18 mcg once a day (QD)
40753199|NCT01663987|DRUG|Placebo|once a day (QD)
40753200|NCT06407778|OTHER|High Intensity Strength Training|"* High-intensity workouts to strengthen the quadriceps and enhance knee function;~* Knee flexion and extension 10 lbs.~* 10RM of hip flexion and extension~* 10RM hip adduction and abduction~* Standing with feet aligned for one minute\*2, standing on one leg's forefoot and the other leg's heel for two minutes\*2, standing on one foot for three seconds\*15, and walking ten meters in a straight line for four minutes~* 4-week program; 3 days/week; Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising"
40753201|NCT06407778|OTHER|Muscle Energy Technique|"The Muscle Energy Technique (MET) to strengthen and flex your quadriceps and hamstrings.~* After maintaining an isometric contraction for ten seconds, a little stretch was maintained for thirty seconds.~* Four contractions every treatment, separated by three seconds of rest. Standing with feet parallel for one minute\*2, standing on one leg's forefoot and the other leg's heel for two seconds\*2, standing on the forefoot for three seconds\*15~* Move in a 10 m by 4 straight line.~* 4-week program; 3 days/week Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising"
40753202|NCT01959971|DRUG|alirocumab|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
40753203|NCT01959971|DRUG|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
40753204|NCT04674800|BIOLOGICAL|MYL-1701P, a proposed biosimilar to Eylea|Open label and single arm
40753205|NCT06500559|PROCEDURE|PRP injection|PRP (0.7 ml = 70 unit) will be injected submucosal disto-buccal and disto-palatal to the maxillary canine like the local anesthesia injection in group I experimental sides
40753206|NCT06500559|PROCEDURE|Combined decortication and PRP injection|Experimental sides will receive PRP injection after performing decortication. After administration of local anesthesia, two-line flap will be performed from the mesial surface of the maxillary second premolar to the distal surface of the maxillary canine Mucoperiosteal flap will be reflected in the buccal side. Two millimeters of marginal crestal bone will be held intact and using a high-speed drill and a round carbide bur (1mm diameter) under copious saline irrigation, the cortical wall will be penetrated to reach marrow spaces. Multiple perforations (10 holes for standardization) in the cortical bone will be created. The surgical site will then rinsed, and the flap will be repositioned and sutured.
40753207|NCT03318159|DRUG|Posaconazole|"Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~\*if posaconazole tablet intolerance: posaconazole suspension 200mg tid"
40753208|NCT05539911|DRUG|Fentanyl|50 mic fentanyl added as an adjuvant
40753209|NCT04484662|OTHER|Potted Mint Plants|We will measure 2 indoor environments (living room and bedroom) for placing potted plants.
41119652|NCT04502901|DRUG|KX0826|investigational AR antagonist
41119653|NCT04502901|OTHER|Placebo|Placebo of KX-826
41119654|NCT02190097|OTHER|Paleolithic diet|see procedures section for more details
41119655|NCT02190097|OTHER|American Diabetes Association diet|see procedures section
41119656|NCT04728724|DRUG|Sintilimab|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
41119657|NCT04728724|DRUG|Chemotherapy|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
41119658|NCT02259543|OTHER|Root conditioning with citric acid+tetracycline solution|Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
41119659|NCT00609908|PROCEDURE|Split skin graft|After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
40926342|NCT00927940|DEVICE|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
40926343|NCT03286127|OTHER|specialized palliative care|specialized palliative care provided in different settings
41119660|NCT00609908|PROCEDURE|skin stretching device|after woundbed preparation the wound is primarily closed by aid of the skin stretching device
41119661|NCT00609908|PROCEDURE|serial excision|as much scar as possible is excised, whereafter the wound is closed
41119662|NCT00609908|PROCEDURE|skin stretching device|after the scar is excised, the wound is primarily closed by aid of the skin stretching device
41119663|NCT01571596|DRUG|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
41119664|NCT05533658|DIETARY_SUPPLEMENT|VisionPure Dietary Supplement|Subjects will consume two softgels capsules of the Treatment (VisionPure) once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
41271928|NCT02312804|DRUG|Paclitaxel|Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
41453410|NCT01187823|DEVICE|Nocturnal oxygen|Nocturnal use of oxygen
41119665|NCT05533658|DIETARY_SUPPLEMENT|Placebo|Subjects will orally consume two softgel capsules of Placebo once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
41119666|NCT05156112|DEVICE|Positive Airway Pressure Device|Each PAP treatment initiation meeting will include 1) mask fitting; 2) psycho-education to what to expect and reviewing PAP machine problem solving; and 3) setting up correct PAP treatment (e.g., auto PAP or in rare conditions, bi-level PAP).
41119667|NCT00409799|DRUG|I-0401 (a new bone graft substitute)|1 time application
41119668|NCT00140790|DRUG|valsartan|valsartan 40 or 160 (80) mg per day
41119669|NCT00004243|DRUG|docetaxel|
41119670|NCT00004243|DRUG|oxaliplatin|
41119671|NCT00300131|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
41119672|NCT00001017|DRUG|Fluconazole|
41119673|NCT00001017|DRUG|Amphotericin B|
41119674|NCT05486598|DRUG|AL8326 tablets|"Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals.~Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach."
41119675|NCT03459677|BEHAVIORAL|Back2School|Modular Trans-diagnostic Cognitive Behavioral Therapy treating school absenteeism in youths
41119676|NCT03459677|OTHER|Treatment As Usual|Aarhus municipality's treatment as usual for youths presenting school absenteeism
40926344|NCT01890629|DRUG|Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin|
41119677|NCT02446145|DRUG|Eltrombopag|"Patients will receive EPAG in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
41119678|NCT02446145|DRUG|Placebo|"Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
41119679|NCT03344588|PROCEDURE|artery preserving varicocelectomy|During sub-inguinal varicocelectomy, testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
41119680|NCT03344588|PROCEDURE|artery ligation varicocelectomy|During sub-inguinal varicocelectomy, all vascular channels will be ligated without identifying or sparing the internal spermatic arteries.
41119681|NCT03390296|BIOLOGICAL|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Given IV
41119682|NCT03390296|DRUG|Avelumab|Given IV
41119683|NCT03390296|DRUG|Azacitidine|Given IV or SC
41119684|NCT03390296|DRUG|Gemtuzumab Ozogamicin|Given IV
41119685|NCT03390296|DRUG|Glasdegib|Given PO
41119686|NCT03390296|DRUG|Glasdegib Maleate|Given PO
41119687|NCT03390296|DRUG|Venetoclax|Given PO
41119688|NCT03390296|DRUG|Azacitidine|Given IV or SC
41119689|NCT00945789|DRUG|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
41119690|NCT00945789|PROCEDURE|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
40926345|NCT04421547|DRUG|Letrozole 2.5mg|This study will investigate the role of Letrozole in patients affected by heavily pretreated platinum resistant ovarian cancer, compared to standard treatment.
41119691|NCT00945789|BIOLOGICAL|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
40926346|NCT04421547|DRUG|Standard single agent chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
41119692|NCT02698813|BIOLOGICAL|umbilical cord mesenchymal stem cells and hyaluronic acid|
41119693|NCT02698813|DRUG|hyaluronic acid|
41119694|NCT03436277|DRUG|L-Carnitine|L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
41119695|NCT03436277|DIETARY_SUPPLEMENT|Sucralose|Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
41119696|NCT02423798|DEVICE|Glucose sensor (Enlite)|This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
41119697|NCT02779998|OTHER|non invasive ventilation|non invasive ventilation is delivered by a specific respirator with inspiratory help mode. NIV mask and parameters are adapted to obtains a Tidal volume ≤ to 8 ml/kg/cycle (if possible ≤ 6 ml/kg/cycle) and a SpO2 superior of 94%.
41119698|NCT02779998|OTHER|Standard oxygen therapy with facial mask|
41119699|NCT04847414|DIAGNOSTIC_TEST|HbA1C, other investigations|we will do some necessary investigations for prospective group
41119700|NCT02806934|PROCEDURE|biological and ultrasound test|biological and ultrasound test 20 days after implantation in order to see the implantation rate
41119701|NCT01897870|BEHAVIORAL|HomeCoMe-program|A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.
41119702|NCT06203873|DEVICE|Biodegradable occluder|Patients assigned in this group will receive PFO occlusion with a biodegradable occluder.
41119703|NCT06203873|DEVICE|Metal occluder|Patients assigned in this group will receive metal occluder for PFO occlusion
41119704|NCT06520137|PROCEDURE|Tooth extraction|Extraction of maxillary third molars
41119705|NCT00580593|DEVICE|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
41119706|NCT00580593|OTHER|sham-NIPPV|a sham-device
41119707|NCT00968149|DRUG|montelukast sodium|one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
41119708|NCT00968149|DRUG|Comparator: Placebo|one placebo chewable tablet daily at bed time for 2 weeks
41119709|NCT00692042|DRUG|AZD1704|One dose, by mouth
41119710|NCT03359967|DRUG|Entresto tablet|Changes in intrathoracic impedance and other related parameters between before- and after Sacubitril/Valsartan treatment collected via previously implanted device algoritm. (OptiVol Fluid Index)
41119711|NCT06148831|DEVICE|Infant Carrier|"The assigned home visitor will provide a participant with an infant carrier and will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client to practice using the carrier and will provide materials to support continued learning.~All home visitors participated in an infant carrier training developed by Nurturely, centered on carrying as a cultural practice, utilizing culturally relevant visuals as well as easy-to-remember acronyms to promote safe and ergonomic use (i.e., the STOP acronym developed by Nurturely, signifying that all knots are Secure, infant is attached high enough to kiss the top of their head and Tight to the caregiver's body, nose and mouth are visible and airway is Open, and hips are Positioned in an ergonomic spread squat)."
41119712|NCT02331745|DRUG|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
41119713|NCT02331745|DRUG|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
41119714|NCT01522898|PROCEDURE|AV nodal ablation|Percutaneous catheter ablation of the AV node.
41119715|NCT01522898|DRUG|Medical Ventricular Rate Control|Ventricular Rate Control with target ventricular rate of 90 beats per minute.
41119716|NCT03015896|OTHER|Laboratory Biomarker Analysis|Correlative studies
41119717|NCT03015896|DRUG|Lenalidomide|Given PO
41119718|NCT03015896|BIOLOGICAL|Nivolumab|Given IV
41119719|NCT04732260|DRUG|Letermovir|"Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.~5 women will receive 240 mg. 5 women will receive 480 mg."
40926347|NCT00002165|DRUG|Nelfinavir mesylate|
40926348|NCT06534892|BIOLOGICAL|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)
40926349|NCT05856591|BEHAVIORAL|Food Resources & Kitchen Skills (FoRKS)|Food Resources \& Kitchen Skills (FoRKS) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes with embedded lessons in kitchen organization, tool use, nutrition, budgeting, and shopping.
41119720|NCT04426916|OTHER|Spondylolisthesis|Spondylolisthesis at a single level
41119721|NCT01981174|PROCEDURE|30-gauge needle|
41119722|NCT01981174|PROCEDURE|32-gauge needle|
41119723|NCT02176538|DRUG|Product 0405|Product 0405 will be administered topically twice daily for 28 days
41119724|NCT02176538|DRUG|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
41119725|NCT03379740|OTHER|E-cigarette|Subject's own e-cigarette
41271929|NCT03122626|BEHAVIORAL|Together in Movement and Exercise (TIME) Program|The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
41453411|NCT02188407|DRUG|Sevoflurane|MAC 3-5 V% during surgery
40926350|NCT05856591|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
41119726|NCT03379740|OTHER|P4M3-1.7%|P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
41119727|NCT03379740|OTHER|P4M3-1.7%LA|P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
41119728|NCT03379740|OTHER|P4M3-3%LA|P4M3 e-liquid concentration of 3% nicotine with lactic acid
41119729|NCT03379740|OTHER|P4M3-4%LA|P4M3 e-liquid concentration of 4% nicotine with lactic acid
41119730|NCT01291381|DRUG|Dermatophagoides pteronyssinus|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
41119731|NCT01291381|DRUG|Pharmacotherapy|For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
41119732|NCT00000675|DRUG|CD4-IgG|
41119733|NCT00812461|DRUG|Placebo|as-needed use, tablets, orally, 6 months
41119734|NCT00812461|DRUG|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
41119735|NCT02214550|DRUG|cyclic microgestin 1/20|Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat
41119736|NCT02214550|DRUG|continuous microgestin 1/20|Continuous OC use - Pills containing hormones will be taken every day for 1 year
41453412|NCT02188407|DRUG|Propofol|Propofol group (P group)- The group anaesthesied with propofol
41271930|NCT04376450|PROCEDURE|Experimental- Nonincised papillae surgical approach|"The basic principle of the technique is the placement of only one buccal horizontal or oblique incision in the mucosa, as apically as possible from the periodontal defect and the marginal tissues, and the raising of a mucoperiosteal flap coronally, which permits apical access to the defect but leaving the marginal tissues intact, acting as a dome for the protection of the clot."
41271931|NCT04376450|PROCEDURE|Active comparator- Entire papilla preservation technique|The entire Papilla Preservation Technique is to preserve the whole integrity of the defect- associated papilla providing a tunnel-like undermining incision. The completely preserved interdental papilla provides an intact gingival chamber to stabilize the blood clot and improve the wound healing process. To provide adequate access for debridement, EPP requires a short buccal vertical releasing incision on the buccal side of the neighboring tooth extending just beyond the mucogingival line.
41271932|NCT00006449|DRUG|naltrexone (Revia)|
41271933|NCT00006449|BEHAVIORAL|broad spectrum treatment|
41271934|NCT00006449|BEHAVIORAL|motivational enhancement therapy|
41271935|NCT03679403|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
41271936|NCT01855256|DRUG|Oxybutynin|Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
41271937|NCT01855256|DRUG|Placebo|Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
41271938|NCT02633449|BEHAVIORAL|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
41271939|NCT02633449|DEVICE|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
40926351|NCT00527488|DRUG|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
40926352|NCT00527488|DRUG|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
40926353|NCT00527488|DRUG|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
40926354|NCT00527488|DRUG|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
41119737|NCT05447871|PROCEDURE|Ultrasound guided single injection modified 4 in 1 block technique|A high-frequency ultrasound probe is placed over the femoral condyle and vastus medialis muscle is identified. The probe is slid proximally till the superficial femoral artery appeared. The probe is slid proximally till the descending genicular artery branching from the superficial femoral artery. The point of interest is 8-10 cm above the femoral condyle. The needle is guided into the Vastus medialis muscle till the nerve to Vastus medialis. At this point, 5-7 mL of the local anaesthetic drug is injected. The needle is guided further in-plane from lateral to medial side to reach the perivascular region and after negative aspiration 25 ml local anaesthetic drug is injected.
41119738|NCT05447871|PROCEDURE|Ultrasound guided adductor canal block technique|The Adductor canal is identified in the middle of the thigh beneath the sartorius muscle using a high-frequency ultrasonic transducer. the probe is slid till the superficial femoral artery appeared in the adductor canal between vastus medialis and adductor longus muscle. A 22-gauge spinal needle is inserted in a lateral to medial plane to reach the perivascular region and after negative aspiration 20 ml local anaesthetic drug is injected, visualised to push the femoral artery.
41119739|NCT05447871|DRUG|Bupivacaine 0.25%|bupivacaine 0.25%
41119740|NCT02324010|DRUG|Sitagliptin|100mg mane for 2 days
41119741|NCT02324010|DRUG|Placebo|Inactive drug (Placebo)
41119742|NCT03569072|RADIATION|Functionally adapted, dose escalated VMAT radiotherapy|Volumetric Modulated Arc Therapy planning and treatment delivery to treat primary and nodal planning target volume with 60 Gy in 30 fractions and a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions while avoiding organs at risk including functional lung, heart and oesophagus.
41119743|NCT03090763|GENETIC|PCR and sequencing|Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
41119744|NCT04452318|DRUG|REGN10933 + REGN10987|Subcutaneous (SC) or Intramuscular (IM) injections
41119745|NCT04452318|DRUG|Placebo|SC or IM injections
41119746|NCT06453798|OTHER|cervical spine exercises|Cervical spine exercise training is a method to improve the neck function through the patient's self-exercise.
41119747|NCT06453798|OTHER|Neuromobilization|Neuromobilization is a technical technique for rehabilitation therapists to loosen the trapped nerves of patients with professional methods.
41119748|NCT03639558|DRUG|Haloperidol + Promethazine + Chlorpromazine|This is the usual treatment given by this hospital during an aggressive psychiatric episode.
41119749|NCT03639558|DRUG|Haloperidol + Promethazine|This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
41271940|NCT02633449|DEVICE|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
41271941|NCT03146286|DIETARY_SUPPLEMENT|Saturated fat|Palm stearin
41271942|NCT03146286|DIETARY_SUPPLEMENT|Placebo|Water
41119750|NCT03588715|DRUG|Pegylated Interferon alpha 2b (peg-IFN-α2b)|Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.
41119751|NCT03588715|DRUG|3BNC117 + 10-1074|Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
41119752|NCT02928224|DRUG|Encorafenib|Orally, once daily.
41271943|NCT03146286|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil, Omega 3 PUFA
41119753|NCT02928224|DRUG|Binimetinib|Orally, twice daily.
41271944|NCT02479789|DRUG|Lidocaine|
41271945|NCT02479789|DRUG|Placebo|
41271946|NCT03688386|BEHAVIORAL|Reading intervention|Written packet with 3 lessons. The first lesson includes how to begin to read and talk to their baby. The second lesson includes reading or talking about the day using parentese talk. The third lesson includes continuing to engage with the baby through interactive reading.
41271947|NCT03688386|BEHAVIORAL|Infant bonding|Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
41271948|NCT03688386|BEHAVIORAL|LENA recording|The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
41271949|NCT03688386|BEHAVIORAL|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
41271950|NCT03688386|BEHAVIORAL|LENA summary|All 3 LENA recording summaries of adult word counts, infant vocalizations, and conversational turns will be summarized in printed form and provided to mother at discharge.
41271951|NCT01535235|DRUG|Lisinopril|Lisinopril 20mg QD x 24 weeks
41271952|NCT01535235|DRUG|Placebo|Placebo QD x24wks
41271953|NCT01048346|BEHAVIORAL|Individual Placement and Support Model|Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
41271954|NCT03376633|BEHAVIORAL|Working on Womanhood (WOW)|A trauma-informed group counseling and clinical mentoring intervention for young women
41271955|NCT02970929|DRUG|SEP-363856|One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
41271956|NCT00123084|BEHAVIORAL|Voice/Respiration Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.
41271957|NCT00123084|BEHAVIORAL|Speech/Articulation Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
41271958|NCT05011396|DRUG|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
41271959|NCT05011396|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
41271960|NCT01106001|DRUG|Levobupivacaine|The treatment group received 150mg of levobupivicaine in 60mls of 0.9% saline. This was injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
41271961|NCT01106001|DRUG|Saline|The placebo group received 60mls of 0.9% saline injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
41271962|NCT05516329|DRUG|A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide|The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60\~120 min after the injection.
41271963|NCT05395221|OTHER|Guided Mediation Virtual Reality App|Guided Meditation Virtual Reality App uses over 40 lush environments with 30 hours of guided meditations on Anxiety, Depression, Maternity, Resilience, Sleep, or Zen and 200 relaxing audio tracks using Virtual reality.
41271964|NCT00642642|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."
41271965|NCT00642642|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."
41271966|NCT02991599|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
41271967|NCT02991599|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
41271968|NCT03752125|DIETARY_SUPPLEMENT|Flavonoid, caffeine|2 flavonoid/caffeine capsules before breakfast, 2 capsules before lunch
41271969|NCT03752125|DIETARY_SUPPLEMENT|Placebo|2 placebo capsules before breakfast, 2 capsules before lunch
40926355|NCT01453582|DRUG|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
40926356|NCT01453582|DRUG|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
41119754|NCT02928224|DRUG|Cetuximab|Standard of care.
41119755|NCT02928224|DRUG|Irinotecan|Standard of care.
41119756|NCT02928224|DRUG|Folinic Acid|Standard of care.
41119757|NCT02928224|DRUG|5-Fluorouracil|Standard of care.
41119758|NCT05680389|DRUG|Minocycline|100 mg twice daily for 3 months
41119759|NCT05680389|DRUG|Placebo|twice daily for 3 months
41119760|NCT06290882|PROCEDURE|Robotic Heller Myotomy|Use five trocar technique with patient in the French position. Establish 12-15 mm Hg pneumoperitoneum. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 7 cm above gastroesophageal junction and 2 cm inferiorly over stomach. Measure myotomy length. Perform anterior fundoplication without mobilizeng fundus of the stomach by dividing short gastric vessels if not necessary. Suture fundus to both cut edges of myotomy, using non-resorbable material.
41119761|NCT06290882|PROCEDURE|Peroral Endoscopic Myotomy|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
41119762|NCT05434273|BEHAVIORAL|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
41271970|NCT00707356|DRUG|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
41271971|NCT03851692|OTHER|Intravenous Cannulation (iv placement)|The aim of our study is to determine whether one should make intravenous attempts placement during the early induction period (at 60seconds) or lately (90 or 120 s) and waiting until the child receives additional sevoflurane inhalation anesthesia.
41271972|NCT02310399|DEVICE|Nucleus ABI541 Auditory Brainstem Implant|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
41271973|NCT03663257|DEVICE|AneurysmFlow|AneurysmFlow R1.0 is an approved (CE labeled, cleared in US, Canada and Argentina), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It provides color coded and vector field representation of a digital subtraction angiography (DSA). It can quantify blood flow rates in the artery based on DSA and 3-D Rotational Angiogram (3DRA) data. It can visualize blood flow patterns in an aneurysm based on DSA data. Specifically, it calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric flow rate quotient before and after Flow Diverter Stent (FDS) implantation in the region of interest. It is manufactured by Philips Medical Systems B.V., a Philips Healthcare company.
41271974|NCT03148210|DRUG|Treatment strategy using evidence-based guidelines for asthma or COPD|The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
41271975|NCT03148210|BEHAVIORAL|Smoking Cessation|Smoking cessation counselling by a qualified educator if currently smoking
41271976|NCT03148210|BEHAVIORAL|Participant Education|Standardized education for asthma or COPD disease
40753210|NCT05945758|PROCEDURE|Injectable resin composite technique.|A metal impression tray was filled with transparent vinyl polysiloxane (EXACLEAR, GC) and used to copy the stone model with the wax-up. Then, the replica will be separated from metal tray and a needle-shaped bur will be used to drill holes through the silicone key ending in the middle of the incisal edge. It will be checked whether the holes were large enough to enable the tip of the composite syringe to pass easily and completely. Neighbouring teeth (mesial and distal one) isolated using Teflon tape, as each tooth will individually be restored for establishment of satisfactory contact points. Following etching and rinsing, the tooth dried, and a dental cord (Ultrampak, Ultradent) will be packed into sulcus for mechanical prevention of subgingival composite flow. Then, the transparent silicone index will be placed in the correct intraoral position, and a syringe filled with flowable composite will be inserted through the hole on the incisal edge.
40753211|NCT05945758|PROCEDURE|Conventional layering technique|the palatal surface will be restored by enamel shade; adapted on the index in the spacing area then The Unica matrix (Polydentia) will be used to restore the proximal wall, and to achieve a good seal with the palatal wall. The matrix can be stabilized with a wedge if necessary. Building the proximal wall using the enamel shade, and the incisal halo by using a dentin shade, the frame to layer the core of the restoration will be ready.
40926357|NCT05748652|DEVICE|digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for anxiety.
40926358|NCT05748652|OTHER|Psychoeducation|Participants will be provided with psychoeducation which will be delivered digitally upon allocation to the psychoeducation arm.
41453413|NCT05485662|OTHER|Hydroxyapatite toothpaste|10% Hydroxyapatite toothpaste
40926359|NCT03015480|BEHAVIORAL|Remote counseling|For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
40753212|NCT02872142|BIOLOGICAL|Albutein 5%|Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.
40753213|NCT02872142|PROCEDURE|Plasma Exchange|Plasma Exchange will be performed using albutein 5% as the replacement solution.
40753214|NCT05615961|DIETARY_SUPPLEMENT|Probiotics (Lab4 probiotics, Cultech, Port Talbot, Wales, UK)|The intervention is a unique blend of probiotic cultures from a well-established manufacturer.
40753215|NCT05615961|DIETARY_SUPPLEMENT|Placebo|Placebo Tablets
40926360|NCT05387499|DRUG|NP-011 (Single Ascending Dose Phase)|The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1
40926361|NCT05387499|DRUG|NP-011 (Multiple Ascending Dose Phase)|The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days
40926362|NCT05387499|OTHER|NP-011 (Placebo)|The participants will receive single dose of NP-011 after a minimum 8 hour fast on Day 1 in Single Ascending Dose part and will receive once daily for 7 days after a minimum 8 hour fast in Multiple Ascending dose part of the study
41271977|NCT05984446|DEVICE|real-rTMS|Each subject will undergo 4 rTMS sessions using a 70-mm figure-eight coil (20Hz for 25 minutes). Target localization will be performed with a stereotaxic neuronavigation system.
41271978|NCT05984446|DEVICE|sham-rTMS|The sham condition will match the real-rTMS protocol, but a sham coil will be used.
41271979|NCT03785054|DRUG|HTL0014242|HTL0014242 is a selective negative allosteric modulator (NAM) for the metabotropic glutamate (mGlu) receptor 5 subtype (mGlu5)
41271980|NCT03785054|DRUG|Placebo oral capsule|Placebo treatment
41271981|NCT04614818|OTHER|Non-intervention research|Non-intervention research
41271982|NCT02976155|OTHER|A standard enteral nutrition protocol|Patients in the experimental arm, the practice of enteral nutrition will based on a standard protocol. The core content of this protocol includes five step：1. Whether the participants need nutrition therapy? 2. The choice of nutrition way? 3. Nasogastric tube or nasointestinal tube? 4. The choice of enteral nutrition type? 5. The target calorie and protein of the participants? And how to achieve these target？(In this study, the practice of the above protocol is the only intervention).
41271983|NCT02507479|DRUG|Thiotepa|Chemotherapy given prior to allogeneic stem cell transplantation
41271984|NCT00006131|DRUG|Valacyclovir|
41271985|NCT05606939|DEVICE|intestinal ultrasound|"All patients will be evaluated using intestinal ultrasound with special emphasis on intestinal wall thickness as well as stratification and Visualization of the vascularization of the bowel using color Doppler sonography also visualization of motility.~Findings of intestinal ultrasound will be compared regrading colonoscopic findings"
41271986|NCT00120614|BEHAVIORAL|Premature infant behavior and development information|
41271987|NCT00120614|BEHAVIORAL|Parental activities to support premature infant information|
41271988|NCT00960271|PROCEDURE|EBUS|a minimally invasive technique of mediastinal lymph node staging using an integrated videoendoscopic device equipped with ultrasound for the localization and transbronchial sampling of lymph nodes in real time
40753216|NCT05611892|COMBINATION_PRODUCT|18F-FDS PET/CT|20 millicurie (mCi) of 18F-FDS in adult patient age group and 2.5 mCi in children (age 12-18 years old) followed by a PET/CT scan.
40753217|NCT04097912|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|75-100mg
40753218|NCT03987607|DEVICE|neuromuscular blockade monitoring|Neuromuscular blockade monitoring via two different types of monitoring devices
41119763|NCT05434273|BEHAVIORAL|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. A governmental health education leaflet and a lecture video will be provided for reference.
41119764|NCT02677129|OTHER|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
41119765|NCT03169894|DRUG|MDGN-002|MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
41119766|NCT00189813|DRUG|YM060|
41119767|NCT05563168|DRUG|DILTIAZEM TEVA 60 mg or placebo|DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.
41119768|NCT05309733|GENETIC|VOR33|VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
41119769|NCT01837875|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The Chronic Disease Self-Management Program (CDSMP) is a 2.5 hour workshop given weekly for six weeks. People with different chronic health problems attend together and support one another in making positive changes in their health. Workshops are facilitated by two trained leaders, one or both of whom are non-health professionals with a chronic disease themselves. It is the process in which the program is taught that makes it effective. Classes are highly participative, and mutual support builds the participants' confidence in their ability to manage their health and maintain active and fulfilling lives.
41271989|NCT03872492|OTHER|Digital Assessment on mobile|"The digital assessment is composed on 5 tests:~* My daily survey~* My evaluation~* My cognition~* My emotions~* My voice~Data will also be collected passively."
41271990|NCT00235521|DRUG|aerosolized iloprost|
41271991|NCT02358811|DEVICE|Magnetic resonance imaging (MRI)|"The acquisition of the image will last 45 minutes with 6 sequences.~* Before any examination, the manipulator will check the absence of contraindication to MRI.~* During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.~* Throughout the examination, a physician will always be present."
41271992|NCT02358811|BEHAVIORAL|Cognitive assessment|"This cognitive assessment will include the following executive tests :~* test of Stroop~* left Trail Making Test A and B~* verbal fluence test~* test of memory of figures direct and inverse in order~* completion of matrices~* Paced Auditory Serial Addition Test (PASAT)"
41271993|NCT04324853|DIAGNOSTIC_TEST|Microscopy ( Urine filtration), UCAA test, qPCR,|Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode worms) of the genus Schistosoma.Schistosomiasis is prevalent in tropical and subtropical areas, especially in poor communities without access to safe drinking water and adequate sanitation.
40753219|NCT00002011|DRUG|Methoxsalen|
40753220|NCT01531803|DRUG|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin)."
40753221|NCT01531803|DRUG|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
40753222|NCT03850431|BEHAVIORAL|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
41453414|NCT05485662|OTHER|Sodium Fluoride Toothpaste|1450 parts per million sodium fluoride toothpaste
41453415|NCT00201396|RADIATION|CCRT|Radiation with weekly Cisplatin
41453416|NCT00201396|DRUG|Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin|Induction C/T + CCRT
41271994|NCT04324853|DIAGNOSTIC_TEST|Microscopy (Kato Katz, Coproculture, Harada Mori, MIF), qPCR,|Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities. They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor.
41271995|NCT00284830|DEVICE|Implantable Pulse Generators|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
41119770|NCT01837875|BEHAVIORAL|Mail-delivered arthritis kit|"The Arthritis Self-Management Tool Kit contains 1) a Self Test to help participants determine how arthritis affects their lives and self-tailor the use of the Tool Kit, including items related to pain, fatigue, physical limitations, and health worries; 2) information sheets: Working with Your Doctor and the Health Care System; Exercise; Medications; Healthy Eating; Fatigue and Pain Management; Finding Community Resources; and Dealing with One's Emotions; 3) information sheets on key process components of the ASMP: Action Planning, Problem Solving, Deciding What to Try, and Individualizing an Exercise Program; 4) The Arthritis Helpbook; 5) audio relaxation and exercise compact discs (CDs); and 6) an audio CD of all material printed on the information sheets."
41119771|NCT01837875|BEHAVIORAL|Support group|"Interested participants will be referred to the Lupus: Listening and Learning Group, a Charleston-based support group affiliated with the Lupus Foundation of America (LFA). One to two LFA-trained facilitators implement the group. The meeting format generally includes a specific discussion topic or an informative presentation such as by a medical or counseling professional, pharmacist, or lupus researcher. This program is followed by time within the group for further interaction and support among the attendees who wish to participate. The Lupus: Listening and Learning Group is open to all lupus patients, family members, friends and supporters, and there is no pre-registration or fee involved."
41119772|NCT01837875|BEHAVIORAL|Listserv|A project listserv will be established to link all intervention participants to facilitate exchange of coping strategies, pose questions, and share preferred educational resources or any other information relative to their everyday and disease-specific experiences and/or participation in the project. Participants will be provided with a URL, from which they will be able to subscribe to the listserv. Once subscribed, they will be able to post and receive messages, managed by a listserv moderator, who will be responsible for distribution to listserv members as appropriate. Participants will have the option to unsubscribe at any time.
41119773|NCT04092231|BEHAVIORAL|Early speech perception test|The early speech test is one of the closed-set response speech discrimination tests,using object identification technique.It was carefully designed for estimation of speech perception abilities in very young children who have extremely low verbal abilities
41119774|NCT05646329|BEHAVIORAL|Motivational Interview|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session.
41119775|NCT00943358|BIOLOGICAL|MF59 H1N1 vaccine|3.75-7.5ug dose
41119776|NCT00943358|BIOLOGICAL|Plain H1N1 vaccine|7.5-15ug
41119777|NCT00947635|DIETARY_SUPPLEMENT|Dietary intervention - supplements|Supplement bar \& spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
41119778|NCT01747486|BIOLOGICAL|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
41119779|NCT04190316|OTHER|Evaluation of fecal RA and environmental contamination of ESBL-PE carrier in ICU|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
41271996|NCT03414957|DIAGNOSTIC_TEST|Hormonal and biochemical blood tests and ultrasound scanning|Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both
41271997|NCT00275431|DRUG|AT-101|Oral
41271998|NCT04827641|OTHER|Severity Grading assessment in children with perioperative unexpected events|Systematic documentation of all unexpected events was carried out by designated team members during daily routine team conferences. Briefly, on-call team members and all other staff reported on any unexpected event that had occurred within the previous 24 hours, after weekends during the past 72 hours. Events included those that had occurred in inpatients, outpatients and in the pediatric emergency department. Data concerning each event included patient demographics, diagnoses, treatments/operations and types of events.
41271999|NCT03461055|OTHER|Lavender|Lavender aromatherapy
41272000|NCT03461055|OTHER|Water|Water
41119780|NCT00584246|DRUG|Pregabalin (Lyrica)|50 - 150 mg po qhs for 2 months
41119781|NCT00584246|DRUG|Placebo|50 - 150 mg po qhs for 2 months
41119782|NCT00362778|DRUG|Insulin|intravenous continuous insulin infusion for 48 hours
41119783|NCT03335748|OTHER|Cognitive training Cogmed program|Cognitive training Cogmed program
41119784|NCT02655588|BEHAVIORAL|Interactive Media-Based Problems Solving Treatment|
41272001|NCT05974306|DEVICE|implantable loop recorder|Implantation of an implantable loop recorder
41272002|NCT00899340|GENETIC|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
41272003|NCT00899340|GENETIC|microarray analysis|microarray analysis
41272004|NCT00899340|GENETIC|protein expression analysis|protein expression analysis
40926363|NCT03341780|PROCEDURE|amblyopia therapy|Any of the following amblyopia training activities may be employed during patching: board games, card games, coloring in O's, comic books, craft projects, crossword puzzles, dot-to-dot patterns, drawing, hammering nails, jacks, jigsaw puzzles, lego and other blocks, marbles, mazes, peg-board activities, perceptual materials, pickup sticks, reading, sewing, shooting games, stringing beads, throwing or hitting games, tracing, and video or computer games.
40926364|NCT03550859|DRUG|Telmisartan/Rosuvastatin 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
40926365|NCT03550859|DRUG|Telmisartan 40mg|Telmisartan 40mg qd for 48 weeks
41272005|NCT00899340|OTHER|immunohistochemistry staining method|immunohistochemistry staining method
41272006|NCT00899340|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
41453417|NCT02031250|DRUG|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
41119785|NCT06105125|DEVICE|Rigenera + bone substitute|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. A small punch of connective tissue will be harvested from the palate in the premolar region. Then the graft will be mechanically dissociated using the Rigenera Machine System rotating speed to 80 rpm, in 1.0 ml sterile physiologic solution. After dissociation, the cellular suspension will be passed through a disposable grid with 100 hexagonal blades filtering cells and components of extracellular matrix with a cut-off of 50 um in an average time of 90 s. Finally, part of the suspension containing AMGs will be seeded on the scaffold material and subsequently compacted within the defect. Flaps will be positioned at the pre-surgical level or slightly coronal without any tension.
41119786|NCT06105125|DEVICE|Bone substitute alone|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. The defect will be filled with the same bone substitute employed in the test group. Finally, flaps will be positioned at the pre-surgical level or slightly coronal without any tension.
41119787|NCT06473090|OTHER|Video group|"Participants will watch a 15-minute educational video at the beginning of the session before their involvement in the 2 high-fidelity simulation scenarios.~The educational video used was developed by experts (in Human Factors and Obstetric Anesthesia) and validated by SFAR and CARO. It depicts poor use of NTS (including CLC) during a maternal cardiac arrest anesthesia scenario and then proper use of NTS during the same scenario."
41119788|NCT06473090|OTHER|Text group|"Participants will read a text-type educational support for 15 minutes at the beginning of the session before their involvement in 2 high-fidelity crisis simulation scenarios.~The text-type educational support, written in French by the same team of experts, covers all the NTS mentioned in the video and has already been used in a previous study"
41119789|NCT04787653|DEVICE|Otoband|Participants with Tinnitus will wear the Otoband set at an effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
41272007|NCT02684305|DRUG|Administration of Propess|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
41272008|NCT02684305|DEVICE|balloon|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
41272009|NCT02684305|DRUG|Intravenous oxytocin infusion|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
41272010|NCT05987761|BEHAVIORAL|PRT for Adolescents|Clinician-led 70-minute PRT sessions targeting social skills once per week at Stanford.
40753223|NCT03850431|BEHAVIORAL|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
40753224|NCT03850431|BEHAVIORAL|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
40926366|NCT01146860|DRUG|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
40926367|NCT01146860|DRUG|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
40926368|NCT05909800|DRUG|Phenofibrate|Administred orally, once daily, for 12 months.
40926369|NCT05909800|DRUG|Placebo|Administred orally, once daily, for 12 months.
40926370|NCT05798611|DRUG|ART0380|Randomized patients will orally receive ART0380.
40926371|NCT02518880|OTHER|Parabolic flight|
40926372|NCT02518880|OTHER|plasma volume measurements|
40926373|NCT05218954|DIAGNOSTIC_TEST|Biomechanical analysis of risk fall|Biomechanical analysis of risk fall in terms of balance
40926374|NCT02390791|OTHER|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
40926375|NCT02390791|OTHER|treatment as usual standard portal|Standard version of myADHDportal.com web software
40926376|NCT01705067|DEVICE|TKA with Journey II BCS Total Knee System|TKA with Journey II BCS Total Knee System
41119790|NCT04787653|DEVICE|Placebo|Participants with Tinnitus will wear the Otoband set at a non-effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
41272011|NCT03471455|DRUG|Isotretinoin|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
41272012|NCT03471455|DRUG|Terbinafine|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
41272013|NCT03471455|DRUG|Itraconazole 200 mg|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
41272014|NCT04444245|PROCEDURE|lipoaspiration harvest tSVF|Use of disposable, sterile microcannula lipoharvest to acquire tSVF
41272015|NCT04444245|PROCEDURE|Platelet Rich Plasma|Standard venipuncture, concentration of PRP in FDA approved device (Emcyte II)
41272016|NCT04444245|PROCEDURE|Endovaginal Ultrasound|Endovaginal Ultrasound guidance to intra-ovarian placement, bilaterally
41272017|NCT04444245|DEVICE|Cellular Isolation cSVF|Digestion of tSVF with Liberase, isolation \& concentration of cSVF in Centricyte 1000
41272018|NCT04444245|DRUG|Normal Saline (NS) .9% 10 mL Injection|10 cc Sterile Normal Saline for Injection
41272019|NCT04444245|DEVICE|emulsification tSVF|Harvested tSVF emulsification with sterile, disposable Nanofat screen device
41272020|NCT01848275|DEVICE|Thermocool®Rcatheter|The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
41272021|NCT01848275|DEVICE|Thermocool®Rcatheter|The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
41272022|NCT05246540|OTHER|Data collection|Data collection
41272023|NCT00271388|DEVICE|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
41272024|NCT04523740|DRUG|Placebo|Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks
41272025|NCT04523740|DRUG|Paracetamol|Patients who use regular paracetamol will now receive 6 to 8 tablets of 500 mg paracetamol per day for 2 weeks
41272026|NCT01207466|DEVICE|Nelfilcon A investigational contact lens|Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
41272027|NCT01207466|DEVICE|Nelfilcon A commercial contact lens|Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
41119791|NCT04088123|DRUG|Ticagrelor Oral Tablet [Brilinta]|A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
41272028|NCT00715130|BEHAVIORAL|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
41272029|NCT02323022|DRUG|IAC regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
41272030|NCT02323022|DRUG|IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
41272031|NCT01743430|OTHER|telerehabilitation|telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
41272032|NCT05525663|BEHAVIORAL|Rehabilitation Intervention|progressive, multi-domain rehabilitation and exercise training intervention
41272033|NCT02427048|BEHAVIORAL|Feedback with Peer Comparison|Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
41272034|NCT03467620|DRUG|Cannabidiol|Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks
41272035|NCT03467620|DRUG|Placebo oral capsule|Administration of one oral placebo capsule daily for a duration of 12 weeks
41272036|NCT02871479|DRUG|SAN007 5% cream|5% EISO in a cream formulation applied twice a day for up to 28 days.
41272037|NCT02871479|DRUG|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
41272038|NCT02871479|DRUG|SAN007 10% cream|10% EISO in a cream formulation applied twice a day for up to 28 days.
41272039|NCT04151108|OTHER|Development of a risk assessment tool based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale) and risk of pressure ulcers (Braden Score), Early Warning Score (EWS), sarcopenia (SARC-F), malnutrition (SNAQ), cognitive status, comorbidity (Charlson comorbidity Index), polypharmacy, muscle strength, and body composition (BIA)
41272040|NCT04151108|OTHER|Development of a risk assessment tool for loss of muscle mass and physical function based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale), Early Warning Score (EWS), cognitive status, sarcopenia (SARC-f), malnutrition (SNAQ), comorbidity (Charlson comorbidity Index), polypharmacy, physical function, physical performance, and body composition (BIA)
40926377|NCT04184258|BIOLOGICAL|Pooled mesenchymal stem cell|Pooled allogenic mesenchymal stem cell derived from olfactory mucosa
41272041|NCT05983393|PROCEDURE|Erector spinae plane block|Erector spinae plane block was performed
41272042|NCT05983393|PROCEDURE|Control|Erector spinae plane block was not applied.
41272043|NCT00558935|DIETARY_SUPPLEMENT|Red Wine|20g alcohol daily/red wine for 4 weeks
41272044|NCT03537040|OTHER|Method of Levels|Talking Therapy
41272045|NCT03112811|DEVICE|Autogenic drainage|The manual technique of the chest physiotherapy to move the secretions
41272046|NCT03112811|DEVICE|Intrapulmonary percussive ventilation|The instrumental technique of the chest physiotherapy to move the secretions
41272047|NCT01948830|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
41272048|NCT01948830|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
41272049|NCT01381094|DRUG|AKB-6548|oral dose administered once daily for 42 days
41272050|NCT01381094|DRUG|Placebo|oral Placebo administered once daily for 42 days
41272051|NCT02296411|DRUG|CHF 5259 12.5 µg|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
40753225|NCT03850431|BEHAVIORAL|Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions|A letter with all types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
41119792|NCT04791592|PROCEDURE|Single-injection, ultrasound-guided bilateral PIF block.|"PIF block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
41119793|NCT04791592|PROCEDURE|Single-injection, ultrasound-guided bilateral TTMP block.|"TTMP block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
41119794|NCT05231317|OTHER|Plant-based diet|16 days with all foods provided
41119795|NCT05231317|OTHER|Western diet|16 days with all foods provided
41119796|NCT06516861|DRUG|Magnesium Sulfate 20 MG/ML|Administered intravenously with a dose of 30 mg/kg
41119797|NCT06516861|DRUG|Lidocaine IV|Administered intravenously with a dose of 1.5mg/Kg
41119798|NCT06516861|DRUG|saline solution|Administered intravenously with 20 ml
41272052|NCT02296411|DRUG|CHF 5259 placebo|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
41272053|NCT04899479|DRUG|SGLT2 inhibitor|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
41272054|NCT04899479|OTHER|Control|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
41272055|NCT02505529|OTHER|Resistance Exercise Training|Behavioral interventions of resistance exercise
41272056|NCT02505529|OTHER|Mental Imagery|Behavioral intervention of mental imagery
41272057|NCT06247969|DEVICE|endotracheal tube|Endotracheal Tube (ETT) is a flexible plastic tube that is inserted through the mouth or nose into the trachea to establish an artificial airway.
41272058|NCT01276288|DRUG|BI 10773|multiple oral doses
41272059|NCT01276288|DRUG|hydrochlorothiazide|multiple oral doses
41272060|NCT01276288|DRUG|torasemide|multiple oral doses
41272061|NCT01276288|DRUG|BI 10773|multiple oral doses
41272062|NCT01276288|DRUG|torasemide|multiple oral doses
41272063|NCT01276288|DRUG|BI 10773|multiple oral doses
41272064|NCT01276288|DRUG|hydrochlorothiazide|multiple oral doses
41272065|NCT00001303|DRUG|Reference Endotoxin|
41272066|NCT00001303|DRUG|Inhaled Nitric Oxide|
41272067|NCT04974788|OTHER|Low Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
41272068|NCT04974788|OTHER|Medium Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
41272069|NCT04974788|OTHER|High Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
41272070|NCT00195650|BIOLOGICAL|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
41272071|NCT01480739|DRUG|100 mg (50 mg x 2) AZD5069|Twice daily for 7 days
40753226|NCT05151965|PROCEDURE|Bankart Repair and Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
41272072|NCT01480739|DRUG|100 mg Placebo|Twice daily for 7 days
41272073|NCT01649700|BIOLOGICAL|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10\^7 cells of autologous adipose-derived mesenchymal stem cells.
41272074|NCT03343821|OTHER|Balance and daily life questionnaire|Patients complete questionnaire
41272075|NCT01878630|DEVICE|Remote Patient Management|"Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:~* weighing scale (Seca 861 with bluetooth, seca gmbh \& co. kg.)~* blood pressure device (UA767PBT with bluetooth, A\&D Ltd.)~* ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)~* patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)~* help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)~at center site:~- electronic patient record (eHealth connect 2.0, T-Systems International)"
41272076|NCT01878630|OTHER|Usual Care|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
41272077|NCT02018692|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
41272078|NCT02018692|DIETARY_SUPPLEMENT|Placebo:Starch|Starch powder
41272079|NCT03044392|OTHER|Next Bolus Interval|Next Bolus Interval 15, 30, or 45 minutes
41272080|NCT02007551|BEHAVIORAL|Mealtime Intervention|The mealtime intervention constitutes once a week visits from a trained volunteer for 8 weeks, each visit lasting 90 minutes and comprising of preparing and sharing a meal together with the participant.
41272081|NCT01859403|GENETIC|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
41272082|NCT01859403|GENETIC|Usual Care|Patients receive the same dietary recommendation regardless of their genetic information
41272083|NCT02065089|OTHER|playing the ipad quiz game|Individualized education to the patient via the quiz game, with optional additional education provided by medical providers.
41272084|NCT03437421|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|"* Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~* Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~* Patients with : 25-OH-D3 \<10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™)."
41272085|NCT05411302|OTHER|Mental health supportive text messages|Text4Support program was developed based on knowledge from randomized controlled trials conducted in Ireland and Alberta and from evaluations of the Text4Mood program. The diagnostic-specific approach is based on an analysis of service data, which suggested that diagnostic clusters for individuals accessing mental health services into 6 categories: mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance use disorders, adjustment disorders and personality disorders. Thus, text message content will focus on 2 dimensions. General range includes messages of self-care, social support, hope, affirmation, and recovery. Specific content will focus on managing symptoms related to the conditions described above. As a component of scalability and inclusiveness, text message content can also be customized based on end-user characteristics. We will explore content that is sensitive to needs based on age group, cultural identity and gender identity.
41272086|NCT05896007|DRUG|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up
40753227|NCT05151965|PROCEDURE|Latarjet Coracoid Transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
40926378|NCT04184258|OTHER|Standard treatment according to the Clinical protocols|Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus
40926379|NCT04200040|BIOLOGICAL|OrienX010 injection|"OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd."
41119799|NCT04914442|DIAGNOSTIC_TEST|Microscopic examination|All the studies cases are microscopically examined using the ordinary stains (hematoxylin and eosin) then the eosinophilic infiltration are counted in 10 high power field manually
41453418|NCT02031250|DRUG|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
40753228|NCT03780322|DEVICE|Armeo Spring Pediatric|"Before intervention, the robotic device will be adjusted to the user's unique dimensions to avoid injury.~Each 45 minute session will include active upper extremity shoulder abduction, shoulder external rotation and/or elbow extension exercises, led by virtual reality game and supported by robotic arm. Sessions will take place 3 times a week for a total of 15 sessions."
40753229|NCT03780322|OTHER|Conventional physical and occupational therapy|"Conventional therapy will combine physical and occupational therapy, including the following activities:~1. Upper extremity weight bearing exercises.~2. Approximation techniques on wrist, elbow and shoulder.~3. Proprioceptive neuromuscular facilitation: shoulder flection, adduction and external rotation and shoulder flection, abduction and external rotation.~4. Scapulothoracic joint mobilization.~5. Stretching of shoulder abductors and external rotators.~6. Hand/wrist facilitation exercises (with ball). This will be carried out in 45 minute sessions, 3 times a week, for a total of 15 sessions."
40753230|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|2,5 mg twice daily (5 mg total daily dose)
40926380|NCT04200040|DRUG|Dacarbazine (DTIC)|Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
40926381|NCT04182464|OTHER|Sucralose|Food additive used to replace sugar providing a sweet taste without calories
40926382|NCT04182464|OTHER|Placebo|Cornstarch without significant physiological effects
40926383|NCT01227824|DRUG|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
40926384|NCT01227824|DRUG|raltegravir|raltegravir 400mg taken twice daily
40926385|NCT01227824|OTHER|GSK1349572 Placebo|GSK1349572 placebo taken once daily
40926386|NCT01227824|OTHER|ABC/3TC|Abacavir/Lamivudine background therapy once daily
40926387|NCT01227824|OTHER|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
40926388|NCT01227824|OTHER|raltegravir Placebo|raltegravir placebo taken twice daily
41119800|NCT04948801|DRUG|Epclusa (sofosbuvir and velpatasvir)|Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
40926389|NCT00045981|DRUG|ALT-711|
40926390|NCT04444830|DRUG|Sprix|Intranasal Ketorolac - used as directed for an appropriate, previously established indication
41119801|NCT03700294|DRUG|ADCT-601|Intravenous (IV)
41119802|NCT02652806|DRUG|FG-4592|
41119803|NCT02652806|DRUG|Epoetin Alfa|
41272087|NCT05896007|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
41272088|NCT05896007|DRUG|Methotrexate|3.5 g/m\^2 ivgtt, D1 of each 28-day cycle
41272089|NCT05896007|DRUG|Temozolomide|150 mg/m\^2 ivgtt, D1-D5 of each 28-day cycle
41272090|NCT02979756|PROCEDURE|Decentralized GDM screening and initial management|Screening for GDM and initialization of nutritional therapy at the first level of care
41272091|NCT04968444|OTHER|Physiotherapy|"Physiotherapy helps to restore movement and function when someone is affected by injury, illness or disability. It can also help to reduce your risk of injury or illness in the future.~This can take the form of~* advice and education~* manual therapy~* exercise prescription~* relaxation"
41272092|NCT04968444|OTHER|Back Pain Workshop|Back workshop is an intervention protocol consisting of an educational program and skills acquisition program, including physical exercises. The session is supervised by a specialist physiotherapist.
41272093|NCT02902094|DEVICE|Drug eluting balloons|
41272094|NCT02902094|DEVICE|Non drug eluting balloons|
41272095|NCT02747914|DEVICE|Transcranial magnetic stimulation|TMS 1Hz under the motor zone of cortex.
41272096|NCT02747914|OTHER|Conventional exercise|Exercise will be administrated in a conventional way.
41272097|NCT03793400|DRUG|Bevacizumab Injection|Anti-vascular endothelial growth factor (VEGF)
41272098|NCT01224548|OTHER|vegan instruction and food accessibility|weekly 1-hr instructions including vegan nutritional information and cooking instructions. vegan menu will be made available at the cafeteria
41272099|NCT01224548|OTHER|control|no intervention in until June 2011. The control group start vegan diet in July 2011.
41272100|NCT02437136|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDACs)
41272101|NCT02437136|DRUG|pembrolizumab|A selective humanized monoclonal antibody (mAb)
41272102|NCT01495494|DEVICE|Marketed Nasal Strip|Breathe Right Nasal Strips - Clear small/medium strip
41272103|NCT01495494|DEVICE|Prototype Nasal Dilator|Prototype Nasal Dilator AB2R11
41272104|NCT02836561|OTHER|Telephone message|A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
41272105|NCT03710421|PROCEDURE|CS1-CAR T Therapy|Undergo CS1-CAR T therapy
41272106|NCT03710421|DRUG|Cyclophosphamide|Given IV
41272107|NCT03710421|DRUG|Fludarabine|Given IV
40753231|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|5 mg twice daily (10 mg total daily dose)
41272108|NCT03710421|PROCEDURE|Leukapheresis|Undergo leukapheresis
40753232|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily (20 mg total daily dose)
40753233|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg twice daily (40 mg total daily dose)
40753234|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|30 mg twice daily (60 mg total daily dose)
40753235|NCT00398905|DRUG|Enoxaparin|40 mg once daily (40 mg total daily dose)
40753236|NCT03094273|PROCEDURE|Saucerization biopsy|2 mm saucerization biopsy of dysplastic nevi
40926391|NCT05336344|BEHAVIORAL|ENCODE|a cognitive behavioral intervention for family caregivers to improve pain management skills and overall coping
41272109|NCT00496366|DRUG|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
40753237|NCT06274476|OTHER|implant placement|ridge splitting piezo surgery and implant placement
40753238|NCT00977873|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
41272110|NCT00496366|DRUG|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
41272111|NCT03689218|DIETARY_SUPPLEMENT|Maamta (Nutritious Food Supplement)|Pregnant women will receive 30 sachets of Maamta during pregnancy and first six months of lactation.
41272112|NCT03689218|DIETARY_SUPPLEMENT|Wawamum (Lipid-Based Nutrient Supplement)|Children 6-24 months will receive 30 sachets of Wawamum every month during the study.
41272113|NCT02794337|RADIATION|SBRT|Intervention involves administering high precision radiation to the tumour in 6-8 fractions over 2-2.5 weeks
41272114|NCT02794337|PROCEDURE|TACE|Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done
41272115|NCT02794337|DRUG|Sorafenib|Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.
41272116|NCT01871883|PROCEDURE|Skin biopsy|Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.
41272117|NCT01871883|PROCEDURE|Oral mucosa specimen|The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
40753239|NCT00977873|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
41119804|NCT06051175|OTHER|Bitter taste perception|"Participants will perform a bitter taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
41119805|NCT06051175|OTHER|Salty taste perception|"Participants will perform a salty taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
41119806|NCT06051175|OTHER|Sweet taste perception|"Participants will perform a sweet taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
41119807|NCT06051175|OTHER|Acid taste perception|"Participants will perform a acid taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
41119808|NCT06051175|OTHER|Umami taste perception|"Participants will perform a umami taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
41119809|NCT04452539|PROCEDURE|Paediatric cardiac surgery|All patients undergoing paediatric cardiac surgery
41272118|NCT00864734|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
41272119|NCT00864734|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
41272120|NCT04846114|PROCEDURE|Dental implant surgery|
41272121|NCT01922921|BIOLOGICAL|HER-2/neu Intracellular Domain Protein|Given ID
41272122|NCT01922921|OTHER|Laboratory Biomarker Analysis|Correlative studies
41272123|NCT01922921|BIOLOGICAL|Pertuzumab|Given per standard of care
41272124|NCT01922921|OTHER|Placebo|Given PO
41272125|NCT01922921|BIOLOGICAL|Polysaccharide-K|Given PO
41272126|NCT01922921|BIOLOGICAL|Trastuzumab|Given per standard of care
41272127|NCT00468234|DRUG|nicotine polacrilex|
41272128|NCT00468234|DRUG|nicotine transdermal system|
40753240|NCT04548050|OTHER|Nurses training|"* Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~* Presentation to all staff of a service protocol for early colostrum donation."
41272129|NCT00468234|DRUG|nicotine inhaler|
41272130|NCT06172556|PROCEDURE|Endovascular coiling, Surgical clipping, Mix|Endovascular coiling, Surgical clipping, Mix
40753241|NCT05365464|DRUG|Progesterone Pill|Orally active progesterone
40753242|NCT05365464|DRUG|hCG|Given by subcutaneous injection
41272131|NCT02783560|BEHAVIORAL|The Sleep Train Program|This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
41272132|NCT02783560|BEHAVIORAL|The Family Mealtimes Program|This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
41272133|NCT00947648|OTHER|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
41453419|NCT02031250|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
41453420|NCT02031250|RADIATION|Boost Radiation to Hypoperfused Volumes|
41119810|NCT01902784|BEHAVIORAL|Storytelling Interview|
41119811|NCT04815616|RADIATION|Radiotherapy|Capecitabine with adjuvant radiotherapy in treatment of Early Stages Breast Cancer
41119812|NCT04085094|DIETARY_SUPPLEMENT|high-salt diet (V1) and low salt diet (V2)|Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
41119813|NCT04085094|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
41119814|NCT04085094|DIAGNOSTIC_TEST|functional MRI|Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
41119815|NCT04085094|OTHER|Pilocarpine test|Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
41119816|NCT04064866|DEVICE|High yield pure PRP|"The investigational product is hemocyte autograft derived from the subject's own blood. Subjects with a clinical diagnosis of discogenic pain had a discogram with ¼ cc to ½ cc of contrast injected by hand (leaving up to ½ cc contrast in the needle lumen and connecting tube); any concordant pain will be noted. Subjects received the injectant delineated by coordinator-provided randomization. Subjects were awake for the entirety of study treatment procedure.~All subjects had blood drawn (50 cc) from any access site and double-centrifuged using the EmCyte Hemocyte Autograft system; the first spin separated the buffy coat, the second spin and subsequent siphoning separated a purified platelet sample."
41272134|NCT00947648|OTHER|Cooked Foods|Diet containing only cooked foods.
41272135|NCT03636906|BIOLOGICAL|RSV (GSK3389245A) lower dose formulation vaccine|1 dose of RSV (GSK3389245A) lower dose formulation vaccine administered intramuscularly at Day 1.
41272136|NCT03636906|BIOLOGICAL|RSV (GSK3389245A) higher dose formulation vaccine|2 doses of RSV (GSK3389245A) higher dose formulation vaccine administered intramuscularly, at Day 1 and Day 31.
41272137|NCT03636906|BIOLOGICAL|GSK's multicomponent meningococcal B vaccine|3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
41272138|NCT03636906|BIOLOGICAL|Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine|3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
41272139|NCT03636906|BIOLOGICAL|GSK's pneumococcal polysaccharide conjugate vaccine|3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.
41272140|NCT03636906|BIOLOGICAL|GSK's meningococcal group A, C, W-135 and Y conjugate vaccine|2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.
41272141|NCT03636906|DRUG|Placebo|1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
41272142|NCT05104944|RADIATION|Serial MRIs|Serial use of MRI at 3, 6, 9 and 12 months to identify disease resolution and thus discontinuation of immobilisation plus standard care.
41272143|NCT01335971|DRUG|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
41272144|NCT01335971|DIETARY_SUPPLEMENT|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
41272145|NCT01335971|OTHER|Placebo|Microcrystalline cellulose once daily by mouth
41272146|NCT05294029|OTHER|standard of care for patients with neuromotor disability|clinical examination, radiological, biological and physiological examinations.
41272147|NCT01676831|DRUG|Topical resiquimod 0.06%|topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
41272148|NCT01676831|DRUG|topical resiquimod 0.03%|topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
41453421|NCT03218150|PROCEDURE|cranioplasty|". The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws."
41272149|NCT02476487|PROCEDURE|FDG PET CT|"FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.~2. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal."
41272150|NCT04271267|OTHER|No Intervention|
41272151|NCT06330909|RADIATION|Radiotherapy (RT) Arm A - IMRT/IGRT/SBRT|"technique: IMRT/IGRT/SBRT~The HypoFocal-SBRT study combines ultra-hypofractionated RT / stereotactic body RT (reduction of treatment time) with a focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts."
41272152|NCT06330909|RADIATION|Radiotherapy (RT) Arm B - IMRT/IGRT|"technique: IMRT/IGRT~Moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide."
41272153|NCT04568837|DRUG|Prednisone 20 Mg|20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group
41272154|NCT05558644|OTHER|single arm for all patients|"* tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~* blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery."
41272155|NCT03648164|OTHER|CHAT-CS Survey|Students will complete a computer-based survey
41272156|NCT02337387|BIOLOGICAL|Blosozumab|Administered SC
41272157|NCT02337387|OTHER|Placebo|Administered SC
41272158|NCT01305512|DRUG|SPARC1028|SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
41272159|NCT01133964|DIETARY_SUPPLEMENT|dairy proteins|Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
41272160|NCT05499520|OTHER|Culturally Tailored Anti-Smoking Messages|Anti-smoking messages will be administered online via a Qualtrics survey.
41272161|NCT00167674|DRUG|Combined short-course zidovudine/nevirapine|300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight \> 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.
41272162|NCT00167674|DRUG|HAART|300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
40926392|NCT06420258|PROCEDURE|Deeper endotracheal intubation|After general anesthesia, endotracheal intubation was conducted using an ultrafine endoscope (GIF-XP260NS, Olympus Corp., Japan), which allows observation of the exact position and avoids blindness caused by laryngoscopy. To prevent balloon compression of the CE after inflating, the endotracheal intubation tube was inserted above the tracheal carina, roughly the upper thoracic esophagus.
41272163|NCT03981601|DRUG|Lovastatin 40 MG|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
41272164|NCT03981601|PROCEDURE|without drug with Bone graft|after tooth extraction, put teh bone graft wifin tooth socket
41272165|NCT06331091|OTHER|Home exercise|Home exercise are done at home without the supervision of a specialist.
41272166|NCT06331091|OTHER|Manual therapy|Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.
41272167|NCT06331091|DEVICE|Neuromuscular electrical stimulation|"Home exercise are done at home without the supervision of a specialist. Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.~Neuromuscular electrical stimulation is the application of electrical current to the muscle through special electrodes in order to increase muscle strength.~Supervised exercise is done under the supervision of a physiotherapist."
41272168|NCT06331091|OTHER|Supervised exercise|Supervised exercise is done under the supervision of a physiotherapist.
41272169|NCT01305499|DRUG|Entinostat days 3, 10|Given orally on days 3, 10
41272170|NCT01305499|DRUG|5AC|
41272171|NCT01305499|DRUG|Entinostat days 10,17|Given orally on days 10, 17
41272172|NCT00825370|DRUG|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
41272173|NCT00825370|DRUG|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
41272174|NCT05853471|DRUG|[18F]MC225|All participants will undergo a PET scan with \[18F\]MC225. No pharmaceutical effects are expected and the study will exclusively have a diagnostic purpose. However, since \[18F\]MC225 is a new PET tracer, it is included in pharmaceutical studies and any study performed with \[18F\]MC225 will be automatically be registered as intervention study.
41272175|NCT03403192|DEVICE|EZ-Blocker|"The EZ-Blocker essentially functions as a bronchial blocker with a 7-Fr shaft with two separate occlusive balloons coming off this shaft in a Y configuration designed to rest on the carina. Once anchored in place the operator can choose to inflate one of the two occlusive balloons to isolate one main stem bronchus or the other. According to the manufactures recommendations the EZ-blocker is placed through a Y-piece adaptor included with the blocker kit. A flexible fiberoptic bronchoscope (FFB) is placed in a separate limb of this Y-piece and this fed through along side the EZ-blocker to visualize and confirm placement of the of the BB. The balloon is then inflated typically under direct vision to occlude that bronchus thus isolating that lung hopefully achieving full lung isolation."
41272176|NCT03403192|DEVICE|DLT|A Double Lumen Tube (DLT) is made of two small-lumen endotracheal tubes of unequal length fixed side by side. The shorter tube ends in the trachea while the longer tube is placed in either the right or left bronchus to ventilate the right or left lung.
41272177|NCT02344576|BEHAVIORAL|DT LVAD Decision Support Intervention|Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
40753243|NCT03379493|BIOLOGICAL|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion
40753244|NCT05380570|RADIATION|Occupational radiation exposure|Ionizing radiation in workplaces
40753245|NCT00756314|BEHAVIORAL|Personalized contraceptive counseling|The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
40926393|NCT02480140|OTHER|Self-regulated constraint-induced movement therapy|There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
40926394|NCT02480140|OTHER|Constraint-induced movement therapy|They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
40926395|NCT02480140|OTHER|Conventional occupational therapy|They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
40926396|NCT02846220|BEHAVIORAL|Overcoming Immunity to Change health coaching|
40926397|NCT05785910|DIAGNOSTIC_TEST|IUDS|a battery of neuropsychological test
40753246|NCT02539394|DRUG|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
40753247|NCT02539394|OTHER|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
40753248|NCT05280158|DRUG|mRNA-1273 (Moderna COVID-19 vaccine)|Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
41119817|NCT04064866|OTHER|Placebo|Placebo injections will have saline placed in centrifuges and run for the duration required for PRP preparation. 3cc of saline will be placed in 3 cc syringes with opaque tape around the barrel to cover the fluid chamber. 1-2 cc of saline will be injected into the nucleus pulposus of each treatment level disc under fluoroscopy for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
41119818|NCT04064866|DEVICE|ProPlaz PPC|Trademarked name of an FDA-cleared product
41119819|NCT01694446|OTHER|Intraduodenal glucose or fructose|
41119820|NCT00731497|DEVICE|Solar Water Disinfection (SODIS)|Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
41119821|NCT05727241|DIAGNOSTIC_TEST|Ultrasound|The intervention is ultrasound examination with three dimensional umbilical cord index, two-dimensional umbilical cord index, and doppler examination of the umbilical cord artery.
41119822|NCT03379051|DRUG|Venetoclax|BCL-2 Inhibitor
41119823|NCT03379051|DRUG|Umbralisib|PI3K-Delta Inhibitor
41119824|NCT03379051|BIOLOGICAL|Ublituximab|Glycoengineered Anti-CD20 mAb
41119825|NCT03379051|DRUG|Lenalidomide|Thalidomide Analog, immunomodulatory agent with antiangiogenic and antineoplastic properties
41119826|NCT01157663|OTHER|Adapted balance training|during 8 weeks
41453422|NCT04627844|DIETARY_SUPPLEMENT|Immediate Feeding|Standard tube feeds begun at an earlier time point
40753249|NCT02144818|DRUG|Ovitrel|Triggering of ovulation with Ovitrel
40753250|NCT02144818|DRUG|Decapeptyl|Triggering with GnRH agonist
40753251|NCT01008527|DRUG|CP 870,893|Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
40926398|NCT02275884|DIETARY_SUPPLEMENT|Dark chocolate (85% cocoa)|
41119827|NCT01157663|OTHER|Balance Training|Balance training with unipedal standing during 8 weeks
41119828|NCT01263002|DRUG|clevudine, Adefovir|"Nucleoside-analogue naive patient : Clevudine 30mg qd~1. Assess the complete virological response(HBV DNA \< 60 IU/ml) at 24 weeks: Only Clevudine 30mg qd~2. Assess not the complete virological response at 24 weeks : Add Adefovir 10mg qd~3. During medication of Clevudine, virological breakthrough : add adefovir 10mg qd~4. During treatment period, composite virological response : stop the medication and F/U for 2 years~5. Recurrence after stopping treatment(HBV DNA \> 2,000IU/ml) retreat medication at composite virological response.~   * complete virological response: HBV DNA \< 60 IU/ml~  * virological breakthrough : During antiviral treatment, HBV DNA increased from nadir to 1 log10IU/ml continuously."
41119829|NCT03923101|DIAGNOSTIC_TEST|Topographic, tomographic and biomechanical analysis.|"The study is based upon data obtained during routine medical follow-ups using~1. the Pentacam high resolution (Oculus, Wetzlar, Germany)~2. the Corvis ST (Oculus, Wetzlar, Germany)~3. the Anterior-Segment Optical Coherence Tomograph (AS-OCT) Casia 2 (Tomey, Nagoya, Japan)~4. the Ocular Response Analyzer (Reichert Technologies, New York, USA)."
40753252|NCT01008527|BIOLOGICAL|Peptides|NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
40753253|NCT01008527|BIOLOGICAL|Oncovir poly IC:LC|The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
41272178|NCT04171609|BEHAVIORAL|Expressive writing|During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
41272179|NCT03371355|DRUG|Placebo|Placebo (Matched with ISIS 703802)
41272180|NCT03371355|DRUG|ISIS 703802 40 mg|ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.
41272181|NCT03371355|DRUG|ISIS 703802 80 mg|ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.
40753254|NCT00754039|DRUG|colesevelam HCl tablets and fenofibrate tablets|Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day
40753255|NCT00754039|DRUG|fenofibrate tablets and Welchol placebo tablets|fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day
40753256|NCT00754039|DRUG|fenofibrate tablets and Welchol placebo tablets|fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
40753257|NCT00920270|DRUG|nebulized colistin|nebulized colistin 75 mg every 12 hours
40753258|NCT00920270|DRUG|antibiotics|conventional parenteral antibiotics
40753259|NCT00158431|PROCEDURE|Arthroscopy plus Medical Management|Arthroscopic Surgery
40753260|NCT00158431|OTHER|Medical Management|education, optimized medication, weight loss where needed, HA or cortisone injections if needed, physiotherapy
41119830|NCT01318382|DEVICE|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
41119831|NCT02459782|PROCEDURE|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia|Landmark Guided single injection vs Ultrasound guided dual quadrant injection
41119832|NCT00521755|DEVICE|Seraffix LTB|laser soldering for soft tissue wounds
41119833|NCT00010738|PROCEDURE|Meditation|
41272182|NCT03371355|DRUG|ISIS 703802 20 mg|ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.
41272183|NCT04919915|DEVICE|HEPA air cleaner|Participants in the intervention group received two HEPA air cleaners per household. They were informed to place the HEPA air cleaners in the child's bedroom and the living room. Field staff provided and discuss how to use the air cleaner which promoted continuous operation of both air cleaners, keeping the child's bedroom door closed, and selected the highest fan speed. Typical use of the HEPA cleaners were questioned during the mid-study and final visits.
41272184|NCT05243888|DIAGNOSTIC_TEST|self-sampling|eligible women receive at their home address a self-sampling kit in addition to the conventional invitation letter
41272185|NCT04928014|OTHER|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
41272186|NCT01700829|DRUG|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
40926399|NCT02275884|DIETARY_SUPPLEMENT|White chocolate (0% cocoa)|
41453423|NCT04627844|DIETARY_SUPPLEMENT|Delayed Feeding|Standard tube feeds begun at delayed time point
41453424|NCT04345133|DEVICE|Dental Implants Insertion Drilling Sequence|Drilling sequence protocol to insert immediate Dental Implants at the Maxilla.
40753261|NCT04635982|OTHER|Kinesiotape of the physical performance|It has done a countermovement vertical jump, a twenty meter sprint and a kinesio tape application technique
40926400|NCT04233918|DRUG|Evinacumab|Part A: Single IV dose Part B \& C: IV dose Q4W
40926401|NCT00797966|DRUG|OPC-34712|Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
40926402|NCT00797966|DRUG|Placebo|Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
40926403|NCT00797966|DRUG|ADT|Tablets, 10 - 225 mgs, dose once daily, 14 weeks
40926404|NCT03357939|DRUG|HLX03|A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
40926405|NCT03357939|DRUG|adalimumab|A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
40926406|NCT04372056|BEHAVIORAL|Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic|Health care professionals
40926407|NCT00465309|PROCEDURE|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat \< 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH \> 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
41119834|NCT06451913|DRUG|Amoxicillin + Saccharomyces boulardii CNCM I-745|At inclusion visit (V1), the Investigator will dispense and ask the subject to take Amoxicillin 1000 mg bid for 14 days + Saccharomyces boulardii 250 mg x 2 twice a day for 21 days
41119835|NCT06451913|DRUG|Amoxicillin + Placebo|At inclusion visit (V1),the Investigator will dispense and ask the subject to take Amoxicillin 1000 mg bid for 14 days + a matching placebo bid for 21 days
41119836|NCT06451913|OTHER|Stool samples|"The subject will be asked to collect thanks to four OMNIgene® •GUT OMR-200 kits :~* an initial stool collection when returning home at D1 (in any case before any intake of amoxicillin and of the investigational medication and up to 1 day after D1).~* a stool collection at home after the phone call 1, Day 7 (stool collection up to Day 7 + 1 day)~* a stool collection at home after the phone call 2, Day 14 (stool collection up to Day 14 + 1 day)~* at home the day of the Visit 2, Day 21 (stool collection up to Day 21 + 1 day)"
41272187|NCT01700829|DRUG|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
40753262|NCT03748563|DIAGNOSTIC_TEST|ds-MCE and EGD|"Procedure of ds-MCE:~The ds-MCE system mainly consists of two parts: the NaviCam magnetically maneuvered capsule endoscopy system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. After completing the esophageal examination, the capsule could be detached from the string through injecting air into the hollow string with the syringe. Then, the examination of stomach under magnetic control and small bowel under the natural action of gastrointestinal peristalsis follows.~Procedure of EGD:~The esophagogastroduodenoscopy (EGD) will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
40753263|NCT02985775|BIOLOGICAL|Donor-derived CMVpp65-specific T cells|About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.
40753264|NCT04266314|DEVICE|Maternal-fetal monitoring|Maternal-fetal monitoring evaluates fetal and maternal heart rate, maternal respirations, fetal movement, and maternal skin conductance (a way to monitor emotional response)
40753265|NCT04266314|OTHER|NICU Network Neurobehavioral Scale|Evaluates neurobehavioral organization, neurological reflexes, motor development, and signs of stress and withdrawal of substance-exposed infants.
40753266|NCT02405065|DRUG|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
40753267|NCT04367454|OTHER|Use of Personal Protective Equipment|As described in the arm descriptions
40753268|NCT06069271|OTHER|Kettlebell swing|The intervention group completed two-handed Russian KBSs using an interval training protocol outlined by Jay et al.10 involving 30 seconds of work followed by 30 seconds of rest for 10 total intervals. Prior to completing the intervention, participants completed a general warmup consisting of 10 non-weighted squats, 10 non-weighted dead-lifts, and 10 dowel rod shoulder flexion repetitions. Participants were instructed to perform all warm-up activities at an intensity of 70% of maximal effort using a Rate of Perceived Exertion scale(RPE).
40753269|NCT02307435|BIOLOGICAL|MSC|subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
40753270|NCT04289272|BEHAVIORAL|Dove Confident Me|Dove Confident Me is a school-based intervention co-created by researchers at La Trobe University (Australia), the Centre for Appearance Research UWE, teachers, students, and education experts, and the Dove Self-Esteem Project (the social mission for personal care brand Dove). The five-session intervention is aimed at adolescents aged between 11-13 years, and targets recognised risk factors for body dissatisfaction, by addressing societal appearance ideals (Session 1), media literacy (Session 2), appearance comparisons (Session 3), appearance-related conversations and teasing (Session 4), and promoting 'body activism' (Session 5). The intervention consists of classroom-based discussion and small group activities, and uses audio-visual materials and worksheets to facilitate learning.
40753271|NCT06092580|BIOLOGICAL|AWT020|Participants receiving AWT020 once every two weeks at designated dose levels
40753272|NCT03094377|OTHER|Multisensory therapy|Sensory stimulation, motor training and ADL training
40753273|NCT03094377|OTHER|Conventional training|Motor training and ADL training
40753274|NCT05688709|BEHAVIORAL|WhatsApp peer support group|YLHIVA assigned to the WhatsApp group will interact with each other and their peer counsellors through one-on-one private communications and on the group chat. The group chat will allow YLHIVA to ask questions, post comments, and reply to one another at any time. We shall share education videos once a week at a time agreed upon with study participants to optimize assimilation of information. In addition, peer counsellor will engage in private WhatsApp calls with youth once a week, to monitor psychosocial state, medication adherence, identify barriers to adherence and counsel YLHIVA. However, youth may initiate in more private communications' when need arises. The peer counsellor will also engage with YLHIVA daily through WhatsApp messages. We will tailor the messages to young people's treatment schedules, clinic appointments, and psychosocial state. Again, youth may text a peer counsellor whenever they wish to do so.
40753275|NCT03281538|DRUG|CR845|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
40753276|NCT04778709|DEVICE|Puros allograft|"Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone."
40753277|NCT00580294|DRUG|Oxymorphone|IV PO
40753278|NCT01941628|DRUG|Rocuronium|Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
41446376|NCT03586622|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® is a dietary supplement that helps maintain the balance of the intestinal flora. VSL#3® has been recognized and classified as GRAS (Generally Regarded as Safe) by a panel of experts in the USA for both adult and pediatric IBD and IBS patients. VSL#3® is a probiotic food containing 450 billion freeze-dried live lactic acid bacteria and bifidobacteria from 8 different strains per bag/sachet: Streptococcus thermophilus BT01, Bifidobacteria (B. breve BB02, B. longum\* BL03, B. infantis\* BI04), Lactobacillus acidophilus BA05, Lactobacillus plantarum BP06, Lactobacillus paracasei BP07, Lactobacillus delbrueckii subsp. bulgaricus\*\* BD08; \*Recently reclassified as B. animalis subsp. lactis \*\* Recently reclassified as L. helveticus. The recommended daily dose is 1-2 bags.
41119837|NCT06451913|OTHER|BSFS : Bristol Stool Form Scale|All included subjects will have to complete a stool diary BSFS (Bristol Stool Form Scale) daily and at each bowel movement, from Day 1 until the end of study treatment (Day 21). The patient will fill the form with the date, the time, and the stool texture.
41119838|NCT06451913|OTHER|GSRS : Gastrointestinal Symptom Rating Scale|All included subjects will have to complete a GSRS (Gastrointestinal Symptom Response Score) questionnaire weekly from Day 1 until the end of the study treatment (Day 21).
41119839|NCT00407082|DRUG|fluocinolone acetonide intravitreal implant|Fluocinolone acetonide ocular implant 0.59mg
41119840|NCT00407082|DRUG|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
41272188|NCT00221364|DRUG|Mass treatment with oral azithromycin to an entire village|
41272189|NCT04514614|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of arthritis by PET/CT.
41272190|NCT04621903|OTHER|Shanshamani Vati Plus|Shanshamani Vati Plus was given as combination of Guduchi (Tinospora Cordifolia; 300 mg) and Pipli (Piper Longum 75 mg) twice daily.
41119841|NCT00002049|DRUG|Thymopentin|
41119842|NCT01837966|OTHER|Lavender oil|2 drops for aromatherapy
41272191|NCT03471325|PROCEDURE|Plaque disclosed with air flow|air polishing with prior plaque disclosing
41272192|NCT03471325|PROCEDURE|Plaque disclosed with rubber cup|rubber cup polishing with prior plaque disclosing
41272193|NCT03471325|PROCEDURE|Non plaque disclosed air flow|air polishing with no prior plaque disclosing
41272194|NCT03471325|PROCEDURE|Non plaque disclosed rubber cup|rubber cup polishing with no prior plaque disclosing
41119843|NCT01837966|OTHER|Placebo|2 drops unscented mineral oil for aromatherapy
41272195|NCT05995535|DRUG|LFX/PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg"
41272196|NCT05995535|DRUG|LFX/PLA-PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg"
41272197|NCT01396369|DRUG|Birth control|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
41272198|NCT01396369|DRUG|Birth control plus Brevail|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
41272199|NCT00183846|DRUG|irinotecan|
41272200|NCT00183846|PROCEDURE|radiation therapy|
41272201|NCT04176861|DEVICE|home-based Brainwave Entrainment Technology|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights
41272202|NCT02138734|BIOLOGICAL|BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). )|"BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, 18, 24,30 and 36 months.~An additional 6 week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included."
41272203|NCT02138734|BIOLOGICAL|BCG( 50mg/Instillation)|"BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, 18, 24, 30 and 36 months.~An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included."
41272204|NCT00018902|DRUG|Fluoxetine|Standard anti-depressant treatment with the SSRI fluoxetine
41272205|NCT00018902|DRUG|Venlafaxine|Standard antidepressant treatment with the non-SSRI medication venlafaxine
41272206|NCT00018902|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT addresses maladaptive beliefs in order to encourage behavioral change
41272207|NCT00018902|DRUG|Citalopram|Standard anti-depressant treatment with the SSRI fluoxetine
41272208|NCT05796479|DRUG|Amlitelimab DP1|"Injection solution 1~Subcutaneous"
41272209|NCT05796479|DRUG|Amlitelimab DP2|"Injection solution 2~Subcutaneous"
41272210|NCT05337618|DIAGNOSTIC_TEST|Full-band Electrocorticography|Diagnosis of spreading depolarizations in continuous electrocorticography
41272211|NCT05337618|COMBINATION_PRODUCT|Treatment Algorithm|Protocol for escalation and de-escalation of physiologic-targeted and pharmacologic therapies to treat and prevent spreading depolarizations
41272212|NCT06064760|BEHAVIORAL|Psychoeducational Workshop on Personal Strengths and Emotional Competences to Improve the Psychological Wellbeing and Quality of Life of Grandparents Caring for Their Grandchildren|"The intervention is a psychoeducational group workshop (6-8 participants). It includes 5 sessions of, approximately, 90 minutes. In addition, 3 months after the end of the workshop, a follow-up call will be organized with the participants. Due to the Covid-19 pandemic, the workshop will be held online.~The sessions are:~* Session 1: Defining my role as grandparent.~* Session 2: Deepening my relationships.~* Session 3: Growing as grandparent.~* Session 4: Discovering my emotional world.~* Session 5: Caring for others and caring for myself."
41272213|NCT02511977|OTHER|peri-implant examination|The prostheses were removed and all implants were evaluated: probing depth, plaque index and bleeding index.
41119844|NCT03320746|DEVICE|Polar Loop 2 activity tracker|"The participants were instructed to aim to reach the daily activity goal, initially set at stage 1 as per the goals set by the trackers' manufacturer. The daily activity goal was based on user's typical daily activities, gender and age. The stage 1 daily activity goal corresponded to \~1h/day of jogging or \~2h/day of walking or \~7h/day household activities or a combination of these activities. The tracker gave an inactivity alert as a vibration and text it's time to move on the screen of the tracker if the user has been still for 55 minutes."
41119845|NCT02272816|DRUG|Carboplatin AUC-10|Carboplatin AUC-10 according to the Calvert formula \[10 x (glomerular filtration rate (ml/min) + 25)\]mg given in 5% glucose over 1 hour every 21 days for 3 or 4 cycles.
41119846|NCT06175000|PROCEDURE|Cognitive Assessment|Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.
41119847|NCT06175000|BIOLOGICAL|Obinutuzumab|Given IV
41119848|NCT06175000|OTHER|Quality of Life Assessment|Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.
41272214|NCT04080206|DRUG|188-0551 Spray|Applied topically twice daily for two weeks
40753279|NCT01941628|DRUG|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
40753280|NCT01081574|DRUG|Bilastine|10 mg/qd/ 7 days.Oral dispersible tablets
40753281|NCT01141543|DRUG|Plerixafor (mozobil)|"Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN"
40753282|NCT04102111|DRUG|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily.
40753283|NCT04102111|DRUG|Placebo|Participants will receive oral tablets of matching placebo twice daily.
40753284|NCT01512537|RADIATION|Narrowband UVB|UVB 3 times a week
40753285|NCT01512537|DIETARY_SUPPLEMENT|Vitamin D and calcium|1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
40753286|NCT04147741|DIETARY_SUPPLEMENT|Pre-Workout Supplement|"One week familiarisation, one-week training, two weeks washout period and one-week training.~15 Minutes before every training, the Pre-Workout Arm (PRE-W) will take a Supplement shake, consisting of some ingredients (Multi-Ingredient, explained before) and the Placebo Comparator Arm (CHO) will drink a Placebo shake, consisting of Maltodextrin."
40753287|NCT04147741|OTHER|Resistance Training|-Resistance Training days (Monday-Wednesday-Friday): Before training starts, Tensiomyography and Energy Feeling will be assessed (Energy Level, Fatigue Level, Feeling of Alertness, and Feeling of Focus on the task). Immediately after finishing, Tensiomyography and Performance (Vertical Jump, Overhead Medicine Ball Throw, and Maximal Mid-Tigh Pull Isometric Strength) will be assessed. Training Protocol: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Parallel Squat; Bench Press; Alternate Box Set-Ups; Shoulder Press; Alternate Lunges; Up-right Row; Hip-Thrust; Squat on Isoinertial Fly-Wheel or Drop Jump). The participants will have to perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2,5 to 5 kg will be added for the next set. Also, whole-body Perceptual Response will be assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
40753288|NCT04147741|OTHER|Endurance Training|- Endurance Training days (Tuesday-Thursday): Energy Feeling Questionnaire will be implemented before training. The training will consist of 30 minutes cycling at their Fatmax Intensity (\~60% Vo2max) on a Cycloergometer (estimated during familiarisation week). Also, the Heart Rate will be recorded during the whole training. Besides, Perception of Effort will be assessed using the 6-20 version of the Borg Scale every 5 minutes during training and 15 minutes after it has been completed.
40753289|NCT04189588|DRUG|Cetirizine HCl 10 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
40753290|NCT04189588|DRUG|Diphenhydramine 50 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
40753291|NCT04189588|DRUG|anti-CD20 such as Rituximab or Paclitaxel|Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
40753292|NCT01576393|BEHAVIORAL|Home-based Family Therapy|12 home-based family therapy sessions
41272215|NCT04080206|DRUG|RLD|Applied topically twice daily for two weeks
40753293|NCT01576393|BEHAVIORAL|office-based family therapy|12 office-based family therapy sessions
40753294|NCT01576393|BEHAVIORAL|WHE|12 Women's Health Education Sessions
40753295|NCT03081078|BEHAVIORAL|Volunteer support|Each participant will be matched with a pair of trained volunteers (under pre-determined safety measures), who will initiate caring contact via telephone or text messages at least twice a month for two months. Participants will be free to respond or not.
40753296|NCT03081078|OTHER|Mobile app|Participants will receive programmed care messages and reminders of community resources and healthcare contacts on a regular basis. The app will also provide simple self-help mood checking and relaxation exercises.
40926408|NCT06294743|PROCEDURE|Posterior tibial nerve neuroprolotherapy|Real-time ultrasound guided needle injecting 10ml of 5% dextrose solution around the posterior tibial nerve to elicit a neurostimulatory response.
40926409|NCT06294743|DRUG|Acetaminophen 500Mg Tab|Oral acetaminophen 500mg tab stat, followed by Q6h if needed.
40926410|NCT01975324|DRUG|dalfampridine|dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
40926411|NCT01975324|DRUG|Placebo|placebo (sugar pill) twice a day for two weeks
40926412|NCT05814354|DRUG|SHR-A1811|SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.
41272216|NCT03052647|DEVICE|Dermaclip|Dermaclip is an adhesive latch device used for skin closure
41272217|NCT03052647|DEVICE|Subcuticular suture|subcuticular suture will be used as the device to close the skin in this arm
40753297|NCT05719597|OTHER|PEP (Positive Expiratory Pressure)|Group A containing 12 participants, will perform Positive expiratory pressure (PEP) technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
40753298|NCT05719597|OTHER|IS (Incentive spirometry)|Group B containing 12 participants, will perform Incentive spirometry technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
41119849|NCT01116635|DRUG|doxorubicin, superabsorbent polymer microspheres, embolotherapy|varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
41119850|NCT00493649|DRUG|Taxotere|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
40753299|NCT03002909|DEVICE|epidural catheter|
40753300|NCT03002909|DEVICE|preperitoneal catheter|
41119851|NCT00493649|DRUG|Cytoxan|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
41119852|NCT00493649|DRUG|Herceptin|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
41119853|NCT04672018|OTHER|Houtou Jianweiling tablet|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
41119854|NCT04672018|DRUG|Omeprazole Tablet|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
41119855|NCT03356223|DRUG|Abemaciclib|"400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
41119856|NCT00223587|OTHER|1 week of treatment discontinuation|1 week of treatment discontinuation during allergic rhinitis season
40753301|NCT05409612|BIOLOGICAL|Supemtek®|"Quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0."
40753302|NCT05409612|BIOLOGICAL|Vaxigriptetra®|Quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
40753303|NCT05086172|BEHAVIORAL|Ultrabrief Behavioral Activation|The ultrabrief behavior activation (UBA) intervention is a condensed version of the LETS ACT intervention. The main treatment elements include: (1) explanation of treatment rationale to facilitate behavior change via increased engagement in values-related activities, (2) identification of participant-specific values via detailed assessment of life areas, values and activities, (3) values-based activity planning and scheduling, and (4) post-treatment planning. The overall goal of behavioral activation (BA) is to shift from values-incongruent behavior (including alcohol use) to behaviors that provide positive reinforcement and environmental reward with the overall goal of increasing the number of engaged-in, value-based activities. This intervention will take 90 minutes.
40926413|NCT05814354|DRUG|Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization).
40926414|NCT03470532|DRUG|buccal infiltration of 4% Articaine with Epinephrine|Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge
40926415|NCT03470532|DRUG|buccal infiltration of 2% Mepivacaine with Epinephrine|Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
41119857|NCT04772300|COMBINATION_PRODUCT|Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter|PTA with an sirolimus drug-coated balloon catheter (SRL-DCB) in the infrapopliteal artery
41119858|NCT04772300|DEVICE|Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA)|PTA with an non-coated balloon catheter (POBA) in the infrapopliteal artery
41272218|NCT00240435|DEVICE|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
41272219|NCT00240435|DEVICE|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
41272220|NCT01948492|DIETARY_SUPPLEMENT|Protein intake|On the study day, the diet will be provided as free amino acids, with calories made up by a liquid diet and protein free cookies. Protein intakes will be varied as 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, 2.0 g/kg/day.
40753304|NCT05014542|PROCEDURE|Acupuncture|Acupuncture treatment includes pricking the skin with acupuncture needles 0.3 x 40 millimetres in size, in the places of prescribed acupuncture points. Placed needles should be manipulated three times, every ten minutes, three times in total. The complete time of treatment is 30 minutes. All treatments will be equal.
40753305|NCT05014542|DRUG|Conventional Medical Treatment|Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
41119859|NCT02586597|DEVICE|Transcranial magnetic stimulation & median nerve stimulation|"Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min."
41119860|NCT01305252|DRUG|treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
41119861|NCT01305252|DRUG|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
41272221|NCT04295590|BEHAVIORAL|Frequency comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).
41272222|NCT04295590|BEHAVIORAL|Intensity comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).
41272223|NCT05646810|DIAGNOSTIC_TEST|Lidocaine (10 mg/ml)|Lidocaine (10 mg/ml) will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
41272224|NCT05646810|DIAGNOSTIC_TEST|Isotonic saline|Isotonic saline will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
41272225|NCT02610309|BEHAVIORAL|Family-Based Crisis Intervention|This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
41272226|NCT06322082|DEVICE|The DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL AG)|"The LiESWT was applied to Pilates and Shock Wave group and Shock Wave group with 0.25 mJ/mm2 of intensity, 3000 pulses of shock, and 3 pulses/s of frequency, applicator was placed on the suprapubic skin area one session in the week for twelve weeks, totaling 12 sessions.~Pilates exercises were performed to Pilates and Shock Wave group and Pilates group. The sessions of Pilates were applied twice a week for twelve weeks, totaling 24 sessions. The 50 min Pilates sessions were divided into three phases: warm-up, strengthening, and stretching. They also received written orientations to perform three exercises and two of the Pilates session at home every day - Conventional pelvic floor exercises performed for all groups include Kegel exercise, squats, bridging, and squeeze and release exercises. These exercises were performed 3 times per day, lasting for 12 consecutive weeks"
41119862|NCT06222983|PROCEDURE|CEA or CAS|After the patient is admitted to the hospital, the supervising doctor comprehensively evaluates the patient's general condition and adopts CEA or CAS treatment. The researcher does not provide advice to the supervising doctor and only observes safety and effectiveness
41119863|NCT02628678|DIETARY_SUPPLEMENT|FOS|
41119864|NCT02285413|BIOLOGICAL|DC vaccination|DC vaccination without cisplatinum
41119865|NCT02285413|BIOLOGICAL|DC vaccination with cisplatinum|DC vaccination with cisplatinum
41272227|NCT02658461|DRUG|Trastuzumab|Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed \>1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
41272228|NCT00316264|BIOLOGICAL|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
40753306|NCT01029964|BEHAVIORAL|Individually and in groups|During three year in a clinical setting.
40753307|NCT01545466|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
40753308|NCT00148538|BEHAVIORAL|Resistance and/or Aerobic Exercise|Resistance and/or Aerobic Exercise
40753309|NCT04167436|OTHER|Prehabilitation|A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
41119866|NCT03920592|BEHAVIORAL|Virtual Reality of Bullying|"Immersive videos (360º) filmed by 12-14 year old pupils who, guided by professional actors, represented the subjective experience of bullying.~Eight different potential situations designed depending on the sex of the pupil were filmed:~Girls:~1. Classmates steal her personal diary~2. Classmates tear her clothing~3. Classmates insult her and steal her belongings~4. Classmates deliberately exclude her in class~Boys:~1. Classmates exclude him while playing with a ball~2. Classmates bother him in the dining room~3. Classmates insult and steal him in class~4. Classmates insult him and steal his belongings"
41119867|NCT02601170|BIOLOGICAL|Platelet-Rich Plasma Intra-Articular Injection|
41119868|NCT02601170|DRUG|Hyaluronic Acid Viscosupplementation|
41119869|NCT01973816|DRUG|Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;|Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
41119870|NCT01973816|PROCEDURE|rectal shaving; rectal disc excision; colorectal resection|
40753310|NCT04476485|OTHER|endocrine therapy|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy. 1. For postmenopausal patients: Extend treatment with aromatase inhibitors 10 years: letrozole or anastrozole or exemestane. 2. For premenopausal patients: An initial 5 years tamoxifen treatment followed by additional 5 years extended tamoxifen treatment. Postmenopausals are treated with aromatase inhibitors 5 years. 3. For patients have completed ovarian function suppression plus initial 5-year aromatase inhibitor treatment: Menopausals: Aromatase inhibitors; Non-menopausals: 5 years of tamoxifen treatment or ovarian function suppression plus 5 years of aromatase inhibitor treatment. 4. For patients have completed ovarian function suppression plus initial 5-year tamoxifen treatment: Menopausals: Aromatase inhibitors for additional 5 years; Non-menopausals: Tamoxifen for additional 5 years.
40753311|NCT05919212|DIAGNOSTIC_TEST|HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment|We study the circulating changes associated with resistance to T-DXd, including changes in HER2 status,studied through a new approach called HER2-2D that simultaneously assesses HER2 amplification and overexpression in blood
40753312|NCT04168411|PROCEDURE|Symptomatic Treatment|Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
40753313|NCT00383851|DRUG|ATN-224|
40753314|NCT00383851|DRUG|Temozolomide|
40753315|NCT00743080|PROCEDURE|Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|"Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).~Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation."
40753316|NCT00743080|PROCEDURE|Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1|"Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).~Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation."
40753317|NCT05534607|BEHAVIORAL|Ola Mau i ka Hula|"The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons.~These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network.~For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly."
40753318|NCT05301231|DIAGNOSTIC_TEST|Genomics (DNA Extraction)|"Blood samples for detection of:~Genes for Dyslipidemia BY WES and NGS (4 GWA) (30 cases) Genes polymorphism for NAFLD/NASH BY TaqMan SNP Genotyping Assay on 10 GWAS"
41119871|NCT01973816|DRUG|Cyproterone acetate 50 mg; estradiol 0.5% percutaneous|Daily intake for 18 months
41119872|NCT01973816|DRUG|Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral|Daily intake during 24 months
41119873|NCT05897632|BEHAVIORAL|Outpatient Evaluation|Subjects will receive an outpatient evaluation within 72 of being discharged from the ED.
41119874|NCT05897632|BEHAVIORAL|Hospitalization Evaluation|Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding.
41119875|NCT03761472|BIOLOGICAL|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2.4 ml solution
41119876|NCT03761472|BIOLOGICAL|Platelet-rich plasma injection|Platelet-rich plasma injection 5ml
41119877|NCT06480942|OTHER|Detection of preload responders by a PLR test|Detection of preload dependency by using PLR test and echocardiography
41119878|NCT03281616|BEHAVIORAL|Diet|Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
41119879|NCT01014273|PROCEDURE|Percutaneous Coronary Intervention|
41119880|NCT00761189|DRUG|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
41119881|NCT05557006|PROCEDURE|left bundle branch pacing|In the procedure of left bundle branch pacing, various QRS morphologies are observed as penetrating the lead into the interventricular septum.
41119882|NCT03532243|PROCEDURE|incremental inspiratory load|inspiratory load ranges between 10 and 40 cm water column (cmH2O)or intolerable to the patient, each load increment for 5cm water column.
41119883|NCT00623987|DRUG|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
41119884|NCT05457244|DEVICE|single-port robotic surgery|Colorectal surgery using the da Vinci SP System will be performed via the umbilicus, McBurney's site or the reverse McBurney's site depending on the sites of lesion. All of these patients will undergo a standard minimally invasive resection in the same fashion as would be carried out with multiport laparoscopic or robotic surgery.
41119885|NCT06294275|BIOLOGICAL|LP-001 Dose 1 (Single)|A single dose of LP-001 (Dose 1) was administered subcutaneously.
41119886|NCT06294275|BIOLOGICAL|LP-001 Dose 2 (Single)|A single dose of LP-001 (Dose 2) was administered subcutaneously.
41119887|NCT06294275|BIOLOGICAL|LP-001 Dose 3 (Single)|A single dose of LP-001 (Dose 3) was administered subcutaneously.
41119888|NCT06294275|BIOLOGICAL|LP-001 Dose 4 (Single)|A single dose of LP-001 (Dose 4) was administered subcutaneously.
41119889|NCT06294275|BIOLOGICAL|LP-001 Dose 5 (Single)|A single dose of LP-001 (Dose 5) was administered subcutaneously.
41119890|NCT06294275|BIOLOGICAL|LP-001 Dose 6 (Single)|A single dose of LP-001 (Dose 6) was administered subcutaneously.
41119891|NCT06294275|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered subcutaneously.
41119892|NCT06294275|BIOLOGICAL|LP-001 Dose 7 (Multiple)|LP-001 (Dose 7) was administered multiple times subcutaneously.
41119893|NCT06294275|BIOLOGICAL|LP-001 Dose 8 (Multiple)|LP-001 (Dose 8) was administered multiple times subcutaneously.
41119894|NCT06294275|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times subcutaneously.
41119895|NCT02931214|DRUG|GMI-1359|
41119896|NCT02931214|DRUG|Placebo|
41119897|NCT05906940|DEVICE|Transcutaneous Vagus Nerve Stimulation|As a vagus stimulation protocol, bilateral auricular stimulation and stimulation frequency of 10 Hz, pulse width of 300 µs, biphasic application for 20 minutes, each participant will be stimulated twice, with at least 48 hours between them.
41119898|NCT03175861|OTHER|Stereotactic radiotherapy|"The patient will have an initial pre-therapeutic assessment in the 8 weeks before the start of radiotherapy Then, radiation therapy planning with 3 free breathing 4D (4 dimensions) scanners performed over 8 days without injection of iodinated contrast agent.~Then the patient will receive his treatment by conventional stereotactic radiotherapy"
40926416|NCT05582954|BEHAVIORAL|EsteemUp|EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.
41119899|NCT04728568|DRUG|Sintilimab|Sintilimab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
41119900|NCT06117579|OTHER|Inspiratory muscle training|"Description of a typical session:~Session duration: between 12 and 20 minutes 3 cycles of 30 repetitions with 1 minute of break between each cycle. The patient should inhale as hard as possible against an inspiratory resistance generated by a valve device."
41119901|NCT02210806|DRUG|A006 DPI|Single dose 110 mcg, 1 inhalation
41119902|NCT02210806|DRUG|A006 DPI|Single dose 220 mcg, 1 inhalation
41119903|NCT02210806|OTHER|Placebo DPI|Placebo, 1 inhalation
41119904|NCT02210806|DRUG|Proventil® MDI|Single dose 90 mcg, 1 inhalation
41119905|NCT02210806|DRUG|Proventil® MDI|Single dose 90 mcg, 2 inhalations
41272229|NCT00316264|BIOLOGICAL|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
40753319|NCT05301231|DIAGNOSTIC_TEST|Epi-genomics|"* blood samples for detection of Expression profiling of plasma microRNAs~* PCR array to determine the altered miRNAs for 168 plasma miRNAs (12 cases)~* Expression analysis of top 5 altered miRNAs (All)"
41119906|NCT01708798|DRUG|Eplerenone|
41119907|NCT01708798|DRUG|Placebo|
41119908|NCT02024685|BEHAVIORAL|Personalized Treatment Recommendations|This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.
41119909|NCT02024685|BEHAVIORAL|Standard patient-physician counseling interaction|Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
41119910|NCT01678872|DRUG|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
41119911|NCT00018603|DRUG|guanfacine|
41119912|NCT05104294|DIAGNOSTIC_TEST|Optical Coherence Tomography- Angiography|Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.
41119913|NCT05104294|DIAGNOSTIC_TEST|Photopic negative response|Both the implicit time and amplitude of PhNR were recorded.
41119914|NCT03118323|OTHER|Questionnaire|Patients are given a questionnaire with items related to personality and their willingness-to-pay for different treatment options.
41119915|NCT00102258|DRUG|Growth Hormone Therapy|
41119916|NCT02866968|PROCEDURE|FLAPS|Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
41119917|NCT01823133|DRUG|gemigliptin only|gemigliptin 50mg qd on day 1\~7
41119918|NCT01823133|DRUG|rosuvastatin only|rosuvastatin 20mg qd on day 1\~7
41119919|NCT01823133|DRUG|gemigliptin and rosuvastatin|gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7
41119920|NCT04425551|PROCEDURE|laser light|laser light destruction of telangiectatic vessels of lower eyelid margin via selective thermolysis
41272230|NCT00316264|BIOLOGICAL|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
41272231|NCT00562380|BIOLOGICAL|ganitumab|
41272232|NCT00562380|OTHER|laboratory biomarker analysis|
40753320|NCT05301231|DIAGNOSTIC_TEST|Proteomics (Glycoproteomics)|blood samples for Identifying glycosylation pattern of five glycoproteins linked with NAFLD/NASH (transferrin, apoC III, haptoglobin, Mac2 binding protein, IgG)
41119921|NCT03067948|BEHAVIORAL|Patient Designated Positive Screen Shared with Provider|Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
41119922|NCT05883475|OTHER|Disabilities of the Arm, Shoulder, and Hand Questionnaire|Upper limb function was assessed with the Turkish version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). The questionnaire DASH is a self-report instrument with 30 items. The total score ranges from 0 to 100, with higher scores indicating a worse upper limb function.
41272233|NCT00562380|OTHER|pharmacological study|
41272234|NCT00562380|PROCEDURE|biopsy|
41272235|NCT04184817|OTHER|Collection of clinical data registered in Easily software|Collection of clinical data registered in Easily software
41272236|NCT04333082|OTHER|Data collection|"collection of patient data~Data collection (demographics, prehospital management, duration of ICU and hospital stay, destination at discharge, date(s) of seizure(s), electroencephalographic (EEG) data, seizure history and etiology, number and duration of SE episodes, medication, types of SE according to the current guidelines from the International League of Epilepsy (ILAE), neuroimaging features, comorbidities, laboratory parameters, complications during and after SE , laboratory testing, vital signs, fluid balance) will be performed from the digital medical records, the electroencephalographic and microbiologic database of patients"
41119923|NCT05883475|OTHER|Arm Motor Ability Test|The test assesses hemiparetic upper extremity functional tasks.The increase in the scores of both subparameters of the scale, which is composed of the parameters of functional ability and quality of movement, indicates an improvement in the motor functions of the upper limbs.
41119924|NCT05883475|OTHER|Nine Hole Peg Test|Fine motor skills of the upper extremities were assessed.The patient was asked to insert the nine sticks in the box on the table into the holes in the other box as quickly as possible and then remove them immediately. As time increases, fine motor skills of the upper extremities decrease
41119925|NCT05883475|OTHER|Pittsburg Sleep Quality Index|"Sleep quality was assessed using the this test.This scale, which provides a quantitative measure of sleep quality, is a 19-item self-report scale. The total score greater than 5 indicates poor sleep quality."
41119926|NCT05883475|OTHER|Functional Independence Measure|This test assessed functional capacity in activities of daily living.The higher a person's score, the higher the level of independence.
41119927|NCT01544855|DIETARY_SUPPLEMENT|omega-3 fatty acids|Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
41119928|NCT01003405|DRUG|KUC-7483|
41119929|NCT01244113|DRUG|propofol|optimization of propofol dose from 1.5 mg/kg to 2.5 mg/kg using Dixon's up and down method during MRI scanning
41272237|NCT05367102|BEHAVIORAL|Supporting Healthy Relationships program|"The investigator will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)"
41272238|NCT00682058|OTHER|Follow-up post-bariatric surgery|Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures (body composition) in this study. Follow-up body composition measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
41272239|NCT00849017|BIOLOGICAL|albiglutide|albiglutide weekly injection
41272240|NCT00849017|BIOLOGICAL|albiglutide uptitration|albiglutide uptitration at week 12
41272241|NCT00849017|BIOLOGICAL|placebo|matching albiglutide placebo weekly injection
41272242|NCT04796519|PROCEDURE|Total knee arthroplasty|Surgical procedure
41272243|NCT04969055|OTHER|Not|Not
41272244|NCT03542994|OTHER|EDP1066|EDP1066 is an orally administered monoclonal microbial
41272245|NCT03542994|DRUG|Placebo oral capsule|placebo
41272246|NCT00265655|DRUG|Satraplatin|Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.
41272247|NCT05548036|DEVICE|OPEP|OPEP (Aerobika (tm)
41272248|NCT03065179|DRUG|Nivolumab/Ipilimumab|IV immunotherapy
41272249|NCT03065179|RADIATION|SBRT|SBRT will be delivered in conjunction with immunotherapy
41272250|NCT00971126|DRUG|sorafenib (Nexavar®), thalidomide (Thado®)|"Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study."
41272251|NCT04782791|DRUG|Nivolumab plus SOX|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA\<1.25 m2, 40mg; 1.25\<BSA\<1.50 m2, 50mg; BSA\>1.50 m2, 60mg. Day 15 to day 21 is the rest period.
41272252|NCT04782791|DRUG|Nivolumab|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.
41272253|NCT04782791|PROCEDURE|Gastrectomy|A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
41272254|NCT04531267|DIETARY_SUPPLEMENT|Individualized dosage of calcium and magnesium|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
41272255|NCT01993472|DRUG|Andrographolides|comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer
41272256|NCT01993472|DRUG|Capecitabine|
41272257|NCT05994170|RADIATION|Reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as 5mm margin from GTVp,including pre-induction chemotherapy tumor extension( CTVp1=GTVp+5mm)
41272258|NCT05994170|RADIATION|Non-reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as whole nasopharynx as well as 5mm margin from GTVp( CTVp1=GTVp+5mm+whole nasopharynx)
41272259|NCT01850615|DRUG|Faster-acting insulin aspart|Administrated subcutaneously (s.c., under the skin) at each main meal.
41272260|NCT01850615|DRUG|basal insulin|Administrated subcutaneously (s.c., under the skin) once daily.
41272261|NCT05961748|OTHER|Multi-disciplinary assessment|Multi-disciplinary assessment
41272262|NCT04101175|PROCEDURE|Evaluation of the procedure of abortion|Observational study using questionnaires
41272263|NCT02149641|RADIATION|Intensity modulated radiotherapy with chemotherapy|
40753321|NCT05301231|DIAGNOSTIC_TEST|Salivary Metabolomics|"Salivary Samples for detecting Salivary Metabolomics~1. Genome analysis (Identification of microbial strains common among Egyptians BY apid RT-PCR (DNA sequencing: 16S rRNA gene amplicons)~2. Microbiome related Metabolites Identification using GC-MS Analysis (the top 5 identified microbial-related metabolites) as metabolomics~3. Meta-genomic assess of three microbiome-related metabolites; lactoferrin, (LPS), (IgA) BY Commercial ELISA kits"
41272264|NCT05804799|DIAGNOSTIC_TEST|Contrast-enhanced liver CT scan|"The contrast-enhanced liver CT scans were obtained from all of the participants.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction."
41272265|NCT02278913|DRUG|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
41272266|NCT02278913|DRUG|Human Insulin|NPH twice a day + Regular insulin before meals
41272267|NCT02571348|PROCEDURE|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
41272268|NCT00889096|DRUG|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
41272269|NCT00889096|DRUG|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
41272270|NCT04790591|PROCEDURE|Same-day surgery|To be allowed same-day discharge certain postoperative criteria have to be met. These are categorized into four dimensions - vital parameters, urinary function, bleeding, and mobilization.
41272271|NCT04597476|DIETARY_SUPPLEMENT|Fucoidan|Fucoidan refers to a class of fucose-enriched sulfated polysaccharides with an average molecular weight of 20,000 Daltons (Da), which can be found in many varieties of edible brown seaweeds and algae . In cell culture studies and animal studies, fucoidan has been shown to possess a range of biological activities, including anti-cancer, anti-inflammatory, and immunoregulatory effects . A recent in vitro study conducted in head and neck squamous cell carcinoma (HNSCC) cell lines (H103, FaDu, and KB) showed that fucoidan could induce cell cycle arrest and possibly apoptosis in a dose-dependent manner, while also enhancing response to cisplatin treatment . In addition, fucoidan has also been shown to inhibit the proliferation of nasopharyngeal carcinoma cells and MC3 human mucoepidermoid carcinoma (MEC) cells .
41272272|NCT04597476|OTHER|Placebo( Potato starch)|Potato starch 4.4gram
41446377|NCT05256992|OTHER|Standard Servies + Ray of Hope Curriculum|Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services available to both study groups by selecting 1-3 hours of coursework from menu of courses that address a variety of needs.
41119930|NCT03775785|DIETARY_SUPPLEMENT|Tailored enteral nutrition|"The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d."
41119931|NCT06258824|DIAGNOSTIC_TEST|Small RNA Sequencing and Validation of candidate miRNAs|Samples were prepared for small RNA sequencing using Qiagen's QIAseq small RNA Library Prep kit, quality controlled using an Agilent Bioanalyzer 2100 and sequenced on an NextSeq 500 system (Illumina, San Diego, USA) using the default single-end 75 base pair protocol to include integrated unique molecular indices (UMIs). Validation was undertaken using Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) either using target-specific stem-loop primer assays (TaqMan) or universal reverse transcription (RT) and locked nucleic acid (LNA) enhanced specific primers with SYBR green I assay detection
41119932|NCT04111328|DRUG|intravenous sufentanil|The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
41119933|NCT04111328|DRUG|subcutaneous sufentanil|The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
41119934|NCT04111328|DRUG|intravenous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .
41119935|NCT04111328|DRUG|subcutaneous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.
41119936|NCT04111328|DRUG|intravenous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .
41119937|NCT04111328|DRUG|subcutaneous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.
41119938|NCT04111328|DRUG|intravenous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.
41119939|NCT04111328|DRUG|subcutaneous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously
41119940|NCT01873326|DRUG|Paclitaxel|
41119941|NCT01873326|DRUG|Ifosfamide|
41119942|NCT01873326|DRUG|Cisplatin|
41119943|NCT01873326|DRUG|Mesna|
41119944|NCT01873326|DRUG|Bleomycin|
41119945|NCT01873326|DRUG|Etoposide|
41119946|NCT01739907|OTHER|Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women|
41119947|NCT00833313|PROCEDURE|Atrial biopsy|Biopsy of left atrial free wall and possibly left atrial appendage
41119948|NCT00704769|DRUG|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
41119949|NCT04626011|PROCEDURE|Tooth extractions|After blood collection tests, Periodontal analysis, Orthopantomography and Anamnestic record each group will receive a full mouth disinfection and needed extractions.
41119950|NCT03036813|DRUG|voxelotor|
41119951|NCT03036813|OTHER|Placebo|
41119952|NCT04928508|DRUG|OK-1|"OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg"
41119953|NCT02077426|OTHER|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
41119954|NCT05300542|OTHER|Topical Placebo Cream|Application of test products before and after irradiation
41119955|NCT05300542|OTHER|Topical Cream with 0.5% Active|Application of test products before and after irradiation
41119956|NCT05300542|OTHER|Topical Cream with 1% Active|Application of test products before and after irradiation
41119957|NCT02757898|DRUG|Biotin-Labeled Red Blood Cells (RBCs)|"500 mL of blood will be drawn from each participant. The blood will be processed into a packed RBC unit.~For participants 1 and 2, the RBCs will be labeled with biotin at three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and the labeled RBCs will be re-infused into the participant on the same day of collection.~For participants 3 through 8, the RBCs will be stored at 2-6 C for 40-42 days before being labeled with three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and re-infused into the participant.~Participants will have a 5 mL blood sample drawn within a few minutes of the re-infusion, the day after the re-infusion and then weekly for 70 days (10 weeks) to track the survival of the infused biotin labeled RBCs."
41119958|NCT01675258|OTHER|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
41119959|NCT05286710|DEVICE|pharmacomechanical thrombectomy (PMT)|After randomization patients will be allocated to pharmacomechanical thrombectomy (PMT) via ipsilateral popliteal venous approach or to PMT via distal calf venous approach, bail-out contralateral femoral access can be used if puncture was failed in calf vein. After PMT treatment, residual thrombus was reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) was conducted if there was residual thrombus. Stenosis of iliac vein was assessed by multiangle venography and intravascular ultrasound (IVUS) was used if necessary. Percutaneous balloon angioplasty (PTA) was conducted if there was \>50% stenosis of the diameter of the iliac vein. A stent was placed if the residual stenosis was \>50% after PTA treatment.
41446378|NCT05256992|OTHER|Standard Services|Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula.
41119960|NCT02764645|DEVICE|CardioGard Cannula|"CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration."
41119961|NCT02764645|DEVICE|22Fr curved Cannula|arterial cannula for use in cardiac surgery
41119962|NCT05742126|DRUG|HSK36273|Multiple continuous IV infusion ascending doses for 5 days
41119963|NCT05742126|DRUG|Placebo|Matching placebo
41119964|NCT05742126|DRUG|Heparin sodium injection|Matching positive control
41119965|NCT04806178|BIOLOGICAL|Bacillus Calmette Guerin|0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
41119966|NCT04806178|OTHER|PLACEBO|0.1 ml 0.9% saline in the same volume as the BCG vaccine in a single dose.
41119967|NCT02971943|PROCEDURE|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging.
41119968|NCT02438904|BIOLOGICAL|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.
41272273|NCT01893749|BEHAVIORAL|CATCH-IT|It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
41272274|NCT00131807|PROCEDURE|Blood Pressure Measurement|
41272275|NCT00131807|PROCEDURE|Questionnaire|
41272276|NCT04401267|DRUG|Intensive Antihypertensive Therapy|Receives intensive antihypertensive therapy
41272277|NCT04401267|DRUG|Conventional Antihypertensive Therapy|Receives conventional antihypertensive therapy
41272278|NCT04401267|OTHER|Symptom Survey|The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
41272279|NCT04401267|OTHER|Semi-structured interview|Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
41272280|NCT00522392|DRUG|bortezomib|Given IV
41272281|NCT00522392|DRUG|lenalidomide|Given PO
40753322|NCT05301231|BEHAVIORAL|Individualized counselling for behavioural modification|"Individualized counselling for behavioral modification (3 sessions):~Nutritional education, Promotion of physical activities and Cognitive \& Psychological support"
41272282|NCT00522392|DRUG|dexamethasone|Given PO
40753323|NCT02522221|DRUG|Warfarin|Warfarin is an oral vitamin K antagonist anticoagulant.
40753324|NCT02522221|DRUG|tecarfarin|Tecarfarin is an oral vitamin K antagonist anticoagulant
41272283|NCT01249235|PROCEDURE|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
41272284|NCT01184690|PROCEDURE|Single-operator double-balloon endoscopy|Single-operator double-balloon endoscopy
41272285|NCT01184690|PROCEDURE|dual-operator double-balloon endoscopy|dual-operator double-balloon endoscopy
41272286|NCT02668614|DEVICE|WR-22 model microwave sensor|
41272287|NCT06541444|DRUG|NK520|The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.
40753325|NCT05064280|DRUG|Pembrolizumab|Given by IV (200 mg IV D1 Q3W)
40753326|NCT05064280|DRUG|Lenvatinib|Given by PO (20 mg PO QD)
41119969|NCT02438904|DEVICE|Miltenyi device|Miltenyi device is used for CD34+ cell infusions) to patients who experience poor graft function after stem cell transplantation (SCT).
41119970|NCT06426823|OTHER|Saline / placebo|NaCl (9 mg/ml)
41119971|NCT06426823|OTHER|GIPR antagonist / study tool|GIP(3-30)NH2
41119972|NCT01692483|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
41119973|NCT01692483|DRUG|Prednisone|Prednisone or prednisolone 5 mg tablet taken orally twice daily
41119974|NCT04665440|OTHER|Voice alone|mother's voice without tactile stimuli
41119975|NCT04665440|OTHER|Voice + tactile stimuli|mother's voice with tactile stimuli
41119976|NCT04476472|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery.
41119977|NCT04145492|DRUG|Vitamin K2|Patients will take 90 ug of vitamin K2
41119978|NCT04145492|DRUG|Cholecalciferol (inactive vitamin D)|Patients will take 10 ug of vitamin inactive vitamin D
41119979|NCT04145492|DRUG|Vitamin K2 and Cholecalciferol|Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D
41119980|NCT01896349|OTHER|IPT+ antidepressant drugs|16 sessions of interpersonal psychotherapy plus antidepressant drugs.
40753327|NCT05226338|DRUG|D-0502|Formulation 1 Formulation 2 Formulation 3
40753328|NCT02137681|DRUG|Rituximab|Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
40753329|NCT04560114|DRUG|Essential oils|"The patient will be invited to inhale the essential oils via the stick:~* 4 times a day before each meal and snack.~* if necessary when nausea appears, as many times as he deems necessary."
40753330|NCT01595178|BEHAVIORAL|Combined BNI|Combination brief negotiated interview (BNI) for patients who smoke and drink
40753331|NCT00666575|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
40753332|NCT00666575|DRUG|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
40753333|NCT04576221|DEVICE|stacked breathing exercise|"• Breath stacking was done using a bag which is a simple device used to give artificial breaths..~* It is best done in a sitting position but can be done reclining or lying flat whichever position is used, try to avoid slouching. If sitting: rest against the back of a chair and keep the shoulders, arms and hands relaxed.~* If using the mouthpiece, place the lips tightly around the mouthpiece to create a tight seal."
40753334|NCT04576221|DEVICE|NIV by CPAP mask|provides pressurized air through a mask to help push air into your lungs and help you breathe
40753335|NCT02551809|BIOLOGICAL|UB-311|Intramuscular injection
40753336|NCT02551809|DRUG|Placebo|Intramuscular injection
40753337|NCT01769118|DRUG|Caffeine|Caffeine will be given according to departmental protocol
40753338|NCT06469775|DEVICE|Low intensity shock wave|6 sessions of low intensity shock wave therapy, applied in 15 minute appointments once weekly.
40753339|NCT06469775|COMBINATION_PRODUCT|Control|Standard of care treatment: phosphodiesterase 5 inhibitor therapy, vacuum erectile device, constriction bands, intracorporal injections, and penile implant.
40753340|NCT05017948|OTHER|Risk score based intervention|Targeted interventions based off of risk score software
41119981|NCT01896349|DRUG|fluoxetine|Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
41119982|NCT01896349|DRUG|sertraline|
41119983|NCT01896349|DRUG|paroxetine|
41119984|NCT01896349|DRUG|Citalopram|
41119985|NCT01896349|DRUG|escitalopram|
41119986|NCT01896349|DRUG|fluvoxamine|
41119987|NCT01896349|DRUG|Venlafaxine|
41119988|NCT01896349|DRUG|Duloxetine|
40753341|NCT03101670|DRUG|filgotinib|one filgotinib oral tablet q.d.
40753342|NCT03101670|DRUG|Placebo Oral Tablet|one placebo oral tablet q.d.
40753343|NCT05333029|BIOLOGICAL|Allogeneic mesenchymal stromal cells (MSCs)|Treatment dose 2 x10\^6 cells/kg (+/- 20%)
40753344|NCT05333029|BIOLOGICAL|Extracorporeal photopheresis (ECP)|Blood is collected through an intravenous (IV) line which is connected to an apheresis machine.The machine adds a chemical that makes the white blood cells sensitive to light. Then the machine shines a light on the cells and then returns the blood to the participant
41119989|NCT01896349|DRUG|Bupropion|
41119990|NCT01896349|DRUG|Lithium|
41119991|NCT01896349|DRUG|Risperidone|
41119992|NCT01896349|DRUG|tranylcypromine|
41119993|NCT01896349|DRUG|Imipramine|
41119994|NCT01896349|DRUG|amitriptyline|
41119995|NCT01896349|DRUG|Clomipramine|
41119996|NCT01896349|DRUG|nortriptyline|
41119997|NCT01896349|DRUG|trazodone|
41119998|NCT01896349|DRUG|Mirtazapine|
41119999|NCT01896349|DRUG|sulpiride|
41120000|NCT03086369|DRUG|Olaratumab|Administered IV
41120001|NCT03086369|DRUG|Nab-paclitaxel|Administered IV
40753345|NCT06092957|DRUG|Cisplatin-based induction chemotherapy|Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.
40753346|NCT06092957|DRUG|Full course of PD-1/PD-L1 blockades|a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
40753347|NCT06092957|RADIATION|Reduced-dose IMRT|GTVnx:60Gy/30F/2.0Gy，CTV1:54Gy/30F/1.8Gy，CTV2:48Gy/30F/1.6Gy
40753348|NCT06092957|RADIATION|Standard-dose IMRT|GTVnx：69.96Gy/33Fr/2.12Gy；CTV1：60.60Gy/33Fr/1.82y；CTV2：54.12Gy/33Fr/1.64Gy
40753349|NCT06092957|DRUG|Concurrent Chemotherapy|Cisplatin 100mg/m2 every 3 weeks for 2 cycles
40753350|NCT06144086|DRUG|Foscenvivint|Administered by intravenous (IV) infusion over 3-4 hours
40753351|NCT04792970|DRUG|Talc|All patients randomized to the Talc arm will receive Talc therapy through the pleural catheter.
41120002|NCT03086369|DRUG|Gemcitabine|Administered IV
41120003|NCT03086369|DRUG|Placebo|Administered IV
41120004|NCT00277914|DRUG|Flibanserin|flibanserin flexible dosing
41120005|NCT06407024|PROCEDURE|laparoscopic transabdominal adrenalectomy|Adrenalectomy performed by laparoscopic approach
41120006|NCT06407024|PROCEDURE|robotic transabdominal adrenalectomy|Adrenalectomy performed by robotic approach
41120007|NCT05906875|OTHER|Lateral Stepping Exercise 1|1. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.
41120008|NCT05906875|OTHER|Active Control Group Exercise 1|1. Seated ankle movements (dorsi-/plantarflexion)hree sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
41120009|NCT05906875|OTHER|Active Control Group Exercise 2|2. Knee extension Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
41120010|NCT05906875|OTHER|Active Control Group Exercise 3|3. Hip flexion Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
41120011|NCT05906875|OTHER|Active Control Group Exercise 4|4. Hip abduction Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
41272288|NCT05963763|BEHAVIORAL|Career Navigator Coaching|"The Career Navigator will support participants with a tailored approach to reach career and financial goals through one or more of the following services, in addition to referrals to other external services (community-based organizations) as needed for 6 months:~1. Career pathway navigation~2. Employee benefit maximization~3. Financial literacy and wealth building~4. Services funds for resources that mitigate specific barriers or needs."
41272289|NCT03099733|OTHER|text message|Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
41272290|NCT03115996|DRUG|REGN3918|Intravenous (IV) or Subcutaneous (SC)
41272291|NCT03115996|DRUG|Placebo|Matching Placebo
41272292|NCT01411787|BEHAVIORAL|Exercise|Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
41272293|NCT00706628|DRUG|BIBF 1120|
41272294|NCT00706628|DRUG|BIBW 2992|
41272295|NCT00706628|DRUG|Sequential BIBF 1120 + BIBW 2992|
41272296|NCT04172090|OTHER|Control|Normal physical activity and standard energy intake
41272297|NCT04172090|OTHER|SIT+E|Reduced physical activity and standard energy intake
41272298|NCT04172090|OTHER|SIT=E|Reduced physical activity and reduced energy intake
41272299|NCT00257634|DRUG|dexamethasone to injury site|
41272300|NCT00289705|PROCEDURE|Surgery|Laparoscopic Roux-en-Y gastric bypass
40753352|NCT05558670|OTHER|PET-fMRI-EEG|Participants perform PET, fMRI, and EEG simultaneously using a MRI compatible EEG cap
41120012|NCT05906875|OTHER|Lateral Stepping Exercise 2|2. Lateral stepping: Performed without and with resistance bands. The participant will perform a series of steps to the side. If using a resistance band, the band will be placed around both ankles in a 'loop' and the participant will perform the lateral stepping. Three sets of 8-12 repetitions will be performed per side per subject.
41120013|NCT05906875|OTHER|Lateral Stepping Exercise 3|3. Single leg stance: The participant will stand on one leg with support as needed. The contralateral knee will be held at 45 degrees throughout the exercise. The instructor will observe to ensure the bent leg does not contact the ground. Three repetitions of static stance per side will be performed with a goal of 30 seconds, and a maximum time of 60 seconds, per repetition.
41120014|NCT05906875|OTHER|Lateral Stepping Exercise 4|4. Staggered stance mini-squat: Participants will stand with the feet hip-width apart and one leg placed a short step forward. The participant will squat straight down keeping the trunk upright and return to an upright position.
41272301|NCT03634982|DRUG|RMC-4630|RMC-4630 for oral administration
41272302|NCT03661684|DRUG|Prednisone|40 mg po q day of Prednisone for 3 days
41272303|NCT02229201|DRUG|Propofol|4-6 mg/kg/h during anaesthesia
41272304|NCT02229201|DRUG|Sevoflurane|0.8 MAC
41272305|NCT00419796|DRUG|Lumiracoxib|
41272306|NCT00643383|DRUG|Combination drug (Acetaminophen + Tramadol)|
41272307|NCT00643383|DRUG|Placebo|
41272308|NCT06488625|DRUG|Low-Dose CICR-NAM|2 g/d CICR-NAM (blinded)
41272309|NCT06488625|DRUG|High-Dose CICR-NAM|3 g/d CICR-NAM (blinded)
41272310|NCT06488625|DRUG|0 g/d CICR-NAM (blinded)|Placebo (blinded)
41272311|NCT06488625|DRUG|Open-Label|3 g/d CICR-NAM (open label)
41272312|NCT01968941|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
41272313|NCT01968941|RADIATION|Conventional Radiotherapy (CRT)|
41272314|NCT04284293|BIOLOGICAL|CNS10-NPC implantation|All patients will receive a single, unilateral, subretinal injection of CNS10-NPC
41272315|NCT01147926|DRUG|Placebo|Placebo matched to Prucalopride tablet orally once daily.
40753353|NCT05374993|DEVICE|3TBA|Induce third molar tooth bud agenesis
40753354|NCT05517785|OTHER|Motor performance tests|Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance
41272316|NCT01147926|DRUG|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (\<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
41272317|NCT02626728|PROCEDURE|laparoscopic assisted transanal surgery (TAMIS)|all patients included recieve laparoscopic assisted transanal minimally invasive surgery
41272318|NCT06179901|PROCEDURE|Integrative Korean Medicine Treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine, cupping, moxibustion.
41272319|NCT06179901|PROCEDURE|lower limb motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
41272320|NCT02912663|DRUG|Verapamil and Magnesium Sulfate|Single dose strategy will be used
41272321|NCT02912663|OTHER|Placebo|Single matching dosing strategy will be used
41272322|NCT00389207|DRUG|nevirapine bid|nevirapine twice daily
41272323|NCT00389207|DRUG|nevirapine qd|nevirapine once daily
41272324|NCT00389207|DRUG|atazanavir|atazanavir once daily
41272325|NCT05124626|PROCEDURE|MIRPE with two bars|Minimally invasive repair of pectus excavatum utilizing two metallic bars
41272326|NCT05124626|PROCEDURE|MIRPE with one bar|Minimally invasive repair of pectus excavatum utilizing one metallic bar
41272327|NCT01237951|DRUG|Palifermin|"60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient."
41272328|NCT01237951|DRUG|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
41272329|NCT01237951|DRUG|Gemcitabine|1875 mg/m\^2 IV (75 mg/ m2 bolus followed by 1800 mg/m\^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
41272330|NCT01237951|DRUG|Busulfan|"32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient."
41272331|NCT01237951|DRUG|Melphalan|60 mg/m\^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
41272332|NCT01237951|PROCEDURE|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
41272333|NCT01237951|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
41272334|NCT04073667|BEHAVIORAL|Exercise|"Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~* To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~* Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~* Teaching the correct scapular position, D. Postural correction exercises;~* Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~  a. Joint position sense:~* Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~  b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~  a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty."
41272335|NCT03590860|DRUG|LY3322207|Administered by SC injection
41272336|NCT03590860|DRUG|Placebo|Administered by SC injection
41272337|NCT04857021|DIETARY_SUPPLEMENT|GABA|oral administration of GABA capsule once daily before sleep
41272338|NCT04857021|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo capsule once daily before sleep
41272339|NCT04673058|PROCEDURE|Spinal Manipulation|Intervention will be administered twice a week for 3 weeks. Each treatment session will be given in 20-minute sessions consisting of 10 minutes of manual examination and 10 minutes of manual treatment.
41272340|NCT04673058|PROCEDURE|Sham Manipulation|The practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position.
41272341|NCT01978704|OTHER|Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal|
41272342|NCT01978704|OTHER|Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal|
41272343|NCT00374556|DRUG|Placebo|3mg placebo capsule, once daily at bedtime
41272344|NCT00374556|DRUG|Eszopiclone|3mg capsule, once daily at bedtime
41272345|NCT02735213|DEVICE|577-MPL|9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250\~400 milliWatts of power(50% threshold power),150\~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.
41272346|NCT02735213|DEVICE|TLT|contimuous wave,100um spot size, 0.05 seconds duration, 55\~60 milliwatts of power, 18\~27 spots,the laser area is the corresponding leakage on mid-phase FA.
41272347|NCT00216034|DRUG|Tegafur-gimeracil-oteracil potassium (TS-1)|From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
41272348|NCT00216034|DRUG|Krestin (PSK)|From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
41272349|NCT00700856|DRUG|add-on pioglitazone|participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
41272350|NCT00700856|DRUG|add-on sulphonylurea|participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
41272351|NCT02649101|DRUG|Thalidomide|Thalidomide tablet 100mg qn po.
41272352|NCT02649101|DRUG|Physician's choice chemotherapy|Investigators will declare no constraint of regimens.
41272353|NCT03476044|DRUG|Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
41272354|NCT03476044|DRUG|Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
41272355|NCT00359892|DRUG|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
41272356|NCT01871506|BEHAVIORAL|Standard Care (SC)|"1. Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~2. 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~3. Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects."
40753355|NCT00465283|DRUG|Donepezil|Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
41272357|NCT01871506|BEHAVIORAL|Intensive Counseling (IC)|"The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~1. Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~2. Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication."
41272358|NCT01278290|DIAGNOSTIC_TEST|Triptorelin acetate and Gonadorelin acetate|Triptorelin acetate test, using aqueous 0.1 mg/m2 subcutaneous. Gonadorelin test using 100 ug intravenous.
41272359|NCT01278290|DIAGNOSTIC_TEST|Gonadorelin acetate and Triptorelin acetate|Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
41272360|NCT05521165|OTHER|therapeutic exercises|strengthening exercises for gluteus medius and APTA guided program for NSCLBP
40753356|NCT00063999|DRUG|Carboplatin|Given IV
40753357|NCT00063999|DRUG|Cisplatin|Given IV
40753358|NCT00063999|DRUG|Doxorubicin Hydrochloride|Given IV
40753359|NCT00063999|BIOLOGICAL|Filgrastim|Given SC
41272361|NCT00866099|OTHER|Educational Dementia training|"Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.~Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified."
41272362|NCT04640727|PROCEDURE|open reduction|A sterile tourniquet is applied and an oblique posterolateral skin incision is made. Superficial dissection is carried out in the plane of the fracture hematoma until the distal lateral corner of the proximal fragment is identified. Once the metaphyseal side of the fracture has been identified, the dissection is carried across the joint to expose the medial articular surface. After exposure of the proximal fragment, the orientation of the distal fragment is defined and the soft tissues are sharply released off the anterior aspect of the distal fragment, with extension carried distally to the radial head. After irrigation and débridement of the fracture hematoma, the distal fragment is reduced with a towel clip. It is important to judge the reduction at the level of the articular surface rather than the metaphysis because plastic deformation or comminution of the metaphyseal fragment may be present. Pins (usually 0.062 inch) are placed percutaneously to secure the fracture.
40753360|NCT00063999|OTHER|Laboratory Biomarker Analysis|Correlative studies
40753361|NCT00063999|DRUG|Paclitaxel|Given IV
40753362|NCT00063999|BIOLOGICAL|Pegfilgrastim|Given SC
40753363|NCT00063999|OTHER|Quality-of-Life Assessment|Ancillary studies
41120015|NCT05906875|OTHER|Lateral Stepping Exercise 5|5. Lateral Reactive Postural Control: The participant will lean into the researcher's hand to shift their center of mass outside of their base of support. Hand placement will be at the glenohumeral joint and the pelvis. The researcher will withdraw support and guard the participant as the participant regains their balance. This is item 6 on the Mini-BESTest assessment that will be incorporated as an intervention. To be performed 3x per side.
41120016|NCT02135042|DRUG|Cisplatin|Given IV
41120017|NCT02135042|OTHER|Clinical Observation|Undergo clinical observation
41120018|NCT02135042|DRUG|Fluorouracil|Given IV
41120019|NCT02135042|DRUG|Gemcitabine Hydrochloride|Given IV
41120020|NCT02135042|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41120021|NCT02135042|OTHER|Laboratory Biomarker Analysis|Correlative studies
41120022|NCT02135042|DRUG|Paclitaxel|Given IV
41120023|NCT02135042|OTHER|Quality-of-Life Assessment|Ancillary studies
41120024|NCT00042848|DRUG|modafinil|
41120025|NCT02833506|OTHER|Laboratory Biomarker Analysis|Correlative studies
41120026|NCT02833506|BIOLOGICAL|Recombinant NY-ESO-1 Protein|Given recombinant NY-ESO-1 protein SC
41120027|NCT02833506|DRUG|Sirolimus|Given PO
41120028|NCT05161429|DRUG|DPP4|Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin
41120029|NCT05161429|DRUG|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide
41120030|NCT05161429|DRUG|Basal Insulin|degludec, detemir, glargine and NPH
41120031|NCT05161429|DRUG|SLGT2|Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin
41120032|NCT05161429|DRUG|SU|Sulfonylurea (SU) including glimepiride, glipizide, and glyburide
41120033|NCT00357097|DRUG|Ropinirole|
41120034|NCT00539734|DRUG|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
40753364|NCT02957123|DRUG|Intranasal auto-M2-BFs|Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
40753365|NCT05040464|DRUG|AZA capsules|oral AZA capsules at a daily dose of 2.5 mg per kilogram,
40753366|NCT05040464|DRUG|MTX|MTX 25 mg SC once a week
40753367|NCT05040464|BIOLOGICAL|blood sample|The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.
40753368|NCT06339762|BEHAVIORAL|Self-Compassion Training|Self-Compassion Training
40753369|NCT05208632|OTHER|INTERSCALEN BLOCK APPLICATION WITH USG|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
40753370|NCT01691807|DRUG|ofatumumab|treatment for NHL
40753371|NCT01691807|DRUG|bendamustine|treatment for NHL
40753372|NCT04578977|BEHAVIORAL|Functional assessment of surgical treatment of terrible triade injury of the elbow|Functional assessment of surgical treatment of terrible triade injury of the elbow
40753373|NCT03856177|BEHAVIORAL|Emotion Induction|Described in arm
40753374|NCT00841074|DRUG|chlorhexidine|0.12% chlorhexidine mouthwash spray, \~1.3 ml, twice a day.
40753375|NCT00841074|DRUG|Placebo mouthwash|Placebo mouthwash spray application of \~1.3 ml twice a day.
41120035|NCT00621569|BEHAVIORAL|Dietary Approaches to Stop Hypertension-The DASH diet|The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
41120036|NCT00621569|BEHAVIORAL|Intervention with no dietary component - information regarding useful life skills|Participants receive information regarding useful life skills in a group setting
41120037|NCT02748317|DRUG|Lactobacillus rhamnosus GG|For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
41272363|NCT04640727|PROCEDURE|closed reduction|we applied a gentle varus force to the elbow while the patient was under general anesthesia, and we attempted to reposition the rotated fragment by directly pushing or by using Kirschner wires as joysticks . After repositioning, we applied gradual direct compression to the distal fracture fragment anteromedially.We then applied slight valgus force to the elbow with the forearm supinated and the elbow fully extended to maintain the reduction. After the fracture reduction was confifirmed to be within 2 mm, especially as seen on the anteroposterior, lateral radiographs,and internal obliquewe used smooth Kirschner wires to perform percutaneous pinning
41272364|NCT00278876|DRUG|Imatinib mesylate (Glivec)|Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
40753376|NCT02330263|DIETARY_SUPPLEMENT|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
40753377|NCT04197323|DRUG|Alprostadil liposomes for injection|40ug,once a day,continuous administration for 2 weeks
41272365|NCT05774821|PROCEDURE|Tricuspid valve surgery|Surgical repair or valve prosthesis implant to treath the regurgitation of the tricuspid valve
41272366|NCT06166836|DRUG|D1553|D1553 orally taken，600mg twice a day
41272367|NCT06166836|DRUG|IN10018（Ifebemtinib）|IN10018 orally taken once daily at approximately the same time each day
41272368|NCT02949830|DRUG|Givosiran|Givosiran by subcutaneous (SC) injection.
41272369|NCT04102150|DRUG|Valemetostat Tosylate|Once a day, 200 mg, oral administration
41272370|NCT04716322|BEHAVIORAL|Adapted Physical Activity|A 16-week health-adapted physical activity program, individualized from baseline evaluation of participants including the specificities of their pathologies
41272371|NCT01128387|DRUG|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
40753378|NCT02882893|DRUG|Clostridium Botulinum A Toxin|
40753379|NCT02882893|DRUG|Clostridium Botulinum A Toxin|
40753380|NCT05233059|BEHAVIORAL|FitEx|FitEx is an 8 week goal-setting, behavior tracking, physical activity intervention with a low dose of social support which will be delivered virtually.
40753381|NCT05233059|BEHAVIORAL|Weekly Yoga Sessions|30 minutes of optional guided yoga online led by a 500 hour yoga teacher once a week for participants in the walking plus yoga arm. Also accompanied by a yoga based newsletter.
40753382|NCT05233059|BEHAVIORAL|Weekly Movement Sessions|30 minutes of optional guided movement online led by a 500 hour yoga teacher once a week for participants in the walking arm. Also accompanied by a movement based newsletter.
40753383|NCT04604093|DEVICE|SMBG Meter|Self Monitoring Blood Glucose Meter
40753384|NCT04604093|DEVICE|FreeStyle Libre 2 System|The Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System
40753385|NCT06210633|OTHER|medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
40753386|NCT06210633|OTHER|endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
40753387|NCT02142829|DRUG|EXPAREL|
40753388|NCT02142829|DRUG|On-Q Pain Ball|bupivacaine HCl 0.25%
40753389|NCT04900857|OTHER|Dry needle|Local twitch responses (LTRs) were obtained by multiple rapid insertions of the needle in and out of the point, similar to Hong's rapid-entry and rapid exit technique. Hong 1994). The needle was not removed from that site for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
40753390|NCT04900857|DEVICE|Localize vibration|the vibration was applied with 110 Hz and 5.57 mm amplitude.
41272372|NCT01508455|DRUG|Dexmedetomidine|
40753391|NCT05520450|BEHAVIORAL|Telematic support group|The participation of each patient in the study has been established for 4 months; the first and last months correspond to the evaluation phase, the remaining two months are for the intervention. A total of 7 group sessions of 90 minutes duration and weekly frequency are scheduled, carried out via telematics and conducted by an emotional well-being professional, a nurse and a social worker. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used for people who have presented their clinical situation. The only difference between participating in the intervention and not participating in the intervention is the participation in a telematic support group and some additional assessments, i.e. not routinely carried out, which are part of this project. The intervention will be carried out in a group format, with a maximum of 12 patients per session.
40753392|NCT05560529|BEHAVIORAL|DBT|Applying DBT modules in group format over 20 weeks
40753393|NCT05560529|DRUG|TAU|Giving TAU (usual pharmacotherapy in BED) over 20 weeks
40753394|NCT05560529|DIAGNOSTIC_TEST|Plasma Ghrelin|Measuring fasting plasma ghrelin pre and post treatment in both arms
40753395|NCT02421965|BEHAVIORAL|FOCUS (Smartphone Application)|Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
40753396|NCT02421965|BEHAVIORAL|WRAP (Wellness Recovery Action Planning)|Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
40753397|NCT02088580|PROCEDURE|Triple Chronotherapy|
40753398|NCT04999293|DRUG|Ticagrelor|Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
40753399|NCT02197104|DRUG|citocoline|Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.
40753400|NCT02927314|DRUG|CF102|orally q12h
40753401|NCT02927314|DRUG|Placebo|orally q12h
41272373|NCT01508455|DRUG|Midazolam|
41272374|NCT01508455|DRUG|Fentanyl|
41272375|NCT01508455|DRUG|Morphine|
41272376|NCT00743795|DRUG|placebo|oral BID
41272377|NCT00743795|DRUG|GS-9190|40 mg oral BID
41272378|NCT00743795|DRUG|Peginterferon Alfa 2a|All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.
41120038|NCT06105333|PROCEDURE|standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline|CrSO2 (Cerebral regional oxygen saturation) monitoring was visible to the clinical team with the same SpO2 target as in the control group. If SpO2 (oxygen saturation) remained between the 10th and 90th centiles and within local limits, and crSO2 was \<10th centile according to published reference ranges, FiO2 (fraction of inspired oxygen) was increased by 10-20% every 60 seconds or respiratory support was started or increased. If crSO2 remained \>10th centile for \>60 seconds or if rSO2 was \>90th centile,FiO2 was reduced by 10-20% or respiratory support was adjusted accordingly. If there was a history of blood loss or clinical signs of blood loss, intravenous fluids (10 mL/kg) were considered.
41120039|NCT06420323|DEVICE|Treatment with NovoX® Cup|NovoX® Cup treatment
41120040|NCT06420323|DEVICE|Treatment with Omnistrip®|Omnistrip® treatment
41120041|NCT02531152|DRUG|Latanoprost|
41120042|NCT02531152|DRUG|SAR366234|
41120043|NCT03169244|DRUG|Bupropion|Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
41120044|NCT03169244|DRUG|Placebo Oral Tablet|Placebo will be initiated on Day 1 and continue throughout the course of the study.
41120045|NCT02200770|DRUG|Inebilizumab|Participants will receive IV inebilizumab 300 mg.
41120046|NCT02200770|OTHER|Placebo|Participants will receive IV placebo matched to inebilizumab.
41120047|NCT01698125|PROCEDURE|Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
41120048|NCT06520332|PROCEDURE|Dental Implant Surgery - short implant group (less than or equal to 6mm)|"A mucoperiosteal flap will be raised in edentulous ridge. A short dental implant (experimental group) will be placed according to the standard protocol.~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
41120049|NCT06520332|PROCEDURE|Dental Implant Surgery - Conventional implant group (greater than or equal to 10mm)|"A mucoperiosteal flap will be raised in edentulous ridge. A standard length implant ( comparative group) ( ≥10mm) will be placed according to the standard protocol in the augmented/native bone .~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
41120050|NCT04290572|DRUG|Isotretinoin capsules|Jelly capsules of isotretinoin
41120051|NCT00343486|DRUG|Solabegron|
41120052|NCT03988842|DRUG|Alteplase|Lyophilized powder for reconstitution in 50mg vials
41120053|NCT03988842|DRUG|Unfractionated heparin|Heparin sodium in 0.45% sodium chloride injection for intravenous use
40753402|NCT05395780|DRUG|MAX-40279|MAX-40279 capsule will be administered orally
40753403|NCT00252889|DRUG|Topotecan and pegylated doxorubicin|Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
40753404|NCT03003897|OTHER|Soluble Fiber|Participants receiving soluble fiber.
41120054|NCT03988842|DRUG|Placebo|Saline solution reconstituted to mimic Alteplase 50mg vial
41120055|NCT03988842|DRUG|Apixaban|Apixaban tablet
41120056|NCT01001936|DRUG|SKI-606|
41120057|NCT00505791|DRUG|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure \> 100 mmHg.
41120058|NCT05454228|BEHAVIORAL|postoperative delirium|Postoperative delirium (POD) occurs within 1 week after surgery in patients, with obvious time characteristics, mainly occurring within 1-3 days after surgery. Postoperative delirium has adverse effects on the short and long term prognosis of patients. Patients with delirium have an increased risk of postoperative complications, perioperative death, longer hospital stay and increased medical costs during hospitalization.
41120059|NCT05508243|OTHER|Hyaluronic Nasal Spray|Health care product - nasal application
41120060|NCT03647969|DRUG|Nivolumab|"Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks"
41120061|NCT03647969|DRUG|Ipilimumab|1mg/kg i.v. d1 over 30 minutes every 6 weeks
41120062|NCT03647969|DRUG|mFOLFOX|Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
41120063|NCT03647969|DRUG|FLOT|"Docetaxel at a dose of 50 mg/m² iv over one hour (day 1), Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin\* at a dose of 200 mg/m² iv over one hour (day 1), Fluorouracil at a dose of 2600 mg/m² iv over 24 hours (day 1) every 2 weeks~\* Note: Leucovorin can be replaced by sodium folinate that is given according to local guideline."
41120064|NCT04238793|DRUG|KLS-2031|KLS-2031 administered by transforaminal epidural injection
41120065|NCT04238793|OTHER|Placebo|Normal Saline (0.9%) administered by transforaminal epidural injection
40753405|NCT03003897|OTHER|Placebo|Participants receiving placebo.
40753406|NCT03522246|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
40753407|NCT03522246|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
40753408|NCT03522246|DRUG|Placebo Oral Tablet|Placebo tablets will be administered twice daily
40753409|NCT03522246|DRUG|Placebo IV Infusion|IV placebo will be administered once every 4 weeks
40926417|NCT05582954|BEHAVIORAL|EsteemUp-G|The gamification elements added to this arm include (1) Badges - digital rewards upon completing important milestones within the programme EsteemUp. (2) Unlockable content - downloadable worksheets of the exercises that they have done in the module, (3) A certification of completion at the end of the program, (4) Goal setting (5) Gamification terminology - All homework assignments will be framed as a 'challenge' that needs to be completed, (6) a progress bar that will indicate how far along the participant is in the program
40926418|NCT04678479|DRUG|Ganaxolone|ganaxolone
41120066|NCT04902378|DEVICE|Tandem t:slim X2 insulin pump with Control IQ technology|The intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology during pregnancy.
41120067|NCT02330926|OTHER|standard care|
41120068|NCT02330926|OTHER|nutritional supplements and advice|
40926419|NCT04998136|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
41120069|NCT02330926|OTHER|home-based self-assisted exercise program|
41120070|NCT02330926|DRUG|Ibuprofen|
41120071|NCT00508924|DRUG|Argatroban|
41120072|NCT00508924|DRUG|Argatroban|
41120073|NCT00508924|DRUG|Argatroban|
40753410|NCT00862277|BIOLOGICAL|Menactra®|0.5 mL, Intramuscular (from a previous study)
40753411|NCT00862277|BIOLOGICAL|Menomune®|0.5 mL, Intramuscular (from a previous study)
40753412|NCT02898441|DEVICE|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
40753413|NCT05612607|DRUG|Immunoglobulin replacement therapy (IGRT)|IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
40753414|NCT03222609|DRUG|Ruxolitinib|Tablet; Oral
40753415|NCT03222609|DRUG|Navitoclax|Tablet; Oral
41120074|NCT00508924|DRUG|Heparin|
41120075|NCT01407393|DEVICE|Glucosanol|2 tablets 3x daily for 12 weeks
41120076|NCT01407393|DEVICE|Placebo|2 tablets 3x daily for 12 weeks
41120077|NCT04771793|BEHAVIORAL|new physical restraint protocols|new physical restraint protocols
41120078|NCT00088413|BIOLOGICAL|PANVAC-V|Patients receive 2 x 10(8) pfu PANVAC-V (vaccinia) subcutaneously on Day 1.
41120079|NCT00088413|BIOLOGICAL|PANVAC-F|Patients receive 1 x 10(9) pfu PANVAC-F (fowlpox) or about days 15, 29, and 43 then every month for 12 doses then every 3 months until disease progression or toxicity.
41120080|NCT00088413|DRUG|Sargramostim (GM-CSF, Leukine)|100g sargramostim will be given subcutaneously at the site of the vaccination on each vaccination day and for three consecutive days thereafter.
41120081|NCT02617069|BIOLOGICAL|botulinum toxin injection|
41120082|NCT02617069|BIOLOGICAL|0.9% normal saline injection|
41120083|NCT02617069|DEVICE|Implantable loop recorder|
40753416|NCT02929121|DRUG|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
40753417|NCT02929121|DRUG|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
41272379|NCT00743795|DRUG|Ribavirin|Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
40753418|NCT01574404|PROCEDURE|Polar body biopsy with PGS|PB biopsy and analysis by comparing the PB results to the FISH/microarray results
41120084|NCT02967458|DRUG|Perflutren Lipid Microsphere Intravenous Suspension|The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
41120085|NCT03036644|DEVICE|e-cigarette (PG+VG without nicotine; low temperature)|
41272380|NCT02363179|BEHAVIORAL|Live preferential music|Live preferential music will be performed for patients in the emergency department.
41272381|NCT04107038|PROCEDURE|General Endotracheal Anesthesia|Participants receive general endotracheal anesthesia for the procedure, as well as analyzing the information from their transesophageal echocardiography per routine clinical care.
40753419|NCT01326897|BEHAVIORAL|Healthy Homes/Healthy Families|"Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a menu of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings."
40753420|NCT01326897|BEHAVIORAL|Health Education|Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
40753421|NCT02429167|DEVICE|Cranial nerve non-invasive neuromodulation via PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
40926420|NCT04998136|DRUG|Placebo (semaglutide 2.4 mg)|Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
41120086|NCT03036644|DEVICE|e-cigarette (PG+VG with nicotine; low temperature)|
41120087|NCT03036644|DEVICE|e-cigarette (PG+VG without nicotine; high temperature)|
41120088|NCT03036644|DEVICE|e-cigarette (PG+VG with nicotine; high temperature)|
41120089|NCT03036644|OTHER|tobacco cigarette|
41120090|NCT06335719|PROCEDURE|BES|Nerve biopsies during surgery + brief electrical stimulation therapy
41120091|NCT06335719|PROCEDURE|Standard of Care surgery|Nerve biopsies during surgery - no brief electrical stimulation therapy
41120092|NCT05097417|COMBINATION_PRODUCT|traditional Chinese medicine and ablation in the primary tumor sites|Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
41272382|NCT04107038|PROCEDURE|Monitored anesthesia care|Participants receive monitored anesthesia care for their procedure.
41272383|NCT02547727|BIOLOGICAL|rabies vaccine|Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
41272384|NCT06256848|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
40753422|NCT02429167|DEVICE|Sham PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
40753423|NCT04641039|PROCEDURE|Anterior lumbar disc annulus removal versus replacement|Owestry scale, SF12, Facet joint arthritis measured with Pathria scale, discal degeneration measured with Modic and Phirrmann scales
41120093|NCT05097417|PROCEDURE|ablation|Patients will be treated with ablation in the primary tumor sites
41120094|NCT03926936|DRUG|Fulvestrant|intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
41120095|NCT00002018|DRUG|Interferon alfa-n3|
41120096|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered once daily for 14 days
41120097|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
41120098|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered once daily for 28 days
41120099|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
41120100|NCT02034773|DRUG|Placebo|Placebo will be administered once daily for up to 28 days
41120101|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
41120102|NCT02034773|DRUG|CC-220|CC-220 1mg (once every 7 days for 28 days)
41120103|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
41120104|NCT03435666|DRUG|Capecitabine|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
41120105|NCT03435666|DRUG|XELODA|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
41120106|NCT05075941|OTHER|Vaccination coverage|proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population
41120107|NCT01618643|PROCEDURE|Acetic acid chromoendoscopy|"Prospective observational pilot study.~We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.~We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray."
41120108|NCT03013452|DEVICE|oPEP|Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
41120109|NCT03013452|BEHAVIORAL|Autogenic drainage|Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
41120110|NCT00738699|DRUG|MORAb-003 (farletuzumab)|Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
40753424|NCT02794311|OTHER|Alcoolpredict|psychological (personality), neuropsychological (executive functions, memory), genetic (snp polymorphisms) and neuro-anatomical (fMRI)
40753425|NCT04643431|DIAGNOSTIC_TEST|Perflutren|The ultrasound contrast agent is used to improve the quality of ultrasound imaging and is infused over 5-10 minutes. The contrast agent consists of the gas-filled microbubbles smaller than the capillary size which circulate in the vascular system. The contrast agent is cleared from the body naturally within 30 minutes.
40753426|NCT00033475|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40753427|NCT02883933|OTHER|Data collection|
40753428|NCT06253429|DRUG|Thioctic Acid 333 MG Oral Capsule|Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes
41120111|NCT00738699|DRUG|0.9% Saline|Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
41120112|NCT00738699|DRUG|Paclitaxel|
40753429|NCT06253429|DRUG|Captopril 25Mg Tab|Oral angiotensin-converting enzyme inhibitors
40753430|NCT05897502|BEHAVIORAL|multimedia education|"The experimental group use multimedia education, 20 minute nutrition education courses each time, a total of 8 courses.~The control group use routine education."
41120113|NCT00566072|BEHAVIORAL|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
41120114|NCT04204993|DEVICE|Lumee Oxygen Platform|Two sensors will be inserted (one in the skin fo the upper arm and one on the side of the chest). A wireless patch reader is placed on top of the skin over the area where the sensor has been placed to measure local oxygen content.
41120115|NCT01876602|BEHAVIORAL|feeling states exercise intervention|exercise prescription based on intensity of exercise that feels good.
41120116|NCT04093752|DRUG|Tirzepatide|Administered SC
41120117|NCT04093752|DRUG|Insulin Glargine|Administered SC
41120118|NCT02200523|DEVICE|SARA electrode|
41120119|NCT02200523|DEVICE|Gold cup|
41120120|NCT04008550|PROCEDURE|Right Heart Catheterization|A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)
41120121|NCT05966350|DIAGNOSTIC_TEST|Diagnosis of sensitive neuronopathy - phase 1|Search of positivity with anti-AGO antibodies test
41120122|NCT05966350|DIAGNOSTIC_TEST|Diagnosis of sensitive neuronopathy - phase 2|Title of anti-AGO antibodies
41120123|NCT05966350|OTHER|Comparison with Chi2 method|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a Chi2 method for qualitative data.
41120124|NCT05966350|OTHER|Comparison of data with parametric Test (T-test)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography, evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a parametric test (T-test).
41272385|NCT06256848|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
41120125|NCT05966350|OTHER|Comparison of data with non-parametric test (ANNOVA)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a non-parametric (ANNOVA).
41120126|NCT03381053|DRUG|Imatinib 400mg|The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
41120127|NCT00332241|DRUG|Aripiprazole|Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks
41272386|NCT03374280|DRUG|pemetrexed/cisplatin intercalating gefitinib|
41272387|NCT03374280|DRUG|pemetrexed/cisplatin|
41272388|NCT02899169|DRUG|Realgar-Indigo naturalis formula|
41272389|NCT02899169|DRUG|all-trans retinoic acid|
41272390|NCT02899169|DRUG|Arsenic trioxide|
41272391|NCT02899169|DRUG|Hydroxyurea|
41272392|NCT03812510|DRUG|A-101|hydrogen peroxide topical solution 45%
41272393|NCT01834404|DRUG|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
41272394|NCT01834404|DRUG|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
41272395|NCT02670876|BEHAVIORAL|Anti-bullying intervention|"The title of each session were as follows :~1. Introduction of intervention and setting rules, building rapport~2. Understanding school bullying (The definition of school bullying and proper coping strategies)~3. Empathy of others ( Practice of understanding victims of school bullying)~4. Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)~5. Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)~6. Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)~7. Communication skills enhancement~8. Increasing self esteem"
41272396|NCT00008385|OTHER|placebo|Given orally
41272397|NCT00008385|DRUG|selenium|Given orally
41272398|NCT03917121|DEVICE|Jet injector|"* The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using Madajet XL injector as per the manufacturer's instructions.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
41272399|NCT03917121|DEVICE|Needle attached dental syringe|"* The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using standard needle-attached syringe in a classical local infiltration.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
41272400|NCT04239846|DRUG|AC-701 Topical Gel 0.3%|AC-701 Topical Gel 0.3%, BID
41272401|NCT04239846|OTHER|Placebo Gel|Placebo Gel, BID
41272402|NCT02291211|DRUG|S-1 plus cisplatin HIPEC|Using cisplatin in HIPEC plus oral S-1
41272403|NCT01886118|PROCEDURE|Endometrial biopsy|A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle
41120128|NCT00332241|DRUG|Placebo|Tablets, Oral, once daily, 8 weeks
41272404|NCT01886118|OTHER|Autologous Endometrial Co-Culture|embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5
41272405|NCT01886118|OTHER|Conventional media culture|embryos are cultured in conventional media
41120129|NCT00014040|DRUG|Nitric Oxide and INOpulse Delivery System|
41272406|NCT03677674|OTHER|Dehydration|Participants will be dehydrated (2% of their body weight) using sauna.
41272407|NCT03766425|DRUG|Aflibercept|subconjunctival injection
41272408|NCT03766425|DRUG|Mitomycin|subconjunctival injection
41272409|NCT04766866|DIAGNOSTIC_TEST|sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation|A ratio cutoff of \>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
41272410|NCT05340972|DIAGNOSTIC_TEST|MEESSI score|The score aimed to predict the AHF patient's future in the month following management for ED
41272411|NCT01624584|BEHAVIORAL|Experimental treatment|six sessions of child anxiety treatment
41272412|NCT01624584|BEHAVIORAL|Traditional Treatment|six sessions of treatment consistent with current practice
41272413|NCT04595565|DRUG|Capecitabine|2000 mg/m² day 1-14 q21 day cycle for eight cycles
41272414|NCT04595565|DRUG|Carboplatin|AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles
41272415|NCT04595565|DRUG|Cisplatin|25mg/m3 weekly or 75 mg/m3 q3w
41272416|NCT04595565|DRUG|Sacituzumab govitecan|10 mg/kg body weight on days 1, 8 q3w
41272417|NCT02055625|BIOLOGICAL|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.
41272418|NCT01150487|PROCEDURE|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
41272419|NCT01150487|PROCEDURE|lymph node collection|An Iliac lymph node collection.
40926421|NCT06401213|BIOLOGICAL|MTX-463|MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.
40926422|NCT06401213|OTHER|Placebo|Matching Placebo-- Normal Saline
41120130|NCT03046810|DEVICE|Wellness toileting system|This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
41120131|NCT00027729|BIOLOGICAL|etaracizumab|
41120132|NCT01866215|OTHER|exercise|cycling at 100W during 60 min
41120133|NCT01866215|DIETARY_SUPPLEMENT|fructose|isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
41272420|NCT01523821|DRUG|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]|Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days
41272421|NCT03406533|DRUG|Midazolam|Midazolam is used as a common medication for sedation in all groups.
41272422|NCT03406533|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
41272423|NCT03406533|DRUG|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
41272424|NCT03406533|DRUG|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
41272425|NCT03406533|DRUG|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
40753431|NCT05853159|OTHER|Basic Laboratory investigations , Cerebrospinal fluid analysis|to detect severity and prognostic factors of Acute Necrotizing Encephalopathy
40753432|NCT02222181|OTHER|Pharmacotherapy Management|"* assessment of patient characteristics as alcoholic, smoker, food, drugs~* Pharmacotherapy follow-up~* to evaluated medication adherence~* Assessment of the individual clinical parameters each patient at baseline and after the educational or pharmacy intervention."
40753433|NCT06454487|OTHER|Isometric Hand Grip Training|IHG training will be performed with an inflatable ball three days per week for 12 weeks (with at least a day of rest between each session) with intensity set based on RPE (Borg CR-10 scale).
40926423|NCT03093584|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
41120134|NCT01866215|DIETARY_SUPPLEMENT|glucose|isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
41120135|NCT05876013|PROCEDURE|ACL reconstruction|Randomized between hamstring and patellar tendon graft
41120136|NCT04775654|DIETARY_SUPPLEMENT|Blackcurrant|Two capsules containing 455mg of CurrantCraft 11% black currant extract.
41120137|NCT04775654|OTHER|Placebo|Two capsules containing an inert material.
41120138|NCT04353310|DRUG|Curcumin|Curcumin 1500mg PO BID
41120139|NCT04353310|OTHER|Placebo|identical in appearance to curcumin
41120140|NCT05953870|OTHER|Music Therapy|slower tempo music that can quiet mind and make patients feel soothed
41120141|NCT00002380|DRUG|Nelfinavir mesylate|
41120142|NCT00002380|DRUG|Saquinavir|
41120143|NCT00432718|PROCEDURE|Saline Instillation before Tracheal Suctioning|
41272426|NCT04980131|DEVICE|Pointed lotus root regulator and guide template aided PPSF|20 patients in group C received PPSF with pointed lotus-style regulator
41272427|NCT04980131|DEVICE|Flat ended lotus root regulator and guide template aided PPSF|20 patients in group B received PPSF with flat ended lotus-style regulator
41272428|NCT02570373|DRUG|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
41446379|NCT06626893|BIOLOGICAL|Functional tests|Functional analyses will be performed on primary sample from each enrolled patient. Isolated blast cells are cultered and incubated with a specific library of drugs (175 drugs) at four different concentrations for 72 hours.
40926424|NCT03093584|BEHAVIORAL|Expressive writing|Expressive writing is a standard psychological method in treatment of exam anxiety
40926425|NCT04531774|BEHAVIORAL|RECHARGE|"RECHARGE is an abbreviated and adapted version of Problem Management Plus (PM+), an evidence-based intervention that helps to cope with stress in times of crisis. Recharge is specifically developed for HCWs as a brief psychological intervention for adults affected by adversity emerging from stress exposure and teaches people three well-documented strategies to manage acute stress. The strategies are: a) managing stress, b) managing worry, c) meaningful activity. It includes psychoeducation, arousal reduction techniques, managing worries and problem-solving skills, behavioural activation, enhancement of meaningful activities, and relapse prevention, which are all based on the principles of cognitive-behavioural therapy.~RECHARGE is delivered online in a 1 to 1 setting between coach and participant. Trained peers (medical doctors, nurses, psychologists) act as coaches."
40753434|NCT06454487|OTHER|CR|Standard of Care
41120144|NCT00925210|PROCEDURE|Sequential pEBUS - ENB|"Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.~If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected."
41120145|NCT00060684|DRUG|Pixantrone (BBR 2778)|
41120146|NCT00060684|DRUG|fludarabine|
41120147|NCT00060684|DRUG|dexamethasone|
41120148|NCT00060684|DRUG|rituximab|
41120149|NCT05193786|PROCEDURE|Different level of PEEP|Different level of PEEP (low versus high) was applied in noninvasive ventilation.
41120150|NCT00925977|DRUG|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
41120151|NCT00925977|DRUG|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
40753435|NCT02441257|PROCEDURE|control ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
40926426|NCT04531774|BEHAVIORAL|Self Study|HCWs are referred to a few recommended webpages that outline well-validated, adaptive coping strategies for managing stress.
40926427|NCT00000931|BEHAVIORAL|Behavioral intervention|
41120152|NCT04124042|BIOLOGICAL|XT-150|plasmid DNA
41120153|NCT04124042|DRUG|Placebo|Placebo is a sterile phosphate-buffered saline
41120154|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
41120155|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
41120156|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
41120157|NCT01316731|OTHER|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
41120158|NCT00044863|BIOLOGICAL|Erbitux (Cetuximab)|400 mg/m2 initial dose, 250 mg/m2 weekly
41120159|NCT05282472|DIAGNOSTIC_TEST|CPET without mask|Regular cardiopulmonary exercise tests were applied to all participants in phase 1.
41120160|NCT05282472|DIAGNOSTIC_TEST|CPET with mask|A 3-layer surgical mask was placed on CPET device's mask and was fixed with a CPET tribune. In phase 2, as using this combined (surgical mask and device's mask) masks, CPETs were performed in all participants again, after 48 hours.
41120161|NCT06519682|DRUG|Nivolumab|All patients will be administered Nivolumab with or without radiation
41120162|NCT06519682|RADIATION|Radiation|Radiation
41120163|NCT04425616|OTHER|Exercise|"At least one and up to three supervised sessions per week including:~* aerobic exercise at a rating of perceived exertion of 11-14 (6-20 scale) accumulating 20 minutes per session~* resistance exercise of 8-10 exercises for 2x 8-15 repetitions performed in a controlled manner and covering the whole body~* Range of motion exercise performed through pain free range of motion covering the whole body to be maintained in good alignment for 10-30 seconds, with some movements held for a second set of 10-30 seconds if stiff"
41120164|NCT04425616|BEHAVIORAL|Psychological and Behaviour Change Support|Instructors will be trained in Healthy Conversation Skills (HCS), Making Every Contact Count (MECC) or equivalent. This will enable them to deliver brief participant centred empowering interventions informed by social cognitive theory. This skill set will be used to support participants in adopting and maintaining the prescribed exercise and diet programme as well as adopting and practicing strategies to self-manage psychological well-being. Participants will be given the option to be provided with a SMARTER goal setting sheet to assist with goal planning. Applicable standardised psychological support resources will be made available to the participants though the Macmillan resource repository that they can access online or in alternative format as necessary, for example relaxation and mindfulness exercises
41272429|NCT04321161|DRUG|Bicanorm|"Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)"
41272430|NCT00940277|BEHAVIORAL|Group Counseling|Group counseling
41446380|NCT06626893|GENETIC|Next Generation Sequencing analysis|For each patient, sequencing analyses will be performed on blast cells (for somatic mutations) and on epithelial cells from buccal swab (for germline mutations)
41446381|NCT06626893|BIOLOGICAL|Microvesicles analysis|Analyses on microvesicles isolated from both Bone Marrow samples and Peripheral Blood Samples will be performed to investigate the microenvironment of the disease.
40753436|NCT02441257|PROCEDURE|spontaneous ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
40753437|NCT03451305|OTHER|Pillow|A soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position
40926428|NCT00000931|BEHAVIORAL|Risk-reduction counseling|
40926429|NCT01910077|DRUG|Tacrobell capsule 1mg|1 capsule, oral, over the period I\&II(crossover)
40926430|NCT01910077|DRUG|Prograf capsule 1mg|1 capsule, oral, over the period I\&II(crossover)
41272431|NCT06441708|OTHER|No intervention|No intervention on patient
41272432|NCT01023282|DRUG|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
41272433|NCT01023282|DRUG|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
41272434|NCT05397236|DRUG|Bupivacaine- Magnesium|Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.
41272435|NCT05397236|DRUG|Bupivacaine dexamethasone|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
41272436|NCT05397236|DRUG|Bupivacaine saline|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
41272437|NCT01717534|DIETARY_SUPPLEMENT|heat-treated lactobacilli or placebo|Daily supplement of sachet with 1 g of powder over a 5 months period.
41272438|NCT01990261|DRUG|Erlotinib|Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
41272439|NCT02487875|OTHER|rehabilitation|
41272440|NCT02406157|DEVICE|577-MPL|Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
41120165|NCT04425616|OTHER|Nutrition|Instructors will receive training in generic nutritional principles in line with recommendations from World Cancer Research Fund (WCRF) and British Dietetic Association, and will work with participant to review own diet and eating habits against WCRF recommendations to enable goal setting and identify links to existing resources reputable websites, outputs and on-line forums. These would include: principles of healthy eating ('eat well' advice), weight management, symptom management, prehab advice before treatment starts, rehab advice during and after treatment. The participant will be asked if they are eating and drinking well or have any concerns at the beginning of each exercise session. Further support will be provided to instructors to address participant concerns or requests for additional information.
41120166|NCT00765271|DRUG|Abacavir|"Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study"
41120167|NCT00765271|DRUG|Darunavir/ritonavir|"Group 1 will be instructed to take~• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)"
41120168|NCT00765271|DRUG|Raltegravir|"Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)"
41272441|NCT02406157|DEVICE|532-SLP|Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
41272442|NCT01895530|DIETARY_SUPPLEMENT|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
41272443|NCT06085183|OTHER|Saline Injection 0.9%|Placebo
41446382|NCT03319394|BEHAVIORAL|The First Twenty|The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.
41446383|NCT03319394|BEHAVIORAL|Comparison|Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
41446384|NCT01665495|PROCEDURE|Extended pericardial drainage by catheter|Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return\<30 ml.
40926431|NCT05062434|OTHER|Academic detailing and audit and feedback intervention|An academic detailing and audit and feedback intervention will be presented to VA cardiac electrophysiologists, and will include quantitative data about the individual physician's facilities cardiovascular implantable electronic device lead implants and national data on lead implants over the past year.
40926432|NCT00156156|DRUG|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for up to 2 years
41120169|NCT00268671|DRUG|Docetaxel|
41120170|NCT02795754|DRUG|GSK2838232 PIB|GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.
41272444|NCT06085183|DRUG|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
41272445|NCT03180814|OTHER|Whole Body Vibration|A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
41272446|NCT05350787|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
41272447|NCT01705691|DRUG|Paclitaxel|80 mg/m2 IV over 60 minutes weekly for 12 weeks
41272448|NCT01705691|DRUG|Eribulin|1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles
41272449|NCT01705691|DRUG|Doxorubicin|60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
41272450|NCT01705691|DRUG|Cyclophosphamide|600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
41272451|NCT05309447|OTHER|data collection|The study entails the collection of clinical, functional, radiological, and biomechanical data.
41272452|NCT03664726|BEHAVIORAL|Episodic Future Thinking|Participants will be instructed to use their episodic future cues as they engage in different decision making tasks.
41272453|NCT03664726|BEHAVIORAL|Episodic Recent Thinking|Participants will be instructed to use their episodic recent cues as they engage in different decision making tasks.
40753438|NCT04947904|OTHER|Reduction of the patient's fluid intake during the first 7 days|The volume of fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in the intensive care unit according to a protocol with instructions to reduce fluid intake as far as possible in terms of maintenance fluids, dilution of medication and artificial nutrition. This protocol will be begun immediately following the patient's inclusion on Day 1 and pursued for 7 days after inclusion (i.e. from Day 1 - to Day 7). The fluid restriction strategy does not involve the administration of any medication (i.e. diuretics). A clinical pharmacist will help the intensive care teams apply the fluid restriction protocol with a daily check. If the restrictive strategy leads to hypovolemia and / or a electrolyte anomaly (sodium, potassium, chloride, etc.), the physician in charge will be authorised to treat these anomalies in conformance with the protocol recommendations.
41120171|NCT02795754|DRUG|GSK2838232 IR1|GSK2838232 will be available as film-coated tablet for oral use
41120172|NCT02795754|DRUG|GSK2838232 IR2|GSK2838232 will be available as film-coated tablet for oral use
41120173|NCT02795754|DRUG|Placebo PIB|Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
41120174|NCT02795754|DRUG|Ritonavir|It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
41120175|NCT00367159|PROCEDURE|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
41120176|NCT03348917|DRUG|7.5% Povidone-Iodine [PVP-I]|Betadine® 7.5% skin cleanser (PVP-I 7.5%)
41120177|NCT03348917|DRUG|4% chlorhexidine skin cleanser|Unity antiseptic hand wash (no alcohol)
41120178|NCT03348917|DRUG|Plain non antibacterial soap|Guardian gel hand wash (not medicated),
41120179|NCT02250235|OTHER|Health risk information|
41120180|NCT02467166|DEVICE|Circa™ Probe|The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
41120181|NCT05012241|DIAGNOSTIC_TEST|Nine Hole Peg Test|At first, each patient will be asked to fill in the questionnaire. Then he/she will be tested by the Nine Hole Peg Test according to the new Czech version of extended manual for this test. Audio recording of verbal instructions will be used.
41120182|NCT04133298|PROCEDURE|Tunneling with laser de-epithelized gingival graft|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
41120183|NCT04133298|PROCEDURE|Tunnelingwith subepithelial connective tissue graf|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid
41120184|NCT03230786|DRUG|Daily injection of KBP/placebo for 12 weeks as add-on to metformin|Daily subcutaneous injection
41120185|NCT00018785|PROCEDURE|donor bone marrow infusion|
41120186|NCT01323231|BEHAVIORAL|XY-Zone|"The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i)."
41120187|NCT04257071|BEHAVIORAL|Usual Care|The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.
41120188|NCT04257071|BEHAVIORAL|OOP Cost Communication and Optimization|OOP Cost Communication and Optimization includes personalized discussion of OOP cost estimates for treatment plan obtained through an online price transparency tool, personalized analysis of patients' expenses by financial counselor, and patient enrollment in any cost optimization opportunities for which patient is eligible using a comprehensive financial navigation program.
41120189|NCT03570437|DRUG|Paclitaxel|80 mg/m2 on three days in a 28 day cycle (with 6 cycles)
41120190|NCT03570437|DRUG|Cediranib|20 mg per day
41120191|NCT03570437|DRUG|Olaparib|Olaparib tablets, 300 mg twice-daily
41120192|NCT02729701|DRUG|Duavee|Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
41120193|NCT04717544|BEHAVIORAL|Intervention Arm|The smoking cessation intervention will include 1) a six-week, 60-75 minute weekly cognitive-behavioral therapy (CBT) smoking cessation counseling group; and 2) smoking cessation medication include varenicline (Chantix), bupropion (Zyban) and nicotine replacement therapy (NRT). Dispensing these medications will include a 15-minute medication management visit with a prescribing clinician. Clients will choose their own preferred treatment. The standard prescription for NRT will include a transdermal patch at a dose that approximates for current average mg of nicotine intake and nicotine gums or lozenges (in either 2 mg or 4 mg strengths). Prescription for varenicline will be 0.5 mg once daily for three days, then 0.5 mg twice daily for the next four days, then 1 mg twice daily thereafter. Absent any contraindications to the drugs listed above, bupropion (Zyban) 150mg will be offered and prescribed once daily for one week, following by bupropion 300 mg once daily thereafter.
41120194|NCT04406792|BEHAVIORAL|DPP only|Participation in the online DPP only with a mixed group of participants at risk for type 2 diabetes and doula divas are not the team leaders.
41446385|NCT06023433|DEVICE|Elastomeric powerchain|Canine distalization by engaging the elastomeric power chains onto the canine brackets.
41446386|NCT05894148|DRUG|Genakumab injection|Group 1: 120mg Q4W，group 2: 200mg Q4W
41446387|NCT05894148|DRUG|placebo|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
41120195|NCT04406792|BEHAVIORAL|Diabetes Prevention Program (DPP) online + doula divas|Participation in the DPP online intervention with doula divas as team leaders.
41120196|NCT05616754|BIOLOGICAL|Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|The antigen protein of this product is designed to be expressed in tandem with Delta variant R319-N356 and Omicron variant R319-N356. The antigen is called DO-RBD for short.
41272454|NCT03664726|BEHAVIORAL|Scarcity Narrative|Participants will read a narrative to induce a scarcity mindset, in which they are asked to imagine a scenario in which they have lost their job and have no current secondary income.
41272455|NCT03664726|BEHAVIORAL|Neutral Narrative|Participants will read a narrative in which they are asked to imagine a scenario in which they have been transferred between departmental jobs, with little change in salary/commute.
41272456|NCT04824378|OTHER|No Intervention.|No Intervention.Only learn ICG image features of different label groups
41272457|NCT05257122|DRUG|Fruquintinib|Fruquintinib 5mg qd, d1-21, q28d
41272458|NCT06158243|OTHER|Sono-anatomical Study|The arm is abducted (90°), externally rotated, with the forearm flexed over the arm (90°). A linear ultrasound probe (8-15 MHz) is placed in front of the humeral head, in a sagittal plane. Location begins at axillary level, vessels, nerves and humerus are identified, and the probe is moved medially to reach and identify the humeral head.
41272459|NCT00188188|DRUG|quinipril|
41272460|NCT05660122|DRUG|Fexuprazan Hydrochloride|Fexuclue Tablet 40mg
41272461|NCT03505268|BEHAVIORAL|Telemedicine|Patients of the Intervention Group will have once biweekly telephonic intervention conversation with dietitian, specialized in diabetes and diabetes nurse. The patients of the control group will have a routine care.
41272462|NCT05390216|PROCEDURE|Partial capsule decortication|The anterior wall of the capsule was removed during the operation.
41272463|NCT03011229|DEVICE|Pro Core Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
41272464|NCT03011229|DEVICE|medtronic Sharkcore Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
41272465|NCT05634902|BEHAVIORAL|CME Educational Intervention|The educational materials for physicians include a recorded CME session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness.
41272466|NCT05634902|BEHAVIORAL|Study Developed Educational Materials for Patients|Patient-oriented materials are incorporated into a mobile responsive website with information/instruction about BPPV, and self-management resources; information/instruction on gaze stabilization exercises for vestibular neuritis
41272467|NCT02970617|OTHER|Memory Intervention|Ring bell after final radiation treatment
41272468|NCT02970617|OTHER|Questionnaire Administration|Ancillary studies
41272469|NCT02970617|RADIATION|Radiation therapy|Radiation therapy with or without chemotherapy
41272470|NCT02582671|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
41272471|NCT02582671|DRUG|Dasabuvir|Tablet
41272472|NCT02582671|DRUG|Ribavirin|Tablet
41446388|NCT00598052|DRUG|Escitalopram|10mg/day
40926433|NCT00156156|DRUG|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
41120197|NCT05616754|BIOLOGICAL|Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|This strain was made from the NCP-RBD receptor binding region of the spike glycoprotein of novel coronavirus expressed in recombinant CHO cells, which was purified and added with aluminum hydroxide adjuvant
41120198|NCT02579031|DEVICE|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
41120199|NCT02579031|DEVICE|Xience|Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
41120200|NCT06154694|RADIATION|Stereo Radiographic EOS Measurements|"Healthy control will undergo a stereo radiographic EOS exam with their arm in various positions.~1. Relaxed standing (0 degree of abduction)~2. 45 degree of abduction in the coronal plane~3. 90 degree of abduction in the coronal plane~4. 120 degree of abduction in the coronal plane~5. 45 degree anterior flexion in the sagittal plane~6. 90 degree anterior flexion in the sagittal plane~7. 120 degree of anterior flexion in the sagittal plane~8. 45 degree extension in the sagittal plane"
41120201|NCT02093312|DIETARY_SUPPLEMENT|Home food-delivery service|A home food-delivery service is offered the intervention group of cancer patients
41446389|NCT01689077|OTHER|Therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
40753439|NCT03152890|DRUG|Insulin|If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
41446390|NCT01370122|OTHER|Survey|
41272473|NCT05422092|DRUG|Canagliflozin|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive canagliflozin on top of metformin as experimental group.
41272474|NCT05422092|DRUG|Pioglitazone|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive pioglitazone 45mg on top of metformin as placebo comparator group.
41272475|NCT04927273|OTHER|Survey|Surveyed neurological and orthopedic surgeons
41272476|NCT05907707|DEVICE|Gamma transcranial alternating current stimulation|tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).
41272477|NCT05907707|DEVICE|Control transcranial alternating current stimulation|tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).
41272478|NCT05907707|DEVICE|EEG headband|At-home, ambulatory, single-channel EEG headband which records brain activity during sleep
41272479|NCT05907707|DEVICE|Actigraphy wristband|At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day
41272480|NCT04004949|OTHER|Assessment of scapular balance angle and upper extremity sensorimotor function|The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores \& scapular balance angle test (SBA).
41446391|NCT04836494|DRUG|BBP-671|BBP-671, oral suspension
41446392|NCT04836494|DRUG|Placebo|Placebo matching BBP-671
41120202|NCT04048382|BEHAVIORAL|Patient Navigation|Spanish-English bilingual peer lay navigators hired by Family Health Centers of San Diego will provide the PN intervention during the study, trained using manuals developed in formative research and via the Patient Navigation Research Program training approach. Services will generally focus on: 1) overcoming community, health system, interpersonal, and individual barriers to accessing PrEP-related healthcare; 2) increasing each patient's knowledge, attitudes, and self-efficacy for initiating and adhering to PrEP; 3) improving communication between the patient and healthcare team through appointment scheduling and reminders; and 4) sexual risk reduction counseling.
41272481|NCT01912755|DRUG|4% articaine with 1:100,000 epinephrine|If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
41272482|NCT01912755|DRUG|2% lidocaine with 1:100,000 epinephrine|If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
41120203|NCT04048382|OTHER|Usual Care|The booklet given is a 2-page booklet including the following information: 1) overview of PrEP; 2) eligibility for PrEP; 3) efficacy of PrEP; 4) safety of PrEP; and 5) obtaining, initiating, and adhering to PrEP. Participants will also be provided with both verbal and written information regarding available sexual health and HIV prevention services, including PrEP, at Family Health Centers of San Diego (FHCSD). Comprehensive HIV-prevention healthcare, including PrEP, is available to study participants at FHCSD at no or minimal cost. If a UC participant is diagnosed with a sexually transmitted infection, including HIV, treatment and follow-up will be coordinated by FHCSD staff as per usual care procedures.
41272483|NCT03939234|COMBINATION_PRODUCT|PD-L1, PD-L2 peptides with Montanide ISA51|PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
41272484|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
41272485|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
41272486|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
41272487|NCT02036320|DEVICE|etafilcon A|Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
41272488|NCT00908284|BEHAVIORAL|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
41272489|NCT00908284|BEHAVIORAL|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
41272490|NCT04626063|DRUG|Magnesium|Patients were treated with etodolac 400mg twice a day plus magnesium oral supplementation once a day for acute low back pain and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
41272491|NCT04626063|DRUG|NSAID|Patients were treated with etodolac 400mg twice a day for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
41272492|NCT04626063|DRUG|paracetamol|Patients were treated with etodolac 400mg twice a day plus 500mg paracetamol twice a day paracetamol for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
41272493|NCT03135886|OTHER|Information Control|The OTPs assigned to this group will be provided access to the NIDA/SAMHSA Blending Initiative product for HIV rapid testing. Resources generated from the HIV rapid testing Blending Initiative product include a fact sheet, resource guide, marketing materials, and an Excel-based budgeting tool. In addition to the HIV-specific materials, the website provides opportunities for training, self-study progress, workshop, and distance learning. OTPs also will receive a link to the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention training website which provides information and training courses. Sites also will receive a hard (or electronic) copy of the ARTAS implementation manual and information about the provision of HIV testing, linkage to care and PrEP.
41272494|NCT03135886|OTHER|HIV and HCV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the program team a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV and HCV testing and evidence--based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV and HCV testing. Also, due to the expense of HCV treatment, and potentially more complicated mechanisms for linking HCV-positive patients to further evaluation and care which may take more time than anticipated, PCs will provide OTPs with basic education and motivation about the importance of HCV testing for reasons other than immediate curative treatment. Information on PrEP also will be provided. The intervention will occur over approximately 29 weeks (or 6 months).
41446393|NCT04836494|DRUG|BBP-671|BBP-671, tablet
41446394|NCT05048797|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan administered by intravenous infusion
41446395|NCT05048797|DRUG|Cisplatin|Investigator's choice of platinum chemotherapy (cisplatin) administered by intravenous infusion
41446396|NCT05048797|DRUG|Carboplatin|Investigator's choice of platinum chemotherapy (carboplatin) administered by intravenous infusion
41446397|NCT05048797|DRUG|Pembrolizumab|Pembrolizumab administered by intravenous infusion
41446398|NCT05048797|DRUG|Pemetrexed|Pemetrexed administered by intravenous infusion
40753440|NCT03209583|DEVICE|Medtronic|Pacing is done by the implanted device after seeing how the electrical system is functioning giving energy when needed to maintain a stable state or rhythm
40753441|NCT03861507|DEVICE|Prostate Brachytherapy|High dose - rate (HDR) brachytherapy
40753442|NCT00300495|DRUG|Amiodarone|Perioperative orally administered
41120204|NCT06384820|DRUG|cemiplimab|Administered Intravenous (IV) infusion every three weeks (Q3W)
41120205|NCT06384820|DRUG|fianlimab|IV infusion Q3W
41272495|NCT03135886|OTHER|HIV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the programs a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV testing and evidence-based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV testing. Information on Pre-Exposure Prophylaxis (PrEP) also will be provided. The intervention will occur over approximately 29 weeks (or 6 months) consisting of four distinct evidence-based phases designed to establish competency in the implementation of organizational change towards establishing HIV testing outcomes among OTP clientele.
41272496|NCT04673981|DIAGNOSTIC_TEST|diagnostic tes for neuropathic pain|Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
41272497|NCT01360203|OTHER|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
41272498|NCT00846742|DRUG|Stanford V Chemotherapy|The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
41446399|NCT00725322|DRUG|Botulinum Toxin A|Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
41446400|NCT00725322|DRUG|Placebo - Saline|Subcutaneous Saline injection given at site of scar neuroma
40753443|NCT00300495|OTHER|Control arm, standard care|Control
40753444|NCT02746731|OTHER|Cardiorespiratory and resistance training.|"A cardiorespiratory and resistance training program for at least 2 to 3 weeks will be conducted 3-times per week, of which two sessions will be supervised by a qualified person of the institute of physiotherapy and one session will be unsupervised and home-based.~Physiotherapy consists of one hour, moderate to intense interval training combined with muscle strength training."
41120206|NCT06285786|OTHER|Ergonomic Training on Patient Handling Techniques|"Each participant will receive an ergonomic training on proper patient handling technique, adhering to the appropriate program to use with the SAMS bed and the Vendlet between session 1 \& 2.~In small groups of 6-10 participants, a healthcare ergonomist (M. Leger) will be responsible to demonstrate, instruct and evaluate each participant on all 4 techniques on the SAMS bed. Each participant will have multiple opportunities to demonstrate their skills.~In the same session, each participant will also receive proper training from a specialized occupational therapist on how to use the Vendlet. Each participant will have multiple opportunities to demonstrate their skills.~After completing the intervention, each participant will be prepared to participate in the post-intervention data collection session in the laboratory."
41120207|NCT02205853|OTHER|The patient-directed (PD) strategy|The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.
41120208|NCT02205853|OTHER|The multi-faceted (MF) strategy|The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
41120209|NCT01006824|OTHER|Capsule endoscopy|Capsule endoscopy
41120210|NCT01006824|OTHER|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
41120211|NCT01976312|OTHER|Sham injection|Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
41120212|NCT01976312|DRUG|Ranibizumab 0.5 mg|Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
41120213|NCT03067142|OTHER|Observational|Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
41120214|NCT05032534|DEVICE|Cone Small, Qufora A/S|Newly developed cone in a softer material and a design matching the use for transanal irrigation.
41120215|NCT05032534|DEVICE|Colotip, Coloplast A/S|Cone currently used for transanal irrigation at the Pediatric Ward, Aarhus University Hospital.
41120216|NCT00424086|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, vero cell derived)|
41120217|NCT00424086|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]|
41120218|NCT04826094|BIOLOGICAL|Env-C Plasmid DNA|2 mg per dose. Administered by intramuscular injection.
41120219|NCT04826094|BIOLOGICAL|HIV Env gp145 C.6980 protein|100 µg per dose. Administered by intramuscular injection.
41120220|NCT04826094|DRUG|Rehydragel®|Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.
41120221|NCT04826094|BIOLOGICAL|ALF43|Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.
41120222|NCT04826094|BIOLOGICAL|dmLT|Adjuvant. Recombinant double mutant Escherichia coli heat labile toxin. 50 µg per dose. Transcutaneous application (needle-free skin patch). 1 mL diluted dmLT added to gauze pad at site of injection.
41120223|NCT04826094|DRUG|Placebo (IM)|0.9% sodium chloride (sterile saline). Administered by intramuscular injection.
41120224|NCT04826094|DRUG|Placebo (TCl)|Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.
41120225|NCT01549756|BEHAVIORAL|bulletin board and teleophone depth interview|qualitative based research
41120226|NCT00002542|DRUG|CMF regimen|
41120227|NCT00002542|DRUG|cyclophosphamide|
41120228|NCT00002542|DRUG|doxorubicin hydrochloride|
41120229|NCT00002542|DRUG|epirubicin hydrochloride|
41272499|NCT00846742|RADIATION|Radiation Therapy|Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
41272500|NCT05413330|DRUG|Triamcinolone Acetonide|Intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of phacoemulsification surgery will be injected at 3.5 mm inferolateral and posterior to the limbus.
41272501|NCT00058864|DEVICE|Energy absorbing and distributing trochanteric pad|
41272502|NCT03290014|DIAGNOSTIC_TEST|polysomnography|Monitoring of brain activity and respiratory variables during sleep
41272503|NCT03290014|DIAGNOSTIC_TEST|Actigraphy|monitoring daily physical activity for 7 days
41272504|NCT03290014|DIAGNOSTIC_TEST|Osler test|Evaluation of subjects´ ability to remain awake
41272505|NCT01755169|DRUG|Ketamine|Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
41272506|NCT01755169|DRUG|Placebo|
41272507|NCT01891643|DRUG|Lenalidomide|
41272508|NCT01891643|DRUG|Dexamethasone|
41272509|NCT01891643|BIOLOGICAL|Elotuzumab|
41272510|NCT03422484|OTHER|Detection and correction of medication error at hospital admission|Detection and correction of medication error at hospital admission
41272511|NCT00264407|DRUG|Hormone Replacement Therapy - HRT|
41272512|NCT02590393|COMBINATION_PRODUCT|E-cigarettes|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks.
41272513|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R|Intramuscular (IM) vaccination of 1 dose of 0.5 mL
41272514|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 25 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
41272515|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 50 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
41272516|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 100 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
41446401|NCT06562933|DEVICE|Sham vacuum|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. The vacuum electrodes will apply continuous vacuum mode for only 10 minutes without delivering interferential current. Following the sham vacuum therapy, a hot pack will be applied to the painful neck area for 20 minutes.
41272517|NCT02639351|BIOLOGICAL|Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)|IM vaccination of 1 dose of 0.5 mL
41272518|NCT05971849|DRUG|kisspeptin 112-121|IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin
40753445|NCT02746731|OTHER|Reference|No preoperative physical therapy training. Patients will be informed to remain physically active (as usual) until surgery.
40753446|NCT04919551|DRUG|vicagrel|Oral administration after fasting/high-fat meal/low-fat meal
41120230|NCT00002542|DRUG|fluorouracil|
41272519|NCT04199923|BEHAVIORAL|Single leg immobilisation|Immobilisation with single leg suspension immobilisation
41272520|NCT04178655|DRUG|Tranexamic acid injection|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
41272521|NCT04178655|DRUG|PLACEBO|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
41272522|NCT05352191|DRUG|Beclomethasone|inhaled 800ug
41272523|NCT04097548|BEHAVIORAL|CenteringPregnancy|Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
41272524|NCT00282243|DRUG|tacrolimus modified release (MR)|Oral
41272525|NCT00282243|DRUG|tacrolimus|Oral
41272526|NCT05422729|BEHAVIORAL|mHealth-supported coaching|The intervention includes two components. Three individual consultation sessions based on a health coaching protocol developed by a multidisciplinary team. A mobile application provides educational information about healthy lifestyles, knowledge quizzes, telemonitoring function and virtual platform for sharing.
41272527|NCT05422729|BEHAVIORAL|Conventional Health coaching|Three individual consultation sessions delivered by a nurse.
41272528|NCT03041727|OTHER|Fascial Manipulation|Fascial Manipulation is a manual therapy that focused on deep muscular fascial.
41272529|NCT03041727|OTHER|Standard exercises protocol|Stretching and strengthening exercises
40753447|NCT02145611|DRUG|Glibenclamide|Glibenclamide
41120231|NCT00002542|DRUG|methotrexate|
41120232|NCT00002542|DRUG|tamoxifen citrate|
41120233|NCT00002542|RADIATION|radiation therapy|
41272530|NCT00401440|DRUG|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
41272531|NCT00401440|DRUG|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
41272532|NCT00263926|BIOLOGICAL|wasp venom|
41272533|NCT04210479|PROCEDURE|Filled-bladder|Urinary bladder filling with 300 ml diluted methylene blue
41272534|NCT04210479|PROCEDURE|non filled-bladder|Pull up the empty (non-filled) urinary bladder using Allis forceps
41272535|NCT04233125|PROCEDURE|Core Decompression|Core Decompression
41272536|NCT04233125|PROCEDURE|PMMA augmentation|Polymethylmethacrylate (PMMA) augmentation
41272537|NCT00575861|DRUG|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
41272538|NCT00638872|DRUG|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
41272539|NCT00638872|OTHER|0.9% NaCl|same as PDRN
41272540|NCT02034123|DRUG|GSK2879552|Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
41272541|NCT03718247|OTHER|Modified Atkins diet|High fat low carbohydrate diet.
41446402|NCT06562933|DEVICE|Interferential Current Therapy Vacuum Electrodes|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the vacuum electrodes. After the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
40753448|NCT02145611|DRUG|Vildagliptin|Vildagliptin
40753449|NCT01494974|DEVICE|FP7 Ahmed Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP7
40753450|NCT01494974|DEVICE|FP8 Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP8
40753451|NCT02002195|DRUG|FOLFOX|Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
40753452|NCT02002195|DRUG|Capecitabine|Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
40753453|NCT00567112|DRUG|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
41272542|NCT05456750|DEVICE|Intravascular laser irradiation of blood|Low intensity intravenous laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
41272543|NCT03115450|DEVICE|Ultrasound|Type of imaging technology to look at organs and structures inside the body
41272544|NCT03115450|DEVICE|Pupilometer|A device that measures pupil size and how it changes.
40753454|NCT00567112|DRUG|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
41120234|NCT05712993|PROCEDURE|V2 thermal radio frequency|V2 targeted thermal radio frequency safely without sustained V3 stimulation
41120235|NCT01831700|DRUG|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
40753455|NCT00567112|DRUG|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
41120236|NCT01831700|DRUG|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
40753456|NCT00567112|DRUG|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
40753457|NCT06424535|OTHER|Chinese medicine for internal or external use、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application of traditional Chinese herbal medicinal cake|"The treatment project a Chinese medicine practitioner based individual needs of the patient, and will be followed by a four-week treatment.~1. Traditional Chinese medicine for internal or external use: prescribe Chinese medicine based on syndrome differentiation and treatment of the patient's condition.~2. Acupuncture or laser acupuncture treatment: Traditional Chinese medicine practitioners select acupuncture points to treat based on the patient's condition, and treat them twice a week for 20 minutes each time.~3. Acupoint massage: Select treatment acupoints and techniques according to the patient's condition, 20 minutes at a time.~4. Traditional Chinese Medicine Cake Acupoint Application: Warm Navel Cream to the CV-4 (Guanyuan) acupoint once a day~5. Nursing and health education and guidance~6. Dietary hygiene education: personalized western nutrition and TCM dietary guidance suggestions based on TCM constitution syndromes."
40753458|NCT06424535|OTHER|Western medicine|Patients will receive routine Western medicine treatments as per individual patient's needs. The medications and bandages can vary due to the depth and size of the burn and scald.
40753459|NCT03898609|OTHER|Dietary intervention|3 weeks
40753460|NCT03952520|OTHER|Standard Approach (SA)|The multifaceted implementation strategies for SA sites were identified through centralized Intervention Mapping. Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies was determined through a formal process with investigators, government stakeholders, and clinical representatives.
41272545|NCT02059824|DEVICE|Aesthesiometer|"The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.~If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period."
41272546|NCT00362973|OTHER|laboratory biomarker analysis|
41272547|NCT00362973|PROCEDURE|needle biopsy|
40926434|NCT05785481|DIAGNOSTIC_TEST|Clinical and instrumental neurological assessment|"During the neonatal period:~neurological objective exam according to the modified Sarnat score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation; an AEEG study within 6 hours of life, for 6 hours; cerebral ultrasound within 6 hours of life, in the third and seventh day of life; a brain magnetic resonance imaging study between the seventh and 14th day of life; an EEG evaluation within 7 days.~After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age:~Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements; evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month; EEG evaluation at the 6th and 12th month."
41120237|NCT04928703|DRUG|Ketamine|Ketamine IV administration
41272548|NCT00362973|PROCEDURE|positron emission tomography|
41120238|NCT05915546|DRUG|Emraclidine|Tablets
41120239|NCT04981158|PROCEDURE|(Epidural /GA using tolerable endotracheal tube (TET) group, group II|patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using TET, through its side port 2mg/kg , lidocaine 2% will be sprayed immediately after intubation when the patient is in flat supine position then the same dose of lidocaine will be repeated 10 minutes before anesthetic discontinuation.
41120240|NCT04981158|PROCEDURE|standard general anesthetic technique, control group, group I|patients will undergo standard general anesthesia with classic endotracheal tube
41272549|NCT00362973|PROCEDURE|radionuclide imaging|
41272550|NCT00362973|RADIATION|fludeoxyglucose F 18|
41272551|NCT03332069|DEVICE|Modulated electro-hyperthermia|Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH
41272552|NCT03332069|RADIATION|External beam radiation|
41272553|NCT03332069|DRUG|Cisplatin|
41272554|NCT03332069|RADIATION|Brachytherapy|High Dose Rate
41272555|NCT00525291|DEVICE|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
40753461|NCT03952520|OTHER|Tailored Approach (TA)|The Tailored Approach includes the multifaceted strategy that will be offered to the Standard Approach condition. It will also be tailored to match site-specific barriers to implementation of SNaP at that site. The strategy for TA sites involves a 2-day site-specific training, monthly coaching calls, and an external technical assistance hotline to help organizations to tailor implementation strategies to address their site-specific needs. At the 2-day TA training, the TA sites will be guided on developing site-specific implementation plans, in which they may use additional implementation strategies that they have identified themselves or selected from a list developed by the central team.
40753462|NCT05349773|PROCEDURE|Pneumatic tourniquet, endoscopic left radial artery harvesting|"Endoscopic radial artery harvesting technique is performed after applying a tourniquet over the distal arm proximally to the elbow. The tourniquet pressure is increased 90 mmHg over the systolic pressure and the tourniquet time will be monitored.~he changes in Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be assessed before and after deflating the tourniquet every 5 minutes for 30 minutes."
40753463|NCT00348374|DRUG|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
40753464|NCT00348374|DRUG|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
40753465|NCT00090402|DIETARY_SUPPLEMENT|Fish Oil|Fish oil capsule
40753466|NCT00090402|DIETARY_SUPPLEMENT|Lipoic Acid|Lipoic acid capsule
40753467|NCT00090402|OTHER|Fish Oil Placebo|Soybean oil placebo capsule
40753468|NCT00090402|OTHER|Lipoic Acid Placebo|Lipoic acid (LA) placebo capsule containing no LA
40753469|NCT05864716|BIOLOGICAL|Colonscopic probiotics spray|20g of multi-strain probiotics powder via colonoscopic spray. The probiotic used in this study is SynPro-15G, which has 15 probiotics, including Bacillus coagulans BC1031, Bifidobacterium bifidum BB14, Bifidobacterium breve BR18, Bifidobacterium animalis subsp. lactis BAL06, Bifidobacterium longum (B. longum) BL986, Lactobacillus acidophilus LA1063, Lactobacillus casei LC122, Lactobacillus delbrueckii subsp. lactis LDL114, Lactobacillus fermentum LF26, Lactobacillus helveticus LH43, Lactobacillus paracasei LPC12, Lactobacillus plantarum LP198, Lactobacillus reuteri LR21, Lactobacillus rhamnosus LRH10, and Streptococcus thermophilus ST37 at a concentration of 2x1010 CFU/g (Synbiotech Corp., Kaohsiung, Taiwan). SynPro-15G is made either as a vial of powder (2x1011 CFU /vial) for colonoscopic spray or as a capsule (2x1010 CFU/capsule) for oral intake.
40753470|NCT04341662|BEHAVIORAL|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination \& Escalation; and 3) an implementation strategy, focusing on simulation-based training with peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with trigger line, and MOTIVE emergency trolley and/or carry case."
40753471|NCT04341662|BEHAVIORAL|Usual care|Health facilities will continue to follow usual care as per the baseline period for the remainder of the intervention phase.
40753472|NCT03517293|BEHAVIORAL|Aerobic Exercise training|
40753473|NCT01457430|DRUG|Icatibant|30 mg subcutaneous dose of Icatibant
41120241|NCT05384691|DRUG|Luspatercept Injection|"All formally included patients will receive 1.75 mg/kg luspatercept administered subcutaneously every three weeks (on day 1 of each 21-day cycle) for a duration of 24 weeks.~Responders at the response assessment (according to HI-E) in week 25 will be further treated with 1.75 mg/kg luspatercept until loss of response for an expected maximum of 18 months."
41446403|NCT06562933|DEVICE|Interferential Current Therapy Carbon-silicon Pad Electrodes|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four carbon-silicon pad electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the carbon-silicon pad electrodes. Following the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
41446404|NCT04306952|BEHAVIORAL|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
40753474|NCT06362200|DEVICE|40 Hz tACS intervention|The central electrode is placed in the CP6 and the other four electrodes are placed around the CP6. 40 Hz tACS group participants will receive alternating current stimulation (40Hz, 2.0mA, 20min/time, three times a day, 40 times in total) for 1 week. Subjects in the placebo comparator group will receive sham tACS for 1 week, which mimics the tACS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs.
40753475|NCT03193307|DRUG|Microgynon® 30|Run in period \& Treatment Period
40753476|NCT03193307|DRUG|BI 409306|Day 18 \& 29 (Treatment Period)
40926435|NCT02648633|RADIATION|Stereotactic Radiosurgery|Subjects will receive a single large dose of radiation to one or more lesions.
41120242|NCT06328023|OTHER|SCOAT 6 to find association|we will use SCOAT 6 to find the association between concussion , sleep and physical performance
41120243|NCT00529100|DRUG|Pemetrexed Phase 1|300 mg/m\^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m\^2 IV; then 500 mg/m\^2 IV, repeated every 21 days (q 21 days) x 2 cycles
40753477|NCT02841631|GENETIC|HPV status and typing of tissue|HPV status and typing of tissue
41272556|NCT00525291|DEVICE|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
41446405|NCT04306952|BEHAVIORAL|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
41446406|NCT04306952|BEHAVIORAL|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours)."
41446407|NCT06090994|DRUG|Huaier granule|Oral administration, 10g once, 3 times a day, starting within 14 days-2 months after surgery. Please refer to the medication manual for specific usage.
41446408|NCT06090994|DRUG|Capecitabine|Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d),day 1-14,with one course of treatment every 3 weeks, for a total of 4-6 courses.
41446409|NCT01776138|OTHER|Collect Blood and Survey Instruments|
41446410|NCT02105220|OTHER|Respiratory mechanics assessment|Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
40753478|NCT00894647|DRUG|imiquimod cream|Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
40753479|NCT00894647|DRUG|placebo cream|cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
40753480|NCT02244528|DRUG|Sildenafil|
40753481|NCT03179709|BEHAVIORAL|Interview|The investigators will perform and analyze semi-structured interviews with enrolled participants.
40753482|NCT04755478|PROCEDURE|Thoracotomy|Participants will undergo lobectomy via open thoracotomy at the discretion of the surgical team.
41120244|NCT00529100|DRUG|Cisplatin Phase 1|"Cohorts 1-3: 25 mg/m\^2 IV, Days 1-3 and 22-24 then 75 mg/m\^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles."
41120245|NCT00529100|PROCEDURE|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
40753483|NCT04755478|PROCEDURE|VATS|Participants will undergo lobectomy via VATS at the discretion of the surgical team.
41120246|NCT00529100|DRUG|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22.
41120247|NCT00529100|DRUG|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
40753484|NCT06049277|OTHER|Mulligan techniques with manual traction|group A will be treated with Mulligan techniques with manual traction.16 patients in group A will be treated with Mulligan Techniques SNAGS in sitting, standing and prone position by applying Antero cranial glide in the direction of treatment plane over the spinous or transverse process and Spinal mobilization with leg movement at 6 to 8 repetitions per sessions and spinal mobilization with leg movement will be performed in side lying, patient facing the physiotherapist while the leg movement may assisted by another person (Physiotherapist/assistant). Sustained transverse glide is given on the desired spinous process with 10 repetitions of offending movement in first session while 10 reps in each of 3 sets in further sessions.
40926436|NCT02648633|DRUG|Nivolumab|3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
41120248|NCT03705234|DRUG|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
41120249|NCT03705234|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
41120250|NCT03107117|BEHAVIORAL|Computer Counseling|two computer counseling online programs for a teen and a parent
41120251|NCT03107117|BEHAVIORAL|Standard Care|A referral for substance use counseling
41120252|NCT02685969|PROCEDURE|18F-Flutemetamol & 18F-FDG|Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
41120253|NCT01179334|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
41120254|NCT01179334|DRUG|Placebo|Placebo for 12 weeks
40753485|NCT06049277|OTHER|McKenzie extension exercises with manual traction|group B will be treated McKenzie extension exercises with manual traction.16 patients in group B will be treated with McKenzie active EEP in prone position with repeated movements along with standard protocols. McKenzie Extension Exercises performed actively in prone position. Extension exercises performed in three stages, initially patient instructed to be just lift the neck and look on front at the eye level, then progressed next and weight bearing on the elbow by lifting up the shoulder and then moved on third and final steps in which complete trunk extension is performed and weight bearing is on the hands.
40753486|NCT03839680|PROCEDURE|Endoscopy|The endoscopy procedure uses an endoscope to examine the interior of a hollow organ or cavity of the body.
40753487|NCT04928638|BEHAVIORAL|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
40753488|NCT04928638|BEHAVIORAL|Written educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
40753489|NCT04612231|BEHAVIORAL|TEACCH School Transition to Employment and Postsecondary Education (T-STEP)|The T-STEP Program is a 12-week transition intervention targeting specific challenges that young adults with ASD experience in executive function, social communication, and emotion regulation including group intervention, internship, and counseling services
40753490|NCT04612231|BEHAVIORAL|Counseling Services Alone|The Counseling Services Alone Intervention will receive 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
40753491|NCT05766371|DRUG|Pembrolizumab|Given IV
40753492|NCT05766371|DRUG|177Lu-PSMA-617|Given IV
40753493|NCT01524458|PROCEDURE|Per-Oral Endoscopic Myotomy|To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
40753494|NCT00676689|DEVICE|SAPIEN Transcatheter Valve Implantation|Device Implantation
41272557|NCT02339467|OTHER|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
41272558|NCT02339467|OTHER|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
41272559|NCT03662295|BEHAVIORAL|Language treatment|Individual speech-language therapy sessions totaling 1.5 to 2.5 hours five days per week. Intervention activities include performing oral and written confrontation and responsive naming, writing single words to dictation, reading single words and sentences aloud, and generating written and spoken picture descriptions.
41272560|NCT00926926|DRUG|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
41272561|NCT00926926|DRUG|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
41272562|NCT00336102|OTHER|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
41272563|NCT00336102|PROCEDURE|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
41446411|NCT05434364|OTHER|Facilitated Tucking|giving facilitated tucking before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
40753495|NCT04903509|DRUG|BI 1820237|BI 1820237
40753496|NCT04903509|DRUG|Placebo|Placebo
40753497|NCT04903509|DRUG|Saxenda®|Saxenda®
40753498|NCT04903509|DRUG|Paracetamol-ratiopharm®|Paracetamol-ratiopharm®
41446412|NCT05434364|OTHER|Swaddling|swaddling before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
41446413|NCT05434364|OTHER|Prone Position|giving prone position before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
40753499|NCT02383173|OTHER|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
40753500|NCT02383173|OTHER|Enhanced Implementation Approach|"Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites"
40753501|NCT02697929|DRUG|sugammadex|
40753502|NCT02697929|DRUG|Neostigmine|
40753503|NCT03967665|DRUG|N-acetyl-L-cysteine|NAC 400 mg three times per day from -14D pre-HSCT to +2 months post-HSCT
40753504|NCT00962455|OTHER|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
40926437|NCT02648633|DRUG|Valproate|Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
40753505|NCT00962455|OTHER|usual practice|Usual practice regarding spirometry execution in family practice
40926438|NCT01527357|BIOLOGICAL|Fibrocaps|Human fibrinogen and thrombin powder, for topical administration.
40926439|NCT01527357|BIOLOGICAL|Gelatin sponge|Absorbable gelatin sponge for topical administration.
40926440|NCT00170001|DRUG|Nexium|40 mg bid dosing
40753509|NCT05383950|DEVICE|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory, cardiac, or geriatric diseases.
40753510|NCT00689052|DRUG|pramipexole ER|
40753511|NCT00689052|DRUG|placebo|
40753512|NCT06182397|DEVICE|MagicTouch PTA Sirolimus drug coated balloon|All patients must first be treated with pre dilatation with a standard balloon angioplasty using any standard balloon catheters at the discretion of the operator. Magic Touch PTA Sirolimus coated balloon catheter is an adjunct treatment that should be used in combination with standard balloon angioplasty. Following successful crossing of wire across the lesion and plain balloon angioplasty of arterial lesion with successful lesion preparation with residual lesion \<30%, subjects will be randomized to receive study device balloon. If patients are assigned to MagicTouch PTA Sirolimus DCB, the Angioplasty of lower limb will be performed with this device in addition to standard balloon angioplasty.
40753513|NCT06182397|DEVICE|Placebo balloon angioplasty|For participants randomized to a Placebo balloon angioplasty group, a Placebo balloon angioplasty in addition to standard balloon angioplasty will be performed.
41272564|NCT00336102|PROCEDURE|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
41120255|NCT01179334|DRUG|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
41120256|NCT01901081|DEVICE|IMES|"Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.~After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months."
41120257|NCT05467319|DRUG|Ferric Derisomaltose Injection|1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion
41120258|NCT05467319|DRUG|Normal saline|100 mL of 0.9% normal saline (w/v) by intravenous infusion
41272565|NCT02966457|DRUG|Colistimethate Sodium|Selective oral intestinal decolonization
41272566|NCT00843570|DRUG|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
41272567|NCT03820492|DIAGNOSTIC_TEST|OCT, FFR, CTA and FFRCT|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
41272568|NCT02052102|RADIATION|Radiation therapy|
40753514|NCT03897010|DEVICE|Socket Graft|5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
40753515|NCT00185055|DRUG|Olmesartan medoxomil|
40753516|NCT00185055|DRUG|Irbesartan|
40753517|NCT00185055|DRUG|Valsartan|
40926441|NCT00170001|DRUG|Sugar Pill|40 mg BID
40926442|NCT04770077|OTHER|Intubation on manikin|Training of medical student to focus on manikin vocal cord before intubation
40926443|NCT02776319|DEVICE|Non-invasive brain stimulation (active)|Non-invasive brain stimulation (active)
40926444|NCT02776319|DEVICE|Non-invasive brain stimulation (sham)|Non-invasive brain stimulation (sham)
40926445|NCT01216371|DRUG|Sunitinib|one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
41120259|NCT06093243|OTHER|data collection|data collection
41120260|NCT02242487|DRUG|CVT-301|
41120261|NCT02269280|DRUG|Azacitidine (AZA) Days 1 - 3|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
41120262|NCT02269280|DRUG|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
41120263|NCT02269280|OTHER|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
41120264|NCT02269280|DRUG|Azacitidine (AZA) Days 1 - 5|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
41120265|NCT05541341|OTHER|tisagenlecleucel|Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study
41272569|NCT06190314|DIAGNOSTIC_TEST|Measure serum vitamin b12 levels|Measure the vitamin b-12 levels in patients that are admitted for stroke of any kind
41272570|NCT05426811|DRUG|Regorafenib|Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks
41272571|NCT05426811|DRUG|Raltitrexed|Raltitrexed:3mg/㎡，ivgtt，d1，Every 3 weeks
41272572|NCT04912167|DRUG|Sacubitril-Valsartan|After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)
40753518|NCT02961582|DEVICE|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
40753519|NCT02961582|OTHER|Personalized Conservative Treatment|The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
40753520|NCT05558254|OTHER|Robert - intervention to enhance muscle strength|"Intervention:~Training will be conducted with the robot ROBERT®. 3 times a week for 8 weeks the patient will conduct 60 repetitions of hip flexion of one leg. The patient is lying supine. ROBERT is attached to the patient's lower leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. The ROBERT is attached to the patient's lower leg and thereby eliminating the gravity of the leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. ROBERT is set in active or guided mode and will be individually adjusted. When practice starts the patient get visual feedback to the range of movement of the hip flexion plus the amount of repetitions conducted and persisting."
40753521|NCT00002480|RADIATION|radiation therapy|
40753522|NCT03008096|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Routine Laparoscopic Sleeve Gastrectomy is performed on obese patients supported by Left-Ventricular Assist Device in order to reach a Body Mass Index sufficient for heart transplantation listing.
40753523|NCT00160615|DRUG|Levetiracetam|"* Pharmaceutical form: Film-coating tablets~* Concentration: 250 mg/ 500 mg~* Route of administration: oral use"
40753524|NCT03387774|DRUG|Cisplatin|"Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy."
40753525|NCT03387774|RADIATION|Intensity Modulated Radiation Therapy|"Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225)."
41272573|NCT04912167|DRUG|Enalapril|After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)
41272574|NCT04912167|DRUG|Valsartan|For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
41272575|NCT00470496|DRUG|HPPH|Given IV
41272576|NCT00470496|DRUG|photodynamic therapy|Undergo laser light exposure
41272577|NCT00470496|PROCEDURE|conventional surgery|Undergo surgery
41272578|NCT05418049|DRUG|Baclofen|30mg - Supplied as 10mg and 20mg tablets
41272579|NCT05418049|DRUG|Memantine|two 10 mg tablets
41272580|NCT05418049|DRUG|Roflumilast|250 mcg capsule
41272581|NCT05418049|DRUG|Placebo|Placebo pill
41272582|NCT05354960|OTHER|Questionnaire validation|Validation and cultural adaption of the German version of the LIMB-Q
41272583|NCT03578679|DRUG|Ivermectin Oral Product|treatment of pediculosis (head lice)
41272584|NCT05028803|DRUG|sodium phenylbutyrate|same as arm/group
41272585|NCT04990167|DRUG|Tiotropium Bromide|Using Tiotropium as a single agent asthma controller medication
41120266|NCT04586309|BEHAVIORAL|Transcendental meditation|"Instruction in the TM technique is taught over five sessions.~1. Introductory session-Review of previous scientific research on the TM program and a vision of possible benefits; Preparation- discussion of the mechanics and origin of the TM technique After the introductory session, a Personal Interview is conducted telephonically-with a teacher of the TM program.~2. Personal Instruction-individual one-on-one instruction in the TM technique. The student learns the mechanics of the TM technique. At the conclusion of this class the student is able to meditate properly.~3. First Day of Verification of Correct Practice and Further Instruction.~4. Second Day of Verification of Correct Practice-understanding the mechanics of the TM technique from personal experiences.~5. Third Day of Verification of Correct Practice-understanding the mechanics of the development of higher human potential and wellness."
41120267|NCT04244500|PROCEDURE|swab sampling|Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
41120268|NCT05505916|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
41120269|NCT04066725|DRUG|Aspirin 81 mg|Participants will be given ASA 81 mg orally once daily for a total of 60 days
41120270|NCT04066725|DRUG|Aspirin 325mg|Participants will be given ASA 325 mg orally once daily for a total of 60 days
41120271|NCT04066725|DRUG|Placebo oral tablet|Participants will be given placebo orally once daily for a total of 60 days
41120272|NCT01854229|DEVICE|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
41120273|NCT01307267|DRUG|PF-05082566|Intravenous, Dose escalation, once per month
41120274|NCT01307267|DRUG|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
41120275|NCT01307267|DRUG|PF-05082566|IV, Dose escalation, once per month
41120276|NCT03572075|DIAGNOSTIC_TEST|assessment of symptoms at the first medical examination|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) at the first medical examination
41120277|NCT03572075|PROCEDURE|pelvic floor physiotherapy|six individual sessions (weeks 1, 3 , 5, 8, 11 from the randomization) with pelvic floor consciousness exercises with mild contractions and relaxation (ex. 'kegel reverse' exercises); respiratory rate control exercises; extra exercises to perform at home are suggested.
41120278|NCT03572075|PROCEDURE|standard care protocol|the treatment is the same as usual in our center
41120279|NCT03572075|DIAGNOSTIC_TEST|assessment of symptoms after four months|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) after four months from the randomization.
41120280|NCT05088954|PROCEDURE|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
41120281|NCT01403168|OTHER|OSTEOPATHY + conventional analgesic treatments|"5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.~The conventional analgesic treatments will be administered in the 15 days following the enrollment."
41120282|NCT01403168|OTHER|Conventional analgesic treatments|These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
41120283|NCT02538107|DRUG|Methoxy-polyethyleneglycol epoetin beta|
41446414|NCT05034874|DRUG|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
41120284|NCT00217841|DRUG|Aurograb|
41446415|NCT05034874|OTHER|Placebo|Saline
41446416|NCT00876967|DEVICE|metallic single use blade|metallic single use blade
40753526|NCT03387774|DRUG|Ulinastatin|"Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy."
40926446|NCT01216371|DRUG|Placebo|one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
41446417|NCT00876967|DEVICE|plastic single use blade|plastic single use blade
41446418|NCT00876967|DEVICE|metallic reusable blade|metallic reusable blade
41446419|NCT00080392|DRUG|DNA Plasmid Vector|
41446420|NCT00080392|DRUG|EW-A-401 DNA Plasmid Vector|
41446421|NCT04521764|BIOLOGICAL|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Given IT
41446422|NCT04521764|PROCEDURE|Computed Tomography|Undergo CT scan
41446423|NCT04521764|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41446424|NCT04521764|PROCEDURE|Biopsy|Undergo tumor biopsy
41446425|NCT04521764|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40753527|NCT05381636|PROCEDURE|Esophageal arterial infusion chemotherapy|Percutaneous femoral artery puncture was performed to search for feeding arterial vessels corresponding to the lesion, and chemotherapeutic drugs were directly injected into the tumor vessels via targeted blood vessels.
41120285|NCT04727840|DRUG|Sodium Zirconium Cyclosilicate Oral Product|"Sodium zirconium cyclosilicate (SZC), a non-absorbed cation exchanger, selectively binds potassium in the intestine. SZC is in a powder form and will be provided to patients in packets containing 5g or 10gm of the medication. Participants will mix the contents of one packet with water (about 45mL). The drink should be stirred and drank immediately. If powder remains in the glass, then water should be added and the remainder of the drink should be consumed. Other medications should be taken 2 hours before or after SZC.~At Day 0 and Day 1, participants will be taking SZC at 10gm three times a day. A serum potassium will be checked on Day 2; if serum potassium is \<5.1mEq/L, then the dose will be decreased to the maintenance dose of 5gm per day. At each serum potassium checks, the medication dosage will be adjusted accordingly."
41272586|NCT05433129|PROCEDURE|Transient hyperemic response|The transient hyperemic response will be tested via carotid compression method. This test will consist of 5 carotid compressions lasting 5 seconds each with a 60 seconds interval between each compression to allow normalization of the CBF to precompression levels, and the total time for this block would be 6 minutes. The ipsilateral common carotid artery will be compressed for this method, and the response of the middle cerebral artery (MCA) blood flow velocity will be assessed using transcranial doppler (TCD) probe (EMS-9D, Delica). The carotid compressions will only be accepted when there is no further decrease in blood flow velocity can be achieved and stable conditions remained during the whole period of the compression. Otherwise, the compression will be terminated and repeated again after 60 seconds. Satisfactory compression is typically considered to result in a reduction in MCA velocity of 50%, at a minimum.
41272587|NCT05433129|PROCEDURE|Orthostatic challenge|The orthostatic challenge response will be evaluated by lying-to-sit and sit-to-stand methods 5 times where sitting and standing positions will be held for 3 minutes each for a total block time of 35 minutes. A baseline in lying position will be collected at the start of the block, then the position will be changed from lying to sit for 3 minutes and then position will be changed to standing for another 3 minutes.
41446426|NCT02977403|BEHAVIORAL|Attention Bias Retraining|Attention retraining program on smartphone where the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
41120286|NCT05799742|PROCEDURE|Bilateral hernioplasty|
41120287|NCT04294329|PROCEDURE|US-guided Quadratus lumborum block.|Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery
41120288|NCT04294329|DRUG|Bupivacaine|Bupivacaine
41120289|NCT04294329|DRUG|Saline|normal saline
41120290|NCT01000831|BIOLOGICAL|adjuvanted Arepanrix|Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
41120291|NCT05976295|DRUG|Jianpi Qushi Huatan Decoction|The treatment group will receive the Jianpi Qushi Huatan Decoction (consisting of Radix astragali, Atractylodes Lancea, Dioscorea oppositifolia, Cyperus rotundus, Lindera aggregata, Aconitum gymnandrum and Ligusticum wallichii, among others). Subjects will take the medication from the first day of inclusion, dissolving and consuming one packet twice a day (morning and evening) for a total of three months.
41120292|NCT05976295|DRUG|Placebo|The control group will receive a placebo treatment.
41120293|NCT00095667|DRUG|lapatinib ditosylate|Given orally
41120294|NCT00095667|OTHER|laboratory biomarker analysis|Correlative studies
41120295|NCT02106182|DRUG|Silodosin|
41120296|NCT02106182|OTHER|Laboratory tests|"Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)"
41120297|NCT02106182|OTHER|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
41120298|NCT02106182|OTHER|12 weeks|
41120299|NCT06041373|DEVICE|Verily Watch Cardio|The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.
41120300|NCT06041373|DEVICE|iRhythm Zio monitor|The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.
41120301|NCT06041373|DEVICE|Schiller CARDIOVIT FT-1|The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.
41446427|NCT02977403|BEHAVIORAL|Sham Comparator: AB Control|"Sham Comparator training where the probe randomly replaces the neutral or food pictures. There is no correlation between picture type and probe location"
41446428|NCT04801654|DIAGNOSTIC_TEST|blood sample|preoperative and at 6 months and 1 year follow-up after the surgery the patients will take a blood sample
41120302|NCT04159493|DRUG|Estriol|Vaginal Application
40753528|NCT05381636|DRUG|Systemic intravenous chemotherapy|Albumin paclitaxel 125 mg / m2, D1, D8 + cisplatin 75 mg / m2, D1, every 3 weeks for 1 cycle
40753529|NCT03912415|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
40753530|NCT03912415|BIOLOGICAL|Bevacizumab|IV infusion
40753531|NCT03912415|DRUG|Paclitaxel|IV infusion
41120303|NCT04159493|DRUG|Placebo|Vaginal Application
41120304|NCT03159273|DIETARY_SUPPLEMENT|Beetroot Juice Group|Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
41120305|NCT02875938|BEHAVIORAL|Simultaneous music and reading lyrics|music with sung lyrics simultaneously with silent reading of the lyrics.
40753532|NCT03912415|DRUG|Cisplatin (or Carboplatin)|IV infusion
40753533|NCT03912415|OTHER|Placebo|Placebo
41272588|NCT05433129|PROCEDURE|Vascular chemo-reactivity|vascular chemo-reactivity will be assessed by varying CO2 concentrations through slow and fast breathing exercises with Capnostream 35 Portable Respiratory Monitor (Medtronic Canada) to monitor EtCO2 through nose clip. The breathing trials will occur two times and each of them will have fast and slow trials along with an interval of normal breathing. First time, the normal, fast and slow breathing trials will be 2.5 minutes long while the second time, these breathing trials will be 1.5 minutes long. The normal respiratory rate for adults is 12 breaths/minute, the target slow respiratory rate will be 5 breaths/minute and fast respiratory rate will be 25 breaths/minute as set by metronome. It has been shown that the EtCO2 has a 10% increase during hypoventilation and almost 50% decrease during hyperventilation compared to normal breathing.
41272589|NCT05433129|PROCEDURE|Neurovascular coupling|The fourth block will evaluate the neurovascular coupling using Automated Neuropsychological Assessment Metrics (ANAM) General Neuropsychological Screening (GNS) Clinical Toolkit which contains 5 tests explained as follows 1) Standard Continuous Performance test will assess sustained attention, concentration and working memory. 2) Manikin test will assess 3D spatial rotation ability, left-right orientation, problem solving and attention. 3) Pursuit Tracking test will measure the visuo-motor control. 4) Switching test will assess divided attention, mental flexibility, and executive function. 5) Stroop test will assess the processing speed, selective attention, interference, and executive functioning with three trial blocks.
41272590|NCT04179903|OTHER|Physical activity|Physical Activity program is performed in a group in a gym and at home
41272591|NCT00123929|DRUG|docetaxel|100 mg/m2 every 3 weeks times 4
41272592|NCT00123929|DRUG|doxorubicin|75 mg/m2 every 3 weeks times 4
41272593|NCT00289822|DRUG|intracoronary infusion of progenitor cells|
41272594|NCT01201499|DRUG|Intrathecal morphine|a single dose of intrathecal morphine (ITM, 4 µcg/kg, or \~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
41272595|NCT01201499|DRUG|Continuous IV remifentanil|a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
41272596|NCT02600299|BEHAVIORAL|Psychoeducation group|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship.
41272597|NCT02600299|BEHAVIORAL|Usual Care|Usual Care
41272598|NCT00080847|BIOLOGICAL|oblimersen sodium|Given IV
41272599|NCT00080847|BIOLOGICAL|rituximab|Given IV
41272600|NCT00080847|DRUG|cyclophosphamide|Given IV
41272601|NCT00080847|DRUG|doxorubicin hydrochloride|Given IV
41272602|NCT00080847|DRUG|vincristine sulfate|Given IV
41272603|NCT00080847|DRUG|prednisone|Given orally
41272604|NCT00080847|OTHER|laboratory biomarker analysis|Correlative studies
41272605|NCT01892722|DRUG|Interferon beta-1a|Administration once weekly via i.m. injections.
41272606|NCT01892722|DRUG|Fingolimod|"Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less."
41272607|NCT01892722|DRUG|Placebo capsule|Matching placebo capsule required for double-dummy masking to blind formulations.
41272608|NCT01892722|DRUG|Placebo i.m. injection|Matching placebo i.m. injection required for double-dummy masking to blind formulations.
41272609|NCT03751293|BIOLOGICAL|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+ T cells/kg
40753534|NCT06356597|DRUG|Tislelizumab with Fruquintinib, Metronidazole|"Metronidazole tablets: One administration cycle is every 6 weeks, and metronidazole tablets are given orally on the 1st to 7th day of each cycle. The medication method is two tablets three times one day.~Teralizumab: Every 3 weeks is a dosing cycle, with 200mg of Teralizumab administered intravenously on the first day of each cycle."
41272610|NCT04117750|DIETARY_SUPPLEMENT|cholecalciferol (vit D3)|42,000 IU oral vitamin D per week and 500 mg calcium carbonate
41272611|NCT05766722|DEVICE|DORA AI|Dora will phone patients on the day of cataract surgery (2 to 4 hours after discharge home) and again at postoperative week three. Dora calls made on the day of surgery will evaluate if the patient has any acute post-operative concerns like pain, and will prompt a postoperative day 1 visit if necessary. Calls to Dora at postoperative week three will result in either a follow-up to check refractive difficulties and/or confirmation of second eye surgery.
41272612|NCT02740309|BEHAVIORAL|Integrated Brief Behavior Therapy (IBBT) Intervention|The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
41272613|NCT02740309|BEHAVIORAL|Treatment as usual|Facilitated community referral for mental health treatment
41272614|NCT01475734|BIOLOGICAL|albiglutide|subcutaneous injection
41272615|NCT01475734|BIOLOGICAL|placebo|subcutaneous injection
41272616|NCT02970773|DRUG|Rivaroxaban Oral Tablet|oral application of Xarelto
41272617|NCT01943656|DEVICE|Tobii™ Eyegaze System|Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
40753535|NCT01845415|BEHAVIORAL|Social Marketing Campaign|The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
41272618|NCT01258920|DRUG|Paliperidone palmitate|Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
41272619|NCT03495492|DEVICE|Dermal Chelation|Dermal chelation with Aqua DetoxTM system for one or more hours one or more times each week.
41272620|NCT03495492|DIETARY_SUPPLEMENT|Nutritional Therapy|Vitamins and minerals that will be taken one or more times a day.
41272621|NCT04290182|BIOLOGICAL|MSC-KI-PL-204|Autologous MSC product
41272622|NCT00363961|BEHAVIORAL|Resistance exercise|resistance exercise vs sham comparison
40753536|NCT01845415|BEHAVIORAL|Intervention components|Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
40753537|NCT03995511|PROCEDURE|Bilateral Sagittal Split Osteotomy|Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
40753538|NCT01852214|DRUG|Prasugrel|Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
40753539|NCT01852214|DRUG|Ticagrelor|Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
40753540|NCT02917538|PROCEDURE|RFA|Both groups will receive radiofrequency ablation treatment
40753541|NCT00711204|DRUG|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
40753542|NCT00382928|DEVICE|Defibrillation of pulseless VT/VF by AECD|In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
40753543|NCT05648357|BIOLOGICAL|Fluarix Tetra Vaccine|A single dose of Fluarix Tetra vaccine administered intramuscularly (IM) on day 1.
41120306|NCT02875938|BEHAVIORAL|Priming with music|priming with music and sung lyrics followed by reading of the lyrics.
41120307|NCT02875938|BEHAVIORAL|Control|control condition using reading materials without music.
41120308|NCT03926442|OTHER|Italian Herb meal|Italian Herb in active breakfast meal
41120309|NCT03926442|OTHER|Cinnamon Meal|Cinnamon in active breakfast meal
41272623|NCT04626713|DEVICE|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro-/ bio-feedback-based game interface that is driven by an EEG algorithm.
41120310|NCT03926442|OTHER|Pumpkin Spice meal|Pumpkin Spice Mix in active breakfast meal
41120311|NCT03926442|OTHER|Placebo meal|Placebo in breakfast meal
41120312|NCT05100589|DIETARY_SUPPLEMENT|PeakATP|Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
41272624|NCT00953394|DRUG|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
40753544|NCT02059642|DRUG|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
41272625|NCT01778244|DRUG|metformin|1000mg/day for 24 weeks
40753545|NCT02059642|DRUG|placebo|Placebo 1400 mg administered orally once daily
40753546|NCT01260831|OTHER|Implementation of Bedside Paediatric Early Warning System|The Bedside Paediatric Early Warning System (Bedside PEWS) is a documentation-based system of care that will replace existing documentation systems for vital signs in inpatient ward areas in hospitals randomized to implement Bedside-PEWS. Frontline staff education within each hospital will occur over a period of three months preceding a 5 week run-in implementation phase, which will be followed by hospital-wide implementation. The Bedside-PEWS documentation record will become the primary method of documentation for vital signs and related data.
40926447|NCT02280122|OTHER|no intervention provided|No Intervention was rendered but the aMMP-8 test was made
41120313|NCT05100589|DIETARY_SUPPLEMENT|Placebo|Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
41120314|NCT03822988|OTHER|no intervention, only complete a survey|we will ask patients to answer to a survey
41120315|NCT05765253|DEVICE|Scorpion Portal Vein Access Kit|Portal Vein Access with Scorpion or Scorpion X set
41120316|NCT05765253|DEVICE|Cook Transjugular Liver Access Set|Portal Vein Access with Ring or Rosch-Uchida set
41120317|NCT05765253|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Transjugular Intrahepatic Portosystemic Shunt (TIPS)
41120318|NCT00825084|DRUG|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
41120319|NCT00825084|DRUG|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
41120320|NCT00825084|DRUG|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
41120321|NCT00825084|DRUG|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
41120322|NCT02092116|DRUG|Romidepsin|Latency reversing agent
41120323|NCT02092116|BIOLOGICAL|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
41120324|NCT02092116|BIOLOGICAL|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
41120325|NCT01368198|OTHER|Systane Balance Lubricating Eye Drops|One instillation of the eye drop in each eye
41120326|NCT01368198|OTHER|OPTIVE™|One instillation of the eye drop in each eye
41272626|NCT05025943|OTHER|Diet intervention|The intervention group will receive diet counseling and information to implement a standard lifestyle intervention plus omega-3 fatty acid enriched foods Diet assessment and counseling provided throughout study.
41272627|NCT05025943|OTHER|Control group|The control group will receive diet counseling and information to implement a standard lifestyle intervention Diet assessment and counseling provided throughout study.
41446429|NCT02565160|PROCEDURE|Intra-articular aspiration of Joint|Procedural sampling of the joint for diagnostic purposes
41446430|NCT02565160|PROCEDURE|Joint irrigation washout|Procedural washout for treatment purposes
41446431|NCT02565160|PROCEDURE|Total Joint Arthroplasty|
41446432|NCT02565160|PROCEDURE|Revision Joint Arthroplasty|
41446433|NCT03590795|OTHER|Sleep survey|The Sleep survey was created by the Collaborative Research Center (CRC), a joint effort of the Australian Government, Academia and Industry \[including Philips\]).
41272628|NCT05513443|PROCEDURE|Irreversible electroporation, IRE|IRE involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death. The technique is used in Sweden today in radical ablative therapies in the treatment of tumors in the liver, kidney and pancreas. Prior to treatment a Foley catheter is placed. During the treatment, which takes place under anesthesia, the patient is placed in gynecological position and the tumour lesion is located with BK transrectal fusion ultrasound. Thereafter the needles are placed transperineal around the tumor in the prostate using a brachytherapy grid (17Ga Civco brachytherapy grid), guided by the ultrasound/MRI fusion images. Through the needles electrical pulses are then sent to treat the tumor in the center using the Nanoknife technique. After treatment patients are treated with diuretics to flush the kidneys post treatment.
41272629|NCT05513443|PROCEDURE|Radical prostatectomy|Radical prostatectomy
41272630|NCT05513443|RADIATION|Radiation therapy|Radiation therapy for prostate cancer
41272631|NCT03537664|PROCEDURE|Root canal preparation|First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.
41272632|NCT03537664|PROCEDURE|Intracanal medication|The second endodontic treatment includes the intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation
41272633|NCT03506503|PROCEDURE|Nanofat grafting|hair loss area will be treated by processed autologous Nanofat grafting
41272634|NCT02219230|DEVICE|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
41272635|NCT02219230|DEVICE|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
41272636|NCT02219230|DEVICE|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
41272637|NCT02405533|DIETARY_SUPPLEMENT|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
41272638|NCT02405533|OTHER|Placebo|Placebo supplementation x 12 months
41272639|NCT05021926|DEVICE|DKL crosslinked sodium hyaluronate 26|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 26 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
41272640|NCT05021926|DEVICE|Juvéderm Voluma™ with lidocaine (Allergan, Inc)|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Voluma™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
41272641|NCT03993717|BIOLOGICAL|SHINGRIX|A single intramuscular injection of the FDA-approved recombinant glycoprotein E herpes zoster (HZ/su) vaccine will be administered in the deltoid muscle of the preferred arm
40753547|NCT01260831|OTHER|Hospital Standard of Care|Hospitals randomized to standard care will continue with established methods of care. This will include the use of calling criteria and/or the expert model to identify children at risk. As in intervention hospitals, existing MET-RRT practices, established staffing and documentation practices will continue.
41120327|NCT03562884|DRUG|BLI800|Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
41120328|NCT03562884|DRUG|Fortrans®|Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
40753548|NCT00006135|DRUG|acyclovir|
40753549|NCT03043937|OTHER|registry|
40926448|NCT00102401|BEHAVIORAL|Internet-based Dyspnea Self-Management Program|
41120329|NCT05961020|DEVICE|Total body vibration|Whole-body vibration (WBV) training has been established as a useful method to improve physical fitness in obese individuals. Vibration stimulus during half squatting might suggest a long-term effect of WBV on the endocrine system
41120330|NCT05961020|OTHER|moderate restricted diet|moderate restricted diet
41120331|NCT05212675|OTHER|Short daily dialysis|7 days 2hours dialysis
41120332|NCT04578392|PROCEDURE|high ligation of ileocolic artery|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
41272642|NCT02623179|OTHER|culture versus Molecular diagnostics|Treatment based on the results of the FH C \& S testing - Odd Numbers on randomization table
41272643|NCT03488199|DEVICE|Stent Acculink ™|Carotid Artery Revascularization using Stents
41272644|NCT03488199|DEVICE|CGuardTM™|Carotid Artery Revascularization using Stents
41272645|NCT01634373|DRUG|Torrent's Quetiapine Fumarate Tablets|
41272646|NCT04318392|OTHER|Breath Analysis|Breath analysis using the ReCIVA device will take place during each study visit.
41272647|NCT04318392|OTHER|Pulmonary Function Tests|Full Pulmonary Function Tests will be performed at baseline and during each study visit if not performed as part of routine clinical care.
41272648|NCT04318392|OTHER|Blood sampling and storage for genetic analysis|Additional voluntary consent will be sought for blood sampling and storage for genetic analysis at baseline.
41272649|NCT04318392|OTHER|Blood sampling and storage of plasma for metabolomic analysis|Blood sampling and storage of plasma for metabolomic analysis will take place during each study visit.
41272650|NCT04318392|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage will be performed at baseline on all participants undergoing investigation with bronchoscopy or EBUS as part of routine clinical care for investigation of suspected sarcoidosis.
41272651|NCT04318392|OTHER|Sputum Culture|Sputum will be collected during each study visit if the patient can spontaneously expectorate and will be sent for routine microbial analysis as well as metagenomic sequencing.
41272652|NCT04318392|OTHER|Spirometry|Spirometry will be performed on all healthy controls prior to enrolment into the study
41272653|NCT00807664|DEVICE|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
41272654|NCT00807664|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
41272655|NCT00398112|DRUG|sunitinib malate|Given orally
40753550|NCT00799864|DRUG|Rilpivirine|Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged \>=12 to \<18 years) up to 240 weeks. Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged \>=6 to \<12 years) or 25 mg once daily for up to 48 weeks.
40753551|NCT00799864|DRUG|Zidovudine|Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
41120333|NCT04578392|PROCEDURE|mesenteric sparing|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
41120334|NCT05208372|DIAGNOSTIC_TEST|CTC test|Circulating tumor cells test of ascites and blood for patients with gastric cancer.
41120335|NCT05208372|DIAGNOSTIC_TEST|ctDNA test|Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
41120336|NCT02395913|DRUG|Surfolase capsule (100mg)|Surfolase capsule one capsule twice one days fasting administration
41120337|NCT02395913|DRUG|Surfolase CR (200mg, T1)|one tablet once one days fasting administration.
41120338|NCT02395913|DRUG|Surfolase CR (200mg, T3)|one tablet once one days fasting administration.
41120339|NCT02395913|DRUG|Surfolase CR (200mg, T4)|one tablet once one days fasting administration.
41120340|NCT03230942|OTHER|Pre-operative education|Verbal and booklet about symptoms and physical conditions pos knee replacement
41120341|NCT03230942|OTHER|Pos-operative rehabilitation|Physical therapy treatment
41120342|NCT03240978|BEHAVIORAL|exercise intervention|A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.
41120343|NCT05834270|DRUG|Single dose tamsulosin 0.4mg|Single dose tamsulosin 0.4mg
41272656|NCT00398112|OTHER|pharmacological study|Correlative studies
41272657|NCT00398112|OTHER|laboratory biomarker analysis|Correlative studies
41272658|NCT02427282|DEVICE|miniscrew-supported Frog molar distalizing appliance|miniscrew 10mm length and 1.7mm diameter FORESTADENT company
40753552|NCT00799864|DRUG|Abacavir|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
40753553|NCT00799864|DRUG|Tenofovir disoproxil fumarate|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).
41120344|NCT05834270|DRUG|Double dose tamsulosin 0.4mg|Double dose tamsulosin 0.4mg
41120345|NCT05747716|DRUG|SBRT, Fruquintinib, Cadonilimab|Radiation: Stereotactic body radiationtherapy (SBRT) for metastatic sites (less than 5) Fruquintinib: 5mg, po, everyday; Cadonilimab: 10mg/kg, iv, q3w
41120346|NCT04403789|OTHER|Exercise Time|Employees will be provided with exercise time of 2 hours per week. The 2 hours should be used in two days. The intervention duration is 12 weeks.
41120347|NCT04403789|BEHAVIORAL|Supervised Group Exercise|The intervention group will receive 2-hours of exercise sessions per week under the supervision of a certified trainer in the gym workplace. The intervention duration is 12 weeks.
40753554|NCT00799864|DRUG|Lamivudine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
40753555|NCT00799864|DRUG|Emtricitabine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
40926449|NCT00102401|BEHAVIORAL|Face-to-face Dyspnea Self-Management Program|
41120348|NCT04374916|DEVICE|Premaquick®|Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.
41120349|NCT04374916|DEVICE|PARTOSURE®|An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
41120350|NCT03692780|DRUG|Careseng 1370|4,000mg granules in sachet
41120351|NCT03692780|DRUG|Placebo|4,000mg granules in sachet
41120352|NCT03833661|DRUG|M7824|Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
41120353|NCT02023710|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
41120354|NCT02023710|DRUG|Carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
41120355|NCT02023710|DRUG|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
41120356|NCT00813059|DRUG|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
41120357|NCT00970658|DRUG|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
41120358|NCT00970658|DRUG|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
41120359|NCT00563446|DRUG|Darbepoetin alfa|
41272659|NCT02427282|DEVICE|Standard Frog molar distalizing appliance|Nance buttons attached to first premolars band
41272660|NCT00446303|DRUG|Azacitidine|"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.~Extension of maintenance in responders after 24 courses until relapse or death."
41272661|NCT02047006|DRUG|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.~Effect of dialysis on levels of rivaroxaban:~Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours."
40753556|NCT03307850|OTHER|Observation During Exercise and Stress|"Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.~Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study."
40753557|NCT05275244|DEVICE|KD Intra-Articular® gel|Depending on the joint, 3 injections will be administrated to the patient: KD Intra-Articular® gel 2.2% - 44 mg in 2 ml - (Pronolis® HD one 2.2%) in the case of shoulder and hip, or KD Intra-Articular® gel 1.6% - 16 mg in 1 ml - (Pronolis® HD mini 1.6%) in the case of the ankle and base of the thumb. The administration of the infiltrations will be with an interval of one week.
40753558|NCT05560633|OTHER|No intervention|No intervention
40753559|NCT03109925|DEVICE|DC Lumi Bead, BTG|Embolic agent which is radio-opaque
40753560|NCT04297267|DRUG|Gemcitabine|Gemcitabine 1250mg/m2,d1,d8,every 3 weeks
40753561|NCT04297267|DRUG|Cisplatin|Cisplatin 75mg/m2,d1，every 3 weeks
40753562|NCT03983070|OTHER|Seated Rowing Ergometer|Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures
40753563|NCT03983070|OTHER|Deadlift|Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.
40753564|NCT03983070|OTHER|Blood flow restriction|An occlusive cuff will be placed around each proximal thigh and inflated to 80% arterial occlusion during exercise sessions.
40753565|NCT00147537|DRUG|CP-751,871|"Phase 2 Arm A:~CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles"
40753566|NCT00147537|DRUG|paclitaxel|"Phase 2 Arm A:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles~Phase 2 Arm B:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles"
41120360|NCT03508518|OTHER|Shared care device in psychiatry (DSPP)|The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion
41120361|NCT03508518|OTHER|Usual Care|psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.
41120362|NCT06113770|OTHER|preparation of the tooth to receive ready made zirconia crown|"Occlusal reduction 1 to 2 mm using flame bur . Open the interproximal contacts. The tooth should be reduced circumferentially by approximately 0.5-1.5mm . The preparation margin should be carefully extended and refined to a feather-edge approximately 1-2mm subgingivally .~Crown size will be determined using try in kit ."
40753567|NCT00147537|DRUG|carboplatin|"Phase 2 Arm A:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles~Phase 2 Arm B:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles"
40753568|NCT00147537|DRUG|CP-751,871|Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
41272662|NCT03731663|BEHAVIORAL|Exposure to pictures of appetizing food (known as Foodporn)|- Participants allocated to the experimental group will watch a 3 minute video presenting a series of pictures of appetizing foods. An audio of a young adult describing herself eating these foods during a trip to London will be played.
40753569|NCT00147537|DRUG|paclitaxel|Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
40753570|NCT00147537|DRUG|carboplatin|Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
40753571|NCT00147537|DRUG|erlotinib|Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
41272663|NCT03731663|BEHAVIORAL|Exposure to neutral pictures|Participants allocated to the control group will watch a 3 minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
40753572|NCT04667728|DEVICE|Professional continuous glucose monitoring (CGM) sensor (iPro™2)|Professional continuous glucose monitoring (CGM) sensor (iPro™2) following treatment adjustments and personalized diet plan
40753573|NCT04420182|OTHER|Virtual Care at Home|Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home
40753574|NCT05804292|OTHER|Questionnaire administration|Questionnaire administration
40753575|NCT02303938|BEHAVIORAL|physical exercise|Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
40753576|NCT01805570|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
40753577|NCT01805570|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
40926450|NCT00385476|BEHAVIORAL|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
40926451|NCT06449274|DEVICE|Drug-coated balloon|Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed. Individual will receive guideline-directed medical treatment.
40926452|NCT06449274|DRUG|Guideline-directed medical treatment|All individuals will receive guideline-directed medical treatment.
41120363|NCT06113770|OTHER|preparation of the tooth to receive CAD CAM PMMA custom made crown|"* Open the interproximal contacts .~* The tooth should be reduced circumferentially by approximately 0.5-1mm .~* The preparation margin should be carefully extended and refined to a feather- edge approximately 1-2mm subgingivally .~* Rubber base impression will be taken by BMS additional silicone kit to the prepared tooth and will be sent to the laboratory to be scanned and to design the crown .~* The final crown will be cemented using glass ionomer cement ."
41120364|NCT00194610|DRUG|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
41120365|NCT00194610|OTHER|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
41120366|NCT04178226|OTHER|Manual Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
41120367|NCT04178226|DEVICE|Laser Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
41120368|NCT05238480|DEVICE|XC mouthguard|Use of a Xtreme Conventional custom-made mouthguard while playing rugby
41120369|NCT05238480|DEVICE|XP mouthguard|Use of a Xtreme Pro custom-made mouthguard while playing rugby
41120370|NCT02364349|DRUG|Bee Venom (BV)|Raw Bee Venom
41120371|NCT02364349|DRUG|Essential Bee Venom (e-BV)|Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
41120372|NCT01941758|BIOLOGICAL|trivalent influenza vaccine|
41272664|NCT04672083|DRUG|CPT31|CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer
41272665|NCT04672083|DRUG|Placebo|matching placebo
40926453|NCT00679445|DEVICE|NeoVista Ophthalmic System|A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.
41120373|NCT01941758|OTHER|laboratory biomarker analysis|Correlative studies
41120374|NCT05832190|OTHER|Standard of care|Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
41120375|NCT05832190|DIETARY_SUPPLEMENT|Biotin supplement|1 capsule per day of Biotin 450µg during 3 months before the surgery.
41120376|NCT05832190|DIETARY_SUPPLEMENT|Fiber supplement|3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery
41120377|NCT01548170|DRUG|Sunitinib|One capsule of sunitinib 50 mg orally. Single dose
41120378|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
41120379|NCT01548170|DRUG|Sunitiinb and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
41272666|NCT00751894|DRUG|Pegfilgrastim (Neulasta, Amgen)|sequential Bayesian study
41272667|NCT03906266|DIAGNOSTIC_TEST|NRS 2002, nutric, SGA and adductor pollicis|NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition
41272668|NCT04874272|OTHER|Chaplain led post-code debrief|an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain
41272669|NCT03609164|PROCEDURE|Suture-bridge augmentation of single-row repair|
41272670|NCT05554003|DRUG|Temozolomide capsule|Metronomic temozolomide 60 mg/die continuously
41272671|NCT02209506|DRUG|MLN3126|MLN3126 tablets
41272672|NCT02209506|DRUG|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
41272673|NCT04954482|OTHER|No Intervention|This is an observation study, with no intervention
41272674|NCT02937805|DEVICE|Moisturizing vaginal and vulvar sea buckthorn oil cream|
40926454|NCT00210938|DRUG|Doripenem|
40926455|NCT02973373|DEVICE|MRI with High-frequency non-invasive ventilation|MRI performed under high-frequency non-invasive ventilation
40926456|NCT02973373|OTHER|MRI without High-frequency non-invasive ventilation|MRI performed without High-frequency non-invasive ventilation
40926457|NCT02270853|DEVICE|sleep apnea screening with ApneaLinkTM|ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
40926458|NCT01143740|DRUG|RO5045337|orally day 1-10 each 28-day cycle, 3 cycles
40926459|NCT02102503|BEHAVIORAL|Standard Treatment|
41120380|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
41120381|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
41120382|NCT05454410|DRUG|MIJ821 Subcutaneous Injection - low dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
41120383|NCT05454410|DRUG|MIJ821 Subcutaneous Injection - medium dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
41120384|NCT05454410|DRUG|MIJ821 Subcutaneous Injection - high dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
41120385|NCT05454410|DRUG|Placebo Subcutaneous Injection|0.9% sodium chloride solution to be administered as a single subcutaneous injection on Day 1
41120386|NCT01058785|BIOLOGICAL|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
41120387|NCT00502424|DEVICE|Splint|
41120388|NCT01337635|DRUG|Vitamin D|Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
41120389|NCT05833906|DRUG|CKR-051 Dose 1|Subjects will be administered 5 g of CKR-051.
41120390|NCT05833906|DRUG|CKR-051 Dose 2|Subjects will be administered 10 g of CKR-051.
40926460|NCT02102503|BEHAVIORAL|MI and Medication review|
41120391|NCT05833906|DRUG|CKR-051 Dose 3|Subjects will be administered 10 g of CKR-051.
41120392|NCT05833906|DRUG|CKR-051 Dose 4|Subjects will be administered 10 g of CKR-051.
41272675|NCT02937805|DEVICE|Moisturizing vaginal and vulvar cream|
41272676|NCT02921425|BEHAVIORAL|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
41272677|NCT01992029|OTHER|Clinical evaluation|Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12
41120393|NCT05833906|DRUG|Placebo|Placebo comparator.
41272678|NCT01992029|PROCEDURE|Muscular biopsy|Muscular biopsy at M0
41272679|NCT01992029|PROCEDURE|Lumbar puncture|Lumbar puncture at M0 and M12
41120394|NCT00002383|DRUG|Saquinavir|
41120395|NCT02045459|BEHAVIORAL|Exercise Program|Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
41120396|NCT03072914|PROCEDURE|RIPC with RIPostC|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
41120397|NCT05341869|PROCEDURE|Para-cervical block|Block of inferior hypogastric plexus with local anesthetic
41120398|NCT05204394|DRUG|VM-1500A-LAI|Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)
41120399|NCT05204394|OTHER|Standard of Care|Any oral 1st line approved HIV treatment regimen
40926461|NCT05810818|DIAGNOSTIC_TEST|Dry Needling|Dry needling treatment will be consisting of two treatments per week
40926462|NCT05810818|DIAGNOSTIC_TEST|Self Stretching|Self stretching groups both will receive a TrP manual interventions and stretching protocol
41120400|NCT03365895|PROCEDURE|Diffusion Tensor Imaging|Undergo non-enhanced MRI using MRN and DTI
41272680|NCT01992029|PROCEDURE|Blood sampling|Blood sampling at M0, M4, M4, M8 and M12
41120401|NCT03365895|OTHER|Laboratory Biomarker Analysis|Correlative studies
41120402|NCT03365895|PROCEDURE|Magnetic Resonance Imaging|Undergo non-enhanced MRI using MRN and DTI
41120403|NCT03365895|OTHER|Questionnaire Administration|Ancillary studies
41120404|NCT02531113|DRUG|RPC1063|
41120405|NCT03022812|OTHER|Neck-specific exercise|Neck-specific exercise
41120406|NCT03828240|OTHER|HIP fracture REhabilitation Programme for the elderly with hip fractures|Eight-week activity-based intervention for elderly with hip fractures; one intervention during the hospital stay, four interventions at the elderly's municipality.
41272681|NCT01992029|OTHER|Neurological assessments|Neurological assessments (MRC score and cognitive scales: MMS and BREF)
41272682|NCT01992029|PROCEDURE|Neuro-muscular biopsy and lumbar puncture|Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy
41272683|NCT01992029|PROCEDURE|Muscular biopsy|Muscular biopsy for patient explored for myopathy
41120407|NCT05692635|DIAGNOSTIC_TEST|MRI of the Brain|An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.
41272684|NCT01992029|PROCEDURE|Blood sample|Blood sample for qRT PCR, detection and quantification for miRNA
41272685|NCT01992029|DEVICE|Cervical spinal cord and brain MRI|ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
41446434|NCT05281861|OTHER|Zirconia reinforced Lithium disilicate (Vita Ambria) ceramic onlay restoration|In experimental group, Participants will be restored with onlay ceramic restorations constructed from zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic
41446435|NCT05281861|OTHER|Lithium disilicate (IPS e-max press) ceramic onlay restoration|In control group, Participants will be restored with onlay ceramic restorations constructed from Lithium disilicate (IPS e-max press) glass ceramic
41120408|NCT05692635|OTHER|Blood draws|Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.
41120409|NCT05692635|OTHER|Quality of Life Questionnaires|Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.
41120410|NCT05692635|DRUG|Gadolinium|Given intravenously
41120411|NCT03427034|DEVICE|BladderLight®|Using a cell collection device to look for the presence of bladder cancer cells
41120412|NCT03273777|PROCEDURE|Drawing of an incision line|Drawing of an incision line prior to skin incision at cesarean section
41120413|NCT01551056|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
41120414|NCT01551056|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
41120415|NCT06519253|OTHER|Virtual reality (VR) music intervention|The VR music intervention consists of musical performance which were already recorded. This is accessible classic music. During the intervention, the participants will be able to see the musicians (and the stage, empty auditorium, etc.) and hear the music.
41120416|NCT06519253|OTHER|Music only control|The control group consists of the same musical performances, with the audio only
41272686|NCT03386708|PROCEDURE|intrauterine injection|intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/one menstrual cycle, total 2 times
41272687|NCT03386708|BIOLOGICAL|human umbilical cord mesenchymal stem cell|2 \* 10\^7 cells (2ml)
41446436|NCT06040606|PROCEDURE|In-Hospital COVID-19 Omicron Infection after surgery|Thoracic Surgery Patients with In-Hospital COVID-19 Omicron Infection after surgery
40753578|NCT05656976|OTHER|Provision of self sampling device by the GP|In a group of 45 GP practices, over a course of 9 months, all long-term unscreened women with a GMD will be addressed by their GP when they consult for any reason. The GP will discuss the pros and cons of screening for cervical cancer, the various options for screening for cervical cancer including the possibility of using a SSD. For this, the GP can use on accessible brochure and video materials. After the woman agrees, she is given a self-taking kit that she can use when and where it suits her and send it to the lab with the prepaid envelope. The woman is informed of the result of the Human Papilloma Virus test result by her GP according to the usual way in the practice (e.g. via letter, by phone or during the next consultation).
41120417|NCT00522951|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
41120418|NCT00522951|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
41120419|NCT00522951|DRUG|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
41272688|NCT03989830|DRUG|second-line chemotherapy|choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
41272689|NCT03989830|DRUG|Recombinant human endostatin|7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
41272690|NCT03026582|DEVICE|Intestinal ultra-sound monitoring|Children diagnosed with either CD or UC will be enrolled at diagnosis or at any time point during follow-up. Patients' characteristics will be retrieved from their medical files including demographic details, disease phenotype, endoscopic and radiologic variables, anthropometric measures, laboratory evaluation, complication and therapeutic regimens. At enrollment and every 3 months for a total period of 2 years all patients will perform intestinal US during regular clinic visits. All other measures including laboratory exams, anthropometric measurements and disease activity indices (either PCDAI for CD or PUCAI for UC) will be performed as part of standard of care.
41120420|NCT03346616|OTHER|Texting Group|See above in arm/group description
41120421|NCT03346616|OTHER|Non Texting Group|See above in arm/group description
41120422|NCT01398124|BIOLOGICAL|Cyclin B1 Peptide|vaccine
41120423|NCT03270124|BEHAVIORAL|Daily Activity Goal|Patients are given a tailored daily activity goal in terms of steps per day for which to aim.
41272691|NCT00284388|PROCEDURE|Simultaneous controlled power measurement|
41272692|NCT00284388|PROCEDURE|Surface EMG measurement|
41272693|NCT03511365|BIOLOGICAL|Probiotic Formulation VSL#3|Probiotic VSL#3 administration.
40926463|NCT03171428|PROCEDURE|Hepatectomy|Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
40926464|NCT00710762|DRUG|BIBF1120|
40926465|NCT00710762|DRUG|Placebo|
40926466|NCT00969982|DRUG|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
41120424|NCT03270124|BEHAVIORAL|Resistance Exercises|Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.
41120425|NCT03270124|BEHAVIORAL|Daily Activity Recording|A Fitbit will be worn by all participants to record daily activity.
41120426|NCT01331824|DRUG|Amrubicin|Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
41120427|NCT06256640|DEVICE|Mandibular advancement Device|Intra oral appliances and more specifically Mandibular Advance Devices (MAD) are one of the established alternatives to treat OSA. Oral appliances and MAD are often used interchangeably but we prefer to call them MAD as it is more descriptive of its mechanism of action. MAD are placed in the mouth to temporarily advance and stabilize the lower jaw forward in order to keep the airway open during sleep.
41120428|NCT02424071|DRUG|Melatonin|
41120429|NCT02424071|DRUG|placebo|
41120430|NCT03380234|OTHER|Worksheets|Worksheets will be distributed to students for them and their parents to complete together. During the first 3 months, the teachers will distribute 1 worksheet every two weeks to the intervention grades, and 1 worksheet in the 4th and 5th months as boosters. The worksheets will deliver information about tobacco smoke, SHS and THS, inviting students and their family members to complete other interesting tasks together.
41120431|NCT03380234|OTHER|Whatsapp messages|A mobile phone number of this study is also provided on the worksheets, through which participants can receive WhatsApp/WeChat/instant messages (1-2 times every week) designed to encourage behavioural change \[15\]. They can then forward selected messages to other members of their household, especially smokers.
41120432|NCT03380234|OTHER|Online quizzes|At the end of each worksheet, a QR code is inserted. By scanning this code, students or parents will be invited to answer 2-3 simple quizzes which allow us to assess students' knowledge obtained from the intervention materials and their avoidance of environmental tobacco smoke.
41120433|NCT03380234|OTHER|Leaflet|A leaflet on smoking and SHS published by the Department of Health will be mailed to the control grades.
41272694|NCT02780791|OTHER|Transplantation into pelvic wall|Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
41272695|NCT02780791|OTHER|Transplantation into the ovary|Ovarian tissue will be transplanted contralateral into the ovary.
41272696|NCT05252689|OTHER|monolithic zirconia single posterior crowns with deep chamfer finish line|deep chamfer of 1 mm average thickness for cervical finish line, a convergence angle of 6-12° on each side and up to 20° total, in some studies, is acceptable and occlusal reduction of 1,5-2 mm
41272697|NCT05252689|OTHER|monolithic zirconia single posterior crowns with vertical finish line|using special round-ended 2 degrees tapered diamond burs a non-working tip (batt bur). It has coronal diameter of 1.2 mm, apical diameter of 0.7 mm, and non- cutting end of 1 mm, which reduces or avoids damage to the connective attachment and allows a tooth-guided preparation procedure
41272698|NCT04290637|OTHER|Cold-water sea swimming|Continue sea swimming for 4-6 weeks
41272699|NCT04290637|OTHER|No cold-water sea swimming|Discontinue sea swimming for 4-6 weeks
41272700|NCT02226341|DRUG|CellCept|"For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144"
40758262|NCT04304196|OTHER|TEMPO|TEMPO is designed as a 7- to 10-week, web-based intervention containing 5 modules to pace patient-caregiver dyads' learning, avoid information overload, and allow sufficient practice time in-between modules . Each module is organized along six key components: needs assessment, tailored information and skills training, goal setting and action planning, motivational and social support, monitoring, automated feedback, and addressing time demands. Overall, modules aim to a) increase dyads' confidence in using strategies to address key psychosocial issues in the acute survivorship phase (e.g., dealing with stress and worry, communicating with partner and family, uncertainty management) and b) assist dyads in developing the self-regulatory skills necessary to meet the physical activity guidelines. Each module specifies a series of online (i.e. didactic material and interactive worksheets) and offline activities (i.e. practicing the proposed skills).
40926467|NCT00969982|DRUG|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
41272701|NCT02226341|DRUG|ACTHar gel|"Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.~Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response."
40926468|NCT04249232|DRUG|Abaloparatide 80 micrograms per Pen dose|prefilled injector pen to deliver 80 micrograms daily subcutaneously
41120434|NCT03472755|OTHER|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
41120435|NCT03472755|OTHER|Direct anterior technique|patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached
41120436|NCT03428958|DRUG|NUC-3373 + leucovorin|NUC-3373 + leucovorin
41120437|NCT03428958|DRUG|NUC-3373|NUC-3373
41120438|NCT03428958|DRUG|NUFOX|NUC-3373 + oxaliplatin
41120439|NCT03428958|DRUG|NUFOX + VEGF pathway inhibitor|NUC-3373 + oxaliplatin + bevacizumab
41120440|NCT03428958|DRUG|NUFOX + EGFR inhibitor|NUC-3373 + oxaliplatin + cetuximab/panitumumab
41120441|NCT03428958|DRUG|NUFIRI|NUC-3373 + irinotecan
41120442|NCT03428958|DRUG|NUFIRI + VEGF pathway inhibitor|NUC-3373 + irinotecan + bevacizumab
41120443|NCT03428958|DRUG|NUFIRI + EGFR inhibitor|NUC-3373 + irinotecan + cetuximab/panitumumab
41120444|NCT03428958|DRUG|NUC-3373 + bevacizumab|NUC-3373 + bevacizumab
41120445|NCT04966416|DIETARY_SUPPLEMENT|Pyrophosphate|50 mg/kg bwt once daily in gelatine capsules.
40926469|NCT04249232|DRUG|Placebo prefilled injector pen|prefilled injector pen to deliver inactive solution daily subcutaneously
40947808|NCT03860610|DIAGNOSTIC_TEST|Muscle activity test|Surface electrodes (Ag/AgCl, Noraxon, U.S.A. Inc., Scottsdale, AZ, USA: 10 mm diameter, 22 mm inter-electrode distance) will be placed bilaterally on glutaeus medius, vastus medialis, semitendinosus, tibialis anterior, gastrocnemius medialis, and peroneus longus muscles. Periods of muscle activity will be defined as intensity above 2 Standard Deviation (SD) of the resting Electromyography (EMG) signal. Duration of overlapping muscle activity between agonists and antagonists normalized to one gait cycle or of a balance test, respectively, will be determined.
41120446|NCT04966416|DIETARY_SUPPLEMENT|Placebo|Glucose in gelatine capsules.
41120447|NCT00003017|BIOLOGICAL|recombinant interleukin-12|
41120448|NCT02206763|DRUG|Momelotinib (MMB)|Tablet(s) administered orally once or twice daily
41120449|NCT02206763|DRUG|Erlotinib|Tablet(s) administered orally once daily.
41120450|NCT00338624|DRUG|oxybutynin chloride extended release|
41120451|NCT04638322|OTHER|HIFT Group|An experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the HIFT method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 min per session. Once the intervention is finished, you will undergo a final evaluation to see if there is a difference or not with the results obtained at the beginning.
41272702|NCT04453774|DEVICE|Covidfree@home|Mobile phone, Covidfree@home app, thermometer, pulse oximeter, smart watch
41272703|NCT02760290|PROCEDURE|Extraperitoneal cesarean section|
41272704|NCT02760290|PROCEDURE|Intraperitoneal cesarean section|
41272705|NCT05015309|DRUG|SH3765 tablet|Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
41272706|NCT00850252|DEVICE|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
41272707|NCT03395678|DEVICE|Microneedling|The exact microneedling settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
41272708|NCT03395678|DEVICE|Fractional non-ablative 1,540nm laser|The exact laser settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
41272709|NCT00591734|DRUG|Bevacizumab|15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
41272710|NCT00591734|DRUG|Everolimus|10 mg by mouth daily
41272711|NCT00277537|DRUG|Mannitol|320mg BD 12 weeks followed by 40 weeks open label
41272712|NCT00277537|DRUG|placebo|BD for 12 weeks
41272713|NCT03431233|DIETARY_SUPPLEMENT|Protein-enriched bar, commercial cereal bar, or water|Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.
41272714|NCT01856101|DRUG|BEZ235|The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
41120452|NCT00354653|DRUG|LAMIVUDINE|
41272715|NCT05596214|COMBINATION_PRODUCT|Curcumin-Berberine (coptis)|dietary supplement
41272716|NCT05596214|COMBINATION_PRODUCT|Placebo|Placebo
41272717|NCT01293617|OTHER|Blackberries|300 g blackberries daily for 5 days
41272718|NCT01293617|OTHER|Gelatin|300 g gelatin per day for 5 days
41272719|NCT05501925|DEVICE|GlideSheath Slender® and conventional arterial sheath|Using the GlideSheath Slender® with the outside diameter 2.46mm
41272720|NCT05501925|DEVICE|Conventional arterial sheath|Placement of 6 French conventional Sheath (TERUMO, Introducer II )
41272721|NCT00809133|DRUG|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
40758263|NCT04304196|OTHER|Usual care|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
41120453|NCT03618524|OTHER|Lower limb hot water immersion|Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
40758264|NCT02217982|DRUG|Simethicone|
41272722|NCT00809133|DRUG|Carboplatin|AUC6 given on day 1 of 21 day cycle
41272723|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
41272724|NCT00809133|DRUG|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
40758265|NCT02217982|DRUG|Loperamide|
41120454|NCT05559281|OTHER|Botulinum|injection of Botulinum Toxin injection in lip muscles following cleft lip repair surgically.
41120455|NCT05559281|PROCEDURE|Fisher technique|The cleft lip will be treated surgically using the Fisher technique only.
41120456|NCT01393067|DEVICE|Non-expandable plastic stent (plastic endoprosthesis)|plastic stent (plastic endoprosthesis)
41272725|NCT00809133|DRUG|BIBW2992|MTD dose of part A
41272726|NCT00809133|DRUG|Paclitaxel|175mg/m2 given on Day 1 of 21 Day cycle
41272727|NCT00809133|DRUG|Carboplatin|AUC6 given on day 1 of 21 day cycle
41272728|NCT00809133|DRUG|Bevacizumab|Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
41272729|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
41272730|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
41272731|NCT00260208|DRUG|Cyclosporine A|Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
41272732|NCT00260208|DRUG|Tacrolimus|Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
41272733|NCT05381831|DRUG|NatestoTM|Administering daily intranasal testosterone, Natesto nasal gel is available as a metered-dose pump. One pump actuation delivers 5.5 mg of testosterone
41272734|NCT04681261|OTHER|this study is not an intervention study|this study is not an intervention study
41272735|NCT05704114|DRUG|Tazarotene 0.045% Lotion|Daily topical use of tazarotene for 16 weeks.
41272736|NCT04034017|OTHER|no intervention|descriptive study, no intervention
41272737|NCT00056199|DRUG|EYE001|
41446437|NCT06516354|DEVICE|Portable sleep apnea screening|Screening of stroke and TIA patients on the stroke inpatient unit using theSTOP BANG questionnaire and portable sleep testing (PST) during inpatient hospitalization, early interpretation of PST results by neurology with prescribed treatment upon discharge from hospital
41446438|NCT03506763|DRUG|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
41446439|NCT03506763|DRUG|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
41446440|NCT03506763|DRUG|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
41272738|NCT04469569|BEHAVIORAL|HPV-PROTECT|HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
41272739|NCT02254343|DEVICE|proximal robot-assisted therapy|
41272740|NCT02254343|DEVICE|distal robot-assisted therapy|
40758266|NCT02217982|OTHER|Peanut Butter|
41272741|NCT02254343|BEHAVIORAL|individualized intensive therapy|
41272742|NCT02862691|DRUG|Acetaminophen/Oxycodone (Oral analgesic)|2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
41272743|NCT02862691|DRUG|Bupivicaine (Injectable local anesthetic)|local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
41272744|NCT03856957|DEVICE|Endocuff colonoscopy|Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).
41272745|NCT03856957|DEVICE|control|colonoscopy without endocuff
41272746|NCT03303989|DRUG|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
41272747|NCT03303989|DRUG|MMF|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
41446441|NCT05694676|OTHER|Assessment of the quality of Genaral Movements (GMs)|The variation, complexity and fluency of movements over a video recording is done and the quality of GMs is classified as normal-optimal, normal-suboptimal, mildly abnormal, and definitely abnormal movements.
40758267|NCT02576704|DEVICE|semi conductor gamma camera|we use a new mathematic technique from entropy analysis to provide precise, objective, automated quantification of perfusion heterogeneity at stress with camera SPECT. This method may be a non-invasive imaging to assess coronary microvascular dysfunction.
41120457|NCT01393067|DEVICE|Covered self-expandable metal stent (cSEMS)|Removable, covered self-expandable metal stent (cSEMS)
41120458|NCT03736434|BEHAVIORAL|Mindfulness and DASH Diet Education|"Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines."
41120459|NCT03736434|BEHAVIORAL|Education group|The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.
40753579|NCT05656976|OTHER|Provision of self sampling device by letter|In the second arm, a second group of 45 GP practices in Flanders will be recruited. With the intervention of the Centre for Cancer Prevention (Flanders), 25 at randomly selected long-term unscreened women with a Global Medical Form (in dutch: 'Globaal Medisch Dossier, GMD) in one of these practices will receive an envelope containing a letter of invitation from their GP for cervical cancer screening, a brochure with the advantages and disadvantages of cervical cancer screening and more specifically the use of a self-taking kit, and a self-taking kit. If the woman wishes, she can use the kit when and where it suits her and send it to the lab with the pre-paid envelope. As in arm A, the woman will be informed of the Human Papilloma Virus test result by her GP according to the usual way in the practice (e.g., by letter, by phone or during the next consultation). All women will receive a study-related reminder letter after 4 months.
41120460|NCT04073199|PROCEDURE|Long Lever Group|"the physiotherapist wears the limb passively towards flexion, external rotation and abduction until the physiotherapist has perception of stretch of the tissues (sensation terminal elastic firm according to the concept of Orthopaedic Manual Therapy for the soft tissue treatment) The patient's own weight stabilizes the proximal segment, in case that the scapula is not stable, the physiotherapist fixes with his free hand the scapula.~The technique will be performed two days a week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)."
41272748|NCT03303989|DRUG|Placebo|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
41272749|NCT03303989|DRUG|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
41272750|NCT01737814|DRUG|Saline|
41272751|NCT01737814|DRUG|MST-188|
41272752|NCT00832819|DRUG|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
41272753|NCT00832819|DRUG|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
41272754|NCT00832819|DRUG|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
40753580|NCT03862053|DRUG|Manuka honey|manuka eyedrops applied to the ocular surface
40753581|NCT02722603|DRUG|gabapentin|75 mg/ml gabapentin syrup
40753582|NCT02722603|DRUG|tramadol|100 mg/ml tramadol oral drops
40753583|NCT02722603|OTHER|placebo tramadol|placebo tramadol oral drops
40753584|NCT02722603|OTHER|placebo gabapentin|placebo gabapentin syrup
40753585|NCT02639559|DRUG|BL-8040|
40753586|NCT02639559|PROCEDURE|Leukapheresis|
41272755|NCT00832819|DRUG|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
41272756|NCT00925847|DRUG|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
41272757|NCT02113657|DRUG|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
41272758|NCT04304456|OTHER|Treatment|Antimicrobial and other treatment modalities such as source control, vasoactive medications, dialysis
41272759|NCT02504255|BIOLOGICAL|Biological samplings|Blood, urine and faecal sampling every 3 months
41272760|NCT02504255|OTHER|Questionnaires|patients fill several questionnaires every month to assess stress and adaptation parameters
41272761|NCT01713634|OTHER|Preflight|4-d controlled diet sessions will occur twice before flight.
41272762|NCT01713634|OTHER|In-flight|4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
41272763|NCT06340919|DEVICE|Sudden Sound Reduction Setting|Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Low, High, or Maximum. Recordings with the different settings will be randomized from trial to trial.
40753587|NCT02639559|PROCEDURE|Hematopoietic cell transplant|
40753588|NCT02111980|DEVICE|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
40753589|NCT00477217|DRUG|Zoledronic acid|
40753590|NCT02080000|OTHER|Optimisation of V-V timing using R wave on surface ECG|
40753591|NCT02080000|OTHER|Standard V-V timing settings|
40753592|NCT03093168|BIOLOGICAL|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
41272764|NCT01677845|RADIATION|Radiation|"Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions."
41272765|NCT03409549|RADIATION|Fluciclovine PET/CT|Fluorine-18 Fluciclovine PET/CT scan of the brain
41272766|NCT00296322|DRUG|cisplatin, mitomycin-C, doxifluridine|"Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)"
41272767|NCT02243501|BEHAVIORAL|Intervention Group|The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
41272768|NCT06120257|PROCEDURE|lithotripsy using Flexible ureteroscope|using Flexible ureteroscope and holmium laser lithotripsy to get high stone clearance rate
41272769|NCT06120257|PROCEDURE|extracorporeal shock wave lithotripsy (ESWL)|using extracorporeal shock wave lithotripsy (ESWL) to get high stone clearance rate
40753593|NCT03093168|DRUG|Fludarabine|dose: 25mg/m2/d
40753594|NCT03093168|DRUG|Cyclophosphamide|Dose: 40mg/kg
40753595|NCT02102828|DEVICE|extended compression|Home use of extended compression therapy and aspirin
40753596|NCT02102828|OTHER|Aspirin|standard therapy of aspirin
40753597|NCT04601909|DRUG|FX-322|active comparator
40753598|NCT04601909|OTHER|placebo|placebo
40753599|NCT03946410|DIAGNOSTIC_TEST|Invitation to screening|Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests
40753600|NCT04295265|DEVICE|smartphone message|Receive daily whatsapp/ SMS message to remind the drug intake
40753601|NCT02278237|BEHAVIORAL|VME Group|Received inhaler education through VME (virtual education module)
40753602|NCT00202995|DRUG|Glatiramer Acetate|20 mg s.c. daily
40753603|NCT00202995|DRUG|Betaseron|250 mg every other day
40753604|NCT00202995|DRUG|Rebif|44 ug 3 times a week
40753605|NCT00002238|DRUG|Interferon beta-1b|
40753606|NCT00002238|DRUG|Zidovudine|
40753607|NCT06172049|OTHER|treatment|the actual treatment CRC patients have reveived
40753608|NCT05130957|OTHER|Massage Application with clove oil|The experimental group is given a massage with clove oil,
40753609|NCT05130957|OTHER|Massage Application without any oil|The control group is given a massage without any oil as a standard midwifery care.
40753610|NCT03569007|DRUG|Larazotide|Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
40753611|NCT03569007|DRUG|Matching Placebo|enteric-coated beads in gelatin capsules
40753612|NCT01205737|BIOLOGICAL|TL011|375 mg/m2 iv every 3 weeks for 8 cycles
40753613|NCT01205737|BIOLOGICAL|Rituximab|375 mg/m2 iv every 3 weeks for 8 cycles
41272770|NCT06120257|PROCEDURE|holmium laser lithotripsy using Karl® Storz MIP set|using holmium laser lithotripsy using Karl® Storz MIP set to get high stone clearance rate
41272771|NCT05650034|RADIATION|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H\&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H\&N SCCs ( pN0 or by PETCT).
41446442|NCT05694676|OTHER|State-Trait Anxiety Inventory-Trait, (STAI-T)|The scale consists of 20 items in total and provides a four-point Likert type measurement (1- anxiety symptom is not present, 4- the symptom lasts all the time). Scores range from 20 (low anxiety) to 80 (high anxiety).
40753614|NCT00245570|DRUG|Comparator: Montelukast|1 dose montelukast 10 mg tablet given orally in one of three treatment periods
40753615|NCT00245570|DRUG|Comparator: Salmeterol|1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
40753616|NCT00245570|DRUG|Comparator: Placebo (montelukast)|1 dose matching-image placebo to montelukast tablet in two of three treatment periods
41120461|NCT04073199|PROCEDURE|Short Lever Group|"It consists of a stretch made by the physiotherapist, with the patient in supine position, with the extremity to be treated in a submaximal position of flexion and external rotation (fixed by the arm and body of the physiotherapist) and realizing the stretch a through the scapula in the medial and caudal dorsal direction.~The technique will be performed two days per week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)"
41446443|NCT05694676|OTHER|Beck Depression Inventory, (BDI)|BDI contains 21 items and rates the depressive symptoms for the last week. Each item has four options and is scored between 0 and 3. The total score ranges from 0 to 63. Higher scores indicate more severe depression
40753617|NCT00245570|DRUG|Comparator: Placebo (salmeterol)|1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
40753618|NCT06319443|DIETARY_SUPPLEMENT|Liquid vinegar|3.5 g acetic acid
40753619|NCT06319443|DIETARY_SUPPLEMENT|vinegar pill|0.022 g acetic acid
41446444|NCT00004796|DRUG|lactulose|
41272772|NCT01629303|PROCEDURE|sacral nerve modulation|"After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 15 days.~Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks"
41272773|NCT01360125|GENETIC|proteomic profiling|
40753620|NCT06539377|PROCEDURE|Living donor liver transplantation|"Liver transplantation from living donor donation (SII/III as left-lateral donation during a two stage-procedure or left lobe donation or right lobe donation) in patients with unresectable intrahepatic cholangiocarcinoma."
40753621|NCT01169909|DRUG|Ranibizumab|Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
40753622|NCT01382407|DRUG|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
40753623|NCT01429935|DRUG|Ginger powder|capsules contain 500mg Ginger powder,every 6hours,for 5 days
40753624|NCT01429935|DRUG|Ibuprofen|capsules of Ibuprofen 400 mg, every 6 hours for 5 days
40753625|NCT01429935|OTHER|placebo|capsules contain starch
41120462|NCT02421159|BEHAVIORAL|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
41120463|NCT02421159|BEHAVIORAL|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
41272774|NCT01360125|OTHER|flow cytometry|
41272775|NCT01360125|OTHER|laboratory biomarker analysis|
40753626|NCT00183391|DRUG|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
40753627|NCT00183391|DRUG|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
41272776|NCT00457405|DRUG|dipyridamole|dipyridamole 200mg twice daily
41272777|NCT05379751|PROCEDURE|Fixation free Spigelian hernia repair with tentacle mesh|Spigelian hernias are repaired through the fixation free placement of a tentacle mesh in preperitoneal sublay thanks the friction exerted by the tentacle straps delivered by a proprietary needle passer crossing trouh the abdominal wall from the preperitoneal space until the subutaneous layer. This procedural approach should also grant a broad overlap of the implant over the hernial defect
41272778|NCT00535340|DRUG|SR58611A|
41272779|NCT02149225|DRUG|APVAC1 vaccine plus Poly-ICLC and GM-CSF|"APVAC1 vaccines (i.d.) will be individually assembled for each patient and can be applied to the patient approx. 3 months after enrollment. APVAC1 drug products are composed of 5 to 10 peptides from the GAPVAC warehouse. The APVAC1 vaccine will be applied concurrent to maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 15 of the first maintenance TMZ cycle, patients will receive 11 vaccinations with APVAC1 drug products during 22 weeks. 578 μg per peptide per vial are used.~Poly ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~The 2. immunomodulator GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
41272780|NCT02149225|DRUG|APVAC2 vaccine plus Poly-ICLC and GM-CSF|"APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. APVAC2 drug products are composed of 1 or 2 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with APVAC2 drug products beginning on day 15 of the 4. maintenance TMZ cycle. Patients will receive 8 vaccinations within 10 weeks. 578 μg per peptide per vial are used.~Poly-ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
41272781|NCT02598414|PROCEDURE|Near-infrared ICG fluorescence imaging|Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
41272782|NCT02598414|PROCEDURE|Traditional bowel anastomosis|Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
41272783|NCT02598414|DEVICE|FireFly™|The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
40753628|NCT03425370|PROCEDURE|Closure of surgical wounds using buried sutures or tissue adhesive on aesthetic outcome.|Effect of replacing buried sutures with tissue adhesive on aesthetic outcome of surgical wounds will be measured using the POSAS.
41120464|NCT00661869|OTHER|Wellness Program|36 weeks of educational and supportive interventions
41120465|NCT05425992|OTHER|Interview|Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
41120466|NCT03764787|COMBINATION_PRODUCT|Radiation+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
41120467|NCT03700853|DIAGNOSTIC_TEST|Dysphagia Trained Nurse Assessment (DTNAx)|Bedside swallowing assessment carried out by trained nurses
41120468|NCT03454646|DRUG|cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)|"The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as non-responders or responders.~Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
41120469|NCT03792620|COMBINATION_PRODUCT|Cyclo Thal Dex Daratumumab|Cyclo Thal Dex Daratumumab
41120470|NCT04149002|BEHAVIORAL|Intervention Arm Weekly IP3 text messages|Subjects will be provided with a pre and post intervention survey, in addition to a narrated Powerpoint presentation focusing on the logistics of their IP3. Subjects will also receive weekly automated text messages to encourage adherence to the need for their IP3.
41120471|NCT04149002|OTHER|Active Control Arm General pregnancy text messages|Subjects will be given pre and post pre questionnaires, in addition to a narrated Powerpoint presentation about the Clinic. Subjects will also be sent weekly text messages with general pregnancy information.
41120472|NCT02402569|DEVICE|32 channels Deep Brain Stimulator|
41120473|NCT03649113|PROCEDURE|sclerotherapy arm|The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
41120474|NCT02382328|DRUG|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
41120475|NCT02382328|DRUG|Placebo|Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
41120476|NCT00111085|DRUG|Clazosentan 1 mg/h|Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
41120477|NCT00111085|DRUG|Clazosentan 5 mg/h|Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
41272784|NCT02842931|DRUG|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
41272785|NCT02842931|DRUG|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
40753629|NCT04461535|DRUG|Adrenocorticotropic hormone|Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.
41120478|NCT00111085|DRUG|Clazosentan 15 mg/h|Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
41120479|NCT00111085|DRUG|Placebo|Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
41120480|NCT05512858|BEHAVIORAL|sensory room|the room has dimmed lighting, sensing games, essential oils, picture books and cookbooks, two heavy blankets (weighing 9 kg and 11 kg), a rocking chair, and a vestibular plate. The occupational therapist will accompany the first entry into the room to create a sensory profile, adjust and instruct on the means, and write a treatment card. The treatment card will record the patient's choices and instructions for arranging the room, and it will be used by the staff members who will admit the patient as needed. Each patient will be able to stay in the room for self-treatment according to the individual treatment card prepared at the first sensory room treatment, up to half an hour.
40926470|NCT03206996|BEHAVIORAL|Exposure therapy|"The therapist, child and family collaborate to set short and long term goals, develop the exposure hierarchy and Subjective Units of Distress (SUD) scale and design their challenge activities (i.e., exposures). The exposure hierarchy lists activities in ascending order from minimal exposure/minimally difficult (e.g, toilet is not flushed and bathroom door is closed while child walks by) to maximum exposure/maximally difficult (e.g., toilet is flushed repeatedly while child is inside the stall with the door closed). Treatment begins with exposure to activities on the lower end of the hierarchy, with adjustments as indicated, to present stimuli that provide a just-right level of difficulty as indicated by the participant's SUD level and therapists clinical judgment. Participants communicate the level of difficulty using their individualized SUD scale. Additionally, the child and family complete home exercises with exposures."
41120481|NCT04630535|PROCEDURE|aorto-bifemoral bypass surgery|aorto-bifemoral bypass surgery (Leriche syndrom, elective AAA repair)
41120482|NCT03084549|DRUG|Administration of Ropivacaïne|Administration of Ropivacaïne in the margins of the episiotomy
41120483|NCT03084549|DRUG|Administration of placebo|Administration of placebo in the margins of the episiotomy
41120484|NCT04470375|BEHAVIORAL|Virtual Reality Pain Neuroscience Education|Use of virtual reality media to provide pain neuroscience education
41120485|NCT05624112|DRUG|Dupilumab|Dupilumab solution in a pre-filled syringe for Subcutaneous injection
41120486|NCT04263519|DRUG|Tacrolimus|Oral Immunosuppressant
41120487|NCT04496830|DEVICE|SOMAscan|Analysis of previously donated cerebrospinal fluid using a SOMAscan assay
41120488|NCT02489695|DRUG|Axitinib|axitinib 10mg twice a day
41272786|NCT02842931|DRUG|R-mNHL-BFM-90|R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
41120489|NCT05845177|PROCEDURE|Primary Total Hip Arthroplasty|All patients surveyed have undergone primary total hip arthroplasty approximately 1 year prior to survey distribution
41272787|NCT02842931|DRUG|R-mNHL-BFM-90 + auto-SCT|R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
41272788|NCT05572476|DRUG|Association of lurbinectedin and durvalumab|"A treatment cycles consists of 3 weeks (i.e. 21 days). Lurbinectedin will be administered by intravenous infusion on Day 1 every 3 weeks.~Durvalumab will be administered by intravenous infusion on Day 1 every 3 weeks."
41272789|NCT05572476|DRUG|Association of carboplatin and etoposide|"Treatment will be administered on a 21-days cycle basis up to a maximum of 6 cycles.~Carboplatin will be administered by intravenous infusion on Day 1 every 3 weeks.~Etoposide will be administered by intravenous infusion on Day 1-3 every 3 weeks"
40753630|NCT03826004|DRUG|Clemastine|Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle
41272790|NCT04996719|DRUG|Rapamune|We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).
41272791|NCT01591070|DRUG|Tacrolimus|0.1% tacrolimus once-weekly application for 10 weeks
40753631|NCT03826004|DRUG|Saline Solution|Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
40753632|NCT02931539|DRUG|Maribavir|Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.
40753633|NCT02931539|DRUG|Ganciclovir|Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
40753634|NCT02931539|DRUG|Valganciclovir|Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
40753635|NCT02931539|DRUG|Foscarnet|Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
41120490|NCT05208242|DRUG|hyperoncotic human albumin solution|20% human albumin solution (presented in 100ml glass bottles)
41272792|NCT01591070|DRUG|Tacrolimus|0.1% tacrolimus twice weekly application for 10 weeks
40753636|NCT02931539|DRUG|Cidofovir|Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
40753637|NCT00160875|DRUG|Irinotecan hydrochloride trihydrate|Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
41272793|NCT02953717|RADIATION|Gamma Knife radiosurgery|GKRS is performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target.
41272794|NCT02953717|RADIATION|Whole Brain Radiation Therapy|Patients in the WBRT group will receive 4 Gy x 5 fractions (total of 20 Gy) in one week, which is a commonly utilized treatment schedule according to Dutch guidelines.
41272795|NCT00087438|RADIATION|stereotactic body radiation therapy|
41272796|NCT06432738|DRUG|ZL-82|This group of subjects take ZL-82
41272797|NCT06432738|DRUG|ZL-82 placebo|This group of subjects take ZL-82 placebo
41272798|NCT00486486|DRUG|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
41272799|NCT00486486|DRUG|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
41272800|NCT03715465|DRUG|Melatonin 0.5 MG|Melatonin tablet
41272801|NCT03715465|OTHER|Dim Light Melatonin Onset (salivary)|Test to determine the time of melatonin onset in saliva under dim light conditions
41272802|NCT04666207|DIAGNOSTIC_TEST|PCR|RT-PCR for SARS-CoV-2
41272803|NCT03314285|OTHER|Sleep Quality|Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.
41272804|NCT04724889|DIAGNOSTIC_TEST|blood test|Blood test to check high sensitivity troponin. Additional blood biomarkers maybe added in light of new research
41272805|NCT01238120|DRUG|Ibuprofen|200 mg BID and 8 hours apart
41272806|NCT01238120|BEHAVIORAL|Home-Based Exercise|A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
41272807|NCT01238120|DRUG|Placebo|200mg BID and 8 hours apart
41272808|NCT00578123|BEHAVIORAL|Quality of Life Questionnaires|Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
41272809|NCT00354302|DIETARY_SUPPLEMENT|calcium carbonate|
41272810|NCT00354302|DIETARY_SUPPLEMENT|calcium citrate|
41272811|NCT00354302|DIETARY_SUPPLEMENT|cholecalciferol|
41272812|NCT00354302|DRUG|alendronate sodium|
41272813|NCT00354302|DRUG|calcium gluconate|
41272814|NCT00354302|DRUG|risedronate sodium|
41272815|NCT00354302|OTHER|laboratory biomarker analysis|
40753638|NCT00160875|DRUG|Cisplatin|Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
40753639|NCT01642849|DIETARY_SUPPLEMENT|high protein diet|6 months on HP diet
40753640|NCT01642849|DIETARY_SUPPLEMENT|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
40753641|NCT04956965|RADIATION|Cardiac electro-mapping|Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
40753642|NCT05050838|OTHER|Transcranial Doppler (TCD)|"TCD ultrasonography is based on the principle of the Doppler effect. According to this principle, ultrasound waves emitted from the Doppler probe are transmitted through the skull and reflected by moving red blood cells within the intracerebral vessels. The difference in the frequency between the emitted and reflected waves, referred to as the Doppler shift frequency, is directly proportional to the speed of the moving red blood cells (blood flow).~Cerebral blood flow (in cm/s) of the middle cerebral artery will be measured with TCD in blood-injured ARDS patients before and one hour after prone positioning (normal ranges: 48 to 72 cm/s)."
41120491|NCT05208242|DRUG|Buffered crystalloid solutions|Buffered crystalloids solutions for all intravenous fluid therapy
41272816|NCT00354302|PROCEDURE|dual x-ray absorptometry|
41272817|NCT00000769|DRUG|Interleukin-4|
41272818|NCT04525755|DRUG|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
41272819|NCT04525755|DRUG|Nicotine Replacement Therapy (NRT)|28 day supply of nicotine patch (1 patch x 28 days @ 14 mg) and lozenge (14 per day x 28 days @ 4 mg)
41272820|NCT02392260|DEVICE|Vasculight|Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
41272821|NCT03745924|DRUG|Nonacog beta pegol|Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
40753643|NCT04898465|OTHER|Social Paediatric Intervention|Family will meet the hospital's social-paediatrician and social worker. Together they will evaluate the need for social support, risk for neglect and refer families for local social services if needed. The visit will contain primary and secondary prophylaxis of child abuse and neglect.
40926471|NCT03206996|BEHAVIORAL|Psycho-education|Child and caregiver receive education and training will be provided to improve the participant's self-awareness of his/her behavioral and emotional response to auditory stimuli, his/her ability to self-report anxiety/emotional response levels, as well as his/her ability to identify useful arousal level modulation/coping strategies. During this phase, the child, caregiver and therapist will collaborate to identify the participant's Subjective Units of Distress Scale (SUD) from 0-10 with each level defined, particularly for what levels are tolerable or intolerable.
41272822|NCT04522492|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|2 booster sessions of cognitive behavioral therapy (CBT) delivered thru internet to patients previously treated with CBT. First session focus on understanding the symptoms of skin picking and training techniques to reverse the habit. Second session focus on comorbid symptoms of anxiety and depression, training strategies to improve it.
41272823|NCT04522492|OTHER|Quality of life promotion|2 videos about quality of life promotion will be send to patients in the active control arm. In the first week, the videos will consist in: social support techniques and sleep hygiene. After one week, 2 another videos will be send, consisting in: guide about healthy diet and about physical exercise.
41272824|NCT03691714|DRUG|Durvalumab|Two hour infusion
41272825|NCT03691714|DRUG|Cetuximab|Two hour infusion for loading dose followed by weekly one hour infusion
40753644|NCT05125627|DRUG|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
40753645|NCT05125627|DRUG|Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
40753646|NCT05706402|DRUG|N-acetylcysteine|Patients will be randomized to receive oral N-acetylcysteine at 600 mg twice daily for 1 week. The randomization will be done via computer software with half of the patients randomized to receive NAC. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
41272826|NCT04471896|DEVICE|Joovv Mini|Infrared light therapy uses certain wavelengths of light that are delivered to the face. This study will use the Joovv Mini.
41272827|NCT03339141|PROCEDURE|Intubation position|The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
41272828|NCT02866344|PROCEDURE|Microwave ablation|Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
41272829|NCT02866344|PROCEDURE|Hepatic resection|Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
41272830|NCT02344810|DRUG|c-Met inhibitor AMG 337|Given PO
40753647|NCT05706402|DRUG|Placebo|Patients will be randomized to receive placebo for 1 week. The randomization will be done via computer software with half receive placebo. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
41120492|NCT05561881|OTHER|popliteal artery and the capsule of the posterior knee (IPACK) block|ultra-sound visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to the lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
40753648|NCT01803737|BEHAVIORAL|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
40947809|NCT03860610|DIAGNOSTIC_TEST|Passive range of motion|Passive range of motion will be assessed for ankle plantar-/dorsiflexion, knee flexion/extension and hip flexion/extension, ab/adduction, internal/external rotation using goniometers and recorded in degrees. The range between two maxima will be recorded.
41272831|NCT02344810|OTHER|placebo|Given PO
41272832|NCT02344810|DRUG|oxaliplatin|Given IV
41272833|NCT02344810|DRUG|leucovorin calcium|Given IV
41272834|NCT02344810|DRUG|fluorouracil|Given IV
41272835|NCT02344810|OTHER|pharmacological study|Correlative studies
41272836|NCT02344810|OTHER|laboratory biomarker analysis|Correlative studies
41272837|NCT00138762|DRUG|torcetrapib/atorvastatin|
41272838|NCT00138762|DRUG|atorvastatin|
41272839|NCT00138762|DRUG|placebo|
41120493|NCT05561881|OTHER|genicular nerves block|ultra-sound transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, A20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming placing of the needle next to each genicular artery a total amount of 20 ml local anesthetic in equal increments at multiple sites.
41120494|NCT00741455|PROCEDURE|Stem Cell Transplant|"Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \> 5 x 106 CD34+cells/kg of recipient.~Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.~Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml."
41120495|NCT00741455|DRUG|G-CSF|10 mcg/kg/day on days 5, 6, and 7
41120496|NCT00741455|DRUG|Fludarabine|25 mg/m2/d IV over 30 minutes on days -6 to -2
41120497|NCT00741455|DRUG|cyclophosphamide|1 g/m2/d IV on days -3 and -2
41120498|NCT00741455|DRUG|Cyclosporine|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
41120499|NCT00741455|DRUG|Methotrexate|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
41272840|NCT00693706|BIOLOGICAL|Trivalent influenza vaccine GSK 138842A|IM injection on Day 0
41272841|NCT00693706|BIOLOGICAL|Fluarix|IM injection on Day 0
41272842|NCT00002025|DRUG|Ganciclovir|
41272843|NCT00686543|DRUG|Posaconazole|Posaconazole will be used for prophylaxis
41272844|NCT05805514|OTHER|Animal source of food and psychosocial stimulation|209 mother-child pair will receive the animal source of food and psychosocial stimulation for 12 months. Child will be recruited within 6-12 months.
41120500|NCT00327561|PROCEDURE|Intensive periodontal therapy|
41120501|NCT00327561|PROCEDURE|Community based periodontal therapy|
41272845|NCT05805514|OTHER|Animal source of food|209 mother-child pair will receive the animal source of food for 12 months. Child will be recruited within 6-12 months.
41272846|NCT05805514|OTHER|Control|209 mother-child pair will receive the control package for 12 months. Child will be recruited within 6-12 months.
41272847|NCT02103686|DRUG|Lyrica|
41272848|NCT02103686|DRUG|Experimental drug|sustained release formulation of pregabalin
41272849|NCT02103686|DIETARY_SUPPLEMENT|High fat meal|
40947810|NCT05096052|DRUG|Galactomannan|Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
41120502|NCT01488734|DIETARY_SUPPLEMENT|Mushroom with 600 IU vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
41120503|NCT01488734|DIETARY_SUPPLEMENT|Mushroom with 4000 IU Vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
41272850|NCT02103686|DIETARY_SUPPLEMENT|fasted|
41272851|NCT06299943|OTHER|Biofeedback gait training by biomechanical target parameter|The patient walks using a treadmill at a comfortable speed until he gets tired. The patient is instructed that when performing a virtual task (in a virtual environment on the screen), his walking will be harmonized (without informing him on what parameter). If it fails to cope, then the zones of permissible changes (on the information columns) will expand, and the virtual task will signal its incomplete completion.
41272852|NCT00422279|DEVICE|Nobel Replace Tapered Groovy|Bone inductive implant placed in supralveoral position or extraction site
41272853|NCT04012749|BEHAVIORAL|Advance directive|Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.
41272854|NCT04012749|BEHAVIORAL|Prepare|Patient invited to use the Prepare For Your Care website (www.prepareforyourcare.org) that will introduce and facilitate advance care planning and guide completion of an advance directive.
41272855|NCT04012749|BEHAVIORAL|Facilitator|Facilitator engages patient to activate advance care planning and to carry out navigation and facilitation aspects of advance care planning. Facilitator can tee up advance care planning activities with the primary care physician.
41272856|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
41272857|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
41272858|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
41272859|NCT00971308|DRUG|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
41272860|NCT00971308|DRUG|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
41272861|NCT00130871|DRUG|levosimendan|
41272862|NCT03561233|DRUG|Omeprazole 20mg|omeprazole 20 mg twice daily 30 minutes before meal for 4 weeks
41272863|NCT02722044|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
40753649|NCT01803737|BEHAVIORAL|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
41120504|NCT01488734|DIETARY_SUPPLEMENT|600 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
41120505|NCT01488734|DIETARY_SUPPLEMENT|4000 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
41120506|NCT01488734|DRUG|Placebo|Placebo for the fortified mushroom arms
41120507|NCT03492424|DEVICE|cryotherapy|Subjects will receive focal cryotherapy for treatment of prostate cancer
41120508|NCT06051955|OTHER|oral sodium sulfate|All participants enrolled in this study will use Oral Sodium Sulfate as their bowel cleansing agent.
41120509|NCT06515301|BEHAVIORAL|Intervention 1: Structured nurse-led telephone call reminders. Intervention 2: Home-visit reminders by health extension workers. Intervention 3: Application-based automated SMS text reminders.|Information already available
41120510|NCT03244813|OTHER|Personalized activity program|Targeted physical activity
41120511|NCT03019913|OTHER|Observational cohort|Evaluation of bedside methods to measure muscularity in critically ill patients
41120512|NCT04643899|DEVICE|Muscle Electrostimulation|"* Scheduled sessions of 20 minutes per day; 5 days a week~* In physiotherapy or in their room for the most dependent patients~* Installation and monitoring by a physiotherapist or by the trained clinical research nurse~* Modalities:~  * Device program n ° 1: 20mn (2mn of warm-up, 15mn of work at 75hz, then 3mn of recovery)~ * 4 electrodes (2 per thigh): large model (5 \* 10 cm) for better comfort - Dura-Stick Plus model (reference 42200)~ * Gradual auto-increase of the intensity to the highest possible value tolerated, nevertheless allowing a contraction"
41120513|NCT03298724|BEHAVIORAL|Teachers and Parents as Partners|A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
41120514|NCT01362153|DRUG|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
41120515|NCT01362153|DRUG|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
41272864|NCT02722044|DEVICE|Autoinjector|Subcutaneous administration
41272865|NCT01724892|DRUG|Dexamethasone|
41272866|NCT01724892|DRUG|Loteprednol etabonate|
41272867|NCT00002113|DRUG|Flucytosine|
41272868|NCT00002113|DRUG|Fluconazole|
41272869|NCT04186611|OTHER|early occupational therapy|"The intervention will be the one usually carried out but earlier and on a daily basis. It will consist of the initial assessment and then positioning and/or carrying out activities of daily living.~The daily duration of the intervention will be about 45 minutes to 1 hour. The overall duration of the intervention will be determined according to the objectives and will be at most equal to the time of stay in the intensive care unit."
41272870|NCT05300087|DRUG|Albuterol Sulfate Inhalation Aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
41272871|NCT05300087|DRUG|Proair HFA (albuterol sulfate) Inhalation Aerosol 90mcg per actuation|MDI, 2 puffs, single dose, fasting
41272872|NCT01104220|OTHER|Weight loss|Bariatric surgery-induced weight loss to achieve \~20%-30% reduction in initial body weight
41272873|NCT02948166|PROCEDURE|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
41272874|NCT02948166|PROCEDURE|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
41272875|NCT00239031|DRUG|Enteric-Coated Mycophenolate Sodium|Enteric-Coated Mycophenolate Sodium
40753650|NCT02151604|DRUG|Inhalation of hyperpolarized xenon gas|The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
40753651|NCT01133977|DRUG|Lenvatinib|Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
40753652|NCT01133977|DRUG|Lenvatinib|Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
40753653|NCT01133977|DRUG|Dacarbazine|Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
40753654|NCT05180773|DRUG|Bromocriptine|Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.
40753655|NCT05180773|DRUG|Placebo|Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
40753656|NCT05180773|DRUG|Guideline Directed Medical Therapy for Heart Failure (GDMT)|GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
41120516|NCT06154746|DIAGNOSTIC_TEST|slit lamb & OCT|"1. The Slit lamb is a biomicroscope. It emits a beam of light that can be varied in height and width. It allows visualization of the anterior segment of the eye. With auxiliary lenses, the examiner can also view the posterior segment. These lenses are simple, affordable, and portable. Although high-end devices like fundus cameras and optical coherence tomography have revolutionized how practitioners detect eye diseases, they can never replace these handheld lenses.~2. OCT is a noninvasive method that yields a cross-section image of the retina by exposing the eye to near-infrared light. Specifically, an emitted light beam is scattered and reflected back by the retinal surface as well as its different layers."
41120517|NCT00203216|DRUG|levetiracetam|Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
41120518|NCT00203216|PROCEDURE|Transcranial Magnetic Stimulation|
41120519|NCT02201043|DRUG|Thalidomide 150mg|
41120520|NCT02201043|DRUG|Thalidomide 100mg|
41120521|NCT02201043|DRUG|Placebo|
41120522|NCT01736891|DRUG|Rasagiline|Tablets, qd
41120523|NCT01736891|DRUG|Placebo|Tablets, qd
41120524|NCT01947634|OTHER|ResMed Apnea Link plus|Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
41272876|NCT03850821|BEHAVIORAL|Connect Social Mechanisms Intervention|"The Get-to-Know-You small group sessions (30 minutes) were designed to increase friendship building skills and involved interactive student-led discussions and activities designed to foster the assets needed to build and support friendships, group cohesion, and staff connections through PA. The PA component of the program (60 minutes) was designed to promote a positive PA social experience and meet youth social affiliation goals. Available games to choose from were novel, inclusive, emphasized teamwork, and centered on social goals. Three different PA stations were offered each program day in which youth rotated. One day each week was designated as a choice day, whereby youth activity preference ratings were used to determine which activities were offered that day."
41272877|NCT01447394|BIOLOGICAL|Pegylated Interferon Lambda|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
40753657|NCT05180773|DRUG|Rivaroxaban|Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.
40753658|NCT05180773|DRUG|Second Placebo|Subjects not on anticoagulation clinically who are randomized to placebo (rather than bromocriptine) will receive a second placebo one tablet by mouth daily for 8 weeks.
40753659|NCT00063037|BEHAVIORAL|Behavioral modification - nutrition education|
40753660|NCT00667979|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
40753661|NCT00667979|DRUG|Placebo|Matching placebo
40753662|NCT04501445|BEHAVIORAL|Written Summary of Rounds|The summary was organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
40753663|NCT00421733|DRUG|Zemplar (paricalcitol ) capsules|Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
40753664|NCT00421733|DRUG|Zemplar (paricalcitol) capsules|Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
40753665|NCT00421733|DRUG|Placebo|Group 1 - Placebo once daily (two placebo capsules once daily)
40753666|NCT05792254|DRUG|Huaier granule|Oral Huai Er granules, 20 g once, 3 times a day, continued to progress or intolerance toxicity.
40753667|NCT00072579|BIOLOGICAL|sargramostim|
40753668|NCT01769443|DRUG|bortezomib|Bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
40753669|NCT01769443|PROCEDURE|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
40753670|NCT03673722|OTHER|Foods consistent with a MDP|We aim to increase MDP by 3 points, according to a 14-point MEDAS score
40753671|NCT03673722|OTHER|Physical Activity|We aim to increase PA to 150 minutes moderate activity per week.
40753672|NCT03673722|OTHER|Control|Participants will be given generic healthy eating advice based
41120525|NCT00807144|DRUG|Tacrolimus (Kidney transplant maintenance immunosuppression)|Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
41272878|NCT01447394|BIOLOGICAL|Pegylated Interferon Alfa-2a|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
41272879|NCT01447394|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
41272880|NCT03767257|DRUG|Colesevelam Pill|For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
40753673|NCT01712074|DRUG|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
41120526|NCT00807144|DRUG|Kidney transplant maintenance immunosuppression|Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
41120527|NCT06414850|BEHAVIORAL|Animal Assisted Therapy (AAT)|A structured AAT program and pharmacological treatment in Experimental group. The same structured program without therapy dog and pharmacological treatment in Control group.
41120528|NCT04775992|OTHER|gabapentoids|Preemptive analgesia
41272881|NCT03747445|PROCEDURE|Roux-en-Y gastric bypass|laparoscopic surgical procedure
41272882|NCT05592340|BEHAVIORAL|Exposure to calorie information|Calories for all foods and beverages
41272883|NCT05592340|BEHAVIORAL|Exposure to carbon footprint information|Carbon footprint labels for all foods and beverages
41120529|NCT04593251|BIOLOGICAL|CALY-002|1-hour intravenous infusion
41120530|NCT04593251|BIOLOGICAL|Placebo|1-hour intravenous infusion
41120531|NCT00785512|DRUG|Nebivolol|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
41120532|NCT00785512|DRUG|Placebo|Matching placebo tablets, oral administration
41120533|NCT06248177|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules
41120534|NCT06248177|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
41120535|NCT00801658|DEVICE|selective Laser Trabeculoplasty (SLT)|
41120536|NCT05705856|DRUG|Ustekinumab|Patients will receive an intravenous induction (adjusted 6 mg/kg dose) followed by subcutaneous 90 mg every 12 or 8 weeks, and will receive dose escalation when response is not effective enough.
41272884|NCT03226990|OTHER|impression technique|impression technique with and without wax spacer
41446445|NCT04311164|OTHER|Questionnaire-based survey|The online questionnaire-based survey is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions, rating scales and validated questionnaire scales to measure general and diabetes/insulin pump-specific behavior, psychological concepts and preferences.
40753674|NCT01712074|OTHER|Placebo|Placebo QD
40753675|NCT03614585|BEHAVIORAL|12 weeks of High-intensity Interval Training|Cardiovascular exercise
40753676|NCT03614585|BEHAVIORAL|12 weeks of Moderate-Intensity Continuous Training|Cardiovascular exercise
40753677|NCT05362799|DRUG|Letrozol (Femara, Novartis)|Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
40753678|NCT05362799|DRUG|Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)|Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
40753679|NCT05362799|DRUG|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
40947811|NCT05096052|DRUG|PLACEBO|A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
41120537|NCT05327049|OTHER|no intervention|treatment of deep carious lesions
41120538|NCT05327049|DEVICE|diode laser|laser light for cavity disinfection
41120539|NCT05327049|DIETARY_SUPPLEMENT|Aloe Vera|herbal dietary supplement for treatment of deep carious lesions
40753680|NCT05362799|DRUG|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
40753681|NCT01404065|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
40753682|NCT03657407|DRUG|Belladonna Opium|Belladonna Opium 16.2-60mg rectal suppository
41120540|NCT00255359|DRUG|XTL-2125|
41120541|NCT02615769|BEHAVIORAL|focused information of spirometry in the invitation|Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.
40753683|NCT03657407|DRUG|Glycerin Suppository|Glycerine rectal suppository
40753684|NCT03683498|BIOLOGICAL|Regulatory T-cell enriched infusion|Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
40753685|NCT06535321|OTHER|vibration training|After modelling, when the vibration platform is closed, all participants of the control group completed the same action as vibration training.
41120542|NCT02615769|BEHAVIORAL|standard invitation|The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
41120543|NCT03212079|BEHAVIORAL|Mycoach Smart Text|Personalized text messages to you cellphone to help you become more active
41120544|NCT03212079|BEHAVIORAL|MyCoach on Amazon Alexa|This is an intelligent voice that you can communicate with via Amazon echo speaker
41120545|NCT00752713|PROCEDURE|cardiac MRI|cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
41120546|NCT01186549|DRUG|Ephedrine 30microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
41120547|NCT01186549|DRUG|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
41120548|NCT01186549|DRUG|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
41120549|NCT01186549|DRUG|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
40753686|NCT06535321|OTHER|vibration training|For the vibration group, vibration training was performed immediately after DOMS modelling.
40753687|NCT06535321|OTHER|Y-shaped kinesio taping|For the kinesio group, Y-shaped kinesio taping was performed 30 min before DOMS modelling.
40753688|NCT06535321|OTHER|Combined vibration training and Y-shaped kinesio taping|For the combined group, the vibration group and kinesio group interventions were performed simultaneously.
40753689|NCT06021444|DEVICE|DKM420|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
40753690|NCT06021444|DEVICE|Conjuran|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
41120550|NCT01186549|DRUG|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
41120551|NCT05574452|DEVICE|ACL reconstruction using the SONAR Femoral Aimer PSI|ACL reconstruction using the SONAR Femoral Aimer PSI
41120552|NCT06044467|DRUG|Anti-human CCL24 monoclonal antibody (CM-101) - Part One|Anti-human CCL24 monoclonal antibody (CM-101) - Part One
41120553|NCT06044467|DRUG|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
41446446|NCT04311164|OTHER|No intervention given.|No intervention was given.
41446447|NCT00372983|DRUG|NOV-205|
40753691|NCT02642276|OTHER|Exercise training|Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
40753692|NCT01287429|OTHER|lung and pleural ultrasound|After the initial diagnostic work-out (medical history, physical examination, EKG, arterious blood gas), the emergency physician will classify dyspnoea in cardiogenic or respiratory dyspnoea and write it down in a specific form (clinical form). Immediately after this, lung and pleural ultrasound will be performed: the physician will describe it and evaluate the etiology again (integrated evaluation form). Then a chest X-ray evaluation will be performed for each patient.
40753693|NCT00202852|OTHER|Placebo|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
40753694|NCT00202852|DRUG|MTX|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
41272885|NCT03982550|BEHAVIORAL|Periodized Resistance Training|Mesocycle I (weeks 1-4) will emphasize muscular hypertrophy to develop a muscular and metabolic base for more intense training in later phases. Training bouts will consist of 4-6 resistance exercises with 2-4 sets per exercise and 8-10 repetitions per set. Mesocycles II (weeks 5-8) and III (weeks 9-12) will emphasize strength development. Training bouts will consist of 4-6 resistance exercises with 3-5 sets per exercise, 4-6 repetitions per set, and linear increases in intensity over time. These parameters were chosen to maximize performance on 4-6 repetition maximum (RM) testing post-intervention, according to the principle of specificity - i.e. specific adaptation to imposed demands.The training loads used will be individually progressed in a safe and effective manner, in order to employ a progressive overload/challenge to the neuromuscular system and elicit the greatest training-induced neuromuscular adaptations possible.
40753695|NCT00202852|BIOLOGICAL|Infliximab|Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
41272886|NCT02493348|DEVICE|Rhythmic Sensory Stimulation|Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
40753696|NCT00202852|DRUG|MTX|3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
41272887|NCT01129947|DRUG|DHEA|DHEA 25 mg tid
41272888|NCT02850848|DRUG|Entigin Film Coated Tablet 0.5mg|
41272889|NCT02850848|DRUG|(Baraclude 0.5mg Tablets|
41272890|NCT01846455|DRUG|2.0mg Buprenorphine/0.5mg Naloxone|Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
41272891|NCT01846455|DRUG|Promethazine|Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
41272892|NCT02986178|BIOLOGICAL|PVSRIPO|A single dose of an oncolytic polio/rhinovirus recombinant (PVSRIPO)
41272893|NCT01284881|DEVICE|MRA|daily wear overnight
41272894|NCT03542682|DEVICE|Quick Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via quick bolus of 15 units per minute during a euglycemic clamp."
41272895|NCT03542682|DEVICE|Standard Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via standard bolus of 1.5 units per minute during a euglycemic clamp."
41272896|NCT01552343|DRUG|Desmopressin|Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
41272897|NCT01552343|DRUG|Placebo|Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
41272898|NCT05438173|DIETARY_SUPPLEMENT|EPA + DHA Ruby-O|Subject will receive a single 1000 mg oral dose of EPA + DHA Ruby-O capsule
40753697|NCT04378088|OTHER|Validation of CEBuS|Validation of a new score for bubbles in the colon.
40753698|NCT04675281|OTHER|2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks|All specimens are fixed with 4% neutral formaldehyde and embedded in paraffin wax in the department of pathology of each participating centre. Afterwards, all samples are sent for analysis to the department of pathology of Nantes university hospital. All biopsies are independently analysed by a group of pathologists who are experts in lung tissue and blinded to clinical information. All biopsies will be analysed using a predetermined semi-quantitative histological scoring grid. The pathologists are asked to assess the degree of: edema, cell necrosis, hyaline membrane formation, proliferation of alveolar type 2 cells, fibrosis, capillary congestion, alveolar edema, neutrophilic infiltration, and microscopic thrombosis. Finally, the following patterns are recorded: exudative diffuse alveolar damage (DAD), proliferative DAD, fibrosis, intra-alveolar haemorrhage, lymphocytic pneumonia, organizing pneumonia, acute fibrinous organizing pneumonia (AFOP), thrombotic microangiopathy.
40753699|NCT04416685|PROCEDURE|primary repair|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
40753700|NCT04416685|PROCEDURE|segmental resection|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
40753701|NCT04416685|PROCEDURE|graft reconstruction|Regarding Level III tumors, complete resection of the tumor was done either by tangential excision or by partial venous excision and subsequent reconstruction. To maintain a secure anastomosis, the mesenteric root was mobilized completely or/and splenic vein was divided.
41120554|NCT06044467|DRUG|Placebo - Study Part One|Placebo Comparator
41272899|NCT05438173|DIETARY_SUPPLEMENT|EPA + DHA Krill Oil|Subject will receive a single 1000 mg oral dose of EPA + DHA krill oil capsule
41272900|NCT03796403|OTHER|Diclofenac|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
41446448|NCT00241020|DRUG|Octreotide|
41272901|NCT06114485|BEHAVIORAL|VIPA Treatment Program|Participants will receive and Alexa device with a behavioral activation program, along with a detailed guidebook about how to utilize the Alexa device and the VIPA program
41272902|NCT06114485|BEHAVIORAL|Alexa with Guidebook|Participants will receive an Alexa device with a detailed guidebook on how to use the device.
40753702|NCT01104272|DEVICE|LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)|Study of Adipose Tissue Treatment Using Focused Ultrasound
40753703|NCT01374789|DRUG|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
40753704|NCT01374789|DRUG|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
40753705|NCT00103753|DRUG|deferiprone|
41272903|NCT05752448|BEHAVIORAL|POSTCare Survivorship transition process|Survivorship coaching intervention
41272904|NCT03791632|OTHER|classical lecture style presentation|classical lecture style presentation
40753706|NCT04591132|DEVICE|kinematic analysis|motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors
40753707|NCT02792634|PROCEDURE|Sleeve-Gastrectomy, Roux en Y gastric bypass|
41120555|NCT06044467|DRUG|Placebo - Study Part Two|Placebo Comparator
41120556|NCT01714960|DRUG|MRZ-99030 eye drops 5mg/mL|
41120557|NCT01714960|DRUG|MRZ-99030 eye drops 20mg/mL|
41120558|NCT01714960|DRUG|Placebo to MRZ-99030 eye drops|
41120559|NCT01897155|OTHER|SBP 20-30% over baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over the baseline. The upper limit of systolic blood pressure is 165 mmHg.
41120560|NCT01897155|OTHER|SBP 20-30% under baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% below the baseline. The lower limit of systolic blood pressure is 75 mmHg
41120561|NCT04456322|DRUG|RT plus Nimotuzumab|Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
40753708|NCT05721950|DRUG|Brigatinib|Brigatinib Tablets
41120562|NCT04456322|DRUG|RT plus Cisplatin|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
41120563|NCT05861193|PROCEDURE|Treatment of the abfraction with BOPT technique|"The steps to follow for the treatment of abfraction using composite resin and the B.O.P.T. technique will consist of:~* Selection of the color of the composite, placement of the retraction cord and chamfering of the coronal margin of the lesion;~* Application of 37% phosphoric acid etching and adhesive in 3 steps; placement of the composite by layers, following the conventional obturation technique.~* Execution of an overfilling with the composite at the level of the cervical emergence profile of the tooth, with the aim of emphasizing said anatomical particularity.~* Removal of the retraction cord.~* Diamond milling with red rim flame diamond bur and contra-angle, positioned from the most apical point of the restoration at an angle of 45º without touching the restored dental portion, with the aim of performing a level rotary gingival curettage from the margin of the restoration.~* Polishing with a fine-grain flame bur, and polishing discs of decreasing granulometry."
41120564|NCT03844152|DIETARY_SUPPLEMENT|Fermented whey concentrate|The investigated dietary supplement is a form of lacto-fermented whey concentrate (FWC), which has been deproteinised and then diluted (1/20) in sugar-free flavoured water to improve palatability. The main solute within the lacto-fermented whey is L-(+)-lactic acid (7%), produced through bacterial fermentation of the milk sugar lactose. The research team will provide non-descriptive bottles of drink to all volunteers. The flavour of the FWC will be masked by the flavoured water. In order to assess compliance and minimize an initial treatment effect, a 14 day run-in period during which only flavoured water is to be consumed will be completed by all volunteers. At the same time, this period will act as a wash-out, as volunteers will be asked to abstain from the use of any dietary supplements during this period and the rest of the study. The daily energy content of the FWC is 4kcal.
41120565|NCT02121002|DRUG|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
41120566|NCT02121002|DRUG|Voltaren Topical Gel, 1%|Opaque, white gel
41120567|NCT02121002|DRUG|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
41120568|NCT01424670|DRUG|Delamanid + OBR|The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
41272905|NCT03791632|OTHER|an intervention in the form of fun workshops|an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
41272906|NCT03791632|OTHER|digital media intervention|digital media intervention
41272907|NCT01245673|BIOLOGICAL|Prevnar- Pneumococcal Conjugate Vaccine (PCV)|After study enrollment, patients will receive Prevnar- Pneumococcal Conjugate Vaccine (PCV). At Day #14, Day #42, and Day #90, Day #120 and Day #150, patients will receive a booster immunization with Prevnar- Pneumococcal Conjugate Vaccine (PCV).
41272908|NCT01245673|OTHER|Activated/costimulated autologous T-cell|For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion \~day 2 post-transplant. The target number of costimulated T-cells for infusion will be \~ 5 x 10e10 T-cells total in 100-500 mL total volume.
41272909|NCT01245673|DRUG|Revlamid® (Lenalidomide)|At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
40753709|NCT06092983|DRUG|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
41272910|NCT01245673|BIOLOGICAL|MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)|After study enrollment, patients will receive both MAGE-A3/GM-CSF \[+ coinjection of 2mg of Hiltonol®(Poly-ICLC)\]. At Day #14, Day #42, Day #90, Day #120 and Day #150 patients will receive an additional immunization with MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC).
41272911|NCT04152382|DRUG|LY3462817 - IV|Administered IV
41272912|NCT04152382|DRUG|LY3462817 - SC|Administered SC
40753710|NCT06092983|DRUG|HS-10383 Placebo|HS-10383 Placebo administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
40753711|NCT04017975|DRUG|Fluorescite|1 mL of Fluorescite will be diluted into 1L of saline. Up to 5mLs of the 1:1000 diluted solution will be applied topically to the cardiac tissue prior to imaging.
41120569|NCT01424670|DRUG|Placebo + OBR|Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
41272913|NCT04152382|DRUG|Placebo - IV|Administered IV
40753712|NCT04017975|DEVICE|Cellvizio 100 Series System with Confocal Miniprobes|The microscopy system will image cardiac tissue.
40753713|NCT03391154|DRUG|levothyroxin|90 female received levothroxine
40753714|NCT05560321|OTHER|Sani24|Disinfectant
40753715|NCT05560321|OTHER|Routine Disinfection|Routine disinfection at the study hospital
40753716|NCT02116062|DEVICE|1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)|
41272914|NCT04152382|DRUG|Placebo - SC|Administered SC
41272915|NCT04152382|DRUG|LY3509754|Administered orally.
41272916|NCT04152382|DRUG|Placebo|Administered orally.
41272917|NCT03399383|OTHER|Patient education|Participation in the standardized education program (90min patient education). During sessions of 90-120 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings. Participants are provided with emergency cards and sets and are trained in self-injection of glucocorticoids.
41120570|NCT04177459|BEHAVIORAL|Health promoting dialogue|Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.
41120571|NCT04177459|OTHER|standard treatment / treatment as usual|Follow-up from primary and secondary health care, and from schools.
41272918|NCT01322815|DRUG|chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
41272919|NCT01322815|DRUG|GI-4000|40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
41120572|NCT02825368|BIOLOGICAL|MMR|0.5 mL, subcutaneous
41120573|NCT02825368|BIOLOGICAL|Tdap|0.5 mL, intramuscular
41272920|NCT01527721|PROCEDURE|Corneal Collagen Cross-Linking (CxL)|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
41272921|NCT01527721|PROCEDURE|Corneal Collagen Cross-Linking combined with t-PRK|For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
41272922|NCT03965143|DEVICE|3D talar augmentation|Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
41272923|NCT05791058|PROCEDURE|ultrasound guided pericapsular nerve group shoulder block|The patient's arm is placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and 20 cc of 0.25% bupivacaine hydrochloride with 4mg dexamesathone will be injected
40753717|NCT02116062|DEVICE|Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)|
40753718|NCT02116062|DEVICE|Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot|
40753719|NCT01447147|DRUG|Placebo|Placebo capsules once daily
41120574|NCT02825368|OTHER|Diphtherinum®|
40753720|NCT01447147|DRUG|CCX140-B|CCX140-B capsules once daily (Group B)
40753721|NCT01447147|DRUG|CCX140-B|CCX140-B capsules once daily (Group C)
40753722|NCT02227264|DRUG|Cinacalcet|Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks
41120575|NCT02825368|OTHER|Pertussinum®|
41120576|NCT02825368|OTHER|Tetanotxicum®|
41120577|NCT02825368|OTHER|Morbilinum®|
40753723|NCT02227264|PROCEDURE|parathyroid adenomectomy|surgical removal of pathologic parathyroid tissue
40753724|NCT04517058|OTHER|psychology therapy|If the symptoms are mild, patients will get the psychology therapy. If it's necessary according to patients' willings, patients will be given SSRIs antidepressant therapy.
40753725|NCT01446510|OTHER|Application of VTE Risk Assessment|Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
40753726|NCT05708378|OTHER|Rocker board training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
41120578|NCT02825368|OTHER|Ourlianum®|
41120579|NCT02825368|OTHER|Sterile saline|0.5 mL, intramuscular
41120580|NCT02825368|OTHER|Sugar pellets|
41120581|NCT01761552|DRUG|Sugammadex Reversal|
41120582|NCT01761552|DRUG|Atropine/Neostigmine|
41120583|NCT01503749|DRUG|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
41272924|NCT05791058|PROCEDURE|ultrasound guided suprascapular and axillary nerve block|The patient will be positioned in a semi-recumbent position with the operating arm on the contralateral shoulder. The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected below the supraspinatous fascia then the posterior surface of the humerus will be visualised in the short axis view. So, the AN and posterior circumflex artery will be visualised longitudinally. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected into space
41120584|NCT01503749|OTHER|Infusion of the mobilized monocyte cells|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
41120585|NCT03958136|PROCEDURE|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis
41272925|NCT05791058|OTHER|general anesthesia without nerve block|this group will receive general anesthesia without nerve block
40947812|NCT05280171|OTHER|Teach back|"Discharge information was explained by the principal investigator. On the day of discharge, pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.~Teach back is a approach which is used in cognitive psychology experiments describing repeating short sequences of information helps to improve repeat back of information. This teach back technique is recommended as a universal precaution by the agency for healthcare research and quality and the national quality forum."
41272926|NCT00778830|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
41272927|NCT00778830|DRUG|FOLFIRI|Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
41272928|NCT00778830|DRUG|FOLFOX|Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
41272929|NCT05765903|OTHER|Standard of Care|"* Diagnosis education.~* Follow-appointment scheduling assistance.~* Offer resources in the community.~* Offer weekly follow-up calls for one month.~* Social Determinants of Health (SDoH) assessment."
41272930|NCT05765903|OTHER|Enhanced Care|"* Additional educational training using computer tablet devices, such as iPads.~* Focus on readmission risk.~* Set-up Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH)."
41272931|NCT01487421|DRUG|insulin aspart|Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
41272932|NCT01487421|DRUG|insulin detemir|Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
41272933|NCT02569034|OTHER|Functional Magnetic Resonance Imaging|"Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia."
40753727|NCT05708378|OTHER|Stable surface training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
41272934|NCT02569034|OTHER|Effort-Expenditure for Rewards Task|"Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations."
41272935|NCT03778489|OTHER|Training|10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
41272936|NCT02293109|DRUG|carfilzomib|Given IV
41120586|NCT03958136|BIOLOGICAL|Biomarkers blood, urine and microbiota samples|Biomarkers blood, urine and microbiota samples for multi-omic analysis
41272937|NCT02293109|DRUG|cyclophosphamide|Given IV
41272938|NCT02293109|DRUG|vincristine sulfate|Given IV
41272939|NCT02293109|DRUG|doxorubicin hydrochloride|Given IV
41272940|NCT02293109|DRUG|dexamethasone|Given PO
41272941|NCT02293109|DRUG|methotrexate|Given IV
41272942|NCT02293109|DRUG|cytarabine|Given IV
41272943|NCT02293109|DRUG|leucovorin calcium|Given IV or PO
40947813|NCT05280171|OTHER|Standard of care|Standard of care
40947814|NCT01908920|OTHER|Osteopathic manipulative treatment|
41120587|NCT03958136|BEHAVIORAL|Patient Reported Outcome (PRO)|Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
41120588|NCT01587053|OTHER|therapeutic education program|
40947815|NCT01908920|OTHER|SHAM|
41272944|NCT02293109|DRUG|methylprednisolone|Given IV
41272945|NCT02293109|BIOLOGICAL|rituximab|
41272946|NCT02293109|OTHER|laboratory biomarker analysis|Correlative studies
41120589|NCT02847689|BEHAVIORAL|Language Treatment|Recording of a mother's voice reading a children's storybook.
41120590|NCT02847689|BEHAVIORAL|Control Treatment|Standard of Care
41272947|NCT01931046|DRUG|Ad5-SGE-REIC/Dkk3|Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
41272948|NCT00352703|DRUG|Kepivance (Palifermin)|
41272949|NCT01793987|DEVICE|Coblation polypectomy|
41272950|NCT04917926|BEHAVIORAL|Financial and social incentives|Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target. Regarding social incentives, participants will be placed in teams of six, receiving feedback of their physical activity performance, rankings within their groups, and positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support.
41272951|NCT04917926|BEHAVIORAL|Financial incentives|Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.
41272952|NCT02995434|DEVICE|Virtual Reality Headset|"The following VR experiences will be used:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe_Lucem__Seize_The_Light_VR/"
41272953|NCT02995434|OTHER|2D PC|"The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/"
41272954|NCT01368796|BIOLOGICAL|Agriflu|0.5mL dose IM vaccination
41272955|NCT01368796|BIOLOGICAL|Fluad|0.5mL dose of vaccine given IM
41272956|NCT01368796|BIOLOGICAL|Intanza|0.5mL dose vaccine given IM
41120591|NCT02309034|BEHAVIORAL|Jump exercise|Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
41120592|NCT02309034|BEHAVIORAL|Aquatic exercise|Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
41120593|NCT02309034|OTHER|Nutritional guidance|Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
41272957|NCT01368796|BIOLOGICAL|Vaxigrip|0.5mL dose vaccine given IM
41120594|NCT05843708|DRUG|Vorasidenib 40 mg Oral Tablet|"Single oral dose of 1×40 mg vorasidenib tablet administered :~* under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~* or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)"
41120595|NCT05843708|DRUG|Ciprofloxacin 500 mg Oral Tablet|Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)
41120596|NCT05843708|DRUG|Vorasidenib 10 mg Oral Tablet|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
41120597|NCT03565055|BEHAVIORAL|IPCST|"Integrative Psychosocial \& Community Skills Training (IPCST) programme~The IPCST programme includes:~1. psychoeducation, internalized stigma reduction, \& strength and coping enhancement~2. motivational interviewing skills~3. Neurocognitive and social cognitive training (Au, Tsang, So, Bell, Cheung, et al., 2015)~4. augmented supported employment with social skills training (Tsang, Fung, Li, Leung \& Cheung, 2010) and~5. family and patient involvement in care"
41120598|NCT03565055|BEHAVIORAL|E.A.S.Y|"The E.A.S.Y. (Early Assessment Service for Young People with Early Psychosis) Programme is a service programme for people suffering from early psychosis.~The E.A.S.Y programme includes:~1. Extensive public education~2. Early referral and assessment~3. Ongoing treatment services"
41120599|NCT03197090|DEVICE|Zenicor ECG|Participants will place their thumbs on the device twice daily and whenever they notice palpitations.
41120600|NCT01879189|BEHAVIORAL|Breast Cancer Screening Decision Aid|The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
41272958|NCT01511445|DEVICE|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
41272959|NCT01511445|DEVICE|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
41272960|NCT04312087|PROCEDURE|Lateral neck sentinel lymph node biopsy|Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.
41272961|NCT04312087|PROCEDURE|Modified lateral neck lymph node dissection|Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
41272962|NCT04312087|PROCEDURE|Super selective lateral neck lymph node dissection|Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
40947816|NCT01908920|OTHER|CONTROL|
40947817|NCT02229331|OTHER|Gait analysis|
41120601|NCT04117789|BEHAVIORAL|Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
40753728|NCT04574700|OTHER|knee joint mobilization and traction|"Grade 3 traction (Kaltenborn)from knee fully flexed to end of available Range of motion(ROM). Traction 30 sec, 10 sec rest period, 4reps, total 2 min of traction.3 sets for a total of 6 min of traction mobilization.Grade3 keltonborn tibiofemoral and tibiofibular anterior, posterior mobilization 3 sets10glides/set, 3 times/week on alternative days for 4 weeks.~TENS for 20 mins in sitting and strengthening exercises i.e. Quadriceps Setting10 reps, air Cycling 2 min for a bout, straight leg raise (SLR) with weight , Full arc extension 10 reps of each exercise will be carried per session except for full-arc extension and air cycling. Air cycling cont. for 2 min for 1 bout of exercise. Measurement will be taken at base level, after first and last session. Treatment will be given for 3 times/week on alternative days for 4 weeks"
40753729|NCT04574700|OTHER|Post isometric relaxation|"Control group include Post isometric relaxation technique on hamstring muscle will be performed in supine lying, hip flexed to 90 degrees knee extended until the point of resistance 20% of maximum effort will be used by patient to create isometric contraction. Patient will be asked to breathe in and hold for 5 to 8 seconds and release both breath and effort then move to new barrier point and process was repeated three times per session~TENS and strengthening exercises as mentioned above.~This treatment regime will be given for 3 times/week on alternative days for 4 weeks."
40753730|NCT03833843|DIAGNOSTIC_TEST|imaging|ECG, Echocardiography and cardiac magnetic resonance imaging
41272963|NCT05654402|DIAGNOSTIC_TEST|Non-invasive measurement of carotid-femoral transit time by Doppler velocimetry (Athys Medical©) - WAKIe R3 2TC®) (PWV in cm/s)|"* Measurement of the carotid-femoral transit time (ms) (recorded on Data Warehouse Connect).~* Measurement of the distance between the carotid and femoral points with a tape measure (m).~* Calculation of the propagation speed of the wave PWV (expressed in m/s).~For all patients PWV in (m/s=) will be collected over three distinct periods:~* Before induction (awake without premedication)~* During general anesthesia or loco-regional anesthesia~* Upon awakening from general anesthesia or lifting of the loco-regional anaesthesia"
41272964|NCT04418921|BEHAVIORAL|Self-regulation: MRehab - Un colegio emocionante, clinical trial with non-immersive virtual reality|The principles of the programme will be based on the following premises for children with ASD: 1) Strengthening communicative attempts; 2) Choose the most natural contexts possible; 3) Establish structured and predictable routines and environments; 4)Visually support information; 5) Adapting our language to the understanding level of the child. On the difficulty of interpreting and responding to social emotions and cues, games of perspectives are of great interest, where the child and therapist describe the same object from different perspectives, beliefs (guess that may be in this box), games with social stories, which are short stories that use pictograms, to help understand especially situations with social ambiguity: 1) describing what happens; 2) orienting the action, indicating to the child what to do in that situation; 3) anticipating and explaining what can happen and how you can feel; 4) developing a strategy that can be applied in similar situations.
41272965|NCT04418921|BEHAVIORAL|Traditional self-regulation program|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom .The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation.Each session will last 50 minutes
41120602|NCT04117789|BEHAVIORAL|Self-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.
41120603|NCT04117789|OTHER|Treatment as usual|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.
41120604|NCT04954638|OTHER|endodontic desinfection|"* outcome assessment of the retreatment of endodontically treated teeth presenting chronic apical periodontitis~* effectiveness of hyperpure chlorine dioxide compared with sodium hypochloride~* using microbiological methods~* outcome assessed by radiological method and clinical evaluation"
41120605|NCT05099575|DRUG|Syntocinon, papal, misotac|Using different drugs to prevent atonic PPH during CD in high risk group
41120606|NCT02021006|DRUG|nitrofurantoin|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
41120607|NCT02021006|OTHER|No prophylaxis|children will be followed, but no antibiotic prophylaxis will be administered
41120608|NCT02021006|DRUG|Amoxicillin-Potassium Clavulanate Combination|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
41120609|NCT02021006|DRUG|Trimethoprim/sulfamethoxazole|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
41120610|NCT02021006|DRUG|Cefixime|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
41120611|NCT02059382|BEHAVIORAL|ChiRunning training|
41120612|NCT02059382|BEHAVIORAL|unblinded accelerometer|
41272966|NCT04644718|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.
41272967|NCT02286388|PROCEDURE|A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~* Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~* Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin)."
41272968|NCT02286388|PROCEDURE|A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~Idem partial excavation arm.~In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin."
41120613|NCT02059382|BEHAVIORAL|participation in online social network|
41120614|NCT02059382|BEHAVIORAL|participation in study website|
41120615|NCT02059382|BEHAVIORAL|Technology support for behavior change|
41120616|NCT00895531|DRUG|Depodur|7.5 mg Depodur via the epidural catheter
41120617|NCT00895531|PROCEDURE|sciatic nerve block|The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
41120618|NCT06176482|DEVICE|Magnetic markers implantation|Surgical implantation of magnetic markers in the upper limb stump to allow the management of an external hand prosthesis
41120619|NCT01247831|PROCEDURE|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
41120620|NCT00044057|DRUG|YM872 (zonampanel), t-PA (alteplase)|
41120621|NCT06295913|DIETARY_SUPPLEMENT|Group 1, hydroxytyrosol-rich extract capsule (Hytolive®)|Following a two-week washout period, the subjects will receive a bottle containing capsules (Hytolive®) (Group 1). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol apart from that provided by the capsule with (Hytolive®).
41120622|NCT06295913|DIETARY_SUPPLEMENT|Group 2, capsule of placebo|Following a two-week washout period, the subjects will receive a bottle containing capsules (Placebo) (Group 2). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol.
41120623|NCT02650544|DRUG|Mirtazapine|Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
41272969|NCT02286388|DEVICE|The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).|"Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.~The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds."
41272970|NCT02286388|DEVICE|The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)|Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
41120624|NCT02650544|DRUG|Placebo|Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
41120625|NCT01683149|DRUG|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
41120626|NCT01683149|DRUG|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
41120627|NCT06117332|DEVICE|Visual prosthesis|"In response to the stimulation/image on the monitor, subjects will be asked to either make a perceptual judgment or perform a simple behavioral task. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, or walking to a target location. Both patient response and reaction time will be recorded.~In some cases, the investigators will also collect data measuring subjects' eye position. This is a noninvasive procedure that will be carried out using standard eye-tracking equipment via an infra-red camera that tracks the position of the subjects' pupil. Only measurements like eye position or eye blinks will be recorded, so these data do not contain identifiable information."
41120628|NCT03657030|DRUG|CVN424|SAD / MAD
41120629|NCT03657030|DRUG|Placebo|Placebo
41120630|NCT04015349|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
41120631|NCT01652417|DRUG|methylprednisolone bolus IV 15 mg/kg/d for 3 days.|methylprednisolone bolus IV 15 mg/kg/d for 3 days.
41120632|NCT05425862|DRUG|Pidnarulex|Pidnarulex is a treatment that is designed to stop the action of a particular protein in the body called Polymerase I, that cancer cells rely on. Laboratory studies show that pidnarulex targets a process involving Polymerase I within cells, which can lead to a decrease in cancer growth. Pidnarulex has been shown to have some anticancer activity in ovarian cancer and haematological cancers.
41272971|NCT05211167|DRUG|Human Erythropoiesis Injection (CHO cell)|Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
41272972|NCT05211167|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
40753731|NCT01197274|DEVICE|Simple blood lancet|Skin prick testing with blood lancet and DuoTip is performed on the back of mite-sensitized person. Allergen(Der p)is placed in 1st and 2nd row whereas histamine is placed in 3rd row. Allergen and normal saline are placed alternately in 4th row. Block randomization were allocated subjects into 2 groups; Group1:blood lancet is performed in 1st row and DuoTip in 2nd row. Group2:DuoTip is performed in 1st row and blood lancet in 2nd row. Blood lancet is applied in 3rd and 4th row in all subjects. A technician performed device applications and another technician who is blinded to device performed all readings. Pain was assessed on a scale from 0 to 10 with 0 being no pain and 10 being the worst imaginable pain
41272973|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T1|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline
41272974|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T2|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation
41272975|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T3|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
41120633|NCT05425862|DRUG|Talazoparib|Talazoparib belongs to a class of drugs called PARP inhibitors, which is currently being used to treat various types of cancer. Talazoparib blocks the function of PARP, a protein that is involved in repairing DNA in cells. By stopping damaged DNA in cells from being repaired, this will lead to accumulation of DNA damage in the cancer cell and ultimately cancer cell death. Talazoparib has established anticancer activity in breast, ovarian and prostate cancers with underlying DNA repair defects. This class of drug have also been used in combination with other treatments such as radiation or chemotherapy to further increase cell death within the cancer.
41120634|NCT06232044|DRUG|Iberdomide|Receive PO
41120635|NCT06232044|BIOLOGICAL|Belantamab Mafodotin|Receive IV
41120636|NCT06232044|DRUG|Dexamethasone|Receive PO
41120637|NCT06232044|PROCEDURE|Echocardiography|Undergo ECHO
41120638|NCT06232044|PROCEDURE|Computed Tomography|Undergo CT
41120639|NCT06232044|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41120640|NCT06232044|PROCEDURE|Positron Emission Tomography|Undergo PET
41120641|NCT06232044|PROCEDURE|Bone Marrow Biopsy|Undergo Bone Marrow Biopsy
41120642|NCT06232044|PROCEDURE|Bone Marrow Aspiration|Undergo Bone Marrow Aspirate
41120643|NCT06232044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41120644|NCT00967434|DRUG|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
41120645|NCT00967434|DRUG|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
41120646|NCT00967434|DRUG|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
41120647|NCT05146440|DRUG|PM14|"Pharmaceutical form: PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety.~Route of administration: PM14 drug product was developed for administration by the i.v. route. Before use, the vials are reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for infusion to give a solution containing 0.5 mg/mL of PM14. Prior to administration, the reconstituted DP solution should be further diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. Each vial of PM14 5.0 mg is a single use vial."
41120648|NCT06495944|DRUG|Dazucorilant|75 mg soft gelatin capsules formulation for oral administration
41120649|NCT06495944|DRUG|Itraconazole|100 mg capsules for oral administration
41120650|NCT00168519|DRUG|nitroprusside, pentalong, imdur, AICAR, isoptin|"Sodium Nitroprusside - one 30 minute intravenous infusion~Pentalong - two tablets orally (total 160mg)~Imdur - two tablets orally (total 120mg)"
41120651|NCT06081049|DRUG|Colchicine|0.5 mg once daily
41120652|NCT06081049|DRUG|Placebo|Once daily
41120653|NCT02282085|DRUG|Aripiprazole Once-Monthly|
41120654|NCT02282085|DRUG|Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)|Oral antipsychotic medication
41120655|NCT06059560|DIETARY_SUPPLEMENT|Nutritional therapy|Intensive nutritional therapy based on real world therapy
41120656|NCT05957653|DRUG|lidocaine and sufentanil|A total of 20ml of 2% lidocaine and 1μg/ml sufentanil was injected into the bladder through the catheter.
41120657|NCT05957653|DRUG|Saline|A total of 20ml normal saline was injected into the bladder through the catheter.
40947818|NCT03539146|OTHER|Dietary fiber|Intake of yogurt containing cascara with 0%, 3%, 7%,13% dietary fiber in a crossover design.
41120658|NCT00262730|DRUG|poly ICLC|20 mcg/kg 3x each week (Maintenance cycles)
41120659|NCT00262730|DRUG|temozolomide|daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
41120660|NCT00262730|RADIATION|radiation therapy|RT: 60 Gy (6 weeks) concomitant therapy
41120661|NCT02722070|DEVICE|3 Tesla Siemens Skyra MRI scanner|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging
41120662|NCT02139696|RADIATION|PET and MRI|Patients will be imaged using PET and MRI at baseline, and twice during treatment
41120663|NCT04261231|PROCEDURE|Surgery and anesthesia|Elective surgery in adults
41120664|NCT02227134|PROCEDURE|Ultrasound|Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
41120665|NCT04968366|BIOLOGICAL|Autologous dendritic cells pulsed with multiple neoantigen peptides.|Each dosage of Dendritic Cells (DC) vaccine contains 2-10 million DC cells, loaded with 5-20 tumor neoantigen peptides. DC vaccine will be administered (i.d) around lymph nodes of the groin and Axillary at 2nd, 3rd, 4th, 7th and 11th week after the completion of concurrent Temozolomide chemoradiation. After 5 injections, the investigator will review subject's tolerance and compliance; and, decide whether to administer more DC vaccines up to 8 injections. For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of Temozolomide adjuvant chemotherapy to assess the patient's immune response. According to the result, investigators will decide whether to perform 1-2 more treatment cycles (5-8 injections/cycle) to strengthen the effectiveness
41120666|NCT04968366|DRUG|Temozolomide adjuvant chemotherapy|Temozolomide is administered as the standard-of-care adjuvant chemotherapy, in combination with the DC vaccines to treat the enrolled patients.
41120667|NCT05085067|OTHER|auto-crossed-linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
41120668|NCT00168649|DRUG|Vitamin A|
41120669|NCT06020885|RADIATION|Split-course hypo-CCRT|"Split-course hypo-CCRT is administered at the following three dose levels:~* Level 1: DT 3000cGy/10 daily fractions/300cGy in the first course, DT 2000cGy/10 daily fractions/200cGy in the second course;~* Level 2: DT 2800cGy/7 daily fractions/400cGy in the first course, DT 2200cGy/10 daily fractions/220cGy in the second course;~* Level 3: DT 2500cGy/5 daily fractions/500cGy in the first course, DT 2500cGy10 daily fractions/250cGy in the second course."
41120670|NCT06020885|DRUG|Induction chemo-immunotherapy|All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.
41120671|NCT06020885|DRUG|Concurrent chemotherapy|Concurrent capecitabine was administered orally at 1000mg/m2 twice daily within half an hour after meals concurrently with radiotherapy.
41272976|NCT03677193|BEHAVIORAL|Playing ICP game|Participants will play the ICP game from their home this is expected to be 30 min \* 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
41120672|NCT04622722|OTHER|Nutren Diabetes|Nutren Diabetes provides energy at 360 kcal per 360 ml
41272977|NCT03530514|DRUG|REGN4461|REGN4461
41272978|NCT03530514|DRUG|Placebo|Placebo-matching REGN4461
41272979|NCT01573312|DRUG|ASO3 Adjuvant|3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
41272980|NCT01573312|BIOLOGICAL|Influenza A/H5N1 Vaccine|3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
41272981|NCT01602731|DEVICE|Automated Medication Dispensing Device|All patients had a pre-filled medication dispensing machine set up at their homes, filled by home health nurses once a month. Safety phone call was made by the AMDD company if doses were missed.
41272982|NCT04739839|OTHER|survey questionnaire|Questionnaire focusing on low back pain in relation to life style, physical activity level, illness perception and quality of life.
41120673|NCT04622722|OTHER|Isocaloric|Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise
41272983|NCT03728088|OTHER|Rating scales concerning non-technical attributes|
41272984|NCT02486861|OTHER|optical coherence tomography|
41272985|NCT05838326|DEVICE|Symmetrical high flow nasal cannula (HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%."
41272986|NCT05838326|DEVICE|Asymmetrical high flow nasal cannula (DUET HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.~A 5-10min 'washout' phase using VM, between different interfaces, will be allowed."
41120674|NCT00224510|DRUG|lamotrigine|
41120675|NCT03300492|OTHER|NK-DLI|"Application of three infusions of ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at \<1x105/kg."
41120676|NCT04536519|OTHER|osteoarthritis management|"The conventional physical therapy will be consisted of an array of protocols being deployed in parallel. This will consist of~* Patient education regarding deforming forces, strategies of prevention and home exercise program~* Decreasing stiffness by controlled active range of motion and mobilization techniques involving join play.~* Mechanical stresses will be controlled in form of support provided by foot wear modification~* Range of motion will be increased muscle stretches and manual mobilization techniques~* Muscle performance and neuromuscular control will be addressed by gentle exercises of low intensity and repetitive exercises.~* Balance improvement by employing balance training activities as part of treatment~* Physical conditioning low impact or non-impact aerobics This conventional exercise will be given as baseline treatment to both of groups."
41120677|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
41272987|NCT01797718|DRUG|Testosterone|1mg/kg every 4 weeks for 6 months
41272988|NCT01797718|DRUG|Letrozole|2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
41272989|NCT05816603|DEVICE|Real Soterix Mini-CT tDCS stimulator|Real transcranial electrical stimulation at 2mA intensity will be delivered to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration.
41272990|NCT05816603|DEVICE|Sham Soterix Mini-CT tDCS stimulator|Sham stimulation to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration. The device will ramp up and ramp down current delivery from 0 mA -2 mA - 0 mA over 30 seconds at the start of the 20-minute protocol with no active stimulation until the end of the 20 minutes, at which time the 30-second ramp up/ramp down will be repeated.
41272991|NCT05749835|OTHER|Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy|After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland.
41272992|NCT05749835|OTHER|Sustained Natural Apophyseal Glides and conventional therapy|Position of therapist: stands beside the patient, while his\\her head is cradled between your body and your right forearm (when you stand at his\\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
41272993|NCT02078479|PROCEDURE|20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).|
41272994|NCT02078479|PROCEDURE|sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).|
41272995|NCT05977842|DEVICE|CTO PCI using DCB-only strategy|Successful CTO recanalization treated with DCB at the occlusion site
41120678|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
41120679|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
41120680|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
41120681|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
41120682|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
41120683|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
41120684|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
41120685|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
41120686|NCT02497716|DRUG|Rivaroxaban (Xarelto, BAY59-7939|Single dose of reconstituted rivaroxaban granules
41120687|NCT00543816|DRUG|MK0767|
41120688|NCT03423277|DEVICE|Easy Stretch Toolkit|Study the use of novel intraoral tools for management of facial burns and other facial disorders
41120689|NCT05107024|DEVICE|RFR-guided step by step balloon dilation|The mean value of the minimum ratio of distal mean pressure to aortic mean pressure (Pd/Pa) in five consecutive complete cardiac cycles was obtained by scanning the diastolic and systolic stages at rest.
41120690|NCT05107024|DEVICE|Traditional balloon dilation|The surgeon determines the optimal size of the semi-compliant balloon based on angiography (balloon to vessel ratio 1.0) and performs adequate predilation to achieve residual stenosis. 30% of vascular anatomy criteria
41120691|NCT02534064|DIETARY_SUPPLEMENT|CALIN+|Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
41120692|NCT02534064|DIETARY_SUPPLEMENT|CALIN+|Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
41120693|NCT03762668|DEVICE|Modified delefilcon A contact lenses|Spherical soft daily disposable contact lens
41120694|NCT03762668|DEVICE|Delefilcon A contact lenses|Spherical soft daily disposable contact lens
41120695|NCT05413629|OTHER|Web-based patient education for the intrauterine insemination (IUI) treatment process|Web-based training is 60 minutes in total, including 4 modules. The web-based training content includes general information about fertility, infertility diagnosis-treatment methods, drugs used in IUI treatment and its application, and issues to be considered after IUI.
41272996|NCT05825248|OTHER|Fine and gross motor treatment only|occupational therapy intervention involving general fine and gross motor activities
41272997|NCT05825248|OTHER|Reflex integration + fine and gross motor treatment|occupational therapy intervention involving general fine and gross motor activities as well as targeted reflex integration exercises
41272998|NCT02520479|DRUG|P-CHOP|Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
40926472|NCT03206996|BEHAVIORAL|Caregiver education/home program development|Parents will be provided with education on home programs to facilitate treatment gains. Home programs will be designed specifically for each participant. Parent education and home programs are provided either concurrently or after the exposure phase for the family to apply these methods to other settings. Home programs can continue as a maintenance program after treatment has ended. At the end of the treatment phase, the study team will conduct the following assessments for a third time: (1) the Sensory Profile, a clinical tool commonly used in OT to assess parent reports of sensory processing difficulties in children, (2) Parent Stress Index - 4 to evaluate stress related to parent-child interactions, and (3) the Modified Khalfa Hyper-acusis Questionnaire to assess the level of hyper-sensitivity to sound.
41120696|NCT01945125|OTHER|rhTSH Group|Patients receiving rhTSH for RIT stimulation
41120697|NCT02817282|OTHER|Hand hygiene implementation strategy|Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
41120698|NCT05798273|PROCEDURE|intra-arterial injection|"All patients will receive an intravenous injection of \[68Ga\]Ga-PSMA-11 (1.5 MBq/kg), followed by a synchronous PET/MRI scan (median duration approximately 50 min) at 45-60 min post-injection.~In case of a positive \[68Ga\]Ga-PSMA-PET signal at the tumor site, patients will return (in 2 weeks) for an intra-arterial injection (i.e., a neuro-interventional procedure) of 68Ga-PSMA-11 (1.5 MBq/kg), followed by a repeat synchronous PET/MRI scan (median duration 50 min) at 45-60 min post-injection."
40926473|NCT02744950|PROCEDURE|Pulley stitches|
40926474|NCT02744950|PROCEDURE|Intermediate Repair|
41120699|NCT05798273|DEVICE|synchronous PET/MRI scan|Scan done at (median duration approximately 50 min) at 45-60 min post-injection.
41120700|NCT05798273|OTHER|Radiopharmacon Contrast agent|Type: \[68Ga\]Ga-PSMA-11 dosage: 1.5 MBq/kg
41120701|NCT04421469|DRUG|Triprilimab(JS001)|"1. JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed;~2. Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation);~3. JS001 maintenance treatment."
41120702|NCT04818931|DRUG|Cefazolin Injection|cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
41120703|NCT00137995|DRUG|Rituximab|375 mg/m² D-2/D1
40926475|NCT00572143|OTHER|ca coli follow-up by GP|patients randomized to follow up by GP
41120704|NCT00137995|DRUG|Etoposide|100 mg/m² D1-D2-D3
41120705|NCT00137995|DRUG|Carboplatine|max 800mg D2
41120706|NCT00137995|DRUG|Ifosfamide + Mesna|5 g/m² from D2 to D13
41120707|NCT00137995|DRUG|Cisplatine|100 mg/m² from D1 to D13
41120708|NCT00137995|DRUG|Cytosine Arabinoside|2000 mg/m²/12 h D2 D3
41120709|NCT00137995|DRUG|Dexamethasone|40 mg From D1 to D4
41120710|NCT00137995|PROCEDURE|Autologous Stem Cell Transplantation|
41120711|NCT00137995|DRUG|BCNU|300mg/m² on D-6
41120712|NCT00137995|DRUG|Etoposide|200 mg/m² from D-6 to D-3
41120713|NCT00137995|DRUG|Cytarabine|100 mg/m² from D-6 to D-3
41120714|NCT00137995|DRUG|Melphalan|140 mg/m² on D-2
41272999|NCT02520479|RADIATION|Radiotherapy|Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
41120715|NCT05382936|DRUG|SL-901|Patients will take study medication daily, with dosage based on their assigned cohort and regimen.
41120716|NCT00819546|DRUG|RAD001|Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
41120717|NCT00819546|DRUG|PKC412|50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
41120718|NCT03990285|DRUG|Axumin, Intravenous Solution|To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
41120719|NCT04680520|OTHER|Experimental (Doublebase Gel® or Diprobase Cream®)|Emollient (Doublebase Gel® or Diprobase Cream®) use on the skin. The emollient should be applied at least once a day.
41120720|NCT04680520|OTHER|Best practice skin care advice booklet|This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
41120721|NCT06521801|OTHER|Observation|Observation
41120722|NCT01467375|DRUG|biphasic insulin aspart|Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
41120723|NCT03206684|DRUG|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight \<45kg were given 3mg once per chemotherapy cycle.
41120724|NCT03206684|DRUG|rhG-CSF|rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight\<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10\^9/L.
41273000|NCT02520479|DRUG|P-CHOP|"Two consolidation cycles of P-CHOP are given after radiotherapy"
41120725|NCT04504786|OTHER|Vitality acupunch (VA) exercise program|The VA had three phases and took 40 minutes to complete.
41273001|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
41273002|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
40947819|NCT03539146|OTHER|Control yogurt|Control yogurt
40947820|NCT03681275|DRUG|Tofacitinib 10 MG [Xeljanz]|administered twice daily for two days
41120726|NCT04504786|OTHER|Control|Participants maintained their daily activities.
41273003|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
41273004|NCT04337437|DRUG|Genakumab|150 mg/1ml/bottle, single subcutaneous injection.
40947821|NCT03681275|DRUG|Placebo to match Tofacitinib|administered twice daily for two days
41120727|NCT04630600|OTHER|No intervention|Normal waiting room without an aquarium
41120728|NCT04630600|OTHER|Partially-equipped aquarium in the waiting area|Waiting room with a partially-equipped Aquarium
41120729|NCT04630600|OTHER|Fully-equipped aquarium in the waiting area|Waiting room with a fully-equipped Aquarium
41120730|NCT02628171|OTHER|Base Diet|Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
41120731|NCT02628171|OTHER|Base Diet with Cashew Nuts|Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
41120732|NCT03788590|DEVICE|Jenscare TAVI|Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.
41120733|NCT00382850|PROCEDURE|Nissen fundoplication|
41120734|NCT03019614|DRUG|Hydrocortisone|Generic hydrocortisone
41120735|NCT03019614|DRUG|Chronocort|Modified formulation of hydrocortisone
41120736|NCT04126707|DRUG|[14C] HQP1351|Orally, single dose of 30mg
41120737|NCT01576107|OTHER|Exercise counseling (behavior change techniques)|4-week exercise intervention for cancer patients of different entities and out-patient regimes.
41120738|NCT01576107|OTHER|Stress-management training|4-week stress-management-training for cancer patients of different entities and out-patient regimes.
41120739|NCT02724592|DEVICE|self assembling peptide P11-4 (Curodont™ Repair)|Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
41273005|NCT04337437|DRUG|Placebo for this trial|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
41273006|NCT00235105|DRUG|Adalimumab 40 mg sc every other week|
41273007|NCT03140319|BIOLOGICAL|Fibroblast|Transplantation of 20 million cell by three injection
41273008|NCT03140319|BIOLOGICAL|Placebo|Injection of Placebo
41273009|NCT04697914|DIAGNOSTIC_TEST|Plantar pressures will be measured in 7 zones using the Footscan® platform following the two-step method. Three plantar pressures measurements were made for each foot.|to protect the metatarsus and prevent the appearance of foot pain.
41273010|NCT03135392|PROCEDURE|Breast Reconstruction with Artificial Implant|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
41273011|NCT03135392|PROCEDURE|Autologous Breast Reconstruction|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
41273012|NCT03135392|PROCEDURE|Neurotization|Nerve will be reconstructed during autologous breast tissue reconstruction
41273013|NCT01332708|BEHAVIORAL|high complex carbohydrates diet given in a diet group|diet groups that meet every week for eight weeks or more.
41273014|NCT01236391|DRUG|PCI-32765|560 mg daily
41120740|NCT02724592|DEVICE|fluoride varnish (Duraphat®)|Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
40753732|NCT02286791|BEHAVIORAL|Mindful Awareness Program|For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks
41120741|NCT02253537|DEVICE|CST001|
41120742|NCT04619290|DRUG|Sublingual Methylene blue|Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
41120743|NCT04619290|OTHER|Control patients|Control patients will be received the conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
41273015|NCT01962220|BEHAVIORAL|Study Intervention for Retention (APFU)|"Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).~Mama Mshauri tasks will include:~* Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.~* Providing tailored individualized health education during home visits.~Additional intervention components include:~* Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.~* Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment."
41273016|NCT00319514|DRUG|Docetaxel|
41273017|NCT03007264|DEVICE|Cold Atmospheric Plasma|CAP will be applied on one volar arm of volunteers for a total of 2 minutes.
41273018|NCT00676507|BIOLOGICAL|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
41273019|NCT00676507|OTHER|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
41273020|NCT00914693|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
41273021|NCT01486862|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
41273022|NCT05192603|DIETARY_SUPPLEMENT|low FODMAP or SSRD|The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant
41273023|NCT04342065|DRUG|Celecoxib capsules|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
41273024|NCT04342065|DRUG|Pregabalin 150mg|received Pregabalin 150mg 2 hours preoperative and the same dose 6 hours postoperative.
41273025|NCT01485614|DRUG|Sitagliptin|Sitagliptin 100 mg tablet administered orally once daily
41273026|NCT01485614|DRUG|Metformin|Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
41273027|NCT01485614|DRUG|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet administered orally once daily
41273028|NCT01485614|DRUG|Placebo to metformin|Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
41273029|NCT01485614|DRUG|Glycemic Rescue 1|Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.
41273030|NCT01485614|BIOLOGICAL|Glycemic Rescue 2|Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
41273031|NCT01449890|BEHAVIORAL|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
41273032|NCT04213651|OTHER|No intervention|There is no intervention for this study
41273033|NCT03095092|DRUG|BIA 6-512 400 mg|4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
41120744|NCT05654948|OTHER|computerised cognitive performance test : MindPulse|In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty
41120745|NCT04414826|BEHAVIORAL|Mindfulness Alone (MO) Intervention|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness and non-reactivity skills.
41273034|NCT05495815|DRUG|6 months of SAT|6 months of oral suppressive antibiotic therapy
41273035|NCT05495815|DRUG|12 months of SAT|12 months of oral suppressive antibiotic therapy
41273036|NCT05495815|DRUG|Indefinite SAT|Indefinite oral suppressive antibiotic therapy
41120746|NCT04414826|BEHAVIORAL|Mindfulness + Compassion Intervention (MC)|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness, non-reactivity, and compassion skills.
41120747|NCT05705505|DRUG|Narazaciclib|Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate
41120748|NCT05705505|DRUG|Letrozole 2.5mg|Tablet
41273037|NCT02544555|PROCEDURE|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
41273038|NCT02544555|PROCEDURE|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
41273039|NCT04100525|BEHAVIORAL|Neuropsychological testing intervention plus follow up|Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
41273040|NCT05943730|DEVICE|Seismofit|The Seismofit device uses seismocardiography to estimate peak oxygen consumption from a resting measurement. This study will assess its validity against the gold standard measure of peak oxygen consumption, cardiopulmonary exercise test, conducted as part of standard care.
41273041|NCT05664620|DIAGNOSTIC_TEST|Risk Stratification Tool|Patients will be allocated to three groups (Low,medium and high risk) by using the Risk Stratification Tool, and High risk patients will receive multidisciplinary treatment assigned to them by a physician
41273042|NCT05426200|BEHAVIORAL|Health Coaching|Patients will work with a health coach by telephone for up to 12 sessions over a 12-16 week period.
41273043|NCT04680650|DRUG|Anesthesia was maintained with sevoflurane|After endotracheal intubation, anesthesia was maintained with 1.5-3% sevoflurane, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DS.
41273044|NCT04680650|DRUG|Anesthesia was maintained with propofol|After endotracheal intubation, anesthesia was maintained with 2-4 μg/mL target-controlled infusion of propofol, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DP.
41273045|NCT00456703|OTHER|intraoperative fluid management|fluid restriction
41273046|NCT00456703|OTHER|fluid restriction|restriction of fluids
41273047|NCT00227201|BEHAVIORAL|Self-affirmation intervention|
41273048|NCT03778437|PROCEDURE|subclavian vein catheterization|Here we introduced a new freehand method, named as Aiming Method, which facilitated the alignment of injection needles with ultrasound beams. During this aiming method, patient is still positioned in Tredelenburg with the arm abducted to 90° and no needle guidance will be used.
41273049|NCT03778437|PROCEDURE|landmark techniques|The patient is positioned in Tredelenburg with the arm abducted to 90°. Venipuncture should occur 1 cm lateral to the curvature of the middle third of the clavicle with the needle pointing horizontally directed at the sternal notch. If subclavian vein is missing at the first try, withdraw the needle and direct horizontally at the cricoid cartilage at the second try.
40926476|NCT04260932|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.
40947822|NCT02758314|OTHER|Evaluation of PD-1/PDL-1 expression.|Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations of peripheral blood by flow cytometry and in tumor tissue by immunohistochemistry in NSCLC, free treatment and healthy subjects
41120749|NCT01820780|OTHER|Natriuretic peptides levels to J7 and J14|
41120750|NCT01820780|OTHER|Consultations specialized to J7 and J14|Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
41120751|NCT01820780|OTHER|Phone calls in 6 months and 12 months|
41120752|NCT01820780|OTHER|Natriuretic peptides levels at 6 months|
41120753|NCT01820780|OTHER|Consultation with the general doctor or the cardiologist to J30 with blood results|
41120754|NCT03107546|DEVICE|Hyalomatrix|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
41120755|NCT03107546|OTHER|Skin graft|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
41120756|NCT06281054|PROCEDURE|Revascularization|Performing PCI or CABG
41120757|NCT01943916|DEVICE|Imagio OA/US (US and OA/US)|opto-acoustic plus gray scale ultrasound
41120758|NCT01943916|DEVICE|Imagio gray scale ultrasound|gray scale ultrasound alone
41120759|NCT04865146|DEVICE|TRIGEN™ INTERTAN™|Femoral fracture treated with INTERTAN 10S Nail
41120760|NCT03457948|PROCEDURE|Arterial Embolization|Undergo TAE
41120761|NCT03457948|BIOLOGICAL|Pembrolizumab|Given IV
41120762|NCT03457948|BIOLOGICAL|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate|Given IV
41120763|NCT03457948|DEVICE|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere RE
41120764|NCT01350024|PROCEDURE|Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine|Frontal Nerve Block 5 cc will be administered preoperatively once.
41120765|NCT01350024|PROCEDURE|Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine|Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
41120766|NCT05552924|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
40947823|NCT03464877|OTHER|Multi-station full-body supervised exercise program|The exercise program was 6-week duration, 2-3 visits per week. It was composed of 7 stations, each consisting of numerous exercises of increasing difficulty. The exercises were grouped together as follows: Hip strengthening and control (Station 1); The squat and its variants (Station 2); Elastic bands and the Bodyblade (Station 3); Abdominal planks and their variants (Station 4); Abdominal strengthening (Station 5); Back extensor strengthening (Station 6); and Lifting techniques (Station 7).
40753733|NCT02286791|BEHAVIORAL|Health Education Program|"For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.~Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support"
40947824|NCT00662454|DRUG|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
41120767|NCT00806169|DRUG|triamcinolone and bevacizumab|
41120768|NCT05330234|DEVICE|OnTrack Tools|"The intervention is the OnTrack Tools system consisting of a graphical user interface (GUI) used to manage patients who are users of the OnTrack rehabilitation system. Participants will be asked to complete clinical and non-clinical tasks in simulation using OnTrack Tools. The themes for the scenarios of use presented in each of the three phases are summarised below:~Phase 1 - Account creation, system onboarding and general system navigation. Phase 2 - Individual patient management. Phase 3 - Content and data management."
41120769|NCT05756335|BEHAVIORAL|(Un)predictable and (un)attended stimuli|Subjects will complete four task conditions in each scan session: (1) Visual Unpredictable, (2) Visual Predictable, (3) Auditory Unpredictable, and (4) Auditory Predictable. In visual and auditory conditions subjects attend to visual or auditory stimuli and ignore the other domain, pressing a button when they detect an infrequently occurring stimulus inversion in the target domain. In unpredictable and predictable conditions, the attended domain either presents random (unpredictable) stimuli, or the same face or word stimuli repeated (predictable).
41120770|NCT00533546|DRUG|Activated Protein C|Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
41120771|NCT03403413|DEVICE|muscle vibration during walking|Baseline assessment of gait followed by 12 sessions (3/week for a month) of gait training with cyclic muscle vibration during walking emulating normal muscle activity of lower extremities in treatment group. Gait assessment both with and without muscle vibration were collected at follow-up after 12 sessions of gait training with muscle vibration.
41120772|NCT03993704|DRUG|LHF-535|Oral suspension administered once daily for 14 days
41273050|NCT03778437|PROCEDURE|Ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique. The patient is positioned in Tredelenburg with the arm abducted to 90°. During the needle insertion, the needle is secured in the needle guidance device which keeps the alignment of needle and ultrasonic beam.
41273051|NCT03146364|DEVICE|Virtual Reality - Virtual Interactive Supermarket|"SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.~Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction"
41273052|NCT00006120|DRUG|docetaxel|
41273053|NCT00006120|DRUG|paclitaxel|
41273054|NCT04048512|PROCEDURE|Resection with intraoperative use of ECMO/CPB|Patients are operated with the use of intraoperative ECMO/CPB
41273055|NCT04048512|PROCEDURE|Resection without intraoperative use of ECMO/CPB|Patients are operated without the use of intraoperative ECMO/CPB
41273056|NCT02131844|OTHER|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
41273057|NCT02131844|OTHER|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
41273058|NCT05212051|BIOLOGICAL|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
41273059|NCT05212051|BIOLOGICAL|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
41273060|NCT01526356|DRUG|Placebo|Study cream is applied nightly to the affected areas on the face.
41273061|NCT01526356|DRUG|Rapamycin|Study cream is applied nightly to the affected areas on the face. Low Dose
41273062|NCT01526356|DRUG|Rapamycin|Study cream is applied nightly to the affected areas on the face. High Dose
41273063|NCT06127329|PROCEDURE|BAI combine with DEB-BACE|"1. First treatment. Only infusion chemotherapy (THP + Platinum + Letitrexed), THP 20 \~30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~2. Second treatment. After infusionchemotherapy, EqualSpheres microsphere used for embolization: EqualSpheres microspheres (400 μm) 1tube was loaded and adsorbed THP (40 \~ 60mg/m2). End point of embolization: stagnation of blood flow in tumor feeding artery."
40753734|NCT04347759|OTHER|Symptom Care at Home-Heart Failure|When participants call, the IVR system will ask them about each of the selected symptoms, and the patient will report symptom presence and severity numerically with the touchtone keypad. Based on symptom severity, intervention group will receive automated coaching messages. There will be a toll-free number for participants to call and a password to log into the system which will be stored on a secure and HIPPA-compliant sever. Calls can be personalized to allow the voice to greet the patient by name.
41273064|NCT03420560|BEHAVIORAL|warmer temperature|Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.
41273065|NCT00456313|DRUG|FLIXOTIDE and SERETIDE|comparator
41273066|NCT00510705|OTHER|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
41273067|NCT00510705|OTHER|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
41273068|NCT00510705|OTHER|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
41273069|NCT03575026|BEHAVIORAL|Music-with-movement|Subjects will listen their preferred music and move their body actively with music
41273070|NCT03575026|BEHAVIORAL|Usual care|Social activity acts as control with similar dose and intensity with intervention arm
41273071|NCT04348851|BEHAVIORAL|Caregiver problem-solving|Registered nurses will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue
41273072|NCT04348851|BEHAVIORAL|Attention Control|The RNs will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare
41273073|NCT01300104|BEHAVIORAL|Exercise|"Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.~Restrictions: None."
40753735|NCT01922661|DRUG|REGN1908-1909|
40753736|NCT01922661|OTHER|placebo|
40753737|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|Online prevention program using positive images
41120773|NCT02740283|BEHAVIORAL|glycemic monitoring|
41120774|NCT02740283|DIETARY_SUPPLEMENT|dietary guide|
41273074|NCT01300104|BEHAVIORAL|Whole grain rye|Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.
40753738|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|Online Program Extended Length
41273075|NCT01300104|BEHAVIORAL|Recommendations|Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
41273076|NCT00119340|DRUG|cyclosporine|
41273077|NCT00119340|DRUG|fludarabine phosphate|
41273078|NCT00119340|DRUG|mycophenolate mofetil|
41273079|NCT00119340|PROCEDURE|peripheral blood stem cell transplantation|
41273080|NCT00119340|RADIATION|radiation therapy|
41273081|NCT04268888|DRUG|Nivolumab and TACE/TAE|Immunotherapy and TACE/TAE
41273082|NCT04268888|PROCEDURE|TACE/TAE|TACE/TAE (as per local practice)
41273083|NCT00716716|DRUG|rFIXFc|As specified in the treatment arm
41273084|NCT01389245|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
41273085|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted at femoral triangle apex|In group 1, the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal).
41273086|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15*2 cm above the location|In group 2, the adductor canal catheter is inserted femur length/15\*2 cm above the location where the nerve block performed in group 1.
41273087|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15 cm below the location|In group 3, the adductor canal catheter is inserted femur length/15 cm below the location where the nerve block performed in group 1.
41273088|NCT01167608|OTHER|No Intervention. This is a cross-sectional survey study.|No intervention.
41273089|NCT02226965|DRUG|PNT2258|
41273090|NCT03601871|DRUG|Thalidomide|Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .
41273091|NCT03601871|DRUG|Dexamethasone|Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4
41273092|NCT03601871|DRUG|5-HT3 antagonists|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
41273093|NCT04584177|BEHAVIORAL|Arm-hand BOOST program|The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.
40753739|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control|Control
41120775|NCT02282267|DRUG|Gefitinib|Iressa 250mg oral daily
41273094|NCT04584177|BEHAVIORAL|Control program|A dose-matched program of strengthening exercises for the lower limbs and general reconditioning
41273095|NCT02792868|OTHER|24 h urines analyses|patient collects urines during 24h
41273096|NCT06329050|DRUG|Losartan|Administration of Losartan tablets(50 mg)
41273097|NCT06329050|DRUG|Placebo|Administration of Placebo tablets
41273098|NCT00294151|PROCEDURE|Vertebroplasty|
41273099|NCT06331624|DRUG|Tazarotene (GRI-0621)|Oral 4.5mg soft gel capsule
41273100|NCT06331624|DRUG|Placebo|Oral 4.5mg soft gel capsule
41273101|NCT05303740|DRUG|Anlotinib|This is an observational study.
41273102|NCT04275427|DEVICE|LA-400 laser acupuncture|low level laser
40753740|NCT01004393|DRUG|Methylnaltrexone bromide|Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
41120776|NCT00295464|DRUG|Betamethasone sodium phos (drug)|
41120777|NCT01869946|DRUG|Ropivacaine|
41120778|NCT00091650|DRUG|Olanzapine|
41120779|NCT00091650|DRUG|placebo|
41120780|NCT04127669|DRUG|OSU 6162|The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-\[3-(methylsulfonyl)phenyl\]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is \> 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.
41120781|NCT04127669|DRUG|Placebo oral tablet|Circular coated tablet (with identical appearance to active treatment tablets 15 mg).
41273103|NCT00882414|DRUG|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
41273104|NCT00882414|DRUG|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
41273105|NCT02304003|OTHER|Structured Physiotherapy Regimen|Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
41273106|NCT02304003|OTHER|Standard Care|Standard follow up in primary care.
41273107|NCT00702143|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
41273108|NCT01551745|BIOLOGICAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
41273109|NCT01551745|DRUG|Bevacizumab|Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
41120782|NCT04863261|OTHER|Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App|The CHORUS App has been developed as a tool for clinicians to easily visualize important patient information from their smart phones. Relevant information is electronically distributed and placed within the corresponding module in the CHORUS HCP mobile app for iOS and Android.
41120783|NCT04082624|BEHAVIORAL|Nutrition condition|Received nutritional information in in-person PowerPoint presentations.
41120784|NCT04082624|BEHAVIORAL|Affective condition|Received information about affective benefits of less sitting in the workplace in in-person PowerPoint presentations.
41120785|NCT04082624|BEHAVIORAL|Instrumental condition|Received information about instrumental benefits of less sitting in the workplace in in-person PowerPoint presentations.
41120786|NCT04082624|BEHAVIORAL|Self-regulation condition|Learned how to self-regulate behavior to sit less in the workplace in in-person PowerPoint presentations.
41273110|NCT06135792|OTHER|Arginine|See arm description
41120787|NCT02487927|BEHAVIORAL|weaning|T piece
41273111|NCT06135792|OTHER|Placebo|See arm description
41273112|NCT00270894|DRUG|epirubicin|epirubicin (100 mg/m\^2) every 2 weeks for 4 cycles
41273113|NCT00270894|DRUG|cyclophosphamide|cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles
40753741|NCT01889563|OTHER|Physical Exercise Training Program Exercise|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
41273114|NCT00270894|DRUG|docetaxel|docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles
40753742|NCT00483509|DRUG|NGR-hTNF|iv q3W 0.8 mcg/sqm NGR-hTNF
40753743|NCT00483509|DRUG|Doxorubicin|iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
40753744|NCT01795937|DRUG|Itraconazole|twice daily
40753745|NCT01795937|DRUG|Atorvastatin|single dose
40753746|NCT01795937|DRUG|Faldaprevir|once daily
40753747|NCT01795937|DRUG|Rosuvastatin|single dose
40753748|NCT01795937|DRUG|Faldaprevir|once daily
40753749|NCT05253235|BEHAVIORAL|SAAF|A 7 session online intervention designed to augment protective processes associated with deterrence of substance use
41120788|NCT01402479|DRUG|Ramipril|ramipril 2.5mg twice a day
41120789|NCT02169869|DEVICE|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
41120790|NCT02169869|DEVICE|Paragard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
41120791|NCT00068601|DRUG|cyclophosphamide|Part of planned chemotherapy regimen
41273115|NCT00270894|DRUG|trastuzumab|trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments
41273116|NCT05346107|DRUG|pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage|The patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
40753750|NCT05253235|OTHER|Receipt of parenting book|Parents will receive a copy of the book, Parenting for Liberation: A Guide for Raising Black Children
40753751|NCT02872688|OTHER|GanedenBC30|
40753752|NCT06378255|DEVICE|Polycation-based new dentinal desensitizer|Dental desensitization treatment
40753753|NCT06378255|DEVICE|GLUMA desensitizer|Dental desensitization treatment
40753754|NCT04784403|DIAGNOSTIC_TEST|SARS-CoV-2 PCR and serology tests|Once the informed consent has been signed, the selected subjects must complete an epidemiological survey and go to a UB sample collection center to perform a PCR and serology test for SARS-CoV-2.
40753755|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
40753756|NCT00281580|DRUG|Placebo|Placebo to Telmisartan and Amlodipine once daily for eight weeks
40753757|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
40753758|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
40753759|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
40753760|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
40753761|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
40753762|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
40753763|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
40753764|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
40753765|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5g once daily for eight weeks
41120792|NCT00068601|DRUG|goserelin acetate|Given subcutaneously
41120793|NCT02725294|OTHER|This is an observational study without an intervention|Not applicable. This is an observational study without an intervention.
41120794|NCT05075486|BEHAVIORAL|Collaborative quality improvement|Hospitals will receive standardized center-specific ECLS data report with benchmarking to feedback on their performance. Evidence-based potential better practice list will be established as a reference for all hospitals. During the intervention period, the hospitals will receive training in collaborative quality improvement method and then develop, implement, and document evidence-based practice changes to reduce adverse outcomes of neonatal ECLS treatment. Compliance with practice changes and neonatal outcomes will be monitored. All hospitals will have access to implementation support and collaborative activities.
41120795|NCT02231983|GENETIC|gene sequencing|Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
41120796|NCT05298020|DRUG|Envafolimab|400mg,sc,d1,Q4W
41273117|NCT04351412|OTHER|Gluma|Gluma is desensitizing agent by (Heraeus Kulzer, Armonk, NY, USA) claimed to treat dentine hypersensitivity in exposed cervical teeth surfaces and was applied to participants using a mini brush applicator tip onto the exposed hypersensitive tooth surface requiring treatment and was allowed to dry for 60 seconds. Then Dentine hypersensitivity (DH) was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
41273118|NCT04351412|OTHER|fluoride varnish|fluoride varnish is usually applied to patients to prevent caries development but was claimed in some cases to also relief dentine hypersensitivity and was applied as a thin layer to the surface of the tooth using an applicator. The varnish set rapidly, and thereafter moisture contamination was not a concern. Patients were advised to not brush or floss their teeth for a couple of hours and to abstain from hot beverages. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
41273119|NCT04351412|OTHER|Tetric N-Bond self-etch adhesive|Tetric N-Bond self-etch adhesive is one step dental adhesive and is also claimed to relief dentine hypersensitivity due to blockage of dentinal tubules. It was applied according to the manufacturer's instructions, in a thick layer, for at least 30 seconds, using a light brushing motion. Then, it was dried with a steady stream of air for 3 seconds and light-cured for 10 seconds. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
41120797|NCT05298020|DRUG|Endostar|210mg，CIV72h，d1-3，Q4W
41273120|NCT03065829|BEHAVIORAL|ASSIST|Wearable sensor technology delivering mindfulness meditation training (MMT) and health promotion (sleep hygiene and physical activity) .
41273121|NCT03065829|BEHAVIORAL|Attention-Control|Wearable sensor technology only viewing biophysical sensor data.
41273122|NCT04801290|PROCEDURE|TIPS insertion|Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.
41273123|NCT05448079|OTHER|Sexual counseling according to the PLISSIT model, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
41273124|NCT01517035|PROCEDURE|Stem Cell Transplantation|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
41273125|NCT01617044|DIETARY_SUPPLEMENT|Probiotics|probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
41273126|NCT01617044|DIETARY_SUPPLEMENT|Placebo|Placebo
41273127|NCT05103150|DIAGNOSTIC_TEST|High-definition white light endoscopy (HD-WLE)|"Evaluation of the duodenal mucosa with HD-WLE (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by one endoscopist, randomly assigned via esophagogastroduodenoscopy.~There were used the following standard endoscopic findings were: a) scalloping or dented aspect of the duodenal folds; b) submucosal vascular pattern; c) mosaicism or micronodular look of the mucosa; d) grooves and fissurations of the mucosa."
41273128|NCT05103150|DIAGNOSTIC_TEST|HD-WLE plus I-Scan optical enhancement (OE) virtual chromoendoscopy with High-definition optical magnification (HD-OM)|"Evaluation of the duodenal mucosa through upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves using a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode one and mode two without HD-OM to obtain an overview of the duodenal surface and identify any changes in the mucosa, then HD-OM will be implemented.~There were used OE criteria as previously validated by Cammarota et al: brightness, Ave/peak, blue, red, surface, contrast, and tone enhancement."
41273129|NCT00220363|DRUG|SPM 907|
40753766|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
40753767|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
41120798|NCT05298020|DRUG|Nab paclitaxel|125mg/m2,iv,d1,d8,Q4W
41120799|NCT05298020|DRUG|Gemcitabine|1000mg/m2, iv,d1,d8，Q4W
41120800|NCT02566902|DEVICE|T-Piece Nebulizer|Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
40753768|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5mg once daily for eight weeks
40753769|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
41120801|NCT02566902|DEVICE|Breath-Enhanced Nebulizer|Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
41120802|NCT02566902|DRUG|Albuterol|One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
41120803|NCT02566902|PROCEDURE|Pre-Treatment Spirometry Measurement|Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
41273130|NCT04844138|BEHAVIORAL|Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program|The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
41273131|NCT05015101|OTHER|Cohort observation|Cohort observation
41273132|NCT02644408|DRUG|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
41273133|NCT02644408|RADIATION|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
41273134|NCT02644408|OTHER|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
41273135|NCT05605756|DRUG|OnabotulinumtoxinA 145 UNT [Botox]|"Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic."
41273136|NCT02069691|DEVICE|virtual reality-cycling training system|
41273137|NCT01393093|PROCEDURE|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
41273138|NCT05152186|DRUG|Topical Solution|Topical administration
41273139|NCT05152186|DRUG|Topical Foam|Topical administration
41120804|NCT02566902|PROCEDURE|Post-Treatment Spirometry Measurement|Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
41120805|NCT00075933|DRUG|ARQ 501|
41120806|NCT00667056|DRUG|tacrolimus ointment|topical
41120807|NCT00667056|DRUG|placebo ointment|topical
41120808|NCT04869761|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Single MSC infusion of 150x10\^6 cells at time zero; intravenous delivery
41273140|NCT05152186|OTHER|Topical|Topical administration
41273141|NCT05192343|DEVICE|Virtual Reality and nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before and during the HSG shooting, the virtual reality and nature sounds application group watched a video with a nature view with virtual reality glasses and listening nature sounds.~Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure.~The women include in the virtual reality and nature sounds application group will make to watch a video with a nature view with nature sounds for 15 minutes before and during the HSG procedure.~Each woman was shown the same video."
40753770|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
40753771|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
41120809|NCT04869761|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions|Two MSC infusions of 75x10\^6 cells at time zero and three months; intravenous delivery
41120810|NCT04246307|DIAGNOSTIC_TEST|TEG® and ClotPro® parameters|"Systemic sampling is performed six times:~* before the surgery (S1)~* during the hepatectomy, 10 minutes before the anhepatic phase (S2)~* in the anhepatic phase, before starting portal vein anastomosis: (S3)~* in the neohepatic phase, 15 minutes after releasing portal vein clamping: (S4)~* in the neohepatic phase, at the end of the surgery: (S5)~Regional sampling from the portal vein representing afferent flow to the liver is performed once:~• in the anhepatic phase, before starting portal vein anastomosis: (R)~Simultaneously with haemostasis and blood gas analyses, the following investigations will be performed (the following tests are also routinely performed at the given time points, independently of this study):~* haemodynamic measurements by PiCCO~* arterial blood gas analysis from radial artery catheter~* central venous blood gas analysis from subclavian vein catheter~* blood temperature measurement in the femoral artery by PiCCO catheter~* hourly urinary output"
41120811|NCT02549313|PROCEDURE|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
41120812|NCT00908505|PROCEDURE|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
41120813|NCT00111813|DRUG|vorinostat|Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
41273142|NCT05192343|OTHER|nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before the procedure started, glasses will put on and training was given to continue. After the groups were formed, a nature-based sound was played to the women in the nature sounds group before and during the HSG shooting.~Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes."
41453425|NCT05746468|BEHAVIORAL|Ecological assessment and intervention|The MBI-EMI app will include five main parts, including virtual counselor, intervention library, weekly mindfulness practice, assessment bank and daily emotion log. In the eight weeks, the virtual counselor will initiate the conversation every day for three times (morning, afternoon and evening) to check the status of the participants. If the participants responded, the virtual counselor would invite the participants to rate their level of depression, stress and anxiety and then recommend appropriate mindfulness practice in the intervention library, such as 3-minute breathing space or mindful eating. The conversation between the virtual counselor and participants will be in the format of menu list and participants can easily choose from different options.
41120814|NCT00111813|DRUG|bortezomib|Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
41120815|NCT04192916|DRUG|DOACs|Direct Oral Anticoagulants
40753772|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
41120816|NCT02496325|PROCEDURE|Ultrasound guided transperineal pudendal nerve block|Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
41120817|NCT00707772|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
41120818|NCT00707772|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
41120819|NCT04381975|BEHAVIORAL|Move in Mind Program|Each of the six Move in Mind sessions will take place once a week for approximately 1.5 hours, with 12-17 individuals participating per class. The material and exercises taught will include physical floor exercises, breathing exercises, as well as awareness training.
41120820|NCT04381975|BEHAVIORAL|6 Week Waitlist Control|The waitlist control group will receive the Move in Mind program after 6 weeks.
41120821|NCT04267458|OTHER|evaluation of sofuspovir containing DAA regien expected insult on kidney|to use different kidney biomarkers to evaluate acute kidney damage after using sofuspovir containing DAA regimen in treatment of HCV
41120822|NCT02560649|DRUG|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
41120823|NCT02560649|DRUG|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
41120824|NCT02560649|DRUG|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
41120825|NCT02560649|DRUG|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
41120826|NCT02560649|DRUG|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
41120827|NCT02560649|DRUG|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
41120828|NCT02560649|DRUG|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
41120829|NCT02560649|DRUG|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
41120830|NCT00495885|DRUG|volinanserin (M100907)|oral, one tablet taken around bedtime
41120831|NCT00495885|DRUG|Placebo|oral, one tablet taken around bedtime
41120832|NCT01154439|DRUG|cytarabine|Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.
41120833|NCT01154439|DRUG|etoposide|Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.
41120834|NCT01154439|DRUG|everolimus|"Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).~Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10."
41120835|NCT01154439|DRUG|idarubicin|Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.
41120836|NCT01154439|DRUG|mitoxantrone hydrochloride|Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
41120837|NCT03712306|OTHER|Dietary advice|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d
41273143|NCT04816240|DRUG|Midodrine|5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90)
40753773|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
40753774|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
41273144|NCT04816240|BIOLOGICAL|Albumin|80grams/week for 2 weeks followed by 40gram/week
41120838|NCT03712306|OTHER|Dietary advice and advice on timing|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d plus advice on consuming protein in close proximity of usual physical activity
41120839|NCT06174779|DRUG|HM11260C|Test drug
41120840|NCT06174779|DRUG|Placebo|Placebo drug
41120841|NCT05900765|DRUG|Zimberelimab 240mg|"AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV"
41120842|NCT00897169|OTHER|Oral Glucose Tolerance Test (OGTT)|A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2
41120843|NCT00897169|OTHER|Euglycaemic hyperinsulinaemic clamp|A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
41120844|NCT01604161|DRUG|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
40753775|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
41273145|NCT04816240|OTHER|Standard Medical Treatment|Standard Medical Treatment
41120845|NCT02436213|OTHER|Cardiopulmonary exercise test|"On Day 1, subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down (within the hour on Day 1), they will fill in a short questionnaire describing how they feel."
41120846|NCT02436213|PROCEDURE|Blood test|On same day (Day 1), the subject will have 20-30mls of blood (that is, 4-6 teaspoonful) taken for analysis.
41120847|NCT02160951|DRUG|LGH447|LGH447, QD
41120848|NCT03829852|DRUG|Regorafenib|Treatment was performed based on physician's discretion
41120849|NCT01411592|OTHER|Multilink|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)
41120850|NCT01411592|OTHER|Panavia 21 TC|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
40926477|NCT06458218|COMBINATION_PRODUCT|Multi-component Interventions|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;~2. A digital health intervention program, EmoEase, for individuals with mental health issues among high-risk COPD population(very familiar with intelligent mobile phone);~3. NicQuit, digital health intervention to smokers;~4. Health education to smokers and individuals with mental health issues;~5. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;~6. To actively include individuals whose blood pressure and glucose are higher than the normal value into the National Essential Public Health Service in China;~7. A CBT-based health education to the BMI abnormal;~8. Pay-for-performance incentives to medical workers."
40926478|NCT04657107|DRUG|S-ketamine|K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
40926479|NCT04657107|OTHER|normal saline|Saline group: pregnant women received saline, intravenous drip
40926480|NCT04657107|DRUG|S-ketamine|K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
40926481|NCT00159497|DEVICE|porous coated Trilogy®|THA
41273146|NCT04816240|OTHER|Placebo|Placebo
41273147|NCT05759052|BEHAVIORAL|self-administered questionnaire|Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
41273148|NCT03757039|DEVICE|Multifocal soft contact lenses|Commercially available contact lenses
41273149|NCT03757039|OTHER|Progressive addition lens spectacles|Per subject's habitual prescription
41273150|NCT01253733|BEHAVIORAL|MD2ME|The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
41273151|NCT01447238|DEVICE|Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe|"Patients will undergo the EUS-FNA procedure, as per standard of care, plus an additional direct visualization (fiber optic probe) and nCLE procedure with the prototype probes, which will add 10 minutes maximum to the EUS-FNA procedure.~The probes will be positioned against the lining of the pancreatic cyst, and images will be acquired. After imaging, fine needle aspiration of the lesion will be performed, as usual."
40753776|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
40753777|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
40753778|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
40753779|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5g once daily for two weeks
40926482|NCT00159497|DEVICE|Trilogy Calcicoat®|THA
41273152|NCT01908348|DIETARY_SUPPLEMENT|Erythritol|
41273153|NCT00352248|PROCEDURE|Tongue Acupuncture (Procedure)|
41273154|NCT01488006|DEVICE|Bigliani/Flatow Shoulder System|Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
40753780|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
40753781|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
40753782|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
40753783|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
40926483|NCT01059929|DRUG|Dexmedetomidine|continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
40753784|NCT05366647|PROCEDURE|canaloplasty|canaloplasty ab interno with tensioning suture
41120851|NCT04620902|OTHER|Tear sampling|Tear sampling using Schirmer's strips
41120852|NCT00003540|DRUG|gemcitabine hydrochloride|
41120853|NCT02416115|DRUG|Ramosetron|Ramosetron was given iv.
41120854|NCT02416115|DRUG|Naloxone|Naloxone added to PCA was given iv.
41120855|NCT02416115|DRUG|saline|Saline was given iv.
41120856|NCT02416115|DRUG|Morphine|Morphine in the PCA was given iv.
41120857|NCT05115058|OTHER|relex Smile module|
41120858|NCT05434234|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
41273155|NCT04899583|DEVICE|Sirolimus Coated Balloon Catheter|a Sirolimus Coated Balloon Catheter designed and produced by Acotec
41273156|NCT04899583|DEVICE|a Paclitaxel Coated Balloon Catheter|a Paclitaxel Coated Balloon Catheter(trade name:Bingo)
41453426|NCT05746468|BEHAVIORAL|Audio-based Mindfulness intervention|The control group will receive audio recordings of how to practice mindfulness at home.
40753785|NCT05366647|PROCEDURE|Gonioscopy-assisted Transluminal Trabeculotomy|Gonioscopy-assisted Transluminal Trabeculotomy ab interno
40753786|NCT05415787|OTHER|Blood sample|2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
40753787|NCT05415787|OTHER|Urine sample|Urine sample is taken during the consultation carried out for the patient's care
40753788|NCT00642265|PROCEDURE|osteosynthesis|operative treatment
40753789|NCT00642265|OTHER|sling|conservative treatment
40753790|NCT04865458|DRUG|HEC89736|HEC89736 tablets QD every 28 days for each cycle
41273157|NCT00710645|DEVICE|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
41273158|NCT02682836|BEHAVIORAL|Walk with Ease|
40753791|NCT03845673|DIETARY_SUPPLEMENT|Psyllium|Psyllium fiber (Konsyl; Konsyl Pharmaceuticals, Easton, Md)
40753792|NCT03845673|DIETARY_SUPPLEMENT|Bowel recipe|consisted of 1 cup of unprocessed wheat bran, 1 cup of applesauce, and 1/4 cup of prune juice.
41120859|NCT03319797|DRUG|NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
41120860|NCT01751958|RADIATION|Epidural steroid injection|Epidural steroid injection
41120861|NCT06519292|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA) at baseline|Detailed imaging of coronary arteries
41120862|NCT06519292|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA) after 1 year|Detailed imaging of coronary arteries
41120863|NCT00181740|DRUG|atomoxetine (Strattera)|
41120864|NCT06517875|DRUG|Momelotinib|Momelotinib will be administered orally.
41120865|NCT06517875|DRUG|Luspatercept|Luspatercept will be administered subcutaneously.
41120866|NCT00944333|DRUG|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
41120867|NCT00944333|DRUG|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
41273159|NCT01380054|BEHAVIORAL|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
41273160|NCT00628186|DEVICE|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
40753793|NCT00003008|DRUG|indinavir sulfate|
40753794|NCT00003008|DRUG|nelfinavir mesylate|
40753795|NCT00003008|DRUG|paclitaxel|
40753796|NCT00003008|DRUG|ritonavir|
40753797|NCT00003008|DRUG|saquinavir mesylate|
40753798|NCT02941952|DEVICE|Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.|
40753799|NCT06413394|OTHER|environmental education|environmental education
40753800|NCT04455750|DRUG|Enzalutamide|Given PO
40753801|NCT04455750|DRUG|Rucaparib camsylate|Given PO
40753802|NCT04455750|DRUG|Placebo|Given PO
40753803|NCT04455750|DRUG|Leuprolide Acetate|Given IM
40753804|NCT04455750|DRUG|Goserelin Acetate|Given SC
40753805|NCT04455750|DRUG|Degarelix|Given SC
40753806|NCT04455750|OTHER|Quality-of-Life Assessment|Ancillary studies
40753807|NCT04455750|OTHER|Questionnaire Administration|Ancillary studies
40753808|NCT00986583|DRUG|Succinylcholine|Succinylcholine will be administered pre-induction over a period of 5 seconds
40753809|NCT03361007|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Patients who were disqualified from surgical cortical valve replacement by decision of the Heart Team.
40753810|NCT04720170|PROCEDURE|Revascularization|Angiogram and IVUS with revascularization of the lateral plantar artery and pedal arch on target foot.
40753811|NCT05446155|DIAGNOSTIC_TEST|Imaging|Diagnostic and prognostic imaging, omics and machine learning methods will be applied
40753812|NCT02207179|DEVICE|LumaScan Image Guided Surgery|
40926484|NCT01059929|DRUG|Propofol|continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
41120868|NCT02663778|BEHAVIORAL|Strength training|weight lifting to increase muscle strength
41120869|NCT02663778|BEHAVIORAL|Endurance training|treadmill walking to increase endurance
41120870|NCT02663778|BEHAVIORAL|Flexibility training|stretches to improve flexibility
41120871|NCT02663778|BEHAVIORAL|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
41120872|NCT02663778|BEHAVIORAL|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
41120873|NCT03080324|DRUG|Fentanyl sublingual|Fentanyl sublingual
41120874|NCT03080324|DRUG|Fentanyl ev|Fentanyl ev
41120875|NCT03080324|DRUG|Placebo sublingual|Placebo sublingual
41120876|NCT03080324|DRUG|Placebo ev|Saline
41120877|NCT04413812|BEHAVIORAL|FREEBASE exercise programme|"The exercise programme will be initialized 1-10 months following bariatric surgery and last for 3 months. The programme will be mainly delivered in two groups consisting of 10-12 subjects each and will be held in the facilities of a fitness studio and remotely at home. The programme consists of 24 units (two per week, the lesson in the fitness studio lasting for 75 minutes and the remote lesson lasting for 45 minutes.This is due to the COVID-19-related social distancing restrictions. The intervention combines the following elements: a) exercise training in a group, b) interactive workshops on basic knowledge of training sciences and techniques of behavior change and c) an individual exercise counselling session.~The programme will be medically supervised and the content will be taught and instructed by members of the research team qualified in exercise science and sports physiology."
41120878|NCT05564611|DRUG|Omalizumab 150mg|A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
40753813|NCT02965131|PROCEDURE|Temporary portocaval shunt|The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
40753814|NCT02255279|BIOLOGICAL|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
40926485|NCT01059929|DRUG|Fentanyl|25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
41120879|NCT03195608|DEVICE|Lane change assistance system|This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
41120880|NCT03195608|BEHAVIORAL|Active Control|Participants will practice their driving on a driving simulator with feedback form a trained interventionist.
41120881|NCT06268990|PROCEDURE|Fecal microbiota transplantation|FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient
41120882|NCT04705311|OTHER|Pain neuroscience education|Neurophysiological education of pain allows patients to explore a wider contribution to pain through the knowledge that pain is often an unreliable indicator of the extent or extent of tissue damage. This aims at reconceptualization from biomedical or structural models to actual biological psychosocial pain models.
41120883|NCT04705311|BEHAVIORAL|Rotator cuff repair rehabilitation|Postoperative rehabilitation programs include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
41120884|NCT02060669|DRUG|Xeloda|Xeloda
41120885|NCT01565148|DRUG|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
41120886|NCT01565148|DRUG|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
41120887|NCT01565148|DRUG|iCo-007 350 mcg and Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
41120888|NCT01565148|DRUG|Ranibizumab and iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
41120889|NCT02250430|DRUG|SB204|Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
41120890|NCT00973115|DRUG|Simvastatin CR|
41120891|NCT00209742|DRUG|UFT|P.O. everyday
41120892|NCT00209742|DRUG|USEL/Leucovorin|P.O. everyday
41120893|NCT00209742|DRUG|Krestin|P.O. everyday
41120894|NCT02912208|DRUG|Eltrombopag/Revolade|Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
41120895|NCT02912208|OTHER|Placebo|The administration is the same of eltrombopag
41120896|NCT00714714|DRUG|Adapalene Gel|adapalene gel 0.3% topically applied daily in a split-face model for two weeks
40926486|NCT01059929|DRUG|Midazolam|0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS\>+2)
41273161|NCT00628186|DEVICE|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
41273162|NCT05929534|DEVICE|active intermittent Theta Burst Stimulation|Each patient will receive two 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
41273163|NCT05929534|DEVICE|sham intermittent Theta Burst Stimulation|Each patient will receive two sham 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
40753815|NCT02255279|BIOLOGICAL|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
40926487|NCT01059929|BEHAVIORAL|Physical and Occupational Therapy|Daily therapy sessions targeting range of motion, strength, and mobility
41273164|NCT00004479|DRUG|midodrine|
41273165|NCT04781075|OTHER|Pain Scale|Maximum Daily Pain Scale will be recorded daily until discharge (typically under 7 days)
41273166|NCT04781075|DRUG|Exparel Injectable Product|Given at the beginning of the surgery for post-operative pain management
41273167|NCT04781075|DRUG|Bupivacaine Injection|Given at the beginning of the surgery for post-operative pain management
40926488|NCT02685475|DRUG|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
41273168|NCT05523934|DRUG|Capsaïcine patch|Patients with complex regional pain syndrome under maximal conventional treatment having a supplementary treatment by a capsaïcin patch.
41273169|NCT04493047|BEHAVIORAL|Mobile health (mHealth) for pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers.
41273170|NCT04774250|DRUG|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
41273171|NCT04774250|DRUG|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
41273172|NCT05247411|OTHER|Educational intervention|"During the videoconference, the following items were investigated and evaluated:~(i) Knowledge on FM: knowledge on symptoms, onset, treatment, strategies and non-pharmacological interventions that can be implemented to improve the quality of life (physical exercise, nutrition, participation in meditative movement practices, mutual aid groups, membership in a patient association, etc.); (ii) Any MC intake or interest in starting the intake of MC; (iii) Knowledge on MC therapy: specific knowledge on the drug, correct intake, adherence, treatment of side effects related to intake and strategies to reduce them; (iv) Self-care: how the person manages his personal life despite a chronic disease, how she or he monitors, recognizes and treats the symptoms in terms of timing and quality; possible presence of caregivers in their life who help in the management of the disease; employment and how FM affects it and daily life."
41273173|NCT00691548|DRUG|Cetuximab-Zr. 89|"Step 1: Determination of the toxicity of two low doses of 89Zr-cetuximab In three patients a standard loading dose of 400 mg/m2 of cetuximab will be administered, partly labelled with 89Zr (60 MBq, 2.5mg) on day 0.~On day 14, a second injection with dose of 250 mg/m2 of cetuximab, partly labelled with 89Zr (60 MBq, 2.5mg), will be given.~Step 2: Determination of the toxicity of one larger dose of 89Zr-cetuximab A standard loading dose of 400 mg/m2 of cetuximab will be administered in 3 patients, a part labelled with 89Zr (120MBq, 5mg)."
41273174|NCT00932516|BEHAVIORAL|South Beach Diet™ with South Beach Diet™ Products|
41273175|NCT00932516|BEHAVIORAL|South Beach Diet™|
40926489|NCT02205554|DRUG|Omnitram|Nine 20 mg doses administered every 6 hours
40926490|NCT02205554|DRUG|Tramadol|Nine 50 mg doses administered every 6 hours.
40926491|NCT02205554|DRUG|Placebo|Nine doses administered every 6 hours.
41273176|NCT00932516|BEHAVIORAL|Calorie restricted diet with South Beach Diet™ Products|
41273177|NCT00932516|BEHAVIORAL|Calorie Restricted Diet|
41273178|NCT00869297|OTHER|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
41273179|NCT00869297|OTHER|Control|Fluids titrated at discretion of anesthesiologist.
41273180|NCT03276741|DIETARY_SUPPLEMENT|gastric soft/bland diet|Patients in the experimental group will have a gastric soft/bland diet available.
40926492|NCT03605602|OTHER|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
40926493|NCT04168710|DRUG|ESP block with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
41273181|NCT00806104|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Dietary supplementation for 4 weeks
41273182|NCT00806104|DIETARY_SUPPLEMENT|Maltodextrins|Dietary supplementation for 4 weeks
41273183|NCT02054702|DRUG|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
41273184|NCT02054702|DRUG|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
41273185|NCT01936740|PROCEDURE|cataract surgery|
41273186|NCT03326934|DIETARY_SUPPLEMENT|Dark chocolate|Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
41273187|NCT03326934|DIETARY_SUPPLEMENT|Milk Chocolate|Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
41273188|NCT03987945|DEVICE|left atrial appendage occlusion devices|All NVAF patients who are admitted for receiving left atrial appendage occlusion procedure, including Watchman, LAmbre, Lefort, and Leftear deveices.
41273189|NCT00254566|OTHER|Moxifloxacin Placebo|1 capsule once daily for 5 days
40753816|NCT00392275|DRUG|Ofloxacin 0.3%|
40753817|NCT00392275|DRUG|Ciprofloxacin 0.3%|
40753818|NCT00392275|DRUG|Levofloxacin 0.5%|
40753819|NCT00392275|DRUG|Ofloxacin 400mg|
40753820|NCT00392275|DRUG|Ciprofloxacin 400mg|
40753821|NCT00392275|DRUG|Levofloxacin 250mg|
41273190|NCT00254566|DRUG|Moxifloxacin|1 X 400mg capsule once daily for 5 days
41273191|NCT00254566|OTHER|Azithromycin SR Placebo|single dose, oral.
41273192|NCT00254566|DRUG|Azithromycin SR|single dose 2.0 g oral
41273193|NCT03295825|DIAGNOSTIC_TEST|Biomarker|Measument of heparin-binding protein in the serum of patients
41273194|NCT03674021|OTHER|Chest Pain Choice visual aid|The Chest Pain Choice (CPC) decision aid is a visual aid that was developed to facilitate shared decision-making between physicians and patients who present to the emergency department with chest pain. The visual aid includes a brief description of what tests have been done thus far to assess the patient's risk of MACE, a graphic representation of the risk as calculated based on the HEART score, as well as the evaluation options available. The visual aid has been modified from its original form for the local context in terms of viable options for further evaluation.
41273195|NCT04567784|DRUG|Cannabidiol (CBD)|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
41273196|NCT04567784|DRUG|Placebo|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
41273197|NCT00957541|DEVICE|Paradym CRT + Physiological Diagnosis (PhD)|All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
41273198|NCT02698189|DRUG|Birabresib Dose 20 mg|Administered as an oral capsule twice a day for 21 consecutive days per cycle.
41273199|NCT00006430|BIOLOGICAL|Autologous dendritic cells transfected with amplified tumor RNA|
41273200|NCT02022826|DEVICE|SmartPill Monitoring System|
41273201|NCT05407792|DRUG|Staphylococcus and Neisseria Tablets|0.3 mg/ tablet, 4 tablets each time, 3 times a day (Shandong Qilu Pharmaceutical Co., LTD.), the course of treatment was more than 3 months.
41273202|NCT05407792|OTHER|On-demand treatment|At the time of enrollment, patients with acute exacerbation of bronchiectasis were given routine treatment. For patients with stable bronchiectasis at the time of enrollment, they are treated as needed (that is, according to the needs of the disease, receive corresponding treatment).
41273203|NCT00747487|DRUG|Idebenone|Idebenone 900 mg/day
41273204|NCT00747487|DRUG|Placebo|Placebo
41273205|NCT00032929|DRUG|Selegiline|
41273206|NCT05491759|DRUG|Product 1 - AquaCelle Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle.
41273207|NCT05491759|DRUG|Product 2 - AquaCelle Fish Oil Ethyl Ester|1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle
41273208|NCT05491759|DRUG|Product 3 - Standard Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).
41273209|NCT06119880|DRUG|Pancreatin Enteric-coated Capsules|pancreatic enzyme replacement therapy
41273210|NCT06119880|OTHER|Routine treatment plan|Routine treatment plan without PERT
40926494|NCT04168710|OTHER|Saline control/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
41273211|NCT03370757|OTHER|3-hour bundled care|Infants in the 3-hour bundled care group will receive diaper changes every 3 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 3 times per week.
41273212|NCT03370757|OTHER|6-hour bundled care|Infants in the 6-hour bundled care group will receive diaper changes every 6 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 4 times per week.
41273213|NCT01625806|DRUG|RO4602522|Single oral dose
41273214|NCT01625806|DRUG|ketoconazole|Multiple oral doses
41273215|NCT02625402|BEHAVIORAL|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
40926495|NCT00217464|DRUG|fulvestrant|intramuscularly
40926496|NCT04896801|RADIATION|MR-guided RT|The dose to the planning target volume (PTV) is 36 Gy (5 x 7.2 Gy) prescribed on the 90% isodose line. The clinical target volume (CTV) is receiving 40 Gy (5 x 8 Gy = 100%). A simultaneous integrated boost (SIB) up to a total dose of 42 Gy (5 x 8.4 Gy = 105%) is delivered to the gross tumor volume (GTV), if present. In addition, relative sparing of the urethra will be applied by avoiding hotspots (V40 Gy \< 1cc) in the urethra. Baseline and adapted treatment plans are generated using intensity-modulated RT
41273216|NCT02625402|BEHAVIORAL|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
41273217|NCT00138216|DRUG|irinotecan hydrochloride|
41273218|NCT00138216|DRUG|temozolomide|
41273219|NCT00138216|DRUG|vincristine sulfate|
41273220|NCT05987215|COMBINATION_PRODUCT|Radiologic diagnosis|Each CT scan is interpreted by a radiologist and is assigned as positive or negative for the diagnosis of otosclerosis
41273221|NCT05987215|DIAGNOSTIC_TEST|Artificial intelligence diagnosis|Each CT scan is screened by the deep learning algorithm and is assigned as positive or negative for the diagnosis of otosclerosis
41273222|NCT01451593|DRUG|Phenytoin|Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
41273223|NCT01451593|DRUG|Placebo|placebo identical in appearance to active IMP (phenytoin)
41273224|NCT00024687|DRUG|SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin|
41273225|NCT06491043|OTHER|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells
41273226|NCT02446587|DEVICE|Mechanical Thrombectomy|Mechanical thrombectomy includes the use of stent retrievers (i.e. Trevo®, Solitaire®, or other stent retriever devices) as recommended by AHA guidelines (July 2015). A stent retriever is delivered directly to a thromboembolus that is occluding a cerebral artery to restore blood flow.
41273227|NCT06124079|OTHER|OPY interactive messaging service|3 specific versions of OPY. information. Each version will deliver the same instructions and information about pain management recommendations, and collect the same information about patient pain experience and side effects. The three versions differ in the motivational techniques interspersed throughout the OPY experience.
41120897|NCT00714714|DRUG|Tretinoin Gel|Tretinoin 0.1% topically applied daily in a split face model for two weeks
41120898|NCT04997213|OTHER|Biofeedback exercises|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program was involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and was individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
41273228|NCT06124079|OTHER|Standard care|Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
41273229|NCT03124043|OTHER|Livongo for Diabetes program|See description in arm/group description.
41273230|NCT02832050|BEHAVIORAL|Play therapy|See previous description of play therapy intervention arm.
41273231|NCT02832050|BEHAVIORAL|Standard of care|See previous description of comparator arm.
40753822|NCT02832947|DRUG|Rivaroxaban 10 mg|At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.
40753823|NCT05142644|PROCEDURE|ultrasound|An extra ultrasound performed during pregnancy
40753824|NCT05493345|BEHAVIORAL|Bridge-building between municipality-based lifestyle programs and community-based physical activities|Four co-created bridge-building activities has been implemented in the municipality of Odsherred, including (1) A digital portal for information and sharing of knowledge, (2) Visits between municipal rehabilitation programs and community-based physical activities, (3) Co-created teams for the target group, and (4) a 'Bridge builder' coordinator.
40753825|NCT05676944|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
40753826|NCT03915054|DRUG|AREG-TRIGGER|"Oocytes in AREG-TRIGGER medium will be mature in AREG + FSH + HSA + Insulin + Estradiol medium.~Per case (6mL) 5940 µL Basal Medium~* 60 µL IVM MIX Do not need to filtrate media."
41120899|NCT04997213|OTHER|Conventional Exercises|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first could be commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
41273232|NCT05823142|BEHAVIORAL|CB Sleep|The CB-sleep intervention is a cognitive behavioral intervention guided by principles and practices from motivational interviewing and the psychology of behavior change, primarily drawing on self-efficacy and action planning theory. The goals of CB-sleep are for participants to achieve adequate sleep duration (7-9 hours per night), adequate sleep efficiency (≥ 85%), and regular sleep timing (\<60-minute differences in bed and wake times). The intervention components include improving sleep knowledge (hygiene), developing a nightly routine, addressing competing activities, modifying environmental conditions, lifestyle (avoiding caffeine and vigorous exercise before bed), technology (limiting or avoiding screens for at least one hour before bed), basic stress-management (progressive muscle relaxation and guided imagery), and self- monitoring.
41273233|NCT04800315|DRUG|CC-93538|Specified dosages on specified days
41273234|NCT04800315|OTHER|Placebo|Specified dosages on specified days
41273235|NCT05147675|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
40753827|NCT03915054|DRUG|CONTROL-TRIGGER|"Oocytes in CONTROL-TRIGGER medium will be mature in FSH + hCG + GH + HSA medium.~Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)"
40753828|NCT01359280|BEHAVIORAL|Adherence Counseling|5 Sessions of theory-based medication adherence counseling
41120900|NCT04601974|GENETIC|lentiviral gene therapy|lentiviral gene therapy to treat drug resistant epilepsy
41120901|NCT02475343|DEVICE|Schiotz tonometer|The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
41273236|NCT01906437|DEVICE|Cardiac Magnetic Resonance Scan|Cardiac Magnetic Resonance Scan
41273237|NCT05779748|OTHER|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
41273238|NCT05261217|DEVICE|The motion 3D II appliance|The motion 3D II appliance treating class II malocclusion
41273239|NCT04439786|DRUG|placebo|the control group will be given the same volume of saline.
41273240|NCT04439786|DRUG|lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
40753829|NCT01359280|BEHAVIORAL|General Health Counseling|5 sessions of health improvement counseling
40753830|NCT01359280|BEHAVIORAL|Text Messages|Daily medication regimen tailored adherence reminders delivered by cell phone
41120902|NCT02475343|DEVICE|UVA/riboflavin|The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
41120903|NCT02475343|DEVICE|femto-LASIK|The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.
40753831|NCT03674450|BEHAVIORAL|Heart Rate Variability Biofeedback Training|The study will utilize the Physiolab GP8 heart rate variability and respiration system on a laptop computer used solely for the study with the proper security passwords to protect participant information. The equipment consists of two electrocardiogram sensors (one per wrist) attached by sports wrist bands, a respiration monitoring belt placed around the upper abdomen, two galvanic skin conductance sensors attached to the fingertips, and a thermistor sensor attached to one of the finger tips. Participants will perform a series of monitored breathing exercises.
41120904|NCT02475343|DEVICE|Tomey SP-100 Pchymeter , Topolyzer Vario|Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
41120905|NCT02475343|DEVICE|Topcon CT-80, Topcon, Japan|Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.
41120906|NCT02475343|DEVICE|Corvis-ST|Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
41120907|NCT00180258|DEVICE|Cardiac Resynchronization Therapy with & without defibrillator|
41120908|NCT05395403|DEVICE|Blood pressure measurement device|The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).
41120909|NCT03403478|OTHER|LICE|No specific exercise will be performed. The participant will walk into the pool accompanied with a researcher for 45 minutes.
41120910|NCT03403478|OTHER|MICE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
41120911|NCT03403478|OTHER|HIIE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
41120912|NCT03403478|OTHER|Aquatic exercise training|"The sessions of the aquatic exercise training will be divided into 3 phases: warm-up (10 minutes), main part (40 minutes) and cool down.~In order to increase intensity to aquatic exercise, the training program will carried out as follows:~From week 1 to 4 the instructors will use a 128 bpm musics in both warm-up and cool down. In main part, will be used a 130 bmp musics.~From week 5 to 8 the instructors will use a 130 bpm musics in both warm-up and cool down. In main part, will be used a 132 bmp musics.~From week 9 to 12 the instructors will use a 132 bpm musics in both warm-up and cool down. In main part, will be used a 135 bmp musics."
40753832|NCT05320757|DRUG|Olaparib|a PARP inhibitor
41120913|NCT04850768|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
41120914|NCT04850768|OTHER|gingival crevicular fluid|GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
41273241|NCT02102750|DRUG|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
41273242|NCT04401657|DIAGNOSTIC_TEST|Fractional flow reserve with adenosine stress testing|ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.
41273243|NCT00815646|DRUG|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
41453427|NCT05106803|DRUG|ciprofloxacin|Antibiotics used in vitro n the study
41453428|NCT01800838|DRUG|silicon phthalocyanine 4|Given topically
41453429|NCT01800838|DRUG|photodynamic therapy|Undergo PDT
41453430|NCT01800838|OTHER|pharmacological study|Correlative studies
40753833|NCT00320320|DRUG|Irinotecan|
40753834|NCT03112187|DRUG|Iron Supplement|Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
41273244|NCT03046420|OTHER|Chart review|This is a retrospective chart review study. The charts of patients who meet the inclusion criteria will be abstracted into a standardized electronic case report form, as described in Section 5. A standardized case report form for each patient will be created so as to collect uniform data. Charts data for one year back to the start date of data abstraction will be included in the study
41273245|NCT00342355|DRUG|Zidovudine|600 mg once daily
41273246|NCT00342355|DRUG|Stavudine|40 mg once daily
41273247|NCT00342355|DRUG|Didanosine|\<60 kg/125 mg twice daily or \>60kg/200 mg twice daily
41273248|NCT00342355|DRUG|Lamivudine|300 mg once daily
40753835|NCT05329883|PROCEDURE|Double-J stent removal|Outpatient ureteral stent removal without antibiotic prophylaxis
40753836|NCT02495935|DEVICE|OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
40753837|NCT02495935|DEVICE|Sham-OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
40753838|NCT04113980|OTHER|music group|The children in the groups were distracted by music 2 minutes before venipuncture, until the process was over
40753839|NCT04113980|OTHER|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before venipuncture, until the process was over
40753840|NCT04113980|OTHER|video group|The children in the groups were distracted by watching video 2 minutes before venipuncture, until the process was over
40753841|NCT03461809|OTHER|Ocular acupuncture|Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
40753842|NCT03744975|DRUG|LCZ 696|Participants will receive Oral LCZ 696 (Entresto 97/103 mg)
40753843|NCT03744975|DRUG|Placebos|Participants will receive 1oral Placebo capsule
40753844|NCT02191397|DRUG|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
40753845|NCT02191397|DRUG|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
40753846|NCT02191397|DRUG|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
40753847|NCT02191397|DRUG|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
40753848|NCT06221254|BEHAVIORAL|COBMINDEX digital application|COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques and practices using digital application.
40753849|NCT06221254|BEHAVIORAL|Human therapist (Control)|COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques from a human therapist (the comperator for learning from the application) and practices using digital application.
40926497|NCT00266877|DRUG|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
41273249|NCT00342355|DRUG|Efavirenz|600 mg once daily
41273250|NCT00342355|DRUG|Lopinavir/Ritonavir|r/LPV 400mg/100mg twice daily
41273251|NCT01668368|OTHER|esophageal balloon|esophageal pressure as a surrogate for pleural pressure
41273252|NCT00875758|PROCEDURE|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
41273253|NCT00875758|PROCEDURE|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
41453431|NCT01800838|OTHER|laboratory biomarker analysis|Correlative studies
40926498|NCT06059131|OTHER|KeenMind|320 mg/d (2 capsules/d) during 3 months
41273254|NCT05814445|OTHER|Neuromuscular exercise program|Participants will complete a neuromuscular program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and training to improve hip and knee muscles strength, proprioception, and core stability.
41446449|NCT06626750|BEHAVIORAL|Summer Treatment Program for Pre-Kindergarteners and Kindergarteners|Children will be concurrently enrolled in our Summer Treatment Program for Pre-Kindergarteners and Kindergarteners (STP-PreK/K). The STP-PreK/K simulates a school-like schedule and runs for 7-weeks and last 7 hours/day, Monday through Friday, with periods of seatwork, large/small group activities, circle time, and classroom meetings along with a recreational period. Academic curriculum are individualized depending upon child's current level. The behavioral modification program uses a visual response cost system in which children lose points for not following classroom rules (these rules are operationalized and determined during the development phase). Dots earned are then used for daily and weekly rewards. In addition to the academic and behavioral modification program, one group of children will participate in social-emotional/self-regulation training exercises on a daily basis designed to teach them social skills and how to control their emotions, behaviors, and attention.
41446450|NCT06626750|BEHAVIORAL|School Readiness Parenting Program (SRPP)|The School Readiness Parenting Program (SRPP) helps parents of young children develop skills that support their child\&#39;s readiness for kindergarten and first grade. It focuses on positive parenting practices that enhance social, emotional, and cognitive development. The sessions cover managing child behaviors, promoting early literacy, and fostering problem-solving skills. Parents learn effective communication, consistent routines, and how to create a supportive home environment.
41446451|NCT06626750|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a structured, goal-oriented therapy that helps individuals identify and change negative thought patterns and behaviors. It focuses on the link between thoughts, emotions, and actions to improve mental health. Specific to the current project, CBT can reduce stress by teaching parents to reframe unhelpful thoughts, manage challenging emotions, and develop effective coping strategies for difficult situations, leading to more positive parenting experiences.
41453432|NCT04880954|PROCEDURE|Soft Tissue Mobilization|Soft Tissue Mobilization will be provided to participants by Licensed Chiropractor focusing on structures of the lower and upper leg. This will be provided for 20 minutes, once per week for 12 weeks.
40926499|NCT06059131|OTHER|Placebo|320 mg/d (2 capsules/d) during 3 months
40926500|NCT02394197|DRUG|Chloroquine phosphate|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
40926501|NCT02394197|DRUG|primaquine|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
41120915|NCT00402246|OTHER|Remote Management|"The Remote Management method of treating patients consists of 3 components:~CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)~Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line~CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.~The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action."
41120916|NCT00402246|OTHER|In-Office Care|Routine in-office care
41120917|NCT05447507|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.5\~1.0 mg/kg/h continuous infusion
41120918|NCT05447507|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
41120919|NCT02639637|DRUG|Sitagliptin|Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
41120920|NCT02639637|DRUG|Placebo|Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
41120921|NCT02639637|DRUG|Neuropeptide Y|During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
41120922|NCT02639637|DRUG|Enalaprilat|Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
41120923|NCT02639637|DRUG|Valsartan 160mg|Valsartan 160 mg/d for 7 days prior to one of the study days.
41120924|NCT01127373|RADIATION|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
41120925|NCT01127373|BEHAVIORAL|BreastQ questionnaire-|MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
40926502|NCT04062500|OTHER|Mortality and Rehospitalization rate|Mortality and Re-hospitalization of acute decompensated heart failure
41273255|NCT05814445|OTHER|Institutional exercise program|Participants will complete an institutional exercise program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and concentric and eccentric knee exercises.
41273256|NCT00486603|DRUG|hydroxychloroquine|see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles
41273257|NCT00486603|DRUG|temozolomide|TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)
41273258|NCT00486603|OTHER|pharmacological study|Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
41273259|NCT00486603|RADIATION|Radiation|Radiation during the first six weeks of treatment Monday-Friday
41273260|NCT05555810|PROCEDURE|clipping or ligation of the cystic duct and the cystic artery in Laparoscopic cholecystectomy|The investigators will make a comparison between clipping and ligation of cystic duct and cystic artery during Laparoscopic cholecystectomy and trying to know advantages and disadvantages of each technique .
41120926|NCT01577225|DEVICE|OPSITE POST-OP VISIBLE|Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
41120927|NCT01577225|DEVICE|Tape and Gauze|Patient will be treated with tape and gauze up to 14 days post surgery
41273261|NCT01933087|BEHAVIORAL|Hand hygiene promotion|The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
41120928|NCT06521151|DIETARY_SUPPLEMENT|egg based diet|egg based diet and audio based nutrition education group (arm-1), egg based diet alone group (arm-2), and audio based nutrition education alone group (arm- 3).
41273262|NCT00751413|DRUG|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
41273263|NCT02844855|BEHAVIORAL|Cognitive tests|MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
41273264|NCT04643184|OTHER|Management Program|Joint management between the geriatric and cardiology team of the geriatric syndromes and heart failure. Education of the patient and their caregiver, preparing them for the transition of care.
41273265|NCT02226666|DRUG|MRI with Multihance|Patients will have Multihance used as an IV contrast agent for their scan.
41273266|NCT02226666|DRUG|MRI with Eovist|Patients will have Eovist used as an IV contrast agent for their scan.
41273267|NCT01574534|DEVICE|Drug eluting balloon|PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany
41273268|NCT01574534|DEVICE|Drug eluting stent|PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
40926503|NCT03553966|PROCEDURE|Prophylactic|Tooth Brushing HA 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.
41446452|NCT06627465|DEVICE|MS Sherpa|The MS Sherpa application is a CE-certified smartphone application (installed on the mobile phone of the patient) that collects digital biomarkers using tests (\~six minutes/test: self-monitoring questionnaires, smartphone 2-MWT, and a smartphone SDMT) once per week in the home environment of the patient.
41446453|NCT06627465|DEVICE|Neurokeys|The NeuroKeys application is a CE-certified application (installed on the mobile phone of the patient) that passively and continuously monitors keystroke dynamics of everyday typing as a digital biomarker.
41446454|NCT06547294|DEVICE|Osprey IV|Utilization of novel needle over catheter commercial insertion device
41446455|NCT06547294|OTHER|Historical Controls|Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)
41446456|NCT06136039|PROCEDURE|Arm I (Sarcopenia)|Same as standard treatment
41120929|NCT01612949|OTHER|photographing head and neck|Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
41120930|NCT04593056|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
41120931|NCT04593056|DRUG|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure
41120932|NCT05796323|OTHER|No intervention.|The subjects will complete a survey related to workplace violance.
41120933|NCT06034522|DEVICE|Adipearl|Injection of the investigational device in the face.
41120934|NCT04377308|DRUG|Fluoxetine|Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration
41120935|NCT02529839|PROCEDURE|Autologous bone marrow transplantation|IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0
41120936|NCT02529839|DRUG|Fludarabine|30mg/m2 on days -6 through -3
41120937|NCT02529839|DRUG|Cyclophosphamide|50mg/kg on days -5 through -4
41120938|NCT02529839|DRUG|Alemtuzumab|3mg on day -3, 9mg on day -2, 12 mg on day -1
41120939|NCT04589520|BEHAVIORAL|HeartBot App|HeartBot is an app designed to enable people 14 years and older to use relaxation tools offered by Heartfulness to deal with daily stress and anxiety in a healthy, productive manner.
41120940|NCT05916001|OTHER|Placebo|A Placebo will be administered per os 3 times per day for 10 days before colorectal surgery
41120941|NCT05916001|DIETARY_SUPPLEMENT|Oral Impact Nestle|Oral Impact Nestle will be administered per os 3 times per day for 10 days before colorectal surgery
41273269|NCT03879291|OTHER|pinpointIQ|The study will utilize physIQ's multivariate analytical methods that detect vital sign relationship changes compared to a patient's individual baseline. Changes in vital signs relationships may be indicative of current or future important clinical events. These changes are indicated through the Multivariate Change Index (MCI), which is a scalar index between 0 and 1, where values close to 0 indicate no significant change from baseline and values close to 1 indicated greater changes from baseline
41120942|NCT05916001|PROCEDURE|Colorectal surgery|Colorectal surgery will include right colectomy, left colectomy, transverse colectomy, anterior rectal resection. All procedures will be performed according to the standard clinical practice.
41273270|NCT01438645|DEVICE|Olympus ScopeGuide|ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
41273271|NCT00432237|DRUG|MK0974 50 mg|
41273272|NCT00432237|DRUG|MK0974 150 mg|
41273273|NCT00432237|DRUG|MK0974 300 mg|
41120943|NCT00494949|DRUG|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
41120944|NCT00494949|DRUG|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
41120945|NCT03818100|RADIATION|Intensity modulated radiotherapy (IMRT)|Simultaneous integrated boost technique using IMRT: 48 Gray (Gy) and 40 Gy will treat tumour and breast tissue respectively, in 15 fractions over 3 weeks.
41273274|NCT00432237|DRUG|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
41273275|NCT06487013|DEVICE|ArcBlate Focused Ultrasound Ablation System|MR-guided High Intensity Focused Ultrasound (MRgHIFU)
41273276|NCT06487013|OTHER|Sham MRgHIFU treatment|Sham MRgHIFU treatment
41273277|NCT03063749|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
40926504|NCT03553966|PROCEDURE|Cleaning teeth|Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.
41120946|NCT03818100|DRUG|Endocrine therapy|Endocrine therapy will commence following completion of radiotherapy, and will continue for 20 weeks.
41120947|NCT03818100|PROCEDURE|Breast conserving surgery|Surgery carried out using local protocol following completion of endocrine therapy.
41273278|NCT03063749|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm
41273279|NCT06217328|DEVICE|Revi System Treatment|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable
41273280|NCT06217328|DEVICE|Revi System - Delayed Activation|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable. The system will be implanted but it will not be turned on until 4 months post implant procedure.
41273281|NCT03777449|RADIATION|CBCT|Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.
41273282|NCT03971981|DIETARY_SUPPLEMENT|100% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
41120948|NCT01131780|DRUG|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
41120949|NCT00974831|OTHER|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
41273283|NCT03971981|DIETARY_SUPPLEMENT|22% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
41273284|NCT02467998|DEVICE|NPWT|SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
41120950|NCT00974831|OTHER|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
41120951|NCT04187599|DEVICE|Paragon CRT®100 Contact Lens|Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
41120952|NCT03495635|BEHAVIORAL|Big Brothers Big Sisters Community-Based Mentoring Program|One-to-one mentoring provided by an adult volunteer with training and ongoing monitoring and support from program staff.
41120953|NCT02639286|DRUG|ISIS 304801|300 mg of ISIS 304801 administered as SC
41120954|NCT02639286|DRUG|Placebo|Placebo administered via SC
41120955|NCT03638427|DIAGNOSTIC_TEST|Menstrual Blood Analysis (Menstrual Blood Analysis)|We will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood from a menstrual pad.
41120956|NCT00700986|DRUG|AZD9056|Oral tablet, 800mg, one single administration
41273285|NCT04125680|BEHAVIORAL|ESL Health Literacy Classes|The intervention will last 8-weeks, and the first and last classes will be devoted to survey assessments. Participants will be asked to reflect on their health knowledge and behaviors, and how they have changed since starting the program. The curriculum administered during the classes will use pedagogies for health literacy as a practice. It will focus on skills needed to learn about lead exposure in the ESL classroom: (1) vocabulary; (2) grammar; and (3) identifying risk factors, symptoms and preventive strategies. A focus on health literacy as practice will include personal engagement using language in context: (1) role-play interactions about lead exposure prevention; (2) discussing views about risk, and how to talk about it with peers and family members; (3) identifying sources of reliable health information; and (4) learning to ask for support and resources.
41273286|NCT06546865|DEVICE|22F Sheath Size|Participants in this group will have the 22F sheath size used in their procedure.
41273287|NCT06546865|DEVICE|26F Sheath Size|Participants in this group will have the 26F sheath size used in their procedure.
41273288|NCT05666089|DRUG|N-acetyl cysteine|intracanal medication of NAC with concentration 1 gm/ml in the form of a paste
41273289|NCT05666089|DRUG|Calcium hydroxide|intracanal medication of calcium hydroxide paste (metapaste)
41273290|NCT01950819|BIOLOGICAL|Induction therapy|All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
41273291|NCT01950819|DRUG|Corticosteroids|All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
41273292|NCT01950819|DRUG|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
41446457|NCT06136039|PROCEDURE|Arm II(Normal)|Same as standard treatment
41273293|NCT01950819|DRUG|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
41273294|NCT01106755|DEVICE|gait training on ground level using BWS|An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.
41273295|NCT01106755|DEVICE|gait training on ground level using BWS associated to FES|An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
41273296|NCT01340183|DRUG|AZD5099|IV Dose
41273297|NCT01340183|DRUG|Placebo|IV Dose
41273298|NCT03906825|DIETARY_SUPPLEMENT|CEAG|Curcuminoids, EPA (OMEGA-3), Astaxanthin, GLA
41273299|NCT03906825|DIETARY_SUPPLEMENT|placebo|placebo
41273300|NCT00743704|OTHER|ozoneexposure|subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
40753850|NCT00005684|DRUG|warfarin|
40753851|NCT00005684|DRUG|heparin|
41273301|NCT03781557|DIETARY_SUPPLEMENT|Docosahexaenoic acid|High-concentrated DHA
41273302|NCT03781557|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|High-concentrated EPA
41273303|NCT03781557|DIETARY_SUPPLEMENT|Olive oil|Olive Oil softgels
41273304|NCT06217679|OTHER|Control Oral Glucose Tolerance Test|control oral glucose tolerance test
41273305|NCT06217679|OTHER|Mixed Exercise|exercise performed in randomized order
41273306|NCT00704470|OTHER|Medical simulator training|Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
41273307|NCT00704470|OTHER|Simulator based crew resource management course|Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
41273308|NCT05756192|OTHER|Educational video|Intervention is a 10-minute animated video that explains cervical cancer screening and prevention.
41273309|NCT00753389|OTHER|None (anesthesia)|anesthesia
41446458|NCT06515405|DRUG|Hydrocortisone|"Cohort members will be considered to be exposed to early hydrocortisone if either:~1. They receive early hydrocortisone started on postnatal day 1 or 2 and given for more than seven consecutive days OR~2. They receive early hydrocortisone started on postnatal day 1 or 2 and are being cared for in a PROHYDRO unit but die on or before postnatal day 8.~PROHYDRO units are defined as units who, at the time the baby was born, had implemented a protocol for use of prophylactic hydrocortisone as part of routine care for babies born less than 28 weeks' gestation. A unit may change from being a non-PROHYDRO unit to a PROHYDRO unit if a new early hydrocortisone protocol is introduced during the study period (2016-2023)."
41446459|NCT01262235|DRUG|TKM-080301|Repeat dose IV infusion.
40753852|NCT05688423|BEHAVIORAL|SIRI Team|"Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~1. Medications for SUD as integral to management of infectious complications~2. Integration of ID and SUD care~3. Longitudinal care with familiar providers~4. Multidisciplinary care and care coordination~5. Tailored antibiotic options and care settings~6. Harm reduction"
40947825|NCT00662454|DRUG|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
41273310|NCT01453504|DRUG|DHAP|Dexamethasone, Cytarabine, Cisplatin
41273311|NCT01453504|DRUG|Everolimus|
41273312|NCT00619229|DRUG|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
41273313|NCT00619229|OTHER|Placebo|Placebo/d i.v. for 15 days
41273314|NCT04490889|DIAGNOSTIC_TEST|NiPGT-A|NiPGT-A is the technique to screen the aneuploidy status of an embryo without invasion technique, such as biopsy. We use SCM to isolate cfDNA, then amplify and analyse the aneuploidy of embryo secreting this material using NGS technique.
41273315|NCT06202248|DEVICE|Experimental: DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
41273316|NCT02388295|DRUG|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
41273317|NCT02388295|DRUG|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
41273318|NCT02395991|DRUG|gadoxetic acid|standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
41273319|NCT02395991|OTHER|Magnetic resonance imaging (MRI)|"Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.~precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state."
41273320|NCT01357213|DRUG|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
41273321|NCT01357213|OTHER|Placebo|Normal saline 100 ml
41273322|NCT00184457|BEHAVIORAL|Strength training intervention|
41120957|NCT00700986|DRUG|Placebo|Single dose
41120958|NCT05086354|BEHAVIORAL|JUMP|Warm-up, stretching, jumping rope, cool-down
41120959|NCT03368768|OTHER|Obtain inform consent via questionnaire of Monkey Survey|This is an internet-based questionnaire study. Therefore, anyone in Thailand can access and answer the questionnaire.
41120960|NCT04498624|PROCEDURE|inverted flap|full thickness macular hole surgery
41120961|NCT04498624|PROCEDURE|peeling internal limiting membrane (ILM)|full thickness macular hole surgery
41120962|NCT01460667|DRUG|IV acetaminophen|IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
41120963|NCT01460667|DRUG|IV normal saline|0.9% normal saline IV, every 6 hours over 30 hours.
41120964|NCT05872724|DRUG|Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab|"* Radiation therapy:~  1. Irradiation mode and dose: 6MV-X-ray (6Megavoltage-X-ray), IMRT or RapidArc-IMRT were used for external radiotherapy. External radiotherapy dose: PTV (Planning Target Volume) 45-50Gy/25 times.~* Chemotherapy:~  1. Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~ 2. Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of consolidation chemotherapy plus immunotherapy are recommended for patients with high risk or MRDc0 (+). Recommended chemotherapy regimen: liposome paclitaxel 135mg/m2 d1 +DDP 25 mg/m2 D1-3, Q21.~* Zimberelimab injection:~  240 mg, IV, q3w. Start the drug one day before the start of postoperative radiotherapy."
41120965|NCT05872724|DRUG|Chemoradiotherapy (small pelvic) + Zimberelimab|"Radiation therapy:~1. Target volume of radiotherapy for small pelvis: CTVp includes tumor bed area, paracentral area and part of vagina; CTVn includes bilateral internal iliac, external iliac and obturator lymphatic drainage areas. Upper boundary to sacroiliac joint level, lower boundary to 2cm below vaginal stump.~Chemotherapy:~Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of adjuvant immunotherapy are recommended for patients in good general condition (ECOG: 0-1) with medium risk and MRDc0 (-).~Zimberelimab injection: 240 mg, IV, q3w. Start the drug one day before the start of posterior radiotherapy."
41120966|NCT03482635|DRUG|Spesolimab|Solution for infusion
41273323|NCT02228499|OTHER|Survey|We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.
41273324|NCT03582358|OTHER|Food weighing|Quantification of food intake over three consecutive days (D5, D6 and D7 then D26, D27 and D28) by weighing the food served and the leftovers at and after mealtimes.
41273325|NCT00324103|DRUG|Structured Treatment Interruptions|
41273326|NCT00879450|OTHER|Booklet|booklet given to parents for home exercises
41273327|NCT00998439|DEVICE|SeQuent® Please|"* 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
41273328|NCT00998439|DEVICE|SeQuent® II|"* 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
41446460|NCT05524532|DIETARY_SUPPLEMENT|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.
41273329|NCT05631132|PROCEDURE|BAL + PAP|May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
41273330|NCT00682630|DRUG|pyronaridine artesunate clinical trial reference tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
41273331|NCT00682630|DRUG|pyronaridine artesunate to-be-marketed tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
41273332|NCT03884686|OTHER|Web-based education resource|Intervention includes fact sheets, question and answers, short videos featuring patients and/or clinicians.
41273333|NCT03330327|BIOLOGICAL|HM12470|HM12470 is a long-acting insulin analogue
41273334|NCT00190060|DRUG|Transdermal testosterone gel (Testogel 1% )|Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
41273335|NCT00190060|DRUG|Matched transdermal placebo gel|Matched transdermal placebo gel, 50mg/d for 6 months
41273336|NCT00500266|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
41120967|NCT03482635|DRUG|Placebo|Solution for infusion
41273337|NCT01955616|DRUG|RM-131|
41273338|NCT01955616|DRUG|Placebo|
41446461|NCT05524532|DIETARY_SUPPLEMENT|Placebo|Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules
41446462|NCT03880461|BEHAVIORAL|Lifestyle Intervention|Behavioral lifestyle intervention
40926505|NCT03553966|DEVICE|Restorative dentistry|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
41120968|NCT00809497|DRUG|Propionyl-L-carnitine Tablets|500mg tablets, oral administration of 2g daily
41120969|NCT01996605|DRUG|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
41120970|NCT01996605|DRUG|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
41120971|NCT01996605|DRUG|Placebo|placebo will be administered spinally
41120972|NCT00254657|DRUG|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
41273339|NCT02441361|OTHER|Exercise training|Exercise training will comprise aerobic and strength exercises
41273340|NCT00643240|RADIATION|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
41273341|NCT00643240|RADIATION|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
41273342|NCT05773391|DRUG|Take probiotics|Take medication for 21 days (Yihuo 0.2g bid+ Jin Bifid2g tid)
41273343|NCT05886361|OTHER|No intervention involved|No intervention involved
41273344|NCT06062719|DRUG|PPI group|80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours
41273345|NCT06062719|DRUG|PPI plus octreotide|octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours
41273346|NCT02550899|PROCEDURE|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
41273347|NCT02550899|PROCEDURE|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
41273348|NCT02550899|PROCEDURE|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
41273349|NCT04300348|DEVICE|Heel2Toe|Heel to Toe (Heel2Toe) is a device that clips on the shoe and provides an instant auditory feedback (a beep) for each correct step characterized by putting the heel first and it provides data on gait parameters
41273350|NCT04300348|OTHER|No-feedback control group|The control group will follow the same protocol as the Heel2Toe group but the device will not be in feedback mode just in data acquisition mode.
41273351|NCT06068582|BEHAVIORAL|Strenghtening the brain|Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.
41273352|NCT06068582|BEHAVIORAL|Strengthening the mind|Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.
40926506|NCT03232125|DRUG|Ramosetron|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
41273353|NCT05812391|PROCEDURE|test|the treatment start with supra-gingival erythritol powerder air polishing followed by sub-gingival erythritol powerder air polishing,supra-gingival debridement and sub-gingival debridement
41273354|NCT05812391|PROCEDURE|conventional|the treatment start with supra-gingival debridement followed by sub-gingival debridement then finished with polishing paste
41446463|NCT05297864|DRUG|Niraparib|The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.
41446464|NCT05696626|DRUG|Lasofoxifene in combination with abemaciclib|5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
40926507|NCT03232125|DRUG|Normal saline|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
41120973|NCT00254657|DRUG|Placebo|
41120974|NCT06299228|OTHER|Experimental Group|Sensorimotor intervention, active range of motion, active assisted range of motion, strengthening
41120975|NCT06299228|OTHER|Control Group|Active range of motion, active assisted range of motion and strengthening
41120976|NCT00182975|DRUG|DHEA replacement|
41120977|NCT03380611|DIETARY_SUPPLEMENT|Wakame|Consumption of 4.8 grams wakame per day for 17 days
41120978|NCT03380611|DIETARY_SUPPLEMENT|Spirulina|Consumption of 4.8 grams spirulina per day for 17 days
41120979|NCT03380611|DIETARY_SUPPLEMENT|Control|Consumption of microcrystalline cellulose for 17 days
41120980|NCT06079515|PROCEDURE|Suprascapular Nerve Block|SSNB group: The patients were asked to sit comfortably in the chair, and the transducer was placed on the spine of the scapula in the coronal plane and moved laterally to observe the supraspinatus notch and the suprascapular nerve. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle on the suprascapular nerve, under the fascia of the supraspinatus muscle.
41120981|NCT06079515|PROCEDURE|Intraarticular Shoulder Injection|IAI group: The patients were asked to sit on the chair with their hands facing the opposite shoulder, and the transducer was placed slightly below the spina scapula. The humeral head was observed by moving laterally. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle entering the skin at a 45-degree angle and applied to the joint space
41446465|NCT05696626|DRUG|Fulvestrant in combination with abemaciclib|Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
41453433|NCT04880954|OTHER|Rehabilitation|Participants will engage in 20 minutes of prescribed at-home exercise 5 times per week, for 12 weeks.
41120982|NCT03666403|PROCEDURE|NIV rate: 0/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
41120983|NCT03666403|PROCEDURE|NIV rate: 10-20/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
41120984|NCT03666403|PROCEDURE|NIV rate: 5-10/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
41120985|NCT06145568|OTHER|Pregnant Women|We want to quantify Minority Americans at risk of pregnancy complications
41120986|NCT03102853|OTHER|Nordic diet|
41120987|NCT03102853|OTHER|Control diet|
41120988|NCT03238261|RADIATION|Chemotherapy and concomitant radiotherapy|Radiotherapy (teletherapy + high or low rate brachytherapy)
41120989|NCT06123871|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
41120990|NCT04050969|PROCEDURE|Bariatric surgery|Participants will undergo either a laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass.
41120991|NCT04050969|PROCEDURE|Atrial Fibrillation (AF) Catheter Ablation|Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
41120992|NCT03887650|DRUG|Liposomal Bupivicaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
41120993|NCT03887650|DRUG|Bupivacaine 0.5%|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
41120994|NCT03278587|OTHER|Community-based screening program|In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.
41273355|NCT05116657|DIAGNOSTIC_TEST|Nasal Lavage and Oral Wash|"* Nasal Lavage: The nasal lavage will be performed using a spray technique. Using a disposable metered-dose inhaler (100 µl per spray), room temperature saline will be sprayed in one nostril while the other nostril is closed. After 5 sprays, the subject will gently exhale through the lavaged nostril and the fluid will be collected in a specimen cup. The procedure will be repeated a minimum of 8 times and a maximum of 15 times in each nostril. After collection, the sample will be placed on ice and processed within 2 hours.~* Oral Rinse: Oral samples will be collected using a standardized procedure in accordance with the Manual of Procedures for Human Microbiome Project.Study participants will rinse their mouth (swish/gargle) with 15 mL sterile normal saline for 1 min, and will expectorate the contents of the mouth into a 50 mL centrifuge tube. Sample should be kept cold on ice until processing."
41273356|NCT01748799|DRUG|Sativex|All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.
41273357|NCT01748799|DRUG|Placebo|All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
41273358|NCT00019955|PROCEDURE|laparoscopic surgery|
41273359|NCT00019955|PROCEDURE|radiofrequency ablation|
41273360|NCT00019955|PROCEDURE|thermal ablation therapy|
41453434|NCT04876716|DRUG|Azole|Dosing according to the SPC
41453435|NCT04876716|DRUG|Anidulafungin|200mg loading dose on day 1 and 100mg QD thereafter
40926508|NCT04153734|DRUG|Pembrolizumab|Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
41273361|NCT04511702|BIOLOGICAL|Pegloticase with MTX|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
41120995|NCT03278587|OTHER|Cataract camp program|In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
41120996|NCT03278587|OTHER|Community health worker program|In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
41273362|NCT04250584|DEVICE|iSlpr™|mandibular advancement device
41120997|NCT01303445|DRUG|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
41120998|NCT01303445|DRUG|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
41120999|NCT01303445|DRUG|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
41121000|NCT01303445|DRUG|Omeprazole alone|omeprazole 80 once daily for 7 days
41121001|NCT01953692|BIOLOGICAL|Pembrolizumab|IV infusion
41273363|NCT04250584|DEVICE|SomnoDent® Classic|mandibular advancement device
41273364|NCT05591781|DEVICE|high frequency chest wall oscillation with vest system|Patients were assigned to 2 groups with pre- and post- treatment protocol application. All patients were thoroughly evaluated before and after treatment protocol application.
41273365|NCT05591781|DEVICE|Lung flute (OPEP)|. Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day for three successive weeks
41273366|NCT01830530|DRUG|Telmisartan|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
41273367|NCT01830530|DRUG|Nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
40753853|NCT05688423|BEHAVIORAL|Treatment as Usual|Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.
41121002|NCT01953692|DRUG|Lenalidomide 20 mg|oral capsule
41273368|NCT01830530|DRUG|placebo|two tablets daily in the morning
41273369|NCT00337233|PROCEDURE|yoga therapy|10 week yoga class
41273370|NCT05029557|BEHAVIORAL|Education and telephone follow ups based on the Chronic Care Model|The effects of Chronic Care Model-based education and telephone follow-up given to patients with COPD on self-efficacy and patient-reported outcomes.
41273371|NCT01149200|DRUG|TC-6499|5mg enteric-coated oral hard gelatin capsule, administered twice daily
41273372|NCT01149200|DRUG|Placebo|placebo as enteric-coated oral hard gelatin capsule, administered twice daily
40753854|NCT02455323|OTHER|Suboccipital inhibitory|According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.
40926509|NCT04153734|DRUG|Cis Platinum|In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
40926510|NCT04153734|DRUG|Carboplatin|In cisplatin-intolerable patients, carboplatin (AUC=6) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
40926511|NCT04153734|DRUG|Pemetrexed|In patients with non-squamous histology, pemetrexed (500 mg/m2) will be administered every 3 weeks until progression or 2 years after initiation (35 cycles) with pembrolizumab.
41121003|NCT01953692|DRUG|Lenalidomide 25 mg|oral capsule
41121004|NCT04134078|DRUG|inhaled nitric oxide|Inhaled nitric oxide at 40 ppm will be administered upto 24 hours post ROSC in patient who developed in hospital cardiac arrest
41121005|NCT04802148|PROCEDURE|membrane guided regeneration|after tooth extraction, the socket was filled with membrane and graft (FDBA)
41121006|NCT04802148|PROCEDURE|collagen plug|after tooth extraction, the socket was filled with collagen plug
41121007|NCT02370758|DRUG|Valganciclovir or Ganciclovir|
41121008|NCT06103916|OTHER|Observational study. Prospective registration of ultrasound data in patients with ovarian tumors for which an ultrasound in according with the IOTA definitions is performed.|From all included patients, prospective data will be collected of the ultrasound(s) performed, the performed treatment and in case of surgery also the final pathological diagnosis. Participating patients will not be subjected to acts or additional procedures or examinations in this study, nor will rules of conduct be imposed.
41121009|NCT01456715|BIOLOGICAL|Gardasil vaccine, Immunogenicity, Booster dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.
41273373|NCT06222944|DRUG|Anlotinib|Anlotinib: 12mg PO, QD, D1-14, Q3W;
41273374|NCT06222944|DRUG|TQB2450|TQB2450: 1200 mg, IV, D1, Q3W
41273375|NCT06222944|DRUG|Albumin-Bound Paclitaxel|125mg/m2 IV D1,8，Q3W
41273376|NCT03192579|DRUG|EPA and high dose rosuvastatin|After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
41273377|NCT03192579|DRUG|Standard dose rosuvastatin|After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.
41273378|NCT05427474|DRUG|Propranolol , gabapentin|The combined therapy of propranolol and gabapentine can prevent the occurrence of paroxysmal sympathetic hyperactivity in traumatic brain injury patients and improve the clinical outcomes in emergency ICU.
41121010|NCT01456715|BIOLOGICAL|Cervarix Vaccine, Immunogenicity, Booster Dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.
41273379|NCT03985176|DEVICE|ROTEM|ROTEM measurements 24,48, 72, 120, 192 and 288 hours from aneurysmal SAH
41273380|NCT03985176|PROCEDURE|EEG|Continuous EEG-monitoring after aneurysm treatment until patient transferred to ward or up to 14 days after aneurysmal SAH
41273381|NCT03985176|PROCEDURE|bilateral compression ultrasound of the lower extremity veins|to exclude asymptomatic deep venous thrombosis once over days 3 to 7
41273382|NCT05601700|DRUG|Letrozole tablets|ATC: L02BG04
41273383|NCT05601700|DRUG|carboplatin AUC 5 and paclitaxel 175 mg/m2|ATC: L01XA02 and ATC: L01CD01 respectively
41273384|NCT06178068|DEVICE|Comparison of bronchodilator effectiveness of nebulizer therapy devices|The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.
41273385|NCT02243384|PROCEDURE|Laparoscopic Hepatectomy|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
41273386|NCT02243384|PROCEDURE|Radiofrequency Ablation|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
41273387|NCT05381350|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)|The COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)was manufactured by Sinovac Research\& Development Co., Ltd.1200SOU inactivated SARS-CoV-2 Omicron strain in 0.5ml of aluminium hydroxide solution per injection.
40926512|NCT04153734|DRUG|nab paclitaxel|In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.
40926513|NCT03338959|BIOLOGICAL|Pembrolizumab|Given IV
40926514|NCT03338959|RADIATION|Radiation Therapy|Undergo radiation therapy
40926515|NCT05165589|DEVICE|ActiveInsights accelerometer device|Accelerometer device
41121011|NCT01109524|DRUG|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
41121012|NCT01109524|DRUG|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
41121013|NCT01109524|DRUG|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
41273388|NCT05381350|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
41273389|NCT01701622|DRUG|febuxostat|"If baseline allopurinol dose \< 300 mg daily, will initiate febuxostat 40 mg daily.~If baseline allopurinol dose \> 300 mg daily, will initiate febuxostat 80 mg daily.~Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks."
41273390|NCT02529527|BEHAVIORAL|MyFamilyPlan|Web-based preconception health education tool (interactive self-assessment) - to be completed by patient
41273391|NCT01491178|DRUG|Prazaxa|Dabigatran etexilate
41273392|NCT03133767|DRUG|Lactated Ringer Solution|2 liters of intravenous lactated ringers solution will be administered by peripheral IV
41273393|NCT03133767|DRUG|Normal Saline 0.9% Infusion Solution Bag|2 liters of intravenous normal saline solution will be administered by peripheral IV
41273394|NCT05283993|OTHER|No intervention|No intervention
41446466|NCT03216967|DRUG|everolimus|Patients with viremia above 2.8 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
41273395|NCT03339895|OTHER|pvı-guided|pvı- guided total amount of crystalloid volume of fluid infused during colorectal surgery pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery If PVI value \<%13 and if MAP\>65mmHg continue with 2 ml/kg/h cristalloid infusion If PVI value \<%13 and if MAP\>65mmHg 5 mcg efedrin intravenous bolus till MAP\>65 mmHg If PVI value \>%13 and MAP\>65 mmHg infuse 250 ml Gelofusine bolus up to PVI value lowers to %13 every 5 minute If PVI value \>%13 and MAP \<65 mmHg infuse 250 ml Gelofusine bolus and 5 mcg efedrin intravenous up to PVI value lowers to %13
41273396|NCT03339895|OTHER|traditional-guided|traditional-guided total amount of crystalloid volume of fluid infused during colorectal surgery traditional-guided fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP \<65 mmHg or \<30%of basal value, infuse 250 ml Gelofusine bolus and 5 mcg efedrin If MAP\>65 mmHg no intervention
41273397|NCT00415220|PROCEDURE|Spinal Manipulation, Microdiscectomy|
41121014|NCT03999034|DIAGNOSTIC_TEST|questionnaire completion|Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
41273398|NCT00376961|BIOLOGICAL|rituximab|375 mg/m\^2 on day 1 for cycles 1-6.
41273399|NCT00376961|DRUG|bortezomib|1.3 mg/m\^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
41273400|NCT00376961|DRUG|cyclophosphamide|750 mg/m\^2 on day 1 of cycles 1-6.
41273401|NCT00376961|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 1 of cycles 1-6.
41121015|NCT02746926|DRUG|tafamidis|
41273402|NCT00376961|DRUG|prednisone|100 mg on days 1-5 of cycles 1-6.
41273403|NCT00376961|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 1 of cycles 1-6.
41273404|NCT00502840|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
40926516|NCT02143050|DRUG|Dabrafenib|
40926517|NCT02143050|DRUG|Trametinib|
41121016|NCT02548221|DEVICE|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
41121017|NCT00640549|DRUG|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
41121018|NCT00640549|DRUG|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
40926518|NCT02143050|DRUG|Metformin|
40926519|NCT03538171|DRUG|Entinostat|Entinostat will be repeatedly administered PO on days 1, 8, 15 and 22 of each treatment cycle. Exemestane PO once daily on day 1-28.
41121019|NCT01068756|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
41121020|NCT01068756|DRUG|Rifampin|Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
41273405|NCT00648401|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fed
41273406|NCT00648401|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fed
41273407|NCT03008187|DRUG|SEL24/MEN1703|SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
41273408|NCT05046028|DIETARY_SUPPLEMENT|Oral nutritional supplements (ONS) with a cooling effect + ONS without a sensor component and taste + standard diet|ONS with a cooling effect and Red Fruits taste. 3 bottles (х 200 ml) per day X 14 days (at severe mucositis period) in addition to a standard diet and other ONS without a sensor component and taste according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
41273409|NCT05046028|DIETARY_SUPPLEMENT|ONS without a sensor component and taste + standard diet|Nutritional support + ONS without a sensor component and taste (cooling effect) in addition to a standard diet according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
41273410|NCT05046028|DIETARY_SUPPLEMENT|Standard diet|Without appropriate nutritional support - not in accordance with current ESPEN guidelines (protein and Energy intake less than 1.5 g/kg/day and 25 and 30 kcal/kg/day). (Historical retrospective control).
41273411|NCT05961228|OTHER|exercise|"Three different posture with and without correction according to the Schroth method"
41446467|NCT02722239|DRUG|Xigduo XR|a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release
41446468|NCT02722239|DRUG|Metformin ER (Glucophage® long)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
41446469|NCT02722239|DRUG|Dapagliflozin (Forxiga)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
41446470|NCT04242823|DIAGNOSTIC_TEST|Automated visual evaluation|Participants will undergo primary hrHPV testing and if positive will be referred for VIA per Botswana and WHO guidelines. Participants will also undergo colposcopy, image capture for automated visual evaluation and biopsy at the time of VIA.
41446471|NCT00217113|BEHAVIORAL|Geriatric home visit and Action Plan|
41446472|NCT06560034|DEVICE|VicorderCS|"1. Vascular Sensor (VCS-VAS-1000) measurement device used with accessories (cuffs and tubes) connected to the device;~2. Data Station (VCS-DAT-1000) for data collection and analysis"
41446473|NCT03420092|DRUG|Form 1 of AZD5718 tablets|The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.
40926520|NCT03538171|DRUG|Placebo|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
40926521|NCT03538171|DRUG|Exemestane|Exemestane PO once daily on day 1-28.
40947826|NCT04863235|BEHAVIORAL|Control Group|Eight week behavioural change program aimed to increase physical activity plus information on general health topics among individuals with prediabetes.
41273412|NCT01137214|DEVICE|Non-invasive positive pressure ventilator|All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
41273413|NCT00895063|BEHAVIORAL|Vocal Exercise|This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.
41273414|NCT02924701|OTHER|Blood samples, fibroscan and questionaires|
41121021|NCT01295697|DRUG|EZN-2208|Experimental
41121022|NCT03680703|BEHAVIORAL|Guided Self-Help Behavioral Weight Loss|Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
41273415|NCT00333996|DRUG|Dexamethasone|
41273416|NCT01136395|DRUG|Rituximab|375mg/m2 4 weeks before ABOi LD transplantation
41273417|NCT01136395|PROCEDURE|living donor transplantation|living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
41273418|NCT01136395|PROCEDURE|deceased donor transplantation|deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK virus (BKV), JC virus (JCV)), respectively
41273419|NCT00224666|DEVICE|Cortex stimulation|
41273420|NCT01841892|BEHAVIORAL|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
41273421|NCT03242655|BEHAVIORAL|HCV GET-Up (Group Evaluation and Treatment Uptake)|Groups will meet for 4 weekly 1-hour sessions facilitated by the PI and focused on providing education, motivation, and behavior change skills, along with an HCV medical evaluation. Patients will then be offered HCV treatment by individual provider after 4-week group evaluation and education intervention.
41273422|NCT05922202|OTHER|Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months|At 12 and 24 months of follow up, cardiovascular events (including hospital admissions), deaths due to cardiovascular disease, deaths due to all-cause, deaths due to COPD will be recorded in COPD outpatients group.
40753855|NCT02455323|OTHER|Spinal manipulative|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility
40926522|NCT00246571|DRUG|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
41121023|NCT00921154|DRUG|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
41446474|NCT03420092|DRUG|Form 2 of AZD5718 tablets|The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.
41446475|NCT03420092|DRUG|Form 3 of AZD5718 tablets|The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.
41446476|NCT03420092|DRUG|Form 4 of AZD5718 tablets|The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.
41446477|NCT03420092|DRUG|Form 5 of AZD5718 tablets|The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.
41121024|NCT04877496|DRUG|History of exposure to anti-CD20 treatment since 01/01/2010|Intravenous treatment history of anti-CD20 treatment since 01/01/2010
41121025|NCT04877496|BIOLOGICAL|Completion of COVID19 vaccine at least 4 weeks ago|Completion of COVID19 vaccination course at least 4 weeks ago.
41121026|NCT02063425|DRUG|Fluoxetine|1 pill of 20mg / day, during 3 months
41121027|NCT02063425|DRUG|Placebo of fluoxetine|1 pill of 20mg/day, during 3 months
41121028|NCT02002052|DRUG|Concurrent platinum-based chemotherapy|Platinum-based concurrent chemotherapy in both arms
41121029|NCT02002052|RADIATION|Standard Radiotherapy, 60 Gy in 30 fractions.|
41121030|NCT02002052|RADIATION|Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions|
41121031|NCT02755116|DRUG|Olanzapine|10mg of olanzapine by mouth prior to anesthetic induction
41121032|NCT02755116|DRUG|Placebo|placebo by mouth prior to anesthetic induction
41121033|NCT00041548|DRUG|nitric oxide for inhalation|given at 20 ppm for 1 hour then weaned off over 4 hours
41121034|NCT00041548|DRUG|Oxygen|given at 20 ppm for one hour, then weaned off over four hours
41121035|NCT04504708|DRUG|ZX-101A|Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
41121036|NCT03678558|OTHER|Cytochalasin B supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Cytochalasin B
40947827|NCT04863235|BEHAVIORAL|Intervention Group|Eight week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes.
41121037|NCT03573518|DRUG|BTX 1503|BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
41121038|NCT03573518|DRUG|Vehicle|Placebo
41121039|NCT04163536|DRUG|Methylprednisolone|In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.
41121040|NCT04163536|DRUG|Placebos|in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
41121041|NCT04713735|DIETARY_SUPPLEMENT|Control: Placebo|Placebo
41121042|NCT04713735|DIETARY_SUPPLEMENT|bovine lactoferrin supplement|600 mg
41121043|NCT02698228|DRUG|Bupivacaine (femoral nerve block)|0.5% bupivacaine
41121044|NCT02698228|DRUG|Morphine|Intravenous injection of 0.1mg/kg of morphine
41121045|NCT02698228|DEVICE|Ultrasound|
41121046|NCT03167034|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
41121047|NCT03167034|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
41121048|NCT00370019|DRUG|Estradiol/Medroxyprogesterone acetate|
41121049|NCT00853918|OTHER|$20 cash|$20 cash incentive mailed with survey
41121050|NCT00853918|OTHER|$50 cash|$50 cash incentive mailed with survey
41121051|NCT00853918|OTHER|$50 check|$50 check incentive mailed with survey
41121052|NCT00853918|OTHER|$100 check|$100 check incentive mailed with survey
41121053|NCT05361733|DRUG|XFB-19|XFB-19 is a first-in-class synthetic tetra-peptide (Acetyl-Lys-D-Ala-D-Val-Asp-NH2) that inhibits the activation of the human CCAAT-enhancer binding protein beta (C/EBPβ) thus mediating the activation of lung myofibroblasts. Activation of myofibroblasts is responsible for the development of lung fibrosis in idiopathic pulmonary fibrosis (IPF).
40947828|NCT00152360|DRUG|Orlistat|See Detailed Description.
40947829|NCT06244017|DEVICE|EEG spectrogram|In the experimental group, the general anesthesia is guided by using the EEG spectrogram.
40947830|NCT06244017|DEVICE|Bispectral index|In the control group, the general anesthesia is guided by using the bispectral index
40947831|NCT02186431|DEVICE|senofilcon A|
41121054|NCT05361733|DRUG|Placebo|No active ingredient drug use to blind participants and investigators
41121055|NCT00392249|BEHAVIORAL|Supervised Treatment of Schizophrenia by a family member|
41121056|NCT05096806|OTHER|Acupuncture|Acupuncture is a non-pharmacological technique that consists in the stimulation of specific points located in the skin surface. Points are stimulated by piercing the skin with fine needles.
41121057|NCT05096806|DEVICE|TENS|TENS is a therapy that uses low voltage electrical current to provide pain relief. A TENS unit consists of a battery-powered device that delivers electrical impulses through electrodes placed on the surface of your skin. The electrodes are placed at or near nerves where the pain is located or at trigger points.
41121058|NCT02476435|DEVICE|Active rTMS|Strong electromagnetic fields (\~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
41121059|NCT02476435|DEVICE|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
41121060|NCT04134611|DEVICE|Hyaluronic acid injection|Injection of Hyaluronic acid in knees of those who has degenerative changes after arthroscopic treatment of lateral patellar compression syndrome
41121061|NCT04134611|DEVICE|No injection of Hyaluronic acid|No injection of Hyaluronic acid was done
41121062|NCT05875714|DRUG|Apremilast|Apremilast (Otezla), oral medication Day 1: 10 mg in the morning. Day 2: 10 mg in the morning and 10 mg in the evening. Day 3: 10 mg in the morning and 20 mg in the evening. Day 4: 20 mg in the morning and 20 mg in the evening. Day 5: 20 mg in the morning and 30 mg in the evening Day 6: 30 mg twice daily Maintenance dosing: 30 mg twice daily
41121063|NCT03584659|DEVICE|Electronic patient-reported outcomes|Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.
41121064|NCT02582736|DRUG|Olanzapine|Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
41121065|NCT02582736|DRUG|Risperidone|Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
41121066|NCT02582736|DRUG|atypical antipsychotics (other)|Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
41121067|NCT02582736|DRUG|typical antipsychotics|Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
40753856|NCT02455323|OTHER|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
40753857|NCT02455323|OTHER|Control group.|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
40753858|NCT04941365|DIAGNOSTIC_TEST|single arm|Blood samples will be collected at baseline(Visit 1), and during therapy at visit 2 (around one month after the treatment starting) and at Visit 3 (around three months after the treatment starting. And, optionally, in case of a disease progression (PD).
41121068|NCT01384240|DRUG|Proflavine Hemisulfate|3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
41121069|NCT03197571|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
41121070|NCT03197571|BIOLOGICAL|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
41121071|NCT03197571|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
41121072|NCT03197571|DRUG|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
41121073|NCT03197571|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
41121074|NCT03197571|DRUG|5Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
41121075|NCT03197571|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
41121076|NCT03197571|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
41121077|NCT03197571|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
41121078|NCT03197571|DRUG|Lovaza|Omega-3-acid ethyl esters
41121079|NCT03197571|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
41121080|NCT03197571|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
41121081|NCT03197571|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
41121082|NCT03197571|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
41121083|NCT03197571|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
41121084|NCT03197571|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
41121085|NCT03197571|BIOLOGICAL|GI-4000|RAS yeast vaccine
41121086|NCT03197571|BIOLOGICAL|GI-6207|CEA yeast vaccine
41446478|NCT03420092|DRUG|Selected form (Form 2 - 5) of AZD5718 tablets|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
40753859|NCT01219075|DIETARY_SUPPLEMENT|soy isoflavones|Given orally
40753860|NCT01219075|OTHER|placebo|Given orally
40753861|NCT01219075|OTHER|questionnaire administration|Ancillary studies
41121087|NCT03197571|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
41121088|NCT03197571|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
41121089|NCT04153747|OTHER|High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)|Pulmonary veins electrical isolation: high-power and short-duration ablation
41121090|NCT04153747|OTHER|Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values|Pulmonary veins electrical isolation: low-power ablation.
41121091|NCT04153747|OTHER|Esophageal endoscopy|Esophageal endoscopy to detect postablation esophageal thermal lesions.
41121092|NCT04153747|DIAGNOSTIC_TEST|Daily 30-seconds ECG|Transtelephonic daily 30-seconds single lead electrocardiogram
41121093|NCT06514222|DRUG|Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given together every 8 hours|Group 1- The patient will receive 400mg ibuprofen plus 1000mg Paracetamol simultaneously every 8 hours for two days.
41121094|NCT06514222|DRUG|Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given alternatively every four hours|Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
41121095|NCT04319432|BEHAVIORAL|Voice rest|The first days will take place in hospitalization to assess patient complience to voice rest. Patients will be instructed to continue voice rest at home up to 7 days accourding to group allocation in the study. The confirmation of voice rest will relay on patient report (telephonic approval), after the voice rest period will end.
41121096|NCT00981643|BEHAVIORAL|Meditation instruction and practice|Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
41273423|NCT03898648|OTHER|Waiting room task|"The waiting room task consists in a computerized neuropsychological task in which the participant is asked to freely choose a chair to sit in a waiting room. In a row of four chairs, the two in the middle are occupied by two males or females. One of the two subjects sitting either has a neutral face, or express a negative emotion (fear or anger).~To make their decision, participants must press the S keyboard button to go left or the L keyboard button to go right in a time limit of 1500 milliseconds.~One third of the time, the cursor moves in the opposite direction to that requested by the participant. For example, if the subject presses S, the cursor moves to the right instead of to the left.~Those reverse trials are used to evaluate their motivation to correct the movement of the cursor.~The participant will repeat the task 360 times for the assessment to be completed."
41273424|NCT02585557|OTHER|Primary Care Practice Support|The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
41273425|NCT00699790|DRUG|CCR2 Antagonist|Tablets, Oral, 50 mg, once daily, 12 weeks
41273426|NCT00699790|DRUG|Placebo|Tablets, Oral, 0mg, once daily, 12 weeks
41273427|NCT04033289|DEVICE|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
41121097|NCT05320666|BEHAVIORAL|Yes You Can…Make Smart Choices! (YYC…MSC!) program|The YYC...MSC! is an 11-lesson curriculum that will be delivered to 9th graders in Newark, New Jersey public schools during 40-minute health classes. The curriculum will be delivered in-person over approximately 2 weeks by NJPAG educators. The goal of the program is to prevent teen pregnancy and enhance character development in youth. Each time an NJPAG educator is in the classroom, they will deliver a single lesson of the curriculum. All NJPAG educators have received internal training for the program. The intervention addresses the following adult preparation subjects: parent-child communication, healthy relationships, healthy life skills, adolescent development, and financial literacy.
41121098|NCT00087880|DRUG|Bupropion and NRT|All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
41121099|NCT01058499|BEHAVIORAL|Mindfulness Based Stress Reduction Program (MBSR)|Traditional eight-week MBSR Program.
41121100|NCT05175898|DEVICE|VA-ECMO|Treatment with veno-arterial extracorporeal membrane oxygenation
41273428|NCT04646148|BEHAVIORAL|Yoga classes|All participants are invited to attend weekly yoga classes.
41273429|NCT03441126|OTHER|Multicenter Quality Improvement program|Participating institutions will not participate in an intervention study. Sites will design and implement local QI programs to improve care within their unit. Local healthcare teams, who are interested in directly and immediately improving patient outcomes, will devise customized tools. The Bright STAR Team will assess the impact of these local QI initiatives on patient health outcomes, using data that are collected as part of the QI programs or through routine clinical care.
41273430|NCT02781974|OTHER|Exercise|Strength and balance exercise in Groups, focusing on lower limb strength, back strength and static and dynamic balance
41273431|NCT03384992|OTHER|Diaphragmatic breathing and relaxation|Education on physiological effects of anxiety, instructions in diaphragmatic breathing and relaxation techniques, and audio-recordings 5-15 minutes in length that provide guided relaxation exercises (autogenic, imagery-based and progressive muscle relaxation).
41273432|NCT03384992|OTHER|Cognitive restructuring|Education on the thought-emotion connection and exercises designed to better understand cognitions associated with increased anxiety and tools to evaluate and replace anxiety-generating cognitions. Includes an interactive tool (thought record) participants complete to facilitate this process.
41273433|NCT03384992|OTHER|Scheduled worry practice|Education on the association between avoidance and increased anxiety, and instructions on actively thinking about feared events to reduce avoidance and engage healthy coping strategies. Interactive tool includes a video-based guided worry practice session and an interactive worksheet and timer.
41273434|NCT03384992|OTHER|Telephone coaching|BCS will receive 5 TeleCoaching calls over a period of 4 weeks, to include one introductory phone call, followed by 4 calls focused each week on the current CSM; if the participant is not randomized to a CSM, TeleCoaching will provide reflective listening and encouragement.
41273435|NCT03384992|OTHER|Usual care|Includes general health, diet-general information and diet-BCSS (breast cancer survivor-specific) information.
41273436|NCT06151925|DEVICE|Laminaria|mechanical method for induction of labor
41273437|NCT06151925|DRUG|Vaginal prostaglandin|Vaginal prostaglandin for ripening
41273438|NCT02531815|BIOLOGICAL|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
40753862|NCT01219075|PROCEDURE|magnetic resonance imaging|Correlative studies
40947832|NCT00333840|DRUG|imatinib mesilate|imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
40947833|NCT00333840|DRUG|interferon-alpha (INF-a)|interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
40947834|NCT00333840|DRUG|cytarabine (ARA-C)|cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
41273439|NCT02531815|DRUG|Placebo|Placebo for PF-06741086, single dose
40753863|NCT01219075|PROCEDURE|biopsy|Correlative studies
40947835|NCT04470271|OTHER|Patients with hepatitis C lost follow up|Patients with chronic HCV who were lost of follow up will be contacted by phone or email. At least 3 phone calls will be made on three different days. In case the patient is not contacted it will be considered lost of follow-up
41121101|NCT05175898|DEVICE|ECMELLA|Treatment with veno-arterial extracorporeal membrane oxygenation plus Impella® micro-axial pump.
41121102|NCT02349503|DRUG|NBI-77860|
41121103|NCT02349503|DRUG|NBI-77860|
41121104|NCT02349503|DRUG|NBI-77860|
41121105|NCT02496377|DRUG|ferrous glycine sulfate Tardyferon|
41121106|NCT02496377|DRUG|Epoetin Alfa|
41121107|NCT02496377|DRUG|ferric carboxymaltose Ferinject|
41121108|NCT05255224|OTHER|Not applicable as observational study|Not applicable as observational study
41273440|NCT05264350|DEVICE|Sialic acid nasal spray|The nasal spray will be self administered twice daily for 8 weeks.
41273441|NCT05264350|DEVICE|Isotonic Saline Nasal Spray|The nasal spray will be self administered twice daily for 8 weeks.
41273442|NCT04370847|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle
41273443|NCT04370847|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
40753864|NCT01219075|OTHER|immunohistochemistry staining method|Correlative studies
41273444|NCT04370847|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
41121109|NCT00945607|OTHER|GRT (Guided Relaxation Training)|Weekly on-site GRT sessions at the center in combination with twice daily independent GRT sessions at home.
41121110|NCT03289468|DIAGNOSTIC_TEST|Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler|The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
41121111|NCT04954001|DRUG|FCN-159|FCN-159 is administered orally in once daily schedule for 28 days a cycle.
41121112|NCT02284412|DRUG|Neostigmine|At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
41121113|NCT02284412|DRUG|Sugammadex|At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
41121114|NCT02284412|DRUG|Water for injection|At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
41121115|NCT04153110|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
41121116|NCT04153110|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
41121117|NCT03971851|OTHER|Frailty risk groups|Patients older than 65 will be separated into groups of varying frailty risk
41121118|NCT05633719|OTHER|Chemotherapy involving cisplatin or carboplatin|Chemotherapy
41121119|NCT05334199|DEVICE|Biodegradable stent|Bronchoscopic placement of biodegradable stent in patients with airway complications after lung transplant
41121120|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
41121121|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
41121122|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
41273445|NCT04370847|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
41273446|NCT04370847|RADIATION|lung ultrasound scans|lung ultrasound scans will be performed while the patient is in the supine position with left lateral tilt by 30 degrees using a 2-5 MHz curved array transducer. The echo comet score (ECS) which corresponds to the amount of EVLW will be obtained by the 28-rib interspaces technique. An increased amount of (EVLW) is diagnosed by multiple B-lines or 'comet tails' which are defined as discrete laser-like vertical hyperechoic reverberation artifacts that arise from the pleural line and extend to the bottom of the screen without fading and move synchronously with lung sliding. The sum of the B-lines found on each of the 28 chest-wall areas yields the ECS.
41273447|NCT04370847|OTHER|Ultrasound Assessment of the Inferior Vena Cava|The IVC largest and smallest diameters will be measured proximal to the opening of the M-mode using s2-4 MHz transducer placed longitudinally in the subcostal region.
41273448|NCT04370847|OTHER|Optic nerve sheath diameter|Optic nerve sheath diameter measurement will be conducted in two axes of transverse and oblique sagittal using a 12-4MHz linear array transducer. Depth of the optic nerve will be localized and marked at 3 mm behind the retinal and optic nerve junction transverse diameter of optic nerve sheath will be calculated. The reported ONSD corresponds to the mean of the four values obtained for each patient transverse and sagittal plane for both eyes.
41273449|NCT04370847|DRUG|ringer acetate|1000 ml ringer acetate will be administered over 2 hours.
41446479|NCT01787695|PROCEDURE|UVA1|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.~The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
40753865|NCT01219075|OTHER|laboratory biomarker analysis|Correlative studies
40753866|NCT01219075|PROCEDURE|mammography|Correlative studies
41446480|NCT01600963|DRUG|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
40947836|NCT01823146|DRUG|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
40947837|NCT01823146|DRUG|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
40947838|NCT03616132|DEVICE|Device: Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
40947839|NCT03008226|DEVICE|Implementation of 9 mm intrabronchial valves|
41121123|NCT00773370|BEHAVIORAL|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
41446481|NCT01600963|DRUG|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
41446482|NCT01600963|DRUG|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
41121124|NCT00773370|BEHAVIORAL|Sittercise|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
41121125|NCT00498511|PROCEDURE|upper gastrointestinal endoscopy, colonoscopy|
41121126|NCT05575622|DEVICE|CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection|Collect peripheral blood sample of 200 HCC patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 by microfluidic chip.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
41121127|NCT06222918|PROCEDURE|Deep Margin Elevation (G-ænial Universal Injectable)|Deep margin elevation (DME), or coronal margin relocation (CMR), is a procedure used to raise or reposition sub-gingival margins into supra-gingival margins using several materials to increase marginal integrity and bonding strength
41121128|NCT05536830|OTHER|Nutrition Status|Participants will be examined by a registered dietitian to assess nutrition status.
41121129|NCT00338650|DRUG|adalimumab|
41121130|NCT03204565|PROCEDURE|coronally advanced flap|coronally advanced flap alone (CAF- control)
41121131|NCT03204565|DEVICE|hyaluronic acid|hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
41121132|NCT02545036|OTHER|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
41121133|NCT04505358|DRUG|PU-AD|active vs placebo
41121134|NCT04505358|DRUG|Placebo|active vs placebo
41121135|NCT02574455|DRUG|Sacituzumab govitecan|10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.
41121136|NCT02574455|DRUG|Eribulin|Administered IV over 2 to 5 minutes at a dose 1.4 mg/m\^2 at North American sites and 1.23 mg/m\^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m\^2 and 0.67 mg/m\^2 for North American and European sites, respectively).
41121137|NCT02574455|DRUG|Capecitabine|1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
41121138|NCT02574455|DRUG|Gemcitabine|800 to 1200 mg/m\^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.
41121139|NCT02574455|DRUG|Vinorelbine|25 mg/m\^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.
41121140|NCT01336543|DRUG|Chemotherapy following concurrent Chemoradiotherapy|"1. NSCLC (Non-Small Cell Lung Cancer)~2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~3. Radiation 59.4 Gy with 2 cycles of PE~4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~5. (Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
41121141|NCT05421364|BIOLOGICAL|Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)|Approximately 9 ml blood from each patient will be collected on the day of the LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. PBMCs (1x106cells/ml) suspended in RPMI 1640 supplemented with 10% HSA will be incubated in the presence of 10 IU/ml hHCG for 48 h. On day 2 after LH peak, fresh PBMCs (1x107 cells) will be also obtained from the same patients, these fresh PBMCs will be immediately combined with the 2-day cultured PBMC and suspended in PBS (2x107 cells/200µl). This cell suspension will be carefully introduced in the uterine cavity by catheter on day 2 after LH peak.
41121142|NCT02003469|DEVICE|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
41121143|NCT05638308|DIAGNOSTIC_TEST|FAZA PET/MRI scan|FAZA PET/MRI scan before the standard of care biopsy for case group
41121144|NCT06235424|DRUG|Del Nido Cardioplegia Solution|The route of cardioplegia delivery differed according to surgeons' preferences. The total dosage of cardioplegia depends on the type of cardioplegia. The standard dose of del Nido cardioplegia in our institution is 1000 ml as an initial dose and is delivered with a system pressure of 90-150 mmHg. The solution is prepared by our hospital's pharmacy. At 60. minute of cross-clamp (XC) if XC time was expected to exceed 90 minutes another dose of solution would be delivered. The volume of an additional dose was 500 ml. The temperature of the delivered del Nido cardioplegia was 4\*C.
41121145|NCT06235424|DRUG|HTK solution|The route of cardioplegia delivery differed according to surgeons' preferences. The dose of the HTK cardioplegia is calculated with an application of 20 mL/kg rule. It is delivered with a system pressure of 90-150 mmHg. If the XC time exceeds 120 minutes additional dose is given (10 mL/kg rule). The temperature of the delivered crystalloid cardioplegia is 4\*C
41121146|NCT00035308|DRUG|Abetimus sodium (LJP 394)|
41273450|NCT04370847|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
41273451|NCT04370847|DRUG|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.
41273452|NCT03792048|PROCEDURE|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
41273453|NCT05972512|OTHER|Placebo|Mode of usage: Two times a day Route of administration: Oral
41273454|NCT05972512|DIETARY_SUPPLEMENT|Botanical extract of standardized biotin|Mode of usage: Two times a day Route of administration: Oral
41273455|NCT05972512|DIETARY_SUPPLEMENT|Botanical extract of standardised biotin with silica|Mode of usage: Two times a day Route of administration: Oral
41273456|NCT01341457|DRUG|LY2603618|Administered intravenously
41273457|NCT01341457|DRUG|Gemcitabine|Administered intravenously
41121147|NCT01647438|BEHAVIORAL|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
41273458|NCT01296906|BEHAVIORAL|Recall conducted by private practices|All practices in these counties will receive training on practice-based R/R using the Colorado Immunization Information System (CIIS or immunization registry). Practices will receive a recommended schedule for conducting recall in 19-35 month children and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone informational systems) in order to assess the effect of these additional interventions.
41273459|NCT01296906|BEHAVIORAL|Recall conducted centrally by local health department|A centralized recall of children 19-35 months will be conducted through local health departments. CIIS will identify a cohort of 19-35 month olds with an who are in need of an immunization and will coordinate up to 3 mailers to children who are not current for recommended immunizations.
41273460|NCT00393718|DRUG|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
41446483|NCT01600963|DRUG|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
40947840|NCT03145363|BEHAVIORAL|Intervention|The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
41121148|NCT01647438|OTHER|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
41121149|NCT03163212|DIETARY_SUPPLEMENT|Lactoferrin/FOS|Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water
41121150|NCT00593489|OTHER|Basal Insulin Initiation Strategy|This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
41121151|NCT03809312|DRUG|Amoxicillin / Clavulanic acid 875mg / 125mg|Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days
41121152|NCT03809312|DRUG|Placebos|Placebos BID x 10 days
41121153|NCT02283749|BIOLOGICAL|Xofigo|This is a radio-isotope
41121154|NCT06284642|DRUG|Urokinase|On the basis of standard treatment for severe neurological conditions, within 24 hours of aneurysm treatment, lumbar drainage combined with intrathecal urokinase injection was started. 30,000 IU urokinase dissolved in 3 ml normal saline was injected into the subarachnoid space, 3 ml normal saline was rinsed into the tube, and the tube was clamped for observation for 2 hours, once a day, for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
41273461|NCT00393718|DRUG|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
41273462|NCT00393718|DRUG|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
41273463|NCT00393718|DRUG|placebo|glibenclamide placebo. Given orally once or twice daily.
41273464|NCT02013544|DRUG|Placebo|
41273465|NCT02013544|DRUG|Prasterone (DHEA)|
41273466|NCT03006653|BEHAVIORAL|Assessment only|Mobile ecological assessment only.
41273467|NCT06330129|DEVICE|CTT Pegasus|The intervention aims to assess the construct validity of trunk flexor, extensor, and rotator muscle strength using the CTT PEGASUS isometric dynamometer (Leipzig, Germany). This involves correlating muscle strength measured isometrically with its physiological determinants: MRI-based anatomical cross-sectional area (CSA) in the lumbar region and muscle activation measured via surface electromyography (EMG) of spine and trunk muscles. Additionally, the intervention will assess the test-retest reliability of isometric strength of trunk flexors, extensors, and rotators.
41446484|NCT03831139|BEHAVIORAL|TIM&SARA|
41273468|NCT04271761|OTHER|Non-interventional, post-market, pilot study of Carina Cochlear System|Several objective acoustic measurements will be performed that do not require active participation from the subject.
41273469|NCT05736263|BEHAVIORAL|Moderate intensity exercise|moderate intensity aerobic exercise trial
41273470|NCT05736263|BEHAVIORAL|High intensity interval exercise|High intensity interval exercise trial
41121155|NCT06284642|DRUG|Placebo|On the basis of standard treatment for severe neurological conditions, the treatment of lumbar drainage combined with intrathecal placebo saline injection was started within 24 hours after aneurysm treatment, 3 ml placebo was injected into the subarachnoid space, 3 ml normal saline was flushed into the tube, and the tube was observed for 2 hours, once a day for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
41121156|NCT01871675|DRUG|IPI-145|
41121157|NCT01871675|DRUG|Rituximab|
41121158|NCT01871675|DRUG|Bendamustine|
41121159|NCT02101281|DRUG|rhNGF 20 µg/mL|1 drop for each eye, twice daily for 28 day
41273471|NCT05736263|BEHAVIORAL|Combined exercise|Combined aerobic and resistance exercise trial
41273472|NCT05736263|BEHAVIORAL|Resistance exercise|Resistance exercise trial
40753867|NCT06100835|OTHER|Complex intervention involving physical activity and behaviour change techniques|"The intervention protocol derives from a previous, extensive, co-creation phase involving end-users as well as relatives, experts, professionals working working with older adults, university students and researchers.~It will be based on a structured group-based PA programme supervised by trained professionals, tailored to participants' needs to include joyful components combined with self-management strategies to encourage behaviour change also beyond the sessions. All participants (including end-users but not only) will also be encouraged to join virtual communities of practice (VCoP) for further support and knowledge exchange."
41273473|NCT06399315|DRUG|ZE46-0134 or placebo|The patients will receive ZE46-0134 or placebo
41273474|NCT06399315|DRUG|Rabeprazole, 20mg oral|Rabeprazole 20 mg daily will be administered for 2 prior ZE46-0134 and 7 co-administered
41273475|NCT00246259|DRUG|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
40753868|NCT02809781|BIOLOGICAL|Intravenous infusion of MSCs|Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
40753869|NCT02809781|DRUG|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
40753870|NCT02563210|OTHER|airway resistance measurement|assessment of airway resistance
40947841|NCT03145363|BEHAVIORAL|Control|"The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough)."
40947842|NCT03677427|RADIATION|Radiation|Radiation in breast cancer
41121160|NCT02101281|DRUG|rhNGF 4 µg/mL|1 drop each eye, twice daily for 28 day
41121161|NCT02948114|OTHER|Control: Cow milk-based infant formula|
41121162|NCT02948114|OTHER|Experimental 1: Cow milk-based infant formula|Experimental 1: Cow milk-based infant formula with prebiotics
41121163|NCT02948114|OTHER|Experimental 2: Cow milk-based infant formula|Experimental 2: Cow milk-based infant formula with probiotics
41121164|NCT02948114|OTHER|Experimental 3: Cow milk-based infant formula|Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
41273476|NCT00246259|DRUG|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
41273477|NCT00585234|OTHER|Digital Photography|Digital Photography
41273478|NCT05798988|BEHAVIORAL|Neurophysiology-based exercise program|Neurophysiology-based exercise program combines physiotherapy exercises and neuro-physiology principles with focus on foot and core functional stabilisation and balance training.
41273479|NCT04059744|DEVICE|Fun-Knee|"Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
41273480|NCT04711837|DRUG|HSK3486|HSK3486 for induction of general anesthesia.
41273481|NCT04711837|DRUG|Propofol|Propofol for induction of general anesthesia.
41273482|NCT04118803|DEVICE|ICD replacement or upgrade|Currently, it is common for patients to survive beyond their initial prophylactic ICD generator. It is unclear whether further benefit related to inappropriate shocks or ATP is derived from long-term device therapy, particularly if there has been a change in the patient's cardiovascular condition.
41273483|NCT01714466|DRUG|NER1006|
41273484|NCT01714466|DRUG|MOVIPREP|
41273485|NCT02872103|DRUG|F-627|F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
41273486|NCT02872103|DRUG|Placebo|Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
41446485|NCT00834717|DRUG|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose fasting
41121165|NCT03446482|OTHER|observation of differents tasks|Evaluation by an external observer (nurse student in research stage or clinical research technician) of the distribution of medical time for the performance of the different tasks of anesthesiologist (in minutes)
41121166|NCT01087255|DEVICE|Electronic Pillbox Monitoring System|Daily exposure for six months
41121167|NCT02627469|BEHAVIORAL|Extended professional oral hygiene care|Weekly professional oral hygiene performed by dental hygienists
41121168|NCT02627469|DEVICE|Electric toothbrush (Oral-B Professional Care 7000)|Weekly professional oral hygiene performed by dental hygienists
41121169|NCT02627469|DEVICE|1100 ppm sodium fluoride dentifrice (Zendium Classic)|Weekly professional oral hygiene performed by dental hygienists
41121170|NCT04575961|DRUG|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles
41121171|NCT04701866|OTHER|Music|Music will be provided via headphones during all 6 ketamine treatments, beginning at the commencement of each infusion and ending 55 minutes later. On the day of each infusion, before the treatment begins, clinicians will discuss music choices with participants in order to select amongst one of several options that have been designed for this purpose (length, genre, intensity, etc.).
41121172|NCT00266448|DRUG|Chlorhexidine solution 4%|
41273487|NCT03060421|DEVICE|Aquamid reconstruction|Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
41273488|NCT03981029|OTHER|4.0mg Folic Acid received through participation in FACT (NCT01355159)|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid intervention are provided below:~Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid"
41273489|NCT03981029|OTHER|Placebo received through participation in FACT|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid placebo are provided below:~Placebo x 4 tablets will be taken daily by oral administration."
41273490|NCT01117376|DRUG|Erythromycin|Erythromycin 250 mg intravenous Q6h for 4 doses
41273491|NCT01117376|DRUG|Methylnaltrexone|Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
41273492|NCT00476099|DRUG|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
41121173|NCT04018859|DEVICE|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to the eyebrows
41121174|NCT04018859|DRUG|Saline|intradermal injections to the eyebrows
41273493|NCT00476099|DRUG|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
40753871|NCT00084279|DRUG|Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin|interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily
41121175|NCT03005925|DEVICE|Smartphone|Smartphone application coupled with a hand dynamometer
41121176|NCT03005925|OTHER|physical follow up|regular visits with the specialist
41121177|NCT01946386|DRUG|LEO 90100 Aerosol, foam|The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
41273494|NCT00476099|DRUG|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
41273495|NCT05289960|OTHER|lung ultrasound|Lung ultrasound score was done at the end of SBT using curved array ultrasound probe 2-5 MHz, Siemens X300, Korea
41273496|NCT04148092|DRUG|ripretinib|orally administered solid dosage form
41273497|NCT03707184|PROCEDURE|Computed Tomography|Undergo PET/CT scan
41273498|NCT03707184|DRUG|Fluciclovine F18|Given IV
41273499|NCT03707184|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
40753872|NCT03322891|OTHER|Educational Supplement|Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.
41121178|NCT01946386|DRUG|Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle|
41121179|NCT01946386|DRUG|LEO 90100 Aerosol, foam, vehicle|
41121180|NCT01946386|DRUG|Daivobet® ointment|
41121181|NCT01946386|DRUG|Dermovate® cream|
41446486|NCT00834717|DRUG|Kytril® 1 mg tablets|2 x 1 mg, single dose fasting
41121182|NCT01946386|DRUG|Synalar® ointment|
41121183|NCT04222946|OTHER|Dry needling|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
41121184|NCT05098132|DRUG|STK-012|pegylated alpha/beta-biased engineered interleukin-2
41121185|NCT05098132|DRUG|Pembrolizumab|anti-PD-1 humanized monoclonal antibody
41121186|NCT04334746|OTHER|Balance measurement tools|Timed Up and Go Test Functional Reach Test One-leg Stance Test Berg Balance Scale
41121187|NCT05831969|DRUG|Lenalidomide|Lenalidomide: 10mg/d, 1-21d/28d orally; until disease progression or intolerable adverse reactions.
41121188|NCT01262339|DRUG|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
41121189|NCT05662449|DEVICE|Syndesmosis fixation using Activascrew|as described prior
41121190|NCT02147717|DEVICE|Laser stimulation|"Infants will be divided in 2 groups:~* Placebo group: Placebo (fake laser stimulation) plus opioid treatment before ETS~* Experimental group: Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
41273500|NCT03406026|OTHER|Balance System Protocol Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. One session consists of 45 minutes of regular physiotherapy and 15 minutes in which exercises will be carried out focused on the balance systems, following the program that is detailed below.
41273501|NCT03406026|OTHER|Control Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. The control group will perform, during the 60 minutes that the session lasts, the usual physiotherapy treatment.
41273502|NCT04852640|PROCEDURE|Active Rehabilitation Program (ARP)|The ARP intervention consists of therapeutic exercises designed to increase shoulder strength and endurance using a cluster of common exercises used for the treatment of shoulder pain. Specifically, the ARP program will focus on increasing scapular motor-control through a phasic program of common therapeutic exercises. This concept has been shown in the literature as capable of reducing shoulder pain and improving function in a variety of pathological conditions, however, the effect of this approach to reducing pain and increasing function for symptomatic shoulder instability is unknown. The selection of exercises and application for each exercise included in the ARP is based on recommendations from the literature and will incorporate participant feedback to customize dosages.
41273503|NCT04852640|PROCEDURE|Nonspecific Passive Intervention (NPI)|The NPI intervention consists of a non-specific treatment approach to shoulder pain that is commonly administered in the clinical setting. Specifically, passive modalities such as ultrasound, massage, and sensory electric stimulation are commonly prescribed in the treatment of shoulder pain to modulate pain. Further, general core strengthening exercises are often implemented. Therefore, the NPI will consist of regularly prescribed passive treatments and general core strengthening exercises, as commonly administered in routine treatment of shoulder pain.
41273504|NCT03793439|DRUG|Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial|Tofacitinib 5mg oral table twice daily for 16 weeks
41273505|NCT03793439|DIAGNOSTIC_TEST|Spirometry|Spirometry testing at baseline, week 4, week 8, week 12, and week 16
41273506|NCT03793439|GENETIC|RNA Sequencing|RNA sequencing test at baseline and week 16
41273507|NCT03793439|DIAGNOSTIC_TEST|Laboratory testing|Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16
40753873|NCT03322891|OTHER|Standard Practice Education|Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.
41273508|NCT03793439|DRUG|Corticosteroid|Taper corticosteroids starting at week 4
41273509|NCT03793439|DRUG|Tofacitinib 5mg [Xeljanz] 1 year open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
40753874|NCT05574244|PROCEDURE|Partial surgery preserving the prostatic apex|Partial Endoscopic resection of prostate to conserve apex
40753875|NCT05574244|PROCEDURE|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
40753876|NCT06090721|DRUG|DMT310|Topical Powder
40753877|NCT06090721|DRUG|Placebo|Placebo Topical Powder
40947843|NCT04180774|BIOLOGICAL|Tag-7 gene modified inactivated tumor cells|Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
40947844|NCT05034562|PROCEDURE|Computed Tomography|Undergo PET/CT
40947845|NCT05034562|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
41121191|NCT02147717|DEVICE|Fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
41121192|NCT05838495|OTHER|formulated liquid diet|will be fed exclusively the pediatric enteral study formula with a feeding tube
41273510|NCT01910792|DEVICE|Sperti Lamp|UV light exposure 3 times per week for 12 weeks
40947846|NCT05034562|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
40947847|NCT05034562|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
40947848|NCT01674283|DRUG|Glucagon|
40947849|NCT01674283|DRUG|placebo|
41121193|NCT02462616|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
41446487|NCT00841659|DRUG|Paroxetine HCl|40 mg Film-Coated Tablet
41121194|NCT03175172|BIOLOGICAL|CRS-207|Administered by IV infusion over approximately 1 hour.
41121195|NCT03175172|BIOLOGICAL|Pembrolizumab|Administered by IV infusion over approximately 30 minutes.
41121196|NCT03969524|DEVICE|MRI|Patients will undergo magnetic resonance imaging (MRI) at baseline (T0) (before NAC) and after the 2nd cycle of neoadjuvant chemotherapy(T2). Histopathological examination (gold standard) of the surgical specimen will be done for each patient and Compared to the results of MRI.
41121197|NCT01595802|DEVICE|Nautilus NeuroWave|"The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.~In this intervention, patients are recorded using the Nautilus Neurowave device."
41273511|NCT03339804|OTHER|Chemotherapy|In chemoteraphy session, doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) were administred in 45 min
41273512|NCT01533727|DRUG|Autologous CIK Transfusion plus Chemotherapy|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
41273513|NCT01533727|DRUG|chemotherapy alone|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
41273514|NCT06044324|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Participants in the active stimulation group will receive the high frequency rTMS to left middle temporal visual area. The left middle temporal visual area will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 100% of RMT.~Stimulation will be delivered to the left middle temporal visual area using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
41273515|NCT03304522|DRUG|VX-150|Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks.
41273516|NCT03304522|DRUG|Placebo|Participants received placebo matched to VX-150 for 6 weeks.
41273517|NCT04790942|DRUG|berberine hydrochloride|the berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months)
41273518|NCT04790942|BEHAVIORAL|lifestyle intervention group|The lifestyle intervention group (CON) mainly includes reducing sodium intake, healthy diet guidance, increasing exercise, quitting smoking and restricting alcohol consumption
41273519|NCT04800380|OTHER|Edpuzzle interactive videos|The effectiveness of the Edpuzzle application will be evaluated in developing the metric and drug dose calculation skills of first year nursing students.
41273520|NCT05439031|RADIATION|Stereotactic Arrhythmia Radiotherapy|Single radiation treatment of 25 Gy with external beam radiation therapy to the pro-arrhythmic region as determined by the cardiologist-electrophysiologist and radiation-oncologist combined
41446488|NCT00841659|DRUG|Paxil®|40 mg Film-Coated Tablet
40753884|NCT02884960|PROCEDURE|Uterine Fibroid Embolization|This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
41121198|NCT01595802|DEVICE|Transcranial Doppler (TCD)|Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
41121199|NCT05780528|OTHER|mulligan mobilization|The patients will receive mobilization with movement technique of lateral glide. the patients will be in supine subject and pronate forearm, during the application of the lateral glide by the physiotherapist, each patient was asked to perform the closure of the fist (provocative but painless gesture in the execution of the technique) for 3 sets of 10 repetitions.
41121200|NCT05780528|OTHER|instrumented assisted soft tissue mobilization|the participant will receive instrumented assisted soft tissue mobilization. The participant's elbow will rest on a table. A lubricant (Vaseline) will be applied to the skin around the elbow prior to treatment and the blade will be cleaned with an alcohol pad. First, the blade will be used to find the exact areas of restriction in the common extensor origin. Then the M2T blade will be used in the treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique)
41121201|NCT05780528|OTHER|conventional treatment|the patients will receive conventional treatment in the form of Ultrasound therapy, conventional transcutaneous electrical nerve stimulation (TENS) - hot pack - stretching and strengthening exercises and wrist rest splints
41121202|NCT01837927|DRUG|NVA237|Once daily for 52 weeks
41121203|NCT01837927|DRUG|Tiotropium Respimat®|Once daily for 52 weeks
41121204|NCT02117752|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
41121205|NCT02117752|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
41121206|NCT02117752|DRUG|sodium lauryl sulfate|Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
41273521|NCT06250257|DRUG|GDMT plus Bromocriptine mesylate|The treatment group will receive bromocriptine 2.5mg PO daily for 1 month together with GDMT.
41273522|NCT05148884|DRUG|NLX-112|NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.
41273523|NCT05148884|DRUG|Placebo|Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
41273524|NCT02988856|DEVICE|Magnetic lid system|Small externally mounted magnetic lid arrays are attached to the eye lid (s). Glasses with a second magnet system may be combined with the arrays depending on the lid condition. The device intends to facilitate eye opening and closing.
41273525|NCT00712101|DRUG|abciximab intracoronary|administer abciximab bolus intracoronary during primary percutaneous coronary intervention
41446489|NCT06446869|DIETARY_SUPPLEMENT|Gyntima Menopause|Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021
41446490|NCT06446869|OTHER|Placebo|Placebo comparator
41446491|NCT01698645|DRUG|PecFent® (fentanyl) nasal spray|
41446492|NCT01934205|DRUG|GSK2140944 (Single dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
41446493|NCT01934205|DRUG|GSK2140944 (Multiple dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
40753885|NCT06218784|DRUG|iN1011-N17 HCl Suspension (Part 1)|Dose: 100 mg b.i.d for 7 days (Multiple Ascending Dose)
40753886|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 1)|Dose: 200, 400, 800 mg b.i.d for 7 days (Multiple Ascending Dose)
41273526|NCT00712101|DRUG|abciximab intravenously|administer abciximab bolus intravenously during primary percutaneous coronary intervention
41273527|NCT05619965|DRUG|sedative|dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion
41273528|NCT05619965|DEVICE|Awake endotracheal intubation by Glidescope videolaryngoscope|Awake endotracheal intubation by Glidescope videolaryngoscope of cervical trauma patient
40753887|NCT06218784|DRUG|Placebo Capsule (Part 1)|Dose: b.i.d for 7 days
41273529|NCT05619965|DEVICE|Awake endotracheal intubation by Fiberoptic bronchoscope|Awake endotracheal intubation by Fiberoptic bronchoscope of cervical trauma patient
41273530|NCT03429868|DEVICE|integrated PET/MRI|"The participants receive an integrated 18F-FDG PET/MRI scan in addition to the conventional 18F-FDG PET/CT on the same day during tumor staging.~Whole body 18F-FDG PET/CT is performed one hour after injection of 10mCi of 18F-FDG. 18F-FDG PET/MRI is done after the PET/CT scan. And no additional 18F-FDG is given to the patients in the PET/MRI scan."
41273531|NCT01390545|DRUG|Veltuzumab|administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
41273532|NCT00928811|DRUG|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
41273533|NCT00928811|DRUG|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
41273534|NCT03521791|DRUG|PRO-155|"PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% \[Lagricel ofteno®\] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
41273535|NCT03521791|OTHER|Placebo|"The placebo is constituted by agents, additives and vehicles, of the formulation PRO-155 without pharmacological activity. It is dispensed in dropper bottle of low density polyethylene for multi-dose administration in the form of ophthalmic solution of 5 mL~Sodium hyaluronate 0.4% (Lagricel ofteno®) 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
41273536|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
41273537|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
41273538|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
41273539|NCT00844493|BIOLOGICAL|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
41273540|NCT01057277|DRUG|RAD001(Afinitor)|Rad001 in combination withCisplatin and Concurrent RT
41273541|NCT04331041|DEVICE|Adaptive stereotactic body radiation therapy|"* Will be administered using MRIdian and Ethos~* 50 Gy in 5 fractions"
41273542|NCT04331041|DRUG|Defactinib|-Oral drug 400 mg twice a day
41446494|NCT05594238|BEHAVIORAL|Telephone Engagement|Brief phone session with a study counselor.
41446495|NCT05594238|BEHAVIORAL|Portal Engagement|Access to a virtual portal where participant messages with study counselors.
41446496|NCT05594238|BEHAVIORAL|MI-CBT|8 one-on-one sessions done over the phone or video chat with a study counselor
41446497|NCT06166277|PROCEDURE|Ablation procedure|Cardioneuroablation procedure or permanent pacemaker placement
41446498|NCT05131113|OTHER|Physical exercise|Physical exercise
40753888|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 2)|Dose: 400 mg QD
40753889|NCT06218784|DRUG|iN1011-N17 Mesylate Capsule (Part 2)|Dose: 400 mg QD
40753890|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
40753891|NCT06218784|DRUG|iN1011-N17 Mesylate Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
40753892|NCT06218784|DRUG|Placebo Capsule (Part 3)|Dose: b.i.d for 14 days
40753893|NCT06547801|DIETARY_SUPPLEMENT|2'-Fucosyllactose|3 g/day of powder orally once daily
40753894|NCT06547801|DIETARY_SUPPLEMENT|Maltodextrin|3 g/day of powder orally once daily
40753895|NCT01433965|DRUG|Lenalidomide|Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
40753896|NCT00257855|DRUG|Lamotrigine|
40753897|NCT04955093|DEVICE|Biofeedback|Technology to provide Heart Rate Variability Biofeedback
40753898|NCT02993432|DEVICE|Foley catheter filled to 80cc|A Foley catheter is inserted through the cervix and filled to 80cc
41273543|NCT04331041|PROCEDURE|Tumor biopsy|-Baseline and 12-14 weeks after end of SBRT (or at time of surgery)
41446499|NCT06627296|OTHER|Exercise Training|"Individuals in the NMES group will have a total of 24 sessions of NMES application with 15 repetitions 3 days a week for 8 weeks and then exercise programs will be performed face-to-face. They will also be given home exercises to continue at home.~In the NMES group, NMES training will be performed for extensor carpi radialis longus (ECRL), extensor carpi radialis brevis (ECRB), abductor pollicis longus (APL), flexor carpi radialis (FCR) muscles. The pencil electrode will be used to stimulate the ECRL, ECRB, FCR and APL muscles in such a way that 30+30+30=90 contractions will be obtained from each muscle. According to the morphologic characteristics of each muscle, different current and will be applied.~P11th program to ECRL and APL : 65 Hz. 200 μs, P13th program to ECRB and FCR 50 Hz, 200 μs will be applied. Exercises includes intrinsic and extrinsic muscle strengthening, stabilization exercises and dart exercises, wrist neuromuscular exercises and perturbation exercises."
40753899|NCT02993432|DRUG|prostaglandin of the clinician's choice|Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
40753900|NCT05281640|BEHAVIORAL|Affect Dysregulation intervention|See relevant study arm for description
41121207|NCT02117752|DRUG|Normal saline|Patches containing normal saline (Negative Control) will be applied to the skin.
40753901|NCT05281640|BEHAVIORAL|Negative Self Concept intervention|See relevant study arm for description
40753902|NCT05281640|BEHAVIORAL|Disturbed Relationships intervention|See relevant study arm for description
40753903|NCT01856829|DIETARY_SUPPLEMENT|Omega-3|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
40753904|NCT01856829|OTHER|Placebo|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
40753905|NCT02835521|PROCEDURE|Reception|
40753906|NCT02835521|DRUG|Joint injection with triamcinolone hexacetonide|joint injection with corticosteroids
41121208|NCT02704507|DRUG|Triamcinolone|topical application nightly to half the face for 4 weeks
41121209|NCT02704507|DRUG|Tretinoin|topical application nightly for 8 weeks
41121210|NCT02704507|DRUG|Emollient|topical application nightly to half the face for 4 weeks
41121211|NCT03345901|DRUG|Pemafibrate|0.2 mg orally BID - twice daily
41453436|NCT02046122|DRUG|Idarubicin|"Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy."
41121212|NCT03345901|DRUG|Placebo|orally BID - twice daily
41273544|NCT04331041|PROCEDURE|Research blood draw|-Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT
40753907|NCT03974490|OTHER|Rhythmic auditory stimulation|Rhythmic auditory stimulation 3 times in a week, and 2 hours of physiotherapy 6 days in a week.
40753908|NCT03274349|PROCEDURE|whole body electromyostimulation exercise|whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
40753909|NCT03274349|PROCEDURE|protein-rich nutrition therapy|protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
40753910|NCT00782379|DRUG|busulfan|110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)
40753911|NCT00782379|DRUG|cyclophosphamide|14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
40753912|NCT00782379|DRUG|fludarabine phosphate|30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)
40753913|NCT00782379|DRUG|mycophenolate mofetil|15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.
40753914|NCT00782379|DRUG|tacrolimus|0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.
40753915|NCT00782379|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patients to received unmanipulated PBSCs on Day 0
40753916|NCT00782379|PROCEDURE|peripheral blood stem cell transplantation|patients to receive unmanipulated PBSCs on day 0
41273545|NCT01172067|DEVICE|Cardiac Resynchronization Therapy|Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.
41121213|NCT04688866|OTHER|Sequencing|This is an observational study, since the assignment of the medical intervention (e.g. cerclage or pessary) is not at the discretion of the investigator. However, cervical samples collected from both groups are subjected to amplicon sequencing for taxonomic classification of microorganisms.
41121214|NCT04185571|DEVICE|PEPA|
41121215|NCT05266066|OTHER|Clinical observation without antibiotic therapy for VAT|Patients will receive standard care plus antibiotic if new organ dysfunction or new infections other than VAT.
41273546|NCT01172067|DEVICE|Optimization using echocardiography|Optimization of the AV/PV and VV delays using echocardiography
41273547|NCT01381081|BIOLOGICAL|platelet-rich plasma|a single intra-articular injection
41273548|NCT01381081|DRUG|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
41273549|NCT05054855|BEHAVIORAL|: Cognitive Support Technology (CST)|"Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment.~CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012)."
41273550|NCT02515513|PROCEDURE|Muscle Tissue Biopsy Sample|During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.
41273551|NCT06327230|PROCEDURE|Thoracic Epidural Analgesia|Thoracic epidural analgesia is performed by a standardized anesthesia team. Patients are positioned in the lateral decubitus position, and routine disinfection is performed. The puncture site is selected at the T7-T9 level. When encountering sudden disappearance of resistance and appearance of negative pressure during needle advancement, it is determined that the needle has entered the epidural space. After confirming needle tip placement in the epidural space with a test dose, an epidural catheter is inserted approximately 3-5cm cephalad and securely fixed in place. The test dose consists of 3 mL of 1% lidocaine injection solution, administered to observe the level of anesthesia, confirming the effectiveness and safety of the epidural anesthesia. Subsequently, a maintenance regimen of 0.15% ropivacaine 250mL with 2.5mg of hydroma.
41273552|NCT03888625|PROCEDURE|Conventional ILM Peeling|peeling with complete removal of the internal limiting membrane (ILM)
41273553|NCT03888625|PROCEDURE|Inverted ILM Peeling|the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
41273554|NCT05736406|COMBINATION_PRODUCT|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 200 J/cm\^2.
41273555|NCT05736406|COMBINATION_PRODUCT|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 400 J/cm\^2.
41273556|NCT03176849|DIETARY_SUPPLEMENT|Vitamin D3|The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
41273557|NCT03176849|DIETARY_SUPPLEMENT|Standard Vitamin D3 Supplementation|"Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally."
41273558|NCT02764541|DRUG|Letrozole|
41273559|NCT02764541|DRUG|Tamoxifen|
41273560|NCT02764541|DRUG|Palbociclib|
41273561|NCT02764541|DRUG|Endocrine Therapy|
41273562|NCT05034640|PROCEDURE|Conventional multiport thoracoscopic surgery|Use 2 or more incisions for multiple instrument entry during the surgery and chest tube placement at the end of the operation.
41273563|NCT05034640|PROCEDURE|Single port site thoracoscopic surgery|Using only 1 incision for multiple instrument entry during the surgery and chest tube placement at the end of the operation. Single port - GelPOINT Mini® port (Applied Medical, Rancho Santa Margarita, California, USA)
41273564|NCT06261879|DEVICE|Special sanitary pad|The special sanitary pad is similar to the normal sanitary pad with 0.01 agar gel only. The agar gel is an approved source of food.
41273565|NCT03663452|BEHAVIORAL|Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS)|TACTICS begins with a mixed methods assessment (using data from medical records, staff surveys, and staff interviews) to identify barriers and facilitators of PE use in each clinic. From a menu of implementation strategies that can be matched to local conditions, an implementation plan is developed in collaboration with clinic personnel and deployed to address specific barriers and leverage strengths at each clinic site over a 5-month period.
41121216|NCT05266066|OTHER|7 day antibiotic course for VAT|Patients will receive standard care plus 7 day course of antibiotic.
41121217|NCT00586222|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
41121218|NCT00586222|OTHER|Placebo|placebo pill of the same size, color, and shape as the dietary supplement.
41121219|NCT05335642|PROCEDURE|EVAR|Endovascular repair of abdominal aortic aneurysms
41121220|NCT00404742|DRUG|Placebo|PO BID
41121221|NCT00404742|DRUG|LX211|0.2 mg/kg, twice a day (BID)
41121222|NCT00404742|DRUG|LX211|0.4 mg/kg, twice a day (BID)
41121223|NCT00404742|DRUG|LX211|0.6 mg/kg, twice a day (BID)
41121224|NCT01460446|DEVICE|Aviva Expert blood glucose meter|
41121225|NCT01460446|DEVICE|Aviva Nano blood glucose meter|
41121226|NCT06311617|DIAGNOSTIC_TEST|Fundus photography and optical coherence tomography|Non-mydriatic fundus photography and optical coherence tomography will be performed at 3 timepoints
41121227|NCT04887675|DIAGNOSTIC_TEST|MRI|Both groups with undergo neuroimaging on 3T magnetic resonance unit (Trio Tim, Siemens, Erlangen, Germany) in the Center for Diagnostic Imaging, Oncology Institute of Vojvodina, Serbia. Multivoxel MRS will be performed in the supratentorial cerebral parenchyma, covering white matter of frontal and parietal lobes, as well as cortical grey matter in frontal and parietal lobes and the whole cingulate gyrus.
41121228|NCT04372004|DIAGNOSTIC_TEST|diagnostic tests for COVID-19 infection|Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA
41121229|NCT02962817|OTHER|Educational intervention|
41121230|NCT02962817|OTHER|Video explaining the clinical practice guidelines on low back pain|
41121231|NCT04108923|DEVICE|Ligasure|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall
41121232|NCT04108923|PROCEDURE|Conventional vessel ligation|Conventional vessel ligation either tying and /or clipping of blood vessels
41121233|NCT05359653|DRUG|Clemastine Fumarate|8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
41121234|NCT05359653|DRUG|Placebo|Matched sugar tablet
41121235|NCT04357951|DRUG|d-cycloserine|D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. It will be paired with 4 sessions of behavior therapy.
41121236|NCT04357951|DRUG|Placebo pill|A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
41121237|NCT04357951|BEHAVIORAL|Behavior Therapy|All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
41273566|NCT03663452|BEHAVIORAL|Prolonged exposure training|Providers will receive a 2-day workshop training in the delivery of prolonged exposure, followed by weekly phone clinical consultation.
41273567|NCT02945592|BEHAVIORAL|Cueing|
41273568|NCT04256928|PROCEDURE|Preoperative electrical clipping|Body hair in the operative field will be clipped with an electrical clipper by hospital personnel during preparation to planned surgery.
41273569|NCT06190587|DIETARY_SUPPLEMENT|Goji Berry|As a functional food goji berry contains 19 amino acids, 21 minerals, a wide range of carotenoids (β-Carotene, Neoxanthin, Cryptoxanthin, Zeaxanthin), polysaccharides, flavonoids, phytosterols, vitamin A, C and E.
41273570|NCT05168930|DRUG|Venetoclax|C4-15
40753917|NCT00862901|DEVICE|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
40753918|NCT00930787|DEVICE|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
41273571|NCT05168930|DRUG|Zanubrutinib|C1-15
41273572|NCT06057311|OTHER|Hippotherapy|The participants in HT Group; received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
40753919|NCT00930787|DEVICE|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
40753920|NCT03536962|OTHER|no intervention|no intervention
41121238|NCT06167213|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
41121239|NCT01254006|DRUG|forskolin, rutin and vitamins B1 and B2|
41121240|NCT01579370|OTHER|Quaternary ammonium|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
41273573|NCT06057311|OTHER|Equine-Assisted Activities Therapy|The participants in the EAAT Group received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
41273574|NCT06057311|OTHER|Control|The Control Group (CG) did not receive any training. The assessments were applied twice to CG at baseline and after 6 weeks. The treatments and assessments were performed by the same physiotherapist in the same environment.
41273575|NCT05040191|OTHER|Traditional Education(control)|The application was made on the model that allows nasogastric tube application and the anatomical structure in the nasogastric region is seen. The student can experience the skill of applying a nasogastric tube to the nasogastric or orgastric region on this model. In the nursing skills laboratory, students were given a demonstration of nasogastric tube application on a model.
40753921|NCT00544687|DRUG|CRx-191|topical (mometasone furoate + nortriptyline HCl)
40753922|NCT00544687|DRUG|mometasone furoate|topical mometasone furoate
40753923|NCT00544687|DRUG|nortriptyline HCl|topical nortriptyline HCl
40753924|NCT00544687|DRUG|Karison® Creme|topical Karison® Creme (clobetasol-17-propinate 0.05%)
40753925|NCT00544687|DRUG|Vehicle|topical (placebo)
40753926|NCT03696667|DEVICE|BCI|As participants listen to the music, the EEG waves of their affective states and their variations detected in real-time is converted into an auditory signal providing direct feedback to participants about their affective states and assisting participants to learn and practice emotion regulation.
40753927|NCT03849612|DEVICE|AID System|AID system
41121241|NCT01579370|OTHER|Bleach|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
41121242|NCT01579370|OTHER|Quaternary ammonium and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
41273576|NCT05040191|OTHER|Haptic interactive virtual reality simulation training|Haptic interactive virtual reality simulation technology; It functions by using haptic gloves that are interactive, visually enhanced, containing three-dimensional video and animation, wearable by students. This program has been developed by a software developer who is an expert in the field of information technologies, using the unreal program with a nine-generation computer with a game engine. All the necessary steps in the NGT application have been in simulation.
41273577|NCT05040191|OTHER|Haptic interactive computer-based simulation training|"Clinical tvr (tactile simulator) produced by a foreign commercial company used in nursing education was used. Clinical tvr simulation applications can be accessed online or downloaded to a computer. This simulator; It functions by using an interactive, visually enhanced 2D, animated, haptic arm that can be held by students like a pen. It includes applications such as nasogastric tube placement, urinary bladder catheter placement, heart massage. These applications can be realized through both mouse and haptic arm computer input devices. clinical tvr; It is a simulator that incorporates the enhanced benefits of haptic feedback through the use of haptic technology. This simulator provides a near-realistic sensory experience where the learner can practice a skill as it actually is. Computer-based simulation with haptic interaction was used in this study with the haptic arm in NGT application skill."
41273578|NCT01914679|DEVICE|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
41273579|NCT00618150|BEHAVIORAL|Patient education|An educational program: Three lessons spaced over 2 weeks.
41273580|NCT02747082|PROCEDURE|Retreatment of root-filled teeth with infection|Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.
41273581|NCT02033226|DEVICE|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
41273582|NCT02033226|DEVICE|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
41273583|NCT03048630|BEHAVIORAL|Education|Owner-to-Worker training about reducing chemical exposures in nail salons
41273584|NCT01815957|DRUG|Rnalozine|. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
41273585|NCT06227832|DRUG|KP-001|KP-001
41273586|NCT06227832|DRUG|Metformin|oral dose of 850 mg Metformin
41273587|NCT06227832|DRUG|Midazolam|oral dose of 2 mg Midazolam
41273588|NCT06227832|DRUG|Clarithromycin|oral doses of 1000 mg Clarithromycin
41273589|NCT04439903|OTHER|Web-based Simulation Tool|Glucose, insulin and meal data from the participants' insulin pump will be collected and entered into the WST, which will generate personalized models of the participants' glucose metabolism to enable replay simulations.
41121243|NCT01579370|OTHER|Bleach and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
41121244|NCT02522468|PROCEDURE|Radioactive Seed Localization|
41273590|NCT02440750|PROCEDURE|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
40753928|NCT03849612|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
41121245|NCT02522468|PROCEDURE|Wire Localization|
41121246|NCT02015546|DRUG|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
41121247|NCT00780351|DEVICE|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
40753929|NCT01129284|DRUG|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
40753930|NCT02792946|DRUG|Acebrophylline|
41121248|NCT00441298|DRUG|Tenofovir gel|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
41121249|NCT00441298|DRUG|Placebo (Universal HEC placebo)|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
41121250|NCT01064336|DRUG|Eltrombopag|Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
41121251|NCT04915261|BEHAVIORAL|Lenient Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
40753931|NCT04168138|DRUG|rhTPO|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)\>20\*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet\>50\*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
40753932|NCT04026516|DEVICE|CAVA Device|The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
40753933|NCT04874441|DIAGNOSTIC_TEST|Diagnosis strategy based on C. glabrata / krusei PCR|For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
40753934|NCT05702619|DRUG|Optional non-IMP pimonidazole|patients will be asked to ingest an oral formulation of pimonidazole hydrochloride (HCl) (Oral HypoxyprobeTM-1). Pimonidazole HCl is a marker for hypoxia in tumour tissue when ingested as an encapsulated solid. Following oral administration, pimonidazole distributes throughout the body where it covalently binds to normal and tumour tissues that have regions of low oxygen concentrations (pO2 of ≤ 10 mmHg at 37oC). The tissue binding can be visualised by immunohistochemistry / light microscopy. The capsules are to be taken within 8-16 hours (optimal timepoint 12 hours) before the planned first biopsy within Arm 1 and before radical prostatectomy for patients in Arm 2. If the patient refuses the pimonidazole, forgets to take it, or if it is not available, the patient can still participate in the study and their samples will be stained for hypoxia post-biopsy.
41121252|NCT04915261|BEHAVIORAL|Strict Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
41121253|NCT04919057|DEVICE|GelPOINT®|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
41121254|NCT05391061|DRUG|Abrocitinib|Tablets
41273591|NCT02440750|DRUG|Dienogest|21 days administration of dienogest 2 mg/die
40926523|NCT00246571|DRUG|Chemotherapy|"The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~1. Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~2. Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~3. Docetaxel - 75-100 mg/m2 every 3 weeks~4. Paclitaxel - 175-200 mg/m2 every 3 weeks~5. Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~6. Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248."
40926524|NCT05232370|DRUG|Angiotensin converting enzyme inhibitor|Angiotensin-converting enzyme inhibitors after Kidney Transplant
40926525|NCT05232370|DRUG|Angiotensin Receptor Blockers|Angiotensin receptor blockers after Kidney Transplant
40926526|NCT04548492|OTHER|Survey|to assess and validate how healthcare professionals can trigger or inhibit the use of modern technology applications in home isolation
40926527|NCT02427178|BIOLOGICAL|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
40926528|NCT01961583|DRUG|18F-Fluciclatide|"Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).~Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy"
40926529|NCT05391191|DEVICE|MitrAssist TRISKELE® transcatheter aortic valve system|Patients were treated with MitrAssist TRISKELE® transcatheter aortic valve system
40926530|NCT01135667|DRUG|clopidogrel|clopidogrel 150 mg once daily for 30 days
41121255|NCT04663698|OTHER|Baseline|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
41121256|NCT04663698|OTHER|MESH-Resistor 5|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow
41121257|NCT04663698|OTHER|MESH-Resistor 10|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow
41121258|NCT04663698|OTHER|Perforated Resistor 7|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow
41453437|NCT02046122|DRUG|Cytarabine|"Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
40926531|NCT01135667|DRUG|Prasugrel 10 mg|Prasugrel 10 mg once daily for 30 days
40926532|NCT03033147|DRUG|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|2 gm of amoxicillin/ clavulanic acid combination orally 30 minutes before root canal treatment
41121259|NCT04663698|OTHER|Perforated Resistor 11|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow
41273592|NCT02440750|DRUG|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
40926533|NCT03033147|DRUG|Oral placebo|placebo 30 minutes before root canal treatment
41273593|NCT02943395|OTHER|E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement|
41273594|NCT02943395|OTHER|E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement|
41273595|NCT05532397|DRUG|QPOP category 1|combination regimens with published data in the setting of gliomas
41273596|NCT05532397|DRUG|QPOP category 2|combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
40753935|NCT05702619|DIAGNOSTIC_TEST|CT-guided Bone Biopsy|A CT-guided biopsy of a bone metastasis that is deemed to be easy to biopsy and in an area without major risk for pathological fracture or bleeding will be taken during the biopsy visit. Patients will receive routine local anaesthetic of the region to be biopsied followed by thorough disinfection of the biopsy site with antiseptic wipes. Patients will be asked to fast on the day of the procedure and to have an intravenous cannula inserted to allow the use of medication causing minimal sedation (for example midazolam and/or fentanyl) during the procedure if required to alleviate discomfort or pain.
40753936|NCT05702619|DIAGNOSTIC_TEST|TRUS-guided Targeted Transperineal Prostate Biopsy|Transperineal Prostate Biopsy will be performed following standard clinical practice of local department. This will include pre-operative oral analgesia and prophylactic antibiotic treatment according to local hospital policy for transperineal prostate biopsies.
40753937|NCT05702619|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy will be performed according to standard of care robotic approach and as relayed to the patient by the attending urologic surgeon. The side effects of the surgery are the ones reported in the literature and the latest participant information leaflet provided prior patient consent (e.g. risk of erection disfunction, incontinence, etc.).
40753938|NCT05702619|DIAGNOSTIC_TEST|Whole-body MRI|Whole-body MR imaging (wbMRI) will be performed once, before or after the biopsy study visit, depending on available examination slots in the Department of Radiology. WbMRI images will allow comparison of the numbers of bone metastases detected by routine bone scan and wbMRI for sensitivity assessment of both techniques for oligometastatic disease.
40753939|NCT05702619|DIAGNOSTIC_TEST|Prostate MRI scans|Patients within Arm 2 will be offered the option to undergo additional MR imaging of the pelvis in addition to any standard of care imaging acquired. In patients who agree to undergo additional scans, MRI scans will be performed on 2 occasions prior to the radical prostatectomy. MRI scans will be acquired on either the MR sim diagnostic scanner, on the MR Linac scanner or on both.
41273597|NCT05011084|DEVICE|Game Ready Cryotherapy with Compression Group|Instead of using the traditional ice-pack cryotherapy (without compression), patients randomized into this group will use the Game Ready device, which uses cryotherapy with compression, during their post-operative treatment care.
41273598|NCT05011084|OTHER|Control Cryotherapy Group|Patients randomized to the control group will use the standard of care, which is using traditional cryotherapy (i.e., an ice pack without compression)
41273599|NCT06227403|BEHAVIORAL|Leadership, Engagement, and youth Activism Program with Mindfulness|The Leadership, Engagement, and youth Activism Program with Mindfulness intervention (LEAP-M) was designed and co-created with youth to improve youth wellbeing by enhancing civic engagement and leadership opportunities and by developing mindfulness in day-to-day life. LEAP-M seeks to foster these improvements in youth of color as a strategy to combat structural racism encountered at school- and neighborhood-levels and to increase youth mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
41273600|NCT06227403|BEHAVIORAL|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential transition skills and digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
41273601|NCT06544239|BEHAVIORAL|Virtual reality basketball asymmetric training|This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
41273602|NCT06544239|BEHAVIORAL|Traditional basketball asymmetric training|This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
40753940|NCT05702619|OTHER|Baseline bloods - for germline testing|"Arm 1 -~* 1-2 x 3.5mL blood samples collected into EDTA tubes for germ line DNA extraction and processing to PBMC for banking and future profiling of immune cell populations~* 1 x 10mL serum tubes for future, biobank related research projects, ie lipidomics, metabolics and microRNA analysis~ARM 2 -~A blood sample (maximum 20ml) will be taken for standard of care blood tests prior to prostatectomy including Full Blood Count, Renal Function and PSA. At the same time these standard of care bloods are taken, additional bloods - a maximum of 30ml - will be taken for research purposes as required for the following downstream analysis:~* Germ line DNA extraction and optional processing to PBMC for banking and future profiling of immune cell populations~* Biobank related research projects, ie lipidomics, metabolics and microRNA analysis"
41121260|NCT05948592|BIOLOGICAL|TP-102|Patients randomised to TP-102 will receive 1 (one) mL of IP solution, applied topically per cm3 of target ulcer. The titre of each bacteriophage in TP-102 is 1x109 PFU/mL (\>1x108 PFU/mL and \<1x1010 PFU/mL). All patients randomised to TP-102 will receive the same concentration per mL. TP-102 will be applied to the target ulcer using a syringe without a needle. The volume of TP-102 to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
41121261|NCT05948592|OTHER|Placebo|Patients randomised to placebo, the volume calculated to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
41121262|NCT04372316|DRUG|methylcobalamin|methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks
41273603|NCT03582111|OTHER|Study of medical records|Study of medical records
41273604|NCT01587950|DRUG|Potassium Nitrate|250 μL of Potassium nitrate solution (either 5% or 2.5%)
41273605|NCT01587950|DRUG|Placebo|Sterile Water
41273606|NCT01780233|DRUG|Fentanyl 400 µg sublingual spray|
41121263|NCT01598259|DRUG|Melatonin|po 1 hour before bedtime
41121264|NCT01598259|OTHER|placebo|po, 1 hour before bed
41273607|NCT01780233|DRUG|Actiq® 400 µg transmucosally|Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
41273608|NCT01780233|DRUG|Fentanyl citrate injection 100 µg intravenously|
40753941|NCT05702619|OTHER|Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1|2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
40753942|NCT05702619|OTHER|Post-pimonidazole bloods for CTCs and ctDNA|ARM 1 - 2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
40753943|NCT05803993|PROCEDURE|Fecal microbiota transplantation (FMT) Single FMT infusion|Single FMT infusion via colonoscopy
40753944|NCT02104011|DRUG|Propranolol|
41121265|NCT00825630|DRUG|Lansoprazole (Lanton)|Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection
40753945|NCT01032278|OTHER|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
40753946|NCT01032278|BEHAVIORAL|Questionnaires|Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
40753947|NCT06278298|DEVICE|Shockwave|CDT and different dose of shockwave
40753948|NCT06278298|OTHER|CDT|CDT
40753949|NCT04860583|OTHER|Renal ultrasound|
40753950|NCT03954873|OTHER|Glucagon-like peptide 2|Human glucagon-like peptide 2
41121266|NCT00825630|DRUG|Omeprezole (Losec)|Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection
41121267|NCT00825630|DRUG|Pantoprazole(Controloc)|Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection
41121268|NCT00825630|DRUG|Esomeprazole (Nexium)|Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
41121269|NCT00421070|PROCEDURE|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
40753951|NCT03954873|OTHER|Saline|Placebo
40753952|NCT03954873|OTHER|Glucose|20% (w/v) glucose infusion for regulating plasma glucose
40753953|NCT03954873|OTHER|Insulin|Actrapid (insulin) for lowering plasma glucose
40753954|NCT02617212|PROCEDURE|Implant surgery|The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.
40753955|NCT02617212|DEVICE|Three abutment dis-/reconnections.|At the active comparator arm, each implant will receive a titanium healing abutment during the surgery, according to manufacturer's recommendations. Three dis-/reconnections of abutments will be performed after the soft tissue healing period: the first, after 8 weeks, for adjustment of the emergence profile by healing abutment changing; the second, 10 weeks after surgery, for intra-oral prosthetic abutment selection; and the third, 12 weeks after surgery, for the prosthetic abutment definitive connection with the manufacturer recommended torque.
40753956|NCT02617212|DEVICE|No abutment dis-/reconnections.|Each experimental arm implant will receive its definitive prosthetic abutment at the surgical procedure. The manufacturer recommended torque will be applied so that no disconnection of the abutment will occur during and after completion of the treatment. The abutment will receive healing caps, which shall remain in position until the end of 12 weeks after surgery.
40753957|NCT00170820|DRUG|Everolimus|
40753958|NCT00198614|DRUG|Carvedilol versus Metoprolol|
40753959|NCT00649571|DRUG|Doxycycline Monohydrate Tablets (100 mg|100mg, single dose fasting
40753960|NCT00649571|DRUG|Adoxa Tablets 100 mg|100mg, single dose fasting
40753961|NCT05259540|DRUG|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously
40753962|NCT04918914|DRUG|Dapsone 100 MG|Dapsone 100-200 md orally daily, along with Cimetadine 400 mg PO TID
40753963|NCT03043469|OTHER|Short-form survey instrument|Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
40753964|NCT03043469|OTHER|Demographic data|height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
41121270|NCT02317874|DRUG|Carboplatin|Given IV
41121271|NCT02317874|DRUG|Paclitaxel|Given IV
41121272|NCT02317874|DRUG|Talazoparib|Given PO
41273609|NCT01780233|DRUG|Naltrexone 50 mg|Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
41273610|NCT03502512|OTHER|Questionnaire Administration|Ancillary studies
41273611|NCT03502512|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery with REVOLVE technique
41273612|NCT03502512|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery with PureGraft technique
41273613|NCT01383031|PROCEDURE|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
41273614|NCT01383031|PROCEDURE|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
41273615|NCT04680117|OTHER|Blood collection|"Blood collection with samples of 15ml max by subject (case or control) at J0, M6 and M12:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max"
41446500|NCT06627296|OTHER|Exercise Training (Control Group)|"Patients in the control group will have face-to-face exercise programs with a physiotherapist for a total of 24 sessions of 15 repetitions 3 days a week for 8 weeks. Exercises will be performed 3 days a week with a physiotherapist. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises.~Exercise training includes intrinsic and extrinsic muscle strengthening, wrist stabilization exercises, dart exercises, wrist neuromuscular exercises using different materials, reactive muscle control, perturbation exercises.~Exercises will be at the limit of pain. Until the 6th month, overloading, strong gripping, weight transfer, rotations and lifting heavy objects should be avoided. Rehabilitation with functional range of motion is important. Exercises will be performed with a physiotherapist 3 days a week. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises."
40753965|NCT03043469|OTHER|Hospital Anxiety and Depression Scale|Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
41121273|NCT04445870|OTHER|data record|Data record on registers without medical files
41121274|NCT01723631|DEVICE|Trap Myelin Test|
41121275|NCT01255670|DRUG|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
41121276|NCT01232712|BIOLOGICAL|ImMucin, hGM-CSF|"* Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin~* After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.~* In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected."
41121277|NCT00257348|DRUG|Capecitabine|
41121278|NCT00257348|DRUG|Docetaxel|
41273616|NCT04680117|OTHER|Saliva sample|Saliva sample by subject at J0
41273617|NCT04680117|OTHER|Nasal|Nasal brushing by subject at J0
41273618|NCT03680937|OTHER|Gavi , Merck® (automated vitrification instrument)|Gavi, Merck ® permits semi-automated vitrification with closed system.
41273619|NCT03680937|OTHER|Vitrification|Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
41273620|NCT04841226|DEVICE|Long-term indwelling Foley catheter|Foley Catheter inserted for up to 28-days
41273621|NCT01097044|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
40753966|NCT03043469|OTHER|Nijmegen questionnaire|Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
40753967|NCT03043469|OTHER|The Self-evaluation of breathing questionnaire|Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
41121279|NCT01724242|DRUG|Vaginal DHEA|
41121280|NCT01724242|DRUG|Placebo|
41121281|NCT03421678|DIAGNOSTIC_TEST|Urine Sample|One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine
41121282|NCT00996229|BEHAVIORAL|Caloric restriction|20-30% CR for 6 months
41121283|NCT00996229|DIETARY_SUPPLEMENT|Omega-3 (fish oil capsules)|2g/day DHA/EPA capsules for 6 months
41121284|NCT00996229|DIETARY_SUPPLEMENT|Placebo|Daily corn oil capsules for 6 months
41121285|NCT00996229|DIETARY_SUPPLEMENT|Resveratrol|daily resveratrol for 6 months
41273622|NCT01097044|DRUG|Placebo|One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
41273623|NCT00620061|DRUG|Lubiprostone 24|24 mcg capsules for oral administration
41273624|NCT03939208|BEHAVIORAL|BRISC|
41273625|NCT03939208|BEHAVIORAL|SAU|
41273626|NCT00433238|BEHAVIORAL|Participants will be screened for depression and cognitive impairment, then receive screening results.|
41273627|NCT01200433|DRUG|dexmedetomidine|Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
41273628|NCT01200433|DRUG|propofol|Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
41273629|NCT05519631|OTHER|electroencephalogram|The EEG is the recording of electrical activity in the brain in different regions of the cortex. The capture of electrical signals is performed by attaching electrodes to the surface of the scalp. As the EEG signal has an amplitude in microvolts (µVpp) it is necessary to use amplifiers, leaving the signal possible to be registered. The electrode-electrolyte interface is very important and must be able to provide a good connection between the skin and the conductive material of the electrode, otherwise the EEG signal, in addition to being contaminated by noise, may suffer distortion.
41273630|NCT05071898|DRUG|Semaglutide Pen Injector [Ozempic]|Participants will receive subcutaneously injected semaglutide (0.25 mg/wk) for 4 weeks followed by semaglutide (0.5 mg/wk) for an additional two weeks.
41273631|NCT05809973|DIAGNOSTIC_TEST|VISA tool|Validation of VISA
41273632|NCT03522129|DRUG|CT1812|Active Study Drug
41273633|NCT03522129|DRUG|Placebo|Non-active study drug
41273634|NCT04345185|OTHER|Infant egg consumption (i.e., age of introduction and frequency of intake)|
41273635|NCT02730156|OTHER|Altitude exposure|Altitude exposure
41273636|NCT02292849|BEHAVIORAL|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
41273637|NCT02292849|OTHER|Standard Mental Health Referral|Standard mental health referral to a community agency
41273638|NCT01261403|BIOLOGICAL|PDA001|Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).
41273639|NCT01261403|DRUG|Vehicle Controlled Placebo|"Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7"
41273640|NCT04159090|DIAGNOSTIC_TEST|F18-PSMA|Patients with moderate or high risk of prostate cancer
41273641|NCT04994925|OTHER|Control ready meal|Supermarket brand lasagne ready meal
41273642|NCT04994925|OTHER|Test ready meal|The Slimming World lasagne ready meal
41273643|NCT04526184|PROCEDURE|aerobic exercise with blood flow restriction|Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.
41273644|NCT04792229|OTHER|Whole Body Viberation|WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
41273645|NCT04964011|OTHER|Board game intervention|In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
41273646|NCT00521781|DRUG|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
41273647|NCT00521781|DRUG|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
41273648|NCT00521781|DRUG|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
41273649|NCT02917590|OTHER|Dual-task obstacle crossing training|Obstacle crossing simultaneously a color word stroop task training
41273650|NCT02917590|OTHER|Single-task obstacle crossing training|Obstacle crossing training
41273651|NCT01397019|DRUG|Oxaliplatin, irinotecan, 5-FU & leucovorin|FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
41273652|NCT05485207|DRUG|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
41273653|NCT02179840|PROCEDURE|Mechanical ventilation adjustment|Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
41273654|NCT03240900|DEVICE|Electrical Stimulation|Electrical stimulation - a needle attached to an cathode polarity will be placed within the intercostal space near the 4th intercostal nerve. A second needle attached to the anode polarity will be inserted into the serratus anterior muscle. Both electrodes will then be attached to a Grass SD9 stimulator and the voltage and frequency of the stimulation will be titrated to the point where contraction of the intercostal muscles is palpable. It will be maintained at this level for one hour at which point the wires will be removed. This technique is part of the standard of care for peripheral nerve surgeries of the extremities and is proven to be safe in humans.
41273655|NCT03240900|PROCEDURE|Placebo|This breast will receive no electrical stimulation; the mastectomy and reconstruction will proceed with no intervention.
41273656|NCT01825902|DRUG|fluorine F 18 fluorothymidine|Undergo 18F-FLT PET
41273657|NCT01825902|RADIATION|fludeoxyglucose F 18|Undergo 18F-FDG PET
41273658|NCT01825902|PROCEDURE|positron emission tomography|Undergo 18F-FLT PET and 18F-FDG PET
41273659|NCT01825902|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
41273660|NCT01825902|OTHER|laboratory biomarker analysis|Correlative studies
40926534|NCT00353756|DRUG|C326, IL-6 Inhibitory Avimer protein|
41273661|NCT05766579|DEVICE|Elastic-compressive stockings|Use of Elastic-compressive stockings at 21 mmHg and 32 mmHg.
41273662|NCT05418764|OTHER|Miyamodel Training|standardized training by performing five hysterectomies on the Miyamodel with a trainer who is a sub-PI at each institution
41273663|NCT01588821|DRUG|Cabozantinib|60 mg daily by mouth
41273664|NCT04947202|DEVICE|Hernioplasty|Hernioplasty is the repair of the defect using mesh patches.
41273665|NCT04453111|BIOLOGICAL|Placenta-derived MMSCs|Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells
40753968|NCT03043469|OTHER|six-minute exercise test|Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
41121286|NCT05027607|PROCEDURE|Bascom's pit-pick|Pit-pick procedure of simple pilonidal sinus disease in the natal cleft in a day-surgery setting.
41273666|NCT04453111|BIOLOGICAL|Bone marrow-derived MMSCs|Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells
41273667|NCT04453111|DRUG|Hyalgan 20 mg in 2 ML Prefilled Syringe|Hyaluronic Acid 20 mg
41446501|NCT06627296|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation
41121287|NCT05167656|OTHER|Intraoral manual therapy|Six intraoral manual therapy sessions based on ischemic compression and pain pressure release of the temporomandibular region muscles, applied bilateral.
41121288|NCT05167656|OTHER|Extraoral manual therapy|Six extraoral manual therapy sessions based on ischemic compression, pain pressure release and pressure sliding of the temporomandibular region muscles, applied bilateral.
41121289|NCT05167656|OTHER|Exercise and counselling|"Information about etiology, contributing and related factors, natural history and prognostic of the pathology of temporomandibular disorders.~Counselling based on: diet, habits like tabacism, stress and anxiety control, physical activity and awareness of dental clenching.~Exercise daily program based on active and passive mobility of the temporomandibular joint, stretching exercises and self massage."
41121290|NCT04970446|DRUG|Antibiotics|All patients will receive a one week course of antibiotic therapy.
41121291|NCT04970446|DIETARY_SUPPLEMENT|Dietician designed diet|All patients will be recommended dietary modification 3 weeks prior to, and during, the study.
41121292|NCT04970446|DRUG|FMT|Anaerobically prepared stool. Dosing will vary according to mode of administration.
41121293|NCT04970446|OTHER|Placebo|Placebo will contain food colourant, 0.9% normal saline and glycerol.
41121294|NCT04459897|OTHER|Evaluation of epithelioid and gigantocellular granulomas within the hepatic parenchyma by histopathology approach.|: Retrospective histopathology review done by an expert of histopathology analysis (DAPI cell labeling). Analysis of the percentage of epithelioid cells and the percentage of gigantocellular granulomas in hepatic parenchyma of patient diagnosed for Hepatitis Granulomatous
41446502|NCT05367440|DRUG|AZD5305|Patients will receive an oral dose of AZD5305 once daily
40753969|NCT03043469|OTHER|Indirect calorimetry|Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
40753970|NCT03043469|OTHER|Oxygen saturation monitoring|The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
40753971|NCT03043469|OTHER|Heart rate variability analysis|Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
41121295|NCT05287217|OTHER|Comparison of medication administration for pain control|Measuring pain control following FESS surgery
41121296|NCT05198531|DRUG|TQB2858 Injection|TQB2858 Injection, a bifunctional fusion protein against Programmed death ligand 1 (PD-LI) and transforming growth factor-β (TGF-β). TQB2858 Injection blocks the PD-1/PD-L1 pathway and neutralizes TGF-β in the tumor microenvironment.
41121297|NCT05198531|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
41121298|NCT05198531|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride, cell cycle-specific antimetabolites, mainly acting on tumor cells in the DNA synthesis phase (S phase cell). Under certain conditions, it can prevent the progression from G1 phase to S phase.
41273668|NCT05412706|DRUG|Niraparib|"Patients will receive Niraparib 200-300 mg orally as an individualized weight and platelet-based, flat-fixed, continuous daily dose.~Niraparib will be administered orally once daily in 28-day cycles."
41273669|NCT00260221|BEHAVIORAL|using VR hypnosis/distraction and audio hypnosis|a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control
41273670|NCT05174091|OTHER|Functional Movement Screen, Spinal Mouse, Core Endurance, Funcitonal Capacity|Due to the difficulties in the diagnosis and treatment of NSLBP, it has been causing many problems such as limitation of activation, socioeconomic burden, and biopsychosocial factors for years. It is thought that the effectiveness of treatment will increase if the needs and problems of individuals with NSLBP are clearly revealed beforehand. Although there are studies on core endurance and physical capacities in individuals with NSLBP in the literature, the number of studies examining functional movement analysis and spinal mobility in individuals with NSLBP is very few. Therefore, aim of this research is to compare functional movement analysis, physical capacity, core endurance, and spinal mobility in individuals with and without NSLBP. With the results we will reveal, we aim to contribute to the evaluation and treatment of patients with NSLBP. Thus, the negative effects of this pathology, which causes serious labor and financial losses, can be minimized.
41273671|NCT02536586|DRUG|LY3023414|LY3023414 administered orally.
41273672|NCT03933943|DRUG|LY3361237|Administered SC
41273673|NCT03933943|DRUG|Placebo|Administered SC
41121299|NCT05198531|DRUG|Cisplatin Injection|After cisplatin enters cells, it reacts with DNA to form cross-links between two points or two strands in DNA, thereby inhibiting DNA replication and transcription, resulting in DNA breaks and miscoding.
41121300|NCT03201822|OTHER|100 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 100 cocoa flavanols/70kg BW.
41273674|NCT04046861|DIETARY_SUPPLEMENT|ascorbic acid,|The vitamin C group will get high dose of intravenous vitamin C (ascorbic acid) before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
41446503|NCT05367440|DRUG|Enzalutamide|Patients will receive an oral dose of Enzalutamide once daily
41446504|NCT05367440|DRUG|Abiraterone Acetate|Patients will receive an oral dose of Abiraterone Acetate once daily
41273675|NCT04046861|OTHER|Placebo (saline)|The placebo group will get saline before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
41121301|NCT03201822|OTHER|200 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 200 cocoa flavanols/70kg BW.
41121302|NCT03201822|OTHER|400 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 400 cocoa flavanols/70kg BW.
41121303|NCT03201822|OTHER|1000 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 1000 cocoa flavanols/70kg BW.
41121304|NCT01553058|DRUG|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
41121305|NCT01553058|DRUG|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
41121306|NCT01553058|OTHER|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
41121307|NCT01558986|PROCEDURE|Cefazolin|Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
41121308|NCT01558986|PROCEDURE|Sterile water|Patients received sterile water only within 30 minutes prior to skin incision
41121309|NCT05877469|OTHER|Mat pilates Training|In this group 22 patients will perform mat pilates training. Patients will be asked to stay comfortable while performing mat pilates exercies that involve different types of movements of whole body like leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, roll down and crisscross to improve the core strength. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
41121310|NCT05877469|OTHER|Functional Training|In this group 22 patients will perform functional training. Patients will be instructed to perform their daily living movements like squatting, reaching, or even carrying a heavy object. These exercises typically use the whole body and emphasize core strength and stability. Functional training typically uses weight-bearing activities that work the core muscles in the torso. the functional movements include involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet and squats. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
41121311|NCT05103358|DRUG|nab-sirolimus|Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
41121312|NCT01206504|BIOLOGICAL|MGAWN1|Humanized monoclonal to West Nile virus. Dose=30mg/kg
41273676|NCT04531384|DEVICE|robot-assisted rehabilitation intelligent treatment|robot-assisted rehabilitation psychotherapy
41273677|NCT04531384|OTHER|standard psychotherapy treatment|standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions
41273678|NCT02575430|OTHER|No treatment: retrospective chart review|
41273679|NCT06074003|OTHER|Seated Rest (Non-exercise control)|Sitting for 30 minutes
41273680|NCT06074003|OTHER|High-intensity interval exercise|Performing a single session of high-intensity interval exercise on a cycle ergometer
41273681|NCT01419509|GENETIC|DNA methylation analysis|
41273682|NCT01419509|GENETIC|microarray analysis|
41273683|NCT01419509|GENETIC|polymerase chain reaction|
41121313|NCT00141349|DRUG|UK-369,003|
41121314|NCT03094182|DRUG|Iron Isomaltoside 1000|Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.
41121315|NCT03094182|DRUG|Normal saline|Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
41121316|NCT05520658|DRUG|combined digoxin and furosemide|one session every 2 weeks for maximum 6 sessions
41121317|NCT05520658|DRUG|5 fluorouracil|5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
41121318|NCT00262301|DRUG|recombinant human C1 inhibitor|IV
41121319|NCT00262301|DRUG|Placebo|IV
41121320|NCT01675895|DRUG|Levobupivacaine lidocaine spinal anesthesia|Spinal anesthesia
41121321|NCT01675895|DRUG|levobupivacaine Spinal anesthesia|spinal anesthesia
41121322|NCT02711436|DEVICE|Computed Tomography Scan|
41121323|NCT02711436|DEVICE|Fast Magnetic Resonance Imaging|
41273684|NCT01419509|OTHER|laboratory biomarker analysis|
41273685|NCT06545227|DEVICE|continuous blood glucose monitoring in a subset of women (n=25) in the early monitoring group.|To continuously monitor blood glucose from baseline to 28 weeks to determine if if there is hyperglycaemia in a subset of women (n=25)
41273686|NCT06545227|OTHER|Collection of urine, maternal blood at baseline and 28 weeks in a subset of women (n=25)|To study maternal metabolome
41273687|NCT06545227|OTHER|Collection of umbilical cord blood, placental samples and cord tissue in a subset of women (n=25)|To study mesenchymal stem cell differentiation, change in fetal epigenetic and placental signalling pathways.
41273688|NCT06545227|OTHER|Maternal and neonatal outcome data collection for all women in the study|Data for maternal and neonatal outcomes will be collected
41273689|NCT01348230|OTHER|Urine samples|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
41273690|NCT00607048|DRUG|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
40753972|NCT03043469|OTHER|Continuous measurement of arterial blood pressure|Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
40753973|NCT03043469|DIAGNOSTIC_TEST|Lung function test|Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
40753974|NCT03043469|OTHER|Respiratory muscle function|Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
40753975|NCT03043469|OTHER|Manual assessment of respiratory motion|Measure of the movements of the thorax while the participant is breathing (non-invasively).
40753976|NCT03043469|OTHER|Breath-hold test|Holding the breath a few times for as long as possible.
40753977|NCT03043469|OTHER|Physical Activity monitoring|Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
40753978|NCT03043469|OTHER|Asthma Control Questionnaire|Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
40753979|NCT00803907|DRUG|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
40753980|NCT00212355|DRUG|NPC-02|zinc acetate
40753981|NCT05082155|DRUG|Bupivacaine 0.25%|Bupivacaine 0.25% will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
40753982|NCT05082155|DRUG|Normal Saline|Normal saline will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
40753983|NCT04375215|PROCEDURE|Selective caries removal|After caries removal restoration of tooth will be performed
40753984|NCT04375215|PROCEDURE|Stepwise caries removal|After caries removal restoration of tooth will be performed
40753985|NCT05507229|BIOLOGICAL|Hillchol vaccine|HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
40753986|NCT05507229|BIOLOGICAL|Shanchol Vaccine|Shanchol™ (Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine)
40753987|NCT00926705|DRUG|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
40753988|NCT00926705|DRUG|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
40753989|NCT01433003|PROCEDURE|Plasma Exchange|Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
40753990|NCT03907566|OTHER|The Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals|Swallowing function will be evaluated by the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
40753991|NCT00252473|DEVICE|MedTec S-frame Immobilization Masks|
40753992|NCT02944461|DRUG|Dapsone 7.5 % gel|Dapsone gel 7.5% applied once daily to truncal acne
40753993|NCT03325257|OTHER|Routine care|This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.
41121324|NCT00739531|DEVICE|Exhaled nitric oxide (eNO)|Subjects will perform a controlled breath maneuver using both the Apieron and NIOX devices. The devices will measure nitric oxide in the subjects' exhaled breath.
41273691|NCT00607048|DRUG|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
41273692|NCT00239850|BEHAVIORAL|lifestyle changes|
40753994|NCT02725606|BIOLOGICAL|Pegylated Recombinant Human G-CSF|subcutaneous
41273693|NCT06041243|OTHER|Game-Based Exercises|Exercises aimed to improve postural balance with four different games
41273694|NCT00594477|RADIATION|IMRT|
41121325|NCT03809416|DEVICE|Lasers|Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
41273695|NCT06226402|DRUG|Hypertonic saline 3% nebulizer|Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
41273696|NCT06226402|DRUG|Intravenous hypertonic saline 3%|Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
41273697|NCT01202461|PROCEDURE|Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation|"all pars plana vitrectomy were accompanied with removal of retinal Internal limiting membrane (ILM) around fovea in round fashion with a dimension of approximately 2 disc diameters.~IVTA was introduced at the end of surgery or on the next day (4mg in 0.1cc). Two weeks afterward, fluorescein angiography guided macular laser photocoagulation which consisted of direct photocoagulation on leaking microaneurysms and application of grid pattern laser was undertaken."
41273698|NCT01097928|PROCEDURE|Catheter directed debulking of Pulmonary Embolus|A catheter will be used to break up the pulmonary embolism
41273699|NCT05374486|DEVICE|NeuroExo co-robot neurorehabilitation system|In this longitudinal study, adult subjects with hemiparesis due to chronic stroke will receive robotic-assisted upper-arm training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG). After one screening visit, two baseline visits for EEG signal screens, six onsite training sessions will be provided with the NeuroExo system, followed by 60 home therapy sessions (2 sessions per day, 5 days per week for 6 weeks). If the participant have completed at least 50 sessions of neurotherapy at home, the participant will complete a set of measurements to assess function of the affected upper arm and brain activity within 3 days after the last session for post-assessment visit, and one-month post follow-up session. The total amount of time for this study is 16-20 weeks.
41273700|NCT02553837|BIOLOGICAL|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
41273701|NCT06159478|DRUG|Binimetinib 15 MG|Binimetinib 45mg is orally administered twice daily.
41273702|NCT04845217|DRUG|Peppermint oil|Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
41273703|NCT04845217|DRUG|Coconut Oil|Enteric coated coconut oil taken by mouth three times daily for 8 weeks
40753995|NCT02725606|BIOLOGICAL|GW003|subcutaneous
40753996|NCT04781985|PROCEDURE|cystoscopy|extraction of the bladder stone via suprapubic incision
40926535|NCT03750370|DEVICE|Doppler ultrasound|Colored Doppler Sonography is well established to illustrate microvascularity and therefore perfusion of the testis. The arterial flow velocities (peak systolic velocity \[PSV\] and end diastolic velocity \[EDV\]) and the resistance indices against this flow (resistive index \[RI\] and pulsatility index \[PI\]) in the testis can be measured with this technique.
41121326|NCT03809416|OTHER|Platelets Rich Plasma|Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).
41121327|NCT03809416|COMBINATION_PRODUCT|Lasers plus Normal Saline Solution|Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
41273704|NCT02207907|DRUG|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
41273705|NCT02207907|DRUG|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
41273706|NCT00289640|DRUG|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
41273707|NCT00289640|DRUG|Ipilimumab|IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
41273708|NCT00289640|DRUG|Ipilimumab|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
41273709|NCT02158078|DEVICE|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
41446505|NCT05367440|DRUG|Darolutamide|Patients will receive an oral dose of Darolutamide twice daily
41446506|NCT05367440|DRUG|Apalutamide|Patients will receive an oral dose of Apalutamide once daily
40753997|NCT05241210|DEVICE|AI program for colonoscopy|Provides real-time feedback on the endoscopist moniter during colonoscopy.
40753998|NCT03355261|PROCEDURE|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
40753999|NCT03355261|PROCEDURE|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
41273710|NCT03819075|DEVICE|Lightwalker Laser (Fotona)|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units. The laser protocol will follow the instructions of the manufacturer (TwinLight protocol) and consists of degranulation of necrotic soft tissue and bone, implant surface disinfection and creating spot bleeding in bone with Er:YAG and deep disinfection and biomodulation with Nd:YAG.
41273711|NCT03819075|OTHER|standard|Granulation tissue elimination, mechanical instrumentation of the implant surface and curettage of intraosseous or supracrestally bone defects will be accomplished using plastic curets, under irrigation with sterile saline solution. Cotton pellets soaked in sterile saline solution will be use to clean debris and remains of removed tissue.
41273712|NCT03056443|DEVICE|Continuous Positive Airway Pressure (CPAP)|The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
41273713|NCT04011202|BEHAVIORAL|Virtual reality gaming program (VR-gaming program)|Participants in the VR-gaming program will receive three 20-30 minutes sessions of VR-gaming per week for the duration of their inpatient stay. Participants will select VR games/program in categories of: Relaxation; Leisure sport and activities; or Action/adventure. The VR-gaming program will be implemented one-on-one, face-to-face by a clinician using the commercially-available Oculus Go system.
41121328|NCT03260140|BEHAVIORAL|behavioral lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention
41121329|NCT03484988|DIETARY_SUPPLEMENT|Placebo oil|The participants were asked to take corn oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
41121330|NCT03484988|DIETARY_SUPPLEMENT|Echium oil|The participants were asked to take echium oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
41121331|NCT03484988|DIETARY_SUPPLEMENT|Mixed oil|The participants were asked to take mixed oil(echium oil,camelina oil,safflower oil) twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
41121332|NCT04820686|DRUG|VBR|VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
41121333|NCT04820686|DRUG|AB-729|AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
41121334|NCT04820686|DRUG|SOC NrtI|Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
41121335|NCT04248998|DIETARY_SUPPLEMENT|Fasting-mimicking diet|Cyclic, 5-day, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low protein diet every three weeks
41273714|NCT02909153|DRUG|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
40754000|NCT03355261|PROCEDURE|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
40926536|NCT02387476|DEVICE|FRESCA mask first night|FRESCA nasal mask first night
41121336|NCT04248998|DRUG|Metformin|Metformin 850 mg twice a day
41121337|NCT04248998|DRUG|Preoperative chemotherapy|"Chemotherapy will consist of:~* four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~* twelve consecutive cycles of weekly paclitaxel 80 mg/mq"
41121338|NCT01266122|BEHAVIORAL|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
41121339|NCT03813498|BEHAVIORAL|HCV articles|The intervention group receive a targeted short article on HCV from WeChat weekly.
41121340|NCT03813498|BEHAVIORAL|general health articles|The control group receive a general health article with no mention of HCV from WeChat weekly.
41121341|NCT03778242|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
41273715|NCT05284695|PROCEDURE|Bariatric surgery|Patients undergoing elective bariatric surgery
41273716|NCT03248921|PROCEDURE|cardiac surgery|cardiac surgery including non-emergency, elective coronary artery bypass grafting surgery with or without valve surgery, aortic or mitral valve surgery
41273717|NCT03506932|DIETARY_SUPPLEMENT|Untreated|Bread made with 20% yellow pea flour that was untreated.
41273718|NCT03506932|DIETARY_SUPPLEMENT|Heat treated with 0% moisture|Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
41273719|NCT03506932|DIETARY_SUPPLEMENT|Heat treated with 10% moisture|Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
41273720|NCT03506932|DIETARY_SUPPLEMENT|Wheat|Bread made with 100% wheat
40754001|NCT03355261|PROCEDURE|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
41121342|NCT03778242|DRUG|normal saline|2 placebo ampoules to TA in 100 ml saline by slow infusion
40754002|NCT03931512|DEVICE|transcranial direct current stimularion|aplication of direct current stimulation on the scalp wiht sponge electrodes
40754003|NCT00337688|DEVICE|isometric joystick|isometric joystick
41121343|NCT01041612|DEVICE|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
41121344|NCT01041612|DEVICE|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
40754004|NCT02083263|DEVICE|Bilevel|3 months
40754005|NCT02083263|DEVICE|PEP mask|3 months
41121345|NCT00809939|DRUG|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
41121346|NCT00809939|DRUG|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
41121347|NCT00809939|DRUG|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
41121348|NCT00809939|DRUG|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
41121349|NCT01890811|DIETARY_SUPPLEMENT|Boost High Protein|Subjects will receive stable amino acid isotopes IV and will receive Boost High Protein with added isotopes to measure anabolic response to a meal.
41273721|NCT03440944|DEVICE|Ultrasound Guided Peripheral IV Catheter|Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.
41273722|NCT03440944|DEVICE|Midline Catheter|Patients randomized to this group will receive a midline catheter. The catheter is 10cm in length.
41273723|NCT03190525|OTHER|Quality of life questionnaires|QLQ-C30
41273724|NCT03871907|BEHAVIORAL|Digital technology|Lifestyle-Focused Text Messaging
41273725|NCT05792826|OTHER|BSZY Cream|The patients receive BSZY Cream twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
41273726|NCT05792826|OTHER|emulsion matrix|The patients receive emusion matrix twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
41273727|NCT00384579|DRUG|Botulinum toxin B|Botulinum Toxin B
40754006|NCT05754775|BEHAVIORAL|Calorie restriction via total food replacement|Restricted foods designed by a clinical nutritionist that delivers to home for diabetic patients.
40754007|NCT05667402|DRUG|TBF regimen|The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.
40754008|NCT05667402|DRUG|modified BuCY2 regimen|The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.
40754009|NCT00712075|BEHAVIORAL|CBSST+PDA|PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
40754010|NCT00712075|BEHAVIORAL|Cognitive Behavioral Social Skills Training|Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
40754011|NCT00712075|BEHAVIORAL|PDA-only|To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
41121350|NCT00204646|DRUG|Adriamycin|
41121351|NCT00204646|DRUG|Ifosfamide|
41273728|NCT00384579|DRUG|Placebo|Placebo
40754012|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 50U|"Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline"
40754013|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 100U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
40754014|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 200U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
40754015|NCT01568229|DRUG|AMG 747|Three dose levels once-daily oral administration
40754016|NCT01568229|DRUG|Placebo|Once-daily oral administration
40754017|NCT01466231|DRUG|Everolimus|Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
40926537|NCT02387476|DEVICE|CPAP Mask first night|CPAP Nasal Mask first night
41121352|NCT00204646|DRUG|Etoposide|
41121353|NCT00204646|DRUG|Carboplatin|
41121354|NCT04547413|BEHAVIORAL|STI/HIV Intervention Behavioral Intervention Program|In addition to standard of care STi/HIV counselling, participants in the intervention arm will also attend a 2-hour educational class and will receive monthly SMS/text messages to reinforce the content of the class.
41121355|NCT06233435|BEHAVIORAL|PADSS|Observe PADSS after total knee arthroplasty at 6 and 24 hours
41273729|NCT01974817|BIOLOGICAL|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
41273730|NCT03010540|DRUG|MORPHINE PLUS FENTANYL|Effect Of Morphine Plus Fentanyl On Emergence Delirium
41273731|NCT03010540|DRUG|Fentanyl|Effect Of Fentanyl Only On Emergence Delirium
41273732|NCT05119387|OTHER|Observation|Observation of genetic characteristics
41121356|NCT01636687|DRUG|Placebo|2 injections of placebo to secukinumab 150mg per dose
41121357|NCT01636687|DRUG|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
41121358|NCT01636687|DRUG|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
41121359|NCT03107767|PROCEDURE|PRO-malleol algorithm|An evidence based algorithm for ankle fractures
41273733|NCT03168516|DEVICE|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)|Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol
41273734|NCT04826900|PROCEDURE|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 200 units to 500 units. The dose range of each target muscle is as below: 20 and 75 units for flexor carpi ulnaris and flexor carpi radials; 12.5-35 units per fascicle in the flexor digitorum sublimis and flexor digitorum profundus (maximum dose: 120 units for each of these muscles); 10-35 units in the flexor pollicis longus; 25-100 units in the brachioradial ; 50-200 units in the biceps brachii; and 25-75 units in the pronator teres
41273735|NCT04826900|OTHER|Robotic therapy (RT)|A wearable robotic hand system will be used in this study. The robotic hand system consisted with a wearable exoskeletal hand, sensor glove, and a control box. On the exoskeletal hand, there are five actuators on each of finger structure that can provide external power to bring individual finger moving. The sensor glove has five sensors that can detect the finger's posture during movement and then manipulates exoskeletal hand via the control box. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeleton hand, and the unaffected hand does the certain transitive and intransitive tasks as the mirror group, and then makes the affected hand do the same movements driven by the exoskeleton robotic hand.
41273736|NCT04826900|OTHER|Robotic mirror therapy (RMT)|Wearable robotic hand system and mirror system will be used in this group.. The patients in the group will wear the robotic hand to do the mirror therapy. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeletal hand, a mirror box with a mirror will be placed in the patient 's midsagittal plane beside the unaffected hand to block his or her view of the affected hand. The patient's unaffected hand does the certain transitive and intransitive tasks and the patient will be instructed to look at the reflection of the unaffected hand in the mirror as if it is the affected hand (the visual input). At the same time the affected hand will be passively moved by the exoskeleton robotic hand which is under the .control of the unaffected hand.
41121360|NCT03763604|DRUG|Abemaciclib|Administered orally.
41273737|NCT04826900|OTHER|Functional task training|After either 45 minutes of RT or RMT, all participants receive 15 minutes of training in functional tasks. The functional tasks included taking up and holding bowl or using eating utensils , bringing a cup for drinking, drying sucks by clips, open ing or closing door , turning on or off the light, cleaning the table or window and so on . The functional tasks training will be bases on the needs and ability of patients.
41273738|NCT02295202|DEVICE|CPAP (REMstar System One Plus - Philips Medical Systems)|Standard device for treating obstructive sleep apnea.
41273739|NCT02295202|DEVICE|Nasal strips|
40754018|NCT05299970|OTHER|Fermented porridge|A millet porridge (fermented or not, depending on group allocation) serving will be provided to participants daily, for consumption. consumption will be directly observed.
40754019|NCT00693303|BEHAVIORAL|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
40754020|NCT01215162|RADIATION|Intra-operative radiation to tumor bed|IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
40754021|NCT04985656|DRUG|Pevonedistat|Pevonedistat IV infusion
41273740|NCT06296563|PROCEDURE|HAIC|FOLFOX-hepatic artery infusion for 2 times.
41273741|NCT06296563|DRUG|Adebrelimab|Adebrelimab 1200mg, ivgtt, d1, q3w,up to one year of use at most.
41273742|NCT06296563|DRUG|Apatinib|Apatinib 250mg, po, qd,q3w,up to one year of use at most.
41273743|NCT02457234|BEHAVIORAL|Cultural immersion|The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
41446507|NCT01758601|OTHER|Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)|
41446508|NCT01758601|OTHER|Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood|
40754022|NCT04985656|DRUG|Decitabine|Decitabine tablets
41446509|NCT00834132|DRUG|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fed
41446510|NCT00834132|DRUG|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fed
40754023|NCT04985656|DRUG|Cedazuridine|Cedazuridine tablets
40754024|NCT02441816|DRUG|Aflibercept|
40926538|NCT03739242|DIETARY_SUPPLEMENT|Nutraceutical combination|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
40926539|NCT03739242|OTHER|Placebo|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
41121361|NCT01218490|PROCEDURE|ovarian cancer surgery|
41121362|NCT06070337|DEVICE|H-Guard|A novel Haemodialyser primer used for one treatment only
41121363|NCT00295724|DRUG|Bicifadine|
41121364|NCT02164240|DRUG|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
41273744|NCT02675777|OTHER|Quality Improvement Intervention|"Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:~1. Identification of a clinical champion and Local Implementation Team.~2. Participatory Design.~3. Training primary care providers and Medical Assistants.~4. EHR clinical decision support tools~5. Weekly facilitated Local Implementation Team meetings.~6. Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.~7. Learning sessions for primary care providers during implementation.~8. Social worker use of an EHR registry with weekly supervision.~9. Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)"
41273745|NCT01977287|DEVICE|Functional Electrical Stimulation|
40754025|NCT02441816|OTHER|Extend Treatment|In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
40754026|NCT02975453|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
40754027|NCT05137613|OTHER|One visit root canal retreatment|The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation
40754028|NCT05137613|OTHER|Two visit root canal retreatment|The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
40754029|NCT04268966|DRUG|Brincidofovir|
40754030|NCT03105401|OTHER|Assessment of hallucinations in Parkinson's disease|Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
40754031|NCT02680496|DEVICE|Lokomat|A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
40754032|NCT02680496|OTHER|Treadmill|A single walking trial in which the patient walks on a treadmill for 30 minutes at comfortable walking speed (body-weight supported if necessary)
41273746|NCT01977287|DEVICE|Ankle Foot Orthosis|
41273747|NCT05213871|OTHER|Instrument-assisted soft tissue mobilization|For IASTM, the subject will be seated in a comfortable position. The subject's forehead will be rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2T blade will be cleaned with an alcohol pad. The M2T blade will be used, at an angle of 45 without causing discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. Subjects will be instructed to put an ice pack on the area if they feel any burning sensations after the session. This procedure will be repeated twice a week for four weeks.
40754033|NCT02680496|OTHER|Overground|A single walking trial in which the patient walks overground for 30 minutes at comfortable walking speed (body-weight supported if necessary)
40926540|NCT04458688|OTHER|Observation of Ocrelizumab as Treatment in RRMS Patients|It is decided by the patient and their physician to begin taking ocrelizumab PRIOR to study enrollment. The study is only observing the effects of ocrelizumab as a pre-decided treatment option for a patient's MS.
41273748|NCT05213871|OTHER|Myofascial release therapy|Firstly, the subject will lay supine with no pillow under his/ her head then the subject will rotate his/her head and neck away from the side which will be treated. Therapist will sit or stand at the corner, edge or top of the treatment table and therapist will place one hand proximal to the shoulder with skin on skin and therapist's fingers pointing towards the subject's elbow on the same side. Other hand of the therapist will be placed inferior to the subject's jaw (body of the mandible), using it as a handle, with fingers pointing towards the top of the subject's head. Then therapist will lean into the subject to the tissue depth barrier, wait and follow each subtle release three-dimensionally. Therapist should avoid forcing the tissue or slipping or gliding over the skin. The technique should be applied for at least five minutes for optimal results. This procedure will be repeated twice a week for four weeks.
41273749|NCT05213871|OTHER|Postural correction exercises (PCE)|Postural correction exercises will be applied for patients in groups A and B. This program will be conducted according to the protocols of exercise will be performed as 3 sets of 10 repetitions each for 2 times/ week for 4 weeks. The patients will be instructed to continue the exercises as a daily home program to influence the self-correction kinesthetic awareness. Exercises will be performed while the patients in a neutral sitting posture
41273750|NCT00543179|DRUG|Somatuline (Lanreotide Autogel®)|
41273751|NCT05983640|OTHER|Video|Just in time training video on hands only CPR
40754034|NCT05863364|DRUG|Low-dose of Rifaximin|The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks
40754035|NCT05863364|DRUG|Conventional dose of Rifaximin|the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks
40754036|NCT01358305|OTHER|Protein Blend|Single intake of approximately 20 grams of total protein
41121365|NCT02164240|DRUG|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
41121366|NCT03177044|BEHAVIORAL|Behavioural treatment|2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
40754037|NCT00553475|DRUG|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
41121367|NCT01356069|OTHER|SB-APP|"SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms"
41121368|NCT01356069|OTHER|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
41121369|NCT02639091|DRUG|BAY 94-9343|"In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)"
41121370|NCT02639091|DRUG|Pemetrexed|Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
41121371|NCT02639091|DRUG|Cisplatin|Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
41121372|NCT01839331|BIOLOGICAL|4 mL injection of Ampion|4 mL Injection of Ampion
41121373|NCT01839331|BIOLOGICAL|10 mL Injection of Ampion|10 mL Injection of Ampion
41121374|NCT01839331|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
41121375|NCT01839331|DRUG|10 mL Injection of Placebo|10 mL Injection of Placebo
41121376|NCT03714815|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
41121377|NCT06215053|OTHER|erector spine plane block|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (MARCAİNE), 10 ml will consist of lidocaine 2% (Aritmal), and 10 ml will consist of physiological saline.
41121378|NCT03066115|DRUG|L-NMMA|See arm description.
41121379|NCT03066115|DRUG|Ketorolac|See arm description.
41121380|NCT03066115|DRUG|Ascorbic Acid|See arm description.
41121381|NCT03066115|PROCEDURE|Intravenous Catheter|Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
41121382|NCT03066115|PROCEDURE|Transcranial Doppler Ultrasound|MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
41121383|NCT02207972|DEVICE|Use of Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
41121384|NCT02207972|PROCEDURE|No ultrasound used|Palpation of anatomical landmarks is used for placement of labor analgesia
41121385|NCT01510977|DRUG|polyethylene glycol, Bisacodyl|After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
41121386|NCT01510977|DRUG|polyethylene glycol|Immediately after first colonoscopy failure, polyethylene glycol 2L addition
41121387|NCT02145143|DRUG|Vemurafenib|
41121388|NCT02145143|DEVICE|serial 124I PET/CT|
41121389|NCT02145143|DRUG|thyrotropin alpha|
41121390|NCT06393595|DIAGNOSTIC_TEST|surface enhanced Raman Spectroscopy|"Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried . The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope . The spectra were excited by laser module with a center wavelength of 785 nm. Each of the obtained spectra was a discrete set of 1700 parameters .~For skin Raman spectroscopy an experimental portable RS system was used, including a 785 nm diode laser , a portable commercially available Raman probe to filter the collected scattered radiation, and a portable spectrometer (QE65Pro, Ocean optics, Florida, USA). The scattered radiation was collected from the upper 1 to 2 mm thick skin layer. The Raman spectral range was 780-1000 nm with resolution of 0.2 nm. Each spectrum was recorded at an exposure time of 20 seconds with three-fold accumulation."
41121391|NCT02773693|BEHAVIORAL|Cognitive Processing Therapy-Cognitive Only (CPT)|Twice weekly CPT over 6 weeks.
41121392|NCT02773693|BEHAVIORAL|Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)|Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
41121393|NCT02773693|BEHAVIORAL|Continuation Cognitive Processing Therapy-Cognitive Only (CPT)|Once weekly continuation CPT over 6 weeks.
40754038|NCT00553475|DRUG|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
40754039|NCT00553475|DRUG|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
40754040|NCT04468009|BIOLOGICAL|Convalescent plasma|Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies
41121394|NCT06369701|DEVICE|Compressive tissue floss band|Compressive tissue flossing (CTF) is a compressive technique that uses a latex elastic band to compress the tissues and restrict the circulation of fluids in the targeted area for a short time. CTF acts on the mechanoreceptors in the underlying fascial layers, causing blood reperfusion of the compressed tissue, and/or causing fascial shearing and the sliding potential of the fascia to be restored (Starrett \& Cordoza, 2015). Proposed benefits from references include improving joint mobility in the joints of the limbs (Starrett \& Cordoza, 2015), improving muscular power, and decreasing pain with motion (Angelopoulos et al., 2021) (Cage et al., 2022) (Jianhong et al., 2021).
41121395|NCT02764944|PROCEDURE|simple non-exposure EFTR|This intervention includes the steps of laparoscopic seromuscular suturing with a barbed suture thread (V-Loc), which results in inversion of the stomach wall; EFTR of the inverted stomach wall from inside the stomach; and finally, endoscopic mucosal suturing with endoloops and clips.
41121396|NCT05374681|OTHER|Medical treatment|Medical treatment alone
41121397|NCT05374681|OTHER|Surgical treatment|Surgical treatment alone
41121398|NCT05374681|OTHER|embolization of the MMA|The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
41121399|NCT03565445|DRUG|ASP1948|Intravenously (IV)
41121400|NCT03565445|DRUG|nivolumab|Intravenously (IV)
41273752|NCT05983640|OTHER|AHA course|AHA Heartsaver CPR course
41273753|NCT05937477|OTHER|Fitbit smartwatch|Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.
41273754|NCT04537611|DIAGNOSTIC_TEST|dHb contrast and gadolinium contrast imaging|see arm description
41273755|NCT01510327|DEVICE|PROMUS Element Everolimus-Eluting Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
41273756|NCT01510327|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
41121401|NCT03565445|DRUG|pembrolizumab|Intravenously (IV)
41121402|NCT00826657|DIETARY_SUPPLEMENT|Vitamin B12|500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
41121403|NCT00826657|DIETARY_SUPPLEMENT|placebo|placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
41273757|NCT01510327|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
41273758|NCT00811252|DRUG|Placebo|capsules; daily; orally
41273759|NCT00811252|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
41273760|NCT00811252|DRUG|Duloxetine|encapsulated tablets; daily; orally
41273761|NCT02800174|DEVICE|Smart nitinol stent implantation|Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
41273762|NCT02800174|DRUG|antiplatelet drug|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
41273763|NCT00391599|PROCEDURE|enema|
40754041|NCT02731768|BEHAVIORAL|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
41121404|NCT03416712|OTHER|Screening survey and accompanying handout for resources|Intervention group will be completing a survey of social determinants of health and providing resources based on caregiver responses.
41273764|NCT04695509|DRUG|"moderate propofol sedation (Bispectral index monitoring 70-90; The Richmond Agitation and Sedation scale (RASS) -2 - -3"|Two peripheral venous blood catheters are placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, noninvasive blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol light-moderate sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting the enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
41446511|NCT01906372|DRUG|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
41446512|NCT05602142|DRUG|[11C]CPPC PET ligand|Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).
41446513|NCT02767804|DRUG|X-396 (ensartinib)|oral ALK inhibitor
41446514|NCT02767804|DRUG|crizotinib|oral ALK inhibitor
41446515|NCT05620511|BEHAVIORAL|Mindfulness based stress reduction|Mindfulness based stress reduction v.s.Relaxation
40754042|NCT02731768|BEHAVIORAL|Social support-enhanced|Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
40754043|NCT02731768|DEVICE|Fitbit Zip|
41121405|NCT01285986|PROCEDURE|Vein collar at the distal anastomosis|Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
41273765|NCT04695509|DRUG|"deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)"|Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
40754044|NCT02731768|DEVICE|Digital body weight scale|
40754045|NCT00000738|DRUG|Nimodipine|
40754046|NCT00000738|DRUG|Zidovudine|
40754047|NCT00083109|DRUG|Fluorouracil|Given IV
41121406|NCT02954211|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere."
41121407|NCT02954211|BEHAVIORAL|Physical therapy|Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
41121408|NCT04313816|OTHER|questionnaire|no intervention at all apart from filling a brief questionnaire
41121409|NCT04544904|DEVICE|PAARx|Prescription Physical Activity Programming Application
41121410|NCT04544904|DEVICE|JM|Joint Management (JM) web-based joint management resource.
41121411|NCT03840421|DRUG|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
41121412|NCT03840421|DRUG|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
41121413|NCT03840421|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor
41121414|NCT03840421|DRUG|cisplatin|IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
41121415|NCT02717117|OTHER|Soup meal|Soup meal as above
41121416|NCT02738320|OTHER|NHCPlus|A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
41121417|NCT02000349|OTHER|PGD|PGD using Next generation sequencing
41121418|NCT05437653|OTHER|Nutritional Drink A|300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
41121419|NCT05437653|OTHER|Nutritional Drink B|300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)
41121420|NCT06261606|OTHER|Hybrid strategy|"A hybrid strategy inclusive of:~1. A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects~2. Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 \[33\]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them.~3. Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors~4. Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131"
41446516|NCT04938635|DRUG|VIT-2763 60 mg QD|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
40754048|NCT00083109|OTHER|Pharmacological Study|Correlative studies
40754049|NCT00083109|DRUG|Suramin|Given IV
40754050|NCT05592730|GENETIC|AMHR2 polymorphism in blood|1 tube of blood taken at the first application
40754051|NCT05592730|GENETIC|AMHR2 polymorphism in granulosa cell|Extraction of granulosa cell from the follicle fluid obtained during OPU
40754052|NCT05297019|PROCEDURE|Hyperbaric Oxygen Therapy|hyperbaric oxygen therapy
40754053|NCT04394000|OTHER|thromboprofylaxis protocol|This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
40754054|NCT04394000|OTHER|standard protocol|This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
40754055|NCT05616780|OTHER|Physiological test|Lung volume measurements will be obtained using nitrogen washout and body plethysmography
40754056|NCT05548777|DRUG|Andexanet alfa|Andexanet alfa
40754057|NCT05548777|DRUG|4F-PCC|Four-Factor Prothrombin Complex Concentrate (4F-PCC)
41273766|NCT03746691|DRUG|Citalopram HCl|Citalopram HCl IV 20 mg in 100 ml saline will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
41273767|NCT03746691|DRUG|Placebos|Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
41121421|NCT04083664|DIAGNOSTIC_TEST|NGAL and Hepcidin|Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia
41121422|NCT01644916|PROCEDURE|Integrated care|Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
41121423|NCT01644916|PROCEDURE|Usual control|Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
41121424|NCT01153880|DRUG|Retapamulin|Prescription sales claim of retapamulin
41273768|NCT00238264|RADIATION|radiation therapy|Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
41121425|NCT01153880|DRUG|Co-prescription of retapamulin and topical mupirocin|Same day prescription sales claims for retapamulin and topical mupirocin
41121426|NCT00535145|DRUG|Treatment as usual (TAU), Paliperidone ER|Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
41121427|NCT04691635|OTHER|evaluation of movements with sensors|evaluation of movements with sensors
41121428|NCT03059212|DEVICE|rTMS|High frequency rTMS for 3 to 10 min to increase the excitability of cortex.
41121429|NCT03059212|BEHAVIORAL|Cognitive training program|A rehabilitation protocol that facilitates attention, memory, execution.
41121430|NCT01620203|OTHER|No intervention/treatment is given|
41121431|NCT02450344|BEHAVIORAL|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
41121432|NCT02450344|BEHAVIORAL|Passive health promotion|An electronic package of information related to alcohol
41273769|NCT04746326|PROCEDURE|Failure conservative treatment|Surgery was performed in patients who failed conservative treatment.
41273770|NCT04746326|PROCEDURE|Surgery|Surgery was performed in patients who had generalized peritonitis and perforation.
41121433|NCT02236793|DRUG|BioChaperone PDGF-BB|
41121434|NCT02236793|OTHER|Standard of Care|
41121435|NCT00834951|RADIATION|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
41121436|NCT05073562|DIETARY_SUPPLEMENT|Iron and folic acid (IFA) supplementation|Weekly IFA supplementation for duration of the study.
41121437|NCT05073562|BEHAVIORAL|Targeted nutrition education|Structured nutrition education package delivered at household level by trained Community Health Assistants (CHAs)
41121438|NCT05073562|DRUG|Mebendazole Pill|One-time deworming treatment with mebendazole.
41121439|NCT05073562|OTHER|Standard nutrition services|Basic nutrition services currently provided at the health facility and at community level in Liberia
41273771|NCT04746326|OTHER|Conservative treatment|Conservative treatment was performed in patients who had no generalized peritonitis and perforation.
41273772|NCT06454864|BEHAVIORAL|Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
41273773|NCT06454864|BEHAVIORAL|Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
41273774|NCT06454864|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching.
41273775|NCT06051630|DRUG|Lidocaine intravenous|Perioperative lidocaine intravenous administration
41273776|NCT06051630|DRUG|Serum saline intravenous|Perioperative serum saline intravenous administration
40754058|NCT01292473|DRUG|Placebo|Placebo was supplied lyophilized in vials.
40754059|NCT01292473|DRUG|Omalizumab|Omalizumab was supplied lyophilized in vials.
40754060|NCT03681093|DRUG|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily administered orally as tablet
41121440|NCT05346523|DEVICE|Isabel Pro - The DDx generator (CDDS)|Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
41121441|NCT00541333|DRUG|Copaxone Injection|
41446517|NCT04938635|DRUG|VIT-2763 60 mg BID|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
40754061|NCT03681093|DRUG|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily administered orally as tablet
40754062|NCT03681093|DRUG|Placebo|Placebo once daily administered orally as tablet
40754063|NCT03576820|DRUG|Lidocaine|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive intranasal lidocaine via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
40754064|NCT03576820|DRUG|Placebo|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive 0.9% sodium chloride solution via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
40754065|NCT01340118|DRUG|Budesonide|once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
40754066|NCT05470725|DRUG|CIN-107|A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).
40754067|NCT00655798|DIETARY_SUPPLEMENT|Placebo|plain yogurt and capsules containing cellulose
40754068|NCT00655798|DIETARY_SUPPLEMENT|Plain Yogurt + mix of anti-oxidants capsules|plain yogurt and capsules containing mix of anti-oxidants
41121442|NCT03209778|OTHER|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
41121443|NCT00495677|DRUG|PF-00232798|Solution, 20 mg. once daily, 10 days
41121444|NCT00495677|DRUG|PF-00232798|Solution, 150 mg. once daily, 10 days
41121445|NCT00495677|DRUG|PF-00232798|Solution, 5 mg. once daily, 10 days
40754069|NCT00655798|DIETARY_SUPPLEMENT|Yogurt containing Lactobacillus helveticus|Yogurt containing the probiotic Lactobacillus helveticus
40754070|NCT00655798|DIETARY_SUPPLEMENT|Yogurt containing Bifidobacterium animalis ssp.|Yogurt containing the probiotic Bifidobacterium animalis ssp.
40754071|NCT03377127|BEHAVIORAL|Pharmacy Managed Diabetes Clinic (PMDC)|The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.
40754072|NCT03377127|OTHER|Standard of Care (SOC)|Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
40754073|NCT01898130|BIOLOGICAL|bevacizumab|Given IV
40754074|NCT01898130|PROCEDURE|quality-of-life assessment|Ancillary studies
41121446|NCT00495677|DRUG|PF-00232798|Solution, 40 mg. once daily, 10 days
41121447|NCT00495677|DRUG|PF-00232798|Solution, 300 mg. once daily, 10 days
41121448|NCT00495677|DRUG|PF-00232798|Solution, 400 mg. once daily, 10 days
41446518|NCT04938635|DRUG|VIT-2763 120 mg BID|Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
41446519|NCT04938635|DRUG|Placebo|Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
41446520|NCT00594035|DEVICE|Spinal Sealant System|
40754075|NCT02398474|DRUG|TFP block ropivacaine|
41121449|NCT04356820|OTHER|acupressure|Data collection took about 10 to 15 minutes. Then the woman invited to the examination room was asked to pull one of the envelopes with the names of the groups. The women who pulled the acupressure envelope were given a semi-sitting position where the acupressure application can feel comfortable and the researcher can easily apply the acupressure points. Before the acupressure application, massage was applied for 30 seconds to ensure circulation. Afterwards, 90 seconds consecutive pressures were applied to the specified acupressure points in a certain order (SP 6, Li 4), taking into account the direction of the meridian. After the examination, the pain formed during the gynecological examination was evaluated by applying the Short Form-McGill Pain Questionnaire without leaving the examination room
41121450|NCT00737542|DRUG|lidocaine|
41121451|NCT00737542|DRUG|NACL 0.9%|
41121452|NCT02014831|DRUG|Cetuximab|"Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
41121453|NCT02014831|DRUG|TIP|"The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
41121454|NCT02646358|DRUG|Vepoloxamer|
41121455|NCT04918758|DEVICE|Purastat Arm|"Generic name of device and principal intended use(s):~Still PuraStat from a CE mark perspective. PuraStat is an aqueous self-assembling peptide solution of 2.5% concentration RADA16~Indication for use:~PuraStat is indicated for haemostasis in the following situations encountered during surgery, when haemostasis by ligation or standard means is insufficient or impractical:~* Bleeding from small blood vessels and oozing from capillaries of the parenchyma of solid organs. Oozing from vascular anastomoses~* Bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures~* Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon."
41121456|NCT04918758|DRUG|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks, this is standard care in patients with haemorrhagic radiation proctopathy in the short term
41121457|NCT02879760|BIOLOGICAL|Ad-MAGEA3|Intramuscular injection
41121458|NCT02879760|BIOLOGICAL|MG1-MAGEA3|Intravenous infusion
41121459|NCT02879760|BIOLOGICAL|Pembrolizumab|Intravenous infusion
41121460|NCT01991301|DRUG|carfilzumib|carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
41121461|NCT05050383|OTHER|Pharyngeal Manometry|Catheters will be passed into the nose and advanced to the pharynx to measure airway pressures during drug-induced sleep.
41121462|NCT05050383|OTHER|Submental Ultrasound|Ultrasound of airway soft tissues
41121463|NCT01053793|OTHER|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
41121464|NCT03000101|OTHER|100% pomegranate juice|125 mL of 100% pomegranate juice twice daily for 12 weeks
40754076|NCT02398474|DRUG|ropivacaine infiltration of the iliac crest bone|
40754077|NCT00060385|DRUG|CHOP regimen|
40754078|NCT00060385|DRUG|EPOCH regimen|
41121465|NCT03000101|OTHER|placebo beverage|125 mL of placebo beverage twice daily for 12 weeks
41121466|NCT01647581|DEVICE|Hemoclip Placement|Placement of hemoclip at polypectomy site for polyps at least 1cm in size
41121467|NCT01647581|DEVICE|NO hemoclip placement|No hemoclip placement (placebo / sham)
41121468|NCT02198469|DRUG|Er:YAG AFL-PDT|Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
41121469|NCT02198469|DRUG|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
41121470|NCT00094016|DRUG|beclomethasone dipropionate|
41121471|NCT01203306|DRUG|bevacizumab + octreotide LAR + capecitabine|long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
41121472|NCT03108703|RADIATION|SBRT|35-40 Gy delivered in 5 fractions
41121473|NCT01087359|DRUG|Melatonin|100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
41121474|NCT00525486|DRUG|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
41121475|NCT05920642|DRUG|Intrathecal morphine administration|Administration of morphine into the spinal canal.
40754079|NCT00060385|DRUG|cyclophosphamide|
40754080|NCT00060385|DRUG|doxorubicin hydrochloride|
40754081|NCT00060385|DRUG|etoposide|
40754082|NCT00060385|DRUG|prednisone|
40754083|NCT00060385|DRUG|vincristine sulfate|
40754084|NCT00060385|RADIATION|radiation therapy|
40754085|NCT06176131|OTHER|Telemedicine-based cross-sector collaboration for patient management|Telemedicine support from the hospital-based cardiology heart-failure team is provided on demand defined by the needs from Primary Care and from the patient rather than plain guideline-based targets
41121476|NCT05920642|DRUG|Parenteral administration of analgesics|Standard postoperative pain management of analgesics using parenteral route of administration.
41121477|NCT00031694|DRUG|paclitaxel|Given IV
41121478|NCT00031694|DRUG|bryostatin 1|Given IV
41121479|NCT06522711|DEVICE|Virtual reality headset|A brief overview of all three virtual reality scenarios will be shown in a consolidated video prior to letting the participant select the preferred scenario. The participant's choice of scenario will then be documented. Once paravertebral blocks are completed and the participants are in supine position and the surgeon is ready to disinfect, the VR headset will be applied on the face of the participants in the intervention group and the chosen scenario will be started. If at any point the patient expresses a desire to stop using VR during the surgery, we will first offer them an alternate scenario. If they reiterate their willingness to stop, with or without having experienced the new scenario, the headset will be removed for the remainder of the surgery.
41121480|NCT06522711|OTHER|Standard of care|Standard of care in anesthesia with patient-controlled sedation.
41121481|NCT04884295|DRUG|XVR011|Single dose of XVR011 via intravenous (IV) infusion
41121482|NCT01625104|OTHER|Non Intervention|Business as usual
41121483|NCT01625104|OTHER|Agressive Intervention Process Improvement Strategies|
41121484|NCT04456751|OTHER|Redo op|Patients with a redo operation
41121485|NCT05010655|DEVICE|Use of Eko DUO Electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
41121486|NCT00086775|BIOLOGICAL|alemtuzumab|
41121487|NCT00086775|BIOLOGICAL|rituximab|
41121488|NCT00086775|DRUG|fludarabine phosphate|
41121489|NCT02703246|PROCEDURE|abdominal morcellation|patients will be randomized to receive abdominal morcellation
41121490|NCT02703246|PROCEDURE|vaginal morcellation|patients will be randomized to receive vaginal morcellation
41121491|NCT05984212|DRUG|Ultrasound guided rectus sheath block with dexmedetomidine|Intervention Group: Ultrasound guided rectus sheath block with 0.5% ropivacaine 20ml at each side (bilateral)
41121492|NCT05984212|DRUG|Ultrasound guided rectus sheath block with normal saline|Control Group: Ultrasound guided rectus sheath block with 0.9% normal saline 20ml at each side (bilateral)
41121493|NCT05634382|DRUG|Intravenous thrombolysis agents|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)
41121494|NCT05634382|PROCEDURE|endovascular thrombectomy|endovascular mechanical thrombectomy with nonspecific device
41121495|NCT04829604|DRUG|ARX788|The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269
41121496|NCT01849978|BEHAVIORAL|Newsletter about physical activity and breast cancer survivors|Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
41121497|NCT01849978|BEHAVIORAL|Changing your habits brochure|"Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA."
41121498|NCT01849978|BEHAVIORAL|Tips for making exercise enjoyable and personally-valued|Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
41121499|NCT01849978|BEHAVIORAL|Testimonials from breast cancer survivors|Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
41121500|NCT02764242|OTHER|Skin prick test|Skin prick tests to local and imported insect sting allergen with different concentration are performed.
41121501|NCT02764242|OTHER|sIgE measurement|sIgE levels to stinging insect allergen and their recombinant venom allergen are measured
41121502|NCT04699786|OTHER|Arm A , Arm B, Arm C, & Arm D|All arms will receive the same intervention, but at different time points. All arms will be offered the option to learn their research results in personalized five-year risk estimate of getting Alzheimer disease dementia. Arms A \& C participants will receive their risk estimate about two weeks after consent is signed and Arms B\& D will receive their risk estimate about one year after consent is signed. The risk estimate returned to participants is based on research results from individual genotyping results, imaging or plasma amyloid testing \& demographic characteristics. All arms will complete psychosocial and cognitive testing. Also, surveys used in this study will ask about participants' experiences and feelings after learning their risk estimate. All arms will receive follow up calls at one week post disclosure of the risk estimate and surveys two, six, and twelve months post disclosure. Arms A \& C will have extra surveys at twenty-four months post disclosure.
41121503|NCT00339131|DRUG|Ultratrace iobenguane I 131|
41446521|NCT00594035|DEVICE|Standard of care|Standard of care: devices intended to provide a watertight closure
41446522|NCT06007729|DRUG|HS-20093|Participants in all subjucts will receive HS-20093 at 10mg/kg
41273777|NCT05122325|DEVICE|Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device|"Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable)."
41273778|NCT05122325|DEVICE|Genital vibration with Ferticare 2.0® vibrator|Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
41273779|NCT05122325|DEVICE|TENS® EMS NMS60 device_sham intervention|"Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the intensity is decreased to lower the sensitive threshold of treatment."
41273780|NCT06095830|DIAGNOSTIC_TEST|Complete blood count|Complete blood count done on admission and on discharge for patients, from which the blood indices of systemic inflammation will be calculated and correlated with outcome
41273781|NCT02185391|PROCEDURE|Audience Response System|patients use during oral presentations an audience response system
41273782|NCT02185391|BEHAVIORAL|Telephone interview|patients receive motivational telephone interviews after their residence in rehabilitation clinics
41273783|NCT01113151|DIETARY_SUPPLEMENT|Mablet (Magnesium-supplement)|3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
41273784|NCT01113151|OTHER|Placebo|3 placebo tablets daily for 12 weeks
41273785|NCT04320836|PROCEDURE|Cervical epidural steroid injection|Interlaminar cervical epidural steroid injection with steroid and normal saline at C6-7 and C7-T1 (standard of care).
41273786|NCT04812561|DIETARY_SUPPLEMENT|Bronch™|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
41273787|NCT04812561|DIETARY_SUPPLEMENT|placebo|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
41273788|NCT01734148|BEHAVIORAL|Relax To Sleep Program|The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
41273789|NCT00006417|PROCEDURE|Stem cell transplantation|
41273790|NCT03866200|DRUG|resveratrol|125 mg/day or 5 ml once per day for 90 days
41273791|NCT03866200|DRUG|Placebo|5 ml once per day for 90 days
41273792|NCT03848819|DEVICE|VitaBreath device|The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
41273793|NCT04836286|BEHAVIORAL|Emotive Intelligent Spaces (EIS)|The EIS leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study11, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
41273794|NCT06070428|OTHER|PAC provision at hospital discharge|Patients randomized to receive the intervention will receive two PACs fitted with True HEPA filters.
41273795|NCT06070428|OTHER|Control non-intervention; PAC without filter|Patients randomized to the control non-interventional arm will receive two PACs with no filters inserted.
41273796|NCT02912364|DRUG|Eslicarbazepine|Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
41273797|NCT02912364|DRUG|Carbamazepine|Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
41273798|NCT05020379|PROCEDURE|Perioperative and postoperative multimodal analgesia|"Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.~The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day."
41273799|NCT05020379|PROCEDURE|ESP Block|Patients in the ESPB group will be placed in a sitting position. A convex probe ultrasound transducer will be placed in a longitudinal parasagittal orientation approximately 3 cm lateral to the spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep face of the erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day.
41273800|NCT04343950|BEHAVIORAL|SMS reminders to enhance colorectal cancer screening|"Cluster randomization instead of individual randomization will be used. The cluster will be invitation week.~Individuals assigned to the experimental arm with a wrong phone number will get a reminder letter (protocol analysis)."
41273801|NCT04343950|BEHAVIORAL|SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:|"Cluster randomization instead of individual randomization will be used. The cluster will be invitation week.~Individuals with a wrong phone number assigned to the experimental arm will not get any reminder (protocol analysis)."
41273802|NCT04343950|BEHAVIORAL|Invitation by SMS to previous participants in breast cancer screening:|Individual randomization. Women assigned to the experimental arm and with a wrong phone number will get an invitation letter (protocol analysis).
40754086|NCT00825175|BEHAVIORAL|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
41121504|NCT01338675|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
41121505|NCT02250118|DRUG|Bevacizumab|Intrapleural Bevacizumab
41121506|NCT06120049|DIAGNOSTIC_TEST|[18F]-MFBG PET CT|"\[18F\]-MFBG will be acquired at the Leuven University hospital on a GE MI4 PET/CT camera, with low dose CT and 120 MBq injected activity. Dynamic imaging between 0-60 minutes and 100-120 minutes (patients) and 0-70 minutes and 90-120 minutes (healthy volunteers).~Venous sampling between 5-120 minutes will be obtained through a second catheter, 6 venous samples will be taken.~In healthy up to 5 control subjects, full arterial sampling (0-120 minutes,) will also be done.~If patient comfort allows, after the dynamic cardiac scan 2 hours post-injection field dynamic scan, a fast late timepoint whole body PET/CT will be taken (2 min/bed position, 11 mAs low dose CT; estimated 10-12 minutes)."
41121507|NCT06120049|DIAGNOSTIC_TEST|[18F]-FE-PE2I PET CT or PET MRI|"\[18F\]-FE-PE2I will be performed at the University Hospital Leuven with the GE Signa simultaneous PET/MR with acquisition at 50-70 minutes postinjection or at the University Hospital in Gent using a Siemens PET/CT, GE MI4 PET/CT.~Injected activity: 120 MBq"
41121508|NCT06120049|DIAGNOSTIC_TEST|[123I]-MIBG SPECT CT|"\[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.~Injected activity: 111 MBq"
41273803|NCT02643550|BIOLOGICAL|Monalizumab|
41273804|NCT02643550|BIOLOGICAL|Cetuximab|
41273805|NCT02643550|BIOLOGICAL|Anti-PD(L)1|
40754087|NCT00825175|DEVICE|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
40754088|NCT05014490|DRUG|Exib 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug
40926541|NCT02642549|BEHAVIORAL|Girls for Health|"The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development."
40926542|NCT02814331|DEVICE|multimodal high-resolution EEG-NIRS|
40926543|NCT02513147|DRUG|Dolutegravir|
41273806|NCT00452712|PROCEDURE|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
41273807|NCT01217502|BEHAVIORAL|Self management program|Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months
41273808|NCT01217502|BEHAVIORAL|self management program|Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
41273809|NCT03202693|DRUG|PA-824|
41273810|NCT02916277|BIOLOGICAL|endocan|to look series Endocan level for 5 days in intubated patients
40754089|NCT05014490|DRUG|Arcoxia® 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
40754090|NCT03302663|DIAGNOSTIC_TEST|MRI scan|Addition of advanced imaging sequences for fetal MRI
40926544|NCT02513147|DRUG|PI|(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine
40926545|NCT02513147|DRUG|2 NRTI|
40926546|NCT02513147|DRUG|2 NRTI|
41121509|NCT06120049|DIAGNOSTIC_TEST|[18F]-MFBG PET dosimetry scans|"\[18F\]-MFBG will be acquired at the Leuven University hospital on a Siemens Truepoint or GE MI4 PET/CT camera or equivalent newer camera, with low dose CT and 120 MBq injected activity.~Three segments of consecutive whole-body scanning with increasing bed position duration will be carried out up to 3 half-lives (physical half-life T1/2 for 18F = 110 minutes): from 0-90 minutes (scan 1-8), 120-150 (scan 9) and 300-330 (scan 10) minutes post injection. In total 10 whole body biodistribution scans will be taken. Urine will be collected and its total activity measured to measure bladder excretion for correction of integrated bladder organ residence. Before each segment, a low dose whole body CT scan (11 mAs) will be acquired for attenuation correction and organ delineation."
40754091|NCT05813483|OTHER|Skinceuticals skin care product(CE)|fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
40754092|NCT05813483|OTHER|fraxel laser therapy|fraxel laser therapy combined with routine moisturizing and sun protection
40754093|NCT00366613|PROCEDURE|Cataract surgery with Perfect Capsule and Sodium Chloride|
41121510|NCT06014697|DIAGNOSTIC_TEST|Optical Coherence Tomography|Assessment of the lesion with a non-invasive OCT scan according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
41121511|NCT06014697|OTHER|Clinical assessment|Clinical assessment of the lesion by a dermatologist according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
41121512|NCT06247046|DRUG|Live SK08 powder|Oral Powder
41121513|NCT06247046|DRUG|Placebo|Oral Powder
41121514|NCT03949101|DRUG|Atropine Sulfate 1 % Ophthalmic Ointment and Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
41121515|NCT03949101|DRUG|atropine 0.01% eye drop|use one drop into subconjunctiva
41121516|NCT03991286|DIETARY_SUPPLEMENT|Astaxanthin 8 mg|experimental
41121517|NCT03991286|OTHER|placebo|Matching placebo pill
41121518|NCT00276796|DRUG|cisplatin|
41121519|NCT00276796|DRUG|paclitaxel|
41121520|NCT00276796|DRUG|topotecan hydrochloride|
41273811|NCT02193789|PROCEDURE|deployment of through the scope covered metallic stent at the stricture site|Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
40754094|NCT00682435|DRUG|Hydromorphone|"1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
40754095|NCT03041480|DIAGNOSTIC_TEST|serum lipid levels and Lp-PLA2|Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis
40754096|NCT06251830|DIAGNOSTIC_TEST|MRI exam with Magnetic Resonance Fingerprinting|"Acquisition of MRI data with technique Magnetic Resonance Fingerprinting"
41121521|NCT05119491|DEVICE|uitrasonography and spirometry|chest uitrasonography and spirometry
40754097|NCT05047887|PROCEDURE|Modified socket shield technique with autogenous dentin graft material (in one side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then Tooth particles will be demineralized using 2% HNO3 (El-Gomhouria CO. Egypt) for 20 minutes to expose the dentin organic matrix.
40926547|NCT04155411|DRUG|Dasatinib|70 mg of Dasatinib orally daily for 12 months
41121522|NCT06520449|DRUG|68Ga-NTA-476|The novel Prostate Specific Membrane Antigen (PSMA) targeting molecule, NTA-476, is comprised of a small peptide targeting moiety that is attached to a linker and dodecane tetraacetic acid (DOTA) cage which enables chelation of the radionuclide 68Ga for Positron Emission Tomography (PET) imaging.
41121523|NCT01872078|DRUG|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
41121524|NCT01872078|DRUG|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
41273812|NCT02193789|DEVICE|Covered Self-expandable Metallic Stents|
41273813|NCT00622193|DRUG|anamorelin HCl|50 mg tablet
41273814|NCT00622193|DRUG|anamorelin HCl|100 mg tablet
41121525|NCT02545920|OTHER|no intervention|observational study
41121526|NCT00316953|DRUG|dasatinib|Given orally
41121527|NCT00316953|OTHER|pharmacological study|Correlative studies
41121528|NCT00316953|OTHER|laboratory biomarker analysis|Correlative studies
41121529|NCT04134273|DRUG|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
41121530|NCT04134273|DRUG|Clindamycin|Clindamycin Phosphate topical gel 1%
41273815|NCT00622193|DRUG|placebo|placebo tablet
40754098|NCT05047887|PROCEDURE|Modified socket shield technique with alloplast graft material (in contralateral side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then alloplast graft will be used
41121531|NCT04134273|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
41121532|NCT05106946|BIOLOGICAL|ThisCART22 cells|0.2-60 x 10\^6 CAR T cells per kg body weight
41121533|NCT00359658|DRUG|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
41121534|NCT00359658|DRUG|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
41121535|NCT00359658|DRUG|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
41121536|NCT06434441|PROCEDURE|Autogenous bone augmentation|Maxillary alveolar bone reconstruction
41121537|NCT01886729|OTHER|transcranial direct current stimulation (tDCS)|
41121538|NCT01188655|DRUG|Enbrel|"The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits."
40754099|NCT06190665|DEVICE|DEB-TACE with visualable microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with visualable microspheres
40754100|NCT06190665|DEVICE|DEB-TACE with PVA microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with polyvinyl alcohol microspheres
40754101|NCT01634750|DRUG|ManNAc|Single dose
40754102|NCT00100477|DRUG|Topotecan|
40754103|NCT00100477|DRUG|Mitozantrone|
40754104|NCT00100477|DRUG|Etoposide|
41121539|NCT04989439|OTHER|Electrical impedance tomography and ultrasonography of the lung|Both EIT and LUS are non-invasive methods and do not pose any additional risk for the patient. The LuMon System with pediatric EIT belts (LuMon Belt, Sentec, Landquart, Switzerland) will be used. The belt will be placed on the thorax circumference of the infant and connected to the LuMonConnector (Sentec, Landquart, Switzerland). Small electrical currents (3 mA, 198 kHz) will be repetitively injected in rotation through adjacent electrode pairs, and voltage changes will be measured by all passive electrodes pairs (scan rate 48 Hz). Changes in lung electrical impedance will be continuously recorded for 5 minutes. EIT data will be analyzed off-line using Matlab (Mathworks, Natick, Massachusetts, USA). The regional tidal volume distribution, the homogeneity of tidal ventilation distribution, regional respiratory system compliance, and alveolar overdistension and collapse will be assessed. LUS will be performed by experienced users, with a 10 MHz linear transducer.
41121540|NCT01739244|DRUG|SYL040012|Ocular topical administration of SYL040012 for 14 consecutive days
40754105|NCT00447369|DRUG|Pregabalin|
40754106|NCT00447369|DRUG|sodium valproate|
41273816|NCT05408689|DEVICE|T1 TENS|The subjects in Group A will received TENS (Burst mode, 9 pulses per burst, pulse frequency =160Hz, burst frequency=2Hz, intensity was set to trigger visible muscular twitches). Two 2 x 3 cm electrodes was attached on T1 level with 2 cm from the spine. Previous study has shown that it was effective to improve the cognitive function in subjects with Alzheimer's disease.
41273817|NCT05408689|DEVICE|Concha TENS|The subjects in Group B will received TENS (25Hz, 0.5mA) on the concha of left outer ear. The electrical stimulation was generated by the portable neurostimulator (Nemos®, Cerbomed, Erlangen, Germany) and was delivered by a titanium electrodes positioning on top of a silicon earplug. Previous study has shown that it was effective to improve the Accelerate extinction memory formation and retention in healthy young adults.
41273818|NCT05408689|DEVICE|Control|The subjects in Group C will receive 30 min sham electrical stimulation on T1 by a placebo-TENS device. The Placebo-TENS was applied by an apparently identical TENS unit. The unit's power indicator light was illuminated, but the unit's electrical circuit had been manually disconnected inside. In order to shape the common mindset, all subjects (except those in the Control group) were informed that they might or might not feel an electrical current, as different stimulation parameters were being applied.
41273819|NCT00024232|BIOLOGICAL|monoclonal antibody huJ591|
41273820|NCT05218811|DEVICE|Cryoablation Assisted Partial Nephrectomy|Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
41273821|NCT05641350|BEHAVIORAL|Barlow's Unified Protocol|Adaptation of the cognitive-behavioral Barlow's Unified Protocol for emotional eating pattern.
41273822|NCT05588427|DIETARY_SUPPLEMENT|Ketone ester|A total of 240g ketone ester supplementation will be provided in one of the 28h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
41273823|NCT05588427|DIETARY_SUPPLEMENT|Placebo|Water, 5% sucralose (w/w), octaacetate (1 mM)
41273824|NCT03386084|DEVICE|microwave diathermy|Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
41273825|NCT01684462|BIOLOGICAL|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4\~8h, commencing within 12 hours of stroke onset
41273826|NCT01684462|DRUG|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4\~8h, commencing within 12 hours of stroke onset
41273827|NCT01271686|DRUG|0.01% bimatoprost|0.01% bimatoprost once in the evening for 4 weeks
41273828|NCT05230147|PROCEDURE|Spinal cord stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord.
41273829|NCT05230147|PROCEDURE|Sham stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation is not delivered.
41273830|NCT02844907|DRUG|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
41273831|NCT02844907|DRUG|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
41273832|NCT02844907|OTHER|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
41273833|NCT05651347|OTHER|Placebo|Tablets, visually identical to the melatonin tablets, but containing no active ingredient are administered three times a day.
41273834|NCT05651347|DRUG|Melatonin 10 MG|Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
40754107|NCT05955833|DIAGNOSTIC_TEST|89Zr-DFO*-trastuzumab PET scan|Patients will be administered 37 MBq 89Zr-DFO\*-trastuzumab and undergo 3 PET scans on the total body PET scanner at day 1, day 2 and day 4 post-injection (p.i.). The first 3 patients will undergo an additional PET 1-2 h p.i. for dosimetry purposes. Three scans are needed for PK modelling and day 4 p.i. is chosen because it is the same time point as in historical controls. Blood samples for (radioactive) PK analysis will be taken at 10 min, 30 min, 1 h and 2 h p.i., and at every PET scan.
40754108|NCT01593111|OTHER|Environmental Intervention|Home-based environmental intervention
40754109|NCT05783050|DEVICE|Wei Nasal Jet Tube|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
41273835|NCT01767584|DRUG|Cephalexin 1g tablets|Reference product
41273836|NCT01767584|DRUG|Cephalexin 1g tablets|Test product
41273837|NCT03185689|BEHAVIORAL|Effectiveness of an intensified DSME in T2D adult patients|
41273838|NCT02503605|DRUG|Biosimilar recombinant FSH|Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
40754110|NCT05783050|DEVICE|Nasal Cannula Oxygen Support|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
41273839|NCT02503605|DRUG|Urinary FSH|Controlled ovarian stimulation with 150 IU/day urinary FSH
41273840|NCT02830802|OTHER|Dr. Hauschka Med Mundspüllösung Salbei / cosmetics|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash. Rinse the mouth vigorously for 30 seconds, for easier timekeeping use the hourglass. Then spit out the mouthwash, do not rinse."
41273841|NCT02830802|OTHER|Placebo|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash."
41273842|NCT01926587|DRUG|oral rigosertib|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
41273843|NCT01926587|DRUG|Azacitidine|Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
41273844|NCT03234335|OTHER|Data collection|Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.
41273845|NCT00323661|DEVICE|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
40754111|NCT01047397|DRUG|1278863A|25mg, 50mg, 100mg
40754112|NCT01047397|DRUG|Placebo|matching placebo
40754113|NCT01742052|DRUG|MT-1303-Low|
41121541|NCT01739244|DRUG|Placebo|Ocular topical administration of placebo for 14 consecutive days
41121542|NCT01203813|OTHER|Electronic Decision Support|"Physicians randomized to the intervention will receive:~1. Electronic alerts during office visits for patients with chronic kidney disease~2. Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
41121543|NCT00167999|DRUG|piperacillin-tazobactam|
41121544|NCT06521567|DRUG|Cobolimab|Cobolimab will be administered
41121545|NCT06521567|DRUG|Dostarlimab|Dostarlimab will be administered
41121546|NCT00004104|BIOLOGICAL|liposomal interleukin-2|
41121547|NCT00004104|BIOLOGICAL|polyvalent melanoma vaccine|
41121548|NCT00004104|BIOLOGICAL|recombinant interferon alfa|
41121549|NCT03800212|DRUG|treatment for ampullary adenocarcinoma|all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).
40754114|NCT01742052|DRUG|MT-1303-Middle|
40754115|NCT01742052|DRUG|MT-1303-High|
40754116|NCT01742052|DRUG|Placebo|
40754117|NCT02305459|DEVICE|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
40754118|NCT02305459|BEHAVIORAL|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.
41121550|NCT02287441|OTHER|Tomato|Tomato Products (tomato)
40754119|NCT06197516|OTHER|Integrated Neuromuscular Inhibition Technique|After palpating the trigger point ischemic compression were applied for 20-60 sec while strain Counterstain for 60-90 sec and MET is for 7-10 sec.
41121551|NCT02287441|OTHER|Raw|Vegetables Prepared Raw (raw).
41121552|NCT04164459|DRUG|Xalost S|One drop one times a day in study eye
41121553|NCT04164459|DRUG|Xalatan|One drop one times a day in study eye
41121554|NCT04164459|DRUG|Taflotan-S|One drop one times a day in study eye
40754120|NCT06197516|OTHER|Neuromuscular Reeducation Technique|Deep pressure were applied along origin and insertion of Piriformis and hamstring muscle combined with active movement of patient for 5 -15 time as per required
40754121|NCT01032343|DIETARY_SUPPLEMENT|Omega-3 PUFA|One capsule (4g omega-3 PUFA) daily for 3 months
40754122|NCT01032343|DIETARY_SUPPLEMENT|Gelatine|One capsule daily for 3 months
40754123|NCT01168180|OTHER|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
40754124|NCT01168180|OTHER|Ultrasound therapy and hot pack|
40754125|NCT05033600|DEVICE|S.C.I.O.|The devices read, emit and entrain Electromagnetic waves of the body.
40754126|NCT05708235|DRUG|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
40754127|NCT05708235|DRUG|Abemaciclib|Abemaciclib is an orally administered CDK4/6 inhibitor
40754128|NCT05708235|DRUG|Inavolisib|Inavolisib is a potent, selective inhibitor of the Class I phosphatidylinositol 3-kinase α (PI3K-alpha isoform (p110-alpha)
40754129|NCT05488353|DRUG|Disitamab Vedotin for Injection,Penpulimab Injection|"After completion of all screening activities, patients confirmed to be eligible will enter the study and receive the following treatments.~Neoadjuvant regimen (up to 4 cycles): Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection."
40754130|NCT04972175|DRUG|50-Hour Intervention - Rapid Insulin lispro|Subcutaneous-delivery of insulin lispro using pump therapy.
40754131|NCT04972175|DRUG|50-Hour Intervention - BC LisPram|Subcutaneous-delivery of BC LisPram using pump therapy.
41121555|NCT00205179|DRUG|Novasoy|100mg/day soy isoflavones
41121556|NCT00205179|DRUG|Placebo|100mg/day matching placebo
41121557|NCT01515436|OTHER|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
41121558|NCT01515436|OTHER|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
41121559|NCT00041938|DRUG|aspirin|325 mg per day
41121560|NCT00041938|DRUG|Warfarin|INR 2.5-3.0; target INR 2.75
41121561|NCT02329639|GENETIC|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
41121562|NCT04533061|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens"
40754132|NCT02856620|OTHER|Observational only|Observational only
41121563|NCT01566968|OTHER|Cough challenge test|Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.
41121564|NCT01566968|OTHER|24 hour ambulatory cough recording|Cough recording by using an ambulatory sound recording device.
41121565|NCT01566968|OTHER|Cough quality of life questionnaire|questionnaire designed to assess impact of cough on a person's life
41121566|NCT00232180|DRUG|Eplerenone|Eplerenone administered on top of background standard heart failure therapy
41121567|NCT01574859|OTHER|levothyroxine|titration of T4 according to biochemical values
41121568|NCT04002622|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
41121569|NCT04861233|OTHER|No Intervention|This is a non-interventional study.
41121570|NCT02309996|BEHAVIORAL|Supervisor Training Program|
41121571|NCT02336438|DIETARY_SUPPLEMENT|glucomannan|Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
41121572|NCT01852071|GENETIC|Infusion of autologous EFS-ADA LV CD34+ (OTL-101)|autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
41121573|NCT01852071|DRUG|busulfan|Busulfan is used for non-myeloablative conditioning
41121574|NCT01852071|DRUG|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
41121575|NCT02344641|DRUG|Exenatide|
41273846|NCT00323661|DEVICE|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
41121576|NCT01277250|BEHAVIORAL|Web-based smoking cessation program|"Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay."
41273847|NCT01755988|OTHER|Educational website (in addition to usual care).|
41273848|NCT01755988|OTHER|Website and interactive platform with telemonitoring.|
41273849|NCT04963478|OTHER|exercise|exercise testing
41273850|NCT00213239|DRUG|Remifentanil|The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
41273851|NCT00213239|DRUG|Remifentanil|The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
41273852|NCT01417676|RADIATION|Radiation: pelvic lymph nodes with boost to prostate|78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
41273853|NCT04814264|BIOLOGICAL|Red blood cells|All transfused red blood cells will be obtained from Canadian Blood Services and will be the standard red blood cell products currently provided in Canada.
40754133|NCT05824676|DEVICE|Variable Angle LCP Patella Plating System|FDA approved device, 510K number of, K210408. The Variable Angle LCP Patella Plating System is a device that can be formed to a patients specific need with various anchoring points to best fix what is needed for fixation.
40754134|NCT05824676|DEVICE|Traditional Fixation|Traditional fixation methods for patellar fracture (screws, suture fixation, wire fixation, other plates).
41121577|NCT01574339|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.~The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a company technical representative."
41121578|NCT02546999|DRUG|botox|The agent will be given only once at point zero in the time scheme for the project.
41121579|NCT02546999|DRUG|placebo|The agent will be given only once at point zero in the time scheme for the project.
41121580|NCT01602640|DRUG|Morphine infusion|Conventional dose
41121581|NCT01602640|DRUG|Fentanyl and Midazolam infusion|Conventional dose
41121582|NCT00622856|BEHAVIORAL|psychological intervention|Psychological intervention
41121583|NCT00622856|BEHAVIORAL|Diabetes education|5 sessions with diabetes nurse
41121584|NCT05589441|DRUG|salbutamol|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
41121585|NCT05589441|DRUG|Insulin|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
41121586|NCT04537403|DRUG|Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
41121587|NCT04537403|DRUG|Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
41121588|NCT00703820|DRUG|Cytarabine|See Detailed Description
41121589|NCT00703820|DRUG|Daunorubicin|See Detailed Description
41121590|NCT00703820|DRUG|Etoposide|See Detailed Description
41121591|NCT00703820|DRUG|Clofarabine|See Detailed Description
41121592|NCT00703820|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
41121593|NCT06189534|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy-based interventions were used to manage social media addiction and; to address associated problems with it. Psychoeducation, problem conceptualization, cognitive distortions and belief identification,Time management,Stress and distress management, Emotional and beliefs modification,Priority and Goal setting, Problem solving skills, Social skill training, Emotional and behavioral activation and Relapse prevention are techniques that will be used in the intervention.
41121594|NCT01674699|DEVICE|EXCOR Pediatric|Ventricular Assist Device
41121595|NCT02892214|PROCEDURE|Pelvic floor physical therapy|
41121596|NCT02892214|DRUG|estriol cream (ovestin)|
41121597|NCT02892214|PROCEDURE|Low-level-laser therapy|
41121598|NCT03248505|DEVICE|Conventional TENS|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) with two electrodes in each side of the lumbar spinal.
41273854|NCT03617705|DEVICE|Skyn Monitor Lab Session 1|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
40754135|NCT03786055|BEHAVIORAL|Somatic Yoga and Meditation (SYM)|A Hanna somatics and somatic yoga and meditation (SYM) protocol was designed to address sensory-motor amnesia and reduce trauma which creates reflex patterns that lead to chronic muscular contractions. The movements use voluntary muscular contraction and slow controlled eccentric contraction, with the constant focus on sensation to increase the resting length of muscles. Movements are performed slowly and gently with the least possible effort and are never forced. The protocol is endorsed by the US Army Surgeon General as treatment for chronic pain. The meditations are trauma informed and evidence based supporting pain modulation, healing and well-being.
41121599|NCT03248505|DEVICE|Burst TENS|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
41121600|NCT03248505|OTHER|Cryotherapy|1,5 Kg of crushed ice pack on lumbar spine.
41121601|NCT03248505|DEVICE|Burst TENS + Cryotherapy|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus 1,5 Kg of crushed ice pack on lumbar spine.
41121602|NCT03248505|DEVICE|Conventional TENS + Cryotherapy|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) plus s 1,5 Kg of crushed ice pack on lumbar spine.
41121603|NCT03248505|OTHER|Placebo TENS|TENS device turned on, but with zero amplitude.
41121604|NCT01414738|RADIATION|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
41121605|NCT02959229|DRUG|Lactoferrin|
41121606|NCT02959229|DRUG|Placebo (for Lactoferrin)|placebo in form of distilled water
41121607|NCT02668250|PROCEDURE|OPTI-AGED|OPTI-AGED is composed of a multi-parametric optimization strategy.
41121608|NCT02668250|PROCEDURE|Usual Care|Patients receive the usual care.
41121609|NCT01714869|OTHER|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
41121610|NCT01808339|DRUG|Fluticasone Furoate (FF)|Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
41121611|NCT01808339|DRUG|Placebo|Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
41121612|NCT05053568|DEVICE|CARTBox|CARTBox performs analysis of cardiac MRI scans. The result is a treatment file that displays optimal targets for left ventricular lead implantation in CRT. This file will be used as an overlay with live fluoroscopy during the implantation procedure in the intervention group.
41121613|NCT03338816|DRUG|Givosiran|Givosiran by SC
40754136|NCT04844346|DIETARY_SUPPLEMENT|Plant stanol mini drinks|Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
41121614|NCT03338816|DRUG|Placebo|Matching placebo (normal saline \[0.9% NaCl\]) by SC
41121615|NCT04251013|DEVICE|Biliary brushing with the RX Cytology brush, Boston Scientific|"Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
41121616|NCT04251013|DEVICE|Biliary brushing with the Infinity® brush, US Endoscopy|"Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
41121617|NCT01154985|DRUG|Placebo capsule|3x Placebo capsules three times a day (TID) for 365 days
41121618|NCT01154985|DRUG|EPA-E 300 mg capsule|2x 300 mg capsules + placebo capsule TID for 365 days
41121619|NCT01154985|DRUG|EPA-E 300 mg capsule|3x 300 mg capsules TID for 365 days
41121620|NCT01017146|DRUG|Tazarotene foam|Tazarotene foam once a day application to the face
41121621|NCT01017146|DRUG|Vehicle Foam|Vehicle Foam once a day application to the face
41121622|NCT04943419|DIAGNOSTIC_TEST|Level of Myeloid-Derived Suppressor Cells|Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.
41121623|NCT00220519|DRUG|Lactobacillus GG|
41121624|NCT03950622|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
41121625|NCT03950622|BIOLOGICAL|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.
41121626|NCT03787966|OTHER|ATOPE-B|Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.
41121627|NCT03787966|OTHER|ATOPE-I|Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
41121628|NCT01884441|DRUG|Bendamustine|"Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles"
41121629|NCT01884441|DRUG|Gemcitabine|Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
41121630|NCT01884441|DRUG|Vinorelbine|Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
41121631|NCT02079844|DRUG|Roflumilast|Roflumilast tablets
41121632|NCT02079844|DRUG|Placebo|Roflumilast placebo-matching tablets
41273855|NCT03617705|DEVICE|Skyn Monitor Field Test with EMA App|After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
40754137|NCT04844346|DIETARY_SUPPLEMENT|Placebo mini drinks|Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).
40754138|NCT04844346|BIOLOGICAL|COVID-19 vaccine|First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
40754139|NCT06213805|PROCEDURE|Minimally invasive microsclerostomy|"MIMS is a filtering glaucoma surgery, which consists of creating a sclero-corneal drainage channel, to allow the flow of aqueous humor and therefore the reduction of intraocular pressure.~This surgery is extremely quick, lasting 3 to 5 minutes, according to recent MIMS studies, in contrast to the duration of a trabeculectomy, the classic glaucoma surgery, which varies between 20 and 60 minutes."
40754140|NCT00636974|PROCEDURE|Combined spinal epidural anaesthesia|
40754141|NCT02449928|DRUG|sodium lactate Ringer's injection(Baxter, ShangHai, China)|use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
40754142|NCT02449928|DRUG|Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)|use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
40754143|NCT05511480|BEHAVIORAL|Interference through learning of a competing motor skill.|Interference through the learning of a competing motor skill.
41273856|NCT03617705|DEVICE|Skyn Monitor Lab Session 2|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
41273857|NCT05747989|PROCEDURE|two-component skin adhesive, Glubran Tiss 2|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
40754144|NCT05511480|BEHAVIORAL|No interference|No interference through the continuation of learning same motor skill
40754145|NCT05516095|DEVICE|Transcranial magnet stimulation|Theta burst stimulation, which is a form of Transcranial magnet stimulation, works by inducing focused magnetic field pulses to make durable changes in the activity of brain regions. The magnetic pulses are transferred to the brain through an electromagnetic coil.
40754146|NCT05516095|DEVICE|Sham Transcranial magnet stimulation|Similar in appearance and give the same sound as the active device, but deliver no magnetic pulse that reach the brain
40754147|NCT01623154|OTHER|Pranactin citric solution|All patients were required to drink the pranactic citric solution to diagnose H.pylori.
40754148|NCT01492803|DIETARY_SUPPLEMENT|Probiotics|"Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)"
40754149|NCT01492803|DIETARY_SUPPLEMENT|Placebo|The placebo sticks will contain approximately 1 g maltodextrin
40754150|NCT04817800|DRUG|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|It will be nasaly administered
41273858|NCT05747989|PROCEDURE|skin is stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
40754151|NCT02834897|RADIATION|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
40754152|NCT02688231|OTHER|Task-oriented upper limb training|"Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.~The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.~The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks."
40754153|NCT02688231|OTHER|Control intervention|"The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).~The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks."
40754154|NCT01655212|DRUG|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
40754155|NCT00887588|DRUG|LCZ696|50 mg, 100 mg and 200 mg tablets
40754156|NCT00887588|DRUG|Valsartan|40 mg, 80 mg and 160 mg tablets
41273859|NCT06349629|DEVICE|3D printed WE43 magnesium alloy|This 3D printed WE43 magnesium alloy has porous structure and suitable mechanical strength, can be stable in the bone support, and gradually degrade to promote bone healing.
41273860|NCT00268814|DRUG|Diacetylmorphine|Diacetylmorphine (i.v.), daily
40754157|NCT00887588|DRUG|Placebo|matching placebo to LCZ696 and Valsartan
41121633|NCT02079844|DRUG|Second generation antipsychotic|Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
41273861|NCT00268814|BEHAVIORAL|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
41273862|NCT00268814|DRUG|Methadone|Methadone (p.o.), daily
41273863|NCT00268814|BEHAVIORAL|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
41273864|NCT05925608|COMBINATION_PRODUCT|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) delivered with the Helix transendocardial delivery catheter (treatment)
41273865|NCT00333216|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Posterior juxtascleral administration of suspension
41273866|NCT00333216|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/ML|Posterior juxtascleral administration of suspension
41273867|NCT00333216|OTHER|Anecortave Acetate Vehicle|Sham posterior juxtascleral administration of suspension
41273868|NCT01636492|DRUG|bitopertin|Single oral dose
41273869|NCT01636492|DRUG|placebo|Single oral dose
41273870|NCT02339948|RADIATION|SBRT|8.0 Gy per fraction for 5 fractions for a total of 40 Gy
40754158|NCT00738517|DEVICE|Immunoadsorption / Immunoglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
41121634|NCT04837976|OTHER|Semi-structured interviews and a consensus workshops using nominal group techniques.|Stage 1 of the study includes individual remote semi-structured interviews (one per participant). Stage 2 involves taking part in a consensus workshop with around 7 other Parkinson's experts, consisting of patients, supportive individuals and healthcare professionals.
41121635|NCT02505321|OTHER|Oral Triglyceride Tolerance Test (OTTT)|Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
41121636|NCT02505321|PROCEDURE|Abdominal fat biopsy (optional)|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
41121637|NCT05765019|OTHER|Spinal mobilization|Spinal mobilization and core stabilization exercise
41121638|NCT05765019|OTHER|Core stabilization exercise|Stabilization exercises for the spine
41121639|NCT00741546|PROCEDURE|Cardiac Surgery|Cardiac Surgery
41121640|NCT01264679|DRUG|Ferumoxytol|IV Ferumoxytol
41121641|NCT03127280|OTHER|Fast Track foley removal|Foley catheter is removed at 4 hours after surgery
41121642|NCT06301204|DRUG|Tranexamic acid injection|tranexamic acid administration 250mg or 500 mg
41121643|NCT06301204|DRUG|Saline|onyl ıv saline (NaCl 0.09%)
41121644|NCT04748575|DIETARY_SUPPLEMENT|Acai smoothie|Smoothie containing 150g acai pulp
41121645|NCT04748575|DIETARY_SUPPLEMENT|Placebo smoothie|Control smoothie matched nutritionally (macronutrients) and sensorially to the acai smoothie.
41121646|NCT01369004|BEHAVIORAL|Daily Self-weighing + weekly feedback+ weekly lessons|Daily self-weighing as a form of self-monitoring of body weight using a smart scale that sends their weights directly to a website (www.bodytrace.com) via the cellular network. They will be able to review weight trends overtime on this website via a graph showing both changes in weight and BMI. They will also receive weekly emailed feedback on their weight loss progress and compliance to the daily self-weighing prescription from a registered dietitian, as well as weekly emailed lessons with content related to behavioral weight control (e.g, how to control portion sizes, how to develop and exercise routine).
41121647|NCT02541461|PROCEDURE|Laparoscopic gastrectomy|(1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
41121648|NCT00900211|GENETIC|microarray analysis|
41121649|NCT00900211|GENETIC|molecular diagnostic method|
41273871|NCT06386328|DRUG|CKD-378, QD, PO|CKD-378, QD, PO
41273872|NCT05142592|DRUG|IPG7236|The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
40754159|NCT00312962|BEHAVIORAL|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
40754160|NCT00312962|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
40754161|NCT05001412|DRUG|Camrelizumab; apatinib; carboplatin; etoposide|2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib
41273873|NCT04387097|DRUG|remifentanil|postoperative drip-infusion of remifentanil
41121650|NCT00900211|OTHER|biologic sample preservation procedure|
41121651|NCT02299752|PROCEDURE|single-gloving system|single-gloving system was used during Catheterization
41273874|NCT04684199|DIETARY_SUPPLEMENT|Melatonin|Comparison between melatonin and placebo (2 weeks each) with active and placebo crossover during the study period of 34-36 days.
41273875|NCT04684199|DIETARY_SUPPLEMENT|Placebo|
41273876|NCT02134600|DIETARY_SUPPLEMENT|Omega-3 enriched fruit juice|"Different doses of omega-3 will be administered to five different groups:~400, 800, 1200, 2400 and 3000 mg/m2."
41121652|NCT02299752|PROCEDURE|double-gloving system|double-gloving system was used during Catheterization. inner and outer gloves were the same size
41121653|NCT03083067|DRUG|Budesonide/formoterol|On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.
41121654|NCT03083067|DRUG|tiotropium bromide|Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.
41273877|NCT05859087|BEHAVIORAL|Counseling|Bedside pregnancy intention screening and family planning counseling with offer of bedside contraception initiation.
41121655|NCT06067035|OTHER|Imaging|Imaging data from patients with small-vessel liver tumours will be compared with histological data.
41273878|NCT05859087|BEHAVIORAL|Flyer|Handing flyer to patient that discusses the importance of talking with their doctor about pregnancy intention and contraception use.
41273879|NCT02601573|DRUG|Grazoprevir|GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
41273880|NCT02601573|DRUG|Elbasvir|EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
41273881|NCT02601573|DRUG|Ribavirin|RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
41273882|NCT02601573|DRUG|Sofosbuvir|SOF 400 mg tablet taken q.d. by mouth in the morning with food.
41273883|NCT04847700|PROCEDURE|Surgical treatment|Endoscopic retrosigmoid minimally invasive vestibular neurectomy
41273884|NCT04847700|PROCEDURE|Surgical treatment|Endoscopic tenotomy of middle ear muscles
41273885|NCT00935883|DRUG|Eculizumab|"Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
41273886|NCT00935883|DRUG|Saline|"Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
41273887|NCT01843010|DRUG|Parecoxib|Parecoxib 40mg will be intravenously infused.
41273888|NCT01843010|DRUG|Placebo|Normal saline 5ml will be intravenously infused.
41273889|NCT02852525|DEVICE|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction
40754162|NCT03283995|OTHER|Cardiac Volume Monitoring VolumeView|hemodynamic measure
41121656|NCT04687293|DEVICE|HUBER (LPG Systems, France)|The HUBER® device consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed. It also comprises, two large handles with force sensors, mounted on a movable column. Its originality is based on its capacity to capture simultaneously the subjects' balance, core stability, core strength and total body strength; and adapt the training accordingly. Indeed, the platform interferes with the balance of the patient who must continually adjust his/her posture by exerting isometric pushing and pulling efforts with the arms. As a result, the device provides postural and muscle adaptation with visual feedback. Due to the constant adaptation of the device, it is thought to enhance muscular strength and improve neuromuscular coordination simultaneously.
41121657|NCT00143949|DRUG|enalapril|
41121658|NCT00143949|DRUG|losartan|
41121659|NCT04997616|DIETARY_SUPPLEMENT|Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)|Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.
41121660|NCT02318134|PROCEDURE|Fecal Microbiota Transplantation|FMT via a nasoduodenal tube with fresh bacteria from healthy donor
41121661|NCT02318134|DRUG|normal saline|Normal saline via a nasoduodenal tube.
41273890|NCT02824484|BEHAVIORAL|GWDP|"In each writing session participants are asked to:~1. Describe memories concerning cancer illness in a chronological order, with an objective and detached attitude~2. Describe: (a) thoughts and emotions perceived during the illness experience; (b) the impact of illness on their daily lives, and how it has changed their attitudes toward life.~3. Focus on their actual situation, think about the entire illness experience, and report on the following aspects: -Their present thoughts and feelings, and how those differ from the ones felt during the illness experience. -To what extent they have come to terms with, understand and appreciate themselves to have dealt successfully with the illness."
41273891|NCT02824484|BEHAVIORAL|Control|Participants are requested to write about events of their daily routine happened during the past week; they are also asked to focus on facts, with an objective and detached attitude.
41273892|NCT03755622|DEVICE|Conventional Transpalatal Arch (TPA)|In Group C, upper molar bands selection will be carried out by direct intra oral procedure. The conventional TPA is made on the stone working models.
41273893|NCT03755622|DEVICE|Transpalatal Arch (TPA) fabricated from 3D reconstructed model|In Group 3D, upper molar bands selection will be carried out on the 3D printed model instead of direct intra oral procedure. The 3D TPA will be fabricated on the 3D reconstructed model while the conventional TPA is made on the stone models.
41273894|NCT02278783|DRUG|regorafenib|Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
41273895|NCT05831085|PROCEDURE|State-of-the-Art Percutaneous Coronary Intervention|supported by intracoronary imaging (e.g., intravascular ultrasound \[IVUS\] or optical coherence tomography \[OCT\]), intracoronary physiology (e.g., fractional flow reserve \[FFR\] or instantaneous wave-free ratio \[iFR\]), contemporary metallic drug-eluting stents (DES), guideline-directed optimal medical therapy \[GDMT\] with advanced cardiovascular and anti-diabetic medications \[e.g., a sodium-glucose cotransporter \[SGLT\]-2 inhibitors\]) in patients with type 2 diabetes and three-vessel coronary artery disease (CAD) (not involving left main)
40754163|NCT03283995|DEVICE|echocardiography|hemodynamic measure
41273896|NCT05831085|PROCEDURE|standard CABG|Coronary-Artery Bypass Grafting
41273897|NCT02038322|DEVICE|The Stork - Conception Aid|
41273898|NCT00004386|GENETIC|recombinant adenovirus containing the ornithine transcarbamylase gene|
41273899|NCT05383690|DEVICE|LED bright light treatment device|Subjects will be instructed to use the bright light treatment device, as early as possible, for 30 minutes each morning. These devices will be equipped with monitoring electronics that will enable us to download their daily degree of use. Participants will also be provided with yellow-tinted blue light blocking glasses and will be instructed to wear them starting 2 hours before bedtime if they are viewing LED or liquid-crystal display screens.
40754164|NCT03650608|DRUG|Cohort 1: HL217 Ophathalmic Solution QD|Cohort 1 (Once a day)
40754165|NCT03650608|DRUG|Cohort 2: HL217 Ophathalmic Solution BID|Cohort 2 (Twice a day)
40754166|NCT03650608|DRUG|Cohort 3: HL217 Ophthalmic Solution QID|Cohort 3 (Four times a day)
40754167|NCT03650608|DRUG|Placebo Ophthalmic solution|Placebo
40754168|NCT06423703|DRUG|Cebranopadol|once daily for 3 days
40754169|NCT06423703|DRUG|Oxycodone IR|four times per day for 3 days
40754170|NCT06423703|DRUG|Placebo|three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
40754171|NCT03275272|DIAGNOSTIC_TEST|level of IGF-1 in infants|Measurment of blood level of IGF-1 in infants
40754172|NCT00443326|DRUG|AMG 714|Dosing Regimen is 6 Doses over 3 Months
41121662|NCT03772015|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
41121663|NCT05372146|PROCEDURE|GSV radiofrequency ablation with concomitant phlebectomy|Radiofrequency ablation with concomitant phlebectomy
41121664|NCT00756067|BIOLOGICAL|Pneumococcal vaccine GSK2189241A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
40754173|NCT03254147|DRUG|warfarin|warfarin
41121665|NCT00756067|BIOLOGICAL|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
41121666|NCT00711581|DEVICE|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
41121667|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
41121668|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel- 40mg/kgBWT Albendazole - 400mg once
41121669|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
41121670|NCT01118754|DRUG|DE-101 ophthalmic suspension|Ophthalmic suspention; QID
41121671|NCT01118754|DRUG|DE-101 ophthalmic suspension|Ophthalmic suspension; QID
41121672|NCT01118754|DRUG|DE-101 ophthalmic suspension vehicle|ophthalmic suspension vehicle; QID
41121673|NCT03010631|DRUG|Cohort 1: Lubiprostone Capsule, Fasted|Lubiprostone soft gelatin capsule administered under fasted conditions
41121674|NCT03010631|DRUG|Cohort 1: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
41121675|NCT03010631|DRUG|Cohort 2: Lubiprostone Sprinkle Formulation, Fed|Lubiprostone sprinkle formulation administered under fed conditions
41121676|NCT03010631|DRUG|Cohort 2: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
41121677|NCT03500393|BEHAVIORAL|Remotely Supervised Exercise (REM)|REM is designed to follow in the tradition of stepped care behavioral interventions. As such, participants who are successfully engaging in the prescribed exercise are provided minimal and automated encouragement and praise. Participants who demonstrate less adherence are given interventions that are tailored in content and intensity, depending on the level of success and the nature of the barriers to success
41121678|NCT03500393|BEHAVIORAL|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
41121679|NCT03443661|DRUG|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
41121680|NCT01049503|OTHER|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
41121681|NCT00443001|DEVICE|Non invasive blood pressure monitor|Updated device and software to improve performance in patients with dysrhythmia
41121682|NCT04203394|OTHER|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
41121683|NCT04203394|OTHER|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
41121684|NCT00050063|BIOLOGICAL|Therapeutic vaccinations from A5058s|Participants will receive assigned interventions assigned in study A5058s.
41121685|NCT04658693|DEVICE|Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode|See arm description
41273900|NCT02830165|OTHER|Laboratory Biomarker Analysis|Correlative studies
41273901|NCT02830165|OTHER|Quality-of-Life Assessment|Ancillary studies
41273902|NCT02830165|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41273903|NCT02814721|DEVICE|Sonic Window ultrasound device|
40754174|NCT03254147|DRUG|dabigatran|Non-vitamin K dependent oral anti-coagulants (NOACs)
41121686|NCT03872310|DEVICE|STARSTIM|Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm\^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
41121687|NCT05122546|DRUG|Cabozantinib S-malate|Given PO
41121688|NCT05122546|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
41121689|NCT05122546|BIOLOGICAL|Nivolumab|Given IV
41121690|NCT01680250|DRUG|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
41121691|NCT00227994|DRUG|Galantamine|Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
41121692|NCT00227994|DRUG|Donepezil|Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
41121693|NCT04875767|DEVICE|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.
41121694|NCT03306368|BEHAVIORAL|Youth Opioid Recovery Support|"The components of the Youth Opioid Recovery Support intervention are:~XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management."
41273904|NCT05657769|DEVICE|Medwell Preventive Care Application|Regular diabetes treatment with additional Medwell application and wearable device.
41273905|NCT05657769|DEVICE|Manual Records|Regular diabetes treatment only with a diary card to record daily activities manually.
41273906|NCT02811744|DRUG|11C-acetate|Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
41273907|NCT05940675|BEHAVIORAL|Food and Nutrition|A key element is that children receive a free of charge healthy do-it-yourself school lunch 4 days per week. The meals adhere to the Nordic Nutrition Recommendations and the Danish Food-Based Dietary Guidelines with focus on fish, wholegrains, fruits and vegetables and drinking water as well as stimulation of children's food literacy. Other intervention components involve the after school clubs, local retail stores and the parents.
40754175|NCT03254147|DRUG|Apixaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
40754176|NCT03254147|DRUG|Edoxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
40754177|NCT03254147|DRUG|Rivaroxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
40754178|NCT04853537|DIETARY_SUPPLEMENT|intermittent fasting diet|intermittent fasting diet to obese pregnant women \>30 BMI and incidence of gestational diabetes
40754179|NCT02834442|DRUG|MT-7117|
40754180|NCT02834442|DRUG|Placebo|
40754181|NCT02455011|BIOLOGICAL|REMD-477|
40754182|NCT02530073|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH and observed/expected length head ratio \<25% (O/E LHR).
41121695|NCT03840902|DRUG|M7824|Participants received intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
41121696|NCT03840902|DRUG|Placebo|Participants received intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
41121697|NCT03840902|DRUG|Durvalumab|Participants received intravenous infusion of durvalumab 10 milligram per kilogram (mg/Kg) over 1 hour q2w up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
41273908|NCT05940675|BEHAVIORAL|Physical Activity (FitFirst)|To ensure that all children reach the recommended 3x30 minutes of vigorous activity per week, we will implement three weekly 40-minute sessions in the school curriculum. These sessions will be carried out throughout the study period and will encompass modified and varied sporting activities and games, which promote motivation, physical literacy, active involvement of all children, and high training intensity.
41273909|NCT05940675|BEHAVIORAL|Sleep and screen media|The aim of this component is to promote healthy sleep and screen media behaviours. Sleep and screen media recommendations will be presented for parents at three parent workshops and in electronic infographics. Teachers/pedagogues will facilitate small assignments on screen media and sleep practices with children during school time. Children will talk about and reflect upon screen media and sleep practices in their family, based on assignments and material from e.g., Medierådet (The Danish Media Council). The results of the children's assignments will be presented to their parents at later workshops. This is done to integrate the children's perspective in the parent workshops, especially in relation to screen media habits.
41273910|NCT05940675|BEHAVIORAL|Community capacity building|Community capacity building in selected local communities. To promote healthier eating, children and families need to be supported within their local community by food environments that make the healthy choice the easy choice and not a challenge in their everyday life. To promote physical activity, the children will be invited to participate in activities in the local sports clubs including camps in the holidays.
41273911|NCT03567655|DRUG|Farlutal tab. 500mg/ Pfizer|Medroxyprogesterone Acetate
41273912|NCT00787111|DRUG|Fluoxetine (prozac)|Formulation: ODT
41121698|NCT03840902|DRUG|Etoposide|Participants received etoposide 50 mg/m\^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.
41121699|NCT03840902|DRUG|Pemetrexed|Participants received pemetrexed at a dose of 500 mg/m\^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.
41121700|NCT03840902|DRUG|Carboplatin|Participants received carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
41121701|NCT03840902|DRUG|Paclitaxel|Participants received paclitaxel intravenously at a dose of 45 mg/m\^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
41121702|NCT03840902|DRUG|Cisplatin|In combination with etoposide, participants received cisplatin 50 mg/m\^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants received cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.
41121703|NCT03840902|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Participants received IMRT 5 fractions per week for about 6 weeks (Total 60 gray \[Gy\]).
41121704|NCT02790281|PROCEDURE|Blood sampling|Blood sample collected at a single visit
41121705|NCT03427346|PROCEDURE|Endoscopic mucosal resection|Endoscopic resection is carried out using a double-channel scope. The lesion borders are marked with a coagulator. Saline liquid and sometimes epinephrine are injected into the submucosal layer to swell the area containing the lesion and elucidate the markings. The resected mucosa is lifted, then trapped and strangulated with a snare, and subsequently resected by electrocautery. Another method of EMR employs the use of a clear cap and prelooped snare inside the cap. After insertion, the cap is placed on the lesion and the mucosa containing the lesion is drawn up inside the cap by aspiration. The mucosa is caught by the snare and strangulated, and finally resected by electrocautery.
41121706|NCT03427346|PROCEDURE|Endoscopic submucosal dissection|After circumferential cutting of the surrounding mucosa of the lesion, fluid is injected into the submucosa to elevate the lesion from the muscle layer, and the connective tissue of the submucosa beneath the lesion is dissected subsequently.
41121707|NCT01854151|OTHER|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
41121708|NCT00516321|DRUG|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
41121709|NCT00516321|DRUG|placebo|matched placebo taken once daily orally
41121710|NCT01593319|DRUG|Ropivacaine|Local injection (fascia iliaca block) using 150 mg ropivacaine
41273913|NCT03291314|DRUG|Axitinib|1. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) \[7\].
41273914|NCT03291314|DRUG|Avelumab|2. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
41121711|NCT01593319|DRUG|Natrium chloride|Placebo injection of Natrium chloride solution
41121712|NCT06408818|BEHAVIORAL|Media Aware Parent - Tween|Media Aware Parent - Tween, is an online program for parents of tweens ages 9-12 designed to help parents have effective conversations with their child about body image, sexual development, gender stereotypes, romantic relationships, and media.
41121713|NCT06408818|BEHAVIORAL|Active Control Resource|Parents will have access to medically-accurate information about topics such as body image, sexual development, gender stereotypes, and romantic relationships.
41121714|NCT06145867|OTHER|Photobiomodulation therapy|deep red light therapy (670nm)
41121715|NCT06516809|DEVICE|DormoTech Vlab SpO2 sensor|The Dormotech Vlab sensor was applied to one of the subject's forehead. Reference pulse oximeters were applied to the right fingers. Blood gas analysis to determine hemoglobin saturation (SaO2) was performed using an ABL-90 Flex Plus multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). The ABL90 Flex Plus contains factory calibration standards and automatically performs regular quality controls.
41121716|NCT00581854|DRUG|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
41121717|NCT03029598|DRUG|Carboplatin|Given IV
41273915|NCT01305447|BEHAVIORAL|Exercise Behaviour Maintenance|Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
41273916|NCT01305447|BEHAVIORAL|Smoking Relapse prevention booklets|Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
41273917|NCT01305447|BEHAVIORAL|Contact control|No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
40754183|NCT03492112|DEVICE|HCV RNA Point of Care|Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.
40754184|NCT03492112|DRUG|Sofosbuvir/velpatasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
40754185|NCT03492112|DRUG|Glecaprevir/pibrentasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
40754186|NCT03865680|DRUG|CPP-ACP|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
40926548|NCT03054129|OTHER|Rehabilitation and balance training|"Stretching will be applied as hold-relax technique in Proprioceptive Neuromuscular Facilitation for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program."
40926549|NCT03054129|OTHER|Rehabilitation program|Rehabilitation program will be same in this group except balance exercises.
40926550|NCT04548843|PROCEDURE|Bone Marrow mobilization|"During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.~A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis"
40926551|NCT04548843|PROCEDURE|Apheresis|Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis
41121718|NCT03029598|OTHER|Laboratory Biomarker Analysis|Correlative studies
41121719|NCT03029598|BIOLOGICAL|Pembrolizumab|Given IV
41121720|NCT04050644|DRUG|Preservative Free drop treatment|Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
41121721|NCT04050644|DRUG|Preserved drop treatment|Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
41121722|NCT02219568|PROCEDURE|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
41121723|NCT02219568|DEVICE|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
41121724|NCT03117582|OTHER|Stool specimen|"The following stool specimen will be collected for this study:~1. 4, 3mL stool specimen from patient~2. 1, 25mL stool aliquot from donor"
41121725|NCT02755415|DEVICE|HIWIN Robotic Gait Training System|HIWIN Robotic Gait Training System is an automatic training system that combines weight-bearing standing, repetitive stepping and gait training
41121726|NCT02755415|OTHER|Static Standing Table|As part of the standard hospital rehabilitation, static standing table allows patient to be in a fully supported standing position
41121727|NCT03311737|COMBINATION_PRODUCT|general anesthesia|The investigators used general anesthesia preoperatively in uniportal VATS lung surgery
41121728|NCT03311737|COMBINATION_PRODUCT|epidural anesthesia|The investigators used general anesthesia combined with epidural anesthesia preoperatively in uniportal VATS lung surgery
41121729|NCT00928824|DIETARY_SUPPLEMENT|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
41121730|NCT03336905|OTHER|Physical activity program and prevention after cancer|Providing a supervised and non-supervised physical activity program for adolescent and Young adult with cancer and improve awareness on cancer prevention recommendations (second cancer risk, healthy lifestyles...)
41121731|NCT06514937|BEHAVIORAL|Emotional Training|Emotional Training Therapy following the programme in the computer
41121732|NCT05077618|OTHER|sampling of dental plaque and blood sample during the treatment|sampling of dental plaque and blood sample analysed on day 1
41121733|NCT03431922|DEVICE|endovascular denervation|multi-electrode catheter-based endovascular denervation
41121734|NCT04092205|DRUG|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
41121735|NCT03230643|DEVICE|Barostim neo implantation|"The Barostim neo Implantation is a new promising treatment option for patients with advanced heart failure (HEFrEF) as it might improve cardiac and vascular function by restoring sympathovagal-balance through its effects on the autonomic nervous system.~In this observational study, data from patients who have received the Barostim neo System as part of clinical routine will be collected and analyzed. The implantation of this new device is not part of the study."
41121736|NCT04291092|DRUG|Immunotherapy|Immunotherapy for brain metastasis
41121737|NCT04291092|RADIATION|WBRT|local therapy for brain metastasis
41121738|NCT04291092|DRUG|Chemotherapy|Chemotherapy for brain metastasis
41121739|NCT02709850|DRUG|IONIS ANGPTL3-LRx|
41121740|NCT02709850|DRUG|Placebo|0.9%NaCl, water, riboflavin
41273918|NCT05239104|OTHER|No intervention|This is an observational study with no intervention
41121741|NCT06187298|DIETARY_SUPPLEMENT|A combined supplement of Berberine and Curcumin (Enterophytol® PLUS) alongside standard of care|(Enterophytol® PLUS) alongside standard of care
40754187|NCT03865680|DRUG|Duraphat|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
41121742|NCT04135040|DIETARY_SUPPLEMENT|L-Amino Acid|8 different lysine intakes (L-Amino Acid and food) will be tested for 8 hours each.
41121743|NCT01622868|OTHER|Laboratory Biomarker Analysis|Correlative studies
41121744|NCT01622868|DRUG|Lapatinib Ditosylate|Given PO
41121745|NCT01622868|RADIATION|Stereotactic Radiosurgery|Undergo SRS
41121746|NCT01622868|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
41121747|NCT02894658|DEVICE|LipiFlow system|LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.
41121748|NCT02894658|PROCEDURE|Warm compresses|"Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit."
41121749|NCT03717467|DRUG|isotonic saline|100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
41121750|NCT03717467|DRUG|Magnesium Sulfate|40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
41121751|NCT00957242|DRUG|warfarin|Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
41121752|NCT00957242|DRUG|placebo|Oral placebo (1mg or 2.5mg)
41121753|NCT01172418|DRUG|Alemtuzumab|Alemtuzumab used as part of combined Induction.
41121754|NCT01172418|DRUG|Daclizumab|Daclizumab used as part of combined induction.
41121755|NCT01172418|DRUG|Thymoglobulin|Thymoglobulin used as part of combined induction.
41121756|NCT06065332|OTHER|Velez Intense Hydration Mask® (biotech cellulose face mask)|Application to one randomized side half of a Velez Intense Hydration Mask® (biotech cellulose face mask)
41121757|NCT03493724|OTHER|telemedecine|to evaluate the diagnostic performance of the photographs made by Smartphone, during requests for emergency dermatological advice
41121758|NCT03173105|DEVICE|active tDCS|TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.
41121759|NCT03173105|DEVICE|sham tDCS|Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session
41121760|NCT03173105|OTHER|Dynamic proprioceptive exercises|The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.
41121761|NCT03173105|OTHER|static proprioceptive exercises|The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
41121762|NCT03075254|DEVICE|A Peltier for Sensory testing|Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.
41121763|NCT03075254|DEVICE|functional magnetic resonance imaging for Brain Neuroimaging|to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
41121764|NCT03075254|DEVICE|fMRI for Spinal Cord Neuroimaging|The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
41121765|NCT05255835|DEVICE|Semiconductor Knee Sleeves|semiconductor elements germanium and carbon within the cotton fabric
41121766|NCT05255835|DEVICE|Cotton Knee Sleeves (Placebo)|cotton fabric knee sleeves
41121767|NCT00915564|DRUG|TMC435|Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
41121768|NCT00915564|OTHER|Methadone|Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily \[extremes included\]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
41121769|NCT03859869|DRUG|Pancrelipase|Pancrelipase is administered orally as capsules with a meal or snack
41121770|NCT03859869|DRUG|Placebo|Placebo is administered orally as capsules with a meal or snack
41121771|NCT00979121|DRUG|Rosuvastatin|Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
41121772|NCT00979121|DRUG|Placebo|Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
40754188|NCT00398242|DEVICE|above or below elbow cast for the last 3 weeks of treatment|
40754189|NCT02011997|PROCEDURE|patients undergo cVATS segmentectomy|
40754190|NCT02011997|PROCEDURE|Patients undergo cVATS lobectomy|
41273919|NCT01661322|DRUG|Aspirin, Dipyradimole, Clopidogrel|Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
40926552|NCT04548843|BIOLOGICAL|MNV-BM-PLC infusion|"The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.~The dosing interval between patients will be at minimum 2 weeks."
40926553|NCT02235727|DRUG|GBR 900|
40926554|NCT02235727|DRUG|Placebo|
41273920|NCT05093127|DEVICE|Carotid Artery Stenting|R-OneTM system is a tool available to physicians for performing CAS without changing the treatment of the pathology. R-OneTM system is designed to remotely deliver and manipulate guidewires and stent/balloon devices during Carotid Artery Stenting. The system is composed of the R-OneTM robotic platform used in combination with two accessories, the Mobile radioprotection screen and a sterile and single-use R-OneTM consumable kit. The physician, seated at the remote radio-protected control station, manipulates guidewires and/or balloon/stent catheters using joysticks on the Command unit.
40926555|NCT05985564|OTHER|imaging diagnosis|no intervention
41273921|NCT01591330|DRUG|LY2140023 Reference form|80-mg tablet administered orally
41273922|NCT01591330|DRUG|LY2140023 Test-Low|80-mg tablet administered orally
41273923|NCT01591330|DRUG|LY2140023 Test-Medium|80-mg tablet administered orally
41273924|NCT01591330|DRUG|LY2140023 Test-High|80-mg tablet administered orally
41273925|NCT03631927|OTHER|Observation|Observation
41273926|NCT04552470|DRUG|Placebo|3 matching placebo tablets taken twice a day (BID)
40926556|NCT04802629|DEVICE|Near-infrared spectroscopy|For NIRS measurements the t-NIRS 1 and NIRO 200 NX (Hamamatsu, Japan) will be used. A cerebral sensor will be placed and fixed with a CPAP (Continuous Positive Airway Pressure) cap on the left forehead and a peripheral sensor on the right forearm. Duration of measurement will be two hours.
40926557|NCT05589090|BEHAVIORAL|Super Skills for Life program|Children in the experimental group received eight sessions of the Super Skills for Life protocol. The intervention was implemented using a structured manual for the therapist and a workbook for the children \[Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández\]. The intervention was administered via an online virtual platform for eight weeks, with each session lasting approximately one hour.
41273927|NCT04552470|DRUG|PF-06882961|Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
41273928|NCT01393587|PROCEDURE|Taking blood samples|
41273929|NCT05191043|OTHER|Kinesio Taping Technique|Kinesio taping is a thin, stretchy, elastic cotton strip with an acrylic adhesive that is approximately the same thickness as the epidermis of the skin. When the taping method is followed correctly, the tape effects on the muscle by facilitating a weakened muscle or relaxing an over-used muscle,decreasing pain, fatigue and increasing tissue recovery. Kinesio Taping facilitation technique will be used with fifty percent stretch on rhomboids bilaterally.
41273930|NCT05191043|OTHER|Routine Physical Therapy|"routine physical therapy includes thermotherapy and Transcutaneous electrical nerve stimulation (TENS), the strengthening exercises of lower and middle trapezius, rhomboids and deep neck flexors. Stretching exercises of upper trapezius, pectoralis major and minor. Mobilization of cervicothoracic junction and postural education.~Thermotherapy and transcutaneous electrical nerve stimulation will be used for 10 minutes in each session. Each exercise will be performed in 3 sets of 10 repetitions. Treatment session will have a duration of 30-45 minutes."
41273931|NCT02846519|DRUG|Esketamine|100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.
41273932|NCT02846519|DRUG|Rifampin|2 capsules (300 mg each) of rifampin.
41273933|NCT00737139|PROCEDURE|Peri-articular injection of marcaine/epinephrine|60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
41273934|NCT00737139|PROCEDURE|Peri-articular injection of marcaine alone|60ml of 0.5% Bupivacaine
41273935|NCT05296967|BEHAVIORAL|chewing|patients are asked to chew chewing gum X 3/ day
41273936|NCT03987750|DRUG|Safinamide Methanesulfonate 150mg|150 mg (free base)
40754191|NCT02087683|OTHER|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.
40926558|NCT05207943|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
40926559|NCT05207943|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
40926560|NCT04066764|DRUG|Rivaroxaban|15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
40926561|NCT04066764|DRUG|Warfarin|3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
40926562|NCT04066764|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
40926563|NCT00729846|DRUG|Bevacizumab|Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
40926564|NCT00729846|DEVICE|verteporfin photodynamic therapy reduced fluence|Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].
40926565|NCT00729846|DEVICE|verteporfin photodynamic therapy standardfluence|Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].
41273937|NCT03987750|DRUG|Safinamide Methanesulfonate 100mg|100 mg (free base)
41273938|NCT03987750|DRUG|Safinamide Methanesulfonate matching placebo|placebo
41273939|NCT02910427|OTHER|Regular salt|Participants eat a regular salt diet.
40926566|NCT00634270|DRUG|Sirolimus|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
40926567|NCT00408044|PROCEDURE|cardiac surgery with sternotomy|
40926568|NCT02316509|DRUG|GDC-0927|GDC-0927 will be administered as per schedule specified in the respective arm.
41121773|NCT02009215|DRUG|Dihydroartemisinin-piperaquine (DP)|Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
41121774|NCT06267690|PROCEDURE|surgery|Patients with suspected pancreatic cancer who underwent contrast-enhanced CT and pathological examinations after the surgery.
41121775|NCT01291810|BIOLOGICAL|TNF Kinoid|TNF Kinoid
41121776|NCT01291810|BIOLOGICAL|WFI|WFI
41121777|NCT06522880|DIAGNOSTIC_TEST|CMV PCR on saliva|Observational study to measure prevalence of CMV shedding by saliva PCR
41121778|NCT01895699|OTHER|Contrast agent|
41121779|NCT06403956|OTHER|Training with video|The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the video group with the hand washing video developed by the researchers within the scope of the course. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
41121780|NCT06403956|OTHER|Training with paint|The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the paint group with the demonstration method using acrylic paint instead of soap. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
41121781|NCT05042375|DRUG|camrelizumab + famitinib|Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
41121782|NCT05042375|DRUG|pembrolizumab|pembrolizumab 200 mg.
41121783|NCT05042375|DRUG|camrelizumab|Camrelizumab for injection, 200 mg.
41121784|NCT06553053|OTHER|"Harmonizing Shaoyang, nourishing spleen and kidney with warmth Acupuncture Group"|Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV12 and bilateral ST36 and GB41 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, GB41, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV4 and bilateral SP6 and GB34 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
41121785|NCT06553053|OTHER|"Nourishing spleen and kidney with warmth Acupuncture Group"|Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3 and LI11 were selected for acupuncture and CV12 and bilateral ST36 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, SP4, KI3 and LI11 were selected for acupuncture and CV4 and bilateral SP6 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
41121786|NCT05318066|DRUG|Ringer Lactate and Norepinephrine infusion|"Arm Fluids (FL)- 500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.~Arm Vasopressor (VP)- Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation."
41121787|NCT05143996|DRUG|CLN-049|\[FLT3\] x \[CD3\] bispecific T cell engager
40926569|NCT01326325|DRUG|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
41121788|NCT04764006|DRUG|Surufatinib|Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks.
40926570|NCT01326325|DRUG|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
40926571|NCT02798614|DEVICE|10-day cast|Removal of plaster cast fixation 10 days after reduction
41121789|NCT00105092|DRUG|Enzastaurin HCL|
41273940|NCT02910427|OTHER|Potassium-enriched salt|Participants eat a potassium-enriched salt diet.
40754192|NCT02087683|OTHER|Control group (Placebo)|Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
40926572|NCT02972476|DRUG|Budesonide & formoterol fumarate and Aclidinium bromide|
40926573|NCT02972476|DRUG|Fluticasone 500 & salmeterol and Aclidinium bromide|
40926574|NCT02972476|DRUG|Fluticasone 250 & salmeterol and Aclidinium bromide|
40926575|NCT02972476|DRUG|Aclidinium bromide & formoterol fumarate|
40926576|NCT00594945|DRUG|Clonazepam|1 Dose
41121790|NCT00417950|DRUG|Acarbose|
41121791|NCT04956575|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
41121792|NCT04956575|BIOLOGICAL|Placebo|0.9% sodium chloride solution for injection
41121793|NCT04956575|BIOLOGICAL|Active Comparator|0.5 milliliter (mL) intramuscular (IM) injection
41121794|NCT00069901|DRUG|CT-2103 (poly(L)glutamate-paclitaxel)|
41121795|NCT00069901|DRUG|carboplatin|
41121796|NCT05004558|OTHER|Remote-based Resistance Exercise Training|All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
41121797|NCT06154876|DEVICE|Cough assist device|"Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise."
41121798|NCT02086097|DRUG|Dexketoprofen trometamol|25m of dexketoprofen (oral intake) every 8 hours
41121799|NCT02086097|DRUG|Ibuprofen|600 mg of Ibuprofen (Oral Intake) every 8 hours
41121800|NCT02086097|DRUG|PLACEBO|INACTIVE SUGAR PILLS
41121801|NCT04877067|BIOLOGICAL|Wharton jelly derived mesenchymal stem cell|WJ-MSC
41121802|NCT04877067|DEVICE|Repetitive electromagnetic stimulation|rEMS
41121803|NCT05356689|OTHER|mechanical traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
41121804|NCT02273544|DRUG|Asasantin ER (new formulation - low)|
41121805|NCT02273544|DRUG|Asasantin ER (new formulation - medium)|
41121806|NCT02273544|DRUG|Asasantin ER (new formulation - high)|
41121807|NCT02273544|DRUG|Asasantin ER - commercial formulation|
41121808|NCT03847259|DIAGNOSTIC_TEST|mechanical posture changes|evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).
41121809|NCT05444426|OTHER|Shoulder Rehabilitation|hot pack, conventional TENS (COMPEX Rehab 400), 1 MHz frequency, 1.5 W/cm² intensity ultrasound (Chattanooga Intelect Ultrasound), active assistive and active range of motion exercises, stretching exercises for the shoulder muscles at the pain limit and posture exercises will be applied.
41121810|NCT01842945|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT) without therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
41121811|NCT01842945|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT) with therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
41121812|NCT04920812|GENETIC|diagnosis of mitochondrial myopathy|• Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
41121813|NCT00737035|BEHAVIORAL|Interactive Healthcare Communication Application|"The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an Ask an Expert system staffed by researchers; and (6) personal stories of others dealing with IPH."
41121814|NCT00737035|BEHAVIORAL|Control Web sites|Only publicly available Web sites on parenting, child development, and trauma will be used.
41121815|NCT03631550|DEVICE|Relivion active|1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation
41121816|NCT03631550|DEVICE|Relivion Sham|1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation
41121817|NCT03437369|DRUG|Ivabradine Oral Tablet|The target dose is 10 to 15 mg / day, administered orally in two doses
41121818|NCT03437369|OTHER|Standard of Care treatment|The study drug will be compared with the standard of Care treatment
41121819|NCT04565119|OTHER|No intervention. This is an observational study.|There are no interventions being tested in the Bio-BOOST study.
41121820|NCT04044807|DIAGNOSTIC_TEST|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
41121821|NCT03989024|DRUG|Gonadorelin|Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months
41121822|NCT03989024|DRUG|Clomiphene|Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
41121823|NCT04565418|BEHAVIORAL|High-intensity interval training|3 times per week high-intensity interval training (HIIT) will be performed on a cycle ergometer for 12 weeks adding up to 36 HIIT sessions
41121824|NCT05652244|DEVICE|Mini-implants|En masse retraction of upper anterior teeth will be applied where mini-implants will be used as an anchor unit. Anterior teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
41121825|NCT05652244|DEVICE|Transpalatal arche (TPA)|Two-step retraction of upper anterior teeth will be applied where transpalatal arches (TPAs) will be used as an anchor unit. Teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
41121826|NCT06215092|OTHER|Psychological assessment|Psychological assessment of cognitive and social-emotional functioning.
41121827|NCT02773524|DRUG|Regorafenib|Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
41121828|NCT02773524|OTHER|Placebo|Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
40754193|NCT03517007|OTHER|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
41121829|NCT02363452|DRUG|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup) or Tablets
41121830|NCT06275035|DRUG|Memantine Oral Tablet|Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy
41121831|NCT02990754|BEHAVIORAL|Physical activity education|Instruction in suitable physical activity options and education about physical activity with CHD.
41121832|NCT04739280|DEVICE|CardioFlux Magnetocardiography|Magnetocardiography
41121833|NCT02578836|PROCEDURE|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
41121834|NCT05146375|BIOLOGICAL|TGFBR2|"TGFBR2 mutation correlation with severity of the aortic disease. Blood sampling. Serum will be analysed by DNA sequencing to detect specific mutations involved in aneurysms.~Cutaneous biopsy. Fibroblast culture will be done to assess the transcriptome analysis."
41121835|NCT02619786|DRUG|Inhaled colistin|75 mg of colistin activity, inhaled per dose, every 12 hours
41121836|NCT03310645|DRUG|BAY1817080|4 different doses over the course of study
41121837|NCT03310645|DRUG|Matching Placebo|Matching placebo for BAY1817080
41121838|NCT00099931|DRUG|vildagliptin|
41121839|NCT01152398|BIOLOGICAL|MVA-BN-HER2|experimental vaccine, subcutaneous injection q4weeks x6
41121840|NCT02224924|OTHER|ABPI|If the patient was assigned to the ABPI group, a blood patch will be administered using the clotted blood in the syringe obtained at the beginning of the procedure. The guiding needle will be retracted up to 1.5-2 cm from the pleural surface, and the blood will be injected steadily and gently as the needle is pulled back out of the pleura. Injection will stop when the operator feels the needle is in subcutaneous tissues.
41121841|NCT02224924|DEVICE|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|If the patient is assigned to BioSentry group, using the manufacturer's deployment device the introducer needle is positioned so that the tip is at least 1.5 cm deep to the visceral pleura. The coaxial introducer needle hub will be prehydrated with a drop of saline, the BioSentry plug housing will be mated and locked to the hub and the plug will be deployed.
41121842|NCT03405714|DRUG|Brivaracetam|"* Pharmaceutical form: Solution for iv injection~* Route of administration: intravenous use~* Concentration: 10 mg/ml"
41121843|NCT03128359|DRUG|Busulfan|Given IV
41121844|NCT03128359|DRUG|Cyclophosphamide|Given IV
41121845|NCT03128359|DRUG|Fludarabine Phosphate|Given IV
41121846|NCT03128359|PROCEDURE|Hematopoietic Cell Transplantation|Undergo PBSC HCT
41121847|NCT03128359|OTHER|Laboratory Biomarker Analysis|Correlative studies
41121848|NCT03128359|DRUG|Melphalan Hydrochloride|Given IV
41121849|NCT03128359|DRUG|Mycophenolate Mofetil|Given IV or PO
40754194|NCT05287100|DRUG|Midodrine Oral Tablet|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
41121850|NCT03128359|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC HCT
41121851|NCT03128359|OTHER|Quality-of-Life Assessment|Ancillary studies
40754195|NCT05287100|OTHER|Standard Medical Treatment|"Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is \< 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to \< 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (\>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3"
40754196|NCT00476788|DEVICE|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
41121852|NCT03128359|DRUG|Tacrolimus|Given IV
41121853|NCT03128359|RADIATION|Total-Body Irradiation|Undergo TBI
41121854|NCT03813433|OTHER|Revascularization|a procedure used to regenerate pulp dentin complex that restores the functional properties of this immature anterior teeth, prevent and resolves apical periodontitis
41121855|NCT01808768|DRUG|Alcaftadine|Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
41121856|NCT01613716|DRUG|Ozurdex|Ozurdex .7 mg injected into the treated eye
41121857|NCT01777750|DEVICE|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
41121858|NCT03755752|PROCEDURE|Phacoemulsification with and without Trypan Blue capsule staining|Phacoemulsification for patients with diabetic retinopathy having cataract in both eyes. One eye underwent phacoemulsification with trypan blue capsule staining and the other eye underwent phacoemulsification without trypan blue.
41121859|NCT06518668|BIOLOGICAL|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK. NKX019 will be administered at a dose of 1 × 109 CAR NK cells (dose normalized for weight for subjects ≤ 50 kg) administered IV.
41273941|NCT02910427|OTHER|Potassium and magnesium-enriched salt|Participants eat a potassium and magnesium-enriched salt diet.
41273942|NCT03719235|OTHER|CBCT|ultra-low dose CBCT
41273943|NCT05338229|DEVICE|the engineer-built system, video-game based Kinect sensor|The engineer-built system, video-game based Kinect sensor was developed by the researcher team.
41273944|NCT03890809|DRUG|BMS-986165|Oral administration
40926577|NCT06297252|DIAGNOSTIC_TEST|standardized clinical psychiatric evaluations|"The intervention consists of a psychiatric consultation including :~* assessment of psychiatric disorders using a MINI test~* information gathering (medical, obstetrical and family history, expected term of pregnancy).~* assessment of suicidal behaviour using the Columbia-Suicide Severity Rating Scale (CSSR-S)~* collection of negative life events over the past 12 months, assessed using the Paykel questionnaire"
40926578|NCT06297252|DIAGNOSTIC_TEST|self-administered psychiatric questionnaire assessments|"* EPICES Score: (Evaluation de la Précarité et des Inégalités de santé dans les Centres d'Examens de Santé):~* MIBS: (Mother to Infant Bonding Scale)~* PAI: (Prenatal Attachment Inventory)~* EDEQ: (Eating Disorder Examination Questionnaire)~* PCL-5: (Post-traumatic Stress Disorder Checklist for DSM-V)~* MARS: (Medication Adherence Rating Scale)~* EPDS: (Edinburgh Postnatal Depression Scale)"
41273945|NCT01454076|DRUG|Ixazomib 2.5 mg|Ixazomib 2.5 mg Capsule B (Cycle 1 only)
41121860|NCT06518668|DRUG|Cyclophosphamide LD|"Cy dose of 1 g/m2 administered IV over 30 to 60 minutes for the purpose of Lymphodepletion Therapy. Cyclophosphamide will help prepare your body to receive the treatment by decreasing the cells from your immune system to make space for the NKX019 cells.~(non-experimental)"
41121861|NCT02713126|DRUG|Placebo|administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks
41121862|NCT02713126|DRUG|Sodium Nitrite|administered orally or inhaled, 40 mg, taken every 4 hours or 3 times per day during waking hours for 12 weeks
41121863|NCT02713126|DEVICE|Accelerometer|External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
41121864|NCT02713126|OTHER|Cardiac Exercise Training|Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
41121865|NCT01149707|DRUG|PUR 0110 Rectal Enema 250 mg|PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
41121866|NCT01149707|DRUG|PUR 0110 Rectal Enema 500 mg|PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
41121867|NCT01149707|DRUG|PUR 0110 Rectal Enema 1000 mg|PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
41121868|NCT01149707|DRUG|Placebo Enema|Placebo Enema, once-daily, intrarectally
41121869|NCT01450228|DRUG|KI1001|Prolonged release melatonin 2mg
41121870|NCT01450228|DRUG|Placebo KI1001|Placebo KI1001 tablets
41121871|NCT03784170|DEVICE|FemPulse System|Device therapy with the FemPulse System
41121872|NCT01088659|DRUG|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
41121873|NCT01088659|DRUG|placebo|orally daily, 96 weeks
41273946|NCT01454076|DRUG|Ixazomib 4 mg Capsule A|Ixazomib 4 mg Capsule A (Cycle 1 only)
40926579|NCT06297252|OTHER|blood sampling|"A blood sample is taken to form an optional biological collection, comprising 3 samples:~* A tube to collect RNA from whole blood.~* A tube to collect serum~* A tube to collect native DNA"
41121874|NCT01088659|DRUG|tenofovir|245mg po daily, 96 weeks
41121875|NCT05101941|PROCEDURE|Immediate dental implants|Implants will be immediately placed in sockets associated with chronic periapical granuloma Extraction of non-restorable Teeth with periapical granuloma and socket debridement will be done then implants will be placed
41121876|NCT00364702|DRUG|methylphenidate|
41121877|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
41121878|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
41121879|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
41121880|NCT01634789|DRUG|bazedoxifene/conjugated estrogens|20 mg / 0.625 mg oral tablet, single dose
41121881|NCT00790413|DRUG|iodine I 131 metaiodobenzylguanidine|
41121882|NCT00790413|DRUG|Fludarabine|
41121883|NCT00790413|DRUG|Thiotepa|
41121884|NCT00790413|PROCEDURE|T-cell depletion|
41273947|NCT01454076|DRUG|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
41273948|NCT01454076|DRUG|Ketoconazole|Ketoconazole 400 mg tablets (Cycle 1 only)
41273949|NCT01454076|DRUG|Rifampin|Rifampin 600 mg capsule (Cycle 1 only)
41273950|NCT01454076|DRUG|Clarithromycin|Clarithromycin 500 mg tablets (Cycle 1 only)
41273951|NCT01454076|DRUG|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
41273952|NCT00184587|DRUG|candesartan cilexetil|
41121885|NCT00790413|PROCEDURE|Haploidentical stem cell transplantation|
41121886|NCT00790413|PROCEDURE|Donor Lymphocyte Infusion|
41121887|NCT00790413|DRUG|Rituximab|
41121888|NCT00790413|PROCEDURE|Co-transplantation of mesenchymal stem cells|
41121889|NCT04103723|PROCEDURE|Preoperative premedication|Every patient with or without a preoperative premedication with midazolam before surgery.
41121890|NCT00083902|DRUG|Thalidomide|
41121891|NCT00083902|DRUG|Dexamethasone|
41121892|NCT03827369|DIAGNOSTIC_TEST|ICU patient|Our study is to measure the coefficient of variation of the HCV of the radial arterial pulse among ICU patients with multiple organ failures (MOF). Patients admitted to Taoyuan General Hospital were recorded during the 6 months study.
41273953|NCT00184587|DRUG|placebo|
41273954|NCT01867489|OTHER|No intervention|
41273955|NCT05240144|OTHER|IHG|Isometric handgrip exercises will be performed for 4 x 2 min with the frequency of 3 days per week for a period of 6 weeks.
41273956|NCT05240144|OTHER|Aerobic exercises|Aerobic exercise according to the American College of Sports Medicine (ACSM) guidelines that provide the specific criteria as 50 minutes exercises for 3 days a week for a period of 6 weeks.
41273957|NCT05240144|OTHER|Sham IHG|Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period
40754197|NCT04784871|BEHAVIORAL|5waysA Intervention|Web-based 10 week intervention, encouraging participants engaging in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
40926580|NCT04011371|PROCEDURE|Cyanoacrylate closure|Cyanoacrylate glue embolization targeting venous insufficiency
40926581|NCT00684047|BIOLOGICAL|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
40926582|NCT00684047|BIOLOGICAL|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
40926583|NCT00684047|PROCEDURE|Manual Compression|Manual Compression. Primary Part (II)
41121893|NCT01189942|DRUG|OMP-21M18|The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
41121894|NCT01230450|PROCEDURE|sub-urethral tape (TVT-O)|Tension free vaginal tape vs. single incision sub-urethral tension free vaginal tape
41121895|NCT01230450|OTHER|stand standard mid-urethral sling (TVT-O)|
41121896|NCT02319434|DEVICE|Ostom-i Alert Sensor|Sensor on ostomy bag.
41121897|NCT01796067|BEHAVIORAL|Motivational and Family Weight Loss|This group will receive the comprehensive motivational and family weight loss intervention.
41121898|NCT01796067|BEHAVIORAL|Basic Health Education|This group will receive the comprehensive basic health education intervention.
41121899|NCT01796067|BEHAVIORAL|Online Intervention|Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.
41121900|NCT01796067|BEHAVIORAL|Online Control|Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
41121901|NCT00858650|OTHER|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
41121902|NCT05136170|DRUG|Oxervate|One drop of the test product will be instilled in both eyes TID
41121903|NCT05136170|OTHER|Vehicle|One drop of the placebo will be instilled in both eyes TID
41121904|NCT00971269|DEVICE|Solesta (Nasha/Dx)|Gel (hyaluronic acid/dextranomer) for intersphincteric injection 4x2 ml and retreatment 4x2 ml after 4 weeks
41121905|NCT00000994|DRUG|Zidovudine|
41121906|NCT02311452|DEVICE|Peripherally Inserted Central Catheter (PICC)|Post-discharge antibiotics delivered via a PICC line.
41121907|NCT03297281|OTHER|Maintenance of OAC in surgery of BPH by PVP.|The maintenance of AVK or DOACs treatment in the perioperative setting (without interruption of oral treatment).
41121908|NCT03297281|OTHER|Discontinuation of OAC in surgery of BPH by PVP.|The discontinuation of AVK or DOACs treatment with perioperative heparin relay during postoperative course.
41273958|NCT03446495|DRUG|Trabectedin + PLD|Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.
41273959|NCT01717248|DRUG|GCS-100|GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
41273960|NCT03132077|PROCEDURE|total knee arthroplasty|surgical intervention for end stage of knee osteoarthritis
40754198|NCT04784871|BEHAVIORAL|5waysA Active wait-list control|Writing activity log in the waiting time. Then, after five months and the writing of activity log, the participants get the web-based intervention and SMS massages, which encourage the participants to engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
40926584|NCT05048069|DRUG|Mucosta®SR Tablets 150mg(Rebamipide)|adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.
40926585|NCT04649372|PROCEDURE|EndoVE|On the day of the procedure, a review of any changes which occurred since the pre-study visit will be conducted. The patient will be placed under general anaesthesia or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes.
40926586|NCT00617669|DRUG|Docetaxel|intravenous infusion given every three weeks
40926587|NCT00617669|DRUG|ZD4054|10 mg oral once daily dose
40926588|NCT00617669|DRUG|Placebo|placebo oral tablet once daily
40926589|NCT00558688|PROCEDURE|Photodynamic therapy|Photodynamic therapy applied to actinic keratoses
40926590|NCT05392114|DRUG|Donidalorsen|Donidalorsen will be administered by SC injection.
40926591|NCT05268627|DRUG|Liraglutide|endoscopy
41273961|NCT03758560|OTHER|Pre-operative Nepali version of pain catastrophizing scale (PCS) questionnaire|Patients will be asked to complete the scores based Nepali version of pain catastrophizing scale (PCS) questionnaire preoperatively
41273962|NCT00000979|DRUG|Zidovudine|
41273963|NCT00000979|DRUG|Didanosine|
40926592|NCT03597646|DEVICE|Kinesio Tape|
40926593|NCT03597646|DEVICE|Threshold Inspiratory Muscle Trainer|
41121909|NCT05748730|BEHAVIORAL|iCHART|"The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.~The Mental Health Screener is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.~The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider."
41121910|NCT05748730|BEHAVIORAL|Treatment As Usual|Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
41121911|NCT01524952|DEVICE|combined thermal and electrical muscle stimulation (cTEMS)|cTEMS in three 60-minute sessions per week for 8 weeks
41121912|NCT04556539|DRUG|SC10914|400mg TID, oral admination on fasting condition
41121913|NCT05031234|DRUG|anaesthesia without opiates|Anaesthesia without opiates for patients undergoing laparoscopic colectomy
41121914|NCT05031234|DRUG|anaesthesia with morphine|anaesthesia with morphine for patients undergoing laparoscopic colectomy
41121915|NCT04705675|BEHAVIORAL|Breastfeeding Education|The mothers were asked to remember the pseudonyms they used on the pretest and to use the same pseudonym on the posttest. Following the pretest, the mothers in the study group were taken into a separate room at the FHC and asked to breastfeed their infants. The mothers' breastfeeding behaviors were observed. After the breastfeeding, each mother was provided an average 30-minute session of individual education. All of the mothers in the study group received the education from the same researcher. Both audio and visual materials were used in the mothers' training.
41121916|NCT05801198|DIETARY_SUPPLEMENT|Artemisia afra or Annua 10g oral infusion/tea per day for 14 days|Participants will be recruited after completing standard malaria treatment, and those who have a positive qRT-PCR for plasmodium gametocyte reservoirs will be randomly assigned to either artemisia afra tea, or artemisia annua tea or into the control group with no intervention
41121917|NCT04036955|OTHER|INFOSA-DEM|Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
41121918|NCT01183936|PROCEDURE|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
41121919|NCT01183936|PROCEDURE|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
41121920|NCT05565534|BEHAVIORAL|Nurse-practitioner led intervention|"* Face-to-face or virtual consultation with NP during chemotherapy infusion with individualized recommendations/medications AND patient education through the Patient Activated Learning System (PALS).~* Weekly follow-ups from NP via phone, Zoom, or in-person (patient directed) for 12 weeks/course of chemotherapy."
41121921|NCT04689685|OTHER|Wearing smartwatch and continous glucose sensor|Patients will be wearing a smartwatch and a continuous glucose meter (CGM) over a maximum duration of 3 months in an outpatient setting.
41121922|NCT00355095|DRUG|Erythropoietin|intravenous daily 3.3 \*10\^4 Units, duration 3 days
41121923|NCT03912831|DRUG|KITE-439|A single infusion of E7 TCR T cells (KITE-439).
41121924|NCT03912831|DRUG|Cyclophosphamide|Administered intravenously.
41121925|NCT03912831|DRUG|Fludarabine|Administered intravenously.
41121926|NCT03912831|DRUG|Interleukin-2|Administered subcutaneously.
41121927|NCT02814838|DRUG|Ladarixin|Ladarixin oral capsule
41121928|NCT02814838|DRUG|Placebo|Placebo oral capsule
41121929|NCT00000223|DRUG|Buprenorphine|
41121930|NCT01605773|DRUG|repaglinide|Dose individually adjusted and conducted according to labeling
41121931|NCT01605773|DRUG|glyburide|Dose individually adjusted and conducted according to labeling
41121932|NCT05297851|DRUG|Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)|10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.
41121933|NCT05297851|DRUG|Control|Standard treatment accordind to the routine clinical practice
41121934|NCT02820116|DRUG|Icotinib|In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
41121935|NCT03022994|OTHER|Duodenum and rectum examination|All subjects will undergo upper gastrointestinal endoscopy and proctoscopy. In addition, it will be also evaluated duodenal and rectal biopsies.
41121936|NCT03185650|DEVICE|tPAD Device|A novel, transnasal aerosol generator
41121937|NCT03185650|DEVICE|PARI LC Star Nebulizer|Standard oral nebulizer
41121938|NCT04766034|BEHAVIORAL|Simulated Grocery Shopping Exercise|Participants will click a link and simulate a shopping experience by selecting a week's worth of Supplemental Nutrition Assistance Program (SNAP)-eligible groceries for their household in a web-based supermarket platform
41273964|NCT05807308|BEHAVIORAL|Technology-based cognitive and artistic therapeutic activities|Therapeutic and artistic activities within the program (drawing, mandala, etc.). The program will be implemented in 6 sessions in two weeks. At the beginning and end of the program, children's anxiety and spiritual well-being levels will be evaluated.
41273965|NCT05549388|OTHER|Front-of-pack labeling|The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.
41273966|NCT02285400|PROCEDURE|CPAP level|CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
41273967|NCT02971592|DEVICE|MDcure|reception of real working MDcure - device that does apply the electromagnetic field
41273968|NCT02971592|OTHER|Mock Device|reception of device that does not apply the electromagnetic field
41273969|NCT06120855|DRUG|Regulated cannabis from authorized pharmacies|"The intervention group is allowed to purchase regulated cannabis in authorized pharmacies. The intervention includes various offers: Participants can choose between cannabis sorts and delivery methods, and they are encouraged to shift from smoking cannabis to vaping cannabis-containing e-liquids, vaporizing cannabis blossoms or using oral cannabis. Vaping / vaporizing electronic devices are also recommended. At the same time, pharmacists offer opportunistic smoking cessation and problematic cannabis, alcohol use and further drug use counseling that conforms to motivational interviewing principles.~Study participants can choose between different cannabis-containing products such as dried cannabis flowers, cannabis concentrates (colloquially called hashish or hash), e-liquids and oral cannabis. Besides the cannabis products, participants can buy vaping or vaporizing electronic devices at the pharmacy (they are not considered as study products)."
41273970|NCT06120855|DRUG|Cannabis from the illicit market|The control group receives no intervention and is expected to continue purchasing cannabis from the illicit market.
41273971|NCT02966314|DRUG|Omalizumab|Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
41121939|NCT02769819|DEVICE|Flexible fiberscope|"* Characteristics of patients will be assessed before induction of general anesthesia~* Glottic visualization will be evaluated by direct laryngoscopy.~* The endotracheal tube will be loaded onto the scope after silicon spray lubrication~* Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position~* With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.~* Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
41273972|NCT02966314|DRUG|Placebos|Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
41121940|NCT01095796|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
41273973|NCT04506112|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention (TranS-C), adapted for cardiac rehabilitation|Participants will complete the TranS-C intervention as adapted for cardiac rehabilitation. TranS-C is a behavioral intervention that is rooted in basic sleep and circadian science and draws from empirically-supported treatments including Cognitive Behavioral Therapy for Insomnia (CBT-I), Interpersonal and Social Rhythm Therapy (IPSRT), chronotherapy, and light therapy. It was designed to promote sleep health across a range of sleep problems. Participants in this group will also continue to receive care as usual, cardiac/sleep-related or otherwise.
41273974|NCT03151889|DEVICE|TENS|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
41121941|NCT01095796|DRUG|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
41273975|NCT05696938|DIETARY_SUPPLEMENT|Wonderlab Nicotinamide Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
40754199|NCT04784871|BEHAVIORAL|5waysA Inactive wait-list control|No activity while the participants wait. After five months of waiting, the participants get the web-based intervention and SMS messages, which encourage participants engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
40754200|NCT01535066|PROCEDURE|acupuncture therapy|Receive acupuncture
41121942|NCT01095796|DRUG|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
41121943|NCT01095796|DRUG|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
41121944|NCT05209581|DIAGNOSTIC_TEST|Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity of refugees/immigrants will be examined via a web-based digital visual acuity chart
41121945|NCT04592575|OTHER|Vestibular Evaluation|Each patient will have a full vestibular evaluation by a physical therapist
41121946|NCT00180505|DEVICE|ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent|A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries. Follow up at 30, 180, 270, 365 days and 2 years.
41121947|NCT04005482|OTHER|Rate control|Rate control according to the Atrial fibrillation - ESC Guidelines 2016
41121948|NCT01261312|DRUG|SGI-110|"* SGI-110 subcutaneous injection administered on Days 1-5~* SGI-110 subcutaneous injection administered on Days 1-5 and 8-12"
41121949|NCT01261312|DRUG|SGI-110|"* SGI-110 administered weekly on Days 1, 8 and 15~* SGI-110 administered weekly on Days 1, 4, 8, 11, 15, and 18"
41121950|NCT06004505|OTHER|Vestibular Rehabilitation|The patients received vestibular rehabilitation treatment in 4 sessions at 15-day intervals and applied the given exercise programs as home exercise in the form of 10 repetitions, 3 times a day. The exercises were performed sitting, standing and walking, respectively. Balance exercises were developed by changing the support area, support surface and arm positions. When they come to each session, the exercise programs are according to the patient's condition; alternating standing and walking forward, backward, tandem and semitandem positions.
41121951|NCT06287489|OTHER|Mediterranean diet|Mediterranean diet for three month
41121952|NCT06287489|OTHER|Regular diet|regular diet
41121953|NCT03005197|DEVICE|Laser Doppler Flowmetry|
41121954|NCT00963625|PROCEDURE|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
41121955|NCT00963625|PROCEDURE|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
41121956|NCT05237453|RADIATION|Photons|MR-guided adaptive radiotherapy
41121957|NCT00212134|DEVICE|Contact lens correction of aphakia|optical correction of infant surgical aphakia with Contact lens
41121958|NCT00212134|DEVICE|Intraocular lens implantation|optical correction of surgical aphakia with intraocular lens
41121959|NCT05110105|BEHAVIORAL|Interactive board game health education|The interactive board game includes risk factors, symptoms, and acute management of stroke. It's a card game combined with (1) addition and subtraction game (risk factors). (2) gestures game (symptoms) (3) matching game (acute management), but in traditional Chinese. The game was implemented in a group (2\~6 individuals) for 40 minutes.
41121960|NCT05110105|BEHAVIORAL|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the stroke prevention video was collected from the internet. Participants were assigned to read the health education flier for 20 minutes. Then watch the stroke prevention video for 20 minutes.
41121961|NCT00459212|DRUG|GTI-2040|Given IV
41121962|NCT00459212|PROCEDURE|pharmacological study|Correlative study
41121963|NCT00459212|PROCEDURE|laboratory biomarker analysis|Correlative study
41121964|NCT04868396|PROCEDURE|Tumor biopsy|Tumor material will be derived from 'left-over' tumor tissue that is not needed for standardised diagnostics (immune histochemistry and molecular testing).
40754201|NCT01535066|PROCEDURE|sham acupuncture|Receive sham acupuncture
41121965|NCT05048758|OTHER|No intervention|No intervention
41121966|NCT00348751|DEVICE|CholGate|
41121967|NCT02872480|OTHER|ACTIVE Training|Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
41121968|NCT00175864|DRUG|Seletracetam (ucb 44212)|
41121969|NCT02396316|DRUG|Aflibercept (Eylea, BAY 86-5321)|After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
41121970|NCT02396316|DRUG|Sham Injection|After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
41121971|NCT02941575|OTHER|Crystal Ultra|Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.
41121972|NCT02941575|OTHER|All ceramic|IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
41121973|NCT04698655|OTHER|Information on treatment options|"Asked to read two A4 pages of information on treatment options (osteoarthritis treatment options)"
41121974|NCT04698655|OTHER|Recommendation from general practitioner|Receive a hypothetical general practitioner recommendation for exercise
41121975|NCT04698655|OTHER|Information on osteoarthritis|Asked to read 1 A4 page of brief information on osteoarthritis
41121976|NCT04313205|DRUG|JKB-122 in capsule or tablet form|JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
41121977|NCT04364139|OTHER|MAP goal less than or equal to 92 mm Hg|Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg
41121978|NCT04364139|OTHER|MAP goal 102-107 mm Hg|Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg
41121979|NCT04364139|DRUG|Ramipril|An angiotensin-converting enzyme inhibitor, (ACEI: ramipril) 2.5 to 10 mg/d
41121980|NCT04364139|DRUG|Amlodipine|A dihydropyridine calcium channel blocker, (DHPCCB: amlodipine) 5 to 10 mg/d
41121981|NCT04364139|DRUG|Metoprolol|A sustained release beta-blocker, (BB: metoprolol) 50 to 200 mg/d
41121982|NCT01845844|DRUG|Ranibizumab 0.3mg/0.05cc|"Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria."
40926594|NCT04622800|OTHER|Exercise, proprioceptive neuromuscular fasilition (PNF) techniques|PNF applications are defined as the autogenous inhibition, reciprocal inhibition, stress relaxation and gate control theory. Anterior elevation / posterior depression will be performed in the form of repetitive contractions using anterior depression / posterior elevation patterns. There will be 10 repetitions, with a 2-minute rest break between each technique. The treatment will continue twice a week for a total of 6 weeks.
40926595|NCT01330017|DRUG|Phenylephrine HCl|10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
40926596|NCT01330017|DRUG|Placebo|Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
40926597|NCT01330017|DRUG|Loratadine|10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
40926598|NCT02673047|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
40926599|NCT00041587|DRUG|IL13-PE38QQR|
40926600|NCT00041587|PROCEDURE|targeted fusion protein therapy|
40926601|NCT00041587|PROCEDURE|surgery|
40926602|NCT01829243|DRUG|Milnacipran|
40926603|NCT01829243|DRUG|Placebo|
40926604|NCT02400411|OTHER|Wheat bread|
40926605|NCT02400411|OTHER|margarine|
40926606|NCT02400411|OTHER|ham|
40926607|NCT02400411|OTHER|soup|
40926608|NCT02400411|OTHER|rye bread|
40926609|NCT00260364|DRUG|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
40926610|NCT00260364|DRUG|Capecitabine orally days 1 -21|
40926611|NCT00260364|DRUG|Erlotinib 100 mg orally days 1-28|
40926612|NCT00260364|DRUG|Bevacizumab 5 mg/kg intravenously every 2 weeks|
40926613|NCT05776888|OTHER|Ofatumumab|There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.
41121983|NCT04277936|DRUG|Levetiracetam 500 mg|Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.
41121984|NCT03399669|DRUG|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
41121985|NCT05381233|OTHER|Gross motor function classification System (GMFCS)|assessment
41121986|NCT05381233|OTHER|Arabic Version of Zarit burden Inventory measure|assessment
41121987|NCT05381233|OTHER|Arabic Version of Chalder Fatigue Scale (CFQ version 11)|assessment
41121988|NCT03305146|GENETIC|Molecular biology analysis of pancreatic intra-cyst fluid|"The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.~For molecular biology technique, the samples will be processed within the UMR_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).~The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( \<50ng) DNA."
41121989|NCT04192305|PROCEDURE|LPV|LPV means tidal volume of 6 ml/kg, inspiratory-expiratory (I/E) ratio of 1/1, positive end expiratory pressure (PEEP) minimum 5 cmH20 and higher during laparoscopy in obese patients, Inspiratory oxygen concentration (FIO2) 40 % during maintenance and extubation while also giving CPAP. Lung recruitment maneuver (LRM) when lung compliance decreases below 40 ml/cmH2O.
41121990|NCT04192305|PROCEDURE|routine LV|Give volume en frequency as required by end tidal carbon dioxide, PEEP and LRM only when saturation drops intra operative, no requirement to use low FIO2 and CPAP during extubation.
41121991|NCT02849054|DEVICE|Measurement of PTPdi|Insertion of pressure transducer catheter to measure gastic and oesophadgeal pressures for calculation of PTPdi
41121992|NCT02849054|DEVICE|TTV at 4ml/kg|Provision of targetted tidal volume of 4ml/kg
41121993|NCT02849054|DEVICE|TTV at 5ml/kg|Provision of targetted tidal volume of 5ml/kg
41121994|NCT02849054|DEVICE|TTV at 6ml/kg|Provision of targetted tidal volume of 6ml/kg
41121995|NCT04005287|DRUG|WST-057 (4% pirenzepine) Lose Dose 2mL|Topical Solution
41121996|NCT04005287|DRUG|WST-057 (4% pirenzepine) High Dose 4mL|Topical Solution
41121997|NCT04005287|DRUG|Placebo Low Dose|Topical Solution
41273976|NCT05696938|DIETARY_SUPPLEMENT|Ordinary Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
40926614|NCT06394362|OTHER|Bispectral index monitor|Bispectral Index (BIS), that was introduced in 1992, is a tool that monitors the depth level of hypnosis through data processing of an electroencephalogram using computer algorithm and presented in the form of processed EEG. Utilizing BIS as a monitoring tool has shown effectiveness in reducing recovery time, prevent awareness, and bring down the amount of anesthesia agent however, as of now, it has not been incorporated into the 2020 American Society of Anesthesiologists (ASA) standard procedure on anesthesia monitoring. aims to comparing the deep hypnotic time duration on two group of geriatric patients which undergoes general anesthesia with BIS monitoring compared to standard monitoring.
40926615|NCT04821505|BEHAVIORAL|Health Education|didactic classroom instruction on improving ones lifestyle through healthier diet, exercise and control of substance use.
40926616|NCT04821505|BEHAVIORAL|Transcendental Meditation|TM is described as simple technique practiced 20 minutes twice a day for deep rest and relaxation.
40926617|NCT06287203|BEHAVIORAL|Addiction Risk Feedback Program|This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program). The information in part 2 of the program will vary between arms.
40926618|NCT01491594|DRUG|Eltrombopag|Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.
40926619|NCT05843227|OTHER|questionnaire on the organizational management|Data are collected through a questionnaire on the organizational management of the pre-operative / intraoperative / postoperative periods.
41273977|NCT02406755|OTHER|one-sensory self care (Todo Dia®)|daily use of odorless body moisturizer (Todo Dia® - Natura)
41273978|NCT02406755|OTHER|multisensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
41121998|NCT04005287|DRUG|Placebo High Dose|Topical Solution
41121999|NCT06435819|OTHER|Embodied Conversational Agent (ECA)|A computer-animated character that can explain a medical illustration to laypersons.
41273979|NCT02406755|OTHER|bi-sensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
41273980|NCT01883037|OTHER|Blood glucose results|The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
40754202|NCT00583804|DEVICE|IST-12|Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
41122000|NCT03795194|DRUG|ampicillin/clavulanate|FDA-approved antibiotic
41273981|NCT01085682|BEHAVIORAL|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
41273982|NCT01085682|BEHAVIORAL|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
41273983|NCT04728204|BEHAVIORAL|Depresijos terapija|Intervention is based on the principles of cognitive behavioral therapy and culturally adapted to elderly Lithuanian population. The main purpose of the intervention is to reduce the symptoms of depression and increase psychological well-being. Intervention contains psychoeducation, examples, exercises and consultation with a psychologist.
41273984|NCT00384956|DRUG|Azacitidine|
41273985|NCT05316896|OTHER|Internal Perturbation|"* Raising and lowering arms 90 degrees forward and sideways with eyes open and closed.~* In tandem stance with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* While standing on one leg with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* Step forward and backward with right and left foot alternately~* Take a step back and step back alternately with right and left foot~* Put the right foot on the step and take it back, then do the same with the left foot and ask the patient to do it quickly.~* First step on the step with the right foot and put the left foot next to it, then step down with the right foot and take the left foot with it, repeat the same with the left foot and ask the patient to do this. rapidly.~* Normal gait, sideways gait, tandem gait, backward gait, raising and lowering the arms forward and sideways 90 degrees, respectively, during back-to-back tandem gait."
41273986|NCT05316896|OTHER|Eksternal Perturbation|"* Front, side, and rear loading and release, pushing and pulling while standing with eyes open and closed~* Front, side and rear loading and release, pushing and pulling while standing in tandem with eyes open and closed~* Loading and releasing from the front, sides and back, pushing and pulling while turning the head left and right while standing~* Front, side and rear loading and release, pushing and pulling while standing up and down with eyes open and closed~* Front, side, and rear loading and release, pushing and pulling while standing on one leg with eyes open and closed~* Holding the ball thrown by physiotherapist~* Kicking a ball thrown by physiotherapist~* Holding the ball thrown by the physiotherapist while standing in tandem, walking, walking sideways, walking in tandem, walking backwards."
41273987|NCT03481270|BEHAVIORAL|Concordant|We will be randomizing across providers - we are particularly interested in racial concordance.
41273988|NCT03496701|DEVICE|Test lens|contact lens
41273989|NCT03496701|DEVICE|control lens|contact lens
41273990|NCT04586491|COMBINATION_PRODUCT|Oral care protocol|Oral care protocol
41273991|NCT02508155|BIOLOGICAL|MEDI7352 for IV infusion|MEDI7352 for IV infusion
41273992|NCT02508155|BIOLOGICAL|Placebo for IV infusion|IV Placebo infusion
41273993|NCT02508155|BIOLOGICAL|MEDI7352 for Subcutaneous Injection|MEDI7352 for subcutaneous injection
41273994|NCT02508155|BIOLOGICAL|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
41273995|NCT04755556|OTHER|home based intensive bimanual training|Home Based Intensive Bimanual Training with Routine Physical Therapy bimanual training includes. functional activities play with ball, make a dough, make beads, make blocks .Routine Physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
40754203|NCT02282033|DEVICE|The Moderato System|The BackBeat Moderato System incorporates traditional pacing modes and algorithms to provide pacing support to patients with all conditions currently indicated for dual chamber pacing. In addition, a special pacing algorithm was developed to reduce blood pressure.
41122001|NCT01340417|OTHER|Measurements of melatonin levels in urine, blood, milk.|Measurements of melatonin levels in urine, blood, milk.
41122002|NCT06251570|OTHER|Evaluation of Dual Task Performance|"The Montreal Cognitive Evaluation Scale will be used to evaluate the cognitive functions of the participants.~Evaluation of Physical Activity Level: The Turkish validity and reliability of the International Physical Activity Questionnaire Short Form made by Sağlam et al. will be used.~Evaluation of Quality of Life: It will be evaluated by the European Organization for Cancer Research and Treatments QLQ-C30 questionnaire.~Fatigue Evaluation: A fatigue severity scale consisting of 9 items will be used.~Dyspnea Assessment: The Modified Medical Research Council Dyspnea Scale will be used.~Respiratory Muscle Endurance: Evaluation will be done by respiratory muscle endurance test at constant threshold load with a Power Breathe device and according to the metronome warning and a MOXY monitor will be used. In evaluation of dual-task performance, an auditory task test will be performed while walking on the treadmill."
41273996|NCT04755556|OTHER|Routine Physical Therapy|Routine physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
41273997|NCT05431244|DRUG|Antiviral treatment in combination with low-dose gemcitabine|-maximun 6 cycles Gemcitabine; 30mg/m2 or 100mg/m2 or 300mg/m2 D1,D8, D15 (Q 1 week,3 times, rest for 1 week, every 4 weeks ) 1,2 cycle Valganciclovir; 900mg D8\~D28 (from 1 week after Gemcitabine iv started, qd, PO, 21days) 3\~6cycle Valganciclovir; 900mg D1\~D28 (from Gemcitabine start date, PO, 28days)
41122003|NCT02909439|DRUG|Sugammadex|Sugammadex will be given for reversal of neuromuscular blockade.
41122004|NCT02909439|DRUG|Neostigmine|Neostigmine will be given for reversal of neuromuscular blockade.
41273998|NCT04239209|BEHAVIORAL|Indirect - other patients|Video depicting an indirect response focusing on a comparison to other patients.
41273999|NCT04239209|BEHAVIORAL|Indirect - physiology|Video of an indirect response focusing on the physiology of the patient.
41274000|NCT04239209|BEHAVIORAL|Redirection|Video of a redirection towards discussing the patient's values and possible future decisions.
41122005|NCT05960435|OTHER|Proprioceptive Neuromuscular Facilitation|PNF, a method used to increase the range of motion of the joint and strengthen the muscles in the newly gained range, is a holistic approach and is based on motor learning principles. PNF stretching involves isometric contraction of the target muscle in addition to static stretching.
41122006|NCT05960435|OTHER|Control Group Exercise|The control group will include static stretching, capsule stretching, progressive ROM exercises and strengthening exercises.
41122007|NCT00197613|DRUG|(A) zidovudine, lamivudine and nevirapine|
41122008|NCT00197613|DRUG|(B) zidovudine, lamivudine and efavirenz|
41122009|NCT00197613|DRUG|(C) zidovudine, didanosine, and nevirapine|
41274001|NCT04239209|BEHAVIORAL|Direct communication|Video of a direct response.
41274002|NCT05518461|DEVICE|iThrive WI Intervention|Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
41274003|NCT02132442|DIETARY_SUPPLEMENT|Ergocalciferol, placebo|Ergocalciferol 50000 IU capsules Microcrystalline cellulose
41274004|NCT03369795|DRUG|Methotrexate|Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.
40754204|NCT03286075|DEVICE|tDCS Anode session|"The aim of this unique anode tDCS session is to study the possibility of enhancing emotional processing, attentional resources and physiological responses in healthy subjects.~The arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
40926622|NCT05326724|DEVICE|Acupuncture|The stainless steel needles are used to insert into the three points of Sishencong and the Baihui, and the Dazhui, once a week, once for 20 minutes, for 12 consecutive weeks.
41122010|NCT00197613|DRUG|(D) zidovudine, didanosine, and efavirenz|
41122011|NCT00197613|DRUG|(E) stavudine, lamivudine, and nevirapine|
41122012|NCT00197613|DRUG|(F) stavudine, lamivudine and efavirenz|
41122013|NCT00197613|PROCEDURE|Adherence Strategy Standard of Care (SOC)|
41122014|NCT00197613|PROCEDURE|Adherence Strategy Community-Based DOT|
41122015|NCT04121936|OTHER|There will be no intervention|There will be no intervention
41122016|NCT03090776|DRUG|Ketamine|low dose bolus and infusion ketamine, administered under general anesthesia
41122017|NCT03090776|OTHER|Placebo saline|bolus and infusion saline, administered under general anesthesia
41122018|NCT01289314|PROCEDURE|TLH|Total laparoscopic hysterectomy (TLH)
41122019|NCT01289314|PROCEDURE|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy (LSH)
41122020|NCT01947088|BEHAVIORAL|Music Therapy|Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
41122021|NCT05618002|DRUG|Lemborexant|For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.
41122022|NCT04414995|DRUG|Paracetamol injection and Ibuprofen injection|Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
41274005|NCT03369795|OTHER|Placebo Arm|Pills equivalent to the study drug arm (10mg) will be given once a week for the first two weeks of the trial, followed by an increase in dose to 15mg of equivalent placebo once a week until week 16.
41274006|NCT03195894|DEVICE|TripleA|
41274007|NCT04261530|BEHAVIORAL|Self-hypnosis/self-care|
41274008|NCT04261530|BEHAVIORAL|Music/self-care|
41274009|NCT04261530|BEHAVIORAL|Self-care|
41274010|NCT04261530|BEHAVIORAL|Psycho-education|
41274011|NCT05710432|OTHER|Quasi-Isometric Neck Flexion|Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction (2 sets of 6-10 flexions).
41122023|NCT04414995|DRUG|Paracetamol injection and normal saline|Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
41122024|NCT04414995|DRUG|Ibuprofen Injection and normal saline|Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
41122025|NCT00338572|BEHAVIORAL|Exercise Program|Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
41274012|NCT05710432|OTHER|Inspiratory Muscle Training|"Patients will be asked to complete 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load).~During each IMT and neck flexion maneuver ultrasound measurements will be performed (measurements of the diaphragm, sternocleidomastoid, parasternal intercostal, internal oblique \[IO\], external oblique \[EO\], transversus abdominis \[TrA\] and rectus abdominis \[RA\] will be taken) and, during the entire period, sEMG monitoring of the target muscles (diaphragm, sternocleidomastoid, parasternal intercostal and EO) will be continued."
41274013|NCT06218927|OTHER|QoL monitoring|QoL questionnaire
41274014|NCT05145465|OTHER|Telerehabilitation group|"All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.~The target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not."
41274015|NCT02185521|OTHER|patient assessment|Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
41274016|NCT03182764|OTHER|No intervention|No intervention
41274017|NCT05863247|OTHER|Patient Reported Outcomes / Biometric data revision|Multivariate statistical analysis will be done to identify the reported biomarkers to characterize patients into the following categories: satisfied without dysphotopsias, unsatisfied with dysphotopsias, satisfied with dysphotopsias, unsatisfied without dysphotopsias.Main outcome measures will be photic phenomena at 6 months of follow-up in correlation with the following pre-surgical parameters: macular ganglion cell complex thickness and/or total ocular and corneal higher-order aberrations (coma, trefoil, spherical aberration). Patients with known contributing factors for the development of dysphotopsias (such as residual refractive error, IOL decentration, posterior capsular opacification) will be excluded from the analyzis.
41274018|NCT01653730|DEVICE|Eclipse 3 portable oxygen concentrator|
41274019|NCT01653730|DEVICE|EverGo portable oxygen concentrator|
41274020|NCT01653730|DEVICE|iGo portable oxygen concentrator|
41446523|NCT02256683|DRUG|Dabigatran etexilate|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
41446524|NCT02256683|DRUG|Phenprocoumon|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
41446525|NCT00418938|DRUG|Panitumumab|6mg/kg IV
41122026|NCT00338572|BEHAVIORAL|Combined Exercise and Diet Program|Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
41122027|NCT00557024|PROCEDURE|RFA|radiofrequency ablation
41122028|NCT00557024|PROCEDURE|radiotherapy after RFA|radiotherapy after RFA
41122029|NCT00252278|DRUG|atomoxetine|
41122030|NCT03002675|DRUG|Bydureon|exenatide (Bydureon) 2mg s.c. 1x/wk
41122031|NCT00925587|DRUG|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
40926623|NCT01358279|PROCEDURE|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
41122032|NCT00151567|DRUG|Tamsulosin|Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
41122033|NCT00151567|DRUG|Placebo|Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
41122034|NCT04664270|BEHAVIORAL|e-CBT|e-CBT + Mindfulness + Problem Solving
41122035|NCT01348217|RADIATION|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node"|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
41122036|NCT01348217|RADIATION|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
40926624|NCT04139200|BEHAVIORAL|Type 1 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
40926625|NCT04139200|BEHAVIORAL|Type 2 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
41122037|NCT01348217|RADIATION|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
40926626|NCT05800431|DEVICE|Non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
41122038|NCT01348217|DRUG|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
41122039|NCT04240613|DEVICE|TVT-O|TVT-O is one of the most popular treatments for urinary incontinence (UI). Its efficacy is well established in patients with pure stress urinary incontinence (SUI). Data reporting long-term outcomes of TVT-O for the treatment of mixed urinary incontinence (MUI) or recurrent SUI is scarce. The objective of this study was to evaluate the efficacy and safety and overall patient satisfaction of TVT-O in different subgroups of UI in a long-term follow-up.
41122040|NCT06104449|DRUG|Opevesostat|Tablets to be taken orally.
41122041|NCT06104449|DRUG|Dexamethasone|Tablets to be taken orally.
41122042|NCT06104449|DRUG|Fludrocortisone acetate|Tablet to be taken orally.
41122043|NCT06104449|DRUG|Hydrocortisone|Tablets to be taken orally as a recue medication.
41122044|NCT02051491|DEVICE|BP-NCPAP|Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.
41122045|NCT02051491|DEVICE|NIHFV|The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
41122046|NCT00364117|BEHAVIORAL|Timely Discharge (Remote Presence Technology)|
41122047|NCT04855903|DEVICE|Covirtua Cognition software|Cognitive training with Covirtua Cognition software
41122048|NCT03278379|DRUG|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
41122049|NCT04193969|DIAGNOSTIC_TEST|Pressure pain assessment using computer controlled cuff algometry|Pressure pain sensitivity is assessed. The pressure is gradually increased and pain is rated by the participant on an electronic visual analogue pain rating scale (VAS) which is connected to the equipment. The assessment is performed on the lower leg and the upper arm. The pain free leg and the left upper arm is used in the patient group. The leg used in the control group will be chosen in a balanced manner meaning that half will receive pressure on the left leg and the other half on the right leg. The pain detection threshold (PDT), pain pressure tolerance threshold (PPT) and pressure pain intensity perceived as 6 on the VAS (VAS6) at the leg site is registered. The PDT and PPT on the arm site is registered.
41122050|NCT04193969|DIAGNOSTIC_TEST|Temporal summation (TS)|10 repeated inflations on the lower leg with a 1 sec interval. The pressure used at each pressure is equivalent the PPT measured at baseline. Each inflation is rated on the VAS. TS is registered as the increase pain intensity.
41122051|NCT04193969|DIAGNOSTIC_TEST|Conditioned pain modulation (CPM)|The cuff on the upper arm is inflated until 70% of the PPT is reached. While the pressure on the arm is kept constant the cuff on the leg is inflated. PDT, PPT and VAS6 pressure at the leg site is registered during the tonic stimulation (pressure on the left arm). The procedure on the leg is repeated within 30 seconds after the pressure is released on the arm site.
41274021|NCT01776125|OTHER|Cheek swab|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
41274022|NCT02918084|DRUG|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)
41274023|NCT02918084|DRUG|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
41274024|NCT03533166|OTHER|Chlorhexidine|0.03% Chlorhexidine + 0.05% CPC mouth rinse
41274025|NCT03533166|OTHER|Placebo|Placebo mouth rinse
41274026|NCT03462095|PROCEDURE|Autologous HSCT|After the 3rd consolidation, T-cell ALL patients, randomized to auto-HSCT will be mobilised by G-SCF and harvested disregarding MRD-status. After completing the 5th consolidation T-ALL patients will be transplanted after non-myeloablative CEAM (CCNU, Ethoposide, ARA-C, Melphalan) conditioning, and after reconstitution will continue 2-years maintenance
41274027|NCT00202592|DRUG|Perindopril|
41274028|NCT02844127|PROCEDURE|Implantable Cardioverter Defibrillator (ICD)|Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
41122052|NCT04193969|DIAGNOSTIC_TEST|Low back pain rating scale (LBPRS-pain)|A questionnaire measuring the intensities of low back pain and leg pain currently, on average the last two weeks and the worst pain within the same period.
41122053|NCT04193969|DIAGNOSTIC_TEST|Oswestry Disability Index|A questionnaire measuring the disability in relation to low back pain and leg pain.
41122054|NCT05370794|DRUG|rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono|recombinant hCG
41122055|NCT05370794|DRUG|rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono|recombinant FSH
41122056|NCT04843475|DIAGNOSTIC_TEST|Echocardiography|Trans-thoracic Echocardiography
41122057|NCT00018668|DRUG|Risperidone|
41122058|NCT00018668|DRUG|Olanzapine|
41122059|NCT00018668|DRUG|Quetiapine|
41122060|NCT04368312|OTHER|No intervention|No intervention, just of questionnaire including validated tests
41122061|NCT03039803|PROCEDURE|uterine closure during cesarean section|
41122062|NCT01897272|BEHAVIORAL|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
41122063|NCT02255877|DEVICE|Zip Surgical Skin Closure|Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
41274029|NCT00717730|DIETARY_SUPPLEMENT|Folic Acid|150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
41274030|NCT00717730|DIETARY_SUPPLEMENT|Vitamin B12|1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
41274031|NCT00717730|DIETARY_SUPPLEMENT|Placebo|Placebo with no active ingredients
41274032|NCT00717730|DIETARY_SUPPLEMENT|Folic acid and vitamin B12|Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
41274033|NCT02006576|DRUG|600 mg ibuprofen three times daily for 48 weeks|
41274034|NCT02006576|OTHER|Placebo three times daily|
41274035|NCT00883493|DRUG|Quetiapine fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
41274036|NCT00883493|DRUG|Lithium carbonate|Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
41446526|NCT00418938|DRUG|Bevacizumab|Either 5mg/kg OR 10mg/kg IV
41446527|NCT00418938|DRUG|Leucovorin|400mg/m\^2 IV (in the vein)
41446528|NCT00418938|DRUG|Irinotecan|180mg/m\^2 IV (in the vein)
41446529|NCT00418938|DRUG|5-Fluorouracil|400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects
41122064|NCT02255877|DEVICE|Steel Staples|Skin Closure device for the closure of the skin layer for surgical incisions.
41122065|NCT03071081|DRUG|TOP1288|Oral TOP1288
41122066|NCT03071081|DRUG|Placebo to TOP1288|Oral placebo to TOP1288
41122067|NCT04480918|DEVICE|Electroconvulsive Therapy (ECT)|ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode
41122068|NCT04480918|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS for the treatment of treatment-resistant depression in an active major depressive episode
41122069|NCT04480918|DRUG|Ketamine|Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode
41122070|NCT04480918|DRUG|Esketamine|Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode
41122071|NCT04480918|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS)|TMS for the treatment of OCD
41122072|NCT01156155|RADIATION|Digital xray of jaw and teeth|one time xray of jaw and teeth
41122073|NCT01156155|PROCEDURE|Blood draw|Three to four tablespoons of blood drawn.
41122074|NCT01156155|OTHER|questionnaires|completed questionnaires regarding patient's health and functional ability.
41122075|NCT01156155|PROCEDURE|Periodontal Examination|Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
41122076|NCT01156155|OTHER|Bilateral digital xray of hands|One time digital xray of hands
41122077|NCT05708144|DIAGNOSTIC_TEST|ICG-SG incubation solution|The fresh excision breast cancer tissues were completely soaked in the incubation solution and performed fluorescence imaging.
41122078|NCT02660970|OTHER|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
41122079|NCT02660970|OTHER|Placebo-band|Children will have to wear a 'placebo-wristband'
41274037|NCT05435521|BEHAVIORAL|Personalized multicomponent exercise program (strength, resistance, balance, and flexibility) (PMEP)|"Physical activity expert will design for each participant a personalized exercise program according to baseline situation and previous physical activity. Both will be measured prior to initiation of activity program. Each participant is free to perform physical activity program at his house, outdoor or in a gym as long as it fulfills the prespecified requirements. Exercise programs will be acquired a more personalized shape during the course of the study.~In order to motivate participants, personal motivational messages will be sent each week through mail contact or using WhatsApp Social Media.~Physical activity will be registered in an activity wristband delivered to each participant at baseline evaluation."
41274038|NCT05435521|OTHER|Body composition|Analyze the effects of PMEP on body composition in each evaluation using an impedance threshold device
41122080|NCT02660970|DRUG|Iberogast|Children will have to take Iberogast drops
41274039|NCT05435521|OTHER|Musculoskeletal and visceral Ultrasound|Quadriceps muscle ultrasound (US) of the rectus femoris measured in each evaluation in order to analyze the effects of PMEP Visceral fat will be analyzed in each visit
41274040|NCT04749212|DIAGNOSTIC_TEST|serum high-sensitivity Troponin I (TnI) and NT-Pro-Brain Natriuretic Peptide (NT-proBNP)|Both biomarkers will be determined in each patient preoperatively and at postoperative day 1 and day 2.Measurements will not necessarily be taken independently of other measurements, meaning that the addition of the biomarker could be included in routine pre or postoperative day-1 and day 2 blood tests.
41274041|NCT04203901|BIOLOGICAL|CMN-001|Autologous Dendritic Cell Therapy
41274042|NCT04203901|BIOLOGICAL|Nivolumab+Ipilimumab|anti-PD-1 and anti-CTLA4 antibodies
41274043|NCT04203901|DRUG|Lenvatinib+Everolimus|TKI+mTOR inhibitors
41274044|NCT03404648|DRUG|C-11 choline PET tracer|C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
41274045|NCT03404648|DRUG|Gadobutrol|Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
41274046|NCT03404648|DEVICE|PET/MR scanner|C11-PET/MR and pelvic mpMRI scan for prostate cancer.
41274047|NCT03995719|OTHER|Preoperative education|65 patients were instructed to a preoperative stoma-education program
41274048|NCT03995719|OTHER|Postoperative education|73 patients, receiving the same information in postoperative period.
41274049|NCT01608334|DRUG|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
41274050|NCT01608334|DRUG|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
41274051|NCT04335487|BEHAVIORAL|PSP PTSD Course|A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
41274052|NCT04335487|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
41274053|NCT05819229|DRUG|Oral antibiotic therapy|"Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days."
41274054|NCT01442298|PROCEDURE|Limb occlusion pressure (LOP)|The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
41274055|NCT01442298|PROCEDURE|conventional measurement method|Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
41274056|NCT05024006|DRUG|Remdesivir|Two intravenous loading doses, then daily infusion for 10 days
41274057|NCT05024006|DRUG|Hydroxychloroquine|Two oral loading doses, then orally twice daily for 10 days
40926627|NCT02342418|DRUG|Tedizolid phosphate|Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
41122081|NCT02660970|OTHER|Placebo-drops|Children will have to take placebo-drops
41122082|NCT00373373|DRUG|Sorafenib|2 x 400 mg/d
41122083|NCT00373373|DRUG|Placebo|Chemotherapy + Placebo
41122084|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
41122085|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
41122086|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
41122087|NCT01070940|DRUG|Placebo|Isotonic saline solution IV priming dose + IV infusion for 1 hour
41122088|NCT00980473|PROCEDURE|Argon Laser Iridoplasty|
41274058|NCT05024006|DRUG|Lopinavir / Ritonavir|Orally twice daily for 14 days
41274059|NCT05024006|DRUG|Interferon beta-1a|Daily injection for 6 days
41274060|NCT05024006|DRUG|Acalabrutinib|Orally twice daily for 10 days
41274061|NCT05740241|OTHER|Elderly|A group of participants with physical activity (protocolized)
41274062|NCT01851837|OTHER|Exercise time|Continuous training, Interval training
41274063|NCT05623566|DEVICE|Picterus Jaundice Pro|In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
41274064|NCT01244737|DRUG|[18F] FLT|\[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
41446530|NCT03966911|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter|Continuous Glucose Monitoring and frequent sample testing
41446531|NCT04161898|DRUG|Upadacitinib|Upadacitinib will be administered as oral tablet
41274065|NCT00128687|BEHAVIORAL|risk reduction|Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (\< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
41274066|NCT02678429|DEVICE|Change DBS programming|Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing
41274067|NCT05764369|BEHAVIORAL|Parenting Wisely Residential Treatment (PWRT)|PWRT experimental intervention
41274068|NCT05764369|BEHAVIORAL|TAU|The TAU condition is the standard of care offered to parents in RT settings.
41274069|NCT01907165|DRUG|Temozolomide|
41122089|NCT00980473|DRUG|Travatan/ Timolol/Azopt|
41122090|NCT01824485|DRUG|viscosupplementation 1+1+1|intra-articular injection with 1 ampoule per week for 3 weeks
41274070|NCT01907165|DRUG|Disulfiram|
41274071|NCT01907165|DIETARY_SUPPLEMENT|Copper gluconate|
41274072|NCT05723887|BEHAVIORAL|Attachment-Based Intervention Program|Attachment-Based Intervention Program
41122091|NCT01824485|DRUG|viscosupplementation 3 at once|single intra-articular injection with 3 ampoules
41274073|NCT03737656|DRUG|Progesterone vaginal ring|Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)
41274074|NCT05229939|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
41287208|NCT05661383|DEVICE|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.~Pleasant odorants will be delivered using passive diffusers placed in the room dedicated to the iTBS protocol, during the all-treatment duration. During the inclusion phase, 10 odors known to be pleasant will be presented to the subject. The 3 best rated by the subject will be chosen for olfactory stimulations. During the iTBS session, a randomly selected odor from the 3 will be presented at the same time as the iTBS treatment."
41287209|NCT05661383|DEVICE|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session."
41287210|NCT02221427|OTHER|Dynamic progression curve|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
41287211|NCT02221427|OTHER|Static labour progression curve (F)|
41287212|NCT03550339|PROCEDURE|SURG|bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults
41287213|NCT03550339|BEHAVIORAL|DIET|dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults
41287214|NCT03550339|BEHAVIORAL|HAES|treatment is based on the previously published procedure (e.g. Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support
41287215|NCT05278793|DRUG|Ferrous fumarate|Ferrous fumarate 200mg oral
41122092|NCT00580112|DRUG|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
41122093|NCT00580112|DRUG|Trabectedin|Trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
41122094|NCT01084707|DRUG|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
41122095|NCT01084707|DRUG|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
41122096|NCT01084707|DRUG|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
41122097|NCT01765543|DRUG|Rifampin|Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
41122098|NCT01765543|DRUG|Vemurafenib|Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
41122099|NCT02219724|DRUG|MOXR0916|MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
41287216|NCT00375245|DRUG|Rapamycin (sirolimus)|Weekly oral doses, dose is assigned at the time of study entry
41287217|NCT00375245|OTHER|Grapefruit Juice|Daily oral doses starting during the second week on study.
41446532|NCT04161898|DRUG|Placebo for Upadacitinib|Placebo for upadacitinib will be administered as oral tablet
41122100|NCT03687892|DEVICE|continuous Theta Burst Stimulation|Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.
41274075|NCT01287754|DRUG|erlotinib [Tarceva]|150 mg daily orally
41274076|NCT04077333|PROCEDURE|Minimal Invasive surfactant administration|Participants enrolled spontaneously breathing preterm infants born between 26.1 and 31.9 weeks' gestational age with signs of respiratory distress syndrome. Preterm infants of the MISA (Minimal invasive surfactant administration) group were assigned to receive surfactant (Calf pulmonary surfactant, Double-Crane Pharmaceutical Co., China) via a 5Fr nasogastric tube with an ophthalmic surgery straight forceps during CPAP/NIPPV-assisted spontaneous breathing.
41274077|NCT04203914|DRUG|Empagliflozin Tablets|Add-on 25mg once daily
41274078|NCT03900195|OTHER|BottlePEP|Positive expiratory device with a bottle
41274079|NCT03704337|DIETARY_SUPPLEMENT|Commercially Available Food Bar|Active
41122101|NCT03687892|DEVICE|intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
41274080|NCT03704337|DIETARY_SUPPLEMENT|Placebo|Placebo
41274081|NCT02163070|DIETARY_SUPPLEMENT|whey drink,|consumption of 220 milliliters of whey drink three times a week,
41274082|NCT02163070|DIETARY_SUPPLEMENT|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
41274083|NCT02163070|DIETARY_SUPPLEMENT|vitamin E|consumption of 400 milligrams of vitamin E three times a week,
40758268|NCT05648747|OTHER|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Italy's government rapidly established diverse public actions, which helped maintain the medical supply. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether pelvic inflammatory disease rates were affected by the COVID-19 pandemic.
40758269|NCT03523663|OTHER|no intervention. measure eye movement data|
40926628|NCT06113380|DEVICE|NTUH-ii, am upper limb rehabilitation robot arm|Rehabilitation programs are planned based on the subject's capabilities, and the differences between assisted rehabilitation with a robot and traditional rehabilitation are compared.
41122102|NCT01675999|OTHER|Perioperative simplified FOLFOX-4 chemotherapy|Preoperative chemotherapy
41122103|NCT01675999|OTHER|Perioperative FOLFOX4+Cetuximab chemotherapy|Preoperative chemotherapy
41122104|NCT01675999|OTHER|Surgery followed by FOLFOX4 chemotherapy|Preoperative chemotherapy
41122105|NCT03532906|DRUG|TAP Block|Injection of Bupivacaine 0.5% 20 ml into the thickness of the right abdominal wall and of Bupivacaine 0.5% 10 ml into the surgical wounds.
41122106|NCT03532906|DRUG|Control|Injection of Bupivacaine 0.5% 10 ml into the surgical wounds
41122107|NCT05264519|OTHER|foot bath intervention|Students in this group will have their feet soaked in water with a temperature of 38-42 degrees for 20 minutes, half an hour before bedtime.
41274084|NCT03550248|BEHAVIORAL|Healthy Together|The Healthy Together (HT) program is designed to reduce overweight and obesity among children and youth in priority populations such as Indigenous, immigrant and refugee, and low income families.The HT program consists of 30 sessions, each of which includes cooking and eating together, physical activity and a learning activity covering topics that promote healthy weights. The HT program is delivered by trained facilitators who are provided with a program manual and resources. Trained facilitators in participating community organizations offer the HT program by integrating it within core programming.
41274085|NCT02380131|DRUG|Oxaliplatin plus Capecitabine|A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
41274086|NCT02380131|DRUG|Herceptin|Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
41274087|NCT06338644|DRUG|Palbociclib|3 weeks on, 1 week off
41274088|NCT05405556|DIAGNOSTIC_TEST|eGFR reporting|"To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~1. only study-related eGFR values \>25% below baseline will be reported to patients and providers~2. all study-related eGFR will be provided to patients and providers"
41274089|NCT00150189|BEHAVIORAL|Sucrose|
41274090|NCT00853983|DRUG|[14C] AZD0530|Solution, Oral, once
41274091|NCT00886990|DRUG|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
41274092|NCT00886990|DRUG|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
41274093|NCT00646659|BIOLOGICAL|cetuximab|
41274094|NCT00646659|DRUG|carboplatin|
41274095|NCT00646659|DRUG|cisplatin|
41274096|NCT00646659|DRUG|docetaxel|
40926629|NCT06113380|OTHER|Traditional upper limb physical therapy|Traditional upper limb physical therapy is performed by the therapist.
41122108|NCT00240149|DRUG|Regular Insulin via Insulin-Glucose Algorithm|
41122109|NCT01198145|DRUG|sulfasalazine|Given orally
41122110|NCT01198145|OTHER|placebo|Given orally
41122111|NCT01130246|DRUG|A-002, varespladib methyl|A-002 administered once daily in addition to atorvastatin and standard of care
41122112|NCT01130246|DRUG|Placebo|Placebo administered once daily in addition to atorvastatin and standard of care
41122113|NCT01985542|DRUG|birch pollen subcutaneous immunotherapy|birch pollen subcutaneous immunotherapy
41122114|NCT01855334|DRUG|Spironolactone|
41122115|NCT01855334|DIETARY_SUPPLEMENT|L-arginine|
41122116|NCT01855334|DRUG|Placebo|
41122117|NCT00132964|DEVICE|Below knee walking cast|Not required
41122118|NCT00132964|DEVICE|Removable ankle brace|not required
41122119|NCT03544736|DRUG|Nivolumab|Experimental: Nivolumab
41122120|NCT03544736|RADIATION|Radiotherapy|Radiotherapy
41122121|NCT03544736|DRUG|Chemotherapy|Chemotherapy
41122122|NCT03544736|PROCEDURE|Surgery|Surgery
41274097|NCT00646659|DRUG|fluorouracil|
41274098|NCT00646659|GENETIC|fluorescence in situ hybridization|
41274099|NCT00646659|GENETIC|molecular genetic technique|
41122123|NCT03336515|DEVICE|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
41122124|NCT03336515|DEVICE|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
41122125|NCT03336515|BEHAVIORAL|Group A-General Recommendation|General recommendation not sleeping in supine position
41122126|NCT06153810|DEVICE|Biofeedback stimulation|Delivery of the vibratory biofeedback stimulus
41122127|NCT03366636|BEHAVIORAL|Project Legacy|"Project Legacy - Project Legacy is a 5-week, twice a week, 10 sessions small group intervention that encourages homeless and at-risk of homeless youth ages 14-19 to imagine a positive future and discuss how current risk behaviors can be a barrier to a successful adulthood. The program includes thinking about the future, the importance of positive social supports, short and long-term goal planning, and decision making. The program also includes life skills building, addressing past and current risk behaviors, linking to resources and navigating service systems, information on contraception and condoms, a healthy life plan and self-sufficiency. The 5 content core elements are the following:~* 1. Thinking about the future~* 2. Present actions to achieve future success~* 3. Safeguarding one's future~* 4. Creating a Healthy Life Plan~* 5. Navigating service systems"
41122128|NCT04842513|DRUG|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
41122129|NCT04649021|BIOLOGICAL|BNT162b2|Intramuscular injection
41122130|NCT04649021|OTHER|Placebo|Intramuscular injection
41274100|NCT00646659|GENETIC|reverse transcriptase-polymerase chain reaction|
41122131|NCT06355492|DEVICE|Virtual reality goggles (VR )|Patients will take buccal infiltration anaethesia using (Virtual reality goggles) that properly adjusted around the patient's head and in front of his/her eyes.
40754205|NCT03286075|DEVICE|tDCS Cathode session|"The aim of this unique cathode tDCS session is to study the possibility of inhibiting or altering emotional processing, attentional resources and physiological responses in healthy subjects.~This arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Cathode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and anode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
40754206|NCT03286075|DEVICE|tDCS Placebo session|"This arm will help compare the effects of stimulation versus no stimulation on emotional processing, attentional resources and physiological responses.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)"
40754207|NCT05639712|DRUG|Placebo|The patient is given standardized questions about their well-being and affective state before and after the administration of placebo intravenously. This is carried out on the operating table right before anesthesia
41122132|NCT06355492|DEVICE|regular screen|Patients will take buccal infiltration anaethesia using (regular screen ).
41122133|NCT04140331|DEVICE|Accelerometer|Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
41122134|NCT01557335|DRUG|Plavix® and PA32540|one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
41122135|NCT01557335|DRUG|EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)|One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
41122136|NCT00507338|PROCEDURE|PCI|early PCI for NSTEMI; primary PCI for STEMI
41122137|NCT03476811|DRUG|0.25% Marcaine at 2ml/hr and pain medications|Subcutaneous pain control with OnQ Subcutaneous Drug pump
41122138|NCT03476811|DEVICE|Placement of OnQ Drug pump|Subcutaneous placement of OnQ drug pump with normal saline infusion
41122139|NCT05412199|DEVICE|Percussion Massage Therapy|Individuals in the percussion massage therapy group will get 3 minutes of percussion massage therapy on the hamstring and gastrocnemius muscles along the origo-insertion in the mid-frequency range.
40758270|NCT03008980|OTHER|Diagnostic Test|
41274101|NCT00646659|OTHER|immunoenzyme technique|
41274102|NCT00646659|OTHER|immunohistochemistry staining method|
41122140|NCT05412199|DEVICE|Graston|Instrument-assisted soft tissue mobilization will be used on the hamstring and gastrocnemius muscles along the 5-minute origo insertion line in the Graston group.
41274103|NCT00646659|OTHER|laboratory biomarker analysis|
41274104|NCT00646659|PROCEDURE|biopsy|
41274105|NCT00646659|RADIATION|3-dimensional conformal radiation therapy|
41274106|NCT00646659|RADIATION|intensity-modulated radiation therapy|
41274107|NCT03669523|DRUG|Denosumab-nivolumab combination|"* Denosumab: 120 mg every 4 weeks subcutaneously~* Nivolumab: 240mg intravenously on day 1 every 2 weeks"
41274108|NCT04523662|DRUG|Camrelizumab Apatinib Mesylas|This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis
41122141|NCT05412199|OTHER|Dynamic Stretching|Dynamic stretching exercises for the hamstring and gastrocnemius muscles will be performed in the dynamic stretching exercise group.
41274109|NCT06172101|OTHER|Free fat flap|Free fat flap In Recurrent neurogenic thoracic outlet syndrome Surgical Treatment
41274110|NCT03109431|BEHAVIORAL|Level 1|"Youth will receive 1-5 text messages per day for at least 12 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.~Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH."
41274111|NCT03109431|BEHAVIORAL|Level 2|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
41274112|NCT03109431|BEHAVIORAL|Level 3|Youth will have be assigned to a Coach trained in a strengths--based Coaching intervention, as well as common foundational theory, principles and skills used in adolescent HIV Evidence-Based Interventions (EBI). Youth preferences will drive the intervention delivery - whether in-person, electronically via the phone, email, text message, social media private messaging.
41274113|NCT03156803|BEHAVIORAL|Healthy eating blog|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
41274114|NCT02633176|DRUG|Cetuximab|400 mg/m\^2 intravenously on day 1,then 250 mg/m\^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m\^2 intravenously every week concurrent with radiotherapy.
41274115|NCT02633176|DRUG|Cisplatin|75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m\^2 intravenously every week concurrent with radiotherapy.
41274116|NCT02633176|DRUG|Docetaxel|75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
41274117|NCT02633176|DRUG|Capecitabine|1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
41274118|NCT02633176|RADIATION|Radiotherapy|60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
41274119|NCT06213428|BIOLOGICAL|Progressive Perfect Probiotic|Participants will be administered an active probiotic for 28 days. Participants will be blinded as to what intervention they are experiencing.
41274120|NCT06213428|OTHER|Placebo|Participants will be administered a placebo for 28 days. Participants will be blinded as to what intervention they are experiencing.
41274121|NCT01136551|DRUG|Huperzine A|Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
41274122|NCT04587115|DRUG|Risperidone|Risperidone 1mg to be used in combination with other drugs
41122142|NCT01616459|BIOLOGICAL|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
41122143|NCT01616459|BIOLOGICAL|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
41122144|NCT01616459|BIOLOGICAL|Synflorix™|Intramuscular injection
41122145|NCT01616459|BIOLOGICAL|Prevnar 13™|Intramuscular injection
41274123|NCT04587115|DRUG|Ziprasidone|Ziprasidone 80mg to be used in combination with other study drugs
41274124|NCT04587115|DRUG|Oxycodone|Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs
41122146|NCT01616459|BIOLOGICAL|Infanrix hexa™|Intramuscular injection
41122147|NCT01464034|DRUG|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
41122148|NCT01464034|DRUG|Pomalidomide|PO daily on Days 1-21, every 28 Days
41122149|NCT01464034|DRUG|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
41274125|NCT04390685|DRUG|Tacrolimus ointment|Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection
41274126|NCT02041962|BEHAVIORAL|Chronic Care Model for Mood Disorders|"The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session."
40926630|NCT02133170|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
41122150|NCT02672930|DEVICE|Electrocardiogram (ECG)|ECG and vital parameters were obtained before and after recommended standard calcium gluconate therapy for hyperkalemia
41122151|NCT02996136|DEVICE|Flu Symptoms|Flu Symptoms
41122152|NCT05800041|DRUG|WTX221|Drug: WTX221 WTX221 infusion once every 30 days for two doses in total Drug: CTX Co-administration of CTX and WTX221 at the initial infusion
41122153|NCT02378597|BEHAVIORAL|Behavioral: Resiliency Intervention|4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
41122154|NCT04103970|BEHAVIORAL|Graded Activity and Pain Education (GAPE)|"GAPE is based on a cognitive behavioral perspective that human behavior is affected by behavioral, cognitive and affective factors, this include the patient's perception of and response to pain. The perspective is a psycho-social perspective which amplify and interact with the individual patient's pathology.~The overall theoretical perspective in GAPE is that fear of movement and/or lack of self-efficacy for exercise can potentially lead to disuse and sedentary behavior, a perspective modified from the fear-avoidance model. In this modified version the patients´ and the physiotherapists´ former experiences, knowledge, and beliefs are factors influencing on the patients´ experience of pain and thereby their self-efficacy for exercise and fear of movement."
41122155|NCT00373386|DRUG|growth hormone|Growth Hormone treatment
41122156|NCT00317577|DRUG|brimonidine, timolol|
41122157|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
41122158|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
41122159|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
41122160|NCT05382754|DIAGNOSTIC_TEST|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
41122161|NCT05382754|DIAGNOSTIC_TEST|In-lab polysomnography|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
41122162|NCT04164316|DEVICE|Kinesio Tape|Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.
41274127|NCT02041962|OTHER|Educational Control|
41274128|NCT05381506|DRUG|Orelabrutinib and Gemox|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin"
41274129|NCT01046188|OTHER|Knowledge Questionnaire|Administered before and after teaching intervention
41274130|NCT01046188|OTHER|Perceived Stress Scale|Administered before and after teaching intervention
41274131|NCT01046188|OTHER|Satisfaction questionnaire|Administered after the intervention and at study completion
41122163|NCT04759482|DIAGNOSTIC_TEST|polysomnography|Polysomnography consisted in recording sleep parameters during one night, using a non-invasive multi-channels device, including respiratory sensors, electrocardiogram and electroencephalogram
41122164|NCT01429805|DEVICE|HipJack Balloon Spacer|Use of the HipJack Kit to maintain distraction of the joint during hip arthroscopy.
41122165|NCT03454529|OTHER|Laboratory Biomarker Analysis|Correlative studies
41122166|NCT03454529|DRUG|Simvastatin|Given PO
41122167|NCT01366898|DRUG|Dexamethasona, Idarubicine, ARA-C, Methotrexate|
41122168|NCT03251222|DRUG|Dexmedetomidine|Intranasal aplication of dexmedetomidine
41122169|NCT03251222|OTHER|Placebo - Concentrate|Intranasal aplication of 0.9% NaCl
40754208|NCT05639712|DRUG|Morphine 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of 2.5 mg morphine intravenously. This is carried out on the operating table right before anesthesia
41122170|NCT04706052|OTHER|Superficial Parotidectomy|Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity
40754209|NCT05639712|DRUG|Morphine 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously . This is carried out on the operating table right before anesthesia
40754210|NCT05639712|DRUG|Morphine 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously . This is carried out on the operating table right before anesthesia
41122171|NCT04216394|PROCEDURE|Emergency general surgery|multidisciplinary surgery performed for traumatic and non-traumatic acute conditions during the same admission in the hospital.
41122172|NCT01479647|DRUG|PH-797804|Tablet, 1 mg, single dose
41122173|NCT01479647|DRUG|PH-797804|Tablet, 1 mg, single dose
41122174|NCT01479647|DRUG|PH-797804|Tablet, 10 mg, single dose
41122175|NCT01479647|DRUG|PH-797804|Tablet, 10 mg, single dose
41122176|NCT01479647|DRUG|PH-797804|Tablet, 24 mg, single dose
41122177|NCT01741441|PROCEDURE|laparoscopic total fundoplication|LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
41122178|NCT01448512|BEHAVIORAL|PartnerPlus Intervention|The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.
41122179|NCT01448512|OTHER|Usual Care|4 time matched sessions focused on health education
41122180|NCT03981926|OTHER|Team-Based Connected Health (TCH)|TCH is an asynchronous, secure online platform where patients can upload images of atopic dermatitis disease and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
41122181|NCT00521131|DRUG|Levocetirizine dihydrochloride|
41122182|NCT01149369|DRUG|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
41122183|NCT01149369|DRUG|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
41122184|NCT03989674|DIETARY_SUPPLEMENT|Anthocyanin|25% w/w anthocyanin extract obtained from black rice
41122185|NCT02102841|PROCEDURE|Skin biopsy|
41122186|NCT02102841|PROCEDURE|Skin suction blister|
41122187|NCT02102841|BIOLOGICAL|Mantoux test|
41122188|NCT00238797|DRUG|Gefitinib|
41122189|NCT06169254|DEVICE|Transcranial current stimulation (tCS)|Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
41122190|NCT01850511|PROCEDURE|Vibrissae trimming|Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
41274132|NCT01046188|OTHER|Web-based IVF teaching|Web-based IVF teaching
40754211|NCT05639712|DRUG|Oxycodone 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously . This is carried out on the operating table right before anesthesia
40754212|NCT05639712|DRUG|Oxycodone 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously . This is carried out on the operating table right before anesthesia
40754213|NCT05639712|DRUG|Oxycodone 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously . This is carried out on the operating table right before anesthesia
41122191|NCT01850511|DRUG|Application of oxymetazoline|Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
41122192|NCT05073159|BIOLOGICAL|Allocating head-of-bed position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
41122193|NCT01896310|DEVICE|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
41122194|NCT03663036|DIAGNOSTIC_TEST|Magnetic Resonance Imaging of the shoulder|Clinical and radiological assessments of the shoulders and the donor sites
41122195|NCT02930200|BEHAVIORAL|Treatment as Usual|Tobacco Treatment Research Program (TTRP) or Treatment as Usual (TAU)
41122196|NCT02930200|BEHAVIORAL|QuitGuide|NCI QuitGuide Treatment App
41122197|NCT02930200|BEHAVIORAL|Smart-T|Smart-Treatment App
41122198|NCT05419570|OTHER|Fluid Loading|Hemodynamic and ventilatory parameters will be recorded at five time points (T1 - T5). After baseline meausrements (T1), additional 5 cmH2O PEEP will be applied to patients for 30 seconds (short time low peep challenge, SLPC). Prior to PEEP lowering T2 measurement will be performed. T3 measurement will be performed one minute after PEEP is decreased to its initial value and will be recorded as the second baseline. Thereafter, 100 ml isotonic saline will be infused over one minute (MFC). T4 measurement will be performed one minute after MFC is completed,. Lastly, T5 measurement will be performed three minutes after additional 400 ml of isotonic saline is infused within 10 minutes to complete 500 ml of fluid loading.
41274133|NCT01046188|OTHER|Didactic lecture|Didactic lecture
41274134|NCT01590342|DRUG|Diclofenac|Diclofenac 75 mg, two doses
41274135|NCT01590342|DRUG|Placebo|Placebo, two doses
41274136|NCT03839602|RADIATION|Reducing CTV|CTVs were delineated in line with tumor stage, i.e. tumor invasion.
40754214|NCT05639712|DRUG|Fentanyl 0.025 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously . This is carried out on the operating table right before anesthesia
40754215|NCT05639712|DRUG|Fentanyl 0.05 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously . This is carried out on the operating table right before anesthesia
41122199|NCT02056236|DRUG|Anti-epileptic drugs|"Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
40754216|NCT05639712|DRUG|Fentanyl 0.1 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously . This is carried out on the operating table right before anesthesia
40754217|NCT06523816|DIAGNOSTIC_TEST|dermoscopy|Dermoscopy is a fast imaging technique that allows an excellent visualization of non-melanocytic skin tumors to diagnose them without invasive interventon.
40754218|NCT05104775|DRUG|GNC-035|Administration by intravenous infusion.
41122200|NCT02056236|OTHER|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
41122201|NCT06394284|DRUG|MDMA-AT|As described above in arm description
41122202|NCT06394284|BEHAVIORAL|SEA-IT|As described in arm description
41122203|NCT06518772|OTHER|hot application|The application procedure started with the application of hot gel packets at a temperature of 40-42°C to the soles of the feet of the women in the intervention group for 20 minutes when cervical dilation reaches 5 cm.
41122204|NCT03791905|DRUG|Paclitaxel|chemotherapy drug
41122205|NCT03791905|DRUG|Cisplatin|chemotherapy drug
41122206|NCT03791905|DRUG|Oxaliplatin|chemotherapy drug
41122207|NCT03791905|DRUG|5-FU|chemotherapy drug
41122208|NCT03791905|DRUG|Leucovorin|chemotherapy drug
41122209|NCT03791905|RADIATION|Intensity-modulated radiotherapy|radiotherapy technique
41122210|NCT03791905|DEVICE|PET|Using PET to evaluate response to induction chemotherapy
41122211|NCT04877652|OTHER|Standard of care|Standard medical treatment of ADHF patients deemed to have insufficient diuretic response.
41122212|NCT03661957|PROCEDURE|Non grafted maxillary sinus floor elevation with simultaneous implant placement|lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure
41122213|NCT03661957|PROCEDURE|using short dental implants for posterior atrophic maxilla|placement of short dental implant with bone height below 8mm
41122214|NCT01284075|BEHAVIORAL|Guided imagery and music therapy|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
41122215|NCT01284075|BEHAVIORAL|White Noise|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
40754219|NCT04017468|DRUG|Vancomycin|Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.
40754220|NCT04317846|OTHER|Intravenous administration of vasodilatory drugs|Administration of the vasodilatory drugs in a different pattern than intra-arterially
40754221|NCT05449262|OTHER|functional resistance training GROUP A|"Session of 45-60 min. Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
40754222|NCT05449262|OTHER|functional resistance training GROUP B|"Session of 45-60 min Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
41122216|NCT01284075|OTHER|No intervention|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
41122217|NCT04056624|DIETARY_SUPPLEMENT|High carotenoid juice|Juice with high carotenoids
41122218|NCT04056624|DIETARY_SUPPLEMENT|Placebo control - Apple juice|Juice with negligible carotenoids
41122219|NCT01608347|DRUG|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
41122220|NCT01608347|DRUG|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
41122221|NCT02721134|OTHER|additional blood tubes|four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
41122222|NCT02995460|BEHAVIORAL|interval training|4x4 high intensity interval training
41446533|NCT04161898|DRUG|Prednisolone|Prednisolone will be administered as oral tablet
41274137|NCT04193683|OTHER|Myofascial Release Technique|Myofascial release technique will bi applied bottom of the feet, back of the legs and hamstrings in both extremities. The practitioner will decide how long she should stay in a region according to the feeling of releasing in the tissue. The technique will be applied to a region at least 3 times.
41274138|NCT04193683|OTHER|Sham-Ultrasound|Sham-ultrasound will be applied to back of legs and thighs in both extremities without pressure and all parameters of the ultrasound device except the timer will be closed.
41274139|NCT01503216|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol, 2000 IU per day, 8 weeks
41274140|NCT01503216|DIETARY_SUPPLEMENT|ergocalciferol|vitamin d2, 2000 IU per day for 8 weeks
41274141|NCT01503216|DIETARY_SUPPLEMENT|Placebo|Placebo
41274142|NCT05486078|DEVICE|MD Tissue Collagen Medical Device|"The Experimental Group will be treated with 2-mL volume ultrasound-guided infiltration of: MD-Tissue (GUNA, Milan-Italy). Composition for 2 ml: collagen 100 micrograms Subjects will be treated with No.1 infiltration per week for 3 consecutive weeks. The infiltrations will be performed in an echoguided mode.~MD-Tissue Collagen Medical Device will be infiltrated into the trochanteric bursa and at the level of the tendons of the gluteus minimus and gluteus medius, particularly at the level of the most degenerated insertional areas."
41274143|NCT06008548|PROCEDURE|TACE|
41274144|NCT01993979|DRUG|Chemotherapy|
41274145|NCT01993979|OTHER|Surveillance|Patients will be closely monitored for early signs of recurrence, for which they will receive treatment as decided in discussion between the clinician and patient. This may include chemotherapy.
41274146|NCT05779891|OTHER|Mulligan Traction Straight Leg Raise Technique|The individuals in the Group A will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Mulligan straight leg raise technique . Three repetitions of Mulligan's Traction Straight Leg Raise will be done with 7 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes.
41274147|NCT05779891|OTHER|Slump Stretching|The individuals in the Group B will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Slump Stretching technique. Five repetitions of Slump stretching technique will be done with 30 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes
40754223|NCT03713788|OTHER|Cold pressor test|Participants placed their non-dominant hand into cold water for 2 minutes
41122223|NCT01188369|DRUG|levosimendan|Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.
41122224|NCT01188369|DRUG|placebo drug|Intravenous infusion, colour identical to levosimendan
41122225|NCT03793361|DRUG|Regorafenib|"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
41122226|NCT03793361|DRUG|Placebo|"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
41122227|NCT00062907|BIOLOGICAL|Recombinant DNA- pVAX/L523S|
41122228|NCT00062907|BIOLOGICAL|Recombinant adenovirus- Ad/L523S|
41122229|NCT05351424|OTHER|Audiovisual Intervention- Radiation Therapy Education|A video with educational information will be shown regarding radiation therapy.
40754224|NCT01636544|PROCEDURE|contralateral healthy tissue biopsy|At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
40754225|NCT04769401|OTHER|Normal Progesterone group|Progesteron supplementation was initiated by the use of 100 mg of a vaginal progesterone tablet two times daily (Lutinus, Ferring Pharmaceuticals) plus 250 mg of intramuscular hydroxyprogesterone caproate in oil twice a week (IMHPC) as luteal phase support (referred to as day 0 of progesterone administration).
41274148|NCT02095301|OTHER|Herbal Beverage|
41274149|NCT06484166|OTHER|Fullerene cream|Patients are instructed to apply a thin layer of the Fullerene cream third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
41274150|NCT06484166|DRUG|Trolamine (Biafine)|Patients are instructed to apply a thin layer of the Trolamine (Biafine) third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
41274151|NCT04022486|OTHER|Incidence, management and risk factors of seizure|Incidence of seizure, management (treatment, paraclinical examinations) and risk factors of seizure in children admitted for severe bronchiolitis
41274152|NCT06428903|DRUG|ADC189 tablet|ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)
41274153|NCT06428903|DRUG|ADC189 granules|ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)
41274154|NCT06428903|DRUG|ADC189 180mg|ADC189 tablet, 180 mg, single oral dose. (Part 2 study)
41274155|NCT01206907|DRUG|oxymorphone IR|oxymorphone IR liquid
41274156|NCT01497171|PROCEDURE|Elevate Mesh|Transvaginal mesh repair of anterior vaginal prolapse
41274157|NCT01497171|PROCEDURE|Anterior Colporrhaphy|Traditional suture repair of anterior vaginal prolapse
41274158|NCT01767402|BIOLOGICAL|PhtD vaccine with/without adjuvant|Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
41274159|NCT01767402|BIOLOGICAL|Pneumovax 23TM|One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
41274160|NCT01767402|BIOLOGICAL|NaCl|One dose administered intramuscularly in the deltoid region of the right arm at month 2.
41274161|NCT00428168|DRUG|Betahistine|Betahistine 24mg BID
41274162|NCT03571464|DEVICE|GGRO Mobile App|"GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards)."
41274163|NCT01120639|DRUG|Temozolomide|75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
41274164|NCT01120639|PROCEDURE|Stereotactic Radiosurgery (SRS)|Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)
41274165|NCT02586480|DEVICE|dual chamber pacemaker with SafeR algorithm|SafeR is an AVB management algorithm: it provides AAI pacing while continuously monitoring AV conduction, it switches to DDD when detecting AVB I, II or III, according to the following criteria: (1) AVB I: 6 long PR intervals, (2) AVB II: 3 blocked atrial events/12 cycles, (3) AVB III: 2 consecutive blocked atrial events. It switches back to AAI mode when needed.
41274166|NCT01454804|DRUG|Pazopanib|Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
40754226|NCT04769401|OTHER|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, 25 mg/d of SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day and the blood sample was taken 2 days later to check serum progesterone levels.
41122230|NCT05351424|OTHER|ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure|Brochure with written information will be given to the subject regarding radiation therapy.
41122231|NCT05351424|OTHER|Audiovisual Intervention- Cancer Clinical Trials Education|A video with educational information will be shown regarding cancer clinical trials.
41122232|NCT05351424|OTHER|NCI Taking Part in Cancer Research Studies Brochure|Brochure with written information will be given to the subject regarding cancer clinical trials.
41122233|NCT06322043|DEVICE|Adipearl|Injection of the investigational device in subcutaneous tissue.
41122234|NCT00158782|DRUG|GW786034|GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
41122235|NCT00158782|DRUG|lapatinib|Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.
41122236|NCT04951362|DRUG|intranasal spray ivermectin|intranasal spray of saline
41122237|NCT04241952|OTHER|Exercise|Bedcycling
41122238|NCT03489187|DEVICE|Visualase Thermal Therapy System|Patients who have previously received treatment with VTTS when used as intended.
41122239|NCT05565508|PROCEDURE|new laparoscopic access technique for group a|new laparoscopic access technique through the epigastric region
41122240|NCT05565508|PROCEDURE|Hasson's technique for laparoscopic access in group b|Hasson's technique for laparoscopic access in group b
41122241|NCT00370383|DRUG|Erlotinib|erlotinib 150 mg/day once daily
41122242|NCT00370383|DRUG|Satraplatin|"satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound."
41122243|NCT00034528|DRUG|Busulfan|0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days. All infusions are anticipated to be given in the outpatient clinic.
41122244|NCT00034528|DRUG|Fludarabine|30 mg/m\^2/d administered as a bolus infusion over 30 minutes for 4 days. All infusions are anticipated to be given in the outpatient clinic.
40754227|NCT00669331|DRUG|Inhaled mannitol|400mg dose of Mannitol BD (twice a day) for 52 weeks
41122245|NCT00034528|DRUG|FK506|0.15 mg/kg taken orally daily for 12 to 14 weeks
41122246|NCT00034528|DRUG|Prednisone|0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
41122247|NCT02332577|DRUG|PRISTINAMYCIN XRP7263|Pharmaceutical form:tablet 500 mg Route of administration: oral
41122248|NCT02332577|DRUG|Amoxicillin|Pharmaceutical form:capsule 500 mg Route of administration: oral
41122249|NCT02332577|DRUG|Amoxicillin Placebo|Pharmaceutical form: capsule Route of administration: oral
41122250|NCT02332577|DRUG|PRISTINAMYCIN Placebo|Pharmaceutical form:Tablet Route of administration: Oral
41122251|NCT01248936|DRUG|RO5185426|
41122252|NCT05386953|DRUG|Normal saline|Patients received normal saline as a maintenance crystalloid during liver transplantation surgery.
41122253|NCT05386953|DRUG|Balanced crystalloid solution|Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
41122254|NCT05936177|OTHER|Patient education|The intervention in this osteoporosis education research will consist of a concise and informative educational session delivered by a physiatrist, utilizing slides prepared based on information from reputable sources such as the International Osteoporosis Foundation website and the World Health Organization (WHO) health education booklet. The session will cover various topics including the definition of osteoporosis, its causes, risks, complications, dietary options, and specific exercise recommendations, with a focus on raising awareness and promoting informed decision-making regarding prevention and treatment options.
41122255|NCT06220149|DIAGNOSTIC_TEST|FIT (fecal immunochemical test)|A FIT (fecal immunochemical test) will be done daily for the 14 days following polypectomy.
41274167|NCT01454804|DRUG|Lapatinib|Starting dose 500 mg by mouth every day for 28 days.
41274168|NCT01454804|DRUG|Trastuzumab (Herceptin®)|"4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase"
41274169|NCT01454804|DRUG|Pazopanib|Starting dose 200 mg by mouth every day for 28 days.
41274170|NCT03536897|RADIATION|IORT|Intraoperative radiation therapy with INTRABEAM system to a dose of 20 Gy
41446534|NCT06627595|DRUG|Immunotherapy|Patients will be treated in accordance with the guidelines for melanoma treatment.
41122256|NCT06285149|DRUG|Icaritin|This product is suitable for patients with unresectable hepatocellular carcinoma who are not suitable for or refuse to receive standard treatment and have not received systemic treatment in the past, and the peripheral blood compound markers of patients meet at least two of the following detection indicatorsItem: AFP\>400 ng/mL; TNF-a\<2.5 pg/mL; IFN-y\>7.0 pg/mL.The conditional approval is based on data from an interim analysis of an enriched population in a randomized controlled Phase 11 clinical trial, and full approval for this indication will be subject to confirmation of the clinical benefit of the product in planned confirmatory trials.
41122257|NCT02555449|DRUG|[¹⁴C]-LY3202626|Administered as solution by mouth
41122258|NCT03632811|OTHER|A structured interview with every patient|The comprehension test will be done through structured interviews in which the principal investigator will ask if the patient has had difficulty understanding the recommendations and questions, will check the interpretation of all items and the understanding of each word by the patient. In case of problems, the investigator will propose and / or test translation alternatives, or will ask the patient to propose alternatives.
41122259|NCT02556138|DEVICE|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
41122260|NCT00632203|DRUG|Temozolomide|5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
41122261|NCT04304924|OTHER|The personalized telephone based intervention|"The personalized telephone based intervention:~1. Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~2. Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
41122262|NCT05961462|BEHAVIORAL|Exercise training|Patients randomized to the exercise group will be offered aerobic exercise plan containing 12 sessions over 4 weeks (3 times per week).
41122263|NCT01625013|DEVICE|Synvisc-One (G-F 20)|Synvisc G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20-gauge needle. Patients will be treated at baseline and followed out to three years. Patients may return for retreatment as early as 4 months post their prior injection if they meet the retreatment criteria pain levels for Worst Knee Pain. If the subjects need another injection, the follow-up cycle will restart at Visit 1 and the subject will be seen every 6 months and followed-up for 3 years.
41122264|NCT00158769|DRUG|Intravenous GR270773 - Phospholipid emulsion|GR270773 (lipid emulsion) is a sterile, white to off-white, semi-translucent liquid for intravenous injection.
41122265|NCT01446497|DRUG|Brimonidine/Timolol mixed combination|Twice per day, 1 drop at each time
41122266|NCT01446497|DRUG|Timolol|Twice per day, 1 drop at each time
41122267|NCT05938166|DEVICE|oral care augmented reality (AR)|Augmented reality (AR) is an extension of perceptible reality, whereby additional information, such as texts or virtual objects, can be displayed in the user's field of vision.The oral care augmented reality (AR) simulation training can train foreign care workers by switching languages (Indonesian) and therefore reduce language-related learning barriers.
41122268|NCT05546307|OTHER|SSEP|Every patient presenting for a SSEP will be offered to participate to the study. If accepted, a randomization will determine whether the examination will be preceded by a relaxation session (Relax Group) or not (control group)
41122269|NCT05546307|OTHER|relaxation session|The relaxation session will be performed by one of the 5 nurses trained in relaxation
41122270|NCT05348096|DRUG|Low-dose ibrutinib|Daily ibrutinib (140mg QD) and itraconazole (100mg BID) for six months.
41122271|NCT02310113|OTHER|NIRS|Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
41274171|NCT06543992|DRUG|Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir|Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.
41274172|NCT03904680|DRUG|Methotrexate|Methotrexate 2.5 mg tablet
41274173|NCT03904680|DRUG|Vitamin D|Vitamin D 200,000 IU ampules
41274174|NCT05779085|OTHER|Dermocosmetic|Use of daily cleanser to treat facial acne
41274175|NCT06145230|OTHER||
41274176|NCT01607892|DRUG|KPT-330|
41274177|NCT04398732|DRUG|Enbrel|As provided in real world practice
41274178|NCT02772783|OTHER|high GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of \~90 is achieved by using corn syrup as a carbohydrate source.
40754228|NCT00669331|DRUG|Matched control|50mg dose of Mannitol BD (twice a day) for 52 weeks
41274179|NCT02772783|OTHER|low GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of \~40 is achieved by using uncooked corn starch as a carbohydrate source.
41274180|NCT02772783|DRUG|euglycemic insulin clamp|Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
41446535|NCT05027503|OTHER|Exercise with hippotherapy simulator|30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.
41122272|NCT01352611|DRUG|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
41122273|NCT04925336|OTHER|Nociceptive stimulation|"These investigations in healthy volunteers will study the association between cerebral and neurovegetative (sympathetic and parasympathetic) electrophysiological responses in response to a controlled and tolerable pain stimulus, determined for each individual. The pain stimulus will be delivered using an electrically conductive glove used in clinical practice for transcutaneous therapeutic stimulation.~The thresholds of nociception and tolerance will be determined in each healthy volunteer."
41122274|NCT02942862|DRUG|Orcein staining|Prognostic value of venous emboli detected by orcein staining
41122275|NCT03721913|OTHER|participation-based intervention|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
41122276|NCT02818335|DRUG|LY3023414 Reference Fasted|Administered Orally
41122277|NCT02818335|DRUG|LY3023414 Test Fasted|Administered Orally
41122278|NCT02818335|DRUG|LY3023414 Test Fed|Administered Orally
41122279|NCT06322316|PROCEDURE|The Ultrasound-guided Retrolaminar Block Group|"The ultrasound probe was placed on the back in a transverse orientation on the lateral side of the posterior median line to identify the lamina of the 5th vertebra, ESM, and transversospinalis muscles of the target segment.~A 38-mm 22-gauge regional block needle was advanced using an in-plane technique. When the puncture needle touched the lamina, 20 mL of 0.25% levobupivacaine was administered between the transversospinalis muscle and lamina. The LA diffusion between the lamina and the ESM indicated a successful puncture."
41122280|NCT06322316|PROCEDURE|The Ultrasound-guided Erector Spinae Plane Block Group|"The ultrasound probe was placed on the back in a transverse orientation to identify the tip of the T5 transverse process as flat, squared-off acoustic shadows with a faint image of the pleura visible. When the tip of the transverse process was centered on the ultrasound screen, the probe was rotated to a longitudinal orientation. In the parasagittal view, the following layers were visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, ESM, and T5 transverse process.~The block needle was inserted in-plane in a cranial-to-caudal direction until contact was made with the T5 transverse process. The correct location of the needle tip in the fascial plane deep to the ESM was confirmed by injecting 0.5-1.0 ml of normal saline and seeing the fluid lifting the ESM off the transverse process without distending the muscle. Then 20 ml levobupivacaine 0.25% was injected."
41122281|NCT02719600|BEHAVIORAL|Virtual reality|Evaluation of observational motor learning using virtual reality
41122282|NCT04324450|DEVICE|MRI|"The MRI protocol is composed of:~* T1-weighted anatomical sequences~* DTI sequences~* resting functional MRI~* 3D MR spectroscopic imaging"
41122283|NCT04324450|BEHAVIORAL|Cognitive assessment|Battery of neuropsychological tests
41122284|NCT03825575|DEVICE|Low level laser therapy (LLLT)|A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
41122285|NCT05669170|BEHAVIORAL|Psychosocial intervention|"The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and the opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem-solving of specific issues that the caregiver brings to the sessions~* Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours."
41122286|NCT05669170|DRUG|Methylphenidate|norepinephrine and dopamine reuptake inhibitor
41122287|NCT05377567|BEHAVIORAL|TAU + FIBRO-On|Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)
41122288|NCT05377567|BEHAVIORAL|TAU + FIBRO-Out|Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)
41122289|NCT05377567|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
41122290|NCT03114410|BEHAVIORAL|Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17|Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and young parent educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of young parent educators delivered the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth received roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
41122291|NCT03292120|OTHER|measure of the SOFA score|The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
41122292|NCT01638026|DRUG|TRIPTORELIN ACETATE, hCG|In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
41274181|NCT02772783|DRUG|primed-variable insulin infusion|A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are \> 400 mg/dl or \< 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
40754229|NCT01428973|DRUG|Mycophenolate mofetil|Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
40926631|NCT02133170|BEHAVIORAL|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
41122293|NCT04788641|DRUG|Tacrolimus|Each subject in this cohort will receive a single dose of oral capsules of tacrolimus on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
41122294|NCT04788641|DRUG|Cyclosporin|Each subject will receive a single dose of oral capsules of cyclosporin on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
41122295|NCT04788641|DRUG|Sodium Zirconium Cyclosilicate|Each subject will receive single oral doses of SZC with tacrolimus (cohort 1) or cyclosporin (cohort 2) under fasted conditions. The doses will be administered after an overnight fast of at least 12 hours.
41122296|NCT04894851|BEHAVIORAL|Contingency Management|Participants in the current study will receive contingencies for improvement in clutter, as measured by a trained, independent in-home rater. Ratings will be completed by after study consent, and once every month thereafter, being conducted at weeks 0, 4, 8, 12, and 16 of treatment. Participants will be reimbursed for each new 1-point reduction in CIR score, a set dollar amount per month for each CIR point reduction they maintain from baseline. Therefore, a perfectly performing patient would earn reimbursement (A CIR reduction of 8 points made in the first month and maintained throughout treatment. If a CIR score is higher than the prior month, the reinforcement schedule will reset to zero.
41122297|NCT02195297|OTHER|ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream|Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
41122298|NCT01837940|DIETARY_SUPPLEMENT|Placebo|Galactooligosaccharide (GOS) and rhamnose in a powder formulation
41122299|NCT01837940|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
41122300|NCT04643340|OTHER|real-time fMRI|Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).
41122301|NCT06009536|OTHER|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
41122302|NCT02990949|OTHER|Timing of trigger|
41122303|NCT04447209|OTHER|Dietary counselling on Food Groups according to IYC Feeding practices, WHO|Monitoring of Dietary diversity and growth
41122304|NCT04282824|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
41122305|NCT04282824|PROCEDURE|Computed Tomography|Undergo PET/CT
41122306|NCT04282824|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
41122307|NCT04282824|DIETARY_SUPPLEMENT|Monosodium Glutamate|Given PO
41122308|NCT04282824|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40926632|NCT02133170|BEHAVIORAL|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
41274182|NCT04804891|BIOLOGICAL|Cell Therapy|Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
41274183|NCT04278911|DIAGNOSTIC_TEST|MMSE and MoCA|This is an observational study. All the patients evaluate with MMSE (Mini-mental State Examination) and MoCA (Montreal Cognitive Assessment), and investigate the incidence and characteristics of cognitive and MACE
41274184|NCT00346827|DRUG|Apomorphine Nasal Powder|
40754230|NCT01428973|DRUG|Sirolimus|Tablets. 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
40754231|NCT04867330|OTHER|Toxicities reduced treatment arm|Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
40754232|NCT03883451|OTHER|Helmet Model|helmet model worn by football players
41122309|NCT00814905|DRUG|saline|A saline infusion after delivery (one dose)
41122310|NCT00814905|DRUG|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
41122311|NCT00814905|DRUG|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
41122312|NCT00814905|DRUG|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
41122313|NCT00189969|BIOLOGICAL|Elstree-BN|
41122314|NCT00124878|PROCEDURE|Male circumcision|Sleeve circumcision
41122315|NCT05989542|DRUG|PLB1001|200mg BID Oral
41122316|NCT04523922|DRUG|40 IU Intranasal Oxytocin|40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
41122317|NCT04523922|DRUG|Placebo|Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
41122318|NCT04523922|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure|12 weekly sessions of COPE therapy for PTSD and AUD.
41122319|NCT05403567|OTHER|Bootle Blast Home Intervention|Children will play BB at home for 8 continuous weeks. Participants will be asked to stop playing at the end of week 8 and the game will be programmatically locked to prevent further play until the post-intervention interviews and assessments are complete.
41122320|NCT01086826|DRUG|RT+CDDP/5-FU|RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.
41274185|NCT04352920|OTHER|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
41274186|NCT01994187|PROCEDURE|Carotid endarterectomy|
41274187|NCT01994187|PROCEDURE|carotid angioplasty|
41274188|NCT04255511|DEVICE|Twin Block|Functional appliance
41274189|NCT04255511|DEVICE|Fixed orthodontic appliance|Braces
41122321|NCT01086826|DRUG|RT+CETUXIMAB|RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.
41274190|NCT02072629|OTHER|Training of VHVs in iCCM|Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
41274191|NCT01027689|DRUG|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
41274192|NCT01027689|DRUG|alprazolam test sublingual tablet|1 mg tablet, single dose
41274193|NCT02321969|DIETARY_SUPPLEMENT|GTE (green tea extract)|6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate \[EGCG\]).
41274194|NCT06288009|PROCEDURE|Running locking suture|In running locking sutures, the first anchoring knot is made at one end of the wound, and a loop of suture is left from the beginning of the throw. The needle is then passed through the loop of suture, locking the suture in place. This is repeated until reaching the end of the wound, where the suture material is then tied to the loop using an instrument tie for the final throw.
41122322|NCT01086826|DRUG|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)"
41122323|NCT01086826|DRUG|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times."
41122324|NCT02234128|DEVICE|Toronto EVLP System™|Extending preservation and assessment time of donor lungs using the Toronto EVLP System
41122325|NCT00253734|BIOLOGICAL|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
41122326|NCT00253734|BIOLOGICAL|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
41122327|NCT01370343|DRUG|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
41122328|NCT01370343|DRUG|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
41122329|NCT00226018|DEVICE|Hand Adapter (Organon, Oss, the Netherlands)|Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
41122330|NCT00226018|DEVICE|Placebo|placebo
41274195|NCT06288009|PROCEDURE|Standard running suture|In standard running sutures, the first anchoring knot is made at one end of the wound, and all of the suture material is pulled through after completing the throw. This is repeated until reaching the end of the wound, where the suture material is then tied.
40754233|NCT06027463|PROCEDURE|Head and neck vascular recanalization|Head and neck vascular recanalization
40758271|NCT00707369|DRUG|Amoxicillin and Metronidazole|tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
40926633|NCT04625296|BEHAVIORAL|Semi-directive interview|Semi-directive interview, lasting a maximum of 45 minutes
41122331|NCT03440034|DRUG|Pioglitazone|Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
41122332|NCT00595413|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
41122333|NCT00595413|DRUG|Atacicept: with loading dose|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
41122334|NCT00595413|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
41122335|NCT00595413|BIOLOGICAL|Adalimumab|Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
41274196|NCT02790489|DIETARY_SUPPLEMENT|Valedia|
41274197|NCT00000402|DRUG|Calcium|
41274198|NCT04412304|DRUG|Dose of Tinzaparin or Dalteparin|The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.
41274199|NCT01395238|BEHAVIORAL|Fathers Supporting Success in preschoolers|Group-based, 8 weekly session for 2.0 hours/week.
41274200|NCT01172379|DRUG|E2007|"Experimental 1 Drug: E2007~0.5 mg 1 tablet per day"
41274201|NCT01172379|DRUG|E2007|"Experimental 2 Drug: E2007~1.0 mg 1 tablet per day"
41274202|NCT01172379|DRUG|E2007|"Drug: E2007~2.0 mg 1 tablet per day"
41274203|NCT01172379|OTHER|Placebo Comparator|Placebo 1 tablet per day
41274204|NCT06190483|DRUG|Diazepam 5 Mg Oral Tablet|Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
41274205|NCT06190483|DRUG|Ascorbic Acid 50 Mg Oral Tablet|Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
41274206|NCT01833871|OTHER|Three dimensional Power Doppler to the myometrial mass|Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
41274207|NCT01833871|OTHER|Uterine artery Doppler|uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
41274208|NCT03384329|DRUG|Resveratrol Pill|Resveratrol 500 mg
41274209|NCT03384329|DRUG|Placebos|Placebo Pills
41122336|NCT05661994|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|"Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18) to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group."
41122337|NCT04418999|DRUG|dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use|Experimental
40754234|NCT02229292|DRUG|Tranexamic Acid|"Active group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure."
41122338|NCT04418999|DRUG|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Active Comparator
40754235|NCT02229292|DRUG|Saline|"Placebo group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure."
40754236|NCT03407911|OTHER|Harvested|Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis
40754237|NCT04447066|OTHER|No intervention|No intervention - VHIT will be used but without intervention
40754238|NCT01038895|DRUG|Ramipril|tablet; 10 mg; od; 3 months
40754239|NCT01038895|DRUG|Experimental|tablet; 300 mg; od; 3 months
41122339|NCT00873613|PROCEDURE|Use of Non-dilated retinal photography|Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
41122340|NCT01845428|DRUG|Pravastatin|After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
41122341|NCT01850836|PROCEDURE|repetitive transcranial magnetic stimulation|
41122342|NCT02553161|DRUG|Escitalopram|Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
41122343|NCT02553161|BEHAVIORAL|Cognitive behavioral Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
41122344|NCT01079065|DRUG|Famotidine|Tablets
41122345|NCT05998252|DEVICE|Alveo HP Balloon Dilatation Catheter|Alveo HP Balloon is intended for dilatation of stenosis in the coronary artery.
41274210|NCT04178148|OTHER|Amikacin dose optimization|Therapeutic drug optimization of amikacin using the BestDose software algorithm
41274211|NCT06247826|PROCEDURE|Blood sampling|Blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis.
40754240|NCT01653262|DRUG|Brivaracetam|
41122346|NCT01877343|DEVICE|CVInsight(TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
41122347|NCT00411216|OTHER|Control exercises|saccadic eye movements against a plain background; no head movements
41122348|NCT00411216|OTHER|gaze stabilization exercises|adaptation and substitutin exercises encorporating retinal lsip and head movements
41122349|NCT01827917|BIOLOGICAL|rabies vaccine|Injection on day 0、7、21
41122350|NCT02745340|OTHER|Acetate by Citrate substitution and vice versa|substitution of acetate by citrate in dialysis fluid
41122351|NCT02298452|DEVICE|Hearing aid.|The hearing aid will be fitted to the individual hearing loss of the subject.
41122352|NCT01105117|DRUG|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
41122353|NCT01105117|DRUG|Flolan®|per Prescribing Information
41122354|NCT04231721|DEVICE|High Resolution Colonic Manometry and 3D-Transit system|Measurement of colonic pressure changes and passage patterns in healthy.
41122355|NCT04292132|PROCEDURE|Implant placement|interforaminal placement of 2 implants
41122356|NCT04292132|PROCEDURE|immediate loading|immediate loading with a locator retained mandibular overdenture
41122357|NCT04292132|PROCEDURE|conventional loading|conventional loading with a locator retained mandibular overdenture 3 months postoperatively
41122358|NCT03268213|BIOLOGICAL|Fecal Microbial Transplantation|"Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy"
41122359|NCT00493350|PROCEDURE|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
41122360|NCT01347892|OTHER|DeNovo NT Natural Tissue Graft|DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
41122361|NCT02111889|OTHER|[11C] kinase inhibitor PET [15O]water PET and tumor biopsies.|\[11C\] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and \[15O\]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
41122362|NCT02379936|DEVICE|The Neo Hilda|"This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.~Point of care method"
41122363|NCT02379936|PROCEDURE|Traditional evaluation|Traditional way of evaluation
41274212|NCT02609581|DRUG|Sublingual Immunotherapy with tablets (mites)|Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
41274213|NCT05973370|DRUG|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
41274214|NCT05973370|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an addon treatment to the current DMARDs treatments for rheumatoid arthritis.
41274215|NCT00541983|DRUG|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
41274216|NCT00541983|DRUG|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
41274217|NCT01062477|BIOLOGICAL|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
41274218|NCT01062477|BIOLOGICAL|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
41122364|NCT02379936|DEVICE|iPhone 4S|
41274219|NCT01062477|BIOLOGICAL|DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine|0.5 mL, Intramuscular (each vaccine)
41274220|NCT01568723|GENETIC|response to therapy|evaluate specific markers for response to therapy at specific intervals pre and post therapy
41274221|NCT04035876|DRUG|Camrelizumab plus apatinib|Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
40754241|NCT03941886|OTHER|Low-dose aspirin in women with high risk of preeclampsia|Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight \<40 Kg, from \<15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor
41122365|NCT05792280|DEVICE|AI system|Patients will undergo EUS examination with the assistance of AI system.
41122366|NCT00683696|DEVICE|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
41122367|NCT00609336|DRUG|gemcitabine hydrochloride|Given IV
41122368|NCT00609336|DRUG|docetaxel|Given IV
41122369|NCT00609336|DRUG|capecitabine|Given PO
41122370|NCT00609336|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
41122371|NCT00609336|DRUG|oxaliplatin|Given IV
41122372|NCT00609336|PROCEDURE|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
41122373|NCT00609336|PROCEDURE|therapeutic conventional surgery|Undergo therapeutic conventional surgery
41122374|NCT00609336|OTHER|laboratory biomarker analysis|Correlative studies
41122375|NCT02932761|DRUG|GnRHa|Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.
41122376|NCT02932761|PROCEDURE|Vaginal repair of CSD|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
41122377|NCT02652689|RADIATION|Diagnostic ultrasound radiation|Recording Doppler ultrasound signals from the right chest wall
41122378|NCT01833923|DRUG|anlotinib|oral medicine.
41122379|NCT00616031|DRUG|carboplatin|
41122380|NCT00616031|DRUG|nitroglycerin|
41122381|NCT00616031|DRUG|paclitaxel|
41122382|NCT04570592|DRUG|Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg|Comparing PONV incidences in both arms
41122383|NCT04570592|DRUG|Granisetron 1 Mg/mL Intravenous Solution|Comparing PONV incidences in both arms
41122384|NCT05191810|BEHAVIORAL|Educational information|Educational information about non-pharmacological supporting treatment of functional constipation, involving recommendation of adequate for age fluid intake
41122385|NCT03741517|RADIATION|18F-FDG-PET|Fludeoxyglucose F18
41122386|NCT03741517|RADIATION|68Ga-DOTATOC-PET|DOTA-tyr3-Octreotide Ga68
41122387|NCT03741517|RADIATION|Computed tomography|Computed tomography of thorax and abdomen with 3-phase contrast
41122388|NCT03741517|OTHER|Core needle biopsy|Core needle biopsy of metastatic lesions
41122389|NCT03741517|OTHER|Phlebotomy|Phlebotomy from peripheral vein
41122390|NCT01511159|DRUG|liraglutide|Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data
41122391|NCT01511159|DRUG|placebo|Single dose by inhalation. Progression to open-label trial part will be based on safety data
41122392|NCT01511159|DRUG|liraglutide|Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
41122393|NCT01511159|DRUG|liraglutide|Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
41122394|NCT01511159|DRUG|insulin human|Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
41122395|NCT01511159|DRUG|insulin human|Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
41122396|NCT01511159|DRUG|liraglutide|24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
41122397|NCT03448510|DEVICE|Irreversible electroporation|The subject will receive Irreversible electroporation procedure which is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane.
41274222|NCT02505984|DRUG|Oxytocin|Study participants will be randomized to a placebo or drug group.
41274223|NCT02505984|DRUG|Placebo|Study participants will be randomized to a placebo or drug group.
41274224|NCT05669521|DRUG|TK-112690|TK112690 treatment Post 5-FU chemotherapy
41274225|NCT05669521|DRUG|Placebo|Placebo treatment Post 5-FU chemotherapy
41274226|NCT06121128|PROCEDURE|Inspiratory Muscle Training (IMT)|"The POWERbreathe™ Plus: an Inspiratory Muscle Training device (IMT) with adjustable resistance.~Intervention lasts 4 weeks, with a frequency of 6 days/week, 2 series of 30 inspirations in the morning and evening.~Resistance based on 60% of the Pressure Maximal Inspiratory (PMI). Progressive increase in resistance every week."
41274227|NCT06121128|PROCEDURE|Normal Breathing|No IMT performed
41274228|NCT04340050|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~300 mL over 4 hours
41274229|NCT05593770|DRUG|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
41122398|NCT03448510|DRUG|Standard Medication|The subject will be prescribed with α-blocker or/and 5α-reductase inhibitors.
41122399|NCT06198114|OTHER|Multi Sensory Therapy|This group will be treated with activity based training by place different( nuts, screws, bullets, coins, paper clips, coloring ,scissor cutting with different shapes , Simulated feeding (by collecting beans with a spoon and transferring them into a container),transfer light and heavy weight objects into empty box. 5 days in a week
41122400|NCT06198114|OTHER|Conventional Therapy|This group will be treated with traditional therapy in which Place toys/objects inside and encourage the student to reach in and pull them out as well as put them back in. Give the student objects that can be put together and pulled apart. Encourage the students to use two hands in an organized manner to manipulate objects (e.g., grasp/release, twist/turn, rotate and examine, open/close, stack, nest).5 days a week for an hour/daily.
41122401|NCT04929067|DRUG|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
41122402|NCT03924037|BEHAVIORAL|Intergenerational Knowledge Sharing group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the Intergenerational Knowledge Sharing group will attend 12 weekly groups taught by tribal elders that focuses on sharing knowledge about the tribe.
41122403|NCT03924037|BEHAVIORAL|Support group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the support group will attend 12 weekly support groups led by a behavioral health specialist that focuses on social support of the youth.
41122404|NCT00352976|DRUG|Cyclophosphamide|Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
41122405|NCT00352976|DRUG|Fludarabine|Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m\^2 intravenous (IV)
41122406|NCT00352976|PROCEDURE|Total Body Irradiation|total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
41122407|NCT00352976|PROCEDURE|Bone Marrow Transplantation|A target of 5 \* 10\^6/kg and a minimum of 4 \* 10\^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.
41122408|NCT00352976|DRUG|Mycophenolate Mofetil|Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 \* 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
41274230|NCT05593770|DRUG|Placebo|Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
41274231|NCT01585389|GENETIC|gene expression analysis|
41274232|NCT01585389|GENETIC|genetic linkage analysis|
40926634|NCT04625296|BEHAVIORAL|Questionnaire : Preparedness for Caregiving Scale|Preparedness for Caregiving Scale - 8 questions
40926635|NCT06116240|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
40926636|NCT06116240|DRUG|AL2846 capsule|AL2846 is a multi-targeted tyrosine kinase receptor inhibitor
40926637|NCT06116240|DRUG|Pemetrexed disodium for injection|Pemetrexed disodium is a multi-target antifolate antineoplastic drug.
41122409|NCT00352976|DRUG|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
41122410|NCT05307536|COMBINATION_PRODUCT|Autologous BMMNCs transplantation and educational intervention|"Biological/ Vaccine: Autologous bone marrow-derived mononuclear cell infusion (BM-MNCs) will be administrated at baseline, and the second infusion will be performed six months after the first administration. For each transplantation, the bone marrow will be harvested through an anterior iliac crest puncture under general anesthesia in the operating theatre. The volume collected depends on the patient's body weight based on our experience from a previous study as follows: 8 ml/kg for patients under 10 kg; \[80 ml + (body weight in kg - 10) x 7 ml\] for patients above 10 kg but no more than 250 ml in total.~Educational intervention: 6 months based on the Early Start Denver Model"
41122411|NCT05307536|COMBINATION_PRODUCT|Educational intervention|Educational intervention: 6 months based on the Early Start Denver Model
41122412|NCT00767754|DRUG|Paxil CR|12 week treatment of Paxil(20-40mg)
41122413|NCT06094231|BEHAVIORAL|Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor|The patients will be educated on how to implement a therapeutic carbohydrate restriction, which consists of 50 to 130 grams of carbohydrate per day, simultaneously they will continue to receive the SGLT-2-Inhibitor dapagliflozin.
41122414|NCT04850586|OTHER|Education Group|The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
41122415|NCT06513975|DEVICE|CART BP|A ring-type medical device worn by the subject that non-invasively measures systolic and diastolic blood pressure, as well as pulse rate.
41274233|NCT01585389|GENETIC|microarray analysis|
41274234|NCT01585389|OTHER|immunohistochemistry staining method|
41274235|NCT01585389|OTHER|laboratory biomarker analysis|
41274236|NCT04201379|OTHER|quality of life assesment|The sociodemographic and clinical characteristics of the individuals who meet the study criteria will be recorded. Evaluations of the participants will be done only once
41274237|NCT05564858|DRUG|FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia|FDA022-BB05, intravenously infusion, q3w
41274238|NCT05564858|DRUG|FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib|FDA022-BB05, intravenously infusion, q3w
41274239|NCT05806242|OTHER|Italian Validation of the Italian Elderly Mobility Scale (EMS-I)|Two physiotherapists independently evaluate the same enrolled patient with the Italian Elderly Mobility Scale (EMS-I) and Barthel Index
40754242|NCT01449994|DEVICE|Activator IV (Activator Methods Int. Phoenix, Arizona)|Instruments gives a defined impulse on specified areas of the body
40754243|NCT04424680|BEHAVIORAL|Advanced Care Planning program of health decisions|Application of an Advanced Care Planning program program for decision-making in patients with advanced Heart Failure, in comparison to usual follow up and care.
40926638|NCT06116240|DRUG|Cisplatin injection|Cisplatin is a chemotherapy drug.
40926639|NCT02787486|OTHER|Blood sampling for Laboratory Developed Test (LDT) analysis|Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT
41274240|NCT02665689|DRUG|ranibizumab|Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
40926640|NCT03207165|DRUG|Milrinone|Patients will be initiated on Milrinone at 0.125 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[0.250, 0.375, 0.5 and \>0.5 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
40926641|NCT03207165|DRUG|Dobutamine|Patients will be initiated on Dobutamine at 2.5 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[5.0, 7.5, 10 and \>10 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
40926642|NCT04407572|OTHER|Serum zinc, vitamin d vitamin b12 levels .|Serum zinc, vitamin d vitamin b12 levels of 45 patients will be measured and evaluated together with the information of the patients.
40926643|NCT05466487|DEVICE|Transcranial Alternating Current Stimulation (tACS)|Stimulation frequency and peak-to-peak intensity will be set to 10Hz and 1.5 milliampere (mA), phase offset will be set to 0 and 100 cycles will be used for ramping up. At the start of the neglect training session, the tACS will be started. When the neglect training session is finished, after maximally 40 minutes, the tACS will be switched off.
41274241|NCT05225155|DRUG|Enoxaparin|Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
41274242|NCT04963829|BIOLOGICAL|gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration|It is a gel that was used in chronic ulcers healing
41122416|NCT06513975|DEVICE|sphygmomanometer|Blood pressure measurement method utilizing a two-headed stethoscope, allowing two observers to simultaneously hear the Korotkoff sounds.
41122417|NCT02390570|OTHER|Patient Capacity Assessment Instrument|The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
41122418|NCT00709423|DRUG|Moxaverine|
41122419|NCT00709423|DRUG|Moxaverin 150mg|intravenous administration
41122420|NCT00709423|DRUG|NaCl|intravenous administration
41122421|NCT01205048|DEVICE|Emervel Classic Lidocaine|20 mg/mL + 0.3% lidocaine
41122422|NCT01205048|DEVICE|Juvederm® Ultra|24mg/mL
41122423|NCT03447249|DRUG|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
41122424|NCT03447249|DRUG|IVA|Participants received IVA orally once daily in the evening.
41122425|NCT03447249|DRUG|Placebo|Participants received placebo matched VX-659/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
41122426|NCT03639896|DRUG|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
41122427|NCT03639896|DRUG|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
41122428|NCT05435313|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
41122429|NCT05435313|DRUG|Fruquintinib|3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC
41122430|NCT05435313|DRUG|Tislelizumab|200mg, ivgtt, d1, 21 days for a cycle
41122431|NCT05435313|DRUG|Raltitrexed|2 mg/m2, hepatic artery infusion for 15 min, d1, 4-6 Cycles
41122432|NCT05435313|DRUG|Oxaliplatin|85 mg/m2, hepatic artery infusion for 2 h, d1, 4-6 Cycles
41122433|NCT05435313|DRUG|Irinotecan|120mg/m2, hepatic artery perfusion for 30-90min, d1, 4-6 Cycles
41122434|NCT02422615|DRUG|Ribociclib|Ribociclib capsules were administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle.
41122435|NCT02422615|DRUG|Fulvestrant|Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
41274243|NCT04963829|BIOLOGICAL|Collagenase ointment|Participants who were subjected to a standardized treatment (collagenase ointment)
40758272|NCT00707369|DRUG|Placebo|Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
41122436|NCT02422615|DRUG|Placebo|Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
41122437|NCT05277441|DIAGNOSTIC_TEST|Novel severity grading system of unexpected events in pediatric surgery|Classification of unexpected events according to the Clavien-Madadi classification for pediatric surgical patients and simultaneously the non-modified Clavien-Dindo classification in more than 10.000 patients who have been treated at a single center from 2017 to 2022.
41122438|NCT03312322|OTHER|High-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s."
41122439|NCT03312322|OTHER|Low-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s."
41122440|NCT03312322|OTHER|Sham transcutaneous electrical nerve stimulation|The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
41122441|NCT06514482|DIAGNOSTIC_TEST|Diagnosis|Diagnosis
41122442|NCT02120430|OTHER|Video|"The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children."
41122443|NCT03804580|DRUG|osimertinib|Non-randomized trial, all patients receive therapy
41274244|NCT04963829|BIOLOGICAL|Gel with 10% peel powder of unripe banana|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum),
41274245|NCT00679887|PROCEDURE|ischemic compression|Active Comparator, ischemic compression, 3 times a week,5 weeks
41274246|NCT04995094|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
40926644|NCT05466487|BEHAVIORAL|Visual Scanning Training (VST)|The most common treatment for neglect is VST, which is an intensive compensation training (see Dutch guidelines for rehabilitation of neglect: Ten Brink, Van Kessel, \& Nijboer, 2017). The aim of this training is to improve visual scanning behavior, that is, to encourage neglect patients to actively and consciously pay attention to stimuli on the contralesional side.
40926645|NCT02298335|DRUG|prednisone|Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
40926646|NCT02195011|DEVICE|SIR-Spheres|Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
40926647|NCT02195011|DRUG|Regorafenib|All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
41122444|NCT01595789|DRUG|Liraglutide|Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
41122445|NCT01595789|DRUG|Placebo|Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
41122446|NCT01761201|DRUG|Levofloxacin|Levofloxacin
41122447|NCT01761201|DRUG|Isoniazid|"300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months."
41122448|NCT05869617|OTHER|Aquatic exercise|"Participants in the aquatic therapy group will receive aquatic therapy in a HydroWorx aquatic therapy pool at Hydrathletics.~In the aquatic therapy group the 20 minutes of aerobic exercise at each visit will involve walking on an underwater treadmill. The intensity of the walking will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on movement patterns that simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or increasing resistance."
41122449|NCT05869617|OTHER|Land-based Exercise|"Traditional land-based training will take place the Hydrathletics gym with similar exercises provided to the aquatic therapy group.~The aerobic exercise for the land-based therapy group will be 20 minutes of treadmill walking. The intensity will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on similar movement patterns to the aquatic therapy group to simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or the resistance used for the exercise."
41122450|NCT05551000|OTHER|Experimental, comparator and control|"To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group."
41122451|NCT02269475|DRUG|MEDI3250|MEDI3250
41122452|NCT02269475|DRUG|Placebo|Placebo
41122453|NCT02509637|DEVICE|Flutter|Flutter is a small device, simple, like a plastic pipe with a mouthpiece at one end and a perforated cover on the other, containing a steel ball resting in a plastic cone inside. When the patient exhales through the flutter expiratory flow causes movement of the ball, creating an oscillatory positive pressure.
41122454|NCT02509637|OTHER|Chest Compression|Manual chest compression is based on the application of forces resulting from the action of respiratory muscles or physiotherapist manual action in order to increase the alveolar pressure creating a pressure gradient to promote change in pulmonary flow and volume.It consists of vigorous compression of the chest at the beginning of expiration or during expiration.
41122455|NCT02509637|OTHER|Control|
41122456|NCT02509637|OTHER|Impulse Oscillometric|"For this measure will be used IOS Jaeger (Jaeger, Wurzburg, Germany). to minimize the effect of the bad positioning of the tongue will use a mouth free-flow, which contains a depressant for keeping the tongue in the mouth soil, stabilizing it and reducing oral resistance. Volunteers will support hands firmly on the cheeks to reduce the effect of oscillation thereof. The measures will be carried out with the volunteer sitting, using nasal, relaxed and your head in neutral clip, breathing normally through the mouthpiece to his lips tightly sealed to prevent air leaks."
41122457|NCT02509637|OTHER|Dyspnea scale|Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
40926648|NCT05623865|OTHER|kinesiotaping|"Kinesio tape will be attached with lymphedema technique.~The bands will be removed prior to each assessment so that they do not affect the evaluator's blinding. After evaluation, the new tape will be fitted by the invesitgatör"
40926649|NCT05623865|OTHER|exercise|"Wrist, finger, elbow range of motion and stretching exercises will be taught to the patients and given as home exercises.~In addition, patients will be given a leaflet containing illustrated and explanatory exercise visuals."
40926650|NCT05637814|DIAGNOSTIC_TEST|SpO2/PIx Measurement and ML Algorithm|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured and an online ML inference model will be used to classify a newborn as healthy versus CCHD as new pulse oximetry data is collected.
40926651|NCT00026611|BIOLOGICAL|Dryvax vaccine|
40926652|NCT01809470|BEHAVIORAL|FIFA2013|Playing FIFA2013 for 1 hour
41122458|NCT02509637|OTHER|Acceptability and tolerance|patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
41122459|NCT02509637|DEVICE|Pulse oximetry|During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures
41274247|NCT04995094|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein. Pembrolizumab will be administered at 200 mg IV Q3W for 9 weeks.
41274248|NCT01686568|DRUG|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
41274249|NCT01686568|DRUG|placebo|
40926653|NCT01809470|BEHAVIORAL|Call of Duty|Playing Call of Duty for 1 hour
41122460|NCT02509637|OTHER|Difficulty sputum|Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
41122461|NCT03767452|DRUG|Xiaflex® 0.58 mg|0.25 mL injections.
41122462|NCT04718909|DRUG|Regorafenib + sintilimab|"Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w."
41122463|NCT04718909|DRUG|Regorafenib|160 mg p.o. qd for 3 weeks of every 4 week cycle.
41122464|NCT03710057|DRUG|Ivabradine|A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.
41122465|NCT03980496|DRUG|Omeprazole|
41122466|NCT01494922|DRUG|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
41122467|NCT04803409|DEVICE|Splenic Ultrasound|Splenic Ultrasound: Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
41122468|NCT03877159|OTHER|There is no intervention.|There is no intervention. This is a retrospective study analysing archived tumour samples.
41274250|NCT00078130|DRUG|Buprenorphine/naloxone|
41274251|NCT04095520|PROCEDURE|Laser Etching|Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.
41274252|NCT04095520|PROCEDURE|Phosphoric acid etching|Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.
41274253|NCT04502615|OTHER|Sand|sand surface
41274254|NCT04502615|OTHER|artificial grass|grass surface
41274255|NCT04502615|OTHER|firm ground|firm surface
40926654|NCT01809470|BEHAVIORAL|Watching TV|Watching TV for 1 hour
40926655|NCT00266864|DRUG|Testosterone Transdermal System (Androderm 5 mg patch)|Testosterone Transdermal System (Androderm 5 mg patch)
41122469|NCT02797444|OTHER|semi-structured interviews|
41122470|NCT01402531|DRUG|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
41122471|NCT04524494|OTHER|biopsy of intestinal tissue|4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)
41122472|NCT04524494|OTHER|blood draw|40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)
41122473|NCT04524494|OTHER|urine collection|Midstream Urine collection
41122474|NCT06232889|DIAGNOSTIC_TEST|Deuterium Glucose Metabolic Imaging with MRI spectroscopy|MRI spectroscopy of the liver, following ingestion of 20 mg deuterium glucose p.o., prior to and after radioembolization treatment for mCRC
41122475|NCT00774904|DRUG|Losartan|Angiotensin II Type 1 Receptor Blockers
41122476|NCT04275908|DEVICE|MHSAFE app|App to detect presence of mental state
41122477|NCT01306500|PROCEDURE|Gastric lavage|8 Fr feeding tube was inserted orally with length equal to distance from the bridge of the nose to the earlobe and from the earlobe to a point halfway between the xiphoid process and the umbilicus. 20ml normal saline was used for gastric lavage. It was ensured that entire amount of normal saline used was removed from stomach.
41122478|NCT01671449|DRUG|S-1|S-1 : 40 mg/m2, twice daily, Day 1-14
41122479|NCT01671449|DRUG|Cisplatin|60 mg/m2/day Day 1
41122480|NCT01671449|DRUG|Oxaliplatin|130 mg/m2/day Day 1
41122481|NCT04034771|DRUG|Melatonin 10 MG Oral Tablet|Melatonin tablets
41122482|NCT04034771|DRUG|Propofol|propofol amp
41122483|NCT04034771|DRUG|Placebo oral tablet|sugar pill manufactured to mimic melatonin tablets
41274256|NCT01403298|BEHAVIORAL|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
41274257|NCT01403298|OTHER|Adolescent Only Health Promotion|An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
41274258|NCT00216567|DRUG|topamax|
41274259|NCT04360304|DEVICE|Echocardiographic exam|"An echocardiographic exam is realised after inclusion, measuring especially :~* LVOT VTI~* Respiratory variation of inferior veina cava diameter For theses two measurements, the manual method is first recorded, and then the automated one is done.~For patients that need fluid resuscitation of at least 250mL in less than 10minutes (indication at the discretion of the physician in charge of the patient), a second echocardiography is done according to the same protocol described before."
41274260|NCT04740229|BEHAVIORAL|Yoga|Moderate-intensity flow-based yoga movements, breathing, and relaxation for 50 minutes, 3 times per week, for 8 weeks
41274261|NCT00004373|DRUG|alprazolam|
40926656|NCT05558501|OTHER|Mild Intermittent Hypoxia|The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2)= 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
41274262|NCT06427109|DIETARY_SUPPLEMENT|Dietary intake of omega-3 fatty acid|Participants were stratified into omega-3 consumption quartiles to assess colorectal adenoma incidence trends
40926657|NCT05558501|OTHER|Sham MIH|"During sham MIH the participants will be exposed to compressed air (the equivalent of room air)."
40926658|NCT04399460|OTHER|Dairy-based commercially available food products|Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses
40926659|NCT04399460|OTHER|Restrictive Eating|Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein
41274263|NCT05704985|BIOLOGICAL|DK210 (EGFR)|Solution for SC administration
41274264|NCT05704985|RADIATION|Radiation therapy|Short regimen radiation therapy (10 fractions or less)
41274265|NCT05704985|BIOLOGICAL|Immune checkpoint blockers|IV administration of approved PD1 blocker
40926660|NCT04550377|DRUG|Cannabidiol|The drug product to be used in this study is an oral formulation of CBD
40926661|NCT04550377|DRUG|Placebo|non-active medication
40926662|NCT01791959|DIETARY_SUPPLEMENT|synbiotic|2 symbiotics capsules per day for 28 weeks
40926663|NCT01791959|OTHER|placebo|2 Maltodexterin capsules as a placebo per day for 28 weeks
41122484|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with placebo.|Volunteers will be provided with the placebo. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
41122485|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP1.|Volunteers will be provided with the collagen-derived product CP1. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
41274266|NCT05704985|DRUG|Chemotherapy|Single agent or combination of not more than two
41274267|NCT06052748|DRUG|AD-223A|PO, Once daily(QD), 8weeks
40926664|NCT01823588|BEHAVIORAL|Nurse-led reminder through email.|"Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.~Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form."
41274268|NCT06052748|DRUG|AD-223B|PO, Once daily(QD), 8weeks
41274269|NCT06052748|DRUG|AD-223C|PO, Once daily(QD), 8weeks
41274270|NCT06052748|DRUG|AD-223A Placebo|PO, Once daily(QD), 8weeks
40754244|NCT04394559|BEHAVIORAL|Discharge Order Sets|Discharge order sets will be implemented in the electronic health record and will provide surgeons a guideline for a recommended dose and duration of opioids for each commonly performed orthopedic surgery.
40758273|NCT04858997|DRUG|Palbociclib|Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
40926665|NCT05477472|DRUG|St John's Wort|daily intake of CERES St John's Wort mother tincture. Dose according to the treating physician.
41274271|NCT06052748|DRUG|AD-223B Placebo|PO, Once daily(QD), 8weeks
41274272|NCT06052748|DRUG|AD-223C Placebo|PO, Once daily(QD), 8weeks
41274273|NCT06117540|DRUG|WX390|WX390 tablet, 1.1 mg once a day
41274274|NCT01936038|OTHER|CPAP|CPAP
41274275|NCT01936038|PROCEDURE|Upper Airway Toning for Improve the Compliance of CPAP|Upper Airway Toning for Improve the Compliance of CPAP
41274276|NCT03424161|DEVICE|Secret RF|Subjects will receive treatment with the Secret RF device
41274277|NCT00246168|DRUG|tramadol hydrochloride + acetaminophen|
41274278|NCT04911387|DEVICE|Intraocular pressure measurments|Intraocular pressure measurements with iCare Home by participants (patients, volunteers) and healthcare staff as well as intraocular pressure measurements with GAT by participants different healthcare staff.
41274279|NCT02183714|DRUG|Songha Night ®|
41274280|NCT02183714|DRUG|Placebo|
41274281|NCT00474916|DRUG|KRN5500|Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
41274282|NCT00474916|DRUG|Placebo|Normal Saline given as dose escalation for placebo
40926666|NCT06117085|DEVICE|CellFX® Percutaneous Electrode (PE) System|Percutaneous treatment with CellFX® Percutaneous Electrode using nanosecond pulse field ablation (nsPFA) technology
40926667|NCT04106414|DRUG|Nivolumab|Nivolumab 480 mg every 4 weeks.
41122486|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP2.|Volunteers will be provided with the collagen-derived product CP2. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
41122487|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP3.|Volunteers will be provided with the collagen-derived product CP3. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
41122488|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP4.|Volunteers will be provided with the collagen-derived product CP4. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
41122489|NCT03182816|BIOLOGICAL|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
40926668|NCT04106414|DRUG|BMS- 986205|BMS-986205 100 mg every 4 weeks.
41122490|NCT00963404|RADIATION|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
41122491|NCT03415360|PROCEDURE|cryoablation|cryoablation of nerve responsible for phantom limb pain
41122492|NCT02254720|DRUG|BEA 2180 BR solution for infusion|
41122493|NCT02254720|DRUG|Placebo|Intravenous infusion
41122494|NCT02254720|DRUG|BEA 2180 BR solution for inhalation|
41274283|NCT06183008|DRUG|Intravenous immunoglobulin|Each patient will during the 30-week trial period get 3 IVIG courses (each total dose 2g/kg) for three consecutive days
41274284|NCT06183008|DRUG|Placebo|Each patient will during the 30-week trial period get 3 placebo courses (each 0.9% saline similar volume) for three consecutive days
41274285|NCT00749606|BEHAVIORAL|Individual telephone intervention|"Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
41274286|NCT00749606|BEHAVIORAL|Group telephone intervention|"Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
41274287|NCT03947541|OTHER|Thoracolumbosacral (TLSO) brace|Patients will be required to wear the TLSO brace when out of bed, beginning on postoperative day 2 through 6 week follow-up period.
41274288|NCT03947541|OTHER|No Bracing|Participants will not wear a brace in the study.
40758274|NCT04858997|DRUG|AI|AI, orally once daily (continuously)
40926669|NCT03587285|BIOLOGICAL|Tcm+ Goserelin acetate+ Bicalutamide|Autologous Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,50 mg bicalutamide administered orally daily
40926670|NCT03587285|BIOLOGICAL|Tcm+Goserelin acetate+Abiraterone acetate|Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,1000 mg abiraterone acetate administered orally daily plus 5 mg prednisone administered orally twice daily
40926671|NCT00627952|DRUG|amlodipine 10 mg|amlodipine 10 mg once daily
40926672|NCT00627952|DRUG|manidipine 20 mg|manidipine 20 mg once daily
40926673|NCT00627952|DRUG|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
41274289|NCT01059448|DRUG|AMG 827|AMG 827 210 mg
40926674|NCT00627952|DRUG|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
40926675|NCT06409793|BEHAVIORAL|mHealth|A 3-month structured exercise and PA intervention, supported by an exercise specialist, with a 3-month follow-up
41122495|NCT02254720|DEVICE|Respimat®|
41122496|NCT02710851|BIOLOGICAL|low dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
41122497|NCT02710851|BIOLOGICAL|low dosage HPV Vaccine(1:2)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:2 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
41122498|NCT02710851|BIOLOGICAL|high dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive high dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
41122499|NCT02710851|BIOLOGICAL|Hepatitis E vaccine,Hecolin®|Participants would intramuscularly receive Hepatitis E vaccine for 3 doses at 0, 1, 6 month.
41122500|NCT06020313|DIETARY_SUPPLEMENT|Resveratrol Experimental|The amount of 500mg per day will be offered for seven days distributed in doses of 100mg per schedule (7am, 10am, 1pm, 4pm and 7pm).
40758275|NCT00874016|DEVICE|Airtraq|Intubation using Airtraq
40926676|NCT02619773|PROCEDURE|mupirocin ointment|Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
41274290|NCT01916395|DRUG|sumatriptan and Treximet|sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
40926677|NCT04619160|DRUG|Propofol|TCI 4 µg/mL start until BIS-value of 50
40926678|NCT04619160|DRUG|Sevoflurane|start 1 MAC, until BIS-value of 50
41122501|NCT06499558|OTHER|Classical Training|Students in the education group will practice family planning education skills in the professional skills laboratory.
41274291|NCT02042066|DEVICE|Omnispec model Vascuspec|Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
41274292|NCT02934607|DRUG|Symbicort pMDI with spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
41274293|NCT02934607|DRUG|Symbicort pMDI without spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
40926679|NCT03842982|DRUG|HIPEC|"HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~* 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~* The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours."
41122502|NCT06499558|OTHER|Standard Patient Interviews|Students in the standardized patient education group will receive training involving a family planning counseling scenario with standardized patients.
41274294|NCT02043886|DRUG|Acarbose|Acarbose 50 mg by mouth given during Meal Test
41122503|NCT06100185|DEVICE|PeakSleep|The PeakSleepTM is a constant current device which delivers stable stimulation as a function of the impedance measured across the electrodes (e.g. it varies voltage to produce a steady current). The device gradually ramps up the current as the impedance decreases during the stimulation session. The device uses stimulation amplitudes in the range of 100uA to 500uA at each electrode pair. Devices will be configured to deliver 100 stimulation trains over 30 minutes where each train is 6 pulses of 0.75Hz trapezoidal stimulation (each train lasts 8 seconds). The inter-train interval is 10 seconds leading to a total stimulation time of \<14 minutes with a maximum dose of 1mA (500uA per electrode pair).
40926680|NCT04708171|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
40926681|NCT04708171|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
40926682|NCT04708171|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
40926683|NCT05986084|DRUG|Cabotegravir Injection [Apretude]|Injection
40926684|NCT04272112|COMBINATION_PRODUCT|IPS e.max CAD, Ivoclar Vivadent|Type: monolithic lithium-disilicate glass ceramic
40926685|NCT04272112|COMBINATION_PRODUCT|BruxZir, Glidewell|Type: high translucent zirconia
40926686|NCT04272112|COMBINATION_PRODUCT|BruxZir*, Glidewell|Type: high translucent zirconia with a mini-veneer of porcelain
40926687|NCT05080244|DIETARY_SUPPLEMENT|Probiotics|2 strains 10x10\^9 UFC/capsule
41122504|NCT06100185|DEVICE|Sham|Sham is delivered with the same devices which are alternatively configured to deliver a trivially low amplitude (e.g. 100uA) waveform of a different frequency (e.g. 25 Hz) for the same treatment duration. Beyond differences in amplitude and frequency of stimulation, devices will be operated in exactly the same way during sham treatment.
41274295|NCT02043886|DRUG|Placebo|Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
41274296|NCT03127449|DRUG|Alflutinib|patients take Alflutinib orally once per day at different dose
41274297|NCT01118910|DRUG|Vusion|Vusion will be applied to areas of intertrigo
41274298|NCT01215084|DRUG|BIIB041 (Fampridine-PR)|A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
41274299|NCT06445374|DRUG|Inhaled Epinephrine|"0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes)."
41274300|NCT01159262|DRUG|Midazolam|Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
41274301|NCT01159262|DRUG|Fentanyl/Morphine|Per package insert, N-PASS scores and investigator discretion.
41274302|NCT01159262|DRUG|Dexmedetomidine|
41274303|NCT01991561|BIOLOGICAL|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
41274304|NCT01991561|BIOLOGICAL|Med dose of H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
41274305|NCT01991561|BIOLOGICAL|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
41274306|NCT01991561|BIOLOGICAL|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
41274307|NCT01991561|BIOLOGICAL|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
41274308|NCT01991561|BIOLOGICAL|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
41274309|NCT02518555|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
40758276|NCT00874016|DEVICE|Direct Laryngoscopy|Intubation using direct laryngoscopy
41274310|NCT02518555|DRUG|Ibrutinib|Given PO
41274311|NCT02518555|OTHER|Laboratory Biomarker Analysis|Correlative studies
41274312|NCT02518555|OTHER|Pharmacological Study|Correlative studies
41122505|NCT02215707|BIOLOGICAL|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
41274313|NCT02518555|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
41274314|NCT02518555|OTHER|Quality-of-Life Assessment|Ancillary studies
41274315|NCT02518555|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
41274316|NCT01446211|DRUG|Gusperimus + glucocorticoids|Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
41274317|NCT01446211|DRUG|cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids|"Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
41274318|NCT04396587|DRUG|Sufentanil|Sufentanil(0.1μg/kg) was administered before anesthesia induction.
41274319|NCT04396587|DRUG|Hydromorphone|Hydromorphone(20μg/kg)was administered before anesthesia induction.
41274320|NCT04396587|DRUG|Oxycodone|Oxycodone(60μg/kg) was administered before anesthesia induction.
41274321|NCT04396587|DRUG|normal Saline|normal saline 10ml
41274322|NCT04313946|DIAGNOSTIC_TEST|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
41274323|NCT05742321|GENETIC|Genotyping|Genotyping will measure the triple nucleotide repeat in the TCF4 gene and search for other known mutations in other genes Blood sample will be performed (genetic analyses).
40926688|NCT05080244|DIETARY_SUPPLEMENT|Placebo|Potato starch and magnesium stearate
41274324|NCT05742321|DIAGNOSTIC_TEST|Histology|Histology will be performed on flat mounted Descemet membrane obtained after Descemetorhexis
41274325|NCT05742321|OTHER|Collection of data|Collection of data of examination for diagnosis of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
41274326|NCT01995890|DRUG|nepafenac|
41274327|NCT03282032|OTHER|One-lung ventilation|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1."
41274328|NCT02718820|DRUG|Docetaxel|Docetaxel 75mg/m2; q21
41274329|NCT02718820|DRUG|Pembrolizumab|Pembrolizumab 200mg, q21
41274330|NCT01811914|OTHER|intraoperative TTE|
41274331|NCT02829879|DRUG|8% arginine/1450ppm sodium monofluorophosphate dentifrice|
40926689|NCT01293227|PROCEDURE|Surgical treatment of distal radius fractures|Surgical repair of distal radius fracture using either intramedullary locked nail or volar locked plate
41274332|NCT02829879|DRUG|5% potassium nitrate/2500ppm sodium fluoride dentifrice|
41274333|NCT00003060|BIOLOGICAL|filgrastim|
41274334|NCT00003060|DRUG|busulfan|
41274335|NCT00003060|DRUG|cyclophosphamide|
41274336|NCT00003060|DRUG|cyclosporine|
41274337|NCT00003060|DRUG|methotrexate|
41274338|NCT00003060|PROCEDURE|allogeneic bone marrow transplantation|
41274339|NCT01205009|DRUG|Ovitrelle|One dose of Ovitrelle 250 mcg
41274340|NCT00988390|BEHAVIORAL|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
41274341|NCT01650805|DRUG|ponatinib|45 mg tablet, taken orally once daily
41274342|NCT01650805|DRUG|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
41274343|NCT04848805|PROCEDURE|liver transplantation|total hepatectomy material was examined by pathology laboratory
41274344|NCT00878124|DIETARY_SUPPLEMENT|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
41274345|NCT00878124|OTHER|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
41274346|NCT03903757|OTHER|DNA methylome and total RNA sequencing|Epigenomics tools combined with bioinformatic analysis to correlate putative useful clinical biomarkers with clinical features
41274347|NCT03656913|DIAGNOSTIC_TEST|Extremely low dose CT|Patients undergoing clinically indicated CT will also receive the extremely low dose CT
41274348|NCT06152887|DEVICE|Sooma Oy (tDCS), Helsinki, Finland|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1)
41274349|NCT06152887|DEVICE|Sooma Oy (Sham), Helsinki, Finland|For the sham treatment, an electrical current will also be increased from 0 mA to 2 mA over the first 30 seconds, however, the current will be ramped back down to 0 mA after the initial ramp-up phase and no stimulation is delivered for the rest of the treatment.
41274350|NCT01002781|DRUG|Tocilizumab|Tocilizumab, IV, 8 mg/kg, every 2 weeks
41274351|NCT05802030|OTHER|Plyometric training|Plyometric training can be described as a type of exercise that involves a rapid and forceful movement that consists of an eccentric contraction, followed by an immediate and explosive concentric contraction. Upper and lower limb plyometrics are exercises that enable an upper and lower body muscle group to react quickly to produce maximal strength
41274352|NCT05802030|OTHER|Routine training|Regular tennis training, including normal fitness training, and injury prevention drills
41274353|NCT00553995|DRUG|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
41274354|NCT00553995|DRUG|Placebo|
41274355|NCT03646084|OTHER|Sleep and Circadian Intervention Program (SCIP) plus rehabilitation program|To study circadian rhythm disorders and sleep disorders and develops the SCIP to improve sleep in the patients.
41274356|NCT03646084|OTHER|Rehabilitation program|Rehabilitation program current clinical practice
41274357|NCT03081689|DRUG|Nivolumab 360 mg|Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
41274358|NCT03081689|DRUG|Paclitaxel 200mg/m2|Paclitaxel 200mg/m2 IV Q3W
41274359|NCT03081689|DRUG|Carboplatin AUC 6|Carboplatin AUC 6 IV Q3W
41274360|NCT03593694|BEHAVIORAL|TECH DM-BAT|Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.
41274361|NCT03593694|BEHAVIORAL|TECH DMBAT Active Comparator|Technology delivered diabetes education and home tele monitoring
41274362|NCT03593694|BEHAVIORAL|TECH DMBAT Other|Technology delivered diabetes education
41274363|NCT06231017|DRUG|Adebrelimab + Cetuximab+ Chemotherapy|Adebrelimab:1200 mg, D1, Q2W+Cetuximab:500 mg, D1, Q2W+FOLFOX6(Q2W) or FOLFIRI(Q2W) until PD or resectability or to max 12 cycles
41274364|NCT05011591|OTHER|Swimming economy|Detailed in arm's section
41274365|NCT01962779|OTHER|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.
40754245|NCT04394559|BEHAVIORAL|Pharmacist-Led Discharge Counseling and Communication|Two visits by a trained inpatient pharmacist, including an intake visit to determine previous barriers to safe medication use, and a discharge counseling session with patients and caregivers regarding safe and effective opioid use after discharge; pharmacist communication with providers regarding the post-discharge pain management plan.
41274366|NCT02955329|DRUG|Nicotine|Participants will vape tobacco leaves with nicotine out of the PAX device.
41274367|NCT02955329|DRUG|Cannabis|Participants will vape marijuana leaves with nicotine out of the PAX device.
41274368|NCT02955329|DEVICE|PAX Loose Leaf Vaporizer|In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.
41274369|NCT06028620|BEHAVIORAL|Trauma Focused-Cognitive Behavior Therapy|TF-CBT consisted of 8 units in which different issues realted to trauma are reviewed. Units are: psychoeducation and parenting skills, relaxation techniques, affective expression and regulation, cognitive coping and processing, trauma narrative and processing, in vivo exposure, co-joint sessions and enhancing safety and future growth.
41274370|NCT02016287|OTHER|Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy|Sequential paclitaxel chemotherapy and radiotherapy
41274371|NCT05005884|DRUG|Oral intake of medication|Prescription of oral phenolics 250 mg two times daily
41274372|NCT05005884|DRUG|Placebo|Prescription of oral phenolics 250 mg two times daily
41274373|NCT00662961|PROCEDURE|Periosteum|Periosteum fixation
41122506|NCT00434304|DRUG|Ropinirole prolonged release/extended release(PR/XR)|Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
41274374|NCT00662961|PROCEDURE|Bone|Bone tunnel fixation
40754246|NCT04394559|BEHAVIORAL|Post-discharge Pain Management Follow-up|An outpatient pharmacist pain management follow-up visit (with additional contact as needed) embedded within routine post-operative care for managing pain and opioid use.
41274375|NCT05241249|DRUG|Bethanechol|Study Drug: Bethanechol (generic), supplied as 50mg oral tablets. Subjects will take 2 tablets (100mg) twice daily. Medication should be taken 1 hour before meals in AM and PM. Medication will be purchased commercially and dispensed at the research pharmacy.
41274376|NCT05241249|DRUG|Gemcitabine|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with gemcitabine at a dose of 1000 mg/m2
41274377|NCT05241249|DRUG|nab-paclitaxel|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with nab-paclitaxel dose at 125 mg/m2
41274378|NCT03639740|DRUG|Secukinumab 150 milligram [Cosentyx]|For intervention description: see arm/group description
40754247|NCT04394559|BEHAVIORAL|Patient Engagement Pain Management App|A mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder.
40754248|NCT05611736|OTHER|cold saline|After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
40926690|NCT03859830|DEVICE|Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
41274379|NCT01355406|DEVICE|FlexStent® Femoropopliteal Self Expanding Stent System|Transcatheter over guidewire placement of an intravascular stent(s)
41274380|NCT05328050|OTHER|Registry|observational, data collection
41274381|NCT05177055|BEHAVIORAL|Group-based light therapy at gradually advanced timing for DSWPD|Light therapy at gradually advanced timing, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
41274382|NCT05177055|BEHAVIORAL|Group-based light therapy at gradually advanced timing for DSWPD and additive bb-glasses|Light therapy (LT) at gradually advanced timing, bb-glasses 12 hrs after LT, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
41274383|NCT05177055|OTHER|6-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
41274384|NCT02806401|DEVICE|landmark|
41274385|NCT02806401|DEVICE|US_Ax|
41274386|NCT02506530|PROCEDURE|intensive decongestive treatment|intensive decongestive treatment
41274387|NCT02506530|DEVICE|Cellu M6|Use of Cellu M6
41274388|NCT04848493|BIOLOGICAL|COVID-19 vaccines|This is an observational prospective study whose general objective is to assess the impact of COVID-19 vaccination in terms of induction of humoral and cell-mediated immune responses in selected fragile (altered immunocompetence) populations.
41274389|NCT02820961|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDAC)
41274390|NCT02820961|DRUG|exemestane|Aromatase inhibitor
41274391|NCT04392193|RADIATION|Proton Particle Therapy|Proton therapy will be delivered in a single fraction using the Probeat-V system
41122507|NCT06180889|DRUG|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
41274392|NCT05232734|DRUG|Caffeine Citrate 20 MG/ML Oral Solution|Caffeine syrup will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
41274393|NCT02867696|OTHER|Standard Care|Subjects in this arm will receive the standard care that is provided by their bariatric surgical team following bariatric surgery.
41274394|NCT02867696|BEHAVIORAL|Technology-based Intervention (TECH)|"Dietary recommendations: based on the subjects' baseline body weight, with calorie goals ranging from 1200-2100 kcal/day.~The physical activity component: unsupervised home-based exercise program. Intensity/Mode: aerobic physical activity recommended at a moderate intensity. Prescription: progress to 250 min/wk by 13th week of the intervention.~Self-monitoring: Jawbone UP3 System includes a wearable device to monitor physical activity and energy expenditure that will transmit real-time feedback on calories expended and physical activity directly to a smart phone. An integrated digital smart scale will also be provided.~Contact: scheduled intervention telephone call: Month 1: One call per week for the first 4 weeks of the study; Months 2-6: One call per month."
41274395|NCT00667706|PROCEDURE|laparoscopic operation Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
41274396|NCT00667706|PROCEDURE|laparoscopic operation Roux-en-Y Gastric bypass|Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of \<50, and \>50, respectively.
41274397|NCT04866927|DIETARY_SUPPLEMENT|Use of stable isotopic dilution to assess protein digestibility from Faba bean and to evaluate amino acid bioavailability|Each participant will receive a test meal containing 13C labelled spirulina, 2H labelled Fava bean and 13C phenylalanine. The test meal will be divided on 11 subdoses: 3 sub-doses will be administrated at T0 and 1 subdose will be administrated at 1, 2, 3, 4, 5, 6 and 7h. The remaining sub-dose will be kept for measurement of IAA in the test meal. After eating the test meal, blood, urine and breath samples will be collected from each participant at the baseline (T0) and after 5-6, 7h and 8h.
41274398|NCT01974791|BEHAVIORAL|GET Living|GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
41122508|NCT06180889|DRUG|KN060 Low|Single dose of KN060 administered as intravenous infusion
41122509|NCT06180889|DRUG|KN060 Middle|Single dose of KN060 administered as intravenous infusion
41122510|NCT06180889|DRUG|KN060 Hight|Single dose of KN060 administered as intravenous infusion
41122511|NCT04702568|DRUG|BCX9930|BCX9930 for oral administration
41122512|NCT01472510|DRUG|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
41122513|NCT01472510|DRUG|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
41122514|NCT01204346|OTHER|MBT|The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.
41122515|NCT01204346|OTHER|treatment as usual|less intensive and structured psychotherapeutic program
41122516|NCT06013072|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental|Combination of pre-probiotic
41122517|NCT06013072|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Inert compound
41122518|NCT01634516|BEHAVIORAL|Dietary support|Face to face intervention plus subsequent telephone support
41122519|NCT01634516|BEHAVIORAL|No dietary support|No face to face intervention or subsequent telephone support
41274399|NCT00572884|OTHER|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
41274400|NCT02338843|DRUG|LJPC-501|Treatment arm
41274401|NCT02338843|DRUG|Placebo|PBO
41274402|NCT05896345|DEVICE|SWL|Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone
41274403|NCT05896345|COMBINATION_PRODUCT|SWL and ODT|Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
41274404|NCT02758964|OTHER|MRI, neurocognitive Testing|A cerebral MRI and neurocognitive testing will be performed before TAVR, before hospital discharge and after 3 months
41274405|NCT03551522|DRUG|Seladelpar|10 mg, 20 mg, or 50 mg
41274406|NCT03551522|DRUG|Placebos|Matching placebo Capsule
41274407|NCT04697563|DEVICE|Laser|real laser beam administered
41274408|NCT04697563|DEVICE|Placebolaser|no laser beam admitted
41274409|NCT03939013|DIAGNOSTIC_TEST|Xpert HCV VL|Use of Cepheid GeneXpert HCV VL test as diagnostic tool to test for HCV RNA for diagnosis of hepatitis C infection, to test for sustained virological response at 12 weeks post treatment completion
41274410|NCT01549301|DRUG|Filgrastim|filgrastim, single dose, s.c., dosage: 5 mcg/kg
41122520|NCT01130194|OTHER|Combination of treatment modalities|"Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.~Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning."
41274411|NCT01549301|DRUG|Filgrastim|filgrastim, single dose, s.c., dosage: 10 mcg/kg
41122521|NCT06315985|OTHER|Experimental group: Listenning to the Turkish Classical Music to pregnant women diagnosed with preeclampsia|The music to be used in the research will be applied together with midwifery practices and is not a treatment option, tool or treatment option for any disease. Although listening to Classical Turkish music has no effect on treatment and care, it does not have a harmful effect on pregnant women. The participant can withdraw from the study at any time without giving any reason. The Personal Information Form, Perceived Stress Scale, and Pittsburgh Sleep Quality Index (PSQI) will be administered to the pregnant women in both groups participating in the study by face-to-face interviews with the individuals on the first day of their admission to the clinic. At the end of the third day, the Perceived Stress Scale and Pittsburgh Sleep Quality Index (PSQI) scales will be re-administered to both groups.
41274412|NCT01549301|DRUG|Filgrastim|Filgrastim, i.v., single dose, dosage: 5 mcg/kg
41274413|NCT01549301|DRUG|Filgrastim|Filgrastim, i.v., single dose, dosage: 10 mcg/kg
41274414|NCT00626873|DRUG|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
41274415|NCT00626873|OTHER|medical chart review|
41122522|NCT02280148|PROCEDURE|Endoscopy of Intravenous Anesthesia|The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
41274416|NCT05412433|BEHAVIORAL|Patient Level|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations
41274417|NCT05412433|BEHAVIORAL|Multilevel|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations, provider electronic health records (EHR) alerts
41274418|NCT05412433|BEHAVIORAL|Control|Standard of care
41122523|NCT02280148|DEVICE|Driving Simulator|
41274419|NCT02730559|OTHER|Motivational Interviewing/Counselling|Motivational Interviewing/Counselling
41274420|NCT01479608|PROCEDURE|Liver transplantation and liver resection|
41274421|NCT01235676|BEHAVIORAL|diet|calorie restriction to reduce weight gain
41274422|NCT01235676|BEHAVIORAL|Exercise|Exercise to reduce weight gain
41274423|NCT05152212|BIOLOGICAL|LVGN7409|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
41274424|NCT03193268|OTHER|Single-blind RTC of PD patients|The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.
41122524|NCT02280148|DRUG|Propofol|2mg / kg
41274425|NCT03193268|OTHER|cycling|Patients must undergo a daily exercise cycle of 1 hour during the intervention
41274426|NCT05129150|OTHER|Ultrasound examination|Ultrasound examination with Tissue Pulsatility Imaging (TPI) TPI is a relatively simple, rapid and non-invasive ultrasound examination which consists of applying a standard ultrasound probe to the acoustic window of the temporal bone to first measure the velocity of the middle cerebral artery in Doppler mode and secondly the cerebral pulsatility (CP) of a region of approximately 10cm2 centred on the middle cerebral artery in B-Echo mode. After collecting the information, the TPI examination will be performed by MRRC staff specially trained in TPI by engineers. The duration of the examination is between 20 and 30 minutes, including hardware installation. Four 30-second PC acquisitions will be collected per examination, with the patient lying supine on the bed in the day hospital room, then one measurement every minute for 3 minutes after standing.
41274427|NCT02337842|BIOLOGICAL|Norovirus GII.4 Challenge Pool CIN-1|Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10\^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10\^2 or 5x10\^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10\^4, 10\^3, 5x10\^2 or 5x10\^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10\^4 or 5x10\^3 or 10\^3 or 10\^2 or 10\^4 or 5x10\^2 or 5x10\^1RT-PCR units.
41274428|NCT02337842|OTHER|Placebo|Placebo: 80 ml of sterile water for oral administration
41122525|NCT00462358|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
41274429|NCT04597164|OTHER|Artificial liver support system|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.
41274430|NCT03069911|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
41274431|NCT03069911|BIOLOGICAL|Control|0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
41274432|NCT04130815|DRUG|Inhaled furosemide|4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
41274433|NCT02314806|DRUG|Irrigation with gentamicin solution|The surgical bed is irrigated with a gentamicin solution
41274434|NCT02314806|DRUG|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
41274435|NCT02314806|DRUG|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
41274436|NCT01664793|BEHAVIORAL|4 Pillars Immunization Toolkit|Pillar 1: Convenient Vaccination Services; Pillar 2: Patient notification about the importance of vaccination and availability of convenient services; Pillar 3: Enhanced Office Systems; Pillar 4: Motivation: Office immunization champion tracks progress towards a goal; Early delivery of donated vaccines for disadvantaged children, staff education, support of effort by research staff.
41274437|NCT01307423|DRUG|Apremilast 20mg|Apremilast 20mg twice daily, orally
41274438|NCT01307423|DRUG|Apremilast 30mg|Apremilast 30mg twice daily, orally
41274439|NCT01307423|DRUG|Placebo|Placebo
41274440|NCT01402219|DRUG|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
41274441|NCT01402219|DRUG|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
41274442|NCT00874380|OTHER|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
41274443|NCT00227058|DRUG|Orotic acid and Glutathione-(Nutritional Supplements)|
40926691|NCT03859830|DEVICE|AK200 Ultra S, extracorporeal circulation conduct of blood purification|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
40926692|NCT01708096|DIETARY_SUPPLEMENT|Modifast|2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day
40926693|NCT01708096|DIETARY_SUPPLEMENT|Normal diet|normal diet 2 weeks before gastric by-pass
40926694|NCT03430713|PROCEDURE|Measure of tooth color|Evaluation of agreement about measure of tooth color between clinicians using two dental shade guides and two spectrophotometers in the determination of the color of maxilary central incisors and canines.
40926695|NCT00006439|BEHAVIORAL|Counseling in the home|
40926696|NCT00727532|DRUG|Sorafenib|400mg by mouth twice daily for 28 consecutive days
40926697|NCT04732000|DRUG|N-acetyl cysteine|Intravenous infusion started during the clinically indicated surgery at a rate of 50mg/kg over 1 hour followed by 50mg/kg over 3 hours. This will be an accumulated total of 100 mg/kg over 4 hours.
40926698|NCT04732000|OTHER|Normal Saline|Intravenous infusion at a time and rate to mimic the active treatment. The infusion will be given over 4 hours beginning during the clinically indicated surgery
40926699|NCT02216812|DRUG|500 mg vitamin c, 1 pill per day for 6 weeks|
41122526|NCT00462358|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
41122527|NCT05859152|OTHER|Zona Pellucida-Bound Sperm Selection for ICSI|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that was bound to the ZP of an immature oocyte.
40926700|NCT02216812|DRUG|1 placebo pill for 6 weeks|
40926701|NCT06246955|BEHAVIORAL|Behavioral Intervention: Group Therapy Session|Attend virtual group therapy sessions
40926702|NCT06246955|OTHER|Survey Administration|Ancillary study
40926703|NCT01453387|DRUG|MSC2015103B|Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
40926704|NCT01453387|DRUG|MSC2015103B|Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
41274444|NCT00839631|DRUG|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
41274445|NCT00002283|DRUG|Trimethoprim|
41274446|NCT00002283|DRUG|Sulfamethoxazole|
41274447|NCT00002283|DRUG|Dapsone|
40754249|NCT05611736|OTHER|saline|After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal will be done using normal saline solution at room temperature
40926705|NCT05604183|PROCEDURE|non-invasive hyperspectral retinoscopy|The Principal Investigator or a trained medical nurse (under the supervision of the principal investigator) will take an image of the retina of the patient with the Mantis Photonics hyperspectral retinoscopy camera.
40926706|NCT05604183|PROCEDURE|blood sample|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will draw a small blood sample according to the standard medical procedures for drawing blood samples.
41122528|NCT05859152|OTHER|Routine Embryologist Selected Sperm|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that has been selected based on morphology and mobility characteristics by the embryologist per routine.
41122529|NCT02561702|OTHER|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
41122530|NCT02561702|DRUG|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
41274448|NCT03898934|DRUG|Vitamin D|receive 6000iu daily for 8 weeks
41274449|NCT03898934|DRUG|Placebo Oral Tablet|placebo for the same period
41274450|NCT00902837|DRUG|Oxycodone naloxone prolonged release tablets (OXN)|
41274451|NCT00902837|DRUG|oxycodone prolonged release tablet|
41274452|NCT00902837|DRUG|oxycodone naloxone tablet|
41274453|NCT05129449|DEVICE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) conducted with motorized PowerSpiral in subjects presenting with surgically altered GI anatomy indicated for ERCP with biliary indication.
41274454|NCT06390670|DIETARY_SUPPLEMENT|Colostrum Bovinum supplementation|In the experimental procedure each athlete was supplemented with a chronic dose of 25 g/day of COL. Supplement was particularly prepared for the study from a first post-delivery milking and had a high content of IgG (60%; certified Colostrum Bovinum; Agrapak, Poland). The COL was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the COL supplement in 250 mL of plain water.
41274455|NCT06390670|OTHER|Placebo treatment|In the control procedure each athlete was supplemented with a chronic dose of 25 g/day of placebo (PLA). PLA was particularly prepared for the study, and was an isoenergetic/isomacronutrient product (high quality protein) prepared for the trial (Agrapak, Poland). The PLA was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the PLA preparation in 250 mL of plain water.
41274456|NCT06084286|BIOLOGICAL|Dual-targeting CLDN18.2 and PD-L1 CAR-T cells|The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.
41274457|NCT00476086|DRUG|Gemcitabine|
41274458|NCT00476086|DRUG|Oxaliplatin|
41274459|NCT00476086|RADIATION|Radiation|
41274460|NCT05640648|BEHAVIORAL|User-Centered Implementation Strategy|"1. 4 participant-facing components: 1a) TB education pamphlet helps index TB persons disclose the need for household screening to contacts. 1b) Contact identification algorithm helps CHWs and index TB persons accurately enumerate contacts. 1c) Sputum collection video instructs contacts to expectorate good-quality sputum. 1d) Community Health Riders transport CHWs, index persons with TB, and contacts by motorcycle taxi, and collect and transport sputum.~2. 3 community health-worker-facing components: a) Weekly CHW meetings create communities of practice (CoP), professionals organized for peer support and systematic learning. Meetings involve problem solving, review of audit and feedback reports, and didactics on TB care, among other activities. 2b) Audit and feedback reports on contact investigation performance indicators weekly (individual CHW) and monthly (health facility). 2c) A group-chat application facilitates peer support among CHWs."
41122531|NCT03707236|BEHAVIORAL|Teledermatology visits|Patients in the treatment arm will be taught by study staff how to take the standardized photos of themselves at treatment week 4 (prior to initiation of teledermatology visits). For patients in the treatment arm, the teledermatology visits will be managed by the study staff. A monthly teledermatology visit will consist of sending facial and truncal (if affected) clinical images to a the study staff using Patient Gateway. Once this is completed, the patient and a member of the study staff will have a scheduled telephone appointment during which the provider will screen for any adverse events and will provide counseling as outlined in iPledge guidelines. The patient will also be asked to verbally complete a monthly survey assessing acne severity, quality of life, cost attributable to the appointment, time missed from school/work, satisfaction with treatment. All photographs will be uploaded in LMR/EPIC in the patient's medical record.
41122532|NCT06409117|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention with scaffold implantation in patients with NSTE/ACS
41274461|NCT05640648|BEHAVIORAL|Standard Implementation Strategy|Once an eligible TB patient agrees to participate, CHWs will visit the patient to assess the eligibility of close contacts to participate. For eligible contacts who agree to participate, the CHW will perform TB symptom screening and arrange subsequent microbiologic, clinical, and/or radiographic evaluation. Those screening TB symptom-positive will be asked to expectorate a sputum sample, unless under age 5. If under age 5 or unable to produce sputum, contacts will be referred to the health centre for evaluation. A CHW will transport sputum samples to the health-centre laboratory for microbiologic evaluation and later report the test results back to the contact. During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
41274462|NCT06131710|OTHER|Isolated Strengthening Exercises|Isolated strengthening exercises can be beneficial for individuals with Patellofemoral Pain Syndrome (PFPS) to help address muscle imbalances and alleviate pain.
41274463|NCT06131710|OTHER|Combined Strengthening Exercises|Combined strengthening exercises for Patellofemoral Pain Syndrome (PFPS) typically include a mix of quadriceps strengthening exercises, hip strengthening exercises, and core stability exercises. The goal is to address muscle imbalances and improve the overall stability of the knee joint.
41122533|NCT01935544|DEVICE|Botulinum toxin injection|
41122534|NCT03960606|COMBINATION_PRODUCT|PUR1900|PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.
41122535|NCT03960606|COMBINATION_PRODUCT|Placebo|PUR1900 placebo
41122536|NCT04512482|DRUG|Bromelain|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
41122537|NCT04512482|OTHER|Powdered sugar|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
41122538|NCT04223258|DEVICE|Automatic Oxygen control|The CLiO device is integral to the Avea infant ventilator and allows automated OXYGEN adjustment aiming to maintain SpO2 within assigned target range using neonatal pulse oximeter. When first started it adopts the FiO2 previously set by the clinician as the initial 'Baseline FiO2' level. Thereafter, the changes to the FiO2 and their frequency depend on whether SpO2 is below, above or within the target range, the trend in SpO2 and all changes are proportionate to the 'Baseline FiO2' level.
41122539|NCT04223258|OTHER|Manual Oxygen Control|In the manual arm the oxygen is adjusted manually by the clinical team.
41122540|NCT00550394|DRUG|quetiapine and placebo|"Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
41122541|NCT00550394|DRUG|Quetiapine and Topiramate|"Dosing Schedule and Titration of Quetiapine:~open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
41122542|NCT00516477|BIOLOGICAL|voretigene neparvovec-rzyl|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
41122543|NCT02201134|DRUG|sevoflurane|
41122544|NCT06099249|DEVICE|ASUS ECG App|The procedure will commence with instructing the participants to become acquainted with the ASUS ECG App. Following this introduction, participants will be asked to sit quietly for a 5-minute resting period before undergoing a 12-lead ECG recording, which will last for approximately 30 seconds. The participant will be guided to simultaneously record a separate single-lead ECG using the ASUS ECG App. Both data streams will be synced together by the Study Staff. Each participant will undergo a total of three trials involving the simultaneous recording of a 12-lead ECG and a single-lead ECG using the ASUS ECG App.
41122545|NCT03737734|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
41122546|NCT06482632|PROCEDURE|Discectomy of Omohyoid|Will be removing the Omohyoid during an anterior cervical discectomy and fusion to compare its effect of dysphagia.
41122547|NCT06482632|PROCEDURE|Control group no discectomy of Omohyoid|Will not be removing the Omohyoid during an anterior cervical discectomy and fusion to compare its effect of dysphagia.
41122548|NCT03074617|OTHER|LTE field|electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)
41122549|NCT03074617|OTHER|sham field|no electromagnetic field
41122550|NCT03218306|DEVICE|Surgical Pleth Index|Effector site concentration of remifentanil based on SPI
41122551|NCT03218306|OTHER|Clinical guidance|Effector site concentration of remifentanil based on hemodynamic data
41122552|NCT05260359|DRUG|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation|SU E 101413 85
41122553|NCT05260359|DRUG|6% Bemotrizinol (BEMT) dispersion in petrolatum|SU-E-101413-82
41122554|NCT05260359|OTHER|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT|SU E 101413 91
41122555|NCT05260359|OTHER|Petrolatum vehicle|SU-E-101413-83
41122556|NCT05260359|OTHER|0.9% Saline|low irritancy control
41122557|NCT05260359|OTHER|Sodium Lauryl Sulfate 0.1% (SLS)|positive control
41122558|NCT05260359|OTHER|Undosed patch|negative control
41122559|NCT03142672|PROCEDURE|pulpotomy|vital endodontic procedure
41122560|NCT03142672|PROCEDURE|tooth filling|tooth filling
41122561|NCT00681603|DRUG|subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)|subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
41122562|NCT03020979|DRUG|Apatinib|Patients will take 500mg apatinib daily orally.
41122563|NCT04046536|DEVICE|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
41122564|NCT04046536|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
41122565|NCT02531737|DRUG|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
41122566|NCT02531737|DRUG|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
41122567|NCT01063972|BEHAVIORAL|Centralized disease management (CDM)|Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
41122568|NCT01063972|BEHAVIORAL|Counseling (C)|Counseling (C) arm will receive counseling without the care coordination services.
41122569|NCT05660941|DRUG|Lispro|Ultra rapid Lispro
41122570|NCT05660941|DRUG|Lispro|Conventional Lispro
41122571|NCT00418613|DRUG|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
41122572|NCT00418613|DRUG|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
41122573|NCT06412770|BEHAVIORAL|Tai chi|Participants will be asked to do Tai Chi for 30 minutes three times a week
41122574|NCT06412770|BEHAVIORAL|Tai Chi imagery|Participants will be asked to do Tai Chi imagery for 30 minutes three times a week
41122575|NCT06412770|OTHER|no-intervention|The comparison group will be given usual care
41122576|NCT03891316|DIAGNOSTIC_TEST|HFIP and Sevoflurane are measured after 3 consecutive days of work.|Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography
41122577|NCT05752175|DRUG|WPV01|WPV01 tablets
41122578|NCT05752175|DRUG|Placebo|Placebo tablets
41122579|NCT03858413|DIAGNOSTIC_TEST|No intervention|No intervention
40926707|NCT05604183|DIAGNOSTIC_TEST|Test of cognitive ability on tablet computer with CoGNIT software|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will give the patient to perform the digital cognitive test on a commercial tablet computer. The Principal Investigator or the medical nurse will be available for the patient to ask questions while the test is ongoing.
40926708|NCT05782816|DRUG|Oxytocin|Low dose oxytocin
40926709|NCT05782816|DRUG|Oxytocin|High dose oxytocin
40926710|NCT00908739|GENETIC|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
41122580|NCT02825641|DRUG|Oxytocin|"Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes."
41122581|NCT02825641|DRUG|Dinoprostone|"Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes."
41122582|NCT03288753|OTHER|Satisfaction questionnaire|Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.
41122583|NCT03288753|BEHAVIORAL|Speech intelligibility in quiet|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
41122584|NCT03288753|BEHAVIORAL|Speech intelligibility in noise|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
41122585|NCT03288753|BEHAVIORAL|VRB (Vocale Rapide dans le Bruit)|Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.
41122586|NCT01969981|PROCEDURE|PICC placement with Sherlock 3CG|
41122587|NCT04597684|PROCEDURE|Cementless Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cementless knees
41122588|NCT04597684|PROCEDURE|Cemented Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cemented knees
41122589|NCT05945017|DIETARY_SUPPLEMENT|Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748|
41122590|NCT00654316|BIOLOGICAL|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
41122591|NCT00973986|DRUG|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
41122592|NCT05357469|DEVICE|Immediate St (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
41122593|NCT05357469|DEVICE|Waitlist ST (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
41122594|NCT03467386|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
41122595|NCT03467386|DRUG|Cyclophosphamide|Given IV
40926711|NCT00908739|OTHER|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
40926712|NCT00908739|OTHER|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
40926713|NCT00252044|DRUG|Pergolide|
40926714|NCT06003179|DRUG|Cyclophosphamide|Conditioning chemo at different doses
40926715|NCT06003179|RADIATION|TLI|radiation given with conditioning chemo
40926716|NCT06003179|DRUG|Fludarabine|Fludarabine given as part of standard treatment
41122596|NCT03467386|BIOLOGICAL|Filgrastim|Administer according to City of Hope standard operating procedures
41122597|NCT03467386|OTHER|Laboratory Biomarker Analysis|Correlative studies
41122598|NCT03467386|OTHER|Quality-of-Life Assessment|Ancillary studies
41122599|NCT03467386|OTHER|Questionnaire Administration|Ancillary studies
41122600|NCT03467386|DRUG|Tacrolimus|Given CIV
41122601|NCT03467386|RADIATION|Total Marrow Irradiation|Undergo TMLI
40754250|NCT02455089|OTHER|GADD34 RNA level measurement.|"Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.~A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months."
40754251|NCT06405425|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
41122602|NCT05640180|DRUG|Finerenone (Kerendia, BAY94-8862)|Retrospective cohort analysis using randomized clinical trials data.
41122603|NCT05640180|DRUG|Sodium-glucose cotransporter-2 inhibitors (SGLT2i)|Retrospective cohort analysis using United States Optum Electronic Health Records data.
41122604|NCT00338442|DRUG|VariZIG™|Biological / Vaccine
40754252|NCT06405425|DRUG|PD-1|Administration by intravenous infusion for a cycle of 3 weeks.
40926717|NCT02557477|DIETARY_SUPPLEMENT|Omega 3/6 fatty acids|Three Omega 3/6 capsules twice daily
41122605|NCT04565834|GENETIC|Analysis of Single nucleotide polymorphisms in each group.|The 6 single nucleotide polymorphisms (SNPs) determined will then be genotyped according to the Thermofisher Taqman technique ona 480 LightCycler (Roche Applied Science). 10% of the genotypes will be confirmed via Sanger sequencing on a 3500xl Thermofisher sequencer according to the manufacturer's recommendations.
41122606|NCT01629316|BEHAVIORAL|Text reminders, counseling, and link coordination|This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination
41122607|NCT01629316|BEHAVIORAL|Standard of care - control arm|The control arm is standard of care for each subject.
41122608|NCT02461264|DRUG|Single red blood packed cells Transfusion|
41122609|NCT02461264|DRUG|Two packed red blood cells Transfusion|
41122610|NCT06430788|BIOLOGICAL|Emapalumab|Emapalumab is an interferon gamma (IFNγ) blocking antibody
41122611|NCT06518876|BIOLOGICAL|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
41122612|NCT00179751|DRUG|CC-5013|
41122613|NCT00179751|DRUG|gemcitabine|
41122614|NCT02351310|DRUG|Betamethasone|Course of ACS given intramuscularly (2 doses of 12 mg, 24 hours apart)
41122615|NCT02351310|GENETIC|Placebo|Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
41122616|NCT05899270|OTHER|3D reconstruction automatic matching system|it is an automatic comparison software for 3D reconstruction based on CT data (3DRACS). It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size and depth of the DLT for lung isolation.
41122617|NCT05899270|OTHER|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and weight and the height is used to guide the depth of DLT insertion.
41122618|NCT00485329|OTHER|Papain|15,000 USP U/ml
41122619|NCT00485329|OTHER|Papain|30,000 USP U/ml
41122620|NCT00485329|OTHER|Papain|60,000 USP U/ml
41122621|NCT01672060|BEHAVIORAL|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
41122622|NCT01672060|BEHAVIORAL|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
41122623|NCT01331044|DIETARY_SUPPLEMENT|Plumpy Nut|to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered \~ 125 kcal/kg in 1st 24 hours, \~ 150 kcal/kg in 2nd 24 hours, then\~200k cal/kg by the third day).
41122624|NCT01331044|DIETARY_SUPPLEMENT|Khichuri and Halwa|"Day 1: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day 125kcal/kg.day~Day 2: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 150kcal/kg.day~Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 175kcal/kg.day~Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 3 feed per day \& khichuri 10gm/kg; 3 feed per day 200kcal/kg.day~Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) \& halwa 20gm/kg; 3 feed per day \& khichuri 20gm/kg; 3 feed per day 200kcal/kg.day"
41122625|NCT04029909|DRUG|Gimatecan 0.6mg/m2/d|0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
41122626|NCT04029909|DRUG|0.8mg/m2/d|0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
41122627|NCT04029909|DRUG|0.4mg/m2/d|0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
41122628|NCT06347575|DEVICE|Implantation of the caverStim device|Implantation of caverStim in SCI patients.
41122629|NCT01837238|DIETARY_SUPPLEMENT|HMB|Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
41122630|NCT01837238|DIETARY_SUPPLEMENT|placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
41122631|NCT02994316|OTHER|Copeptine dosage in children with diabetic ketoacidosis at diagnosis|Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
41122632|NCT01039155|DRUG|Azacitidine|Given IV
41122633|NCT01039155|OTHER|Laboratory Biomarker Analysis|Correlative studies
41122634|NCT01039155|DRUG|Oxaliplatin|Given IV
41122635|NCT01039155|OTHER|Pharmacological Study|Correlative studies
41122636|NCT00274469|DRUG|fulvestrant|500 mg intramuscular injection
41274464|NCT00900003|GENETIC|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
41274465|NCT00900003|OTHER|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
41274466|NCT01364987|DRUG|ASP015K|oral
41274467|NCT01364987|DRUG|Mycophenolate Mofetil|oral
41274468|NCT00492219|DEVICE|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
41274469|NCT00492219|DEVICE|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
41274470|NCT03732924|DIAGNOSTIC_TEST|Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement|To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.
41274471|NCT02235818|DEVICE|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
41274472|NCT02235818|DEVICE|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
40754253|NCT06435845|DRUG|Anti-(integrin beta-3) human monoclonal antibody|human monoclonal anti-human platelet antigen (HPA)-1a immunoglobulin G antibody
41122637|NCT00274469|DRUG|anastrozole|1 mg oral tablet
41274473|NCT05436249|DEVICE|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~1. Overt finger tapping in time with a flashing cue.~2. Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
40926718|NCT02557477|DIETARY_SUPPLEMENT|Placebo|Three placebo capsules twice daily
40926719|NCT03521895|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Patients observed with regular and irregular treatment course
40926720|NCT01138176|PROCEDURE|Cooling|Reduction of rectal temperature to 33.5 C
41122638|NCT01353001|BEHAVIORAL|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
41274474|NCT05436249|BEHAVIORAL|At-home therapy|"Participants are assigned to groups where they will practice each day for 3 weeks at-home.~1. Group 1: Imagery only.~2. Group 2: Overt finger tapping only.~3. Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that they are finger tapping in time with the flashing cue, using the imagery strategies identified during their previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
41274475|NCT01146925|DRUG|CRMD-001-Deferiprone|CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
41274476|NCT01146925|DRUG|Placebo|3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
41274477|NCT02214849|BEHAVIORAL|LATCH Intervention|
41274478|NCT01573442|DRUG|testosterone|10.4 mg
41274479|NCT01573442|OTHER|placebo|
40754254|NCT03096990|DRUG|apremilast|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
40754255|NCT02035228|DEVICE|Abdominal Stimulation - low / early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the first half of exhalation"
40926721|NCT02930980|DEVICE|Investigational Software loaded on Micra device|Subject will receive an investigational software loaded on subject's Micra device
41274480|NCT01167296|DEVICE|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
41274481|NCT02109237|PROCEDURE|Assessment of sleep disorders and treatment if required|Assessment of sleep disorders and treatment if required
41122639|NCT01353001|BEHAVIORAL|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
41122640|NCT01353001|BEHAVIORAL|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
40754256|NCT02035228|DEVICE|Abdominal stimulation - low/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the second half of exhalation"
41122641|NCT01421667|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
41122642|NCT01421667|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion
41122643|NCT01379482|DRUG|Multimodal treatment|"3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.~Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.~Neo-adjuvant chemotherapy:~Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)~Hyperthermic intraoperative chemotherapy:~Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)~Early postoperative chemotherapy:~5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)"
41122644|NCT05760235|PROCEDURE|Endoscopic sleeve gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free15. The procedure will be performed with the patient in supine position. Carbon dioxide will be blown to stretch the gastric lumen. An initial endoscopic evaluation will be performed immediately to confirm the absence of any contraindication to ESG before suturing. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch.
41122645|NCT01388361|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
41122646|NCT01388361|DRUG|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
41122647|NCT01388361|DRUG|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
41122648|NCT03926039|BEHAVIORAL|sharing decision-making program|Sharing decision-making talks and decision-making assistance tools used in the process
41122649|NCT00788034|DRUG|Lu AA21004|5 or 10 mg/day
41122650|NCT00788034|DRUG|Placebo|Once daily
41122651|NCT00088738|DRUG|[18F] SPA-RQ|
41122652|NCT03244449|OTHER|No apply|
41122653|NCT04484753|OTHER|Home Exercise Sheet|Received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
41122654|NCT04484753|OTHER|Ipelvis mobile application|Received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
41122655|NCT04484753|BEHAVIORAL|Home exercise sheet + Pelvic Physiotherapy|Performed 12 Pelvic Physiotherapy sessions, in group, once a week and received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
41274482|NCT00013078|PROCEDURE|Physical restoration intervention|
41274483|NCT01443013|OTHER|Renal Transplant|urinary sample at month 3, 6 and 12
40754257|NCT02035228|DEVICE|Abdominal Stimulation - low/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current throughout exhalation"
41122656|NCT04484753|BEHAVIORAL|Ipelvis mobile application + Pelvic Physiotherapy|Performed 12 pelvic physiotherapy sessions, in group, once a week and received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
41274484|NCT04939155|BIOLOGICAL|SARS-CoV-2 mRNA vaccine|mRNA vaccine for COVID
41274485|NCT04558697|DRUG|Shepherd's Purse extractum oleosum vagitories|Shepherd's Purse extractum oleosum vagitories will be administered once daily for 5 days
41274486|NCT04558697|DRUG|Tea tree oil vagitories|Tea tree oil vagitories will be administered once daily for 5 days
41274487|NCT04558697|DRUG|Hyperici extractum oleosum vagitories|Hyperici extractum oleosum vagitories will be administered once daily for 5 days
41274488|NCT04558697|DRUG|Vagitories - Probiotic|Vagitories - Probiotic will be administered once daily for 5 days
41274489|NCT02509325|DEVICE|Parkinson's Kinetigraph|
40926722|NCT01943474|DEVICE|AccuCath IV Catheter Device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
41122657|NCT01969461|BEHAVIORAL|Motivational Enhancement Therapy (MET)|The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
41274490|NCT00956384|PROCEDURE|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
41274491|NCT00956384|PROCEDURE|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
41274492|NCT03463772|PROCEDURE|standard IVF|Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be inseminated using ICSI or conventional IVF according to the seman analysis. All embryos will be cultured to blastocyst stage and be vitrified.
41274493|NCT03463772|DRUG|In vitro maturation|Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
41274494|NCT06165588|OTHER|Tour de France|Participating in the Tour de France as cyclist
41274495|NCT01660815|DRUG|florbetapir (18F)|IV injection, 370 MBq (10mCi), single dose
41274496|NCT00030082|DRUG|isolated perfusion|
41274497|NCT00030082|DRUG|melphalan|
41274498|NCT05474092|DEVICE|Aeson Total Artificial Heart|Heart Replacement Therapy
41274499|NCT06422182|DRUG|Bupivacain 25% (Erector Spinae Plane Block)|Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.
41274500|NCT06422182|DRUG|Morphine (Intravenous patient-controlled analgesia)|Patients received intravenous patient-controlled analgesia (IV-PCA) by morphine
41274501|NCT06041750|PROCEDURE|Elective surgical procedure under general anesthesia|The incidence of postoperative pulmonary complications in OSAS patients undergoing elective surgery under general anesthesia will be determined.
41274502|NCT01629849|DRUG|Placebo to BI 1021958 qd|tablet
41274503|NCT01629849|DRUG|BI 1021958 bid|tablets
41274504|NCT01629849|DRUG|Placebo to BI 1021958 bid|tablets
41274505|NCT01629849|DRUG|BI 1021958 qd|tablet
41274506|NCT02522819|DEVICE|CPAP|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
41274507|NCT02522637|OTHER|Exercise training|"The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each \< 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%."
41274508|NCT03232307|DRUG|Dexamethasone|Given PO
41274509|NCT03232307|DRUG|Ibrutinib|Given PO
41274510|NCT03232307|DRUG|Lenalidomide|Given PO
41274511|NCT03232307|BIOLOGICAL|Rituximab|Given IV
41274512|NCT02566512|OTHER|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
41274513|NCT02566512|OTHER|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
41274514|NCT02786069|DRUG|Propionyl L-carnitine Hydrochloride|500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
41274515|NCT05533801|DRUG|Lecanemab|Lecanemab will be administered subcutaneously using a vial and syringe.
41274516|NCT05533801|DRUG|Lecanemab|Lecanemab will be administered subcutaneously using AI.
41274517|NCT01734343|DEVICE|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
41274518|NCT01734343|DEVICE|PhysIOL microAY|same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
41274519|NCT01963494|BEHAVIORAL|Dyadic planning intervention|Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.
41274520|NCT01963494|BEHAVIORAL|Individual planning intervention|Target persons form action plans on their own.
41274521|NCT01963494|BEHAVIORAL|General motivational treatment|Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
41274522|NCT02810990|DRUG|Bosutinib|"Bosutinib is given orally accordingly with this scheme:~A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16~At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).~Bosutinib dose is then managed as follows :~C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 \> 1% at week 12: 400 mg OD from week 17 to week 52~All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns)."
41274523|NCT01339455|PROCEDURE|AHSCT|"AHSCT Procedure:~1. Mobilization and Harvesting:~   * Cyclophosphamide~  * Rituximab~  * GSCF~  * Dexamethasone~  * Apheresis~2. Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):~   * Cyclophosphamide~  * MESNA~  * Rabbit ATG~  * Rituximab~  * Methylprednisolone~  * Stem Cell infusion~  * GSCF"
41274524|NCT00156663|BEHAVIORAL|Caring for Women Veterans|
41274525|NCT02913989|OTHER|Smoking habits characterization|
41274526|NCT04516304|DIETARY_SUPPLEMENT|Placebo|4 tablets/d (2 in the morning and 2 in the evening)
41274527|NCT04516304|DIETARY_SUPPLEMENT|S-equol|4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
41274528|NCT00047567|DRUG|zonisamide|
41122658|NCT04224792|OTHER|Center-based exercise program|A routine individualized exercise prescription and supervised exercise sessions at a minimum of once per week for 11 weeks with an exercise prescription updated monthly.
41274529|NCT00371267|BEHAVIORAL|Telephone-delivered Cognitive Behavior Therapy|Telephone-delivered cognitive behavior therapy for pain management
41274530|NCT00371267|OTHER|Telephone-delivered Patient Education|Telephone-delivered patient education regarding chronic pain
41274531|NCT03569267|DRUG|OLX10010|A cell penetrating asymmetric siRNA (cp asiRNA)
40754258|NCT02035228|DEVICE|Abdominal stimulation - med/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the first half of exhalation"
41122659|NCT04224792|OTHER|Home-based exercise program|A one-time supervised exercise session with Cardiac Rehabilitation staff and a routine individualized exercise prescription for exercises to do at home. Additionally, weekly telephone followup calls by a clinical exercise physiologist for 11 weeks consisting of an exercise tip.
41274532|NCT03569267|DRUG|Placebo|Placebo
41274533|NCT05443022|RADIATION|Photobiomodulation|Participants will receive an application of low intensity light directly in the region of the three pairs of salivary glands. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
41274534|NCT05443022|RADIATION|Simulation of Photobiomodulation|The placebo group will have a simulation of the application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
41274535|NCT05384561|OTHER|Smell training|For 12 weeks, morning and evening, smell four different odors or four odorless substances for a total of five minutes per session.
41274536|NCT05237557|BEHAVIORAL|Preoperative nurse dialogue|Performance of a preoperative nurse dialogue prior major visceral surgery
41274537|NCT02945982|DRUG|Entecavir+Carvedilol|The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
41274538|NCT02945982|DRUG|Entecavir+Carvedilol+ Fuzheng Huayu|The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
41274539|NCT03714126|DEVICE|Cordio Medical|Recording to an app, no interference to the regular care
40754259|NCT02035228|DEVICE|Abdominal stimulation - med/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the second half of exhalation"
40754260|NCT02035228|DEVICE|Abdominal Stimulation - med/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current throughout exhalation"
40926723|NCT01943474|DEVICE|Conventional IV Catheter Device|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
41122660|NCT01238146|DRUG|bendamustine hydrochloride|Given IV
41122661|NCT01238146|DRUG|obatoclax mesylate|Given IV
41122662|NCT01238146|BIOLOGICAL|rituximab|Given IV
41274540|NCT05786157|OTHER|Alcohol Administration|Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
41274541|NCT04687124|DIETARY_SUPPLEMENT|Fish oil|Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
41274542|NCT04687124|OTHER|standard care|No specified intervention
41274543|NCT00634231|BIOLOGICAL|AdV-tk|
41274544|NCT00634231|DRUG|valacyclovir|
41274545|NCT00634231|RADIATION|Radiation|
41274546|NCT02204865|DEVICE|Pacemaker/ICD|Implantation of an ICD or CRT device with ApneaScan function
41274547|NCT03184948|DEVICE|Brilliance|The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
41274548|NCT00644592|DRUG|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
41122663|NCT05591755|DRUG|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
41122664|NCT05591755|DRUG|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)
41122665|NCT05591755|DRUG|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)
41122666|NCT05591755|DRUG|Experimental: Vehicle ophthalmic solution (n = 56)|Experimental: Vehicle ophthalmic solution (n = 56)
41122667|NCT05574075|DIAGNOSTIC_TEST|Diffusion tensor imaging|white matter imaging markers
41122668|NCT02094807|DRUG|NSAID|Will be used if other drugs are not tolerated.
41122669|NCT02094807|PROCEDURE|thoracic epidural anesthesia|Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
41122670|NCT02094807|DRUG|opioids|During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
41122671|NCT02094807|DRUG|paracetamol|100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
41122672|NCT02094807|PROCEDURE|operative fixation of rib fractures|Fractures will be stabilized on the outside of of the ribs.
41122673|NCT02387658|PROCEDURE|translesional gradient measurement|Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
41122674|NCT00304031|DRUG|Concurrent temozolomide|Daily oral temozolomide (75 mg/m2) up to 49 doses.
41122675|NCT00304031|RADIATION|Concurrent radiation therapy|60 Gy in 2 Gy fractions
41122676|NCT00304031|DRUG|100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
41122677|NCT00304031|DRUG|75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle|Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
41122678|NCT03819829|OTHER|Blood sample|Blood sample
41122679|NCT05161585|DIAGNOSTIC_TEST|ctDNA dynamic monitoring|ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total.
41122680|NCT05973279|OTHER|Tecno Body Prokin Isokinetic Balance System|It provides objectively measurable data in static and dynamic balance measurements. The moving balance platform of the system, which is driven by air piston servo motors, can measure at a working angle of 15 degrees in all directions. The results can be monitored and recorded live on the screen on the device. From these data, each individual's static and dynamic balance score is obtained by summing the forward-backward standard deviation and right-left standard deviation.
41274549|NCT00644592|DRUG|Fenofibrate|160 mg/day orally for 4 weeks
41274550|NCT06362785|DEVICE|Virtual Reality|The intervention group will engage in immersive virtual reality sessions with interactive activities involving functional movements of the spine and limbs in a virtual environment using Meta Quest 3 goggles. The intervention will last for 6 weeks, comprising a total of 12 sessions, with a maximum duration of 30 minutes of virtual reality and 15 minutes of rest (45 minutes in total per session).
41274551|NCT05092607|DIAGNOSTIC_TEST|Venous and Capillary blood sampling|"Venous sample at the bend of the elbow (7mL) taken immediately after the nasopharyngeal sample.~Capillary blood sampling, for patients included in participating centers"
41274552|NCT03637049|DRUG|PBI-4050 and midazolam|A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
41274553|NCT02987855|PROCEDURE|Lipoaspiration|Closed syringe harvesting subdermal fat
41274554|NCT02987855|PROCEDURE|ADcSVF isolation|Isolation of AD-cSVF from lipoaspirate via enzymatic digestion
41274555|NCT02987855|PROCEDURE|Normal Saline IV|Normal Saline IV containing autologous AD-cSVF
41274556|NCT02249741|DRUG|Treated with Ibandronic acid as per protocol|treated with Ibandronic acid at a dose of 150 mg once a month for six months
41446536|NCT05027503|OTHER|Respiratory Physiotherapy|Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
41274557|NCT06015490|OTHER|Conditioned Stimulus: Sucrose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
41274558|NCT06015490|OTHER|Conditioned Stimulus: Glucose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of glucose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
41122681|NCT05973279|OTHER|Restorative Therapies RT300 leg/arm/cor:|RT300 is a motorised treatment system. In general there are 3 systems; Passive therapy, Active therapy and a combination of active therapy with some assistance from the motor. The device can be used from a chair, wheelchair or bed and there are two variants that can be used separately; Leg system, Arm system. Electrodes placed on the skin over specific muscle groups are connected via a cable or wirelessly to the RT300. These are used to stimulate peripheral motor nerves, causing the muscles to work. The software of the SAGE controller unit of the RT300 monitors the treatment process, including the stimulation patterns sent to the arms or legs, and the operation of the ergometer motor to produce smooth cycling motion. Contraindicated in the presence of lower limb fractures or pregnancy.
41122682|NCT05973279|OTHER|CSMI (CYBEX) Humac Norm Isokinetic Test and Exercise System|22 isolated joint movement models, 4 resistance modes (isokinetic, isotonic, isometric and passive) and a large number of reports to meet the measurement and exercise needs of today's clinicians and researchers. The exercise modes of the device include; Continuous passive movement, multi-angle isometry, proprioception training, standard and eccentric focused isokinetic strengthening, deceleration training, dynamic isotonic training, strength training. Test modes of the device include; Proprioceptive, co-measured, standard isokinetic, concentric/eccentric isokinetic, intermittent stroke isokinetic test.
41274559|NCT06015490|OTHER|Conditioned Stimulus: Fructose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of fructose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
41274560|NCT06015490|OTHER|Conditioned Stimulus: Sucrose (aim 2)|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
41274561|NCT06015490|OTHER|Conditioned Stimulus: High Fructose Corn Syrup (aim 2)|Participants will consume flavored beverage solutions containing 110 calories of high fructose corn syrup in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
41274562|NCT06015490|OTHER|Conditioned Stimulus: Sucrose + Non-nutritive Sweetener (aim 2)|Participants will consume flavored beverage solutions containing a non-nutritive sweetener and 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
41274563|NCT02013219|DRUG|Alectinib|Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
41274564|NCT02013219|DRUG|Atezolizumab|Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
41274565|NCT02013219|DRUG|Erlotinib|Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
41274566|NCT01520246|GENETIC|gene expression analysis|
40754261|NCT02035228|DEVICE|Abdominal Stimulation - high/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current for the first half of exhalation"
41274567|NCT01520246|OTHER|laboratory biomarker analysis|
41446537|NCT04509167|BIOLOGICAL|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 8 weeks.
40754262|NCT02035228|DEVICE|Abdominal Stimulation - high/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at hig stimulation current for the second half of exhalation"
40754263|NCT02035228|DEVICE|Abdominal Stimulation - high/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current throughout exhalation"
40754264|NCT06244251|PROCEDURE|TU-LESS|TU-LESS group will receive TU-LESS for myomectomy; MPLS group will receive MPLS for myomectomy
40754265|NCT06244251|PROCEDURE|MPLS|Patients with uterine who plan to receive MPLS for myomectomy
41274568|NCT05227729|DIAGNOSTIC_TEST|Measurement of blood flow in descending aorta by suprasternal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
41274569|NCT05227729|DIAGNOSTIC_TEST|Measurement of blood flow in descending aorta by transoesophageal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
41274570|NCT02341612|OTHER|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
41274571|NCT02341612|OTHER|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
41274572|NCT02341612|OTHER|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
41274573|NCT02341612|OTHER|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
41274574|NCT02341612|OTHER|passive recovery|The control group was exposed to treatment after the EIMD protocol.
41274575|NCT03115190|DIAGNOSTIC_TEST|General Practitioner diagnosis with Heart score|All patients seen by the general practitioner (GP) at the GP cooperation and agreeing to participation will be evaluated with the Heart score. This is a score including history, electrocardiogram, age, risk factors and troponin to assess whether a patient is at high risk for acute coronary syndrome. The troponins asked for in the Heart score are at arrival of the patient, not regarding the time of onset of chest pain. We shall use point of care (POC) troponin, thereby modifying the Heart score. The GP must realize that the POC troponin is not reliable on its own with one test. If the Heart score is low, it is acceptable and safe to not refer the patient, it is however not safe to refer the patient solely on negative troponin result.
41274576|NCT02585427|DIETARY_SUPPLEMENT|low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil|
41274577|NCT00976755|DRUG|everolimus|"Everolimus:~10mg daily"
40926724|NCT04597242|DRUG|Exebacase|Patients will receive a single IV infusion of exebacase in addition to antistaphylococcal antibiotics prescribed by the treating physician. Patients with normal renal function or mild renal impairment will be administered a dose of 18 mg of exebacase; patients with moderate or severe renal impairment will be administered a dose of 12 mg; patients with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg.
41274578|NCT05258227|OTHER|Conservational Physical Therapy and Proprioceptive Strength Training|The proprioceptive training cycle consist of squats, single leg stand, slide steps , forward and backward step, toe walking , heel walking , side sway etc.
41274579|NCT05258227|OTHER|Conservational Physical Therapy and Core Instability Strength Training|Core stability is essential part of lower limb rehabilitation; it is also known protocol which includes group of exercises in both standing and sitting improving biomechanics and functional performance of the body.
41274580|NCT00316875|DRUG|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
41274581|NCT00316875|DRUG|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
41274582|NCT02137044|BEHAVIORAL|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
41274583|NCT04724525|OTHER|soft contact lens Toric|soft contact lens toric with different axis and power that use in human's eye
41274584|NCT04626622|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
41274585|NCT04626622|DRUG|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
41274586|NCT03136939|OTHER|No intervention|No intervention
41274587|NCT06295445|PROCEDURE|care cardio-pulmonary ultrasound|Evaluation of the heart and lung conditions in shocked patients using focused cardio-pulmonary ultrasound for treatment guidance and their implication on the patient's outcome
41274588|NCT06295445|OTHER|treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management|treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management
41274589|NCT03849729|DRUG|Phentermine|This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
41274590|NCT03849729|OTHER|Placebo|his is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
40754266|NCT04216004|BEHAVIORAL|Controlled-Feeding Intervention|All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
41274591|NCT02154646|DRUG|LY2157299|Administered orally
41274592|NCT02154646|DRUG|Gemcitabine|Administered IV
40754267|NCT04216004|DIETARY_SUPPLEMENT|Non-dairy beverage|Isolated amino acid, fatty acid, and monosaccharide beverage matched to the macronutrient content of 8 fl oz whole milk.
40754268|NCT04216004|OTHER|Full-fat milk|3 daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
41274593|NCT05863611|OTHER|arms|During the research, a questionnaire form (age, gender, educational status, etc.) in which your demographic information will be recorded for evaluation purposes and a consent form for participation in the study will be filled. Standardized Mini Mental Test will be applied. Then fragility will be evaluated with the Fried Fragility Index. Fall assessment will be assessed with the Fall Risk Self-Assessment Scale. Balance assessment will be made with the Tinetti Balance and Gait Assessment.
41274594|NCT01254344|DRUG|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
41274595|NCT01254344|DRUG|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
41274596|NCT01254344|DRUG|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
41274597|NCT01254344|DRUG|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
41274598|NCT06162455|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
41274599|NCT06162455|DRUG|200- ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
41274600|NCT05207761|DRUG|D565|Q.D. in both eye
41274601|NCT05207761|DRUG|D930|T.I.D in both eye
41274602|NCT05150132|DEVICE|Oral-B Genius® 8000 power toothbrush with CrossAction brush head with smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone was activated in the PTB with the app group
40754269|NCT04216004|OTHER|Fat-free milk|3 daily servings (cup-eq) of fat-free (0%) commercial cow's milk.
41274603|NCT05150132|DEVICE|Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone were not activated in the PTB without the app group.
41274604|NCT05150132|DEVICE|Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. They were instructed to brush with the Modified Bass technique.
41274605|NCT05269576|OTHER|Clinical practice|Period of 5 days where medical students carry out hospital clinical practices with real patients supervised by professionals who teach them at the same time.
40926725|NCT01673347|BIOLOGICAL|Meniscal Allograft|Meniscal allograft
40754270|NCT03927716|DRUG|SB206 12%|Topically once daily
40926726|NCT02635646|OTHER|Family and interdisciplinary approach|"Family and interdisciplinary approach that includes:~1. nutritional counseling,~2. physical activity counseling,~3. psychological counseling,~4. metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling."
40754271|NCT03927716|DRUG|Placebo|Topically once daily
40754272|NCT03376009|DIAGNOSTIC_TEST|Blood sample for serum and plasma biomarkers:|Serum/plasma biomarkers: Approximately 10ml (3 teaspoons) of blood will be extracted to measure pre-specified biomarkers of renal injury including kidney injury molecule-1 (KIM-1), cystatin C and neutrophil gelatinase-associated lipocalin (NGAL). Samples will then be stored to facilitate measurement of additional biomarkers in the future.
40754273|NCT03376009|DIAGNOSTIC_TEST|Urine sample for biomarkers|Urinary biomarkers: A random urine sample will be obtained to measure urinary protein to creatinine ratio (uPCR), KIM-1 and liver-type fatty acid binding protein (L-FABP)
40926727|NCT02635646|OTHER|individual approach|"individual approach that includes:~1. nutritional and physical activity counseling in individual appointments,~2. metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually."
40926728|NCT04153162|DEVICE|Stereotactic body radiation therapy|Stereotactic body radiation therapy delivered to reduce LVOTO in patients with HCM
41122683|NCT01952769|BIOLOGICAL|MDV9300|"The study will be done in the following manner:~1. Evaluation of MDV9300 and radiation-~   1. Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.~  2. Cohort B -3 patiens: if no toxicity \>grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity\> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity\> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given~2. Evaluation of MDV9300 and cyclophosphamide~After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:~Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2"
41122684|NCT00687713|DRUG|Bupropion|150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
41122685|NCT00687713|OTHER|Placebo|Placebo
41122686|NCT00047931|DRUG|VRC-HIVDNA009-00-VP|
41274606|NCT05269576|OTHER|Clinical simulation|Clinical simulation classes through 2 sessions of 5 simulated cases each day. All students actively participate in one or two of the simulation cases and observed and discussed all the cases in the debriefings of all of them.
41274607|NCT06196411|BEHAVIORAL|Task-oriented Training|Task-oriented training will be applied to study group 5 days a week, for a total of 6 weeks, in addition to Bobath training. Task-oriented training will consist of performing the lying, sitting, standing and walking exercises by performing tasks for specific goals. Exercises will be perform by accomplishing tasks such as touching the ball with the upper or lower extremities, reaching for the ball, crossing various tracks to move blocks from one place to another, walking through obstacles or climbing stairs.
41274608|NCT06196411|BEHAVIORAL|Bobath Training|Bobath Concept includes sensory, perceptual and adaptive exercises aimed at improving function through mobilisation, weight-bearing, practicing more normal movement patterns and performing more efficient, less effortful tasks.
41274609|NCT05052489|OTHER|registy|Children with diarrhea were registered in the hospital. Baseline information of the children was recorded and followed up to observe the distribution of disease types, clinical manifestations, treatment plans and clinical outcomes
41274610|NCT03735940|OTHER|Spot monitoring device, excl. Sham|o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
41274611|NCT02060734|PROCEDURE|Lidocaine|Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
41274612|NCT02060734|OTHER|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
41274613|NCT03724448|DRUG|aleozen|treatment with herbal medicine
41274614|NCT03724448|DRUG|Placebo Oral Tablet|No aleozen treatment
41274615|NCT03588689|PROCEDURE|Continuous fascia iliaca block|Regional nerve block performed under ultrasound guidance. A catheter will be left in place to allow ongoing infusion of local anesthetic.
40758277|NCT02174770|OTHER|Blood Flow Restriction (BFR) Training|This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
41122687|NCT05674136|DEVICE|INVSENSOR00061|Noninvasive pulse oximeter sensor
41122688|NCT04657172|DRUG|Pilocarpine Ophthalmic|Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
41122689|NCT04657172|DRUG|Placebo|Vehicle ophthalmic solution administered with the Optejet microdose dispenser
41274616|NCT03588689|DRUG|Ropivacaine|Ropivacaine local anesthetic will be used for the fascia iliaca block
41274617|NCT01617538|DRUG|atorvastatin|40mg per day,duration for 24 weeks
41274618|NCT02514044|DRUG|Dexedrine|10 mg immediate release of Dexedrine
41274619|NCT02514044|DEVICE|Active tDCS|1.5 mA tDCS anodal tDCS
41274620|NCT02514044|BEHAVIORAL|Speech Therapy|60 min of speech therapy
41274621|NCT02514044|DRUG|Placebo|
41274622|NCT02514044|DEVICE|Sham tDCS|
41274623|NCT04710784|BEHAVIORAL|Sexual health information|We will provide participants with sexual health information, that is basic, accurate, and directly contributes to health-promoting decisions and behavior, once a week at the beginning of the study.
41274624|NCT04710784|BEHAVIORAL|I-TEST branded HIVST package|The I-TEST branded HIVST package will include HIV self-testing (HIVST) kits, referral coupons, condoms, female or male hygiene products, and instructions on how to use the I-TEST photo verification App or USSD (Unstructured Supplementary Service Data) system to verify the HIVST results. Study participants will be referred to a youth-friendly health clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment and PrEP referral.
41274625|NCT04710784|OTHER|Follow-up testing and clinic assessments|Information to encourage routine retesting for HIV every 6 months and linkage to the youth-friendly clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment, and PrEP referral. Additionally, follow-up surveys will be administered to assess HIV testing, sexual behavior history, youth participation experience, and other related outcomes will be collected from enrolled participants.
41274626|NCT00430118|DRUG|asparaginase|
41274627|NCT00430118|DRUG|cyclophosphamide|
41274628|NCT00430118|DRUG|cytarabine|
41274629|NCT00430118|DRUG|daunorubicin hydrochloride|
41122690|NCT03434496|DEVICE|Gait Trainer 3|With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
41122691|NCT05425953|OTHER|No intervention other than obtaining biopsies|Biopsies will be obtained.
41122692|NCT01406223|DRUG|Varenicline|
41122693|NCT01406223|DRUG|Bupropion|
41122694|NCT01406223|DRUG|Nicotine patches|
41122695|NCT01406223|OTHER|Placebo varenicline|
41122696|NCT01406223|OTHER|Placebo bupropion|
41122697|NCT01406223|OTHER|Placebo patch|
41122698|NCT03646136|PROCEDURE|Retained fluid|Retained fluid
41122699|NCT03646136|PROCEDURE|Emptied fluid|Emptied fluid
41122700|NCT03580369|BIOLOGICAL|Ligelizumab|Liquid in vial
41122701|NCT03580369|BIOLOGICAL|Omalizumab|Lyophilized powder for solution in vial
41122702|NCT03580369|OTHER|Placebo|Liquid in vial
41122703|NCT04156789|DIAGNOSTIC_TEST|Home sleep apnea testing|Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
41122704|NCT00901901|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily
41122705|NCT00901901|DRUG|Erlotinib (Tarceva)|Erlotinib 150 mg once daily
41122706|NCT00901901|DRUG|Placebo|Matching erlotinib placebo 150 mg once daily
41122707|NCT02472275|DRUG|Antiandrogen Therapy|Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
41122708|NCT02472275|OTHER|Laboratory Biomarker Analysis|Correlative studies
41122709|NCT02472275|DRUG|Multitargeted Tyrosine Kinase Inhibitor PLX3397|Given PO
41122710|NCT02472275|RADIATION|Radiation Therapy|Undergo radiation therapy
41122711|NCT03866967|BIOLOGICAL|AK105|intravenous (IV) infusion
40754274|NCT03376009|DIAGNOSTIC_TEST|Cardiac bio-impedance (Cardioscreen Medis)|Cardiac bio-impedance - a non-invasive assessment of cardiac output, cardiac index and systemic vascular resistance index using the bio-impedence technique (Cardioscreen 1000 Medis) Cardiac bio-impedance is performed by attaching sticky electrodes to the participant's neck and thorax. These electrodes pass a very low, constant and alternating current (1.5 mA, 86 kHz) across the thorax, which is imperceptible to the patient. This provides beat by beat data on cardiac output and haemodynamic measurements.
41122712|NCT01186159|DRUG|Parecoxib Sodium|40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
41122713|NCT02208596|DRUG|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
41122714|NCT02208596|DRUG|propofol|
41122715|NCT02208596|DRUG|Etomidate|
41122716|NCT00038454|DRUG|Hemolink (hemoglobin raffimer IV solution)|
41122717|NCT02742571|OTHER|non applicable|
41122718|NCT02133820|DRUG|4 mg 12 hourly capsule - strong pain killer fasted|
41122719|NCT02133820|DRUG|4 mg 12 hourly capsule - strong pain killer fed|
41122720|NCT02133820|DRUG|12 hourly capsule strong painkiller with antagonist fasted)|
41122721|NCT02133820|DRUG|4 mg 12 hourly capsule strong painkiller with antagonist fed|
41122722|NCT04856826|DEVICE|ultrasound guidance and therapeutic communication|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
41122723|NCT01753986|BEHAVIORAL|Brief Alcohol Intervention plus Standard Batterer Intervention|Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
41122724|NCT01753986|BEHAVIORAL|General Health Improvement Intervention plus Standard Batterer Intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
41122725|NCT06521411|BEHAVIORAL|CSA model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided in subsidized weekly boxes for 20 weeks to community members at Brooklyn Grange Farm in Sunset Park at a fee of $5, which was determined to be acceptable by community members. Participants that receive SNAP benefits can use their EBT card to cover their $5. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
41122726|NCT04404166|BEHAVIORAL|PINGS 2|Home BP monitoring, medication reminders using phone alerts, and patient education on hypertension, cardiovascular risk reduction \& stroke
41122727|NCT05099341|OTHER|HDRS-17 depression scale|Measuring the severity of depression
41122728|NCT05099341|BIOLOGICAL|Blood sampling|3 tubes of 5 ml
41122729|NCT03665779|DRUG|isosorbide mononitrate|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times
41122730|NCT03665779|DRUG|Placebo|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
41122731|NCT01263613|PROCEDURE|tumor biopsy and blood draw|tumor biopsy and blood draw during and after chemotherapy
41122732|NCT04695197|DRUG|Artemether-lumefantrine (AL)|Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 \>=35 80 + 480; Twice daily for 3 days (total, six doses)
41122733|NCT04695197|DRUG|Pyronaridine-artesunate (PA)|Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to \< 8 60 + 20 8 to \<15 120 + 40 15 to \<20 180 + 60 20 to \<24 kg 180 + 60 24 to \<45 360 + 120 45 to \<65 540 + 180 \>=65 720 + 240; Once-daily for 3 days (total, three doses).
41122734|NCT01456013|DEVICE|RenalGuard Therapy|Induced Diuresis with matched replacement
41122735|NCT01456013|DRUG|Standard Therapy|Standard of care for patients at risk of CIN
41274630|NCT00430118|DRUG|dexamethasone|
40926729|NCT02848443|DRUG|Trifluridine/tipiracil hydrochloride (S 95005)|Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
40926730|NCT02848443|DRUG|Oxaliplatin|Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
41122736|NCT02616068|DRUG|Transdermal Patch|Transdermal patch 100 mg once a day for 7 days
40926731|NCT02848443|DRUG|Bevacizumab|Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
40926732|NCT02848443|DRUG|Nivolumab|Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
41122737|NCT02616068|DRUG|Loxoprofen sodium|Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days
40926733|NCT00004581|DRUG|Lopinavir/Ritonavir|
40926734|NCT00004581|DRUG|Nevirapine|
40926735|NCT00366093|DRUG|Eszopiclone|eszopiclone 3 mg
41122738|NCT02616068|DRUG|Placebo (for loxoprofen sodium)|Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days
41122739|NCT02616068|DRUG|Placebo (for transdermal patch)|Placebo (for transdermal patch 100 mg) once a day for 7 days
41122740|NCT05239013|DRUG|Nitroglycerin ointment|2 cm (30mg) of 2% nitroglycerin applied 2 cm from the styloid process of the anterior forearm
41122741|NCT02267824|DEVICE|Extraoral OrthoPulse® PBM|Patients carry out daily extraoral OrthoPulse® PBM treatments at home.
41122742|NCT02267824|OTHER|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
41122743|NCT02724956|DEVICE|Ambu AuraGain|Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
41122744|NCT02724956|DEVICE|Teleflex LMA Protector|Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
41122745|NCT02724956|DEVICE|Ambu aScope|Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
41122746|NCT05481242|OTHER|retrospective observational study|retrospective observational study
41122747|NCT06515678|DRUG|arm A - angiotensin converting enzyme inhibitors (ACEi)|"Patients with ACEi monotherapy before or within 6 months following debulking surgery.~ACEi will be defined as any drugs from the Anatomical Therapeutic Classification C09AA with an indication for hypertension, including but not limited to: captopril, enalapril, lisinopril, perindopril, ramipril, quinapril"
41122748|NCT06515678|DRUG|arm B - calcium channel blockers (CCBs)|"Patients with CCB monotherapy before or within 6 months following debulking surgery.~CCBs will be defined as any drugs from the Anatomical Therapeutic Classification C08CA with an indication for hypertension, including but not limited to: amlodipine, felodipine, isradipine, nicardipine, nifedipine"
41122749|NCT06515678|DRUG|arm R - angiotensin receptor blockers ARB|"Patients with angiotensin receptor blocker (ARB) before or within 6 months following debulking surgery.~ARBs will be defined as any drugs from the Anatomical Therapeutic Classification C09CA with an indication for hypertension, including but not limited to: losartan, valsartan, irbesartan, candesartan or olmesartan medoxomil."
41122750|NCT02328963|DRUG|Everolimus|"Everolimus : 0.75 bid, targeted to 3-8 ng/ml~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
41274631|NCT00430118|DRUG|doxorubicin hydrochloride|
40758278|NCT02174770|OTHER|Standard ACSM-guided strength training|This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
40758279|NCT04466033|DEVICE|Magneto Microcatheter|All patients will be treated with Magneto Microcatheter
40926736|NCT00366093|DRUG|Placebo|placebo tablet
41274632|NCT00430118|DRUG|etoposide|
41274633|NCT00430118|DRUG|ifosfamide|
41274634|NCT00430118|DRUG|mercaptopurine|
40926737|NCT03775538|DRUG|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
40926738|NCT03775538|DEVICE|Renishaw Drug Delivery System|Stereotactically implanted device
40926739|NCT06139042|DIAGNOSTIC_TEST|Blood drawing|The participants had their blood drawn.
40926740|NCT05772988|DIETARY_SUPPLEMENT|Beta-alanine|Beta-alanine
40926741|NCT05772988|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
40926742|NCT04069364|BEHAVIORAL|TinnitusTipps|Self-helf tips for managing chronic tinnitus will be given via smartphones.
40926743|NCT00105365|DEVICE|Shoe insert|Subjects with knee OA underwent gait analysis and knee pain and function assessment at baseline while wearing walking shoes and after four weeks of wearing walking shoes with lateral-wedged insoles.
41122751|NCT02328963|DRUG|mycophenolic acid|"Mycophenolic acid :~1080 mg bid for one month, then 720 mg bid~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
40926744|NCT00105365|OTHER|walking shoes|walking shoes
41122752|NCT05531708|BIOLOGICAL|Anti-mesothelin CAR-T cells|D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
40758280|NCT02364271|OTHER|Thrombolysis in myocardial infarction score|An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
40758281|NCT02364271|BIOLOGICAL|routine blood test for hs-cTnT|Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
40758282|NCT02364271|OTHER|HEART score|The modified HEART score of each patient was determined retrospectively by a research assistant.
40926745|NCT05873660|OTHER|No treatment given|No treatment given
41122753|NCT05531708|DRUG|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
41122754|NCT05531708|DRUG|Cyclophosphamide|D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
41122755|NCT06278870|DRUG|disitamab vedotin|disitamab vedotin 2mg/kg iv q2w
41122756|NCT06278870|DRUG|Pyrotinib|pyrotinib 400mg po q28d
41122757|NCT06278870|DRUG|trastuzumab|trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d
41122758|NCT06278870|DRUG|Pertuzumab|pertuzumab 840mg for the first cycle, 420mg for subsequent treatments iv q21d
41274635|NCT00430118|DRUG|methotrexate|
41274636|NCT00430118|DRUG|prednisone|
40926746|NCT01873703|DRUG|pracinostat|Histone deacetylase inhibitor (HDACi)
40926747|NCT01873703|DRUG|Placebo|Placebo
40926748|NCT01873703|DRUG|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
40754275|NCT03376009|DIAGNOSTIC_TEST|Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor)|"Aortic pulse wave velocity (APWV) a non-invasive measure of arterial function using oscillometric recordings to detail peripheral and central haemodynamics. This will be measured using two different techniques:~TensioMed Arteriograph: After a rest period a blood pressure cuff inflates and deflates twice on the arm. This takes \~3 minutes and should cause only mild, temporary discomfort. The test will routinely be performed in duplicate to ensure accuracy of results.~SphygmoCor: A pressure sensor is held over the radial pulse at the wrist to analyse the pulse wave. Then held over the carotid artery and/or femoral artery to assess the speed of the pulse wave through the body. The probe is similar to an ultrasound probe and should not cause any discomfort."
40754276|NCT03376009|DIAGNOSTIC_TEST|Optical Coherence Tomography (Spectralis OCT)|"OCT is a non-invasive imaging test which uses light waves to take cross sectional images of the back of the eye. Examination of the retinal and retinal nerve fibre layer thickness, macular volume, and choroidal thickness provides an assessment of generalised systemic microvascular injury. A strong correlation between choroidal thickness and renal dysfunction has previously been shown in patients with chronic kidney disease (Balmforth C et al, JCI Insight 2016).~The participant is asked to sit in front of the OCT machine and rest their chin on a support to keep it motionless. The equipment will then scan the eye without touching it. Scanning takes about 5 - 10 minutes."
40926749|NCT03493932|DRUG|Nivolumab|OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
40926750|NCT03493932|DRUG|BMS-986016|Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
41122759|NCT06278870|DRUG|taxane drug|Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer guideline recommendations
41122760|NCT05554185|DIETARY_SUPPLEMENT|aspirin 100mg and probiotics 1 bag|taking aspirin 100mg and probiotics 1 bag per day from 14-16 weeks of pregnancy until 35 + 6 weeks of pregnancy or emergency delivery.
41122761|NCT02346526|PROCEDURE|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
41122762|NCT02346526|PROCEDURE|CT scan|Standard CT scans will be carried out prior to treatment, week 9, and week 25.
41122763|NCT02346526|PROCEDURE|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
41122764|NCT02346526|DRUG|Radium-223 dichloride|Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.
41122765|NCT02346526|PROCEDURE|bone scan|Standard bone scans will be carried out prior to treatment, week 9, and week 25.
41122766|NCT03766971|BEHAVIORAL|7 days of Tobacco Cessation|Participants will be randomly assigned to 7 days of tobacco cessation.
41122767|NCT03766971|BEHAVIORAL|21 days of Tobacco Cessation|Participants will be randomly assigned to 21 days of tobacco cessation.
41122768|NCT03766971|DRUG|Cannabis|Participants will receive cannabis.
41122769|NCT02265432|BEHAVIORAL|General physical activity educational materials|
41274637|NCT00430118|DRUG|thioguanine|
41122770|NCT02265432|DEVICE|Wearable activity tracking devices (fitbit)|
41122771|NCT02265432|OTHER|online map|
41122772|NCT02265432|OTHER|Personalized text messages|
41274638|NCT00430118|DRUG|vincristine sulfate|
41274639|NCT00430118|DRUG|vindesine|
41274640|NCT00430118|RADIATION|radiation therapy|
41274641|NCT05679882|OTHER|Masking Sounds|Masking sounds will be played from outdoor speakers.
41274642|NCT05679882|OTHER|No Masking Sounds|No masking sounds will be played from outdoor speakers.
41274643|NCT01561664|OTHER|muscle and fat biopsy|muscle and fat biopsy
41274644|NCT06109545|PROCEDURE|Laparoscopy|Patients included in this study will have diagnostic laparoscopy type WOLF done after checking all above ultrasound parameters of malignant tumor. This procedure will be done under general anathesia then a verses needle will be used at umbilicus or at palmer point if the mass is large or in cases of umbilical hernia or previous abdominal or pelvic surgery, then Fagotti criteria will be assessed
41274645|NCT01152606|DRUG|trastuzumab [Herceptin]|There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
41274646|NCT00061386|BEHAVIORAL|Nutrition and physical activity program|
41274647|NCT05589493|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by dental implants following the All-on-4 Concept arrangement.
41274648|NCT05134909|DEVICE|Customized contact lens|The customized lenses are designed to correct the eye's optical aberrations.
41274649|NCT00635102|DRUG|D-Cycloserine PO and Glycine IV|Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
41274650|NCT00635102|DRUG|Placebo D-Cycloserine PO and placebo Glycine IV|Placebo
41274651|NCT00635102|DRUG|Placebo D-Cycloserine PO and Glycine IV|
41274652|NCT00635102|DRUG|D-Cycloserine PO and placebo Glycine IV|
41274653|NCT00002462|BIOLOGICAL|bleomycin sulfate|
41446538|NCT03759717|OTHER|Observation|Understanding the biology of skull base tumors will teach the investigators about the genesis and/or mechanisms of treatment resistance. The investigators hope to ultimately identify new targets which will add to the armamentarium by which to treat these tumors.
41446539|NCT03896126|OTHER|Observational|There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
41446540|NCT01512628|DRUG|Pentaspan, voluven, volulyte|Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
41446541|NCT06535932|DEVICE|Amara View Minimal Contact Full Face Mask|The Amara View Full-Face Mask is a minimal contact full face mask manufactured by Philips Respironics (Murrysville, PA) that covers the mouth and seals under the nose compared to traditional full-face masks which seal over the nose. The Amara View mask is intended to reduce discomfort on the bridge of the nose. There is no forehead arm, offering patients an enhanced design to keep the field of vision clear.
41122773|NCT04987294|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
41122774|NCT04987294|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
41122775|NCT05251844|OTHER|receiving an email|The email informed that the employee has had been identified as having accessed a patient's electronic medical record without a known work-related purpose and that unauthorized access is a privacy violation.
41122776|NCT04769596|DEVICE|NEUROMARK™ System|The NEUROMARK™ System is designed to deliver energy to the nasal cavity intended to interrupt nasal nerves aimed to reduce symptoms related to Chronic Rhinitis.
41274654|NCT00002462|DRUG|doxorubicin hydrochloride|
41274655|NCT00002462|DRUG|mechlorethamine hydrochloride|
41274656|NCT00002462|DRUG|prednisone|
41274657|NCT00002462|DRUG|procarbazine hydrochloride|
41122777|NCT04769596|DEVICE|Sham Device|A Sham device will be used in the nasal cavity
41122778|NCT00004440|DRUG|ibuprofen|
41122779|NCT03315481|PROCEDURE|SAX catheter insertion|Suture-method catheter inserted in the short axis of the adductor canal
41122780|NCT03315481|PROCEDURE|LAX catheter insertion|Suture-method catheter inserted in the long axis of the adductor canal
41274658|NCT00002462|DRUG|vinblastine sulfate|
41274659|NCT00002462|DRUG|vincristine sulfate|
41274660|NCT00002462|RADIATION|low-LET cobalt-60 gamma ray therapy|
41274661|NCT00002462|RADIATION|low-LET photon therapy|
41274662|NCT00002462|RADIATION|radiation therapy|
41274663|NCT04036825|DIETARY_SUPPLEMENT|Liquid Nutritional Supplement from Hospital Product|Liquid Nutritional Supplement from Hospital Product is given 2 times daily for 14 days
41122781|NCT03485950|DRUG|Cefepime|Given IV
41122782|NCT03485950|DRUG|Ceftolozane|Given IV
41122783|NCT03485950|OTHER|Laboratory Biomarker Analysis|Correlative studies
41122784|NCT03485950|DRUG|Meropenem|Given IV
41122785|NCT03485950|DRUG|Piperacillin-Tazobactam|Given IV
41122786|NCT03485950|DRUG|Tazobactam|Given IV
41122787|NCT02378779|OTHER|Questionary SF12 and PEDT (Premature Ejaculation Diagnostic Tool)|The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
41274664|NCT04036825|DIETARY_SUPPLEMENT|Placebo|Standard nutritional supplement is given 2 times daily as placebo for 14 days
41274665|NCT03173469|OTHER|magnetic resonance imaging of breast|all patients will undergo preoperative MRI
41274666|NCT00867750|DEVICE|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
41446542|NCT06535932|DEVICE|F40 Minimal Contact Full Face Mask|The AirFit F40 is a minimal contact FFM manufactured by ResMed (San Diego, CA) that rests softly and securely under the patients nose and is designed to let patients sleep in any position and move freely throughout the night. The mask consists of three cushion sizes and three headgear sizes. Headgear adjustments can be made with magnetic clips that easily snap on and off.
41122788|NCT02378779|OTHER|Total attention|Total attention of the GP to approach the subject of premature ejaculation during all the consultation
41122789|NCT02378779|OTHER|Humour|Use the humour to approach the subject of premature ejaculation
41122790|NCT02378779|OTHER|Take the drama out|Take the drama out to approach the subject of premature ejaculation
41122791|NCT02378779|OTHER|Question about premature ejaculation|Question about premature ejaculation during the GP consultation
41122792|NCT02378779|OTHER|Symptoms of premature ejaculation|GP's observation about signs of premature ejaculation
41122793|NCT02378779|OTHER|Help to verbalize|Help for the patient to speak about premature ejaculation
41122794|NCT02850744|DRUG|PQR309|80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
41122795|NCT04978233|OTHER|sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID|The intervention consists of having confirmed COVID-19 infected participants register for the Opal app and complete a daily questionnaire on symptoms related to their physical and mental health as well as on certain key vital signs (e.g., oxygen saturation, heart rate, temperature). A nurse will check the questionnaire results each day and determine the need for a teleconsultation with an infectious disease physician. Participants will be followed up for a minimum of 14 days, depending on their symptoms.
41122796|NCT05967429|DIAGNOSTIC_TEST|The neutrophil-to- lymphocyte ratio|It was calculated by dividing the neutrophil count by the lymphocyte count.
41122797|NCT05967429|DIAGNOSTIC_TEST|Prognostic nutrition index|It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL
41122798|NCT04042207|DEVICE|Low Glucose Predictive Suspend system|consists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)
41122799|NCT04042207|DEVICE|DBLHU System|DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
41122800|NCT05280275|DRUG|Belantamab Mafodotin-Blmf|"Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes."
41122801|NCT05280275|DRUG|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
41122802|NCT05280275|DRUG|Lenalidomide|Lenalidomide will be administered per os.
41122803|NCT05280275|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
41122804|NCT03488394|GENETIC|Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.|"The drug product target dose is more or equal to 8x10\^6 CD34+ cells/Kg, with a minimum dose of 4x10\^6 CD34+ cells/Kg and a maximum dose of 35x10\^6 CD34+ cells/Kg.~The product will be injected intravenously."
41122805|NCT02797184|DRUG|KNO3, potassium nitrate|Potassium nitrate (KNO3) will be given orally in 2 gelatin capsules, which will be compounded by the Barnes-Jewish Hospital Pharmacy. The doses are 10 mmol and 20 mmol KNO3.
41122806|NCT02065024|DIETARY_SUPPLEMENT|b-cryptoxanthin plus phytosterols|
41122807|NCT03479034|OTHER|ScalaMed ePrescription application|Mobile phone application (Android and Apple) for storing electronic prescriptions
41122808|NCT00859794|OTHER|fMRI|Subjects will perform cognitive tasks during MRI scanning sessions to gather data about cognitive functions.
41122809|NCT00859794|OTHER|Neuropsychological Testing|Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsychological evaluations for analysis.
41122810|NCT00859794|OTHER|Additional electrode implantation|Subjects will typically have between 100-300 electrodes implanted as part of their surgery. Additional electrodes will be implanted that are able to record from smaller, more specific parts of the brain. This will allow for better understanding of how the brain is wired.
41122811|NCT00859794|OTHER|Electrical brain stimulation|Intracranial or extracranial electrodes will be used to deliver electrical brain stimulation (amplitude 0.5-8.0mA) or sham stimulation of between 0.4 and 3000 milliseconds during cognitive task periods.
41122812|NCT06075524|PROCEDURE|Biospecimen Collection|Undergo blood and optional stool/tissue sample collection
41122813|NCT06075524|OTHER|Electronic Health Record Review|Medical records are reviewed
41122814|NCT03335397|DEVICE|M-learning application|Mobile application with interactive contents available for android platform and Apple's operating system.
41122815|NCT03335397|OTHER|Traditional learning process|Traditional content available in university library.
41122816|NCT01691079|DRUG|ipratropium bromide|Inhaled ipratropium bromide administered before exercise.
41122817|NCT01691079|DRUG|Placebo|Inhaled placebo administered before exercise.
41122818|NCT04194710|BIOLOGICAL|Autologous Cytokine Rich Serum|"Proteins, called cytokines, released from blood platelets and leukocytes, play an important role in the repair and regeneration of the injured tissue that causes lateral epicondylitis.~Autologous Cytokine Rich Serum is prepared by the medical devise Q-Cytokine (CE MED31489) from patient's blood. The company Tecnologia Regenerativa Qrem S.L., with licence number 7096-PS from Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), is the manufacturer of this product. Q-Cytokine is a lab-in-a-box devise, and consist of an automatic centrifuge and a sterile disposable kit. After 9 steps of centrifugation, that take place in 36 minutes, Cytokine Rich Serum is obtained. This Cytokine Rich Serum is then injected to the epicondyle.~Patients randomized to this treatment will receive 1 injections of Autologous Cytokine Rich Serum right after randomization and another one after 15 days.~This process will take place at outpatient clinics."
41122819|NCT04194710|PROCEDURE|Arthroscopic Resection|"Surgical treatment of resection by arthroscopy is the standard treatment for chronic epicondylitis. The surgery is performed in the operating room under local anesthesia and lasts approximately 30 minutes. During the surgery, the doctor accesses the tendon by arthroscopy to perform an exeresis of the degenerated tendon. After the operation, the patient is directed to the recovery room where the responsible doctor will perform a physical examination and examination before leaving the center.~This process will take place at the major ambulatory surgery center of the investigator's hospital."
41274667|NCT00867750|DRUG|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
41274668|NCT01816503|DRUG|No intervention|This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
41122820|NCT05783791|DIAGNOSTIC_TEST|Newborn Screening Assay|"The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~* Is noninvasive~* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~* Does not by design or intention introduce energy into a subject, and~* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study."
41122821|NCT00002072|DRUG|Epoetin alfa|
41122822|NCT03974503|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|ERRT is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in trauma-exposed adults.
41122823|NCT03974503|BEHAVIORAL|Sleep and Nightmare Management|This is a manualized protocol developed to be of similar length but exclude the active components of standard ERRT.
41122824|NCT04716855|OTHER|Quality of life and daily living activities assessment tests|
41122825|NCT00991549|BEHAVIORAL|interdisciplinary intervention or meeting-seminars|one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
41122826|NCT00436631|BEHAVIORAL|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
41122827|NCT04286269|OTHER|Music Based Intervention|Participants assigned to MBI will receive a total of 1.5 hours of music intervention 5-6 sessions per week. Music will be alternating: 30 minutes on and 30 minutes off and will be played when the subject is awake to cue pacification and initiate the sleep process. Music will be delivered through headphones using an MP3 player.
41122828|NCT04286269|OTHER|Sham Treatment|Participants assigned to the control group will have the same treatment as the MBI group, but with no sound played through the headphones.
41122829|NCT03569982|OTHER|Integrative medicine care|Including acupuncture, relaxation/breathing, and manual/touch modalities
41122830|NCT01339234|OTHER|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
41122831|NCT05741645|OTHER|Kinesiotaping|During the kinesio taping of the erector spina vs multifidus muscles, the patient is in a standing position. Kinesiotape is applied with 50% tension and stays in the patient for 30 minutes.
41122832|NCT05741645|OTHER|Sham Kinesiotaping|The elastic taping will be randomly applied to a place outside the area to be measured, without stretching, and without causing any effect.
41122833|NCT03296540|DRUG|Prasugrel (Crushed tablets)|loading dose of 6 crushed tablets 10mg Prasugrel
41122834|NCT03296540|DRUG|Prasugrel (Integral tablets)|loading dose of 6 integral tablets of 10mg Prasugrel
41122835|NCT02680457|DRUG|Insulin Degludec|Insulin Degludec 10 IU SC every 24 hours for 6 days
41122836|NCT02680457|DRUG|Insulin Glargine|Insulin Glargine 10 IU SC every 24 hours for 6 days
41274669|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
41274670|NCT00982566|DRUG|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
41446543|NCT06561763|DRUG|Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine|Albumin paclitaxel 200g/m2, intravenous drip administration, d1; Cisplatin 60 mg/m2， Intravenous , d1; Capecitabine, 1000mg/m2, orally administered D1-14； Triprolizumab injection 240mg, intravenous D1; Nivolumab 400mg, intravenous D1; Q3W 1 cycle, 3 cycles Period, 3 weeks in total
41122837|NCT05264168|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
41122838|NCT05264168|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
41122839|NCT00960024|BEHAVIORAL|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
41122840|NCT00960024|BEHAVIORAL|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
41446544|NCT06561763|DRUG|Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine|Cisplatin 80 mg/m2， Intravenous drip administration, d1; Gemcitabine, 1000mg/m2,Intravenous ，D1,D8； Triprolizumab injection 240mg, intravenous ； Nivolumab 400mg, intravenous； Q3W 1 cycle, 3 cycles
41446545|NCT05235568|DEVICE|VALVOSFT intervention|Treatment of the calcific aorta valve by non-invasive ultrasound therapy
41122841|NCT01264289|DRUG|Finasteride|Finasteride Tablets 5 mg
41122842|NCT03042039|OTHER|New Care|New organisational care model delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform).
41274671|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
41274672|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
41122843|NCT03622749|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-Invasive neuromodulation
41122844|NCT00168753|DRUG|Alefacept|IM
41274673|NCT00129025|PROCEDURE|Hypofractionated radiotherapy|
41122845|NCT03352596|OTHER|low frutose diet|
41122846|NCT03206515|DEVICE|18F Peel-Way Sheath|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath
41446546|NCT06060145|OTHER|Plants placed in an office environment|The intervention group will be provided with an intervention consisting of 34-38 potted plants arranged in an office environment for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
41122847|NCT03206515|DEVICE|18F access sheath with a suction-evacuation function|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
41122848|NCT05357742|BEHAVIORAL|Individualized basic need navigation and lifestyle coaching and skills training|During each session participants will receive the manualized study intervention which includes 1) DKD education, 2) Individualized basic needs navigation, and 3) Lifestyle coaching and skills training. Participants will be provided a FORA 2-in-1 device with glucose test strips to allow testing at least once a day. The device automatically uploads blood pressure and glucose readings to a secure server in real time and the health educator will have access to this secure server. Readings will be used to guide lifestyle coaching and skills training.
41122849|NCT05357742|BEHAVIORAL|Enhanced usual care|During each session participants will receive DKD education only.
41122850|NCT03481816|BIOLOGICAL|ETBX-071; adenoviral PSA vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
41122851|NCT03481816|BIOLOGICAL|ETBX-061; adenoviral MUC1 vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
41122852|NCT03481816|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
41122853|NCT00003612|BIOLOGICAL|trastuzumab|
41122854|NCT00003612|DRUG|carboplatin|
41274674|NCT05916352|DIETARY_SUPPLEMENT|Caffeine Supplement|Caffeine tablet
41274675|NCT06112587|BEHAVIORAL|strength training|A targeted 8-week strength-training course was offered as an intervention in combination with ergonomics and posture corrections and recommendations
41274676|NCT02901171|BEHAVIORAL|ACT group treatment combined with smartphone application|The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
41446547|NCT06060145|OTHER|Devoid of any plant presence in an office environment|Participants assigned to the control group will be exposed to an office environment devoid of any plant presence for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
41122855|NCT00003612|DRUG|paclitaxel|
41122856|NCT02382744|DEVICE|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
41122857|NCT02382744|DEVICE|Ultrasound guidance + nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
41122858|NCT00544752|OTHER|16|indoor temperature of 16 degrees celcius
41122859|NCT00544752|OTHER|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
41122860|NCT00544752|OTHER|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
41122861|NCT05384470|DRUG|Marihuana|Two doses of marijuana given.
41122862|NCT05384470|DEVICE|BID2 Instrument - breathalyzer|The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.
41122863|NCT03450200|OTHER|exercises for diabetic peripheral neuropathy|Hands, fingers, and foot exercises for diabetic peripheral neuropathy to improve activities of daily living, and decreases the signs and symptoms of DPN
41122864|NCT03450200|OTHER|Health education for diabetic foot care|Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.
41274677|NCT02901171|BEHAVIORAL|ACT group treatment|
41274678|NCT02901171|BEHAVIORAL|Group based Behavioural Support Programme|The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
41274679|NCT00469079|DRUG|Nicotine gum and lozenge|Nicotine replacement
41274680|NCT00469079|OTHER|Taboka|smokeless tobacco product
41274681|NCT00469079|OTHER|Camel Snus|smokeless tobacco product
41446548|NCT02705573|DRUG|Mannitol|In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
40926751|NCT05256706|DIAGNOSTIC_TEST|SomaSignal Informed Medical Management SSCVD|For participants randomized to the Informed arm, the SSCVD test results will be provided to the participant's clinicians approximately 2-4 weeks after the baseline blood draw. Clinicians will discuss results with the participant and make adjustments to the care plan as needed based on the SSCVD test results within 50 days of receiving results. Clinicians may advise participants to (i) either change the doses of existing medications within existing guidelines, (ii) prescribe additional guideline-based medications, (iii) advise additional lifestyle interventions, or (iv) advise no change. This information will be documented in the case report forms. This test is neither intended to diagnose cardiovascular disease (CVD) nor replace the standard of care protocols for this disease. The physician should not rely solely on this information to make a decision on the best course of action for this patient.
41446549|NCT03424915|BEHAVIORAL|Harvard Health Professionals survey|Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.
40926752|NCT05256706|OTHER|Standard of Care|Clinicians will provide the standard of care based on routine test results and without the SSCVD results. The SSCVD and SomaSignal Metabolic Factor Panel results from participants from both the baseline and 6-month period will be provided to the study team at the 6-month study visit. The SomaSignal Metabolic Factor tests include evaluation of Liver Fat, Glucose Tolerance, Kidney Function, Alcohol Impact, Cardiorespiratory Fitness/oxygen consumption (VO2) max, Resting Energy Rate, Body Fat Percentage, Visceral Fat, and Lean Body Mass. Any recommendations made to the participant by the physicians, based on obtaining the aforementioned test results will be collected.
40926753|NCT02812888|DRUG|thionamide treatment for 3 months|Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
41446550|NCT03424915|OTHER|Blood draw|Participant will provide a blood sample
41446551|NCT03424915|OTHER|CPET Procedures|CPET with 12-lead ECG
41446552|NCT03424915|OTHER|stool sample|Research stool sample (within ±1 week of surgery), if possible
40926754|NCT01607827|PROCEDURE|Polyp removal upon insertion and withdrawal|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back."
41274682|NCT03469011|DRUG|Imatinib Oral Tablet|3+3 trial design. Cohorts of 3-6 patients with escalating imatinib doses. No intra-patient dose escalation allowed.
41274683|NCT02252861|OTHER|Percutaneous Left Atrial Appendage Closure in routine care|The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
41274684|NCT03737825|DEVICE|Computerized gaming rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
41274685|NCT03737825|DEVICE|Computerized gaming rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
41274686|NCT01935219|BEHAVIORAL|Goal Management Training|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
41446553|NCT03424915|PROCEDURE|Research Tissue sampling|Sample of the tumor and normal breast tissue may be taken from the tissue removed during breast cancer surgery if there is enough tissue left over for research testing.
41446554|NCT04007796|BEHAVIORAL|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
40754277|NCT03376009|DIAGNOSTIC_TEST|Arterial Spin Labelling Magnetic Resonance Imaging|"Magnetic resonance imaging using arterial spin labelling (ASL-MRI) This promising quantitative technique has the potential to identify dysregulated renal perfusion, stratify risk of AKI in pre-OLT patients, and to monitor alterations in renal haemodynamics in the post transplantation setting.~* We aim to recruit 5 participants with 'normal' renal function (eGFR≥60ml/min/1.73m2) and a further 5 participants with 'abnormal' renal function (eGFR\<60ml/min/1.73m2)~* ASL-MRI will be performed in this subgroup during the week of OLT assessment and then repeated at 6-weeks post transplantation in those participants who undergo OLT during the study period."
41274687|NCT01935219|BEHAVIORAL|Processing Speed Training|9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week
41274688|NCT01935219|BEHAVIORAL|Brain Health Workshop|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
41274689|NCT00596544|BEHAVIORAL|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
40758289|NCT02505074|PROCEDURE|Valve replacement with the Melody valve|This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.
40926755|NCT01607827|PROCEDURE|Polyp removal upon withdrawal only|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques."
40926756|NCT00594425|DRUG|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
41122865|NCT02263573|OTHER|PEP'C-R|"Preliminary session of calibration and tolerance: Test of Borg: determination of VT1 for 10 minutes, 3 min pedaling at 25 W and then 20 minutes pedaling on VT1 determined during the exercise test (ET) -10%.~Session 1: 30 min of pedaling at constant load VT1 determined during exercise testing (EE) - 10%.~Session 2 Session 17: increase in the burden of BASE (5 BASE \* 5 min: 25 min) by 10% and decrease in relation to the load of the PIC (5 PIC \* 1 min: 5 min) to get a cumulative charge of the same session. Changes in heart rate (HR) determine the evolution of sustained loads: a decrease of 10 bpm in heart rate leads to an increase by 10% in the intensity of the base (PIC load remains constant).~Session 18 = Session 1."
41122866|NCT02263573|OTHER|Control group usual activities|Participants in the control group will not follow the intervention PEP'C-R. They will continue their usual activities for 9.5 weeks and will be assessed before and after this period. After the study, they will be offered the benefit of the conventional program of the PEP'C.
41122867|NCT03277534|OTHER|Electrical stimulation|sensory electrical stimulation was applied prior to upper limb functional training
41122868|NCT03277534|OTHER|Sham electrical stimulation|electrodes were placed on the same location as the Electrical stimulation condition, but no electric current was applied
41122869|NCT03241017|DRUG|Durvalumab|Immunotherapy with Durvalumab after ASCT
41122870|NCT02598596|BIOLOGICAL|Pegloticase|Pegloticase, IV
41122871|NCT02598596|DRUG|Azathioprine|Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
41122872|NCT03649243|DRUG|Propolis spray|Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
41122873|NCT01673516|PROCEDURE|The SymplicityTM Renal Denervation System|For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
40926757|NCT00416897|DRUG|chemotherapy|
41446555|NCT04007796|BEHAVIORAL|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
41122874|NCT01673516|DEVICE|The HOTMAN® System|"Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co"
41122875|NCT06439732|DEVICE|Acumen IQ cuff|Use of Acumen IQ cuff for haemodynamic monitoring
41122876|NCT05848609|DIAGNOSTIC_TEST|Geriatric Assessment|Geriatric assessment to evaluate cognitive function, functional status and quality of life before and after surgery
41122877|NCT06113458|BEHAVIORAL|Standard and One-time Training|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
41274690|NCT00596544|BEHAVIORAL|questionnaires|Those women who have a FSFI score \> 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
41446556|NCT04794816|OTHER|Questionnaire Administration|Complete questionnaire
41446557|NCT06547177|OTHER|fruit juice|During labor, one group will follow the routine while the water group will only take water and fruit juice group will take water and fruit juice.
41446558|NCT05911633|DEVICE|BioPearl™|TACE
41274691|NCT06383494|DEVICE|LMA supreme group|Patient in this group received LMA supreme (one of laryngeal airway management device) for airway management during general anesthesia
41446559|NCT01836380|BEHAVIORAL|Exercise Training|
40926758|NCT00416897|DRUG|dexamethasone|
40926759|NCT00416897|PROCEDURE|plasmapheresis|
40926760|NCT01604278|DRUG|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
41274692|NCT06383494|DEVICE|I-gel group|Patient in this group received I-gel laryngeal (one of laryngeal airway management device) for airway management during general anesthesia
40926761|NCT01604278|DRUG|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
40926762|NCT00657410|DRUG|dexamethasone|
40926763|NCT00657410|DRUG|prednisone|
40926764|NCT00657410|PROCEDURE|quality-of-life assessment|
40926765|NCT02217527|DRUG|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
40758290|NCT05866445|DEVICE|Wearable BP device|Wearable study BP device to be worn for 8 hours within study participation.
40926766|NCT02217527|DRUG|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
40926767|NCT03469778|DEVICE|Robotic Therapy|Robotic Therapy
40926768|NCT04120103|BEHAVIORAL|Doll therapy|The patient will then be given the doll to be used in the research by the caregiver and the researcher. Intervention group (accepting the baby) will be evaluated in terms of interaction with the baby, communication with employees and other patients and participation in daily life activities for 60 days. In addition, the agitation symptoms of the patients during the 60 days they spend with the baby will be evaluated by CMAI and cognitive level by MMSE.
40926769|NCT04120103|OTHER|Routine nursing care|The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
40926770|NCT00167869|BEHAVIORAL|dairy peptides|
40926771|NCT02452931|DRUG|Leuprolide Acetate 45 mg|Subcutaneous injection
40926772|NCT03811275|BEHAVIORAL|Virtual Reality (A) then Task (B)|Participants will use their intact arm to perform virtual reality tasks while perceiving a reflected virtual image of their paretic arm.
40926773|NCT03811275|BEHAVIORAL|Task (B) then Virtual Reality (A)|Participants will use their paretic arm to perform real tasks in a structured environment, with a practice and feedback schedule organized by a physical or occupational therapist, or graduate student.
40926774|NCT05792657|BEHAVIORAL|High dosage in-person exercise coaching|High dosage (one hour each week) of in-person exercise coaching by an exercise professional.
40926775|NCT05792657|BEHAVIORAL|Medium dosage in-person exercise coaching.|Medium dosage (one hour every other week) of in-person exercise coaching by an exercise professional.
40926776|NCT05792657|BEHAVIORAL|Low dosage in-person exercise coaching|Low dosage (one hour every month) of in-person exercise coaching by an exercise professional
41122878|NCT06113458|BEHAVIORAL|Standard and Practice Facilitation|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
41122879|NCT06113458|BEHAVIORAL|High-intensity and One-time Training|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
41122880|NCT06113458|BEHAVIORAL|High-intensity and Practice Facilitation|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
41122881|NCT03643900|DEVICE|pancreatic duct stenting|Place the pancreatic duct stent
41122882|NCT03643900|DRUG|rectal indomethacin|rectal indomethacin 100mg at preoperative 30min
41122883|NCT00698919|OTHER|Observational study|"This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision."
40926777|NCT01650129|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
40926778|NCT01650129|DRUG|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
40926779|NCT00164970|DIETARY_SUPPLEMENT|Vitamin B12|
40926780|NCT00164970|DIETARY_SUPPLEMENT|folate|
41446560|NCT04492930|BEHAVIORAL|14:10 Regimen|14 hours of fasting, followed by a 10-h diet regimen that includes a fasting snack at 12 hours from the start of the fasting period
41122884|NCT03578536|DEVICE|Recovery Rapids|This project utilizes a new gaming system technology called Recovery Rapids. The game is custom-made by Games That Move You, LLC and runs on an XBOX platform with motion input via a Kinect system.
40758291|NCT05866445|DEVICE|24-hour ambulatory blood pressure monitor|24-hour ambulatory blood pressure monitor to be worn for 24-hours during study participation.
41122885|NCT00301652|DRUG|mycophenolate mofetil|MMF,1.0g/d
41446561|NCT04492930|BEHAVIORAL|12:12 Regimen|12 hours of fasting, followed by a 12-h diet regimen
40758292|NCT01744626|DRUG|CC-292|Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
40926781|NCT00654147|DRUG|Raltegravir & Lopinavir/ritonavir|Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor
40926782|NCT00654147|DRUG|Raltegravir and emtricitabine/tenofovir|Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors
40926783|NCT06072898|DRUG|Psilocybin|Psilocybin (\[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate), 25mg PO.
40926784|NCT06072898|OTHER|Microcrystalline cellulose|MCC (excipient), 25mg PO.
40926785|NCT06072898|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy in the form of reassurance, integration, and de-escalatory techniques (if needed). Facilitating rapport and a positive environment.
40926786|NCT01538784|DRUG|YF476|"Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:~Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth~Groups A \& B were dosed alternately, at weekly intervals"
40926787|NCT01503112|OTHER|No intervention, observational study|
40926788|NCT05618561|DIAGNOSTIC_TEST|EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test|Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.
40926789|NCT03387488|DEVICE|StingrayTM, Medtronic®|Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic®
40926790|NCT05191056|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day for 8 weeks
40926791|NCT05191056|DIETARY_SUPPLEMENT|MelaGene drink|consume 1 bottle per day for 8 weeks
40926792|NCT02889744|DEVICE|Arctic Sun|Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
40926793|NCT00769327|DRUG|imatinib mesylate|
40926794|NCT00769327|DRUG|nilotinib|
40926795|NCT00769327|GENETIC|cytogenetic analysis|
40926796|NCT00769327|GENETIC|fluorescence in situ hybridization|
41446562|NCT02393144|DEVICE|Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System|Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
40926797|NCT00769327|GENETIC|microarray analysis|
40926798|NCT00769327|GENETIC|mutation analysis|
40926799|NCT00769327|GENETIC|polymerase chain reaction|
40926800|NCT00769327|GENETIC|polymorphism analysis|
40926801|NCT00769327|OTHER|laboratory biomarker analysis|
40926802|NCT00392379|DRUG|Nicotine Lozenges|Nicotine lozenges, 4 mg
40926803|NCT00392379|DRUG|Placebo lozenge|Placebo lozenge
41122886|NCT03556085|DEVICE|Venous sinus stenting (Serenity River)|Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
41122887|NCT03593876|BEHAVIORAL|Strategy Training|This study will use an adapted form of strategy training for people with communication impairments.
41122888|NCT00033098|DRUG|Metyrapone|
41122889|NCT03192215|DRUG|Apixaban|5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
41122890|NCT03192215|DRUG|Aspirin|Aspirin 81 mg by mouth once daily.
41122891|NCT01586936|DRUG|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
41122892|NCT01392638|OTHER|sugar pill|Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
41122893|NCT01392638|DRUG|sildenafil|Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
41122894|NCT00110552|DRUG|Salvia officinalis (sage)|oral dosage
41122895|NCT06224946|DIAGNOSTIC_TEST|soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio|the soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio for pre-eclampsia diagnostic
41446563|NCT02393144|DEVICE|Cardiotocography, Bionet FC1400 Fetal Monitor|Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
41446564|NCT02393144|OTHER|Amniotomy|Artificial rupture of membranes to assess meconium staining and induce labor speed.
40758293|NCT01744626|DRUG|Rituximab|Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
40926804|NCT02836509|DRUG|Paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
40926805|NCT02836509|DRUG|Ibuprofen|800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
41122896|NCT03826875|DRUG|Fluoxetine|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life
40926806|NCT05309876|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
41122897|NCT03826875|DRUG|Placebo|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life
41122898|NCT00257998|PROCEDURE|Mobilization|manualtherapy techniques
41122899|NCT02713906|DEVICE|X-Ray Knee Guide group|
41122900|NCT00440011|DRUG|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
41122901|NCT00440011|DRUG|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
41122902|NCT06237816|OTHER|Patient Education Intervention|Multimedia Educational Videos
41122903|NCT06237816|OTHER|Provider Education Intervention|Provider workshops via zoom
41446565|NCT02393144|DRUG|Analgesics, Opioid, Meperidine|Administration of meperidine for labor analgesia.
40926807|NCT01659879|BEHAVIORAL|Multimedia information|
40926808|NCT01659879|BEHAVIORAL|verbal information|
40926809|NCT03295565|DRUG|Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
40926810|NCT03295565|DRUG|Abiraterone|Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day
40926811|NCT03295565|DRUG|Enzalutamide|Enzalutamide 160mg oral taken daily
40926812|NCT05026190|DIAGNOSTIC_TEST|transrectal ultrasound|we perform trus to identify the cause of azospermia and its type either obstructive or not
40926813|NCT02325973|DEVICE|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
40926814|NCT00655915|OTHER|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
40926815|NCT05830110|DEVICE|Active Vibrotactile Coordinated Reset|Gloves providing vibrotactile coordinated reset stimulation
40926816|NCT05830110|DEVICE|Sham vibrotactile coordinated reset|Gloves providing sham vibrotactile coordinated reset stimulation
40926817|NCT03641300|DEVICE|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
41122904|NCT03976570|BEHAVIORAL|Occupational Therapy|Occupational therapy to children with subthreshold attention deficit hyperactivity disorder
41122905|NCT03279224|BIOLOGICAL|Allogenic FMT|"Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
41122906|NCT03279224|BIOLOGICAL|Autologous FMT|"1. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
41122907|NCT02823938|OTHER|existing database on data collection.|This is an observational study on an existing database.
41122908|NCT04580316|BEHAVIORAL|Parental active presence|The parents were allowed to stand close to their children, do handholding, eye contacting and help in explaining the dentist's instructions.
41122909|NCT04580316|BEHAVIORAL|Parent passive presence|Parents were instructed to sit silently in the dental clinic behind the patient with no eye contact, and without a spoken word only to reassure their children
41122910|NCT00977158|PROCEDURE|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
41122911|NCT02374307|OTHER|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
41122912|NCT00105807|BEHAVIORAL|participation in low intensity exercise|
41122913|NCT00105807|BEHAVIORAL|participation in art and music activities|
41122914|NCT00598377|DRUG|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
41122915|NCT01244672|PROCEDURE|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
41122916|NCT01244672|PROCEDURE|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
41122917|NCT05246124|OTHER|Zumba dance exercise|The intervention was Zumba dance done 3 times a week during the 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
41122918|NCT01037634|DRUG|Oseltamivir|3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
41122919|NCT06006949|DRUG|Roxadustat|Roxadustat (150 mgqod)
41122920|NCT06006949|DRUG|Luspatercept|Luspatercept (1.0 mg/kg, subcutaneously injection every 3 weeks, adjusted according to blood pattern, up to 1.75mg/kg)
41122921|NCT00911521|DRUG|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
41122922|NCT02303327|RADIATION|EBRT + HDR brachytherapy boost|Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
41122923|NCT02303327|RADIATION|Hypofractionated Dose Escalation Radiotherapy|Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
41122924|NCT02303327|DRUG|Androgen deprivation therapy|28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
41122925|NCT05517616|DRUG|[14C ]APG-2575|orally, single dose of 400 mg / 200 μCi \[14C\] APG-2575
41122926|NCT02990117|OTHER|No Intervention|No Intervention
41122927|NCT01932203|DRUG|aspirin|100mg once a day
41122928|NCT01932203|DRUG|cilostazol|200mg once a day
41122929|NCT02262468|RADIATION|x ray|
41122930|NCT05749523|BEHAVIORAL|Exercise|Exercise vs non-exercise
41122931|NCT00991497|DEVICE|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
41122932|NCT05815030|OTHER|video informational/educational intervention|Videos relating to PrEP use, its benefits, side effects, and other information. The educational/round-table video will highlight individuals from diverse backgrounds and identities who will share their experiences using PrEP, including perceived benefits and effectiveness, experienced barriers to PrEP uptake, their reasons for using PrEP, and their own self-efficacy. The control group's (generic / standard video) materials will be focused on PrEP uptake without a kink identity perspective. The treatment group's materials, however, will include videos that feature kink-identified individuals who discuss PrEP uptake through a kink perspective.
41122933|NCT06083766|BEHAVIORAL|hormone therapy|Determine how gender affirming hormone therapy affects muscle physiology
41122934|NCT05208125|BIOLOGICAL|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).|Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg), and 1 x MVA.HTI (2x108pfu)
41122935|NCT05208125|OTHER|Normal saline solution|Intramuscular administration of normal saline solution
41122936|NCT05830942|BEHAVIORAL|Walking Exercise|aerobic walking exercise using complex (cognitively engaging) walking tasks
41446566|NCT02393144|DRUG|Labor augmentation, Oxytocin|Oxytocin infusion for augmentation of labor.
41274693|NCT06383494|DEVICE|GMA-Tulip|Patient in this group received GMA-Tulip (one of laryngeal airway management device) for airway management during general anesthesia
41274694|NCT04222829|PROCEDURE|Megadose Shinbaro Pharmacopuncture|"Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.~Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases."
41274695|NCT05372809|BIOLOGICAL|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
41274696|NCT05372809|OTHER|Control|"Standard care is defined in this protocol to include the following:~* Debridement~* Collagen-alginate primary wound dressing~* Local offloading with felt pad for wounds on weight bearing surfaces~* Foam~* Multi-layer compression dressing~* Off-loading device such as a full-length boot or total contact cast (if full-length boot cannot accommodate the patient) or surgical shoe for ulcers in non-weight bearing locations"
41274697|NCT04452643|BIOLOGICAL|BACMUNE (MV130)|BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
41274698|NCT04452643|OTHER|Placebo|Placebo is a solution on sodium chloride at 0.9%
41274699|NCT04080011|DEVICE|NP-PWD|Application of NP-PWD device.
41274700|NCT04965519|DRUG|RC48-ADC|2.0mg/kg IV every 2 weeks
41274701|NCT04052737|DRUG|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
41274702|NCT04052737|DRUG|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
40926818|NCT03641300|DEVICE|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
41122937|NCT05830942|DEVICE|Prefrontal Active tDCS|20 minutes of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
41122938|NCT05830942|DEVICE|Prefrontal Sham tDCS|30 seconds of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
41122939|NCT01052259|DRUG|Deoxyspergualin|100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
41122940|NCT00186849|DRUG|Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|See Detailed Description section for details of treatment interventions.
41122941|NCT00186849|PROCEDURE|Peripheral Blood Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
41122942|NCT05537675|OTHER|To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax|Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
41274703|NCT05356793|DRUG|SCH-1|Novel anti-infective eyedrop
41274704|NCT05356793|DRUG|Placebo|SCH-1 vehicle minus active components eyedrop
41274705|NCT05240261|DRUG|Quetiapine|Quetiapine 25 mg / day
41274706|NCT01725139|DRUG|GSK2126458|GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
41274707|NCT01725139|DRUG|Placebo|Matching placebo will be available
41274708|NCT00459030|OTHER|educational intervention via internet|additional cancer screening information via password protected internet site
41274709|NCT00459030|OTHER|educational intervention mailed|
41274710|NCT00459030|OTHER|No additional educational intervention|
40758294|NCT04572269|OTHER|No Intervention|This protocol does not involve an intervention of drug/device, diet, exercise or PAP compliance.
41122943|NCT02239913|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.
41122944|NCT02239913|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
41274711|NCT00416533|DRUG|docetaxel|
41274712|NCT00416533|DRUG|doxorubicin hydrochloride|
40926819|NCT02335671|PROCEDURE|Intra-operative Magnetic Resonance Imaging (MRI)|
41274713|NCT00416533|DRUG|prednisone|
41274714|NCT00849589|BEHAVIORAL|Computerized screening and brief physician advice|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
41446567|NCT02393144|DRUG|Labor induction, Oxytocin|Oxytocin infusion for induction of labor.
41446568|NCT02393144|DRUG|Cervical ripening, labor induction, Dinoprostone|Administration of dinoprostone pessary for cervical ripening and labor induction.
41446569|NCT00840398|DRUG|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
40926820|NCT02335671|OTHER|Mass Spectrometer Analysis of Tissue Sample|Analysis of Tissue Sample
40926821|NCT03879343|OTHER|Known diagnosis of attention deficit / hyperactivity disorder|Clinical group includes subjects with clinical diagnosis of attention deficit / hyperactivity disorder
40926822|NCT02066987|BEHAVIORAL|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
41122945|NCT02239913|DRUG|Phentermine|The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.
41122946|NCT02239913|DRUG|Topiramate|The pharmacodynamic effects of chronic topiramate will be determined.
41122947|NCT02479217|DRUG|Docetaxel|
41122948|NCT02479217|DRUG|Xeloda|
41122949|NCT02830906|DRUG|ramosetron|intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
41122950|NCT02830906|DRUG|Ondansetron|intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
41122951|NCT06060119|DEVICE|microneedling|The operative sites will be anaesthetized with 2% lignocaine hydrochloride with adrenaline(1:80,000).Electric microneedling pen device model THAPPINKTM is used. Microneedling is carried out on the isolated site involving one tooth mesially and distally and 1.5mm apical to marginal gingiva each for 30-40 second intermittently. When pin point bleeding observed on the area of gingiva it is irrigated with sterile saline solution. Patient will be instructed to refrain from consuming hot beverage and brushing in that area for one day to avoid mechanical trauma. A total of 4 session of micro needling procedure will be carried out in one subject at 10 days intervals upto 40days
41122952|NCT04949503|DRUG|nimotuzumab|Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).
41122953|NCT03658616|DRUG|WO3970|Application of cream to each axilla
41122954|NCT03658616|DRUG|Placebo (WO3988)|Application of cream to each axilla
41122955|NCT02542683|OTHER|structured physical activity program|a structured modest physical activity program
41122956|NCT04592393|DIAGNOSTIC_TEST|Abbreviated PB MRI|Annual non-contrast PB MRI.
41122957|NCT04592393|GENETIC|Gene mutation test|K-ras and GNAS mutation test. Being performed once as a baseline test at the enrollment.
41122958|NCT04592393|DIAGNOSTIC_TEST|Conventional follow-up|Any of followings: scheduled CECT, MRI, USG, EUS, tumor marker (CA 19-9) during the study period.
41122959|NCT01643499|DRUG|oxaliplatin|Given IV
41122960|NCT01643499|DRUG|irinotecan hydrochloride|Given IV
41122961|NCT01643499|DRUG|leucovorin calcium|Given IV
41122962|NCT01643499|DRUG|fluorouracil|Given IV
41122963|NCT01643499|OTHER|laboratory biomarker analysis|Correlative studies
41274715|NCT00849589|BEHAVIORAL|Computerized SBA with technological extenders|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
41122964|NCT04750070|DRUG|Dopamine|Children will receive dopamine, 8 microgram/kg.min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
41122965|NCT04750070|DRUG|adrenaline|Children will receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
41122966|NCT04750070|DRUG|Blood Transfusion|Children will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
41122967|NCT06010862|BIOLOGICAL|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
41122968|NCT06010862|BIOLOGICAL|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
41122969|NCT06181695|DRUG|Sufentanil|Administration of intranasal sufentanil
41122970|NCT06130228|DIETARY_SUPPLEMENT|Multi-ingredient supplement (PDT-MIS)|Supplementation with active PDT-MIS daily
41122971|NCT06130228|DIETARY_SUPPLEMENT|Placebo (PLA)|Supplementation with inactive placebo
41122972|NCT01036724|DEVICE|Cardiac Mapping|Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX\[TM\]) and measuring the amount of radiation exposure duration for each.
41122973|NCT03786042|BEHAVIORAL|E-cigarette ad exposure|Participants view a series of e-cigarette TV commercials
41122974|NCT03786042|OTHER|non e-cigarette TV commercials|Participants view a series of non e-cigarette TV commercials
41122975|NCT00995904|DRUG|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
41122976|NCT00995904|DRUG|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
41122977|NCT00995904|DRUG|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
41122978|NCT00873405|PROCEDURE|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
41446570|NCT00840398|DRUG|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
41446571|NCT00000915|BEHAVIORAL|Vaccine preparedness|
41446572|NCT04006457|DRUG|PF-06651600|50 mg oral tablets/capsules
40926823|NCT02066987|BEHAVIORAL|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
40926824|NCT02066987|BEHAVIORAL|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
40926825|NCT04585009|DRUG|GSK3923868|GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
40926826|NCT04585009|DRUG|Matching placebo|Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
40926827|NCT04585009|DEVICE|Monodose RS01|Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
40926828|NCT03758755|DEVICE|Blood Flow Restriction Therapy|A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once the exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.
40926829|NCT03758755|OTHER|ACL Reconstruction rehabilitation|post-operative rehabilitation according to current standards of care
40926830|NCT00403169|DRUG|lenalidomide|drug
40926831|NCT00081510|DRUG|Lonafarnib|
40926832|NCT00081510|DRUG|Placebo|
40926833|NCT00081510|DRUG|anastrozole|
40926834|NCT02921061|DRUG|Cladribine|Given IV
40926835|NCT02921061|DRUG|Cytarabine|Given IV
40926836|NCT02921061|DRUG|Decitabine|Given IV
40926837|NCT02921061|BIOLOGICAL|Filgrastim|Given SC
41122979|NCT00873405|PROCEDURE|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
40926838|NCT02921061|OTHER|Laboratory Biomarker Analysis|Correlative studies
40926839|NCT02921061|DRUG|Mitoxantrone Hydrochloride|Given IV
40926840|NCT05205473|PROCEDURE|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves 12.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (12.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
40926841|NCT05205473|PROCEDURE|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator 12.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (12.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
41122980|NCT03311893|PROCEDURE|natural orifice surgery|evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
41122981|NCT04748939|BIOLOGICAL|recombinant subunit herpes zoster vaccine|vaccine administration
40926842|NCT04839562|DRUG|Solriamfetol 75 MG|Daily oral consumption
40926843|NCT04839562|DRUG|Solriamfetol 150 MG|Daily oral consumption
40926844|NCT04839562|OTHER|Placebo|Placebo
40926845|NCT05349201|OTHER|KYMRIAH|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\]) or Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) refractory, in relapse post transplant or in second or later relapse
40926846|NCT05349201|OTHER|YESCARTA|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])
41122982|NCT01077986|DRUG|Capecitabine|Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
41122983|NCT01077986|DRUG|Cetuximab|Cetuximab will be administered weekly, starting at day 8.
41122984|NCT01077986|DRUG|Everolimus|Everolimus will be administered daily, starting on day 1.
41122985|NCT06116708|DEVICE|Kalogon AF Prototype Smart Cushion|The Kalogon cushion is a dynamic smart cushion that utilizes a combination of foam and 5 adjustable air cells to intelligently redistribute weight and increase comfort for users. The air cells are used to modulate interface pressures and adjust where support or pressure reductions are provided based on input from the controller's pressure sensing system.
41122986|NCT06116708|DEVICE|Standard Seat Cushion from Air Force|This is the standard seat cushion that was provided by the United States Air Force to use for this study. It is a high-density, molded polyurethane foam.
41122987|NCT00753480|DRUG|D4064A|
40926847|NCT03737227|RADIATION|Cinematographic recording|Cinematographic recording during flexion and extension of the lumbar spine.
40926848|NCT04963842|BEHAVIORAL|Use of bio-plastic food packaging material and avoidance of plastic food packaging material|The bio-plastic food packaging material will be used by the study participants for 5 days and no plastic packaged food will be consumed.
40926849|NCT06492655|DRUG|CKD-383(Fed)|After maintaining NPO for at least 10 hours before a high-fat meal, take a high-fat meal within 20 minutes on each medication day, and take CKD-383 two tablets orally with 150 mL of water at room temperature.
40926850|NCT06492655|DRUG|CKD-383(Fasted)|After maintaining NPO for at least 10 hours before dosing, and take CKD-383 two tablets orally with 150 mL of room temperature water with 30g of sugar added on each dosing day.
40926851|NCT02524600|DEVICE|myocardial IQ-SPECT imaging applied to scintigraphic imaging|
40926852|NCT02524600|DEVICE|scintigraphic imaging|
41122988|NCT03640195|OTHER|Device: Transcutaneous acupoint electrical stimulation and seeds for auricular acupressure|"Experimental group received Acupoint stimulation, Transcutaneous acupoint electrical stimulation20 minutes/weeks, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3). each point is 1min, 5days/week, 3 times/day."
41122989|NCT01255501|DRUG|NI-0701|
41122990|NCT01255501|DRUG|Placebo|
41122991|NCT05664204|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation|Strategy would reduce the need for invasive mechanical ventilation in the first 28 days without increasing adverse events
41274716|NCT00635622|DRUG|LACTIN-V|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10\^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
40926853|NCT00255424|DRUG|ferumoxytol or oral iron|
40926854|NCT00775203|DRUG|Trazodone Hydrochloride (HCl) Extended-Release Tablets|
40926855|NCT00775203|DRUG|Placebo|
40926856|NCT00701623|DRUG|heparin|patients will receive the application of one of two types of heparin directly on the injured area
40926857|NCT00701623|DRUG|heparin|patients will receive the application of one of two types of heparin directly on the injured area
41122992|NCT03748186|DRUG|STRO-002|intravenous antibody drug conjugate
41122993|NCT00510302|BEHAVIORAL|Questionnaire|Questionnaire regarding melanoma risk-reduction.
40926858|NCT00701623|DRUG|folder water|patients will receive the application of folder water directly on the injured area
40926859|NCT04278274|PROCEDURE|artificial intelligence prediction system|The tumor ROI in the post- neoadjuvant treatment MRI images will be manually delineated, and further subjected to the AI prediction system arm to verify the predictive accuracy of this AI prediction system in identifying the pCR individuals from non-pCR patients with LARC.
41122994|NCT00510302|BEHAVIORAL|Interview|Interview via telephone about topics related to melanoma risk-reduction.
41122995|NCT03143842|DEVICE|Vagus Nerve Stimulation|Delivering electrical pulses to the Vagus Nerve
41274717|NCT00635622|DRUG|Placebo control substance|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
41274718|NCT02331576|DRUG|rocaine|
40758295|NCT06018376|DRUG|Systemic oncological treatment|Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
40758296|NCT02958072|OTHER|LeucoPatch|LeucoPatch is an fully autologous growth factor-containing dressing
40926860|NCT04278274|PROCEDURE|the radiologists|The enrolled patients will be assigned to the trained experienced radiologists to evaluate their predictive accuracy in identifying the pCR individuals from non-pCR patients
40926861|NCT04138966|DEVICE|Nol-Index|Multiparametric monitor that studies that establishes an index as a surrogate to nociception
40926862|NCT04138966|DEVICE|Skin Conductance|Measures skin conductance as a surrogate to nociception
40926863|NCT00368290|DRUG|Modafinil|300mg a day for 8 weeks
40926864|NCT00368290|DRUG|placebo|placebo pills for 8 weeks
41122996|NCT00386958|DRUG|Povidone-Iodine|
41122997|NCT02670109|DRUG|Carmustine|300mg/m2, IV, in 3 hours, during day -4
41122998|NCT02670109|DRUG|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
41122999|NCT02670109|DRUG|Carboplatin|1400/m2, IV, in 1 hour, during day -3
41123000|NCT02670109|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
41123001|NCT02670109|DRUG|Busulfan|16mg/kg, Oral, during day -4
41123002|NCT06061744|OTHER|Minimally invasive surgery|laparoscopic or robotic surgical approach for the treatment of gallbladder cancer
41123003|NCT00867867|DRUG|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
41123004|NCT00867867|DRUG|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
41123005|NCT00867867|DRUG|Placebo|9.3 mg once per day, 6 days per week, for 9 months
41123006|NCT03769870|DRUG|Teneligliptin 20mg/day|cross-over
41123007|NCT03769870|DRUG|Atorvastatin 40mg/Day|cross-over
41123008|NCT03769870|DRUG|Teneligliptin 20mg/day + Atorvastatin 40mg/day|cross-over
41123009|NCT05604391|PROCEDURE|Free gingival graft placed apically|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing it in the apical region of the gingival recession according to the randomly selected positioning technique.
41274719|NCT02331576|DRUG|Fentanyl|
41274720|NCT03101072|OTHER|"Fixed long antibiotic course of 14 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
41274721|NCT03101072|OTHER|"Fixed short antibiotic course of 7 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
41274722|NCT03101072|OTHER|"Individualized duration of antibiotic therapy"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
41274723|NCT00940706|DEVICE|TreadMill|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session."
41274724|NCT00940706|OTHER|Physical activity in groups|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time."
41274725|NCT00940706|BEHAVIORAL|Monitoring physical activity|Activity monitoring with accelerometers
41274726|NCT04515355|BEHAVIORAL|Ready for MS|Receive 'ready for MS' programme in addition to standard care.
41123010|NCT05604391|PROCEDURE|Free gingival graft placed coronally|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing the coronal region of the gingival recession according to the randomly selected positioning technique.
41123011|NCT00780234|PROCEDURE|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
41123012|NCT00780234|PROCEDURE|quantitative high resolution CT scan|High resolution CT scan of the chest
41123013|NCT00780234|DRUG|PIOGLITAZONE VS. PLACEBO 30 mg|"Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare."
41123014|NCT03145155|BEHAVIORAL|Integrating services for noncommunicable diseases in continuum of care for mothers and children|The intervention package will comprise of two components, (1) utilization of CoC card and (2) health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will be distributed to mothers by midwives at the time of receiving ANC. The CoC card includes CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given by Public Health Supervisors 2 at the health facilities. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
41274727|NCT04294888|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
41274728|NCT05068856|DRUG|HRS2543|"Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set.~Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC."
41274729|NCT05012748|OTHER|Ketogenic diet|The ketogenic diet will consist of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant. The diet does not dictate time of consumptions. The food regime will be strictly followed every day for 3 weeks, where the investigator will contact the participants every day to secure adherence.
41274730|NCT04920409|OTHER|FAWGT diet|Composed of 15% protein, 55% CH and 30% fat of which \< 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.
40758297|NCT00951873|DRUG|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
40926865|NCT00368290|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
40926866|NCT04563832|OTHER|Standardized respiratory management program|Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years
40926867|NCT04563832|OTHER|CoughAssist|self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)
41274731|NCT04920409|OTHER|Usual diet (UD)|Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content
41274732|NCT02452333|PROCEDURE|Oncoplastic Approach Excisional Breast Biopsy|Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.
40926868|NCT05116527|DRUG|Marijuana, Hash, THC, or Grass|Marijuana flower with a high THC content
40926869|NCT05116527|DRUG|Placebo|Placebo THC - marijuana flower with no THC content
41123015|NCT03145155|BEHAVIORAL|Ordinary health education for pregnant women|The ordinary health education intervention will cover schedule for ANC, delivery and PNC; danger signs; birth preparedness and nutrition. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
41123016|NCT04900766|DRUG|Mitoxantrone Hydrochloride Liposome Injection|20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
41123017|NCT01185561|BEHAVIORAL|Psychoeducational intervention|The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
41123018|NCT01429350|DRUG|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
41123019|NCT01429350|DEVICE|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
41123020|NCT06324981|BEHAVIORAL|Generic text messages|The same unidirectional text message will be sent each week for 9 weeks.
41123021|NCT06324981|BEHAVIORAL|Interactive AI chatbot text messaging|Each week for 9 weeks, patients will be sent four messages that are specific to the LE8 topic for that week and with each message, they will be invited to engage with the chatbot to ask more questions about that topic. The first message of the week will be informational about the topic consistent with how the AHA provides information: 1) to understand readings and levels, 2) to encourage people to track levels, and 3) to offer specific skills building strategies. The fourth message will ask them to report out on short term (i.e., things they can do that week) plans for self-management for that topic and again invite their engagement with the chatbot to reinforce support for their plans.
41123022|NCT06324981|BEHAVIORAL|Proactive pharmacist support|Pharmacists that will proactively facilitate effective engagement with patients.
41123023|NCT04410367|DRUG|18F fluciclovine|18F fluciclovine injection, 185 MegaBecquerel (MBq) (5 Millicurie (mCi)) ± 20%, delivered as an intravenous bolus
41123024|NCT02330458|PROCEDURE|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall \>3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
41123025|NCT06133049|DRUG|Ozanimod|Women with MS who were exposed to ozanimod during pregnancy
41123026|NCT06133049|DRUG|Select DMTs other than ozanimod|Women with MS exposed to select DMTs other than ozanimod during pregnancy
41123027|NCT06133049|DRUG|No DMTs|Women with MS not exposed to any DMTs during pregnancy
41123028|NCT05000710|DRUG|Durvalumab|Durvalumab administered IV over 60 minutes at a dose of 1500 mg every 4 weeks
41123029|NCT05000710|DRUG|Tremelimumab|Tremelimumab administered IV over 60 minutes at a dose of 300 mg , twice: at C1D1 and C4D1
41123030|NCT05000710|RADIATION|Low dose irradiation|21 days after the first immunotherapy treatment 11 fractions of 3 Gy will be administrated to metastatic or primary lesion/s over 2 weeks and one day
41123031|NCT00840177|DRUG|cytarabine|1.5 g/m2/day given by continuous IV on days 4-7
41123032|NCT00840177|DRUG|idarubicin|12 mg/m2/day given intravenously over 10-15 minutes on days 4-6
41123033|NCT00840177|DRUG|pravastatin sodium|1,280 mg/day given orally on days 1-8
41123034|NCT05831644|DRUG|C21|C21 is an angiotensin II type 2 receptor agonist (ATRAG)
41123035|NCT02034903|OTHER|Feedings warmed with commercial warmer|
41123036|NCT05952895|PROCEDURE|Conventional quadrant-wise scaling and root planing (SRP)|SRP was conducted at baseline, after saliva collection and periodontal assessment, starting with the upper right quadrant and continuing clockwise over four visits at weekly intervals. SRP was performed under local anesthesia by the same periodontist (B.A.) by use of ultrasonic instruments (Mini Piezon, EMS, Nyon, CH) and manual periodontal curettes (Gracey curets, scaler Hu-Friedy, Chicago, IL). All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Self-performed plaque control measures consisted of toothbrushing using the modified Bass technique with a medium toothbrush and a regular toothpaste with fluoride twice a day and interdental cleaning using dental floss and/or interdental brushes once a day.
41123037|NCT05927896|DIAGNOSTIC_TEST|6-item Carpal Tunnel Syndrome Symptoms Scale|6-item Carpal Tunnel Syndrome Symptoms Scale is a self-reported 6 item questionnaire.
40926870|NCT05677672|BIOLOGICAL|Human TH-SC01 Cell Injection|Single injection of 0.6×10\^7,1.2×10\^8, 1.8×10\^8 cells/kg
40926871|NCT05677672|OTHER|Saline solution|saline solution will be given at the same quantity and following the same schedule
41274733|NCT02452333|PROCEDURE|Conventional Excisional Breast Biopsy|Conventional Excisional Breast Biopsy
41274734|NCT02452333|OTHER|Tezel Method of Breast Volume Measurement|Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle
41446573|NCT04006457|BIOLOGICAL|Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
41123038|NCT00978042|DEVICE|Juvéderm® VOLUMA XC|Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
41274735|NCT02452333|OTHER|Cosmetic Assessment|Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
41274736|NCT04733820|DRUG|Adjuvant chemotherapy|Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
41274737|NCT01530243|DRUG|Placebo|same as tolterodine and terazosin dose
41274738|NCT01530243|DRUG|Terazosine|2 mg BID
41274739|NCT01530243|DRUG|Tolterodine|2 mg daily
41274740|NCT01530243|DRUG|Tolterodine + Terazosin|2mg daily and 2mg BID
41274741|NCT00477087|DRUG|Mitoxantrone|Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.
41274742|NCT00477087|DRUG|GM-CSF|GM-CSF is a biologic response modifier, classified as a colony stimulating factor.
41274743|NCT05777928|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy involves vertical resection of a major part of the stomach, and a tubular remnant is retained along the lesser curvature.
41274744|NCT05777928|PROCEDURE|OverStitch™ Endoscopic Suturing System|Overstitch endoscopic procedure makes a review of gastro-jejunal anastomosis reducing surgical complications
41274745|NCT04737044|OTHER|Study 1: MRBS|MRBS as added sugar based on their habitual diet
41274746|NCT04737044|OTHER|Study 2: White sugar & education module|White sugar for daily usage (\<10% daily energy intake)
41274747|NCT04737044|OTHER|Study 2: MRBS & education module|MRBS for daily usage (\<10% daily energy intake)
41274748|NCT00737529|DRUG|lenalidomide|25mg oral capsules continuous days 1-21 each of a 28 day cycle
41274749|NCT03375385|DRUG|dexmedetomidine/ propofol|The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).
41446574|NCT04006457|BIOLOGICAL|Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
41123039|NCT01184326|DRUG|pazopanib|
41123040|NCT01184326|DRUG|everolimus|
41123041|NCT01556724|DRUG|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
41123042|NCT04692909|DEVICE|dTMS with mPFC stimulation|dTMS with Brainsway's H7 device, stimulating the mPFC.
41123043|NCT03595969|DIAGNOSTIC_TEST|Relative copy number of mitochondrial DNA|Mitochondria are responsible for multiple cellular functions including regulation of energy production, modulation of oxidation-reduction status, generation of reactive oxygen species and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome comprised of independently replicating double stranded DNA (mtDNA).
41123044|NCT00000834|DRUG|Lamivudine|
41123045|NCT00000834|DRUG|Methotrexate|
41123046|NCT00000834|DRUG|Zidovudine|
41123047|NCT02991534|BEHAVIORAL|CV Toolkit Components|"* Patient completes a CV self screener.~* Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~* Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program"
41123048|NCT00078624|OTHER|Traditional exercise therapy for knee osteoarthritis|Exercises include stretching, strengthening, and aerobic exercise
41123049|NCT00078624|OTHER|Knee stability training|The addition of agility and perturbation training techniques to the traditional exercise program
41123050|NCT01796236|DEVICE|Minimally invasive surgery and BA400|The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
41123051|NCT01796236|DEVICE|Traditional surgery and BA300|The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
41123052|NCT03582722|DRUG|Orlistat|Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months.
41123053|NCT03582722|DRUG|Placebo capsule|Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.
41123054|NCT03582722|DIETARY_SUPPLEMENT|Multivitamin|A multivitamin will be provided to be taken once daily, at bedtime.
41123055|NCT01836133|DRUG|Erlotinib 150 mg|
41123056|NCT00869011|OTHER|Endurance exercise|Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
41123057|NCT02903199|DIETARY_SUPPLEMENT|Whey Protein|Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
41123058|NCT02903199|DIETARY_SUPPLEMENT|Hydrolysed Protein|Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
41123059|NCT02903199|DIETARY_SUPPLEMENT|Placebo|Placebo intervention administered immediately prior to breakfast and lunch meals.
41123060|NCT00199407|DRUG|Istradefylline (KW-6002)|
41123061|NCT01612312|PROCEDURE|Thrombectomy|Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
41274750|NCT02421861|BEHAVIORAL|Anxiety Management in the ICU|"The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and optional modules based on each participant's anxiety experience and preference."
41274751|NCT02421861|OTHER|Usual Care (UC)|The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C\&L service; (2) referral to psychiatry C\&L service; or (3) pharmacologic management.
41274752|NCT01796002|DRUG|Romidepsin + CHOP|Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
41274753|NCT01796002|DRUG|CHOP|CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
41274754|NCT01696357|DEVICE|Automated Device for Asthma Monitoring (ADAM)|Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
41274755|NCT01337401|DRUG|Cediranib|30mg once daily, oral until disease progression
41274756|NCT01337401|DRUG|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
41274757|NCT03651843|OTHER|Questionnaire|Women who have recently given birth in the Lille metropolitan area fill in a self-administered questionnaire asking them about their perception of occupational risk during pregnancy and their knowledge of their right to work during pregnancy.
41274758|NCT04713943|DIETARY_SUPPLEMENT|>Your< Iron Syrup|Once daily dose of \>Your\< Iron Syrup in the amount of 1 mg/kg body weight of elemental iron for 12 weeks
41274759|NCT04713943|OTHER|Placebo|Once daily dose of placebo syrup for 12 weeks
41274760|NCT06036966|DRUG|Hetrombopag|All the enrolled 34 patients will be given hetrombopag 5mg per day for 8 weeks when they start to take Niraparib as maintenance therapy
41274761|NCT01644877|DRUG|DAS181 dry powder, formulation F02|
41274762|NCT01644877|DRUG|Lactose Placebo|
41274763|NCT00001087|DRUG|Ritonavir|
41274764|NCT00001087|DRUG|Nelfinavir mesylate|
41274765|NCT00001087|DRUG|Efavirenz|
41274766|NCT00001087|DRUG|Levocarnitine|
41274767|NCT00001087|DRUG|Adefovir dipivoxil|
40758298|NCT00951873|DRUG|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
41123062|NCT01612312|PROCEDURE|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
41274768|NCT00001087|DRUG|Saquinavir|
41274769|NCT00001087|DRUG|Lamivudine|
41274770|NCT00001087|DRUG|Stavudine|
41274771|NCT00001087|DRUG|Zidovudine|
41274772|NCT00001087|DRUG|Zalcitabine|
41274773|NCT00001087|DRUG|Didanosine|
41123063|NCT01714492|DEVICE|Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|Sigma PS RP TKA including a polyethylene insert with 4 beads
41123064|NCT04933526|DRUG|Flumatinib|Flumatinib 600mg QD orally form 1 to 12 months
41123065|NCT04933526|DRUG|Dasatinib|Dasatinib 100mg QD orally form 1 to 12 months
41123066|NCT01286714|DEVICE|CLIP OST|
41123067|NCT06293508|BEHAVIORAL|Standard Health Communication Intervention|Participants in this group will receive links and materials related to breast cancer screening from official sources (e.g. MOH, Non-governmental organizations (NGOs), etc.) that is already readily available and accessible by the Malaysian public. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
41123068|NCT06293508|BEHAVIORAL|Behavioural Change Health Communication Intervention|Participants receive health communication materials designed using persuasive behavioural change communication principles and behavior science to promote breast cancer screening. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
41123069|NCT02503397|DEVICE|Auditory brainstem evoked response (ABR)|Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
41123070|NCT04065958|BEHAVIORAL|Yoga-mindfulness|Body-mind therapy
41123071|NCT04065958|BEHAVIORAL|Patient education and physiotherapy|Lectures and physiotherapy
41123072|NCT05264844|OTHER|Masking tape|IV catheters will be fixed with masking tape
41274774|NCT00820430|OTHER|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
41123073|NCT04965415|BEHAVIORAL|Health Links + Leadership Training|Help businesses undergo transactional (i.e., business management practices) and transformational (i.e., business leadership and culture) change. Transactional change component: Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.Transformational change component: The experimental arm includes TWH leadership training for small business owners and other senior leaders. This is a three-month training that includes assessments, in-person training, and virtual training transfer activities. The goal is to help the leader understand their organization's current approach to TWH, identify areas for improvement, and to take action.
41123074|NCT04965415|BEHAVIORAL|Health Links|Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - create a culture of both safety and health. Health Links does this by helping businesses incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.
41123075|NCT01424397|DRUG|SB-705498|12mg intranasal
41123076|NCT01424397|DRUG|FP|200ug intranasal
41123077|NCT01424397|DRUG|placebo|placebo intranasal
41123078|NCT04439747|OTHER|Ultrasound, DXA, hormonal tests|Diagnostic tests in selected groups with investigation of revealed hormonal disorders
41123079|NCT03307278|BIOLOGICAL|House dust mite|As a stimulant to induce inflammasome activation
41274775|NCT03404362|PROCEDURE|Bone Metastases Pain treatment|Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)
41274776|NCT06246383|DIETARY_SUPPLEMENT|Q Actin|cucumber extract
41274777|NCT00378118|OTHER|Abbott-rapid HIV antibody test|Abbott will be used to test serum or whole blood
41274778|NCT00378118|OTHER|OraQuick Rapid HIV-1/2 Antibody test|OraQuick for oral fluid HIV antibody testing
41274779|NCT03419793|DEVICE|segmental vibration device|segmental vibration device
41274780|NCT03419793|OTHER|physical therapy exercises|
41274781|NCT02232256|DRUG|CALPXT96|Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
41274782|NCT03617731|DRUG|Lenalidomide|25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
41123080|NCT02008916|DRUG|Secukinumab|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).
41123081|NCT02008916|DRUG|Placebo secukinumab|Placebo to AIN457 (Secukinumab)
41123082|NCT04605016|DEVICE|Hydrophilic surface implants|A dental implant with hydrophilic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
41274783|NCT03617731|DRUG|Bortezomib|all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
41274784|NCT03617731|DRUG|Dexamethasone|20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
41274785|NCT03617731|DRUG|Isatuximab|10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)
40758299|NCT00951873|DRUG|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
41123083|NCT04605016|DEVICE|Hydrophobic surface implants|A dental implant with hydrophobic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
41123084|NCT03419299|OTHER|Tube Feeding Application|A smart device application was developed and used to help residents determine the best enteral nutrition prescription for patients admitted to the ICU
41123085|NCT03853161|OTHER|Vapotherm|A form of non invasive ventilation used in newborns
41123086|NCT03853161|OTHER|NIPPV|A form of non invasive ventilation used in newborns
41274786|NCT03026738|PROCEDURE|Laparoscopic anterior mesh rectopexy|fixation of the rectum anteriorly using laparosopy and polypropylene mesh
41274787|NCT03026738|PROCEDURE|Laparoscopic posterior mesh rectopexy|fixation of the rectum posteriorly using laparosopy and polypropylene mesh
41274788|NCT03026738|DEVICE|polypropylene mesh|A strip of polypropylene mesh will be introduced and sutured.
41274789|NCT06292897|OTHER|observational study|observational study
41274790|NCT01478555|DRUG|ISV 101|Bromfenac in DuraSite
41274791|NCT04888611|BIOLOGICAL|Camrelizumab plus GSC-DCV|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and GSC-DCV IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
41274792|NCT04888611|BIOLOGICAL|Camrelizumab plus Placebo|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and Placebo IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
41274793|NCT04836039|OTHER|A questionnaire and scales.|Participants will be evaluated by applying a questionnaire and scales created by the researcher physiotherapists based on the researches and examples in the literature.
41274794|NCT01380899|PROCEDURE|Biopsy of skin|Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
41274795|NCT00755820|BEHAVIORAL|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
41274796|NCT00755820|BEHAVIORAL|Exposure Therapy + Placebo|Exposure therapy with placebo medication
41274797|NCT00755820|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy
41123087|NCT06423534|BEHAVIORAL|Breastfeeding Health Educational Program|Breastfeeding is a mother's priceless gift to her infant and nature's own method of nurturing a baby. Therefore, this study will be conducted to evaluate the primigravida mother's breastfeeding's knowledge, attitude and corrective technique through the implementation of an educational program and to ascertain the efficacy of such a program.
41274798|NCT01536301|DRUG|Standard Care morphine hydrochloride|Post-operative analgesia including morphine (patient controlled analgesia).
41274799|NCT01536301|DRUG|Oxycodone|Post-operative analgesia including oxycodone (patient controlled analgesia).
41274800|NCT00764725|DRUG|conventional DMARD combination|MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
41274801|NCT00764725|BIOLOGICAL|MTX plus anti-TNF|MTX + infliximab; can be changed to MTX + etanercept within protocol
40754278|NCT06270394|DRUG|68Ga-Fibroblast activation protein inhibitor|Fibroblast activation protein (FAP), a type II transmembrane serine protease with dipeptidyl peptidase and endopeptidase activities. FAP is a specific surface marker for activated fibroblasts in the mesenchyme of tumors, which account for 90% of the stroma of epithelial neoplasms. FAP inhibitors (FAPIs) can specifically target and bind to FAP. These inhibitors that are radiolabeled with gallium 68 (68Ga-FAPIs) can be probes for visualization of the FAP tumor stroma. Previous studies have demonstrated that 68Ga-FAPI-04 is not dependent on blood glucose levels, has an equal or better tumor-to-background ratio, and clearly visualizes primary tumors and their metastatic foci. In addition, previous studies on 68Ga-FAPI-04 have focused on PET/CT and the efficacy of PET/MR with FAPI for postoperative evaluation of GI tumors remains to be clarified.
41274802|NCT01203488|DRUG|Vitamin A|5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
41274803|NCT01203488|OTHER|Sham Procedure|Control infants received a sham procedure rather than placebo injections.
41274804|NCT03760588|DRUG|Sacubitril/valsartan|Target dose 97/103 mg b.i.d .
41274805|NCT03360812|OTHER|Online training resource|Please see information included in the description of the intervention group.
41274806|NCT01996787|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
41274807|NCT01996787|DEVICE|Clariti with Handling Tint|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
41274808|NCT00332904|DRUG|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
41274809|NCT00332904|DRUG|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
41274810|NCT03088969|OTHER|questionnaire RTWSE|The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
41274811|NCT03078062|DRUG|Dexamethasone|Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia
41274812|NCT03078062|DRUG|Normal saline|Administration of a single-dose of Normal saline during spinal anesthesia
41274813|NCT00752986|DRUG|ZD6474 (Vandetanib at the dose of 100 mg)|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
41274814|NCT00752986|DRUG|Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)|Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
41274815|NCT00752986|DRUG|Fulvestrant|All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
41274816|NCT00752986|DRUG|ZD6474 (Vandetanib at the dose of 300 mg)|300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
41123088|NCT02229812|DRUG|alteplase|
41123089|NCT05429307|OTHER|Population|Turkish Validity and Reliability of The Exercise Sensitivity Questionnair Scale to Turkish society and to make its validity and reliability in Turkish.
41123090|NCT05521672|DRUG|Adipose derived allogenic mesenchymal stem cells (adAMSC)|adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure
41274817|NCT00752986|DRUG|Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)|Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
41274818|NCT00797121|PROCEDURE|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
41123091|NCT03484416|DRUG|Calcium Carbonate 1500 Mg with Vitamin D|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
41123092|NCT04980872|DRUG|Miransertib|Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
41274819|NCT01586091|DRUG|Levocetirizine Oral Tablet|
40926872|NCT01943357|BEHAVIORAL|Diabetes Self Management Program|The interventions include modeling and action-planning to enhance self-efficacy.
40926873|NCT00852514|DEVICE|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
40926874|NCT00003296|BIOLOGICAL|filgrastim|
40926875|NCT00003296|DRUG|pegylated liposomal doxorubicin hydrochloride|
40926876|NCT00562666|OTHER|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
40926877|NCT01577290|BEHAVIORAL|Internet-administered Mindfulness Training Program|A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.
40926878|NCT01577290|BEHAVIORAL|Discussion group|Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
40926879|NCT00101829|DRUG|Rituximab|1000 mg intravenous infusion
40926880|NCT04726098|DRUG|Dexamethasone high dose|High doses: dexamethasone 20 mg/day 5 days + 10 mg/day 5 days (total 10 days)
40926881|NCT04726098|DRUG|Dexamethasone low dose|Low doses: dexamethasone 6 mg/day 10 days.
40926882|NCT05712486|OTHER|High force hip Lateral distraction|Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying high force of distraction.
40926883|NCT05712486|OTHER|Placebo force hip lateral distraction|Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying placebo force of distraction.
40926884|NCT02562118|DRUG|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
40926885|NCT02622906|DRUG|Pasireotide|60 mg per month of the Pasireotide during 6 months
40926886|NCT02622906|DRUG|Placebo|Vehicule injection per month during 6 months
40926887|NCT05642650|DEVICE|novel wearable device|Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps after discharge.
40926888|NCT01230203|PROCEDURE|Computed tomography scan versus color duplex ultrasound|Computed tomography scan versus color duplex ultrasound
40926889|NCT04555967|DEVICE|SAPIEN 3 Ultra System|Transcatheter aortic valve implantation
40926890|NCT01615497|BEHAVIORAL|Standard Treatment as Usual (TAU)|Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
41123093|NCT04030624|DEVICE|Remote Electronic Patient Monitoring|The Remote Patient Monitoring intervention is a remote monitoring system intended for use by healthcare professionals for the collection of physiological data in home and healthcare settings. Patient information is displayed on a computer located at the medical institution. Throughout the day, patient data from the remote monitoring system are presented on the clinician user interface (e.g., temperature, blood pressure, heart rate, respiration rate). Data are transmitted from sensors to the patient's smart phone.
40754279|NCT03132259|DRUG|high dose dexmedethomidine|Dexmedethomidine continuous drip 0.5 mcg/kg/hr a
40754280|NCT03132259|DRUG|low dose dexmedethomidine|Dexmedethomidine continuous drip 0.2 mcg/kg/hr
40926891|NCT01615497|BEHAVIORAL|Web-based CBT4CBT for alcohol plus TAU|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
40926892|NCT01615497|BEHAVIORAL|Web-based CBT with minimal clinical contact|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
40926893|NCT04716556|BIOLOGICAL|Convalescent plasma|Convalescent plasma will be collected by healthy donors, recovered by COVID19 and, after standard preparation and dosage of neutralizing antibodies, it will be administered to patients with SARS-CoV2 pneumonia
40926894|NCT06482242|BEHAVIORAL|My Best Alaska Life|MBAL's combination of digital innovation, inclusive content, and youth-driven design positions it as a leading-edge intervention in the field of sexual health, with the potential to significantly impact the lives of Y/YA in AK and beyond. The open-access digital website enhances the reach and engagement of MBAL, particularly among adolescents who may prefer to seek information and support online in a private, self-paced setting. By allowing youth to fill out this tool at their own pace and return to their home page as they want to reflect/change answers, they can update it as their lives change. Additionally, MBAL incorporates interactive elements (question types of open response, ranking, scales, drag/drop; journaling prompts \& space) and personalized features (ex. avatars of common AK animals designed by Y/YA), allowing users to tailor their life planning experience according to their individual needs and preferences and return to their answers.
40926895|NCT05592873|DRUG|Neoadjuvant chemoradiotherapy (CRT)|Patients with histological diagnosis of locally advanced rectal adenocarcinoma \[clinical T3-T4N0M0 or T(any)N+M0\] were treated with neoadjuvant CRT followed by curative intent elective surgery between January 2014 and December 2019.
40926896|NCT02225613|OTHER|Usual protocol|
40926897|NCT02225613|OTHER|Spa protocol|
40926898|NCT02735499|DRUG|onabotulinum toxin A|Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
40926899|NCT02186301|DRUG|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
40926900|NCT02186301|DRUG|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
41123094|NCT01576029|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
41123095|NCT01576029|DRUG|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
41123096|NCT05875987|DEVICE|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
41123097|NCT04896034|DEVICE|MILTA Device|Patients in MILTA Device group will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
41123098|NCT04896034|DEVICE|" control 1  fake MILTA device"|Patients in group control 1 will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
41123099|NCT04290819|DIETARY_SUPPLEMENT|Creatine Monohydrate|0.1g/kg of body weight (pre measured creatine) and 3mg/kg of body weight (pre measured micronized cellulose powder-caffeine placebo) self administered 1 hr prior to working out mixed in water.
41123100|NCT04290819|DIETARY_SUPPLEMENT|Creatine Monohydrate and Caffeine|0.1g/kg body weight (pre measured creatine) and 3mg/kg body weight (pre measured caffeine) self administered 1hr prior to working out mixed in water.
41123101|NCT04290819|DIETARY_SUPPLEMENT|Caffeine|3mg/kg of body weight (pre measured caffeine) and 0.1g/kg of bodyweight (pre measured maltodextrin- creatine placebo) self administered 1 hr prior to working out mixed in water.
41123102|NCT04290819|DIETARY_SUPPLEMENT|Placebo|0.1g/kg of body weight (pre measured maltodextrin) and 3mg/kg of body weight (pre measured micronized cellulose powder) self administered 1 hr prior to working out mixed in water.
41123103|NCT03208868|DIETARY_SUPPLEMENT|Leucine enriched essential amino acid (EEA/LEU)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
41123104|NCT03208868|DIETARY_SUPPLEMENT|Balanced amino acid supplement (BAA)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
41123105|NCT01957969|DEVICE|Sacral Nerve Stimulation|
41123106|NCT04771351|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
41123107|NCT04771351|DRUG|Placebo|Diluent solution
41123108|NCT01555099|DRUG|AZD5423|oral inhaled
41123109|NCT01555099|DRUG|Budesonide|oral inhaled
41123110|NCT01555099|DRUG|Placebo|oral inhaled
41123111|NCT01381406|DRUG|TIO|Patients receiving tiotropium bromide at index within the study period.
41123112|NCT01381406|DRUG|TIO+FSC|Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
41123113|NCT02292329|DIETARY_SUPPLEMENT|Acai puree, frozen blended it with banana|150g of acai fruit, frozen blended it with banana.
41123114|NCT02292329|DIETARY_SUPPLEMENT|Control Macronutrient matched|Macronutrient matched control in water and also prepared with banana.
41123115|NCT01236560|BIOLOGICAL|Bevacizumab|Given IV
41123116|NCT01236560|DRUG|Temozolomide|Given PO
41123117|NCT01236560|DRUG|Vorinostat|Given PO
41123118|NCT05600335|PROCEDURE|ERAS protocol|Patients with esophageal cancer have undergone RAME using ERAS protocol and conventional management strategy
41123119|NCT00243529|BIOLOGICAL|autologous dendritic cell vaccine|
41123120|NCT03257644|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
41123121|NCT00468806|DRUG|GSK598809, using [11C]-(+)-PHNO|
41123122|NCT01942018|PROCEDURE|POEM|Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
41123123|NCT02441881|DEVICE|Venefit|Endovenous radiofrequency device
41123124|NCT02441881|DEVICE|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency device
41123125|NCT02441881|DEVICE|Endovenous Radiofrequency|Endovenous radiofrequency device
41274820|NCT01586091|DRUG|Fexofenadine 60 Mg Oral Tablet|
41123126|NCT02424318|DRUG|Topiramate|topiramate 25mg twice 1 week -\> topiramate 50mg twice 7 weeks
41123127|NCT00402259|DRUG|Esomeprazole IV|
41123128|NCT00402259|DRUG|Omeprazole IV|
41123129|NCT00484055|DRUG|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
41123130|NCT00484055|PROCEDURE|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
41123131|NCT05376436|DIAGNOSTIC_TEST|Exercise challenge test (ECT)|Baseline demographic, clinical and rest lung functions were recorded. ECT was performed on treadmill according to fixed protocol. Clinical data during ECT was recorded. (visit 1- performed with nose clip, visit 2- performed without nose clip). Lung function were measured and recorded at fixed time after ECT and after bronchodilator administration.
41123132|NCT03224390|OTHER|digital family planning screening and referral service|Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
41123133|NCT02089763|BIOLOGICAL|pegylated recombinant human arginase|
41123134|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
41123135|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
41123136|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
41123137|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
41274821|NCT01586091|DRUG|Placebo Oral Tablet|
41274822|NCT01800188|PROCEDURE|Hemodialysis|A 4 hour hemodialysis with a standardized liquid meal after one hour
41274823|NCT01800188|PROCEDURE|Hemodiafiltration|A 4 hour hemodiafiltration with a standardized liquid meal after one hour
41446575|NCT03029364|BEHAVIORAL|Study Protocol|"Participants will complete three study protocols 7 - 28 days apart which includes:~* 3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~* 2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~* Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention."
40754281|NCT01121354|DRUG|Cefazolin 2g for Injection USP and Dextrose Injection USP|Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
41123138|NCT04113096|DRUG|Stage IV Breast Cancer Placebo|20 mg once daily for 6 months
41123139|NCT04113096|DRUG|Stage IV: Colon Cancer Placebo|20 mg once daily for 6 months
41123140|NCT04113096|DRUG|Cervical Cancer Stage IV Placebo|20 mg once daily for 6 months
41123141|NCT04113096|DRUG|Cancer of the Prostate Placebo|20 mg once daily for 6 months
41123142|NCT06074549|DEVICE|DynamX Novolimus-eluting Coronary Bioadaptor System|All patients will receive at least one DynamX Bioadaptor implant in a commercial setting in accordance with the product's Instructions for Use
41123143|NCT05728008|DRUG|Ustekinumab|a human monoclonal antibody to interleukin IL 12/23 p40. It is indicated in the treatment of adult patients with moderately to severely active UC. The induction phase consists of approximately 6 mg/kg intravenous dose administration. After the induction, the maintenance phase consists of a 90mg subcutaneous dose every 8 weeks.
41123144|NCT05728008|DRUG|Tofacitinib|Jak inhibitor. It is indicated in the treatment of adult patients with moderately to severely active UC who have experienced inadequate response or have lost the response or who are intolerant to conventional therapy or to a biological agent. The induction phase consists of 10mg twice daily for 8 to 16 weeks. After the induction, the maintenance phase consists of 5mg x twice daily.
40754282|NCT01121354|DRUG|Cefazolin 1.5g|Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
41123145|NCT00026234|DRUG|floxuridine|Given intra-arterially
41123146|NCT00026234|DRUG|dexamethasone|Given intra-arterially
41123147|NCT00026234|DRUG|oxaliplatin|Given IV
41123148|NCT00026234|DRUG|capecitabine|Given orally
41123149|NCT00548418|DRUG|Topotecan|
41123150|NCT00548418|DRUG|Cisplatin|
41123151|NCT00548418|DRUG|Bevacizumab|
41123152|NCT05704920|OTHER|IA|The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
41446576|NCT00015665|DRUG|Voriconazole|
40754283|NCT02427672|DEVICE|Transcranial direct current stimulation|
40754284|NCT02427672|DEVICE|Sham transcranial direct current stimulation|
40754285|NCT05508594|DRUG|CT001|Intranasal
40754286|NCT05508594|DRUG|Placebo|Intranasal
40754287|NCT05508594|DRUG|Sufentanil|Intranasal
40754288|NCT05508594|DRUG|Ketamine|Intranasal
40754289|NCT00315029|BEHAVIORAL|evidence based decision aid|evidence based decision aid
41123153|NCT05704920|OTHER|Not IA|The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
41123154|NCT05212181|DEVICE|H-Man|H-Man device will be deployed to patients for onboarding and home-based training.
41123155|NCT04353531|DEVICE|High-flow nasal cannula|High-flow nasal cannula is a modality of oxygen device that can provide gas flow meets or exceeds patient inspiratory flow demand (flow can be set at 10-60 L/min), it has been proven to improve oxygenation and reduce intubation rate in hypoxemic patients.
41123156|NCT04353531|DEVICE|Surgical mask|A procedure mask will be used to cover patient's face after HFNC is initiated.
41123157|NCT04353531|PROCEDURE|bronchoscopy examination|is a procedure that allows a doctor to examine the inside of the lungs, including the bronchi, which are the main pathways into the lungs. During a bronchoscopy, a doctor inserts a thin tube containing a light and camera into the lungs through the nose or mouth or via artificial airway such as intubation or tracheotomy tube
41123158|NCT04353531|PROCEDURE|intubation|Intubation is the process of inserting a tube, called an endotracheal tube (ET), through the mouth and then into the airway. This is done so that a patient can be placed on a ventilator to assist with breathing during anesthesia, sedation, or severe illness.
41123159|NCT04353531|PROCEDURE|tracheostomy|A tracheostomy is a medical procedure - either temporary or permanent - that involves creating an opening in the neck in order to place a tube into a person's windpipe. The tube is inserted through a cut in the neck below the vocal cords. This allows air to enter the lungs.
41123160|NCT04353531|DEVICE|nebulization|A nebulizer is a piece of medical equipment that a person with asthma or another respiratory condition can use to administer medication directly and quickly to the lungs
41123161|NCT04353531|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange.
41123162|NCT04980274|OTHER|Intervention focused on identified organ dysfunction(s)|Intervention focused on identified organ dysfunction(s)
41123163|NCT00547352|DRUG|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
41446577|NCT05169710|DRUG|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg Tablet (supplied in one 200mg tablet and one placebo tablet)
41446578|NCT05169710|DRUG|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)
41446579|NCT05169710|DRUG|Placebo|Placebo tablet (supplied in two tablets)
41274824|NCT01800188|PROCEDURE|Meal test|A 3 hour standardized liquid meal test without dialysis
41274825|NCT04378426|DRUG|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50% nitrous oxide and 50% oxygen plus intravenous saline
41274826|NCT04378426|DRUG|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
41123164|NCT00547352|DRUG|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
41123165|NCT04210180|DRUG|Varenicline|0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.
41123166|NCT04210180|OTHER|e-cigarette|Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.
41123167|NCT00296868|DRUG|ascorbic acid (vitamin C) versus placebo|
41123168|NCT06411743|BIOLOGICAL|Recombinant Human Albumin Injection|Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.
41123169|NCT06411743|BIOLOGICAL|Human Albumin|Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.
41123170|NCT01471756|PROCEDURE|Standard of Care Procedure as described in ARM|Standard of Care Procedure as described in ARM
41123171|NCT06134258|OTHER|mixed meal test|mixed meal test after fasting
41123172|NCT00799396|DRUG|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
41123173|NCT00799396|DRUG|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
41123174|NCT00130156|DRUG|Bunazosin|Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.
41123175|NCT00130156|DRUG|Doxazosin|Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
41123176|NCT00130156|DRUG|Valsartin|After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
41123177|NCT01335828|DEVICE|Medical ultrasound device (ShearWave system)|"Echography (all modes) and elastography ShearWave system"
41274827|NCT04378426|DRUG|Nitrogen|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
41274828|NCT04378426|DRUG|Oxygen|inhaled gas
41274829|NCT04378426|DRUG|Saline|Placebo infusion
41274830|NCT03064464|OTHER|None Intervention|It is observational study, no interventios to any of the three study arms
41123178|NCT02362139|DRUG|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation\<4cm).
41123179|NCT02887898|DEVICE|Automated bolus calculator|
41123180|NCT02887898|OTHER|Education|
41123181|NCT01811706|DRUG|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
41123182|NCT01811706|DRUG|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
41123183|NCT03409913|RADIATION|FDG PET/CT|Conventional FDG PET/CT including head in order to asses cranial arteries.
41123184|NCT04277221|BIOLOGICAL|Autologous Dendritic Cell/Tumor Antigen, ADCTA|ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.
41123185|NCT05715437|DRUG|Bupivacaine plus Normal Saline|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
41123186|NCT05715437|DRUG|Bupivacain and ketamine|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
41123187|NCT02206750|OTHER|Clean Air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
41274831|NCT05200793|DRUG|Empagliflozin 25 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
41274832|NCT05200793|DRUG|Linagliptin 10 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
41274833|NCT05200793|DRUG|Metformin 1500 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
41123188|NCT02206750|OTHER|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
41123189|NCT03896815|DRUG|INCB054329|
41274834|NCT00684814|DRUG|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered after an overnight fast of at least 10 hours
41274835|NCT00684814|DRUG|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered after an overnight fast of at least 10 hours
41274836|NCT04177303|DRUG|Metformin|Participants will be randomized to metformin 2000 mg
41274837|NCT04177303|DRUG|Placebo|Participants will be randomized to placebo
41274838|NCT02415309|DRUG|2 mg Melatonin|40 patients will randomly receive 2 mg melatonin
41274839|NCT02415309|DRUG|10mg Melatonin|40 patients will randomly receive 10 mg melatonin
41274840|NCT02415309|OTHER|Placebo|40 patients will randomly receive a placebo/sugar pill
41274841|NCT00921869|DRUG|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
40754290|NCT00315029|BEHAVIORAL|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
40926901|NCT05666115|DIETARY_SUPPLEMENT|Probiotic group|During the first 4 weeks, patients will be instructed to take two capsules of Enterelle plus (Bromatech lab, Manno, Switzerland) during morning time, before or after breakfast. Enterelle plus contains specific strains, i.e., S boulardi, E faecium, and acidophilus, that contribute to reduce the mycotic flora and modulate the gastrointestinal transit. For the next 8 weeks, participants will be told to ingest two capsules of Adomelle (Bromatech lab, Manno, Switzerland) at night, during or right after dinner. Adomelle contains several strains, including Bifidobacterium breve, that help to reduce abdominal fat, pain, and gas, and control the frequency of deposition
40926902|NCT05666115|OTHER|Exercise group|This type of intervention has shown to benefit patients with several chronic conditions 23, including axSpA 13. Exercises combined high knees, lunges, basic burpees, plank, skipping, mountain climbers, and squats with jumps. The training routine will be conducted three times per week, and each session will last around 8 minutes (2 sets of 4 minutes, with a 10 second rest between them). All sessions will be individually tailored and supervised by a senior professional with a degree in Physiotherapy and Sciences of Physical Activity and Sport. Overall, participants will be told to continue exercising if low to moderate bearable pain appeared during training.
40926903|NCT01143233|OTHER|control formula|infants are fed a commercial hydrolyzed formula
40926904|NCT01143233|OTHER|intervention formula 1|formula has hydrolysed protein and a different protein content
41123190|NCT03771352|DEVICE|RxSight RxLAL|The patients will be assessed for 6 months
41123191|NCT05748015|DIAGNOSTIC_TEST|quantification of sensory and autonomic small nerve fibers by punch skin biopsy|We'll perform a punch skin biopsy of 3mm from thigh, leg and fingertip and we'll quantify peripheral sensory and autonomic nerve fibers.
41123192|NCT05748015|DIAGNOSTIC_TEST|Cardiovascular Reflexes testing|Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
41123193|NCT05748015|OTHER|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms|We'll characterize patients' symptoms through the administration of clinical scales such as: COMPASS 31 autonomic symptoms scale; Small Fiber Neuropathy Symptom Inventory Questionnaire (SFN-SIQ), the Pain Detect Questionnaire and the Total neuropathy score
41123194|NCT00006786|BIOLOGICAL|bevacizumab|
41123195|NCT00006786|DRUG|fluorouracil|
41123196|NCT00006786|DRUG|irinotecan hydrochloride|
41123197|NCT00006786|DRUG|leucovorin calcium|
41123198|NCT00192946|PROCEDURE|Temporary cardiac resynchronization therapy|
41123199|NCT04245644|BEHAVIORAL|use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins|enrolled patients will be asked details regarding their daily drug use, before and after diagnosis of pancreatic cancer
41123200|NCT04008316|DRUG|Colchicine|colchicine 1mg/day
41123201|NCT03668197|BIOLOGICAL|microbiological analysis|microbiological analysis of the peritoneal fluid
41123202|NCT05045196|BEHAVIORAL|Health promoting conversations|The Health-promoting conversations intervention is a conversation model between the patient, family members, and a trained nurse. Patients and families included in the study will, after submitting base-line-data, be randomized to
41123203|NCT03567941|DRUG|Placebo|Tablet orally administered under fasting
41123204|NCT03567941|DRUG|Hydrocodon bitartrate-acetaminophen arm 1|Tablet orally administered under fasted conditions
41123205|NCT03567941|DRUG|Hydrocodon bitartrate-acetaminophen arm 2|Tablet orally administered under fed conditions
41123206|NCT03567941|DRUG|Reference|Tablet orally administered under fasted conditions
41123207|NCT05510310|PROCEDURE|Breast stimulation|By breast pump
41123208|NCT05510310|BIOLOGICAL|Oxytocin|Oxytocin will be administered intravenously and titrated
41123209|NCT05297214|DIAGNOSTIC_TEST|serum creatinine and Other investigations will be done according to the case|following up AKI patients with serum creatinine,Urine out put, CBC,Serum electrolytes,renal functin test,Liver function test,urine analysisand specific investigations according to case
41123210|NCT04866238|DEVICE|Vestibular fixed appliances|The fixed appliances will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
41123211|NCT04866238|DEVICE|Clear aligners|The clear aligners will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
41123212|NCT01637246|DRUG|Any Fixed Combination Therapy|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
41123213|NCT05346575|BEHAVIORAL|Teaching Obesity Treatments to Adult Learners (TOTAL)|TOTAL includes both video component and motivational telemedicine calls delivered via VA Video Connect (VVC) by a study interventionist. We will invite study participants to watch the 18-minute video at least once. The motivational component of TOTAL will consist of three telemedicine-based (VVC), one-on-one, 30-minute calls at 1 week, 6 months, and 12 months after randomization. This timing was selected so Veterans would have regular interactions with the interventionist within one year of initiating the intervention. Each motivational session will be tailored to where Veterans are in the treatment initiation process. Electronic outcome assessment surveys will be sent to the participants at baseline, at each motivational telemedicine visit, and for the 18 month assessment.
41123214|NCT05346575|BEHAVIORAL|Usual care|The usual care group will be electronically sent the 1-week, 6-month, 12-month, 18-month assessments. All usual care participants will be offered the opportunity to watch the educational video component of TOTAL after the final outcome assessment is performed (18 months post-randomization). Veterans in the usual care arm will also have access to the MOVE! program via referrals from the PCP or self-referral to MOVE!. If they initiate treatment in MOVE!, they may progress through MOVE! and receive obesity medications or be referred for bariatric surgery if they choose to do so.
41123215|NCT05551455|OTHER|Nutritional/dietary intake manipulation ('Normal')|Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.
41274842|NCT06075303|BEHAVIORAL|Modified Cycles|
41123216|NCT05551455|OTHER|Nutritional/dietary intake manipulation ('Low')|Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).
41123217|NCT00092300|DRUG|MK0966, rofecoxib|
41123218|NCT00092300|DRUG|Comparator: valdecoxib|
41123219|NCT05646004|DEVICE|Cataract surgery|Implantation of 621 lens
41123220|NCT02187536|DRUG|Telmisartan|
41123221|NCT02187536|DRUG|Simvastatin|
41123222|NCT02187536|DRUG|Telmisartan placebo|
41123223|NCT03752034|OTHER|Muscle Fiber Fragments (MFFs)|During the rotator cuff repair procedure, a biopsy of muscle will be taken from the pectoralis major and processed under sterile conditions in the operating room to obtain MFFs. The final product, composed of autologous MFFs in suspension, will be delivered via targeted injection into the muscle belly of the supraspinatus through the Naviaser Portal with visual guidance after rotator cuff repair is complete.
41123224|NCT03035396|DEVICE|Diassess Influenza A and B Test|
41123225|NCT05851677|DRUG|Disitamab vedotin|recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
41123226|NCT02555475|OTHER|community based hepatitis C care and treatment|
41123227|NCT03640949|DRUG|Vasopressin, Arginine|20 IE of vasopressin per dose for a maximum of four doses (80 IU)
41123228|NCT03640949|DRUG|Methylprednisolone|40 mg methylprednisolone once
41123229|NCT03640949|DRUG|NaCl|Placebo
41123230|NCT03581487|BIOLOGICAL|Durvalumab|Given IV
41123231|NCT03581487|DRUG|Selumetinib|Given PO
41123232|NCT03581487|BIOLOGICAL|Tremelimumab|Given IV
41123233|NCT03037892|DRUG|Midazolam, Fentanyl|Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain.
41123234|NCT03037892|DRUG|Midazolam, Remifentanil|The patient in group 2 Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
41123235|NCT03037892|DRUG|Remifentanil|The group 3 patient will receive only Remifentanil in the same doses as given in group
41123236|NCT02932579|OTHER|Pharmacogenomic Testing|Saliva collection (5mL)
41123237|NCT02932579|DRUG|Ibuprofen|400 mg
41123238|NCT02932579|DRUG|hydroxycontin/acetominophen|hydroxycontin 2.5 mg, acetominophen 325 mg
41123239|NCT02932579|DRUG|acetominophen|650 mg
41123240|NCT02932579|DRUG|Oxycontin/acetominophen|5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
41123241|NCT00397475|DRUG|Colecalciferol|
41123242|NCT04246944|PROCEDURE|harvesting induced membrane|The induced membrane will be harvested during the second step of the bone reconstruction.
41123243|NCT02960204|DRUG|Emricasan|
41123244|NCT02960204|DRUG|Placebo|
41123245|NCT05182385|DRUG|Blinatumomab|"All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).~All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)~Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type."
41123246|NCT05182385|DRUG|Venetoclax|"In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.~In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.~Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type."
41123247|NCT05408572|BIOLOGICAL|SON-1010 (IL12-FHAB)|SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.
41123248|NCT04255290|OTHER|Leg Squat Lounge|The players assigned to the experimental group will receive an intervention through plyometric and eccentric hamstring exercises
41123249|NCT04255290|OTHER|Control group|The subjects included in the control group will perform an eccentric work protocol
41123250|NCT05344807|DIAGNOSTIC_TEST|Renal DMSA Scintigraphy|patient injected with Tc99mDMSA then imaged after 2-4 hours by gamma camera
41123251|NCT00858117|BIOLOGICAL|Alemtuzumab|Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
41123252|NCT00858117|BIOLOGICAL|Rituximab|Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
41123253|NCT01956552|OTHER|biopsy or cytopuncture|
41123254|NCT02648503|DRUG|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
41123255|NCT02648503|DRUG|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
41123256|NCT01834846|PROCEDURE|no-touch|The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
41274843|NCT04372095|PROCEDURE|oral smears|oral smears
41274844|NCT01122355|DRUG|lipid modification|1) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
41274845|NCT04234217|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)
41274846|NCT04234217|OTHER|Niacin|Suppression of lipolysis by niacin infusion
41274847|NCT03215784|DIETARY_SUPPLEMENT|Fish Oil|
40754291|NCT04889911|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a psychosocial intervention focused on addressing the effects of self-stigma on individuals diagnosed with severe mental illnesses. For the present study, the intervention has been modified to address the needs of youth who have recently experienced a first episode of psychosis.
41123257|NCT01834846|PROCEDURE|conventional|The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
41123258|NCT06433102|OTHER|Visual perceptual training based on the lateral masking paradigm|Visual perceptual training is a novel rehabilitation approach aimed at enhancing visual performance through practice of visual tasks. Patients received visual perceptual training based on the lateral masking paradigm every other day. Each training session consisted of 9 stages, totaling 900 trials, lasting 35 to 45 minutes. The stimuli consisted of a central Gabor patch with relatively low contrast positioned in the central fixation area, along with co-linear high-contrast Gabor patches distributed above and below the central stimulus. These stimuli were presented on a Liquid Crystal Display (LCD) monitor, with a training distance of 150 cm.
41123259|NCT03032913|PROCEDURE|Blood samples|Blood samples for both group
41123260|NCT03032913|PROCEDURE|Portal vein blood sample|Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group
41123261|NCT03000049|OTHER|bedside blood culture|
41123262|NCT02672722|DRUG|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
41123263|NCT02672722|OTHER|Exercise|
41123264|NCT02672722|OTHER|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
41123265|NCT00445315|DRUG|PF-00868554|300 mg BID
41123266|NCT00445315|DRUG|PF-00868554|450 mg BID
41123267|NCT00445315|DRUG|PF-00868554|100 mg BID
41123268|NCT00445315|DRUG|PF-00868554|300 mg TID
41123269|NCT00445315|DRUG|Placebo|Placebo
41123270|NCT04961021|PROCEDURE|Strabismus surgery|Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle
41123271|NCT05146271|PROCEDURE|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome
41123272|NCT03213327|DEVICE|StayOk web application|Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices
41123273|NCT03554460|DEVICE|dual-limb NIV|dual-limb NIV was served with servo i ventilator
41123274|NCT00004387|PROCEDURE|fetal nigral transplantation|
41123275|NCT06340100|OTHER|find association between vestibular impairment , cognitive fiunction with concussin|SCOAT 6 is a standardized tool used for evaluating athletes suspected of having a concussion. It includes a variety of components such as symptom evaluation, cognitive assessment, balance evaluation, and a neck examination. it helps in assessing the severity of the injury, tracking recovery, and making return-to-play decisions. Dr. Robert Cantu, a prominent figure in sports concussion research, has proposed guidelines for the management of concussions. These guidelines typically involve recommendations for the evaluation, treatment, and return-to-play decisions for athletes who have sustained concussions
41123276|NCT03875040|BEHAVIORAL|kinesiophobia|patients who have a high-level or low-level kinesiophobia have been evaluated.
41123277|NCT01298934|DRUG|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
41123278|NCT05908669|DIAGNOSTIC_TEST|Deuterium metabolic imaging|MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
41123279|NCT03498196|DRUG|Avelumab|avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
41123280|NCT04804930|PROCEDURE|picture|We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns
41123281|NCT04750850|OTHER|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
41123282|NCT04750850|OTHER|Usual care|Usual routine as walking and activities of daily living.
41123283|NCT04828590|OTHER|No intervention|Due to observational study
41123284|NCT03041584|PROCEDURE|Guided placement|implant placement with use of guide
41123285|NCT03041584|PROCEDURE|Non-guided placement|conventional implant placement
41123286|NCT03041584|DEVICE|Astra Tech TX implant|
41123287|NCT00073255|DRUG|hokt3g1 (ALA-ALA)|
41123288|NCT06081075|OTHER|Genetic testing|Rapid whole genome sequencing
41123289|NCT00404573|DRUG|RGH-188|
41123290|NCT04071756|DRUG|Topical Tazarotene|This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin
41123291|NCT04071756|OTHER|Placebo|A substance that has no therapeutic effect, used as a control in testing new drugs
41123292|NCT05443464|BIOLOGICAL|OSSM-001|Direct IV infusion of OSSM-001
41123293|NCT03427021|DRUG|Oxaliplatin|Infusion
41123294|NCT00003834|DRUG|fluorouracil|
41123295|NCT00003834|DRUG|leucovorin calcium|
41123296|NCT00003834|DRUG|oxaliplatin|
41123297|NCT03576833|DEVICE|Elipse Balloon system|intragastic balloon
41123298|NCT02095717|DRUG|Curcumin|
41123299|NCT02095717|DRUG|Placebo|
41123300|NCT02095717|DRUG|Taxotere|
41274848|NCT03215784|DIETARY_SUPPLEMENT|Probiotic|
41274849|NCT03215784|DIETARY_SUPPLEMENT|Placebo|
40926905|NCT01143233|OTHER|intervention formula 2|formula has hydrolysed protein, different protein content and pro- and prebiotics
40926906|NCT01143233|OTHER|intervention formula 3|formula has hydrolysed protein, different protein content and pro- and prebiotics
40926907|NCT04620707|DEVICE|RGS based training and monitoring|The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
40926908|NCT04620707|BEHAVIORAL|Therapy as usual|The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
40926909|NCT00770146|DRUG|Mipomersen sodium|200 mg/mL
40926910|NCT00770146|DRUG|Placebo|1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
40926911|NCT03310333|DRUG|Propess® (dinoprostone)|"The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score \<6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis."
40926912|NCT03310333|DEVICE|cook cervical pipening balloon|• In dinoprostone vaginal group: the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
40926913|NCT03874429|DEVICE|T2259|Sodium Hyaluronate and Trehalose
40926914|NCT03874429|DEVICE|Vismed multi|HA
40926915|NCT05026814|OTHER|Interview after one year or more from the treatment received|Questionnaires to evaluate the satisfaction with treatment, the motivations and expectations for the treatment, the general well-being, the sexual function and the genital selfimage
40926916|NCT06066229|OTHER|Questionnaire- Delphi method|Identify important evaluation criteria for lung transplant patients by rating each criterion
40926917|NCT00819793|DEVICE|CentriMag Ventricular Assist System|All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
40926918|NCT03505931|DEVICE|Implantation of Eluvia stent|Implantation of Eluvia stent
40926919|NCT02248675|BEHAVIORAL|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
41274850|NCT03499509|OTHER|Low Glycemic Diet|"Low Glycemic (LG) diet: The LG diet will be made up of foods that do not stimulate insulin secretion. The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., High-Protein SlimFast). Dinner will be a frozen entrée (e.g., Atkins, Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be nuts, berries, and full-fat dairy products (one serving per day), and will be used to adjust the calorie level of each day's meals to individual calorie needs."
41287218|NCT04149522|DEVICE|Mepitel Film®|As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.
40926920|NCT02248675|OTHER|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
40926921|NCT01673152|DIETARY_SUPPLEMENT|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
41123301|NCT00919594|BEHAVIORAL|Interpersonal Psychotherapy for Mothers (IPT-MOMS)|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
41123302|NCT00919594|BEHAVIORAL|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
41123303|NCT03352024|OTHER|Relational care|Relational care is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
41123304|NCT03352024|OTHER|Hypno-analgesia|Hypno-analgesia is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
40754292|NCT04889911|OTHER|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
41123305|NCT02333513|DRUG|Lomustine/Vincristine/Procarbazine|
41123306|NCT03000842|DEVICE|transcutaneous vagal nerve stimulation on|electrical current on positioned in the ear to estimate vagal branch of auricular nerve
40926922|NCT01673152|DIETARY_SUPPLEMENT|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
40926923|NCT02183753|OTHER|wood smoke|
40926924|NCT02183753|OTHER|clean air|
40926925|NCT02890615|BEHAVIORAL|Depression self-care|Toolkit and coaching
40926926|NCT05214079|DEVICE|Left paratracheal pressure|Applying Left Paratracheal pressure and testing its effectiveness using gastric tube . in addition , by using the dynamometer , the CP 50 is defined.
40926927|NCT05117918|OTHER|SUFU Clinical Care Pathway for Overactive Bladder|Treatment of OAB via the SUFU clinical care pathway
40926928|NCT05117918|OTHER|Telemedicine|Delivery of care via telemedicine
40926929|NCT05577520|PROCEDURE|Sinus floor augmentation|
40926930|NCT01765478|DRUG|HM71224 single ascending dose|
40926931|NCT01765478|DRUG|HM71224 food effect|
40926932|NCT01765478|DRUG|HM71224 Multiple ascending dose|
40926933|NCT00002805|BIOLOGICAL|filgrastim|
40926934|NCT00002805|DRUG|cladribine|
40926935|NCT00002805|DRUG|cytarabine|
40926936|NCT00002805|DRUG|etoposide|
40926937|NCT00002805|DRUG|methotrexate|
40926938|NCT00002805|DRUG|mitoxantrone hydrochloride|
40926939|NCT00002805|DRUG|therapeutic hydrocortisone|
41123307|NCT03000842|DEVICE|transcutaneous vagal nerve stimulation off|an electrical current off positioned in the ear to estimate vagal branch of auricular nerve
41274851|NCT03499509|OTHER|High Glycemic Diet|"High Glycemic (HG) diet: The HG diet will conform to United States Department of Agriculture (USDA) guidelines (http://health.gov/dietaryguidelines/2015/guidelines/). The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., SlimFast). Dinner will be a frozen entrée (e.g., Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be fruit, fat-free dairy products, and low-fat bars (e.g., Optifast), and will be used to adjust the calorie level of each day's meals to individual calorie needs."
40926940|NCT00002805|PROCEDURE|allogeneic bone marrow transplantation|
40926941|NCT00002805|PROCEDURE|autologous bone marrow transplantation|
40926942|NCT00002805|PROCEDURE|peripheral blood stem cell transplantation|
40926943|NCT00002805|RADIATION|low-LET cobalt-60 gamma ray therapy|
41123308|NCT06431347|BEHAVIORAL|Social Determinants of Health Questionnaire|Participants will also complete a questionnaire about financial barriers to care within the past year, including income bracket and difficulty affording cost-of-living or medical expenses.
41123309|NCT03501264|BEHAVIORAL|Online Game|LGBTQ Bullying game
41123310|NCT03501264|BEHAVIORAL|LGBTQ Resources|This group receives LGBTQ Resources
40926944|NCT00002805|RADIATION|low-LET electron therapy|
40926945|NCT00002805|RADIATION|low-LET photon therapy|
40926946|NCT05930366|PROCEDURE|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
40926947|NCT05930366|PROCEDURE|Gingival Depigmentation using Diode Laser|GINGIVAL DEPIGMENTAION USING DIODE LASER
40926948|NCT04156542|BEHAVIORAL|Basic School Lunchroom Nudges|"The intervention consists of three components: 1) serving fresh fruit in attractive bowls in at least two locations on the lunch line; 2) providing descriptive names for the vegetables; and 3) increasing amount of plain milk availability by 10% and placing it in front of the chocolate milk. For the vegetable naming intervention, researchers first developed, printed, and laminated descriptive vegetable name cards (2x4). Some examples included Savory Collard Greens, and \[School Mascot\] Salad. Cafeteria staff affixed name cards to the serving line sneeze-guards in front of the vegetables for the day. For the fruit intervention, we purchased and delivered two ceramic bowls to the intervention school. The cafeteria staff filled the bowls and put them in different locations on the lunch line. For the milk intervention, cafeteria staff increased the amount of plain milk available by 10% and placed plain in front of chocolate milk in the coolers."
40926949|NCT05441878|DRUG|20% albumin|Albumin arm for resuscitation fluid
40926950|NCT05441878|DRUG|Balanced salt solution|Only Balanced salt solution will be used.
40926951|NCT04612296|GENETIC|Research genetic analysis|Genetic analysis of DNA extracted from saliva. Participants can opt in to receive individual results of research genetic analysis for a predefined panel of clinically actionable cardiomyopathy genes.
40926952|NCT03509415|DIAGNOSTIC_TEST|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
41123311|NCT02730923|DRUG|AZD2014|"Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone~Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.~Route of Administration Oral~Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))~Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
41123312|NCT02730923|DRUG|Anastrozole|"Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
41123313|NCT00394407|DRUG|sliding scale regular insulin|SSRI acqhs
41123314|NCT00394407|DRUG|glargine basal insulin and glulisine prandial insulin|glargine insulin once a day and glulisine insulin three times a day as long as patient eating
40926953|NCT03446144|DRUG|IONIS-FB-Lrx|Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70
40926954|NCT03446144|DRUG|Placebo (sterline saline 0.9%)|Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
40926955|NCT02369601|OTHER|non- intervention study|Study design is non-interventional. Patient therapy will not be affected by study participation.
40926956|NCT05532423|DRUG|Beetroot Juice - Active|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This juice will be the active juice, meaning it has the high nitrate content that is of interest. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
40926957|NCT05532423|DRUG|beetroot juice - Placebo|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This drink will be the placebo drink, which means all of the nitrate has been extracted, however it tastes and smells the same as the active drink. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
40926958|NCT03016143|BIOLOGICAL|Allantoic Split Inactivated Seasonal flu Vaccine|Allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/ Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).
40926959|NCT03016143|BIOLOGICAL|VAXIGRIP|Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine. Sanofi Pasteur Serial Number N3E681V
40926960|NCT05694143|OTHER|Education Intervention|"This intervention is based on the Health Belief Model Theory, which examines the attitudes and beliefs of adolescents with enhanced knowledge and perceived disease risk. As a result, It aims to build on adolescents' skills and behaviours rather than increase their knowledge, beliefs, and relative skills. In order to develop the education program, health promotion experts with a special interest in changing obesity-related behaviours will assist the researcher.~The intervention is specifically designed to help adolescents:~* To know facts, statistics and harmful effects of obesity and overweight.~* To know facts about physical activity and its importance.~* To know facts about a healthy diet and its importance.~* Definition of BMI and calculating the BMI.~* To read the Nutrition Facts label.~* To develop decision-making and self-care education."
40926961|NCT05694143|OTHER|No Intervention|They will have their regular curriculums and normal physical activity routine
40926962|NCT00998764|DRUG|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
40926963|NCT04501562|OTHER|Examinations|Participants will undergo focused examinations that include measurement of height, weight, waist circumference, body composition analysis, baseline data collection and blood pressure examinations. Resting electrocardiography will be performed to ascertain sinus rhythm.
40926964|NCT04501562|OTHER|Cardiovascular Tests|Specific quantitative cardiac ageing-related outcome parameters will be examined by multimodal techniques including two-dimensional transthoracic echocardiogram, and/or non-contrast magnetic resonance imaging/magnetic resonance spectroscopy.
40926965|NCT04501562|OTHER|Bio-specimen collection|Bio-specimens collected will include fresh blood, urine and/or stool specimens.
40926966|NCT04501562|OTHER|Clinical/health outcome collection|Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.
40926967|NCT04360655|PROCEDURE|bronchoscopic microwave intervention|bronchoscopic microwave intervention
40926968|NCT04360655|DRUG|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
40926969|NCT00521300|DRUG|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
40926970|NCT00521300|PROCEDURE|Direct surgery for acromegaly|Direct transsphenoidal surgery
40926971|NCT02844686|OTHER|Cardiac SPECT|3-D dynamic acquisition of cardiac SPECT at rest and after pharmacological stress
40926972|NCT03963739|OTHER|Interview|Undergo interview
41123315|NCT02596490|BEHAVIORAL|Questionnaires|"Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention."
41123316|NCT02596490|BEHAVIORAL|Meditation and Discussion Sessions|"Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
41123317|NCT02596490|BEHAVIORAL|Cancer-Related Discussion Program|Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
41274852|NCT05643664|PROCEDURE|prosthetics of the abdominal aorta|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology.
41274853|NCT05643664|PROCEDURE|prosthetics of the abdominal aorta after determining the safe zones of clamping|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology. Before surgery, multispiral computed tomography data is evaluated using artificial intelligence and safe zones of aortic and arterial clampings are determined. Intraoperatively, clamping is performed in the settlement zones.
41274854|NCT05653895|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol
40926973|NCT03963739|OTHER|Questionnaire Administration|Ancillary studies
40926974|NCT01629199|DRUG|rhEGF(recombinant human Epidermal Growth Factor)|
40926975|NCT01629199|DRUG|placebo of rhEGF(recombinant human Epidermal Growth Factor)|
40926976|NCT00184769|DRUG|somatropin|
40926977|NCT03339297|DRUG|Defibrotide|6.25 mg/kg via 2-hour IV infusion every 6 hours
40926978|NCT03339297|DRUG|Standard of Care|Administered according to local institutional guidelines, physician preference, and patient need.
41123318|NCT01203995|BEHAVIORAL|Nutrition information|Brief nutrition education with take home reference materials and portion size tools
40926979|NCT00177047|PROCEDURE|Stem Cell Transplant|As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
40926980|NCT00177047|DRUG|Cyclophosphamide + Mesna|Cyclophosphamide: 4mg/m\^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
40926981|NCT00177047|DRUG|Melphalan|Administered intravenously 200 mg/m\^2
40926982|NCT00177047|BIOLOGICAL|Granulocyte-colony stimulating factor|Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
40926983|NCT04097743|BEHAVIORAL|Coping Statement|Daily practice of coping statement
40926984|NCT04176042|BEHAVIORAL|Track 1|Intervention + Follow-up
40926985|NCT04176042|BEHAVIORAL|Track 2|Wait list + Intervention
40926986|NCT01937104|DRUG|Desflurane|"Anesthesia with desflurane in both Group 1 and Group 2~- adjust MAC to maintain BIS between 40-60"
40926987|NCT01937104|DRUG|Remifentanil|"Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%"
40926988|NCT01937104|DEVICE|Ultrasonographic measurement of ONSD|Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area (4 cm deep) using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by averaging 4 measured values.
40926989|NCT01937104|PROCEDURE|Mechanical ventilation|After tracheal intubation, the lungs of the patients were then ventilated with oxygen in air (1:2) using a tidal volume of 8-10 mL/kg and a respiratory rate of 10-12/min, and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
40926990|NCT01937104|PROCEDURE|Trendelenburg position - 30 degree|Trendelenburg position - 30 degree
40926991|NCT01937104|PROCEDURE|Reverse Trendelenburg position - 30 degree|Reverse Trendelenburg position - 30 degree
40926992|NCT04049682|BEHAVIORAL|Delayed School Start Time|Francis Parker High School implemented 45-minute later school start time.
40926993|NCT02178839|DIETARY_SUPPLEMENT|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
41123319|NCT01203995|BEHAVIORAL|Nutrition education and exercise training|Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
41123320|NCT05871112|OTHER|Use of dynamic tensioner|Assessment of femoral component rotation with a use of a dynamic tensioner in extension and 90 degrees of flexion. The tensioner was put between tibial plane cut and posterior condyles of the femur and tensioned to the same thickness of insert as in the full extension
41123321|NCT04328155|PROCEDURE|Hotpack Group|Hotpack Group received 20 minutes hotpack to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
41123322|NCT04328155|PROCEDURE|Infrared Group|Infrared Group received 20 minutes infrared to hamstring muscles region at prone position and participants stretchted the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15. seconds .
41123323|NCT04328155|PROCEDURE|Ultrasound Group|Ultrasound Group received 5 minutes 1 M-Hz, 1,5 watt/cm2 ultrasound therapy to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
40926994|NCT02178839|DIETARY_SUPPLEMENT|Maltodextrin|8.5 g/d Maltodextrin
40926995|NCT01743001|DRUG|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
40926996|NCT01743001|DRUG|Placebo|Macitentan-matching placebo oral tablet once daily
40926997|NCT04411381|OTHER|Telemedicine|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
41123324|NCT04328155|PROCEDURE|Control|Control Group participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
41274855|NCT05653895|DRUG|Metformin|Metformin
40926998|NCT03458598|PROCEDURE|Rectus sheath block|Rectus sheath block under ultrasound
40926999|NCT03458598|PROCEDURE|Bilateral rectus sheath catheter|A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.
40927000|NCT03458598|DRUG|Patient controlled opioid analgesia (PCA)|Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
40927001|NCT03458598|PROCEDURE|Subcutaneous injection saline placebo|Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed
41123325|NCT01733862|OTHER|Data collection|"Data sheet. Data will be collected and is planned to be analysed at the following time points:~Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016."
41123326|NCT02213744|DRUG|MM-302|
41123327|NCT02213744|DRUG|Gemcitabine|
41123328|NCT02213744|DRUG|Capecitabine|
41123329|NCT02213744|DRUG|Vinorelbine|
41123330|NCT02213744|DRUG|Trastuzumab|
41123331|NCT03890848|BEHAVIORAL|Wechat application reminder intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
41123332|NCT03890848|BEHAVIORAL|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
41123333|NCT00779870|OTHER|bronchoscopy|bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
41123334|NCT03855007|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
41123335|NCT03855007|DRUG|MTX|MTX，7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.
41123336|NCT03855007|DRUG|HCQ|HCQ，200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
41123337|NCT03855007|DRUG|Pred|Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
41123338|NCT03122158|DRUG|Escitalopram|Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
41123339|NCT04408872|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|EGD: ENDOSCOPIC PROCEDURE DURING WHICH THE ESOPHAGUS, STOMACH AND DUODENUM ARE VISUALISED WITH A TINY CAMERA IMPLANTED AT THE END OF AN ENDOSCOPE.
41123340|NCT04408872|DIAGNOSTIC_TEST|Endoscopic ultrasound (EUS)|EUS: SAME AS EGD, BUT IN ADDITION HAS AN INTEGRATED ULTRASOUND PROBE WHICH ALLOWS TO EXAMINE THE PANCREAS, LIVER AND BILIARY SYSTEM.
41123341|NCT01643616|DRUG|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
41123342|NCT01643616|DRUG|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
41123343|NCT01643616|DRUG|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
41123344|NCT01643616|DRUG|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
41123345|NCT01643616|DEVICE|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
41123346|NCT01643616|DEVICE|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
41123347|NCT06024824|RADIATION|Dose-Painted Intensity Modulated Radiotherapy|"Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT.~Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose. Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.~Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions."
41123348|NCT01725464|DEVICE|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
41123349|NCT00094822|OTHER|PI Discretion|PI Discretion
41123350|NCT05901896|OTHER|there are no intervention|no intervention
41123351|NCT00320762|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
40927002|NCT01962168|DEVICE|Evolution® Biliary Stent - Uncovered|Commercially available device
41123352|NCT02463448|BIOLOGICAL|Autologous Muscle Derived Cells|A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the sample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
41123353|NCT03372070|DEVICE|cNEP|soft silicon collar applied to anterior neck with negative pressure
41123354|NCT02200094|DRUG|Low dose of Telmisartan, once daily|
41123355|NCT02200094|DRUG|High dose of Telmisartan, once daily|
40927003|NCT02984943|DEVICE|Hyperbaric Oxygen|30 treatments of Hyperbaric Oxygen.
40927004|NCT01904773|DRUG|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
40927005|NCT01701518|DRUG|Ozurdex|biodegradable 0.7mg dexamethasone implant
41123356|NCT06013137|OTHER|Therabot|The participants assigned to the experimental group will interact with an artificial intelligence therapy chatbot to alleviate symptoms associated with depression, anxiety, and eating disorders. The control group will not have access to this smartphone chatbot app.
41123357|NCT04672967|DIAGNOSTIC_TEST|BioROSA MAP test|The BioROSA MAP test is a blood test that is being developed to predict ASD risk
41123358|NCT05028660|DIAGNOSTIC_TEST|GAG score|blood and urine samples to determine GAG scores
41123359|NCT03797924|DRUG|Receive ICBN with ropivacaine|ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
41123360|NCT03797924|BEHAVIORAL|No ICBN block|The site of injection will be prepped with tinted chlorhexidine
41123361|NCT01437605|DRUG|MAGE-A3 ASCI injections without Poly IC:LC|MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
41123362|NCT01437605|DRUG|MAGE-A3 ASCI injections with Poly IC:LC|MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
41274856|NCT05653895|COMBINATION_PRODUCT|Acetyl-L-Carnitin, L Arginine, Co-Q10|Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10
41274857|NCT00785577|DRUG|Placebo|"LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks"
41274858|NCT00785577|DRUG|Pregabalin|"Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
40927006|NCT00984620|DRUG|BI 201335|BI 201335
41123363|NCT04498234|PROCEDURE|ultrasound guided erector spinae plane block with bupivacaine 0.25% And ultrasound guided Paraveretebral block with bupivacaine 0.25 %|One groupvwill receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4 and the other group willreceive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
41123364|NCT04702256|DRUG|Obinutuzumab administration|"Obinutuzumab administration by intravenous infusion (IV), IV of methylprednisolone, oral mycophenolate mofetil, no prednisone (or if required for extrarenal manifestation(s): less than 10mg/day at any time, less than 7.5mg/day after 6 months and less than 5mg/day after 9 months).~Hydroxychloroquine will be strongly recommended for all the patients."
41123365|NCT04702256|DRUG|Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil|"IV of methylprednisolone, oral prednisone (according to the PNDS), and oral mycophenolate mofetil.~Hydroxychloroquine will be strongly recommended for all the patients."
41123366|NCT04702256|DRUG|Administration of methylprednisolone, paracetamol and dexchlorpheniramine|Prior to infusion of obinutuzumab, patients receiving obinutuzumab will receive premedication including 100 mg of methylprednisolone, paracetamol and dexchlorpheniramine.
41123367|NCT03310866|DEVICE|fiberoptic, airway|classic fiberoptic bronchoscope, fenstrated airway
41123368|NCT03310866|DEVICE|fiberoptic, Machintosh|oral fiberoptic brochoscopic, Machintosh laryngoscope
41123369|NCT02487069|PROCEDURE|HSCT from MSD|HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
41123370|NCT02487069|PROCEDURE|HSCT from MUD|HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
41123371|NCT02487069|PROCEDURE|HSCT from HRD|HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
41123372|NCT02487069|DRUG|Cyclosporin A|CsA is used in all the patients for GVHD prophylaxis.
41123373|NCT02487069|DRUG|Methotrexate|MTX is used in all the patients for GVHD prophylaxis.
41123374|NCT02487069|DRUG|Antithymocyte globulin|ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
41123375|NCT02487069|DRUG|Mycophenolate mofetil|MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
41123376|NCT02454283|DRUG|Vanoxerine HCl|
41123377|NCT02454283|DRUG|Placebo|
41274859|NCT00785577|DRUG|LY545694 21 mg|"LY545694 21 mg BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
41274860|NCT00785577|DRUG|LY545694 49 mg|"LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks."
41274861|NCT00785577|DRUG|LY545694 105 mg|"LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks"
41274862|NCT05988814|DRUG|FOLFIRINOX treatment|"Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression"
41274863|NCT00341328|BIOLOGICAL|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
40927007|NCT00984620|DRUG|BI 201335|BI 201335
41123378|NCT01319617|DEVICE|SENSIMED Triggerfish|Soft contact lens-based device intended for continuous recording of relative changes in IOP
41123379|NCT02376530|BEHAVIORAL|Nutrient profiling|Nutrient profiling system will be present during shopping session.
41123380|NCT02376530|BEHAVIORAL|Price Changes|Price changes will be present during shopping session.
41123381|NCT00432016|DRUG|zidovudine|
41123382|NCT00432016|DRUG|amdoxovir|
41123383|NCT00432016|PROCEDURE|pharmacokinetic sampling|
41123384|NCT00822367|DIETARY_SUPPLEMENT|Glucerna; Ensure; SlimFast|Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
41123385|NCT02389855|PROCEDURE|NeuroBlate® System Therapy|
41123386|NCT01598870|OTHER|Diagnostic tests|Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
41274864|NCT00278525|DRUG|standard of care|standard of care medication will be given
41274865|NCT00278525|PROCEDURE|stem cell transplantation|The following is intervention: stem cell transplantation after conditioning regimen
41274866|NCT02267486|OTHER|Standard therapy of Alzheimer Dementia (AD)|
41274867|NCT02267486|OTHER|Observation|
41274868|NCT04341779|COMBINATION_PRODUCT|Point-of-care viral load testing and tenofovir adherence testing|Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants
41274869|NCT00420030|DRUG|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
41274870|NCT03561727|PROCEDURE|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
41287219|NCT03841877|PROCEDURE|endodontic treatment|The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.
41123387|NCT06517459|BEHAVIORAL|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting,4 and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems.
41123388|NCT02275611|DRUG|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
41123389|NCT02275611|DRUG|Intranasal Placebo Spray|Intranasal Placebo Spray
41123390|NCT06324630|OTHER|Produce Prescription Delivery|Fruit and vegetable box delivery
41123391|NCT06324630|OTHER|Healthy Meal Kit Delivery|Ingredients to cook healthy meals delivered to home
41123392|NCT06324630|OTHER|Produce Prescription Mobile Market|Voucher to purchase fruits and vegetables at a mobile market
41123393|NCT04044651|DRUG|Lenvatinib|lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
41123394|NCT04044651|DRUG|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
41123395|NCT01905462|OTHER|Data Collection|Analyses of data collected within the CPRD GOLD database.
41123396|NCT01905462|BIOLOGICAL|Cervarix|Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
41123397|NCT03463460|OTHER|Laboratory Biomarker Analysis|Correlative studies
41123398|NCT03463460|BIOLOGICAL|Pembrolizumab|Given IV
41123399|NCT03463460|DRUG|Sunitinib Malate|Given PO
41123400|NCT05673434|BIOLOGICAL|TM4SF1-positive chimeric antigen receptor T-cell therapy|"Specification: 50mL/bag. Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 10-20 min."
41123401|NCT02498717|DEVICE|GameReady|Cryotherapy and compression
41123402|NCT02498717|OTHER|RICE|SOC ice and elevation
41123403|NCT03021369|DEVICE|Pleural drainage system|Pleural drainage system is connected to the chest tubes after surgery.
41123404|NCT04502472|BIOLOGICAL|Convalescent plasma transfusion|Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.
41123405|NCT04033107|DRUG|Vitamin C|Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.
41123406|NCT04033107|DRUG|Metformin|Participants will orally take metformin 4g daily.
41123407|NCT03632616|OTHER|PANQOLI (quality of life instrument)|A quality of life instrument, the PANQOLI, will be administered prior to endoscopic intervention, and at 1,3, 6 and 12 months post-intervention.
41123408|NCT01522573|PROCEDURE|EUS guided ERCP|Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
41123409|NCT00103324|DRUG|lapatinib ditosylate|Given orally
41123410|NCT00103324|OTHER|laboratory biomarker analysis|Correlative studies
41123411|NCT03933371|DEVICE|Colon Capsule Endoscopy|The capsule endoscopy will be ingested by the participant. This device captures images along the large bowel. This images are stored in an external memory and afterwards they are downloaded in a computer
40754293|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
41123412|NCT05035004|DEVICE|Post exercise hot water immersion|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max), followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
41123413|NCT05035004|DEVICE|Exercise|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max).
41123414|NCT05035004|DEVICE|Hot water immersion|Participants will complete 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C), followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
41123415|NCT03917303|DRUG|Adalimumab|episodic treatment with subcutaneous adalimumab for 6 months
41123416|NCT03917303|DRUG|standard step-up care|conventional step-up care starting with corticosteroids
41123417|NCT01074567|DRUG|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
41123418|NCT04131153|PROCEDURE|"three-step radiofrequency ablation"|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
40927008|NCT00984620|DRUG|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha
40927009|NCT00984620|DRUG|Ribavirin (RBV)|Ribavirin (RBV)
40927010|NCT00227071|BEHAVIORAL|exercise|
40927011|NCT05171452|BIOLOGICAL|Urine and stoll samples|Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)
40927012|NCT06112873|OTHER|Quality of Life Questionnaire|Patient (or Parent)-Reported Outcomes via specific questionnaires
40927013|NCT04140123|DRUG|ZSP1601|ZSP1601 tablets be taken orally for 28 days.
41123419|NCT04131153|PROCEDURE|radiofrequency ablation|Conventional radiofrequency ablation
41123420|NCT00937131|DRUG|Rituximab|Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
41123421|NCT00972075|DRUG|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
41123422|NCT00972075|DRUG|placebo|one tablet per day 2 hours before going to bed
41123423|NCT00991107|DRUG|HE3286|HE3286 20 mg (10 mg BID) for 28 days
41123424|NCT05035446|PROCEDURE|single-incision plus one-port laparoscopic surgery|The investigators use the technique of adding one operation hole on the basis of single-port laparoscopy in some patients.
41123425|NCT05035446|PROCEDURE|conventional laparoscopic surgery|It usually requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy.
41123426|NCT02411084|BIOLOGICAL|Begelomab|BEGEDINA® (Begelomab) is a murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4) and is produced by biotechnological means.
41123427|NCT02411084|BIOLOGICAL|Conventional Second-line Treatment|"There are no approved second-line treatments for aGvHD and due to the life-threatening nature of the disease it was agreed with the FDA and EMA that BEGEDINA® would be compared with best conventional second-line treatments which will be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center and which may vary between centers. Treatments are generally biological products and could include anti-thymocyte globulin, monoclonal antibodies, such as anti-CD147, basiliximab, daclizumab and alemtuzumab; mycophenolate mofetil; anti-TNF-alpha; pentostatin; dinileukin diftitox; N-acetyl-cysteine; sirolimus; and visulizumab."
41123428|NCT05862246|OTHER|Clinical examination|No intervention, only clinical examination
41123429|NCT06009094|DRUG|VC005|VC005 group with Local topical application
41123430|NCT06009094|DRUG|VC005 Placebo|VC005 Placebo group with Local topical application
40927014|NCT04140123|DRUG|ZSP1601 Placebo|Subjects will receive matching placebo of ZSP1601
40927015|NCT02642588|DIETARY_SUPPLEMENT|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
40927016|NCT02826720|OTHER|No intervention was applied|No intervention was applied
40927017|NCT05850494|DRUG|HFA MDI|"* Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
41123431|NCT00871130|PROCEDURE|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
41123432|NCT00067496|DRUG|Modafinil|
41123433|NCT04955431|BEHAVIORAL|Sleep Restriction|Participants will be allowed \~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.
41123434|NCT04955431|BEHAVIORAL|Normal Sleep|Participants will be allowed \~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
41123435|NCT00308997|DEVICE|1-hertz Repetitive Transcranial Magnetic Stimulation|Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
41123436|NCT00308997|DEVICE|Active 1-Hertz Repetitive transcranial magnetic stimulation|Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
41123437|NCT03429972|DEVICE|Elasto-Gel™|Elasto-Gel™ hypothermia mitts and slippers contain glycerine, which has thermal properties, allowing use for cold therapies.
41123438|NCT03429972|DRUG|Paclitaxel|80mg/m\^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
41123439|NCT00036244|DRUG|RG1068 (Synthetic Human Secretin)|
41123440|NCT05402813|OTHER|Pure Tone Audiometry Assessment|Collection of Pure Tone Audiometry data performed in routine practice during study period
41123441|NCT05402813|OTHER|Quality of Life Questionnaires|Collection of Quality of Life questionnaire's answers during study period
41274871|NCT03561727|PROCEDURE|Layered closure technique|he first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia closed with 2 continuous sutures beginning at both ends of the wound. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer of the continuous suture will start at the lateral border of rectus abdominis muscle, process laterally to the lateral end of the wound involving internal oblique abdominal muscle fascia. Subsequently, the suture will be led out on the anterior surface of the external oblique abdominal muscle, put through by the created loop in the medial direction and processed medially to close the external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
41274872|NCT04917783|BEHAVIORAL|Passport Card|"After receiving neurocognitive testing, caregivers in the health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations along with their written report. Then, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback passport card and evaluation report."
41274873|NCT04917783|BEHAVIORAL|No Passport card|After receiving neurocognitive testing and verbal feedback from the psychologist, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback and evaluation report, but not the passport card.
41274874|NCT04604925|BEHAVIORAL|Remote patient monitoring for hypertension|Intervention involves practices making available remote physiologic monitoring treatment management services allowable under Medicare for blood pressure (and weight if desired) to Medicare patients in the practice when ordered by the patient's clinician.
41274875|NCT03669978|PROCEDURE|Creation of a bone and arterial panorama using EndoNaut® software.|"The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software."
41274876|NCT05551130|OTHER|Restoration|Restorations completed with these materials.
41274877|NCT01901887|DRUG|Study Juice|The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
41274878|NCT01901887|DRUG|Placebo Juice|The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
41274879|NCT05300048|DRUG|Serabelisib|serabelisib administered orally
41274880|NCT05300048|OTHER|Insulin Suppressing Diet|3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
41274881|NCT05300048|DRUG|Nab paclitaxel|nab-paclitaxel administered intravenously weekly
41274882|NCT03845530|DIAGNOSTIC_TEST|Blood Test|Blood test taken and sent for laboratory analysis
41274883|NCT06147024|OTHER|historical control|Received a conventional preoperative assessment
41274884|NCT06147024|OTHER|3D printed lesion model|Received 3D printed lesion models for preoperative planning
41274885|NCT01543321|DRUG|Tetrabenazine|"Treatment with tetrabenazine consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"
41274886|NCT01543321|DRUG|Placebo|"Treatment with placebo consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"
40754294|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
40927018|NCT05850494|DRUG|HFO MDI|"* Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
40927019|NCT01701752|BIOLOGICAL|FP-01.1 + Placebo|
40927020|NCT01701752|BIOLOGICAL|FP-01.1 + TIV|
40927021|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant + Placebo|
40927022|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant + TIV|
40927023|NCT01701752|BIOLOGICAL|Adjuvant + TIV|
40927024|NCT01701752|BIOLOGICAL|Placebo + TIV|
40927025|NCT01701752|BIOLOGICAL|FP-01.1|
40927026|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant|
40927027|NCT01701752|OTHER|Placebo|
40927028|NCT01722695|OTHER|Dialyzer comparison|"Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).~The order of dialyzers used will be randomly assigned to the patient at randomization."
40927029|NCT02983097|DRUG|Rituximab|Rituximab 375 mg/m²
40927030|NCT02983097|DRUG|Cisplatin|Cisplatinum 100 mg / m²
40927031|NCT02983097|DRUG|Carboplatin|Carboplatinum AUC5
40927032|NCT02983097|DRUG|Dexamethasone|Dexamethasone 40 mg
40927033|NCT02983097|DRUG|Cytarabine|Cytarabine 2000 mg/m², administered twice
40927034|NCT02983097|DRUG|Lenalidomide|5-20 mg administered either d1-d7, or d-6-d7
40927035|NCT02983097|DRUG|PegFilgrastim|PegFilgrastim 6 mg
40927036|NCT02983097|PROCEDURE|peripheral stem cell collection|collection of peripheral stem cells for autologous stem cell transplantation
40927037|NCT05202938|DIAGNOSTIC_TEST|ultrasound cardiography|Ultrasound to check heart functions and systolic ejection fraction.
40927038|NCT05202938|DIAGNOSTIC_TEST|FDG PET scan|FDG venous injection and positron emission tomography scan.
41274887|NCT01495988|DRUG|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
41274888|NCT01495988|DRUG|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
41274889|NCT01495988|DRUG|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
41123442|NCT02944760|OTHER|Low-Level Light Therapy|The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
41274890|NCT01552876|DEVICE|etafilcon A|A daily wear contact lens
41123443|NCT00988858|DRUG|LY2603618|150 milligram per square meter (mg/m\^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
41123444|NCT00988858|DRUG|Pemetrexed|500 mg/m\^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
41123445|NCT03017625|OTHER|Blood is drawn|Blood analyses
41274891|NCT01552876|DEVICE|nelfilcon A|A daily wear contact lens
41274892|NCT01552876|DEVICE|Filcon II 3|a daily disposable
41274893|NCT00745108|DRUG|tibolone|oral 1.25 mg tablet, once daily, for 2 years
41274894|NCT00745108|DRUG|Tibolone 2.5 mg|oral 2.5 mg tablet, once daily, for 2 years
41274895|NCT00745108|DRUG|CE/MPA|oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
41274896|NCT01083108|OTHER|Roux-en-Y Gastric Bypass|The surgical group will be studied before and 6 days after bariatric surgery.
41274897|NCT01083108|OTHER|Caloric Restriction|The non-surgical group will be studied before and after receiving a hypocaloric diet for 6 days mimicking the typical postoperative diet.
41274898|NCT00754156|DEVICE|ABRA Abdominal Closure System|ABRA Abdominal Closure System
40754295|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
40927039|NCT05202938|DIAGNOSTIC_TEST|Palmitate PET scan|C11-Palmitate venous injection and positron emission tomography scan.
41274899|NCT00754156|DEVICE|V.A.C. Therapy|V.A.C. Therapy Alone
40927040|NCT05202938|DIAGNOSTIC_TEST|Acetate PET scan|C11-Acetate venous injection and positron emission tomography scan.
41123446|NCT01522924|OTHER|Counseling practice sessions|Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
41123447|NCT00764335|PROCEDURE|total hip arthroplasty one side|unilateral total hip arthroplasty
41123448|NCT00764335|PROCEDURE|total hip arthroplasty both sides|bilateral total hip arthroplasty
41123449|NCT02729506|PROCEDURE|Transarterial Radioembolization|Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
41274900|NCT00754156|DEVICE|KCI ABThera|KCI ABThera
41274901|NCT03960528|PROCEDURE|Erector spinae plane block|Bilateral 20 ml Bupivacaine 0.25% + lidocaine 1% injected between erector spinae muscles and transverse process under direct vision.
41274902|NCT03960528|PROCEDURE|Control group|20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
41274903|NCT01276821|DRUG|L-Epinephrine and Normal Saline (0.9%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
41274904|NCT01276821|DRUG|L-Epinephrine and Hypertonic Saline (3%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
41274905|NCT04636905|OTHER|Questionnaires|Participants will be asked to complete a series of questionnaires assessing quality of life and other general health outcomes
41274906|NCT05658757|OTHER|Regular sweetened commercial foods|"This is your usual habits period. Consume the chosen, sweetened commercial products of your choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat the regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as your usual habits if more often.~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume these regular sweetened beverages as you usually do."
41287220|NCT01563510|PROCEDURE|Laparoscopic operation|Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
40927041|NCT05202938|DIAGNOSTIC_TEST|Blood sampling|Collecting 20ml of venous blood.
40927042|NCT01341392|DRUG|CKD-501|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
40927043|NCT01341392|DRUG|amlodiopine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
40927044|NCT01341392|DRUG|CKD-501 amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
40927045|NCT06243523|BEHAVIORAL|The stress management psychoeducation program based on Neuman's Systems Model|The stress management psychoeducation program will be implemented in six sessions with individual interviews lasting approximately 45-60 minutes, three times a week for the spouses of patients in intensive care. The first session includes the meeting and introduction of the psychoeducation program. The second session includes the adaptation process to the intensive care unit. The third, fourth and fifth sessions include methods of coping with stress. The sixth session includes evaluation and termination of the psychoeducational program. Quantitative data of the research will be collected with the pre-action and post-action Psychological Distress Scale and the Stress Coping Styles Scale. Qualitative data of the research will be collected through semi-structured individual in-depth interviews conducted after the action.
40927046|NCT02034136|DIETARY_SUPPLEMENT|Ginsenoside|3.0 g/ d for 28 days
40927047|NCT02034136|DIETARY_SUPPLEMENT|Dietary fiber fill|3g/day, 28days
40927048|NCT04523727|DRUG|ferric citrate|oral tablets
40927049|NCT04426760|PROCEDURE|Transcervical resection of fibroids|Transcervical resection of fibroids
40927050|NCT04426760|PROCEDURE|Myomectomy per laparoscopy or laparotomy|Myomectomy per laparoscopy or laparotomy
40927051|NCT06090292|DEVICE|Real TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz).
40927052|NCT06090292|DEVICE|Real FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left hand opponens pollicis, first lumbrical and first dorsal interosseous muscles. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
40927053|NCT06090292|DEVICE|Sham TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz) however the ultrasound head will be flipped so that the active side faces away from the scalp.
41287221|NCT01563510|PROCEDURE|Open operation|Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
40927054|NCT06090292|DEVICE|Sham FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left biceps and long finger flexors. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
40927055|NCT01122264|DRUG|Tadalafil|Administered orally for 24 weeks.
40927056|NCT01122264|DRUG|Sildenafil Citrate|Administered orally for 24 weeks.
40927057|NCT02916121|DIETARY_SUPPLEMENT|folic acid 5 mg/cap|the intervention includes folic acid 5 mg/d and vitamin B12 500 ug/d
40927058|NCT02916121|OTHER|Placebo|placebo
40927059|NCT00718237|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)|Rotateq orally administered 3 times
40927060|NCT00718237|BIOLOGICAL|Comparator: Comparator: Placebo (unspecified)|Placebo orally administered 3 times
41287222|NCT01987544|OTHER|Ergometer Training|
41287223|NCT01987544|OTHER|Motivation|
41287224|NCT00793923|DRUG|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
41287225|NCT00793923|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
41123450|NCT02729506|PROCEDURE|Transarterial Chemoembolization using drug-eluting beads|"TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device."
41274907|NCT05658757|OTHER|Allulose sweetened commercial foods|"This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~* If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~* If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits."
41123451|NCT00065832|BEHAVIORAL|Reading Instruction|
41274908|NCT05658757|OTHER|Whole and minimally processed and sweetened foods|"Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast product in place of your usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as your usual habits if more often~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that you usually do.~This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines."
41123452|NCT01007396|OTHER|1-step tuberculin skin test (TST) and blood sampling|In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
41123453|NCT05609734|OTHER|no intervention, only observational retrospective study|no intervention, only observational retrospective study
41123454|NCT06450496|BEHAVIORAL|Positive parenting on-line program|Positive parenting on-line program focused on parenting and personal competences relevant for parents with adolescents exhibiting mental health problems
41123455|NCT05166070|DRUG|RD133|The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
41123456|NCT05957731|OTHER|Routine physical therapy|Both groups received routine physical therapy, which encompasses various components such as electrotherapy, strength training for both lower and upper limbs, gait training, and occupational therapy.
41123457|NCT05957731|OTHER|antagonist contract relax|antagonist contraction i used to improve spasticity and range of motion in stroke patients
41123458|NCT05957731|OTHER|agonist contract relax|agonist contraction is used to improve spasticity and range of motion in stroke patients
41123459|NCT01631851|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
41274909|NCT03182530|DEVICE|ulnar artery compression device|a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.
41274910|NCT03182530|DEVICE|radial artery compression device guided with plysthmography|a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis
41274911|NCT03182530|DEVICE|radial artery compression device|patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
40927061|NCT03518476|BEHAVIORAL|intensive multi-disciplinary education program on tobacco treatment for pharmacists|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
41123460|NCT00687856|PROCEDURE|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
41274912|NCT05680558|DRUG|UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis|Extracorporeal Photopheresis (ECP)
41274913|NCT05680558|DEVICE|THERAKOS® CELLEX photopheresis system|THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
41123461|NCT05931510|OTHER|Myofscual release|I will apply myofascial release on group A patients and observse its effects on shin splint
41123462|NCT05931510|OTHER|Post isometric relaxation.|I will apply post isonetric relaxation on group b patients and observe effects on shin splint
41123463|NCT05889299|DRUG|OMS906 study drug|OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals
41123464|NCT06009458|DEVICE|Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear|Acuity 200™ Orthokeratology Contact Lenses are intended to be worn overnight with removal during following day. The lenses are designed to produce a temporary reduction of myopia by reversibly altering the curvature of the cornea. The lenses are manufactured from fluoroxyfocon A, which is a gas permeable contact lens material composed of a siloxanyl fluoromethacrylate copolymer. The material name fluoroxyfocon A is registered with United States Adopted Name (USAN).The Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens is available in spherical, asymmetrical, aspheric, and tangential lens designs to best fit the individual cornea, using corneal topography and/or diagnostic lenses.
41123465|NCT03058445|DEVICE|Echocardiography|Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
41123466|NCT03058445|DEVICE|CVC|Injection of 5 ml of saline
41123467|NCT03980873|BEHAVIORAL|ESTEEM (Effective Sikills to Empower Effective Men)|"ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (Barlow et al., 2010).~Is an individually-delivered cognitive behavioral treatment with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation abilities; reducing maladaptive cognitive, affective, and behavioral avoidance patterns; and improving motivation and self-efficacy for enacting behavior change"
41123468|NCT01791816|DRUG|Phenylephrine|"Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.~If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion."
41123469|NCT01791816|DRUG|L-Ng-monomethyl Arginine (L-NMMA)|Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
41123470|NCT02554786|DRUG|Indacaterol acetate/Mometasone furoate|
41123471|NCT02554786|DRUG|Mometasone furoate|
41123472|NCT02554786|DRUG|Salmeterol xinafoate/fluticasone propionate|
41123473|NCT00867256|DEVICE|Large Diameter Metal on Metal|
41123474|NCT04174768|PROCEDURE|Bariatric surgery|Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
41123475|NCT01113931|DRUG|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
41123476|NCT01113931|DRUG|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
41123477|NCT02292004|DEVICE|ACL Repair with MIACH Scaffold|Surgical insertion of the MIACH scaffold to promote ACL healing/repair
41274914|NCT03501056|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
41274915|NCT03501056|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
41274916|NCT06192121|OTHER|Web Based Education|In this research, a reminder message will be sent 3 times a week along with web-based training.
41274917|NCT05591989|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
40927062|NCT03518476|OTHER|Control arm|Participants in control arm will receive a non-tobacco related training or educational session
40927063|NCT00732004|DEVICE|Silicone Hydrogel Contact Lenses|
40927064|NCT00732004|DEVICE|1x PMBH preserved MPS|
40927065|NCT00732004|DEVICE|1x Polyquad/Aldox MPS|
40927066|NCT02489916|DRUG|CM4307|CM4307 300mg bid, each 4 week cycle
40927067|NCT04996004|DRUG|Ontorpacept (TTI-621)|Ontorpacept (TTI-621) will be administered by intravenous infusion.
41123478|NCT02292004|PROCEDURE|Standard ACL Reconstruction|Standard surgical reconstruction of the ACL with autograft hamstring tendon
41123479|NCT04992585|DEVICE|Percutaneous transhepatic implantation of self-expandable metal stent|A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease
41123480|NCT06515834|DRUG|FE 999301|To assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
41123481|NCT06515834|DRUG|Placebo|Placebo to assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
41123482|NCT04295993|DRUG|Methylene Blue|The patient will receive Methylene Blue bolus with a dose of 2 mg/kg over 10 minutes.
41123483|NCT04295993|DRUG|Norepinephrine infusion|The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg
41123484|NCT03003624|DEVICE|Colorado® microdissection needle|The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.
41287226|NCT00982722|DRUG|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
41123485|NCT03003624|DEVICE|Cautery tip|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
41123486|NCT03003624|DEVICE|BP blade|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
41123487|NCT04572945|DIAGNOSTIC_TEST|kidney function test|laboratory and imaging
41123488|NCT00002446|DRUG|Posaconazole|
41123489|NCT00002446|DRUG|Fluconazole|
41123490|NCT00826475|BEHAVIORAL|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
41123491|NCT00826475|BEHAVIORAL|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
41123492|NCT00448734|DRUG|Picoplatin|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
41123493|NCT00448734|DRUG|docetaxel|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
41123494|NCT06455488|PROCEDURE|Ventricular Tachycardia Ablation|This is a surgical ablation meant to reset patients irregular rhythm back to sinus.
41123495|NCT06455488|DEVICE|ICD Implant|A pacemaker or defibrillator implant to prevent SCD
41123496|NCT06455488|DRUG|Antiarrhythmic drug|Drug therapies
41123497|NCT06455488|DIAGNOSTIC_TEST|EKG|Monitoring EKG testing done on registry patients
41123498|NCT06455488|DIAGNOSTIC_TEST|Cardioversion|Monitoring cardioversions on registry patients
41123499|NCT06455488|DIAGNOSTIC_TEST|Echocardiogram|Monitoring echocardiogram testing done on patients
41123500|NCT01011946|DEVICE|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
41123501|NCT01562834|DRUG|somatropin|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
41123502|NCT01562834|DRUG|placebo|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
41123503|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
41123504|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
41123505|NCT01625234|DRUG|Phase I: X-396 (ensartinib)|Oral, ALK inhibitor
41123506|NCT01625234|DRUG|Phase II: X-396 (ensartinib)|Expanded Cohort
41123507|NCT01690416|PROCEDURE|Traditional palpation technique|
41123508|NCT01690416|PROCEDURE|Ultrasound DNTP|
41123509|NCT00133458|DRUG|Albendazole|
41123510|NCT05558423|BEHAVIORAL|Time Restricted Eating|Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.
41123511|NCT02928354|DRUG|Treatment A - AZD7594|Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
41123512|NCT02928354|DRUG|Treatment B - AZD7594|Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
41123513|NCT02928354|DRUG|Treatment C - AZD7594|Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
41123514|NCT01286064|DEVICE|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
41123515|NCT01286064|DEVICE|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
41123516|NCT05028673|DRUG|Lu AG06466 Capsule|Hard capsule
40927068|NCT04996004|DRUG|Doxorubicin|75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
41287227|NCT00982722|DRUG|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
40927069|NCT01073046|DEVICE|Naso-Gastric/Jejunal Tube|Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
40927070|NCT05982067|OTHER|mindfulness-based phsycial exercise intervention|The intervention is 12 weeks, two times a week. The MIPE intervention will be conducted in a hybrid way, a combination of face-to-face and at home, by a qualified mindfulness therapist and a qualified sport coach. Specifically, the participants will attend the face-to-face sessions once every two weeks and in other weeks, they will perform the intervention at home using videos and templates. The face-to-face sessions will be conducted at the health care centre. The intervention of each session will include 1) introduce the theme of this session, 2) mini lectures about the theme; 3) mindfulness practice related to the theme; 4) tips of keeping mindfulness during PE; 5) warm up: lead with mindfulness words; 6) resistance exercise; 7) cool down: lead with mindfulness words; 8) discussion.
40927071|NCT05982067|OTHER|health education|The number of sessions, duration, frequency, group size and delivery modality will be similar to the intervention group. The topics of the health education are the care of common diseases in the older adults, including hypertension, diabetes, osteoporosis, COPD, dementia, depression. Each session is about 70 min (same as intervention group), including 10-20 min lecture and 50-60 discussion and sharing.
40927072|NCT04387643|DIETARY_SUPPLEMENT|Ayurvedic Kadha|Kadha (also called Kwath and Kashaya) is a type of ayurvedic formulation prepared by boiling herbs in water. Water and herbs are main ingredients of these preparations. The preparation of Kadha uses dry herbs, which are dried under the sun or in the shade, as directed for the individual herb. Then, the herbs are pounded to form a coarse powder
40927073|NCT03848871|DRUG|Enstilar|Enstilar foam applied to affected area once daily
40927074|NCT00796887|DRUG|Extended-Release Niacin|500mg tablet once daily
40927075|NCT00796887|DRUG|Extended-Release Niacin|1000mg tablet once daily
40927076|NCT00796887|DRUG|Placebo|Placebo tablet once daily
40927077|NCT01695278|BEHAVIORAL|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
40927078|NCT03985878|DRUG|Eteplirsen|Eteplirsen IV infusion once weekly.
40927079|NCT01167387|DIETARY_SUPPLEMENT|PREOP|a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL
40927080|NCT01167387|OTHER|water|The control group will receive plain water with the same volume and timing of treatment.
40927081|NCT02442401|DEVICE|The negative pressure wound therapy|
40927082|NCT04599179|DEVICE|self-expandable metal stent|self-expandable metal stent endoscopic positioning
40927083|NCT02837081|OTHER|Prospective audit strategy of antimicrobial stewardship|applying prospective audit as a different strategy of antimicrobial stewardship
40927084|NCT02837081|OTHER|preauthorization strategy of antimicrobial stewardship|applying preauthorization as one strategy of antimicrobial stewardship
40927085|NCT00045474|PROCEDURE|adjuvant therapy|
40927086|NCT00045474|RADIATION|iodine I 125|
40927087|NCT01534182|DRUG|Fingolimod|0.5 mg orally once a day
40927088|NCT01534182|DRUG|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
40927089|NCT01534182|DRUG|Glatiramer acetate (GA)|20 mg subcutaneously once a day
40927090|NCT04779216|DRUG|Romosozumab Prefilled Syringe|Romosozumab 210mg Injection monthly for 12 months
40927091|NCT04779216|DRUG|Placebo|Placebo Injection monthly for 12 months
40927092|NCT04779216|DRUG|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at 12 months through 24 months.
40927093|NCT00266669|DRUG|Topical organogel with nitroglycerin|
40927094|NCT00052442|DRUG|pralatrexate|
40927095|NCT02438358|DRUG|LUM015|
40927096|NCT02438358|DEVICE|LUM 2.6 Imaging Device|
40927097|NCT03454009|BEHAVIORAL|Multimodal hygiene intervention|hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer.
41123517|NCT05028673|DRUG|Lu AG06466 Tablet|Film-coated tablet
41123518|NCT05028673|DRUG|Antacid|Oral suspension
41123519|NCT05294393|DRUG|Placebo Comparator: N/S 0.9%|12 ml N/S 0.9% at the end of surgery
41123520|NCT05294393|DRUG|Ropivacaine 10%|12 ml solution of 100mg ropivacaine at the end of surgery
41123521|NCT05294393|DRUG|Ropivacaine 10% plus magnesium sulphate 10mg/kg|12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery
41123522|NCT04717869|DIAGNOSTIC_TEST|Ultrasound|2D ultrasound image collection
41123523|NCT04717869|DIAGNOSTIC_TEST|Biomarker Analysis|Inflammatory and nutritional biomarker analysis
41123524|NCT04717869|OTHER|Frailty Index|A Frailty Index Questionnaire be completed by patients or their surrogates to determine the presence of frailty at ICU admission
41123525|NCT00984048|OTHER|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
41123526|NCT04644341|COMBINATION_PRODUCT|cardiovascular and respiratory systems monitoring|only one group of individuals to observe the impact of COVID-19 on their cardiovascular and respiratory systems in long term.
41123527|NCT02499159|DRUG|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
41123528|NCT02499159|DRUG|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
41123529|NCT05311527|DEVICE|Urolift|Urolift Implant
41123530|NCT05311527|RADIATION|SABR|Stereotactic Body Radiation Therapy for prostate cancer
41123531|NCT00212693|DRUG|ONO-2506PO|
41123532|NCT01650896|OTHER|Geriatric assessment review|Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
41274918|NCT05443334|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
40927098|NCT04600011|OTHER|Physical and occupational therapy (PT/OT)|"Neurologic-specialized and -certified physical and occupational therapists will provide each participant with an initial in-person PT/OT evaluation/treatment session with oversight from a Movement Disorders Neurologist, followed by 4 virtual home visits with tele-PT/OT and care partner supervision every 2 weeks, and culminating with a final in-person evaluation, all with a focus on personalized training in core areas contributing to a patient's individual fall risk, much like in-person visits. Virtual home safety surveillance with the mobile virtual platform is an additional feature of this intervention that aims to optimize the home environment to reduce external factors contributing to fall risk."
40927099|NCT04600011|OTHER|Home Safety Evaluation (HSE)|The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
41123533|NCT02678936|BIOLOGICAL|PRP|Application of platelet-rich plasma during surgery
41123534|NCT04623567|DRUG|Jiangtang Tiaozhi recipe|The Jiangtang Tiaozhi recipe is a combination of several Chinese herbs, which has been granted a patent (No. ZL 2013 1 0373659.7)
41123535|NCT04623567|DRUG|Metformin|The metformin tablets (500mg) will be administrated.
41123536|NCT00152087|DEVICE|Brachytherapy|
41123537|NCT03081611|DEVICE|Ram cannula|Ventilatory support for preterm infants using Ram cannula
41123538|NCT03081611|DEVICE|Short nasal prongs|Ventilatory support for preterm infants using short nasal prongs
41123539|NCT03531840|DRUG|Olaparib|All subjects will take olaparib by mouth twice per day until disease progression or unacceptable toxicity
41123540|NCT03531840|DEVICE|ClinOmics|Non-significant risk (NSR) device
41123541|NCT03945123|DIETARY_SUPPLEMENT|Red ginseng|Red ginseng tablet 120g
41123542|NCT06152640|DEVICE|Deep transcranial magnetic stimulation|"Neuronavigation: The coil is positioned 4cm in front of the scalp point and foot motor cortex, corresponding to the ACC. The Brainways H7 coil with fluid cooling is used to obtain a greater depth of stimulation, up to about 6 cm below the cortex.~dTMS intervention: The intervention targets are at the left and right ACC, once per day, for 28 days. A total of 28 treatments are given. Stimulation mode: stimulation frequency 1Hz, stimulation intensity 100% RMT, number of pulses 150, sequence interval 20s, total 6 trials, 900 pulses."
41123543|NCT06152640|DEVICE|Sham deep transcranial magnetic stimulation|"Neuronavigation: The sham coil is positioned 4 cm in front of the scalp point and foot motor cortex, corresponding to the ACC.~Sham dTMS intervention: The intervention targets are at the left and right ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field), once per day, for 28 days. A total of 28 treatments are given."
41123544|NCT06152640|OTHER|Basic treatment|According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.
41123545|NCT05096559|DEVICE|Microcirculation cytocam|Visualization of tongue microcirculation
41123546|NCT00237991|BIOLOGICAL|Hepatitis A|
41123547|NCT02623894|OTHER||No intervention study is an observational study
41123548|NCT04244058|DRUG|Amantadine + L-DOPA|Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg
41123549|NCT04244058|DRUG|NMDA blocker|NMDA blocker
41123550|NCT02065193|BEHAVIORAL|ADOS/ADI-R/Clinical assessment|
41123551|NCT02172872|DRUG|standard combination chemotherapy|"1. Cycle 1~   1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~2. Cycle 2~   1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~3. Cycle 3 (mini-ICE)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days~4. Cycle 4 (mini-ICE) (optional)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days"
41123552|NCT02172872|DRUG|decitabine|"1. Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days~2. Cycle 2~   1. if bone marrow (BM) blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~3. Cycle 3~   1. if BM blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~4. Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days~5. Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days~Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available."
41274919|NCT04132050|DRUG|R788|Oral administration
40927100|NCT03635671|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Retinal scans will be acquired at each follow up visit
41274920|NCT04132050|DRUG|Placebo|Oral administration
41274921|NCT04196114|DEVICE|STIMO-2 device implantation|Implantation of SCS lead in epidural space and implantation of neurostimulator in abdominal region
41274922|NCT03415555|PROCEDURE|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.
40927101|NCT00815854|DIETARY_SUPPLEMENT|Folic Acid|5 mg of folic acid taken daily for 3 months in an open label fashion
40927102|NCT00815854|OTHER|Placebo|Subjects may receive placebo (a sugar pill) for 4 months
41274923|NCT03415555|DRUG|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
40927103|NCT05176561|BEHAVIORAL|Auditory-Cognitive Training|"Treatment Participants will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Participants with spend 1 hour auditory training use Angel Sound and one hour of auditory cognitive training using auditory portions of Posit Science. A clinical paradigm including reviewing results, providing strategies and positive feedback and strategies in the 1 hour virtual meeting of clinician and participant. Practice for next week is assigned.~Control group intervention follows the same time and procedure but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search)."
40927104|NCT05176561|BEHAVIORAL|Non-auditory Cognitive Training|Participant will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Control group intervention follows the same time and clinical paradigm, but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search).
40927105|NCT01143805|DRUG|Tasocitinib 10 mg oral tablet|Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet
40927106|NCT01143805|DRUG|Tasocitinib 10 mg IV Infusion|Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion
41274924|NCT03415555|PROCEDURE|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
40927107|NCT06129357|BEHAVIORAL|180 individuals who applied to the Periodontology Clinic were included in the study. Individuals were divided into 3 groups as healthy (n=60), gingivitis (n=60) and periodontitis (n=60).|Diagnostic Test: Full periodontal chart A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
41123553|NCT03628885|BEHAVIORAL|Top Concern Tailored Intervention|General Vaccine Information video plus a brief (\< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns.
41123554|NCT03628885|BEHAVIORAL|All Concerns Tailored Intervention|General Vaccine Information video plus one or more brief (\< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns.
41123555|NCT05772923|RADIATION|Contact x-ray brachytherapy|With contact x-ray brachytherapy an intraluminal radiation boost up to 90 Gy is applied to the primary rectal tumour, with minimal collateral damage to the surrounding normal tissues due to minimal penetration of the 50 kVolt therapy.
41123556|NCT05772923|PROCEDURE|Local excision|Local excision will basically be performed by the TAMIS-procedure (transanal minimally invasive surgery).
41123557|NCT04790357|OTHER|Current guidelines|doppler ultrasound and/or angio CT-scan of the cervical arteries, angio CT-scan of the intracranial arteries, TTE wich can be supplemented by a TEE at the discretion of the investigator. The TEE is not mandatory
41274925|NCT03415555|DRUG|paracetamol|Paracetamol will be given i.v. every 6 hours.
41274926|NCT04931602|DIAGNOSTIC_TEST|Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan|investigations for secondary causes of osteoporosis
41274927|NCT03294993|DEVICE|Ultrasound assess|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
41274928|NCT01869335|DEVICE|radiography|
41274929|NCT01869335|DEVICE|MRI (magnetic resonance imaging)|
41274930|NCT00109421|BEHAVIORAL|Project ÒRÉ|Community-based adolescent social network HIV/STI intervention tailored to African American culture
41274931|NCT05267821|DRUG|Anakinra|See information in arm/group descriptions
41274932|NCT05267821|DRUG|Placebo|See information in arm/group descriptions
41274933|NCT01461681|PROCEDURE|Symptom Management Service for Heart failure|The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
41274934|NCT00380562|BEHAVIORAL|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
40927108|NCT00329446|DRUG|Quetiapine Fumarate|
40927109|NCT00329446|DRUG|Escitalopram oxylate|
41123558|NCT04790357|OTHER|cc-MRI|of one-shot cardiac-cervical-intracranial MRI: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
41123559|NCT01651767|DRUG|Placebo|Form=suspension, route=oral.
41123560|NCT01651767|DRUG|JNJ-47910382|Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
41123561|NCT04129203|DEVICE|Versi Retriever thrombectomy|Mechanical thrombectomy using Versi Retriever
41123562|NCT04578496|DRUG|Afamelanotide|
41123563|NCT00103363|OTHER|cytology specimen collection procedure|
41123564|NCT00103363|OTHER|physiologic testing|
41123565|NCT00103363|PROCEDURE|annual screening|
41123566|NCT00103363|PROCEDURE|study of high risk factors|
41274935|NCT01982825|BEHAVIORAL|Online intervention arm|See online intervention arm
41274936|NCT01982825|BEHAVIORAL|Online control arm|See online control arm
41274937|NCT02586857|DRUG|ACP-196|Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
41274938|NCT03973450|OTHER|Registration of familial forms and associated neoplasia|Retrospective registration of associated endocrine and non-endocrine neoplasia and potential familial setting
41274939|NCT00642330|DRUG|oral ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
41274940|NCT00642330|DRUG|intravenous ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
41274941|NCT03420976|DIETARY_SUPPLEMENT|Novel Supplement Based Therapy|"Supplements and Dosage:~Detox Support: Liver-G.I. Detox BID for 30 days GI Support: L-Glutamine Powder 2 scoops QD for 35 days Microbial Balance: MicroDefense 1 capsule QD for 49 days Microbial Balance: A.C. Formula II 2 capsules BID for 49 days Probiotic: Probiotic-5 1 capsule QD for 49 days Digestive Enzymes: Digestive Enzymes Ultra with Betaine HCl As needed up to 6 longer term"
40927110|NCT02097017|DRUG|Lidocaine|will local application of lidocaine to the cervix alleviate pain of laminaria insertion
41274942|NCT04996693|DIAGNOSTIC_TEST|Imaging on Scanner with Spectral Imaging Capabilities|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.
41274943|NCT04996693|DIAGNOSTIC_TEST|CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)|Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
41274944|NCT04996693|DIAGNOSTIC_TEST|CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)|Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
41274945|NCT03827161|DIETARY_SUPPLEMENT|Glucosamine|Given PO
41274946|NCT03827161|OTHER|Placebo|Given PO
40927111|NCT02097017|OTHER|placebo comparator|
41123567|NCT03028389|PROCEDURE|limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
41123568|NCT06107101|DRUG|Mepolizumab|100mg of mepolizumab every 4 weeks subcutaneously for 6 months
41123569|NCT00761553|OTHER|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
41274947|NCT04730518|BEHAVIORAL|Yoga-based group therapy|see above
41274948|NCT00382837|DRUG|Epratuzumab|
41274949|NCT03709563|DIETARY_SUPPLEMENT|Oral Nutraceutical Supplement|Standardized Botanicals. Take 4 capsules by mouth daily with a meal
40927112|NCT04134403|DRUG|STASIS|Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
40927113|NCT02398994|DRUG|Intravenous Methylprednisolone|
40927114|NCT02398994|DRUG|Intravenous Immunoglobulin|
41123570|NCT00761553|DIETARY_SUPPLEMENT|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
41123571|NCT05363449|DRUG|UHE-103 Cream|UHE-103 is an investigational combinational therapy containing keratolytic and antifungal
41123572|NCT05363449|DRUG|Naftin (naftifine hydrochloride) Cream|Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug
41123573|NCT02187887|BEHAVIORAL|Personalized normative feedback|Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
41274950|NCT03709563|DIETARY_SUPPLEMENT|Placebo|Placebo. Take 4 capsules by mouth daily with a meal
41274951|NCT00520598|BIOLOGICAL|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
41274952|NCT00520598|DRUG|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
41274953|NCT00520598|DRUG|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
41274954|NCT00520598|BIOLOGICAL|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
41274955|NCT00520598|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
41274956|NCT00520598|BIOLOGICAL|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
41287228|NCT01805115|DRUG|Oral misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
40927115|NCT05779384|OTHER|It was an observational study|data collected concerning the incidence of exacerbations
41123574|NCT06037993|DIETARY_SUPPLEMENT|Ultra-micronized Palmitoylethanolamide (PEA)|"Palmitoylethanolamide (PEA) is an N-acylethanolamine (AE), produced on demand by different cell types as a response to actual or potential damage, proven to down-regulate central and peripheral activity of mast cells and non-neuronal cells (e.g., astrocytes, microglia) and to exert protective functions against glutamate neuro-toxicity, accounting for its naturally-occurring anti-inflammatory, analgesic, and anticonvulsant properties. Due to the shared pharmacodynamic properties, PEA is considered as the endogenous equivalent of Cannabidiol (CBD). A growing body of literature has confirmed the role of PEA in most neurobiological mechanisms underpinning several neuropsychiatric conditions both in clinical and preclinical settings. The effect of PEA over neuroinflammation and glutamate signaling may represent a promising biobehavioral mechanism underlying the clinical utility of its oral supplementation in CHR state."
41123575|NCT04553523|DEVICE|Hydrus Microstent|Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
40927116|NCT05596097|DRUG|Zanubrutinib|Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days
40927117|NCT00265356|PROCEDURE|PET diagnostic imaging|PET diagnostic imaging
40927118|NCT00225927|PROCEDURE|radioguided seed localization for nonpalpable breast cancers|radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery
40927119|NCT00084890|DRUG|carboplatin|30 minute infusion dosed based on glomerular filtration rate of patient
40927120|NCT00084890|DRUG|docetaxel|escalating doses ofstarting at 25 milligrams per meter squared
40927121|NCT05373069|PROCEDURE|Mechanical ischemic preconditioning of diep-type flap|"Mechanical ischemic preconditioning: Performing series of reperfusion ischemia on the flap pedicle, before cold ischemia of the flap (flap harvesting before vascular mechanical anastomoses at the recipient site)~* 10 min of clamping with single-use microvascular forceps~* 10 min declamping~* 10 min of tightening with pliers~* 10 min declamping Either preconditioning for 40 minutes, simulating 2 cycles of ischemia reperfusion prior to flap harvesting and cold ischemia before revascularization."
40927122|NCT04976270|DRUG|GLPG3667|GLPG3667 capsules
40927123|NCT04976270|DRUG|Placebo|Matching placebo capsules
40927124|NCT03725462|DEVICE|Cardioskin|Subjects have a monitoring with cardioskin and comparator
40927125|NCT03725462|DEVICE|Neuronaute|Subjects have a monitoring with Neuronaute and comparator
40927126|NCT04022733|DRUG|Moderate neuromuscular block|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
40927127|NCT04022733|DRUG|Deep neuromuscular block|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
40927128|NCT03331510|OTHER|Strength testing before and after arthroscopic Latarjet|After patients, based on the ISI-Score, were assigned to treat their shoulder instability with an arthroscopic Latarjet procedure, they are eligible for this study. Strength of different involved muscles, as well as ROM will be measured before and at several time points after surgery.
40927129|NCT03011892|DRUG|Ruxolitinib 0.15% Cream QD|Ruxolitinib 0.15% cream QD
40927130|NCT03011892|DRUG|Ruxolitinib 0.5% Cream QD|Ruxolitinib 0.5% cream QD
40927131|NCT03011892|DRUG|Ruxolitinib 1.5% Cream QD|Ruxolitinib 1.5% cream QD
40927132|NCT03011892|DRUG|Ruxolitinib 1.5% Cream BID|Ruxolitinib 1.5% cream BID
40927133|NCT03011892|DRUG|Triamcinolone 0.1% Cream BID|Triamcinolone 0.1% cream BID
40927134|NCT03011892|DRUG|Vehicle Cream BID|Vehicle cream BID
40927135|NCT00314587|PROCEDURE|1 or 2 elastic stable intramedullary nails|
40927136|NCT01528865|DRUG|Lamivudine|"Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks."
40927137|NCT01528865|DRUG|Tenofovir disoproxil fumarate|300 mg once a day p.o. for 16 weeks.
40927138|NCT04942197|OTHER|use pregnancy management application|Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.
40927139|NCT05565417|DRUG|IMT-009|Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.
40927140|NCT05565417|COMBINATION_PRODUCT|Fruquintinib|Fruquintinib will be administered according to the FDA-approved United States Prescribing Information (USPI).
40927141|NCT03095196|DEVICE|Multipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via multipolar left ventricle lead, in failing heart patients treated by maximal drug therapy.
40927142|NCT03095196|DEVICE|Bipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via bipolar left ventricle lead (group B), in failing heart patients treated by maximal drug therapy.
40927143|NCT03095196|DRUG|HF drugs|full medical therapy to treat HF symptoms and its progression.
40927144|NCT05457582|DRUG|Placebo plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
40927145|NCT05457582|DRUG|PCSK 9 Inhibitor plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
40927146|NCT01857596|DRUG|bupropion, Lorexys low-dose, Lorexys moderate-dose|Lorexys is a proprietary fixed-dose combination of two agents
40927147|NCT02299739|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
40927148|NCT02299739|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
40927149|NCT02299739|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
41123576|NCT04553523|PROCEDURE|Cataract surgery|Cataract surgery performed using standard anesthesia and phacoemulsification techniques
41123577|NCT04553523|DEVICE|Monofocal IOL|Commercially available monofocal intraocular lens as determined by the investigator
41123578|NCT02107261|DRUG|incobotulinumtoxin A|Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
41123579|NCT02107261|DRUG|Placebo|matching placebo
40927150|NCT02299739|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
40927151|NCT02299739|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
40927152|NCT03567317|DEVICE|CPAP withdrawal|Patients randomized to withdrawal will stop CPAP use for one week before study evaluations. Patients will also undergo a polysomnography to confirm the presence of severe OSA.
40927153|NCT06119958|DRUG|DWC202313|Experimental Drug 1
40927154|NCT06119958|DRUG|DWC202314|Experimental Drug 2
40927155|NCT02375789|DEVICE|Active RhinoChill|"The device is intended for use for the reduction of temperature via the nasal cavity.~The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity."
40927156|NCT02375789|DEVICE|Placebo RhinoChill|The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
41123580|NCT01929759|DRUG|Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)|Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
41123581|NCT05296772|BIOLOGICAL|JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody|Weekly infusion at the designated dose level until disease progression, withdrawal or up to two years
41123582|NCT05296772|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|200 mg, once every three weeks until disease progression, withdrawal or up to two years
41123583|NCT02897882|OTHER|Lung transplant|Pain evaluation
41123584|NCT01318967|DRUG|Furosemide|Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
41123585|NCT01318967|OTHER|Placebo|
41123586|NCT02262767|DRUG|PF-06649751|Experimental Pfizer compound.
41123587|NCT02262767|DRUG|Trimethobenzamide Hydrochloride|Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
41123588|NCT00569387|BIOLOGICAL|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
40754296|NCT01168479|RADIATION|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
41287229|NCT01805115|DRUG|Sublingual misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
40927157|NCT00523367|PROCEDURE|24 hour pH testing|24 hour pH testing will be used to screen patients
40754297|NCT01168479|RADIATION|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
40754298|NCT03467945|DRUG|Metformin/Gliclazide Fixed Combination|Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
40927158|NCT03475953|DRUG|Phase 1 : Regorafenib|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
40927159|NCT03475953|DRUG|Phase 1 : Avelumab|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
40927160|NCT03475953|DRUG|Phase 2 : Regorafenib|Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
40927161|NCT03475953|DRUG|Phase 2 : Avelumab|Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
41123589|NCT05297175|DEVICE|Trammpolin medial meniscus prosthesis|Implantation of the Trammpolin medial meniscus prosthesis in patients with a severe medial meniscus damage
41123590|NCT03210896|DIETARY_SUPPLEMENT|Orange juice|Sub group I will drink Orange juice and have repeat measures.
41123591|NCT05469841|OTHER|Systemic pain assessment|Pain will be evaluated via i) pupillometry with 3 successive measurements ii) Behaviour Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT) score evaluated by an investigator (physician) iii) evolution of physiological parameters (ie heart rate, blood pressure, respiratory rate) iv) Nociception Level Index (NOL) index.
41123592|NCT03792932|PROCEDURE|Laparoscopic distal pancreatectomy|Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
41123593|NCT03792932|PROCEDURE|Open distal pancreatectomy|Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
41123594|NCT03308292|OTHER|Exercise|Aerobic exercise program
40754299|NCT03467945|DRUG|Metformin|Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.
41287230|NCT01805115|DRUG|Vaginal misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
41123595|NCT00982917|BEHAVIORAL|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
41123596|NCT00982917|BEHAVIORAL|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
41123597|NCT00933257|DRUG|LACTIC ACID(ND)|Treatment duration 5 weeks
41123598|NCT05880355|DRUG|Dapansutrile|Oral inhibitor of NLRP3
41123599|NCT05880355|OTHER|Placebo|Non-active placebo
41123600|NCT05493449|COMBINATION_PRODUCT|UHT Milk|In this group of participants, UHT milk, 180 mL was provided and results were compared with control and flavored milk group
41123601|NCT05493449|COMBINATION_PRODUCT|Flavored Milk|In this group of participants, flavored milk, 180 mL was provided and results were compared with control and UHT group
41123602|NCT00495976|OTHER|A commercially produced cordial drink|
41123603|NCT06342154|BEHAVIORAL|Endorphin Massage|The person who will perform the endorphin massage opens his hands with his palms facing himself and draws a semicircle with the nails of his middle, ring and little fingers touching the sacrum. Then, a semicircle is drawn with the fingertips from each side of the spine, starting from the sacrum to the shoulder area, towards the waist area, As a result of this process, a palm shape is drawn on the back. Effleurage is applied from the shoulders to the arms up to the elbows. Effleurage is applied towards the shoulders by pressing from the elbows upwards with the back of the thumb. Effleurage is applied up to the sacrum by pressing circular movements with two thumbs on both sides of the spine. Effleurage is applied from the sacrum to the neck by pressing with two thumbs in a circular motion on both sides of the spine (approximately 1.5 cm apart). Lastly, effleurage is applied to the neck area and scalp, then petrissage (rubbing) is applied and the massage is completed.
41123604|NCT01477255|BEHAVIORAL|iPad|The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
41123605|NCT02909413|DRUG|Desﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Desﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
41123606|NCT02909413|DRUG|sevoﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Sevoﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, 50％O2 and 1.7-2.0% Sevoflurane.
41123607|NCT02290613|DRUG|Ambrisentan|"Titration:~As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.~Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan and placebo will be administered orally with or without food intake."
40754300|NCT03467945|DRUG|Gliclazide|Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
41123608|NCT02290613|DRUG|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets)
41123609|NCT00391196|DRUG|Placebo|Subjects receive placebo plus non-pharmacological weight loss program.
41123610|NCT00391196|DRUG|CP-945,598|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
41123611|NCT00391196|DRUG|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
41123612|NCT06522958|DIETARY_SUPPLEMENT|High Dissolving Transitional Food|Transitional foods are solid foods that rapidly change texture in the presence of moisture (e.g., water or saliva) or temperature change. Duration of consumption of the investigational agent will include the time of the surgery until the second post-operative evaluation. This is estimated to be approximately 1-2 months in total.
41123613|NCT00220675|DRUG|Erythropoietin infusion|
41123614|NCT05239156|DEVICE|Janesse|"Device: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.~The subjects will receive at baseline the first investigational medical device by the Investigator in accordance with the clinical investigation plan."
41123615|NCT03756571|OTHER|Ankle Foot Orthoses-Footwear Combination|This is a solid AFO with angle of ankle in AFO and shoe modifications per algorithm based on physical exam and visual observation of lower extremity kinematics through stance phase of walking.
41123616|NCT03756571|OTHER|Traditional Solid Ankle AFO (TSAFO)|This is a solid ankle AFO with angle of ankle in AFO at 90 degrees or neutral dorsiflexion/plantarflexion.
41123617|NCT00709098|DRUG|iloprost|Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
40754301|NCT02213991|DEVICE|Intraoperative radiotherapy using Intrabeam®|"Operation day~1. Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~2. Purse string suture pulles up tissues and wraps up the applicator.~3. Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~4. After IORT, applicator was out of the operative field, and usual wound closure will be done.~   * Postoperative period~     * Chemotherapy WBRT (46 Gy) for 4\~5 weeks~    * Endocrine therapy or target therapy"
40754302|NCT01206270|DRUG|Testosterone undecanoate|Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
40927162|NCT03475953|DRUG|Phase 2: low-dose Regorafenib|Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day
41274957|NCT05314673|DRUG|Preoperative Intra-lesional Bevacizumab Injection in primary pterygium|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture Any intraoperative complication was noted and was treated accordingly. All patients received dexamethasone + tobramycin eye drops postoperatively 4 times a day in the 1st week. The eye drops were tapered over 4 weeks.~Patients were examined 30 days before bevacizumab injection (D-30), before surgery (day 0: D0) and then at D7, M1, M3, and M6 after surgery."
41274958|NCT05314673|PROCEDURE|pterygium surgery without adjunctive therapy|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture"
41274959|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
41274960|NCT01121289|DRUG|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
41274961|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
41274962|NCT01121289|DRUG|NN1218|0.4 U/kg body weight injected subcutaneously (under the skin)
40927163|NCT05617495|OTHER|Mindfulness + fMRI Neurofeedback|Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.
40927164|NCT00203814|DRUG|Sulfadoxine-pyrimethamine|
40927165|NCT00203814|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
41123618|NCT00709098|DRUG|iloprost|Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
41123619|NCT01747070|OTHER|tDCS and EAC sham|The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
41123620|NCT01747070|OTHER|tDCS sham and EAC sham|For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
41123621|NCT01747070|OTHER|tDCS sham and EAC|For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
41123622|NCT01747070|OTHER|tDCS and EAC|For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
41123623|NCT03872635|OTHER|oral carbohydrate liquid|patients undergoing neoadjuvant chemotherapy and radical hysterectomy with bilateral pelvic lymph node dissection were randomized to receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
41123624|NCT01691846|DRUG|aleglitazar+metformin|150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
41123625|NCT01691846|DRUG|placebo+metformin|Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
41123626|NCT04385680|DRUG|Chlorhexidine Gluconate vaginal solution 0.05%|preoperative vaginal preparation
41123627|NCT00585052|DRUG|Paclitaxel|Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly
41123628|NCT00585052|DRUG|Lovastatin|Lovastatin, 80 mg, po, daily will be self-administered by the subject.
41123629|NCT04999917|DIAGNOSTIC_TEST|high-resolution PET-CT specimen imaging.|"A single intravenous injection of 18F-FDG (0.80 MBq/kg) is given between 30 minutes and 3 hours before tumor resection.~Surgical resection of the breast tumor (= main specimen) under general anesthesia.~The main specimen is imaged using the Aura 10 PET-CT Specimen Imager (XEOS Medical, Ghent, Belgium). In case of positive margins, the surgeon will perform oriented cavity shaving. The cavity shaves and lymph nodes (if any) are also imaged using the Aura 10 PET-CT Specimen Imager (for scientific purposes only).~The main specimen and if applicable the cavity shaves and lymph node(s) are processed following standard-of-care routine: from tissue samples to HE-stained and IHC-stained sections. The histopathological margin status shall be reported according to the ASCO-CAP guidelines, and shall be compared to the PET-CT images of the resected specimens."
41123630|NCT04032353|OTHER|Medical Consortium|subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
41123631|NCT04476810|DEVICE|kahook dual blade|Combined Phacoemulsification and Excisional Goniotomy with the Kahook Dual Blade
41123632|NCT05519202|DRUG|S-1,Oxaliplatin, Penpulimab|S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1)
41123633|NCT02431273|DRUG|TDF IVR|
41123634|NCT02431273|DRUG|TDF-FTC IVR|
41274963|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
41274964|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
41287231|NCT01805115|DRUG|Control|The control group was not given any cervical priming agents or placebo.
41287232|NCT03187379|DRUG|Exparel|Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
40927166|NCT02310009|DRUG|Anakinra (AN)|
40927167|NCT02310009|BEHAVIORAL|Exercise (EX)|
40927168|NCT02310009|BEHAVIORAL|Control (CON)|
40927169|NCT02365142|BIOLOGICAL|100 million Bone marrow mesenchimal stem cells|100 million Bone marrow mesenchimal stem cells with PRGF
40927170|NCT02365142|BIOLOGICAL|Platelet Rich plasma (PRGF)|3 injections of PRGF
41274965|NCT05426148|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®|The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.
41274966|NCT01422330|DRUG|Etravirine|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
41274967|NCT04085432|OTHER|Self administered questionnaire and Clinical evaluation|Self administered questionnaire and clinical evaluation
41274968|NCT00104871|DRUG|Bortezomib|Administered IV at the dose of 1.3 mg/m\^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
41274969|NCT03709615|BEHAVIORAL|Internet delivered CBT for social anxiety disorder|"An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006:~Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial."
41274970|NCT04976465|DRUG|Anticoagulation|"Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~   Other Names: HCQ~3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~   Other Names: Asp~4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH"
41123635|NCT02431273|DRUG|TDF-FTC-MVC IVR|
41123636|NCT00790894|DRUG|ixabepilone|Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
41123637|NCT00790894|DRUG|ixabepilone|Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
41123638|NCT02376842|BEHAVIORAL|Severe sepsis early warning best practice alert|
41123639|NCT02376842|BEHAVIORAL|Standard care|
41123640|NCT00621634|DIETARY_SUPPLEMENT|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
41274971|NCT04976465|DRUG|Without Anticoagulation|"Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ"
40927171|NCT01252693|DRUG|Ozarelix|Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
41274972|NCT04791384|DRUG|Abemaciclib|taken orally
41274973|NCT04791384|DRUG|Elacestrant|taken orally
41274974|NCT01126346|BEHAVIORAL|HIPEC Orientation|Introduction to SRB (survivorship resource book); Clinic Tour; Lunch with Question and Answer Session
41287233|NCT03187379|DRUG|Bupivacaine|60cc Bupivacaine
40754303|NCT01206270|DRUG|Castor Oil|4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
40927172|NCT01252693|DRUG|Goserelin|Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
40927173|NCT05953441|OTHER|AI-powered doctor|AI-powered virtual doctor
41123641|NCT00621634|DIETARY_SUPPLEMENT|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
41123642|NCT06243094|DRUG|Antibiotic|All antibiotic therapy characteristics are monitored.
41123643|NCT03621735|DEVICE|Burst-SCS/sham SCS|"The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
41123644|NCT03621735|DEVICE|Sham SCS/Burst-SCS|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
41123645|NCT00000969|DRUG|Zalcitabine|
41123646|NCT00000969|DRUG|Didanosine|
41123647|NCT02395978|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
41123648|NCT02395978|DRUG|placebo|Placebo contained corn starch.
41123649|NCT04605731|BIOLOGICAL|Durvalumab|Given IV
41123650|NCT04605731|BIOLOGICAL|Tremelimumab|Given IV
41123651|NCT01812096|OTHER|Subcutaneous bortezomib|
41123652|NCT01812096|OTHER|Intravenous bortezomib|
40758300|NCT04670315|DIAGNOSTIC_TEST|Telematic evaluation of motor function|Validation of the Telematic Spanish Version of the Fugl Meyer Assessment Scale
40758301|NCT04985110|DRUG|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
40758302|NCT04985110|DRUG|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
40758303|NCT06098352|BEHAVIORAL|PEBL Continuous Performance Task|A PEBL version of the Conners Continuous Performance Task
40927174|NCT05953441|OTHER|Human-controlled doctor avatar|Virtual doctor avatar controlled by the medical student.
40927175|NCT02211911|DRUG|Bisacodyl|
40927176|NCT02211911|DRUG|Sodium picosulfate|
41123653|NCT05850975|OTHER|intervention with this name in MindEase app|MindEase is an app which provides interventions against anxiety. The interventions are based on mindfulness, acceptance and commitment therapy, and cognitive behavioural therapy.
41123654|NCT05850975|OTHER|reading about anxiety|Participants are given an educational text to read about anxiety.
41274975|NCT01126346|BEHAVIORAL|Consultation with Survivorship Navigator|Weekly psychosocial support via phone from Survivorship Navigator for 3 weeks prior to HIPEC; Inpatient consults occurring 3 to 4 days post-HIPEC and biweekly for 2 weeks and weekly until hospital discharge; Post-Hospital Discharge consults via phone twice per month for one month
41123655|NCT05367336|DRUG|Morphine|second group will be receiving morphine
41274976|NCT01126346|OTHER|Questionnaires|Questionnaires Completed at 4 time points: T1 pre-HIPEC orientation, T2 with in 1 week of orientation, T3 1 month post HIPEC and T4 3 months post HIPEC. Questionnaires include Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
41274977|NCT00757315|DEVICE|NdYag Laser(hair removal laser) plus topical corticosteroid|NdYag laser and topical corticosteroid are applied to one half of the scalp.
41274978|NCT00757315|DRUG|Topical corticosteroid alone|topical corticosteroid alone is applied to one half of the scalp
41274979|NCT01274221|DRUG|SPD489|1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
41274980|NCT01274221|OTHER|Placebo|1 capsule per day for one week of the double-blind crossover phase
41274981|NCT02158559|DRUG|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
41274982|NCT02158559|DRUG|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
41274983|NCT04909606|OTHER|nurse-led prevention program|"Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)~The nurse-led prevention program will include:~1. A video explaining corticosteroids related adverse events and adequate preventive measures~2. An individual interview with the trained nurse~3. A consultation with a dietetician~4. An individual sheet summarizing appropriate non-pharmacological preventive measures for the participant~5. An individual sheet summarizing appropriate pharmacological preventive measures for the referent physician~6. Phone calls at week-12, week-24 and week-36 to ensure the appropriate implementation of preventive measures"
41274984|NCT04909606|OTHER|Current care|Subjects randomized to the standard of care group will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
41274985|NCT02497703|DEVICE|Knee robot|
41274986|NCT00558090|DRUG|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
41274987|NCT04628507|OTHER|Spent media collection|Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
41274988|NCT03880877|DRUG|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
40758304|NCT02743312|DEVICE|Torso Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
41274989|NCT03880877|GENETIC|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
41274990|NCT03880877|GENETIC|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
41274991|NCT03880877|GENETIC|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
41274992|NCT03880877|DRUG|Leucovorin and 5-FU|Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
41274993|NCT03305640|PROCEDURE|acetabular fracture surgery|acetabular fracture surgery
41274994|NCT05621356|OTHER|A nasal fluid Basophil Activation Test (BAT)|a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.
41274995|NCT02557087|DRUG|Hyoscine|
41274996|NCT02557087|DRUG|Pethidine|
41274997|NCT06192576|DRUG|Olipudase alfa|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
41274998|NCT03435978|BEHAVIORAL|MetS+|
41274999|NCT03435978|OTHER|MetS-|Data processing from Patient Medical Files
41275000|NCT05705726|DEVICE|ultrasound guided facia iliaca block|Patient will received ultrasound guided fascia iliaca block by 20 ml Bupivacaine 0,25% .
41275001|NCT05705726|DRUG|Intravenous drug|Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .
41275002|NCT05255003|BIOLOGICAL|Enoxaparin|"I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count \< 25,000/µL: hold anticoagulation"
41275003|NCT05255003|BIOLOGICAL|Dalteparin|"I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count \< 25,000/µL: hold anticoagulation"
40927177|NCT01821573|DRUG|botulinum toxin type A|"Experimental arm group:~* 150 Units in rectus femoris ( 3 ml and 3 points)~* 70 units in medial gastrocnemius (1.4 ml and 1 point)~* 70 units in lateral gastrocnemius ( 1.4 ml and 1 point)~* 60 units in soleus ( 1.2 ml and 3 points)"
41275004|NCT05255003|BIOLOGICAL|Tinzaparin|"I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count \< 25,000/µL: hold anticoagulation"
41287234|NCT04364217|DEVICE|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
41287235|NCT00603044|DRUG|fluticasone furoate|treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
40758305|NCT02743312|DEVICE|Sham Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.
41123656|NCT05367336|DRUG|Fentanyl|third group receiving fentanyl
41123657|NCT03272399|OTHER|Diet/nutrition intervention|The intervention will be administered through food products rather than dietary supplements
41123658|NCT04775667|OTHER|questionnaires for clinical assessments|questionnaires for clinical assessments
41123659|NCT05942092|PROCEDURE|Breast conserving surgery|Breast conserving surgery after lesion's localization with ROLL or magnetic seed
40927178|NCT01821573|DRUG|injection of NaCl 0.9%|"Placebo comparator group: injection of NaCl 0.9%:~* 3 ml of NaCl 0.9% in rectus femoris in 3 points~* 1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~* 1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~* 1.2 ml of NaCl 0.9% in soleus in 3 points"
40754304|NCT03791697|OTHER|Telehealth 2 week postoperative visit|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes. (Intent to treat)"
40754305|NCT00773110|DRUG|20% Human albumin solution|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
40927179|NCT05358340|DIAGNOSTIC_TEST|Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI)|A dye, known as a contrast agent, will be injected through a needle that is inserted into a vein in the arm or hand. Subsequent magnetic resonance imaging will follow.
40927180|NCT05245396|DRUG|Ref (TF2)|Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
41123660|NCT02880137|DRUG|Perflutren Lipid Microsphere|Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20 MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.
41123661|NCT02880137|PROCEDURE|RTMPE|Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
41123662|NCT04576975|DRUG|Ketamine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
41123663|NCT04576975|DRUG|Dexmedetomidine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
41123664|NCT04576975|DRUG|Normal Saline 0.9%|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
41123665|NCT06191666|BEHAVIORAL|Group-based education and discussion|Group-based education and discussion (60 minutes each per week, virtual and in-person) based upon guidelines for nutrition for cancer survivorship (e.g., follow a plant-based diet with a variety of vegetables, fruits, whole grains, and legumes; limit alcohol intake; reduce consumption of highly processed foods and foods high in salt; achieve a weekly calorie deficit of approximately 3500 kcal for weight loss)
41123666|NCT06191666|BEHAVIORAL|Individual 1:1 counseling|Individual 1:1 counseling sessions (30 minutes each per month, virtual) with an RD to review progress and address barriers
41123667|NCT06191666|BEHAVIORAL|Group based behavioral skills development and cooking demonstrations|Group-based behavioral skills development sessions and cooking demonstrations (60-90 minutes each per month, in-person) to focus on behavior change techniques (e.g., self-monitoring, goal setting) and nutrition skills (e.g., recipe development, label reading).
41123668|NCT06191666|BEHAVIORAL|BfitBwell|This program consists of a supervised exercise program developed by a cancer exercise specialist and based upon the NCCN guidelines for physical activity during cancer survivorship and other recommendations.
41123669|NCT00424645|DRUG|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
41123670|NCT00424645|DRUG|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
41123671|NCT00274261|DRUG|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
41123672|NCT00274261|DRUG|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
41123673|NCT02115828|DRUG|Vismodegib|
41123674|NCT01119313|DRUG|LAS 41002|LAS 41002, once daily
41123675|NCT01119313|DRUG|Active|Active, once daily
41123676|NCT06061575|DRUG|Acetaminophen|fever will be managed with acetaminophen
41123677|NCT06061575|DRUG|Ibuprofen|fever will be managed with ibuprofen
41123678|NCT04370314|OTHER|Dental prosthetics|Implant-supported crowns
41275005|NCT05589818|DRUG|Pembrolizumab|Patients will be treated with the standard dose of pembrolizumab for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV. Patients will be offered this schedule, also an FDA-approved option, at the discretion of the treating physician, based on tolerability of the q3week regimen and clinician assessment of need for closer follow up intervals. Pembrolizumab will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or death.
41275006|NCT02614209|DEVICE|In Vitro diagnostic tests|Prospective blood collection
41275007|NCT00703313|DRUG|1.5% levofloxacin ophthalmic solution|1 drop instilled at each visit
41123679|NCT02058108|DRUG|Telbivudine|Patients of any age and weight\< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
40754306|NCT00773110|DRUG|Gelofusin|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
40754307|NCT02916771|DRUG|Ixazomib|Oral, proteasome inhibitor
40754308|NCT02916771|DRUG|Lenalidomide|Oral, immunomodulatory agent
41123680|NCT02058108|DRUG|Placebo|Patients of any age and weight \< 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
40754309|NCT02916771|DRUG|Dexamethasone|Oral, steroid
40754310|NCT05472181|DEVICE|rTMS (Repetitive TMS)|TMS stimulation produce electromagnetic pulses that can directly changes the neural firing in the brain. The rTMS applies the magnetic pulses in a repetitive manner, and can induce either an inhibitory or excitatory effect on cortical neurons. In this study we use high frequency rTMS (10 Hz) to provide the excitatory effect.
41123681|NCT03299322|DRUG|Jia Wei Yang He granule|This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time
41123682|NCT03299322|DRUG|Jia Wei Yang He granule Placebo|Made from 1/20 doses which has certain taste, but no therapeutic effect
41123683|NCT05328271|DIETARY_SUPPLEMENT|Beta-Aminoisobutyric Acid|All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol.
41123684|NCT01218698|DRUG|Losartan Potassium Tablets|
41123685|NCT00826280|DRUG|regadenoson|IV
41123686|NCT00826280|DRUG|overencapsulated caffeine|oral
41123687|NCT00826280|RADIATION|technetium|IV
41123688|NCT00826280|DRUG|placebo|oral
41123689|NCT04386356|DEVICE|Orotracheal intubation with either Macintosh laryngoscope versus Airtraq video laryngoscope|Tracheal intubation will be performed by first year anaesthesia trainee using either Macintosh laryngoscope or Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
41123690|NCT03886402|DEVICE|GID SVF-2|Treatment of erectile dysfunction with the subjects own cells
41123691|NCT01073358|PROCEDURE|Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
41123692|NCT01985334|DRUG|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
40754311|NCT05472181|BEHAVIORAL|Speech training|The behavioural training will include reading sentences in which a syllable is spoken in time to a rhythmic beat.
40927181|NCT05245396|DRUG|Evobrutinib MR-T1|Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.
40927182|NCT05245396|DRUG|Evobrutinib MR-T2|Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.
40927183|NCT05245396|DRUG|Evobrutinib MR-T3|Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.
41123693|NCT01985334|DRUG|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
41123694|NCT01985334|DRUG|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
41123695|NCT01985334|DRUG|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
41123696|NCT01985334|DRUG|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
41123697|NCT01985334|DRUG|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
41123698|NCT01985334|DRUG|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
41123699|NCT01193894|OTHER|Profermin|Medical Food (food for special medical purposes)
41123700|NCT01193894|OTHER|Fresubin|Medical food (food for special medical purposes)
41123701|NCT05123742|DIAGNOSTIC_TEST|COVID-19 Testing|Testing for the SARS-CoV-2 virus
41123702|NCT05821569|OTHER|Standard approach|Adoption of standard approach (derived by Unicef guidelines) to breastfeed
41123703|NCT05821569|OTHER|Biological nurturing|Adoption of biological nurturing approach to breastfeed
41123704|NCT03636334|BEHAVIORAL|Computer-based decision support system|At intervention sites, physicians will receive training and support on use of the DSS, which will be installed on their local IT system. Individuals eligible for DSS at Intervention sites will be randomized or assigned to different drug sequence protocols for BP-lowering therapy using their current antihypertensive medications, co-morbidities, and intolerance to medications and according to the assignment plan in the Algorithm. If the protocol is not suitable for the patient because of new co-morbidities, medication intolerance or contraindication, the DSS will recommend switching to a new protocol.
41123705|NCT02320877|DEVICE|Mandibular Advancement Device (Somnomed Flex)|The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature
41123706|NCT04144335|BIOLOGICAL|N-803 and bNAbs|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
41123707|NCT04144335|BIOLOGICAL|haNK™ Cells|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
41275008|NCT00703313|DRUG|0.5% moxifloxacin hydrochloride ophthalmic solution|1 drop instilled at each visit
41275009|NCT00703313|DRUG|0.3% gatifloxacin ophthalmic solution|1 drop instilled at each visit
40754312|NCT05914259|OTHER|No Intervention|Following the manner of observational study, no intervention will be provided in the study.
40758306|NCT02743312|DEVICE|Fitbit Flex|Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
40758307|NCT04928131|OTHER|No intervention - retrospective observational cohort study|
41123708|NCT03682250|DEVICE|FreeStyle Libre Pro|A FreeStyle Libre Pro will be used to identify hypoglycemic episodes
41123709|NCT03682250|DEVICE|Holter monitor|A Holter monitor will be used to measure heart's activity
41123710|NCT05741489|DEVICE|Continuous glucose monitoring (CGM)|The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.
41123711|NCT03333018|DRUG|Aclidinium bromide|Administered as monotherapy, prescribed as recorded in the database.
41123712|NCT03333018|DRUG|Aclidinium bromide/formoterol|Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.
41123713|NCT03333018|DRUG|Other COPD medication|"Other COPD medication including:~tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database."
40758308|NCT01756365|PROCEDURE|Surgical transplantation of ACCE|The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency.
41123714|NCT00345150|DRUG|Ng-monomethyl-L-arginine (drug)|
41275010|NCT05668221|BEHAVIORAL|Prehabilitation|Prehabilitation includes exercise prescription, cognitive function assessment and training, nutritional optimisation at least 4 weeks prior to surgery
41275011|NCT04321811|OTHER|Observation of patients with known, suspected, or at risk for COVID-19 infection|Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.
41275012|NCT05212025|DRUG|Adavosertib|Taken Orally
41275013|NCT05212025|DRUG|Gemcitabine|Intravenous Infusion
41275014|NCT03333473|BEHAVIORAL|PPFP Clinical and Counseling Skills|Facilities will receive whole-site orientations on PPFP basics and skills Through training of trainers, followed by classroom and model-based and clinical-based practice, providers will receive training in PPDP counseling and service provision.
41275015|NCT03333473|BEHAVIORAL|Facility-Level Leadership Management and Governance Training|The intervention will strengthen leadership management and governance practices required to help managers establish PPFP services at the facility level.
41275016|NCT04217343|DIAGNOSTIC_TEST|Allosure/Allomap/Cytokines testing|All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.
41275017|NCT03793543|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
41275018|NCT02938182|DRUG|clopidogrel|clopidogrel troche 75 mg daily for three months
41275019|NCT04519944|DRUG|Edoxaban|This is an observational, prospective study; no treatment will be administered.
41275020|NCT03046251|DRUG|Natalizumab|
41275021|NCT02712775|DRUG|Minocycline (yes/no)|
40927184|NCT05245396|DRUG|Evobrutinib MR-T4|Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.
40927185|NCT05245396|DRUG|Evobrutinib MUPS-C1|Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.
40927186|NCT05245396|DRUG|Evobrutinib MUPS-C2|Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.
41123715|NCT01199133|DRUG|Dpte and Dfar Allergen Extracts|300 IR, once a day, for one year.
41123716|NCT01199133|DRUG|placebo|once a day, for one year.
41275022|NCT02712775|DRUG|Placebo|Saline
41275023|NCT06487949|DRUG|valsartan-amlodipine 80/5 mg FDC|fix dose combination of valsartan 80 mg and Amlodipine 5 mg given as single pill
41275024|NCT06487949|DRUG|valsartan 80 mg and amlodipine 5 mg as free combination|Free combination of valsartan 80 mg and amlodipine 5 mg given separately
40927187|NCT05245396|DRUG|Evobrutinib MUPS-C3|Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.
40927188|NCT05245396|DRUG|Evobrutinib MUPS-C4|Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.
40927189|NCT05245396|DRUG|Evobrutinib MR-T adapated|Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.
41123717|NCT03292913|BEHAVIORAL|Positive Health Check|Positive Health Check (PHC) is an online intervention that delivers tailored evidence-based prevention messages to human immunodeficiency virus (HIV) positive patients through a series of brief interactive videos designed to simulate a conversation with an human immunodeficiency virus (HIV) primary care provider.
41275025|NCT02262403|OTHER|Blood and feces sampling|Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
41275026|NCT02355301|PROCEDURE|orthopedic|Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
41275027|NCT05192187|OTHER|Cross-sectional self-report (questionnaires)|"participants in this group will be ask to complete questionnaires on one occasion (i.e., cross-sectional investigation). The questionnaires will consist of a self-developed questionnaire and standard questionnaires. The main aspects of the self-developed questionnaires are~* perceived harmfulness of activities (selection of PHODA-SeV)~* cognitions about lifting and pain~* reasons for avoidance behaviour (lifting)~Standardised questionnaires include~* NRS for pain~* TSK-11~* FABQ~* RMDQ"
40758309|NCT00311831|BEHAVIORAL|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
40758310|NCT00311831|BEHAVIORAL|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
40927190|NCT01802918|DRUG|GSK2838232|Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
40927191|NCT01802918|DRUG|Placebo|Visually matching GSK2838232
40927192|NCT01802918|DRUG|Ritonavir|100mg tablets once daily for 12 days
40927193|NCT05702749|PROCEDURE|Microsurgical resection of VS|Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.
40927194|NCT05702749|RADIATION|Stereotactic radiosurgery|Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.
40927195|NCT05702749|OTHER|PREHAB|A PREHAB visit will be done once weekly for 3 weeks to determine exercise regimen prior to surgery or radiotherapy. Therapy includes balance exercises (twice daily), gaze stabilization exercises (12-20 minutes daily), and habituation exercises (as applicable).
40927196|NCT03712709|DIAGNOSTIC_TEST|Truenat MTB|The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.
41275028|NCT03378570|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.
41275029|NCT05991024|BEHAVIORAL|the incisional hernia recurrent|Recurrence after repair was the main outcome
41275030|NCT03596164|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
41275031|NCT03596164|DEVICE|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.
41275032|NCT03596164|DEVICE|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
41275033|NCT03596164|DEVICE|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
41275034|NCT00125047|BIOLOGICAL|Typhoid Vi vaccine|Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.
40927197|NCT06427343|DRUG|High-dose ferric derisomaltose|"After baseline assessment, participants will be randomized in a 1:1 ratio to receive a high-dose IV iron regimen and a low-dose IV iron regimen. After the initial iron repletion, ferritin concentration and TSAT were measured every three months and the results used to determine the dose of ferric derisomaltose during follow-up.~In the high-dose group, participants will receive repeat iron dosing as long as the serum ferritin was not \>700 ng/mL, or if TSAT was not \>40% during follow-up."
40927198|NCT06427343|DRUG|Low-dose ferric derisomaltose|In the low-dose group, participants will receive repeat iron dosing if ferritin \<100 ng/mL or if ferritin 100-300 ng/mL and TSAT \>20% during follow-up.
40927199|NCT01649843|PROCEDURE|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
40927200|NCT02278523|DEVICE|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
41123718|NCT03292913|BEHAVIORAL|Standard of Care|Standard of care for patients with human immunodeficiency virus (HIV) (this includes standard of care practices around antiretroviral therapy (ART) initiation, adherence and retention)
41275035|NCT00125047|BIOLOGICAL|Hepatitis A vaccine|single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
41275036|NCT04366999|PROCEDURE|SG|SG involved a vertical gastric resection beginning 4-6 cm from the pylorus and ending 1-2 cm from the His angle, using linear staplers with the guidance of a 36 French intragastric bougie.
40927201|NCT01479426|DIETARY_SUPPLEMENT|EFLA400|EFLA400(960mg/day)for 12 weeks
40927202|NCT01479426|DIETARY_SUPPLEMENT|Placebo|Placebo(960mg/day) for 12 weeks
40927203|NCT01107379|DEVICE|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
41123719|NCT02974465|PROCEDURE|Biofeedback Electromyography|protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
40927204|NCT03513445|DRUG|Morphine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
40927205|NCT03513445|DRUG|Epinephrine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
40927206|NCT03513445|DRUG|naropin|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
40927207|NCT01055652|DRUG|Dapagliflozin|10mg, oral, once daily
40927208|NCT00966784|OTHER|Dietary Fibers|
41123720|NCT02974465|PROCEDURE|Sham Biofeedback Electromyography|consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
41275037|NCT04366999|PROCEDURE|RYGB|RYGB entails the creation of a 15-30 mL (approximate) gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb.
41275038|NCT04366999|PROCEDURE|OAGB|OAGB entails the creation of a long gastric tube by beginning 2 cm below the angular incisure starting from the lesser curvature side and then divided vertically upward by linear cutting staplers as calibrated with a 36 French bougie, followed by the creation of a single gastrojejunal anastomosis with an afferent biliopancreatic limb of 200 cm.
41275039|NCT00541307|DEVICE|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface|Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
41275040|NCT00431392|DRUG|Phenylephrine|
41275041|NCT00431392|DRUG|NG-Monomethyl-L-Arginine|
40927209|NCT03030742|OTHER|Survey|"A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~* Satisfaction with pain control 2-4 weeks postpartum~* Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~* Patient characteristics associated with high opioid use~* Methods of storage and disposal of unused opioids"
40927210|NCT01976039|OTHER|rhinopharyngeal retrograde clearance (RRC)|The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation
41275042|NCT00431392|DRUG|Propanolol|
41275043|NCT00431392|DRUG|Atropine|
40927211|NCT01431209|OTHER|Laboratory Biomarker Analysis|Correlative studies
40927212|NCT01431209|DRUG|Ruxolitinib Phosphate|Given PO
41123721|NCT02974465|PROCEDURE|Conventional Physical Therapy Treatment|All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,...), exercise programs, electrotherapy, myofascial techniques, etc...
41275044|NCT04406571|OTHER|Data record|Data record
41275045|NCT00481481|DRUG|tacrolimus|immunosuppression
41275046|NCT04514263|OTHER|OHIP-14 Administration|All patients fulfilled the OHIP-14 questionnaire three times: six hours, seven days and twenty-one days after the biopsy
41275047|NCT04514263|OTHER|VNS Administration|All patients fulfilled the VNS scale three times: six hours, seven days and twenty-one days after the biopsy
41275048|NCT03182439|DEVICE|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
41275049|NCT03182439|DEVICE|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
41275050|NCT03182439|DEVICE|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
41275051|NCT03182439|DEVICE|Apple Watch|Apple Watch Heart Rate Monitoring Device
41275052|NCT01967043|DRUG|Oraxol|Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
41123722|NCT06107751|OTHER|Ramped position group|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
41123723|NCT06107751|OTHER|Sniffing position group|This position will be achieved by placing a 7 cm pillow under the occiput.
41275053|NCT01412437|DIETARY_SUPPLEMENT|diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
41275054|NCT01412437|DRUG|sapropterin dihydrochloride|20 mg/kg for 4 months
41123724|NCT02894879|DEVICE|BreatheMAX®|"Modify chest physical therapy~* oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set~* oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms rises 10 times/set total 5 set/day"
41123725|NCT02894879|OTHER|Routine treatment|"Routine chest physical therapy~* Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms raised 10 times/set total 5 set/day"
41123726|NCT00226889|DRUG|bosentan|
41123727|NCT02224105|DRUG|BI 653048 BS|
41123728|NCT02224105|DRUG|Prednisolone low|
41123729|NCT02224105|DRUG|Prednisolone high|
41123730|NCT02224105|DRUG|Placebo|
41123731|NCT02224105|DRUG|sodium chloride infusion|
41123732|NCT02224105|DRUG|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|
41123733|NCT01717820|DIETARY_SUPPLEMENT|Freeze-dried whole-grape powder|Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
41123734|NCT04134793|PROCEDURE|radiofrequency ablation|bipolar radiofrequency ablation by ablation forceps
41275055|NCT01412437|DRUG|sapropterin dihydrochloride|
41275056|NCT04964258|DRUG|TAK-105-a|TAK-105-a subcutaneous solution.
41275057|NCT04964258|DRUG|TAK-105-a Placebo|TAK-105-a placebo-matching solution.
41275058|NCT05464095|DEVICE|mHealth Intervention|The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
41275059|NCT05464095|DEVICE|Usual Care|The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.
41123735|NCT04437641|OTHER|Tobacco questionnaire|"A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.~Provision of minimal advice (oral and a leaflet from the anti-smoking centre) to parents who smoke by the paediatrician following the child.~For parents who smoke, evaluation at 3 months of the impact of this minimal advice by another questionnaire during the usual follow-up of the patient at 3 months or by telephone contact."
41275060|NCT03177161|OTHER|15 Patient Reported Health Status Questions|The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
41275061|NCT03176290|DIAGNOSTIC_TEST|Fibro-α score = (1.35 (numeric constant) +AFP (IU ml-1) × 0.009584 + aspartate aminotransferase (AST)/alanine aminotransferase(ALT) × 0.243 - platelet count (×109 l-1) × 0.001624).|Radiological investigations included Abdominal Doppler ultrasound, Magnetic Resonance Elastography(within 3 months of liver biopsy) and fibroscan.
41275062|NCT03758586|OTHER|Computerized spatial skill training|The spatial skills training session consisted of six practice trials that were run in a sequence. The objective of each practice was to manipulate the simulated robotic arm to grab the cubes and move them to a desired location using keyboard keys. The participant was required to reach a decision based on the visual-spatial information, before initiating subsequent movements of the simulated robotic arm. Each practice trial presented an initial state of the cubes in front of the robotic arm, and a target position of the cubes.
41275063|NCT03758586|OTHER|Watching a presentation regarding robotic surgery|Watching a 20-35 minute long power-point presentation regarding the history of robotic surgery.
41275064|NCT03004560|PROCEDURE|Standard Laparoscopic Approach|Minimally invasive laparoscopic surgery with 5-10 mm incisions.
41275065|NCT03004560|PROCEDURE|Percutaneous Approach|Minimally invasive laparoscopic surgery with 2-3 mm incisions.
40927213|NCT03708562|DEVICE|everlinQ endoAVF System|The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
40927214|NCT03086564|BIOLOGICAL|ADCC & TACE|Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2\*10\^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.
41123736|NCT01391832|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.
41123737|NCT01391832|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
41123738|NCT01391832|DEVICE|Repetitive Transcranial Magnet Stimulation (rTMS)|For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
41123739|NCT03733119|DRUG|Akt/ERK Inhibitor ONC201|Given PO
41123740|NCT03733119|DIETARY_SUPPLEMENT|Methionine-Restricted Diet|Given PO
41123741|NCT00185549|BEHAVIORAL|CF. DOC|
41123742|NCT03131869|OTHER|Thickened Beverages Nectar|Thickened beverages in nectar consistency
41123743|NCT03131869|OTHER|Thickened Beverage Honey|Thickened beverages in honey consistency
41123744|NCT06338540|OTHER|Black color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the black caries color related to history of pain , ICDAS , pulp exposed and microbial load
41123745|NCT06338540|OTHER|dark brown color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the dark brown caries color related to history of pain , ICDAS , pulp exposed and microbial load
40927215|NCT03086564|PROCEDURE|TACE|TACE solely in the first day of a clinical course.
40927216|NCT02472509|DRUG|Ursodeoxycholic Acid|"Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.~Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose."
41275066|NCT05641649|DRUG|Sodium valproate and valproic acid extended release tablet|Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.
41275067|NCT02049502|BIOLOGICAL|biologically active human fecal microbiota|instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
41275068|NCT02049502|PROCEDURE|sigmoidoscopy|
41275069|NCT02534649|PROCEDURE|Newly obtained biopsy and Blood samples collection|"For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.~Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.~All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report."
41275070|NCT00962715|BIOLOGICAL|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
41275071|NCT00962715|DRUG|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
41275072|NCT00962715|DRUG|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
41275073|NCT01322828|PROCEDURE|Distal bicep tendon reconstruction|Randomized to either a single incision technique or a double incision technique.
41275074|NCT00975091|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
41123746|NCT06338540|OTHER|light brown color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the light brown caries color related to history of pain , ICDAS , pulp exposed and microbial load
41123747|NCT06338540|OTHER|yellow color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the yellow caries color related to history of pain , ICDAS , pulp exposed and microbial load
41275075|NCT00975091|DRUG|Entecavir|Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
41275076|NCT05989503|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titration at the discretion of the treating physician
41123748|NCT01627652|OTHER|altitude|the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
41123749|NCT05958836|DEVICE|pacemaker|Micra TPS or traditional PM group
41275077|NCT05989503|DRUG|SGLT2 inhibitor|Either empagliflozin or dapagliflozin 10 mg/day
41123750|NCT06435650|COMBINATION_PRODUCT|Cannabis suppositories and mindful-compassion for anal pain|This is a combined intervention that includes mindful-compassion and cannabis suppositories for anal pain
41123751|NCT06435650|BEHAVIORAL|Mindful-compassion|Mindful-compassion
41123752|NCT04454879|DRUG|Roxadustat|Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.
41275078|NCT01846780|PROCEDURE|PTA & stenting|PTA \& stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
41275079|NCT05595876|PROCEDURE|stent retriever thrombectomy|The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.
41275080|NCT05595876|PROCEDURE|contact aspiration thrombectomy|A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
41275081|NCT03358472|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
41275082|NCT03358472|DRUG|Epacadostat|Epacadostat administered orally twice daily.
41123753|NCT05493644|OTHER|Remedial treatment within 3 months|Remedial therapy was performed within 3 months
41123754|NCT05493644|OTHER|Remedial treatment within 3 to 6 months|Remedial therapy was performed within 3 to 6 months
41275083|NCT03358472|DRUG|Cetuximab|Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.
41275084|NCT03358472|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks for \</= 6 cycles.
41275085|NCT03358472|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks for \</= 6 cycles.
41275086|NCT03358472|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously every 3 weeks for \</= 6 cycles.
41275087|NCT04081805|PROCEDURE|LASER|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
41275088|NCT04081805|PROCEDURE|Micro Ablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured
41275089|NCT04081805|DRUG|Promestriene|The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
41275090|NCT05303493|BIOLOGICAL|Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI|Evaluate the safety and tolerability of CC prebiotic in addition to ICI in patients with NSCLC and melanoma
41275091|NCT06071611|OTHER|Experimental: Oxygen-Ozone (O2-O3)|Oxygen-Ozone (O2-O3) treatment by rectal insufflations for 5 weeks (3 sessions for week).
41123755|NCT05493644|OTHER|Remedial treatment within 6 to 12 months|Remedial therapy was performed within 6 to 12 months
40927217|NCT06363266|BEHAVIORAL|TEMPO|"Stage 1 interventions (week 1-12): After 12 weeks, response will be determined. At recruitment, at least one member of the dyad must report anxiety symptoms defined as a Hospital Anxiety and Depression Scale (HADS)-Anxiety subscale score \> 6. After Stage 1, for the dyad to be TEMPO Responder, both members' anxiety scores on the HADS-Anxiety must be \< 6 or decreased by at least 2 points. If both members of the dyad had anxiety symptoms at recruitment, then both must meet a response criterion. As soon as one dyad member does not meet the response criterion, the dyad is TEMPO non-responder.~Stage 2 interventions (week 14-25): TEMPO responders continue with TEMPO. Non-responders will be re-randomized to: a) more time with TEMPO or b) add non-health care professional guidance (8 x 20-minute telephone calls). Guides' training will include TEMPO review, their role and the manual. Semi-structured exit interview will gather guides' experiences."
41123756|NCT05493644|OTHER|Remedial treatment after 12 months|Remedial therapy was performed after 12 months
41123757|NCT05180851|DRUG|Recombinant L-IFN adenovirus injection|Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
41123758|NCT03167944|DEVICE|Low thermal electrosurgery system|PEAK Plasmablade
41123759|NCT03167944|DEVICE|Conventional Electrocautery|Conventional Electrocautery
41123760|NCT00017472|BIOLOGICAL|apolizumab|Given IV
41123761|NCT00017472|OTHER|laboratory biomarker analysis|Correlative studies
41123762|NCT00017472|OTHER|pharmacological study|Correlative studies
41123763|NCT05956613|PROCEDURE|Partial pulpotomy|Use of newly introduced bioceramic putty in partial pulpotomy
41123764|NCT05003778|OTHER|Traditional equipment resistance training|Participants will undergo 6 weeks of traditional equipment resistance training
41123765|NCT05003778|OTHER|Minimal equipment resistance training|Participants will undergo 6 weeks of minimal equipment resistance training
41123766|NCT05003778|OTHER|Blood flow restriction training|Participants will undergo 6 weeks of blood flow restriction training
41123767|NCT02444858|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous injection(5×10\^5/kg) ，once a day,a total of three times.
41123768|NCT02444858|OTHER|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
41123769|NCT01596933|DIETARY_SUPPLEMENT|BioMega SDA®|Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
41275092|NCT06071611|OTHER|Active Comparator: Oxygen (O2)|Oxygen (O2) treatment by rectal insufflations for 5 weeks (3 sessions for week).
41275093|NCT06071611|OTHER|Placebo Comparator: Placebo (Air)|Air treatment by rectal insufflations for 5 weeks (3 sessions for week).
41275094|NCT01129752|OTHER|No intervention|there is no intervention for this study
41275095|NCT03756792|BEHAVIORAL|Normal Education Material|Patients will receive standard educational material about Mohs micrographic surgery.
41275096|NCT03756792|BEHAVIORAL|Vignette|Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.
41275097|NCT02036229|DRUG|ivermectin cream 0.5%|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
40927218|NCT06363266|OTHER|Active Monitoring dyads' anxiety|"Stage 1 interventions (week 1-12): Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices).~Stage 2 interventions (week 14-25): Dyads not responding to active monitoring will be stepped up to TEMPO; responders to active monitoring will only be invited to complete the follow-up measures."
40927219|NCT00497042|DEVICE|Self Adjusting File|
40927220|NCT00882570|DRUG|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
40927221|NCT00882570|DRUG|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
40927222|NCT04951323|DRUG|anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
40927223|NCT02294760|DEVICE|Subsensory|The stimulation is set to 90% of the sensory threshold.
40927224|NCT02294760|DEVICE|OFF|The stimulation is turned OFF.
40927225|NCT06506370|OTHER|nonsurgical periodontal treatment|The patients underwent treatment in accordance with the guidelines of the European Federation of Periodontology (EFP). Initially, patients were informed of their condition, educated on oral hygiene practices, and advised to cease detrimental habits such as smoking. Following this, supragingival cleaning was conducted using ultrasound, with manual subgingival instrumentation utilizing a reduced set of Gracey curettes for pockets exceeding 4 mm with persistent bleeding or greater than 6 mm.
40927226|NCT00298753|PROCEDURE|fluid restriction for 14 days (15ml fluid per kg weight)|
40927227|NCT05264948|DIAGNOSTIC_TEST|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
40927228|NCT02762773|PROCEDURE|non-dissection of inferior rectus sheath|Non-dissection of inferior rectus sheath
40927229|NCT02762773|PROCEDURE|control|Dissection of inferior and superior aspect of the rectus sheath
40927230|NCT05772351|DRUG|micronized flavonoid fraction|"Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work."
41123770|NCT01596933|DIETARY_SUPPLEMENT|Sunflower oil high oleic|Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
41123771|NCT05437952|DIETARY_SUPPLEMENT|Taurine and Exercise (Tau+Ex)|"Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks"
41123772|NCT05437952|OTHER|Placebo and Exercise (PL+Ex)|"Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks."
41123773|NCT05437952|DIETARY_SUPPLEMENT|Taurine (Tau)|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
41123774|NCT05437952|OTHER|Placebo (PL)|Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
40927231|NCT00002455|BIOLOGICAL|Corynebacterium granulosum P40|
41275098|NCT04007484|DEVICE|Hemoperfusion|Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
41275099|NCT04629729|DRUG|FT819|Experimental Interventional Therapy
40927232|NCT00002455|PROCEDURE|adjuvant therapy|
40927233|NCT00837733|PROCEDURE|Endometrial biopsy|Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
40927234|NCT00837733|PROCEDURE|Endometrial Biopsy|Biopsy catheter
40927235|NCT04058171|DIAGNOSTIC_TEST|Treadmill walking test|Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
40927236|NCT00713310|DRUG|Asacol 400 mg|"High dose:~17-\<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-\<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-\<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM"
41275100|NCT04629729|DRUG|Cyclophosphamide|Lympho-conditioning agent
41275101|NCT04629729|DRUG|Fludarabine|Lympho-conditioning agent
41275102|NCT04629729|DRUG|IL-2|Biologic response modifier
41275103|NCT04629729|DRUG|Bendamustine|Lympho-conditioning agent
41275104|NCT04360265|OTHER|No Investigational Product|No investigational product will be administered in this follow-up trial.
40927237|NCT00713310|DRUG|Asacol 400 mg|"Low dose:~17-\<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-\<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-\<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM"
40927238|NCT01974765|DRUG|Enzalutamide|All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
40927239|NCT02183103|DRUG|meloxicam rapid release tablet, 12mg, UH AC62MU|
40927240|NCT01390064|BIOLOGICAL|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
40927241|NCT00813969|BIOLOGICAL|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
40927242|NCT04486001|BIOLOGICAL|PSC-04|adipose stem cells derived from screened donor lipoaspirate and culture expanded.
40927243|NCT03655002|DRUG|Cyclophosphamide|Given IV
40927244|NCT03655002|BIOLOGICAL|Cytokine-based Biologic Agent IRX-2|Given SC
40927245|NCT03655002|BIOLOGICAL|Nivolumab|Given IV
40927246|NCT06361381|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|"Both concha will be swabbed with an alcohol wipe before applying a thin layer of conductive gel. An ear clip electrode will be placed in the concha of both ears.~A frequency of 25 Hz will be applied with a pulse duration of 200 µs. Every 5 minutes, the subject will be asked if the intensity can be increased, decreased or remain the same to maintain the same level of intensity. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm."
41123775|NCT03165175|BEHAVIORAL|prescription drug-abuse education smartphone application|As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
41123776|NCT04406701|OTHER|Ceres|This will be a self-administered survey on eating habits and their relationship to coping strategies and economic level among nurses.
41123777|NCT03451721|DEVICE|ImageReady™ MR Conditional Defibrillation System|Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
41123778|NCT02891915|DRUG|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
41275105|NCT04360265|DRUG|Adjuvant Immunosuppression (IS) Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IS therapy.
41275106|NCT02763956|DEVICE|GelStix™ Nucleus Augmentation Device|Intradiscal Gelstix insertion
40927247|NCT06361381|DEVICE|Placebo Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|For placebo TaVNS, the intensity will be increased to a sensory level and then decreased to 0 mA. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm.
40927248|NCT06361381|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS will be applied on subject's forearm at a strong but comfortable intensity
41123779|NCT02891915|DRUG|Amoxicillin-clavulanate|A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
41123780|NCT02891915|DRUG|Cefdinir|Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
41123781|NCT02891915|OTHER|Placebo|Placebo
41123782|NCT05451095|DRUG|BI 474121|BI 474121
41123783|NCT05451095|DRUG|Placebo|Placebo
40927249|NCT00176189|DEVICE|All ceramic FPDs|
40927250|NCT03405779|PROCEDURE|Lung ultrasonography|Mechanically ventilated patients suffering from pulmonary diseases will undergo a lung ultrasonography during their stay in the intensive care unit (ICU)
40927251|NCT06032845|DRUG|Tislelizumab|a PD-1 immune check inhibitor
40927252|NCT06032845|DRUG|Lenvatinib|Lenvatinib capsules
40927253|NCT06032845|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
40927254|NCT06034990|OTHER|10-min online survey|This is a cross-sectional study. The data are collected by a 10-min online survey administered to included physicians which will be distributed via online channels such as such as official website or Facebook pages of Society of intensive care or Society of nephrology of corresponding countries.
40927255|NCT02864901|DRUG|KSL-W|Plaque reducing gum
40927256|NCT02864901|DRUG|Chewing Gum Placebo|
40927257|NCT03581890|OTHER|Socioeconomic position|"Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~1. age- and sex-adjusted available income the year before surgery~2. Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~3. Urbanicity (in four officially, predefined categories)."
40927258|NCT00506532|DRUG|Surfactant (calfactant)|
41123784|NCT05451095|DRUG|Ketamine hydrochloride|Ketamine hydrochloride
41123785|NCT00055705|BIOLOGICAL|PV701|
41123786|NCT03490045|OTHER|Diaper Incentive|A diaper incentive will be distributed to participants in the Intervention condition at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final distribution of diapers.
41275107|NCT02763956|OTHER|Placebo|Intradiscal saline injection
41275108|NCT02415790|DRUG|E2027|Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
41275109|NCT02415790|DRUG|E2027 matching placebo|E2027 matching placebo capsule will be administered.
41275110|NCT03614572|BEHAVIORAL|Group MI|refer to the arm description
41275111|NCT03941002|DIAGNOSTIC_TEST|Assesment of diaphragm function|Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation
41275112|NCT00925600|BIOLOGICAL|Denosumab|Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
40927259|NCT00130312|DRUG|Sulodexide|100 mg gelcap in the morning and evening
40927260|NCT00130312|DRUG|Placebo|1 placebo gelcap in the morning and evening
40927261|NCT06125470|BEHAVIORAL|Uptake of quality Reproductive health and Family planning products, information and Services|Strengthening capacity of health facilities and outreach to deliver quality reproductive and family planning services and address demand side barriers to the uptake of the services
40927262|NCT06125470|BEHAVIORAL|Capacity building of facility based and community based healthcare providers (public and private sector) on FP /SRH|"Training sessions on FP / SRH including FP Methods - LARC, PPIUD - Task Sharing \& Shifting for facility based healthcare providers at provincial level for Master Trainers with trickle down sessions at district level.~Training on Sayana Press, ECP, Balance Counselling Strategy and Life Skills Based Education for community-based healthcare providers including LHWs at district level."
40927263|NCT06125470|BEHAVIORAL|Adolescent Engagement|Identification of adolescent-friendly spaces through community based platforms including LHW health houses for girls and village health committees for boys with context-appropriate arrangements for LSBE and SRH counselling.
40927264|NCT06125470|BEHAVIORAL|Renovation and Refurbishment of selected healthcare facilities|Identification and improvement/ renovation of public and private healthcare facilities to strengthen the quality, provision and delivery of FP/SRH services, especially counselling, to catchment population
40927265|NCT06125470|BEHAVIORAL|Use of Data for Effective Decision-making|Improvement in data recording at the source level with reporting at existing platforms i.e. DHIS and LHW-MIS and use of this data for local decision making
40927266|NCT06125470|BEHAVIORAL|Procurement of FP/SRH medical supplies and equipment|Provision of commodities / supplies for shortest-time possible in facilities having stock-outs
40927267|NCT05060939|DIAGNOSTIC_TEST|COVID-19 vaccinated people|Patients with at least one dose of COVID-19 vaccine tested for SARS-CoV-2 infection with RT-PCR on respiratory specimen. RT-PCR, serological testing and viral sequencing will be applied on patient's samples
40927268|NCT03616223|DRUG|FX-322|Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate
40927269|NCT03616223|DRUG|Placebo|Intratympanic injection
41123787|NCT03490045|OTHER|Conditional Cash Transfer Condition|Participants in the control condition will receive the cash equivalent value of the diapers distributed to the Experimental Condition for their participation at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final conditional cash transfer.
41123788|NCT04135885|DRUG|Folic Acid|The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
41123789|NCT04135885|DRUG|Placebos|Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
41123790|NCT05855291|DIAGNOSTIC_TEST|PET/MRI|The participants receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
41123791|NCT03133234|DRUG|osimertinib|Oral dose of 80mg once daily
41123792|NCT03015311|DRUG|Intensive BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
41123793|NCT03015311|DRUG|Standard BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
41123794|NCT01236846|DIETARY_SUPPLEMENT|Fortified Yogurt Drink|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
41123795|NCT01236846|DIETARY_SUPPLEMENT|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
41123796|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis before any systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after which physician choice adjuvant systemic therapy is permitted
41123797|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after physician choice neo adjuvant systemic therapy. Physician choice adjuvant therapy is allowed after surgery
41123798|NCT00797017|DRUG|fentanyl|Infection, starting with 12mcg/h (flexible dose)
41123799|NCT00797017|DRUG|fentanyl|(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
41123800|NCT00797017|DRUG|fentanyl|Bone Fracture, starting with 12mcg/h (flexible dose)
41123801|NCT00797017|DRUG|fentanyl|(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
41123802|NCT00797017|DRUG|fentanyl|Other Deformity, starting with 12mcg/h (flexible dose)
41275113|NCT00925600|BIOLOGICAL|Placebo|Prefilled syringe for subcutaneous (SC) injection
41275114|NCT05262764|DRUG|JARDIANCE®|JARDIANCE®
41123803|NCT00797017|DRUG|fentanyl|(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
41275115|NCT02134886|DRUG|Erlotinib Hydrochloride|Given PO
41275116|NCT02134886|OTHER|Laboratory Biomarker Analysis|Correlative studies
41275117|NCT02134886|OTHER|Pharmacological Study|Correlative studies
41275118|NCT02134886|OTHER|Quality-of-Life Assessment|Ancillary studies
41275119|NCT04267640|BIOLOGICAL|AMG0001|AMG0001 is a DNA Plasmid encoding hepatocyte growth factor (HGF) administered intramuscularly
41275120|NCT04267640|BIOLOGICAL|Placebo|Matching placebo
41275121|NCT02160457|OTHER|Intervention with IGA|"Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis~The instrumented gait analysis consists of four steps:~1. Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)~2. Impairment-Focused Interpretation~3. Recommendation for interdisciplinary interventions~4. Dissemination of recommendations~The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group."
41275122|NCT00234949|DRUG|cefdinir|
41275123|NCT00234949|DRUG|cephalexin|
41446580|NCT02709057|BEHAVIORAL|Lifestyle intervention|Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
41446581|NCT05511363|DRUG|KarXT|KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
41446582|NCT05511363|DRUG|Placebo|Placebo Capsules
41123804|NCT00797017|DRUG|fentanyl|Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
41123805|NCT05950542|DRUG|Baricitinib|JAK inhibit0rs
41123806|NCT04741113|OTHER|An online 15-minute educational module|"An online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion"
41123807|NCT02355236|DRUG|Naproxen/Esomeprazol 500/20mg|Tablet, b.i.d.
41123808|NCT02355236|DRUG|Celecoxib 200mg|Capsule, o.d.
41123809|NCT02355236|DRUG|Naxozol-Placebo|Tablet (which is identical to Naxozol), b.i.d.
41123810|NCT02355236|DRUG|Comparator-Placebo|Capsule (which is identical to Celebrex), o.d.
41123811|NCT05125874|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
41123812|NCT01884805|DEVICE|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
41123813|NCT01420549|DRUG|Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
41123814|NCT01420549|DRUG|Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
41123815|NCT05877807|DRUG|Baclofen|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
41275124|NCT05014178|DIAGNOSTIC_TEST|Sodium-23 MRI|Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.
41275125|NCT01016626|DRUG|CKD-4101 tablet|"CKD-4101 tablet 1000 mg~* 500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)"
41275126|NCT01016626|DRUG|Mycophenolate Mofetil capsule|"Mycophenolate Mofetil capsule 1000 mg~* 250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)"
41275127|NCT06543771|DIAGNOSTIC_TEST|Safety Test ABO and ABTest Card®|Pre transfusional control with the Safety Test ABO device (reference device) and the ABTest Card® device (comparator).
41275128|NCT04774003|DRUG|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1
41275129|NCT04774003|DRUG|Placebo|Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1
41275130|NCT04774003|DRUG|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1
41287236|NCT02345161|DRUG|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
41287237|NCT02345161|DRUG|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
41287238|NCT02345161|DRUG|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
41275131|NCT05219695|PROCEDURE|Harmonic motion imaging guided focused ultrasound (HMIgFUS)|"Harmonic motion imaging guided focused ultrasound (HMIgFUS) is a combined treatment and imaging method, in which focused ultrasound (FUS) is used to thermally ablate tissue and harmonic motion imaging (HMI) is used for FUS guidance and monitoring. FUS applies high intensity focused ultrasound waves at its specified target to heat the tissue over a specified duration, causing cell death at the target area. HMI is an elasticity imaging technique which induces dynamic tissue vibrations at the target for tissue elasticity characterization.~One of the inclusion criteria for this study is that participants must be scheduled for surgical excision of their breast tumor. In this study, HMIgFUS will be applied to anesthetized participants immediately prior to their scheduled surgery. HMI imaging will also be performed immediately prior to and after HMIgFUS application."
41275132|NCT05747690|DEVICE|KIO015|Innovative carboxymethyl chitosan-based biomaterial intended for intradermal injection
41275133|NCT01771783|DRUG|ACEI-ARB-RI|
41275134|NCT01771783|DRUG|ARB-RI-ACEI|
41275135|NCT01771783|DRUG|RI-ACEI-ARB|
41275136|NCT02658448|DRUG|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
41275137|NCT01392833|DRUG|methylprednisolone|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
41275138|NCT01392833|DRUG|azathioprine|azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
41275139|NCT01392833|DRUG|prednisone|prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
41275140|NCT04420130|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks
41275141|NCT04420130|DRUG|Chemotherapy|The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
41275142|NCT04420130|PROCEDURE|Ablation|First give pancreatic cancer patients with liver metastases to ablation of liver metastases
41275143|NCT03566212|DEVICE|Conventional Syringe|local anesthesia was administered in first group using Conventional syringe
41275144|NCT03566212|DEVICE|Camouflage Syringe|local anesthesia was administered in second group using Camouflage syringe
41275145|NCT06275217|BEHAVIORAL|Mindfulness-based yoga program|The intervention includes mindfulness-based components and yoga practice. Once a week for 10 weeks, with 1.5 hours in each session (30 minutes mindfulness-based practice and 1 hour yoga practice). A well-trained research personnel will facilitate the mindfulness-based section, and a qualified yoga instructor will facilitate the yoga section.
41275146|NCT06275217|OTHER|Psychoeducation|Knowledge of perinatal mental health, stress-related management, postnatal nutrition, exercise habit and sleep hygiene will be provided to the participants in the psychoeducation group. It is a group-based intervention delivered in hybrid mode including face-to-face and online group-based class. Once a week for 10 weeks, with 1.5 hour in each session.
41275147|NCT02537041|PROCEDURE|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
41275148|NCT02537041|PROCEDURE|MRI|
40927270|NCT04180384|DRUG|Oraxol|"Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate"
41123816|NCT05877807|OTHER|Placebo|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
41275149|NCT00749203|DRUG|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
40927271|NCT03645343|DEVICE|Activator|This appliance is constructed in one piece to guide the position of the mandible on closure
41123817|NCT06375603|OTHER|Ultrasound scans|Clinical experts will conduct non-invasive ultrasound scans from the specified nerve or plane block views and record the acquired data.
40927272|NCT03645343|DEVICE|Twin Block|This appliance is constructed in two pieces to guide the position of the mandible on closure
41275150|NCT00749203|DRUG|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
41275151|NCT02241486|DRUG|Sublingual Fentanyl Spray|Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
41275152|NCT05871203|OTHER|Gene sequencing|Participants were taken blood samples for gene sequencing at three time periods: before, after, and 24 hours after the end of the surgery
41275153|NCT00702676|DRUG|Quetiapine Fumarate|Tablet, Oral, once daily
40927273|NCT06324227|OTHER|multimodal music therapy|music therapy
41123818|NCT05937646|DEVICE|AWARE|AWARE is a platform with a visualization dashboard that sits on top of pre-existing, comprehensive EHR systems. AWARE provides clinical decision support tools for the ICU, Emergency Departments and other critical care areas right at the patient's bedside.
41275154|NCT00702676|DRUG|Quetiapine Fumarate|Tablet, Oral, once daily
41275155|NCT04426630|OTHER|mHealth for heart failure patients in Uganda|Patients at Uganda Heart Institute will be enrolled in an mHealth program intended to promote self-care for heart failure and improve their healthcare quality of life.
41287239|NCT02345161|DRUG|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
40927274|NCT06324227|OTHER|no intervention|no intervention
41123819|NCT05937646|DEVICE|Electronic Health Record (EHR)|An Electronic Health Record (EHR) is an electronic version of a patients medical history, that is maintained by the provider over time, and may include all of the key administrative clinical data relevant to that persons care under a particular provider, including demographics, progress notes, problems, medications, vital signs, past medical history, immunizations, laboratory data and radiology reports.
41123820|NCT01307085|PROCEDURE|remote ischemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
41123821|NCT03237975|BEHAVIORAL|Be the Expert for Your Own (BEYO)|"The BEYO program is structured adopting solution focused therapy (SFT). The basic principles for SFT are focusing on positive change and establishing groups driven by goals rather than problems. Solutions are generated through searching for strengths, skills, resources that working in clients' lives.~The common flow for structured sessions contains 7 steps: 1) Health education; 2) Discuss self-care experience and identify deficit; 3) Describe exceptions; 4) Identify the strengths; 5) Miracle question and scaling; 6) Establish the solution; 7) Action plan."
41123822|NCT03237975|OTHER|Routine health education|The control group will receive routine health education.
41123823|NCT05230459|GENETIC|AB-1003 dose level 1|Single intravenous infusion of AB-1003 gene therapy at dose level 1
41123824|NCT05230459|GENETIC|AB-1003 dose level 2|Single intravenous infusion of AB-1003 gene therapy at dose level 2
41123825|NCT05230459|OTHER|Placebo|Single intravenous infusion of Placebo
41123826|NCT01541436|DEVICE|Remote Ischemic Preconditioning, Capsaicin, UV-B|The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
41123827|NCT00310635|BIOLOGICAL|Meningococcal C conjugate vaccine|
41123828|NCT05000424|OTHER|Clary Sage Massage Oil|This massage oil contains clary sage oil. Five drops will be used daily.
41123829|NCT05000424|OTHER|Inert Massage Oil|This massage oil consists entirely of plant based oils. Five drops will be used daily.
41123830|NCT02696161|OTHER|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
41123831|NCT02696161|OTHER|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
41123832|NCT05456698|DRUG|Inotuzumab ozogamicin|"Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15.~Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity."
41123833|NCT03778515|DIAGNOSTIC_TEST|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
41123834|NCT04577924|OTHER|Interview|"Trained research assistants would abstract the data as per a preset proforma. The data would be collected from the patient (if coherent), pre-hospital care provider or primary care provider.~Data would was also obtained from patient records and the proforma filled by the attending doctors on duty.~Follow up of cases would be done until discharge from the hospital."
41123835|NCT00220038|BEHAVIORAL|smell tests|subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
41123836|NCT02343029|OTHER|Individualised aerobic exercise training|During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
41123837|NCT02343029|OTHER|Waiting Control|After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
41123838|NCT02426138|OTHER|Medically Tailored Meal Delivery (MTM)|Patients will receive delivery of medically tailored meals for 12 weeks
41123839|NCT02426138|OTHER|Usual Care + Choose MyPlate|Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks
41123840|NCT00687219|BIOLOGICAL|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
41123841|NCT00687219|DRUG|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening \>=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening \>=12g/dL and \<14g/dL; treatment duration is 48 weeks
41123842|NCT05048251|DEVICE|cTBS|continuous theta burst stimulation
41123843|NCT05048251|DEVICE|iTBS|intermittent theta burst stimulation
41123844|NCT05048251|DEVICE|sham|sham stimulation
41123845|NCT02538458|DRUG|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
41123846|NCT02538458|DRUG|3 % hypertonic saline up to 24H|"* Treatment by inhalation of 3 % hypertonic saline, up to 24H.~* followed by 48h of placebo : isotonic saline inhalation. Placebo control group."
41123847|NCT02512250|OTHER|Registry|
41123848|NCT02459015|DEVICE|Implantation|A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
41123849|NCT01951170|DRUG|Tocilizumab|162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
40927275|NCT03990844|DIETARY_SUPPLEMENT|Okra seed|Noodle enriched with 10% and 20% Okra seed flour.
41123850|NCT00016250|DRUG|MKC-1|
41287240|NCT02345161|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
41123851|NCT04599088|OTHER|Brain functional MRI with simplified urodynamics|"Structural:~MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.~Functional:~With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image."
40927276|NCT00277082|DRUG|9-NC in aerosol reservoir|Samples will be minced or centrifuged and L9NC extracted by chromatography. L9NC will be measured by HPLC or mass spectrometry
40927277|NCT03489954|OTHER|Evaluation|Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.
40927278|NCT04503733|DRUG|Q4W GMA301 IV injections (300 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
40927279|NCT04503733|DRUG|Q4W GMA301 IV injections (600 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
40927280|NCT04503733|DRUG|Q4W GMA301 IV injections (1000 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
41123852|NCT03760354|DRUG|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
41275156|NCT03465033|OTHER|Early Physiotherapy|"From T1 to T2 patients will perform 3 daily repetitions of active exercises:1 5 repetitions of oral opening exercises and bilateral manual progressive stretching, protrusion and maximum lateralization of the jaw on both sides, holding each movement for 5s and a session of cryotherapy applied to the masseter, temporal and suprahyoid muscles for 120s in two 60s sessions. They will also perform 30 repetitions of exercises aimed at improving the labial seal (inflate cheeks) and the symmetry of the upper lip (broad smile). From T2 to T3 30 repetitions of the same exercises will be performed and passive progressive opening will be implemented by clamping Patients will also perform isometric contraction exercises in opening, closing, laterotrusion, protrusion and retrusion. Each movement will be repeated 5 times and it will remain for 5s."
41275157|NCT04738955|DRUG|Micafungin Sodium|micafungin sodium ≥ 100, \<200mg/time, once a day, intravenous drip. Low dose group
41275158|NCT00977652|PROCEDURE|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
41275159|NCT00977652|PROCEDURE|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
41275160|NCT00426673|DRUG|Brivaracetam (ucb34714)|
41275161|NCT03596346|OTHER|Rapeseed ingredient (RI)|2 snack bars daily containing 10 g of RI each.
41275162|NCT03596346|OTHER|Control product without added RI|2 snack bars daily containing 0 g of RI.
41446583|NCT05964140|DRUG|Different post-operative antibiotic regimens following surgical treatment of mandible fractures|"The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control)."
41123853|NCT03760354|OTHER|Placebo|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
40927281|NCT04503733|DRUG|Q4W GMA301 IV injections (1800 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
40927282|NCT04503733|OTHER|Q4W placebo IV injections|Placebo is indistinguishable from GMA301.
40927283|NCT06053710|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
41123854|NCT04251442|DEVICE|OrthoSensor Verasense Technology|IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.
41123855|NCT06516328|OTHER|Observational|GCF and saliva samples obtained.
41123856|NCT00645359|PROCEDURE|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
41275163|NCT00627666|BIOLOGICAL|anti-thymocyte globulin|
41275164|NCT00627666|DRUG|busulfan|
41275165|NCT00627666|DRUG|fludarabine phosphate|
41275166|NCT00627666|DRUG|leucovorin calcium|
41275167|NCT00627666|DRUG|methotrexate|
41275168|NCT00627666|PROCEDURE|allogeneic bone marrow transplantation|
41275169|NCT00627666|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41275170|NCT00627666|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
41275171|NCT02941367|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
41275172|NCT02941367|DRUG|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
41275173|NCT02941367|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
41275174|NCT02941367|DRUG|basal insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
41275175|NCT02844361|OTHER|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
41275176|NCT02844361|OTHER|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
41275177|NCT02792140|DRUG|Naltrexone|one week
41275178|NCT02792140|OTHER|Placebo|one week
41275179|NCT01812642|DRUG|JNJ-37822681|JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
41275180|NCT01812642|OTHER|Placebo|Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
41275181|NCT03011125|DRUG|dexlansoprazole injection|
41275182|NCT03011125|OTHER|placebo|
41275183|NCT03606382|DIAGNOSTIC_TEST|HostDx Fever Test|HostDx Fever test to distinguish between viral and bacterial infections
41275184|NCT03606382|DIAGNOSTIC_TEST|HostDx Sepsis Test|HostDx Fever test to determine the severity of a presented, suspected infection.
41275185|NCT06182631|DEVICE|Buzzy Bee|The Buzzy is a vibrating palm-sized device with removable ice wings developed by MMJ Labs Atlanta, GA. It uses Melzack and Wall's Gait Control theorywhich asserts that activation of non-nociceptive fibers can interfere with signals from pain fibers thereby inhibiting pain.
41275186|NCT06182631|DRUG|Vapocoolent|Vapocoolent is a volatile refrigerated liquid, ie ethyl chloride, which is supposed to feel like the skin is numb before insertion of the IV.
41275187|NCT06182631|OTHER|Placebo|A band will be placed on the arm before IV insertion for placebo effect.
41275188|NCT00036114|DRUG|aripiprazole|
41275189|NCT05198648|OTHER|Trigeminal cardiac reflex|Trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
41275190|NCT05198648|OTHER|Non-trigeminal cardiac reflex|No trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
41275191|NCT05409105|DIETARY_SUPPLEMENT|Mangoes|Frozen mangoes, 2 cups per day, 2 weeks
41275192|NCT05409105|DIETARY_SUPPLEMENT|Water|2 cups/day bottled water, 2 weeks
41275193|NCT02521129|DEVICE|Biopsy Track Ablator (STARmed, Goyang, Korea)|After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
41275194|NCT02939521|PROCEDURE|Surgery|
41275195|NCT03514914|BEHAVIORAL|The CHARM2 Intervention|CHARM2 intervention will involve gender, culture \& contextually-tailored family planning and gender equity counseling.
40927284|NCT05403398|DIETARY_SUPPLEMENT|B. subtilis CU1|2 billion CFUs daily, for 4 weeks
41275196|NCT01761734|BEHAVIORAL|text message|
41275197|NCT01724281|OTHER|No intervention, only follow up|
41275198|NCT00618722|DRUG|Deoxycholic Acid Injection|
41275199|NCT00618722|DRUG|Placebo|
41275200|NCT00332202|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
41275201|NCT00332202|DRUG|placebo|oral, daily
41275202|NCT01856114|DRUG|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
41275203|NCT01856114|OTHER|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
40927285|NCT03894371|DEVICE|Thermage FLX|Thermage FLX system for the correction of mild to moderate laxity of the skin of the face, neck, and eyelids.
41275204|NCT01856114|BEHAVIORAL|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
41275205|NCT05490992|OTHER|Behavioral Skills Training In-person|"Both an in-person and virtual telehealth version of Behavioral Skills Training (BST) was compared to the Car seat check-up traditional car seat educational method and BST telehealth was compared to BST in-person."
41275206|NCT02539706|DRUG|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
41275207|NCT02539706|DRUG|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
40927286|NCT00400608|DRUG|ADVAIR HFA|
40927287|NCT00400608|DRUG|ADVAIR DISKUS|
41123857|NCT00225797|DRUG|Oxymorphone Extended Release|
41123858|NCT04938752|DRUG|DA-2811|single dose administration (one tablet once a day)
41123859|NCT04938752|DRUG|DA-2811-R|single dose administration (one tablet once a day)
41123860|NCT00374192|DRUG|Eszopiclone|3 mg per day
41123861|NCT00374192|DRUG|Placebo|Placebo
41123862|NCT00225004|PROCEDURE|DEXA scan|orto
41123863|NCT05217849|BEHAVIORAL|Tai Chi|Tai Chi is an ancient Chinese form of exercise/martial art that involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
41123864|NCT05217849|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|PLIE is a gentle, mindful movement exercise program that integrates elements of Eastern and Western exercise modalities to develop mindful body awareness and enhance social connection.
41123865|NCT05217849|BEHAVIORAL|Health and Wellness Education|This on-line class will consist of hour-long lectures/talks about various topics related to healthy aging and wellness.
41123866|NCT02847715|DEVICE|ePRIME|ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
41123867|NCT06516315|PROCEDURE|Preoperative ultrasound examination.|Preoperative ultrasound examination performed the day before or the day of surgery.
41123868|NCT06516315|PROCEDURE|Peroperatoire angiography procedure and QFR analysis|Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
41275208|NCT05980234|DEVICE|Total Hip Arthroplasty with Longevity IT Oblique Liners|Primary or Revision Total Hip Arthroplasty using the Longevity IT Oblique liners according to the approved indications and compatible device.
41123869|NCT02929147|DRUG|Morphine|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
41123870|NCT02929147|DRUG|Dexketoprofen|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
41275209|NCT05980234|DEVICE|Total Hip Arthroplasty with Longevity IT Offset Liners|Primary or Revision Total Hip Arthroplasty using the Longevity IT Offset liners according to the approved indications and compatible device.
41275210|NCT06334679|OTHER|Cold Gel Packet Application|Cold gel packs will be placed on the burn areas of the patients in the maturation phase and applied for 20 minutes.
41275211|NCT00165009|DEVICE|Resolution clip (endo-clipping device)|Resolution clip (endo-clipping device)
41275212|NCT06441630|DRUG|AD-227A|Per Oral, 1 Tablet, Once a day for 8 weeks
41123871|NCT02929147|DRUG|Placebo|In the Group 3 the PCA will contain placebo.
41123872|NCT02807805|DRUG|Abiraterone Acetate|Given PO
41123873|NCT02807805|DRUG|Niclosamide|Given PO
41123874|NCT02807805|DRUG|Prednisone|Given PO
41123875|NCT06389435|PROCEDURE|Patients will be randomized to undergo TKR or RTKR|Total knee replacement (control group)
41123876|NCT02210442|BEHAVIORAL|educaguia intervention|Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
41123877|NCT02210442|OTHER|control group|Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
41123878|NCT06357559|DEVICE|OCTA|Optical Coherence Tomography Angiography
41123879|NCT03406936|DRUG|Daily interruption of midazolam|daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
41123880|NCT01497704|DRUG|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
41123881|NCT05494294|PROCEDURE|Intraorally de-epithelialization|In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.
41123882|NCT05494294|PROCEDURE|Extraorally de-epithelialization|In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
41123883|NCT06205251|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
41123884|NCT05136157|DRUG|Rapid-Acting Insulin|50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS
41275213|NCT06441630|DRUG|AD-227B|Per Oral, 1 Tablet, Once a day for 8 weeks
41446584|NCT02905435|DEVICE|Biodegradable Temporizing Matrix|The Biodegradable Temporizing Matrix (BTM) (also known as NovoSorb BTM) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
41446585|NCT00298415|DRUG|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
41275214|NCT06441630|DRUG|AD-227C|Per Oral, 1 Tablet, Once a day for 8 weeks
41275215|NCT06441630|DRUG|Placebo of AD-227B|Per Oral, 1 Tablet, Once a day for 8 weeks
41275216|NCT06441630|DRUG|Placebo of AD-227C|Per Oral, 1 Tablet, Once a day for 8 weeks
41275217|NCT04976452|OTHER|Multi-component teaching content|The students assigned to Group 1 will undergo interactive module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines. Following completion of the module, students will be presented with a powerpoint lecture by the Primary Investigator on Blood Pressure. Students will then undergo a competency examination that assesses their ability to measure blood pressure following the guidelines of the American Heart Association.
41123885|NCT04811716|DRUG|Pozelimab|Administered Sub-cutaneous (SC) per protocol
41123886|NCT04811716|DRUG|Cemdisiran|Administered SC per protocol
41275218|NCT02261441|OTHER|Observational and noninterventional study|No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.
41275219|NCT04078750|BEHAVIORAL|Tailored medication adherence plan|Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
41275220|NCT04223466|PROCEDURE|Subxiphoid surgery procedure|Subxiphoid procedure for thymectomy
41123887|NCT03745950|DRUG|Olaparib Oral Capsule|- Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
41123888|NCT03745950|DRUG|Placebo oral capsule|- Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
41123889|NCT01093820|DRUG|methoxy-polyethyleneglycol epoetin beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
41123890|NCT05715398|DRUG|BR790+anlotinib|BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
41275221|NCT04223466|PROCEDURE|VATS surgery procedure|VATS procedure for thymectomy
41123891|NCT00006198|DRUG|thalidomide|
41123892|NCT00006198|PROCEDURE|chemoembolization with doxorubicin/collagen|
41123893|NCT05412316|OTHER|Intervention: Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
41123894|NCT01139944|GENETIC|DNA methylation analysis|
41123895|NCT01139944|GENETIC|polymerase chain reaction|
41123896|NCT01139944|OTHER|laboratory biomarker analysis|
41123897|NCT00252369|DRUG|Infliximab|
41123898|NCT00252369|PROCEDURE|Instillation of fibrin glue|
41123899|NCT03116620|OTHER|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
41123900|NCT01408524|DRUG|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
41123901|NCT01408524|DRUG|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
41123902|NCT03786211|PROCEDURE|IANB by the guide of Panoramic|IANB will be injected by the guide of panoramic radiograph
41123903|NCT03786211|PROCEDURE|IANB without the guide of Panoramic|IANB will be injected without the guide of panoramic radiograph, in the routine way.
41275222|NCT01800721|BEHAVIORAL|SNAP|Behavioral: SNAP 7 group sessions, and 1 individual session
41275223|NCT01800721|BEHAVIORAL|SNAP Control|Behavioral: SNAP control 7 group sessions
41123904|NCT00387452|BEHAVIORAL|Aerobic Exercise and Strength Exercise|6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.
41123905|NCT00387452|BEHAVIORAL|Strength training|6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
41123906|NCT03136042|OTHER|physiotherapy techniques|oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
41123907|NCT03136042|OTHER|hypertonic saline 3%|four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
41123908|NCT03136042|OTHER|saline + physiotherapy maneuvers|sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
41123909|NCT02978716|DRUG|Trilaciclib|G1T28
41123910|NCT02978716|DRUG|Gemcitabine|Gemcitabine
41123911|NCT02978716|DRUG|Carboplatin|Carboplatin
41123912|NCT03608787|BEHAVIORAL|S-STOP|Pseudo-intoxicated patrons will enter each participating establishment and attempt to be served an alcoholic beverage. In the intervention phases, feedback on staff performance will be provided to owners/managers along with supporting materials and a link to a website with a video of a typical pseudo-intoxicated patron. Staff will be provided with a link to a website providing tips for preventing overservice.
41123913|NCT00096915|DRUG|Darbepoetin Alfa|"QM administration for 32 weeks, allowable doses:~15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg"
41123914|NCT05286489|COMBINATION_PRODUCT|Qigong exercise|The qigong style they learned is known as 18 Forms Tai Chi Internal Qigong. It is a kind of physical and mental exercise (internal qigong) that focuses on relaxation, deep breathing, and slow and coordinated movements and uses the mind to guide these movements. There are a total of 18 upper and lower body movements, and all of the techniques are performed while either standing or semi squatting. qigong practice session was initiated immediately and continued for about 6 minutes. Each participant in the qigong group performed 18 Forms Tai Chi Internal Qigong once and was assessed immediately afterward in sitting (to measure the vascular outcomes) and lying (to measure the upper limb circumference) positions. The control participants were given no specific exercise instruction after the baseline assessment. Instead, they were asked to rest (sit quietly in the laboratory) for 6 minutes and then participated in the postassessment directly
41123915|NCT05035303|PROCEDURE|Nor-Epinephrine injection versus saline during PCNL|The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
41275224|NCT02746510|GENETIC|Array comparative genomic hybridization|For each of the 150 patients deoxyribose nucleic acid (DNA) exactracted from a jugal mucosae sample will be analysed by the cytogeneticist and a CGH-a will be performed.
41275225|NCT05110066|PROCEDURE|Pulmonary endarterectomy|Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.
41275226|NCT05110066|PROCEDURE|Balloon pulmonary angioplasty|Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.
41275227|NCT01918254|DRUG|Paclitaxel|Paclitaxel IV infusion will be administered as per schedule described in individual arm.
41275228|NCT01918254|DRUG|Pertuzumab|Pertuzumab IV infusion will be administered as per schedule described in individual arm.
41275229|NCT01918254|DRUG|Lumretuzumab|Lumretuzumab will be administered as per schedule described in individual arm.
41275230|NCT01201213|DRUG|local anaesthetic injection|Single bolus of drug for pain relief in early labour
41275231|NCT01082276|DRUG|Lurasidone HCl|40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
41275232|NCT01231412|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
41275233|NCT01231412|DRUG|Cyclosporine|Given PO or IV
40927288|NCT04306991|DEVICE|Auscultation using an electronic stethoscope (EKO CORE 4)|"* Auscultation using an electronic stethoscope (EKO CORE 4). Record of at least 3 cardiac cycles.~* Measurement of cardiac output using echocardiography."
40927289|NCT01378546|DRUG|3,4-diaminopyridine|Treatment will begin with 5mg three times a day or less.
41123916|NCT03680417|BIOLOGICAL|Measles-Rubella (MR) Vaccine|Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
41123917|NCT01622400|OTHER|Therapeutic education HTA Vasc|The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
41123918|NCT05463913|DRUG|18F-FDG|Patients will receive a single intravenous injection of 3 MBq/kg 18F-FDG
41123919|NCT05463913|RADIATION|PET/CT imaging|Patient will undergo 2 CT acquisitions and multiple PET emission scans.
41123920|NCT01501604|DRUG|BKM120|100 MG PO QD in cycles of 28 days
41123921|NCT03276403|DEVICE|PiCCO Catheter|The PiCCO Catheter is an investigational device intended to measure lung water content in individuals requiring advanced haemodynamic monitoring. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
41123922|NCT02055742|DEVICE|illumigene CT and NG assays, illumipro-10|
41123923|NCT00704314|DRUG|Simvastatin|80 mg Simvastatin daily for 8 weeks
41123924|NCT00704314|DRUG|Placebo|The placebo was identical in appearance and was provided by the same manufacturer
41123925|NCT06518369|OTHER|Prehabilitation|"Prehabilitation program for 4-6 weeks before surgery will include:~* Review of the frailty risk analysis calculator score obtained in the frailty study (#2212-74)~* Review of lab results including complete blood count, creatinine, albumin, and prealbumin~* Review of chronic conditions.~* An office visit or telehealth visit to review instructions on instructions on nutrition, exercise, smoking cessation, and optimization of chronic disease.~* Drinking surgery immunonutrition drinks twice daily for 5 days before surgery.~* Educational information and video instruction~* Weekly phone calls to motivate, ensure adherence, and assess progress.~* Measurements of hand grip strength and body weight"
41123926|NCT01892683|DRUG|General anesthesia with propofol|Study subjects will undergo general anesthesia with propofol according to the clinical standard protocol practiced at the hospital of the University of Munich.
41123927|NCT00864552|DRUG|Kogenate (BAY14-2222)|Patients with severe haemophilia A (\<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
41123928|NCT02035670|OTHER|Two-step diagnostic strategy|"The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.~The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC\& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive."
41123929|NCT03964870|DIAGNOSTIC_TEST|Diagnostic of polymorphisms in malignant hyperthermia|Identify and catalogue the variants or polymorphisms in the RYR1 and CACNA1S genes in the Spanish population.
41275234|NCT01231412|DRUG|Fludarabine Phosphate|Given IV
41275235|NCT01231412|DRUG|Mycophenolate Mofetil|Given PO
41275236|NCT01231412|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
41275237|NCT01231412|DRUG|Sirolimus|Given PO
41275238|NCT01231412|RADIATION|Total-Body Irradiation|Undergo TBI
41275239|NCT04720703|BEHAVIORAL|Newsletters|Similar to prior empirical pediatric obesity interventions (Elder et al., 2009), the active attention waitlist control group will receive monthly newsletters that focus on physical activity, healthy eating, and screen time. These newsletters will be based on standard materials from the We Can program of the National Heart, Lung, and Blood Institute (NHLBI).
41287241|NCT00624338|DRUG|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
41287242|NCT00624338|DRUG|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
41446586|NCT00298415|DRUG|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
41275240|NCT04720703|BEHAVIORAL|Family-based Telehealth Intervention|All communications related to the intervention will occur through weekly small group video conferencing calls via Zoom and emails or text messages. The intervention will include diverse topics proven effective in prior interventions (Davis et al., 2019; McLean et al., 2003), including reading food labels, eating out, eating at social gatherings, sticker charts, praising/rewarding healthy choices, healthy foods available at home, portion sizes, healthy/easy/low-cost cooking ideas, goal setting, monitoring screen time, exercise opportunities available in neighborhood, family exercise ideas, and healthy sleep. The research team will also send relevant video/audio clips, brochures, reminders (text messages and emails) every week.
41275241|NCT01580930|BEHAVIORAL|exercise training|12 weeks, 5 days of week, 40 min per session of exercise training
41275242|NCT01580930|BEHAVIORAL|sedentary time reduction|participants provided with strategies to decrease sitting
41275243|NCT01580930|BEHAVIORAL|exercsie training plus sedentary time reduction|12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
41275244|NCT04475328|DRUG|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
41275245|NCT04475328|DRUG|Placebo of AngongNiuhuang pill|This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.
41275246|NCT04475328|OTHER|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke
41275247|NCT00645086|DRUG|clarithromycin extended-release tablets|5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
41275248|NCT00645086|DRUG|clarithromycin immediate-release tablets|7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
41275249|NCT01512589|RADIATION|Proton Beam Therapy (PBT)|1.8 Gy (Relative Biologic Equivalence ((RBE)) to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
41275250|NCT01512589|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|1.8 Gy to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
41123930|NCT06523205|DIAGNOSTIC_TEST|Clinical Measurements and Saliva Sample Collection|"Saliva samples will be collected from all patients. Clinical parameters will also be recorded. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist will record all clinical parameters using manual probing.~Following sampling, saliva samples will be stored at -80°C until analysis. Concentrations of Tenascin-C, IL-4, IL-6, and IL-1beta will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in saliva samples."
41123931|NCT00002287|DRUG|Zidovudine|
41123932|NCT02567656|DRUG|RP6530|Tablet starting at 200 mg
41123933|NCT05235906|DRUG|Surufatinib+Sintilimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Sintilimab injected intravenously 200mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
41123934|NCT05358457|BEHAVIORAL|Familiar Metacognitive Training|The original metacognitive training program consist of 8 therapeutic units and 2 complementary. Seven of the therapeutic units address cognitive deviations and errors that are frequently seen in problem solving in schizophrenia, involved in the formation and maintenance of delusions. The other three units work with metacognition and the aims of the progra, as a psychoeducation session, so in total the MCTf will include 11 sessions.
41275251|NCT01512589|BEHAVIORAL|Questionnaires|Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
41123935|NCT01337622|PROCEDURE|No check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
41123936|NCT01337622|PROCEDURE|Routine check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
41275252|NCT02154594|DRUG|Acacia catechu|
41275253|NCT02154594|DRUG|Chlorhexidine gluconate|
41275254|NCT02154594|OTHER|Distilled water|
41275255|NCT00041314|DRUG|carboplatin|
41275256|NCT00041314|DRUG|exisulind|
41275257|NCT00041314|DRUG|gemcitabine hydrochloride|
41275258|NCT03231514|DIETARY_SUPPLEMENT|Carbohydrate Supplement (Carb10)|2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
41275259|NCT03231514|OTHER|Diet|2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)
41275260|NCT03231514|OTHER|Exercise|All groups will participate in a standardized exercise intervention.
41275261|NCT04792866|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Comparing 3D FLAIR versus Coronal T2-WI MRI in detecting Optic Neuritis
41275262|NCT03973814|DEVICE|Thermax Blood Warmer|Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
41275263|NCT05690321|DRUG|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
41275264|NCT05690321|DRUG|Placebo|Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
41275265|NCT04994756|PROCEDURE|Stroke/Thrombectomy/Aneurysm-specific surgical procedures|Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.
41275266|NCT04222517|PROCEDURE|Incisional hernia repair by the mesh implant in sublay retromusuclar position|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
41287243|NCT00624338|OTHER|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
40927290|NCT04869748|OTHER|Perfetti method|"* Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Participants received a 15-minute session of Perfetti method on affected elbow flexor.~* Participants were asked to concentrate on the position of their elbows.~* Protocol has 4 steps of training starting from 2 positions; full flexion and full extension 3 positions; full flexion, elbow flexion 90 degree and full extension 4 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 45-60 degree and full extension 5 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 90 degree, elbow flexion 45-60 degree and full extension of elbow.~* After therapist passively moved elbow joint to a position, participant guessed the position of his/her elbow. If the answers were correct consecutively for 10 times, the therapist increased the number of positions according to the protocol."
40927291|NCT04869748|OTHER|passive stretching|"* Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Each participant received gentle passive stretching of elbow flexor and maintained in full elbow extension position for 15 minutes."
40927292|NCT00314483|DRUG|Mesenchymal Stem Cell Infusion|
40927293|NCT06052098|DEVICE|The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system|Procedure: In combination with guided bronchoscopy and CBCT, the ablation catheter is placed in the target lesion. CBCT confirms the tool in the lesion, adjusts the position of the ablation catheter, and monitors the extent of ablation.
40927294|NCT06052098|DEVICE|The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system|Procedure: The ablation needle is punctured into the lesion under CT guidance. The extent of the ablation is monitored by CT.
40927295|NCT03780023|OTHER|Questionnaire|All patients will receive three questionnaires at four different time points during their radiation treatment. The time points are 1) before treatment, 2) during the first week of treatment, 3) at the end of treatment (6-8 weeks after treatment begins), and 4) one year after treatment ends.
40927296|NCT04998201|DRUG|ARO-APOC3|ARO-APOC3 Injection
40927297|NCT04998201|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl)
40927298|NCT04514354|BEHAVIORAL|GEST|On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.
40927299|NCT05999162|PROCEDURE|Minimally invasive surgery|Minimally invasive surgery includes laparoscopic surgery or robotic surgery for the treatment of colorectal surgery.
40927300|NCT02412488|OTHER|Out of cathlab insertion|"Insertion of the Reveal LINQ device in the out-of-cathlab setting (out of the operating room, cardiac catheterization or electrophysiology laboratory)."
40927301|NCT01104376|DRUG|Efavirenz|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
40927302|NCT01104376|DRUG|voriconazole|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
40927303|NCT05292300|DIETARY_SUPPLEMENT|Cornelian Cherry (Cornus mas L.)|"Patients in Cornelian Cherry Group and Cornelian Cherry and Diet Group will receive 20 g/day freeze-dried powder Cornelian Cherry supplement."
40927304|NCT05292300|BEHAVIORAL|Diet|"Patient in Diet Group and Cornelian Cherry and Diet Group will be given a personalized diet and be followed up by a dietician."
41123937|NCT01339130|BEHAVIORAL|Computerized tests and Electrophysiological measurements|"* Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.~* Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).~* Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires."
41123938|NCT00593697|DRUG|trastuzumab (9 weeks) + docetaxel|"Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) (HT x3 -\>FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)"
41123939|NCT00593697|DRUG|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)
41123940|NCT05490134|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
41287244|NCT04408456|DRUG|HCQ|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
41287245|NCT04408456|OTHER|Standard therapy|Home quarantine for 2 weeks plus social distancing plus personal hygiene
41123941|NCT05490134|DRUG|Saline|0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
41123942|NCT01037985|DRUG|EXC 001|Multiple intradermal injections of EXC 001 and placebo
41123943|NCT01037985|DRUG|Placebo|Multiple intradermal injections of EXC 001 and placebo
41123944|NCT05364216|BEHAVIORAL|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
41123945|NCT05364216|PROCEDURE|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3 cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
41123946|NCT05364216|BEHAVIORAL|The assessment of cognitive function|Participants were assessed for MMSE and MoCA at the same period as the group C
41123947|NCT00663624|DRUG|aspart insulin|subcutaneous aspart insulin every 2 hours
41123948|NCT00663624|DRUG|Usual care as prescribed by the ED physicians.|Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
41123949|NCT00335049|DEVICE|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
41123950|NCT00335049|DEVICE|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
41123951|NCT05265481|DEVICE|Tourniquet|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg
41123952|NCT05265481|DEVICE|Manual Tapping|The investigators will apply tapping directly over the vein manually to increase the vein dimension.
41123953|NCT05265481|DEVICE|Device tapping|The investigators will apply tapping directly over the vein with a massage device to increase the vein dimension.
41123954|NCT03504423|DRUG|CPI 613, mFolfirinox|CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
41123955|NCT03504423|DRUG|Folfirinox|Folfirinox
41123956|NCT00998881|DRUG|Teneligliptin 20 mg|
41123957|NCT00998881|DRUG|Placebo|
41123958|NCT06427863|DRUG|Ornidazole|Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days
41123959|NCT06427863|DRUG|Placebo|Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
41123960|NCT02189915|DRUG|Creatine monohydrate|
41123961|NCT01074294|DRUG|OPDC-34712|OPDC-34712 tablets, daily, Orally.
41123962|NCT01074294|DRUG|Placebo|Matching-placebo tablets, daily, Orally.
41123963|NCT01074294|DRUG|Stimulant Therapy|Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
41123964|NCT01211405|DRUG|Low dose MDMA|30 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 15 mg MDMA 1.5 to 2 hours later
41123965|NCT01211405|DRUG|Medium dose MDMA|75 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 37.5 mg MDMA 1.5 to 2 hours later
41123966|NCT01211405|DRUG|Full dose MDMA|125 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 62.5 mg MDMA 1.5 to 2 hours later
41123967|NCT01211405|BEHAVIORAL|Therapy|Non-directive therapy during each session
41123968|NCT04085874|BEHAVIORAL|Promotion of Food-based recommendations|Prolonged contact through weekly home visits and monthly group meeting for 12 weeks
41123969|NCT04085874|BEHAVIORAL|Nutrition counseling from standard health services care|once nutrition counselling from health services
41123970|NCT03433690|BEHAVIORAL|HIIT|High Intensity Interval Training for twelve weeks
41123971|NCT03433690|BEHAVIORAL|Moderate training|Moderate training for twelve weeks
41123972|NCT02917512|DRUG|HU00701|Cyclosporine 0.01% + 3% trehalose
41123973|NCT02917512|DRUG|HU007|Cyclosporine 0.02% + 3% trehalose
41123974|NCT02917512|DRUG|Restasis|Cyclosporine 0.05%
41123975|NCT02917512|DRUG|Placebo|Vehicle
41123976|NCT01671267|BEHAVIORAL|Strength training|
41123977|NCT01671267|BEHAVIORAL|Ergonomic|
41123978|NCT01766154|DRUG|Tirofiban|A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
41123979|NCT00244959|DRUG|anastrozole|1 mg orally daily for 12 months
41123980|NCT00244959|PROCEDURE|adjuvant therapy|treatment received after breast cancer surgery
41123981|NCT05296213|DRUG|Silver diamine fluoride- potassium iodide|SDF-KI (riva star, SDI.Ltd )was applied ( as a professional application) by micro brush over the early enamel lesions on the buccal surface of molar teeth
41123982|NCT05296213|DRUG|Casein phosphopeptide amorphous calcium phosphate|CPP-ACP (tooth mousse, GC, Matraville Sydney, Australia) was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
41123983|NCT05296213|DRUG|experimental tricalcium silicate|prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
41123984|NCT05779215|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
41123985|NCT00127049|DRUG|gemcitabine, ifosfamide, cisplatin, G-CSF|
41123986|NCT02730871|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
41123987|NCT02730871|DRUG|Brinzolamide/brimonidine vehicle|Inactive ingredients used as placebo comparator
41287246|NCT04154618|DEVICE|Continuous wireless vital sign monitoring|Infants will receive wireless vital sign monitoring throughout their birth hospitalization.
40927305|NCT02095132|DRUG|Adavosertib|Given PO
40927306|NCT02095132|DRUG|Irinotecan Hydrochloride|Given PO
40927307|NCT05507788|DEVICE|Wheelchair air cushion|Reaching tasks during each of the seating conditions decribed in the Arms section.
40927308|NCT05955573|DIAGNOSTIC_TEST|xray|radiological description
41123988|NCT02730871|DRUG|Travoprost 0.004%/timolol 0.5% solution|1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
41123989|NCT00452270|DRUG|Xylometazoline|
41123990|NCT04146519|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
41123991|NCT04146519|OTHER|Placebo|Saline solution
41123992|NCT03373708|DRUG|Epirubicin|100mg/m2
41123993|NCT03373708|DRUG|Cyclophosphamide|600mg/m2
41123994|NCT03373708|DRUG|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
41123995|NCT03373708|DRUG|Goserelin acetate|3.6mg every month
41123996|NCT03373708|DRUG|Tamoxifen|10mg twice daily oral
41123997|NCT03373708|DRUG|Letrozole|2.5mg every daily oral
41123998|NCT02883660|GENETIC|Genocept Assay|battery of pharmacogenetic tests relevant to psychiatry
41123999|NCT05293431|OTHER|Transcranial Alternate Current Stimulation|tACS utilizes low-amplitude alternating currents to modulate brain activity and entrain specific brain oscillations depending on the applied stimulation frequency
41124000|NCT05293431|OTHER|Sham stimulation|Sham stimulation will simulated the real tACS stimulation
41124001|NCT00532142|DRUG|Intravitreal Triamcinolone|
41124002|NCT00532142|PROCEDURE|Radial Optic Neurotomy|
41124003|NCT00532142|OTHER|Placebo - Sham Intravitreal Injection|
41124004|NCT02204982|DRUG|Duvelisib|PI3K Inhibitor
41124005|NCT02204982|DRUG|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
41124006|NCT02204982|DRUG|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
41124007|NCT00073749|DRUG|Inotuzumab ozogamicin [CMC-544]|CMC-544, IV, dose escalation trial
41124008|NCT02941484|PROCEDURE|early oral intake|early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
41287247|NCT00011895|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
41446587|NCT01709903|DRUG|QVA149|QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
41446588|NCT01709903|DRUG|Fluticasone/salmeterol|Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.
41446589|NCT01709903|DRUG|Placebo to QVA149|Placebo to QVA149 with SDDPI
40927309|NCT00000460|BEHAVIORAL|Low intensity exercise|
40927310|NCT00000460|BEHAVIORAL|High intensity exercise|
40927311|NCT01565304|BEHAVIORAL|POWER Through Choices|10-session group-based sexual education curriculum
40927312|NCT06074042|OTHER|previous pulmonary tuberculosis|Previous pulmonary tuberculosis is comprehensively evaluated by the self-reported medical history, T-SPOT.TB test and radiological findings.
40927313|NCT03229174|DRUG|Droxidopa|Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
40927314|NCT03229174|DRUG|Placebo|Placebo (sugar pill)
40927315|NCT02592642|BEHAVIORAL|Self-management Program, Workbook, Video, Pedometer|Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
41124009|NCT02941484|PROCEDURE|jejunostomy tube feeding (JTF)|The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
41124010|NCT02484599|BEHAVIORAL|Computerized attention training (CAT)|Three sessions of active computerized attention training.
41124011|NCT02484599|BEHAVIORAL|Sham computerized attention training (control condition)|Three sessions of sham computerized attention training.
41124012|NCT03750968|DRUG|Carotenoid Group|Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
41124013|NCT03750968|DIETARY_SUPPLEMENT|Control Group|Placebo ingredients: Safflower oil
41124014|NCT04177147|OTHER|Clinical decision support via alert tool|The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
41124015|NCT05946421|DEVICE|exhaled breath analysis|non invasive technology to measure components of exhaled breath
41124016|NCT05993078|DRUG|0.9% NaCl 2000ml|The patient will undergo NS 2000ml intravenous infusion swiftly after IVT.
41124017|NCT05993078|DRUG|0.9% NaCl 0ml|The patients receive an NS 200-400ml after IVT
41124018|NCT04432389|BIOLOGICAL|ALLOB|After thawing, ALLOB® is a ready-to-use product for local administration at fracture site.
41124019|NCT04432389|OTHER|placebo|Placebo injected is a saline solution injectable grade (4 mL of 0.9% NaCl) filled in single-dose vial
41124020|NCT02617771|DRUG|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
41287248|NCT00011895|DRUG|Efavirenz|
41287249|NCT01272531|DRUG|Mood stabilizer treatment|lithium or valproate
41287250|NCT00775307|DRUG|PAZOPANIB|400 mg/day (24 weeks)
41446590|NCT01709903|DRUG|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol with Accuhaler
41446591|NCT01793558|PROCEDURE|Forced-air warming|In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
41446592|NCT03418753|DIAGNOSTIC_TEST|EyeBOX for ICP|non-invasive ICP Score algorithm using eye-tracking data from the EyeBOX(TM) device, which tracks the movement of the pupils over time
41124021|NCT03753308|BIOLOGICAL|Blood Sampling|5 x Lithium Heparin Tubes WITHOUT DARK GREEN GEL, 5 ml- v. 4 ml Blood volumes collected as part of the usual care and this research comply with the recommendations of Jarde's law for an observational study (less than 80 ml in one day and less than 160 ml over 30 consecutive days for a subject over 40kg).
41124022|NCT03753308|BIOLOGICAL|Liver biopsy|"The liver biopsy is part of the usual care and it follows the usual procedure of CHUGA:~The patient is placed in a supine position and received a transitory sedation, MEOPA gas (Kalinox®). Also, an ultrasound scan is performed. Local disinfection followed by local anesthesia with Xylocaine® are performed. The biopsy is performed with the Hepafix 17 gauge needle. 1 passage is carried out to obtain a biopsy fragment of at least 20 mm for the diagnosis (if the passage is unsuccessful, a second passage can be performed strictly as part of the usual care and not as part of research). If the biopsy is\> 20 mm, a fragment of the excess biopsy specimen (10% or 2 mm) will be cut and used for research in groups 1b and 2. This division is performed by the clinician directly on the fresh specimen"
41124023|NCT02437006|OTHER|exercise|cycle ergometry
41124024|NCT03886116|OTHER|Exercise|3 sets of 10 forearm exercises performed twice in the Morning and Evening for 6 weeks.
41124025|NCT02901197|BEHAVIORAL|Education and Reminder Posters|See arm description
41275267|NCT04222517|PROCEDURE|Incisional hernia repair by the mesh implant in sublay retromusuclar position with using a local hemostatic Hemoblock|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space. Used a local hemostatic Hemoblock 15 ml in this space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Used a local hemostatic Hemoblock 15 ml in subcutaneus space. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
41275268|NCT06012669|DIETARY_SUPPLEMENT|High dose Human Lactoferrin|Dietary Supplement and Food Ingredient
41275269|NCT06012669|DIETARY_SUPPLEMENT|Low dose Human Lactoferrin|Dietary Supplement and Food Ingredient
41275270|NCT06012669|DIETARY_SUPPLEMENT|Active Control Bovine Lactoferrin|Dietary Supplement and Food Ingredient
41275271|NCT01805648|DRUG|rhTPO|Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10\^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10\^9/L～100×10\^9/L.
41275272|NCT00569257|DRUG|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
40927316|NCT02592642|BEHAVIORAL|Instructional Workbook, Video, and Pedometer|Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
41124026|NCT02901197|OTHER|Policy Change|See arm description
41124027|NCT05608213|PROCEDURE|Lenvatinib Plus I-125 Seed Brachytherapy|Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients. Iodion-125 seeds will be implanted into the the target lesions (viable intrahepatic tumor and/or vascular tumor thrombus) under CT guidance according to the pre-operative planning within 7 days after lenvatinib administration. Iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
41124028|NCT05608213|DRUG|Lenvatinib|Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients.
41124029|NCT00162422|DRUG|albuterol|
41124030|NCT00098319|DRUG|Folic acid (0.4mg vs. 4.0mg)|
41124031|NCT05481905|DRUG|ENX-101|Adjunctive treatment to current antiseizure medication
41124032|NCT05492409|BIOLOGICAL|GNR-069|Once a week as a subcutaneous injection.
41124033|NCT00294840|DEVICE|PET-CT|
41124034|NCT03844919|DEVICE|rTMS + CBIT|"Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).~The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10."
41275273|NCT02770807|DRUG|EryDex Low dose DSP|EDS-EP dose range of \~5-10 mg DSP/infusion
41275274|NCT02770807|DRUG|EryDex High dose DSP|EDS-EP dose range of \~14-22 mg DSP/infusion
41275275|NCT02770807|DRUG|Pooled Placebo|EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
41275276|NCT03054363|DRUG|Tucatinib in Combination with Palbociclib and Letrozole|"Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily"
41275277|NCT03054363|DRUG|Tucatinib in Combination with Palbociclib and Letrozole|Subjects Tucatinib 300 mg PO BID Palbociclib 75mg PO daily 21 days on followed by 7 days off Letrozole 2.5 mg PO daily.
41287251|NCT00775307|DRUG|Placebo|Placebo 400 mg/day (24 weeks)
41446593|NCT05537129|PROCEDURE|Total Gastrectomy|The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
41124035|NCT03844919|BEHAVIORAL|Sham rTMS + CBIT|Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
41124036|NCT03063866|DRUG|Propofol|Propofol 1 mg/kg i.v
41124037|NCT03063866|DRUG|Midazolam|Midazolam 3 mg i.v
41275278|NCT05057390|DIETARY_SUPPLEMENT|New Human Milk Fortifier (NHMF)|"The case study product will be added to human milk during the hospitalization and will continue after discharge for at least 1 week (7 days), to obtain community data. NHMF prescription will be specified on an individual basis by the investigating Dietitian responsible for the infant's nutritional management. The intervention period will end when the infant does not require NHMF (according to local neonatal guidelines and/or clinical indication).~The case study product will be labelled specifically for the case study and will be available in a powder format.~Full preparation, storage and safety instructions will be given to the parent/caregiver by the investigating Dietitian before commencing the case study product to ensure its correct and safe use."
41275279|NCT02706938|OTHER|Head of bed elevation|Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
41275280|NCT02706938|OTHER|Standard treatment|Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
41275281|NCT00326261|PROCEDURE|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
41275282|NCT00326261|PROCEDURE|Ultrasound|
41275283|NCT01920906|PROCEDURE|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
41275284|NCT01075087|DRUG|Placebo|Bilateral TAP block using sterile normal saline.
41275285|NCT01075087|DRUG|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
40927317|NCT02592642|DEVICE|Para-spinal TENS|Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
40927318|NCT02592642|DEVICE|Para-spinal Placebo TENS|Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine \[NeuroTrac TENS from Verity Medical Ltd (U.K.)\] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
41124038|NCT03063866|DRUG|Fentanyl|fentanyl 0.5 ug/kg
41124039|NCT05619952|DIETARY_SUPPLEMENT|Mushroom Powder|Ground shiitake mushrooms or ground white button mushrooms
41124040|NCT01409824|OTHER|CDSS|Clinical Decision Support System
41124041|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
41124042|NCT01309932|DRUG|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 24 weeks
41124043|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
41124044|NCT01309932|DRUG|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 24 weeks
41124045|NCT01309932|BIOLOGICAL|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks
41124046|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks
41124047|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks
41124048|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks
41124049|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks
41275286|NCT04721353|DRUG|Prazosin Hydrochloride|prazosin hydrochloride oral 1-25 mg/day
41275287|NCT00004165|BIOLOGICAL|filgrastim|
40927319|NCT02592642|DEVICE|Prototype Spinal Stenosis Belt|Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
41124050|NCT01309932|DRUG|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 16 weeks
41124051|NCT01309932|DRUG|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 16 weeks
41124052|NCT01309932|DRUG|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
41124053|NCT01309932|DRUG|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Tablets, Oral, 0 mg, Once daily, 24 weeks
41124054|NCT01309932|DRUG|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
41124055|NCT01309932|DRUG|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 16 weeks
41124056|NCT04045782|DRUG|single arm|switch from originator (Humira) to biosimilar (Imraldi)
41124057|NCT00186784|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|treatment for 10 days
41124058|NCT05326607|DEVICE|Prototype of adaptive eyeglasses|The tested investigational medical device is a prototype of semi-integrated eyeglasses.
41124059|NCT05326607|DEVICE|Comparator|The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.
41124060|NCT06324903|OTHER|echocardiography and percutaneous cardiac catheterization|pre- cardiac catheterization, intraprocedural and post-catheterization echocardiography.
41124061|NCT00154011|DRUG|rosiglitazone (drug)|
41124062|NCT03516942|OTHER|Quality-of-Life Assessment|Ancillary studies
41124063|NCT03516942|OTHER|Questionnaire Administration|Ancillary studies
41275288|NCT00004165|DRUG|melphalan|
41275289|NCT00004165|PROCEDURE|peripheral blood stem cell transplantation|
41275290|NCT00000851|DRUG|Stavudine|
41275291|NCT00000851|DRUG|Didanosine|
41124064|NCT02119650|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
41275292|NCT01390389|DRUG|Coenzyme Q10|"Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~* Visit 1 (baseline) start at 400mg once a day for two weeks~* Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
41275293|NCT02976415|OTHER|In-Bed Cycling|20 minutes of in-bed cycling, either active, passive or a combination of active and passive.
41275294|NCT04547257|DEVICE|Seraph 100|Bloodfiltration with Seraph 100
41275295|NCT00863616|DEVICE|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
41275296|NCT04982133|DIETARY_SUPPLEMENT|Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment|"At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk."
40754313|NCT05385523|PROCEDURE|Rhomboid Intercostal and Sub-Serratus block technique (RISS)|The patient will be placed in lateral position. A linear ultrasound transducer of frequency 6-12 MHz will be placed medial to the lower border of the scapula in a sagittal plane. A 38-mm 22-gauge will be inserted under real-time in-plane from craniocaudal between the rhomboid major and intercostal muscles. After negative aspiration, single injection of 10 ml of the local anesthetic mixture will be administered at the T6 7 level. The spread of local anesthetic solution under the rhomboid muscle will be visualized by ultrasonography. Then the ultrasound probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscle for the sub-serratus block at T 8-9 level. The needle will be advanced from its previous position and a further of 10 ml of the local anesthetic mixture will be injected.
41124065|NCT02119650|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
41124066|NCT02119650|DRUG|Pemetrexed|500 mg/m\^2 administered as an intravenous infusion over 10 minutes
41124067|NCT02119650|DRUG|Cisplatin|75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
41124068|NCT04542005|BEHAVIORAL|q3h albuterol|Using q3h albuterol as discharge criteria from hospital
41124069|NCT05836116|OTHER|Evaluation of Muscle Activation|"Evaluation of Muscle Activation The sEMG device, which is a surface EMG system (Myomonitor, Delsys Inc, Boston, MA), was used to measure the lateral and medial muscle activation levels of the latissimus dorsi.~Electrode placement was determined according to SENIAM (Surface Electromyography for Non-Invasive Evaluation of Muscles) criteria.~Evaluation of the Gibbosity Trunk rotation (gibbosity) assessments were performed using Adam's test and using a scoliometer . The bending test (Adam's test) is performed in both standing and forward bending positions. The standing version was used in our study.Each measurement equal to 0° on the scoliometer was defined as symmetry at the measured level of the trunk. All other scoliometer values were defined as asymmetry.~Evaluation of the Cobb Angle Cobb angles of the curves of the individuals participating in the study were measured with the MicroDicom application."
41124070|NCT00632749|DRUG|BI 811283 (d 1 and 15)|BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle
41124071|NCT00632749|DRUG|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
41124072|NCT00632749|DRUG|BI 811283 (d1)|BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
41124073|NCT00632749|DRUG|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
41124074|NCT05401474|DEVICE|High Flow Nasal Cannula at 30L/min|Flow will be set at 30L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
41124075|NCT05401474|DEVICE|High Flow Nasal Cannula at 45L/min|Flow will be set at 45L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
41124076|NCT05401474|DEVICE|High Flow Nasal Cannula at 60L/min|Flow will be set at 60L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
41124077|NCT04421924|PROCEDURE|thrombelastogram|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm
41124078|NCT04421924|PROCEDURE|standard of care|2) In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR\>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
41124079|NCT06083155|DIAGNOSTIC_TEST|Coronary Function Test|All participants are referred for a clinically indicated coronary function test
41124080|NCT06083155|OTHER|Patient questionnaires|All participants that consent will receive yearly followup questionnaires for 5 years after their initial consent
41124081|NCT01521052|DEVICE|dTMS treatment (H1 Coil)|All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
41124082|NCT01840826|OTHER|RED-D Care Management|The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
41124083|NCT01858831|DRUG|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
41124084|NCT01858831|DRUG|Atovaquone|Atovaquone
41275297|NCT04354428|DRUG|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy
41275298|NCT04354428|DRUG|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy
41275299|NCT04354428|DRUG|Azithromycin|Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy
41275300|NCT04354428|DRUG|Folic Acid|Eligible participants in a household will receive folic acid and an additional intervention drug
40927320|NCT02592642|DEVICE|Sham Spinal Stenosis Belt|Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
40927321|NCT06071728|DIETARY_SUPPLEMENT|Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)|Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.
41275301|NCT04354428|DRUG|Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]|Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy
40927322|NCT05610189|DRUG|Tavapadon|Oral tablets
40927323|NCT03761797|DRUG|TRADIANCE® Combination Tablets AP|Fixed dose combination
41275302|NCT05548478|PROCEDURE|Transepithelial PRK/MMC|transepithelial photorefractive keratectomy (PRK) and mitomycin C addition
41275303|NCT05548478|PROCEDURE|Alcohol-Assisted PRK/MMC|photorefractive keratectomy (PRK) assisted by alchol and mitomycin C addition
41275304|NCT05102565|BEHAVIORAL|sleep education program|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
41275305|NCT06432764|DRUG|AZD7798|Each participating patient will receive the study drug as specified in the study protocol.
41275306|NCT06432764|DRUG|[11C]AZ14132516|A single microdose (≤ 10 μg) of radiopharmaceutical \[11C\]AZ14132516 will be extemporaneously prepared and administered to each participant prior to each PET examination
40758311|NCT04619745|OTHER|Individualized Home and Play-Based Physical Activity Plans|Play-based, parent led interventions optimized to support age appropriate physical activity, and motor skills among young children with congenital heart defects.
40927324|NCT03761797|DRUG|TRADIANCE® Combination Tablets BP|Fixed dose combination
41124085|NCT01898585|DRUG|Zelboraf|Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
41124086|NCT03685071|OTHER|role of CBC as prognostic tool in sepsis.|"Our study will be conducted on children who admitted to PICU in Assuit University Hospital .CBC parameters as TLC , platelet count , and Hb will be evaluated at time of admission , another CBC will be done at 5th day and another one at day of discharge or last one before death.~* patients will be classified into three groups according to the outcome(discharge, mortality and has morbidity sequel.)~* correlation between the outcome and CBC will be done."
41124087|NCT00015067|DRUG|Methylphenidate|
41124088|NCT06465446|BIOLOGICAL|Tislelizumab|IV infusion
41275307|NCT01504932|DIETARY_SUPPLEMENT|BRB Lozenge|ARM I: Patients will be instructed to begin BRB administration and continue daily for up to 6 months.
41275308|NCT01504932|OTHER|Survey Administration|Patients will complete a baseline survey documenting any family history of cancer. Patients will then provide a history of tobacco, alcohol and mouthwash use, complete the Head and Neck Cancer Inventory Survey (HNCI), the Insomnia Severity Index (ISI) Survey, and the Brief Fatigue Inventory (BFI) Survey. Patients will receive a trial-specific logbook to record their usages.
41275309|NCT01504932|OTHER|Laboratory Biomarker Analysis|Patients will provide blood, urine, saliva, and cheek scrape samples. These biological samples will be evaluated for the presence of BRB components (as a measure of compliance) and assessed for BRB-responsive gene expression, respectively.
41275310|NCT01504932|OTHER|pharmacological study|Correlative studies
41275311|NCT01246492|DIETARY_SUPPLEMENT|Artificial Sweeteners|A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
41275312|NCT03023748|DRUG|Intravenous Paricalcitol|Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
41275313|NCT03607344|PROCEDURE|Cohort|Patients undergoing ambulatory laparoscopic sacrocolpopexy
40927325|NCT01762020|DEVICE|3M Cavilon No Sting Barrier Film|Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care
40758312|NCT00335426|PROCEDURE|Spinal manipulative therapy|
40927326|NCT01762020|DRUG|Standard Preparation|standard creams
40927327|NCT02609503|DRUG|Pembrolizumab|Pembrolizumab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable
40927328|NCT02609503|RADIATION|Intensity Modulated Radiation Therapy|Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks
41124089|NCT06465446|BIOLOGICAL|IMM01|2.0mg/kg, IV infusion
41124090|NCT06465446|DRUG|Bendamustine|IV infusion
41124091|NCT06465446|DRUG|Gemcitabine|IV infusion
41275314|NCT06320444|PROCEDURE|232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)|"Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task.~Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation.~These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory)"
41275315|NCT04145466|BEHAVIORAL|High-fat diet|"The high-fat diet will consist of \~40% energy from fat and \~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
41275316|NCT04145466|BEHAVIORAL|High-carbohydrate diet|"The high-carbohydrate diet will consist of \~20% of energy from fat and \~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
41275317|NCT00332787|DRUG|Fluoxetine|
41275318|NCT02602509|DRUG|Celecoxib|
41275319|NCT02602509|DRUG|Rifampicin|
41275320|NCT02602509|DRUG|Pyrazinamide|
41275321|NCT04626830|OTHER|Mobile Application Intervention|Participants appointed to the intervention group will receive the mobile application intervention for six months after enrollment. The mobile app (OKTED) intervention will consist of completing responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses.
41275322|NCT00885365|DRUG|tobramycin / Bramitob|300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
41275323|NCT00885365|DRUG|tobramycin / TOBI|300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
41275324|NCT04057209|RADIATION|Single Vocal Cord Irradiation (SVCI)|The following planning aim will be pursued: full coverage of the PTV with at least 95% of the prescribed dose and a maximum (0.03 cc) PTV dose of \<107%: 16 x 3.63 = 58.08 Gy in 5 fractions per week using 5 to 9 static IMRT or VMAT.
41275325|NCT04057209|PROCEDURE|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|"The TLM has to be performed using a CO2 laser, coupled to an operative microscope, at 4-8W in ultrapulse mode. The type of cordectomy performed must be mentioned using the following classification according the classification of the European Laryngological Society.~The type of resection chosen should provide complete removal of the primary lesion with negative margins.~Surgery will generally be performed within 3 weeks after randomization and not more than 6 weeks after panendoscopy.~The extent of the cordectomy must include a complete anterior, posterior, inferior and supero-lateral mucosal and deep soft tissue margin."
41446594|NCT05429268|DRUG|Tafasitamab|Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.
41446595|NCT05429268|DRUG|Lenalidomide|Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
40758313|NCT00713193|DRUG|Cyclosporine|2-3 mg/kg orally in a twice day divided dose for 6 months
40758314|NCT00713193|DRUG|Prednisone|1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
40758315|NCT04098783|OTHER|Home visit, health education|
40927329|NCT04204070|PROCEDURE|Accuro|A research coordinator recorded the depth of the EDS from skin, the number of attempts to perform the epidural anesthesia, the repositioning of the epidural needle either in the same space or in different space, the time taken for space localisation (it is defined as time taken in seconds from skin puncture until the successful space localisation).the total time of the procedure ( time measured from the patient is fully draped and in the proper sitting position till the end of insertion of the epidural catheter ) Any complications such as paresthesia during catheter insertion, dural puncture, blood in catheter and root irritation will be recorded
40927330|NCT04204070|PROCEDURE|APAD|APAD
41275326|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 80mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
41275327|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 40mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
41275328|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 40mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
41275329|NCT04242537|DEVICE|High flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a high flow nasal cannula with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
41275330|NCT04242537|DEVICE|Low flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a low flow nasal cannula coupled with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
41275331|NCT03106532|DRUG|PHP-201 0.25% ophthalmic solution|3 drops daily, 28 days
41275332|NCT03106532|DRUG|PHP-201 0.5% ophthalmic solution|3 drops daily, 28 days
41275333|NCT03106532|DRUG|Placebo ophthalmic solution|3 drops daily, 28 days
41275334|NCT01883141|PROCEDURE|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots
41275335|NCT06292078|BEHAVIORAL|Instructional Skill-Building Learning Approach (ISLA)|The Inclusive Skill-building Learning Approach (ISLA) is a school-wide, multi-component, instructional and restorative alternative to exclusionary discipline that begins with universal prevention grounded in positive, preventative classroom strategies for all students, and layers on additional supports for students in need.
41275336|NCT05694598|GENETIC|VGR-R01|CYP4v2-coding gene delivered by AAV vector
41446596|NCT04430725|PROCEDURE|Computed Tomography with Contrast|Undergo contrast-enhanced CT
41446597|NCT04430725|PROCEDURE|Microwave Ablation|Undergo microwave ablation
41446598|NCT04430725|OTHER|Questionnaire Administration|Ancillary studies
41446599|NCT04430725|PROCEDURE|Wedge Excision|Undergo wedge resection
41446600|NCT06556849|DEVICE|Defocus Incorporated Multiple Segments (DIMS)|To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.
41446601|NCT02264678|DRUG|Administration of ceralasertib|An oral formulation of ceralasertib will be used. In Module 2 Part A1, patients will receive a single dose of ceralasertib on Day 1, followed by 4 to 6 days washout, before multiple dosing.
41275337|NCT02852226|OTHER|Pre Exposure Prophylaxis|Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.
41275338|NCT02852226|BEHAVIORAL|Characteristics of women who enroll|The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.
41275339|NCT02852226|BEHAVIORAL|referral sources of women who enroll|Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
41275340|NCT04836949|DEVICE|Shear Wave Elastography of prostate|A 12-core template biopsy is planned as during a conventional prostate biopsy. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy. Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.
41124092|NCT02988089|DRUG|Clarithromycin susceptibility dependant strategy|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
41124093|NCT02988089|DRUG|2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )|Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
41124094|NCT02988089|DRUG|proton pump inhibitor (PPI) and Colloidal Bismuth Pectin|all patients need these two drugs.
41124095|NCT02988089|DRUG|amoxicillin and clarithromycin or amoxicillin and furazolidone|patients in the 6 antibiotics dependant group will use these intervention.
41124096|NCT02988089|DRUG|amoxicillin and furazolidone or amoxicillin and tetracycline|salvage therapy for negative culture when the results of culture are negative
41124097|NCT02988089|DRUG|amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin|salvage therapy for failed eradication if failed with AST guided eradication therapy
41124098|NCT05279157|PROCEDURE|Implantation|Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient
40754314|NCT05385523|PROCEDURE|General Anaesthesia|"Fentanyl (1 μg/kg), propofol (2-3mg/kg) and atracurium (0.3-0.5 mg/kg) will be injected intravenously 3-5 minutes after oxygenation. A single-lumen endotracheal tube will be used to complete ventilation. The ventilator ventilation mode is volume control mode, and the patient's end-expiratory carbon dioxide level is maintained at 35-40 mmHg throughout the anesthesia process. During the anesthesia maintenance phase, 2% sevoflurane mixed with 60% oxygen.~After general anaesthesia induction, all patients will receive RISS block with different local anesthetic drug mixture according to randomization."
40754315|NCT05385523|DRUG|dexamedatomidine|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
40754316|NCT05385523|DRUG|dexamethasone|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.
40754317|NCT05385523|DRUG|saline|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
40754318|NCT03636269|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
41124099|NCT05279157|PROCEDURE|Lipoaspiration|"Procedure: Lipoaspiration The patient will have a liposuction surgery from which the autologous ADASCs implant in the cornea will be obtained.~Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs with or without scaffold in the intrastromal cornea of the patient"
41124100|NCT00025610|DRUG|carboplatin|
41124101|NCT00025610|DRUG|cyclophosphamide|
41124102|NCT00025610|DRUG|doxorubicin hydrochloride|
41124103|NCT00025610|DRUG|etoposide|
41124104|NCT00025610|DRUG|vincristine sulfate|
41124105|NCT02772471|DEVICE|HS-1000|
40754319|NCT03636269|DRUG|Placebo|IV placebo administered three times/week
40754320|NCT05285163|BEHAVIORAL|palliative care educatiom|The patients in the intervention group were presented palliative care training in addition to their usual care
40754321|NCT01356056|DEVICE|Kinesia HomeView|Quantifies motor symptom severity in the home
41275341|NCT04836949|DEVICE|Conventional Prostate Ultrasound|A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
41275342|NCT00002586|DRUG|13-cis retinoic acid|
41275343|NCT00002586|DIETARY_SUPPLEMENT|Tocopherol|
41124106|NCT04678375|DIAGNOSTIC_TEST|Retinal diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
41124107|NCT03647956|DRUG|Atezolizumab|Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
41124108|NCT03647956|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
41124109|NCT03647956|DRUG|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer.
41124110|NCT03647956|DRUG|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
41275344|NCT03696329|DRUG|Tetrabenazine Tablets 25 mg|
41275345|NCT05641883|COMBINATION_PRODUCT|CardiaMend with antiarrhythmic|Pericardial patch with antiarrhythmic drug (amiodarone) topically applied
41275346|NCT02386774|DEVICE|Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml|used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
41275347|NCT02386774|DEVICE|Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)|"used for Multifluorescence IVCM~* anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)~* Fluorescein 0,5%, Rose Bengal , Infracyanine"
41275348|NCT02386774|PROCEDURE|microangiography|realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
41275349|NCT05347615|PROCEDURE|IOL Implantation:EDOF lens|A EDOF lens is implanted in the dominant eye
41275350|NCT05347615|PROCEDURE|IOL Implantation: Monofocal lens|A monofocal lens is implanted in the non dominant eye.
41275351|NCT02554305|DEVICE|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
41275352|NCT02554305|DEVICE|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
41275353|NCT00803114|DRUG|Preservative-free epidural morphine|One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery
41275354|NCT00803114|DRUG|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
41275355|NCT02318095|DRUG|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
41275356|NCT02318095|RADIATION|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
41275357|NCT02318095|OTHER|Sugical resection|Surgical resection of the pancreas post radiation therapy
41275358|NCT02318095|DRUG|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
41446602|NCT02264678|DRUG|Administration of ceralasertib in combination with olaparib|An oral formulations of ceralasertib and olaparib will be used. In Module 2 Part A2, patients will receive either a single or twice daily dose of ceralasertib followed by 4 to 6 days washout, before multiple dosing with ceralasertib and olaparib. In Module 2 Part B, patients will receive ceralasertib and olaparib at the dose, frequency and schedule recommended from Module 2 Part A2. Cycle 0 may be omitted at the discretion of the sponsor.
41124111|NCT03752151|DEVICE|MARVEL 2 Algorithm Monitor Mode then Adaptive Mode|Software download into implanted Micra device and programmed to MARVEL 2 Monitor Mode then MARVEL 2 Adaptive Mode
41124112|NCT03287622|BEHAVIORAL|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
41124113|NCT03287622|BEHAVIORAL|Nudge|Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids
41124114|NCT05698459|BIOLOGICAL|OH2 injection|OH2 injection administered by transcatheter Intraarterial infusion
41275359|NCT02351362|BEHAVIORAL|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
41275360|NCT05629039|BEHAVIORAL|Volitional Help Sheets|The volitional help sheet is an intervention which provides an opportunity for people to actively plan their behavioural changes by using a list of situations and solutions. The list of situations are critical situations which provoke unwanted behaviour, and the solutions are the responses to overcome the situations which urge the unexpected behaviour. In the context of smoking behaviour, the list of situations is the situations that will provoke cigarette uptake and the list of solutions is the appropriate responses to reduce or stop the urge to smoke.
41275361|NCT05693584|OTHER|distraction|diverting the patient's attention with virtual reality glasses
41275362|NCT00928330|DRUG|GDC-0941|Oral repeating dose
41275363|NCT00928330|DRUG|Trastuzumab|Intravenous repeating dose
41275364|NCT00928330|DRUG|trastuzumab-MCC-DM1|Intravenous repeating dose
41275365|NCT00609921|DRUG|ARQ197|treatment
41275366|NCT02599402|DRUG|Nivolumab|
41275367|NCT02599402|DRUG|Ipilimumab|
41275368|NCT05888116|DEVICE|Hidrante HA|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
40754322|NCT01368731|PROCEDURE|Prophylactic use of coagulation therapy|The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
41124115|NCT05594511|PROCEDURE|Muscle-energy mandibular technique|A single session will be used with the mandibular musculoenergy technique. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
41124116|NCT05594511|PROCEDURE|Sham technique|A single session with a sham technique simulating the suboccipital muscle inhibition technique will be used. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
41124117|NCT06411834|BEHAVIORAL|Decision navigation tool|An electronic, interactive form that guides patients through the major factors that influence their decision-making in thyroid cancer
40754323|NCT02276833|OTHER|intra-articular space injection of SVF|intra-articular injection of autologous adipose SVF derived in the same surgical procedure
41124118|NCT01599793|DRUG|cabozantinib|Given PO
41124119|NCT01599793|OTHER|laboratory biomarker analysis|Correlative studies
41124120|NCT01599793|PROCEDURE|magnetic resonance imaging|Undergo MRI
41124121|NCT04207424|PROCEDURE|Emblization of the gastro-epiploic arcade|Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles
41124122|NCT02622568|DRUG|Veregen only|Topical application of Veregen 15% ointment on affected areas twice daily
41124123|NCT02622568|PROCEDURE|Cryotherapy and Veregen|Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
41124124|NCT02955719|DRUG|Sertraline|
41124125|NCT02955719|DRUG|Venlafaxine|
41124126|NCT02955719|OTHER|CBT/Psychological Therapy|
41124127|NCT02955719|OTHER|Psychiatric Consultation|
41124128|NCT02955719|OTHER|Lifestyle Intervention Resources|
41124129|NCT03055689|BEHAVIORAL|Educational telephone intervention|Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
41124130|NCT03055689|BEHAVIORAL|Standard education for colonoscopy|Standard education for bowel preparation at the time of colonoscopy scheduling
41275369|NCT05888116|DEVICE|Cumlaude Hidrante Interno®|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
41275370|NCT00003688|BIOLOGICAL|dactinomycin|
41124131|NCT06518070|DIAGNOSTIC_TEST|Cerviray AI|Patient was screened using Cerviray AI, Cerviray AI evaluation by expert anc compared to VIA test in the same day.
40754324|NCT02013908|PROCEDURE|Acupuncture plus standard ED management|
40754325|NCT02013908|PROCEDURE|Standard ED management alone|
40754326|NCT05936138|DRUG|LY3502970|Administered orally.
41124132|NCT01321164|DEVICE|Full Body UV Therapy System UV 7002 plus fumaric acid esters|"Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.~Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months"
40758316|NCT01027754|DRUG|Varenicline|Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
40758317|NCT01027754|DRUG|Placebo|Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
41124133|NCT01321164|DRUG|Fumaric acid esters|Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
41124134|NCT03825978|BEHAVIORAL|Prenatal Genetic Counseling|In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
41124135|NCT03562338|OTHER|Manual Therapy and Exercise (Physiotherapy Intervention)|Participants in this group will receive a 6-weeks program of mobilization and progressive exercise for the neck flexors, 2 times a week.
41124136|NCT03562338|OTHER|Usual Care (Physiotherapy Intervention)|Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
41124137|NCT00110929|DRUG|AMG 073|
41124138|NCT02387242|DRUG|Rifampicin|Single oral dose of rifampicin
41124139|NCT00639860|DEVICE|OSSIX-Plus|resorbable collagen membrane
41124140|NCT03475316|BEHAVIORAL|Social Dancing|90-min dance sessions twice weekly for 6-months. The session includes warm-up, dance and cool down.
41275371|NCT05649176|OTHER|Diet without soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the experimental diet but does not contain soy.
41275372|NCT05649176|OTHER|Diet with soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the comparator diet but contains soy.
41275373|NCT00837187|DRUG|Intravenous dexmedetomidine|100 ug
41275374|NCT00837187|DRUG|Intranasal dexmedetomidine|100 ug
41275375|NCT02079727|DRUG|chondroitin sulfate|
41275376|NCT02079727|DRUG|celecoxib|
41275377|NCT02079727|DRUG|placebo|
41275378|NCT01961531|DEVICE|Accuboost APBI|28Gy delivered in 5 daily fractions
41275379|NCT05891171|DRUG|AB598|Administered as specified in the treatment arm
41275380|NCT05891171|DRUG|Zimberelimab|Administered as specified in the treatment arm
41275381|NCT05891171|DRUG|Carboplatin|Administered as specified in the treatment arm
41275382|NCT05891171|DRUG|Pemetrexed|Administered as specified in the treatment arm
41275383|NCT05891171|DRUG|Fluorouracil|Administered as specified in the treatment arm
41275384|NCT05891171|DRUG|Leucovorin|Administered as specified in the treatment arm
41275385|NCT05891171|DRUG|Oxaliplatin|Administered as specified in the treatment arm
41275386|NCT05065112|PROCEDURE|Pulmonary veins isolation + Cartofinder-guided ablation|The individualised mapping with Cartofinder intends to identify areas with the repetitive atrial activation patterns which are targeted with focal or linear ablation anchored on at least one end in an anatomical or electrical barrier.
41275387|NCT05065112|PROCEDURE|Pulmonary veins isolation|Wide area circumferential pulmonary veins isolation
41275388|NCT03424226|DRUG|Acetazolamide|a diuretic and commonly used medication for prevention and treatment of acute mountain sickness
41275389|NCT06430892|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Patients presented with acute myocardial infarction undergoing primary percutaneous coronary intervention with stent deployment
41124141|NCT03475316|BEHAVIORAL|Treadmill Walking|Each session starts with 5-10 minutes of warm-up walking at comfortable speed. Speed is gradually increased to the level at which participants felt it is 'somewhat hard' for two 35 minute sessions with breaks in between followed by 5-10 minute cool down period (total 90 min to match dance group).
41124142|NCT02787031|PROCEDURE|Neuraxial anesthesia|
40927331|NCT05301374|BEHAVIORAL|Watching Cartoon|Children in the cartoon group before the procedure, they chose one of the cartoons predetermined by the researchers. The children in the cartoon group started watching a cartoon of their choice 2 minutes before the procedure and they kept watching until the procedure was ended.
41124143|NCT02787031|PROCEDURE|General anesthesia|
41124144|NCT01168544|DIETARY_SUPPLEMENT|loading dose Vitamin D and 50.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
41124145|NCT01168544|DIETARY_SUPPLEMENT|loading dose and 25.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
41124146|NCT01168544|DIETARY_SUPPLEMENT|Vitamin D 800 IU /day|800 IU vit D3/day
41124147|NCT03035994|OTHER|Real-Time Biofeedback|A custom written MatLab script will sample bilateral peak vertical ground reaction forces and display the magnitude in real time on a screen placed in front of the participant. A target line will be placed in the middle of the screen which corresponds to one of the three loading conditions. Participants will be instructed to alter their movement in an attempt to match each limb's vertical ground reaction force to the target line.
41124148|NCT02158819|DEVICE|Total knee arthroplasty with Visionaire|Patient Specific Instrumentation
41124149|NCT05070559|OTHER|Active Release Technique|"Patients in this group will receive Active Release Technique along with conventional therapy. ART will be given with patient seated, elbow flexed and resting on the treatment table, forearm in midprone \& wrist in neutral position and then the therapist will work on the common extensor tendon by applying pressure to the tendon distal to their attachment at the elbow. The patient will start with the elbow bent and wrist straight. As the therapist hold the muscles, the patient will extend the elbow and pronate and flex the wrist while the therapist move the pressure proximally, attempting to release adhesions around and between muscle planes. Total of 15 repetitions for of 10 minutes.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
41275390|NCT04617288|OTHER|Ultrasound Therapy, SNAGs|
41275391|NCT05491122|BEHAVIORAL|Increasing or decreasing daily total fluid intake|1-week intervention where the intake of drinking water will either be increased (if habitually low) or decreased (if habitually high). The total fluid intake (TFI) prescriptions during the intervention are derived from the mean TFI of habitually high and habitually low drinkers from a sex, age and country matched population. Specifically, habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI. The diurnal saliva cortisol response at rest will be examined at the end of both experimental periods and the saliva cortisol response to an acute psychological stress will be examined at the end of the habitual experimental period only.
40758318|NCT01019057|PROCEDURE|ILIF|Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.
40927332|NCT02299518|DRUG|mitoxantrone hydrochloride|Given IV
40927333|NCT02299518|DRUG|etoposide|Given IV and PO
41275392|NCT05421000|PROCEDURE|WALANT|Wide awake local anesthesia without tourniquet for distal radius fracture surgery
41275393|NCT05421000|PROCEDURE|Locoregional anesthesia and tourniquet|Locoregional anesthesia and tourniquet for distal radius fracture surgery
41275394|NCT02725502|DRUG|Linagliptin|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
40758319|NCT06500871|DRUG|Diclofenac Potassium|NSAID
40927334|NCT02299518|DRUG|cytarabine|Given IV
40927335|NCT02299518|DRUG|selinexor|Given PO
40927336|NCT02299518|OTHER|laboratory biomarker analysis|Correlative studies
40927337|NCT02299518|OTHER|pharmacological study|Correlative studies
40927338|NCT04718844|DRUG|SLN124|SLN124 for subcutaneous (s.c.) injection
41124150|NCT05070559|OTHER|Graston Technique Group|"Patients in this group will receive IASTM along with conventional therapy. In graston technique proper application of GT3 which include application of a cream to the common extensor tendon. The GT3will be then used to common extensor tendon. In areas of increased tissue restriction, more required pressure with GT3 is applied using increased force and shorter strokes over the areas of restriction. Ice will be offered as needed for pain management after each session.~The study includes interventional protocol of 4 weeks. The sessions will be given 3 times a week for 4 weeks.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
41275395|NCT02725502|DRUG|Placebo|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
40927339|NCT04718844|DRUG|Placebo|Sodium chloride for s.c. injection
41124151|NCT02006758|DEVICE|EnligHTN™ Renal Denervation System|The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
41124152|NCT00774124|OTHER|telemonitoring|Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
41124153|NCT00774124|OTHER|Standard of care|Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
41124154|NCT00780949|OTHER|intestinal biopsies|intestinal biopsies during routine endoscopy
41124155|NCT00546754|DRUG|losartan potassium (+) hydrochlorothiazide|losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
41275396|NCT05729841|OTHER|Ocean row|the Talisker Whisky Atlantic Challenge annual ocean rowing race.
41275397|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
41275398|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
41124156|NCT00546754|DRUG|Comparator: Valsartan (+) Hydrochlorothiazide|Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
41275399|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
41275400|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
41275401|NCT00947349|DRUG|BI 201335 NA low placebo|Placebo
41275402|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
41275403|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
41275404|NCT00947349|DRUG|BI 201335 NA high|BI 201335 NA high
40927340|NCT00000803|DRUG|Delavirdine mesylate|
40927341|NCT00000803|DRUG|Zidovudine|
40927342|NCT00000803|DRUG|Didanosine|
41124157|NCT05837455|DEVICE|VENTANA MIB-1 Ki67 assay|Ki67 scoring determination (standard of care) utilizing the Ki67 MIB-1 assay (clone 30-9) (VENTANA) will be performed at baseline, Week 4 (+/- 14 days - high-risk group only), and at time of surgery in accordance with the International Ki67 in Breast Cancer Working Group guidelines.
41124158|NCT05837455|DEVICE|Oncotype DX® Recurrence Score|Oncotype DX® Recurrence Score (RS) testing - assessing expression of 21 genes including 16 cancer-related genes and 5 reference genes - will be performed as standard of care in a central laboratory (Exact Sciences) on RNA extracted from formalin-fixed paraffin-embedded core-biopsy samples.
41124159|NCT05837455|DEVICE|PAM50-based Prosigna breast cancer gene signature assay|This PAM50-based Prosigna breast cancer gene signature assay for intrinsic molecular subtype determination will be performed on formalin-fixed, paraffin-embedded (FFPE) core-biopsy samples.
41275405|NCT00947349|DRUG|BI 201335 NA low|BI 201335 NA
41275406|NCT00947349|DRUG|BI 201335 NA high placebo|placebo
41275407|NCT00947349|DRUG|BI 201335 NA high|BI 201335 NA high
41275408|NCT00947349|DRUG|Placebo|
41275409|NCT01478958|DIETARY_SUPPLEMENT|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
41275410|NCT01478958|DIETARY_SUPPLEMENT|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
41275411|NCT01478958|DIETARY_SUPPLEMENT|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
41275412|NCT01221857|DRUG|NiCord®|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
41275413|NCT00900796|OTHER|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
41275414|NCT00251602|DRUG|Atropine|One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
41275415|NCT00251602|DRUG|Propranolol|One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline
41275416|NCT00251602|DRUG|Normal Saline|One-time 0.25 ml/min infusion over 30 minutes
41275417|NCT02205450|DRUG|Recombinant Somatropin|
40927343|NCT01908881|BEHAVIORAL|Group Workshop|The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
41275418|NCT00000264|DRUG|30% Nitrous oxide|
40927344|NCT01908881|BEHAVIORAL|Usual Care|"According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team."
40927345|NCT00717704|DRUG|ixabepilone|by vein once every 3 weeks
40927346|NCT00717704|DRUG|Dasatinib|by mouth once daily
40927347|NCT02195414|DEVICE|NeoVas BCS|The NeoVas First-in-Man study is a prospective, two centers, single arm trial, which will enroll a total of 30 patients. The hypothesis of this study is to evaluate clinical feasibility, safety, and efficacy of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion. The primary endpoint is a composite endpoint of cardiac death, target vessel related myocardial infarction, and ischemia driven target lesion revascularization (TLF) at 1 month follow up. At 6 months, 1, 2, 3, 4 and 5 years follow-up, clinical endpoints include TLF (its individual components), Patient-oriented cardiac event (all cause death, all MI, and all revascularization) target vessel revascularization, scaffold thrombosis.
41275419|NCT00000264|OTHER|0.35 g/Kg ethanol|
41275420|NCT00000264|OTHER|0.7 g/Kg ethanol|
41275421|NCT00000264|OTHER|0 g/Kg ethanol|
41275422|NCT02509208|DEVICE|SurgiClot haemostatic dressing|haemostatic dressing
41275423|NCT01044355|DEVICE|CPAP|6 weeks treatment with fixed CPAP
41275424|NCT01044355|DEVICE|APAP|6 weeks of treatment with auto-titrating positive airway pressure
41275425|NCT00432692|PROCEDURE|Falls Prevention Program|
41275426|NCT03284450|OTHER|DPFT|The DPFT described previously (Redding et al., 2009) involves the repetition of a 'dance phrase' representative of contemporary dance, with each phrase separated by a 2 minute rest period. For the present study the originally described test was extended; the adapted protocol involved 10 x 1 minute movement phrases, each separated by 2 minutes rest.
41275427|NCT03284450|OTHER|SSRS|The SSRS (Howatson \& Milak, 2009) involved 15 x 30 m sprints with a rapid 10 m deceleration phase, with each sprint departing every 65 seconds.
41275428|NCT02285829|DRUG|Rocuronium Bromide, Cisatracurium Besylate|Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF \>0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
40927348|NCT03363022|DRUG|Standard Medical Treatment|Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
40927349|NCT03363022|OTHER|Fecal Microbiota Transplant|"Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of ∼50 g will be considered adequate.~250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.~Enema to be held for 30 minutes."
41124160|NCT05837455|DRUG|Anastrozole|Standard of care
41124161|NCT05837455|DRUG|Combination anthracycline and/or taxane based treatment|Standard of care
41124162|NCT03246724|DRUG|Triazolam|"This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg"
41275429|NCT02086227|DRUG|Glucagon for Injection (Fresenius Kabi USA)|Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
41275430|NCT02086227|DRUG|Glucagon for Injection (Bedford Laboratories)|Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
41275431|NCT02421393|OTHER|supervised exercise training|"Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of weight bearing exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity."
41275432|NCT03310125|DRUG|Colchicine|Over-encapsulated 0.5mg tablet twice daily
41275433|NCT03310125|DRUG|Placebo|Matching placebo capsule twice daily
41446603|NCT02264678|DRUG|Administation of ceralasertib in combination with durvalumab|An oral formulation of ceralasertib will be used. Durvalumab is given via IV infusion. In Module 3 Part A, patients will receive an initial single dose of ceralasertib on Day 1, followed by multiple dosing in combination with durvalumab. In Module 3 Serial Tumour Biopsy Extension and Part B expansion cohorts, patients will receive ceralasertib at the dose, frequency and schedule recommended from Module 3 Part A, in combination with durvalumab.
41275434|NCT01262898|DRUG|GSK962040 (5 mg tablet)|5 mg tablet
41275435|NCT01262898|DRUG|GSK962040 (25 mg tablet)|25 mg tablet
41275436|NCT01262898|DRUG|GSK962040 (125 mg tablet)|125 mg tablet
41275437|NCT01262898|DRUG|Placebo|matching placebo tablet
41446604|NCT02264678|DRUG|Administration of ceralasertib monotherapy|Module 4 Part A and Module 4 Part B Cohort 3: During C0, patients will receive ceralasertib monotherapy orally once a day on 3 non-consecutive days and ceralasertib twice a day on 5 consecutive days. After the patients have completed C0 (Part A) they may transition to Module 4 Part B cohort 3 where they will continue to receive ceralasertib monotherapy
41124163|NCT03246724|DRUG|Midazolam|"This will be used for intravenous sedation. This injection or sodium chloride 0.9% will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1.0 mg~Dose for BMI greater than or equal to 35: 2.0 mg"
41124164|NCT03246724|DRUG|Microcrystalline Cellulose|"This will be used for the oral placebo. This capsule or a triazolam capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1 capsule~Dose for BMI greater than or equal to 35: 2 capsule"
41124165|NCT03246724|DRUG|Sodium chloride 0.9%|"This will be used for the intravenous placebo.This injection or midazolam will be administered depending on the randomized treatment group.~Dose for BMI less than 35: volume to match volume of active intravenous medication~Dose for BMI greater than or equal to 35: volume to match volume of active intravenous medication"
41124166|NCT00575549|OTHER|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
41124167|NCT00936182|DRUG|Fluconazole|Fluconazole daily for 30 days
41124168|NCT03104036|OTHER|Faecal bacterial transplantation|Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline
41124169|NCT03104036|DRUG|Mesalazine 4G Enema|Standard mesalazine enema
41124170|NCT00124735|DRUG|Rocuronium bolus maintenance|Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation
41124171|NCT00124735|DRUG|rocuronium continuous infusion maintenance|Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
41124172|NCT00972439|DRUG|Oral Contraceptive: Ortho-Novum® 1/35|
41124173|NCT00972439|DRUG|Oral Contraceptive: Ovcon Fe®|
41124174|NCT02338024|BEHAVIORAL|Modified Antiretroviral Treatment Access Study intervention|
41124175|NCT00774852|DRUG|abatacept|Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
41124176|NCT00774852|DRUG|cyclophosphamide|500 mg intravenous infusion every 2 weeks for 12 weeks
41124177|NCT00774852|DRUG|azathioprine|2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
41124178|NCT00774852|DRUG|prednisone|60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
41124179|NCT00774852|DRUG|abatacept placebo|Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
41124180|NCT00774852|DRUG|azathioprine placebo|Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
41124181|NCT06229301|PROCEDURE|AI-predicted Nomogram|
41124182|NCT05221281|BEHAVIORAL|Multimodal intervention consisting of four core components|"Core Component 1: Individualized Assessment: Each participant will undergo individualized assessment of their biopsychosocial risk profile (PIBD INTERMED), self-efficacy (IBD-SES-A), function (IBD-DI), transition readiness (TRAQ) and IBD knowledge (IBD-KID2), and depression, anxiety and activation.~Core Component 2: Transition Navigator: Participants will be assigned a transition navigators, who will have knowledge of IBD, an understanding of the care pathway involved in transitioning IBD patients, and the skills and ability to provide psychosocial support.~Core Component 3: Participant Skills-building: Skills-building materials delivered virtually. Navigators will also be trained as motivational coaches and will lead separate personalized virtual sessions targeting individual skills that have been identified as deficient during the assessment phase.~Core Component 4: eLearning Curriculum: Organized online eLearning modules with reinforcement of knowledge by the navigators."
41124183|NCT05221281|BEHAVIORAL|Standard of care|"The control group will be provided a standardized version of routine care for transition. In addition to recruiting centers' standard of care, all participating centers will implement the following transition interventions:~1. A written letter explaining the goals of transition to the patient and family.~2. Completion of age-appropriate checklists to ensure adolescents are meeting milestones of transition (developed by the TRACC Network).51~3. Annual online live educational webinars on transition and adolescent issues (hosted by the CIDsCaNN Education Committee).~4. Completion of the Pediatric INTERMED,52 with appropriate biopsychosocial intervention.~5. Completion of a transfer-of-care summary letter sent to the receiving adult gastroenterologist using a standardized letter template.53~The Control Group may also receive any interventions currently in place in their participating care center, but will not receive the formal 4-component intervention described below."
41124184|NCT00770757|DRUG|CC-4047|
41124185|NCT00861770|OTHER|Ultrafiltration|Ultrafiltration based on standard of care.
41124186|NCT00861770|OTHER|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
41124187|NCT05137834|OTHER|Exercise|Post-surgical exercise
41124188|NCT02335554|BEHAVIORAL|MoodHacker|Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.
41124189|NCT02335554|BEHAVIORAL|Alternative Care|Online information about depression from government and other trusted sources to educate users about depression.
41124190|NCT02140645|DRUG|linagliptin|non-randomized
41124191|NCT04881175|DEVICE|Non-Invasive Treatment|Single-arm group using the FlexSure Applicator device.
41124192|NCT02785029|DEVICE|OCT|
41124193|NCT01222442|DRUG|AZD3199|Single dose, oral inhalation
41124194|NCT01222442|DRUG|Moxifloxacin|Single dose, oral encapsulated tablet
41124195|NCT01222442|OTHER|Placebo comparator|Single dose, oral inhalation
41124196|NCT00468052|DRUG|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
41124197|NCT00468052|DRUG|fentanyl|1 microgram/kilogram as a bolus
41124198|NCT02824458|DRUG|Apatinib|Patients will be treated with Apatinib, 250/500/750 mg(dose determined from Part A of study) p.o., daily
41124199|NCT02824458|DRUG|Gefitinib|Patients will be treated with Gefitinib, 250 mg p.o., daily
41124200|NCT02824458|DRUG|Placebo|
41275438|NCT00646295|DEVICE|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes|Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
41124201|NCT05134324|OTHER|active rTMS|Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed contralateral abductor pollicis brevis (APB).The patient received robotic therapy for upper extremity just after each active TMS sessions.
41124202|NCT05134324|OTHER|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for upper extremity just after each sham TMS sessions.
41275439|NCT03372525|DEVICE|HFOV|Infants were randomized to HFOV
41275440|NCT03372525|DEVICE|CMV|Infants were randomized to CMV
41275441|NCT02537678|BEHAVIORAL|Stepped Care TF-CBT|Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
41275442|NCT02537678|BEHAVIORAL|Standard TF-CBT|Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
41124203|NCT05134324|OTHER|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the C3/C4 (International 10/20 Electroencephalogram System) area, corresponding to the location of the affected hemisphere primary motor cortex (M1), and cathodal to the contralateral supraorbital region. The patient received robotic therapy for upper extremity just after each active tDCS sessions.
41124204|NCT05134324|OTHER|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
41124205|NCT05462067|DEVICE|AT LARA IOL|EDOF IOL for treatment of cataract
41124206|NCT05462067|DEVICE|AT LISA Tri IOL|Trifocal IOL for treatment of cataract
41124207|NCT03609359|DRUG|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.
41124208|NCT03609359|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
41124209|NCT00277277|BEHAVIORAL|Healthium|
41124210|NCT01477268|DRUG|Zoloft (antidepressant)|Zoloft 50-200 mg po od x 12 weeks
41124211|NCT02907905|BIOLOGICAL|capillary sampling|"After elution in buffer (PBS-Tween azide and thiamol) eluate 200 microliter is processed on automated techniques (Siemens Centaur XL and Diasorin) after adjustment of the figures according to ISO 15189 scope B.~The results are qualitatively made and sent to the teams. The return of results, a proposal for appropriate care in the event of contact with virus (anti-HAV HCV HBV) through a rendering consultation results"
41124212|NCT06143501|DIAGNOSTIC_TEST|Blood Sample|6 ml blood (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
41124213|NCT06143501|DIAGNOSTIC_TEST|Stool Sample|pea-sized amount (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
41124214|NCT06143501|DIAGNOSTIC_TEST|Urine Sample|8 ml (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
41124215|NCT06053606|DEVICE|cryoablation of atrial fibrillation using only 28 mm size balloon|all applications in all PVs are done with 28 mm balloon
41124216|NCT06053606|DEVICE|cryoablation of atrial fibrillation using expandable balloon (28 / 31 mm)|first applications in LSPV and RSPV are done with 31 mm balloon
41124217|NCT04556981|BIOLOGICAL|M72/AS01E Mycobacterium tuberculosis vaccine|Participants will receive an intramuscular dose of M72 (10 micrograms of recombinant fusion protein) reconstituted with AS01E (an adjuvant system), on Day 1 and Day 29
41124218|NCT04556981|BIOLOGICAL|Placebo|Participants will receive an intramuscular dose of saline (0.9% NaCl), on Day 1 and Day 29
41124219|NCT00402896|DRUG|ZD6474|300 mg/day orally for 10 weeks.
41124220|NCT01638975|BEHAVIORAL|Response Inhibition Training Program|This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
41124221|NCT05953363|DEVICE|BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes|Insertion of a BD NRFit™ spinal needle and optional BD NRFit™ Spinal Introducer Needle using a BD NRFit™ Syringe to perform the neuraxial procedure.
41124222|NCT01145729|BEHAVIORAL|Biomarker Feedback|Providing providers biomarker feedback on childhood secondhand smoke exposure
41124223|NCT06516705|BEHAVIORAL|Hypoglycemia education|Hypoglycemia education : incleded introduction to blood glucose, hypoglycemia symptoms and treatment (15-15 rule), prevention of hypoglycemia (diet and exercise), and medication treatment.
41124224|NCT00945321|DRUG|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
41275443|NCT03171922|BEHAVIORAL|Internet Diet|ID group have online dietary coach every 2 weeks
41275444|NCT03171922|BEHAVIORAL|Clinic Diet|CD group have every 2 weeks visit at clinic
41287252|NCT03653715|DEVICE|Clerio Vision LIRIC-modified Bifocal Contact Lens|Within this arm the investigational acofilcon B material bifocal contact lens, which has been modified with the laser and is the focus of the study, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
41124225|NCT00945321|DRUG|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
41124226|NCT00945321|DRUG|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
41275445|NCT03114033|OTHER|Targeted therapeutic mild hypercapnia|Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg
41275446|NCT03114033|OTHER|Targeted normocapnia (Standard care)|Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg.
41275447|NCT06228157|BEHAVIORAL|Routine therapy|The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
41275448|NCT06228157|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41275449|NCT02549950|PROCEDURE|Peizocorticision|Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement
41275450|NCT02549950|PROCEDURE|Conventional Orthodontic Mechanics|Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
41275451|NCT01588223|OTHER|Lipid identification|The lipids are identified using Mass Spectrometry
41275452|NCT04429022|DRUG|Gabapentin|600mg PO PO x 1 prior to surgery (in pre-op) 300mg PO BID for 7 days post op
41275453|NCT04429022|DRUG|Acetaminophen|Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN post op
41275454|NCT04429022|DRUG|Celecoxib|Celecoxib 200mg PO q 12h x 7d post op
41275455|NCT04429022|DRUG|Ketorolac|30mg IV once at end of hysterectomy procedure
41275456|NCT04429022|PROCEDURE|Paracervical block with ropivacaine|0.5% ropivacaine; 10 mL bilaterally (2 point) for total of 20mL
41275457|NCT04429022|PROCEDURE|Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites|0.5% ropivacaine; at all laparoscopic port sites; another 10mL ropivacaine in total
41275458|NCT04429022|DRUG|Hydromorphone|1mg IV PRN q3h, post op, while inpatient
41275459|NCT04429022|DRUG|Oxycodone|To be discharged home with: 12 tabs of 5mg PRN q4h
41275460|NCT03124225|DRUG|DMARD|
41275461|NCT00876031|DRUG|trofosfamide, idarubicin, etoposide|oral maintenance therapy for 6 months
41275462|NCT02461017|OTHER|Assess for Audible Endotracheal Leak|In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.
40927350|NCT03363022|OTHER|Placebo|Placebo will be identical and non medicinal to the Fecal Microbiota Transplant
41275463|NCT02461017|OTHER|Assess for Endotracheal Leak with direct visualization under rigid bronchoscope|In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
41275464|NCT04212000|DRUG|Levoketoconazole|Levoketoconazole tablet
41275465|NCT04212000|DRUG|Ketoconazole|Ketoconazole tablet
41275466|NCT03602092|OTHER|Observation|This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
41275467|NCT05714904|DRUG|ZVS101e|ZVS101e is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene.
41275468|NCT04591093|DEVICE|FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated
41275469|NCT01973283|DRUG|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
40927351|NCT00344942|DRUG|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
40927352|NCT00344942|DRUG|placebo|a double spray into each nostril once daily
40927353|NCT03003299|DEVICE|Edwards SAPIEN 3/SAPIEN 3 Ultra THV|Edwards SAPIEN 3/SAPIEN 3 Ultra THV system with the associated delivery systems.
41124227|NCT00945321|DRUG|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
41124228|NCT02979184|OTHER|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
41124229|NCT06497374|DRUG|Efgartigimod Alfa Injection|Efgartigimod+IVMP; IVMP; Efgartigimod
41124230|NCT06497374|DRUG|High-dose intravenous methylprednisolone|Efgartigimod+IVMP; IVMP; Efgartigimod
41124231|NCT03884296|BIOLOGICAL|FluMist|Quadrivalent, live, attenuated influenza vaccine, intranasal spray
41124232|NCT03773835|DRUG|HSK3486|Mmanual IV bolus injection completed in 1 minute.
41275470|NCT04917874|BIOLOGICAL|Open Label Topical Beremagene Geperpavec (B-VEC)|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
41275471|NCT03204344|DIETARY_SUPPLEMENT|Oral carbohydrate (Outfast)|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above."
40927354|NCT05307367|BEHAVIORAL|Exercise training|Patients will be enrolled in a 8 week, supervised, single-leg kicking training intervention (1h, or as long as possible, 60-70% peak workload (PWL), 2-5 days a week). Healthy age-, body weight-, gender- and activity level-matched control subjects will undertake the intervention matched to the %PWL obtained by the patients who complete the study.
41124233|NCT02241538|DEVICE|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
41124234|NCT02241538|DEVICE|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
41124235|NCT02241538|DEVICE|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
41124236|NCT02241538|DEVICE|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group did not receive additional exercise.
41124237|NCT02548806|DRUG|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
41124238|NCT02548806|DRUG|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
41275472|NCT03204344|OTHER|Routine fasting|"For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary."
41275473|NCT01964248|DRUG|Placebo|Placebo cream applied 2 hours before blood sample
40927355|NCT00813943|DRUG|Cilengitide (2-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
40927356|NCT00813943|DRUG|cilengitide (5-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
41124239|NCT02548806|DRUG|Catapres 100μg|Catapres tablet 100μg, single dose
41124240|NCT05459701|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once daily for 24 weeks.
41275474|NCT01964248|DRUG|lidocaïne/prilocaïne 5%|Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
41275475|NCT00250393|DRUG|Istradefylline (KW-6002)|
41275476|NCT00628355|DRUG|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
41275477|NCT00628355|PROCEDURE|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
40927357|NCT00813943|DRUG|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
41124241|NCT05459701|OTHER|Placebo|Placebo
41124242|NCT05490524|DEVICE|GATEKEEPER|The GATEKEEPER is a digital platform that allows patients and caregivers to record their day-to-day symptoms and other parameters such as quality of life using means such as apps and wearable devices that record both self-report (quality of life, depression, anxiety) and physiological data (mobility, pain, sleep patterns, heart rate), and allows healthcare professionals to monitor these data and tailor healthcare so to prevent and intervene in symptoms that may be occurring.
41124243|NCT02306954|BIOLOGICAL|High Dose IL-2|High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
41124244|NCT02306954|RADIATION|SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
41124245|NCT03394885|DRUG|Atezolizumab|1200mg IV q3weeks
41446605|NCT02264678|DRUG|Administration of ceralasertib and olaparib|"Module 4 Part B Cohort 1:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with olaparib as decided by the investigator."
40927358|NCT00813943|RADIATION|Radiotherapy|Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
41124246|NCT03394885|DRUG|Carboplatin|5-6mg/ML IV q3 weeks
41124247|NCT03394885|DRUG|Paclitaxel|70-80 mg/m2 IV q1 week
41124248|NCT03394885|DRUG|Bevacizumab|15 mg/kg IV q3 weeks
41124249|NCT05177939|DRUG|NPB-01|NPB-01 will be administered for the treatment of autoimmune encephalitis
41124250|NCT05177939|DRUG|NPB-01-ME|NPB-01-ME will be administered for the treatment of autoimmune encephalitis
41124251|NCT00496743|DEVICE|Low-dose total skin electron beam therapy (4 Gy)|
41124252|NCT04425863|DRUG|Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.
41124253|NCT04425863|OTHER|Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|36 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, 1 Aspirin tablet daily for 30 days. Inpatient treatment in ward care, including Low flow washed oxygen or oxygen concentrator
41124254|NCT04425863|OTHER|Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.|48 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, Enoxaparin 100 IU/kg (ca. 1 mg/kg) daily until transfer to ward care. Then continue with inpatient treatment in ward care.
41124255|NCT02540525|DEVICE|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
41124256|NCT02540525|DEVICE|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
41124257|NCT02819414|DRUG|Paracetamol drops|15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
41124258|NCT02819414|OTHER|Placebo|2.25 ml/kg/dose x 4/day of sterile water to be given for three days
41124259|NCT04460807|DRUG|Exemestane|Exemestane in addition to standard therapy, in Experimental arm.
41124260|NCT04460807|OTHER|Placebo oral tablet|Placebo in addition to standard therapy, in Control arm.
41124261|NCT05436119|DIETARY_SUPPLEMENT|GrowBaby|Virtual group educational visits will cluster women in the same trimester of pregnancy teaching trimester-specific diet and lifestyle modification, further customized to the individual using limited micronutrient and gene variant analysis. Each woman will receive base multi-nutrient and probiotic supplementation with customization if identified needs cannot be met with diet and lifestyle modification alone.
41124262|NCT01421407|DEVICE|Ultrasonic ablation device|High Intensity Focused Ultrasound treatment
41124263|NCT01910896|DEVICE|Overnight Intensive Patch|Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
41124264|NCT00917202|DRUG|Methylenblue|
41124265|NCT01091740|DEVICE|ZES resolute (Endeavor Resolute)|2nd generation drug eluting stent, which is coated with zotarolimus
41124266|NCT01091740|DEVICE|EES (Xience)|2nd generation drug eluting stent, which is coated with everolimus
41124267|NCT05223517|DEVICE|Acupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted to 60-70mm in Ciliao and Huiyang, 6-10 mm in Shenmen and 10-20mm in other acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times (except for Ciliao) to achieve deqi sensation and manipulated every ten minutes during 20-minute maintenance in prone and supine position respectively.~Participants receive acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
41287253|NCT03653715|DEVICE|Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens|Within this arm the control etafilcon A material bifocal contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
41446606|NCT02264678|DRUG|Administration of ceralasertib and durvalumab|"Module 4 Part B Cohort 2:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with durvalumab as decided by the investigator."
40927359|NCT04322539|DRUG|Fruquintinib|Oral VEGFR inhibitor
40927360|NCT04322539|DRUG|Placebo|Placebo capsule
40927361|NCT04858971|OTHER|Perception of information source|Participants will see the same health advice, with no source or one of three other sources indicated
41275478|NCT03071718|OTHER|Mediterranean diet|"Subjects in the Med-D group will be assigned a personalized diet prepared on the basis of own eating habits as established by 7-d food diary recalls. Energy values of habitual diets will be kept unchanged during Med-D intervention. Briefly, Med-D will be prepared so as to achieve a weekly consumption of:~* 7 portions of milk or yogurt plus whole grain cereals,~* 7 portions of nuts (30g)~* At least 3 portion of absolute legumes~* 14 portions of vegetables~* 21 portions of fruit~* 4 portions of whole grain pasta~* 3 portions of whole grain pasta with vegetables or legumes~* 7 portions of whole grain bread~* 3 portions of fish~* Extravirgin olive oil as unique source of discretional fats All subjects will be requested not to change physical activity levels during the 8 week intervention period."
41275479|NCT03071718|OTHER|Control Diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
41275480|NCT04610099|DEVICE|Banded Sleeve Gastrectomy|banded sleeve gastrectomy
41275481|NCT04610099|DEVICE|Standard SG|Standard SG
41275482|NCT05601206|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
41124268|NCT05223517|DEVICE|Sham Acupuncture|"Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 20-minute maintenance in prone and supine position respectively.~Participants receive sham acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
41275483|NCT05601206|BEHAVIORAL|Enhanced Usual Care|Usual care from health providers
41124269|NCT04770649|BIOLOGICAL|COVID-19 vaccine|Any vaccine for COVID-19
41124270|NCT00613405|OTHER|Stress + cue exposure|Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
41275484|NCT00680225|DRUG|Ranibizumab injection and TTT - ICG based|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
41275485|NCT01249170|BEHAVIORAL|First year program|Information on group that underwent new educational program
41275486|NCT01249170|OTHER|Control comparison|Information from group that did not undergo new first year program
41275487|NCT02594501|DEVICE|COBRA PzF|
41275488|NCT02594501|DEVICE|Drug Eluting Stent|
40927362|NCT01993095|BEHAVIORAL|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week.
40927363|NCT01993095|BEHAVIORAL|Behavioral: Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
41124271|NCT00613405|OTHER|No stress + cue exposure|Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
41124272|NCT00249769|BIOLOGICAL|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake. After reconstitution, it turns into a transparent orange red liquid. Its container is a vial. It is stored and transported between 2°C to 8°C and protected from light. Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
41275489|NCT06060301|DRUG|sulfasalazine 500 MG|The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
41446607|NCT02264678|DRUG|Administration of ceralasertib in combination with AZD5305|An oral formulations of ceralasertib and AZD5305 will be used. In Module 5 Part A, patients will receive a single dose of ceralasertib on cycle 0 Day 1 as per dose level cohort. In Module 5 Part B, patients will receive ceralasertib and AZD5305: C1 onwards (as per dose level cohort allocated).
41275490|NCT06060301|DRUG|corticosteroids|The patients will use topical corticosteroids 4 times per day.
41275491|NCT04125537|BEHAVIORAL|IHI Breakthrough Collaborative Model|Staff teams at participating dialysis centers take part in a quality improvement/collaborative learning model that was initially planned to include three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement kidney supportive care best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project. Patients at the sites then receive care that has been improved via this staff education and quality improvement activities.
41275492|NCT04957173|OTHER|Lifestyle intervention|"The intervention includes a total of 17 virtual meetings and aims to achieve a weight loss of 0.8 to 1% of the initial weight per week.~This will include 3 successive phases:~1. A significant calorie restriction (A minimum deficit of 800 kcal / day of their daily energy expenditure) for a period of 4 weeks;~2. A moderate calorie restriction (minimum deficit of 500 kcal / day of their daily energy expenditure) for a period of 4 weeks;~3. A maintenance phase of weight loss for 16 weeks.~4. An optional phase of monthly follow-ups for a period of 3 months (no intervention)"
41275493|NCT03728049|DIAGNOSTIC_TEST|CT-ADP performed during TAVI procedure|The CT-ADP will be performed in the catheterization laboratory and revealed to the operator. The decision to undertake corrective procedure will be based on CT-ADP on top of standard methods of PVR assessment.
41275494|NCT03728049|OTHER|No CT-ADP performed during TAVI procedure|PVR assessment with the standard methods only (TTE and/or angiography and/or hemodynamics but excluding TEE and CT-ADP). The decision to undertake corrective procedure will be left at the discretion of the operator.
41275495|NCT01028352|DRUG|Duloxetine|"Patients will be treated with open-label duloxetine:~* 30 mg daily x 7 days, then~* 60 mg daily x 3 weeks, then~* If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~* If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~* After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician."
41275496|NCT01179529|DRUG|Omalizumab (Xolair®)|
41275497|NCT04376619|OTHER|remote ischemic preconditioning|inflation and deflation of cuff 5min each cycle repeated 3 times
41275498|NCT04376619|OTHER|KDIGO guidelines|KDIGO stands for Kidney disease Improving global outcomes guidelines, and have guidelines for prevention and treatment of AKI which is considered standard of care.
41275499|NCT00701987|DRUG|ALS-357|Topical application of ALS-357
41275500|NCT05600127|DRUG|Avelumab|3 cycles of avelumab (800mg, every 2 weeks)
41275501|NCT04970706|PROCEDURE|ACL reconstruction|All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
41275502|NCT02272790|DRUG|Adavosertib|Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.
41275503|NCT02272790|DRUG|Paclitaxel|"Paclitaxel will be administered as a 1-hour IV infusion (± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.~Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards."
41275504|NCT02272790|DRUG|Carboplatin|Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.
41275505|NCT02272790|DRUG|Gemcitabine|Gemcitabine 800 mg/m² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.
41275506|NCT02272790|DRUG|PLD|PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
41275507|NCT02270567|DEVICE|NETest|Non-invasive blood test
41275508|NCT03744650|BEHAVIORAL|"Care4Heart programme"|"A 4-week mHealth programme in the form of a smartphone app, named Care4Heart, has been developed. The content and scope of the design are developed by a thorough literature review and an extensive analysis of existing education leaflets and brochures used to prevent CHD. The contents are specified and tailored to the working population.~The app is developed by a team of software engineers from Computing School of NUS. Several functions include: (1) app using instructional video; (2) easy-to-read information on healthy lifestyle toward heart health, including information about the disease, CHD risk factors (e.g. diet, smoking cessation), stress, physical exercises and relaxation techniques; and (3) scheduled reminders for doing exercise and relaxation"
41275509|NCT05373238|PROCEDURE|Early discharge|Early discharge
41275510|NCT00803556|DRUG|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
41275511|NCT00803556|DRUG|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
41275512|NCT00803556|DRUG|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
41446608|NCT02264678|DRUG|Administration of ceralasertib in combination with carboplatin|An oral formulation of ceralasertib will be used. In Module 1 Part A, patients will receive a single dose of ceralasertib on Day 1, followed by multiple dosing in combination with carboplatin. A maximum of 6 cycles (21 days per cycle) of treatment will be given. In Module 1 Part B, patients will receive ceralasertib and carboplatin at the dose, frequency and schedule recommended from Module 1 Part A.
41446609|NCT06626815|BEHAVIORAL|Lateral Kangaroo Position|Newborns in the lateral kangaroo position group will be positioned diagonally on their mothers chests, with their heads placed between the mothers breast and collarbone.
41446610|NCT06626815|BEHAVIORAL|Reverse Kangaroo Position|Newborns in the reverse kangaroo position group will be positioned vertically with their backs in contact with the mothers chest.
41446611|NCT01919112|DEVICE|tDCS|Anodal tDCS will be administered with swallowing exercises
41446612|NCT02331563|DRUG|Dexmedetomidine|ultrasound guided transvers abdominis plane block
41446613|NCT02331563|DRUG|0.25 % bupivacaine|ultrasound guided transvers abdominis plane block
40927364|NCT02694718|DRUG|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.
41124273|NCT00249769|BIOLOGICAL|Measles Vaccine (MV)|"The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO).~SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979."
41446614|NCT01196390|DRUG|Carboplatin|Given IV
41124274|NCT02034292|DRUG|Clopidogrel|
41446615|NCT01196390|OTHER|Laboratory Biomarker Analysis|Correlative studies
41275513|NCT00792779|DRUG|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
41446616|NCT01196390|DRUG|Paclitaxel|Given IV
41124275|NCT02034292|DRUG|Aspirin|
41124276|NCT02034292|DRUG|APD791|
41124277|NCT02034292|DRUG|Placebo|
41124278|NCT01250769|DEVICE|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
41124279|NCT01250769|DEVICE|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
41124280|NCT03941067|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands
41124281|NCT01989741|OTHER|Sleep restriction|4 hours sleep by night during one week
41124282|NCT01111513|DRUG|48-hour ropivacaine infusions|Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
41124283|NCT01111513|DRUG|Single dose ropivacaine|Patients receive 20 ml of ropivacaine 0.5% pre-operation
41124284|NCT01111513|DRUG|Patient controlled analgesics|Patient controlled analgesics alone, no femoral block
41124285|NCT03669822|OTHER|Standard of care|Care decisions driven by local physicians; this is an observational cohort.
41124286|NCT00891631|BEHAVIORAL|iSBIRT|Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.
41124287|NCT00891631|BEHAVIORAL|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
41124288|NCT06521619|PROCEDURE|Femoral and sciatic nerve blocks|Patients receiving Adductor canal block and infiltration of posterior capsule of knee
41124289|NCT00503906|DRUG|Avastin|
41124290|NCT00503906|DRUG|Gemcitabine|
41124291|NCT00503906|DRUG|Abraxane|
41124292|NCT06082635|DRUG|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles
41124293|NCT06082635|DRUG|Crizotinib|Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles
41124294|NCT06290791|PROCEDURE|two level lumbar decompression with BESS procedure received one drain.|patients who underwent two level lumbar decompression with BESS procedure received one drain.
41124295|NCT06290791|PROCEDURE|two level lumbar decompression with BESS procedure received two drain.|patients who underwent two level lumbar decompression with BESS procedure received two drains
41124296|NCT04393389|DEVICE|"AcoArt Orchid (0.035), AcoArt Tulip (0.018) and AcoArt Litos (0.014) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd."|All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment
41124297|NCT05264675|PROCEDURE|primary suture|Primary suture of the EPL-tendon
41124298|NCT05264675|PROCEDURE|EIP-transfer|transfer of the EIP-tendon to the EPL-tendon
41124299|NCT00832169|DRUG|AZD1386|1 dose of oral solution
41287254|NCT03653715|DEVICE|Johnson & Johnson 1-Day Acuvue Moist Contact Lens|Within this arm the control etafilcon A material single vision contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
41124300|NCT03865056|DEVICE|Optiflow (High-flow Nasal Cannula)|Optiflow will be applied for 20 minutes
41124301|NCT03865056|DEVICE|Non-invasive Ventilation|non-invasive ventilation will be applied for 20 minutes
41124302|NCT02852824|DRUG|BI 655130 (spesolimab)|
41124303|NCT02852824|DRUG|Placebo|
41124304|NCT02703558|DRUG|Phenazopyridine|
41124305|NCT02703558|DRUG|Fluorescein|
41124306|NCT03323203|DEVICE|FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA|Tissue oxygenation was monitored using a tissue oximeter based on near-infrared spectroscopy (FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA). The oximeter had four cables with each cable connected to an adhesive probe.
41124307|NCT05168085|DIETARY_SUPPLEMENT|Eggs|Providing 1 egg per day fo 6 months to infants
41124308|NCT06003517|PROCEDURE|Screening with PSI check list|Screening PSI with institutional check list
41124309|NCT06366984|OTHER|plastibell|plastibell used for circumcision
41124310|NCT06366984|OTHER|open method|open method used for circumcision
41124311|NCT03794024|DEVICE|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
41124312|NCT03794024|DEVICE|The Axium Neurostimulator System|The Axium Neurostimulator System is indicated for spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome Types I and II
41124313|NCT03103048|DIAGNOSTIC_TEST|Without bandages|All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
41124314|NCT03103048|DIAGNOSTIC_TEST|With placebo|All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
41124315|NCT03103048|DIAGNOSTIC_TEST|With bandage|All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
41124316|NCT03103048|DIAGNOSTIC_TEST|With tensioned bandage|All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
41124317|NCT00999167|DRUG|HPN-100|Part B: 6 mL BID for 16 weeks.
41124318|NCT00999167|DRUG|Placebo|Part B: same as experimental arm
41124319|NCT03840122|OTHER|ACB + IPACK block with injection of local anesthetic|"ACB + IPACK block with injection of local anesthetic which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
41124320|NCT03840122|OTHER|ACB + IPACK block without injection|ACB + IPACK block without an injection of local anesthetic
41446617|NCT01196390|OTHER|Quality-of-Life Assessment|Ancillary studies
41124321|NCT06288334|OTHER|1-3 Cetirizine Pharmacokinetic samples|Limited sampling strategy was used in this study. For each child, only 1\~3 blood samples were collected before and after cetirizine administration.
40754327|NCT00079781|PROCEDURE|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
40754328|NCT00079781|DEVICE|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
40754329|NCT00036465|BEHAVIORAL|Treatment regimen change|
40754330|NCT03307096|PROCEDURE|Microperc surgery|Parents are treated by Microperc Percutaneous Nephrolithotomy
41275514|NCT05017545|BIOLOGICAL|carfilzomib|"Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert.~Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant."
41275515|NCT05017545|BIOLOGICAL|belatacept|Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.
41275516|NCT05017545|PROCEDURE|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
41124322|NCT04965272|DRUG|Cariprazine 0.75 mg/day|Oral Capsule
41275517|NCT01696461|DRUG|Plerixafor|
41124323|NCT04965272|DRUG|Cariprazine 1.5 mg/day|Oral Capsule
41275518|NCT05526534|DEVICE|heated humidified high flow nasal cannula oxygen therapy, HFNC|HFNC can accurately provide 21% \~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.
41275519|NCT05526534|DEVICE|Nasal cannula oxygen|Nasal cannula oxygen has become a routine part of postoperative treatment
41275520|NCT00016458|DRUG|anti-thymocyte globulin|
41275521|NCT00016458|DRUG|cyclophosphamide|
41446618|NCT01196390|RADIATION|Radiation Therapy|Undergo radiation therapy
41446619|NCT01196390|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41446620|NCT01196390|BIOLOGICAL|Trastuzumab|Given IV
41446621|NCT06082960|DRUG|GS-9911|Tablets administered orally
41446622|NCT06082960|DRUG|Zimberelimab|Administered intravenously
40754331|NCT03307096|PROCEDURE|FURS|Parents are treated by FURS
41124324|NCT04965272|DRUG|Cariprazine 3.0 mg/day|Oral Capsule
41124325|NCT04965272|OTHER|Placebo|Oral Capsule
41124326|NCT06118749|DIAGNOSTIC_TEST|Antigen detection Rapid Diagnostic Test prototype|The study will focus on the usability and diagnostic performance of the RDT in blood and/or urine from patients with visceral leishmaniasis.
41446623|NCT05638490|OTHER||no intervention
40754332|NCT02070380|DRUG|MultiHance 0.1 mmol/kg|MultiHance administered at 0.1 mmol/kg
40754333|NCT02070380|DRUG|Dotarem|Dotarem administered at 0.1 mmol/kg
40754334|NCT02070380|DRUG|MultiHance 0.05 mmol/kg|MultiHance administered at 0.05 mmol/kg
40754335|NCT00976300|DRUG|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
40754336|NCT00976300|DRUG|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
40758320|NCT05250557|DIAGNOSTIC_TEST|Fractional flow reserve|Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).
40758321|NCT00170365|BEHAVIORAL|Restorative Yoga|
41124327|NCT03577223|OTHER|Whole Eggs|3 whole eggs per day for 4 weeks
41124328|NCT03577223|OTHER|Egg White-Based Egg Substitute|3-egg equivalent of egg white-based egg substitute per day for 4 weeks
41124329|NCT01121991|DRUG|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
41124330|NCT03760913|DRUG|OLP-1002 (Test): Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
41124331|NCT03760913|DRUG|OLP-1002 (Test): Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
41124332|NCT03760913|OTHER|Placebo: Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
41446624|NCT02435264|OTHER|Healthier Dining Program Intervention|The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
41275522|NCT05662592|DEVICE|Broadband Light|Broadband Light device will be used for treatment of pigmented skin lesions
41275523|NCT04490629|DEVICE|Lyoplant Onlay|Lyoplant Onlay is a kind of latest artificial Dura Mater
41124333|NCT03760913|OTHER|Placebo: Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
41275524|NCT04490629|DEVICE|DURAFORM|DURAFORM is a kind of conventional artificial Dura Mater
41124334|NCT01792934|DRUG|XELOX regimen according to standard procedures|
41275525|NCT01120626|DRUG|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
41275526|NCT01120626|DRUG|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
41275527|NCT01262183|DRUG|CRT + Panitumumab|Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
41124335|NCT01792934|DRUG|FOLFOX regimen according to standard procedures|
41124336|NCT01792934|PROCEDURE|Surgery|
41124337|NCT01792934|OTHER|radiofrequency ablation (RFA)|
41124338|NCT01792934|OTHER|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
41124339|NCT01792934|RADIATION|stereotactic body radiation therapy (SBRT)|
41124340|NCT01792934|DRUG|Bevacizumab|may be added to both regimens according to standard procedures
41275528|NCT01262183|DRUG|Concurrent chemoradiation therapy without panitumumab|Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
41124341|NCT01792934|PROCEDURE|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
41124342|NCT00329264|DRUG|Quetiapine fumarate|
41124343|NCT00571298|PROCEDURE|Extrapleural pneumonectomy (EPP)|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
41124344|NCT00571298|DRUG|Cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
41124345|NCT00571298|DRUG|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
41275529|NCT04769557|DRUG|paracetamol|tablet paracetamol 500 mg
41275530|NCT04769557|DRUG|Placebo|placebo
41275531|NCT03482661|OTHER|magnetic steering|The capsule was controlled to pass through the pylorus by magnet steering.
41275532|NCT03576144|DRUG|BI 1265162|Multiple rising inhaled doses
41275533|NCT03576144|DRUG|Placebo|Multiple rising inhaled doses
41124346|NCT00571298|DRUG|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
41124347|NCT00571298|DRUG|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
41124348|NCT00571298|PROCEDURE|Pleurectomy/Decortication|Resection of the lining of the lung (pleura), while the lung remains intact.
41124349|NCT03411941|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|IVT(Intravitreal) aflibercept treatment in routine clinical practice.
41124350|NCT05570838|DEVICE|Functional Electrical Stimulation|Functional Electrical Stimulation consist on applying a current on the damaged muscles when the patient is doing a task that requires them. 120 repetitions will be made on the 6 first sessions and 180 repetitions will be done after the sixth session
41124351|NCT05570838|DEVICE|Hand Robotic-Assisted Therapy|The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.
41124352|NCT01163981|OTHER|Use of ultrasound guidance in cannulation|Use of guidance with duplex ultrasound to complete cannulation of dialysis access
41124353|NCT04924218|PROCEDURE|endoscopic surgical intervention|The researchers investigated whether endoscopic surgical procedures performed due to various indications (hematuria, urinary tract stone, suspected bladder mass) in the patient group who had undergone radical prostatectomy, caused a change in urinary incontinence level. The researchers divided the endoscopic instruments used into 3 groups and evaluated whether there was a difference in urinary incontinence level between rigid cystoscope, flexible cystoscope and ureterorenoscope groups.
41124354|NCT02721901|BEHAVIORAL|iEAT Manual Intervention|The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
41275534|NCT06367322|DRUG|Statin|"The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP.~Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy."
41275535|NCT05655585|OTHER|Active Release Technique|Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension
41275536|NCT05655585|OTHER|Mulligan Bent Leg Raise|Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur
41275537|NCT00432809|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass
41275538|NCT00432809|PROCEDURE|Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
41275539|NCT04880811|DRUG|Afatinib|Afatinib is orally administered at 40mg Qd of each 21 day cycle.
41275540|NCT04880811|DRUG|Toripalimab|Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.
41124355|NCT02721901|BEHAVIORAL|Control group|The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
41124356|NCT05766319|DEVICE|Withings ScanWatch|"Withings ScanWatch, from which the following features will be used:~* Measurement of peripheral oxygen saturation (%)~* Automatic recording of heart rate (beats/min)~* Automatic recording of activity (step count) (numbers/day)"
41124357|NCT05766319|DEVICE|Withings BPM Connect|"Withings BPM connect, from which the following feature will be used:~o Measurement of non invasive bloodpressure (mmHg)"
41124358|NCT05766319|DEVICE|Withings Body|"Withings Body (Scale), from which the following feature will be used:~o Measurement of body weight (kg)"
41124359|NCT02229721|DRUG|Syntocinon Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
41124360|NCT02229721|DRUG|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
41124361|NCT05320289|DEVICE|AblaCare System|"The intervention includes the short-term use of the AblaCare System, which is comprised of three elements: (1) the AblaCare Needle-Catheter Ablation Device (NCAD) (the Device) a 16G echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secure onto a vaginal ultrasound probe; (2) the AblaCare Adapter which is clipped onto the ultrasound probe; and (3) the AblaCare Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use AblaCare NCAD for ovarian tissue ablation.~Once th patient is under conscious sedation, the physician guides the AblaCare system transvaginally with the use of a transvaginal ultrasound. Once the AblaCare device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue."
41124362|NCT03722316|OTHER|Immersive Nature Video|"An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg-Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
41124363|NCT03722316|OTHER|Neutral Video|"This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., \<1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
41275541|NCT06487052|COMBINATION_PRODUCT|Standard Catheter-Directed Low Dose Thrombolysis|Using femoral or jugular vein access the mechanical blood clots fragmentation by PigTail 6F catheter circular rotational movements. For unilateral thromboembolism, the PigTail catheter is positioned in the obstructed branch of the pulmonary artery, 1 mg of alteplase is injected as a bolus, followed by a micro-jet injection of 1 mg/hour. For bilateral thromboembolism, the PigTail catheter is positioned in the pulmonary trunk with a bolus of 2 mg alteplase followed by an infusion of 2 mg/hour. The total duration of infusion will be 9 hours, the total dose of alteplase will be 10 mg for unilateral lesions and 20 mg for bilateral lesions. During the alteplase infusion, unfractionated heparin is continued with a target activated partial thromboplastin time (aPTT) of 50 to 60 seconds. After completion of the procedure, UFH therapy is continued for 24 hours, followed by a change to oral anticoagulants.
41124364|NCT02300675|BEHAVIORAL|therapeutic education program|
41275542|NCT06487052|DRUG|Standard Anticoagulation|Therapy with UFH with targeted аPTT lasts for 24 hours (no more than 48 hours in total). Then the change to oral anticoagulants is performed
41275543|NCT02618369|DEVICE|MR-Guided High Intensity Focused Ultrasound|Target treatment of bone lesion using High Intensity Focused Ultrasound
41124365|NCT05898191|OTHER|vaginal laser treatment|non-ablative vaginal laser application
41275544|NCT00780403|DRUG|Desloratadine|desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
41275545|NCT00780403|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
41275546|NCT01468649|DEVICE|NIR Imaging with FLARE and Mini-FLARE Imaging System|A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
41124366|NCT04430634|OTHER|Myblu variant A|Use of Myblu e-cigarette with flavor A 2.4% nicotine
41124367|NCT04430634|OTHER|Myblu variant B|Use of Myblu e-cigarette with flavor B 3.6% nicotine
41124368|NCT04430634|OTHER|Myblu variant C|Use of Myblu e-cigarette with flavor C 2.5% nicotine
41275547|NCT06357286|BEHAVIORAL|Work opportunities|Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
41124369|NCT04430634|OTHER|Myblu variant D|Use of Myblu e-cigarette with flavor D 4.0% nicotine
41124370|NCT04430634|OTHER|Myblu variant E|Use of Myblu e-cigarette with flavor E 3.6% nicotine
41124371|NCT04430634|OTHER|Myblu variant F|Use of Myblu e-cigarette with flavor F 2.4% nicotine
40927365|NCT02694718|DRUG|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
41275548|NCT03394638|OTHER|Access to online eLearning module|Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.
41275549|NCT03394638|OTHER|Access to measurement devices|Patients in the device group have, in addition to patients in the Online group, access to 4 measuring devices, including: weight scale, oximeter, activity bracelet and blood pressure device. Those devices are connectable to their mobile phones where patients can view their own progress.
41275550|NCT03394638|PROCEDURE|Conventional group|All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
41275551|NCT00222105|DRUG|Doxil|Doxil 40 mg/m2 IV day 1
41275552|NCT00222105|DRUG|Thalidomide|50-100 mg day 1-28
41124372|NCT04430634|OTHER|Myblu variant G|Use of Myblu e-cigarette with flavor G 4.0% nicotine
41124373|NCT04430634|OTHER|Myblu variant H|Use of Myblu e-cigarette with flavor H 3.6% nicotine
41124374|NCT06447389|OTHER|retraction cordu (SURE-CORD®PLUS)|The evaluation of the effectiveness of retraction cords in determining the restoration margin in the fabrication of short fixed partial dentures for patients with missing teeth.
41124375|NCT02088372|DEVICE|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
41124376|NCT05288959|DEVICE|Session 2: Single-pulse TMS (spTMS)|Uni-focal TMS (MagVenture, Farum, Denmark) is delivered to one brain area while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The targeted brain areas and TMS intensities may vary across runs. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coil.
41124377|NCT05288959|DEVICE|Sessions 3 - 5: Paired associative stimulation (PAS)|During each PAS run, bi-focal TMS (MagVenture, Farum, Denmark) is delivered to two brain areas while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The asynchronies between the two TMS coils are kept constant within each session but differ across sessions. Within each session, to observe PAS effects on connectivity, uni-focal spTMS is delivered to the stimulated areas before and after the PAS modulation while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. In addition, resting-state EEG/EMG and a behavioral measure (bimanual task coordination) are recorded before and after the PAS modulation. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coils.
41124378|NCT00792636|DRUG|sumatriptan and naproxen sodium combination tablet|sumatriptan 85mg and naproxen sodium 500mg
41124379|NCT00792636|DRUG|sumatriptan tablet|sumatriptan 85mg
41124380|NCT00792636|DRUG|naproxen sodium tablet|Naproxen sodium 500mg
41124381|NCT04847375|DRUG|exogenous surfactant|Nebulized Surfactant would be administered by face mask which has a nebulizer
41124382|NCT02477514|DRUG|midazolam|2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
41275553|NCT00222105|DRUG|Dexamethasone|Dexamethasone 40 mg day 1-4 and 15-18
41275554|NCT04328480|DRUG|Colchicine|"The colchicine dosage schedule will vary according to the following scenarios:~1. In patients not receiving Lopinavir/Ritonavir~   * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~  * The next day 0.5 mg bid for 14 days or until discharge.~2. In patients receiving Lopinavir/Ritonavir~   * Loading dose of 0.5 mg (day 1)~  * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~   * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~  * Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube."
41275555|NCT04328480|OTHER|Local standard of care|Local standard of care for COVID-19 SARS moderate /high-risk patients
40927366|NCT00998777|PROCEDURE|Shoulder Strengthening|The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
41275556|NCT06318884|DRUG|SCTB35 injection|SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.
41275557|NCT06387056|DRUG|Rezvilutamide|240mg by mouth once a day for 24 weeks.
40947850|NCT01528033|DEVICE|Vacuum Assisted Closure®|"Vacuum Assisted Closure® (V.A.C.®) Therapy within a maximum study treatment time of 42 days.~VAC® Therapy Systems used within the trial are ActiV.A.C.®, InfoV.A.C.®, V.A.C. Freedom®, V.A.C. Via® and VAC Ulta®. All used systems are equally eligible for the treatment of subcutaneous abdominal wounds and should be used according to availability and local preferences within the trial site.~Systems differ regarding user surface and display and processing of data. For the treatment of subcutaneous abdominal wounds the V.A.C.® Granufoam Dressing (size medium and big) is recommended."
41124383|NCT02477514|DRUG|rosuvastatin|10 mg tablet administered as a single oral dose on Days 3 and 16
41124384|NCT02477514|DRUG|tedizolid phosphate|200 mg oral tablet administered once daily on Days 5-17
41124385|NCT05443685|DRUG|ADX-629|"Subjects 10-50 years old will be administered ADX-629 250 mg tablets twice daily.~Subjects 5-9 years old will be administered ADX-629 125 mg tablets twice daily."
41124386|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
41124387|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
41275558|NCT06387056|DRUG|Goserelin Microspheres for Injection|3.6mg by intramuscular injection once 4 weeks for 24 weeks.
41275559|NCT06387056|DRUG|Docetaxel|70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
41275560|NCT06387056|DRUG|Pamiparib|60mg by mouth twice a day for 20 weeks.
41275561|NCT06387056|DRUG|Cisplatin|70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
41275562|NCT06387056|DRUG|Tislelizumab|200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
41275563|NCT00777543|OTHER|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
41275564|NCT00777543|DIETARY_SUPPLEMENT|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
41275565|NCT00777543|DIETARY_SUPPLEMENT|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
41275566|NCT01999738|DRUG|EC1456 and EC20|"EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging."
41275567|NCT02377102|PROCEDURE|Physical Therapy|12 weeks of supervised physical therapy.
41275568|NCT04072432|DRUG|RBT-3|intravenous administration
41275569|NCT00005104|DRUG|clomiphene citrate|
41275570|NCT00005104|DRUG|metformin|
41275571|NCT05381402|OTHER|Questionnaire|Questionnaire to assess the impact of COVID 19 on psoriasis patients
41275572|NCT03111030|BEHAVIORAL|ProacTive SCI|"Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include:~1. An assessment of motivated the participant is to be physically active~2. A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided.~   B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles.~3. Progress and barriers will be reassessed and discussed."
41275573|NCT00948961|BIOLOGICAL|CDX-1401 in combination with Resiquimod and/or Poly-ICLC|CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks.
41275574|NCT00948961|BIOLOGICAL|CDX-1401|
41275575|NCT00948961|BIOLOGICAL|Resiquimod|
41275576|NCT00948961|BIOLOGICAL|poly-ICLC|
41275577|NCT05793619|DEVICE|Prototypes (816-v1 301) to (816-v1 355) every week|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
40927367|NCT05343468|DEVICE|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
40927368|NCT01513200|DRUG|Unfractionated heparin (UFH)|UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
40927369|NCT01513200|DRUG|Bendavia|Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
40927370|NCT01513200|DRUG|Saline (0.9%, sterile, for infusion)|Saline (placebo) Constant IV infusion for 4 hours
41275578|NCT05793619|DEVICE|Prototypes (816-v1 301) to (816-v1 355) every two weeks|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
41275579|NCT01834495|DEVICE|Balloon expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
41275580|NCT01834495|DEVICE|Self expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
41275581|NCT01542307|BIOLOGICAL|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
41275582|NCT01542307|BIOLOGICAL|Room air|Placebo
41275583|NCT01682005|OTHER|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
41287255|NCT03653715|DEVICE|Clerio Vision Single Vision Contact Lens|Within this arm the control acofilcon B material single vision contact lens, the material of which is commercially available from Contamac Ltd, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
41287256|NCT05218629|DRUG|Anlotinib, PD-1 inhibitor|Anlotinib, 8-12 mg/day, orally, day 1-14; PD-1 inhibitor 200 mg iv, every 21 days one cycle
41275584|NCT05153382|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly meetings and individual therapy conducted in 60 minute biweekly sessions. Family participation in skills training is highly encouraged. Skills training proceeds as follows: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants by cell phone for in-vivo skills coaching between sessions.
41275585|NCT03920969|BEHAVIORAL|Sports activity|Evaluation of physical activity using the International Physical Activity Questionnaire (IPAQ) short version.
41275586|NCT02446392|OTHER|No intervention.|
40927371|NCT00697580|BEHAVIORAL|Nutrition|Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
41124388|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
41124389|NCT02251652|DRUG|Ingenol Mebutate|Ingenol mebutate 0.05% gel
41275587|NCT05464017|DEVICE|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|"An improvement to the mHealth triage tool using a machine learning approach, optimizing the efficiency of call schedule and the prediction of which patients are most likely to benefit from follow-up care given data collected at the hospital through the Cameroon Trauma Registry, as well as post-discharge phone contact attempts and survey information. The backbone of the estimators is the ensemble machine learning algorithm the Superlearner, which has been applied to medical contexts, including injury and trauma. It is a theory-driven method based on cross-validation, which combines potentially many different learners (e.g., standard regression, tree regression, random forest, neural nets) such that the model chosen (a weighted average of the learners) is asymptotically equivalent to the so called Oracle - the learner that fits optimally for the data-generating distribution. Note, double-robust CV-TMLE versions of this estimator are available as the tmle3mopttx function in tlverse."
41275588|NCT01477021|DRUG|cyclophosphamide|Given IV
41124390|NCT02251652|PROCEDURE|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
41124391|NCT02799134|DRUG|Dexamethasone|
41124392|NCT02799134|DRUG|Vitamin C|
41275589|NCT01477021|BIOLOGICAL|NY-ESO-1-specific T cells|Given IV
41124393|NCT02559349|OTHER|Stool Collection|
41124394|NCT03877016|PROCEDURE|TENS|TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation
41124395|NCT01798667|DRUG|DA-8031|
41275590|NCT01477021|OTHER|laboratory biomarker analysis|Correlative studies
41275591|NCT05564338|DRUG|Sitravatinib|Administered orally
41275592|NCT05564338|DRUG|Tislelizumab|Administered intravenously
41275593|NCT05564338|DRUG|sitravatinib-matching placebo|administered orally
41275594|NCT05564338|DRUG|tislelizumab-matching placebo|administered intravenously
41287257|NCT04377529|BEHAVIORAL|Local Champion|Local champions (physiotherapists) will co-develop the champion training support based on a comprehensive behavioural analysis, previous implementation work and evidence-based theory. The study team will provide this training and support to the champions, who will then provide additional support to their peers participating in the study.
40927372|NCT00697580|BEHAVIORAL|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
41124396|NCT01798667|DRUG|Placebo|Placebo of DA-8031, undistinguishable
41124397|NCT04306705|DRUG|Tocilizumab|Administered as an intravenous infusion.
41124398|NCT04306705|OTHER|Standard of care|Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
41124399|NCT04306705|PROCEDURE|Continuous renal replacement therapy|Catheter insertion site is femoral vein.
41124400|NCT06102616|DIAGNOSTIC_TEST|measure Osteocalcin level|in gingival crevicular fluid before and during orthodontic tooth movement
41124401|NCT05512182|DRUG|Chemotherapy|Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle Neratinib : Week 1: 120 mg, Week 2: 160 mg, Week 3 and onwards: 240 mg/QD/Oral/Once daily Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle
41124402|NCT00670046|DRUG|valproic acid|given orally
41275595|NCT01865734|OTHER|Physical therapy after initial podiatry visit|Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.
41124403|NCT00670046|OTHER|standard of care follow-up|participant follow the standard of care for patient with metastatic prostate cancer
41275596|NCT01865734|OTHER|Usual care provided by podiatry|Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
41275597|NCT00061711|DRUG|Hormone Replacement Therapy|
41275598|NCT00061711|DRUG|Cimicifuga racemosa (Black Cohosh)|
41275599|NCT00061711|DRUG|Multibotanical phytoestrogen formula|
41275600|NCT03822910|DIAGNOSTIC_TEST|Pattern Separation Paradigm|Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
41275601|NCT03822910|DIAGNOSTIC_TEST|Sequential Associative Mismatch Paradigm|used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).
41446625|NCT04569773|BEHAVIORAL|Impact of Event Scale-Revised|The IES-R is a validated 22-item self-report scale measuring psychological stress reactions after a major life or traumatic event.1-3Items are rated with reference to the past 7 days on a 5-point scale, ranging from 0 to 4. Three subscale scores are calculated by taking the mean of the item responses: Intrustion (8 items), Avoidance (8 items), and Hyperarousal (6 items). The total score is similarly computed by taking the mean of all 22 items. All scores range from 0 to 4, with higher scores indicating higher event-related distress. Internal consistency estimates(Cronbach's alpha) for all scores range between 0.79 to 0.92.
41124404|NCT02828943|BEHAVIORAL|IMT with High Resistance EMT|
41124405|NCT02828943|BEHAVIORAL|IMT with Low Resistance EMT|
41124406|NCT00347204|DRUG|ketorolac (Acular LS)|
41124407|NCT00347204|DRUG|Nepafenac (Nevanac)|
41124408|NCT03438903|DEVICE|Repeat exams of OCT device|All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices
41124409|NCT05551286|OTHER|A rehabilition programme for young adult cancer survivors|The programme consists of 22 sessions focusing on; 1) everyday life (energy conservation, cognitive challenges, fatigue); 2) Physical activity; 3) psychological issues; 4) work and study d; 5) sexuality and relationship; 7) rights and finance, and 8) goal setting. The sessions include both education, workshops, and engagement in different activities and will be delivered by a multidisciplinary team.
41124410|NCT02798367|BEHAVIORAL|CBT-I plus placebo|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)
41124411|NCT02798367|DRUG|CBT-I plus Melatonin 3 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
41124412|NCT02798367|DRUG|CBT-I plus Melatonin 5 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
41124413|NCT00466869|DRUG|Betahistine|
41124414|NCT01294215|DRUG|Nifedipine (Adalat, BAYA1040)|Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)
41124415|NCT01422603|DRUG|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
41124416|NCT01422603|DRUG|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
41124417|NCT05273944|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
41124418|NCT02379260|OTHER|Interview with a sociologist|
41275602|NCT03822910|DIAGNOSTIC_TEST|Encoding Plasticity Paradigm|Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
41275603|NCT00116454|DRUG|131 I-lipiodol|intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
41275604|NCT05986643|BEHAVIORAL|Exergame+Neurofeedback|Electroencephalography (EEG) is a device that measures the electrical activity of the brain (brain waves). There are several frequencies of brain waves when we are awake; alpha (medium), beta (fast), and theta (slow). Alpha frequencies of brain activity are linked to maintaining balance, with more alpha activity being associated with poorer balance. EEG neurofeedback treatment involves placing electrodes on a person's head to monitor and change brain activity by giving cued audio or visual feedback. It has been used in PwP to show improvements in balance and walking. Other preliminary research in PwP has shown that exercise can also improve balance.
41275605|NCT05986643|BEHAVIORAL|Exergame [alone]|"The exergame, delivered in virtual reality, involves travelling down a road (to give optic flow) whilst dodging balls that move towards the participant by either shifting their body either to the left or right. They are also be instructed to stand still and catch stars that appear and these will be used to score points and are associated with a monetary reward, ensuring motivation.~This group will receive SHAM feedback."
41275606|NCT00646893|PROCEDURE|Preimplantation Genetic Diagnosis (PGD)|"one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by no result rescue (Colls et al. 2007)"
41275607|NCT03913754|OTHER|Psycho-social consequences of lupus erythematosus|It will be necessary to take into account the psychosocial experience of the disease \[47\] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease). The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
41275608|NCT06160050|BEHAVIORAL|Breakthrough Parenting Curriculum: Transforming trauma across generations|The BPC (Breakthrough Parent Curriculum): Navigating Trauma Across Generations is a 10 module course adapted from the NCTSN training called Caring for Children Who Have Experienced Trauma: A Workshop for Resource Parents (RPC). The BPC is specifically designed for parents who have been involved with (or are at risk for being involved with)the child welfare system. The course provides information about the impact of trauma on the development, attachment, emotions and behaviors of children while holding space for parents to learn together about concrete strategies for managing daily and ongoing challenges and enhancing their relationships with their children. All while acknowledging the challenges of parenting a child who has experienced trauma, while having experienced your own trauma.
41275609|NCT06488677|BEHAVIORAL|Lifestyle changes (diet and physical activity)|Nurse-led telephone personalized dietary and PA advice
41275610|NCT03551548|DRUG|Spironolactone 25mg|25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
41275611|NCT03551548|DRUG|Placebo oral capsule|oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
41275612|NCT05811065|DEVICE|OPTIVF dosage|Opt-IVF dosage
41275613|NCT05811065|DEVICE|traditional drug treament|Traditional drug treatment
41275614|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #1|Vagus nerve stimulation parameters #1
41275615|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #2|Vagus nerve stimulation parameters #2
41275616|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #3|Vagus nerve stimulation parameters #3
41275617|NCT02500537|DEVICE|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
41275618|NCT00511303|DRUG|STI571|
41275619|NCT03058744|DRUG|IDP-118 Lotion|Lotion
41275620|NCT03058744|DRUG|HP Monad Lotion|Lotion
41275621|NCT03058744|DRUG|Ultravate Cream|Cream
41275622|NCT03058744|DRUG|Tazorac Cream|Cream
41275623|NCT04851184|DEVICE|Gaze stabilization Exercises using Virtual Reality Device|Participants will utilize a wireless virtual reality headset to perform their gaze stabilization exercises to better control the background and visual field as well as collect data related to speed, excursion, and duration of head movements.
41275624|NCT04851184|BEHAVIORAL|Gaze stabilization non-instrumented|Participants will perform gaze stabilization exercises in a non-instrumented manner. Subjects are instructed to focus on a letter on a piece of paper held at arm's length. They are instructed to move their head back and forth as quickly as they can while keeping the letter in focus. The total duration of the exercise (from 10 - 240 seconds) and background complexity (simple to complex moving) are increased gradually according to patient symptoms.
41275625|NCT05653375|OTHER|Mindfulness-based psychoeducation program|In this study, a mindfulness-based psychoeducation program was applied to the experimental group, 2 times a week for 4 weeks, with a total of 8 sessions, including methods such as meditation, body scanning, mindful eating, and breathing work. Measurement tools were applied to the experimental and control groups before and after the program.
41275626|NCT05653375|OTHER|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
41275627|NCT03142100|DEVICE|cochlear implants and hearing aids|speech perception tests and bimodal fitting
41275628|NCT05613270|DIAGNOSTIC_TEST|18F-FES PET/CT scan|Patients with suspected metastatic ER-positive breast cancer underwent 18F-FES PET/CT after an injection of 185-222 MBq (5-6 mCi) 18F-FES to image lesions of metastatic breast cancer.
41275629|NCT03156036|DRUG|Capecitabine plus temozolomide VS Capecitabine|"For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day"
40927373|NCT00697580|BEHAVIORAL|Circuit Training & Nutrition|Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
40927374|NCT04006600|PROCEDURE|Sphincter saving proctectomy|"After rectal resection, when colorectal anastomosis is subperitoneal, it is currently recommended to perform a protective stoma to reduce the potential consequences of a fistula. This stoma, which is intended to be temporary, appears to be permanent in 6 to 32% of cases in the literature.~The objective of the study is therefore to look for a statistical link between the persistence of a permanent stoma and the intraoperative difficulty represented by pelvic anatomical stress."
40927375|NCT02676128|BEHAVIORAL|Twine Collaborative Care Application|This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.
40927376|NCT02676128|BEHAVIORAL|Information-Motivation-Behavioral Skills Model of ART Adherence|Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
40927377|NCT02536183|DEVICE|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
40927378|NCT02536183|DRUG|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
41124419|NCT00000234|DRUG|Buprenorphine|
41124420|NCT01534741|OTHER|dialyzer comparison|Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.
41124421|NCT01534741|DEVICE|Dialyzer|Comparison Dialyzer FX60 versus Cordiax60
41275630|NCT03512236|DRUG|BC Pram Ins|Injection of BC Pram Ins
41275631|NCT03512236|DRUG|Symlin® and Humulin®|Injection of pramlintide and human insulin
41275632|NCT03512236|DRUG|Humalog®|Injection of lispro
41275633|NCT03512236|DRUG|Placebo|Injection of 0.9% NaCl
41275634|NCT05738915|DIAGNOSTIC_TEST|CRP/Albumin ratio in IBD|Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease.
41275635|NCT02748343|DEVICE|allograft bone|Use of the allograft bone to treat the bone defect in patients
41275636|NCT02748343|DEVICE|tissue-engineered bone|Use of the tissue-engineered bone to treat the bone defect in patients
40927379|NCT02841878|GENETIC|Analysis on colorectal biopsy|
40927380|NCT01874678|DRUG|TS-1/Cisplatin|
40927381|NCT04772742|DRUG|Placebo|Placebo - solution for infusion
40927382|NCT04772742|DRUG|Eptinezumab|Eptinezumab - 100 mg, solution for infusion
41124422|NCT03510676|DEVICE|NiTiDES|
41124423|NCT05457049|DIAGNOSTIC_TEST|Molecular residual disease test|OncoMRD Lung
41124424|NCT01082575|DEVICE|Oxygen Monitoring|No intervention
41124425|NCT00359606|DRUG|5-Fluoro-2-Deoxycytidine (FdCyd)|Given PO and IV
41124426|NCT00359606|OTHER|Laboratory Biomarker Analysis|Correlative Studies
40927383|NCT04325555|DRUG|PrEP|The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.
40927384|NCT00711516|DRUG|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
41124427|NCT00359606|OTHER|Pharmacological Study|Correlative Studies
41124428|NCT00359606|DRUG|Tetrahydrouridine (THU)|Given PO and IV
41124429|NCT06357234|DRUG|Aprepitant|Two doses of 40mg (2ml) Aprepitant. One to be given on the morning of surgery and the second on the morning of post-op day 1
41124430|NCT06357234|DRUG|Placebo|Two doses of dextrose syrup (2ml). One to be given on the morning of surgery and the second on the morning of post-op day 1
41124431|NCT03447496|PROCEDURE|Closed reduction|The children were treated with closed reduction.
41124432|NCT03447496|PROCEDURE|Open reduction|The children were treated with Open reduction.
41124433|NCT05326789|DEVICE|REBOA catheter|balloon occlusion of the aorta during cardiac arrest to optimize coronary and cerebral perfusion.
41124434|NCT05296889|DEVICE|posterior stabilization for the cervical spine|The Ennovate® Cervical Spinal System is a posterior stabilization for the cervical and upper-thoracic spine. The implants are used for the posterior monosegmental and multisegmental stabilization of the occipitocervical junction and of the cervical and upper thoracic spine.
40927385|NCT00711516|DRUG|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
41124435|NCT03449173|DRUG|Sunitinib|small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor
41275637|NCT00446030|DRUG|Docetaxel|"75 mg/m\^2 administered IV on Day 1 for Cycles 1-6~All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg)."
41275638|NCT00446030|DRUG|Doxorubicin|50 mg/m\^2 administered IV on Day 1 for Cycles 1-6
41275639|NCT00446030|DRUG|Carboplatin|6 mg/mL/min (target area under the curve \[AUC\] dose) administered IV on Day 1 for Cycles 1-6
41275640|NCT00446030|DRUG|Cyclophosphamide|500 mg/m\^2 administered IV on Day 1 for Cycles 1-6
40927386|NCT00528541|BIOLOGICAL|botulinum toxin type A|200 Units at Visit 1 (Day 1)
40927387|NCT00528541|BIOLOGICAL|botulinum toxin type A|750 Units at Visit 1 (Day 1)
41124436|NCT02768545|DRUG|Ezetimibe|Ezetimibe 10 mg per day before and after transplant
41124437|NCT06150508|BEHAVIORAL|O2O digital healthcare service|The O2O service includes a mobile app and web-based portal that allows patients to monitor their blood glucose levels, track their medication use and physical activity, receive personalized feedback and education, and communicate with healthcare providers. The treatment group will receive a blood sugar checker and blood pressure checker that send the records automatically to the application through Bluetooth.
41124438|NCT04218890|DIAGNOSTIC_TEST|Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin|urinary sample
41124439|NCT06027489|BEHAVIORAL|Music|In the second and third months, participants listened to a song that lasted 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song to be played was determined by examining the literature, the song was composed by researcher Juan Sebastian Martin-Saavedra and was named Occasio Adolore (Music Piece No. 5-559-355 and Phonogram No. 12-105-295) by the author copyright institution of Colombia. registered under. While the researcher is composing the song, it is to create a piece of music that will reduce the pain felt, activate positive emotions and relax the person. The composed song is available online within the scope of the published article (https://soundcloud.com/jss-martin/occasio-adolore).
41124440|NCT06027489|BEHAVIORAL|Drawing Group|: In the second and third months, the participants will be asked to paint for 29 minutes and 32 seconds (the duration of the intervention was determined in parallel with the music group in order not to create variability between the groups) for four days (three days before menstruation and the first day of menstruation). The type of paint to be used in the drawn picture (dry pen, crayon or watercolor) is left to the availability of the participants, and it will be stated that they prefer colors and drawings that will raise their emotions, focus their drawings and feed positive emotions in the picture to be drawn.
41124441|NCT00926354|DRUG|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
41124442|NCT04014439|DIAGNOSTIC_TEST|Ratio of Neutrophil to Lymphocyte|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
41124443|NCT04014439|DIAGNOSTIC_TEST|Level of Prealbumin Serum|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
41124444|NCT06343532|DRUG|SXC-2023|200 mg capsules
41124445|NCT06343532|DRUG|SXC-2023 Placebo|200 mg capsules
41124446|NCT03964376|OTHER|Nasal High Flow|Delivery of oxygen via OptiflowTM system (AirvoTM, Fisher \& Paykel Inc.) with airflow of 20 to 50 Litre/minute
41124447|NCT03964376|OTHER|Usual Care|Delivery of oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via face mask
41275641|NCT00446030|DRUG|Trastuzumab|A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy
41275642|NCT00446030|DRUG|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
41275643|NCT02752828|DRUG|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41275644|NCT02752828|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41275645|NCT02752828|DRUG|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: oral"
41275646|NCT01479972|BIOLOGICAL|VPM1002|Tuberculosis vaccine
41275647|NCT01479972|BIOLOGICAL|BCG|commercially available live vaccine BCG
41275648|NCT05235113|DEVICE|Tele-Exergame Platform|Subjects will perform exercises remotely twice a week with tele-exergaming platform.
41275649|NCT05235113|DEVICE|No Tele-Exergame Platform|Subjects will perform exercises in the home exercise twice a week without tele-exergaming platform.
41275650|NCT05407623|BEHAVIORAL|PAX Good Behavior Game|"PAX GBG is packaged into ten specific tools that the teachers are trained to introduce in in their classroom management practice. The program introduces verbal and visual cues that facilitate prosocial and attentive behaviors One of the core elements of the program is the PAX-game, meaning that the children - while focusing on ordinary school tasks like math - get to play a game in teams where each team tries to make as few classroom rules infractions as possible during a certain period of time. The teams that succeed in achieving predetermined goals get a reward (often a fun and desirable activity) that serves as a reinforcer of prosocial and task-oriented behaviors.~Supervision is performed individually with each teacher and included that the PAX-trainer observes a lecture given by the teacher before each supervision session."
41275651|NCT05407623|BEHAVIORAL|Count on Me!|"Count on me! is set in adventure game where the child has an avatar that travels thru different worlds/platforms by using their mathematical skills. The child starts of in the home of the avatar, in a house like environment, where the child discovers a magical map that brings the child into a different world called Numberia. During the adventures in Numberia the child learns that it has certain skills, called the mathemagical powers, that will be used to liberate Numberia from the evil Prince Claw that has captured all the beautiful things (e.g., the birds that used to sing in the forest).~Count on me! was developed within a behavior analytic framework using a nonlinear programming process."
41275652|NCT05407623|BEHAVIORAL|Collegial Learning Community|"Collegial learning community is a feasible way of professional learning for teachers according to the five cyclical steps. The teachers go through the first step that is to assess the skill or knowledge gaps for students, using various data sources (for example testing, grades, surveys, student interviews). The second step is to reflect upon what skills the teacher needs to acquire in order to help the students to meet the goals. The third step is to deepen the professional knowledge and skills. The fourth step is engaging the students in the new practice, and in the fifth step to evaluate the impact the new practice has had on student outcomes.~In Collegial learning community teachers take help from their peers in each of these steps in a structured way. For example, way of deepening tacit or procedural knowledge (in step two) is to visit a colleague during class and make observations on their classroom practice."
41275653|NCT03651076|DEVICE|Traxi panniculus retraction (Clinical Innovations, LLC)|class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
41275654|NCT05163665|PROCEDURE|Closure type|Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.
41275655|NCT05191628|BIOLOGICAL|Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated amniotic membrane placed by the investigator during macular hole surgery
41275656|NCT03900780|PROCEDURE|PGT-A|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
41275657|NCT03900780|PROCEDURE|Control|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
41275658|NCT04724148|DRUG|Fentanyl|To assess the accuracy of HVPG in TIPS after injecting a dose of 1\~2 mg/kg fentanyl.
41275659|NCT00049348|BIOLOGICAL|epoetin alfa|
41275660|NCT00049348|BIOLOGICAL|filgrastim|
41275661|NCT00049348|DRUG|cisplatin|
41275662|NCT00049348|DRUG|fluorouracil|
41275663|NCT00049348|DRUG|gemcitabine hydrochloride|
41275664|NCT00049348|PROCEDURE|adjuvant therapy|
41275665|NCT00049348|PROCEDURE|conventional surgery|
41275666|NCT00049348|PROCEDURE|neoadjuvant therapy|
41275667|NCT00049348|RADIATION|radiation therapy|
41275668|NCT05106530|DIAGNOSTIC_TEST|Holter, ECG|Incidence of arrhythmias in Holter monitoring among coronary artery ectasia patients as compared to normal coronary artery patients.
41275669|NCT05057364|OTHER|Heart Smart Virtual Self-Management Group|The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.
41275670|NCT05669742|DRUG|Empagliflozin|sodium-glucose transport protein two inhibitor
41275671|NCT05669742|DRUG|olanzapine|antipsychotics
41275672|NCT00566787|DEVICE|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
41275673|NCT05446948|DEVICE|beveled 27G+ vitrectomy system|The device is a novel 27G+ vitrectomy system, whose probe tip is beveled.
40754337|NCT06174532|PROCEDURE|Traditional Medthod|Before surgery, the patient's lower jawbone tumor is replicated using a 3D-printed original model without adjustments. Then, the model undergoes manual modification by drilling and adjusting the jawbone model at the tumor site using drills and manual instruments. Subsequently, the reconstructed model is formed preoperatively based on this modified model. During surgery, the patient isn't guided by surgical guides, and the incision lines are relatively dependent on the surgeon. Additionally, while fixing the remaining bone after the sectioning, the surgeon uses pre-bent fixation plates made earlier to assist in stabilizing the bone.
41275674|NCT05446948|DEVICE|standard 25G+ vitrectomy system|The device is a traditional instrument, and its probe tip is flat.
41275675|NCT02395549|DRUG|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel
41275676|NCT02395549|DRUG|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel
41275677|NCT02395549|DRUG|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel
41275678|NCT02395549|DRUG|Vehicle Control Gel|
41275679|NCT01870544|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|LGG will be administered orally for 44 days
41275680|NCT01870544|DIETARY_SUPPLEMENT|Placebo|placebo will be administered daily for 44 days
41275681|NCT04537442|DRUG|IM21 CAR-T cells|"IM21 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days~Other Names:~Fludarabine Cyclophosphamide"
41275682|NCT04785612|BIOLOGICAL|RSVPreF|A single dose of 120 mcg RSVpreF for intramuscular injection
41446626|NCT04569773|BEHAVIORAL|Reproductive Concerns Scale|The RCS is a 14-item, 5-point Likert-type self-report measure that assesses concern among cancer survivors whose reproductive ability may have been impaired or lost due to disease and/or treatment. Answers are rated on a 5-point scale (0 to 4), and a single total score is produced by summing responses to all 14 items (range, 0-56 points). A higher score represents more reproductive concerns, and a lower score represents fewer reproductive concerns. In the RCS validation study, internal consistency reliability was 0.91 among long-term female cancer survivors and 0.81 among control women.
40927388|NCT03340103|DIETARY_SUPPLEMENT|LUTEIN ofta 0,5 gocce|LUTEIN ofta 0,5 gocce, containing a solution of 5% Lutein and 2,5% Zeaxanthin with excipients (Corn starch, glucose, potassium sorbate, xanthan gum, citric acid)
40927389|NCT03340103|DRUG|Placebo|Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
40927390|NCT00542438|BEHAVIORAL|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
40927391|NCT00542438|BEHAVIORAL|Environmental Assessments|Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
40927392|NCT05653531|OTHER|Blood sample|Liver blood tests (AST, ALT, PAL, GGT, bilirubin, PT) will be performed before each ICI injection during the first three injections and again at 6 months.
40927393|NCT00949767|DRUG|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
41124448|NCT03014518|OTHER|Clinical assessments and blood samples; follow-up for 12 mos|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
41124449|NCT03014518|OTHER|Clinical assessments and blood samples; no 12mo follow-up|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
41124450|NCT03208881|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
41124451|NCT03428620|OTHER|High Velocity Low Amplitude mobilization|Mobilizations will be performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
41275683|NCT04785612|OTHER|Placebo|A single Placebo dose for intramuscular injection to match experimental vaccine
41124452|NCT03428620|OTHER|Exercise protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
41275684|NCT05106361|BEHAVIORAL|MOSAIC Plus|"Those in the experimental arm will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
41275685|NCT05106361|BEHAVIORAL|MOSAIC|Those in the active comparator will receive a mentor mother intervention named Mother AdvocateS In the Community (MOSAIC). This does not include the IPT component.
41275686|NCT01770340|BIOLOGICAL|Radical prostatectomy with implantation of allograft|Interposition of resected neurovascular bundles with allograft Avance®
41275687|NCT01770340|PROCEDURE|Radical prostatectomy without implantation of allograft|No interposition of resected neurvascular bundles
41275688|NCT01116193|DRUG|Lenalidomide plus dexamethasone|Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
41275689|NCT03757598|OTHER|ePartogram use|Electronic partograph based on WHO standard paper partograph is given in Android tablet used by provider monitoring clients in labor. Providers had received training in using the ePartogram and ongoing trouble shooting.
41275690|NCT05324072|OTHER|no intervention|observational study
41275691|NCT02562625|DRUG|Pembrolizumab|Powder solution for infusion
41275692|NCT02562625|RADIATION|Radiotherapy|24Gy
40927394|NCT00949767|DRUG|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
40927395|NCT00949767|DRUG|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
41275693|NCT04144621|PROCEDURE|ICSI|Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
41275694|NCT05107180|DIAGNOSTIC_TEST|drug screen|urine sample
41275695|NCT01941225|DRUG|Inhaled iloprost 5.0 mcg|Single administration
40927396|NCT00949767|DRUG|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
40927397|NCT00949767|DRUG|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
41275696|NCT01941225|DRUG|Placebo|Single administration
41275697|NCT00047411|OTHER|Cardiopulmonary Resuscitation|Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines
40754338|NCT06174532|PROCEDURE|Virtual surgical planning|Before surgery, the patient's lower jawbone is 3D-printed, designed to remove the tumor mass, and create a suitable margin for reconstructive plate bending. Subsequently, the reconstruction plate is pre-bent preoperatively based on this model. During surgery, the patient is guided by specific surgical guiding tools: cutting guides. Additionally, while fixing the remaining bone after sectioning, the surgeon is assisted by bone fixation instruments to stabilize the alignment of the two bone fragments according to anatomical structure and then proceeds to use pre-bent reconstruction plates to secure the bone.
40754339|NCT02277366|PROCEDURE|Fluorescence Bronchoscopy/Narrow Band Bronchoscopy|Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
40754340|NCT04229381|PROCEDURE|Physical Therapy|Undergo physical therapy
40754341|NCT04229381|OTHER|Quality-of-Life Assessment|Ancillary studies
41124453|NCT02863315|DEVICE|tsDCS|"Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on."
41124454|NCT03818893|DRUG|Combination of GEN0101 and Pembrolizmub|New Combination immunotherapy GEN0101 and Pembrolizmub
41124455|NCT00885924|DRUG|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
41124456|NCT00885924|DRUG|Placebo|NaCl 0.9%
41124457|NCT03498768|OTHER|Questionnaire Administration|Subjects will be invited to complete a detailed questionnaire regarding personal information, known risk factors for lung cancer and psychological status.
40754342|NCT04229381|OTHER|Questionnaire Administration|Ancillary studies
41124458|NCT05900921|DRUG|Trilaciclib|IV infusion, d1
41124459|NCT05900921|DRUG|Carboplatin|IV infusion, d1
41124460|NCT05900921|DRUG|Paclitaxel|IV infusion, d1
41124461|NCT05900921|DRUG|Tislelizumab|IV infusion, d1
41124462|NCT01340716|OTHER|Tai Chi Chuan exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.
41275698|NCT00047411|DEVICE|Automatic External Defibrillation|Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
41275699|NCT00507247|DRUG|Daptomycin|6mg/kg/day IV for at least 10 days.
41275700|NCT06216093|BIOLOGICAL|EuRSV|Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
41275701|NCT06216093|OTHER|Placebo Comparator|Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
41275702|NCT00146042|DRUG|Docetaxel|
40754343|NCT04229381|PROCEDURE|Relaxation Therapy|Undergo progressive muscle relaxation
41124463|NCT01340716|OTHER|stretching exercise|patients in this group held weekly classes of two stretching for 12 weeks.
41275703|NCT00146042|DRUG|Trastuzumab|
41275704|NCT00146042|PROCEDURE|Erythromycin Breath Test (ERMBT)|
40754344|NCT00666978|BEHAVIORAL|smoking cessation intervention|
40754345|NCT00666978|DRUG|bupropion hydrochloride|
40927398|NCT00949767|DRUG|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
40927399|NCT00949767|DRUG|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
40927400|NCT00949767|DRUG|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
40927401|NCT00736047|BIOLOGICAL|NIC002|
40927402|NCT00736047|BIOLOGICAL|Placebo|
41124464|NCT02752503|DRUG|Nalmefene|
40927403|NCT02294942|DRUG|RANCAD|Extended-Release RANCAD
40927404|NCT05184010|DEVICE|ulnar nerve mini open release|the ulnar nerve mini open release was performed before arthroscopic release for elbow
41124465|NCT01346254|DRUG|Vildagliptin|50mg tablets once daily 20 min before breakfast for 3 months
41124466|NCT01346254|DRUG|Pioglitazone|30mg tablets once daily 20 min before breakfast for 3 months
41124467|NCT01346254|BEHAVIORAL|Life-Style Modification|All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
41124468|NCT00063713|DRUG|VELCADE TM (bortezomib) for Injection|
41124469|NCT05045534|DRUG|Comparison of TB-840 treatment with Placebo|Single dose or Multiple Dose of TB-840 treatment
41124470|NCT00971724|DRUG|Placebo|Oral administration, once daily, for 15 days
41124471|NCT00971724|DRUG|Prednisolone|Oral administration
41275705|NCT02279511|DRUG|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
41275706|NCT02279511|DRUG|PLACEBO|Infusion of 500 mL of saline solution. (IV)
41275707|NCT00367757|PROCEDURE|Ablate AF triggers via PVI|Trigger-based ablation guided by pulmonary vein antrum isolation
41275708|NCT00367757|PROCEDURE|Substrate via CFAEs|Substrate-based ablation using an approach targeting CFAEs
41275709|NCT00367757|PROCEDURE|Combined approach for AF ablation|Combined trigger and substrate based approach
41275710|NCT01667848|DEVICE|Optitherm® device activated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
41275711|NCT01667848|DEVICE|Optitherm® device inactivated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
41275712|NCT00312520|DRUG|prednisolone|
41275713|NCT00312520|DRUG|methylprednisolone|
41275714|NCT00831376|DRUG|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
41275715|NCT00831376|DRUG|racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
41275716|NCT00831376|DRUG|placebo|Patients will be asked to take two puffs four times a day for 2 weeks
41275717|NCT03475225|DRUG|Cholecalciferol|Cholecalciferol delivery
41275718|NCT03475225|DRUG|Placebo Oral|manufactured to mimic Cholecalciferol
40927405|NCT05184010|DEVICE|without ulnar nerve mini open release|arthroscopic release for elbow stiffness alone without ulnar nerve mini open release
41124472|NCT00273624|DRUG|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
40927406|NCT02994888|DRUG|Cetuximab|All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
41124473|NCT00273624|DRUG|Placebo|placebo
41124474|NCT05172323|DEVICE|3DCT-scan|A contrast CT-scan of the coronary arteries will be performed and 3D analyzed to determine the best angle for the C-arm during Percutaneous Coronary Intervention (PCI) for stent implantation. Furthermore determining the amount and localization of calcium in the right coronary artery (RCA) and diameter and length of RCA. The use of IVUS will be used to determine the degree of calcium.
41124475|NCT05172323|OTHER|Angiography guided PCI|Standard of care is angiography guided PCI of the ostium of the RCA. The use of IVUS will be used to determine the degree of calcium.
41124476|NCT04719858|BEHAVIORAL|#LIFEGOALS|"Digital health behaviour change intervention including:~1. self-regulation component with Fitbit: goal setting, monitoring, feedback;~2. narrative component: every week participants receive a new episode (2-5 minutes) of a youth series modeling the target behaviours;~3. chatbot component: automated virtual coach that will send encouraging messages and give an automated answer to user questions.~Participants install the #LIFEGOALS app on their own mobile phone and are asked to use the app during 12 consecutive weeks. Three times per week a notification will be sent to encourage engagement with the intervention."
41124477|NCT00405158|PROCEDURE|Acupuncture treatment|
41124478|NCT00405158|PROCEDURE|Administration of oxytocin nasal spray|
41124479|NCT00405158|PROCEDURE|Improved breast milk removal|
41124480|NCT00405158|PROCEDURE|Warmth applied to breasts|
40927407|NCT05886985|DRUG|MatriPlax|MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
40927408|NCT02788877|DRUG|aflibercept|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.
40927409|NCT06363188|DEVICE|Radial Extracorporeal shockwave|a device used by physiotherapist to treat various musculoskeletal problems and it was here firstly used to accelerate the bone healing process after bone fracture
41124481|NCT00405158|PROCEDURE|Breast massage|
41124482|NCT00405158|DRUG|Anti-pyretic medication, paracetamol|
40927410|NCT04521712|DIAGNOSTIC_TEST|2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor|All women enrolled in this study will have a 2-hour 75-g oral glucose tolerance test performed immediately postpartum (within 4 days of delivery), at 4-6 weeks postpartum, and at 6 months postpartum. Enrolled women will also wear a continuous glucose monitor for 10 days at each of these time periods. Both women and their infants will have skin fold thickness measured at each of these 3 study visits to estimate body fat composition. Additionally umbilical cord blood and placental biopsies will be collected at delivery and stored for future research.
40927411|NCT03478436|DRUG|Doxycycline|Doxycycline 40 mg capsules
41124483|NCT00405158|DRUG|cefadroxil|
41124484|NCT00405158|DRUG|penicillin|
41446627|NCT04569773|BEHAVIORAL|Decision Regret Scale|"The DRS is a 5-item, 5-point Likert-type self-report measure that assesses distress or remorse after a health-care decision.5 Items are rated on a scale from 1 (strongly agree) to 5 (strongly disagree). Two of the statements (items 2 and 4) are phrased in the negative direction.~A single, total score is produced by first reversing the scores of the 2 negatively phrased items, then taking the mean of the 5 items. This mean is then rescaled to range from 0 to 100 by subtracting 1, then multiplying by 25. A score of 0 indicates no regret, whereas a score of 100 indicates high regret. Internal consistency reliability coefficients for the DRS range from 0.81 to 0.92."
41124485|NCT00405158|DRUG|flucloxacillin|
41124486|NCT03055559|DIETARY_SUPPLEMENT|Globifer Forte|
41124487|NCT06178588|PROCEDURE|Biopsy|Undergo tumor biopsy
41124488|NCT06178588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41124489|NCT06178588|PROCEDURE|Computed Tomography|Undergo PET/CT scan
41124490|NCT06178588|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41124491|NCT06178588|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41124492|NCT06178588|BIOLOGICAL|Sacituzumab Govitecan|Given IV
41124493|NCT00145470|DRUG|Asenapine|Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.
41124494|NCT00145470|DRUG|Placebo|Placebo fast dissolving SL tablets, BID
41124495|NCT03167736|OTHER|electric dry needling, manipulation|HVLA thrust manipulation to lumbar spine. Dry needling to lumbar/sacral paraspinal muscles and gluteus medium/minimus muscles. Treatment may include dry needling of the piriformis muscle, quadrates lumborum muscle and perineurial needling of sciatic/tibial nerve. Up to 12 treatment sessions over 6 weeks.
41124496|NCT03167736|OTHER|conventional physical therapy|Impairment-based manual therapy, stretching, strengthening and electrothermal modalities targeting the lumbar/sacral spine and hips. Up to 12 treatment sessions over 6 weeks.
41124497|NCT05496842|BEHAVIORAL|Multimodal pulmonary rehabilitation|The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
41275719|NCT00779129|DRUG|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
40927412|NCT01282970|DRUG|BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
40927413|NCT01282970|DRUG|Placebo to BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
40927414|NCT04043624|DRUG|Lidocaine|regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
41124498|NCT05487118|DEVICE|Placebo PBMT + MCE|Placebo PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, without any emission of therapeutic dose. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
41124499|NCT05487118|DEVICE|Active PBMT + MCE|Active PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, with a dose of 30 J per site. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
41124500|NCT06433219|DRUG|Tuvusertib (M1774)|Tuvusertib will be administered orally
41124501|NCT06433219|DRUG|Niraparib|Niraparib will be administered orally
41124502|NCT06433219|DRUG|Lartesertib (M4076)|Lartesertib will be administered orally
41124503|NCT02641938|DRUG|Dexmedetomidine|Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
41275720|NCT00779129|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
41275721|NCT02504541|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
41275722|NCT06061445|COMBINATION_PRODUCT|Radiotherapy combined with TKI and Anti-PD-1 Antibody|After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.
41124504|NCT02641938|DRUG|Normal Saline|Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
41124505|NCT01824420|DRUG|Detrusitol 4mg QD and Oxybutynin ER 5mg QD|Study group
41124506|NCT01824420|DRUG|Detrusitol 4mg QD|Control group
41275723|NCT01315574|DRUG|Travoprost|One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
41275724|NCT01315574|DRUG|Latanoprost|One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
41275725|NCT00948740|DRUG|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
41275726|NCT03511339|DEVICE|TecTraum device|"A non-invasive hypothermic therapy (cold therapy) TecTraum device that provides localized cooling of the head and neck."
41275727|NCT05745662|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
41275728|NCT03773952|DRUG|PBF-677|oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
41275729|NCT03773952|DRUG|Placebo oral capsule|Oral capsules
41275730|NCT03425903|DEVICE|Whole body cryotherapy sessions|Whole body cryotherapy (WBC) 10 sessions of 3 minutes at a temperature of -196ºC (point of evaporation of liquid nitrogen), on the basis of three sessions a week.Fills in questionnaires.
41275731|NCT05229965|DRUG|Paracetamol|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
41275732|NCT05229965|DRUG|Paracetamol Codeine|14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
41275733|NCT05229965|DRUG|Paracetamol caféine|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
41275734|NCT06053021|DRUG|aspirin, clopidogrel, cilostazol, and dipyridamole|Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
40927415|NCT04043624|DRUG|Saline|IV bolus of saline, followed by continuous infusion of saline
41124507|NCT00211731|BEHAVIORAL|Chronic Disease Self Management Course|
41124508|NCT02209246|OTHER|PROMIS CAT Pain Interference|
41275735|NCT04753125|BEHAVIORAL|follow-up by telephone|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
41275736|NCT04753125|BEHAVIORAL|follow-up via a game in a smartphone app|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
40927416|NCT02674854|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop daily in the evening (PM) in both eyes (OU)
40927417|NCT02674854|DRUG|Netarsudil (AR-13324) ophthalmic solution 0.02%|1 drop daily in the evening (PM) in both eyes (OU)
41124509|NCT02209246|OTHER|PROMIS CAT Pain Behavior|
41124510|NCT02209246|OTHER|PROMIS CAT Physical Function|
41124511|NCT02209246|OTHER|MISS-21|
41124512|NCT03144518|OTHER|Positive Affect Intervention|See Previous Description
41124513|NCT03144518|OTHER|Neutral Control Intervention|See Previous Description
41124514|NCT03144518|BIOLOGICAL|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
41124515|NCT06521944|BIOLOGICAL|RSV Vaccine|RSV Vaccine approved for administration to pregnant individuals between 32 weeks, 0 days and 36 weeks, 6 days of gestation
41124516|NCT06521944|OTHER|Non-exposure to RSV Vaccine|Pregnant individuals who are not exposed to the RSV vaccine
41275737|NCT04753125|BEHAVIORAL|conventional follow-up by a health professional|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
41275738|NCT04203303|OTHER|Observational|Observational
40927418|NCT02674854|DRUG|Latanoprost ophthalmic solution 0.005%|1 drop daily in the evening (PM) in both eyes (OU)
40927419|NCT01718977|OTHER|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
40927420|NCT01718977|OTHER|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
40927421|NCT03138993|BEHAVIORAL|Patient decision aid|Web-based patient decision aid plus a paper workbook.
40927422|NCT03138993|BEHAVIORAL|General sleep education|Web-based information about sleep plus a paper workbook
40927423|NCT05055245|OTHER|cycles|Patients are grouped according to the number of IVF/ICSI cycles.
40927424|NCT03483064|OTHER|Interferential current|interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold
40927425|NCT01640327|BIOLOGICAL|Trivalent influenza virus vaccine (TIVf)|A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
40927426|NCT01525992|BEHAVIORAL|Community pharmacist-led diabetes education program|A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
40927427|NCT01525992|OTHER|Usual care|The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
40927428|NCT03920540|COMBINATION_PRODUCT|GC1111|GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
40927429|NCT03920540|COMBINATION_PRODUCT|Comparator|Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
41124517|NCT00890305|DRUG|CT-011|
41275739|NCT03934762|BIOLOGICAL|Placebo|A placebo solution that will not include aloe vera will be applied on the quadriceps of one of the lower limbs.
40927430|NCT01262352|DRUG|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
41275740|NCT03934762|BIOLOGICAL|Natural Aloe Vera|Natural aloe vera solution including peel and leaf from aloe will be applied on the the quadriceps of one of the lower limbs.
40754346|NCT00666978|GENETIC|gene expression analysis|
40754347|NCT00666978|GENETIC|polymerase chain reaction|
40927431|NCT01262352|DRUG|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
40927432|NCT01237483|DRUG|Erbitux|To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
41124518|NCT00890305|DRUG|FOLFOX|"FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours)."
41124519|NCT03480451|OTHER|Multi-Disciplinary Patient Centered Rehab and Education|"This project is being withdrawn. No revisions to Intervention is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
41275741|NCT03934762|BIOLOGICAL|Aloe vera soup|Aloe vera solution including aloe vera soup will be applied on the the quadriceps of one of the lower limbs.
41275742|NCT02673281|OTHER|Walnut shake|walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
41275743|NCT02673281|OTHER|Placebo shake|placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
41275744|NCT03153852|DRUG|Modified Jessner's solution|Modified Jessner's solution will be applied on the right side until frosting
40754348|NCT00666978|OTHER|counseling intervention|
40754349|NCT00666978|OTHER|educational intervention|
40754350|NCT00666978|PROCEDURE|psychosocial assessment and care|
40754351|NCT06151665|PROCEDURE|single file rotary|Kedo-S plus file is the fifth generation of pediatric files will be used in pulpectomy of primary molars
40754352|NCT06151665|PROCEDURE|Conventional Manual K files|Stainless-steel K files is the golden standard files used in pulpectomy of primary molars
40927433|NCT05915039|OTHER|Computer Assisted Learning (CAL) Module|The students assigned to Group A will undergo interactive CAL module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines.
40927434|NCT02602756|RADIATION|Protontherapy|Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
40927435|NCT02577393|DRUG|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
40927436|NCT02577393|DRUG|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Patients begin medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
40927437|NCT02577393|DRUG|mLDG|mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
40927438|NCT03554811|DEVICE|Functional electrical stimulation assisted supine cycling (FESC)|A supine cycle ergometer attached to a six-channel stimulator will be used for FESC. Surface electrodes will be applied to the hamstrings, quadriceps, and calf muscles on both legs. Muscles will be stimulated at specific stages throughout the cycling phase. Each session will start with a 1 minute motor-driven passive cycling warm-up at a rate of 20 revolutions per minute. Patients will continue with passive, active-assisted, or active cycling, according to their level of participation. If the patients stop cycling actively, the ergometer will revert to passive cycling.
40927439|NCT03554811|OTHER|Conventional early exercise and mobility interventions|These interventions will be based on the patient's alertness and medical stability, and includes activities to maintain or increase limb range of motion and strength, in and out of bed mobility, sit to stand, and transfer training, as well as assisted ambulation.
40927440|NCT04109339|DRUG|Oxytocin|During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.
40927441|NCT01373827|DEVICE|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
40927442|NCT05164107|DEVICE|Globe Mapping and Pulsed Field Ablation System (Globe PF System)|During the procedure, the Globe Catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the left atrium (LA) will be followed by pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI). Additional PFA or radiofrequency (RF) ablation lesions may be created as deemed appropriate by the Investigator. Intracardiac electrogram mapping with the Globe PF System will be used to confirm PVI.
40927443|NCT00934843|DRUG|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
40927444|NCT00934843|DRUG|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
41446628|NCT03459235|OTHER|quality of life|Assessment of the impact of digestive sequelae (LARS score) and genitourinary sequelae (score IPSS, USP, FSFI et IIEF) in Patients With Rectal Cancer using validated questionnaires on quality of life (EORTC QLQ-C30 et QLQ-CR 29).
40754353|NCT01324466|DRUG|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
40754354|NCT01324466|DRUG|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
40927445|NCT02279407|DRUG|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
40927446|NCT02279407|DRUG|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
40927447|NCT02279407|DRUG|Dapagliflozin|10 mg administered as 10 mg tablet
40927448|NCT02279407|DRUG|Placebo|Placebo matching to dapagliflozin 10 mg
41275745|NCT03153852|DRUG|Glycolic acid|Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes
40754355|NCT04779593|OTHER|Clinical examination|Clinical data will be recorded (general clinical examination, height, weight, blood pressure,heart beat, alcohol and tobacco consumption, antecedent) as well as concurrent medication at each follow-up visit.
40927449|NCT01456975|PROCEDURE|Aortic valve reimplantation using Valsalva prosthesis|Aortic valve reimplantation (David procedure)using Valsalva prosthesis
40927450|NCT02151773|DRUG|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
40927451|NCT03455790|DIAGNOSTIC_TEST|Aerobic Capacity|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
40927452|NCT04905498|BEHAVIORAL|Commercial Advertising Literacy Training|"Children were shown food commercials and in between those commercials they saw and heard statements such as These foods won't make you happy and Those foods are so unhealthy."
41124520|NCT01006577|PROCEDURE|side-to-end anastomosis|Low anterior resection for rectal cancer \< 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
41124521|NCT01006577|PROCEDURE|colon j pouch|Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
41124522|NCT00990808|DRUG|anacetrapib|\[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.
41275746|NCT03153852|DRUG|Trichloroacetic acid|Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
41275747|NCT03642561|DEVICE|radiotherapy ablation|We using Cool Tip system or RITA system to perform RFA
41275748|NCT03642561|DEVICE|transarterial chemoembolization(TACE)|TACE treatment is a first line treatment for BCLC stage B HCC
41124523|NCT00990808|DRUG|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
41124524|NCT00990808|DRUG|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
41275749|NCT04273724|OTHER|Targeted Interventions for Impairments Identified During Geriatric Assessment|Participants will be referred for specific evidence-based interventions based on impairments identified during a baseline comprehensive geriatric assessment.
41275750|NCT01591005|PROCEDURE|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes
41275751|NCT01591005|PROCEDURE|endarterectomy|carotid endarterectomy
41275752|NCT01591005|PROCEDURE|carotid stenting|percutaneous transluminal angioplasty and stenting
41446629|NCT04222413|DRUG|Metarrestin|Phase IA: Loading dose on Day 1 of Cycle 1 for Dose Levels 1-7. Loading dose on Days 1 and 3 of Cycle 1 for Dose Levels 8-11. After the loading dose on Day 1 or Days 1 and 3 of Cycle 1, continue on Mondays-Wednesdays-Fridays of every following cycle. Phase IB: PO according to the dose and schedule estimated during Phase IA
40754356|NCT04779593|OTHER|SF36 questionnaire|"At D0, M12 and M24. This 36 item patient reported survey of patient's health is the most commonly used and validated health survey instrument for appraising quality of life.~Items are grouped in 8 scaled scores exploring multiple dimension of global health (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).~Scoring will be performed as recommended by the SF-36 instruction manual to create the eight scale scores. Furthermore, these subscales sum to obtain the total SF-36 score and will be summarized into two composite scores (physical and mental quality of life)."
41275753|NCT05066685|OTHER|All participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
41275754|NCT01021007|DRUG|Iodine|Rinse 2 times per day for 6 weeks
41275755|NCT01021007|OTHER|water|Use 2 times per day for 6 weeks
41275756|NCT03104582|PROCEDURE|ERCP Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.
41275757|NCT03104582|PROCEDURE|PTBD Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
41275758|NCT01311778|DRUG|Cannabidiol|"Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl."
41275759|NCT01311778|DRUG|Fentanyl|All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
41275760|NCT03977233|DRUG|Oxaliplatin|85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle
41446630|NCT00426621|DRUG|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
41446631|NCT00426621|DRUG|Placebo|4 grams per knee, 4 times per day, for 12 weeks
40927453|NCT04905498|BEHAVIORAL|Control|Children were shown food commercials that were the same length as the other group but did not receive any information about whether the content was truthful.
41275761|NCT03977233|DRUG|Leucovorin|400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle
41446632|NCT06627712|DRUG|SBRT+PD-1 Inhibitor + Chemotherapy|"Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
41446633|NCT06627712|DRUG|PD-1 Inhibitor + Chemotherapy|"Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
41446634|NCT05806177|DRUG|AD16 30mg、40mg|AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
41446635|NCT05806177|DRUG|AD16 Placebo 30mg、40mg|AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
41446636|NCT02061280|DRUG|fluticasone/salmeterol 250/50 Dry Powder Inhaler|Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
41446637|NCT02061280|DRUG|fluticasone/salmeterol 100/50 Dry Powder Inhaler|Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
41446638|NCT02061280|DRUG|fluticasone 100mcg Dry Powder Inhaler|Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
41446639|NCT01602380|DRUG|faslodex 500mg|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
41446640|NCT01602380|DRUG|arimidex 1mg|oral tablet 1 daily
41446641|NCT01602380|DRUG|faslodex dummy|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
41446642|NCT01602380|DRUG|arimidex dummy|oral tablet 1 daily
41446643|NCT00776763|DRUG|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
41446644|NCT06241118|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
41275762|NCT03977233|DRUG|Irinotecan Hydrochloride|180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle
40927454|NCT01622634|BEHAVIORAL|Sprint Interval Exercise|Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.
40927455|NCT01622634|OTHER|Higher PRO Diet|Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.
40927456|NCT01622634|OTHER|Higher CARB Diet|Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
41275763|NCT03977233|DRUG|5-FU|400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
41287258|NCT01880346|DIETARY_SUPPLEMENT|Vitamin D Powder|Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
41287259|NCT01880346|DIETARY_SUPPLEMENT|Vitamin D Oil|Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
41287260|NCT01134510|DRUG|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
41446645|NCT06241118|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
41446646|NCT06241118|DRUG|Topical corticosteroids|Pharmaceutical form: Various Topical formulation Route of administration: Topical
41446647|NCT06241118|DRUG|Topical tacrolimus or pimecrolimus|Pharmaceutical form: Various Topical formulation Route of administration: Topical
41446648|NCT03574571|DRUG|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
41446649|NCT03574571|DRUG|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
41446650|NCT03574571|DRUG|Radium-223|Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
41446651|NCT04571021|OTHER|I-DEPT|Implementation of the novel triage algorithm
41446652|NCT04571021|OTHER|DEPT|Existing triage algorithm
41446653|NCT03810963|COMBINATION_PRODUCT|HIIT-FES Cycling combined with Nutritional Counseling|High intensity interval training functional electrical stimulation cycling for 30 minutes, three days per week for eight weeks, Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
41446654|NCT03810963|OTHER|Nutritional Counseling Only|Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
40927457|NCT03523923|BEHAVIORAL|Collaborative Care|"Up to 12 phone sessions over 16 weeks from Collaborative Care Manager (CCM).~Session 1: Establish rapport, perform structured clinical assessment explain the rationale and parameters of the intervention, provide brief education on pain and together with the participant create an overall treatment plan and detailed follow-up plan.~Sessions 2-12 Components:~* Care Management Weekly monitoring of response to treatment using standardized measures.~* Collaborative Medical Management: Optimized management of problem areas. Medication recommendations will follow evidence-based treatment algorithms with consultation of supervisors.~* Psychosocial Treatment: Evidence based, focus on pain self-management skills/education, initially on foundational skills including: (1) pain education; (2) relaxation skills training; (3) behavioral activation and goal setting; 4) importance of physical activity and (5) motivational interviewing to promote adherence to healthcare and goals."
40927458|NCT03915860|DRUG|Trifarotene|Topical Cream
40927459|NCT02715297|RADIATION|SRT to the resection cavity|46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
40927460|NCT01100957|PROCEDURE|tracheal intubation with a single use flexible videoscope|tracheal intubation with a single use flexible videoscope
40927461|NCT00561860|DEVICE|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
40927462|NCT05576974|DRUG|Pegsitacianine|Infusion of the Pegsitacianine-Intraoperative fluorescence imaging
41124525|NCT00990808|DRUG|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
41124526|NCT05237570|PROCEDURE|Interradicular septum window|In this group, the maxillary sinus will be accessed through a window in the interradicular septum and the membrane will be elevated, carrying out the regeneration of the area to facilitate subsequent implant placement.
41124527|NCT05106270|DIAGNOSTIC_TEST|Atrial pressure measurement using transseptal puncture sheath|both left and right atrial pressure was measured using transseptal puncture sheath before and after combined procedure
41124528|NCT01248260|DIETARY_SUPPLEMENT|Folic Acid|4mg of higher strength folic acid once a day until delivery
41124529|NCT06403020|PROCEDURE|Block|qadratus lumboroum (QL) block
41124530|NCT01083316|DRUG|Bortezomib|"Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4"
41124531|NCT01083316|DRUG|Dexamethasone|"Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days"
41124532|NCT01083316|DRUG|Melphalan|"Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
41124533|NCT05622123|DRUG|68Ga-NODAGA-Exendin-4|PET/CT imaging after injection with 68Ga-NODAGA-exendin-4
41275764|NCT05278234|BEHAVIORAL|STEPS|Participants will initially meet with a community health worker (CHW) for a 1-hour orientation at the participant's home, a Henry Ford Health System site or the University of Michigan Detroit Center, or virtual. The CHW will show participants how to use the web modules. Participants will be given (or mailed) a wearable activity tracker to use throughout the course of the 7-week program. Each week participants will watch a brief video on the STEPS website; they may also be asked to complete handouts in the workbook. They will have a weekly 30-minute telephone session with the CHW. CHWs will review the weekly topic, help participants practice new skills, and set a related goal. CHWs will screen for social needs and make appropriate community referrals. Participants will set walking goals each week, using step-count data from the physical activity tracker. Participants will track daily step counts.
41275765|NCT02360098|OTHER|Emergence from Anesthesia|There are no study related interventions in this study and perioperative care of these patients will be as per our standard practice The only study related protocol would be collecting the data on the emergence from anesthesia. The data will be collected from the time of turning off the anesthetic agents till the discharge from recovery room. Data collected include, vital signs, Glasgow coma scale( GCS), and Riker agitation- sedation score.. The patients will be assessed every 5 minutes for the first 30 minutes and every 10 minutes for the next 60 minutes.
41275766|NCT04744558|OTHER|Low carb high fat ketogenic dieting|Macronutrient ratios for low carb high fat ketogenic diet were 20 %, 5 %, 75 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
41124534|NCT01981031|DRUG|BioChaperone® Combo|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
41124535|NCT01981031|DRUG|Humalog® Mix25|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
41124536|NCT02035904|DRUG|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
41124537|NCT02035904|DRUG|saline|patient controlled infusion from the 2nd day after surgery
41124538|NCT02035904|DRUG|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
41124539|NCT02035904|DEVICE|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
41124540|NCT02035904|DRUG|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
41124541|NCT02035904|DRUG|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
41124542|NCT03221959|DEVICE|Medical Device Vittamed 205|Intracranial pressure measurement
41124543|NCT05744596|OTHER|Incisura biopsy analysis|a pathologist blinded to the other biopsies analyzes the biopsy from the incisura
40927463|NCT04739176|OTHER|One-on-one rehabilitation program including computerized mirror therapy in addition to standard rehabilitation.|atients will be admitted to the day hospital 2 days a week for 9 weeks. They will participate in a one-on-one rehabilitation program conducted by a multidisciplinary team including a physiotherapist, psychomotor therapist, occupational therapist and a physical activity monitor. Patients will also participate in 12 computerized mirror therapy sessions (twice a day, 2 days a week, from week 4 to 6 of the program).
40927464|NCT04348227|BEHAVIORAL|Enhanced hygiene measures|Wether or not hygiene measures dictated by the pandemic of severe acute respiratory syndrome coronavirus 19 , reduce multi drug resistant pathogens isolated in endotracheal aspirates.
40927465|NCT02045953|DEVICE|VENTOLIN Mini-Spacer|VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
41275767|NCT04744558|OTHER|Low carb high fat non-ketogenic dieting|Macronutrient ratios for low carb high fat non-ketogenic diet were 20 %, 15 %, 65 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
41275768|NCT02773329|OTHER|sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
41446655|NCT06556602|OTHER|MPACT|Four components are part of this intervention: 1) accredited training about patient centered, trauma-informed care and the standard of care under the current federal regulation (42CFRpart8), 2) education about trauma and trauma symptoms including vicarious (work related) trauma and navigation to symptoms screening and resources including treatment, 3) reflective supervision for counseling, case management and peer staff, and 4) clinic self assessment for trauma-informed and patient centered care
41124544|NCT01227265|DRUG|Preladenant|Preladenant 2 mg or 5 mg oral tablet taken twice daily
41124545|NCT01227265|DRUG|Placebo|Preladenant-matching placebo oral tablet taken twice daily
41446656|NCT05865652|DIAGNOSTIC_TEST|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
41446657|NCT05790772|BEHAVIORAL|Vigorous Exercise|50 minutes of running on a treadmill
41446658|NCT01852721|BEHAVIORAL|Experimental: Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
41446659|NCT01852721|BEHAVIORAL|Experimental: Women and Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
41446660|NCT06596148|OTHER|Access to Shingrix dashboard|The investigators will build and grant access to a clinical dashboard that exists behind the VA firewall. The dashboard will identify Veterans from each VA facility who are receiving immunosuppressants (prescribed via the VA). The dashboard will also provide information about the number of Shingrix vaccines each patient has received (which have been documented within the VA electronic health record). VA clinicians will have access to view information about patients based on their VA electronic health record permissions.
40927466|NCT02045953|DEVICE|Aerochamber Plus spacer|Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
40927467|NCT00393042|DRUG|Dexmethylphenidate|10, 20, 25-30 mg.
41124546|NCT02574442|DEVICE|In Vivo Confocal Microscopy Probe|Participants will have 2 areas on their cervical imaged by the confocal probe.
41275769|NCT02773329|OTHER|Intervention without game-based exercise|Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
41275770|NCT04701125|DEVICE|selective head-neck cooling using PolarCap system|Players receiving selective head-neck cooling after SRC
41275771|NCT04269551|DRUG|BIVV020|Pharmaceutical form:solution for injection Route of administration: intravenous
40927468|NCT00393042|DRUG|Mixed Amphetamine Salts, ER|10, 20, 25-30
40927469|NCT00393042|DRUG|placebo|randomized placebo week during each 4 week period
41275772|NCT01491087|BIOLOGICAL|DTacP IPV//PRP~T combined vaccine: PENTAXIM®|0.5 mL, Intramuscular
41275773|NCT00297414|OTHER|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
41275774|NCT00004255|BIOLOGICAL|anti-thymocyte globulin|
41275775|NCT00004255|BIOLOGICAL|filgrastim|
41275776|NCT00004255|DRUG|cyclophosphamide|
40927470|NCT00538785|BIOLOGICAL|Motavizumab|15 mg/kg IM administered at monthly intervals
41275777|NCT00004255|DRUG|fludarabine phosphate|
41275778|NCT00004255|DRUG|methylprednisolone|
41275779|NCT00004255|DRUG|tacrolimus|
41446661|NCT02975856|DIETARY_SUPPLEMENT|Table Red Wine|
41446662|NCT02975856|DIETARY_SUPPLEMENT|Young Port Red Wine|
40927471|NCT00538785|BIOLOGICAL|Palivizumab|15 mg/kg IM administered at monthly intervals
41124547|NCT06345170|OTHER|The DIR/Floortime™ Therapy Program|The DIR/Floortime™ therapy program will be applied by the therapist in the clinic for 50 minutes, 2 days a week for 12 weeks
41275780|NCT00004255|PROCEDURE|allogeneic bone marrow transplantation|
41275781|NCT00004255|PROCEDURE|in vitro-treated bone marrow transplantation|
41275782|NCT00004255|RADIATION|radiation therapy|
41275783|NCT01925703|DRUG|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
40927472|NCT01908738|DRUG|paracervical block with 1%lidocaine|"To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes"
40927473|NCT01908738|DRUG|10%lidocaine spray|
40927474|NCT05271279|BIOLOGICAL|OVV-01 Injection+IBR900 Cell Injection|"2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10\^9 cells per cycle.~OVV-01 injection will be first administered at W1D1 and then at W4D1 followed by every 2 weeks as a treatment cycle, for a total of 6 doses; after the test in the high-dose group is completed, the investigator and sponsor will determine whether to adjust the dosing frequency of OVV-01 (such as once a week) based on the result evaluations. The IBR900 cell injection will be first administered at W1D3 and W1D5 for 2 infusions, and then at W4D3 and W4D5, followed by every 4 weeks as a cycle, for a total of 4 doses, and cell infusions will be conducted at W1, W4, W8 and W12, respectively."
40927475|NCT00728143|DIETARY_SUPPLEMENT|Highly viscous polysaccharide enriched biscuits|10 g of highly viscous polysaccharide
40927476|NCT05532696|DRUG|ABT-101|Patients will receive ABT-101 by oral administration on a 28-day cycle
40927477|NCT02593071|BIOLOGICAL|RSV-F Vaccine|
40927478|NCT02593071|BIOLOGICAL|Phosphate Buffer Placebo|
40927479|NCT04810728|DRUG|Extract Psidii guava|2 Capsule Extract Psidii guava, three times daily
40927480|NCT04810728|COMBINATION_PRODUCT|Standard therapy for Covid-19 patient|(Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
40927481|NCT00621621|DEVICE|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
40927482|NCT03381833|DRUG|LJPC-401|subcutaneous injection, up to 20 mg per week from week 26 to 52
40927483|NCT03381833|DRUG|LJPC-401|subcutaneous injection, up to 20 mg per week from week 1 to 52
40754357|NCT04779593|OTHER|AIMS2_SF questionnaire|At D0, M12 and M24. The Arthritis Impact Measurement Scales 2 Short Form (AIMS2-SF) is a specific tool to measure changes in global health, pain, mobility and social function in patients with arthritis. It was described in 1992 in patients with rheumatoid arthritis and osteoarthritis and include 26 items that are summarized in scales according to a predefined scoring system: mobility, physical activity (walking, bending, lifting), dexterity, household activity (managing money and medications, housekeeping), social activities, activities of daily living, pain, depression, and anxiety. The French translation has been validated and this questionnaires has been widely used in the rheumatology field to assess quality of life of patients with arthritis. Because HFE related arthropathy is very similar to osteoarthritis this questionnaire is ought to be adequate in this setting.
41124548|NCT06345170|OTHER|The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program|The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program will be applied by the parents at home, 2 days a week, for an average of 30 minutes a day, for 12 weeks
41124549|NCT03833440|DRUG|Durvalumab (MEDI4736)|"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"
41275784|NCT04705467|DEVICE|Gynecological brachytherapy|Management of gynecological malignancies is done through brachytherapy treatment, which involves the delivery of radiation via radioactive sources that are placed into or in close proximity to the tumour.
41275785|NCT03399461|OTHER|Patient Interview guide|The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.
41287261|NCT01134510|DRUG|Placebos|NS (comparable volume as intervention) twice weekly x 4wks
40754358|NCT04779593|OTHER|WOMAC questionnaire|At D0, M12 and M24. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used questionnaires specifically assessing lower limb (hips and knee) osteoarthritis. It measures five items for pain, two for stiffness and 17 for functional limitation and had been translated in French.
40927484|NCT06242444|DRUG|Experimental Dentifrice|Dentifrice containing 1150 ppm fluoride and 5% KNO3.
40927485|NCT06242444|DRUG|Placebo Control Dentifrice|Dentifrice containing 0 ppm fluoride and 5% KNO3.
40927486|NCT06242444|DRUG|Reference Dentifrice|Dentifrice containing 1100 ppm fluoride as SnF2.
40927487|NCT05179551|PROCEDURE|Proximal Medial Gastrocnemius Recession|. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied
40927488|NCT06444009|DRUG|Ivonescimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
40927489|NCT06444009|DRUG|Cadonilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
40927490|NCT06444009|DRUG|Penpulimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
40927491|NCT01407042|PROCEDURE|mobile-bearing unicondylar knee arthroplasty|mobile-bearing unicondylar knee arthroplasty
40927492|NCT00177710|DRUG|Amphotericin B|
40927493|NCT04234724|OTHER|Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.|Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
40927494|NCT03441672|BEHAVIORAL|Meaning of Screening|Interactive technology game providing education about prenatal screening and what the results may mean.
40927495|NCT04340219|OTHER|Survey administration|Covid-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, WHO Quality of Life-BREF
41124550|NCT03833440|DRUG|Monalizumab (IPH2201)|"1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"
41124551|NCT03833440|DRUG|Oleclumab (MEDI9447)|"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"
40927496|NCT03433729|OTHER|Patient agenda form|On arrival at the clinic patients are given an agenda form to prompt them to think about what issues they wished to discuss with their doctor. The form contains a prompt list of items they can tick, free space to write their own items, and a prompt to consider what is the most important issue for them and what they would like to happen before they leave their clinic appointment.
40927497|NCT04173598|BEHAVIORAL|Cognitive Adaptation Training for Caregivers (CAT Famille)|Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.
41124552|NCT03833440|DRUG|Ceralasertib (AZD6738)|"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"
41124553|NCT03833440|DRUG|DOCETAXEL|"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"
41275786|NCT03399461|OTHER|Caregiver interview guide|The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.
41275787|NCT03399461|OTHER|Sociodemographic questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.
41275788|NCT03399461|OTHER|Pediatric quality of life (PedsQL) questionnaire|The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.
41275789|NCT03399461|OTHER|Clinical questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.
41275790|NCT03483532|DIETARY_SUPPLEMENT|Lit Control pH Up|dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A
41275791|NCT03483532|DIETARY_SUPPLEMENT|dry cocoa extract|(Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.
41275792|NCT04144972|DEVICE|Medtronic Summit RC+S or Percept RC|The investigators will perform DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. Closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion after initial, efficacy evaluation.
41275793|NCT03027167|DRUG|Aspirin|
41275794|NCT03027167|DEVICE|(Post- discharge) Mechanical Compression Device|
41275795|NCT00927485|DRUG|Calcumin (Curcumin)|Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
41275796|NCT00927485|OTHER|Risk Factor Questionnaire|Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
41275797|NCT00927485|OTHER|Blood samples|Three tubes of blood at visits 0, 4 and 12 months.
41275798|NCT00927485|OTHER|Biopsies (Sigmoidoscopy)|Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
41275799|NCT00927485|OTHER|Biopsies (Upper endoscopy)|Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.
41275800|NCT04996056|DRUG|TNX-1300|TNX 1300 200 mg Intravenous injection
41275801|NCT04996056|OTHER|Usual Care|Usual Care per the Emergency Department protocol for Cocaine Intoxication
41275802|NCT00206973|PROCEDURE|mannitol test|
41446663|NCT03442491|PROCEDURE|Hayman's Haemostatic Suture|After the uterus is exteriorised, bimanual compression is applied to check whether this stopped the bleeding, before the suture is applied. A number 2 polyglactin suture on a straight needle is used to transfix the uterus from front to back, just above the reflection of the bladder, and is then tied above the fundus of the uterus, while an assistant applies bimanual compression.
41275803|NCT01128712|DRUG|Pregabalin|150 mg /day
41275804|NCT01128712|DRUG|Pregabalin|450 mg/day
41446664|NCT05239195|OTHER|Video Laryngoscope|Laryngoscope with a camera and a video screen
41275805|NCT03542838|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
41275806|NCT03542838|DRUG|Saline|Saline is a normal physiological solution
41275807|NCT05602428|DRUG|esketamine sub-anesthetic,|the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
41275808|NCT05602428|DRUG|esketamine sub-anesthetic|Esketamine subanesthetic dose combined with lumbar plexus block was used
41275809|NCT05602428|DRUG|esketamine sub-anesthetic|general anesthesia was performed with esketamine subanesthetic dose.
40927498|NCT04173598|BEHAVIORAL|Usual Care|Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
40927499|NCT05053932|OTHER|blood collection|blood collection
41446665|NCT05239195|OTHER|Direct Laryngoscope|Laryngoscope without a camera or a video screen
40927500|NCT03947411|DRUG|Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
40927501|NCT03947411|DRUG|Xiyanping injection+Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
40927502|NCT00124839|DRUG|Naltrexone|Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
41124554|NCT03833440|DRUG|Savolitinib|"600 mg QD~1 cycle = 28 days"
41124555|NCT01035034|PROCEDURE|Hybrid MIDCAB/PCI|"MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
41275810|NCT04468477|DEVICE|6 Lead ECG|Patients will be assessed with the Kardiamobile device.
41275811|NCT05035420|DEVICE|Fitbit|Performance of the NIRS biosensor will be explored in comparison to this commercial wearable.
41275812|NCT05035420|DEVICE|Douglas Bag|The Douglas Bag will be used for inducing hypercapnia.
40927503|NCT03160547|OTHER|Usual Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
40927504|NCT03160547|OTHER|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
40927505|NCT00584740|DRUG|AIN457|10 mg/kg
40927506|NCT00584740|DRUG|Placebo|Matching placebo to AIN457
40927507|NCT06023576|OTHER|antihypertensive medications|"One or more of the following medications may be used in both randomization groups to achieve SBP goals:~* Angiotensin converting enzyme inhibitors (ACEI)~* Angiotensin receptor blockers (ARBs)~* Beta-blockers (BB)~* Thiazide-type diuretics~* Calcium channel blockers~* Aldosterone antagonists~* Alpha1-receptor blockers.~* Direct vasodilators~* Loop diuretics"
40927508|NCT06023576|DIAGNOSTIC_TEST|Blood pressure measurement|Home BP Monitoring (HBPM)-Throughout the study period, patients will perform HBPM at baseline, month 6, and month 12 (end of treatment). At each of these timepoints, HBPM will be performed for 7 days with 2 morning and 2 evening readings for each day (measured 1-min part).
40927509|NCT06023576|DIAGNOSTIC_TEST|Echocardiogram|At baseline, month 6, and month 12
40927510|NCT06023576|OTHER|Symptom-limited cardiopulmonary exercise test|Consecutive patients in each treatment group who meet the eligibility criteria for exercise testing will be offered to participate in CPET at the time of consent. Patients who agree will undergo CPET (baseline, 6 months, and 12 months) until the target accrual of 33 patients per group is met.
40927511|NCT06023576|OTHER|Quality of Life Measures|FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.
40927512|NCT06023576|DIAGNOSTIC_TEST|Biomarkers|Research blood samples will be collected at baseline, 3 months, and 6 months
40927513|NCT03320525|DIETARY_SUPPLEMENT|T-ChOS|T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
40927514|NCT02871882|RADIATION|Gastric Emptying test|participants eat a standardized meal labeled with radioactive markers (99mTc DTPA \[diethylenetriaminepentaacetic acid\] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
40927515|NCT02871882|OTHER|Mixed Oral Glucose Tolerance test|Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
41124556|NCT01035034|PROCEDURE|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
41124557|NCT01557985|DRUG|Bupivacaine|The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
41124558|NCT02343913|DEVICE|PAC checklist|
41124559|NCT04513314|DRUG|Valproate|Valproate sodium (enteral or intravenous) will be administered at a dosage of 10 to 15 mg/kg/day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day.
41275813|NCT05035420|DEVICE|Periflux 6000 EPOS|Tissue oxygen saturation measured by the Periflux 6000 will be compared with peripheral tissue saturation measured with the NIRS biosensor both at rest and during the induced hypercapnia, paced breathing and breath holding.
41124560|NCT04513314|DRUG|Quetiapine|Enteral quetiapine dosing on Day 3: 25 mg to 50 mg twice daily. Increase in increments of 50 mg/day to 100 mg/day divided two on Days 4 and 5 to range of 50-400 mg/day by Day 7. Further adjustments can be made in increments of 25-50 mg twice a day, in intervals of not less than 2 days. Recommended dose range is 150-750 mg/day.
41446666|NCT02891863|DEVICE|LEVER Acute Study System|The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
40927516|NCT02871882|DRUG|Conjugated bile acids sodium|500 mg tablets taken orally twice daily for 28 (+/- 4) days
40927517|NCT02871882|OTHER|Placebo|Placebo tablets taken orally twice daily for 28 (+/- 4) days
40927518|NCT03956355|DRUG|Tapinarof|Tapinarof cream, 1%, applied once daily
40927519|NCT03956355|DRUG|Vehicle Cream|Vehicle cream applied once daily
40927520|NCT00830869|DRUG|IXAZOMIB|"All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m\^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established."
40927521|NCT01789931|DEVICE|"Lifebeam"|"The lifebeam sensor will be attached to the participant's skin during the HTT."
40927522|NCT05413577|BEHAVIORAL|Mindfulness training|The intervention recordings taught the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording had the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
41124561|NCT04513314|OTHER|Standard of Care|Standard of Care is a combination of IV dexmedetomidine (D), midazolam (M), ketamine (K) and propofol (P), at the discretion of treating physician.
41275814|NCT05035420|DEVICE|BIOPAC|The BIOPAC system will be used to record the PPG signal, cardiovascular hemodynamics, and respiratory parameters in order to noninvasively monitor the heart rate, heart rate variability, respiratory rate, respiratory effort index, and arterial oxygen saturation.
41275815|NCT05035420|DEVICE|Flowmet|Flowmet will be used for a measurement of arterial blood flow within the finger or toe. Flowmet outputs a PPG waveform that will be compared with the NIRS biosensor.
40927523|NCT03782831|PROCEDURE|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
40927524|NCT03782831|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
40927525|NCT03782831|DRUG|Placebos|intravenous injection every 2 weeks
40927526|NCT01711060|DRUG|oxytocin|
40927527|NCT01711060|PROCEDURE|balloon catheter|
40927528|NCT05552144|DEVICE|Hum by Colgate Smart Kids Toothbrush (battery powered) - 490000006871|The first 15 caregivers and their children who meet the inclusion/exclusion characteristics and sign an Informed Consent Form/provide assent will be entered into the study. The caregivers will be asked to supervise the tooth brushing experience of the children with hum Kids toothbrush twice a day for 4 weeks using the associated app. The caregivers will also be asked to fill out questionnaires and participate in interviews regarding the children's brushing habits and experiences.
40927529|NCT00729391|BEHAVIORAL|Woman-Focused Intervention (Women's Health CoOp)|Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.
40927530|NCT00729391|BEHAVIORAL|Nutrition (Attention-Control)|Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.
40927531|NCT00729391|BEHAVIORAL|VCT Only|Participants in this group will receive VCT only.
40927532|NCT02636140|OTHER|Light|A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
40927533|NCT03442400|DEVICE|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire|We will measure the degree of flow-limitation of intermediate severity coronary steonses using the iFR/FFR Verrata Plus coronary pressure/flow wire before and after transcatheter aortic valve replacement.
41124562|NCT00150241|DRUG|CP-526,555 (varenicline)|
41124563|NCT05614336|BIOLOGICAL|Blood sample|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
41124564|NCT00909324|DRUG|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
41275816|NCT05035420|DEVICE|NIRS|a. Each subject will be monitored with the multimodal system for 10 minutes while sitting quiescent on a chair in resting position. All screening index parameters will be collected and recorded. b. Each subject will be studied for approximately 60-80 minutes while being exposed to a mild Hypercapnia (5% CO2), paced breathing and breath holding followed by a 10-minute recovery time after each task.
41275817|NCT04207398|PROCEDURE|Transjugular intrahepatic portosystemic shunts|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. A small metal device called a stent is placed to keep the connection open and allow it to bring blood draining from the bowel back to the heart. TIPS may successfully reduce internal bleeding in the stomach and esophagus in patients with cirrhosis and may also reduce the accumulation of fluid in the abdomen (ascites).
41275818|NCT04207398|OTHER|Nonselective β-blocker (NSBB)+ endoscopic band ligation (EBL)|Combination therapy of nonselective β-blocker (NSBB) and endoscopic variceal ligation (EBL) will be used for participants in this group. NSBB, which will be titrated to the maximum tolerated dose aiming to decrease the heart rate by 25%, with a lower limit of 50 beats per minute, was started at day 5 after the index bleeding, unless a contraindication was present (severe arrhythmia, severe obstructive chronic obstructive pulmonary disease, or known intolerance). Endoscopic variceal ligation sessions started 2 weeks after the index bleeding and were performed every 2-4 weeks thereafter until eradication of varices, followed by endoscopic surveillance and retreatment, if indicated, every 6-12 months.
41446667|NCT03723044|OTHER|EEG and occulometry|Each participants will spend two sessions of EEG and occulometry during a visual cognitive task where she/her will be presented with multi-stable visual stimuli to gaze at for one or two minutes. Depending on the experimental conditions, the participant will provide or not her/his perceptual state (i.e. which stimulus has been perceived ).
41446668|NCT04962945|PROCEDURE|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
40927534|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
40927535|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
40927536|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
40927537|NCT00911443|BIOLOGICAL|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
40927538|NCT00911443|DRUG|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
40927539|NCT01221844|DIETARY_SUPPLEMENT|Lattoglobina (Grunenthal) containing bLf|One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
40927540|NCT01221844|DRUG|FerroGrad by Abbott|Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
40927541|NCT05255185|PROCEDURE|domino therapy|The investigators evaluated routine blood test results, C-reactive protein level, the erythrocyte sedimentation rate, and other indicators. X-rays and CT scans of the surgical site were obtained and the Musculoskeletal Tumor Society (MSTS) score was calculated. Treatment involved debridement and lavage of the prosthesis, and systemic and local antibiotics.
40927542|NCT02830984|PROCEDURE|EST+LBD+ENBD|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
40927543|NCT02830984|PROCEDURE|EST+LBD|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
40927544|NCT04985396|DRUG|Platelet Rich Plasma (PRP) group|Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
40927545|NCT00445016|PROCEDURE|peripheral regional anesthesia|evaluation and description of adverse effects
40927546|NCT03653871|BEHAVIORAL|Performing Arts Instruction|Professionally delivered performing arts curriculum
40927547|NCT06094062|OTHER|App-based treatment support|The intervention includes a smartphone app that patients will download on their smartphones. Medication intake, symptom course and well-being will be tracked over treatment duration. If symptoms worsen, the pharmacist will contact the patients and counsel them based on their adherence and well-being data. Patients who still have symptoms after the 30 days of treatment will receive a final counseling by the pharmacy, and if necessary will be forwarded to the treating physician.
40927548|NCT04951297|OTHER|None, just observation|None ,just observation test
40927549|NCT03774823|DEVICE|RF and PEMF|RF and PEMF treatment is deployed using either a small or large handpick applied to the skin and moved slow random patterns homogeneously over the area of treatment
40927550|NCT03774823|DEVICE|Ultrasound|Ultrasound is applied to the subject by placing a probe on the treatment area and moving it rapidly and homogeneously over the treatment area
41124565|NCT00909324|DRUG|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
41124566|NCT06387381|DRUG|68Ga-PSFA|Each subject receives a single intravenous injection of 68Ga-PSFA.
41124567|NCT04646031|DRUG|T89 capsule|T89 capsule, an medicinal product for oral use under active INDs in the US is a botanical drug containing 75mg active substance of the water extract of Danshen and Sanqi.
40754359|NCT04779593|OTHER|EQ-5D-5L questionnaire|At D0, M12 and M24. The EQ-5D is a standardized instrument which evaluates the generic quality of life (http://www.euroqol.org/). It is a preference-based health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers given to EQ-5D permit to find 243 health states that can be converted into utility score anchored at 0 for death and 1 for perfect health. EQ-5D is an instrument developed in Europe, widely used in cost-utility analysis. It has been validated in a representative sample of French population.
40927551|NCT02500576|BIOLOGICAL|Aldesleukin|Given IV or SC
40927552|NCT02500576|DRUG|Cyclophosphamide|Given IV
40927553|NCT02500576|DRUG|Fludarabine Phosphate|Given IVPB
40927554|NCT02500576|OTHER|Laboratory Biomarker Analysis|Correlative studies
40927555|NCT02500576|BIOLOGICAL|Pembrolizumab|Given IV
41124568|NCT03927820|OTHER|Benefits investigation|The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.
41124569|NCT04695483|DRUG|Corifollitropin alfa|Controlled ovarian stimulation long-acting protocol
41124570|NCT04695483|DRUG|Follitropin Beta|Daily controlled ovarian stimulation protocol
41124571|NCT05043805|DRUG|Dextromethorphan|add on therapy
41124572|NCT05043805|OTHER|placebo|add on therapy
40927556|NCT02500576|OTHER|Quality-of-Life Assessment|Ancillary studies
40927557|NCT02500576|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Given IV
40927558|NCT00137839|DRUG|Erlotinib|
40927559|NCT04598256|PROCEDURE|Endoscopic procedure|Esophagogastroscopy and colonoscopy
40927560|NCT06157216|DRUG|MRD-guided therapy|MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
40927561|NCT02604017|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
41124573|NCT06052436|BIOLOGICAL|Allogeneic thyTreg 5.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
41124574|NCT06052436|BIOLOGICAL|Allogeneic thyTreg 10.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
41124575|NCT00223067|DRUG|TAIZ|
41124576|NCT05527613|OTHER|whatsapp application with oral hygiene reminder for orthodontic patients|Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
41446669|NCT04962945|PROCEDURE|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
41446670|NCT06559293|DIAGNOSTIC_TEST|laryngeal ultrasound|laryngeal ultrasound with linear probe will be positioned on the patient's neck. A list of anatomical sites to be visualised will be determined beforehand. Once all the pre-determined structures have been visualised, in an axial and sagittal plane, we will note the position of the ultrasound probe and its orientation. This will enable us to determine the ideal position of the ultrasound probe for obtaining all the elements of interest on a section that will be called the reference section.
41446671|NCT01806272|DRUG|rhGM-CSF|The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
41446672|NCT01806272|DRUG|Compound Vitamin B12|Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
41446673|NCT00002890|BIOLOGICAL|lintuzumab|
40754360|NCT04779593|BIOLOGICAL|Blood Sample Complete blood count|Blood Sample Complete blood count at D0, M6, M12, M18 and M24/end follow-up visit
41124577|NCT02639975|DRUG|PBF-677|once daily oral administration
41124578|NCT02639975|DRUG|Placebo|once daily oral administration
41275819|NCT03293654|DRUG|MB02|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
41275820|NCT03293654|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
41275821|NCT03293654|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
41275822|NCT05791981|BEHAVIORAL|Harmony & Health Intervention|"Participants will attend group in person sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation.~Participants will be instructed to practice the exercises at home 2 times each week during the entire 6-month period. You will be given instructions and a yoga mat, belt, and block. After your Week 9 assessment, you will attend in-person or Zoom sessions 1 time each month over the final 4 months of the study"
41275823|NCT05791981|BEHAVIORAL|Attention Control|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and well-being topics. After your Week 9 assessment, you will have the ability to attend additional in-person or Zoom health education sessions 1 time each month over the final 4 months of the study.
41275824|NCT05791981|DEVICE|Fitbit|Participants will be given a Fitbit and instructions on how to use it. The Fitbit will record your physical activity and report it to the study staff.
41275825|NCT03947229|DRUG|Clopidogrel mono-therapy|Patients will receive clopidogrel (75 mg once daily) monotherapy without co-administration of aspirin for 24 months after randomization.
41275826|NCT03947229|DRUG|Dual-antiplatelet therapy|Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.
41275827|NCT05388669|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
41275828|NCT05388669|DRUG|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Amivantamab injection will be administered subcutaneously by manual injection.
41275829|NCT05388669|DRUG|Amivantamab Intravenous|Amivantamab will be administered by IV infusion.
41275830|NCT00816036|BEHAVIORAL|Smoking Cessation Guideline Implementation|"1. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit."
41446674|NCT04349475|DIETARY_SUPPLEMENT|Intervention Omega 3 Supplementation|Participants will supplement 4g of Omega 3 fish oil daily (750DHA/250EPA)
41446675|NCT04349475|DIETARY_SUPPLEMENT|Control Safflower Oil|Participants will consume 2.5g of a Safflower oil supplement daily
41446676|NCT06557343|DIAGNOSTIC_TEST|Single Cell Sequencing|Sequencing of all viable single cells present in deep bronchial brushings using transcriptomics to identify what cells are present and what they are doing.
41446677|NCT01224704|OTHER|Hypertonic saline infusion|Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.
41446678|NCT01224704|OTHER|Water deprivation|24 hour water deprivation
41446679|NCT01798719|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
41446680|NCT01798719|BEHAVIORAL|General Advice|Only general advice about diet
41446681|NCT06628180|DEVICE|LIFU|Application of low-intensity focused ultrasound for neuromodulation
41446682|NCT06628180|DEVICE|Sham LIFU|Sham application of LIFU - will appear the same to participants.
41446683|NCT04086108|DIETARY_SUPPLEMENT|Tomato|A maximum of 1 kilo pureed tomatoes, containing 1 gram of GABA.
41446684|NCT04086108|DIETARY_SUPPLEMENT|GABA supplement|1 gram of GABA dissolved in water.
41446685|NCT04086108|DIETARY_SUPPLEMENT|Glutamate supplement|A maximum of 8 grams glutamate, adjusted to amount of glutamate given in the tomato arm. Dissolved in water.
41446686|NCT02456285|PROCEDURE|Primary/Bowel-first Surgery|Patients undergoing primary/bowel-first surgery as part of a staged curative procedure. The liver metastases will be resected in a second planned operation.
41446687|NCT02456285|PROCEDURE|Liver-first surgery|Patients undergoing liver-first surgery as part of a staged curative procedure. The colorectal primary will be resected in a second planned operation.
40754361|NCT04779593|BIOLOGICAL|Blood Sample Iron panel|Blood Sample Iron panel (serum ferritin, serum iron and serum transferrin to determine transferrin saturation according to randomization group (at M6, M12 and M18) at D0, M6, M12, M18 and M24/end follow-up visit and at each bloodletting.
40754362|NCT04779593|BIOLOGICAL|Blood Sample Fasting Glucose|Blood Sample Fasting Glucose at D0 and M24/end follow-up visit
40754363|NCT04779593|BIOLOGICAL|Blood sample lipid panel|Blood sample lipid panel (total cholesterol, triglycerides, HDL, LDL) at D0 and M24/end follow-up visit
41446688|NCT02456285|PROCEDURE|Synchronous resection surgery|Patients undergoing a synchronous colorectal primary resection and liver resection in a single operation.
41446689|NCT02456285|PROCEDURE|No surgery|Patients who have no surgery.
41446690|NCT04185363|DRUG|Maralixibat|All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) twice daily
41446691|NCT05981794|DEVICE|Electrical heating pad|A powered heating pad
41446692|NCT05981794|DEVICE|Sham heating pad|A heating pad that is not powered on
41446693|NCT03031821|DRUG|Metformin|Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
41446694|NCT03031821|DRUG|Placebo Oral Tablet|"Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration"
41446695|NCT05691530|DRUG|rDENdelta30/31-7164|The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10\^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.
41446696|NCT05524051|DRUG|TIN816|TIN816
41446697|NCT05524051|OTHER|Placebo|Placebo
41446698|NCT01426633|DRUG|Gemcitabine + Trabectedin|Combination therapy of gemcitabine and trabectedin
41446699|NCT04538378|DRUG|Olaparib|Olaparib tablet will be administered at a total daily dose of 600 mg orally in two divided doses, approximately 12 hours apart.
41446700|NCT04538378|DRUG|Durvalumab|Durvalumab will be administered IV into a peripheral or central vein on Day 1 of every cycle at a flat dose of 1,500 mg.
41446701|NCT05548465|DRUG|Remifentanil Hydrochloride|Subjects will receive remifentanil anesthesia for operative analgesia.
41446702|NCT05548465|DRUG|Sufentanil Citrate|Subjects will receive sufentanil and remifentanil anesthesia for operative analgesia.
41446703|NCT04966299|DIETARY_SUPPLEMENT|Eryhtritol|"Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks~EryClot-Pilot:~Erythritol 50g dissolved in 300mL water administered once per visit~EryClot:~Erythritol 50g dissolved in 300mL water administered once per visit"
41446704|NCT04966299|DIETARY_SUPPLEMENT|Sucrose|Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
41446705|NCT04966299|DIETARY_SUPPLEMENT|Glucose|Glucose 75g dissolved in 300mL water administered once per visit
41446706|NCT04966299|DIETARY_SUPPLEMENT|Fructose|Fructose 25g dissolved in 300mL water administered once per visit
41446707|NCT04966299|DIETARY_SUPPLEMENT|Xylitol|Xylitol 33.5g dissolved in 300mL water administered once per visit
41446708|NCT04966299|DIETARY_SUPPLEMENT|Water|300mL water administered once per visit
41446709|NCT05870332|DEVICE|GI Genius (GIG)|"GIG is an artificial intelligence unit that assists human colonoscopist in real-time to detect polyps during colonoscopy.~Four months collection period prior to activating GIG, then four months with GIG, and Four months afterwards without GIG"
41446710|NCT00152451|DRUG|Seletracetam (ucb 44212)|"* Pharmaceutical form: oral capsules~* Concentration: 10 and 50 mg~* Route of administration: oral administration"
41446711|NCT03186651|DEVICE|TVS|Efficacy of a novel intra-vaginal device for temporary reduction of urine leakage in women suffering from stress urinary incontinence and to evaluate the safety and ease of use.
40754364|NCT04779593|BIOLOGICAL|Blood sample liver panel|Blood sample liver panel (total bilirubin, Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma-Glutamyl Transferase) at D0 and M24/end follow-up visit
41124579|NCT06499441|OTHER|Myofascial induction in gastrocnemius|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
41446712|NCT06562855|GENETIC|Peripheral blood sampling|
41446713|NCT05661591|DRUG|SHR2554 Tablets|SHR2554 Tablets+ Fluconazole Capsules
41446714|NCT05661591|DRUG|Fluconazole Capsules|SHR2554 Tablets+ Fluconazole Capsules
41446715|NCT02261389|OTHER|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
41446716|NCT01111448|DRUG|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
41446717|NCT05370807|DRUG|Regorafenib 40 MG Oral Tablet|Patients take 2 regorafenib oral tablets of 40 mg daily
41446718|NCT05370807|DRUG|Triplet therapy|Regorafenib in combination with BRAF- / MEK- inhibitors
41446719|NCT06562465|PROCEDURE|dietary and exercise management|Dietary and exercise management: dietary management by providing tailored recipes, health education lectures, science competitions, etc；exercise management:develop weekly and monthly exercise plans for children of different ages, and have physical education teachers lead them in exercising.
41446720|NCT06562465|PROCEDURE|no dietary and exercise management|NO dietary and exercise management:do not implement dietary and exercise management related to the experimental group
41446721|NCT01575457|BEHAVIORAL|Career Counseling and Motivational Interviewing|The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
41446722|NCT02193724|OTHER|Skin Biopsy|A very small skin sample will be taken from the participant's arm. This will only be performed while the patient is under sedation for clinical purposes (e.g. exam under anesthesia, MRI, or other procedure requiring sedation).
41446723|NCT02193724|OTHER|Blood Draw|About 1 teaspoon of blood will be drawn from the participant's arm or from a central line catheter if present. Blood collection will be done at the same time the participant has blood drawn for routine clinical care.
40754365|NCT04779593|BIOLOGICAL|Blood sample C reactive protein|Blood sample C reactive protein at D0 and M24/end follow-up visit
41124580|NCT06499441|OTHER|Preassure release|Also called ischaemic pressure. Three cycles of pressure are applied to the trigger point of the gastrocnemius muscle until the pain disappears on pressure.
41446724|NCT04210557|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil, which in turn is connected to the scalp. The stimulator generates a changing electric current within the coil which induces a magnetic field; this field then causes a second inductance of inverted electric charge within the brain itself.
41446725|NCT02919540|OTHER|Kangaroo care approach|skin to skin contact between stable preterm infants and their naked mother's chest
41446726|NCT05436028|DEVICE|Transcatheter Tricuspid Valve Intervention|"Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb).~Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement."
41446727|NCT03280953|DIAGNOSTIC_TEST|Assessing fluid responsiveness by PWTT value|PWTT value will be analysed to find the cutoff values compared by esophageal doppler and pulse pressure variation.
40927562|NCT02386670|OTHER|tDCS + CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions will promote transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely)."
41446728|NCT06157268|OTHER|Natural history and non therapeutical therapy|"This study concerns a natural history study part and a muscle fatigability part.~For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation."
41446729|NCT03129841|BEHAVIORAL|Early dinner+Diet|Subjects are asked to eat dinner meals between 7:00- 7:30 PM in the ED group, while they are on a multidisciplinary weight loss plan for 12 weeks.
41446730|NCT03129841|BEHAVIORAL|Late dinner+Diet|Subjects are asked to eat their dinner meal between 10:30-11:00PM, while they are on a multidisciplinary weight loss plan for 12 weeks.
41446731|NCT06627673|DEVICE|Total Knee Arthroplasty|Primary Total Knee Arthroplasty with a PEEK femoral component
40754366|NCT04779593|PROCEDURE|Bloodletting - control group|Patients treated with bloodletting according to current guidelines (ferritin alone). Patient will undergo bloodletting with a goal of maintaining a serum ferritin equal or lower than 50 g/L according to current clinical practice guidelines (French and European).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.
41275831|NCT04126837|OTHER|Diagnosis and treatment|Monocentric, Prospective and Biomedical Research excluding Health Product
40754367|NCT04779593|BIOLOGICAL|BioBank|Blood sample will be collected for BioBank at D0, M12 and M24.
40754368|NCT04779593|OTHER|Medico-economical|Medico-economic data will be collected at each follow up visit.
40947851|NCT01528033|OTHER|Standard conventional wound therapy|Standard conventional wound therapy (SCWT) according to institutional clinical standards within a maximum study treatment time of 42 days
40947852|NCT00014118|DRUG|carboplatin|
40947853|NCT00014118|DRUG|paclitaxel|
40947854|NCT00014118|PROCEDURE|conventional surgery|
41275832|NCT01397851|DEVICE|Insecticide-treated net (BASF Incerceptor)|One per farmer, once during the 2010-2011 season
41275833|NCT00870688|DRUG|sodium valproate|valproate sustained release minitablets, once daily.
41275834|NCT02133417|DEVICE|Quantitative Transmission Ultrasound|Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
41275835|NCT03173703|DEVICE|Implant the XenoSure patch|The LeMaitre XenoSure patch will be used when close the repaired vessel
41275836|NCT03173703|PROCEDURE|Repair/reconstruction of the diseased vessel|The diseased vessel is surgically repaired such as removing the clots.
41275837|NCT03173703|DEVICE|Implant the Vascular-Patch|The B. Braun Vascular-Patch will be used when close the repaired vessel
41275838|NCT00190775|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
41275839|NCT00190775|DRUG|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
41275840|NCT05700461|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib."
41275841|NCT01287663|DRUG|Permethrin impregnated|
41275842|NCT01287663|DRUG|no Permethrin impregnated|
41275843|NCT03420638|DRUG|Adjunct Exparel (bupivacaine liposome suspension 1.3%)|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\] i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension 1.3% (13.3 mg/mL) on each side.
41275844|NCT03420638|OTHER|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
41275845|NCT00674011|DRUG|Bevacizumab|Given as part of standard of care or another research protocol
41275846|NCT02833025|DEVICE|Thrombin generation and Platelet Function Testing|Point-of-care testing of thrombin generation, platelet function, and rotational thromboelastometry
41275847|NCT04114305|BEHAVIORAL|ECD Intervention|"Modeled on the Early Learning Resource Unit's Family \& Community Motivator home visiting program and Philani Mentor Mothers home visiting program in South Africa. Program provided stimulation in 5 domains: cognitive, receptive and expressive language, gross and fine motor skills, also covered topics in maternal and child health, nutrition and social services.~Comprised primarily of home visits beginning during pregnancy and continuing until the child was 18 months. ECD MM taught the parent/caregiver about ages and stages of growth, helped facilitate responsive parenting and early learning opportunities for their children, demonstrated use of toys and books to stimulate the child, provided families with picture books, and taught caregivers to create toys and books for their child. Community parenting information play groups and educational talks on ECD at the clinic supplemented home visits."
41275848|NCT05657262|OTHER|Pre-post test|Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.
41275849|NCT05657262|BEHAVIORAL|experimental group|The experiment group will be applied with the Z technique.
41275850|NCT04042480|DRUG|SGN-CD228A|SGN-CD228A administered into the vein (IV; intravenously)
41275851|NCT04910685|DRUG|Elenestinib|Elenestinib oral tablet
41275852|NCT04910685|DRUG|Placebo|Placebo oral tablet
41275853|NCT05661955|DRUG|BGB-A445|administered intravenously
41275854|NCT05661955|DRUG|Tislelizumab|administered intravenously
41275855|NCT04837014|OTHER|prescription for regular acetaminophen and naproxen|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
41275856|NCT04837014|OTHER|prescription for regular acetaminophen , naproxen and dilaudid|prescription for regular acetaminophen , naproxen and dilaudid
41275857|NCT05884658|PROCEDURE|vNOTES : natural vaginal orifice transluminal endoscopic system for hysterectomies|hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)
41275858|NCT05884658|PROCEDURE|laparoscopic hysterectomy|laparoscopic hysterectomy uses a standardized procedure with or without surgical robot
41275859|NCT06574035|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy focuses on the unique needs of men. A culturally adapted CBT program will be administered to participants as it has demonstrated increased effectiveness for marginalized populations. Cognitive Behavioral Therapy (CBT) aligns well with these cultural needs due to its individualized approach, non-judgmental stance, collaborative nature, and emphasis on empowerment through skills building.
41275860|NCT06574035|BEHAVIORAL|Exercise|Research demonstrates a preference for physical activity interventions among men with chronic illnesses, while highlighting limited access to fitness facilities in low-income urban areas as a barrier to participation. Online physical activity interventions have shown efficacy and cost-effectiveness in improving health behaviors, with virtual exercise programs for low-income African American populations demonstrating significant reductions in depressive symptoms. Therefore participants will receive exercise to help improve their diabetes self-management behaviors and depressive symptoms.
41275861|NCT06574035|BEHAVIORAL|Group Discussions - Ongoing Support|Participants will join group discussions that will serve as on-going support. The small group component is designed to foster self-efficacy, autonomous motivation, and enjoyment by integrating skills building, personal values, spirituality, and goal setting. This approach has shown positive outcomes in previous pilot studies with African American men, serving as a source of vicarious learning and social support.
41275862|NCT06657677|DIETARY_SUPPLEMENT|40mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
40947855|NCT00014118|RADIATION|radiation therapy|
40947856|NCT04134702|OTHER|Acupuncture|Acupuncture and ear acupuncture using indwelling fixed needles, that will remained in situ several days after surgery until the patients will experience pain
40947857|NCT01033851|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course
41275863|NCT06657677|DIETARY_SUPPLEMENT|100mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
41275864|NCT06657677|DIETARY_SUPPLEMENT|180mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
41275865|NCT01606462|DRUG|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
41275866|NCT04026789|OTHER|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
41275867|NCT04026789|OTHER|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
41275868|NCT00499265|DRUG|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
41275869|NCT00499265|DRUG|Serine Proteinase Inhibitor WX-671|oral, daily
41275870|NCT00499265|DRUG|Serine Proteinase Inhibitor WX-671|oral, daily
41275871|NCT05442385|OTHER|Evidence based management|clinical patterns , laboratory investigations , radiology , lines of managements and outcome of each modality of treatment
41275872|NCT01931865|DRUG|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
41275873|NCT02087566|DRUG|600 mg linezolid|
41275874|NCT05916872|OTHER|experimental group|Patients will receive Proprioceptive Neuromuscular Facilitation (contract-relax) technique with EMS
40947858|NCT01033851|BEHAVIORAL|Stress Management Education|8 week course
41275875|NCT05916872|OTHER|control group|Patients will receive conventional therapy.
41275876|NCT00147927|BEHAVIORAL|Sequential emails and web support|
41275877|NCT04147949|DRUG|AV-101|Oral capsules taken twice daily for 14 days
41275878|NCT04147949|DRUG|Placebo|Oral capsules taken twice a day for 14 days
41275879|NCT00099671|DRUG|Recombinant human interleukin-7|
41124581|NCT04137497|DIAGNOSTIC_TEST|The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)|All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.
41275880|NCT03711383|DIETARY_SUPPLEMENT|Inulin and Resistant Starch|12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g
41275881|NCT03711383|DIETARY_SUPPLEMENT|Inulin|12g per inulin in combination with maltodextrin per day the day before the CID
41275882|NCT03711383|DIETARY_SUPPLEMENT|Placebo|isocaloric maltodextrin before test day
41275883|NCT03467906|OTHER|In-laboratory assessment|Participants will stay in the laboratory for two days and one night during which they will complete questionnaires, have blood drawn, and have other measurements taken.
41275884|NCT00303550|DRUG|Intravenous iclaprim|
41275885|NCT00303550|DRUG|Intravenous linezolid|
41275886|NCT00629083|DEVICE|Bulkamid|Bulking injection with Bulkamid injection device
41275887|NCT00629083|DEVICE|Contigen|Transurethral bulking injection
41275888|NCT03567187|DEVICE|iovera|The iovera° device is 510(k)-cleared (K133453 and K161835) and is used to form a precisely controlled, sub-dermal cold zone of -20 to -88.5 degrees Celsius to temporarily disrupt peripheral nerve function, ultimately blocking pain. It is not indicated for the treatment of central nervous system tissue.
41275889|NCT06276387|BEHAVIORAL|Mindfulness Program|Participants will receive eight weekly 2.5-hour group sessions and one day-long silent retreat, delivered online. Intervention content will include the MBSR program, which has been extensively studied with many different chronic conditions, and augmentations for individuals with rheumatic diseases. Each MBSR session will include meditation practices (e.g., sitting meditation, body scan, gentle hatha yoga, walking meditation, mindfulness of daily activities, awareness of pleasant and unpleasant events) and review of home practice. Participants will complete daily home practices for about 45 minutes per day and log their practice.
41275890|NCT05453799|DRUG|Vudalimab|Given IV
41275891|NCT05647213|BIOLOGICAL|iPSC-CL|Autologous IPSCL
41275892|NCT03880812|OTHER|Societal cost|Annual societal cost information to the US for carpal tunnel release surgery was displayed.
41275893|NCT01883570|OTHER|training in visual search strategy|
41275894|NCT01883570|OTHER|access to a library of chest x-rays without search strategy|
40927563|NCT02386670|OTHER|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely)."
40927564|NCT02146144|PROCEDURE|ILM Peeling|"common surgical procedure:~For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens~For all patients:~* Central and peripheral 25 Gauge vitrectomy~* dissection of the epimacular membrane~* injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity~* Intraoperative picture to see the possible spontaneous ILM peeling~* If no spontaneous ILM peeling, the patient will be randomized at the operating block~Specific surgical procedure:~• • Randomization into two groups:~* Arm 1: no peeling, where the ILM peeling will not be made~* Arm 2: active peeling, where the ILM peeling will be made"
41124582|NCT05629793|OTHER|Experimental tests|Walking for 6 minutes, sitting down and getting up from a chair for 1 minute and finally the cold test (Cold pressor) where the hand is introduced for 1 minute in water at 4ºC. The patient will be monitored by means of a Polar H10 chest strap, as used in sports, continuously and 02 saturation, TA and voice (exhalation while saying /a/ and dry cough) will be collected before and after the tests. Finally, skin conductance will be monitored by performing baseline tracing and then control while performing the cold test.
41275895|NCT06278623|DEVICE|Focal Muscle Vibratory Energy (EVM) Treatment|"The patients involved in the study will undergo muscle vibratory stimulation in association with conventional rehabilitation treatment three times a week, for three weeks for a total duration of 9 sessions in association with conventional treatment.~The vibration will be applied at a frequency of 100 Hz and an amplitude of 0.2 cm for 30 minutes (three sessions of 10 min each with 1 min break in between) three times a week for three weeks at the level of the quadriceps femoris and triceps surae bilaterally for balance improvement and stimulation of proprioception and in the trapezius and trunk extensor muscles bilaterally for pain relief."
41275896|NCT02834130|BEHAVIORAL|Evaluation of psychological and psychopathological|
41275897|NCT05638321|DEVICE|MIMS|sterile surgical device made of stainless steel and plastic, which is coupled to a rotating system. The surgical device consists of stainless steel micro trephine, covered by a small needle and rotating mechanism behind it. Mechanical rotation of the surgical device is achieved by the rotating system which is comprised of a 1) Controller which dictates the activation pulse duration and RPM, 2) a Motor, and 3) Footswitch.
41275898|NCT04662593|BEHAVIORAL|Whole Health Program|A mind-body-spirit intervention to improve health and well-being including weight loss.
41275899|NCT04432428|DRUG|Sufentanil Sublingual Tablet|"all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition.~max dose per hour : 3 tablets of 15µg sufentanil"
41275900|NCT04927312|DRUG|PF-06947386|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.
41275901|NCT04927312|DRUG|Metronidazole|Metronidazole 0.5 g solution for injection.
41275902|NCT00371319|DRUG|tacrolimus|0.06-0.1 mg/kg/day
41275903|NCT00371319|DRUG|mycophenolate mofetil|2-3 gm/day
41275904|NCT01480986|DRUG|Irinotecan combined with cisplatin, octreotide lar|Phase 1 irinotecan 180mg/m\^2，ivgtt，90min，D1 Cisplatin 50 mg/m\^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
41275905|NCT05173896|DRUG|Tadalafil 20 MG|Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
41275906|NCT05173896|DRUG|Placebo|Daily dose of oral over-encapsulated placebo tablets for three months.
41275907|NCT06656429|DRUG|Transforaminal Epidural Steroid Injections|Transforaminal Epidural Steroid Injections
41275908|NCT06656234|DRUG|Glofitamab|Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling.
41275909|NCT06656234|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
41275910|NCT05537038|BIOLOGICAL|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
40927565|NCT00136383|DRUG|paroxetine versus duloxetine|
41124583|NCT00199082|DRUG|Adriamycin|
41275911|NCT05537038|BIOLOGICAL|BNT164b1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
41275912|NCT05537038|OTHER|Placebo|Placebo
41275913|NCT06656832|OTHER|Heart Failure network care|Patients will receive three visits within the first three months after randomization for improving heart failure therapy at a cardiologist or the outpatient heart failure clinic
41275914|NCT06435507|DRUG|IM-250 (50 mg)|Single dose
41124584|NCT00199082|DRUG|Cyclophosphamide|
41124585|NCT00199082|DRUG|Cytarabine|
41124586|NCT00199082|DRUG|Dexamethasone/Prednisolone|
41275915|NCT06435507|DRUG|IM-250 (100 mg)|Single dose
41275916|NCT06435507|DRUG|IM-250 (200 mg)|Single dose
41275917|NCT06435507|DRUG|IM-250 (400 mg)|Single dose
41275918|NCT05446298|DRUG|ONC-392|ONC-392 will be given by IV infusion, q3w.
41275919|NCT05446298|DRUG|Pembrolizumab|Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
41275920|NCT05154474|OTHER|Standard|Standard follow-up with clinical exams, functionnal test at baseline, Ct scan MNA, IPAQ, SARC-F and SarQOL questionnaires
40927566|NCT01371032|DEVICE|VideoMiller|Video-Miller laryngoscope, using the screen (Video laryngoscopy group)
40927567|NCT01371032|DEVICE|Direct Laryngoscopy|Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
40927568|NCT00480987|DRUG|Oxaliplatin|30 mg/m\^2 IV days 1-4
40927569|NCT00480987|DRUG|Fludarabine|30 mg/m\^2 IV days 2-6
41275921|NCT03510793|DRUG|balanced anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia
41446732|NCT04487158|BEHAVIORAL|Small Changes|The Small Changes program is an evidence-based 6-month weight-management program. The program runs weekly for 3 months followed by by-weekly contact for 3-months (1x in-person group and 1x phone call). This program uses behaviour change strategies to help with weight loss. The Small Changes approach is different from traditional dieting programs because it encourages modest changes to diet and physical activity which are not overly taxing to maintain. Participants are asked to reduce their nutritional intake by 200-400 calories per day. You will also be asked to increase their daily step count by 2000-3000 steps. Weekly intervention topics include: Monitoring, Nutrition, Physical Activity, Breaking the Chain, External Cues, Mindful Eating, Body Image, Stress, Sleep, Social Support, Social Eating, and the Stoplight Guide.
41446733|NCT04487158|BEHAVIORAL|INSPIRE|The INSPIRE program is a modification to the Small Changes program. It combines elements of positive psychology and behaviour change to help with weight loss. The first four weeks of the program are oriented towards improving well-being and include topics such as values, self-compassion/mindfulness, character strengths, and gratitude. The remaining 8 weeks mirrors the Small Changes program in making modest changes to diet and physical activity to achieve weight loss. Participants are asked to reduce their nutritional intake by 200-400 calories per day. Participants will also be asked to increase their daily step count by 2000-3000 steps.
40927570|NCT00480987|DRUG|Cytarabine|500 mg/m\^2 by IV continuous infusion days 2-6
40927571|NCT04047797|DRUG|Ixazomib|Given by mouth
40927572|NCT04047797|DRUG|Ixazomib Citrate|Given by mouth
40927573|NCT04047797|BIOLOGICAL|Rituximab|Given Intravenous
41124587|NCT00199082|DRUG|VP16|
41124588|NCT00199082|DRUG|Ifosfamide|
41124589|NCT00199082|DRUG|Methotrexate|
41124590|NCT00199082|DRUG|G-CSF|
41446734|NCT05854784|DRUG|Afamelanotide 16 MG|Eligible patients will receive one dose of afamelanotide 16mg every 28 days (up to six doses), as a controlled-release formulation.
40927574|NCT05337033|DRUG|MPL-001|"CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol."
40927575|NCT02854475|PROCEDURE|Venous blood collection|weekly within two weeks
41124591|NCT00199082|DRUG|Rituximab|
41124592|NCT00199082|DRUG|Vincristine/Vindesine|
41124593|NCT00199082|PROCEDURE|Irradiation (in specific conditions)|
41124594|NCT02190708|DRUG|PQ912|from day2 up to day6 twice daily oral dose of PQ912
41275922|NCT03510793|DRUG|Total intravenous anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
41275923|NCT06468579|DRUG|GT20029|Stage 1: GT20029 gel single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
40927576|NCT02854475|PROCEDURE|Raman spectroscopy|weekly within two weeks, on the volar forearm, using a RiverDiagnostics gen2-SCA Skin Composition Analyzer
40927577|NCT00735189|OTHER|anticoagulation clinic care|Patient receives care from the outpatient anticoagulation management service
40927578|NCT00735189|OTHER|usual care|patient receives usual anticoagulation care from their regular primary care physician
40927579|NCT06046352|PROCEDURE|Electrophysiological study (and ablation when appropriate)|Electrophysiological study (and ablation when appropriate)
40927580|NCT01514162|DEVICE|Trifecta valve|surgical replacement of aortic valve
40927581|NCT02901756|DIETARY_SUPPLEMENT|Antemig|Participants were instructed to take one tablet every morning for three months.
40927582|NCT01781273|OTHER|Ethanol|During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
41124595|NCT02190708|DRUG|Midazolam|single oral dose on day1 and day 6
41124596|NCT02190708|DRUG|Omeprazole|single oral dose on day1 and day6
41124597|NCT03024034|DRUG|TP-271|single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
41124598|NCT02754596|DRUG|Travoprost Intraocular Implant, high elution|Surgical implant placed within the eye to elute travoprost.
41124599|NCT02754596|DRUG|Travoprost Intraocular Implant, low elution|Surgical implant placed within the eye to elute travoprost
41124600|NCT02754596|DRUG|Timolol Maleate Ophthalmic Solution, 0.5%|Instillation of one drop of timolol in the study eye twice daily
41124601|NCT05360901|BEHAVIORAL|IntelliCare with automated motivational messaging|Digital mental health intervention with automated motivational messaging
41124602|NCT00000119|DEVICE|Heparin Surface-Modified Intraocular Lens|
41124603|NCT06409299|DRUG|Azithromycin 40 MG/ML|Maintenance Antibiotic treatment
40927583|NCT01781273|OTHER|Cranberry juice|100 mL cranberry juice is provided in a 250 ml container.
40927584|NCT03443947|DEVICE|Tongue depressor group|using a tongue depressor to assess airway score without tongue protrusion
40927585|NCT03443947|PROCEDURE|control group|airway assessment after tongue protrusion
40927586|NCT02254239|DRUG|Brentuximab Vedotin|Given IV
41275924|NCT06468579|DRUG|GT20029 matching placebo|Stage 1: GT20029 gel matching placebo single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution matching placebo multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
40927587|NCT02254239|DRUG|Everolimus|Given PO
40927588|NCT02254239|OTHER|Laboratory Biomarker Analysis|Correlative studies
40927589|NCT02254239|OTHER|Pharmacological Study|Correlative studies
40927590|NCT04095637|DEVICE|Medial knee arthroplasty|Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
40927591|NCT03769584|OTHER|Follow-up questionnaire|Online- Questionnaire investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
41446735|NCT01075282|DRUG|Insulin Glargine|
41446736|NCT01075282|DRUG|LY2189265|
40927592|NCT03769584|OTHER|Follow- up interview|Semi- structured Interview investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
40927593|NCT00712062|DRUG|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
40927594|NCT00913692|DRUG|Glutamine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
40927595|NCT00913692|DRUG|Glycine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
41124604|NCT06409299|OTHER|Placebo|Placebo
41124605|NCT06326931|DEVICE|thermal pulsation|Single, in-office bilateral treatment with Systane iLux thermal pulsation
41124606|NCT06326931|OTHER|warm compress|Twice daily, 10-minute at-home treatment with Bruder warm compress mask for 8 weeks
41275925|NCT04140487|DRUG|Azacitidine|Given IV
41275926|NCT04140487|DRUG|Gilteritinib|Given PO
41275927|NCT04140487|DRUG|Venetoclax|Given PO
41446737|NCT01075282|DRUG|Metformin|
41446738|NCT01075282|DRUG|Glimepiride|
41446739|NCT00052377|BIOLOGICAL|aldesleukin|Given SC
41446740|NCT00052377|BIOLOGICAL|recombinant interleukin-12|Given SC
41446741|NCT00052377|OTHER|laboratory biomarker analysis|Correlative studies
41446742|NCT04334863|DRUG|WP1066|"WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle."
40927596|NCT03032770|DEVICE|two-dimensional ultrasound and color Doppler|the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (\<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
41124607|NCT00557492|DRUG|Avastin (bevacizumab)|10 mg/kg, days 1, 15, 29 and 43
41124608|NCT00557492|DRUG|Gemzar (Gemcitabine)|On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
41124609|NCT00557492|RADIATION|external beam radiotherapy|3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
41275928|NCT05243017|GENETIC|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
41275929|NCT06656299|DEVICE|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block
41275930|NCT06656299|DRUG|Bupivacaine injection|5 ml local anesthetic for each trocar sides
41275931|NCT06656299|DRUG|paracetamol, tramadol, and ondansetron|"As standard multimodal analgesia, 20 min before the end of the surgery patients will receive 1 g of paracetamol, 1-2 mg/kg of tramadol, and 4 mg of ondansetron via intravenous infusion.~All patients will be recovered in the PACU, and after confirming an Aldrete score of \>9, a PCA (patient-controlled analgesia) device will be installed with morphine prepared at a dose appropriate for the patient's age. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. When patients have a Numerical Rating Scale (NRS) score is ≥ 4, 1 mg/kg iv tramadol will be administered as a rescue analgesic"
41275932|NCT06656468|DEVICE|Pacemaker and defibrillator|Leadless pacemaker implantation procedure performed accordng to usual clinical practice. The indication for pacemaker implantation will be based on current guidelines.
41275933|NCT04060615|PROCEDURE|percutaneous coronary intervention|PCI of the chronic total occlusion of the coronary artery
41446743|NCT03599193|DRUG|Tazarotene Lotion, 0.1%|DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off
41446744|NCT03599193|DRUG|Tazarotene Cream, 0.1%|Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours
41446745|NCT06555406|BEHAVIORAL|Time-restricted eating for 8 weeks|limiting food intake to 10 hours per day
41446746|NCT03145623|DRUG|Elbasvir and Grazoprevir|Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program
41275934|NCT01295333|DRUG|the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation|
41446747|NCT05387109|DRUG|penpulimab combined with anlotinib|penpulimab: fixed dose of 200 mg, administered on the first day of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14, orally once a day, about half an hour before breakfast (the daily dose should be as much as possible), taken with warm water, and repeated every 3 weeks
41275935|NCT01295333|DRUG|The initiation of LT4 as soon as the first biological signs of hypothyroidism.|
41446748|NCT03876054|DEVICE|Spinal cord stimulation (SCS)|Subjects will be implanted with market-released Abbott SCS systems
41446749|NCT03876054|DEVICE|Dorsal root ganglion stimulation (DRG)|Subjects will be implanted with market-released Abbott DRG system
41275936|NCT03459040|DRUG|Alpha 1-Antitrypsin|AAT will be given either in the hospital or the outpatient clinic two times per week.
41275937|NCT00469937|DRUG|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
41275938|NCT00469937|PROCEDURE|cognitive assessment|cognitive assessment
41275939|NCT00469937|PROCEDURE|quality-of-life assessment|quality-of-life assessment
41446750|NCT05412576|DRUG|Lidocaine Hydrochloride 2% Injection Solution|Injectable
41446751|NCT05412576|DRUG|0.9% NaCl|Injectable
41446752|NCT04178122|GENETIC|Result disclosure|Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.
41446753|NCT00540423|DRUG|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
41446754|NCT00540423|DRUG|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
41124610|NCT04805216|PROCEDURE|Blood test|"Participants will have blood tests at baseline (nearest 30 day incremental time point after 2nd dose of Covid-19 vaccine, +/- 7 days):~* T, B \& NK cells~* Full Blood Count and differential~* Serum Immunoglobulins~* Antibodies against VZV, CMV, Rubella~* Quantiferon assay (T-Cell response)~* Covid antibody assay (LIAISON® SARS-CoV-2 S1/S2 IgG quantitative assay)~Participants will have blood tests during follow up (after second dose of Covid-19 vaccine) with a window of +/- 7 days:~* Blood test 2 - performed at the next 30 day time point (Covid antibody assay)~* Blood test 3 - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~* Blood test 4 (optional) - performed at the next 30 day time point (Covid antibody assay)~* Blood test 5 (optional) - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~  * Quantiferon assay will be only be performed where possible."
41124611|NCT00164216|DRUG|mefloquine plus artesunate|
41124612|NCT05736185|DEVICE|PEEP selection|Electric impedance tomography-guided PEEP titration
41124613|NCT03664960|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
41124614|NCT03951805|DRUG|Insulin icodec|Administered subcutaneously SC once weekly. Starting dose will be 70U.
41124615|NCT03951805|DRUG|Insulin Glargine|Administered subcutaneously SC once daily.The starting dose will be 10U.
41124616|NCT03807661|PROCEDURE|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
41124617|NCT03807661|DEVICE|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
41124618|NCT03000595|DRUG|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
41124619|NCT03000595|DRUG|Placebo|The vehicle cream
41124620|NCT02966275|DEVICE|Glucagon-only bionic pancreas - glucagon|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
41124621|NCT02966275|DEVICE|Glucagon-only bionic pancreas - placebo|A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
41124622|NCT01404585|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 12 weeks
41124623|NCT01404585|DRUG|BMS-817399|Tablets, Oral, 200 mg, twice daily, 12 weeks
41124624|NCT01404585|DRUG|BMS-817399|Tablets, Oral, 400mg, twice daily, 12 weeks
41124625|NCT02379819|DEVICE|Nucleus Hybrid L24 Implant|
41124626|NCT01003834|BEHAVIORAL|Computerized brief intervention|Intervention based on Motivational Interviewing technique
41124627|NCT01003834|BEHAVIORAL|Computerized health screening|Behavioral intervention
41124628|NCT01003834|BEHAVIORAL|Computerized assessment|Behavioral intervention
41124629|NCT01003834|BEHAVIORAL|Therapist-delivered motivational intervention|Behavioral intervention
41124630|NCT00258297|DRUG|gefitinib|
41124631|NCT00258297|PROCEDURE|conventional surgery|
41124632|NCT00258297|PROCEDURE|enzyme inhibitor therapy|
41124633|NCT00258297|PROCEDURE|neoadjuvant therapy|
41124634|NCT00258297|PROCEDURE|protein tyrosine kinase inhibitor therapy|
41124635|NCT00258297|PROCEDURE|surgery|
41124636|NCT00677469|DRUG|Cholestyramine|2 grams BID
41124637|NCT00677469|DRUG|Cholestyramine|1 gram BID
41124638|NCT00677469|DRUG|Placebo powder|1 gram BID
41446755|NCT00540423|DRUG|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
41446756|NCT00540423|DRUG|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
41446757|NCT03797703|DRUG|Lidocaine Hydrochloride 2% gel enema|Insertion of Lidocaine Hydrochloride 2% gel enema rectally immediately following the procedure.
41446758|NCT06626620|DRUG|Magnesium Sulphate infusion|Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes
41446759|NCT06626620|DRUG|Terbutaline Infusion|Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours
41446760|NCT05479058|DRUG|Filgotinib|Administered orally once daily
41446761|NCT05479058|DRUG|Placebo|Administered orally once daily
41446762|NCT06068855|DRUG|BOTOX|Intramuscular Injections
41446763|NCT06068855|DRUG|Placebo|Intramuscular Injections
41446764|NCT04857138|DRUG|RO7300490|Participants will receive RO7300490, as described in the Arm Descriptions.
41446765|NCT04857138|DRUG|Atezolizumab|Participants will receive Atezolizumab, as described in the Arm Descriptions.
41446766|NCT03049215|DEVICE|Lumen Apposing Metal Stent (LAMS)|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst.
40927597|NCT06274138|BEHAVIORAL|haptonomy|Pregnant women in the intervention group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. Information will be given that Haptonomy will consist of five sessions. Haptonomy will be applied by the researcher together with the partner. Each session will last for 40 minutes. The effectiveness and continuity of sessions will be planned between 3 to 7 days. One week after completing the five sessions of haptonomy, pregnant women will again complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
40927598|NCT05038345|PROCEDURE|Pull through surgery|The principal purpose of pull through surgery for Hirschsprung disease is to remove aganglionic bowel and reconstruct the intestinal tract by connecting the normally innervated bowel just above the anus so that normal sphincter function is preserved.
40927599|NCT00880464|BIOLOGICAL|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
40927600|NCT04168632|OTHER|OPTIMAT|The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
40927601|NCT02523469|BIOLOGICAL|ALT-803|
40927602|NCT02523469|BIOLOGICAL|Nivolumab|
40927603|NCT04738305|OTHER|Dignity Therapy|"The Italian version Dignity Therapy intervention (Chochinov HM 2015) has been delivered. Intervention questions were not previously delivered to patients.~DT interview was provided to patients by Specifically trained Nurses. Interviews were audio-recorded and transcribed then revised by the patients to develop the final Generativity Document. Generativity Document was delivered to patients that could share it with their loved ones."
40927604|NCT06132581|DEVICE|Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
40927605|NCT06132581|DEVICE|Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.
41124639|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Group meeting|One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement
41124640|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Individual meetings|Individual meetings focusing on adherence issues with a multidiscilinary team
41446767|NCT03049215|DEVICE|LAMS plus double pigtail stent|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst. The double pigtail stent is a routinely used plastic biliary stent.
41446768|NCT01488435|DIETARY_SUPPLEMENT|Cow's milk|Powdered whole cow's milk
40927606|NCT06132581|DEVICE|Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.
40927607|NCT00991952|DRUG|alvocidib|Given IV
41124641|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Monthly phone calls|Monthly phone calls to detect urgent adherence-related issues
40927608|NCT00991952|DRUG|irinotecan hydrochloride|Given IV
40927609|NCT00991952|OTHER|laboratory biomarker analysis|Correlative studies
41124642|NCT01461759|DRUG|Doctaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
41124643|NCT01461759|DRUG|Cisplatin|Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
41124644|NCT00229658|DRUG|pramlintide acetate|Subcutaneous injection prior to each major meal
41446769|NCT01488435|DIETARY_SUPPLEMENT|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
40927610|NCT04677478|OTHER|Impact of respiratory isolation on quality of life|Semi-structured interviews
40927611|NCT02447705|DRUG|telbivudine|telbivudine replace Lamivudine
40927612|NCT05765773|BIOLOGICAL|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
41124645|NCT00550823|DEVICE|Cardiac CT 0BRILLIANT 64|Cardiac CT
41124646|NCT03610789|DEVICE|REDAPT|REDAPT Monolithic Sleeveless Stems and Acetabular Cup Components
41124647|NCT00586313|DEVICE|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
41124648|NCT00586313|PROCEDURE|Tru-cut|Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
41124649|NCT06058767|DIAGNOSTIC_TEST|Otoacoustic Emissions Testing|An OAE (Otoacoustic Emissions) test is a non-invasive, quick, and commonly used hearing screening method. It is a non-behavioral test to access the function of the cochlea, which is the inner ear's sensory organ responsible for detecting sound.
41124650|NCT06058767|DIAGNOSTIC_TEST|Pure Tone Audiometry|The PTA testing is a hearing screening method used to assess an individual's ability to hear pure tones at different frequencies and at different sound levels. It is a behavioral test in which a child is conditioned to perform a play-based task upon hearing sounds at multiple frequencies.
41446770|NCT03170219|COMBINATION_PRODUCT|subcutaneous furosemide and sc2wear device|subcutaneous furosemide administered via sc2wear device vs. standard of care
41446771|NCT04722198|DIETARY_SUPPLEMENT|PS128|daily ingestion 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
41275940|NCT00469937|RADIATION|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
41275941|NCT06116305|OTHER|No intervention|No intervention
41446772|NCT00881634|DRUG|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
41446773|NCT00881634|DRUG|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
41446774|NCT04342663|DRUG|Fluvoxamine|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.
40927613|NCT04641520|OTHER|Shoulder clinical testing with isokinetic strength assessment|All the participants had a shoulder clinical testing including shoulder rotators range of motion and isokinetic rotator muscle strength testing
40927614|NCT03725423|DRUG|Apatinib|250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
41446775|NCT04342663|DRUG|Placebo|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
41446776|NCT00849797|DRUG|Oxcarbazepine|600 mg Tablet
41446777|NCT00849797|DRUG|Trileptal®|600 mg Tablet
41446778|NCT06118697|PROCEDURE|Esophageal stimulation with high resolution esophageal manometry and nutritive oral feeding therapy|Subjects will be given weekly pharyngo-esophageal stimulation guided by high resolution impedance manometry for 4 weeks. During this time of study intervention, every feed will start with nutritive oral stimulation with at least 5 mL of the infant's prescribed diet.
41446779|NCT06287281|OTHER|heel hight shoes|stand upright for 2 hours wearing your own shoes with heels at least 7 cm high
41446780|NCT05341453|PROCEDURE|Individual physiotherapy (SMA-SOC)|Therapeutic procedures according to the recommended standard (SMA-SOC) will be used in the therapy. Elements of breathing gymnastics, vibration techniques, stretching, eccentric and concentric exercise procedures will be combined. Individual physiotherapy will be conducted on the basis of set goals from the kinesiological examination, it will be adapted to the individuality of the child - his cooperation, fatigue and sleep time.
41446781|NCT05341453|PROCEDURE|Hippotherapy|"HT by CP is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators anticipate it´s effect for children with SMA.~Based on a special type of examination, this method precisely determines the type / breed of the horse according to the biomechanics of the movement of its back in the step, the position of the child and the neurophysiological function of the back - differentiation or sensorimotor skills. Furthermore, according to the course of therapy, the physiotherapist determines the pace of the horse's step, its length, selects special manual contacts according to the current situation and adjusts the duration of therapy to the client's fatigue.~Therapy will be performed by therapists with professional competence to perform hippotherapy by children with CP."
41446782|NCT05341453|PROCEDURE|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA. The purpose of this activity is to clean the horse, its possible guide, stroking and contact with the horse, work from the ground.
41446783|NCT06040086|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.
41446784|NCT06040086|DRUG|Tozorakimab|Administered subcutaneously tozorakimab and placebo throughout the study.
41446785|NCT04272216|DEVICE|Treatment with HydroPearl via radial access|This is an observational study collecting data on patients who are already being treated with HydroPearl on-label per standard of care.
41446786|NCT01830335|DRUG|Indomethacin|
41446787|NCT01830335|DRUG|Placebo|
41446788|NCT01515891|DRUG|BIA 9-1067|90 µCi (3.33 MBq) \[14C\]-labeled of 100 mg BIA 9-1067 (single-dose).
41124651|NCT05401513|OTHER|Pilates Group|The individuals of the Pilates group will perform specific exercises of the method, which will involve mobility, stability and muscular resistance. The exercises will progress according to the level of difficulty (basic, intermediate and advanced), load and repetition every three or four weeks.
41275942|NCT01175369|BEHAVIORAL|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
41446789|NCT01050556|OTHER|Placebo|daily, 24 weeks
41275943|NCT00994188|PROCEDURE|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
41275944|NCT01306981|DRUG|Ranibizumab|Intravitreal injection of ranibizumab, 0.5mg in 0.05ml
41275945|NCT01306981|DRUG|Saline|Subconjunctival injection of 0.05ml saline 0.9% w/v
41446790|NCT01050556|DIETARY_SUPPLEMENT|folic acid|400 ug/d for 12 or 24 weeks
41446791|NCT01050556|DIETARY_SUPPLEMENT|folic acid|800 µg/d for 12 or 24 weeks
41446792|NCT01050556|DIETARY_SUPPLEMENT|creatine|3 mg/d for 12 weeks
41446793|NCT01050556|DIETARY_SUPPLEMENT|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
41275946|NCT02974244|DRUG|exenatide once weekly|exenatide treatment in the customary clinical care in the USA
41275947|NCT02974244|DRUG|basal insulin|basal insulin treatment in the customary clinical care in USA
41275948|NCT06227130|BEHAVIORAL|MindYou|A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work.
41275949|NCT04253132|DRUG|Tolfenamic Acid|Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.
41275950|NCT04253132|DRUG|Placebos|oral placebo
41124652|NCT04784026|OTHER|Gait assessment (single)|The single walk will be evaluated with a 10-meter walking test and a G-Walk portable device.
41124653|NCT04784026|OTHER|Dual task gait assessment (motor+motor)|The dual task gait, 10-meter walking test and a motor (carrying a full water glass) will be combined with the task and evaluated with the G-Walk portable device.
41275951|NCT02603523|BEHAVIORAL|Senior Dance|The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
41275952|NCT02687269|DRUG|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
41275953|NCT02687269|DRUG|Placebo|Patients receive Placebo twice daily in the three days before surgery
41275954|NCT00550498|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
41275955|NCT06380140|PROCEDURE|Open Tension-free Inguinal Hernia Repair|A blood sample is taken the day after surgery
41446794|NCT03135236|BEHAVIORAL|Parent training|Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
41446795|NCT02102815|DRUG|Dexamethasone|Dexamethasone 0.15mg/kg mixed with NSS up to 50 mL IV slowly push over 5 minutes
41446796|NCT02102815|DRUG|Normal saline|NSS 50 mL IV slowly push over 5 minutes
40927615|NCT04097782|BEHAVIORAL|Antenat education|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
40927616|NCT00469170|DEVICE|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
40927617|NCT04140227|DRUG|NOV03|100% Perfluorohexyloctane
40927618|NCT02398279|DIETARY_SUPPLEMENT|L-Arginine|Experimental supplement
40927619|NCT02398279|OTHER|Placebo|Placebo capsules in the same color and shape with the experimental supplement
41124654|NCT04784026|OTHER|Dual tak gait assessment (motor+cognitive)|The dual task gait will be combined with a 10-meter walking test and a cognitive (1-back test) task and evaluated with the G-Walk portable device.
41124655|NCT02253459|DRUG|UTD1 Injection plus capecitabine|
41124656|NCT02253459|DRUG|Capecitabine|
41124657|NCT05957016|PROCEDURE|CIETAI-R|"1. phase I: (1) Chemo-Immulo-embolization via Tumor Arterial, CIETAI: DSA guided tumor artery infusion of oxaliplatin 130 mg/m2+PD-1 inhibitor (Tirelizumab) 200mg, followed by gelatin sponge particles (350-560um) embolization~2. phase II: Chemoradiotherapy: IMRT：45Gy/25f/5w+capecitabine 1000，po. Bid d1-14, q3w Tirelizumab)200mg ivggt, d1, q3w"
41124658|NCT00504023|DRUG|imiquimod|The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
41124659|NCT00504023|PROCEDURE|biopsy|Punch biopsy and photography will be performed at the baseline and 12 week time points.
41124660|NCT00504023|PROCEDURE|therapeutic conventional surgery|If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
41124661|NCT04433975|BEHAVIORAL|Psychosocial Pain Management (PPMI)|The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
41124662|NCT04433975|BEHAVIORAL|Enhanced Usual Care (EUC)|The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
41124663|NCT04810767|OTHER|Questionnaire|Pain experienced assessed by questionnaire described by Nikolajsen et al, 2004
41124664|NCT03749785|OTHER|Regular carbohydrate feeding|60 ml of water with 5 g sucrose given every 5 minutes 14 times up until 70 minutes followed by 5 g sucrose after 75 minutes in a 250 ml solution
41124665|NCT03749785|OTHER|Single carbohydrate bolus|60 ml of water given every 5 minutes 14 times up until 70 minutes followed by 75 g sucrose after 75 minutes in a 250 ml solution
41124666|NCT00479700|DRUG|SAM-531|
41124667|NCT04124120|PROCEDURE|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
40927620|NCT02100709|DEVICE|BiLevel Noninvasive Ventilation|Positive pressure applied through an oro-nasal mask. The pressure is altered between inspiration and expiration.
40927621|NCT04122456|RADIATION|Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.
40927622|NCT04122456|OTHER|No Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.
40927623|NCT05869357|OTHER|cream containing 2.5% sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
40927624|NCT05869357|OTHER|cream containing 5%sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
40927625|NCT05869357|OTHER|cream containing 10%sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
40927626|NCT05869357|OTHER|cream base|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
40927627|NCT01336361|OTHER|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
40927628|NCT03751254|DEVICE|Stellaris Elite|The Stellaris and the Stellaris Elite platform will be used in myopic patients (axial length \> 25.0 mm) during cataract surgery
40927629|NCT02522871|DEVICE|OCS™ Liver System|
40927630|NCT02522871|OTHER|Control|
40927631|NCT00344890|PROCEDURE|Anterior Cervical Discectomy and Fusion|1,2,3,or 4 level surgery
40927632|NCT04079673|PROCEDURE|Patient controlled epidural analgesia|Patient controlled epidural analgesia with marcaine 0.66mg/ml +fentanyl 1.75mcg/ml for postoperative pain control
40927633|NCT04079673|DRUG|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine 1mg/ml for postoperative pain control
40927634|NCT02475824|DRUG|Midazolam®|midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
41275956|NCT01175928|DEVICE|Sham device|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
41275957|NCT01175928|DEVICE|NormaTec PCD (Peristaltic Pulse PCD)|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
41275958|NCT04224363|PROCEDURE|staining from cervical esophagus to esophagogastric junction|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
40927635|NCT02475824|DRUG|"Meperidine (pethidine®)"|Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
41446797|NCT03746795|DEVICE|Spirometric examinations realized using the EIT|Spirometric examinations will be realized using the EIT alone.
41124668|NCT04124120|PROCEDURE|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
41124669|NCT03282526|DIAGNOSTIC_TEST|Whole body plethysmography|Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
41124670|NCT02538341|BIOLOGICAL|Herpes Zoster (HZ) Vaccine|
40927636|NCT02475824|DRUG|Propofol®|Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
40927637|NCT02475824|DRUG|Dexmedetomidine (Precedex®)|Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
40927638|NCT04645121|DEVICE|Carbon Monoxide-based Rebreathing|6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.
41124671|NCT02538341|DRUG|Placebo|
41124672|NCT01819571|DRUG|Fluid loading (Voluven)|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
41124673|NCT05090631|GENETIC|DNA analysis|GWAS
41275959|NCT04224363|PROCEDURE|staining from esophagogastric junction to cervical esophagus|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
41275960|NCT01880450|BEHAVIORAL|Project Prepared|Behavioral intervention to reduce sexual risk and promote healthy relationships
41446798|NCT03746795|DEVICE|Simultaneous measurement by spirometer and EIT|Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
41446799|NCT04411576|DIAGNOSTIC_TEST|Throat swab sample for measuring current infection with SARS-CoV-2|Throat sample taken by the study participant to be analyzed with RT PCR for the presence of SARS-CoV-2 viral nucleic acids.
41446800|NCT04411576|DIAGNOSTIC_TEST|Blood sample for serology to measure past infection with SARS-CoV-2|Blood samples for serology to be analyzed for the presence of SARS-CoV-2 antibodies.
41446801|NCT06562062|PROCEDURE|Extra-articular Lateral Column Lengthening Procedure|Lateral column lengthening (LCL), originally described by Evans, is an established procedure to correct stage II adult acquired flatfoot deformity (AAFD). However, the relative position between the facets is violated, and other problems may include nonunion, malunion, and calcaneocuboid (CC) joint subluxation. Herein, we report a modified extra-articular technique of LCL with hockey-stick osteotomy, which preserves the subtalar joint as a whole, increases bony apposition to enhance healing ability, and preserves the insertion of the calcaneofibular ligament to stabilize the posterior fragment to promote adduction of the forefoot
41446802|NCT02552758|BIOLOGICAL|omega-3 fatty acid|omega-3 fatty acid
40927639|NCT04645121|DEVICE|Bioimpedance|Measures total volume, intra and extracellular volume.
40927640|NCT04645121|RADIATION|Radioactive labelling of erythrocytes and albumin|Measure blood volume, plasma volume and erythrocyte volume.
41275961|NCT01880450|BEHAVIORAL|TEEN|Control condition the promote communication, decision-making skills etc.
41275962|NCT04108507|PROCEDURE|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
41275963|NCT06432777|OTHER|Characteristics of patients and Campylobacter bacteraemia episodes|Variables: characteristics of the patients (demographic characteristics; characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count etc.; chronic inflammatory bowel disease \[IBD\]), the bacteria (species, antimicrobial susceptibility) and the infection (clinical presentation, evolution, treatment received)
41275964|NCT03943329|PROCEDURE|Standard of Care|"Will receive the standard of care free-hand technique of distal screw placement, as treated by Dr. Egol or Dr. Tejwani."
41446803|NCT02552758|BIOLOGICAL|placebo|placebo
41446804|NCT02552758|DEVICE|positron emission tomography (PET)|
41446805|NCT06562842|OTHER|Regular exercise|Participants will perform regular exercise training for 12 weeks, followed by 4 weeks of detraining.
41124674|NCT02831816|DRUG|ZuraPrep|Apply topically.
41124675|NCT02831816|DRUG|ChloraPrep|Apply topically.
41275965|NCT03943329|PROCEDURE|Distal targeting device technique of distal screw placement|The second group will be the interventional group which will use the distal targeting device technique of distal screw placement and will be treated by Dr. Konda and Dr. Leucht. All relevant data to the study will be collected intra-operatively.
41275966|NCT01931514|DRUG|Torrent's Montelukast Sodium chewable Tablets 5mg|
41275967|NCT01931514|DRUG|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
41275968|NCT03097887|PROCEDURE|Omega Loop Gastric Bypass|Bariatric/metabolic surgical procedure
41275969|NCT03097887|DEVICE|Bilitec 2000™|The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.
41275970|NCT03097887|DEVICE|V-Loc|Sewing device to perform the anti-reflux sutures.
41275971|NCT05237388|DRUG|Baricitinib|One pill daily
41275972|NCT05237388|DRUG|Placebo|Baricitinib placebo pill
41275973|NCT06193473|BEHAVIORAL|Intervention Group: Group to which the clinical pharmacist makes recommendations|The drugs administered to patients within 24-48 hours after hospitalization were recorded. A detailed medication review will be conducted by the clinical pharmacist during the participants' hospitalization.As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
41275974|NCT01495871|DIETARY_SUPPLEMENT|Amino Acids|15 grams amino acids two times per day for 6 weeks
41275975|NCT01495871|DIETARY_SUPPLEMENT|Placebo of inert compounds|Placebo two times per day for 6 weeks
41275976|NCT01495871|DIETARY_SUPPLEMENT|Valine|2.5 grams valine supplementation two times a day for 6 weeks
41275977|NCT00576771|PROCEDURE|PSV|Pressure Support Ventilation
41275978|NCT00576771|PROCEDURE|NAVA|Neurally Adjusted Ventilatory Assist
41446806|NCT06562842|OTHER|Control comparator|Participants will remain sedentary throughout the 16-weeks intervention period.
41446807|NCT03410784|DRUG|Pembrolizumab|Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles
41446808|NCT03410784|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles
41446809|NCT03410784|DRUG|Carboplatin|Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles
41446810|NCT04503603|DRUG|Lanadelumab|Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.
41124676|NCT02831816|DRUG|ZP Vehicle|Apply topically.
41275979|NCT00576771|PROCEDURE|patient-controlled|assisted controlled MV through a button
41275980|NCT05043584|DEVICE|Fluobeam LX, Fluoptics, Grenoble, France|See arm description
41446811|NCT04503603|OTHER|Placebo|Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.
41446812|NCT01053585|DRUG|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
41124677|NCT04423796|DEVICE|Robotic-assisted early mobilization|The early mobilization is done by robotic assistance devices.
41124678|NCT04423796|OTHER|Early mobilization|Early mobilization by health care professionals without robotic assistance.
41124679|NCT05127681|RADIATION|HR-pQCT|Patients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture
41124680|NCT05127681|BIOLOGICAL|Blood sample|Patients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels
41124681|NCT05127681|RADIATION|Dual energy X-ray absorptiometry|A dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.
41124682|NCT05127681|OTHER|medical data collection|Data of healthy men is already available
41124683|NCT00439413|DRUG|Selegiline Transdermal Patch|Selegiline cm(2) via transdermal system
41124684|NCT00439413|DRUG|Placebo|Matching placebo via transdermal system
41124685|NCT00439413|BEHAVIORAL|Smoking Cessation Counseling|Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
41124686|NCT00002156|DRUG|Fomivirsen sodium|
41124687|NCT00002156|DRUG|Ganciclovir|
41275981|NCT00162773|DRUG|omalizumab|150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
41275982|NCT00162773|OTHER|Placebo|150-375 milligrams depending on body weight and serum IgE.
41275983|NCT02241473|OTHER|Training|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
41275984|NCT03652909|DEVICE|Ascending Hearing Technologies device|Personal Sound Amplification Device
41275985|NCT02071940|DRUG|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
41275986|NCT00393562|DRUG|modafinil|
41275987|NCT00393562|DRUG|methylphenidate|
41446813|NCT01053585|DRUG|Placebo|Placebo single 'dose' 90 minutes prior to study
41446814|NCT06219941|DRUG|AZD0901|Antibody-drug conjugate/Biologic
41446815|NCT06219941|DRUG|5-Fluorouracil|Chemotherapy agents
41446816|NCT06219941|DRUG|Leucovorin|Chemotherapy agents
41446817|NCT06219941|DRUG|l-leucovorin|Chemotherapy agents
41446818|NCT06219941|DRUG|Irinotecan|Chemotherapy agents
41446819|NCT06219941|DRUG|Nanoliposomal Irinotecan|Chemotherapy agents
41446820|NCT06219941|DRUG|Gemcitabine|Chemotherapy agents
41446821|NCT01131637|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
41446822|NCT01131637|DRUG|placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
41446823|NCT06118255|DRUG|fenfluramine|The study drug, fenfluramine HCl, is an oral solution to be administered in equal doses twice daily (BID). It will be based on the current dose and participant's weight (kg).
41124688|NCT03671252|DRUG|FOLFOXIRI|Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
41124689|NCT03671252|DRUG|XELOX|XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
41124690|NCT03671252|OTHER|Chemoradiotherapy|"Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks."
41275988|NCT02835495|BEHAVIORAL|HELP Vets Intervention|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
41275989|NCT02835495|BEHAVIORAL|Individual Education Program|Participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the nutritionist will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle.
41275990|NCT05999305|OTHER|Teaching the critical care nursing course with an Escape Room game|A teacher will begin with a 1.5-hour lecture, followed by an escape room game to reinforce learning through case studies for another 1.5 hours. The first section of the game will be a ten-minute pre-brief. The game will then begin promptly at a designated time and will be played in groups of six to seven students, with each group seated separately in a classroom. The game will last up to fifty minutes, during which all groups will be assisted to complete puzzles within the time limit. After the game, a fifteen-minute debriefing session will be held by the teacher, during which the students will reflect on their performance and what they learned about the cases and related topics. The teacher will finally provide feedback and support to the groups during this session.
41275991|NCT05999305|OTHER|Teaching the critical care nursing course with a case-based learning|Students in the comparison group will also receive a 1.5 hour lecture which is the same as those in the intervention group. Another 1.5 hour is a case-based learning session, with six sessions in total over six weeks. The case-based learning sessions will include a pre-brief, teamwork, and debrief, and will be facilitated by the same teacher and teaching assistant and will primarily be provided with paper-based case studies.
41275992|NCT03467230|DEVICE|NoL Index|Use of the PMD-200 in an observational study
41275993|NCT03185676|OTHER|Bilberry|A bilberry based probiotic beverage
41275994|NCT03185676|OTHER|beverage without bilberries or probiotics|A control beverage without bilberries or probiotics
41275995|NCT01097902|DRUG|Ibuprofen|800 mg oral one time only
41275996|NCT01097902|DRUG|Placebo tablet|Placebo tablet oral one time only
41275997|NCT03251547|DRUG|NovoSeven|To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding
41275998|NCT00300027|DRUG|BMS-582664|
41275999|NCT04472689|DRUG|Lidocaine|patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
41276000|NCT04472689|DRUG|Normal saline|patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation
41276001|NCT03333577|DEVICE|SoundArc|non-surgical attachment method for wearing a bone conduction hearing system
41276002|NCT01747902|PROCEDURE|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
41276003|NCT01747902|PROCEDURE|Biceps Tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
41276004|NCT00269009|BEHAVIORAL|CHERL|
41276005|NCT02704962|DRUG|full-dose olanzapine|trifluoperazine 5mg/d
41276006|NCT02347293|OTHER|High levels of indigestible carbohydrates|
41276007|NCT02347293|OTHER|Low levels of indigestible carbohydrates|
41276008|NCT04900402|OTHER|Survey|International Physical Activity Questionnaire Short Form (IPAQ) and Quality of Life Scale for Children (PedsQL)
41276009|NCT06274593|DEVICE|OCT|Peripapillary angiography (OCT) at baseline and each year during 3 year
41276010|NCT05377632|PROCEDURE|Robotic-assisted laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN)|laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN) include bilateral tumors or tumors in a solitary kidney. Relative indications include familial renal cancer syndromes such as Von Hippel-Lindau, hereditary leiomyomatosis, or hereditary papillary renal cell carcinoma. Patients with chronic kidney disease are generally offered nephron sparing surgery for hope of future renal function preservation. This reasoning also applies to those patients with preexisting diseases that may threaten a solitary kidney such as uncontrolled diabetes and hypertension.
41276011|NCT02983084|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed appliance
41276012|NCT03739970|DIETARY_SUPPLEMENT|Investigational Product (Silk Peptide)|"* Ingredient: Silk Peptide~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 9g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
41124691|NCT03671252|PROCEDURE|TME operation|TME operation
41124692|NCT03671252|PROCEDURE|efficacy evaluation|chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
40927641|NCT04268849|DRUG|Ferumoxytol|Ferumoxytol (30 mg/mL) intravenous injection in single use vials.
41124693|NCT06257680|BIOLOGICAL|ReT01 ACT|Patients were infused with ReT01 ACT injection after pretreatment, and subjects were closely observed for 24 hours after each infusion.
41446824|NCT03294460|DRUG|Alcohol (Oral)|Oral Self-administration
41124694|NCT04303325|DRUG|Esketamine|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine 0.2mg/kg.
41124695|NCT04303325|DRUG|Saline Solution|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
41276013|NCT03739970|DIETARY_SUPPLEMENT|Control Group - Placebo Product|"* Ingredient: Microcrystalline Cellulose~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 0g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
41276014|NCT00932997|BEHAVIORAL|telephone-based intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
41276015|NCT00932997|OTHER|counseling intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
41276016|NCT00932997|OTHER|educational intervention|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
41276017|NCT00932997|OTHER|questionnaire administration|Baseline and 9 months after enrollment and intervention
41276018|NCT00932997|PROCEDURE|psychosocial assessment and care|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
41446825|NCT03294460|DRUG|Alcohol (IV)|IV Self-administration
40927642|NCT04268849|DRUG|Saline|Placebo for Ferumoxytol
40927643|NCT04268849|DRUG|Ferrous sulfate tablets|ferrous sulfate tablets containing 60 mg elemental iron
40927644|NCT04268849|DRUG|Vitamin C|Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
40927645|NCT06332638|DRUG|Tegoprazan 12.5mg|Oral administration of one tablet of Tegoprazan 12.5mg twice daily for 14 days.
40927646|NCT06332638|DRUG|Tegoprazan 25mg|Oral administration of one tablet of Tegoprazan 25mg once daily for 14 days.
40927647|NCT06332638|DRUG|Famotidine 20mg|Oral administration of one tablet of Famotidine 20mg twice daily for 14 days.
40927648|NCT03254576|OTHER|Functional MRI|
41124696|NCT00142285|DRUG|Zinc sulphate (20 mg)|
41124697|NCT02392234|DRUG|VX-661/Ivacaftor|Fixed dose combination tablet, oral use
41124698|NCT02392234|DRUG|Ivacaftor|Tablet, oral use
41124699|NCT02392234|DRUG|Placebo matched to VX-661/ ivacaftor|Fixed dose combination tablet, oral use
41124700|NCT02392234|DRUG|Placebo matched to Ivacaftor|Tablet, oral use
41124701|NCT05398861|DRUG|Utidelone Combined with Bevacizumab|Utidelone： 30 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle Bevacizumab：10mg/kg (IV), on day 1 of each 21 days.
41124702|NCT04857294|PROCEDURE|TMJ unilateral discectomy|All patients underwent general anesthesia with nasotracheal intubation, managed in most cases with intravenous anesthesia protocol, usually with remifentanil infusion. Intraoperative steroids, usually dexamethasone, were administered primarily to minimize postoperative swelling. A classic preauricular incision or a root of helix inter tragus notch incision (RHITNI) was used in most cases, as previously described. No bandage or special care was performed after the surgery. No air washing restrictions were recommended.
41276019|NCT00932997|PROCEDURE|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
41276020|NCT06229379|DEVICE|"Digital twin patient"|"Digital twin patient can serve as patients with specific diseases for medical students to acquire disease history and thus practice clinical questioning skills."
41276021|NCT06229379|BEHAVIORAL|Interaction with real patients|As in traditional medical education, medical students need to interact with real patients to practice history collection skills.
41276022|NCT01492673|DRUG|Cyclophosphamide, Topotecan, and Bevacizumab|The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
40927649|NCT05048550|DEVICE|Near vision spectacles|Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
40927650|NCT04686058|DRUG|Propofol 10 MG/ML Injection|
40927651|NCT04686058|DRUG|Midazolam injection|
40927652|NCT04686058|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection|
40927653|NCT04686058|DEVICE|target controlled infusion pump|
41446826|NCT03294460|DRUG|Alcohol (Ethanol)|IV and Oral Self-administration
41446827|NCT00224718|PROCEDURE|Endovascular repair (with endograft)|An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).
41276023|NCT06356740|BIOLOGICAL|Blood sample|"blood test to assess :~* human leukocyte antigen (HLA)-B\*5701 status to identify risk of allergy or hypersensitivity to abacavir (the study treatment)~* IFN-signature ans IFN-alpha dosage~* human immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus (HCV) serologies~* Human chorionic gonadotropin (βHCG)~* HERVs dosage A biological collection will also be created. The total volume of blood collected specifically for the research for the entire duration of the study is 62.5 millilitre (mL) maximum."
41446828|NCT00224718|PROCEDURE|Open repair|Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
41276024|NCT06356740|DRUG|Treatment :Abacavir 600 mg/lamivudine 300 mg|Patients randomised to the experimental arm will be required to take 1 tablet (600 mg lamivudine and 300 mg abacavir) once daily for 6 months in addition to their usual treatment.
41276025|NCT06356740|OTHER|Lupus Impact Tracker questionnaire|Patients will be asked to complete the Lupus Impact Tracker questionnaire at visit V1 (randomisation visit), visit 3 (at 6 months of treatment) and visit 4 (12 months after visit 1).
41276026|NCT04337957|OTHER|geriatric nephrology|Collection of the geriatrician's opinion
41446829|NCT03024086|DRUG|DWJ1252|DWJ1252 and Placebo of Gasmotin
41446830|NCT03024086|DRUG|Gasmotin|Gasmotin and Placebo of DWJ1252
41446831|NCT01318551|DRUG|BAY85-3934|single dose, 20 mg
41446832|NCT01318551|DRUG|BAY85-3934|single dose, 40 mg (optional)
40927654|NCT04686058|DEVICE|patient-controlled sedation pump|
40927655|NCT02744742|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
40927656|NCT02744742|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
40927657|NCT02744742|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
40927658|NCT02744742|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
41276027|NCT02729129|OTHER|Diesel exhaust exposure with filtered facemask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a filtered facemask.
40927659|NCT06257043|PROCEDURE|Transcatheter aortic valve replacement|A total of 3000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled at 30-50 centers. The devices used will be all post-market transcatheter aortic valves approved for use in China. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
40927660|NCT05818605|BEHAVIORAL|Moderate Intensity Exercise Program|Subjects randomized to the EXER arm will undergo 24 weeks of Moderate Intensity Exercise Training (MIET). Patients will be signed up for 60-minute exercise sessions, 3 times a week
40927661|NCT02872220|DRUG|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
41124703|NCT04423016|DEVICE|Near Infrared Spectroscopy monitoring|Non-invasive continuous monitoring of cerebral oxygenation
41124704|NCT04423016|DEVICE|Electrical velocimetry and pulse oximetry|Non-invasive continuous monitoring of cerebral oxygenation
41276028|NCT02729129|OTHER|Diesel exhaust exposure with sham mask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a sham facemask.
41276029|NCT01213056|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Cognitive Behavioral (Active treatment condition)
40927662|NCT02872220|DRUG|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
40927663|NCT02872220|DRUG|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
40927664|NCT02872220|DRUG|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
40927665|NCT04170478|DEVICE|Echolaser X4 system|Transperineal laser ablation
41124705|NCT05443737|BEHAVIORAL|Multi-component oncofertility care intervention|The multi-component oncofertility care intervention includes: (1) an adaptive and smart default electronic health record-based oncofertility needs screen and referral pathway, (2) telehealth oncofertility counseling as indicated, and (3) telehealth oncofertility financial navigation as indicated.
41276030|NCT02688413|DEVICE|MindMotionPRO|The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
40927666|NCT02951676|PROCEDURE|Extraction|Extraction of impacted third molar teeth
40927667|NCT03638843|PROCEDURE|Gastric mucosal devitalization|Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
40927668|NCT00573729|OTHER|Pulsed Dye Laser 577 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
40927669|NCT00573729|OTHER|Pulsed Dye Laser 595 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
41124706|NCT06518915|DEVICE|baroloop system|Participants will have the baroloop device implanted for selective stimulation of the vagus nerve.
41124707|NCT00804648|DRUG|Timolol Maleate in Sorbate|0.5%
41446833|NCT01318551|DRUG|BAY85-3934|single dose, 80 mg (optional)
41446834|NCT01538459|DRUG|Dexamethasone|8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.
41446835|NCT01538459|DRUG|Bupivacaine|Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
41446836|NCT06453915|DRUG|18F-DPA-714|positron emission tomography scan using 18F-DPA-714 as an imaging tracer.
41446837|NCT06453915|DRUG|18F-FDG|positron emission tomography scan using 18F-FDG as an imaging tracer.
41446838|NCT02702895|BEHAVIORAL|In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
41446839|NCT06280781|DIAGNOSTIC_TEST|MRI Scans|"The regular use of MRI in active surveillance will lead to greater confidence in active surveillance for patients with low and medium risk prostate cancer. This is because such a strategy is likely to detect cancer progression earlier with fewer invasive biopsies. Those patients randomised to the intervention arm will have additional MRI scans. These will be non-contrast so there is no risk from having repeated 1-2 yearly injections of gadolinium contrast. Patients with contraindications to MRI will not be taking part in the study so will not be exposed to an unnecessary MRI.~Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \>/=4."
40927670|NCT01436162|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
40927671|NCT01436162|DRUG|Antidepressant + Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
40927672|NCT00069888|DRUG|Docetaxel|
41446840|NCT03693014|RADIATION|Stereotactic Body Radiotherapy|(27 Gy over 3 fractions)
41446841|NCT03693014|BIOLOGICAL|Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab|The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder)
41446842|NCT06322264|DIAGNOSTIC_TEST|Measurement of variation in heart rate|The children will be given a portable device that will monitor their heart rate, enabling the recording of the rate of their pulse.
40927673|NCT02617485|DRUG|Rituximab|375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
40927674|NCT02617485|DRUG|Doxorubicin|50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
40927675|NCT02617485|DRUG|Vincristine|1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
40927676|NCT02617485|DRUG|Cyclophosphamide|750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
40927677|NCT02617485|DRUG|prednisone|100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
40927678|NCT00539760|DRUG|GSK1827771|GSK1827771 will be administered using injection via subcutaneous (SC) route.
41446843|NCT06237049|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)/RIV|Combination of BNT162b2 (Omi XBB.1.5) and RIV
41446844|NCT06237049|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)|Licensed COVID-19 vaccine
41446845|NCT06237049|BIOLOGICAL|RIV|Licensed recombinant influenza vaccine
41446846|NCT06237049|OTHER|Normal saline placebo|Normal saline (solution for injection)
41446847|NCT04728828|BIOLOGICAL|Serological COVID-19 vaccine immunogenicity|Serological test
41446848|NCT06619184|PROCEDURE|NCEHFORSCS transplantation|One vitiligo lesion of participans treated with NCEHFORSCS transplantation including follicle unit extraction (FUE) procedure from the occipital area, laboratory procedure for preparation of cell suspension, and transplantation of NCEHFORSCS.
40927679|NCT00539760|DRUG|Placebo|Placebo to GSK1827771 for Injection will be administered via SC route
40927680|NCT01063933|DRUG|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
41124708|NCT00804648|DRUG|Timolol hemihydrate|0.5%
41124709|NCT00804648|DRUG|Timolol maleate gel forming solution|0.5%
41124710|NCT04255979|DRUG|HY209|6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
41124711|NCT01773746|OTHER|Neonatal Resuscitation|CPAP or Positive Pressure Ventilation will be provided.
41276031|NCT02688413|OTHER|Self-Directed Prescribed Exercises|GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
41276032|NCT04287153|DEVICE|Cryotherapy on abdomen and saddlebags|Application of variable temperature (-10°c to -7°c) on the treated areas using the cryotherapy device FG660L-006 (Beijing ADSS Development CO., Ltd)
41276033|NCT00249379|DRUG|Acamprosate|Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence
41276034|NCT05292755|DRUG|Carboxymethylcellulose (CMC) Artificial Tears|A pack of 21 vials of artificial tears containing carboxymethylcellulose 0.5% will be given to subjects in the treatment group.
41276035|NCT05292755|DRUG|Preservative-free, CMC-free Artificial Tears (control)|A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
41276036|NCT06656208|OTHER|Pubic symphysis manipulation|Manipulation was applied in the crook lying position with 5 repetitions hold for 10 sec and ask the patient to apply max. Contraction in Abduction and then relax. Whereas, the therapist applies a rapid stretch to a new barrier and is held for 10 seconds.
41276037|NCT06656208|OTHER|Traditional sacroiliac treatment|Mobilization was applied in prone lying position on sacroiliac joint, 30 Oscillations per set for 15 seconds, 3 sets on effected side.
41276038|NCT05211895|DRUG|Durvalumab|Durvalumab IV (Intravenous infusion)
41276039|NCT05211895|DRUG|Domvanalimab|Domvanalimab IV (Intravenous infusion)
41276040|NCT05211895|OTHER|Placebo|Placebo IV (Intravenous infusion)
41276041|NCT06656741|BEHAVIORAL|Resting State|Resting state is a mental state and a research paradigm that people do nothing and idle as much as possible to show their baseline neuro signals. In this task, we instructed participants to rest with their eyes opened for 6 minutes. The VR environment of blue sky and swaying meadow was presented to the participants throughout this task.
41276042|NCT06656741|BEHAVIORAL|Mindful Breathing|Mindful breathing is a state that people focus on their inner sensation. In this task, the meadow's motion in the VR environment corresponded to the participants' inhalation and exhalation, as detected by the respiration belt. The participants were instructed to focus mentally on their bodily sensations as they breathed, with the meadow's sway as a visual cue.
41276043|NCT06656741|BEHAVIORAL|Guided Breathing|Guided breathing refers to the breath training technique that trainees are guided to inhale and exhale according to a fixed tempo. In this task, meadow swayed in a fixed tempo of 4 seconds back and 6 seconds forth. The participants were instructed to synchronize their inhalation with the meadow's backward motion (lasting 4 seconds) and their exhalation with its forward motion (lasting 6 seconds).
41276044|NCT06656741|BEHAVIORAL|Breath Counting|Breath counting refers to the breath training technique that trainees mentally count the numbers of breath cycles they have finished in a certain period of time. In this task, similar to the mindful breathing task, the meadow's motion was synchronized with the participants' breathing patterns. During the 6 minutes, we instructed the participants to breathe naturally and mentally count their breathing cycles.
41276045|NCT05677139|OTHER|None (Observational Study)|Not applicable since it's an observational study.
41276046|NCT06574633|BEHAVIORAL|In-person therapy|Participants will be referred to in-person therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
40947859|NCT06221670|DRUG|Toripalimab|This is a prospective, open, single-center, single-arm phase II clinical study with no driver mutations identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.
41276047|NCT06574633|BEHAVIORAL|Telehealth therapy|Participants will be referred to telehealth therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
41276048|NCT06504381|GENETIC|DB107-RRV|Given intracranially (IC) during resection and intravenously (IV) immediately following
40947860|NCT05384678|DRUG|N,N-Dimethyltryptamine (54 mg)|A dose rate of 0.6 mg/min will be administered
41124712|NCT01074788|BEHAVIORAL|mind body therapy|mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
41124713|NCT03902132|OTHER|Core Stability exercises group|Core Stability Exercises were given in addition to the traditional physical therapy treatment as given to the control group. It included moist heat pack (10mins), Transcutaneous Electrical Nerve Stimulation (10 min), and strengthening regimen (2 sets with 15 isometric repetitions each).
41124714|NCT03902132|OTHER|Traditional low back physical therapy group|The control group was given traditional low backache physical therapy management such as moist heat pack, TENS, and strengthening regimen (2 sets with 15 isometric repetitions each)
41124715|NCT02616900|DEVICE|eSight Eyewear|primary intervention
41124716|NCT00490100|DRUG|Increlex|
40947861|NCT05384678|DRUG|N,N-Dimethyltryptamine (108 mg)|A dose rate of 1.2 mg/min will be administered
40947862|NCT05384678|DRUG|N,N-Dimethyltryptamine (162 mg)|A dose rate of 1.8 mg/min will be administered
40947863|NCT05384678|DRUG|N,N-Dimethyltryptamine (216 mg)|A dose rate of 2.4 mg/min will be administered
41124717|NCT03697733|PROCEDURE|fractional curettage|Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
41124718|NCT02132559|DRUG|DHEA|
41124719|NCT04733833|DRUG|VB-201 + Standard of care|Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care
41124720|NCT04733833|DRUG|Standard of care|Standard of care
41276049|NCT06504381|GENETIC|DB107-FC|Given orally (PO)
41276050|NCT06504381|RADIATION|Radiation Therapy (RT)|Undergo RT
41276051|NCT06504381|DRUG|Temozolomide|Given PO
41276052|NCT06504381|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo standard of care MRI
41124721|NCT06298305|DEVICE|Quantib prostate (Quantib B.V. Rotterdam, The Netherlands) software|Quantib Prostate is an AI-driven solution that provides an intuitive workflow for assessment of prostate MRI. The product integrates essential prostate MRI reading features into one workflow making it easy for the user to read, assess and report each patient case from within the same software interface. With automatic forwarding in place, the software preprocesses the MRI right after scanning. This allows the user to access calculations and analysis immediately when they open the software interface. Thanks to these features, the professional may experience an accelerated workflow, making it easier to manage their heavier workload.
41276053|NCT06504381|PROCEDURE|Surgical resection|Undergo non-investigational tumor resection
41276054|NCT04918121|DRUG|Yutiq 0.18 MG Drug Implant|a sustained-release steroid insert (Yutiq)
41276055|NCT02694783|BIOLOGICAL|PyVST|ex vivo generated polyomavirus-specific T cells from HLA-matched donor
41276056|NCT05818683|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
41276057|NCT05818683|DRUG|Cetrelimab|Cetrelimab will be administered by intravenous infusion.
41124722|NCT03589625|OTHER|Solar Suitcase|"The intervention is a Solar Suitcase. The Solar Suitcase comes with: 2 LED lights, 1 battery, 1 aluminum glass 100 watt solar panel, 2 rechargeable LED headlamps, 1 universal cell phone charger, 1 USB adapter, 1 fetal Doppler, 1 AA/AAA battery charger and expansion box (provides 2 additional lights).~Installers will teach health workers how to use and maintain the Solar Suitcase on the day of installation. Within one week following installation, the contractor will contact the facility over the phone and/or in-person to check if there are any problems with the Suitcase. Additional checks will be made to ensure the solar suitcase is functioning and being used properly."
41124723|NCT03563690|OTHER|treatment1|"1. Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~2. operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes."
41124724|NCT03563690|OTHER|treatment2|"1. Acupoints：Needling points are the same to the above group~2. operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes."
41124725|NCT03563690|OTHER|treatment3|"1. Acupoints：treating points are the same to the above group~2. Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes."
41124726|NCT03563690|OTHER|treatment4|"1. Acupoints：Needling points are the same to the above group~2. Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes."
41124727|NCT03563690|OTHER|treatment5|"1. points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~2. Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 \* 25mm single-use needle with the depth of 1-2mm."
41124728|NCT03563690|DRUG|Celebrex|Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
41124729|NCT00421889|DRUG|belinostat|
41124730|NCT00421889|DRUG|Paclitaxel|
41124731|NCT00421889|DRUG|Carboplatin|
41124732|NCT03245424|DRUG|ivosidenib (AG-120)|Patients will receive ivosidenib 500 mg by mouth once daily on 28-day cycles
41124733|NCT05871658|BEHAVIORAL|electroacupuncture|electroacupuncture were inserted into bilateral Zusanli (ST36), Sanyinjiao (SP6), Hegu (LI4) and Quchi (LI11), and Yintang (EX-HN3). Electroacupuncture parameters selected the sparse wave, the frequency was 4 Hz, the stimulation intensity was tolerated by the patient.
41124734|NCT01855516|DRUG|Heparin|
41276058|NCT05818683|DRUG|Cabazitaxel|Cabazitaxel will be administered by intravenous infusion.
41276059|NCT05818683|DRUG|Docetaxel|Docetaxel will be administered by intravenous infusion.
40947864|NCT05384678|DRUG|Placebo|A Placebo (saline infusion) will be administered.
41276060|NCT05818683|DRUG|Apalutamide|Apalutamide will be administered orally.
41276061|NCT05818683|DRUG|Enzalutamide|Enzalutamide will be administered orally.
40947865|NCT05384678|DRUG|N,N-Dimethyltryptamine (108 mg) + dose titration|A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration
41124735|NCT02570022|DRUG|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
41124736|NCT02570022|PROCEDURE|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
41124737|NCT02570022|DRUG|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
41124738|NCT00281554|DRUG|RSD1235|IV
41124739|NCT03041064|OTHER|50/100|SPF
41124740|NCT03041064|OTHER|100/50|SPF
41124741|NCT03803475|DRUG|Ga-68 labeled PSMA-11|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
41276062|NCT05818683|DRUG|Darolutamide|Darolutamide will be administered orally.
41276063|NCT05818683|DRUG|Abiraterone acetate plus prednisone (AAP)|Abiraterone acetate plus prednisone (AAP) will be administered orally.
41276064|NCT01552434|BIOLOGICAL|Bevacizumab|Given IV
41276065|NCT01552434|BIOLOGICAL|Cetuximab|Given IV
41276066|NCT01552434|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41276067|NCT01552434|OTHER|Pharmacological Study|Optional correlative studies
41276068|NCT01552434|DRUG|Temsirolimus|Given IV
41276069|NCT01552434|DRUG|Valproic Acid|Given PO
41276070|NCT03254056|PROCEDURE|Conventional technique|Conventional technique: In this group; S-retractors will be used to visualize the fascia and a single interrupted stitch will be placed using 0-vicryl suture.
41446849|NCT06619184|PROCEDURE|MPG procedure|"Another vitiligo lesion treated with MPG procedure~Follow up The dressing was removed by the researcher on day 8 The participants were asked to attend for follow-up at the clinic on week 2, 4, 8, 12, and 16 after the two procedure were done.~At 2, 4, 8, 12 and 16 weeks of follow-up visits, any possible complications were evaluated and digital photographs of the lesions were taken for evaluating the two procedure efficacy using its parameter: appearance of repigmentation (AOR), total number of repigmentation NSV lesions, extent area of repigmentation, and color match"
41276071|NCT03254056|PROCEDURE|Berci technique|Berci group: In this group; the fascial incision will be closed with the fascial closure device, (Berci Fascial Closure instrument) using 1 interrupted stitch with 0-vicryl suture.
41276072|NCT05267626|DRUG|AU-007|Monoclonal Antibody Targeting IL-2
41276073|NCT05267626|DRUG|Aldesleukin|IL-2
41276074|NCT05267626|DRUG|Avelumab|Monoclonal Antibody Targeting PD-L1
41276075|NCT04022746|PROCEDURE|Magnetic Resonance Elastography|Undergo multiparametric MRI/MRE
41276076|NCT04022746|PROCEDURE|Magnetic Resonance Imaging|Undergo multiparametric MRI/MRE
41276077|NCT06518629|OTHER|Photobiomodulation with low power laser|All groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whitness HP, FGM, Joinville, SC, Brazil). Three whitening sessions will be carried out, considering a seven-day interval between sessions.
41276078|NCT06657417|DEVICE|Video laryngoscopy|Standard video laryngoscopy before video laryngoscopy with additional larynGuide overlay
41276079|NCT06657417|DEVICE|Video larnygoscopy|Video laryngoscopy with additional larynGuide overlay before standard video laryngoscopy
41276080|NCT06234267|BEHAVIORAL|Eat, Play, Sleep|The Eat, Play, Sleep study will test health promotion text messages developed following guidelines for text message program development, aligned with established recommendations for diet, physical activity, and sleep in cancer survivorship and prevention. Feasibility of text message delivery and acceptability of the text message content related to dietary quality, physical activity, and sleep hygiene health behaviors will be tested in delivery to participants (cancer survivor/caregiver dyads) who indicate difficulty engaging in dietary quality, physical activity, or sleep hygiene behaviors.
41446850|NCT06502301|OTHER|Cross-sectional study|This is not intervention study.
41124742|NCT03803475|DEVICE|Positron emission tomography-computed tomography (PET/CT)|Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session
41124743|NCT03803475|DEVICE|Positron emission tomography-magnetic resonance imaging (PET/MRI)|A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session
41124744|NCT03065569|DRUG|Bupivacaine|16 mL of 0.125% bupivacaine
41124745|NCT03208491|OTHER|serious games use|This program has enabled several SGs to be developed that allow physical and cognitive workouts to be carried out with a therapist
41124746|NCT03208491|OTHER|usual care|usual care of patient
41124747|NCT02400931|PROCEDURE|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
41124748|NCT02400931|PROCEDURE|no mask ventilation|
41124749|NCT02400931|DRUG|Rocuronium|
41124750|NCT02867059|DRUG|(+)-SJ000557733|(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20_SJ733_Challenge Protocol_v2.0_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
41124751|NCT03966898|DRUG|SHR6390 Tablets|SHR6390 Tablets
41124752|NCT03966898|DRUG|Placebo Tablets|Placebo Tablets
41124753|NCT03966898|DRUG|Letrozole or Anastrozole Tablets|Letrozole or Anastrozole Tablets
41124754|NCT01661569|OTHER|Headspace On-the-go app|Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
41276081|NCT06649045|DRUG|Orforglipron|Administered orally.
41276082|NCT06649045|DRUG|Placebo|Administered orally.
41276083|NCT03668223|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
41276084|NCT06657287|OTHER|Mixed meal test|The biochemical parameters, blood pressure, and heart rates of participants undergoing the mixed meal test will be recorded over a 5-hour period.
41276085|NCT04333966|BEHAVIORAL|Interactive Social Networking Site Parent Based Intervention|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
41276086|NCT04333966|BEHAVIORAL|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call to Action: A Guide for Families.
41276087|NCT04036617|DRUG|NaQuinate|SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
41276088|NCT04036617|DRUG|Placebo|SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
40947866|NCT02552784|BEHAVIORAL|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
41124755|NCT00609297|OTHER|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
41124756|NCT00609297|OTHER|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
41124757|NCT00609297|OTHER|survey administration|Given to patient and caregivers throughout the study
41124758|NCT03903822|DRUG|PF-06700841|PF-06700841 topical cream
41124759|NCT03903822|DRUG|Vehicle (Placebo)|Vehicle topical cream
41124760|NCT00818246|DEVICE|Sham light|
41124761|NCT00818246|DEVICE|LumiPhase-R™, OPUSMED Inc. Montreal, Canada|660 nm wavelength delivered in a sequential pulsing mode
41124762|NCT06274086|PROCEDURE|Two-session catheter-directed sclerotherapy|"After receiving the first session of catheter-directed sclerotherapy, each patient carries the catheter overnight and is closely monitored in the patient ward. Then, the patient receives the second session the next day. The catheter is removed after the second session.~The procedure was performed under intravenous sedoanalgesia using a combination of 25 mg pethidine hydrochloride and 50 mg fentanyl. Devices used during the procedure included:~* An 18-gauge, 20-cm Chiba biopsy needle (Cook, Bloomington, IN, USA);~* A 0.035-inch hydrophilic guidewire (Terumo, Tokyo, Japan);~* A 7- or 8.5-F pigtail catheter (Dawson-Mueller Drainage Catheter; Cook)."
41276089|NCT04200612|BEHAVIORAL|Equine-Assisted Psychotherapy|Equine-Assisted Psychotherapy (EAP) involves working on the psychological goals set between the client and the mental health professional. This is done through the experiential interactions between the clients and the horse. This experiential aspect is vital as it allows clients to process the emotions, thoughts and behaviors that were expressed during sessions with the horse.
41276090|NCT04200612|BEHAVIORAL|Equine-Assisted Activities|Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.
41276091|NCT04200612|OTHER|Placebo-control group|This group will only be watching movies related to horses and they are told that this is another form of EAP even though this is not the case. This type of intervention has not been known to provide any therapeutic effect relevant to the study and thus is used as the placebo-control.
41276092|NCT00056706|PROCEDURE|Transient deafferentation|
41276093|NCT04960358|PROCEDURE|Surface Electromyography|will be applied Surface Electromyography to assess Flexion Relaxation Response
41276094|NCT04740411|BEHAVIORAL|The Common Elements Toolbox (COMET)|COMET is an online unguided self-help intervention that lasts approximately 60-80 minutes.
41276095|NCT02956655|OTHER|Fasting therapy|The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
41276096|NCT02956655|DRUG|Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)|"Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up."
41276097|NCT02956655|OTHER|Exercise|Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
41276098|NCT02956655|BEHAVIORAL|Lifestyle guidance|Lifestyle guidance is provided by specific physicians through phone calls
41276099|NCT02956655|DEVICE|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
41124763|NCT03323775|DIAGNOSTIC_TEST|Suprathreshold stimulation|Intraoperatively, radiofrequency needles will be placed on specific nerves targeted using parallel needle placement technique under image guidance. These nerves will have identified by the diagnostic injections carried out previously. The nerves will be located using 50 Hz sensory stimulation. The targeted medial branches (dorsal ramus in the case of L5) will be stimulated using suprathreshold stimulation (up to three times the sensory detection threshold) to identify the pain referral area. Motor stimulation of 2 Hz will be used to identify the multifidus muscle as well as to evaluate the close proximity to major spinal nerve to improve the safety of the procedure.
41124764|NCT02294617|OTHER|Electronic Cigarette|Subject will use electronic cigarette for 3 days.
41124765|NCT02294617|OTHER|Nicotrol Inhaler|Subjects will use the Nicotrol Inhaler for 3 days.
41124766|NCT02420431|BEHAVIORAL|Metacognitive Therapy|Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
41124767|NCT02420431|BEHAVIORAL|Cardiac Rehabilitation (treatment as usual)|Stress management, relaxation training, exercise and dietary advice.
41124768|NCT00933712|DRUG|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
41276100|NCT01518530|DEVICE|Occiflex Robotic Intervention System|Occiflex is a robotic system which is comprised of a cradle moved in a three dimension space with six degrees of freedom. It allows the therapist to tailor a personalized course of 3-D mobilization of the head and neck.
41276101|NCT02601144|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation
41124769|NCT02405013|DRUG|Sofosbuvir|Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
41276102|NCT06181955|OTHER|Extracorporeal Shock Wave Therapy|The ESWT was performed by an ESWT instrument (Chattanooga) once a week for four consecutive weeks (a total of four sessions).
41276103|NCT06181955|OTHER|conventional physical therapy|Conventional physical therapy consisted of ultrasound therapy and three types of knee-strengthening exercises.
41276104|NCT06488950|BIOLOGICAL|GC203 TIL(gene-edited TIL) or autologous TILs|the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample
41276105|NCT05617170|OTHER|Rehabilitation|"50 case of acute cerebrovascular stroke patients will subject to implanted early rehabilitation programme based on telemedicine if avilable .~50 control patients of acute cerebrovascular stroke patients will subject to ordinary rehabilitation techniques ."
41276106|NCT05199584|DRUG|ENV-101 (taladegib)|tablets dosed once-daily
41276107|NCT01262430|PROCEDURE|OtisMed|OtisMed Custom-fit Shapematching Guides
41276108|NCT01262430|PROCEDURE|Computer Assisted Surgery (CAS)|Stryker Navigation System
41276109|NCT02904226|DRUG|JTX-2011|Specified dose on specified days
41276110|NCT02904226|DRUG|Nivolumab|Specified dose on specified days
41276111|NCT02904226|DRUG|Ipilimumab|Specified dose on specified days
41276112|NCT02904226|DRUG|Pembrolizumab|Specified dose on specified days
41276113|NCT05013840|BEHAVIORAL|Filling in an online survey|Physicians are asked to fill in an online survey regarding 1) goals to treat patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
41276114|NCT05607134|OTHER|selected physical and occupational therapy program|The children in this group will receive a selected physical and occupational therapy programs one hour three times weekly for eight successive weeks.
41276115|NCT05607134|DEVICE|Radial Extracorporeal Shock Wave|The children in this group will receive in addition to the selected physical therapy and occupational program as single session of shock wave intervention once per week for four eight successive weeks using (STORZ MEDICAL AG, Tagerwilen, Schweiz) device. rESWT will be applied on flexor carpi ulnaris, flexor carpi radialis, in the middle of the muscle belly and tendons of flexor digitorum on the palm. The treatment protocol of rESW will follow; 1500 shoots for each muscle; 0.030 mj/mm2; 4 HZ with pressure 1 bar will be used.
41276116|NCT05607134|DEVICE|Peripheral magnetic stimulation|"The children in this group will receive in addition to the selected physical therapy program peripheral magnetic stimulation (PMS) therapy for twenty minutes, three sessions per week, for eight successive weeks using Peripheral magnetic stimulation device A MAGNUM XL Pro, Globus, Italia. The PMS consisted of 2000 stimuli at a stimulation frequency of 20Hz, a train duration of 1 second, and an intertrain interval of 2 seconds. Intensity was individually set at 10% to 100% of the maximum stimulus intensity."
41276117|NCT05452382|PROCEDURE|Partial colecctomy|Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum
40947867|NCT05192967|BEHAVIORAL|Pandemic preparedness via video|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.
41124770|NCT02405013|DRUG|Ribavirin|Ribavirin weight-adjusted dosing (1000mg BID in patients \< 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
41124771|NCT02405013|DRUG|Sofosbuvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
41124772|NCT02405013|DRUG|Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
41124773|NCT02500758|PROCEDURE|Preparatory handwash|Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.
41276118|NCT05452382|PROCEDURE|Hemicolectomy|Formal right hemicolectomy including terminal ileum, cecum, and ascending colon
41276119|NCT01284192|DRUG|ASP3026|Tablet
41276120|NCT03614247|PROCEDURE|Retrograde intrarenal surgery|The procedure was performed with the patient in the dorsal lithotomy position under general anesthesia. Firstly, diagnostic ureteroscopy was done with a 6/7.5 Fr semi-rigid ureteroscope (Richard Wolf, Knittlingen, Germany). A 0.035mm double-tipped sensor guidewire was placed to the renal pelvis. A 10/12 Fr ureteric access sheath (Cook Medical, Indiana, USA) was used. A 7.5 Fr flexible ureteroscope (Flex X2, Karl Storz, Tuttlingen, Germany) was used for the main procedure. The stones were fragmented using a Holmium:Yttrium Aluminum Garnet laser (272 microns). At the end of each procedure, a double-j ureteric catheter and urethral catheter were routinely placed.
41276121|NCT03614247|PROCEDURE|Micro-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 4.8 Fr for micro PNL (PolyDiagnost, Pfaffenhofen, Germany). Stone fragmentation was carried out using laser in micro PNL. No nephrostomy was placed in any patient whom underwent micro PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
41287262|NCT03915691|PROCEDURE|Catheter ablation of atrial tachycardia: Ripple Mapping guided.|Ripple Mapping is used to map the atrial tachycardia mechanism. Using the scar thresholding technique the Ripple Map is interpreted and catheter ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using Ripple Mapping. This can include lesions created at previous ablation procedures.
40927681|NCT03584945|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment team will offer a course of up to 12 cognitive behavioral therapy (CBT) (45 minute sessions for 12 to 16 weeks), augmented by medication treatment when clinically indicated based on the clinical treatment standards. Due to Covid, therapy sessions are offered via remote video conference (in clinic sessions made available if clinically indicated). Cognitive-behavioral therapy (CBT) is a treatment based on learning and cognitive theories. CBT for Obsessive-Compulsive Disorder (OCD) involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
41124774|NCT02500758|PROCEDURE|Preoperative surgical scrubbing using 3% PCMX|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
41124775|NCT02500758|PROCEDURE|Preoperative surgical scrubbing using 4% CHG|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
41124776|NCT03688139|BEHAVIORAL|Engage Therapy|"Engage therapy is designed to help individuals with depression become involved in activities they previously enjoyed but have not been participating in since developing depression. In Engage therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding activities of their choice."
41124777|NCT03688139|BEHAVIORAL|Supportive Therapy|Supportive therapy is designed to provide a warm and supportive environment in which individuals with depression can feel comfortable expressing their thoughts and feelings. In supportive therapy, therapists help patients identify themes in their thinking, provide reassurance, emphasize coping skills, and provide guidance as needed.
41446851|NCT04313855|DIAGNOSTIC_TEST|SMS in the early detection of postoperative neuropathic pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
41446852|NCT04906148|OTHER|Advertisement content (explicit vs. implicit)|Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content
40927682|NCT03584945|OTHER|Community Referral as appropriate|Participants with Obsessive Compulsive Symptoms will be referred to the community for treatment
41446853|NCT04906148|OTHER|Advertisement content (true vs. misleading)|Participants will be randomly assigned to view an advertisement with either true or misleading messaging content
41446854|NCT00994058|DEVICE|Electrical Inhibition (EI) Uterine Pacemaker|"An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.~Patients with preterm contractions (\< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS)."
41446855|NCT05661916|DRUG|ALN-TTRSC04|ALN-TTRSC04 will be administered by subcutaneous (SC) injection.
41446856|NCT05661916|DRUG|Placebo|Placebo will be administered by SC injection.
41124778|NCT05111951|BEHAVIORAL|Mobile health-delivered physical exercise and support for physical activity|Mobile health-delivered physical exercise sessions, prescription of an individual exercise-regime and support for physical activity through behavior change techniques.
41124779|NCT05111951|BEHAVIORAL|Mobile health-delivered behavior change techniques.|Mobile health-delivered behavior change techniques following the core elements of the Swedish model for physical activity on prescription.
41124780|NCT03898310|DIETARY_SUPPLEMENT|Cranberry extract capsules|Participants in the treatment arm will receive cranberry extract capsules.
41124781|NCT03898310|DIETARY_SUPPLEMENT|Placebo capsule|Participants in the placebo arm will receive placebo capsules.
41124782|NCT03432338|OTHER|inquiries|Inquires reported to clinician.
41124783|NCT04185961|DEVICE|EVERA-RAPHA with 60mmHG|Apply EVERA-RAPHA with 60mmHG for 4weeks
41446857|NCT05232825|DRUG|Ocrelizumab IV|IV Injection
41446858|NCT05232825|DRUG|Ocrelizumab SC|SC Injection
41124784|NCT04185961|DEVICE|EVERA-RAPHA with 100mmHG|Apply EVERA-RAPHA with 100mmHG for 4weeks
41287263|NCT03915691|PROCEDURE|Catheter ablation of atrial tachycardia: Conventional mapping guided.|Conventional activation mapping is used to map the atrial tachycardia mechanism. The resultant (activation) map is interpreted and ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using conventional mapping. This can include lesions created at previous ablation procedures.
41276122|NCT03614247|PROCEDURE|Ultra-mini PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 7.5 Fr for ultramini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using laser in ultramini PNL. No nephrostomy was placed in any patient whom underwent ultramini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
41446859|NCT05232825|DRUG|Methylprednisolone IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
41124785|NCT01138254|DEVICE|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
40927683|NCT02847572|PROCEDURE|Cataract Surgery|All patients wil be having intraocular lens surgery
40927684|NCT03158792|DRUG|Enoxaparin 20Mg/0.2mL Prefilled Syringe|Enoxaparin 20mg subcutaneously once daily
41124786|NCT01138254|OTHER|no intervention|no intervention
41124787|NCT03742050|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
40927685|NCT03158792|DRUG|Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml|Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
40927686|NCT03398278|DRUG|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fast state
40927687|NCT03398278|DRUG|OXYCONTIN®|Orally taking OXYCONTIN® 40mg in fast state
41124788|NCT04024176|OTHER|Gait analysis|The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
41124789|NCT04138316|DRUG|Candesartan|Treatment with Candesartan
41124790|NCT03122236|BEHAVIORAL|Neurorehabilitation of Standard Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
41124791|NCT03122236|BEHAVIORAL|Neurorehabilitation of Complex Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
41124792|NCT03122236|DEVICE|Sham Transcranial Direct Current Stimulation (Sham tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
41124793|NCT03122236|DEVICE|Active Transcranial Direct Current Stimulation (Active tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
41124794|NCT03561519|OTHER|Fecal Microbiota Transplantation (FMT)|Fecal suspension administered in colonoscopy into the cecum of the patient.
41124795|NCT03561519|OTHER|Placebo|As a placebo a fecal suspension made of patients own feces is administered into the cecum of the patient in colonoscopy.
41124796|NCT06302920|DEVICE|Kinesiotape|Lymphatic correction technique
41124797|NCT05676346|GENETIC|LUTS|Patients included in this group are subjects with lower urinary tracto symptoms. An oral mucosa swab will be used to extract a genetic specimen
41124798|NCT04119063|DEVICE|powered orthosis|Novel powered leg brace to provide assistance during walking.
41124799|NCT02368626|DEVICE|EndyMed Pro™ RF Micro-Needles|RF Micro-needles ablation treatments
40927688|NCT02815280|DRUG|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
40927689|NCT02815280|DRUG|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
40927690|NCT02540889|BEHAVIORAL|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
40927691|NCT00231556|DRUG|topiramate|
40927692|NCT02747433|DEVICE|Robot-Assisted Therapy (RT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (1 hr sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Robot training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home \& community.
40947868|NCT05192967|BEHAVIORAL|Pandemic preparedness via classical method|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.
41124800|NCT04434742|OTHER|Complex interventions|An advanced practice nurse (APN) from a hospital discharge team visited them to familiarize him/herself with their condition and prepare a discharge plan. A face-to-face or telephone call handover between the APN and the project nurse case manager (NCM) was performed before the client was discharged. The past and current medical conditions, medical and nursing management, and follow-up appointments were discussed. After discharge home, the NCM, functioning as the leader of health-social care team, conducted the initial assessment in the first home visit to identify the client's health and social problems within one week of discharge. Community workers, supervised by both the nurse case manager and social worker, provided telephone follow-up and subsequent home visits to monitor the client's progress and provide support when necessary.
41276123|NCT03614247|PROCEDURE|Mini-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 12 Fr for mini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in mini PNL. No nephrostomy was placed in any patient whom underwent mini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
41124801|NCT04434742|OTHER|Usual care|Social call was given to this group.
41276124|NCT03614247|PROCEDURE|Standard PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 24 Fr for standard PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in standard PNL. A nephrostomy was placed in all standard PNL patients at the end of the procedure
41276125|NCT04732663|OTHER|No Intervention|Cross-sectional study, no intervention.
41276126|NCT03984409|DIETARY_SUPPLEMENT|Kroger low calorie orange juice beverage|Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved
41276127|NCT04853940|OTHER|Data collection and clinical testing of subjects|6-months follow-up with clinical testing at 3 and 6 months
41276128|NCT01162525|PROCEDURE|Percutaneous tibial nerve stimulation (pTNS)|A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
41276129|NCT04419103|OTHER|no intervention|Natural exposure of iodine.
41276130|NCT03088514|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice (70ml daily) with or without inorganic nitrate
41276131|NCT03693872|DRUG|Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
41276132|NCT03693872|DRUG|Dopaminergic Agonist + Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
41124802|NCT03068624|BIOLOGICAL|Aldesleukin|Given SC
41276133|NCT01571492|PROCEDURE|L2 Paravertebral catheter nerve block|A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.
41276134|NCT01571492|PROCEDURE|Continuous Lumbar plexus nerve block|A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
41276135|NCT01744561|BEHAVIORAL|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
41276136|NCT00482963|DRUG|levonorgestrel, efavirenz|
41276137|NCT00194350|PROCEDURE|Test for Factor V Leiden gene mutation|
41124803|NCT03068624|BIOLOGICAL|Autologous CD8+ SLC45A2-specific T Lymphocytes|Given via hepatic arterial infusion via central catheter
41124804|NCT03068624|DRUG|Cyclophosphamide|Given IV
41124805|NCT03068624|BIOLOGICAL|Ipilimumab|Given IV
41276138|NCT01479348|DRUG|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|18FdCyd radiotracer
41276139|NCT01479348|DRUG|Tetrahydrouridine intravenous (IV)|Total dose of THU = 350 mg/m\^2, IV
41276140|NCT01479348|DRUG|Tetrahydrouridine (oral)|Total dose of THU is 3000 mg, oral
41276141|NCT01479348|DIAGNOSTIC_TEST|Positron emission tomography (PET)/Computed tomography (CT)|One prior CT and 3 sequential whole body PET
41276142|NCT00420914|PROCEDURE|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
41276143|NCT01468519|DRUG|Insulin|Insulin via continuous subcutaneous insulin infusion
41276144|NCT01468519|DRUG|Insulin|insulin via multiple daily injections
41276145|NCT06478953|DIAGNOSTIC_TEST|FA Pneumonia Panel|A single BioFire® FilmArray® Pneumonia Panel assay will be performed on a respiratory clinical specimen.
41276146|NCT06172907|BEHAVIORAL|Young Adults Coping with Cancer Together Intervention|This intervention is based on cognitive-behavioral therapy and couples' therapy. It aims to improve cancer and caregiving-related self-efficacy and coping, as well as promote relationship maintenance in context of cancer. The intervention will be delivered by a trained mental health practitioner and include didactics, experiential exercises, and home practice.
41124806|NCT00040313|DRUG|pegaptanib sodium (Macugen)|
41124807|NCT00752453|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
41124808|NCT00752453|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
41124809|NCT00752453|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
41124810|NCT00002755|BIOLOGICAL|filgrastim|
41124811|NCT00002755|DRUG|CMF regimen|
41124812|NCT00002755|DRUG|cyclophosphamide|
41446860|NCT05232825|DRUG|Diphenhydramine IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
41446861|NCT05232825|DRUG|Dexamethasone given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
41446862|NCT05232825|DRUG|Desloratadine given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
41446863|NCT05921214|BEHAVIORAL|VAULT Phase 5|This is an input-based vocabulary learning treatment based on principles of statistical learning.
41446864|NCT06626607|DRUG|CCB use|Postoperative antihypertensive medication includes CCB
41446865|NCT06626607|DRUG|non-CCB use|Postoperative antihypertensive medication does not include CCB
40927693|NCT02747433|DEVICE|Robot & Task-Oriented Training (RT-TOT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (30 min sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Task oriented training will be delivered for remaining 30 mins of each treatment session. Robot and task oriented training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home \& community.
41124813|NCT00002755|DRUG|doxorubicin hydrochloride|
41276147|NCT01365221|DRUG|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
41276148|NCT01365221|DRUG|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
41276149|NCT02436109|DEVICE|Ultrasound|Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
41276150|NCT03003819|DEVICE|Control Collagen Wound Dressing|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
41446866|NCT03720691|DEVICE|Real rTMS Supplementary motor area|There will be a series of four rTMS blocks separated by 10 minutes. Each block will consist of 15 to 25 pulse trains of 1-second duration at 25 Hz, with an intertrain interval of 10 seconds.
41446867|NCT03720691|DEVICE|Sham rTMS Supplementary motor area|There will be no real brain stimulation in Sham rTMS, and participant will be blinded.
40927694|NCT03093688|BIOLOGICAL|Infusion of iNKT cells and CD8+T cells|The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) and CD8+T cells(1E7\~1E9) in one course of treatment.
41124814|NCT00002755|DRUG|fluorouracil|
41124815|NCT00002755|DRUG|methotrexate|
41124816|NCT00002755|DRUG|tamoxifen citrate|
41124817|NCT00002755|DRUG|thiotepa|
41124818|NCT00002755|PROCEDURE|autologous bone marrow transplantation|
41124819|NCT00002755|PROCEDURE|peripheral blood stem cell transplantation|
41124820|NCT00002755|RADIATION|low-LET cobalt-60 gamma ray therapy|
41124821|NCT00002755|RADIATION|low-LET electron therapy|
41124822|NCT00002755|RADIATION|low-LET photon therapy|
41276151|NCT03003819|DEVICE|Test Collagen Matrix|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
41276152|NCT02354833|DRUG|Phenylephrine|
41446868|NCT05039996|BEHAVIORAL|education and relaxation program|randomized controlled trial
41446869|NCT05739019|OTHER|frozen embryo transfer|transfer one or two embryos in frozen embryo transfer cycles
41446870|NCT01524185|BEHAVIORAL|FamilyLive|Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
41446871|NCT01524185|BEHAVIORAL|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
41446872|NCT06085703|DRUG|Henagliflozin|Henagliflozin will be initiated and maintained at 5mg/day every morning. If necessary, the dose can be increased to 10mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
41446873|NCT06085703|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
41446874|NCT05815394|DRUG|177Lu-labeled NY108|Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.
41124823|NCT01863485|DRUG|CM082 Tablet|CM082 tablets taken orally once a day on 28-day cycles
41124824|NCT04700189|DEVICE|ab interno canaloplasty|A modification of traditional canaloplasty procedure. Can be combined with or done without cataract surgery.
41124825|NCT02192242|OTHER|acute ischemic pain|acute ischemic pain was induced by treadmill exercise
41124826|NCT05363436|DRUG|Oxycodone|Providers had to prescribe 15 oxycodone pills to each patient discharge
41124827|NCT02320370|DEVICE|NeuroConn DC Stimulator Plus tDCS|transcranial electrical stimulation intervention with two experimental protocols
41124828|NCT05706870|DRUG|GN-037|GN-037
41124829|NCT05706870|DRUG|Clobetasol 17-propionate|Clobetasol 17-propionate
41124830|NCT05706870|DRUG|Placebo|Placebo
41124831|NCT03487172|DEVICE|poly-L-lactic acid to right knee|Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.
41124832|NCT03487172|DEVICE|poly-L-lactic acid to left knee|Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.
41124833|NCT00003542|BIOLOGICAL|pegylated interferon alfa|
41124834|NCT04164784|BEHAVIORAL|therapeutic monitoring|According to the glucose lever recorded by FreeStyle Libre H (Flash Continuous Glucose Monitoring System) ,the investigators give the intervention group instructions to adjust their diet and lifestyle to abtain a good glucose control.
41124835|NCT05694442|OTHER|Lipmatte K|Lipmatte K contain ingredients that may hydrate and brighten the lip
41276153|NCT02354833|DRUG|Norepinephrine|
41446875|NCT06438640|BEHAVIORAL|My Anesthesia Choice-HF Model|Brief clinician training on shared decision making, paired with provision of a 1-page tabular format conversation aid listing answers to frequently asked questions regarding common anesthesia options for hip fracture surgery (spinal anesthesia; general anesthesia)
41124836|NCT04725136|BIOLOGICAL|FURESTEM-AD inj|Repeated administration group: 3 times high or low dose at 4 week intervals. Single administration group: 1 time high or low dose, 2 times placebo injection at 4 week intervals Placebo: 3 times placebo injection at 4 week intervals.
41124837|NCT02129283|BEHAVIORAL|Simulation training|End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
41124838|NCT03117426|DEVICE|SYMFONY IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.
41124839|NCT03117426|DEVICE|AT LISA tri 839MP IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
41124840|NCT04834141|OTHER|FlexiCurve ruler method to assess thoracic kyphosis angle|The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.
41124841|NCT04307511|DRUG|Ticagrelor|60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
41124842|NCT04307511|DRUG|Aspirin|Aspirin
41124843|NCT04613700|DRUG|Secretin|Native hormone
41124844|NCT04613700|OTHER|Placebo|Saline
41124845|NCT05398289|DRUG|4-week duration of antibiotic therapy|The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
41276154|NCT02739087|PROCEDURE|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.
41124846|NCT05398289|DRUG|6-week duration of antibiotic therapy|The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
41124847|NCT01644994|COMBINATION_PRODUCT|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
41124848|NCT01571804|DRUG|Placebo|to receive two identical placebo capsules 1 hr before surgery
41124849|NCT01571804|DRUG|pregabalin|one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
41124850|NCT01571804|DRUG|pregabalin|two capsules of pregabalin 150 mg 1 hr before surgery
41124851|NCT05990816|DIAGNOSTIC_TEST|Blood works for homocysteine levels|In a single patient group of 80 people, the natural course of homocysteine after total joint arthroplasty will be examined by blood work analyzes at the 1,2,3,4 and 6th weeks after operation
41124852|NCT06515691|PROCEDURE|M-TAPA block|After the wound closure is completed and the patient is still under genaral anesthesia the M-TAPA block ill be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied on each side. The total volume will be 60 ml.
41124853|NCT06515691|PROCEDURE|Postoperative pain management|ibuprofen 400mg (Ibuprofen-PF®) intravenous (IV), and tramadol (Contramal®) 100 mg IV will be administered to all patients 20 minutes before wound closure. After surgery, Ibuprofen 400 mg will be given three times a day. A patient-controlled analgesia (PCA) system containing 10 mcg/ml fentanyl will be provided to all patients without continuous infusion. Patients can administer boluses of 0.35 mcg/kg with a 15-minute lockout period and a maximum dose of 100 mcg per hour. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV tramadol (Contramal®) 100 mg will be given as a rescue analgesic.
41124854|NCT04884165|DEVICE|Remote monitoring of home mechanical ventilation (NIV) using SRETT|Patients will use the SRETT device attached to their home ventilator.
41124855|NCT04884165|OTHER|Home mechanical ventilation (NIV) without remote monitoring|Usual care
41124856|NCT00448669|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
41124857|NCT00448669|DRUG|Placebo Oral Tablet|
41124858|NCT03481751|DIAGNOSTIC_TEST|Diagnostic test: Ultrasound|Transabdominal ultrasound of the bowel for categorization of disease activity
41276155|NCT02739087|DEVICE|Magnetic resonance imaging|
41276156|NCT00838487|OTHER|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
41446876|NCT00023166|DRUG|PEG-paclitaxel|
41124859|NCT00644514|BIOLOGICAL|Endotoxin - lipopolysaccharide (LPS)|Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
41124860|NCT05209555|DIAGNOSTIC_TEST|MoCA|MoCA test to identify Mild Cognitive Impairment
41124861|NCT05209555|DEVICE|BAMCOG|Three games, compared to the MoCA to identify Mild Cognitive Impairment
41276157|NCT00838487|OTHER|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
41446877|NCT03994952|DEVICE|Sway Balance Application|Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.
41446878|NCT03994952|DEVICE|Balance Tracking Systems|This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
41446879|NCT00795821|DRUG|LY2216684|Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
41446880|NCT00795821|DRUG|Placebo|Dose: 3 tablets QD for 10 weeks
41124862|NCT05209555|DIAGNOSTIC_TEST|DeltaScan|EEG to detect acute encephalopathy
41124863|NCT05209555|DIAGNOSTIC_TEST|Salivette|To collect saliva for cortisol analysis
41124864|NCT05209555|DIAGNOSTIC_TEST|Pilocarpine iontophoresis|To collect sweat for cortisol analysis
41124865|NCT04294173|BEHAVIORAL|video education|tracheostomy care will be given to student nurses with video training
41124866|NCT01784744|OTHER|Hydroworx Pool at 98 degrees Fahrenheit|
41124867|NCT01784744|OTHER|Hydroworx Pool at 102 degrees Fahrenheit|
41124868|NCT02025257|OTHER|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
41124869|NCT05220943|BEHAVIORAL|Video|This 5-minute video presents clips with voiceover narration summarizing and highlighting the key safety points in the Center for Surgical Innovation (CSI) location.
41124870|NCT06181916|BEHAVIORAL|Amp|Amp is a virtual support system mHealth app that provides information and social support to help young Black men who have sex with men (YBMSM) living with HIV achieve better HIV care continuum outcomes and overall well-being.
41276158|NCT04214080|OTHER|Neurodevelopmental treatment (NDT)|NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.
41276159|NCT04214080|OTHER|Feeding and oral-motor intervention strategies|Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.
41276160|NCT04214080|OTHER|Neck and trunk stabilization exercises|Trunk control affects head control. After gaining head control, it causes jaw stability and oral motor control (tongue control and lip closure). All of these affect communication and quality of life.
41276161|NCT01408238|BIOLOGICAL|Four different concentrations of Secale cereale allergen extract, positive control and negative control|4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
41276162|NCT01312194|PROCEDURE|Root canal therapy in one visit|Patient was anesthetized with local anesthetic solutions, and the caries was removed. The tooth was isolated with rubber dam and access to pulp chamber was completed. Cleaning and shaping preparation was achieved with manual and rotatory endodontic instruments.The ideal working length was determined by an electronic apex locator and periapical radiography. Irrigation was performed with 5.25%NaOCl solution. The smear layer was removed by 10% citric acid. The cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
41276163|NCT01312194|PROCEDURE|Root Canal Therapy in two-vist|The treatment protocol was the same as described for one visit group. In the first visit, after cleaning, shaping and smear layer removal, the root canals were medicated with a calcium hydroxide paste and sterile distilled water (1:1) and the pulp chamber was sealed with a minimum 3mm thickness temporary filling restoration. After 10-12 days, during the second visit, the medication was removed, and the cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
41276164|NCT02220387|OTHER|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
41276165|NCT02220387|OTHER|exposure to polycyclic aromatic hydrocarbons exhaust|history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
41276166|NCT02635204|DRUG|DFD06 Cream|Twice daily topical application for 14 days.
40927695|NCT04012489|PROCEDURE|Breath Stacking|Patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
40947869|NCT04186936|DRUG|Combination Caplet with Loperamide HCl and Simethicone|Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
41124871|NCT01259557|DRUG|Botulinum Toxin Type A|2 times, Intra-muscular injection, Maximum dosage total 60U
41124872|NCT00843687|DRUG|Risperidone long-acting injectable|
41124873|NCT04355221|PROCEDURE|pulsed radiofrequency|Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device
41124874|NCT06331494|DRUG|Butylphthalide|Butylphthalide Sodium Chloride injection for 10±3 days, oral Butylphthalide soft capsules for day 11±3 to day 180.
41124875|NCT06331494|DRUG|Placebo|Butylphthalide Placebo injection for 10±3 days, oral Butylphthalide Placebo soft capsules for day 11±3 to day 180.
41124876|NCT01421836|PROCEDURE|ERCP-guided stent insertion|ERCP guided stent insertion for malignant biliary obstruction
41124877|NCT01421836|PROCEDURE|EUS guided stent insertion|EUS-guided stent insertion for malignant biliary obstruction
41124878|NCT00077493|DRUG|BL22 immunotoxin|BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
41124879|NCT00077493|PROCEDURE|antibody-drug conjugate therapy|CD22 antibody, RFB4 on day 7
41124880|NCT00077493|PROCEDURE|immunotoxin therapy|tested for immunogenicity to CAT-8015 before each cycle and at end of study.
41124881|NCT00077493|PROCEDURE|monoclonal antibody therapy|administered intravenously over 30 minutes.
41124882|NCT06282822|OTHER|Transthoracic echocardiography|All enrolled patients underwent noninvasive transthoracic echocardiography.
41124883|NCT00710567|DEVICE|DuraHeart Left Ventricular Assist System (LVAS)|The DuraHeart LVAS is implanted in using open heart surgery
41124884|NCT00107159|BIOLOGICAL|autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine|
41276167|NCT02635204|DRUG|Vehicle Cream|Twice daily topical application for 14 days.
41276168|NCT02631304|PROCEDURE|Elective cardiac surgery|Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
41446881|NCT00006453|DRUG|carboplatin|
41124885|NCT01384890|RADIATION|VMAT with CBCT|volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification
40927696|NCT04012489|PROCEDURE|Air Stacking|The same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
41124886|NCT01384890|RADIATION|VMAT with kV-ray|Volumetric modulated arc therapy (VMAT) with kV-ray position verification
41124887|NCT03380013|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Each neonate will have a structural exam completed assessing each body region (head, cervical, thoracic, lumbar, sacral, pelvic, rib cage, and abdominal regions) for underlying somatic dysfunctions prior to each treatment. The specific OMT techniques used will be left to the discretion of the treating physician and will not be based on a predetermined protocol. Treatment techniques will consist of myofascial release, balanced ligamentous tension, balanced membranous tension, and osteopathy in the cranial field. Total treatment time will be 15 minutes. The features of the osteopathic structural exam which will be recorded on paper by the treating physician at the time of the evaluation. The paper will be marked only with the research identifier.
41276169|NCT04279197|DRUG|Fuzheng Huayu Tablet|FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
41276170|NCT04279197|DRUG|Vitamin C tablets|Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral；
41276171|NCT04279197|DRUG|Placebo|Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
41124888|NCT01010685|PROCEDURE|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
41124889|NCT03005119|DRUG|PTL201|Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
41124890|NCT03005119|DRUG|Placebo Oral Capsule|Placebo seamless gelatin matrix green beads containing excipients only
41276172|NCT04279197|OTHER|respiratory function rehabilitation training|Health exercise, once a day
41276173|NCT00722293|DRUG|Doxorubicin|Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
41276174|NCT00722293|DRUG|Pazopanib (GW786034)|Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg
41276175|NCT00722293|DRUG|Epirubicin|Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
41446882|NCT00006453|DRUG|gemcitabine hydrochloride|
41446883|NCT04934098|DEVICE|Adjustable Compression Wrap|The material will be delivered, adapted, and oriented for the daily use of the adjustable compression wrap (Ready Wrap®). The wrap allows for easy use because it is the pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compression properties, it can be used as a therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)). The institutional protocol for the control of the lymphedema phase will be respected, in which the orthosis is used at home for the longest period possible, with the only removal for bathing and sleeping; in addition, skincare and therapeutic exercises for the upper limbs should be performed daily.
41446884|NCT04934098|DEVICE|Compression Bandage|Evaluation, skincare, compression bandaging, and guidance on therapeutic exercises for upper limbs. The material used for binding is tubular mesh, foam, elastic compression bandage. Therapy will be followed according to the institutional protocol for the lymphedema reduction phase, in which it will be reassessed twice a week for 30 days.
41446885|NCT02450539|DRUG|Abemaciclib|Administered orally
40927697|NCT06185140|OTHER|cardiac rehabilitation program|Cardiac rehabilitation program
41124891|NCT02714075|OTHER|Ferric Pyrophosphate and Zinc Oxide|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO) and micronutrients
41124892|NCT02714075|OTHER|Ferric Pyrophosphate and Zinc Sulphate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Sulphate (ZnSO4) and micronutrients
41124893|NCT02714075|OTHER|Ferric Pyrophosphate, ZnO, Citric Acid and Trisodium Citrate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO), Citric Acid (CA) and Trisodium Citrate (TSC) and micronutrients
41124894|NCT02714075|OTHER|Ferric Pyrophosphate, ZnSO4, CA/TSC|Extruded rice fortified with Ferric Pyrophosphate, ZnSO4, CA/TSC and micronutrients
41124895|NCT02714075|OTHER|Ferric Pyrophosphate, ZnO, CA, EDTA|Extruded rice fortified with Ferric Pyrophosphate, ZnO, CA, EDTA and micronutrients
41124896|NCT02714075|OTHER|Ferrous Sulphate|Extruded rice fortified with micronutrients, Ferrous Sulphate solution will be added at consumption
40927698|NCT06185140|OTHER|TELEA platform|TELEA platform
40927699|NCT02769897|BEHAVIORAL|Physical exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
41446886|NCT02450539|DRUG|Docetaxel|Administered IV
41446887|NCT03922763|PROCEDURE|Anatomical cut|Surgeon-derived cut based on patient's anatomy
41446888|NCT03922763|PROCEDURE|Cutting guide|Angle cut at 132.5 degrees based on cutting guide
40927700|NCT02758379|DEVICE|Shockwave Coronary Lithoplasty System|Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
40927701|NCT06521450|PROCEDURE|anti incontinence surgery|anti incontinence surgery with prolapse surgery will be performed simultaneously
41276176|NCT02628925|DEVICE|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
41276177|NCT04271462|OTHER|Comparing two CO2 absorbers in the ventilator circuit|"General anaesthesia will be induced with a standardised regimen (propofol 0.8-2.5 mg·kg-1, sufentanil 0.2 - 0.5 µg·kg-1 and rocuronium 0.5 - 1 mg·kg-1). After tracheal intubation, anaesthesia will be maintained with sevoflurane targeted at 1 MAC end tidal concentration (corrected for age using the formula by Mapleson) in 40% O2. Different ventilator settings will be compared for 30 minutes (in randomised order):~I. Sodalime, FGF 2.0 L min-1. II. Amsorb Plus®, FGF 2.0 L min-1. III. Soda lime, FGF, 0.5 L min-1. IV. Amsorb Plus®, FGF 0.5 L min-1. FGF=fresh gas flow."
41446889|NCT05173298|DRUG|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
41276178|NCT02366962|BIOLOGICAL|ASP7374|subcutaneous
40927702|NCT04566445|DRUG|GT005: Medium Dose|The study will test two doses of GT005: Medium Dose and High Dose.
40927703|NCT04566445|DRUG|GT005: High Dose|The study will test two doses of GT005: Medium Dose and High Dose.
40927704|NCT00093665|DRUG|cisplatin|
40927705|NCT00093665|DRUG|fluorouracil|
40927706|NCT00093665|RADIATION|radiation therapy|
40927707|NCT03838809|DEVICE|surface electromyography-biofeedback|Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.
40927708|NCT01638442|DRUG|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
40927709|NCT01638442|DRUG|CHR-2797|"Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~--------------------------------------------------------------------------------"
40927710|NCT03513848|DEVICE|Retimer|The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (\~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
41124897|NCT03706521|DRUG|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study.
41124898|NCT04250935|DIAGNOSTIC_TEST|Patients with cognitive dysfunction|Mini Mental Test Those with a score below 21 points
41124899|NCT00903851|DRUG|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
41124900|NCT01204359|RADIATION|Iodine 131|iodine 131，185、370、555mBq，6 months
41124901|NCT05555719|DEVICE|Mandibular Protraction Appliance|Mandibular Protraction Appliance was installed on fixed orthodontic appliance
41124902|NCT05555719|DEVICE|PowerScope Appliance|PowerScope Appliance was installed on fixed orthodontic appliance
41276179|NCT04924426|PROCEDURE|TTC immersion|TTC immersion
41276180|NCT03671122|DIAGNOSTIC_TEST|Cardiac imaging in the PREFERS and CABG PREFERS cohorts|performed at baseline and after 1 year
41276181|NCT03671122|OTHER|Biomarker analysis in the PREFERS and CABG PREFERS chorts|blood samples will be taken for biomarker analysis at baseline and after 1 year
41276182|NCT03671122|PROCEDURE|Cardiac biopsies in the CABG PREFERS cohort|myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG
41276183|NCT01283256|DRUG|zonisamide|zonisamide 100mg tablets
41276184|NCT06325449|BEHAVIORAL|STREAM program|The STREAM program is a 24-week weight-loss program which includes meal replacement, dietician coaching/teaching and weekly visits with a physician.
41276185|NCT02792257|DRUG|Dronabinol (Marinol®)|5mg - 10mg daily dose
41276186|NCT02792257|DRUG|Placebo|Daily dose
41276187|NCT01475955|DRUG|Broad Area ALA 1-hour incubation|20% ALA, broad area, 1 hour incubation
41276188|NCT01475955|DRUG|Broad Area ALA 2 hour incubation|20% ALA broad area 2-hour incubation
41276189|NCT01475955|DRUG|broad area ALA 3-hour incubation|20% ALA broad area 3 hour incubation
41446890|NCT02421822|OTHER|Fitwits office tool and games|Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
40927711|NCT03513848|DEVICE|Retimer placebo|The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
40927712|NCT01486043|DRUG|Metformin|All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
40927713|NCT00140361|DRUG|Sulfadoxine-pyrimethamine|
40927714|NCT00140361|DRUG|sulfadoxine-pyrimethamine plus artesunate|
40927715|NCT00140361|DRUG|lumefantrine plus artemether|
40927716|NCT00140361|BEHAVIORAL|Sleeping under insecticide-treated bednet|
41124903|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
41276190|NCT01475955|DRUG|Spot ALA 2 hour incubation|20% ALA spot 2 hour incubation
40927717|NCT02402738|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|
40927718|NCT02402738|BEHAVIORAL|Enhanced Treatment as Usual|
40927719|NCT00893620|DEVICE|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
40927720|NCT01565343|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi)
41446891|NCT00494338|DRUG|Docetaxel|
41446892|NCT04342936|DRUG|Camrelizumab|A humanized monoclonal immunoglobulin
41124904|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
41124905|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
41124906|NCT01412736|DRUG|Placebo|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
41124907|NCT02035631|BEHAVIORAL|Diet|The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.
41124908|NCT02035631|BEHAVIORAL|Physical activity|The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).
41276191|NCT01475955|DRUG|Vehicle PDT|Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
41276192|NCT01475955|DEVICE|Blue Light Treatment|10 J/cm2 blue light delivered at 10 mW/cm2
41276193|NCT04945382|DEVICE|Scotchbond Universal 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Scotchbond universal 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
41446893|NCT04342936|DRUG|Investigator's choice of Chemotherapy|"Participants will receive one of the following chemotherapies for up to 6 cycles:~Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin."
41446894|NCT05119725|DEVICE|continous 3 day EKG monitoring with S-Patch Cardio|continous 3 day EKG monitoring with S-Patch Cardio
41446895|NCT05006794|DRUG|GS-9716|Tablet(s) administered orally
41446896|NCT05006794|DRUG|Docetaxel|Administered intravenously
40754369|NCT04779593|PROCEDURE|Bloodletting - experimental group|"Patients treated with bloodletting according to transferrin saturation and serum ferritin. Patients will undergo bloodletting with a goal of maintaining a serum transferrin saturation equal or lower than 50 % and a serum ferritin lower than the upper limit of the normal range (300 g/L for men and 200 g/L for women).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit."
40754370|NCT03422471|OTHER|Hyperinsulinemic Hypoglycemic Clamp|Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.
41276194|NCT04945382|DEVICE|Single Bond 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Single Bond 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
41276195|NCT05930860|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
41446897|NCT05006794|DRUG|sacituzumab govitecan-hziy|Administered intravenously
41446898|NCT05221554|PROCEDURE|Computer-navigated THA surgery|Navigation software coupled with real-time modeling software will be used to plan optimal acetabular cup for patients undergoing THA.
40754371|NCT06491576|DRUG|BGT-002|taking the study drug orally
40754372|NCT06491576|DRUG|Placebo|taking the placebo orally
41124909|NCT02035631|BEHAVIORAL|Minimal diet intervention|Some basic diet recommendations
41124910|NCT02035631|BEHAVIORAL|Minimal physical activity intervention|Some basic recommendations on physical activity
41446899|NCT05221554|PROCEDURE|Standard of care THA surgery|Patients already underwent THA procedure with manual placement of acetabular cup with conventional instrumentation.
41446900|NCT02464553|OTHER|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
41446901|NCT00955448|DEVICE|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
41446902|NCT00955448|PROCEDURE|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
40754373|NCT04023474|PROCEDURE|Platelet Rich Fibrin (PRF) Application|Platelet Rich Fibrin application to flap defect.
40754374|NCT04874779|OTHER|non|follow up investigations
41124911|NCT04553458|DEVICE|Radiofrequency ablation|Radiofrequency ablation of the tumour
41124912|NCT04553458|DRUG|Trance-arterial chemoembolization|Trance-arterial chemotherapy
41124913|NCT04553458|PROCEDURE|Liver resection|non-anatomical or anatomical liver resection
41124914|NCT04553458|COMBINATION_PRODUCT|Combined radiofrequency ablation + percutaneous ethanol injection|combined therapy
41446903|NCT03223779|DRUG|TAS-102|Trifluridine stops DNA replication which may prevent the cancer cells from growing
41446904|NCT03223779|RADIATION|Photon SBRT|SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
41446905|NCT03930732|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
41446906|NCT03930732|DRUG|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
41446907|NCT03930732|DRUG|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
41446908|NCT03930732|DRUG|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
41446909|NCT03930732|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
41446910|NCT00663234|DRUG|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
41124915|NCT04553458|DRUG|Percutaneous ethanol injection|Percutaneous ethanol injection of HCC
41124916|NCT04553458|DRUG|Systemic chemotherapy|Systemic chemotherapy
41124917|NCT04553458|DRUG|Sorafenib|Sorafenib
41124918|NCT04553458|DIETARY_SUPPLEMENT|Viscum|Viscum for HCC
41124919|NCT04553458|DRUG|Symptomatic treatment|Symptomatic treatment
41124920|NCT05951140|OTHER|Usage of the PROTEIN-Application|Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
41446911|NCT01349257|DRUG|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
41124921|NCT04116372|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
41124922|NCT02612233|DRUG|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
41124923|NCT02766517|DRUG|Capsaicin|Administered topically
41124924|NCT05592028|DEVICE|transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy|XDP patients will receive unilateral or bilateral transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy.
41124925|NCT05310916|DRUG|Dapagliflozin 10mg Tab plus another oral hypoglycemic agent|Dapagliflozin is a member of Sodium-glucose co-transporter 2 inhibitors class which in addition to its glucose control effect, has reno-protective and cardioprotective effects, controls blood pressure and causes weight loss.
41124926|NCT05310916|DRUG|Two oral hypoglycemic agents other than dapagliflozin|Two oral anti-diabetic agents not including sodium-glucose co-transporter 2 inhibitors
41124927|NCT02634892|DEVICE|PRO-TECT|Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
41446912|NCT05264363|DEVICE|VIPUN Gastric Monitoring System prototype|The Investigational Medical Device (IMD) is used simultaneously with the reference device (solid state high-resolution manometry) to record gastric intraluminal pressure for approximately 2.5 hours.
40947870|NCT04186936|DRUG|Loperamide HCl|Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.
40947871|NCT04186936|DRUG|Simethicone|Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
40754375|NCT01336972|DRUG|Tolvaptan|Tolvaptan was supplied as 15 and 30 mg tablets.
41124928|NCT00010777|PROCEDURE|Multiple Component Mind/Body therapy|
41124929|NCT02574806|PROCEDURE|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
41124930|NCT01095822|DRUG|Aliskiren + Valsartan|Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
41124931|NCT05917015|DIETARY_SUPPLEMENT|Treatment|Participants will receive daily 2 tablets of Proglucamune for a duration of 6 weeks. Each tablet contains \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
41124932|NCT05917015|OTHER|Placebo|Participants will receive daily 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
41124933|NCT02005406|DEVICE|Experimental group and control groupl|JET
41124934|NCT00220740|DRUG|Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
41446913|NCT03432663|DRUG|Intravenous amiodarone(1)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached
40947872|NCT01377571|BIOLOGICAL|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
41446914|NCT03432663|DRUG|Intravenous amiodarone(2)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached
41446915|NCT04125914|BEHAVIORAL|Behavioral Dietary Intervention|Record food intake
41446916|NCT04125914|OTHER|E-mail|Receive e-mails
41446917|NCT04125914|BEHAVIORAL|Exercise Intervention|Undergo exercise
41446918|NCT04125914|OTHER|Health Promotion and Education|Receive text messages
41446919|NCT04125914|OTHER|Internet-Based Intervention|Join Facebook page
41446920|NCT04125914|OTHER|Questionnaire Administration|Ancillary studies
41446921|NCT04125914|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching
41446922|NCT06203210|DRUG|Ifinatamab deruxtecan|12 mg/kg intravenous dose on Day 1 of each 21-day cycle
41446923|NCT06203210|DRUG|Topotecan|Topotecan will be administered per local SoC.
40927721|NCT04264052|DIAGNOSTIC_TEST|CBE & MRI|"The diagnostic tests will be consisted by two visits.~In the first visit participants will undergo a medical history assessment and they will complete questionnaires related to the lung function (MRC Dyspnoea score, Dyspnoea-12 questionnaire, and Visual Analogue Scale). A spirometry will be performed to assess the lung function. Bronchoscopy will be performed at rest in a semi-supine position (on a reclined bed) and then during exercise on a treadmill.~In the second visit, spirometry and questionnaires will be performed prior to resting and during exercise measurements on a magnetic resonance imaging (MRI) scan.~Rest: Structural imaging of the neck and chest will be performed followed by dynamic imaging of the airways during several inspiratory and expiratory manoeuvres. No IV contrast media will be used."
40927722|NCT01456910|BEHAVIORAL|Resistance Training Program|Frequency, volume, repetitions, load, interval
40927723|NCT03829800|DIETARY_SUPPLEMENT|Ensure® Abbott Nutrition|Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
40927724|NCT03829800|DIETARY_SUPPLEMENT|Glucerna® Abbott Nutrition|Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
40927725|NCT03829800|DIETARY_SUPPLEMENT|Diasip® Nutricia Advanced|Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
41276196|NCT04990739|DRUG|MTB-9655|"MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime."
41276197|NCT05021809|DRUG|Calcium hydroxide intracanal medication application|The patient will be anaesthized with Articaine hydrochloride 40 mg/ml + 1/100000 Epinephrine bitartrate solution . Then the rubber dam isolation will be conducted, the access will be opened and then cleaning and shaping will be done by using Protaper Next rotary file system and irrigation by sodium hypochlorite 2.5% by side vented needle, EDTA 17%, sodium hypochlorite and the final rinse by saline where the canal will be dried by absorbent paper point. The application of calcium hydroxide intracanal medication will be done according to the manufacturer instructions then temporization by glass ionomer will be applied .
41276198|NCT03855072|PROCEDURE|customized fixation plate|"* All cases will undergo one surgery under general anesthesia.~* Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~* Amucoperiosteal flap was reflected to expose the lateral mandibular ramus to the posterior border and the sigmoid notch~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* 3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~* The customized fixation plate is positioned to fix the proximal and distal segment together after setback"
41276199|NCT03855072|PROCEDURE|maxillomandibular fixation|"* All cases will undergo one surgery under general anesthesia.~* incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint to assure accuracy of the mandibular position."
41446924|NCT06203210|DRUG|Amrubicin|Amrubicin will be administered per local SoC.
41446925|NCT06203210|DRUG|Lurbinectedin|Lurbinectedin will be administered per local SoC
41446926|NCT00919113|DRUG|2% sodium chondroitin sulfate|Weekly 20 mL Intravesical instillation
41446927|NCT00919113|DRUG|Placebo|The identical buffer used in Uracyst for the same administration
41446928|NCT06066047|OTHER|TOUCH ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~Throughout the treatment, the practitioner maintained a focused attention on touch by voluntarily and constantly directing attention to the sensation/perception of the hands, perceiving texture, density, temperature, reactivity and motility of the tissue."
40927726|NCT03829800|DIETARY_SUPPLEMENT|Glicolab®|Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
41124935|NCT00220740|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
41124936|NCT06522035|DRUG|Allocetra|Intra-articular injecton of Allocetra into the target joint.
41124937|NCT01805219|OTHER|GPS and accelerometer recording (s) during exercises|
41124938|NCT03716336|OTHER|Resistance exercise|Resistance exercise were performed for all participants in group (A) only included 9 exercise for big muscles of upper limbs (shoulder flexors muscles, shoulder extensors and shoulder abductors), lower limbs (hip flexors, hip extensors and knee flexors and knee extensors) and abdominal muscle using moderate work load (60 - 75% of IRM) 1set of 10 repetitions, progressing to 2 sets of 10 repetitions after four weeks for 20 minutes
41124939|NCT03716336|OTHER|Aerobic exercise|aerobic exercise were performed on treadmill. For 20 minutes. All patients in both groups (A,B) had attended the program of a resistance exercises and followed by aerobic exercise for 8 weeks in form of 20 minutes walking on the treadmill without inclination.
41124940|NCT03716336|DIETARY_SUPPLEMENT|diet restriction|All participants in both groups (A,B) were instructed to follow a moderate restricted diet limited to (1800-2000) kcal/ day under supervision of a certified dietician. The diet contained: Protein and fibers: 20% carbohydrate: 50-60%, fat: low 20%.
41446929|NCT06066047|OTHER|AUDITORY ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~During the treatment, the operator's attention was focused on acoustic signals delivered through earphones. The beeps were delivered at random intervals between 0.5 and 2.0 seconds. The operator had to count the number of acoustic signals produced during the treatment period."
41446930|NCT05972759|OTHER|Forced and voluntary exercise|Twenty-five participants with PD utilizing the Medtronic Percept PC DBS system will be enrolled for this project and complete a single bout of both FE and VE. The 150-minute experimental session will be completed in the OFF antiparkinsonian and Off-DBS state.
41446931|NCT02004769|DRUG|Trastuzumab|Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
41446932|NCT02004769|DRUG|Docetaxel|Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
41446933|NCT02004769|DRUG|Capecitabine|Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
41446934|NCT05659576|DRUG|Sucralfate|"1. Sucralfate, 1 gram/10 mL oral suspension By mouth, take 10 mL twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.May increase frequency up to 4 times per day, per physician discretion. Or~2. Sucralfate 1 gram tablets By mouth, take one (1) tablet mixed in 15-30 mL warm water twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.~The frequency of sucralfate can be adjusted at anytime at the treating physician's discretion after the patient has started it at twice a day, and the patient may discontinue sucralfate at anytime after RT completion, per physician discretion. May increase frequency up to 4 times per day, per physician discretion."
41124941|NCT01655563|DRUG|Tacrolimus|Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
41446935|NCT05659576|OTHER|Usual Care|Standard supportive care by using opioids.
40754376|NCT04280861|OTHER|Multicomponent Intervention|Multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
41124942|NCT02910713|DEVICE|Intranasal Tear Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
41124943|NCT05128968|PROCEDURE|endotracheal intubation|Endotracheal intubation is performed in simple head extension or sniffing position using a McGrath MAC videolaryngoscope.
41124944|NCT01821989|DIETARY_SUPPLEMENT|Lactoferrin|dose of 100 mg/day
41124945|NCT01821989|DIETARY_SUPPLEMENT|Lactoferrin|dose of 150 mg/kg/ twice daily
41124946|NCT01821989|DIETARY_SUPPLEMENT|Placebo|in form of distilled water
41124947|NCT02345720|DEVICE|etafilcon - PVP (multi-focal)|The investigational contact lens must be worn at least six hours daily.
41446936|NCT05659576|OTHER|One consent|Patient will sign one consent form.
41446937|NCT05659576|OTHER|Two consent|Patient will sign two consent forms.
41446938|NCT04738448|BEHAVIORAL|Art Therapy Group|The art therapy intervention will be executed by the same Medical University of South Carolina (MUSC) board-certified art therapist for each group. The art therapist is a masters-level, licensed practitioner who has experience working in the healthcare system and treating providers. The same art therapy practices that are utilized in daily practice at MUSC will be employed in this study, with a focus on reducing burnout symptoms. Pilot testing of the intervention has been performed informally at MUSC with positive feedback reported by healthcare providers.
41446939|NCT05007067|DEVICE|DELTA Multihole TT|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
41124948|NCT02374463|BEHAVIORAL|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
41276200|NCT01882361|DRUG|injectable naltrexone|Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
41276201|NCT01882361|DRUG|placebo comparator|this placebo has no specific pharmacological activity
41276202|NCT01009294|DRUG|Ataluren|Oral powder
41276203|NCT01009294|DRUG|Chronic Corticosteroid Therapy|Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
41276204|NCT02367950|BEHAVIORAL|Exercise|10 exercise sessions with a personal trainer
41276205|NCT04425655|DRUG|Fludarabine|30mg/m2 days 1 through 5
41276206|NCT04425655|DRUG|Vyxeos|100U/m2 days 1, 3 5 in induction, 65U/m2 days 1 and 3 for consolidation
41276207|NCT05369806|BEHAVIORAL|Interactive two-way SMS dialogue|This study uses Mobile WACh, a human-computer hybrid system that enables two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day. Women who experience pregnancy or infant loss will be enrolled into an infant loss track. The NLP model will be applied to incoming participant messages. Those flagged as urgent by the model will be flagged within the SMS system, allowing study nurses to triage and appropriately respond to those messages.
41276208|NCT05085002|DRUG|Lerociclib + Letrozole or Fulvestrant|All participants (1L and 2L populations) will receive an AI (letrozole) or fulvestrant plus lerociclib 150 mg BID.
41276209|NCT05527184|DRUG|IMGN151|IMGN151 is an antibody-drug conjugate (ADC).
41276210|NCT01276886|DRUG|antibiotic|
41276211|NCT01276886|PROCEDURE|Colonic resection with or without stoma|
41276212|NCT04831450|DRUG|Cemiplimab-Rwlc|350 mg Cemiplimab administered via intravenous infusion over 30 minutes on Day 1 of a 21-day cycle.
41276213|NCT01350869|DEVICE|Xience|Patients with Xience
41276214|NCT02588378|PROCEDURE|multi-modal cSLO imaging|
41276215|NCT03198221|DRUG|Golytely|bowel preparation
41446940|NCT06627946|PROCEDURE|TAP group|Local anesthesia 0.25% bupivacine was administered in the TAP plane
41446941|NCT03033810|DEVICE|Fractional flow reserve and instantaneous wave-free ratio|"1. To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~2. The development of software for the automatic detection of the lowest point of microvascular resistance."
41446942|NCT06384807|DRUG|PBI-410|PBI-410 will be administered as an IV infusion on Day 1 of each 21-day cycle.
41446943|NCT06384807|DRUG|Cemiplimab|cemiplimab (350mg) will be administered as an IV infusion on Day 1 of each 21-day cycle
41276216|NCT03198221|DRUG|Clenpiq|bowel preparation
41276217|NCT00552266|DRUG|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
41276218|NCT01569581|BIOLOGICAL|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
41276219|NCT01569581|BIOLOGICAL|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
41276220|NCT01569581|BIOLOGICAL|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
41276221|NCT01569581|BIOLOGICAL|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
41276222|NCT00728546|DRUG|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
41276223|NCT05569135|DEVICE|Laser ablation|A diode-laser that has been reported to be safe and effective in several treatments including pilonidal disease, anal fistula, hemorrhoids, and vascular ablation was used to obtain shrinkage of pilonidal cyst
41276224|NCT02622932|DRUG|Anlotinib and 14C-labeled Anlotinib|oral
41276225|NCT02082197|DRUG|ABT-SLV176|ABT-SLV176 administered daily
41124949|NCT02374463|BEHAVIORAL|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
41124950|NCT03032458|DRUG|Pethidine|pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
41124951|NCT03032458|DRUG|Ketorolac|ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
41124952|NCT03032458|DRUG|Xylocaine Gel|Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
41276226|NCT06337396|DIAGNOSTIC_TEST|WGS and transcriptome analysis|In light of the inconsistencies between the CNV and the phenotypic outcome, we expect that WGS analysis will reveal that part of these CNVs have a more complex structure than the one disentangled by CMA and FISH. We hypothesize that CNV should reflect a perturbed genome folding configuration at several hierarchical levels of chromatin organization, such as disruption of TADs boundaries. To investigate this aspect, we plan to examine expression profiles of immortalized lymphoblastoid B-cell lines (LBLs) derived from normal controls and patients. We expect to find a subset of down- or up-regulated genes located inside the rearranged region which in turn may alter the expression of other genes, possibly leading to perturbation of disease-related pathways
41276227|NCT03270748|DRUG|GvHD prophylaxis|Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
41124953|NCT03548857|OTHER|Lung transplantation|Single or double lung transplantation in patients with COPD
41124954|NCT06330298|BEHAVIORAL|Treatment social cognition and emotion regulation (T-ScEmo)|T-ScEmo is a multifaceted treatment protocol that has the overall aim to improve social cognition, regulation of social behaviour and social participation in everyday life (Westerhof et al., 2017; 2019). The treatment includes, in addition to practicing social cognitive skills throughout the treatment, close involvement of a significant other, and homework assignments. The treatment consists of three modules that address 1) perception of social information including facial expressions of emotions, 2) perspective taking and understanding of social information and 3) regulation of social behaviour. The treatment contains 15-one hour live treatment sessions with a neuropsychologist and 5 online practice sessions, once or twice a week. In the online sessions, the patient can practice the information at home as a neuropsychologist is available for questions. When patients find it too difficult to practice individually at home, there is a opportunity to offer these sessions as live sessions
41124955|NCT00137722|BEHAVIORAL|Education of providers and their staff|
41124956|NCT00137722|BEHAVIORAL|Case management|
41124957|NCT00137722|BEHAVIORAL|Payment for desired behaviors|
41124958|NCT01891084|DRUG|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
41124959|NCT01891084|DRUG|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
41124960|NCT01891084|DRUG|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
41124961|NCT04458454|DIAGNOSTIC_TEST|Relaxin ELISA Kit|Ovarian stimulation was carried out from day 3 of the menstrual cycle using a fixed protocol, with recombinant (Gonal-F, Pergoveris) or human menopausal gonadotropins (Meriofert), GnRH antagonist (ganirelix 0.25 mg). A recombinant human chorionic gonadotropin Ovitrel 250 μg or a GnRH agonist, Diferelin 0.2 mg, was used as an ovulation trigger.
41124962|NCT03529305|DEVICE|rTMS|Receive rTMS treatment to the primary motor cortex (M1)
41124963|NCT03529305|OTHER|Physical therapy|Receive physical therapy
41124964|NCT02538653|OTHER|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
41124965|NCT02538653|OTHER|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
41124966|NCT00031785|DRUG|megestrol acetate|
41124967|NCT00031785|RADIATION|radiation therapy|
41124968|NCT02167958|DRUG|Fludarabine|"Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).~For decreased creatinine clearance (\< 61 mL/min) determined by the Cockcroft Formula:~Cockcroft-Gault CrCl = (140-age) \* (Wt in kg) \* (0.85 if female) / (72 \* Cr)~Fludarabine dosage should be reduced per standard of care."
41124969|NCT02167958|DRUG|Cyclophosphamide|"Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide \[50mg/kg\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~."
41276228|NCT00303810|DRUG|carboplatin|
41276229|NCT00303810|DRUG|cisplatin|
41276230|NCT00303810|DRUG|cyclophosphamide|
41276231|NCT00303810|DRUG|etoposide phosphate|
41276232|NCT00303810|DRUG|high-dose chemotherapy|
41276233|NCT00303810|DRUG|lomustine|
41276234|NCT00303810|DRUG|methotrexate|
41276235|NCT00303810|DRUG|thiotepa|
41276236|NCT00303810|DRUG|vincristine sulfate|
40927727|NCT03632486|OTHER|Bedside Ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.~* Lung ultrasound to assess for pleural effusions and sonographic b lines."
40927728|NCT04013399|DEVICE|Continuous Positive Airway Pressure|The device is an auto-adjusting pressure device with an integrated humidifier. Pressure is adjusted based on airway resistance.
41276237|NCT00303810|RADIATION|radiation therapy|
41276238|NCT03763786|DRUG|Cetrorelix Acetate|Used a standard
40927729|NCT03098888|PROCEDURE|bronchoalveolar lavage|bronchoalveolar lavages performed for cytological assessment in critically ill patients with lung diseases, intubated or not
40927730|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF glucosamine salt|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) glucosamine salt
40927731|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF calcium salt 1|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 1
40927732|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF calcium salt 2|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 2
41124970|NCT02167958|DRUG|Mesna|"Pre-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.~Post-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide."
41124971|NCT02167958|RADIATION|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
41124972|NCT02167958|OTHER|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
41124973|NCT02167958|DRUG|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
41124974|NCT02167958|DRUG|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
41124975|NCT02167958|DRUG|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is \> 1,000/mm3 for three consecutive days.
41124976|NCT05621499|DRUG|HAIC|Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles
41124977|NCT05621499|DRUG|Sintilimab|200mg，iv，d1，q3w，a total of 3 cycles
41124978|NCT05621499|DRUG|Lenvatinib|12 or 8mg/kg，po，qd，a total of 3 cycles
41124979|NCT02796586|OTHER|Counseling|Participants will be randomly assigned to group versus individual contraceptive counseling
41124980|NCT00412308|PROCEDURE|Tidal volume used in mechanical ventilation|
41276239|NCT04747405|OTHER|therapy group|therapy group of maximum 8 people repeated twice
41276240|NCT00049127|DRUG|Imatinib Mesylate|Given PO
40927733|NCT01162798|OTHER|infant formula|test infant formula fed to infants until 6 months corrected gestational age
40927734|NCT01162798|OTHER|control infant formula|commercially available infant formula
40927735|NCT04322370|PROCEDURE|Standard of Care Surgical Procedure|Zone 2 Flexor Tendon surgical repair will be performed by the principal investigator per standard of care. The same technique of tendon repair will be performed for all patients.
41276241|NCT00049127|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41276242|NCT00049127|OTHER|Pharmacological Study|Optional correlative studies
41276243|NCT03411343|PROCEDURE|Interscalene Block|Injection with ultrasound guidance of 20mL of levobupivacaine 0.5% with 5 micrograms of epinephrine per mL in the interscalene groove of the brachial plexus.
41276244|NCT03411343|PROCEDURE|Costoclavicular Infraclavicular Block|Ultrasound guided brachial plexus block injecting 20mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in between the cords of the brachial plexus at the costoclavicular infraclavicular space.
41276245|NCT06006975|RADIATION|Computed Tomography (CT) and Computed Tomography Angiography (CTA)|CT and CTA examinations are performed as a routine procedure to evaluate SAH severity and to diagnose cerebral vasospams and delayed cerebral ischemia.
41276246|NCT06006975|DIAGNOSTIC_TEST|Multimodal physiological monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) measured in middle cerebral artery and heart rate.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
41276247|NCT04278131|DRUG|BS01|Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
41276248|NCT03373019|DRUG|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
41276249|NCT00590161|DRUG|pentoxifylline (PTX)|400 mg PO tid
41276250|NCT00590161|DRUG|placebo|placebo tid
41446944|NCT04544618|DEVICE|Virtual reality operating room simulation|The virtual reality simulation will begin with the participant sitting on a hospital bed wearing the virtual reality headset and holding the controllers. Participants will be oriented to the environment and provided with an explanation of how to navigate through the simulation (for approximately 2 minutes). Next, participants will explore the virtual operating room for a minimum of 5 minutes, or longer if desired. Following the exploration period, the scripted portion of the simulation will be begin. Here, participants will be taken through the mock anesthetic induction process (the virtual anesthetist will speak to the patient and walk them through the steps and the virtual nurse will assist). The simulation ends after the virtual oxygen mask is placed over the participant's mouth and the screen darkens.
41124981|NCT02808767|DRUG|Prasugrel|Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose
41124982|NCT02808767|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose
41124983|NCT03298789|OTHER|Activation exercise|Two series of 4 activation exercise will be included in the intervention.
41124984|NCT03298789|OTHER|7 series of static stretching|7 series of 4 20 seconds static stretches will be conducted.
41124985|NCT00431834|DEVICE|Cardioblate System Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
41124986|NCT00431834|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
41276251|NCT01407120|BEHAVIORAL|New Beginnings Program|A preventive intervention for divorced families.
41276252|NCT02730806|BEHAVIORAL|NLP|NLP techniques, such as VKD, visual/auditory/kinesthetic swishes, modified especially for PTSD, will be implemented one-on-one with each woman in this arm.
41276253|NCT00021294|DRUG|eflornithine|
41276254|NCT00021294|DRUG|triamcinolone|
41276255|NCT03642184|DRUG|Empagliflozin|Dosage adjustment based on glucose targets . Once daily
41276256|NCT03642184|DRUG|Linagliptin|Dosage adjustment based on glucose targets. Once daily
41276257|NCT02066064|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy
41276258|NCT02066064|PROCEDURE|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
41276259|NCT01162850|DIETARY_SUPPLEMENT|Polypodium Leucotomos|Oral capsule at 240 mg taken twice a day for 12 weeks
41276260|NCT01162850|DIETARY_SUPPLEMENT|Placebo|240 mg Placebo taken orally twice daily created by company which manufactured active ingredient
41276261|NCT05091138|DRUG|Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
41276262|NCT05091138|DRUG|Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
41446945|NCT06046820|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
40754377|NCT00721890|DIETARY_SUPPLEMENT|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
41124987|NCT00002036|DRUG|Anti-HIV Immune Serum Globulin (Human)|
40754378|NCT05259176|DEVICE|transcranial Direct Current Stimulation (tDCS)|Direct current transcranial stimulation will be applied for 20 minutes over the left posterior parietal cortex with an intensity set to 2 mA.
40754379|NCT05259176|DEVICE|Sham stimulation (sham-tDCS)|The same positioning of electrodes as the stimulation condition will be used, but the current will be applied for 30 seconds and then progressively reduced.
41124988|NCT01581372|OTHER|Pharmacist care|Pharmacist prescribing, education, drug management
40754380|NCT05259176|DEVICE|Behavioural|Treatment for upper limbs ideomotor apraxia (Smania et al., 2000)
41446946|NCT06046820|DRUG|Control Arm (Conventional Therapy)|Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm.
41446947|NCT05604014|BEHAVIORAL|My Health Coach|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
41446948|NCT02728999|PROCEDURE|Steep Trendelenburg|"•Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
41446949|NCT02728999|PROCEDURE|Decreased Trendelenburg|"•Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
41446950|NCT05388266|OTHER|Mask ventilation|Mask ventilation is performed under paratracheal pressure or no pressure in a randomized, crossover manner.
41446951|NCT00820885|DRUG|teduglutide|subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
41446952|NCT00820885|DRUG|teduglutide|Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
41446953|NCT00820885|DRUG|tedguglutide|lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
40927736|NCT04322370|DEVICE|VersaWrap Treatment|is intended to manage and protect tendon injuries where there is no significant loss of tendon tissue
41124989|NCT00505934|DRUG|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily).~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily)."
41124990|NCT02869334|DEVICE|Active Transcranial direct current stimulation (tDCS)|Active tDCS, where an extremely weak electric current passes through the brain
41276263|NCT01217775|DRUG|PH80|PH80 intranasal spray 800 nanograms
41276264|NCT01217775|DRUG|Placebo intranasal spray|Placebo intranasal spray
41276265|NCT03717740|DRUG|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
41276266|NCT03717740|DRUG|Placebo|Patients will take an inert tablet similar in appearance, color, and consistency from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
41276267|NCT03116880|PROCEDURE|Endovascular aortic repair|Endovascular aortic repair
41276268|NCT03652922|DRUG|Reactivation Mismatch|"Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative."
41276269|NCT06018883|DRUG|Ascorbate|Vitamin C 900 mg/day, three times a day, orally.
41276270|NCT06018883|DRUG|Nab paclitaxel|Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks
41276271|NCT06018883|DRUG|Gemcitabine|Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
41276272|NCT03051633|BEHAVIORAL|Be Under Your Own Influence|School based anti-drug use communications campaign
41446954|NCT05402358|OTHER|Acceptance and Commitment Therapy Group Intervention|The intervention consists of 7, 2-hour weekly sessions. Session 1 focused on introductions, outlining sessions and sharing experiences. Session 2 introduced key techniques used in the psychological approach (ACT) including mindfulness and understanding difficult thoughts and feelings. Session 3 explored ideas of primary and secondary suffering and reviewed the workability of current coping strategies. Session 4 asked participants to clarify their own personal values. Session 5 focused on goal setting and utilising problem solving skills. Session 6 considered barriers to change including assertiveness communication skills. Session 7 reviewed topics covered over the 6 weeks previously and explored pacing and preparing for setbacks. Finally a follow up 8 weeks later brought participants back for a reunion to review progress with goals and offer an opportunity to address any ongoing issues.
41446955|NCT01439451|PROCEDURE|perturbation training|The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
41446956|NCT00635648|DRUG|caspofungin acetate|Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
41124991|NCT02869334|DEVICE|Sham Transcranial direct current stimulation (tDCS)|Sham (inactive or placebo) tDCS
41124992|NCT02869334|BEHAVIORAL|Auditory Remediation|Computer program designed to improve discrimination between sounds
41124993|NCT02869334|BEHAVIORAL|Control computer activities|Computer program (e.g. games), which are not designed to improve discrimination between sounds
41124994|NCT00476385|DRUG|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
41124995|NCT00371670|DRUG|balicatib (AAE581)|
41124996|NCT04308083|PROCEDURE|dental implant placement|Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
41124997|NCT03011489|DEVICE|Vacuum formed aligners|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is a modified step in Figueroa's technique.
41276273|NCT00897702|OTHER|Blood draw|A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.
41276274|NCT00897702|OTHER|immunoenzyme technique|
41276275|NCT00897702|PROCEDURE|biopsy|
41276276|NCT00897702|PROCEDURE|histopathologic examination|
41276277|NCT01903876|BEHAVIORAL|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
41276278|NCT01903876|BEHAVIORAL|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
41276279|NCT04821284|DRUG|Gemcitabine Hydrochloride|Given IV
41276280|NCT04821284|DRUG|Nab-paclitaxel|Given IV
41276281|NCT04821284|DRUG|Fluorouracil|Given IV
41276282|NCT04821284|DRUG|Irinotecan Hydrochloride|Given IV
41124998|NCT00775294|DRUG|Maraviroc|Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
41124999|NCT04907513|OTHER|Assessment of the Motivational State|A motivational interviewing algorithm developed in Rothschild Hospital for this study will be used. The results range between 0% (worst motivational state) to 100% (best motivational state).
41125000|NCT01859559|PROCEDURE|Ultrasound-guided peripheral intravenous access line placement|The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
41125001|NCT01859559|PROCEDURE|Landmark Approach to peripheral intravenous access line placement|ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
41125002|NCT00570466|BEHAVIORAL|Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
41125003|NCT00570466|BEHAVIORAL|Web and DVD knowledge|Web and DVD based knowledge games
41125004|NCT03190603|DRUG|Celecoxib|Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
41125005|NCT01302158|DRUG|ASP1941|oral
41125006|NCT01302158|DRUG|Glimepiride|oral
41125007|NCT04638816|DEVICE|Restylane Volyme|Hyaluronic Acid: Injectable gel for contouring effect (of cheek volumization).
41125008|NCT04638816|DEVICE|Restylane Lyft Lidocaine|Hyaluronic Acid: Injectable gel for projection effect (of cheek augmentation).
41125009|NCT02624258|BIOLOGICAL|CD19 RNA redirected autologous T-cells (RNA CART19 cells)|Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
41125010|NCT03480776|DRUG|Acetylsalicylic acid|81 mg PO daily or 325 mg PO daily
41276283|NCT04821284|DRUG|Leucovorin Calcium|Given IV
41276284|NCT04821284|DRUG|Oxaliplatin|Given IV
41276285|NCT04821284|OTHER|Perflubutane Microbubble|Oxaliplatin
41276286|NCT04821284|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
41276287|NCT04821284|OTHER|Quality-of-Life Assessment|Ancillary studies
41276288|NCT04821284|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41276289|NCT04821284|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41276290|NCT04439890|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
41276291|NCT04439890|DRUG|Carboplatin injection|Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
41276292|NCT04439890|DRUG|Pemetrexed disodium f Injection|Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
41276293|NCT04439890|DRUG|Placebo|Placebo
41276294|NCT02612909|BIOLOGICAL|IVACFLU-A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
41276295|NCT02612909|BIOLOGICAL|Placebo|Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
41276296|NCT06447012|DIAGNOSTIC_TEST|Colonoscopy|No intervention required from this study, however images will be obtained from patient presenting for colonoscopy
41276297|NCT00499707|DRUG|rosiglitazone maleate/metformin hydrochloride|rosiglitazone maleate/metformin hydrochloride
41276298|NCT01245244|DRUG|Morphine|Morphine oral mixture
41276299|NCT01245244|OTHER|orange juice|orange juice
41276300|NCT04561180|DRUG|EG-009A|Administered as an Intramuscular injection
41276301|NCT04561180|DRUG|EG-009A Placebo|Administered as an Intramuscular injection
40927737|NCT03109912|BEHAVIORAL|Personalized-Coaching Interventions|At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
41446957|NCT01348438|DEVICE|Medtronic Engager Transcatheter Aortic Valve Implantation System|Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
41446958|NCT06561906|OTHER|Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing|Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP
41446959|NCT04922554|DRUG|Omadacycline Oral Tablet|omadacycline 300 mg orally, once daily (150 mg tablets x 2)
41446960|NCT04922554|DRUG|Placebo|placebo tablets resembling omadacycline orally, once daily (x 2 tablets)
41446961|NCT03554473|DRUG|M7824|Arm A \&amp; B: 2400mg IV over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.
41446962|NCT03554473|DRUG|Topotecan|Arm B: 1 mg/m2 IV over 30 minutes days 1-5 on a 3-week cycle.
41446963|NCT03554473|DRUG|Temozolomide|Arm C and progressive disease patients on Arm A: 200 mg/m2 PO days 1-5 on a 4-week cycle
41446964|NCT04822259|DEVICE|JOURNEY II BCS Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
41446965|NCT04822259|DEVICE|JOURNEY II CR Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
41446966|NCT05028608|DRUG|Elinzanetant (BAY3427080)|Elinzanetant given orally as a single dose in Period 1 and in Period 2.
41446967|NCT05028608|DRUG|Midazolam|Midazolam given orally as single dose in Period 1 and in Period 2.
40927738|NCT03109912|BEHAVIORAL|Motivational Messages|Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
40927739|NCT03109912|BEHAVIORAL|Online Exercise Tutorials|Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
41125011|NCT03480776|OTHER|Placebo|One tablet PO daily
40927740|NCT03109912|BEHAVIORAL|Social Support and Peer Challenges|Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
41125012|NCT02345603|PROCEDURE|Cryo-therapy|Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
41276302|NCT04561180|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
40927741|NCT00555425|BEHAVIORAL|Behavioral: Buprenorphine/naloxone maintenance (Mtn)|Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.
40927742|NCT00555425|BEHAVIORAL|Behavioral: Buprenorphine/naloxone detoxification (Dtx)|Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
41446968|NCT05028608|DRUG|Carbamazepine|Carbamazepine given orally twice daily in Period 2 .
41446969|NCT06467513|DRUG|Esketamine hydrochloride injection|The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.
41446970|NCT05079828|DIAGNOSTIC_TEST|18F-PSMA-1007|PET/CT scan using 18F-PSMA-1007
41276303|NCT04561180|DRUG|Dexamethasone|The comparator, Administered as an Intravenous infusion
41446971|NCT05079828|DIAGNOSTIC_TEST|68Ga-PSMA-11|PET/CT scan using 68Ga-PSMA-11
41446972|NCT06348888|DRUG|BAY2927088|Oral
41446973|NCT06348888|DRUG|Itraconazole|Capsule, 100 mg, oral.
41446974|NCT06348888|DRUG|Carbamazepine|Tablet, 100 mg, 200mg and 300mg, oral.
41446975|NCT06487273|DEVICE|SIMEOX|Use of the CE-marked SIMEOX medical device. No specific limitation of the number of use but recommendation to use it daily (and more if needed).
41276304|NCT05238051|OTHER|Gastric residual volume measurement stopped.|GRV is checked during routine enteral nutrition, but we think that GRV prolongs the time to reach target calories and does not reduce complications.
41276305|NCT03423355|DRUG|Dapagliflozin (Forxiga®)|10mg p.o. daily
41446976|NCT06487273|OTHER|Remote Physiotherapy|Remote Physiotherapy with physiotherapists, once a month for the first 3 months and once every 3 months after
41446977|NCT04819386|OTHER|Active vision therapy sessions with the NEIVATECH Virtual Reality-based system|The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).
41446978|NCT02524691|DEVICE|Use of Rapid Immunoassay Tests for the Detection of PROM|Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.
41125013|NCT00504322|GENETIC|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10\^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
41125014|NCT00504322|GENETIC|Placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
40927743|NCT02158364|DRUG|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
41125015|NCT01915459|BIOLOGICAL|Botulinum toxin type A(Botulax®)|IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
41125016|NCT01915459|BIOLOGICAL|Botulinum toxin type A(Botox®)|
41125017|NCT03155113|OTHER|blood drawing|Before starting therapy a blood sample will be collected from any subject.
41125018|NCT04761042|OTHER|WAYA-Wilderness|"The wilderness intervention includes challenging tasks in order to help participants' overcome and master new physical and psychological challenges in an unknown environment, with the idea to support self-efficacy, self-esteem, and ability to recover from adversity. The program is designed to encourage participants to connect with nature as to experience gratitude for the richness of the natural world, a sense of calmness and trust upon spending time in nature, and to be more physically active in nature.~Elements previously described Participants will continue in a three-month program at home (on-line supported) after the initial 8-days in order to empower participants to incorporate elements of the onsite wilderness program into their daily life. An individualized a plan for activities will be developed together with the participant.~After three months, there will be a re-visit with follow up on outcome measures and reconnection."
41125019|NCT04761042|OTHER|WAYA-Holiday|"An attention control group (information in Detailed description)"
41125020|NCT03810859|BIOLOGICAL|Blood sample|Adults : 7 to 10 mL Childs : 2 to 4 mL
41125021|NCT01143142|BEHAVIORAL|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
41125022|NCT03394534|OTHER|CGA group|CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
41125023|NCT01150656|GENETIC|gene expression analysis|
41125024|NCT01150656|GENETIC|microarray analysis|
41125025|NCT01150656|GENETIC|protein expression analysis|
41125026|NCT01150656|GENETIC|reverse transcriptase-polymerase chain reaction|
41125027|NCT01150656|GENETIC|western blotting|
41125028|NCT01150656|OTHER|laboratory biomarker analysis|
41125029|NCT01150656|OTHER|pharmacological study|
41125030|NCT01086982|DRUG|Octreotide acetate LAR|30 mg, single dose
41125031|NCT01086982|DRUG|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|30 mg, single dose
41125032|NCT04436289|BEHAVIORAL|Home Link|In the Home Link intervention, a team will conduct home visits to (1) provide a structured clinical assessment; (2) reconcile medications, (3) provide psychosocial support through patient-centered counseling, and (4) assess home needs (food security). These visits will start one week after discharge and be repeated every two weeks until the participant is stabilized and ready to initiate lower intensity clinic-based services or three months have elapsed.
41125033|NCT04033315|DEVICE|L-PLUS meter|Blood Glucose Monitoring System
41125034|NCT00585156|DRUG|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
41125035|NCT01020643|DRUG|controlled administration of propofol|comparison of propofol sedation
41125036|NCT00105313|DRUG|MEDI-507|
41125037|NCT01150916|PROCEDURE|BNP, SAAG, ascites total protein, echocardiography|diagnostic tests
41125038|NCT01420458|DRUG|Experimental|Bioequivalence of two drug formulations
41125039|NCT02753738|DRUG|Escitalopram|Tablet 10mg, 21 days
41125040|NCT02753738|DRUG|Placebo|Tablet, 21 days
41125041|NCT02753738|OTHER|3xMR scan (fMRI, DTI, strucutral MRI)|3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms
41125042|NCT02753738|BEHAVIORAL|Association learning paradigm|21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
41125043|NCT02753738|BEHAVIORAL|Association re-learning paradigm|21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
41125044|NCT00903162|DRUG|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
41125045|NCT00903162|DRUG|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
41125046|NCT00903162|DRUG|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
41125047|NCT02395744|OTHER|Paclitaxel administration using the OPC|
41125048|NCT02886195|DRUG|pemetrexed|500mg/m2 ivgtt d1, per three weeks
41125049|NCT02886195|DRUG|cisplatin|80mg/m2 ivgtt d1, per three weeks
41125050|NCT02886195|DRUG|Erlotinib|150mg po. every day
41125051|NCT05150912|OTHER|Manual therapy|strching neck
41125052|NCT04321603|BEHAVIORAL|Walking|Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.
41125053|NCT04625231|BEHAVIORAL|Educational Shared-Decision Making Tool|Patients received a short video presentation on pain management, use of over the counter medication, side effects of opioids and over-the-counter medications and ability to choose the amount of opioid pills up to the standard care amount.
41276306|NCT03423355|DRUG|Hydrochlorothiazide 25 mg|25mg p.o. daily
41276307|NCT03423355|DRUG|Placebo matching Dapagliflozin|Placebo matching Dapagliflozin p.o. daily
41276308|NCT05655117|OTHER|AI based eye screening|The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre
40927744|NCT04043390|DIAGNOSTIC_TEST|CRP and Molbio Truenat MTB|A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.
40927745|NCT04043390|DIAGNOSTIC_TEST|CRP and Xpert ULTRA MTB/RIF|A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.
40927746|NCT04043390|DIAGNOSTIC_TEST|standard test Xpert|The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).
40927747|NCT04043390|DIAGNOSTIC_TEST|Culture as reference standard|The investigators will use culture to assess the sensitivity of schemes 1 and 2
40927748|NCT02384057|OTHER|Computerized cognitive training program|1000 minutes of computerized cognitive rehabilitation with C8 sciences program
41446979|NCT06562504|DEVICE|Transcranial direct current stimulation (tDCS)- anodal group|2mA/20mins/session;
40927749|NCT02384057|OTHER|Conventional cognitive rehabilitation|Same amount of conventional cognitive rehabilitation
40927750|NCT03149627|OTHER|Estimates - prevalence of lifetime/chronic HBV infection|Estimation of the prevalence and correlates of lifetime HBV infection defined as hepatitis B core antibody (HBcAb) positivity and chronic HBV infection defined as HBsAg positivity.
40927751|NCT03129256|DRUG|Apatinib Mesylate tablet combined with S-1 capsules|Oral use with low-dose Apatinib combined with S-1 until disease progression
40927752|NCT02068768|DEVICE|Avenue® L Interbody Fusion System (LDR Spine)|PEEK, intervertebral cage for interbody fusion of the lumbar spine
40927753|NCT03289520|DRUG|Clopidogrel|
40927754|NCT03289520|DRUG|Placebo|
40927755|NCT00430183|DRUG|docetaxel|75 mg/m\^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
40927756|NCT00430183|DRUG|LHRH agonist|Given intramuscularly
41125054|NCT01970813|DEVICE|acupuncture and bee venom acupuncture point injection|acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
41125055|NCT01970813|DEVICE|sham acupuncture and normal saline injections|sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
41125056|NCT00016341|BIOLOGICAL|filgrastim|
41125057|NCT00016341|DRUG|cisplatin|
41125058|NCT00016341|DRUG|doxorubicin hydrochloride|
41125059|NCT00016341|DRUG|megestrol acetate|
41125060|NCT00016341|DRUG|paclitaxel|
41125061|NCT00016341|DRUG|tamoxifen citrate|
41125062|NCT01013584|DIETARY_SUPPLEMENT|cholecalciferol|daily dose
41125063|NCT01715636|DRUG|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg|
41125064|NCT04373434|BEHAVIORAL|Health Homes/Healthy Families (HH/HF) Intervention|The HH/HF Intervention involves coaching calls, text messages and intervention materials that are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention. The intervention is delivered over a 12 week period.
41125065|NCT04373434|BEHAVIORAL|Control|"Participants in the control condition will receive two mailings on healthy eating, the first from the Dietary Guidelines For Americans 2015-2020, 8th Edition and the second from Choose MyPlate. Additionally, both mailings will include a food diary from the Centers for Disease Control and Prevention. Mailings will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes being targeted in the HH/HF intervention, but without the home environment emphasis. Control group participants will receive their home environment profile with a list of healthy actions upon completion of the study."
41446980|NCT06562504|DEVICE|Transcranial direct current stimulation (tDCS)- sham group|0mA/20mins/session
41446981|NCT06562504|DEVICE|transcranial alternating current stimulation (tACS)-tACS group|1.5 mA/20 min/session; 6HZ, theta
40927757|NCT00430183|PROCEDURE|surgery|Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
40927758|NCT02101697|BEHAVIORAL|HIV Stigma Reduction Intervention|"The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma."
41125066|NCT01240434|PROCEDURE|Trocar site closure|The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
41125067|NCT01435252|DRUG|Cetuximab|Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
41125068|NCT02494336|PROCEDURE|Trans-incisional rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.
41276309|NCT01923025|DRUG|RO5545965|Single dose
41446982|NCT00262392|DRUG|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
41446983|NCT01908556|DRUG|Letrozole|
41446984|NCT04037722|DIETARY_SUPPLEMENT|Whey|45 g whey + 20 g maltodextrin
41446985|NCT04037722|DIETARY_SUPPLEMENT|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
41446986|NCT00773149|DRUG|Alemtuzumab (CAMPATH 1H) associated to G-CSF|"All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months."
41276310|NCT02951273|OTHER|Study of cerebral blood flow|"Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.~Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml."
41276311|NCT01888094|OTHER|Ultrasound-guided cannulation and examination|
40927759|NCT04661761|DIAGNOSTIC_TEST|Paraffin Pellets from Aurosan GmbH|1 to 2 minutes pre-chewing time chewing Paraffin Pellets from Aurosan GmbH, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
41276312|NCT02860793|OTHER|Bone marrow aspiration|
41446987|NCT04035187|DRUG|fast itraconazole tablet|100mg dose
41276313|NCT02860793|OTHER|Blood sampling|
41276314|NCT03381443|OTHER|different assessments|coded survey about NTS and assessment
41276315|NCT05504109|PROCEDURE|mitral valve replacement through full sternotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
41276316|NCT05504109|PROCEDURE|mitral valve replacement through right mini thoracotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
40754381|NCT05378607|BEHAVIORAL|Incentivization based on gradually increasing, externally chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the subgoal chosen by the study coordinator. Subgoals will gradually increase from the participant's baseline adherence up to 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
41125069|NCT02494336|PROCEDURE|Laparoscopic guided rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
41276317|NCT05461443|DIETARY_SUPPLEMENT|Probiotic|
41446988|NCT04035187|DRUG|medium itraconazole tablet|100mg dose
41446989|NCT04035187|DRUG|slow itraconazole tablet|100mg dose
40927760|NCT04661761|DIAGNOSTIC_TEST|Chewing wax from the Saliva-Check Buffer from GC Europe|1 to 2 minutes pre-chewing time chewing wax from the Saliva-Check Buffer from GC Europe, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
40927761|NCT01456377|DRUG|predinose oral|1 mg for kg for 3 wekees
41125070|NCT02494336|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
41446990|NCT04035187|DRUG|oral itraconazole solution|100mg dose
41446991|NCT00064831|DRUG|Black Cohosh Extract (BCE)|
41446992|NCT06015984|BEHAVIORAL|Traning|In order to participate in the training module, a user name and password will be given to the initiative group, the link to be used in the self-managed and asynchronous training platform will be shared, and it will be ensured that it participates in the web-based nurse training, and the training will last for eight weeks.
41446993|NCT05245006|DRUG|89Zr-DFO-YS5|3 mCi will be administered intravenously
41446994|NCT05245006|BIOLOGICAL|YS5 antibody|20 or 50 mg administered intravenously
41446995|NCT05245006|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Imaging which combines a CT scan and a PET scan
41446996|NCT05245006|PROCEDURE|Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)|Imaging which combines an MRI scan and a PET scan
40927762|NCT01456377|DRUG|placebo group|use a oral placebo
40927763|NCT01763242|OTHER|EMAN|See details on ESA Synchronization and Dosing in Detailed Description Above
41125071|NCT04045938|OTHER|Low Glycemic Index or Glycemic Load|Dietary pattern focused on low glycemic index foods or on a low glycemic load
41125072|NCT03586258|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests
41125073|NCT03586258|OTHER|Brain Imaging|Anatomical, diffusion, and/or functional MRI
41125074|NCT03586258|OTHER|Galvanic Vestibular Stimulation (GVS)|Stimulation versus Sham
41446997|NCT02193763|PROCEDURE|Ultrasound assisted lumbar puncture|An investigator will perform beside ultrasound on the spinal area using a bedside ultrasound device. Attempts will be made to visualize the spinous processes and vertebral bodies in the general lumbarsacral area, as well as the presence of CSF in the thecal space below the conus medullaris, and identify the optimal location to perform the LP. This will be marked with a skin marker (If no CSF or abnormal anatomy is visualized, the LP will be advised to be postponed or cancelled). The treating physician will then proceed with the LP guided by the skin markings.
41446998|NCT02125981|DRUG|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
41446999|NCT02125981|DRUG|Placebo|taking placebo drug
41447000|NCT06119763|DIAGNOSTIC_TEST|anti dfs70 antibodies|blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre
41447001|NCT05722496|OTHER|Aerobic pedaling exercise|aerobic exercise in the form of leg pedaling exercise in semi-supine position using leg ergometer by different intensities
41447002|NCT02113722|PROCEDURE|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation via a video
41447003|NCT02113722|PROCEDURE|Standard of Care|Medical therapy
41447004|NCT05583409|RADIATION|SBRT+Osimertinib|Received SBRT after three months of Osimertinib treatment
41447005|NCT05583409|DRUG|Osimertinib 80 MG|Osimertinib 80mg, po, Qd
41447006|NCT02440711|DEVICE|Energy storing foot (ESF)|A commercially-available energy storing prosthetic foot
41125075|NCT06176391|DEVICE|Spinal Cord Stimulation|Single lead placement in the posterior thoracic epidural space (T1-T4) connected to a subcutaneous battery
41447007|NCT02440711|DEVICE|Modified running specific foot (mRSF)|A running specific prosthetic foot customized for both running and walking activities
41447008|NCT00445796|DRUG|Artesunate|
41447009|NCT00445796|DRUG|Amodiaquine|
41125076|NCT02778659|DRUG|Zolpidem|The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
41447010|NCT02722421|DRUG|Levonorgestrel|Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
41447011|NCT02722421|DRUG|Efavirenz|Participants will receive efavirenz-based ART as part of standard of care
40754382|NCT05378607|BEHAVIORAL|End of year 1 adherence prize drawing|Participants will have a chance to participate in a prize drawing at the end of year 1 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on reaching 90% in the three months preceding the end of year 1.
40754383|NCT05378607|BEHAVIORAL|SMS motivational messages + reminder of prize drawing|Participants will receive weekly motivational messages with a reminder of their upcoming prize drawing throughout year 1 of the study.
41125077|NCT02778659|DRUG|Placebo|The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
41125078|NCT04074096|RADIATION|Stereotaxic radiosurgery (SRS)|For patients randomised to arm B only: Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases \>5 mm).
41125079|NCT04074096|DRUG|Binimetinib Oral Tablet|All patients: binimetinib 45 mg PO BID.
40754384|NCT05378607|BEHAVIORAL|Year 2 re-allocation based on year 1 performance|In Year 2 of the study, participants who have reached 90% by the end of year 1 will no longer be given sub-goals and instead will be eligible for prize drawings if they maintain the fixed level of 90% or higher. Those who have not reached 90% by the end of year 1 will be allocated to the intervention group that showed the highest effectiveness in year 1.
40754385|NCT05378607|BEHAVIORAL|End of Year 2 viral suppression prize drawing|Participants will have a chance to participate in a prize drawing at the end of Year 2 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on achieving viral suppression by the end of Year 2.
40754386|NCT05378607|BEHAVIORAL|Incentivization based on gradually increasing self-chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the self-chosen subgoal. While self-chosen, subgoals are subject to a minimum threshold determined by baseline adherence working towards 90% adherence. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
41125080|NCT04074096|DRUG|Encorafenib Oral Capsule|All patients: encorafenib 450 mg PO QD
41125081|NCT04074096|DRUG|Pembrolizumab|All patients: pembrolizumab 200 mg IV Q3W
41125082|NCT02885636|DRUG|Albuterol|": Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"
41447012|NCT03353896|DEVICE|Wear novoTTF-200A|Wear novoTTF-200A device
41447013|NCT03353896|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
41447014|NCT05394350|DRUG|MK-1088|Oral Tablet
41447015|NCT05394350|BIOLOGICAL|Pembrolizumab|IV Infusion
41447016|NCT01845272|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
41447017|NCT01845272|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
40754387|NCT05378607|BEHAVIORAL|Incentivization based on a fixed adherence goal|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000 or 10,000 Ugandan Shillings if adherence matches or exceeds the fixed adherence goal of 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
40754388|NCT05378607|BEHAVIORAL|SMS motivational messages|The control group will also receive weekly motivational messages but without the reminder of the upcoming prize drawing.
41125083|NCT02885636|OTHER|Saline placebo|Saline inhaled through a nebulizer as a single dose
41125084|NCT03617315|DRUG|Hylauronic Acid|Schirmer Test, BUT test and OSDI test. Previous and After treatment
41125085|NCT00575614|DRUG|prucalopride|1 mg o.d.
41125086|NCT00575614|DRUG|placebo|o.d.
41125087|NCT00760136|PROCEDURE|Computed Tomography|CT imaging of bilateral knee
41125088|NCT01332045|PROCEDURE|continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
41125089|NCT01332045|PROCEDURE|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
41125090|NCT02036112|PROCEDURE|conventional ELAPE|device
41125091|NCT02036112|PROCEDURE|Individual ELAPE|device
41125092|NCT04223388|DIETARY_SUPPLEMENT|Lactobacillus plantarum 276|5 Billion CFU/dose, serving size = 1 capsule/day
41125093|NCT04223388|OTHER|Placebo|Placebo product, serving size = 1 capsule/day
41447018|NCT05517681|OTHER|non-ICG|Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection. The separation should extend from the center to the left, reaching the left paracolic sulcus lateral to the genital vessels. The Superior hypogastric nerve is protected by freeing it at the angle of the common iliac artery on both sides, afterwards, the vessel is free along the surface of the plexus from caudal to cephalic side to reach the root of the IMA. Switching lymph node visualization patterns. Based on the operator's experience and the extent of lymph node visualization, the lymph nodes at the root of the IMA were removed with an ultrasonic knife . The dissection continues caudally along the IMA, preserving the arterial sheath. Expose the left colonic artery, superior rectal artery, and sigmoid artery, maximum preservation of the IMA peripheral plexus while clearing their surrounding lymph nodes.
41447019|NCT05517681|DRUG|ICG|Dilute ICG to 2.5 mg/ml with its accompanying sterilized water for injection. Slow injection with a 1ml syringe in 4 parts of the tumor，Inject 0.25ml per site . Procedure started after lymph node visualization.The operation was consistent with the control group.
41447020|NCT02152046|PROCEDURE|ROP exam with spring loaded retractor|
41125094|NCT04739137|DIAGNOSTIC_TEST|DDiVAT Testing|Participants will self examine his/her distance visual acuity via application in a simulation room of our department with certain predetermined environmental lighting conditions using the same smart devices.
41125095|NCT04739137|DIAGNOSTIC_TEST|Distance visual acuity assessment via ETDRS chart|The distance visual acuity of each participant will be measured with the conventional method via ETDRS chart
41125096|NCT06087549|DRUG|Pericapsular nerve group block using 0.2% ropivacaine|Unilateral ultrasound guided pericapsular nerve block using 0.5mL/kg 0.2% Ropimol (max 20mL)
41276318|NCT05270603|OTHER|ICARUS intraoperative adverse events calculator|"The ICARUS calculator is a web-based tool that uses answers to Boolean, yes/no questions to determine the iAE grade (appendix I). The calculator providers iAE grade outputs for the 5 iAE classification systems.~https://garnmile.com/iaecalc/~Development of the ICARUS calculator was performed as follows: Referencing the 5 classification systems, we first assembled a list of Boolean questions based on the iAE grade descriptions. This list was distilled to the minimum number of questions necessary to represent all descriptions in the combined list of iAE grades. Next, these questions were used to independently establish the conditional logic required to determine iAE grade for each classification system. The questions and logic were translated into Hypertext Preprocessor (PHP), a server-side programming language, and JavaScript, a client-side scripting language."
41276319|NCT00518349|DEVICE|Passive bending function|Colonoscope with a passive bending function
41276320|NCT00518349|DEVICE|No passive bending function|Examination using standard colonoscope without passive bending function
41276321|NCT06656689|PROCEDURE|Rezum (water vapor thermal therapy)|Rezum or water vapor thermal therapy is a procedure that involves injecting steam at 103°C into the prostate tissue to induce necrosis and reduce the size of the enlarged prostate.
41276322|NCT06656221|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 2000mg on Cycle 1 Days 1-2
41276323|NCT06656221|DRUG|Glofitamab|Glofitamab is given intravenously at a dose of 2.5mg on Cycle 1 Day 8. Glofitamab is given intravenously at a dose of 10mg on Cycle 1 Day 15. Glofitamab is given intravenously at a dose of 30mg on Day 1 of Cycles 2-6
41276324|NCT06656221|DRUG|Bortezomib|Bortezomib is given intravenously at a dose of 1.6 mg/m² on Days 1, 8, and 15 of Cycles 1-12.
41276325|NCT06656221|DRUG|Orelabrutinib|Orelabrutinib is given orally at a dose of 150 mg daily on Days 1-21 of Cycles 1-12.
41276326|NCT06655987|OTHER|Unrestrained Femoral Internal Rotation (UFIR) manipulation|This is the primary intervention applied to the experimental group. It involves a high-velocity, low-amplitude thrust at the greater trochanter of the affected hip, intended to improve joint mobility and potentially address neuromuscular dysfunction contributing to hip pain and weakness.
41276327|NCT06655987|OTHER|Sham manipulation|This serves as the control intervention. It involves gentle hand placement over the affected hip\&#39;s external rotators for a brief duration. This is intended to mimic the physical contact of the UFIR manipulation without actually delivering the therapeutic thrust.
41276328|NCT06656624|DRUG|Ribociclib combined with AI±OFS|Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
41276329|NCT06656624|DRUG|physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS|Docetaxel: 100mg/m2 IV drip every 21 days; Paclitaxel: 175mg/m2 every 21 days, IV drip; Paclitaxel for Injection (Albumin Bound): 100\~150mg/m2 IV drip every 7 days; Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week; Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
41276330|NCT05574153|DIAGNOSTIC_TEST|Cardiac MRI|Participants will undergo an oxygenation-sensitive cardiac MRI and, during the scan, perform a vasoactive breathing maneuver composed of a period of paced hyperventilation followed by a voluntary maximal breath hold.
41276331|NCT06411821|DRUG|Ulixertinib|300 mg twice daily, for every 28-day cycle.
41276332|NCT00740805|DRUG|Cyclophosphamide|Given IV
41276333|NCT00740805|DRUG|Doxorubicin Hydrochloride|Given IV
41276334|NCT00740805|OTHER|Laboratory Biomarker Analysis|Correlative studies
41276335|NCT00740805|OTHER|Pharmacological Study|Correlative studies
41276336|NCT00740805|DRUG|Veliparib|Given PO
41276337|NCT06176352|DRUG|Faricimab|Faricimab 6 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
41125097|NCT06087549|DRUG|Erector Spinae Plane Block using 0.2% ropivacaine|Unilateral ultrasound guided erector spinae block using 0.5mL/kg 0.2% Ropimol (max 20mL)
41125098|NCT06087549|OTHER|Standard care|No erector spinae block and no pericapsular nerve group block
41125099|NCT01646450|DRUG|Icotinib|Icotinib: 125mg, oral administration, three times per day.
41125100|NCT03991754|PROCEDURE|transcatheter aortic valve implantation|transcatheter aortic valve implantation
41125101|NCT03189472|DEVICE|Active tDCS|low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
40927764|NCT02102373|DEVICE|polyethylene glycol 3350|Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
41125102|NCT03189472|DEVICE|Sham tDCS|The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
41276338|NCT06176352|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
40927765|NCT01322776|DRUG|Combination of Bortezomib, Fludarabine and Cyclophosphamide|bortezomib 1.3mg/m\^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m\^2 i.v. on days 1\~3 of each 28-day cycle cyclophosphamide i.v. on days 1\~2 of each 28-day cycle
40927766|NCT01653132|DRUG|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
40754389|NCT02842281|OTHER|Fructan|Short-chain oligosaccharide primarily composed of fructose polymers
40754390|NCT02842281|OTHER|Maltodextrin|Polysaccharide produced from starch
40927767|NCT01653132|DRUG|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
40927768|NCT06451731|BEHAVIORAL|PHOLEXSEM|Phonological, Lexical, and Semantic training
40927769|NCT06451731|BEHAVIORAL|PACE|See arm description
40927770|NCT02700503|BEHAVIORAL|Encourage 2.0|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
41125103|NCT00390273|DRUG|Metformin|
41125104|NCT03285542|DEVICE|DERMABOND|DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
41276339|NCT06176352|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Participants will undergo the sham procedure at study visits where no study drug is to be administered, in order to maintain masking.
41125105|NCT03285542|DEVICE|Staples|staples for skin closure
41276340|NCT06430541|DRUG|Psilocybin|A tryptamine that produces its behavioral effects primarily by acting as post-synaptic agonists at serotonin 5-HT2A and 5-HT2c receptors.
41276341|NCT06582602|BIOLOGICAL|MK-2060|Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
41276342|NCT06582602|BIOLOGICAL|Placebo|Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.
41276343|NCT06161025|DRUG|R-DXd|R-DXd will be administered as an intravenously (IV) infusion
41276344|NCT06161025|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion
41276345|NCT06161025|DRUG|Paclitaxel|Paclitaxel will be administered as an IV infusion
41276346|NCT06161025|DRUG|Topotecan|Topotecan will be administered as an IV infusion
41276347|NCT06161025|DRUG|PLD|PLD will be administered as an IV infusion
41276348|NCT04627740|DRUG|Retroviral vector-transduced autologous T cells to express anti-ALPP CARs|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
41276349|NCT00977977|DRUG|Rituximab Infusion|Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
41276350|NCT00977977|DRUG|Oral Cyclosporine|Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
41276351|NCT02312024|DEVICE|Use of CytoSorb adsorber|Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
41276352|NCT03783195|OTHER|Sugar drink|A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
41447021|NCT02152046|PROCEDURE|ROP exam with screw retractor|
41447022|NCT04247945|BIOLOGICAL|Cotransplant with MSCs|Co-transplantation of MSCs during allogeneic HSCT
41276353|NCT04817254|DRUG|TMZ|150 mg/m2 on days 1-5 of cycles 1-6
41276354|NCT04817254|DRUG|ipilimumab 3mg/kg|3 mg/kg q 4 weeks for cycles 1-4
41276355|NCT04817254|DRUG|Nivolumab|1 mg/kg IV q2weeks for cycles 1-4, then 480 mg q 4 weeks for cycles 5-16
41447023|NCT03532035|DRUG|Brincidofovir|Subjects will receive BCV administered as a continuous IV infusion over 2 hours twice weekly (on Days 1, 4, 8, and 11) for a period of 2 weeks (total of 4 doses).
41447024|NCT03532035|DRUG|Standard of Care|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin."
41447025|NCT05893563|OTHER|Standard Post-Operative Clinic Visit|In clinic, the joint will be assessed (ROM, stability testing), standard X-rays will be taken of the joint, and patient reported outcomes (questionnaires) will be completed by patient (WOMAC, UCLA, VR12, EQ5D, Oxford Hip).
40754391|NCT05356611|BEHAVIORAL|Engage|Engage is a 9-week, behavioral-based, psychotherapy treatment protocol for late-life depression.
40754392|NCT04707183|DRUG|Lidocaine IV Infusion|Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.
40754393|NCT04707183|DRUG|2% Lidocaine via ESPB|10 ml of 2% lidocaine will be infused through ESPB in treatment group
40754394|NCT02957227|DEVICE|No intervention is part of this study but patients use an EEG device during observational data collection.|
40754395|NCT01990352|DRUG|Pegylated liposomal doxorubicin|Doxil will be administered intravenously at 30mg/m2 on days 1 of a 21 day cycle.
40754396|NCT03721107|BIOLOGICAL|Blautix|Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.
40754397|NCT03721107|OTHER|Placebo|Placebo control
40927771|NCT01190735|DRUG|Caffeine alkaloid|"The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed."
41125106|NCT05786235|OTHER|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled in the study during the first trimester of gestation or later, if the diagnosis of APS is made during pregnancy followed by clinical practice. During the quarterly visits scheduled by clinical practice, the following will be collected relevant clinical information and the additional biological samples for analysis of serum levels of sFlt-1 and PlGF. A follow-up postpartum visit is scheduled by clinical practice at 6 weeks after completion of delivery.
41125107|NCT05786235|OTHER|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled during the performance of prenatal diagnosis, routinely chosen by the patient, at which the relevant clinical information and the additional biological sample . Collection of biological material in the 2nd and 3rd TM of gestation will take place at occasion of the routinely scheduled ultrasound scans . A postpartum follow-up visit is scheduled by clinical practice at 6 weeks after the completion of delivery.
41125108|NCT05319626|OTHER|compression socks|The compression socks have a clinical pressure of 23-30 mm Hg. The socks are dressed to the participants based on the manufacturer's sizing guidelines.
41125109|NCT05319626|OTHER|textured insoles|The textured insoles have small, pyramidal peaks with centre-to-centre distances of approximately 2.5 mm (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
41125110|NCT05319626|OTHER|smooth socks|The smooth socks are a commercial stocking that does not have a compression feature, but has a similar thickness and color to the compression stocking. They have standard size.
41125111|NCT05319626|OTHER|smooth insoles|The smooth insoles have a completely flat surface (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
41125112|NCT00706875|BEHAVIORAL|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
41125113|NCT00706875|BEHAVIORAL|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
41125114|NCT03111160|PROCEDURE|SMILE procedure using lower energy (100, 105, and 110 nJ)|Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
41125115|NCT03111160|PROCEDURE|SMILE procedure using conventional energy (115 to 150 nJ)|The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
41125116|NCT04351828|PROCEDURE|Blood draw once a time|Investigation of intestinal permeability by measuring serum zonulin levels in blood sample
41125117|NCT01790672|DIETARY_SUPPLEMENT|Ethanol|Vodka Absolut
41125118|NCT01790672|OTHER|Water|Lemon-flavored water
41125119|NCT01790672|DIETARY_SUPPLEMENT|Alcoholized wine|Wine 13º or wine 8º
41125120|NCT01790672|DIETARY_SUPPLEMENT|De-alcoholized wine|Wine 0º
41276356|NCT04817254|DRUG|ipilimumab 1mg/kg|1 mg/kg q 4 weeks for cycles 1-4
41276357|NCT05675709|BEHAVIORAL|Training and Education|Undergo group trainings
40927772|NCT05676593|DEVICE|Freestyle Libre 2|The FSL will be placed on patient for 28 days to measure interstitial glucose
40927773|NCT05676593|OTHER|Therapeutic education|Therapeutic education
40754398|NCT04849507|DEVICE|transcutaneous auricular vagus nerve stimulation|Stimulation of the auricular branch of the left vagus nerve paired with oromotor feeding.
40754399|NCT03834259|PROCEDURE|sitting position|keeping the patient in a sitting position after spinal anaesthesia
40927774|NCT02856191|OTHER|Holter|
40927775|NCT04705740|OTHER|ERCP|ERCPs performed annually by an endoscopist
40927776|NCT04825197|DRUG|Poractant Alfa Intratracheal Suspension [Curosurf]|up to 4 doses (100 mg Kg) of Poractant alfa every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV.
40927777|NCT02906384|RADIATION|hippocampus avoidance|conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
40927778|NCT01097200|DEVICE|Elevate mesh|The correction of the prolapse can be made by this new technique.
40927779|NCT01097200|DEVICE|Sacrocolpopexy|Attach a mesh between the vagina and the promontorium.
41125121|NCT06266845|BEHAVIORAL|In-person Escape Room|The in-person escape room will be conducted in the nursing laboratory of a Higher Education Institution (HEI), equipped with a high-fidelity mannequin to simulate a critical patient and create a realistic environment. Participants will be divided into groups, with one group entering at a time as requested. During the in-person escape room, participants will interact with the patient mannequin, hospital equipment and devices, as well as with objects and clues in the environment. The game duration will be 30 minutes to ensure equal conditions among participants and prevent time distortions. Interactions and participants' performance will be recorded by the facilitator, guiding the feedback.
41125122|NCT06266845|BEHAVIORAL|Virtual Escape-Room|The virtual escape room will be conducted in a classroom of an HEI, utilizing an online platform that allows the virtual reproduction of the game. Each group will have access to a tablet or computer to participate in the game provided by the researcher. During the game, participants will interact with the platform interface and solve challenges to escape the virtual room within 30 minutes. Thus, each group will have a maximum of 30 minutes to complete the escape room, ensuring equal conditions among participants. Records of interactions and participant performance will be logged for later analysis and feedback.
41125123|NCT04718610|OTHER|Osteopathic intervention|Nerve vagus stimulation
41125124|NCT04718610|BIOLOGICAL|CRP assessment|Blood CRP will be assessed during trial
41125125|NCT04718610|BEHAVIORAL|QLQ-C30 questionnaire|Completion of QLQ-C30
41125126|NCT04979715|PROCEDURE|physitherapy follow-up|preoperative patient informaiton, information leaflet and Physiotherapy meeting will be held every 2 weeks for 3 months
41125127|NCT04979715|OTHER|control|no intervention; preoperative patient informaiton and information leaflet
41125128|NCT03440008|OTHER|Dynamic 3D bone motion capture|Two x-ray systems will image the subjects ankle while they walk, allowing us to calculate ankle joint angle and alignment
41125129|NCT03440008|DEVICE|wedged insole|medial or lateral wedge (appropriate for varus or valgus misalignment) will be applied during 1 data collection session to evaluate effect of wedging on misalignment
41125130|NCT02261506|OTHER|7 days of adequate antibiotic treatment durations|We will not be randomizing patients to any specific antibiotic regimen. Patients will be randomized to fixed durations of adequate treatment: 7 versus 14 days. The selection of antibiotic(s) will be at the discretion of the treating team, although the research team will check to ensure that the selected antibiotics have an 'adequate' spectrum of coverage for the bacterial pathogen(s) isolated in the blood culture.
41125131|NCT02261506|OTHER|14 days of adequate antibiotic treatment durations|
41125132|NCT01522794|DRUG|NOX-H94|single i.v. infusion
41125133|NCT01522794|DRUG|Placebo solution|single i.v. infusion
41125134|NCT04833179|BIOLOGICAL|fecal transplant|"Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. All donors will undergo a screening process that will include a detailed medical history, blood work and fecal tests. Only after passing the screening, the donor will be added to the groups of donors that will participant in this study.~The treatment will be givenin the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment."
41276358|NCT04690699|BIOLOGICAL|Lerapolturev|Lerapolturev administered via intravesical instillation once
41276359|NCT04690699|OTHER|5% DDM|5% DDM and saline washes
41276360|NCT06651411|BEHAVIORAL|STARS (Scalable Technology for Adolescents and youth to Reduce Stress)|"The intervention is a chatbot-based stress management intervention developed by the World Health Organization (WHO). It consists of 10 sessions, which include: Introduction (1), Psychoeducation (2), Emotion Regulation (3, 4), Behavior Activation (5, 6), Managing Problems (7), Thought Challenging (8, 9), and Relapse Prevention (10). Each session consists of psychoeducation and exercise parts. Trained e-helpers contact participants to support them individually weekly.~The effect of the intervention will be compared against a control group that receives basic psychoeducation. The intervention is provided in Lithuanian."
41276361|NCT06651411|BEHAVIORAL|Basic psychoeducation|Basic psychoeducation includes basic information on stress management.
41276362|NCT03525873|OTHER|Laboratory Biomarker Analysis|Correlative studies
41125135|NCT04833179|OTHER|placebo|placebo
41276363|NCT03525873|DRUG|Methylphenidate|Given PO
41276364|NCT03525873|OTHER|Physical Activity|Participate in physical activity
41276365|NCT03525873|OTHER|Placebo|Given PO
41276366|NCT03525873|OTHER|Quality-of-Life Assessment|Ancillary studies
41276367|NCT03525873|OTHER|Questionnaire Administration|Ancillary studies
41276368|NCT05033002|BEHAVIORAL|Labda Siku Moja stigma reduction intervention|The Labda Siku Moja stigma reduction intervention is a tailored stigma reduction intervention for women living with HIV in Tanzania. It is comprised of five ethnodramas (video stories) culturally and linguistically relevant to the Tanzanian women living with HIV.
41276369|NCT06079216|BEHAVIORAL|Volunteer Led Making Connections Thru Music|Volunteer led Group music therapy-based intervention
41276370|NCT06079216|BEHAVIORAL|Staff Led Making Connections Thru Music|Staff led Group music therapy-based intervention
41276371|NCT01687790|DEVICE|molecular breast imaging (Discovery)|
40754400|NCT03834259|PROCEDURE|supine position|keeping the patient in supine position after spinal anaesthesia
40754401|NCT01942980|RADIATION|Radiation therapy Brain metastasis in breast cancer|Radiation
41276372|NCT02612870|DEVICE|Sienna+ retro|Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
41276373|NCT02612870|DEVICE|Sienna+ peri|Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
41276374|NCT02612870|DEVICE|Sienna+ retro 4-6|Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
41276375|NCT02612870|DEVICE|Sienna+ peri 4-6|Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
41125136|NCT02352675|OTHER|Intraoperative Blood Sample|Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
41125137|NCT00975585|DEVICE|senofilcon A|soft contact lens, 2-week replacement indicated
41125138|NCT00975585|DEVICE|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
41276376|NCT02612870|DEVICE|Technetium 1|Sentinel node marking with Technetium 1 day before surgery
41276377|NCT00942162|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
41276378|NCT03206801|PROCEDURE|Kidney transplant biopsy|Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
41276379|NCT03213652|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41276380|NCT03213652|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
41276381|NCT03213652|PROCEDURE|Bone Scan|Undergo a bone scan
41276382|NCT03213652|PROCEDURE|Computed Tomography|Undergo a CT scan
41276383|NCT03213652|DRUG|Ensartinib|Given PO
41276384|NCT03213652|OTHER|Laboratory Biomarker Analysis|Correlative studies
41276385|NCT03213652|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41276386|NCT03213652|OTHER|Pharmacological Study|Correlative studies
41276387|NCT03213652|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
41125139|NCT04115423|DRUG|Tocilizumab|A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.
41276388|NCT03213652|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
41276389|NCT03213652|PROCEDURE|X-Ray Imaging|Undergo an x-ray
41276390|NCT06285422|DRUG|SC262|SC262 is an allogeneic CAR -T cell therapy
41276391|NCT00881660|DEVICE|Goldballoon Detachable Balloon and delivery microcatheter|"Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center."
41276392|NCT06004804|BEHAVIORAL|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
41276393|NCT06004804|BEHAVIORAL|Mindfulness Meditation|Seeks to help individuals achieve present moment awareness, self-compassion, and acceptance of chronic pain. It will use techniques such as the body scan, grounding, mindful breathing, mindful walking, loving kindness, and compassionate breathing.
41276394|NCT06004804|BEHAVIORAL|Cognitive Behavioral Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
41276395|NCT04216342|BIOLOGICAL|Fx-5A peptide complex|subject will receive a slow I.V. infusion of the Fx-5A peptide complex as described in Table 1. Five to 10 mL of blood will be collected at 30min (+/- 5min\*), 1h (+/- 10min\*), 2h (+/- 10min\*), 4h (+/- 15min\*), 8h (+/- 30min\*), 12h (+/- 30min\*), and 24h (+/- 30min\*) for laboratory tests and to be stored for research tests. The patient will be dismissed, as inpatient, 24-36 hours after the beginning of the treatment.
41276396|NCT06350630|DRUG|Hydroxychloroquine Oral Tablet|Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years
41276397|NCT06350630|DRUG|Placebo oral tablet|placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )
41276398|NCT06333340|DRUG|Oxytocin|Patient is given oxytocin 5 IU diluted in 10 mL normal saline, administered intravenously over 1 min, followed by continuous infusion of 250 mIU/min over 4 hours.
41276399|NCT06333340|DRUG|Carbetocin|Patient is given carbetocin 100 mcg diluted in 10 mL normal saline, administered intravenously over 1 min, followed by placebo infusion for 4 hours.
40927780|NCT02042820|OTHER|In vivo confocal microscopy (IVCM)|IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
41447026|NCT05893563|OTHER|Study-Specific Outcomes|Patients will complete additional questionnaires (SF12 and HHS), will undergo RSA and CT imaging for implant stability analysis, and will provide a stool sample for gut microbiome analysis.
41447027|NCT00031707|DIETARY_SUPPLEMENT|eicosapentaenoic acid|
41447028|NCT00031707|DRUG|megestrol acetate|
41447029|NCT00031707|OTHER|placebo|
40927781|NCT01261468|DEVICE|Active SCS|SCS IPG activated
41125140|NCT04115423|DRUG|Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)|Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
41276400|NCT04640623|DRUG|TAR-200|TAR-200 will be administered transuretherally.
40927782|NCT01261468|DEVICE|Deactivated|SCS IPG deactivated
41276401|NCT04640623|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
40927783|NCT05273073|DIETARY_SUPPLEMENT|Probiotics|Each sachet consists of 30 billion colony-forming units (CFU) of six viable probiotic strains (Lactobacillus acidophilus BCMC® 12130 (107 mg), Lactobacillus casei subsp. BCMC® 12313 (107 mg), Lactobacillus lactis BCMC® 12451 (107 mg), Bifidobacterium bifidum BCMC® 02290 (107 mg), Bifidobacterium infantis BCMC® 02129 (107 mg), and Bifidobacterium longum BCMC® 02120 (107 mg).
41125141|NCT05806060|DRUG|VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
41125142|NCT05806060|DRUG|nab-paclitaxel, with maintenance of capecitabine|Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
41125143|NCT05806060|DRUG|Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1|TPC
41276402|NCT03904927|OTHER|Radiation, Surgery or Radiofrequency ablation|Patients with no more than 4 metastases located in less than 3 organs/ lymphatic drainage regions treated with combined systemic therapy and radiation, surgery or radiofrequency.
41276403|NCT03904927|DRUG|Systemic therapy|"1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy."
41276404|NCT06208488|DRUG|Gefurulimab PFS-SD|Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.
40927784|NCT05273073|DIETARY_SUPPLEMENT|Placebo|Placebo samples were identical to the probiotics in term of taste and texture without live microbial cells.
40927785|NCT03189290|PROCEDURE|posterior Quadratus Lumborum Block (QLB)|Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block
41276405|NCT06208488|DRUG|Gefurulimab AI|Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.
41276406|NCT05822752|DRUG|Budigalimab|Intravenous (IV) Infusion
41447030|NCT05909358|BIOLOGICAL|CAd3|CAd3 candidate vaccine which is one of the investigational products
41447031|NCT05909358|BIOLOGICAL|ChAdox1|ChAdox1 candidate vaccine which is one of the investigational products
40927786|NCT00002543|DRUG|gallium nitrate|
41125144|NCT05806060|DRUG|VEGFR and TPC|VEGFR bevacizumab and TPC
41276407|NCT05822752|DRUG|Livmoniplimab|Intravenous (IV) Infusion
41447032|NCT05909358|BIOLOGICAL|rVSV-SUDV|rVSV-SUDV candidate vaccine which is one of the investigational products
41447033|NCT05909358|OTHER|Control|Placebo
41447034|NCT05159921|OTHER|Access to an automated conversational agent (SurgInfoBot)|See above under arm/group descriptions.
41447035|NCT00932841|OTHER|Placebo|One packet PO daily x 8 weeks.
40927787|NCT02361580|OTHER|Diary|Subject keeps diary of recovery
40927788|NCT00170924|DRUG|Valsartan|
40927789|NCT05579743|OTHER|Remote wound monitoring technology|Healthy.io developed a professional-user wound management system that captures wound measurements and analyzes tissue distribution in real time through a smartphone application. Clinical oversight of the healing status of the wound via remote imaging and expert review allows for real time intervention when stagnation or worsening of a wound is detected. Patients with wounds on their legs will receive access to Healthy.io's mobile app and will be able to perform self-scans of their wound which will be automatically sent to the medical professionals, thus allowing them to assess the wound remotely.
41276408|NCT05822752|DRUG|Lenvatinib|Oral: Capsule
41276409|NCT05822752|DRUG|Sorafenib|Oral: Tablet
40927790|NCT04517279|BEHAVIORAL|Invest in My Recovery Bank|The intervention has not be fully developed. It will be created in partnership with individuals serving in peer provider roles.
40927791|NCT04517279|BEHAVIORAL|Usual Care Peer Services|Usual peer services involves supporting the process of change for individuals with mental health disorder to improve their health and wellness, live a self-directed life, and strive to reach their full potential.
40927792|NCT03220698|DEVICE|Tracheal ultrasonography|Tracheal ultrasonography
40927793|NCT05999760|DEVICE|evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge|Evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
40927794|NCT05999760|DEVICE|chewing efficiency by electromyograph(E.M.G)|Evaluation of chewing efficiency of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
41276410|NCT06656442|DRUG|Trimetazidine|an anti-ischemic medication.
41447036|NCT00932841|DRUG|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
41447037|NCT00932841|DRUG|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
41447038|NCT01744587|OTHER|Epigallocatechin Gallate (EGCG)|EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
41447039|NCT01744587|DIETARY_SUPPLEMENT|Placebo|Placebo qd (2# bid) for 3 years
41447040|NCT06601140|DEVICE|EMOCARE software|Use of the EMOCARE software on the digital device of participant (smartphone, computer, etc.). The participant can activate and deactivate the software whenever he wishes.
41447041|NCT01899989|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
41447042|NCT01899989|DRUG|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
40754402|NCT06375876|BEHAVIORAL|Single-session intervention (SSI)|The SSI focuses on increasing hope among women who experience IPV using facts about the brain and IPV research, stories from survivors, and writing exercises.
41125145|NCT04295915|DEVICE|Specimens that meet inclusion criteria|Specimens that have been de-identified and considered remnant by the laboratory (fresh specimens) or were contrived by the laboratory (using bacterial isolates with no identifying information) can be enrolled into the study.
41125146|NCT00541268|DEVICE|ICD|Intracardioverter defibrillators from 2 different manufacturers
41125147|NCT00541268|OTHER|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
41276411|NCT05415410|DRUG|Apraglutide|Apraglutide is a new, synthetic glucagon-like peptide 2 (GLP-2) receptor agonist which acts as a gut targeted regenerative approach that is intestinotrophic with a mode of action that improves absorption and enhances gut barrier function.
41276412|NCT06178614|DRUG|JNJ-87890387|JNJ-87890387 will be administered.
41276413|NCT04709549|BEHAVIORAL|Diabetes Prevention Program + Job and Legal Services|"Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.~Job readiness services will be provided by YMCA SF service connectors, trained staff with expertise in employment services who are bi-lingual in English/Spanish and/or Cantonese/English to serve the needs of the community. Service Connectors will assist with providing employment services (e.g job search, potential placement and retention services, relationship development with partners and employers) and job readiness instruction/training."
41276414|NCT04709549|BEHAVIORAL|Diabetes Prevention Program|Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.
41276415|NCT06638112|PROCEDURE|Brachial Plexus Block|Interscalene brachial plexus block with 0.75% ropivacaine. Intraoperative sedation with remimazolam.
41276416|NCT06638112|PROCEDURE|General Anesthesia (control group)|General anesthesia with propofol, fentanyl and rocuronium for induction, and with sevoflurane for maintenance. Brachial plexus block with 0.5% ropivacaine for intra- and postoperative analgesia.
41125148|NCT01278420|DEVICE|Tecnis MF|30 subjects will be implanted with the Tecnis MF
41125149|NCT01278420|DEVICE|ReSTOR|30 subjects will be implanted with ReSTOR
41125150|NCT03764475|DRUG|Roflumilast|Roflumilast cream 0.3% for topical application
41125151|NCT02291913|DRUG|Everolimus|
40754403|NCT02267525|DRUG|Velusetrag|
41125152|NCT02291913|DRUG|Exemestane|Anti-estrogen therapy
41125153|NCT02291913|DRUG|Tamoxifen|Anti-estrogen therapy
41125154|NCT02291913|DRUG|Fulvestrant|Anti-estrogen therapy
40927795|NCT05999760|OTHER|masticatory performance(questionnaire)|Evaluation of masticatory performance of Versacryle and CAD/CAM partial dentures by questionnaire on day one, on first month, and on the second month of prosthesis delivery.
40927796|NCT06092125|DEVICE|PET/MR|PET/MR device is used for pre-treatment evaluation and efficacy follow-up of four types of diseases
40927797|NCT04033588|DEVICE|Freedom® Total Knee System|To evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis.
40927798|NCT04571229|DRUG|L-MTP-PE|L-MTP-PE will be administered at a dose of 2mg/m2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
40754404|NCT02267525|DRUG|Placebo|
40754405|NCT05167058|DEVICE|Cardiologs Platform|Smartwatch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
40754406|NCT00560638|DRUG|loteprednol etabonate ophthalmic suspension, 0.5%|TID
40754407|NCT00560638|DRUG|loteprednol etabonate ophthalmic suspension, 0.5%|QID
41125155|NCT02291913|DRUG|Anastrozole|Anti-estrogen therapy
41125156|NCT02291913|DRUG|Letrozole|Anti-estrogen therapy
41125157|NCT02291913|DRUG|Toremifine|Anti-estrogen therapy
41125158|NCT03283371|DRUG|Natalizumab|As specified in the treatment arm.
40754408|NCT00560638|DRUG|vehicle of loteprednol etabonate|TID or BID according to the randomization
40927799|NCT05047445|BIOLOGICAL|COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection|Two 0.2 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 0.2 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
40927800|NCT05047445|BIOLOGICAL|COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection|Two 1.0 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 1.0 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
41125159|NCT03283371|OTHER|Placebo|As specified in treatment arms.
41125160|NCT02779634|DRUG|ubiquinol|Ubiquinol three times daily
41125161|NCT02779634|DRUG|Placebo|Sugar pill three times daily
41125162|NCT02403297|DEVICE|Quik Check PD|The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
41276417|NCT06657196|OTHER|No Intervention: Observational Cohort|No intervention.
41447043|NCT04216329|DRUG|Selinexor|Selinexor will be administered orally at an initial dose of 80 mg. The first dose will be given on day 2 of radiation and will thereafter be administered weekly on the second day of weekly radiation on weeks 1, 2, 4, and 5. If this dose level is tolerated, the dose will be escalated to 60 mg twice a week (days 1 and 4) on weeks 1,2,4,5. The third and final dose level will also be 60mg administered twice weekly for 6 weeks starting on days 1 and 4 radiation.
41447044|NCT04216329|DRUG|Temozolomide|Temozolomide will begin on the first day or evening prior of radiation and be administered orally daily at a dose of 75 mg/m\^2 during the radiation treatment. Temozolomide will continue until the completion of radiation and then will be stopped. Beginning 1-month post-radiation therapy (RT), the adjuvant temozolomide will be given per standard of care.
41447045|NCT04216329|RADIATION|Generic Radiation therapy (RT)|Radiation therapy (RT) will be administered daily (Monday to Friday)
41447046|NCT04216329|OTHER|Selective serotonin receptor (5-HT3) antagonists|Anti-emetic for breakthrough nausea.
41447047|NCT04216329|OTHER|Olanzapine|2.5mg to 5mg once a day if weight loss is rapid.
41447048|NCT04216329|DIETARY_SUPPLEMENT|Salt tablets|To treat hyponatremia, add salt tablets to participants diet per institutional guidelines.
41447049|NCT04216329|OTHER|Anti-diarrheal|Treat diarrhea with an anti-diarrheal per institutional guidelines
41447050|NCT02599558|DEVICE|Cytosponge|A capsule with a string attached with a sponge inside is swallowed. The string is held without any tension to allow the capsule to move into the stomach. The string will be held for five minutes to allow the capsule to dissolve in the stomach; a round mesh sponge about the size of a quarter is released.
41447051|NCT02028715|DRUG|Placebo|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
41447052|NCT02028715|DRUG|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
41447053|NCT06025279|OTHER|Ultrasound Scan|Clinical professionals will conduct non-invasive ultrasound scans from the specified body views and subsequently save the acquired data.
41447054|NCT04674072|OTHER|Reverse Nordic curl exercise|The reverse Nordic curl is a body-weight exercise which mainly works the quadriceps and hip flexors. It has a large eccentric component, meaning the muscles are working whilst lengthening.
41447055|NCT04674072|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
41447056|NCT03099915|OTHER|completion of self-reported questionnaires|Single completion: Participants will have to complete self-reported questionnaires based on gina criteria and 12-item general health questionnaire
41447057|NCT05191680|DRUG|Apalutamide Oral Tablet [Erleada]|Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.
41447058|NCT05191680|DRUG|Placebo|Placebo to match apalutamide
41447059|NCT06449534|BEHAVIORAL|Patient Education|It includes evaluation of the treatment process and past sessions. Simple shoulder biomechanics, function, and what caused the injury were explained to the patients. In order to increase patients' participation in treatment, it was emphasized what the treatment does and that the patient should cooperate in order to heal. During their treatment, patients are instructed to regulate their daily living activities, avoid overhead and repetitive movements of the arm, bags weighing more than 2-3 kg, etc. It was recommended not to carry them. Patients were informed about alternative sleeping positions.
41447060|NCT06449534|BEHAVIORAL|Exercise Therapy|Participants in both groups were included in a structured exercise program consisting of exercises recommended in the literature. This exercise program includes joint range of motion exercises, stretching exercises and strengthening exercises and was carried out under the supervision of a physiotherapist for 6 weeks. Joint range of motion and strengthening exercises are recommended as 3 sets of 10 repetitions, and stretching exercises are recommended as 5 repetitions for 20 seconds. Exercises appropriate to the patients' clinical conditions and progression were selected by the physiotherapist and included in the program.
41447061|NCT06449534|BEHAVIORAL|Cold Application|Following each exercise treatment, cold-pack will be applied for 15 minutes. During col-pack application, patients in the Group 1 group will listen to classical music selected by us, while patients in the Group 2 will rest quietly. There are a total of 40 songs by Bach, Mozart, Beethoven and Andre Rieu on our CD player, and patients have the right to choose and listen to the song they want.
41447062|NCT01322880|BEHAVIORAL|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
41447063|NCT01322880|BEHAVIORAL|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
41447064|NCT00354159|DEVICE|Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)|Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.
40754409|NCT04556097|BEHAVIORAL|Care Ecosystem|"The Care Ecosystem model uses a telephone-based intervention to support persons with dementia and their care partners, screening for common dementia-related problems and providing modular standardized support protocols and caregiver education. Specially trained health care navigators systematically identify needs and address health status, advance care planning, medication management and management of challenging behaviors. Health care navigators receive backup support from a nurse, social worker, dementia specialist, and pharmacist, and maintain close communication with the primary care provider of the persons with dementia.~This Care Ecosystem model will be adapted to augment the dementia care provided by experienced Integrated Care Management Program nurse care managers engaged in the care of high-risk, high-cost patients in a large health system."
41447065|NCT01344590|OTHER|Normal Saline|Standard saline procedure will be utilized.
41447066|NCT01344590|OTHER|Ethanol 70% pharmaceutical grade|70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
40754410|NCT02268487|DRUG|Sertraline|Treatment
40927801|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants|Two 0.8 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
40927802|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participants|Two 4.0 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
40927803|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participants|A single 0.8 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
41125163|NCT06519617|DRUG|Yi Qi Yang Yin Decoction|The Yi Qi Yang Yin Decoction (Dihuang 15g, Baihe 12g, Nanshashen 15g, celery Qinghao 10g, Malt 10g, Shengma 6g, Chaihu 6g) prescription for patients eligible for qi and yin deficiency was 200 ml twice daily for 12 weeks.
41125164|NCT06519617|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate Tablets 200-400mg daily for 12 weeks.
41125165|NCT03873896|DIAGNOSTIC_TEST|Stimulated skin wrinkling test|Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)
41125166|NCT03873896|PROCEDURE|Digital Nerve Block|A digital nerve block is performed by injecting a total of 3 millilitres of 2% Lidocaine at the base of the ring finger of randomized hand of the volunteer. The effect of the block is confirmed clinically before proceeding with the study data collection. Please see the description for more details on the procedure
41125167|NCT01737021|OTHER|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
41125168|NCT01782170|DRUG|Iocide Oral Rinse|
41125169|NCT01782170|DRUG|Placebo|
41125170|NCT04826822|DRUG|Spironolactone + Dexamethasone|Low doses of orally administered spironolactone and dexamethasone
41125171|NCT04826822|DRUG|Standard-of-care SARS-CoV-2 treatment|Standard-of-care SARS-CoV-2 treatment administered according to the local guidelines
40754411|NCT02065804|DRUG|Bupivacaine|injection, once, 5 min
40754412|NCT02743754|OTHER|Standard therapy|The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
40754413|NCT02743754|OTHER|Hyperbaric Oxygen|The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
40754414|NCT05634928|OTHER|collection data|collection data
40927804|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants|A single 4.0 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
40927805|NCT02012868|PROCEDURE|bariatric surgery|
41125172|NCT04131907|DEVICE|Optilume BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
41125173|NCT04131907|DEVICE|Optilume Sham Device|21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)
41125174|NCT03567252|BEHAVIORAL|Walking Group|Participants will walk 1 kilometer to a Farmer's Market.
41125175|NCT06445699|OTHER|Photodynamic therapy|A number of studies have reported that PDT can accelerate wound healing by inactivating local bacterial infection and colonization of bacterial biofilm, promoting wound re-epithelialization.
41125176|NCT06445699|OTHER|Hydrogel dressing|Hydrogel dressing is widely applied in clinical practice to improve the regeneration ability of wound granulation tissue, promote the division and migration of epithelial cells, speed up wound healing and relieve the pain.
40927806|NCT04572360|OTHER|Cardiorespiratory Exercise|Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training
40927807|NCT04572360|OTHER|Modified Bai He Gu Jin Tang|The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.
40927808|NCT00065130|DRUG|human insulin|
40927809|NCT00065130|DRUG|insulin NPH|
40927810|NCT00065130|DRUG|insulin aspart|
41276418|NCT06656780|BEHAVIORAL|SIT|"Participants will undergo 2 day (8 hours each) Stress Inoculation Training . This will be done in 3 steps:~Step 1: focus on education about the human body and brain and shift to hands on skills practice to improve performance in stressful conditions and is designed to improve self-and-situational awareness and the ability to manipulate reactions and responses in the body on purpose to enhance performance~Step 2: focuses on improving mental self-awareness and gaining skills in Mental Agility and Mental Flexibility~Step 3: participants will have specific simulations and real-world opportunities to practice the skills learnt."
41276419|NCT06656780|BEHAVIORAL|DCA-FF|Participants will undergo 8-week Standard Firefighting Training
41276420|NCT06657443|OTHER|First Session|Introductions, explanation of the purpose and content of the project, realisation of the pre-test application. Giving the assignment with the theme of 'Nursing and Society' between peer mentors and mentees.
41276421|NCT06657443|OTHER|Second Session|Training of peer mentors on communication techniques, interview methods and empathic approach.
41276422|NCT06657443|OTHER|Third session|Sharing postcasts on communication techniques, interview methods and empathic approach with peer mentors.
41276423|NCT06657443|OTHER|Fourth session|Training of peer mentors on social motivation and leader-member interaction
41276424|NCT06657443|OTHER|Fifth Session|Sharing postcasts with peer mentors on social motivation and leader-member interaction.
41276425|NCT06657443|OTHER|Sixth Session|Presentation of 'Nursing and Society' themed assignments of peer mentors and mentees as a group (Composition, poem, poster, presentation, role play, etc. are left free among the students) and post-test application.
41276426|NCT06657690|DRUG|Irinotecan liposome|Irinotecan liposome injection, 50mg/m2, D1、D15, ivgtt, Q4w.
41276427|NCT06657690|DRUG|S-1|S-1, D1-D14, BID, p.o., Q4w (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose).
41276428|NCT06657144|DRUG|CHS-114|Sterile solution for infusion
41276429|NCT06657144|DRUG|Toripalimab|Sterile solution for infusion
40927811|NCT01074047|DRUG|Azacitidine|75 mg/m\^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
40927812|NCT01074047|DRUG|Conventional Care Regimen|"Physician pre-selects prior to randomization from one of the following:~* Intensive chemotherapy (cytarabine 100-200 mg/m\^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~* Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~* Best Supportive Care only; until study end"
40927813|NCT03089762|BIOLOGICAL|Intra-articular injection of SVF plus PRP|administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
40927814|NCT04949919|OTHER|aerobic training by a cycle ergometer and Biodex system 4 pro|cyclic aerobic training in moderate-intensity and high-intensity interval training plus isokinetic resistance training prior to HD. 60 training sessions in 6 months.
40927815|NCT04671472|DRUG|NPC-09|The drug will be administered by the oral route with the same manner
40927816|NCT04671472|DRUG|NPC-09 placebo|The drug will be administered by the oral route with the same manner
40754415|NCT03258957|OTHER|Fresh Milk|Mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day, other time, feed frozen milk
40927817|NCT04450810|OTHER|Observation of serum and salivary NLRP3 levels|Evaluation of serum and salivary NLRP3 levels
40927818|NCT04745273|DRUG|Ondansetron 4 MG (Kemoset 4mg)|Ondansetron 4mg (iv) will administer to participants
40927819|NCT04745273|OTHER|Salin solution|Salin solution 2ml (iv) will administer to participants
40927820|NCT05509894|DRUG|Ngenla|As provided in real world practice
40927821|NCT02420782|DRUG|ASP6282|oral
40927822|NCT02420782|DRUG|Itraconazole|oral
40927823|NCT02420782|DRUG|Pilocarpine|oral
40927824|NCT02420782|DRUG|Placebo|oral
40927825|NCT02420782|DRUG|Midazolam|oral
40927826|NCT00003798|DRUG|motexafin gadolinium|
40927827|NCT00003798|RADIATION|radiation therapy|
40927828|NCT02692651|DRUG|Fidaxomicin|Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
40927829|NCT02692651|DRUG|Vancomycin|Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
41276430|NCT04840121|DIAGNOSTIC_TEST|AdhesioRT|AdhesioRT, a novel diagnostic genetic assay, developed by ovo R\&D scientists, helps to predict the endometrial receptivity and embryo implantation.
41276431|NCT05335538|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
41276432|NCT01103739|DRUG|PF-04531083|PF-04531083: 100mg to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
41276433|NCT01103739|DRUG|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
41276434|NCT01103739|DRUG|PF-04531083|PF-04531083: a dose to be selected depending on results from Cohort 1 to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
41276435|NCT01103739|DRUG|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
40754416|NCT03061214|DRUG|Semaglutide 0.5 mg|Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
40754417|NCT03061214|DRUG|Semaglutide 1.0 mg|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
41125177|NCT05894252|OTHER|Walking Interventions|"Participants in the intervention group will be required to complete a 30-minute walk five days a week for 12 weeks. This will be in addition to any regular walking or exercise they are currently doing, which will be assessed via a questionnaire at baseline. In the control group, participants will be asked to continue with their daily routines and usual level of physical activity.~The baseline measurements will be taken before the intervention at week zero. Subsequently, all the participants will attend a virtual meeting (screening visit) to learn about the key aspects of the research, including the required actions of the control and intervention groups, how to use the act watch and report the required data. All participants in the intervention group and the control group will be required to wear acti watches, which will be given to them for free."
41125178|NCT00931710|DRUG|valsartan, amlodipine, HCTZ|combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
41125179|NCT00931710|DRUG|Losartan, HCTZ followed by valsartan, amlodipine, HCTZ|losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
41276436|NCT03427437|DRUG|Bupivacaine|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
40754418|NCT03061214|DRUG|Sitagliptin placebo|Sitagliptin placebo tablets taken once-daily for 30 weeks
40754419|NCT03061214|DRUG|Sitagliptin|100 mg sitagliptin tablets taken once-daily for 30 weeks
40754420|NCT03061214|DRUG|Semaglutide placebo 0.5 mg|Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
40754421|NCT03061214|DRUG|Semaglutide placebo 1.0 mg|Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
40754422|NCT03212469|DRUG|Durvalumab|"Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses~Safety run of the triple combination:~Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
40754423|NCT03212469|DRUG|Tremelimumab|"Preliminary steps : Safety Runs~Safety run of the triple combination:~Tremelimumab at 75mg/Q4W for up to 4 doses~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
41125180|NCT04761536|OTHER|Rectal cancer case centralization|In November 2016, the decision to centralize rectal cancer patients to only one surgical unit was taken, with only two surgeons performing the procedures. Furthermore, a close collaboration with local Gastroenterology Units and General Practiotioners was started in order to increase colorectal cancer case referral to our unit. At the same time, we decided to promote the use of laparoscopy and to implement ERAS protocol in our colorectal surgery practice.
41276437|NCT03427437|DRUG|Adrenalin|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
41125181|NCT03158805|DRUG|LIRAGLUTIDE|3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
41276438|NCT03427437|DEVICE|Ultrasound|caudal block was performed by ultrasound method
41276439|NCT01596491|PROCEDURE|quantitative sensory testing (QST)|with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
40754424|NCT03212469|RADIATION|SBRT|"Preliminary steps : Safety Runs~Safety run of the dual combination:~SBRT at C1D15.~Safety run of the triple combination:~SBRT at C1D15.~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
40754425|NCT00932503|DEVICE|Vicryl plus|triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
40754426|NCT03518203|DRUG|Eculizumab|Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
40754427|NCT05003336|DRUG|Xiangshao Granules|dissolve 1 sachet (4 g) in water to be drank 3 times a day after meal for 8 weeks
41276440|NCT01475890|DIETARY_SUPPLEMENT|Vitamin D3|7000IU per day of vitamin D3 for 12 months.
41276441|NCT01475890|DIETARY_SUPPLEMENT|Placebo|Once a day for 12 months.
40754428|NCT05003336|DRUG|Xiangshao Granules Placebo|Xiangshao Granules Placebo
40754429|NCT00561821|DRUG|Esmirtazapine|one tablet daily
40754430|NCT00561821|DRUG|Placebo|one tablet daily
40754431|NCT01111487|DEVICE|Expiratory positive airway pressure (EPAP) by face mask.|Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
40754432|NCT01163500|DIETARY_SUPPLEMENT|Coenzyme Q10|coenzyme Q10 supplements 60 mg/day and 150 mg/day
40754433|NCT01163500|OTHER|Placebo|Placebo controlled (dextrin)
40927830|NCT06275490|BIOLOGICAL|Partially Demineralized Dentin Block|"The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size 400-800 μm. Afterwards.~-Prepare the partially demineralized dentin block, the L-PRF membranes will be cut into small pieces and mixed with the dentin particles at a ratio of 2 membranes to 0.5 g of dentin, providing a 1:1 volume ratio. The liquid fibrinogen will be added to the homogeneous mixture, and while shaping the mixture into the desired form it will be gently stirred for approximately 10 seconds. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming a sturdy block known as the dentin block, which serves as a convenient and compact graft .The extracted socket will be filled with partially demineralized autogenous dentin graft."
40927831|NCT06275490|BIOLOGICAL|L-PRF block|The same procedure will be performed for preparing the L-PRF block by mixing the L-PRF membranes with xenograft. In both groups, the placed graft will be covered with a L-PRF membrane .The L-PRF clots obtained after 12 min of centrifugation will be placed in the Xpression box (IntraSpin, Intra-Lock, Florida, USA) for 5 min to gently compress (by gravity) into membranes.
41125182|NCT03158805|OTHER|Placebo|Placebo injection
41125183|NCT06366399|BEHAVIORAL|Resistance Exercise Timing|1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises
41125184|NCT01571570|DRUG|TMC435 150 mg capsule|single oral dose of 150 mg TMC435 150 mg capsule
41125185|NCT01571570|DRUG|TMC435 150 mg oral suspension (20 mg/mL)|single oral dose of 150 mg TMC435 oral suspension
41125186|NCT01571570|DRUG|TMC435 150 mg oral solution (10 mg/mL)|single oral dose of 150 mg TMC435 oral solution
41125187|NCT01571570|DRUG|TMC435 150 mg capsule concept K|single oral dose of 150 mg TMC435 capsule concept K
41125188|NCT01571570|DRUG|TMC435 150 mg capsule concept L|single oral dose of 150 mg TMC435 capsule concept L
41125189|NCT02810236|PROCEDURE|Ultrasound|Ultrasound will be performed.
41276442|NCT03853421|DRUG|Sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
41125190|NCT02810236|BEHAVIORAL|Discussion|Radiologist will discuss with the patient the findings on mammogram.
41276443|NCT05792202|PROCEDURE|microfracture procedure|double raw repair combined with microfracture procedure which promotes tendon healing by releasing growth factors
41276444|NCT05792202|PROCEDURE|only double raw repair|the double raw repair was used to repair the tendon tear
40754434|NCT04642066|OTHER|Cold water immersion|Full body CWI in open standing, except the head (same location, timing), frequency three times a week in the duration of 7-10 minutes. Swimming was permitted. Volunteers must not use neoprene aids (gloves, shoes), caps were allowed. Volunteers should be in the final phase submerged in water, above which there should only be the head and neck. The upper limbs were below the water surface. Non-neoprene footwear was permitted. Volunteers entered the water continuously without stopping. The time of stay in water was calculated from the first contact of the foot with water. On average, the whole body needed to be immersed in water within 30 seconds.
40754435|NCT04642066|OTHER|No cold water immersion|People without cold water immersion
40754436|NCT01253356|DEVICE|IABP|Insertion of intra-aortic balloon \< or = 3 hours before noncardiac surgery and maintained \> or = 12-24 hours after surgery
40754437|NCT03394846|BEHAVIORAL|Test of Existing MI Products|Three widely available MI products (GoNoodle, Take10, ABC for Fitness) will be tested by teachers in their classrooms. Teachers will participate in the study for four weeks (one baseline week, one week for each product).
40754438|NCT01573728|BEHAVIORAL|Low dose exercise|Exercise totaling 50 minutes per week and low intensity
40754439|NCT01573728|BEHAVIORAL|Public Health Exercise|At least 150 minutes at moderate intensity
41125191|NCT04746833|BEHAVIORAL|SUMMIT|multicomponent web-based application focused on pain self-management skills
41125192|NCT04746833|BEHAVIORAL|control|My Pain Diary app
41125193|NCT05979922|BEHAVIORAL|Mindfulness-based Cognitive Coping|Participants will receive the Caring Mind mobile app containing the Mindfulness-based Cognitive Coping program.
41125194|NCT05979922|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a downloadable workbook and online resources.
41125195|NCT01431430|DRUG|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
41125196|NCT01431430|DRUG|Cholecalciferol 12 000 UI|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
41125197|NCT02530216|OTHER|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|"AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint."
41125198|NCT03401138|OTHER|Preoperative Stroke Volume(SV)-guided fluid optimization|"Preoperative SV-guided hemodynamic optimization will be commenced with patients receiving 250ml fluid challenges over five minutes aiming to maximize SV. Maximal SV is defined as absence of a sustained rise in SV by at least 10% in response to a fluid challenge.~PPI will be obtained from the Masimo Radical 7 (Masimo, Irvine, CA, USA) and NIRS from Invos 5100C (Medtronic, Minneapolis, MN, USA).~BV measurements will use pulse dye densitometry (PDD) with Indocyanine Green (ICG). We will use the Dye Densitogram 3300 analyser Nihon Kohden (Tokyo, Japan) for registration of the spectrophotometrical absorption of ICG and calculation of BV."
41125199|NCT05297136|PROCEDURE|Pancreatic Stenting|Pancreatic stent of appropriate size and length is inserted to the pancreatic duct before distal pancreatectomy
41125200|NCT05297136|PROCEDURE|No Stent|No preoperative stenting with distal pancreatectomy alone
41125201|NCT01972724|DRUG|Pioglitazone|Pioglitazone tablets
41125202|NCT01972724|DRUG|Metformin|Metformin as prescribed in clinical practice
41125203|NCT01972724|DRUG|Sulfonylurea|Sulfonylurea as prescribed in clinical practice
41125204|NCT01006434|OTHER|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
40927832|NCT05608928|DIETARY_SUPPLEMENT|VSL#3|VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.
40927833|NCT05608928|DEVICE|Capscan device|"The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body."
41125205|NCT00639795|PROCEDURE|Thoracic Paravertebral Nerve Block|One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia
41125206|NCT00639795|PROCEDURE|Thoracic Paravertebral Nerve Block|Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
41125207|NCT03366506|OTHER|Observation|
40927834|NCT05608928|COMBINATION_PRODUCT|Placebo|microcrystalline cellulose
40927835|NCT01847131|DRUG|oxymetazoline|0.05% Oxymetazoline nasal sprays were commercially available.
41125208|NCT00039000|DRUG|HSPPC-96 or Oncophage|
41125209|NCT01657604|DRUG|Peginterferon α2b|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
41125210|NCT01657604|DRUG|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
41125211|NCT05959590|DRUG|Ferumoxides 11.2Mg Solution for Injection|the drug will be injected at a single dose of up to 7 mg/Kg and MRI will be performed after 24 hrs.
41125212|NCT03785405|DRUG|sacubitril/valsartan|"Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules \[12.5 mg (4 granules), 31.25 mg (10 granules), in capsules\] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)"
41125213|NCT05018013|DRUG|Ammoxetine hydrochloride enteric-coated tablets|Ammoxetine hydrochloride enteric-coated tablets
41125214|NCT05018013|DRUG|Duloxetine hydrochloride enteric-coated capsules|Duloxetine hydrochloride enteric-coated capsules
41125215|NCT05018013|DRUG|Placebo to Ammoxetine|Placebo to Ammoxetine
41125216|NCT05018013|DRUG|Placebo to Duloxetine|Placebo to Duloxetine
41125217|NCT01290185|DEVICE|Placement of different catheters for continuous nerve block|Placement different catheters adjacent to the femoral
41125218|NCT03809936|DEVICE|real tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
41125219|NCT03809936|DEVICE|sham tDCS|For the sham condition(sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
40754440|NCT03052257|BEHAVIORAL|Educational - glaucoma|Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation. An individualized schedule for dosing of glaucoma medications. Individualized suggestions for improving adherence based on the subject's responses to the (SASES).
40754441|NCT03052257|BEHAVIORAL|Dose monitoring and reminder|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder through AdhereTech will be activated."
40754442|NCT03052257|BEHAVIORAL|Educational - general|The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.
41276445|NCT06179992|DEVICE|GGED mobile app|The intervention will be done through an app named GGED, which is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
40927836|NCT01847131|DRUG|Placebo nasal spray|Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
40927837|NCT00649545|BIOLOGICAL|adalimumab|40 mg every other week
40927838|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
41276446|NCT06154629|DIETARY_SUPPLEMENT|Botanical ingredient|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
41276447|NCT06154629|DIETARY_SUPPLEMENT|Control group|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
41276448|NCT04028037|PROCEDURE|FTPGT treated patients|"The recipient bed will be prepared according to Langer\&Langer modified technique. Intrasulcular incision will be performed from at least one tooth mesial and one tooth distal to the tooth with gingival recession, without vertical incisions.A split-thickness flap will be raised.The harvest of palatal graft will be done using FTPG technique. An incision, parallel to the gingival margin, deep to the bone, will be made. At the center of this incision, a U shaped one about 1-2mm deep will made, with the convex side towards the palatine vault.The width of the U incision will be equal to the width of the GR and the length will be 1mm greater.A split-thickness dissection of the area surrounding the U shaped incision will be done.The graft will be removed by detaching it from the bony surface.The graft will be made up of an apico-lateral portion of connective tissue and periosteum, and of a full-thickness central part.The palatal graft will be adapted to the recipient site and sutured."
41447067|NCT04681391|DEVICE|transCranial direct current stimulation|In the present study, we applied DC Brain Stimulator Plus to stimulate right temporoparietal junction (rTPJ). The target electrode was placed over the location of rTPJ; on the other hand, the return electrode was placed over the left supraorbital area. That is, during anodal tDCS, the anode was placed over CP6, and the cathode was placed over left supraorbital area; conversely, during cathodal tDCS, the cathode was placed over CP6, and the anode was placed over left supraorbital area. For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. On the other hand, same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds. Therefore, participants could feel the skin sensation but did not have the after-effects of tDCS.
41447068|NCT04806763|DEVICE|Menicon Z Night|To assess the use of Menicon Z Night contact lenses for reducing myopia progression in children
41447069|NCT04806763|DEVICE|Control|Distance, single-vision glasses were used as control
40927839|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
40927840|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks and 1 drop Timolol ophthalmic solution 0.5% twice daily for 52 weeks
40927841|NCT01268280|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
40927842|NCT01268280|DRUG|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
40927843|NCT01268280|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
40927844|NCT05428124|OTHER|In vitro fertilisation|In vitro fertilisation
41125220|NCT05965141|DRUG|Aribulin;carboplatin;bevacizumab|Aribulin combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive recurrent ovarian cancer.
41276449|NCT04028037|PROCEDURE|CAF+SCTG treated patients|According to De Sanctis \& Zucchelli, a tension-free trapezoidal flap will be elevated by the split-full-split technique and the anatomic papillae will be de-epithelialized. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. The height of the graft was equal to the distance between the buccal bone crest and the CEJ. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap, sutured about 2mm over the CEJ by 5-0 silk sutures.
41276450|NCT03862456|OTHER|Azithromycin|azithromycin (500 mg/24h/3 days)
41276451|NCT03862456|OTHER|Metronidazole|metronidazole (500 mg/8h/7 days)
41276452|NCT03325309|OTHER|Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
41276453|NCT06249529|DEVICE|Airway Bypass|Bypass stent(s) are implanted to allow air trapped in the parenchyma to escape
41276454|NCT01217606|DRUG|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
41276455|NCT01217606|DRUG|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
41276456|NCT00613626|DRUG|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
41276457|NCT00613626|DRUG|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
41276458|NCT00613626|DRUG|Placebo|Matched placebo oral daily
41276459|NCT00613626|DRUG|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
41276460|NCT02700529|DRUG|ubenimex|
41276461|NCT02700529|OTHER|placebo|
41276462|NCT05855356|PROCEDURE|Rehabilitation|respiratory physiotherapy, personalized aerobic and strength training
41276463|NCT05855356|PROCEDURE|Standard of Care|Behavioural and Medical management
41276464|NCT03392766|DEVICE|single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and bronchial blocker.
41276465|NCT03392766|DEVICE|double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube.
41276466|NCT06487156|DRUG|Nivolumab + ipilimumab|As per product label
41276467|NCT02276261|PROCEDURE|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
40927845|NCT04163289|DRUG|Fecal Microbiota Transplantation|Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
41276468|NCT02276261|PROCEDURE|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
41276469|NCT00455637|BIOLOGICAL|Botulinum toxin type A|
40927846|NCT05282914|DRUG|administration of UI058|UI058 1Tab/day for 7days
40927847|NCT05282914|DRUG|administration of UIC202004|UIC202004 1Tab/day for 7days
41276470|NCT03742778|BEHAVIORAL|Incentivizing reflection|Participants receive bonus incentives for reflecting on their workouts
41276471|NCT03742778|BEHAVIORAL|Incentivizing exercise|Participants receive bonus incentives for exercising
41276472|NCT02154750|DEVICE|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
17358278|NCT06553599|DRUG|AZD5004|Active IMP daily during 36 weeks
41276473|NCT02154750|DEVICE|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
41276474|NCT06282692|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg|Dose : 1 dose 0.5 ml containing 5 µg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
41276475|NCT02931448|DEVICE|Dosage of the blood HbCO thanks to the carboxymeter MASIMO RAD 57|
40754443|NCT03052257|BEHAVIORAL|Dose monitoring|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
40754444|NCT02922712|DRUG|NISE|Nise 200mg Max per day in 2 divided doses
41125221|NCT00813657|BEHAVIORAL|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, \~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (\~8 minutes), followed by toning and very light resistance exercises (\~20 minutes) and a light intensity cool-down (\~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
41125222|NCT01962090|OTHER|Thoracic Spine Thrust in Seated Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
40754445|NCT03383081|BIOLOGICAL|Low dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);
40754446|NCT03383081|BIOLOGICAL|High dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \* 10\^7 cells (5ml)
41276476|NCT01523080|DRUG|Acetaminophen|Extended release Gel tabs 650 mg
41276477|NCT01819935|DRUG|linezolid (Zyvox)|As prescribed-this is retrospective cohort of existing clinical data.
41276478|NCT01819935|DRUG|vancomycin|As prescribed-this is retrospective cohort of existing clinical data.
17358279|NCT06553599|DRUG|Placebo|Placebo daily during 36 weeks
41276479|NCT01702116|PROCEDURE|extralevator APR|"Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
40754447|NCT03383081|PROCEDURE|Intraarticular injection|Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
40754448|NCT01775709|DEVICE|PE tube with Duckbill Valve|PE tube with Duckbill Valve
40754449|NCT04673695|DRUG|Lixiana(D006)|NOAC(Factor Xa inhibitor)
41276480|NCT01702116|PROCEDURE|APR|standard Abdominoperineal Resection For Rectal Adenocarcinoma
41276481|NCT01238003|OTHER|Interpretation of blood test results|Interpretation of blood test results
41276482|NCT01929070|DRUG|HCP1007|
41276483|NCT01929070|DRUG|Omarco and Crestor|
41276484|NCT05520879|DIETARY_SUPPLEMENT|Sharnali 1|"The intervention is food product, made from locally available food ingredients in Bangladesh.~Sharnali 1 made from rice, lentil, dried skimmed milk, sugar, vegetable oils and micronutrient premix."
40754450|NCT04673695|DRUG|CKD-344|NOAC(Factor Xa inhibitor)
40927848|NCT06080724|DRUG|Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone|already described
41276485|NCT05520879|DIETARY_SUPPLEMENT|Sharnali 2|Sharnali 2 made from chick peas, dried skimmed milk, sugar, vegetable oils and micronutrient premix.
41276486|NCT02628587|DRUG|Generic clopidogrel|"Comparison of different brands of clopidogrel:~\*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
41447070|NCT05167981|OTHER|RETAINWORKS|The experimental group is eligible to receive the full set of RETAINWORKS intervention activities. The program includes a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Participants receive intensive case management and care coordination by health and employment services RTW navigators. Financial incentives are offered to participants and medical providers for milestone attainment and training achievement.
41447071|NCT01456221|DIETARY_SUPPLEMENT|Omega3 and an hypocaloric diet.|Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
41447072|NCT01456221|DIETARY_SUPPLEMENT|Sunflower oil with an hypocaloric diet.|Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
41447073|NCT03810586|DEVICE|Non-invasive measurement of blood pressure|Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)
41447074|NCT02741687|DRUG|Sitagliptin|Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) \> 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
41447075|NCT02741687|DRUG|Placebo|Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
41125223|NCT01962090|OTHER|Thoracic Spine Thrust in Supine Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
41125224|NCT01737489|BEHAVIORAL|LACE|commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
40927849|NCT06131528|OTHER|Relaxation Breathing Exercises Group|This group will preform Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing
40927850|NCT06131528|OTHER|Usual Care Group|The control group received lifestyle modifications that are an important part of hypertension management
40927851|NCT04999852|DEVICE|Safe and Sound Protocol|SSP is a non-invasive acoustic vagus nerve stimulator consisting of 5 hours of filtered and processed music designed to promote efficient regulation of autonomic state, and available through an app. The SSP is delivered via a mobile app and may fall under the heading of medical devices under the category of software functions/mobile medical applications.
40927852|NCT04999852|BEHAVIORAL|Psychotherapy|All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.
40927853|NCT00007007|PROCEDURE|management of therapy complications|
40927854|NCT00007007|PROCEDURE|quality-of-life assessment|
40927855|NCT03507530|OTHER|Assessments|Falls related assessments, functional physical performance evaluations and quality of life assessments.
40927856|NCT02236182|DRUG|Ipratropium Bromide low dose|
41125225|NCT01737489|BEHAVIORAL|NOOK|will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
40927857|NCT02236182|DRUG|Placebo|
40927858|NCT02236182|DRUG|Ipratropium Bromide high dose|
40927859|NCT05592743|DRUG|Vorasidenib|Oral therapy
41125226|NCT04860401|DEVICE|Measurement of tissue oxygenation with novel diagnostic near-infrared spectroscopy device (OxyPrem) (no clinical decisions based on oxygenation levels)|The precision of OxyPrem is assessed by repeated measurements of tissue oxygenation and hemoglobin concentration. The accuracy of OxyPrem is assessed by comparing the measurement data to those acquired simultaneously by established NIRS devices and standard clinical monitoring devices. In substudy 1, healthy adult subjects are enrolled, in substudy 2, measurements are conducted on preterm neonates.
41447076|NCT02741687|DRUG|Supplemental insulin (insulin lispro)|"Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) \>240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
41276487|NCT02628587|DRUG|Patent clopidogrel|"Comparison of different brands of clopidogrel:~\*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
41447077|NCT02741687|DRUG|Supplemental insulin (insulin aspart)|"Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) \>240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
40927860|NCT03603509|DRUG|Fluad Vaccine|FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza. disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is. approved for use in persons 65 years of age and older.
40927861|NCT03603509|DRUG|Fluzone High-Dose|FLUZONE® HIGH-DOSE vaccine is indicated for people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.
40927862|NCT05343533|DIETARY_SUPPLEMENT|Probiotic|After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.
40927863|NCT06391190|DRUG|Albumin-Bound Paclitaxel, cisplatin, Sintilimab|with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation; followed by Sintilimab 200mg Q3W for 8 cycles
40927864|NCT04112589|DRUG|Quizartinib|Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.
40927865|NCT04112589|DRUG|Fludarabine|30 mg/m2 intravenous days 1 to 4 of the cycle
40927866|NCT04112589|DRUG|Cytarabine|2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle
40927867|NCT04112589|DRUG|Idarubicin|10 mg/ 2 intravenous days 1 to 3 of the cycle
40927868|NCT04112589|DRUG|glycosylated G-CSF|daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle
40927869|NCT05491460|DRUG|Apixaban 5 MG Tab|oral intake
40927870|NCT05491460|DRUG|Dabigatran 150 MG Tab|oral intake
40927871|NCT05491460|DRUG|Edoxaban 60Mg Tab|oral intake
40927872|NCT05491460|DRUG|Rivaroxaban 20 MG Tab|oral intake
41125227|NCT02173717|DRUG|Dabigatran etexilate|150 mg Dabigatran etexilate
41276488|NCT01472276|BEHAVIORAL|Web-based program|Provided with the web-based program
41276489|NCT00098787|BIOLOGICAL|bevacizumab|Given IV
41276490|NCT00098787|DRUG|fluorouracil|Given IV
41276491|NCT00098787|DRUG|irinotecan hydrochloride|Given IV
41276492|NCT00098787|DRUG|leucovorin calcium|Given IV
41276493|NCT00098787|DRUG|Oxaliplatin|Given IV
41276494|NCT03874234|DRUG|GSK3186899|GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.
41276495|NCT03874234|DRUG|Placebo|Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
41276496|NCT06139289|PROCEDURE|EVD placements in the OR versus the bedside.|Reducing EVD-related complications
41276497|NCT01624142|BIOLOGICAL|Evolocumab|Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
41276498|NCT00003558|DRUG|carboplatin|
41447078|NCT02741687|DRUG|Long acting basal insulin (insulin detemir)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) \>180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between \>180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG \>241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
41447079|NCT02741687|DRUG|Long acting basal insulin (insulin glargine)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) \>180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between \>180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG \>241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
40927873|NCT00706849|DRUG|mipomersen sodium|200 mg /mL
40927874|NCT00706849|DRUG|placebo|1 mL matching placebo
40927875|NCT03330002|DEVICE|CE-marked MANTA vascular closure device (VCD)|Compile real word data on MANTA VCD.
41447080|NCT00828815|DRUG|TMC125|
40927876|NCT04911374|OTHER|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants
40927877|NCT04911374|OTHER|Aveeno Face Milk SPF 40+|Sunscreen to be applied after application of face moisturizer and eye cream in the morning. Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day.
40927878|NCT01649453|DEVICE|Pathwork® Tissue of Origin Test|
40927879|NCT03253419|OTHER|Home for Life mobile application|Utilize home application to provide the participant with an understanding and recommendations to potentially decrease home hazards that may lead to risk of falls in their home.
40927880|NCT05365854|PROCEDURE|Alveolar Recruitment Maneuver (ARM)|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
40927881|NCT02591329|BEHAVIORAL|Mail-out hard copy materials (education plus self-regulatory strategies examples)|
40927882|NCT02591329|BEHAVIORAL|Standard Care|
40927883|NCT05384145|OTHER|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
41125228|NCT02173717|DRUG|Rifampicin|600 mg Rifampicin
41125229|NCT06224517|OTHER|Rehabilitation|The intervention includes daily physical and occupational therapy sessions tailored to each patient's functional status. In this study, stroke patients will undergo a four-week rehabilitation therapy program comprising 60-minute daily sessions of physical and occupational therapy. The physical therapy includes balance training, mobility and strengthening exercises, while occupational therapy covers sensorimotor and fine motor training, and ADL activities.
41125230|NCT02318407|DRUG|AMG 403|AMG 403 for the treatment of subjects with osteoarthritis
41125231|NCT02318407|DRUG|Placebo|contains no active drug
41125232|NCT02035046|PROCEDURE|Samplings of blood|
41125233|NCT02035046|PROCEDURE|Sampling of urine|
41125234|NCT02035046|PROCEDURE|Measure of the blood pressure|
41125235|NCT02035046|PROCEDURE|glycemia test|
41125236|NCT05983185|BEHAVIORAL|Prism adaptation therapy|The investigators' research and clinical group is the US leader in implementing this intervention for spatial neglect and have brought it to more than 50 clinical centers, hospitals, and treatment organizations.
40927884|NCT04939506|BEHAVIORAL|COVID-19 Vaccine Education at the Point of COVID-19 Testing|A rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel. The intervention will include: 1) 15 minute vaccine counseling, 2) print material 3) referral to a dedicated vaccine website with feedback forums and 4) opportunity to sign-up for one-on-one vaccine counseling with a clinical pharmacist
40927885|NCT05061680|DEVICE|endoscopic short duration papillary large balloon dilation|During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
40927886|NCT00942071|BIOLOGICAL|MVA-NP+M1|1. Intradermal injection at 5 x 10\^7 pfu at day 0
41447081|NCT03740295|DIETARY_SUPPLEMENT|Coconut oil and epigallocatechin gallate|600 mg of epigallocatechin gallate (EGCG) and 60 ml of coconut oil (3600 mg of TGCM) per day, divided into two doses (one in the morning and one at noon)
41447082|NCT03740295|OTHER|Placebo|Lactose
41447083|NCT03629054|DRUG|Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)|single dose
41447084|NCT03629054|DRUG|Empagliflozin|single dose
41447085|NCT03629054|DRUG|Linagliptin|single dose
41447086|NCT03629054|DRUG|Metformin HCl|single dose
41447087|NCT04418297|DRUG|CT-G20|oral tablet
40754451|NCT05375266|OTHER|Sampling|This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.
40927887|NCT00942071|BIOLOGICAL|MVA-NP+M1|2.Intramuscular injection at 5 x 10\^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10\^8 pfu/ml at day 0
40927888|NCT00942071|BIOLOGICAL|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
40927889|NCT02587247|DRUG|TF2 antibody/68Ga-IMP-288|TF2 antibody coupled with 68Ga-IMP-288
41276499|NCT00003558|DRUG|etoposide|
41276500|NCT00003558|DRUG|fluorouracil|
41276501|NCT00003558|DRUG|leucovorin calcium|
41276502|NCT00003558|DRUG|paclitaxel|
41276503|NCT00762346|DRUG|zometa|zometa 4mg i.v. every 4 weeks for up to 2 years
41276504|NCT03118622|DEVICE|Pentax|Intubation using Pentax video laryngoscope in Pentax group
41276505|NCT05731960|DRUG|Dexamethasone|10 mg IV dexamethasone provided immediately after spinal anesthesia
41276506|NCT05731960|DRUG|Metoclopramide|10 mg IV metoclopramide provided immediately after spinal anesthesia
41276507|NCT03487445|DRUG|Selatogrel 8 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
41276508|NCT03487445|DRUG|Selatogrel 16 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
41276509|NCT04525729|DRUG|Rituximab|To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.
40927890|NCT03976869|DRUG|AZD7594|During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
41276510|NCT04525729|DRUG|RAS 2410|To evaluate the efficacy and safety of RASi in patients with IgAN.
41276511|NCT03534037|DRUG|Febuxostat 40 mg|Febuxostat 40 mg orally per day plus dietary control only
41447088|NCT04418297|DRUG|Placebo|oral tablet
41447089|NCT03356691|OTHER|Complementary Spiritist Therapy|"Complementary Spiritist Therapy:~1. Prayer: for 1 to 2 minutes.~2. Spiritual education: reading and commentary of the Gospel according to Spiritism, about 7 minutes.~3. Spiritist passe, for 2-min.~4. Fluid therapy."
41276512|NCT03534037|DRUG|Benzbromarone 50mg|Benzbromarone 50mg orally per day plus dietary control only
41276513|NCT03534037|OTHER|Control|Dietary control only
41276514|NCT01802359|DRUG|No intervention|This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
41276515|NCT05111314|RADIATION|Gallium Ga 68 Gozetotide|Given IA
41276516|NCT05111314|PROCEDURE|Hepatic Artery Embolization|Undergo hepatic artery embolization
41276517|NCT05111314|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
41276518|NCT02125214|DEVICE|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
41276519|NCT01640847|DRUG|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
41276520|NCT04039139|BEHAVIORAL|Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
41447090|NCT03356691|OTHER|Prayer|Individuals will receive prayer during 1 to 2 minutes.
41447091|NCT03356691|OTHER|"Spiritist passe"|"Individuals will receive Spiritist passe during 5 to 10 minutes."
41447092|NCT03356691|OTHER|laying on of hands with intent to heal|Individuals will receive laying on of hands with intent to heal during 5 to 10 minutes.
41447093|NCT03356691|OTHER|Fluid therapy.|Individuals will receive fluid therapy.
41447094|NCT03356691|OTHER|No-fluid therapy.|Individuals will receive no-fluid therapy.
41276521|NCT04039139|BEHAVIORAL|Mind Body Intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
41276522|NCT03162289|OTHER|Fasting|Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.
41276523|NCT03162289|OTHER|Vegan|Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
41276524|NCT03784196|OTHER|Conservative rehabilitation|WAD participants underwent 2-weeks rehabilitation.
41276525|NCT01496664|PROCEDURE|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
41276526|NCT04407715|PROCEDURE|The Effect Of Minimal and High Flow Anesthesia on Optic Nerve Sheath Diamater|The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow.
41276527|NCT02122627|DRUG|Vitamin D|Colecalciferol 16.800 IU per week
40754452|NCT01801527|BEHAVIORAL|Telerehabilitation group|Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
41125237|NCT01727375|OTHER|Circadian light|"Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.~Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation."
41125238|NCT05591872|DRUG|LD+I+TRB|Same as in the arm description
41125239|NCT02356341|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
41276528|NCT02122627|DRUG|Placebo|
41276529|NCT04579549|DEVICE|Saliva Assay|saliva assay test for high concentrations of SARS-CoV-2
41276530|NCT04052139|DRUG|Low-dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks. In week 1, participants will take 4.5mg of naltrexone once daily. In week 2, participants will take 4.5mg of naltrexone once daily, and a placebo capsule twice daily. In weeks 3 through 7, participants will take 1 placebo capsule with 4.5 mg mg of naltrexone once daily, and 2 placebo capsules twice daily. In week 8, in days 1-4 participants will take 4.5 mg of naltrexone with a placebo capsule once daily and 2 placebo capsules twice daily; in days 5-7, participants will take 4.5 mg of naltrexone once daily, and a placebo capsule twice daily.
41276531|NCT04052139|DRUG|Gabapentin|Dose will begin at 300 mg daily (300 mg qd), in week 2 the dose will be titrated up to 900 mg daily (300 mg tid). In week 3, the dose will be titrated to 1800 mg daily ( 2 capsules of 300 mg tid) and participants will remain on that dose until week 8. In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
41276532|NCT04052139|DRUG|Placebo|In week 1, participants will take 1 placebo capsule once daily. In week 2, participants will take 1 placebo capsule three times per day. In weeks 3 through 7, 2 placebo capsules three times per day. In week 8, in days 1-4 participants will take 2 placebo capsules three times per day; in days 5-7, participants will take 1 placebo capsule three times per day. The placebo medications will be composed of lactose and will not contain active ingredients.
41276533|NCT02785809|OTHER|Pausing oral contraceptive|
41276534|NCT05363917|DRUG|Natrunix with MTX placebo (+folate)|True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
41276535|NCT05363917|DRUG|Natrunix placebo with MTX (+folate)|Natrunix placebo with MTX (+folate)
40754453|NCT01151631|DEVICE|occipital nerve stimulation|Low occipital bilateral Quad Plus, midline to laterally directed, secured by titan anchors, connected to Versitrel. No trial stimulation. Suggested stimulation parameters: Pulse width: 450, Amplitude: protocol, Rate: 60
40754454|NCT05165966|BIOLOGICAL|High-dosage of COVID-19 vaccine (Vero cell), Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
41125240|NCT05384366|DRUG|Neoadjuvant chemotherapy|doublet of taxane and carboplatin
40754455|NCT05165966|BIOLOGICAL|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
41447095|NCT03526757|OTHER|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
41447096|NCT03526757|OTHER|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
41125241|NCT04549831|GENETIC|Massive parallel sequencing of host genome|Massive parallel sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing different clinical outcomes from asymptomatic to severely affected patients in order to identify the genetic determinants of severe COVID-19 and the genetic protective factors.
41447097|NCT04422457|OTHER|68Ga-DX600 PET/CT|DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning
41447098|NCT06626854|DEVICE|RF-PNS|Noninvasive peripheral nerve stimulator using interferential multi source radio frequency
41447099|NCT04398147|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
41447100|NCT04398147|BIOLOGICAL|Placebo|Intramuscular administration
41276536|NCT00817271|DRUG|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
41447101|NCT00735540|OTHER|Observational|Data summary only
41447102|NCT00684697|DIETARY_SUPPLEMENT|iron|High, intermediate and low iron dosage orally for 2 months
41447103|NCT05294276|OTHER|no intervention related|no intervention related
41447104|NCT06548581|DEVICE|SpeedPlate™ Rapid Compression Implants|MTP and/or TMT joint fixation with SpeedPlate™ Rapid Compression Implants
40927891|NCT00263861|PROCEDURE|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
40927892|NCT05472701|BEHAVIORAL|Diet order: WFPB, PBMA, Animal|Participants followed the WFPB, PBMA, and Animal diets (in this order) for 4 weeks each.
41276537|NCT00817271|DRUG|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
41276538|NCT01668277|DRUG|7.2% NaCl|
41276539|NCT01668277|DRUG|0.9% NaCl|
40927893|NCT05472701|BEHAVIORAL|WFPB, Animal, PBMA|Participants followed the WFPB, Animal, and PBMA diets (in this order) for 4 weeks each.
41125242|NCT02543125|DEVICE|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
41276540|NCT03069651|OTHER|Virtual Care|The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
41447105|NCT03545880|OTHER|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
41447106|NCT03545880|OTHER|Placebo|Individuals will not perform any action after the application of trigger point dry needling
41447107|NCT05869721|OTHER|Yoga|The yoga forms are designed from the modified traditional Hatha yoga style consisting of pranayama, asana, meditation with additional relaxation elements. The selected postures will engage core and upper limb muscle and which proposed to strengthen the whole body, increase flexibility of shoulder and limbs, particularly, improve upper limb mobility and functions; also, the progression of the yoga therapy is targeted to reach the variations of postures. The combined relaxation elements reinforced to achieve restoration of the body so as to improve sleep.
41447108|NCT06099652|DRUG|611 300 mg Q2W|611 subcutaneous (SC) injection
41447109|NCT06099652|DRUG|611 450 mg Q2W|611 subcutaneous (SC) injection
41447110|NCT06099652|DRUG|Matching placebo|placebo subcutaneous (SC) injection
41447111|NCT01783366|DEVICE|TUBE EXCHANGER|
41447112|NCT05049239|BEHAVIORAL|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.
41447113|NCT05049239|BEHAVIORAL|Physical training combined with cognitive support.|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.~The cognitive support consists of person centred individual occupational therapy with focus on daily time management skills and planning and organisation in daily life, i.e. make time for physical exercise. The number of session during the intervention period depend on the participants needs and is estimated to 4-6 sessions."
40754456|NCT05733533|DRUG|HRS-2261 oral tablet|HRS-2261 oral tablet, oral, BID
41125243|NCT02543125|DEVICE|NHFOV|"For infants in the NHFOV-group who failNHFOV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
41125244|NCT03918967|DRUG|CT-G11|oral tablet of CT-G11 Experimental Drug
41125245|NCT03918967|DRUG|CT-G20|oral tablet of CT-G20 Experimental Drug
41125246|NCT03918967|DRUG|CT-G11 Placebo|oral tablet of Placebo
41125247|NCT03918967|DRUG|CT-G20 Placebo|oral tablet of Placebo
41125248|NCT00032435|DRUG|PAL-40 Active|
41125249|NCT00032435|DRUG|PAL-40 Placebo|
41125250|NCT03815136|OTHER|Chewing Gum|Patients of CG group chewed one piece of sugarless gum for approximately 15 min every 30 min at the first hour of the examination.
41125251|NCT03815136|OTHER|Control|The control group will not chew chewing gum while undergoing capsule endoscopy
41125252|NCT00997490|DRUG|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
40927894|NCT05472701|BEHAVIORAL|PBMA, WFPB, Animal|Participants followed the PBMA, WFPB, and Animal diets (in this order) for 4 weeks each.
40927895|NCT05472701|BEHAVIORAL|PBMA, Animal, WFPB|Participants followed the PBMA, Animal, and WFPB diets (in this order) for 4 weeks each.
41125253|NCT00997490|DRUG|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
40927896|NCT05472701|BEHAVIORAL|Animal, WFPB, PBMA|Participants followed the Animal, WFPB, and PBMA diets (in this order) for 4 weeks each.
40927897|NCT05472701|BEHAVIORAL|Animal, PBMA, WFPB|Participants followed the Animal, PBMA, and WFPB diets (in this order) for 4 weeks each.
40927898|NCT04950868|DRUG|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
40927899|NCT03529071|BEHAVIORAL|CKD-Question Prompt Sheet|The CKD-QPS is a list of 31 questions specific to CKD stage 3 patients about treatment options and self-care management designed to activate patient communication with their providers and question-asking.
40927900|NCT00868179|DRUG|Pradax|Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
40927901|NCT00510965|DRUG|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
40927902|NCT01832168|PROCEDURE|Robotic Assisted Laparoscopic Prostatectomy|Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
41125254|NCT05325931|DEVICE|kalifilcon A Daily Disposable Multifocal|kalifilcon A Daily Disposable Multifocal low add and high
41125255|NCT05325931|DEVICE|samfilcon A for Presbyopia|Ultra for Presbyopia Low and High Add Contact Lenses
41125256|NCT05408624|PROCEDURE|ultrasound transvaginal drainage|Ultrasound-guided transvaginal drainage of TOA by a puncture under simple sedation or analgesia with/or under general anesthesia
41125257|NCT05408624|PROCEDURE|laparoscopy|Laparoscopy for drainage of TOA under general anesthesia
41125258|NCT02740400|PROCEDURE|EBUS-GS|The equipment for EBUS-GS includes super-thin bronchoscope BF-P260F, endobronchial ultrasonic system EU-M30S, ultrasonic probe UM-S20-17S, and guided sheath kit K201. All facilities are provided by Olympus Co. The EBUS-GS procedure was performed by thoracic surgeons. The patient was in supine position, under general anesthesia, and provided ventilatation through laryngeal mask. First, the operator placed super-thin bronchoscope into the bronchus of interest, inserted the probe covered with GS through a work channel. Later, adjusted the bronchoscope and probe to obtain classical ultrasonic graphs. The assistant fixed the bronchoscope, pulled the probe out, and placed the brush and biopsy forceps, respectively, through the GS. This process was assisted using x-ray fluoroscope or not.
41125259|NCT02740400|PROCEDURE|CT-TTNB|The devices for CT-TTNB includes Lightspeed VCT spiral CT(GE co.) and Quickcore(COOK Co.) biopsy kit. The kit includes a sheath(5cm in length and 16G in outer diameter) and a automatic biopsy needle(15cm in length and 18G in outer diameter). The patient stays in supine, prone or lateral position according to the lesion's location. The first chest CT scan is performed to confirm the location of the lesion and make an optimal entry point. Then, after sterilization and 2% lidocaine local anesthesia, the sheath is stabbed into chest wall through the entry point. The second CT scan is performed to make sure that the sheath stays in proper angle and depth. The operator places the needle through the sheath and enter the lesion. Then fire the biopsy needle and repeat the procedure twice or third time. The last CT scan is conducted to determine whether pneumothorax or hemorrhage occurred.
41125260|NCT03079700|BIOLOGICAL|Trichuris suis eggs|Live eggs from swine whipworm, Trichuris suis
41125261|NCT01893970|BEHAVIORAL|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
41125262|NCT01893970|BEHAVIORAL|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
41125263|NCT02125110|DEVICE|MRI|
41125264|NCT02125110|OTHER|neuropsychological assessment|
41125265|NCT01322477|OTHER|F18-FDG PET/CT|
41125266|NCT00181311|PROCEDURE|hysterectomy|
41125267|NCT05685433|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
41125268|NCT05893719|DEVICE|iNedit, iNdeep, iNtercept|Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept
41125269|NCT04294862|DRUG|TNP-2092|TNP-2092 for injection 100mg/vial
41276541|NCT00876642|DRUG|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
41276542|NCT00631878|DRUG|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
40927903|NCT01832168|OTHER|Application of Absorbable Hemostat|Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
41447114|NCT05896995|OTHER|Pilates Exercise|Pilates exercises target the deep muscles of the core, including the abdomen, lower back, hips, and glutes, while also engaging the whole body.
41447115|NCT05896995|OTHER|Mckenzie Exercise|The McKenzie Method emphasizes self-treatment and active patient involvement in the management of their condition. It involves a systematic assessment process to determine the most appropriate exercises and interventions for an individual based on their specific symptoms and movement responses.
41447116|NCT06492590|BEHAVIORAL|Multicomponent intervention|Multicomponent intervention based on psycho-education and physical rehabilitation.
41276543|NCT05929495|DRUG|Metformin|"The investigator will identify potential participants and confirm the diagnosis of GBM. Subjects will be screened within 6 weeks before starting treatment.~Treatment will involve:~* Administration of the standard or partial Stupp protocol (Radiotherapy + Temozolomide) in combination with Metformin for 6 weeks,~* Treatment with only Metformin for 4 weeks;~* Resumption of adjuvant TMZ + Metformin treatment continuously until the end of the enrollment period."
41276544|NCT02426814|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use.
41125270|NCT06398600|PROCEDURE|Caudal|In the prone position , linear transducer will be first positioned transversely on the middle line. The two sacral cornua appear as two hyperechoic structures ,two hyperechoic band structures are present between the two sacral cornua. The superficial is the sacrococcygeal ligament (SCL) and the deep is the dorsal surface of the sacrum. The sacral hiatus is a hypoechoic area between two band-like hyperechoic structures. In longitudinal view, the block needle will be inserted using the in plane technique .The block needle can be visualized in real time piercing the SCL entering the hiatus but cannot be visualized beyond the apex of the hiatus. It is therefore proposed to limit the extension of the needle tip beyond the tip of the sacral hiatus to 5 mm to avoid perforating the dura mater. After the needle is inserted in the caudal canal, 20 ml of 0.25% bupivacaine will be injected.
41125271|NCT06398600|PROCEDURE|Quadratus lumborum plane block|The patient is placed in the prone position , under aseptic conditions with the sterile convex probe is placed in a transverse view at the triangle of the QL muscle and the middle thoracolumbar fascia. The projected needle path is advanced in-plane until the needle tip is visualized between the middle thoracolumbar fascia and the QL muscle . After confirming the location of the needle with 2-3 ml of saline and then aspiration, 20 ml of 0.25% bupivacaine is injected in this plane with confirmation by visualizing hydro dissection . the procedure is applied to the opposite side using the same dose to achieve bilateral block.
41447117|NCT00042874|DRUG|alvocidib|Given IV
41447118|NCT00042874|DRUG|irinotecan hydrochloride|Given IV
40927904|NCT01832168|OTHER|Application of dehydrated human amniotic membrane|Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
41447119|NCT00042874|DRUG|fluorouracil|Given IV
41447120|NCT00042874|DRUG|leucovorin calcium|Given IV
41447121|NCT00042874|OTHER|laboratory biomarker analysis|Correlative studies
41447122|NCT04387786|DRUG|Dornase Alfa|nebulized in-line endotracheal dornase alfa co-administered with albuterol
41447123|NCT03621995|OTHER|Malondialdehyde and Catalase level measurement|Malondialdehyde and Catalase level measurement by colorimetric method
41447124|NCT02353936|DRUG|BIBW2992|"International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily"
41447125|NCT02348281|DRUG|Bicalutamide|150mg, po, qd, d1-28
41447126|NCT02300103|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
41447127|NCT02300103|DRUG|RBV|Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
41447128|NCT06366815|OTHER|Different Phenotypes of non ambulant patients with Duchenne Muscular Dystrophy|clinical and functional data collection of non ambulant patients with Duchenne muscular dystrophy
40927905|NCT06054204|DEVICE|lateral bony window|bony window will be made on lateral maxillary sinus wall using piezo-electric device after elevation of full thickness mucoperiosteal membrane
41125272|NCT02433782|OTHER|Myofascial therapy|Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
41125273|NCT02515071|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
41125274|NCT02515071|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
41447129|NCT02272803|DRUG|Lenalidomide|
41125275|NCT03001440|OTHER|KAB survey|The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
41125276|NCT00681213|DRUG|Tacrolimus/Sirolimus|
41125277|NCT00681213|DRUG|Tacrolimus/MMF|
41125278|NCT00681213|DRUG|Neoral/Sirolimus|
41125279|NCT00290069|DRUG|Tacrolimus|
41125280|NCT00290069|DRUG|Rapamycin|
41447130|NCT02272803|DRUG|Dexamethasone|
41447131|NCT02272803|BIOLOGICAL|Elotuzumab (BMS-901608)|
41447132|NCT03192163|OTHER|Survey|31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
41447133|NCT03965429|OTHER|Blood samples (additional tubes from care) longitudinal|Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).
41447134|NCT03965429|OTHER|Blood samples (additional tubes from care) at inclusion|"In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.~In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification."
40927906|NCT00714571|BEHAVIORAL|Mnemonic strategy training (MST)|
40754457|NCT05733533|DRUG|Matching placebo to HRS-2261|Matching placebo to HRS-2261, oral, BID
40927907|NCT00714571|BEHAVIORAL|Repeated exposure (XP)|
40927908|NCT00714571|BEHAVIORAL|Subtracting Cues training|
40927909|NCT05920083|OTHER|CPAP withdrawal|2 weeks of CPAP withdrawal
40927910|NCT05193227|DRUG|ST-01|Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
40927911|NCT05193227|DRUG|Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)|Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
40927912|NCT03088085|PROCEDURE|Self-mobilization|Subjects will mobilize thoracic spine and ribs with a foam roller every night before going to bed.
40927913|NCT03088085|PROCEDURE|Sleep Education|Subjects will be educated on sleep hygiene in order to improve likelihood of having good sleep.
40927914|NCT02778360|DEVICE|Neurofeedback NFT|"The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.~The training is personalized according to patient's characteristics."
40927915|NCT02778360|DRUG|Methylphenidate MPH|Drug prescribed with a first titration period until an optimal dose.
41447135|NCT05569291|DEVICE|Automated Coaching Program (ACP)|A semiautomated tele coaching program (application installed on a smartphone device with real time feedback and motivational messages) and a step counter (Fitbit Charge 4) providing direct feedback on total daily number of steps, walking time, time in at least moderate PA and movement intensity during walking.
41447136|NCT05569291|OTHER|Manual Coaching Program (MCP)|A telecoaching program using a step counter (Fitbit Charge 4) without this custom smartphone application but with the Fitbit application. This intervention will be more focused on weekly personal feedback from a coach by telephone.
41447137|NCT01911676|DRUG|PF-03463275|
40927916|NCT01998984|DRUG|ingenol mebutate|
41447138|NCT01911676|DRUG|Placebo|
41447139|NCT00715442|DRUG|Sunitinib|50 mg by mouth daily for 28 consecutive days
41447140|NCT00715442|PROCEDURE|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
41447141|NCT03785730|PROCEDURE|Non-restorative cavity control - NRCC group|The proximal cavities will be enlarged with metallic sandpaper, exposing the cavity, to allow access for toothbrushing associated with 1000 ppm fluoride toothpaste.
41447142|NCT03785730|PROCEDURE|Restoration with resin composite - RCR group|In control group, the treatment will be performed after prophylaxis and relative isolation. The selective carious tissue removal will be performed with appropriate dentin curettes. The acid conditioning will be performed only in enamel for 15 s with 37% phosphoric acid gel, and then the application of the adhesive system and restoration of resin composite will be conducted.
41447143|NCT01773408|DRUG|RO5503781 MBP|Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
41447144|NCT01773408|DRUG|RO5503781 SDP|Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
41447145|NCT01773408|DRUG|Idarubicin|Idarubicin will be administered as per standard clinical practice.
40927917|NCT01998984|OTHER|Placebo|
40927918|NCT02409108|DEVICE|Exatherm-TBH system|One treatment of Total Body Hyperthermia
40927919|NCT04840836|BEHAVIORAL|Telehealth-supported LARC provision|"Provision of LARC in routine care will include a hybrid model of telehealth-supported long-acting reversible contraception (LARC) service provision in a network of 6 school-based health centers (SBHCs) in New York City that serve adolescents and young adult high school students age 13-22 years (hereafter referred to as adolescents)."
40927920|NCT02700633|DEVICE|Pacemaker|
40927921|NCT04042935|DRUG|Alpha Lipoic Acid|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
40927922|NCT03821662|BEHAVIORAL|OT Diabetes Self-Management Intervention|Occupational therapy chronic disease self-management intervention.
40927923|NCT01278927|BEHAVIORAL|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
40927924|NCT01278927|BEHAVIORAL|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
41276545|NCT02426814|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
41276546|NCT04423848|OTHER|Home Hospital for Lymphoma|Remote monitoring and home-based care designed for hospitalized patients with lymphoma
41447146|NCT01773408|DRUG|Daunorubicin|Daunorubicin will be administered as per standard clinical practice.
41447147|NCT01773408|DRUG|Cytarabine|Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.
41447148|NCT01682421|DRUG|Weak steroid (Flurolon, Allergan)|
41447149|NCT01682421|DRUG|Potent steroid (Maxidex, Alcon)|
41447150|NCT04356508|DRUG|Nivolumab|Single dose at 0.3mg/kg
41447151|NCT05755282|DRUG|Post-market foam alcohol-based hand sanitizer #1|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
41447152|NCT05755282|DRUG|Post-market foam alcohol-based hand sanitizer #2|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
41447153|NCT03915600|OTHER|Quinoa|Personalized diet added with quinoa
41447154|NCT03915600|OTHER|Flaxseed|personalized diet added with flaxseed
41447155|NCT03915600|OTHER|Quinoa and Flaxseed|personalized diet added with quinoa and flaxseed
41447156|NCT05651958|OTHER|Nebulizer|Active Comparator: Nebulization every 3 days with the other medicine to the active comparator.
41447157|NCT05651958|OTHER|Breathing Technique|15 repeatations of Breathing in morning and evening
41447158|NCT00620880|BEHAVIORAL|Blood sample|
41447159|NCT05323981|DRUG|HS627(210mg/7ml)|Intravenous drip of 420mg HS627
41447160|NCT05323981|DRUG|HS627(420mg/14ml)|Intravenous drip of 420mg HS627
41447161|NCT05323981|DRUG|Perjeta|Intravenous drip of 420mg PERJETA
41447162|NCT03519464|BIOLOGICAL|Gardasil 9|Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
41447163|NCT04320563|PROCEDURE|Rexon-eye|This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.
41447164|NCT00042783|BIOLOGICAL|D1/3-MAGE-3-His fusion protein|
41447165|NCT00042783|BIOLOGICAL|SB-AS02B adjuvant|
41447166|NCT06031883|DRUG|Ketamine|Total intravenous anesthesia in craniotomy
40927925|NCT01278927|BEHAVIORAL|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
40927926|NCT01278927|OTHER|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
41447167|NCT03767374|PROCEDURE|Inguinal swab sample|Inguinal samples using swab at cross-sectional visit
41447168|NCT03767374|PROCEDURE|Anal swab sample|Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
41447169|NCT03767374|PROCEDURE|Fecal sample|Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
41447170|NCT03767374|OTHER|Risk factor assessment|Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization
41447171|NCT03168503|DIETARY_SUPPLEMENT|LGG+Promitor™|synbiotic
40927927|NCT04970953|PROCEDURE|Right heart catheterization|Right heart catheterization will be performed via a brachial access under sonographic guidance and hemodynamic measurements will be performed in a semi-supine position.
40927928|NCT02538783|BEHAVIORAL|Escalating Lottery|Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
40927929|NCT05793229|OTHER|observation|observation
41276547|NCT04563364|OTHER|Interdisciplinary hospital-home intervention|The intervention will start in NICU and to be continued at home with the support of ICT. The NICU intervention will have theoretical and practical components, the theoretical one will be about motor development in premature infants, and practical one will have strategies for motor early intervention, it will be demonstrated with pediatric simulator and parents should be demonstrate it with a infant: 1Sensorial motor stimulation, visual and auditory follow-6up; Tactile integration 3Extension muscle activation 4Middle line integration 5Alignment reaction stimulation in prone position 6Flexor muscle activation with transition to lateral position 7Flexor muscle activation with transition to sitting position 8Facilitation of reciprocal flexion and extension lower limbs. All parents will receive a motor sensorial kit that will include roller, visual tags, blankets and rattles, it will be for apply the strategies for motor early intervention, and will be supported by ICT
40927930|NCT00450008|DRUG|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
40927931|NCT00450008|DRUG|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
40927932|NCT00450008|DRUG|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
40927933|NCT05406193|OTHER|Patient-centred complex intervention in complicated multimorbidity (CIM2)|CIM2 is the second version of the Patient-centred complex intervention in complicated multimorbidity
40927934|NCT01238588|DRUG|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
40927935|NCT02530047|GENETIC|MSC-INFβ|"MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.~Starting dose: 10\^5 MSC/kg once a week for 4 treatments."
40927936|NCT02530047|BEHAVIORAL|Questionnaires|Symptom questionnaire completed once a week for 4 weeks.
41276548|NCT04563364|OTHER|Convencional treatment|Control group will receive a conventional treatment given by the institutions
41276549|NCT06258525|RADIATION|Standard of care oxaliplatin-based chemotherapy|mFOLFOX6 or CAPOX
41276550|NCT06258525|DIETARY_SUPPLEMENT|S-adenosylmethionine (SAMe) supplement|(400 mg tablet): 2 tablets taken orally AM and 1 tablet PM daily (total 1,200 mg daily) prior to surgical resection
41447172|NCT03168503|DIETARY_SUPPLEMENT|Promitor™|Soluble Corn Fiber
41447173|NCT03168503|DIETARY_SUPPLEMENT|LGG-PB12+Promitor™|synbiotic
41447174|NCT03168503|DIETARY_SUPPLEMENT|Maltodextrin|Control
41447175|NCT03259139|BEHAVIORAL|Video games and violence|Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.
41447176|NCT00304733|DEVICE|cast vs. shoe|
41447177|NCT05312554|DEVICE|Iris FIT™ PFO closure system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Iris Patent foramen ovale occluder according to the INSTRUCTIONS for Use (IFU)
41447178|NCT04198701|DEVICE|Medtronic PulseSelect Pulsed Field Ablation (PFA) System|Adult subjects with a history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of entrance block and, where assessable, exit block with the PulseSelect PFA System.
41447179|NCT05513001|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
41447180|NCT05513001|DRUG|Placebo|Placebo
41125281|NCT05955989|OTHER|soft lining of complete denture processed by 3 different techniques.|soft lining for complete denture
41125282|NCT04048668|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
41125283|NCT04810260|BEHAVIORAL|Use mobile health app (WellXcel) to increase knowledge|Download the app (WellXcel) to the mobile device
41125284|NCT02241070|BEHAVIORAL|mindulness-based intervention|"A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance."
41125285|NCT04491201|OTHER|Customized questionnaire|A customized questionnaire will be delivered by the social software WeChat to the specific hospital which has been randomly sampled, and all physicians of Obstetrics and Gynecology in this hospital will fill the questionnaire anonymously.
41276551|NCT06258525|PROCEDURE|Surgery|At 1-Month
41276552|NCT03022422|BIOLOGICAL|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
41276553|NCT03022422|BIOLOGICAL|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
41276554|NCT06656143|OTHER|Traditional Physical therapy|"The exercise program included the strengthening of the deep cervical flexor and shoulder retractor muscles and also stretching of the pectoralis and cervical extensor muscles.~(3 sets of 12 repetitions) Strengthening Deep Cervical Flexors Lying chin tuck Lying chin tuck with head lift. Strengthening Shoulder Retractors Standing shoulder pull back with elastic Shoulder pull back with weight Stretch Cervical Extensors Chin drop Stretch Pectoralis Muscle Bilateral Pectoral stretch"
41276555|NCT06656143|OTHER|Diaphragmatic Myofascial Release|To release the diaphragm, the patient was positioned in the supine position. The therapist stood at the head of the patient. The therapist made manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th) with hypothenar regions of the hands and last three fingers. During the patient's inspiration, the therapist was gently pulling the points of hands contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist deepened hand contacts towards the inner costal margins Exercise Program (3 sets of 12 reps) Strengthening deep cervical flexors Strengthening shoulder retractors Stretching Cervical Extensors Stretching Pectoralis Muscle
41276556|NCT06655077|OTHER|RA PRO Dashboard|The RA PRO Dashboard was developed by UCSF rheumatology investigators in collaboration with the UCSF SOMTech Unit. Briefly, investigators used a human-centered design approach to build a new, EHR-integrated, patient-facing visualization tool that displays RA outcome data to RA patients during clinical visits. The RA PRO dashboard was tailored for deployment at the UCSF Health's rheumatology clinic using a EHR side-car application (Salesforce). The dashboard was launched into the production environment in August 2021. With the launch, investigators integrated quality improvement, user monitoring, and lean management techniques to promote use of RA outcomes and the dashboard (for clinicians granted access) during clinical visits.
41276557|NCT00499551|DEVICE|Iontophoresis second generation Eyegate II device|
41276558|NCT03685448|DRUG|Cabozantinib|The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
41276559|NCT00702624|DRUG|Corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
41276560|NCT00702624|BIOLOGICAL|recFSH (follitropin beta)|Daily recFSH administered under protocol P05690
41276561|NCT00702624|DRUG|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
41276562|NCT00702624|BIOLOGICAL|human chorion gonadotropin (hCG)|hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690
41125286|NCT01990508|BEHAVIORAL|Targeted beverage education and financial incentives|
41125287|NCT01990508|BEHAVIORAL|Traffic-light labeling of all beverages in store|All beverages in the supermarket will be labeled as red, yellow, or green
41125288|NCT06495359|OTHER|immunization education program|The content of the immunization education program for parents was created by researchers based on the literature. Expert opinions will be obtained from 7 people who are experts in the fields of child health and disease nursing and public health nursing for the training program. The training program consists of 30 minutes. The education program will be delivered to parents in the form of a 30-minute training session using the face-to-face education model. Interactive education methods that enable parents' participation will be used.
41276563|NCT00702624|BIOLOGICAL|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
41276564|NCT00702624|DRUG|placebo-recFSH (follitropin beta)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
41276565|NCT00702624|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
41276566|NCT00702624|BIOLOGICAL|open-label recFSH (follitropin beta)|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
41276567|NCT03107195|DRUG|Imaging Time|Participants will be asked to be imaged at an additional time point.
41276568|NCT04766853|DRUG|Dexamethasone|Dexamethasone 5mg/ml
41276569|NCT04766853|DRUG|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
41276570|NCT06347159|DRUG|EDG-7500|Liquid suspension formulation of EDG-7500
41276571|NCT06347159|DRUG|EDG-7500|Solid oral formulation of EDG-7500
41447181|NCT05513001|DRUG|LOU064 (open label)|LOU064 (open-label) active treatment
41125289|NCT06419569|OTHER|high power laser|Sessions will performed with scanning in longitudinal and perpendicular direction on the medial and lateral sides of the knee with Laser scanner machine. handpiece was positioned in contact and perpendicularly while the patient in a supine lying position with the knee flexed at 30° to open the joint surfaces to the laser beam (optical windows). The scanning was performed transversely and longitudinally in the anterior, medial, and lateral aspects of the knee joint with emphasis on the application on the joint line between the tibial and femoral epicondyles. The total energy delivered to the patient during one session was 1,250 J through three phases of treatment. The initial phase is performed with fast manual scanning with a total of 500 J. In the initial phase, the laser fluency is set to two successive subphases of 710 and 810 mJ/cm2 for a total of 500 J.
41447182|NCT06324864|BEHAVIORAL|START NOW Adapted|"The START NOW skills-training combines aspects of cognitive behavioral therapy (CBT), motivational interviewing (MI), dialectical behavior therapy (DBT), Acceptance and Commitment Therapy (ACT) and trauma-sensitive care. Studies in different contexts have shown START NOW's effectiveness in terms of reducing behavioral problems, reducing hospitalization rates, improving mental health functioning and increasing satisfaction rates. The culturally adapted version will be contextually adapted to different cultural backgrounds and the experience of migration. In ten sessions, participants learn about emotions and are introduced to the START NOW skills. These skills, called SLOW DOWN, TAKE A STEP BACK, ACCEPT, RESPECT and TAKE ACTION, are strategies or techniques that can be used to better manage stress and difficult emotions."
41447183|NCT00858780|DRUG|Etanercept|50 mg etanercept once weekly + methotrexate
41447184|NCT00858780|DRUG|Etanercept|25mg etanercept once weekly + methotrexate
40927937|NCT05117671|OTHER|data collection to classify infection status|Review of medical records of all selected cases (TKA/THA patients) to classify infection status according to different classifications (EBJIS, MSIS/ICM 2013, ICM 2018).
41447185|NCT00858780|DRUG|Placebo|Placebo comparator once weekly + methotrexate
41447186|NCT03480763|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
41447187|NCT03480763|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose
41447188|NCT03480763|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
41447189|NCT05404789|OTHER|Centrifugation|Subjects will participate in up to seven different centrifuge profiles over a single day of training (approximately 8 hours). Exposures are design to simulate a spaceflight profile using acceleration anticipated for commercial spaceflights.
41447190|NCT03034356|DRUG|Levetiracetam|Anticonvulsant drug
41447191|NCT03034356|DRUG|Placebo|Placebo
40927938|NCT00276042|DRUG|Faropenem Medoxomil|
41125290|NCT06419569|OTHER|low level laser|patients will receive laser with 0.5 W to gain energy density of 6 J/cm2, and total energy of 240 J during one session. LASER apparatus that will be used is Chattanoga Intelect Laser with 850nm wavelength and 200mW power Lasers. Same three phases like HPL with different energy dose. First phase: Fast manual scan 100 J. Second 10 point joint line phase with evey point 14 seconds and 4J to deliver a total of 40 J in this phase. Third phase: Slow manual scan 100 J.
41287264|NCT06428773|OTHER|Exercise|Participants were randomly divided into two groups: the exercise group and the control group. The exercise group performed moderate-intensity aerobic exercise on a stationary bicycle ergometer for 30 minutes during hemodialysis sessions, three days a week over 12 weeks. Additionally, the exercise group engaged in walking exercise for 30 minutes, three days a week outside of hemodialysis sessions, maintaining the heart rate between 50-60%. The exercise group also performed isolated exercises to expand wrist vessels, including wrist and elbow flexion, extension, and rotation, repeated 10 times, 2-3 days a week outside of hemodialysis sessions.
41447192|NCT02367872|DRUG|TAK-272|TAK-272 tablet
41447193|NCT00863330|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
40927939|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 0.5km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
40927940|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 0.8km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
40927941|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 1.1km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
40927942|NCT03133962|OTHER|Adult patients who are candidates for a CAP or long-term central catheter placement|Evaluate the feasibility of finding the correct positioning of the distal end of the PAC or of the long-term catheter by cardiac ultrasound in comparison with the brightness scopy, reference method.
40927943|NCT02378805|DRUG|ACE-inhibitor|observational study!
40927944|NCT02378805|DRUG|AT1-inhibitor|observational study!
40927945|NCT02378805|DRUG|HMG-Coenzyme inhibitor (statin)|observational study!
40927946|NCT02378805|DRUG|Spironolactone|observational study!
40927947|NCT02378805|DRUG|Paricalcitol|observational study!
40927948|NCT02378805|DRUG|SGLT2 inhibitor|observational study!
40927949|NCT01150344|DRUG|Malarone (atovaquone + proguanil combination)|4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
40927950|NCT01150344|DRUG|RIAMET (artemether + LUMEFANTRIN combination)|4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
40927951|NCT05980767|DEVICE|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation.
40927952|NCT00040456|DRUG|Mg Pidolate|Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
41125291|NCT06419569|OTHER|conventional physical therapy|the patients will receive conventiobal physical therapy in the form of Exercise therapy program (1) Warm-up exercises: Walking at the usual speed on a flat surface for 10 min with hamstring and calf gentle stretches.(2) Major exercises for knee OA: Straight leg raise, quadriceps setting, heel raise, one leg balance, step ups, and quadriceps strengthening exercises. The US protocol consists of continuous ultrasonic waves of 1 MHz frequency and 1 W/cm2 intensity applied with a 5-cm diameter applicator. The patients will be placed in a supine position, and the US applied to the medial and lateral parts (5 min on each side) of the knee in circular movements with the probe at right angles to ensure maximum absorption of the energy.
41276572|NCT06653439|PROCEDURE|Bilateral ultrasound guided Subcostal Quadratus Lumborum Block|Bilateral ultrasound guided Subcostal Quadratus Lumborum Block (total of 40 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock- in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients. Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis.
41276573|NCT06653439|PROCEDURE|Control|Patients in this group will not be performed plane blocks. Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock- in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients. Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis.
41276574|NCT06653439|DRUG|IV morphine PCA|IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
41276575|NCT01560351|DEVICE|rTMS|Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
41276576|NCT00283010|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
41276577|NCT00283010|OTHER|Educational DVDs|
41276578|NCT03142607|DRUG|Metronidazole gel|1% Metronidazole gel
41276579|NCT03142607|DRUG|Chlorhexidine Gluconate|0.2% Chlorhexidene gluconate gel
41276580|NCT06657040|OTHER|MUSIC|The intervention group will receive a soundtrack through individual choice of anti-noise headphones. The music offer platform will be provided by an application developed by MusicCare (www.music.care/en/index.html) in two periods of the day (09:00 and 16:00), lasting 45 minutes each, for up to seven postoperative days or until discharge from the unit (whichever occurs first). MusicCare has been widely tested in several countries and there are a large number of publications in anesthesiology, ICU, cardiology and neurology, among other specialties, demonstrating its safety and efficacy69,70. Patients who were hospitalized for more than 48 hours, that is, who received a minimum of 4 intervention periods, will be considered as patients with effective intervention. Patients with less time will be evaluated in the form of intention to treat.
41276581|NCT04475341|BIOLOGICAL|BMS + Bone Marrow Aspirate Concentrate|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
41276582|NCT04475341|PROCEDURE|BMS alone|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
41276583|NCT01474577|OTHER|questionnaire|Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
41276584|NCT06041555|OTHER|3 MRI sequences (T2*, IVIM and Multi Echo-Gradient), without injection, are performed|Generate 3D maps of intra-tumoral hypoxia and characterize their evolution during treatment thanks to the establishment of a prospective database of MRI sequences
41276585|NCT03618030|DRUG|PRC-063 oral capsules|Daily dose
40927953|NCT00040456|DRUG|Placebo|The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
40927954|NCT05428878|DIAGNOSTIC_TEST|ANS Watch|"1. ANS Watch will be used to record the pulse waves~2. Constitution questionnaire will be used to measure the constitution type"
40927955|NCT03332511|DRUG|Nilotinib|Nilotinib 300mg twice-daily
41276586|NCT03618030|DRUG|Placebo oral capsules|Daily dose
41287265|NCT06116383|DEVICE|NIRS|Renal perfusion will be evaluated with NIRS
41287266|NCT00091793|DRUG|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
40927956|NCT02208401|PROCEDURE|conventional cold snare polypectomy|conventional cold snare polypectomy
40927957|NCT02208401|PROCEDURE|Cold snare polypectomy with suction|Cold snare polypectomy with suction
41447194|NCT05801315|DEVICE|Glycine powder air polishing|Peri-implant mucositis sites treated with a glycine powder air polishing device (Air-Flow Master Piezon®).
41447195|NCT05801315|DEVICE|Full mouth ultrasonic debridement|Peri-implant mucositis sites are treated with thin ultrasonic tips.
41447196|NCT02127463|DRUG|MC-1101|Topically, two times a day, morning and bedtime
41447197|NCT02127463|DRUG|MC-1101 Vehicle|Topically, two times a day; morning and bedtime
41447198|NCT04702685|DRUG|Ropivacaine|Local anesthetic for injection
41447199|NCT04702685|OTHER|Placebo|Bandage will be placed in the presumed injection site while patients in under general anesthesia
41447200|NCT05398094|DRUG|Sotorasib|AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.
41447201|NCT06416800|DRUG|Digoxin|Oral; Tablet
41447202|NCT06416800|DRUG|Rosuvastatin|Oral; Tablet
41447203|NCT06416800|DRUG|Metformin|Oral; Tablet
41447204|NCT06416800|DRUG|Povorcitinib|Oral; Tablet
41447205|NCT06416800|DRUG|Probenecid|Oral; Tablet
41447206|NCT02557035|DRUG|Palonosetron|
41447207|NCT02557035|DRUG|Dexamethasone|
41447208|NCT04198363|DRUG|Vonoprazan|Vonoprazan Tablets
41447209|NCT04198363|DRUG|Amoxicillin|Amoxicillin Capsules
41447210|NCT04198363|DRUG|Clarithromycin|Clarithromycin Tablets
41447211|NCT04198363|DRUG|Bismuth Potassium citrate|Bismuth Potassium citrate
41447212|NCT04198363|DRUG|Esomeprazole|Esomeprazole Tablets
41447213|NCT03261167|DRUG|Botulinum toxin A (GSK1358820)|GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
41447214|NCT03261167|DRUG|Placebo|Placebo injection will contain sodium chloride (0.9 mg).
41447215|NCT00164307|BEHAVIORAL|Parent assisted social skills training|
41447216|NCT05406518|OTHER|Psychosocial intervention|Psychosocial intervention based on the model of family therapy.
41447217|NCT04384289|PROCEDURE|Nursing care based on the Transitonal Care Model|Nursing care carried out in collaboration with a multidisciplinary team in line with Transitonal Care Model for elderly patients who have undergone open heart surgery
40927958|NCT06078800|DRUG|YL-17231|After a screening period of approximately 14 days, eligible patients will receive oral YL-17231 once or twice daily until documented disease progression, unacceptable AEs, intercurrent illness preventing further administrations of study treatment, investigator's decision to withdrawal, the patient's consent of withdrawal, pregnancy, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient's consent of withdrawal, lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
41125292|NCT04431375|BIOLOGICAL|Plasma Exchange|Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
40927959|NCT00151203|DRUG|Clarithromycin, Lenalidomide, Dexamethasone|"Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.~Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.~Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles."
41447218|NCT04882241|BIOLOGICAL|Pembrolizumab|IV infusion
41125293|NCT04431375|DRUG|Tenofovir|Tenofovir \[antiviral\] 300mg PO once a day .
41125294|NCT04431375|OTHER|Fecal Mircobiota Transplantation|FMT for 7 days
41447219|NCT04882241|DRUG|Placebo|IV infusion
41447220|NCT04882241|DRUG|Cisplatin|IV infusion
41447221|NCT04882241|DRUG|Capecitabine|Oral tablets
41447222|NCT04882241|DRUG|5-fluorouracil|IV infusion
41447223|NCT04882241|DRUG|Docetaxel|IV infusion
41447224|NCT04882241|DRUG|Oxaliplatin|IV infusion
41447225|NCT04882241|DRUG|Leucovorin|IV infusion
41447226|NCT06627114|BEHAVIORAL|nutrition education program|"Nutritional Guidance: Emphasizing a balanced diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats while reducing processed foods, sugars, and saturated fats.~Weight Management: Encouraging gradual weight loss if overweight, as this can significantly improve liver health.~Individualized Plans: Tailoring nutrition education to the individual needs, preferences, and any other underlying health conditions.~Monitoring and Support: Providing ongoing support and education to help participants make sustainable changes and track their progress."
41447227|NCT06627114|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Omega-3 Arm:1000 mg omega-3 fatty acids soft gel capsules twice daily, to be taken orally with meal.
41447228|NCT06627114|OTHER|control group|receive routine care at the outpatient clinic. At baseline, a physician will explain the laboratory test results and the natural history of NAFLD to the patients.
41447229|NCT05231785|DRUG|ALN-APP|ALN-APP will be administered intrathecally (IT)
41447230|NCT05231785|DRUG|Placebo|Placebo will be administered IT
41447231|NCT04540094|DRUG|Human albumin|Any preparation of 5% Human Albumin Solution which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study
40927960|NCT05306821|OTHER|Comprehensive electronic tool in the electronic medical chart|Use of a comprehensive electronic tool in the electronic medical chart to help the stratification of risk of VTE and the subsequent prescription of an adequate thromboprophylaxis
41447232|NCT04540094|DRUG|Balanced crystalloid solution|"Any preparation of intravenous balanced crystalloid which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study."
41447233|NCT03717805|OTHER|POAM|The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
41447234|NCT03927768|DIAGNOSTIC_TEST|Predictive Model|Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.
40754458|NCT05224648|DEVICE|TOF scan train of four ratio monitoring|Device : TOF Scan For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
40927961|NCT05306821|OTHER|Educative sessions|Educative sessions on thromboprophylaxis
41125295|NCT00006017|DRUG|becatecarin|Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
41125296|NCT04290533|DEVICE|Active High Definition transcranial Direct Current Stimulation (HD-tDCS)|TDCS is a non-invasive neuromodulation technique that modulates membrane potentials by means of small electrical currents. Electrical currents induced by tDCS electrodes produce an electrical field that modulates the excitability of brain areas. In the present HD-tDCS montage, one anodal electrode and four return electrodes are applied. Hereby, the anodal electrode modulates the excitability of the targeted area, whereas the other 4 electrodes return electrical currents that flow away from that area. Direct currents will be transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2) with a current intensity of 1.5 mA. The HD-tDCS session will last for 20 minutes in total, with a 60 sec ramp at the beginning and end of the session. The electrodes will be filled with conductive gel and plugged into an EEG cap, with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system).
41125297|NCT04290533|DEVICE|Sham High Definition transcranial Direct Current Stimulation (HD-tDCS)|For the sham-condition, the placement of the electrodes was identical to active HD-tDCS stimulation with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system). The direct current, also transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2), was increased in a ramp-like fashion over 60 seconds until it reached 1.5 mA. Directly after ramp-up, the current intensity was gradually switched off over 60 seconds, followed by 20 minutes without active stimulation. Sham procedures for tDCS mimic the transient skin sensation at the beginning of active HD-tDCS, without producing any conditioning effects on the brain. Consequently, participants are reliably blinded for sham tDCS.
41125298|NCT01813773|DRUG|Intravitreal Aflibercept Injection (IAI)|EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
41287267|NCT00091793|DRUG|Placebo|Placebo given at day 1, month 6, month 12 and month 18
41287268|NCT03328039|DEVICE|Garmin wearable device|Physiological data capture only
41447235|NCT03927768|DIAGNOSTIC_TEST|Breast Imagers|Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
41447236|NCT05741164|PROCEDURE|Biopsy|Undergo tumor biopsy
41447237|NCT05741164|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41447238|NCT05741164|PROCEDURE|Computed Tomography|Undergo CT scan
41447239|NCT05741164|BIOLOGICAL|Pembrolizumab|Given IV
41447240|NCT05741164|DRUG|Propranolol|Given PO
41447241|NCT05741164|OTHER|Questionnaire Administration|Ancillary studies
41447242|NCT01824940|BEHAVIORAL|Standard care|"Standard Care:~* Exclusive breastfeeding promotion for all infants, birth to 6 months~* Strengthened PMTCT (prevention of mother to child transmission of HIV) services~* Strengthened Village Health Worker system"
41447243|NCT01824940|OTHER|WASH|"WASH:~* Standard care interventions~* Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space~* Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths."
41447244|NCT01824940|DIETARY_SUPPLEMENT|Infant and young child feeding|"IYCF:~* Standard care interventions~* Provide 20 g/d Nutributter from 6-18 months~* Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness."
41447245|NCT01824940|OTHER|WASH and Nutrition|"WASH AND IYCF interventions~* Standard care interventions~* All WASH interventions~* All IYCF interventions"
40927962|NCT05306821|OTHER|Pocket card|Pocket card (guide for thromboprophylaxis)
40754459|NCT05224648|DEVICE|ITF device tetanus stimulation monitoring|Device ITF For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
40927963|NCT03487692|OTHER|Diabetes MESSAGES Program|Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
40927964|NCT03487692|OTHER|Diabetes MESSAGES Program (second trial)|During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
40927965|NCT03718975|DEVICE|Successor of Phonak Audéo B90|Successor of the most recent Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
41125299|NCT00946413|BEHAVIORAL|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
41125300|NCT00946413|BEHAVIORAL|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
41125301|NCT05617742|DIAGNOSTIC_TEST|68Ga-FAPI-46|68Ga-FAPI-46 is a radioactive diagnostic agent for PET imaging in the detection of Fibroblast Activation Protein (FAP) positive tumor cells in cancer patients
41125302|NCT05066958|BIOLOGICAL|boost anti-viral immunity after T-cell depleted HSCT|"* Registration and informed consent sign~* Screening clinical and laboratory examination, assessment of compliance with inclusion criteria~* Survey of the recipient and potential donors~* Donor selection~* The study of the immune response to relevant antigens in the donor and recipient~* Pre-transplant conditioning~* Stimulation of the donor and apheresis of peripheral blood mononuclear cells~* Graft processing~* The manufacturing of cell product~* Transplant Infusion~* Antigen-primed memory DLI infusion~* Inpatient care until day +30~* Outpatient monitoring and screening"
41125303|NCT05015010|DRUG|Alectinib|600 mg p.o. (four 150 mg capsules) twice daily with food (within 30 minutes after a meal, in the morning and evening).
40754460|NCT02327780|OTHER|FODMAP diet|
40754461|NCT05099588|OTHER|Other: observational study|Observational study
40927966|NCT03718975|DEVICE|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
40927967|NCT02557074|DRUG|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
41125304|NCT01782846|DRUG|Ixprim®|
41125305|NCT01782846|DRUG|Dafalgan-Codeine®|
41125306|NCT01043601|DRUG|Inhaled PT005|inhaled, twice daily for 1 week duration
41125307|NCT01043601|DRUG|Inhaled Placebo|inhaled, twice daily for 1 week duration
41125308|NCT01043601|DRUG|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
40927968|NCT02557074|DRUG|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
40927969|NCT05561075|DIETARY_SUPPLEMENT|Pterostilbene cocrystal|One capsule with Pterostilbene cocrystal
41125309|NCT06135922|BIOLOGICAL|EBV-TCR-T cells|The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10\^6/kg to 1×10\^8/kg EBV-TCR-T cells per dose.
41125310|NCT01495624|OTHER|ropivacaine plus dexamethasone anesthetic|Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
41287269|NCT03133481|PROCEDURE|Adductor Canal Nerve Block|Adductor Canal never technique
41447246|NCT05044338|DIAGNOSTIC_TEST|imaging|(1) Build the first full information big data cloud platform for diagnosis, treatment and clinical research of senile valvular disease in China (2) To establish a cohort of elderly patients with valvular disease in China and a complete database covering clinical information, functional, imaging evaluation, treatment and follow-up; (3) To analyze the clinical characteristics, functional status and imaging characteristics of senile valvular disease in China, and to understand the current situation of diagnosis and treatment; To establish a whole process standardized comprehensive evaluation system of clinical indicators of senile valvular disease combined with a variety of imaging for Chinese people.
40927970|NCT05561075|DIETARY_SUPPLEMENT|Pterostilbene free form|One capsule with Pterostilbene free form
40927971|NCT03110939|OTHER|hyperthermic perfusion|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)
40927972|NCT06354556|DRUG|HRS-1893 tablet|HRS-1893 tablet single dose
40927973|NCT06354556|DRUG|Verapamil tablet|Verapamil tablet 80 mg tid
40927974|NCT03699475|BIOLOGICAL|rivogenlecleucel|Biological: T cells transduced with caspase 9 safety switch
40927975|NCT03699475|DRUG|rimiducid|administered to inactivate rivogenlecleucel in the event of GVHD
40927976|NCT03699475|DRUG|Cyclophosphamide|GVHD prophylaxis
40927977|NCT03699475|PROCEDURE|haplo-HSCT|treatment for disease
40927978|NCT05891132|DRUG|10 ml of lidocaine 2%|10 ml of lidocaine 2% for perineal infiltration at the time of crowning
41125311|NCT01495624|OTHER|ropivacaine plus saline plus dexamethasone anesthetic|Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
41447247|NCT03874052|DRUG|Ruxolitinib|Given PO
41447248|NCT03874052|DRUG|Venetoclax|Given PO
40927979|NCT05891132|DRUG|lidocaine prilocaine cream 15gm|Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.
40927980|NCT03680456|DRUG|Ferric carboxymaltose|maximum of 750mg in U.S. is given, maximum of 1000mg in EU
40927981|NCT03680456|DRUG|Crystalloid|an equivalent volume dose of Natriumchlorid is administered
40927982|NCT04617873|PROCEDURE|Bilateral STN-DBS and T10-T12 SCS|simultaneous stimulation of bilaterally-STN-DBS combined with spinal cord stimulation
41125312|NCT02492516|BIOLOGICAL|mesenchymal stem cells|mesenchymal stem cells injection via peripheral vein.
41125313|NCT02034916|DRUG|talazoparib|
41125314|NCT04219215|DEVICE|100% O2 in oxygen chamber|Application of 100% O2 in an hyperbaric oxygen chamber
41125315|NCT04219215|DEVICE|21% O2 in oxygen chamber|Application of ambient air (21% O2) in an hyperbaric oxygen chamber
41125316|NCT05576857|OTHER|Doppler ultrasonography|All volunteers will be monitored with cerebral oximeter, asked to answer the Montreal cognitive assessment test and cervical blood flow values and optic nerve sheath diameter will be determined with Doppler ultrasonography.
41447249|NCT05327777|DRUG|Oxycodone|Investigators provided set opioid prescriptions for 10 pills each patient.
40754462|NCT03807167|OTHER|Mattis Dementia Rating Scale|This scale was developed to assess the cognitive status of patients with neurodegenerative diseases. There are 37 items that are presented in a fixed order and grouped into five sub-scales: attention, initiation, construction, conceptualization and memory. Patients and healthy subjects with a score below 125 are not included because of major cognitive impairment.
40927983|NCT00198887|PROCEDURE|Operations research|
40927984|NCT05062395|PROCEDURE|Computed Tomography|Undergo FDG PET CT
40927985|NCT05062395|OTHER|Fludeoxyglucose F-18|Undergo FDG PET CT
40927986|NCT05062395|OTHER|Low Carbohydrate High Fat Diet|low carbohydrate and high fat diet for 48-72 hours
40927987|NCT05062395|PROCEDURE|Positron Emission Tomography|Undergo FDG PET CT
40927988|NCT00076375|DRUG|Nanocrystalline silver cream (NPI)|
40927989|NCT01077375|DRUG|Placebo|"* Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~* Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period."
40927990|NCT01077375|DRUG|Milnacipran|"* Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~* Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period."
40927991|NCT05148520|BEHAVIORAL|5A's model|"(1) Ask - ask youth smokers about their smoking habit, (2) Advise - advise youth smokers to quit smoking, (3) Assess - assess youth smokers about their willingness to quit smoking, (4) Assist - assist youth smokers who are willing to make a quit attempt, and (5) Arrange~- arrange for follow-up."
40927992|NCT01695876|DRUG|AMG 357|Oral administration available in varying dose strength.
40927993|NCT01695876|DRUG|Placebo|Matching placebo to AMG 357 containing no active drug
40927994|NCT02642939|DRUG|Mifepristone|Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
41125317|NCT01736514|DRUG|febuxostat|oral
41125318|NCT01736514|DRUG|Allopurinol|oral
41125319|NCT00914589|DRUG|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
41125320|NCT00914589|DRUG|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
41287270|NCT03133481|DRUG|Femoral Nerve Block|Traditional technique
41125321|NCT00914589|DRUG|placebo|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
41125322|NCT00450359|PROCEDURE|breast imaging study|
41125323|NCT00450359|PROCEDURE|comparison of screening methods|
41125324|NCT00450359|PROCEDURE|radiomammography|
41125325|NCT00198146|DRUG|Zenapax|
41125326|NCT04106869|OTHER|Hyperventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (\<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
41125327|NCT04106869|OTHER|Hypoventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
41125328|NCT03644849|DEVICE|CO2RE® (Syneron Candela Corp, Wayland, MA)|The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.
41125329|NCT03644849|OTHER|Sham laser treatment|A physician who is not blinded will perform a sham laser treatment on blinded subjects.
41125330|NCT01794858|OTHER|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
41125331|NCT03210454|OTHER|Smallholder Marketing|The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
41125332|NCT03210454|OTHER|Intimate Partner Violence (IPV) Prevention Training|IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
41447250|NCT05327777|BEHAVIORAL|Zero Opioid Protocol|Investigators provided no opioid prescriptions at discharge and instead provided information on non-narcotic pain control.
41447251|NCT00261391|DRUG|Marimastat|
41125333|NCT01327664|BIOLOGICAL|AIN457|
41125334|NCT00087139|DRUG|ixabepilone|Given IV
41125335|NCT03359317|BEHAVIORAL|jogging|Jogging as instructed for 1 year
41125336|NCT00117026|DRUG|Placebo|Placebo for benfotiamine
41125337|NCT00117026|DRUG|Benfotiamine|300mg/day
41125338|NCT03898024|DRUG|SHR-1222|Pharmaceutical form: water injection; Route of administration: subcutaneous
41125339|NCT03898024|DRUG|Placebo|Pharmaceutical form: water injection; Route of administration: subcutaneous
41125340|NCT06173713|DEVICE|Emphasys Hip Solutions|Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem
41125341|NCT01869179|BEHAVIORAL|Community of Voices choir program|Attend weekly choir sessions for 12 months at the Senior Center. All choir sessions will include activities that focus on cognitive, psychosocial, and physical engagement components Choir sessions will last 90 minutes each with a 10 minute break. Take part in 3-4 informal choir concerts.
41125342|NCT01869179|BEHAVIORAL|Wait-list control group|
41125343|NCT06004765|DRUG|Lenalidomide|10mg/d \*21 days, 28 days for 1 course
41125344|NCT06004765|DRUG|Azacitidine|75mg/m2/d\*5 days, 28 days for 1 course
41447252|NCT06371807|DRUG|Pembrolizumab injection|(KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting
40754463|NCT03807167|OTHER|Unified Parkinson 's Disease Rating Scale-III|This scale is used to rate the severity of extra-pyramidal symptoms (akinesia, rigidity and tremors). These symptoms may be the cause of reduction of motor activity apart from any reduction in motivation, they onstitute a confounding factor that it should be controlled.
41125345|NCT01864889|BIOLOGICAL|anti-CD19-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
41125346|NCT06035536|DEVICE|Symphony™ plus Off-loading|Application of Symphony™
41125347|NCT06035536|DEVICE|Wound Dressing comprising of calcium alginate Fibracol|Application of Wound Dressing comprising of calcium alginate Fibracol.
41125348|NCT00265200|DRUG|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
41125349|NCT05406765|DRUG|Bupivacaine Injection|One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
41125350|NCT01739270|PROCEDURE|supraclavicular brachial plexus block|
41287271|NCT00687453|DRUG|Insulin glargine at bedtime instead of NPH|Insulin glargine at bedtime substituting for NPH insulin at bedtime
41447253|NCT06623591|DEVICE|active Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
40927995|NCT04959071|PROCEDURE|Vacuum assisted closure VAC vs conventional dressing|"In participants undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours.~In participants with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily."
40927996|NCT03757013|DRUG|Apremilast|Apremilast
41447254|NCT06623591|DEVICE|sham Transcutaneous auricular vagus nerve stimulation|In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
41447255|NCT05664243|BIOLOGICAL|Autologous genetically modified gamma-delta T cells|Arm A: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance
41447256|NCT05664243|BIOLOGICAL|Allogeneic genetically modified gamma-delta T cells|"Phase 1b and Arm B: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with D1 of TMZ 150mg/m2~Arms C: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance"
41447257|NCT06071468|DEVICE|UltraGuideCTR (Device) with Ultrasound Guided Carpal Tunnel Release (CTR-US)|The UltraGuideCTR is a commercially available medical device specifically developed to facilitate CTR-US. The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically \< 5 mm) wrist incision using continuous US guidance. The working tip of the UltraGuideCTR consists of two inflatable balloons that border a centrally located, retractable retrograde cutting knife. When inflated with sterile saline, the balloons increase the diameter of the tip from 4 mm to 8 mm. After the tip is positioned within the transverse safe zone of the carpal tunnel, the balloons are inflated to create space in the carpal tunnel, the blade is activated, and the TCL is transected in a retrograde manner. Following TCL transection, the blade is recessed, the balloons deflated, and the device is removed. The TCL is probed to ensure a complete release. The entire procedure is performed using US guidance.
41447258|NCT06071468|PROCEDURE|Endocscopic CTR|"Endoscopic CTR makes one or two short incisions to introduce instruments for visualizing. The key procedural steps involved in Endoscopic CTR are listed below.~1. Following the delivery of anesthesia, the surgeon makes a small wrist incision (usually less than 1.5 cm), with or without a small palmar incision (usually less than 1.5 cm, depending on whether they are using a single portal or double portal technique, respectively.~2. A series of dilators and raspers are used to create space in the carpal tunnel and clear synovial tissue from the undersurface fo the TCL.~3. A camera attached to a narrow tube (endoscope) is inserted into the carpal tunnel.~4. The transverse carpal ligament (which forms the roof of the carpal tunnel) is identified.~5. Using specialized cutting instruments and endoscopic guidance, the surgeon transects the TCL.~6. Endoscopic visualization and/or probing are used to confirm a complete release.~7. The wound(s) is/are typically closed with sutures."
40927997|NCT05171725|DIAGNOSTIC_TEST|EEG,PSG|concurrent overnight sleep study with full electroencephalography (in-lab or at home)
40927998|NCT05171725|DIAGNOSTIC_TEST|biosample collection (blood and CSF)|blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information
40927999|NCT05171725|DIAGNOSTIC_TEST|neuropsychological testing|paper and pencil, as well as tablet based cognitive testing
40928000|NCT05171725|DIAGNOSTIC_TEST|actigraphy|week long actigraphy assessment with concurrent sleep diary acquisition
40928001|NCT05171725|DIAGNOSTIC_TEST|clinician assessment|standard clinical assessment by an expert clinician in the respective field of brain disorders
40928002|NCT00950677|DRUG|Byetta (exenatide)|exenatide 5 mcg subcutaneously
41125351|NCT04764994|DEVICE|Armeo®Spring ((Task-oriented upper extremity rehabilitation system)|Armeo®Spring is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The Armeo Spring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury or other neurological diseases and injuries. It combines an adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
40928003|NCT00950677|DRUG|Symlin (pramlintide)|pramlintide 60 mcg subcutaneously
41125352|NCT04764994|OTHER|Conventional Physical Therapy Program|This intervention t will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises.
41125353|NCT03580135|DRUG|Propolis|One and half gram of Standardized Propolis Extract powder (Y.S. Eco Bee Farms Propolis Powder) at 100% was mixed with 1.75 mL of polyethylene glycol (Continental Chemicals, New Delhi, India) to form a thick consistency on a clean dry glass slab with a metal spatula. The paste was carried to the pulp stumps with a metal carrier and then condensed lightly to a thickness of 2 - 3 mm followed by placement of thick mix of GIC to seal the cavity and covered by st.st crown.
40928004|NCT04150406|DIETARY_SUPPLEMENT|Flexofytol|Curcuma extract
40928005|NCT04150406|OTHER|Placebo|placebo
40928006|NCT02558829|DRUG|Macimorelin|macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
40928007|NCT02558829|DRUG|Insulin|Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose
40928008|NCT01652300|BEHAVIORAL|two educational sessions|The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
40928009|NCT01652300|BEHAVIORAL|no education|women in the control group received no education
41447259|NCT06071468|PROCEDURE|Open CTR|"OCTR is the most commonly used CTR technique in the United States.The key procedural steps involved in OCTR are listed below.~1. Following the delivery of anesthesia, an incision is made in the palm directly over the carpal tunnel.~2. The surgeon cuts through the palmar fascia to identify the TCL.~3. The surgeon transects the TCL with a scalpel and/or similar cutting instruments.~4. The surgeon inspects the carpal tunnel to ensure proper decompression.~5. The wound is closed with sutures."
41447260|NCT02570958|DRUG|Indocyanine Green|In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
40928010|NCT01764802|OTHER|behavioral, psychological or informational intervention|Participate in enhanced standard care
40928011|NCT01764802|OTHER|behavioral, psychological or informational intervention|Participate in psychological intervention
40928012|NCT00311298|DIETARY_SUPPLEMENT|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
40928013|NCT00311298|DIETARY_SUPPLEMENT|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
40928014|NCT01197443|BEHAVIORAL|Parent-only Group|Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
41125354|NCT03580135|DRUG|Mineral Trioxide Aggregate|MTA paste will be prepared as per the manufacturers' instructions to obtain a putty-like consistency. The mixture will be delivered to the pulp stumps and condensed lightly with a moistened sterile cotton pellet to ensure a thickness of 2 to 3 mm. A thick mix of glass ionomer cement (GIC) will applied over the MTA and covered by st.st crown.
41125355|NCT02530190|DEVICE|intermittent pneumatic compression|20 minutes of intermittent pneumatic compression to lower extremities
41287272|NCT00687453|DRUG|NPH twice-daily|Addition of morning NPH to bedtime NPH
41287273|NCT00974779|DEVICE|HCO1100 dialyzer|Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks
41447261|NCT05178927|DEVICE|HoloLens v2|The HoloLens v2 will be used to access the participant's hologram \& set the participant up for treatment. Standard of care methods will be utilized to confirm treatment set-up.
41447262|NCT02895802|BEHAVIORAL|Verbal instructions with picture diagram|verbal instructions and picture diagram
41125356|NCT02530190|PROCEDURE|massage|20 minutes of massage to lower extremities
41447263|NCT02895802|BEHAVIORAL|Verbal instructions with video of ADSC|Verbal instructions and watching video depicting ADSC
41447264|NCT02895802|BEHAVIORAL|verbal instructions w. video of w/o DS|verbal instructions and watching video depicting person without DS washing her hands
41447265|NCT02895802|BEHAVIORAL|verbal instructions w. video w/DS|verbal instructions and watching video depicting person with DS washing his hands
41447266|NCT01936662|DEVICE|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
41447267|NCT01936662|DEVICE|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
41447268|NCT02072096|DRUG|Glimepiride|Administered orally
41125357|NCT02233595|RADIATION|Chemoradiation|
41125358|NCT04953273|OTHER|Vigitrauma|Case management algorithm using early phone contact
41125359|NCT06328985|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
41447269|NCT02072096|DRUG|Metformin|Administered orally
41125360|NCT06328985|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
41447270|NCT02072096|DRUG|Pioglitazone|Administered orally
41447271|NCT02072096|DRUG|Acarbose|Administered orally
41447272|NCT02072096|DRUG|Linagliptin|Administered orally
41447273|NCT02072096|DRUG|Sitagliptin|Administered orally
41447274|NCT02072096|DRUG|Liraglutide|Administered subcutaneously (SC)
41447275|NCT02072096|DRUG|Insulin Glargine|Administered SC
40754464|NCT03807167|OTHER|Mini Neuropsychiatric Investigation|This is a structured interview that allows rapid screening in about 20 minutes of troubles Psychiatric. It is based on short questions to which the patient must answer yes or no and on a decision tree. Patients must validate clinical diagnoses of depression.
40754465|NCT03807167|OTHER|Montgomery and Asberg depression Rating Scale|This scale is composed of 10 items from 0 to 6 from a semi-structured interview, to obtain a total depression score of 0 to 60 (0 no depression, 60 maximum intensity of depression).
40754466|NCT03807167|OTHER|Clinical Global Impression|heterosexual assessment that rates the severity of symptoms suicidal and changes in suicidal symptoms. Any subject with a score greater than 4 is not included.
40928015|NCT01197443|BEHAVIORAL|Parent + Child Group|The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
40928016|NCT03134079|OTHER|apple crisp|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
40928017|NCT03134079|OTHER|tea|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
41276587|NCT06217250|PROCEDURE|Traditional EMR|Conventional EMR with thermal ablation of resection margins: initial submucosal injection of saline and methylene blue and subsequent piecemeal resection with 10- or 15-mm diathermic snare with subsequent thermal ablation of resection margins with snare tip soft coagulation.Nevertheless, this technique is associated with the emergence of serious adverse events (SAEs), including delayed bleeding (PPB), electrocautery-induced post-polipectomy syndrome (PPS), and perforation(4).
41276588|NCT06217250|PROCEDURE|"the cold snare (CO), underwater technique (W), and the use of submucosal lift (L) in both study arms"|"The cold-EMR technique, as opposed to the conventional approach, employs a specialized snare that enables tissue transection without the need for electrical current, particularly in appropriately selected lesions. This approach yields the same efficacy outcome as the conventional procedure but offers the advantage of reducing the risks associated with polypectomy, which are often secondary to the use of diathermic current. Subsequently, the lesion fragments are retrieved for histological examination. Furthermore, the use of underwater setting, as demonstrated for hot EMR, could improve the effectiveness of cold-EMR."
41276589|NCT05274438|DRUG|JS001+Imatinib mesylate|"This study consisted of two phases: the first phase was the dose exploration phase, and the second phase was the extension group. In phase I, 3 patients were enrolled, starting with imatinib monotherapy, 400mg qd, for 2 cycles (6 weeks), followed by imatinib 400mg qd combined with toripalimab 240mg q3w. If DLT was not observed, the original dose was extended to 37 patients in phase ii; If there was 1 DLT in the first stage, the number of patients in the first stage was extended to 6. If there was no DLT, the patients entered the extended stage. If ≥2 DLT cases occurred in the first phase, imatinib was reduced to 300mg QD and toripalimab 240mg q3W, and the 3+3 study was restarted. If DLT≤1 case, enter extended group (imatinib 300mg qd and toripalimab 240mg q3W); The longest cumulative use period of the two drugs was 2 years. When patients develop disease progression or develop intolerable toxicity, treatment is ended and follow-up for survival is entered."
41276590|NCT06585306|BEHAVIORAL|jaw lift, increasing oxygen flow, mask ventilation, intubation|When patients develop hypoxemia, the above interventions are sequentially employed to improve their oxygenation status.
41276591|NCT06657482|BEHAVIORAL|Delayed school start time|The intervention group will start school two hours later on Mondays (at 10.15 ± 15 min) and one hour later on Tuesdays (9.15 ± 15 min) and to ordinary school start time (8.15 ± 15 min) for the rest of the week
41276592|NCT04698187|DRUG|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
41276593|NCT04698187|DRUG|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
41276594|NCT06488781|DRUG|Azithromycin|Azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses
41276595|NCT06488781|DRUG|Placebo|Placebo given in place of other two active drugs
41276596|NCT04708587|DRUG|dual anti-platelet therapy at least 6 months|Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
41276597|NCT04708587|DRUG|dual anti-platelet therapy 3months or less|Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
41276598|NCT00030576|DRUG|cisplatin|
41447276|NCT02072096|DRUG|Exenatide once weekly (QW)|Administered SC
40928018|NCT03134079|OTHER|oatmeal|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
40928019|NCT02325791|DRUG|Suptavumab 30 mg/kg|Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.
41276599|NCT00030576|DRUG|erlotinib hydrochloride|
41276600|NCT06651476|DRUG|oxytocin|Oxytocin 10 IU will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
40928020|NCT02325791|DRUG|Placebo Matched to Suptavumab|Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.
40928021|NCT02325791|DRUG|Suptavumab 30 mg/kg- 1 Dose|Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.
40928022|NCT02325791|DRUG|Suptavumab 30 mg/kg - 2 Doses|Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
40928023|NCT03705936|DEVICE|rTMS|rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.
40928024|NCT05820659|BEHAVIORAL|peer rejection task and impossible puzzle task|"Peer rejection task: Adolescents will be informed that two peers will take turns to choose who they will chat with for different topics. Participants will not be chosen by virtual White peers 75% of the time. In reality, White peers are computerized avatars and whether or not adolescents are chosen by those peers is programmed with PsychoPy software.~Impossible puzzle task: Adolescents will be asked to fit all puzzle pieces into a wooden frame with a wrong piece provided."
40928025|NCT02788162|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - X71-144)
40928026|NCT00862420|DRUG|clopidogrel (SR25990)|oral administration (tablets)
41125361|NCT06328985|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
41276601|NCT06651476|DRUG|placebo|A placebo will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
41276602|NCT04833036|DRUG|Irinotecan|180 mg/m2, ivgtt d1，q2w
41276603|NCT04833036|DRUG|cetuximab|500 mg/m2, ivgtt d1，q2w
41276604|NCT00002850|DRUG|ciprofloxacin|Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
40928027|NCT00862420|DRUG|ticlopidine|oral administration (tablets)
40928028|NCT06430827|DRUG|irinotecan hydrochloride liposome injection|rinotecan hydrochloride liposome injection (70mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
41125362|NCT03892564|DRUG|MC2-01 Cream, irradiation|One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
41125363|NCT03892564|DRUG|MC2-01 Cream, no irradiation|One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
41125364|NCT03892564|DRUG|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
41125365|NCT03892564|DRUG|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
41447277|NCT02072096|DRUG|Exenatide twice daily (BID)|Administered SC
41447278|NCT06249711|DEVICE|Active stimulation with Diadem ultrasonic transducer array|Diadem ultrasonic transducer array delivers focused low-intensity ultrasound stimulation
41447279|NCT06249711|DEVICE|Sham stimulation with Diadem ultrasonic transducer array|Diadem ultrasonic transducer array delivers focused zero-intensity ultrasound stimulation
41447280|NCT04196907|DEVICE|Rad-67 Pulse CO-Oximeter and DCI Mini sensor|Noninvasive Pulse CO-Oximeter device and sensor are used to measure hemoglobin.
41447281|NCT06627803|DRUG|Alcohol (Oral)|Participants will drink a beverage that will have alcohol or no alcohol. The amount of alcohol consumed will be similar to consuming around 3-4 drinks, with breath alcohol concentration peaking at or around the legal limit for driving (0.08%).
41447282|NCT03747276|OTHER|Clinical Trial Kiosk|Kiosk will consist of a patient facilitator and a computer with access to general information about clinical trials and information specific to active clinical trials at the facility. Patients will be made aware of the kiosk via a large banner visible in the clinic above the kiosk.
41125366|NCT03892564|DRUG|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
41447283|NCT02615249|BIOLOGICAL|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
41125367|NCT00203411|DRUG|Capecitabine (Xeloda)|1000mg/m\^2 administered orally twice daily for two weeks followed by one week rest period
41125368|NCT00203411|DRUG|Bevacizumab|7.5 mg/kg IV will be administered every 3 weeks
41287274|NCT00974779|DEVICE|regular dialysis polyamide|Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
41276605|NCT00002850|DRUG|ofloxacin|Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
41447284|NCT04432584|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight \>=100kg). Dosing schedule will be as described above.
40928029|NCT06430827|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle
41447285|NCT04432584|DRUG|Eculizumab|Eculizumab will be administered at a dose of 900 mg every 2 weeks, as per the dosing schedule described above.
41447286|NCT04281472|BIOLOGICAL|efgartigimod PH20 SC in stage B|Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC
40928030|NCT05154968|DRUG|Sodium chloride|Administered SC infusion.
41447287|NCT04281472|OTHER|placebo in stage B|Stage A: N/A, stage B: placebo
41447288|NCT06190977|OTHER|Otago Exercise Program|Exercises will include Intensity: 10 repetitions of each set for the first two weeks and 15 repetitions of each set for the last two weeks, Frequency 3 sessions per week for 4 weeks. Time= 40-45 minutes
41125369|NCT06136351|DRUG|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
40928031|NCT05154968|DRUG|Citrate buffer|Administered SC infusion.
41125370|NCT06136351|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
41125371|NCT06136351|DRUG|Bendamustin|90mg/m\^2 ivgtt, D0 of each 28-day cycle
41125372|NCT06337058|BEHAVIORAL|Experimental group (motivational interview)|"For the menopausal women with sexual dysfunction in the experimental group, pre-test data were obtained by applying the 'Personal Information Form', the 'Sexual Quality of Life Scale-Woman' and the 'Sexual Self-Efficacy Scale' before starting the motivational interviews. After the pre-test data were obtained, a total of 4 sessions of motivational interviews were provided, one session per week for four weeks. At the end of four weeks, post-test data were obtained by applying the Arizona Sexual Experiences Scale, Sexual Quality of Life Scale-Women and Sexual Self-Efficacy Scale.~The researcher received a training on motivational interview techniques before implementing the intervention for menopausal women in the experimental group."
41125373|NCT04886505|DEVICE|Electrolytic eCLIPs Bifurcation System|The electrolytic eCLIPs bifurcation system will be implanted into patients with bifurcated saccular intra-cranial aneurysms.
41125374|NCT01470508|BEHAVIORAL|Cognitive Behavioral Therapy|Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
41125375|NCT01470508|BEHAVIORAL|Cognitive Behavioral Therapy with Family Enhancement|Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.
40928032|NCT05154968|DRUG|Mannitol|Administered SC infusion.
41125376|NCT03197116|OTHER|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
40928033|NCT05154968|DEVICE|Prefilled Autoinjector|Used to administer the drug through SC infusion.
40928034|NCT00204555|DRUG|Imiquimod|
40928035|NCT05535205|OTHER|Digital preoperative assessment|a digital preoperative assessment for patient requiring surgery
40928036|NCT05535205|OTHER|Face-to-face preoperative assessment|a face-to-face preoperative assessment for patient requiring surgery
40928037|NCT01373671|DEVICE|SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM|DBT scan
40928038|NCT00782587|DRUG|Chemophase|40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
41125377|NCT03197116|OTHER|No other|No additional reminder will be offered
41276606|NCT00002850|DRUG|160 mg trimethoprim and 800 mg sulfamethoxazole|Begin oral TMP-SMX when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet \[TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole\] every 12 hours for two months..
41276607|NCT06651957|OTHER|Biospecimen Collection|Specimen swabs will be obtained.
41276608|NCT06651957|OTHER|Questionnaires|Given to participants
41276609|NCT06656169|DRUG|Subcutaneous polyvidone collagen|Use collagen-polyvidone at a dose of 0.2 ml, applied to the affected area of the hand.
41447289|NCT06190977|OTHER|General TKR pprotocol|Exercises will include Intensity: 10 repetitions of each set, Frequency 5 sessions per week for 4 weeks. Time= 30 minutes
41447290|NCT03669250|DRUG|CVN058|CVN058 will be given at two doses, a low does and a high dose
41447291|NCT03669250|OTHER|Placebo comparator|inactive placebo
41447292|NCT03778307|BEHAVIORAL|Psychophysiological fear conditioning and extinction task|Behavioral task to assess psychophysiological measures of fear
41447293|NCT03778307|BEHAVIORAL|Eyetracking task|Behavioral task to assess dysphoria-relevant attention allocation
41447294|NCT02882776|DIETARY_SUPPLEMENT|Ginger drink|Ginger powder dissolved in water
41125378|NCT04447482|DEVICE|ENB with image-guided lung biopsy|Electromagnetic navigational bronchoscopy system with tip tracked instruments.
41447295|NCT03465839|BEHAVIORAL|Education for improving handovers quality|Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.
41447296|NCT03465839|BEHAVIORAL|Education for improving bedside handovers|In addition to the education for improving handovers quality, the following intervention will be implemented for nurses assigned to the study department. The course will be supplemented by a section of the duration of an hour, containing 1) information on the principles underlying bedside handovers; 2) how to handle information in front of the patient and on his / her direct involvement; 3) role-playing of the bedside handover will be performed, assigning the roles of nurse and patient among the participants to bring out impressions linked to the functions.
41447297|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
41125379|NCT04447482|PROCEDURE|Conventional Bronchoscopy guided by Fluoroscopy|Bronchoscopic lung biopsy with fluoroscopy.
41125380|NCT06028672|DRUG|Toripalimab|200mg q2w intravenous
41125381|NCT06028672|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
41125382|NCT00150813|DRUG|Levetiracetam|Pharmaceutical form: oral tablets Route of administration: Oral use
41125383|NCT02582424|OTHER|PD-L0101|92% EPA+6 mg ATX+50 mg TCT GG BID
41276610|NCT06656169|OTHER|saline solution|administer saline solution at a dose of 0.2 ml, applied to the affected area of the hand.
41276611|NCT04576442|BEHAVIORAL|Asthma-PASS|The investigator will collaborate with the student's primary care provider (PCP) by sending a letter via facsimile, and/or email to ensure appropriate medications are prescribed or adjusted and rescue medications are available at school. Community Health Workers (CHWs) will follow up with PCPs as needed to provide reminders about prescriptions for controlled medications and to ensure a MAF is provided to schools to allow rescue medication administration by nurses. CHWs will work with local pharmacies when possible to have prescribed medications delivered to schools and homes. For students without a PCP, we will refer families to one of Montefiore Medical Center's 20 practices throughout the Bronx. For students without medical insurance or who are unable to go to a Montefiore clinic, the NYC DOE physicians who routinely attend NYC schools will provide medical care and prescribe appropriate medications.
41276612|NCT04576442|BEHAVIORAL|Basic Asthma Management (AM)|PCPs and caregivers will be notified that children in the AM group have persistent/uncontrolled asthma that warrants use of guideline-based preventative medications.
41276613|NCT04576442|BEHAVIORAL|Child/Caregiver Education session|The investigator will provide in-school child asthma education sessions delivered by trained, bilingual (English-Spanish) Community Health Workers (CHWs) using an established manualized protocol from past and current studies designed to improve knowledge and self-efficacy. Each child will receive two 1-on 1, 20-minute developmentally appropriate educational sessions at school 3-4 weeks apart. Sessions will cover: 1) asthma basics, symptoms and triggers; and 2) medications and correct administration technique. Caregivers will be called after each child session to highlight key points reviewed with the child and answer questions.
41287275|NCT04170140|OTHER|No intervention|Questionnaire
41447298|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
41447299|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
41447300|NCT03492138|DRUG|ONC201|625mg
41447301|NCT03492138|DRUG|Ixazomib|Dose to be determined in Phase 1 of study
41447302|NCT03492138|DRUG|Dexamethasone|40mg
41125384|NCT02582424|OTHER|placebo|placebo
41125385|NCT02432950|DIETARY_SUPPLEMENT|Dietary Intervention|Participate in the PNP
41125386|NCT02432950|OTHER|Educational Intervention|Participate in the PNP
41125387|NCT02432950|OTHER|Laboratory Biomarker Analysis|Correlative studies
41125388|NCT02432950|OTHER|Quality-of-Life Assessment|Ancillary studies
41125389|NCT01902147|OTHER|Postoperative Quality Recovery Scale (PQRS)|The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
41125390|NCT02828618|PROCEDURE|PDS (Primary Debulkdung Surgery)|PDS with maximum effort to achieve the goal of complete gross resection
41125391|NCT02828618|PROCEDURE|6 cycles of standard chemotherapy|6 cycles of standard chemotherapy after Primary Debuling Surgery
41125392|NCT02828618|PROCEDURE|Timing of surgery after 3 cycles of standard NACT, IDS|Timing of surgery after 3 cycles of standard NACT
41125393|NCT02828618|PROCEDURE|IDS|IDS with maximum effort to achieve the goal of complete gross resection after NACT
41125394|NCT02828618|DRUG|3 cycles of standard chemotherapy|3 more cycles (for a total of 6) of standard chemotherapy after IDS
41125395|NCT06336473|PROCEDURE|skin biopsy|Samples will be taken under local anaesthetic (after injection of 1 cc of Xylocaine without adrenaline) using a 4 mm diameter dermal biopsy punch. The biopsy will be performed on the buttocks. Fragments are stored in 15-mL polypropylene tubes in PBS at 4°C.
41447303|NCT03036748|DIETARY_SUPPLEMENT|Standardized sodium diet|Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
41447304|NCT03036748|DRUG|Tbl amiloride|Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
41447305|NCT01631552|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered via intravenous (IV) infusion
41447306|NCT01342939|OTHER|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
41447307|NCT01342939|OTHER|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
41447308|NCT01342939|DIETARY_SUPPLEMENT|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
41447309|NCT01342939|OTHER|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
41447310|NCT01342939|OTHER|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
41447311|NCT06415591|DEVICE|Percutaneous electrical nerve field stimulation|FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.
41125396|NCT01405807|DRUG|Alemtuzumab|Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
41125397|NCT02851667|BEHAVIORAL|Resident training programs|A total of 24 resident training programs such as talks, day camp and thematic activities were delivered in the intervention estate by CFSC from June to November 2011. Each program included an introduction to the concepts of Learning Family and family 3Hs as well as how to promote family 3Hs through learning and communicating with family, delivered by interactive games and workshops.
41125398|NCT03052335|DEVICE|Pillcam® COLON 2 Capsule|The second generation of PillCam colon capsule endoscopy (CCE-2) is 11.6 mm × 31.5 mm in size and has two imagers, that each have a 172° angle of view, allowing for almost 360° visual coverage of the colon. CCE-2 has an adaptive frame rate from 4 to 35 images per second. This means that the camera is able to capture up to 35 pictures while in motion whereas 4 images per second are captured when it is virtually stationary. During the examination the patient wears a sensor array which is attached to the abdomen and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the workstation and a video is generated.
41125399|NCT03052335|PROCEDURE|Colonoscopy|Optical colonoscopy is the standard method for evaluating the colon
41447312|NCT06200116|OTHER|Non-Interventional Study|Non-interventional study
41447313|NCT01664767|OTHER|Sulfur Thermal water|
40928039|NCT05958693|DRUG|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
41447314|NCT01664767|OTHER|Placebo|
41447315|NCT03659565|BEHAVIORAL|Enhanced Pre-Visit Consultation|The Intervention Group will be given access to the optimized personal health record and will use Zoom as part of the pre-visit consultation.
41447316|NCT03659565|BEHAVIORAL|Usual Care Control|Caregivers and patients will participate in usual pre-visit process.
41125400|NCT01582100|DEVICE|Reletex|Neuromodulation device worn on the wrist
41276614|NCT05040529|PROCEDURE|pure laparoscopic donor hepatectomy|pure laparoscopic donor hepatectomy: patients who underwent pure laparoscopic right or right extended hepatectomy for liver donation at gangnam severance hospital
41276615|NCT05040529|PROCEDURE|conventional open donor hepatectomy|conventional open donor hepatectomy: patients who underwent conventional right or right extended hepatectomy for liver donation at gangnam severance hospital
41447317|NCT03489629|DRUG|Trimethoprim Sulfamethoxazole (TMP/SMX)|"Dosing if \< 40 kg: 8 mg/kg trimethoprim/40 mg/kg trimethoprim sulfamethoxazole given twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing is ≥ 40 kg: 320 mg/1600 mg twice daily for 14 days during Days 1-14 and Days 29-42."
41447318|NCT03489629|DRUG|Minocycline|"If a subject has an allergy to or intolerance to TMP/SMX, they may be treated with minocycline provided they are 8 years of age or older.~Dosing if \< 50 kg: 2 mg/kg orally twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing if ≥ 50 kg: 100 mg twice daily for 14 days during Days 1-14 and Days 29-42."
41447319|NCT03489629|DRUG|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 5 days during Days 1-5 and Days 29-33.
41447320|NCT03489629|DRUG|Chlorhexidine Gluconate|For subjects able to swish without swallowing, 0.12% chlorhexidine gluconate oral rinse will be used twice daily for 14 days during Days 1-14 and Days 29-42.
41276616|NCT04036084|DIAGNOSTIC_TEST|Cerebral Magnetic resonance imaging (MRI)|Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
41447321|NCT03489629|BEHAVIORAL|Environmental Decontamination|"Subjects will be instructed to wipe down all high touch surfaces and medical equipment with surface disinfection wipes daily during Days 1-21 and Days 29-49.~Subjects will also be instructed to wash all linens and towels in hot water once weekly during weeks 1-3 and weeks 5-7."
41447322|NCT04256486|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a faith based organization setting.
41447323|NCT01647828|DRUG|OMP-59R5|OMP-59R5 administered intravenously
41447324|NCT01647828|DRUG|Gemcitabine|administered intravenously
41447325|NCT01647828|DRUG|Placebo|administered IV
41447326|NCT01647828|DRUG|Nab-Paclitaxel|administered intravenously
41447327|NCT00669162|DRUG|Docetaxel|20mg/m2 IV weekly for 7 weeks
41447328|NCT00669162|RADIATION|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
41125401|NCT01748110|BEHAVIORAL|Intensive Fitness Intervention|This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up monthly with a health counselor to verify progress.
41447329|NCT00669162|DRUG|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
41125402|NCT01748110|BEHAVIORAL|TRIMM|text message intervention.
41276617|NCT06657729|OTHER|Succiometry|Assessement of sucking performance by measuring pressures (suction, crushing) with a succiometer every 10 days. This instrument consists of a standard silicone teat for premature newborns, which is connected via two silicone tubes to pressure micro-sensors. These pressure sensors measure the child's sucking activity on the teat. This activity is characterised by suction and crushing movements. It is a non-nutritive sucking activity (no fluid is delivered). Sucking performance is recorded during a period of calm awakening of the infant and over a period of 5 minutes, and is part of routine care since non-nutritive sucking is a common practice in neonatal unit. The first measurement will be taken in the first week of life and then every 7-10 days until discharge from the neonatal unit.
41276618|NCT05242887|DIAGNOSTIC_TEST|Delirium screening using 3D-CAM and UB-CAM|Patients will be evaluated with 3D-CAM and UB-CAM by a trained examiner (geriatrician, resident or neuropsychologist). On the same day, they will be given a reference diagnosis of delirium based on DSM-V criteria by another trained examiner, blind to the results of the UB-CAM and 3D-CAM.
41276619|NCT01986335|BIOLOGICAL|DTP/HB/Hib Vaccine|DPT/HB/Hib vaccine (Bio Farma)
41447330|NCT03617198|BIOLOGICAL|CD4 CAR+CCR5 ZFN T-cells|A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
41447331|NCT03904329|DRUG|Oral Anticoagulant|Oral tablets of anti coagulations either warfare or NOACs
41447332|NCT01745679|DRUG|Ceftriaxone treatment|ceftriaxone will be administered à high dose : \> or equal to 75mg/kg/day or 4 gr/day
41447333|NCT01260389|BEHAVIORAL|pharmaceutical care intervention|Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
41447334|NCT01399385|DEVICE|MR Imaging Techniques - 1|Group 1 will consist of subjects with a 10-year total CHD risk \<10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
41447335|NCT01399385|DEVICE|MR Imaging Techniques - 2|Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
41447336|NCT01399385|DEVICE|MR Imaging Techniques - 3|Group 3 will consist of subjects with a 10-year total CHD risk \>20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
41447337|NCT01399385|DEVICE|MR Imaging Techniques - 4|Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
41447338|NCT02942823|OTHER|"The serious game KOP"|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
41276620|NCT02774590|DRUG|Timolol|Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
41447339|NCT03167437|DRUG|Vorinostat|It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study
41447340|NCT03167437|DRUG|Ustekinumab|Ustekinumab inhibits the bioactivity of human IL-12 and IL- 23 by preventing these cytokines from binding to the IL- 12Rbeta1 receptor protein expressed on the surface of immune cells. It is FDA approved for the treatment of adult patients with active psoriatic arthritis and more recently, in September 2016, ustekinumab has been approved for the treatment of patients with Crohn s disease.
41447341|NCT05439252|BEHAVIORAL|Exercise Snacking|Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are sit-to-stand from a chair, seated overhead arm raises, march on the spot, seated arm raises and shoulder touches, and seated calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.
41447342|NCT04021511|OTHER|OAR application by a nurse|As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
41276621|NCT00986531|DRUG|AZD8529|2 capsules by mouth for 3 days
41276622|NCT00986531|DRUG|Placebo to match AZD8529|2 capsules by mouth for 3 days
41276623|NCT05999799|DRUG|GSK1070806|GSK1070806 will be administered.
41276624|NCT05999799|DRUG|Placebo|Placebo will be administered.
41276625|NCT02610985|DEVICE|3-D laparoscopy|3-D laparoscopy
41125403|NCT06137105|DRUG|eltrombopag and romiplastim|"Group I: eltrombopag and romiplastim~Group II : recived corticosteroid."
41125404|NCT03632759|DRUG|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
41125405|NCT03632759|DRUG|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
41125406|NCT02378896|BEHAVIORAL|Personalized Computer Program|Training with a personalized computerized inhibitory training program
41125407|NCT02378896|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
41125408|NCT05293808|DRUG|aspirin 100 mg bis in die|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
40928040|NCT05958693|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
41447343|NCT06561568|DIAGNOSTIC_TEST|Conventional physical therapy|Conventional physical therapy protocol for chondromalacia patellae consist of stretches to warm up and cool down Resistance training ,in which patient will perform each exercise for 3 sets of 10 repetitions. Each repetition will be given with a 10 second hold.
41447344|NCT06561568|OTHER|Kinesiotaping|"Kinesio tape will be applied on Vastus medialis Oblique and around the patella.~• Frequency: 3 times a week for 4 weeks."
41447345|NCT00429416|DRUG|L-leucyl-L-leucine Methyl Ester (LLME)|Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
41447346|NCT00429416|DRUG|Fludarabine|Fludarabine 30 mg/m2 prior to HSCT infusion
41447347|NCT00429416|DRUG|Cytarabine|Cytarabine 2gm/m2 prior to HSCT infusion
41125409|NCT05293808|DRUG|aspririn 200 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
41125410|NCT05293808|DRUG|aspirin 100 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
41125411|NCT04264013|BEHAVIORAL|Exercise|Participants will exercise in a supervised facility twice weekly and consume their habitual diet.
41125412|NCT04264013|BEHAVIORAL|Exercise plus diet (egg)|Participants will exercise in a supervised facility twice weekly and consume an addiitonal 4 eggs per day.
41125413|NCT05356676|OTHER|Isometrics|"Isometric neck extension -individuals will be taught to place their dominant hand posterior to their head at occiput. Then, they will be told to firmly push the head backwards against that hand, and hold for five seconds and repeat 5 times. • Participants will be asked to place the right hand flat on the same side of the head. Next.~they will be instructed to firmly push the head against right hand and hold for 5 seconds and repeat five times. Same exercise will be repeated with the left hand against the left side of the head as well.~• Participants will be taught to place their right hand on their right cheek. Then, they will be told to rum the face against the right hand and wait for 5 seconds and repeat five times. Same exercise was repeated with the left hand on the left cheek as well."
41125414|NCT05356676|OTHER|Combination Therapy|"1. In supine position, the patient will be instructed to take a deep breath in order to relax the body whilst holding his/her shoulders and neck in a comfortable posture.~2. the patient will bend his/her knees and place their feet flat on the floor, and will hold the posture without any other neck movement. Then the patient will be asked to raise their dominant arm to 90° shoulder flexion along with full elbow extension and scapular protraction.~   This posture will be held for 10 seconds before returning to the prior position with 3 laps, 10 repetitions with a one-minute break between.~3. in quadruped position, the patient will lift up their arms alternatively with shoulder abduction and 120 ° flexion. This posture will be held for 10 seconds before returning to the starting position for three laps, 10 repetitions with a 30-second break in between. Participants will be instructed to perform these for 3 times a week for 4 weeks."
41125415|NCT01226849|DRUG|bortezomib, rituximab, ifosphamide, etoposide, carboplatin|Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
41276626|NCT02610985|DEVICE|2-D laparoscopy|2-D laparoscopy
40928041|NCT05724043|DEVICE|SmartJournal|SmartJournal is a tablet application with three modules: Module 1 offers a system for simple check-box registration of daily oral hygiene routines. This module also includes an open text field where the caregiver can give a brief description of strategies used if the patient shows resistant behaviors. Module 2 offers a system for monitoring the patient's oral health through monthly check-ups. This module is an image-based, interactive learning- and assessment tool. Upon completion of the monthly oral health assessment health personnel receive a summary report with suggestions for tailored preventive and/or curative measures to be initiated. Module 3 offers an easily accessible knowledge base which includes information on geriatric oral health, standard equipment and procedures for daily oral hygiene routines for patients with various care needs. It also includes scientifically documented strategies that may be used to approach patients with dementia refusing oral care assistance.
41447348|NCT00429416|DRUG|Cyclophosphamide|Cyclophosphamide 1gm/m2 prior to HSCT infusion
41447349|NCT00429416|DRUG|Tacrolimus|Tacrolimus given before and after HSCT infusion
40928042|NCT03492840|DRUG|RZL-012|The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites
41276627|NCT01966510|OTHER|Cord Blood Transplantation|
41447350|NCT00429416|DRUG|Mesna|Mesna 1gm/m2/day given prior to HSCT infusion.
41447351|NCT00429416|BIOLOGICAL|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF given post HSCT infusion
41276628|NCT04767425|RADIATION|Brachytherapy|• 3D image-based cervical cancer brachytherapy will be delivered as 4 sessions x 7 Gy High Dose Rate (HDR) brachytherapy
41276629|NCT01608152|BEHAVIORAL|Focus Group|Attend a focus group
41276630|NCT01608152|OTHER|Internet-Based Intervention|Have access to the game
41276631|NCT01608152|BEHAVIORAL|Interview|1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
41447352|NCT00429416|PROCEDURE|Hematopoietic stem cell transplantation (HSCT)|CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
40928043|NCT01251640|DRUG|BAY86-9766+Gemcitabine|Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
41125416|NCT03465813|BEHAVIORAL|CaringGuidance After Breast Cancer Diagnosis|CaringGuidance After Breast Cancer Diagnosis, psychoeducational, Internet-accessible program
41125417|NCT06142357|OTHER|Secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription will be enrolled
41125418|NCT05278533|DIETARY_SUPPLEMENT|BioPlete™ Advanced Formula|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
41125419|NCT05278533|DIETARY_SUPPLEMENT|Placebo|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
41125420|NCT05166590|BEHAVIORAL|Sleep Restriction|Sleep Deprivation
41125421|NCT05178459|DIAGNOSTIC_TEST|Neuropathy measurement|Patient will step on Withings WBS08 and on the Sudoscan to get their sudomotor dysfunction caused by the neuropathy evaluated.
41125422|NCT05298813|BIOLOGICAL|IBIO123|IBIO123 1 mg, 5 mg and 10 mg
41447353|NCT06623227|DIETARY_SUPPLEMENT|Placebo|Capsule contains substances that are safe, non-active, and commonly used in pharmaceuticals (microcrystalline cellulose) with an appropriate coloring dye and in the active arms, Vitamin E and C. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
41125423|NCT05298813|OTHER|Placebo|Matching Placebo
41125424|NCT01808534|DRUG|palifosfamide|Given IV
41125425|NCT05452902|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
41447354|NCT06623227|DIETARY_SUPPLEMENT|Vitamin E and C|Capsule Vitamin E (Natural Vitamin E, d-alpha tocopherol) 150 IU or 200 IU containing also Vitamin C 100 mg or 200 mg b.id depending on age. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
41447355|NCT04184167|OTHER|intermittent fasting 4 months before ICSI|women will start intermittent fasting before starting ICSI by 4 months
40928044|NCT03303027|DEVICE|6-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 6-0
40928045|NCT03303027|DEVICE|5-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 5-0
41125426|NCT05452902|BEHAVIORAL|Nutrition Education|12 weeks of implementing eating tips and tracking food.
41125427|NCT03865199|BEHAVIORAL|Narrative Intervention|"Participants in the intervention group will first view a digital story on a tablet with headphones that will combine a fictional patient's abortion story with basic medical and social facts regarding abortion. After viewing the narrative, participants will be asked to write a narrative either on a tablet provided or on paper with the prompt: Patients have different thoughts and feelings about their experiences when they have this procedure. Tell a story (about yourself or someone else, real or imaginary) that might help another patient feel supported."
41125428|NCT00243503|DRUG|SU011248/Trastuzumab|SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
41447356|NCT06626698|OTHER|Static stretching|A passive static stretch of the posterior leg muscles will be performed with the subject in a supine position and knees extended, starting with the ankle at 90º and continuing until reaching the maximum tolerated dorsiflexion.
40928046|NCT01185834|DEVICE|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
41125429|NCT06282107|PROCEDURE|BiSAAE|SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into bilateral adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines
41125430|NCT06282107|PROCEDURE|traditional triple antihypertensive treatment|traditional triple antihypertensive treatment
41125431|NCT02162225|DRUG|beet juice (Unbeetable)|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
41125432|NCT03216213|OTHER|Frame|Vignette is framed in a way that nudges participant to leave a legacy
41125433|NCT03216213|OTHER|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
41447357|NCT06626698|DEVICE|Electrical muscle elongation|The intervention will be performed with the subject in a supine position with knees extended. Electrodes will be placed on the gastrocnemius muscles of the leg being assessed. The parameters will be selected. Static stretching will begin until resistance is felt, at which point the intensity of the electrical current will be increased to induce a visible and tolerable contraction. Simultaneously, the subject will be asked to perform an isometric contraction of the antagonist muscles, resisted by the investigator. When the subject feels the stretch again, the intensity of the current will be increased once more until a new movement barrier is reached.
41447358|NCT01212276|DRUG|MORAb-028|Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
41447359|NCT00027053|DRUG|Trazodone|50 to 150 mg qhs
41447360|NCT00027053|DRUG|Placebo|
41447361|NCT04093570|DRUG|ASTX727|ASTX727 film-coated, immediate-release FDC tablets
41447362|NCT00205777|DRUG|Bazedoxifene Acetate|BZA 20mg, daily, oral
41447363|NCT00205777|OTHER|Placebo|Placebo, daily, oral
40928047|NCT01257360|DRUG|Panitumumab|Panitumumab 6 mg/kg BW will be administered IV every 2 weeks (q2w) on day -14, 1, 15, 29 (and 43, in case radiotherapy is still ongoing due to delays) of the radiotherapy.
40928048|NCT01257360|RADIATION|Radiation of the pelvis|Radiation is applied at single doses of 1.8 Gy at the ICRU 50 reference point, once daily, five times a week, adding up to 28 fractions over almost 6 weeks and a total reference dose of 50.4 Gy.
40928049|NCT01618812|PROCEDURE|Lateral lengthening osteotomy of calcaneus|Use of artificial bone graft
40928050|NCT00208546|DRUG|21Capecitabine + bevacizumab + oxaliplatin|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
40928051|NCT00208546|DRUG|1Capecitabine + oxaliplatin + bevacizumab + cetuximab|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
41447364|NCT01015703|BIOLOGICAL|CoVaccine HT|intramuscular injection, dose escalation
41447365|NCT03595800|PROCEDURE|Hematopoietic stem cells transplantation|Allogeneic Hematopoietic stem cells transplantation
40928052|NCT04633408|BEHAVIORAL|STAR-C Virtual Training and Follow-up (STAR-VTF)|STAR-C Virtual Training and Follow-up (STAR-VTF) is adapted from an evidence-based, in-person program that trains family caregivers to manage BPSD (behavioral and psychological symptoms of dementia)
41447366|NCT06154408|DIETARY_SUPPLEMENT|omega-3 fatty acids|The active treatment, supplied by Soloways, LLC., contained omega-3 fatty acids (1000 mg of fish oil, of which 600 mg were eicosapentaenoic acid and 300 mg docosahexaenoic acid) per capsule. The subjects will take 2 capsules daily.
41447367|NCT06154408|DIETARY_SUPPLEMENT|Placebo|placebo capsules identical in appearance, matched for color coating, shape, and size with omega-3 fatty acids capsule
40928053|NCT03120988|BIOLOGICAL|Lavage with Platelet Poor Plasma (PPP)|Lavage of 50cc PPP
41447368|NCT06475846|DRUG|HRS5580|HRS5580; low dose
41447369|NCT06475846|DRUG|HRS5580|HRS5580; middle dose
41125434|NCT02576275|DRUG|Duvelisib|Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles
41447370|NCT06475846|DRUG|HRS5580|HRS5580; middle dose
41447371|NCT06475846|DRUG|Ondansetron|Ondansetron
41447372|NCT06475846|DRUG|blank preparation|blank preparation.
41447373|NCT06559657|DEVICE|eKare Insight, imitoMeasure Mobile App, Visitrak|The wound size of the patients was measured with three different methods. Wound depth was measured using manual method and three-dimensional imaging devices.
41447374|NCT05114512|OTHER|RAPTOR protocol: hybrid in-person + telehealth physical therapy services|All participants will receive the RAPTOR intervention, which includes 2 in-person physical therapy visits and 8 telerehabilitation visits. Participants will attend an initial in-person PT evaluation to meet their provider, receive a hands-on assessment of their impairments and functional limitations, and receive instruction in an initial home exercise program. The remainder of their visits will be completed remotely, using a telerehabilitation platform. At the conclusion of care, the patient will return to the clinic for a follow-up assessment and training on their final home exercise program.
41125435|NCT02576275|DRUG|Placebo|Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
41447375|NCT01022879|PROCEDURE|vitrectomy|
41447376|NCT00486239|BEHAVIORAL|TLE Arm 1|Behavioral/cognitive testing
41447377|NCT00486239|BEHAVIORAL|Emotion Memory Test|Behavioral/cognitive Measure
41447378|NCT00486239|BEHAVIORAL|Emotion Memory Testing|Behavioral/cognitive testing
41447379|NCT00486239|BEHAVIORAL|Emotion Memory Testing|Behavioral/cognitive testing
41125436|NCT02576275|DRUG|Rituximab|IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
41125437|NCT02576275|DRUG|Bendamustine|IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
41276632|NCT06657014|OTHER|mind-mindedness|The Mind-Mindedness Training Intervention is a structured program designed specifically for primary caregivers of preschool-aged children (ages 4 to 7) who exhibit signs of social anxiety. This intervention is unique because it focuses on enhancing caregivers' understanding and responsiveness to their children's emotional and mental states through the concept of mind-mindedness.
41447380|NCT04632641|DEVICE|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|The Perclose ProGlide Suture-Mediated Closure System (SMC) will be used to close the vein access site(s) at the completion of the large-bore procedure in order to achieve hemostasis.
41447381|NCT04632641|OTHER|Figure 8 Suture - LARGE-BORE PROCEDURES|A figure 8 suture will be done as a closure strategy in order to achieve hemostasis in large-bore procedures.
41447382|NCT03192007|DEVICE|Magnetic Resonance Imaging|Investigate anatomic and functional characteristics of transplant kidneys using MRI
41447383|NCT04548830|PROCEDURE|Transbronchial cryobiopsy|After enrollment, and pre-treatment procedures are complete, patients will undergo flexible bronchoscopy with a therapeutic bronchoscope under general anesthesia via an advanced airway at Memorial Hospital in an inpatient or outpatient setting.
41447384|NCT00849576|DRUG|Regular Human Insulin|0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
41447385|NCT00849576|DRUG|Insulin Lispro|90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
41125438|NCT05512052|DEVICE|Hannah Cervical Cup (2 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (2 mm Delta) displaces the cervical tissue by 2 mm.
41447386|NCT00849576|DRUG|Insulin VIAject™ (75%)|75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
41447387|NCT00849576|DRUG|Insulin VIAject™ (90%)|90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
41447388|NCT06103812|DEVICE|Hyalo4 Skin Gel|The evaluation of performance and safety of Hyalo4 Skin Gel in the amelioration of bed wound appearance after 14 days of treatment.
41447389|NCT03516539|DEVICE|Group ML|Mcgrath videolaryngoscope
41447390|NCT03516539|DEVICE|Group DL|Macintosh laryngoscope
41447391|NCT06462027|DRUG|Packed Red Blood Cells (1 unit)|500 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
41447392|NCT06462027|DRUG|Packed Red Blood Cells (2 units)|1000 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
41447393|NCT06462027|OTHER|Saline|Control subjects will receive 500mL of normal saline intravenously.
41447394|NCT05785832|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM|The t:slim X2 insulin pump with Control-IQ technology 1.5 is derived from the commercially available t:slim X2 with Control-IQ, with additional features. It will be used with the Dexcom G6 CGM.
41125439|NCT05512052|DEVICE|Hannah Cervical Cup (4 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (4 mm Delta) displaces the cervical tissue by 4 mm.
41276633|NCT06644183|DRUG|Roginolisib|Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.
41447395|NCT05785832|DEVICE|Standard Therapy plus continuous glucose monitoring (CGM)|Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.
41447396|NCT01847495|DRUG|Irinotecan|40mg/m2 x 3-5 days
41447397|NCT01847495|RADIATION|CyberKnife|45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
41447398|NCT02916862|DIETARY_SUPPLEMENT|Soluble Corn Fiber (SCF) without Calcium|Participants will consume a supplement with 12 g/day of SCF for 12 months
41447399|NCT02916862|COMBINATION_PRODUCT|Soluble Corn Fiber (SCF) + Calcium|Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
41447400|NCT02916862|DIETARY_SUPPLEMENT|Placebo|Participants will consume a supplement without SCF or calcium carbonate for 12 months
41447401|NCT02916862|COMBINATION_PRODUCT|Placebo + calcium|Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
41447402|NCT04155450|OTHER|Extension Biased External Limb Loading Exercises|"Begin in the quadruped position and progress the intensity by~1. Flexing one upper extremity~2. Extending one lower extremity with a leg slide~3. Extending one lower extremity by lifting it off the mat~4. Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~   Progress to prone position:~5. Extending one lower extremity~6. Extending both lower extremity"
41447403|NCT04155450|OTHER|McKenzie Extension Exercise Protocol|"Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
41447404|NCT04155450|OTHER|Moist Heat|Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
41447405|NCT01065857|DRUG|Sodium picosulphate, light magnesium oxide and anhydride citric acid.|2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).
41447406|NCT01065857|DRUG|Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.|4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).
41447407|NCT05518123|DRUG|Rimegepant|Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase
41276634|NCT06644183|DRUG|Venetoclax|B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.
41276635|NCT06644183|DRUG|Rituximab|Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.
40928054|NCT05047627|BEHAVIORAL|Smartphone-Based Digital Intervention|The digital intervention will be a prototype, and the current trial will be used to continue to both develop and refine the intervention. The current intervention will be based on a combination of cognitive-behavioral principles. As with prior research, the mobile platform will be delivered via Qualtrics, a HIPAA compliant and mobile-friendly platform. The cognitive-behavioral therapy will be primarily based on components with strongest support in digital interventions. The app will continuously collect passive sensing data on patterns in 1) sleep duration and quality;(2) light (3) location; (4) movement (5) social contact including duration and frequency of incoming and outcoming calls and text messages; (6) screen time; and (7) heart rate variability; (8) sound levels captured through passively collected smartphone The platform will deliver interactive interventions where participants will view texts and images, and it will also allow user interaction.
40928055|NCT05640752|DIAGNOSTIC_TEST|2019 ESC guideline-determined diagnostic strategy|ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP ≤5% are classified into low risk group and ones with ESC-PTP ≥15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL ≥15% are classified into high risk group and ones with RF-CL \<15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
41276636|NCT06656377|BEHAVIORAL|exercise intervention|A total of 25 prediabetic adults of either gender will participate in the study they will engage in exercise at intensities of 50%, 60%, 70%, or 80% of their predicted maximum heart rate (PMHR). In duration they will exercise for 15, 30, 45 and 60 minutes, and in timing protocol they will exercise at various time points after having breakfast. Blood samples were collected at four time points i.e. at fasting, pre-exercise and post-exercise at 30 and 60 minutes to measure glucose, insulin, and C-peptide levels.
41276637|NCT03456011|OTHER|Battlefield Acupuncture|Battlefield Acupuncture gold semi permanent needles
41276638|NCT06656871|DIETARY_SUPPLEMENT|iron supplementation|The iron tablet group received iron supplementation (30 mg, 1 tablet/day of iron) for 4 weeks
41276639|NCT06656871|DIETARY_SUPPLEMENT|Biostimulated lettuce supplementation|the intervention group SwE lettuce group received lettuce biostimulated with Ecklonia Maxima algae (SwE lettuce, 100 grams/day) daily for 4 weeks
41276640|NCT06656403|DRUG|0.1% sodium hyaluronate|After baseline measurement, 0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
41276641|NCT03832387|DEVICE|Non-invasive mechanical ventilation|
41276642|NCT03832387|DEVICE|Continuous positive airway pressure|
41276643|NCT03832387|DEVICE|Venturi mask|
41276644|NCT03832387|DEVICE|Reservoir mask|
41276645|NCT06378827|DRUG|Dexmedetomidine|Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
41276646|NCT05832762|PROCEDURE|Endovascular treatment (EVT) + Best medical treatment (BMT)|"Endovascular treatment (EVT) in the experimental arm can be performed with any recanalization strategy based on the operator's choice, and anatomical and radiological situation: MT using aspiration or stent retriever, with or without stenting (CE-labelled) or angioplasty. In case of acute stenting, the use of antiplatelet drugs will be based on the operator's preference, anatomical situation, and risk of hemorrhage.~Best medical treatment (BMT) : Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies."
41276647|NCT05832762|PROCEDURE|Best medical treatment (BMT)|Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies.
41276648|NCT01961427|DIETARY_SUPPLEMENT|sodium nitrate|Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate
41276649|NCT01961427|DIETARY_SUPPLEMENT|Beetroot juice|concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
41276650|NCT02479347|DRUG|Chlorhexidine|Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
41276651|NCT02479347|DRUG|Povidone-Iodine|Preoperative skin preparation with povidone-iodine 10% aqueous solution
41276652|NCT02048904|DRUG|Sitagliptin|Sitagliptin 100 mg/day for 3 months
41125440|NCT05512052|DEVICE|Hannah Cervical Cup (6 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (6 mm Delta) displaces the cervical tissue by 6 mm.
41125441|NCT00823472|DRUG|Mild stimulation|Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
41125442|NCT06221059|DRUG|HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo|Drug：HRS-1780 tablet Drug：Henagliflozin Proline tablet Drug：HRS-1780 tablet placebo Drug：Henagliflozin Proline tablet placebo
41125443|NCT05758766|DIETARY_SUPPLEMENT|Plant-based omega-3-FA|Plant-based omega 3 Fatty Acids
41125444|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 10 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 10 µg)
41125445|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 10 µg|Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)
41125446|NCT04602975|BIOLOGICAL|Injection Adjuvanted Placebo|Intramuscular injection of Placebo with alhydrogel
41125447|NCT04602975|BIOLOGICAL|Injection Placebo|Intramuscular injection of the not adjuvanted Placebo
41125448|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 2 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 2 µg)
41125449|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 2 µg|Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)
41125450|NCT02076568|BEHAVIORAL|Education - Diabetes and Partnership|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Partnership was created. The module covers specific and detailed aspects of the topic partnership such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible."
41125451|NCT06480825|OTHER|Performance of ultrasonographic scan|Ultra-high frequency ultrasonographic scan of gingival tissues
41125452|NCT05048680|PROCEDURE|Hypoxia and/or Exercise|Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.
41125453|NCT01521169|OTHER|1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).|1 = Intervention with test product 1 (0,8g of plant sterol/day)
41125454|NCT01521169|OTHER|2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).|2 = Intervention with test product 2 (1,6g of plant sterol/day)
41125455|NCT01521169|OTHER|3 - low-fat dairy fermented product (drinkable) without plant sterols.|3 = Intervention 3 (1 control product/day)
41125456|NCT06150833|BIOLOGICAL|Boya IVIG|"The initial dose and other dose changes will be determined by the investigator on a case-by-case basis aiming to prevent infection and minimum serum IgG levels of 5 g/L. The total number of doses administered will depend on the treatment regimen and run-in period:~* Between 16 and 20 intravenous injections for participants receiving infusions every 28 days, or;~* Between 21 and 25 intravenous injections for participants receiving infusions every 21 days"
41125457|NCT05114967|OTHER|mPAS questionnaire|The modified Preoperative Anxiety Scale (mPAS) questionnaire as given in the article by Viola et al will be used after permission from the authors
41125458|NCT02118064|BIOLOGICAL|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes.
41125459|NCT04867824|DIETARY_SUPPLEMENT|Case (use of inhaled vanilla essential oil)|Use of inhaled vanilla essential oil during frenotomy for a tongue-tie
41125460|NCT04867824|DIETARY_SUPPLEMENT|Control (use of inhaled lavender essential oil)|Use of inhaled lavender essential oil during frenotomy for a tongue-tie
41276653|NCT02048904|DRUG|Placebo|Placebo 1 pill/day for 3 months
41276654|NCT03031561|DEVICE|Ultrasound|Undergo standard ultrasound
41276655|NCT03031561|DEVICE|MicoPure ultrasound|Undergo MicoPure ultrasound
41447408|NCT05518123|DRUG|Placebo|Matching placebo with every other day dosing during DBT phase
41447409|NCT02818751|DRUG|Escitalopram|Patients being randomized to receive escitalopram.
41447410|NCT02818751|OTHER|Placebo|Patients being randomized to receive placebo.
41125461|NCT03655262|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.
41125462|NCT03097679|DEVICE|Pulsar Stent|Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
41276656|NCT03031561|PROCEDURE|Biopsy of Breast|Undergo breast biopsy or surgical resection
41447411|NCT06006273|DRUG|Eribulin|Given by vein (IV)
41447412|NCT06006273|DRUG|Irinotecan|Given by vein (IV)
41447413|NCT06006273|DRUG|Temozolomide|Given by PO
41125463|NCT03097679|DEVICE|LifeStent Flexstar Vascular Stent|Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
40754467|NCT03807167|OTHER|Apathy diagnostic criteria|The clinical criteria make it possible to make a diagnosis of apathy with a functional repercussion. It is based on a lack of motivation felt by the patient, causing a functional or social impact that is not the consequence of a disturbance of consciousness or a disability engine. The cognitive, emotional and behavioral dimensions are affected.
41125464|NCT04534400|RADIATION|thoracic CT-scan|Automated measurement
41125465|NCT01535690|OTHER|photodynamic therapy and periodontal debridement|At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
41447414|NCT02332967|OTHER|Whey predominant starter formula|Milk powder product given to babies between 1 week and 4 months
41125466|NCT05262738|DRUG|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects will undergo cervical ripening with 50 micrograms of vaginal misoprostol every 4 hours.
41125467|NCT05262738|DRUG|25 Micrograms Vaginal Misoprostol (Control)|Subjects will undergo cervical ripening with 25 micrograms of vaginal misoprostol every 4 hours.
41125468|NCT06005857|OTHER|Standard hand therapy + home digital application-based exercises|Standard post-operative hand rehabilitation and home digital application-based exercises
41125469|NCT06005857|OTHER|standard hand therapy + home paper-based exercises|Standard post-operative hand rehabilitation and home paper-based exercises
41125470|NCT00134069|DRUG|sorafenib tosylate|Given orally
41125471|NCT00134069|DRUG|cetuximab|Given IV
41125472|NCT00134069|DRUG|irinotecan hydrochloride|Given IV
41125473|NCT05439395|DEVICE|Sternum Closure after Cardiac Surgery|Sternal closure using Steelex® Sternum Set after CABG or cardiac valve replacement / reconstruction.
41125474|NCT02460393|DRUG|Humanized TNFα monoclonal antibody|"Subcutaneous injection of different doses for healthy people~Subcutaneous injection of different doses in healthy people"
41125475|NCT02460393|OTHER|placebo|Subcutaneous injection of different doses for healthy people
41125476|NCT01894074|BEHAVIORAL|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
41125477|NCT01894074|BEHAVIORAL|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
41125478|NCT00084552|RADIATION|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
41447415|NCT02332967|OTHER|Whey predominant starter formula + 40% palmitic acid|Milk powder product containing 40% of palmitic acid
41447416|NCT02332967|OTHER|Whey predominant starter formula + 50% palmitic acid|Milk powder product containing 50% of palmitic acid
41447417|NCT00247195|BEHAVIORAL|Culturally Congruent Assessment and Treatment|Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
41125479|NCT00093496|DRUG|gemcitabine hydrochloride|Given IV
41125480|NCT00093496|DRUG|tanespimycin|Given IV
41125481|NCT03484910|OTHER|Exercise therapy|Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback
41125482|NCT02647905|DEVICE|Continuous Glucose Monitoring System|Accuracy and safety assessment of a continuous glucose monitoring device
41125483|NCT02515305|DRUG|Clindamycin and Benzoyl Peroxide Gel (combination)|
41125484|NCT02515305|DRUG|Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)|
41125485|NCT02515305|DRUG|Placebo gel (combination)|
41125486|NCT04379557|PROCEDURE|Catheter Ablation|Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
41125487|NCT05239650|DRUG|HLX07|1000mg
41125488|NCT05239650|DRUG|HLX10|200mg
41125489|NCT05239650|DRUG|mFOLFOX6|OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
41125490|NCT02355275|PROCEDURE|Home Exercise Program|All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
41125491|NCT02645942|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine 1400 mg daily for 8 weeks
41125492|NCT02645942|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 8 weeks
41125493|NCT01579916|BIOLOGICAL|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
41125494|NCT01579916|OTHER|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
41125495|NCT00083967|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
41125496|NCT01102673|DRUG|PF-04991532|The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
41125497|NCT01102673|DRUG|Placebo|Placebo to match PF-04991532 will be provided
41125498|NCT05614349|DRUG|Paxlovid|This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.
40928056|NCT05640752|DIAGNOSTIC_TEST|2016 NICE guideline-determined diagnostic strategy|For subjects assigned to NICE strategy, ones with nonanginal chest pain and normal ECG were classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG were classified into high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
40928057|NCT05570331|DIAGNOSTIC_TEST|HPV integration test|HPV-positive patients who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT.
40928058|NCT00838864|DRUG|ceftrioxone|500 mg iv q12h for 3 days
40928059|NCT00838864|DRUG|ceftrioxone|500 mg q12h for 7 days
41125499|NCT05614349|DRUG|Other|As this trial progresses, therapeutics for SARS-CoV-2 in out-patient settings to be evaluated will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee, which will evaluate the latest evidence on new therapeutics and makes recommendations to the Steering Committee.
40928060|NCT02085031|PROCEDURE|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.
40928061|NCT02085031|PROCEDURE|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
41125500|NCT05614349|OTHER|Other|As this trial progresses, therapeutics for SARS-CoV-2 in out-patient settings to be evaluated will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee, which will evaluate the latest evidence on new therapeutics and makes recommendations to the Steering Committee.
41276657|NCT04398901|OTHER|Neurodevelopmental assessments|The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.
41276658|NCT06458764|OTHER|Questionnaire|none, it's a incidence-prevalence study
40928062|NCT02924415|BEHAVIORAL|Tele-care support|Psychoeducation treatment based on telemedicine
40928063|NCT02924415|OTHER|Control group|Standard care
40928064|NCT04280809|DEVICE|GaAlAs laser|GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2. Each patient was irradiated 3 times consecutively right after surgery, day 1 and day 2 after surgery
40928065|NCT03829878|DRUG|CP101|Orally administered donor derived full spectrum microbiota
40928066|NCT03829878|DRUG|Placebo|Placebo for CP101
40928067|NCT06208956|DRUG|Dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy.
41276659|NCT02569515|DRUG|Epoetin Beta|Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
41276660|NCT02639377|DRUG|Chlorhexidine gluconate|
41276661|NCT02639377|DRUG|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
41447418|NCT02197195|DIETARY_SUPPLEMENT|Chocolate Milk|
41125501|NCT00972049|DRUG|AZD2516|Capsule administered once orally. Specific dose depends on dose panel.
41125502|NCT00972049|DRUG|Placebo|Capsule administered once orally
41125503|NCT00001958|DRUG|Hydroxyurea|
41125504|NCT03220100|OTHER|Stepped Palliative Care|Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
41125505|NCT06221436|BEHAVIORAL|Mental Imagery|"Olfactory mental imagery is the ability to detect an odor in the absence of any odor stimulus.~Participants will be asked to choose their 4 favorite fragrances from 20 different scents (such as rose, lavender scent) determined by the researcher and proven to have positive effects on mind-body therapy. The determined odors will be visualized by the researcher and picture cards measuring 15X12 cm (for example, a card with a rose picture for the rose smell, etc.) will be created. Participants will visualize the smell by looking at the picture cards, so they will be expected to make their breathing exercises more effective. Vagus breathing technique will be combined with olfactory mental imagery."
41125506|NCT02010944|DRUG|solifenacin succinate|oral
41125507|NCT02010944|DRUG|mirabegron|oral
41125508|NCT02010944|DRUG|mirabegron/solifenacin succinate|oral
41125509|NCT04670887|PROCEDURE|Delayed surgery|Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.
41125510|NCT04670887|PROCEDURE|Immediate surgery|Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
41125511|NCT02590432|DRUG|Linaclotide|Linaclotide capsules, orally, once daily.
41125512|NCT00739908|DRUG|CX157 (TriRima)|Six capsules administered three times a day for six weeks.
41125513|NCT00739908|DRUG|Placebo|Six capsules administered three times a day for six weeks.
41125514|NCT04751838|OTHER|no intervention|no intervention
41125515|NCT00409838|DRUG|Abatacept|Intravenous (IV) solution, - weight tiered (500 mg \<60 kg); (750 mg 60-100 kg); (1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
41125516|NCT00409838|DRUG|Methotrexate|Tablets, Oral, ≥ 15 mg, weekly, 6 months
41125517|NCT00409838|DRUG|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
41125518|NCT00409838|DRUG|Abatacept|Solution, intravenous, 10 mg/kg, every 28 days
41125519|NCT00409838|DRUG|Methotrexate|Tablets, oral, 15 mg weekly to be adjusted according to patient condition
41125520|NCT02846909|DRUG|Progesterone|400mg progesterone pessaries
41125521|NCT05758012|DRUG|oxytocin|Participants will be randomized to receive Oxytocin after delivery of the baby's head and shoulders
41447419|NCT02197195|DIETARY_SUPPLEMENT|Fruit Drink|
41125522|NCT05758012|DRUG|Carbetocin|Participants will be randomized to receive Cabetocin after delivery of the baby's head and shoulders
41125523|NCT00891332|DRUG|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
41125524|NCT02438059|BEHAVIORAL|SoSu-liv website and app|A 38 weeks web- and app-based tool for lifestyle changes intervention.
41125525|NCT01407458|OTHER|Upper Limb Exercises|Upper limb exercises
41447420|NCT02197195|BEHAVIORAL|Exercise|
41447421|NCT00078039|DRUG|Paliperidone ER|
41447422|NCT05181969|DEVICE|Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)|Lipoprotein apheresis Method I
41447423|NCT05181969|DEVICE|Lipid filtration (Octo Nova®, Diamed Medizintechnik)|Lipoprotein apheresis Method II
41447424|NCT05181969|DEVICE|Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)|Lipoprotein apheresis Method III
41447425|NCT05181969|DEVICE|Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)|Lipoprotein apheresis Method IV
41125526|NCT01407458|OTHER|Normal physical exercises|Exercises usually done by children in physical education classes
41125527|NCT00642850|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
41125528|NCT06349655|DRUG|Azvudine|Antiviral drug
41125529|NCT06349655|DRUG|Paxlovid|Antiviral drug
41125530|NCT01690572|DEVICE|Paclitaxel coated balloon catheter|Dilatation of the target lesion
41125531|NCT01690572|DEVICE|"uncoated balloon catheter sprinter legend"|Dilatation of the target lesion
41125532|NCT06371170|DRUG|Rivaroxaban|Oral anticoagulation
41125533|NCT03746470|PROCEDURE|ACL reconstruction preserving insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis, preserving their insertion at the level of the hamstring.
41125534|NCT03746470|PROCEDURE|ACL reconstruction detaching insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis tendons completely detached from their insertion at the hamstring.
41125535|NCT00684242|DRUG|Lenalidomide|10 mg by mouth daily
41125536|NCT01294956|OTHER|Lubricant Eye Drop|1 drop in each eye, four times a day for 42 days
41125537|NCT01294956|OTHER|Refresh Liquigel|1 drop in each eye, four times a day for 42 days
41125538|NCT03698084|PROCEDURE|venepuncture|sample collection for analysis
41125539|NCT03698084|PROCEDURE|nasopharyngeal swab|sample collection for analysis
41125540|NCT02378922|BIOLOGICAL|Gene-Modified HIV-Protected Hematopoietic Stem Cells|Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
41447426|NCT06627257|DRUG|LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose|2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
41447427|NCT06627257|DRUG|LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose|10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
41447428|NCT06627257|OTHER|Placebo Comparator: Placebo|Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
41447429|NCT01079845|BEHAVIORAL|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
41447430|NCT04112823|DRUG|Dexamethasone 4mg|Dexamethasone 4mg + metoclopramide 10mg, intravenously
41447431|NCT04112823|DRUG|Dexamethasone 16mg|Dexamethasone 16mg + metoclopramide 10mg, intravenously
41447432|NCT05224531|DRUG|CS1 Administration|CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
41447433|NCT04988464|BEHAVIORAL|Sleep Scholar|A single-session, internet-based insomnia intervention for college students
41125541|NCT02378922|OTHER|Laboratory Biomarker Analysis|Correlative studies
41125542|NCT02378922|OTHER|Transplant Conditioning|Undergo high-dose chemotherapy or chemoradiotherapy
41276662|NCT02119611|DEVICE|Deep Brain Stimulation management|The DBS surgery will be performed according to standard of care in the centers of referral. If performed at the NIH, this will be done under protocol 11-N-0211 or other protocols permitting DBS surgery depending on future availability.
41276663|NCT06657326|DEVICE|BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent|Stent implantation
41447434|NCT04988464|BEHAVIORAL|Building Healthy Habits|A single-session, self-guided, internet-based intervention focused on healthy eating and exercise
41447435|NCT05025527|DIAGNOSTIC_TEST|biparametric MRI (bpMRI)|Men go for the bpMRI for PCa (prostate cancer) screening, those who had a suspicious result will go for the next confirmation test
41125543|NCT01401023|DRUG|Tigecycline|: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
41125544|NCT03224858|OTHER|SUMMIT intervention|See description in experimental arm.
41125545|NCT03224858|OTHER|Enhanced usual care|See description in active comparator arm.
41447436|NCT05025527|DIAGNOSTIC_TEST|Prostate cancer antigen (PSA)|Men go for the PSA test for PCa screening, those who had a suspicious result will go for the next confirmation test
41447437|NCT00240032|DRUG|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
41447438|NCT00240032|DRUG|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
41447439|NCT01462279|DRUG|Thiamine|200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
41276664|NCT06657326|DEVICE|BioFreedom™ stainless steel Biolimus A9™-coated stent|Stent implantation
41125546|NCT02240420|BEHAVIORAL|Life Style Counseling (Star-Mama)|"Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources"
41125547|NCT01219790|RADIATION|external radiotherapy|All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
41125548|NCT01219790|DRUG|Acide zoledronic|The administration of zoledronic acid as defined under the Authorisation on the Market.
41447440|NCT05715463|OTHER|Resource sheets|Arm 1 is the control arm which will receive the standard of care resource sheets. Patients in this arm will receive cultivated resource sheets for any SDoH-related needs that they screen positive for or request additional information on.
41447441|NCT05715463|OTHER|Community Resource Specialist|The CRS will help guide patients to the necessary community-based resources to help address their specific SDoH needs that impact their health and their ability to access sustained, high quality medical care. This may include forms to arrange for subsidized transportation to and from medical appointments or applications for Section 8 housing. The community resource specialist will reach out to patients in Arm 2 a minimum of 2 times per month, with more interactions guided by patients needs. All outreach attempts and contacts will be documented in EPIC and in REDCap. Actions taken by the CRS will be shared with members of the patient's healthcare team as appropriate (with EPIC notes routed to the rheumatologist and primary care provider, and if indicated and relevant, a social worker, nutritionist, prior CRS, nurse or mental health provider if previously involved in the patient's care).
41447442|NCT05715463|OTHER|Nurse Navigator|The nurse navigator will both work with the CRS to connect the patient with community-based resources, independently connect the patient with relevant resources, and also help coordinate the patient's medical care and mental health needs. The nurse patient navigator will conduct her own needs assessment (the nurse navigator high risk assessment questionnaire at the time of the first conversation with the patient, originally developed as part of the MGB integrated care management program) and her actions will be guided by their responses. She will reach out to patients a minimum of 2 times per month with an increase in communication around patient appointments as reminders, and more frequent communication on a case-by-case basis depending on active illnesses, frequency of outpatient appointments, and needs of the patient. All outreach attempts and contact will be documented in EPIC and in REDCap and similar to the CRS, be shared via EPIC with the care team as indicated.
40928068|NCT06208956|DRUG|Propofol|Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reach 3. During the whole process, propofol is given intermittently to maintain Ramsay score 3 to 4. If body movement happen, propofol 10mg will be administrated every time.
40928069|NCT02261025|DRUG|acetylsalicylic acid|75-100mg,per day
40928070|NCT03787381|DEVICE|Ultrasound|Vaginal ultrasound examination
40928071|NCT03758885|DRUG|Nolasiban|Nolasiban single oral administration
41125549|NCT04010435|DEVICE|repetitive transcranial magnetic stimulation|high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere.
41125550|NCT04010435|DEVICE|Galvanic stimulation|galvanic stimulation of the vestibular apparatus
41447443|NCT05248711|BEHAVIORAL|Calm Daily Move|The Daily Move is a series of short, 5-min videos outlining mindful movement exercises. The Daily Move is part of the Calm app's library of content.
41447444|NCT02412358|DEVICE|toothbrush|
41125551|NCT04098575|DRUG|Empagliflozin|drug
41125552|NCT03420196|OTHER|Supervised exercise program|"It will consist in a supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium"
41125553|NCT03420196|OTHER|Non supervised exercise program|"It will consist in a non supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium"
41125554|NCT01408394|DRUG|Ecopipam immediate release form|Tablet containing 100 mg of the immediate release form of ecopipam
41125555|NCT01408394|DRUG|90 mg controlled release form|This is the 90 mg controlled release form
41125556|NCT01408394|DRUG|180 mg controlled release form|This is the 180 mg controlled release capsule
41125557|NCT01595282|DRUG|Ketorolac|For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
41125558|NCT01595282|DRUG|Ibuprofen|For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
41125559|NCT03006367|DRUG|NFC-1 100 mg|
40754468|NCT03807167|OTHER|walking speed test|The patient is timed to walk 10m. A speed \<1m / sec is a criterion exclusion because it shows severe sarcopenia and constitutes a bias.
40754469|NCT03807167|OTHER|accelerometer presentation|accelerometer presentation and pose
41125560|NCT03006367|DRUG|NFC-1 200 mg|
41125561|NCT03006367|DRUG|NFC-1 400 mg|
41125562|NCT03006367|DRUG|NFC-1 800 mg|
41125563|NCT03697707|BIOLOGICAL|DCP-001|allogeneic dendritic cell vaccine
41125564|NCT06084572|OTHER|Questionnaires|FSSG \& BEDQ
41125565|NCT00257075|DRUG|Risperidone, oral tablets|
41125566|NCT00212251|BEHAVIORAL|moderate exercise and healthy, low-fat diet|
41125567|NCT00112034|DRUG|Methotrexate|
41447445|NCT03730363|DRUG|Pentamidine|Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.
41447446|NCT01794845|DRUG|Erbitux|Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.
40754470|NCT03807167|OTHER|data acquisition from the accelerometer|withdrawal of the accelerometer and data acquisition from the accelerometer
40928072|NCT03758885|DRUG|Placebo|Placebo single oral administration
41125568|NCT00112034|DRUG|IV methylprednisolone|
41125569|NCT01470300|OTHER|Energy density feeding study|In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit \& vegetables, decreased fat, added plain water).
41125570|NCT04545918|DEVICE|Follicle Clarity|Mask Region-based Convolutional Neural Network in Ultrasound Follicle Identification
41125571|NCT04736485|DRUG|perioperative treatment|FLOT + Spartalizumab
41125572|NCT04080141|DIAGNOSTIC_TEST|Multiple psychometric questionnaire|At the time of first contact (T0) only women were subjected to Hamilton's rating scale for depression (HRSD or HAM-D), Hamilton's rating scale for anxiety (HRSA or HAM-A), Beck Depression Inventory (BDI-II). At the follow up after 1 year from the first examination (T1) they were subjected to a questionnaire with multiple psychometric tests for mother and her partner. The female version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Beck Depression Inventory (BDI-II), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF). The male version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF).
41276665|NCT06327152|DRUG|Caffeine|"Infants randomized to receive caffeine will continue to receive caffeine at the current weight-based dose (which is the standard of care maintenance dose of 10-15 mg/kg/day) given every 24 hours. The weight-based dose calculated using the weight at the time of enrollment will be the weight-based dose used for the duration of the study. The dose will be weight adjusted every 7 days, starting on the day of enrollment. Caffeine will be given enterally, via nasogastric tube or by mouth.~The study drug (caffeine) will be administered for a maximum of 4 weeks. The study drug will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The study drug will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications."
41276666|NCT06327152|OTHER|Sterile Water Placebo|"Infants randomized to the placebo group will be given sterile water at an equivalent volume to the volume if caffeine were to be given, using the previous weight-based caffeine dose. The placebo will be given every 24 hours. The dose/volume will be weight adjusted every 7 days, starting on the day of enrollment. The placebo will be given enterally, via nasogastric tube or by mouth.~The placebo will be administered for a maximum of 4 weeks. The placebo will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The placebo will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications."
41276667|NCT04910217|PROCEDURE|Conventional rehabilitation|Patients will undergo conventional rehabilitation
41276668|NCT04910217|PROCEDURE|Leg/lower body exerciser device intervention.|Patients will undergo leg/lower body exerciser device therapy.
41276669|NCT04910217|PROCEDURE|Lokomat intervention|Patients will undergo therapy with Lokomat Pro FreeD device intervention.
41276670|NCT04990076|PROCEDURE|Hysterectomy|Surgery includes different types of hysterectomy: vaginal hysterectomy, total abdominal hysterectomy and laparoscopic or Robotic hysterectomy. The type of hysterectomy does not influence histological outcome, as long as the uterus is removed in one part (no power morcellation). Indications for surgery and the type of surgery are according to the departments' protocols. If the patient is deemed to be inoperable due to the extent of the disease, a representive biopsy (e.g. trucut biopsy) will be accepted if sufficiently motivated by the oncology team.
41276671|NCT06651567|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
41276672|NCT06651567|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
41276673|NCT04486560|DEVICE|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
41276674|NCT00762151|OTHER|Negative Control (Regular Toothpaste)|Regular Toothpaste
41276675|NCT00762151|OTHER|Positive Control (anti-plaque/anti-bacterial toothpaste)|Standard anti-plaque and anti-bacterial toothpaste
41276676|NCT00762151|DRUG|Prototype (AN0128 Toothpaste)|AN0128 Toothpaste
41447447|NCT01794845|DRUG|Taxotere|Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.
41447448|NCT01794845|RADIATION|Low Dose Fractionated Radiation Therapy|Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
40928073|NCT02853227|OTHER|digital photography|Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.
40928074|NCT03593473|DRUG|Intranasal Oxytocin|Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
41276677|NCT01661257|DRUG|Infliximab|
41447449|NCT02542254|DRUG|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
41447450|NCT02542254|DRUG|Ipratropium|40 micrograms ipratropium administered using a pMDI
40928075|NCT03593473|DRUG|Placebo|Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
40928076|NCT04174014|PROCEDURE|Recruitment manoeuvre|PEEP increment and decrement
41447451|NCT02542254|DRUG|RPL554|6 mg RPL554 administered using a nebuliser
41447452|NCT02542254|DRUG|Salbutamol matched placebo|Placebo pMDI
41447453|NCT02542254|DRUG|Ipratropium matched placebo|Placebo pMDI
41447454|NCT02542254|DRUG|RPL554 matched placebo|Nebulised placebo
41125573|NCT04080141|PROCEDURE|Clinical psychiatric examination|At the time of first contact (T0) only women were subjected to psychiatric clinical examination
41125574|NCT01376700|BIOLOGICAL|Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)|Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
41447455|NCT05594693|OTHER|Questionnaire|Electronic self-report questionnaires before and after integrative interventions, and monthly.
41447456|NCT05594693|OTHER|Physical Exam|Physical measures before and after integrative interventions, and monthly. Thoracic kyphosis will be measured with a non-invasive gravity dependent inclinometer (Isomed Inc.).
41447457|NCT06366750|BIOLOGICAL|barzolvolimab|subcutaneous administration
41447458|NCT06366750|OTHER|Matching Placebo|subcutaneous administration
41447459|NCT02750878|OTHER|Informational Handout|
41125575|NCT02247817|DEVICE|Hybrid CRT-D/P implantation|
41125576|NCT04444804|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Dosage at the discretion of the treating physician
41125577|NCT04444804|DRUG|LMWH and Phenprocoumon|Dosage at the discretion of the treating physician
41125578|NCT04256512|DEVICE|Medical Device Usage and Evaluation|Wear Elasto Gel Therapy Mittens and Foot Wraps
41447460|NCT03639181|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
41125579|NCT04256512|OTHER|Questionnaire Administration|Ancillary studies
41125580|NCT01178034|GENETIC|Calculate warfarin dose using demographic/genetic algorithm|Age, body weight and genetic to calculate warfarin dosage
41125581|NCT03829436|DRUG|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
41125582|NCT03829436|DRUG|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily
41125583|NCT03829436|DRUG|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
41447461|NCT00348543|PROCEDURE|laser treatment|
41447462|NCT02220049|DRUG|Bortezomib|
40754471|NCT03807167|OTHER|Apathy Evaluation Scale,|clinician version and near-helping version. It's a hetero rating scale from an interview semi structured by a trained clinician. It assesses cognitive, emotional and behavioral apathy than three items of various apathy. The total score ranges from 18 (total absence of apathy) to 72.
41125584|NCT03829436|DRUG|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
41125585|NCT04530149|DRUG|Acetaminophen|receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain
41125586|NCT04530149|DRUG|Bupivacain|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
41125587|NCT04530149|DRUG|Saline|The injection of saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
41125588|NCT01506934|DRUG|linifanib|"Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)~Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)"
41125591|NCT04164940|OTHER|Brief alcohol intervention|Brief alcohol intervention already implemented in daily routine by the individual hospitals.
41125592|NCT01676558|DRUG|131I-rituximab|
41447463|NCT03373643|DIAGNOSTIC_TEST|OSA screening|Full night polysomnography
41447464|NCT01712906|BIOLOGICAL|3.50±0.25logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
41447465|NCT01712906|BIOLOGICAL|4.25±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
41447466|NCT01712906|BIOLOGICAL|5.00±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
41447467|NCT01712906|BIOLOGICAL|0 logCCID50/ml|0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
41447468|NCT01712906|BIOLOGICAL|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
41447469|NCT04353362|DRUG|Ofloxacin|400 mg, 1 time per day for 5 days
41447470|NCT04353362|DRUG|Amoxicillin|500 mg, 3 times per day for 7 days
41447471|NCT04353362|DRUG|Metronidazole|500 mg, 3 times per day, for 7 days
41447472|NCT05630755|DRUG|DOR/ISL|DOR/ISL 100 mg/0.25 mg oral tablets once daily
41447473|NCT05630755|DRUG|BIC/FTC/TAF|BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
41447474|NCT05630755|DRUG|Placebo to BIC/FTC/TAF|0 mg oral tablets once daily
41447475|NCT05630755|DRUG|Placebo to DOR/ISL|0 mg oral tablets once daily
41447476|NCT00729976|DRUG|Ibuprofen suppository|5-10mg/Kg of ibuprofen
41447477|NCT00729976|DRUG|Ibuprofen Suspension|5-10mg/Kg
41447478|NCT05602766|DRUG|NGENLA (Somatrogon)|Dosage, Frequency: Refer to the latest package insert.
41125593|NCT04484675|DRUG|Milrinone inhalation|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
41125594|NCT04484675|DRUG|Milrinone infusion|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
41125595|NCT01837394|PROCEDURE|Block of the SN and ONP|7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
41125596|NCT01837394|PROCEDURE|Placebo block|7.5 ml of isotonic saline solution 154 mmol/l injected at each site
41125597|NCT01837394|DRUG|Paracetamol|
41125598|NCT01837394|DRUG|Morphine|5 mg as needed
41125599|NCT01837394|DRUG|Ondansetron|4 mg i.v. as needed in the PACU
41125600|NCT01837394|DRUG|Metoclopramide|10 mg tablet as needed in the postoperative period after discharge from the PACU
41125601|NCT04890067|OTHER|Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
41125602|NCT04704258|PROCEDURE|TAVI (Transcatheter Aortic Valve Implant)|Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures
41125603|NCT04704258|DEVICE|FLOWer Embolic Protection System|FLOWer Embolic Protection System
41125604|NCT02075736|PROCEDURE|KTP laser|
41125605|NCT02075736|PROCEDURE|TUR-P|device
41125606|NCT01693211|DEVICE|Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)|Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
41125607|NCT01693211|DEVICE|Manual (CCC technique with Utrata forceps)|Capsulorhexis and pre-fragmentation are performed manually.
41125608|NCT04762758|DRUG|(RS)-baclofen, naltrexone hydrochloride and D-sorbitol|oral fixed dose combination
41125609|NCT04762758|DRUG|Placebo|liquid oral solution
41125610|NCT02376790|DRUG|Etanercept|Etanercept was administered by subcutaneous injection once a week
41125611|NCT02376790|DRUG|Methotrexate|Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.
41125612|NCT02376790|DRUG|Placebo to Etanercept|Placebo to etanercept was administered by subcutaneous injection once a week.
41125613|NCT02376790|DRUG|Placebo to Methotrexate|Placebo to methotrexate capsules taken orally once a week.
41125614|NCT04773678|DRUG|CBP-201|CBP-201 subcutaneous (SC) injection.
41125615|NCT04773678|DRUG|Placebo|Placebo subcutaneous (SC) injection.
41125616|NCT05050799|DEVICE|Central Venous Access|The Surfacer® Inside-Out® Access Catheter System is intended to obtain central venous access to facilitate catheter insertion into the central venous system for patients with upper body venous occlusions or other conditions that preclude central venous access by conventional methods.
41125617|NCT01510717|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
41125618|NCT01510717|DEVICE|AcrySof® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
41125619|NCT00003222|BIOLOGICAL|aldesleukin|Systemic subcutaneous delivery of low-dose IL-2.
41125620|NCT00003222|BIOLOGICAL|gp100 antigen|
41125621|NCT00003222|BIOLOGICAL|incomplete Freund's adjuvant|
41125622|NCT00003222|BIOLOGICAL|sargramostim|
41125623|NCT00003222|BIOLOGICAL|tetanus peptide melanoma vaccine|
41125624|NCT00003222|BIOLOGICAL|tyrosinase peptide|
41125625|NCT02182336|DRUG|BI 201335 NA|"1. 480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10~2. 240 mg BI 201335 NA bid from day 11 to 23"
41125626|NCT02182336|DRUG|Caffeine|days 1, 10 and 19
41125627|NCT02182336|DRUG|Warfarin sodium|days 1, 10 and 19
41125628|NCT02182336|DRUG|Vitamin K|days 1, 10 and 19
41125629|NCT02182336|DRUG|Omeprazole|days 1, 10 and 19
41125630|NCT02182336|DRUG|Dextromethorphan hydrobromide|days 1, 10 and 19
41125631|NCT02182336|DRUG|Midazolam HCl solution|Days 3 and 21
41125632|NCT02182336|DRUG|Midazolam HCl oral syrup|days 1, 10 and 19
41125633|NCT02182336|DRUG|Digoxin|Days 2 and 20
41125634|NCT05229835|OTHER|Time restricted eating and exercise|We apply time restricted eating, exercise alone and combined
41125635|NCT02813369|DRUG|naloxegol|non-interventional study where patients are exposed to naloxegol during normal clinical practice
41125636|NCT02813369|DRUG|non-PAMORA laxative|non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
41125637|NCT04279366|BEHAVIORAL|Lifestyle intervention|The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
41125638|NCT00529789|DRUG|duloxetine|20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is \>40 kg, initial dose is 30 mg, then titrated up.
41125639|NCT04870749|DIAGNOSTIC_TEST|IPP,IPSS,VPSS|Prostate volume, IPSS, VPSS and IPP were determined after urological examinations of the patients.
41125640|NCT01919450|DRUG|Regadenoson|Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
41125641|NCT01919450|RADIATION|Rubidium-82|Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
41447479|NCT04942535|BEHAVIORAL|Social Incentive Gamification|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Each participant signs a pre-commitment contract. Participants are entered into a game with their family members. Each family receives 70 points weekly. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family keeps its points; if not, they lose 10 points. The participant is notified the following day if they were the family rep.~At the end of the week, if the family has 40 points or more, they advance 1 level. If they have less than 40 points, the family drops down 1 level. Each family team starts in the middle of 5 levels.~At the end of the intervention, families in the top 2 levels receive a small gift.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
41447480|NCT04942535|BEHAVIORAL|Social Goals through Incentives to Charity|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Families select a charity at the beginning of the intervention. They are informed that $20 is available each week to be donated to a charity of their choice. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family gets credit for meeting their goal; if not, the entire family does not get credit. The participant is notified the following day if they were the family rep.~If the family achieves their goal on at least 4 of 7 days in a week, $20 is donated to charity.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
40928077|NCT04479462|PROCEDURE|total joint arthroplasty|The surgery includes primary, revision or partial joint arthroplasty.
41447481|NCT04942535|BEHAVIORAL|Daily Performance Feedback|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
41447482|NCT04164706|DEVICE|HumiGard device|HumiGard is a CE marked device that delivers warmed humidified CO2 during laparoscopic surgery
41447483|NCT04164706|OTHER|Standard care (with sham HumiGard device)|Standard methods of keeping the patient warm whilst in theatre, including warmed IV fluids, warming blankets/forced air warming devices.
41447484|NCT06040723|DEVICE|EndoMind|The EndoMind system is equipped with an AI model for predicting the Hill grade during gastroscopy.
41447485|NCT01386853|DRUG|Pitavastatin|2 mg QD
41447486|NCT01386853|DRUG|Atorvastatin|10 mg QD
41447487|NCT05651243|DIETARY_SUPPLEMENT|Ketone Ester Supplement|Oral ingestion of a ketone supplement combined with a flavoring agent and diluted in water
41447488|NCT05651243|OTHER|Placebo|Oral ingestion of cellulose combined with a flavoring agent and diluted in water
41447489|NCT06626165|DRUG|Mirikizumab|Mirikizmgab will be administered based on the result of Geboes score Grade ≥ 3.2.
41447490|NCT06626165|DRUG|Vedolizumab|Vedolizmab will be administered based on the result of Geboes score Grade 3.1.
41447491|NCT01954277|DEVICE|Electroacupuncture|Eletroacupuncture performed using acupuncture needles.
41447492|NCT01954277|DEVICE|Placebo Sham|Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
41447493|NCT01160796|DRUG|placebo|1x14-day course of treatment during 4 cycles
41447494|NCT01160796|DRUG|Lcr35®|1x14-day course of treatment during 4 cycles
40928078|NCT05060809|DRUG|oral vitamin k1 (phylloquinone)|The enrolled patients received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session to ensure compliance. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) before and 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by a semi-quantitative grading system developed by Kauppila.
40928079|NCT03643978|OTHER|Decision aid|The decision aids aim to inform the patients about the diagnosis and the treatment options. They aim to help the patient prioritize and make an informed decision.
41447495|NCT01894802|DEVICE|Implantation of CRS Arrays|Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
40928080|NCT06036446|PROCEDURE|Cervical cerclage|Transvaginal cervical cerclage placed between 24 0/7 - 26 6/7 weeks of gestation.
41125642|NCT00710775|PROCEDURE|surgical replacement of the aortic stenotic valve|Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
41125643|NCT01646749|DIETARY_SUPPLEMENT|Differences in protein content (En%) of meals|The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
41125644|NCT04680845|BEHAVIORAL|Self-affirmation|According to self-affirmation theory (Steele, 1988), defensiveness arises because people are motivated to defend their global sense of self-worth, which in the present case is threatened by perceptions of hearing aids/loss. However, if a person's self-image can be bolstered (affirmed) in a domain that is important to them, thereby preserving self-integrity, the individual should be less likely to process the threatening (i.e., stigmatizing in the present context) information defensively (Steele, 1988).
41125645|NCT03718013|DEVICE|accelerated deep TMS|subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks
40928081|NCT06036446|DRUG|Vaginal Suppository Progesterone|Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
41125646|NCT03718013|DEVICE|standard deep TMS|standard deep TMS treatment: once a day, during 4 weeks
41125647|NCT01643538|BEHAVIORAL|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
41447496|NCT00467597|DRUG|Levodopa (delivered intravenously)|"IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit."
41125648|NCT01643538|BEHAVIORAL|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
41447497|NCT00491192|DRUG|Diclofenac|
41447498|NCT05848713|DRUG|Heparin|"Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.~Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement."
41447499|NCT02839252|BEHAVIORAL|Iggy and the Inhalers Asthma Education for Kids|It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
41447500|NCT05547737|DRUG|Camrelizumab|Cross - line treatment of Camrelizumab in non-small cell lung cancer
40928082|NCT00537901|RADIATION|First-Line Bevacizumab and Chemotherapy|Chemotherapy
40928083|NCT00537901|DRUG|Bevacizumab|Chemotherapy
40928084|NCT01289782|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
40928085|NCT01289782|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
41125649|NCT01643538|BEHAVIORAL|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
41125650|NCT01643538|BEHAVIORAL|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
41125651|NCT03928522|DRUG|hand mixed vancomycin|hand mixed vancomycin powder into cement
41125652|NCT03928522|DRUG|hand mixed tobramycin|hand mixed tobramycin into cement
40928086|NCT01289782|DRUG|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
40928087|NCT01289782|DRUG|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
40928088|NCT06129513|BEHAVIORAL|Bilateral resistance exercise|A bout of bilateral resistance exercise consisting of barbell back squat, leg leg press and leg extension
40928089|NCT06129513|DIETARY_SUPPLEMENT|Whey protein|Following execution of bilateral resistance exercise, participants will ingest 32 g protein from whey protein isolate
40928090|NCT06129513|DIETARY_SUPPLEMENT|Plant-blend protein|Following execution of bilateral resistance exercise, participants will ingest 32 g protein from plant-blend protein isolate
41125653|NCT03928522|DEVICE|pre-mixed tobramycin|this cement is already pre-mixed with tobramycin
40928091|NCT00320359|DRUG|Intravenous topotecan/cisplatin|"Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.~Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan."
41447501|NCT03725345|BEHAVIORAL|MRI Scanner|Participants will enter the MRI scanner and complete a series of computer tasks that include noise blasts while undergoing brain scans that measure the structure and function of the brain
41125654|NCT00623194|DRUG|insulin detemir|Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
41287276|NCT04954846|DIETARY_SUPPLEMENT|OMNi-BiOTiC SR-9|"The Probiotic contains the following ingredients:~Maize Starch, Maltodextrin, Inulin, Potassium Chloride, Hydrolysed rice protein, Magnesium Sulphate, Fructooligosaccharides, Amylase, Manganese Sulphate~Additionally, the following bacterial strains are included:~Lactobacillus Casei W56, Lactobacillus Acidophilus W22, Lactobacillus Paracasei W20, Bifidobacterium lactis W51, Lactobacillus salivarius W24, Lactococcus lactis W19, Bifidobacterium lactis W52, Lactobacillus plantarum, Bifidobacterium bifidum W23"
41447502|NCT02533466|OTHER|Sodium fluoride + potassium nitrate|Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
41447503|NCT02533466|OTHER|Potassium nitrate|Experimental toothpaste containing 5% potassium nitrate
41447504|NCT03428880|DRUG|Morphine|spinal morphine is done before cesarean section
41447505|NCT03428880|DRUG|Quadratus lumborum block|a US Block QLB is done after surgery
41447506|NCT06626139|DRUG|Psilocybin|Healthy participants will receive up to 25 mg psilocybin.
41125655|NCT00623194|DRUG|insulin aspart|Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
41125656|NCT00640159|DRUG|Zelapar|Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
41447507|NCT06626139|BEHAVIORAL|Context 1|Drug administration will take place in a context (Context 1) that is expected to modulate acute and post-acute drug effects.
41125657|NCT06264869|PROCEDURE|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)
41125658|NCT06264869|PROCEDURE|Interdental guided creeping technique (IGCT) and collagen membrane (CM)|Interdental guided creeping technique (IGCT) and collagen membrane (CM)
41125659|NCT02042703|DEVICE|anterior segment OCT|
41125660|NCT00491959|PROCEDURE|Cultured oral mucosa cell sheet transplantation|Cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area. Therapeutic contact lenses will be applied after surgery.
41125661|NCT04719026|OTHER|Full-mouth periodontal examination using computerised Florida probe|It is an observational study to investigate the prevalence of periodontitis in cases and controls.
41125662|NCT01730352|DRUG|H. pylori triple therapy|Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
41125663|NCT01153113|BIOLOGICAL|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 5x106 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
41125664|NCT01153113|BIOLOGICAL|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 1x107 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
41125665|NCT01635712|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
41125666|NCT02023346|BEHAVIORAL|surveys and cognitive tests|
41125667|NCT02586090|BEHAVIORAL|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
41125668|NCT02586090|BEHAVIORAL|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
41125669|NCT01438034|DRUG|kisspeptin 112-121|0.24 nmol/kg
41125670|NCT01438034|DRUG|GnRH|75 ng/kg
41125671|NCT00830934|PROCEDURE|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
41125672|NCT00830934|PROCEDURE|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
41276678|NCT05177484|DRUG|oral ferric maltol|The intervention group will commence a course of oral ferric maltol provided oral intake has recommenced and the control group will receive standard care. All patients will have blood tests checked again at day 3 and day 5 postoperatively if they remain as an inpatient. If they are found to be anaemic on either of these two blood tests they will, at this stage, enter their allocated treatment pathway. If a patient shows no evidence of anaemia on either day 2, 3 or 5 blood tests they will be withdrawn from the study. Patients will continue treatment according to their randomisation allocation until 12 weeks after the operation, at which point the patient attends a routine surgical outpatient follow-up clinic. During the outpatient visit the participants will undergo their final blood testing and questionnaire completion.
41447508|NCT06626139|BEHAVIORAL|Context 2|Drug administration will take place in a context (Context 2) that is expected to modulate acute and post-acute drug effects.
41447509|NCT06626139|DRUG|Placebo|Healthy participants will receive an inactive placebo.
41447510|NCT02330939|OTHER|Low fat- Low glycemic index meal|
40928092|NCT00320359|DRUG|Intravenous etoposide/cisplatin|"Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.~Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3."
41125673|NCT04826978|BEHAVIORAL|Auditory environment|Auditory environment
41125674|NCT00872872|DRUG|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
41125675|NCT04379869|DRUG|NNZ-2591|Single dose of NNZ-2591
41125676|NCT04379869|DRUG|Placebo|Comparator for double-blind MAD
41125677|NCT05820594|BIOLOGICAL|Intradermal BCG (bacillus calmette-guerin) vaccine AJV|Participants will receive a one off dose of BCG (bacillus calmette-guerin) Vaccine AJV which contains the Danish Strain of Mycobacterium bovis BCG at a dose of 6 - 24 x 105 CFU (three times the standard dose). This will be injected intradermally into the upper deltoid region.
41125678|NCT00377182|DRUG|Copegus|1000/1200mg po daily for 4 weeks
41125679|NCT00377182|DRUG|PEGASYS|180 micrograms sc weekly for 4 weeks
41125680|NCT00377182|DRUG|RO5024048 1500mg|1500mg po bid for 4 weeks
41125681|NCT00377182|DRUG|RO5024048 3000mg|3000mg po bid for 4 weeks
41276679|NCT03494283|BEHAVIORAL|Practice Behaviour|Improve and modify practice of the practicers and of the professionals who are framing to decrease the injury incidence.
41276680|NCT00121823|BIOLOGICAL|FP9 ME-TRAP|
41276681|NCT00121823|BIOLOGICAL|MVA ME-TRAP|
41276682|NCT05781048|DRUG|HRS-6209|HRS-6209
41447511|NCT02330939|OTHER|MUFA- Low glycemic index meal|
41276683|NCT05902728|DRUG|HLX208|Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fed state
41276684|NCT05902728|DRUG|HLX208|Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fast state.
41276685|NCT05902728|DRUG|HLX208|450 mg
41276686|NCT05902728|DRUG|HLX208|900 mg
41276687|NCT05902728|DRUG|Itraconazole 200 mg|200 mg
41276688|NCT05902728|DRUG|Rifampicin|600mg
41276689|NCT06351293|DEVICE|Defyne Treatment in Nasolabial Fold|Defyne will be injected into left or right nasolabial fold, per randomization.
41276690|NCT06351293|DEVICE|RHA3 Treatment in Nasolabial Fold|RHA3 will be injected into left or right nasolabial fold, per randomization.
41276691|NCT05507424|PROCEDURE|Prone Positioning|Newborn will be prone position for 30-60 seconds during delayed umbilical cord clamping
41276692|NCT05507424|PROCEDURE|Supine Positioning|Newborn will be supine position for 30-60 seconds during delayed umbilical cord clamping
41276693|NCT00896961|DRUG|EF5|
41276694|NCT00896961|OTHER|diagnostic laboratory biomarker analysis|
41276695|NCT00896961|OTHER|pharmacological study|
41276696|NCT04543500|OTHER|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
41276697|NCT03478826|OTHER|ILD|100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
41276698|NCT03478826|OTHER|Healthy|100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
41125682|NCT03582592|BEHAVIORAL|Fluid Distribution Timetable|It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
41125683|NCT04562675|BEHAVIORAL|LHA intervention|For the IG, a 4-hour lesson consisting of 4 chapters and leaflets was delivered over 4 weeks, with one chapter per hour per week. Each LHA visited the assigned mother in the IG four times in a 4-week period.
41125684|NCT04562675|OTHER|brochure-only|brochure-only for control group (CG)
40928093|NCT03273569|PROCEDURE|PDI-UC protocol|Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
41276699|NCT03478826|OTHER|Pneumonia|100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
41276700|NCT02031679|DRUG|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
41276701|NCT02031679|DRUG|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
41276702|NCT03963973|DRUG|RDN-929 oral capsule|low, medium and high dose
41276703|NCT03963973|DRUG|Placebo oral capsule|matching placebo dose
41276704|NCT05327062|DEVICE|CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment|"The following information and data will be obtained from the routine clinical work up of the patients: Patient demographics, cardiovascular medical history, and clinical examination; 12-lead ECG; Standard echocardiography; Computed tomography angiography for visualization of atria, ventricle, and coronary sinus.~Imaging data will be transferred to the cloud-based web-platform using a dedicated software provided by study sponsor. Data processing includes evaluating the quality of the data and calculation of various anatomical and electrical parameters, and identification of the target zone as a point in the target vein closest to the latest activation zone.~LV-lead location is based on the information provided by the dedicated software followed by visual X-ray based verification of anatomically suitable/most desirable position.~The patient will undergo CRT device implantation according to local protocols."
40928094|NCT05853731|DEVICE|Green light emitting diode|Green light therapy via light emitting diode (LED) in the 520 nanometers (nm) range at 4 lux intensity for up to 5 hours per day, as tolerated.
40928095|NCT05853731|DEVICE|White light emitting diode|Filtered white light via light emitting diode (LED) displayed for up to 5 hours per day, as tolerated
40928096|NCT02417493|BEHAVIORAL|Simulation of epinephrine self-injection|
41276705|NCT03702933|DIETARY_SUPPLEMENT|D-serine|dosage
41276706|NCT06656104|DEVICE|Reference strategy|Routine strategy based on the usual catheters and infusion systems used during the reference period
41276707|NCT06656104|DEVICE|Experimental strategy|EDELVAISS multi-infusion strategy as routine strategy during the experimental period
41276708|NCT00460993|DRUG|Lunesta|"Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4."
41276709|NCT06656572|GENETIC|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
41276710|NCT06656572|DIAGNOSTIC_TEST|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
41276711|NCT00073190|BEHAVIORAL|Osteoporosis Education|
41276712|NCT02149992|DIETARY_SUPPLEMENT|myo-inositol|myo-inositol, oral, 2g, twice a day for 5 days total
41447512|NCT02330939|OTHER|SAFA- Low glycemic index meal|
41447513|NCT02330939|OTHER|Low fat- High glycemic index meal|
41125685|NCT02127749|DRUG|Endotoxin|Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
41125686|NCT02127749|DRUG|Vancomycin, Metronidazole, Ciprofloxacin|ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
41125687|NCT01715194|DEVICE|Telemedicine intervention|Patients undergoing telemedicine intervention
41125688|NCT04025164|RADIATION|Hypofractionated Radiotherapy|daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week
41125689|NCT04025164|RADIATION|Conventional fractionated Radiotherapy|daily fractions, 2 Gy per fraction, five fractions per week
41125690|NCT02574611|DRUG|Neostigmine|
41125691|NCT02574611|DRUG|Glycopyrrolate|
41125692|NCT02574611|OTHER|Saline (Placebo)|
41125693|NCT02574611|DEVICE|High Resolution Colonic Manometry|
41125694|NCT02596919|OTHER|photography|photography of meibomian glands
41125695|NCT00275392|BEHAVIORAL|Vestibular rehabilitation|vestibular adaptation and substitution exercises
41125696|NCT00275392|BEHAVIORAL|Placebo|placebo vestibular exercises
41125697|NCT04840433|DEVICE|MACE|Using magnetically assisted capsule endoscopy to examine oesophagus and stomach
41125698|NCT01094184|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
41125699|NCT01094184|DRUG|Paclitaxel|Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
41125700|NCT01094184|DRUG|Docetaxel|Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
41125701|NCT05910203|OTHER|The effectiveness of education|Training will be provided on smoking cessation.
41125702|NCT01732120|PROCEDURE|Off-clamp partial nephrectomy|
41125703|NCT03807752|DIETARY_SUPPLEMENT|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
41125704|NCT03807752|DIETARY_SUPPLEMENT|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
41125705|NCT04255693|BEHAVIORAL|diet adherence|"This type of intervention is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his usual diet or it contained substantial changes."
41125706|NCT04255693|BEHAVIORAL|No diet adherence|"A-posteriori established intervention based on the examinations at the end-point"
41125707|NCT04255693|BEHAVIORAL|Change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data
41125708|NCT04255693|BEHAVIORAL|No change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data
41125709|NCT04255693|BEHAVIORAL|Use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes."
41125710|NCT04255693|BEHAVIORAL|No use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data."
41125711|NCT03848572|DIAGNOSTIC_TEST|Repetitive assessment of PRECISE-DAPT score|The PRECISE-DAPT score, which takes into consideration age, creatinine clearance, haemoglobin, white blood-cell count and previous spontaneous bleeding, will be reassessed every 3 months during the 12-month follow-up period
41125712|NCT01310348|DEVICE|whole-body vibration (WBV)|The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.
41125713|NCT01310348|DEVICE|WBV (Sham stimulation)|Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
41125714|NCT04027439|DRUG|Part A: RPL554|1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
41125715|NCT04027439|DRUG|Part B: RPL554|Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
41125716|NCT04027439|DRUG|Placebos|"Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A."
41125717|NCT03112135|DRUG|Tranexamic Acid|TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
41125718|NCT03112135|DRUG|Tranexamic Acid|Topical TXA 1 gm diluted in 200 ml saline
41125719|NCT03112135|DRUG|Adrenalin|Topical adrenaline 1 mg diluted on 200 ml saline
41125720|NCT02189434|OTHER|Serum procalcitonin lab draws|"Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.~These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients."
41125721|NCT05461313|OTHER|Constrained Liner|Subjects in this arm will receive a constrained liner with one of the following implants: Freedom Constrained Acetabular Liner (Zimmer Biomet), G7 Freedom Constrained Acetabular Liner (Zimmer Biomet) or Lubinus Acetabular Cup with a safety ring (LINK)
41125722|NCT05461313|OTHER|Dual Mobility|Subjects in this arm will receive a dual mobility cup with the following implant: Avantage Dual Mobility Cup (Zimmer Biomet)
41125723|NCT00231504|PROCEDURE|Blood samples|Blood samples
41125724|NCT01532388|BEHAVIORAL|eScreen|Web based self-monitoring of problematic alcohol and drug use.
41447514|NCT02330939|OTHER|MUFA- High glycemic index meal|
41287277|NCT04954846|DIETARY_SUPPLEMENT|Placebo|The Placebo contains no bacterial strains, only the prebiotic ingredients found in OMNi-BiOTiC SR-9.
41447515|NCT02330939|OTHER|SAFA- High glycemic index meal|
41447516|NCT03849651|DRUG|Cyclophosphamide|"Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.~intravenously (IV) once daily (QD) on day -9"
40928097|NCT06514534|DRUG|ABL001/Asciminib|"The study treatment for this clinical trial is an investigational drug called asciminib, which is marketed under the brand name Scemblix®. Asciminib is a compound that is being evaluated for its efficacy and safety in the treatment of the target condition.~The minimum dose of asciminib to be administered in this study is 200 mg, while the maximum dose is 400 mg. The dose is planned as 200 mg twice a day (BID).~The drug will be administered orally, allowing for convenient and non-invasive administration."
40928098|NCT04843436|DEVICE|Symani Surgical System|Robotically Assisted Microsurgery
40928099|NCT06370078|DRUG|Albumin Human|To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.
40928100|NCT00870233|BEHAVIORAL|online platform WEBCORE|Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
40928101|NCT00641316|PROCEDURE|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
41125725|NCT05989841|BEHAVIORAL|RISE Guide|Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.
41125726|NCT05989841|BEHAVIORAL|Relaxation Control|"Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention."
41125727|NCT04068272|DRUG|Bosentan|Eyedrop
41125728|NCT04068272|DRUG|Placebo|Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
41125729|NCT05089461|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV), 20 mg/m\^2. Solid tumors: every 3 weeks (q3w, 1 cycle), Lymphoma: every 4 weeks (q4w, 1 cycle).
41125730|NCT01630902|DRUG|Torrent's Felodipine Extended-Release Tablets|
41125731|NCT01125124|DRUG|Silver Nitrate|Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
41125732|NCT02109601|OTHER|Extensive bedside training for accessing patient portal|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
41125733|NCT02109601|OTHER|Limited bedside training on patient portal use.|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
41125734|NCT03003286|BEHAVIORAL|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.
41125735|NCT03003286|BEHAVIORAL|Parents and Teachers Supporting Students (PATSS)|The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
41447517|NCT03849651|BIOLOGICAL|Fludarabine|"Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.~fludarabine phosphate IV QD on days -8 to -4"
41447518|NCT03849651|DRUG|Thiotepa|Thiotepa is a cell-cycle nonspecific polyfunctional alkylating agent.
41447519|NCT03849651|DRUG|Melphalan|"Melphalan, a derivative of nitrogen mustard, is a bifunctional alkylating agent. Melphalan is active against tumor cells that are actively dividing or at rest.~melphalan IV QD on days -2 to -1"
41447520|NCT03849651|BIOLOGICAL|G-csf|G-csf (granulocytic colony stimulating factor), is a biosynthetic hematopoietic agent that is made using recombinant DNA technology in cultures of Escherichia coli. G-CSF stimulates production, maturation and activation of neutrophils. In addition, endogenous G-CSF enhances certain functions of mature neutrophils, including phagocytosis, chemotaxis and antibody--dependent cellular cytotoxicity.
41447521|NCT03849651|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide. Following glomerular filtration, mesna disulfide is rapidly reduced in the renal tubules back to mesna, the active form of the drug.
41447522|NCT03849651|DEVICE|CliniMACS|Cells for infusion are prepared using the CliniMACS
41447523|NCT03849651|BIOLOGICAL|ATG (rabbit)|"Anti-thymocyte globulin is a purified, pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes.~rabbit anti-thymocyte globulin IV daily over 6 hours on days -5 to -3,"
40928102|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
40928103|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
40928104|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
40928105|NCT05356520|PROCEDURE|Endoscopy Ivor-lewis|Endoscopy Ivor-lewis
41125736|NCT03991416|BEHAVIORAL|Understanding Your Baby|Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.
41125737|NCT03991416|BEHAVIORAL|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
41125738|NCT00435318|PROCEDURE|Iontophoresis|
41125739|NCT00429338|PROCEDURE|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
41125740|NCT00429338|PROCEDURE|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
41125741|NCT03101371|DRUG|Catheter insertion with Povidone Iodine|The catheter will be treated with Povidone Iodine prior to insertion.
41276713|NCT02149992|DEVICE|Continuous glucose monitoring surveillance|monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
41276714|NCT02149992|DEVICE|Glucose monitoring|patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
41447524|NCT03849651|DRUG|Blinatumomab|"Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that mediates formation of a synapse between T cells and the CD19+ target cell, resulting in lysis of that CD19+ cell.Blinatumomab will be given to patients with a history of CD19+ malignancy as determined by St. Jude hematopathologist review of current and historical specimens and reports.~blinatumomab IV for 28 days beginning at least 1 week post-DLI"
41125742|NCT03101371|PROCEDURE|Standard of care catheter insertion|Catheter inserted right out of package.
41125743|NCT01828554|DRUG|Xeloda|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
41125744|NCT06358534|BEHAVIORAL|psychoeducation based on acceptance and commitment therapy|psychoeducation based on acceptance and commitment therapy prepared by the researchers was applied individually to the patients
41125745|NCT02564536|DRUG|Pacritinib|-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
41125746|NCT02564536|DRUG|Decitabine|-From commercial stock
41125747|NCT01367236|DRUG|standard care|"* atazanavir 300 mg daily~* ritonavir 100 mg daily~* tenofovir 245 mg daily\*~* emtricitabine 200 mg daily\*"
41125748|NCT01367236|DRUG|novel treatment|"* darunavir 800 mg daily~* ritonavir 100 mg daily~* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*~* maraviroc 150 mg once daily"
41125749|NCT01948024|DRUG|SAPHRIS|10 mg BID sublingual tablet
41125750|NCT01948024|DRUG|Asenapine|10 mg BID sublingual tablet
41125751|NCT03417479|OTHER|Gabapentin|
41125752|NCT05606484|OTHER|Exercise with non-immersive virtual reality|Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
41125753|NCT05606484|OTHER|Exercise with a static pedal|Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.
41125754|NCT02752230|PROCEDURE|Laparoscopic Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass
41125755|NCT02752230|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
41276715|NCT01486264|BIOLOGICAL|Xeomin®|Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
41276716|NCT06144008|BEHAVIORAL|Answering questionnaire|A questionnaires for each group has been developped and will be distributed for voluntary and anonymous completion.
41276717|NCT06286722|OTHER|Progressive, individualized and structured exercise program|See description under Arms
41276718|NCT06311578|DRUG|JNJ-87704916|JNJ-87704916 will be administered as an intratumoral injection.
41276719|NCT06311578|DRUG|Cetrelimab|Cetrelimab will be administered.
41276720|NCT04488822|DRUG|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
41447525|NCT03849651|BIOLOGICAL|TCRα/β+|IV on day 0 and may receive an additional dose on day 1
41447526|NCT03849651|BIOLOGICAL|CD19+|IV on day 0 and may receive an additional dose on day 1
41447527|NCT03849651|BIOLOGICAL|CD45RA-depleted DLI|infusion IV
40928106|NCT05356520|PROCEDURE|Laparoscopic transabdominal enlarged gastrectomy|Laparoscopic transabdominal enlarged gastrectomy
40928107|NCT04966910|BEHAVIORAL|Stay Connected|Stay Connected is a menu-driven set of strategies to combat loneliness, anxiety and depression in older adults based on behavioral activation principles.
40928108|NCT04966910|BEHAVIORAL|Treatment as usual|Regular check-ins, resource/referral provision
41447528|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Baseline|Before the study beginning, eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. A total of 150 days will be required for the equilibration of tracer in the body i.e. elimination from soft tissue and deposition in the bone. After equilibration, a baseline period of 42 days will occur, during which no blueberry products will be provided.
41447529|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Low|One food or beverage product containing freeze-dried blueberry powder equivalent to 0.75 cups of fresh blueberries will be provided daily for 42 days.
41447530|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Medium|Two food or beverage products containing freeze-dried blueberry powder equivalent to 1.5 cups of fresh blueberries will be provided daily for 42 days.
41447531|NCT02630797|DIETARY_SUPPLEMENT|Blueberry High|Four food or beverage products containing freeze-dried blueberry powder equivalent to 3 cups of fresh blueberries will be provided daily for 42 days.
41447532|NCT03531827|DRUG|enzalutamide|enzalutamide is an androgen receptor (AR) antagonist that is standard care therapy for metastatic prostate cancer
41447533|NCT03531827|DRUG|CRLX101|CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
41447534|NCT06012812|DRUG|SHR-1819 injection|SHR-1819 injection 300 mg Q2W
41447535|NCT04107064|BEHAVIORAL|NaW|Participants will receive assistance with finding employment, onboarding, training, and so on.
41447536|NCT04107064|BEHAVIORAL|NaW-DS|Participants will receive assistance with onboarding and training 6 months after the initiation of their employment.
41447537|NCT06120153|DIAGNOSTIC_TEST|POC PCR-test device|"The analysis will follow an intention-to-treat principle, that is, contacts in the intervention period will be analyzed as randomized, regardless of whether the POC PCR test was actually performed for a given contact. As sensitivity analysis, the data will be analyzed in a per-protocol spirit, defining the intervention at the contact level as a POC PCR test performed."
40754472|NCT03807167|OTHER|fatigue Visual Analog Scale|To date, there is no valid fatigue scale in the depression of the elderly subject, a fortiori in French. The fatigue scale in adult depression includes has been validated with an EVA (Visual Analogue Scale) (38). We therefore propose to use this type of evaluation to control this aspect.
41125756|NCT00321152|OTHER|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
41125757|NCT03200808|DRUG|mixed methylene blue compound injection|Every patient received intradermal mixed methylene blue compound injection twice.
41125758|NCT00462475|DRUG|Recombinant Growth Hormone, Genotropin (Pfizer)|
41125759|NCT02763449|BEHAVIORAL|Self-monitoing|Participants will self-monitor their physical activity level via activity monitors
41125760|NCT02409667|BIOLOGICAL|Secukinumab|Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
41125761|NCT02138123|PROCEDURE|IOL-shell technique|Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group. What was different was that before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
40754473|NCT03807167|OTHER|executive function|"* Modified Card Sorting Test MCST(Modified Card Sorting Test) (Wisconsin Test): This test assesses conceptualization, attention and mental flexibility using a deck of cards.~* Trail Making Test (TMT): This test is used to assess mental flexibility.~* Fluences verbal: This test tests the capacities of setting up search strategies in memory semantics and oral language.~* Stroop Paradigm: This test is used to evaluate the resistance to interference, ie the patient's ability to inhibit some over-learned and automated responses."
40928109|NCT03661476|BEHAVIORAL|Oculo-Motor Exercises (OME)|"Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
40928110|NCT01185301|BIOLOGICAL|adalimumab|Pre-filled syringe every other week
40928111|NCT01185301|DRUG|methotrexate|weekly oral capsule dosing
40928112|NCT05679427|RADIATION|radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively|Two protocols of stereotactic ablative radiotherapy, in one vs five fractions ( the later with SIB) are compared
40928113|NCT02911207|BEHAVIORAL|patients choose one creative activity and one physical activity|taking part in 2 activities (a creative one and a physical one)
40928114|NCT02697669|OTHER|18F-FDG PET|Imaging
40928115|NCT06371183|DEVICE|Colonoscope|Endoscopy for lower GIT
40928116|NCT04199702|OTHER|Same day discharge|Patients will be discharged the same day they undergo catheter ablation of atrial fibrillation.
40928117|NCT00234247|OTHER|Long Term Follow-Up|Extended and enhance the follow-up of the NHLBI iNO RCT by assessing the effects of iNO use on: 1.) long term clinical and childhood developmental outcomes; 2.) family impact, and; 3.) healthcare costs of prematurity-associated respiratory failure.
40928118|NCT03480464|BEHAVIORAL|App-technology to increase physical activity|The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery
40928119|NCT06240767|BIOLOGICAL|Granulocyte infusion|The number of single granulocytes per infusion was 2.0-5.0×10\^10, with an interval of 2±1 day and 5 continuous infusions.
40928120|NCT03503890|DRUG|rovalpituzumab tesirine|intravenous
40928121|NCT00289055|DEVICE|stent|Cordis SMART™ Nitinol Stent
40928122|NCT00289055|DEVICE|angioplasty|balloon angioplasty
40928123|NCT05841173|DIETARY_SUPPLEMENT|"PanTrek"|"The intervention is represented by the investigational product PanTrek, shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product PanTrek (per 1 dose):~* Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg);~* Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial);~* Apple juice concentrated 2.5% - 7,5 g;~* Potassium beta-hydroxybutyrate - 4,5 g;~* Magnesium beta-hydroxybutyrate - 500 mg;~* E211 sodium benzoate - no more than 5 mg;~* E202 Potassium sorbate - no more than 3,6 mg;~* Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021."
40928124|NCT05841173|BEHAVIORAL|Physical Trainings|Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).
41125762|NCT02138123|PROCEDURE|Conventional procedure|In this procedure, a IOL was not implanted until all the nuclear fragments were removed.
40928125|NCT05841173|OTHER|Placebo|The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.
40928126|NCT05841173|BEHAVIORAL|Diet|The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.
40928127|NCT06080139|BEHAVIORAL|Refugee parenting education in a participatory community|"Parents will vote for one of the 5 previously studied refugee parenting curriculums: 1) Creating Opportunities Through Mentoring Parenting Involvement and Safe Space (COMPASS); 2) GenerationPMTO; 3) Happy Families; 4) Family Strengthening Intervention for Refugees (FSI-R).~Researchers will use a model of Learning by Observing and Pitching In (LOPI), to empower community members in the learning process. LOPI is a multicomponent way of organizing group learning that improves collaboration, alertness, and executive functions such as perspective-taking and self-regulation in addition to specific skills learning and has been used in many indigenous and indigenous-heritage communities of the Americas."
40928128|NCT02127268|DRUG|Thymosin-α1|with Thymosin-α1 1.6mg twice a week
40928129|NCT02359175|DRUG|Bupivacaine in epidural catheter|Bupivacain to be given in epidural catheter
40928130|NCT02359175|DRUG|Fentanyl in epidural catheter|Fentanyl to be given in epidural catheter
40928131|NCT02359175|DRUG|Placebo (for Bupivacain and Fentanyl i epidural catheter)|Saline to be given in epidural catheter
41125763|NCT01300975|DRUG|pentavalent antimony|3 intralesional injections of antimony at D1, D3 and D7
41125764|NCT01300975|PROCEDURE|cryotherapy|Frozing of lesions with liquid nitrogen ad D1 and D14
41125765|NCT01300975|DRUG|placebo cream|topical emollient crean 3 times a day during 21 days
41125766|NCT04785950|DRUG|Low-dose levonorgestrel intrauterine systems (LNG-IUS)|Any low-dose intrauterine system (IUS) marketed in Spain
40928132|NCT02359175|DRUG|Oral Paracetamol|Paracetamol to be given orally
41125767|NCT05076942|RADIATION|Radiotherapy combined with cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
41276721|NCT00327938|DEVICE|Measuring of skin conductance|
40928133|NCT02359175|DRUG|Oral NSAID|NSAID to be given orally
40928134|NCT02359175|DRUG|Oral opioids|Opioids to be given orally
40928135|NCT02359175|DRUG|Placebo (for oral opioids)|Placebo tablets to be given instead of oral opioids
41125768|NCT05076942|DRUG|Cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
41125769|NCT00912600|OTHER|Intensive Care Unit admission|Intensive Care Unit admission
41276722|NCT00327938|PROCEDURE|Tetanic stimuli|
41287278|NCT04296292|OTHER|In-depth interviews|In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
41287279|NCT02952742|DRUG|Black Cohosh|Vital Nutrients Black Cohosh Extract
40928136|NCT02040727|BEHAVIORAL|Resistance Training|Supervised strength training 3 days per week for 24 weeks
40928137|NCT02040727|BEHAVIORAL|No Resistance Training|No supervised strength training throughout the study
40928138|NCT03844711|OTHER|Transcutaneous electrical diaphragmatic stimulation (TEDS)|"* Stage I: In the first day (group 1) the parameters will be with 30 Hz frequency and the second day (group 2) will be with 80 Hz, with one-day interval between interventions. The TEDS will be applied with symmetrical biphasic pulsed current, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.~* Stage II and III:The TEDS will be applied with symmetrical biphasic pulsed current, the parameters will be with 30 Hz frequency, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue."
40928139|NCT03844711|OTHER|Inspiratory Muscle Training (IMT)|- Stage II and III: The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax. Inspiratory muscle training will start with a minimum load of 50% and progress to 60% of the MIP. The patients will perform daily training, being two sets of 30 breaths, one in the morning and one in the afternoon.
40928140|NCT03844711|OTHER|Conventional physiotherapy|- Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
40928141|NCT04156516|BEHAVIORAL|HEART|sexual health intervention
40928142|NCT04156516|BEHAVIORAL|HealthyMinds|Growth mindsets of personality and mental health
40928143|NCT05863598|BEHAVIORAL|Enhancing protective factors|Participants will watch some short movies and infographics, and will be asked to argue for the importance of body image flexibility, body functionality appreciation, etc.
40928144|NCT05863598|BEHAVIORAL|Expressive writing|Participants will reflect and write about any cognitions or emotions they can have in relation to their bodies.
40928145|NCT01908400|BIOLOGICAL|Intravenous transfer of BMMNC|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
40928146|NCT01141777|DIETARY_SUPPLEMENT|Spirulina platensis|Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
40928147|NCT01141777|DIETARY_SUPPLEMENT|Soya bean|Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
40928148|NCT00573287|DRUG|clozapine|clozapine--tabs, 450mg. max, daily, 24 weeks
40928149|NCT00573287|DRUG|risperidone|risperidone--tabs, 6mg max, daily, 24 weeks
41276723|NCT06657573|BEHAVIORAL|An AI-enabled chatbot tailored for influenza vaccine consultation|The AI-enabled influenza vaccine chatbot can be accessed online through WeChat or any web browsers. The foundation of this chatbot is an expansive knowledge database, constructed with information sourced exclusively from healthcare authorities such as China CDCs and Health Departments, and thoroughly verified by public health experts. This database integrates data on the disease's burden, susceptibility, and severity, along with in-depth details about the vaccines, including their importance, efficacy, safety, and recommended demographics and timing for vaccination. It also covers types and costs of vaccines, societal norms such as vaccination guidelines, expert recommendations, and vaccination trends both in China and internationally. It also includes misinformation and fact-checking contents and provides information about vaccination services such as locations and appointment scheduling.
40754474|NCT03807167|OTHER|MRI|An MRI lasting 30 minutes is programmed
40754475|NCT03807167|OTHER|Apathy Motivation Index|"This is a self-questionnaire of 18 items, each side on a 5-level Likert scale (0: not everything at 4: very often). It differentiates between behavioral apathy and social apathy.~Emotional."
40754476|NCT05318378|DIAGNOSTIC_TEST|BIXAM|Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together
40754477|NCT00752362|DEVICE|Milennium Matrix® (Control)|Percutaneous coronary intervention with bare metal stent
40754478|NCT00752362|DEVICE|Infinnium®|Percutaneous coronary intervention with paclitaxel-eluting stent
40754479|NCT00752362|DEVICE|Supralimus®|Percutaneous coronary intervention with sirolimus-eluting stent
40754480|NCT04916665|DRUG|Teduglutide|bridging intestinal failure with teduglutide until reconstruction
40754481|NCT04209803|DRUG|Minoxidil 5% topically and oral NAC 600 mg|Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally
40754482|NCT04265118|DEVICE|Sidewards Tilting Bed|Sidewards tilting of the bed is hypothesized to induce a body position change in sleeping subjects.
40754483|NCT02296359|BIOLOGICAL|Influenza Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
40754484|NCT05902858|DEVICE|Conventional intubation with hyperangulated videolaryngoscope|After the induction of general anesthesia, the patient will undergo conventional intubation with hyperangulated videolaryngoscope
40754485|NCT05902858|DEVICE|Intubation with ProVu TM video stylet combined with hyperangulated videolaryngoscope|After the induction of general anesthesia, the patient will undergo intubation with ProVu TM video stylet combined with hyperangulated videolaryngoscope
40754486|NCT05902858|DEVICE|Intubation with ProVu TM video stylet combined with standard Macintosh laryngoscope|After the induction of general anesthesia, the patient will undergo intubation with ProVu TM video stylet combined with standard Macintosh laryngoscope
40754487|NCT00666614|OTHER|Sleep Environment Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
40754488|NCT00666614|OTHER|Normal Hospital Environment|Normal Hospital Environment
40754489|NCT03167424|DEVICE|Treatment of restenosis|Treatment of in-stent restenosis
40754490|NCT05552495|DRUG|CKD-386(4) F1|1 Tablet
40754491|NCT05552495|DRUG|CKD-386(4) F2|1 Tablet
40754492|NCT05552495|DRUG|D013, D326, D337|D013 1 Tablet, D326 1Tablet, D337 1 Tablet
40928150|NCT06273683|OTHER|Hand-held bipolar energy instrument|A bipolar energy instrument is used for complete salpingectomy at the time of cesarean delivery.
40928151|NCT06273683|OTHER|Traditional suture ligation|Traditional suture ligation technique is used for complete salpingectomy at the time of cesarean delivery.
40928152|NCT00473980|DRUG|Indomethacin, celecoxib, esomeprazole|
40928153|NCT00694538|DEVICE|Interferential Laser therapy|Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
41447538|NCT03739502|DRUG|Hyperbaric oxygen|"The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).~However, UCB as a graft source for a bone marrow transplant has drawbacks related to the limited cell dose available for transplant and defects in homing. Homing is the process of UCB stem cell lodging in the bone marrow. If the homing is not efficient it could delay the re-population of the stem cells (or engraftment), possibly lead to engraftment failure, and delay the rebuilding of the immune system after transplant. This could, in turn, provide a higher risk to infection after the UCB transplant."
40928154|NCT03999775|DIETARY_SUPPLEMENT|Calcium, vitamin D and bioactive collagen peptides supplement|
40928155|NCT03999775|DIETARY_SUPPLEMENT|Calcium and vitamin D supplement|
40928156|NCT00089674|DRUG|AMG 162|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
41447539|NCT06469307|OTHER|DIVERSE Review Process|A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.
41447540|NCT02463981|DEVICE|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
41447541|NCT05241639|DIAGNOSTIC_TEST|Pentacam|Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar
40928157|NCT00089674|DRUG|Placebo|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
40928158|NCT06284629|DEVICE|Neptune|Neptune is a software algorithm that utilizes data from wrist-worn sensors to track Parkinson motor symptoms and displays them in an easy to understand graph. Neptune Care is a mobile app that includes a patient portal, where patients can self-report symptoms, view their motor data and get medication reminders, and a physician portal, where the treating physician can view the objective motor data and patient-reported outcomes prior to a clinical visit.
40928159|NCT06284629|OTHER|Standard clinical care|Treatment and management according to standard clinical care
40928160|NCT02793856|DRUG|Cyclophosphamide|To deplete Tregs before collecting peripheral blood
41125770|NCT04827524|OTHER|Anthropometric measurement|The demographic information and birth histories of the subjects included in the study will be taken first. Anthropometric measurements of all subjects will be measured with the Star Scanner device. The Star Scanner 3 dimensional data collection system is a scanning system that enables the anthropometric head measurements of the baby to be taken in just 2 seconds. The advantages of this device is that it does not emit any harmful beams during evaluation, it does not have any harmful effects on health, and that it is an application that will not disturb babies.
41447542|NCT05501704|DRUG|Tamoxifen|Taken orally
40754493|NCT04330339|BEHAVIORAL|Fasting|Fasting
40754494|NCT05736913|BIOLOGICAL|ID BNT162b2 vaccine|intradermal BNT162b2 vaccine
40754495|NCT05736913|BIOLOGICAL|IM BNT162b2 vaccine|intramuscular BNT162b2 vaccine
41125771|NCT02132949|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 500 mg/m\^2 IV on Day 1 of each cycle q3w.
41125772|NCT02132949|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.
41447543|NCT05501704|DRUG|Anastrozole|Taken orally
41447544|NCT05501704|DRUG|Degarelix|Subcutaneous (under the skin) injection
41447545|NCT05501704|DRUG|Abemaciclib|Taken orally
41447546|NCT06618339|BEHAVIORAL|Mindfulness-based intervention|8 Session Mindfulness-based intervention
40928161|NCT02793856|OTHER|PD-1 Knockout T Cells|Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
40928162|NCT04764266|DIAGNOSTIC_TEST|Heparansulfate and Syndecan 1|Blood samples will be collected from the patient at 5 different time points. Three perfusate samples will be collected during normothermic machine perfusion (4,9ml each).
40928163|NCT05106764|OTHER|No intervention|This is non-interventional study.
41447547|NCT03069963|DRUG|Z0063|"Pharmaceutical form: chewable tablets~Route of administration: oral"
41447548|NCT03069963|DRUG|Gaviscon|"Pharmaceutical form: chewable tablets~Route of administration: oral"
41447549|NCT01788800|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|9 sessions of CBT including psychoeducation and interoceptive exposure
41447550|NCT02082808|DRUG|DTG|DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
40754496|NCT05908032|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
40754497|NCT05908032|BIOLOGICAL|Placebo|Placebo
40754498|NCT02477033|DIETARY_SUPPLEMENT|Butyricicoccus pullicaecorum 25-3T|
40754499|NCT02477033|OTHER|Maltodextrin|
40754500|NCT01693237|OTHER|Group psychotherapy|20 sessions of systemic and narrative group therapy
41125773|NCT02132949|DRUG|Docetaxel|Participants will receive docetaxel at a starting dose of 75 mg/m\^2 IV for the first cycle and the dose may be escalated to 100 mg/m\^2 for subsequent cycles q3w.
41287280|NCT02952742|OTHER|Placebo|Inactive comparator resembling the Black Cohosh formulation in appearance. Ingredients include: cellulose; caramel color; powdered yellow dye; and powdered red dye.
41125774|NCT02132949|DRUG|Doxorubicin|Participants will receive doxorubicin 60 mg/m\^2 IV on Day 1 of each cycle q2w.
41125775|NCT02132949|DRUG|Epirubicin|Participants will receive epirubicin 100 mg/m\^2 IV on Day 1 of each cycle q3w.
41125776|NCT02132949|DRUG|Paclitaxel|Participants will receive paclitaxel 80 mg/m\^2 IV given weekly.
41125777|NCT02132949|DRUG|Pertuzumab|Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
41125778|NCT02132949|DRUG|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
41125779|NCT00654589|DRUG|Deferasirox|
41125780|NCT04659018|BIOLOGICAL|blood collection|A 5ml blood sample will be taken in a dry tube when the venous line necessary for the general anaesthesia for the colonoscopy is placed.
41125781|NCT05055700|BEHAVIORAL|Mobile app with prenatal genetic testing information|In the intervention group, participants will be asked to download, register, and review a mobile app on their own mobile phones before their appointment with maternal-fetal medicine specialists. This mobile app includes prenatal genetic testing information about amniocentesis, chorionic villus sampling, nuchal translucency screening, cell-free DNA, triple/quad/penta screening, anatomy ultrasound, and carrier screening.
41125782|NCT03375892|OTHER|Deep Inspiration Breath Hold during Radiation|The DIBH technique involves the patient breathing to a specified threshold and then holding that level of inspiration during every radiation therapy field delivered.
41125783|NCT03375892|OTHER|Free breathing during radiation|The patient will be instructed to breathe freely.
41125784|NCT03562325|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The main target in ACT for ME/CFS (as for Fibromyalgia and Chronic pain in previous studies by our group) is to promote a shift of perspective in life from symptom reduction (when it does not work) to a valued life. As such it entails acceptance and exposure to discomfort, in order to lessen the effects of negative experiences (symptoms, emotions, thoughts) on behaviours in everyday life.
41125785|NCT02652091|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
41125786|NCT02652091|DEVICE|BETACONNECT device|Used to apply Betaseron.
41125787|NCT06159569|DEVICE|LACRIACT|"LACRIACT is is a preservative free ophthalmic sterile medical device solution. The solution is packaged in closable vials of inert material that does not affect the contents (clear low-density polyethylene), each vial contains 0.5 ml of solution.~Eligible patients will start the treatment. Patients will receive the box of eye drops, and will be instructed on how to self-administer 1 drop in each eye 4 times a day for 30 days starting from the day following the visit."
41125788|NCT00160498|DRUG|Lercanidipine|
41447551|NCT02082808|DRUG|DCV|DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
41447552|NCT01958294|DEVICE|MICHI Neuroprotection System|
41447553|NCT01373515|BIOLOGICAL|DCP-001|4 bi-weekly vaccinations
41447554|NCT05509023|DRUG|ADX-914|Subcutaneous administration of ADX-914
41447555|NCT05509023|DRUG|Placebo|Subcutaneous administration of Placebo
41447556|NCT00486187|DRUG|rosiglitazone|
41125789|NCT05607823|OTHER|Core Stabilization Training|Core Stabilization training will be based on dynamic neuromuscular stabilization and consists of three stages. In the first session, it is to teach the simultaneous activation of the transversus abdominis, pelvic floor, multifidus and diaphragm muscles and to improve muscle coordination and proprioception in the entire spinal region. In the second and third phases, exercises will be made more intense to improve muscular endurance and stability. The difficulty of the exercises will be increased by working in different positions, using resistance bands, exercise balls and body weight, and adding movements to the extremities. A total of 10 sessions of treatment program will be applied to the patients for ten weeks, once a week.
41125790|NCT05607823|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
41125791|NCT05607823|OTHER|Conventional Physiotherapy|Conventional physiotherapy consists of home exercise and patient education. Patient education consists of parafunctional behaviors, habits, a diet with soft food, and posture education. The exercises consist of exercises for the mandible, cervical and thoracic region and breathing. All movements are planned to be done at home 3 times a day, every day of the week.
41287281|NCT01041573|BIOLOGICAL|IC51 Japanese Encephalitis|6 mcg or 3 mcg im. at day 0 and day 28
41287282|NCT01041573|BIOLOGICAL|Havrix®720|0.5 ml im. at day 0 and month 7
40754501|NCT01693237|OTHER|Group psychotherapy with feedback|20 sessions of systemic and narrative group therapy
41287283|NCT01041573|BIOLOGICAL|Prevnar|0.5 ml im. at day 0 and day 56 and month 7
41287284|NCT00077454|DRUG|erlotinib hydrochloride|Given orally (PO)
41287285|NCT00077454|DRUG|temozolomide|Given PO
41287286|NCT00077454|OTHER|pharmacological study|Correlative studies
41287287|NCT00077454|OTHER|laboratory biomarker analysis|Correlative studies
41447557|NCT00486187|DRUG|metformin or sulfonylurea|
41447558|NCT01186458|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
41447559|NCT01186458|DRUG|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
40754502|NCT03255499|BEHAVIORAL|Exercise|Exercise
40754503|NCT03255499|BEHAVIORAL|Cognitive|Cognitive
40754504|NCT03255499|BEHAVIORAL|Active control|Active control, including a blend of computer games, board games, quizzes, trivia
41447560|NCT01186458|DRUG|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
41447561|NCT05544123|OTHER|pathological stage|breast cancer molecular subtyping and pathological TNM stage
41447562|NCT04101396|DIETARY_SUPPLEMENT|diabetic diet|Patients with gestational diabetes will be seen by the dietitian to be taught diet modification
41125792|NCT05938816|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|MBSR consists of weekly two-hour sessions for eight weeks, and a 7.5 hour retreat between weeks 6 and 7. The MBSR intervention will be facilitated by an experienced and certified MBSR teacher. MBSR curriculum strongly encourages completion of home practice assignments (\~30 minutes daily) to help integration of concepts into daily life. Participants will receive audio CDs and a DVD to help guide home practice.
41125793|NCT05938816|BEHAVIORAL|Health and Wellness Education (HWE)|HWE is a didactic-based group intervention designed as an active comparator for randomized-controlled trials of MBSR. HWE provides instruction to participants regarding improving their emotional and physical health. In contrast to MBSR, there are no attempts to train participants' breathing, movement, or meditation habits or practices. HWE is administered in 8 weekly 2.5-hour classes with home practice to be completed between sessions (matched to MBSR for amount and effort). HWE also features one extended 7.5-hour retreat, similar to MBSR.84 Dr. Autumn Gallegos (consultant) has conducted trials of MBSR among veterans with PTSD using a HWE control group, and will provide mentorship to the PI in administering the HWE intervention. Dr. Kaplan and a trained RA will facilitate HWE.
40928164|NCT06070220|BEHAVIORAL|traditional occupational therapy intervention and client-centered intervention|"Traditional occupational therapy intervention and client centered intervention were given to the participants.~CC intervention is a dynamic approach that involves a systematic therapy process, that is, in which the participant and the therapist are active in the treatment process. In the current study, a treatment program was designed over a maximum of 5 occupations in which participants evaluated after THA indicated problems in activities of daily living according to COPM. This systematic and dynamic program consists of 4 phases: (1) client-centered goal setting, (2) negotiating an intervention plan, (3) the actual intervention, (4) an evaluation of the outcome and finally reporting to relevant others."
41125794|NCT01955226|OTHER|Tegaderm CHG clear dressing|Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
41125795|NCT01955226|OTHER|Standard clear Tegaderm dressing|Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
41125796|NCT05088798|DRUG|18F-Fluoro Dopa PET/MRI Imaging|The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
40754505|NCT05029362|BEHAVIORAL|SmokefreeSGM|Participants will have access to a text-based smoking cessation program tailored to sexual minority individuals (SmokefreeSGM). The text-based program will be beta-tested by these participants for a period of 2 weeks before and 10 weeks after their quit date. Messages originated from the text-based smoking cessation program will be sent by a fictitious quit coach who will offer evidence-based advice on quitting smoking based on real-life experiences of sexual minority individuals.
41125797|NCT02054923|PROCEDURE|Implementation of routine videorecording|All screening centres (clusters) assigned to the routine video recording group will receive an appropriate number of video recorders and DVDs for each colonoscopy room. Screening centre coordinators will be responsible for the implementation of routine video recording of all screening colonoscopies (only withdrawal) in the centres. Every three months screening centre coordinators will be asked to send back all recorded DVDs. All the recorded DVDs will be reviewed to verify ceacal intubation and withdrawal time by the PCSP team and then stored.
41125798|NCT02054923|BEHAVIORAL|No routine videorecording|Screening centres (clusters) assigned to the control group will not receive video recorders and DVDs but will be allowed to record colonoscopies on demand.
41287288|NCT03835663|DIAGNOSTIC_TEST|No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes|Standard upper GI endoscopy with biopsies
41287289|NCT05058378|DEVICE|perfusion index measurement|Clip will be attached to the patient's toe for perfusion index measurement
40754506|NCT01250314|OTHER|Radiology|Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).
40928165|NCT06070220|BEHAVIORAL|Traditional occupational therapy intervention|"The following training procedure, which included exercise, transfer activities and home arrangements, was followed in common in both groups:~1. st day: After the operation, exercises to strengthen the muscles of the participants (thigh, hip and trunk muscles) were explained verbally and visually. Each exercise consists of 3 sets of 12 repetitions. Exercises were updated in bed, sitting or standing, depending on the participant's functional status, pain and fatigue. Additionally, transfer activities training was provided.~2. nd day: The exercises taught to the participants on the first day were repeated. Following these exercises, participants were given verbal instructions on gait training, and then gait training began. According to the pain and fatigue status of the participants, gait exercises were continued.~3. rd day: The work done on the first and second day was repeated. Pre-discharge home arrangements training was provided."
40928166|NCT02562690|OTHER|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
41125799|NCT01721291|DRUG|SALBUTAMOL|"In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY."
41125800|NCT00168415|BIOLOGICAL|Botulinum Toxin Type A|100 U up to 6 times during the study depending on the response to treatment
41125801|NCT00002893|DRUG|fluorouracil|
41125802|NCT00002893|DRUG|leucovorin calcium|
41276724|NCT03138564|BEHAVIORAL|SPIRIT|"SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role.~During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences.~Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record."
41276725|NCT03138564|BEHAVIORAL|Comparison Condition|As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes.
41447563|NCT05908097|DEVICE|Virtual Reality Avatar Intervention|In the Virtual Reality Avatar Intervention experience, participants will see an avatar resembling themselves in a park setting. The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
41447564|NCT05908097|DEVICE|Virtual Reality Empty Park|The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
40928167|NCT00802815|DRUG|Etanercept|50 milligrams subcutaneously every week
40928168|NCT04278105|DEVICE|HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
41125803|NCT00002893|DRUG|raltitrexed|
40928169|NCT04278105|DEVICE|Sham HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
40928170|NCT04278105|OTHER|Upper extremity rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
41125804|NCT01514149|DRUG|CJC-1134-PC Injection|CJC-1134-PC administered weekly by subcutaneous injection
41125805|NCT01514149|DRUG|Weekly placebo for CJC-1134-PC Injection|Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
41125806|NCT00006349|DIETARY_SUPPLEMENT|vitamin E|
41125807|NCT00006349|DRUG|donepezil hydrochloride|
41125808|NCT00006349|OTHER|placebo|
41125809|NCT02265354|BEHAVIORAL|Collective-Intelligence computer tailored health communication|
40928171|NCT05008978|OTHER|Test 1|25g of available carbohydrates from White bread with 25g of available carbohydrates from Banana consumed simultaneously at time 0 min
40928172|NCT05008978|OTHER|Test 2|25g of available carbohydrates from Banana consumed at time -15 min and 25g of available carbohydrates from white bread consumed at time 0 min
40928173|NCT05008978|OTHER|Test 3|25g of available carbohydrates from White bread consumed at time 0 min and 25g of available carbohydrates from Banana consumed at time 15 min
40928174|NCT05008978|OTHER|Test 4|25g of available carbohydrates from White bread with 25g of available carbohydrates from Papaya consumed simultaneously at time 0 min
40928175|NCT05008978|OTHER|Test 5|25g of available carbohydrates from White bread with 25g of available carbohydrates from Apple consumed simultaneously at time 0 min
40928176|NCT00889616|DRUG|BSAM2/Alhydrogel + CPG 7909|
40928177|NCT01658813|DRUG|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
40928178|NCT04515862|OTHER|Breastfeeding education|The importance of breastfeeding Benefits of breastfeeding for mother and baby Structure of the breast and milk production Breastfeeding techniques and positions Breastfeeding problems and breast care
40928179|NCT04486898|OTHER|Music group|Music group will be given music intervention or listen to music for 30 minutes ,3 times a week for the period of 5 week duration. Music will be selected as per participant's preference
41125810|NCT02265354|BEHAVIORAL|Rule-based computer tailored health communication|
40928180|NCT05774392|OTHER|Observational|Observational
41125811|NCT05205798|BEHAVIORAL|Food consumption using plates with a diameter of 23 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 23 cm.
41125812|NCT05205798|BEHAVIORAL|Washout period|No interventional food consumption for 1 week
41125813|NCT05205798|BEHAVIORAL|Food consumption using plates with a diameter of 31 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 31 cm.
41276726|NCT05388357|OTHER|Intervention Procedure: PCI|Percutaneous Coronary Intervention
41125814|NCT04453332|DRUG|Oral hormone therapy (estradiol and micronized natural progesterone)|Oral hormone therapy - estradiol 1mg every day and micronized natural progesterone 200mg only 14 days a month
41125815|NCT04453332|DRUG|Non-oral hormone therapy (estradiol and micronized natural progesterone)|Percutaneous estradiol gel 1.5mg every day and micronized progesterone 200mg vaginal only 14 days a month
41125816|NCT01400958|DRUG|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
41125817|NCT01400958|DRUG|Placebo|Placebo x 42 days; THEN, No More Placebo
41125818|NCT05814146|DRUG|Dialysate bicarbonate concentration|"Assess how a lower dialysate bicarbonate affects:~* QTc duration during and between hemodialysis sessions~* PVC burden during and between hemodialysis sessions~* Clinically significant arrhythmia during and between hemodialysis sessions~* Intradialytic hypotension~* Adverse symptoms during hemodialysis sessions"
41125819|NCT05814146|DEVICE|Dialysate bicarbonate concentration - telemetry monitoring|Patients will be monitored with telemetry on both arms of the trial.
41125820|NCT02594631|PROCEDURE|ESWL|Patients in this arm will receive ESWL for treatment of acute calcular urinary retention
41125821|NCT02594631|PROCEDURE|Endoscopic treatment|Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
41276727|NCT06657768|DRUG|LY4006895|Administered IV
41276728|NCT06657768|DRUG|Placebo|Administered IV
41276729|NCT05250856|DRUG|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
41276730|NCT05250856|DRUG|Placebo|Placebo, (0.9% Sodium Chloride for IV infusion)
40928181|NCT02213133|DRUG|Selinexor (KPT-330)|Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
40928182|NCT04328207|OTHER|No Financial Incentive|Standard of care eye health education
40928183|NCT04328207|BEHAVIORAL|Financial Incentive|Patients who are referred for an in-person follow-up exam will receive a financial incentive once the referral visit is completed.
40928184|NCT03419975|DRUG|TJO-002|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
40928185|NCT03419975|DRUG|Latanoprost|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
40928186|NCT03717428|DEVICE|Daily Weighing Group|The Experimental group will weigh themselves everyday
40928187|NCT03717428|DEVICE|Control group|This group will be weighed and measured at the beginning and end of the study and will not be weighing themselves daily
40928188|NCT01191216|DRUG|1-methyl-d-tryptophan|
40928189|NCT01191216|DRUG|docetaxel|
40928190|NCT01191216|OTHER|diagnostic laboratory biomarker analysis|
40928191|NCT01191216|OTHER|pharmacological study|
41125822|NCT02837211|BEHAVIORAL|Tapered Low Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.~The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.~From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period."
41276731|NCT04079023|PROCEDURE|Sleeve Gastrectomy|Subtotal vertical gastrectomy
41276732|NCT03314805|DRUG|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
41276733|NCT03314805|DRUG|Placebo|500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
41276734|NCT03314805|PROCEDURE|EC Chemotherapy|Epirubicin plus Cyclophosphamide every 21 days
40928192|NCT06345196|BEHAVIORAL|motivational interview|Motivational interviewing will be conducted in four sessions and the session duration will be maximum 40 minutes. The session will be conducted individually and online once a week. For the individual interview, the appropriate day and time will be determined with the individuals with diabetes and the researcher before the first session and the sessions will continue on the same day and time every week. The researcher will remind the participant about the time of the session by calling the participant by phone one day before each session. Motivational interview sessions will be held online on the Whatsapp platform.
41125823|NCT02837211|BEHAVIORAL|Traditional Low-Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.~Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level."
41125824|NCT04056702|DRUG|Elexacaftor-tezacaftor-ivacaftor exposure|Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
41125825|NCT04497766|DRUG|Nebulized Magnesium sulfate|MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes
41125826|NCT04497766|DRUG|Intravenous magnesium sulphate|pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
40754507|NCT01250314|OTHER|Biological, biochemical and genetic samples|"\*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone~Urinary samples :~Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample~\*Assessment of possible determinants of fractures in man~Blood samples plasma (5 ml):~* Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH~* Homocysteine~* IGF1~  * Extraction of DNA for a genetic polymorphism study:~Sample of 10 ml of blood on EDTA for DNA extraction.~Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor~Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way."
40754508|NCT05257980|DIETARY_SUPPLEMENT|Dietary supplement (ONS)|At baseline, the investigating dietitian/nurse will record several measures, including clinical history and symptoms over the previous 24 hours. In addition, patients who are already receiving an ONS will continue their prescribed ONS for 1 day in which their gastrointestinal tolerance, ONS compliance and acceptability will be recorded. All patients will then receive standardised dietary advice in addition to one of the four trial ONS products daily for 28 days. The type of ONS will be agreed with the patient and the investigating dietitian/nurse, and the ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The type of ONS prescribed will be the same throughout the 28 days and will be taken orally.
40928193|NCT01785173|PROCEDURE|Endoscopic-guided gauze pledgetting|By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
40754509|NCT05265364|RADIATION|IMRT with SIB|moderate hypofractioation using 2.5gy/fr in prostate cancer patients usig IMRT SIB technique
40754510|NCT00327431|GENETIC|Cheek swab samples for DNA|
40928194|NCT01785173|PROCEDURE|Cotton-tipped applicator gauze pledgetting|In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
40928195|NCT03493659|BEHAVIORAL|Standing during Concept Test|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test.
40928196|NCT03493659|BEHAVIORAL|Standing during regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during their regular tutorial sessions.
41125827|NCT01280513|DIETARY_SUPPLEMENT|High protein intake|30% of energy intake coming from proteins
41125828|NCT01280513|DIETARY_SUPPLEMENT|Low Protein intake|9% of energy intake coming from proteins
41125829|NCT06461390|DRUG|Norepinephrine|NE Group (Fluid loading with early norepinephrine administration group) NE Group will receive ringer lactate bolus 20 ml/kg along with norepinephrine infusion at 0.1 mcg/kg/minute until MAP\&gt;5 percentile. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed, with or without continued norepinephrine infusion according to the treatment group
41125830|NCT06461390|DRUG|Ringer's Lactate|Fluid Group will receive ringer lactate bolus 20 ml/ kg only. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed
41276735|NCT03429075|DRUG|Psilocybin + Placebo|Multiple dosing days psilocybin vs 6 weeks of daily placebo
40928197|NCT03493659|BEHAVIORAL|Standing during Concept Test and regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test and during their regular tutorial sessions.
41276736|NCT03429075|DRUG|Psilocybin + Escitalopram|Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
41276737|NCT05548686|OTHER|adapted physical activity|3 sessions of adapted physical activity per week during 12 weeks for each patient
41276738|NCT06170645|OTHER|APA program|An APA program of 12 weeks, 2 sessions of 1h/week for mixed endurance, strengthening and stretching work. The program can be realized at home or in structure.
40928198|NCT02981459|DRUG|Mirabegron|daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
40754511|NCT05092776|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
40754512|NCT05092776|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for subcutaneous Injection), 2 mL in the 4 mL-glass vial. The placebo will contain no active pharmaceutical ingredients.
40754513|NCT02388100|PROCEDURE|Capillary HbA1c collection|
40754514|NCT04476680|DIETARY_SUPPLEMENT|Vitamin D|Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.
40928199|NCT06061614|GENETIC|NGGT002|NGGT002
40928200|NCT01027273|BEHAVIORAL|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
41125831|NCT03284567|BEHAVIORAL|Football fitness|"The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors"
41125832|NCT05654467|BIOLOGICAL|Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)|The nOPV3 vaccine containing approximately 10\^5.5, 10\^6.0, or 10\^6.5 CCID50 per dose.
41125833|NCT05654467|BIOLOGICAL|Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 control and challenge vaccine (mOPV3) containing ≥ 10\^5.8 CCID50 per dose.
41125834|NCT03606915|BEHAVIORAL|pain evaluation|collect CSF during spinal anesthesia
41125835|NCT04783025|BEHAVIORAL|Blended Gaming COVID-19 Training System (BGCTS)|"BGCTS is a blended training programme integrated with games and short video clips for Residential Care Home staffs to learn the principles of infection control and reinforce actions needed to stop the spread of COVID-19 within the RCHs, and to care for those residents suspected of having COVID-19. The contents of the training will refer to the evidence-based contents from The COVID-19 Risk Communication Package For Healthcare Facilities.~Dosage of the intervention. Staffs are encouraged to learn each topic independently in 15 minutes. It will take a total of 120 minutes to complete all eight topics in 2 weeks. Staffs will attend two 30-minute face-to-face group sessions conducted by research nurse (and the Infection Control Officer of the RCH) to clarify concepts (one per week; after playing the games). Scores and progress bar will be shown to the staff so as a form of motivation to encourage continuous participation in the training."
41276739|NCT06170645|OTHER|Active transcutaneous VNS|After each APA session, a 1h-tVNS session is delivered on the conchae aurea of the left ear, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
41125836|NCT04783025|BEHAVIORAL|Usual care, infection control briefing|Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staffs. Usually the briefing is irregular, non-standardized and determined by ICOs, depending on when the ICOs receive the information about infection control practice from Centre for Health Protection of the Hong Kong government. The format and duration of this briefing is determined by the ICO. Some ICOs deliver the infection control information in the form of posters or a written document, and circulate these materials to all staffs.
41125837|NCT04537936|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
41125838|NCT04537936|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
41125839|NCT04537936|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
41125840|NCT04537936|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
41276740|NCT06170645|OTHER|Sham transcutaneous VNS|After each APA session, a 1h-tVNS session is delivered on the left earlobe, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
40754515|NCT05084885|OTHER|Online therapy|Standard counseling provided over the internet.
40754516|NCT02344927|OTHER|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
40754517|NCT02344927|OTHER|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
40754518|NCT01218256|OTHER|Physical exercise training|aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
40754519|NCT00619398|DRUG|Prograf|Oral
40754520|NCT00619398|DRUG|FK506MR capsule|Oral
41125841|NCT00166322|PROCEDURE|IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion
41125842|NCT03852615|DIAGNOSTIC_TEST|Pre operation Blood sample for AMH|Blood sample for Anti Mullarian Hormone (AMH) analysis will be taken during preparation for surgery, while inserting vein line and taking the customary blood samples.
41276741|NCT05581043|DIETARY_SUPPLEMENT|3-hydroxybutyrate (3-OHB)|The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).
41276742|NCT01733355|RADIATION|[F18] T807|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
41276743|NCT04807894|DRUG|Vaginal Cream with Applicator|Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.
41276744|NCT00847340|PROCEDURE|Biopsy Excisional|Biopsied from genital warts will be taken through an excisional procedure. Homeostasis will be obtained by using apply of Monsel solution. Biopsied sample will be splinted in order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the pathology laboratory for haematoxiline - eosine paint and lecture.
41276745|NCT04544566|DEVICE|Test product A|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
41276746|NCT04544566|DEVICE|Test product B|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
41276747|NCT04544566|DEVICE|Comparator|Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
41276748|NCT05047913|DRUG|18F-FTX|Given By IV
41276749|NCT03584009|DRUG|Venetoclax|Venetoclax was administered orally, 800-mg tablet beginning on Cycle 1 Day 1 until the 9th October 2020.
41276750|NCT03584009|DRUG|Fulvestrant|Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
41276751|NCT06494579|DRUG|Lamivudine|Lamivudine is used in the management of human immunodeficiency virus (HIV) and Hepatitis B Virus. It is being repurposed here to assess if this can improve response to cancer immunotherapy
41276752|NCT06494579|DRUG|PD-L1 Blocker|PD-1 or PD-L1 blocking antibodies; there are around a dozen of these FDA approved for varying indications, and whatever is administered to a patient as standard of care (FDA APPROVED) will be continued in the patients and administered in combination with lamivudine.
41276753|NCT03603743|BEHAVIORAL|exercise training in heart failure with HIIT|to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.
41276754|NCT06292013|DRUG|Lepodisiran Sodium|Administered SC
41276755|NCT06292013|DRUG|Placebo|Administered SC
41276756|NCT00632580|DRUG|intraarticular injection with ropivacaine|
40754521|NCT02634697|BEHAVIORAL|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
41276757|NCT00632580|DRUG|extraarticular injection with ropivacaine|
41276758|NCT04697225|BEHAVIORAL|weight loss strategies|Participants will receive recommendations on how to increase physical activity, decrease caloric intake, monitor their weight, and track the related behaviors and progress.
41276759|NCT04697225|BEHAVIORAL|weight loss coaching sessions and email support|Participants will receive weekly coaching sessions and tailored support emails.
41276760|NCT02861170|BEHAVIORAL|Brief Mindfulness-Based Intervention|In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
41276761|NCT04865848|PROCEDURE|Dental local anesthesia|Dental local anesthesia
41276762|NCT00534534|BEHAVIORAL|Repeated behavioural intervention without any drugs|"All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period."
41276763|NCT03851510|DEVICE|Vector ventilator|The Vector ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with the primary cause being COPD. This device is not intended for life support. It may be used to screened for the presence and abolishment of expiratory flow limitation. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments. The vector ventilator will titrate and treat EFL using non-invasive ventilatory support.
41276764|NCT03851510|DEVICE|Resmon Pro|The Resmon Pro uses the forced oscillation technique (FOT) which is a noninvasive method to measure the mechanical properties of the lung and airways during tidal breathing. In addition to measuring total impedance (resistance and reactance), the Resmon Pro can measure expiratory flow limitation which is a key index of respiratory obstruction
41287290|NCT06203808|OTHER|COMPLETION OF QUESTIONNAIRES|Both groups of patients will complete quality of life questionnaires at the time of treatment information, at 3 months, 6 months and at 12 months.
41276765|NCT05888025|BEHAVIORAL|Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T)|MBCT-T will be delivered in groups of four to eight subjects by telephone using a conference line with NYULH WebEx. Participants will receive a workbook containing session content and home practice logs and audio guides for home practice. Subjects will complete individual orientation sessions with the MBCT-T facilitator prior to start of the group sessions. The four subsequent weekly group sessions are approximately 90 minutes long. Participants will be encouraged to practice daily meditation in between group sessions for 20-30 minutes, six days per week
41125843|NCT03852615|DIAGNOSTIC_TEST|3 month post operation blood sample for AMH|Additional blood sampling that will include a single tube containing 3 cc of blood for analysis of AMH will be taken three month from operation.
41125844|NCT02795052|PROCEDURE|Intravenous and Intranasal BMSC|Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)
41276766|NCT02669693|DIETARY_SUPPLEMENT|bread without olives|
41276767|NCT02669693|DIETARY_SUPPLEMENT|bread with olives|
41276768|NCT00089557|DRUG|Capsaicin Dermal Patch|
41276769|NCT02906553|DRUG|Glyceryl Trinitrate|
41276770|NCT02906553|DRUG|Placebo|
41276771|NCT01769911|DRUG|carmustine|Given IV
41276772|NCT01769911|DRUG|cytarabine|Given IV
41276773|NCT01769911|DRUG|melphalan|Given IV
41276774|NCT01769911|DRUG|etoposide|Given IV
41276775|NCT01769911|DRUG|O6-benzylguanine|Given IV
40754522|NCT02088411|DRUG|Diclofenac|
41125845|NCT06326125|BEHAVIORAL|TICK-B|TICK-B as art-based distraction
41125846|NCT06326125|DRUG|TKTX-Cream|TKTX-Cream as local anesthesia cream
41125847|NCT06326125|OTHER|TICK-B and TKTX-C|TICK-B and TkTx-C as combined intervention approche (pharmacology and non-pharmacology)
41125848|NCT05103618|DRUG|[F-18] Fluorodopa Positron Emission Tomography|Subjects will receive FDOPA imaging at baseline and 2-3 months after practicing the OM Meditation for evaluation of the dopamine function, \[F-18\] Fluorodopa (FDOPA), dose (5-10 mCi, ± 20%) will be injected intravenously into an antecubital vein. In accordance with the standard imaging protocol for FDOPA; subjects will be pre-medicated with 200 mg of carbidopa orally approximately one hour prior to injection.
41276776|NCT01769911|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo transduced and/or non-transduced transplant
41276777|NCT01769911|PROCEDURE|peripheral blood stem cell transplantation|Undergo transduced and/or non-transduced transplant
41276778|NCT01769911|OTHER|laboratory biomarker analysis|Correlative studies
41276779|NCT02547623|DRUG|Dexamethasone|depot intracameral
41276780|NCT02547623|DRUG|Prednisolone|Prednisolone eye drops 1%
41276781|NCT06299098|DRUG|Trevogrumab-Part A|Administered IV or SC in Part A
41276782|NCT06299098|DRUG|Trevogrumab-Part B and Part C|Administered SC in Part B, Part C
40754523|NCT02088411|DIETARY_SUPPLEMENT|Wobenzym|
40754524|NCT02088411|OTHER|Placebo|
40754525|NCT01053065|DRUG|Atorvastatin - Cholestyramine - Sitosterol|
40754526|NCT05613088|DRUG|MORAb-202|Specified dose on specified days
41125849|NCT05103618|BEHAVIORAL|OM Meditation|Couple pairs will engage in OM Meditation together approximately 3-4 times a week approximately 2-3 months.
41276783|NCT06299098|DRUG|Garetosmab|Administered IV in Part B
41276784|NCT06299098|DRUG|Semaglutide|Administered SC in Part B and Part C
41276785|NCT06299098|DRUG|Matching Placebo-Part A|Administered IV or SC in Part A
41276786|NCT06299098|DRUG|Matching Placebo-Trevogrumab|Administered SC in Part B and Part C
41276787|NCT06299098|DRUG|Matching Placebo-Garetosmab|Administered IV in Part B
40754527|NCT05613088|DRUG|Paclitaxel|Specified dose on specified days
40754528|NCT05613088|DRUG|Pegylated Liposomal Doxorubicin (PLD)|Specified dose on specified days
40754529|NCT05613088|DRUG|Topotecan|Specified dose on specified days
41125850|NCT05049421|DIAGNOSTIC_TEST|Echocardiography|Full 2D and 3D echocardiography with special focus on right ventricular function
41125851|NCT00204672|DRUG|Achipex|
41125852|NCT04019509|DIAGNOSTIC_TEST|blood test|blood test for thyroid antibodies and thyroid function (TSH, FT4)
41125853|NCT04019509|OTHER|follow up treatment outcome|questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery
41276788|NCT06657183|DEVICE|Alio Smart Patch™|"Alio Smart Patch is a non-invasive wearable biosensor that combines a unique, multi-sensor, wearable device with a provided- based portal to track sequentially the participant's physiologic, hematologic and electrolyte data. It works in conjunction with a home hub data relay system and an end-to-end cloud software data path. The system has been developed to enable home monitoring for multiple key metrics by healthcare provider caring for participants.~Enhanced Care Management (ECM) is a comprehensive, system-centric approach crafted to bridge the latent gaps in traditional care paradigms. ECM provides an exhaustive review of a participant's medical history and their personalized social needs, addressing both in a cohesive, participant-focused strategy.~This intervention couples Quantify Remote Care's Enhanced Care Management with the Alio Smart Patch technology."
41276789|NCT06222892|DRUG|Camlipixant|Camlipixant will be administered.
41276790|NCT06168409|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~• 2 mg per tablet."
41276791|NCT06168409|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
41276792|NCT06654648|OTHER|Combined exercise nutrition intervention group|Combination Product: Combined exercise and nutrition intervention Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks). Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol. Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink.
41125854|NCT05937685|BEHAVIORAL|BP REACH Intervention|Educational materials, written and digital. Home blood pressure monitor and self management education from BP REACH coach. Monthly coaching calls from BP REACH coach. Medication management by pharmacist
41125855|NCT05835375|OTHER|EQ-778|"1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)"
41125856|NCT05835375|OTHER|Placebo|"1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)"
40754530|NCT04667559|DEVICE|Conformis iTotal Identity Knee Replacement System|The iTotal® Identity KRS is a tri-compartmental semi-constrained knee prosthesis composed of three components: a Femoral Component, a Tibial Component, and a Patellar Component.Using patient imaging, a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. The treatment allows for the placement of a cemented metallic device designed from the patient's natural bone geometry. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation.
40754531|NCT06126744|BIOLOGICAL|MVR-C5252|MVR-C5252 is a genetically modified next generation oncolytic herpes simplex virus 1 (oHSV1) with an active domain of human IL-12 and Fab fragment of anti-PD-1 antibody. This is a Phase 1 open label study designed to determine the safety and tolerability of MVR-C5252. The dose-escalation portion of the study will be conducted in 4 stages to evaluate the safety of infusion and determination of the MTD/RP2D followed by efficacy assessment.
40754532|NCT03103308|OTHER|Walk Training and Transplant|Subjects will receive free activity monitors and have three training sessions per week for the duration of their bone marrow transplant treatment
41125857|NCT01499316|PROCEDURE|High Flow oxygen|10 minute shigh flow oxygen
41125858|NCT01499316|PROCEDURE|Room Air|Room air breathing
41125859|NCT01245400|DEVICE|Z-Lig|ACL replacement
41125860|NCT01245400|DEVICE|allograft|ACL replacement
41125861|NCT02563119|PROCEDURE|Gastric Bypass or Sleeve gastrectomy|
41276793|NCT06654648|OTHER|Conventional medial care group|"Conventional medial care Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
41276794|NCT04154098|DEVICE|Scapula orthosis assistance|Participants are elevating their arm while their scapula is assisted by the scapula orthosis
41125862|NCT04703283|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
41276795|NCT04154098|PROCEDURE|Manual scapula assistance|Participants are elevating their arm while their scapula is assisted by a trained personnel
41276796|NCT04154098|OTHER|No assistance|Participants are elevating their arm without being assisted
41125863|NCT01696916|PROCEDURE|6-minute walking test|submaximum exercise test
41125864|NCT03750214|DEVICE|Biop Colposcopy System|"The procedure stages:~1. Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.~2. Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.~3. A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.~4. A questionnaire completed by the user after the Biop procedure, with regards to system usage~5. Image Registration analysis"
41125865|NCT00056966|DRUG|ANTI-CD45|400ug/kg Day-5 through Day-2
41276797|NCT04154098|OTHER|Functional Test|Participants perform a functional test once without (NO) and once with (OA) the orthosis
41125866|NCT00056966|DRUG|CAMPATH-1H|Day -8 through Day -6 Dosed per Institutional SOP
41125867|NCT00056966|DRUG|FK506|Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
41125868|NCT00056966|DRUG|Fludarabine|Day-8 through Day-5 30 mg/m2
41125869|NCT00056966|RADIATION|Total Body Irradiation|Day-1 single dose 450 cGy
41276798|NCT06143878|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
41276799|NCT06143878|DRUG|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
41276800|NCT06143878|DRUG|Deucravacitinib|Deucravacitinib will be administered orally.
41276801|NCT06143878|DRUG|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
41276802|NCT06655285|OTHER|This was a retrospective study and no patient intervention was performed.|This was a retrospective study and no patient intervention was performed.
41125870|NCT00056966|PROCEDURE|Stem cell infusion|Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count \>2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count \>2 x 108/kg) will be substituted.
41125871|NCT00331136|DRUG|Pyronaridine-Artesunate|Once a day for 3 days
41125872|NCT02059616|DRUG|Amlodipine 5mg|Daily oral administration for 8 weeks
41125873|NCT02059616|DRUG|Amlodipine 10mg|Daily oral administration for 8 weeks
41125874|NCT02059616|DRUG|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
41125875|NCT02059616|DRUG|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
40928201|NCT01027273|BEHAVIORAL|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
41125876|NCT03803748|DEVICE|Eyestil Plus®|• To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis
41125877|NCT03094169|DRUG|AVID100 IV|AVID100 is administered once every 3 weeks
41125878|NCT03986840|OTHER|Exercise training|A multicomponent exercise program
41125879|NCT00371787|DEVICE|Soft contact lens|Soft contact lens
41125880|NCT06266936|OTHER|No intervention|The study involves longitudinal monitoring of the state of health of the specific population of students in care courses, from their entry into university studies (first year) until their final year of study, i.e. from 5 to 13 years depending on the course and the different universities.
41125881|NCT03338868|OTHER|Body composition|evaluated by Bodystat®1500 Bio-impedance Analyzer
41125882|NCT03338868|OTHER|Physical activity level|assessed by the International Physical Activity Questionnaire-7
41125883|NCT03338868|OTHER|Musculoskeletal pain intensity|evaluated with Visual Analog Scale
41125884|NCT03338868|OTHER|Quality of life|assessed by the Nottingham Health Profile
41125885|NCT03338868|OTHER|Psychological Well-Being|assessed by the Hospital Anxiety and Depression Scale
41125886|NCT03338868|DIAGNOSTIC_TEST|Blood tests|Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.
41125887|NCT01606813|OTHER|Usual Care|Standard care
40928202|NCT03302182|DRUG|Ritonavir for cycle1 and NORVIR for cycle 2|During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .
40754533|NCT03103308|OTHER|Activity Monitoring and Transplant|Subjects will receive free activity monitors for the duration of their bone marrow transplant treatment
40928203|NCT03302182|DRUG|NORVIR for cycle 1 and Ritonavir for cycle 2|During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .
41125888|NCT01606813|BEHAVIORAL|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
41125889|NCT01606813|BEHAVIORAL|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
41125890|NCT01606813|BEHAVIORAL|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
41125891|NCT05546710|DEVICE|miraDry treatment|The miraDry device is non-invasive and uses microwave energy, focused at the dermal/hypodermal interface, to thermally impact the sweat glands. The treatment area is identified (hair bearing area of the axilla) and high-volume anesthesia is delivered. The miraDry template is selected based upon the size of the treatment area and temporarily applied to the patient's skin. A new miraDry bioTip is attached to the miraDry Handpiece for each treatment session. The Handpiece is then placed on the surface of the skin in the area to be treated. The treatment cycle is activated by a button on the Handpiece. Multiple placements of the Handpiece are required to treat a full axilla in one treatment session.
41125892|NCT00976651|DRUG|human menopausal gonadotropin|200 IU per day in the late follicular phase
41125893|NCT04776096|DRUG|Bepotastine Besilate 1.5% PF|Bepotastine besilate 1,5% Preservative free ophthalmic solution
41125894|NCT04776096|DRUG|Olopatadine Hydrochloride 0.2% BAK|Olopatadine hydrochloride 0.2% with BAK as preservative
41125895|NCT06262282|BIOLOGICAL|mycobacteriophage|mycobacteriophage phage that has been found effective in killing participants NTM infection
41125896|NCT03712150|DEVICE|tdcs|application of optimised parameters of tDCS (anodal stimulation, 1.5 mA, 10 min) over the unconditioned hemisphere reverses the brain and behavioural consequences of inhibitory pre-conditioning
41125897|NCT03166085|DRUG|PU-H71|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
41125898|NCT03166085|DRUG|Nab-paclitaxel|nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1
41447565|NCT05025137|OTHER|Flexi-Bar Exercise|"In the experimental group, the Flexi-Bar was adopted as the tool for active vibration exercises. Featuring light weight and ease of operation, it weighs only 460 grams and has a vibration frequency of 4-5 Hz. With diversified functions, the Flexi-Bar can improve posture, burn fat, strengthen connective tissue, enhance body shape, and increase muscle strength.~The 12-week Flexi-Bar exercise course in this study was created by two assistant professors specializing in rehabilitation (one with an occupational therapy certificate and the other with a physical therapy certificate). The course, composed of one 60-minute class per week for a total of 12 weeks, progressed gradually from basic activities (e.g., standing with both feet) to advanced activities (e.g., standing with one foot)."
40928204|NCT06210932|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum videos|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), A series of videos are developed based on the SEED curriculum, with specific themes for children in K2 and K3, each video last for approximately 10-12 minutes. They will watch three videos per week for a total of four weeks. The videos will be designed to promote social, emotional, and ethical development.
40928205|NCT02273739|DRUG|Enasidenib|Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
41447566|NCT05025137|OTHER|Multi-Component exercise|Alternatively, in the control group, the Multi-Component exercise was adopted, which included aerobic, resistance, flexibility, and balance exercises. The course was composed of one 60-minute class per week for a total of 12 weeks. The design was based on the ACSM's recommendations for the multiple-component exercise of the elderly (Chodzko-Zajko et al., 2009) and videos of the National Health Exercises for the Elderly formulated by the Ministry of Health and Welfare (Ministry of Health and Welfare, 2017). The course was created and led by a physical therapist to gradually progress from sitting postures to standing and walking postures. Additionally, the intensity of the exercises was adjusted according to the participants' physical conditions; fitness equipment was introduced when appropriate.
41447567|NCT03034096|DRUG|Propofol|Maintenance of general anesthesia with propofol infusion
40928206|NCT01766700|BEHAVIORAL|2 no calorie beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
41125899|NCT01630824|OTHER|Structured education program|structured education program after kidney transplantation
41125900|NCT05374525|DRUG|APRETUDE|Available as intramuscular injection.
41125901|NCT05374525|DRUG|Cabotegravir OLI|Available as marketed orally administered tablets.
41125902|NCT02577120|DEVICE|Epiceram Skin Barrier Function|Epiceram is a non-sterile, viscous, lipid-rich emulsion
41125903|NCT02577120|BIOLOGICAL|Vaseline Petroleum Jelly|A skin protectant used for temporarily protecting minor cuts, scraps, burns, and helps to protect and help relieve chapped or cracked skin and lips.
41125904|NCT02577120|BIOLOGICAL|Ceramiseal|Topical serum designed to fortify delicate skin with essential lipids. The proprietary blend of naturally occurring lipids contained in Ceramiseal are designed to improve the barrier function of your skin's outer layer; thereby restoring critical moisture balance and improving physical appearance and function.
41125905|NCT03578198|DRUG|Rituximab + MG4101|"1. Induction phase:~   * Rituximab (Truxima) 375mg/m2 IV Weekly (X4)~  * MG4101 3x107 cells/kg IV Weekly (X4)~2. Maintenance phase~   * Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)~  * MG4101 3x107 cells/kg IV q 4 weeks (X4)"
41125906|NCT03954275|OTHER|no intervention|no intervention
41276803|NCT03114449|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling fixed needles at specific AA points
41276804|NCT03114449|DEVICE|Sham auricular acupuncture|Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
41276805|NCT01717638|BIOLOGICAL|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
41276806|NCT01717638|BIOLOGICAL|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
41276807|NCT05428709|BEHAVIORAL|Acute Exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
41276808|NCT03622645|DEVICE|Assessment of Range of Motion with Leap Motion sensor|An ROM measurement method called as HandROM by us will be developed with leap motion sensor
41276809|NCT00759629|OTHER|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
41276810|NCT00759629|OTHER|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
41447568|NCT03034096|DRUG|Volatile Agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
41447569|NCT05578443|DRUG|10g Astragalus|Astragalus tablets 10g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
41125907|NCT02555215|DRUG|dimethyl fumarate|administered orally
41125908|NCT00697060|DRUG|Imexon + docetaxel|Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
41125909|NCT04141514|OTHER|therapeutic fasting|fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)
41125910|NCT01426698|PROCEDURE|delayed cord clamping|at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
41447570|NCT05578443|BEHAVIORAL|Routine treatment|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
40928207|NCT01766700|BEHAVIORAL|2 water beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
40928208|NCT02282345|OTHER|Laboratory Biomarker Analysis|Correlative studies
40928209|NCT02282345|DRUG|Talazoparib|Given PO
40928210|NCT00534261|DRUG|Interferon beta-1a|IM injection
40928211|NCT00167297|DRUG|Atomoxetine|
40928212|NCT02253927|DRUG|BILR 355 - D1|
40928213|NCT02253927|DRUG|BILR 355 - D2|
40928214|NCT02253927|DRUG|BILR 355 - D3|
40928215|NCT02253927|DRUG|BILR 355 - D4|
40928216|NCT02253927|DRUG|Ritonavir|
40928217|NCT02253927|OTHER|high fat breakfast|
40928218|NCT00062816|DRUG|ISIS 14803, peginterferon alfa, ribavirin|
40928219|NCT06008912|OTHER|Calisthenic Exercises|Exercises for upper extremity, lower extremity and trunk which applying just patient's own body weight via using body mechanics. There is no need for any tools for exercises.
40928220|NCT06008912|OTHER|Aerobic Exercises|Exercises which loading cardiovascular, respiratory and muscular system at the same time. Treadmill training will apply in the study.
41125911|NCT04302142|DEVICE|ventilation with critical intracuff pressure (Pcr)|Once the intra-cuff pressure is measured and recorded, the cuff will be deflated by drawing the air 0.5ml per step with each step lasting 3 breaths until a leak, in which a 10% reduction in expiratory volume over the inspiratory tidal volume, is detected.Cuff will then be reinflated until the expiratory tidal volume reaches the inspiratory tidal volume and the discrepancy between the inspiratory and expiratory tidal volume is less than 10 percent. If the intra-cuff pressure applied by the anesthesia care team is inadequate and the discrepancy between the inspiratory and expiratory tidal volume is 10% or greater, the cuff will be further inflated with air 0.5ml per step with each step lasting 3 breaths until it reaches Pcr. This Pcr will be maintained during the entire anesthesia time until extubation.During the course of surgery, if any leak is detected, the cuff will be re-inflated by 0.5ml of air until the leak is not detectable.
41447571|NCT05578443|DRUG|20g Astragalus|Astragalus tablets 20g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
41447572|NCT04263714|BEHAVIORAL|Exercise|Aerobic exercise and resistance exercise
41447573|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
40928221|NCT03720392|DRUG|FMT|FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
40928222|NCT03720392|DRUG|Placebo|a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
40928223|NCT04710771|OTHER|Prone Lying Position|patient lies on his/ her stomach facing floor.
40928224|NCT04710771|OTHER|alternate nostril breathing|patient inspires with one nostril at a time, right or left one by one and expires by mouth.
40928225|NCT01343823|DRUG|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
40928226|NCT01343823|DRUG|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
40928227|NCT01343823|DRUG|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
40928228|NCT01343823|DRUG|placebo|Administered as two SC 3 mL injections
40928229|NCT01343823|DRUG|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
40928230|NCT01343823|DRUG|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
40928231|NCT03313661|DRUG|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
40928232|NCT03313661|DRUG|Gliclazide|gliclazide (60-120 mg)
40928233|NCT05763589|OTHER|No intervention is involved|No intervention is involved
40928234|NCT01781091|DEVICE|INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION|
40928235|NCT01781091|DEVICE|Conventionals Modes|
40928236|NCT04861402|DEVICE|The ICP monitoring will be performed in a non-invasive method developed by Brain4Care|"The ICP monitoring will be performed in a non-invasive way through the cranial deformation method developed by Brain4Care Inc.~The selected patients will be monitored until 1h/day for 7 sequential days or even discharge. The clinical outcomes such as ventilatory status will be noted (if the subject is under oxygen supplementation, using non-invasive mechanical ventilation or intubated), the ventilatory parameters during the monitorization will be analyzed in the intubated group (or those from a non-intubated group who was intubated during the seven days of hospitalization) including IFO2, CV, PEEP, driving pressure, and pressure plate as well as ventilatory asynchronies. Some changes in ventilatory parameters during monitorization will be noted. These procedures will be applied to all groups, excepted to the healthy group. This last group will be monitored only once for 30 minutes at the Federal University of São Carlos (UFSCar)."
41125912|NCT04302142|DEVICE|ventilation with critical intracuff pressure (Pcr)|Pcr is obtained just as it is done in the intervention group. The cuff will then be reinsufflated to the actual cuff pressure the care team initially chose. The care team will be blinded to the measured critical cuff pressures and hence will maintain the usual level of intracuff pressure in the control group during the entire anesthesia time.
41125913|NCT00145236|DRUG|Nebivolol|
41125914|NCT03575936|DEVICE|Home INR Monitoring|The self-monitoring group will monitor INR at home using the AlereTM Home Monitoring Service. They will call in the weekly results to Alere or submit online via the patient portal, which is the standard protocol among home monitoring patients. Alere will then upload the information to a password-protected HIPAA compliant website that only study investigators will be able to access. Pharmacists will have real-time access to the test results via the web interface. Pharmacists can follow up in real time if the patient forgets to self-test. An alert will also be sent to the pharmacists via email to follow up on any out of range results. This will help streamline pharmacists' workload to dedicate face-to-face time for patients that require such intervention. All home monitoring patients will be seen in clinic by the pharmacist at the end of the 3-month randomization period in order to assess compliance with meter-use and re-evaluate meter-use competency.
41125915|NCT03575936|PROCEDURE|Standard of Care|The patients in the standard of care group will have a clinic visit with the pharmacist at least once every 4 weeks or earlier, as deemed necessary by the pharmacist. The duration of the randomization period will be three months. At the end of the 3-month randomization period, patients will be provided the opportunity to cross over from the home INR monitoring group to the pharmacist-managed clinic group, or vice versa. The remainder of the study duration (post-3 month analysis) will purely be for observational purposes, in order to account for the loss of randomization and potential bias. The total duration of the study will be one year.
41276811|NCT05710718|DEVICE|PureWick™ System|The PureWick™ FEC is intended for non-invasive urine output management in female patients. The PureWick™ FEC is a flexible, contoured external catheter that is positioned against the area where urine exits the female body. The PureWick™ FEC will be connected to the PureWick™ Urine Collection System (PUCS) via connector tubing. The PUCS uses suction (not felt by the user) to pull voided urine through the device, regardless of the urine flow rate. Urine continues through vinyl tubing until it reaches a collection canister, away from the body.
41447574|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-30g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 30 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 32 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
41447575|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-40g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 40 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 24 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
41447576|NCT03595436|DIETARY_SUPPLEMENT|Whey Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g whey protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
41447577|NCT03595436|DIETARY_SUPPLEMENT|Carbohydrate Control|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 5 g mixed protein (from yogurt and peanut-butter), 59 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
41447578|NCT03711448|DRUG|prednisone treatment|tapering prednisone regimen
41447579|NCT03711448|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
41447580|NCT03711448|OTHER|questionnaires|HAQ ; SF-36 ; FACIT-fatigue
41447581|NCT03711448|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
41447582|NCT00371839|PROCEDURE|Audiological Evaluation|Tests of hearing, cognition, and speech perception
41276812|NCT05710718|DEVICE|Hollister® Female Urinary Pouch External Collection Device|It is designed to be emptied and should be attached to a drainage bag. The FUP is made with hydrocolloid skin adhesive and polymer/copolymer plastics.
41276813|NCT02016248|RADIATION|Stereotactic Ablative Body Radiotherapy as Monotherapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
40754534|NCT05116644|OTHER|NONE - this is a cross-sectional survey design|NONE - this is a cross-sectional survey design
41447583|NCT03548194|DRUG|BNC210|BNC210 300 mg b.i.d
41447584|NCT03548194|DRUG|Placebo|Placebo b.i.d.
41447585|NCT03710629|OTHER|Patients with driver genes|Patients with driver genes
40928237|NCT04161768|DRUG|Norfloxacin|Norfloxacin 400 mg daily
40928238|NCT04161768|DRUG|Itopride|Itopride 50 mg three times daily
41125916|NCT06514417|OTHER|US-guided external oblique intercostal block|"After induction of general anesthesia, external oblique intercostal block will be performed (8) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz).~the patient will be positioned supine, and a linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib. 20 ml of bupivacaine 0.25% will be injected between the plane of the external oblique and the intercostal muscles. The drug will be injected after a negative aspiration.~The contralateral side block will be performed in a same manner."
41447586|NCT01850173|DEVICE|A vertical vibration platform Fitybe|They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
41125917|NCT01030107|BEHAVIORAL|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
41447587|NCT03583398|PROCEDURE|transcatheter aortic valve implantation, surgical aortic valve replacement|Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
40754535|NCT02349828|DRUG|Acyclovir|
40754536|NCT00344669|DRUG|Albendazole 400 mg, given 6 monthly|
41125918|NCT01030107|BEHAVIORAL|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
41276814|NCT02016248|RADIATION|Stereotactic Ablative Body Radiotherapy as a Boost|The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.
41276815|NCT03572088|DRUG|Terlipressin|Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)
41447588|NCT04981262|DIETARY_SUPPLEMENT|Stimulance|Intervention with Prebiotic supplement
40754537|NCT00655356|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
40928239|NCT00415298|DRUG|DACH polymer platinate AP5346|
40928240|NCT00415298|DRUG|oxaliplatin|
40928241|NCT00415298|GENETIC|gene expression analysis|
40928242|NCT00415298|OTHER|immunohistochemistry staining method|
40928243|NCT00415298|OTHER|pharmacological study|
40928244|NCT00415298|PROCEDURE|biopsy|
40928245|NCT02397564|DEVICE|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
40928246|NCT05658523|BIOLOGICAL|Bivalent Moderna|A single standard dose of the bivalent Moderna (mRNA-1273.214) COVID-19 vaccine containing equal amounts of mRNAs (25μg of each mRNA sequence) that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 \[BA.1\]) with mRNAs encapsulated in lipid nanoparticles, will be administered on day 0 of the study.
40754538|NCT00655356|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
40928247|NCT05658523|BIOLOGICAL|Novavax|A single dose of Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms), will be administered on day 0 of the study.
40928248|NCT04650061|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|With MI, the key goal is to empower the patient to commit to follow CPAP therapy, while providing empathic support, in a positive atmosphere, and without prejudice. The nurse does not directly advocate for behavior change (i.e. use CPAP as prescribed), but asks key questions to help the patient explore their feelings about the change, weighs the pros and cons of such change, and allows the patient to realize the discrepancy between the current risk (that is, not using CPAP as directed) and the benefits with good adherence.
40928249|NCT04650061|DEVICE|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
40928250|NCT02943083|BEHAVIORAL|Relaxation Exercise|Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
40928251|NCT00004382|DRUG|tin mesoporphyrin|
40928252|NCT00004382|PROCEDURE|Phototherapy|
40928253|NCT03830905|DRUG|XC221|Participants will receive 200 mg XC221 once a day during 3 days
40928254|NCT03830905|DRUG|Placebo|Participants will receive Placebo once a day during 3 days
41125919|NCT04121546|BEHAVIORAL|Telecare Intervention|Patients will meet with a care coordinator to discuss current opioid use pattern and potential reduction strategies. Participants will fill out baseline measures. A 6 week positive psychology intervention will also be introduced in which patients will practice different techniques each week over 6 weeks, and will then practice incorporating a single technique into daily practice for the remaining 6 weeks. During the first 6 weeks, patients will have weekly check in meetings with a care manager to report on any withdrawal symptoms. These meetings will space to ever other week during the remaining 6 weeks. Possible treatment adjustments will be discussed between the care coordinator and primary investigator at weekly meetings. At the completion of the 12 week study, patients will complete outcome measures.
41125920|NCT02118870|DRUG|Treatment 90 days DAPT|Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
41125921|NCT02118870|DRUG|Treatment 360 days DAPT|Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
41125922|NCT03134300|DIAGNOSTIC_TEST|Cytokine from blood|Blood draw- one intraoperative, one 3 weeks postoperative
41125923|NCT05949359|OTHER|Nintendo RingFit-augmented exercise program|"Participants in the NRE group received an 8-week exercise training program using the Nintendo RingFit (60 minutes for each session, two sessions a week). In each session, the participants first performed 5 minutes of walk-up exercises (i.e., simple jogging), followed by 50 minutes of Nintendo RingFit exercises and 5 minutes of cool down exercises.~The exercise intensity, in terms of repetitions, holding time of the exercise and advancement to difficult tasks, progressed gradually in 8 weeks."
41125924|NCT00061906|DRUG|celecoxib|Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.
41125925|NCT04558723|OTHER|ICD/CRT-D implantation|ICD/CRT-D implantation (if indicated)
41125926|NCT00744913|DRUG|Nicoderm patches|Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
41276816|NCT03572088|DRUG|normal saline|Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
41276817|NCT05384301|OTHER|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
41276818|NCT06656195|OTHER|glueus maximus strengthening|In week 1 SIJ Mobilization along with ,Single leg bridge ,alternating leg lifts ,clam Exercise,Prone hip extension with knee flexion. In week 2 SIJ Mobilization along with Side-squats,Star excursion exercise,Forward step-down.In week 3 SIJ Mobilization along with bilateral squat ,single leg squat ,split squat/lunge ,frontal step up ,lateral step up.In week 4 SIJ mobilization along with bilateral squat with a band and hip extension against resistance was done.Three times a week for 4 weeks In each session, a total of two sets of 12 repetitions each were carried out, with a 1 min rest time between sets.
40754539|NCT04403126|OTHER|forgiveness education intervention|The forgiveness education intervention primarily teaches the concept of forgiveness through stories. We chose the kind of stories that should appeal to children ages 10 through 12. Each lesson is planned according to the following procedure: story-telling/movie-watching, discussion, and in-class activities.
40928255|NCT02257671|DRUG|Oral contraceptive|Neovletta
41125927|NCT00744913|OTHER|Counselling|Women in this arm of the study will receive standard counseling only.
41125928|NCT00999336|DRUG|Betrixaban|80 mg betrixaban qd for 8 days
41125929|NCT02752659|PROCEDURE|Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference|
41125930|NCT05152849|DRUG|AXA1125|AXA1125 administered BID with or without food
41125931|NCT05152849|DRUG|Placebo|Matching Placebo administered BID with or without food
41276819|NCT06656195|OTHER|hamstring stretching group|SIJ mobilization and Soft tissue mobilization along with Static Hamstrings stretching (3 sets, 15 repetitions with a holding time of 15 seconds ,3 times a week for 4 week) and Dynamic hamstrings stretching(3 set, 15 repetitions with a holding time of 1 second, 3 times a week for 4 weeks.
41276820|NCT00343902|DRUG|Crataegus Special Extract WS 1442|
40928256|NCT02785289|DEVICE|Vaginal swab|Vaginal cell collection will be performed with the two types of indicated swab.
40928257|NCT05101798|DRUG|5-Aminolevulinic acid Hydrochloride|The closure consists of colorless glass vial (Type II, Ph Eur) and bromobutyl-rubber stopper ø 20 mm (Type I, Ph Eur) and flip cap. The powder for oral solution is intended for single (partial) use. To prepare the ready-to-use solution the content of one vial is dissolved in 50 ml of water or apple juice. The concentration of the reconstituted solution is 3%. Gleolan® is administered orally to patients prior to tumor removal by surgery (20 mg/kg BW). The reconstituted solution may be prepared up to 24 hours prior to use if protected from light. It should be given 3 hours (range 3-5 hours) prior to planned induction of anesthesia for surgery, although its effect is present for up to 8-12 hours. This step is critical for an optimal visualization of tumor tissue due to pharmacokinetic properties of Gleolan®.
40928258|NCT03056599|DRUG|Multiple drug microinjection|This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
41125932|NCT02920034|DEVICE|Radiofrequency denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
41125933|NCT02920034|DEVICE|Radiofrequency denervation of renal arteries and branches|Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
41125934|NCT02920034|DEVICE|Ultrasound denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
41125935|NCT03836222|DRUG|PCS499|MR tablet
41276821|NCT03519048|PROCEDURE|Nasofibroscopy|every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter
41125936|NCT03836222|DRUG|Trental|comparator tablet
41125937|NCT01964781|DRUG|Tranexamic Acid|Topical administration - does it reduce surgical bleeding?
41125938|NCT01964781|DRUG|Bupivacaine|Topical Bupivacaine- does it reduce surgical pain?
41125939|NCT01964781|DRUG|Adrenaline|Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
41125940|NCT01964781|DRUG|tranexamic acid plus saline|
41125941|NCT01964781|DRUG|saline|
41125942|NCT02002845|DEVICE|robotic surgery using the da Vinci Surgical System|
41125943|NCT03277404|PROCEDURE|Root canal treatment with smear layer removal|Canal were irrigated with Naocl and EDTA to remove smear layer
40928259|NCT03056599|DEVICE|CIVO device|Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.
40928260|NCT01642810|BEHAVIORAL|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
41125944|NCT03277404|PROCEDURE|Root canal treatment without smear layer removal|only sodium hypochlorite was used for irrigation
40928261|NCT01642810|OTHER|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
40928262|NCT05503667|DRUG|Furmonertinib|Furmonertinib 80 mg/day for 16 weeks
40928263|NCT05503667|DRUG|Bevacizumab|bevacizumab 400 mg/4 weeks i.v. for 4 times
40928264|NCT03315091|DRUG|Treatment A - AZD1775 administered under fasted conditions|Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
40928265|NCT03315091|DRUG|Treatment B - AZD1775 administered under fed conditions.|"Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor."
40928266|NCT03265964|DRUG|Uridine|Uridine is the active treatment in this clinical trial.
40928267|NCT03265964|DRUG|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
41125945|NCT02717468|DEVICE|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the digital artery (ClearSight®)|
41125946|NCT02717468|DEVICE|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the radial artery (Pulsioflex®).|
41125947|NCT04105712|BEHAVIORAL|Dietary Change (low in highly processed foods)|For post-dietary change, food is provided for 3 days (participants provide own food and do food journals the other 2 days to confirm adherence). University of Michigan's Nutrition Obesity Research Center (NORC)'s Metabolic Kitchen prepares the food. Low HP food diet is based on prior methods where participants are placed on an isocaloric diet composed of 5% or less of calories from added sugar and 10% or less of overall calories from total sugar. No foods that meet the criteria for a HP food (defined by Kant and colleagues) that corresponds to: sweeteners (sugar, candy, etc); carbonated and non-carbonated beverages (fruit drinks, sweetened / diet beverages, etc.); baked / dairy desserts (cookies, ice cream, etc.); salted snacks (potato chips, etc.) and fast foods (pizza, cheeseburgers, etc.) are included in diet portions. The overall macro nutrient composition of the diet will be approximately 20-25% of kcal from protein, 30-35% of kcal from fat, and 40-50% of kcal from carbohydrates.
41125948|NCT02405559|DRUG|Indocyanine Green|Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg
41125949|NCT03738384|DEVICE|Knee Connect + Visual Feedback System|A device to measure knee angle. It sends data a smartphone or tablet to be displayed as part of a visual feedback system.
41276822|NCT03519048|OTHER|Low Dose Chest CTscan|every year in patients with tobacco consumption history of \> 20 pack-year
40754540|NCT04739345|DRUG|Pentoxifylline|400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health
41125950|NCT04860505|DRUG|Doxycycline|Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.
41276823|NCT03519048|OTHER|injected CT-scan|the first performed 12 months after inclusion
41125951|NCT04860505|DRUG|Biktarvy|Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.
41125952|NCT00038636|DRUG|Lopinavir/ritonavir|
41125953|NCT00038636|DRUG|Ritonavir|
41125954|NCT01345422|OTHER|Wii Balance Board|Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
41125955|NCT00421759|DEVICE|Vibrating Insoles|Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
41125956|NCT01623908|DRUG|Zoledronate|4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
41125957|NCT00448552|DRUG|capecitabine|
41125958|NCT00448552|DRUG|oxaliplatin|
41125959|NCT06514391|PROCEDURE|compressive single piece dental implant|4 inter-foraminal single piece compressive dental implants were placed in the mandible via flapless protocol by the aid of stereolithographic surgical guide
41125960|NCT05283408|DRUG|Dexmedetomidine infusion|Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
41125961|NCT05283408|DRUG|Co-administration dexmedetomidine and low-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
41125962|NCT05283408|DRUG|Co-administration dexmedetomidine and high-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
41125963|NCT03098589|DRUG|Revlimid|Revlimid
41125964|NCT03631290|BEHAVIORAL|Deprescribing Intervention|"The deprescribing program was implemented as a clinical quality improvement project for patients receiving dialysis. Patients taking specific potentially inappropriate medications (PIMs) were identified in the medical record. The PIMs of interest included gabapentinoids, clonidine, alpha blockers, muscle relaxants, and Z-drugs. If their nephrologist agreed to attempt deprescribing the PIM, either the nephrologist (Provider Only Communication) or a study team member (pharmacist or nurse, Provider/Patient Communication) would engage the patient in discussion about deprescribing. This discussion included patient education materials about the risk of the medication. If the patient agreed, they were provided taper instructions (if indicated) and were followed up at 1 month and 3 months.~The patient was also invited to enroll in a study to be interviewed about the deprescribing decision and experience, and undergo brief assessment of geriatric problems at baseline and at 3 months."
41125965|NCT04415775|OTHER|Game based treadmill Program|Participants will be expected to play several cognitive computer games while standing on a sponge pad (10-min warm-up and while walking on the treadmill at your self-selected comfortable speed. (Dual-task treadmill training). This would be done in intervals of 2-4 min with rest periods for a total time of 35 minutes Treadmill speed and the difficulty level of the cognitive games will progress depending on participant performance and comfort level.
41125966|NCT04415775|OTHER|Conventional Gait Rehabilitation|Participants will undergo a mixture of current gait training programs available for people with Parkinson's Disease. The protocol will be a Warm-up exercise consisting of rhythmical large movements (10 minutes), as well as video game practice while standing (i.e., single-task; 10 minutes). Treadmill walking in intervals of 2-4 minutes with rest periods. Walking over the ground while negotiating through obstacles. (10 minutes) The speed of the treadmill will be progressed gradually and as tolerated.
41125967|NCT02448576|RADIATION|prophylactic cranial irradiation|Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
41125968|NCT02147093|DEVICE|Test (multi-focal)|contact lens was to be worn a daily wear.
41125969|NCT02147093|DEVICE|Control (Sphere)|contact lens was to be worn a daily wear with spectacles
41125970|NCT01964534|DRUG|ABI-007|ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
41125971|NCT01964534|DRUG|Gemcitabine|1000 mg/m² IV /30min (day 1, day 8, day 15)
41125972|NCT01964534|DRUG|simplified LV5FU2|Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
41125973|NCT02523222|DIETARY_SUPPLEMENT|40% Dextrose gel|40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
41125974|NCT02252822|BEHAVIORAL|Overcoming Bulimia Online Programme|
41125975|NCT05698758|DRUG|Dextrometropine and 0.9% sodium chloride solution|Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
41125976|NCT04930406|OTHER|Physical therapy|Had to receive 10 or more visits of physical therapy during the cancer treatment period to qualify for intervention group.
41125977|NCT00018096|BIOLOGICAL|LPS endotoxin, saline, HDM|instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
41125978|NCT05058040|DRUG|Sodium Oligomannate Capsules|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
41125979|NCT02259049|DIETARY_SUPPLEMENT|L-tyrosine|Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
41125980|NCT02259049|DIETARY_SUPPLEMENT|Sugar Pill|Each subject will receive a sugar pill BID for 24 hours.
41125981|NCT03449771|OTHER|self-administered questionnaire|The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale).
41276824|NCT03519048|OTHER|whole body PET-CT|annual whole body PET-CT (the first at 6 months after inclusion)
40928268|NCT05356728|DRUG|Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop|One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
41125982|NCT06225310|DRUG|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in t
40928269|NCT01403233|DIETARY_SUPPLEMENT|cogniVida 50mg/day|2 capsules 25 mg (total 50 mg) cogniVida™ once a day
41125983|NCT06225310|DRUG|Ruxolitinib|elective inhibitor of Janus kinase (JAK)
40928270|NCT01403233|DIETARY_SUPPLEMENT|cogniVida100mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
40928271|NCT01403233|DIETARY_SUPPLEMENT|Rebaudioside-A 303.7mg/day|4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
41125984|NCT06225310|DRUG|Methylprednisolone|Glucocorticoid, steroid
40754541|NCT02853773|OTHER|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with artificially sweetened drinks
40928272|NCT05121779|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.
40928273|NCT05121779|DRUG|18F-FDG|Intravenous injection of one dosage of 4.44-5.55 MBq(0.12-0.15mCi)/Kg 18F-FDG. Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.
40928274|NCT00997113|DRUG|propofol|1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
40928275|NCT00997113|DRUG|alfentanil|alfentanil 10 ug/kg immediately prior to propofol dose
40928276|NCT00545129|DRUG|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
40928277|NCT00545129|DRUG|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
41125985|NCT01862016|PROCEDURE|APRV|Pressure ventilation mode allowing early spontaneous breathing
41125986|NCT01862016|BIOLOGICAL|arterial blood gas measurement each morning|
41125987|NCT01079949|DRUG|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
41125988|NCT01079949|DRUG|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
41125989|NCT01079949|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
41125990|NCT01079949|DRUG|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (\>=) 14 mm, and maintained until at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
41125991|NCT04504136|PROCEDURE|Serial Biopsy|"During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach."
40928278|NCT01528540|DRUG|Placebo|This group will include placebo.
40928279|NCT01528540|DRUG|Antioxidant plus Pregabalin|This group will contain combination of antioxidant cocktail and pregabalin
40928280|NCT06275477|DIAGNOSTIC_TEST|68Ga-FAPI46|Depending on the situation, it is planned that this evaluation will be transversal (performing \[68Ga\] Ga-FAPI PET/CT at baseline) or longitudinal (performing \[68Ga\] Ga-FAPI PET/CT at baseline and at 3/6 months for patients benefiting from an intensification of therapeutic management at inclusion).
41125992|NCT02847013|DRUG|TAP block w Liposomal bupivacaine|TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)
41125993|NCT02847013|PROCEDURE|TAP block w normal saline|TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
41276825|NCT03519048|PROCEDURE|Lugol upper gastrointestinal endoscopy|the first performed 12 months after inclusion
41276826|NCT03519048|PROCEDURE|Biopsy|In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.
40754542|NCT02853773|OTHER|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with sugary drinks drinks
40928281|NCT05622162|DRUG|Radiopharmaceutical 18F-JK-PSMA-7|"The Investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography.~18F-JK-PSMA-7 is administered as direct intravenous injection. One single administration of 2-4 MBq/kg of 18F-JK-PSMA-7 is scheduled in each patient included in this study."
40928282|NCT05622162|DRUG|Radiopharmaceutical 18F-Fluorocholine|"The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study."
40928283|NCT03048136|DRUG|Nivolumab|Specified dose on specified days
40754543|NCT02853773|OTHER|ingestion of a test meal with water|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with waters
40754544|NCT01478087|DEVICE|Mysorba|Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.
40928284|NCT03048136|DRUG|Ipilimumab|Specified dose on specified days
40928285|NCT06432296|DRUG|M701|Intra-peritoneal infusion of M701 in experimental group (M701 group_
40928286|NCT06432296|PROCEDURE|paracentesis|Puncture and Draiange of ascites from the peritoneal cavity in both experimental group and control group
40928287|NCT03290482|DIAGNOSTIC_TEST|Barium Esophagram|Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
40928288|NCT03290482|DEVICE|EsophaCap|Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)
40928289|NCT03290482|DIAGNOSTIC_TEST|Physical Examination and Questionnaires|Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
40928290|NCT06401629|DIAGNOSTIC_TEST|NPRP criteria|Under the NPRP criterion, the plasma glucose level at each time point (TP1, TP2, and TP3) is multiplied by its weight (Doi et al. 2022), and the sum of these products yields the unified Doi's Weighted Average Glucose (dwAG) value for each woman. The dwAG is then categorized into four groups: a dwAG of 6.8 or lower, \>6.8 to ≤7.5, \>7.5 to ≤8.6, and above 8.6 mmol/L, indicating normal gestational glycemia (NGG), impaired gestational glycemia (IGG), gestational diabetes mellitus (GDM), and high-risk gestational diabetes mellitus (hGDM), respectively (Doi et al. 2022).
40928291|NCT06401629|DIAGNOSTIC_TEST|IADPSG criteria|The IADPSG criteria define GDM as any one of the three-time points above specific thresholds: the time point prior to glucose ingestion (TP1) is considered abnormal when the fasting plasma glucose (FPG) value is ≥ 5.1 mmol/L, the 1-hour time-point after glucose ingestion (TP2) is considered abnormal when the value is ≥ 10 mmol/L, and the 2-hour time-point after glucose ingestion (TP3) is considered abnormal when the Post-Load Plasma Glucose levels are ≥ 8.5 mmol/L (Metzger et al. 2010). Put simply, meeting any one of these cut-offs results in a GDM diagnosis, regardless of whether the other time points show normal values or not (Metzger et al. 2010).
41125994|NCT06522724|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information about self-management during the treatment process, the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise.
40928292|NCT00383474|DRUG|Bortezomib|Given IV
40928293|NCT00383474|OTHER|Laboratory Biomarker Analysis|Correlative studies
40928294|NCT00383474|DRUG|Tipifarnib|Given orally
40928295|NCT02661711|DRUG|Aflibercept|"2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.~Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye."
40928296|NCT06058988|DRUG|Trastuzumab deruxtecan|All participants will receive T-DXd prior to indicated brain tumor resection/biopsy
40928297|NCT01267695|DRUG|imatinib mesylate|Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.
40928298|NCT01267695|PROCEDURE|conventional surgery|All the patients should receive elective surgery with R0 resection.
40928299|NCT04240678|OTHER|Electronic HBV Alert|Electronic HBV Alert deployed in electronic medical charts of at risk patients
41276827|NCT06657664|PROCEDURE|cryotherapy with sterile saline at 2.5ºC|the root canals are given a final irrigation with 20 mL cold (2.5oC) saline solution for 5 minutes before obturation
41447589|NCT00480038|OTHER|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
41447590|NCT04683913|BEHAVIORAL|Foot rotation modification|"The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable."
40928300|NCT03415776|PROCEDURE|Hemodialysis|Renal replacement therapy
40928301|NCT02882074|DRUG|Human albumin|human albumin 5% during surgery
40928302|NCT02882074|DRUG|Hydroxyethyl starch|6% Hydroxyethyl starch 130/0.4 during surgery
40928303|NCT05170633|DEVICE|Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)|70 random infant will receive the packed red blood cell transfusion with the Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
40928304|NCT03020446|DEVICE|Sorbion Dressing|Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
40928305|NCT00769665|OTHER|Systane Ultra|Re-wetting ocular eye drop
40928306|NCT00769665|OTHER|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
40928307|NCT04422275|DRUG|Budesonide|The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.
40928308|NCT04422275|BEHAVIORAL|High-Concentration Essential Oil|High-concentration essential oil will include 1 ml of essential oil per jar.
40928309|NCT04422275|DRUG|Placebo|The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
40928310|NCT04422275|BEHAVIORAL|Low-Concentration Essential Oil|Low-concentration essential oil will include 0.1 ml of essential oil per jar.
40928311|NCT00288743|DRUG|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
40928312|NCT01692821|DRUG|100% oxygen breathing|100% oxygen breathing - 30 minutes
40928313|NCT01692821|DRUG|15% oxygen in N2 breathing|15% oxygen in N2 breathing - 30 minutes
40928314|NCT01692821|DRUG|12% oxygen in N2 breathing|12% oxygen in N2 breathing - 30 minutes
40928315|NCT00627146|DRUG|ChAgly CD3|6 days treatment 8mg/d intravenous
40928316|NCT00627146|DRUG|Placebo|6 days
40928317|NCT01529801|DEVICE|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
40928318|NCT01529801|DEVICE|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
41447591|NCT04683913|OTHER|Waiting Period - Delayed Group|Participants allocated to the Delayed Group will wait 6 weeks after their initial baseline, then complete a second baseline to provide a control condition. After the second baseline they will enter the intervention.
41447592|NCT06626919|BIOLOGICAL|anito-cel|Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain
41447593|NCT06626919|DRUG|Standard Lymphodepletion regimen|Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion
41447594|NCT04756921|DRUG|Pyrotinib|Pyrotinib 400mg po qd
40928319|NCT01529801|DEVICE|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
40928320|NCT01254942|OTHER|B4 Clinic|Fracture Follow-Up Clinic plus Exercise Program
40928321|NCT01254942|OTHER|Usual Care|
41125995|NCT06522724|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of three hours daily. The program will be applied individually to each patient and include in-bed assisted exercises, airway clearance techniques, effective cough exercises, pursed-lips breathing, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
41125996|NCT06109493|BEHAVIORAL|ACT|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
41276828|NCT06657664|PROCEDURE|intaoral cryotherapy|ice sticks (wrapped in sterile gauze if needed) using plastic pipette droppers filled with freezed sterile water are placed intraorally in the mouth on the apices of the treated tooth on both buccal and palatal sides for 30 minutes
41276829|NCT06657664|PROCEDURE|Both intracanal and intraoral cryotherapy|Canal is irrigated with iced saline for 5 minutes before obturation . Root canal is obturated and coronal restoration is done. Then, application of intraoral cryotherapy is performed by ice sticks for 30 minutes.
41276830|NCT06657664|DEVICE|Low Level Laser Therapy|laser irradiation on the soft tissues covering the apices of the tooth on both buccal and palatal surfaces respectively
41276831|NCT06657664|PROCEDURE|Control (Standard treatment)|, all occlusal contacts were reduced by 1 mm
41276832|NCT04957563|BEHAVIORAL|olfactory rehabilitation|treatment for improve olfactory function
41276833|NCT02086019|DRUG|Conservative Arm|crossover to angiogram only if predefined criteria met
41276834|NCT02086019|PROCEDURE|Invasive Arm|angiogram with PCI or CABG revascularisation if appropriate
41276835|NCT00435552|PROCEDURE|Ease-It Spray|
41276836|NCT04814979|DEVICE|Low-intensity pulsed ultrasound (LIPUS)|Low-intensity pulsed ultrasound (LIPUS) consists of frequencies usually ranging from 0.75- 1.5 MHz at intensities \<100mW/cm² (usually about 30mW/cm²) and usually pulsed at 1:4. The transducer head is strapped or otherwise held in place and remains stationary for treatment periods in the region of 20 minutes. Again, US medium is used for efficient sound transfer to deeper tissues. This modality was approved by the FDA in the United States in 1994 for the accelerated healing of fresh fractures and then approved by the same body in 2000 for the treatment of established non-union fractures. The studies presented to the FDA demonstrated that LIPUS had a positive effect during all three main stages of fracture healing, i.e. inflammatory, reparative and remodelling by enhancing angiogenesis, chondrogenesis and osteogenesis.
41276837|NCT04814979|OTHER|Routine physical therapy|"Gentle hamstrings stretching for 15 seconds 3 times a day. Flexibility of these muscle reduces stress to the lumbar region thus enhances the spino-pelvic rhythm (lumbar motion/pelvic motion). Strengthening of abdominal muscles (transversus abdominis and internal oblique). Training of these stability muscles in the lumbar spine provides a solid foundation for the individuals to integrate them into their functional movement patterns. Exercises focusing on these muscles have been shown to significantly decrease pain and disability in people with spondylolysis. Each exercise will be performed as 3 sets of 10 repetitions on alternate days."
41276838|NCT03756090|DRUG|Palbociclib|Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
41276839|NCT03756090|DRUG|Placebo oral capsule|Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
41276840|NCT03756090|DRUG|Epirubicin|Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.
41276841|NCT03756090|DRUG|Cyclophosphamide|Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
41276842|NCT03756090|DRUG|Paclitaxel|Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
41276843|NCT03258814|BEHAVIORAL|Active Supervised Training (AST)|The active supervised and standardized training consisted of 24 units of exercise within 20 weeks performed in certified training centers and was focused on back fitness, core strengthening and patient engagement to treat back pain and functional impairment.
41276844|NCT03258814|BEHAVIORAL|Standard of Care (SOC) Physiotherapy|Standard of care physiotherapy as used in this study included active as well as passive training and massages according to the physiotherapist discretion.
41447595|NCT01688011|DRUG|Luspatercept|Prescribed by treating physician as per product label.
41447596|NCT02421653|DIETARY_SUPPLEMENT|MNP90|90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
41447597|NCT02421653|DIETARY_SUPPLEMENT|MNP45|45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
41125997|NCT00081601|DRUG|CEP-701|
41125998|NCT05326971|PROCEDURE|gastroscopy|Gastroscopy to evaluate the effect of long term exposure of TDF or TAF on enterocytes
41276845|NCT00425490|DRUG|sitagliptin|
41276846|NCT04700267|DRUG|GLPG3970 film-coated tablet|GLPG3970 for oral administration
41276847|NCT04700267|DRUG|Placebo film-coated tablet|Placebo for oral administration
41276848|NCT04775823|PROCEDURE|Hybrid composite nano-ceramic|Indirect bonding the hybrid composite nano-ceramic restoration to the tooth to be restored of worn dentition patients
41276849|NCT04241029|DIETARY_SUPPLEMENT|IDOFORM®Travel|Four capsules IDOFORM®Travel orally every 24 hour (12\*10\^9 cfu/day) for eight weeks.
41447598|NCT02421653|DIETARY_SUPPLEMENT|IODISED OIL|200 mg iodine oil capsule; oral route; once at study start
41447599|NCT02421653|DIETARY_SUPPLEMENT|INERT OIL|Non-iodised evening primrose oil capsule; oral route; once at study start
41447600|NCT02421653|DIETARY_SUPPLEMENT|INERT MNP|Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
41447601|NCT02421653|DIETARY_SUPPLEMENT|NON-IODISED MNP|Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
41447602|NCT04009447|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week CBT-I therapy to help improve sleep quality
40754545|NCT00775515|PROCEDURE|laparoscopic prostatectomy|laparoscopic prostatectomy
41125999|NCT00943917|OTHER|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
41447603|NCT02992964|DRUG|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
41447604|NCT06627998|DIAGNOSTIC_TEST|Diagnostic (chest x-ray /DXA)and clinical data collected for clinical practice|Biochemical, clinical and radiological data performed for clinical practice will be retrospectively collected. Osteoporosis and vertebral fractures will be diagnosed through DXA scan and vertebral morphometry.
41447605|NCT02236858|DEVICE|HEPA Air Cleaner|Air cleaners containing HEPA and carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time.
41447606|NCT02236858|DEVICE|Sham HEPA Air Cleaner|Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
41447607|NCT05787678|BIOLOGICAL|Dupilumab|600 mg (two 300 mg injections), followed by 300 mg monthly
41447608|NCT06476093|DRUG|Anlotinib hydrochloride|Anlotinib#12mg#PO#Q3W#d1-14# SRT#depends
41447609|NCT02275403|PROCEDURE|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
41447610|NCT02275403|OTHER|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
41447611|NCT02282722|OTHER|Investigational informed consent for chemotherapy|Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
41447612|NCT02282722|OTHER|Usual, standard-of-care informed consent for chemotherapy|The enrolling site's institutional standard-of-care informed consent materials.
41447613|NCT01923909|DRUG|Intra-articular platelet-rich plasma|Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
41447614|NCT01923909|DRUG|Intra-articular corticosteroid injections|Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
41447615|NCT06368076|BEHAVIORAL|Exercise|High intensity interval training on a bike or pedaltrainer from the wheelchair.
41447616|NCT04190160|DRUG|IDegLira|A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme
41447617|NCT03371186|OTHER|Community Health Worker|The intervention is designed to address these primary drivers of underutilization of reproductive, maternal, newborn, and child health services in rural Nepal, namely: poverty, lack of social support, and poor birth planning. The investigators have worked with a cadre of Community Healthcare Workers who, in addition to the responsibilities of local community health volunteers, have added responsibilities, training, and managerial support. These women support their community members in their homes to identify and overcome social barriers and plan for emergency healthcare needs. The goals are to increase utilization of services, maternal and neonatal health knowledge, self-efficacy, social support, and emergency planning among mothers
41447618|NCT03371186|OTHER|Continuous Surveillance|Each patient identified by a Community Health Worker will undergo a complete diagnostic evaluation by the hospital-based clinicians and will be enrolled in the study only if they are identified as currently pregnant, have recently given birth, or have a child under the age of 24 months. Continuous surveillance systems ensure that the entire population is surveyed every three months and has a three month touchpoint with a Community Health Worker.
41447619|NCT03371186|OTHER|CB-Integrated Management of Newborn and Childhood Illness|Safe delivery care; effective neonatal resuscitation; management of childhood diarrhea, malnutrition, and pneumonia; and treatment of traumatic and congenital surgical conditions can reduce child mortality. Community Based Integrated Management of Newborn and Child Illness (CB-IMNCI) has shown substantial reductions in neonatal and early child mortality. Community Health Workers will use CB-IMNCI as the clinical protocol for ongoing care to the community.
41126000|NCT00943917|DRUG|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
41276850|NCT02478684|OTHER|30 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant
41126001|NCT00943917|OTHER|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
41276851|NCT02478684|OTHER|60 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
41276852|NCT01086787|OTHER|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
41276853|NCT02908906|DRUG|JNJ-63723283|JNJ-63723283 will be administered by IV infusion or SC injection or infusion.
41276854|NCT06583083|DRUG|Sintilimab with P-GEMOX Regimen|Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
41276855|NCT06583083|DRUG|P-GEMOX Regimen|Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
41276856|NCT05747924|DRUG|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
41276857|NCT05747924|DRUG|Placebo|Placebo will be administered via intravenous (IV) infusion
41276858|NCT00260130|OTHER|food in fluid form|dietary intake of fluid forms of vegetables
41276859|NCT00260130|OTHER|food in solid form|dietary intake of solid forms of vegetables
41276860|NCT05455320|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
41276861|NCT05455320|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
41276862|NCT05455320|DRUG|Pomalidomide|Pomalidomide will be administered orally.
41276863|NCT05455320|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously.
41276864|NCT03884075|DRUG|Semaglutide|Semaglutide injection once weekly
41276865|NCT06199466|DRUG|Gemcitabine|Given by IV
41276866|NCT06199466|DRUG|Nab-paclitaxel|Given by IV
41276867|NCT06199466|DRUG|YL-13027|Given by PO
41276868|NCT04820179|DRUG|Cabozantinib + Atezolizumab|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
41276869|NCT06653621|DRUG|Bupivacaine liposome|Subjects receive liposomal bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
41276870|NCT06653621|PROCEDURE|Nerve block mode : adductor block|Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for adductor block under ultrasound guidance.
41276871|NCT06653621|DRUG|Bupivacaine|Subjects receive bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
41276872|NCT06653621|PROCEDURE|Nerve block mode: femoral triangle block|Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for femoral triangle block under ultrasound guidance.
41276873|NCT05484193|DRUG|GnRH agonist|GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles
41276874|NCT05484193|DRUG|Progesterone|vaginal progesterone for luteal phase support
41276875|NCT02606552|DRUG|Dabigatrain plus aspirin|Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
41276876|NCT02606552|DRUG|Dabigatrain plus clopidogrel|Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
41276877|NCT02606552|DEVICE|Amplazter Cardiac Plug (ACP)|Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
41276878|NCT04725682|DRUG|Tacrolimus|a single dose of 1 mg capsule per period
40928322|NCT03872076|OTHER|Experimental|"The Drom Jump technique with the legs flexed will be performed with the patient standing in front of a bench 30 cm high by 100 cm wide. The physiotherapist will be placed lateral to the athlete. The subject will be asked to jump up from the box or bench, with the hip and knees in semi-reflexion, with his hands on his hip and he will be asked for an explosive jump, followed by a jump downwards falling the floor of the same way.~The technique of lateral jumps on cones will be carried out by means of unipodal jumps, achieving a distance of 50 cm between cones. The physiotherapist will stand in front of the athlete. The subject will be asked to perform a lateral unipodal explosive jump by flexing the hip and knee."
41126002|NCT04099875|DIAGNOSTIC_TEST|ultrasound|Ultrasound is a type of imaging. It uses high-frequency sound waves to look at organs and structures inside the body.
41276879|NCT06657248|DEVICE|univation® XF Pro|Primary medial unicompartmental knee arthroplasty
41276880|NCT06366373|OTHER|A mental health art exhibition|"The specific intervention measure is the Second Mental Health Art Science Exhibition scheduled to take place in Wuhan, China from April 27 to May 27, 2024. Organized by Qixi Charity, an NGO led by individuals with lived experience of mental disorders, as well as their family members and friends, the exhibition will feature offline artworks created by these individuals and other contributors. The exhibited artworks aim to reflect the diverse dimensions of mental health and ill-health."
41276881|NCT06366373|OTHER|printed or online education materials|The specific intervention measure is to provide printed or online education materials within the first month after the baseline survey
41276882|NCT06596304|OTHER|Low intensity-resistance training with lower limb blood flow restriction|In the LIRT-BFR, participants will perform 4 sets of 20 bilateral leg presses and knee extensions repetitions with BFR at 30% of 1-RM, with 30-second rest intervals between sets, in an estimated total of 30-minute session per participant. Cuffs will be placed in the upper thighs and inflated with a pressure that is 1.3 times the individual's ankle systolic blood pressure in the data collection day for the entirety of the training session with a commercial cuff (width×length; 11×85 cm, SC10™, Hokanson, Inc., WA, USA).
41276883|NCT06596304|OTHER|High Intensity Resistance Training|In the HIRT participants will perform bilateral leg presses and knee extension without BFR at 75% of one-repetition maximum (1-RM), for 3 sets of 10 reps, with 2-minute rest intervals, in an estimated total of 30-minute session per participant.
41276884|NCT06657469|OTHER|Attention Functions Training (AFT)|The AFT protocol included 18 group-based sessions, 75 minutes each, administered twice a week over a nine-week period. The training focused on improving sustained attention, selective-spatial attention, and executive attention through computerized tasks like the Conjunctive Continuous Performance Task and Go/No-Go tasks.
41276885|NCT06657469|OTHER|Executive Functions Training (EFT)|The EFT protocol included similar session structures with a focus on executive functions such as working memory, cognitive flexibility, and problem-solving. Tasks included computerized games such as visual puzzles.
41276886|NCT06656156|OTHER|Proprioceptive neuromuscular facilitation technique|"Experimental group was given proprioceptive neuromuscular facilitation technique (PNF) along with conventional treatment.~PNF will be applied on iliopsoas and hamstring muscles, 3 repetitions/session with a break of 2 minutes/repetition (10 second isometric Contraction then 10 second stretch)~Treatment contains total 12 sessions (3 times/week for 4 consecutive weeks)"
41126003|NCT06221917|OTHER|Face-to-face|FTF group are participants who will learn simple sutures physically present with the instructor in the same room.
41447620|NCT03371186|OTHER|Group Antenatal and Postnatal Care|The proposed model will change antenatal and pediatric care in three major ways: 1) conduct care in a group setting, 2) provide expert and facilitated peer counseling, and 3) incorporate emergency planning. The group setting is designed to create a supportive social network among women facing similar challenges. The opportunity for counseling beyond the current standard will promote detailed emergency planning and the sharing of context-specific advice from peers to overcome barriers to access care. This intervention draws on the strength within communities of women to change health-seeking behaviors.
41447621|NCT03371186|OTHER|Balanced Post-Partum Contraceptive Counseling|Research on interventions to improve postpartum contraception suggest strategies that bridge the continuum of reproductive health care-antenatal care, labor and delivery, postnatal care, and infant care-are more effective than short term, stand-alone counseling sessions. The structured counseling module incorporated in the intervention will be partially adapted from the Balanced Counseling Strategy, an interactive contraceptive counseling method developed by the Population Council in accordance with the World Health Organization's tiered effectiveness guidelines. Prior studies in clinical settings in Nepal have demonstrated increased uptake of modern contraceptive methods, especially of long-acting reversible contraceptives with use of balanced counseling.
41447622|NCT02319980|PROCEDURE|Extracranial-intracranial bypass surgery|All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
40754546|NCT04767646|PROCEDURE|Intensive rehabilitation program with CPNB|"The patient will have an intensive rehabilitation program (two 30-minute kinesitherapy sessions every day and 30-minute occupational therapy sessions 5 days a week) with the CPNB.~The patient will have follow-up consultation at 1 month, 3 month, 6 month and 1 year after the beggining of the intensive rehabilitation program"
41126004|NCT06221917|OTHER|Live-streaming|One general surgeon (FH) will teach the participants how to do simple sutures on a mannequin, starting by explaining, then doing a live-demo step-by-step of simple wound suturing. The instructor uses a GoPro Hero 8 device on her head which is connected to the internet and produced live-streaming video, which will then be watched by LS group.
41126005|NCT04743440|DEVICE|Bronchoscopic endotracheal intubation through a supraglottic airway device|Prior to trial commencement, participants will be asked to watch a video demonstrating preparation and conduction of the procedure (bronchoscopic endotracheal intubation through a supraglottic airway device) in a patient not involved in the project. Afterwards they will submit an online test, examining knowledge of the procedure relating to the procedure checklist. After participants have watched the demonstration video and submitted the online test, trial investigator will demonstrate the procedure in the manikin; subsequently, they have the opportunity to train the procedure in the manikin with both Igel and Auragain - training estimated to take less than 30 minutes. Afterwards, they will have the opportunity to train the procedure on manikins, on their own discretion, as per usual standards for maintaining airway competence at the Anaesthesiology Department.
41126006|NCT05562089|DEVICE|A Paclitaxel Drug-Coated Balloon|Size: 2.0mm-4.0mm x 15-30mm Coated drug: Prevail TM
41126007|NCT05443542|DEVICE|Virtual Reality|Game to be played is a commercially available VR game
41126008|NCT05443542|OTHER|Control intervention|Sodoku, crossword puzzles
41126009|NCT03102034|BIOLOGICAL|D46/NS2/N/ΔM2-2-HindIII|10\^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops
41126010|NCT03102034|BIOLOGICAL|Placebo|Isotonic diluent; administered as nose drops
41126011|NCT01939899|DRUG|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
41126012|NCT06260670|DEVICE|Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ Catheter|"Subjects will receive ElectroGraphic Flow™ (EGF) mapping with Ablamap® Software and a commercially available 64-pole basket mapping catheter (FIRMap™ Catheter, Abbott Laboratories, Abbott park, IL). The FIRMap™ catheter will be inserted into the right and left atrium to acquire 1 minute recordings of electrical signals in several standardized positions, and turn these into electrographic flow (EGF) maps.~Subjects will receive concomitant high density (HD) electroanatomical mapping of these regions with the commercially available Ensite Precision mapping system and Advisor™ HD Grid mapping catheter (Abbott Laboratories, Abbott Park, IL)."
41126013|NCT00732966|DRUG|losartan|with losartan 50 mg once daily for one month
41126014|NCT00732966|DRUG|valsartan|valsartan 160 mg once daily
41126015|NCT04345068|BEHAVIORAL|Calm Meditation Mobile App|The Calm app is downloadable by participants onto their smartphone. The Calm app is used to deliver the meditation intervention to experimental group participants.
41276887|NCT06656156|OTHER|Conventional treatment|"Conventional treatment contains tens and hotpack.~Tens Will be applied for 20 minutes and hotpack for 10 minutes~Total 12 sessions (3 times/week for 4 consecutive weeks)"
41447623|NCT02507128|DRUG|liraglutide|Liraglutide were taken 30 min before PCI.
40928323|NCT03872076|OTHER|Control|"Elastic bands will be combined with isometric exercises in 3 sets of 10 repetitions each. The exercises they will perform are front squat. On the one hand, separating the legs at the height of the shoulders with hip and knee flexion, with the elastic band above the knees, maintaining the position 20 seconds.~In the following exercise, with the elastic band on the ankle, in unipodal support at the same time that the contralateral limb is free of support, the hip will be flexed at 45º with full knee extension, requesting the athlete to keep the tension 20 seconds, performing 3 sets of 10 repetitions."
41447624|NCT02507128|DRUG|placebo|Placebo were taken 30 min before PCI.
41447625|NCT03908736|DRUG|Zinc Picolinate 15 Mg|zinc picolinate, 15 mg/day for 6 months
40754547|NCT03940092|OTHER|MRI|"This is a prospective, non-randomised, exploratory study on healthy female volunteers (\>18 years), and female patients (\>18 years) diagnosed with primary breast cancer.~Healthy volunteers will be scheduled for an 23Na-MRI examination.~Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery."
40754548|NCT03940092|OTHER|PET/MRI|Patients undergoing neo-adjuvant chemotherapy will undertake up to two (2) combined PET/MR examinations with FDG and 23Na-MRI
40754549|NCT01292265|BIOLOGICAL|Certolizumab Pegol|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
41447626|NCT06627751|BIOLOGICAL|Mezigdomide|Given PO
40928324|NCT00593242|BIOLOGICAL|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
40928325|NCT00593242|OTHER|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
40928326|NCT05113303|DEVICE|Navigated Revision Total Knee Arthroplasty|Patients in the case group receive a Columbus® Revision knee prosthesis, implanted with computer assisted surgery
40928327|NCT05113303|DEVICE|Manual Revision Total Knee Arthroplasty|Patients in the control group will correspond to a historical cohort of patients in which manual jig-assisted knee revision was done.
40928328|NCT04148729|DRUG|ESP block|Ultrasound guided ESP block will perform with 15 ml bupivacaine+ 5 ml lidocaine at the T10 level bilaterally. 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly will perform for postoperative analgesia.
40928329|NCT04148729|DRUG|Control Group|In this group Ultrasound guided ESP block will not perform. Postoperative analgesia will provide with 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly.
41447627|NCT06627751|DRUG|Carfilzomib|Given IV
40754550|NCT03765359|DRUG|metforminhydrochloride|metformin 500 mg tablets and insulin
40928330|NCT05579171|DEVICE|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
40928331|NCT05579171|DEVICE|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
40928332|NCT05527938|OTHER|web-based intervention|"1. Establishing management teams.~2. Establishment of a nursing intervention team.~3. Daily uploading of health intervention records~4. Regularly delivering related health knowledge.~5. Home visiting~6. Psychological guidance. The health teachers in the team should closely understand the psychological trends of the patients during the telephone follow-up and home visits and verbally communicate more with the children to stimulate them to develop good living habits and increase their confidence in healing."
40928333|NCT03309046|OTHER|REACH Individual Session|Individual telephone session with parent
40928334|NCT03309046|OTHER|Education Webinar|Videos with information on caregiving
40928335|NCT03190044|DIETARY_SUPPLEMENT|PACR|Daily assumption of PACR for a 3-month period
40928336|NCT03190044|DIETARY_SUPPLEMENT|Placebo|Daily assumption of placebo
41276888|NCT06656546|DIAGNOSTIC_TEST|Tracheal Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. A linear transducer will be placed perpendicular to the trachea at the level of the cricoid membrane. During ETI, visualization of the ETT moving within the trachea, specifically behind the cricothyroid membrane, indicates successful intubation. In contrast, if the ETT is mistakenly placed in the esophagus, a double-lumen appearance lateral to the trachea, created by the ETT within the esophagus, suggests esophageal intubation.
41447628|NCT06627751|DRUG|Dexamethasone|Given PO
40928337|NCT01710410|DEVICE|active transcranial Direct Current Stimulation|Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
40928338|NCT01710410|DEVICE|sham transcranial Direct Current Stimulation|Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
40928339|NCT00859638|BEHAVIORAL|Physiotherapy|group self-management classes
40928340|NCT00859638|BEHAVIORAL|Occupational Therapy|group self-management classes
40928341|NCT00859638|BEHAVIORAL|Capacity Building|workshops and case reviews with primary health care team members
40928342|NCT04269850|BIOLOGICAL|allogeneic fecal microbiota|Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.
40928343|NCT04269850|DRUG|Ruxolitinib|Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.
41447629|NCT06627751|PROCEDURE|Echocardiography|Undergo ECHO
41447630|NCT06627751|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41447631|NCT06627751|PROCEDURE|Computed Tomography|Undergo PET/CT
41447632|NCT06627751|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT guided tumor Biopsy
41447633|NCT06627751|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration biopsy
41447634|NCT06627751|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41447635|NCT06627751|PROCEDURE|Biospecimen Collection|Undergo blood and saliva sample collection
41447636|NCT04317417|BEHAVIORAL|EMPOWER|"Participants will receive weekly material for a total of 5 weeks consisting of 1-2 days of didactic content and several days of brief, real-life skills practice and reporting taking approximately 10-15 minutes to complete. Adolescents and young adults cannot skip ahead, but they can return to old lessons or exercises if they choose. Most exercises are done in a diary format in which past responses are displayed next to their new ones, so that every time they visit that exercise they see their growing list of past positive experiences. Participants will be permitted up to 8 weeks to complete this self-guided intervention."
41447637|NCT00002880|DRUG|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
41447638|NCT02589093|DEVICE|Stimulation|
40754551|NCT03765359|DRUG|Placebo Oral Tablet|Placebo tablets mimic metformin 500 mg tablets and insulin
40754552|NCT00506311|DRUG|Fibrin Sealant|Tisseel applied externally to the dissected groin area.
40928344|NCT04269850|DRUG|Methylprednisone|Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
41126016|NCT04345068|BEHAVIORAL|Health Education Podcast Mobile App|The health education podcast mobile app mirrors the intervention group's app experience, but provides educational content via podcasts as an active comparator.
40928345|NCT05763355|PROCEDURE|Biopsy|Biopsies will be performed under local anaesthesia. In all patients with a suspicious lesion (PIRADSv2.1 3-5) noted on the mp-MRI, the software-based image fusion biopsies will be obtained collecting 3 to 5 cores per target area according to its volume, 10-12 systematic cores of the remaining areas of the prostate will be collected from sectors specified in the PIRADSv2.1 prostate map.
40928346|NCT00821444|DRUG|ziprasidone|40 mg capsule, single dose x 3
40928347|NCT00821444|DRUG|B16 Fasted|40 mg tablet, single dose X 3
40928348|NCT00821444|DRUG|B16 Fed|40 mg tablet, single dose X 3
40928349|NCT01532193|OTHER|Decreased oxygen concentration|"The oxygen concentration is decreased during the in Vitro embryo culture."
41126017|NCT00093015|DRUG|Placebo|Volume and dose frequency changes resembling dosing in the active treatment group
41126018|NCT00093015|DRUG|darbepoetin alfa|Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
41126019|NCT04071106|DRUG|Turmeric Extract|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
41126020|NCT04071106|DRUG|Turmeric Extract in Olive oil|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
41126021|NCT04071106|DRUG|Petrolatum|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
41126022|NCT04071106|DEVICE|NB-UVB|Patients will receive 2 sessions of NB-UVB phototherapy and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
41126023|NCT04071106|DRUG|calcipotriol/ Betamethasone|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
41126024|NCT00885313|DRUG|DHA250|DHA 250 mg/kg/d
41126025|NCT00885313|DRUG|DHA500|DHA 500 mg/kg/d
41126026|NCT00885313|DRUG|PLACEBO|placebo
41126027|NCT00885313|BEHAVIORAL|Lifestyle intervention|lifestyle intervention \[including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity\], for 12 months.
41126028|NCT02876016|DEVICE|functional MRI|locate the cerebral bases in functional imaging
41287291|NCT01620996|BEHAVIORAL|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
41447639|NCT05098743|BEHAVIORAL|Medisafe smartphone mobile application|The medication adherence smartphone mobile application (app) will provide reminders to take individual patient medications and offers medication information and a social support feature.
40754553|NCT01267136|DRUG|Codeine with acetaminophen|Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg \[=0.3 mL/kg\] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
40928350|NCT05837169|OTHER|Mindfulness-based stress reduction|The control group will be assessed with the study surveys at baseline, will not receive MBSR intervention for the following 8 weeks, and will subsequently be reassessed with the study surveys at the same time points as the intervention group. At the end of the recruitment and follow-up of all the participants, the study will end and the control group will be able to receive the MBSR intervention free of charge according to the preference of the participants.
40928351|NCT04335201|DRUG|Defibrotide Injection|Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
41126029|NCT02155868|OTHER|Correction rSO2 desaturation.|"Predefined protocol of interventions for correcting rSO2 desaturation (\< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood \< 35 mmHg; mean arterial pressure \< 60 mmHg; central venous pressure \> 10 mmHg; cardiac index \< 2.0 l/min/m2; mixed venous oxygen saturation \< 60%; hemoglobin \< 65 g/L during cardiopulmonary bypass or hemoglobin \< 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption."
41126030|NCT02155868|OTHER|Standard treatment|Standard treatment
40928352|NCT00236951|DRUG|iron sucrose injection USP|
40928353|NCT00236951|DRUG|stable erythropoietin therapy|
40928354|NCT01715597|DRUG|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
40928355|NCT01715597|DRUG|Normal saline|normal saline 500ml IV
40928356|NCT05167552|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
40928357|NCT05167552|OTHER|Standard treatment of type Allergic Rhinitis according to the clinical protocols|Standard treatment of type Allergic Rhinitis according to the clinical protocols
40928358|NCT05167552|OTHER|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
40928359|NCT00377130|OTHER|Self Administered Stress Management|"The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training."
40928360|NCT05628259|BEHAVIORAL|Tele-Nursing based Motivational Interviewing|A motivational interview (MI) program based on the telenursing approach was applied to the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.
40928361|NCT02723045|PROCEDURE|Open Lichtenstein Hernioplasty|
41447640|NCT05098743|BEHAVIORAL|Printed medication list|Patients will receive a printed out medication list from their electronic medical record.
40928362|NCT02723045|PROCEDURE|Laparoscopic TEP Hernioplasty|
40928363|NCT05428189|DIAGNOSTIC_TEST|Plaque Disclosing Agent|A plaque disclosing agent is applied on teeth to detect plaque. Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
40928364|NCT05428189|DEVICE|Airpolishing and ultrasonic debridement|Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
40928365|NCT01057875|OTHER|caffeine|Starbuck's Grande Pike Roast coffee
40928366|NCT01057875|OTHER|No caffeine|Starbuck's Grande Pike Roast Decaffeinated Coffee
41126031|NCT02809599|BEHAVIORAL|DIZZTINCT|The intervention, DIZZTINCT, is a multi-faceted educational and care-process based intervention designed to improve the guideline-concordant care of patients with BPPV in the emergency department. The intervention includes six main components: the recruitment and training of local champions who will serve as colleague experts in the community; interactive hands-on educational sessions that address BPPV mechanisms, evidence and practice; a high-yield decision-aid web application for self study and point of care use; development of a referral network for follow up care; follow-up educational sessions to review successes and barriers amongst the intervention group; and other resources developed locally in partnership with the community medical providers.
41126032|NCT02040363|PROCEDURE|Muscular biopsy|
41447641|NCT02579733|DRUG|Azathioprine|
40754554|NCT01267136|DRUG|Tramadol suspension|Liquid tramadol 1.05 mg/kg \[=0.3 mL/kg\] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
40754555|NCT04774146|PROCEDURE|pars plana vitrectomy|silicone oil active aspiration and isovolumetric BSS replacement followed by irrigation and /o gas fluid exchange
40754556|NCT04343833|PROCEDURE|Immediate dental implants|At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
41126033|NCT02040363|OTHER|5-10 weeks sport training|
41126034|NCT03513367|OTHER|Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale|"Scaling in multidisciplinary consultations in the form of a self-administered questionnaire with the help of a third party (psychologist). The child and his / her parent complete the questionnaire independently. The result of the questionnaire will then be scored.~To validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale. The validation process is confirmatory, the scale being widely used in English. The scale will measure the quality of life of the child using two independent assessments : children and their parents."
41126035|NCT03513367|OTHER|The following data of motor function|In parallel, the following data are collected on the day of the consultation: assessment of motor function (MFM, use of a wheelchair, age of loss of walking); assessment of respiratory function (EFR, FVC, respiratory assistance, type of respiratory aid); evaluation of cardiac function (FE); assessment of nutritional status (weight, height, BMI, nutritional support by gastrostomy), school status; ongoing drug treatments (corticosteroids, IEC).
41126036|NCT02137616|DRUG|risperidone|Risperdal tablets
41126037|NCT02137616|DRUG|olanzapine|olanzapine tablets
41126038|NCT02137616|DRUG|Quetiapine|quetiapine tablets
41126039|NCT02137616|DRUG|Aripiprazole|Aripiprazole tablets
41126040|NCT03175159|BEHAVIORAL|IMPACT|Ten counseling sessions
40928367|NCT04537780|OTHER|Placebo|Placebo tabled every day
40928368|NCT04537780|DRUG|Montelukast|Montelukast 10 mg daily at bed time.
41126041|NCT03175159|BEHAVIORAL|Standard of Care|Two counseling sessions
41126042|NCT02915315|DIETARY_SUPPLEMENT|salt|The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
41126043|NCT05112549|DRUG|Nivolumab [Opdivo]|Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
41447642|NCT02579733|DRUG|Placebo|
41447643|NCT02222064|BEHAVIORAL|Mindfulness|Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
41447644|NCT04067739|OTHER|non interventional study|non interventional study
41447645|NCT00625222|PROCEDURE|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
41447646|NCT02485951|PROCEDURE|Central air injection|Air was injected inside the trephination site in the central injection group.
41447647|NCT02485951|PROCEDURE|Peripheral air injection|Air was injected at the corneal periphery outside the trephination site.
40928369|NCT02003274|OTHER|Clamp-Mixed Meal|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
40928370|NCT02003274|OTHER|IVGTT-Mixed Meal Arm|"Standard clinical parameters will be assessed in all subjects.~Metabolic tests:~A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
40928371|NCT04644731|DEVICE|Aquadex™ System|Ultrafiltration for fluid removal
40928372|NCT04892056|OTHER|Friction Mechanics|anterior segment retraction using elastomeric power chains
41276889|NCT06656546|DIAGNOSTIC_TEST|Lung Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. Following ETI, the presence of lung sliding will be evaluated using ultrasound with the aid of a linear probe.The transducer will be placed bilaterally along the mid-axillary line, between the second and fifth intercostal spaces, in a coronal orientation. After the ETT is placed and ventilation is initiated, the movement of the visceral and parietal pleura will be assessed. The presence of sliding motion between these pleural layers during ventilation indicates successful intubation, whereas the absence of this movement suggests a failed intubation.
41276890|NCT06656546|DIAGNOSTIC_TEST|Diaphragm Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Curvilinear Probe (2-8 MHz) or the eSaote MyLab Seven Curvilinear Probe (1-8 MHz), will be selected based on suitability for the procedure at the time. Using a curvilinear transducer, the probe will be placed along the mid-axillary line, approximately at the seventh to ninth intercostal spaces, in a coronal orientation. The movement of the diaphragm during ventilation will be assessed over the spleen and liver. Diaphragmatic motion during ventilation indicates successful ETI, while the absence of bilateral diaphragmatic movement suggests esophageal intubation. If diaphragmatic movement is only observed on one side, it is indicative of endobronchial intubation.
41447648|NCT04022122|PROCEDURE|Usual Care follow-up in a heart failure program.|Standard follow-up involves hospital and primary care for HF patients. In this context, physicians and nurses experienced in the care and management of HF direct care. HF care is based on 1) active detection of newly admitted HF patients, 2) planned educational interventions to improve self-care, 3) completion of a comprehensive psychosocial assessment of patients and caregivers, 4) discharge planning and home transition coordination involving the hospital HF team and Primary Care teams, 5) structured and planned evidence-based follow-up shortly after discharge from hospital.
40754557|NCT04190771|BEHAVIORAL|TAU + multicomponent treatment NAT-FM|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30 min.)~* Mindfulness techniques (30 min.)~* Physical exercise in a natural environment / nature exposure (30 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
40754558|NCT04190771|BEHAVIORAL|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
40928373|NCT04892056|OTHER|Frictionless Mechanics|anterior segment retraction using closing loops
40928374|NCT03390101|DRUG|BCD-085 Q2W|"In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54."
40928375|NCT03390101|DRUG|BCD-085 Q4W|In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.
40928376|NCT03390101|DRUG|Placebo|"In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54."
40928377|NCT00357929|PROCEDURE|Permissive hypercarbia|
40928378|NCT05733403|DRUG|isotonic solution|Isotonic solutions are IV fluids that have a similar concentration of dissolved particles as blood.
41126044|NCT00248235|BEHAVIORAL|Exercise|
41447649|NCT05452772|DRUG|Psilocybin|Participants will received two psilocybin sessions, 1 week apart
41126045|NCT02962284|DRUG|abiraterone acetate with Methylprednisolone|YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
41126046|NCT04354389|DRUG|DAS181|4.5 mg b.i.d
41126047|NCT04354389|DRUG|Placebo|q.d. or b.i.d.
40754559|NCT02858661|OTHER|Nasopharyngeal swab|
40754560|NCT06063720|DEVICE|Endoscreen QC|Artificial intelligence monitoring of effective withdrawal time
40754561|NCT02668315|BIOLOGICAL|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
41126048|NCT04354389|DRUG|DAS181|4.5 mg q.d.
41126049|NCT00507884|PROCEDURE|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
41126050|NCT01746641|DRUG|Remifentanil|
41126051|NCT01746641|DRUG|Propofol|
41126052|NCT05465382|DEVICE|Saline Lavage|Three rounds of 10cc of sterile 0.9% normal saline will be injected into the injured ankle joint and withdrawn from the joint using an anteromedial 16-gauge needle attached to a 10cc syringe.
41447650|NCT05452772|DRUG|Niacin|Participants will received two niacin sessions, 1 week apart
41447651|NCT04743765|OTHER|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.
41447652|NCT02509143|PROCEDURE|High-dose acupuncture with intravenous infusion of ramosetron|"Three sessions of acupuncture will be provided within 48 hours after surgery. Electrical stimulation with an alternating frequency of 2 to 100 Hz will be applied to selected points (PC6 to LI4, ST36 to ST37, and bilateral SP6).~An embedded acupuncture technique for preoperative anxiety will be applied to the bilateral acupuncture points of Liver (LI4), Heart 7 (HT7), Stomach (ST36), Yin-Tang, ear Shen-Men,and ear sympathetic and will be removed the next day. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience. The same stimulation of P6 points and antiemetics will be provided to the P6 acupuncture-point stimulation group."
41447653|NCT02509143|DEVICE|P6 stimulation with intravenous infusion of ramosetron|Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
41447654|NCT02509143|DRUG|Intravenous infusion of ramosetron|"Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea."
41447655|NCT02174926|PROCEDURE|Elective laparoscopic sigmoid resection|
41126053|NCT05677594|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|Magnetic resonance imaging of the entire body from skull base through distal thighs/knees without contrast material
41126054|NCT03976557|DEVICE|BIP CVC|Central venous access with noble metal coated CVC
41126055|NCT03976557|DEVICE|Standard CVC|Central venous access with standard uncoated CVC
41126056|NCT00940524|DRUG|Dasatinib, Mitoxantrone, Cytarabine|"INDUCTION- Dasatinib† (dose levels 1-3) \*continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC \> 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) \*continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29"
41126057|NCT01800487|DRUG|silymarin|140 mg three times a day for 4 weeks
41126058|NCT01800487|DRUG|Placebo|Placebo (silymarin) 1 tab three times a day for 4 weeks
40754562|NCT03393975|BIOLOGICAL|BAX930|Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg BAX 930 ORT during Period 1 and Period 2 and switch to BAX 930 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of BAX-930.
40754563|NCT03393975|BIOLOGICAL|Standard of care|Participants will receive Investigator-recommended Standard of care (SoC).
40754564|NCT05157789|OTHER|SMS|In the study, text message will be sent to relatives of the patients for informing and the effect will be determine on the level of anxiety during cardiovascular surgery.
40754565|NCT01455844|DRUG|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
40754566|NCT01455844|OTHER|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
40754567|NCT01455844|DRUG|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
40754568|NCT01529112|DRUG|Lenvatinib|
40754569|NCT01529112|DRUG|Lenvatinib matched placebo|
40754570|NCT01529112|DRUG|BSC|
40754571|NCT05100992|PROCEDURE|Percutaneous Coronary Interbention|Percutaneous Coronary Interbention
41126059|NCT03753984|OTHER|Low-level laser therapy|In both arms will be applied Low-level laser therapy and induced muscle fatigue.
40754572|NCT05062369|DEVICE|TaskFlow Transcranial Electrical Stimulation device|The TaskFlow Transcranial Electrical Stimulation device (TaskFlow-TES) is a custom brain stimulation device developed in-house at the University of Minnesota. Each tDCS intervention will last 20 minutes of either (i) 10 active (2-mA) or (ii) 5 active and 5 sham transcranial direct current stimulation (tDCS) over the course of 10 treatment sessions.
40754573|NCT05062369|BEHAVIORAL|Executive Function Focused Cognitive Training|Working memory focused training occurs on a computer and consists of a variety of exercises selected to (i) place demands on the executive and storage functions of working memory (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across verbal, visual and spatial modalities. Training tasks are developed in-house. Tasks for each participant are delivered from and responses, audio, and video are stored on the HST server. The aim of using multiple tasks that require executive functions is to engage brain network functional connectivity in a number of different ways to promote generalization. Investigators will monitor each participant's training and customize the intervention to balance challenge and engagement. In addition, pre- and post-intervention, participants will perform 4-minute versions of a word and a spatial 3-back task identical across all weeks (but differing from the assessment versions).
40928379|NCT05733403|DRUG|Noradrenaline|Noradrenaline itself is classified as a sympathomimetic drug: its effects when given by intravenous injection of increasing heart rate and force and constricting blood vessels make it very useful for treating medical emergencies that involve critically low blood pressure.
41126060|NCT00664690|DRUG|celebrex|400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
41126061|NCT00664690|DRUG|placebo|placebo given preop and BID postop
41126062|NCT05225753|DIAGNOSTIC_TEST|hemoglobin serum value|post-operative anemia evaluated with hemoglobin serum value
41126063|NCT00112359|DRUG|AZLI 75 mg three times a day (TID)|
41447656|NCT02174926|DIETARY_SUPPLEMENT|Conservative treatment|Written lifestyle guidance and fiber supplements
41126064|NCT00112359|DRUG|Placebo three times a day (TID)|
41126065|NCT04079244|BEHAVIORAL|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children."
41276891|NCT06656325|DEVICE|Erchonia® FX405|"Procedure administrations with the Erchonia® FX-405 will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Erchonia FX405 takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing (SRP) prior to the administration of the first procedure with the Erchonia FX405, and a second time at the 3-month study midpoint assessment visit."
40928380|NCT02686281|DRUG|GMC-252-L-Lysine|
40928381|NCT02686281|OTHER|Placebo|
41126066|NCT04079244|BEHAVIORAL|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
41447657|NCT04872075|OTHER|Concert|People attending a concert in a closed area, with a mask
41276892|NCT06656325|DEVICE|Placebo Laser|"Procedure administration with the Placebo Laser (emitting non therapeutic light) will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Placebo Laser takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing (SRP) prior to the administration of the first procedure with the Placebo Laser, and a second time at the 3-month study midpoint assessment visit."
41126067|NCT04788212|BEHAVIORAL|Group Behavioral Activation Therapy for Autism Spectrum Disorder|This will be a modification of the Group Behavioral Activation Therapy program (Chu et al., 2009) for treatment of depression, anxiety and/or anger in autistic adults.
41126068|NCT05663801|DRUG|Use of Bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and patients will be given 30 mL of 0.25% bupivacaine hydrochloride and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
41126069|NCT05663801|DRUG|use of Ketamine as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL of 0.25% bupivacaine hydrochloride plus ketamine hydrochloride (1 mg/kg) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
41276893|NCT05049785|OTHER|Counseling|Attend nutrition counseling sessions
41276894|NCT05049785|BEHAVIORAL|Exercise Intervention|Complete PA sessions
41276895|NCT05049785|OTHER|Informational Intervention|Receive nutrition handouts
41276896|NCT05049785|DIETARY_SUPPLEMENT|Nutritional Intervention|Attend tasting sessions
41276897|NCT05049785|OTHER|Questionnaire Administration|Ancillary studies
41276898|NCT03057444|DIETARY_SUPPLEMENT|SymbioIntest|The intervention is 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
41276899|NCT03885297|DRUG|Saxenda|Obesity pharmacotherapy
41276900|NCT03885297|OTHER|Lifestyle modification|Tier 3 NHS weight management
41447658|NCT04872075|DIAGNOSTIC_TEST|Rapid nasopharyngeal antigen test for Sars-Cov-2|A nasopharyngeal swab at inclusion (up to 3 days before concert) to confirm eligibility
41447659|NCT04872075|DIAGNOSTIC_TEST|Saliva Sample|Saliva samples sent by participant at Day0 and Day7
41447660|NCT00247923|PROCEDURE|Hysteroscopic resection of endometrial polyps. (TCRP)|
41447661|NCT06627660|PROCEDURE|Valsalva maneuver|Closure of the nose and mouth during expiration for 20 sec
41447662|NCT02286466|BEHAVIORAL|Health Education Program|Participants in the control group will receive a health education program using a tablet computer identical to the intervention group. The content of this program is adapted from a health education intervention used as the control condition for a cognitive behavioral stress and affect management intervention in a NIH-funded randomized controlled trial of a quality of life intervention for patients with advanced prostate cancer (R21CA102761, PI: Penedo). The program consists of the same number of sessions as the intervention group and includes general information about health and well-being. Specifically, control participants will learn information about topics such as healthy eating, exercise, memory and cognition, and side effects in the context of a cancer diagnosis and treatment.
41276901|NCT03885297|DIAGNOSTIC_TEST|Metabolomics|Small molecule intermediates and products of metabolism
41276902|NCT03885297|DIAGNOSTIC_TEST|miRNA|Small non-coding RNA molecules
41276903|NCT06387615|OTHER|Active cTBS|Active stimulation
41276904|NCT06387615|OTHER|Sham|Control stimulation
41276905|NCT06386458|DEVICE|AThrough radiofrequency transseptal puncture system|Utilizing AThrough radiofrequency transseptal puncture system for left atrial access
41276906|NCT06386458|DEVICE|Traditional mechanical transseptal puncture needle|Utilizing Traditional mechanical transseptal puncture needle for left atrial access
41276907|NCT00902629|PROCEDURE|Early surgery|Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
41276908|NCT02707770|OTHER|Pulmonary Rehabilitation|
41276909|NCT02083276|DRUG|Pivmecillinamhydrochlorid|PO 400 mg x3 for 7 days
41276910|NCT03812809|DRUG|BPI-7711|BPI-7711: 180mg, QD, oral
41126070|NCT05663801|DRUG|Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL 0.25% Bupivacaine hydrochloride plus Magnesium Sulfate ( 28 ml Bupivacaine 0.25% plus 2ml magnesium sulfate 50%) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
41126071|NCT03828968|DIAGNOSTIC_TEST|bladder scan|Measurement of vesical volume by bladder scan
41126072|NCT05470088|OTHER|Neuroimaging (MRI)|Multimodal magnetic resonance imaging
41126073|NCT03908060|DRUG|Methadone|One intravenous administration of methadone (0.2 mg/kg ideal body weight)
41126074|NCT03908060|DRUG|Morphine|One intravenous administration of morphine (0.2 mg/kg ideal body weight)
41126075|NCT03350698|BIOLOGICAL|Gardasil-9|3 vaccine series
41126076|NCT00180934|PROCEDURE|Reirradiation with concomitant chemotherapy|
41126077|NCT01807481|DRUG|Mircera|Once Monthly Mircera
41126078|NCT01063881|DRUG|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
41126079|NCT01189929|DRUG|Demcizumab|Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain. Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your eligibility to take part in this study, and then if you are enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab administered once every 2 weeks, and gemcitabine and Abraxane® administered weekly for 3 weeks, out of every 4 weeks. After 9 weeks, you will undergo assessments to determine the status of your disease. If there is no evidence of progression of your disease or if your tumor is smaller, you will continue to receive one additional infusion of demcizumab, and you will continue to receive infusions of gemcitabine and Abraxane® once weekly for 3 consecutive weeks out of every 4 weeks until it has been shown that your cancer has progressed. You will undergo assessments every 8 weeks thereafter to determine the status of your disease.
41126080|NCT01189929|DRUG|Abraxane®|Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
41126081|NCT01189929|DRUG|Gemcitabine|Gemcitabine will be administered intravenously over 30 minutes initially at a dose of 1000 mg/m2 once a week for 3 weeks in a row, followed by a week of rest. If you develop side effects during this time period, your physician may decide to hold or reduce the dose of gemcitabine.
41126082|NCT04554108|OTHER|therapeutic strategy|Outpatient management strategy of acute non-severe osteomyelitis in children with oral antibiotic therapy compared to a standard strategy with conventional hospitalization and intravenous antibiotic therapy
41126083|NCT00283205|BEHAVIORAL|Yoga|
41126084|NCT02909192|DEVICE|Light Therapy Device|
41126088|NCT02315456|PROCEDURE|capsulorhexis|
41126089|NCT06165146|DRUG|Repaglinide|Administered orally.
41126090|NCT06165146|DRUG|Pirtobrutinib|Administered orally.
41126091|NCT04544982|OTHER|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
41126092|NCT04544982|OTHER|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
41126093|NCT01048476|DIETARY_SUPPLEMENT|lutein|Dietary Supplement: 20mg Lutein; daily supplementation one year
41126094|NCT01048476|DIETARY_SUPPLEMENT|Lutein|Dietary Supplement: 10mg Lutein; daily supplementation one year
41126095|NCT01048476|DIETARY_SUPPLEMENT|placebo|Dietary Supplement: placebo; daily supplementation one year
41447663|NCT02286466|BEHAVIORAL|CBT Mobile Application|The CBT intervention is brief, consisting of 6 modules lasting approximately 30 minutes each. Sessions focus on skills for relaxation, coping with cancer-related worries, as well as activity planning and pacing. Prior to starting the program, a trained research assistant will meet with participants in a private office setting to orient them to the software and instruct them on the use of the mobile tablet device. Once patients are comfortable with the functions and features of the mobile app, they will be encouraged to self-administer the intervention on their study-issued tablet at home and during their regularly scheduled oncology visits, for example while receiving chemotherapy infusion or waiting for a doctor's appointment or tests.
41447664|NCT02131077|BIOLOGICAL|ALLO-ASC-TI|
41126096|NCT01048476|DRUG|Lutein and zeaxanthin|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
41126097|NCT06379516|OTHER|Moisturising Cream (5%)|This intervention is a moisturiging cream of concentration 5% for topical application to the respective test sites.
41126098|NCT06379516|OTHER|Moisturising Cream (10%)|This intervention is a moisturiging cream of concentration 10% for topical application to the respective test sites.
41126099|NCT06379516|OTHER|Coconut Oil|This intervention is a 100% pure coconut oil product (Parachute Pure Coconut Oil) for topical application to the respective test sites.
41126100|NCT01838343|OTHER|Ultrasound|Goal-directed ultrasound using a GE Vscan performed by a critical care fellow trained in ultrasonography.
41126101|NCT03941119|OTHER|VR-therapy|Wearing a Virtual Reality head mounted device allows the user to become immersed in a virtual environment. We have assembled a library of 3-10 minute 360-degree films from a variety of nature settings. The VR films were intentionally chosen to be calming in distinctive ways, as supported by the literature around nature visualization and wellbeing. By varying 1) the lengths of the films (3, 5, and 10 minutes), 2) the types of natural elements (greenery, earth, sky, water), 3) distance of view (close-ups, vistas), 4) motion (flowing water, wind in trees), 5) sound, and 6) presence of different elements (humans/animals, scenery, urban sites, etc.), the content provides a wide range of attributes that can be collaboratively selected by the individual, caregiver, or health care provider for each individual. We will display these films on commercially available VR equipment and will provide audio matching the film using commercially available headphones.
41126102|NCT03753932|DEVICE|Fixed prosthodontics|The intervention takes place six months after finishing radiotherapy.
41276911|NCT06346522|DRUG|Gabapentin (Gaptin ®) 400mg oral capsule once|After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission
41447665|NCT02131077|DRUG|Placebo|
41447666|NCT02007733|OTHER|Serial Weights|We will collect serial weights on all children enrolled in this study.
40754574|NCT01502072|DRUG|Ribavirin|Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.
40754575|NCT01502072|DRUG|Ribavirin|One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).
41126103|NCT02731599|PROCEDURE|treadmill training with cues|20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
41126104|NCT06030700|OTHER|Controlled Conditions|Use of FoodImage app to take pictures of food and/or receipts.
41126105|NCT05585346|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
41126106|NCT05585346|DRUG|Oral vitamin B1|Oral vitamin B1 10mg, times/day
41126107|NCT05444075|OTHER|a method for communication|"the Arabic alphabet (arranged in the traditional order) printed on double-sided cardboard, with one copy facing the person and one facing the doctor.~The code will be in the case of a positive selection (the desired line or letter) by looking up or one blink, but in the case of a negative selection (not the desired line or letter), it will be by looking down or two blinks.~The person will choose the letters of each word and then choose the end of the word and after selecting all the words of the sentence choose the end of the sentence.~After the strategy has been taught to the subject, he or she will be asked to communicate with the physician using this way."
41126108|NCT02523170|DEVICE|AQ-Flex 19 probe (Mauna Kea Technologies, Paris)|Needle-based Confocal Laser Endomicroscopy (nCLE)
40754576|NCT00606099|DRUG|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
41126109|NCT00319293|DRUG|Metformin|
41126110|NCT05656560|BEHAVIORAL|Clinical decision support (CDS)-Commitment nudge|EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
41126111|NCT05656560|OTHER|Clinician education|Brief, online education module for primary care clinicians
41126112|NCT05656560|BEHAVIORAL|Clinical decision support (CDS)-Justification nudge|EHR clinical decision support alerts-clinician rational for high risk polypharmacy
41126113|NCT06014372|DRUG|Envafolimab|Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.
41126114|NCT06014372|DRUG|CAPEOX|The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
41276912|NCT06346522|DRUG|Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule|After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission
41276913|NCT04940923|DIAGNOSTIC_TEST|MRI|"T2 weighted and DTI MRI images of brachial plexus and wrist. Quantitative sensory tests include warm and cold detection and pain thresholds, paradoxical heat sensation, mechanical detection thresholds, mechanical pain sensation and thresholds, wind up ratios, vibration thresholds and pressure pain thresholds.~Clinical tests include standard neurological tests and test for heightened nerve mechanosensitivity.~Blood serum to analyse inflammatory proteins. Questionnaires include neck disability index, painDETECT, PTSD8, pain catastrophising scale, eq-5D-5L, DASS 42 and global perceived recovery"
41276914|NCT04261543|OTHER|High protein and early exercise|High protein is defined as protein prescription of ≥2.2 gram/kg body weight and early exercise is defined as starting cycle ergometry intervention within 24 hours of randomization
41276915|NCT04261543|OTHER|Usual Care|Usual care group has protein prescription of ≤1.2 gram/kg body weight and exercise at the discretion of attending clinicians
41276916|NCT03864276|DRUG|inhalation (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
41276917|NCT03864276|DRUG|total intravenous (propofol) anesthesia|Anesthesia is induced and maintained with propofol and sufentanil
41276918|NCT02144649|DIETARY_SUPPLEMENT|dietary intervention (tangerine tomato juice)|Group II will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks).
41447667|NCT02007733|OTHER|IVC/Aorta Ultrasound|We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.
41447668|NCT02007733|OTHER|Clinical Assessment|We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
41447669|NCT00268203|BIOLOGICAL|Iodine I 131 Tositumomab Therapeutic Regimen|Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
40754577|NCT00606099|DRUG|adefovir dipivoxil|Active Comparator
41447670|NCT05303649|DEVICE|Noninvasive transcranial brain stimulation: excitatory iTBS|600 pulses (3 pulses at 50 Hz given every 200 milliseconds in 2-second trains at 10-second intervals, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 Device: Magstim Co., Wales, UK.
40928382|NCT04994470|BEHAVIORAL|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
40928383|NCT04994470|BEHAVIORAL|Two-week web-based text messages containing fun facts|"The web-based sham comparator consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham comparator, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
41447671|NCT05303649|DEVICE|Noninvasive transcranial brain stimulation: inhibitory cTBS|600 pulses (3 pulses at 50 Hz, repeated at 5 Hz, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 homologue Device: Magstim Co., Wales, UK.
40754578|NCT00310479|DEVICE|Magnetic Resonance Spectroscopy (3Tesla)|
40754579|NCT04720833|DIETARY_SUPPLEMENT|dried plum|Dried plum
40928384|NCT02706223|OTHER|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
41126115|NCT04139434|DRUG|LP-108|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
41276919|NCT02144649|DIETARY_SUPPLEMENT|dietary intervention (red tomato juice)|Group III will consume two 5.5 oz. cans of red tomato juice every day until their scheduled surgery (approximately 4 weeks).red tomato juice
41276920|NCT02144649|OTHER|questionnaire administration|Men enrolled in the study will be asked to complete a 3-Day Food Record and a series of additional questionnaires (urologic symptom and quality of life questionnaire) at home.
41276921|NCT02144649|OTHER|Correlative studies|Blood and urine samples at enrollment and blood, urine, and prostate tissue at the time of surgery to determine compliance with the intervention product and tomato phytochemical biodistribution. Additionally, we will correlate each type of tomato juice with lycopene presence in plasma, urine, and tissue provided by subjects on the day of surgery.
41276922|NCT06334211|DRUG|FP-020|MMP-12 inhibitor
41276923|NCT06334211|OTHER|placebo|placebo
41276924|NCT05391438|OTHER|Meal-timing|We propose a cross-over, proof-of-concept study to measure glycemic and metabolic responses to a test meal (controlled for macronutrient profile and caloric amount) administered at various times of the day (early vs. afternoon vs. late) in thirty Latino adolescents (ages 13-19 years), with obesity, without diabetes, to determine how timing of eating impacts glycemic response to the test meal after a 16-h fasting period. All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period. Baseline and post-meal samples will be assayed for glucose, insulin, c-peptide, GLP-1, GIP, PP at times -10, -5, 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 minutes after glucose.
41447672|NCT05303649|BEHAVIORAL|Individual speech-language therapy (SLT)|45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).
41447673|NCT05303649|DEVICE|Sham TBS simulating left hemispheric iTBS|Sham TMS coil positioned exactly like an active TMS coil resulting in a very good approximation of the auditory effects Device: Magstim Co., Wales, UK.
40754580|NCT04720833|DIETARY_SUPPLEMENT|Calcium and vitamin D|Calcium and vitamin D supplement
40928385|NCT02706223|OTHER|Nurse led|Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
40754581|NCT01341938|DRUG|Commit® nicotine lozenges (4 mg) & self-help materials|"Participants provided with instructions on standard use of lozenge for nicotine replacement therapy (NRT) \& instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
40754582|NCT01341938|BEHAVIORAL|Commit® nicotine lozenges (4 mg) & phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + lozenge nicotine replacement therapy (NRT) + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
40928386|NCT00001965|DRUG|Cyclosporine A|
40928387|NCT01325220|DRUG|arbaclofen|5 mg bid
40928388|NCT01325220|DRUG|arbaclofen|10 mg bid
40928389|NCT01325220|DRUG|arbaclofen|10 mg tid
40928390|NCT01325220|DRUG|Placebo|tid
41126116|NCT04139434|DRUG|LP-108 and azacitidine|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD, with azacitidine at the standard dose of 75 mg/m2 on Day 1 - Day 7 of each 28-day cycle (weekly schedule) or on Days 1-5, 8, 9 of each 28-day cycle (5-2-2 schedule), according to institutional guidelines.
41126117|NCT00278304|RADIATION|brachytherapy|
41126118|NCT00278304|RADIATION|radiation therapy|
41126119|NCT04251169|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as 30 minutes IV infusion every 3 weeks beginning in Cycle 1
41447674|NCT05539027|DRUG|Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)|patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
40928391|NCT01099709|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
40928392|NCT01099709|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
40928393|NCT03046277|OTHER|No intervention|No intervention
40928394|NCT00215670|DRUG|pegaptanib sodium (Macugen)|
40928395|NCT06506487|BEHAVIORAL|Doll Therapy|Doll therapy involves the use of lifelike dolls to provide comfort and reduce behavioral and psychological symptoms in people with dementia. The therapy includes activities such as holding, dressing, and interacting with the dolls under the guidance of trained caregivers.
40928396|NCT00130442|DRUG|PI-88 and dacarbazine|190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
40928397|NCT00130442|DRUG|dacarbazine or DTIC|intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
41447675|NCT05539027|DRUG|Branched-chain amino acids (BCAA), enriched solution (Aminoleban)|patients will receive BCAA enriched solution (Aminoleban)
41447676|NCT06517719|OTHER|lutetium (177Lu) vipivotide tetraxetan|This is an observational study. There is no treatment allocation. The decision to initiate lutetium vipivotide tetraxetan will be based solely on clinical judgement.
41126120|NCT04251169|DRUG|Paclitaxel|Paclitaxel will be administered at the 80 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 21-day cycle (beginning in Cycle 2). On days of scheduled infusions of pembrolizumab and paclitaxel (i.e., Day 1 of every cycle), paclitaxel is to be administered after infusion of pembrolizumab
41126121|NCT00930306|DRUG|AZD2066|12 doses, Given as capsule, 2 mg \& 8 mg
40928398|NCT00853268|DRUG|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
40928399|NCT00853268|DRUG|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
40928400|NCT00716833|DRUG|Etoricoxibe|Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
40928401|NCT00716833|DRUG|Placebo|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
40928402|NCT04303923|PROCEDURE|Ultrasonography|The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.
40928403|NCT00081861|DRUG|Avastin|10 mg/kg given intravenously every 2 weeks for 4 doses.
41126122|NCT00930306|DRUG|Caffeine|2 doses, Given as Tablet, 2x50 mg
41126123|NCT00930306|DRUG|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
41126124|NCT00930306|DRUG|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
41126125|NCT00930306|DRUG|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
40928404|NCT00081861|DRUG|Rituximab|375 mg/m\^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
40928405|NCT03521804|DEVICE|SoundBite™ Crossing System Active Wire 14|Successful crossing of the CTO into the true arterial lumen distal to the occlusion, following use of the SoundBite™ Crossing Wire during the procedure and using antegrade only approach. An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (i.e. Stingray). The absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.
40928406|NCT00828373|DRUG|Placebo|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
41447677|NCT05968638|OTHER|Regular Diet|Regular Diet
41447678|NCT05968638|OTHER|Ketogenic Diet|Ketogenic Diet
40928407|NCT00828373|DRUG|Lidocaine|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
40928408|NCT04644367|OTHER|Tai Chi intervention|TC classes will be 60 minutes long, offered three times per week over a 12-week period. The participants who receive the TC intervention will be encouraged to attend at minimum two of the three sessions offered per week. The TC classes will follow the same order that will begin with a 5 to 10 minutes warm up, 40 minutes of core activities, and 5 minutes of cool-down. The training intensity and difficulty level of the TC program will gradually proceed from low, moderate, to advance. The classes will be offered in a group setting at a convenient location within a community centre or gymnasium. Alternatively, classes will be offered outdoors in the park or by the canal during the spring-summer months. Due to the COVID-19 situation, additional adaptive measures will be taken using online social platforms such as ZOOM or Hangout to deliver the classes.
41126126|NCT05491135|BIOLOGICAL|HMB002|The solution containing microbeads will be infused manually into the peritoneal cavity under ultrasound guidance, with usually a 50ml syringe, as a single infusion or several infusions, to achieve in excess of 25 million hepatocytes per kilogram of the body weight.
41126127|NCT01611545|GENETIC|Pharmacogenomics|Utilizing pharmacogenomics to determine the most effective treatment
41126128|NCT01678079|DIETARY_SUPPLEMENT|Encapsulated Calcium|The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
41126129|NCT01678079|DIETARY_SUPPLEMENT|Non-capsulated Calcium|The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg). This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
41126130|NCT04623489|BEHAVIORAL|¡Vivir Mi Vida! Lifestyle Intervention|
41126131|NCT05607199|DRUG|AUR103|Twice Daily
41126132|NCT02986984|OTHER|There is no intervention|There are no interventions
41447679|NCT06627127|DEVICE|Target stimulation (HGN, AC, GG, Strap muscles)|Stimulation of the HGN or GG along with AC or strap muscles.
40754583|NCT01341938|BEHAVIORAL|Phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
40928409|NCT04644367|OTHER|Regular Physical Activity (control) group|Regular Physical Activity group who will not be receiving the TC intervention
40928410|NCT05003271|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions.
41126133|NCT04946682|DIAGNOSTIC_TEST|Types of etiological diagnostic methods|In Group of mNGS, all patients will be tested by meta next generation sequncing on admission, while patients in Group of PCR will be tested by polymerase chain reaction in accordance with the method in the guidelines.
41126134|NCT05470231|DIETARY_SUPPLEMENT|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
41126135|NCT04751799|DEVICE|Virtual reality headset before colposcopy|Patients wear a virtual headset presenting 360° 3D views of relaxing environments
41126136|NCT04751799|DEVICE|Virtual reality headset during colposcopy|Patients wear a virtual headset presenting 360° 3D views of distracting environments
40754584|NCT06005831|OTHER|sandbag|The standard sandbag used in our clinic, 20 × 20 × 3 cm3 in dimensions and 3 kg in weight
40754585|NCT01037465|DRUG|N-acetylcysteine|N-acetylcysteine
40928411|NCT04615455|DRUG|ASCs|ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.
40928412|NCT04615455|DRUG|Cryostor CS10|CryoStor® CS10 freeze medium
40928413|NCT04095533|OTHER|Tibialis anterior muscle cross-sectional area assessment by ultrasound|"Assessed using bedside ultrasound with repeat assessments every second day up to 2 weeks of ICU admission, or until discharge from ICU to yield an overall rate of muscle area decline reported as a %/day average muscle atrophy rate.~Tibialis anterior cross-sectional area assessments will be assessed by measurement ultrasound to both legs with portable bedside ultrasound. The cross sectional area will be measured in cm\^2 at 5 cm distal to the lateral eminence of the tibial tuberosity along the muscle belly. Image processing will be performed at the bedside using features available on the ultrasound device. Muscle boundaries will be marked on the device and the cross-sectional area (computed from the perimetral contour of the muscle section) will be determined. This process will be repeated for two times for each leg."
41126137|NCT03266081|DRUG|0.75% bupivacaine|topical anesthetic
41126138|NCT03279406|DEVICE|Percutaneous Left Atrial Appendage Occlusion|Percutaneous left atrial appendage occlusion in routine care for patients with atrial fibrillation
41126139|NCT05064124|DEVICE|CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
41126140|NCT04910698|DRUG|Antibiotic|Antibiotic duration of treatment defined if the patient belonged to long course or short course group.
41126141|NCT01019213|OTHER|Septal pacing|Septal lead activated
41447680|NCT06563271|DRUG|Dexketoprofen Trometamol 50 Mg/mL Solution for Injection|Dexketoprofen 50 mg administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
41447681|NCT06563271|DRUG|Ibuprofen 100 MG/ML Solution for Injection|"Ibuprofen 100 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).~Group P: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion)."
41447682|NCT06563271|DRUG|Paracetamol 10 Mg/mL Solution for Injection|Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
41447683|NCT06563271|DRUG|isotonic saline|Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.
41447684|NCT02257554|BEHAVIORAL|education|Discussion of surgical expectations with patients
40754586|NCT01037465|DRUG|Placebo|Placebo
40754587|NCT04418505|DEVICE|Vielight RX Plus|The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
40754588|NCT03917836|DIAGNOSTIC_TEST|endoscopy and histology|diagnostic evaluation of chronic gastritis
40754589|NCT04269187|DRUG|Theophylline|Theophylline oral 200 mg daily for 12 days
40754590|NCT01607008|OTHER|MRI imaging|"3 total MRI imaging studies:~1. pre standard radiation treatment~2. during standard radiation treatment~3. post standard radiation treatment"
41126142|NCT01019213|OTHER|His lead activated|His lead will be activated 80 ms before septal lead
41126143|NCT03002428|DRUG|Teriparatide (PF708)|Subcutaneous injection
41126144|NCT03002428|DRUG|Teriparatide (Forteo)|Subcutaneous injection
41126145|NCT01617369|DEVICE|Hypertonic Saline|2.8% NaCl x 4ml via nebulizer
41126146|NCT01771484|DEVICE|External automated abdominal binder|Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
41126147|NCT05596331|OTHER|eye-tracker|Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity
41126148|NCT04449835|PROCEDURE|Intracept Procedure|radio frequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
41126149|NCT03492866|DRUG|Gentamicin Sulfate|Topical treatment of 1 side of the scalp twice daily during 6 months
41126150|NCT01700296|BEHAVIORAL|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~1. 10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~2. Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
41447685|NCT05462080|DIAGNOSTIC_TEST|Ceraxis product|All patients will have their symptoms evaluated using the Ceraxis product
41447686|NCT02226289|DRUG|Bevacizumab|bevacizumab with the latest received cytotoxic regimen
40754591|NCT00537797|OTHER|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
41447687|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group A will receive 3 cycles of sintilimab plus platinum-based chemotherapy
41276925|NCT03486730|DRUG|BT1718|Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.
41276926|NCT04734990|DRUG|Azacitidine|Given IV or SC
41447688|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group B will receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab
41447689|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group C will receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab.
41447690|NCT02505347|OTHER|No splint|Can move arm as tolerated with no restrictions on mobility
41276927|NCT04734990|DRUG|Seclidemstat|Given PO
41276928|NCT03592459|DEVICE|Macy Catheter|Undergo placement of Macy catheter
41447691|NCT02505347|DEVICE|Splint|Wear splint for 6 weeks, only to remove for rehab and personal care
41447692|NCT06392711|BIOLOGICAL|Mesenchymal Stromal Cells (MSC) Dose Level 0|10 (8-12) x 10\^6 MSCs
41447693|NCT06392711|BIOLOGICAL|Mesenchymal Stromal Cells (MSC) Dose Level 1|20 (16-24) x 10\^6
40754592|NCT01642667|DRUG|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
40754593|NCT01642667|DRUG|Placebo|
40928414|NCT04095533|OTHER|Muscle strength assessment|Assessed using clinical bedside evaluation every second day with the Medical Research Council Sum Score. This is a clinical assessment of strength of 6 different muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) on each side of the body and recorded as a score between 0 (flaccid) and 5 (full strength).
41276929|NCT03592459|PROCEDURE|Pain Therapy|Receive opioids via Macy catheter
41276930|NCT03592459|OTHER|Questionnaire Administration|Ancillary studies
40754594|NCT05298969|PROCEDURE|Temporalis Myofascial flap|Improvement of speech and feeding quality in patients with palatal defects by temporalis myofascial flap
40754595|NCT03004495|DRUG|CHF5259 and CHF6001|b.i.d. for 14 days
40754596|NCT03004495|DRUG|CHF5259 + placebo|b.i.d. for 14 days
40754597|NCT03004495|DRUG|CHF6001 + placebo|b.i.d. for 14 days
40754598|NCT03004495|OTHER|Placebo|b.i.d. for 14 days
40928415|NCT01329835|BEHAVIORAL|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
40928416|NCT01329835|OTHER|brochure|brochure given after randomization
41276931|NCT03592459|OTHER|Survey Administration|Ancillary studies
41447694|NCT03076437|COMBINATION_PRODUCT|Drugs and Anti-CD19-CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine)."
40928417|NCT03495544|DIAGNOSTIC_TEST|PD-L1 expression|IHC testing of PD-L1 expression level in tumor tissue samples
40928418|NCT04578080|DEVICE|Transcranial direct current stimulation|Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
40928419|NCT05606003|BEHAVIORAL|Multi-Level Multi-Component Intervention (MLI)|The strategic components of our multi-level, multi-component intervention (MLI) include: 1. Building testing access for vulnerable populations, 2) Community Health Worker (CHW)-delivered navigation to SARSCoV- 2 testing and access and reinforce risk mitigation recommendations, 3) 2-1-1 helpline-referrals and navigation to FDA approved SARSCoV- 2 testing (and self sampling once approved) and risk mitigation education, and 4) social marketing and small media campaign to provide geo-targeted messages promoting testing and COVID risk mitigation behaviors. We selected these components because of their evidence base, their current use by partners in response to COVID 19, and confidence that they can be adapted through a community engaged process as described.
41276932|NCT06656962|DRUG|Telitacicept 160mg|Telitacicept for Injection combined with standard therapy (Prednisone and Cyclophosphamide) for the treatment of ANCA-associated nephritis (AAGN).
41276933|NCT06656962|DRUG|Prednisone (and methylprednisolone)|Methylprednisone shock therapy (500mg, 3 times), followed by Prednisone (1 mg·kg·d and a pre-determined tapering guideline \[PEXIVAS regimen\]).
41276934|NCT06656962|DRUG|Cyclophosphamide|Cyclophosphamide, intravenous injection, once every 2 to 3 weeks, 0.75 g/m² each time, the maximum cumulative dose of 8g
40754599|NCT00420407|DRUG|normal saline control|no vasopressin added to bolus or 5 hour continuous infusion
40754600|NCT00420407|DRUG|vasopressin|vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
40754601|NCT02181621|DEVICE|Iodosorb|Cadexomer iodine gel
40754602|NCT02181621|DEVICE|Solosite gel|Hydrogel
40754603|NCT05524792|OTHER|no interventional study|no interventional study
40754604|NCT04725981|PROCEDURE|Total laparoscopic hysterectomy|Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0
40928420|NCT05606003|BEHAVIORAL|Community Just-In-Time Adaptive Intervention (Community JITAI)|This intervention includes the same MLI components described above, with an added JITAI approach. Community and stakeholder partners will use real-time data related to testing and other relevant information generated by the Epidemiologic Surveillance and Analysis team (ESA) in Aim 1, as well as other information based on their community and stakeholder experience and tacit knowledge about factors influencing testing determinants, to adapt intervention activities as needed to optimize access to testing.
40928421|NCT00825773|DEVICE|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
40928422|NCT06105671|DRUG|Symbicort|Participants are administered 54 μg Formoterol and 1920 μg Budesonide
41447695|NCT02390518|RADIATION|Stereotactic Radiosurgery|"Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.~Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a and 1a Expansion (starting at Dose Level 3) Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a \*Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a~\*\*Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy~Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions."
40754605|NCT03272893|BEHAVIORAL|Acceptance and Commitment Therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
40928423|NCT06105671|DRUG|Formoterol|Participants are administered 54 μg Formoterol from an inhaler device
40928424|NCT06105671|DRUG|Formoterol|Participants are administered 120 μg Formoterol in a capsule, which is taken orally
40928425|NCT06105671|DRUG|Placebo|Participants are administered placebo
40928426|NCT06105671|DRUG|Mannitol|Participants are administered 600 mg Bronchitol
40928427|NCT01613976|DRUG|Panobinostat|
40928428|NCT05150639|OTHER|IVF|Women planning to undergo frozen embryo transfer IVF procedure will be included. Samples will be obtained, but no study intervention will be applied. Pregnancy outcome data will be obtained, following frozen embryo transfer, to correlate against other data from samples (vaginal microbiome etc).
40928429|NCT01450904|PROCEDURE|Quadriceps incision < 2 cm|MIS-TKA was performed with less than 2 cm Quadriceps incision length
40928430|NCT01450904|PROCEDURE|Quadriceps incision 2-4 cm|MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
40928431|NCT01450904|PROCEDURE|Quadriceps incision > 4 cm|MIS-TKA was performed with more than 4 cm Quadriceps incision length
40928432|NCT05965271|DEVICE|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
41447696|NCT01885819|BIOLOGICAL|Autologous stromal vascular fraction cells|
40754606|NCT01123525|DRUG|Adenosine|1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
40754607|NCT02289014|OTHER|online stress Management program|Active treatment group
40928433|NCT05682573|DIAGNOSTIC_TEST|hospitalized patient|Collect the patient's whole blood for testing
40928434|NCT03633760|DRUG|Bilastine 40mg single dose|Single-dose only cohort treatment duration is 1 day. After the screening period, eligible subjects will be allocated to receive a single dose of 40 mg of bilastine
41126151|NCT01066767|DRUG|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
41126152|NCT05719519|PROCEDURE|Initial periodontal therapy and 3D intraoral scanning|Initial periodontal therapy using GBT ( guided biofilm therapy) principle and 3D intraoral scanning
41126153|NCT05423119|BEHAVIORAL|conventional therapy|upper limb rehabilitation with and without technologies
41126154|NCT04587648|OTHER|NA, observational study|NA, observational study
41126155|NCT05210569|DEVICE|Vivity|Vivity intraocular lens (IOL)
40754608|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
40754609|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
40754610|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
40754611|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
40754612|NCT02531386|DEVICE|6 blood glucose monitoring systems for self-testing (blood glucose meters)|
40928435|NCT03633760|DRUG|Bilastine 20mg single-dose followed by multiple-dose|Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9.
40928436|NCT01295268|OTHER|Emu Oil|Subjects will apply a specified amount of emu oil daily to area.
40928437|NCT01295268|OTHER|Inert oil|A specified amount of inert oil will be applied daily to area.
40928438|NCT04191083|BEHAVIORAL|Motor imagery|This group will perform motor imagery training on motor learning of different motor tasks
40928439|NCT04191083|BEHAVIORAL|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group on motor learning of various motor tasks.
41447697|NCT04444063|PROCEDURE|Non-Incised Papilla Surgical Approach|"Horizontal or oblique incision is done on the buccal mucosa as far as possible from the marginal keratinized tissue and the inter dental papilla The horizontal/oblique incision is extended mesio-distally enough to allow proper visualization of the defect A full thickness flap is elevated apico- coronally to expose the coronal limit of the defect Scaling and root planning are done using mini-curettes and power driven ultrasonic tips with care trying to maintain fibers attached to the cementum Granulation tissue is removed with mini-curettes detached from the bony walls and removed from the base of the papilla carefully with microblades and microscissors .~1ry soft tissue closure will be performed by horizontal mattress suture 2mm from the edges of the incision as a first line of closure and then simple interrupted suture as a second line of closure using (5-0, 6-0) polypropylene suture."
41447698|NCT04038866|OTHER|rehabilitation gait with dual task|
41447699|NCT04038866|OTHER|rehabilitation gait without dual task|
41447700|NCT02241577|PROCEDURE|Surgical treatment|Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
41447701|NCT02241577|PROCEDURE|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
41447702|NCT03499353|DRUG|TALAZOPARIB|Talazoparib 1mg/day
41447703|NCT04333264|PROCEDURE|suction drainage|After primary total hip arthroplasty closed suction drainage will be used.
40928440|NCT04191083|BEHAVIORAL|Action observation|This group will perform action observation training on motor learning of various motor tasks.
40928441|NCT04191083|BEHAVIORAL|Placebo intervention|This group will watch a video of a landscape without the presence of people.
40928442|NCT06514651|DRUG|MAQ-001|MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade
40928443|NCT06514651|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system
40928444|NCT03109847|DRUG|Metformin Hydrochloride|Given Orally
40928445|NCT03109847|OTHER|Radioactive Iodine|Undergo radioactive iodine treatment
40928446|NCT03109847|OTHER|Placebo|Given orally
40928447|NCT02542930|RADIATION|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
40928448|NCT02542930|DRUG|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
40928449|NCT00400153|DRUG|Atrovent Respimat (20 mcg)|
40928450|NCT00400153|DRUG|COMBIVENT MDI (36/206 mcg)|
40928451|NCT00400153|DRUG|Combivent Respimat (20 mcg/100 mcg)|
40754613|NCT06207227|DEVICE|VITA AV Clinical System|The VITA AV Clinical System that works on the principle of negative pressure suction to the vaginal wall to treat VA, based on the idea of the clinical application in wound healing which is intended to elicit improvements in the rate of angiogenesis, moisture and HA production post-treatment. It is believed that the VITA AV Clinical System will provide a more effective treatment by improving the underlying cellular deficiencies associated with VA.
40928452|NCT00400153|DRUG|Placebo via corresponding inhaler for blinding purposes|
40928453|NCT04898621|DIETARY_SUPPLEMENT|75g fructose solution|Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.
40928454|NCT04898621|DIETARY_SUPPLEMENT|150g fructose solution|Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.
40928455|NCT05770674|DRUG|1 Month vs. 12 Months DAPT|"Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation~1. 1 Month following PCI, followed by clopidogrel monotherapy~2. 12 Months following PCI"
40928456|NCT06402994|OTHER|Electrophysiological experiment|Neural envelope tracking to conversational speech at different intensities
40928457|NCT06402994|BEHAVIORAL|Speech audiometry|Speech perception assessment at different intensities
40928458|NCT03239691|DRUG|ACT-709478 for oral use|Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
41447704|NCT04333264|PROCEDURE|no suction drainage|After primary total hip arthroplasty closed suction drainage won't be used.
41447705|NCT05597631|DEVICE|G-IVF PLUS|Experimental
41447706|NCT05206851|OTHER|Manual Lymphatic Drainage and Hot Pack|"Application of hot pack for 20 minutes at low back in sitting, and then the participant will perform deep diaphragmatic breathing for 10 minutes, following these steps:~1. Sitting in comfortable position~2. One hand is placed over chest and other on abdomen.~3. Inhale deep through the nose.~4. Exhale through mouth, completely, counting back from 4 to 1. Application rotary or stationary circle over low back in side lying position, in pregnant females. A session of 20-30 minutes of Manual Lymphatic Drainage will be given biweekly.~And at the end of Manual Lymphatic Drainage application, deep breathing for 10 minutes will be performed again."
41447707|NCT05206851|OTHER|Hot Pack|Hot pack will be applied at low back, for 20 minutes as home based protocol.
41447708|NCT05942469|BEHAVIORAL|FOREST|"The skill sessions will include didactic content defining the skill, rationale for including the skill in FOREST, and research demonstrating that practice of the skill increases positive emotion. In addition, the group will practice the skill together and will discuss ways to practice the skill at work as well as outside of work. Throughout the month, PEAs will implement the FOREST skill of the month in other existing meetings, check-ins, and team outings.~Concurrently, a module in UCAN's learning management system (LMS) will become available. The LMS modules will contain skill-related content similar to what is taught in the skill sessions, including a thorough definition of the skill, examples of ways to utilize the skill, a review or summary of the skill, and several knowledge questions to check for comprehension. The LMS content may include text, audio, images, and video components."
41447709|NCT02635750|DRUG|BI 409306|
41447710|NCT02635750|DRUG|Donepezil|
40928459|NCT03239691|DRUG|Placebo|Matching placebo available as matching capsules for oral administration
41447711|NCT06543355|DEVICE|Modified Battlefield Acupuncture + National Acupuncture Detoxification Association protocol|The delivery of modified BFA + NADA will be administered in a setting designed to ensure that patients are comfortable, with their backs well-supported. With regards to needling technique, participants' ears will be cleaned, and sterile acupuncture needles will be placed on the BFA or NADA points, using proper technique. Auricular acupuncture needles are thin, between 0.12 - 0.18mm, and are less than 1 inch long. The needles will remain in the ear until the session is complete. On the alternative ear, seeds are another modality of auricular acupuncture treatment that will be used. Seeds are comprised of small circular balls comprised of a natural plant, no more than 1.5 mm diameter size. The seeds are attached to a small piece of adhesive tape and are placed on one's ear. The seeds remain on the ear and the given point can be massaged and stimulated as indicated.
41447712|NCT02754089|DRUG|Rhus Coriaria L.(Rhus)|500 mg twice daily after meals for 6 weeks
41447713|NCT02754089|DRUG|Placebo|500 mg twice daily after meals for 6 weeks
41447714|NCT05291819|OTHER|Imaging informed treat-to-target|"A treat-to-target treatment strategy incorporating information from ultrasound assessment of joints, tendons and entheses (at every visit), and magnetic resonance imaging (MRI) of spine and sacroiliac (SI)-joints at baseline and 1 year, in addition to clinical information~Specifically, this means that these additional measures will be added to conventional treat to target:~* If evidence of enthesitis (power Doppler\>0 in enthesis) or axial inflammation (SPARCC score ≥ 2\* in SI-joint or SPARCC score ≥ 5 in presence of clinical symptoms of axial disease) on imaging the patient will progress directly to biological disease modifying antirheumatic drug in the treatment algorithm~* If evidence of ongoing inflammation (power Doppler\>0) on ultrasound assessment of joints, tendons or enthesis, the patient will be classified as not having reached their treatment target"
41447715|NCT05291819|OTHER|Conventional treat-to-target|Patients are treated according to an algorithm based on current European recommendations. The conventional treatment target, applicable to both arms and the target in the conventional arm, is all of: Disease Activity index in PSoriatic Arthritis (DAPSA) remission (≤4), Enthesitis ≤1, Psoriasis Body Surface Area ≤3%
41447716|NCT04802759|DRUG|Giredestrant|30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
41447717|NCT04802759|DRUG|Abemaciclib|150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
41447718|NCT04802759|DRUG|Ipatasertib|400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
41447719|NCT04802759|DRUG|Inavolisib|9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
41126156|NCT05380089|OTHER|Increasing water intake|Participants randomly assigned to the experimental group will be instructed to maintain habitual solid food choices and to increase water intake to achieve a total water intake of ≥45ml/kg/day.
41447720|NCT04802759|DRUG|Ribociclib|600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
41447721|NCT04802759|DRUG|Everolimus|10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
41447722|NCT04802759|DRUG|Samuraciclib|360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
41447723|NCT04802759|DRUG|PH FDC SC|On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
41447724|NCT04802759|DRUG|Palbociclib|125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
41447725|NCT04802759|DRUG|Atezolizumab|840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
41447726|NCT05441670|BEHAVIORAL|Art and Physical Therapy|45 minutes of Art Therapy followed by 30 minutes of Physical Therapy, Monday through Friday for 2 weeks
41447727|NCT05441670|BEHAVIORAL|Physical Therapy|30 minutes of Physical Therapy, Monday through Friday for 2 weeks
40754614|NCT05358912|DRUG|Vasopressor Agent|"Patients will receive vasopressor agents according to Surviving Sepsis Campaign Guidelines 2021"
41126157|NCT01608568|DEVICE|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
40928460|NCT04075812|DEVICE|Neuromuscular Stimulator|
40928461|NCT01753778|DEVICE|Cryo-Touch III Device|Treatment with Cryo-Touch III
40928462|NCT04307342|PROCEDURE|MIPO with Extra-articular Distal Humeral Anatomical Plate|MIPO with Extra-articular Distal Humeral Anatomical Plate
40754615|NCT05358912|DRUG|Crystalloid Solutions|"Patients will receive crystalloid solutions according to Surviving Sepsis Campaign Guidelines 2021"
40754616|NCT05358912|PROCEDURE|Invasive Blood Pressure Monitoring|Invasive blood pressure monitoring will be performed through an intra-arterial cannula placed in the radial artery. Philips Intellivue mx 500 monitors will be used for bedside monitoring.
40754617|NCT05358912|PROCEDURE|Intra-Abdominal Pressure Monitoring|"IAP will be measured indirectly by monitoring the pressure in the bladder.~Bladder pressure will be measured through an indwelling Foley catheter every twelve hours. Twenty-five mL of sterile normal saline will be injected in each measurement and readings will be recorded with a pressure transducer."
41126158|NCT00996749|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO
41126159|NCT00996749|OTHER|bone scan|Correlative studies
41126160|NCT00996749|OTHER|dual x-ray absorptometry|Correlative studies
41126161|NCT00996749|OTHER|laboratory biomarker analysis|Correlative studies
41126162|NCT00996749|PROCEDURE|biopsy|Correlative studies
40928463|NCT02222025|OTHER|Injury Prevention Programme|The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
40928464|NCT04384367|DRUG|Rizatriptan 10 mg + Naproxen 550mg|oral - single dose
40928465|NCT04384367|DRUG|Maxalt 10Mg Tablet|oral - single dose
40928466|NCT04384367|DRUG|Flanax 550mg|oral - single dose
40928467|NCT04384367|DRUG|Placebo oral tablet|oral - single dose
40928468|NCT00885001|PROCEDURE|Short Arc Banding|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
41126163|NCT04011813|OTHER|Hypotaurine : antioxidant and osmoregulator|"Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing"
41126164|NCT03324724|BEHAVIORAL|Integrative cognitive-affective therapy for adolescents (ICAT-A)|Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
41126165|NCT04699058|DIAGNOSTIC_TEST|COVID-antibody test|Questionnaire and COVID-antibody test for all participants
41126166|NCT00007163|DRUG|J695|
41126167|NCT05587699|DRUG|CKD-843 A 45mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
41276935|NCT04407767|BEHAVIORAL|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
40754618|NCT05358912|OTHER|Abdominal Perfusion Pressure|APP will be calculated with the following formula: (Mean arterial pressure) - (Intra-abdominal Pressure)
40928469|NCT00558129|DEVICE|X-STOP®|Surgical implantation of X-STOP IPD device
40928470|NCT00558129|PROCEDURE|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
40928471|NCT04671953|DRUG|BMS-986165|Specified dose on specified days
41126168|NCT05587699|DRUG|CKD-843 A 45mg|Single Injection
40928472|NCT04671953|DRUG|Metformin|Specified dose on specified days
40928473|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 10 mg|Delamanid (300 mg once daily \[QD\]) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg thrice-weekly \[TIW\]) + OPC-167832 (10 mg QD) for 17 weeks
40928474|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 30 mg|Delamanid (300 mg once daily \[QD\]) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg thrice-weekly \[TIW\]) + OPC-167832 (30 mg QD) for 17 weeks
40928475|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 90 mg|Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (90 mg QD) for 17 weeks
40928476|NCT05221502|DRUG|RHEZ|RHEZ for 8 weeks followed by 18 weeks of rifampin and isoniazid (for a total of 26 weeks)
40928477|NCT00965328|PROCEDURE|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
40928478|NCT00965328|PROCEDURE|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
40928479|NCT01439698|DEVICE|Radio Frequency ablation Probe|Any probe that can conduct radiofrequency ablation within biliary ducts.
41126169|NCT05587699|DRUG|CKD-843 A 55mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
41126170|NCT05587699|DRUG|CKD-843 A 55mg|Single Injection
41126171|NCT05587699|DRUG|CKD-843-R|0.5mg/day, 9 Month
41126172|NCT00630487|DRUG|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
41126173|NCT00630487|DRUG|Somatropin|Fixed doses for patients: MALE: \< 45y 0,4 mg, \> 45y 0,2mg FEMALE: \< 45y 0,5mg, \>45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
41126174|NCT03382470|OTHER|Antimicrobial stewardship advice|A basic antimicrobial stewardship team will be created at each site. The team will provide advice on the treatment of urinary tract infections and asymptomatic bacteriuria during the second half of the study.
41126175|NCT00325000|BEHAVIORAL|Interpersonal Psychotherapy|
41126176|NCT00325000|DRUG|sertraline or amitriptyline|
41126177|NCT00280228|BEHAVIORAL|Adolescent Skills Parent Management Parent-Adol Negotiation|Acute treatment for 12 weeks followed by three monthly booster sessions.
41126178|NCT00280228|BEHAVIORAL|Treatment as Usual|Standard outpatient treatment for behavioral problems and substance use
41126179|NCT02806674|DEVICE|The eradication times of the patients|The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group
41126180|NCT02806674|DEVICE|The result of 13C-urea breath test after treatment|The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
41447728|NCT06376500|DEVICE|tDCS with cognitive training programme|Participants will complete tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. The training session will last for 20 minutes and it is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
41447729|NCT05962476|DEVICE|Transcutaneous vibro-acoustic device|Wearable device which sends low-frequency sound vibrations through the skin.
41447730|NCT03587545|OTHER|Probiotic nasal spray|Total daily nasal administration of 2\*10\^8 CFU of probiotic bacteria delivered via 2 servings.
41447731|NCT03587545|OTHER|Placebo nasal spray|Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)
41447732|NCT02863822|BEHAVIORAL|Low FODMAP Diet|Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
41447733|NCT02863822|BEHAVIORAL|Choose My Plate Diet|Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
41447734|NCT05348876|DRUG|Darolutamide (Nubeqa, BAY1841788)|600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
41126181|NCT02984332|OTHER|Lower limb immobilisation (leg brace)|
41126182|NCT03782870|DIAGNOSTIC_TEST|echocardiography, lab tests|
41126183|NCT01965665|DEVICE|MediHoney HCS dressing|
41126184|NCT06324786|BEHAVIORAL|IBMT|IBMT is an effortless mindfulness technique
41276936|NCT04407767|BEHAVIORAL|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
41276937|NCT06657612|OTHER|No intervention|No intervention
40754619|NCT03683199|PROCEDURE|Rhinoplasty|"The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts."
40754620|NCT04032431|BEHAVIORAL|Telerehab VR intervention|Training with VR system using software specifically designed to reproduce activities of daily living
40754621|NCT04880889|DRUG|BL 3000|capsule 500 mg
41126185|NCT06324786|BEHAVIORAL|NF|NF is a mental training technique.
41126186|NCT05051982|DEVICE|Sedline EEG in View|EEG monitor (Sedline) will be in full view of the Anesthesiologist during surgery.
40754622|NCT04880889|DRUG|Reference Pantogar|capsule
41126187|NCT00530153|BEHAVIORAL|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
41126188|NCT00530153|DIETARY_SUPPLEMENT|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
41126189|NCT05209477|OTHER|lung ultrasound assessment|"In patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio \< 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~1. baseline, in supine position under protective ventilation~2. after two minute of recruitment maneuver in pressure controlled ventilation~3. at 1 hour following prone positioning application"
41447735|NCT03012451|BEHAVIORAL|Advancing Adolescents|"The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities."
41447736|NCT06134453|OTHER|Reiki/Sham Reiki|Reiki will be applied to the patients by the research nurse who is at the Reiki master level. Sham Reiki will remain in the same position and for the same duration as if Reiki was performed by a healthcare professional who has not received Reiki training, but Reiki energy will not be given to the patient. No intervention will be made to the control group.
41447737|NCT04754984|BEHAVIORAL|Pelvic floor workshop|Physiotherapist-led workshop on managing pelvic floor symptoms
41447738|NCT02016274|OTHER|Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy|Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
41447739|NCT02441686|DRUG|Bortezomib|
41447740|NCT02441686|DRUG|Lenalidomide|
41447741|NCT02441686|DRUG|Dexamethasone|
41447742|NCT02441686|PROCEDURE|Stem Cell Mobilization|
41447743|NCT02441686|PROCEDURE|Autologous Stem Cell Transplant|
41126190|NCT03574103|BEHAVIORAL|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements), without restriction in time for feeding, for 8 weeks.
41126191|NCT03574103|BEHAVIORAL|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 12 p.m. to 8 p.m.) and 16 hours of fasting, for 8 weeks.
41126192|NCT03574103|BEHAVIORAL|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 8 a.m. to 4 p.m.) and 16 hours of fasting, for 8 weeks.
41276938|NCT05670977|DIETARY_SUPPLEMENT|Study product plus collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
41276939|NCT05670977|DIETARY_SUPPLEMENT|Study product without collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
41276940|NCT01501643|DEVICE|Non invasive positive pressure ventilation|At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
41276941|NCT01501643|DEVICE|Spirometry|Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
41276942|NCT00001189|PROCEDURE|radiotherapy|
41276943|NCT05275114|DEVICE|tDCS stimulation with hand task|30 minutes of intervention including tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
41276944|NCT05275114|DEVICE|sham tDCS stimulation with hand task|30 minutes of intervention including sham tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
41276945|NCT06654557|OTHER|Placebo beverage, kiwi-strawberry flavor (Part 1 and Part 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
41447744|NCT06276660|OTHER|BCTT|"Participants will complete the Buffalo Concussion Treadmill Test, which involves individuals walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter."
41126193|NCT02629224|DRUG|ASP8825|Oral
40754623|NCT04880889|DRUG|BL3000 Placebo|capsule 500 mg
40754624|NCT04880889|DRUG|Pantogar - Placebo|capsule
40754625|NCT00501943|DRUG|Avonex (Interferon beta 1a)|
40754626|NCT00501943|DRUG|Riluzole|
40754627|NCT00501943|DRUG|Placebo|
41126194|NCT02019459|OTHER|Very low nicotine content cigarettes|
41126195|NCT02019459|OTHER|standard nicotine content cigarettes|
41126196|NCT05865834|OTHER|A smartphone application|app will have 2 modules: Chill zone and sleep; Chill zone has 9 sub-modules which are meditation, breathing techniques, family time, art time, funny sayings, reframe stress and relax, diet and cooking tips, mini courses and how to become better. The sub-modules of sleep are: wind down, sleep music, storytelling, nature sounds and beautiful nature. These modules will be approved by a clinical psychologist to help people with symptoms of depression and anxiety. Skills learned include emotion recognition, emotional management, behavioral activation (being active), recognizing and challenging unhelpful thoughts and cognitive restructuring to plan for their future.
41126197|NCT05865834|OTHER|Pictorial educational leaflets|the control group will receive self-reading educational leaflets, the majority of which are pictorial. These leaflets will be approved by a clinical psychologist to help people with symptoms of depression and anxiety.
41126198|NCT04657887|BIOLOGICAL|Voncento®|Solution for injection
41126199|NCT04059042|BEHAVIORAL|Music Listening|Participants will have pain threshold testing while listening to silence, music, or nature sounds.
41126200|NCT00262782|DRUG|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
40754628|NCT04140929|OTHER|Oral Health Tool Box|Please see, description of the intervention group
40754629|NCT01229670|OTHER|exercise|"* 1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~* 2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min"
40754630|NCT02653755|DEVICE|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
40754631|NCT01723839|DRUG|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide|19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
40754632|NCT00872287|PROCEDURE|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
40754633|NCT00872287|PROCEDURE|SILS|Single transumbilical incision laparoscopic cholecystectomy
40754634|NCT06334718|BEHAVIORAL|Interviews and simulation|Work package 1: interview study Work package 2: simulated cardiac arrest study with AED delivered by drone following a simulated emergency (999) call.
40754635|NCT01163565|DEVICE|Ligasure Device|Ligasure device used to seal blood vessels during left or right side of a total thyroidectomy. Traditional method of hand ties/clips on contralateral side.
41276946|NCT06654557|OTHER|0% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
41276947|NCT06654557|OTHER|0% carbohydrate electrolyte solution without glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
41276948|NCT06654557|OTHER|1% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
41276949|NCT06654557|OTHER|6% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
41276950|NCT06654557|OTHER|6% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
41126201|NCT05369936|OTHER|Aromatherapy|Lavender will be inhaled through three phases
40928480|NCT03642704|DRUG|Reinforced preventive ARV therapy|"If the mother is HIV-1 or HIV 1/2 infected:~* zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~* nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks."
41126202|NCT05369936|OTHER|Placebo|Vapors of the distal water will be inhaled through three phases
41126203|NCT05237752|DRUG|LG00034053|a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis
41126204|NCT06274099|OTHER|nursing care|It is thought that this study, in which individualized care will be based on comfort theory, will lead to individualized care in chronic diseases.
41126205|NCT03591159|OTHER|Membran Sweeping|Cervical Membrane Sweeping by digital examination
41126206|NCT05746754|RADIATION|CSI|30 Gy in 10 fractions to CNS
41276951|NCT06654557|OTHER|6% carbohydrate electrolyte solution with glycerol beverage (Part 2 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
40928481|NCT06251479|BEHAVIORAL|behavioral 1|verbal and non verbal tasks
40928482|NCT06251479|BEHAVIORAL|behavioral 2|verbal and non verbal tasks with other partecipants
40928483|NCT06251479|DEVICE|neuromodulation 1|registration with neurophysiological tecniques during verbal and non verbal tasks
41447745|NCT06276660|OTHER|Dynamic ExIT|The modified EXiT test will complete a 12 minute treadmill interval program followed by a dynamic circuit (10 squat jumps, 10 side to side push ups and 10 medicine ball rotations), jump ball toss, zig zag agility and arrow agility. Parameters will be recorded the same as the established dynamic EXiT test; heart rate and RPE will be recorded at 0, 2, 6:30 and 12 minutes of the treadmill program as well as after the second trial of each activity. The time to complete two trials of the zig zag agility and arrow agility will also be recorded.
41447746|NCT05444803|OTHER|femoral nerve block|Patients will be performed a femoral nerve block using bupivacaine thirty minutes before the performing of spinal block.
41447747|NCT05444803|OTHER|peri-capsular nerve group block|Patients will be performed a peri-capsular nerve group block using bupivacaine thirty minutes before the performing of spinal block.
41447748|NCT04741776|BEHAVIORAL|Resilience Enhancement Skills Training|Family therapy
41126207|NCT02967861|BEHAVIORAL|Pranayama|Pranayama is the breathing exercise through the nostrils. It enhances the systemic immunity which in turn enhances the overall defense mechanism of an individual.
41447749|NCT04741776|BEHAVIORAL|Problem-Solving Individual Therapy|Individual therapy
41447750|NCT02510118|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
41447751|NCT02510118|DRUG|XELOX|XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks
41447752|NCT02510118|DRUG|Placebo ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
41126208|NCT02967861|PROCEDURE|Scaling and root planing|It is a mechanical debridement of dental plaque.
41126209|NCT05707624|OTHER|video education|In the study, there are 2 groups in total: the intervention group (n=50) which videos of approaching the febrile child was watched once a week and 2 videos, and the control group (n=49) which no other application is made except for the routine procedure of the hospital
41126210|NCT05707624|OTHER|the routine procedure|the routine procedure
41126211|NCT03358446|OTHER|A group|"The optimal range of leg abduction was defined as the range without overlap in A group and the range presenting that the overlap was less-than half of the diameter of femoral vein in S group.~A1 angle defined the point that the femoral vein and artery started non-overlapping interval when increasing the angle of the leg in the A group and the A2 angle is defined the point that the femoral vein and artery ended non-overlapping interval."
40928484|NCT06251479|DEVICE|neuromodulation 2|registration with neurophysiological tecniques during verbal and non verbal tasks with other partecipants
40928485|NCT05530629|DEVICE|resistance training|resistance training lasts for 12 weeks, three times a week, one hour each time, and the program of resistance training in the experimental group was divided into 10 exercises: Chest press, Lat pull down, Shoulder press, Squat, Leg extension, Leg curl, Bicep curl, Triceps extension, abdominal crunches, lower back exercises.
41126212|NCT03358446|OTHER|S group|B1 is the angle at which the overlap starts at the half of the femoral vein radius when increasing the angle of the leg in the S group, B2 is the angle at which overlap starts at half or more of the femoral vein radius again. In the range of B1 and B2 angles, they are overlapped by half or less of the femoral vein radius.
41276952|NCT00817414|DRUG|LCI699-matching placebo|LCI699-matching placebo oral capsules
41276953|NCT00817414|DRUG|LCI699|LCI699 oral capsules
41276954|NCT06657703|DRUG|HC022|Administered as specified in the treatment arm
41276955|NCT06657703|DRUG|Placebo|Administered as specified in the treatment arm
41276956|NCT06602141|PROCEDURE|Muscle Biopsy|This procedure is used to sample muscle cells from the leg Vastus Lateralis (thigh) muscle.
40928486|NCT05530629|DEVICE|Normal P.E. course|Carry out general teaching content according to the college syllabus lasts for 12 weeks , three times a week, one hour each time, and the program of Normal P.E. course in the control group will be Physical recovery exercises, learn and practice queue formation, calisthenics, five step fists, long fist and Basic movements of Gymnastics gradually changed by week.
41276957|NCT06602141|PROCEDURE|Adipose Biopsy|This procedure is used to sample fat tissue from the abdomen (belly).
40928487|NCT01962038|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Gym and home based aerobic and resistance exercises
41276958|NCT06602141|OTHER|Glucose Clamp|In this test, we will measure the effect of insulin by giving you insulin and glucose (sugar) intravenously through an IV line in your arm.
41126213|NCT00951691|BEHAVIORAL|Enhanced acute medical rehabilitation|"Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. J American Medical Director's Association, 2012 for details and outcome data."
41126214|NCT00951691|BEHAVIORAL|Treatment as usual|Standard treatment with physical and occupational therapies
41447753|NCT02510118|DRUG|ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
41447754|NCT06328829|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
40928488|NCT01962038|BEHAVIORAL|Stretching Exercises|Gym and home based stretching exercises
41276959|NCT06602141|OTHER|Accelerometer|The tri-axial accelerometer measure activity and uses those values to estimate the number of calories burned based on your height, weight, age, and gender. The monitor also evaluates physical effort and the body's response to different activities.
40928489|NCT01962038|BEHAVIORAL|Cognitive Training|Group-based cognitive training
40928490|NCT01235598|OTHER|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
40928491|NCT01235598|BIOLOGICAL|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
41126215|NCT00879710|DRUG|simvastatin or ezetimibe|Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
41126216|NCT03072316|OTHER|3D surface imaging|3D photography
41126217|NCT03072316|OTHER|semi-structured interview|qualitative analysis using semi structured interview
40754636|NCT01423084|BIOLOGICAL|Serogroup B meningococcal vaccine|"All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination"
40928492|NCT01235598|BIOLOGICAL|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
40928493|NCT04253886|DEVICE|Ovassapian Fibreoptic Intubating Airway|The fibreoptic bronchoscope remains one of the most important methods of intubating patients particularly when there is difficulty with intubation.Facilitating fiberoptic oropharyngeal intubation procedure, specific airways have been devised to push the tongue anteriorly to clear a passage for the fibrescope into the trachea. Of these airways Ovassapian Fibreoptic Intubating Airway (Kendall, Argyle, New York, New York, USA) and Fekry Oral Intubating Airway (Ameco Tech, Cairo, Egypt).
41126218|NCT03072316|OTHER|applanation tonometry|measurement of breast compressibility
41126219|NCT00995631|PROCEDURE|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
41126220|NCT03189589|DRUG|GSK2269557 500 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
41126221|NCT03189589|DRUG|GSK2269557 750 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
41126222|NCT04613375|DIAGNOSTIC_TEST|Urine sample collection|Serotype specific UAD (urinary antigen detection) test
41126223|NCT04613375|DIAGNOSTIC_TEST|Saliva collection|Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR
41126224|NCT02376244|OTHER|High intensity interval training (HIIT)|Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
41126225|NCT02376244|OTHER|Standard care|Standard care cardiac rehabilitation according to current guidelines
40928494|NCT01447212|DRUG|Hydromorphone, Injectable|Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
40928495|NCT01447212|DRUG|Diacetylmorphine, injectable|Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
40928496|NCT01447212|DRUG|Hydromorphone, liquid oral|Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
40928497|NCT01447212|DRUG|Diacetylmorphine, liquid oral|Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
41447755|NCT06328829|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
41447756|NCT06328829|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
41447757|NCT03162159|OTHER|Collection of growth and bone maturation data|
41126226|NCT02809989|DRUG|Ovaleap®|"About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births)."
41276960|NCT06602141|OTHER|Endurance Exercise|Visit the study site 3 times a week to engage in endurance exercise training for approximately 12 weeks. Each session will last approximately 75 minutes, and exercise group can choose to use either a stationary bike or a treadmill to complete the training.
41447758|NCT00000956|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
41276961|NCT06602141|OTHER|Physical activity/ dietary habits|Visit the study site bi-weekly to get weight measurements and speak to the study team about weight maintenance and participant physical activity/dietary habits.
41276962|NCT06602141|OTHER|Heavy Water Labeling Period|Participants in both control groups will be required to drink heavy water, which is ordinary water that is enriched with deuterium (stable, non-radioactive isotope) and called deuterium-labeled water, for 12 weeks.
41276963|NCT03245814|BEHAVIORAL|Service Dog|A service dog trained to perform tasks that are specific to PTSD
41447759|NCT00429221|BEHAVIORAL|Tailored Medication Messages for Parents|
41447760|NCT02342535|BEHAVIORAL|Physical Activity|Culturally tailored physical activity intervention for South Asian women and their children.
41447761|NCT06359015|DRUG|Metformin|"Oral Metformin schedule:~Day 1: 500 milligrams in morning Day 2: 500 milligrams two times a day Day 3: 1000 milligrams in morning, 500 milligrams in evening Day 4 onwards: 1000 milligrams two times a day based on individual tolerance~Oral Esomeprazole schedule:~40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance."
41447762|NCT06359015|DRUG|Esomeprazole|40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance.
41447763|NCT01105299|DRUG|CJ anastrozole 1 mg tablet|
40928498|NCT02996032|OTHER|Vascular and Pulmonary Ultrasound|
40928499|NCT02239120|DRUG|optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
40928500|NCT02239120|DRUG|placebo to ASA|placebo to comparator drug
40928501|NCT02239120|DRUG|placebo to optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
40928502|NCT02239120|DRUG|placebo to dabigatran etexilate|placebo
40928503|NCT02239120|DRUG|ASA 100 mg|active comparator drug
40928504|NCT02239120|DRUG|dabigatran etexilate|active drug
40754637|NCT00463775|DRUG|Topiramate|SSRI plus topiramate SSRI plus placebo
41276964|NCT00188084|PROCEDURE|DNA Index|
41276965|NCT00188084|PROCEDURE|S-Phase%|
41276966|NCT00188084|PROCEDURE|CD45 expression|
41276967|NCT00188084|PROCEDURE|P16 metabolic way|
41276968|NCT02867306|DRUG|ASP1707|Oral
41276969|NCT02867306|DRUG|methotrexate (MTX)|Oral
41276970|NCT05779163|DRUG|LBL-033 for Injection|Initial dose - MTD; Q2W; intravenous infusion
40928505|NCT06148194|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 30 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 30 mL-bottle that is used for probiotic 1 and 2.
40928506|NCT06148194|COMBINATION_PRODUCT|Probiotic 1|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device (Product declaration: No. 210001337/PCBA-HN) in accordance with manufacturing standards approved by the Hanoi Health Department, Ministry of Health, Vietnam (Certificate No. YT117-19), and ISO 13485:2016. LiveSpo Navax product is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 1 billion CFU/mL x 30 mL.
41447764|NCT02569138|DEVICE|Modified Insole|hard and thin shoe insert between the foot sole and base of the footwear
41447765|NCT02569138|DEVICE|Non-Modified Insole|regular shoe insert between the foot sole and base of the footwear
41447766|NCT02451163|DIETARY_SUPPLEMENT|wheat polysaccharides|Consumed once daily for 12 weeks.
41447767|NCT02451163|DIETARY_SUPPLEMENT|maltodextrin|Consumed once daily for 12 weeks.
41447768|NCT00456898|DRUG|desvenlafaxine sustained release (DVS SR)|
41447769|NCT00456898|DRUG|Paroxetine|
41447770|NCT00456898|DRUG|Codeine|
40754638|NCT03230565|DRUG|Ropivacaine|Patient will be given a continuous infusion of local anesthetic.
40754639|NCT03230565|DRUG|Ropivacaine|Patient will be given a scheduled intermittent bolus of local anesthetic.
40754640|NCT02815254|OTHER|High intensity functional exercise|
40754641|NCT02815254|OTHER|Low intensity functional exercise|
40754642|NCT00322426|DEVICE|Sensory Cueing Device|
40754643|NCT04315961|DRUG|Blinded drug dose conditions|Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
40754644|NCT02563431|DEVICE|SYSTAM - SP-ED|"* Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~* Daily passive mobilisation of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)"
40754645|NCT02563431|DEVICE|Ultrasling ER 15°Donjoy - 4P-ED|"* Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~* A training of the patient and members of family on pathology, risk, use of material~* Daily passive mobilization of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis."
40928507|NCT06148194|COMBINATION_PRODUCT|Probiotic 2|In Vietnam, LiveSpo Navax Kid is manufactured as a Class-A medical device (Product declaration: No. 220002534/PCBA-HN) in accordance with manufacturing standards approved by the Hanoi Health Department, Ministry of Health, Vietnam (Certificate No. YT117-19), and ISO 13485:2016. LiveSpo Navax Kid is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 0.6 billion CFU/mL x 30 mL.
40928508|NCT02822547|DRUG|Peginterferon alfa-2a|Patients will receive Peginterferon alfa-2a according to the standard medical practice
41126227|NCT01202513|DRUG|Bimatoprost 0.03% topical ophthalmic solution|
41126228|NCT05599282|DRUG|Amino Acid Supplement|Four capsules of Amino Acid Supplement will be taken once a day for 90 days.
41126229|NCT05599282|OTHER|Placebo|Four capsules of Placebo will be taken once a day for 90 days.
41276971|NCT00956826|DEVICE|Agit Vacuum|With an electrode and a regular vacuum device
41447771|NCT00550329|DRUG|Glipizide GITS|
41447772|NCT06623695|OTHER|Exercise|SGG performed the exercise program on a fixed ground surface. SGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
41447773|NCT06623695|OTHER|Exercise|USGG participants completed the exercise program on a bosuball. USGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
41447774|NCT06408168|DRUG|Fulvestrant|Given by PO
41447775|NCT06408168|DRUG|Repotrectinib|Given by IV
41447776|NCT00636129|BEHAVIORAL|Relaxation Response + Stress Management Curriculum|Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
41447777|NCT06060834|DIETARY_SUPPLEMENT|Topical Botanical Agent|Cayenne Pepper, Coconut Water, Kelp, Lemon Juice, Oxynex LM, Potassium Sorbate, Red Palm Oil, Rose Water, Saw Palmetto, vitamin C
41447778|NCT02307994|DRUG|75IU uFSH|
41447779|NCT05422469|DEVICE|Medtronic Percept RC neurostimulator|Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted
41447780|NCT04563481|OTHER|Hand Therapy via Telerehabilitation|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton...) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
41447781|NCT04563481|OTHER|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton...) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
41447782|NCT03946436|DEVICE|Active video games|Participants played the active video game Virtua tennis 4 on a playstation kinect device
41447783|NCT03946436|OTHER|tennis training process|Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.
41447784|NCT00009945|DRUG|clodronate|1600 mg PO daily
41447785|NCT00009945|DRUG|placebo|2 pills PO daily
41447786|NCT06488846|OTHER|INVITE-Home|Curriculum to train Treatment Buddies, selected by the people with HIV, to administer LAI-ART at home with supervision of a Study Nurse.
41447787|NCT06488846|OTHER|Clinic-Administered LAI-ART|People with HIV who continue to receive LAI-ART in clinic
41447788|NCT06488846|OTHER|Oral ART|Oral ART
41447789|NCT06182293|OTHER|Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota|Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.
41447790|NCT00405860|DRUG|CellCept (mycophenolate mofetil)|
41447791|NCT02374112|DIETARY_SUPPLEMENT|Creatine|Creatine supplementation
41447792|NCT02374112|OTHER|Placebo|Placebo supplementation
41447793|NCT05795959|BEHAVIORAL|Receive education on precision medicine|Patients who consent to participating in the study and are randomized to the intervention group, will meet 1 on 1 with a trained lay VA volunteer. The trained lay VA volunteer will conduct phone calls with patients until the end of the 1 month enrollment period to deliver education regarding precision medicine.
40754646|NCT04618965|DRUG|control group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
40754647|NCT04618965|DRUG|Intrathecal dexmedetomidine|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
40754648|NCT04618965|DRUG|Intravenous dexmedetomidine|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
41126230|NCT05713526|BEHAVIORAL|Telehealth service|Researchers will send educational materials (video and e-brochures) about childhood vaccinations to the participants' mobile phones at regular intervals, answer their questions over the phone and send reminder messages before the vaccination appointment.
41126231|NCT06214442|OTHER|Evaluations of the mechanical properties of the achilles tendon in different phases of the menstrual cycle|Monitoring assessments to verify the effect of different phases of the menstrual cycle on the neuromechanical properties of the Achilles tendon.
41126232|NCT01501617|BIOLOGICAL|Hair Stimulating Complex (HSC)|Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
41447794|NCT05582967|OTHER|Completion of focused Electronic Case Report Form|All patients will have a focussed Electronic Case Report Form completed collecting information around Presenting complaint, Past Medical History, Family History, Physical Examination findings, and Investigations.
41447795|NCT04752605|BEHAVIORAL|Finnish ENGAGE together|Early childhood education workers play games with children during day care. The games (e.g. ball games, puzzles, Simon says) target children's executive functions and self-regulatory skills, e.g. inhibition, attention, and emotion regulation. The first phase of the intervention (6 weeks) includes play sessions (15 minutes each day) for all children as well as a parents' evening to encourage playing at home. In the second phase (8 weeks), more individualized small group play sessions (3 times a week, 30 minutes at once) are arranged for the children that show difficulties in self-regulation after the first phase. Also, a parents' group including 6 group sessions and 2 phone calls is arranged for their parents in this phase. The participating parents are asked to play the games for 20 minutes each day with their children. During the group meetings, the parents share their experiences of playing at home and receive support and guidance from 2 health care professionals.
40754649|NCT01934231|DRUG|Amoxicillin-Potassium Clavulanate Combination|The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
40754650|NCT00026403|DRUG|cisplatin|
40754651|NCT00026403|DRUG|gemcitabine hydrochloride|
40754652|NCT00026403|RADIATION|radiation therapy|
40754653|NCT03280615|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
41126233|NCT01501617|DEVICE|Dulbecco's Modified Eagle Medium, DMEM|Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
41276972|NCT01158183|DRUG|BAY86-5046_Interferon-beta-1b|Electronic questionnaires
41276973|NCT01870466|DRUG|Cilostazol|cilostazol bid for 7 days
41276974|NCT01870466|DRUG|Simvastatin|simvastatin qd for 7 days
41276975|NCT01870466|DRUG|Rosuvastatin|rosuvastatin qd for 7 days
41447796|NCT01750294|DRUG|Chlorthalidone|
41447797|NCT04296123|BEHAVIORAL|Step training|A 12-week step training consisting of two 30-minute training session per week. The participants will be instructed to stand upright and step on different targets on a plastic mat repeatedly.
41447798|NCT03713866|DIAGNOSTIC_TEST|EP Imaging and Testing|"Magnetic Resonance Imaging: pre-procedure imaging is standard care prior to catheter ablation procedures for VT to document anatomy of the heart.~120-Lead Body Surface Mapping: a 120-lead ECG will be recorded using a standardized mapping protocol. 120 disposable radiolucent silver chloride (Ag/AgCl) surface electrodes will be placed on the torso in 18 strips and connected via cables to an advanced acquisition system.~Noninvasive programmed stimulation (NIPS) study will be performed using the patient's implanted defibrillator, and is part of standard practice during a VT catheter ablation."
41447799|NCT01559363|DRUG|Tesevatinib|Pharmaceutical form: Tablets Route of administration: Oral
41447800|NCT05988840|OTHER|Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.|Using the tool developed by Emobot, EMOACQ-1 is a study that passively and non-interventionaly collects data by capturing patients' facial expressions throughout the day, and then measures the correlation between emotional signals and the results of measurement questionnaires used in psychiatry.
41447801|NCT05533411|DRUG|Donanemab|Administered IV.
41447802|NCT05533411|DRUG|Placebo|Administered IV.
41447803|NCT02401906|OTHER|MRI|
41126234|NCT04038736|DEVICE|C-Scan System|During C-Scan procedure the subject swallows the C-Scan cap. The capsule travels painlessly through the gastrointestinal tract, seeking polyps, the precursors of colorectal cancer. It is essential to increase the stool's contrast by ingesting radio-opaque material. During the passage of the capsule in the gastrointestinal tract, it transmits information to a recorder attached to the back. In order to collect data about the instantaneous localization of the capsule traveling in the colon additional sensors are embedded in the recorder on the back side. After the capsule is expelled, the data from the recorder is downloaded to an acquisition workstation. Later, the data is transferred to a processing workstation where dedicated software visualizes and analyses the data.
41126235|NCT06435169|DIAGNOSTIC_TEST|Lasegue's, Freiberg's and, FAIR (Flexion Adduction Internal Rotation) tests.|The Straight Leg Raise test or Lasegue test, is also crucial in detecting disc herniation and neural compression. Lasègue's sign is said to be positive if the angle to which the leg can be raised (upon straight leg raising) before eliciting pain is \<45°.The presence of Piriformis syndrome was investigated in these patients with Freiberg and FAIR tests. Freiberg's test elicits pain by passively internal rotation of the extended hip, when the patient is in supine. The purpose of this test is on the one hand stretching of the irritated Piriformis Muscle (PM), on the other hand provoking sciatic nerve compression. The FAIR test is a sensitive and specific test for detection if irritation of the sciatic nerve by the piriformis. FAIR stands for flexion, adduction and internal rotation. Also known as piriformis test.
41276976|NCT05920356|DRUG|Sotorasib|Oral administration
41276977|NCT05920356|DRUG|Pembrolizumab|Intravenous administration
41276978|NCT06559839|OTHER|Vestibulocortical Stimulation|50cc of cold water (4℃) irrigated to the right external ear canal, at 1-2 cc/second, with the patient laying supine.
41276979|NCT06559436|DRUG|Intravenous thrombolysis|Patients in the TNK treatment group will receive TNK intravenous thrombolysis after MeVO is determined, and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg,
41447804|NCT03877939|DIAGNOSTIC_TEST|Blood samples collection for analysis|"Blood samples:~Blood samples will be collected for the determination of the levels of various biomarkers (Kisspeptins and miRNAs), which are molecules that regulate the expression of proteins and can serve as markers for predicting pregnancy viability. Additionally, after biochemical or week 10 of clinical pregnancy confirmation, blood samples will be collected for KIR and HLA-C typing, Oral glucose tolerance test (OGTT) and analysis of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b.~Uterine biopsy (only in patients with BP):~Uterine biopsy samples will be collected also after biochemical pregnancy confirmation for the determination of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b."
41447805|NCT06432751|OTHER|Post Operative Acute Kidney Injury|"Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file"
40754654|NCT03280615|DIETARY_SUPPLEMENT|Corn oil|Corn oil will be the placebo comparator for omega 3 fatty acids supplement
40754655|NCT02763748|PROCEDURE|Laparoscopic endoscopy combined surgery|
41276980|NCT06559436|OTHER|Standard medical management|Standard medical management
41276981|NCT05529654|DEVICE|Impella 5.5 with SmartAssist|For subjects enrolled in the Trial, the Impella 5.5 will be placed intra-operatively during the index cardiac surgical procedure
41276982|NCT03767244|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
41276983|NCT03767244|DRUG|Androgen Deprivation Therapy (ADT)|Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).
41276984|NCT03767244|DRUG|Placebo|Participants will receive matching placebo oral tablets daily.
41276985|NCT06656091|DRUG|simmitinib|simmitinib 6mg,QD ,3 weeks on 1 week off
40754656|NCT02763748|PROCEDURE|laparoscopic and endoscopic cooperative surgery|
40754657|NCT02763748|PROCEDURE|Single-arch laparoscopic and endoscopic cooperative surgery|
40754658|NCT01649583|DEVICE|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
41276986|NCT06656091|DRUG|investigator's choice of chemotherapy,include docetaxel or irinotecan.|docetaxel injection 75mg/m\^2,d1,every 3 weeks or ilinotecan injection 180mg/m\^2,d1,every 2 weeks
40928509|NCT03970408|PROCEDURE|MNT1|"Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping."
41447806|NCT01412281|BIOLOGICAL|Virosomal influenza vaccine (AdImmune HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
41447807|NCT01412281|BIOLOGICAL|Virosomal influenza vaccine (CSL HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
41276987|NCT02443402|DRUG|Sitagliptin|Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) \< 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
41447808|NCT01717950|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel®|The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
41447809|NCT01717950|BIOLOGICAL|Gluco-Pyranosylphospho-Lipid A Aqueous Formulation|GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
41447810|NCT06556043|OTHER|cM1 transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cM1 group will receive AtDCS stimulation at 2 mA during acquisition phase.
41447811|NCT06556043|OTHER|cPPC transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cPPC group will receive AtDCS stimulation at 2 mA during acquisition phase.
41447812|NCT06556043|OTHER|iCBM transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The iCBM group will receive AtDCS stimulation at 2 mA during acquisition phase.
41447813|NCT06556043|OTHER|sham transcranial direct current stimulation|For the Sham group, the montages of the paired electrode placements will be randomly selected from the other three pairs using blocks of size 3, so that the three types of montages will have equal opportunities to be used in the Sham group. The intensity will be set at 0 mA for the Sham group. There will be a 30-second ramp-up for the Sham group. Once the current reaches 2 mA in the ramp-up period, it will drop to 0 mA for the entire 20 minutes during learning for the Sham group.
41447814|NCT04223791|DRUG|DOR/ISL|100 mg DOR/ 0.75 ISL FDC tablet taken orally once daily
41447815|NCT04223791|DRUG|BIC/FTC/TAF|50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily
41447816|NCT04223791|DRUG|Placebo to BIC/FTC/TAF|Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily
41447817|NCT04223791|DRUG|Placebo to FDC DOR/ISL|Placebo to FDC DOR/ISL in a tablet taken orally, once daily
41447818|NCT05809180|DRUG|Rituximab|Rituximab 375mg/m2 ivgtt d1;
41447819|NCT05809180|DRUG|Orelabrutinib|Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;
41447820|NCT05809180|DRUG|Pomalidomide|Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.
41276988|NCT02443402|DRUG|Placebo|One pill daily until discharge
41276989|NCT02443402|DRUG|Regular Human Insulin|Continuous intravenous insulin given to ICU patients with a BG \> 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
41447821|NCT05809180|DRUG|Pro-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
41447822|NCT05809180|DRUG|R-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
41447823|NCT05509309|BEHAVIORAL|APERS-based model|APERS-assessments followed by in-service training, APERS-feedback and on-site coaching to improve primary school classroom quality for students with ASD/SCC
41447824|NCT02970123|BEHAVIORAL|Sit Less, Interact, Move More (SLIMM)|
41447825|NCT04579653|DEVICE|transcutaneous electrical nerve stimulation devices|electrical stimulation through surface electrodes
41276990|NCT02443402|DRUG|Insulin glargine|"When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate \>2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.~Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day~The basal insulin dose will be adjusted as follow:~* If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change~* If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day~* If fasting and pre-dinner BG is \> 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day~* If fasting and pre-dinner BG is \< 100 mg/dL in the absence of hypoglycemia: stop glargine"
41447826|NCT03789110|DRUG|Nivolumab|Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
41447827|NCT03789110|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
41447828|NCT00217763|DRUG|3APS|
41447829|NCT04867837|DRUG|Octaplex|Four-factor prothrombin complex concentrate (4F-PCC)
41447830|NCT04603547|DEVICE|Transcutaneous Carbon Dioxide Monitoring|Once an infant is identified as being eligible for TH treatment and hypothermia was initiated according to the department clinical practice guidelines, and written informed consent was obtained from one of the parents, tcPCO2 monitoring can be started. Transcutaneous CO2 will be measured by SenTec Digital Monitor (software version SW-V07.00; MPB SW-V05.00.12) with V-Sign™ Sensor (SenTec AG, Thervil, Switzerland). Also, we will use small blood samples (0.2 ml) from clinical blood draws up to 4 times following starting transcutaneous CO2 monitoring for measuring blood gas for research purposes.
41447831|NCT00023881|DRUG|bortezomib|
41447832|NCT03493945|BIOLOGICAL|M7824|1,200 mg IV once every 2 weeks
40754659|NCT01954511|OTHER|Manual therapy|The patient was supine with the cervical spine in a neutral position. The therapist brought about a contact of the occipital bone with the ﬁrst ﬁnger and medial aspect of the hand, and other hand over the frontal region of the patient's head. The mobilizing force was delivered by ﬂexing the upper cervical region using a combination of cephalic traction with the occipital hand and caudal pressure with the frontal hand. This technique was applied for 10 minutes
40928510|NCT01958827|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
40754660|NCT01954511|OTHER|Manual therapy|The patient was prone with the cervical spine in a neutral position. The therapist placed the tips of his thumbs on the posterior surface of the C5 spinous process, while the other ﬁngers rested gently around the patients' neck. This technique was applied for 9 minutes
40928511|NCT02907476|BEHAVIORAL|Iyengar Yoga|
41276991|NCT02443402|DRUG|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
41276992|NCT02443402|DRUG|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG \> 400 mg/dL; 7-9 units of insulin aspart"
41276993|NCT05037929|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W.
41447833|NCT03493945|DRUG|N-803|8-15 mcg/kg subcutaneous every 2 weeks
41447834|NCT03493945|BIOLOGICAL|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).
41447835|NCT03493945|BIOLOGICAL|FPV-Brachyury|FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
41447836|NCT03493945|DRUG|Epacadostat|600 mg orally twice daily (1200 MG total)
41447837|NCT01429363|PROCEDURE|Targeted disc decompression|The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
40928512|NCT02907476|BEHAVIORAL|Walking|
40928513|NCT06200142|DIAGNOSTIC_TEST|Untargeted metabolomics|Untargeted metabolomics in bloodspots and in plasma
40928514|NCT06200142|GENETIC|WES and WGS|WES reanalysis and WGS analysis
40928515|NCT03072771|DRUG|Blinatumomab|-Blinatumomab is a bispecific T cell engaging antibody
40928516|NCT03072771|PROCEDURE|Autologous stem cell transplant|-Standard of care
40928517|NCT03072771|DRUG|Carmustine|-Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.
40928518|NCT03072771|DRUG|Etoposide|-Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
40928519|NCT03072771|DRUG|Cytarabine|-Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.
41447838|NCT05000957|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1.5 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
41447839|NCT05000957|DIAGNOSTIC_TEST|Blood analysis|Taking blood from a vein for clinical blood analysis, glucose test, hepatitis B, C viruses, human immunodeficiency viruses and syphilis test, blood clotting tests, blood type and rhesus factor determination (to include the participant in the study).
41447840|NCT05000957|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
40928520|NCT03072771|DRUG|Melphalan|-Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.
40928521|NCT03072771|PROCEDURE|Peripheral blood draws|-Day +42, Day + 43, Day +56, and Day +100
41276994|NCT05037929|DRUG|Placebo|Participants will receive SC placebo Q2W.
41447841|NCT05000957|DIAGNOSTIC_TEST|Electrocardiography|Electrocardiography investigation to determine cardiac abnormalities (to include the participant in the study).
41126236|NCT06212843|OTHER|plyometric training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step."
41447842|NCT05000957|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation, oncocytology (to include the participant in the study).
41126237|NCT06212843|OTHER|conventional exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats"
41276995|NCT06656338|OTHER|Higher HEI-2020 diet followed by lower HEI-2020 diet|Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
41126238|NCT02097069|DIETARY_SUPPLEMENT|Folic acid|Folic acid 400 mcg/day
40754661|NCT01954511|DEVICE|Pressure biofeedback device|Device: Stabilizer - Chattanooga Group Inc., Chattanooga, Tennessee, USA The cranio-cervical flexor stabilization exercise was done 10 times holding 10 seconds the flexing position graded through feedback from a pressure biofeedback device
41126239|NCT02097069|DIETARY_SUPPLEMENT|Myo-inositol|myo-inositol 2000 mg twice a day
41126240|NCT02097069|DIETARY_SUPPLEMENT|D-Chiro-inositol|D-chiro inositol 250 mg twice a day
41126241|NCT02097069|DIETARY_SUPPLEMENT|Myo-inositol plus D-chiro inositol|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
41126242|NCT03176654|PROCEDURE|HVLAT manipulation|HVLAT will be performed 10 minutes after the first blood draw.
41126243|NCT03176654|PROCEDURE|Sham HVLAT manipulation|Sham HVLAT will be performed 10 minutes after the first blood draw.
41126244|NCT00558454|DRUG|Iron|Ferrous succinate mixture
40928522|NCT01410851|OTHER|dietary treatment|A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
40928523|NCT02014870|OTHER|1:1000 Live wild-type A/California/H1N1 2009|1:1000 dilution of neat virus
40928524|NCT02014870|OTHER|1:100 Live wild-type A/California/H1N1 2009|1:100 dilution of neat virus
40928525|NCT02014870|OTHER|1:10 Live wild-type A/California/H1N1 2009|1:10 dilution of neat virus
40928526|NCT02315443|DRUG|Nerinetide (NA-1)|
40928527|NCT02315443|DRUG|Placebo|
40928528|NCT02760043|DRUG|Dexamethasone|8mg (2mL) of Dexamethasone added to standard LIA mixture
40928529|NCT02760043|OTHER|0.9% NaCl Placebo|2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture
40928530|NCT02760043|DRUG|LIA Combination Mixture|150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
41126245|NCT02545738|DRUG|Liraglutide|active treatment
41126246|NCT02545738|DRUG|placebo|placebo
41126247|NCT04845386|DEVICE|TOF Cuff on arm|The TOF Cuff will be installed on one arm in opposite of TOF Scan. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
41276996|NCT06656338|OTHER|Lower HEI-2020 diet followed by higher HEI-2020 diet|Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
41276997|NCT06180382|DRUG|Adalimumab|Administration of adalimumab with optimisation either 80 mg every 14 days by subcutaneous injection, or the same dose of 40 mg every 7 days.
40928531|NCT05224011|DEVICE|Boppli Infant Blood Pressure Monitor|The intervention is a medical device for the non-invasive measurement of blood pressure in infants
40928532|NCT00356837|PROCEDURE|Ultrasound|use ultrasound to confirm diagnosis of extremity fractures
41126248|NCT04845386|DEVICE|TOF Cuff on lower leg|The TOF Cuff will be installed on one lower leg. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
41126249|NCT04845386|DEVICE|TOF Scan on toe|The TOF Scan will be installed on hallux . After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
41126250|NCT04845386|DEVICE|TOF Scan on adductor pollicis|The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
41276998|NCT06180382|DRUG|Vedolizumab|Strategy B: administration of vedolizumab 300mg by infusion at baseline, 14 days, 42 days and 60 days, followed by a dose of 108mg every fortnight by subcutaneous injection.
41126251|NCT04845386|DEVICE|TOF Scan on corrugator supercilii|The TOF Scan will be installed on corrugator supercilii. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
41126252|NCT03789734|BIOLOGICAL|BLS-M22|BLS-M22 250mg/capsule
41126253|NCT03789734|OTHER|Placebo|BLS-M22 placebo 250mg/capsule
41126254|NCT00533494|BEHAVIORAL|physician feedback (A)|Feedback information to physicians
41126255|NCT00225407|DRUG|Smoking of cannabis cigarettes (different strength)|
41126256|NCT04726449|OTHER|Screening for acute confusional state|The intervention will consist of two psychometric test to screen for acute confusional state with the usual physical examination by the emergency physician. The neurological examination abnormalities will be noted
41126257|NCT00581035|BIOLOGICAL|Prevenar and Meningitec|1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
41126258|NCT00581035|BIOLOGICAL|Prevenar|1 dose at 2,3.5,6 and 12 months
41126259|NCT00581035|BIOLOGICAL|Meningitec|1 dose at 2,6 and 12 months
41126260|NCT06522178|OTHER|Patient' ages|Patients were divided into two groups according to their ages.
41126261|NCT03647241|DEVICE|Self-Ligating Brackets|These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.
41276999|NCT06356350|OTHER|Conventional neuromuscular exercises|Conventional neuromuscular exercises represent a contemporary physiotherapeutic approach. These exercises aim to improve neuromuscular control, strength, and endurance in various muscles surrounding the included joint, contributing to the correction and maintenance of proper posture.
41277000|NCT06356350|OTHER|Core based exercises|Core based exercises increase overall mobility, relieve pain, improve posture, and support spinal alignment. Especially important for children who are still growing is to slow or stop the progression of deformities because of the asymmetrical loading pattern.
41277001|NCT05224102|DRUG|Faricimab|Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.
41277002|NCT05208229|DIAGNOSTIC_TEST|WB-MRI|Baseline CT scan (minimum thorax/abdomen/pelvis) and WB-MRI evaluations will be collected: as per clinical practice and Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, the assessments must not be performed more than 12 weeks prior to study entry and baseline WB-MRI should be performed within 2 weeks from CT scan; CT and WB-MRI will be done at the end of Lutetium 177 PSMA (177Lu-PSMA) therapy and during post-treatment follow-up
41277003|NCT00843180|OTHER|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
41277004|NCT00022932|DRUG|Iodine-131 Anti-B1 Antibody|
41277005|NCT03280212|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets.
40928533|NCT04456231|DRUG|Plenvu|Patients will receive Plenvu for preparation of endoscopy
41277006|NCT01876589|DEVICE|Bioresorbable vascular scaffold|Drug eluting coronary stent, resorbable in 2-3 years
41277007|NCT01876589|DEVICE|Xience Prime|Drug eluting metallic stent
41277008|NCT05626088|OTHER|No Intervention|This is a non-interventional study.
40928534|NCT05279404|OTHER|electroacupuncture|Electroacupuncture at Neiguan and Jianshi acupoint
41447843|NCT05000957|DIAGNOSTIC_TEST|Colposcopy|Colposcopy investigation to determine pre-malignant and malignant lesions of cervix, vagina or vulva (to include the participant in the study).
41447844|NCT05000957|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
41126262|NCT03647241|DEVICE|Traditionally-Ligated Brackets|These brackets are used in the conventional manner, where the orthodontist is obliged to use elastic modules to engage the arch into the slot of the bracket.
41126263|NCT03647241|PROCEDURE|Corticotomy|Corticotomy without flap elevations will be performed in order to induce acceleration in tooth movement during the orthodontic treatment in only one group.
41447845|NCT05000957|DIAGNOSTIC_TEST|Doppler ultrasonography|Ultrasound investigation for assessing blood flow in the tissues of vulva region (to evaluate procedure efficiency).
41447846|NCT05000957|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
41447847|NCT05000957|DIAGNOSTIC_TEST|Biopsy of the vaginal wall|Sampling of the vaginal wall material in the posterior fornix area including the mucous membrane and muscle layer will be performed during colporrhaphy or any pelvic surgical procedure for histological, immunohistochemical studies, and optical coherence tomography (elastography) (to evaluate procedure efficiency)
41447848|NCT05000957|DIAGNOSTIC_TEST|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
41126264|NCT06371508|BEHAVIORAL|Education based on breast cancer and breast examination|Training for the intervention group will be provided with a 40-45 minute training organized by one of the researchers.
41277009|NCT05511038|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Injection, 2mg (equivalent to 50 µL solution for injection)
41277010|NCT04899336|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
41277011|NCT04899336|OTHER|Placebo|Matching placebo will be administered as an IM injection.
41277012|NCT01578902|RADIATION|Stereotactic ablative body radiotherapy|35Gy/5 fractions/29 days
41277013|NCT01849133|RADIATION|external fractionated radiotherapy|conventional external beam radiotherapy
41277014|NCT01849133|RADIATION|intraoperative radiotherapy|Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
41277015|NCT00140855|BIOLOGICAL|ipilimumab|
41277016|NCT06656494|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
41277017|NCT06656494|DRUG|Azacitidine|Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol，once daily on days 1-7 of each 28-day cycle.
41277018|NCT03430310|OTHER|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. The participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
41447849|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Distress Inventory Questionnaire|Pelvic Floor Distress Inventory Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
41447850|NCT05000957|DIAGNOSTIC_TEST|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
41447851|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Impact Questionnaire|Pelvic Floor Impact Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
41447852|NCT05000957|PROCEDURE|Anterior and/or posterior colporrhaphy|Surgical procedure to repair pelvic organ prolapse followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
41447853|NCT05000957|PROCEDURE|Pelvic surgical procedure|Any pelvic surgical procedure which do not affect condition of vagina, vulva and paraurethral region followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
41447854|NCT05000957|OTHER|Physical examination|Pelvic examination (to include the participant in the study and observe throughout the study)
41447855|NCT05000957|OTHER|Сonsultation|Сonsultation of a therapist about the absence of contraindications for surgical treatment (to include the participant in the study)
40928535|NCT02799420|DEVICE|GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France|The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.
41447856|NCT05000957|GENETIC|Buccal smear|"Buccal smear to performing genetic testing.~The following markers will be analyzed:~ESR1 rs2234693, ESR1 rs2228480, COL3A1 rs1800255, COL14A1 rs4870723, MMP9 rs3918253, MMP10 rs17435959, LOXL1 rs2304719, WNT4 rs3820282, MMP2 rs243865, TIMP2 rs2277698, CD31 / PECAM1 rs1131012, Ki67 rs11016076."
41447857|NCT05247723|DEVICE|Standard IV Cannula for aspiration of testicular sperm|After local anesthesia, a wide bore 14-G standard IV cannula was introduced near the lower pole of the testis. The needle was withdrawn and the catheter introduced into the testicular tissue. A 20-ml syringe was secured to the catheter and constant negative pressure applied and secured with a clamp. Back and forth motions were performed covering as many areas of the testis as possible.
41447858|NCT05247723|PROCEDURE|Micro-TESE|Conventional Microscopic Testicular Sperm Extraction (Micro-TESE), Open Testicular Biopsy using surgical Microscope
41447859|NCT06127407|DRUG|Ivosidenib 500mg|Provided as tablets, taken orally as two 250mg tablets once daily.
41447860|NCT06127407|DRUG|Placebo|Provided as tablets, taken orally once daily.
40928536|NCT02799420|DEVICE|white light endoscopy (WLE)|The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
41126265|NCT02915432|BIOLOGICAL|3 mg/kg anti-PD-1 mAb JS001 Q2W|"This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.~If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment."
40928537|NCT02106923|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
41126266|NCT02915432|BIOLOGICAL|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
40928538|NCT02106923|DRUG|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
40928539|NCT02106923|DRUG|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
40928540|NCT02106923|DRUG|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
40928541|NCT02106923|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
40928542|NCT02106923|DRUG|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
40928543|NCT06434402|BEHAVIORAL|Behavioral Intervention|Write about cancer experiences
40928544|NCT04329689|OTHER|The Septal myectom|"The Septal myectomy is the preferred treatment of most patients with HOCM, and many studies have documented relief of symptoms and satisfactory late patient survival after relief of outflow tract gradients.~valve repair or replacement may be necessary"
40928545|NCT04597060|DEVICE|Thermomechanical system with corticosteroids|The device in this study using Novoxel - Tixel®
40928546|NCT04597060|OTHER|corticosteroid injection|corticosteroid injection using TA 10mg/ml
40928547|NCT03856268|PROCEDURE|'Surgical Menopause' Group|Women undergoing laparoscopic oophorectomy surgery ('surgical menopause') will be enrolled at Pennington Biomedical.
40928548|NCT03856268|DRUG|'Drug-Induced Menopause' Group|Women undergoing gonadal suppression via leuprolide acetate (Lupron \[AbbVie Inc.\]) will be enrolled at the University of Colorado-Denver.
40928549|NCT01642121|OTHER|laboratory biomarker analysis|Correlative studies
41447861|NCT06031844|DRUG|DFV890|oral film-coated tablets
41447862|NCT06031844|DRUG|Placebo|oral film-coated tablets
40928550|NCT03157570|BEHAVIORAL|Exercise|7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
40928551|NCT03345966|DIAGNOSTIC_TEST|Bmi-1 antibody|B-lymphoma Moloney murine leukemia virus insertion region-1
41126267|NCT02915432|BIOLOGICAL|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
41126268|NCT05878470|BEHAVIORAL|video|A brief (119 seconds) social contact-based video. The video presented a young Black man in his early twenties, a professional actor, sharing his scripted personal story of struggles with psychotic illness and raising themes of recovery and hope.
41126269|NCT03725059|BIOLOGICAL|Pembrolizumab (K)|IV infusion Q3W
41126270|NCT03725059|DRUG|Placebo (P)|Normal saline or dextrose IV infusion Q3W
41126271|NCT03725059|DRUG|Paclitaxel (X)|IV infusion QW
41126272|NCT03725059|DRUG|Doxorubicin (A)|IV infusion either in Q2W or Q3W
41126273|NCT03725059|DRUG|Epirubicin (E)|IV infusion either in Q2W or Q3W
41126274|NCT03725059|DRUG|Cyclophosphamide (C)|IV infusion either in Q2W or Q3W
41126275|NCT03725059|DRUG|Endocrine therapy|Variable endocrine therapy for up 10 years
41277019|NCT03430310|OTHER|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
41277020|NCT06650566|DRUG|LM-299|Administered intravenously
41277021|NCT06657079|DRUG|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
41277022|NCT06657079|DRUG|Placebo|Saline inhaler
41447863|NCT04532879|DEVICE|HygiPrep (HyGIeaCare System)|Controlled gravity-based high-volume colon irrigation
41447864|NCT05303532|DRUG|Durvalumab|Fixed dose of 1500 mg via IV infusion upon enrollment visit and every 4 weeks thereafter.
41447865|NCT06627387|OTHER|Balance Training Using Augmented Reality|"The intervention will be carried out in two phases. The first phase will take place at Vall d\&amp;#39;Hebron Hospital, where patients will undergo balance training under the supervision of a physiotherapist. The scheduled dose will be 60 minutes daily, three days a week for four weeks. If the patients meet the inclusion criteria, the intervention will be extended for two more weeks at home. For this task, the involvement of a family member as a training partner will be essential. Relatives will receive training on using the system in the hospital and must be present whenever the patient undergoes the training at home. Three assessments will be carried out during the six weeks of the study. At the beginning of the intervention (Day 0 ), a second is once the hospital intervention has been carried out (Week 4 ), and the last is once the home intervention has been carried out (Week 6)."
41447866|NCT05917522|BIOLOGICAL|Abatacept|Injection: 125 mg/mL of a clear to slightly opalescent, colorless to pale-yellow solution in a single-dose prefilled ClickJect autoinjector
41126276|NCT03725059|RADIATION|Radiation therapy|Variable radiation therapy per local standard of care
41126277|NCT03725059|PROCEDURE|Surgery|Surgery for breast cancer
41447867|NCT05917522|PROCEDURE|Standard of Care at US Transplant Centers|Control group, remaining on SOC (Tacrolimus/ Mycophenolic Acid (MPA)/ Prednisone (Pred))
41447868|NCT05921188|BEHAVIORAL|VAULT Phase 4|Children will receive an input-based word learning treatment that is designed based on principles of statistical learning.
41447869|NCT03488147|DRUG|Esomeprazole|20 mg esomeprazole tablet
40928552|NCT00296608|DRUG|fluorouracil|
40928553|NCT00296608|DRUG|leucovorin calcium|
40928554|NCT00296608|PROCEDURE|conventional surgery|
41126278|NCT03901989|DEVICE|zeolite|given for a period of 12 months
41126279|NCT03901989|DEVICE|cellulose|given for a period of 12 months
41126280|NCT04244942|DEVICE|CERAMENT BVF|CERAMENT BONE VOID FILLER is a synthetic biphasic bone graft substitute.
41126281|NCT03311516|OTHER|New functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
40928555|NCT00296608|RADIATION|radiation therapy|
40928556|NCT04187287|OTHER|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will given for 3 weeks, 1 days in a week. moreover 10-12 minutes cold pack will apply for every session
41126282|NCT03311516|OTHER|functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
41126283|NCT01755936|OTHER|Cardiac Magnetic Resonance Imaging|For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
41126284|NCT01755936|OTHER|Echocardiography|Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
41126285|NCT01755936|OTHER|72 hour Holter Monitor|This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
41126286|NCT02480205|DEVICE|NeuroBox to deliver the NeuroPAP|"The patients will be studied during the following conditions:~* On conventional NIPPV device with the clinically prescribed settings (30 min)~* With NeuroPAP and no change of Pmin (=peep) (60 min)~* With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)~* During CPAP delivered with NeuroPAP device (15 min)~* Again with original NIPPV device and settings for 30 minutes"
41447870|NCT03488147|DRUG|Placebo Oral Tablet|resembling esomeprazole tablet
41447871|NCT00957021|DEVICE|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
41447872|NCT04796480|DIETARY_SUPPLEMENT|YOGURT|Group 1 was given yogurt
41447873|NCT04796480|DIETARY_SUPPLEMENT|LACTOSE FREE FORMULA MILK|Group 2 was given lactose free formula milk
41447874|NCT06193889|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
41447875|NCT06193889|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
40928557|NCT04187287|OTHER|Deep Friction Massage|Deep Friction Massage will given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
41126287|NCT03305536|DIETARY_SUPPLEMENT|Vitamin K2 (Menaquinone 7) + Vitamin D3|Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
41126288|NCT06425250|OTHER|Management, progression and risk factors for failure of BJI caused by Campylobacter spp.|Description of demographic data (sex, age), comorbidities (ASA and Charlson scores), orthopedic and septic history, and surgical and medical management (antibiotic therapy)
41126289|NCT06425250|OTHER|Description of the evolution and risk factors for failure of osteoarticular infections caused by Campylobacter spp.|"Failure of treatment: defined according to a composite criterion bringing together~* persistence of the infection under treatment, and/or~* recurrence of the infection after stopping antibiotic therapy, and/or~* need for surgical revision for septic reasons more than 5 days after initial treatment, and/or~* superinfection, and/or~* definitive explantation of the material, and/or~* decision for suppressive antibiotic therapy, and/or~* amputation, and/or~* death linked to infection"
41126290|NCT03199404|DEVICE|TRAP|Mechanical thrombectomy performed with the combination of a stent retriever that is partially re-sheathed and withdrawn under constant aspiration along with the use of a balloon guide catheter for distal flow control during thrombectomy.
41126291|NCT04216381|DIAGNOSTIC_TEST|Trauma Specific Frailty Index Questionnaire|questionnaire to assess patient's pre-injury health condition
41126292|NCT00258830|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
41447876|NCT02804815|DRUG|Aspirin 100mg|Aspirin 100mg
41447877|NCT02804815|DRUG|Aspirin 300mg|Aspirin 300mg
41447878|NCT02804815|DRUG|Placebo 100mg|Placebo 100mg
41447879|NCT02804815|DRUG|Placebo 300mg|Placebo 300mg
41447880|NCT00834431|DRUG|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
41447881|NCT00834431|DRUG|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
40754662|NCT01121458|DRUG|Clevidipine|The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP\< 80 mmHg), hypertension (SBP\>150 mmHg), tachycardia (120 beats per minute), bradycardia (\<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
41447882|NCT00004148|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
41447883|NCT04722458|OTHER|Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29)|LURN SI-29
41447884|NCT04722458|OTHER|IPSS|International Prostate Symptom Score
41447885|NCT04722458|OTHER|UDI-6|Urogenital Distress Inventory
41447886|NCT02129140|DEVICE|Hernia graft/mesh|observational group
41447887|NCT03837158|PROCEDURE|early loading|two TiZr implants on SLA surface
41447888|NCT03837158|PROCEDURE|immediate loading|four TiZr implants on SLA surface
41447889|NCT00414180|DRUG|Bupropion SR|
41447890|NCT00835614|DRUG|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
41447891|NCT00835614|DRUG|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
41447892|NCT03835767|OTHER|Peanut powder and Oat flour|Peanut powder with 46% protein content is manufactured by PB2. Oat flour is manufactured by GF Harvest.
41447893|NCT03835767|OTHER|Peanut flour and Oat flour (placebo for peanut flour)|Peanut flour (12% light roast) with 50% protein content is manufactured by Byrd Mill. Oat flour is manufactured by GF Harvest.
41447894|NCT03835767|OTHER|Dry Milk Powder and Corn Starch (placebo for Milk powder)|Dry milk powder with 36% protein content is manufactured by Giant Food. Corn starch is Argo brand.
41447895|NCT03835767|OTHER|Baked milk and Rice milk (placebo for Baked milk)|Baked milk will be in the form of a muffin provided by the NIH CC Nutrition Department. Rice milk is manufactured by Rice Dream brand.
41447896|NCT06559800|BEHAVIORAL|YourSkills: Cognitive behavioral therapy for children/youth with role-plays in virtual reality|A program for children/youth with anger problems or aggressive behaviors based on social learning theory and cognitive behavior therapy (CBT), incorporating virtual reality (VR) when conducting brief role-plays. The program includes similar strategies as other CBT-oriented programs for anger problems, with the addition of VR for practicing skills.
41447897|NCT01862601|DEVICE|JetTouch Needle-free injection system|Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
41447898|NCT03461445|DRUG|Envarsus|Patients will be randomized to receiving Envarsus instead of IR Tacrolimus
41447899|NCT03461445|DRUG|IR Tacrolimus|Patients will be randomized to receiving IR Tacrolimus instead of Envarsus
41447900|NCT05496920|DIAGNOSTIC_TEST|FD-PET/CT|Standard of care PET/CT with full dose (FD) of the radiopharmaceutical
41447901|NCT05496920|DIAGNOSTIC_TEST|LD-PET/CT|Additional low dose PET/CT performed within protocol defined time frame LD-PET/CT with additional ultra-low dose CT-less reconstruction
41447902|NCT03030664|DIETARY_SUPPLEMENT|L.reuteri|Each day, at about the same time, the subjects will be given 5 drops (1x10\^8 CFU) of the study product in connection with feeding
41447903|NCT03030664|DRUG|Placebo|Same formulation as study product, without probiotics.
41447904|NCT06390319|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
41447905|NCT06390319|DRUG|Vincristine|Given IV.
41447906|NCT06390319|DRUG|Daunorubicin|Given IV.
40754663|NCT02246036|DEVICE|APD probe|The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).
41447907|NCT06390319|DRUG|Calaspargase pegol|Given IV.
41126293|NCT00258830|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
41126294|NCT01404598|DRUG|naproxcinod 750 bid|naproxcinod 750 bid
41126295|NCT01404598|DRUG|naproxcinod 3000 mg od|naproxcinod 3000 mg od
41126296|NCT01404598|DRUG|naproxen 500 mg bid|naproxen 500 mg bid
41126297|NCT04838860|DRUG|Siltuximab|Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.
41126298|NCT02551536|DRUG|Montelukast|
41126299|NCT02551536|DRUG|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
41126300|NCT02551536|DRUG|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
41126301|NCT03874819|DEVICE|Medium cut-off dialyzer|Treatment using a Medium Cut-Off Dialyzer
41126302|NCT03874819|DEVICE|High-flux dialyzer|Treatment using a high-flux dialyzer
41126303|NCT02867072|PROCEDURE|Open appendectomy|
41126304|NCT02867072|PROCEDURE|Laparoscopic appendectomy|
41126305|NCT04436900|PROCEDURE|Panretinal Photocoagulation (PRP)|PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
41126306|NCT02877797|DEVICE|Cap|cap assisted esophagogastroduodenoscopy
41126307|NCT04095715|OTHER|Haemostasis consultation|Haemostasis consultation
41126308|NCT04095715|BIOLOGICAL|Standard management of patients suspected of thrombopathy|Standard management of patients suspected of thrombopathy
41126309|NCT05910411|DEVICE|Inelastic compression|Inelastic compression used in the treatment of lymphedema
41126310|NCT05611060|BEHAVIORAL|Building Healthy Life Skills Program|The intervention provides education and training in the long-term mental and physical health consequences of childhood adversity and emotion regulation skills.
41126311|NCT03947346|OTHER|Urine sample|The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.
41126312|NCT03500822|PROCEDURE|Metronome-paced tachypnea|three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2
41126313|NCT03500822|PROCEDURE|Expiratory-stenosis breathing|three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm
41126314|NCT02076659|DRUG|F8IL10|"Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
41126315|NCT02076659|DRUG|Methotrexate|"Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
41126316|NCT01078285|BEHAVIORAL|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
41126317|NCT01078285|BEHAVIORAL|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
41126318|NCT04319913|DEVICE|analgesia nociception index|Analgesia nociception index (ANI) could objectively monitor how pain the participant is. In the experimental group, the care provider would decrease the dose of narcotics (remifentanil) if the ANI value is above 70, and increase the dose if the ANI value is under 50.
41126319|NCT04522466|DRUG|Hydroxychloroquine (HCQ)|"Hydroxychloroquine (HCQ) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/L.~Measure pharmacokinetics and pharmacodynamics of Hydroxychloroquine (HCQ)."
41126320|NCT04811924|DRUG|Application of 0.02% MMC over 60 seconds post corneal crosslinking.|Topical application of 0.02% MMC on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after MMC application.
41126321|NCT04811924|DRUG|Corneal crosslinking without the application of 0.02% MMC|Topical application of placebo on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after placebo application.
41126322|NCT01291472|DRUG|Ketorolac Tromethamine|After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
41126323|NCT03781375|DRUG|Etanercept|Administered by subcutaneous injection twice a week
41126324|NCT03781375|DRUG|Placebo to Etanerceot|Administered by subcutaneous injection twice a week
41126325|NCT03781375|DRUG|Methotrexate|Administered orally or subcutaneously once a week at the same dose as prior to study entry
41126326|NCT03904069|DRUG|AMG 553|AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy
41126327|NCT06440642|DEVICE|tonopen|Intraoculer pressure will be measured in the supine position after intubation (T1), during pneumoperitoneum (T2), when placed in steep trendelenburg posıtıon (T3), at the end of the operation when pneumoperitoneum is terminated (T4), after being placed back in the supine position (T5), and 10 minutes after being placed back in the supine position (T6).
41447908|NCT06390319|DRUG|Dasatinib|Given PO
41447909|NCT06390319|DRUG|Venetoclax|Given PO (ETP, near-ETP, and MPAL only).
41447910|NCT06390319|DRUG|Bortezomib|Given IV (T-LLy only).
41447911|NCT06390319|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Given Intrathecal (IT), Age adjusted.
41447912|NCT06390319|DRUG|Cyclophosphamide|Given IV.
40754664|NCT01310114|BIOLOGICAL|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
41126328|NCT06464224|BEHAVIORAL|low respiratory effort|patients under respiratory effort lower than -1,5 cmH2O (P0,1) and/or -7 cmH2O (Pocc)
41126329|NCT06464224|BEHAVIORAL|high respiratory effort|patients under respiratory effort higher than -3,5 cmH2O (P0,1) and/or -15 cmH2O (Pocc)
41447913|NCT06390319|DRUG|Cytarabine|Given IV or IT.
41447914|NCT06390319|DRUG|Mercaptopurine|Given PO.
41447915|NCT06390319|DRUG|Nelarabine|Given IV
41126330|NCT05284565|DEVICE|Reading of the skin prick allergy test|"A double reading of the forearm will be performed with the Nexkin DSPT device. Also, two healthcare professionals will perform, consecutively, the manual reading according to their usual practice. Nexkin DSPT device provides a semi-automatic wheal detection, presenting the user an initial set of potential wheals and information about them (as their measure).~Healthcare professional can then discard, add and/or confirm wheals by visual validation, and add/edit wheal information. The device automates the test reading process, digitises the results, and quantifies."
41126331|NCT05933213|DRUG|Mescaline sodium enteric-coated tablets|Induction period: orally, twice a day, at 720-1440 mg/d； Maintenance period: orally, twice a day, 360-540mg/d
41447916|NCT06390319|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
41277023|NCT03102684|OTHER|Secondhand exposure to e-cigarette aerosols (low)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with low resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
41277024|NCT03102684|OTHER|Secondhand exposure to e-cigarette aerosols (high)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with high resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
41277025|NCT05567796|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
40928558|NCT05266573|OTHER|Exercise Group|The exercise program is led by an individual who has a background in exercise physiology and is trained by the Physical Therapist. The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components: warm-up period (dual task activity and walking progressively), stretching/strengthening/balance (gradual progression of activities and repetitions for 30 minutes), and obstacle course (6 to 15 minutes of obstacle course and challenged walking).
41126332|NCT05933213|DRUG|Morte-mescaline|Induction period: orally, twice a day, 1-2 g/d; Maintenance period: orally, twice a day, 0.5-0.75 g/d
41126333|NCT05933213|DRUG|Glucocorticoids|glucocorticoids
41277026|NCT05567796|DRUG|Semaglutide|Participants will recieve semaglutide subcutaneously.
41277027|NCT05567796|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide.
41277028|NCT05567796|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide.
41277029|NCT04673357|DRUG|Ustekinumab|Ustekinumab will be administered intravenously in induction period and subcutaneously in maintenance period.
41277030|NCT04673357|DRUG|Placebo|Matching placebo will be administered as SC injection.
41277031|NCT00097539|BIOLOGICAL|Somatrem|
41277032|NCT00097539|BIOLOGICAL|Somatropin|
41277033|NCT02298101|DRUG|Technetium-99m - Diethylenetriaminepentaacetic acid|Solution placed on the nebulizer reservoir
41277034|NCT02298101|DEVICE|Aeroneb Solo Adapter|Nebulizer
41277035|NCT02298101|DEVICE|Opti-Mist Plus Nebulizer|Standard jet nebulizer
41277036|NCT02298101|OTHER|Planar scintigraphy|Imaging technique to investigate whole lung deposition
41277037|NCT02298101|OTHER|Single photon emission computed tomography|Imaging technique to investigate regional pulmonary deposition
41277038|NCT02298101|OTHER|Spirometry|FEV1, FVC assessment
41277039|NCT06601712|OTHER|Adherence support strategy A|Community health worker (CHW) support through monthly home visits to remind the caregiver to administrate the PDMC drugs
41277040|NCT06601712|OTHER|Adherence support strategy B|SMS/phone reminders from the qualified community health officers (ASCQ) to the community health workers (CHW) to administrate the PDMC drugs
41277041|NCT06601712|OTHER|Control|No reminders
41277042|NCT05268848|OTHER|Thermographic photo|Barefoot patient, thermographic photo of the sole of the feet is taken
41277043|NCT03308851|PROCEDURE|Piezocorticision|The piezocorticision is a procedure that aims to accelerate the movement of teeth during an orthodontic treatment. It consists of a local anaesthesia followed by an incision of the buccal mucosa and an incision in the alveolar bone with a piezotome.
41277044|NCT03308851|PROCEDURE|Osteoperforation|The osteoperforation is a procedure that aims to accelerate the movement of teeth during orthodontic treatment. It consists of a local anaesthesia followed by perforations of the buccal mucosa and alveolar bone using a specific osteoperforation tool.
41447917|NCT06390319|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
40928559|NCT00000973|DRUG|Pyrimethamine|
40928560|NCT00000973|DRUG|Leucovorin calcium|
41126334|NCT05527912|DRUG|Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy|"All subjects received two courses of the following treatment:~Rituximab ，375mg/m²， D1； Chidamiade ，20mg ，biw， d1-14； Zanubrutinib ，160mg， bid， d1-21；~three weeks for a period of treatment, all subjects complete tumor assessment after two courses of treatment, patients which achieve complete remission continue for up to 8 sessions, patients achieve partial response and stable disease combined use of the following CHOP threapy to 6 courses, Patients with progressive disease dropped out of this research.~CHOP Therapy:~Cyclophosphamide， 750mg/m² ，D1； Vincristine， 1.4mg/m² ，D1 (maximum：2mg)； Doxorubicin or pirarubicin， 50mg/m²， D1； Prednisone ，30mg ，tid， D1-5."
41447918|NCT02597374|DEVICE|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
41447919|NCT01501253|DRUG|CKD-828 2.5/40mg|fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
41447920|NCT01501253|DRUG|CKD-828 2.5/80mg|Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
41447921|NCT01501253|DRUG|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg monotherapy
41126335|NCT06111924|OTHER|Task oriented circuit training based telerehabilitation|Task oriented circuit training based telerehabilitation (TOCT-TR) via video conference call will be provided for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
41126336|NCT06111924|OTHER|Clinic based Task oriented circuit training|Clinic based Task oriented circuit training (TOCT-CR) will be provided in clinic as in person training for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
41126337|NCT00233090|DRUG|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
40754665|NCT01310114|DRUG|Placebo|Thawed placebo
41277045|NCT06642753|BIOLOGICAL|immediate implant with buccal plate augmentation using sticky bone|"* Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the pouch ."
41447922|NCT03224663|OTHER|Module based learning|self-reading method using learner's guide module on FBNC provided by Department of Pediatrics.administered 45 minutes
41447923|NCT03224663|OTHER|Mobile application based learning|"learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters , videos , Modules.administered 45 minutes"
41126338|NCT00233090|DRUG|Placebo|daily dose of placebo for four weeks.
41126339|NCT06091449|OTHER|High fidelity simulation|Within the scope of high reality simulation application; The ideal number of students to take part in each simulation was determined to be 10. On the simulation day, the researchers responsible for the simulation application will introduce the environment and the tools and equipment they will use in the simulation application, so that they can make preliminary preparations for the students. It will last 60 minutes in total, including preliminary information (10 minutes), simulation time (15 minutes) and evaluation/analysis session (35 minutes).
41126340|NCT06091449|OTHER|Virtual reality|"For the virtual reality-based simulation application, students can log in to the virtual reality-based simulation program prepared in line with the Diabetes Mellitus scenario using their username and password; They will receive modular training integrated into the simulation. The expected time for students to complete the modular training is 30 minutes. Students who complete the module will be asked to take a 10-minute break and then participate in a virtual reality-based simulation application.The application of high-fidelity simulation is the same in both groups."
41126341|NCT03727958|DIAGNOSTIC_TEST|Lung and coronary CT assessment|Subjects will undergo simultaneous coronary arteries and thoracic CT assessment
41126342|NCT03727958|DIAGNOSTIC_TEST|Coronary CT assessment|Subjects will undergo coronary arteries CT assessment only
41126343|NCT03450434|DRUG|XC8 Oral Tablet|1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
41447924|NCT05804227|DRUG|Ulixertinib|Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
41447925|NCT06043349|COMBINATION_PRODUCT|Platelet-Rich Plasma and Topical 5% Minoxidil|The intervention group will receive three PRP injections during three months in addition to the topical 5% minoxidil.
40754666|NCT04469946|DEVICE|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
40754667|NCT05890001|DRUG|BLI5100|Patients will take BLI5100 once daily, orally, for up to 29 weeks.
40754668|NCT04518943|BEHAVIORAL|Walking|Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
41126344|NCT03450434|DRUG|Placebo Oral Tablet|Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
41126345|NCT04336436|BEHAVIORAL|Mindfulness training|Mindfulness training
41126346|NCT04336436|BEHAVIORAL|Nutritional consult|Nutrition counseling and development of a personalized nutrition plan
41126347|NCT01448681|OTHER|No Interventions|
41126348|NCT01933802|BIOLOGICAL|intrathecal administration of autologous MSC-NP|Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
41126349|NCT01609218|DRUG|LY2140023|
41126350|NCT01609218|DRUG|Aqueous activated charcoal|
41126351|NCT01762475|DRUG|Sildenafil|
41126352|NCT00910832|DRUG|Eductyl suppository|one suppository every morning during 21 days
41126353|NCT00910832|DRUG|Placebo suppository|placebo suppository every morning during 21 days
41126354|NCT04086849|DIAGNOSTIC_TEST|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
41126355|NCT02438137|DRUG|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
40754669|NCT05610150|DEVICE|Myobrace Functional Appliance|An Appliance for treating growing Class II patients with mandibular deficiency
40928561|NCT00000973|DRUG|Zidovudine|
41126356|NCT02438137|DRUG|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
41126357|NCT03172234|OTHER|oral amantadine sulfate|In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
41126358|NCT03172234|DRUG|oral gabapentin|In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
41126359|NCT03172234|DRUG|Placebo Oral Tablet|in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
41277046|NCT06642753|BIOLOGICAL|immediate implant with sticky bone as a filling material in the jumping gap|"Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the jumping gap."
41277047|NCT05015387|PROCEDURE|Minimally invasive non-surgical therapy|Under local anesthesia subgingival instrumentation with ultrasonic and hand instruments and magnification (4.5x) was performed.
41277048|NCT05015387|COMBINATION_PRODUCT|Subgingival application of collagen hydrogels with proanthocyanidins|Patients received collagen hydrogel chips with proanthocyanidins from Pelargonium sidoides root extract, placed subgingivally in periodontal pockets with PPD≥4mm after minimally invasive non-surgical therapy.
40928562|NCT06366269|OTHER|Acupuncture|traditional and electroacupuncture
40928563|NCT06366269|BEHAVIORAL|Behavioral management|based on American urologic association guidelines
41277049|NCT05015387|DIAGNOSTIC_TEST|Collection of saliva samples|For MMP-3/TIMP-1 detection, the collection of saliva samples was performed using Salivette (SARSTEDT AG and Co, Germany) saliva sample collection kit. Saliva samples were collected at the baseline for all patients and 8 weeks after treatment. Samples were centrifuged at 3500 rpm (2 min), aliquoted and protease inhibitors cocktail (1 mg/ml) was added to each sample. All samples were stored at -80oC. MMP-3, TIMP-1 concentration in saliva samples was examined using commercial ELISA kits (Elabscience, USA) and Multiskan Microplate Photometer (Thermo Fisher Scientific) at 450 nm wavelength. Saliva MMP-3/TIMP-1 samples were collected before treatment and 8 weeks after treatment.
41277050|NCT02456584|DRUG|DMPA 150|injectable contraceptive
41277051|NCT02456584|DRUG|DMPA 300|injectable contraceptive
41277052|NCT02456584|DRUG|DMPA 104|injectable contraceptive
41277053|NCT01969266|DRUG|Treatment A: PCI-32765|840 mg capsule formulation administered by mouth on Day 1
41277054|NCT01969266|DRUG|Treatment B: PCI-32765|840 mg solution formulation administered by mouth on Day 1
41277055|NCT02085811|OTHER|radiography standard|
41277056|NCT01784887|DRUG|Procellera|PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
41277057|NCT05875168|DRUG|DS-3939a|One IV infusion Q3W on Day 1 of each 21-day cycle
40928564|NCT06366269|OTHER|Physical therapy|pelvic floor with biofeedback
40928565|NCT04646564|DRUG|standard of care|patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
40928566|NCT04646564|RADIATION|radiotherapy + standard of care|"Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT.~Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist."
41277058|NCT06131840|DRUG|PF-08046050|Given into the vein (IV; intravenous)
41277059|NCT06656351|DRUG|Tafenoquine 100mg|Tafenoquine
41277060|NCT03702725|DRUG|Ibrutinib|Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.
40928567|NCT01444807|DRUG|sorafenib|sorafenib 400 mg bid
40928568|NCT02665403|OTHER|Play intervention|participants received around 30 minutes of hospital play interventions each day, conducted by hospital play specialists. Such interventions consisted of structured and non-structured activities. All these activities were given at the patients' bedside, with or without parental supervision, either once or spreading over an hour, depending on the ward routine.
40928569|NCT02665403|OTHER|control|Children received standard medical and nursing care, such as vital signs observation, pharmacological treatment and wound and pain management as a control treatment
41126360|NCT04091178|DIETARY_SUPPLEMENT|VITAMIN D|ORAL SOLUTION (2 ml) at 100.000 UI
41126361|NCT01881412|DRUG|fluticasone|During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.
41126362|NCT01881412|OTHER|Standard Asthma Discharge Instructions|Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
41126363|NCT04779853|DIAGNOSTIC_TEST|Blood samples for pertussis antibody testing|Blood samples will be sent to the laboratories of the National Centers of Expertise within 24-48 hours of blood collection. The samples will be transferred to the reference laboratory of SPCSEEM in Almaty, Kazakhstan. Serum samples will be stored in the reference laboratory at a temperature of -20 C.
41126364|NCT00138541|DRUG|vildagliptin|
40928570|NCT01142089|DRUG|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
41126365|NCT04710849|DIAGNOSTIC_TEST|Serum metabolic markers|Ultraperformance liquid chromatography / mass spectrometry (LC-MS) and gas chromatography / mass spectrometry (GC-MS) methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure.
41126366|NCT02007590|DEVICE|Aerosure 25 Hz|Active Aerosure device
41126367|NCT02007590|DEVICE|Aerosure Sham|Device designed to appear identical to active device but with HFAO mechanism disabled
41126368|NCT02436317|DEVICE|Point Of Care Ultrasound|Examination with an ultrasound machine
41126369|NCT03794999|DRUG|Benralizumab-exposure|Exposure is defined as any dose of benralizumab for any length of time from 8 weeks prior to Last Mentrual Period (LMP) through the end of pregnancy, as reported by the mother and validated through medical record review. The 8-week cut-off prior to LMP is based upon the terminal half-life of benralizumab of approximately 15 days (clearance of benralizumab is based on five half-lives).
41126370|NCT03794999|DRUG|Exposure to other asthma medications|Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
41126371|NCT05989269|OTHER|Modified lab reporting|If appropriateness of culturing i.e., clinical criteria for pneumonia testing does not meet the algorithm AND there is growth of one or more organism(s) that are not considered normal upper respiratory flora, during the intervention period, the result will be modified to reflect the likelihood of asymptomatic colonization.
41126372|NCT02139436|OTHER|FES-row-training|
41126373|NCT02139436|OTHER|Arms-only-row training|
41126374|NCT02139436|OTHER|Time Control|
41126375|NCT00238901|DRUG|Basiliximab|
40928571|NCT01142089|DRUG|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
40928572|NCT01459289|OTHER|leaflet|
40928573|NCT01459289|OTHER|counseling and leaflet|
40928574|NCT05081102|DRUG|FDC of oxycodone 5 mg/ibuprofen 400 mg|receive one (1) experimental drug tablet (FCD of oxycodone 5mg/ibuprofen 400mg) + one (1) Tylex® placebo.
40928575|NCT05081102|DRUG|Tylex|receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
41126376|NCT00415402|DRUG|Vitamin D3|
41126377|NCT06092255|RADIATION|Postoperative radiotherapy for SVZ|GBM patients who met the inclusion criteria received radiotherapy range and dose based on the EORTC outline principles. The ipsilateral and contralateral SVZ areas received 56Gy and 40Gy respectively, with a fractionated dose of 2Gy. Concurrent chemotherapy with temozolomide and six cycles of adjuvant temozolomide chemotherapy were performed at the same time as radiotherapy.
41126378|NCT02216552|DIETARY_SUPPLEMENT|Resveratrol|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
41277061|NCT03702725|DRUG|Lenalidomide|Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.
41277062|NCT03702725|DRUG|Dexamethasone|Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.
41277063|NCT04606381|DRUG|Ami-LC-MD|Participants will receive amivantamab admixed with rHuPH20 SC infusion.
41126379|NCT02216552|DIETARY_SUPPLEMENT|Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
41126380|NCT03754959|DRUG|BI 1358894|Film-coated tablet
41126381|NCT03754959|DRUG|Placebo|Film-coated tablet
41126382|NCT03754959|DRUG|Midazolam|Solution for injection
41126383|NCT02134951|DRUG|Ketamine|intravenous infusion of saline solution with ketamine
41126384|NCT02134951|DRUG|Normal saline|Normal saline will be used for placebo in this group
41126385|NCT04376567|PROCEDURE|One stage approach|Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
41126386|NCT05493969|DRUG|Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)|Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.
41277064|NCT04606381|DRUG|Ami-LC|Participants will receive amivantamab SC infusion.
41277065|NCT04606381|DRUG|Ami-HC|Participants will receive amivantamab SC infusion.
41277066|NCT04606381|DRUG|Ami-HC-CF|Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
41277067|NCT04606381|DRUG|Lazertinib|Participants will receive lazertinib orally as a film-coated tablet.
41277068|NCT06656676|BEHAVIORAL|WePrEP: A shared decision-making tool|WePrEP will be bilingual, both patient- and provider-facing, stored on the provider's electronic device (and will have the capability to integrate with electronic health records in the future to enable scalability), and easily accessible during in-person or virtual patient-provider encounters. WePrEP is designed to present pertinent PrEP information to transgender women and their PrEP service providers to stimulate discussions about PrEP choice and support adherence (once a PrEP strategy has been chosen). We hypothesize that this will ensure selection of the ideal PrEP method and improve subsequent adherence.
41277069|NCT06656676|BEHAVIORAL|Active comparator: CDC recommendations for discussing PrEP|Standard of care recommendations to discuss PrEP with potential end-users, endorsed by the CDC.
41126387|NCT04669028|DRUG|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.
41126388|NCT04669028|DRUG|Placebo|capsules that do not contain NE3107
41126389|NCT06090513|COMBINATION_PRODUCT|Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation|TSO500; detect single nucleotide variants (SNV), INDELs, copy number alterations (CNAs), microsatellite instability (MSI), and tumor mutation burden (TMB) in eligible patients; ELIA software to interface clinic EMR to lab; Consultations and molecular tumor boards by molecular genetic pathologist (MGP)
41126390|NCT06090513|DIAGNOSTIC_TEST|limited genetic testing or no testing|Minimal genetic testing for eligible patients or treatment without testing
41126391|NCT03939312|DRUG|Atogepant|Atogepant Tablets
41126392|NCT03598946|DEVICE|Urinary test|Women use a home urinary test themselves
41126393|NCT04971070|OTHER|Observation and follow-up|Observation and follow-up study
41277070|NCT06657495|DRUG|TD0015|TD0015 is black, dark brown inside pilulae and has special smell of herbal, slightly sour then bitter taste.
41277071|NCT06657495|DRUG|TD0015 Placebo|Placebo was packed in pack 5g
41277072|NCT06600906|DRUG|Hyperpolarized 13C-Pyruvate|Given intravenously (IV)
41277073|NCT06600906|PROCEDURE|Computed tomography (CT)|Undergo CT imaging
41277074|NCT06600906|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI imaging
41277075|NCT05983848|RADIATION|99mMaracticaltide imaging|7.3.1 99mTc-maraciclatide imaging This will be undertaken at baseline and optionally at 8-12 weeks. Not more than 75 µg of 99mTc-maraciclatide will be administered intravenously with an activity as close as possible to 740 MBq. Static whole-body imaging will be undertaken after a maximum of 2 hours with further dedicated views of the hands and feet. Total image acquisition time will be approximately 30 minutes. Images will be scored by quantitative and semi-quantitative methods by a blinded observer.
41277076|NCT06601192|DRUG|zelicapavir (therapeutic dose)|Subjects will receive zelicapavir (TD) once per treatment period.
41277077|NCT06601192|DRUG|zelicapavir (supratherapeutic dose)|Subjects will receive zelicapavir (SD) once per treatment period.
41277078|NCT06601192|DRUG|Placebo|Subjects will receive zelicapavir matching placebo once per treatment period.
41277079|NCT06601192|DRUG|moxifloxacin|Subjects will receive moxifloxin once per treatment period.
41277080|NCT05381909|DRUG|BGB-24714|administered orally
41277081|NCT05381909|DRUG|Paclitaxel|administered intravenously
41277082|NCT05381909|DRUG|Carboplatin|administered intravenously
41277083|NCT05381909|DRUG|Docetaxel|administered intravenously
41277084|NCT06390137|DEVICE|Frequency Specific Microcurrent|The participant will receive an FSM treatment of 40 Hz on channel A and 97 Hz on channel B at 200 uamp with alternating current with a sharp square wave slope for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest. The TENS unit will be wrapped in an opaque bag so that the device is indistinguishable from that of the sham treatment.
41277085|NCT06390137|DEVICE|Sham microcurrent treatment|The participant will receive a sham FSM treatment with the machine off wrapped in an opaque bag for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest.
41277086|NCT05552222|DRUG|Teclistamab|Teclistamab will be administered as SC injection.
41277087|NCT05552222|DRUG|Daratumumab|Daratumumab will be administered as SC injection.
41277088|NCT05552222|DRUG|Lenalidomide|Lenalidomide will be administered orally.
41277089|NCT05552222|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously (IV).
41277090|NCT05552222|DRUG|Talquetamab|Talquetamab will be administered as SC injection.
41277091|NCT06649994|DEVICE|Active iTBS of the DLPFC|Participants will receive a 3 minutes intermittent Theta Burst Stimulation of the DLPCF of the left hemisphere while not performing any other task
41126394|NCT06269731|BEHAVIORAL|Hamilton depression Rating Scale|also known as the Ham-D is the most widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. Although the scale was designed for completion after an unstructured clinical interview, The scale has been translated into a number of languages including French, German, Italian, Thai , Turkish and Arabic version by Mostafa Lotfy.
41277092|NCT06649994|DEVICE|Active iTBS of the vmPFC|Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vmPFC while not performing any other task
41126395|NCT02866942|DRUG|Administration of Live attenuated influenza vaccine (LAIV)|
41126396|NCT04338399|DRUG|Buparlisib & Paclitaxel|Investigation drug plus paclitaxel
41126397|NCT05639400|DEVICE|Thoraflex Hybrid|Thoraflex Hybrid is designed for the open surgical repair of aneurysms and/or dissections in the aortic arch and descending aorta with or without involvement of the ascending aorta. There are two types of Thoraflex Hybrid implants, namely the Plexus 4 and the Ante-Flo versions. Each patient receives one Thoraflex Hybrid device (either the Plexus 4 or Ante-Flo).
41126398|NCT05639400|DEVICE|RelayPro NBS|The RelayPro NBS Thoracic Stent-Graft System is an endovascular device intended for treatment of thoracic aortic pathologies such as aneurysms, pseudoaneurysms, dissections, penetrating ulcers and intramural hematoma.
41126399|NCT04747561|DRUG|18F-PEG3-FPN|For clinically suspected or confirmed melanoma patients and healthy volunteers, integrated PET/MR imaging was performed using targeted melanin-specific imaging agent 18F-PEG3-FPN. Meanwhile, the general imaging agent 18F-FDG was compared with MR multi-sequence and multi-parameters
41126400|NCT02413866|BEHAVIORAL|Calorie restriction only|Participants randomly assigned to this group will be instructed to reduce their daily energy intake to 95% of their resting metabolic rate.
41126401|NCT02413866|BEHAVIORAL|Sleep & calorie restriction|Participants randomly assigned to this group will be instructed to reduce their total time in bed by 90 minutes 5 days a week, in addition to restricting their dietary intake to approximately 95% of their resting metabolic rate.
41126402|NCT04017793|BEHAVIORAL|Mindfulness Based Stress Reduction|Structured 8-week training program teaching about increased mindfulness strategies and gentle stretching.
41126403|NCT04017793|BEHAVIORAL|Relaxation Group|8-weekly group discussion meetings reviewing relaxation techniques and other stress reduction strategies with an emphasis on social support.
41126404|NCT00204113|DEVICE|Multi-purpose rehabilitation frame|
41126405|NCT00204113|DEVICE|Surface Functional Electrical Stimulation|
41126406|NCT05834894|OTHER|exposure(s) of interest : intensive care unit|Low muscle mass is highly prevalent at hospital admission, and muscle mass generally decreases during hospital stay, especially in critically-ill patients. We would like to mesure muscle mas in critically ill patients and determine the association between outcomes.
41126407|NCT02890524|DEVICE|night guard|60 days before and after intervention with the night guard
41126408|NCT02890524|DEVICE|placebo night guard|60 days before and after intervention with the placebo night guard
41277093|NCT06649994|DEVICE|iTBS of the vertex (sham)|Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vertex while not performing any other task
41447926|NCT06043349|DRUG|Topical 5% Minoxidil|The intervention group will receive topical 5% minoxidil as standard therapy for male androgenetic alopecia.
41447927|NCT05009212|PROCEDURE|Endoscopic stricturotomy|Endoscopic stricturotomy for bowel stricture (\<5 cm)
40754670|NCT05610150|DEVICE|Twin Block|An Appliance for treating growing Class II patients with mandibular deficiency
40754671|NCT06465901|OTHER|Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower|Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
40928576|NCT03725254|PROCEDURE|lymphadenectomy|The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.
41126409|NCT06135246|DEVICE|High Intensity Laser Therapy|Participants will receive high-intensity laser therapy using an 810nm continuous wave diode laser (Multiwave locked System (MlS) provided by aSa). The laser applicator has a flat top hat beam profile with a spot size of 1cm2. The laser will be delivered in direct contact mode perpendicularly to the ulcer surface. Each 1cm2 area of the venous ulcer and a 1cm margin of periwound skin will be treated sequentially using a overlapping grid pattern to cover the entire ulcer area, with a 1 second exposure time per point. This results in a laser energy density of 4J/cm2 delivered to each point.
41126410|NCT06135246|OTHER|Standard Care|Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).
41126411|NCT01736449|DRUG|Bevacizumab|
40754672|NCT06465901|OTHER|Intraoperative wound wash (e.g. Granudacyn)|Intraoperative wound wash (e.g. Granudacyn)
41126412|NCT03329612|PROCEDURE|Remote Ischemic Preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions.
40928577|NCT03725254|RADIATION|chemoradiotherapy|Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).
41277094|NCT06649994|BEHAVIORAL|Computerized inhibitory control training|"Participants will perform the task of the FoodT app for 10 minutes immediately after iTBS (taking advantage of time of maximum brain potentiation, Rossi et al., 2009).~This task pairs high-calorie meals with the no-go cue. Images appear on the left, right or center of the smartphone screen and they must touch it or not (depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses: If the image has a green border around it, you must tap the image and win 1 point. But if the image has a red border around it, you must inhibit the tapping response or you will lose 1 point. Participants must respond as quickly and accurately as possible and improve reaction time.~Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal"
41277095|NCT06026332|DRUG|ADSTILADRIN|Non-interventional
41277096|NCT06653855|OTHER|Dry Static Cupping|A myofascial decompression cupping set with a precision pressure pump will be used to perform dry static cupping to the adductor and hamstring muscle groups of the affected limb, using a negative pressure of 300mmHg for eight minutes each.
41277097|NCT06653855|OTHER|Placebo cupping|The same protocol will be used as stated for the Dry static cupping intervention, with the only difference being that the cup will be pumped to 50mmHg instead of 300mmHg.
41277098|NCT06653855|OTHER|Standard physical therapy treatment|"Treatment will consist of typical physical therapy interventions performed for patients with spasticity of the lower extremity after stroke. These may include, but not be limited to:~* Balance exercise~* Therapeutic exercise~* Neuromuscular/muscular coordination exercise~* Manual (hands on) therapy~* Gait training~The treating physical therapist is left with the autonomy of the standard physical therapy treatment (within the above stated groups of interventions) because patients with the diagnosis of stroke do not all present with the same type or level of impairment. Furthermore co-morbidities (e.g., hypertension) and/or functional level (wheelchair bound vs. independent ambulator) may necessitate different treatment strategies. Therefore, while the general categories of treatment will remain the same across all study patients, it is expected that the treating physical therapist provides patient-specific interventions."
41277099|NCT05514665|DEVICE|Diffuse Optical Tomography|Neonates once hemodynamically stable will undergo diffuse optical tomography measurements of functional brain connectivity at the bedside within 3-7 days after birth.
41277100|NCT03840876|DEVICE|WEI NASAL JET (WNJ)|Jet ventilation was achieved with WEI NASAL JET (WNJ) connected to a manual jet ventilator (Driving pressure: 40 psi, fraction of inspired oxygen: 100% O2, Respiratory rate: 25/min, I/E ratio: 40%)
41277101|NCT06657404|DRUG|use Amiodarone, Bisoprolol and Digoxin|"Amiodarone 200mg tid orally for 1 week, then reduced to 200mg bid orally for another week.~The dose of amiodarone will be reduced to 200mg bid orally for 1 week, and then 200mg qd maintenance treatment will be started in the 3rd week of dosing.~Bisoprolol 2.5-5mg qd oral treatment, the specific dose is decided by the investigator.~Digoxin 0.125mg qd orally."
41447928|NCT05009212|PROCEDURE|Endoscopic balloon dilatation|Endoscopic balloon dilatation for bowel stricture (\<5 cm)
41447929|NCT03502811|DEVICE|MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR/XTR system.
41447930|NCT01789463|OTHER|Self rehabilitation|
40928578|NCT02276027|DRUG|BYL719|BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
41126413|NCT04053270|DRUG|Afamelanotide|16mg subcutaneous implant
41126414|NCT04053270|DRUG|Placebo|Placebo subcutaneous implant
41447931|NCT01789463|OTHER|Self rehabilitation plus physiotherapy|
41447932|NCT02290262|OTHER|Comprehensive phase one rehabilitation|"Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.~The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse."
40754673|NCT06465901|OTHER|DACC surgical wound dressing (e.g. Leukomed Sorbact)|DACC surgical wound dressing (e.g. Leukomed Sorbact)
41126415|NCT02711865|BIOLOGICAL|IGF1R antibody MK0646|
41126416|NCT02711865|OTHER|Saline solution|
41126417|NCT00180791|DRUG|Etoposide, carboplatin, melphalan, cisplatin, thiotepa|
41126418|NCT04623554|BEHAVIORAL|Prehabilitation program|The prehabilitation program includes combined high-intensity interval training on a cycle ergometer and machine-based resistance exercise of large muscle groups supervised by a physiotherapist. Exercise sessions will take place in physiotherapy departments at local hospitals or in municipality rehabilitation centres 3 times a week during the neoadjuvant chemotherapy period and ending in the week before breast surgery (maximum estimated 29 weeks depending on number of chemotherapy cycles, dose delays and time of breast surgery). Participants will be screened for psychological distress four times and in case of moderate-severe distress be advised to visit the local Cancer Society Support Center where participants will be assessed and offered free services based on their psychosocial needs and available offers. Participation will be monitored.
41126419|NCT06030817|DIAGNOSTIC_TEST|99mTc-CNDG SPECT/CT|Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.
41126420|NCT03064594|PROCEDURE|Cornual pregnancy|we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
40928579|NCT02276027|DRUG|INC280|INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
40928580|NCT02276027|DRUG|LDK378|LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
41126425|NCT01323166|PROCEDURE|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
41447933|NCT04806035|BIOLOGICAL|TG-1801|It is a bispecific, first-in-class, CD47 and CD19 antibody
41447934|NCT04806035|BIOLOGICAL|Ublituximab|recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks
41447935|NCT06318130|DEVICE|Fixed helix, lumenless pacing lead.|Patients will be randomised to the fixed helix, lumenless pacing lead design during LBBP implantation.
41447936|NCT06318130|DEVICE|Extendable helix, stylet-driven pacing lead.|Patients will be randomised to the extendable helix, stylet-driven pacing lead design during LBBP implantation.
41126426|NCT04986475|OTHER|Music Therapy|Music therapy was performed by listening to the ney sound during the non-stress test procedure.
41126427|NCT00328666|BEHAVIORAL|Iyengar yoga|
41277102|NCT00885443|DRUG|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
41126428|NCT00328666|BEHAVIORAL|Enhanced nutritional care classes|
41126429|NCT05879705|OTHER|Parent intervention|Family centered, strength-based, Occupational therapy intervention program
41126430|NCT02520219|DRUG|GDP|GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.
41126431|NCT02520219|BIOLOGICAL|Endostar|"Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.~Repeated every 21 days."
41126432|NCT06328868|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
41277103|NCT00885443|DRUG|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
41277104|NCT00851903|DRUG|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
41277105|NCT00851903|DRUG|Sitagliptin|Oral administration. 100mg film-coated tablets.
41277106|NCT00851903|DRUG|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
41277107|NCT06372977|DIAGNOSTIC_TEST|kappa index|CSF albumin /serum albumin ratio (Qalb) k-index = (CSF kFLC/serum kFLC)/Qalb
41277108|NCT02581709|BEHAVIORAL|Countering cognitive impairment|The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
41277109|NCT04528485|OTHER|Sea swimming|8 sessions of swimming activities in the sea
41447937|NCT06620939|DRUG|Levonorgestrel Intrauterine System (LNG-IUS)|Participants in the intervention group will receive Mirena placement after hysteroscopic polypectomy
41277110|NCT03289962|DRUG|Autogene cevumeran|Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.
41277111|NCT03289962|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.
41277112|NCT03263091|DRUG|Roxadustat|Oral tablets
41447938|NCT04471922|DRUG|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
41447939|NCT04471922|DRUG|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
41447940|NCT04471922|DRUG|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
41447941|NCT01016782|DRUG|0444|A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
41447942|NCT06627374|DIAGNOSTIC_TEST|Patent Ductus Arteriosus in neonates|Neonates admitted to Neonatal care Unit after birth, undergoing hsPDA (hemodynamically significant Patent Ductus Arteriosus) closure according to standard clinical practice, will be included.
41447943|NCT02667951|OTHER|A home-based caregiver-training program|A home-based caregiver-training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
41447944|NCT06406725|DIAGNOSTIC_TEST|Point-of-Care Ultrasound of the Airway|Patients who are recruited will have an ultrasound performed of their larynx while they are on noninvasive positive pressure ventilation and then a second ultrasound when they are removed from noninvasive positive pressure ventilation. Between the two ultrasounds, the otolaryngology team will perform their fiberoptic nasolaryngoscopy, as per standard unit protocol and patient care.
41447945|NCT05832658|DEVICE|With EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with game-based emg-biofeedback.
41447946|NCT05832658|BEHAVIORAL|Without EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with only verbal feedback.
41447947|NCT05832658|BEHAVIORAL|Usual Care|Patient and family education will be provided by the investigator. In addition, each patient will be evaluated and oral motor exercises and thermal tactile stimulation will be given to each patient when necessary.
41447948|NCT00333645|DRUG|Caspofungin|
41447949|NCT03957226|DEVICE|e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)|The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.
41447950|NCT01497587|DRUG|insulin detemir|Single dose, 0.5 U/kg, administered s.c. (under the skin)
41447951|NCT06628115|DEVICE|cerament V or G|Cerament V or G implantation into forefoot or mid foot bone, and 7-10 days of oral antibiotics.
41447952|NCT01637480|OTHER|Lumbopelvic manipulation|High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
41447953|NCT05043103|COMBINATION_PRODUCT|Lecigon® based on European Medicines Agency (EMA) SmPC|There might be different brand names in other countries
41447954|NCT04322344|DRUG|Escin|treatment with escin or escinate sodium
41447955|NCT04322344|DRUG|standard therapy|antiviral drugs
41447956|NCT03875547|DRUG|Refixia®|Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
41447957|NCT05281120|DEVICE|Low-level mechanical vibrations WITH vertical sinusoidal acceleration|Small platform designed to induce vertical, sinusoidal acceleration.
40928581|NCT02276027|DRUG|MEK162|MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
40928582|NCT00726141|BEHAVIORAL|Brief intervention, Motivational Interviewing, Expert System|Motivational Interviewing, stage-tailored self-help manual, physician letter, expert system feedback letter
40928583|NCT02311101|DRUG|Mitomycin C|Given intravesically
40928584|NCT04937400|OTHER|Daily screening for delirium|Each child will be screened twice daily for delirium throughout the transplant hospitalization
40928585|NCT03777631|PROCEDURE|Catheter ablation|CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
40928586|NCT05378139|DEVICE|Vital signs measurements with new app|Patients vital signs are monitored through an app for the nurses to use
40928587|NCT00185653|PROCEDURE|Autologous followed by non-myeloablative allogeneic transplantation|
41126433|NCT06328868|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
41447958|NCT05281120|DEVICE|Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration|Small platform designed to NOT induce vertical, sinusoidal acceleration
40928588|NCT06435559|OTHER|Neurotablet® and Neuropsychological evaluations|The experimental group will carry out cognitive rehabilitation using the Neurotablet device. The cognitive rehabilitation will be performed for 10 consecutive weeks, once a week for 1 hour. Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
41447959|NCT05459571|BIOLOGICAL|Axicabtagene Ciloleucel|Administered intravenously
41447960|NCT05459571|DRUG|Cyclophosphamide|Administered intravenously
41447961|NCT05459571|DRUG|Fludarabine|Administered intravenously
41447962|NCT05459571|DRUG|Dexamethasone|Administered orally or intravenously
41447963|NCT05238857|OTHER|Assessment|There will be no intervention. Only assessments will be taken from the patients and data will be analyzed.
41447964|NCT01312844|DRUG|Scopolamine|Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
41277113|NCT03263091|DRUG|Placebo|Oral tablets
41447965|NCT06627361|DEVICE|PRO-FLEX PIVOT Foot evaluation|The subject will wear the PRO-FLEX PIVOT foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
41447966|NCT06627361|DEVICE|Class III ESAR Foot evaluation|The subject will wear his usual Class III ESAR Foot foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
41447967|NCT00611364|OTHER|Physical Therapy and education meetings|Physical therapy was realized three two times per week and education meeting every fifteen days
41447968|NCT00611364|OTHER|education meetings|This group only participed of education meeting (every fifteen days)
41126434|NCT06328868|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
41126435|NCT01728974|OTHER|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
41126436|NCT05914896|DRUG|HighOsmo|This group received a priming solution with high osmolality
41126437|NCT01932970|DRUG|Etelcalcetide|Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
41126438|NCT05424666|PROCEDURE|Harvesting method and Fat graft preparation method|"The procedure begins by identifying the areas where the fat will be collected Then the sample is collected by micro-incision using a fine suction cannula or during conventional liposuction. The fat cells are taken from an area of the body where there is a reserve (generally, in the abdomen, hips, knees, inner thighs, buttock) The collected fat cells are then subjected to a sterile centrifugation for a few minutes so as to separate the cells that will be injected (intact fat cells) from the elements that must not be injected (fat cells destroyed by the sample, non-fat cells such as than blood cells).~Injection of fat cells into the breasts The reinjection of fat (lipofilling) is performed using micro-cannulas allowing incisions of the order of 1-2 mm in different angles and in multiple directions so as to increase the contact area between the grafted cells and the recipient tissues allowing a good grip of the injection."
41126439|NCT04734600|DEVICE|Electronic Treadmill device|"group A:PN-7001M Panasonic Treadmill 130 kg, frequency 50 HZ, input voltage AC220 V, input power 100W+_ 10 will usefor aerobic training program ,start by 1pbm grading to 2pbm speed and increase according to patient abilities during sessions ,0% treadmill inclination angle for two month as a total treatment period for study group patients.~Patients in this group will participate in aerobic training as march walking on treadmill for 45 mints duration for session 3 times per week, start with 5 mints warm up beginning and 5 mints cooling down at end session, in addition to their medical program and burger exercises"
41277114|NCT03380858|DEVICE|colectomy|colectomy resection
41277115|NCT02318602|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
41277116|NCT02886429|DRUG|Bupivacaine|Ultrasound guided paravertebral block with bupivacaine
41277117|NCT02886429|DRUG|Dexmedetomidine|Ultrasound guided paravertebral block with dexmedetomidine
41277118|NCT05056831|BEHAVIORAL|Behavioral Intervention|Attend face-to-face mind-body sessions
41277119|NCT05056831|OTHER|Best Practice|Receive usual care
41277120|NCT05056831|OTHER|Informational Intervention|Receive targeted text messages
41447969|NCT06628089|OTHER|Questionnaire|A questionnaire for primary healthcare physicians designed to evaluate knowledge about H. Pylori mode of transmission, symptoms, complications and treatment.
41447970|NCT04418219|DRUG|Cyclophosphamide|alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
41277121|NCT05056831|OTHER|Quality-of-Life Assessment|Ancillary studies
41277122|NCT05056831|OTHER|Questionnaire Administration|Ancillary studies
41277123|NCT04404335|DIAGNOSTIC_TEST|Crevicular fluid analysis by using ELISA testing.|Samples of crevicular fluid (fluid existing in the space between the gums and the roots of the teeth) will be obtained from healthy and periodontal patients. In periodontal patients, samples will be taken before and after receiving a routine course of periodontal treatment (root scale and polish) to assess the levels of a peptide called LL-37 and inflammatory cytokines (IL-4, IL-6, IL-10): Samples will then be analysed using laboratory procedures (ELISA)
41277124|NCT04957888|OTHER|none intervention|none intervention.
41447971|NCT04418219|BIOLOGICAL|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine
41447972|NCT04418219|BIOLOGICAL|Pembrolizumab|1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475
41447973|NCT04418219|BIOLOGICAL|Recombinant Interferon Alpha 2b-like Protein|Novaferon, Recombinant IFN Alfa-2b-like Protein
41447974|NCT04418219|OTHER|Questionnaire Administration|Ancillary studies
41447975|NCT04418219|OTHER|Quality of Life Assessment|Ancillary studies
41447976|NCT04089553|DRUG|AZD4635|"In Module 1, participants will receive AZD4635 75 mg capsule orally QD for first 14 days and thereafter will continue to receive 75 mg orally QD Q4W.~In Module 2, participants will receive AZD4635 50 mg / 75 mg capsule orally QD Q2W of 28-day cycle for the first 4 doses and Q4W thereafter.~In both modules, participants will receive treatment until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first."
40754674|NCT02544087|DRUG|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
41447977|NCT04089553|DRUG|Oleclumab|In Module 2, participants will receive oleclumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q2W of 28-day cycle for the first 4 doses and Q4W thereafter until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
41447978|NCT04089553|DRUG|Durvalumab|In Module 1 after monotherapy of AZD4635, participants will receive durvalumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q4W until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
41126440|NCT04734600|OTHER|myofascial release technique|"group B:The myofascial release technique group will receive a 45 mints session time, for3 times per week for two months in addition to their medical program and burger exercises. Before the MF will starte, patient will rested in a relaxed prone position for 15 to 30 mints and also after end session time, MF protocol will applied as follow sequence over all period of total treatment sessions (8) week.:~thoracolumbar cross hand facial release technique for at least 5 mints for every barrier depth area, started by one hand will place on high thoracic area with pressure applied cephalic, the other hand was placed directly on the lower lumbo -sacrum area pushing caudal and arms are crossed to maximize as leverage as the barrier sense of softening will occurre and release sense on fascia under hand (release done at transverse alternative with longitudinal direction)alternation same methods to affected leg"
41447979|NCT05546060|DRUG|Venetoclax|Venetoclax 100mg qd d1，200mg qd d2，400mg qd d3-56
41126441|NCT03888768|DRUG|MonoFer|Administration of IV Monofer will be given according to body weight as recommended by the drug manufacturer.
41126442|NCT02061501|OTHER|Optometric therapy during 6 months|Optometric therapy during 6 months, once a week
41126443|NCT02061501|OTHER|Optometric therapy during 12 months|Optometric therapy once a week, during 12 months
41126444|NCT03650543|DRUG|amoxicillin clarithromycin omeprazole 1|Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
41277125|NCT03487822|BEHAVIORAL|Path Pain|The intervention examines the effects of PATH-Pain on emotion regulation to improve self-management of pain and pain-related disability in older adults with chronic pain, negative emotions, and cognitive impairment. This intervention consists of 8 weekly therapy sessions by a licensed clinician trained in Path Pain, 4 monthly boosters upon completion of therapy, and optional monthly group educational sessions.
41447980|NCT05546060|DRUG|Dexamethasone|Dexamethasone 10mg/m2 qd d1-14, 5mg/m2 qd d15-28, 2.5 mg/m2 qd d29-42, and 1.25mg/m2 qd43-56
40928589|NCT06435559|OTHER|Neuropsychological evaluations|Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
40928590|NCT03557996|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush
40928591|NCT03557996|DRUG|Sodium Fluoride Varnish|NaF will be applied with a brush
40928592|NCT05946304|BEHAVIORAL|moderate-intensity continuous exercise training (MICT) group|Exercise session: Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 70-85% peak HR - 35min; Cool-down: 60-70% peak HR - 15min.
41126445|NCT03650543|DRUG|amoxicillin clarithromycin omeprazole 2|The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
41126446|NCT04183452|DRUG|17-Hydroxyprogesterone Caproate 250 mg IM Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
40754675|NCT02544087|DRUG|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
41126447|NCT04183452|DRUG|17-Hydroxyprogesterone Caproate 275 mg SC Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
41126448|NCT06475248|OTHER|Placebo Technique|For the technique performed in the control group, the researcher will come into contact with the volunteers' chests. This contact will be maintained for the same period of time as the experimental group (6 minutes).
41277126|NCT05639764|DEVICE|Oculus Quest 2|A specific immersive virtual reality software designed to address chronic shoulder pain on the Oculus Quest 2 device.
41277127|NCT05639764|DEVICE|Oculus Quest 2|"a VRi placebo intervention with the game Tsuro, which consists of a puzzle-based strategy game where the patient will have to solve a maze by placing pieces."
41447981|NCT05546060|DRUG|Etoposide|Etoposide 75mg/m2 qw d1-56
41447982|NCT06350240|BEHAVIORAL|Exercise|An exercise program that can be easily applied at home and in the park, which will support the psychomotor, tactile and proprioceptive-rich sensory development specific to children with joint hypermobility. The family will be instructed to do these exercises for 30 minutes a day for 5 days in total, 2 days a week in the playground and 3 days at home for 6 weeks, and the family will be asked to keep a diary to see whether they do the exercises or not.
41126449|NCT06475248|OTHER|Stretching technique|"Stretching technique for the upper trapezius and sternocleidomastoid: the volunteer will be in supine position on the couch, the researcher will perform the technique from the contralateral side of the muscle to be treated, the hand will contact the ipsilateral shoulder to stabilize, meanwhile, with the other hand, contact the upper trapezius and perform a rhythmic pull in contralateral rotation. This technique is performed bilaterally."
41126450|NCT06475248|OTHER|Inhibition of the suboccipital|"Inhibition of the suboccipital: the participant is in the supine position, the researcher will position himself behind the patients head. In this technique, contacts will be made on the suboccipital area with the 2nd, 3rd and 4th fingers of both hands. Make a slight pull with your body backwards and wait that there is relaxation of muscular tensions."
41126451|NCT03592602|PROCEDURE|arm abduction and adduction|All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
41126452|NCT00111631|DRUG|DPP-IV Inhibitor|Escalating doses po bid
41126453|NCT00111631|DRUG|Metformin|As prescribed
41126454|NCT00111631|DRUG|Placebo|po bid
41126455|NCT05350904|OTHER|Hybrid of telehealth and in-person physical therapy services|The experimental group will receive a hybrid of telehealth and in-person physical therapy services to address an in-home functional skill in children with moderate to severe disability.
41277128|NCT06250387|PROCEDURE|Endobronchial ultrasound transbronchial cryobiopsy|"Endobronchial Ultrasound (EBUS) :~EBUS is usually performed under general anesthesia using a laryngeal masque. It has a linear ultrasonography with a 7.5 MHz frequency. The distal part of the endoscope contains a water filled balloon used as a liquid interface, camera, light source and a working channel. The needle is protected by a sheath to prevent working channel damage. The endoscope is connected to a processor that reflects both endobronchial and ultrasound images on a screen.~EBUS - TBNA : EBUS - Transbronchial needle aspiration EBUS - TBCB: EBUS - Transbronchial Cryo Biopsy"
41277129|NCT01696812|PROCEDURE|electrode position|
41277130|NCT05503953|DRUG|AGSAVI|Uptitation
41277131|NCT05503953|DRUG|AGLS|Uptitration
41277132|NCT05637268|DRUG|Camrelizumab|Camrelizumab 200mg iv q2w
41277133|NCT05637268|DRUG|Paclitaxel|150mg/m² iv d1 q2w
41277134|NCT05637268|DRUG|Cisplatin|50 mg/m² iv d2 q2w
41277135|NCT03417440|OTHER|Physical Activity (PA) Tracker App|This PA tracker app auto-monitors PA and provides a text-based summary of goal progress, thereby targeting self-regulation and outcome expectation.
41277136|NCT03417440|OTHER|On Your Feet|On Your Feet is a specialty app feature designed to be paired with a PA tracker app and reduce sedentary activity-a health risk factor largely independent of insufficient PA. This feature utilizes self-regulatory and behavior change techniques including goal-setting, progress feedback, and prompting. Accumulated sedentary activity time is displayed alongside self-selected goals; reminders to stand are sent at a user-specified frequency; and general tips and previously compiled, older adult-identified strategies to reduce sedentary activity are texted. Additionally, messages about the benefits of reducing sedentary activity and overcoming barriers are sent.
41277137|NCT03417440|OTHER|Coach Me|Coach Me is a specialty app feature designed to be paired with a PA tracker app and includes daily messages that assist older adults in discovering practical ways to integrate PA into their daily routines and overcoming PA barriers. Blending PA with productive activity facilitates PA engagement in older adults. In Coach Me, suggestions on how to intensify daily activities are tailored based on user selections from an activity inventory. This app feature helps older adults become more active in a minimally intrusive way, while allowing for engagement in productive and meaningful activities. Coach Me asks users to select obstacles to PA encountered in the previous week. Based on those selections, the app sends strategies on how to overcome those barriers, thereby targeting self-efficacy.
41277138|NCT03417440|OTHER|Proof Positive|"Proof Positive is a specialty app feature designed to be paired with a PA tracker app and capitalizes on the beneficial effects that exposure to positive aging messages and stereotypes has on health and PA. When activated, users (a) receive texts describing how old age does not equate to physical inability, (b) obtain information about the benefits of growing older, and (c) are presented with a weekly positive aging stereotype task modeled after a computerized series. This last function exposes users to blocks of positive priming words. Primers are quickly flashed to allow perception without awareness while users focus on a simple icon that represents PA. Icons are intended to provide an additional PA cue, maintain user interest, and increase the external validity."
41447983|NCT06350240|BEHAVIORAL|Exercise+texture insoles|In addition to exercise, children in this group will have an individual textured insoles made to suit the child's foot. The child will be asked to place textured insoles inside his shoes and use the textured insoles for 6-8 hours.
41126456|NCT01483066|DEVICE|ShapeMatch Technology|ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
41126457|NCT05794568|DEVICE|OITcontrol app monitoring|App to monitor OIT patients
41126458|NCT04516057|DRUG|Nabilone|After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
41126459|NCT04516057|OTHER|Placebo|After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
41126460|NCT03660618|DEVICE|laser speckle flowgraphy|blood flow state of the skin as real time two dimensional image
41126461|NCT06514183|OTHER|Clinical diagnosis of recurrence|Clinical diagnosis of recurrence
41126462|NCT06234956|BIOLOGICAL|BIMERVAX|BIMERVAX
41277139|NCT06253923|DRUG|Amantadine Hydrochloride|MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl).
41277140|NCT06253923|DRUG|Placebo|The placebo for this study is 0.9% Sodium Chloride IV Solution.
41277141|NCT06456177|DEVICE|Assessment of nociception in obstetric patients during epidural analgesia|Comparing nociception in obstetric patients during epidural analgesia, subjectively, by Visual analog scale and objectively by monitoring Nociception level Index
41126463|NCT01503970|DEVICE|Arthroscopic matrix encapsulated chondrocyte implantation|Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
41126464|NCT02339519|DEVICE|LMA CLASSIC|Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
41126465|NCT02339519|DEVICE|LMA FASTRACH|Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
41126466|NCT02339519|DEVICE|LMA SUPREME|Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
41126467|NCT04514718|DEVICE|Holmium laser|low energy holmium laser
41126468|NCT04110054|DRUG|S-600918|Tablets for oral administration
41126469|NCT04110054|DRUG|Placebo to S-600918|Tablets for oral administration
41277142|NCT01574573|BEHAVIORAL|Self support, group sessions|Self support,group sessions
41277143|NCT05833217|PROCEDURE|Adipose Tissue Biopsy|After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Participants will have a local anesthetic prior to the procedure. The needle fat biopsy will be repeated at quarterly intervals for one year (every 3 months). We will also draw 1 10mL tube of blood at each biopsy for measurement of inflammatory cytokines.
41277144|NCT05833217|DIAGNOSTIC_TEST|Steady State Plasma Glucose (SSPG) Test|An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if participants are insulin sensitive or insulin resistant. This test is approximately 5-6 hours in length. Participants will be asked to fast for 12 hours. The insulin sensitivity test is designed to measure how well your cells remove glucose from your blood in response to insulin. During this test participants will have two small catheters (tubing) placed in their veins (I.V. lines). The total amount of blood that will be drawn during this test will be 140 mL of blood (approximately 9.5 tablespoons). Insulin is a natural hormone, and octreotide (a synthetic hormone) is a drug that temporarily blocks the secretion of insulin from your pancreas. A member of the research team is present and monitoring the results along with the nursing staff.
41126470|NCT00920972|DRUG|Treatment Plan 1: Stratum 1|Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
41126471|NCT00920972|DRUG|Treatment Plan 2: Strata 2, 3, or 4|Day -50 to -21: Hydroxyurea 30mg/kg PO q day... Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
40754676|NCT02544087|DRUG|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
41126472|NCT00920972|DRUG|GVHD Regimen A: UCB Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV
41126473|NCT00920972|DRUG|GVHD Regimen B: BM Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV
41126474|NCT02664558|DRUG|ubenimex|
41126475|NCT02664558|OTHER|placebo|
41126476|NCT04944563|PROCEDURE|Segmentectomy|Patients receive segmentectomy
41277145|NCT05819892|DRUG|Paclitaxel|Given by IV (vein)
41277146|NCT05819892|DRUG|Carboplatin|Given by IV (vein)
41277147|NCT05819892|DRUG|Dostarlimab|Given by IV (vein)
41277148|NCT05819892|DRUG|Cisplatin|Given by IV (vein)
41277149|NCT06573853|PROCEDURE|Focal Pulsed Field Ablation (PFA)|Patients in the PFA group underwent ablation procedures utilizing a force-sensing PFA catheter for the treatment of PSVT.
41277150|NCT06573853|PROCEDURE|Focal Radiofrequecy Ablation (RFA)|Patients in the PFA group underwent ablation procedures utilizing force-sensing RFA catheters for the treatment of PSVT.
41277151|NCT03006211|OTHER|Nitrogen protoxide|
41277152|NCT03006211|OTHER|Oxygen|
41277153|NCT04477603|DEVICE|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
41277154|NCT05836090|BEHAVIORAL|Family Spirit Strengths (FSS)|The FSS intervention consists of psychoeducational components that emphasize the importance of mental and emotional health as part of overall wellness, and seek to normalize experiences of stress, to de-stigmatize help-seeking, and to build hope. Core content focuses on awareness of the connections between thoughts, feelings, behaviors, and spirituality, and imparts related self-help skills. It also specifically builds in connection to culture, land and others as coping strategies. The FSS lessons were developed based on culturally adapting the Common Elements Treatment Approach (CETA).
41447984|NCT01576458|DRUG|ursodeoxycholic acid|450 mg/day for 14 days
40754677|NCT03644446|BIOLOGICAL|Bisoprolol plasma residual concentration dosage|Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance \< 30mL/min, mild altered between 30-60mL/min, normal \> 60mL/min as estimated by the CKD-EPI formula)
41447985|NCT01576458|DRUG|Placebo|placebo
41126477|NCT04944563|PROCEDURE|Lobectomy|Patients receive lobectomy
41126478|NCT00074919|BIOLOGICAL|alglucosidase alfa|20 mg/kg qow
41126479|NCT03148600|BEHAVIORAL|Pelvic floor and bowel behavioural training|Physiotherapist-led pelvic floor muscle and bowel behavioural training
41126480|NCT03148600|OTHER|Standard arm|Standard medical and nursing care
41277155|NCT05836090|BEHAVIORAL|Family Spirit Nurture|The active control Family Spirit Nurture, is an evidence-based nutrition education curriculum that has been previously tested with Navajo communities which focuses on age-appropriate parental feeding practices, including snack routines, avoidance of sugar-sweetened beverages (SSB) and promotion of water consumption.
41277156|NCT02920125|DRUG|SUVED|Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
41277157|NCT02920125|COMBINATION_PRODUCT|REIMMUGEN|Whole Cow colostrum in powder put in capsules; 300mg each
41277158|NCT02920125|OTHER|Grain flour placebo|Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
41277159|NCT02367846|DRUG|Combined Oral Contraceptive (COC)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
41277160|NCT02367846|DRUG|Contraceptive Vaginal Ring (CVR)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
41277161|NCT02197325|DEVICE|PICSO|Pressure controlled Intermittent Coronary Pressure Occlusion
41277162|NCT03678974|BEHAVIORAL|Exercise Prescription|The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
41277163|NCT04692675|DIAGNOSTIC_TEST|mpMRI|3T endorectal coil MR imaging of the prostate gland
41277164|NCT02498821|DEVICE|Chest X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
41277165|NCT02498821|DEVICE|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
41277166|NCT02498821|PROCEDURE|Peripherally Inserted Central Catheter (PICC)|A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
41277167|NCT02333227|DIETARY_SUPPLEMENT|Xylitol gum|This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
41277168|NCT05158348|DRUG|Dexmedetomidine Hydrochloride|Group A will receive post-operative nebulised dexametomidine and lidocaine.
41126481|NCT03085433|DEVICE|Microfluidic Sperm Sorting|Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.
41126482|NCT03085433|PROCEDURE|in vitro fertilization|ivf/icsi
41277169|NCT05158348|DRUG|Nebulized lidocaine|Group B will receive post-operative will receive nebulised lidocaine
41277170|NCT05158348|DRUG|Local infiltration of lidocaine|group C will receive intra-operative local infiltration of lidocaine
41277171|NCT04929210|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
41277172|NCT04929210|DRUG|Placebo|Matching placebo will be administered as subcutaneous injection.
41277173|NCT04538664|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
41277174|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.
41277175|NCT04538664|DRUG|Carboplatin|Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.
41277176|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.
41126483|NCT05092841|DRUG|PXT3003|Patients will be administered PXT3003 twice daily (bid) at 10mL.
41126484|NCT05092841|DRUG|PXT3003 placebo|Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.
41126485|NCT01615770|BEHAVIORAL|cognitive behavior therapy|At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
41126486|NCT03261908|GENETIC|detection of genotype|detection of genotype by next generation sequencing
41277177|NCT04382261|PROCEDURE|Scaling and root planing|Full mouth or quadrant SRP
41447986|NCT05415891|BEHAVIORAL|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with the study's community collaborative board, including representatives from the HIV care and advocacy communities as well as community members. The training is a whole-site training to address stigma as a barrier to accessing substance use and mental health services by persons living with HIV. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to persons living with HIV in order to reduce stigma-related barriers to mental health and substance use healthcare in Positive Impact Health Centers and increase retention in healthcare services for persons living with HIV.
41447987|NCT05415891|DEVICE|You℞ Decision prescribing platform|The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.
40928593|NCT05946304|BEHAVIORAL|high-intensity interval training (HIIT) group|Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals); Cool-down: 60-70% peak HR - 10min.
40928594|NCT02553668|DRUG|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
41126487|NCT03666468|OTHER|PlayMed|A highly immersive role-playing computer game focused on Paediatric Asthma and Seizure management
40928595|NCT02553668|DEVICE|Facemask|
41126488|NCT03666468|OTHER|Online Package|Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
41126489|NCT03666468|OTHER|Paper Guidelines|Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
41126490|NCT03676582|DIAGNOSTIC_TEST|Acoustic analysis plus pulse oximetry|Acoustic analysis plus pulse oximetry
41126491|NCT01746706|DEVICE|PET amyloid tracer (Florbetapir F18 AV45 F18|
41126492|NCT02672033|RADIATION|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
41126493|NCT02672033|RADIATION|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
41126494|NCT02672033|OTHER|Laboratory Biomarker Analysis|Correlative studies
41447988|NCT04476511|DRUG|Cholecalciferol|tablet containing 30.000IU cholecalciferol
41447989|NCT05723393|PROCEDURE|Erector spinae plane block|fascial plane injection guided by ultrasound
41447990|NCT05104723|DRUG|XELJANZ (tofacitinib)|The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
40754678|NCT06110182|DIETARY_SUPPLEMENT|enteral or parenteral nutritional support|Parents will be classified based on whether they received enteral or parenteral nutritional support during treatment.
41126495|NCT02672033|PROCEDURE|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
41126496|NCT01182649|DEVICE|coronary stent|coronary angioplasty with stent implantation
41126497|NCT01182649|DEVICE|stent|coronary angioplasty with stent implantation
41126498|NCT01536834|DEVICE|Medical Device|
41126499|NCT00809068|DRUG|fenofibrate and tibolone|fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
41126500|NCT00809068|DRUG|tibolone|tibolone 2.5 mg daily 23 weeks
41126501|NCT00634075|DRUG|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
41277178|NCT03213665|DRUG|Tazemetostat|Given PO
41277179|NCT05550532|DRUG|Aticaprant|Aticaprant tablet will be administered orally.
41277180|NCT05550532|OTHER|Placebo|Placebo tablet will be administered orally.
41447991|NCT00018213|DRUG|Naltrexone Hydrochloride|
41447992|NCT00018213|DRUG|Transdermal Nicotine|
41447993|NCT00003766|DRUG|O6-benzylguanine|
41447994|NCT06496568|DRUG|Inavolisib|Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.
41447995|NCT06496568|DRUG|Atezolizumab|Participants will receive atezolizumab, 1200 mg, as IV infusion Q3W on Day 1 of each 21-day cycle.
41447996|NCT01904513|DIETARY_SUPPLEMENT|Pasteurized Whole Milk|
41447997|NCT01904513|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GR-1|
41447998|NCT00880139|PROCEDURE|Blood sampling|Determination of cytokine plasma levels (ELISA)
41447999|NCT00880139|PROCEDURE|Noninvasive measurement of systemic hemodynamics|performed once
41448000|NCT00880139|PROCEDURE|Visual acuity assessment|ETDRS charts
41448001|NCT00880139|DEVICE|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
41448002|NCT00880139|PROCEDURE|Ophthalmic examination and fundus photography|7 + 1 standard fields
41448003|NCT00880139|DEVICE|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
41448004|NCT00880139|DEVICE|High resolution optical coherence tomography (OCT)|performed once
41448005|NCT01173835|BEHAVIORAL|Incentives for being tobacco free|Students who join the program will be entered into regularly scheduled drawings throughout the school year to earn incentives for being tobacco free.
41126502|NCT00634075|DRUG|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
41126503|NCT05222646|DRUG|Metoclopramide|Will receive single dose of 10mg of Metoclopramide intramuscularly
41126504|NCT06322212|DIETARY_SUPPLEMENT|Thiamine|Participants will be provided instruction to take one 500 mg capsule of Thiamine (Vitamin B1) each day in the morning for 3-months.
41126505|NCT06322212|OTHER|Placebo|Participants will be provided instruction to take one capsule (placebo) each day in the morning for 3-months.
41126506|NCT06420570|PROCEDURE|Thoracic Surgery|Patients will either undergo thoracic surgery, specifically thoracotomy (traditional method of chest surgery using a large surgical incision) or video-assisted thoracic surgery (minimally invasive method using video cameras)
41126507|NCT03953859|GENETIC|double strand break|an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
41126508|NCT03604146|BEHAVIORAL|Medical quality control intervention strategy|Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
41126509|NCT03643055|DIAGNOSTIC_TEST|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.
41126510|NCT03955575|DRUG|Liraglutide 6 MG/ML|Liraglutide as injections.
41126511|NCT03955575|DRUG|Colesevelam|3 x 625 miligram 2 times a day.
41126512|NCT00461019|PROCEDURE|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
41126513|NCT05729997|OTHER|Listening to live classical music|The group of musicians perform music in the hemodialysis room while patients receive treatment.
41126514|NCT00588471|DRUG|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
41126515|NCT00588471|DRUG|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
41126516|NCT05043272|BIOLOGICAL|SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
41126517|NCT02128113|DRUG|Vehicle Ophthalmic Solution|Opthalmic suspension manufactured to mimic RTA 408 suspension
41126518|NCT02128113|DRUG|Omaveloxolone Ophthalmic Suspension 0.5%|0.5% ophthalmic suspension of RTA 408
41126519|NCT02128113|DRUG|Omaveloxolone Ophthalmic Suspension 1%|1% ophthalmic suspension of RTA 408
41126520|NCT02463214|OTHER|Engineered Room|"Touchless devices:~Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors~Copper products:~Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.~Titanium dioxide paint:~Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote"
41126521|NCT03096236|DEVICE|EFTR|EFTR with the FTRD developed for gastric resection (gFTRD).
41126522|NCT02183506|DRUG|Metformin|
41126523|NCT02183506|DRUG|BI 1356 BS|
41126524|NCT00232375|DRUG|Insulin|
41126525|NCT02831361|DRUG|Gemigliptin|
41126526|NCT02831361|DRUG|Gemigliptin placebo|
41126527|NCT02831361|DRUG|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
41126528|NCT02831361|PROCEDURE|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25"
41448006|NCT05883644|DRUG|Durvalumab|Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion
41448007|NCT05883644|DRUG|Tremelimumab|Participants will receive single dose of 300 mg through IV infusion at Day 1
41126529|NCT03983759|DRUG|sintilimab maintenance|the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
41126530|NCT04511767|OTHER|Do not take any interventions|Do not take any interventions
41126531|NCT00574834|DRUG|Ramipril|Ramipril 20 mg once daily for 6 months
41126532|NCT00574834|DRUG|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
41126533|NCT00574834|DRUG|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
41126534|NCT00410254|DRUG|HCV-796|
41126535|NCT00410254|DRUG|midazolam|
41126536|NCT03344094|DRUG|ocrelizumab|FDA-approved MS drugs
41126537|NCT00645034|DRUG|placebo|placebo by mouth as a single dose
41277181|NCT03593915|COMBINATION_PRODUCT|Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine|"PHASE 1b:~Decitabine administered as an intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion (hybrid dosing) Once the maximum dose of alvocidib administered via hybrid dosing has been determined, 2 cohorts of patients will receive azacitidine followed by alvocidib administered as an IV infusion. Azacitidine may be administered as either an IV bolus over 10 to 40 minutes or as a subcutaneous (SC) injection on either a 7 day or 5-2 2 schedule. Regardless of which azacitidine schedule or route of administration is used, alvocidib will be given on Day 10 as a 30-to-60 minute IVI~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design using the RP2D of alvocidib administered as a 30-to-60 minute IV infusion determined in the Ph1b study to explore efficacy of alvocidib when administered in sequence after azacitidine."
41277182|NCT00283387|DRUG|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
41277183|NCT00283387|DRUG|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
41277184|NCT02828267|BEHAVIORAL|Brief Negotiational Intervention|This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
41277185|NCT02828267|BEHAVIORAL|Standard Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use.
41277186|NCT02828267|BEHAVIORAL|Personalized Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use. Information in this text will be personalized based on the participants specific reasons for reducing their alcohol use rather than a standard text content.
41277187|NCT06657625|OTHER|Sepsis Performance Improvement Program|Training/awareness for medical and paramedical staff; creation of informational posters; development of an institutional pathway in the emergency department; creation of a protocol ; establishment of a sepsis team with a dedicated contact number.
40754679|NCT01415453|PROCEDURE|Ultrasound Stimulus|Short pulses of focused ultrasound will be directed at spots on the retinal surface.
41126538|NCT00645034|DRUG|sildenafil|sildenafil 100 mg by mouth as a single dose
41126539|NCT03293875|BEHAVIORAL|Encuentro|a behavioral intervention designed to increase HIV testing rates and reduce behaviors that place individuals who use drugs at risk of contracting HIV
41126540|NCT02362867|DEVICE|Balanced Knee System|A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
41126541|NCT02191098|DRUG|ALT-803|Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
41126542|NCT05891366|DRUG|WAL0921|Investigational product WAL0921
41126543|NCT05891366|DRUG|Placebo|Placebo product
41126544|NCT03452982|OTHER|sentinel node technique|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
41126545|NCT01920191|BIOLOGICAL|IMA 950|
41126546|NCT01920191|BIOLOGICAL|Poly ICLC|
41126547|NCT01920191|OTHER|Immunomonitoring|Blood samples, DTH analysis
41277188|NCT01858103|DRUG|BMN 110|
41126548|NCT01449617|DRUG|Aspirin plus clopidogrel|"Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.~Aspirin will be given at the dose of 100-325mg/day."
41126549|NCT03304834|DEVICE|ECHOPULSE|Patient are treated with the HIFU device and the physician is doing a compressive bandage.
41126550|NCT01762059|DEVICE|Bi-homonal Bionic Pancreas|A computer algorithm will automatically deliver insulin lispro and glucagon based on the signal from a minimally invasive continuous glucose monitor.
41126551|NCT01762059|OTHER|Usual care|
41126552|NCT03304041|DIETARY_SUPPLEMENT|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
41126553|NCT03304041|DIETARY_SUPPLEMENT|Traditional dietary advice|"Traditional dietary advice(TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~traditional dietary advice for 3 weeks"
41126554|NCT06521424|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
41448008|NCT05343481|BIOLOGICAL|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus immunotherapeutic
41277189|NCT02010203|BIOLOGICAL|HS-410|Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
41126555|NCT06521424|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
41277190|NCT02010203|BIOLOGICAL|Placebo|Injection containing sterile solution but no cells
41277191|NCT02010203|BIOLOGICAL|BCG|Vaccine derived from a live bacterium
41277192|NCT04368754|OTHER|Questionnaire|Patients evaluated with different questionnaire.
41277193|NCT04377945|DRUG|Part 1, JM-010 component Group A|JM-010 component Group A
41277194|NCT04377945|DRUG|Part 1, JM-010 component Group B|JM-010 component Group B
41277195|NCT04377945|DRUG|Part 1, JM-010 component Group C|JM-010 component Group C
41277196|NCT04377945|DRUG|Part 1, Placebo Group|Placebo Group
41277197|NCT04377945|DRUG|Part 2, JM-010 combination Group A|JM-010 combination Group A
41277198|NCT04377945|DRUG|Part 2, JM-010 combination Group B|JM-010 combination Group B
41277199|NCT04377945|DRUG|Part 2, JM-010 component Group C|JM-010 component Group C
41277200|NCT04377945|DRUG|Part 2, Placebo Group|Placebo Group
41448009|NCT05343481|BIOLOGICAL|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus immunotherapeutic
41448010|NCT05343481|BIOLOGICAL|Nivolumab|Human immunoglobulin G4 monoclonal antibody
41126556|NCT03014375|DRUG|BIA-5-453|Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
41277201|NCT02090543|DRUG|Phenprocoumon (Marcumar)|common use, no requirements (real life situation)
41277202|NCT02090543|DRUG|Rivaroxaban (Xarelto, BAY-59 7939)|common use, no requirements (real life situation)
41277203|NCT04152759|DRUG|Drug: BAT2506 injection Other Names: Simponi(EU-licensed)|"Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)"
41277204|NCT01715844|DIETARY_SUPPLEMENT|L-citrulline|Patients will take 3-gr of L-citrulline/day for 7 days
41277205|NCT02604004|DRUG|Epivir ® tablet 150-mg single dose (drug reference)|Bioequivalence lamivudine 150 mg tablets fasting condition
41277206|NCT02604004|DRUG|Lamivudine 150-mg tablet single dose (drug test)|Bioequivalence lamivudine 150 mg tablets fasting condition
41277207|NCT06257212|DRUG|BCG vaccine (Danish strain 1331)|Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.
41277208|NCT06257212|DRUG|MMR Vaccine|Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.
41448011|NCT03342157|DRUG|senna/docusate|Stimulant laxative
41448012|NCT05999253|PROCEDURE|Modified thoracolumbar plane block (mTLIP)|"Modified thoracolumbar plane block (mTLIP): under ultrasound-guided, the lateral compartment of the longissimus muscle and iliocostal muscle muscles are imagined and the block needle is placed in the interfascial plane of these two muscles and local anesthesic solution is appliced.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia."
41448013|NCT05999253|PROCEDURE|Erector spinae plane block (ESP)|"Erector spinae plane block (ESP): After determining the vertebral spinal process and trapezius, rhomboid major and erector spinae muscles with ultrasound guidance, the block needle is advanced in the cranio-caudal direction with an in plane approach and local anaesthetic solution is applied to the plane between the erector spinae muscle and the transverse process when the needle rests on the transverse process.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia"
40754680|NCT01064284|DRUG|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
40754681|NCT01064284|DRUG|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
41126557|NCT05865561|OTHER|VOC sampling|"* Systematic sampling during the day: Samples every 3 hours (9am, 12pm, 3pm, 6pm, 9pm) until the end of the follow-up period.~* Sampling in case of epileptic seizure : Sampling during the seizure (from t0 to t+5 min), whatever the time.~The samples will be taken using a compress on the forehead, the palms of the hands and the back of the neck. The compress will then be placed in a freezer bag and the person with epilepsy will be asked to exhale into the bag, if he/she is able to do so, before closing it."
41277209|NCT06257212|DRUG|Placebo|Subcutaneous saline + intradermal saline at inclusion and after 3 months.
41277210|NCT06653218|OTHER|No interventions|It is a observational study
41277211|NCT06653218|OTHER|Not have interventions|It is a observational study
41277212|NCT06559501|BEHAVIORAL|Integrated case manager care|comprises 8 sessions delivered by case managers. Case managers will provide up to 6 low-intensity sessions in the hospital or the community (if the patient is discharged before completing the required sessions), with content and duration tailored to patient preferences. Post-discharge, patients will receive 2 follow-up sessions with case managers to ensure a smooth transition into the community.
41277213|NCT06653166|DEVICE|bougie (S Guide)|bougie (S Guide)
41277214|NCT06653166|DEVICE|videolaryngoscopy|videolaryngoscopy hyperangulated or Macintosh
41277215|NCT04592237|DRUG|Cabazitaxel|Given IV
41277216|NCT04592237|DRUG|Carboplatin|Given IV
41277217|NCT04592237|BIOLOGICAL|Cetrelimab|Given IV
41277218|NCT04592237|DRUG|Niraparib|Given PO
40928596|NCT04386915|DRUG|GST-HG141 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
40928597|NCT04386915|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
41126558|NCT05953675|DRUG|Ethanol 70%|Once a week, the catheter will be closed with 3 mL ethanol 70% lock-solution after a completed hemodialysis. The fluid will stay in the catheter until next hemodialysis (ca. 48 hours). The fluid will be aspirated before the hemodialysis. Standard lock-solution of isotonic saline with heparin will be used for the remaining two hemodialysis procedures of the week.
41126559|NCT05953675|DRUG|Isotonic saline with heparin|Standard procedure of isotonic saline used as lock-fluid after completed hemodialysis.
41126560|NCT00589875|BIOLOGICAL|CAN-2409|Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.
41126561|NCT00589875|DRUG|Valacyclovir|Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
41126562|NCT00589875|DRUG|Temozolomide|Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.
41126563|NCT00589875|RADIATION|Radiation therapy|Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.
41126564|NCT03759236|BEHAVIORAL|Health Messaging via SMS|This intervention aims to provide health education on topics including HPV Vaccination, Cervical Cancer screening, contraceptive methods, menstrual problems, diet and exercise geared towards women with children of vaccination age.
41126565|NCT03759236|BEHAVIORAL|CDC Health Pamphlets|This intervention aims to provide health education on the HPV Vaccination to women with children of vaccination age.
41126566|NCT00558506|DRUG|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
41126567|NCT05674149|DEVICE|camera|photographs using multi-spectral camera
41126568|NCT04595461|OTHER|Video Education|Patients receive four short YouTube videos explaining chronic rhinosinusitis and endoscopic sinus surgery
40928598|NCT01022827|OTHER|massage|For the massage group, a physical therapist with 8 years of clinical experience in manual therapy provided the massage on the posterior deltoid, infraspinatus, and teres minor of the involved shoulder for 18 minutes \[about 6 minutes for each muscle and order was random\] two times a week for 4 weeks. The techniques of massage included petrissage for 3 minutes and rolling for 3 minutes of soft tissues
40928599|NCT03888638|PROCEDURE|Hepatectomy|Removal of a part of the liver because of tumor
40928600|NCT01031420|DRUG|single arm dose dense MVAC|standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
40928601|NCT00906971|OTHER|diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage|Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
41126569|NCT04595461|OTHER|Control|Standard patient education with verbal and written education
40928602|NCT03014882|DRUG|L-Carnitine and N-acetyl cysteine|
41126570|NCT02660294|BIOLOGICAL|platlet rich plasma|Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
41126571|NCT03003572|OTHER|Blood samples|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
41448014|NCT04023981|DEVICE|Parafricta bootees|Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
40928603|NCT03786627|OTHER|Combined NMES and motor control|This group will receive the neuromuscular electrical stimulation using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral lumbar multifidus muscles. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total stimulation time is 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. It is believed to restore the motor units in individuals with arthrogenic muscle inhibition. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
40928604|NCT03786627|OTHER|Motor control and placebo NMES|This group will the neuromuscular electrical stimulation without turning the electrical current for 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
40928605|NCT02140476|DEVICE|Bipolar vessel sealing and cutting device|This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
41277219|NCT03885284|DRUG|mFOLFIRINOX|"Chemotherapy will consist of mFOLFIRINOX in 14-day cycles x 12 as used in the PRODIGE 24 study:~* Irinotecan 150 mg/m2 IV day 1~* Oxaliplatin 85 mg/m2 IV day 1~* Leucovorin 400 mg/m2 IV day 1~* 5-fluorouracil 2,400 mg/m2 IV days 1-3 (no bolus)~* Pegfilgrastim 6 mg SC on-body injector day 3 (optional, up to investigator's discretion, can alternatively do day 4 without on-body injector)~* Suggested supportive care medications: fosaprepitant 150 mg IV day 1, dexamethasone 12 mg IV day 1, ondansetron 16 mg IV day 1, dexamethasone 4 mg PO q AM days 2-3, ondansetron 8 mg PO BID days 2-3."
41277220|NCT03885284|RADIATION|Proton beam radiation|Proton beam radiation will consist of 5 daily doses of 5 GyE total, ideally administered Monday through Friday but can be administered within 7 business days, between cycles 6 and 7
41448015|NCT05553444|BEHAVIORAL|Self-management intervention|"The procedure will be based on the A - B - A'/B' design. After recruitment, patients will attend an initial session with CLS where written and oral information about the study will be provided. In this study, the A phase will serve as baseline to establish fluctuation in pain intensity prior to initiating the treatment.~During phase A, patients will be assessed every day for a minimum of 8 days and maximum of 14 days.~During phase B, CLS will facilitate the intervention based on the initial session, pain levels during phase A and the patients' goals. During phase B, patients will attend a 1-hour weekly session over 6 weeks.~During phase A', the participants will be followed weekly for 12 weeks. During the phase A', participants will not receive treatment.~Phase B' contains 3 x 1 hour criterion-based booster sessions which are delivered over 3 consecutive weeks."
41448016|NCT00537095|DRUG|Vandetanib|300 mg oral once daily oral dose
41448017|NCT00537095|OTHER|Placebo|
41448018|NCT03961204|OTHER|Data Collection|No study treatment was administered as part of this study
40928606|NCT02140476|PROCEDURE|Conventional thyroidectomy|Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
40928607|NCT05532670|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
40928608|NCT04371874|DRUG|Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin|The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
40928609|NCT01090895|DRUG|Vitamin C|Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
41448019|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment A|
41448020|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment B|
41448021|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment C|
41448022|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment D|Placebo
41448023|NCT01274988|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
41448024|NCT01274988|OTHER|methadone maintenance treatment|methadone maintenance treatment
40928610|NCT01090895|DRUG|Placebo|Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
40928611|NCT05820737|DIETARY_SUPPLEMENT|EF2001|One capsule to be consumed once a day
40928612|NCT05820737|DIETARY_SUPPLEMENT|beLP1|One capsule to be consumed once a day
40928613|NCT05820737|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed once a day
41277221|NCT06421636|DRUG|REGN7999|Administered subcutaneous (SC)
41277222|NCT06421636|DRUG|Placebo|Administered SC
41448025|NCT04388358|DRUG|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day|All patients were treated with mixed formula of Chinese medicine for one month
41448026|NCT00346190|DRUG|Alendronate|
41448027|NCT00064038|DRUG|dexamethasone|Given orally
41448028|NCT00064038|DRUG|lenalidomide|Given orally
41126572|NCT05986305|BEHAVIORAL|Go Act|Go Act sessions address becoming a parent who can 'Go Act,' caring for one's self as a parent, understanding and managing youth health needs, working with health providers as partners, and working with other service providers such as schools and vocational services. The intervention uses motivational interviewing, story-telling with self-disclosure, psycho-education introduced with a know-want to know-learned strategy, problem-solving, role play, and practice outside of class.
41126573|NCT05986305|BEHAVIORAL|Peer|During Peer sessions facilitators lay ground rules for respectful and confidential sharing and encourage group discussion. The group provides a format to make personal connections through shared identity. Participants may discuss strategies for individualized advocacy, so that they learn from the experiences of others.
41126574|NCT01913691|DRUG|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
41277223|NCT04495660|DEVICE|Near InfraRed Spectroscopy (fNIRS)|Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort
41448029|NCT00064038|OTHER|placebo|Given orally
41126575|NCT01485406|BIOLOGICAL|Pneumococcal vaccine GSK2830930A|1 dose administered intramuscularly
41126576|NCT01485406|BIOLOGICAL|Synflorix™|1 dose administered intramuscularly
41126577|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 50µg|
41126578|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 75µg|
41126579|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 100µg|
41277224|NCT04495660|BEHAVIORAL|Passive perceptual stimulation|Passive perceptual stimulation: For this passive task the child is on his parents' lap in front of a screen. He will see images, hear everyday noises and watch small videos. Duration 8-10 minutes.
41277225|NCT04495660|BEHAVIORAL|Task A not B|Task A not B: the child will play with an adult who will hide an object under a cloth several times. The child will have to find the hidden object. Duration 10 minutes maximum
41277226|NCT04495660|BEHAVIORAL|VSWMT task|VSWMT task: the child will be on the parents' lap in front of a screen and will watch a monkey hiding bananas in the trees several times. Duration of 10 minutes maximum.
41126580|NCT05674669|DRUG|Placebo/Lysergic Acid Diethylamide (LSD) 75µg|
41277227|NCT04495660|BEHAVIORAL|Perceptual Go-No-Go|Perceptual Go-No-Go: This perceptual task consists in the discrimination of images (faces) and sounds (words) through 3 conditions (auditory, visual and visuo-auditory) presented independently of each other and lasts 15 to 20 minutes in total. It is presented by means of a computer
40754682|NCT05414253|DEVICE|Parallel Assignment|Single-centre randomized, parallel design, clinical trial with a 2 week follow-up
41126581|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 50µg/75µg|
41126582|NCT02550951|PROCEDURE|lymphangiography|
41126583|NCT00162344|DRUG|Technetium Tc99m Sestamibi|
41448030|NCT01101620|DRUG|Levosimendan|
41448031|NCT01385163|BEHAVIORAL|Treatment as usual|Standard psychosocial counseling
41448032|NCT01385163|BEHAVIORAL|Voluntary Savings/Loans Assoc|economic intervention for group savings and loans
40928616|NCT04501029|DRUG|Gimatecan|Patients will receive gimatecan orally at the recommended dose level on day 1-5 every 4 weeks.
41126584|NCT00978016|DRUG|arbaclofen placarbil-Cohort 1|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
41126585|NCT00978016|DRUG|Placebo-Cohort 5|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
41448033|NCT01385163|BEHAVIORAL|Cognitive Processing Therapy|group 12 session intervention
41448034|NCT02779400|DEVICE|Self testing INR device|the procedure involves a series of repeated measurements of INR with the studied device
41126586|NCT00978016|DRUG|arbaclofen placarbil-Cohort 2|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
41448035|NCT00499759|BEHAVIORAL|Resting vitals|The fitness assessments will include the assessment of resting vitals including, blood pressure, heart rate, and hemoglobin saturation (pulse oximeter).
41126587|NCT00978016|DRUG|arbaclofen placarbil-Cohort 3|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
41126588|NCT00978016|DRUG|arbaclofen placarbil-Cohort 4|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
41126589|NCT00978016|DRUG|PPI|Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
41126590|NCT00004257|DRUG|fluorouracil|
41126591|NCT00004257|DRUG|oxaliplatin|
41126592|NCT00004257|PROCEDURE|conventional surgery|
41126593|NCT00004257|RADIATION|radiation therapy|
41126594|NCT02097381|DRUG|Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir|"Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day)."
41126595|NCT02421185|DRUG|JNJ-42756493 (erdafitinib)|"Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.~Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1."
41126596|NCT05087758|OTHER|Matrion|Decellularized placental membrane applied to Wagner 1 and 2 diabetic foot ulcers
41277228|NCT04495660|BEHAVIORAL|Verbal memory task|Verbal memory task :the child will be presented with 5 lists of 5 words which he will have to restore after a predefined delay of a few seconds. Its duration does not exceed 10 minutes.
41277229|NCT04495660|BEHAVIORAL|The sensory room|The sensory room: the child will sit in the middle of a carpet and play with the adult. He will hear everyday noises and see light effects. Duration 8-10 minutes
41277230|NCT05794139|DRUG|NMD670|Tablets
41277231|NCT05794139|DRUG|Placebo|Tablets
41277232|NCT03246074|DRUG|Fostamatinib 100 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 100 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
41126597|NCT05087758|OTHER|Conventional Care Wound Management|Advanced wound care with debridement and dressings
41126598|NCT03287713|DRUG|oxygen therapy|conventional nasal prongs vs nasal high flow oxygen during Pulmonary Rehabilitation in Interstitial Lung Disease.
41277233|NCT03246074|DRUG|Fostamatinib 150 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 150 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
41277234|NCT03246074|DRUG|Fostamatinib 200 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 200 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
41277235|NCT01059149|DEVICE|repetitive transcranial magnetic stimulation|MagPro x100 (MagVenture A/S, DANEMARK)
41277236|NCT00577590|DRUG|Metformin|Metformin is taken alone
41126599|NCT05766540|DRUG|Aripiprazole 10 MG|Aripiprazole hroup will receive Aripiprazole 10 mg/day along with Clozapine and Metformin
41277237|NCT00577590|DRUG|Rosiglitazone|Rosiglitizone is taken with Metformin
41277238|NCT00577590|DRUG|Lovaza|Lovaza is taken with Metformin
41277239|NCT04649385|DRUG|BGB-15025|Administered orally once or twice daily (QD or BID)
41277240|NCT04649385|DRUG|Tislelizumab|Administered 200 mg intravenous (IV) infusion
41277241|NCT04197713|DRUG|Adavosertib|Given PO
41277242|NCT04197713|DRUG|Olaparib|Given PO
41277243|NCT02504905|DEVICE|TMS|single TMS pulses at intensities in random order from 0 to 100% (increasing at 5% intervals) of stimulator output at a frequency of 0.1 Hz. Three pulses will be delivered at each intensity. MEPs will be recorded and their amplitudes will be plotted against the corresponding stimulation intensity. This curve will provide three significant parameters: (a) S50 intensity (intensity for which we get a MEP 50 % of its maximal size); (b) estimated resting motor threshold (RMT): the abscissa where the tangent to the slope crosses the x axis; and (c) the maximum MEP ( plateau value).
41126600|NCT01900249|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
41126601|NCT01900249|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
41126602|NCT01900249|DRUG|Placebo|Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
41126603|NCT03903692|DEVICE|Marine polysaccharide dressing|The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.
41126604|NCT03903692|DEVICE|Carboxymethylcellulose dressing|The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
41277244|NCT03391869|BIOLOGICAL|Ipilimumab|Given IV
41277245|NCT03391869|PROCEDURE|Local Consolidation Therapy|Undergo radiation and/or surgery
41277246|NCT03391869|BIOLOGICAL|Nivolumab|Given IV
41277247|NCT03391869|OTHER|Quality-of-Life Assessment|Ancillary studies
41277248|NCT03391869|RADIATION|Radiation Therapy|Undergo radiation
41277249|NCT03391869|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41277250|NCT03804151|BEHAVIORAL|FitSpirit intervention|The study evaluates the effects of the FitSpirit intervention on divers health markers of adolescents. Participants freely register to the intervention via their school. Physical activities and event are organized by the schools with the help of the FitSpirit organization.
41277251|NCT03431220|DEVICE|RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device|NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.
41277252|NCT06011486|COMBINATION_PRODUCT|Lymphocyte infusion (ImmuneCellVir-I)|Infusion of donor CMV specific cells into patients eligible to the trial
41277253|NCT06656767|OTHER|No intervention|This study utilises pre-collected samples only.
41448036|NCT00499759|BEHAVIORAL|Body Composition|Body composition and body circumference measurements (anthropometry) will be the only assessments performed multiple times during the study to monitor possible changes in the body composition and swelling of the patients. Body composition analyses will be performed via skinfold measurements following generalized three-site skinfold equations for male and females as recommended by the ACSM, 2005 and via the utilization of a bioelectrical impedance body fat analyzer device.
40928617|NCT03869268|DRUG|Aspirin|Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
40928618|NCT03869268|DRUG|Ticagrelor|Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
40928619|NCT05551442|PROCEDURE|To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.|The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.
41126605|NCT04063514|OTHER|Focused Ultrasound|With focused ultrasound, there is an expected accentuation of local perfusion and potential temporary opening of the blood brain barrier with the aim is to provide better delivery of therapeutic agents including medication, particulates and cellular elements for treatment of neoplastic, inflammatory and degenerative brain diseases. The present study seeks to investigate differences in perfusion between areas treated and untreated by this modality in order to further explore its use in clinical application for the treatment of brain disease.
41126606|NCT00676091|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
41126607|NCT00676091|BIOLOGICAL|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
41126608|NCT02182479|DRUG|Berodual® via Respimat®, high dose|
41126609|NCT02182479|DRUG|Berodual® via Respimat®, low dose|
41126610|NCT02182479|DRUG|Berodual® via MDI, high dose|
41126611|NCT02182479|DRUG|Placebo Respimat®|
41126612|NCT02182479|DRUG|Placebo MDI|
41126613|NCT06209684|PROCEDURE|Titanium|Spinal stabilization using titanium screws and rods
41126614|NCT06209684|PROCEDURE|Carbofix|Spinal stabilization using CarboFix screws and rods
41126615|NCT00039234|BIOLOGICAL|aldesleukin|
41126616|NCT00039234|DRUG|histamine dihydrochloride|
41126617|NCT05927220|DIAGNOSTIC_TEST|Biopsy Specimens Histopathology|paraffin-embedded blocks with sections from the tumor will be selected. Patterns of invasion will be recorded by for all cases by histopathologists
41448037|NCT00499759|BEHAVIORAL|Timed Get-up and Go test (TGUG).|"The functional mobility of the subjects that will participate in the study will be assessed through the Timed Get-up and Go test (TGUG). The administration of the TGUG includes measuring a distance of 3 meters from the legs of a straight-backed armchair with a seat height of approximately 46 centimeters. The subject will be asked to sit with the back against the chair with the arms on the arm rests. When instructed to begin the test (on the command Go), the subject will have to stand upright then walk at a normal walking pace toward the 3 meters mark placed on the ground, turn around, return to the chair, and sit down. The stopwatch was started on the word Go and stopped when the subject gets back to starting position."
41448038|NCT00499759|BEHAVIORAL|Cardiorespiratory assessment|The cardiorespiratory assessment will be performed on a recumbent cycle ergometer. Subjects will be asked to cycle at a target submaximal intensity of 60 % of their percentage of heart rate range until a RPE (Rate of Perceived Exertion) of 7 is reached on the modified Borg Scale or when the subject requests termination. The Borg modified RPE scale is a scale ranging from 0 to 11 where 0 means no exertion at all and 11 equals to an exertion of absolute maximum. The total time cycling and heart rate (HR) at the end of the test will be recorded immediately after the test is completed.
40928620|NCT05551442|DEVICE|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
40928621|NCT04121351|OTHER|Singing participation|Participants will follow a 15 minute protocol consisting of the components of a Singing for Lung Health class, and a short period walking on a treadmill.
41126618|NCT00961831|DRUG|F-18 (BAY85-8050)|Cancer patients, injection of BAY 85-8050, PET/CT
41126619|NCT00961831|DRUG|F-18 (BAY85-8050)|Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
41126620|NCT00446459|DRUG|mycophenolate mofetil (CellCept)|500mg - 1,000mg, taken PO, twice daily.
41126621|NCT02993094|DRUG|Ixazomib|Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
41126622|NCT02993094|DRUG|Carboplatin|Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
41277254|NCT06656455|DRUG|sevoflurane via LMA|In Group S, co-induction is used whereby the patient continues to receive 8% sevoflurane through the facemask followed after IV insertion by propofol 2mg/kg and fentanyl 1mic/kg administration. Thirty seconds afterwards, an age-appropriate LMA will be inserted. Sevoflurane is maintained initially at a concentration of 2%. The ventilation at first is assisted manually until the child starts breathing. If movement requires interruption of the exam, a bolus of propofol 1mg/kg is given and sevoflurane is increased by 1% until a maximal sevoflurane concentration of 4%. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, sevoflurane will be turned off until the proper airway intervention is taken to achieve saturation above 95% and sevoflurane will be resumed at a concentration decreased by 1%.
40754683|NCT03543020|RADIATION|radiation therapy to brain|OSL placed over the scalp for initial 5 fractions for patients undergoing partial/ whole brain radiation therapy
41126623|NCT01932632|OTHER|Medication Minimization|Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
40928622|NCT06001411|BEHAVIORAL|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
40928623|NCT06001411|BEHAVIORAL|control group|Patients in the control group (C group) received standard perioperative care without any prone position training.
40754684|NCT03981198|DEVICE|Soliton Rapid Acoustic Pulse (RAP)|Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.
40754685|NCT00534586|DRUG|Propofol|TCI 0.5 mcg/ml 1.0 mcg/ml
40928624|NCT03614975|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
41126624|NCT06124768|PROCEDURE|Percutaneous mechanical thrombectomy (PMT) by the modified approach|The modified approach includes the ipsilateral calf venous access and the contralateral femoral venous access. Through contralateral femoral venous access, a hydrophilic guide wire and a catheter will be crossover through the thrombus side to the distal calf vein. The ipsilateral calf venous access will be punctured under the guidance of ascending venography. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
41126625|NCT06124768|PROCEDURE|Percutaneous mechanical thrombectomy (PMT) by the traditional approach|The traditional approach will be punctured from the ipsilateral popliteal vein under ultrasound guidance. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
41126626|NCT04524247|DEVICE|Physician Modified Endografts|"Modification procedure Description of modified device is detailed in Section 3.5 of IDE. In summary, the steps involved in modification of the Zenith Alpha thoracic stent grafts are;~1. Unsheathing of the stent graft~2. Retrieval of a trigger wire from the inner cannula of the delivery system~3. Rerouting of the trigger wire along the stent graft~4. Removal of proximal barbs.~5. Creation of fenestrations and/or branch cuffs~6. Placement of radiopaque markers around the fenestrations/ branch cuffs~7. Placement of temporary and/or permanent diameter constraining ties~8. (Optional) Placement of preloaded wires through the fenestrations/branch cuffs"
41126627|NCT00976495|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
41126628|NCT00976495|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
41126629|NCT00976495|DRUG|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
40754686|NCT00534586|DRUG|Remifentanil|continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
40754687|NCT00534586|DRUG|S-Ketamine|continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
40754688|NCT00534586|DRUG|Sevoflurane|via face mask 0.40 Vol% 0.80 Vol%
40928625|NCT03614975|BIOLOGICAL|Fluzone inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
40928626|NCT03211806|BEHAVIORAL|Sedentary Behavior|Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor
40928627|NCT03211806|DEVICE|Bluetooth-enabled activity monitor|Monitoring activity using a Bluetooth-enabled activity monitor
40928628|NCT05612412|OTHER|Morning Exercise|Standardized treadmill exercise session starting at approximately 0700
40928629|NCT05612412|OTHER|Evening Exercise|Standardized treadmill exercise session starting at approximately 1800
40928630|NCT00828438|DRUG|Lorcaserin 10mg|
41126630|NCT06455683|PROCEDURE|Glaucoma Surgery|"One of 5 Types of Interventions will be performed~1. Trans-trabecular meshwork surgery with or without an implant~2. Trans-scleral surgery with or without implant~3. Ciliary Body Treatment~4. Suprachoroidal surgery with or without implant~5. External Non Incisional Treatment"
41126631|NCT00485459|DRUG|Atomoxetine Hydrochloride|
41126632|NCT00485459|DRUG|Placebo|
41126633|NCT00530569|PROCEDURE|Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.
41277255|NCT06656455|DRUG|Propofol with oxygen via simple mask|"In group P, the sevoflurane will be discontinued, and propofol 1 mg/kg and fentanyl 1µg/kg will be administered IV. Propofol pump is maintained initially at a rate of 200mic/kg/min. with oxygen at 3 liters/min via facemask.~If movement requires interruption of the exam, a bolus of propofol 1mglkg is given and the infusion rate is increased by 20mic/kg/min up to a maximal rate of 350mic/kg/min. The total number of boluses needed will be recorded as the need for additional sedation. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, the infusion pump will be stopped until the proper airway intervention is taken to achieve saturation above 95% with spontaneous breathing. Afterwards, the propofol pump will be resumed at a rate decreased by 20mic/kg/min."
41277256|NCT02978222|BIOLOGICAL|FRα peptide plus Adjuvant (GM-CSF)|Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
40928631|NCT06082401|DEVICE|hemodiafiltration (HDF)|Hemodiafiltration (HDF) is a variation of conventional HD. By the addition of a substitution solution, convection forces are significantly increased. This substitution solution is added to the blood and is completely removed again in the dialyzer. This increases the negative pressure on the dialysate side and the removal of toxins through convection. The substitution solution can be added in a pre-dilution (before the dialyzer) or post-dilution (after the dialyzer) manner. Pre-dilution is associated with longer run times, less filter clotting, but is also less effective in removing toxins. Post-dilution offers a better toxin clearance capacity, but is associated with an increased risk of filter clotting. Several studies have shown that HDF provides higher clearance rates for both small and middle molecule solutes. Moreover, effective cytokine removal has been shown in HDF both in acute and chronic renal disease patients.
41126634|NCT06517641|DRUG|Haploidentical donor bone marrow transplant|"Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1. HSCT: Eligible patients will receive a haploidentical donor bone marrow transplant."
41126635|NCT06517641|DRUG|Unrelated donor bone marrow transplant|"Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1. HSCT: Eligible patients will receive an unrelated donor bone marrow transplant."
41126636|NCT00000777|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
41448039|NCT00499759|BEHAVIORAL|Handgrip evaluation|Handgrip strength will be tested using a handgrip dynamometer. Subjects will be asked to stand and hold the handgrip dynamometer in one hand lined with the forearm that will be placed beside the body. Maximum grip strength is then determined without swinging the arm and by squeezing the handgrip dynamometer as hard as possible using one brief maximal contraction with no extraneous body movement. The test will be administered three times for each hand with a one-minute rest in between trials. The best score within the three trials for each arm will be the one that will be used for analysis.
41448040|NCT00499759|BEHAVIORAL|Dynamic muscular endurance|Subjects will be asked to squat to a 75 degree knee angle with moderate speed, pressing back against the ball at all times. This is repeated as many repetitions as it takes for the subject to report an RPE of 7 or wishes to stop. The second test is the biceps curl exercise. The biceps curls exercise test will follow a protocol developed at the Rocky Mountain Cancer Rehabilitation Institute (RMCRI), Greeley, Colorado. The protocol involves the administration of the exercise biceps curls, done with dumbbells. Subjects will be asked to perform as many repetitions as possible during an alternated biceps curl exercise using a percentage of their body weight as resistance.
41126637|NCT03272087|DEVICE|Thoracoscopy|50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
41126638|NCT03272087|DEVICE|VATS (thoracoscopy)|50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
41126639|NCT00121849|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
41126640|NCT03822520|DRUG|Celecoxib|Celecoxib 400mg capsule
41126641|NCT03822520|DRUG|Moxifloxacin|Moxifloxacin 400mg tablet
41126642|NCT03822520|OTHER|Water|Pure water 150ml
41126643|NCT03882450|PROCEDURE|Flexible fiberoptic laryngoscopy|Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.
41126644|NCT03882450|PROCEDURE|Laryngeal ultrasonography|Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.
41126645|NCT03389919|BIOLOGICAL|MSC administration (intraosseal)|MSCs will be administered under local anesthesia to the iliac crests after receiving informed consent from the patient.
41277257|NCT02978222|DRUG|Adjuvant (GM-CSF) Alone|Intradermal injection 125 μg GM-CSF
41448041|NCT04888338|OTHER|Data Capture|Treatment related data is collected
41448042|NCT04888338|OTHER|Electronic Medical Record|Medical records are reviewed
41448043|NCT00343213|PROCEDURE|colposcopy|
41126646|NCT04225507|BEHAVIORAL|Diet and exercise coaching|All participants will receive diet and exercise goals and coaching.
41126647|NCT04225507|OTHER|CPAP Treatment|CPAP treatment for sleep apnea and CPAP education and adherence coaching.
41126648|NCT03741049|DEVICE|Scalpel Bougie technique (plastic laryngeal model)|ScalpelBougie Set
41277258|NCT06656182|OTHER|Cervical and Thoracic SNAGs|cervical SNAGs (C3-C7) and thoracic SNAGs (T1-T12) with 6 repetitions of 1 set three times per week for 4 weeks along with scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
41277259|NCT06656182|OTHER|traditional physical therapy and scapular mobilizations|scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
41448044|NCT04640129|DRUG|PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate|Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy
41448045|NCT04640129|DRUG|Tenofovir Disoproxil Fumarate|TDF monotherapy
41448046|NCT04352205|DRUG|Bortezomib|Given SC
41448047|NCT04352205|BIOLOGICAL|Daratumumab|Given IV
41448048|NCT04352205|DRUG|Dexamethasone|Given PO and IV
41448049|NCT04352205|DRUG|Lenalidomide|Given PO
41448050|NCT04352205|DRUG|Thalidomide|Given PO
41126649|NCT03741049|DEVICE|Seldinger technique (plastic laryngeal model)|Melker Set
41126650|NCT03741049|DEVICE|Surgical technique (plastic laryngeal model)|Scalpel and speculum
41126651|NCT03741049|DEVICE|Scalpel Bougie technique (porcine laryngeal model)|ScalpelCric Set
41126652|NCT03741049|DEVICE|Surgical technique (porcine laryngeal model)|Scalpel and speculum
40928632|NCT06082401|DEVICE|Ex vivo lung perfusion (EVLP)|"Lung transplantation has become a standard treatment for patients suffering from end-stage lung diseases. One of the major obstacles in the modern transplant era is the fact that the need for organs by far exceeds availability. This leads to growing waiting lists with mortality rates ranging between 10-30%. On the other hand, up to 80% of offered lungs from brain dead donors are rejected because they do not meet predefined donor selection criteria.~Recently, ex vivo lung perfusion (EVLP) has become available as a tool to expand the donor pool. Based on experimental work by Stig Steen, the Toronto lung transplant group developed an EVLP system with the purpose to evaluate lungs with uncertain quality. Consequently, Aigner et al. have expanded the indications for EVLP by showing that primarily unacceptable donor lungs can be reconditioned and then become suitable for transplantation. This concept of organ repair by EVLP has recently been highlighted by a number of publications."
40928633|NCT04503915|PROCEDURE|different estrogen supplementation modes|The different estrogen supplementation modes are randomized into two groups.
40928634|NCT01138878|OTHER|Questionnaire|Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
40928635|NCT01138878|OTHER|Focus Group Discussion|FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
40928636|NCT01138878|OTHER|HIV test (serum or salivary)|An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
40928637|NCT01138878|OTHER|Semi-structured telephone interview|Telephone interview administered to patients offered an HIV test during the pilot period
40928638|NCT02264873|DRUG|Decitabine|Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
40928639|NCT03894176|OTHER|Plasma PTX3 concentration|Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI
40928640|NCT04703101|DRUG|Capecitabine|Given IV
41448051|NCT03806257|OTHER|Enhanced Physical Therapy Protocol|A structured physical therapy protocol that requires subject to ambulate more frequently than the standard-of-care patient.
41448052|NCT06063460|DIAGNOSTIC_TEST|Periodontal examination|Periodontal Examination Routine In routine periodontal examination, measurements of plaque score, gingival score, pocket depths, and attachment loss will be utilized.
41448053|NCT06063460|OTHER|baseline questionnaire about sociodemographic characteristics, smoking habits, oral hygiene habits, halitosis, smell and taste perception|"Each patient participating in the study will complete a questionnaire detailing their age, gender, height, weight, smoking status, frequency of dental brushing, diabetes status, total annual household income, and Covid-19 history. In addition, a visual analogue scale and self-reported periodontal status questionnaire will be completed.~Personal Periodontal Condition Questionnaire This questionnaire comprises of eight questions regarding the participants' periodontal condition.~Graphical Analog Scale Patients were asked to rate their perception of taste, smell, and bad breath between 0 and 100 on this scale. Sense of smell (0-I cannot smell at all, 100-I can smell perfectly), sense of taste (0-I cannot taste at all, 100-I can smell perfectly), mouth. The odor will be graded from 0 (no bad breath) to 100 (extremely awful breath)."
41448054|NCT06063460|OTHER|phase I periodontal treatment|Phase I periodontal treatment will be applied by same expert.
40928641|NCT04703101|DRUG|Fluorouracil|Given IV
41448055|NCT06063460|OTHER|1. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 1st month, filling the questionnaire about halitosis, smell and taste perception.
40928642|NCT04703101|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41126653|NCT02035605|DRUG|ALN-AT3SC|Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
41126654|NCT02035605|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
41126655|NCT04761016|OTHER|Usual Care|The current I-POP health model includes: 1) BSW HWC primary care medical home (for uninsured or Medicare patients), 2)BSW HWC providing diabetes prevention, nutrition education, weight loss, farm stands, physical activity programming (in collaboration with its onsite City of Dallas Park and Recreation Center), 3) BSW HWC programming at community sites in 75210, 4) Referrals to Parkland Hatcher Station clinic that provides health care to Medicaid patients, 5) Referrals between Parkland Hatcher Station and BSW HWC programming, 6) Community improvement in collaboration with Frazier Revitalization Inc. Individuals will have access to resources within our current, ongoing I-POP Health model, but without CHW navigation between BSW HWC and local service providers. Participants will complete follow-up visits for collection of study measures with study personnel at 6- and 10- months. At the end of the 10-month follow-up period, participants receive an assigned CHW and CHW-navigation.
41448056|NCT06063460|OTHER|3. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 3rd month, filling the questionnaire about halitosis, smell and taste perception.
41448057|NCT03807180|OTHER|Tai Chi (exercise)|Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
41448058|NCT05068284|DRUG|ABBV-154|Intravenous (IV) Infusion; Subcutaneous Injection
41448059|NCT05068284|DRUG|Placebo|Intravenous (IV) infusion; Subcutaneous Injection
41448060|NCT05068284|DRUG|ABBV-154|Subcutaneous Injection
41448061|NCT05068284|DRUG|Placebo|Subcutaneous Injection
41448062|NCT06000085|PROCEDURE|restoration of proximal cavities of primary molars with flowable giomer|removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x
41448063|NCT06000085|PROCEDURE|restoration of proximal cavities of primary molars with highly viscous glass ionomer cement|removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte
40928643|NCT04703101|DRUG|Leucovorin|Given IV
40928644|NCT04703101|DRUG|Oxaliplatin|Given IV
40928645|NCT04703101|OTHER|Quality-of-Life Assessment|Ancillary studies
40928646|NCT04703101|BEHAVIORAL|Surveillance|Undergo NOM
41448064|NCT06336993|DRUG|herbal compound|patients were instructed to take the herbal compound twice a day for 3 weeks, 200 to 300ml each time, composition of herbal compound of BSTL was BaiShao 9g, ChuanNiuXi 15g, DanShen 15g, DiLong 9g, DuHuo 9g, DuZhong 15g, GouJi 15g, QinJiao 9g, SangJiSheng 15g, XiXianCao 9g, XuChangQin 9g and YanHuSuo 9g, and herbs were provided by the Traditional Chinese Medicine pharmacy of Tongde Hospital in Zhejiang Province.
40754689|NCT03903770|DEVICE|Upper extremity rehabilitation|Participants receive the SUPER intervention 3 times per week for 1 hr, during 4 weeks. For participants with a low recovery potential for hand function, the SUPER interventions consists in robot-assisted reaching movements and unilateral and bilateral VR activities. The robot-assisted activity consists of a reaching task to six targets placed at maximal reach distance. For the VR activity, we use a reach and grasp VR activity based on a shopping task. Participants with good potential for hand recovery also receive 30 min of electromyography-triggered muscle stimulation, combined with the VR activity. The muscle stimulation is triggered when the participant attempts to grasp a virtual object and helps with hand opening movements.
41126656|NCT04761016|OTHER|I-POP + CHW navigation|Individuals randomized to this condition will be paired with a CHW to assist with navigation of I-POP Health resources at BSW HWC and entities in local zip codes. CHW navigation will occur through monthly one-on-one follow-up visits for a period of 10-months. Participants will complete study visits for collection of data measures at baseline, 6- and 10- month timepoints. Study participation ends with completion of 10-months data measures.
41126657|NCT00005943|BIOLOGICAL|aldesleukin|
41126658|NCT00005943|BIOLOGICAL|staphylococcal enterotoxin B|
41126659|NCT05938426|DEVICE|ET-101|Patients have training sessions twice a day. Each training session takes about 10\~25 minutes. Cognitive training programs include meditation, cognitive training, and cognitive testing.
41126660|NCT05938426|DEVICE|Sham Device|Sham device has only cognitive function test excluding training programs.
41126661|NCT06499766|OTHER|Biodiversity intervention by inactivated microbial extract|Participants use the lotion including microbial extract on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
41126662|NCT06499766|OTHER|Placebo intervention by colored lotion|Participants use the lotion including safe, non-active coloring ingredient on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
41448065|NCT06336993|DRUG|Celecoxib|Celecoxib (Ouyi Pharmaceutical Co., LTD., H20203296) was used twice a day for 3 weeks, 200mg/ time, to treat NSLBP;
41448066|NCT05073380|BEHAVIORAL|Intervention Group - PRO-ECO Intervention|The PRO-ECO intervention will be tailored to individual sites. Through collection of focus group and baseline data, the intervention will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective interventions outlined in the literature have informed the development of the intervention foundation and potential tailoring.
40754690|NCT06056570|DRUG|dontinurad|dotinurad alone
40754691|NCT06056570|DRUG|dotinurad + allopurinol|dotinurad + allopurinol 300mg
40754692|NCT06056570|DRUG|allopurinol|allopurinol 300 mg alone
40754693|NCT01043029|DRUG|aleglitazar|Aleglitazar 150 mcg po daily for 52 weeks
40754694|NCT01043029|DRUG|pioglitazone|Pioglitazone 45 mg po daily for 52 weeks
40928647|NCT04703101|PROCEDURE|Total Mesorectal Excision|Undergo TME
40928648|NCT02571738|BIOLOGICAL|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
40928649|NCT02571738|OTHER|Control|Standard of Care
40928650|NCT01686802|DRUG|oral morphine|
40928651|NCT01686802|DRUG|Ibuprofen|
40928652|NCT02290431|DRUG|LBH589 (panobinostat)|Panobinostat (PAN) capsules were supplied at dose strengths of 10 mg and 15 mg. and dosed at 20mg during treatment phase 1 (21 days) and treatment phase 2 (42 days)
41126663|NCT04506775|DEVICE|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
40928653|NCT02290431|DRUG|bortezomib|Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) \& treatment phase 2 (42 days).
40928654|NCT02290431|DRUG|dexamethasone|Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days \& treatment phase 2 (42 days)
40928655|NCT05753579|BEHAVIORAL|Spinal Mobilization|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion.
40928656|NCT05753579|BEHAVIORAL|Stabilization Exercise|Diyafragmatik solunum ile kombine edilen, pasif-aktif kas iskelet sistemi ve nöral sistemi aktive eden bir yaklaşımdır. Bu yaklaşımda derin çekirdek kaslar olarak transversus abdominis, multifudus kasları aktive edilmektedir
40928657|NCT04678206|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
40928658|NCT04678206|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
40928659|NCT02108262|BIOLOGICAL|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
40928660|NCT02108262|BIOLOGICAL|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
40928661|NCT06229314|DEVICE|Inspiratory muscle training|In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient\&#39;s current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.
40928662|NCT03603067|PROCEDURE|Ocular surgery|Different ocular surgeries (including vitreoretinal surgery, cataract surgery, anti-glaucoma surgery etc) will be performed in one eye of the patient. In monophthalmic patient group the surgery will be performed in eye with better visual acuity.
40928663|NCT05512468|DRUG|carbon dye|Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
40928664|NCT02785237|DEVICE|Coroflex® ISAR Drug-eluting stent|Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
40928665|NCT02785237|DEVICE|Ultimaster® Drug-eluting stent|Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
40928666|NCT05088239|DRUG|prophylactic antibiotics duration|Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
40928667|NCT01585012|DEVICE|Cervical cap (Focus Touch™ Conception System)|Cervical cap
40928668|NCT02311218|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 and PTA 5289|Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
40928669|NCT02311218|DIETARY_SUPPLEMENT|Placebo|Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
41126664|NCT04506775|PROCEDURE|Radial artery catheterization|Radial artery catheterization is the standard of care for measuring blood pressure continuously throughout surgery.
40928670|NCT05602896|OTHER|Sepsis education|The education program has been reviewed and approved by BJH Center for Practice Excellence
40928671|NCT01535300|PROCEDURE|Ultrasonography of the trachea|Ultrasonographic measurement of the minimal transverse tracheal diameter
40928672|NCT05251129|DRUG|Atorvastatin 80 Mg Oral Tablet|Higher intensity statin
40928673|NCT01761071|DRUG|topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
41126665|NCT00611559|BIOLOGICAL|Infanrix™ penta|Subjects received a booster dose
41126666|NCT00611559|BIOLOGICAL|Infanrix™ hexa|Subjects received a booster dose
41126667|NCT04030533|DRUG|Guselkumab (SC): Dose 1|Participants will receive a single dose of guselkumab (dose 1) subcutaneously.
41126668|NCT04030533|DRUG|Guselkumab (SC): Dose 2|Participants will receive a single dose of guselkumab (dose 2) subcutaneously.
41448067|NCT05073380|BEHAVIORAL|Wait List Group - Normal Daily Practice|ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO intervention.
41448068|NCT02374710|PROCEDURE|ACL Reconstruction: Anterior Tunnel|ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
41126669|NCT04030533|DRUG|Guselkumab (IV): Dose 1|Participants will receive a single IV infusion of guselkumab (dose 1).
41126670|NCT04030533|DRUG|Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2).
41126671|NCT04030533|DRUG|Ustekinumab 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.
41126672|NCT05342246|PROCEDURE|Endodontic retreatment|retreatment of the patent root canal only without attempt to retrieve the separated instrument
41126673|NCT05610787|DEVICE|EXCOR Active Driving System for Pediatric VAD|The EXCOR Active Driving System - will be used with the EXCOR Pediatric VAD.
41126674|NCT03665532|BEHAVIORAL|Youth Engagement in Services|Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
41126675|NCT00277355|DRUG|minocycline|Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)
41126676|NCT00277355|DRUG|Matching placebo|Matching placebo 1 capsule twice daily, 18 months treatment duration.
41126677|NCT02178241|DRUG|Eribulin Mesylate|Given IV
41126678|NCT02178241|DRUG|Gemcitabine Hydrochloride|Given IV
41126679|NCT05778526|BEHAVIORAL|Virtual reality|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session of the Social VR intervention lasts for a maximum of 20 minutes. The intervention contains three real-life virtual scenarios, including (1) a classroom and playground, (2) an MTR station and compartment, and (3) a supermarket and restaurant.
41126680|NCT05778526|BEHAVIORAL|Traditional social skills training|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session lasts for a maximum of 20 minutes. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise.
41448069|NCT02374710|PROCEDURE|ACL Reconstruction: Posterior Tunnel|ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
41448070|NCT05356091|DRUG|Sevoflurane|Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.
41448071|NCT05356091|DRUG|Remimazolam|Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
41126681|NCT00000936|DRUG|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
41126682|NCT00000936|DRUG|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
41126683|NCT00000936|DRUG|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
41126684|NCT00808405|DRUG|acyclovir|400mg taken orally three times daily for 5 days
41448072|NCT04570748|PROCEDURE|Capsule repair|Direct anterior hip arthroplasty with or without capsule repair
41448073|NCT04570748|PROCEDURE|capsulectomy|capsulectomy without repair
41448074|NCT01222234|DRUG|Cholecalciferol - CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
41126685|NCT00808405|DRUG|matching placebo|matching placebo taken orally three times daily for 5 days.
41126686|NCT00735852|DRUG|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
41126687|NCT05598554|OTHER|Telerehabilitation|Chair-based yoga with telerehabilitation was applied to the study group for 45 minutes a day, 2 days a week, for 6 weeks.
41126688|NCT05598554|OTHER|information|A one-session training was provided on the effects of exercise on quality of life.
41126689|NCT04340479|DIAGNOSTIC_TEST|Ultrasound lung imaging as part of FAST+ evaluation|"FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:~1. Anterior midclavicular right and left (apical, medial, basal)~2. Posterior paraspinal right and left\* (apical, medial, basal)~   \*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.~3. Lateral axillary medial right and left (apical and basal)~Specifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings."
41448075|NCT01222234|DEVICE|Calcitriol - CKD|Calcitriol 0.25 mcg once daily for 8 weeks
41448076|NCT01222234|DRUG|Cholecalciferol - non-CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
41448077|NCT06391450|DRUG|Empagliflozin 10 MG|Oral
41448078|NCT06391450|DRUG|Placebo|Oral
41448079|NCT06557954|DIAGNOSTIC_TEST|human PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m)|PAX1m/JAM3m, with or without HPV testing and cytological pathology for cervical cancer screening
41448080|NCT03867890|OTHER|no intervention|
41448081|NCT05853445|OTHER|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
41448082|NCT06623162|DRUG|gemcitabine + cisplatine|4 cycles
40928674|NCT01761071|DRUG|topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
40928675|NCT04531631|DRUG|Dorzagliatin|tablet
40928676|NCT04531631|DRUG|placebo|placebo
40928677|NCT03794882|COMBINATION_PRODUCT|Quadratus Lumborum Block|30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.
40928678|NCT03794882|PROCEDURE|Standard Medical Management|Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
40928679|NCT02220998|DRUG|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
40928680|NCT02220998|DRUG|SOF|SOF 400 mg tablet administered orally once daily
41126690|NCT02919449|BIOLOGICAL|MV-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
41126691|NCT02919449|BIOLOGICAL|Atezolizumab|Atezolizumab will be administered every 3 weeks
41126692|NCT05736133|OTHER|Physiotherapist-led primary care model for hip and knee pain|"1. Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~2. Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~3. Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management or presented with group exercise options. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations such as comorbidity or frailty. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral. All individuals may have their medications reviewed by a physician if deemed appropriate by the PT or requested by the participant."
41126693|NCT05736133|OTHER|Usual physician-led primary care model for hip and knee pain|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
41448083|NCT04486066|BEHAVIORAL|Mindfulness-Based Stress Reduction|In MBSR, participants meet by video for 2 hours per week for 8 weeks in a group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
40928681|NCT02220998|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
41126694|NCT00862043|DRUG|Sildenafil Citrate|40 mg t.i.d.
41126695|NCT00862043|DRUG|Placebo|Placebo t.i.d.
41126696|NCT00000958|BIOLOGICAL|MTP-PE/MF59|
41126697|NCT00000958|BIOLOGICAL|Env 2-3|
41126698|NCT05101954|PROCEDURE|Concentrated Growth Factors (CGF)|Concentrated Growth Factors membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
41126699|NCT05101954|PROCEDURE|Platelet-Rich Fibrin (PRF)|Platelet-Rich Fibrin (PRF) membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
41126700|NCT05100784|BIOLOGICAL|HSSA test|Human Sperm Survival Assay testing performed on different batches of different types of IVF consumables. In practice, 3 consumables from the same batch will be tested with 3 different sperms to ensure the repeatability of the result / test.
41126701|NCT03801148|DRUG|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
40754695|NCT02166762|PROCEDURE|QLV interval measurement|Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
40754696|NCT01091415|PROCEDURE|calcium phosphate bone cement injection|volar locking plate alone versus calcium phosphate bone cement as well as volar locking plate
40928682|NCT01551940|DRUG|Botox injection|Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
40928683|NCT01551940|DRUG|Placebo injection|A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
40928684|NCT01246154|OTHER|EXERCISE TRAINING|EXERCISE TRAINING
40928685|NCT05726877|OTHER|ventilation strategy|Titrating positive end-expiratory pressure
41126702|NCT03801148|DRUG|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
41126703|NCT03801148|DRUG|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
40928686|NCT04612023|OTHER|Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)|Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
41126704|NCT03801148|DRUG|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
41126705|NCT03594500|OTHER|PockeTalker|The intervention group will receive PockeTalkers (hearing assistance devices) while they receive care in the ED
41126706|NCT03594500|OTHER|No PockeTalker|The control group will not receive PockeTalkers while they receive care in the ED
41126707|NCT01189149|PROCEDURE|IV fluids|Infants will be allocated to IV fluids
41126708|NCT01189149|PROCEDURE|Naso/oro gastric tube feedings|Infants will be allocated to naso/oro gastric tube feedings
41448084|NCT04486066|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 video sessions in a group format, while retaining all essential elements.
40928687|NCT05441332|OTHER|EOS Radiation|One EOS exam of lower extremities
41126709|NCT03609008|DRUG|Levcromakalim|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
41126710|NCT03609008|DRUG|Saline|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
41126711|NCT02520349|DEVICE|MarkTen and e-Go e-cigarettes|
41126712|NCT04318834|OTHER|Tumour and germline molecular profiling|Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing
41126713|NCT03002259|DRUG|Dexamethasone|Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
41126714|NCT01198366|BIOLOGICAL|AERAS-402 1.5 x 10^10 vp|
41277262|NCT06656598|DRUG|Carboplatin|Neoadjuvant treatment with Carboplatin AUC 5 D1 (3 cycles of 4 weeks).
40928688|NCT05441332|BEHAVIORAL|Semi-structured interview|Semi-structured interview to identify factors influencing patient adherence behavior for a sub-group of 15 patients. By phone, between 1 to 3 months after inclusion.
41126715|NCT01198366|BIOLOGICAL|AERAS-402 3.0 x 10^10 vp|
41126716|NCT01198366|BIOLOGICAL|AERAS-402 1.0 x 10^11 vp|
41126717|NCT01198366|BIOLOGICAL|Placebo|
41126718|NCT00350792|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles
41126719|NCT00350792|DRUG|carboplatin|Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
41126720|NCT04646733|OTHER|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet. This diet has 4 phases, two of weight loss until reaching the ideal weight (attack and cruise) and two of maintenance (consolidation and stabilization). During the first 2 phases, it allows 100 foods (28 vegetables). The first phase lasts 3-10 days and 72 high-protein, low-fat foods are allowed. In the second phase, there are alternate days between consuming the low glycemic index vegetables plus protein and the next day with just protein. The first two phases are ad libitum. Phase 3 (consolidation) aims to avoid rebound and begins the introduction of complex carbohydrates and legumes in individual servings. In phase 4 (stabilization), the subject returns to a free diet. However, three basic rules are introduced: protein one day a week, the exercise of at least 20 min/day (optional) and consumption of 3 tablespoons of oat bran/day.
41277263|NCT06656598|DRUG|Paclitaxel|Neoadjuvant treatment with Paclitaxel 80mg/m² D1 (3 cycles of 4 weeks).
41448085|NCT04486066|OTHER|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
40754697|NCT03270241|DEVICE|Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet|This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for Vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with Vitiligo and normal skin in healthy participants.
41448086|NCT05905276|OTHER|ERAS Protocol|The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
41448087|NCT05905276|OTHER|Standard of Care|Patients in the usual care arm of the EMBRACE trial will experience the present-day care pathway of ambulatory TURBT at Johns Hopkins Hospital.
41448088|NCT00736190|DRUG|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
41448089|NCT06513052|OTHER|Commercial cocoa|daily intake of a beverage made with 8 grams of commercial cocoa low in flavanols, dissolved in 200 mL of low-fat, lactose-free milk
41126721|NCT04646733|OTHER|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water. Beverage contained 1.6 g of betaG per portion according to FDA recommendations corresponding to 50 % of betaG required per day. Weekly bags containing oat mixture were provided on day 0 and in the third week of the trial. No additional instructions about diet, exercise program or pharmacological treatment was implemented.
41448090|NCT06513052|OTHER|High flavonols Cocoa|Daily intake of a beverage made with 8 grams of cocoa high in flavanols, dissolved in 200 mL of low-fat, lactose-free milk.
41448091|NCT06404463|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
40754698|NCT00209638|DRUG|irinotecan|
40754699|NCT00209638|DRUG|S-1|
40928689|NCT03396757|PROCEDURE|Standard strategy|"RRT is initiated within 12 hours after documentation of serum urea concentration \>40 mmol/l and/or an oliguria/anuria for more than 72 hours. The timing of its initiation will be recorded and RRT will continue until criteria for cessation are observed. This arm corresponds to the delayed strategy in the published AKIKI trial (NEJM 2016),"
41126722|NCT04503772|PROCEDURE|Preoperative SRS|Patient will be treat with preoperative SRS and then surgery for brain metastases is realized within 3 days.
41126723|NCT04611932|DRUG|CKD-330 Tab. and D090 Tab.|1T
41126724|NCT04611932|DRUG|CKD-333 Tab.|1T
41448092|NCT06404463|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
40928690|NCT03396757|PROCEDURE|Delayed strategy|"RRT will be initiated only if one or more of above-mentioned potentially severe situations occur (identical to those used during the observational study) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). The physician in charge will be allowed to try a medical treatment. Patients will not receive RRT whatever the duration of anuria/oliguria if any above-mentioned indication for RRT is not present. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the no further delayed RRT strategy, with special care to avoid dialysis disequilibrium syndrome (see below).~The decision to initiate RRT in the delayed strategy arm of the trial will have to be approved by the attending physician(s) involved in patient's care in order to make sure that it corresponds to her/his usual practice."
40928691|NCT03989739|DEVICE|Da Vinci|
40928692|NCT02233478|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate Juice alone
41126725|NCT04039906|DEVICE|Removal of needle with using ANDYs|"1. ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~2. Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~   Identify the number of syringes processed by ANDY.~3. After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary."
40928693|NCT02233478|DIETARY_SUPPLEMENT|Soybean Flour Protein|Soybean Flour Protein combined with Pomegranate Juice
40928694|NCT02233478|DIETARY_SUPPLEMENT|Soy Isolate Protein|Soy Isolate Protein combined with Pomegranate Juice
40928695|NCT04779749|OTHER|Data extraction from medical files|Data extraction from medical files
41448093|NCT06404463|DRUG|Doxorubicin|Doxorubicin, a widely used chemotherapy drug, belongs to the anthracycline class and is effective against various cancers, including breast cancer, leukemia, and sarcomas. It works by intercalating with DNA and inhibiting topoisomerase II, leading to DNA damage and disruption of DNA replication and transcription processes within cancer cells. Despite its efficacy, doxorubicin may cause side effects such as cardiotoxicity and bone marrow suppression, limiting its long-term use in some patients.
40754700|NCT00893581|DRUG|Quetiapine & Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
40754701|NCT00893581|DRUG|Lithium and Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
40754702|NCT00893581|OTHER|Healthy Controls|Healthy control (patients given placebo -- sugar pill intended to mimic drug)
40928696|NCT03965273|BEHAVIORAL|Full TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Community and Social Norms Change Component; iv) Facilitated sessions with mothers' groups and (separate) fathers' groups; v) 2-days intensive facilitated workshop with selected religious leaders and influential people; vi) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vii) Trainings of girls, boys and parents with special interest in activism.
41277264|NCT06656598|DRUG|Cemiplimab|Neoadjuvant treatment with Cemiplimab (Libtayo®) 350 mg D1-D21 (3 cycles of 4 weeks).
40754703|NCT04875845|BEHAVIORAL|Fasting for elective surgery|6-hours and 8-hours fasting before elective surgery
40754704|NCT00908687|BIOLOGICAL|A/H5N1|A/H5N1 Low Dose
41277265|NCT06656598|RADIATION|Curative hypofractionated radiotherapy|Curative hypofractionated radiotherapy (55 Gy/20fr) after the end of neoadjuvant treatment.
41277266|NCT06656598|DRUG|Cemiplimab (maintenance)|Maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks after the end of radiotherapy (12 months).
41448094|NCT06404463|DRUG|Cyclophosphamide|Cyclophosphamide is a chemotherapy medication commonly used to treat various types of cancers, including lymphoma, leukemia, and breast cancer. It belongs to the class of alkylating agents and works by crosslinking DNA strands, which prevents cell division and leads to cell death. While effective in treating cancer, cyclophosphamide can also cause side effects such as nausea, vomiting, and suppression of the immune system.
40928697|NCT03965273|BEHAVIORAL|Light TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Facilitated sessions with mothers' groups and (separate) fathers' groups; iv) 2-days intensive facilitated workshop with selected religious leaders and influential people; v) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vi) Trainings of girls, boys and parents with special interest in activism.
40928698|NCT04693143|OTHER|A randomized controlled open-label clinical trial.|This was a single-center; open-label randomized controlled trial performed at a Pediatric Intensive Care Unit (PICU) in tertiary care hospital
40928699|NCT02873585|DEVICE|Stationary intraoral tomosynthesis|Bitewing radiographs using a stationary intraoral tomosynthesis unit
40928700|NCT02873585|DEVICE|Standard conventional bitewing radiography|Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
40928701|NCT01461057|DRUG|Capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
40928702|NCT01461057|DRUG|Cisplatin|80 mg/m2 on Day 1 of each cycle
40928703|NCT01461057|DRUG|Pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
40928704|NCT01461057|DRUG|Pertuzumab|840 mg once every three weeks
40754705|NCT00908687|BIOLOGICAL|A/H5N1|A/H5N1 High Dose
40928705|NCT01461057|DRUG|Trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
40928706|NCT01847807|DRUG|low dose Astragalus|
40928707|NCT01847807|DRUG|high dose astagalus|
41448095|NCT06404463|DRUG|Epirubicin|Epirubicin, a chemotherapy medication, is part of the anthracycline class and is used in the treatment of various cancers, including breast cancer, ovarian cancer, and soft tissue sarcoma. It functions by interfering with DNA replication and RNA synthesis within cancer cells, ultimately leading to cell death. Despite its efficacy, epirubicin can cause side effects such as nausea, hair loss, and bone marrow suppression.
40754706|NCT00908687|BIOLOGICAL|LT Adjuvant Patch|LT Adjuvant Patch Low Dose
40754707|NCT00908687|BIOLOGICAL|LT Adjuvant Patch|LT Adjuvant Patch High Dose
40754708|NCT03622931|DRUG|Standard chemotherapy|Chemotherapy
40754709|NCT03622931|DRUG|Romiplostim|
40754710|NCT03622931|DRUG|Placebos|
40928708|NCT00824070|DRUG|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
40928709|NCT00824070|DRUG|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
40928710|NCT00824070|DRUG|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
40928711|NCT02864485|PROCEDURE|live donor liver transplantation|live donor liver transplantation
40928712|NCT03848156|OTHER|biopsy|Biopsy of nasal polyp for RNA sequencing
40928713|NCT02507960|DEVICE|The Gamma Pod|Immobilization of breast during radiation.
41126726|NCT02316301|DRUG|Long interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
41277267|NCT06656559|DRUG|Envafolimab and Surufatinib|Envafolimab: 150mg, SC, qw Surufatinib: 150mg, p.o., qd
41448096|NCT06528093|DRUG|BI 765883|BI 765883
40928714|NCT02507960|DEVICE|CT simulation|See arm description
40928715|NCT02483533|DRUG|LIPO-202|
40928716|NCT02483533|DRUG|Placebo|
40928717|NCT00002339|DRUG|Fluconazole|
40928718|NCT00869778|BIOLOGICAL|εPA-44|subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
40928719|NCT00869778|OTHER|Placebo|subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
41448097|NCT06528093|DRUG|gemcitabine|gemcitabine
41448098|NCT06528093|DRUG|nab-paclitaxel|nab-paclitaxel
41448099|NCT06502327|OTHER|Instructions A|"Instructions A are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins."
40928720|NCT03862508|OTHER|Plyometric exercises|"Jump Drop Jump, dropping the subject from a height of 30cm and then make a vertical jump.~Long jumps asking the athletes to take momentum and make a leap forward trying to reach the greatest possible distance.~Jump Countermovement jump unilaterally, alternating the lower extremities. Jumps 180º with the athletes maintaining a semi-squat position. Jump Countermovement jump repeatedly starting from an upright position and the upper extremities in both hips.~All the exercises will be done through 8 repetitions per session during the first two weeks, increasing two repetitions every two weeks (until reaching 12 repetitions at the end of the intervention).~For the realization of each one of the exercises, the ballasted weight will be used (Powerinstep® model)."
40928721|NCT00115323|BEHAVIORAL|Problem Solving|Problem solving intervention
40754711|NCT06493071|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.
41448100|NCT06502327|OTHER|Instructions B|"Instructions B are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins."
41448101|NCT06596356|DRUG|[14C] TS-172|Subjects will receive single dose of about 30 mg of TS-172 containing 1 MBq \[14C\]TS-172 as an oral solution
41448102|NCT04699396|PROCEDURE|Mobilisation With Movement 1|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the talus were performed, followed by 3 sets of 10 repetitions of a glide applied to the fibula."
41448103|NCT04699396|PROCEDURE|Mobilisation With Movement 2|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the fibula were performed, followed by 3 sets of 10 repetitions of a glide applied to the talus."
41448104|NCT04699396|OTHER|Placebo|The Placebo group participants performed the same number of sets and repetitions (6 sets of 20 repetitions) of lean/lunge forward into dorsiflexion, without any glide application.
40754712|NCT06493071|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation will target the ear lobe using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Participants will perform 4 hours of stimulation per day for a period of 30 days. Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
40754713|NCT06426381|BEHAVIORAL|Therapeutic Touch|Asymmetric energy fields can be balanced using the therapeutic touch method and treatment becomes easier. In this way, the person regains his health or can be helped to regain his health.
40754714|NCT02285959|DRUG|Bevacizumab|
40754715|NCT05034978|OTHER|no intervention|evaluating the performance of a novel point-of-care test
40754716|NCT05436912|DRUG|Selpercatinib|Administered orally.
40754717|NCT01728961|DRUG|Artemether/Lumefantrine (AL)|
40754718|NCT02520947|DEVICE|BIS|Bispectral index monitoring
40754719|NCT02520947|DRUG|Desflurane|volatile agent for maintenance of anesthesia
40754720|NCT05914649|OTHER|IV normal saline (999 mL infusion)|999 mL of IV normal saline will be infused intravenously
40754721|NCT05914649|OTHER|IV normal saline (50 mL infusion)|50 mL of IV normal saline will be infused intravenously as a placebo control.
40754722|NCT03390400|DEVICE|Femtosecondlaser-assisted|Femtosecondlaser-assisted Cataract Surgery will be performed bilateral on the same day with different laser settings.
40754723|NCT03390400|PROCEDURE|Anterior Capsulotomy|Cataract Surgery
40754724|NCT03390400|PROCEDURE|Lens Fragmentation|Cataract Surgery
40754725|NCT05823883|DRUG|DW6014|"Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition"
40754726|NCT06145594|OTHER|EMA Monitoring|Weekly prompts to participants' smart phones for collection of PHQ-9 data
40754727|NCT06145594|OTHER|Scheduling Maintenance TMS sessions|When threshold score is reached, the participants is offered TMS maintenance treatments
40928722|NCT00115323|BEHAVIORAL|Attention Control|Attention control intervention
40928723|NCT06505408|DIETARY_SUPPLEMENT|Multivitamin|4 capsules of Perelel Health Conception Support Multivitamin Pack (consisting of vitamins, minerals, and omega ingredients) consumed daily for 12 weeks
40928724|NCT06505408|DIETARY_SUPPLEMENT|Placebo|4 placebo capsules consumed daily for 12 weeks
40928725|NCT01699971|PROCEDURE|Hernia repair|Hernia repair admodum Lichtenstein with polypropylene mesh
40928726|NCT01699971|PROCEDURE|Hernia repair|Hernia repair with Ultra Pro Hernia System (UHS)
40928727|NCT01699971|PROCEDURE|Hernia repair|Hernia repair with Prolene Hernia System(PHS)
40928728|NCT01125787|DRUG|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
40928729|NCT05477433|BEHAVIORAL|diabetes mellitus type 1|"Pittsburgh Sleep Quality Index PSQI: It is used to detect sleep disturbance or deficits. The PSQI has a scoring key that can be used to calculate a patient's seven subscores, which range from 0 to 3. The subscores are added together to produce a global score that ranges from 0 to 21. A global score of 5 or higher denotes poor sleep quality, The Strengths and Difﬁculties Questionnaire (SDQ) The SDQ is a well-validated screening tool for children and adolescents aged 4-17 years that can identify behavioural and emotional issues,Emotional Avoidance Strategy Inventory for Adolescents (EASI) is used. The EASI-A is a 17-item assessing the use of emotionally avoidant strategies in adolescents and higher scores means significants use avoidant strategies, The Toronto Alexithymia Scale (TAS-20) is a self-administered 20-item questionnaire which assesses difficulties in identifying and describing emotions. TAS scores were significantly higher in alexithymia"
40928730|NCT00570232|DRUG|Erlotinib|150 mg per day by mouth for 12 months
40928731|NCT02737033|DRUG|Rhodiola|Rhodiola rosea 800mg
40928732|NCT02737033|DRUG|Placebo|innocuous pill manufactured to mimic Rhodiola
40928733|NCT04034797|OTHER|Photography teletransmission|A photography of the trauma is teletransmitted to SAMU's physician
40928734|NCT04034797|OTHER|No photo|Usual management without photography teletransmission
40928735|NCT00241501|DRUG|Esomeprazole (Nexium)|
40928736|NCT03313232|OTHER|ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations
40928737|NCT03313232|OTHER|ROAT with oxidized R-limonene at 1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration
40928738|NCT02761837|BEHAVIORAL|IVR call/text|For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text
40928739|NCT02761837|BEHAVIORAL|Email|Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
40928740|NCT06131671|OTHER|Whole-body electrical stimulation|"The parameters adopted for the treated group will be: symmetrical biphasic current, pulse width of 400 µs, frequency of 80 Hz, contraction time of five seconds and decreasing rest time, varying from 10 to 5 s. The intensity will be individually adjusted to the patient's maximum tolerance limit to produce visible muscle contraction.~The session time will be 15 to 20 minutes and the number of contractions will increase with each week of training.~Concomitant to the electrical stimuli, exercises will be performed for the elbow flexors and extensors, spine flexors and extensors, knee flexors and extensors, hip flexors and extensors and the calf muscles."
40928741|NCT04900064|BEHAVIORAL|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI). The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
40928742|NCT04900064|BEHAVIORAL|Self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering self-help CBT will need four days of reading and two days of training as well as regular supervision to be able to make initial assessments and problem profiling and use the self-help books.
40928743|NCT04465201|DEVICE|Impella CP with Smart Assist (Circulatory Support System)|Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
40928744|NCT00195845|DRUG|Galantamine|
40928745|NCT00195845|DRUG|Placebos|
40928746|NCT02811276|OTHER|Diet|The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.
40928747|NCT04662580|DRUG|ARX517|ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
40928748|NCT03381742|DRUG|Ticagrelor|ticagrelor 45 mg twice daily for 5 consecutive days at least.
40928749|NCT03381742|DRUG|ticagrelor|ticagrelor 90 mg once daily for 5 consecutive days at least.
40928750|NCT03381742|DRUG|ticagrelor|ticagrelor 90 mg twice daily for 5 consecutive days at least.
40928751|NCT03381742|DRUG|clopidogrel|clopidogrel 75 mg once daily for 5 consecutive days at least.
40928752|NCT03878693|DRUG|Fomepizole|IV 4-MP.
40928753|NCT03878693|DRUG|APAP|Oral APAP
40928754|NCT03709576|DRUG|Pevonedistat|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
41448105|NCT03497130|OTHER|skin care regimen|These participants will be asked to apply skin care regimen, the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks.
41448106|NCT02210117|BIOLOGICAL|Bevacizumab|Given IV
41448107|NCT02210117|PROCEDURE|Biopsy|Undergo biopsy
41448108|NCT02210117|BIOLOGICAL|Ipilimumab|Given IV
41448109|NCT02210117|OTHER|Laboratory Biomarker Analysis|Correlative studies
40928755|NCT03709576|PROCEDURE|transplant|Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.
40928756|NCT03709576|DRUG|Azacitidine|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
40928757|NCT06288594|BEHAVIORAL|Application Plus Online Therapist Support Group|Participants in the therapist-supported group will receive weekly 20-30 minute online sessions for five weeks, with content based on a semi-structured manual. After 80% completion of the psychoeducation module, the coping module becomes available, and similarly, the exposure module follows. These sessions will be conducted in adherence to a structured manual, with the therapist introducing the module of the week, guiding through exercises, assigning homework, and reviewing the previous assignments. Sessions include module introductions, exercises, homework assignments, and application use review. Feedback and PCL-5 scores guide post-session recommendations. A random 40% of sessions will undergo fidelity checks by doctoral-level psychologists.
40928758|NCT06288594|BEHAVIORAL|Application Only Group|"Participants allocated to this group will have access to the TraumaRelief mobile application over a five-week period, with the exception of the online module component. The application's deployment strategy ensures a structured progression through its features: participants will gain access to the subsequent modules only after completing 80% of the preceding module. Initially, they will engage with the psychoeducation module; upon completion of at least 80% of this module, the coping with symptoms module will become available. Similarly, successful engagement with 80% of the coping module will unlock the imaginary exposure module. This sequential module access is designed to reinforce the acquisition of knowledge and skills in a stepwise manner, paralleling the structure provided to the TraumaRelief Mobile Application with Therapist Support group, yet without the additional therapist interaction."
40928759|NCT04121624|DEVICE|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the smartphone application and the non-invasive reference method (upper arm cuff).
40928760|NCT05451927|DIETARY_SUPPLEMENT|Phaseolus Vulgaris|Weight loss
40928761|NCT05451927|DIETARY_SUPPLEMENT|Placebo|Placebo
40928762|NCT05950152|DRUG|Meloxicam Injection 30mg|meloxicam injection 30mg every 24 hours for up to 2 dose
40928763|NCT05950152|DRUG|Meloxicam Injection 60mg|meloxicam injection 60mg every 24 hours for up to 2 dose
40928764|NCT05950152|DRUG|Nacl 0.9%|IV Placebo every 24 hours for up to 2 doses
40928765|NCT03288792|DEVICE|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
40928766|NCT03148119|DRUG|QRH-882260 Heptapeptide|topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a 5 amino acid linker \[Gly-Gly-Gly-Ser-Lys\] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
40928767|NCT03148119|DEVICE|Scanning Fiber Endoscope|Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
40928768|NCT04379271|DRUG|IMU-838|"Tablets will be taken BID with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable).~If the patient is intubated for ventilation, IMP is to be given via a gastric tube. The tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube."
40928769|NCT04379271|OTHER|Placebo|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for IMU-838
40928770|NCT03739229|BIOLOGICAL|Placebo|2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
40928771|NCT03739229|BIOLOGICAL|H7N9 LAIV|2 intranasal administrations of H7N9 live influenza vaccine
40928772|NCT04421768|BEHAVIORAL|cervical exam training|Each nurse will then examine 1 sets of 10 high-fidelity silicone task trainers approximately three per week for a maximum of 20 sessions (200 repetitions total). For each set of 10 exams, the estimates will recorded on an answer sheet. A cumulative summation analysis will be performed on each participant. When an individual nurse achieves competence her training will be suspended
40928773|NCT00871507|DRUG|JNJ-38431055 Dose 1|Liquid suspension/solution of JNJ-38431055 administered as a single dose
40928774|NCT00871507|DRUG|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose.
40928775|NCT00871507|DRUG|Placebo|Placebo suspension/solution and Placebo capsule administered as single doses
40928776|NCT00871507|DRUG|JNJ-38431055 Dose 2|Liquid suspension/solution of JNJ-38431055 administered as a single dose
40928777|NCT01728233|DRUG|Dacomitinib|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
40928778|NCT03304444|DRUG|Bupivacaine|bupivacaine hydrochloride used in TAP block
40928779|NCT03304444|DRUG|liposomal bupivacaine|liposomal bupivacaine used in TAP block
40928780|NCT06147375|DRUG|Tacrolimus or Cyclosporine A|The protocol of IS withdrawal:Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks. Week 5-8 medication reduction to taking Tac / CsA 4 times a week . Week 9-12 reduction to taking Tac/ CsA 3 times a week. Week 13-18 reduction to taking Tac / CsA 2 times a week . Week 19-24 reduction to taking Tac/ CsA once per week. Week 25, the recipients will stop taking Tac/ CsA.
40928781|NCT04598399|BEHAVIORAL|Mindfulness Based Relapse Prevention|7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.
41448110|NCT02210117|PROCEDURE|Metastasectomy|Undergo metastasectomy
41448111|NCT02210117|BIOLOGICAL|Nivolumab|Given IV
41448112|NCT02210117|PROCEDURE|Therapeutic Conventional Surgery|Undergo nephrectomy
41448113|NCT01442558|DRUG|Bupivacaine|Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
40928782|NCT04598399|BEHAVIORAL|Relaxation/ meditation|7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants
40928783|NCT03905109|DRUG|ABX464|ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.
40928784|NCT03905109|DRUG|Placebo|In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.
40928785|NCT02328053|PROCEDURE|collagen crosslinking group|collagen crosslinking with riboflavin and Ultraviolet A
40928786|NCT02328053|DRUG|Topical anti-fungal therapy|topical antifungal medications like natamycin eye drops and voriconazole eye drops
40928787|NCT01779076|PROCEDURE|30% oxygen|
40928788|NCT01779076|PROCEDURE|100% oxygen|
40928789|NCT02241096|DRUG|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
40928790|NCT04919447|PROCEDURE|pacemaker implantation|cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients.
40928791|NCT05410951|DIAGNOSTIC_TEST|Illumina panel|"Determination of germline mutations using a recent panel including 113 genes from the Illumina protocol"
40928792|NCT01501045|DEVICE|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS (rTMS)
40928793|NCT01501045|DEVICE|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS
40928794|NCT05680805|DRUG|Metformin Hydrochloride|Metformin 1500 mg/day in 3 divided dose for 24 weeks
40928795|NCT03375073|OTHER|Positive communication during medical transmission|Use of positive communication for medical transmission to the anaesthetic team who takes over the patient.
40928796|NCT05835895|GENETIC|GNSC-001|intra-articular injection
40928797|NCT05835895|DRUG|transient immune-modulation|oral
40928798|NCT05835895|DRUG|transient immune-modulation|intra-articular injection
40928799|NCT05835895|DRUG|Placebo|intra-articular injection
40928800|NCT02817399|DEVICE|Functional electrical stimulation|Electrical stimulation that cause muscle contraction while walking
40928801|NCT02817399|DEVICE|Neuro-muscular electrical stimulation|Electrical stimulation that cause muscle contraction in a stationary position
40928802|NCT02817399|PROCEDURE|Active exercises|Subjects will receive training exercise according to ACL reconstruction protocol
40928803|NCT05767879|DRUG|Encorafenib + Binimetinib|"In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated."
41126727|NCT02316301|DRUG|Short interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
41126728|NCT02928172|DEVICE|qCON-qNOX|Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor
41126729|NCT02928172|DEVICE|BIS|Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
41126730|NCT04531800|PROCEDURE|Concentrated growth factor|In the concentrated growth factor (CGF) group, CGF was applied to the surgical area (n=14), and the area was primarily closed after additional releasing incisions.
41126731|NCT04531800|PROCEDURE|Non-concentrated growth factor|In the non-CGF group, the surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy.
41126732|NCT04326140|DEVICE|mirror therapy|The affected side wears the machine, assists by the machine, and performs the same action with the good hand. According to the posture condition, selects two suitable actions in the three actions (all fingers open, all fingers close, all fingers open and close). The action is 10 minutes each.
41277268|NCT06656364|DEVICE|Esprit BTK System|The Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter.
41277269|NCT06559709|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
41277270|NCT06559709|OTHER|Dietary Intervention|Receive 3 meals per day and snacks
40928804|NCT01153776|PROCEDURE|64-slice CT angiography|the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
40928805|NCT04392700|DRUG|Tenofovir disoproxil fumarate 300mg|Take the medicine once a day ，300mg/d
40928806|NCT04392700|DRUG|Entecavir 0.5 mg|Take the medicine once a day，0.5 mg/d
40928807|NCT00732901|DRUG|Escitalopram|Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
40928808|NCT00732901|DRUG|Placebo|Once daily days 1-28
40928809|NCT04783675|DRUG|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission
40928810|NCT06505720|PROCEDURE|Arthroscopic management of acute pediatric septic hip infecion|Three-portals tractionless hip arthroscopy will be used to treat acute pediatric septic hip infection
40928811|NCT06505720|PROCEDURE|Open debridement of acute pediatric septic hip|surgical drainage and debridement of acute septic hip in children via classic lateral approach
40928812|NCT00294710|DRUG|Aliskiren|
40928813|NCT04572438|PROCEDURE|Tracheostomy|Tracheostomy is a procedure that creates a surgical airway in the windpipe to improve oxygenation of the lungs.
40928814|NCT04482023|BEHAVIORAL|Training video on anxiety, fear and loneliness in the COVID-19 environment.|Video with the actions identified as essential to address the diagnosis of anxiety, fear and loneliness in the environment COVID-19 identified by a group of experts.
40928815|NCT00672659|DRUG|Citalopram + Pipamperone|Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
40928816|NCT00672659|DRUG|Citalopram|Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
40928817|NCT03721445|DEVICE|continuous positive airway pressure|Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
40928818|NCT05535010|PROCEDURE|Transforaminal epidural steroid injection(TFESI)|TFESI procedure will be applied again in the 3rd week and 3rd month for the patients whose NRS score decreased by less than 50 percent after the first procedure.
40928819|NCT01733212|DRUG|Ginger|Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
40928820|NCT01733212|DRUG|Placebo Oral Tablet|Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
40928821|NCT02586883|OTHER|bronchial ddp test|bronchial ddp test during endoscopy, nasal smear, bronchial smear
40928822|NCT04438070|DIAGNOSTIC_TEST|COVID-19 Swab|Nasal, Oral-Nasal combined or Nasopharyngeal swab
41448114|NCT03270254|DEVICE|light activated dye photodynamic therapy (PDT)|light activated dye photodynamic therapy-PDT to periodontal pockets
40754730|NCT06514248|DEVICE|V5med Lung AI|"During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed on the left window and the same original without any AI mark with be display on the right window. Deeming a nodule, the radiologist will mark location. These may or may not correspond to the locations of the CADe markers. As in the baseline study, the radiologist will assign a level of suspicious to each mark and provide a Lung-RADS score and the size of longest dimension."
40754731|NCT04223687|OTHER|Sugar-Sweetened Beverage Warning Label|Labels with a pictorial warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research.
40754732|NCT04223687|OTHER|Neutral label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
40754733|NCT02481141|DRUG|5-ALA-SFC|Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC
40754734|NCT02481141|DRUG|Placebo|
40754735|NCT02458495|BEHAVIORAL|Diabetes MAP Intervention|
40754736|NCT04920292|DRUG|Oxfendazole|Oxfendazole is a benzimidazole anthelminthic drug.
40754737|NCT04920292|DRUG|Placebo|The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
40754738|NCT02735642|BEHAVIORAL|SMART Randomization 1 - Referral|Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
40754739|NCT02735642|BEHAVIORAL|SMART Randomization 1 - Referral and SMS|Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
40754740|NCT02735642|BEHAVIORAL|SMART Randomization 2 - SMS|Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
40928823|NCT05926076|OTHER|Treatment plan|Patients with different diagnoses will get different treatment options
40928824|NCT02747979|OTHER|hemodialysis only|hemodialysis treatment only
40928825|NCT02747979|OTHER|hemodialysis plus hemoperfusion(HA330)|combination of hemodialysis and hemoperfusion (HA330) treatment
40928826|NCT02747979|OTHER|hemodialysis plus hemoperfusion(HA130)|combination of hemodialysis and hemoperfusion (HA130) treatment
40928827|NCT01111929|DRUG|Counseling for LAM+ LNG-EC|"They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer."
40928828|NCT00560521|BEHAVIORAL|CPAP|Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
41126733|NCT04326140|DEVICE|robotic-assisted training|The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
41126734|NCT04326140|DEVICE|sham mirror therapy|The mirror was masked. The intervention was the same as the mirror therapy.
41277271|NCT06559709|OTHER|Dietary Intervention|Meet with dietitian
41448115|NCT05025163|DRUG|1.23% fluoride foam application|topical application of fluoride foam every 6 months
41448116|NCT05025163|DRUG|2.26% fluoride varnish application|topical application of fluoride varnish every 6 months
41448117|NCT00507572|OTHER|Medical Chart Review|Medical records are reviewed
40754741|NCT02735642|BEHAVIORAL|SMART Randomization 2 - Incentive|Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
40928829|NCT03954678|BEHAVIORAL|Exercise Group|For the first two days after their pre-operative visit, participants will be asked to continue their present level of exercise and activity, which will be monitored by pedometer. Participants will begin the activity intervention on study Day 3. Participants will be instructed to take 10,000 steps per day, recording their daily steps with a pedometer. Participants also will be provided with resistance bands and instructed on how to safely perform 10 whole-body strength training exercises. They will be instructed to perform the exercises once per day, three days a week. Participants will complete the exercise intervention until they have surgery, which is typically 12 to 48 days after the pre-operative visit.
40928830|NCT03954678|DIETARY_SUPPLEMENT|Nutrition Group|Participants in the nutrition group will be provided with a liquid over-the-counter nutrition supplement (i.e. Boost or Ensure) to consume. Participants will be instructed to consume 1 bottle, 2 times per day, beginning 5 days before surgery and continuing 5 days post-operatively.
40928831|NCT03314246|OTHER|FAST|Fasting Algorithm for Singaporeans with Type 2 Diabetes
40928832|NCT03314246|OTHER|Standard of care|Standard of care
40928833|NCT03899636|DRUG|Modified FOLFIRINOX Regimen|Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
40928834|NCT03899636|DEVICE|NanoKnife System|IRE using NanoKnife System
40928835|NCT01382147|DRUG|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
40928836|NCT05053373|DEVICE|Electroacupuncture group|
40928837|NCT05053373|DEVICE|Sham electroacupuncture group|
40928838|NCT05053373|BEHAVIORAL|Pelvic floor muscle training|
40928839|NCT00167856|DRUG|Venalafaxine hydrochloride|Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
40928840|NCT00977301|DRUG|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
40928841|NCT00977301|DRUG|olanzapine|15 mg olanzapine single dose
40928842|NCT00977301|DRUG|olanzapine|10 mg olanzapine single dose
40928843|NCT01537107|DRUG|vismodegib|Given PO
40928844|NCT01537107|DRUG|sirolimus|Given PO
41126735|NCT01911767|DRUG|Dimethyl fumarate|Administered as specified in treatment arm.
41126736|NCT01911767|DRUG|Peginterferon beta-1a|Administered as specified in treatment arm.
40928845|NCT01537107|PROCEDURE|positron emission tomography|Correlative studies
40928846|NCT01537107|PROCEDURE|computed tomography|Correlative studies
40928847|NCT01537107|OTHER|pharmacological study|Correlative studies
40928848|NCT01537107|OTHER|laboratory biomarker analysis|Correlative studies
40928849|NCT01537107|RADIATION|fludeoxyglucose F 18|Correlative studies
40928850|NCT04991818|OTHER|OneBiome microbiome profiling service|participants will be asked to complete the user experience of the OneBiome service
40928851|NCT02995369|DEVICE|DryShield|DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
40928852|NCT02995369|OTHER|Cotton rolls|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
40928853|NCT03889483|DEVICE|NeuroCatch™ Platform|The NeuroCatch™ Platform consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
40928854|NCT00000791|DRUG|Glycovir|
40928855|NCT00000791|DRUG|Zidovudine|
40928856|NCT05664698|BEHAVIORAL|SKILLS-ER|The intervention (SKILLS-ER) has been developed by the research group, and aims to increase a participant's emotion regulation capacity by targeting different stages of the emotion regulation process proposed by the extended process model of emotion, i.e. identification, selection, implementation and monitoring (Sheppes, Suri \& Gross, 2015). SKILLS-ER will comprise of eight sessions and include identification and differentiation of emotions, tolerance/acceptance of emotions, education of different regulatory skills, as well as on how to select, implement and monitor strategies. Sessions will take place at the Uppsala child- and adolescent psychiatry outpatient unit and consist of activating and experiential exercises administered by a clinical psychologist. Participants will gain access to internet-delivered material, such as homework assignments in-between sessions. SKILLS-ER will be delivered individually to the participants, where their parents will be involved in some sessions.
41126737|NCT01040689|DRUG|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
40928857|NCT03149367|PROCEDURE|levator muscle resection with fixed sutures technique|The levator muscle is approached through skin incision and the muscle shortened and sutured directly to the tarsus then the skin crease reformed with interrupted sutures which pick up the underlying levator muscle
41126738|NCT01040689|DRUG|Placebo (for olodaterol BI1744)|Placebo (olodaterol low and high dose)delivered by Respimat
41126739|NCT01040689|DRUG|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
41448118|NCT01539096|PROCEDURE|tDCS: noninvasive brain stimulation|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
41277272|NCT06559709|OTHER|Medical Chart Review|Ancillary studies
41126740|NCT01040689|DRUG|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
41126741|NCT01040689|DRUG|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
41126742|NCT00171431|DRUG|Tegaserod|
41277273|NCT06559709|OTHER|Questionnaire Administration|Ancillary studies
41277274|NCT04141696|DRUG|Ketamine|Given intravenously over 40 minutes
41277275|NCT04141696|DRUG|Midazolam (placebo)|Given intravenously over 40 minutes
41277276|NCT00601900|BIOLOGICAL|Bevacizumab|Given IV
40928858|NCT03149367|PROCEDURE|Levator muscle resection with adjustable sutures technique|The adjustable sutures technique in which the sutures passes through the levator muscle into the tarsal plate and out through the skin edge .the skin crease is formed separately so that adjusting the suture doesn't open the wound, the suture can be adjusted according to the result up to 4 days post operative.
40928859|NCT06057740|BEHAVIORAL|Acceptance and commitment therapy (ACT)|ACT is a psychological intervention that aims to improve psychological flexibility, the ability to hold thoughts and emotions lightly in a given context and pursue valued ends (Hayes et al., 1999; Twohig \& Levin, 2017).
40928860|NCT06057740|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT is a psychological intervention which targets cognitions and behaviors in attempt to change emotions.
40928861|NCT00401362|DRUG|SC Methylnaltrexone|Dose 1
40928862|NCT00401362|DRUG|SC Placebo|
40928863|NCT00401362|DRUG|SC Methylnaltrexone|Dose 2
40928864|NCT06401187|OTHER|Bar overdenture|use of bar attachments as retentive mean of denture
40928865|NCT00637143|DRUG|Tacrolimus|Oral
40928866|NCT00637143|DRUG|Cyclosporine|Oral
40928867|NCT00189410|DRUG|Pegylated Liposomal Doxorubicin and Carboplatin|
40928868|NCT01845987|DRUG|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
40928869|NCT01845987|DRUG|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
40928870|NCT05476484|DRUG|SQ SLIT-tablet|SQ grass SLIT-tablet and/or SQ house dust mite SLIT-tablet
40928871|NCT05384977|DRUG|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
40928872|NCT00815178|BEHAVIORAL|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
41126743|NCT03619642|OTHER|Robotic assessment of finger proprioception|The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .
40754742|NCT02735642|BEHAVIORAL|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
40928873|NCT00815178|BEHAVIORAL|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
40928874|NCT05820997|DRUG|Ropivacaine|Paravertebral at the T7-10 levels bilaterally with 5 cc of 0.5% ropivacaine at each level
40928875|NCT00816023|DRUG|ecallantide|infusion administered IV over the duration of the surgical procedure
40928876|NCT00816023|DRUG|placebo|solution for IV infusion over the duration of the surgical\>\> procedure
40928877|NCT03070743|PROCEDURE|Posterior Approach Compression Distraction Reduction Surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
40928878|NCT01985854|DRUG|Propofol|
40928879|NCT01985854|DRUG|Desflurane|
40928880|NCT04626141|DRUG|Abaloparatide|Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
40928881|NCT04626141|DRUG|Placebo|Placebo will be dispensed as a 30-day supply of disposable pen injections.
40928882|NCT05032157|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
40928883|NCT05032157|DRUG|Placebo|Placebo
40928884|NCT05032157|DRUG|LOU064 (open-label)|LOU064 (open -label) active treatment
40928885|NCT04153214|BEHAVIORAL|cycling|Participants will have a portable pedal machine under their desk and will use it 60minutes per day
40928886|NCT04825353|PROCEDURE|Endoscopic compbined guided PCNL|patient undergo stone removal by ECIRS
40928887|NCT04825353|PROCEDURE|Standard PCNL|patient undergo SPCNL
40928888|NCT03787979|OTHER|Lumbopelvic stiffening technique|"Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
41126744|NCT01835639|DIETARY_SUPPLEMENT|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks|Supplements will be provided as oral capsules.
41126745|NCT03637296|OTHER|Critical time intervention|Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
41126746|NCT04802382|DRUG|Placebo administration|patients will receive the placebo treatment in addition to Standard of Care
40928889|NCT03787979|OTHER|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
40928890|NCT01596556|DRUG|Nicotine|both groups will be given nicotine lozenges before a VO2 test and a HTT.
41126747|NCT04802382|DIAGNOSTIC_TEST|Confirm SARS-CoV-2 infection|patients will be tested for SARS-CoV-2 on days 1, 14 and 28
41126748|NCT04802382|PROCEDURE|Physical Examination|patients will undergo a physical examination on days 1-14 and day 28
40928891|NCT01596556|OTHER|cigarette smoking|the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
41126749|NCT04802382|PROCEDURE|Vital Signs|patient's vital signs will be measured on days 1-14 and day 28
41126750|NCT04802382|DIAGNOSTIC_TEST|Hematology blood test|patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
41126751|NCT04802382|DIAGNOSTIC_TEST|Biochemistry blood test|patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
41126752|NCT04802382|OTHER|NEWS score|patient's NEWS score will be evaluated on days 1-14 and day 28
40928892|NCT06377488|DEVICE|JJVC Investigational Multifocal Toric Contact Lens manufactured in Senofilcon A (C3) material with UV blocker / HEV filter|Test Lens
40928893|NCT03177629|DRUG|treatment : H. pylori eradication|"treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO"
40928894|NCT04065165|DRUG|Telotristat Ethyl|250 mg TID orally
40928895|NCT04065165|DRUG|Lanreotide|120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
40928896|NCT01761032|DEVICE|Tanning|Participants will be placed under a tanning canopy for 4-10 minutes.
40928897|NCT02043600|BEHAVIORAL|Yoga|12-week Hatha Yoga intervention 90 minutes once a week
41126753|NCT04802382|DIAGNOSTIC_TEST|PK test|PK test will be performed on day 1 only (only in Brazil sites)
41126754|NCT04802382|DIAGNOSTIC_TEST|blood test for inflammatory markers|patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
41126755|NCT04802382|DIAGNOSTIC_TEST|D-dimer test|patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
40754743|NCT02735642|OTHER|All participants. Approximately (N=1200)|"HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire."
40754744|NCT01220063|RADIATION|Radiation|10 Gy for 4 times (total 40 Gy)
40754745|NCT01220063|DRUG|Irinotecan|40 mg/m² : Day 1 and day 8
40928898|NCT02043600|BEHAVIORAL|Self-care|Self-care books are provided for self-directed use
41126756|NCT04802382|OTHER|VAS scale|patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
41126757|NCT04802382|DIAGNOSTIC_TEST|Urine pregnancy test for women of childbearing potential|patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
41126758|NCT04802382|PROCEDURE|ECG|patients will undergo an ECG examination on days 1, and day 28
41126759|NCT04802382|OTHER|COVID-19-Impact on Quality of Life Questionnaire|patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
41126760|NCT04802382|DRUG|CimetrA-1|patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
41126761|NCT04802382|DRUG|CimetrA-2|patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
41126762|NCT04350541|OTHER|High-intensity interval training|Exercise with high-intensity intervals followed by active rest
41126763|NCT04350541|OTHER|Continuous aerobic training|Interval Moderate-intensity aerobic training without intervals
41277277|NCT00601900|OTHER|Laboratory Biomarker Analysis|Correlative studies
40928899|NCT02111278|OTHER|Lumbar Manipulation|The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.
41126764|NCT05413889|BEHAVIORAL|Epic 30-day unplanned readmission risk score|If a patient is identified as having a high risk of readmission defined as readmission risk \>20%, a link to transitional and supportive care services (TSC) will be appear in the story board.
41126765|NCT01723267|OTHER|3D follicles assessment|3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
41277278|NCT00601900|DRUG|Letrozole|Given PO
41448119|NCT01539096|BEHAVIORAL|Constraint induced movement therapy (CIMT)|Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
41448120|NCT01539096|PROCEDURE|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
41448121|NCT06556823|OTHER|CLNDT+ Conventional PT in Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
41448122|NCT06556823|OTHER|CLNDT+ Conventional PT in non Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
41448123|NCT06556823|OTHER|SMWLM+ Conventional PT in Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
41126766|NCT01723267|OTHER|2D follicles assessment|2D ultrasound in IVF treatment (vs 3D ultrasound)
41126767|NCT00587275|DRUG|AST-120|Oral, sachet, 2 grams daily for 4 weeks
41126768|NCT00587275|DRUG|Celphere CP-305|Oral, sachet, 2 grams daily for 4 weeks
41126769|NCT02853565|DRUG|CAN008|The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
41277279|NCT00601900|OTHER|Questionnaire Administration|Ancillary studies
41277280|NCT00601900|DRUG|Tamoxifen Citrate|Given PO
41277281|NCT06025747|DRUG|Abemaciclib|Given PO
41126770|NCT03214185|PROCEDURE|IVF/ICSI|in vitro fertilization or intracytoplasmatic sperm injection
41126771|NCT03214185|GENETIC|PGS 2.0|Blastocysts are selected by PGS 2.0(NGS based) and only euploid embryos will be transferred.
41126772|NCT03214185|OTHER|Conventional embryo morphology evaluation|Blastocysts are selected by morphology criteria and only good-scored embryo will be transferred.
41126773|NCT01634919|DEVICE|chronic hepatitis C|acoustic radiation force impulse ultrasonography
41277282|NCT06025747|PROCEDURE|Computed Tomography|Undergo CT
41277283|NCT06025747|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41277284|NCT06025747|RADIATION|Radiation Therapy|Undergo radiation therapy
41277285|NCT06025747|PROCEDURE|Therapeutic Surgical Procedure|Undergo surgery
41277286|NCT05990803|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
41277287|NCT05990803|DRUG|SI-B003|SI-B003 was administered by intravenous infusion every 3 weeks (Q3W).
41277288|NCT06169215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
41277289|NCT06169215|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41277290|NCT06169215|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40928900|NCT02111278|OTHER|Sham Manipulation|The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
40928901|NCT02111278|OTHER|Physical Therapy|Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
40928902|NCT01578512|BEHAVIORAL|Face-to-Face|Face-to-Face behavioral weight loss
41126774|NCT05618132|DIAGNOSTIC_TEST|Acetylcholine rechallenge|"STEP 1 consists of verapamil 1mg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is given (step 2). If verapamil suppresses spasm, ACH rechallenge (ACHR) is performed after 3 minutes.~In STEP 2, patients with persistent spasm after verapamil or with spasm after ACHR receive NTG 200µg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is delivered again. If refractory spasm occurs, atropine 1mg IV is given. Coronary spasm is considered suppressed once ACHR can no longer provoke spasm. NTG 200µg IC is given as final drug regardless of spasm.~ACHR consists of ACH 100 or 200µg IC depending on the dose that previously provoked the coronary artery spasm (both microvascular and epicardial spasm)."
41277291|NCT06169215|DRUG|Bortezomib|Given SC
41448124|NCT06556823|OTHER|SMWLM+ Conventional PT in non Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
41126775|NCT04229368|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D will be given at doses commonly given to patients with low vitamin D levels
40928903|NCT01578512|BEHAVIORAL|Web-based|Web-based behavioral weight loss
41126776|NCT04974567|OTHER|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
41277292|NCT06169215|PROCEDURE|Computed Tomography|Undergo CT
41277293|NCT06169215|BIOLOGICAL|Daratumumab|Given SC
41277294|NCT06169215|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
41277295|NCT06169215|DRUG|Dexamethasone|Given PO
41277296|NCT06169215|DRUG|Lenalidomide|Given PO
41277297|NCT06169215|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41277298|NCT06169215|PROCEDURE|Positron Emission Tomography|Undergo PET
41277299|NCT06169215|DRUG|Selinexor|Given PO
41277300|NCT00219908|DRUG|Mitoxantrone|
41277301|NCT02739464|OTHER|Exercise + SOC PT/OT|
41277302|NCT02739464|OTHER|SOC PT/OT|
41277303|NCT05987644|DRUG|Alectinib|600mg taken orally, twice daily for 25 Cycles Cycle = 4 weeks (28 days)
41277304|NCT05987644|RADIATION|Stereotactic Radiosurgery|SRS dose varies by brain met size and location
41277305|NCT01239927|PROCEDURE|Primary sigmoid resection with end colostomy (Hartmann)|
41277306|NCT01239927|PROCEDURE|Primary sigmoid resection and immediate anastomosis with diverting stoma (PRA)|
41126777|NCT04694937|DEVICE|heart rate variabilty measured by pulse oximetry|"Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points."
41126778|NCT05207241|OTHER|provides guidance on gravitationally assisted breastfeeding|Prior to the first breastfeeding after delivery, the guidance of gravitationally assisted breastfeeding will be provided. The primary breastfeeding position is advised to be the sitting position, supplemented by the lateral position with a time ratio of 4:1. The following guidance will also be given: (1) participating women breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding.
41126779|NCT04166487|DRUG|Pembrolizumab|predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
41126780|NCT04166487|DRUG|PEMETREXED|administered per standard practice, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
41126781|NCT04166487|DRUG|CARBOPLATIN|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
41126782|NCT04166487|DRUG|PACLITAXEL|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
41126783|NCT04166487|DIAGNOSTIC_TEST|InVision|Plasma draw for clinical test performed at C1D1 and C2D1; plasma draw for research testing performed at other timepoints per protocol.
41126784|NCT02682485|DRUG|Cipro, metronidazole, neomycin combo|During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
41126785|NCT02682485|PROCEDURE|Serial Endoscopic Surveillance|Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
41126786|NCT02682485|DRUG|Saline|During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
41126787|NCT04800042|DIAGNOSTIC_TEST|Diagnostic test|Blood iron status : ferritin and transferrin saturation factor
41126788|NCT03822234|PROCEDURE|Modified ileal conduit|Modified ileal conduit (Extraperitonealization)
41126789|NCT04674995|PROCEDURE|Stent placement|All interventional procedures have been performed in the operating room with a Dumon rigid bronchoscope under general anesthesia. Neodymium-doped yttrium aluminium garnet laser photoresection was performed at 15-30 watts and pulse duration of 0.5-1.0s whenever indicated. A silicone stent was placed.
41126790|NCT00477893|DRUG|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
41126791|NCT00477893|DRUG|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
41126792|NCT03401372|DRUG|Doxycycline|Oral doxycycline 100mg twice daily
41126793|NCT03401372|DRUG|Bortezomib|1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle
41126794|NCT03401372|DRUG|Cyclophosphamide|300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle
41126795|NCT03401372|DRUG|Dexamethasone|40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
41126796|NCT03049319|DEVICE|Psoriashield in the presence of a non-UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
41126797|NCT03049319|DEVICE|Psoriashield in the presence of a UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
41126798|NCT03049319|DEVICE|Psoriashield|The psoriashield will be applied to patient's back.
41126799|NCT03049319|DEVICE|Xtrac laser in the presence of a non-UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
41126800|NCT03049319|DEVICE|Xtrac in the presence of a UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
41126801|NCT03049319|DEVICE|Xtrac laser|The Xtrac laser will be applied to patient's back.
41126802|NCT00115011|DRUG|Escitalopram|
41126803|NCT02252042|BIOLOGICAL|Pembrolizumab|200 mg intravenous (IV) on Day 1 of each 3-week cycle.
41126804|NCT02252042|DRUG|Methotrexate|40 mg/m\^2 IV (may be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle
41126805|NCT02252042|DRUG|Docetaxel|75 mg/m\^2 IV on Day 1 of each 3- week cycle
41448125|NCT02125461|DRUG|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
41126806|NCT02252042|BIOLOGICAL|Cetuximab|400 mg/m\^2 IV loading dose on Day 1 and 250 mg/m\^2 IV on Days 8 and 15 of Cycle 1, followed by 250 mg/m\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
41126807|NCT02698475|DRUG|Ustekinumab 0.75 mg/kg|Participants weighing less than (\<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
41277307|NCT05035498|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
40928904|NCT01578512|BEHAVIORAL|Single session|The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
40928905|NCT06165770|PROCEDURE|laparoscopy|Conservative or surgery treatment for cornual pregnancies
40928906|NCT05198544|DEVICE|Hēlaquis Matrix is a hyaluronic acid matrix (HaM)|Hēlaquis Matrix is a hyaluronic acid matrix (HaM) derived from the American Alligator and indicated for the treatment of chronic wounds. Hyaluronic Acid (HA) is a naturally occurring non sulphated glycosaminoglycan consisting of a linear sequence of D-glucuronic and N -acetyl-Dglucosamine. It is present in connective tissue and plays a role in several biological processes including tissue repair.
40928907|NCT03812627|OTHER|Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections|"All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter"
40928908|NCT03812627|OTHER|Autopsy|Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.
40928909|NCT02879149|DEVICE|AUGMENT® Bone Graft|AUGMENT® Bone Graft
40928910|NCT02879149|PROCEDURE|Standard of Care|Autologous Bone Graft
41126808|NCT02698475|DRUG|Ustekinumab 45 mg|Participants weighing greater than or equal to (\>=) 60 kg to less than or equal to (\<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.
40928911|NCT06393959|PROCEDURE|Caudal epidural pulsed radiofrequency|The patient lied in prone position. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a 22- gauge 150-mm RF cannula with 20 mm active tip was advanced through the sacrococcygeal ligament into the caudal epidural space under floroscopic guidence. A few milliliters contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, an electrode was connected to the cannula, and stimulation was conducted with impedance measured between 250 and 350 Ohms A different sensation or feeling such as fullness, impression, tingling, pulling or plethora at the rectal and/or coccygeal region was observed by the patients when 50 Hz was applied with 0,4 to 0,7 V sensory stimulation. No leg muscle contraction was observed with 2 Hz motor stimulation at 2 V. PRF was performed for 600 s at 5 Hz using a 5-ms pulse width at 55 V, avoiding electrode tip temperatures above 42 C.
40928912|NCT06393959|PROCEDURE|Caudal epidural steroid enjection|The patient lied in prone position and aseptic techniques were adopted. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a spinal needle was advanced through the sacrococcygeal ligament into the caudal epidural space under fluoroscopic guidance. The needle tip was confirmed by negative aspiration for blood or cerebrospinal fluid, then a few milliliters of contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, a total of 10 ml mixture of saline and 8 mg dexametzone was administered into the epidural space.
41448126|NCT02125461|OTHER|PLACEBO|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
41448127|NCT05327894|DRUG|Blinatumomab|1st cycle: 15 μg/m2/day as a 4 week continuous IV infusion for patients with a M1 marrow. For patients with a M2/M3 marrow a step-dosing strategy is required with a dose of 5 μg/m2/day in week 1 followed by 15 μg/m2/day in weeks 2, 3, and 4.
40928913|NCT03549793|BEHAVIORAL|Dance Therapy|the intervention is aimed to ameliorate, through dancing, crucial motor symptoms in PD patients, as walking, balance, postural changes and arm swing
40928914|NCT03549793|BEHAVIORAL|exercises without dance|the intervention consists of exercises aimed at training the walking, the balance, the postural changes and the arm swing
40928916|NCT02965092|GENETIC|Second generation CAR-T cells|
40928917|NCT03551925|BEHAVIORAL|Treatment as Usual Plus Occupational Therapy|The IMeds consists of a three-step process that leads the client from the reflection of past performance, to goal setting, and onto strategy identification and implementation. This intervention guides the client through identifying strategies in the following six areas: altering the medication management activity, advocacy, assistive technology, environmental modifications, and securing refills on time (Schwartz et al., 2017).
40928918|NCT03551925|BEHAVIORAL|Treatment as Usual|A clinical pharmacist counsels participants on proper medication adherence.
40928919|NCT04567732|COMBINATION_PRODUCT|injection of Filtered Autologous Adipose Tissue|Single injection of Filtered Autologous Adipose Tissue
40928920|NCT04567732|DRUG|Placebo|Single injection of Placebo
40928921|NCT03199443|DIAGNOSTIC_TEST|EMG pelvic floor|EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
41277308|NCT05035498|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
41277309|NCT06657560|DRUG|HRS-9231|HRS-9231
41448128|NCT05327894|DRUG|Blinatumomab|2nd cycle: 15 μg/m2/day as a 4 week continuous iv infusion
41448129|NCT05201339|PROCEDURE|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
40928922|NCT05479669|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiograms will be performed at inclusion. Echocardiographic parameters that will be evaluated are measures of atrial size (including left atrial volume, right atrial dimensions, left ventricular function and dimensions (including left ventricular dimensions, septal wall thickness, posterior wall thickness, systolic function, Simpson biplane left ventricular ejection fraction), parameters of diastolic dysfunction (including E, A, E/A ratio, deceleration time, E' and E/E' ratio) and valve (dys)function.
40928923|NCT05479669|DIAGNOSTIC_TEST|24 hour Holter monitoring|24-hours Holter monitoring will be used to determine markers of increased risk of ventricular arrhythmias, such as non-sustained ventricular tachycardias, and ventricular premature beats and doublets. Also the presence and pattern of AF and runs of supraventricular tachycardias are determined.
40928924|NCT05479669|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Multiple short-axis cine images will be acquired throughout the entire LV with a steady-state free precession sequence. Left ventricular volumes, ejection fraction and myocardial mass will be measured on the short-axis stacks at end diastolic and end systolic frames. Ten to 15 minutes after an intravenous bolus injection of a gadolinium-based contrast agent late gadolinium enhancement will be performed with a segmented inversion recovery gradient-echo sequence, using the same image orientation as in the short-axis stacks. The presence, location and morphology of myocardial fibrosis will be described. The extent of myocardial scar will be quantified using computer-assisted planimetry and expressed as a percentage of left ventricular mass. Pre- and post-contrast T1 measurements will be obtained using a single-shot modified Look Locker inversion recovery sequence. Extracellular volume (a measure of diffuse myocardial fibrosis) will be quantified.
40928925|NCT05479669|DIAGNOSTIC_TEST|99mTc-HDP scan|Patients will receive a 99mTc-HDP scan. 3 hours after the technetium 99m-hydroxymethylene diphosphonate bolus injection, imaging will be performed using a gamma-camera equipped with a collimator which guides individual gamma-rays emitted by the radionuclide. For planar imaging, a collimator will be used to transfer only those gamma-rays which pas in a perpendicular course. Sequentially, a SPECT-CT will be performed in the same session to improve sensitivity. SPECT/CT will be performed on a SPECT/CT dual head gamma camera system. SPECT images will be acquired using a 128 x 128 matrix, 180 degrees of rotation, 64 views, 15s per view. Visual image analysis will be performed by two blinded and experienced nuclear medicine physicians. Data will be scored according to a routine scoring system on a scale from 0 (no cardiac uptake of 99m technetium and normal bone uptake) to 3 (high cardiac uptake, higher than bone uptake).
40928926|NCT05479669|DIAGNOSTIC_TEST|ECG|A 12-lead electrocardiogram will be performed at the 1-year and 2-year follow-up visit to determine the heart rhythm and heart rate.
40928927|NCT04918901|COMBINATION_PRODUCT|NO Severe COVID-19|Non-severe and critically ill patients with COVID-19
40928928|NCT02292901|DEVICE|Macintosh laryngoscope|
40928929|NCT02292901|DEVICE|McGrath Mac videolaryngoscope|
40928930|NCT04590248|DRUG|Adavosertib|The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
40928931|NCT06403488|DRUG|Letrozole 2.5mg|specific aromatase inhibitor
40928932|NCT01597115|PROCEDURE|Duplex ultrasonography|
40928933|NCT05520242|OTHER|Use of small animation movies to increase response in a national health survey|Inclusion of animation movies in the invitation cover letter to a national health survey is tested in an embedded randomized controlled trial in the Danish National Health Survey 2021.
40928934|NCT06325332|OTHER|Nirsevimab|Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection
41448130|NCT05201339|PROCEDURE|Hean and Neck Rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
41448131|NCT03242213|BEHAVIORAL|Mobile App|The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
40928935|NCT00574964|OTHER|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
40928936|NCT03444077|DIAGNOSTIC_TEST|Use of the Trauma Induced Coagulopathy Clinical Score (TICCS) as a diagnostic tool.|The TICCS will be calculated on the site of injury for the patients taken in charge in the intervention group. Those patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS \< 10 will be classified as not in need for DCR.
40928937|NCT03444077|DIAGNOSTIC_TEST|Regular care|Patients from the control group will be evaluated by clinicians using the local usual clinical Tools.
40928938|NCT03444077|OTHER|STTTOPPP the bleeding|"* Surgical team pre-activation~* Trauma team pre-activation~* Transfusion team pre-activation~* Tranexamic acid (administration of 1 gram of TXA if documented hyperfibrinolysis)~* O negative RBC transfusion as soon as possible~* Plasma and Platelets transfusion as soon as possible~* Permissive hypotension (restrictive use of crystalloids: no more than 500 milliliters before definitive control of the bleeding is achieved)~* Prophylaxis (initiate antithrombotic prophylaxis as soon as the bleeding is under control and coagulation tests are normal, first evaluation before the 24th hour after trauma)"
40928939|NCT03444077|OTHER|Regular Care|Regular local pre-hospital care.
41448132|NCT03553979|BEHAVIORAL|Stress management program (SM)|Participants follow the SM program.
40928940|NCT02905396|DEVICE|Spinal cord stimulation|implantation of spinal cord stimulator
40928941|NCT04397887|PROCEDURE|micro-surgical varicocelectomy|Sub-inguinal micro-surgical varicocelectomy
41448133|NCT03553979|BEHAVIORAL|Stress management + Buddy program (SM-B)|In addition to receiving the SM, participants in the SM-B will also receive one-to-one support through a buddy.
41448134|NCT03257735|DIAGNOSTIC_TEST|next-generation sequencing|"1. Patients' cerebrospinal fluid, blood and tumor tissue were collected within 3 days before treatment at diagnosis.~2. Patients' cerebrospinal fluid and blood were extracted at the time of first evaluation of efficacy after treatment (TKI began after 1 month or chemotherapy after 2 cycles).~3. Patients' cerebrospinal fluid and blood were extracted at first time of tumor progression，and re-biopsy of tumor tissue was done as much as possible.~All the samples were tested by next-generation sequencing."
41448135|NCT04356729|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.
40928942|NCT00204243|DRUG|Naltrexone|surgically implanted naltrexone releasing during 5 to 6 months
40928943|NCT00204243|DRUG|Methadone|Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
41277310|NCT04635176|DRUG|Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone)|real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
41277311|NCT04635176|DRUG|Sham iPACK block with 20ml normal saline|Sham iPACK block with 20 ml Normal saline
41277312|NCT04008017|DIAGNOSTIC_TEST|Eosinophilic Cationic Protein biomarker|3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
40754746|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.
40928944|NCT00986284|DRUG|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
40928945|NCT00480948|BEHAVIORAL|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing \~49% of C16:0 at sn-2 position), 24 wk
40928946|NCT00480948|DIETARY_SUPPLEMENT|Control|Standard vegetable oil based infant formula
40928947|NCT04445389|DRUG|GX-19|DNA vaccine expressing SARS-CoV-2 S-protein antigen
40928948|NCT04445389|DRUG|Saline|Saline
40928949|NCT05627778|DRUG|68Ga-PSMA-11|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-11. Tracer doses of 68Ga- PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
40928950|NCT05627778|DRUG|68Ga-P15-041|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P15-041. Tracer doses of 68Ga- 15-041 will be used to image lesions of prostate cancer by PET/CT.
40928951|NCT05828641|PROCEDURE|Supination-flexion maneuver|In the Supination-flexion group, the forearm will be supinated first, followed by full flexion of the elbow joint (Supination-flexion maneuver).
40928952|NCT05828641|PROCEDURE|Hyperpronation maneuver|In the hyperpronation group, the forearm will be pronated with the child's palm facing down (hyperpronation maneuver).
40928953|NCT01126671|DRUG|Supplemental Vitamin D|Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.
40928954|NCT02660008|DRUG|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
41277313|NCT05240937|BEHAVIORAL|mindfulness-based self-compassion will be applied|A mindfulness-based self-compassion program will be applied to this group of patients who have had breast cancer and have fully completed their treatment.
41277314|NCT01796132|DRUG|SSRI/SNRI|Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
41277315|NCT06657521|DIETARY_SUPPLEMENT|osteoimplant|Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
41126809|NCT02698475|DRUG|Ustekinumab 90 mg|Participants weighing \>100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
41126810|NCT01391767|DEVICE|NuOss XC|NuOss XC is a bone grafting material that will be placed in extraction socket site.
41126811|NCT03305445|DRUG|Ipilimumab|Ipilimumab (1mg/kg)
40754747|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss program + Groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.
40928955|NCT02660008|DRUG|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
40928958|NCT04332809|PROCEDURE|saline-gentamicin irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline-gentamicin solution
40928959|NCT04332809|PROCEDURE|saline irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline solution
40928960|NCT05371873|PROCEDURE|Liver resection method|undergo anatomical or non-anatomical resection of liver cancer
40928961|NCT04690062|DRUG|Brolucizumab-Dbll|intravitreal injection of Brolucizumab (BEOVU)
40928962|NCT01940978|DRUG|Methylphenidate ER|Watson generic, starting dose 18mg QD
40928963|NCT01940978|DRUG|Cyproheptadine|cyproheptadine hydrochloride
40928964|NCT00424255|DRUG|Lapatinib|Dual ErbB1/2 inhibitor
40928965|NCT00424255|RADIATION|Chemoradiation|Radiation plus platinum based chemotherapy
40928966|NCT00424255|OTHER|Placebo|Placebo
41126812|NCT03305445|DRUG|Nivolumab|Nivolumab (3mg/kg)
41126813|NCT00418795|DRUG|recombinant human porphobilinogen deaminase (Porphozym)|
41126814|NCT03160521|DRUG|Risperidone ISM 75 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
41126815|NCT03160521|DRUG|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
41126816|NCT03160521|DRUG|Placebo of Risperidone ISM|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
41277316|NCT06657521|DIETARY_SUPPLEMENT|Placebo Oral Tablet|2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
41277317|NCT06023108|DEVICE|Orthokeratology|OK lenses will be used to evaluate the condition that causes dry eye in the treatment of myopia.
41277318|NCT06023108|DEVICE|Spectacles|Spectacles will be used to evaluate the condition that causes dry eye in the treatment of myopia.
41448136|NCT04356729|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
41448137|NCT02811003|DEVICE|Rotation Medical Bioinductive Implant|Placement of bioinductive implant over repair of insertional Achilles tendinopathy
41448138|NCT06503900|BIOLOGICAL|mRNA COVID-19 vaccine|ACIP-CDC recommended vaccine
41448139|NCT06503900|BIOLOGICAL|IIV4 (quadrivalent inactivated influenza vaccine)|ACIP recommended vaccine
40928967|NCT05828927|BEHAVIORAL|Eco-mapping tool|The web application allows caregivers to visually identify and organize their existing social network (family, friends, community of worship, and others) to assist with their support needs, tailored to their context. For each of the six support social support domains (in-home, informational, communication, financial, emotional and spiritual, transportation (e.g., emotional, informational, practical), the enCompass web application prompts the individual to identify members of their network. After completing each domain, caregivers are presented with a visual social support
40928968|NCT05828927|BEHAVIORAL|Caregiver-coach study visits|Caregivers engage in up to 8 manualized, telephone/videoconference visits with a trained caregiver coach. The caregiver coach uses the study manual and interview guide to provide support for caregiver support-seeking and problem-solving.
41126817|NCT04122885|COMBINATION_PRODUCT|PIPAC with oxaliplatin|Oxaliplatin 92 mg/m2 BSA, applied as an aerosol for 30 min under normothermic conditions at 12-15 mmHg pressure
41448140|NCT05351567|OTHER|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY FOR INFERTILITY FEMALES
41448141|NCT05150223|OTHER|traditional strength training|traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband). Participation in the traditional strength training group will complete these exercises with a load and without time limitations and speed.
41448142|NCT05150223|OTHER|Power training|progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
41448143|NCT04716582|BEHAVIORAL|Sitting interrupted by light physical activity|Each 30 minutes will be 25 minutes sitting followed by 5 minutes walking that designed as prescribed walking route outside laboratory corridor.
41448144|NCT04716582|BEHAVIORAL|Sitting with cognitive task|Participants will perform online cognitive task during prolonged sitting.
40754748|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss + Incentives|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
40754749|NCT04369326|OTHER|Community-Based TPT Initiation|Community-based care delivery model for pediatric tuberculosis evaluation and initiation of preventive therapy
41448145|NCT04716582|BEHAVIORAL|uninterrupted sitting|Participants will watch documentary during prolonged sitting.
41448146|NCT06556329|OTHER|Robot (Intervention)|The research team will bring a socially assistive, artificially-enhanced robot during intravenous insertion procedures.
41448147|NCT05667142|DRUG|XEN1101|XEN1101 capsules
40928969|NCT05254054|OTHER|whole body vibration|The whole body vibration is used when vibrations (mechanical oscillations) of a certain frequency are transferred to the human body. Humans are exposed to vibration through a contact surface that is in a mechanical vibrating state. It has been considered as an alternative and safe method for neuromuscular training and may be incorporated into current neuromuscular rehabilitation programs so as to enhance muscle recovery
40928970|NCT05254054|OTHER|Conventional exercise training|A set of conventional exercises designed for ACL rehabilitation
40928971|NCT03588962|BIOLOGICAL|In-stent restenosis|Patch tests for the metals applicated in each of the patients
40928972|NCT03726398|DRUG|Opsumit 10 Mg Tablet|Oral tablet taken once daily
40928973|NCT01576159|OTHER|Running exercise|During this type of exercise intervention, subjects performed weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
41126818|NCT04122885|PROCEDURE|Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy|If complete cytoreduction possible (CC-0). Application time 60 min, T 41-43 °C
41448148|NCT05667142|DRUG|Placebo|Placebo capsules
41448149|NCT05667142|DRUG|XEN1101|XEN1101 capsules
41448150|NCT04803487|OTHER|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the Chinese Micro Hand S surgical robot.
40754750|NCT00510471|DRUG|autologous immunoglobulin idiotype-KLH conjugate vaccine|
40754751|NCT01837550|BEHAVIORAL|Intervention group|The intervention group followed a five-week program that consisted of reading material, home training assignments, online and telephone interaction with an audiologist, and participation in a discussion forum.
40754752|NCT01837550|BEHAVIORAL|Control group|The control group only had access to reading material.
41448151|NCT04803487|OTHER|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the da Vinci surgical robot.
41448152|NCT01601158|BIOLOGICAL|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
40754753|NCT05032911|DIAGNOSTIC_TEST|sensorimotor control analysis using inertial sensor technology|Inertial Measurement Unit (IMU) sensors will measure sensorimotor control variables including active range of motion, movement speed, acceleration, smoothness of motion, head repositioning accuracy and motion coupling patterns
40754754|NCT01682720|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
40754755|NCT01682720|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
41448153|NCT01601158|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
40928974|NCT01576159|OTHER|Cycling exercise|During this type of exercise intervention, subjects performed a partial weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
40928975|NCT01576159|OTHER|Swimming Exercise|During this type of exercise intervention, subjects performed a non-weight bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
40928976|NCT02582177|DRUG|Candicort®|Apply on the affected area and around it twice a day
40928977|NCT02582177|DRUG|Nizoral®|Apply on the affected area and around it twice a day
40928978|NCT02582177|DRUG|Baycuten N®|Apply on the affected area and around it twice a day
40928979|NCT02582177|DRUG|Canesten®|Apply on the affected area and around it twice a day
40928980|NCT01864356|DRUG|NT100|
40928981|NCT01864356|DRUG|Placebo|
40928982|NCT04178369|OTHER|Proximal And Distal Tibiofibular Joint Manipulations|"For PTFJ, the experimental intervention will be based on previously published methods. Physiotherapist will make contact with the fibular head, extending to the popliteal fossa. The associated soft tissue will be pulled in a lateral direction until the metacarpophalangeal joint will be firmly stabilized behind the fibular head.~For DTFJ, the experimental intervention will be conducted according to previously published methods. Physiotherapist will grasp and stabilize the distal tibia with one hand and grasp the distal fibula between the finger and thenar eminence of the other hand. The fibula will be translated posteriorly until the restrictive barrier (end range) will be engaged. Then a high-velocity, low-amplitude thrust will be applied through the fibula in a posterior-superior direction."
40928983|NCT04178369|OTHER|Bobath Treatment|All participants will be given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept for 5 days a week, 45 minutes each. The techniques will be applied by a physiotherapist who is specialized in Bobath concept. 35 different techniques will be used to improve the selective control and weight transfer of the pelvis in sitting, standing and supine/side lying positions. Moreover, soft tissue mobilization will be also used to relieve tension and loosen stiff tissues to provide biomechanical alignment and reduce pain.
41448154|NCT06225921|DRUG|Adebrelimab|Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.
41448155|NCT06225921|DRUG|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
40754756|NCT01682720|DRUG|Placebo to match SOF|Placebo to match SOF administered orally once daily
40754757|NCT01682720|DRUG|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
40928984|NCT00734955|DEVICE|49-channel optical spectrometer|
40928985|NCT01402336|DRUG|GnRH antagonist (Cetrorelix)|In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
40928986|NCT01402336|DRUG|Conventional GnRH agonist (Triptorelin)|Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
40928987|NCT00721903|PROCEDURE|Ultrasound Scan|10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.
40928988|NCT00721903|PROCEDURE|Mammography and Ultrasound|To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
41448156|NCT06225921|DRUG|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
41126819|NCT00352131|DRUG|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
41126820|NCT03247842|PROCEDURE|suprascapular nerve block|Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,
41126821|NCT03413085|DEVICE|soft contact lens|"Group A~Group B"
41126822|NCT03693066|OTHER|Ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
41126823|NCT03693066|OTHER|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
41126824|NCT03693066|OTHER|Control|
41126825|NCT04957849|PROCEDURE|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery
41126826|NCT04957849|PROCEDURE|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach
41126827|NCT00127387|DRUG|Enbrel|
41126828|NCT04854772|BEHAVIORAL|Mind Body Syndrome Therapy for Long Covid|The intervention consists of a mind-body based intervention for the COVID long haul syndrome. The components of the intervention include knowledge therapy, desensitization, emotional expression, and stress reduction techniques.
41126829|NCT05121259|OTHER|ExerciseGuide Intervention Group|The single group which will be given access to the eight-week ExerciseGuide UK website containing a tailored physical activity programme and supportive and educational resources.
41126830|NCT04629625|BIOLOGICAL|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
41126831|NCT04629625|BIOLOGICAL|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
41126832|NCT04629625|BIOLOGICAL|Placebo|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
41126833|NCT00002945|BIOLOGICAL|aldesleukin|IV
41126834|NCT00002945|BIOLOGICAL|filgrastim|IV
41126835|NCT00002945|DRUG|cyclophosphamide|IV
41126836|NCT00002945|DRUG|cytarabine|IV
41126837|NCT00002945|DRUG|etoposide|IV
41126838|NCT00002945|DRUG|idarubicin|IV
41126839|NCT00002945|DRUG|melphalan|IV
41126840|NCT00002945|PROCEDURE|peripheral blood stem cell transplantation|IV
41126841|NCT00002945|RADIATION|radiation therapy|delivered to the cancer cells
41277319|NCT06657235|OTHER|Transitional Care Program|Participants will receive personalized risk-factor management stroke care from a multidisciplinary team trained by our neurologists to understand the needs of stroke survivors and the nuances of stroke care. Risk factor data from in-home devices, health records, and self-reports will be collected along with functional status and behavioral data obtained through validated questionnaires and an occupational therapy evaluation. Syntrillo's neurology provider will review this data, assess the participant through a telemedicine encounter, and create a comprehensive secondary prevention plan to supplement the participant's care plan at discharge. The participant will be monitored continuously while on the platform and up-to-date reports will be shared with the participant's relevant care providers every 30 days or as needed. Data generated through these clinical encounters will be de-identified and used for subsequent development of Syntrillo's stroke management technology.
41277320|NCT06476808|DRUG|BMS-986463|Specified dose on specified days
41277321|NCT00942006|DRUG|doxycycline|100 mg bid, 14 days
41277322|NCT00942006|DRUG|ceftriaxone|2g x 1 iv, 14 days
41277323|NCT05087030|DRUG|RGB-14-P|Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
41277324|NCT05087030|DRUG|Prolia®|Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
41277325|NCT04644900|OTHER|chewed mint gum|In the preoperative waiting area before transferring to the operating room,patients in group G chewed mint gum for 2 minutes and then spit it out.
41277326|NCT04644900|OTHER|Mouthwash|Patients in the mouthwash group took 15 ml honeysuckle antibacterial mouthwash in their mouths, and vomited them out after 2 minutes
41277327|NCT01301326|DEVICE|subthreshold and threshold laser treatment|subthreshold laser treatment
41277328|NCT01301326|DEVICE|Threshold laser treatment|threshold laser treatment
41277329|NCT05966818|DRUG|Dapagliflozin and Standard therapy (ACEI or ARB).|Dapagliflozin (Diglifloz) 10 mg orally once daily for 24 weeks and the standard therapy (ACEI or ARB).
41277330|NCT05966818|DRUG|Standard Therapy (ACEI or ARB).|Standard Therapy which include either ACEI or ARB for 24 weeks.
41277331|NCT05498272|DRUG|Olaparib|300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles)
41277332|NCT05498272|DRUG|LHRH agonist|Total duration of therapy will be for 180 days with use of agent as per institutional standards
41277333|NCT01748227|BEHAVIORAL|Peer-Delivered Pain Self-Management|Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
40754758|NCT01765881|DRUG|Misoprostol|administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
40754759|NCT01765881|DRUG|Dinoprostone|administration of one sustained released pessary of 10 milligrams by intravaginal route
41277334|NCT01902108|DRUG|Bupivacaine|Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
41277335|NCT01902108|DRUG|Clonidine|Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
41277336|NCT05153343|DRUG|flonoltinib 25mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
40928989|NCT00017485|DRUG|HPPH|
40928990|NCT04353804|OTHER|Treatment Arm: Computerized Cognitive Rehabilitation|Treatment Arm: Computerized Cognitive Rehabilitation
40928991|NCT04353804|OTHER|Active Control computer games|Active Control computer games
41126842|NCT03997994|DEVICE|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter coated with a proprietary coating containing the drug and carriers.
41126843|NCT00213395|DEVICE|Interface for noninvasive ventilation|
41126844|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h
41126845|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h
41126846|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h
41126847|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h
41126848|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h
41126849|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
41126850|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h
41126851|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
41277337|NCT05153343|DRUG|flonoltinib 50mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
41277338|NCT05153343|DRUG|flonoltinib 100mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
41277339|NCT05153343|DRUG|flonoltinib 150mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
41277340|NCT05153343|DRUG|flonoltinib 225mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
41126852|NCT00624442|DRUG|Placebo|IV infusion for 2 hours
41126853|NCT00624442|DRUG|Placebo|IV infusion for 24 hours
41126854|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
41277341|NCT05153343|DRUG|flonoltinib 325mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
41277342|NCT00317044|DRUG|Esomeprazole|Esomeprazole 40 mg twice daily
41277343|NCT00317044|DRUG|Esomeprazole|Esomeprazole 40 mg once daily
41277344|NCT00317044|DRUG|Placebo|Placebo twice daily
41277345|NCT06656806|DRUG|Measure concentrations of CBD in spot urine collections from subjects treated with inhaled CBD|Measure concentrations of CBD in spot urine collections from subjects with generalized anxiety disorder treated with inhaled CBD
41277346|NCT06656806|DRUG|Determine the presence and concentration of CBD in subject's plasma with inhaled CBD|Determine the presence and concentration of CBD in plasma of subjects with generalized anxiety disorder treated with inhaled CBD
41126855|NCT00624442|DRUG|Placebo|IV infusion for 72 hours
41277347|NCT06656702|DRUG|Psilocybin|Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.
41277348|NCT00644267|BEHAVIORAL|Telemedicine|Telemedicine reporting of blood pressure, weight, physical activity
41277349|NCT00443521|DRUG|Triamcinolone Acetonide 4 mg intravitreal injection|
41277350|NCT00443521|PROCEDURE|Panretinal photocoagulation|
41277351|NCT00716443|DRUG|tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream)|Apply tetracaine/lidocaine cream once on one side of the face prior to Restylane® injections
41126856|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
41126857|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
41126858|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
41126859|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
41126860|NCT00909649|PROCEDURE|fibrin glue in breast surgery|fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
41126861|NCT06043817|DRUG|STX-721 (Escalated)|STX-721 dose will be escalated per Safety Evaluation Team (SET) decision and BLRM-design.
41126862|NCT06043817|DRUG|STX-721 (2 doses)|Participants will receive 2 doses of STX-721.
41126863|NCT06043817|DRUG|STX-721 (RP2D)|Participants will receive the RP2D of STX-721.
41277352|NCT00716443|DRUG|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections
41277353|NCT03429218|DRUG|TP-0184|Oral dose once weekly for 4 weeks
41277354|NCT02954315|OTHER|Almonds|
41277355|NCT06657755|DIAGNOSTIC_TEST|Immunohistochemistry|This intervention will specifically focus on evaluating the role of ENPP1 in bladder cancer patients, distinguishing it from other interventions by targeting immune evasion and chemoresistance pathways. The intervention will include a combination of targeted molecular therapies and immunotherapy, aimed at assessing the therapeutic potential of ENPP1 inhibition in improving treatment outcomes for bladder cancer patients. This differs from previous studies by integrating advanced biomarker analysis and personalized treatment approaches based on ENPP1 expression levels.
41126864|NCT04620421|OTHER|Rhythm-based Multitask Training|Participants will be assigned to a weekly one-hour RYMA session for six months, followed by a six-month follow-up period without training. An experienced instructor will perform the RYMA sessions, which consists of a wide variety of rhythm-based multitask exercises performed to improvised piano music. The RYMA intervention is inspired by Dalcroze eurhythmics and exercises consists of components such as 1) coordination between hands and/or feet, 2) dissociation between hands and/or feet, 3) movements based on musical cues (e.g. follow the tempo), 4) movement inhibition based on musical cues, 5) handling of props (e.g. balls, scarfs, and plates), 6) pair or group-based coordination movements (e.g. clapping each other's hands and mirroring movements), 7) memorizing and repeating of rhythmic patterns, and 8) quick motoric responses to unexpected cues.
40754760|NCT04757857|DRUG|Rivaroxaban 10 mg|Rivaroxaban pharmaceutical form will be tablets of 10 mg
40754761|NCT01173926|DRUG|insulin degludec|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
40928992|NCT01920646|OTHER|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
41126865|NCT00139984|DEVICE|24 hour blood pressure measurement|
41126866|NCT02011854|DEVICE|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
41126867|NCT02011854|DEVICE|Acupuncture|
41277356|NCT02490657|DRUG|Inhaled iloprost|"Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.~Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb."
41277357|NCT02490657|DRUG|normal saline (Saline 0.9%)|
40754762|NCT01173926|DRUG|insulin degludec/insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
40928993|NCT05344755|OTHER|Plantar Sensorial Training|In addition to the routine treatment, plantar sensorial training will be added.
41126868|NCT01629589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
41277358|NCT05077761|DEVICE|Active High-intensity laser therapy|"High-intensity laser therapy will be used in the contact method, with the laser beam irradiated over the hamstring muscle. Dosage and parameters for the laser will be calculated.~Parameters-~1. Wavelength- 980 nm~2. Intensity/Power density- 3W/cm2~3. Emission mode- Continuous Emission~4. Energy (Joules)- 490 J~5. Irradiation time- 70 Sec on each point~6. Peak power- 15 Watt~7. Irradiation points- 09"
41277359|NCT05077761|DEVICE|Sham High-intensity laser therapy|Sham High-intensity laser therapy will be used in the contact method, without the laser beam irradiation over the hamstring muscle.
41277360|NCT06656611|OTHER|HPV self sampling|Selected women will perform a vaginal self-sampling using a swab
41277361|NCT05792384|PROCEDURE|transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe|Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe
41277362|NCT05792384|PROCEDURE|transbronchial lung biopsy with biopsy forceps|Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung biopsy with biopsy forceps
41277363|NCT03865472|OTHER|Questionnaire Administration|Ancillary studies
40928994|NCT05344755|OTHER|Control Group|Routine physiotherapy management of the Hallux valgus
40928995|NCT04290728|DEVICE|Apnea with high-flow nasal cannula|Application of oxygenation with high-flow nasal cannula with a rate of 2L/kg/min
40928996|NCT04290728|OTHER|Apnea|Apnea without any application of oxygenation
41277364|NCT03865472|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
41277365|NCT03865472|PROCEDURE|Sham Intervention|Undergo sham rTMS
41277366|NCT03040154|OTHER|"Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)"|
41277367|NCT03040154|OTHER|Usual Care Video that is publicly available|
41277368|NCT00322114|DIETARY_SUPPLEMENT|lycopene|Given orally
41277369|NCT00322114|OTHER|placebo|Given orally
41277370|NCT01636557|DRUG|Sirukumab|Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
40928997|NCT03203343|PROCEDURE|Operation - PIRS|Operation by its known design for PIRS group
40928998|NCT03203343|PROCEDURE|Operation - MARCY|Operation by its known design for MARCY group
40928999|NCT05633303|OTHER|Substrate guided ablation|Ablation strategy implemented will be dependent on the Arm the patient has been allocated to based on the presence of underlying LVZs.
41277371|NCT01636557|DRUG|Midazolam|Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
41277372|NCT01636557|DRUG|Warfarin|Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
41277373|NCT01636557|DRUG|Vitamin K|Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
40929000|NCT05461573|DRUG|Drospirenone|LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28 consecutive days, in consecutive cycles for 12 months (13 medication cycles) without a break in daily tablet intake.
41126869|NCT01629589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
41277374|NCT01636557|DRUG|Omeprazole|Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
41277375|NCT01636557|DRUG|Caffeine|Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
41277376|NCT06656728|OTHER|Blood-based liquid biopsy|Venous blood sample will be taken from the patient as part of the routine blood tests taken as part of the work at the Medical Center
40929001|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
41277377|NCT04295902|DEVICE|C-MAC indirect videolaryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Tuttlingen, Germany) with blades Miller nr 0 and Miller nr 1.
41277378|NCT04295902|DEVICE|Direct laryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
41277379|NCT01504503|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
41277380|NCT01504503|DRUG|Aricept|Aricept 10 mg Tablets
40929002|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
41277381|NCT00006383|DRUG|liposomal vincristine sulfate|
40754763|NCT01173926|DRUG|insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
40929003|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
40929004|NCT00395057|DRUG|Ranibizumab 500µg|Ranibizumab 500µg injections at Day 1, Month 1, Month 2
40929005|NCT04559529|DRUG|Levetiracetam (LEV) 500 mg|The levetiracetam pill will look just like the placebo pill.
40929006|NCT04559529|DRUG|Placebo|The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
41126870|NCT03750539|RADIATION|Standard radiotherapy|External Bean Pelvic Radiation: 50 Gy in 15 fractions, with weekly cisplatin.
41126871|NCT03750539|RADIATION|hypofractionated radiotherapy|External Bean Pelvic Radiation: 37.5 Gy in 15 fractions, with weekly cisplatin.
41126872|NCT03750539|PROCEDURE|Radical hysterectomy|Radical hysterectomy and pelvic and paraaortic lymph node resection
41126873|NCT01968967|DRUG|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
41126874|NCT01968967|OTHER|Placebo|subcutaneous injection every 2 weeks for 12 months
41277382|NCT05026775|BEHAVIORAL|Initial Medication Adherence (IMA)|"The IMA intervention is a shared-decision making intervention that promotes health literacy and patient participation in the decision making process during the recommendation and prescription of a new drug for the management of a cardiovascular disease and diabetes.~The IMA intervention has four main components: training for healthcare professionals (general practitioners (GP), nurses and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; intervention decision aids (leaflets and website); implementation of the IMA intervention during the GP's consultation; and information support provided by the nurses and community pharmacists that will use the intervention decision aids to explore the patients's doubts and harmonise and standardise the discourse between primary healthcare professionals."
41277383|NCT05026775|OTHER|Usual care|Health professionals in the usual care group will prescribe medication and provide information as usual.
40929007|NCT05015985|OTHER|Music-Care|music relaxation by a specific hardware and software program application (MUSIC-CARE)
40929008|NCT05015985|OTHER|control group|music relaxation using a music playlist supply (control group)
40929009|NCT02031965|BIOLOGICAL|oncolytic HSV-1716|Given IT
40929010|NCT02031965|DRUG|dexamethasone|Given IV
40929011|NCT02031965|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
41126875|NCT06241716|PROCEDURE|Ultrasound-assisted localization, US-AS|In the US-AS group, ultrasonic prescan to determine the best intervertebral space, best puncture Angle and best puncture depth. The optimal puncture section considered by the operator was selected to record the best gap, puncture Angle and depth.
40929012|NCT02031965|OTHER|laboratory biomarker analysis|Correlative studies
40929013|NCT05662566|PROCEDURE|Epidural replacement|"Insufficient analgesic effect of epidural anesthesia to the extent were replacement of the catheter is needed.~Defined as insertion of a new epidural catheter"
40929014|NCT04300959|DRUG|Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks."
40929015|NCT04300959|DRUG|Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks."
40929016|NCT00004644|DRUG|acyclovir|
41126876|NCT06241716|PROCEDURE|Real-time ultrasound guidance, US-RTG|In the US-RTG group, the optimal puncture section considered by the operator was selected and recorded directly in the plane of the paracentral transverse section, out of the plane of the paracentral sagittal section or in the plane of the paracentral sagittal section for real-time ultrasound guided lumbar epidural anesthesia.
41126877|NCT02245555|DRUG|Tamsulosin|
40754764|NCT00225758|DRUG|Lapatinib|1500 mg po daily for 26 weeks or longer
40929017|NCT05436873|DEVICE|MR-HIFU|MRI guided High Intensity Focused Ultrasound sonication.
41126878|NCT01117584|DRUG|ipragliflozin|oral tablet
41126879|NCT01117584|DRUG|Placebo|oral tablet
40929018|NCT05474664|DRUG|Camostat mesylate|"1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day~2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day"
40929019|NCT01244490|DRUG|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
40929020|NCT01244490|DRUG|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
40929021|NCT01244490|DRUG|Placebo Comparator|Placebo
40929022|NCT03703401|DIAGNOSTIC_TEST|Hysterosalpingo-contrast-sonogram|A contrast ultrasound scan to examine fallopian tube pathology and blockage
40929023|NCT01487577|DRUG|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
40929024|NCT03608761|DRUG|Rebamipide|rebamipide 2%
40929025|NCT03608761|BIOLOGICAL|autologous serum|AS for 3 months
41126880|NCT01117584|DRUG|Metformin|oral tablet
41126881|NCT03746938|DEVICE|VB-C01|Surgical implant of VB-C01 (Collagen membrane seeded with allogeneic stem cells isolated from adipose tissue, ADSC).
40929026|NCT03608761|OTHER|autologous serum and rebamipide 2%|rebamipide and autologous serum for 3 months
41126882|NCT03612375|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
41126883|NCT03612375|OTHER|smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
41126884|NCT04468412|DIAGNOSTIC_TEST|Carotid Artery Reactivity Testing|The carotid artery reactivity (CAR) test assesses macrovascular endothelial function by measuring the carotid artery diameter in response to sympathetic stimulation. Participants are in the supine position with the neck extended for assessment of the carotid artery. Left carotid artery diameter is recorded continuously during baseline (30 seconds) and during immersion of the right hand up to the wrist in icy water (4°C) for 3 minutes. CAR can either represent a dilatory response (normal endothelial function) or a constrictive response (endothelial dysfunction) of the carotid artery.
41126885|NCT05723666|OTHER|Group watching virtual reality glasses|A nature video will be watched with virtual reality glasses.
41126886|NCT05530161|OTHER|hypocalcemia|hypocalcemia or normocalcemia
41126887|NCT01912300|BEHAVIORAL|experimental condition: Passvice Video game; Avtive Video game; Exercise|
41126888|NCT05538494|OTHER|BFR intervention|"Training is applied to this group using low-load exercises with restriction of blood flow. Based on the variables used by the major part of the protocols used in studies on the ERFS, the protocol that will be applied to this group will consist of the following parameters.~* Training: 1 series of 30 repetitions followed by 3 series of 15 repetitions of squats~* Rest between series: Duration of 45 seconds.~* Workload: 30% of 1RM.~* Cadence: 2 seconds for the concentric phase and 2 seconds for the eccentric phase (2:2).~* Cuff pressure: The inflation pressure will be individualized for each individual.~A pressure equivalent to 80% of the minimum pressure necessary for the total occlusion of the femoral artery.~• Cuff placement: proximal quadriceps."
41126889|NCT05538494|OTHER|High load intervention|"A program will be applied to this group of exercise with high loads as a method of treatment in which the following will be applied parameters:~* Training: 4 series of 12 repetitions of squats.~* Rest between series: Duration 2 minutes.~* Workload: 70% of 1RM."
41277384|NCT04723030|DRUG|carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)|"Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.~Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week."
41277385|NCT02532049|BIOLOGICAL|ChAd63 Pfs25-IMX313|
41277386|NCT02532049|BIOLOGICAL|MVA Pfs25-IMX313|
41277387|NCT04915248|DRUG|Daratumumab|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
40754765|NCT05705804|DRUG|Pitavastatin|Pitavastatin 4 mg will be given.
40929027|NCT03460015|DRUG|Sevoflurane|"During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped)."
41126890|NCT02285270|DEVICE|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
41126891|NCT03936023|DRUG|Saxagliptin|Saxagliptin dispensing claim is the exposure
40929028|NCT03460015|DRUG|Propofol|"In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped."
40929029|NCT00958997|DRUG|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
40929030|NCT00958997|BIOLOGICAL|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
40929031|NCT02380690|BEHAVIORAL|Peer Coach Assignment|Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
40929032|NCT01398878|BEHAVIORAL|Intervention work shift|Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
41126892|NCT03936023|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
41126893|NCT03618758|DRUG|Paclitaxel|"Intraperitoneal application of Paclitaxel Phase 1: Dose determination of Paclitaxel (Recommended Dose) Starting from 40mg/m² upto 100mg/m² maximum~Phase 2: Intraperitoneal Paclitaxel with recommended dose"
41126894|NCT03618758|DRUG|mFOLFOX6 regimen|Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
41126895|NCT01742169|BEHAVIORAL|Outreach and Reminder Intervention|This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
41126896|NCT04547764|DRUG|triple antibiotic paste (TAP)|root canal treatment of pulpally involved teeth.
41126897|NCT04547764|DRUG|Vitapex (calcium hydroxide/iodoform paste)|root canal treatment of pulpally involved teeth.
41126898|NCT02796729|PROCEDURE|Magnetic resonance imaging|MRI offers excellent images of the brain and is an important tool for diagnosing metastatic brain tumors. MRI scans are often used to plan treatments such as surgery and radiotherapy. When imaging participants with metastatic brain tumors, a contrast agent is often injected intravenously to highlight the relatively small tumours in the MRI. The standard metal-based MRI contrast agent is Health Canada approved and contains a material called gadolinium. MRI studies that use gadolinium-based contrast agents are called gadolinium enhanced MRI.
41126899|NCT02796729|DRUG|Gadovist (Gadobutrol)|Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
41126900|NCT02796729|DRUG|50% dextrose solution|50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
41277388|NCT04915248|DRUG|Bortezomib|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
41126901|NCT01645033|OTHER|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
41126902|NCT01645033|OTHER|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~* Teaching about the treatment program~* Teaching important ideas about sexual behaviors risks~* Increasing knowledge about specific sexually transmitted diseases~* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]"
41126903|NCT04420767|DEVICE|tDCS|Individuals undergo 20min daily sessions receiving actual tDCS to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
41126904|NCT04420767|DEVICE|Sham brain stimulation|Individuals undergo 20min daily sessions receiving sham stimulation to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
41126905|NCT04420767|BEHAVIORAL|Go-No GO task|During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
41277389|NCT04915248|DRUG|Dexamethasone|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
41277390|NCT04680884|DRUG|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
41277391|NCT04680884|DRUG|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
41448157|NCT06627075|PROCEDURE|Surface Guided RadioTherapy (SGRT) without mask|"Firstly, patients are positioned in a vacuum mattress that moulds their head, neck and shoulders for a reference scan.~During the treatment sessions, patients are positioned according to the reference scan, using the surface camera system.~Once the observed offsets have been applied, the patient's surface is captured. Treatment can then begin, with continuous monitoring of displacements by the surface camera system. Automatic beam interruption is provided during treatment in the event of motion detection exceeding the standard tolerance threshold (\>3 mm).~If the use of a thermoformed mask during your treatment prove necessary, for whatever reason, will not result in a halt to the research.~Patients receive between 10 and a max of 35 radiotherapy sessions. The follow-up period begins after the last radiotherapy session, and patients are assessed at 4 or 6 weeks and at 3 months by a radiotherapist."
41448158|NCT02871076|DEVICE|Acupuncture|Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
41448159|NCT06183125|BEHAVIORAL|Traditional Chinese Medicine-based program|"Week1-2: one health talk session(60 mins); three workshops (each workshop will last for 60-90mins) to provide hands-on training in Baduanjin, acupressure techniques, mindful stretching, and effective strategies to combat sedentary behavior in the workplace.~Week 3-4: group practice sessions will take place for one hour every other day throughout the workweek; website support."
41448160|NCT01811953|DRUG|Empagliflozin|medium dose oral administration
41448161|NCT01811953|DRUG|Metformin|oral administration
41448162|NCT01811953|DRUG|Empagliflozin|low dose of Empagliflozin oral administration
40929033|NCT06213675|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
40929034|NCT06213675|PROCEDURE|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
40929035|NCT04013243|DRUG|Magnesium Sulfate|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
41277392|NCT04680884|DRUG|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
41448163|NCT01811953|DRUG|Empagliflozin/Metformin|low dose of Empagliflozin
41448164|NCT01811953|DRUG|Metformin|oral administration
41448165|NCT01811953|DRUG|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
41448166|NCT01811953|DRUG|Empagliflozin|medium dose oral administration
40929036|NCT04013243|DRUG|Placebo|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
41126906|NCT02966613|DEVICE|GMK Medacta Total Knee arthroplasty|Total Knee arthroplasty
41126907|NCT00224406|DRUG|repertaxin|
41448167|NCT01811953|DRUG|Metformin|oral administration
41448168|NCT01811953|DRUG|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
41448169|NCT06542237|DRUG|YCT-529|In the Phase 1b part of the study, 4 dosing cohorts and one optional 5th cohort with 4 participants will be evaluated (up to 20 participants): 15, 45, 90 and 180 mg. In the Phase 2a part, up to 3 cohorts of up to 10 participants (up to 30 participants) will receive doses within the range of doses that was well tolerated and had biological activity in the Phase 1b portion.
41448170|NCT05789173|DRUG|Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)
41448171|NCT05789173|DRUG|Efavirenz, Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)
41448172|NCT00789308|DRUG|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
41126908|NCT04351386|DEVICE|AF Detection|Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG
41277393|NCT04680884|OTHER|Standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
41448173|NCT00789308|DRUG|Heparin|Anticoagulation
41448174|NCT00789308|DRUG|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
41448175|NCT00789308|DRUG|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
41448176|NCT00789308|DRUG|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
41448177|NCT00789308|DRUG|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
41448178|NCT00789308|DRUG|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
41448179|NCT00789308|DRUG|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
41277394|NCT01073150|DRUG|Tea Tree Oil|Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks
41277395|NCT04339868|DRUG|Terlipressin|Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine
41277396|NCT04339868|DRUG|Placebo|0.9% NaCl plus norepinephrine and/or epinephrine
41277397|NCT00110305|DRUG|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
41277398|NCT00110305|DRUG|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
41277399|NCT00110305|DRUG|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
41277400|NCT00110305|DRUG|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
41277401|NCT00110305|DRUG|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
41277402|NCT05152355|DRUG|Budesonide 200 microgram/Puff, HFA MDI|Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
41277403|NCT05152355|DRUG|Budesonide 100 microgram/Actuation Powder for Inhalation|Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
41448180|NCT00789308|DRUG|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
41448181|NCT05512104|PROCEDURE|bone marrow aspirate and biopsy|fiow cytometry of bone marrow aspirate
41448182|NCT02442687|DRUG|JKB-121: 5 mg twice daily|
41448183|NCT02442687|DRUG|JKB-121: 10 mg twice daily|
40929037|NCT05404360|DEVICE|BrainsWay Deep TMS HAC/H7-Coil|The BrainsWay HAC/H7-Coil Deep TMS System is composed of four main components: an electromagnetic H7/HAC-Coil, TMS stimulator, cooling system and positioning arm.
41126909|NCT03257410|DEVICE|Theranova 400 dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
41126910|NCT03257410|DEVICE|Elisio-17H dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
40754766|NCT05705804|DRUG|Pitavastatin plus Ezetemibe|Pitvastatin 4 mg plus ezetemibe 10 mg will be given.
40754767|NCT05705804|DRUG|Atorvastatin|Atorvastatin 40 mg will be given.
41126911|NCT03333109|BIOLOGICAL|Erenumab|70 mg/mL pre-filled syringe administered subcutaneously
41126912|NCT03333109|OTHER|Placebo|Matching placebo in pre-filled syringe administered subcutaneously
41126913|NCT06510881|PROCEDURE|Rhinoplasty with or without cleft alveolus repair|"* Group (A) : Correction of nasal deformity will be carried out using costochondral cartilage strut for support of septum and lengthening of columella . A concomitant iliac bone graft is taken to reconstruct the alveolar bone . This group age will be above 8 years .~* Group (B) : Patients who present early before age of 8 years will have rhinoplasty session only . Another session will be prepared for cleft alveolus at age of 8 years ."
41126914|NCT00604955|DRUG|Paromomycin sulfate|Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
41126915|NCT03377205|DEVICE|Compression screws and neutralization plate|Open reduction and internal fixation with screws and plate
41126916|NCT03377205|DEVICE|Acumed Fibular Rod System|intramedullary nailing of fibula
41126917|NCT02633215|DEVICE|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
41126918|NCT00176800|DRUG|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
41126919|NCT00176800|PROCEDURE|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
41126920|NCT00176800|PROCEDURE|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
41126921|NCT03483649|DRUG|HLX04|HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
41126922|NCT03483649|DRUG|US-Avastin®|US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
41126923|NCT03483649|DRUG|EU-Avastin®|EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
41126924|NCT03483649|DRUG|CN-Avastin®|CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
41126925|NCT05729503|DRUG|Lidocaine 2% Injectable Solution|Cotton tip applicator pre-soaked with lidocaine
41126926|NCT05729503|DRUG|Placebo|Cotton tip applicator pre-soaked with saline
41126927|NCT00289835|DEVICE|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
41126928|NCT01198431|BEHAVIORAL|Sleep duration|Duration of sleep per night
41126929|NCT04654598|OTHER|BPA levels|BPA (bisphenol A) in urine, blood and follicle fluid samples
41126930|NCT06211972|BEHAVIORAL|OpiVenture|"OpiVenture, a targeted psychosocial intervention, complements opioid agonist therapy for opioid use disorder. Adapted from proven interventions like PreVenture, it unfolds over three sessions. Session one covers introductions, an ice-breaker, trait overview, strengths/limitations discussion, goal setting, and homework. Session two reviews homework, explores coping strategies, weighs alternatives, introduces hot thoughts, reviews trait-specific hot thoughts, and assigns homework. The concluding session involves reviewing homework, identifying personal hot thoughts, challenging them through a cognitive-behavioral exercise, applying insights to goal setting, and concluding with a wrap-up."
41126931|NCT06340087|OTHER|10% Sucrose|10% sucrose corresponding to a regular soft drink
41448184|NCT02442687|DRUG|Placebo|
41448185|NCT06627322|DRUG|Dual-combination therapy|Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.
41448186|NCT06627322|DRUG|Triple-combination therapy|Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
40929038|NCT05404360|DEVICE|BrainsWay Deep TMS Sham Coil|"The experimental system has two coils in the same helmet, a sham and active coil.~The sham coil has a similar acoustic artifact as the active coil and it administers a superficial stimulation to maintain blinding. The system assigns the active or sham coil based on the patient ID during the high frequency treatment."
40929039|NCT00021073|DRUG|alvocidib|Given IV
40929040|NCT00021073|DRUG|leucovorin calcium|Given IV
40929041|NCT00021073|DRUG|fluorouracil|Given IV
40929042|NCT00021073|DRUG|irinotecan hydrochloride|Given IV
40929043|NCT01147627|DRUG|exenatide injection|Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
41126932|NCT06340087|DRUG|Sucrose+ Hesperetin|Addition of hesperetin increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
41126933|NCT06340087|OTHER|7% Sucrose|7% sucrose to match the caloric content of the sugar-reduced hesperetin intervention
41126934|NCT01146522|DRUG|LCQ908|
41126935|NCT01146522|DRUG|Placebo|
41126936|NCT00076648|DRUG|Poly SFH-P Injection|
41126937|NCT02071043|DRUG|Capecitabine|Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3
41126938|NCT02071043|DRUG|Oxaliplatin|Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
41126939|NCT05224024|PROCEDURE|Retzius-repairing robot-assisted radical prostatectomy|Repairing the retzius space which is opened during the standard robot assisted radical prostatectomy.
41126940|NCT05801367|DRUG|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
41126941|NCT05801367|DRUG|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
41126942|NCT00936416|PROCEDURE|Inulin and PAH clearance and MRI|"GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes."
41126943|NCT04324099|OTHER|neuroimaging session (with simultaneously acquired eye-tracking)|neuroimaging session, including two functional neuroimaging paradigms (ca. 15-20 minutes each) and a short structural image acquisition (mprage) for coregistration. Functional Magnetic Brain Imaging (fMRI) and simultaneous eye-tracking data will be collected during the paradigms: 1) an emotion processing paradigm (adapted from Passamonti et al., 2010); and 2) an emotional Go/noGo paradigm (adapted from Hare et al., 2008).
41126944|NCT04324099|OTHER|Questionnaire (for children) assessing traumatic experiences (Childhood trauma questionnaire (CTQ))|The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.
41126945|NCT04324099|OTHER|Social and Health Assessment (SAHA) questionnaire (for children)|Self reported survey assessing social and mental health with four aspects of parenting determined (parental involvement, parental warmth, parental control, and inconsistency of parenting).
41126946|NCT04324099|OTHER|Massachusetts Youth Screening Instrument (MAYSI-2) (for children)|"The Massachusetts Youth Screening Instrument (MAYSI-2) is a screening instrument developed for detecting mental health needs in youth aged 12-17. Designed as a low-cost, easily administered tool, it screens for multiple issues and can be administered in 10-15 minutes. It is divided into seven scales composed of 52 questions that are designed to detect alcohol/drug use, angryirritable behavior, depression-anxiety, somatic complaints, suicide ideation, thought disturbance, and traumatic experience. Youths answer YES or NO concerning whether each item has been true for them within the past few months."
41126947|NCT04324099|OTHER|Interpersonal Reactivity Index (IRI) (for children)|The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales
41277404|NCT00312130|DRUG|Vildagliptin|
41277405|NCT04727515|DRUG|fentanyl 2µg/kg intravenously and maintained with isoflurane|Anesthesia will be induced using titration of intravenous propofol till loss of verbal contact and fentanyl 2µg/kg intravenously and maintained with isoflurane (end tidal up to 1.5%), oxygen in air 50:50 via a laryngeal mask.
41277406|NCT04727515|PROCEDURE|Axillary nerve Block|Axillary block will be performed using ultrasound technique. Patients will receive an axillary block under ultrasound guidance using a linear 5-12 MHz probe.
41448187|NCT06627322|DEVICE|Dexcom G7, Pasta|Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.
41448188|NCT03317444|DRUG|TRC101|Oral suspension
41448189|NCT03317444|DRUG|Placebo|Oral suspension
41448190|NCT06557551|OTHER|Thin catheter surfactant|Surfactant given through thin catheter inserted under video laryngoscopy at or after 5 minutes of life
40929044|NCT01147627|DRUG|Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R|Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
40929045|NCT01147627|DRUG|Pioglitazone|Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
40929046|NCT02604121|DEVICE|Orcellex® Rovers brush|transepithelial brushing
40929047|NCT02226679|DEVICE|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
41448191|NCT03827395|BIOLOGICAL|HEV 239|Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.
41448192|NCT03827395|OTHER|Placebo|0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 \[4.5 - 7.0\]).
41126948|NCT04324099|OTHER|Youth Psychopathic Traits Inventory (YPI) (for children)|self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.
41126949|NCT04324099|OTHER|Reactive Proactive Questionnaire (RPQ) (for children)|The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
41126950|NCT04324099|OTHER|Emotion Regulation Questionnaire (for children)|10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)
41126951|NCT04324099|OTHER|Basic Empathy Scale (BES) (for children)|The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.
41448193|NCT01870258|OTHER|ANN prediction of myocardial infarction|
41448194|NCT06468254|DRUG|Statin|Statin Group: Conventional chemotherapy and maintenance therapy combined with statins.
41448195|NCT06468254|DRUG|Sugar pill|Control Group: Conventional chemotherapy and maintenance therapy alone.
41448196|NCT03631628|DEVICE|Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)|The stimulator is a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching, to provide sensory stimulation to both paretic and intact arms. Two pairs of disposable surface electrodes will be applied over the median nerve from the carpal tunnel to the flexor digitorum superficialis and the superficial radial nerve from the extensor pollicis longus to the extensor digitorum communis, with the cathode on the proximal site, and the anode on the distal site.
41448197|NCT03631628|BEHAVIORAL|Mirror Therapy (MT)|"A customised angle-adjustable frame with a mirror board will be used. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of mirror, and paretic arm will be placed behind the mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively.~Participants will be encouraged to focus on the image of intact arm when performing upper limb exercises bilaterally."
41448198|NCT03631628|BEHAVIORAL|sham-Mirror Therapy (sham-MT)|"A customised angle-adjustable frame with a mirror board will be used while the reflecting surface of the mirror was covered with paper. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of covered mirror, and paretic arm will be placed behind the covered mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively."
41448199|NCT03631628|BEHAVIORAL|Conventional Rehabilitation Program|Standardized upper limb training
41448200|NCT03966651|DRUG|PRRT with 177Lu-DOTATATE|Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
41126952|NCT04324099|OTHER|Pubertal Development Scale (PDS) (for children)|self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
41126953|NCT04324099|OTHER|Alabama Parenting Questionnaire (APQ) (for parents)|The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)
41277407|NCT01839474|DEVICE|CPAP|Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
40754768|NCT03488485|DRUG|Direct Acting Antivirals|DAAs given in patients with viremic chronic hepatitis C
40754769|NCT00201773|DRUG|Exemestane|25 mg orally once per day for 16 weeks.
40754770|NCT00201773|DRUG|Celecoxib|given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
41277408|NCT01989663|DRUG|1% vaginally applied tenofovir gel|
41277409|NCT01989663|DRUG|Tenofovir film- 10mg|
41126954|NCT04324099|OTHER|Inventory of Callous Unemotional Traits (ICU) (for parents)|24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits.The ICU has three subscales: Callousness, Uncaring, and Unemotional. The ICU is made up of statements with a 4-point Likert scale, ranging from 0 (Not at all true) to 3 (Definitely True), with higher scores indicating greater CU traits.
41448201|NCT05132426|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|"Myofascial release of the thoracic inlet is a treatment involving gentle pressure applied to shoulders and neck to move the tissue in different directions.~Pectoral traction will have the doctor gently grasp and slowly pull the armpit area with a slow pulling force applied towards the shoulders.~Diaphragm release with MFR consists of the doctor touching below the ribs on each side and gently applying pressure to move the tissue from side to side.~Fascial release of the breast will have the doctor encircling the breast with their hands and inducing anterior traction. The doctor then induces motion in all directions. The doctor will then locate the affected spot and use a direct stripping motion from the base of the breast toward the areola until the restriction is released.~Thoracic pump has the doctor placing their hands over the chest wall on each side and applying pressure and releasing pressure several times to generate a pumping action of about 100 times per minute."
41448202|NCT01683045|DEVICE|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
41448203|NCT05370768|BEHAVIORAL|Parenting Mindfully Intervention|Includes meditation and using meditation and mindfulness in everyday life and in parenting interactions.
41126955|NCT04324099|OTHER|Child Behavior Checklist (CBCL) (for parents)|"The eight empirically-based syndrome scales are:~1. Aggressive Behavior~2. Anxious/Depressed~3. Attention Problems~4. Rule-Breaking Behavior~5. Somatic Complaints~6. Social Problems~7. Thought Problems~8. Withdrawn/Depressed. Higher scores indicate greater Problems."
41126956|NCT04324099|OTHER|Griffith Empathy Measure (GEM) (for parents)|self-report 23-item measure of empathy in which the respondent answers each item on a nine-point Likert scale from strongly disagree to strongly agree
41126957|NCT04324099|OTHER|Social Responsiveness Scale (SRS) (for parents)|Social Responsiveness Scale (SRS) measures social ability of children from 4 years to 18 years old. It is used primarily with individuals with Autism Spectrum Disorder (ASD), family members of individuals with ASD, and others who have social impairments. Parent or teacher questionnaire (65 items on a 4-point Likert scale). High scores are associated with more severe social impairments.
41126958|NCT05738369|DIETARY_SUPPLEMENT|Biogaia L. reuteri Prodentis® lozenges|Participants were instructed to use the lozenges twice daily after brushing their teeth; once in the morning and once in the evening
41126959|NCT05738369|DIETARY_SUPPLEMENT|Hersheyland Ice Breakers Mints sugar free lozenges|Hersheyland Ice Breakers Mints sugar free lozenges
41126960|NCT03510169|DEVICE|NeoVest|Negative pressure ventilation with NeoVest
41126961|NCT03762772|DRUG|TAF/EVG Vaginal Insert|1 combination vaginal insert (20mg TAF/16mg EVG)
41126962|NCT02738307|OTHER|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
41126963|NCT00701701|BIOLOGICAL|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Cyclophosphamide: 250 mg/m\^2 IV q4w after Myozyme infusion for 6 months.
41126964|NCT00701701|BIOLOGICAL|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m\^2 IV weekly beginning the day after Myozyme infusion for 4 weeks (an optional additional 2nd cycle could be administered at the discretion of the investigator); Methotrexate: 15 mg/m\^2 subcutaneous qow on the day after Myozyme infusion for 6 months.
41126965|NCT03298074|DRUG|Apatinib|Apatinib, 500mg,po qd for continuous administration
41126966|NCT03298074|DRUG|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
41126967|NCT02522598|DRUG|VVZ-149 injections|Colorless, transparent liquid in water for injection
41448204|NCT02663921|OTHER|Part A: Baseline-Week 2|"The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:~1. Immediately after the light exposure;~2. 30 minutes after light exposure; and~3. 1 hour after light exposure."
41448205|NCT02663921|OTHER|Part B: Week 4-Week 12|"The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography~1. Visual Clinical Assessment~2. Spectroscopy~3. Colorimetry"
40754771|NCT00201773|OTHER|Correlative studies|
41126968|NCT02522598|DRUG|Placebo|water for injection
41126969|NCT05692817|DEVICE|Low-Intensity Pulsed Ultrasound|"The total sample will be randomly divided into two equal groups (according to method of application of the lipus on the intervention side)as follows: ■ Group I: will include 8 patients who will receive lipus with maxillary canine retraction that will be performed every (3 weeks) on intervention 6 sides according to a standardized protocol.~▪ Group II: will include 8 patients who will receive lipus that will be performed every (1 week) on intervention sides according to a standardized protocol."
41277410|NCT01989663|DRUG|Tenofovir Film-40 mg|
41277411|NCT01989663|OTHER|HEC Placebo Gel|
41277412|NCT01989663|OTHER|Placebo Vaginal Film|
41277413|NCT05904587|DEVICE|SureSmile® VPro™|the pain is recorded when the patient is biting on the mouthpiece of the device during the debonding procedure
41277414|NCT05904587|OTHER|ortho technology, sports advantage, thermal forming soft EVA 3mm|the pain is recorded when the patient is biting on the EVA sheet during the debonding procedure
40929048|NCT00174772|DRUG|docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
41126970|NCT03036176|BEHAVIORAL|Play-based family centered stimulation|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
40929049|NCT00174772|DRUG|docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin|docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
40929050|NCT05463198|DEVICE|CM-1600|Subjects undergoing blood donation will be connected to the CM-1600 device.
40929051|NCT04786509|DIAGNOSTIC_TEST|Field tests|In this study we used three different standardized running tests, one sub-maximal test - Cooper 2400 m (C), and two maximal (all-out) tests - 100 m sprint (S) and shuttle run (SR).
40929052|NCT05143710|DIAGNOSTIC_TEST|PRES in PE or E|patients diagnosed with posterior reversible encephalopathy syndrome with preeclampsia or eclampsia
40929053|NCT01319331|DRUG|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
41126971|NCT03036176|OTHER|no intervention|On the other hand, the control SAM group did not receive the guided psychomotor/psychosocial stimulation services although they had access to the playground facilities. Both the intervention and the control groups received all the routine medical care and dietary rehabilitation services at the hospital.
41277415|NCT05904587|OTHER|cotton roll|the pain is recorded when the patient is biting on the cotton roll during the debonding procedure
41277416|NCT06657066|DRUG|Beclomethasone 200mcg, salbutamol 100mcg , Beclomethasone 200 mcg/Formoterol 6 mcg, 250 mg of lyophilized saccharomyces boulardii|Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram plus Saccharomyces boulardii, available in sachet from employed in this research containing 250 mg of lyophilized saccharomyces boulardii. It was given daily for three months
41277417|NCT06657066|DRUG|Control (Standard treatment)|The control arm will receive only standard treatment for asthma i.e Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram.
41277418|NCT04177498|DRUG|Rigosertib Sodium|given PO or 72 hour continuous infusion
41277419|NCT04177498|OTHER|Quality-of-Life Assessment|Ancillary studies
41277420|NCT06653777|DRUG|Pemigatinib|Pemigatinib will be administered orally once daily for 2 weeks followed by a 1-week off (intermittent schedule 2/1).
41277421|NCT06447506|DRUG|GSK1070806|Participants will receive GSK1070806.
41277422|NCT05453903|DRUG|Bleximenib|Participants will receive bleximenib.
41277423|NCT05453903|DRUG|Venetoclax (VEN)|Participants will receive VEN.
41277424|NCT05453903|DRUG|Azacitidine (AZA)|Participants will receive AZA.
41277425|NCT05453903|DRUG|Cytarabine|Participants will receive cytarabine
41277426|NCT05453903|DRUG|Daunorubicin or Idarubicin|Participants will receive daunorubicin or idarubicin
41277427|NCT05054036|DRUG|MoviPrep|Split-dose MoviPrep bowel preparation
41277428|NCT05054036|DRUG|Golytely|Split-dose GoLYTELY bowel preparation
41277429|NCT06483477|OTHER|Standard skin care|From the start of radiotherapy, standard skin care has to be performed by the patient. This may vary at the participating centers. At the site in Lübeck, it includes fatty cream with 2-10% urea (fatty cream alone, if patients do not tolerate urea) and, in case of pruritus, addition of mometasone furoate cream. In case of grade ≥2 moist desquamation or grade ≥3 radiation dermatitis, each day antiseptic agents will be administered for wound cleansing followed by administration of silicon or calcium alginate bandage. This treatment will be continued until moist desquamation radiation disappears and radiation dermatitis improves to grade 2. Fatty cream with 2-10% urea is applied to the irradiated skin four times daily. Mometasone furoate cream: In addition to the fatty cream with 2-10% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
41277430|NCT06483477|DEVICE|Reminder App|In addition to standard skin care, patients are supported by a Reminder App. The purpose of the app is to remind the patients in an intuitive, unobtrusive and supportive way to perform skin care. By default, patients are reminded four times a day, but they will also be able to define a notification schedule that best suits their personal needs. The patients may postpone each required care procedure for up to 2 hours. With each procedure, the patients are guided through the skin care with simple and self-explanatory illustrations. To increase the patients' motivation, they will additionally earn points for regular and punctual performed care procedures. The patients receive a hand-out including instructions how to properly perform skin care, but they can also find an information page within the application that includes similar instructions.
41277431|NCT06412341|BEHAVIORAL|Accepting your Body after Cancer|See 'Arm Description'
41277432|NCT06412341|BEHAVIORAL|Macmillan body image booklet|See 'Arm Description'
41448206|NCT05130762|DEVICE|BD PureHub™ Disinfecting Cap Placements: Attachments/removals|Attachment/Removals of BD PureHub™ Disinfecting Cap
41448207|NCT02376881|DRUG|Erythropoietin|20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
41448208|NCT02376881|OTHER|placebo|100 ml normal saline in 2 hr for 3 successive days
40929054|NCT05551247|DRUG|Envafolimab|300mg,sc,d3,Q3W;
40929055|NCT05551247|DRUG|recombinant human endostatin (endostatin)|210mg,civ,d1-3,Q3W
40929056|NCT05208918|PROCEDURE|Epidural steroid|Injection of Depo-Medrol of affected dermatomes
40929057|NCT05208918|PROCEDURE|PRF plus steroids injection|Pulsed radiofrequency with temperature 42 degrees for 6 minutes to be applied to the dorsal root ganglion plus injection of Depo-Medrol of affected dermatomes
40929058|NCT00830791|DRUG|MK-0941 20 mg|Two 10-mg tablets of MK-0941 administered as a single oral dose.
41448209|NCT06265753|OTHER|Gastrocinemius Function Massage|The purpose of gastrocnemius massage is to alleviate muscle stiffness in the gastrocnemius muscle and enhance mobility in the foot and ankle of the individuals involved. During the GFM application, the patient assumes a prone posture on a suitable treatment bed. The therapist positions themselves behind the patient's side and secures the patient's foot between their hip and ilium.The therapist firmly holds the gastrocnemius muscle using both hands and applies pressure to the ankle, causing it to move in the direction of dorsiflexion. Simultaneously, the therapist applies mobilisation in the cranial direction, following the same path as the gastrocnemius muscle fibres, using both hands. Afterwards, the therapist gently pulls the arm and trunk backwards until the foot and gastrocnemius muscle become relaxed. The application is sustained in a rhythmic manner . We will apply this massage aproximately 10 min to experimental group.
40929059|NCT00830791|DRUG|MK-0941 5 mg|MK-0941 administered as one single 5-mg tablet.
40929060|NCT04637828|DRUG|GNS561|study drug
41126972|NCT05952258|DEVICE|Magnetic stimulation|The magnetic stimulation to the pelvic floor muscle will be provided by the Emsella® chair: which will be activated for 28 minutes at each treatment session. The treatment arm will receive up to 100% intensity at each treatment session.
41126973|NCT05952258|DEVICE|Sham Magnetic stimulation|The sham arm will receive up to 5% intensity at each treatment session
40929061|NCT03609398|BIOLOGICAL|RVF Vaccine|1.0 mL dose given SQ in upper arm
40929062|NCT01413633|PROCEDURE|cholecystectomy|single incision laparoscopic cholecystectomy
40929063|NCT03986073|DRUG|TQ-F3083 capsule 10 mg|Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.
41126974|NCT04418973|OTHER|VOCs analysis in exhaled air|using an electronic nose and a mass spectrometry
41126975|NCT00202436|PROCEDURE|Phlebotomy|Removal of 500 ml whole blood
41277433|NCT05535361|DEVICE|Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome|The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.
41277434|NCT04882878|OTHER|Placebo|Placebo will be administered intravenously.
41277435|NCT04882878|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
41277436|NCT04882878|DRUG|Standard-of-care treatment|Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
41277437|NCT03106779|DRUG|Asciminib|40 mg tablets was taken orally twice a day (BID)
41277438|NCT03106779|DRUG|Bosutinib|500 mg tablets was taken orally once daily (QD)
41277439|NCT05593432|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
41277440|NCT05593432|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
40929064|NCT03986073|DRUG|TQ-F3083 capsule 20 mg|Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.
40929065|NCT03986073|DRUG|TQ-F3083 blank analog capsule|Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
40929066|NCT03986073|DRUG|TQ-F3083 blank analog capsule|Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
40929067|NCT03986073|DRUG|Linagliptin blank analog tablet|Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
40929068|NCT03986073|DRUG|Linagliptin tablet|Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
40929069|NCT00103727|DRUG|Talnetant|talnetant
40929070|NCT00103727|OTHER|placebo|Placebo Comparator
41126976|NCT00202436|PROCEDURE|Erythrocytapheresis|machinal removal of erythrocytes
41126977|NCT06145932|DEVICE|real rTMS|treated with 1HZ rTMS 1800 pulses / day,for 10 days
41126978|NCT06145932|DEVICE|sham rTMS|treated with sham rTMS 1800 pulses / day,for 10 days
41126979|NCT00051298|DRUG|Olanzapine|
41126980|NCT00051298|DRUG|Placebo|
41126981|NCT00402428|DRUG|albumin interferon alfa-2b|900 mcg or 1200mcg every two week for 48 weeks
41126982|NCT00402428|DRUG|peginterferon alfa-2a|180 mcg once a week for 48 weeks
41126983|NCT00402428|DRUG|Ribavirin|"1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,\> 75kg)"
41126984|NCT02517892|PROCEDURE|Biopsy|
41277441|NCT02532231|OTHER|Laboratory Biomarker Analysis|Correlative studies
41277442|NCT02532231|BIOLOGICAL|Nivolumab|Given IV
41277443|NCT06399757|DRUG|APL-5125|APL-5125 is an oral drug (capsule) taken daily in 28-day cycles
41277444|NCT05879133|BEHAVIORAL|Questionnaires|Survey
41277445|NCT05879133|OTHER|Fit Bit|measures physical activity
41277446|NCT05832307|OTHER|Existing Influenza Vaccination Practices|Usual care is defined as the existing inpatient influenza vaccination practices that currently exist at a given site.
41277447|NCT05832307|OTHER|Standardized inpatient influenza vaccination program|Intervention A: The basic intervention is the inpatient influenza vaccination program Intervention B: The intensified intervention is the multifaceted influenza vaccination strategy (Intervention A) plus a learning collaborative
41277448|NCT06657339|PROCEDURE|Therapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)|"The patient will undergo therapeutic endoscopy under general anesthesia, either as outpatient or inpatient care, based on the recommendations of the investigating physician, taking into account anesthetic risks and comorbidities. Two CE-marked gastric suturing devices may be used at the discretion of the investigating center based on their practices~OverStich™ allows for tissue fixation via a gastroscope, creating a durable suture through a transabdominal fixation technique. The procedure lasts about 45 minutes and includes measures to prevent vomiting.~Endomina™ is a single-use device that captures the gastric mucosa to create successive plications, allowing for effective suturing along the greater curvature of the stomach."
41277449|NCT04253392|DEVICE|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
41448210|NCT06265753|OTHER|Sham application|The sham application was conducted when the patient was lying face down, with the hands placed on the gastrocnemius muscle without any movement. We will apply this application aproximately 10 min to experimental group.
41448211|NCT05936554|DEVICE|whole body vibration|to improve muscle power and balance.
40929071|NCT00103727|OTHER|risperidone|Active Comparator
40929072|NCT02879396|BEHAVIORAL|PA4LE Program|"1. Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)~2. Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)~3. Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)~4. Patient understanding of red flag indicators of worsening condition and appropriate next steps~5. Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness \& Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms"
40929073|NCT00575835|DIETARY_SUPPLEMENT|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
40929074|NCT00575835|DIETARY_SUPPLEMENT|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
40929075|NCT01133990|DRUG|FOLFIRI|FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.
40929076|NCT01133990|DRUG|E7820|E7820 will be administered orally in tablet form once daily, every day of each 28-day treatment cycle.
41126985|NCT05343494|BEHAVIORAL|Lifestyle Intervention|"The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom."
41126986|NCT04037813|PROCEDURE|Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx|"For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut."
41126987|NCT05681234|RADIATION|18F-RD2|Patients will receive 5-10 mCi 18F-RD2
41126988|NCT05145205|PROCEDURE|Sleeve gastrectomy|"Bougie was applied over the lower curvature to adjust the gastric tube then longitudinal amputation of the stomach was performed for about 4 to 6 cm per pecker of the pylorus to the corner of His. No supportive materials were used, and over-suturing of the basic line performed only over the points of bleeding.~All resected specimens were sent to histopathology laboratory for examination."
41277450|NCT06656936|BEHAVIORAL|PharmFIT|The PharmFIT intervention involves the following components: referral notice to patient, FIT ready notification, FIT ready reminders, FIT distribution, FIT completion reminders, negative and positive results notification, patient navigation support.
41277451|NCT06220604|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
41277452|NCT06220604|DRUG|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
41277453|NCT06220604|DRUG|Deucravacitinib|Deucravacitinib will be administered orally.
41448212|NCT05936554|OTHER|Functional strength training|used in treatment of hemiparetic cerebral palsy and provides postural stability while promoting balance independence with confidence and muscle power
41448213|NCT03600363|DRUG|Metformin|metformin (1.0g, bid) as a maintenance therapy in patients with complete remission
40929077|NCT01133990|DRUG|Bevacizumab|Bevacizumab will be administered at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle.
40929078|NCT05883670|DRUG|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
40929079|NCT02946931|DRUG|Prizbind®|Prizbind®
41126989|NCT05145205|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|An antecolic and antegastric RYGB become executed with a 150 cm alimentary limb with both a linearly or circularly kink (25 mm) gastrojejunostomy in step with the desire of the surgeon. A 50-cm-lengthy biliopancreati
41277454|NCT06220604|DRUG|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
41448214|NCT03600363|DRUG|Placebos|oral placebos as a maintenance therapy
41448215|NCT05802563|DEVICE|fitness tracker|Study subjects will wear a Fitbit fitness tracker
41448216|NCT05377164|BEHAVIORAL|food choices|Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.
41448217|NCT00840658|BEHAVIORAL|Interactive injection and sexual risk intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
41448218|NCT00840658|BEHAVIORAL|Interactive Sexual Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
41126990|NCT03322124|DRUG|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
41126991|NCT03322124|OTHER|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
41277455|NCT06631287|DRUG|Baricitinib|4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.
41126992|NCT06374004|OTHER|Exercise Group|The exercises will be given as a home program and each exercise will be performed 2 times a day for a total of 12 weeks. Participants will perform the exercises 1 day a week under the supervision of a physiotherapist. The exercise program lasts approximately 30 minutes.
41448219|NCT00840658|BEHAVIORAL|Interactive Injection Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
41448220|NCT00840658|BEHAVIORAL|Lecture-format presentation|60 minute lecture-format presentation on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). There are no theory-driven active skill building elements oriented towards safer sex or safer injection.
41448221|NCT05694546|BEHAVIORAL|Community Health Worker Post-Discharge Intervention|Clients will be offered a community-based follow-up from a community health worker after hospital discharge.
41448222|NCT02854826|OTHER|SAFE Care model of care|"SAFE Care Model Site Intervention:~1. Endorse best practices for frail patients;~2. Identify frail patients promptly using multi-dimensional screening and assessments;~3. Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;~4. Develop electronic health record templates for patient-centered interprofessional frailty notes;~5. Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.~6. Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail."
41448223|NCT01300273|DIETARY_SUPPLEMENT|Compound α-Ketoacid Tablet|30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.
41448224|NCT03999645|PROCEDURE|Early laparoscopic cholecystectomy|within 72h from symptom onset
41448225|NCT03999645|PROCEDURE|Late laparoscopic cholecystectomy|after 72h up to seven days from symptom onset
41448226|NCT02313558|DRUG|Dentifrice Containing Ilex Rotunda Thunb|Use the dentifrice to brush teeth twice a day for 12 weeks
41448227|NCT02313558|DRUG|Control dentifrice|Use the dentifrice to brush teeth twice a day for 12 weeks
41448228|NCT00185757|DRUG|Cytokine Induced Killer Cells|CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
41448229|NCT06623344|OTHER|Magnetic Resonance Imaging with or without Contrast|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
41448230|NCT00002939|DRUG|irinotecan hydrochloride|
41448231|NCT00002939|DRUG|paclitaxel|
41277456|NCT06631287|OTHER|Placebo|Encapsulated, pre-formed tablet PO once daily for 24 weeks.
41277457|NCT05420766|BEHAVIORAL|Shortened Sleep|In this experimental condition, children go to bed 90 minutes later than their typical bedtime during Week 2 of the 4-week protocol.
41448232|NCT06628349|DIETARY_SUPPLEMENT|Whey Protein Isolate 90%|Commercially available animal based protein powders
41448233|NCT06628349|DIETARY_SUPPLEMENT|Soy Protein Isolate (90% Protein)|Commercially available plant based protein powders
41448234|NCT06628349|DIETARY_SUPPLEMENT|Organic Pea Protein Isolate|Commercially available plant based protein powders
41448235|NCT06628349|DIETARY_SUPPLEMENT|Placebo (Water)|Normal drinking water
41448236|NCT04884841|OTHER|Patients diagnosed with postoperative complications|Patients diagnosed with postoperative complications (Acute kidney injury, Chronic Kidney disease, Infection, Delirium, MACCE, Myocardial infarction, Postoperative pulmonary complications, major bleeding, ECMO, IABP....)
41448237|NCT04884841|OTHER|Patients without postoperative complications|Patients without postoperative complications
41448238|NCT02258035|OTHER|Blood draw|Sampling of 100-150 ml of blood
41448239|NCT06393738|DRUG|ARV-393|Oral dose of ARV-393 at a specified dose schedule will be taken in 28-day cycles
41277458|NCT05420766|BEHAVIORAL|Stabilized sleep|In this control condition, children go to bed at their usual time throughout the 4-week protocol.
41277459|NCT06556108|BIOLOGICAL|ALPP CAR-T cells|T cells genetically engineered with a CAR targeting ALPP (ALPP CAR) that display specific reactivity against ALPP target cells
41277460|NCT06556108|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
41277461|NCT06556108|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
41277462|NCT02432807|DRUG|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1%
41126993|NCT06374004|OTHER|Thoracic Mobilization Group|The exercises will be given as a home program and each exercise will be performed 2 times a day for a total of 12 weeks. Participants will perform the exercises 1 day a week under the supervision of a physiotherapist. The exercise program lasts approximately 30 minutes. Thoracic mobilization will be applied to segments where passive accessory movement is insufficient or painful. 30 repetitions/4 sets will be applied to each determined segment. Thoracic mobilization will be performed with the patient lying prone position.
41448240|NCT06015958|OTHER|Streptococcus salivarius M18 toothpaste (1 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
41126994|NCT02222493|BIOLOGICAL|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
41126995|NCT02222493|BIOLOGICAL|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
41277463|NCT02432807|DRUG|Placebo|Placebo
41277466|NCT06131398|DRUG|AMG 355|Short-term intravenous (IV) infusion
41277467|NCT06131398|DRUG|Pembrolizumab|Short-term IV infusion
41277468|NCT05985681|PROCEDURE|Biospecimen Collection|Undergo blood sample and vaginal swab collection
41277469|NCT05985681|BIOLOGICAL|HPV16 RG1 VLP Vaccine|Given IM
41277470|NCT05985681|OTHER|Questionnaire Administration|Ancillary studies
41277471|NCT05985681|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given via injection
41277472|NCT05985681|OTHER|Saline|Given IM
41277473|NCT06655922|DIAGNOSTIC_TEST|FAPI Imaging|Studies have shown that imaging with radionuclide-labeled fibroblast activation protein inhibitor (FAPI) is a reliable technique for detecting myocardial fibrosis and activated CFs in arteries. Preliminary evidence suggests that FAPI imaging can assess plaque characteristics and the status of myocardial fibrosis in various cardiovascular diseases.
41277474|NCT06642974|OTHER|Education module on learning disabilities|Data will be collected for a period of one -year. samples will be equally distributed among experimental and control group. Socio -demographic data and knowledge and attitude of primary school teachers on learning disability will be assessed by interview method using questionnaire. Control group will receive general information on children with learning disabilities while experimental group will receive education training program. After 15 days again education program will be repeated as a reinforcement. Pre and posttest will be conducted for both the groups at one-month interval. Required data will be collected for one-year period by interview method using questionnaire. Competency assessment will be done by using checklist on identification of learning disabilities Teachers' competency for experimental group then the competency will be verified by education counselor . As a follow up of the research study, after one-month interval no of referral by each teacher will be collected to m
41277475|NCT06642974|OTHER|pamphlet on learning disability|Education pamphlets will be provided to total of 67 samples
41277476|NCT03311126|DRUG|Bendamustine|Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of chronic lymphocytic leukemia (CLL) and for indolent B cell non-Hodgkin lymphomas (NHLs) progressing during or within 6 months of rituximab or a rituximab - containing regimen.
41277477|NCT03311126|DRUG|Obinutuzumab|Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 monoclonal antibody (mAb).
41277478|NCT04764188|DRUG|Alectinib|Participants will receive alectinib in accordance with local clinical practice and local labeling.
41277479|NCT04987281|PROCEDURE|Computed Tomography|Undergo CT
41277480|NCT04987281|DRUG|Indocyanine Green Solution|Given via injection
41448241|NCT06015958|OTHER|Streptococcus salivarius M18 toothpaste (10 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
41448242|NCT00582179|PROCEDURE|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I\&D.
41448243|NCT00582179|DEVICE|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I\&D.
41448244|NCT04003363|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
41448245|NCT02402660|DRUG|ALK-001|Daily, oral administration for 24 months
41448246|NCT02402660|DRUG|Placebo|Daily, oral administration for 24 months
41448247|NCT00896688|PROCEDURE|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
41277481|NCT04987281|DEVICE|Therapeutic Bronchoscopy|Undergo bronchoscopy using Ion robotic bronchoscope
41277482|NCT06523803|DRUG|ZW171|Administered per protocol requirements
40929080|NCT05991921|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|"TENS application, postpartum 10-12. at hours and 14-16. It was applied twice for 30 minutes each. Researcher 1 programmed the TENS unit and was the only researcher who knew whether TENS was active or in placebo mode.~Two pairs of TENS electrodes were placed on the upper and lower border of the cesarean section incision line. A total of 4 electrodes were used in a sterile package for each participant. TENS stimulation was applied at a frequency of 100 Hz and was increased starting from 0 mA. The participant's stimulation was fixed at the mA level, where he felt optimal but did not feel discomfort.~The pretest data were applied to the participants who met the inclusion criteria and volunteered to participate in the study, by the researcher 2 in the patient rooms 10 hours after the cesarean section. Post-test data were obtained by the same investigator 16 hours after cesarean section."
41448248|NCT06560866|BEHAVIORAL|Just Care for Families|Just Care for Families is a behavioral intervention to address the needs of families involved in or at-risk for involvement with the child welfare system. Just Care involves treatment components, supported by ongoing purposeful engagement: (1) Substance use treatment including contingency management and positive reinforcement, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; (4) Community building including indigenous and external social supports; (5) Systems navigation; and (6) provision of assistance with basic needs including assistance with housing and employment.
40929081|NCT05991921|OTHER|Plasebo-Fake TENS|Participants in the placebo group 10-12 postpartum. at hours and 14-16. Two pairs of TENS electrodes were placed at the same time as the intervention group. TENS electrodes were attached to the participants in this group for 30 minutes, the device was operated but no electric current was applied.
41126996|NCT05421117|PROCEDURE|Laparoscopic adnexal mass extraction|Compared with open procedures, Minimally invasive surgery (MIS) is associated with faster recovery times, better patient quality of life, and lower postoperative complication rates. The removal of an adnexal mass from the abdominal cavity is performed most commonly using the suprapubic, trans umbilical (TU), or trans vaginal (TV) route.
41126997|NCT04962750|DEVICE|Low level laser therapy|Low level laser therapy from suitable machine
41126998|NCT04962750|OTHER|Sham device|The device wasn't working
41126999|NCT06031116|PROCEDURE|depigmentation|gingival depigmentation
41127000|NCT04900467|BIOLOGICAL|Pfizer|BNT162b2 (Comirnaty®), Pfizer/BioNTech, mARN vaccine,
41127001|NCT04900467|BIOLOGICAL|Moderna|mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular
41277483|NCT05452603|DEVICE|96-hour off IBP wireless pH monitoring capsule|The endoscopic pH measurement capsule will be placed 6cm above the squamocolumnar junction, determined endoscopically, in the sedated patient. Then the plot will be read.
41277484|NCT05827159|DRUG|Naltrexone Pill|In the MAUD component, some participants will receive oral Naltrexone in the ED.
41448249|NCT00357461|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|
41448250|NCT00357461|BIOLOGICAL|gp100:280-288(288V) peptide vaccine|
41127002|NCT05121467|OTHER|Pain Assessment|Visual Analogue Scale (VAS) were included in the study
41127003|NCT05121467|OTHER|Assessment of Muscular Endurance|The endurance of the 9 muscles/muscle groups including cervical flexor, extensor, deep flexor muscles, trunk flexor, extensor, lateral flexor, and stabilizer muscles, upper extremity, and scapular muscles (mm. serratus anterior and trapezius) were evaluated based on the assessment instructions given in the studies of Edmonston et al., Grimmer et al., Evans et al., Reece et al., ACSM guideline
41127004|NCT05121467|OTHER|Assessment of Neck Awareness|The Turkish version of the Fremantle Neck Awareness Questionnaire (FreNAQ) which was developed by Wand et al. to assess neck awareness in patients with chronic neck pain was used in this study
41127005|NCT05121467|OTHER|Assessment of Fear of Movement|The fear of movement was assessed by the Turkish version of the Tampa Scale of Kinesiophobia which originally developed by Kori et al.
41448251|NCT00357461|BIOLOGICAL|incomplete Freund's adjuvant|
41448252|NCT00357461|BIOLOGICAL|ipilimumab|
41127006|NCT01639131|DRUG|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
41448253|NCT06628024|OTHER|Milk|Milk
40929082|NCT02373501|PROCEDURE|Intra-abdominal repair|Intra abdominal repair of uterine incision
40929083|NCT02373501|PROCEDURE|Extra-abdominal repair|Extra abdominal repair of uterine incision
41127007|NCT01639131|DRUG|Docetaxel|intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle
41127008|NCT01639131|DRUG|Filgrastim or Pegfilgrastim|filgrastim (granulocyte colony-stimulating factor \[G-CSF\]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
41127009|NCT04467671|COMBINATION_PRODUCT|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
40929084|NCT04401527|DRUG|Sodium Nitrite|Continuous intravenous infusion of Sodium Nitrite Injection
40929085|NCT04401527|DRUG|Normal Saline|Continuous intravenous infusion of Normal Saline
41127010|NCT00822120|BIOLOGICAL|bleomycin sulfate|
41127011|NCT00822120|BIOLOGICAL|filgrastim|
41127012|NCT00822120|DRUG|ABVD regimen|
41127013|NCT00822120|DRUG|BEACOPP regimen|
41277485|NCT05827159|DRUG|Naltrexone Injection|In the MAUD component, some participants will receive a dose of XR-NTX (injection) in the ED.
41277486|NCT05827159|BEHAVIORAL|Brief Negotiation Interview|Brief Negotiation Interview (BNI) has four key components: (1) permission to discuss substance use, (2) feedback on the health consequences of ongoing substance use, including making a connection between the ED visit and substance use, (3) motivational enhancement, and (4) negotiation and advice.
41448254|NCT06628024|OTHER|Yoghurt|Yoghurt
41448255|NCT00620958|BEHAVIORAL|Individual cognitive behavioral therapy (ICBT)|ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
40929086|NCT00928122|DEVICE|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
40929087|NCT00928122|DEVICE|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
40929088|NCT00928122|DEVICE|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
41127014|NCT00822120|DRUG|cyclophosphamide|
41277487|NCT05827159|DRUG|Gabapentin Pill|In the MAUD component, ancillary treatment with gabapentin will be provided.
41277488|NCT01947023|PROCEDURE|Biopsy|Undergo tumor biopsy
41277489|NCT01947023|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41277490|NCT01947023|PROCEDURE|Computed Tomography|Undergo CT
41277491|NCT01947023|DRUG|Dabrafenib|Given PO
41277492|NCT01947023|DRUG|Dabrafenib Mesylate|Given PO
40929089|NCT00928122|DEVICE|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
40929090|NCT00928122|DEVICE|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
40929091|NCT03874312|DIAGNOSTIC_TEST|Linear ultrasound (US) assessment of the internal jugular vein|Evaluation of jugular vein distensibility at rest and after Valsalva maneuver by US at the time of the RHC. US-guided IJV is routinely performed at the time of vein cannulation.
40929092|NCT05146453|PROCEDURE|Pectointercostal fascia blocks|PIF blocks will be placed at the conclusion of surgery with the surgical drapes in place. The blocks are performed using a high frequency linear transducer with aseptic technique. The ultrasound probe is placed longitudinally 3 cm from the sternum at the level of the 4th-6th intercostal space. Using an in-plane approach, an echogenic needle will be advanced into the fascial plane between pectoralis major and the external intercostal muscles. Peripheral nerve block catheters will then be inserted and secured to the skin surface with tegaderm. For patients weighing over 70 kg, 20 mL of 0.5% ropivacaine will be administered. This will be reduced to 15mL per side for patients weighing less than 70 kg. A CADD™ pump will be connected to each catheter and programmed to deliver 20 mL boluses of ropivacaine 0.2% starting at postoperative hour 2. The boluses will be staggered every 2 hours on alternate sides until hour 24. The catheters will be removed 24 hours post-operatively.
40929093|NCT05146453|OTHER|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
40929094|NCT00001860|DRUG|Sandostatin LAR Depot versus transsphenoidal surgery|
41127015|NCT00822120|DRUG|dacarbazine|
41127016|NCT00822120|DRUG|doxorubicin hydrochloride|
40929095|NCT05245448|DRUG|Tetrandrine|Administered orally
41127017|NCT00822120|DRUG|etoposide|
41277493|NCT01947023|PROCEDURE|Echocardiography|Undergo ECHO
41277494|NCT01947023|DRUG|Lapatinib|Given PO
41277495|NCT01947023|DRUG|Lapatinib Ditosylate|Given PO
41277496|NCT01947023|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41277497|NCT01947023|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41127018|NCT00822120|DRUG|prednisone|
41127019|NCT00822120|DRUG|procarbazine hydrochloride|
41127020|NCT00822120|DRUG|vinblastine sulfate|
41127021|NCT00822120|DRUG|vincristine sulfate|
41127022|NCT04255706|DEVICE|biometric measurement IOLMaster 700|Three biometric measurements will be performed with 3 devices for all the patients included
41277498|NCT01947023|PROCEDURE|Positron Emission Tomography|Undergo PET
41277499|NCT06145750|DIAGNOSTIC_TEST|Ability to order FirstLook™|FirstLook™ is a commercially available, validated next generation sequencing assay of plasma cell-free DNA (cfDNA) that analyzes the distribution of cfDNA fragment sizes to indicate the presence of possible lung cancer. FirstLook™ is intended to be used by a qualified healthcare provider and is not a replacement for computed tomography (CT) or low-dose computed tomography (LDCT). FirstLook™ is validated for use in individuals aged 50 or older who either currently or previously smoked cigarettes and accumulated 20 pack-years or more of exposure.
41277500|NCT06145750|OTHER|Continuing Medical Education for Lung Cancer|Physician practice will receive standard education on lung cancer screening for CME credit.
41277501|NCT02511522|OTHER|Best Supportive Care|Including analgesics, palliative care and/or pain specialist assessment as needed
41127023|NCT04255706|DEVICE|biometric measurement Lenstar LS 700|Three biometric measurements will be performed with 3 devices for all the patients included
41127024|NCT04255706|DEVICE|biometric measurement Anterion Heildelberg|Three biometric measurements will be performed with 3 devices for all the patients included
41127025|NCT03973034|DIAGNOSTIC_TEST|Low depth whole genome sequencing|Low depth whole genome sequencing of the peripheral blood samples from different groups.
41127026|NCT02616276|OTHER|Control breakfast|It consists of 350 ml of water at room temperature.
41127027|NCT02616276|OTHER|High glycemic index breakfast|It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
41127028|NCT02616276|OTHER|Low glycemic index breakfast|It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
41127029|NCT04019444|BIOLOGICAL|ChAd155-RG|The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.
41127030|NCT04019444|OTHER|Placebo|0.9% Sodium Chloride, USP injection.
41127031|NCT04019444|BIOLOGICAL|Rabies Vaccine|The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation
41277502|NCT02511522|RADIATION|Palliative Radiation Therapy|8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
41277503|NCT05841030|OTHER|No Intervention|There is no interventional treatment administered to the participants as a part of this study.
41277504|NCT05939414|DRUG|AAA617|Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm
41277505|NCT06560359|DIETARY_SUPPLEMENT|F&V|The intervention includes the healthy breakfast plan (daily delivery of balanced breakfast containing at least one piece of fruits, vegetables and other regular diet) and fruit box plan (weekly delivery to home). The selection of fruits and vegetables will consider seasonal availability to ensure freshness and variety. The standardized breakfast will be prepared and delivered by a professional catering service, ensuring consistency in portion size and quality. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
41277506|NCT06560359|DIETARY_SUPPLEMENT|No F&V|The intervention only includes breakfast plan (daily delivery of balanced breakfast containing regular diet without fruits and vegetables) for 12 weeks. The standardized breakfast will be prepared and delivered by a professional catering service, ensuring consistency in portion size and quality. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
41277512|NCT06400121|DRUG|Apimostinel Infusion, Intravenous|Single injection of Apimostinel (10mg)
41277513|NCT06400121|BEHAVIORAL|Cognitive Training|8 sessions of digital active training
41277514|NCT06400121|BEHAVIORAL|Sham Training|8 sessions of digital sham training
41127032|NCT02238769|DEVICE|18F-FluoroethylCholine PET|18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
41127033|NCT06389890|PROCEDURE|Pancreatic resection procedure|Pancreatic resection procedure
41127034|NCT06282354|OTHER|Type of post-operative appointment|remote post-operative appointment for small or medium urooncology procedures
41127035|NCT02973594|DRUG|Ivabradine|
41127036|NCT02973594|DRUG|Placebo|
41127037|NCT00585624|DIETARY_SUPPLEMENT|Impact Advanced Recovery|Nutritional supplement
41127038|NCT00585624|DIETARY_SUPPLEMENT|No supplement|No supplement
41127039|NCT05176054|OTHER|Health service program|The program will be implemented into the experimental group, the program has been designed as a three-stage model including hospital management, transition care, and post-acute stage care.
41127040|NCT05733507|PROCEDURE|IVT with tenecteplase or alteplase|Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.
41448256|NCT00620958|BEHAVIORAL|Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)|Parent relationship training will teach the parent ways to communicate with the child and to solve problems to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
41448257|NCT00620958|BEHAVIORAL|Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT)|Parent reinforcement training will teach the parent strategies for managing the child's behavior through the use of positive rewards and positive parental behaviors to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
41448258|NCT06627894|BEHAVIORAL|Therapist-Assisted Internet Cognitive-Behavioral Therapy for Depression|Good Days Ahead (MindStreet, Inc.)
41448259|NCT06627894|BEHAVIORAL|Active Control|Depression education, symptom monitoring, and standard depression care
41448260|NCT06488911|DRUG|FDC tablet (OCA 5 mg + BZF 400 mg SR)|Participants will be administered with FDC tablets once daily.
41448261|NCT00633672|DRUG|Esomeprazole|20mg Oral tablet once daily
41448262|NCT00633672|DRUG|Ranitidine|150mg oral twice daily
41448263|NCT00633672|DRUG|Esomeprazole|40mg oral tablet once daily
41448264|NCT03664609|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.
41448265|NCT03807440|DRUG|Empagliflozin|Empagliflozin
41448266|NCT03807440|DRUG|Sodium Glucose Transporter 2 inhibitor|Sodium Glucose Transporter 2 inhibitor
41448267|NCT03807440|DRUG|Dipeptidyl-peptidase 4 inhibitor|Dipeptidyl-peptidase 4 inhibitor
41277515|NCT06400121|DRUG|Isotonic Solution, Intravenous|Single injection of placebo
41277516|NCT06637176|DEVICE|Laser speckle contrast imaging|"LSCI measurements will be taken before and after the formation of the anastomosis, with the surgeon blinded to the measurements to prevent any influence on surgical decision-making. The surgery will be performed as standard-of-care, unaffected by the LSCI measurements.~Following the surgery, the LSCI images will be presented to the surgeon, who will complete a questionnaire assessing whether the LSCI images, if presented perioperatively, would have influenced their decision regarding the location of the anastomotic site. Additionally, the surgeon will be asked if they consider LSCI to be a useful intraoperative tool in general. The surgical case and the series of LSCI images will also be presented to an independent surgeon, who will answer the same set of questions.~The LSCI measurements will be correlated with 30-day complication rates, with a specific focus on anastomotic leakage (AL).~Microcirculation is assessed using LSCI at a wavelength of 785 nm (MoorFLPI-2, Moor Instruments"
41277517|NCT02484417|BIOLOGICAL|RSV A2|Intranasal inoculation of healthy volunteers with 10\^5 or 10\^6.3 plaque forming units (PFU) of RSV A2.
41448268|NCT03807440|DRUG|Glucagon-like peptide 1 agonist|Glucagon-like peptide 1 agonist
41448269|NCT04302961|OTHER|Auditory Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that does not cause the auditory tool to elicit a noise.
41448270|NCT04302961|OTHER|No Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that they perceive to be their normal walking speed and mechanics.
40929096|NCT05245448|DRUG|Placebo|Administered orally
40929097|NCT03249688|OTHER|Regular health advice|Routine healthy lifestyle counseling
40929098|NCT03249688|BEHAVIORAL|Multidomain lifestyle|Nutritional guidance, exercise, cognitive training, vascular risk monitoring
40929099|NCT03249688|DIETARY_SUPPLEMENT|Medical food|Medical food product (Fortasyn Connect)
40929100|NCT01671943|DEVICE|Ice-Sense3TM|Ice-Sense Cryoprobe
41448271|NCT00388531|DRUG|Depocyte®|Depocyte® is a cytostatic drug
41448272|NCT05687123|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
41448273|NCT05687123|PROCEDURE|Computed Tomography|Undergo a CT scan
41448274|NCT05687123|DRUG|Lutetium Lu 177 Dotatate|Given IV
41448275|NCT05687123|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41448276|NCT05687123|PROCEDURE|Positron Emission Tomography|Undergo a SSR PET/CT scan
41448277|NCT05687123|DRUG|Sunitinib Malate|Given PO
41448278|NCT05271890|PROCEDURE|Immediate non-surgical periodontal treatment and oral hygiene instructions|
41448279|NCT05174390|DIAGNOSTIC_TEST|Coala Heart Monitor Pro|thumb- and chest-ECG
41448280|NCT05971056|OTHER|Care transition|Cancer care is transitioned to a satellite site.
41448281|NCT05971056|OTHER|No care transition|Cancer care is not transitioned to a satellite site.
40929101|NCT03460743|BIOLOGICAL|Study group - quadrivalent recombinant hemagglutinin influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
41127041|NCT05733507|PROCEDURE|Intervention Name : Tirofiban and IVT with tenecteplase or alteplase|IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
41127042|NCT00766649|DRUG|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
41448282|NCT03750448|OTHER|Telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
41448283|NCT03750448|OTHER|No intervention|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
41277518|NCT03570892|DRUG|Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)
41277519|NCT03570892|DRUG|Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)|"Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT.~\*Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy"
41277520|NCT06645340|OTHER|This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length|This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length, and routine laboratory parameters.
41277521|NCT04964869|PROCEDURE|epinephrine solution injection|epinephrine solution injection at least 1 ml to the post- sphincterotomy wound
41277522|NCT06418711|DRUG|Clofazimine Inhalation Suspension|Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.
41277523|NCT06418711|DRUG|Placebo|Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.
41277524|NCT05887635|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
41277525|NCT05402384|DRUG|AVTX-801|"Medical grade D-galactose~dosage:2.0 g/kg/day"
41277526|NCT05402384|DRUG|Placebo|Matching placebo
41277527|NCT02363335|OTHER|Placebo|mixed meal
41277528|NCT02363335|OTHER|Roflumilast/Sitagliptin|Both Roflumilast and Sitagliptin together
41277529|NCT02363335|OTHER|Sitagliptin|This is already known to increase GLP-1 \&amp; GIP secretion.
41277530|NCT02363335|OTHER|Roflumilast|This is already known to increase GLP-1 \&amp; GIP secretion
41277531|NCT03814746|DRUG|Crizanlizumab (SEG101)|"Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion.~IV."
41277532|NCT03814746|DRUG|Placebo|Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
41277533|NCT06642545|DRUG|Disitamab Vedotin|Disitamab Vedotin 2.0mg/kg,intravenous infusion, every 2 weeks
41277534|NCT06642545|DRUG|RC148|20mg/kg, intravenous infusion, once every 2 weeks
41277535|NCT06642545|DRUG|Albumin-bound Paclitaxone|125 mg/m2,intravenous infusion, D1-8, every 3 weeks
41448284|NCT03750448|OTHER|Unsupervised rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
41277536|NCT06642545|DRUG|Toripalimab|240mg,intravenous infusion, once every 3 weeks
41277537|NCT04898634|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
41277538|NCT05803941|DRUG|AAA617|Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent clinical interventional Novartis sponsored clinical trials.
41277539|NCT06471257|COMBINATION_PRODUCT|Budesonide/Albuterol metered dose inhaler, MDI|Combination Product (Drug + Device)
41277540|NCT06471257|COMBINATION_PRODUCT|Albuterol sulfate metered dose inhaler, MDI|Combination Product (Drug + Device)
41277541|NCT05098483|PROCEDURE|Regeneration in primary molars by using MTA|Regenerative endodontic procedure in nonvital primary molars using MTA capping material
41277542|NCT05098483|PROCEDURE|Regeneration in primary molars by using biodentine|Regenerative endodontic treatment in primary molars with biodentine as capping material
41127043|NCT01765231|DRUG|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
41448285|NCT04157335|BIOLOGICAL|Benralizumab 30 mg|"Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
41277543|NCT05098483|PROCEDURE|Conventional Root canal treatment in primary molars|Removal of pulp tissue from the canals of primary molars
41448286|NCT04157335|BIOLOGICAL|Matched placebo|"Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
41277544|NCT03422822|DRUG|Abrocitinib 100 mg|In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
41448287|NCT04516915|DRUG|IMU-838|IMU-838 twice daily at 22.5mg doses for 14 days
41448288|NCT04516915|DRUG|Oseltamivir|Oseltamivir twice daily at 75mg doses for 14 days
41448289|NCT06563154|DIAGNOSTIC_TEST|Exercise Capacity Assessment|To examine the relationship between exercise capacity and physical fitness of dyslipidemia patients and quality of life, cognitive status and health literacy.
41448290|NCT06563154|DIAGNOSTIC_TEST|Physical Fitness Assessment|"* 1-Minute Sit-to-Stand Test: Participants will be asked to sit down and stand up for 1 minute without pausing, and the repetition number will be recorded.~* Timed Up-and-Go Test: Participants will be asked to get up, walk a distance of 3 meters, return and sit down again. The time spent during this track will be recorded.~* Peripheral muscle strength assessment: Participants will be asked to resist the resistance by producing maximum isometric force during the movement, and the maximal force will be evaluated with a dynamometer. The quadriceps femoris muscle, shoulder abductor muscles and hand grip strength will be used for the assessment.~* Flexibility assessment: Participants will be asked to reach towards the tips of their toes while sitting. During this time, the distance between the participant's fingertips and toes will be measured."
41448291|NCT06563154|OTHER|Quality of Life Assessment|Participants' quality of life will be assessed with the Turkish version of the Short Form Quality of Life Questionnaire (SF-36). The questionnaire consists of 36 questions that examine quality of life from different perspectives. It examines quality of life in the subcategories of physical function, physical role difficulty, pain, general health, vitality (energy), social function, emotional role difficulty and mental health. The score for each category varies between 0-100, with a high score indicating a good quality of life.
41448292|NCT06563154|OTHER|Physical Activity Assessment|Participants' physical activity level will be assessed with the Turkish version of the International Physical Activity Scale - Short Form (IPAQ-SF). The IPAQ-SF evaluates the physical activities of the participants in the last 7 days based on sitting time, walking time, moderate and vigorous physical activities.
41448293|NCT06563154|OTHER|Cognitive Health Assessment|Participants' cognitive health will be assessed with the with the Turkish version of the Mini Mental State Examine (MMSE). The test is scored between 0-30. Scores of 25 and above are considered normal. A total score of less than 10 indicates severe impairment. Scores between 10-19 indicate moderate dementia. Scores between 19-24 indicate early dementia.
41448294|NCT06563154|OTHER|Health Literacy Assessment|Participants' health literacy will be assessed with the Turkish version of the HLS-EU-47 health literacy survey. The survey consists of 47 questions. Each item is assessed with one of the following options: Very difficult (1), difficult (2), easy (3), very easy (4) and I don't know. A high total score indicates good health literacy. A total score of 0-25 points indicates insufficient health literacy, \>25-33: problematic - limited health literacy, \>33-42: sufficient health literacy, \>42-50: excellent health literacy.
41448295|NCT03372876|DIETARY_SUPPLEMENT|Protein and carbohydrate supplementation|Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
41448296|NCT06628167|BEHAVIORAL|Transportation|Participants with ordered low dose CT and participants with scheduled low dose CT are offered free transportation to and from appointment. Participants with ordered low dose CT are also offered assistance in connecting with scheduling staff.
41277545|NCT03422822|DRUG|Abrocitinib 200 mg|In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
41448297|NCT06628167|BEHAVIORAL|Scheduling|Participants with ordered low dose CT are offered assistance in connecting with scheduling staff.
41277546|NCT03422822|DRUG|Placebo|For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
41277547|NCT03422822|DRUG|Abrocitinib 100 mg|For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
41127044|NCT01765231|DRUG|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
41127045|NCT04209712|BIOLOGICAL|haploid allogeneic NK cell therapy|NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.
41127046|NCT03137836|BEHAVIORAL|Intervention|"Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM ."
41127047|NCT05007587|DRUG|Lenvatinib|8mg lenvatinib (weight\<60kg) or 12mg lenvatinib (weight\>60kg) QD
41277548|NCT03422822|DRUG|Abrocitinib 100 mg|In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
41277549|NCT03422822|DRUG|Abrocitinib 200 mg|In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
41277550|NCT06294600|DRUG|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
41277551|NCT06294600|DRUG|Tablets|Oral tablets of similar appearance to active study drug
41448298|NCT01315990|DRUG|FOLFIRI + Cetuximab|"1. Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).~2. FOLFIRI regimen~Administration Schedule:~Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)~* Irinotecan 180 mg/m² iv , 90 min on day 1~* Folic acid (racemic) 400 mg/m², 120 min on day 1~* 5-FU 400 mg/m² bolus on day 1~* 5-FU 2400 mg/m² iv over 46 h on day 1 to 2"
41448299|NCT02974907|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
41448300|NCT02974907|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
41448301|NCT06622239|DRUG|Naltrexone|naltrexone 50mg for 6 weeks
40929102|NCT03460743|BIOLOGICAL|Control group - quadrivalent inactivated influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
41448302|NCT06622239|DRUG|Placebo|placebo for 6 weeks
41448303|NCT00767481|DRUG|Travoprost/Brinzolamide|Eye drop suspension, once daily
41277552|NCT05787704|OTHER|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)"
41277553|NCT06647888|DRUG|Envlo Tablet|Envlo Tab. 0.3mg
41448304|NCT00767481|DRUG|Cosopt|Eye drop solution, one drop BID
41448305|NCT04571294|PROCEDURE|removal of para-aortic lymphnodes (PALN)|During pancreaticoduodenectomy, para-aortic lymphnodes (PALN) will be removed for the surgeon
41277554|NCT06647888|DRUG|Envlomet SR Tablet|Envlomet SR Tablet 0.3/ Metformin1,000mg
41277555|NCT05877144|PROCEDURE|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
40929103|NCT03034668|DIETARY_SUPPLEMENT|CS16-003 Full dose|350 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts
40929104|NCT03034668|DIETARY_SUPPLEMENT|CS16-003 Half dose|175 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts + maltodextrin 175 mg
40929105|NCT03034668|DIETARY_SUPPLEMENT|Placebo|Maltodextrin: 350 mg
40929106|NCT06312696|OTHER|SMT|"SMT will be provided by a licensed chiropractor with at least 5 years' experience.~Treatment will last 15 to 20 minutes each and include a brief history and examination of the cervical spine. SMT will consist of low velocity, variable amplitude spinal mobilization to the cervical spine - Maitland grades 3 or 4. Spinal segments will be determined by the chiropractor using manual palpation and the patients' response to care. Drop-table or instrument-assisted SMT will not be allowed."
41277556|NCT05877144|OTHER|Medical Device Usage and Evaluation|Receive LiSWT
41277557|NCT05877144|PROCEDURE|Duplex Ultrasound|Undergo DDUS
41448306|NCT06626802|PROCEDURE|Balloon Dilation + Topical Mitomycin|Patients with recurrent esophageal strictures in Group A will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Mitomycin applied topically at stricture site (post dilation)
40754772|NCT06193629|DRUG|Lang Qingata|Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.
40754773|NCT06193629|DRUG|placebo|Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use
40929107|NCT06312696|OTHER|Light Massage|Light Massage will be provided as a pseudo-sham intervention to control for time, attention, and touch by a licensed chiropractor with at least 5 years' experience to control for touch and is intended to be delivered gentler and shorter than recommended for therapeutic massage.
40929108|NCT03250364|DEVICE|Multilayer bandage|See arm/group descriptions
40929109|NCT03250364|DEVICE|Double compression bandage|See arm/group descriptions
40929110|NCT03250364|DEVICE|Cohesive bandage|See arm/group descriptions
40929111|NCT03250364|DEVICE|Adhesive compression bandage|See arm/group descriptions
41277558|NCT05877144|OTHER|Survey Administration|Ancillary studies
41277559|NCT05877144|PROCEDURE|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
41277560|NCT05877144|PROCEDURE|Sham Intervention|Receive sham LiSWT
41277561|NCT05877144|PROCEDURE|Duplex Ultrasound|Undergo DDUS
41277562|NCT05877144|OTHER|Survey Administration|Ancillary studies
41277563|NCT05519215|DEVICE|ECHELON 3000 Stapler|There is no intervention, beyond necessary clinical care, in this study. Echelon 3000 Stapler is used for transection and resection in LSG or lung surgical procedure per its IFU.
41277564|NCT05405426|OTHER|Red blood cell transfusion|The intervention is a strategy for when red blood cell transfusion will be administered (see description of Arms). However, volume of RBC transfused in the two arms is not specified by this study. Red blood cell transfusion strategy for ECMO weaning and decannulation is not specified by this study. Red blood cell transfusion after ECMO decannulation is not specified by this study.
41448307|NCT06626802|PROCEDURE|Balloon Dilation + Injection Triamcinolone|Patients with recurrent esophageal strictures in Group B will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Triamcinolone, injected with a sclerotherapy injector, at stricture site (post dilation)
41448308|NCT05561166|OTHER|EPIDREAM Questionnaire|EPIDREAM Questionnaire (questionnaire about dreams and epileptic seizures)
41448309|NCT02273492|DRUG|Asasantin ER|
41448310|NCT02273492|OTHER|Standardized breakfast|
41448311|NCT01169558|DRUG|Bevacizumab|5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
41448312|NCT01169558|DRUG|Fluoropyrimidine-based Chemotherapy|Fluoropyrimidine-based chemotherapy administered according to standard of care.
40929112|NCT03250364|DEVICE|Kinesiotaping bandage|See arm/group descriptions
40929113|NCT03250364|OTHER|Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression|"MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg."
40929114|NCT03250364|OTHER|Upper limb exercises|After the bandage will be put, proprioceptive neuromuscular facilitation exercises without resistance in two diagonal in asymmetrical reciprocal patterns with the affected limb will be taught. The first diagonal into flexion from hitch hike to swat fly, and into extension from swat fly to hitch hike, and the second diagonal from hand in opposite pocket to carry tray, and into extension from carry tray to hand in opposite pocket. These exercises must be done at home two times per day, ten repetitions each exercise.
40929115|NCT03250364|BEHAVIORAL|Educational strategy|Instructions about lymphatic system anatomy and pato-physiology, the prevention and identification of possible lymphedema complication or infection, how to use and exercise this arm, avoidance of trauma, injury, an excess of heat and arm constriction.
41127048|NCT05007587|DRUG|mFOLFOX regimen|HAIC was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.3mg/m2 , from hour 4 to 5 on day 1.
41127049|NCT05007587|DRUG|ROX regimen|HAIC was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
41127050|NCT01811394|RADIATION|protons|Treatment is performed using 16 x 4 GyE protons
41127051|NCT01811394|RADIATION|carbon ions|Treatment is performed using 16 x 4 GyE carbon ions
41127052|NCT04160936|DRUG|Marcaine Injectable Product|Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration
41127053|NCT02394106|DRUG|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
41127054|NCT02394106|OTHER|Placebo|Normal saline, 1000 ml, administered once
41127055|NCT03590275|DRUG|FOLFIRINOX|Patients treated with first-line FOLFIRINOX (oxaliplatin + irinotecan + lederfolin + 5-fluorouracil) as per clinical practice were included in the study
40754774|NCT03548792|RADIATION|RSA radiostereometric analysis|Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs
40929116|NCT05470257|OTHER|Cast|Application of fiberglass long arm cast.
41277565|NCT05881408|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
41277566|NCT05881408|GENETIC|placebo|Single IV infusion of matching placebo
40754775|NCT03548792|BEHAVIORAL|Clinical comparison|ActivePAL, walking speed
40929117|NCT02541383|DRUG|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
40929118|NCT02541383|DRUG|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
40929119|NCT02541383|DRUG|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
41127056|NCT00245791|DRUG|Levofloxacin|
41127057|NCT02334436|BIOLOGICAL|Botulinum toxin, Type A|Botulinum toxin, Type A
41127058|NCT02334436|OTHER|0.9% sterile, unpreserved saline|Placebo Comparator Arm
41127059|NCT02934789|PROCEDURE|Hysteroscopic myomectomy with Truclear|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
41127060|NCT02934789|DRUG|Medical therapy|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
41127061|NCT00105963|BEHAVIORAL|Education about infant crying|
41127062|NCT06288607|DEVICE|High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China)|Patients are randomly assigned to be treated with high-intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China) on one side, and the other side is not treated.Before treatment, patients are allowed to sign an informed consent form. Before and after treatment, the L\*a\*b\* values of the lesion area and the area around the lesion are detected using 3nh HIGH-QUALITY COLORMETER colorimeter (Konica-Minolta Company, Japan), and photos of the patient's treatment area and dermatoscope observation results are taken. Before treatment, a 2-3mm thick medical condensation gel is evenly applied on the face. During the process, D4.5+D3.0 transducer are used.
41127063|NCT03290859|PROCEDURE|Titrate propofol monotherapy infusion to effect|Train anesthesia providers in a standardized protocol for titrating propofol infusion to effect.
41127064|NCT06151301|DIAGNOSTIC_TEST|serum procalcitonin|predicting the severity of intoxication
41127065|NCT06151301|DIAGNOSTIC_TEST|C-reactive protein|predicting the severity of intoxication
41127066|NCT05304624|DEVICE|laser|these lasers are routinely used in dental practice
41277567|NCT04811092|DRUG|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1
41277568|NCT04811092|OTHER|Placebo|Placebo
41277569|NCT05239845|DIETARY_SUPPLEMENT|Prebiotic|The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
41277570|NCT05239845|OTHER|Control|Maltodextrin
41277571|NCT01386385|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-conformal RT
41127067|NCT00732849|DRUG|Reconvan, Dipeptiven, Omegaven|Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
41127068|NCT03494959|DRUG|Pentaglobin|Antimicrobial treatment active against the multidrug-resistant strain should be started in case of neutropenic fever (oral temperature ≥38.3°C or temperature ≥38.0°C sustained over a one-hour period). Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days. Empirical treatment should be subsequently streamlined according to microbiological results (both positive and negative). Pentaglobin should be started within 12h from the onset of fever, regardless of the presence of hemodynamic stability.
41277572|NCT01386385|DRUG|Carboplatin|Given IV
41277573|NCT01386385|OTHER|Laboratory Biomarker Analysis|Correlative studies
41277574|NCT01386385|DRUG|Paclitaxel|Given IV
41448313|NCT01710722|DRUG|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
41448314|NCT01710722|DRUG|Leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
41448315|NCT01710722|DRUG|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
41448316|NCT03922555|DRUG|ASTX727|ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
41448317|NCT06627231|DRUG|TEV-56286|Oral capsule
41127069|NCT03217240|PROCEDURE|Cardiac Magnetic Resonance - MRI|All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.
41277575|NCT01386385|OTHER|Placebo Administration|Given PO
41277576|NCT01386385|DRUG|Veliparib|Given PO
41277577|NCT03978273|DEVICE|Night-time brace + virtual-brace|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Additionally :~* They will perform 5 sessions of postural rehabilitation exercises per week (each of 30 minutes) with the virtual-brace (MD).~* They will have also follow up consultations with a physiotherapist every 21 days, to evaluate treatment observance and to adapt postural exercises according to the results and difficulties encountered.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
41277578|NCT03978273|OTHER|Night-time brace only|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
41277579|NCT03740334|DRUG|Ribociclib|Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)
41277580|NCT03740334|DRUG|Dexamethasone|Corticosteroids are commonly used to treat ALL.
41448318|NCT06627231|DRUG|[14C]-TEV-56286|Oral capsule
41448319|NCT04251429|OTHER|CPH-NEW Healthy Workplace Participatory Program|A participatory program for increasing effectiveness of occupational health and safety committees or peer-led employee teams through root cause analysis, prioritizing health and safety needs for effective problem-solving, identifying feasible interventions, and presenting these to senior leadership. Interventions are selected and implemented by leadership and evaluated by both teams.
41448320|NCT04736303|DEVICE|BIS|The implementation of BIS monitoring
41448321|NCT00051779|DRUG|CAL|
41448322|NCT05213663|OTHER|assessment|To examine the awareness of parents of Cerebral Palsy children about the disease, physiotherapy and rehabilitation.
41448323|NCT00433719|DRUG|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
41448324|NCT06186414|DRUG|SIM0237|Several dose levels of SIM0237 will be administered as a single agent for evaluation
41448325|NCT06186414|DRUG|SIM0237 and BCG|Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
41448326|NCT06186414|DRUG|SIM0237|RD level of SIM0237 will be administered as a single agent for evaluation
41448327|NCT06186414|DRUG|SIM0237 and BCG|RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
41448328|NCT06196047|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
41277581|NCT03740334|DRUG|Everolimus|Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation
41277582|NCT00710190|DEVICE|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
41448329|NCT06196047|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg loading dose of cilostazol administered within 24 hours of first-ever ischemic stroke followed by 100 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
41448330|NCT01055795|DRUG|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~1. 3-6, All study drugs administered per dose level~2. 3-6, All study drugs administered per dose level~3. 3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B \& C; 30, Recommended Phase II Dose for all three compounds"
41448331|NCT02199873|DRUG|BIIX 1 XX - single rising dose|
41448332|NCT02199873|DRUG|Placebo|
41448333|NCT00274651|DRUG|belinostat|
41448334|NCT02477787|BIOLOGICAL|allogeneic, donor-derived NK cells|"Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.~For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.~Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions."
41448335|NCT00000458|DRUG|sertraline (Zoloft)|
41448336|NCT00000458|BEHAVIORAL|cognitive behavior therapy|
41448337|NCT05125900|OTHER|Proximal box elevation using one of the tested materials|Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite
41448338|NCT06466317|BEHAVIORAL|Honey intake with walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines in addition to consuming natural honey (2ml/kg honey will be taken.. This dose will be divided into two halves, the first half will be taken at 7 am and the other half will be taken at 7 pm for 12 weeks)
41448339|NCT06466317|BEHAVIORAL|Walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines for 12 weeks)
41448340|NCT05456685|DRUG|Mirvetuximab soravtansine|Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called FRα. It is being developed for the treatment of participants with recurrent platinum-sensitive, high grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with FRα expression. FRα positivity will be defined by the Ventana FOLR1 Assay.
41448341|NCT05456685|DRUG|Carboplatin|Carboplatin is considered to be the treatment agent of choice in relapsed PSOC.
41448342|NCT01147939|DRUG|Elacytarabine|Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
41448343|NCT01147939|DRUG|Investigator's Choice|E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
41448344|NCT02985060|DEVICE|Arctic Sun|"1. Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~   Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~2. Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~3. Recovery phase:Rewarming velocity: 0.05\~0.1℃ (within 30 hours)"
41448345|NCT02985060|OTHER|Standard treatment|"1. All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~2. In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~3. Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~4. Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days."
41448346|NCT02985060|DRUG|Saline|
41448347|NCT05581407|BIOLOGICAL|TETRALITE|LiteVax Adjuvanted Seasonal Influenza Vaccine
41448348|NCT03259165|DRUG|Nitrates|"For patients randomized to the Nitrate intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)~2. SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times. (May be repeated) (Held if SBP decreases to \< 120 mmHg)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm."
40929120|NCT03951168|BEHAVIORAL|Routine Management|Routine Management Model of Health Education for diabetes Patient will receive the Routine Management Model of Health Education for Diabetes. After the patient was admitted to hospital, the responsible nurse carried on the diabetes health education for the patient. There are no regulations on the path and time of education. Interspersed with diabetes health education at work. Follow up 2 weeks with phone call after discharge. This is the current clinical model in hospital.
41127070|NCT03217240|OTHER|Cardiopulmonary Exercise Test|Participants will be asked to undergo a cardiopulmonary exercise test (CPET). Participants will need to wear a mask. Several electrodes will be placed on the chest to record heart activity during exercise. Participants will need to pedal for at least 8-12 minutes. Pedalling will be instructed to report any symptoms such as chest discomfort, shortness of breath, leg fatigue or dizziness. A small probe will be placed on participant's finger during the test to measure the oxygen content in the blood. Immediately after exercising, participants will rest for 5-10 minutes while the blood pressure and electrocardiogram are monitored. The results will be read by a cardiologist.
41127071|NCT03217240|OTHER|Blood Sampling for all participants|Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
41127072|NCT00769353|BEHAVIORAL|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
41127073|NCT00769353|BEHAVIORAL|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
41127074|NCT00051571|DRUG|SGN-15|
41448349|NCT03259165|DRUG|Loop Diuretics|"For patients randomized to the Diuretic intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. Patients receive 1 inch topical nitropaste~2. IV Loop diuretic dose = patients total oral dose (max dose of 200 mg IV)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm."
41127075|NCT00051571|DRUG|Docetaxel|
41127076|NCT01291628|DEVICE|socks containing copper-oxide fibers|The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.
41448350|NCT00419640|DEVICE|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
41448351|NCT00419640|DEVICE|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
41448352|NCT00419640|DEVICE|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
41448353|NCT00419640|DEVICE|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
41448354|NCT05913128|PROCEDURE|Glandular Urethral Disassembly technique|For Primary Distal Hypospadius Repair
41448355|NCT05990127|DRUG|AK104|AK104 IV, q3w
41448356|NCT05990127|DRUG|Tislelizumab|Tislelizumab IV, q3w
41448357|NCT05990127|DRUG|carboplatin|carboplatin IV, q3w
41448358|NCT05990127|DRUG|Pemetrexed|Pemetrexed IV, q3w (for Nonsquamous NSCLC)
41448359|NCT05990127|DRUG|Paclitaxel|Paclitaxel IV, q3w (for squamous NSCLC)
41448360|NCT00308906|DRUG|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
41448361|NCT03251755|BEHAVIORAL|Yoga|Exercise promotion using Chinese Yoga
41448362|NCT04737330|DRUG|Secukinumab|Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
41127077|NCT00203554|GENETIC|Poly methylmetacrylate, PMMA|
41127078|NCT04738201|OTHER|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
41448363|NCT04737330|DRUG|Placebo|Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
41448364|NCT04723134|COMBINATION_PRODUCT|Folinic acid calcium salt|Folinic acid (2.5%) by combination with Placebo
41448365|NCT06495996|DEVICE|Percutaneous mechanical thrombectomy (PMT)|Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus.
41448366|NCT03579394|PROCEDURE|Retarded IDS (Interval Debulking Surgery)|"Patient will receive 6 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C6D1. After surgery patient will undergo 2 more courses of carboplatine and paclitaxel chemotherapy~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
41448367|NCT03579394|PROCEDURE|Standard IDS (Interval Debulking Surgery)|"Patient will receive 3 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C3D1. After surgery patient will undergo 5 more courses of carboplatine and paclitaxel chemotherapy.~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
41127079|NCT04386772|PROCEDURE|PVE with coils plus TAGM|PVE with TAGM distally and coils proximally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on future liver remnant (FLR) side for patients with pCCA when obstructive jaundice is present.
41448368|NCT05740098|BEHAVIORAL|Best Practices|Five As plus referral to a quit line
40929121|NCT03951168|BEHAVIORAL|Standardized Management|Standardized Management Model of Health Education for Diabetes The patients were educated by full-time diabetic education nurses according to diabetes education path. Including diabetes diet, exercise, drugs, hypoglycemia, diabetic foot, and so on. Telephone follow-up was performed at 2 weeks and 4 weeks after discharge and 12 and 24 weeks follow-up in diabetes education clinic. Develop telephone follow-up standardized content and implement telephone follow-up according to standardized content.Full-time education nurses carry on education according to diabetes mellitus health education path table.
41448369|NCT05740098|BEHAVIORAL|Financial Incentives|Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.
41448370|NCT05740098|DRUG|Nicotine Replacement Therapy|Nicotine patches and gum/lozenge provided together for dual therapy
41448371|NCT02726360|BEHAVIORAL|survey|The ILR Scale, a non-English language proficiency self-assessment.
41448372|NCT02726360|BEHAVIORAL|Audio record|Audio record the initial visits between patients and their treating physician
41448373|NCT01820091|DRUG|Folotyn|A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
41448374|NCT01820091|DRUG|Fusilev|Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
41448375|NCT06622330|OTHER|Positioning|Children in the experimental group were given 30 minutes of wrapping and 30 minutes of fetal position after aspiration.
41277583|NCT04695977|DRUG|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
41448376|NCT04876001|BEHAVIORAL|Brief Behavior Therapy for Insomnia|"The BBTI consists of two in-person sessions on week 1 and 3 and two sessions on week 2 and 4 as the booster delivered by phone call."
41448377|NCT04672044|DEVICE|Active rTMS and exercise|active
41448378|NCT04672044|COMBINATION_PRODUCT|Sham rTMS+Exercise|sham
41448379|NCT05315297|DEVICE|PEMF device|PEMF device wear overnight daily for four weeks
41448380|NCT05315297|DEVICE|Sham PEMF device|Sham PEMF device wear overnight daily for four weeks. Sham PEMF devices do not emit a radiofrequency electromagnetic field but are otherwise identical in appearance to the PEMF device
41448381|NCT04146805|DRUG|BLD-0409|For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
41448382|NCT04146805|DRUG|Control: Placebo|Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
41127080|NCT04386772|PROCEDURE|PVE with multiple coils|Procedure: PVE with multiple coils PVE with multiple coils proximally and distally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on FLR side for patients with pCCA when obstructive jaundice is present.
41127081|NCT01302600|DRUG|Olesoxime|Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
40929122|NCT02915874|BEHAVIORAL|Acceptance and Commitment Therapy|
41127082|NCT01302600|DRUG|Placebo|0.1ml/kg once a day with food at dinner.
41127083|NCT01974843|DRUG|Levobupivacaine|in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
41127084|NCT01974843|DRUG|Bupivacaine|in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
41127085|NCT03695757|BIOLOGICAL|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
41127086|NCT03695757|BIOLOGICAL|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
41127087|NCT00324350|DRUG|hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents|type 2 diabetes treatments, per standard of care
41127088|NCT02697201|DRUG|Intralipid|0.55 ml/kg/h
41127089|NCT02697201|DRUG|Saline|0.55 ml/kg/h for
41448383|NCT04752696|DRUG|Onvansertib|Oral capsule
41448384|NCT04752696|DRUG|Nanoliposomal irinotecan|Intravenous infusion
41448385|NCT04752696|DRUG|Leucovorin|Intravenous infusion
41448386|NCT04752696|DRUG|Fluorouracil|Intravenous infusion
41448387|NCT00765635|DRUG|drops intilation (Taponoto ® )|four drops, unique doses
41448388|NCT00765635|DRUG|drops intilation (Otocerum®)|four drops, unique doses
40929123|NCT00720018|DRUG|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
41127090|NCT06545565|DRUG|sodium acetate group will receive sodium acetate in the neonatal PN.|This group will receive sterile sodium acetate daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
41127091|NCT06545565|DRUG|sodium chloride group will receive sodium chloride in the neonatal PN.|This group will receive sterile sodium chloride daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
41127092|NCT05532475|DIAGNOSTIC_TEST|measurement of vitreous level of tumor necrosis factor alpha|measurement of vitreous level of tumor necrosis factor alpha using ELISA technique
41277584|NCT04695977|DRUG|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
41277585|NCT00681551|DRUG|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
41277586|NCT00681551|DRUG|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
41448389|NCT00765635|DRUG|drops intilation (Placebo)|Placebo
41448390|NCT05286229|DRUG|ABBV-383|Intravenous (IV) Infusion
41448391|NCT05315713|DRUG|Mosunetuzumab SC|Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
41448392|NCT05315713|DRUG|Tiragolumab|Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
41448393|NCT05315713|DRUG|Atezolizumab|Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
41448394|NCT05315713|OTHER|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
41448395|NCT06485284|BEHAVIORAL|El Camino|"El Camino is a goal-setting sexual health promotion program. El Camino's lessons and activities:~* Are anchored in sexual health promotion and goal-setting~* Incorporate a goal achievement model throughout the curriculum~* Are designed with a focus on the needs of Latino youth~* Focus on the most effective forms of contraception, including long-acting reversible contraceptives~The El Camino curriculum contains eleven 45-minute lessons and is divided into three sections, or arcs. The three arcs focus on goal setting, sexual and reproductive health, and healthy relationships."
41448396|NCT06485284|BEHAVIORAL|Life skills program|Youth enrolled in the control condition will receive one of several curricula focused on life skills or leadership, depending on the site and implementation period. These curricula include PODER, an 11-session curriculum that focuses on youth leadership development; Youth Encuentros, a psychoeducational curriculum focused on mental health; El Joven Noble, a youth leadership curriculum; and Courageous Queens, a socio-emotional and character strengthening curriculum.
41448397|NCT03260153|DRUG|Deproteinised Calf Blood Serum Injection|
41448398|NCT03260153|DRUG|Placebo (Sodium Chloride)|
41448399|NCT02855853|OTHER|serious game et virtual reality|
41448400|NCT02855853|OTHER|Nintendo Wii|
41127093|NCT03942445|PROCEDURE|Gastrocnemius muscle biopsy|In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.
41127094|NCT05188300|PROCEDURE|Freestyle pedicled perforators propellers flaps for meningomyelocele defects|Freestyle pedicled perforators propellers flaps for meningomyelocele defects reconstruction with sequential advance in perforators dissection, large number cases, and detailed successful technique.
41448401|NCT05059262|DRUG|vimseltinib|CSF1R inhibitor
41448402|NCT05059262|DRUG|Placebo|Placebo
41448403|NCT06154083|DRUG|Follitropin-delta (Rekovelle) 20 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
41448404|NCT06154083|DRUG|Follitropin-delta (Rekovelle) 15 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
41448405|NCT00461435|PROCEDURE|hyperbaric oxygen therapy|
41448406|NCT01793584|PROCEDURE|Laparoscopic hysterectomy|LAVH, TLH
41448407|NCT01793584|PROCEDURE|Abdominal hysterectomy|TAH
41127095|NCT02993211|DEVICE|Bipolar transurethral standard resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
41127096|NCT02993211|DEVICE|Bipolar transurethral en bloc resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
41127097|NCT06407882|BEHAVIORAL|Conductive Exercises|Conductive education (CE) is a useful educational system for the management of motor disabled individuals whose disability and dysfunction was due to the damage to the central nervous system, mainly at the pre-, peri- or post-natal period of life. Conductive exercises basically include task-oriented learning within highly structured programs and conductors who are trained in special education and therapy administer the conductive education program
41127098|NCT06407882|BEHAVIORAL|Routine Physical Therapy|Group B will perform routine physical therapy (RPT) alone. Active and passive movements, Passive stretching, strengthening exercises, weight bearing exercises.
41127099|NCT05804994|DEVICE|Elgydium Clinic Sensileave Gel (V063B - DP3003)|Tested product is applied/used only once a day before whitening tray wear.
41277587|NCT04704180|BEHAVIORAL|Facilitation Tuchking Position|The nurse placed the neonate in the facilitated tucking position by rolling up a sizeable sterile towel in a U-shape and covering it with covers available in the unit and then placed the neonate in a supine position. The physiological parameters at admission and in the 15th and 30th minutes of facilitated tucking were recorded. In the 30th minute of facilitated tucking, the researcher and the observer nurse completed the COMFORTneo simultaneously but separately. The neonate was in the facilitated tucking position until delivered to its mother. The researcher and the observer nurse had a full view of the neonate's face and body when completing the COMFORTneo, which took them about two minutes. After the neonate stabilized (within the first half an hour to an hour), it was delivered to its mother for breastfeeding based on specialist consent. The first breastfeeding was performed and completed the LATCH by researcher and the observer nurse.
41277588|NCT05180786|OTHER|Error Fields|Participants will complete a reaching experiment using the robotic arm with error fields turned on.
41277589|NCT05180786|OTHER|No Error Fields|Participants will complete a reaching experiment using the robotic arm with error fields turned off.
41127100|NCT05165459|DEVICE|Venous leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
41277590|NCT01495026|DRUG|Dutasteride (0.5mg, fasted state)|Open-label, randomized, single dose, multi-stage, cross-over study
41277591|NCT01495026|DRUG|Dutasteride (0.5mg, fed state)|Commercial formulation of Dutasteride 0.5mg
41277592|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
41277593|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC containing faster-release enteric-coated pellets
41277594|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC bioequivalent to Harnal-D tablets
41277595|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)|FDC bioequivalent to Harnal-D tablets
41277596|NCT01495026|DRUG|Harnal-D Tablets with water (fasted state)|Commercial formulation of Harnal-D Tablets
41448408|NCT04298086|OTHER|Exercise Treatment|Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill at under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service.
41448409|NCT04298086|OTHER|Plant-Based Diet|Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
41448410|NCT04298086|OTHER|Physical activity|Treadmills and low-calorie recipes will be provided to patients in the counseling arm.
41448411|NCT04298086|OTHER|Nutrition counseling|Nutrition program including regular counseling by exercise physiologists and registered dieticians (RDs).
41448412|NCT04298086|OTHER|Replication Exercise Test|Exercise capacity will be reassessed by a replication exercise test at week 6 in the intervention group only.
41448413|NCT00377117|PROCEDURE|Management|
41448414|NCT00377117|PROCEDURE|Screening|
41127101|NCT02448524|DEVICE|MiStent|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
41127102|NCT02448524|DEVICE|TIVOLI|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
41127103|NCT05786872|DEVICE|dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
41127104|NCT06145802|BIOLOGICAL|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
41277597|NCT01495026|DRUG|Harnal-D Tablets with water (fed state)|Commercial formulation of Harnal-D Tablets
41277598|NCT01495026|DRUG|Harnal-D tablets without water (fasted state)|Commercial formulation of Harnal-D Tablets
41277599|NCT05422079|OTHER|Non-specific lumbar exercise group|Subjects perform a conventional lumbar exercise program twice a week.
41277600|NCT05422079|OTHER|motor control lumbar exercises|Subjects perform a lumbar stabilization exercise program.
41277601|NCT05422079|OTHER|motor control lumbar exercises with ultrasound echography feedack|Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
41277602|NCT04266574|DEVICE|Near Infrared Spectroscopy (NIRS)|"The anesthesiologist will apply optodes before induction of anesthesia and before preoxygenation, to detect baseline NIRS level, NIRS will be monitored continuously up to post-anaesthesia care unit (PACU) discharge, or up to three the investigator's after ICU admission.~When a decrease in NIRS value over 10% is detected, or if NIRS value is below 60%, patients will start hemodynamic optimization, to reverse the reduction in NIRS and return to baseline values, according to a predefined protocol."
41448415|NCT05654363|PROCEDURE|Administration of morphine by intrathecal route|Lumbar puncture was performed before the induction of general anesthesia, in the operating room. Spinal anesthesia was performed in sitting position using a midline approach into the L3-L4 or L4-L5 interspaces with a 25ga pencil-point spinal needle administering 75-100 mcg morphine, with or without local anesthetic (levobupivacaine 0,5% 10-15 mg or bupivacaine 0,5% 10-15 mg or ropivacaine 0,5% 10-15 mg), depending on the anesthesiologist's preference. General anesthesia was then conducted according to clinical practice. All patients were transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery. Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
41448416|NCT05654363|PROCEDURE|Administration of morphine by intravenous route|General anesthesia was conducted according to clinical practice and a morphine bolus was administered before emergence from anesthesia according to clinical needs. All patients were then transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery and received Patient-Controlled Analgesia (PCA) with morphine 1mg/mL (CADD®-Solis 2110 Infusion System, Smiths Medical ASD, Inc., USA, 1 mL bolus on demand, no background infusion, 7 minute lockout, max 8 mg/h). Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
41448417|NCT06150196|BEHAVIORAL|Mindfulness-based Stress Reduction class|9-week standard Mindfulness-based Stress Reduction class training on mindfulness techniques, medication, and yoga
40929124|NCT02970201|OTHER|EpxDialysis|The EpxDialysis intervention consists of automated SMS text or voice messages delivered to the patient's preferred phone number three times per week. These messages provide details about the subject's upcoming hemodialysis session, anticipatory guidance regarding clinically-concerning symptoms, as well as the option for direct call routing to the dialysis center for rescheduling sessions.
41127105|NCT02901522|OTHER|telemonitoring|Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
40929126|NCT01995045|DRUG|Triamcinolone|Retrobulbar anesthesia
41127106|NCT02901522|OTHER|Spirometry (baseline)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
41127107|NCT02901522|OTHER|Spirometry (20 - 22weeks)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
40929127|NCT01995045|DRUG|Bupivicaine Hydrochloride|Retrobulbar anesthesia
40929128|NCT05700643|DIETARY_SUPPLEMENT|Montmorency cherry supplement|Montmorency cherry supplement
40929129|NCT05700643|DIETARY_SUPPLEMENT|Control|Placebo
41127108|NCT02901522|OTHER|Teleconsultation|The general practioner received phone call to asthma care.
41127109|NCT03972046|DRUG|Talimogene laherparepvec (T-Vec)|Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
41127110|NCT03972046|DRUG|Dabrafenib (BRAF Inhibitor)|Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
41127111|NCT03972046|DRUG|Trametinib (MEK Inhibitor)|Trametinib (MEK Inhibitor) 2 mg by mouth once a day
41277603|NCT04266574|DEVICE|Standard Care|Controls will be treated according to standard of care, maintaining a MAP≥65 and an adequate cardiac output according to the hemodynamic monitoring chosen by the anesthesiologist (invasive blood pressure monitoring or pulse contour monitors). NIRS will be recorded also in controls, but caring anesthesiologists will be blinded to NIRS.
41277604|NCT04661813|OTHER|EXTRA-CVD Virtual Care|"The original EXTRA-CVD intervention was developed to improve blood pressure and cholesterol control among People Living with HIV. The intervention will be adapted to the post-COVID healthcare delivery landscape as a virtual intervention delivered by phone, teleconference, internet support groups, and nurse care coordination."
41277605|NCT03084523|DRUG|Ferumoxytol Injectable Product|Patients will be administered a single dose of ferumoxytol as an MRI contrast
41277606|NCT06205030|DRUG|anti-diabetic herbal drug|All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
41277607|NCT05601973|DRUG|Amivantamab|Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is \<80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.
41127112|NCT04778670|DIAGNOSTIC_TEST|AI CAD|The Lunit INSIGHT MMG will be used as the AI CAD in our study. Initially, version 1.6.1.1 will be installed. The software version will be continuously updated with subsequent software releases, after confirming in a historic calibration dataset that the performance is improved. The operating point will be set based on a historic calibration dataset to attain a joint sensitivity of breast cancer detection of AI and first reader which is 2% higher than for first and second reader.
41127113|NCT04778670|DIAGNOSTIC_TEST|Radiologist reading|Standard of care, each radiologist will assess the mammography examination, making a binary flagging decision (flag the examination to continue to consensus discussion, or not)
41277608|NCT05601973|DRUG|Lazertinib|Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.
41277609|NCT05601973|DRUG|Zirabev|Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.
41277610|NCT03809624|DRUG|INBRX-105 - PDL1x41BB antibody|The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
41277611|NCT03809624|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
40754776|NCT05371223|DRUG|Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine|"Each combined course is constituted by two consecutive 28-day cycles of systemic chemotherapy (three adminstrations per cycle: days 1,8 and 15) and one cycle of PIPAC administered within 10-13 days from the last administration of systemic chemotherapy. Between each combined course a 7-10 days pause is observed.~The recommended dose of Nabpaclitaxel in combination with Gemcitabine is 125 mg/m2 administered endovenous over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. The concurrent recommended dose of Gemcitabine is 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of Nabpaclitaxel administration on Days 1, 8 and 15 of each 28-day cycle.~A pressurized aerosol containing Nabpaclitaxel at the dose of 112,5 mg/m2 diluted in a total volume of 200 ml of NaCl 0.9% is applied through the nebulizer inside the abdominal cavity during laparoscopy."
40754777|NCT00240773|DRUG|acetaminophen|4 grams daily for six months
40754778|NCT00240773|DRUG|naproxen|750 mg daily for 12 months
40754779|NCT00240773|DRUG|acetaminophen|4 grams daily for 12 months
40754780|NCT00240773|DRUG|naproxen|750 mg daily for six months
40754781|NCT02099591|DRUG|Naloxegol|Opioid Antagonist
41127114|NCT03862963|BEHAVIORAL|Standard of diabetes care|The standard of diabetes care consisted of standard treatment protocols used by the MOH Diabetes Clinic. These included placing T2D patients on anti-hyperglycemic agents appropriate to their HbA1c levels (including sulfonylureas, metformin, and insulin) and providing oral and written information about the importance of maintaining a healthy weight, eating a healthy diet, and getting regular exercise. Participants in the control group were instructed not to make changes in their diet and activity levels during the study.
41277612|NCT02183454|DEVICE|OrbusNeich COMBO stent|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
40754782|NCT03568786|PROCEDURE|End-inspiratory pause 10%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 10% of the total inspiratory time
40754783|NCT03568786|PROCEDURE|End-inspiratory pause 30%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 30% of the total inspiratory time
40754784|NCT04089085|BEHAVIORAL|STRONGer Together|STRONGer (Successes/Strengths, Triggers, Remember your medications, Ongoing communication, Never give up!, Gratitude) Together is an asthma educational and cognitive behavioral skills intervention for children between 8 - 12 years of age. The intervention is implemented in small groups in 30-minute sessions.
40754785|NCT02405637|DRUG|simulated amniotic fluid 20cc/kg/day enterally|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
40754786|NCT02405637|DRUG|distilled water|distilled water 20 ml/kg/day for maximum of 7 days.
40754787|NCT03438656|BEHAVIORAL|Behavioral Activation|The Adolescent Behavioral Activation Program (ABAP) will be used as the BA protocol. ABAP was developed and validated by McCauley, Dimidjian et al. to adapt BA to adolescents. ABAP is a 12-week protocol that utilizes an idiographic approach to foster rewarding experiences, effective problem solving, and goal attainment, and decrease avoidance, barriers to activation, and depressive rumination that may be contributing to depression severity and maintenance.
41277613|NCT00310180|DRUG|Anastrozole|Given PO
41277614|NCT00310180|DRUG|Exemestane|Given PO
40754788|NCT05506631|PROCEDURE|Outpatient Foley balloon placement|Cervical ripening with balloon placement in the outpatient setting
41277615|NCT00310180|OTHER|Laboratory Biomarker Analysis|Correlative studies
40754789|NCT05506631|PROCEDURE|Inpatient Foley Balloon placement|Cervical ripening with balloon placement in the inpatient setting
40929130|NCT04577157|BEHAVIORAL|"mHealth usingWhatsApp multifaceted educational and reminder module intervention to improve adherence"|"This multifaceted educational and reminder module is named Health@click. The content of the reminder module has been made based on The Health Belief Model and self-determination theory.~1. Daily notes for medication reminders,~2. Daily a voice message with the same content will be delivered.~3. Daily Graphics-based Reminder (GBR).~4. Twice-weekly Graphics-based Messages (GBM) according to Health believe model and Self-determination theory constituents.~5. Once-weekly lifestyle advice through video~6. Hypertension at a glance, complete information will be provided(Optional)~7. 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects, and interaction with different foods (Optional)."
41127115|NCT03862963|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention consisted of a high-fiber, low-fat, mostly plant-based diet and 30-60 minutes per day of culturally-relevant, moderate intensity exercise. Participants initially received 12 weeks of group educational classes and some prepared meals and then followed the lifestyle intervention on their own for the remaining 12 weeks. Group classes included informative sessions on healthy eating, exercise (both aerobic and strength training), and stress management, as well as hands-on cooking classes. Classes were delivered as a combination of PowerPoint presentations, practical workshops, dine-outs, shopping tours, and cooking classes with spouses.
41127116|NCT04172038|BEHAVIORAL|Physical Therapy|Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).
41127117|NCT04172038|BEHAVIORAL|Move 2 Health (M2H)|"Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~1. Sleep~2. Physical Activity~3. Nutrition~4. Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~5. Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.)."
41127118|NCT04172038|BEHAVIORAL|MORE Mindfulness|"Throughout the intervention, three core areas are emphasized. Activities include exercises and at-home work for participants to reinforce these core areas.~1. Mindfulness~2. Cognitive reappraisal~3. Savoring of positive experiences"
41277616|NCT00310180|DRUG|Letrozole|Given PO
41277617|NCT00310180|OTHER|Quality-of-Life Assessment|Ancillary studies
41277618|NCT00310180|RADIATION|Radiation Therapy|Undergo radiation therapy or partial breast irradiation
41277619|NCT00310180|DRUG|Tamoxifen Citrate|Given PO
41277620|NCT03217162|DRUG|surfactant combined with mechanical ventilation (MV)|surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
41277621|NCT03217162|DRUG|mechanical ventilation (MV)|mechanical ventilation (MV) is given to the infant with ARDS
41277622|NCT01064648|DRUG|Cediranib Maleate|Given orally
41277623|NCT01064648|DRUG|Cisplatin|Given IV
41277624|NCT01064648|OTHER|Laboratory Biomarker Analysis|Correlative studies
40754790|NCT02953964|OTHER|Behavioral: perceptual-based memory encoding training|Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
40929131|NCT04183751|OTHER|scale study|Forms and questionnaires will be used. The data will be collected by the researchers by face to face interview technique.
40929132|NCT02708082|DEVICE|OCT scanning and HFA perimetry|Imaging of the optic nerve and nerve fiber layer / measurement of visual field
41127119|NCT02987192|DEVICE|pen type 27 gauge needles|minimally invasive group patients will receive pen type 27 gauge needles.
41127120|NCT02987192|DEVICE|cutting type 22 gauge needles|traditional group patients will receive cutting type 22 gauge needles.
41277625|NCT01064648|DRUG|Pemetrexed Disodium|Given IV
41277626|NCT01064648|OTHER|Placebo Administration|Given orally
41277627|NCT03695601|OTHER|Standard of Care|Other Standard measures for monitoring rejection: Endomyocardial Biopsy, Echocardiogram, Angiography, Intravascular Ultrasound, Donor-specific HLA Antibody
41277628|NCT06260163|DRUG|Guselkumab Subcutaneous|Guselkumab will be administered subcutaneously.
41277629|NCT06260163|DRUG|Guselkumab Intravenous|Guselkumab will be administered intravenously.
41277630|NCT02793284|RADIATION|18F-DCFPyL PET/CT scan|PET/CT scan using the radioactive agent 18F-DCFPyL
41277631|NCT02014948|OTHER|Exercises|The individuals who make up this group performed exercises for 10 consecutive sessions.
41448418|NCT06150196|BEHAVIORAL|Brain Health Education class|9-week Brain Health education class that involves lectures/discussion about how the brain works and recovers after brain injury
41448419|NCT01079858|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
41448420|NCT06059625|PROCEDURE|rotatori cuff repair|rotatori cuff repair
41127121|NCT01974102|BEHAVIORAL|Lifestyle counseling|Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.
41127122|NCT01974102|BEHAVIORAL|Parenting Mindfully for Health (PMH)|Active participants will receive 8 weeks of mindfulness based parenting stress reduction (PMH) plus nutritional and physical activity counseling for 8 weeks.
41127123|NCT02831231|DRUG|xanomeline tartrate|xanomeline tartrate, 75 mg capsule, TID
41127124|NCT02831231|DRUG|Trospium chloride|trospium chloride, over encapsulated 20 mg tablet, BID
41127125|NCT02326181|DEVICE|inspiratory pressure training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .
41127126|NCT02326181|DEVICE|mixed training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
41127127|NCT02179268|DRUG|sertraline|50mg, 50-150mg/d,qd for one year
41127128|NCT02179268|DRUG|citalopram|20mg, 20-40mg/d,qd,for one year
41127129|NCT02179268|DRUG|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
41127130|NCT02179268|DRUG|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
41127131|NCT02179268|BEHAVIORAL|control|50min, every week for three months, every month, for nine months
41277632|NCT06108661|PROCEDURE|Conventional Physical Therapy|"Moist heat therapy for 10 minutes for 3 times per week (alternatively) for 2 weeks.~TENS was applied for 15 minutes, 3 times per week (alternatively) for 2 weeks. Stretching protocol for deep lumbar spinal muscles was employed. The frequency was 3 times per week (alternatively) for 2 weeks."
40929133|NCT00251004|DRUG|Everolimus|oral, bis in diem/twice a day (bid)
40929134|NCT00251004|DRUG|Mycophenolic Acid (MPA)|2 oral capsules of mycophenolic acid 360mg administered bid
41127132|NCT04291638|BEHAVIORAL|Remote Caregiver Training|The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.
41127133|NCT04291638|BEHAVIORAL|Remote Intensive Group Behavioral Treatment (IGBT)|The remote IGBT is a 5-day videoconferencing-based treatment program that delivers cognitive behavioral therapy to children and their caregivers in a group format across 2-3 hours per day.
41127134|NCT02134262|DRUG|Cyclophosphamide or Bendamustine|Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.
41127135|NCT02134262|GENETIC|Dose Level -1|CD19-CAR-T \[1 x 10\^5 cells/kg x 1 day and 2 x 10\^5 cells/kg x 1 day Intravenous (IV)\] are administered.
41127136|NCT02134262|GENETIC|Dose Level 1|CD19-CAR-T \[1/3 x 10\^6 cells/kg x 1 day and 2/3 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
41127137|NCT02134262|GENETIC|Dose Level 2|CD19-CAR-T \[1 x 10\^6 cells/kg x 1 day and 2 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
41127138|NCT02134262|GENETIC|Dose Level 3|CD19-CAR-T \[1/3 x 10\^7 cells/kg x 1 day and 2/3 x 10\^7 cells/kg x 1 day Intravenous (IV)\] are administered.
41127139|NCT00457119|DRUG|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
41277633|NCT06108661|PROCEDURE|Slump Stretching|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
41277634|NCT06108661|PROCEDURE|ELDOA|"ELDOA will be performed as per the tolerance of the patient (Max hold time=60sec) for 2 weeks (alternatively). For L4/L5 spinal segment patient sits on the floor, arms at the side legs relaxed.~For L5/S1 segment the patient lies on his or her side with torso perpendicular to a wall with the sitz bone pressing into the wall. The patient swing the legs up so that he or she is lying on his or her back with the legs perpendicular up the wall and the sitz bone pressing into the wall. The arms are lying by the sides."
40929135|NCT00251004|DRUG|Cyclosporine A (CsA)|CsA dose adjustments were based on CsA trough levels (C0).
40929136|NCT00251004|DRUG|Basiliximab|All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
41127140|NCT02168400|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
41127141|NCT04682418|DEVICE|xvision Spine sytem|pedicle screw placement will be performed using the XVS navigation system
41127142|NCT05783570|BIOLOGICAL|EU307 CAR-T Cell|"* Dose to be administered: a single dose~* IV administration~* Dosing rate: To be administrated at a rate of approximately 2 mL/min"
41127143|NCT00326196|DEVICE|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
41127144|NCT00326196|PROCEDURE|Coronary artery bypass graft (CABG)|coronary bypass
41127145|NCT00414024|DRUG|Tegaserod|
41277635|NCT06143631|DRUG|Letrozole 2.5mg|Oral letrozole 2.5mg/day
41127146|NCT04946487|PROCEDURE|total laminectomy|Total laminectomy removes the posterior ligamentous complex (PLC) at the fusion and superior levels.
41127147|NCT05514275|DRUG|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
41277636|NCT06143631|OTHER|Placebo|Placebo capsule
41277637|NCT02220881|DEVICE|Mold making silicone toe separator|Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
41277638|NCT02220881|OTHER|Observation|The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
41277639|NCT06618651|DRUG|SHR-3821 injection|SHR-3821 injection
41127148|NCT05800236|PROCEDURE|Gastrectomy|Patients operated on for curative purposes at the Bordeaux University Hospital for gastric adenocarcinoma of any type or stage and Collection of two venous blood tubes
41127149|NCT05113095|BIOLOGICAL|Darvadstrocel|Darvadstrocel injection
41127150|NCT02029235|DRUG|Acetaminophen/Ibuprofen|Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
41127151|NCT02029235|DRUG|Acetaminophen/Hydrocodone|Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
41277640|NCT04190550|DRUG|Cytarabine|Given IV
41277641|NCT04190550|DRUG|Idarubicin Hydrochloride|Given IV
41277642|NCT04190550|DRUG|Navtemadlin|Given PO
41277643|NCT03818269|PROCEDURE|Subcutaneous pressure measurement|Subcutaneous interstitial measurement at D1 and D2
41277644|NCT06589726|DRUG|Placebo|Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.
41277645|NCT06589726|DRUG|Moxifloxacin|Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.
41277646|NCT06589726|DRUG|Enpatoran low dose|Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.
41277647|NCT06589726|DRUG|Enpatoran high dose|Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.
41277648|NCT02037126|DRUG|Psilocybin|this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.
40929137|NCT00251004|DRUG|Corticosteroids|Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
40929138|NCT02218476|DRUG|CoQ10|
41277649|NCT02037126|DRUG|Diphenhydramine|This drug will be used as the control. Diphenhydramine is a histamine blocker.
41277650|NCT04971590|OTHER|Participant completed survey|Participants will be required to complete the participant survey.
40929139|NCT02218476|DRUG|Placebo|
40929140|NCT00126880|DRUG|AVX754|apricitabine, 600mg BID or 800mg BID
41277651|NCT04971590|OTHER|Medical chart review|Data will be collected from medical charts of participants.
41277652|NCT06132893|DRUG|BHV-7000|BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
41277653|NCT06132893|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
41277654|NCT06132893|DRUG|Placebo|Matching placebo taken once daily
41277655|NCT06296264|DEVICE|Standard ultrasound|Placement of IV line using standard ultrasound.
41277656|NCT06296264|DEVICE|Ultra-portable ultrasound|Placement of IV line using ultra-portable ultrasound.
41277657|NCT02112448|DRUG|continuous infusion|Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
41277658|NCT02112448|DRUG|as needed dosing|morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..
41277659|NCT02112448|DRUG|Acetaminophen|Acetaminophen will be given every 4 hours for a total of 24 hours.
41448421|NCT04531969|OTHER|Spa therapy and conventional physical therapy|"HP application +deep heater application + TENS. HP application: A hotpack wrapped in a towel for 20 minutes will be placed on the knee and surrounding soft tissues.~Deep heater application: The application will be performed with a therapeutic ultrasound device at a dose of 1.5watt / cm2 for each string for 6 minutes.~TENS application:TENS device with two electrodes surrounding tendon will be performed for 30 minutes at low-frequency current application.~Spa therapy: A conventional water bath water at 38 ° C will be applied in the pool for 20 minutes a day."
41127152|NCT01303510|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
41277660|NCT02112448|DRUG|ketorolac|Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
41448422|NCT02849951|DRUG|LT-02|12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
41448423|NCT02849951|DRUG|LT-02 Placebo|12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo
41448424|NCT05814783|BEHAVIORAL|supported digital CBTI|in session support for adherence to and engagement with digital CBTI
41448425|NCT05814783|DEVICE|digital CBTI|CBTI app
41448426|NCT06562998|DRUG|Pentoxifylline|Pentoxifylline 400mg twice daily plus paclitaxel based regimens for 12weeks.
41448427|NCT06344143|DIAGNOSTIC_TEST|Various labs and imaging tests|Dexamethasone Suppression Test, Adrenocorticotropic Hormone (ACTH), Salivary Cortisol Levels, Vasopressin Stimulation test, Fasting Glucose, Fasting Insulin, Complete Metabolic Panel (CMP), Gamma-glutamyl transferase (GGT), Sex Hormone Binding Globulin, Cat scan of abdomen/Pelvis, Whole body dual energy x-ray absorptiometry (DXA) scan, Ultrasound Fibroscan Transient Elastography
41448428|NCT05324033|RADIATION|multiparametric MRI on the bladder|comparison between mpMRI and histopathology
41448429|NCT05324033|PROCEDURE|diagnostic cystoscopy +/- TURBT|conventional way of diagnosis
41448430|NCT06249139|BEHAVIORAL|Compass for Care (Well-being intervention)|Participants receive 12 weekly modules containing interactive activities and static content and tailored messages delivered via text message or email. The intervention focuses on five self-care behaviors critical to ADRD caregiver well-being: 1) taking time to recharge; 2) finding information about your loved one's diagnosis and needs; 3) discovering your strengths and limits; 4) exploring outside help; and 5) seeking emotional support.
41127153|NCT03426800|OTHER|Acupuncture and training|Acupuncture twice in the week in 3 weeks combined with training in 6 weeks
41127154|NCT03830567|OTHER|Pharmacist prescription|Pharmacist prescribed hormonal contraception (initiation or continuation).
41277661|NCT06056973|DRUG|jinghua weikang capsule|Oral Jinghua Weikang Capsule, two capsules each time, three times a day
41277663|NCT03817671|OTHER|5% O2|Culturing embryos in 5% O2 just after thawing and till embryo transfer
41277664|NCT03817671|OTHER|2% O2|Culturing embryos in 2% O2 just after thawing and till embryo transfer
41277665|NCT00794586|DRUG|FTI, AZLI|Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
41448431|NCT06249139|BEHAVIORAL|Compass for Care (Safety intervention)|Participants receive 12 weekly modules and tailored messages delivered via text message or email. The intervention focuses on safety behaviors (e.g., weather safety, first aid, home safety, etc.)
41448432|NCT06043388|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
41448433|NCT06043388|BIOLOGICAL|Placebo|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
40929141|NCT00126880|DRUG|3TC|3TC, 150mg BID
41277666|NCT00794586|DRUG|Placebo, AZLI|Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
41277667|NCT03277196|DRUG|IVA|Granules for oral administration.
41277668|NCT06620107|DEVICE|noninvasive high frequency oscillation ventilation|"cases of group A extubated on NHFOV, and it will be provided by CNO, Medin device, Germany) via binasal prongs with the following parameters:~* MAP of 6 cmH2O and will be titrated targeting a FiO2 ≤ 25-30%, maximum FiO2 will be 40% and target oxygen saturation will be 90-95%.~* Frequency of 8 Hz and can be changed within the range of 8-12 Hz.~* Amplitude of 7 cmH2O and can be titrated within the range of 7-10 cmH2O according to PaCO2."
41448434|NCT06466733|PROCEDURE|Embolization of the middle meningeal artery|Embolization of the middle meningeal artery ipsilateral to the chronic subdural hematoma is performed infusing embolic polyvinyl alcohol (PVA) microparticles.
41448435|NCT06466733|PROCEDURE|Surgical Evacuation via burr hole or craniotomy|The standard of care for chronic subdural hematoma, burr hole or craniotomy are performed ipsilateral to the lesion.
41448436|NCT03886129|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound (TCD)|Participants will undergo an assessment of brain blood flow using TCD, with two small ultrasound probes held in place on the temples with a customised headframe. During the assessment, heart rate, breathing and blood pressure will also be monitored using a 3 lead ECG, nasal capnography and Finometer® respectively. The assessment will comprise three recordings. Firstly, participants will sit quietly for 5 minutes. Next, they will be asked to sit quietly for one minute before standing and remaining standing for 5 minutes. Lastly, they will be asked to stand and then complete a squat-stand manoeuvre in time with a computer sequence. A tilt sensor attached to the thigh will measure the efficiency and angle of the squatting motion. The squat-stand manoeuvre will consist of 15 squats and participants will be informed that they should try and complete all 15 squats if possible.
41448437|NCT04838353|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
41127155|NCT03830567|OTHER|Clinician prescription|Clinician prescribed hormonal contraception (initiation or continuation).
41448438|NCT04992390|BEHAVIORAL|Brief digital imagery-competing task intervention|"First session guided by a researcher: A memory cue followed by playing the brief digital imagery-competing task with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session and record their intrusive memories (symptom monitoring)."
41277669|NCT06620107|DEVICE|noninvasive positive pressure ventilation|"NIPPV will be provided by any type of neonatal ventilator available in the unit via binasal prongs starting with the following parameters:~* Positive end expiratory pressure (PEEP) of 5 cmH2O and can be titrated to 8 cmH2O according to the oxygenation .~* Peak inspiratory pressure (PIP) of 15 cmH2O and can be titrated to 25 cmH2O ,according to oxygenation , PaCO2 level and the chest expansion .~* FiO2 ≤ 25-30% and can be increased to 40 % maximally targeting oxygen saturation of 90-95% .~* Inspiratory time of 0.40-0.50 s .~* Rate of 30 bpm and can be increased to maximum 50 bpm .~* Synchronization will not be applied."
41277670|NCT06629389|DRUG|Cannabidiol 100 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
41277671|NCT06629389|DRUG|cannabidiol 300 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
41448439|NCT01410227|BIOLOGICAL|Recombinant von Willebrand factor (rVWF)|Intravenous administration
40919223|NCT03917407|DRUG|DUR-928 (Moderate AH)|"A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion."
41127156|NCT03528213|DRUG|Sodium Lactate light dose|bolus 2.5ml/kg then 0.25ml/kg/h
41127157|NCT03528213|DRUG|Sodium Lactate high dose|bolus 2.5ml/kg then 0.5ml/kg/h
41277672|NCT06629389|DRUG|Cannabidiol 400 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
41277673|NCT06629389|DRUG|Placebo|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
41127158|NCT03528213|DRUG|Normal saline|normal saline at physician discretion
41127159|NCT03861052|DRUG|Tirzepatide|Administered SC
41448440|NCT01410227|DRUG|Placebo|Syringe supplied with physiologic saline solution for infusion
41448441|NCT01410227|BIOLOGICAL|Recombinant factor VIIII (rFVIII)|Intravenous administration
41448442|NCT06628102|DIAGNOSTIC_TEST|Chest CT Scan|Chest CT Scan
41448443|NCT00177164|DRUG|Injectable Risperidone (Consta) or oral antipsychotic|"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"
41448444|NCT06167317|DRUG|GS-0201|Pill administered orally
41448445|NCT06167317|DRUG|Sacituzumab Govitecan|Administered intravenously
41448446|NCT03648580|DIETARY_SUPPLEMENT|Ensure Complete powder|Supply the Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
41448447|NCT03648580|OTHER|verbal nutrition education|give the verbal nutrition education
41127160|NCT03861052|DRUG|Dulaglutide|Administered SC
40929142|NCT00924781|DRUG|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
40929143|NCT00924781|DRUG|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
40929144|NCT00924781|DRUG|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
40929145|NCT04456153|DRUG|Experimental Group|Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days
40929146|NCT04456153|DRUG|Placebo Group|Continued standard of care therapy together with matching placebo
41127161|NCT02297919|BEHAVIORAL|Effectiveness of Internet Based Obesity Control Programme|
41127162|NCT01503372|DRUG|Pazopanib|Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
41127163|NCT01503372|DRUG|5-FU, Oxaliplatin, Leukovorin (FLO)|Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
41127164|NCT01303796|DRUG|Sapacitabine|Oral sapacitabine capsules
41127165|NCT01303796|DRUG|Decitabine|Decitabine intravenous
41127166|NCT05811936|BEHAVIORAL|Survivorship Needs Assessment Planning (SNAP) tool|"SNAP includes 2 educational survivorship modules for caregivers and survivors. There are 3 main elements: needs assessment, a tailored care plan and a mobile support app. SNAP uses pre-specified categories of needs, resources, and messaging behind the scenes to automate the identification, rating and management of high priority needs. Generated tailored care plans include referrals, messages and educational materials mapped to prioritized dyad-reported concerns addressing survivorship domains (diagnosis, treatment, follow-up care). Care plans and referrals are reviewed with an Advanced Practice Provider. Barriers to uptake are addressed, goal-oriented action planning is refined with brief mobile app training. Dyads receive a personalized binder with care plan, referrals, and an action plan. Dyads receive e-monitoring for 6 weeks to check in and identify barriers with algorithm-driven messaging to reinforce progress, provide further resources and encouragement."
41127167|NCT04463875|DIETARY_SUPPLEMENT|magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10|Supplementation per os
41127168|NCT06016400|DRUG|Alfacalcidol Oral Solution|Alfacalcidol Oral Solution 1ug a day
41127169|NCT06016400|DRUG|Placebo|Placebo
41277674|NCT04083495|BIOLOGICAL|ATLCAR.CD30 T cells|Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10\^8 CAR-T/m\^2 with a maximum dose of 5 × 10\^8 CAR-T cells
41277675|NCT04083495|DRUG|Bendamustine|70 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion
41448448|NCT04724616|OTHER|Educational Program (CARTOON)|CARTOON is an interdisciplinary psychoeducational intervention program. It consists of five teaching sessions: 1) hand hygiene, not grasping the face, 2) sneezing etiquette, 3) wearing a mask, 4) social distancing, and 5) theoretical knowledge about the coronavirus. Using special exercises and games, information about the coronavirus is conveyed in a child friendly manner.
40919261|NCT05728099|DEVICE|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations coupled with SpiroGym app. per training session .
40929147|NCT03551080|BIOLOGICAL|Lipopolysaccharide|Endotoxin at 0.8 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
41127170|NCT05126342|DRUG|Niraparib|Niraparib starting dose of study treatment will be based upon the patient's baseline body weight and baseline platelet count. Patients with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 10\^9/L may start with niraparib 300 mg (3 x 100 mg capsules) daily unless the dose has not already been reduced to 200 mg in a prior treatment line. Patients with a baseline body weight \<77 kg or a baseline platelet count \<150 x 10\^9/L will be administered niraparib 200 mg (2 x 100 mg capsules) daily.
41127171|NCT05126342|DRUG|Dostarlimab|Dostarlimab (TSR-042) is administered 500 mg iv Q3W for the first 12 weeks. For the remainder of the study dostarlimab (TSR-042) is administered 1000 mg iv Q6W.
41127172|NCT04914403|BIOLOGICAL|UMC119-06-05|Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05
41277676|NCT04083495|DRUG|Fludarabine|30 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion
41277677|NCT04083495|DRUG|Cyclophosphamide|300 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
41277678|NCT04875728|DRUG|Cefazolin|Given IV
40929148|NCT03551080|BIOLOGICAL|Placebo|Saline administered intravenously
40929149|NCT05346445|DRUG|Fluoxetine 20 MG|Participants received non-hormonal treatment with fluoxetine.
40929150|NCT05346445|DRUG|Citalopram 20mg|Participants received non-hormonal treatment with citalopram.
40929151|NCT02036554|DRUG|Everolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
41277679|NCT04875728|PROCEDURE|Resection|Undergo standard of care surgical resection
41277680|NCT05646056|DEVICE|Software|Observation only
41127173|NCT04802018|DEVICE|Clinical decision support system based on non-invasive multimodal monitoring|Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
41127174|NCT03445364|OTHER|Use of different injection pressure during primary PCI|Using ACIST injector during the PCI it is possible to change injection pressure - in one arm low pressure of 200psi, and in the second arm average pressure of 550psi
41127175|NCT00000749|BIOLOGICAL|rgp120/HIV-1 SF-2|
41127176|NCT02136641|DRUG|Midazolam|Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.
41127177|NCT02136641|DRUG|Midazolam+Fentanyl Combination|Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
41127178|NCT02136641|DRUG|Midazolam+Ketamine Combination|Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
41127179|NCT00144287|DRUG|Tipranavir/Ritonavir|
41448449|NCT03372187|BEHAVIORAL|DIET-MS|Following the completion of testing, all 20 participants will be placed into the DIET-MS group and will follow the prescribed diet plan for 12 weeks. At the end of the 12 weeks, the participants will return to complete follow up testing.
41127180|NCT06364852|DRUG|LY007|FC and LY007 infusion
41127181|NCT06296992|BEHAVIORAL|12-week TEAM peer mentor program|A 12-week peer-led behavioural intervention that supports increased physical activity. It will consist of 3 weekly contacts between participants and peer mentors that will be a mix of in-person, virtual, and texting. The intervention components and communication between adolescents and peer mentors with T1D will be guided by SDT, and designed to overcome the key psychosocial barriers to PA. The peer mentors that complete the training will deliver a 12-week intervention to increase behavioural skills that foster autonomy for goal setting and overcoming barriers to PA.
41127182|NCT03791593|DRUG|Evolocumab|Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
41127183|NCT02987816|DEVICE|Sham tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
41127184|NCT02987816|DEVICE|Anodal tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
41127185|NCT03791008|OTHER|Risk based screening|Breast cancer risk measurement, screening recommendations and shared decision making
41127186|NCT05054920|OTHER|concentric exercises|concentric exercises for rotator cuff. internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
41448450|NCT01126463|DRUG|188Re-SSS Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
41448451|NCT04312113|DRUG|Adipose derived, autologous mesenchymal stem cells|Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
41448452|NCT01602939|DRUG|Cladribine and pegylated interpheron alpha-2a|"Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.~Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months."
41448453|NCT06443385|BEHAVIORAL|PDMP Legal Mandate E-mail|E-mails highlighting the state's legal requirements to use the PDMP. There will be one initial email and one follow-up email one month later.
40929152|NCT02036554|DRUG|Tacrolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
40929153|NCT02036554|DRUG|Mycophenolic acid|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
40929154|NCT02767544|PROCEDURE|Vaginal wound local analgesia after laparoscopic hysterectomy|
41127187|NCT05054920|OTHER|eccentric exercises|Eccentric exercises exercises for rotator cuff internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
41127188|NCT05054920|OTHER|Stretching|stretching exercise for posterior capsule and pectoralis minor each stretch will be done for 30 seconds and repeated 3 times
41127189|NCT00147719|DRUG|Colesevelam hydrochloride|
41127190|NCT04564365|DRUG|beta-blocker|To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
41127191|NCT00692185|DRUG|Olanzapine|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
41127192|NCT00692185|DRUG|Placebo|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
41277681|NCT04550494|PROCEDURE|Biopsy|Undergo biopsy
41277682|NCT04550494|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41277683|NCT04550494|PROCEDURE|Computed Tomography|Undergo CT scan
41277684|NCT04550494|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41277685|NCT04550494|DRUG|Talazoparib|Given PO
40929155|NCT06171711|BEHAVIORAL|Exposure Therapy|The proposed study will explore whether Exp-AN works via inhibitory learning (i.e., decreasing anxious beliefs and increasing anxiety tolerance) and/or between-session habituation (i.e., decreasing anxiety levels across therapy sessions), and the importance of targeting anxiety about eating versus weight gain. Results will provide information about the degree to which all three mechanisms of action (i.e., changes in anxiety ratings, anxious beliefs, and tolerance of anxiety) predict improved AN symptomatology across both treatments. Research that discovers whether specific treatments (e.g., Exp-AN) work in the way the investigators think they do (e.g., by increasing tolerance of anxiety), and whether modifying intervention targets (e.g., tolerance of anxiety) helps people get better (e.g., reduced AN symptomatology), will ultimately lead to more personalized, mechanism-based, and effective treatments (Insel 2014; Insel et al., 2010).
41277686|NCT02568904|OTHER|Alcohol|every participant will drink vodka at a dose of 2ml/kg bodyweight
41277687|NCT02568904|OTHER|Glucose|oral Glucose tolerance test
41277688|NCT02568904|OTHER|Fructose|oral fructose tolerance test
41277689|NCT02568904|OTHER|vehicle|control (water)
41277690|NCT02226354|DIETARY_SUPPLEMENT|Ahiflower oil|9.73 ml per day for 28 days
41277691|NCT02226354|DIETARY_SUPPLEMENT|Flaxseed oil|9.73ml per day for 28 days
41277695|NCT02262806|DRUG|Metreleptin|A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with partial lipodystrophy.
41277696|NCT04689308|DRUG|MH048|Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
40929156|NCT02263131|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
41127193|NCT04221828|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
41277697|NCT03222271|DEVICE|Extubation to NIV|Weaning using NIV immediately after extubation with the mentioned parameters
41277698|NCT03323749|COMBINATION_PRODUCT|elamipretide|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
41277699|NCT03323749|COMBINATION_PRODUCT|placebo comparator|40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
40919262|NCT05728099|DEVICE|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations per training session. Participants will be given the practice log to track training adherence.
40929157|NCT02263131|BIOLOGICAL|VAXIGRIP Prefilled Syringe INJ.|VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
41127194|NCT03602950|BIOLOGICAL|PRP|autologous PRP will be injected subcutaneously before skin closure at time of elective CS
41127195|NCT05371275|DRUG|Palbociclib|125 mg of palbociclib once daily for 21 consecutive days
41277700|NCT03323749|COMBINATION_PRODUCT|elamipretide open label treatment|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
41277701|NCT06056427|BIOLOGICAL|HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)|Participants will receive autologous HB-adMSCs through intravenous infusion only, with a treatment duration of 18 weeks, infusion rate 4-5mL/min and total volume of 250 mL Sodium chloride 0.9%. Each participant will receive a total of 6 doses of HB-adMSCs with a dosing regimen of approximately 2 weeks between infusion 1 and infusion 2, and 4 weeks between the remaining infusions.
41277704|NCT02338986|DRUG|Plasma|Plasma
41277705|NCT05928806|DRUG|Botensilimab|Botensilimab 75mg IV
41277706|NCT05928806|DRUG|Balstilimab|Balstilimab 450mg IV
41277707|NCT05928806|DRUG|Ipilimumab|Ipilimumab 1mg/kg IV
41277708|NCT05928806|DRUG|Nivolumab|Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV
41277709|NCT06631079|BIOLOGICAL|NECVAX-NEO1|Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
40919263|NCT02874144|DRUG|AZ compound|40 mg three times daily po for 12 weeks
41277717|NCT06077864|DRUG|survodutide|once weekly subcutaneous injection
41277718|NCT06077864|DRUG|Placebo|once weekly subcutaneous injection
41277719|NCT06448988|OTHER|Park Bench position|To evaluate, during the procedure, the variation in regional distribution of intrapulmonary volume in the dependent and non-dependent lung regions in patients undergoing neurosurgical intervention between supine and Park-Bench position.
41277720|NCT03768063|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
41127196|NCT06108024|DRUG|SM-020 gel 1.0%|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
41127197|NCT06108024|DRUG|Vehicle gel|Vehicle gel will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
41127198|NCT01032668|DRUG|Clopidogrel|high dose clopidogrel continuing after percutaneous coronary intervention
41127199|NCT02632071|DRUG|ACY-1215|An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
41277721|NCT03768063|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
41127200|NCT02632071|DRUG|Nab-paclitaxel|"Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle"
41127201|NCT04149808|DEVICE|Mepilex Ag (burn dressing)|Dressing for low to medium exuding burns and wounds.
41127202|NCT04149808|DEVICE|Xeroform Dressing|Standard of care dressing for low to medium exuding burns and wounds.
41127203|NCT00257881|DRUG|CMD-193|
41127204|NCT01306786|DRUG|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
41127205|NCT01306786|DRUG|Triple therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
41127206|NCT04047719|DIAGNOSTIC_TEST|Karius Test|Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma
41127207|NCT03195075|PROCEDURE|Endoscopic ultrasonography guided biliary drainage|Endoscopic ultrasonography guided biliary drainage includes rendezvous techniques, endoscopic ultrasonography guided choledochoduodenostomy, and endoscopic ultrasonography-guided hepatogastrostomy using self-expandable metal stent will be done for group 1
41277722|NCT03768063|DRUG|Alectinib|Alectinib will be administered as directed per the parent study.
41277723|NCT03768063|DRUG|Cobimetinib|Cobimetinib will be administered as directed per the parent study.
41127208|NCT03195075|PROCEDURE|Percutaneous trans-hepatic biliary drainage|Percutaneous trans-hepatic biliary drainage in interventional radiology department using self-expandable metal stent will be done for group 2
41127209|NCT06515457|DIETARY_SUPPLEMENT|Eye Empower|Participants will take three capsules of the Eye Empower supplement daily for three weeks.
41127210|NCT05948774|DRUG|MT200605 for Injection|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
41127211|NCT05948774|DRUG|MT200605 Placebo|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
41127212|NCT06140732|DRUG|camrelizumab and apatinib|camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
41277724|NCT03768063|DRUG|Vemurafenib|Vemurafenib will be administered as directed per the parent study.
41277725|NCT03768063|DRUG|FAP IL2V|FAP IL2V will be administered as directed per the parent study.
40919264|NCT02874144|OTHER|Collection of Biological Specimens|collection of biomarkers for analysis of nasal disease
40919265|NCT02874144|DRUG|Intranasal corticosteroid|QD Nasal Spray
40919266|NCT02874144|DRUG|Placebo|looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
40919267|NCT06017999|DRUG|XG005 tablet|Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.
41277726|NCT03768063|DRUG|Venetoclax|Venetoclax will be administered as directed per the parent study.
41277727|NCT03768063|DRUG|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
41277728|NCT03768063|DRUG|Pembrolizumab|Pembrolizumab will be administered as directed per the parent study.
41277729|NCT03768063|DRUG|Sunitinib|Sunitinib will be administered as directed per the parent study.
41277730|NCT03768063|DRUG|Niraparib|Niraparib will be administered as directed per the parent study.
41277731|NCT03768063|DRUG|Cabozantinib|Cabozantinib will be administered as directed per the parent study.
41277732|NCT03768063|DRUG|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
41277733|NCT03768063|DRUG|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
40919268|NCT06017999|DRUG|Placebo tablet|Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.
41448454|NCT06443385|BEHAVIORAL|PDMP Clinical Benefit E-mail|E-mails highlighting the clinical benefits of having access to the PDMP and checking the PDMP before prescribing opioids. There will be one initial email and one follow-up email one month later.
41448455|NCT00540995|DRUG|busulfan|Given IV
41127213|NCT06160518|BEHAVIORAL|Virtual reality|artificial construction of 3D environment via mobile technology. It included a head-mounted device (HMD) with 3D-enabled goggles, sensory input devices and headphones, which together allow a multisensory experience to divert a child's attention.
41127214|NCT02332512|DRUG|Apatinib|
41127215|NCT02332512|DRUG|Placebo|
41127216|NCT04532749|DRUG|Seltorexant|Participants will receive Seltorexant tablets.
41448456|NCT00540995|DRUG|etoposide|Given IV
41448457|NCT00540995|RADIATION|intensity-modulated radiation therapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
41127217|NCT04532749|DRUG|Placebo|Participants will receive matching placebo tablets.
41127218|NCT02352909|OTHER|Education|Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.
41127219|NCT02352909|OTHER|Exercise program|A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.
41127220|NCT02352909|OTHER|Gait retraining|Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
41127221|NCT00174252|DRUG|Genotonorm (Somatropin)|0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
41127222|NCT03399604|DRUG|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
41127223|NCT06522893|OTHER|Percutaneous neuromodulation|Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
41448458|NCT00540995|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
41127224|NCT00874536|DIETARY_SUPPLEMENT|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
41127225|NCT00874536|DIETARY_SUPPLEMENT|Placebo|
41127226|NCT04608305|BIOLOGICAL|IIBR-100, low dose (prime)|Single administration of IIBR-100 1\*10E5 pfu/ml
41127227|NCT04608305|BIOLOGICAL|IIBR-100 medium dose (prime)|Single administration of IIBR-100 1\*10E6 pfu/ml
41127228|NCT04608305|BIOLOGICAL|IIBR-100 high-dose (prime)|Single administration of IIBR-100 1\*10E7 pfu/ml
41127229|NCT04608305|BIOLOGICAL|IIBR-100 low-dose (prime-boost)|Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
41127230|NCT04608305|OTHER|Saline Placebo (single)|Single administration of saline placebo
41127231|NCT04608305|OTHER|Saline Placebo (double)|Two administrations of saline placebo, 28 days apart
41127232|NCT04608305|BIOLOGICAL|IIBR-100 medium-dose (prime-boost)|Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart
41127233|NCT04608305|BIOLOGICAL|IIBR-100 high-dose (prime-boost)|Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart
41127234|NCT04608305|BIOLOGICAL|IIBR-100 top-dose (prime-boost)|Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
41127235|NCT00566735|DRUG|Razadyne|The starting dose of study medication is 4 mg twice a day
41127236|NCT00566735|DRUG|Placebo|4 mg, 2 times a day
41127237|NCT04797923|DRUG|1. Treatment: IP chemotherapy + Systemic chemotherapy|1. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1\~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
41127238|NCT04797923|PROCEDURE|2. Response evaluation after 4 cycles of IP + systemic chemotherapy|"2. Response evaluation after 4 cycles of IP + systemic chemotherapy~* Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.~* If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.~* IP chemotherapy should not exceed total of 8 cycles."
41277734|NCT03768063|DRUG|Emactuzumab|Emactuzumab will be administered as directed per the parent study.
41277735|NCT03768063|DRUG|Rucaparib|Rucaparib will be administered as directed per the parent study.
41448459|NCT00540995|PROCEDURE|allogeneic bone marrow transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
41448460|NCT00540995|PROCEDURE|peripheral blood stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
41448461|NCT00540995|RADIATION|tomotherapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
41448462|NCT01194648|OTHER|questionnaire administration|
41448463|NCT01194648|PROCEDURE|assessment of therapy complications|
41448464|NCT01194648|PROCEDURE|high-intensity focused ultrasound ablation|
41448465|NCT01194648|PROCEDURE|multiparametric magnetic resonance imaging|
41448466|NCT01194648|PROCEDURE|quality-of-life assessment|
41448467|NCT01194648|PROCEDURE|transperineal prostate biopsy|
41277736|NCT00257751|PROCEDURE|Aprotinine|
41448468|NCT01194648|PROCEDURE|transrectal prostate biopsy|
41448469|NCT04778501|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
41448470|NCT03862573|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
41448471|NCT06619093|OTHER|blood sampling|3 additional citrate tubes (2.7mL)
41127239|NCT06270628|BEHAVIORAL|Exercise group|Live-remote exercise sessions, personalized to the patients main side-effect
41448472|NCT00869193|DIETARY_SUPPLEMENT|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
41127240|NCT00276601|DRUG|arsenic trioxide|
41127241|NCT00276601|DRUG|cytarabine|
41127242|NCT00276601|DRUG|daunorubicin hydrochloride|
41127243|NCT00276601|DRUG|mercaptopurine|
41127244|NCT00276601|DRUG|methotrexate|
41127245|NCT00276601|DRUG|tretinoin|
41127246|NCT04133337|DRUG|Apatinib|Apatinib Mesylate Tablets
41127247|NCT04133337|DRUG|SHR-1210|Camrelizumab for Injection
41448473|NCT00869193|DIETARY_SUPPLEMENT|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
41448474|NCT04211935|DEVICE|Use of PCA|A commercially available PCA pump will be connected to the patient's intravenous line at the end of the MIRPE operation.
41448475|NCT04211935|DEVICE|Use of ESB for postoperative pain control after MIRPE|Pediatric anesthesiologists will place ESB at the time of the MIRPE operation if study participants are randomized into this group.
41448476|NCT04211935|DEVICE|Use of INC for postoperative pain control after MIRPE|Pediatric surgeons will perform INC during the MIRPE operation if they are randomized to this group.
41448477|NCT02504450|DRUG|Adasuve|Inhaled medication to treat acute agitation in the emergency department
41448478|NCT02504450|DRUG|Alternative medications|Medication given to treat acute agitation in the emergency department
41448479|NCT01931553|OTHER|Standardized attending morning rounds|
40929158|NCT05709132|BEHAVIORAL|iPeer2Peer Program|Behavioral: iPeer2Peer Support Mentorship Program is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
41127248|NCT05519670|DRUG|Niraparib Oral Product|Niraparib + capecitabine treatment
41127249|NCT04758416|PROCEDURE|biopsy or surgical pathology in metastases|biopsy or surgical pathology in extrahepatic/liver/brain metastases
41127250|NCT04758416|DRUG|68Ga-HER2 affibody,18F-FDG, 18F-FES|68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
41127251|NCT04896736|OTHER|Multisite tissue oxygenation-guided care|"The following intervention algorithm is intended to be used as a guidance only. We emphasize the different aspects that can cause changes in SctO2/SstO2 in a systematic approach. We avoid recommending a concrete drug and method of dosing for a specific condition.~Manage tissue perfusion Preload: overall picture including direct observation of the heart, findings of echocardiography, urine output, blood loss, labs results, HR, BP, PPV, SVV, fluid responsiveness (SV increase \>/= 10% following 250 ml fluid bolus) Contractility: direct observation of the heart, findings of echocardiography Stroke volume and heart rate: important determinants of CO Systemic vascular resistance: important determinant of BP Regional vascular resistance: important determinant of tissue perfusion along with perfusion pressure Maintain autoregulation: normalize CO2, avoid potent vasodilators~Manage arterial blood oxygen content~Manage tissue metabolic activity"
41127252|NCT04896736|OTHER|Usual care|Usual care in this study means the standard perioperative care. Patients who are meant to receive usual care will receive both cerebral and muscular tissue oxygen saturation monitoring; however, the monitor screen will be covered and the monitoring data will not be used to guide clinical care.
41448480|NCT04884308|BIOLOGICAL|BCG TICE Vaccine|Intradermal vaccination with BCG TICE
41448481|NCT05751447|DIAGNOSTIC_TEST|Lymph node puncture, bronchoscopy|Included patients will undergo an extra lympn node punction through oesophagus and/ or an extra bronchoscopy.
41448482|NCT04099758|BEHAVIORAL|Mindfulness of the breath meditation|A 10-minute mindfulness of the breath meditation practice
41448483|NCT04099758|BEHAVIORAL|Audio-recording control|10 minute non-fiction audio-recording delivered online
41277737|NCT03886168|OTHER|Signal processing intervention of a biomedical device|This is a signal processing intervention of an FDA approved biomedical device for study participants that have received the cochlear implant based on clinical recommendations (i.e. not study related). Based on image processing of pre- and post-implant CT, cochlear segmentation, electrode scalar localization, and definition of the electrode-to-neural interface, the investigators will manipulate the stimulus delivery of the incoming signal within the FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
41277738|NCT04707872|DIAGNOSTIC_TEST|MMDx diagnostic test|Microarray test of gene expression in heart biopsies
41127253|NCT01355549|BIOLOGICAL|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
41127254|NCT00902213|BEHAVIORAL|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
41277739|NCT04707872|DIAGNOSTIC_TEST|Prospera|Donor derived cell-free DNA in patient blood
41277740|NCT04707872|DIAGNOSTIC_TEST|HLA antibody|Centralized measurement of HLA antibodies in patient blood
41277741|NCT00042809|DRUG|paclitaxel|Given IV
41277742|NCT00042809|BIOLOGICAL|trastuzumab|Given IV
41277743|NCT00042809|DRUG|erlotinib hydrochloride|Given orally
41277744|NCT00042809|OTHER|laboratory biomarker analysis|Correlative studies
41277745|NCT00042809|OTHER|pharmacological study|Correlative studies
41448484|NCT05870215|OTHER|Visit 1: Clinical exam and questionnaires|Medical history and examination, including vital signs, inhaler technique and adherence check (using prescript refills via the Dossier Santé Québec and/or calls to the community pharmacy), 5-item Asthma Control Questionnaire (ACQ-5), dyspnea rated on the modified Medical Research Council scale (mMRC), visual analog scale (VAS) for six respiratory symptoms, Pittsburgh Vocal Cord Dysfunction Index, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale.
41448485|NCT05870215|OTHER|Visit 1: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
41448486|NCT05870215|OTHER|Visit 1: Inflammometry|Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray
41448487|NCT05870215|OTHER|Visit 2: Clinical exam and questionnaires|Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.
41448488|NCT05870215|OTHER|Visit 2: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
41448489|NCT05870215|OTHER|Visit 2: Inflammometry|SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)
41448490|NCT05870215|OTHER|Visit 3: e-mail|ACQ-5, peak flow measurement, and questions about the patient's asthma management.
41127255|NCT00902213|BEHAVIORAL|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
41277746|NCT04493164|DRUG|Ivosidenib|Given PO
41277747|NCT04493164|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
41277752|NCT01829048|DRUG|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
41277753|NCT01829048|DRUG|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
41277754|NCT01829048|DRUG|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
41277755|NCT01829048|DRUG|Placebo|Placebo Q12h
41277756|NCT02626377|BEHAVIORAL|Support provided by social worker|Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.
41277757|NCT02626377|OTHER|Information booklet receipt|Caregivers will only receive an information booklet (which informs about existing structures and actions)
41277758|NCT04161040|BEHAVIORAL|Performance-based incentives|Participants will earn $1 per minute of engagement in physical activity.
41277759|NCT06381583|DIAGNOSTIC_TEST|EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)|A panel of circulating microRNA, whose expression level is tested in cell-free derived samples.
41448491|NCT06358469|PROCEDURE|Surgery|Re-excision of vulvar cancer margin
41448492|NCT06358469|OTHER|Active Surveillance|The investigator will follow the patient to watch for side effects and keep track of patient's health
41448493|NCT06359002|DRUG|BYON4413|BYON4413 will be administered by IV infusion.
41448494|NCT01221129|OTHER|Acclimation|11 mg Zn/day as a controlled intake level
41127256|NCT06371755|DEVICE|Ultrasound examination with REMS technology|The proposed study is defined as interventional because it introduces an ultrasound examination in the standard clinical routine. The diagnostic approach does not vary during the study and the prescription of any therapeutic treatment is performed on the basis of the conventional DXA diagnosis. This ultrasound examination does not involve additional risks for the patient with the benefit of not using ionizing radiation; it lasts only few minutes and can be performed without moving the patient from the same bed on which he is already positioned for DXA examination.
41127257|NCT00507767|DRUG|dasatinib|Given PO or via PEG tube
41127258|NCT00507767|PROCEDURE|pharmacological study|Correlative studies
41127259|NCT00507767|PROCEDURE|laboratory biomarker analysis|Correlative studies
41127260|NCT06350812|DRUG|PB-119|Administered subcutaneously once a week
41127261|NCT06350812|DRUG|Placebo|Administered subcutaneously once a week
41127262|NCT01324310|DRUG|Romidepsin|Romidepsin 8 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
41127263|NCT01324310|DRUG|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
41127264|NCT04496388|BEHAVIORAL|exercise|different type of exercise
41127265|NCT04496388|BEHAVIORAL|No exercise intervention|No exercise intervention
41127266|NCT02476409|DRUG|tolvaptan|Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
41127267|NCT02476409|OTHER|Placebo|Placebo for tolvaptan
41127268|NCT03035851|BEHAVIORAL|Aerobic exercise|
41127269|NCT03035851|BEHAVIORAL|Stretch and Strength|
41127270|NCT05194696|BEHAVIORAL|Questionnaire|Patients have to answer a questionnaire about their caffeine consumption habits during lifetime
40754791|NCT02953964|OTHER|Behavioral: semantic-based memory encoding training|Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
40919269|NCT03935568|DRUG|PU-AD|3 cohorts receiving a single oral dose of PU-AD at one time.
40919270|NCT03935568|DRUG|Placebo|3 cohorts receiving a single oral dose of Placebo at one time
40919271|NCT03935568|DRUG|Placebo|2 cohorts receiving multiple oral dose of Placebo at one time
41127271|NCT04210037|DRUG|APG-1252|APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.
41127272|NCT04210037|DRUG|Paclitaxel|80 mg/m˄2 on days 1 and 8 of a 21-day cycle
41127273|NCT00831688|DEVICE|Meniett(C) device by MedTronic|pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
41127274|NCT00831688|DEVICE|placebo treatment|device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
41127275|NCT01921075|OTHER|normal dietary behavior|normal dietary behavior during examination days
41127276|NCT01921075|OTHER|Magnetic resonance spectroscopy|Non-invasive diagnostic procedure
41127277|NCT02358005|PROCEDURE|Extracorporeal shock wave therapy 60mj|
41127278|NCT02358005|PROCEDURE|Extracorporeal shock wave therapy 120mj|
41127279|NCT02358005|PROCEDURE|non extracorporeal shock wave therapy|
41127280|NCT03347851|OTHER|MRI|Enrolled patients will complete a non-contrast cardiac MRI
41127281|NCT03347851|OTHER|Transthoracic echocardiography exam|Enrolled patients will complete a transthoracic echocardiography exam.
41448495|NCT01221129|OTHER|Dietary zinc depletion|\< 1 mg Zn/day achieved by providing a liquified diet of defined nutrient content
40919272|NCT03935568|DRUG|PU-AD|2 cohorts receiving multiple oral dose of PU-AD at one time
40919273|NCT06073483|DEVICE|Toumai Endoscopic surgery System|5G remote gastrectomy on subjects using the Toumai endoscopic surgery system
40919274|NCT04206280|BEHAVIORAL|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
40919275|NCT04206280|BEHAVIORAL|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
40919276|NCT02715440|DRUG|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs
40919277|NCT01138917|DEVICE|ReCell and Split-thickness skin graft|The surgeon will be required to select two similar non-contiguous injury areas with both areas being at least 100cm2 and second degree depth/severity. One area will be treated using ReCell and the second using Split-thickness Skin Graft.
40919278|NCT03246997|OTHER|Autumn Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
40919279|NCT03246997|OTHER|Spring Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
40919280|NCT03485300|DIAGNOSTIC_TEST|Liver and kidney function tests for patients with chronic liver or kidney diseases|Tests will be done to patients with history suggestive of chronic liver or renal diseases or for patients clinically suspected
40919281|NCT03485300|BEHAVIORAL|Non compliance of the patient|I will order all my patients to take the drug at 10 am and assure the daily in taking of the dose and they will be followed up
40919282|NCT03485300|DRUG|Drug or food interactions|The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
41277760|NCT05531357|DIAGNOSTIC_TEST|Transvaginal ultrasound scans|"Transvaginal ultrasound scans to map ovarian follicle growth and ovulation, finger-prick blood sampling for dried blood spot (DBS) hormonal assays and urine sampling for hormone metabolites, every consecutive day for an interovulatory interval.~Weekly venipuncture samples will be taken for standard ELISA hormonal assays. The hormones of interest are FSH, LH, estradiol, progesterone, AMH, inhibins A and B, GDF-9 and BMP-15."
41277761|NCT02226484|DRUG|Quercetin|Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
41127282|NCT05021341|DIETARY_SUPPLEMENT|Berberine|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (500 mg of berberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
41277762|NCT00845429|BIOLOGICAL|Influenza virus vaccine - cell based (2007-2008 Formulation)|0.5 mL, Intramuscular
41277763|NCT00845429|BIOLOGICAL|Influenza virus vaccine - cell-based (2007-2008 Formulation)|1.0 mL, Intramuscular
41277764|NCT00845429|BIOLOGICAL|Influenza virus vaccine (2007-2008 Formulation)|0.5 mL, Intramuscular
41277765|NCT03500744|PROCEDURE|Erector spinae plane block|Ropivacaine 0.5% 20 mL at each site of ESPB
41277766|NCT03500744|PROCEDURE|Sham block|Skin infiltration only
41277767|NCT00403104|DRUG|ONO-2506PO|1200 mg QD / 18 months
41127283|NCT05021341|DIETARY_SUPPLEMENT|Dihydroberberine 200|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (200 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
41277768|NCT00403104|DRUG|ONO-2506PO|0 mg QD / 18 months
41277769|NCT00021983|BIOLOGICAL|BL22 immunotoxin|
41277770|NCT02262130|DRUG|Omalizumab|
41277771|NCT04968418|DEVICE|APDM OPAL system wearable IMU|The OPAL system contains wearable IMUs with a sampling rate of 128 Hz and a resolution of 17.5 bits. Each IMU has a size of about 44mm 40mm 14mm × × and weighs less than 25 gm.
41277772|NCT05435430|OTHER|PERSPECTIVE, MULTICENTRIC and observational|we will enroll women with 25-45ys old and previously SARS-COV2 infection. first outcome to be investigate the impact of SARS-COV2 infection on female reproductive health and the main clinical-laboratory parameters (FSH, LH, AMH) relating to women with procreative research, in a path of medically procreation assisted programm and on any quantitative variations, duration and periodicity of the menstrual cycle after Covid infection compared to the pre-infection period.
41277773|NCT03354845|OTHER|Deprescribing intervention|Pharmacists assessed the appropriateness of target symptomatic medications and potential for discontinuation. After discussion with pharmacists and consideration of patients' and caregivers' preferences regarding discontinuation or dose reduction, doctors would deprescribe these symptomatic medications. Symptom recurrence, adverse drug withdrawal events (ADWEs), and the need for drug re-initiation or initiation of new symptomatic control medications after deprescribing were monitored and documented in the 1st, 2nd and 6th weeks.
41277774|NCT03180736|DRUG|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
41277775|NCT03180736|DRUG|Pomalidomide|Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.
41277776|NCT03180736|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
41277777|NCT06092970|DRUG|RBT-1|Intravenous administration
41277778|NCT06092970|DRUG|Placebo|Intravenous administration
41277779|NCT04708067|DRUG|Bintrafusp Alfa|Given IV
41277780|NCT04708067|PROCEDURE|Biopsy|Undergo biopsy
41277781|NCT04708067|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
41277782|NCT06400537|BIOLOGICAL|A-319|A-319 will be infused intravenously.
41277783|NCT05553860|OTHER|Speech positioning technique|Speech positioning technique
41277784|NCT06630390|DRUG|Daridorexant 50 mg|Administered consistent with labeling from the US Food and Drug Administration.
41277785|NCT06630390|OTHER|Placebo|Identical appearing to daridorexant
41277786|NCT06479603|DRUG|Nintedanib|The subjects will receive oral nintedanib. It will be prescribed to be taken after meals with 12 hrs gap between doses. The drug will be started at a dose of 100 mg twice daily. After 2 weeks, the dose will be titrated up to 150 mg twice daily, which will be continued till the end of 52 weeks. The standard-of-care immunosuppressive treatment will be continued along with the study drug (nintedanib). In case of intolerance to the 300 mg/day dose of nintedanib, the dose will be reduced to 100 mg twice daily. In case of severe adverse effects, the drug will be stopped and reintroduced after a period of up to 1-4 weeks. A dose of 100 mg twice daily will be started and continued. One attempt to titrate the dose up to 150 mg twice daily will be permitted.
41277787|NCT06479603|DRUG|Standard of care|The subjects will receive the standard-of-care immunosuppressive treatment alone that may include glucocorticoids and other steroid-sparing agents that the subject would already be receiving.
41448496|NCT01221129|OTHER|Dietary zinc repletion|15 mg Zn/day as a daily supplement plus normal habitual diet without restriction
40929159|NCT04800666|PROCEDURE|Stellate Ganglion Block|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
40929160|NCT04800666|PROCEDURE|Facial Nerve Block|Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )
40929161|NCT04800666|DRUG|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
40929162|NCT03813368|PROCEDURE|Whipples pancreatico-duodenectomy|Classic whipples and pylorus preserving
40929163|NCT00004393|DRUG|risperidone|
40929164|NCT02318108|OTHER|Mentored organizational change|Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
40929165|NCT02318108|OTHER|Education only|Practices are given basic education related to population-based care and are given feedback on performance.
40929166|NCT04608461|DRUG|Pumpkin seed extract containing cream|Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
40929167|NCT00674154|DRUG|Cholecalciferol|2800 IE daily in 52 weeks
40929168|NCT03255330|DRUG|Gabapentin|Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
40929169|NCT03255330|DRUG|Metamizol|Standardized treatment
40929170|NCT03255330|DRUG|Tramadol|Standardized treatment
40929171|NCT05861180|DEVICE|inclinometer, smart phone goniometer and laser beam|devices to objectively assess proprioception of the neck
40929172|NCT01467778|DEVICE|ELAPR|ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
40929173|NCT01467778|DEVICE|ELAPR|Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
40929174|NCT04932798|DIAGNOSTIC_TEST|Resting ECG (if first visit is done on site only)|"The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface.~This test requires around 15 minutes of the participant's time."
40929175|NCT04932798|DIAGNOSTIC_TEST|24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)|The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.
40929176|NCT04932798|DIAGNOSTIC_TEST|3-month AF detection monitoring using the Apple Watch|Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.
40929177|NCT04609111|DRUG|No aspirin|1-month prasugrel monotherapy followed by clopidogrel monotherapy
40929178|NCT04609111|DRUG|1-month DAPT|1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
41277788|NCT05227352|BEHAVIORAL|Biophilic design experience|Recharge Rooms are immersive, biophilic private spaces featuring multisensory input that is inspired by nature.
41277789|NCT06252649|DRUG|FOLFIRI Regimen|Combination of irinotecan, leucovorin, and 5-fluorouracil given intravenously Q2W.
40929179|NCT04520269|DRUG|Pacritinib|3+3 design Dose Level 1 :200mg BD every 4 weeks Dose Level -1 :200mg OM, 100mg ON every 4 weeks Dose Level -2 :100mg BD every 4 weeks
40929180|NCT03303703|OTHER|RENEwS|The intervention participants will meet with a trained interventionist for five 60-minute sessions as a group (two groups of five participants each). In the sessions time will be divided between didactic presentation of material, active practicing of techniques, group work focused on case studies, and worksheets for further practice at home. Topics covered within the intervention include emotional awareness, balancing emotional and physical wellbeing, selecting and implementing emotion regulation strategies (such as situation selections, mindfulness, engagement/avoidance, reappraisal, and emotional sharing), and emotional monitoring.
40929181|NCT06259500|OTHER|observational|Profiling the function of iPSC derived Arcuate neurons and PBMC derived microglia
40929182|NCT03473457|BIOLOGICAL|CART therapy in Acute myeloid leukemia(AML)|one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
40929183|NCT04357301|DEVICE|Closed-loop vasopressor|The system will adjust the norepineprhine infusion rate based on a target SAP of 130 mmHg in 20 patients
40929184|NCT03745820|DRUG|BIIB104|Administered as specified in the treatment arm
40929185|NCT03745820|OTHER|Placebo|Administered as specified in the treatment arm
40929186|NCT00133978|OTHER|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
41277790|NCT06252649|DRUG|Sotorasib|Immediate-release solid dosage form administered PO.
41277791|NCT06252649|DRUG|Panitumumab|Administered IV Q2W.
41277792|NCT06252649|DRUG|Bevacizumab-awwb|Administered IV Q2W.
41277793|NCT05889143|DRUG|Ezetimibe/Rosuvastatin|Patient treated with Crezet Tablet
41277794|NCT06102044|DIETARY_SUPPLEMENT|Zinc Supplements|Dispersible zinc sulfate tablets
41277795|NCT06102044|DIETARY_SUPPLEMENT|Placebo Supplements|Dispersible placebo tablets
41277796|NCT05439616|DRUG|Cariprazine|Oral Capsules or Oral Solution
41277797|NCT05439616|DRUG|Placebo|Oral capsules or Oral Solution
41277798|NCT05067595|PROCEDURE|Colonoscopy|Undergo lower FMT via colonoscopy
41277799|NCT05067595|BIOLOGICAL|Fecal Microbiota Transplantation|Given upper FMT PO
41277800|NCT05067595|BIOLOGICAL|Fecal Microbiota Transplantation|Undergo lower FMT via colonoscopy
40929187|NCT00133978|OTHER|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
40929188|NCT00133978|OTHER|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
40929189|NCT00133978|OTHER|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
40929190|NCT00162955|DRUG|Valsartan|Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
40929191|NCT01568801|BEHAVIORAL|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
40929192|NCT01082822|BIOLOGICAL|cell sheet pellets and cell sheet fragment|the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
40929193|NCT02576769|OTHER|No intervention|
40929194|NCT02732522|DRUG|Sublingual misoprostol|
40929195|NCT02732522|DRUG|Vaginal misoprostol|
40929196|NCT02702596|OTHER|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
41277801|NCT05067595|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given dietary fiber supplementation PO
40929197|NCT02702596|BEHAVIORAL|Depression Education Fotonovela|"Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues"
40929198|NCT02702596|BEHAVIORAL|Standard Education|The the use of a pamphlet to educate people about depression.
40754792|NCT02953964|OTHER|Behavioral: Cognitive stimulation group (control group)|Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
40754793|NCT04597333|DRUG|Dinoprostone|Dinoprostone vaginal insert.
41127284|NCT05021341|DIETARY_SUPPLEMENT|Dihydroberberine 100|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (100 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
41127285|NCT05021341|DIETARY_SUPPLEMENT|Placebo|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (Maltodextrin placebo) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
41127286|NCT00369109|OTHER|biologic sample preservation procedure|
41127287|NCT00369109|OTHER|immunohistochemistry staining method|
40754794|NCT04597333|DEVICE|Cervical ripening balloon.|Double lumen cervical ripening balloon.
41127288|NCT00369109|OTHER|laboratory biomarker analysis|
41127289|NCT00369109|PROCEDURE|biopsy|
40754795|NCT03799367|DEVICE|Drug delivery during breastfeeding|This study aims to give a vitamin B12 supplement to babies during breastfeeding. 30 mother-infant pairs will be recruited. The supplement will be placed into a nipple shield, both of which are commercially available, and the mother will breastfeed her baby as usual. Before and after the feed, we will 1) collect a small blood sample from the baby to see whether the vitamin levels in the infant have increased, 2) ask the mother to participate in two short interviews about her expectations and experiences using the Therapeutic Nipple Shield.
40929199|NCT00912444|DRUG|Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
41127290|NCT05220111|PROCEDURE|Cardiac surgical operation (valve, aorta, coronary arteries)|Quality of life assessment using EQ-5D-3L
41127291|NCT03372694|BEHAVIORAL|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training will be carried out between every two cycles of chemotherapy. Rehabilitation training is mainly composed of gymnastics qigong, which has long been regarded as a form of rehabilitation in Traditonal Chinese Medicine. According to the poor pulmonary function of patients with lung cancer after operation, Liu Zi Jue lung exercise is chosen to strengthen the pulmonary function of the human body in Chinese traditional health culture. Liu Zi Jue lung exercise intervention will be lead by an expert instructor, five times a week, 15 min/time.
41127292|NCT03372694|DRUG|TCM|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
40754796|NCT00387309|DRUG|Methylnaltrexone (MOA-728)|
41127293|NCT03372694|OTHER|Rehabilitation Education|General health education
41277802|NCT05067595|OTHER|Survey Administration|Ancillary studies
40754797|NCT02360501|DRUG|Docetaxel|75mg/㎡,d1
40754798|NCT02360501|DRUG|Cisplatin|25mg/㎡,d1-3
40754799|NCT02360501|DRUG|Capecitabine|2000mg/㎡,d1-14
40754800|NCT00831155|DRUG|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
40754801|NCT05286385|DEVICE|CP1150 Sound Processor|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor
40929200|NCT00912444|DRUG|Docetaxel, cyclophosphamide|Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
40929201|NCT03446261|DRUG|Rosuvamibe® Tab|Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks
40929202|NCT03446261|DRUG|Monorova® Tab|Rosuvastatin 10mg qd for 8 weeks
40929203|NCT01711385|BEHAVIORAL|Enhanced intervention|Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
40929204|NCT03734484|DIAGNOSTIC_TEST|InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between various Gram-type infections.
41448497|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
41448498|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
41448499|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
40929205|NCT01216007|DRUG|propofol|In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.
40929206|NCT01216007|DRUG|sevoflurane|In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
40929207|NCT02101112|DRUG|Apixaban|
40929208|NCT00256477|BEHAVIORAL|Sudarshan KRIYA Breathing Technique|
40929209|NCT03361176|DRUG|Injectable sodium deoxycholate|Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
41127294|NCT03372694|DRUG|placebo|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
41127295|NCT05590559|DRUG|Morphine|Opiates
41127296|NCT05590559|OTHER|Ultrasound-guided erector spinae plane block|PVB
41127297|NCT03048994|DIETARY_SUPPLEMENT|Glutamine|"* Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.~* IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.~* An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration."
41127298|NCT03048994|DIETARY_SUPPLEMENT|Placebo|"* Nutritional support will be continued as per managing ICU team discretion.~* Management of severe sepsis will be continued as per managing ICU team discretion.~* Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.~* To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out."
41127299|NCT01854385|DRUG|Sumatriptan 100 mg|This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
41448500|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
41448501|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
41448502|NCT01117623|DRUG|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
40929210|NCT03361176|COMBINATION_PRODUCT|Injectable sodium deoxycholate with Triamcinolone acetate|Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
40929211|NCT02332668|BIOLOGICAL|Pembrolizumab|IV infusion
40929212|NCT01536275|OTHER|Late parenteral nutrition|Withholding parenteral nutrition during the first 7 days of ICU stay
40929213|NCT02691598|DRUG|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
41127300|NCT01816672|DEVICE|AutoloGel|Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
41127301|NCT01816672|OTHER|Usual and Customary Care|Standard of care treatment twice weekly for 2 weeks then weekly
40929214|NCT01389362|DRUG|Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|2 sachets to be taken daily
40929215|NCT01389362|DRUG|Placebo comparator|2 sachets to be taken daily
41127302|NCT05573724|DRUG|AZD5305|"In Part A, the participants will receive a single dose of AZD5305 on Day 1 and Day 7.~In Part B, the participants will receive AZD5305 once daily."
40929216|NCT00474656|DEVICE|High-frequency oscillation|
41127303|NCT05573724|DRUG|Itraconazole|In Part A, the participants will receive Itraconazole twice daily on Day 4 and once daily on Days 5-12
41127304|NCT00177177|DRUG|L-carnosine (dietary supplement)|an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
41127305|NCT00662519|DRUG|Neulasta (Pegylated)|Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
41277803|NCT05067595|PROCEDURE|Biospecimen Collection|Undergo tissue, stool, stool swabs, and blood sample collection
41448503|NCT01117623|DRUG|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
41448504|NCT01117623|DRUG|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
41448505|NCT02045849|DRUG|GSK2140944 capsule|Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
41448506|NCT02045849|DRUG|GSK2140944 tablet|Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
41448507|NCT02045849|DRUG|Itraconazole capsule|Capsule containing Itraconazole with a unit dose strength of 100 mg
41448508|NCT06559995|DIETARY_SUPPLEMENT|"ketone supplement D-beta-hydroxybutryric acid and R-1,3 butanediol 12g of ketones,"|ketone supplement
41448509|NCT06559995|DIAGNOSTIC_TEST|magnetic resonance imaging session|1.5 hour magnetic resonance imaging session
41127306|NCT00662519|DRUG|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
41127307|NCT00662519|DIETARY_SUPPLEMENT|Mixed Meal Tolerance Test (MMTT)|This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
41127308|NCT00662519|OTHER|Blood test|HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
41127309|NCT00662519|OTHER|DNA Test|The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
41127310|NCT03387254|DEVICE|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
41127311|NCT03387254|DEVICE|VR + sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
41127312|NCT00003867|DRUG|capecitabine|
41277804|NCT01974323|DRUG|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
41277805|NCT01974323|DRUG|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
41277806|NCT03433625|BEHAVIORAL|Behavioural experiments for intolerance of uncertainty (BE-IU)|CBT
41277807|NCT04561505|PROCEDURE|Holmium laser enucleation of prostate|surgical management of BPH by Holmium laser enucleation using 0.9% saline fluid for irrigation
41277808|NCT04561505|PROCEDURE|monopolar transurethral resection of prostate|surgical management of BPH by monopolar TURP using distilled water for irrigation
41277809|NCT01039207|OTHER|Laboratory Biomarker Analysis|Correlative studies
41277810|NCT01039207|BIOLOGICAL|Rilotumumab|Given IV
41277811|NCT04714086|DRUG|Avapritinib|Avapritinib will be administered orally at 300 mg QD.
41277812|NCT03959436|DRUG|Carbetocin|Carbetocin as the primary uterotonic for all cesarean sections
41277813|NCT03431610|DRUG|SB414 2%|Twice daily
41127313|NCT00003867|DRUG|irinotecan hydrochloride|
41127314|NCT06392412|BEHAVIORAL|fi-VR Cognitive Training|All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. Participants in the fi-VRCT will use the virtual reality system with head-mounted display and handheld controllers. The fi-VRCT will be administered by an experienced research assistant.
41127315|NCT06392412|BEHAVIORAL|Traditional Cognitive Training|All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. The CT control program will include cognitive board games designed to improve various cognitive capacities. Certified community occupational therapists will lead the CT control group.
41277814|NCT03431610|DRUG|SB414 6%|Twice daily
41277815|NCT03431610|DRUG|Vehicle|Placebo comparator
41277816|NCT03968965|DEVICE|3D MvIGS Spine Navigation|The 7D Surgical MvIGS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw implantation in patients undergoing posterior fixation in single or multiple levels. The surgical light containing the machine vision cameras is the sole luminaire during image guided surgery.
41277817|NCT03968965|OTHER|2D Fluoroscopy|Pedicle screws will be placed using 2D fluoroscopy as the intraoperative imaging modality.
41277818|NCT05073692|DRUG|SU|Exposure to the class of drugs known as Sulfonylureas (SU)
41277819|NCT05073692|DRUG|DPP4|Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
41277820|NCT05073692|DRUG|SGLT2i|Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
41277821|NCT05073692|DRUG|GLP-1RA|Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
41277822|NCT05073692|DRUG|SGLT2i or GLP-1RA|Exposure to either SGLT2i or GLP-1RA
41277823|NCT05073692|DRUG|Linagliptin (DPP4)|Exposure to agent Linagliptin (DPP4)
40929217|NCT00474656|DEVICE|Conventional lung-open mechanical ventilation|
41277824|NCT05073692|DRUG|Exenatide (GLP-1RA)|Exposure to agent Exenatide (GLP1-RA)
41277825|NCT05073692|DRUG|Liraglutide (GLP-1RA)|Exposure to agent Liraglutide (GLP-1RA)
41277826|NCT05073692|DRUG|Empagliflozin (SGLT2i)|Exposure to agent Empagliflozin (SGLT2i)
41277827|NCT05073692|DRUG|Glimepiride (SU)|Exposure to agent Glimepiride (SU)
41277828|NCT05073692|DRUG|Glipizide (SU)|Exposure to Glimepiride (SU)
41277829|NCT05073692|DRUG|Glimepiride (SU) or Glipizide (SU)|Exposure to agent Glimepiride (SU) or Glipizide (SU)
41277830|NCT05073692|DRUG|SU or DPP4 (excluding saxagliptin and alogliptin)|Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
41277831|NCT05073692|DRUG|Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)|Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
41277832|NCT04637867|OTHER|Collection of blood, salivary and nasopharyngeal samples.|"Each visit M6 and M12~* Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)~* Salivary sample~* Nasopharyngeal sample"
40929218|NCT00352352|PROCEDURE|Tongue Acupuncture (Procedure)|
41127316|NCT04175899|OTHER|Pharmacist-led Oral Chemo Care Program (POCCP)|"Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients."
41127317|NCT00149591|PROCEDURE|coronary balloon-angioplasty with stenting|
41127318|NCT05854446|OTHER|Survey|In this survey, The experts will be asked open-ended questions based on the literature research and patient surveys carried out by the researchers in the first round to identify key themes related to myofascial pain syndrome, including the disease burden, patient journey, and unmet diagnosis and treatment needs. In subsequent rounds, the experts will rate the importance of each theme and provide additional feedback.
41448510|NCT06559995|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage, visually matched, three times a day before meals, by mouth for 4 days plus 1 dose on day 5 for magnetic resonance imaging session visit.
41448511|NCT00815087|DEVICE|Functional electrical stimulation|15 sessions of VitalStim® therapy, 60 minutes per session
41448512|NCT00815087|BEHAVIORAL|Exercise home program|Daily exercise training
40929219|NCT00374205|DRUG|Artesunate plus Amodiaquine|Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
41448513|NCT03685305|BEHAVIORAL|Hypocaloric diet with hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. Counseling will include specific instructions on a dietary manipulation which may reduce hunger, in order to facilitate dietary adherence.This will include tracking of the strategy. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
40929220|NCT00374205|DRUG|Artemether-Lumefantrine|Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
41127319|NCT03791736|PROCEDURE|Injection of sandostatine|Intramuscular injection of sandostatin 30 mg 3 days before surgery
41127320|NCT02437422|BIOLOGICAL|SANGUINATE|Single two-hour infusion of SANGUINATE
41127321|NCT01750684|DRUG|AC105|
41277833|NCT04972383|COMBINATION_PRODUCT|Platelet Rich Plasma|In the Platelet Rich Plasma group, 4mL Platelet Rich Plasma was given.
41277834|NCT04972383|COMBINATION_PRODUCT|Hyaluronic Acid|In the Hyaluronic group, 3mLHYAJOINT Plus was given.
41127322|NCT01750684|OTHER|Placebo|
41127323|NCT06394375|DRUG|Dexmedetomidine|OFA
41127324|NCT06394375|DRUG|Fentanyl|Given as analgesia in opioid balanced anesthesia (control) group
41127325|NCT03169413|GENETIC|Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.|Gene study
40754802|NCT05286385|DEVICE|CP1150 NF|Speech perception tests whilst the subject is fitted with the CP1150 modified firmware (the addition of notch filters at 978Hz, 1956Hz, 2934Hz, 3912Hz).
41127326|NCT04941703|DRUG|Magnesium Citrate plus probiotic|296 ml magnesium citrate
41127327|NCT04667858|DEVICE|Home Ovulation Test|Visual read home ovulation test
40754803|NCT05286385|DEVICE|CP1150 + FF|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor with ForwardFocus.
41127328|NCT04359069|OTHER|Urinary catheter removal on postoperative day 1|Urinary catheter will be removed on day 1 (experimental) instead of day 3 (standard of care).
41127329|NCT04359069|OTHER|Urinary catheter removal on postoperative day 3|Urinary catheter will be removed on day 3 (standard of care)
41127330|NCT00291954|BIOLOGICAL|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
41127331|NCT00291954|BIOLOGICAL|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
41127332|NCT03710798|DIETARY_SUPPLEMENT|Low carbohydrate high fat diet|Energy balanced low carbohydrate high fat diet during 6 weeks. Then 6-week reintroduction of a healthy normal diet
41127333|NCT02691169|DRUG|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
41127334|NCT01288443|DRUG|Alirocumab|Two SC injections in the abdomen only.
41127335|NCT01288443|DRUG|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
41127336|NCT01288443|DRUG|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
41127337|NCT05144659|PROCEDURE|Double faced transverse preputial onlay island flap|A well-established one-stage repair of penile hypospadias called Double faced transverse preputial onlay island flap
41448514|NCT03685305|BEHAVIORAL|Hypocaloric diet without hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
41448515|NCT05497063|DRUG|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine|Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
40754804|NCT05286385|DEVICE|CP1110|Speech perception tests whilst the subject is fitted with the CP1110 Sound Processor.
41127338|NCT05144659|PROCEDURE|Transverse inner preputial onlay island flap|A second well-established one-stage repair of penile hypospadias called Transverse inner preputial onlay island flap
41448516|NCT05497063|DRUG|G-COSPE® tablets|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
41448517|NCT02577653|OTHER|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
41448518|NCT06627569|BEHAVIORAL|Exercise|12 weeks of aerobic exercise, with 4 sessions per week.
40754805|NCT06081465|DRUG|VG290131|The study drug and matching placebo will be administered orally.
41448519|NCT02535923|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
40754806|NCT04452370|DRUG|oral etoposide + anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
40754807|NCT04002427|DRUG|Intravenous Infusion|30 µg \[14C\]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion.
40754808|NCT04002427|DRUG|Inhaled dose|A single inhalation on one occasion.
40754809|NCT03905174|DEVICE|custom made device|surgical intervention to place custom made orthopaedic device
41127339|NCT03570970|DRUG|Banapenem|Banapenem to be used anti-infection
41127340|NCT04508010|OTHER|IVR|Participants will receive an IVR survey
41127341|NCT04508010|OTHER|CATI|Participants will receive a CATI survey
41127342|NCT03656211|OTHER|Telephone interview|"Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility.~All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview."
41127343|NCT01099566|DRUG|Prasugrel|Prasugrel will be given as loading dose (60mg) on the first trial day two hours prior to endotoxin infusion. Prasugrel is an orally administered prodrug that is converted in the liver by CYP to its active metabolite.
41127344|NCT01099566|DRUG|Placebo|A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
41127345|NCT05819242|DIAGNOSTIC_TEST|Angulus|Smartphone app
41127346|NCT05808595|DIETARY_SUPPLEMENT|AlphaWave® L-Theanine|One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.
41127347|NCT05808595|OTHER|Placebo|One capsule of Placebo will be taken twice daily for 28 days.
41448520|NCT02535923|BEHAVIORAL|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
40754810|NCT06501235|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|An adaptation of the Robles and Peralta's (2010) stress management program will be followed. This program includes key techniques from the CBT approach, such as deactivation techniques, cognitive restructuring, and assertiveness training.
41127348|NCT02084420|DRUG|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
40919283|NCT02285036|BIOLOGICAL|vaccination PPV23|All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
41127349|NCT02084420|DRUG|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
41127350|NCT04139005|BEHAVIORAL|Awareness|The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.
41127351|NCT04139005|BEHAVIORAL|Connection|The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.
40929221|NCT04957433|DIAGNOSTIC_TEST|Blood Specimen|Blood and Sputum Specimen Samples
40929222|NCT01293578|OTHER|Diabetes Medication Choice Cards|Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
40929223|NCT03761771|DEVICE|colonoscopy withdrawal with the ADS monitoring|During the testing of trained ADS, when the system doubts colonic lesions from the input data of the test images, a rectangular frame was displayed in the endoscopic image to surround the lesion. If the system confirmed it as the colonic lesions, a sound of reminder will be played and the types of lesions (non-adenomatous polyps, adenomatous polyps and colorectal cancers) will be classified by the system. We adopted several standards to define the identification and classification of colonic lesions: 1) when the system identified and confirmed any lesion in the images of no polyps or cancers, the results were judged to be false-positive. 2) when the system both confirmed and correctly localized the lesions in images (IoU \> 0.3), the results were judged to be true-positive. 3) when the system did not confirm or correctly localize the lesions, the results were judged as false-negative. 4) when system confirmed no lesions in the normal images, the results were judged to be true-negative.
40929224|NCT03017820|PROCEDURE|Biopsy|Undergo tumor biopsy
41448521|NCT03026153|BEHAVIORAL|Control Group Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
41448522|NCT03026153|BEHAVIORAL|Intervention Group Oral Survey 2|Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
41448523|NCT03811977|DIETARY_SUPPLEMENT|Lutein syrup|12- week dietary supplementation with lutein syrup (20 mg lutein/day)
41448524|NCT03811977|DIETARY_SUPPLEMENT|Placebo syrup|12- week dietary supplementation with placebo syrup (0 mg lutein/day)
40754811|NCT06501235|BEHAVIORAL|Virtue-Based Intervention (VBI)|A Well-being Training based on Contemplative Practices (WTCP) (Cebolla \& Alvear, 2019; Alvear \& Cebolla, 2023) will be followed. WTCP combines mindfulness practices with various activities based on virtues such as gratitude, altruism, or compassion. This program focuses on generative or constructive meditations, and puts special emphasis on virtuous actions, emotion regulation (both positive and negative emotions) and compassion, and includes strategies from positive psychology, such as strengths-based interventions, savoring, kindness, or the three good things.
40754812|NCT05786196|DEVICE|Ab-interno canaloplasty utilizing the iTrack Advance device|360 degree microcatheterization and viscodilation of Schlemm's canal
40929225|NCT03017820|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41277835|NCT04469491|DRUG|inhaled type I interferon|The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
40754813|NCT05786196|DEVICE|Ab-interno canaloplasty utilizing the OMNI Surgical System|360 degree microcatheterization and viscodilation of Schlemm's canal
40754814|NCT00274794|BIOLOGICAL|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
40929226|NCT03017820|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41277836|NCT04469491|DRUG|WFI water nebulization|The interventional arm includes a WFI water nebulization comparator.
41277837|NCT05178901|BIOLOGICAL|PHV02|live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection
41277838|NCT05178901|OTHER|Placebo|Lactated Ringer's Solution. The placebo will be administered as a single intramuscular injection
40929227|NCT03017820|PROCEDURE|Computed Tomography|Undergo SPECT/CT
40929228|NCT03017820|DRUG|Cyclophosphamide|Given IV
40929229|NCT03017820|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40929230|NCT03017820|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
41448525|NCT06259630|DRUG|Nicotine|Participant receives oral dose of nicotine
41448526|NCT06259630|DRUG|Placebo oral capsule|Participant receives oral dose of placebo
41448527|NCT02281253|DIETARY_SUPPLEMENT|dietary fibre plus L-carnitine bread|"The enriched bread consisted of a mix of wheat flour, vegetable flour, rye flour, wheat gluten, soy protein, soluble and insoluble dietary fibre, inulin, guar gum, L-carnitine salt, diacetyl tartaric, enzymes, ascorbic acid, water and yeast.~Patients were recommended to consume the bread twice per day with main meals."
41277839|NCT04285528|DRUG|General anesthetia Fentanyl and Propofol|Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
41127352|NCT04139005|BEHAVIORAL|Insight|The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
41127353|NCT05246943|DIAGNOSTIC_TEST|D-dimer and lower limb venous duplex|D-dimer blood test- The D-dimer assay detects the presence of fibrin degradation products, which can indicate the breakdown of a fibrin clot Lower Limb Venous Duplex- Using an ultrasound to visually look for a clot
41127354|NCT03054415|PROCEDURE|endoscopy|colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
41127355|NCT00674752|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
41127356|NCT00674752|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
41127357|NCT00674752|DRUG|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime
41127358|NCT05212298|DIETARY_SUPPLEMENT|The gel contains a mixture of glucose and maltodextrin|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
41277840|NCT04285528|COMBINATION_PRODUCT|PFK|A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
41277841|NCT05016245|COMBINATION_PRODUCT|TheraSphere™ Yttrium-90 Glass Microspheres|"TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit"
40754815|NCT00274794|BIOLOGICAL|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
40754816|NCT02531711|OTHER|Diet A|Experimental analgesic dietary intervention
41127359|NCT05212298|DIETARY_SUPPLEMENT|Herbal compound low-dose|The total amount of herbal compound capsules is 557 mg.
41127360|NCT05212298|DIETARY_SUPPLEMENT|Herbal compound high-dose|The total amount of herbal compound capsules is 1114 mg.
41127361|NCT00909961|DRUG|Zoledronic acid|
41127362|NCT00167765|DRUG|Abciximab|
41127363|NCT02359448|DRUG|Melatonin|An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
41127364|NCT03656042|DRUG|Filgrastim (75mcg/0.3ml)|"Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~1. 10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~2. Non-treatment"
41127365|NCT00525954|DRUG|A-002|
41127366|NCT05792488|BEHAVIORAL|Coach|Coaching to a healthy lifestyle
41127367|NCT05792488|BEHAVIORAL|App|The app will coach people to a healthy lifestyle
41127368|NCT05792488|OTHER|Standard of care|Patients will receive standardized lifestyle advice by their specialist
41127369|NCT00795184|DEVICE|Imaging procedures (NBI)|"Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.~Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.~Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.~After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites."
41127370|NCT00795184|DEVICE|HDWLE|
41127371|NCT00795184|DEVICE|pCLE|
41127372|NCT00873782|OTHER|Retrograde high pressure transvenous perfusion with normal saline|Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
41127373|NCT05660356|DRUG|Growth Hormone|Pfizer provided GH therapy
41127374|NCT05660356|DRUG|Placebo|Pfizer provided placebo
41127375|NCT05728034|BEHAVIORAL|Injectable PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about injectable PrEP), visit those pages, and return to the main results page.
41448528|NCT02281253|DIETARY_SUPPLEMENT|Placebo bread|The placebo group received commercially available bread with a similar macronutrient composition and energy intake to that consumed by the enriched bread group but without L-carnitine and dietary fibre. Patients were recommended to consume the bread twice per day with main meals.
41448529|NCT02926040|PROCEDURE|Irreversible electroporation|
41448530|NCT04686435|OTHER|Non-surgical treatment such as physiotherapy, exercise, corticosteroid injection, medication, acupuncture|Treatment consisting of different non-surgical interventions as recommended by the orthopedic specialist and decided upon in shared decision making with the patient
41448531|NCT04686435|PROCEDURE|Surgery|Surgery can consist of rotator cuff repair, Bankart repair, subacromial decompression, biceps tenodesis or tenotomy, acromioclavicular joint resection.
41448532|NCT05337241|DEVICE|Saline Enhanced Radiofrequency (SERF) Ablation|The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates
41448533|NCT04661163|OTHER|Psychotherapy|Virtual Reality Avatar Therapy is a psychotherapeutic intervention targeting auditory hallucinations
41448534|NCT04775004|OTHER|Bone marrow venting procedure (BMVP)|The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
40754817|NCT02531711|OTHER|Diet B|Healthy comparator diet
41127376|NCT05728034|BEHAVIORAL|Oral PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about oral PrEP), visit those pages, and return to the main results page.
41127377|NCT03017469|OTHER|ARISE|"1. Full day (7.5 hours) workshop consisting of a resilience-focused seminar facilitated by our Employee Assistance Provider (EAP) \[Shepell\], an introduction to hospital based resources including EAP and health and wellness offerings, and an introduction to self-care and self-care techniques including yoga and stretches, stress relief using the senses and mindfulness~2. Half day (3.75 hours) workshop focusing on the following self-care techniques: mindfulness, yoga and stretching, and creative and reflective reading and writing~3. Peer support through social media engagement (closed Facebook group) for 3 months post-intervention participation~4. Five online, instructor-guided mindfulness sessions (Zoom)"
41127378|NCT00002697|BIOLOGICAL|filgrastim|
41127379|NCT00002697|BIOLOGICAL|sargramostim|
41127380|NCT00002697|DRUG|carboplatin|
41277842|NCT05016245|PROCEDURE|conventional Transarterial Chemoembolization(cTACE)|conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.
41277843|NCT06328777|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
41277844|NCT06321575|DEVICE|Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)|Golazo® Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo® Accustrike atherectomy catheter, and 2) the Golazo® motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.
41277845|NCT02656472|DRUG|Tranexamic acid|TXA Loading dose: 31 mg/kg diluted to 2 ml/kg Normal saline (NS) -in syringe
41277846|NCT02656472|DRUG|Epsilon Aminocaproic Acid|Aminocaproic acid Loading dose: 75 mg/kg diluted to 2 ml/kg NS
40754818|NCT00047632|DRUG|Interferon gamma-1b|100 mcg, SQ, 3x per week
40929231|NCT03017820|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
41127381|NCT00002697|DRUG|etoposide|
41127382|NCT00002697|DRUG|ifosfamide|
41127383|NCT00002697|PROCEDURE|autologous bone marrow transplantation|
41127384|NCT00002697|PROCEDURE|bone marrow ablation with stem cell support|
41127385|NCT00002697|PROCEDURE|peripheral blood stem cell transplantation|
41127386|NCT00002697|RADIATION|radiation therapy|
41277847|NCT04007276|DRUG|brimonidine tartrate ophthalmic solution 0.025%|Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
41277848|NCT04007276|OTHER|sterile balanced saline solution|Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.
40929232|NCT03017820|BIOLOGICAL|Cemiplimab|Given IV
41127387|NCT04707001|OTHER|Catheterization based on ultrasound|Bladder volume ultrasound
41127388|NCT04707001|OTHER|Catheterization based on evaluation of symptoms|Ask for symptoms: Need to urinate, lower abdominal pain
41277849|NCT06618157|DEVICE|Cerebellothalamic optimized deep brain stimulation|A deep brain stimulation plan will be created by maximizing the cerebellothalamic pathway on the patient-specific connectomic deep brain stimulation model
41448535|NCT04775004|OTHER|Platelet Rich Plasma (PRP)|The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
41448536|NCT06560450|DEVICE|Stride One|Stride One is a smart insole that provides real-time audio feedback (cues) to the patient when performing a certain exercise. The goal of Stride One is to allow patients to practice walking more intensively and with higher quality during rehabilitation.
41448537|NCT02833181|DEVICE|BIS monitor|Monitoring circadian variation of EEG
41448538|NCT06627452|OTHER|Dynamic Neuromuscular Stabilization Training|Patients will be taught how to perform exercises in different developmental positions both manually and verbally by the DNS therapist. In the DNS concept, proper breathing patterns are important alongside stabilization, and elastic bands will be used to regulate intra-abdominal pressure (IAP) and teach correct breathing. The elastic band will be secured around the chest just below the ribcage, and the patient will be asked to expand the elastic band in all directions while inhaling, thereby regulating the IAP. After teaching IAP guidance, exercises will be conducted in developmental positions with IAP regulation. The exercises will be conducted twice a week under the supervision of a physiotherapist, and three days at home, with sessions lasting approximately 30 minutes, for a total of five days a week over a period of 12 weeks.
41448539|NCT06627452|OTHER|Pelvic Floor Muscle Training|Pelvic floor exercises involving both slow and fast muscle contractions will be taught to patients through vaginal palpation. During fast contractions, patients will be instructed to quickly contract and relax their pelvic floor muscles. During slow contractions, patients will be asked to gradually squeeze their pelvic floor muscles, hold for 10 seconds, and then slowly relax. Each set of pelvic floor exercises will consist of 10 fast contractions and 10 slow contractions. Patients will perform pelvic floor exercises twice a week with a physiotherapist and three days at home. The exercises will be done in sets throughout the day, lasting approximately 30 minutes, and will be conducted over a period of 12 weeks.
41448540|NCT05143801|DEVICE|High-intensity interval exercise with surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition while wearing surgical face mask
41448541|NCT05143801|DEVICE|High-intensity interval exercise with surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition while wearing surgical face mask
41448542|NCT05143801|OTHER|High-intensity interval exercise without using a surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition without wearing a surgical face mask
41127389|NCT02844439|DRUG|Tesevatinib|
41277850|NCT06618157|DEVICE|Pallidothalamic optimized deep brain stimulation|A deep brain stimulation plan will be created by maximizing the Pallidothalamic pathway on the patient-specific connectomic deep brain stimulation model
41448543|NCT05143801|OTHER|High-intensity interval exercise without using a surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition without wearing a surgical face mask
41127390|NCT04717570|DEVICE|Foldax TRIA Mitral Valve|Mitral Valve Replacement
41127391|NCT02695264|DEVICE|HS-1000 recording|
41127392|NCT04190108|DIAGNOSTIC_TEST|Fecal calprotectin assay|FC levels were measured at baseline with Bühlmann fCAL Turbo, Switzerland® kit.
41127393|NCT05374694|DIAGNOSTIC_TEST|Physiological invasive coronary evaluation|Performance of FFR, IMR and acetylcholine test (Only patients in groups 3 and 4 will undergo the acetylcholine test)
41448544|NCT05794685|PROCEDURE|adductor canal block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle (adductor canal block).
41448545|NCT05794685|PROCEDURE|4 in one block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery (4 in one block).
41448546|NCT03036228|DRUG|Karonudib|Dose escalation of administration with Karonudib.
41448547|NCT00372086|DRUG|Rosiglitazone|
40919284|NCT02285036|BIOLOGICAL|vaccination PNEUMOVAX 23|Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
41127394|NCT02572700|OTHER|Clinical examination, blood sampling, ultrasonic assessment, and questionnaires|Visits include clinical examination, questionnaires (pain, comorbidity, lifestyle, work status) and ultrasonography of joints and entheses, blood samples, and only at baseline x-ray of hands and feet.
41127395|NCT03693937|RADIATION|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
41127396|NCT04682288|DRUG|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
41127397|NCT04238858|BIOLOGICAL|Platelet rich plasma|blood is drawn from the patient's antecubital vein and inserted into four 3.0 ml vacutainer tubes that contain trisodium citrate. These four tubes were placed in a centrifuge machine, and centrifugation was carried out at 2500 rpm (580×g) for 8 min within a 30-min blood collection period. As a result of centrifugation, the plasma was separated in the vacutainer tubes from the remaining blood components. Three different layers formed in the tubes: red blood cells at the bottom, aPRP in the middle layer, and aPPP in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe, and it was immediately injected into the subtenon space of each eye.
41277851|NCT06618157|OTHER|No deep brain stimulation|Patients will also be tested without any deep brain stimulation
41277852|NCT06618157|DEVICE|Usual care deep brain stimulation|Patient will also be tested with the deep brain stimulation clinical settings that were previously established during usual care with their neurologist
40919285|NCT05396599|DEVICE|Model DIU|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
40919286|NCT05396599|DEVICE|Model DFW|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
40919287|NCT05396599|DEVICE|Model ZCT|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
40919288|NCT02365233|DRUG|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
41448548|NCT00245882|BEHAVIORAL|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
41448549|NCT00245882|BEHAVIORAL|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
41448550|NCT06619275|DRUG|Ripretinib|Switch-Control Tyrosine Kinase Inhibitor
41448551|NCT05543720|DEVICE|Medly|Medly will enable patients with HF, COPD, Hypertension, Mental Health, or Diabetes to input measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
41448552|NCT00004786|DRUG|iloprost|
41448553|NCT05724784|BEHAVIORAL|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
41448554|NCT04762966|DRUG|Metformin|Level of Metformin blood concentration
41448555|NCT04652622|DEVICE|Mindful Garden|Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.
41448556|NCT00827463|BIOLOGICAL|dosage of the NFS and iron|a blood test will be made.
41448557|NCT05618587|DRUG|Lithium|Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.
41448558|NCT05618587|DRUG|Placebo|Inactive pill
41448559|NCT01368991|DEVICE|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
41448560|NCT01368991|PROCEDURE|Conventional closure|conventional closure, no kryptonite applied
41448561|NCT05275881|DEVICE|Virtual Reality|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the the RV group, The session will be started before the gesture and the patient will wear the helmet throughout the act. In case of pain and / or restlessness, the child will receive analgesics.
41448562|NCT05275881|DRUG|Usual Practices|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the control group, the child will receive the usual care: nitrous oxide, anxiolytics, opioid analgesics, psychotropic and benzodiazepine
41127398|NCT02132455|PROCEDURE|colonoscopy|colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
41448563|NCT02882282|OTHER|Laboratory Biomarker Analysis|Correlative studies
41448564|NCT02882282|OTHER|Patient Observation|Undergo observation
41448565|NCT02882282|BIOLOGICAL|Pembrolizumab|Given IV
41448566|NCT03034694|OTHER|teledermatology consult|teledermatology consult
41127399|NCT01823224|DRUG|"2 capsules Oral Tylenol 2000 mg and IV salt water"|"The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly."
41448567|NCT03034694|OTHER|Routine Care|The patient will undergo imaging but this report will not be put into the chart.
41448568|NCT00583999|OTHER|no interventions, only regular blood-draw|No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
41448569|NCT01167829|DRUG|Oral Testosterone|Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
41448570|NCT01167829|DRUG|Acyline|300 ug/kg injection on Day 0
41448571|NCT06597370|OTHER|Gene expression mRNA of IgG anti-spike|"b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule.~c) Sample processing:~* tRNA extraction from all samples.~* cDNA synthesis~* Real time PCR performance."
40919289|NCT02365233|DRUG|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
41127400|NCT01823224|DRUG|"IV tylenol 1000mg and 2 oral capsule sugar pills"|"IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group."
41127401|NCT00198315|COMBINATION_PRODUCT|Medpulser electroporation with Bleomycin|Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
41127402|NCT00198315|PROCEDURE|Tumor surgical excision|Patients have their tumor surgically removed.
41127403|NCT03728764|OTHER|Preterm infant formula|Preterm infants will receive Stage 1 investigative product as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive stage 2 preterm formula from when 1.8 kg of body weight is achieved until 1 month after hospital discharge.
41127404|NCT06322446|OTHER|Exercise|16-week exercise intervention: At the beginning of the intervention, we will conduct a face-to-face familiarisation session with the exercises of the training programme. The intervention will consist of 2 sessions/week for 16 weeks. Each session consists of three stages: (i) Warm-up: 10 min of joint mobility and low intensity exercises involving the musculature to be worked in that session; (ii) Main part: circuit training mainly composed of strength exercises targeting the different muscle groups of the body and playing activities (iii) Cool down: 10 min with guided breathing work and stretching of the main muscle groups worked
41127405|NCT02652442|BEHAVIORAL|Centrifugation Distance|To determine optimal distance off-axis, participants were rotated in a darkened rotary chair booth with 1 ear positioned 3.5 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period. Following a 2-week washout period, participants were rotated in a darkened rotary chair booth with 1 ear positioned 7.0 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period.
41127406|NCT02652442|BEHAVIORAL|Centrifugation Duration|To determine optimal duration, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes. Participants received 5 sessions in a 1-week period.
41127407|NCT02652442|BEHAVIORAL|Centrifugation Schedule|To determine optimal schedule, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes (determined to be optimal in Exp 2). Participants received biweekly sessions for a total of 5 sessions.
41127408|NCT01125254|DRUG|Amlodipine|5mg po for 12 months
41127409|NCT05260398|BEHAVIORAL|Mightier Online Gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
41127410|NCT02417376|DEVICE|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
41127411|NCT02417376|DEVICE|Gracey curettes|set of 7 instruments number #1-14
41127412|NCT00785915|DRUG|AZD6765|single administration and once daily for 5 days
41127413|NCT00785915|DRUG|Placebo|single administration and once daily for 5 days
41127414|NCT01091649|DRUG|ABT-450|Low dose ABT-450 / ritonavir see Arm Description for more information
41127415|NCT01091649|DRUG|ritonavir|ritonavir see Arm Description for more information
41127416|NCT01091649|DRUG|ABT-450|High dose ABT-450 / ritonavir See Arm Description for more information
41127417|NCT03908775|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for nasotracheal intubation in children undergoing dental interventions. Nasotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
41127418|NCT03908775|DEVICE|Direct Laryngoscope|An intubating device that is used for nasotracheal intubation. Nasotracheal intubation was applied by anesthesiologist with direct laryngoscope.
41127419|NCT02644369|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
41127420|NCT02143375|DEVICE|810 Diode Laser|The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
41127421|NCT00137098|DRUG|Caffeine|
41127422|NCT00731614|BEHAVIORAL|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
41127423|NCT00731614|BEHAVIORAL|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
41127424|NCT00731614|BEHAVIORAL|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
41127425|NCT04770324|DEVICE|Interposition supraciliary implant|Surgical placement of 2 interposition supraciliary implant in the supraciliary space
41127426|NCT05343715|BIOLOGICAL|Agalsidase beta from Biosidus 1 mg/kg|Patients received an infusion of 1 mg/kg of Agalsidase Beta from Biosidus. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
40919290|NCT02365233|DRUG|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
41448572|NCT06439576|DRUG|Faricimab|The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
41127427|NCT05343715|BIOLOGICAL|Fabrazyme (agalsidase beta) 1 mg/kg|Patients received an infusion of 1 mg/kg of Fabrazyme. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
41448573|NCT01939990|DRUG|Placebo|The placebo looks like the study drug but it does not contain active ingredients.
41448574|NCT01939990|DRUG|Nebivolol|5 to 10mg per day
41448575|NCT06500858|OTHER|Exercise Intervention|Receive a welcome package with exercise equipment
41448576|NCT06500858|OTHER|Exercise Intervention|Participate in virtual-exercise sessions
41448577|NCT06500858|OTHER|Exercise Intervention|Receive access to optional drop-in classes
41448578|NCT06500858|OTHER|Health Promotion and Education|Receive monthly newsletters
41448579|NCT06500858|OTHER|Internet-Based Intervention|Receive access to online fitness buddy matching program
41448580|NCT06500858|OTHER|Physical Activity|Participate in a walking program
41127428|NCT02247375|DRUG|Low dose of BIIL 284 BS tablets|
41448581|NCT06500858|OTHER|Questionnaire Administration|Ancillary studies
41448582|NCT05572398|BEHAVIORAL|STAC-T|Middle school participants will complete online modules to learn about anti-bullying techniques and bystander intervention.
41448583|NCT02632968|PROCEDURE|Pinhole surgery with and without buttons|
41448584|NCT00747305|DRUG|sunitinib malate|
41448585|NCT00747305|GENETIC|gene expression analysis|
41448586|NCT00747305|GENETIC|reverse transcriptase-polymerase chain reaction|
41448587|NCT00747305|GENETIC|western blotting|
41448588|NCT00747305|OTHER|immunohistochemistry staining method|
41448589|NCT00747305|OTHER|laboratory biomarker analysis|
41448590|NCT00747305|PROCEDURE|adjuvant therapy|
41448591|NCT00747305|PROCEDURE|neoadjuvant therapy|
41127429|NCT02247375|DRUG|High dose of BIIL 284 BS tablets|
41127430|NCT02247375|DRUG|Placebo|
41127431|NCT01602913|DRUG|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
41127432|NCT01602913|DRUG|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
41448592|NCT00747305|PROCEDURE|therapeutic conventional surgery|
41448593|NCT03375957|DRUG|ATx201|two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms
41448594|NCT03375957|DRUG|ATx201 Placebo Gel|two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
41448595|NCT06628037|BIOLOGICAL|SN514-066b|Enzyme debrider
41448596|NCT05635448|BEHAVIORAL|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
41448597|NCT05635448|BEHAVIORAL|No intervention - waitlist control|No intervention - waitlist control
41448598|NCT06068491|OTHER|Vet-CALD|Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
41448599|NCT04626154|DIAGNOSTIC_TEST|Objectively monitoring thoracoabdominal asynchrony|Objectively monitoring thoracoabdominal asynchrony
41448600|NCT05885412|GENETIC|RP-A601|RP-A601 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, human plakophilin 2 (PKP2), transcript variant 2a (PKP2a)
41448601|NCT01747668|DIETARY_SUPPLEMENT|Similac Prenatal Vitamin soft-gel capsule|One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
41448602|NCT01747668|DIETARY_SUPPLEMENT|Placebo (soybean oil and dl-alpha-tocopheryl acetate)|Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
41448603|NCT05144451|DIAGNOSTIC_TEST|Transcranial Doppler|"Transcranial Doppler-derived parameters; pulsatility index (PI), resistance index (RI), mean flow velocity (Vmean) will be recorded before induction of anesthesia (T1).~After induction, TCD parameters, Hemodynamic variables including heart rate (HR), invasive mean arterial blood pressure (MAP), and central venous pressure (CVP) together with Arterial blood gases (ABG analysis with values of PH, PCO2, PO2, blood oxygen saturation SO2 and bicarbonate HCO3), end-tidal carbon dioxide (ETCO2) and body temperature will be recorded too. Just before skin incision (T2), at the end of anhepatic phase 5 minutes before reperfusion (T3), 5 minutes after reperfusion (T4) and at the end of surgery (T5).~Postoperatively at ICU, TCD parameters, Hemodynamic variables, and ABG will be obtained 24 hours postoperative (T6) and at discharge from ICU (T7)."
41448604|NCT04066088|OTHER|Placebo|Placebo will be administered same times as GXR
41277853|NCT06377059|DEVICE|WARD|Heart rate and respiratory rate is measured using Isansys lifetouch (Isansys Lifecare, Oxfordshire, UK), single-lead ECG monitor. An ECG is recorded as a 10-second segment every minute. Heart rate is derived once per minute from the R-R interval, and similarly, the RF is calculated from the changes in thoracic impedance once per minute. Blood pressure is monitored with either Meditech BlueBP-05 (Meditech Ltd., Budapest, Hungary) or A\&D TM-2441 (A\&D company Ltd., Tokyo, Japan). Both are non-invasive oscillometric, cuff-based blood pressure monitoring devices. Peripheral oxygen saturation was measured with NonIn WristOx 3150 (Nonin Medical Inc., Minnesota, USA) pulse oximeter, which is a photoplethysmograph with a sampling frequency of 75 Hz.
41127433|NCT01602913|DRUG|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
41127434|NCT03459989|DIAGNOSTIC_TEST|Ultrasound|Samsung H60 Ultrasound
41127435|NCT05629845|PROCEDURE|endoscopic ultrasound-guided therapy|EUS-guided glue injection will be used for secondary prevention of EV or GV rebleeding.
41127436|NCT05629845|PROCEDURE|conventional endoscopic therapy|conventional endoscopic therapy (VBL for EV or glue injection for GV) for secondary prevention of EV or GV rebleeding.
41127437|NCT04634682|DIETARY_SUPPLEMENT|MYODM|Formulated composition containing Theobroma cacao supplemented with caffeine
41127438|NCT05387044|RADIATION|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
41127439|NCT03592732|OTHER|Blood sample|Blood sample
41127440|NCT00003459|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
41127441|NCT04215172|DRUG|Macrolides|administration of azithromycin three times weekly for six months
41127442|NCT03205072|DEVICE|Spy Glass DS|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
41127443|NCT00754000|OTHER|Observation|AE monitoring and EPIC QOL survey
41127444|NCT05213312|DRUG|Nivolumab|Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;
41127445|NCT05213312|DRUG|Cisplatin|80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles
41127446|NCT05213312|DRUG|Paclitaxel|175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles
41127447|NCT05213312|DRUG|5Fluorouracil|800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles
41127448|NCT05213312|PROCEDURE|Esophagectomy (minimally invasive)|4-6 weeks after neoadjuvant therapy.
41127449|NCT06038695|DEVICE|Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB|"* Fibro-Gide is the Volume-Stable Collagen Matrix.~* Recombinant human platelet-derived growth factor-BB will be found within the device of GEM21S."
41127450|NCT01637402|DRUG|Abiraterone Acetate|"Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration"
41127451|NCT01637402|DRUG|Prednisone|5 mg, twice daily, oral administration
41127452|NCT00995696|BEHAVIORAL|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
41127453|NCT04147494|PROCEDURE|Computed Tomography|Undergo PET/CT scan
41127454|NCT04147494|RADIATION|Gallium Ga 68 FAPi-46|Given IV
41127455|NCT04147494|RADIATION|Gallium Ga 68-labeled PSMA-11|Given IV
41127456|NCT04147494|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
41127457|NCT04147494|RADIATION|18F-FDG|Given IV
41127458|NCT06045208|OTHER|Foot exercise|This group will engage in an 8-week foot intrinsic strengthening training
41127459|NCT06045208|OTHER|Lower Extremity Exercise|This group will engage in an 8-week lower extremity strengthening training
41277854|NCT02638246|BEHAVIORAL|Internet-delivered, Incentive-based intervention + Motivational Interviewing|Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
41277855|NCT02638246|BEHAVIORAL|Internet-delivered, non-contingent incentives + Motivational Interviewing|
41277856|NCT05370911|DRUG|Psilocybin|"The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms"
41127460|NCT01401231|BEHAVIORAL|Behavioral activation psychotherapy|Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
41127461|NCT01401231|OTHER|Usual care|Continued usual care (could include referral for medication or psychotherapy)
41127462|NCT06186375|OTHER|Patients with planned biotherapy|Single additional volume of blood (10 ml) to be collected using the PAXgene system at the same time as the routine blood test before starting biotherapy.
41127463|NCT02355041|BEHAVIORAL|Meal Replacement-based Weight Loss Diet|
41448605|NCT04066088|DRUG|Guanfacine extended release (GXR)|The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
41448606|NCT02137330|DEVICE|Swallowable Obalon® Gastric Balloon|
41448607|NCT00493805|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization"
41448608|NCT00493805|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
41127464|NCT02355041|BEHAVIORAL|Educational Video|Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
41127465|NCT04295382|DEVICE|Software Application|A software application targeting suicidal ideation via interactive exercises.
41448609|NCT05047536|DRUG|KZR-261|KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.
41448610|NCT06311929|DRUG|PD-1 monoclonal antibody and lenvatinib|Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
41448611|NCT06311929|DRUG|PD-1 monoclonal antibody|Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
41127466|NCT04559126|DRUG|EDP-297|EDP-297 Oral solution
41127467|NCT04559126|DRUG|Placebo|placebo to match EDP-297
41127468|NCT06514677|PROCEDURE|Ultrasonic Carbon Tip|Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment
41127469|NCT06514677|PROCEDURE|Titanium Curette|Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment
41127470|NCT00163046|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
41127471|NCT00163046|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime for 28 days
41127472|NCT04124432|DRUG|Cannabis|Cannabis will be smoked
41127473|NCT04124432|DRUG|Nicotine|Nicotine will be smoked or vaporized
41127474|NCT05484648|DRUG|Dexamethasone|"Dexamethasone has been used to generally favorable results in peripheral nerve blocks as adjunct. Several studies have reported prolongation in the duration of ropivacaine, mepivacaine and bupivacaine when used in combination with dexamethasone.~Various mechanisms for the beneficial adjunctive effect of dexamethasone with Local Anesthetics (LA) have been proposed. One theory suggests that the improved analgesia and increased blockade duration is due to its anti-inflammatory properties. It also acts as a local vasoconstrictor and thus may act by reducing LA absorption. Furthermore, it also increases the activity of inhibitory potassium channels on nociceptive C-Fibers."
41127475|NCT05484648|DRUG|Dexmedetomidine|Dexmedetomidine is another promising drug being used as a local anaesthetic adjuvant in peripheral nerve blocks. It is an alpha-2 agonist, which has shown to have prolonged duration of postoperative analgesia when given with LA for peripheral nerve blocks with other beneficial effects such as reducing the opioid consumption. Alpha-2-agonists such as dexmedetomidine cause hyperpolarization-activated cation currents which inhibit the transmission of nociceptive fibers.
41127476|NCT00879333|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
41127477|NCT00879333|DRUG|Everolimus placebo|Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
41127478|NCT00879333|DRUG|Best Supportive Care (BSC)|Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
41448612|NCT01215279|DRUG|AZD2423|100 mg oral treatment once daily for 28 days
41448613|NCT01215279|DRUG|Placebo to AZD2423|Oral treatment once daily for 28 days
41448614|NCT05360394|DEVICE|Paclitaxel Coated Balloon|CAS treated with PCB only
41448615|NCT05360394|DEVICE|Paclitaxel Coated Balloon and Stent Graft|CAS treated with PCB first before deployment of stent graft
41127479|NCT00426829|DRUG|Bevacizumab|10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
41127480|NCT00426829|RADIATION|Proton Radiation Therapy|3 Gy dose/fraction x 20 fractions.
41127481|NCT05529641|OTHER|Diaphragmatic resistance training|6 weeks home exercise of diaphragmatic resistance training will be emphasized.
41127482|NCT05529641|OTHER|Cervical stabilization exercise|Participants will finish 6 weeks supervised cervical stabilization exercise in person by physical therapist. Dissociated movement and movement control will be emphasized during cervical stabilization exercise.
41127483|NCT05783843|BEHAVIORAL|Pictorial Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different pictorial warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
41448616|NCT05843994|OTHER|online survey|Participants will complete an online survey and submit photographs.
41448617|NCT04626245|BEHAVIORAL|Mindfulness training|Phone-delivered brief mindfulness training based on principles of MBSR
41448618|NCT00465621|DRUG|Xalatan|
40929233|NCT01797172|PROCEDURE|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
40929234|NCT01797172|PROCEDURE|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
40929235|NCT02099071|DRUG|ACT-389949 1 mg|
40929236|NCT02099071|DRUG|ACT-389949 5 mg|
40929237|NCT02099071|DRUG|ACT-389949 20 mg|
40929238|NCT02099071|DRUG|ACT-389949 50 mg|
40929239|NCT02099071|DRUG|ACT-389949 100 mg|
40929240|NCT02099071|DRUG|ACT-389949 200 mg|
40929241|NCT02099071|DRUG|ACT-389949 500 mg|
40929242|NCT02099071|DRUG|ACT-389949 1000 mg|
40929243|NCT02099071|DRUG|Placebo|
40929244|NCT00911001|BEHAVIORAL|No Drug|Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
40929245|NCT00673270|DRUG|Fludrocortisone|50 µg of fludrocortisone per os
41448619|NCT04350697|PROCEDURE|Aortic Surgery|Surgery for aortic and/or aortic valve diseases
41448620|NCT00645853|DRUG|AZD0837|Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
40929246|NCT00673270|DRUG|Hydrocortisone|50 mg of intravenous hydrocortisone
40929247|NCT00673270|DRUG|Placebo of Fludrocortisone|Tablet of placebo of Fludrocortisone
40929248|NCT00673270|DRUG|Placebo of Hydrocortisone|2 ml of isotonic saline solution
40929249|NCT03963375|DRUG|Cladribine|All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
40929250|NCT04496934|BEHAVIORAL|Exercise|Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
40929251|NCT02633618|BIOLOGICAL|Analgecine|Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
40929252|NCT02633618|BIOLOGICAL|Neurotropin|a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
41127484|NCT05783843|BEHAVIORAL|Text Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different text-only warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
41127485|NCT05783843|BEHAVIORAL|No Warnings (Control)|Participants will be shown a single package without a warning. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study.
41127486|NCT03401320|DRUG|Letrozole ISM|2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
41127487|NCT02295189|DRUG|Ketorolac Tromethamine|anti-inflammatory injection
41127488|NCT02295189|DRUG|Triamcinolone Acetonide|corticosteroid injection
41127489|NCT00774397|DRUG|BI 201335 NA 240 mg QD / LI|240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
41127490|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
41277857|NCT00886938|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study|Repetitive transcranial magnetic stimulation, pilot study
41448621|NCT00645853|DRUG|VKA INR 2-3|Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
41127491|NCT00774397|DRUG|BI 201335 NA 120mg QD / LI|120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
41448622|NCT01929486|BIOLOGICAL|Mogamulizumab|Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
41448623|NCT02584608|DRUG|ACTIMMUNE|
41127492|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
41277858|NCT01599559|OTHER|observation|observation
40929253|NCT04570059|BEHAVIORAL|Counselling on textured food introduction between 8 and 15 months|"Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months."
40929254|NCT04465136|DEVICE|CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)|CES is a brain stimulation device with 2 electrodes on the bilateral earlobe. It uses Alternating current to stimulate the brain including thalamus, vagus nerve system and influence EEG and neurotransmitters like gamma-aminobutyrate. Stimulation was applied at a current intensity that can be adjusted continuously to provide between 10 and 600 micro-ampere and frequency of 0.5Hertz for 60 minutes, everyday for 6 weeks, total 42 sessions.
40754819|NCT02608346|PROCEDURE|Blood sampling|"Patients will have a blood draw at each visit to the hospital,~* with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam~* with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation"
41127493|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
41127494|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
41127495|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
41127496|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
41127497|NCT00774397|DRUG|BI 201335 NA 240 mg BID|240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
40754820|NCT06501261|BEHAVIORAL|CALM psychotherapy|psychotherapy sessions
40754821|NCT03983655|DEVICE|High Frequency Low Intensity TMS|125 hz, 10 gauss, 2 times daily for 6 monts
40754822|NCT04621786|DEVICE|Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface|The Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD-ECT Multi-Channel Stimulation Interface will reduce ECT current amplitude for amplitude-seizure titration.
40754823|NCT00378560|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
40754824|NCT00378560|BIOLOGICAL|Comparator: Placebo|Placebo 0.5 ml injection in 3 dosing regimen
40754825|NCT00259701|DEVICE|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
40754826|NCT01433978|DRUG|Eltrombopag|
40754827|NCT01433978|DRUG|Avatrombopag|
41127498|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
41448624|NCT03878121|BIOLOGICAL|Ad4-Env145NFL|10\^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.
41127499|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
41127500|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
41127501|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
41127502|NCT00774397|DRUG|Placebo|Placebo
41448625|NCT03878121|BIOLOGICAL|Ad4-Env150KN|10\^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.
40919291|NCT03828071|PROCEDURE|Autologous hematopoietic stem cell transplantation|"Stem cell mobilization and collection: Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m2) for 2 days and granulocyte colony-stimulating factor (G-CSF) at 5-10 μg/kg per day was administered when the level of peripheral leucocytes was \< 1×109/L. Peripheral leukocyte counts were monitored, and harvesting was performed when the peripheral white blood cell level rebounded .~Conditioning and reinfusion of stem cells: The conditioning regimen consisted of intravenous cyclophosphamide (40 mg/kg/day × 4 days) 5 days before transplantation (a total dose 160 mg/kg) and rabbit antithymocyte globulin (ATG) (2.5mg/kg/day × 3 days) 4 days before transplantation. The dose of cyclophosphamide and ATG could be reduced according to the patients' condition."
40929255|NCT05860101|OTHER|Compassion-Focused Therapy|Compassion Focused Therapy (CFT) is based on the premise that we have three emotion regulation systems, the threat, drive and soothing systems. It has been suggested that our psychological wellbeing is dependent on maintaining a balance between these three systems, and if we lose this balance, e.g. the threat or drive systems become more dominant, then we start to experience emotional difficulties (Gilbert, 2009). In this study, participants are given various exercises to develop their soothing system, and help them to balance overactive threat.
41127503|NCT05374642|BEHAVIORAL|cognitive training|tablet-based cognitive training for 12 weeks, 30 minutes each time, at least 5 times a week
41127504|NCT05374642|BEHAVIORAL|active control|tablet-based cognitive training tasks with weak or no difficulty changes, 5 times a week, 30 minutes each time for 12 weeks
41127505|NCT00002381|DRUG|Nelfinavir mesylate|
41127506|NCT00002381|DRUG|Nevirapine|
41127507|NCT00002381|DRUG|Stavudine|
41277859|NCT01599559|RADIATION|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
41127508|NCT03149302|OTHER|Local neck treatment (LNT)|The local neck treatment consists of cervical mobilization and specific therapeutic exercises (30 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
41127509|NCT03149302|OTHER|LNT plus sensorimotor exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes). The sensorimotor exercises include cervical joint position sense and oculomotor training. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
41277860|NCT05620342|BIOLOGICAL|iC9.GD2.CAR.IL-15 T Infusion|iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.
41277861|NCT04516252|BEHAVIORAL|BodyWorks Intervention|BodyWorks (BW), a Comprehensive Behavioral Family Lifestyle Interventions (CBFLI), a national, empirically validated, curriculum-based 7-week program will be implemented (Borden et al., 2012; DHHS, 2013)
41127510|NCT03149302|OTHER|LNT plus balance exercises|The local neck treatment (30 minutes) plus the balance exercise program (15 minutes).The balance program includes with static balance and progress to dynamic balance and gait. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
41127511|NCT03149302|OTHER|LNT plus sensorimotor/balance exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes) and the balance exercises (15 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
41277862|NCT04516252|BEHAVIORAL|Canine Curriculum|Using our team's expertise in veterinary medicine, human-animal interaction, and animal behavior modification, develop an empirically-based, 7-week module on canine health and behavior.
41448626|NCT03878121|BIOLOGICAL|VRC-HIVRGP096-00-VP (Trimer 4571) with alum|500-mcg dose of protein boost vaccine formulated for intramuscular administration.
41127512|NCT00962702|DEVICE|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
41127513|NCT05806476|DIETARY_SUPPLEMENT|caffeine|1.75mg / kg body mass of caffeine x 3 times a day during the run-in days and 3mg / body mass of caffeine once on the experimental days
41127514|NCT05806476|DIETARY_SUPPLEMENT|placebo|1.75mg / kg body mass of microcrystalline cellulose x 3 times a day during the run-in days and 3mg / body mass of microcrystalline cellulose once on the experimental days
41448627|NCT04642781|DIAGNOSTIC_TEST|reading of a text|Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.
40929256|NCT03780400|BEHAVIORAL|Osteoarthritis Physical Activity Care Pathway|The intervention includes brief physical activity (PA) counseling delivered via phone by a PA Counselor trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA counselor will assess readiness for change in PA and will utilize appropriate PA counseling components to assess participant's PA preferences/needs, as well as referral to PA resources and goal setting. Approximately two weeks after the initial call, the PA counselor will contact participants to check in on whether they have successfully connected with PA programs or resources discussed, review progress toward PA goals and set new goals. Participants will be provided with linkage to PA programs and resources to include: self-directed, group classes/community, physical therapy and other clinical/supervised programs. Three months after the initial call, the PA counselor will call participants to assess PA and stage of change using appropriate PA counseling components and goal setting.
40929257|NCT06468384|PROCEDURE|thoracic erector spinae plane (ESP) block|The thoracic erector spinae plane (ESP) block is a regional anesthesia technique used for pain management in complex regional pain syndrome. This procedure involves injecting 20 ml of 0.25% bupivacaine into the deep layers of the erector spinae muscles. The patient is positioned appropriately, and the injection site is identified using anatomical landmarks and ultrasound guidance, at the T2 level. A needle is then inserted perpendicularly until it contacts the transverse process, at which point the local anesthetic is administered. The primary objective is to provide significant pain relief.
40929258|NCT05244642|DRUG|Penpulimab|A humanized monoclonal immunoglobulin.
40929259|NCT05244642|DRUG|Investigator's choice of Chemotherapy|Participants will receive one of the following chemotherapies, including but not limited to DHAP (cisplatin 100mg/m2 D1, high dose cytarabine 2 mg/m2 q12h D2, dexamethasone 40mg D1-4, Q3W); ESHAP (etoposide 40 mg/m2 D1-4, cisplatin 25 mg/m2 D1-4, high dose cytarabine 2 mg/m2 D5, methylprednisolone 500mg D1-4, Q3W); DICE (dexamethasone 10mg/m2 D1-4, ifosfamide 1.0g/m2 D1-4, cisplatin 25mg/m2 D1-4, etoposide 60 mg/m2 D1-4, Q3W); ICE (ifosfamide 5 mg/m2 D2, carboplatin AUC 5 D2, etoposide 100 mg/m2 D1-3, Q3W); IGEV (ifosfamide 2 mg/m2 D1-4, gemcitabine 800 mg/m2 D1, D4, vinorelbine 20mg/m2 D1, prednisone 100 mg D1-4, Q3W); GVD (gemcitabine 1g/m2 D1, D8, vinorelbine 20 mg/m2 D1, D8, liposome doxorubicin 15 mg/m2 D1, D8, Q3W); MINE (etoposide 65mg/m2 D1-3, ifosfamide 1.33g/m2 D1-3, mitoxantrone 8mg/m2 d1, Q3W); GemOx (gemcitabine 800mg/m2 D1, D8, oxaliplatin 85mg/m2 D1, Q3W); GemOx (gemcitabine 1000mg/m2 D1, oxaliplatin 100mg/m2d1, Q2W).
41277863|NCT04516252|BEHAVIORAL|Ecological Momentary Assessment|Ecological Momentary Assessments (EMA) of physical activity will be conducted using mobile phones for 7 weeks of the BW program, prospectively collecting data on 4 days per week (Saturday to Tuesday) (Dunton et al., 2011; Liao et al., 2016).
40929260|NCT03291301|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia including psychoeducation, sleep restriction, stimulus control, cognitive restructuring, and relaxation.
40929261|NCT03291301|OTHER|Acupressure|Acupressure, a non-invasive therapy, is commonly used in Traditional Chinese Medicine
40929262|NCT00004190|DRUG|gemcitabine hydrochloride|
40929263|NCT00004190|DRUG|oxaliplatin|
41127515|NCT06085989|BEHAVIORAL|Infant directed singing|In every known human culture and historical period, infant-directed singing exists as a natural feature of parental care for newborn infants. Infant-directed singing is effective in regulating infant affect and in capturing an infant's attention for a longer period than infant-directed speech. Parental stress significantly decreases when parents are encouraged to use their own voices to soothe their infants with a song or a lullaby of their choice.
41127516|NCT06085989|BEHAVIORAL|Standard care|Standard breastfeeding support to mothers with breastfeeding difficulties provided by health care professionals.
41127517|NCT00679770|DRUG|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
41127518|NCT00679770|DRUG|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
41277864|NCT04516252|BEHAVIORAL|Physical Activity Trackers|Three types of consumer-grade wireless personal activity trackers (PATs): FitBit Inspire® designed for children 8 years of age and older; FitBit Inspire® for adults (Diaz et al., 2015; Espinoza et al., 2017); and FitBark®, wireless, global positioning systems (GPS)-based personal activity trackers for dogs (Patel et al., 2017). This approach will allow us to evaluate quantity (number of steps) and intensity of physical activity in the adolescents, their parents, and their dogs, as well as to synchronize Fitbit Ace and FitBark to establish the amount of shared physical activity of adolescents and their dogs.
41277865|NCT06334939|DEVICE|Bispectral Index Monitoring|"Study patients will undergo perioperative bispectral index and BIS suppression ratio (SR) monitoring under anesthesia. The lowest BIS and BIS SR values and the values taken at 10-minute intervals will be recorded throughout the case.~The Richmond agitation scale will be calculated in the recovery room after anesthesia."
40929264|NCT03596632|DRUG|Fenebrutinib|200-mg (100 µCi) oral solution 14C/12C\]-fenebrutinib
40929265|NCT02324543|DRUG|Gemcitabine|IV on days 4 and 11 of a 21 day cycle
40929266|NCT02324543|DRUG|Taxotere|IV on days 4 and 11 of a 21 day cycle
40929267|NCT02324543|DRUG|Xeloda|Twice a day orally on days 1 through 14 of a 21 day cycle
40929268|NCT02324543|DRUG|Cisplatin|IV on days 4 and 11 of a 21 day cycle
41127519|NCT00679770|DRUG|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
41277866|NCT04091217|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
41448628|NCT05312216|DRUG|Durvalumab plus Lenvatinib|"Durvalumab: 1500mg, iv.drip, Q4w Lenvatinib: 8mg, QD (body weight \< 60kg) or 12mg, QD (body weight ≥ 60kg)~Number of cycle: until subjects withdrawing the informed consent OR progressive disease OR developing unacceptable toxicity events"
41448629|NCT02770222|DRUG|Selexipag|Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
41448630|NCT02770222|DRUG|Gemfibrozil|Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
41448631|NCT02770222|DRUG|Rifampicin|Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
41127520|NCT00679770|DRUG|Vehicle|Once daily application for 90 days and 3x weekly for 90 days
40929269|NCT02324543|DRUG|Irinotecan|IV on days 4 and 11 of a 21 day cycle
41448632|NCT00615667|DRUG|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
40929270|NCT01274260|DRUG|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
40929271|NCT01274260|DRUG|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
40929272|NCT00042029|DRUG|MK0869, aprepitant|
40929273|NCT00042029|DRUG|Comparator: placebo|
40929274|NCT00832039|DRUG|sodium-selenite|An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
41448633|NCT05612204|PROCEDURE|Biopsy under MRI|Biopsy under MRI
40929275|NCT00832039|DRUG|Placebo|An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
40929276|NCT00832039|PROCEDURE|Procalcitonin guided therapy|"Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline \>=50%: no change in causal therapy; PCT drop from baseline \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT \<=1.0 ng/ml: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \>=50%: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control."
41127521|NCT00175812|DRUG|all-trans retinoic acid (ATRA)|All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
41448634|NCT06508905|OTHER|Sleep buddy|The toy chosen as a sleep companion was introduced to the children in the experimental group and they were told that it would accompany them for 3 days during their hospitalization. Before giving the sleep companion, parents and children were informed about the sleep companion and their questions about the study were answered. Children who did not have their own sleep companion were included in the sample. The child was encouraged to sleep and spend time with the given sleep buddy and the family was also informed.
41127522|NCT00175812|DRUG|Valproic acid|Valproic acid, highest dose without side effects from day 3 until progression
40929277|NCT01412918|DEVICE|The Inhibitor™ Tinnitus Masking Device|The Inhibitor™ Tinnitus Masking Device
41277867|NCT04091217|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.
40929278|NCT04692727|OTHER|Exercise program|"* Hamstring, quadriceps, gastrocnemius, iliopsoas, iliotibial band (ITB), lateral and medial retinaculum stretching exercises~* Isometric exercises of vastus medialis, gluteus medius and external rotators~* Isotonic exercises of vastus medialis, gluteus medius and external rotators~* Closed kinetic chain exercises~* Balance and coordination exercises~* Core stabilization exercises"
40929279|NCT04692727|OTHER|McConnel patellar taping technique|Individuals are placed in a supine position with their knees extended and the quadriceps relaxed. A 5 cm wide hypoallergenic band is applied transversely over the patella without affecting the position of the patella. Then, it is started at the lateral edge of the patella with a rigid tape. The tape is terminated at the medial femoral condyle after a medial pull and / or medial tilt to the patella.
41127523|NCT00175812|DRUG|Theophyllin|Theophyllin, targetted serum level 50-100 from day 3 until progression
41127524|NCT02697877|DRUG|Regadenoson|
41127525|NCT04060017|DRUG|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
41127526|NCT04060017|OTHER|Placebo|Placebo
41127527|NCT04316936|DRUG|Omidria|phenylephrine 1% and ketorolac 0.3% intraocular solution
41127528|NCT04316936|DRUG|Dextenza (dexamethasone ophthalmic insert) 0.4mg|intracanalicular dexamethasone insert
41127529|NCT04316936|DRUG|Dexycu, 9% Intraocular Suspension|dexamethasone intraocular suspension
41127530|NCT04316936|DRUG|Prednisolone Acetate 1%|standard postoperative ophthalmic drop regimen
41127531|NCT03348722|OTHER|Active surveillance|PSA testing (every 3 months, then every 6 after 30 months), clinical visit and DRE every 6 months, prostate biopsy after 1, 4 and 7 years
41127532|NCT03348722|PROCEDURE|Radical prostatectomy|Radical prostatectomy (open, laparoscopic or robotic)
41277868|NCT05984745|DRUG|Coenzyme Q10 Forte® capsules|Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
40929280|NCT04692727|OTHER|Femoral rotational taping technique|This technique is applied in a standing position and hip extreme external rotation. Taping is started on the vastus medialis and is pulled diagonally from the anterior of the leg to the lateral and ends on the trochanter major.
41127533|NCT03348722|RADIATION|Radiotherapy|External radical radiotherapy or brachitherapy
41127534|NCT03348722|PROCEDURE|Other radical treatments|High intensity focal ultrasound, cryotherapy, others
41127535|NCT05857020|DEVICE|Auricular Acupressure|"Auricular Acupressure (AA) utilizing all-natural vaccaria ear seeds will be applied to 5 designated sites on each participant's ear (total of 10 seeds placed per patient).~Participants will be asked if they consent to having their ear placement photographed after placement (optional) and audio recorded during interventionist ear seed placement (optional) in collaboration with the BAApress training fidelity study."
41127536|NCT01472900|DEVICE|2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)|2 passes of 2940nm Er:YAG laser
41127537|NCT01472900|DRUG|Benzoyl Peroxide gel|2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
41127538|NCT04422236|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creation of anastomoses during laparoscopic bariatric surgery, manufactured by Ezisurg Medical.
41127539|NCT03608995|DIAGNOSTIC_TEST|Premaquick (Diagnostic test)|"PREMAQUICK® is a rapid multiparametric test which aim to detect the presence of IGFBP-1 (Insulin-like Growth Factor-Binding Protein 1), fragmented IGFBP-1 and IL-6 (Interleukin 6) in vaginal secretions. By combining biomarkers of myometrial activation, cervical maturity and inflammation / infection, PREMAQUICK® integrates the main pathogenic mechanisms responsible for premature delivery, which makes it possible to predict or, on the contrary, rule out the risk of childbirth within 7 to 14 days. This test is intended for in vitro diagnostic use.~Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and then 3 drops are deposited in each wells of the test device for 10 minutes. Visual reading should be done between 10 and 15 minutes."
41127540|NCT03608995|DIAGNOSTIC_TEST|Quikcheck fFN ™|- The Hologic QuikCheck fFN test is intended to be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions. The presence of fetal fibronectin in cervicovaginal secretions between 22 weeks, 0 days and 34 weeks, 6 days of gestation is associated with elevated risk of preterm delivery. Quick Check fFN test® is a 10 min, one-step, visual test consists of a sterile polyester-tipped applicator, fetal fibronectin test strip, and sample extraction buffer. The QuikCheck fFN is a solid-phase immunogold assay which aim to detect fetal fibronectin. A positive specimen will result in two visible lines and a negative specimen will result in one visible line (control).
41277869|NCT06021457|DRUG|RBT-1|Intravenous administration
41277870|NCT06021457|DRUG|Placebo|Intravenous administration
41127541|NCT04876417|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
41448635|NCT02143245|DIAGNOSTIC_TEST|Synovial Biopsy|Synovial biopsy is a procedure using a guided needle, where 6 to 8 small tissue samples with be extracted from the shoulder using an x-ray guided needle.
41127542|NCT04876417|DEVICE|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
41127543|NCT01290341|DRUG|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
41127544|NCT01290341|DRUG|Placebo|Topical; applied once daily for two weeks.
41127545|NCT04679662|DEVICE|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
41277871|NCT05516914|DRUG|LBL-007 Injection|Initial dose - MTD; Q3W; intravenous infusion
41277872|NCT05516914|DRUG|Tislelizumab Injection|Initial dose; Q3W; intravenous infusion
41277873|NCT05516914|DRUG|Cisplatin Injection|Initial dose；Q3W; intravenous infusion
41277874|NCT05516914|DRUG|Gemcitabine Hydrochloride for Injection|Initial dose；Q3W; intravenous infusion
41277875|NCT05516914|DRUG|Docetaxel injection|Initial dose；Q3W; intravenous infusion
41277876|NCT04513158|BIOLOGICAL|Convalescent Plasma|Plasma obtained from individuals previously diagnosed with SARS-CoV-2 (COVID-19) is administered to hospitalized patients meeting inclusion/exclusion criteria and have provided informed consent.
41277877|NCT04923893|DRUG|Bortezomib|Bortezomib will be administered SC.
41277878|NCT04923893|DRUG|Dexamethasone|Dexamethasone will be administered orally.
41277879|NCT04923893|DRUG|Lenalidomide|Lenalidomide will be administered orally.
41448636|NCT02143245|DIAGNOSTIC_TEST|Open Tissue Biopsy|During the standard of care revision surgery, 6 to 8 small tissue samples will be taken in order to test for infection. This is standard of care treatment. As part of this study, an additional 1 to 2 samples of tissue would be taken in order to develop a test to determine more precisely what type of infection there may be.
40919292|NCT02569099|OTHER|Caregiver training|One hour training of family caregivers on the basic function of the brain and the stroke condition and its management in the home.
40919293|NCT04665089|DRUG|Erythromycin|"Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~* Pro-inflammatory cytokine (TNF alpha)~* Anti-inflammatory cytokine (IL-10)~* Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)"
40919294|NCT04642391|DRUG|Cosyntropin|Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
40919295|NCT01929499|BIOLOGICAL|cytokine-induced killer cells|
41127546|NCT06321224|OTHER|Breathing exercises|Breathing exercises will be performed 3 days a week during 2 menstrual periods.
41127547|NCT06321224|OTHER|Control|No intervention will be made to the control group and they will be asked to continue their routine lives.
41448637|NCT00161785|BIOLOGICAL|FSME-IMMUN 0.5ml|
41448638|NCT04677075|PROCEDURE|mastectomy|mastectomy either simple or modified radical
41448639|NCT02643407|DRUG|Docetaxel|60mg/m2
41448640|NCT02643407|DRUG|Nedaplatin|80mg/m2
41448641|NCT02643407|DRUG|Cisplatin|75mg/m2
41127548|NCT01874964|BEHAVIORAL|Methadone Maintenance|Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
41127549|NCT01874964|BEHAVIORAL|Linkage to methadone maintenance|Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
41127550|NCT01311622|DRUG|warfarin|2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
41127551|NCT01311622|DRUG|fostamatinib|2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
41448642|NCT05096286|DEVICE|Ethos Therapy|FDA-approved treatment planning system
41127552|NCT01154192|DRUG|Dexamethasone|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
41448643|NCT04964973|DEVICE|Control|Post-surgical physiotherapeutic activity.
41448644|NCT04964973|DEVICE|Experimental|Post-surgical physiotherapeutic activity with the application of the technique
41448645|NCT04964973|DEVICE|Placebo|Post-surgical physiotherapeutic activity with the application of the non-activated technique
41448646|NCT06149767|DRUG|Adebrelimab|"The medication regimen for all enrolled patients is as follows, and the dose can be adjusted during treatment due to adverse reactions and other circumstances:~Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times.~First of all, after 2 cycles of concurrent chemoradiotherapy, the sequential chemotherapy combined with adbalizumab for 2-4 cycles, and the subsequent investigators selected Adbalizumab or other drugs to maintain the treatment according to the patient's situation or the patient's own will until the disease progressed or intolerable toxicity occurred or the subjects voluntarily withdrew from the study.adebrelimab until disease progression or intolerable toxicity or the subject voluntarily withdrew from the study。"
41448647|NCT01714622|PROCEDURE|subtotal gastrectomy with gastroduodenostomy|
41448648|NCT01714622|PROCEDURE|subtotal gastrectomy with Roux-en-Y gastrojejunostomy,|
41448649|NCT01714622|PROCEDURE|total gastrectomy with Rou-en-Y esophagojejunostomy|
41448650|NCT02318420|OTHER|The PartoMa intervention|WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training
41448651|NCT06014424|DRUG|CBD|Participants in this arm will receive CBD for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
41448652|NCT06014424|OTHER|Placebo|Participants in this arm will receive placebo for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
41127553|NCT01154192|DRUG|recombinant human chorionic gonadotropin (r-hCG)|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
41277880|NCT04923893|DRUG|Cilta-cel|Cilta-cel infusion will be administered.
41277881|NCT04923893|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
41277882|NCT04923893|DRUG|Fludarabine|Fludarabine will be administered intravenously.
41448653|NCT03705117|BIOLOGICAL|V565|Capsules for oral administration
41127554|NCT02129595|DIETARY_SUPPLEMENT|placebo|A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
41127555|NCT02129595|DIETARY_SUPPLEMENT|resveratrol|resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
41127556|NCT05986734|DRUG|Cutaquig|Subcutaneous immunoglobulin products are administered at the same monthly dose (0.4-0.8 g/kg), evenly divided into 3-5 administrations per month, subject to monitoring of the pre transfusion IgG level with target IgG values of at least 7 g/L.
41127557|NCT00962234|OTHER|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
41127558|NCT00962234|BIOLOGICAL|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
41127559|NCT00962234|PROCEDURE|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
41127560|NCT03610594|OTHER|Kalaripayattu|Combination of Exercise, breathing, meditation, combat practices
41127561|NCT00986375|BEHAVIORAL|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
41127562|NCT00986375|BEHAVIORAL|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
41127563|NCT06371300|DEVICE|Red LLLT|Mask with LEDs emitting at wavelengths of 633nm to facial and eyelids region with their eyes closed
41448654|NCT01983735|DRUG|TELMINUVO Tab. (80/2.5mg)|"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~* With the others investigation product placebo 1 tab QD 2 weeks."
41448655|NCT01983735|DRUG|TELMINUVO Tab. (80/5mg)|"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~* With the others investigation product placebo 1 tab QD 6 weeks."
41448656|NCT01983735|DRUG|S-amlodipine 2.5mg|"* S-amlodipine 2.5mg QD 2 weeks~* With the others investigation product placebo 1 tab QD 2 weeks."
41127564|NCT06371300|DEVICE|Blue LLLT|Mask with LEDs emitting at wavelengths of 428nm to facial and eyelid regions with their eyes closed
41127565|NCT06371300|DEVICE|Sham Red LLLT|Mask with LEDs emitting at wavelengths of 633nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
41277883|NCT02531516|DRUG|Apalutamide|
41277884|NCT02531516|DRUG|Bicalutamide|
41277885|NCT02531516|DRUG|Bicalutamide Placebo|
41448657|NCT01983735|DRUG|S-amlodipine 5mg|"* S-amlodipine 5mg QD 6weeks~* With the others investigation product placebo 1 tab QD 6 weeks."
41448658|NCT04026243|PROCEDURE|QL block|U/S guided Transmuscular Quadratus Lumborum Block
40919296|NCT02437110|DRUG|Darunavir|Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.
40919297|NCT02437110|DRUG|Ritonavir|Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100mg twice daily.
41277886|NCT02531516|DRUG|Apalutamide Placebo|
41277887|NCT02531516|DRUG|GnRH (agonist)|
41277888|NCT02531516|RADIATION|74-80 Grays (units of radiation)|
41277889|NCT06241430|DEVICE|CardioMEMS|Hemodynamic-guided optimization will be performed using the CardioMEMS CardioClip device.
41448659|NCT04026243|PROCEDURE|TF block|U/S guided Transversalis Fascia Plane Block
40929281|NCT01405066|BEHAVIORAL|Radiation Dose Audit Reports|Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
40929282|NCT01405066|BEHAVIORAL|Educational Seminar: Radiation Dose Reduction|Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
40929283|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 6mg lutein/day|2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
40929284|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
40929285|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
40929286|NCT04473573|DEVICE|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
40929287|NCT01138943|DRUG|Synthodont|"15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse"
40929288|NCT01138943|DRUG|Soludent|"15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days~Arm: Experimental: non alcohol chlorhexidine mouthrinse"
40929289|NCT00104598|DRUG|Bupropion|
40929290|NCT00104598|BEHAVIORAL|Smoking Abstinence Program|This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
41448660|NCT06119685|DRUG|IDP-023|NK cell therapy
41448661|NCT06119685|DRUG|Rituximab|Anti-CD20 antibody therapy
41448662|NCT06119685|DRUG|Daratumumab|Anti-CD38 antibody therapy
41448663|NCT06119685|DRUG|Interleukin-2|Immune cytokine
41448664|NCT06119685|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
41448665|NCT06119685|DRUG|Fludarabine|Lymphodepleting chemotherapy
40929291|NCT03049293|DRUG|Midazolam|The impact of Midazolam levels in follicular fluid.
40929292|NCT02677324|DRUG|ABT199|Oral BCL-2 antagonist
41448666|NCT06119685|DRUG|Mesna|Chemoprotectant
41448667|NCT02922569|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
41448668|NCT02922569|OTHER|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
40929293|NCT02741180|OTHER|3D Imaging|"roadmapping of electrophysiology (EP) procedures"
41448669|NCT02922569|OTHER|Mindfulness Training|Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
41448670|NCT02922569|OTHER|Traumatic Brain Injury Information Session|Ten minutes of viewing traumatic brain injury related news, information, and programs.
41448671|NCT06532513|OTHER|Family-Centered Goal-Oriented Physiotherapy and Rehabilitation Application|Family centered goal-oriented physiotherapy and rehabilitation applications aim to enhance the functional level of severely affected children with dyskinetic cerebral palsy children through individualized activities conducted by family members at home. The program focuses on specific goals determined collaboratively by the family, physiotherapists, and physician, with regular monitoring and assessments to track progress.
41448672|NCT03240991|OTHER|Quality of life|Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score
40929294|NCT02741180|OTHER|Late Gadolinium Enhancement (LGE)|useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
40929295|NCT05884632|RADIATION|Daily Adaptive RadioTherapy|Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
40929296|NCT00937885|BEHAVIORAL|Implementation of reminiscence|
40929297|NCT01155882|PROCEDURE|Whipple at the Splenic Artery (WATSA)|
40929298|NCT05585944|DIAGNOSTIC_TEST|Genotyping of rs1883832C/T related single-nucleotide polymorphism|Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
41127566|NCT06371300|DEVICE|Sham Blue LLLT|Mask with LEDs emitting at wavelengths of 428nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
41127567|NCT02974322|DRUG|GED-0301|GED-0301
41127568|NCT02974322|DRUG|Placebo|Placebo
41127569|NCT01662154|DEVICE|Neurometer assessment|Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.
41448673|NCT00960414|BEHAVIORAL|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detailed nutritional education.
41448674|NCT04802057|DRUG|SAR445088|"Pharmaceutical form: solution for injection~Route of administration: IV and SC (Part 1) IV (Part 2)"
41448675|NCT00721435|PROCEDURE|3D Tomosynthesis and ultrasound imaging|3D tomosynthesis \& ultrasound imaging for scanning masses or healthy breast tissue
41448676|NCT00830024|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
41448677|NCT00830024|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
41448678|NCT04989387|DRUG|INCA00186|INCA00186 will be administered every 2 weeks or 4 weeks as per protocol
41448679|NCT04989387|DRUG|Retifanlimab|Retifanlimab will be administered every 4 weeks as per protocol
41448680|NCT04989387|DRUG|INCB106385|INCB106385 will be administered orally once or twice a day.
40919298|NCT02437110|DRUG|Dolutegravir|Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 50mg once daily.
41127570|NCT01662154|DEVICE|Nerve stimulator assessment|Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
41127571|NCT01255514|DRUG|high dose dexamethsone|high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
41127572|NCT03488745|BEHAVIORAL|IntelliCare + Phone Coaching|IntelliCare is composed of 13 separate, native apps. Each app targets a specific aspect of mental health (e.g., reducing worry, increasing social support, tracking negative thoughts). The apps are available to the public in both Android and iPhone stores. Participants will be asked to try two new IntelliCare apps every week, for 7 weeks. Phone coaching will occur at Day 0, before using any of the apps, and the third week of app usage.
41127573|NCT01704196|DRUG|Nepicastat|120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
41127574|NCT01704196|DRUG|Placebo|
41127575|NCT05742815|OTHER|No intervention|This is an observational collection of data from purchased donor milk samples
41127576|NCT06215391|DEVICE|3d printed mask|"* Concurrent, prospective, non-randomized inclusion, cross-over design. A minimum of 6 patients will be included for each group, COPD, and ALS.~* T0: Patient enrollment (informed consent signing), retrospective review of the respirator log (1 month prior), variable extraction (extracting EDF files from the respirator log and data obtained from ResScan).~* During the first week, a 3D scan of the patient's face will be conducted, and the personalized 3D-printed mask (M3D) will be manufactured.~* Once ready, the mask will be fitted, and the 1-month evaluation period will begin (T1: after 1 month of M3D use). The respirator card will be downloaded in the same manner as at T0, and a respiratory polygraphy (RP) will be scheduled.~* T2: At the end of the study month, the patient will resume using a similar MC, which is new and well-fitted. After one month of MC use, the respirator log will be reviewed, and a new RP will be conducted."
41277890|NCT03191786|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered via IV infusion once every three weeks (QW3).
41277891|NCT03191786|DRUG|Vinorelbine|Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.
41277892|NCT03191786|DRUG|Gemcitabine|Gemcitabine will be administered per relevant local guidelines and SmPC management.
41277893|NCT03474965|DRUG|Crizanlizumab|Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
41277894|NCT05591911|DIAGNOSTIC_TEST|Urine PCR testing|The urine PCR panel will be performed to evaluate the bacterial growth in the patient's urine who is admitted with acute urinary tract symptoms.
41277895|NCT06621407|PROCEDURE|24 hours active subperiostal drainage|24 hours active subperiostal drainage after single burr hole evacuation of a chronic subdural hematoma
41127577|NCT05025241|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
41127578|NCT02840929|PROCEDURE|Second-look OGD|Second-look OGD within 16 to 24 hours after primary OGD
41127579|NCT02840929|DRUG|Esomeprazole|
41277896|NCT06621407|PROCEDURE|24 hours passive subdural drainage|24 hours passive subdural drainage after single burr hole evacuation of a chronic subdural hematoma
40919299|NCT02437110|DRUG|Tenofovir alafenamide (TAF)|Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 25mg once daily.
41127580|NCT00862706|DRUG|Telbivudine/LDT600A|Oral once daily
40919300|NCT05382442|DRUG|AK112|AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity
40919301|NCT05382442|DRUG|AK117|AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity
40919302|NCT05382442|DRUG|Oxaliplatin|Oxaliplatin via IV infusion
40919303|NCT05382442|DRUG|Capecitabine|Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
41127581|NCT03095872|DEVICE|CO2-laser|Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
41277897|NCT06495710|OTHER|Blood pressure treatment algorithm|Single or combination antihypertensive therapy as needed: 1) amlodipine (2.5-10 mg), 2) telmisartan (20-80 mg) or losartan (25-100 mg), 3) chlorthalidone (6.25-25 mg), or 4) spironolactone (12.5-50 mg). a two-drug regimen with either amlodipine + chlorthalidone or telmisartan + chlorthalidone will be initiated following randomization. If a diuretic is contraindicated, amlodipine + telmisartan will be initiated. For those over 75 years, either amlodipine or telmisartan will be initiated at baseline if SBP is \<140 mmHg. In the standard treatment group (SBP goal of \< 140 mmHg), participants will either be prescribed amlodipine or telmisartan/losartan as initial therapy. If \>3 medications are necessary to reach the intensive goal and no first line options remain, potassium sparing diuretics or direct vasodilators will be considered.
41277898|NCT06618313|DRUG|JCXH-213,an mRNA-LNP based in vivo CAR therapy|JCXH-213 infusion
41277899|NCT05328947|OTHER|Modified Functional Reach and Functional Reach|Establishment of Modified Functional Reach Test (mFRT) and Function Reach Test (FRT) values for individuals with no functional impairments.
41448681|NCT06276153|OTHER|no interventions|retrospective registry cohort with no other specific interventions
41448682|NCT02681939|DRUG|Tulsi(Ocimum sanctum Linn.) capsules|
40929299|NCT05710380|OTHER|Risk Map Decision Support System (DSS).|The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
40929300|NCT05710380|RADIATION|Magnetic Resonance Imaging (MRI)|A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
40929301|NCT05710380|PROCEDURE|Magnetic Resonance Imaging (MRI) Guided Biopsy|A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.
40929302|NCT04438564|OTHER|Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer|Diagnosis and acceptance of breast cancer, colon rectal cancer, ovarian cancer, and endometrial cancer by the clinical Western medicine team.
40929303|NCT04549974|OTHER|Heat exposure|Participants will be exposed to heat exposure via a water-perfused suit to increase internal body temperature by 1.5 degrees Celsius.
40929304|NCT04879602|BEHAVIORAL|suction with bronchoscopy|suction with bronchoscopy
41448683|NCT06627478|DRUG|NKF-INS(G)|Single subcutaneous dose of 0.5 IU/kg administered over three periods
41448684|NCT06627478|DRUG|US-Lantus®|Single subcutaneous dose of 0.5 IU/kg administered over three periods
40929305|NCT04403269|DRUG|IgIV|2 infusion at D1 and D2 (0.8 g / kg by IV infusion)
40929306|NCT03487978|DIAGNOSTIC_TEST|resting-state functional MRI|"1. To ensure inter-ictal fMRI, confirm that the subject has no migraine for at least 48 hours before the procedure.~2. Record the time difference between the date on the day of fMRI and the date of the last headache attack and record whether the headache on the day of fMRI is absent or not.~3. On the third day after MRI, examine whether the subject has headache or not."
40929307|NCT01275339|DRUG|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
40929308|NCT01275339|DRUG|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
41448685|NCT06627478|DRUG|EU-Lantus®|Single subcutaneous dose of 0.5 IU/kg administered over three periods
41448686|NCT02407548|DIETARY_SUPPLEMENT|coenzyme Q10 vitamin E softgel|4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
41448687|NCT02407548|DIETARY_SUPPLEMENT|coenzyme Q10 softgel|4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
41448688|NCT02407548|DIETARY_SUPPLEMENT|placebo softgel|4 placebo softgels per day. Keep normal lift style unchanged.
41448689|NCT02812420|BIOLOGICAL|Durvalumab|Given IV
41127582|NCT03095872|DRUG|Vaseline|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home."
41277900|NCT06132256|DRUG|Axatilimab|Administered as intravenous (IV) infusion
41277901|NCT06132256|OTHER|Placebo|Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.
41277902|NCT06587256|DEVICE|Mouth Tape|A single piece of silicone tape placed vertically over the lips. When positioned properly the participant can still inhale/exhale and cough around the tape if needed, but will tend to keep mouth closed otherwise.
41277903|NCT06590116|OTHER|Physical therapy|Patients with low back pain will receive a combination of education, spinal manipulative therapy, and exercise as prescribed by their physical therapist
41277904|NCT06590116|OTHER|Physical therapist provider|Physical therapists will provide a combination of education, spinal manipulative therapy, and exercise to their patients with low back pain participating in the study
41277905|NCT02790229|OTHER|anti-gravity treadmill (alter G®)|Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
41277906|NCT02790229|OTHER|standardized physiotherapy|Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
41277907|NCT03750500|DEVICE|Biofeedback device|12-week exercise program performed through the device
41277908|NCT03750500|BEHAVIORAL|Education on falls risk|Education on falls risk factors and how to minimize them
41277909|NCT03750500|OTHER|Medication review|Medication will be reviewed to reduce sedative drugs and minimize interactions
41277910|NCT03750500|DIAGNOSTIC_TEST|Visual and auditory screening|Patients will go through visual and auditory screening as part of their regular care
41277911|NCT00109811|BIOLOGICAL|PSA:154-163(155L) peptide vaccine|Given subcutaneously
41448690|NCT02812420|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystectomy with pelvic lymph node dissection
41448691|NCT02812420|BIOLOGICAL|Tremelimumab|Given IV
41448692|NCT04369937|RADIATION|IMRT (Intensity Modulated Radiotherapy)|Radiation therapy
40919304|NCT05382442|DRUG|Irinotecan|Irinotecan via IV infusion
40919305|NCT05382442|DRUG|Leucovorin|Leucovorin via IV infusion
40919306|NCT05382442|DRUG|5-fluorouracil|5-fluorouracil via IV infusion
40919307|NCT00049985|DRUG|Darbepoetin Alfa|
40929309|NCT02925793|DRUG|DS107|
40929310|NCT02925793|OTHER|Vehicle cream|
41127583|NCT03095872|DRUG|Bepanthen|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home."
41127584|NCT05134649|DRUG|BOTOX|Intramuscular Injection
41127585|NCT03631433|DRUG|Ibuprofen 600 mg|identical appearing tablets containing 600 mg of ibuprofen
41127586|NCT03631433|DRUG|ibuprofen 600 mg and acetaminophen 650 mg|identical appearing tablets of the combination of ibuprofen and acetaminophen
41127587|NCT01571466|DRUG|Vaccination|"* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16"
41127588|NCT01571466|DRUG|Placebo|3 immunisations at week 0, 4 and 16
41127589|NCT01362075|PROCEDURE|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
41127590|NCT01362075|PROCEDURE|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
41127591|NCT00140400|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
41127592|NCT02629679|BEHAVIORAL|Regular scholastic system and organized sports|This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
41127593|NCT02629679|BEHAVIORAL|Regular scholastic system|The group will consist of children who are regularly in school, but not being involved in organized sport activities
41277912|NCT00109811|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously
41277913|NCT00109811|OTHER|laboratory biomarker analysis|Correlative studies
41448693|NCT04369937|DRUG|Pembrolizumab|A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.
41448694|NCT04369937|DRUG|Cisplatin|Chemotherapy
41448695|NCT04369937|BIOLOGICAL|ISA101b|ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16.
41448696|NCT02147379|DRUG|Lurasidone|
41448697|NCT05980598|DRUG|TransCon TLR7/8 Agonist|TLR7/8 agonist prodrug
41448698|NCT05980598|DRUG|Pembrolizumab|A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding
41448699|NCT05980598|DRUG|TransCon IL-2 β/γ|Sustained systemic release of IL-2 β/γ with selective receptor binding that may stimulate the immune system to kill cancer cells
41448700|NCT06563284|OTHER|AURORA Mobile App|"Enrolled subjects will be asked to download the app for free from their smartphone store.~Weekly/bi-weekly updates were collected, and therapy adherence was facilitated with timed alerts. Patients completed the EQ-5D-5L, PSQI, PHQ-9 and GAD-7 questionnaires every four months to track quality of life, sleep quality, depression and anxiety."
40929311|NCT04325399|OTHER|Volitional help sheet|
40929312|NCT00003409|DRUG|motexafin gadolinium|
40929313|NCT00003409|RADIATION|radiation therapy|
41448701|NCT00174551|DRUG|prazosin|
41448702|NCT01576705|DRUG|thyroid hormone and folinic acid|thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
40929314|NCT01216605|DRUG|Syntocinon 24 IU|
41127594|NCT04325685|DRUG|Control|Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation
40929315|NCT01216605|DRUG|Placebo|
41127595|NCT04325685|DRUG|Antiseptic Solution|Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation
41127596|NCT04325685|DRUG|Bacteriophage|Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
41127597|NCT02348866|OTHER|method of laundering and donning scrubs|
41277914|NCT04634578|DRUG|Bevacizumab|"All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.~Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution."
41277915|NCT00813748|DRUG|Xolair|
41277916|NCT03268629|BEHAVIORAL|Mindfulness-Based Joyful Sleep|"The proposed Mindfulness-Based Joyful Sleep program will be conducted weekly, 2 hours per session, 8 sessions, group-based program in mindfulness."
41277917|NCT03268629|BEHAVIORAL|CBT-I|The CBT-I program was delivered to groups of 10-15 individuals over the course of eight, weekly, 2-hour sessions, for a total of 16 contact hours.
41277918|NCT01330290|DRUG|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
41277919|NCT01525758|DRUG|SI000413|1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
41277920|NCT01525758|DRUG|microcrystalline cellulose|identical number of tablets to active drug groups
41277921|NCT05089708|DRUG|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
41277922|NCT05089708|DRUG|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
41448703|NCT02294981|DEVICE|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
41448704|NCT05162105|OTHER|Short rest (8 hour) between two consecutive shifts.|Participants will have shortened rest opportunity (8 hours) between two consecutive shifts, due to the shift work schedule.
41448705|NCT05162105|OTHER|16 hour rest opportunity between to consecutive shifts.|Participants will have a 16 hour rest opportunity between shifts, due to shift work schedule.
40929316|NCT01294527|DEVICE|Wireless cardiac stimulator implant to pace the left ventricle for CRT|Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
40929317|NCT04010539|DRUG|Gepotidacin|Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
41277923|NCT01879020|DRUG|TA-8995|Drug: TA-8995 1mg
40929318|NCT04010539|DRUG|Ceftriaxone|Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
41277924|NCT01879020|DRUG|TA-8995|Drug: TA-8995 2.5mg
41277925|NCT01879020|DRUG|TA-8995|Drug: TA-8995 5mg
41277926|NCT01879020|DRUG|TA-8995|Drug: TA-8995 10mg
41277927|NCT01879020|DRUG|TA-8995|Drug: TA-8995 25mg
41277928|NCT01879020|DRUG|Placebo|Placebo (TA-8995 1mg)
41277929|NCT01879020|DRUG|Placebo|Placebo (TA-8995 2.5mg)
41277930|NCT01879020|DRUG|Placebo|Placebo (TA-8995 5mg)
41277931|NCT01879020|DRUG|Placebo|Placebo (TA-8995 10mg)
41277932|NCT01879020|DRUG|Placebo|Placebo (TA-8995 25mg)
41277933|NCT04147884|DEVICE|Millipede Transcatheter Annuloplasty Ring System (Millipede System)|The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.
41277934|NCT03643770|COMBINATION_PRODUCT|Upper extremity training/Armeo Spring|Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
41277935|NCT06218901|DRUG|immunotherapy|
41277936|NCT06218901|DRUG|Targeted Therapy Agent|
41277937|NCT04357171|PROCEDURE|Low anterior resection with protective loop ileostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning ileostomy is performed.
41448706|NCT01811758|BEHAVIORAL|Culturally Specific CBT|
41448707|NCT01811758|BEHAVIORAL|Standard CBT|
41448708|NCT02043522|DRUG|Radioisotope|One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
41448709|NCT03608228|OTHER|Measuring electrical signals from the brain|If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
41448710|NCT03501511|BEHAVIORAL|IDF modules|Patients in this arm will receive Pre-Ramadan education using IDF module for 4 weeks prior to Ramadan fasting
41448711|NCT03501511|BEHAVIORAL|Conversational Maps|Patients in this arm will receive Pre-Ramadan Education using Ramadan Fasting Diabetes conversation map for 4 weeks prior to Ramadan fasting
41448712|NCT01034215|BEHAVIORAL|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
41448713|NCT01034215|BEHAVIORAL|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
41277938|NCT04357171|PROCEDURE|Low anterior resection with protective loop transverse colostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning transverse colostomy is performed.
41277939|NCT05726591|DEVICE|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
41277940|NCT02999503|BEHAVIORAL|Nutritional education|Nutritional education trough a personal online nutritional consultant
41277941|NCT01787071|OTHER|Fluid challenge|Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
41277942|NCT03624569|OTHER|Bagel|A bagel will be consumed daily for 2 weeks.
41277943|NCT03624569|OTHER|Potato|A potato will be consumed daily for 2 weeks.
41277944|NCT02812004|DEVICE|Ultra Q Reflex YAG laser (Ellex)|"Group 1 receives up to 2 sessions of vitreolysis performed with the Ultra Q Reflex YAG laser (Ellex). There is no cut off for total energy per treatment session.~For the sham treatment in group 2, the physician quickly manipulates the light switch of the laser's slit lamp to create light flashes and simulate laser pulses."
41277945|NCT05900115|BEHAVIORAL|Media Ready Parent|The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
41448714|NCT05723250|OTHER|Table-based Educational Intervention|Tablet based educational tool with videos about care coordination, cancer knowledge and self-advocacy.
40929319|NCT04010539|DRUG|Azithromycin|Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
40929320|NCT02128100|DRUG|Folfirinox|"* Oxaliplatin 85 mg/m² for over 2 hours,~* Leucovorin 400n mg/m² for over 2 hours,~* Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~* Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~* Fluorouracil 2400 mg/m² as a slow infusion over 46 hours"
40929321|NCT02128100|RADIATION|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
41127598|NCT01917942|DEVICE|Humidification|Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
41127599|NCT01917942|OTHER|Standard of Care|SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
41127600|NCT01154387|DRUG|Anti-Thymocyte Globulin|1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
41448715|NCT06559930|OTHER|Traditional Neurological Rehabilitation + Dual Task Focused Training|Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration. Dual-task exercises, an important aspect of post-stroke rehabilitation, target both motor and cognitive functions. Dual tasks are activities that require performing two different tasks at the same time. These types of exercises are used to increase patients' attention, improve coordination, and help them perform daily living activities more effectively.
41127601|NCT01154387|DRUG|TOL101|Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
40919308|NCT00970385|DRUG|CHOP21|"CHOP regimen:~* cyclophosphamide 750 mg/m2 intravenously (IV) day 1~* doxorubicin 50 mg/m2 IV day 1~* vincristine 1,4 mg/m2 (maximum 2 mg) day 1~* prednisone 100 mg/m2/D from D1 to D5."
40919309|NCT00970385|DRUG|VIP/ABVD|"VIP regimen:~* etoposide 100 mg/m2/D IV from D1 to D3~* ifosfamide 1000 mg/m2/D from D1 to D5~* cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~* doxorubicin50 mg/m2/D on D1 and D14~* bleomycin 10 mg/m2/D~* vinblastine 10 mg/m2/D~* dacarbazine 375 mg/m2/D"
40919310|NCT00970385|RADIATION|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
40919311|NCT00579384|DRUG|JNJ-26489112|Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.
40929322|NCT01240265|DIETARY_SUPPLEMENT|Vitamin D3|150,000 IU orally given once
40929323|NCT01240265|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU given orally daily for 28 days
40929324|NCT04594057|BEHAVIORAL|Gaze and Postural Retraining Exercise|"Gaze and Postural Stability The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
40929325|NCT05161039|DEVICE|Serranator|Serranator® PTA Serration Balloon Catheter manufactured by Cagent Vascular
40929326|NCT05161039|DEVICE|POBA|Plain balloon angioplasty device
40929327|NCT02797054|BEHAVIORAL|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
40929328|NCT02797054|BEHAVIORAL|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
40929329|NCT02797054|BEHAVIORAL|Usual care|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
40929330|NCT05098275|DRUG|DA-5210 10/500mg|single dose administration (one tablet once a day)
40929331|NCT05098275|DRUG|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
40929332|NCT00239525|DEVICE|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
40947873|NCT04296110|BEHAVIORAL|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to practice breathing at their resonance frequency using the Inner Balance device daily for 5-15 mins for the duration of the 12-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the intervention.
41448716|NCT06559930|OTHER|Traditional Neurological Rehabilitation|Rehabilitation programs that start early after stroke and continue at regular intervals throughout life support the individual in regaining his quality of life and performing his daily functions. These programs can help patients increase their functional independence, improve their quality of life, and ensure their social integration. Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration.
41127602|NCT01154387|DRUG|TOL101|Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
41127603|NCT01154387|DRUG|Steroids|IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
41127604|NCT01154387|DRUG|Tacrolimus|Oral administration started by 6 days post-transplantation and continued for 6 months
41127605|NCT01154387|DRUG|Mycophenolate mofetil (MMF)|Oral administration started by Day 1 post-transplantation and continued for 6 months
41127606|NCT03262831|OTHER|Yoga|The yoga practice, Gentle Hatha and Restorative Yoga, will be based on protocols that have been found to decease fatigue and weight gain by helping the participant gain insight in recognizing stress responses and ways to relax
41127607|NCT03262831|PROCEDURE|Blood draw|"* Baseline and end of treatment~* To evaluate change in inflammatory markers (CRP, IL-6, and TNF)"
41127608|NCT03262831|BEHAVIORAL|FACT-G questionnaire|"* 7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~* Answers range from 0=not at all to 4=very much"
41127609|NCT03262831|PROCEDURE|Weight measurement|-Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment
41127610|NCT03262831|BEHAVIORAL|Recent Physical Activity Questionnaire|-To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.
41127611|NCT03262831|BEHAVIORAL|NHANES Food Questionnaire|-To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.
41127612|NCT00459524|BEHAVIORAL|Questionnaire|Questionnaires taking about 30 minutes to complete.
41127613|NCT00459524|BEHAVIORAL|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
41127614|NCT02610608|OTHER|ovarian stimulation|evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
41277946|NCT05900115|BEHAVIORAL|Active Control Program|The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
41277947|NCT04407169|OTHER|no intervention|There will be no intervention. It is only an observationnal study
41277948|NCT05912517|DRUG|Nipocalimab|Nipocalimab will be administered as an intravenous infusion.
41277949|NCT05912517|DRUG|Placebo|Placebo will be administered as an intravenous infusion.
41277950|NCT00327392|DRUG|AQUAVAN® (fospropofol disodium) Injection|
41277951|NCT02475200|DEVICE|Atherectomy|Selectively cut and remove atheromatous plaque in the lower extremities. Debulking and removal of atherosclerotic burden plaque with Phoenix Atherectomy System.
41277952|NCT06656026|DRUG|ZSP1273 granules|Oral
41277953|NCT05757869|DRUG|Milvexian|Milvexian will be administered orally.
41277954|NCT05757869|DRUG|Apixaban|Apixaban will be administered orally.
41277955|NCT05757869|DRUG|Placebo|Milvexian matching milvexian placebo will be administered orally.
41277956|NCT05757869|DRUG|Apixaban Placebo|Apixaban matching apixaban placebo will be administered orally.
41277957|NCT03466411|DRUG|Guselkumab Dose 1|Guselkumab will be administered by IV infusion.
41277958|NCT03466411|DRUG|Guselkumab Dose 2|Guselkumab will be administered by SC injection.
40929333|NCT00239525|DRUG|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
40929334|NCT04477278|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation recording consisted of instruction in focused attention on breath and body sensations and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
40929335|NCT04477278|BEHAVIORAL|History of Osteopathy|The history of osteopathy recording introduced patients to the founder of osteopathy, Andrew Taylor Still, and his philosophy of healing.
40929336|NCT02758405|DRUG|Bupivacaine|0.125% Bupivacaine plus fentanyl 2mcg/ml
40929337|NCT02758405|DRUG|Fentanyl|0.125% Bupivacaine plus fentanyl 2mcg/ml
41277959|NCT03466411|DRUG|Guselkumab Dose 3|Guselkumab will be administered by IV infusion.
41277960|NCT03466411|DRUG|Guselkumab Dose 4|Guselkumab will be administered by IV infusion.
41277961|NCT03466411|DRUG|Guselkumab Dose 5|Guselkumab will be by SC injection.
41277962|NCT03466411|DRUG|Guselkumab|Guselkumab will be administered by IV infusion and SC injection.
41277963|NCT03466411|DRUG|Ustekinumab|Ustekinumab will be administered by IV infusion and SC injection.
41448717|NCT01391273|DRUG|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
41448718|NCT01391273|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
40929338|NCT02758405|DEVICE|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
41448719|NCT02915445|BIOLOGICAL|EpCAM CAR-T cells|Patients included will be infused the autologous T cells armed with CAR recognizing EpCAM. After infusion, cytokines and other medical test will be performed.
40929339|NCT00466492|PROCEDURE|Sedation or no sedation during mechanical ventilation|No sedation to critically ill patients
40929340|NCT01197001|DRUG|Amlodipine plus Losartan|Amlodipine/Losartan low dose
41127615|NCT00370942|DRUG|GW823093C A|A=45 mg
41127616|NCT00370942|DRUG|GW823093C B|B=30 mg
41127617|NCT00370942|DRUG|GW823093C C|C=25 mg
41127618|NCT06511284|OTHER|High protein dose|High dose of protein (2.0 g/kg) will prescribed for home enteral nutrition
41127619|NCT06511284|OTHER|Usual protein dose|Usual dose of protein (1.5 g/kg) will prescribed for home enteral nutrition
41277964|NCT03466411|DRUG|Placebo|Placebo will be administered as IV infusion.
41277965|NCT04924322|DRUG|Enoxaparin|Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.
41277966|NCT04657822|DRUG|Crizanlizumab|Concentrate for solution for infusion for Intravenous use
41277967|NCT06121050|OTHER|Pet visit|Intensive care patients visited by their pets for 20 minutes
41277968|NCT04974307|DEVICE|OrCam MyEye 2|The OrCam MyEye 2 is a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs. Its advertised functions include text reading, facial recognition, and product identification.
41277969|NCT03574207|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.
41277970|NCT05476796|DRUG|Trifluridine/Tipiracil|Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
41448720|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
41448721|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
41448722|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
41448723|NCT06563349|DRUG|Intravenous magnesium sulfate|Intraoperative intravenous magnesium sulfate infusion.
41448724|NCT06563349|DRUG|Normal saline infusion|Intraoperative intravenous normal saline infusion.
40929341|NCT01197001|DRUG|Amlodipine, Losartan|Amlodipine, Losartan
41127620|NCT03467529|OTHER|Non interventional study|Non interventional study
41127621|NCT02638337|DRUG|Ospemifene|60 mg tablet
41448725|NCT06396858|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
41127622|NCT02638337|DRUG|Placebo|Tablet identical to the ospemifene tablet without drug
41277971|NCT05476796|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
41448726|NCT06396858|DRUG|Colchicine 0.5 MG|Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
41448727|NCT06396858|DRUG|Placebo Rivaroxaban|Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
41448728|NCT06396858|DRUG|Placebo Colchicine|Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
40919312|NCT00579384|DRUG|Placebo|Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
40919313|NCT03890666|DRUG|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:~* Device 1: Albuterol eMDPI~* Device 2: Albuterol eMDPI Patient-facing smart device application (App)~* Device 3: DHP Cloud solution)~* Device 4: Provider-facing dashboard (dashboard)"
40919314|NCT03890666|DRUG|albuterol|Standard of care albuterol-administering rescue inhaler
40919315|NCT06038747|OTHER|Self-Monitoring|The post-session battery consists of two self-report scales measuring both positive and negative affective reactions of the participants toward their therapist during the therapy session. The general feedback is a brief text that encourages participants to share and discuss their feelings and reflections with their therapist.
40919316|NCT06038747|OTHER|Individual Psychotherapy|Individual psychotherapy sessions
40929342|NCT03021174|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise
40929343|NCT03021174|BEHAVIORAL|Nutrition Education Control|12 weeks of implementing eating tips
40929344|NCT01857557|OTHER|Aerobic exercise|Patients receiving exercise program in addition to usual headache care
40929345|NCT02776020|DEVICE|CorrecDose Infrared Monitor|The monitor is attached to patient's wrist and ear in order to measure changes in propofol concentrations in blood
40929346|NCT00146783|DRUG|Sulphadoxine-pyrimethamine|
40929347|NCT00146783|DRUG|Sulphadoxine-pyrimethamine, amodiaquine|
40929348|NCT00600145|DRUG|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
40929349|NCT00600145|OTHER|Placebo|Placebo
40929350|NCT06298604|DEVICE|EUS-guided standard fine needle biopsy|Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 19-gauge standard fine needle biopsy device (Boston Scientific, USA) is inserted on it to obtain the sample or specimen.
40929351|NCT06298604|DEVICE|EUS-guided motorized fine needle biopsy|Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 20-gauge motorized fine needle biopsy device (Limaca, Israel) is inserted on it to obtain the sample or specimen.
40929352|NCT00576680|DRUG|RAD001|Given orally once a day
40929353|NCT00576680|DRUG|Temozolomide|Taken orally once a day for one week followed by a one-week break period
41127623|NCT04611334|BEHAVIORAL|heart rate variability biofeedback|Heart rate variability biological feedback training is carried out in the outpatient meeting room of the hospital, including once a week, 30 minutes of hospital training each time, using Medea physiological feedback device portable Bluetooth physiological signal Feedback system (Medical Device Input No. 027390). Designed as two stages, stage one (the first week) first teaches the subject how to perform abdominal breathing, and connects the physiological feedback device to monitor the patient's breathing and heart rate changes, and sets the breath per minute according to the subject's resonance frequency . Stage two (second-four weeks) guide the case to understand the resonance relationship between breathing and heart rate, and then achieve the effect of matching heart and breath. It is also equipped with a pressure relief device (Helico Inc., New York, NY, USA) for self-practice at home.
40929354|NCT05324865|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
40929355|NCT02022176|OTHER|Glucose Uptake|Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
40929356|NCT02022176|OTHER|Resting metabolic rate|Resting metabolic rate is measured by indirect calorimetry after an over-night fast
40929357|NCT02022176|OTHER|Nitrite infusion|Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
41127624|NCT01065506|BEHAVIORAL|Cognitive Behavioral Treatment|Cognitive Behavioral Treatment
41127625|NCT01065506|DRUG|Nicotine Patch|Nicotine Patch
41127626|NCT01065506|BEHAVIORAL|Wellness Program|Wellness Program
41127627|NCT01065506|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise
41127628|NCT02755259|DRUG|Acetazolamide|
41127629|NCT02755259|DRUG|Placebo|
41127630|NCT02075554|DEVICE|CALIBER|Expandable interbody spacer
41127631|NCT00423020|DRUG|Erythropoietin|
40929358|NCT03967691|DRUG|Tocilizumab infusion|Tocilizumab (8mg/kg body weight diluted to 100 ml NaCl 0.9%) will be infused over 1 hour
40929359|NCT03967691|DRUG|Saline 0.9%|100 ml NaCl 0.9% will be infused over 1 hour
40929360|NCT04733794|PROCEDURE|Stoma reversal|Patients will receive a comprehensive intervention to addresses bowel, sexual, and urinary dysfunction. Patients meeting appropriate inclusion criteria will be approached at a clinic visit with their surgeon. If they agree to participate, they will complete an initial baseline questionnaire. Questionnaires will be distributed on iPads during their clinic visit
40929361|NCT03188042|DEVICE|rtACS Stimulation|Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.
40929362|NCT03188042|DEVICE|Sham Intervention|A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
40947874|NCT04296110|OTHER|Music Relaxation Therapy|We will determine what genre of music is most relaxing to them and ask them to listen to this type of music using the spotify app for 5-15 mins a day for 12 weeks. If they do not have access to a device that they can listen to spotify on, an ipod will be provided. They will be asked to complete a 2-question survey via Redcap daily that asks them if they have listened to the designated music that day and for how long.
40929363|NCT05847712|OTHER|Simulated work in the heat|Participants perform a continuous moderate-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
41127632|NCT01605409|PROCEDURE|Emergency cardiopulmonary bypass under ongoing CPR|"Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT."
41127633|NCT01605409|PROCEDURE|Standard ACLS|"Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible."
41127634|NCT05047458|DRUG|ALXN2050|Powder-in-capsule (PIC).
40929364|NCT03729362|BIOLOGICAL|Cipaglucosidase Alfa|Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).
41127635|NCT05047458|DRUG|Placebo|PIC.
41127636|NCT04851743|OTHER|Dry needling|The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
41127637|NCT00405054|DRUG|MK0457|IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
41127638|NCT01334489|DEVICE|Arabin Cervical Pessary|"The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain."
41127639|NCT04185636|DEVICE|MolecuLight i:X imaging|The MolecuLight i:X Imaging Device will be used to take standard (ST) and fluorescent (FL) images of each graft site. The MolecuLight i:X will also be used to take measurements of the wound using the measurement feature of the device.
41127640|NCT01256242|DEVICE|Augment Rotator Cuff|rhPDGF-BB and bovine collagen matrix
41127641|NCT01256242|PROCEDURE|Standard Suture Repair|standard suture repair
41127642|NCT01258036|RADIATION|HRpQCT|High Resolution peripheral Quantitative Computerized tomography
41127643|NCT01258036|BIOLOGICAL|Sampling|Urine and blood samples
41127644|NCT01258036|RADIATION|Bone absorptiometry|DXA at the lumbar spine, hip, radius and whole body
41127645|NCT01343797|OTHER|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
41127646|NCT00005820|DRUG|nitrocamptothecin|
41127647|NCT06426966|DIETARY_SUPPLEMENT|Berberine|Berberine is an alkaloid derived from plants native to China called Rhizoma coptidis, Cortex phellodendrine and Hydrastis canadensis. These plants are used in the treatment of infectious diarrhea, inflammation, DM2, non-alcoholic fatty liver disease, dyslipidemias, cardiovascular diseases, and obesity. They have been shown to improve insulin sensitivity and stimulate glucose uptake through the activation of AMP-activated protein kinase (AMPK)
40929365|NCT03729362|DRUG|Miglustat|Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.
40929366|NCT03729362|BIOLOGICAL|Alglucosidase Alfa|Participants received an IV infusion dose over a 4-hour duration Q2W.
40929367|NCT03729362|DRUG|Placebo|Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
40929368|NCT01552733|DEVICE|'Inmotion Arm Robot'|To improve limb function in those with limb impairment
40929369|NCT01552733|OTHER|Standard of care|Rehabilitation Therapy
40929370|NCT06254222|OTHER|No intervention|No intervention
41127648|NCT06426966|DIETARY_SUPPLEMENT|Gymnema sylvestre|"Gymnema sylvestre also known as meshashringi, is a plant from central and southern India. The leaf extract has been used as a laxative, diuretic, and cough suppressant; Likewise, it has antimicrobial, antihypercholesterolemic, and hepatoprotective activities. It is associated with antioxidant properties . Its adjuvant effect has been reported in the therapy of type 2 diabetes, revealing how its active compounds can influence glucose regulation and improve insulin sensitivity."
41127649|NCT04000516|BEHAVIORAL|Time restricted feeding|Restricting the eating window to about 8 hours a day, during waking hours.
41127650|NCT01515501|PROCEDURE|Endoscopic mucosal resection (EMR)|EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
41448729|NCT05624788|OTHER|No Intervention|Participants who self-identify as American Indian or Alaska Native with any indication requiring referral to a specialist after a primary care provider standard of care visit will be observed to collect data, using several surveys at 6 and 12 months. No additional specialty care visits will be added for the purpose of this study given the intent to observe medical care received following primary care provider referral. Referral to a specialist will be based on local clinical practice.
40754828|NCT01433978|DRUG|Standard of care|"Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
40754829|NCT00134498|DRUG|torcetrapib/atorvastatin|
40754830|NCT00134498|DRUG|atorvastatin|
40754831|NCT04105660|OTHER|Training for EEG monitoring|Training for reading EEG curves during anaesthesia
40754832|NCT04105660|OTHER|Standard monitoring|Standard monitoring including clinical parameters and BIS index
40754833|NCT05986058|BEHAVIORAL|Golden Circle|The original Golden Circle project was deployed in response to the COVID-19 pandemic and the need to implement remote social services in South Korea. Golden Circle had the aim of building a case management model using a healthcare-oriented automation system based on wearable devices (smartwatches and mobile applications). Through innovative system expansions, the goals were to promote healthful CVH and physical function and cultivate self-care management skills in older Korean adults.
40754834|NCT05203237|BIOLOGICAL|VK2735|Administered SC
40754835|NCT05203237|BIOLOGICAL|Placebo|Administered SC
40754836|NCT05203237|DRUG|VK2735 Placebo|Administered orally
40929371|NCT05832931|DRUG|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
40754837|NCT05203237|DRUG|VK2735 Drug|Administered orally
40754838|NCT01991535|DEVICE|Spontaneous Ventilation Mode|"Respiratory rate and duration of inspiration are controlled by the patient.~Device model: Stellar 150® (ResMed, Australia)."
40754839|NCT01991535|DEVICE|Controlled Ventilation Mode|"Ventilator maintains the positive end-expiratory pressure until the patient inspires. At that point, the ventilator reaches the support pressure in a predetermined time. The patient fixes the respiratory rate and the duration of inspiration, triggering all the cycles.~Device model: Stellar 150® (ResMed, Australia)."
40754840|NCT01991535|DEVICE|Simulator Ventilation Mode|"Ventilator maintains a continuous positive airway pressure during the entire cycle.~Device model: Stellar 150® (ResMed, Australia)."
40754841|NCT04180423|DEVICE|Off-the-Shelf Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Off-the-Shelf implants use standard sizing.
41127651|NCT05566249|DEVICE|ArtiSential|Articulating laparoscopic instrument
41127652|NCT05092113|DRUG|a compound glutamine capsule/a compound glutamine capsule simulated placebo|A compound glutamine capsule/a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
41448730|NCT04171115|DRUG|G03-52-01|G03-52-01 administered intramuscularly
40929372|NCT05832931|DRUG|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
40929373|NCT05832931|DRUG|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
40929374|NCT04439565|GENETIC|movement|aortic dissection or aneurysm patients this is an observation cohort study about a Non-syndromic Familial Aortic Dissection without intervention.
40929375|NCT03306797|OTHER|STANDARD REHAB|"The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training with at least 6 exercises selected from:~wrist~* ulnarization radialization~* prono-supination~* horizontal flexion-extension~* vertical flexion-extension hand~* grasping~* pinching~* extensors~* interosseous shoulder-elbow~* vertical flexion-extension~* push forward"
40929376|NCT03306797|DEVICE|SONICHAND|"The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises selected from the list. The Leap Motion Controller is managed with an ad-hoc developed application that is able to associate the movements with a 4 notes arpeggio or with a modulated texture.~With the first mode the movement produces and modulates an harmonic progression built on the consecutive grades of the major scale played as ascending and descending arpeggio with also a volume crescendo and decrescendo.~With the second mode, the movement modulates the volume and the low-pass cutoff frequency of a synthetic texture."
40929377|NCT04858178|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
40929378|NCT04858178|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
40929379|NCT04858178|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
40929380|NCT04858178|DEVICE|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation will be applied at T7-L1 spinal segments to assess alterations in autonomic neuroregulation.
40929381|NCT03547115|DRUG|voruciclib monotherapy|Voruciclib will be administered orally
40754842|NCT04180423|DEVICE|Customized Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Customized implants are customized individually made knee implants which are designed specific to each patient's unique anatomy.
40754843|NCT00017186|DRUG|epirubicin hydrochloride|
40929382|NCT03547115|DRUG|voruciclib and venetoclax|Voruciclib and Venetoclax will be administered orally
41127653|NCT03150446|DEVICE|flexible cystoscopy|After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy. If the stent was well-placed, the flexible cystoscope was withdrawn. If the double-J stent was not visualized in the bladder, the surgeon pushed the stent inferiorly using a laparoscopic instrument and monitor A until the stent came out through the ureteral orifice on monitor B.
40754844|NCT00017186|DRUG|gemcitabine hydrochloride|
41127654|NCT04620200|DRUG|Nivolumab|3mg/kg
40754845|NCT03383133|DRUG|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
41127655|NCT04620200|DRUG|Ipilimumab|1mg/kg
41448731|NCT04171115|DRUG|Placebo|Placebo administered intramuscularly
41127656|NCT02462759|DRUG|Nusinersen|Administered by intrathecal injection.
40754846|NCT05556187|OTHER|Individualized automated oxygen titration|Automated oxygen titration based on the oxygen saturation during the entire day.
41127657|NCT02462759|PROCEDURE|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
41127658|NCT02583113|DEVICE|Total and Unicompartment Knee Replacement|Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
41127659|NCT04337931|DRUG|sotigalimab|Sotigalimab is a CD40 agonistic monoclonal antibody
41127660|NCT03556449|DIAGNOSTIC_TEST|High resolution ultrasound|Using a high-frequency linear array transducer (18L6 HD)
41448732|NCT05502835|DEVICE|pulse pressure variation|Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
41448733|NCT05502835|OTHER|conventional fluid management|Infusion of 6 ml/kg/hr. Ringer's solution.
41448734|NCT01733134|DRUG|Tolvaptan|Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
41448735|NCT01733134|DRUG|placebo|Patient in the placebo group will receive tolvaptan in addition to standard therapy
41127661|NCT05700487|OTHER|PELVIC FLOOR EXERCISES|Regular Pelvic floor exercises was performed three times a day for six months in the postoperative period
41127662|NCT01217905|DRUG|AZD7687|Oral suspension
41127663|NCT05773092|DRUG|Oral S-1 + Oral Osimertinib|S-1 (40mg) will be given orally twice a day (daily) from Day 1 to 14 (21 day cycle), and Osimertinib (80mg) will be given orally daily continuously.
41127664|NCT01463176|BEHAVIORAL|Music Therapy|Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
41127665|NCT03607175|DRUG|Triamcinolone-impregnated CMC foam|same information as included in the arm/group descriptions
41127666|NCT03607175|DEVICE|Propel Stent|same information as included in the arm/group descriptions
40754847|NCT02514746|BIOLOGICAL|Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine|0.5 mL subcutaneous injection
40754848|NCT05344274|DIAGNOSTIC_TEST|Indocyanine Green Angiography|Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow
40754849|NCT05344274|BIOLOGICAL|Isocapnic Oxygen|Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.
40754850|NCT05344274|DIAGNOSTIC_TEST|Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)|Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates
40754851|NCT03325803|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
40754852|NCT03325803|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 150 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
40754853|NCT03325803|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
40754854|NCT03325803|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
40919317|NCT02690571|OTHER|Bronchoscopy|The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
40919318|NCT05919706|BEHAVIORAL|Patient Education with Game-Based Mobile Technology and Motivational Interviewing|Education program, game-based mobile technology and motivational interview were applied to the patients in the experimental group. The patients' self-management, quality of life, and satisfaction level scores for the intervention were determined.
40919319|NCT01832584|DIETARY_SUPPLEMENT|RGC|
40919320|NCT01832584|DIETARY_SUPPLEMENT|Placebo|
41127667|NCT02958696|DRUG|HTL0018318|Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
41127668|NCT03514836|BIOLOGICAL|DCVac/PCa|"Oncolytic adenovirus containing immunostimulatory cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF). This is an experimental therapy.~DCVac/Pca consists of activated autologous dendritic cells. This is an experimental therapy."
41127669|NCT03514836|DRUG|Cyclophosphamide|immunomodulatory medication given around the ONCOS-102 dosing
41127670|NCT05786352|PROCEDURE|ERAS protocol|The combination of interventions explained in arm descriptions.
41448736|NCT03166267|DEVICE|External fixator|Tibia fracture (AO 41-43) treated with external fracture fixation (large external fixator)
41448737|NCT00506376|BEHAVIORAL|Interview|Interview that will take about 20 minutes to complete.
40919321|NCT05194371|RADIATION|definitive radiotherapy or definitive chemoradiotherapy|A total dose of radiation therapy should be more than 50Gy
40919322|NCT03438370|OTHER|Three monthly ART supply at CAGs|Sites where three monthly ART supply will be provided at outreaches
40919323|NCT03438370|OTHER|Six monthly ART supply at outreaches|Sites where six monthly ART will supply will be provided at outreaches
40919324|NCT04636216|BEHAVIORAL|COPE parent training|Weekly 1.5 hour parent training meetings for eight weeks
40919325|NCT02610504|DEVICE|Durolane|single injection of 3ml
40919326|NCT05680532|DIETARY_SUPPLEMENT|Black raspberry|Experimental group subjects were requested to take 50 g of Black Raspberry powder for 4 weeks.
40919327|NCT05680532|OTHER|Placebo|Placebo group subjects were requested to take 50 g of dextrin for 4 weeks.
40919328|NCT05258188|OTHER|Instrument-assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization is used for a mechanical benefit for the therapist providing deeper approach and braces remodeling of connective tissues through dissolution of extravagant fibrosis, while provoking repair and reconstructing forwarded by the recruitment of fibroblast.
41127671|NCT06307743|PROCEDURE|rapid local ischemic postconditioning|Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
41127672|NCT02663219|BEHAVIORAL|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
41127673|NCT02964741|DEVICE|Active Comparator|non-invasive brain stimulation (active protocol)
41277972|NCT05476796|DRUG|FOLFOX regimen|Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
41127674|NCT02964741|DEVICE|Sham Comparator|non-invasive brain stimulation (sham protocol)
41127675|NCT03450460|BEHAVIORAL|Peer support|The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
40754855|NCT03325803|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
40947875|NCT03467048|DEVICE|McGrath videolaryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
41277973|NCT05476796|DRUG|Nivolumab|Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
41277974|NCT04375800|DRUG|Doravirine|DOR capsules (3.2 to 100 mg); sachets (3.2 to 100 mg); or tablets (100 mg) taken once or twice daily by mouth.
41277975|NCT04375800|DRUG|2 NRTIs|Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
41277976|NCT04899908|RADIATION|Stereotactic Radiation|Focused radiation beams to treat tumors
40754856|NCT02526316|BIOLOGICAL|P16_37-63 peptide combined with Montanide® ISA-51 VG|Patients will receive P16_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
40929383|NCT03743974|PROCEDURE|arthroscopic shoulder surgery of rotary cuff (ISB)|ISB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
41127676|NCT05420480|PROCEDURE|Two-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
41127677|NCT05420480|PROCEDURE|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
40754857|NCT02526316|BIOLOGICAL|P16_37-63 peptide without Montanide® ISA-51 VG|Patients will receive 30 mcg P16_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
40754858|NCT03941262|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
40754859|NCT03941262|DRUG|Avelumab|Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).
40754860|NCT03941262|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
40754861|NCT06307444|PROCEDURE|Ultrasound-Guided Stellate Ganglion Block|high frequency (6 to 13 MHz) linear transducer will be placed perpendicular to the tracheal axis at the cricoid cartilage and will be moved inferiorly until the superior aspect of the thyroid gland is visualized. Later, the transducer should be relocated laterally to visualize the anterior aspect of the Chassaignac's tubercle on \[\]the C6 transverse process. The carotid artery, internal jugular vein, thyroid gland, trachea, Longus colli, and Longus capitis muscle, prevertebral fascia, the root of C6 spinal nerve, and transverse process of C6 can be identified. Color Doppler will be used to detect the position of the vessels. With an in-plane approach, 22 to 25 gauge echo-enhanced needle is placed beside the trachea with a lateral to medial direction.
40754862|NCT06307444|PROCEDURE|T2 T3 (High Thorathic) ESP Block|We will count the laminae in the cephaled-to-caudal direction, starting from the C7 using the US to determine the exact vertebral level where the needle will be inserted. A linear high-frequency ultrasound probe will be used to perform the blocks. After the determination of the needle insertion site, the US probe was placed over the spinous processes of the vertebrae at the midline in the longitudinal plane. The US probe will then slid laterally from the spinous processes to visualize the transverse process. The needle will be advanced posterior-to-anteriorly, in the caudal to cephalic direction using the in-plane orientation within paraspinal muscles, targeting the transverse process. When the tip of the needle reaches and contact the transverse process, the local anesthetic drugs(0.2-0.3ml/kg(11) of bupivacaine 0.25% 8mg Dexamethazone) will be administered
40754863|NCT01691092|DRUG|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
40754864|NCT05759364|DRUG|IV Papaverine 80 mg|Opium alkaloid antispasmodic drug
40754865|NCT05759364|DRUG|Placebo|Placebo
41127678|NCT05420480|PROCEDURE|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
40754866|NCT04568512|DIAGNOSTIC_TEST|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
40754867|NCT04568512|DIAGNOSTIC_TEST|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
41127679|NCT04413838|DRUG|NIVOLUMAB|IV injection within 30 minutes of 24ml file (=240 mg) containing NIVOLUMAB BMS(Bristol-Myers Squibb) 10mg/ml (immune check point inhibitor targeting PD-1) on top of routine standard of care for COVID-19 infection
41127680|NCT04413838|OTHER|Routine standard of care|No intervention is planned in this arm. Patients will follow routine standard of care for the COVID-19 treatment
41127681|NCT05099549|DRUG|AFM24|Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
41127682|NCT05099549|BIOLOGICAL|SNK01|Patient-specific ex-vivo expanded autologous natural killer cells.
41127683|NCT02157116|DRUG|cisplatin|
41127684|NCT02157116|DRUG|Docetaxel|
41127685|NCT02157116|DRUG|Pegfilgrastim|
41448738|NCT01927744|DRUG|Docetaxel|75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
41448739|NCT01927744|DRUG|Erlotinib|150 mg by mouth daily continuously until the day before surgery.
41448740|NCT01927744|OTHER|Placebo|150 mg by mouth daily continuously until the day before surgery.
40754868|NCT02057380|DRUG|linsitinib|oral
40754869|NCT02057380|DRUG|erlotinib|oral
40754870|NCT02057380|DRUG|paclitaxel|Intravenous (IV) infusion
40754871|NCT02057380|DRUG|Bortezomib|Subcutaneous or IV
40754872|NCT02057380|DRUG|Dexamethasone|IV, Oral
40754873|NCT04472208|DEVICE|Ambulatory monitoring solution|Subjects participating in this study will be monitored with the site's standard of care primary monitor and the evaluable device as the secondary monitor.
40754874|NCT01975285|DRUG|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
40754875|NCT01975285|DRUG|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
40754876|NCT01155310|DRUG|Helium/Oxygen 78%/22%|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
40754877|NCT01155310|DRUG|Air/Oxygen|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
40754878|NCT01257893|DRUG|Aspirin (acetylsalicylic acid)|Aspirin one 81 mg capsule per day for 10-14 consecutive days
40754879|NCT01257893|DRUG|Placebo|1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
40754880|NCT05789069|DRUG|HFB200603|Participants will be administered HFB200603 as described in the experimental arm.
40754881|NCT05789069|DRUG|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
40754882|NCT01596244|BEHAVIORAL|Microclinic|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
41448741|NCT01927744|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
40929384|NCT03743974|PROCEDURE|arthroscopic shoulder surgery of rotary cuff (CSB)|SCB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
40754883|NCT05165524|DEVICE|QS Nd:YAG laser|Patients will be treated with Quality-switched (QS) Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (MedLite® C6) operating at a wavelength of 1064 nm, fluence range from 2.1 J/cm2 to 8.1 J/cm2 with a 4-6mm spot size.
41448742|NCT01927744|BEHAVIORAL|Phone Call|Phone call made to patient 1 time each year after the end of treatment visit.
41448743|NCT01927744|DRUG|Chemotherapy|Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
40754884|NCT05165524|DRUG|Triple cream|Patients will be treated with a triple brightening cream (Pigmanorm®), applied daily, three times per week for 12 weeks on the lesion. Interruption for 4 days will be adopted in case of irritation/redness. 50+ sun protection cream will be used as well during the treatment period.
40754885|NCT04414202|PROCEDURE|tumorectomy with axillary dissection (sentinel lymph node)|All patients will have local excision of the primary tumor following appropriate clinical work-up. Surgery will be done according to usual local practice with a complete excision of the tumor. The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.
40754886|NCT04414202|RADIATION|per-operative partial irradiation|20 Gy of per-operative partial irradiation at the tumor site during the surgery
40754887|NCT06434506|OTHER|no intervention|No intervention
40754888|NCT03172559|RADIATION|Stereotactic body radiotherapy|The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
41448744|NCT04295486|DRUG|Aspirin|Non-enteric coated 81 mg Aspirin tablet.
41448745|NCT04422730|BEHAVIORAL|Psychological evaluation|Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups
41448746|NCT05703854|DRUG|CAR.70/IL15-transduced CB-derived NK cells|Given by IV (vein)
41448747|NCT05703854|DRUG|Fludarabine phosphate|Given by IV (vein)
41448748|NCT05703854|DRUG|Cyclophosphamide|Given by IV (vein)
41277977|NCT04899908|DRUG|AGuIX gadolinium-based nanoparticles|Intravenous injection
41277978|NCT04899908|OTHER|Placebo|Intravenous infusion
41277979|NCT00503399|DRUG|Teriparatide|20 µg/day sc for 18 months
41277980|NCT00503399|DRUG|Risedronate|35 mg/week po for 18 months
41448749|NCT01087502|DRUG|Glimepiride|1-4 mg daily after 12 weeks
41448750|NCT01087502|DRUG|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
41448751|NCT01087502|DRUG|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
40929385|NCT01115803|DRUG|LY2584702|Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
40929386|NCT01115803|DRUG|Erlotinib|"Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity."
40929387|NCT01115803|DRUG|Everolimus|Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
41127686|NCT06151314|PROCEDURE|Dental implants.|5 conventional implants measuring from 4 to 5 mm in width and 7 to 10mm in length according to the bone width were inserted in the mandible from right premolar area to left premolar area
41448752|NCT01087502|DRUG|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
41277981|NCT06118528|DEVICE|Blur Obfuscation|Blurring is applied to the RGB images.
41448753|NCT01087502|DRUG|Linagliptin|5 mg once daily
41448754|NCT05706909|DEVICE|Genex with ABMC|Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure
41448755|NCT05432804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41448756|NCT05432804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41448757|NCT05432804|DRUG|Selinexor|Given PO
41448758|NCT05432804|DRUG|Temozolomide|Given PO
41277982|NCT06118528|DEVICE|Cartoon Obfuscation|Cartoonization is applied to the RGB images.
41277983|NCT06118528|DEVICE|Edge Obfuscation|A black background and simple outlines of objects/people are applied to the RGB images.
41277984|NCT06118528|DEVICE|No Obfuscation (raw)|No editing is performed on the RGB images.
41277985|NCT06656949|PROCEDURE|injecting indocyanine green (ICG) dye Intraoperative|injecting indocyanine green (ICG) dye Intraoperative for patients with endometrial cancer
41277986|NCT06655896|BIOLOGICAL|rapcabtagene autoleucel|single infusion of rapcabtagene autoleucel
41277987|NCT06655896|BIOLOGICAL|rituximab|rituximab intravenous infusion (i.v.) as per protocol
41277988|NCT06228326|BIOLOGICAL|KB707|Genetically modified herpes simplex type 1 virus
41448759|NCT06627985|DIAGNOSTIC_TEST|GPT-4o|Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
41448760|NCT06627985|DIAGNOSTIC_TEST|GPT-4o mini|Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o mini. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
41277989|NCT03684655|DRUG|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
41277990|NCT05771428|DRUG|ABBV-552|Oral Capsule
41277991|NCT05771428|DRUG|Placebo for ABBV-552|Oral Capsule
41277992|NCT05273151|DEVICE|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
41277993|NCT00860470|DIETARY_SUPPLEMENT|Iron (27 mg) - folic acid (600 ug)|"Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
40754889|NCT04632381|DRUG|Zotatifin|Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).
40754890|NCT04632381|DRUG|Placebo|5% dextrose injection, USP
41277994|NCT00860470|DIETARY_SUPPLEMENT|Multiple micronutrient|"Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).~Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
41277995|NCT02725788|DEVICE|New PIV Dressing|A commercially available breathable, transparent film dressing with a soft-cloth border, notch and securement tape strip. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until the PIV catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
41277996|NCT02725788|DEVICE|Standard PIV Dressing|A commercially available breathable, transparent film dressing used with a one inch width piece of Transpore™ medical tape. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
41277997|NCT05910827|DRUG|HMBD-001|HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
41277998|NCT05910827|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
41277999|NCT05910827|DRUG|Cetuximab|Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
41278000|NCT04365374|DEVICE|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
41278001|NCT04365374|RADIATION|Stereotactic Radiation Therapy|External Beam Radiation Therapy
41278002|NCT06301854|DRUG|TPN171H|10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.
41278003|NCT06379347|DIAGNOSTIC_TEST|POCUS performed on clinical indication|POCUS performed on clinical indication
40754891|NCT01210443|DRUG|Sitaxentan|sitaxentan sodium 100 mg
41448761|NCT06627985|DIAGNOSTIC_TEST|MedicalGPT|Input all patient medical records, including text, examination reports, and imaging data, into MedicalGPT. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
40919329|NCT05258188|OTHER|Compressive Myofascial Release Technique|Compressive Myofascial Release Technique is a technique of soft tissue stretching that uses compression and sustained myofascial stretches to create a releasing force in the targeted area
41127687|NCT05577936|DEVICE|XPERIENCE Advanced Surgical Irrigation|A clear, colorless, aqueous solution that is indicated for use in the cleansing and removal of debris, including microorganisms, from wounds. Soak for 3 minutes for a total volume of 1L
41127688|NCT05577936|OTHER|Standard of Care Irrigation|17.5 mL povidone-iodine with 500 mL normal saline: solution (0.35%) for 3 minutes for a total volume of 1L (including a normal saline rinse)
40919330|NCT00229424|DRUG|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
40919331|NCT00229424|DRUG|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
40919332|NCT00229424|OTHER|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
40919333|NCT02972567|DIETARY_SUPPLEMENT|Lactobacillus spp|9 log10 cfu/capsule. 1 capsule/day for 12 weeks
40919334|NCT02972567|DIETARY_SUPPLEMENT|Control|Maltodextrin
40919335|NCT05973721|BIOLOGICAL|phage|The treatment group was given one phage each time, once a day for two weeks
40919336|NCT04500561|DRUG|YY-20394|Yy-20394 combined with Gemcitabine and Oxaliplatin was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of Gemcitabine and Oxaliplatin was treated according to clinical standards.
41448762|NCT06627985|DIAGNOSTIC_TEST|Claude-3.5 Sonnet|Input all patient medical records, including text, examination reports, and imaging data, into Claude-3.5 Sonnet. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
41448763|NCT06627985|DIAGNOSTIC_TEST|Claude 3 Haiku|Input all patient medical records, including text, examination reports, and imaging data, into Claude 3 Haiku. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
41448764|NCT06627985|DIAGNOSTIC_TEST|Real Doctors|Retrospectively collect the diagnostic and treatment recommendations from the corresponding departments involved in the multidisciplinary treatment of past patients, as well as the overall recommendations.
41448765|NCT03560843|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction
41448766|NCT00573313|DRUG|S-adenosylmethionine|Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
41448767|NCT00573313|DRUG|Placebo|Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
40754892|NCT04993911|OTHER|Experimental Group|"Assessment will be performed pre and post of intervention. Intervention will be given 3 days a week for 8 weeks. Each session will include a 5-min warm-up on a fitness bike or treadmill before commencement of the program and a 5-min cool period. Participants of this group will receive balance training with conventional treatment. Participants will perform between 2 sets of 5 and 7 repetitions of each exercise.~Single leg balance~* Walking forward~* Walking backward~* Side stepping~* Walk heel to toe~* Static exercises with eyes close or open~CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position"
40919337|NCT04253054|OTHER|Cardiovascular risk factors|Different level of cardiovascular risk factors, such as aging, hypertension, diabetes, dyslipidemia, smoke, alcohol drink, obesity and et al, associated with genetics, environments and lifestyles
41448768|NCT03462342|DRUG|Olaparib Pill|"For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
41448769|NCT03462342|DRUG|AZD6738|"For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
41448770|NCT05384769|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy
41448771|NCT05384769|PROCEDURE|Low Dose Computed Tomography of the Chest|Undergo low dose CT
41448772|NCT05384769|OTHER|Survey Administration|Ancillary studies
41448773|NCT00169364|DEVICE|positron emission tomography|
41448774|NCT00952939|GENETIC|fluorescence in situ hybridization|At time of surgery
41448775|NCT00952939|OTHER|laboratory biomarker analysis|At time of surgery
40919338|NCT04253054|OTHER|Aging related health problems|Aging related health problems
40919339|NCT03584581|DIETARY_SUPPLEMENT|Olive polyphenols|The amount of polyphenols to be supplied is within the ranges of absolute biosecurity food described by different authors and used in different studies.
40919340|NCT03584581|DIETARY_SUPPLEMENT|Control|Placebo
40919341|NCT03196492|OTHER|No intervention|No intervention
41278004|NCT04815096|DRUG|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
41448776|NCT00952939|PROCEDURE|fine-needle aspiration|At time of surgery
41448777|NCT00952939|PROCEDURE|therapeutic conventional surgery|At time of surgery
41448778|NCT00952939|OTHER|Questionnaires|The MINI (a structured psychiatric interview) will be administered to all patients that had a pre or post-operative HADS score for suggestive or probable depression or anxiety. A semi-structured interview would be administered to those patients who had some or full decision regret pre-operatively. After completion of the interview, the MINI, a structured psychiatric interview, will be administered.
41448779|NCT03187821|PROCEDURE|Laser peripheral iridotomy|location of laser peripheral iridotomy
41448780|NCT02393014|PROCEDURE|Simple physical exercises|"1. The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~2. The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~3. The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not."
41448781|NCT04332445|OTHER|Hyaluronic Acid Gel|Health care product - to be apllied on the subject's skin
41448782|NCT05078879|DRUG|Empagliflozin|This is an open-label pilot study to evaluate the efficacy, safety, and tolerability of empagliflozin as a treatment for severe congenital neutropenia (SCN) in patients with glucose-6-phosphatase 3 (G6PC3) deficiency. Participants will be on a 12-month daily regimen of empagliflozin at a starting dose of 10 mg (phase A), which may be increased after 2 months to 25 mg (phase B). Evaluate the safety and efficacy of the biomarker response (the change in absolute neutrophil count \[ANC\] after one year of empagliflozin treatment relative to baseline ANC prior to drug treatment) in patients with G6PC3 deficiency.
41448783|NCT03658954|BEHAVIORAL|Advice|Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep health advice.
41278005|NCT04077463|DRUG|Lazertinib|Lazertinib will be administered orally.
40919342|NCT01039103|DRUG|PEG-liposomal prednisolone sodium phosphate|PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
41278006|NCT04077463|DRUG|Amivantamab|Amivantamab will be administered as an intravenous (IV) infusion.
41448784|NCT03658954|BEHAVIORAL|Self-monitoring|Participants will complete daily smartphone-based sleep and alcohol diaries for two weeks.
41448785|NCT03658954|BEHAVIORAL|Feedback|Participants will receive feedback once per week for two weeks on their sleep and alcohol consumption, using all possible data derived from Philips actiwatches and SCRAM ankle biosensors \& tailored coaching with a health coach
41278007|NCT04077463|DRUG|Carboplatin|Carboplatin will be administered as IV infusion.
41278008|NCT04077463|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion.
40919343|NCT01039103|DRUG|Methylprednisolone|Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
41278009|NCT04030130|BEHAVIORAL|NDURE|NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months).
41278010|NCT03367156|DRUG|Dexamethasone|Given PO
41278011|NCT03367156|OTHER|Placebo|Given PO
41278012|NCT03367156|OTHER|Questionnaire Administration|Ancillary studies
41278013|NCT04855695|DRUG|Acalabrutinib|"Each study drug is given according to a different schedule:~Acalabrutinib: Oral, dosage per protocol, start cycle 1 and beyond according to schedule outlined in protocol"
41278014|NCT04855695|DRUG|Venetoclax|Venetoclax: oral. daily, dosage per protocol, start cycle 3 and beyond according to schedule outlined in protocol
41278015|NCT04855695|DRUG|Obinutuzumab|Obinutuzumab: intravenous infusion, dosage per protocol, drug during cycles 2 and beyond according to schedule outlined in protocol
41278016|NCT05091346|DRUG|E7386|E7386 tablet.
41278017|NCT05091346|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
41278018|NCT05091346|DRUG|Lenvatinib|Lenvatinib capsule.
41278019|NCT06657534|PROCEDURE|Push-pull technique|push-pull technique as described by McBride et al, J Infus Nurs 2018
41278020|NCT06657534|PROCEDURE|SOC (Standard of care)|Standard of care method to obtain blood with waste blood
41278021|NCT06129084|GENETIC|FGFR Testing|Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.
41278022|NCT05379634|DRUG|Nipocalimab|Nipocalimab will be administered intravenously in double-blind period and LTE period.
41127689|NCT02681900|BEHAVIORAL|Self-affirmation manipulation task|Participants in the self-affirmation condition indicate their most important value, give three examples of why this value is important to them and one example of something they had done to demonstrate its importance.
41127690|NCT02681900|BEHAVIORAL|Control task|People in the control condition indicate their least important value, three examples of why that value could be important to someone else, and describe something that person could do to show its importance.
41127691|NCT03575624|BEHAVIORAL|Nutritional and goal-setting education, yoga|"This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice"
41127692|NCT01333800|DRUG|Beclomethasone|200 to 400 mcg per day for 6 months
41127693|NCT01333800|DRUG|Ciclesonide|80 to 160 mcg per day for 6 months
41127694|NCT02839395|OTHER|No intervention- base line|the subject will sited in a dim light room. No screen light illumination.
41127695|NCT02839395|OTHER|Acute|The subject will be sited in front of computer screen light illumination for 2 hours.
41278023|NCT05379634|OTHER|Placebo|Nipocalimab matching placebo will be administered intravenously in double-blind period.
41278024|NCT05379634|DRUG|Glucocorticoids|Prednisone or equivalent will be administered orally as Glucocorticoid.
41278025|NCT03754933|BIOLOGICAL|Ad/PNP|Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase
41278026|NCT03754933|DRUG|Fludarabine Phosphate|Fludarabine phosphate is an anticancer agent currently used to treatment patients with chronic lymphocytic leukemia.
41278027|NCT06135337|DEVICE|Thioderm Elate|Test Device
41278028|NCT06135337|DEVICE|Juvéderm Ultra 3|Active Comparator Device
41278029|NCT03542188|BEHAVIORAL|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
41278030|NCT03542188|BEHAVIORAL|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.
41278031|NCT05219812|DRUG|BAY2395840|Tablet, intake orally.
41278032|NCT05219812|DRUG|Placebo for BAY2395840|Tablet, intake orally.
41278033|NCT01737775|PROCEDURE|Diaphragmatic amplitude measurement|Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
41278034|NCT02203682|DRUG|Doxycycline hyclate|Tab. Doxycycline 50 mg PO per day for 12 weeks
41278035|NCT02203682|DRUG|Placebo|Tablet placebo for 12 weeks
41448786|NCT05874843|DIAGNOSTIC_TEST|Thromboelastography (TEG 6S)|The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.
41127696|NCT02839395|OTHER|Chronic|The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
41278036|NCT06475404|BIOLOGICAL|verenafusp alfa 6 mg/kg|Single intravenous administration of 6 mg/kg of verenafusp alfa
41278037|NCT06475404|BIOLOGICAL|verenafusp alfa 9 mg/kg|Single intravenous administration of 9 mg/kg of verenafusp alfa
41278038|NCT06475404|BIOLOGICAL|verenafusp alfa 12 mg/kg|Single intravenous administration of 12 mg/kg of verenafusp alfa
41278039|NCT03216616|BEHAVIORAL|Cognitive Behavioural Therapy|
41278040|NCT06657456|DIETARY_SUPPLEMENT|Phytosterol-rich extract|Experimental product: extract rich in phytosterols
41127697|NCT00843934|DRUG|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
41127698|NCT00843934|DRUG|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
41127699|NCT02203500|DRUG|Lacidipine|
41127700|NCT02203500|DRUG|Telmisartan|
41127701|NCT03551379|DEVICE|Double Balloon Endoluminal Platform|A DBA platform will be use din this registry study to facilitate ESD
41127702|NCT03311360|DEVICE|drug-coated balloon|Orchid and Dahlia DCB
41127703|NCT03311360|DEVICE|bare metal stent|any type of bare metal stent
41127704|NCT01841671|BIOLOGICAL|IPV|Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
41127705|NCT01841671|BIOLOGICAL|bOPV|As indicated
41127706|NCT01841671|BIOLOGICAL|mOPV type 2|Administered at 28 weeks of age to all study participants
41127707|NCT01841671|BIOLOGICAL|Rotarix|Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
41127708|NCT00750620|DRUG|YM178|oral
41278041|NCT06657456|DIETARY_SUPPLEMENT|Placebo|Product with identical characteristics to the experimental product.
41278042|NCT06656988|DRUG|CO2|CO2 will be used as contrast medium sparing strategy during peripheral angiography
41278043|NCT06656988|DRUG|Iodinated Contrast Media (ICM)|Iodinated contrast medium will be used as in routine care during peripheral angiography
41278044|NCT04726306|DIAGNOSTIC_TEST|Otic Barotrauma Grading System|Otic Barotrauma Grading System Placards for TEED Score and the OGS grading system.
41278045|NCT06602362|OTHER|Partnered sex involving choking|When a subject submits a survey indicating that they engaged in partnered sex involving choking, they will be asked to come in for data collection within 24 hours of survey submission.
41448787|NCT03090880|DRUG|Tinzaparin Sodium|Subcutaneous tinzaparin 4,500 IU once daily for six months.
41448788|NCT00360607|DRUG|Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.|
40929388|NCT04367571|OTHER|Osteopathic Manipulative treatment (OMT)|"OMT techniques were focused on correcting the dysfunctions found before each OMT session and included myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field.~OMT group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
41448789|NCT00360607|DRUG|Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited|
41448790|NCT00360607|DRUG|Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.|
40929389|NCT04367571|OTHER|Manual Placebo (MP)|"The MP treatment consists of passive touch without joint mobilization in a protocolled order. The practictioners will be standing next to the bed, they'll touch lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they'll touch for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest for 5 minutes each.~MP group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
41127709|NCT02808351|DRUG|Berberine|
41127710|NCT02524769|DRUG|conjugated estrogen|0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
41127711|NCT00333372|DRUG|Z-338|
41127712|NCT00281892|BIOLOGICAL|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
41127713|NCT00281892|DRUG|Fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
41127714|NCT05340231|DRUG|TACE protocol|"Transarterial infusion chemotherapy: Oxaliplatin(85mg/m\^2)+Raltitrexed(3mg) Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)，The endpoint for embolization was defined as stagnation of blood flow of the posterior mesenteric artery.~Intervention cycle：4W; Treatment times: 2. followed by mFOLFOX6"
41127715|NCT05340231|DRUG|Neoadjuvant Chemotherapy|mFOLFOX6, Q2W
41278046|NCT06602362|OTHER|Partnered sex not involving choking|When a subject submits a survey indicating that they engaged in partnered sex that did not involve any choking, they will be asked to come in for data collection within 24 hours of survey submission.
41278047|NCT06657261|PROCEDURE|The patient group receiving deep and superficial serratus anterior plane block|The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
40754893|NCT04993911|OTHER|Control Group|"Participants of this group will receive only conventional therapy which will include; before beginning the program, each session will feature a 5-minute warm-up on a fitness bike or treadmill, followed by a 5-minute cool-down. Participants of this group will receive only conventional therapy which will include.~* CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position"
40754894|NCT01928537|DRUG|rigosertib sodium|
41127716|NCT02813954|DEVICE|Blood Gas Sampling|analyzing amniotic fluid by blood gas device
41448791|NCT00360607|DRUG|Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.|
41448792|NCT05836103|BEHAVIORAL|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
41448793|NCT01321567|DRUG|rabeprazole sodium|Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
41127717|NCT06404723|DIAGNOSTIC_TEST|Fibrinogen to albumin Ratio and C-reactive to Albumin Ratio|to detect their relation to disease activity to use as predective and prognostic tools
41127718|NCT05299346|OTHER|Follow up|Comprehensive follow up in dedicated follow up unit
41448794|NCT06627023|DEVICE|Implant Placement with Conical or Butt-Joint Connection|Thirty eight patients were enrolled in the study and received randomly allocated implants with conical and butt-joint implant-abutment connection type. A standard healing abutment was placed after 6 months for two weeks. The definitive screw retained crowns were manufactured in a digital workflow. The soft tissue profile was digitized using IOS on following stages: pre-op, post-op: immediately, two, 7 and 14 days, pre-exposure, immediately after exposure, two weeks after exposure (pre-delivery), immediately after crown delivery, 6 and 12 months post-op.
41448795|NCT00063687|DRUG|Oxypurinol|
41448796|NCT00099151|BEHAVIORAL|Caloric Restriction (CR)|
41448797|NCT00099151|BEHAVIORAL|Exercise|
41448798|NCT04773600|DRUG|Roflumilast Cream|Roflumilast cream 0.15% for topical application
41448799|NCT04773600|DRUG|Vehicle cream|Vehicle cream for topical application
41448800|NCT00744679|DRUG|Natalizumab|Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
41448801|NCT00155220|DEVICE|Low Stretch Bandage and Kinesio Tape|
41448802|NCT06474936|BEHAVIORAL|Food education|During the consultations are planned at least 6 nutritional education sessions in which the general nutritional advice provided by the Mediterranean Diet will be exposed, and some paper materials can be delivered according to the needs of each individual. 3 in-person meetings and 3 online meetings are planned. Both online and in-person food education sessions will be conducted by experienced nutrition experts monthly. These sessions will cover a range of topics, including the principles of the Mediterranean diet, practical cooking skills, meal-planning strategies, and tips for incorporating Mediterranean-style dishes into daily life
41278048|NCT06657261|PROCEDURE|The patient group receiving a combination of deep serratus anterior plane block and transverse thoracic muscle plane block|The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
41127719|NCT00201149|BEHAVIORAL|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
41278049|NCT01798303|DRUG|LY2940094|Administered orally
41278050|NCT01798303|DRUG|Placebo|Administered orally
41448803|NCT01602575|BEHAVIORAL|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
41448804|NCT03828708|OTHER|Iron in infant formula|Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
41278051|NCT01299025|OTHER|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
41278052|NCT00444015|DRUG|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
41278053|NCT06604325|DRUG|Tranexamic acid injection|All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
41278054|NCT06604325|DRUG|Placebo|All women recruited to Group B will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
41448805|NCT06621784|OTHER|Core stabilization exercises|In most studies, exercises focused on the extremities have been researched. We believe that the positive effects of the core region on walking and postural stability will play a significant role in the treatment of knee osteoarthritis.
41448806|NCT06621784|OTHER|Classical exercise therapy|In the first group of our study, we prescribed exercises that have been proven effective in many studies, are frequently prescribed, and focus on joint range of motion and quadriceps strengthening
41448807|NCT01442376|DRUG|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
41448808|NCT01442376|DRUG|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
41448809|NCT01442376|DRUG|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
41448810|NCT01442376|DRUG|Placebo to Ondansetron|
41448811|NCT01442376|DRUG|Placebo to Ondansetron|
41448812|NCT01442376|DRUG|Placebo to Palonosetron|
41448813|NCT00636545|DRUG|Oblimersen (Genasense)|Intravenous
41448814|NCT00636545|DRUG|Oblimersen (Genasense)|Intravenous
41448815|NCT00700739|DEVICE|DISCOVER™ Artificial Cervical Disc|DISCOVER™ Artificial Cervical Disc
41448816|NCT00700739|DEVICE|ACDF|Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
40929390|NCT06076278|PROCEDURE|resistance exercise|Isometrics contraction of quadriceps Supine straight leg raise Leg lifts in prone position Passive knee flexion Passive knee extension Resistance knee extension Resistance knee flexion Isometric terminal knee extension in lying and mini-squat Concentric and isometric knee extension and flexion in sitting Frequency: A total of 12 sessions, thrice a week, for 4 consecutive weeks. Time Duration: Approx. 25 to 30minutes
41448817|NCT01461785|BIOLOGICAL|Addition of PRP ( platelet rich plasma) to the lipograft|"27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).~The lipograft of Group A will be enriched with 3ml of autologous PRP"
41448818|NCT01461785|PROCEDURE|Lipofilling of the midface|The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
41448819|NCT00137254|DRUG|Insulin|IV insulin
41127720|NCT03239301|PROCEDURE|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
41127721|NCT03239301|PROCEDURE|Robotic REhabilitation|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. Assistive component of the robotic arm was adjusted in accordance with motor level of each patient. Variety and difficulty of games were chosen according to the ability and functional status of the patients. Variety and difficulty level of the games were modified according to progress of patients by the same physiotherapist.
41278055|NCT05648474|DIAGNOSTIC_TEST|Somatosensory evoked potential [SSEP] intraoperative monitoring|No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery
41278056|NCT04646395|DRUG|Tafasitamab|200 mg powder for reconstitution with 5 ml water for injection
41278057|NCT04646395|DRUG|Acalabrutinib|100 mg hard gelatin capsules
41278058|NCT05142709|DRUG|Anti-PD-1 Immune Checkpoint Inhibitors|used as 1st line treatment for metastatic ESCC.
41278059|NCT06584279|DIAGNOSTIC_TEST|Biopsy of the prostate and pathological diagnosis|Whether the index-lesion-contralateral systematic biopsy was performed
41278060|NCT05878184|DRUG|SC291|SC291 is an allogeneic CAR-T cell therapy
41278061|NCT06028438|DRUG|Placebo|Placebo will be administered intravenously.
41278062|NCT06028438|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
41448820|NCT00137254|DRUG|Stable Isotopes|IV administration of stable isotopes
41448821|NCT00137254|DRUG|Indocyanine Green|IV administration of ICG
41127722|NCT00733174|DRUG|Rosiglitazone|tablet
41127723|NCT00733174|DRUG|Placebo|
41278063|NCT06028438|DRUG|Certolizumab|Certolizumab will be administered subcutaneously.
41127724|NCT01804387|DRUG|telbivudine plus adefovir|telbivudine 600 mg qd plus adefovir 10 mg qd
41278064|NCT06401980|DRUG|Darolutamide|Darolutamide will be supplied in bottles as 300 mg film-coated tablets for oral intake
41278065|NCT06401980|OTHER|Standard of care|"* Docetaxel~* Cabazitaxel~* LuPSMA~* Radium 223~* Olaparib, in case of BRCA1 or 2 mutated or HRR deficient tumors~The standard of care is chosen by the local investigator and respecting the country specific approvals."
41278066|NCT02659930|DRUG|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
41127725|NCT01804387|DRUG|lamivudine plus adefovir|lamivudine 100 mg qd plus adefovir 10mg qd
41127726|NCT03484741|BIOLOGICAL|MSC and PRP|MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.
41278067|NCT02659930|DRUG|pomalidomide|pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
41278068|NCT05784246|DRUG|Mirikizumab IV|Administered IV
41278069|NCT05784246|DRUG|Mirikizumab SC|Administered SC
41278070|NCT05426356|DEVICE|Surgical Intervention|Surgical sacral fracture fixation and SI joint fusion using iFuse-TORQ
41278071|NCT05426356|OTHER|Non-Surgical Management|Non-surgical management (NSM) is any treatment deemed appropriate for the subject that does not involve surgery.
41448822|NCT04454229|OTHER|Direct oral penicillin challenge|The patient will receive a single dose of oral penicillin, following baseline vital signs.
41448823|NCT04454229|OTHER|Standard of care|Routine management as per the treating clinicians that include skin prick and intradermal beta-lactam testing, followed by oral penicillin challenge in the setting of negative skin testing.
41448824|NCT04764175|BEHAVIORAL|Telephone All Nations Breath of Life|Same as described above.
41448825|NCT04764175|BEHAVIORAL|Comparison Program|Same as described above.
41448826|NCT00299871|DRUG|LIXISENATIDE (AVE0010)|
41448827|NCT02208128|DRUG|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
41127727|NCT06371456|PROCEDURE|epidural catheter placement|after sterilization of the back, local anesthesia injection (xylocaine 5 ml) at lumbar 4-5 level, then advancing the epidural needle till loss of resistance by air occurs and the epidural catheter inserted then aspiration through the catheter will be done to confirm that no accidental cerebrospinal fluid or blood are aspirated and to observe the dew sign inside the outer portion of the epidural catheter near the back of the patient
41278072|NCT06132568|DEVICE|VITALYST System|The VITALYST System is a temporary ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively in hemodynamically stable subjects with severe coronary artery disease.
41448828|NCT06626997|DIETARY_SUPPLEMENT|Kombucha tea|"During Visit 1 (week 0), a fasting blood test must be performed at the IMDEA Alimentación facilities to obtain different markers: blood lipids, blood glucose, etc. Approximately 20 mL will be extracted (for comparison, keep in mind that a donation requires 450 mL). The blood sample will be extracted by qualified nursing staff from the UNILABS Laboratory. The blood tests based on the security and privacy requirements for handling samples will be carried out by the same laboratory.~You will also be asked to provide the stool sample that you must have collected at home prior to attending that visit with the material provided at the screening visit (V0) and at the intermediate visit (V2)."
41448829|NCT04352062|DRUG|Melatonin|
41448830|NCT04352062|OTHER|placebo|
41448831|NCT04352062|DRUG|Pantoprazole 40mg|pantoprazole 2 x 40mg
41448832|NCT04352062|DRUG|Amoxicillin|Amoxicillin 2 x 1000mg
41448833|NCT04352062|DRUG|Levofloxacin 500mg|Levofloxacin 2 x 500mg
41448834|NCT04480983|DEVICE|Multidetector Computerized Tomography (MDCT)|To evaluate the role of MDCT in diagnosis of non traumatic causes of acute abdomen in pediatric patients with clinical and surgical correlation.
40929391|NCT00600054|BIOLOGICAL|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
40929392|NCT03956069|BIOLOGICAL|blood sample|for patient and its parents
41127728|NCT00077675|DRUG|Telavancin|Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days
41278073|NCT05553132|COMBINATION_PRODUCT|Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier|Cartilage cells are being used from the rim of the defect in the hip and recycled to help make new cartilage in the hip. There are not enough cartilage cells to fill the defect so cartilage cells need to be mixed with MSCs. MSCs or Mesenchymal Stem Cells are naturally occurring cells that provide growth factors and cell signals that play a role in tissue repair. MSCs can be found in bone marrow and in the fatty tissues (i.e., area under the skin of the belly or breast) of patients. Fibrin glue is a product made from the naturally occurring compounds in blood which cause clotting. This glue hardens into a gel-like substance into which cells such as cartilage cells (chondrons) and AMSCs can be placed.
41278074|NCT05041101|DRUG|Eribulin Mesylate|Given IV
41278075|NCT05041101|DRUG|Grapiprant|Given PO
41448835|NCT05633862|DRUG|BI 1015550|BI 1015550
41448836|NCT03095248|DRUG|Selumetinib|Continuous twice daily dosing; oral agent
41448837|NCT00830414|DRUG|medroxyprogesterone acetate|IM Injection
41448838|NCT00830414|DRUG|medroxyprogesterone acetate|IM injection
41448839|NCT03644550|DRUG|LMB-100|Given intravenous (IV) at recommended phase 2 dose (RP2D) on days 1, 3 and 5 of two (2) 21 day cycles.
40929393|NCT03956069|GENETIC|genome sequencing|whole genome sequencing
41448840|NCT03644550|BIOLOGICAL|Pembrolizumab|Given intravenous (IV) at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.
41448841|NCT04605211|BEHAVIORAL|Online Mindfulness Meditation|Complete online audio-based mindfulness meditation exercises
41448842|NCT04605211|OTHER|Internet-Based Webinars|Attend webinars
41448843|NCT05492032|DEVICE|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
40929394|NCT01569464|DRUG|Rotigotine|"Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)"
40929395|NCT01569464|OTHER|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.~7 weeks (titration plus maintenance)"
41127729|NCT00077675|DRUG|vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
41127730|NCT00279981|DEVICE|Diagnostic|
41127731|NCT03486574|DIAGNOSTIC_TEST|Positive result from pathological test|Presence/absence of gastric cancer will be evaluated by upper gastroendoscopy or results of pathological test
41278076|NCT05634499|DRUG|Giredestrant|Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles. After completion of 6 cycles, the participant and investigator can choose to continue study treatment for an additional 18 cycles or discontinue study treatment and receive investigator-determined care.
41448844|NCT05492032|DEVICE|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
40929396|NCT05272436|DEVICE|Virtual Reality Upper Limb Motor Impairment Rehabilitation|Patients wore a VR headset while undergoing their physical rehabilitation at home
40754896|NCT04188626|BEHAVIORAL|Driving simulator sessions|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving. This autonomous driving will be interrupted by take-over requests related to events that disrupt autonomous driving. During autonomous driving, the driver will have to disengage from driving by performing non-related driving tasks. During each non-related driving tasks, a take-over request will be sent. Electrophysiological (EEG, ECG, EDA, EMG, respiration) and behavioural data will be recorded before, during and after the take-over control.
40754897|NCT01190371|DRUG|Artesunate|Oral, once daily, 7-day regimen of artesunate 2mg/kg/day
40754898|NCT05647382|DIAGNOSTIC_TEST|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
40754899|NCT02501785|BEHAVIORAL|Caregiver Reaction Assessment (CRA)|
40929397|NCT00397943|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
40929398|NCT00397943|BIOLOGICAL|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system|Intramuscular injection, 2 doses at 0, 1 month
40929399|NCT00397943|BIOLOGICAL|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline|Intramuscular injection, 2 doses at 0, 1 month
40929400|NCT00397943|BIOLOGICAL|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
41127732|NCT01577524|DRUG|Povidone-Iodine|Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
40929401|NCT06178705|BEHAVIORAL|Helpful Parenting Program Intervention|8-10 sessions with 60 minutes duration once in a week will be conducted with the parents in group and one-on-one setting. Helpful parenting program would be based on social learning theory, behavior modification and couple counseling. The program will be used as an intervention strategy with parents to built insight about their child's emotional \& behavioral issues. Different strategies to teach parenting skills will also be used as an intervention. Further more, this program will target parents' psychological distress and couples' problematic conflicts regarding parenting
40929402|NCT04318145|DRUG|PL-3994 Aqueous Intravenous Solution Dose Ascention|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
40929403|NCT04318145|DRUG|PL-3994 Aqueous Intravenous Solution Single Dose|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
40929404|NCT05896280|PROCEDURE|EST|Stones are taken by cutting the papillary sphincter
40929405|NCT05896280|PROCEDURE|ECPP|During ERCP, a generous biliary sphincterotomy (\>1 cm) will be performed to facilitate large stone extraction by use of a lithotripsy basket and a stone extraction balloon. After all stone fragments were cleared from the bile duct, this group will undergo ECPP after EST. A single-pigtail biliary stent will be placed (suspended overlength biliary stent, 7F × 20 cm). Then the rotatable repeatable opening and closing of soft tissue clamps (referred to as harmony clips, Mico-Tech, ROCC-D-26-195) should be applied to extend the bile duct axially, linear clamp the incised duodenal papilla, taking care to avoid clamping the bile duct stent, and removing the bile duct stent 3 weeks after ECPP.
40929406|NCT03411837|BIOLOGICAL|Dupilumab|Biologic (monoclonal antibody)
40929407|NCT03276520|DIAGNOSTIC_TEST|ethyl glucuronide|alcohol urine screening with ethyl glucuronide
40929408|NCT03276520|DIAGNOSTIC_TEST|ethanol|alcohol urine screening with ethanol
40929409|NCT03989869|OTHER|Immediate treatment|Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy
40929410|NCT04581629|DRUG|Encaleret|Tablets administered orally
40929411|NCT00210860|DRUG|topiramate|
41127733|NCT01577524|DRUG|Saline|Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
41127734|NCT05524714|DIETARY_SUPPLEMENT|solubilized Xanthohumol low dose|single administration of 2 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol and 2 soft gelatine capsules containing only micelles
41127735|NCT05524714|DIETARY_SUPPLEMENT|solubilized Xanthohumol high dose|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
41127736|NCT05524714|DIETARY_SUPPLEMENT|native Xanthohumol low dose|single administration of 2 hard gelatine capsules each containing 43 mg native Xanthohumol and 2 hard gelatine capsules containing silicon dioxide
41127737|NCT05524714|DIETARY_SUPPLEMENT|native Xanthohumol high dose|single administration of 4 hard gelatine capsules each containing 43 mg native Xanthohumol
41127738|NCT00310973|BEHAVIORAL|Social Network Intervention|
41127739|NCT00913289|BIOLOGICAL|adipose tissue derived stromal cells|dosage
40929412|NCT02725489|BIOLOGICAL|Vigil|Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
41127740|NCT00753493|DRUG|intravenous topiramate|Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
41127741|NCT04691024|OTHER|Exercise|Spinal stabilization exercises
41278077|NCT06059586|BEHAVIORAL|Pelvic health therapy|Female Sexual Function Index (FSFI) and VAS Pain Scale Questionnaires, Physical Therapy Evaluation including Pelvic Floor Muscle Examination, Dilator Education
41127742|NCT03614273|DRUG|Hypertonic saline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
41127743|NCT03614273|DRUG|Adrenaline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
41278078|NCT06059586|DEVICE|Dilator feasability|Patient Adherence to Vaginal Dilation Questionnaire
40929413|NCT02725489|DRUG|Durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
40929414|NCT06019338|OTHER|Pain Diary use|Validation of a pain diary specifically designed to capture pain dimensions of Trigeminal Neuralgia
40929415|NCT02110602|OTHER|Diet high in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
40929416|NCT02110602|OTHER|Diet low in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
40929417|NCT01181401|DRUG|TPF induction chemotherapy|Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
40929418|NCT01181401|DRUG|TPF experimental|Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
40929419|NCT01181401|RADIATION|Standard Radiochemotherapy (HART)|Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
40929420|NCT04545970|COMBINATION_PRODUCT|Facial cleanser|Facial cleanser to be used by study participants
40929421|NCT04545970|COMBINATION_PRODUCT|Facial moisturizer|Bland moisturizer to be used by study participants after serum in the evening.
40929422|NCT04545970|COMBINATION_PRODUCT|Sunscreen|Sunscreen to be applied after application of serum in the morning.
40929423|NCT04297657|OTHER|Counselling|o An appointment was made with the women in the experimental group at a time when they were available and a suitable environment was arranged in the hospital. The counselling programme of the experimental group was conducted in four sessions one week apart. In addition, each woman in the experimental group was given a counselling booklet and compact disc. The interviews lasted between 15- 45 minutes. The topics of interest among women were noted in the interviews and after the information on the subject was received, feedback was given to the relevant woman through a phone call.
40929424|NCT06020638|DEVICE|Experimental group|THE EFFECTS OF NASOPHARYNGEAL SUCTION POSITIVE PRESSURE
40929425|NCT06020638|DEVICE|control group|THE EFFECTS OF NASOPHARYNGEAL SUCTION NEGATIVE PRESSURE
40929426|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
40929427|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
41127744|NCT00515814|DEVICE|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation \& mobility.
41127745|NCT04337944|PROCEDURE|Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
41127746|NCT05033522|BIOLOGICAL|AlloStim® immunotherapy|3 cycles of intradermal and intravenous administrations
41278079|NCT04630145|DRUG|Bedaquiline|Participants will receive BDQ tablets only/
40929428|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
40929429|NCT04707547|BIOLOGICAL|immunotherapy with Nivolumab|After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.
40929430|NCT04707547|PROCEDURE|Radiofrequency Ablation|The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.
40929431|NCT02614469|DRUG|Inosine|Inosine, 1000 mg
40929432|NCT01418560|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
40929433|NCT04390932|OTHER|Enhanced TA|The enhanced TA is characterized by the personalization of the conversation, the verbalization of a joint participation in the process, the full presence of the therapist in the development of the exercise protocol, and the inclusion of behaviors such as active listening, empathy, and encouragement. In addition, therapist's body language transmits confidence, security, and attention.
40929434|NCT04390932|OTHER|Limited TA|The limited TA does not consider the personalization of the conversation, uses a unidirectional verbalization and is imperative about the instructions provided to the participant, the therapist is intermittently absent during the therapeutic exercise sessions and uses a neutral or negative nonverbal language cues.
40929435|NCT04390932|OTHER|Therapeutic exercise protocol.|Three 45-60 minute sessions of supervised therapeutic exercise (combination of aerobic, isometric, and isotonic exercise) delivered within a one-week period.
40929436|NCT05277948|OTHER|active thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
41127747|NCT05033522|DRUG|FOLFOX regimen|Comparative arm: Physician Choice of FOLFOX4 chemotherapy
41127748|NCT05033522|DRUG|Sorafenib|Comparative arm: Physician Choice of Sorafenib
41127749|NCT05033522|DRUG|Lenvatinib|Comparative Arm: Physician's Choice of Levantinib
41278080|NCT04630145|DRUG|Clarithromycin|Participants will receive CAM 400 or 500 mg twice a day.
41278081|NCT04630145|DRUG|Ethambutol|Participants will receive 500 to 750 mg daily (maximum daily dose of 1.0 gram \[g\]) or 15 mg/kg once a day.
40947876|NCT03467048|DEVICE|Direct laryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
41127750|NCT05353894|DRUG|GNS561 oral tablets and capsules|Two formulations and Two dosage will be compared
41278082|NCT04630145|DRUG|Rifampicin|Participants will receive daily dose is 450 mg (maximum 600 mg) RFP capsule once a day.
41278083|NCT04630145|DRUG|Rifabutin|Participants will receive daily dose of RBT 300 mg or 150 mg capsules once a day.
40754900|NCT02501785|BEHAVIORAL|The Caregiver Quality of Life - Cancer (CQOLC)|
40754901|NCT00216658|DRUG|fentanyl|
40754902|NCT05686720|DRUG|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 5.0×10\^7 and 2.0×10\^8 cells. The infusion is given every 2 weeks.
40754903|NCT04202783|OTHER|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
40754904|NCT04556825|DRUG|PRP|After the arthroscopic operation was completed, a local PRP with 4ml was injected
40754905|NCT04556825|DRUG|normal saline|After the arthroscopic operation was completed, a local normal saline injection with same ml was performed
40754906|NCT02149797|PROCEDURE|Four port laparoscopic cholecystectomy|Classical four port laparoscopic cholecystectomy
40754907|NCT02149797|PROCEDURE|SILC-Pick'n roll-Beginning (group I)|"SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided"
40754908|NCT02149797|PROCEDURE|SILC-Pick'n roll-Experienced (group II)|Similar technique of SILC-Pick'n roll-Beginning (group I) was used
41278084|NCT06376149|BEHAVIORAL|M3 Intervention group|The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
41278085|NCT06376149|BEHAVIORAL|M3 Waitlist Group|The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
41278086|NCT06090071|DEVICE|LaseMD Laser|The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.
40929437|NCT05277948|OTHER|sham thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile sham thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile sham electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
40947877|NCT00263770|DEVICE|soft palate implant|
40929438|NCT03386877|PROCEDURE|periodontal regeneration|Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
40929439|NCT05313776|OTHER|Magnetic Resonance Imaging|IMR is a non-invasive imaging technology that produces three dimensional detailed anatomical images. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects the change in the direction of the rotational axis of protons found in the water that makes up living tissues.
41127751|NCT03807908|OTHER|Tape|"The patient will be placed into maximal flexion of the lumbar spine prior to the tape being applied. The vertical strips will be applied on either side of spine, on the erector muscle group; from the lower PSIS with and end around the twelfth rib. The third strip of tape will be applied horizontally to superior to the posterior superior iliac spines (PSIS) and extend over the 2 vertical strips of tape. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
41127752|NCT03807908|OTHER|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction (at the level of the lower rib cage over the T12-L1 spinous processes) with no tape-tension. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
41127753|NCT02482701|DEVICE|Captivator™ EMR|The Captivator ™ EMR Device is indicated for endoscopic mucosal resection (EMR) in the upper gastrointestinal (GI) tract.
41127754|NCT05142046|DRUG|Fluid balance|The intervention consists of classic and standardized anesthesia management of children undergoing cardiac surgery. All the data links to the fluid management will be extracted from the patient's chart in the intraoperative period as well as complications during the hospitalization in the postoperative period.
41127755|NCT03987243|BEHAVIORAL|Structured Pressure Ulcer Prevention Education|Structured education for performance weight shift maneuvers and pressure ulcer prevention will occur during the initial visit for each subject. The education method used aligns with principles of the social cognitive theory to facilitate learning. The purpose in providing the education is to ensure all of the participants receive uniform instruction in how to perform weight shifts and to facilitate understanding of the importance of completing them as a protective measure against pressure ulcer development. Because each participant will come into the study at varying levels of understanding about pressure ulcer risk and knowledge of how to complete weight shift maneuvers, the education component is critical to ensure all participants are provided with the same information in the same way.
41127756|NCT03987243|OTHER|Mobile Seat Interface Pressure Mapping System (IPM)|This mobile IPM system was designed to provide visual information about seat interface pressure distribution to compensate for lack of sensation on the sitting surface. This variable will be toggled on and off between the intervention and control phases of the study. The participants will have access to the visual feedback while learning how to complete weight shift maneuvers at the initial visit and then again at home during the intervention phases (weeks 2 and 4). During the control phases (weeks 1 and 3), they will not have access to the visual feedback from the pressure map
41127757|NCT03136172|DEVICE|NIRS (near Infra-red spectroscopy)|"1. NIRS, INVOS 5100 cerebral/somatic oximeter monitor (Somanetics Corp, Troy, Michigan, USA)~2. Radical-7 pulse oximeter (Masimo Corp, Irvine, CA, USA)~3. Echocardiography (Phillips HD 15 Ultrasound system, CA, USA)"
41127758|NCT01296646|DRUG|Naltrexone|50 mg oral naltrexone once/day
41127759|NCT01296646|BEHAVIORAL|Brenda Therapy Sessions|participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
41127760|NCT01296646|DRUG|Placebo|An inactive pill to control for non-pharmacological responses.
41127761|NCT03358433|OTHER|Exercise|
41127762|NCT00976105|DRUG|Zolpidem or placebo - Hypnotic drug given for sleep disorders|The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
41127763|NCT00976105|DRUG|GSK1521498 or placebo|The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
41278087|NCT06090071|DEVICE|Sciton Laser|The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.
41278088|NCT06090071|DRUG|Phyto A+ Brightening Treatment|Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
40929440|NCT03269552|DRUG|Carfilzomib|Given IV
40929441|NCT03269552|OTHER|Laboratory Biomarker Analysis|Correlative studies
40929442|NCT03269552|BIOLOGICAL|Rituximab|Given IV
40929443|NCT02456103|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
40929444|NCT00494598|DRUG|Sufentanil|200 mcg intra-arterial one time bolus
40754909|NCT05410795|DIAGNOSTIC_TEST|Magnetic resonance imaging|Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.
41127764|NCT01462799|BEHAVIORAL|PBL in patient education|The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.
41127765|NCT01462799|BEHAVIORAL|Mailed patient information|During the study year patients in this control group will receive mailed patient information about life style changes.
41127766|NCT00715884|DEVICE|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
41127767|NCT00715884|DEVICE|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
41278089|NCT06477042|OTHER|Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score|Change in quality-of-life score assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) between the 2-month early visit and inclusion in the poor-prognosis group.
41278090|NCT03215030|DRUG|Modakafusp alfa|Modakafusp alfa intravenous infusion.
41278091|NCT03215030|DRUG|Dexamethasone|Dexamethasone.
41278092|NCT06108284|DEVICE|Intervention Arm (Biphasic cuirass ventilation)|Patients in this arm will be placed on Biphasic cuirass ventilation
41278093|NCT05932732|DEVICE|HydraFacial Syndeo System|Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.
40754910|NCT02513641|DEVICE|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of \~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
41127768|NCT04353089|OTHER|Basic life support courses|4 hours certified basic life support courses
41278094|NCT05932732|DRUG|ReGen-GF|The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
40754911|NCT03517020|DRUG|Torrent's Nebivolol Tablets|
40754912|NCT03517020|DRUG|Forest Pharmaceuticals Inc's Bystolic Tablets|
40754913|NCT05854264|DIETARY_SUPPLEMENT|standard enteral nutrition|standard enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
41278095|NCT05932732|DEVICE|HydraFacial Elite MD System|Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.
41278096|NCT06084806|DRUG|[18F]F-ARAG PET|Two imaging sessions
41278097|NCT04868123|DEVICE|Transcutaneous Nerve Stimulation (TENS)|Transcutaneous nerve stimulation (TENS) is a simple home base treatment to manage pain. It involves electrical current applied to the skin through self-adhering electrodes, using a TENS3000 device (TENSPros.com).
41127769|NCT04428710|OTHER|assessment with psychometric questionnaire|"At the initial genetic consultation patients are informed about hereditary cancer risk and the genetic testing process. At the second genetic counseling appointment, after patients done tests, all participants were informed about the study purpose, and they signed the informed consent before the psychometric assessment. Those patients who agreed to participate, they were given the questionnaires to fill in. Also, background characteristics were reported including age, marital relationship, level of education, psychiatric antecedents.~The time for completion the self-report measures was about 10 minutes. The psychometric assessment was occurred prior to delivering the results of genetic testing."
40929445|NCT04880330|DEVICE|Cryo-Auriculotherapy|1 session of cryo-auriculotherapy with device with nitrous oxyde on 15 auricular points.
40929446|NCT04880330|DEVICE|Sham comparator|1 session of cryo-auriculotherapy with device without nitrous oxyde on 15 auricular points.
40929447|NCT00689442|DRUG|JTT-705 600 mg and atorvastatin 20 mg|"* JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment~* Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments"
40929448|NCT00689442|DRUG|Placebo and atorvastatin 20 mg|"* Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
40929449|NCT03573011|DIAGNOSTIC_TEST|[18F]PSMA-11|18F-PET imaging
40929450|NCT01662414|DIETARY_SUPPLEMENT|Whey protein|1 sachect (10 g) 2times/ day
40929451|NCT01662414|DIETARY_SUPPLEMENT|Soy protein|1 sachect (10g) 2times/day
40929452|NCT01850433|BEHAVIORAL|Internet based CBT for body dysmorphic disorder|
40929453|NCT01511055|DRUG|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
40929454|NCT05675683|DRUG|Capmatinib|Patients receiving Capmatinib
40929455|NCT00873470|PROCEDURE|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
40929456|NCT06400017|DEVICE|microelectrode stimulation of DBS|"Contact selection: According to the electrode position in the image (target reconstruction through CT scan), the electrode located in the substantia nigra is selected as the negative electrode, the contact near the upper part of the substantia nigra is selected as the positive electrode, and the bipolar stimulation mode is selected.~Stimulation parameters: The frequency was selected as 0/10/130Hz, the pulse width remained unchanged at 90μs, the side effects of patients were observed, and the voltage was slowly increased to 2.0V; The patient voltage was 0 during the spurious stimulation. The washout period was 1 hour"
40929457|NCT04652739|DRUG|Lycopene Softgel, 10 Mg|Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.
41278098|NCT04868123|BEHAVIORAL|Mindfulness Meditation|Mindfulness mediation is a guided mediation process to improve awareness of being present in the moment.
41278099|NCT06656858|OTHER|Static stretching|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds
40929458|NCT04652739|DRUG|Prednisolone|Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
40929459|NCT05367375|PROCEDURE|removing osteophyte at patellofemoral joint|to compare anterior knee pain between removing patellofemoral joint osteophytes and non-removing patellofemoral joint osteophytes after medial unicompartmental knee arthroplasty
41278100|NCT06656858|OTHER|PNF stretching|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds.
41278101|NCT06656858|OTHER|Static stretching with BFR|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
41278102|NCT06656858|OTHER|PNF stretching with BFR|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
41453438|NCT02046122|BIOLOGICAL|DLI|"HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10\^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
41278103|NCT06656858|OTHER|Control|No stretching was applied to the control group. An information brochure about hamstring injuries was provided to the participants.
40754914|NCT05854264|DIETARY_SUPPLEMENT|specialized nutrition|specialized enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
40754915|NCT03606213|BIOLOGICAL|PENNVAX-GP|PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.
40929460|NCT03443557|OTHER|oral nutrition supplement|receiving prescription of oral nutrition supplement during hospitalization
40929461|NCT01544088|BEHAVIORAL|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
40929462|NCT01544088|BEHAVIORAL|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
40929463|NCT01006603|DRUG|Saxagliptin|5 mg, oral tablet, once daily
41127770|NCT00998413|BEHAVIORAL|Multifaceted intervention|multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
41448845|NCT05492032|BEHAVIORAL|Cognitive training|Participants will complete an online cognitive training program consisting of 10 consecutive daily weekday training sessions while they receive either the active or sham tDCS stimulation. Each training session will last for 20 minutes. The online cognitive training program will comprise five exercises assessing information processing speed and executive function capacities. Each exercise will take approximately 4 minutes to complete. Given many studies, across different neurological/neuropsychiatric diagnoses, especially for people with autism, it has long been established that social skills and functioning are closely related, and multiple studies have shown that executive function training can improve social functioning in autism or vice versa (i.e. social skills training improves executive functioning in autism), it is reasonable to include cognitive training in this tDCS protocol.
40929464|NCT01006603|DRUG|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
40929465|NCT00409305|DRUG|Betahistine|
40929466|NCT00409305|BEHAVIORAL|Dietary counseling|
40929467|NCT00786851|DRUG|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
40929468|NCT03127800|DRUG|Morphine sulphate|5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
40929469|NCT05244980|DRUG|TDM-105795|TDM-105795 topical solution
40929470|NCT05244980|DRUG|Placebo|Placebo for TDM-105795 topical solution
40929471|NCT00677430|BEHAVIORAL|Questionnaire|A brief questionnaire packet will be completed.
40929472|NCT00677430|PROCEDURE|Digital Imaging|Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
40929473|NCT00149448|BEHAVIORAL|TB Contact Priority Model|
41127771|NCT03433794|BEHAVIORAL|Alcohol 101 Plus (TM)|It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
41278104|NCT06657807|BEHAVIORAL|Online CBT|Online CBT targeting anxiety in pediatric asthma
41278105|NCT01672892|RADIATION|Standard radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. Whole pelvis treated with a four-field technique (AP/PA/R lateral/L lateral) to 45 or 50.4 Gy at 1.8 Gy/fraction. The dose is prescribed to the isocenter which is defined as the intersection of the four beams and can be normalized to an isodose line between 97-100%. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
41278106|NCT01672892|RADIATION|intensity-modulated radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. All targets treated simultaneously. The vaginal planning target volume (PTV) (ITV with 7.0 mm margin) and nodal PTV receives 45 Gy in 25 fractions or 50.4 Gy in 28 fractions. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
41278107|NCT06408259|DRUG|Ozanimod|Specified dose on specified days
41278108|NCT06408259|DRUG|Fingolimod|Specified dose on specified days
41448846|NCT00154739|DRUG|Gemcitabine|
41448847|NCT00154739|DRUG|Cisplatin|
41448848|NCT00154739|DRUG|Epirubicin|
41448849|NCT05336422|OTHER|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
41448850|NCT00705666|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
41448851|NCT00705666|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
41448852|NCT01003938|DRUG|Topotecan|
40754916|NCT03606213|BIOLOGICAL|INO-6145|INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.
40754917|NCT03606213|BIOLOGICAL|INO-9012|The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
40754918|NCT03606213|DEVICE|CELLECTRA® 2000|Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
40929474|NCT03957460|OTHER|SpHb monitoring|Subjects receive the continuous and noninvasive hemoglobin monitoring (SpHb monitoring).
40929475|NCT06206954|BEHAVIORAL|MyHealthPath Tool|Tailored, brief online tool to help patients learn about weight treatment options
41278109|NCT06408259|OTHER|Placebo|Specified dose on specified days
41448853|NCT01003938|DRUG|Erlotinib|
41448854|NCT06574620|GENETIC|Genetic testing|Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.
41448855|NCT06574620|PROCEDURE|Optional biopsy|Optional collection of tumour tissue and normal tissue prior to the first dose of treatment and/or after the last dose of treatment.
41448856|NCT02260063|DRUG|Epinastine syrup|
41448857|NCT02260063|DRUG|Epinastine tablets|
41448858|NCT01741545|BIOLOGICAL|Pegylated-Interferon-lambda|
41448859|NCT01741545|DRUG|Ribavirin|
41448860|NCT01741545|DRUG|Daclatasvir|
41448861|NCT04124315|OTHER|Accelerometry|Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).
41448862|NCT04124315|OTHER|Daynamica app|Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
41453439|NCT04307680|DEVICE|Peritron perineometer|Perineometry will be used to assess quality of each observed treatment modality.
40929476|NCT06206954|BEHAVIORAL|MyHealthPath Guide|Informational material to help patients learn about weight treatment options
40929477|NCT03882931|OTHER|Theta Burst Transcranial Magnetic Stimulation|Theta Bursts are short bursts of stimulation at high frequencies, which are applied 5 times per second
41278110|NCT01549990|DRUG|Sevoflurane|maintenance of general anesthesia with sevoflurane
41278111|NCT01549990|DRUG|desflurane|maintenance of general anesthesia with desflurane
41278112|NCT02795988|BIOLOGICAL|IMU-131|IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
41278113|NCT02795988|DRUG|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.|Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
41278114|NCT04943588|DIAGNOSTIC_TEST|HCV RNA (PCR)|We will test HCV positive patients after treatment to observe if they achieve SVR
40929478|NCT03882931|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
40929479|NCT03882931|OTHER|Sham|The investigators will simulate theta bursts pulses similar to the Theta Burst Transcranial Magnetic Stimulation groups but without stimulation.
40929480|NCT03091972|PROCEDURE|Pulmonary vein isolation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
40929481|NCT03091972|PROCEDURE|Contact force assisted left atrial linear ablation|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.
40929482|NCT03091972|PROCEDURE|left atrial linear ablation without contact force monitoring|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
40947878|NCT00263770|OTHER|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
40947879|NCT00993876|DRUG|citalopram|20 to 30 mg per day for 4 weeks
41278115|NCT04943588|DIAGNOSTIC_TEST|HCV Antibody test (Point of care)|HCV antibody test used to establish if patients have had or are actively infected with HCV
41278116|NCT04943588|DIAGNOSTIC_TEST|AST/ALT and platelets measurement|AST/ALT and platelets to determine APRI score
41278117|NCT06656897|BEHAVIORAL|FallScape for Persons with Alzheimer's disease or a related Dementia (FS-D)|FS-D is a multimedia behavioral intervention for use by family Caregivers (CG) of Persons with Alzheimer's disease or a related dementia (PwADRD) who are living at home and classified as at moderate to high risk for falls. FS-D will create, customize and support CG-provided daily multimedia sessions for PwADRD using structured learning techniques.
41278118|NCT04889872|DEVICE|SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA|Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA heart valve
41127772|NCT03433794|BEHAVIORAL|Booster|Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).
41127773|NCT03433794|BEHAVIORAL|Lilly for Better Health|This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
41127774|NCT06232681|BEHAVIORAL|Progressive relaxation exercise|The intervention group will take one month progressive relaxation exercise starting from the hospitalisation to the clinic
41127775|NCT01594957|DRUG|LCQ908|Participants will receive a single oral dose of LCQ908
41127776|NCT03124017|OTHER|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart|
41127777|NCT01086813|DRUG|AZD3043|single dose/IV, bolus over 60secs - infusion over 30 mins
41127778|NCT04138394|DRUG|Ascorbic Acid|Patients will receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours).
41127779|NCT04138394|DRUG|placebo|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
41127780|NCT03852069|DIETARY_SUPPLEMENT|Inulin|Patient receive inulin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of inulin-rich vegetables
41127781|NCT03852069|DIETARY_SUPPLEMENT|Placebo|Patient receive maltodextrin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of vegetables poor in inulin
41127782|NCT00176202|DRUG|Divalproex Sodium|Divalproex sodium is a mood stabilizer
41127783|NCT00176202|DRUG|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
41127784|NCT05643456|PROCEDURE|surgery|"69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group 30 patients had two muscles surgery; bilateral lateral rectus recession.~The 2nd group 39 patients had three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking."
41448863|NCT03045458|DEVICE|tissue level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 tissue-level implants 12 mm in length and 4.8 mm in diameter were inserted in Group I. Cover screw was removed and replaced with healing abutments.
41448864|NCT03045458|DEVICE|Bone level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted inGroup II. Three months later, second-stage surgery was performed and implant exposed into the oral cavity. Cover screw was removed and replaced with healing abutments. Three months waited for second surgery in bone level implants.
40947880|NCT00993876|DRUG|reboxetine|4 to 8 mg per day for 4 weeks
41127785|NCT03220724|BIOLOGICAL|CH505TF|Administered by intramuscular (IM) injection in the thigh
41127786|NCT03220724|BIOLOGICAL|CH505w53|Administered by IM injection in the thigh
41127787|NCT03220724|BIOLOGICAL|CH505w78|Administered by IM injection in the thigh
41127788|NCT03220724|BIOLOGICAL|CH505 M5|Administered by IM injection in the thigh
41127789|NCT03220724|BIOLOGICAL|GLA-SE adjuvant|Admixed with all CH505 gp120 proteins
41127790|NCT03220724|BIOLOGICAL|Placebo|Administered by IM injection in the thigh
41127791|NCT05473416|OTHER|McKenzie back extension exercise|McKenzie's back extension exercise consists; start with your belly facing down on the mat. Angle your legs in line with your hips, point your toes, and breathe into the next movement. Gently bending your elbows, push yourself up off the floor, until you feel the extension in your back. Be mindful not to lock your elbows as you support your weight with your hands and wrists for 10 seconds. Take deep inhales and exhales as you move in and out of the pose. Patients will be performed these activities under the supervision of physiotherapist.
41127792|NCT05473416|OTHER|Pilates pelvic tilt exercise|Pilates pelvic tilt exercise consists; lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Pull your belly button in toward your spine, pushing your pelvis up toward the ceiling. Tighten your gluteus and hip muscles as you tilt your pelvis forward. Hold for 10 seconds.
41127793|NCT05473416|OTHER|Baseline treatment|Postural guidelines + proper lifting technique + stretch break Rest
41127794|NCT01181154|DRUG|rituximab (Mabthera®)|1000 mg at day 1 and day 15
41127795|NCT01181154|DRUG|Placebo|equivalent volume total
41453440|NCT02981095|PROCEDURE|Thyroidectomy|Thyroidectomy performed by the same surgical and anesthesia team
40947881|NCT00993876|BEHAVIORAL|interpersonal psychotherapy|
41127796|NCT02612142|BEHAVIORAL|physical exercise|endurance-training or stretching (sham exercise)
41127797|NCT00730509|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate and vitamin B12|children with cystic fibrosis were supplementated for 6 months with 5-MTHF, 7,5 mg/day ; vitamin B12, 0,5 mg/day
41127798|NCT05588817|GENETIC|PCR polymorphism|PCR polymorphism in Rhomatoid arthritis patients in Egypt
41127799|NCT01279668|DRUG|Montelukast|10mg tablets, once per day for 28 days.
41127800|NCT01279668|DRUG|Placebo|tablets, once per day for 28 days.
41127801|NCT06364553|DEVICE|Esophageal self-expandable metal stent|The Leufen Esophageal aixstent ® (Leufen Medical GmbH) is indicated for the treatment of malignant esophageal strictures and postoperative stenosis. It is comprised of two components: an implantable metallic stent and the delivery system. After the procedure, the stent remains at the intended location, within the patient while the delivery system is removed.
41127802|NCT00824642|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
41127803|NCT00824642|DEVICE|placebo|placebo TENS applied prior to exercise
41127804|NCT03113409|DRUG|Buprenorphine|Buprenorphine will be administered daily
41127805|NCT03113409|DRUG|Naltrexone|On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
41127806|NCT03113409|DRUG|Vivitrol|Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
41127807|NCT01260896|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
41127808|NCT01260896|DRUG|Effexor® XR|150 mg Extended-Release Capsule
40929483|NCT04043780|DEVICE|Decompression prototype splint for carpal tunnel syndrome|This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.
41127809|NCT03894436|COMBINATION_PRODUCT|Ultrasound assessment of diaphragm thickness in B-mode|assess the thickness of diaphragm needed as a tool for prediction of extubation and proper timing of weaning from mechanical ventilation in the ICU which is measured by B mode ultrasound in ventilated cancer patients
41127810|NCT02659124|DEVICE|AmnioFix plus Standard of Care|Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
41127811|NCT02659124|PROCEDURE|Standard of Care|Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
41278119|NCT01492010|DIETARY_SUPPLEMENT|whey protein|25 g whey protein
40929484|NCT04043780|DEVICE|Standard splint for carpal tunnel syndrome|This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
41127812|NCT04897633|DEVICE|transcranial electric stimulation|Simon's task assessment when under tDCS
41127813|NCT03035084|DRUG|Vitamin D3|Single oral dose of 50,000 IU of vitamin D3
41127814|NCT03035084|DRUG|Vitamin D2|Single oral dose of 50,000 IU of vitamin D2
41127815|NCT03035084|DRUG|Placebo oral capsule|Placebo oral capsule
41278120|NCT01492010|DIETARY_SUPPLEMENT|whey protein supplemented with leucine|6.25 g whey protein supplemented with free form leucine
40929485|NCT05672667|DRUG|intravenous oxytocin|Oxytocin given by intravenous route
40929486|NCT05672667|DRUG|intranasal oxytocin|Oxytocin given by intranasal administration
40929487|NCT01095094|DRUG|ritonavir|Given orally
40929488|NCT01095094|DRUG|lopinavir|Given orally
40929489|NCT00541190|OTHER|Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA|Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
40929490|NCT05622409|OTHER|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
40929491|NCT03935399|DRUG|Oxytocin|10 IU oxytocin (Pitocin) for intramuscular injection
41127816|NCT05521386|DRUG|Caffeine|Single pill in an acute dose of 5 mg per kg of body mass
41127817|NCT05521386|DRUG|Placebo|Single pill in an acute dose of 5 mg per kg of body mass
41127818|NCT05866978|BEHAVIORAL|Integrated Approach to Health, Wellbeing, and Productivity at Work (ITASPA)|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish context among blue-collar workers.
41127819|NCT03447236|BEHAVIORAL|Feuerstein Program|Mediated learning cognitive enhancement program
41278121|NCT01492010|DIETARY_SUPPLEMENT|whey protein supplemented with essential amino acids|6.25 g whey protein supplemented with essential amino acids devoid of leucine
41453441|NCT02981095|DRUG|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
40929492|NCT03935399|DRUG|Saline|1.5 ml preservative free saline for intramuscular injection
40929493|NCT04304157|DRUG|Dexmedetomidine|Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
41127820|NCT00651859|DRUG|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
41127821|NCT00651859|DRUG|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
41127822|NCT00651859|DRUG|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
41448865|NCT05329311|PROCEDURE|ERATS protocol applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying the ERATS protocol will be investigated.
41448866|NCT05329311|PROCEDURE|ERATS protocol not applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying without the ERATS protocol will be investigated.
41448867|NCT01701323|BIOLOGICAL|Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion|Given IV
41448868|NCT01701323|DRUG|Cytarabine|Given IV
40929494|NCT05441306|DEVICE|Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).
41448869|NCT01701323|DRUG|Filgrastim|Given SC or IV
40754919|NCT02936271|OTHER|Vasculera|"Vasculera is a specially formulated prescription medical food product. This study compares Vasculera to placebo at reducing post procedural pain, bruising and edema for patients requiring an intervention for lower extremity venous disease.~Patient will be randomized to receive Active Vasculera or Vasculera Placebo. The study product will be taken for two weeks prior to the patient's planned procedure and continued for four weeks after their procedure. If multiple procedures are required the patient will be instructed to use the product throughout treatment."
40754920|NCT02936271|OTHER|Placebo|
40754921|NCT03725735|BEHAVIORAL|CBT for problem gambling with emotion regulation|CBT group treatment for problem gambling with emotion regulation focus, with 8 sessions.
40754922|NCT01795755|BEHAVIORAL|Mentalization based inpatient treatment.|1-3 month of inpatient treatment
40754923|NCT01795755|BEHAVIORAL|Horse assisted Therapy (HAT)|A structured program of 12 X 90 minute HAT sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists who are also Level I Riding Instructors.
40754924|NCT06353932|OTHER|keeping the endotracheal tube cuff pressure within a certain range|The endotracheal tube cuff pressures of the study group patients were kept within the range of 20-25 cm H2O.
40754925|NCT02306785|DRUG|TP05 Coating D|One radio-labelled tablet given to subjects
40754926|NCT02306785|DRUG|TP05 Coating E|One radio-labelled tablet given to subjects
40754927|NCT02306785|DRUG|TP05 Coating H|One radio-labelled tablet given to subjects
40929495|NCT05441306|DEVICE|Epic®MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
40929496|NCT03490981|OTHER|Treatment as usual (TAU)|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
40947882|NCT01518023|OTHER|Interview, questionnaire, updated biochemical tests|Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
41127823|NCT01074359|DRUG|A0001 (alpha-tocopherolquinone)|28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
40754928|NCT02798952|BIOLOGICAL|Engerix-B Kinder|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
41127824|NCT01074359|DRUG|Placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
41127825|NCT01550549|DRUG|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
40754929|NCT06539650|OTHER|Fractal Paced|The intervention consists in a single session of metronome paced strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with fractal external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
41127826|NCT03592524|BEHAVIORAL|Fasting Ramadan|Muslims recipients refrain from eating and drinking anything from dawn until sunset(14-15 hours)
41448870|NCT01701323|DRUG|Fludarabine Phosphate|Given IV
41448871|NCT00446966|DRUG|Omega Three Polyunsaturated fatty acids|2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
41448872|NCT03611335|BEHAVIORAL|CATCH Interviews|Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
41448873|NCT05884320|DRUG|Sacituzumab Govitecan|Given by IV (vein)
41448874|NCT04009434|DEVICE|Mitral Valve Clipping|Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.
40929497|NCT03490981|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6 weeks. Brief CBT-CP session outlines and patient handouts are included in the appendix. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
40929498|NCT02299973|PROCEDURE|FMT with donor stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from a healthy pool of donors and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the treatment group
40929499|NCT02299973|PROCEDURE|FMT with own stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from the patients and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the control group
40929500|NCT05243173|OTHER|Sequencing|Laboratory analysis of samples
40929501|NCT01445548|DRUG|Sirolimus|
41127827|NCT03158415|BEHAVIORAL|T1DToolkit.org mobile diabetes education|"Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults."
41127828|NCT01970410|DRUG|teriflunomide|14 mg oral teriflunomide daily
40929502|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 10 mcg/kg IV
40929503|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 100 mcg/kg IV
40929504|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 200 mcg/kg IV
40929505|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 25 mcg/kg IV
40929506|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 50 mcg/kg IV
40929507|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of Placebo IV
41127829|NCT00545519|DRUG|thymoglobulin|
41127830|NCT00052364|DRUG|oxaliplatin|Given IV
41127831|NCT00052364|OTHER|laboratory biomarker analysis|Correlative studies
40929508|NCT05849285|OTHER|TLC Clinic|Patients of the TLC clinic - receive coordinated multidisciplinary and specialized care from a team
40929509|NCT00983697|PROCEDURE|therapeutic conventional surgery|
40929510|NCT00983697|RADIATION|fludeoxyglucose F 18|
41127832|NCT04169256|DRUG|HYR-PB21|HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen
41127833|NCT04169256|DRUG|Liposomal bupivacaine|Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen
41127834|NCT04169256|OTHER|Normal Saline|Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen
41448875|NCT04009434|DEVICE|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
41448876|NCT00035139|DRUG|methylphenidate|
40929511|NCT02370576|OTHER|rating scale application|"Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.~rating scale application"
40929512|NCT00568633|PROCEDURE|Allogeneic HSCT|Allogeneic, 5+ of 6 HLA-matched PBSC transplant from sibling, mobilized to target of 5 x 10e6 CD34+ cells/kg and \< 7 x 10e8 CD3+ cells/kg.
40929513|NCT00568633|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg for 5 days by IV
40929514|NCT00568633|DRUG|Cyclosporine (CSP)|6.25 mg/kg twice daily oral
40929515|NCT00568633|DRUG|Mycophenolate mofetil (MMF)|15 mg/kg twice daily oral
41127835|NCT03933137|OTHER|Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (P-POSSUM) score|P-POSSUM score's variables are divided into physiological parameters (age, cardiac, respiratory, ECG, systolic blood pressure, pulse rate, haemoglobin, leukocyte count, urea, sodium plasma, potassium plasma, and GCS) and operative parameters (operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD).
41127836|NCT02337036|OTHER|Pharmacokinetic|Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus
41127837|NCT02337036|OTHER|Pharmacogenetic|Pharmacogenetic study
41448877|NCT06596226|BEHAVIORAL|Pathways Parent Mediated Intervention|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written version of the program manual. Sessions will review information about social communication, infusing mutual gaze in social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with practice feedback and self-reflection.
41448878|NCT06596226|BEHAVIORAL|Pathways Parent Mediated Intervention without Mutual Gaze|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written version of the program manual. Sessions will review information about social communication, social sensory routines, and naturalistic developmental behavioral strategies described in the program manual. Interventionists will demonstrate intervention strategies and provide caregivers with practice feedback and self-reflection.
41448879|NCT04948905|OTHER|Evaluation using the Self-Defining Memory Questionnaire|"This questionnaire consists of 3 pages. Page 1 gives a clear, concise definition of a memory that defines the self. This enlightens the subject on what is expected and helps him/her consider the phenomenological characteristics of the Self-Defining Memory. Page 2 recalls the 6 essential characteristics of the Self-Defining Memory. Page 3 allows the practical application of what has been understood about the questionnaire. At least 3 memories are asked of the participants. Each memory is rated as follows : On a scale of 0 - 6 for each of the following emotions, participants note how they feel when recalling each memory. Happy, Sad, Angry, Fearful, Surprised, Ashamed,Disgusted,Guilty, Interested, Embarrassed, Contemptful, Proud. 0 = not at all, 3 = Moderately and 6 = Extremely.~Participants must then use the same scale to indicate the vividness and importance of the memory.~They must also note the approximate number of years ago the memory took place (to the nearest whole number)."
41448880|NCT05100212|BIOLOGICAL|cord blood-RBC concentrates|Patients in the experimental arm are candidates to receive CB-RBC units until the completion of 31 weeks of postmenstrual age (31+6). In case of unavailability of an ABO/Rh matched CB-RBC unit, patients receive adult -RBC (standard transfusions).
41127838|NCT02337036|DRUG|Tacrolimus|These Patients are treated with tacrolimus after the Liver Transplantation
41127839|NCT01053325|DRUG|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
41127840|NCT01053325|DRUG|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
41127841|NCT05171985|PROCEDURE|Dexmedetomidine sedation|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.
40754930|NCT06539650|OTHER|Isochronus Paced|The intervention consists in a single session of metronome paced strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with isochronus external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
40929516|NCT00568633|RADIATION|Total lymphoid irradiation (TLI)|80 cGy/fraction radiotherapy in 10 fractions.
40929517|NCT00568633|DRUG|Methylprednisolone sodium succinate|1.0 mg/kg for 5 days by IV
40929518|NCT00568633|DRUG|Best standard care|"Intervention consist of:~* Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation"
40929519|NCT00789074|DRUG|Varenicline|Varenicline 1mg twice daily
40929520|NCT00789074|DRUG|Placebo|Placebo 1mg BD
40929521|NCT00237510|DRUG|terazosin|
40929522|NCT03473080|BEHAVIORAL|Internet CBT|The treatment consists of a standard cognitive behavior therapy for OCD with additional treatment components to make the treatment better suited for children and adolescents with Autism Spectrum Disorder.
40929523|NCT04439253|DRUG|Crizotinib|Given PO
41127842|NCT00004831|DRUG|cysteine hydrochloride|
41127843|NCT05979038|DRUG|Metformin|Patients in the intervention arm will take metformin 500mg three times a day
41127844|NCT05243784|BEHAVIORAL|MOVI-HIIT intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 20 at high intensity (85-90% of HR -heart rate- max) followed by 10 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities."
40754931|NCT06539650|OTHER|Self Paced|The intervention consists in a single session of strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, at at participants' own self pace (with no metronome). The rest between sets will be set at 2 minutes of rest between sets.
40929524|NCT06463275|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument).
40929525|NCT03316183|OTHER|Perioperative and postoperative management|Cerebral oximetry informed perioperative management
40929526|NCT04651101|DIAGNOSTIC_TEST|coronary angiography|extent of coronary artery disease in invasive coronary angiography
40929527|NCT02616601|DRUG|Generic Fluorouracil Cream|Topical cream, generic formulation of the brand product.
40929528|NCT02616601|DRUG|Carac® (Fluorouracil) Cream|Topical cream, brand product.
40929529|NCT02616601|DRUG|Vehicle Cream|Topical cream, placebo. Has no active ingredient.
40929530|NCT06492343|OTHER|fMRI based neurofeedback|participants will receive neurofeedback from their brain in order to modify their own brain function
41127845|NCT01261052|DEVICE|The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
41127846|NCT01261052|DEVICE|The Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
41127847|NCT04859296|DRUG|Placebo|Vaporized placebo
41448881|NCT05100212|BIOLOGICAL|adult donor RBC concentrates|Patients in the comparator arm are candidates to receive adult donor-RBC units
41453442|NCT02981095|DRUG|Saline Solution|%0.9 sodium chloride solution, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
40929531|NCT03633877|DEVICE|DuraporeTM and Hy-Tape®|Medical tapes
40929532|NCT03224780|DIAGNOSTIC_TEST|maternal serum creatine kinase|Biochemical marker
40929533|NCT03224780|DIAGNOSTIC_TEST|3D Doppler ultrasound|Doppler for placental vessels
40929534|NCT01165580|DRUG|valganciclovir [Valcyte]|oral dose, Days 1 and 2
40929535|NCT04016584|BEHAVIORAL|Diabetes Pueblo|These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
40929536|NCT00777218|DRUG|propranolol|standard pediatric doses, based on body weight
40929537|NCT00777218|DRUG|zonisamide|standard pediatric dosages, based on body weight
40929538|NCT00777218|DRUG|topiramate|standard pediatric dosages, based on body weight
40929539|NCT06437704|OTHER|Brain training game Lumosity|. Group A, the experimental group will be trained using five selected games i.e. Speed Match, Memory Matrix, Tidal treasure, Ebb and Flow and Lost in Migration from Lumosity for a period of 30 sessions , 30 min/ day over the span of 6 weeks.
40929540|NCT06437704|OTHER|Simulation game simcity buildit|Group B, the active control will be trained for the same number of sessions using a simulation game, SimCity Build it, for a period of 30 sessions , 30 min/ day over the span of 6 weeks.
40929541|NCT02750215|DRUG|Capmatinib (INC280)|treatment with Capmatinib (INC280)
40929542|NCT02379845|DEVICE|NBTXR3|One intratumor implantation by injection
40929543|NCT02379845|DEVICE|Radiation therapy|5 weeks/50 Gy (5 x 2 Gy by week)
40929544|NCT05523687|DRUG|[14C]-PC14586|Single, oral dose of \[14C\]-PC14586
41127848|NCT04859296|DRUG|Low CBG|Vaporized CBG (5 mg)
41448882|NCT04871308|DRUG|Dexmedetomidine|"Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.~From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins."
40754932|NCT03148782|BEHAVIORAL|OST Intervention for participants with Organizational skill difficulties|Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
40929545|NCT06146998|OTHER|3D health education model|explanation combined with 3D health education model
41127849|NCT04859296|DRUG|High CBG|Vaporized CBG (15 mg)
41278122|NCT03717922|DEVICE|Low Intensity Focused Ultrasound Pulsation to Amygdala|Low intensity focused ultrasound pulsation will be administered to the amygdala in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 10Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the amygdala and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
41448883|NCT04871308|DRUG|Control|During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.
41448884|NCT05892081|BIOLOGICAL|Colloidal oatmeal|The colloid oatmeal had the following component: Colloidal Oat (5gm), stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
40754933|NCT03536065|BEHAVIORAL|Opioid Reduction Intervention|Patient education discharge sheet, nursing education, opioid prescription reduction based on Pre-Intervention data
40754934|NCT03536065|BEHAVIORAL|Current Care|Current unchanged care provided; unchanged provider prescribing and unchanged education of patients prior to intervention
40754935|NCT06358989|OTHER|HOMA IR|Homa ir
40929546|NCT06146998|OTHER|Verbal explanation|Regular explanation
40929547|NCT00331552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
40929548|NCT00331552|DRUG|cyclophosphamide|Given orally
40929549|NCT00331552|BIOLOGICAL|trastuzumab|Given IV
40929550|NCT02484859|DRUG|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
40929551|NCT02484859|DRUG|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.
40929552|NCT02484859|DRUG|Metoprolol|0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
40929553|NCT01465191|DRUG|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
40929554|NCT04673110|DIAGNOSTIC_TEST|Neutrophil to Lymphocyte Ratio and C-reactive protein|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
40754936|NCT03014388|OTHER|autogenous bone|Autogenous bone graft (gold standard). sinus lift with autogenous bone.
40754937|NCT03014388|OTHER|Mineralized plasmatic matrix|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
40929555|NCT02309619|PROCEDURE|lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.|Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
40929556|NCT02661178|DRUG|emodepside (BAY 44-4400)|
40929557|NCT02661178|DRUG|placebo|
41127850|NCT04859296|DRUG|Low THC|Vaporized THC (5 mg)
41127851|NCT04859296|DRUG|High THC|Vaporized THC (15 mg)
41127852|NCT04899011|OTHER|Questionnaire|"Questionnaire about taste and salivary disturbance before surgery, 10 days, 4 months and 1 year after surgery.~Questionnaires include characteristics of taste disturbance, and specific impact on quality of life."
41278123|NCT03717922|DEVICE|Low Intensity Focused Ultrasound Pulsation to Entorhinal Cortex|Low intensity focused ultrasound pulsation will be administered to the entorhinal cortex in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the entorhinal cortex and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
41448885|NCT05892081|BIOLOGICAL|Cold cream|It is composed of stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
41448886|NCT06047171|BIOLOGICAL|ALE.F02|ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.
41448887|NCT06047171|DRUG|Rituximab|Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
41448888|NCT06047171|DRUG|GlucoCorticoid|Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
41448889|NCT06047171|DRUG|Cyclophosphamid|Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
41448890|NCT06047171|DRUG|Placebo|Drug product that will contain no active ingredient
41448891|NCT06047171|DRUG|Immunosuppressive Agents|Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
41448892|NCT01112761|DEVICE|Transcranial direct current stimulation|Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
41448893|NCT06603532|OTHER|low-load blood flow restriction (BFR) training|The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in the BFR group exercised with blood flow restriction caused by an inflatable cuff placed on the proximal part of the thigh and inflated to 120-140 mmHg. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
41448894|NCT06603532|OTHER|low-load resistance training|The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in SHAM-BFR group performed an identical exercise protocol as experimental (BFR) group, while having thigh cuff inflated to only 20 mmHg, which did not affect normal muscle blood flow. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
41448895|NCT04235595|OTHER|Connective Tissue Manipulation|The application was delivered with the participant in a sitting position, with the entire back and sacral regions left exposed. The treatment was administered to the sacral, lower thoracic and pelvic regions.
41448896|NCT04235595|OTHER|Transcutaneous Electrical Nerve Stimulation|TENS was administered with the participant lying face down with a flat cushion underneath the abdomen. TENS was administered via 2 channels of electrodes placed with the sacral region in the middle. The intensity of the current was increased until the participant felt it.
41448897|NCT06173050|DEVICE|PAP System A (with Amalfi) then PAP System B (with CLA11)|PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
41448898|NCT06173050|DEVICE|PAP System B (with CLA11) then PAP System A (with Amalfi)|PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
41278124|NCT04205552|DRUG|Nivolumab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
41278125|NCT04205552|DRUG|Relatlimab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
41278126|NCT05586334|BIOLOGICAL|Collection of vaginal secretions|In all women included: Vaginal secretion sampling at the time of the obstetrical emergency consultation.
41278127|NCT05586334|BIOLOGICAL|Collection of the placenta and the membranes|In cohort 1, for 30 patients at the Port Royal Maternity Hospital, the placenta and membranes will be collected after delivery
41278128|NCT05586334|OTHER|Administration of EPDS questionnaire|In cohort 3, the EPDS questionnaire will be administered to all participants after the consultation in the emergency department.
41448899|NCT04123587|DRUG|discontinuation of Sulfonylureas|"1. Discontinuation of sulfonylurea, alternative drug administration.~2. If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~3. if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent"
41448900|NCT05724394|OTHER|Culturally Adapted Getting Better Bite By Bite (Ca-GBBB) intervention|The Ca-GBBB strongly focuses on enhancing participant's motivation and belief in their ability to change. The intervention will be comprised of 16-week training program delivered over four months.
41448901|NCT06436183|DRUG|Camoteskimab|Drug Product
41448902|NCT06436183|DRUG|Placebo|Inactive substance
41448903|NCT05269069|OTHER|Assessment of body composition, bone mineral density and bone marrow adiposity.|DXA for body composition and bone mineral density, MRI for bone marrow adiposity and blood tests (leptine, CTX, P1NP)
40754938|NCT05541471|DRUG|VX-548|Tablets for oral administration.
40754939|NCT05541471|DRUG|Midazolam|Syrup for oral administration.
40929558|NCT01535664|OTHER|Withdrawal of dalfampridine-ER 10mg|"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~* On drug Day-7 (visit 1) through Day 1 (visit 2)~* Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~* On drug Day 15±2 days (visit 5)"
41448904|NCT03889912|DRUG|Cemiplimab|Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 3-12 weeks prior to scheduled surgery
41448905|NCT06432985|BEHAVIORAL|Focus Group|In 60-minute focus groups, participants will be categorized based on their survey responses and engaged in semi-structured discussions using open-ended questions and probes to gather detailed information. The moderators will follow best practices in qualitative research, introducing the topic of smoking cessation in the context of cancer screening and treatment and guiding the discussions from broader issues to participant-generated examples.
41453443|NCT05138094|PROCEDURE|Minimally invasive simultaneous resection|One minimally invasive surgical procedure wherein both the primary colorectal carcinoma and the liver metastases are removed.
40754940|NCT05541471|DRUG|Digoxin|Tablets for oral administration.
40754941|NCT01061710|DRUG|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
40754942|NCT04076579|DRUG|Olaparib|Olaparib taken by mouth twice daily
40754943|NCT04076579|DRUG|Trabectedin|Trabectedin administered intravenously (IV) every 21 days
40754944|NCT02241915|PROCEDURE|Open Colorectal Surgery|
40754945|NCT02241915|PROCEDURE|Laparoscopic Surgery|
40754946|NCT01701635|BEHAVIORAL|Disclosure intervention|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
40754947|NCT01701635|BEHAVIORAL|usual care|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
40754948|NCT05808127|BEHAVIORAL|PainTracker|The PainTracker tool reframes the patient visit around improving functional status and obtaining functional goals, understanding psychological concerns that may exacerbate pain such as traumatic stress, anxiety, and depression. This approach may promote an increase in referrals for physical therapy, mental health counseling, and psychiatric follow-up.
40754949|NCT01098357|DRUG|Biochaperone PDGF-BB Low dose|BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
40754950|NCT01098357|DRUG|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
40754951|NCT01098357|DRUG|Regranex|Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
40754952|NCT01098357|DRUG|Biochaperone PDGF-BB Very Low Dose|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
40754953|NCT03730701|BEHAVIORAL|Prevention program for stroke|The prevention program include individual and group intervention sessions supported by a digital platform. The program will be personally tailored in relation to what the person needs and what to change and the individuals rediness for change. The digital platform will support the person during and in between sessions by prompting goals and goal-fulfilment, logging activities, step counts and provide a forum for sharing and reflection.
40754954|NCT01827943|DRUG|Temsirolimus|Temsirolimus
40754955|NCT05343650|DEVICE|NOVAPAK nasal packing applied to forearm|Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm.
40929559|NCT00224653|PROCEDURE|Mechanical Ventilation|
40929560|NCT00323869|DRUG|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
40929561|NCT00323869|DRUG|Gemcitabine|Nucleoside analog
40929562|NCT00323869|DRUG|Carboplatin|Alkylating agent
40929563|NCT00618553|OTHER|Questionnaire|Questionnaire regarding quality-of-life that lasts about 30 minutes.
40929564|NCT00618553|BEHAVIORAL|Pulmonary Rehabilitation|Rehabilitation treatment given over about 3-4 weeks.
40929565|NCT05130671|DRUG|Standard of care|Standard of care treatment as per the hospital guidelines
40929566|NCT05130671|DIETARY_SUPPLEMENT|Investigational treatment|Combination of quercetin and curcumin as add-on to the standard of care
40754956|NCT05343650|DEVICE|NOVAPAK nasal packing applied to nasal cavity|A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes
40754957|NCT00276380|DRUG|EGb761|EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
41448906|NCT06432985|BEHAVIORAL|Contingency Management|Participants will provide baseline data on their recent substance use and smoking habits and severity. They will receive a CO monitor and iCO app and will upload videos verifying smoking abstinence a minimum of once per day, 5 times per week. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through Remote (mobile) CO monitoring. They will receive clinician feedback at the time of each CO reading, following established VA protocols for CM.
40929567|NCT03773445|DIAGNOSTIC_TEST|Golimumab trough levels|Golimumab trough levels taken immediately before the administration of the next subcutaneous dose of golimumab
40929568|NCT03773445|DIAGNOSTIC_TEST|Antibodies to golimumab|Antibodies to golimumab taken immediately before the administration of the next subcutaneous dose of golimumab
40929569|NCT03773445|DIAGNOSTIC_TEST|Histology|Histology of colonic biopsies using the Geboes Index
40929570|NCT03773445|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy to evaluate the endoscopic activity by a Mayo endoscopic subscore
40929571|NCT03551262|DEVICE|OTSC|Positioning of OTSC in bleeding peptic ulcer
40929572|NCT03551262|DEVICE|TTS clip|Positioning of TTS clip in bleeding peptic ulcer
41278129|NCT06042686|DEVICE|RF Health MAC Device|Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
40754958|NCT00276380|DRUG|Placebo|Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
40754959|NCT00276380|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
40754960|NCT04799639|DRUG|Sindilimab +paclitaxel+ cisplantin|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles
40929573|NCT02894008|DRUG|ChAd63-KH|ChAd63-KH in adults and adolescents with persistent PKDL.
40929574|NCT00647829|DRUG|valdecoxib|valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
40929575|NCT00647829|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
40929576|NCT00647829|DRUG|placebo|placebo tablet by mouth for 2 doses over a 24-hour period
40929577|NCT03872011|DRUG|Vitamin C,thiamine,hydrocortisone|"Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU."
40929578|NCT03872011|DRUG|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
41127853|NCT03631238|DIAGNOSTIC_TEST|Blood sampling for total cholesterol and homocysteine and cognitive assessment by psychometric tests.|"all participant are subjected to cognitive assessment by psychometric tests by using the arabic version of Mini Mental State Exam (MMSE) and Memory Assessment Scale (MAS).~Blood samples were collected in the morning using 10 mL yellow top (plain) Vacutainer tubes.~Lipid profile (triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) were measured by Assiut university labs using Cholesterol Kits and analyzed by COBAS Integra analyzer.~Total cholesterol levels were calculated using the sum of the LDL and HDL plus one-fifth of triglyceride levels.~Samples of serum homocysteine are collected, centrifuged to separate plasma within 30 minutes after venipuncture and stored in specialized container in the Department of Clinical Pathology at (-20◦C) temperature.~Total homocysteine was measured by ELISA technique, Sinogen kits (Research Use Only) and Statfax-2100 microplate analyzer."
41127854|NCT02564744|DRUG|Debio 1562|Administered as IV Infusion.
41448907|NCT06432985|BEHAVIORAL|Behavioral Counseling (Cognitive Behavioral Therapy, CBT)|Participants will receive a 5-session smoking cessation behavioral counseling for approximately 15-20 minutes weekly. Sessions may be held by secure video conference or by telephone, per participant preference. Sessions will use CBT principles with MI incorporated for resolving reluctance to quit.
40929579|NCT01721980|DRUG|GLPG0974|
41127855|NCT02564744|DRUG|Rituximab|Administered as IV Infusion.
40929580|NCT01721980|DRUG|Placebo|
40929581|NCT02324127|DEVICE|hsp90|Detect plasma Hsp90α concentration of lung cancer patients
41127856|NCT01605448|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
41127857|NCT01354444|DRUG|Carvedilol|target dose of 25 mg daily which is half the maximum dose used in clinical practice
41127858|NCT01354444|DRUG|Placebo|a pill that will look like the active drug but will not contain any carvedilol
40929582|NCT02093026|DRUG|Rituximab|Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
40929583|NCT02093026|DRUG|Methotrexate|Participants will receive methotrexate 10-25 mg/week orally or parenterally.
40929584|NCT02093026|DRUG|Methylprednisolone|Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
40929585|NCT02093026|DRUG|Folic Acid|Participants will receive folic acid \>= 5 mg/week or equivalent.
40929586|NCT01346215|BIOLOGICAL|heparin sodium|5000 UI/mL
40929587|NCT01346215|BIOLOGICAL|heparin sodium|5000 UI/mL
40929588|NCT06057155|DIAGNOSTIC_TEST|ultrasound optic nerve sheath diameter assessment|ultrasound optic nerve sheath diameter assessment
40929589|NCT01567228|OTHER|CHICA GIS (enhanced electronic medical record)|An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
40929590|NCT02240147|BEHAVIORAL|home-based exercise training|During a 30 minute face-to-face motivational interview with an exercise specialist, the patient will be advised and coached about his exercise prescription, on how to implement it in his own daily life and on how to prevent relapse. Furthermore, the patients will receive instructions on how to monitor their exercise intensity and on recognizing adverse signals. During the following 12 weeks, patients will be asked to exercise 4.5 hours per week within the prescribed exercise intensity range according to the guidelines.
40929591|NCT03993093|OTHER|CD4 cell count|CD4 cell count from treatment naive HIV patients
40929592|NCT06087419|DRUG|chidamide|30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)
40929593|NCT06087419|DRUG|Venetoclax Oral Tablet|400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)
40929594|NCT06087419|DRUG|Inotuzumab Ozogamicin|0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)
40929595|NCT04622228|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
40929596|NCT04622228|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of atezolizumab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
40929597|NCT04622228|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
40929598|NCT04622228|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
40929599|NCT04622228|RADIATION|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.
40929600|NCT01931631|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
40929601|NCT01931631|BEHAVIORAL|ADA diet|Diet in accordance with the American Diabetes Association
40929602|NCT02232880|DRUG|Abatacept|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
40929603|NCT02232880|DRUG|Placebo|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
40929604|NCT02712814|DRUG|Topical hormonal cream (estrogen)|Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
40929605|NCT02712814|PROCEDURE|Pelvic floor physical therapy|PF physical therapy once weekly for 3 months
40929606|NCT02712814|PROCEDURE|Low Level Laser therapy|non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
40929607|NCT01625260|BIOLOGICAL|ALT-801|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
40929608|NCT01625260|DRUG|Gemcitabine|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
40929609|NCT02382250|BEHAVIORAL|Survey|Survey will be given to all participants
40929610|NCT06050603|DEVICE|TMS|"The target locations of TMS will be cortical regions defined by either anatomical landmarks or functional regions derived from the individual's functional and structural MRI for Aim 1. TMS target locations for Aim 2 and 3 are determined by Aim 1's results. These TMS target regions will be guided by a navigation system.~TMS will be parametrically varied with combinations of pulse strength and frequencies based on experimental conditions. TMS strength will be referred to the resting motor threshold (rMT), which will be determined independently for each participant. TMS pulses will be delivered at fixed time instants for Aim 2 and at time instants based on the phase of oscillatory neural activity for Aim 3."
40929611|NCT05155462|OTHER|One or two phone call|Phone call to collect patient data
40929612|NCT04104269|DIAGNOSTIC_TEST|Heart rupture|Free wall rupture and Ventricular septal rupture
41127859|NCT05663346|OTHER|Cannabis & Cancer digital educational intervention|The Cannabis \& Cancer intervention is available on Moodle learning management system in French language. It aims to influence nurses' self-efficacy, attitudes, intentions, and knowledge regarding the safe and efficient use of cannabis by young adults diagnosed with cancer.
40929613|NCT04284150|DRUG|Dexmedetomidine; Midazolam;|Treatment of supraventricular tachycardia in patients with non-cardiac surgery by dexmedetomidine during the perioperative period
40929614|NCT01466543|DRUG|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, one time
40929615|NCT01466543|DRUG|Placebo|Placebo
40929616|NCT03461354|OTHER|MucoLox|MucoLox formulation, with MucoLox as the delivery vehicle, combined with preserved water, beta-glucan, dexpanthenol, and glutamine
40929617|NCT03461354|OTHER|Sodium Bicarbonate|Sodium bicarbonate oral rinse
40929618|NCT01797770|DRUG|polyethylene glycol|mechanical bowel preparation with polyethylene glycol one day prior to surgery
40929619|NCT01797770|OTHER|No Preparation|No laxatives or bowel preparation
40929620|NCT03374618|OTHER|Blood sample|Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
40929621|NCT03347578|DIAGNOSTIC_TEST|Ultrasonography|Diaphragmatic ultrasound was performed to investigate diaphragmatic function after thoracic surgery
40929622|NCT04803123|DRUG|Copanlisib|Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.
41127860|NCT05663346|OTHER|Standard information regarding cannabis use in oncology|Participants will be offered basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
41448908|NCT06432985|BEHAVIORAL|TUD Treatment as Usual (TAU)|Participants assigned to TAU will receive referral to VA Tobacco Cessation Clinic and provision of the VA Telequit quitline. The VA Tobacco Cessation Clinic is modeled after VA Tobacco Cessation Clinics across all VA facilities and involves delivery of brief counseling and pharmacotherapy for TUD if desired. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for a recommended minimum of five sessions to develop a quit plan and receive counseling, strategies to prevent relapse, and weekly proactive follow-up calls based on National Cancer Institute guidelines.
41448909|NCT05705869|DIAGNOSTIC_TEST|NT-proBNP|NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.
41278130|NCT04807361|BEHAVIORAL|Auditory biofeedback traing|Subjects who wear MFCLs for myopia control will receive one episode of auditory biofeedback training, and their accommodative responses to various demands (0, 2.5, 3, and 4 D) before and after the training were measured using a power refractor.
41448910|NCT03349567|BEHAVIORAL|Audit-and-feedback|We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
40929623|NCT00419809|DRUG|SB-681323 oral tablets|
41127861|NCT06407804|OTHER|Thrower's Ten Exercise Program|No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 2 sets for 10 repetitions with 1 minute rest between sets.
41127862|NCT06407804|OTHER|Routine physical therapy.|"In this, the exercises will be performed in 2 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min Per Session)"
41127863|NCT01557036|DEVICE|Pipeline Embolization Device|Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
41127864|NCT01211184|DIETARY_SUPPLEMENT|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
41278131|NCT05087056|COMBINATION_PRODUCT|MenABCWY vaccine|Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.
41278132|NCT05087056|COMBINATION_PRODUCT|Placebo|Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.
41278133|NCT01275638|DRUG|Prednisolone|Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
41278134|NCT06018337|DRUG|DB-1303/BNT323|IV
41278135|NCT06018337|DRUG|Capecitabine|Oral
41278136|NCT06018337|DRUG|Paclitaxel|IV
41278137|NCT06018337|DRUG|Nab-paclitaxel|IV
41278138|NCT06078384|DRUG|Pembrolizumab 25 mg/ml|"Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion."
41278139|NCT06078384|DRUG|Paclitaxel injection|Injectable solution for IV administration. Dose of 80 mg/m² weekly.
41278140|NCT04387292|PROCEDURE|Ophthalmologic exam|"* Visual acuity (ETDRS exam)~* Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test~* Lipiview~* Eye pressure measurement (air tonometer)~* Wide field retinophotography~* Multicolor and auto-fluorescence retinophotography~* Indocyanine green retinal angiography~* Optical coherence tomography (OCT) B posterior pole scan~* OCT Angiography (OCT-A) of the optic nerve and posterior pole~* Adaptive optics~* Visual field (Humphrey)"
41278141|NCT03050125|DEVICE|Hypo-osmolar drop 1|180 mOsmol sterile saline drops used as a contact lens rewetting drop.
41278142|NCT03050125|DEVICE|Hypo-osmolar drop 2|240 mOsmol sterile saline drops used as a contact lens rewetting drop.
41448911|NCT05309135|DRUG|HCEC-1|HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor
41448912|NCT04418349|PROCEDURE|"posterior component separation modified TAR technique Transversus Abdominids Release"|"Evaluation of posterior component separation modified TAR technique Transversus Abdominids Release in the treatment of parastomal hernia"
41448913|NCT05513677|DEVICE|M4D|Coated catheter
40929624|NCT06505811|BEHAVIORAL|Guaranteed Income ($500/monthly)|Participants receive $500 monthly for up to 18 months.
40929625|NCT06505811|BEHAVIORAL|Active Comparison ($20/monthly)|Participants receive $20 monthly for up to 18 months.
40929626|NCT02060448|BEHAVIORAL|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
41448914|NCT05513677|DEVICE|Standard of Care|Standard of Care
41453444|NCT05138094|PROCEDURE|Minimally invasive two-stage resection|Two minimally invasive surgical procedures wherein the primary colorectal carcinoma and the liver metastases are removed
40929627|NCT02060448|BEHAVIORAL|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
40929628|NCT06227598|OTHER|Procedure: Additional biopsies collection|Procedure: Additional biopsies collection We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
40929629|NCT00309660|DRUG|Rosiglitazone|
41278143|NCT03050125|DEVICE|Iso-osmolar drop|300 mOsmol sterile saline drops used as a contact lens rewetting drop.
41278144|NCT05220150|DEVICE|FFC-MRI scan|Undergo one FFC-MRI scan.
41278145|NCT04720157|DRUG|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
41278146|NCT04720157|DRUG|68Ga-PSMA-11|Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
41278147|NCT04720157|DRUG|ARDT|Administered orally on a continuous basis as per package insert and guideline
41278148|NCT04720157|DRUG|ADT|ADT are administered as per physician order
41278149|NCT04810052|BEHAVIORAL|Behavioral Intervention|Perform 1 nice thing
41278150|NCT04810052|BEHAVIORAL|Behavioral Intervention|Write a letter or note of gratitude
40919344|NCT01305590|OTHER|Survey to Understand Medication Adherence among HIV Patients|"We want to better understand how this particular population would react to commitment devices designed to increase medication adherence. We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
41278151|NCT04810052|BEHAVIORAL|Behavioral Intervention|Track daily activities
41278152|NCT04810052|OTHER|Interview|Ancillary studies
41278153|NCT04810052|OTHER|Quality-of-Life Assessment|Ancillary studies
41278154|NCT04810052|OTHER|Questionnaire Administration|Ancillary studies
41278155|NCT05117970|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
41278156|NCT04314687|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.
41127865|NCT01211184|DIETARY_SUPPLEMENT|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
41127866|NCT01211184|BEHAVIORAL|Fasting.|The patient is fasting from midnight before the surgery.
41127867|NCT01419210|OTHER|Pre-study Questionnaire|Assess the interest level for various CAM topics through feedback received from the study participants
41127868|NCT01419210|OTHER|Educational Presentations|Attend a two-hour presentation each week for four weeks
41127869|NCT01419210|OTHER|CAM Therapies|Integrate the CAM topics of highest interest into participant's regular care
41448915|NCT03359863|DRUG|Pirfenidone|Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.
41127870|NCT01419210|OTHER|Post-study Questionnaire|Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
41127871|NCT03961841|RADIATION|chemoradiation with weekly 5Fu and oxaliplatin|5Fu 225 mg/m2 IV daily continuous infusion；oxaliplatin 40 mg/m2/week
41127872|NCT03961841|DRUG|Perioperative mFLOT|Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles
41127873|NCT03961841|DRUG|Perioperative FOLFOX|Perioperative oxaliplatin 85 mg/m2; 5Fu 2.8g/m2 civ 48 hours; repeated every 2 weeks; total of 12 cycles
41127874|NCT02929420|DRUG|Xiaoru Sanjie capsules|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
41127875|NCT02929420|DRUG|Xiao Yao pills|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
40919345|NCT00422864|DRUG|oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
40919346|NCT00422864|DRUG|fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
40919347|NCT00422864|DRUG|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
40919348|NCT00422864|PROCEDURE|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
40919349|NCT05006300|OTHER|Topialyse Baume Barrière|Evaluation of the efficacy of the cosmetic product SVR TOPIALYSE Baume Barrière on the reduction of topical corticosteroid consumption in children from 3 months to 17 years old presenting mild to moderate atopic dermatitis after 28 and 56 days of use, at one or two apllications /day.
40919350|NCT04158843|PROCEDURE|Radical resection|Radical resection is performed, and the cutting edge is negative.
40919351|NCT04158843|RADIATION|Radical radiotherapy|Radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy).
40919352|NCT04158843|OTHER|Palliative treatment|Including palliative internal fixation, radiotherapy, systemic chemotherapy, endocrine therapy or targeted therapy
40929630|NCT01556347|DRUG|Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis|
40929631|NCT00586664|DRUG|Bepreve (bepotastine besilate ophthalmic solution) 1.5%|sterile ophthalmic solution
40929632|NCT00586664|DRUG|placebo comparator|sterile ophthalmic solution
40929633|NCT00586664|DRUG|Bepotastine Besilate Ophthalmic Solution 1.0%|sterile ophthalmic solution
40929634|NCT01594151|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway at visit 1
40929635|NCT00923364|DRUG|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
40929636|NCT00923364|DRUG|Fludarabine(Fludara,Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
40929637|NCT00923364|PROCEDURE|Total Body Irradiation (TBI)|200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
40929638|NCT00923364|PROCEDURE|Allogeneic Hematopoietic Stem Cell (HSC)|stem cell transplant
40929639|NCT00923364|DRUG|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
40929640|NCT01879579|OTHER|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
40929641|NCT03665857|BEHAVIORAL|a multicomponent intervention|"1. School-level policies Students will not be allowed to drink sugar-sweetened beverage or eat unhealthy snacks in schools and drinking water will be advocated.~2. Monitoring of students' weight and height Students will be monitored their weight and height monthly.~3. Promotion of physical activity Students will be required to perform at least 60 minutes of moderate to vigorous physical activity each day in school and increase their physical activity outside school (reaching 30 minutes per weekday and one hour per weekend day).~4. Health education activities Health education activities will be provided for students (10 sessions, 40 minutes per session, 2-3 weeks once), parents and school teachers.~5. The mobile application The mobile application will disseminate health education knowledge among students, parents and teachers, monitor and provide feedback of students' BMI status and diet and physical activity behaviors."
40929642|NCT00416728|DRUG|Aliskiren|
40929643|NCT00416728|DRUG|Valsartan|
40929644|NCT04112498|DRUG|relatlimab|Specified dose on Specified days
40929645|NCT04112498|DRUG|nivolumab|Specified dose on Specified days
40929646|NCT04112498|DRUG|rHuPH20|Specified dose on Specified days
40929647|NCT04972643|DIETARY_SUPPLEMENT|EPA|EPA 2000mg Soft capsules
40929648|NCT04972643|DIETARY_SUPPLEMENT|DHA|DHA 2000mg Soft capsules
40929649|NCT04972643|DIETARY_SUPPLEMENT|Placebo|Placebo Soft capsules
41127876|NCT03992274|OTHER|Enhanced implementation of PrEP|During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
41127877|NCT05055752|DRUG|Pharmaceutical-lipid aspirin (PL-ASA)|Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
41127878|NCT01432106|DRUG|Aliskerin/Valsartan and Rampiril|"Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)"
41127879|NCT04400734|OTHER|No intervention, observational study|no intervention
41127880|NCT03234374|COMBINATION_PRODUCT|INL-001 (bupivacaine HCl collagen implant)|3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
41127881|NCT03234374|DRUG|Marcaine 0.25% infiltration|Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
41127882|NCT02426229|DRUG|dabigatran etexilate|dabigatran etexilate 75mg orally twice a day for 6 months
41278157|NCT04314687|BIOLOGICAL|Conditioned Medium|Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.
40929650|NCT05117957|DRUG|Sorafenib|Subjects will receive sorafenib 600mg orally daily. When dose reduction is necessary during the treatment of HCC, the sorafenib dose should be reduced to 400mg once daily. Escalation of sorafenib from a daily dose of 600mg to 800mg (400mg twice daily) is allowed if the subject who is tolerating the 600mg sorafenib dose level well. Treatment will continue until progression, unacceptable toxicity, withdrawal of consent, or study end, whichever occurs first.
40929651|NCT02510755|OTHER|MRI|
40929652|NCT06234332|OTHER|No Interventions|No intervention This is an observational study without any intervention
40929653|NCT02258984|DEVICE|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
40929654|NCT05321056|DEVICE|masks (surgical mask, respirator)|The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model in the procedure room for measuring droplet exposure.
40929655|NCT06553859|OTHER|No intervention conducts.|The type and method of breast reconstruction with sillicon implants and ADM implanting is now the standard treatment of breast cancer in korea. no any specific intervention has occurred during the surgery.
40929656|NCT01085500|BEHAVIORAL|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
40929657|NCT01085500|PROCEDURE|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
41278158|NCT04314687|OTHER|Standard Therapy|Standard therapy for cerebral palsy such as physiotherapy
40929658|NCT06134531|DRUG|MR001|"Dose Level 1: 0.5 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 1 cycle~Dose Level 2: 2 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 3: 6 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 4: 10 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 5: 15 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 6: 20 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle"
40929659|NCT05277480|DRUG|Apatinib+IE|apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
40929660|NCT05277480|DRUG|IE|ifosfamide ivgtt ; etoposide ivgtt .
40929661|NCT01073371|DRUG|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
40929662|NCT01834859|BEHAVIORAL|Multidisciplinary outpatient program|Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
40929663|NCT01834859|BEHAVIORAL|Inpatient lifestyle program|Diet (phase 1) and lifestyle intervention (phase 2)
40929664|NCT05578027|PROCEDURE|Mild moxibustion with moxa stick|To conduct this intervention, we used moxa sticks which were 1.5 cm in diameter, 13 cm long, and weighed 12 gram to perform mild moxibustion manipulation at the control acupoint (the left side Pishu acupoint) or Mingmen acupoint in 2 trial phases. The main ingredient of the moxa was dried mugwort leaf, produced in Vietnam. All moxa materials were obtained from the Sai Gon TCS Co., Ho Chi Minh City, Vietnam.
40929665|NCT03023670|PROCEDURE|cardiopulmonary bypass|Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
40929666|NCT03023670|PROCEDURE|cardiopulmonary bypass|Low rate (4\\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
40929667|NCT03348592|DIETARY_SUPPLEMENT|Oligofructose-enriched inulin (p-inulin)|
40929668|NCT03348592|OTHER|No treatment|Patients do not take a supplement during the first 8 weeks or the last 8 weeks of the study.
40929669|NCT04856670|PROCEDURE|Cataract surgery|Cataract surgery- Manual or femtosecond laser assisted
40929670|NCT02755532|DRUG|Bupivacaine 0,25%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
40929671|NCT02755532|DRUG|Bupivacaine 0,5%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
40929672|NCT04413227|DRUG|Pegylated Recombinant Human Endostatin（PEG-ENDO）|PEG-ENDO 1 mg/kg or 2 mg/kg or 4 mg/kg or 6 mg/kg or 8 mg/kg+Docetaxel 75 mg/m2，once every 3 weeks at day 1
40929673|NCT00645788|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
40929674|NCT00645788|DRUG|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
40929675|NCT00645788|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
40929676|NCT00645788|DRUG|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
40929677|NCT02115126|BIOLOGICAL|LMP2A-loaded conventional DC vaccine|"Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be \> 1.5.~Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be \> 1.5.~Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination."
40929678|NCT02115126|BIOLOGICAL|DUK-CPG-001|"On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.~DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.~Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination."
40929679|NCT01030601|DRUG|Dexamethasone sodium phosphate|0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
40929680|NCT05354674|DRUG|Bevacizumab|"AEM A：The specialist's decision to add bevacizumab to chemotherapy will be based on their own judgment~ARM B：The patient's PET/CT imaging, pathology, and clinical information were input into the signature, and the FOLFOX+Bevacizumab regimen was selected when the output label was 1. FOLFOXIRI chemotherapy regimen was selected when the output label was 0"
41448916|NCT03873363|DEVICE|PS TKA|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
41448917|NCT03873363|DEVICE|CR TKA|Implantation of a cruciate retaining Total Knee Arthroplasty.
40929681|NCT04191460|DRUG|cRGD-ZW800-1.|Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery
40929682|NCT02095314|BIOLOGICAL|Pentavalen|Batch 5010613
40929683|NCT01490398|DRUG|Rosuvastatin|After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is \> 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
40929684|NCT03272789|OTHER|Interviews with coach|For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
40929685|NCT02145702|OTHER|Aerobic Exercise|Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
40929686|NCT02145702|PROCEDURE|Standard Care Dialysis|12 weeks of standard of care.
40929687|NCT04054947|BEHAVIORAL|Suicide Prevention Program|Structured care management to improve adherence to discharge planning.
40929688|NCT00376818|BEHAVIORAL|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
40929689|NCT00376818|OTHER|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
40929690|NCT00376818|OTHER|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
40929691|NCT00376818|OTHER|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
40929692|NCT00376818|BEHAVIORAL|mind-body intervention procedure|"Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges."
40929693|NCT00376818|PROCEDURE|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
40929694|NCT01850927|PROCEDURE|Remote ischaemic preconditioning|
40929695|NCT01850927|PROCEDURE|Control|
40929696|NCT04980326|BEHAVIORAL|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, will be adapted for use on a smartphone or other device with internet access during Phase 1 of RESPOND. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
41127883|NCT05365191|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Participants undergo sentinel lymph node biopsy for breast cancer, and use blue dye/Tc99m radioisotope as primary tracer. Indocyanine green near infrared fluorescence as secondary tracer for mapping.
41127884|NCT01579968|DRUG|eptacog alfa (activated)|Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
41127885|NCT03185052|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
41448918|NCT04050254|DEVICE|Real tDCS|Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
40929697|NCT04980326|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
40929698|NCT04980326|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a brief intervention consisting of providing basic information for peer support in times of emotional distress
40929699|NCT02787070|DRUG|PQ supervised|
40929700|NCT02787070|DRUG|PQ unsupervised|
40929701|NCT04758000|DRUG|Metformin Hydrochloride|"Metformin will be administrated according with patients body mass index (BMI).~Patients between 14 and 18 years old or with BMI ≤ 20: 500 mg two times a day Patients older than 18 years or with BMI \> 20: 850 mg two times a day.~In all cases, metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified."
40929702|NCT02628665|DRUG|photosensitizer(photofrin)|photosensitizer(photofrin): 2mg/kg
40929703|NCT02628665|DEVICE|630 nm laser irradiation (DIOMED)|630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
40929704|NCT04761627|DRUG|Ustekinumab|Participants will receive subcutaneous (SC) injection of ustekinumab.
40929705|NCT04761627|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
41278159|NCT04706572|OTHER|Stimulation with external auditory bio-feedback|Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone
40929706|NCT04643301|DRUG|Liraglutide Pen Injector|Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
40929707|NCT05204303|DIAGNOSTIC_TEST|24-hour pH-impedance monitoring|Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.
40929708|NCT05204303|OTHER|Symptom questionnaires|Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)
40929709|NCT05204303|OTHER|ROME IV Diagnostic Questionnaire|A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)
40929710|NCT02166177|DRUG|Autologous regulatory T cell product|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
41278160|NCT02249052|DRUG|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
41278161|NCT02249052|DRUG|placebo|Placebo
40929711|NCT04002570|OTHER|blood samples collection|blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.
40929712|NCT06024343|PROCEDURE|MPD Repair or Reconstruction|During laparoscopic or robotic pancreatic tumor enucleation, if the main pancreatic duct (MPD) is damaged due to its proximity or encasement by the tumor, MPD repair or reconstruction is performed.
40929713|NCT03963401|DRUG|PF-06700841|Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
41448919|NCT04050254|DEVICE|Sham tDCS|Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
40929714|NCT03963401|OTHER|Placebo|Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
40929715|NCT06136988|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W
40929716|NCT06136988|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W
40929717|NCT06136988|DRUG|Cisplatin for injection|Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W
40754961|NCT04146909|DIAGNOSTIC_TEST|Hyperinsulinemic-euglycemic clamp|After an overnight fast and an equilibration period lasting 2 hours, the 2-step euglycemic-hyperinsulinemic clamp study will be performed. A primed-continuous infusion of regular insulin will be given at 8 mU/(m2 × min) during the first 2 hours, and increased to 40 mU/(m2 × min) for the subsequent 2 hours. Plasma glucose levels will be measured every 5 min, and a variable glucose infusion will be initiated to maintain levels at ∼90 mg/dl. Plasma samples will be drawn at baseline and throughout the infusion period for measurement of isotope enrichment, insulin, NEFA, glycerol turnover, and additional hormones which may be altered with lactation. Approximately 160 mL of blood will be drawn at this visit.
40929718|NCT06136988|DRUG|Paclitaxel|Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W
40754962|NCT02245724|BIOLOGICAL|Stem Cell|Autologous bone marrow mononuclear cell transplantation
40929719|NCT06136988|RADIATION|Simultaneous Radiotherapy|Radiotherapy (28×1.8Gy)
40929720|NCT05049720|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
40929721|NCT02269189|DRUG|BIIL 284 BS, high dose|
40929722|NCT02269189|DRUG|BIIL 284 BS, low dose|
40929723|NCT02269189|DRUG|Placebo|
41278162|NCT01033994|BIOLOGICAL|AS902330|10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
41448920|NCT04050254|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
40754963|NCT01819480|PROCEDURE|Transoral robotic surgery|Transoral robotic surgery using the daVinci robot to remove primary tumor
40754964|NCT03942055|DEVICE|Sonosite Edge II Ultrasound|Certified by UAB Biomedical and Clinical Engineering Dept- certification #9365 Mechanism of Action: Point of Care Bedside Ultrasound
40754965|NCT00941421|DEVICE|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
40754966|NCT00049309|DIETARY_SUPPLEMENT|dietary intervention|
40754967|NCT00049309|DIETARY_SUPPLEMENT|flaxseed|
41127886|NCT04592185|DEVICE|Fenestrated Anaconda™ Device|Treatment of complex abdominal aortic aneurysms
41127887|NCT00419341|BIOLOGICAL|Human Normal Immunoglobulin for Subcutaneous Administration|
41278163|NCT02574221|DRUG|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
41278164|NCT02574221|DRUG|cavity protection toothpaste|0.243% sodium fluoride toothpaste
41278165|NCT04813744|PROCEDURE|Atraumatic restorative treatment|
41448921|NCT03510260|OTHER|Study Group I|Study group I (e-confirmed consent only) will receive an electronic invitation to complete the consent process electronically.The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group).
40929724|NCT05272085|PROCEDURE|Ultrasound Guided Lavage|After local anesthesia of subcutaneous tissue, lavage will be performed under the guidance of ultrasound using an 18-gauge needle with injectors filled with 4 ml of saline. The needle will be advanced to the center of the calcific deposit. The injector will be kept as parallel to the ground as possible. The plunger of the injector will be pushed with a gently pressure and then released. Calcific deposits are expected to be filled into the syringe along with saline. It is predicted that the clear saline will gradually turn white and become cloudy due to the incoming calcific deposits. When the color of the liquid becomes cloudy, the syringe will be removed without moving the needle, and a new syringe containing 4 ml saline will be placed in its place. Thus, the aspirated calcific deposits will not be reinjected. The same process will be repeated with a new saline filled syringe. After the procedure, 2 ml dexamethasone and 3 ml lidocaine will be injected in subacromial bursa.
40929725|NCT05272085|PROCEDURE|Ultrasound Guided Subacromial Bursa Injection|2 ml dexamethasone and 3 ml %2 lidocaine will be injected in the subacromial bursa using a 21-gauge needle under ultrasound guidance.
40929726|NCT05204407|DIETARY_SUPPLEMENT|Luteolin|The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form
40929727|NCT05204407|DIETARY_SUPPLEMENT|Placebo|The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form
41278166|NCT02167269|DEVICE|Baby EAR|A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
41278167|NCT01129193|OTHER|Pharmacodynamic Studies|"Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).~Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3."
41278168|NCT01129193|OTHER|Fatigue Inventory|Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.
41278169|NCT01129193|OTHER|Pharmacogenomic studies|Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.
40929728|NCT06425627|PROCEDURE|spinal anesthesia|An intrathecal anesthetic technique.
40929729|NCT06425627|PROCEDURE|general anesthesia|An intravenous (combined with inhalation) anesthetic technique.
41278170|NCT01129193|DRUG|AR-42|Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
40754968|NCT04527731|DEVICE|Accelerometry|Participants are asked to wear an accelerometer during the day for a period of seven days.
40754969|NCT00621322|BIOLOGICAL|GSK Biologicals' AS01B adjuvant|Intramuscular injection, 2 doses
40754970|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1|Intramuscular injection, 2 doses
40929730|NCT04321785|OTHER|Placebo|placebo capsule (mannitol)
41278171|NCT01662999|DRUG|Saxagliptin|
41278172|NCT01662999|DRUG|Dapagliflozin|
41278173|NCT05463133|DRUG|Sirolimus|Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
41448922|NCT03510260|OTHER|Study Group II|The study group II will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent
40929731|NCT04321785|OTHER|Caffeine|caffeine capsule (80 mg of caffeine plus mannitol)
40929732|NCT00954252|DRUG|CHF 5074|1x, oral capsule, single dose
40929733|NCT00954252|DRUG|placebo|placebo, oral capsule, single dose
41448923|NCT03510260|OTHER|Control Group|Subject will go through the consenting process at the day of surgery at the preop visit as standard in our institution only.
40929734|NCT00954252|DRUG|CHF 5074|2x, oral capsule, single dose
40929735|NCT00954252|DRUG|CHF 5074|4x, oral capsule, single dose
40929736|NCT00954252|DRUG|CHF 5074|8x, oral capsule, single dose
40929737|NCT00954252|DRUG|CHF 5074|16x, oral capsule, single dose
41448924|NCT01038960|BEHAVIORAL|Exercise training|3 months supervised interval training
40754971|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2|Intramuscular injection, 2 doses
40754972|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3|Intramuscular injection, 2 doses
40929738|NCT00954252|DRUG|CHF 5074|24x, oral capsule, single dose
41127888|NCT06436326|DEVICE|Continuous glucose monitor|"Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set), respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 14 days after starting to wear), the investigators will provide a glucose monitor report. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor report was given approximately 14 days after starting to wear."
41127889|NCT06436326|BEHAVIORAL|Perinatal nursing care for gestational diabetes|Individual nursing care and consultation for pregnant women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support.
41127890|NCT06436326|OTHER|Blood glucose meters (BGM)|"Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 14 days of glucose monitoring at 24-32 weeks of pregnancy, a glucose monitor report will be given to the participants. After the 14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor report will be given to the participants."
41127891|NCT02848794|DRUG|Apatinib and Irinotecan|Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
41127892|NCT03638674|OTHER|DXA + CT|Two dual-energy X-ray scans + CT scan
41127893|NCT02755805|BEHAVIORAL|CO-OP|
41127894|NCT02755805|BEHAVIORAL|Attention Control|
41127895|NCT00954668|PROCEDURE|immediate angiography and revascularization|immediate angiography \< 2 hours after randomization
41127896|NCT00954668|PROCEDURE|early invasive angiography|early invasive angiography 12-72 h after randomization
41127897|NCT06505954|OTHER|Survey study|Survey study among medical students about lower urinary tract symptoms
41127898|NCT02325349|DRUG|radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
41127899|NCT06318507|COMBINATION_PRODUCT|Fecal microbial diversity|Fecal microbiome diversity via 16S rRNA and metagenomic sequencing
41127900|NCT04824274|DRUG|fentanyl|Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
41127901|NCT04824274|DRUG|morphine|Morphine 75 mcg will be injected intrathecally during spinal anesthesia.
41127902|NCT04824274|PROCEDURE|Transversus abdominis plane block|Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.
41127903|NCT04824274|PROCEDURE|Sham block|Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.
41127904|NCT04729972|COMBINATION_PRODUCT|NT-501 CNTF implant|Single implantation of CNTF-secreting NT-501 device into one eye
41127905|NCT02461628|BEHAVIORAL|Malaria RDT & conditional voucher for ACT from retail sector|Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test
41127906|NCT00439270|DRUG|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
41127907|NCT00439270|DRUG|Docetaxel|Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.
41127908|NCT03565484|DRUG|susceptibility guided therapy|Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.
41278174|NCT05463133|DRUG|Cyclophosphamide|Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
41278175|NCT05463133|DRUG|Alemtuzumab|Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
41448925|NCT05647005|OTHER|Classical music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to classical music for 30 minutes after the babies are fed.
40929739|NCT06418464|DEVICE|AP-A Dosage Decision Support System|The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.
40929740|NCT02430129|PROCEDURE|Total knee arthroplasty|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
40929741|NCT02430129|PROCEDURE|Unicompartment knee arthroplasty|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
40929742|NCT02430129|DEVICE|Persona|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
40929743|NCT02430129|DEVICE|Oxford|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
40929744|NCT03123185|DRUG|Placebo|Tablet and solution formulation
40929745|NCT03123185|DRUG|BI 705564 (Test)|Fed state
40929746|NCT03123185|DRUG|BI 705564 (Reference)|Fasting state
40929747|NCT05573412|OTHER|Cellular analysis|Previously cryopreserved samples will be analyzed for total nucleated cell count (TNC), cell viability and proliferative potential
40929748|NCT01695668|DRUG|Lotemax|Ophthalmic corticosteroid. It decreases inflammation of the eye
40929749|NCT01695668|DRUG|Restasis|Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
41127909|NCT03565484|DRUG|personal medication history guided therapy|Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
41278176|NCT05463133|DRUG|Busulfan|Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
41278177|NCT05463133|BIOLOGICAL|Pheripheral blood stem cells|Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
40929750|NCT04330105|DEVICE|ECG, HolterECG ,Echocardiography|ECG, HolterECG ,Echocardiography to determine any type of arrythmia,ischaemic heart disease,valvular heart disease,systolic and diastolic dysfunction
40929751|NCT01060345|DRUG|Polyphenon E|three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
41127910|NCT03565484|DRUG|salvage treatment for failed eradication|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
41448926|NCT05647005|OTHER|Harp music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to harp music for 30 minutes after the babies are fed.
41453445|NCT02066038|DRUG|Erlotinib|150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
41453446|NCT06050239|DRUG|177Lu-PSMA-0057|The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.
40754973|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1|Intramuscular injection, 2 doses
41127911|NCT05465018|DEVICE|Happy Flow / Baseline|Baseline (without make-up or mask)
40929752|NCT01252303|BEHAVIORAL|Nutrisystem|Nutrisystem meal replacements for 12 weeks
40929753|NCT05275361|BEHAVIORAL|Social Contact Reminder|-The social contact will remind patient about screening mammogram appointment
40929754|NCT00196183|PROCEDURE|trigger-guided catheter-ablation|trigger-guided ablation of paroxysmal atrial fibrillation
40929755|NCT00196183|PROCEDURE|trigger+substrate-guided catheter ablation|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
41278178|NCT05463133|DRUG|Emapalumab-Izsg|Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.
40929756|NCT02607644|DEVICE|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA) for Control group
40929757|NCT02607644|DEVICE|Laryngeal Tube (LT)|Laryngeal Tube (LT) for Intervention group
40929758|NCT05696366|DRUG|Sotagliflozin|Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.
40929759|NCT05696366|DRUG|Volagidemab|Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
40929760|NCT01312623|OTHER|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
40929761|NCT00409331|DRUG|Amifostine|500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
41278179|NCT05463133|DRUG|Tociluzumab|Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
41278180|NCT05463133|DRUG|Total Body Irradiation|Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
41127912|NCT05465018|DEVICE|Make-up|To test device on participant who is wearing facial make-up
41127913|NCT05465018|DEVICE|Sunglasses|To test device on participant who is wearing sunglasses
41127914|NCT05465018|DEVICE|Face mask|To test device on participant who is wearing a facial mask
41127915|NCT05465018|DEVICE|Minimum requirements camera|To test the minimum requirements of the camera
41127916|NCT05465018|DEVICE|Worst case hardware|To test if software still works with an older smartphone
41127917|NCT05465018|DEVICE|Damaged lens|To test if software is still working when the lens of the smartphone is damaged
41127918|NCT05465018|DEVICE|Face or chest outside test frame|To test software if the participants face or chest is outside the test frame
41278181|NCT06656819|DEVICE|Magstim Rapid2|"AIM 1: Investigate the estradiol effect on spinal circuit excitability post afferent (sensory) mediated subthreshold motor priming in young healthy women and men.~AIM 2: Characterize the Input output property of spinal circuit excitability following descending drive (motor) mediate priming in young healthy participants~AIM 3: Examine the estradiol effect on spinal circuit excitability following descending drive (motor) mediated priming in young healthy females"
41278182|NCT05829057|BIOLOGICAL|Intravenous injection of P-IL-2|Ia :Single dose intravenous injection of P-IL-2；
41278183|NCT05829057|BIOLOGICAL|P-IL-2 plus Anti-PD-1 Monoclonal Antibody|Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；
40929762|NCT00409331|PROCEDURE|Intensity- Modulated Radiation Therapy|2.0 to 2.2 Gy delivered in 30 fractions
40929763|NCT01445054|DRUG|111Indium CHX-A|111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
40929764|NCT00749814|DIETARY_SUPPLEMENT|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
40929765|NCT00749814|OTHER|Placebo tablets|Placebo
40929766|NCT01435551|OTHER|Hypnotherapy|1 year study,1 hour session per month for 9 months, 3 remaining months evaluation
40929767|NCT02940106|DEVICE|Cryotop device|a different device for oocyte vitrification (with a very high cooling rate)
40929768|NCT02940106|DEVICE|CBSvit device|a different device for oocyte vitrification (with a lower cooling rate)
40929769|NCT01311635|DRUG|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
40929770|NCT01311635|DRUG|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
40929771|NCT01311635|DRUG|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
40929772|NCT05990621|BIOLOGICAL|Anti-CD70 CAR-T cells|0.6×106/Kg ～ 5.0×106/Kg; cells will be infused intravenously.
40929773|NCT01271582|DRUG|Irinotecan, 5FU, leucovorin|FOLFIRI regimen every 2 weeks \[irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)\]
40929774|NCT03844295|DEVICE|Activated Inspire® Upper Airway Stimulation System|At first, INSPIRE® device will be active a month
40929775|NCT03844295|DEVICE|Inactivated Inspire® Upper Airway Stimulation System|"After 15 days wash-out INSPIRE® device will be inactivated for a second period of one month."
40929776|NCT06278233|DEVICE|Transcranial direct current stimulation|TDCS involves applying a weak electrical current across the head through electrodes placed on the scalp and modulating the resting membrane potential of neurons in the underlying cortex.
40929777|NCT01407003|DRUG|LIK066|Participants will receive a single or multiple doses of LIK066
40929778|NCT01407003|DRUG|Placebo|Participants will receive a single or multiple doses of a matching placebo
40929779|NCT04942457|BEHAVIORAL|Fasting|Prolonged fasting for 7-10 days (caloric intake \<500 kcal in liquid form)
40929780|NCT04095676|PROCEDURE|VATS group|VATS procedure with drainage, including rinse with NaCl
40929781|NCT04095676|PROCEDURE|Drain and intrapleural therapy group|Drainage with pigtail and Intrapleural therapy
40929782|NCT05688826|DIETARY_SUPPLEMENT|Sugar|75 g sugar dissolved in 0.8 dl water and flavored with lemon. Ingested during 5 minutes
40929783|NCT00791076|DRUG|Placebo|2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
40929784|NCT00791076|DRUG|Pancreatic Polypeptide (PP)|2pmol/kg-1/min-1 PP infused continuously over 72 hours.
40929785|NCT02925533|DRUG|B-701|B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
40929786|NCT02925533|DRUG|Pembrolizumab|Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
40929787|NCT03516903|DRUG|Methotrexate|ddMTX-LDE (Methotrexate carried by a lipid nanoemulsion)
40754974|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2|Intramuscular injection, 2 doses
40754975|NCT06504732|DRUG|IAH0968|Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.
40929788|NCT03516903|DRUG|Placebo|Placebo-LDE (Lipid nanoemulsion)
40929789|NCT03516903|DRUG|Folic Acid|Folic acid pill
40929790|NCT00629278|BIOLOGICAL|trastuzumab|
40929791|NCT00629278|DRUG|aromatase inhibition therapy|
40929792|NCT00629278|DRUG|cyclophosphamide|
41278184|NCT06657716|DEVICE|ANTERION investigational|"Device: ANTERION investigational~Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)"
41278185|NCT06600711|DRUG|Nitazoxanide|5 mL suspension (100 mg), 2x/day for 3 days
41278186|NCT06600711|DRUG|Placebo|identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x/day for 3 days
41278187|NCT06617481|DRUG|18F-rhPSMA-7.3 (Posluma)|PET Scan using Posluma for detection of early recurrence of prostate cancer.
41278188|NCT03810989|DEVICE|infra-red sauna|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
40929793|NCT00629278|DRUG|docetaxel|
40929794|NCT00629278|DRUG|doxorubicin hydrochloride|
40929795|NCT00629278|DRUG|epirubicin hydrochloride|
40929796|NCT00629278|DRUG|fluorouracil|
40929797|NCT00629278|DRUG|paclitaxel|
40929798|NCT00629278|DRUG|releasing hormone agonist therapy|
40929799|NCT00629278|DRUG|tamoxifen citrate|
40929800|NCT00629278|PROCEDURE|adjuvant therapy|
40929801|NCT00629278|RADIATION|radiation therapy|
40929802|NCT00029510|DRUG|Magnesium|
40929803|NCT02508298|PROCEDURE|HVPG|HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
40929804|NCT02508298|DRUG|Indocyanine Green Retention test|As decribed in arm descriptions
40929805|NCT02508298|DEVICE|Liver stiffness measurement|As decribed in arm descriptions; perfromed by ARFI
40929806|NCT02508298|DEVICE|Spleen stiffness measurement|As decribed in arm descriptions; performed by ARFI
40929807|NCT03248700|OTHER|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
40929808|NCT01546402|DRUG|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
40929809|NCT01546402|PROCEDURE|Cataract surgery|Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
40929810|NCT04935671|DIETARY_SUPPLEMENT|chamomile tea n saffron|20 mg of chamomile and 1 mg saffron in a teabag given twice daily for a month in combination with allopathic treatment for depression.
40929811|NCT05036811|OTHER|data collection|data collection
40929812|NCT00004727|DRUG|aspirin|
40929813|NCT00004727|DRUG|ticlopidine|
40929814|NCT00877773|DRUG|Temsirolimus|25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
41278189|NCT03810989|DEVICE|argometer and treadmill|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
41127919|NCT05530317|BEHAVIORAL|Cardiac Rehabilitation|Exercise prescriptions will be based on the heart rate performance during the baseline CPET. The intensity of the exercise prescription and level of monitoring will be tailored to the individual participant's performance on their baseline CPET according to guidelines. Exercise will be prescribed by a Cardiac Exercise Physiologist in accordance with standard cardiac rehabilitation protocols. Resistance exercise activities will also be incorporated. Recumbent exercise will be utilized based on assessment by exercise physiologist and patient. Dietary counseling, smoking cessation counseling for smokers, and medication counseling will be incorporated according to standard cardiac rehabilitation protocols. Participants are asked to commit to attending at least 24 sessions, of which 12 (one per week for 12 weeks) must be in person. Participants will be allowed to select a fully in-person approach (36 sessions) or hybrid approach (12-24 in person, 12-24 virtual for up to 36 total sessions).
41127920|NCT03428633|DRUG|Ropivacaine|Paravertebral block using ropivacaine preoperatively and postoperatively
41127921|NCT03428633|DRUG|Morphine|Morphine intraoperatively and postoperatively
41127922|NCT04286113|BEHAVIORAL|control group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
41127923|NCT04286113|BEHAVIORAL|Lifestyle management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
41127924|NCT01784575|OTHER|Patient Navigator Intervention|The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
41127925|NCT01340859|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
40754976|NCT00859274|DRUG|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
40929815|NCT02620371|PROCEDURE|modified pectoral block|"Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line."
40929816|NCT00401388|DRUG|Perifosine|Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
40929817|NCT00401388|OTHER|Loperamide|All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.
40929818|NCT00401388|OTHER|Allopurinol|Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.
40929819|NCT00401388|OTHER|Antiemetics|Antiemetic prophylaxis will be administered at the treating investigator's discretion.
40929820|NCT00347841|DRUG|Bimatoprost 0.03%, Latanoprost|
40929821|NCT00235170|DEVICE|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
41127926|NCT04689178|OTHER|Invitation letter + GP reminder|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test, AND GPs will receive the list of their 40-65 year-old patients who did not perform a PAP test over the last 3 years
40754977|NCT01528852|DRUG|Chlorhexidine 4%|4% liquid solution used for cord cleaning once daily for 10 days
40754978|NCT01528852|DRUG|Chlorhexidine 4%|Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
40754979|NCT01528852|OTHER|Control cord cleaning solution|Mild soapy solution used to clean cord once daily for 10 days
40929822|NCT06278610|DIAGNOSTIC_TEST|PELVIC EXENTERATION|PELVIC EXENTERATION
40929823|NCT04473482|BEHAVIORAL|Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool|The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.
40929824|NCT00157287|PROCEDURE|Evidence based weaning protocol|
40929825|NCT03932006|DRUG|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
40929826|NCT03932006|DRUG|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
40929827|NCT03932006|DRUG|Imrecoxib|Imrecoxib 0.1g twice a day,orally
41127927|NCT04689178|OTHER|Invitation letter|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test. GPs will NOT receive any list of their non-adherent patients.
41127928|NCT02261649|DEVICE|Medoc Advanced Medical Systems PATHWAY Model ATS|30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
40754980|NCT06009497|DRUG|Romiplostim|Romiplostim 10 µg/kg, subcutaneous injection, once a week.
40929828|NCT00476671|PROCEDURE|lumbar puncture, MRI, MRS|lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
40929829|NCT02602678|PROCEDURE|Supine then Prone position|One hour in supine position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash-out) and one hour in prone position with CPAP (+7 cmH2O)
40929830|NCT02602678|PROCEDURE|Prone then supine position|One hour in prone position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash out ) and one hour in supine position with CPAP (+7 cmH2O)
40929831|NCT00335231|DRUG|gatifloxacin ophthalmic (ZYMAR)|
40929832|NCT04281238|OTHER|Yoga group|Yoga training 3 days a week for 8 weeks. In addition to this, home exercises 5 days a week for 8 weeks
40929833|NCT04281238|OTHER|Control group|Home exercises 5 days a week for 8 weeks
40929834|NCT03682809|DRUG|Systane Complete|Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
40929835|NCT03206905|PROCEDURE|Endoscopic Sleeve Gastroplasty|endoscopic, rather than surgical approach, to perform sleeve gastroplasty
40929836|NCT03206905|BEHAVIORAL|Diet and Exercise|nutritional/exercise counseling
40929837|NCT03328182|DEVICE|New oral endotracheal tube holder|The single arm study product is designed to hold a standard or subglottic ET tube.
40754981|NCT06009497|DRUG|Ciclosporin|Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml.
40754982|NCT06034652|DEVICE|Integra® Gentrix® Surgical Matrix|Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic \& reconstructive surgery.
41127929|NCT02261649|PROCEDURE|Cold water bath|The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
41127930|NCT02261649|DEVICE|MRI scanner|An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
41127931|NCT02261649|OTHER|Questionnaires|The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
41127932|NCT01268306|DEVICE|B+L Biotrue MPS and B+L PureVision|Subjects use Bausch \& Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
41127933|NCT03470376|DIETARY_SUPPLEMENT|Nutraceutical combination (NC)|An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen
41127934|NCT03470376|BEHAVIORAL|No nutraceutical combination (noNC)|Prosecution of standardized diet regimen for 3 months
41127935|NCT05618951|OTHER|Lower Trapezius Strengthening Exercises|"Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra"
41127936|NCT02479672|DEVICE|laryngoscopy|Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
41127937|NCT02479672|PROCEDURE|Manual Inline Stabilization|Manual immobilization of Patient's neck with intention to minimize movement from baseline position
41127938|NCT02479672|DEVICE|VividTrac®|
41127939|NCT05838677|BEHAVIORAL|Pain at Work Toolkit|Online toolkit providing advice and signposting to help people self-manage chronic or persistent pain at work. Access to optional phone call support from an occupational therapist providing individually tailored advice.
41127940|NCT05838677|OTHER|Active control|Treatment as usual which will vary depending on the employing organisation but may include, for example, line manager support, occupational health input etc. Access to optional non-specialist phone call support from a study researcher.
41127941|NCT03947216|DRUG|Active drug: pimavanserin 17mg (2 strength tablets)|Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
41127942|NCT03947216|DRUG|Placebo: 2 tablets containing same excipients except active compound|Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
41127943|NCT03947216|BEHAVIORAL|Assessment of severity of ICD (impulse control disorders)|Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
41127944|NCT03947216|BEHAVIORAL|Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors|Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
41278190|NCT03810989|DEVICE|combination of sauna and hot bath|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
41278191|NCT04545736|DRUG|Metformin hydrochloride|Metformin is commercially produced in immediate and extended release. Participants will receive an immediate release formulation of metformin of 500mg daily at study entry. This dose will be titrated up weekly in 500mg increments to reach a goal of 2000mg daily maximum. Once participants \>=17 years of age reach 2000mg metformin immediate release they will switch to an extended-release formulation (1000mg twice a day by mouth). Participants \>= 17 years of age that cannot tolerate 2000mg will be permitted to reduce their daily dose to a minimum of 1000mg/day. Because metformin extended release is not FDA-approved for children under the age of 17, participants under 17 will remain on the immediate release formulation. For these participants who remain on standard formulation, the maximum tolerated dose between 1000mg and 2000mg/day will be given.
41278192|NCT06606028|PROCEDURE|Blood Specimen Collection|Approximately 20 mL of peripheral blood (10 mL per tube, x 3 Streck tubes) will be drawn at each time point
41278193|NCT06606028|PROCEDURE|Tumor Tissue Collection|Formalin-fixed paraffin embedded tumor tissue samples (tissue blocks of 12 x 10 millimeter (mm) unstained slides) derived from biopsy or surgical resection will be collected at screening
41127945|NCT03947216|BEHAVIORAL|Assessment of quality of life|Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
41127946|NCT03947216|BEHAVIORAL|Assessment of depression|Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)
41278194|NCT06606028|OTHER|Medical Record Review|Medical records will be reviewed to collect standard of care p16 staining by immunohistochemistry and/or high-risk human papillomavirus (HPV) DNA or RNA testing that is performed as part of standard of care
40754983|NCT01507727|DRUG|Tolvaptan|Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
40754984|NCT01507727|DRUG|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
40754985|NCT02681042|PROCEDURE|Left atrial appendage closure|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
40754986|NCT02681042|DEVICE|SentreHeart Lariat®|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
40929838|NCT05355493|BEHAVIORAL|Time to Exhaustion cycling test|After completing the MF/control task. Participants will be asked to take place on the cycle ergometer. Participants will perform a 3-min warm-up at 40% of peak power output followed by a rectangular workload at a power output corresponding to their predetermined respiratory compensation point (±80% PPO). RPM was freely chosen between 60 and 100 RPM and was recorded every minute. TTE was measured from the start until the pedal frequency was less than 60 RPM for more than 5s. This TTE task was chosen, based on a previous study of Marcora et al. (2009), who found that mental fatigue impairs physical performance. A researcher will sit behind the subject to ensure compliance with treatment. Subjects will be equipped with a heart rate monitor to continuously follow up heart rate. Subjective psychological assessment will take place with a M-VAS-scale, the NASA-TLX, the success motivation and intrinsic motivation scales, Karolinska Sleepiness Scale and visual analog scale for boredom.
40929839|NCT05355493|BEHAVIORAL|Go/NoGo task|Participants are to react to different stimuli displayed on a computer screen, preceded by a screen with general instructions. Two different stimuli were present at the same time: a Go or NoGo stimulus, and a left or right stimulus (meaning that four combinations are possible: GoRight, GoLeft, NoGoRight and NoGoLeft). If a Go-stimulus is presented, participants are instructed to react to the left or right stimuli with the corresponding arrows. However, if a NoGo stimulus is presented, participants are instructed to refrain from reacting to the either the left or right stimuli. This proposed paradigm measures attention, response inhibition and working memory. Stimuli will be presented for 500 ms, with a varying interstimulus time between 1100 and 1700 ms. Outcomes for Go trials include reaction time and accuracy while the outcome for NoGo trials is only accuracy.
41127947|NCT03947216|BEHAVIORAL|Assessment of cognition|Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.
41127948|NCT03947216|BEHAVIORAL|Assessment of severity of Parkinson Disease|Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
41127949|NCT03947216|PROCEDURE|Blood analysis|Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56
41127950|NCT03947216|PROCEDURE|Cardiac monitoring|Electrocardiogram will be realized at day 0, 28 and 56.
41127951|NCT04327843|BEHAVIORAL|Customized Adherence Enhancement|Customized Adherence Enhancement (CAE): CAE targets key areas relevant to adherence in chronic psychotic disorders (CPD): 1.) inadequate understanding of mental disorder, 2.) lack of adequate medication-taking routines, 3.) poor communication with care providers and 4.) substance use which interferes with adherence and recovery. CAE delivered components are selected based upon findings from the ROMI and AMSQ. CAE will be delivered in approximately 8 sessions by a nurse interventionist, ideally at the same time that the long-acting injectable (LAI) is administered.The intervention is guided by a detailed manual and uses components and resources that are available in lower- and middle-income countries (LMICs). Social worker interventionists will be trained to deliver CAE-L.
41127952|NCT04327843|DRUG|Haloperidol Decanoate|Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
41127953|NCT03759249|OTHER|Sleep medical treatment|"The participant ungo Standard Sleep medical diagnostics. If a sleep disorder is diagnosed in the interventional Group the applicable therapy is conducted.~If the participant is randomized in the waiting Group the applicable Therapy is initiated after study completion."
40754987|NCT00625378|DRUG|Sorafenib (Nexavar, BAY43-9006)|At the same dose and schedule as in the participants' original clinical trials
40754988|NCT00699166|DRUG|DNK333|25 mg and 100 mg oral doses, each taken twice daily
40754989|NCT03439878|DIETARY_SUPPLEMENT|Galactose|Co-ingestion of d-galactose with a high-fat meal
40754990|NCT03439878|DIETARY_SUPPLEMENT|Glucose|Co-ingestion of d-glucose with a high-fat meal
40754991|NCT01654250|DRUG|NWP09|Methylphenidate, variable dose, daily dosing, 1 week duration
40754992|NCT01654250|DRUG|Placebo|Placebo
40754993|NCT03033212|OTHER|Therapist-Guided Rehabilitation|Rehabilitation consists of exercises guided by a certified physical therapist. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
40754994|NCT03033212|OTHER|Self-Guided Rehabilitation|Rehabilitation consists of self-guided exercises with provided instructions. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
40754995|NCT05643144|DEVICE|Continuous Glucose Monitoring|CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.
40754996|NCT01259024|DEVICE|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
40929840|NCT05211687|OTHER|Smart-home for freezing of gait|"A projector, Kinect camera and computer are located 2 meters from the walking area. Participants walk nine times back and forth on the walking track, in each of three walking conditions:~1. Baseline: participants walk in a comfortable pace. The walking track consist a rectangle created by a white light projected on the floor. Based on in this walking condition, step width and cadence are calculated to determine the individual parameters of the cueing.~2. Light-stripes: The walking area consist of 4-5 white light-stripes. Space between the stripes is 110% of the participant step length. Participants are instructed to walk over the stripes.~3. Metronome: The walking track consist of a rectangle created by a white light projected on the floor, and in addition metronome beats are delivered by the computer. Beats frequency are 90% of the cadence. Participants are instructed to match their steps to the metronome beats.~Each walking condition up to 90 seconds."
40929841|NCT05337397|PROCEDURE|Laser ablation|Laser ablation of non-Muscle invasive bladder tumors in outpatient settings.
40929842|NCT04508543|OTHER|Non-verbal communication score|1. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).
40929843|NCT05038176|BEHAVIORAL|MANUP|Intervention will include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
40929844|NCT04665193|DIAGNOSTIC_TEST|Rapid Antigen Test|Antigen Technology Lab-based test and Point of care test
40929845|NCT02052414|DRUG|Gabapentin ER|"Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits."
40929846|NCT01492543|DRUG|Tegafur Gimeracil Oteracil Potassium Capsule|Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg\*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
41127954|NCT06521541|BEHAVIORAL|Multimodal prehabilitation program|Patients adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.Patients were evaluated for changes during neoadjuvant therapy and postoperative recovery
41127955|NCT06521541|BEHAVIORAL|ERAS program|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
41127956|NCT03762434|OTHER|mobile application|"Mobile app: The participants can view the Life style modification program by using the app. In addition, a membership area of the app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.~Booklet : The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management."
41127957|NCT05224557|OTHER|No intervention|No intervention
41127958|NCT00023920|BIOLOGICAL|bevacizumab|Given IV
41278195|NCT05036278|BIOLOGICAL|Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).|"Dosage Levels:~* 40 IU/kg/dose two times per week~* 50 IU/kg/dose every 5 days~* 60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU."
40754997|NCT03573765|PROCEDURE|Shoulder arthroplasty|Any form of joint replacement of the glenohumeral joint including prosthetic and excision.
40754998|NCT03573765|PROCEDURE|Elbow arthroplasty|Any form of joint replacement of the elbow joint including prosthetic and excision.
41127959|NCT00023920|DRUG|idarubicin|Given IV
41127960|NCT00023920|DRUG|cytarabine|Given SC
41448927|NCT02908776|DIETARY_SUPPLEMENT|Probiotic|Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
40929847|NCT00711074|DRUG|AZD5672|single dose 200mg aqueous solution
40929848|NCT01921088|OTHER|real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)|Subjects are provided with RT-fMRI-NF.
40929849|NCT01921088|BEHAVIORAL|Ambulatory Training|Subjects are provided with an ambulatory training.
40754999|NCT03573765|PROCEDURE|Hand and wrist arthroplasty|Any form of joint replacement of joints of the hand and wrist including prosthetic and excision.
40929850|NCT05513118|DIAGNOSTIC_TEST|Periodontal clinical examination and gingival crevicular fluid, saliva, dental plaque, serum sampling|"Probing pocket depth was defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) was measured as distance from cementoenamel junction to the base of pocket and recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva was obtained by each participant. Subgingival dental plaque was collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Gingival crevicular fluid samples were collected with absorbent paper strips. Serum samples were also collected at the time of visit."
40929851|NCT06522984|DRUG|Tranexamic acid injection|"to evaluate and compare efficacy of:~* Fractional Er: YAG laser combined with topical hydroquinone.~* Intradermal injection of tranexamic acid combined with topical hydroquinone cream.~* Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma."
40929852|NCT01574833|DEVICE|pulsed electromagnetic field|PEMF treatment
40929853|NCT01574833|DEVICE|sham|sham treatment
40929854|NCT05849961|DEVICE|Exactech Hip Systems|The Exactech Hip System comprises a fixed-bearing hip joint prostheses used in treating human hip joint diseases as part of THA. These prostheses include a combination of the components and are available in a range of sizes to accommodate varying anatomical requirements.
40929855|NCT01481129|DRUG|Akt Inhibitor MK2206|Given PO
40929856|NCT01481129|OTHER|Laboratory Biomarker Analysis|Correlative studies
40929857|NCT01481129|OTHER|Pharmacological Study|Correlative studies
40929858|NCT02263170|OTHER|MRI (magnetic resonance imaging)|Assessment of the sphincter morphology
40929859|NCT02263170|OTHER|US (ultra sound)|Assessment of the sphincter morphology
40929860|NCT02263170|OTHER|FLIP (functional luminal imaging probe)|Assessment of the biomechanical properties of the sphincter region
40929861|NCT02263170|OTHER|HRAM (high resolution anal manometry)|Assessment of the biomechanical properties of the sphincter region
40755000|NCT03573765|PROCEDURE|Nerve decompression|Open or endoscopic release of peripheral nerve entrapment - subdivided by anatomical site of compression. Specific subgroups will include carpal tunnel and cubital tunnel release.
40929862|NCT02096575|OTHER|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. The NO group will get two placebo pills and the standard care group will get one 5/325 mg Vicodin, and 1 mg of Ativan 30 minutes before the procedure. The standard care group will get oxygen intraoperatively.~NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention.~All patients will get local anesthesia via a standardized PCB."
40929863|NCT03381157|OTHER|Observational General Movements Assessments|GMs assessment has been increasingly used to predict motor dysfunction, especially the Cerebral Palsy (SP), since its introduction 25 years ago. The GMs assessment is based on the visual holistic perception of normal and abnormal movements of the body. This approach focuses on spontaneous movements of the baby rather than reflexes, tonus, and reactions
40929864|NCT06396182|OTHER|group (A ) study group :virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller).|"group (A ) study group : virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller):~The VR cycling session utilized the VZFIT VR Exercise Bike (VZFIT, Cambridge, MA), games were selected as preliminary pilot trials indicated these games to be most intense. Players maneuvered during VR gameplay by pedaling and steering their virtual character by leaning their bodies left and right. (Daniel et al., 2020).~group (B) control group :Cycling by traditional stationary bike: Participants will require to continuously pedal using the pulse oximeter for HR monitor. Research personnel monitored participants during the session adjusting pedal-resistance to ensure that the participants stayed within their target HR zone. (Daniel et al., 2020)."
40929865|NCT04896645|DEVICE|Digihaler Albuterol Device by TEVA|Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home
40929866|NCT03947554|DIETARY_SUPPLEMENT|HRG80 Panax ginseng|Panax ginseng containing 63.4 mg ginsenosides
40929867|NCT03947554|DIETARY_SUPPLEMENT|Panax ginseng|Panax ginseng containing 19.6 mg ginsenosides
40929868|NCT03947554|DIETARY_SUPPLEMENT|Placebo|800 mg excipient
40929869|NCT01500343|DRUG|Saccharomyces boulardii|1 gram per day, during 3 months
40929870|NCT05370703|BEHAVIORAL|My A:care|Mobile application with Motivational messages
40929871|NCT05370703|BEHAVIORAL|Smart Coach|Mobile application with Motivational messages
40929872|NCT00817128|PROCEDURE|PEPT|Pain Exposure Physical Therapy
40929873|NCT00817128|PROCEDURE|CBO standard|Standard therapy as defined in CBO guideline 2006
40929874|NCT05498701|DRUG|Tafamidis free acid tablet (Test)|12.2 mg tafamidis free acid tablet (Test)
40755001|NCT03573765|PROCEDURE|Tendon repair|Open or arthroscopic repair or reconstruction of tendons of the shoulder, hand and upper limb in general.
40755002|NCT03573765|PROCEDURE|Joint stabilisation|Any procedure designed to increase stability of a joint, including soft tissue and bony blocking procedures.
41448928|NCT02908776|OTHER|Placebo|Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
40755003|NCT03573765|PROCEDURE|Excision/division/release of palmar fascia|Any procedure performed for treatment of Dupuytren's contracture.
40755004|NCT03573765|PROCEDURE|Surgical fixation of fractures|Any internal or external fixation of upper limb fractures - analysed by anatomical site.
40929875|NCT05498701|DRUG|Tafamidis meglumine capsule (Reference)|Commercial 20 mg tafamidis meglumine capsule (Reference)
41278196|NCT03672318|DRUG|CAR138 T Cells|"The MTD is defined as the dose at which approximately 0.20 of subjects experience DLT dose escalation guided by the continual reassessment method (CRM).~Six dose levels will be evaluated:~Dose level 1: 5X10\^6 cells/m\^2 Dose level 2: 1X10\^7 cells/m\^2 Dose level 3: 2.5X10\^7 cells/m\^2 Dose level 4: 5X10\^7 cells/m\^2 Dose level 5: 1x10\^8 cells/m\^2 Dose level 6: 2x10\^8 cells/m\^2~Six subjects will be enrolled at the MTD to better characterize safety at that dose level.~Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.~The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m\^2 and fludarabine 30 mg/m\^2 given once daily for three days."
41278197|NCT02650414|BIOLOGICAL|Cohort 1|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22 cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22 cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22 cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22 cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22 cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22 cells/kg"
41278198|NCT02650414|BIOLOGICAL|Cohorts 2|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22-65s cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22-65s cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22-65s cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22-65s cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22-65s cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22-65s cells/kg"
41278199|NCT02650414|BIOLOGICAL|Cohort 3|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.5-2.5x10\^6 CAR T cells/kg Day 2, 75% fraction: 1.5-7.5x10\^6 CAR T cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.25-1.25x10\^8 CART22-65s cells Day 2, 75% fraction: 0.75-3.75x10\^8 CART22-65s cells"
41278200|NCT04975958|DRUG|AN2025|oral administration
40929876|NCT00155870|BEHAVIORAL|questionnaires|
40929877|NCT01889095|DRUG|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
40929878|NCT01889095|DRUG|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
40929879|NCT05834855|DRUG|Rituximab|Treatment with rituximab
40929880|NCT06409832|DRUG|Rimegepant 75 mg|Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention
40929881|NCT03940976|DRUG|Afatinib|Afatinib is orally administered at 40mg Qd of each 28 day cycle.
41127961|NCT02481466|BEHAVIORAL|Portfolio diet and structured exercise|"Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily."
41278201|NCT04975958|DRUG|AN0025|oral administration
41278202|NCT04975958|DRUG|Atezolizumab 1200 mg in 20 ML Injection|infusion
41278203|NCT04701307|BIOLOGICAL|Dostarlimab|Given IV
41278204|NCT04701307|DRUG|Niraparib|Given PO
40929882|NCT03500185|OTHER|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
40929883|NCT03500185|OTHER|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
40929884|NCT00700076|DRUG|Ketamine and Org 25935|Oral administration of Org 25935 16 mg and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
41278205|NCT06528431|DRUG|Clinical tapering strategy|Clinical Tapering strategy : Adalimumab injections will be progressively spaced out according to DAS28 assessment every 3 months
41278206|NCT06528431|DRUG|Step Wedge trial|Step Wedge trial : At baseline, all the patients will receive in this study the standard adalimumab dosing regimen. At subsequent time points (steps), patients will begin the intervention of interest, here the tapering adalimumab strategy. The time at which a patient begins the intervention will be randomized. We fixed the time steps duration to 3 months that corresponds the frequency of there commended follow-up of RA patients
41278207|NCT06533592|PROCEDURE|Continous suture technique|Duct-to-duct anastomosis will be performed using continuous suture technique for study group
41278208|NCT06533592|PROCEDURE|Interrupted suture technique|Duct-to-duct anastomosis will be performed using an interrupted suture for control group,
41278209|NCT04225598|DRUG|CAM2038|Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
41448929|NCT01108445|DRUG|Everolimus|Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
41448930|NCT01108445|DRUG|Sunitinib|50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
40929885|NCT00700076|DRUG|Placebo and Ketamine|Oral administration of placebo and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
40929886|NCT00743236|PROCEDURE|cold ischemia procedure|Cold ischemia followed by partial nephrectomy
40929887|NCT00743236|PROCEDURE|warm ischemia procedure|Warm ischemia followed by partial nephrectomy
40929888|NCT00535574|DRUG|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
40929889|NCT00535574|DRUG|bexarotene|75 mg/day 6 weeks
40929890|NCT02176824|BEHAVIORAL|Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Sleep deprivation, Sleep phase advance, and Bright light therapy
40929891|NCT02176824|BEHAVIORAL|Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|
40929892|NCT02176824|OTHER|Treatment as usual|
40929893|NCT06247397|DEVICE|Added high-flow oxygen therapy|Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.
40929894|NCT06247397|OTHER|Standard care|Standard care with low-flow oxygen therapy in accordance with clinical routine.
40929895|NCT02630199|DRUG|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
40929896|NCT02630199|DRUG|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
40929897|NCT00282464|DRUG|Placebo|Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
41278210|NCT04225598|DRUG|Buprenorphine Sublingual Product|"COWS ≥ 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS \>≥ 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder).~COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD."
41278211|NCT06529796|DRUG|IXP|Tablet for oral administration.
40929898|NCT00282464|DRUG|Geodon (Ziprasidone)|Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
41278212|NCT02040142|PROCEDURE|HIPEC|
40929899|NCT05292144|DEVICE|Xperience Pro|Patients in whom treatment with (Xperience Pro) has been attempted
41278213|NCT02040142|DRUG|Mitomycin C|
41278214|NCT05139030|DRUG|bupivacaine liposome injectable suspension|Adductor canal block with EXPAREL
41278215|NCT05139030|DRUG|Bupivacaine Hydrochloride|Adductor Canal Block with bupivacaine HCl
41278216|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Open Label Pilot|"As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations targeting those currently KT inactive will be made on a per-client basis as part of the open-label pilot. We will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain their perspective of the acceptability and feasibility of implementing the CAPABLE-Transplant intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype."
40929900|NCT02617901|RADIATION|Left hand DXA|"All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
40929901|NCT02600754|BEHAVIORAL|IT-PST|5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
40929902|NCT02600754|BEHAVIORAL|IT-SCM|5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
40929903|NCT04381338|OTHER|Pulmonary and Motor Rehabilitation|Pulmonary and Motor Rehabilitation in ICU
40929904|NCT05871515|DEVICE|3D ultrasound|A 3D ultrasound is performed preoperatively to measure various aneurysm characteristics
40929905|NCT04845529|DEVICE|transcranial direct current stimulation (tDCS)|We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.
40929906|NCT02763969|DRUG|BMS-986202|
40929907|NCT02763969|DRUG|Placebo|
40929908|NCT02763969|DRUG|Interferon alpha-2a recombinant|
40929909|NCT02763969|DRUG|Famotidine|
40929910|NCT02763969|DRUG|Ustekinumab|
40929911|NCT01067443|DRUG|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
40929912|NCT01067443|DRUG|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
40929913|NCT01067443|DRUG|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
40929914|NCT02699788|DEVICE|Multifunction Cardiogram|
40929915|NCT01653379|DRUG|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
40929916|NCT02652767|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
40929917|NCT02652767|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
40929918|NCT05340647|PROCEDURE|Preserflo microshunt|Implantation of Preserflo microshunt (Santen) to lower intraocular pressure
40929919|NCT05340647|PROCEDURE|Trabeculectomy|Trabeculectomy surgery to lower intraocular pressure
40929920|NCT05340647|PROCEDURE|Other MIGS|Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure
40929921|NCT02103543|OTHER|physical therapy|physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions
40929922|NCT02103543|PROCEDURE|lumbar interlaminar epidural steroid injection|single lumbar interlaminar epidural steroid injection
40929923|NCT02103543|DRUG|epidural steroid injection|Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
40929924|NCT01702181|DRUG|OPA-15406|0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
40929925|NCT01702181|DRUG|Tacrolimus|0.1% concentration of tacrolimus.
40755005|NCT03573765|PROCEDURE|Soft tissue release/debridement/excision|Any removal or release of soft tissue for treatment of stiffness, functional impairment or pain. Specific subgroups will include trigger finger release, subacromial surgery and surgery for frozen shoulder.
40755006|NCT03573765|PROCEDURE|Intra-articular injection|Any intra-articular injection
40929926|NCT01702181|DRUG|Placebo|
40929927|NCT00767182|OTHER|blood sample|biological markers evaluated : D-Dimer, sEPCR
40929928|NCT00814879|DRUG|Raltegravir|400 mg BID
40929929|NCT00814879|DRUG|Atazanavir|300 mg BID
40929930|NCT00814879|OTHER|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
40929931|NCT01706900|OTHER|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
40929932|NCT01706900|OTHER|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
41278217|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Randomized Control Trial|As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
41278218|NCT01797523|DRUG|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
41278219|NCT01797523|DRUG|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
40755007|NCT06329297|DEVICE|CGM monitor|blood glucose sensor used to monitor interstitial glucose
40929933|NCT03175848|RADIATION|Chemotherapy,radiotherapy|Pelvic,pelvic-inguinal,or extended field radiotherapy：Therapy 45 - 50 Gy in 1.7 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks for PTV Brachytherapy: Therapy 5-6 fractions of 4-6Gy prescribed to the high-risk CTV or A piont.
40929934|NCT01891526|DRUG|9-cis-retinoic acid|Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
40929935|NCT00604214|DRUG|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
40929936|NCT00604214|DRUG|Placebo|0.9% sodium chloride, intravenous, 96 hours
41127962|NCT02481466|BEHAVIORAL|DASH-like diet and structured exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers."
41278220|NCT01797523|DRUG|Everolimus|10 mg by mouth once daily in a 28 day cycle.
41278221|NCT06557512|RADIATION|Hypofractionated Stereotactic Radiosurgery (SRS)|Undergo Hypofractionated Stereotactic Radiosurgery
41278222|NCT06557512|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
41278223|NCT06557512|PROCEDURE|Computed Tomography (CT)|Undergo CT imaging
40755008|NCT00393146|DRUG|GW856553|Study drug
40755009|NCT01217515|DRUG|Diltiazem hydrochloride 4% cream|3 times daily
40755010|NCT01217515|DRUG|Diltiazem hydrochloride 2% cream|3 times daily
40755011|NCT01217515|OTHER|Placebo|3 times daily
40755012|NCT02080728|DRUG|Ropivacaine 500mg/100ml Naropeine|
40755013|NCT02080728|DRUG|0.9% sodium chloride BAXTER|
40755014|NCT00976391|BIOLOGICAL|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
40755015|NCT00976391|DRUG|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
41127963|NCT02481466|BEHAVIORAL|Portfolio diet and routine exercise|"Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
41127964|NCT02481466|BEHAVIORAL|DASH-like diet and routine exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
41127965|NCT06413095|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
41127966|NCT06413095|COMBINATION_PRODUCT|MK-0482 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
41278224|NCT04747145|DEVICE|Radiation|60 Gy to be delivered over 30 daily treatments in six weeks. Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
41278225|NCT04747145|DRUG|Concurrent Chemotherapy (Temozolomide)|75mg/m\^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
41278226|NCT04747145|DRUG|Adjuvant Chemotherapy (Temozolomide)|Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m\^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
41278227|NCT03408132|DRUG|FE203799|FE203799 5 mg subcutaneous once weekly
41448931|NCT06425562|OTHER|Full lung function|This includes spirometry, body plethysmography and single breath gas transfer test. These are all non-invasive physiological measurements / lung function tests. Measures flow volumes, lung volumes and gas transfer respectively.
41448932|NCT06425562|OTHER|Multiple breath nitrogen washout|Non-invasive physiological measurement / lung function test. 100% oxygen is inhaled and the nitrogen concentration in the lungs is measured. This test gives information on the ventilation distribution in the lungs.
41127967|NCT06413095|COMBINATION_PRODUCT|MK-4830 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
41278228|NCT06480734|OTHER|symptom-based scoring system (symptom-questionnaire, paper version)|The patients are asked to complete a paper-based questionnaire (symptom-based scoring system, paper version) once a week during and up to 24 weeks following radiotherapy. The patients state and score symptoms potentially associated with pneumonitis, namely cough, shortness of breath and fever. Scoring points are assigned to severity of the symptoms, and sum scores are used to identify pneumonitis. During the radiotherapy course, patients complete the questionnaire prior to regular appointments with a physician. Following radiotherapy, they are contacted by phone (to minimize the number of hospital visits) once a week for completion of the questionnaire. In case of an increase of the total score when compared to baseline, patients receive a follow-up phone call after 3 days, are asked to come to the hospital as outpatients or are admitted to hospital.
41278229|NCT04312126|DEVICE|MRI system|MRI system - GE Discovery MR750 3T
41278230|NCT04312126|DEVICE|MEG system|MEG system The CTF MEG 275 Magnetoencephalography (MEG) scanner system
41278231|NCT05518149|DRUG|Aticaprant|Aticaprant 10 mg tablet will be administered orally.
40755016|NCT06468917|BEHAVIORAL|1st day removal of abdominal drain|once POPF is excluded in middle-low risk pancreatic resection, abdominal drains can be removed
41278232|NCT02143414|PROCEDURE|Biopsy|Undergo a biopsy
41278233|NCT02143414|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
40755017|NCT05026385|BEHAVIORAL|Intervention|Targeted nutrition advice, progressive resistance training exercise, and self-management support
40755018|NCT04934865|DEVICE|Patients treated for their lung cancer.|"In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.~In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator."
41278234|NCT02143414|BIOLOGICAL|Blinatumomab|Given IV
41278235|NCT02143414|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
41127968|NCT03107169|OTHER|FMT|Patients in the FMT group received FMT-FURM
41127969|NCT03107169|DRUG|Vancomycin|Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)
41127970|NCT00084396|DRUG|letrozole|
41127971|NCT00084396|PROCEDURE|conventional surgery|
41127972|NCT01541059|DRUG|Placebo injection|Injection of saline solution into the vestibular capsule of each tooth to be extracted.
41127973|NCT01541059|DRUG|Ropivacaine injection|Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
41127974|NCT03547102|DIETARY_SUPPLEMENT|Cherry concentrate|
41127975|NCT03547102|DIETARY_SUPPLEMENT|Placebo concentrate|
41278236|NCT02143414|PROCEDURE|Computed Tomography|Undergo a CT scan
41278237|NCT02143414|DRUG|Dasatinib|Given PO
41278238|NCT02143414|PROCEDURE|Echocardiography|Undergo ECHO
41278239|NCT02143414|PROCEDURE|Lumbar Puncture|Undergo a lumbar puncture
41278240|NCT02143414|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41278241|NCT02143414|DRUG|Mercaptopurine|Given PO
41278242|NCT02143414|DRUG|Methotrexate|Given PO
41278243|NCT02143414|DRUG|Methotrexate Sodium|Given PO
41278244|NCT02143414|DRUG|Prednisone|Given PO
41278245|NCT02143414|DRUG|Vincristine|Given IV
41278246|NCT02143414|DRUG|Vincristine Sulfate|Given IV
41278247|NCT02143414|PROCEDURE|X-Ray Imaging|Undergo an x-ray
40929937|NCT00695201|DRUG|Floxuridine, Oxaliplatin, CPT-11|For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
41278248|NCT06237881|DRUG|KSQ-001EX|Given by IV
41278249|NCT06237881|DRUG|Interleukin-2|Given by IV
40929938|NCT00695201|DRUG|Floxuridine, Oxaliplatin, CPT-11|For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
40929939|NCT00357032|DRUG|belinostat|Given IV
41278250|NCT06237881|DRUG|Cyclophosphamide|Given by IV
41278251|NCT06237881|DRUG|Fludarabine|Given by IV
40755019|NCT02730286|OTHER|observational study|application of several standard instruments in patients with rheumatoid arthritis
40929940|NCT00357032|OTHER|laboratory biomarker analysis|Correlative studies
41278252|NCT06431373|DRUG|Brepocitinib PO QD|Brepocitinib PO QD
41278253|NCT06431373|DRUG|Placebo PO QD|Placebo PO QD
41278254|NCT05095935|OTHER|N/A observational registry|N/A observational registry
41278255|NCT04420793|OTHER|Questionnaire|3 voice recording tasks and 1 text entry task will be performed.
40755020|NCT03924076|DIETARY_SUPPLEMENT|UHT Milk + Lactobacillus plantarum IS-10506|125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group
40755021|NCT03924076|DIETARY_SUPPLEMENT|UHT Milk|125 ml UHT milk given to placebo group
40755022|NCT01862029|DRUG|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
41278256|NCT06644612|PROCEDURE|Light Weight Mesh|Participants will undergo abdominal hernia repair using light-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
41278257|NCT06644612|PROCEDURE|Heavy Weight Mesh|Participants will undergo abdominal hernia repair using heavy-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
41278258|NCT04122196|DRUG|Pregabalin 300mg|Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
41278259|NCT04122196|DRUG|Placebo oral tablet|Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
41278260|NCT03232541|OTHER|Standard care|A) Standard antiemetic treatment means receiving ordinary antiemetic medications. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
41448933|NCT06425562|OTHER|Impulse oscillometry|Non-invasive physiological measurement / lung function test. This technique superimposes sound waves on tidal breathing. The patient can breathe normally trough the device, no forced respiratory maneuvers are required. It gives information on the reactance and resistance of the lung.
41448934|NCT04241757|DIAGNOSTIC_TEST|ElectroCardioGram (ECG)|Collection of results ElectroCardioGram (ECG).
40929941|NCT00522132|DRUG|Artesunate|intravenous application
40929942|NCT03740815|PROCEDURE|Serratus plane block|Ultrasound guided injection of local anesthetic between latissimus dorsi and serratus muscles at mid axillary line.
40929943|NCT03740815|PROCEDURE|Axillary dissection|Axillary dissection is a surgical procedure that incises the axilla to identify, examine, or remove lymph nodes.
40929944|NCT03740815|PROCEDURE|Intravenous sedation|Administration of sedatives thru an intravenous access to achieve relaxion and improve operative conditions.
40929945|NCT05996991|OTHER|Positive expectation speech regarding spinal manipulative therapy|Patients will watch a short video with positive expectations regarding spinal manipulative therapy.
40929946|NCT05996991|OTHER|Neutral expectation speech regarding spinal manipulative therapy|Patients will watch a short video with neutral expectations regarding spinal manipulative therapy.
40929947|NCT05996991|OTHER|Negative expectation speech regarding spinal manipulative therapy|Patients will watch a short video with negative expectations regarding spinal manipulative therapy.
40929948|NCT05996991|PROCEDURE|Spinal Manipulative Therapy|One session of Spinal Manipulative Therapy. The researcher will administer a posterior and inferior push on the opposite anterior superior iliac spine (ASIS) while passively rotating the subject on the side to be manipulated. The spinal manipulations will be repeated four times during a 5-minute period, with impulses oscillating between the right and left ASIS. In addition, we will administrate mobilizations (anterior-posterior central mobilization), applied for 1 minute in each lumbar vertebra (from L5 to L1), using grade I joint mobilization (patients positioned in the ventral decubitus position).
40929949|NCT00216866|DRUG|Dalteparin|
40929950|NCT00216866|DRUG|Warfarin|
40929951|NCT02723071|DRUG|Ocrelizumab|Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
40929952|NCT03099343|BEHAVIORAL|Location-based Tailored Messaging|The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
40929953|NCT01844167|PROCEDURE|Noxipoint Therapy (NT)|"• For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation."
40929954|NCT01844167|PROCEDURE|Physical therapy(PT)|•Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
40929955|NCT03643471|DEVICE|MRI|Magnetic resonance imaging with advanced sequences including volumetry, spectroscopy and tractograpghy.
40929956|NCT04642001|OTHER|Photon Laser III-DMC (without radiation emission) + My First- Colgate|Positioning of the FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
40929957|NCT04642001|OTHER|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rapid Relief / GSK|Positioning of FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
40929958|NCT04642001|RADIATION|Photon Laser III-DMC (with irradiation emission) + My First- Colgate|Emission of FBM therapy (Photon Laser III / DMC), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
40929959|NCT04642001|COMBINATION_PRODUCT|Photon Laser III-DMC (with irradiation emission) +Sensodyne® Rapid Relief / GSK|Emission of FBM therapy (Photon Laser III / DMC), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
40929960|NCT04689412|DRUG|Resveratrol|Nasal administration of resveratrol
40929961|NCT02555280|DEVICE|coflex® Interlaminar Technology|Decompression plus coflex® Interlaminar Technology
40929962|NCT02555280|PROCEDURE|Decompression|Decompression alone
40929963|NCT01087866|DRUG|Metformin|
40929964|NCT01087866|DRUG|Insulin|
40929965|NCT04926402|OTHER|Kangaroo Care Education Program|It is a special method of caring for a premature infant in which the baby is positioned for at least 1 hour a day in an upright skin-to-skin and chest-to-chest contact with its mother.
41448935|NCT03981731|OTHER|Cardiac coherence|"An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation.~- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape."
41448936|NCT05437068|OTHER|Oral Nutritional Supplement (ONS)|ONS plus dietary counseling
40929966|NCT02967380|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
41453447|NCT05168787|DRUG|sacubitril/valsartan|Sacubitril belongs to a class of drugs called neprilysin inhibitors and valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). They work by relaxing blood vessels so that blood can flow more easily, which makes it easier for your heart to pump blood to your body.
40755023|NCT02950974|DRUG|Sterofundin|Fluid loading
40755024|NCT02950974|DRUG|NSS|Fluid loading
40755025|NCT01730976|DIETARY_SUPPLEMENT|Vitamin D 2,000 I.U.|
40755026|NCT03099863|DRUG|Cystoscopic Fluid containing Neosporin G. U. Irrigant|Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
40755027|NCT03099863|PROCEDURE|Cystoscopy|Diagnostic cystoscopy performed during pelvic floor surgery
40755028|NCT03099863|DRUG|Cystoscopic Fluid/Placebo|Normal saline cystoscopic fluid
40755029|NCT04512183|OTHER|High-Fidelity Simulation|Teaching strategy based on high-fidelity simulation, which simulates the reality of health care to promote meaningful learning.
40755030|NCT04512183|OTHER|Low-Fidelity Simulation|Teaching strategy based on low-fidelity simulation, which simulates the reality of health care using less technological and less interactive mannequins.
41278261|NCT03232541|DEVICE|Sham acupuncture|"B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6 using the telescopic Park Sham Device. The sham-needle is blunt and glides upward into its handle instead of penetrating. Marking tubes hold the needle in place. The therapist gives an illusion of manipulating the needle by turning it three times until it touches the skin, but no specific needle sensation (deqi) will occur. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model."
40929967|NCT02967380|DRUG|Gadobenate Dimeglumine|Given IV
40929968|NCT02967380|DRUG|Gadobutrol|Given IV
40755031|NCT03098927|BEHAVIORAL|Motor imagery training|Motor imagery training
40755032|NCT05084378|DRUG|Povidone-Iodine Lavage Solution|0.35% povidone-iodine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.35% povidone-iodine and sterile isotonic saline solution may also be used.
40929969|NCT02967380|RADIATION|Gadopentetate Dimeglumine|Given IV
40929970|NCT02117206|DRUG|L-arginine (L-arginine Veyron)|
40929971|NCT02117206|DRUG|Nacl|
40929972|NCT04662827|DIETARY_SUPPLEMENT|Palmithylethanolamid|PEA 3x/d
40929973|NCT04662827|OTHER|placebo|placebo 3x/d
40929974|NCT01190423|BEHAVIORAL|Family Based Therapy for young adults|Individual and Group Therapy Sessions
41278262|NCT03232541|DEVICE|Genuine acupuncture|C) Acupuncture will be administered bilaterally to the standard antiemetic point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpi radialis. Sharp acupuncture needles will be inserted into a depth of a half body-inch. The needles will be manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurres. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
41278263|NCT04837417|DIAGNOSTIC_TEST|Pathologic group|"Voluntary Activation level will be determined with the interpolate twitch technique (ITT), both during isometric contractions (knee at 40° flexion) and during isokinetic contraction at angular velocity equal to 100°/s.~Vastus Medialis and Soleous H-reflex will be measured. Cortical excitability and interhemispheric connectivity will be measured through transcranial magnetic stimulation (TMS).~Tests of balance in standing will be performed using the EquiTest platform. Individuals will be requested to perform three different tasks: Sensory Organization test, Adaptation Test upward/downward, Motor Control test backward/forward. Surface electromyography from lower limbs will be recorded.~Through TMS driven by neuronavigation, the cortical representation of the Quadriceps muscle will be studied.~Gait analysis will be performed on a treadmill mounted on force sensors. Participants will walk at increasing velocities from 0.4 m/s to 1.6 m/s. Speed will be increased of 0.2 m/s every 30 s."
40929975|NCT00877097|DRUG|Klodronate and Kliogest|
40929976|NCT00877097|PROCEDURE|Placebo+ Kliogest|
40929977|NCT00877097|DRUG|Bonefos|
40929978|NCT04048785|OTHER|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
40929979|NCT02901665|OTHER|FCC intervention|Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
40929980|NCT02792621|DIETARY_SUPPLEMENT|Acipimox|Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
40929981|NCT02792621|DIETARY_SUPPLEMENT|placebo|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
40929982|NCT04985344|DRUG|Propranolol Oral Product|Child will receive oral propranolol (syrup). The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.
40929983|NCT04985344|DRUG|Placebo|Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.
40929984|NCT04985344|OTHER|memory reactivation|90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.
40929985|NCT01498094|PROCEDURE|High Flow Nasal Cannula Oxygen Therapy|Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
40929986|NCT01498094|OTHER|Standard low flow oxygen|Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
40929987|NCT04101201|DIETARY_SUPPLEMENT|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
40929988|NCT04101201|OTHER|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
40929989|NCT00360152|PROCEDURE|Fine needle aspiration biopsy (FNAB)|
40929990|NCT00360152|PROCEDURE|Sentinel Lymph Node Biopsy|
40929991|NCT05599776|OTHER|Smart ring assisted physiotherapeutic intervention|the effect of a smart ring (Oura), a wearable activity tracker assisted physiotherapeutic intervention on the risk of poor outcome measured on patient reported post-operative outcome (Oxford Knee Score) 12 months after a primary total knee replacement.
40929992|NCT06098677|DIETARY_SUPPLEMENT|Carotenoids supplementation|Daily oral supplementation of a soft gel capsule containing 10mg lutein (L), 10mg meso-zeaxanthin (MZ) and 2mg zeaxanthin (Z).
40929993|NCT06098677|DIETARY_SUPPLEMENT|Placebo|Daily oral supplementation of a soft gel capsule containing only placebo oil
40929994|NCT03462901|PROCEDURE|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures .|A group of 15 patients admitted to Assiut university with midshaft clavicular fractures treated by operative fixation of the fracture by single elastic rod through medial approach under image intensifier
40929995|NCT00412490|BEHAVIORAL|Questionnaire|Written survey at 1 Month \& 6 Months post surgery.
40929996|NCT00412490|BEHAVIORAL|Interview|One-on-One meeting lasting about one hour, at 1 Month \& 6 Months post surgery.
40929997|NCT04829578|OTHER|Hypnosis|Chronic idiopathic pruritus is treated by hypnosis
40929998|NCT02814500|DRUG|DP-R212|Investigational product is prescribed to all of randomized subjects
40929999|NCT02814500|DRUG|Amlodipine|Investigational product is prescribed to all of randomized subjects
40930000|NCT02814500|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
40930001|NCT02456480|DRUG|CLS001|topical gel
40930002|NCT02456480|DRUG|Vehicle|topical gel
40930003|NCT02067052|PROCEDURE|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
40930004|NCT02067052|PROCEDURE|Surgery|Vulvectomy \& lymphadenectomy
40930005|NCT06163820|DRUG|Bevacizumab|Bevacizumab is a humanised monoclonal antibody with molecular weight 167kD that inhibits all isoforms of the vascular endothelial growth factor (VEGF) and is produced from a Chinese hamster ovary mammalian system. It has high specificity for isoform-A and has a half-life of \~21 days.
41278264|NCT03797560|OTHER|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-health-care Qigong exercise that has been practiced by Chinese people for at least eight hundred years. It consists of eight sets of simple movements. By combining meditation with slow, graceful movements, deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear, previous clinical trials have demonstrated that Ba-Duan-Jin can improve sleep quality, physical health, and mental health in patients with various chronic diseases"
41278265|NCT03797560|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
41278266|NCT05995704|DRUG|Apraglutide|Peptide analogue of GLP-2
40755033|NCT05084378|DRUG|Chlorhexidine Lavage Solution|0.05% chlorhexidine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.05% chlorhexidine and sterile isotonic saline may also be used.
40755034|NCT05084378|DRUG|Topical Antibiotic|2 grams Vancomycin powder
41278267|NCT05995704|DRUG|Placebo|Matching placebo to apraglutide
40755035|NCT05084378|DRUG|Saline Lavage Solution|1 litre of sterile isotonic saline
40755036|NCT06359535|DRUG|HSK21542|This study is an economic study and does not interfere with patients' medical treatment.
41278268|NCT05995704|DRUG|Acetaminophen|Acetaminophen mixed with a liquid meal
40755037|NCT06359535|DRUG|Placebo|Placebo
40755038|NCT03378635|DRUG|Dasiglucagon|Glucagon analog
40755039|NCT03378635|DRUG|GlucaGen|Native glucagon
40755040|NCT03378635|DRUG|Placebo|Placebo for dasiglucagon
40930006|NCT06163820|DRUG|Ipilimumab|Ipilimumab is an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Ipilimumab is a recombinant human immunoglobulin monoclonal antibody that binds CTLA4 and blocks the interaction between CD80/86 and CTLA4.
40755041|NCT06344286|DIETARY_SUPPLEMENT|Minimal enteral nutrition|The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
40755042|NCT06344286|DIETARY_SUPPLEMENT|Distilled water|The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
40930007|NCT06163820|DRUG|Nivolumab|Nivolumab ia an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Nivolumab is a fully human monoclonal IgG4 antibody targeting PD-1 which demonstrates activity across a range of tumours.
40930008|NCT06163820|RADIATION|Hypofractionated stereotactic radiotherapy|Hypofractionated stereotactic radiotherapy (hSRT) will be delivered to previously untreated brain metastases in eligible participants. hSRT will be delivered to all symptomatic brain metastases, all brain metastases \>1 cm and all brain metastases located in eloquent areas of the brain. hSRT will be commenced after the first cycle of nivolumab plus ipilimumab and completed before the second cycle of nivolumab plus ipilimumab. hSRT should be commenced within 1 week from the planning MRI.
41278269|NCT04151602|BEHAVIORAL|Smoked illicit drug use|The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
41278270|NCT06098079|DRUG|Naltrexone-Bupropion (NB) Combination|A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.
40930009|NCT04561999|DEVICE|Elastography|Performance of Ultrasound, Elastography
40930010|NCT03363425|DRUG|Lidocaine Iv|Lidocaine Iv
40930011|NCT03363425|DRUG|Dexmedetomidine|dexmedetomidine iv
41278271|NCT06098079|DRUG|Placebo|A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
41278272|NCT05087888|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41278273|NCT05087888|PROCEDURE|Magnetic Resonance Imaging|Undergo functional MRI
40930012|NCT03363425|DRUG|Normal saline|placebo
41278274|NCT05087888|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
41278275|NCT05087888|OTHER|Questionnaire Administration|Complete questionnaires
40930013|NCT05764070|DEVICE|non-invasive auricular vagus stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased.
40930014|NCT05764070|DEVICE|Placebo Non Invasive Vagus Stimulation|Placebo Non Invasive Vagus Stimulation
40930015|NCT06491667|DIAGNOSTIC_TEST|CBC|Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
40930016|NCT06491667|DIAGNOSTIC_TEST|C-reactive protein|Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
40930017|NCT04631991|DIAGNOSTIC_TEST|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
40930018|NCT01752036|RADIATION|Post-operative, Stereotactic Body Radiation Therapy (SBRT)|All participants received SBRT at 600 cGy x 5 fractions
40930019|NCT02487342|OTHER|milk|small serving (217 mL) of british semi-skimmed milk
40930020|NCT02487342|OTHER|orange fruit-juice|small serving (217 mL) of orange juice
40930021|NCT00064298|DIETARY_SUPPLEMENT|fruit and vegetable extracts|Given orally
40930022|NCT00064298|DIETARY_SUPPLEMENT|placebo|Given orally
40930023|NCT06200025|OTHER|Cue-based speech therapy in virtual reality|Treatment applied with virtual reality headsets to provide 3d visual and auditory cues to individuals in a virtual environment. A treatment environment where the provision of cues can be controlled by the therapist, interacting with 3d clues and receiving feedback on the accuracy of the named objects.
40930024|NCT06200025|OTHER|Cue-based speech therapy|Treatment involving the assessment of language skills and the presentation of communication strategies to the individual, including the use of personalized phonological cues.
40930025|NCT04738318|DRUG|Glucocorticoids|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
40930026|NCT04738318|DRUG|Saline|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
40930027|NCT05334095|DEVICE|Perclose ProGlide|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Perclose ProGlide.
40930028|NCT05334095|DEVICE|Angio-seal VIP|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Angio-seal VIP
40930029|NCT01924702|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
40930030|NCT01924702|DEVICE|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
40930031|NCT00000253|DRUG|10% N2O|
40930032|NCT00000253|DRUG|20% N2O|
40930033|NCT00000253|DRUG|30% N2O|
40930034|NCT00000253|DRUG|40% N2O|
40930035|NCT06276985|DEVICE|low intensity pulsed ultrasound and iPRF|iPRF and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
41278276|NCT04716634|DRUG|Tislelizumab|Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
40930036|NCT04934943|DIAGNOSTIC_TEST|mini_FC|100 ml of Crystalloids infused over 1 minute - data recording and new baseline - FC 4 ml/kg in 10 minutes - data recording
40930037|NCT02097927|BEHAVIORAL|Mango-flavour beverage|The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
40930038|NCT01190787|DRUG|velcade subcutaneous melphalan prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
40930039|NCT01190787|DRUG|velcade cyclophosphamide prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
40930040|NCT01190787|DRUG|velcade prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
40930041|NCT00540098|DRUG|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
41278277|NCT04716634|DRUG|Fruquintinib|Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
40930042|NCT00540098|DRUG|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
40930043|NCT00540098|DRUG|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
40930044|NCT00540098|DRUG|Placebo + relaxation|placebo pill once daily + regular relaxation training
40930045|NCT01030367|DRUG|PETN, ISDN|Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
40930046|NCT00230477|DRUG|Hepsera|
40930047|NCT00230477|DRUG|Hepsera and lamivudine|
40930048|NCT00732043|DIETARY_SUPPLEMENT|pomegranate extract|8 oz per day, 48 months
40930049|NCT00732043|DIETARY_SUPPLEMENT|pomegranate juice|8 oz per day, 48 months
40930050|NCT00732043|DIETARY_SUPPLEMENT|placebo|8 oz per day, 48 months
40930051|NCT02764190|BEHAVIORAL|I-ACT with Check Yourself|
40930052|NCT02884700|BIOLOGICAL|Real-time PCR testing of lower respiratory tract samples|qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
41278278|NCT06617923|DRUG|Senaparib|Participants will receive orally 80mg daily Days 1-28 of a 28 day cycle.
41278279|NCT06617923|DRUG|Temozolomide|Participants will receive orally 20mg daily Days 1-21 of a 28 day cycle.
40930053|NCT00204945|DRUG|nesiritide|a bolus, then infusion of nesiritide for 10-15 minutes
40930054|NCT00534469|BIOLOGICAL|aldesleukin|
40930055|NCT00534469|BIOLOGICAL|filgrastim|
40930056|NCT00534469|DRUG|busulfan|
40930057|NCT00534469|DRUG|cytarabine|
40930058|NCT00534469|DRUG|etoposide|
40930059|NCT00534469|DRUG|idarubicin|
40930060|NCT00534469|PROCEDURE|autologous hematopoietic stem cell transplantation|
40930061|NCT00534469|PROCEDURE|bone marrow transplantation|
41127976|NCT00731341|PROCEDURE|Cryoablation for the treatment of uterine fibroids|Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
41127977|NCT02013700|BIOLOGICAL|Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|
41127978|NCT02013700|BIOLOGICAL|matched placebo|The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
41127979|NCT01738438|DRUG|Cabozantinib|
41127980|NCT04870398|PROCEDURE|Vital Pulp therapy-Partial pulpotomy|Removal of inflamed pulp tissue, hemostasis and placement of pulpotomy material
41127981|NCT00882934|OTHER|Induction to efficient treatment|Informative letters.
41127982|NCT00882934|OTHER|Doubt to the efficacy of treatment|Informative letters.
40930062|NCT00534469|PROCEDURE|peripheral blood stem cell transplantation|
40930063|NCT00534469|RADIATION|total-body irradiation|
40930064|NCT00290407|DRUG|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
40930065|NCT00290407|DIETARY_SUPPLEMENT|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
40930066|NCT06154681|OTHER|World Digital Detox Family Program|The Self-Help World Digital Detox Family Program spans four weeks and offers a structured approach to tackle the rising issues associated with the overuse of screens, social media, and digital devices within families. This intervention provides practical tools and strategies to be implemented on a weekly basis.
40930067|NCT06109922|DIETARY_SUPPLEMENT|Active|40g bio-active whey protein concentrate powder containing phospholipids
40930068|NCT06109922|DIETARY_SUPPLEMENT|Placebo|Around 40g pea protein powder not containing phospholipids
40930069|NCT05073094|DRUG|Esmolol|Esmolol injected intravenously and added to cardioplegia solution
40930070|NCT05073094|DRUG|Placebo|Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
40930071|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
40930072|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
40930073|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
40930074|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
40930075|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
40930076|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
40930077|NCT00677053|DRUG|TAK-442|Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
40930078|NCT00677053|DRUG|TAK-442|Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
40930079|NCT00677053|DRUG|Placebo|Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
40930080|NCT04722055|DIAGNOSTIC_TEST|Multigene Methylation Detection Kit|Eligible participants are required to take stool samples for multigene methylation detection and gene sequencing, undergo colonoscopy examination, and have a biopsy when necessary (gold standard).
40930081|NCT03726554|DEVICE|Comprehensive Reverse Porous Augmented Glenoid|Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.
41127983|NCT00882934|OTHER|Induction to ineffective treatment|Informative letters
41127984|NCT02103361|DRUG|Ustekinumab|
41127985|NCT02103361|DRUG|Guselkumab|
41127986|NCT00563134|DRUG|GR270774|
41278280|NCT06656533|OTHER|Repeated Transcranial magnetic stimulation (rTMS)|Transcranial Magnetic Stimulation (TMS) involves a procedure where parts of the participants brain will be non-invasively (i.e. indirectly) stimulated by magnetic pulses. These magnetic pulses induce very brief activity in brain areas underlying the TMS coil. TMS will be performed by giving repetitive pulses (rTMS). rTMS has shown promise to reduce cortical hyperexcitability and to improve subjective measures of sleep quality and insomnia symptoms in patients with insomnia disorder. The goal of this study is to optimize the impact of rTMS therapy on sleep outcomes for patients with insomnia disorder.
40930082|NCT03726554|DEVICE|Comprehensive Mini Humeral Tray|The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.
40930083|NCT02281097|OTHER|Stimulation|Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
40930084|NCT02281097|OTHER|Placebo|Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
40930085|NCT03127098|BIOLOGICAL|ETBX-011|ETBX-011 immunization was administered by subcutaneous (SC) injection.
41127987|NCT04197622|DRUG|Hydrochlorothiazide|12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
40930086|NCT03127098|BIOLOGICAL|ALT-803|ALT-803 was administered by SC injection.
40930087|NCT06167343|PROCEDURE|ACL reconstruction|In addition to surgical reconstruction, any structures that may have been injured concomitantly (meniscus, other ligament) will be repaired in the same surgery.
40930088|NCT03716570|DRUG|BIIB054|Administered as specified in the treatment arm.
40930089|NCT03716570|DRUG|Placebo|Administered as specified in the treatment arm.
40930090|NCT02184351|DRUG|Roxanes's clotrimazole troches|
40930091|NCT02184351|DRUG|Mycelex® troches|
40930092|NCT03433339|DEVICE|Active transcutaneous spinal direct current stimulation|Active anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
40930093|NCT03433339|DEVICE|Sham transcutaneous spinal direct current stimulation|Sham anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
41127988|NCT03910855|BEHAVIORAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
41127989|NCT03910855|OTHER|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
41127990|NCT00334776|BIOLOGICAL|MART-1 antigen|
41127991|NCT00334776|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|
41127992|NCT00334776|BIOLOGICAL|therapeutic autologous dendritic cells|
41127993|NCT00334776|BIOLOGICAL|tyrosinase peptide|
41127994|NCT03709706|DRUG|Lete-cel|lete-cel will be administered to eligible participants.
41127995|NCT03709706|DRUG|Pembrolizumab|Pembrolizumab will be administered to eligible participants.
41127996|NCT04448652|DRUG|NSAID|no other intervention than described in the groups.
41278281|NCT06655883|DRUG|Suvorexant|Oral Tablet
41278282|NCT06655883|DRUG|Placebo|Oral Tablet
41278283|NCT04859946|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
41278284|NCT04859946|DRUG|Busulfan|Given IV
41278285|NCT04859946|DRUG|Cyclophosphamide|Given IV
41278286|NCT04859946|DRUG|Fludarabine|Given IV
41278287|NCT04859946|DRUG|Itacitinib|Given PO
41278288|NCT04859946|DRUG|Tacrolimus|Given IV or PO
41278289|NCT04859946|DRUG|Thiotepa|Given IV
41278290|NCT06656013|BEHAVIORAL|Motivational Interview|After the preparation session, 4 sessions of motivational interviewing will be applied. Motivational interviewing techniques will be used in the interviews to target behavioral change.
41278291|NCT05843721|DEVICE|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
41278292|NCT06656247|OTHER|Online consenting|The design and establishment of an innovative digital tool (a software application) to implement the dynamic consent and allowing interaction among healthcare professionals and patients
41278293|NCT06657300|DRUG|PRP|A single dose of 1 ml PRP (Vacusera) was injected into the 1st CMC joint of the first group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
41278294|NCT06657300|DRUG|Corticosteroid|A single dose of 20 mg(1ml) of methyl-prednisolone (Depo-Medrol) (complemented to 1 ml by adding 0.5 ml of saline) was injected to the 1st CMC joint of the second group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
41278295|NCT05923073|DRUG|Guselkumab|Guselkumab will be administered either intravenously or subcutaneously.
41278296|NCT05923073|DRUG|Placebo|Week 12 induction responders will be administered placebo (matching guselkumab up to Week 48) SC at protocol specified time points to maintain the blind.
41278297|NCT06642480|DRUG|Post Operative Analgesia|administering 100 mg of intravenous tramadol 30 minutes before the operation is completed
41448937|NCT04766905|PROCEDURE|Mini Lateral Shoulder Approach (MLSA)|"The skin incision is about 4 to 5 cm made by the distal acromial edge in sagittal plane, The dissection takes place slightly over the acromial edge proximally and over the origin of the acromial deltoid part (the middle part of deltoid origin) distally.~After clearly revealing the region of the medial deltoid origin on the acromion, the acromionic deltoid origin is skinned only; of the edge of the acromion, and that maybe accrued by electric knife pen or periosteal elevator, without exposure the clavicular deltoid origin in the front and the deltoid origin on the spine of scapula in the back, the origin of the acromial deltoid is distanced laterally and distally, where the lateral edge, the lower surface of the acromion, under acromial bursa and the rotator cuff are exposed clearly."
41448938|NCT01639911|DRUG|Alisertib|Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
41448939|NCT01639911|DRUG|Pazopanib|Pazopanib at the assigned dose once a day continuously for the duration of treatment.
41278298|NCT06642480|DRUG|Post Operative Analgesia|VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed. It was observed in the recovery room at 30, 60, and 120 minutes.
41448940|NCT01067950|PROCEDURE|Isolated Pancreas Transplant|
41448941|NCT01067950|DRUG|Intensive Insulin Therapy|
41448942|NCT02380976|DRUG|combination drug: DW330SR, DW1030|
41448943|NCT02380976|DRUG|DW340|
41448944|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
41448945|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
41448946|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
41448947|NCT01660243|DRUG|Placebo|Placebo (2capsules) once daily for 8 weeks
41448948|NCT02622867|OTHER|Lactobacillus plantarum 3547|During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
41448949|NCT02622867|DIETARY_SUPPLEMENT|Maltodextrin|During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
41448950|NCT03829670|DIAGNOSTIC_TEST|Cytochrome P450 test|Blood samples will be drawn for cytochrome P450 testing.
41448951|NCT06403033|DEVICE|Mini-implant-supported Twin-Block|Mini-implants will support the Twin-Block appliance during the functional treatment.
41448952|NCT06403033|DEVICE|Twin-Block|This is the main appliance that will be used to correct the Class II deformity.
41448953|NCT03183609|OTHER|Gluten Flour in Protein Shake|15 Grams Gluten Flour BID
41278299|NCT06656754|OTHER|Isometric Reaching|"The intervention of Isometric Reaching is the process of restricting the participant's hand movement in place, while using the forces they apply to the robot handle to drive a reaching arm simulation"
41278300|NCT03655028|BEHAVIORAL|rhythmically auditory stimulation enhanced music|Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program
41278301|NCT03655028|BEHAVIORAL|control|Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program
41448954|NCT03183609|OTHER|Rice Flour in Protein Shake|15 Grams Rice Flour BID
41448955|NCT04129177|OTHER|Implementation of a bundle of surgical infection preventive measures|A bundle of six preventative measures is recommended to the VINCat hospitals. Bundle measures were: systemic and oral antibiotic prophylaxis, mechanical bowel preparation (MBP), laparoscopic surgery, maintenance of normothermia, and the use of a double-ring wound retractor.
41448956|NCT05091424|DRUG|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab
41448957|NCT05091424|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.
41448958|NCT05091424|DRUG|Venetoclax|Participants will receive daily oral venetoclax
41448959|NCT06563037|OTHER|No intervention|This is an observational study
41448960|NCT04515095|OTHER|Water-only Fasting|Participants consume only water for at least 7 days in an in-patient, residential setting with 24 hour medical supervision.
41448961|NCT06395792|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
41448962|NCT06627088|DRUG|LY4100511 (DC-853)|Administered oral dose
41448963|NCT06627088|DRUG|[14C]-LY4100511 (DC-853) Administered oral dose|Administered oral dose
41448964|NCT06627088|DRUG|LY4100511 (DC-853)|Administered oral dose
41448965|NCT06627088|DRUG|[14C]-LY4100511 (DC-853)|Administered IV infusion
41448966|NCT05897619|BEHAVIORAL|Experimental: Maya Perinatal Cognitive Behavioral Skills App|The intervention includes the completion of a mobile skills app teaching evidence-based strategies tailored for perinatal mood and anxiety. Modules include psychoeducation, skill information, practice exercises, and homework.
40930094|NCT01048489|BEHAVIORAL|Health education in the high school|"(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco."
40930095|NCT02270437|DRUG|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
40930096|NCT05364801|OTHER|Survey|Online anonymous survey
40930097|NCT04666077|BEHAVIORAL|Home-based MT through Supervised, Supported Singing (H3S)|"Daily singing of song of kin. The song of kin will be derived from an assessment session and evaluation inclusive of an interview under the supervision of Dr. Joanne Loewy and her team at the Louis Armstrong Center for Music and Medicine (LACMM). The interview will include the participant and their study partner who will assist in identifying musical preferences and relevant cultural experiences. A recording of prescribed song protocols will be provided. Participants and study partners will be directed to plan a minimum of 1 hour a day in which the participant will sing along with the study partner-administered song of kin. A diary will be provided to the study partner to record the time of day, amount of time spent and comments on the activity. Study staff will contact the members of this group to confirm compliance with the activity."
40930098|NCT04666077|BEHAVIORAL|Individualized Music Therapy (IMT)|The Individualized Music therapy (IMT) conducted by the LACMM staff. It will be administered by a certified music therapist twice weekly for 45 minutes. The sessions will employ extensive clinical improvisation based on the songs of kin utilized in the H3S condition. Compliance will be measured with a weekly log which will record dates and times of each condition.
40930099|NCT04666077|OTHER|Attention Control (AtCon)|"The attention control (AtCon) will meet with the LACMM team for an interview in which they will be asked about music preferences and music experiences. They will answer any questions from participant and caregiver about music experiences. Study staff will contact the members of this group at the same schedule as the H3S group to assess music activity engagement. This will measure unplanned exposure and minimize drop-in music activity which could contaminate the control condition."
40930100|NCT02969603|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging as reference
40930101|NCT02969603|OTHER|Magnetic Resonance combined with Positron Emission Tomography|Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle
40930102|NCT02940002|DRUG|BAY1003803|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
40930103|NCT02940002|DRUG|Clobetasol propionate|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
40930104|NCT02940002|DRUG|Betamethasone/calcipotriene|Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
40930105|NCT04294745|PROCEDURE|Buccal infiltration|Injection of local anaesthetic parallel to the Long axis of the tooth in the depth of buccal sulcus
40930106|NCT04294745|PROCEDURE|Inferior alveolar nerve block|Standard technique of mandibular nerve block
40930107|NCT03869827|OTHER|necrotizing enterocolitis|Collection of necrotizing enterocolitis diagnosis, as well as its severity, are based on the classification of Belle modified in 3 stages: 1) Suspected, 2) Proven, 3) Advanced
41127997|NCT01232959|DEVICE|Transvaginal Cholecystectomy|A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
41127998|NCT06207981|DRUG|induction chemotherapy (mDCF)|"Induction chemotherapy consists of mDCF administered every 2 weeks:~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day IV for 2 days)"
41127999|NCT06207981|DRUG|Concomitant chemotherapy (Capecitabin + Mitomycin-C)|Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given
41128000|NCT06207981|RADIATION|radiotherapy|"Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~* 49.5 Gy (5 x 1.65 Gy/week) to the pelvis~* 60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes"
41128001|NCT00328692|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
41128002|NCT00328692|DRUG|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
41128003|NCT02446340|DRUG|dalazatide|Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
41128004|NCT02446340|DRUG|placebo|Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
41128005|NCT02398487|DEVICE|cigalike with nicotine|cigalike 24 mg nicotine or 16 mg nicotine
41128006|NCT02398487|DEVICE|Personal Vaporizer with nicotine|Personal Vaporizer 16 mg nicotine or 9 mg nicotine
41128007|NCT02424201|DRUG|Misoprostol|experimental
41128008|NCT02424201|DRUG|vitamin c|control
41128009|NCT00698113|PROCEDURE|Massage|"Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.~Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol."
41128010|NCT00698113|OTHER|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
41128011|NCT05397262|OTHER|Hyperthermia|Deep Regional Hyperthermia (RHT) 1-2/week up to 10 sessions a type of cancer treatment in which body tissue is exposed to high temperatures (up to 113°F).
41128012|NCT05397262|RADIATION|Radiotherapy|50,4 Gy (28 x 1,8 Gy) plus Boost: If R0: 5,4 Gy; If R1/2: 9 Gy
41128013|NCT05397262|DRUG|Chemotherapy 5-Fluorouracil|600 mg/m\^2 civ 120h; d 1-5, 29-33
41128014|NCT05397262|DRUG|Chemotherapy Cisplatin|20 mg/m\^2; d1-5, 29-33
41128015|NCT00557596|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
41128016|NCT00960141|DRUG|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
41128017|NCT00960141|DRUG|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
41128018|NCT00960141|DRUG|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
41128019|NCT06213233|DRUG|Placebo|Participant will take placebo days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
41128020|NCT06213233|DRUG|Cannabidiol|Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
41128021|NCT00758550|DEVICE|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
41278302|NCT06642610|DEVICE|CGM Dynamic Index (CDI)|participants will undergo IV placement for a one-time OGTT and a one-time insertion of a CGM. The CGM will be worn for up to 10 days. The data collected will be used to develop the CDI. A person with CFRD and already using CGM, we will just collect their personal CGM data and they are not required to have OGTT or HbA1c visit.
40930108|NCT02447783|DIETARY_SUPPLEMENT|Control Capsules|Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
41128022|NCT00758550|DEVICE|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
41128023|NCT02477813|DRUG|Temozolomide|200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
41128024|NCT04218383|DEVICE|Transcranial Direct Current Stimulation|Anode placed over the OFC and cathode placed over the right primary motor cortex.
41278303|NCT06220201|DRUG|CC-97540|Specified dose on specified days
40930109|NCT02447783|DIETARY_SUPPLEMENT|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
40930110|NCT05776602|DIAGNOSTIC_TEST|Fast MRI (Neuromix)|Diagnostic performance, correlation, agreement
40930111|NCT00005001|BIOLOGICAL|HIV-1 Immunogen|
41128025|NCT00137800|DRUG|OSI-774 (Tarceva)|Once daily without interruption as long as there is no disease progression or serious side effects experienced.
41128026|NCT00035100|DRUG|epothilone b|
41128027|NCT03778541|DRUG|Temozolomide|75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.
41128028|NCT03778541|RADIATION|hypofractionated radiotherapy|the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
41128029|NCT02727205|DRUG|Rotigotine Transdermal System|
41128030|NCT05058677|DRUG|aerosolized 2% lidocaine (20mg/ml)|The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
41128031|NCT05058677|DRUG|instilled 0.9% sodium chloride (NS)|The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
41128032|NCT05058677|DRUG|instilled 2% lidocaine solution|The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
41278304|NCT06220201|DRUG|Fludarabine|Specified dose on specified days
41278305|NCT06220201|DRUG|Cyclophosphamide|Specified dose on specified days
41278306|NCT05501873|DEVICE|FARAPULSE Pulsed Field Ablation system|Any subject who has signed the informed consent and for whom the FARAPULSE Pulsed Field Ablation system has been inserted into the body, and pulsed field ablation treatment has been received, are assigned to the treatment group.
41278307|NCT01363843|DRUG|FOLFOX6|FOLFOX6
41128033|NCT05058677|PROCEDURE|Endotracheal Suctioning (ETS)|ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline).
41278308|NCT01363843|RADIATION|RT with concurrent chemotherapy|IMRT 50.4Gy with chemotherapy
40930112|NCT05138471|DEVICE|transcranial direct current stimulation (tDCS)|tDCS intervention will consist in placing two electrodes, the cathode on the supraorbital surface on the same side as the painful knee, and the anode on the parietal area, corresponding to the area of the primary motor cortex, on the opposite side. The intensity will be 2 milli amperes (mA) and stimulation will be 20 minutes. The placebo will generate an initial sensation, and then descend until the stimulation is turned off.
40930113|NCT05138471|DEVICE|TENS|TENS intervention will consist in placing two electrodes on the sides of the patella of the affected knee. The frequency will be 10Herzts and the intensity will remain at a sensitive threshold level, without reaching the motor. The placebo will generate a sensation of current to descend to the minimum value that the equipment allows. Stimulation will last for 20 minutes.
40930114|NCT05138471|BEHAVIORAL|Exercise and General Education|The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.
40930115|NCT00000187|DRUG|Ritanserin|
40930116|NCT00002975|DRUG|aminolevulinic acid|
40930117|NCT05977725|DIAGNOSTIC_TEST|Hand Doppler Ultrasound|Hand Doppler Ultrasound to assess the Hand Acceleration Time (HAT)
40930118|NCT03097354|OTHER|no intervention/observational survey study design|no intervention/observational survey study design
40930119|NCT02935829|OTHER|Glucose as reference food|Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40930120|NCT02935829|OTHER|White bread as reference food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40930121|NCT02935829|OTHER|Carob snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40930122|NCT02935829|OTHER|Chocolate cookie snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40930123|NCT02935829|OTHER|Carob preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
40930124|NCT02935829|OTHER|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
41128034|NCT01449760|OTHER|Physical Therapy|These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
40930125|NCT00127621|PROCEDURE|early tracheotomy|
40930126|NCT00127621|PROCEDURE|prolonged endotracheal intubation|
40930127|NCT02323360|RADIATION|SBRT|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions
40930128|NCT02323360|PROCEDURE|TACE|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
40930129|NCT01331018|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow harvest
41128035|NCT01449760|OTHER|Wii Balance Board|These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
41128036|NCT05427305|DRUG|TAB008|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
41278309|NCT01363843|PROCEDURE|Surgery|
41278310|NCT05302752|OTHER|Magnetic phrenic nerve stimulation|"The intervention consists of bilateral rapid magnetic phrenic nerve stimulation on the neck using different stimulation intensities.~On one visit, the effect of increasing chest wall stiffness and respiratory muscle work by adding incrementally small weights to the chest/abdomen will be investigated."
41128037|NCT05427305|DRUG|Bevacizumab|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
41128038|NCT06086067|OTHER|Aerobic session|This session will consist of an aerobic training session performed on a cycle ergometer.
41128039|NCT01158417|DRUG|Placebo|oral
41128040|NCT01158417|DRUG|Resveratrol 40 mg oral three times a day|Drug
40930130|NCT01331018|BIOLOGICAL|Filgrastim|Given SC
41128041|NCT01158417|DRUG|Resveratrol 500 mg oral once daily.|Resveratrol 500 mg oral once daily.
41128042|NCT00288288|PROCEDURE|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
40930131|NCT01331018|BIOLOGICAL|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
40930132|NCT01331018|OTHER|Laboratory Biomarker Analysis|Correlative studies
40930133|NCT01331018|PROCEDURE|Leukapheresis|Undergo leukapheresis
40930134|NCT01331018|DRUG|Methylprednisolone|Given IV
40930135|NCT01331018|DRUG|Plerixafor|Given SC
40930136|NCT01331018|DRUG|Prednisone|Given PO
40930137|NCT01040078|BIOLOGICAL|7.5ug H1N1 Influenza vaccine|0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
40930138|NCT01040078|BIOLOGICAL|15ug H1N1 vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
40930139|NCT01040078|BIOLOGICAL|seasonal influenza vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
40930140|NCT03320304|DEVICE|Vagal Nerve Simulation (VNS) Therapy|A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
40930141|NCT02514954|DRUG|Biochaperone® Combo|Subcutaneous injection of an individualized dose
40930142|NCT02514954|DRUG|Humalog® Mix25|Subcutaneous injection of an individualized dose
41278311|NCT06540235|DEVICE|Otolith Device Active|The device will be providing different levels of stimulation hypothesized to affect the vestibular system
41278312|NCT06540235|DEVICE|Otolith Device Inactive|The device will be providing no stimulation to measure test-retest
41278313|NCT00327444|DRUG|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
41278314|NCT00327444|DRUG|Placebo|Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
41278315|NCT00327444|DRUG|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
40930143|NCT00672113|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
40930144|NCT00672113|DRUG|Coracten|Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
41278316|NCT01938859|DRUG|Lithium|Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
41278317|NCT01938859|DRUG|Quetiapine|Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
41278318|NCT01938859|DRUG|Shuganjieyu capsule|Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
41278319|NCT04062955|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary counseling
41278320|NCT04062955|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
41278321|NCT04062955|OTHER|Questionnaire Administration|Ancillary studies
41278322|NCT04178590|DRUG|SRP + Injectable Platelet-Rich Fibrin|Injectable Platelet-Rich Fibrin application as adjunct to scaling and root planing
41278323|NCT04178590|DRUG|SRP + placebo|Saline application during scaling and root planing
40930145|NCT04610697|BEHAVIORAL|Cognitive Remediation|Cognitive Remediation consists of exercises, preferably supported by coaching, aimed at engaging cognitive skills and, as a result, at improving cognition as well as functional and clinical outcomes.
40930146|NCT04610697|BEHAVIORAL|Active Control|Active control condition for cognitive remediation, matched in terms of session modality, number, duration, frequency, and format.
40930147|NCT01246466|DEVICE|Hybrid: AtriCure Bipolar System & EP ablation procedure|AtriCure Bipolar System plus a catheter ablation
40930148|NCT04964193|DRUG|Elzsa film-coated tablet|Administered with 240 mL of water
40930149|NCT04964193|DRUG|Diane-35 Sugar-coated tablet|Administered with 240 mL of water
40930150|NCT02004639|RADIATION|Masticators sparing techniques|
40930151|NCT02004639|OTHER|electro-acupunture treatment|electro-acupunture treatment and sham-EA
40930152|NCT00376714|DRUG|GSK233705|
40930153|NCT04309123|DEVICE|TransAeris System|The TransAeris System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).
41278324|NCT04746586|OTHER|Circulating MiRNA indentification|Identification of circulating miRNA useful to discriminate between worsening and stable forms of AIS
40930154|NCT05353803|OTHER|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure
40930155|NCT01018446|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
40930156|NCT05506605|DRUG|Doravirine 100Mg Tab|Switch from Etravirine to Doravirine
41278325|NCT02882607|BEHAVIORAL|Mzanga Samala Moyo Wako ([Mzanga] Peer Groups|8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
41278326|NCT02191748|PROCEDURE|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
41278327|NCT02191748|DRUG|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
41278328|NCT01477905|DEVICE|Remi50 with prime|for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING
41278329|NCT01477905|DEVICE|Remi20 with prime|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
40930157|NCT00912561|BEHAVIORAL|Intense aerobic exercise|3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
41128043|NCT00288288|PROCEDURE|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
41128044|NCT04989296|DIAGNOSTIC_TEST|Peripheral blood samples were obtained following the standard procedures.|Taking 4 ml of peripheral blood from patients on an empty stomach.
41448967|NCT06003335|BEHAVIORAL|Regular message delivery|Regular messages will be sent regularly to each participant over the 12-week study period. As personalisation is a core process in enabling behavioural change, the intervention content, frequency, and timing of the messages will be based on the participants' self-care needs and preferences, which will be surveyed at baseline. If no specific preferences are provided, we will plan the message delivery to decrease in frequency over time as this trend has shown the highest effectiveness in existing studies. The format of messages will be mainly texts, but other formats such as pictures and voice messages will also be considered for addition to the content library to suit a wide range of preferences.
40930158|NCT01585584|DRUG|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
40930159|NCT05543434|DRUG|Hyaluronic acid|anti-inflammatory, anti-edematous, osseoinductive.
40930160|NCT02832583|DEVICE|Regenkit BCT-HA Cellular Matrix|To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
41128045|NCT02186743|OTHER|Personalized Dietary Advice|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
41128046|NCT05792293|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects
41128047|NCT05792293|OTHER|Placebo|Placebo
41128048|NCT03554889|BIOLOGICAL|NK Cell adaptive transfer|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
41448968|NCT06003335|BEHAVIORAL|Chat-type support message delivery|Chat-based support will be given to the participants in addition to the regular message delivery. Instant messaging will be used to communicate directly with the participants. We plan to recruit 10 student RAs who have been trained in the delivery of interactive instant messages (IMs) to provide chat-type support to encourage increased physical activity and interaction. Participants will be invited to set physical activity goals and action plans through the chat-type support. Participants will receive a personalised summary of their physical activity weekly and will be encouraged to reflect on this through a real-time chat (around 5 minutes). They will also be encouraged to establish a plan of how they can adjust their physical activity goal going forward. When addressing the participants' queries or any ethical concerns, the student RAs will be instructed to immediately report to the Principal Applicant and supervisors who are experienced and trained research nurses.
41448969|NCT05370417|OTHER|Use of fluoride toothpaste|The participants received oral hygiene instructions - routine brushing twice per day with toothpaste containing 1000 ppm of fluoride. All participants received a toothbrush and toothpaste to ensure standardization. The aim of this intervention was to assess whether the participants' brushing technique would improve with desensitization.
40930161|NCT05304832|OTHER|Aqua-Plyometric Exercise|The aqua-plyometric training was conducted for 45 minutes, twice weekly, for 12 successive weeks. The training was geared toward the lower body and was conducted under close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
41448970|NCT05370417|RADIATION|Photobiomodulation|"For laser application, the following dosimetric parameters will be used:~Low level laser diode (infra red) wavelength 808nm with a power of 100mW. Three sessions: initial session, after 48 hours and after one month. LLL was applied to three perpendicular points in contact with the surface on the mesial vestibular and distal cervical faces and in the center of the occlusal face. An energy of 1 J was applied for 10 seconds at each point."
41448971|NCT05370417|PROCEDURE|Simulated Laser Therapy|The same application described in the laser therapy group will be simulated, with the device turned off.
41448972|NCT05370417|PROCEDURE|Sealant application|A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
41448973|NCT06562348|OTHER|Standard of care|Patients will be offered palliative systemic treatment according to standard of care. Response evaluation will be performed with the imaging-based RECIST according to standard guidelines. Treatment pauses according to institutional guidelines. Blood samples will be analyzed retrospectively to evaluate ctDNA.
41448974|NCT06562348|OTHER|ctDNA-RECIST guided palliative systemic treatment|"Patients are offered palliative systemic treatment according to standard of care. Response evaluation will be performed using ctDNA-RECIST.~ctDNA is measured before start of treatment. If the baseline sample is ctDNA negative the patient is transferred to an observational cohort, and sampling procedures continues as in the standard arm. If the baseline sample is ctDNA positive the patient continues in the ctDNA-RECIST guided arm. Treatment response is evaluated according to ctDNA-RECIST, and further sampling follows a predefined decision schedule."
41448975|NCT05069571|OTHER|Endoangel|Collecting the colonoscopy videos and analyzing the correlation between withdrawal overspeed proportion and adenoma detection rate.
40930162|NCT05304832|OTHER|Standard physical therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 40 minutes, two times a week for 12 successive weeks.
41128049|NCT03554889|DRUG|Nimotuzumab|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
41128050|NCT02746549|OTHER|renal perfusion|measurement of renal perfusion with MRI arterial spin labelling technique
41128051|NCT06008236|BEHAVIORAL|Progressive Muscle Relaxation and Breathing Exercises|Progressive relaxation exercise is a method that provides relaxation in the whole body by voluntary, regular relaxation of large muscle groups in the human body. Exercise helps individuals to be able to feel the difference between tension in the muscles and relaxation, and to learn to relax on their own in case of tension. Deep breathing exercise supports the maximum ventilation of the lung by correct breathing using the diaphragm.
41128052|NCT02926196|DRUG|MSB0010718C|MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
41128053|NCT01144559|PROCEDURE|Continuous Infusion|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.
41128054|NCT01144559|PROCEDURE|Bolus Administered|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
41128055|NCT00332319|DRUG|GW679769|
40930163|NCT00328978|DRUG|Quetiapine|
41128056|NCT04095884|PROCEDURE|blood sampling|observational study and no intervention will be given. only blood samples collected and treated with iron supplements
41128057|NCT00826995|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
40930164|NCT00075439|DRUG|gefitinib|Given orally
40930165|NCT00075439|OTHER|laboratory biomarker analysis|Correlative studies
41128058|NCT06116968|DRUG|Aficamten|5-20mg
41128059|NCT01025323|BEHAVIORAL|Lifestyle modification|DASH diet and exercise advice
41128060|NCT01025323|BEHAVIORAL|Lifestyle modification|DASH diet, exercise with systematic instruction by a dietician and/or coordinator
41128061|NCT03176888|BEHAVIORAL|Reduced-exertion, high-intensity interval training (REHIT)|As in arm/group description
41278330|NCT00783627|PROCEDURE|Angiography|Angiography done at the J1 visit
40930166|NCT03824509|OTHER|Chart Review|"Study staff at PBMC (Cardiologist and two clinical researchers) will be responsible for maintaining all data related to this study in REDCap. Patient data to be included in this secondary data analysis will originate from MMC and PBMC.~Case-patient data to be included from MMC will be identified by an EPIC data request from Enterprise Reporting. The elements of the data request will be patients who have had a stroke or TIA, atrial fibrillation, and a transthoracic echocardiogram at MMC from 2014-2017."
40930167|NCT06364293|OTHER|Observational design does not include interventional behavior.|Observational design does not include interventional behavior.
40930168|NCT01042782|DRUG|RAD001 and MitomycinC|"RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks"
40930169|NCT00214604|DRUG|Rosuvastatin|10mg
40930170|NCT00214604|DRUG|rosuvastatin|20mg
40930171|NCT00214604|DRUG|pravastatin|40mg
40930172|NCT04930380|OTHER|phone interview|Cases and controls will receive a phone interview
40930173|NCT02869984|DRUG|Ramosetron|
40930174|NCT00140543|DRUG|sirolimus versus mycophenolate mofetil|
40930175|NCT03849027|DRUG|Methoxyflurane|Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®) according to the recommended dosing schedule.
40930176|NCT03849027|DRUG|Placebo|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.
40930177|NCT02329366|OTHER|Specimen Collection|. In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
40930178|NCT06485115|DEVICE|Digital Telerehabilitation (Euleria Home)|After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the EG patients will perform the Digital Telerehabilitation program at home. The three weekly sessions will be asynchronous (with the caregiver's supervision if necessary). At each Unit, the physiotherapist will develop the training sessions on the Home- based Digital Telerehabilitation program and monitor the training execution provided by the digital device to adapt the rehabilitation treatment to the patients' improvements/difficulties. The Digital Telerehabilitation device (Euleria Home, Euleria Health) will consist of one wearable sensor and an app on a tablet that guides the patient through the customized exercise-therapy path configured by the professional. The sensor is worn on different body segments to monitor movements and provides real-time feedback on angles, balance, and repetitions.
40930179|NCT06485115|OTHER|Conventional therapy|After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the CG patients will be advised to perform the Self-management activities learned during the in-hospital rehabilitation training without home-based Digital Telerehabilitation devices.
40930180|NCT01072565|OTHER|SMBG to guide clinical decisions|The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
40930181|NCT01072565|OTHER|SMBG and CGM|The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
40930182|NCT01514786|BEHAVIORAL|Colorectal Web|The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
40930183|NCT03026101|OTHER|Nitroglycerin|Intra-arterial adminstration to dilate external carotid artery branches to replicate migraine pain
40930184|NCT00874614|RADIATION|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
40930185|NCT03146598|OTHER|No intervention as it is a observational study|No intervention as it is a observational study
40930186|NCT01463137|BEHAVIORAL|Attention bias modification|All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
41128062|NCT03176888|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey \& Greer (2012)
41128063|NCT02230137|BEHAVIORAL|Text message arm|Text message sent before each injection of insulin
41128064|NCT02969759|OTHER|Skin Biopsy|
41278331|NCT04442607|DEVICE|artificial intelligence image processing|Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive.
41278332|NCT00787293|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
41278333|NCT00643149|DRUG|amoxicillin|10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
41448976|NCT02949167|BEHAVIORAL|MyHealth|The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
40930187|NCT00475423|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
40755043|NCT04299425|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
40930188|NCT01551420|DEVICE|Advanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic IMU controlled
41278334|NCT00643149|DRUG|azithromycin SR|60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
41278335|NCT02317510|PROCEDURE|combined anesthesia|Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy
41278336|NCT02317510|PROCEDURE|general anesthesia|General anesthesia for laparoscopic cholecystectomy
41278337|NCT05195606|OTHER|Auditory stimulus|Auditory stimulus will be applied to the patients in intervention group A. For the auditory stimulus, the sound recording of the relatives of the patients will be taken and the patients will be listened to with headphones.
41278338|NCT05195606|OTHER|Tactile stimulus|Tactile stimulus will be applied to the patients in the intervention group B. The tactile stimulus will be performed by the researcher with a foot massage to be applied to the patient.
41278339|NCT05859451|DEVICE|Tobacco Heating System (THS)|Participant who are not willing to quit cigarette smoking during the study duration will switch from cigarettes to using THS
41278340|NCT05859451|OTHER|Smoking abstinence|Participant who are willing to quit cigarette smoking and will not use any electronic nicotine delivery system during the study duration
41278341|NCT01014715|OTHER|Phase II - Preoperative Radiation followed by Lumpectomy.|Sequential investigative question. All procedures are standard of care
41278342|NCT04433117|BIOLOGICAL|Shefabone|Silica-calcium phosphate composite.
41278343|NCT04433117|BIOLOGICAL|Bio-Oss|Xenograft Bone substitute. Bone from animals.
41278344|NCT04073745|OTHER|Quality-of-Life Assessment|Ancillary studies
41278345|NCT04073745|OTHER|Questionnaire Administration|Ancillary studies
40930189|NCT01551420|DEVICE|Advanced upper limb prosthetic EMG-PR controlled|Advanced upper limb prosthetic EMG-PR controlled
41278346|NCT04073745|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41278347|NCT02505048|DRUG|rucaparib|600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
41278348|NCT02926339|BEHAVIORAL|Teens Against Tobacco Use presentation|Students receive a series of 3 anti-tobacco presentations delivered by older peers
41278349|NCT03707717|DRUG|Bimekizumab|Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
41278350|NCT05419388|DRUG|RO7247669|Participants will receive intravenous (IV) RO7247669 Q3W
41278351|NCT01046812|DRUG|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
41278352|NCT01745003|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes-anode and cathode. We will be using this device to investigate fibromyalgia.
40930190|NCT05449483|DRUG|tislelizumab+ Paclitaxel + Cisplatin|tislelizumab combined with chemotherapy
41448977|NCT00567463|DEVICE|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
40930191|NCT01455129|DRUG|Tiotropium|18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
40930192|NCT01455129|DRUG|placebo|placebo, once daily, inhaled by HandiHaler
40930193|NCT02782078|BIOLOGICAL|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
40930194|NCT00914303|DRUG|AZD3241|Oral Tablet, Repeated Administration
40930195|NCT00914303|DRUG|Placebo Tablet|Oral Tablet. Repeated Administration
41278353|NCT04820270|OTHER|Autologous T regulatory cells|Enriched autologous T regulatory cells are given back to the patient at the time of islet transplantation
41278354|NCT06214312|DIAGNOSTIC_TEST|Lung Ultrasounds|An ultrasound exam of the lungs to identify possible areas of atelectasis.
41448978|NCT06402799|BEHAVIORAL|Home-based E-biking|The e-biking intervention consists of 3 sessions per week at the beginning of the study and gradually increases over the training period to 6 sessions per week, with three of these sessions being online and group-supervised. Heart rate will be monitored as well as power in Watt at each session.
41448979|NCT03632031|DEVICE|Oasis Extracellular Matrix|Patients will receive OASIS Extracellular Matrix according to the Instruction for Use
41448980|NCT04666636|DRUG|Placebo|Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
41448981|NCT04666636|DRUG|Mirabegron|Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
41448982|NCT03692611|BEHAVIORAL|Skills TO Manage Pain (STOMP)|12 week pain self management (PSM) intervention incorporating social cognitive theory constructs.
40755044|NCT02018809|BEHAVIORAL|Medication Adherence Partner|
40755045|NCT02018809|DEVICE|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
41128065|NCT03000257|DRUG|Venetoclax|Tablet taken orally
41128066|NCT03000257|DRUG|Rovalpituzumab Tesirine|Intravenous infusion
41128067|NCT03000257|DRUG|ABBV-181|Intravenous infusion
41128068|NCT01700205|OTHER|Type of Formula|infant formula
41128069|NCT05299034|DIAGNOSTIC_TEST|Multiparametric imaging|MR perfusion or multiparametric CT including NCCT, CTA and CTP
41448983|NCT03692611|BEHAVIORAL|comparison group|Participants in this arm will receive usual care as given by providers but no behavioral PSM intervention.
41448984|NCT03841617|DRUG|Thyrogen|intramuscular injection administered once/day for 2 consecutive days at Week 3; then once annually for subjects who meet criteria.
41448985|NCT03841617|RADIATION|I-131|therapeutic dose administered orally to treat thyroid cancer at Week 8. 5-7 days later, the post-treatment I-131 Whole Body scan w/ SPECT is performed; then administered once annually, if the patient needs to be re-treated
41448986|NCT03841617|RADIATION|I-124|one capsule ingested orally once at Week 3, and Week 8; then administered once annually to subjects who meet criteria.
41128070|NCT05299034|DIAGNOSTIC_TEST|Non contrast CT+CT angiography|NCCT+CTA
41128071|NCT02700269|OTHER|mBEADS|Evaluate approaches using magnetic bead capture, isolation, and surface tension valve transfer of biomarkers to improve the sensitivity of already approved malaria RDTs.
41448987|NCT03841617|OTHER|Thyroid hormone withdrawal|withdrawal of thyroid hormone during weeks 4 through 8
41448988|NCT04958915|DIAGNOSTIC_TEST|Knee joint 30° flexion scan|The patient was placed in the supine position, and the knee joint was naturally placed in the knee joint special coil, and the knee joint 30° flexion position scan.
41448989|NCT06192888|DRUG|Glofitamab|IV Glofitamab
41448990|NCT06192888|DRUG|Obinutuzumab|IV Obinutuzumab
41448991|NCT06192888|DRUG|Lenalidomide|Oral Lenalidomide
41448992|NCT06623084|OTHER|Platelets characterization|To identify platelet features that correlate with liver disease progression and to study the mechanistic relationship between gut dysbiosis, metabolome composition, inflammation, and platelet activation in chronic liver disease.
40930196|NCT01285947|DEVICE|Thermage|Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
40930197|NCT01285947|OTHER|Needle Application|30-gauge needle insertion into skin
40930198|NCT01285947|DEVICE|VBeam Laser|Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
40930199|NCT01285947|DEVICE|Ulthera|"Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm"
40930200|NCT05720754|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
40930201|NCT05720754|DEVICE|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
40930202|NCT02019901|OTHER|Nurse-led clinic|
40930203|NCT03860935|DRUG|acoramidis|TTR stabilizer administered orally twice daily (BID)
41128072|NCT04379375|BEHAVIORAL|Nudge|Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
41128073|NCT04062396|DEVICE|Eurosets REMOWELL 2 oxygenator|The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
41128074|NCT04062396|DEVICE|LivaNova INSPIRE oxygenator|INSPIRE oxygenator has no filtration system for extracavitary inlet
41448993|NCT05920486|DEVICE|High-Intensity Laser Therapy (HILT)|High-Intensity Laser Therapy (HILT) is a non-invasive treatment that utilizes high-powered lasers to deliver therapeutic doses of energy to damaged tissue. In this study, HILT will be used to treat sacroiliitis, a condition that affects the sacroiliac joint in the lower back and pelvis. HILT will be administered using a Class IV laser with a wavelength of 980 nm, power output of 10 W, spot size of 0.5 cm, and a dose of 60 J/cm2 per session. The laser will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of HILT is to promote cellular repair and regeneration, reduce pain, and improve function in patients with sacroiliitis. Participants in the HILT group will receive HILT treatment as the primary intervention in this study.
40930204|NCT03860935|DRUG|Placebo Oral Tablet|Non-active control administered orally twice daily (BID)
40930205|NCT00202527|DEVICE|Nasal continuos positive airway pressure|
40930206|NCT03168529|DRUG|Ivabradine|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
40930207|NCT03168529|DRUG|Placebo|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
41128075|NCT00167921|DRUG|Premarin® Vaginal Cream|
41128076|NCT00167921|DRUG|Premarin® oral tablets|
41128077|NCT03877575|OTHER|No specific intervention. Collection of clinical data|
41128078|NCT01785446|DRUG|Effect of dexmedetomidine on cisatracurium and sufentanil consumption|In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
41128079|NCT01785446|DRUG|Consumption of cisatracurium and sufentanil in different age groups.|For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
41453448|NCT03564587|BEHAVIORAL|AWAKE|Behavioral intervention called Achieving Wellness After Kancer in Early Life (AWAKE) is focused on increasing hope in order to improve quality of life and health-promoting behaviors in survivors of young adult cancer. The AWAKE mobile app contains eight modules for participants to complete over 8 weeks with the ability to review prior modules. Participants receive a prompt on their mobile device weekly to complete each module and/or they will receive a text reminder. The app includes health education messaging, weekly homework assignments, the ability to track progress towards goals with self-monitoring and graphical depictions of progress, videos of inspirational materials, and a portal for interacting with their coach.
40930208|NCT01920035|DEVICE|UroCool (Local cooling/hypothermia)|These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
40930209|NCT00233831|DEVICE|Generator of electromagnetic millimeter waves|
40930210|NCT04272879|OTHER|Observational Group|Those requiring NIV following an acute exacerbation of COPD
40930211|NCT05496231|BIOLOGICAL|HPV9 High formulation|3 doses of a high formulation investigational adjuvanted HPV9 vaccine intramuscularly (IM) on Day 1, Month 2, and Month 6.
40930212|NCT05496231|BIOLOGICAL|HPV9 Medium formulation|3 doses of a medium formulation investigational adjuvanted HPV9 vaccine administered IM on Day 1, Month 2, and Month 6.
40930213|NCT05496231|BIOLOGICAL|HPV9 Low formulation|3 doses of a low formulation investigational adjuvanted HPV9 vaccine administered IM on Day 1, Month 2, and Month 6.
40930214|NCT05496231|BIOLOGICAL|Gardasil 9|3 doses of the marketed HPV vaccine (Gradasil 9) administered IM on Day 1, Month 2, and Month 6.
40930215|NCT01108978|DRUG|Placebo|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
40930216|NCT01108978|DRUG|Dehypotin|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
40930217|NCT06272097|BEHAVIORAL|Intervention program based on TIME-CDST tool led by wound specialist nurses|Based on the TIME CDST tool led by wound specialist nurses, which includes the following four areas: A. Assess patient, well-being and wound; B. Bring in multidisciplinary team and informal carers to promote holistic patient care; C. Control or treat underlying causes and barriers to wound healing; D. Decide appropriate treatment.
40930218|NCT06272097|BEHAVIORAL|A routine wound care program|A routine wound care program of wound cleaning and dressing changes
40930219|NCT00879944|OTHER|Blood pressure|Blood pressure will be measured once while patient is seated
41448994|NCT05920486|DEVICE|Sham High-Intensity Laser Therapy (HILT)|Sham HILT is a non-invasive treatment that mimics the appearance and sensation of HILT but does not deliver any laser energy to the affected tissue. In this study, Sham HILT will be used as a control intervention for the treatment of sacroiliitis. The device used for Sham HILT will look and feel the same as the HILT device, but will not emit any laser energy. The device will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of Sham HILT is to provide a credible control intervention that does not have any specific therapeutic effect on the sacroiliac joint. Participants in the Sham HILT group will receive Sham HILT treatment as the primary intervention in this study.
41128080|NCT01937494|DRUG|histamine-benzylic alcohol (magistral preparation)|passive exposure to histamine during a bronchial hyperresponsiveness challenge
41128081|NCT01872494|OTHER|local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
41278355|NCT06656975|BEHAVIORAL|Brief Cognitive Therapy|"This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes."
40930220|NCT00879944|OTHER|Height|Height will be measured in centimeters at the time of enrollment
40930221|NCT00879944|OTHER|Weight|Weight will be measured in kilograms at enrollment
40930222|NCT00879944|OTHER|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
40930223|NCT00879944|OTHER|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
40930224|NCT00897338|OTHER|flow cytometry|laboratory analysis
41128082|NCT01872494|OTHER|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
41128083|NCT01872494|DRUG|0.33% ropivacaine 250ml|
41278356|NCT06656975|BEHAVIORAL|Social Prescribing|"This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes."
41278357|NCT06656975|OTHER|Enhanced Usual Care|Participants will receive an informational booklet on improving loneliness. Participants may initiate or continue Collaborative Care for other conditions on a not research basis.
41278358|NCT03026803|DRUG|Oxaliplatin|Given IV
41278359|NCT03026803|DRUG|Capecitabine|Given PO
41278360|NCT01726361|BEHAVIORAL|Multidimensional Treatment Foster Care|Out of home placement in MTFC family for 10-12 months
41278361|NCT01726361|BEHAVIORAL|Treatment as usual|Other kinds of out of home placement
41278362|NCT06657378|OTHER|No Intervention|This is a non-interventional study.
41448995|NCT02648438|DRUG|AZD7594 Solution for infusion (150 μg intravenous formulation)|Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
40755046|NCT01029197|BEHAVIORAL|CBT and exposure therapy for PTSD|The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
40930225|NCT00897338|OTHER|fluorescence activated cell sorting|laboratory analysis
40930226|NCT00897338|OTHER|immunohistochemistry staining method|laboratory analysis
40930227|NCT00897338|OTHER|immunologic technique|laboratory analysis
40930228|NCT00897338|OTHER|biomarker analysis|laboratory analysis
40930229|NCT03025789|DRUG|Fexinidazole|Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
41128084|NCT01872494|DRUG|flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.|
41128085|NCT03835559|PROCEDURE|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
41128086|NCT03835559|PROCEDURE|Surgical stripping|All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.
41128087|NCT03754036|BEHAVIORAL|Sleep manipulation|Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.
41278363|NCT02981290|DRUG|Renodapt|Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
41278364|NCT02981290|DRUG|Mycept|Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
41278365|NCT02981290|DRUG|Cellmune|Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
41448996|NCT02648438|DRUG|AZD7594 Oral suspension (1200 μg oral formulation)|0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
41448997|NCT02648438|DRUG|AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
41448998|NCT02648438|DRUG|AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
40930230|NCT03893344|DIAGNOSTIC_TEST|detection of STAT4 gene|Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample
40930231|NCT04692740|DRUG|Chlorambucil, Oral, 2 Mg|Eligible patients will be treated with Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1-6). After restaging, responder patients (complete or partial response) and those with stable disease will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days every 28 days until disease progression or unbearable toxicity, patient refusal or medical decision. Patients' clinical data will be collected pseudo-anonymously and a sequential identification code number will be assigned to each patient enrolled in the study.
40930232|NCT04443595|PROCEDURE|Dual-scopic pancreatic necrosectomy（DPN）|Treatment of Acute Severe Pancreatitis with DPN
40930233|NCT00663442|DRUG|OROS methylphenidate|18, 36, 54 mg
41278366|NCT02981290|DRUG|CellCept|CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
41278367|NCT01725165|OTHER|Clinical Observation|Undergo clinical observation
41278368|NCT01725165|RADIATION|External Beam Radiation Therapy|Undergo EBRT
41278369|NCT01725165|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41278370|NCT01725165|OTHER|Quality-of-Life Assessment|Ancillary studies
41278371|NCT01725165|PROCEDURE|Standard Follow-Up Care|Undergo standard maintenance therapy
40930234|NCT01595945|PROCEDURE|Gastric bypass|Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
40930235|NCT01595945|BEHAVIORAL|Caloric restriction|Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
40930236|NCT01924429|DRUG|Lisdexamfetamine|Escalating stepped dose titration: 30, 50 or 70mg
40930237|NCT01401959|DRUG|Eribulin|1.4 mg/m\^2 IV Days 1 and 8, every 21 days for six cycles
40930238|NCT01401959|DRUG|Trastuzumab|6 mg/kg IV Day 1 every 21 days
40930239|NCT03971877|DIAGNOSTIC_TEST|Rapid Polymyxin NP test|From rectal swabs of patients admitted in ICU and oncohaematology ward, investigators will use first a new culture medium (SuperPolymyxin) for screening the colistin resistant Gram negative and then a new rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth micro-dilution (BMD) method.
41278372|NCT01725165|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41278373|NCT05243641|DRUG|Neratinib|Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.
41278374|NCT05243641|DRUG|Capmatinib|Capmatinib will be supplied at 200 mg and 150 mg tablets
41448999|NCT02648438|DRUG|AZD7594 Pressurized inhalation suspension (400 μg) by pMDI|Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
41449000|NCT00227370|DRUG|valganciclovir|valgan 900mg QD x 9 months post lung transplant
41449001|NCT00227370|OTHER|Placebo|
41449002|NCT00685464|DRUG|Abciximab|Intravenous.
41449003|NCT00685464|DRUG|Abciximab|Intracoronary
40930240|NCT04863209|OTHER|Upper cervical manipulation|The patient will receive an upper cervical manipulation as described in the Experimental Group 1.
40930241|NCT04863209|OTHER|Sphenopalatine ganglion manipulation|The patient will receive a sphenopalatine ganglion as described in the Experimental Group 2.
40930242|NCT04507373|DRUG|Simvastatin 40mg|40mg oral daily for 10 weeks
40930243|NCT00118521|PROCEDURE|Foot Orthotics|
40930244|NCT00118521|PROCEDURE|Physiotherapy|
40930245|NCT00830778|PROCEDURE|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
40930246|NCT00830778|PROCEDURE|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
40930247|NCT05200494|PROCEDURE|Recruiting Maneuver|Airway pressure will be increased to 30 cmH2O for 30 seconds at the end of the bronchoscopy
40930248|NCT02985931|OTHER|Diagnostic imaging scans of SPECT and MRI|
40930249|NCT02702245|DIETARY_SUPPLEMENT|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
40930250|NCT02702245|DIETARY_SUPPLEMENT|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
40930251|NCT02702245|OTHER|Placebo Comparator: Control|75 g pure glucose.
40930252|NCT03833518|OTHER|Rehabilitation using motorized glove for stroke and spinal cord injury|Individuals with hand impairment due to stroke or spinal cord injury will wear a motorized glove (Gloreha Sinfonia), or exoskeleton, as part of a rehabilitation protocol to improve dexterity. For each exercise, participants will attempt to do the action, receiving assistance as necessary via powered motors that can move each finger through its passive range of motion based on the current and target position.
40930253|NCT03833518|OTHER|Functional MRI for stroke and spinal cord injury|All participants will undergo 3 functional MRI's (fMRI's), two at the beginning of the experiment to document brain activity related to movement intention and ability to sense movement. A third MRI will be performed after the rehabilitation is completed to document the change in brain activity related to movement intention and ability to sense movement.
40930254|NCT03833518|OTHER|Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury|Stimulation of the nervous system may be performed using a magnetic stimulator. TMS of the central nervous system is optional. Whether or not a participant undergoes TMS will depend upon their consent, their eligibility for TMS (i.e. no seizure history), and their neurological response to TMS.
40930255|NCT06074770|OTHER|no intervention|Natural exposure of iodine
40930256|NCT02496507|OTHER|Sit-stand workstation|After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
40930257|NCT00929214|DRUG|Standard Therapy|"Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist."
41453449|NCT05308316|OTHER|Sucrose cigarettes|Winston brand cigarettes will be modified by adding a mixture of sucrose to each cigarette at 2 levels so that the amount of total (originally present and added) sugar content in these cigarettes matches median and highest levels found in popular brands analyzed
41453450|NCT03648710|OTHER|Peer Community Health Worker|Participants will be communicating with their CHWs on a weekly basis, which is consistent with other successful community health worker protocols with published efficacy. Community Health Workers will be peers with sickle cell disease, who have successfully transitioned and are under 30 years of age.
40930258|NCT00929214|PROCEDURE|Local Therapy|"Surgery and/or Radiation Therapy~With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks."
40930259|NCT02655770|DRUG|Liraglutide|
40930260|NCT02655770|DRUG|Placebo|
40930261|NCT05879510|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration."
40930262|NCT00636987|DEVICE|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
40930263|NCT00644644|OTHER|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
40930264|NCT04667143|DRUG|Retagliptin, Henagliflozein, metformin XR|Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR
40930265|NCT02478398|BIOLOGICAL|Short ragweed pollen allergen extract|One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.
40930266|NCT02478398|BIOLOGICAL|Placebo|One placebo sublingual tablet, QD for up to 35 weeks.
40930267|NCT02478398|DRUG|Self-injectable epinephrine|Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
40930268|NCT02478398|DRUG|Albuterol/Salbutamol|Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma
40930269|NCT02478398|DRUG|Loratadine|5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms
40930270|NCT02478398|DRUG|Olopatadine|Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms
40930271|NCT02478398|DRUG|Mometasone furoate monohydrate|Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms
40930272|NCT04744376|OTHER|QoR15|Quality of Recovery 15 questionnaire (QoR-15) is a measurement tool that evaluates the recovery quality of patients after surgery and anesthesia by the patient himself.
40930273|NCT04744376|OTHER|ACS risk calculator|American College of Surgeons risk calculator is a risk prediction tool for abdominal surgery. It calculates the risk of possible postoperative complications according to the type of surgery, ASA score, and patients' preoperative co-morbidities.
40930274|NCT04744376|OTHER|Clavien - Dindo classification|It is a classification for postoperative complications.
40930275|NCT00752596|DRUG|Azimilide 2HCl|One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
40930276|NCT02101814|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery)|
40930277|NCT03920384|BEHAVIORAL|Experimental intervention arm|Psychological therapy for psychosis with new therapy components
40930278|NCT03920384|BEHAVIORAL|Active control arm|Standard psychological therapy for psychosis without new therapy components
40930279|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 150mg/day (75mg BID)
40930280|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 300 mg/day (150mg BID)
40930281|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 600/day (300mg BID)
40930282|NCT00219544|DRUG|Placebo|Placebo
40930283|NCT03473418|DRUG|Ketoconazole|Ketoconazole as a topical vaginal gel
40930284|NCT03473418|DRUG|Terconazole|Terconazole 80 mg as a topical vaginal cream
40930285|NCT05930015|BEHAVIORAL|Music intervention only|Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for eight weeks
40930286|NCT05930015|BEHAVIORAL|Sports games intervention only|Sports games intervention only The effect was achieved by replacing the school's originally physical education classes with sports games of the researchers' choice; twice a week for eight weeks
40930287|NCT05930015|BEHAVIORAL|Music and sports games intervention|Music and sports games intervention, the effect was achieved by replacing the school's physical education classes with sports games of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for eight weeks
40930288|NCT03504137|OTHER|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
41449004|NCT06253572|OTHER|Education|"Educational Skills Program Based on Constructivist Learning Approach~Instructors need to receive training to improve their teaching skills during their graduate education and after their appointment as instructors. In this study, it is aimed to design and implement an Educational Skills Program based on the Constructivist Learning Approach. The design of the training program was based on the Dick, Carey and Carey (DCC) Instructional Design Model, which is widely known among instructional design models and influenced by constructivism theory. It is aimed that the training skills training program will be carried out by taking adult education into consideration and will be learner-centered. In this study, the training plan is based on the Constructivist Learning Approach 5E model, which is proven to be effective in the literature and widely used. The training program will be conducted through distance education to reach instructors living in different cities and to create common time."
40930289|NCT04411862|DIETARY_SUPPLEMENT|Phosphatidyl Choline|2.1 g Phosphatidylcholine daily in addition to lifestyle modification
40930290|NCT04411862|BEHAVIORAL|Lifestyle modification|Lifestyle modification and health education by Clinical Pharmacist
40930291|NCT03917433|BEHAVIORAL|Virtual Reality Exposure Therapy|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
40930292|NCT03917433|BEHAVIORAL|Tactile Feedback|In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
40930293|NCT03917433|BEHAVIORAL|Point-based Rewards|Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
40930294|NCT04529187|DRUG|Midazolam|To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.
40930295|NCT04529187|DRUG|Dexmedetomidine|To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
40930296|NCT04834960|OTHER|Minimizing Missed Opportunities for Vaccination (MOV)|This bundle of interventions has four components that include: (1) Disseminate (vaccination awareness among healthcare providers and child caregivers); (2) Document (vaccination status); (3) Deploy (vaccines); and (4) Discharge (provide advice/referrals for catch-up and routine vaccinations).
40930297|NCT01874990|DIETARY_SUPPLEMENT|high sodium diet|The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
40930298|NCT01874990|DIETARY_SUPPLEMENT|low-salt diet|
41449005|NCT06371703|RADIATION|automated system in reducing radiation exposure|evaluate the effectiveness of the automated system in reducing radiation exposure for radiographers involved in PET/CT procedures.
41449006|NCT03124511|PROCEDURE|Surgery for breast cancer|Breast cancer resection performed via lumpectomy or mastectomy with or without sentinal node biopsy and axillary lymph node dissection.
41449007|NCT00325663|PROCEDURE|Acupuncture|
41449008|NCT03287154|DEVICE|Active tDCS stimulations|20 min, 2mA
41128088|NCT03284359|BEHAVIORAL|Pre-Consent Nudge Bundle|The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
41128089|NCT01075152|DRUG|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
41449009|NCT03287154|DEVICE|Sham tDCS|20 min, Sham
41449010|NCT06594523|DRUG|Denifanstat|Tablet
41449011|NCT06594523|DRUG|Placebo|Matching Tablet
41449012|NCT03168659|DEVICE|HeartLight|HeartLight Endoscopic Ablation System
41449013|NCT03168659|PROCEDURE|Ablation|Pulmonary vein isolation ablation
41449014|NCT06627179|DRUG|Intravitreal Injection of Ultevursen|Up to 4 doses over a 24-month period
41449015|NCT06627179|OTHER|No intervention, will not receive any active study intervention|Sham-procedure (no experimental drug administered)
41449016|NCT06617468|DIAGNOSTIC_TEST|computer-aided diagnosis with explainable AI|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with explainable AI.
41128090|NCT01075152|BIOLOGICAL|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
41128091|NCT02770326|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|
41128092|NCT02304614|OTHER|3D surface imaging using a non portable and portable camera|The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
41128093|NCT02304614|OTHER|Patient reported outcome measure (PROM): BREAST-Q|The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
41128094|NCT02304614|OTHER|2D photography|The participant will have standard medical photography of their breasts (the face will not be shown)
41128095|NCT02304614|OTHER|Applanation Tonometry|A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
41128096|NCT00887224|DRUG|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
41128097|NCT00887224|DRUG|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
41128098|NCT00887224|DRUG|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
41128099|NCT04679675|OTHER|Usual Care|Subjects will receive Kaiser Permanente Washington standard of care.
41128100|NCT04679675|BEHAVIORAL|Education|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening.
41128101|NCT04679675|BEHAVIORAL|Direct Mail|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will also receive an insert describing the home-based cervical cancer screening option and that a kit will be sent within 1 week. An HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
41449017|NCT06617468|DIAGNOSTIC_TEST|computer-aided diagnosis with deep learning|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with deep Iearning.
41449018|NCT01074424|GENETIC|proteomic profiling|
41449019|NCT01074424|OTHER|laboratory biomarker analysis|
41449020|NCT06628011|OTHER|Intervention group/training group|We will assess the short-term effects through a 12-week intervention, and its long-term effects after 1-year. Both the intervention group (IG) and control group (CG) will receive two sessions of aerobic interval training at the Exercise Training Clinic, situated at the Department of Psychosis and Rehabilitation, Psychiatry Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. One training session consists of 36 minutes of high intensity training (HIT).
41449021|NCT01406353|PROCEDURE|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
41449022|NCT00707330|DRUG|Clarithromycin|Prolonged release tablet, 500 mg, 1 tablet a day for a week
41449023|NCT04572243|DRUG|Placebo|Placebo matching to lorcaserin oral tablet, administered as oral suspension.
41449024|NCT04572243|DRUG|Lorcaserin|Lorcaserin oral tablet, administered as oral suspension.
41449025|NCT06628128|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
41449026|NCT04356313|DEVICE|GORE® EXCLUDER® Iliac Branch Endoprosthesis|Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component
41449027|NCT00669721|DRUG|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
41449028|NCT00669721|DRUG|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
41449029|NCT01899352|PROCEDURE|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
41453451|NCT03648710|OTHER|Mobile Health|A mobile health application created as a resource for young adults transitioning.
40930299|NCT02840084|DEVICE|Aspen(TM) Ultrasound System|"Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.~The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts."
40930300|NCT00216892|DRUG|Calcipotriol, (calcipotriol + betamethasone)|
40930301|NCT04575792|BEHAVIORAL|Practicing oral habits|children who practice one or more of the specified oral habits ( mouth breathing, object sucking, or tongue thrusting) are considered exposed.
40930302|NCT02882152|PROCEDURE|femoral nerve blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve at the end of the surgery"
40930303|NCT02882152|PROCEDURE|morphine|Intrathecal morphine injection
40930304|NCT04178356|OTHER|Proprioceptive Neuromuscular Facilitation Training|The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.
40930305|NCT04178356|OTHER|Control Group|Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
40930306|NCT06198140|OTHER|myofascial release and quick icing|In experimental group the individuals will receive myofascial release and quick icing. Quick icing will be on ankle dorsiflexors by using ice pack in the target area. Quick icing will be applied for 10 minutes (time of application 10 seconds and a rest for 20 seconds). This treatment protocol will be 6 times/week for 4 weeks in the hospital setting. Mayofascial release will be given on the target ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
40930307|NCT06198140|OTHER|myofascial release|In control group the individuals will receive only myofascial release on ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
40930308|NCT05988502|OTHER|auricular acupressure|"The well-trained researcher nurse in this study was performed the AA intervention. First of all, the participant was instructed to find a comfortable position. Disinfect the ears using cotton with 75 % alcohol was then provided and followed by placed vaccaria seeds (Beijing, China) with an adhesive patch onto the unilateral each selected auricular acupoint (left ear first) Participants were pressed each acupoint by thumb and index finger for one minute, four times a day, five days a week, remove the taped seeds on the 6th day, and then replaced the opposite ear two days after. They were noted that they experienced various sensations while pressing, including numbness, swelling, mild pain, or warmth. Seeds were taped on the other side of the ear weekly for two weeks.~Two TCM physicians verified the conduct of the AA protocol, which consisted of a selection of acupoints, length of stimulation time, finding location of acupoint, and procedure of practice."
40930309|NCT01470443|DRUG|Oxaliplatin|Oxaliplatin 130mg/㎡, day 1, every 3 weeks
40930310|NCT01470443|DRUG|Oxaliplatin|Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
40930311|NCT03473938|DEVICE|Spatz3 AIGB|Implantation of Spatz3 AIGB balloon.
40930312|NCT01386905|DEVICE|BAROnova™ TransPyloric Shuttle™ (TPS™)|Subjects will undergo an endoscopic procedure to deliver the TPS™ into the stomach. The TPS™ moves freely without any physical attachment or invasive anchoring to tissue to reduce gastric outflow.
40930313|NCT02755792|BEHAVIORAL|Calligraphy Training|
41449030|NCT03169062|DEVICE|Gated Stationary Chest Tomosynthesis|The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
41449031|NCT04640142|BIOLOGICAL|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion.
41449032|NCT06592222|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
41449033|NCT06592222|DRUG|Standard of care|Standard of care
41449034|NCT02408367|BEHAVIORAL|Exercise|30 minutes endurance training at 75% of the Maximum heart rate
40930314|NCT02755792|BEHAVIORAL|iPad Training|
40930315|NCT01643980|DRUG|Vaginal micronized progesterone|200 mg vaginal route per day
41128102|NCT04679675|BEHAVIORAL|Opt-in|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will receive an Opt-in Insert describing the home-based cervical cancer screening option and how to request a kit. Individuals can request a kit by phone or through a webpage. Individuals who request a kit will receive the HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
41128103|NCT02161146|DRUG|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
41128104|NCT02161146|DRUG|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
41128105|NCT02161146|DRUG|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
40755047|NCT01029197|OTHER|Treatment as Usual|Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
41128106|NCT05166057|OTHER|Synchronized online telerehabilitation exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient by videoconference.
41128107|NCT05166057|OTHER|Videobased telerehabilitation exercise program|A video containing breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be given to the patient and will be asked to exercise regularly.
41128108|NCT05166057|OTHER|Hospital based outpatient exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient in the hospital..
41128109|NCT00797212|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
41128110|NCT05532501|DRUG|Oral Oxytocin|Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
41128111|NCT05532501|DRUG|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds
41128112|NCT05532501|DRUG|Oral placebo|Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
41128113|NCT05532501|DRUG|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds
41128114|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg intact tablet|20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
41128115|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
41128116|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg suspension|20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
41128117|NCT03307044|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
41449035|NCT02408367|BEHAVIORAL|Relaxation|30
41449036|NCT01347749|BEHAVIORAL|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
40930316|NCT01643980|DEVICE|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
40930317|NCT00497809|DRUG|AVI-014 versus Filgrastim|3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
41449037|NCT01347749|BEHAVIORAL|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
41449038|NCT01472432|DRUG|Placebo|Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
41449039|NCT01472432|DRUG|vildagliptin|50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.Plus Metformin and/or Sulfonylurea
41453452|NCT04854460|DRUG|Revemact|1 tablet contains 6 mg Ivermecin
40755048|NCT04869410|PROCEDURE|Modification Broselow Tape|Intubation using modified Broselow Tape prediction for predicting ETT size
40755049|NCT04869410|PROCEDURE|Cole Formula|Intubation using Cole Formula prediction for predicting ETT size
40930318|NCT04334538|DIETARY_SUPPLEMENT|S-RUTF|Children will receive approximately 175 kcal/kg/d of standard ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
40930319|NCT04334538|DIETARY_SUPPLEMENT|oat RUTF|Children will receive approximately 175 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
40930320|NCT04389814|DIAGNOSTIC_TEST|Biochemical markers|Multiple biomarkers of myocaridial ishemia will be obtained serially to calculate thier time of their release according to their release kinetics
40930321|NCT05944978|DRUG|GNC-035|GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.
41128118|NCT03307044|OTHER|Questionnaire Administration|Ancillary studies
41128119|NCT04069416|PROCEDURE|living donor liver transplantation|liver graft from a living donor
41128120|NCT02506270|DEVICE|Airseal Trocar|28 patients are treated with the AirSeal insufflation and trocar system
41128121|NCT02506270|DEVICE|conventional trocar|28 patients are treated with a conventional insufflation and trocar system
41128122|NCT04898569|DRUG|Ferinject|Ferric carboxymaltose injection
41128123|NCT04898569|DRUG|Normal Saline Flush|placebo
41128124|NCT01596296|DEVICE|Transcervical foley catheter|16 French foley catheter insertion
41128125|NCT01596296|DRUG|Dinoprostone 10mg|Dinoprostone vaginal insertion
41128126|NCT05631808|OTHER|Epicardial adipose tissue volume and attenuation|Epicardial adipose tissue volume and attenuation assessed by CT are the exposure factors in this study.
40930322|NCT02431247|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
41449040|NCT04192591|DEVICE|Superion™ IDS device|The Superion™ IDS is a minimally-invasive spinal implant that treats LSS symptoms by limiting extension at the symptomatic level that compresses the neural elements and is designed for percutaneous surgical placement.
41449041|NCT03157115|DEVICE|Kinocardiography|"This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group."
41449042|NCT06345235|DIAGNOSTIC_TEST|blood test|Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in groups 1, 2, 3
41449043|NCT04715451|OTHER|Novel Swaddle|A novel swaddling method.
40930323|NCT02431247|DRUG|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
41449044|NCT00850148|PROCEDURE|Anwar|Anwar surgical method
40930324|NCT02431247|DRUG|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
40930325|NCT02431247|DRUG|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
40930326|NCT02431247|DRUG|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
40930327|NCT02431247|DRUG|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
40930328|NCT00859261|PROCEDURE|Experimental 3D Breast Ultrasound imaging|Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
41128127|NCT04434651|PROCEDURE|SPGB|Sphenopalatine Ganglion Block using 2% lidocaine in block group. Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge a syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril SPGB using normal saline is performed in the control group
41128128|NCT03274076|DRUG|Tofacitinib|Oral medication tofacitinib 5 mg twice a day for 24 weeks.
41128129|NCT03274076|DRUG|Placebo Oral Tablet|Oral Placebo 5 mg twice a day for 24 weeks
41128130|NCT05861570|DRUG|normal saline|Ultrasound guided injection using 3ml normal saline
41128131|NCT05861570|DRUG|(Sodium Hyaluronate (Hyruan One , LG)|Ultrasound guided injection using 3ml of Sodium Hyaluronate
41128132|NCT05861570|DRUG|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
41128133|NCT05861570|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 4ml of 40mg triamcinolone acetonide
41128134|NCT05394636|OTHER|None, pure observational study|None, pure observational study
41128135|NCT00351299|DRUG|Dexmedetomidine|dexmedetomidine infusion titrated to effect
41449045|NCT00850148|PROCEDURE|Melles|Melles surgical method
41453453|NCT04854460|DRUG|Stromectol (first dose)|2 tablet contain 6 mg Ivermecin
41453454|NCT04854460|DRUG|Stromectol (second dose)|2 tablet contain 6 mg Ivermecin
41128136|NCT00351299|OTHER|Standard of Care|Standard of care per treating physician preference
41128137|NCT03469596|DIAGNOSTIC_TEST|MRI sequence|several MRI sequence before and after contrast product injection.
41128138|NCT03360513|OTHER|general group|The sample comprised maxillary and mandibular dental casts of 70 Caucasian Brazilian individuals (28 men and 42 women) with an average age of 16.4 years, all of which had natural normal occlusion with at least four of the six keys to normal occlusion. 14 The first item of the first key was considered essential for sample selection(Angle Class I molar relationship). Another inclusion criterion was that individuals should be at least 15 years of age with no odontogenic abnormalities and all permanent teeth in occlusion.
41453455|NCT00000136|DRUG|Foscarnet|60 mg/kg every 8 hours, 90 mg/kg/day
40930329|NCT00859261|PROCEDURE|Experimental Photoacoustic Imaging|Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
40930330|NCT00000527|DRUG|aspirin|
40930331|NCT00000527|DRUG|dipyridamole|
40930332|NCT03830177|DRUG|Natural Treatment|The participant will be given the treatment, which contains all natural ingredients, and a kit of all necessary materials to take home with them, which will include a set of instructions. The kit will contain the instruction handout and their treatment. They will be instructed to apply the treatment to their scalp, wait seven minutes, and then rinse their scalp. They will perform this entire procedure once per day for 14 days.
40930333|NCT04157556|OTHER|Yo-Yo Intermittent Recovery Test Level 1|"The test is a standard test battery with progressively increasing speeds. After every 40-m run (2x20 m), active rest is performed by walking or jogging at a distance of 10 m (2x5 m). for 10 seconds. Participants are trying to adjust their speed according to incoming audio signals.The test is terminated when the participants can not reach the signal twice. The test ends in 10-20 minutes depending on the level of participants.~Reference Bangsbo, J., Iaia, F. M., \& Krustrup, P. (2008). The Yo-Yo intermittent recovery test. Sports medicine, 38(1), 37-51.~Krustrup, P., Mohr, M., Amstrup, T., Rysgaard, T., Johansen, J., Steensberg, A., ... \& Bangsbo, J. (2003). The yo-yo intermittent recovery test: physiological response, reliability, and validity. Medicine \& Science in Sports \& Exercise, 35(4), 697-705."
40930334|NCT05357820|DRUG|AB-106, Itraconazole|single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17
40930335|NCT05357820|DRUG|AB-106, Rifampicin|single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21
40930336|NCT05409378|DEVICE|The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)|Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation
40930337|NCT05408793|DEVICE|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.
40930338|NCT00794027|BEHAVIORAL|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
40930339|NCT00794027|BEHAVIORAL|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
40930340|NCT05696028|DEVICE|Gamma counter|DTpA
40930341|NCT03733431|DEVICE|Gammacore device|Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.
40930342|NCT03733431|DEVICE|Gammacore sham device|Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.
40930343|NCT02975362|OTHER|Acupuncture Treatment|Acupuncture Treatment Acupoint selection base on disease stage combined adjunct acupuncture acupoint base on syndrome differentiation.①Base on disease stage: Flaccid paralysis period: DU24, DU20, Motor Area , LI15, LI14, LI11, SJ5, LI4, GB31, EX-LE2, GB34, ST36, ST40.Spastic period: DU24, DU20, Motor Area , SJ10, SJ13, LI10, SJ8, SJ5, SJ4, SJ4, BL37, BL40, BL39, BL55, BL57, ST41, GB40, BL60.②Base on syndrome differentiation:Excess syndrome of yang-type: LR3, ST37; Deficiency syndrome of Yang-type: KI3, BL23; Excess syndrome of yin-type: SP9, GB20;Deficiency syndrome of Yin-type: CV6, BL23.③Electroacupuncture acupoint: Flaccid paralysis period: LI15, LI4, GB31, ST40; Spastic period: SJ13, SJ5, BL40, BL57.30minutes each time,twenty times / treatment course，two treatment courses in total.
40930344|NCT02975362|OTHER|Rehabilitation Treatment|Rehabilitation treatment The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists
40930345|NCT02866851|OTHER|Monitoring by Web-application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
40930346|NCT00887744|DEVICE|Aperius® Percutaneous Interspinous Spacer|Implantation of the Aperius® device
41128139|NCT01824056|DRUG|18F-FDG|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
40930347|NCT01054183|DEVICE|GlideScope Ranger Intubation|Intubation with GlideScope Ranger Video Laryngoscope
41453456|NCT00000136|DRUG|Ganciclovir|5 mg/kg every 12 hours, 5 mg/kg every 24 hours
41453457|NCT05303441|PROCEDURE|percutaneous coronary intervention|conventional coronary angiography
40755050|NCT03464448|DRUG|Teriflunomide|AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase.
40755051|NCT03898973|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV)|Intramuscular Injection. Participants will receive the inactivated flu vaccine into anterior quadriceps.
41128140|NCT03050957|DIETARY_SUPPLEMENT|menthol|Alimentary bolus supplemented with menthol
41128141|NCT01979276|DRUG|Romidepsin|Romidepsin intravenously on days 1 and 15 of a 28-day cycle
41128142|NCT01979276|DRUG|pomalidomide|Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle
41128143|NCT01979276|DRUG|Dexamethasone|Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
41128144|NCT04797468|DRUG|HLX23|administered IV.
41128145|NCT01913314|DRUG|[^14C]-LY2835219|Administered as oral solution
41128146|NCT05667116|DRUG|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
41128147|NCT01440933|DRUG|Magnesium Sulfate|1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
41128148|NCT01440933|DRUG|Placebo comparator|1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
41128149|NCT04579250|BIOLOGICAL|VRC-FLUNPF0103-00-VP (H10ssF-6473)|The vaccine is composed of the haemagglutinin (HA) stem domain from A/Jiangxi/IPB13/2013 (H10N8) influenza genetically fused to the ferritin protein from H. pylori. Purified H10ssF-6473 displays eight well-formed HA trimers that antigenically resemble the native H10 stem viral spikes.
41128150|NCT03776500|DRUG|PBTZ169|PBTZ169 crystalline supplied as powder for oral solution
41128151|NCT03776500|DRUG|Placebo|matching placebo supplied as powder for oral solution
41128152|NCT04653506|DRUG|Paracetamol 1000 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
41128153|NCT04653506|DRUG|Ibuprofen 400 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
41128154|NCT02684435|DRUG|Perflutren lipid microsphere|Dosing per approved package label
41128155|NCT04243941|DRUG|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
41128156|NCT00144066|DRUG|platinum-based chemotherapy alone (up to six cycles)|
40930348|NCT01054183|DEVICE|Direct Laryngoscopy|Intubations will be done with direct laryngoscopy.
41128157|NCT00144066|DRUG|platinum-based chemotherapy followed by maintenance therapy with gefitinib|
41449046|NCT02380794|DRUG|Danshen Gegen Capsule|"Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.~Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption."
40930349|NCT02954042|DEVICE|Pelvital probe|Pelvital probe
41128158|NCT01089335|PROCEDURE|Histological investigation of the SN|99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
41128159|NCT01943305|BIOLOGICAL|Japanese Encephalitis vaccine|IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
41128160|NCT01943305|BIOLOGICAL|Yellow Fever vaccine|STAMARIL, 1 dose (0.5 ml)
41128161|NCT03681366|DEVICE|DISC3.5 plus|The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
41128162|NCT00387075|PROCEDURE|[123I]β-CIT and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, \[123I\]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
40930350|NCT02954042|DEVICE|Placebo Probe|Placebo Probe
41128163|NCT00387075|DRUG|[123I]β-CIT|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
41128164|NCT01462175|DRUG|RO5503781|
41128165|NCT06396598|OTHER|Educational Activity|Review education materials
41128166|NCT06396598|OTHER|Electronic Health Record Review|Ancillary studies
41128167|NCT06396598|OTHER|Internet-Based Intervention|Participate use the electronic symptom monitoring program to log symptoms
40930351|NCT06255366|DRUG|Caroxime sodium sulfonate|Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
40930352|NCT06255366|DRUG|Desmopressin|Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
41128168|NCT06396598|OTHER|Media Intervention|Watch a video
41128169|NCT06396598|OTHER|Survey Administration|Ancillary studies
41449047|NCT02380794|DRUG|Placebo|
40930353|NCT06255366|DRUG|0.9% Sodium Chloride Injection|Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
41128170|NCT00829634|DRUG|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
41128171|NCT00829634|DRUG|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
41128172|NCT00578916|DRUG|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
41128173|NCT04842253|DEVICE|High flow nasal cannula|HFNC during deep sedation undergoing radiofrequency ablation for atrial fibrillation.
41128174|NCT06509646|OTHER|Tia Chi Exercise|"• Yang style 24-posture short-form (16) for 30 minute It consists of 24 unique movements that are performed in a sequence. The form is designed to be easy to learn and can be completed in about six minutes.~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks"
41128175|NCT06509646|OTHER|Frenkel's Exercise|"Frenkel's exercises 30 minutes (Through these exercises, the patients would learn how to stay balanced and prevent falls by using their visual, somatosensory, and vestibular systems).~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks"
41128176|NCT02078232|DEVICE|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
41128177|NCT02078232|DEVICE|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
41128178|NCT04228913|OTHER|Root Canal Obturation Technique|This study aims to compare the effects of three different obturation techniques(cold lateral condensation,thermoplasticized solid-core carrier method, cold free flow compaction technique) on postoperative pain following the endodontic therapy
41128179|NCT04046159|DRUG|Low-dose tamoxifen|Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect
41128180|NCT04046159|RADIATION|Whole breast radiotherapy|Ipsilateral breast tumor recurrence and side effect
41128181|NCT03793413|PROCEDURE|Lingual frenotomy|A lingual frenotomy will be performed using a CO2 laser - using the NFANT bottle feeding system, the intervention arm will be compared against the observation arm to determine if there are changes in lingual mobility parameters during bottle feeding.
41128182|NCT00781118|DEVICE|Guardian System|There is no intervention in this study. The device is a diagnostic only.
41128183|NCT06322368|OTHER|Myofunctional and respiratory training program|The patients will receive exercises included in a myofunctional approach and a respiratory training focused on inspiratory and expiratory muscles using a device.
41128184|NCT06322368|OTHER|Range of motion and thermal and mechanical stimulation exercising|The patients will receive the standard treatment of speech and language therapy including range of motion exercises (open and close the mouth) and thermal and mechanical stimulation in the orofacial region.
41128185|NCT03865706|DRUG|Inulin Oral Suspension|Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube
41128186|NCT03865706|DRUG|Placebo Oral Suspension|250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
41449048|NCT03935815|DRUG|Ropivacaine injection|30 mL of 0.25% ropivacaine will be administered on both the right and left sides with a 20 gauge, 4 inch ultrasound needle using a SonoSite ultrasound machine with a linear transducer probe. The tip of the ultrasound needle will be placed posterior to the quadratus lumborum muscle (QL2) made in the plane between the quadratus lumborum muscle and thoracolumbar fascia.
40930354|NCT02218177|DRUG|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
41449049|NCT03935815|PROCEDURE|Sham treatment|A sham procedure with a superficial 22 gauge needle stick will be performed without injectate.
40930355|NCT02218177|DRUG|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
40930356|NCT02218177|PROCEDURE|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
40930357|NCT05703633|OTHER|uDCD treatment|Thrombolytic treatment/prevention ex-vivo to kidneys procured from patients after circulatory arrest
40930358|NCT04869553|OTHER|Management pain with distraction methods ABC|"Every patient will receive :~* The usual pain management of their ward (Treatment A),~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)"
40930359|NCT04869553|OTHER|Management pain with distraction methods BCA|"Every patient will receive :~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)"
41128187|NCT03865706|DRUG|Broad-spectrum antibiotics|Standard of care treatment for infections
41128188|NCT02313675|DRUG|Acetaminophen|
41128189|NCT02313675|DRUG|Ketorolac Tromethamine|
41128190|NCT02313675|DRUG|Saline|
41128191|NCT03821636|PROCEDURE|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
41128192|NCT03821636|PROCEDURE|Long alimentary limb Roux-en-Y gastric bypass|Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
41128193|NCT02458924|BIOLOGICAL|Niacin skin test|Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
41128194|NCT04781790|OTHER|Bone Marrow Failure|without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.
40930360|NCT04869553|OTHER|Management pain with distraction methods CAB|"Every patient will receive :~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)~* The usual pain management of their ward with a hypnosis session (Treatment B)"
41128195|NCT02109575|DIAGNOSTIC_TEST|Blood Draw of up to 10 ml|In a laboratory setting, the blood will be spun for plasma and buffy coat, DNA will be extracted for processing using the diagnostic test. The results of the test are not provided back to the clinical setting.
41278375|NCT06656585|OTHER|Individual food selectivity protocol|"Children in the experimental group wear Oculus headsets and interact with virtual foods for 20 minutes. In the Pairing in the Kitchen phase, Oculus is removed. Two identical plates with 6 foods are placed in front of the child. The operator, seated next to the child, interacts with the food without eating it, maintaining a positive expression, and discussing non-food topics. No prompts to eat are given, and the child can leave at any time. Progress to the next phase if the child sits calmly for 30 seconds across 3 sessions.~Shaping Phase: Two identical plates are prepared. The operator comments on the food and keeps a small container of the child's favorite food visible but out of reach. Any food-related behavior is reinforced with praise and the favorite food. Target behaviors are adjusted if no response occurs for 15 seconds or if negative emotions are observed. Differential reinforcement is used."
41278376|NCT06656585|OTHER|Traditional food selectivity protocol|"Step 1:Pairing in the Kitchen Propose enjoyable activities in the kitchen. Move to Step 2 when the child plays in the kitchen for 5 minutes over 3 consecutive sessions.~Step 2:Transition to Kitchen Two plates with 6 identical foods are placed in the kitchen. The operator engages the child in a welcome game, waiting 30 seconds for spontaneous interaction. If no response, the operator prompts the child to go to the kitchen. If the child doesn't follow within 30 seconds, the session is postponed. The operator sits next to the child and interacts with the food, without encouraging the child to eat. Progress when the child stays seated for 30 seconds without problem behavior for 3 sessions.~Step 3:Shaping Two plates are prepared, and the operator comments on the food. A visible container with the child's favorite food is used for reinforcement. Target behaviors are reinforced with praise and the favorite food. Adjust behaviors if there's no response for 15 seconds or negative emotions occur"
41278377|NCT04397276|DRUG|JNJ-70218902|JNJ-70218902 will be administered.
41278378|NCT06656130|OTHER|Pranayama|Pranayama is the practice of breath regulation. It's a main component of yoga, an exercise for physical and mental wellness. The practice of pranayama involves breathing exercises and patterns. Patient purposely inhale, exhale, and hold his/her breath in a specific sequence.
40930361|NCT02160002|PROCEDURE|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
41128196|NCT00702884|DRUG|sunitinib malate|Sunitinib 37.5 mg daily for a 4 week cycle
41128197|NCT04905797|DIAGNOSTIC_TEST|Emotional Stop Signal Task|Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.
41449050|NCT03393780|DRUG|Follitropin Delta|The Intervention (solution for injection) is delivered with an injection pen. The REKOVELLE® dose will be based on recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the following diagnostic test from ROCHE: ELECSYS AMH Plus immunoassay.
40930362|NCT02160002|PROCEDURE|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
40930363|NCT00627614|OTHER|breast imaging study|"1. A set of vibro-acoustography (VA) scans will be taken of the breast by an experimental vibro-acoustography device that uses ultrasound for imaging.~2- An ultrasound scan (sonography) of the breast using a clinical ultrasound machine may be taken during the procedure."
40930364|NCT03726996|DRUG|Desipramine|Study drug (desipramine) provided in tablet form to be taken daily.
41128198|NCT04905797|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry
41128199|NCT04905797|OTHER|World Health Organizations Disability Assessment Schedule (WHODAS 2.0)|Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.
40930365|NCT03558412|COMBINATION_PRODUCT|CODOX-M/IVAC|Given ivgtt
41128200|NCT04905797|DIAGNOSTIC_TEST|Personality Inventory for DSM-5 (PID-5)|Self-rated personality traits through Personality Inventory for DSM-5 (PID-5). Self-reported scores on domains of personality traits. Higher scores in one domain indicate more pronounced traits in this domain.
41128201|NCT04905797|DIAGNOSTIC_TEST|Stop Signal Task (CANTAB)|The estimate of time where an individual can successfully inhibit their responses 50% of the time.
41278379|NCT06656130|OTHER|Jacobson's progressive muscle relaxation technique|Jacobson's relaxation technique is a type of therapy that focuses on tightening and relaxing specific 14 muscle groups in sequence. It's also known as progressive relaxation therapy. By concentrating on specific areas and tensing and then relaxing them, patient can become more aware of his/her body and physical sensations,
41278380|NCT02845869|DEVICE|THOR Laser LX2 System|Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
41128202|NCT04905797|DIAGNOSTIC_TEST|Intra-Extra Dimensional Set Shift (CANTAB)|"1. The number of trials for which the outcome was an incorrect response (subject pressed the incorrect button within the response window), calculated across all assessed trials.~2. The total number of times that the subject chose a wrong stimulus - i.e. one incompatible with the current rule, adjustment for every stage that was not reached."
41128203|NCT04905797|DIAGNOSTIC_TEST|Spatial Working Memory Test (CANTAB)|"1. The number of times the subject incorrectly revisits a box in which a token has previously been found. Calculated across all assessed four, six and eight token trials.~2. The number of times a subject begins a new search pattem from the same box they started with previously. If they always begin a search from the same starting point, we infer that the subject is employing a planned strategy for finding the tokens. Therefore, a low score indicates high strategy use (1 = they always begin the search from the same box), a high score indicates that they are beginning their searches from many different boxes. Calculated across assessed trials with 6 tokens or more."
41128204|NCT04905797|DIAGNOSTIC_TEST|Multitasking Test (CANTAB)|"1. The number of trials for which the outcome was an incorrect response.~2. The median latency of response (from stimulus appearance to button press). Calculated across all correct, assessed trials.~3. The difference between the median latency of response on the trials that were congruent versus the trials that were incongruent. A positive score indicates that the subject is faster on congruent trials and a negative score indicates that the subject is faster on incongruent trials. A higher incongruency cost indicates that the subjects take longer to process conflicting information.~4. The difference between the median latency of response during assessed blocks in which both rules are used versus assessed blocks in which only a single rule is used. A positive score indicates that the subject responds more slowly during multitasking blocks and indicates a higher cost of managing multiple sources of information."
41278381|NCT02845869|DEVICE|Sham Therapy|The therapeutic light will be turned off but the system will produce similar noises and mild heat.
41278382|NCT04640714|BEHAVIORAL|CONTINUity of care Under Management by Video visits (CONTINUUM-V)|Video visit by nurse practitioner within 3 business days of hospital discharge.
41278383|NCT02886715|DRUG|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.
41278384|NCT02886715|DRUG|Tazorac®|Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
41278385|NCT02886715|DRUG|Placebo|Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
41278386|NCT06656845|DEVICE|Genus, a self-management app for patients with knee osteoarthritis|The self-management app (Genus) will include weekly reminders with information videos on knee osteoarthritis and treatment options, exercise videos, quizzes, questionnaires, and a platform for remote monitoring by health professionals.
41278387|NCT04887298|DRUG|Liposomal Annamycin (L-Annamycin)|2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)
41278388|NCT06296394|OTHER|Parenthood|The intervention group will consist of participants who became first time parents to children under 5 years of age.
41278389|NCT06037954|OTHER|Questionnaires|Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)
41278390|NCT06037954|OTHER|Interviews|Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.
40930366|NCT03558412|DRUG|Decitabine|Given ivgtt
40930367|NCT00133731|DRUG|Otamixaban (XRP0673)|
41449051|NCT01748773|DRUG|Oxaliplatin|Participants will receive oxaliplatin 100 mg/m\^2 IV on Day 1 of Cycles 1-3.
41449052|NCT01748773|RADIATION|Radiation|Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.
40930368|NCT00133731|DRUG|Unfractionated Heparin|
40930369|NCT00133731|PROCEDURE|Percutaneous Coronary Intervention|
40930370|NCT00829283|BEHAVIORAL|Behavioral Weight Loss|weekly individual sessions for 6 months
40930371|NCT00829283|BEHAVIORAL|Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy|weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
40930372|NCT00829283|DRUG|Placebo|One pill daily
40930373|NCT00829283|DRUG|Sibutramine/Orlistat|Sibutramine 15 mg daily or Orlistat 120mg TID
40930374|NCT05023824|DRUG|alpha-blocker or 5-ARI withdrawal|Withdrawal of either alpha-blocker or 5-ARI
40930375|NCT05023824|DRUG|Maintenance of alpha-blocker and 5-ARI|Maintenance of alpha-blocker and 5-ARI
41449053|NCT01748773|DRUG|Capecitabine|Participants will receive capecitabine 850 mg/m\^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
40930376|NCT05959980|PROCEDURE|Posterior cervical fixation surgery|These patients will undergo posterior cervical fixation in the form of cervical lateral mass screw fixation in extension without decompression under general anesthesia.
40930377|NCT01732653|OTHER|TT+VR|subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
41128205|NCT04905797|DIAGNOSTIC_TEST|Cambridge Gambling Task Test|"1. The proportion (0 - 1) of all trials where the subject chose the majority box color. Calculated over all assessed trials from both the ascending and descending conditions in which the number of boxes of each color differed.~2. Risk adjustment is a measure of sensitivity to risk, based on the ability to modify choices in the light of information about the probability of different outcomes and to track the optimal outcome on eaeh trial. The measure is calculated from the average proportion of points that the subject ehose to bet with, taking into aeeount the number of colored boxes in the majority.~3. Allows for the dissociation between risk taking and impulsivity by determining whether subjects simply just place a bet at the first opportunity. Calculated as CGT Risk Taking for all trials from the descending condition minus CGT Risk Taking for all trials from the ascending condition."
41128206|NCT04738656|DIETARY_SUPPLEMENT|Diet plan|Mediterranean style is a non-restricted diet plan compared with the open protein diet plan
41128207|NCT01611493|DEVICE|Osseotite Prevail Implant|Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
41449054|NCT01748773|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
41449055|NCT04823169|OTHER|podobarometry|podobarometric measures on day 7 and day 30
40930378|NCT01732653|OTHER|TT alone|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
40930379|NCT02536833|DRUG|SM04690|
40930380|NCT02536833|DRUG|Placebo|
40930381|NCT03597217|DRUG|PF-05221304|3, 10, 50 mg
40930382|NCT03597217|DRUG|PF-05221304|50 mg multiple dose
40930383|NCT03597217|DRUG|Placebo|Placebo
40930384|NCT02426489|DEVICE|MRI + PEM image|Effect of positron emission mammography on diagnostic accuracy
40930385|NCT02392533|OTHER|Education|Education
40930386|NCT05632744|DEVICE|CG-100 Intraluminal Bypass Device|Subjects will be treated with the CG-100 Intraluminal Bypass Device
40930387|NCT04050020|BIOLOGICAL|Platelet-Rich Plasma (PRP)|All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
40755052|NCT06306976|PROCEDURE|Elective Midline Laparotomy|"Patients with midline ventral incisional hernia with a range of hernia morphology who plan to undergo open retromuscular VHR.~Hernia repair:~All study patients will have an open retromuscular repair with/without additional lateral MFR (TAR or EOR at the discretion of the operating surgeon). All repairs beginning with retrorectus dissection to the level of the linea semilunaris.~All patients will have permanent mesh reinforcement of the abdominal wall (large-pore, midweight polypropylene). Fascia will be closed over the mesh with 0 or 2-0 polydioxanone slowly absorbable suture using a small-bite technique and a 4:1 suture length:wound length ratio."
40755053|NCT06306976|PROCEDURE|Imaging: Ultrasound|"Ultrasound procedure will involve the following steps:~1. For control group 1 and group 2 patients, Images will be taken at two points along the bilateral RA; at the level of the umbilicus and midway between the umbilicus and xiphoid process. Bilateral external oblique (EO), internal oblique (IO), and transversus abdominis (TA) images will be performed at the level of the anterior axillary line midway between the costal margin and iliac crest."
40930388|NCT04050020|BIOLOGICAL|Normal saline injection|All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
41128208|NCT01611493|DEVICE|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
41128209|NCT03576521|COMBINATION_PRODUCT|CT + Ocoxin-Viusid|"The included patients received the Ocoxin-Viusid nutritional supplement at a rate of 75 ml daily (25 ml in 3 doses every 8 hours) administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
40930389|NCT04369820|OTHER|draw blood|40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.
40930390|NCT05024643|PROCEDURE|Endonasal endoscopy|"Complete sphenoethmoidectomy; Draf type IIa, IIb, and III according to defect location.~Defect less than 3 mm closed by a plug of fat and facia lata or middle turbinate mucosa.~Defect more than 3 mm closed by underlying facia lata, underlying cartilage, and overlay facia lata."
40930391|NCT02914145|DRUG|Dihydroartemisinin-piperaquine|Mass drug administration
41128210|NCT03576521|COMBINATION_PRODUCT|CT + Placebo|"The included patients received the OV placebo in oral solution at a rate of 75 ml daily (25 ml in 3 doses every 8 hours), administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
41449056|NCT05780463|DRUG|MP0420|MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.
41449057|NCT05780463|DRUG|Placebo|Commercially available 0.9% sodium chloride solution
40930392|NCT03221764|DRUG|Amiodarone with CoSeal|CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients \[8\]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
40930393|NCT03221764|DEVICE|CO2 driver|The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
41128211|NCT06124573|DRUG|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
41128212|NCT03628313|OTHER|Transthoracic ultrasound|Patients are prospectively identified during echocardiography performed in the echocardiography laboratory of the two participating centers when a diagnosis of aortic stenosis is made.
41128213|NCT05308069|DEVICE|Single vision contact lens|Subjects will wear a single vision soft contact lens only during the study visit
41128214|NCT05308069|DEVICE|Multifocal contact lens|Subjects will wear a multifocal soft contact lens only during the study visit
41128215|NCT02587169|DRUG|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
41128216|NCT01995903|DIAGNOSTIC_TEST|MRI(magnetic resonance imaging)|Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
41128217|NCT01658241|DRUG|panobinostat|40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
41128218|NCT04132167|PROCEDURE|perturbation training|exercises for body stability in different positions (bridge, sitting, quadrupedal, half- kneeling, kneeling, standing, monopodalic) performed with visual biofeedback; transfers training performed in front of a mirror; ambulation training with courses drawn on the ground in a straight line and with more complex tracks with visual controlin particular using the protocols seated balance/strength training, standing bal- ance/weight-bearing training, mobility training and closed-chain training;
41128219|NCT00829036|DEVICE|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
41128220|NCT02972788|DRUG|Enamel Matrix Proteins Derivative|Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
41128221|NCT02972788|OTHER|Saline|Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
41128222|NCT00918203|BIOLOGICAL|Olaratumab|15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.
41128223|NCT00918203|DRUG|Paclitaxel|200 mg/m2 is then administered IV over 3 hours
41128224|NCT00918203|DRUG|Carboplatin|AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
40930394|NCT00829933|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
40930395|NCT00829933|DRUG|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
41128225|NCT00124254|PROCEDURE|Silicone metacarpophalangeal joint arthroplasty|Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
41128226|NCT00124254|OTHER|Usual care|Non-surgical usual care
41128227|NCT03918252|DRUG|Nivolumab Injection|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
41128228|NCT03918252|DRUG|Ipilimumab Injection|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
41128229|NCT01588951|DRUG|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
41128230|NCT01588951|DRUG|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
40930396|NCT00943943|DRUG|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
41128231|NCT01574716|DRUG|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
41128232|NCT01574716|DRUG|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
41128233|NCT01574716|DRUG|Docetaxel|IV, Day 8 of every cycle until disease progression
41128234|NCT01574716|DRUG|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
41128235|NCT01574716|DRUG|Docetaxel|IV, Day 8 of every cycle until disease progression
41128236|NCT01574716|DRUG|Placebo|
41128237|NCT05437770|OTHER|BFR (Blood-Flow Restricted exercise)|The BFR group performs unilateral training with the knee-OA diagnosed leg first. BFR exercise is performed with a pneumatic cuff placed at the top of the thigh on the leg being trained. The cuff will be inflated to 60-80 % of the total arterial occlusion pressure (AOP). The participant will afterwards perform training of the knee extensors in a leg press exercise machine and a leg extension exercise machine with a load corresponding to 30 % of the maximal load (1RM = Repetition Maximum).
40755054|NCT06306976|OTHER|Tensiometry|"For all study patients, an analog spring-tensiometer will be used to assess intraoperative tension required to bring the fascia to the midline for closure. The tensiometer is attached to a clamp attached to the fascia at the midpoint of the hernia defect. Tension required for medialization to the midline will be performed after adhesiolysis (baseline), retrorectus dissetion, incision of the PLIO (if performed), and after completion of TAR or EOR (if performed).~Control group 2 patients will be undergoing first time laparotomy and will have tensiometry performed."
40755055|NCT01640535|DRUG|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
40755056|NCT01640535|DRUG|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
40755057|NCT01640535|DRUG|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
40755058|NCT01044693|DRUG|Placebo|Placebo capsule
40755059|NCT01044693|DRUG|Nebivolol 5 mg|Nebivolol 5mg single oral dose
40755060|NCT01044693|DRUG|metoprolol tartrate 50 mg|metoprolol tartrate 50 mg single oral dose
40755061|NCT01044693|DRUG|Sildenafil25 mg|Sildenafil 25 mg single oral dose
40755062|NCT04228003|DIETARY_SUPPLEMENT|Pendulum Glucose Control formulation for T2D|"All bacteria contained in the study product formulation are commensal organisms that have been repeatedly documented to inhabit the human GI tract under normal circumstances. Pendulum's Glucose Control Formulation consists of five human commensal microbial strains including butyrate producing and mucin-degrading strains. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
40755064|NCT02913573|DEVICE|Ultrasound|Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
40755065|NCT02913573|DRUG|0.25% bupivacaine|Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
40755066|NCT04293965|DRUG|Single ascending dose of X842|A total of 7 dose groups will be set for the ascending dose: 5.6 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg. In the 5.6 mg dose group, 4 subjects will receive X842; in the 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg dose groups, 8 subjects in each group will receive X842. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
40930397|NCT00943943|DRUG|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
40930398|NCT00943943|DRUG|Sorafenib|"First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).~Dose Level 0 = 400 mg orally twice daily."
41128238|NCT05437770|OTHER|Standard rehabilitation|The GLA:D programme involves a circuit training program with four stations. Each station involves two to six exercises where the participants perform 10-15 repetitions over 2-3 sets, which depends on the participants pain- and functional level. Following the 8 weeks GLA:D programme, participants will continue 4 weeks of team group training performing similar neuromuscular lower limb exercises as for the first 8 weeks.
41128239|NCT01797666|DRUG|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
41128240|NCT04180579|DEVICE|PAXMAN Scalp Cooler|Scalp cooling will occur with each dose of chemotherapy.
41128241|NCT02809794|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
41128242|NCT02545634|DIETARY_SUPPLEMENT|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
41128243|NCT02545634|OTHER|Placebo|
41128244|NCT02920710|DRUG|Repository Corticotropin Injection|"* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)"
41128245|NCT03196882|DRUG|40mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
41449058|NCT05780463|BIOLOGICAL|Remdesivir|Antiviral agent
41449059|NCT01430533|DRUG|azelaic acid pre foam formulation|
41449060|NCT01430533|DRUG|Vehicle pre foam formulation|
41449061|NCT01430533|DRUG|Water|
40930399|NCT01266083|BIOLOGICAL|WT1 peptide vaccine|Six vaccinations of the WT1 peptide preparation (1.0 ml of emulsion) will be administered on weeks 0, 2, 4, 6, 8, and 10. All vaccinations will be administered subcutaneously with vaccination sites rotated among extremities. Patients who are clinically stable and have not had disease progression, may receive up to 6 more vaccinations administered appropriately every month.
41128246|NCT03196882|DRUG|20mg/day of iron|Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
40930400|NCT04397666|DIAGNOSTIC_TEST|conjunctival RT PCR|conjunctival sample in covid-19 patients
40930401|NCT06194019|DEVICE|lung ultrasonography|N-terminal pro-brain natriuretic peptide (NT-proBNP) as a biomarker for detection volume overload.
40930402|NCT01116479|OTHER|Blood transfusion|Blood transfusion with packed erythrocytes
40930403|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
41128247|NCT03196882|DRUG|80mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
41128248|NCT02101138|DRUG|Dexpramipexole|Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
41128249|NCT06012175|DIETARY_SUPPLEMENT|Melatonin|One 3 mg melatonin tablet every night before bedtime for 12 weeks
41128250|NCT06012175|DIETARY_SUPPLEMENT|Placebo|One placebo tablet, having an identical appearance to the melatonin tablet, every night before bedtime for 12 weeks
41128251|NCT00468156|BEHAVIORAL|written materials only|related to fruit/vegetable servings/day
41128252|NCT00468156|BEHAVIORAL|written materials|related to fruit/vegetable servings/day
41128253|NCT00468156|BEHAVIORAL|telephone support|related to fruit/vegetable servings/day
41128254|NCT02588313|DIETARY_SUPPLEMENT|Mango fruit powder|Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
41128255|NCT02827474|OTHER|Patient Interview|Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.
41128256|NCT02827474|OTHER|Provider Interview|For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
41128257|NCT04200287|BEHAVIORAL|Online decision aid tool|The decision aid intervention will be presented via a website
41128258|NCT03253367|OTHER|Blood is obtained, mostly during routine venipuncture|
41278391|NCT06037954|OTHER|30-minute telephone or videoconference sessions|"Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are:~1. Provide education about depression and treatment options~2. Identify treatment preferences and a personal goal achievable with mental health care~3. Assess barriers to treatment initiation~4. Recommend a referral using standardized referral options~5. Address barriers to accessing care"
41278392|NCT04246047|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
41278393|NCT04246047|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
40930404|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
40930405|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
40930406|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
40930407|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
40930408|NCT00263276|DRUG|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
41278394|NCT04246047|DRUG|Bortezomib|Proteasome Inhibitor
40930409|NCT00263276|DRUG|metformin|Tablets, Oral, \>/= 1500 mg, Once daily, 12 weeks.
41278395|NCT04246047|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity
40755067|NCT04293965|DRUG|Multiple ascending dose of X842|Two dose groups will be set, including the groups receiving the recommended phase II dose and a higher dose; Eight subjects will be enrolled in each group, with half male and half female, who will receive X842 once daily for 5 consecutive days. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
41278396|NCT06657586|OTHER|neuromuscular exercises|The exercise was applied in 18 sessions of 6 weeks.The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
41278397|NCT06657586|OTHER|conservative treatment|The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
40930410|NCT05329038|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
41278398|NCT05574140|DIAGNOSTIC_TEST|Cardiac MRI|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images
41278399|NCT03534648|DRUG|PF-06865571 administered Day 7-14|PF-06865571 administered Q12hr on Days 7-14
41278400|NCT03534648|DRUG|PF-06865571 administered Day 1-14|PF-06865571 administered Q12hr on Day 7-14
40930411|NCT03320694|DRUG|Metformin|metformin 500mg twice daily \& increased until 2500mg till normoglycemia was achieved and was continued till delivery
41278401|NCT03534648|DRUG|PF-05221304 administered Day 1-14|PF-05221304 administered Q12hr on Days 1-14
41278402|NCT03534648|DRUG|PF-05221304 administered Day 7-14|PF-05221304 administered Q12hr Days 7-14
41449062|NCT06185088|DEVICE|Coda® Balloon Catheters|A balloon device that will be introduced into participants' intestine over a guide wire to test the radial stretch of the small bowel.
40930412|NCT03320694|DRUG|Insulin|The insulin group was given 3 S/C injections of regular insulin \& one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
41278403|NCT06487377|BIOLOGICAL|IX001 TCR-T cells|IX001 TCR-T cell injection will be administered intravenously after lymphodepletion.
41278404|NCT05008328|OTHER|Music therapy plus standard care during an SBT|If the participant is randomly assigned to standard care plus music therapy, a music therapist will enter the room five minutes prior to the start of the breathing trial and begin to play quiet music on a guitar. The nurse will reduce medicine to bring the participant to an alert state. The music therapist will introduce themselves and the music intervention, and will continue to play quiet guitar music and sing softly while the respiratory therapist begins the breathing trial. The music therapist will continue playing and singing for 20 minutes into the breathing trial.
41449063|NCT06185088|DEVICE|Double Balloon Endoscope (DBE)|A balloon device that will be introduced retrograde through the ileostomy and the inter-balloon distance will be increased causing stretch on the intestine to test longitudinal stretch. The DBE will only be used if a participant tolerated the Coda® Balloon Catheter intervention.
40755068|NCT04293965|OTHER|Food Effect|Twelve subjects (appropriate ratio of male to female) screened for eligibility will be randomized into Group A and B. The 6 subjects in Group A will take the study drug (X842) in fasted condition and subject in Group B will take the study drug in fed condition in the 1st cycle. In the 2nd Cycle, subjects in Group A will take the study drug in fed condition, and subjects in Group B will take the study drug in fasted condition. The interval between the two cycles is at least 7 days.
40930413|NCT00338897|DRUG|SR123781A|
40930414|NCT01569243|OTHER|Text messages|"* Participants will receive diabetic medical care as usual.~* Participants will be given an ActiHealth pedometer to measure daily activity.~* In addition, they will be enrolled to receive the study text messages."
40930415|NCT01569243|OTHER|Usual care|"* Participants will receive diabetic medical care as usual.~* In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity)."
40930416|NCT04505501|DRUG|N-803|N-803 is a novel IL-15 superagonist complex that enhances NK cell and CD8+ T-cell proliferation and activation.
40930417|NCT00591578|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
41278405|NCT05008328|PROCEDURE|Standard care during an SBT|The patient's nurse will reduce sedatives so the patient is alert and awake. The respiratory therapist will introduce themselves to the patient and inform them of the SBT, stating they will turn off the ventilator machine and allow the patient to breathe independently. The respiratory therapist will switch off the ventilator and leave the room. The respiratory therapist and nurse will both be available throughout the SBT, and the ventilator will automatically turn on if the patient stops breathing. The SBT will last for 30-60 minutes.
41278406|NCT01716819|OTHER|Urine sample|dosages on one spot and 24h collection
41278407|NCT01716819|OTHER|Blood sample|dosages
40755069|NCT05168566|DRUG|Sutetinib Maleate Capsule|Study drug to be taken orally with or without food (with food preferred) for up to13 cycles
40755070|NCT05939609|OTHER|Ballistic Stretching Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
40930418|NCT00591578|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
40930419|NCT00591578|DRUG|Valsartan|Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
41278408|NCT01716819|OTHER|Assessment of sleep apnea syndrome|
41278409|NCT01716819|OTHER|Electrocardiogram|
41278410|NCT01716819|OTHER|Glucose tolerance test|
41278411|NCT01716819|OTHER|Echocardiography|
41278412|NCT01716819|OTHER|cardiac and abdominal magnetic resonance imaging|
41278413|NCT01716819|OTHER|Ambulatory blood pressure monitoring|
41278414|NCT01716819|OTHER|Echotracking|
41278415|NCT01716819|OTHER|Pulse wave velocity|
41278416|NCT01716819|OTHER|Composition of body mass by Dual x-ray absorptiometry|
41278417|NCT03234114|DRUG|Triple antithrombotic therapy|Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)
41278418|NCT03234114|DRUG|Dual antithrombotc therapy-1|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus clopidogrel 75 mg q.d. (Sanofi, France)
41278419|NCT03234114|DRUG|Dual antithrombotc therapy-2|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain)
40755071|NCT05939609|OTHER|Extender Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
40755072|NCT05939609|OTHER|Kinesiotaping|It will be applied 4 times a week for 6 weeks and before starting on-water training.
40755073|NCT02948075|DRUG|Quisinostat|
40755074|NCT02948075|DRUG|Paclitaxel|
40755075|NCT02948075|DRUG|Carboplatin|
40755076|NCT02618395|DRUG|SPARC001A|
40755077|NCT02618395|DRUG|SPARC001B|
40755078|NCT02618395|DRUG|Reference001 - Hydrocodone|Hydrocodone-acetaminophen
40755079|NCT03347539|DEVICE|Nexplaon|This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon. Nexplanon has already been FDA approved and its efficacy and safety studied.
40930420|NCT01027390|BEHAVIORAL|physical training exercise|physical exercise training at the work site during work time
41278420|NCT06655974|OTHER|Health-related social needs decision support system|The health-related social needs decision support system uses machine learning models to make recommendations for screening to ED providers and staff during patient visits.
40930421|NCT01411553|OTHER|Disposable ECG-LW|Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
40930422|NCT05457894|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine|solution for intramuscular injection, 0.5 ml
40930423|NCT05457894|BIOLOGICAL|Ultrix®, Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
40930424|NCT04718103|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
40930425|NCT04718103|BIOLOGICAL|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
41128259|NCT01645566|BEHAVIORAL|instruction|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
41128260|NCT02776475|PROCEDURE|Sacral neuromodulation device turned off|Each patient will be to have the sacral neuromodulation device turned off for four consecutive weeks.
41278421|NCT01455350|PROCEDURE|Multimodal physiotherapy|10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.
41278422|NCT01455350|DRUG|lidocaine|10 weeks of daily topical 5% lidocaine application
41278423|NCT02592005|OTHER|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
41278424|NCT02555800|DRUG|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
41449064|NCT03476603|DRUG|Irbesartan|Patients are tested for their normal prescription irbesartan medication
40930426|NCT02150902|PROCEDURE|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF \>10g, FTI \> 500 g-sec and minimum ablation duration \>10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
41449065|NCT05301218|PROCEDURE|angioplasty|Coronary angioplasty, also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart
41449066|NCT05635812|OTHER|Neuropsychological assessment|neuropsychological assessment and clinical scales duration: 3 hours
41449067|NCT05635812|OTHER|EEG experimentation|duration: 1 hour
41449068|NCT05635812|OTHER|Oculometry experimentation|duration: 30 minutes
40930427|NCT02150902|PROCEDURE|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
40930428|NCT02815488|DRUG|CHF6297 (Part 1 - SAD)|Single doses of CHF6297 at each period (for up to 3 periods per subject)
40930429|NCT02815488|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
40930430|NCT02815488|DRUG|CHF6297 (Part 2 - MAD)|Twice daily doses of CHF6297 for 7 days
40930431|NCT02815488|DRUG|Placebo (Part 2 - MAD)|Twice daily doses of placebo matching CHF6297 for 7 days
40930432|NCT02815488|DRUG|CHF6297 (Part 3)|Twice daily doses of CHF6297 for 14 days
40930433|NCT02815488|DRUG|Placebo (Part 3)|Twice daily doses of placebo matching CHF6297 for 14 days
41128261|NCT02324296|DRUG|ifosfamide|PEI regimen may be a possible therapeutic option, with high activity and an acceptable toxicity profile.
41128262|NCT06191016|DEVICE|Vagal nerve stimulation|Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications
41128263|NCT06191016|DEVICE|Sham vagal nerve stimulation|control will receive sham stimulation to vagal nerve along with prescribed medications
41128264|NCT02080754|OTHER|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
41128265|NCT02080754|OTHER|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
41128266|NCT05950867|DIAGNOSTIC_TEST|ECG + echocardiography|Electrocardiogram and echocardiography
41128267|NCT05950867|OTHER|Answering questionnaires|Answering questionnaires about polyneuropathy symptoms (NTSS -6, COMPASS31, NIS, mPND) and also cardialogical symptoms (KCCQ-12).
41128268|NCT04540003|OTHER|Access to School Based Health Centre|The SBHC will be staffed by a family physician, two pediatricians and a developmental pediatrician, each with at least one half-day of clinic time per week from September through June. The SBHC is also staffed by a clinic coordinator who is responsible for booking appointments on a first-referral, first-serve basis.
40930434|NCT02815488|DRUG|CHF6297 (Part 4)|Twice daily doses of CHF6297 for 7 days
41128269|NCT04048681|BEHAVIORAL|diet soda|12 oz can of artificially sweetened cola beverage (Diet Coke planned to be used but similar to Diet Pepsi or other Diet Colas)
41128270|NCT04048681|BEHAVIORAL|Regular soda|12oz can of regular cola beverage (Coke planned but similar to Pepsi or other regular cola sodas)
40755080|NCT04729426|OTHER|Peanut Ball Position|The group of healthy pregnant women who meet the inclusion criteria will be determined by randomization according to the order of application to the delivery room. A group (intervention group) will be given positions using the peanut ball tool in active phase and transition phase and the positions will be changed every 30 minutes.
40755081|NCT05339659|DEVICE|mHealth Intervention|Mobile health (mHealth) app to motivate and support quitting smoking.
40755082|NCT00069550|DRUG|dextromethorphan|
40755083|NCT00069550|DRUG|donepezil hydrochloride|
40755084|NCT04677361|COMBINATION_PRODUCT|MILs™ in Combination with Pembrolizumab|Efficacy and Safety of MILs™ in Combination with Pembrolizumab in Patients with NSCLC and SCLC
40755085|NCT01679665|BIOLOGICAL|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval
40755086|NCT01679665|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 4 weeks interval
40755087|NCT01602458|PROCEDURE|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
41128271|NCT04048681|BEHAVIORAL|Carbonated Water|12oz can of carbonated water (sparking water, selzter water) unflavored
41128272|NCT01991275|DRUG|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
41128273|NCT01991275|DRUG|The intrathecal morphine injection|A single injection of morphine intrathecally
41278425|NCT02555800|DRUG|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
40930435|NCT02815488|DRUG|Placebo (Part 4)|Twice daily doses of placebo matching CHF6297 for 7 days
40930436|NCT02370446|OTHER|personalized medication log|
40930437|NCT02370446|OTHER|standard of care|
40930438|NCT02370446|BEHAVIORAL|questionnaires|
41128274|NCT05447936|DIETARY_SUPPLEMENT|Jarlsberg cheese|Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day
41128275|NCT02348632|DRUG|JZP-110|
41128276|NCT05780619|DIAGNOSTIC_TEST|Transcranial Doppler|Measurement of resistance index on the middle cerebral artery (MCA) (index test) and the Holter (reference test). Patients will be randomized for order of tests
41278426|NCT02555800|OTHER|Placebo|Saline solution
40930439|NCT02370446|BEHAVIORAL|Cognitive Interview|
40930440|NCT03696927|DEVICE|Active Powered Prosthesis (APEX) for Spinal Cord Injury|The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
40930441|NCT01931709|RADIATION|fludeoxyglucose F 18|Undergo FDG PET
40930442|NCT01931709|DEVICE|positron emission tomography|Undergo FDG PET
40930443|NCT01931709|DEVICE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
40930444|NCT01931709|OTHER|laboratory biomarker analysis|Correlative studies
40930445|NCT03678870|OTHER|Opioid Education Handout|a single page handout with information about how to use medications for pain after discharge.
40930446|NCT01423604|DRUG|Capecitabine|Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
40930447|NCT01423604|DRUG|Ruxolitinib|Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)
40930448|NCT01423604|DRUG|Placebo|Placebo matching ruxolitinib
40930449|NCT06454266|DRUG|ORM regimen|"The subjects received ORM regimen treatment every 21 days for a total of 6 cycles. The specific medication is as follows  Obutinib tablets 150mg qd d1-21 (suspended 2 days before MTX use until MTX drops to safe concentration) Rituximab 375mg/m2, d1 Methotrexate 3g/m2, d2"
41128277|NCT03919721|BEHAVIORAL|Applied Behavioral Analysis|Children are receiving Applied Behavioral Analysis therapy to treat their autism. Therapy is comprised of 15-20 discrete programs that are intended to shape specific behaviors. Tutors collect data on child's performance towards goals. For each child, some of the programs will be tracked with paper data collection methods, others will use electronic data collection. This study is to test the usefulness of the electronic data collection system to replace paper in existing interventions.
41128278|NCT03985774|PROCEDURE|Transcarotid revascularization|The ENROUTE Transcarotid Neuroprotection System (NPS) has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease The ENROUTE Transcarotid Neuroprotection System is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis
41128279|NCT06244875|OTHER|Sampling|Blood and cerebrospinal fluid sampling during the diagnostic visit
41128280|NCT00276276|DRUG|topotecan|
41128281|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^4 pfu delivered intramuscularly
40930450|NCT01603524|OTHER|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~1. Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~2. Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~3. Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~4. Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
41128282|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^5 pfu delivered intramuscularly
41128283|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^6 pfu delivered intramuscularly
41128284|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^7 pfu delivered intramuscularly
41128285|NCT04794218|OTHER|Placebo/Diluent|N/A delivered intramuscularly
41128286|NCT05623033|OTHER|The study is an observational study without intervention|The study is an observational study without intervention
41128287|NCT00079846|DRUG|Implitapide|
41128288|NCT00903474|OTHER|questionnaire administration|
41128289|NCT00903474|OTHER|study of socioeconomic and demographic variables|
41128290|NCT00903474|PROCEDURE|CAM exercise therapy|
41128291|NCT00903474|PROCEDURE|psychosocial assessment and care|
41128292|NCT00903474|PROCEDURE|quality-of-life assessment|
41128293|NCT00903474|PROCEDURE|stress management therapy|
41128294|NCT04677192|COMBINATION_PRODUCT|Microwave Ablation combination with chemotherapy|Microwave Ablation combination with chemotherapy. Maximum tumor diameter ≤ 3cm, single microwave needle, maximum tumor diameter\> 3cm, double ablation needle, the ablation range completely covers the lesion ≥ 0.5cm in order to obtain a satisfactory ablation margin. After the operation, contrast ultrasound is performed again to confirm the ablation edge. Enhanced MRI or CT to evaluate the ablation effect 4 weeks after surgery. Selection of chemotherapy regimen refers to the 2020 NCCN Guidelines for Pancreatic Cancer. First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen: If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.
41128295|NCT02369289|OTHER|bone mineral density test|
40930451|NCT01603524|BEHAVIORAL|OMSC + Performance Feedback Group|The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
40930452|NCT01077752|DRUG|continuous ropivacaine preperitoneal infusion|Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours
40930453|NCT01077752|DRUG|intravenous lidocaine infusion|Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours
40930454|NCT01077752|DRUG|parenteral analgesia combining acetaminophen and morphine|parenteral analgesia combining acetaminophen and morphine
40930455|NCT01077752|DRUG|NaCl|NaCl
41128296|NCT02745249|BEHAVIORAL|Maternal Nutrition Behavior change|
41128297|NCT04409470|DIAGNOSTIC_TEST|Blood gas sampling from artery and vein|Patients included in this study are treated according to clinical routine. After inclusion, sampling of an arterial blood gas and a venous blood gas is performed simultaneously or as close in time as possible. Because the venous blood gas analysis sample can be taken directly from the patient's peripheral venous catheter, no additional venous puncture is usually required and the additional amount of blood that may be required is approx. 1 ml (the assay requires about 500 µl). In the very rare cases where it is not possible to establish a peripheral venous catheter within a reasonable time, the sample will be acquired from a new venous puncture together with other venous routine samples.
40930456|NCT01809977|PROCEDURE|collagen cross-linking procedure (total removal)|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
41278427|NCT01053312|DRUG|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels (MBq).
41278428|NCT04391764|DRUG|Naltrexone|Naltrexone at a dose of 50 mg per day
40930457|NCT01809977|PROCEDURE|collagen cross-linking procedure (partial removal)|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
41278429|NCT04391764|DRUG|Placebo oral tablet|Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.
41278430|NCT01836861|DRUG|IPI-145|Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145
41278431|NCT03935971|DRUG|Dupilumab|See arm/group description
40930458|NCT01779271|DRUG|Pelubiprofen|
41128298|NCT03351699|DRUG|MK-4250|MK-4250 tablets for oral administration
41128299|NCT02961868|OTHER|Abdominal and supra-aortic trunks vascular imaging|Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.
41278432|NCT05201781|DRUG|Cilta-cel|Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
41278433|NCT05965037|DEVICE|FLUYDO NC percutaneous transluminal coronary angioplasty balloon catheter|The FLUYDO NC is a rapid exchange percutaneous transluminal non-compliant coronary angioplasty balloon catheter. It is a single use only medical device, non-implantable, non-pyrogenic and sterilized with ethylene oxide and CO2 mixture. The distal portion has a hydrophilic coating and consists of two lumens: one for balloon inflation and deflation, the other for guidewire advancement and retraction. The product is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion.
41278434|NCT03444337|DEVICE|Catheter Ablation|
41278435|NCT04029376|DRUG|Iberogast®|The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.
41278436|NCT04430907|BIOLOGICAL|HPV 9-valent Vaccine, Recombinant|"After consent, participants will complete an intake survey confirming eligibility. Participants will also complete a survey asking about knowledge, attitudes, and beliefs around vaccination, including HPV vaccination, as well as breastfeeding intentions.~After survey completion, the participant will be asked if they would like to be administered the HPV vaccine, Gardasil 9. If participants do not agree, they will be contacted 1-week later for the follow-up survey. If participants do agree, the project coordinator will notify the study physician, who will place an order for the vaccine. The vaccine will be administered to the patient prior to discharge from the hospital. Participants will be contacted 1-week later for the follow-up survey."
40930459|NCT01779271|DRUG|Loxoprofen|
40930460|NCT05022511|BEHAVIORAL|Screening status|Women are offered check-up on screening status in both CCU and CRC screening. If a woman is not up to date in one or both screening programmes, she will be offered a self-sampling device and/or a FIT kit.
40930461|NCT01311869|DIETARY_SUPPLEMENT|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
40930462|NCT01311869|DIETARY_SUPPLEMENT|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
41128300|NCT02961868|GENETIC|Blood sampling (genetic)|A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.
40930463|NCT06094985|GENETIC|DNA exome sequencing of tumor and blood|A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5.
40930464|NCT05392933|DIAGNOSTIC_TEST|Ultrasound guided piriformis muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) 5 ml %2 lidocaine injection
40930465|NCT00635076|OTHER|placebo|Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
40930466|NCT00635076|DRUG|alprazolam XR|Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
40930467|NCT02166671|BIOLOGICAL|HBV booster vaccination 1dose|
40930468|NCT01677390|DRUG|SGN-75|1-2 mg/kg IV every 21 days
40930469|NCT01677390|DRUG|everolimus|10 mg PO daily
41128301|NCT02961868|OTHER|Blood sampling (biomarkers)|A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
41128302|NCT02961868|OTHER|Urine sampling|A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
41128303|NCT04045301|BIOLOGICAL|Omalizumab 16mg/kg|Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
41128304|NCT04045301|BIOLOGICAL|Omalizumab 8mg/kg|Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
41128305|NCT04045301|BIOLOGICAL|Placebo|Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.
41128306|NCT04045301|OTHER|Multi-food oral immunotherapy (OIT)|Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
41449069|NCT00634205|DRUG|Valproate plus doxorubicin|Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
41449070|NCT00089011|DRUG|fludarabine phosphate|Given IV
41449071|NCT00089011|RADIATION|total-body irradiation|Undergo radiotherapy
41449072|NCT00089011|DRUG|mycophenolate mofetil|Given IV or PO
40930470|NCT03190642|DRUG|Methylprednisolone|Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
40930471|NCT01153464|BEHAVIORAL|Recovery Support Counseling|Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
40930472|NCT06309394|DRUG|INCB099280|INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
40930473|NCT05517278|OTHER|SurgX Antimicrobial Wound Gel|In addition to standard of care, at time of surgery, SurgX applied on the incision after closure and then re-applied at the time of first bandage change on day of discharge.
40930474|NCT05517278|OTHER|Standard of Care|The control group will receive standard of care.
40930475|NCT00004904|BIOLOGICAL|anti-thymocyte globulin|
40930476|NCT00004904|BIOLOGICAL|filgrastim|
41449073|NCT00089011|DRUG|tacrolimus|Given IV or PO
41449074|NCT00089011|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
40930477|NCT00004904|DRUG|cladribine|
40930478|NCT00004904|DRUG|cyclophosphamide|
41449075|NCT00089011|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
41449076|NCT00089011|OTHER|laboratory biomarker analysis|Correlative studies
41449077|NCT00348764|DRUG|lauromacrogol|
40930479|NCT00004904|DRUG|etoposide|
40930480|NCT00004904|DRUG|methylprednisolone|
40930481|NCT00004904|DRUG|tacrolimus|
40930482|NCT00004904|PROCEDURE|allogeneic bone marrow transplantation|
40930483|NCT00004904|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
40930484|NCT04685161|PROCEDURE|Surgical extrusion|Invasive treatment option for fractured tooth
40930485|NCT04685161|DEVICE|Fibre post|Easy approach for treatment
40930486|NCT02523612|PROCEDURE|Biopsy|
40930487|NCT02523612|PROCEDURE|Blood sample|
41128307|NCT02023866|DRUG|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
41128308|NCT01964300|BIOLOGICAL|peginterferon alfa-2b|Given subcutaneously (SC)
41449078|NCT02264977|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|
41449079|NCT04366544|OTHER|Part A1: Survey|Online
41449080|NCT04366544|OTHER|Part A2: Sample collection|Blood and Stool
41449081|NCT04366544|OTHER|Part B:|EEG and fMRI
41449082|NCT04006808|BIOLOGICAL|PED-HZ/su|GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.
41449083|NCT00304187|DRUG|Erythromycin|Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
41449084|NCT00304187|DRUG|Placebo|Placebo, 250 mg or 500 mg, three times a day for 6 weeks
41449085|NCT00143364|DRUG|varenicline (CP-526,555)|
41449086|NCT03345043|BIOLOGICAL|VAL-339851|Escalating dose levels
41449087|NCT03345043|OTHER|Placebo|Saline
41449088|NCT02658487|DRUG|Cytarabine|Given IV
41449089|NCT02658487|DRUG|Vosaroxin|Given IV
41449090|NCT00216736|DRUG|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
41449091|NCT00216736|DRUG|placebo|Single dose oral placebo at ED discharge
41449092|NCT03185208|DRUG|Lithium Carbonate|See lithium carbonate arm
40930488|NCT01830777|DRUG|Brentuximab Vedotin|Intravenously on Day 1 during re-induction therapy. Intravenously every 21 days during maintenance therapy
41449093|NCT03185208|DRUG|Placebo oral capsule|See placebo arm
41449094|NCT05247567|BIOLOGICAL|serum punction|A blood sample inclusion and at the end of study visit
41449095|NCT05247567|BIOLOGICAL|skin swab in elbow folds|passage of a cotton swab in the crease of the elbow at the inclusion
41449096|NCT04215328|DIETARY_SUPPLEMENT|Mixed-Meal|Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses
41449097|NCT04215328|DIETARY_SUPPLEMENT|Electrolyte Solution|Electrolyte Solution 500mLs by tube daily in 4 doses
41449098|NCT05316454|BEHAVIORAL|self-efficacy support|self-efficacy support
41449099|NCT01198964|PROCEDURE|Low-level cortical stimulation|A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
41449100|NCT03835689|BEHAVIORAL|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focused on skill learning for parents
41449101|NCT04184947|DRUG|SGLT2 inhibitor|New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice
41449102|NCT04184947|DRUG|GLP-1 receptor agonist|New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
41449103|NCT00042835|DRUG|cisplatin|Given IV
41449104|NCT00042835|DRUG|etoposide|Given IV
41449105|NCT00042835|DRUG|erlotinib hydrochloride|Given orally
41449106|NCT00042835|RADIATION|radiation therapy|Undergo radiotherapy
41449107|NCT00042835|DRUG|docetaxel|Given IV
41449108|NCT00042835|DRUG|paclitaxel|Given IV
41449109|NCT00042835|DRUG|carboplatin|Given IV
41449110|NCT00042835|OTHER|laboratory biomarker analysis|Correlative studies
41449111|NCT05986188|OTHER|Pathways to Potential|Pathways to Potential stations MDHHS caseworkers, called success coaches, in local elementary, middle, and high schools. After identifying a social or material need that is a barrier to school attendance (e.g., transportation barriers, caregiver unemployment), success coaches connect students and families to community resources and public assistance.
41449112|NCT01165632|PROCEDURE|biopsy|Correlative studies
41449113|NCT01165632|PROCEDURE|computed tomography|Undergo computed tomography
41449114|NCT01165632|PROCEDURE|therapeutic conventional surgery|Undergo stereotactic craniotomy
40930489|NCT01830777|DRUG|Mitoxantrone|Intravenously on Days 3-7 of re-induction therapy.
40930490|NCT01830777|DRUG|Etoposide|Intravenously on Days 3-7 of re-induction therapy.
40930491|NCT01830777|DRUG|Cytarabine|Intravenously on Days 3-7 of re-induction therapy.
40930492|NCT02251522|DEVICE|ConforMIS Total Knee Replacement System|Total knee replacement system using a patient specific implant.
40930493|NCT02251522|DEVICE|Off-the-Shelf Knee Replacement System|Total knee replacement system not using a patient specific implant.
41449115|NCT01165632|RADIATION|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
41449116|NCT01165632|RADIATION|radiation therapy|Undergo radiation therapy
41449117|NCT01165632|PROCEDURE|magnetic resonance imaging|Undergo magnetic resonance imaging
41449118|NCT01165632|PROCEDURE|positron emission tomography|Undergo positron emission tomography
41449119|NCT01165632|DRUG|fluorine F 18 fluorodopa|Given IV
41449120|NCT06133816|BEHAVIORAL|Framed Introductory Message A|Randomly assign patients to receive introductory message encouraging them to complete the survey (version A).
41449121|NCT06133816|BEHAVIORAL|Framed Introductory Message B|Randomly assign patients to receive introductory message encouraging them to complete the survey (version B).
41449122|NCT06133816|BEHAVIORAL|Framed Introductory Message C|Randomly assign patients to receive introductory message encouraging them to complete the survey (version C).
41449123|NCT06133816|BEHAVIORAL|Framed Tobacco Use Message A|Randomly assign patients to receive norming message related to tobacco use (version A).
41449124|NCT06133816|BEHAVIORAL|Framed Tobacco Use Message B|Randomly assign patients to receive norming message related to tobacco use (version B).
41449125|NCT06133816|BEHAVIORAL|Financial Incentive|Randomly assigned patients to be entered into a drawing to receive a $100 gift card.
41449126|NCT06116136|DRUG|S095029|Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W).
41449127|NCT06116136|DRUG|pembrolizumab 200 mg (KEYTRUDA ®)|Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).
41449128|NCT01112722|BIOLOGICAL|Apitox, purified honeybee toxin, lyophilized in saline|intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
41449129|NCT01112722|BIOLOGICAL|histamine|imitates pain and erythema of honeybee venom
41449130|NCT00429962|DRUG|intravitreal ranibizumab|intraocular injection
41449131|NCT00429962|DRUG|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
41449132|NCT03260686|OTHER|experimental|video guide for upper limb exercise
41449133|NCT02197741|DRUG|opiate with bolus|
41449134|NCT03937557|DIAGNOSTIC_TEST|photofinder levicam|Exam frontal, bilateral Temporal and occipital scalp by photofinder levicam and compare the pros and cons with the data from scalp biopsy.
41449135|NCT03552003|OTHER|Treatment for clinical practise|Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
41449136|NCT02729987|BEHAVIORAL|WorkGuru|A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.
41278437|NCT06655961|OTHER|Garden Activities Program|When we look at the studies evaluating the effect of gardening activities on hospitalized children; it is seen that mostly children's opinions about therapeutic gardens are included and studies involving active gardening activities are limited. Shao et al. (2020) gave hospitalized children a task about garden plants and made them full this task through active participation and mobile games. However, it is seen that the gardening activity applied in this study was limited to a 5-minute task. The most important difference of our study from these studies is that a standardized gardening activity program will be applied to hospitalized children during their hospitalization and the active participation of the child will be ensured.
41278438|NCT06655961|OTHER|Clinical routine treatment and nursing care protocol|Within the scope of the clinic routine treatment and nursing protocol; the decision to hospitalize the child, orientation to the clinic, execution of hospitalization paperwork, room placement, invasive intervention and treatment procedures are carried out. Treatment and care hours are revised according to individual order characteristics; 08.00-20.00, 08.00-16.00-00.00, 06.00-12.00-18.00-00.00 are planned considering the time order. 13.00-15.00 are the visiting hours. The child is not allowed to leave the clinic except for any medical purpose. No intervention will be applied to the control group of this study until the discharge process takes place.
41278439|NCT06656416|DRUG|ALTO-100|ALTO-100 40 mg tablet BID
41128309|NCT01964300|OTHER|laboratory biomarker analysis|Correlative studies
41128310|NCT03717506|DRUG|GDC 268 Lotion|GDC 268 is a topical lotion
41278440|NCT06656416|DRUG|Placebo|Placebo tablet BID
41449137|NCT04790526|OTHER|Eccentric Exercises Dose|Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance
41449138|NCT04008563|PROCEDURE|Bariatric Surgery|Patients who are randomized to the intervention group will receive a progestin intrauterine device and be referred for bariatric service to undergo bariatric surgery within 3 months of their study consent.
41449139|NCT00003470|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41449140|NCT05831657|OTHER|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
41449141|NCT05831657|OTHER|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
41449142|NCT03334058|DRUG|ARGX-113|human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)
41128311|NCT03717506|DRUG|Clindamycin Phosphate Lotion 1%|Clindamycin Phosphate Lotion is an FDA-approved drug product
41128312|NCT03717506|DRUG|GDC Vehicle Lotion|GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
41128313|NCT02419703|DEVICE|STAR™ Tumor Ablation System|Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
41128314|NCT00707473|DRUG|Carboplatin|Given IV
41128315|NCT00707473|OTHER|Chemoradiotherapy|Undergo chemoradiotherapy
41128316|NCT00707473|DRUG|Cisplatin|Given IV
41449143|NCT04500015|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
41128317|NCT00707473|PROCEDURE|Definitive Surgical Resection|Undergo surgery
41449144|NCT04500015|DRUG|Placebo Comparator|3 tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
41449145|NCT00000666|DRUG|Pyrimethamine|
41449146|NCT01889407|DRUG|Idarubicin|8 mg/m2, iv drip on days 1-3
41449147|NCT06627881|OTHER|Continuous aerobic kayak training program|Sitting in a special chair on the Kayak Pro® Speed Stroke PRO ergometer. 5-minute warm-up and continuous training, for 30 minutes on the ergometer at a moderate to vigorous intensity, 5 days a week.
41449148|NCT06627881|OTHER|Aerobic Endurance Circuit Program|Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, light intensity training with upper body strengthening, 5 days a week.
41449149|NCT06627881|OTHER|High intensity interval program with rope|Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, vigorous intensity undulating rope training using the interval method, 5 days a week.
41128318|NCT00707473|DRUG|Docetaxel|Given IV
41128319|NCT00707473|DRUG|Fluorouracil|Given IV
41128320|NCT00707473|PROCEDURE|Quality-of-Life Assessment|Correlative studies
41128321|NCT00707473|RADIATION|Radiation Therapy|Undergo radiation therapy
41128322|NCT00727909|DEVICE|Hearing Aid Treatments|"Hearing aid treatments:~Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)"
41128323|NCT05502094|OTHER|Heart Rate Variability Measurement|The heart rate variability of the participants will be measured with the Polar H10 device with a measurement time of 5 minutes.
41128324|NCT03079817|OTHER|Yoga Meditation|Yoga meditation using motor imagery to perceive movement patterns
41128325|NCT03079817|OTHER|Proprioceptive Drills|Active balance and proprioception drills
41128326|NCT00665340|DRUG|Placebo|Matching placebo
41128327|NCT00665340|DRUG|Levitra (Vardenafil, BAY38-9456)|5m, 10 mg and 20 mg 1 h prior to sexual intercourse
41128328|NCT06120218|PROCEDURE|Emergent Stenting|Emergent Stenting in acute ischemic stroke caused by tandem occlusions
41128329|NCT05065203|PROCEDURE|planned or unplanned Cesarean, operative, or non operative delivery|All types of delivery
41128330|NCT00311714|DRUG|CS-8958 formulated as dry powder|
41128331|NCT00311714|OTHER|Placebo|
41449150|NCT03864380|DIAGNOSTIC_TEST|Color retinography|Non mydriatic color retinography within 1 month before and within 1 hour after the marathon
41128332|NCT00299572|DRUG|alendronate (Fosamax)|
41128333|NCT02837796|PROCEDURE|transobturator tape|
41128334|NCT01108003|DRUG|broccoli sprout extract|Given orally
41128335|NCT01108003|OTHER|laboratory biomarker analysis|Correlative studies
41128336|NCT01108003|OTHER|Mango Juice|given orally
41128337|NCT01183598|DRUG|tocilizumab [RoActemra/Actemra]|maintenance dose
41128338|NCT04235738|OTHER|Observational|"ER2 is a simple and standardized clinical tool. The results of the questionnaires performed in ER2 study will be used. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies. Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
41449151|NCT03864380|DIAGNOSTIC_TEST|OCT-A|Optical Coherence Tomography - Angiography within 1 month before and within 1 hour after the marathon
41449152|NCT03864380|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure measurement within 1 month before and within 1 hour after the marathon
41449153|NCT06625255|BEHAVIORAL|Parent Education - Promoting Playfulness|Parents will participate in 2, 45 minute parent education sessions promoting playfulness through information about child development, parent stressors, and parent advocacy.
41449154|NCT04618900|PROCEDURE|Sinus floor elevation with a grafting material|The use of grafting material for sinus floor elevation
41449155|NCT02163382|DEVICE|Neurovent Monitor XIII|Nasogastric tiube installation to monitor EAdi
41449156|NCT02163382|DEVICE|Neurovent Monitor XIII|RIP jacket installation
41449157|NCT02163382|DEVICE|Neurovent Monitor XIII|Ventilator change (if a different ventilator was used prior to the study).
41449158|NCT02163382|DEVICE|Neurovent Monitor XIII|Determination of NAVA parametersVentilator
40755088|NCT01602458|PROCEDURE|Silicone Pressure Garment Therapy (SPGT)|"SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.~The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment."
40930494|NCT01351870|RADIATION|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
41128339|NCT05038618|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 400 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
41128340|NCT03814369|DEVICE|AmplifEYE|AmplifEYE colonoscopy
41128341|NCT04968938|DRUG|3,4-methylenedioxymethamphetamine|Behavioral: Therapy
41128342|NCT02040831|BIOLOGICAL|RSV LID ΔM2-2 Vaccine|10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
41128343|NCT02040831|BIOLOGICAL|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
41128344|NCT02816398|DEVICE|Percutaneous creation of an arteriovenous fistula|Use of catheter system for percutaneous creation of an arteriovenous fistula
41128345|NCT03542305|DRUG|Lorlatinib|Lorlatinib single oral dose
41449159|NCT02163382|DEVICE|Neurovent Monitor XIII|Second period with conventional NIV settings
41449160|NCT06627647|DRUG|Rilvegostomig|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
41449161|NCT06627647|DRUG|Pembrolizumab|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
40755089|NCT02301793|BEHAVIORAL|Nurse education in contemporary format|Education about VTE was delivered through a web-based contemporary interactive format
41128346|NCT05825274|DEVICE|Cathodal tDCS|We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
41128347|NCT02884245|DRUG|Estrogens|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
41278441|NCT06656637|BEHAVIORAL|Memory Drilling|"The experimental group will receive the additional intervention during their seven sessions with their care providers. The intervention is computerized memory drills training. This training includes the completion of a list learning memory task (HVLT) and then a PM practice task conducted on the computer at each session."
41449162|NCT06627647|DRUG|Carboplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
41449163|NCT06627647|DRUG|Cisplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
41449164|NCT06627647|DRUG|Pemetrexed|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
41449165|NCT03742895|DRUG|Olaparib|Olaparib 300 mg administered BID as two, 150 mg oral tablets.
41449166|NCT05490563|DRUG|SLS-005|SLS-005
40755090|NCT02301793|BEHAVIORAL|Nurse education in traditional format|Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
40930495|NCT01351870|RADIATION|Hyperfractionated Radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
41278442|NCT06656637|BEHAVIORAL|Compensatory Strategies|Participants learn compensatory strategies to assist with their memory performance. This involves both external strategies, such as calendering and setting alarms, and internal strategies, like imagery and mnemonics.
40930496|NCT02996643|DEVICE|Ultrasound Assisted Group|A custom brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
41278443|NCT06656637|BEHAVIORAL|Cognitive Processing Therapy|This is PTSD-targeted therapy.
41278444|NCT06656286|DEVICE|Intra-Uterine suturing by X-TACK device and hysteroscope|"After general anesthesia and entering the abdomen with the laparoscope, Truclear hysteroscope with X-tack attached will be inserted to the uterine cavity. Insertion of normal saline to the cavity and applying 4 points suturing to the uterus. The procedure will be monitored by external laparoscopic camera located in the abdominal cavity. After the hysterectomy the uterus will be opened and the suture will be examine.~A preoperative intrauterine incision using a hysteroscope, followed by suturing, will be considered based on the success of the first procedure."
41278445|NCT06657209|PROCEDURE|Insulin resistance testing|Steady state Plasma Glucose test
40930497|NCT02554279|DRUG|menotropin|
40930498|NCT02554279|DRUG|recombinant FSH|
40930499|NCT00559832|OTHER|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
40930500|NCT05940454|PROCEDURE|Pericapsular nerve group block|"The patient's arm is externally rotated and abducted at 45 degrees. A longitudinal linear ultrasound probe is placed between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle on it, a 50 mm needle is inserted with the in-plane technique. When the needle passes through the deltoid muscle and touches the subscapularis tendon, a hard bone-like tissue is felt and the needle is not advanced any further. It is noteworthy that the subscapularis tendon is very rigid and resistant to needle penetration when performing the pericapsular nerve group block. The needle tip is placed between the deltoid muscle and the subscapularis tendon and a local anesthetic drug (20 ml, %0.5 bupivacain hydrochlorur) is injected"
40930501|NCT05249335|DRUG|OST|The subject will receive Orafang for colonoscopy
40930502|NCT05249335|DRUG|2L-PEG/Asc|The subject will receive 2L-PEG/Asc for colonoscopy
40930503|NCT01981057|OTHER|Numeta|parenteral receipt prescribed with Numeta
41278446|NCT06657209|PROCEDURE|OGTT|Will collect 5 blood draws during the test to measure insulin secretion
41278447|NCT06657209|PROCEDURE|Fat biopsy|Needle biopsy to gather a sample of abdominal subcutaneous fat
41449167|NCT05490563|DRUG|Placebo|Placebo (sodium chloride injection, 0.9%, USP)
41278448|NCT06657209|RADIATION|DXA scan|Whole body DXA scan
41278449|NCT06657209|PROCEDURE|MRI|Abdominal MRI
41278450|NCT06657209|PROCEDURE|1H-MRS|Spectroscopy of the abdominal region
41278451|NCT06657209|DRUG|Tirzepatide|16 weeks started at 2.5mg/week and increased to 5mg/week dose
41278452|NCT06657209|DRUG|Pioglitazone|16 weeks at a 45mg/day dose
41278453|NCT06657105|DRUG|EE/LNG|EE/LNG tablet will be administered orally.
41278454|NCT06657105|DRUG|Baxdrostat|Baxdrostat tablet will be administered orally.
41449168|NCT02993562|DRUG|Levothyroxine|Normal treatment with levothyroxine.
41449169|NCT00755677|OTHER|Pulses|subjects consume 1 pulse food daily for eight weeks
41449170|NCT00809250|BIOLOGICAL|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
40755091|NCT02129881|BIOLOGICAL|Autologous regulatory T Cell Product|Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
40755092|NCT04999020|DRUG|Ravulizumab|Intravenous dosing will consist of a loading dose followed by maintenance doses administered every 8 weeks (q8w). The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
40755093|NCT04999020|DRUG|Placebo|Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
40755094|NCT03191032|OTHER|Early sensory re-education of the hand with a sensor glove model|Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
40755095|NCT03253627|BEHAVIORAL|Health Enhancement Program|The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition-without mindfulness instruction-using similar modalities to MBSR training for a matched schedule.
40755096|NCT03253627|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
40755097|NCT03357172|BIOLOGICAL|Blood Sample|Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2
40755098|NCT03357172|BIOLOGICAL|Bone marrow aspiration|Additional bone marrow aspiration before graft, D30, D90, Y1
40755099|NCT03357172|BIOLOGICAL|Blood sample|Before donation
40755100|NCT03357172|BIOLOGICAL|Allogeneic hematopoietic stem cell sample|Allogeneic hematopoietic stem cell sample
40930504|NCT01981057|OTHER|Individual|parenteral receipt prescribed individually
41278455|NCT05274750|BIOLOGICAL|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) will be administered using a pre- filled syringe.
41449171|NCT05458687|OTHER|Chinese herbal medicine decoction、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application、Nursing/Diet and health education and guidance|"* Chinese herbal medicine decoction: prescribed three times a day, seven days a week, and lasts for up to one weeks.~* Acupuncture or Laser acupuncture pen treatment: twice a week, once for 20 minutes,up to a total of one week.~* Acupoint Tuina massage: once a day for up to 20 minutes each time, for up to a week.~* Acupoint application of traditional Chinese herbal medicinal cake: Apply warm navel ointment in our hospital to CV 4 (Guanyuan) point every day, and remove after getting up the next day, seven days a week for up to one week.~* Nursing and health education and guidance: teach the patients and their family members the matters needing attention in daily life.~* Diet and health education:give personalized Traditional Chinese Medicine diet guidance and recommendations in accordance with Traditional Chinese Medicine physique syndrome."
41449172|NCT02873845|OTHER|Preliminary validation of the COBQoL questionnaire|
41449173|NCT00857454|DRUG|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 60 days
41449174|NCT02258074|DRUG|Nicotinamide|
40755101|NCT00180700|BEHAVIORAL|Hypnosis|
40755102|NCT02838706|PROCEDURE|Surgery for hip fracture|
40755103|NCT04613089|OTHER|Natural History|Natural History and Clinical Follow Up.
40755104|NCT01266057|DRUG|Hydroxychloroquine|Starting dose of 200 mg by mouth every day for a 21 day cycle.
40755105|NCT01266057|DRUG|Sirolimus|Starting dose of 2 mg by mouth every day for a 21 day cycle.
40755106|NCT01266057|DRUG|Vorinostat|Starting dose of 200 mg by mouth per day for a 21 day cycle.
40930505|NCT02491229|OTHER|Hepafast|Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
40930506|NCT02491229|OTHER|LOGI diet|For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
40930507|NCT02726308|DRUG|Dexamethasone|5 mg I.V. Dexamethasone just before induction
40930508|NCT02726308|DRUG|10 ml/kg Ringer's lactate|Intra-operative 10 ml/kg Ringer's lactate solution .
41278456|NCT05274750|DRUG|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
41278457|NCT05786482|BEHAVIORAL|Online mind-body wellness program|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)
40930509|NCT02726308|DRUG|30 ml/kg Ringer's lactate|Intra-operative 30 ml/kg Ringer's lactate solution .
40930510|NCT03055377|DRUG|N-acetyl cysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)
40930511|NCT03055377|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
40930512|NCT02250833|DRUG|CKD-828|Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
40755107|NCT03929055|DEVICE|Physiological assesment|"1. Arterial blood gas analysis.~2. esophageal pressure variation during inspiration and expiration~3. Arterial blood pressure, central venous pressure (CVP), heart rate.~4. diaphragmatic contraction detected by ultrasound"
40755108|NCT02115672|DRUG|BL-8040|BL-8040 will be added to imatinib to improve CML response.
40755109|NCT02773537|DRUG|Femoral nerve catheter and sciatic nerve block|This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.
41128348|NCT04752072|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation|"The first (formulation) session enables linking present difficulties and traumatic events, identifying current issues/concerns, and collaboratively agreeing on the order of modules based on symptom severity and client readiness.~The PTSD module provides narrative exposure to the traumatic memories and targets re-experiencing, avoidance and hyperarousal symptoms. The AD module focuses on identifying and labelling feelings, emotion management, distress tolerance, acceptance of feelings and experiencing positive emotions. The NSC module focuses on staying in the present moment and combating dissociation; self-compassion and mindfulness skills; challenging thinking patterns and developing a balanced view of self. The DR module focuses on exploring and revising maladaptive schemas; effective assertiveness; awareness of social context; and flexibility in interpersonal expectations and behaviours displayed in social interactions."
41128349|NCT04752072|BEHAVIORAL|Treatment as usual|The first session will involve a mental health assessment by either a psychiatrist or psychologist. A treatment package will be developed based on the information collected during the assessment. Details of the interventions delivered to each participant receiving TAU, which will include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, will be recorded.
41128350|NCT05877872|PROCEDURE|Reduced-target resection|Patients receive surgery according to pSTV-post-IC.
41128351|NCT05877872|PROCEDURE|Full-target resection|Patients receive surgery according to pSTV-pre-IC.
41128352|NCT05877872|DRUG|Adjuvant immunotherapy|Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
40930513|NCT02250833|DRUG|Telmisartan|- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
40930514|NCT02250833|DRUG|S-amlodipine|- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
40930515|NCT06057974|OTHER|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational model for healthcare staff working in NICUs. It aims to improve the ability of the members of the NICU healthcare team to I) observe the infants' individual behaviors and needs, II) support parents to take the initiative and share their observations and understanding of their infant's behaviors and to collaboratively plan the infant's care with the healthcare staff, III) understand the individual story of the family regarding parenthood through a dialogue with parents, and IV) involve parents in the decision-making about the care of their baby from an early stage of care through to the preparation for discharge. The final goal is to improve the care culture in the NICUs by changing the attitudes of the healthcare staff and the care practices of the unit to be more in line with family-centered care principles.~It usually takes 1.5 years for each NICU to complete the intervention."
40930516|NCT03121651|DEVICE|RL-adaptive application|"Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each:~1. young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team,~2. young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and~3. young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app.~The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened."
40930517|NCT03108781|DRUG|Lavender Oil|Lavender Oil twice a day; one month on the face and one month on the legs
40930518|NCT03108781|DRUG|sunflower oil|placebo twice a day (sunflower oil); one month on the face and on month on the legs
41128353|NCT03447457|DEVICE|High-flow oxygen|HFNC is continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min and a FiO2 adjusted to maintain a pulse oxymetry at least 92%
41128354|NCT03447457|DEVICE|Standard oxygen|nasal cannula, face mask or non-rebreathing reservoir mask
41128355|NCT03925649|BIOLOGICAL|HB-adMSCs|single infusion of HB-adMSCs
41128356|NCT00821301|DRUG|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
41128357|NCT05736094|DEVICE|SURF|Dual-frequency ultrasound
41128358|NCT00262015|BIOLOGICAL|· Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)|
41128359|NCT00133250|DRUG|Abciximab|Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
41128360|NCT00133250|OTHER|Placebo Heparin Sodium|Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
41128361|NCT04195919|DRUG|Evogliptin 5mg|Participants receive Single oral administration of Evogliptin 5mg on day1
41128362|NCT04195919|DRUG|Evogliptin 5mg|"Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period"
41128363|NCT03981588|OTHER|Imaging studies|Patients will undergo different imaging and clinical follow-up procedures to run out cardiotoxicity
41128364|NCT03057600|DRUG|Paclitaxel|standard weekly paclitaxel in 28-day cycles
41128365|NCT03057600|DRUG|CB-839|CB-839 administered as oral tablets twice daily (BID)
41128366|NCT02412033|DRUG|Misoprostol|400 µg misoprostol vaginally 3 hours before IUD insertion.
41128367|NCT02412033|DRUG|Placebo|This group will receive placebo
41128368|NCT00868504|OTHER|no intervention|no intervention
41449175|NCT02258074|DRUG|Lanthanum Carbonate|
41449176|NCT02258074|DRUG|Placebo (for Nicotinamide)|Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
40930519|NCT01415739|OTHER|laboratory biomarker analysis|Correlative studies
40930520|NCT05340270|DRUG|PD-1 inhibitor+GP|PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
41128369|NCT01753167|DRUG|MCMV3068A|Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
41128370|NCT01753167|DRUG|MCMV5322A|Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
41128371|NCT01753167|DRUG|Placebo|Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
41128372|NCT03053505|BIOLOGICAL|faecal human microbiota transplant (FMT)|"Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.~Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT."
41278458|NCT05786482|BEHAVIORAL|Online mind-body wellness program + Weekly Check-ins|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief weekly check-ins
41449177|NCT02258074|DRUG|Placebo (for lanthanum carbonate)|Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
41449178|NCT02179294|DRUG|Pethidine|100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
41449179|NCT02179294|DRUG|Remifentanil|"Dedicated intravenous cannula for remifentanil administration PCA protocol~* PCA bolus remifentanil 40 μg~* Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes."
41449180|NCT03786341|DEVICE|with auxiliary illuminator|Ambulation training with laser quad-cane for 15 minutes and typical physical therapy with strengthening and balance training for 15 minutes.
41449181|NCT06578650|DEVICE|Synthetic Electrospun Fiber Matrix|Patients who are eligible for enrollment will be treated with Synthetic Electrospun Fiber Matrix immediately after surgical resection to the resulting wound
40755110|NCT02773537|DRUG|Adductor canal catheter and selective tibial block|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.
40930521|NCT05340270|DRUG|GP|Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
40930522|NCT02538861|DIAGNOSTIC_TEST|SPECT Imaging Test at Baptist hospital|Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
40930523|NCT02538861|DIAGNOSTIC_TEST|CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital|The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
40930524|NCT02538861|DIAGNOSTIC_TEST|SPECT Imaging Test at West Kendall Baptist Hospital|Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
40930525|NCT06221527|PROCEDURE|conventional group|fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border
40930526|NCT05644847|OTHER|Whole Body Vibration Training|WBV training will be performed on a commercial vibrating platform (Healthmate HM01-08VF Gym Fitness Equipment Step Vibration Machine, China), which produces vertical sinusoidal vibrations. Participants in the dynamic WBV group will be provided with dynamic exercises along with WBV training. The vibration speed level will be progressed from level 5 to level 10 during the course of the treatment sessions
40930527|NCT05644847|PROCEDURE|Core Stability Training|Core stability exercises will include pelvic bridge, straight leg bridge, modified kneeling with elbow support and leg lifts and squats, with 60 seconds rest interval between each activity. All these core exercises will be performed on a stable surface and will be progressed in difficulty by increasing the no. of repetitions and no. of sets on a weekly basis. Every session will be preceded by 5 minutes of warm-up and end with 5 minutes of cool-down exercises.
40930528|NCT03008564|OTHER|Ultrasound scanning of the lower limb in volunteers|"Several reference points will be marked by anatomical landmarks and/or ultrasound: the anterior superior iliac spine; base of patella; apex of the femoral triangle A measuring tape will be used to measure the anterior superior iliac spine (landmark); the base of the patella (landmark); apex of femoral triangle (ultrasound); and distal most portion of adductor canal (Point B described earlier; ultrasound). We will then measure the ASIS to: 1) base of patella; 2) apex of femoral triangle; and 3) Point B. We will repeat the same procedure on the opposite leg. Once complete, the volunteer will be allowed to dress and leave. The procedure should take approximately 10-20 minutes for each volunteer. The following things will be recorded for each subject:~* Age~* Gender~* Weight~* Height~* BMI~* Distance of ASIS to base of patella~* Distance of Point A to base of patella~* Distance of Point B to base of patella~* Distance of apex of femoral triangle to base of patella"
40930529|NCT03277833|DIETARY_SUPPLEMENT|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
41128373|NCT03053505|DRUG|Vancomycin or Fidaxomicin|"Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13)."
41128374|NCT02189174|DRUG|CLR457|
41128375|NCT01418794|DEVICE|High dose rapamycin stent|Concentration of rapamycin is 2.5%
41128376|NCT01418794|DEVICE|Low dose rapamycin stent|Concentration of rapamycin is 1.5%
41128377|NCT03874169|DEVICE|E4 wristband|A biosensor watch that monitors the patient's heartbeat, heart rate variability, skin conductance, and temperature in order to discover if they are having a GI bleed
41128378|NCT04437043|OTHER|quality of life questionnaires|pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
41449182|NCT05709496|RADIATION|De-escalated radiotherapy to be delivered on the Elekta Unity Unity MR-linac|30 Gy in 5 fractions to the whole prostate with 45 Gy in 5 fractions to the dominant lesion
41449183|NCT03546738|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
40755111|NCT02773537|DRUG|Adductor canal catheter only|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
41128379|NCT00785200|OTHER|Chlorhexidine|Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
41128380|NCT00785200|OTHER|Water|Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
41128381|NCT00042731|DIETARY_SUPPLEMENT|Lycopene|Daily administration as outlined in treatment arm(s)
41128382|NCT00042731|DIETARY_SUPPLEMENT|Multivitamin|Daily administration as outlined in treatment arm(s)
41128383|NCT00042731|DIETARY_SUPPLEMENT|Soy isoflavones|Daily administration as outlined in treatment arm(s)
41128384|NCT04003324|BEHAVIORAL|Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults|Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
40755112|NCT01881633|DRUG|ISU302|
40755113|NCT01881633|DRUG|Placebo|
40930530|NCT03277833|DIETARY_SUPPLEMENT|Placebo|Placebo, parallel design
40930531|NCT02982512|DRUG|Dexmedetomidine|Administration of dexmedetomidine a different concetrations
40930532|NCT02643056|DRUG|Panitumumab|IV administration every 2 weeks
40930533|NCT06099145|DEVICE|Hephaï|Used of the HEPHAI medical device as a tool to improve the delivery of inhaled treatments for asthma and COPD
40930534|NCT03024580|DRUG|Megestrol Acetate 160Mg Tablet|Megestrol acetate 160 mg PO daily
40930535|NCT03024580|DRUG|Anastrozole 1Mg Tablet|Anastrozole 1 mg PO daily OR
41449184|NCT03546738|PROCEDURE|Sham spinal cord stimulation|No spinal cord stimulation is provided
40755114|NCT02944045|DRUG|Methylprednisolone|"Methylprednisolone intra veinous~* Day 1 to 5 : 30mg twice per day~* Day 6 to 10 : 30mg per day~* Day 11 to 21 : 20mg per day"
40930536|NCT03024580|DRUG|Letrozole 2.5Mg Tablet|Letrozole 2.5 mg PO daily OR
40930537|NCT03024580|DRUG|Exemestane 25 MG|Exemestane 25 mg PO daily
40930538|NCT03024580|DRUG|Tamoxifen 20Mg Tablet|Tamoxifen 20 mg PO daily
40930539|NCT03024580|DRUG|Fulvestrant 50Mg Solution for Injection|Fulvestrant 500 mg IM d1, d14, d28 and q28 days
40930540|NCT02050542|PROCEDURE|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
40930541|NCT02050542|PROCEDURE|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
41128385|NCT01876966|DRUG|Etravirine|200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
41128386|NCT01876966|DRUG|Darunavir/ritonavir|DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
40930542|NCT04739371|DRUG|Insulin, Regular, Human|The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
40930543|NCT04739371|DRUG|Placebo|The spray will last a few seconds and then the participant will be asked to sniff to aid the saline into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
40930544|NCT00657826|DEVICE|ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm|Isolated aortic valve replacement with a size 19mm valve
40930545|NCT03344523|DRUG|Iron protein succinylate oral solution|Iron protein succinylate oral solution
40930546|NCT03344523|OTHER|standard treatment|standard treatment
40930547|NCT00169442|BIOLOGICAL|Tritanrix™-HepB/Hiberix™ Kft.|GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine.
40930548|NCT00169442|BIOLOGICAL|Tritanrix™-HepB/Hiberix™|GSK Biologicals' combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine
40930549|NCT00169442|BIOLOGICAL|Hiberix™|GSK Biologicals' Haemophilus influenzae type b vaccine
40930550|NCT00169442|BIOLOGICAL|Polyribosil-Ribitol-Phosphate (PRP) vaccine|plain PRP polysaccharide vaccine
40930551|NCT00169442|BIOLOGICAL|Tritanrix™-HepB Kft|GSK Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary.
40930552|NCT04800952|OTHER|blood samples and filtered fluid will be collected.|"Arterial blood samples will be collected just before the commencement of continuous venovenous haemofiltration (CVVHF) and 1 h after the termination of CVVHF.~Prefilter and post-filter venous blood samples and filtered fluid will be collected 1 and 3 h after the commencement of CVVHF and at the end of CVVHF."
40930553|NCT05216601|BIOLOGICAL|MVC-COV1901|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region. Group A and B
40930554|NCT05216601|BIOLOGICAL|MVC-COV1901(Beta)-15|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-15 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
41128387|NCT01876966|DRUG|artemether/lumefantrine|3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets \[20/120 mg\] at 0, 8, 24, 36, 48, and 60 hours)
41128388|NCT00401869|DRUG|Epoetin alfa|
41128389|NCT01534546|DRUG|Oxaliplatin capecitabine|capecitabine：1000 mg/m2 ，bid, d1\~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
41128390|NCT01534546|DRUG|Oxaliplatin S-1|S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
41128391|NCT01534546|DRUG|Oxaliplatin S-1|S-1: 40\~60mg bid，d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
41128392|NCT03916146|BEHAVIORAL|Parent Training Intervention|Adapted version of the Family Check-Up/Everyday Parenting intervention
41128393|NCT05793307|GENETIC|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
41128394|NCT00003593|DRUG|asparaginase|Given IV
41449185|NCT03546738|DEVICE|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead."
40755115|NCT02944045|DRUG|Placebo|saline serum
40755116|NCT05647252|DRUG|Whole Body and nasal decolonization with octenidin (Octenisan Set)|"Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.~Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period"
41128395|NCT00003593|DRUG|cytarabine|Given IT
41128396|NCT00003593|DRUG|daunorubicin hydrochloride|Given IV
40930555|NCT05216601|BIOLOGICAL|MVC-COV1901(Beta)-25|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-25 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
40930556|NCT00112398|PROCEDURE|Extended interventions by advanced level prehospital providers|may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
40930557|NCT03938753|DEVICE|Audéo M90-T|Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
40930558|NCT02802670|DRUG|[14C]-GDC-0810|Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of \[14C\]-labeled GDC-0810 on Day 1.
40930559|NCT03324581|DRUG|OPC-64005|OPC-64005 film coated tablets
40930560|NCT03324581|DRUG|Atomoxetine|Atomoxetine gelatin capsules
40930561|NCT03324581|DRUG|Placebo|OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
40930562|NCT06263946|DEVICE|Essilor® Stellest® spectacle lenses|patients will be asked to wear Essilor® Stellest® spectacle lenses more than 12 hours per day for 24 months.
40930563|NCT00248885|PROCEDURE|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
41128397|NCT00003593|DRUG|methotrexate|Given IV
41128398|NCT00003593|DRUG|therapeutic hydrocortisone|Given IT
41278459|NCT04894591|DRUG|Zepzelca|Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.
40930564|NCT01889381|DRUG|Bone marrow cell-based therapy & 1-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
40930565|NCT03233269|BEHAVIORAL|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment via a prerecorded video. The Music Therapist will then engage the patients in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
40930566|NCT04785521|RADIATION|Stereotactic radiosurgery|Gamma Knife stereotactic radiosurgery (SRS-GK)
40930567|NCT04785521|DIAGNOSTIC_TEST|Blood samples|Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.
40930568|NCT05046444|DIAGNOSTIC_TEST|Next Generation Sequencing|NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods
40930569|NCT00807573|DRUG|Paclitaxel|Day 1: Paclitaxel (90 mg/m\^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m\^2 over 60 minutes)
41128399|NCT00003593|DRUG|thioguanine|Given IV
41128400|NCT04756271|BIOLOGICAL|SARS-Cov-2 neutralizing antibody titer|Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine
41128401|NCT03471559|DRUG|Cannabidiol|single or multiple dosing
41278460|NCT06586489|BEHAVIORAL|Virtual Reality Natural Landscape Exposure|Participants will view immersive virtual natural landscapes using virtual reality (VR) headsets for 10 minutes, three times a week, over eight weeks. They will choose the natural landscapes they wish to visit and admire, allowing for personalized engagement with the virtual environment.
41278461|NCT06586489|BEHAVIORAL|Tablet Screen Natural Landscape Exposure|Participants will watch immersive virtual natural landscapes on a tablet screen for 10 minutes, three times a week, over eight weeks. Participants can select the natural landscapes they prefer to view during the sessions, providing a personalized experience.
41449186|NCT04144998|DIAGNOSTIC_TEST|central sensitization inventory (questionnaire)|T.G. Mayer, R. Neblett, H. Cohen, et al. The development and psychometric validation of the central sensitization inventory Pain Pract, 12 (2012), pp. 276-285
40930570|NCT00807573|DRUG|Pemetrexed|Day 1: Pemetrexed (500 mg/m\^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
40930571|NCT00807573|DRUG|Bevacizumab|Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
40930572|NCT04541251|DRUG|Camrelizumab + Nab-paclitaxel + Carboplatin|The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
40930573|NCT04903379|OTHER|Education|An explanation of contemporary pain science and a description of effective treatment strategies used by people with a history of persistent pain.
41449187|NCT00159458|DRUG|Gemcitabine and oxaliplatin|
41449188|NCT03283358|BEHAVIORAL|Person-centered follow up|
41449189|NCT02990286|DRUG|Rituximab|Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)
41449190|NCT02990286|DRUG|Placebo of Rituximab|500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)
41449191|NCT02990286|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months."
41278462|NCT01877655|BIOLOGICAL|ASP0113|Intramuscular injection
41278463|NCT01877655|DRUG|Placebo|Intramuscular injection
41278464|NCT04515836|DRUG|Olaparib|Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
41278465|NCT04491279|PROCEDURE|Home 'General' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the general exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
41449192|NCT04745234|DRUG|Mogamulizumab|"For the first 28-day induction cycle (C1), mogamulizumab 1 mg/kg will be administered as an IV infusion through a 0.22- or 0.2-μm in-line filter over at least 60 minutes on Days 1, 8, 15, and 22.~For all subsequent 28-day cycles (C2, 3, 4, etc.), mogamulizumab 2 mg/kg will be administered as an IV infusion over at least 60 minutes on Day 1 of each subsequent therapy cycle."
41449193|NCT02611440|BEHAVIORAL|Pharmaceutical care|"Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.~Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.~HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load."
40930574|NCT04516837|DRUG|Eltrombopag|Eltrombopag 25-75 mg oral daily according to platelet response.
40930575|NCT04516837|DRUG|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
40930576|NCT02288377|DRUG|lanreotide|Patients will receive lanreotide 120 mg every 28 days until disease progression
40930577|NCT02288377|DRUG|Placebo|
40930578|NCT04224545|DRUG|Colchicine Pill|Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.
40930579|NCT04224545|DRUG|Placebo|Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
40930580|NCT02045303|DEVICE|Contact Ultrasound Therapy|Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
40930581|NCT02045303|DEVICE|Noncontact Ultrasound Therapy|Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
40930582|NCT04493840|DRUG|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
40930583|NCT04493840|DRUG|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
40930584|NCT01812980|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|"WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
40930585|NCT03619811|DIAGNOSTIC_TEST|Reflux Band® Upper Esophageal Sphincter (UES) Assist Device|UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
40930586|NCT05204875|RADIATION|X-ray Velocimetry|X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
41128402|NCT00982644|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
41128403|NCT00982644|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
41128404|NCT04160741|OTHER|Radiation and warm environment|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
41449194|NCT04277507|DEVICE|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
41449195|NCT01834183|DRUG|Tivozanib|
41449196|NCT01834183|DRUG|Gemcitabine|
40930587|NCT00911885|BEHAVIORAL|Dietary Intervention|The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
40930588|NCT04592484|BIOLOGICAL|CDK-002|CDK-002 administered intratumorally
40930589|NCT03355443|PROCEDURE|Retroflexion|Retroflexion technique in colonoscopy means turning the colonoscope tip 180 degree in order to look backward in the colon and rectum.
40930590|NCT03355443|PROCEDURE|Re-examination|Re-examination in colonoscopy means examining the cecum and ascending colon twice in the routine fashion.
40930591|NCT03219463|DIETARY_SUPPLEMENT|Ginger|3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
41128405|NCT04160741|OTHER|Warm environment|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
41128406|NCT04160741|RADIATION|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
41278466|NCT04491279|PROCEDURE|Home 'Neuropilates' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the neuropilates exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
41278467|NCT04491279|PROCEDURE|Supervised Neuropilates Group Class|Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (a chartered physiotherapist who is also a pilates instructor).
41278468|NCT04491279|PROCEDURE|Supervised General Exercises Group Class|Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility
41278469|NCT05222139|BIOLOGICAL|COVID-19 vaccination|Monitoring COVID-19 vaccination
41278470|NCT06357754|BIOLOGICAL|Idecabtagene vicleucel|As per product label
41278471|NCT06357754|BIOLOGICAL|Lisocabtagene maraleucel|As per product label
41278472|NCT06635135|DRUG|Aticaprant|Aticaprant will be administered orally.
41278473|NCT06635135|OTHER|Placebo|Placebo will be administered orally.
41278474|NCT06448377|PROCEDURE|Videolaryngoscopy|Situations in which the practitioner performs endotracheal intubation using a videolaryngoscope during airway intervention will be included in this group.
40930592|NCT02491359|DRUG|Carfilzomib|Given IV
40930593|NCT02491359|OTHER|Laboratory Biomarker Analysis|Correlative studies
40930594|NCT02491359|OTHER|Quality-of-Life Assessment|Ancillary studies
40930595|NCT02491359|OTHER|Questionnaire Administration|Ancillary studies
40930596|NCT01221740|DRUG|Savella|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
40930597|NCT00294281|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
41128407|NCT04160741|OTHER|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
41128408|NCT01499849|DRUG|Rolapitant|(4 X 50 mg capsules) 200 mg PO
41128409|NCT01499849|DRUG|Granisetron|10 mcg/kg IV
41128410|NCT01499849|DRUG|dexamethasone|20 mg PO and 8 mg PO
41128411|NCT01499849|DRUG|Placebo|(4 X 0 mg capsules) 0 mg PO
41128412|NCT00177619|DRUG|Alendronate|
41128413|NCT01778842|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
41128414|NCT01778842|DRUG|Prasugrel|Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
41128415|NCT01818869|DRUG|AZD8848|Multiple doses inhaled IMP via a nebulizer
41128416|NCT01818869|DRUG|Placebo to match AZD8848|Multiple doses inhaled matching placebo via a nebulizer
41128417|NCT04456413|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
41128418|NCT04456413|OTHER|Best Supportive Care|Patients will receive best supportive care. Patients randomized to this arm may receive plasma should they require hospitalization for progression of COVID-19 disease.
40930598|NCT05280483|DRUG|ABSK021 with fed state|25 mg ABSK021 (1x25 mg ABSK021 capsule) with food
40930599|NCT05280483|DRUG|ABSK021 with fasted state|25 mg ABSK021 (1x25 mg ABSK021 capsule) without food
40930600|NCT04244812|OTHER|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
40930601|NCT04244812|DEVICE|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
40930602|NCT00704665|DRUG|Relaxin|10 ug/kg/day or 25 ug/kg/day
40930603|NCT00704665|DRUG|Relaxin|Placebo
40930604|NCT01680133|OTHER|Hyperinsulinemic euglycemic clamp|
40930605|NCT05488821|DRUG|QLH11906|QLH11906 only
40930606|NCT02292784|DRUG|Retosiban|This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
40930607|NCT02292784|DRUG|Atosiban|This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
40930608|NCT02292784|DRUG|Placebo|This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
40930609|NCT03331471|PROCEDURE|alveolar recruitment maneuver|applying alveolar recruitment maneuver using the anesthesia machine
40930610|NCT03331471|PROCEDURE|conventional ventilation|conventional ventilation using the anesthesia machine
41128419|NCT00635869|BEHAVIORAL|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
41128420|NCT00635869|BEHAVIORAL|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
41278475|NCT06448377|PROCEDURE|FOB|Situations in which the practitioner performs endotracheal intubation using a fiberoptic bronchoscope during airway intervention will be included in this group.
40930611|NCT05009433|BEHAVIORAL|High intensity interval training program for pregnant women|"Pregnant women will participate in 8-week HIIT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression and stage of pregnancy. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month HIIT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
40930612|NCT05009433|BEHAVIORAL|Moderate intensity continuous training program for pregnant women|"Pregnant women will participate in 8-week MICT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate intensity continuous exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises, relaxation and visualization of pregnancy or childbirth (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month MICT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
41128421|NCT00635869|BEHAVIORAL|Placebo|didactic education sessions on physical assessment
41128422|NCT04405310|BIOLOGICAL|Convalescent Plasma of patients with COVID-19|Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.
41128423|NCT04405310|OTHER|placebo (hartmann plus albumine)|use of albumin 20% in 250cc of Hartmann solution
41128424|NCT03700554|DEVICE|Pleuralvent™|Pneumothorax treatment with Pleuralvent™ device (Heimlich valve device)
41128425|NCT03700554|PROCEDURE|Chest tube|Chest tube insertion
41128426|NCT00222924|BEHAVIORAL|weight loss/ exercise|
41128427|NCT05603182|DRUG|PRA052|PRA052
41128428|NCT05603182|OTHER|Placebo|Placebo
41128429|NCT01701401|DRUG|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
41128430|NCT01701401|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
41278476|NCT06448377|PROCEDURE|FOB+Aintree|Situations in which the practitioner performs endotracheal intubation using a Fiberoptic intubation via LMA with aintree catheter during airway intervention will be included in this group.
41278477|NCT06448377|PROCEDURE|Classic intubation with laryngoscopy|Situations in which the practitioner performs endotracheal intubation using a macintosh laryngoscope during airway intervention will be included in this group.
40930613|NCT05009433|BEHAVIORAL|Standard obstetric care with extended education on healthy lifestyle|Pregnant women will get standard obstetric care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity in the perinatal period and selected aspects of pregnancy and motherhood. Educational classes will be conducted online in real time, at least once every two weeks, until one year postpartum.
40930614|NCT05009433|BEHAVIORAL|High intensity interval training program for nonpregnant women|"Nonpregnant women will participate in 8-week HIIT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month HIIT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
40930615|NCT05009433|BEHAVIORAL|Moderate intensity continuous training program for nonpregnant women|"Nonpregnant women will participate in 8-week MICT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate continuous intensity exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises and relaxation (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month MICT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
40930616|NCT05009433|BEHAVIORAL|Standard health care with extended education on healthy lifestyle|Nonpregnant women will get standard health care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity and selected aspects of preparation to pregnancy and motherhood. Classes will be conducted online in real time, at least once every two weeks, for a period of 20 months.
40930617|NCT01975831|DRUG|Durvalumab|Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
40930618|NCT01975831|DRUG|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
40930619|NCT04382664|BIOLOGICAL|UV1|UV1 vaccine (300 μg) will be injected intradermally.
40930620|NCT04382664|BIOLOGICAL|Sargramostim|Sargramostim (75 μg) is used as a vaccine adjuvant.
40930621|NCT04382664|BIOLOGICAL|Ipilimumab|Ipilimumab is dosed according to label.
41128431|NCT03948438|PROCEDURE|Endoscopic septotomy|Patients will be placed in left lateral decubitus position, either in conscious sedation or under deep sedation with propofol or endotracheal intubation.The procedure will be performed with a flexible standard endoscope and started with initial endoscopic examination with suction of possible retained material insidethe diverticulum. An incision of the bridge between the ZD and the esophagus will be done (using one endoscopic procedure as POES or FESD or other)
41128432|NCT03791996|PROCEDURE|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
41128433|NCT04569123|DEVICE|real stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver vibration for the treatment group.
41128434|NCT04569123|DEVICE|No stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver no vibration for the control group during therapy.
41128435|NCT01505166|BIOLOGICAL|Vigil™ Vaccine|Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
41128436|NCT01505166|DRUG|Placebo|Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
41278478|NCT06448377|PROCEDURE|Others|Cases in which intubation cannot be performed, those who are awakened from anesthesia, or those in whom a surgical method is used for airway access will be included in this group.
41278479|NCT06355531|DRUG|FNP-223|Oral tablets
41278480|NCT06355531|DRUG|Placebo|Oral tablets
41278481|NCT06496178|DRUG|Petosemtamab|MCLA-158
41278482|NCT06496178|DRUG|Investigator's Choice|Cetuximab
41278483|NCT06496178|DRUG|Investigator's Choice|Methotrexate
41278484|NCT06496178|DRUG|Investigator's Choice|Docetaxel
40930622|NCT04382664|BIOLOGICAL|Nivolumab|Nivolumab is dosed according to label.
40930623|NCT02547883|DRUG|Cessation of statin|The intervention evaluated is the cessation of statin
40930624|NCT04281953|DIAGNOSTIC_TEST|High frequency audiometry|Simple hearing test
40930625|NCT04281953|OTHER|Short-Form 36-Item Questionnaire (SF-36)|Questionnaire on quality of life (Short Form 36 Item- SF-36)
40930626|NCT04281953|OTHER|Hearing handicap inventory for adults/elderly (HHIA/HHIE)|Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)
40930627|NCT04281953|OTHER|Tinnitus handicap inventory (THI)|Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
40930628|NCT03218683|DRUG|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses
40930629|NCT03218683|DRUG|AZD5991 + Venetoclax|Ascending oral doses of AZD5991 and/or venetoclax until no longer tolerated or disease progression
40930630|NCT06332469|BEHAVIORAL|Internet based education and support program for patients awaiting kidney transplantation|"A guided internet based support an education program consisting of 9 modules running over 9 weeks. First, an introductory module is given that involves goal setting, followed by two educational modules with information regarding kidney disease, treatment and self-care in severe renal failure and while waiting for kidney transplantation, and kidney transplant-specific areas. Supportive content consist of three behavioral components spread over five modules/weeks and are based on cognitive behavioural therapy principles. The last module is a summation focusing on consolidating the knowledge learned during the program.~Each module consists of texts, illustrations, short films, reminders to practice physical activity and weekly homework for which the participants receive feedback from a contact person."
40930631|NCT05178745|DRUG|Fluorouracil|Pharmaceutical Form: solution for injection Route of Administration: intravenous (IV), intravenous or intra-arterial infusion
40930632|NCT05178745|DRUG|Aflibercept|Pharmaceutical Form: concentrate solution for infusion Route of Administration: IV infusion
40930633|NCT05178745|DRUG|Irinotecan|Pharmaceutical Form: solution for injection Route of Administration: IV infusion
40930634|NCT01592656|RADIATION|Functional Respiratory Imaging|CT-scan of thorax. At baseline, after 1 month and after 6 months.
40930635|NCT01592656|OTHER|Lung compliance measurement|At baseline
40930636|NCT01592656|DEVICE|Non-invasive ventilation (Respironics)|Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 \> 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
40930637|NCT04584697|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).
40930638|NCT04584697|DRUG|Placebo|Diluent solution
40930639|NCT05398081|DRUG|Cefuroxime (Zinnat®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used
40930640|NCT05398081|DRUG|Ceftriaxone (Rocephin®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
40930641|NCT01967784|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
40930642|NCT00579085|DRUG|Ketamine|IV Ketamine .35mg/kg times ten days.
40930643|NCT00579085|OTHER|IV NSS|Placebo inactive ingredients
40930644|NCT00579085|OTHER|Normal Saline|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)"
40930645|NCT01097876|DRUG|PF-04447943 25 mg|25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
40930646|NCT01097876|DRUG|Placebo PF|Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
40930647|NCT01092065|DRUG|AFQ056 with L-dopa|hard gelatin capsule to be taken bid for six weeks
40930648|NCT01092065|DRUG|Placebo|hard gelatin capsule to be taken bid for six weeks
40930649|NCT04591574|BIOLOGICAL|Red Blood Cells (Transfusion)|Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines
40930650|NCT00588952|DRUG|Ketamine and Placebo|Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes
40930651|NCT01112683|DRUG|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 \& 10 mg/d divided dose week three, 10mg/BID week four).
40930652|NCT01112683|DRUG|Placebo|These are identically-looking pills to those in the Memantine Arm.
40930653|NCT04457895|BEHAVIORAL|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)"
40930654|NCT04457895|OTHER|no intervention|no yoga session at home and no yoga -therapeutic educatuion session
40930655|NCT05370456|DEVICE|Local application of a HA gel for the treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction and HA gel will be applied.
40930656|NCT05370456|PROCEDURE|Treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
40930657|NCT00495079|DRUG|Marqibo® (vincristine sulfate liposomes injection)|Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
40930658|NCT01459939|DIETARY_SUPPLEMENT|Rose-hip powder capsules|5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
40930659|NCT01459939|DIETARY_SUPPLEMENT|Placebo|5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
40930660|NCT06068920|OTHER|Distress evaluation|To evaluate the effects of psychological distress caused by living with a chronic disease such as rheumatoid arthritis.
40930661|NCT05999604|DRUG|Ocrelizumab Injection [Ocrevus]|Semestrial administration
40930662|NCT05999604|DRUG|Ocrelizumab Injection [Ocrevus]|Annual administration
40930663|NCT00240474|DRUG|Telmisartan 80 mg + hydrochlorothiazide 12.5 mg|
40930664|NCT00240474|DRUG|Amlodipine 10 mg + hydrochlorothiazide 12.5 mg|
40930665|NCT04358601|DEVICE|Triathlon PS Knee System with all-polyethylene tibial components|Primary Total Knee Replacement
40930666|NCT04358601|DEVICE|Triathlon PS Knee System with metal-backed modular components|Primary Total Knee Replacement
40930667|NCT02556476|PROCEDURE|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
40930668|NCT02556476|PROCEDURE|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
40930669|NCT02556476|PROCEDURE|renal replacement therapy|the procedures used to treat acute kidney injury
40930670|NCT02556476|PROCEDURE|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
41128437|NCT00083551|DRUG|Thalidomide|All patients will be randomly assigned to receive thalidomide 400 mg as an oral, once daily dose throughout induction and 100mg between transplants after platelets are greater than 50,000μl and 200 mg post transplant consolidation, and a reduced dose of 100 mg on alternating days during the first year of maintenance and 50 mg qod thereafter versus no thalidomide. Thalidomide will be held during conditioning, transplant procedure, and recovery following transplant. It may be resumed once plateletrecovery is complete after each transplant
41128438|NCT00083551|DRUG|Ara-C|"Cytarabine (Ara-C) 400 mg/m2 in 250 ml D5W over one hour daily for four days (on days -5, -4, -3, -2).~Start infusion 30 minutes after completion of BCNU on day -5."
41128439|NCT00083551|DRUG|BCNU|Carmustine (BCNU) 300 mg/m2 in 1 liter of D5W in glass bottle (protect from light) to infuse over 2 hours on day -5. Check blood pressure every 15 minutes during infusion and 30 minutes after completion
40930671|NCT04843488|PROCEDURE|Guided bone regeneration with a PTFE membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws.
41128440|NCT00083551|DRUG|Cisplatin|"Cisplatin\* 15 mg/m2/day Continuous infusion 1-4 (DCEP CYCLE 2) Cisplatin\* 7.5 mg/m2 Continuous infusion 1-4 (DPACE cycle)~\*Cisplatin doses will be modified for renal insufficiency as follows: Cisplatin dose Creatinine 15 mg/m2 (full dose) \< 1.5 mg/dl 10 mg/m2 1.6 - 2.0 mg/dl 7.5 mg/m2 2.1 - 3.0 mg/dl 0 mg (hold Cisplatin) \> 3.0 mg/dl"
41128441|NCT00083551|DRUG|Cytoxan|Cycle 2 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cycle 3 - CAD and PBSC Collection #1 Cyclophosphamide 750 mg/m2/day Continuous infusion 1-4 Cycle 4 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cytoxan/VP-16 and PBSC Collection-Cyclophosphamide 2 grams/m2 (Total dose 4 gm/m2) IV by CI 1 and 2 Post-Transplant Consolidation-Cyclophosphamide 300 mg/m2 Continuous infusion 1-4
41128442|NCT00083551|DRUG|Dexamethasone|Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as \< 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20
41128443|NCT00083551|DRUG|Doxorubicin|Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
40930672|NCT04843488|PROCEDURE|Guided bone regeneration with a PTFE+collagen membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws and covered with a Collagen membrane subsequently.
40930673|NCT05366205|DIETARY_SUPPLEMENT|Oral nutritional supplement|Enteral nutritional emulsion(TPF-T) will be given by oral intake,400ml per day, lasting for 7-10 days.
40930674|NCT05366205|BEHAVIORAL|Nutrition consultation|Nutritional treatment advice will be given
40930675|NCT02073266|PROCEDURE|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
40930676|NCT04232709|OTHER|Shared electronic patient record|MedChart allows access to a shared electronic patient record that contains selected information related to a patient's cancer treatment. If a patient contacts the after-hours telemedicine service, the oncology nurse will have access to this shared record
41128444|NCT00083551|DRUG|Etoposide|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
41128445|NCT00083551|DRUG|Filgrastim|G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
40930677|NCT06104839|DRUG|NXC736|oral administration
40930678|NCT06104839|DRUG|Placebo|oral administration
40930679|NCT05965648|BEHAVIORAL|Families FORWARD (Focusing on Relationships, Well-being, and Responsibility aheaD)|Families FORWARD aims to engage families in planning for adulthood earlier and more actively. Program skills include communication and problem-solving; guided practice in setting realistic goals, breaking down goals into incremental action steps, and problem-solving barriers to goal attainment; repeated engagement in future-oriented communication; and training on how to navigate transition-related and adult services. Parents/caregivers will participate in six or seven telehealth sessions (60-75 minutes each). Youth on the autism spectrum will have the option of participating in up to three program sessions to increase collaborative planning within the family. Families will identify and work toward individualized transition planning goals that may fall within any area of planning or functioning (e.g., housing, education, guardianship).
40930680|NCT05415384|DEVICE|Cryoablation of Intercostal Nerves|Using Atricure device, cryoice, intercostal nerves 3-8 will be ablated in the experimental arm. This is in addition to mechanical fixation of rib fractures and multimodal systemic therapy.
40930681|NCT05415384|PROCEDURE|Standard surgical treatment of patients with multiple rib fractures|Standard surgical treatment of patients with multiple rib fractures
40930682|NCT00976118|DRUG|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
40930683|NCT00976118|DRUG|placebo|matching placebo to masitinib
41278485|NCT06491745|OTHER|ESWT+PT+corticosteroid injection, ESWT group|ESWT group. Patients in the ESWT group will receive ESWT, physical therapy, and both shoulder joint (glenohumeral joint, GHJ) and SASD bursa injection for 2 times in a 2-week interval. 3ml triamcinolone (1ml triamcinolone= 10mg) will be added to 3ml 1% xylocaine to make 6ml injectate. Among them, 4ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. After withdrawing the needle to subcutaneous layer, another 2ml injectate will be injected into the SASD bursa of the affected shoulder under US guidance.
41278486|NCT06491745|OTHER|Sham ESWT+PT+corticosteroid injection, SHAM group.|SHAM group. The participants will receive the same dosage and technique of corticosteroid posterior GHJ and SASD bursa injection for 2 times at 2 weekly interval as participants do in the ESWT group. For creating a single-blinded condition, they will also receive 4 ESWT treatments at weekly interval except that the energy flux density is set at 0.04 mJ/mm2. For sham ESWT, the machine still makes a noise with every shock wave delivered in order to enhance the sham design.
41278487|NCT05138419|OTHER|"CKD What You Need To Know Workbook System"|139 page Workbook including CKD Action Plan, Web-Based Resources, Interactive CKD Patient education material
40930684|NCT03636698|OTHER|chorioamnionitis|It is a observation research. We didn't intervene anything. The chorioamnionitis groups included the infants whose mothers were diagnosed chorioamnionitis by placental histopathology.
40930685|NCT01226121|BIOLOGICAL|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
40930686|NCT04519203|DEVICE|SPI|Either standard monitoring alone or added with SPI
41128446|NCT00083551|DRUG|Recombinant GM-CSF|GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
41128447|NCT00083551|DRUG|Interferon-alpha-2b|AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod
41128448|NCT00083551|DRUG|Melphalan|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
41278488|NCT05138419|OTHER|CKD Action Plan|Goals based on international guidelines that can protect kidney function (1 knowledge and 10 action goals) Patient education material used separately for control arm.
41449197|NCT06213649|DRUG|Polyhexamethylene biguanide (PHMB)|PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
40930687|NCT04519203|DEVICE|Standard|Standard monitoring alone
40930688|NCT01281527|DRUG|Paliperidone Palmitate|50 - 150 mg eq. every 30 days
40930689|NCT03361644|BEHAVIORAL|High-Intensity Interval Training|Participants assigned to HIIT will participate in treadmill exercise in intervals consisting of 1 minute intervals of challenging intensities with recovery periods in between, gradually increasing the number of intervals over the course of the study.
41128449|NCT00083551|DRUG|Vincristine|Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.
40930690|NCT03361644|BEHAVIORAL|Moderate-Intensity Continuous Training|Participants assigned to CMIT will participate in constant moderate intensity treadmill exercise, gradually increasing the duration of the exercise over the course of the study.
40930691|NCT03274375|DRUG|IA session|10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.
40930692|NCT03274375|DRUG|Rituximab|"Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~* at least 1 day before each IA session~* the last injection will occur after the last session IA (minimum one day after)"
40930693|NCT00636701|DEVICE|Repetitive Transcranial Magnetic Stimulation|We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
40930694|NCT06398405|OTHER|Epigallocatechin-3-gallate|Epigallocatechin-3-gallate is administered in a solution with a concentration of 4400 umol/L
40930695|NCT03937921|DRUG|Gadavist 15Ml Solution for Injection|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
40930696|NCT05330078|DRUG|Botulinum toxin type A|Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.
40930697|NCT05330078|DRUG|Vehicle|Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
40930698|NCT05242796|DEVICE|Low frequency magnetic therapy|
40930699|NCT05043376|DRUG|Standard of care|Standard COVID-19 care as per the hospital guidelines
40930700|NCT05043376|DIETARY_SUPPLEMENT|BLIS K12|Daily 2 oral BLIS K12 tablets for up to 14 days.
40930701|NCT00973349|BIOLOGICAL|MF59-eH1N1_f|8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
40930702|NCT01792570|DRUG|RPV + DRV/r|Switch to dual HAART
40930703|NCT01792570|DRUG|continue the PI/r-containing HAART.|Continue the on-going triple drug HAART.
40930704|NCT05877287|OTHER|mindfulness-based stress reduction program|The FTSA program will be carried out once a week for 60 minutes, for 8 weeks, in a total of 8 sessions. The program will be conducted in face-to-face groups. Sessions will be held in a suitable area in the practice area. In each 60-minute session, it is planned to be 20 minutes of narration on the subject of the session, accompanied by a power point presentation, and the remaining 40 minutes of exercise, meditation practices and sharing experiences.
41449198|NCT06213649|DRUG|Topical corticosteroid|Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
40930705|NCT00899080|GENETIC|gene expression analysis|
40930706|NCT00899080|GENETIC|reverse transcriptase-polymerase chain reaction|
40930707|NCT00899080|OTHER|immunoenzyme technique|
41449199|NCT06213649|OTHER|Topical placebo|An artificial tear ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
40930708|NCT00899080|OTHER|laboratory biomarker analysis|
40930709|NCT00899080|OTHER|platelet aggregation test|
41128450|NCT04255212|OTHER|Soft tissue treatment|Participants will be asked to sit in front of a medical table with their forearms supinated and relaxed. 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side will be administered by keeping the hands contact on the skin of the participants for all the treatment duration. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Stimuli frequencies will be about 0,2-03 Hz. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
40930710|NCT01625533|PROCEDURE|Standard Coronary Angiography|Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.
40930711|NCT01625533|PROCEDURE|Dual-axis Rotational Coronary Angiography|Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
40930712|NCT02463552|DRUG|Naproxen|The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
40930713|NCT06321341|DRUG|Vespireit|Buspirone
40930714|NCT06321341|DRUG|Arlevert|Dimenhydrinate + Cinnarizine
40930715|NCT04814238|PROCEDURE|Aortic Root Surgery|First time, isolated, minimally invasive (mini-sternotomy, RALT) aortic root or aorta surgery
40930716|NCT01753050|DEVICE|Stroke volume monitoring|Pulse contour stroke volume monitoring
40930717|NCT01687374|DRUG|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
40930718|NCT01687374|DRUG|Placebo|Saline injection daily for 8 weeks.
40930719|NCT00172159|PROCEDURE|Hepatic resection|
41278489|NCT05138419|OTHER|CKD Web-based Resource List|CKD Patient education material used separately for control arm
41278490|NCT05138419|OTHER|Food Label reading exercise|CKD Patient education material used separately in all arms.
41278491|NCT04752215|DRUG|BI 765049|BI 765049
41449200|NCT06314633|OTHER|Hair cut|Hair locks and follicles will be cut twice in winter and spring
41449201|NCT06314633|OTHER|Socio-economic questionnaires|Information about parents education levels and professional occupation, geographic area, children gender, indoor and outdoor children's environmental exposures
41449202|NCT04504747|OTHER|molecular analysis of blood and tumor|RNAseq, DNAseq, CTCs
40930720|NCT00821509|BEHAVIORAL|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
40930721|NCT00821509|BEHAVIORAL|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
40930722|NCT00769483|DRUG|MK-0646|Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
40930723|NCT00769483|DRUG|Gemcitabine|1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
40930724|NCT00769483|DRUG|Erlotinib|100 mg by mouth daily.
40930725|NCT05942209|DIAGNOSTIC_TEST|ECO-LEAK transvaginal ultrasound|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day an ultrasound - ecoenema is performed. First, the Foley catheter is inserted via the transanal route with instillation of 180cc of serum under ultrasound guidance with a probe in the vagina, using a sagittal and midline cut. In case there is the appearance of free pelvic fluid (previously absent) or an increase in free fluid compared to the baseline examination (fluid present at the beginning of the examination) around the anastomosis/pelvic area, the test will be considered positive.
40930726|NCT05942209|DIAGNOSTIC_TEST|ECO-LEAK with CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed, along with an ecoenema.
40930727|NCT05942209|DIAGNOSTIC_TEST|CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed
40930728|NCT04551339|DIETARY_SUPPLEMENT|PreserVision AREDS formulation soft gels or tablets|Two tabs taken daily for three months
40930729|NCT04551339|DIETARY_SUPPLEMENT|Multivitamin with 11mg of zinc|One tab taken daily for three months
40930730|NCT02572739|DEVICE|PICCO|measurements based on thermodilution
40930731|NCT02572739|DEVICE|NICCOMO|measurements based on impedance
41449203|NCT03984565|DRUG|Cannabidiol|High-CBD, low-THC sublingual product formulated in palm oil
41449204|NCT03984565|DRUG|Placebo|Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.
41449205|NCT02287844|OTHER|XOS|5 g of XOS everyday for 4 weeks.
41449206|NCT02287844|OTHER|INU-XOS|1 g of XOS and 3 g of inulin everyday for 4 weeks.
40930732|NCT00001282|DRUG|Zidovudine (AZT) & Interleukin-2 (IL2)|
40930733|NCT04715334|DEVICE|Mollii suit|The Mollii suit is a new technology of electrical stimulation in the form of whole-body garment with multiple electrodes individually programmed to stimulate the selected muscles. Based on preliminary studies, it is suggested that the Mollii suit improves spasticity. Recent studies also proposed that it improves mobility, gait, function and quality of life. However, these studies are based on qualitative and subjective measures.
40930734|NCT02836743|DRUG|Circadin|Slow-release melatonin
40930735|NCT02836743|DRUG|Placebo|
40930736|NCT05888012|DEVICE|basket catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The basket catheter is made of nickel-titanium wires which can be manipulated to trap and withdraw stones.
40930737|NCT05888012|DEVICE|balloon catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The balloon catheter is made of latex, which is inflated after passing the stone, thus pushing the stone outwards.
41449207|NCT02287844|OTHER|Placebo|6.64 g of maltodextrins everyday for 4 weeks.
40930738|NCT00273507|DRUG|Carboplatin and Paclitaxel|
40930739|NCT00268580|BEHAVIORAL|Asthma Care Pathway|Asthma care provided using standardized asthma care pathway
40930740|NCT05452174|DRUG|Mirtazapine|Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.
40930741|NCT03535571|DIETARY_SUPPLEMENT|Salmon Protein Hydrolysate|4g of salmon protein hydrolysate per serving.
40930742|NCT01561027|DRUG|CNV1014802|Administered as specified in treatment arm.
40930743|NCT01561027|DRUG|Placebo|Administered as specified in treatment arm
40930744|NCT01415089|BEHAVIORAL|FOCUS-Web|A 3-session individually tailored, interactive, web-based program providing support and education for cancer patients and one of their family caregivers.
41278492|NCT04752215|DRUG|ezabenlimab|ezabenlimab
41278493|NCT06372717|DRUG|APL-4098|APL-4098 is administered orally in 28-day cycles
41449208|NCT03017729|BIOLOGICAL|Botulinum toxin type A|This is an observational study designed to reflect real world clinical practice in the use of abobotulinumtoxinA. AbobotulinumtoxinA injected doses, frequency of injections, number of injection sites and volume injected per site are in accordance with the current USPI and physician's clinical practice.
41449209|NCT04375943|DRUG|Antidiabetic|Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
41449210|NCT03073850|DRUG|Antiplatelet|ASA or clopidogrel
41449211|NCT03073850|DRUG|Low dose oral anticoagulant|Edoxaban of 30mg
41449212|NCT03073850|DRUG|Standard dose oral anticoagulant|Edoxaban of 60mg
41449213|NCT05219864|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
40930745|NCT04607278|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic supplementation was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
40930746|NCT04607278|DIETARY_SUPPLEMENT|Prebiotic|The prebiotic was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
40930747|NCT04607278|DIETARY_SUPPLEMENT|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
41128451|NCT04255212|OTHER|Mechaninsms explanation|Participants will be instructed with a 10 minutes lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
41449214|NCT05219864|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
41128452|NCT04255212|OTHER|Control Group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
41278494|NCT06372717|DRUG|Azacitidine and APL-4098|Azacitidine is administered at the standard dose of 75mg/m2 on Day 1 - Day 7 of each 28-day cycle; APL-4098 is administered orally.
41278495|NCT04879329|DRUG|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks.
40755117|NCT05647252|BEHAVIORAL|Questionnaire for study participants immediately after the decolonization|"A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).~The questionnaire is handmade and validated by the Investigators."
40930748|NCT02853630|DRUG|Metformin|Participant will be instructed to take Metformin tablets as per instructions given by the physician.
40930749|NCT02853630|DRUG|Vildagliptin|Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
40930750|NCT03522142|DRUG|INCB081776|INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.
40930751|NCT03522142|DRUG|INCMGA00012|INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
40930752|NCT03828370|BEHAVIORAL|B-SMART Intervention Group|The B-SMART mobile web app will contain four modules: 1) Supporting Abstinence, 2) Shared Positive Activities, 3) Common Challenges for Family Members with IID, and 4) Effective Communication. Within each module there will be a series of learning activities, including presentation text, interactive engagement, and videos. All app content will be available in both English and Spanish, based on user language preference.
40930753|NCT03828370|BEHAVIORAL|Usual and Customary Information Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on the IID installed in their vehicle and the manufacturer information provided about the IID in PDF format, in both English and Spanish. This constitutes a UC group, as such pamphlets are widely available to DWI offenders who have IIDs installed in their vehicles. Thus, providing this pamphlet represents a standard information provision for first-time DWI offenders and their CFMs.
40930754|NCT01178827|DRUG|trospium chloride|trospium chloride (60mg) once daily for 10 days
40930755|NCT01178827|DRUG|oxybutynin IR|oxybutynin IR (5 mg) three times daily for 2 days
40930756|NCT01178827|DRUG|oxybutynin IR placebo|oxybutynin IR placebo three times daily for 2 days
40930757|NCT03813797|DEVICE|Airseal®|Medical device set to the mode Airseal®, pressure adjustment between 5 and 7 mmHg
40930758|NCT03813797|DEVICE|Standard Insufflation|"Medical device set to the mode Standard Insufflation, pressure adjustment between 12 and 15 mmHg"
40930759|NCT02643069|OTHER|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
40930760|NCT04044443|DEVICE|IMPEDE, IMPEDE-FX or IMPEDE-FX RapidFill|Peripheral vascular embolization
40930761|NCT01565499|DRUG|Nab-paclitaxel|
40930762|NCT03764488|DRUG|Tofersen|Administered as specified in the treatment arm.
40930763|NCT03764488|DRUG|99mTc-MAG3-BIIB067|Administered as specified in the treatment arm.
40930764|NCT00479921|BIOLOGICAL|Trivalent influenza subunit vaccine|
40930765|NCT05475613|PROCEDURE|Downstaging procedures containing immunotherapy|Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously according to the manufacturer's instruction. Other combination regimens, such as locoregional therapies or targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers.
40930766|NCT05475613|PROCEDURE|Liver transplantation|Patients with successful downstaging therapy at the end of the observation phase will enroll and undergo liver transplantation unless major medical or oncological contraindications should occur during the waiting phase.
40930767|NCT00082472|DRUG|Doxorubicin HCl Inhalation Solution|
40930768|NCT00082472|DRUG|Docetaxel|
40930769|NCT00082472|DRUG|Cisplatin|
41278496|NCT04879329|DRUG|pembrolizumab|Given by IV on Day 1 of each 6-week cycle.
40930770|NCT05897970|DIAGNOSTIC_TEST|Return-to-sport (RTS) follow-up|All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
40930771|NCT02503995|BEHAVIORAL|Physical Exercise Participation|
40930772|NCT02051816|DEVICE|Video Laryngoscopy|
40930773|NCT02051816|DEVICE|Apneic Oxygenation|
40930774|NCT02051816|DEVICE|Direct Laryngoscopy|
40930775|NCT02051816|DEVICE|No Apneic Oxygenation|
41278497|NCT02240862|DEVICE|Carotid Artery Stent|Placement of a stent within the carotid artery
41278498|NCT05142241|PROCEDURE|Biopsy|Undergo biopsy
41278499|NCT05142241|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40930776|NCT01836874|DRUG|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
40930777|NCT05778383|DIETARY_SUPPLEMENT|Zinc Acetate|Each participant allocated in the intervention arm will be treated as Standard of Care and will be supplemented with 240mg of Zinc Acetate
40930778|NCT00005566|BEHAVIORAL|Desperation Scale|
40930779|NCT01150474|DRUG|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
40930780|NCT01150474|DRUG|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
40930781|NCT05084495|DIAGNOSTIC_TEST|Global peak atrial longitudinal strain and ECG|During the follow-up period the patient will have four clinical visits, during which clinical data, advanced echocardiographic data (strain and speckle tracking) and ECGs (Glasgow criteria) will be collected
40930782|NCT05649202|OTHER|Xpert® HCV Viral test|an additional sample of 5 ml of blood will be taken for real-time HCV PCR by Xpert®, in addition to the blood samples taken as part of routine care.
40930783|NCT05649202|OTHER|FibroScan® test|A non invasive test made on a small area of skin coated with a gel
40930784|NCT04973189|DRUG|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.
40930785|NCT04973189|DRUG|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.
41278500|NCT05142241|PROCEDURE|Computed Tomography|Undergo CT
41278501|NCT05142241|DRUG|Talazoparib|Given PO
41278502|NCT05142241|DRUG|Temozolomide|Given PO
41278503|NCT03785600|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
41278504|NCT03785600|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
41278505|NCT04754087|DEVICE|Vivacit-E and Longevity (HXLPE) Liners|This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.
40930786|NCT04973189|DRUG|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.
40930787|NCT04973189|DRUG|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
40930788|NCT01176942|DIETARY_SUPPLEMENT|Probiotic bacterium Bifidobacterium lactis|Probiotic placebo controlled intervention
40930789|NCT01663753|DEVICE|18F-FDG-PET|
40930790|NCT01081548|DRUG|atorvastatin|20 mg
40930791|NCT01081548|DRUG|atorvastatin|20 mg
41278506|NCT04704934|DRUG|Trastuzumab deruxtecan|6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
41278507|NCT04704934|DRUG|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
41278508|NCT04704934|DRUG|Paclitaxel|80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
40930792|NCT01871064|DEVICE|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
40930793|NCT03279471|DRUG|Sertraline|Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks based on their tolerability to the medication. Dosing is capped at 125mg/day.
40930794|NCT03279471|BEHAVIORAL|CBT/BIACA|Participants receive 16 weeks of BIACA therapy.
40930795|NCT03279471|DRUG|Placebo|Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
40930796|NCT01106469|DRUG|JNJ-41443532|25mg tablet once daily
40930797|NCT01106469|DRUG|JNJ-41443532|250mg tablet once daily
40930798|NCT01106469|DRUG|JNJ-41443532|1500mg once daily (with 250mg tablets)
41278509|NCT04258618|BEHAVIORAL|CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS|Cognitive Behavioral Therapy for insomnia (CBT-I) with rTMS (repetitive Transcranial Magnetic Stimulation) will be performed as part of this study by the PI. This includes weekly, one hour sessions addressing sleep for 6 weeks.
41278510|NCT04258618|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants in this study will be undergoing repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder as part of their clinical treatment. This involves magnetic stimulation with specific settings to a specific region of the brain to help treat depression. Treatment time ranges, but is around 30 minutes per session and occurs 5 days a week for 6 weeks.
40930799|NCT01106469|DRUG|JNJ-41443532|100mg tablet once daily
41278511|NCT04516681|DRUG|Ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
41278512|NCT04516681|DRUG|FOLFOX Protocol|Oxaliplatin 130 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks
41278513|NCT04516681|DRUG|Adebrelimab|20mg/Kg intravenously every 3 weeks
41278514|NCT04417660|DRUG|M7824|Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
41278515|NCT02595905|DRUG|Cisplatin|Given IV
41128453|NCT04255212|OTHER|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
41449215|NCT04609280|RADIATION|Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)|Delivered over 6 weeks in 30 daily fractions in the adjuvant setting and over 6.5 weeks in 33 daily fractions in the definitive setting. In the adjuvant setting, areas with positive surgical margins or nodal stations with pathologic extranodal extension will receive 63 Gy. Margin negative resection bed and involved nodal stations without extranodal extension will receive 54 Gy. Low-risk elective nodal volumes (i.e. ceCTV) will receive 51 Gy. In the definitive setting, gross disease will receive 69.96 Gy, areas at high-risk for subclinical disease will receive 60 Gy, and areas at low-risk for harboring subclinical disease (i.e. ceCTV) will receive 52.8 Gy.
40930800|NCT01106469|DRUG|JNJ-41443532|1000mg once daily (with 250mg tablets)
40930801|NCT01106469|DRUG|Placebo|Matching placebo
40930802|NCT01106469|DRUG|JNJ-41443532|500mg once daily (with 250mg tablets)
40930803|NCT04173208|OTHER|Fecal microbial transplant|Fecal microbial transplant
40755118|NCT01950598|PROCEDURE|Boston KPro type I - fresh graft|Boston KPro mounted on fresh corneal carrier graft for implantation
40755119|NCT01950598|PROCEDURE|Boston KPro type I surgery - frozen graft|Boston KPro mounted on frozen corneal carrier graft for implantation
40755120|NCT03468465|DRUG|Solifenacin Succinate|10 mg tablet daily during 75 days maximum
40930804|NCT04173208|OTHER|Placebo|Placebo
40930805|NCT04944862|BIOLOGICAL|CDX-0159|administered intravenously
40930806|NCT04944862|DRUG|Normal saline|administered intravenously
41128454|NCT01647932|DRUG|hydrochlorothiazide|hydrochlorothiazide according to clearance of creatinine; \>50ml/min 25mg daily, 20-50ml/min 50mg daily amd \<20ml/min 100mg daily.
41128455|NCT01647932|DRUG|Placebo|Placebo according to clearance of creatinine; \>50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd \<20ml/min 2 pills daily.
41128456|NCT04394897|COMBINATION_PRODUCT|Remifentanil-Propofol admixture|
41278516|NCT02595905|OTHER|Laboratory Biomarker Analysis|Correlative studies
41278517|NCT02595905|OTHER|Placebo Administration|Given PO
40755121|NCT03468465|DEVICE|Neuro-Muscular Stimulators (NMS)|Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
40930807|NCT00479583|DRUG|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
40930808|NCT00479583|DRUG|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
41128457|NCT05999682|OTHER|apigenin|Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
40930809|NCT01989260|DEVICE|Anti-adhesive gel|4mls of anti-adhesive gel coated to the randomized ovary
40930810|NCT01174433|DEVICE|Tryton|Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
40930811|NCT01214174|DRUG|IBI-10090|
40930812|NCT03266198|OTHER|No intervention|No intervention
40930813|NCT03486275|DEVICE|Hygie|Prototype video game called Hygie, accessible on the Internet, on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
40930814|NCT03486275|DEVICE|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva), about the 5 most common reasons of consultation in general practice, accessible on the Internet.
40755122|NCT02379897|OTHER|Diet|
41128458|NCT05999682|OTHER|sterilized water|Intragastric tube injection of 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
40755123|NCT05591287|PROCEDURE|Contrast enhanced harmonic Endoscopic Ultrasound|Solid pancreatic masses suspected for PDAC detected by cross-sectional imaging and confirmed at EUS will be enrolled. The
41128459|NCT00294736|DRUG|Tarceva|Dose Escalation: 150-350+ mg/day
41128460|NCT03529994|OTHER|Enrollment|All infants enrolled will have work of breathing assessed.
41128461|NCT00087022|BIOLOGICAL|girentuximab|Given IV
41128462|NCT00087022|OTHER|placebo|Given IV
41128463|NCT00476463|DRUG|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
40930815|NCT03590431|DIETARY_SUPPLEMENT|extrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine, low protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 50 µg/L. The iodine content of the extrinsically labelled milk will be adjusted to the required concentration (same as intrinsic iodine milk) by adding iodine in form of potassium iodide.
40930816|NCT03590431|DIETARY_SUPPLEMENT|intrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine, high protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 600 µg/L. This concentration will define final supplemental iodine given to the participants (adapting the total portion size).
40930817|NCT03590431|DIETARY_SUPPLEMENT|water iodine solution|300 ml water delivering ≈ 200 µg iodine (control)
40930818|NCT01723696|DIETARY_SUPPLEMENT|Vitamin C +prenatal vitamin|Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
40930819|NCT01723696|DIETARY_SUPPLEMENT|Placebo tablet+prenatal vitamin|
40930820|NCT00736177|PROCEDURE|Embryo cryopreservation|Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.
40930821|NCT00736177|PROCEDURE|Fresh embryo transfer|Subjects in the Control group will receive fresh embryo transfer.
40930822|NCT02927067|DRUG|Maribavir|Participants will receive 400 mg of maribavir BID orally.
40930823|NCT02927067|DRUG|Valganciclovir|Participants will receive valganciclovir tablets orally.
40930824|NCT02927067|OTHER|Placebo|Participants will receive placebo tablets matched to either maribavir or valganciclovir.
40930825|NCT06374251|PROCEDURE|Discussion|Participate in narrative medicine sessions
40930826|NCT06374251|OTHER|Interview|Ancillary studies
40930827|NCT06374251|OTHER|Survey Administration|Ancillary studies
40930828|NCT03538574|BEHAVIORAL|CBT-I|CBT-I is a behavioral treatment for insomnia
40930829|NCT03538574|BEHAVIORAL|MAP-I|MAP-I is a mindfulness meditation treatment for insomnia
40930830|NCT01705782|BIOLOGICAL|E. coli endotoxin, US standard|
40930831|NCT00738192|DRUG|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
40930832|NCT00738192|DRUG|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
40930833|NCT00738192|DRUG|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
40930834|NCT04906915|DRUG|Ketamine|The efficacy of ketamine was assessed by calculating oxygen supply and consumption
40930835|NCT00531986|DRUG|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
40930836|NCT00531986|DRUG|HAART|Patients will continued their current HAART
40930837|NCT01813045|PROCEDURE|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
41278518|NCT02595905|DRUG|Veliparib|Given PO
41278519|NCT04630028|DRUG|Ustekinumab Dose Based on BSA and Body Weight|As per BSA and body weight Ustekinumab will be administered SC and IV.
41278520|NCT04630028|DRUG|Matching Placebo|Placebo will be administered subcutaneously.
41278521|NCT04586426|DRUG|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
40930838|NCT01813045|RADIATION|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
40930839|NCT01813045|RADIATION|CT-coronary angiogram|CT-coronary angiogram following CT-PET scan. Standard protocol.
40930840|NCT03397654|DRUG|Pembrolizumab|Pembrolizumab solution
40930841|NCT03397654|COMBINATION_PRODUCT|Trans-arterial chemoembolization|Doxorubicin injected through the hepatic blood supply directly to the cancer-affected part of the liver, then gelatin sponge particles injected to block the blood vessels supplying the tumour
40930842|NCT01415193|PROCEDURE|Selective Tibial Nerve block|Use of selective pain block.
40930843|NCT01415193|PROCEDURE|Sciatic Nerve Block|Use of Sciatic Nerve Block
40930844|NCT02176720|DRUG|FDOPA PET|\[18F\]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
40930845|NCT02302430|DRUG|Oxytocin|20 International Units Intranasal Oxytocin
40930846|NCT02302430|OTHER|Placebo comparator|Saline nasal spray
40930847|NCT03976180|DEVICE|Stadard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care
40930848|NCT03976180|DEVICE|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
40930849|NCT03976180|DEVICE|HFNO with intermediate FiO2 (50%)|In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
41278522|NCT04586426|DRUG|Teclistamab|Teclistamab will be administered by SC injection.
41278523|NCT04586426|DRUG|Daratumumab|Daratumumab will be administered by SC injection.
40755124|NCT04740346|DIAGNOSTIC_TEST|Computed tomography, Chest X-ray, and blood test|CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
40755125|NCT03377998|OTHER|skin biopsy|Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
40755126|NCT02992431|BEHAVIORAL|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
40755127|NCT02992431|OTHER|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
40755128|NCT02326688|OTHER|Kinematic analysis of trunk compensation|
40755129|NCT01467856|PROCEDURE|PAP Device Procedure|"Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.~Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP \> 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic."
40755130|NCT05051358|PROCEDURE|Therapeutic Endoscopic Ultrasound|Therapeutic Endoscopic Ultrasound or Interventional Endoscopy for Gastrointestinal Indications
40755131|NCT01585701|BIOLOGICAL|AT13148|Days 1, 3, 5 of a weekly schedule in dose escalation cohorts of three patients. Continuous dosing until progression or unacceptable toxicity develops up to a maximum of 12 cycles.
40755132|NCT04014192|DRUG|Dapagliflozin|Treated with dapagliflozin 10mg/d for one week.
40930850|NCT03976180|DEVICE|HFNO with high FiO2 (100%)|In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
40930851|NCT04958512|DRUG|Yangxue Qingnao pill|The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
41278524|NCT05132582|DRUG|Tucatinib|300mg given by mouth (orally) twice daily
41278525|NCT05132582|DRUG|Trastuzumab|6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
41278526|NCT05132582|DRUG|Pertuzumab|420mg given by IV every 21 days
40930852|NCT04958512|DRUG|Hydergotoxine mesylate tablets|The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months
40930853|NCT04958512|OTHER|blank control group|There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.
40930854|NCT00125684|DRUG|morphine|
41278527|NCT05132582|DRUG|Combination product: Trastuzumab + Pertuzumab|600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
40755133|NCT04014192|DRUG|Empagliflozin|Treated with empagliflozin 10mg/d for one week.
40755134|NCT04014192|DRUG|Canagliflozin|Treated with canagliflozin 100mg/d for one week.
40755135|NCT00000778|DRUG|Isoniazid|
40755136|NCT00000778|DRUG|Pyridoxine hydrochloride|
40755137|NCT00000778|DRUG|Levofloxacin|
41278528|NCT05132582|DRUG|Placebo|Given orally twice daily
41449216|NCT00651131|DRUG|daptomycin|daptomycin i.v. 4 mg/kg q24h for 7-14 days
40930855|NCT04482985|DRUG|Meclizine Hydrochloride|Meclzine is given to all study participants to prevent seasickness. Meclizine plasma levels are determined from both the meclizine responders and non responders group.
40930856|NCT03579654|BIOLOGICAL|Proscavax|Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
40930857|NCT05505994|DRUG|DWP16001|DWP16001 A mg tablet
41128464|NCT04362046|PROCEDURE|Hysteroscopic uterine resection|"Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications."
41128465|NCT01953224|BEHAVIORAL|Game-based intervention|"Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback."
41128466|NCT01953224|DEVICE|Smartphone|
40930858|NCT05505994|DRUG|Dapagliflozin|Dapagliflozin tablet
40930859|NCT05505994|DRUG|DWP16001 Placebo|DWP16001 Placebo tablet
40930860|NCT05505994|DRUG|Dapagliflozin Placebo|Dapagliflozin Placebo tablet
40930861|NCT01101191|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
40930862|NCT01101191|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
41128467|NCT06179667|BEHAVIORAL|Mobile Application|"It is aimed to develop the mobile application to address the problems and training needs of informal caregivers regarding the caregiving process. In this context, in order to determine the needs of caregivers, face-to-face in-depth interviews will be held with caregivers using the Semi-Structured Questionnaire for Qualitative Interviews at the University of Health Sciences GTRH Geriatrics Department. The content of the mobile application will be created according to the topics determined as a result of qualitative research. Technical development of the application will be carried out by the web application designer."
40930863|NCT03410264|BEHAVIORAL|CR-EXP|See arm/group descriptions
40930864|NCT03410264|BEHAVIORAL|EXP-CR|See arm/group descriptions
40930865|NCT03410264|BEHAVIORAL|Stress Management|See arm/group descriptions
40930866|NCT00400478|DRUG|Rituximab|Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
40930867|NCT04459429|DEVICE|Change of cannula size|During nasal High Flow Therapy with fixed flow of 8 l/min, the cannula size will be changed from smaller-to-larger or larger-to-smaller
40930868|NCT02195687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
40930869|NCT02195687|DRUG|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
40930870|NCT06123182|BEHAVIORAL|Episodic Future Thinking|During the audio recorded guided imagery exercise participants will be asked to think in detail of a future (6 months to a year) where they have made healthy choices regarding physical activity and are physically active.
40930871|NCT06123182|BEHAVIORAL|Episodic Recent Thinking|During the audio recorded guided imagery exercise participants will be asked to think about a routine weekly activity.
40930872|NCT06123182|BEHAVIORAL|Positive Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the positive outcomes and sensations associated with an exercise bout.
40930873|NCT06123182|BEHAVIORAL|Neutral Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the physical sensations associated with an exercise bout.
40930874|NCT06123182|BEHAVIORAL|HIIT Exercise Intervention|"The high intensity interval training (HIIT) will be conducted 2 times per week for 6 weeks. The duration of each individual exercise session will last about 45 minutes. After the 5-minute warm-up at 30% peak workload, HIIT will consist of repeated 1-minute high intensity bursts (on interval) alternated with 1-minute interval recovery (off interval) for 25 minutes. The on interval will begin at 80% of peak watts (range: 75%-85%) followed by the off interval at 10% of peak watts. The session will end with up to 10 minute cool-down at 20% peak workload."
40930875|NCT01169597|DRUG|prednisone|prednisone 12.5 mg daily po
41128468|NCT02111096|DRUG|LY2409021|Administered orally
41128469|NCT02111096|DRUG|Sitagliptin|Administered orally
41128470|NCT02111096|DRUG|Placebo|Administered orally
41128471|NCT02111096|DRUG|Metformin|Administered orally
41128472|NCT02111096|DRUG|Sulfonylurea|Administered orally
41128473|NCT03676413|DRUG|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study
40930876|NCT04879979|BEHAVIORAL|MAAT|MAAT consists of 8 weekly visits of 45 minutes duration and can be delivered effectively through videoconference technology (Vidyo). Participants will be asked to download the Vidyo App on their mobile phone or tablet. Vidyo is a HIPPA compliant, encrypted software with adequate bandwidth for highest quality videoconferencing intended for telehealth. It is the primary software for UPMC Telemedicine. Survivors are provided a workbook to reinforce learning, mastery and application of skills in daily life covered in each MAAT visit. The workbook provides reading structured within each of the 8 visits with guides for application of strategies as homework
40930877|NCT00005779|DRUG|Interleukin-12|
41128474|NCT03676413|DRUG|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the study
41128475|NCT03676413|DRUG|Placebo|twice daily inhalation throughout the study
41128476|NCT02909959|DRUG|Sulforaphane|The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
41128477|NCT02909959|DRUG|Placebo|Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
41128478|NCT00044564|DRUG|Bay 59-8862|75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
41128479|NCT05298358|BIOLOGICAL|RIC alloBMT w PTCy in refractory SSc|"The preparative regimen:~* Thymoglobulin 0.5 mg/kg IV day -9~* Thymoglobulin 2 mg/kg IV Days -8, -7~* Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5~* Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2~* Total body irradiation (TBI) 400cGy~* Day 0- infusion of unmanipulated bone marrow~The GVHD prophylaxis regimen:~* Cy 50 mg/kg IV Days 3, 4~* Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL. Sirolimus may be substituted for tacrolimus.~* Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35~* Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.~Supportive care:~* Mesna- 10 mg/kg/ IV Day 3, 4~* Patients will receive infection prophylaxis and treatment according to institutional guidelines."
41128480|NCT05769244|OTHER|near-infrared spectroscopy (NIRS)|NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
41128481|NCT03948295|DIETARY_SUPPLEMENT|Lipid Challenge|After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
41128482|NCT03220334|DRUG|Platelet rich plasma|The experimental group was treated with PRP for artificial gastric ulcer after ESD.
41128483|NCT03220334|DRUG|Normal saline|The control group was treated with normal saline for artificial gastric ulcer after ESD.
41128484|NCT05249842|DIAGNOSTIC_TEST|Spirometric evaluation|Evaluation of: forced vital capacity (FVC),, FEV1', FEV 1/FVC, FEF 25-75
41128485|NCT05249842|DIAGNOSTIC_TEST|Physical component summary|Evaluation of the physical component summary of SF-36 quality of life
41128486|NCT05249842|DIAGNOSTIC_TEST|6MWT|6 minute walk test
41128487|NCT04452201|BEHAVIORAL|Guided Participation|GP couples' participation together in development of communication competencies in the context of infant care will be supported by a handbook and telephone guidance structured for collaboration with the nurse/research assistant beginning at approximately 2 weeks of age. Two face-to-face sessions are expected prior to hospital discharge, followed by 5 or 6 monthly phone sessions. If the baby is inpatient at the time an intervention session is to take place, the session may be done face-to-face, if more convenient than a phone session for the parents.
41449217|NCT00194363|BEHAVIORAL|Strength training|13 weeks of supervised strength training (twice weekly for 90 minutes per session), 39 weeks of unsupervised strength training (twice weekly for 90 minutes per session)
40930878|NCT00005779|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
40930879|NCT06433596|OTHER|Platelet-rich plasma|3 injections of 10 cc of autologous Platelet Rich Plasma (PRP), weeks 1, 5 and 9
40930880|NCT06433596|OTHER|Shock waves therapy|6 sessions of focal shock waves, 1 per week
40930881|NCT06433596|OTHER|Placebo PRP|3 injections of 10 cc of saline solution, weeks 1, 5 and 9
40930882|NCT06433596|OTHER|Sham shock waves therapy|6 sessions of sham shock waves, 1 per week
40930883|NCT00174239|DRUG|cabergoline|
40930884|NCT00174239|DRUG|controlled-release levodopa / carbidopa|
40930885|NCT00136604|BIOLOGICAL|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
40755138|NCT01270555|DRUG|Bupropion SR|100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
40930886|NCT00136604|BIOLOGICAL|Mencevax ACWY|GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine
40930887|NCT00136604|BIOLOGICAL|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
40930888|NCT00136604|BIOLOGICAL|Meningitec|Wyeth's MenC CRM197 conjugated vaccine, Meningitec
40930889|NCT06161077|DIAGNOSTIC_TEST|Voice Biomarker Screening Too|The investigators will develop a screening tool using voice that can predict disease severity in idiopathic subglottic stenosis
40930890|NCT02362568|PROCEDURE|Ultrasound cervical exploration|The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
41128488|NCT00817154|BEHAVIORAL|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
41128489|NCT01105988|OTHER|Radiologic exams|FLT PET scan x 2 MRI scan x 2
41128490|NCT05777304|DEVICE|wearable device|IMU sensors and EMG sensors
41128491|NCT05014035|BEHAVIORAL|Resistance Exercise|This is an 8-week exercise program, delivered using a hybrid approach of in-person, in-home supervised exercise, and virtual delivery of exercise via zoom. Individuals will participate in resistance exercise 3 days per week for 8 weeks.
41128492|NCT04380558|OTHER|Pulmonary rehabilitation|"Patients will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
40755139|NCT01594372|PROCEDURE|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
40755140|NCT01594372|PROCEDURE|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
40930891|NCT02155946|DEVICE|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
40930892|NCT02155946|DEVICE|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
40930893|NCT05883826|BEHAVIORAL|sexual health training|The 16-hour sexual health training will be given for 4 weeks. Case discussions using the PLISSIT Model will be held in the training content.
40930894|NCT01363414|DRUG|0.18% sodium hyaluronate|one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
40930895|NCT01363414|DRUG|0.9% sodium chloride solution|one drop of sterile 0.9% sodium chloride solution in the other eye
40930896|NCT05236595|OTHER|Individualized drug matching per genetic disease|Patient phenotype and samples will be evaluated for individualized therapeutic drug development
40930897|NCT02402842|DRUG|Docetaxel, Cisplatin and 5-Fluorouracil|Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
40930898|NCT06032481|PROCEDURE|surgery|Patients confirmed cervical cancer were undergone radical hysterectomy with pelvic lymphadenectomy
40930899|NCT05249218|OTHER|Phase B - Extra 1 Phe exchange from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g
40930900|NCT05249218|OTHER|Phase C - Extra 2 Phe exchanges from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g
40930901|NCT05249218|OTHER|Phase D - Extra 1 Phe exchange from milk or yoghurt|Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt
40930902|NCT05249218|OTHER|Phase E - Extra 2 Phe exchanges from milk or yoghurt|Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily
40930903|NCT06136442|DRUG|Atogepant|atogepant in real life in Italy
40930904|NCT05399576|DRUG|Nicorandil|Prophylactically combined intracoronary of Nicorandil and verapamil
40930905|NCT05399576|DRUG|Saline|intracoronary of 4ml saline
40930906|NCT00708253|DEVICE|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
41128493|NCT06451016|DIETARY_SUPPLEMENT|Vitamin D supplements|70 mcg/day (equal to 2800 IU) of cholecalciferol
41128494|NCT06451016|DIETARY_SUPPLEMENT|Placebo|Matching Placebo
41128495|NCT00220649|DRUG|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
41128496|NCT03421301|DIETARY_SUPPLEMENT|dietary portfolio|The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.
41128497|NCT03074656|OTHER|Therapeutic drug monitoring|Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies
41128498|NCT03074656|OTHER|Standard care|Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
41128499|NCT03385031|OTHER|CBCT imaging|CBCT imaging at first and last fraction of radiotherapy treatment
41128500|NCT05839067|BEHAVIORAL|Care-HF|Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.
41128501|NCT00228475|DRUG|Pulmicort (budesonide) Turbuhaler|
41128502|NCT03024021|DEVICE|Near-infrared spectroscopy (NIRS) (INVOS®, Covidien)|As we start the targeted temperature management protocol (24 hours of hypothermia adjusted to 33-36 C and afterwards up to five days of normothermia \[36.5 C\]) NIRS sensor pads will be placed over the right and left frontal area. Regional cerebral oxygen values will be continuously recorded at the NIRS monitor. Tests to assess neurological outcome will be performed. Patients will be assessed in terms of neurological performance tests and regional cerebral oxygen.
41128503|NCT05454475|OTHER|Change the water injection temperature|Water injection is a routine procedure for endoscopy of small probe ultrasound, and our intervention is to change the water temperature and observe the effects of different water temperatures on patient safety and comfort.
41128504|NCT00934817|DRUG|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
41128505|NCT00934817|DRUG|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
41128506|NCT00893555|DRUG|voriconazole|TDM (through level of 2-5mg/L).
41128507|NCT00893555|DRUG|voriconazole (dosing according to the SPC)|No serum concentrations are determined
41128508|NCT05001659|OTHER|computer simulator and mannequin simulator|compared two different training simulators with respect to training effectiveness in ACLS training.
41128509|NCT02405702|OTHER|restrospective study|
41449218|NCT04738968|DEVICE|Cochlear implant|A cochlear implant is standard care for profoundly deaf persons. It enables hearing through electrical stimulation of the auditory nerve.
41128510|NCT04334317|DRUG|TAK-071|TAK-071 tablet.
41128511|NCT04334317|DRUG|Placebo|TAK-071 placebo-matching tablet.
41128512|NCT06081608|DIAGNOSTIC_TEST|kidney function test|blood sample for kidney function test
41128513|NCT00505336|DRUG|Eplerenone|oral Eplerenone titrated to 50mg for duration of 12 months
41128514|NCT00505336|OTHER|No additional treatment|normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers
41128515|NCT00505336|DRUG|Atorvastatin|oral Atorvastatin 40mg
41128516|NCT05474404|DIAGNOSTIC_TEST|Cervical smear test|collection of cervical cells using spatula
41128517|NCT02148705|DRUG|NexoBrid|
41128518|NCT02148705|PROCEDURE|Standard of Care (SOC)|
41128519|NCT02148705|DRUG|Gel Vehicle|
41128520|NCT04826406|DRUG|Camrelizumab combined Apatinib regimen|Camrelizumab 200mg iv every 2 weeks; Apatinib,250 mg/day.
41128521|NCT00570700|DRUG|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
41128522|NCT02005159|OTHER|Microbiological studies|
41128523|NCT04452383|DRUG|Ketamine + propofol|effect of adding ketamine to propofol for patients undergoing DISE surgery
41128524|NCT04452383|DRUG|propofol|effect of IV propofol alone for patients undergoing DISE surgery
41449219|NCT03887884|DRUG|CVT-301|Levodopa Inhalation Powder
41128525|NCT01485887|DRUG|Venlafaxine ER|Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
41278529|NCT06351358|DEVICE|Sculptra treatment|Subjects will receive treatment of Sculptra at baseline. Subjects will receive a second treatment of Sculptra at Week 4 visit. At the Week 8 visit, subjects will receive an optional treatment of Sculptra.
41278530|NCT06351358|DEVICE|Restylane Treatment|Subjects will receive treatment Restylane Lyft or Restylane Contour at baseline. Subjects will receive an optional touch-up of Restylane Lyft or Restylane Contour at Week 4 visit.
41278531|NCT04634552|DRUG|Talquetamab|Talquetamab will be administered SC until disease progression.
41278532|NCT04307667|BIOLOGICAL|Whole lung antigen challenge (WLAC)|Whole lung antigen challenge with cat hair, house dust mite, or short ragweed allergen extracts.
41128526|NCT03746613|DEVICE|HEARO|Robotic system for otological procedures
41128527|NCT02094560|DRUG|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
41128528|NCT03551600|PROCEDURE|Near-infrared spectroscopy (NIRS)|NIRS analyzes regional oxygen saturations (rSO2)
41128529|NCT05829512|OTHER|Validity and reliability study|Face-to-face questionnaire study
41128530|NCT06009393|DRUG|SHR-1918|Three administration
41128531|NCT01756924|DRUG|CEM-102|
41128532|NCT01756924|DRUG|IV or Oral standard of care antibiotics|
40919353|NCT06531551|OTHER|The group to which Acupressure will be applied in each fraction|Acupressure application protocol will be started after patient information. This process is planned to take 30 minutes.Before the application, approximately 20 seconds of warming and rubbing without direct pressure on the acupressure points will be performed to reduce tissue sensitivity and prepare the points for acupressure. Subsequently, the researcher will apply pressure with the thumb on the predetermined acupressure points, considering the individual's pain threshold, with 10 seconds of pressure followed by two seconds of relaxation without lifting the finger, in consecutive presses following the rhythm of breathing. A digital clock (belonging to the researcher) will be used to determine the duration of the acupressure application.
41128533|NCT01756924|DRUG|Rifampin|
41128534|NCT01777009|PROCEDURE|Primary Total Knee Replacement Surgery|Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
41128535|NCT01401218|OTHER|Electronic Medical Record (EMR) Review|"measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.~potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,"
41278533|NCT04307667|RADIATION|[18F]FEPPA|\[18F\]FEPPA is a radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia.
41278534|NCT05634577|DRUG|Mitotane|Given by PO
41278535|NCT05634577|DRUG|Pembrolizumab|Given by vein (IV)
41278536|NCT06066580|DRUG|Sevasemten|Sevasemten is administered orally once per day
41278537|NCT06003959|OTHER|Routine nursing care|Preterm infants in the control group did not receive any intervention other than the routine feeding protocol applied in the clinic.
41128536|NCT06167434|DEVICE|Future Cardia™ Insertable Cardiac Monitoring (ICM) System|The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.
41128537|NCT03414645|BIOLOGICAL|CAM-101 10%|fibrinogen-depleted human platelet lysate
41449220|NCT03887884|DRUG|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
41449221|NCT03774537|DRUG|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg
41449222|NCT03774537|DRUG|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
40919354|NCT04572230|DEVICE|Endovascular treatment of intracranial aneurysms using a flow-diverting stent|The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.
40919355|NCT04384081|DRUG|BI 456906|Solution for injection
40919356|NCT04384081|DRUG|Placebo|Solution for injection
40919357|NCT03399201|PROCEDURE|General anesthesia|induction with the intravenous anesthetic (Propofol) and maintenance with the inhalational anesthetic (Sevoflurane)
40919358|NCT03399201|PROCEDURE|Neuraxial anesthesia|Spinal anesthesia will be applied via the local anesthetic ( Bupivacaine).
40919359|NCT03399201|DIAGNOSTIC_TEST|Spirometer|Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)
40919360|NCT03523598|OTHER|Placebo gel + Normal Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be normal (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
40919361|NCT03523598|OTHER|Placebo Gel + Potassium Nitrate Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be normal tooth paste (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the 5% Potassium Nitrate gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
40919362|NCT03523598|OTHER|Potassium Nitrate Gel + Normal Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be Potassium Nitrate containing (Sensodyne).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
40919363|NCT03260049|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy
40919364|NCT03353740|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
40919365|NCT01700309|BEHAVIORAL|Young and Active|The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
40919366|NCT05411575|DRUG|Plerixafor 20 MG/ML [Mozobil]|Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
40919367|NCT05411575|OTHER|Placebo|Placebo continuous intravenous infusion for 7 days
40919368|NCT05998889|BEHAVIORAL|Experimental group|Education, Graded Pain Exposure Exercises and Graded Motor Imagery. One supervision a week/9 weeks + exercises at home + encourage returning relevant activities despite pain
40919369|NCT05998889|BEHAVIORAL|Control group|Graded Motor Imagery following the GRaMI protocol, One supervision a week/9 weeks + exercises at home, activities encourage but pain contingency.
40919370|NCT05636800|DEVICE|Swift System|"Localized microwave energy applied to the distinct AK lesion. Each subject will receive treatment for a maximum of 2 visits (4-week interval between treatment).~For AK lesions assessed as Thin AK (Olsen Grades 1 and 2): Set at 3W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions). There will be approximately 20 seconds between each repeat dose.~For AK lesions assessed as Thick AK (Olsen Grade 3): Set at 4W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions).~As the AK lesions may be larger than 3mm in diameter, the dose administered to one AK lesion may require overlapping applications with the applicator tip. Ensure there is approximately 20 seconds between each repeat dose administered"
40919371|NCT05807165|RADIATION|Hypofractionated Stereotactic Radiotherapy (HF-SRT)|The administered dose-fractionation schemes range between 30 and 35 Gy delivered within two weeks with a dose per fractionation ranging from 6 to 7 Gy.
40919372|NCT05807165|RADIATION|Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) plus memantine|"* The prescribed dose is 30 Gy delivered in 12 fractions for therapeutic or adjuvant WBRT.~* The prescription of memantine for finally twice-daily dosing will be prescribed as follows:~  * During the first 3 weeks concurrent with the delivery of hippocampus-sparing WBRT, 5-mg morning dose will be initially prescribed \[Week 1 -3\]~ * 5-mg twice a day in the following week \[Week 4\]~ * A morning dose of 10 mg and an evening dose of 5 mg in the following week \[Week 5\]~ * 10-mg twice a day for the subsequent weeks up to Week 24 \[Week 6 - 24\]"
41278538|NCT06003959|OTHER|breastfeeding support system|The body weight of preterm infants in the experimental group was measured and recorded each morning before their first feeding. Mothers of these infants were asked to complete the Mother-Infant Attachment Scale (MIAS) prior to the procedure. The physician determined the appropriate amount of breast milk the infant should receive during feeding. Before each feeding, the neonatal nurse ensured the sterile preparation of the milk and transferred it to the Breastfeeding Support System. The mothers were then prepared for the procedure, with the neonatal nurse explaining how the breastfeeding support system worked. Once both the mother and baby were ready, the baby was placed at the mother's breast. After feeding, the mothers were asked to complete the MIAS again.
40755141|NCT04286139|BEHAVIORAL|SHAPE|The SHAPE intervention provides information for carers, and maintains the dignity and autonomy of the person with dementia, supporting them in planning for the future with their family. The person with dementia attends an online 10 week facilitator lead group based course. It is designed to develop self-management skills in areas including decision-making, symptom management and social interaction. It also provides information on the disease process and the development of healthy behaviors in a supportive learning environment to prevent problems that are common in the later stages of the disease. The adjunctive e-learning platform for carers provides the same information that the person with dementia receives plus additional material and signposting to support them in their role. This will empower the whole family to support and enable more effective self-management by the person with dementia, and enhance their ability to plan ahead together and make key decisions jointly.
40919373|NCT00257257|DRUG|Rimonabant (SR141716)|
40919374|NCT01640392|BEHAVIORAL|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
40919375|NCT00004913|DRUG|cisplatin|
40919376|NCT00004913|DRUG|docetaxel|
40919377|NCT00004913|DRUG|fluorouracil|
40919378|NCT00004913|DRUG|leucovorin calcium|
40919379|NCT03084783|DRUG|Dexamethasone|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
40919380|NCT05437302|DEVICE|prism spectacle|a prism is dispensed in prescription glasses
40919381|NCT06250335|OTHER|Prebiotic Food-Enriched Diet|Given by PO
40919382|NCT06250335|DRUG|Ipilimumab|Given by IV
40919383|NCT06250335|DRUG|Nivolumab|Given by IV
40919384|NCT01227135|DRUG|hydroxychloroquine|
40919385|NCT01227135|DRUG|imatinib mesylate|
40919386|NCT01227135|GENETIC|cytogenetic analysis|
40919387|NCT01227135|GENETIC|polymerase chain reaction|
40919388|NCT01227135|OTHER|laboratory biomarker analysis|
40919389|NCT01227135|OTHER|pharmacological study|
40919390|NCT03560518|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration)
40919391|NCT03560518|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration)
41128538|NCT03414645|BIOLOGICAL|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
41128539|NCT03414645|BIOLOGICAL|CAM-101 30%|fibrinogen-depleted human platelet lysate
41128540|NCT05174520|OTHER|Routine Physical Therapy|Routine physical therapy will be provided to group A for 25 minutes thrice a week for 4 weeks.
41128541|NCT05174520|OTHER|Muscle Energy Technique|Muscle Energy technique along with Routine physical therapy will be provided to group B for40 minutes thrice a week for 4 weeks.
41128542|NCT00736463|DRUG|Simvastatin|One arm of randomized crossover
41128543|NCT00736463|DRUG|Atorvastatin 80 mg|Second arm of randomized crossover
41128544|NCT00073372|DRUG|Abciximab|
41128545|NCT02254759|DRUG|Midazolam, IV|2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).
41128546|NCT02254759|DRUG|Midazolam, oral|0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.
41128547|NCT02254759|DRUG|RO5186582|RO5186582 120 mg film-coated release tablet.
41128548|NCT00692913|DRUG|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
41128549|NCT00692913|DIETARY_SUPPLEMENT|Calcium Supplement 500 mg|"Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day)."
41128550|NCT00692913|OTHER|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
41128551|NCT00258609|DRUG|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
41128552|NCT05461235|DRUG|Pembrolizumab|2mg/kg or 200mg,iv,q3w
41449223|NCT04636034|PROCEDURE|Sphenopalatine Ganglion Block with Local Anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL
41449224|NCT04636034|PROCEDURE|Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)|Block performed with bilaterally inserted q-tips with isotone NaCl
41128553|NCT05461235|DRUG|Nivolumab|3mg/kg or 240mg,iv,q2w
41449225|NCT04636034|PROCEDURE|"Sham-block with Placebo (Isotone NaCl)"|Block performed with bilaterally inserted q-tips with isotone NaCl. The q-tips are inserted a maximum of 3 cm into the nasopharynx thus not reaching the mucus above the ganglion.
40919392|NCT03406741|BEHAVIORAL|psychometric evaluation|Wechsler type composite scales (WISC)
40919393|NCT03406741|BEHAVIORAL|neuropsychological evaluation|Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
40919394|NCT01331252|OTHER|semi-recumbent|Patient rests in a semi-recumbent body position
40919395|NCT01331252|OTHER|supine|Patient rests in a supine position
40919396|NCT00496600|DRUG|Patupilone|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
40919397|NCT00496600|DRUG|RAD001|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
40919398|NCT00490529|BIOLOGICAL|CpG-MCL vaccine|CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection.
40919399|NCT00490529|BIOLOGICAL|PF-3512676|PF-03152676 is a synthetic immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) moledule containing unmethylated cytosine and guanine (CpG) motifs. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of antitumor immune reactions.
40919400|NCT00490529|PROCEDURE|Vaccine-primed T-cells|Vaccine primed T-cells are the post-vaccination leukapheresis harvest of peripheral blood mononuclear cells. Each collection is approx 1 x 10e10 CD3+ T-cells.
40930907|NCT00708253|DEVICE|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
40930908|NCT04059367|DRUG|NNC9204-1177|Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
40930909|NCT04059367|DRUG|Cocktail of 5 already approved drugs|5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study
40930910|NCT01751802|DRUG|Ecopipam|Antagonist of the dopamine D1 receptor
40930911|NCT01751802|DRUG|Placebo|Placebo for Ecopipam
40930912|NCT03230305|OTHER|Ethnographic interview|"If a patient is invited to participate in the a clinical trial, inclusion's status (included or/not) will be sought.~* If included: an ethnographic interview will be held with patient (or his representant) who agreed to participate in the clinical trial, his family caregivers, his physician(s) in charge of him and the trial and, and clinical studies technician responsible for management.~* If not included, an ethnographic interview has offered to him, his caregivers, his physician(s) in charge of him and the trial and clinical studies technician responsible for management. In parallel, the reasons for non-inclusion are collected from a pre-established epidemiological questionnaire.~If a patient is not invited to participate,an ethnographic interview will be held with his physician(s) in charge of him and the clinical trial and with clinical studies technician responsible for management.The reasons for non-invitation will be collected from an epidemiological survey multiple choices."
40930913|NCT03745430|DRUG|Ramucirumab|8 mg/kg (days 1 and 15, q4w) until disease progression
40930914|NCT04038203|DEVICE|Resonance Raman Spectroscopy (RPS)|RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
40930915|NCT00005031|DRUG|irofulven|
40930916|NCT06408155|OTHER|Isometric Task|The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.
40930917|NCT01644370|DRUG|HAART|as per Thai HIV Treatment guidelines
41278539|NCT03748641|DRUG|Niraparib|Participants will receive niraparib 200 mg capsules or tablets once daily.
41278540|NCT03748641|DRUG|Abiraterone Acetate|Participants will receive AA 1000 mg tablets once daily.
41278541|NCT03748641|DRUG|Prednisone|Participants will receive prednisone 10 mg tablets daily.
41278542|NCT03748641|DRUG|Placebo|Participants will receive matching placebo once daily.
40930918|NCT03787043|DRUG|FDC(MP-513 10mg/Metformin XR 750mg)|
40930919|NCT02859818|OTHER|therapeutic education program|
40930920|NCT01884727|DIETARY_SUPPLEMENT|Salt Water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
41128554|NCT05461235|DRUG|Sintilimab|200mg,iv,q3w
41278543|NCT03748641|DRUG|New Formulation of Niraparib and Abiraterone Acetate (AA)|Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
41278544|NCT04882098|DRUG|Guselkumab|Participants will receive guselkumab as SC injection.
41278545|NCT04882098|DRUG|Placebo|Participants will receive matching placebo as SC injection.
41128555|NCT05461235|DRUG|Toripalimab|3mg/kg or 240mg,iv,q2w
41128556|NCT05461235|DRUG|Camrelizumab|200mg,iv,q2w or q3w;3mg/kg,iv,q3w
41128557|NCT05461235|DRUG|Tislelizumab|200mg,iv,q3w
41128558|NCT05461235|BIOLOGICAL|NK-Cell or DC-Cell|50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10\^6 cells/Kg) was completed on day 14.
41128559|NCT00527267|DRUG|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
41128560|NCT00527267|DRUG|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
41128561|NCT02330588|BEHAVIORAL|Eat It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention\*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~\*Two brief questions about children's grain portion sizes and sugar sweetened beverage intake were presented."
41128562|NCT02330588|BEHAVIORAL|Move It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention\*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~\*Two brief questions about children's moderate-to-vigorous physical activity (MVPA) and screen time were presented."
41128563|NCT02330588|BEHAVIORAL|eHealth Control|The eHealth Control group (1) screened children's weight status, and (2) provided parents with the opportunity select resources and services to help prevent obesity in children.
41128564|NCT04105816|DEVICE|892.1550 Ultrasonic pulsed doppler imaging system|Use of the ultrasound to measure quadriceps volume
41128565|NCT04105816|DIAGNOSTIC_TEST|Thigh circumference measurement|Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
41128566|NCT01006772|OTHER|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
41128567|NCT02488148|BEHAVIORAL|Hot yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
41128568|NCT02488148|BEHAVIORAL|Non-heated yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
41128569|NCT02701296|DRUG|Ropivacaine with Epinephrine|Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles
41128570|NCT02701296|DRUG|Ropivacaine|Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
41128571|NCT01664741|DRUG|Nicotine patch - transdermal|21 mg patch
41128572|NCT01664741|DRUG|placebo|
41128573|NCT00476905|DEVICE|Spectral Diagnosis Probe|The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
41128574|NCT05602207|DRUG|Abrocitinib|100 mg Abrocitinib once daily (QD) for 12 weeks
41128575|NCT04977700|BEHAVIORAL|Intervention Group|Test the developed algorithm that delivers location-based, tailored sun safety advice to Strava users through Strava comments for acceptability, ways of interacting with it, and barriers/willingness to allowing access.
41278546|NCT02951598|DRUG|Florbetapir F 18 PET Scan|Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
41278547|NCT06100432|DRUG|DLBS5055 200mg|1x1 caplet
41278548|NCT06100432|DRUG|Placebo DLBS5055|1x1 caplet
41449226|NCT04039022|DRUG|AXS-05 (dextromethorphan and bupropion) oral tablets|Oral tablets, taken twice daily for up to 12 months.
41449227|NCT01554397|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
40919401|NCT00490529|PROCEDURE|Autologous hematopoietic stem cell transplant (HSCT)|Regular medical procedure
41449228|NCT01554397|DRUG|Cisplatin|Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
40919402|NCT00490529|DRUG|Rituximab|375 mg/m² by infusion
40919403|NCT00490529|DRUG|Standard induction chemotherapy|Patient-specific, regular medical care treatment as determined by treating oncologist
41449229|NCT00243347|DRUG|AZD2171|oral tablet
41449230|NCT03911206|BEHAVIORAL|Inspiratory muscle training (IMT)|IMT exercises at home will gradually ramp up
41128576|NCT06104423|DRUG|Nebivolol 5 mg|1 tablet of study medication to be administered orally according to instructions of Investigator.
41128577|NCT06104423|DRUG|Ramipril 2.5/5/10 mg|1 tablet of study medication to be administered orally according to instructions of Investigator.
41128578|NCT02848105|DRUG|VPA|Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
41128579|NCT05122468|PROCEDURE|Connective tissue Harvest and CAF|A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level. In control sites, the graft will be adapted to cover each exposed root to the CEJ, and stabilized with either 6-0 resorbable sutures (with the knot placed under the papillary area) or a non-resorbable suture with the knot on the palatal side. For suturing of the graft, interrupted sutures or sling sutures (anchored to periosteum apical to the graft and hanging around the neck of the experimental teeth) may be used.
41128580|NCT05122468|PROCEDURE|Connective tissue Harvest and Tunnel|"A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level.~In test sites, the graft should be slid through the tunnel. To accomplish the adequate position of the graft into the tunnel, 2 sutures are first placed, 1 at the most mesial and the other at the most distal aspect of the tunnel. The needles should pass underneath the tunnel and exit through the largest or most central gingival recession, the one through which the grafting tissue will be introduced. With these 2 sutures already inside the tunnel, the graft is bitten on both ends with vertical mattress sutures."
41128581|NCT06394206|OTHER|Specialized Unit|The participant will be visited every three months for one year
41128582|NCT06394206|OTHER|Usual Follow-Up|The participant will be visited as usual, it means they will be visited at Digestive Consultation
41128583|NCT00995592|BEHAVIORAL|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
41278549|NCT06100432|DRUG|Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)|1x2 caplets
41278550|NCT06100432|DRUG|Placebo Multivitamin|1x2 caplets
41278551|NCT05702034|DRUG|Milvexian|Milvexian will be administered orally.
41278552|NCT05702034|DRUG|Placebo|Placebo will be administered orally
41449231|NCT03911206|BEHAVIORAL|Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
41449232|NCT03911206|BEHAVIORAL|IMT and Exercise|Combining IMT training and exercise
41449233|NCT05105607|DRUG|D-4517.2|Subcutaneous (SC) injection
40919404|NCT00490529|DRUG|Cyclophosphamide|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
40919405|NCT00490529|DRUG|Filgrastim|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
40919406|NCT01583829|BEHAVIORAL|Neurofeedback|3 times per week for 45 minutes for a total of 40 sessions
40919407|NCT01583829|BEHAVIORAL|Cognitive Training|3 times per week for 45 minutes for a total of 40 sessions
40919408|NCT01583829|OTHER|Waitlist Control|6 30 minute calm breathing sessions over the course of 4 months
41278553|NCT05838573|DRUG|Metformin treatment|Participants assigned to the metformin group will receive 500mg metformin three times daily (tid) for 24 weeks. The initial dose will be 500 mg orally in the evening for the first two days, followed by an increase to 500mg twice a day for the subsequent two days. By day 5, the dosage will be further increased to 500mg tid. The highest tolerated dosage will be maintained for participants who could not tolerate the maximum dosage.
41449234|NCT04185272|BIOLOGICAL|analysis of BTN and BTNL status|analysis of BTN and BTNL expression in colon cancer and hepatic metastasis
40930921|NCT01884727|DIETARY_SUPPLEMENT|ASEA water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
41449235|NCT05163691|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
40930922|NCT04485416|DRUG|Eltrombopag|Eltrombopag is an orally administered small-molecule nonpeptide TPO-R agonist.
40930923|NCT06097143|OTHER|Flowable Giomer|Pre-reacted Glass Ionomer (PRG) filler is added to resin to create giomer, a dental adhesive material. Fluoride release and recharge, acid resistance, an anti-plaque effect, dentin remineralization, and acid buffering capacity are some of the benefits of giomer.
40930924|NCT06097143|OTHER|Flowable Nano-filled composite with S-PRG barrier coat|"Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.~The PRG Barrier Coat is a resinous coating substance that shields the enamel surface from demineralization brought on by acidic attack. Near the coated surface, S PRG filler ions in PRG Barrier Coat have been found to have an acid-neutralizing effect. F and Sr released by PRG Barrier Coat can be effectively absorbed by the tooth substrate to prevent demineralization thus hindering the progression of caries."
40930925|NCT06097143|OTHER|Flowable Nano-filled composite|Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.
40930926|NCT00531687|DRUG|Paclitaxel|"Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
40930927|NCT00531687|DRUG|Cisplatin|"cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
40930928|NCT00531687|DRUG|Gemcitabine|"gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered"
40930929|NCT04709939|OTHER|OPAT|Observation of patients who are discharged from the hospital on OPAT.
40930930|NCT04709939|OTHER|Focus Group|Focus group with infectious disease physicians who prescribe OPAT to patients but were not involved in the study.
40930931|NCT05669248|DIAGNOSTIC_TEST|mid covid-19 patients|Collect the patient's whole blood for testing
40930932|NCT01850602|DRUG|PA21|
40930933|NCT01850602|DRUG|Sevelamer hydrochloride|
40930934|NCT02539615|DEVICE|ForeCYTE Breast Aspirator|
40930935|NCT02717377|BEHAVIORAL|physical activity|
40930936|NCT00527670|PROCEDURE|Normal Controls|The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
40930937|NCT00527670|PROCEDURE|Recurrent Hernia|This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
40930938|NCT01744145|OTHER|Interventional 40-60|This group will receive the intervention aged 40-60
41449236|NCT05163691|DRUG|Placebo|GH001 Placebo administered via inhalation
41449237|NCT00170729|DRUG|Prednisolone acetate|
41449238|NCT05637762|OTHER|- EEG video recording or extension of an EEG video recording planned as part of the care - Wearing a connected heart rate and motion recording patch|The study consists of creating a database to develop an algorithm using machine learning methods.
41449239|NCT00873990|OTHER|Total etch bonding agent (5th generation)|"Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds."
40930939|NCT01744145|OTHER|Interventional 60 and above|This group will receive the intervention aged 60 and above.
40930940|NCT00822809|DRUG|Catumaxomab|"Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"
40930941|NCT00822809|DRUG|Prednisolone|25 mg premedication
40930942|NCT05587946|OTHER|Experimental group|In recent years, virtual reality has been widely used as a distraction practice in clinical medical care to relieve pain. Virtual reality is a method of viewing computer images to isolate the individual from real life for a while. Virtual reality glasses, consisting of a head-mounted display and glasses connected to a mobile phone, is a computer technology that creates a 3D environment. The virtual reality application, which was originally designed for entertainment purposes, started to be used in the medical field to reduce pain during invasive procedures in parallel with the developments in computer technologies. It is preferred in clinical practice as an easily accessible, non-invasive and inexpensive method.
40930943|NCT00184574|DRUG|biphasic insulin aspart|
41449240|NCT00873990|OTHER|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
40930944|NCT00184574|DRUG|metformin|
41128584|NCT02782507|BEHAVIORAL|CBT for Distressing visual hallucinations|"Eight to ten sessions of manualised CBT for distressing visual hallucinations based on existing treatment manuals (ie. Kingdon \& Turkington, 2004, Morrison et al., 2005), delivered over 8 to 12 weeks by CBT therapists.~Subjects will continue to receive treatment as usual throughout the therapy period and will receive appropriate prescription of medication if requested or clinically indicated."
41128585|NCT01433315|BEHAVIORAL|sleep restriction|restricted sleep
41128586|NCT01194011|BEHAVIORAL|questionnaire|This research tool was a written questionnaire, did not do invasive or the subjects are exposed to physical danger on the experiment, so now there is no harm in this research and test more than minimal risk.
41128587|NCT02130557|DRUG|Bosutinib|Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.\[1\] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
41128588|NCT02130557|DRUG|Imatinib|"Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator."
41128589|NCT00006241|BIOLOGICAL|filgrastim|
40930945|NCT04554004|DIAGNOSTIC_TEST|CCTA, CT-MPI, DSA, FFR|The patients who enrolled the study will undergo coronary CT angiography(CCTA), dynamic CT-MPI, invasive coronary angiography and invasive computation of fractional flow reserve (FFR)
40930946|NCT01574742|DRUG|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
40930947|NCT03667300|DRUG|Evogliptin|This group will take daily evogliptin 5mg per oral, not linagliptin.
40930948|NCT03667300|DRUG|Linagliptin|This group will take daily linagliptin 5mg per oral, not evogliptin
40930949|NCT01574001|BEHAVIORAL|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
40930950|NCT01574001|BEHAVIORAL|Antismoking intervention with minimal early follow-up|"Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke"
40930951|NCT01574001|BEHAVIORAL|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
40930952|NCT02021656|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily without regard to food
40930953|NCT06102018|DIAGNOSTIC_TEST|Collect blood and urine，pathological specimens if necessary|Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube
40930954|NCT02439333|DEVICE|Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)|Nasal high flow therapy
40930955|NCT02439333|DEVICE|nasal catheter or Venturi mask|Conventional oxygen therapy
40930956|NCT03402048|DRUG|Carboplatin|
40930957|NCT03402048|DRUG|Gemcitabine|
40930958|NCT03402048|DRUG|Pemetrexed|
40930959|NCT03402048|DRUG|Docetaxel|
40930960|NCT03402048|DRUG|Vinorelbine|
41128590|NCT00006241|DRUG|chemotherapy|
41128591|NCT00006241|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
41128592|NCT00006241|PROCEDURE|peripheral blood stem cell transplantation|
41128593|NCT00006241|RADIATION|radiation therapy|
41128594|NCT00152672|DEVICE|nCPAP vs oral appliance|
41128595|NCT04396782|OTHER|Physioterapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
41128596|NCT04396782|OTHER|standard physiotherapy rehabilitation|"static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.~This group will perform only five minutes of virtual reality play, but will not use their lower limbs. This way, the results of rehabilitation will not be affected and therapists and patients will be blinded."
40930961|NCT06233760|OTHER|Rheumatic diseases Mistreatment Scale (RDMS)|In 2012 Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS), prior to its application, translation, cultural adaptation, and validation were performed.
40930962|NCT06233760|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
41128597|NCT00257049|DRUG|levofloxacin|
41128598|NCT05845515|PROCEDURE|laparoscopic orchiopexy|laparoscopic or open orchiopexy and comparison between the two groups
41128599|NCT04788459|BIOLOGICAL|COVID-eVax|Plasmid DNA Vaccine for COVID-19
41128600|NCT04788459|DEVICE|Cliniporator® and EPSGun|IGEA Electroporation Device
41128601|NCT03788200|PROCEDURE|Bracing|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
41128602|NCT03788200|PROCEDURE|posterior C1-C2 instrumented fusion|Treatment arm #2 (posterior C1-2 instrumented fusion): Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
41128603|NCT03615612|OTHER|QuickSee refractive error assessment + glasses|QuickSee refractive error assessment + glasses
41128604|NCT05750966|DRUG|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours)|The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
41128605|NCT05750966|DRUG|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days)|The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
40919409|NCT02161900|OTHER|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
40919410|NCT00629967|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
40919411|NCT00629967|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
40919412|NCT01630993|OTHER|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
40919413|NCT05254977|DRUG|Standard Preparation|Any kind of intervention received to reduce adverse effects
40919414|NCT01604356|PROCEDURE|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device \[Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L\] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
40919415|NCT04655196|OTHER|SOLUS-D + weekly feedback by a coach|internet-based self-help
40919416|NCT04655196|OTHER|SOLUS-D + weekly automated messages|internet-based self-help
40919417|NCT00040300|DRUG|Racivir|
40919418|NCT00030459|DRUG|cisplatin|
40919419|NCT00030459|DRUG|mitomycin C|
40919420|NCT00030459|DRUG|vinblastine sulfate|
40919421|NCT00030459|DRUG|vinorelbine tartrate|
40919422|NCT00985699|GENETIC|polymorphism analysis|
40919423|NCT00985699|OTHER|laboratory biomarker analysis|
40919424|NCT00985699|OTHER|pharmacogenomic studies|
40919425|NCT03687463|DRUG|Decitabine|Decitabine for injection
40919426|NCT04798651|BIOLOGICAL|blood sample|28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
40919427|NCT04798651|BIOLOGICAL|cerebro-spinal fluid|1 ml of cerebro-spinal fluid
40919428|NCT05412602|PROCEDURE|full spine corrective protocol|36 chiropractic adjustments over 12 weeks (3 visits per week) with in office spinal traction on the 3D Denneroll Traction Table, as well as supplemental home exercises
40930963|NCT06233760|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
40930964|NCT06233760|OTHER|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
40930965|NCT06233760|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
40930966|NCT06233760|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
40930967|NCT06233760|OTHER|Big Five Inventory|The BFI-10 is a 10-item scale measuring the Big Five personality traits Extraversion, Agreeableness, Conscientiousness, Emotional Stability, and Openness.
40930968|NCT06233760|OTHER|Family APGAR Questionnaire|Family APGAR questionnaire is used to evaluate family function, in the context of family medical care
40930969|NCT00603772|DRUG|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
40930970|NCT00719264|DRUG|RAD001(everolimus)|10 mg qd
41128606|NCT00116649|DRUG|imiquimod cream|imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
41128607|NCT05228184|DRUG|Tirosint®-SOL|Dosage will be according to the USPI and Standard of Care.
41128608|NCT05228184|DRUG|Levothyroxine Sodium|Tablets will be crushed and dissolved in solution. Dosage will be according to the USPI and Standard of Care.
41128609|NCT05783531|OTHER|VMood|VMood is a digital mental health intervention adapted from an evidence-based in-person intervention. It uses supported self-management approaches, consisting of bibliotherapy (the Antidepressant Skills Workbook) and supportive coaching from a social worker that are provided via the smartphone app. The individual is supported in the use of the skills over the course of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.
41128610|NCT05783531|OTHER|Enhanced treatment as usual|Participants in the control arm will receive enhanced treatment as usual in the form of usual care from primary care centres and a brief introduction to depression video through the VMood app.
41128611|NCT03657316|BEHAVIORAL|nutrition education|"The content of the three days workshop:Healthy diet, Diet-related health risks and diseases, Physical activity The sustained multi-component program will be based on The three days nutritional and physical education workshop Enhanced physical education Involvement of the morning broadcast in provision of messages for students about nutrition and physical activity Brochure including key messages about diet and physical activity will be designed and sent to parents of the intervention classes of students A monthly telephone call or a text message will be sent to the parents to remind them about the commitment to the dietary health practices.~Message to school administration to prevent selling of soft drinks and to sell healthy food A monthly session for three months will be held to remind the students with the messages"
41128612|NCT04305197|DRUG|ICP-022|Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
40930971|NCT00719264|DRUG|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
41128613|NCT04305197|DRUG|ICP-022|Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
41128614|NCT04305197|DRUG|ICP-022|Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
41128615|NCT04305197|DRUG|Placebos|Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
41128616|NCT00589277|BEHAVIORAL|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
41128617|NCT00589277|BEHAVIORAL|Standard care counseling + standard materials|Standard messages for quitting smoking
41449241|NCT06004973|DEVICE|STAR Particles|A 1.5-gram dose of STAR particles (10% concentration in aloe vera ointment) will be applied to the eight application sites (forearm and hand) and 100 mg of aloe vera will be applied to the control site on one of the forearms. Two rubbing cycles (20 and 30 cycles at 1 cycle/second) and three pressures (40, 60, and 80 kPa) will be evaluated.
40930972|NCT00719264|DRUG|bevacizumab|10 mg/kg every 2 weeks
40930973|NCT05778643|BEHAVIORAL|TaKeTiNa music therapy|TaKeTiNa music therapy uses a group to perform music together. Each member of the group is needed for the synchronization of the whole group. The group actively makes Music with hands, feet, and the voice. At the same time, the therapist frequently introduces new elements into the process and challenges the group in this playful manner. Through this, patients consistently report an increase in mindful awareness and an alleviation of many depressive symptoms, although these effects have not been shown in controlled studies yet.
40930974|NCT02566408|OTHER|One-on-one interview|Undergo one-on-one interview about KAPs towards PA
40930975|NCT02566408|OTHER|Survey Questions|Complete survey
40930976|NCT04172129|DEVICE|Total Hip Arthroplasty|
40930977|NCT01343225|DRUG|atripla|once a day
40930978|NCT01343225|DRUG|darunavir ritonavir raltegravir|as directed
40930979|NCT03631108|DIAGNOSTIC_TEST|OCTA (ZEISS)|All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens.
41128618|NCT00470314|DRUG|L-Ornithine L-Aspartate|
41128619|NCT00800579|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
41128620|NCT00800579|DRUG|Placebo|Inhaled volume-matched placebo in sterile saline
41128621|NCT00146172|DRUG|neratinib|HKI-272
41128622|NCT04307550|DRUG|Isopropyl alcohol|10 inhalations of an isopropyl alcohol pad
41128623|NCT04307550|OTHER|Placebo|10 inhalations of a sterile saline pad
41128624|NCT01768793|BEHAVIORAL|Standard Parents As Teachers (PAT)|Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
41128625|NCT01768793|BEHAVIORAL|Parents As Teachers Plus (PAT+)|Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
41449242|NCT06382896|OTHER|No intervention|This was an observational study
40930980|NCT04192227|BEHAVIORAL|EnHAncing BehavIors through wellness TreatmentS (HABITS)|Six 75-minute sessions via live video conference wherein participants will receive training in areas of health, wellness and quality of life. Classes will be supplemented with independent homework assignments and discussion on a closed social media forum with peers and facilitators.
40930981|NCT03660085|BEHAVIORAL|PC-PEP|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
40930982|NCT04077476|BEHAVIORAL|Online Yoga + Facebook|Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.
40930983|NCT04077476|BEHAVIORAL|Online Yoga|Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
40930984|NCT01894568|DRUG|Insulin Peglispro|Administered SC using a prefilled pen.
40930985|NCT01894568|DRUG|Insulin Glargine|Administered SC using a prefilled pen
40930986|NCT01894568|DRUG|Oral Antihyperglycemic Medications (OAMs)|Administered orally
40930987|NCT01894412|BIOLOGICAL|Etanercept (Enbrel)|
40930988|NCT01894412|BIOLOGICAL|HD203|
40930989|NCT01990144|DRUG|Bendamustine+Rituximab|"Patients will receive :~* Rituximab 375 mg/m2 intravenously on day 1\*~* Bendamustine 90 mg/m2 intravenously on days 2 and 3\*\* Treatment will be administered on a 28-day cycle basis.~  * Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.~    * After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice."
40930990|NCT04467996|DEVICE|Intrauterine balloon tamponade|Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.
40930991|NCT02473692|OTHER|Online Migraine Treatment Optimization|"The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:~1. Introduction to the series~2. Getting to know migraine~3. Making the most of your medical care~4. Partnering with your doctor~5. Best use of migraine medication~6. Keeping tabs on your migraine~7. Take home message (summary)"
40930992|NCT03102190|DRUG|Verapamil Hydrochloride Intranasal|Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
40930993|NCT05089071|DEVICE|Assist by artificial intelligence system for colon polyp detection|Assist by artificial intelligence system for colon polyp detection
40930994|NCT02749123|DRUG|lidocaine 5% patch|10cmx 14 cm transdermal patch sealed in its own pouch
40930995|NCT02749123|DRUG|lidocaine 3.6%, menthol 1.25%|10cmx 14 cm transdermal patch sealed in its own pouch
41128626|NCT05912088|BEHAVIORAL|Intervention Group|Subjects will participate in groups of about 14 to implement the program.
41128627|NCT05912088|BEHAVIORAL|Control Group|Subjects will receive the usual care advice
41128628|NCT01943669|DEVICE|ReWalk™ device|Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
41128629|NCT02082652|DRUG|Etonogestrel|Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
41128630|NCT01865474|DRUG|DLBS1033|1 DLBS1033 tablet 490 mg thrice daily for 2 months
41128631|NCT01865474|DRUG|placebo tablet of DLBS1033|1 placebo tablet of DLBS1033 thrice daily for 2 months
41128632|NCT05619705|BEHAVIORAL|Healthy for Two-Health Coaching (H42)|The H42-HV intervention includes health coaching calls, H42 web based app, mobile phone-based tracking.
41128633|NCT05619705|BEHAVIORAL|Maintain Healthy in Pregnancy and Postpartum(mHIPP)|A brief video on maternal warning signs that is available in English or Spanish.
41128634|NCT04768712|BEHAVIORAL|Weight bearing aerobic exercise|Weight bearing aerobic exercise three times per week.
41128635|NCT06438094|PROCEDURE|Root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft|A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.
41128636|NCT06438094|PROCEDURE|Reconstruction of the CEJ with a composite restoration followed by root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft|Reconstruction of the CEJ with a composite restoration will be performed in B+ and B- defects prior to root coverage surgery. A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.
41128637|NCT03443700|DEVICE|EKSO-GT|Each rehabilitation session with EKSO-GT will last (operating time) 30-40 minutes. Such training will be carried out for 3 sessions per week, during the first 4 consecutive weeks of the study period (i.e. 12 total sessions per patient).
40755142|NCT03893916|PROCEDURE|MEG - EEG HR|"MEG : Magnetoencephalography is the study of the magnetic fields produced by the electrical activity of the brain.~MEG signals are obtained while the patient is placed in a device specific to this technique. The latter comprises a recording chamber, recording sensors which are placed in a cryostat and an electronic measuring system. The magnetic fields are measured while the subject is placed in a shielded magnetic chamber protecting it from variations in the ambient magnetic field (displacement of metal masses, sector ...).~EEG HR: High Resolution EEG is defined as the recording of cerebral electrical activity with 128 electroencephalographic electrodes and with high temporal resolution usually followed by the use of source localization tools. The HR EEG is therefore derived from standard EEG techniques, but requires a higher number of electrodes and the use of source localization tools."
40755143|NCT00395447|PROCEDURE|Straight-forward Device Replacement|
40755144|NCT00395447|PROCEDURE|Device Replacement with Upgrade|
40755145|NCT03649087|OTHER|Vitrification|Vitrification of ovarian tissue
40755146|NCT04483219|DRUG|TKI ± anti-PD-1 antibody|"After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~1. Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~2. Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years."
40755147|NCT06009354|OTHER|Rehabilitation|The control group will receive post-operative usual practices. The study group will receive multi-component education in addition to the usual practices.
40755148|NCT04029038|BIOLOGICAL|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|Given IV
40755149|NCT04029038|DRUG|Cyclophosphamide|Given IV
40755150|NCT04029038|DRUG|Fludarabine|Given IV
41278554|NCT05838573|DRUG|Placebo treatment|Parallel-dose adjustments will be made for the placebo group to maintain consistency in dosing between the two groups.
41449243|NCT02286479|PROCEDURE|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
40930996|NCT02749123|DRUG|Placebo|patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
40930997|NCT03754231|OTHER|Heart rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
40930998|NCT03754231|OTHER|Respiratory rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
41449244|NCT02286479|PROCEDURE|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
40755151|NCT03497286|BEHAVIORAL|Text-based mentorship|The treatment is a text-based peer-to-peer mentorship program for new mothers to promote the healthy development of young children by enhancing the parenting skills of the children's parents. Volunteer mentors who are experienced parents are paired with the parents of newborns. Mentors use text messaging to communicate with, support and encourage new parents while providing best-practice information, answers to the parents' questions, suggestions regarding activities to foster healthy development, and reminders about key milestone activities. The typical NurturePA mentor-mother pair communicates back-and-forth multiple times per week, at any time of the day.
40755152|NCT03497286|BEHAVIORAL|Control text messaging|Control participants will receive periodic texts from NurturePA with information about child safety and health.
40755153|NCT05881330|DEVICE|ArtiAid Intra-articular Injection|Inject ArtiAid® in the affected joint at weekly interval for 5 weeks.
40755154|NCT04355689|DRUG|NPI-001|oral tablet
40755155|NCT04355689|OTHER|Placebo|Placebo tablets
41449245|NCT00387153|DRUG|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
41449246|NCT04711057|OTHER|Community-based PA program|After completing the PR program, the experimental group (EG) will enroll in a 6-month personalized community-based PA program, which should be attended twice-weekly, minimum. During the first month the physiotherapist will guide patients through all available physical activities; afterwards, patients will be asked to choose one or two activities, according to their preference, which they'll attend for five more months. Physiotherapists' support will gradually decrease over time.
41449247|NCT04711057|OTHER|Pulmonary Rehabilitation|Exercise training, twice a week, and education and psychosocial support once every other week during 12 weeks.
40930999|NCT05811650|BEHAVIORAL|Oral Health Counseling and promotion|The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
40931000|NCT02910375|OTHER|Cohort A|Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
40931001|NCT02910375|OTHER|Cohort B|Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
40931002|NCT04604847|DIAGNOSTIC_TEST|blood test|blood test to explore BDNF level
40931003|NCT05602311|DRUG|General anesthetic|Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
41128638|NCT03443700|PROCEDURE|Standard neurorehabilitation locomotor training|Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
41128639|NCT05398055|DRUG|Azithromycin + Doxycycline|azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days
41128640|NCT05398055|DRUG|Placebo + Doxycycline|doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses
41128641|NCT03209700|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
41128642|NCT05690152|DEVICE|EyeSimplify web-browser-based visual field test|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
41128643|NCT01231438|DRUG|Renvela|800mg t.i.d. over 2 weeks
41128644|NCT01231438|DRUG|Etalpha|0.25ug o.d. for 2 weeks
40755156|NCT03268161|DIAGNOSTIC_TEST|Mutational analysis of clonal B cells|"Mutational analysis based on medullary or blood samples stored in a bio-bank during routine lymphocyte phenotyping.~Mutations affecting MYD88 (MYD88 L265P mutation), CXCR4 (Whim-like CXCR4 mutation) loci are sought."
40755157|NCT04231565|DRUG|Tenofovir alafenamide Fumarate|Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.
41128645|NCT00733811|DRUG|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
41128646|NCT00733811|DRUG|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
41128647|NCT01767350|PROCEDURE|Blood withdrawal for DNA|"Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up."
41128648|NCT04807790|OTHER|Telerehabilitation based structured home program applications|"The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study."
40755158|NCT00170755|DRUG|Darifenacin|Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
40755159|NCT01294930|OTHER|Urine density|measurement of urine color, density and plethysmographic variability index before and during surgery.
41128649|NCT00140725|DRUG|Lamivudine plus Polyethylene glyco-interferon alfa-2b|
41128650|NCT00140725|DRUG|Lamivudine|
41128651|NCT03177824|DRUG|Sildenafil Citrate 25Mg Tab|Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
41128652|NCT03177824|DRUG|Placebo Oral Tablet|Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
40755160|NCT00514397|DRUG|motexafin gadolinium|
40755161|NCT00514397|DRUG|temozolomide|
41128653|NCT02627391|OTHER|Early surgical aortic valve replacement|
41128654|NCT02627391|OTHER|Delayed Surgical aortic valve replacement|
41128655|NCT01057459|OTHER|laboratory biomarker analysis|Correlative studies
41128656|NCT00879749|BIOLOGICAL|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
41128657|NCT00879749|BIOLOGICAL|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
41128658|NCT00879749|BIOLOGICAL|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
41128659|NCT00879749|BIOLOGICAL|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
41128660|NCT00879749|BIOLOGICAL|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
41128661|NCT00879749|OTHER|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
41128662|NCT03572257|DRUG|Quetiapine|Patients randomized to the study treatment group will received quetiapine at 0.5 mg/kg, three times a day for 10 days. Doses can be increased up to a maximum of 6 mg/kg/day, in increments of 0.5 mg/kg, based on the subject's clinical delirium symptoms. PRN doses of 0.5 mg/kg can be given up to three times a day based on the clinical judgement of the subject's ICU care team.
41128663|NCT03572257|OTHER|Placebo|Patients randomized to the placebo group will be given an equivalent volume of sterile liquid or sugar pill, based on the individual subjects dosing preference or ability. Dosing will be done on the same schedule as the quetiapine group
41128664|NCT03932162|DRUG|Insulin-Like Growth Factor 1|Growth factor protein
41128665|NCT03932162|OTHER|No Insulin-Lie Growth Factor 1|No Insulin-Like Growth Factor 1 will be given.
41128666|NCT06210659|BEHAVIORAL|Theory of Planned Behavior Based Training Program|"Theory of Planned Behavior Based Training Program will be implemented. The training program will consist of 4 sessions. First session; It will consist of the definition, symptoms and treatment approaches of primary dysmenorrhea. Content of the second session; It will consist of lifestyle interventions in dysmenorrhea. Content of the third session; It will consist of the importance of physical activity in primary dysmenorrhea. The fourth session consists of a group walk.~Students will be monitored for 3 menstrual cycles. Starting from the end of the first menstrual period after completion of the training session, students will be asked to record their daily step count using a pedometer. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated. After the training sessions are completed, students will be given an end-of-menstrual motivational interview for 3 menstrual cycles."
41128667|NCT05076110|DRUG|Oxycodone|5 mg tablets every 4 hours postoperatively as needed for pain control
41128668|NCT05076110|DRUG|Ibuprofen|800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day
41128669|NCT05076110|DRUG|Gabapentin|300 mg three times a day for 5 days then wean off by day 10 postoperatively
41128670|NCT05076110|DRUG|Acetaminophen|1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day
41128671|NCT05076110|DRUG|Methocarbamol|500 mg three times a week for 2 weeks postoperatively
41128672|NCT00575419|DRUG|N-acetylcysteine|"* Dose Level 1: 150 mg/kg/day~* Dose Level 2: 300 mg/kg/day~* Dose Level 3: 600 mg/kg/day~* Dose Level 4: 900 mg/kg/day~* Dose Level 5: 1200 mg/kg/day"
41128673|NCT01630226|DRUG|Neoadjuvant Cisplatin Chemotherapy|Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
41128674|NCT01718041|DRUG|Experimental: VRS-317|Active treatment arm
41128675|NCT03903614|BEHAVIORAL|SML|SML consists of supervised handwriting practice, fitness exercises, and fine motor speed drills that preferentially belabor a participant's right eye, ear, hand and leg during therapy.
41128676|NCT03903614|BEHAVIORAL|CON|CON consists of supervised handwriting practice, fitness exercises, and fine motor speed drills on the participant's dominant hand.
41128677|NCT01778907|OTHER|Genotype information accompanied by a drug dosing advice|Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
41128678|NCT06367023|BEHAVIORAL|Rajyoga Meditation Practice|The intervention will be given for 3 months, For 6 days one hour per day Rajyoga meditation basic course will be provided, followed by 1 hour daily spiritual lesson, Positive thinking and motivation classes will be provided to the intervention group and in control group standard treatment will be given.
41128679|NCT04405921|DRUG|Hydroxychloroquine 200 Mg Oral Tablet|orally or via gastric tube
41128680|NCT04405921|DRUG|Azithromycin 250 MG|orally or via gastric tube
41128681|NCT04305821|OTHER|Dosage of S100β protein|Dosage of S100β protein
41128682|NCT02911441|BEHAVIORAL|Cognitive Behavioral Therapy|
41128683|NCT02378649|DRUG|Sildenafil|Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
41128684|NCT02378649|DRUG|Placebo|Placebo comparator concomitant with best practice usual care
41128685|NCT00533910|DRUG|Rifaximin|550mg BID rifaximin for 8 weeks
41128686|NCT00533910|DRUG|placebo|same as the experimental arm
41128687|NCT01267370|DIETARY_SUPPLEMENT|Soy polysaccharide fiber|"Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and \> 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)"
41128688|NCT05913349|BEHAVIORAL|Group Cognitive Behavioral Therapy (GCBT)|Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.
41128689|NCT02150616|BEHAVIORAL|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
41128690|NCT02150616|BEHAVIORAL|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
41128691|NCT02150616|DRUG|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
41128692|NCT02150616|DRUG|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
41128693|NCT01096472|DRUG|LAS41003|Once daily
41128694|NCT01096472|DRUG|LAS189961|Once daily
40931004|NCT00746408|OTHER|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
40931005|NCT01830023|DEVICE|cardiac ultrasound examination|cardiac ultrasound examination to examine the vitality
40931006|NCT00035347|DRUG|IV azithromycin|500 mg once daily
40931007|NCT00035347|DRUG|ceftriaxone|1 gram once daily for 2 to 5 days
40931008|NCT00035347|DRUG|oral azithromycin|2 x 250 mg once daily
40931009|NCT00035347|DRUG|IV levofloxacin|500 mg once daily
40931010|NCT00035347|DRUG|oral levofloxacin|500 mg once daily
40931011|NCT05216666|PROCEDURE|Lateral approach|Total hip arthroplasty performed through a lateral surgical approach (Gammer)
40931012|NCT05216666|PROCEDURE|Posterior approach|Total hip arthroplasty performed through a posterior surgical approach (Moore)
40931013|NCT04080687|DEVICE|Ankle-foot orthosis|Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)
40931014|NCT06433271|BEHAVIORAL|Transdiagnostic Behavior Therapy (TBT)|TBT manualized treatment incorporates daily exposure exercises from up to four categories of avoidance that are most characteristic of the emotional disorders (i.e., situational, interoceptive, imaginal, and positive emotional).
40931015|NCT06433271|BEHAVIORAL|Treatment as Usual-Problem Solving Therapy (TAU-PST)|PST is an evidence- based psychotherapy implemented in VA Primary Care - Mental Health Integration (PC-MHI), with hundreds of VA providers trained in the intervention nationally. The primary aim of PST is to improve a patient's ability to cope with stressful events by adopting an adaptive perspective to stressors and using goal-focused, problem-solving behaviors to manage the problems associated with the stressors.
40931016|NCT04028661|DEVICE|3D printed Modified Twin Block Appliance|It is a functional appliance for mandibular advancement designed digitally on virtual models.
40931017|NCT06040268|DRUG|Advair HFA|6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily
40931018|NCT06040268|DRUG|Placebo|HFA134a inhaler
41128695|NCT01096472|DRUG|LAS189962|Once daily
40755162|NCT00514397|PROCEDURE|adjuvant therapy|
40755163|NCT00514397|PROCEDURE|quality-of-life assessment|
40755164|NCT00514397|RADIATION|radiation therapy|
40755165|NCT03211858|DRUG|Insulin aspart|SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 millimoles/liter \[mmol/L\] \[\<180 milligram/deciliter {mg/dL}\]) while avoiding hypoglycemia.
40931019|NCT02408432|OTHER|Laboratory Biomarker Analysis|Correlative studies
40931020|NCT02408432|OTHER|Standard of Care|Undergo mesenchymal stem cell infusion
40931021|NCT02408432|DRUG|Mesenchymal Stem Cell Transplantation|Undergo mesenchymal stem cell infusion
40931022|NCT02680678|OTHER|Colloid Preload|preload infusion
40931023|NCT02680678|OTHER|colloid co-load|co-load infusion
40931024|NCT02680678|OTHER|Crystalloid preload|preload infusion
40931025|NCT02680678|OTHER|Crystalloid Co-load|co-load infusion
40931026|NCT00600509|DRUG|Levetiracetam|
40931027|NCT04309799|DEVICE|Tear Restore Mask|The Tear Restore Mask will be used for 10 minutes
40931028|NCT02895009|DEVICE|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
40931029|NCT02895009|DEVICE|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
40931030|NCT03400982|DIAGNOSTIC_TEST|Bone densitometry measurement|Bone densitometry and measurement of body composition
40931031|NCT01923168|DRUG|alpelisib|BYL719 + Letrozole
40931032|NCT01923168|DRUG|buparlisib|BKM120 + Letrozole
40931033|NCT01923168|DRUG|Placebo|Placebo (of BYL719 or BKM120) + Letrozole
40931034|NCT00132106|DRUG|phentolamine|
40931035|NCT01396330|BEHAVIORAL|stress|3 professional safe drive training courses each lasting 30 minutes
41128696|NCT04639869|DRUG|Phenyramydol HCl 400 mg Film Tablet|Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
41128697|NCT04639869|DRUG|Cabral 400 mg Film Tablet|Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
41128698|NCT00001968|DRUG|Amprenavir|
41128699|NCT00001968|DRUG|Ritonavir|
41128700|NCT00001968|DRUG|Abacavir|
41128701|NCT00001968|DRUG|Lamivudine|
41128702|NCT00898352|PROCEDURE|regional lymph node dissection|
41128703|NCT00898352|RADIATION|radiation therapy|
40931036|NCT04828473|DEVICE|Allay Lamp|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~* It is not an implant~* It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
40931037|NCT04983212|OTHER|periodontal control|patient were called and visited in the dentistry department and gingival sulcus were gentle probed to assess gingiva and peri-implant tissues status
40931038|NCT01955798|PROCEDURE|Laparoscopic direct entry Trocar|Laparoscopic direct entry with trocar
40931039|NCT01955798|PROCEDURE|Laparoscopic entry Veress needle|Laparoscopic entry with Veress needle
41453458|NCT05625607|PROCEDURE|Transcatheter mitral valve-in-valve implantation|Transcatheter transfemoral mitral valve-in-valve implantation is an alternative for surgery redo in high-surgical-risk patients with bioprosthetic valve failure. The procedure is performed via femoral vein access. By the transseptal puncture (in the postero-inferior part of the interatrial septum) and balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle. The valve is expanded in the mitral position during rapid ventricle pacing.
40931040|NCT01955798|DEVICE|Trocar|
40931041|NCT01955798|DEVICE|Veress needle|
40931042|NCT02496572|DRUG|Short course MDR-TB treatment regimen|"Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration."
40931043|NCT02723318|BEHAVIORAL|Financial Coaching|One-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
40931044|NCT02723318|BEHAVIORAL|Access to Referrals to Social Services|
40931045|NCT03674931|BEHAVIORAL|musical practice|Intensive weekly musical keyboard training over 12 months
40931046|NCT03674931|BEHAVIORAL|music education|Recreative weekly musical courses without practice over 12 months
40931047|NCT03325660|OTHER|whole body vibration|pelvic floor exercises
40931048|NCT02347696|BEHAVIORAL|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
41128704|NCT02379715|DRUG|Remifentanil|
40931049|NCT02347696|BEHAVIORAL|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
40931050|NCT02347696|BEHAVIORAL|Endurance Activity (EA)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1."
40931051|NCT02347696|BEHAVIORAL|EA+Resistance Training (RT)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~* Progression: increase of 1-2.5 kg\*week-1~* Training of all muscle groups in the same session"
40931052|NCT02347696|BEHAVIORAL|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
40931053|NCT02347696|BEHAVIORAL|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
40931054|NCT05380362|OTHER|Venous Angioplasty|venous angiogram to look for lesions or flaps and then plastying vessels open.
40931055|NCT05380362|OTHER|Sham Angioplasty|Patients will be brought to the angio suite and will not know if they are having the venous angioplasty or not.
40931056|NCT00641927|DRUG|Venlafaxine|37.5 mg - 375 mg daily, 12 Weeks
40931057|NCT00641927|DRUG|Lithium Carbonate|300 mg - 2100 mg daily, 12 weeks
40931058|NCT04142879|DEVICE|Viz Device Software|Viz uses artificial intelligence to automatically detect, triage and notify stroke specialists of suspected large vessel occlusion (LVOs) and computed tomography angiogram (CTA) imaging. Viz includes functionality to automatically process computed tomography perfusion (CTP) images. Additionally, Viz includes a mobile non-diagnostic image viewer and HIPAA-compliant secure messaging.
40931059|NCT00812695|DEVICE|CPAP|Gold standard treatment for Obstructive sleep apnea
40931060|NCT02088515|DRUG|Nedaplatin|
40931061|NCT02088515|DRUG|Cisplatin|
40931062|NCT02088515|DRUG|Docetaxel|
40931063|NCT01854944|DRUG|Brexpiprazole 1mg to 4mg|
40931064|NCT06092060|DIETARY_SUPPLEMENT|the group GS (probiotic)|The probiotic-supplemented group will receive 2 capsules of freeze-dried powder of a probiotic mixture containing the following bacterial strains twice a day, 3-month: Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus salivarius W24
40931065|NCT06092060|DIETARY_SUPPLEMENT|the group GP (placebo)|The placebo group will receive 2 capsules consisting of the probiotic product carrier, which is corn starch and maltodextrin, twice a day, 3-month.
40931066|NCT06343714|DRUG|FB1003|Subcutaneous (SC) injection
40931067|NCT06343714|DRUG|Placebo|Subcutaneous (SC) injection
40931068|NCT03610100|DRUG|Acelarin|825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
40931069|NCT03610100|DRUG|Gemcitabine|1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
40931070|NCT05070546|BIOLOGICAL|Ad26.RSV.preF-based Vaccine|Participants will receive a single IM injection of an RSV vaccine.
40931071|NCT05070546|OTHER|Placebo|Participants will receive a single IM injection of matching placebo.
40931072|NCT04288544|DIETARY_SUPPLEMENT|Microalgae|Open, monocentric intervention study in crossover design
40931073|NCT04288544|DIETARY_SUPPLEMENT|Omega-3-fatty acid capsule|Open, monocentric intervention study in crossover design
40931074|NCT04288544|DIETARY_SUPPLEMENT|sea fish|Open, monocentric intervention study in crossover design
40931075|NCT05325710|BEHAVIORAL|Study nurse intervention|Contact everay 4 months with a dedicated study nurse
40931076|NCT02553954|PROCEDURE|Collection of healthy skin tissue|Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
40931077|NCT02599051|DEVICE|Mini-arc|We will place a single incision sling at the time of surgery for stress urinary incontinence
40931078|NCT02599051|DEVICE|Monarc|We will place a transobturator sling at the time of surgery for stress urinary incontinence
40931079|NCT01434316|DRUG|Dinaciclib|Given IV
40931080|NCT01434316|DRUG|Veliparib|Given PO
40931081|NCT05934188|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The Magnetic Resonance Imaging protocol will comprise both structural and functional sequences.
40931082|NCT05934188|BEHAVIORAL|Neuropsychological protocol|Neuropsychological tests will be administered to participants to assess general cognitive state and a range of high-level cognitive functions (memory, executive, language). In addition, disease-specific tests will be administered to patients to investigate disease staging and the level of disability and autonomy.
40931083|NCT05934188|BEHAVIORAL|Eating habits|Information on eating habits will be derived from food questionnaires.
40931084|NCT05934188|DIAGNOSTIC_TEST|Microbiome analyses|The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).
40931085|NCT05934188|DIAGNOSTIC_TEST|Inflammatory markers|Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.
40931086|NCT05934188|DIAGNOSTIC_TEST|Alzheimer's Disease biomarkers|The Alzheimer's Disease biomarkers will be measured in the plasma of prodromal Alzheimer's Disease patients.
41128705|NCT02379715|DRUG|Desflurane|
41128706|NCT03781349|DEVICE|MENS|
41128707|NCT03781349|DEVICE|TENS|
41128708|NCT00753545|DRUG|AZD2281|Tablets Oral BID
41128709|NCT00753545|DRUG|matching placebo|matching placebo bid
41128710|NCT00185276|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
41128711|NCT00185276|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
40931087|NCT04672681|BEHAVIORAL|Play-based physical activity intervention|The intervention group will participate in a six-month play-based physical activity intervention starting from their initiated treatment. The intervention combines hospital and home-based physical activity. Three days a week, there will be 45 minutes of group-based physical activity at the hospital during admissions or appointments at the outpatient clinic, supervised by an exercise professional or pediatric physiotherapist. Children who are isolated during treatment are offered supervised individual 45 min. training sessions 3 times a week as a substitute. During the other four days a week, or on days where the family is at home, the parents administer the play-based physical activity. At inclusion, the parents receive education and supervision on conducting play-based physical activity with their child in the hospital room or at home. They will receive inspiration material containing numerous different plays, games, and activities in different intensities.
40931088|NCT00014755|DRUG|anti-thymocyte globulin|
40931089|NCT00014755|DRUG|cyclophosphamide|
40931090|NCT00014755|DRUG|filgrastim|
40931091|NCT00014755|DRUG|prednisone|
40931092|NCT00014755|PROCEDURE|peripheral blood stem cell transplantation|
40931093|NCT00014755|PROCEDURE|irradiation|
40931094|NCT05375773|OTHER|PVP-I Nasal Irrigation and gargling|The solution is prepared by the researcher, which contains 0.5% PVP-I and 2.27% hypertonic saline
40931095|NCT00706498|DRUG|BI 2536|
40931096|NCT02853799|OTHER|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|"1. Placement of feeding tube stomach (oral- or naso-gastric tube)~2. Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~3. There will be five blood glucose checks in each data collection period.~4. If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated."
40931097|NCT02853799|DIETARY_SUPPLEMENT|Osmolite 1.2 cal/ml Enteral Feeds|Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
40931098|NCT05353140|DEVICE|The WATCHMAN/WATCHMAN FLX device|Watchman device was an umbrella-shaped, self-expanding, nitinol structure with a porous partial polyethylene terephthalate membrane (160 um mesh) and 10 struts. The membrane portion of the structure faces into the body of the left atrial to block embolization of thrombus and provide scaffolding on which endothelialization can occur. The On July 21st, 2020, the FDA approved the next generation LAAO device, named Watchman FLX. This newiteration of the Watchman LAAO platform offers full capability of recapture and redeployment of the device, decreasedmetallic exposure, an increased number of contact points for sealing, a fully rounded delivery shape, and precision anchors designed to provide optimal device engagement with the LAA.
40931099|NCT05353140|DRUG|Rivaroxaban + Clopidogre|Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.
40931100|NCT05353140|DRUG|Aspirin + Clopidogrel|Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.
40931101|NCT03539796|PROCEDURE|Dural puncture epidurals (DPE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle, but no medications will be injected. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-PF 3mg will be given via epidural after delivery of the fetus.
41128712|NCT03951142|DRUG|Losartan|This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.
41128713|NCT01253213|DRUG|BR55|One to two bolus (2nd bolus optional) of BR55 per patient
41128714|NCT00575016|BIOLOGICAL|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U \> Week 12; injection into the detrusor
41128715|NCT00575016|BIOLOGICAL|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
41128716|NCT00575016|BIOLOGICAL|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
41128717|NCT00575016|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
41128718|NCT02027259|BEHAVIORAL|Behavioral activation (BA)|The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
41128719|NCT00247351|PROCEDURE|Cryoablation|
41128720|NCT01847534|OTHER|Supplemental PN|
41128721|NCT01847534|OTHER|Standard Care|
41128722|NCT05461053|DRUG|LMX 4 Topical Cream|The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
41128723|NCT01772212|DRUG|Terbinafine 250 mg|Test product
41128724|NCT01772212|DRUG|Terbinafine 250 mg|Reference product
40931102|NCT03539796|PROCEDURE|Traditional epidurals (EPI)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. The catheter will be inserted 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-preservative free (PF) 3mg will be given via epidural after delivery of the fetus.
40931103|NCT03539796|PROCEDURE|Combined-spinal epidural technique (CSE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle and 12mg bupivacaine, 10mcg fentanyl, 200mcg morphine-PF. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. No epidural test dose will be given immediately compared to the above procedures secondary to intrathecal injection of local anesthetic with this CSE technique. Only after approximately 1 hour after intrathecal injection will a test dose of 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine for the remainder of the procedure if necessary.
40931104|NCT00503945|DEVICE|Nasal continuous positive airway pressure (nCPAP)|
40931105|NCT04344743|DEVICE|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
40931106|NCT02973880|DRUG|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
40931107|NCT02973880|DRUG|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
41128725|NCT03367338|OTHER|Low-phosphate diet|Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g
41128726|NCT02350400|DEVICE|DEBIRI|DEBIRI TACE
41128727|NCT04671875|DRUG|Recombinant Humanized Monoclonal Antibody MIL93|"PART I :The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg,respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL93 every 3 or 2 week on Day 1.~PART II:One recommended dose will be conducted from 6 dose groups based on results of PART I."
41449248|NCT01403363|DRUG|use of fentanyl patch that was halved|A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
40931108|NCT02050126|DEVICE|Lumenis UltraPulse Encore.|Treatment using Lumenis UltraPulse Encore.
40931109|NCT03252340|DRUG|ADSTEM Inj.|"1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial."
40931110|NCT03978793|DEVICE|MyTPill, a digital pill|MyTPill is a digital pill containing an approved medication
41128728|NCT05162716|DEVICE|Single-chamber pacemaker implantation with left bundle branch area pacing|A prepectoral single-chamber pacemaker is implanted with a 3830 (Medtronic) IS-1 pacing lead screwed via the right ventricle in the deep interventricular septum in order to capture the left Purkinje system on the left ventricular endocardial side.
41128729|NCT01687751|DRUG|Dexmedetomidine|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
41128730|NCT01687751|DRUG|Midazolam|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
41278555|NCT05838573|OTHER|Baseline assessments|Schizophrenic participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations.
41278556|NCT05838573|OTHER|Volunteer assessments|Apart from psychiatry scales(Hamilton Depression Scale, Young Mania Rating Scale and Self-reporting Inventory-90), other assessments for the healthy subjects are the same as the baseline for sczhiophrenic participants.
41278557|NCT06417515|DRUG|Xiao-Yao-San|Patients who received Xiao-Yao-San 9 g/day (Kaiser Pharmaceutical Co. Ltd.) were selected for the Xiao-Yao-San group by traditional Chinese doctor with 8 years of experience.
41278558|NCT06417515|OTHER|Weight loss class(WLC) group|Participants who attended the WLCs in our hospital and were willing to participate in our study were included in the WLC group (control group). Our WLCs consisted of 8 sessions of 2-hour dietary advice/exercise guidance and 1 session of weight-loss consultation in 3 months. The participants assessed their weights at the beginning, at 1.5 months, and after every class. They underwent pre-PSG tests in the beginning and post-PSG tests after 3 months of lectures.
41449249|NCT03073798|DRUG|Roflumilast|500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms
41449250|NCT03073798|DRUG|Placebo|500 mcg of placebo is used
41449251|NCT05755113|DRUG|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
41449252|NCT03419247|PROCEDURE|Fresh tumor tissue biopsy|A type of surgical procedure that will use a thin needle to remove a sample of tumor tissue.
41449253|NCT03419247|PROCEDURE|Blood draw|Blood will be taken by a needle from a vein.
41449254|NCT03419247|PROCEDURE|Archival tumor tissue collection|A sample of tumor tissue that was taken by biopsy or surgery before agreeing to take part in this study will be collected.
41449255|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
41449256|NCT01955200|DRUG|Cilostazol|(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
41449257|NCT01955200|DRUG|Ticagrelor|(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
41449258|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
41449259|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
41449260|NCT00954460|DRUG|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
41449261|NCT02343796|OTHER|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
41449262|NCT02343796|DEVICE|everStick|GC, Belgium
41449263|NCT05887427|OTHER|Neural Mobilisation|Transcutaneous Electrical Stimulation, hotpack, ultrasound and neural mobilization(radial,ulnar,median)
41449264|NCT05887427|OTHER|Conservative physiotherapy|Hotpack,Transcutaneous Electrical Stimulation ,Ultrasound
41128731|NCT02513043|DRUG|medical abortion|medical abortion
41128732|NCT00914966|BIOLOGICAL|C1 inhibitor (human) [C1 INH]|
41128733|NCT05185167|DRUG|Anesthetics, General Desflurane Maintenance|Comparison of dna damage of desflurane maintenance with propofol maintenance according to comet analysis
41128734|NCT05185167|DRUG|Anesthetics, General Propofol Maintenance|Comparison of dna damage of propofol maintenance with desflurane maintenance according to comet analysis
41128735|NCT00000852|PROCEDURE|Allogeneic lymphocyte transfer|
41128736|NCT01158248|BIOLOGICAL|panitumumab|
41128737|NCT01158248|DRUG|cisplatin|
41128738|NCT01158248|RADIATION|brachytherapy|
41128739|NCT01158248|RADIATION|external beam radiation therapy|
41128740|NCT01368744|DEVICE|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Groups: OSNA Breast Cancer System"
41128741|NCT04954885|PROCEDURE|Biospecimen Collection|Undergo stool sample
41128742|NCT04954885|OTHER|Physical Performance Testing|Undergo short physical performance battery
41128743|NCT04954885|OTHER|Physical Performance Testing|Perform 6-minute walk test
41128744|NCT04954885|OTHER|Questionnaire Administration|Complete questionnaires
41449265|NCT04310345|BEHAVIORAL|Animal-Assisted Interactions|Child and caregivers will spend approximately 10-5 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
41449266|NCT03642808|OTHER|rehabilitation program|Availibility of patients to complete a rehabilitation program during 8 weeks and to come back 4 times for a careful medical examination
41449267|NCT01828203|DRUG|Minocycline|
41449268|NCT01828203|DRUG|Placebo|
41449269|NCT01828203|PROCEDURE|Surgical spinal cord decompression|Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
41449270|NCT01828203|PROCEDURE|Maintenance of minimum mean arterial pressure (MAP)|Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
41449271|NCT03781934|DRUG|MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|MIV-818 - oral capsules; pembrolizumab - IV
41449272|NCT03781934|DRUG|MIV-818 (fostroxacitabine bralpamide) + lenvatinib|MIV-818 - oral capsules; lenvatinib - oral capsules
41449273|NCT05437848|DRUG|Experimental: Cotadutide|Cotadutide: subcutaneous (SC) injection
40755166|NCT03211858|DRUG|NovoLog/NovoRapid|NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 mmol/L \[\<180 mg/dL\]) while avoiding hypoglycemia.
41128745|NCT03597087|PROCEDURE|Anesthesia before transurethral resection of the bladder tumor|"General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle"
41128746|NCT03597087|DRUG|Anesthesia|"General anaesthesia : propopol~Spinal anaesthesia : bupibacaine"
41128747|NCT05949567|OTHER|urodynamic exam in sitting and lying position|Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)
41278559|NCT06033001|DRUG|[Lu-177]-PNT2002|\[Lu-177\]-PNT2002, is a radiopharmaceutical investigational drug. \[Lu-177\]-PNT2002 targets a specific protein that is located on the surface of prostate cancer cells called PSMA. \[Lu-177\]-PNT2002 delivers radiation to your cancer by binding to the PSMA which helps destroy the cancer cells. \[Lu-177\]-PNT2002 is administered intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment.
41278560|NCT04641286|OTHER|Body motion categorisation|All patients will receive passive motion categorisation monitoring
41278561|NCT06203002|DRUG|Placebo (blinded)|LX9211 matching placebo tablets
41278562|NCT06203002|DRUG|LX9211 (blinded)|LX9211 (blinded) tablets
41278563|NCT02595944|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41278564|NCT02595944|PROCEDURE|Computed Tomography|Undergo CT
41278565|NCT02595944|PROCEDURE|Echocardiography|Undergo ECHO
41278566|NCT02595944|BIOLOGICAL|Nivolumab|Given IV
41278567|NCT02595944|OTHER|Observation|Undergo observation
41278568|NCT02595944|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
41278569|NCT03842709|DRUG|Pramipexole Oral Tablet|Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
41278570|NCT03842709|OTHER|Placebo|Administration of placebo
41278571|NCT06002152|DRUG|Bupivacaine|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of 0.25% bupivacaine on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
41278572|NCT06002152|DRUG|Placebo|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
41278573|NCT05731947|DRUG|Revumenib|Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
41278574|NCT05731947|DRUG|Chemotherapy|Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
41278575|NCT05268380|DIAGNOSTIC_TEST|Covid-19, TB and HIV diagnosis|GeneXpert (sputum) will be used to diagnose active TB disease, IGRA will be used to diagnose latent TB infection, PCR will be used to diagnose Covid-19 active infection, HIV rapid test will be used to diagnose HIV seropositivity.
41278576|NCT04935944|RADIATION|CBCT radiation|CBCT scanning
41278577|NCT02936752|DRUG|Entinostat|Given PO
41278578|NCT02936752|BIOLOGICAL|Pembrolizumab|Given IV
41278579|NCT06105138|DIETARY_SUPPLEMENT|200mg Cannabidiol oral solution|"200mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment)."
41449274|NCT05437848|OTHER|Placebo|Placebo subcutaneous injection
41449275|NCT00822744|DRUG|SSR411298|"Form: capsule~Route: oral administration with food"
41449276|NCT00822744|DRUG|Escitalopram|"Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food"
41449277|NCT00822744|DRUG|Placebo (for SSR411298)|"Form: capsule~Route: oral administration with food"
41449278|NCT02267707|DRUG|nab-paclitaxel|Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
41449279|NCT02267707|DRUG|Gemcitabine|Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
41449280|NCT03142022|OTHER|No intervention - Diagnostic polysomnography at 1 year after lung transplantation|
40755167|NCT03211858|DRUG|Insulin glargine (HOE901)|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
40755168|NCT00004061|BIOLOGICAL|filgrastim|
40755169|NCT00004061|BIOLOGICAL|palifermin|
41449281|NCT04560725|DRUG|11C-Choline|11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the \[68Ga\]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
41449282|NCT00229944|DRUG|Azithromycin|
41449283|NCT03225664|BIOLOGICAL|Pembrolizumab|Given IV
41449284|NCT03225664|OTHER|Pharmacokinetic Study|Correlative studies
41449285|NCT03225664|DRUG|Trametinib|Given PO
41449286|NCT04949737|BIOLOGICAL|Helicobacter Pylori detection|"Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup.~Additional data will be collected through a questionnaire."
41449287|NCT05848115|DEVICE|Bi-level Positive Airway Pressure|An appropriately sized vented BiPAP face mask with a good seal will be applied and monitored by trained respiratory therapists. Patients will be started on an inspiratory peak airway pressure (IPAP) of 10 cm of water and expiratory positive airway pressure (EPAP) of 5 cm of water per Children's Hospital Colorado (CHCO) clinical pathway. BiPAP pressures will be titrated to effect per the treating physician, using assessment of physical examination, vitals, and asthma score per institutional clinical pathway. Study participants will remain on BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the ongoing use of BiPAP or not.
40755170|NCT00004061|DRUG|cyclophosphamide|
41449288|NCT05848115|DEVICE|Sham Bi-level Positive Airway Pressure|The sham BiPAP will have pressure attenuated using an orifice restrictor as described in previous double blinded studies using sham non-invasive ventilation. With this set-up pressures no greater than 2 cm of water have been documented at the location of the face mask. This will ensure that the patient is not receiving positive pressure with any effectiveness or deleterious effects. Study participants will remain on sham BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the use of BiPAP or not.
41449289|NCT00221299|DRUG|Risedronate|One 35mg tab of risedronate/placebo taken once a week for one year.
41449290|NCT00221299|DRUG|Parathyroid Hormone|This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
41449291|NCT06263842|PROCEDURE|modified Elamrousy approach for socket shield technique|the jumping gap will be filled with AWTG
41449292|NCT06263842|PROCEDURE|conventional socket shield|the jumping gap will be left ungrafted
41449293|NCT06263842|PROCEDURE|combined socket shild with xenograft|the jumping gap will be filled with xenograft
41449294|NCT04325386|OTHER|Education Sessions|Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
40755171|NCT00004061|DRUG|etoposide|
40755172|NCT00004061|DRUG|ifosfamide|
40755173|NCT00004061|PROCEDURE|peripheral blood stem cell transplantation|
40755174|NCT00004061|PROCEDURE|quality-of-life assessment|
40755175|NCT00004061|RADIATION|radiation therapy|
40755176|NCT04908527|BEHAVIORAL|Walking to OR|Patients, after being prepared for the OR, walk to the operating room
40755177|NCT03073304|DRUG|Crystalloid based prime solution|Crystalloid based prime solution
40755178|NCT03073304|DRUG|Erythrocyte based prime solution|Erythrocyte based prime solution
40755179|NCT00825448|PROCEDURE|Hospitalization for a week|Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
41128748|NCT03624972|BEHAVIORAL|Starting the Conversation Video|The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
41449295|NCT04325386|OTHER|No Education Session|No Education Session
41449296|NCT01885897|BIOLOGICAL|ALT-803|Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
41449297|NCT03459339|DEVICE|Tethered Capsule Endomicroscopy (TCE)|Tethered Capsule Endomicroscopy will be used to detect Barrett's Esophagus
41449298|NCT03698357|BEHAVIORAL|interactive video balance-based exercise|Interactive video balance-based exercise :10 minutes of warm up exercise, 30 minutes of Interactive video balance-based exercise and 5 minutes of cool down exercise.
40755180|NCT03947021|RADIATION|Computed tomography (CT) scan|A CT scan of thorax and heart will be performed in the CT+BSPM group.
40755181|NCT03947021|DEVICE|Body-surface potential mapping|Measurement of 256-lead body-surface electrocardiogram
40755182|NCT05925855|OTHER|US with fastum|apply fastum on trigger point with US
40755183|NCT05925855|OTHER|US with reparil|apply reparil on trigger point with US
40755184|NCT05925855|OTHER|US with plain gel|apply gel on trigger point with US
40755185|NCT05339061|DEVICE|Endovascular Treatment of Complex abdominal or Thorocoabdominal aneurysms (TAAA).|"Modification~* Deploy the graft on the sterile, surgical table~* Mark out on the graft the locations of the fenestrations on the graft adjusting as necessary~* Using handheld electrocautery, fashion the fenestration in the appropriate location on the moistened graft material in order to prevent inadvertent progression of the fenestration size~* If the fenestration is going to remain as such, then a snare is used to fashion the marker on the fenestration with 5-0 stitch~* If the fenestration is going to be made into a branch, then an appropriately sized, self-expanding stent is beveled and fashioned to be 15 mm long and sewn to the fenestration in addition to a snare with the 5-0 stitch~* Two orientation markers are placed at the proximal edge and distal edge of the graft consisting of portions of the snare sewn to the anterior portion of the graft in a J fashion with a 5-0 stitch"
40919429|NCT04590833|BEHAVIORAL|Supervised walking on a treadmill|Each participant will be provided with an individualized target heart rate zone based on his/her age. Heart rate during exercise will be measured using a finger pulse oximeter. Following baseline measures, participants will receive instructions on how to use a finger pulse oximeter by a student. For participants who are not physically fit or are just engaging in regular exercise, they will be advised to start walking on a treadmill at a comfortable pace for 5 to 10 minutes at one time.46 Exercise duration and intensity will be progressed from week 3 to week 5, until participants will walk at 40-59% of heart rate reserve based on their age, which will be maintained throughout the study.
40931111|NCT02188043|BEHAVIORAL|Relay Model|"The Clinical staff hand out and collect lifestyle - questionnaires to admitted patients, and screen by 10 alcohol questions (AUDIT) , and report score to outpatient Alcohol Clinic.~Based on the questionnaire that the patient filled out, the Alcohol therapist perform a brief Motivational Intervention on patients with an AUDIT score of 8+, focusing the patients alcohol consumption habits and offer an appointment to patients with an AUDIT score of 16+."
41128749|NCT03624972|BEHAVIORAL|Sexual and Menopausal Health Resources|Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal \& sexual health clinic.
40931112|NCT00280670|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
41128750|NCT03440346|OTHER|Few-foods diet|The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
41128751|NCT01072838|RADIATION|APBI (Dose Escalation)|"Accelerated, hypofractionated partial breast radiotherapy.~3 dose schemes followed for 6 months each."
41128752|NCT01072838|DEVICE|Contura MLB Breast Brachytherapy Catheter|
41128753|NCT04715269|DRUG|Alprazolam|Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency
41128754|NCT04715269|OTHER|Placebo|Empty capsule
41128755|NCT02415088|PROCEDURE|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
41128756|NCT02415088|PROCEDURE|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
41128757|NCT03213145|DRUG|intraconazole|Subjects will receive itraconazole once daily from Day 5 through Day18
41128758|NCT03213145|DRUG|Rifampin|Subjects will receive rifampin once daily from Day 5 through Day 16
41128759|NCT03213145|DRUG|EDP 305|Subjects will receive EDP 305 once daily on Day 1 and Day 14
41128760|NCT06175299|BEHAVIORAL|Adherence Promotion With Person-centered Technology (APPT) System with Social Functions|The system has seven games for cognitive training and two social interactions functions: a chat function and a leaderboard function.
41128761|NCT00592345|RADIATION|Proton Beam Radiation|Administered over a period of 12 weeks.
41128762|NCT00592345|RADIATION|Photon Beam Radiation|Administered over a period of 12 weeks.
41128763|NCT00592345|RADIATION|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
41128764|NCT01170624|DEVICE|ICD|Paradym CRT model 8750 - Paradym DR model 8550 - Paradym VR model 8250
41128765|NCT00948168|DRUG|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
41128766|NCT01780649|PROCEDURE|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI
41128767|NCT01780649|PROCEDURE|ICSI|ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
41128768|NCT02673216|OTHER|No intervention|
41128769|NCT01515241|DRUG|CER-001|Weekly injection
41128770|NCT04478487|DIETARY_SUPPLEMENT|Medolac human milk based human milk fortifier (MHMHMF)|MHMHMF is admixed with expressed or donor human milk in graded doses according to tolerated feed volume according to established guidelines and maintain adequate micronutrient levels.
41128771|NCT04105387|PROCEDURE|Early Tracheostomy Change|The treatment group will have the first tracheostomy change on postoperative day 4 by an Otolaryngology physician (attending or fellow) on the study team.
40931113|NCT01307020|DRUG|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
40931114|NCT01307020|DRUG|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
40931115|NCT01307020|DRUG|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
40931116|NCT01307020|DRUG|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
40931117|NCT01307020|DRUG|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
41128772|NCT01526954|DEVICE|TissuGlu Surgical Adhesive|TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
41128773|NCT06454929|PROCEDURE|operative|open reduction : fixation by k-wires or screws
41128774|NCT06454929|PROCEDURE|non-operative|close reduction : by cast Immobilization
41128775|NCT04089930|DIAGNOSTIC_TEST|Immunogenicity|anti-VZV IgG titer and cell-mediated immunity (VZV-stimulated T cell spots)
41128776|NCT03869970|BEHAVIORAL|REST|The REST group will be recommended to return to school and light physical and cognitive activity as soon as tolerated- but no sooner than 48 hrs post-injury per current consensus recommendations. Notifications from the Fitbit app will be turned off, and step goal will be set at 500, to minimize positive feedback and reminders from achievement of activity goals
41128777|NCT03869970|BEHAVIORAL|ACTIVITY|ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.
41128778|NCT03869970|BEHAVIORAL|mHEALTH|mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.
40931118|NCT01307020|DRUG|Placebo|Placebo, oral film-coated table, once
40931119|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
41128779|NCT05279066|DEVICE|Biostrap Wristband|The Biostrap Wristband device is a non-invasive optical sensor that monitors changes in arterial pulse volume using Photoplethysmography (PPG). PPG is frequently used in wearable sensors to detect heart rate as well as other metrics such as heart rate variability (HRV) and respiratory rate. The raw biosignals recorded by the wristband device will be further processed to estimate the ejection fraction and cardiac output.
40931120|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
40931121|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
40931122|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
40931123|NCT05059899|BEHAVIORAL|Exercise group|The exercise group will receive a 12-week home-based exercise programme, with a wearable activity watch to regulate physical activity behaviour. This group will also receive biweekly telephone calls from the investigator.
40931124|NCT02875574|DRUG|Any treatment regimen|Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
40931125|NCT02875574|OTHER|Bacterial mutation|Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
40931126|NCT05317806|DRUG|Metformin Extended Release Oral Tablet|daily metformin treatment vs. no treatment with metformin
40931127|NCT03689933|DEVICE|Root analog implant|a custom made root analogue implant made from milled titanium
40931128|NCT03253471|DRUG|AL-611|AL-611 tablets
40931129|NCT03253471|DRUG|Placebo|Placebo to Match AL-611
40931130|NCT02238171|DRUG|Atrovent® inhalets|
40931131|NCT01981369|DRUG|Dexmedetomidine|Intravenous sedation with dexmedetomidine
40931132|NCT01981369|DRUG|Propofol|Intravenous sedation with propofol
40931133|NCT01981369|PROCEDURE|Infraclavicular block|All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.
40931134|NCT01509690|OTHER|Multidisciplinary, intensive and collaborative care|"No specific study drugs, devices or procedures are involved.~Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access \[arteriovenous (AV) fistula or graft\] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications."
40931135|NCT01512290|OTHER|Theta Burst Transcranial Magnetic Stimulation|This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
40931136|NCT06052215|BEHAVIORAL|Online Information Cards Education|Providing family planning education to women through online information cards
41128780|NCT05971875|PROCEDURE|vNOTES vs Vaginal Hysterectomy|Comparison of vNOTES vs VH
41128781|NCT05971875|PROCEDURE|vNOTES vs Laparoscopic Hysterectomy|Comparison of vNOTES vs LH
41128782|NCT01290003|DRUG|Piperacillin-Tazobactam and Amikacin|Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
41128783|NCT03109080|DRUG|Olaparib|five levels of dose, per os administration, twice daily each day
41128784|NCT03109080|RADIATION|Radiation therapy|3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy
41128785|NCT04365205|PROCEDURE|Endobronchial biopsy|Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.
41128786|NCT04589975|PROCEDURE|laparoscopic surgery|
41449299|NCT03698357|BEHAVIORAL|Conventional physiotherapy|conventional physiotherapy: 10 minutes of warm up exercise, 30 minutes conventional physiotherapy and 5 minutes of cool down exercise. Conventional physiotherapy contains rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on.
41449300|NCT03476226|OTHER|Cognitive Dysfunction Coping Strategy Teaching Sheet|Demographic sheet, Fact-Cog3, and teaching tool at baseline then week 4 and 8 Fact Cog3 and reinforcement of tool, at week 16 evaluation and Fact-Cog3
40931137|NCT01002820|DRUG|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
40931138|NCT02755688|PROCEDURE|Thoracoscopic Surgical ablation|Thoracoscopic approach to isolate pulmonary veins, ganglionic plexi ablation and left atrial appendage exclusion
41128787|NCT05088421|DRUG|BWC0977|"SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days."
40931139|NCT02755688|PROCEDURE|Catheter ablation|Ablation using contact force technology to isolate pulmonary veins and create linear lesions.
40931140|NCT04971330|DIAGNOSTIC_TEST|Access HCV|"All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status"
40931141|NCT00539201|DRUG|GSK706769|
40931142|NCT04368247|DIAGNOSTIC_TEST|Skin Fluorescent Imaging|Application of reagents, then imaging and scoring
41449301|NCT05581329|PROCEDURE|Acupuncture|Acupuncture is a method of inserting very thin needles into special points on the body which are called acupoints. To conduct this intervention, we will use disposable acupuncture needles the size of 0.30 x 13 mm to acupuncture the control acupoint (Yuji - LU10) in the first session and the research acupoint (Houxi - SI3) in the second session.
40755186|NCT04381559|BEHAVIORAL|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
40755187|NCT04381559|BEHAVIORAL|Applied Relaxation|12 sessions of AR will serve as our second, control arm. In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response.86 AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety.87 This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition.88 Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety.87 However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
40755188|NCT02769481|DRUG|Bexagliflozin|20 mg, tablet
40755189|NCT02769481|DRUG|Placebo for Bexagliflozin|inactive tablet to match active comparator bexagliflozin
40755190|NCT02769481|DRUG|Glimepiride|2, 4 or 6 mg, capsule
40755191|NCT02769481|DRUG|Placebo for Glimepiride|inactive capsules to match active comparator glimepiride
40755192|NCT05852990|COMBINATION_PRODUCT|Glutamine plus L. reuteri|Glutamine plus Lactobacillus reueri twice daily for up to 6 weeks or death
40755193|NCT05541328|OTHER|Tisagenlecleucel|The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
40755194|NCT02388256|DEVICE|acupuncture|"Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience."
40755195|NCT02388256|OTHER|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
40755196|NCT04882605|GENETIC|MHC typing|Allelic genotyping resolution of MHC genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, -DPB1 and -DRB3/4/5) using Illumina technology.
40931143|NCT04486274|OTHER|MOSE|After each pass, the stylet will be introduced into the needle, the material will be released onto a smear slide, and a macroscopic on-site quality evaluation (MOSE) of the specimen will be performed by the endoscopist.
40931144|NCT06112964|PROCEDURE|MRI/ Functional MRI|Participants will undergo an MRI scan lasting approximately 1 hour to examine the structure and function of the brain. During the scan, they will also be asked to perform computer based tasks. This is called functional MRI.
40931145|NCT06112964|BEHAVIORAL|Self-reported questionnaires|Participants will complete questionnaires covering subjective measures relating to food attitudes and intake, and report-based measures of relevant psychopathology including depression and anxiety. These will be derived from standardised scales already used clinically, including the setting of eating disorders and normative studies of the neuroscience of appetite.
40931146|NCT06112964|BEHAVIORAL|Computer based tasks|"Participants will complete computer based tasks which are focused specifically on aspects of appetite-related and reward behaviours. Typically, such behaviours are characterised under the following sub-headings:~i) Motivation (the amount of effort, cognitive or physical, that a person is prepared to expend in order to gain access to food), ii) Valuation (the relative rating of foods in comparison to each other and to non-food items), and iii) Hedonic response (the subjective pleasure experienced in consumption) to food intake"
40931147|NCT03458715|DRUG|SGLT2 inhibitor (Empagliflozin 25 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
40931148|NCT03458715|DRUG|DPP4 inhibitor (Linagliptin 5 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
40931149|NCT03230669|OTHER|cbt4cbt|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
41128788|NCT05088421|DRUG|Placebo|SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
41128789|NCT00862030|PROCEDURE|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
41128790|NCT00325767|DRUG|nebulized albuterol (2.5 mg/3ml/dose)|
41128791|NCT00325767|DRUG|nebulized levalbuterol (1.25 mg/3ml/dose)|
41278580|NCT06105138|DIETARY_SUPPLEMENT|30mg Cannabidiol oral solution|"30mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment)."
41278581|NCT06105138|DIETARY_SUPPLEMENT|Placebo|"Placebo administered in the laboratory prior to a standard dose of alcohol.~The placebo was made up for the study and contained reverse-osmosis water, gum arabic, MCT (Medium Chain Triglyceride) oil, citric acid, plus the addition of a natural food color, used at \<0.1%."
40931150|NCT02777749|DRUG|Bupivacaine|15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
40931151|NCT02116218|PROCEDURE|acupuncture|Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
40931152|NCT02116218|PROCEDURE|Vaccaria seed|We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
40931153|NCT00621803|DRUG|Probiotic Lactobacillus casei rhamnosus (Lcr35)|
40931154|NCT00781352|DRUG|nitrous oxide|65% nitrous oxide administered during surgery
40931155|NCT00781352|DRUG|nitrogen|Nitrogen administration during surgery
40931156|NCT01952782|DRUG|Kisspeptin 112-121|Subjects will receive up to 10 IV doses of kisspeptin 112-121
40931157|NCT01952782|DRUG|Naloxone|Subjects will receive one IV dose of naloxone followed by an IV infusion of naloxone.
40931158|NCT01952782|DRUG|GnRH|Subjects will receive up to 10 doses of IV GnRH
40931159|NCT01245361|DRUG|Infliximab|Infliximab 3 mg/kg wk 0,2,6
40931160|NCT01245361|DRUG|sodium chloride|Group II : Placebo wk 0,2,6
40931161|NCT04412993|OTHER|withdraw blood samples|withdraw blood sample from gorup O donors
40931162|NCT06047184|DRUG|BEBT-209 capsules|BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
40931163|NCT06047184|DRUG|Letrozole tablets|Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.
40931164|NCT06047184|DRUG|Fulvestrant|Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
40931165|NCT05404984|OTHER|Dry cupping with core stabilization exercises|12 patients will receive dry cupping technique for 10 minutes followed by 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
40931166|NCT05404984|OTHER|Core stabilization exercises|A total of 12 patients will perform 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
40931167|NCT00936429|BIOLOGICAL|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
40931168|NCT00936429|BIOLOGICAL|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
40931169|NCT02483052|DEVICE|RejuvenAir|RejuvenAir
40931170|NCT01000038|OTHER|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
41128792|NCT00325767|DRUG|nebulized placebo (3ml/dose)|
40931171|NCT01000038|OTHER|Walking|Half hour daily, five days a week for 8 weeks
40931172|NCT03751306|PROCEDURE|Transcranial Photobiomodulation|"Photobiomodulation Rehabilitation:~Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) ."
41128793|NCT06299670|DRUG|Thalidomide|Patients will get only Thalidomide
41128794|NCT06299670|DRUG|Hydroxy Urea|Patients will get only Hydroxyurea
41128795|NCT06299670|DRUG|Combinations|Combination Of Thalidomide \& Hydroxyurea
41128796|NCT03739658|OTHER|Education|Cognitive-Based Neuromuscular Training has the content of focusing on different tasks at the same time and coordinating on neuromuscular functions as well as football-specific movements. Game-Based Training (OTE), which includes football, tennis, bowling, shooting, racing and climbing games, consists of active video games of game consoles, which are frequently used among young people.
41278582|NCT06158139|BIOLOGICAL|iC9-CAR.B7-H3 T cell infusion|iC9-CAR.B7-H3 T cell product will be administered via intravenous injection over 5 - 10 minutes.
41449302|NCT04383587|OTHER|Serologic testing|COVID19 IgG antibody testing to be performed
40755197|NCT04882605|GENETIC|KIR typing|Allelic genotyping resolution of all 13 KIR genes (KIR2DL1, KIR2DL2/2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS3/2DS5, KIR2DS4, KIR3DL1/3DS1, KIR3DL2, KIR3DL3), 2 KIR pseudogenes (KIR2DP1 and -3DP1) using Illumina technology.
40931173|NCT03751306|PROCEDURE|Transcranial Photobiomodulation (Placebo)|"Photobiomodulation Placebo Therapy:~The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off."
40931174|NCT03751306|PROCEDURE|Cardiorespiratory Rehabilitation|"Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives."
41449303|NCT06319482|DEVICE|Proactive CPAP Therapy|CPAP machine uses Artificial Intelligence to make predictions and preventions of future apneic events to auto-adjust pressure.
41449304|NCT06319482|DEVICE|Conventional APAP Therapy|CPAP machine relies on the detection of respiratory events to determine how to react and auto-adjust pressure.
41449305|NCT05777005|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
41449306|NCT05777005|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
41449307|NCT05777005|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
41449308|NCT05777005|BEHAVIORAL|Counselor-led individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
41449309|NCT05777005|BEHAVIORAL|Chatbot-led group support|Participants will receive three months of chatbot-led group support via WeChat.
41449310|NCT04955158|DRUG|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack (Group D) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
40931175|NCT02548468|DRUG|Fludarabine|Given IV
41449311|NCT04955158|DRUG|Ketamine|50 mg ketamine soaked pharyngeal pack (Group K) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
41449312|NCT04955158|OTHER|saline 0.9%|20 ml 0.9% saline soaked pharyngeal pack (Group C) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
41449313|NCT06409377|DRUG|Precedex 200 MCG in 2 ML Injection|Patients received dexmedetomidine (1.5 μg/kg) as single injection over 10 minutes.
41449314|NCT06409377|OTHER|C group:|Patients received propofol (2 mg/kg), fentanyl (1 μg/kg), and atracurium (0.5 mg/kg).
41449315|NCT05429463|BIOLOGICAL|Sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
41449316|NCT05429463|DRUG|Carboplatin|AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
41449317|NCT05429463|DRUG|Albumin-Bound Paclitaxel|260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
41449318|NCT03785262|DEVICE|Uroshield|The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
40755198|NCT04882605|GENETIC|Assessment of KIR-based prediction scores|Compiling donor/recipient MHC and KIR typings into 28 major KIR-based prediction scores
40931176|NCT02548468|RADIATION|Total-Body Irradiation|Undergo TBI
40931177|NCT02548468|BIOLOGICAL|T Cell-Depleted Donor Lymphocyte Infusion|Undergo donor CD3+ enriched T lymphocyte infusion
40931178|NCT02548468|DRUG|Cyclophosphamide|Given IV
40931179|NCT02548468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSC transplant
41449319|NCT03785262|DEVICE|Sham Uroshield|The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
41449320|NCT05457413|PROCEDURE|Sleeve gastrectomy|Bariatric surgery
41449321|NCT06562959|BEHAVIORAL|Fluid Restriction Program|In order to design the fluid restriction program content (booklet). The fluid restriction program included (a) General small-group discussion sessions, (b) individualized consultations, and (c) follow-up sessions. In the group discussion sessions, children in both the study and control groups were divided into subgroups (6 participants per each). In the group discussion sessions, children in both the study and control groups were divided into subgroups. The sessions were conducted in the meeting room of the Hemodialysis unit lasts for 45 minutes. In the Individualized Consultations, children then were provided tailored, age-appropriate education. The researchers also arranged for regular follow-up for one months.
41449322|NCT06562959|OTHER|Intervention Bundle (Fluid Restriction Program and Auricular Acupressure|the study group received the Fluid Restriction Program and Auricular Acupressure in four acupoints namely, Shenmen, Kidney Concha, Point Zero and Upper Tragus. The researcher's finger gently pressed on each determined acupoints in a circular movement with a clockwise direction for three minutes.
41449323|NCT02182713|DRUG|Salbutamol sulfate/Ipratropium bromide|Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
40755199|NCT03193385|PROCEDURE|closed reduction|Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
41128797|NCT04075396|DRUG|Lazertinib|Participants will receive Lazertinib tablets once daily.
41128798|NCT00034489|DRUG|pemetrexed|
41128799|NCT00034489|DRUG|gemcitabine|
41449324|NCT02182713|DRUG|Salbutamol|Salbutamol 100 mcg per puff
41453459|NCT03711591|DEVICE|Conventus Cage PH device|The Conventus CAGE™ PH (PH Cage) is a permanent implant comprised of an expandable scaffold, made from nitinol and titanium, which is deployed into the medullary canal and provides a structure to which fractured bone fragments are attached using fragment screws.
40755200|NCT00420056|DRUG|PD-0332991|125 mg, oral, Days 1-21 of a 28-day cycle
40931180|NCT02548468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
40931181|NCT02548468|DRUG|Mycophenolate mofetil|Given IV
40931182|NCT02548468|DRUG|Tacrolimus|Given IV
40931183|NCT01721785|DRUG|GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]|Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
41128800|NCT01441284|DRUG|pramipexole|pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
41128801|NCT01441284|DRUG|placebo|placebo
41128802|NCT04931524|DRUG|carbon-14-[14C]-ANG-3777|Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
41128803|NCT06100159|DEVICE|Tympanostomy tube insertion|Ventilation tube insertion in the tympanic membrane
41128804|NCT00643188|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of atrial fibrillation
41128805|NCT00643188|OTHER|Conventional treatment|The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.
41128806|NCT01000805|DRUG|Duloxetine|Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
41453460|NCT00129038|DRUG|modified-release dipyridamole/aspirin|
41453461|NCT00129038|DRUG|aspirin|
41453462|NCT00095160|DRUG|852A|
41453463|NCT04469751|DIAGNOSTIC_TEST|invasive blood pressure monitoring|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
40931184|NCT03539224|DRUG|Dolutegravir (DTG)|DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks
40931185|NCT03539224|DRUG|Lamivudine (3TC)|Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.
40931186|NCT02091674|DEVICE|Hyaluronic acid|Injected gel
40931187|NCT00085228|BIOLOGICAL|oblimersen sodium|
40931188|NCT00085228|DRUG|docetaxel|
40931189|NCT05546801|OTHER|questionnaire|questionnaire on postnatal development
40931190|NCT02436655|PROCEDURE|surgical aortic valve replacement|open heart aortic valve replacement
41449325|NCT06628297|DIAGNOSTIC_TEST|PET|PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Four 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. Two consecutive 5-minute scans are conducted of the heart and brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce heart vasodilation, adenosine is infused (140 g/kg/min) for 6 min and a scan of the heart is repeated. To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Myocardial perfusion is calculated using CarimasCE software version 1.3.1. (Turku, Finland). Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
40931191|NCT00158821|DRUG|Viread (tenofovir disoproxil fumarate)|Tenofovir DF 300 mg tablets once daily
40931192|NCT00158821|DRUG|Sustiva (Efavirenz)|efavirenz capsules 600 mg once daily
40931193|NCT00158821|DRUG|Epivir (Lamivudine)|lamivudine 150 mg tablets twice daily
40931194|NCT00158821|DRUG|Zerit (Stavudine) Placebo|stavudine placebo capsules twice daily
40931195|NCT01599143|BEHAVIORAL|Teaching Mindfulness-based Stress Reduction strategies|Daily meditation, Hatha yoga,and cognitive restructuring
40931196|NCT05184439|PROCEDURE|Adductor magnus tenodesis for recurrent patellar dislocation|In all 33 patients (39 knees) adductor magnus tenodesis was performed to stabilise the patella. Adductor magnus tendon was harvested, cut proximally and fixed to the patella with proper tension.
41128807|NCT01000805|DRUG|Placebo|Participants received placebo QD, po for 8 weeks.
41128808|NCT02634450|DEVICE|Alere q|
41453464|NCT01782937|DRUG|KHK4827|140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
40931197|NCT04046588|DIAGNOSTIC_TEST|Infrared thermography|A thermal imager (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) will be used to record thermal images. The temperature of corresponding sites on the Heart and Lung meridians will be analyzed.
40931198|NCT04046588|PROCEDURE|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian, respectivey. During moxibustion, the temperature change of relevant sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~1. Intervention in the Heart meridian: moxibustion will be performed above the acupoint HT3 of the Heart meridian~2. Intervention in the Lung meridian: moxibustion will be performed above the acupoint LU5 of the Lung meridian."
40931199|NCT04212143|OTHER|there is no intervention|There is no intervention in this study. It is observational only.
40931200|NCT05338398|DEVICE|Bocaliner|Bocaliner is a soft, orally inserted device that has been demonstrated to increase the oral retention of oral, topical therapies such as mouthwashes and gels.
40931201|NCT05338398|DRUG|Benzydamine|Benzydamine is an anti-inflammatory and antibiotic mouthwash that has shown promise for the treatment of radiation-induced oral mucositis.
40931202|NCT03000803|BEHAVIORAL|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
40931203|NCT03000803|BEHAVIORAL|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
40931204|NCT02686190|OTHER|Luxtherapy|
40931205|NCT06185270|DIAGNOSTIC_TEST|SPPB|Short Physical Performance Battery using the automated device (Andantefit)
40931206|NCT04331197|DRUG|Clomiphene Citrate 50mg|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
40931207|NCT04331197|DRUG|Letrozole 2.5mg|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
40931208|NCT02902679|DRUG|BMS-986177|
40931209|NCT00703703|DRUG|Darifenacin|Darifenacin tablets 15 mg once daily
40931210|NCT00703703|DRUG|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
40931211|NCT00703703|DRUG|Placebo|Placebo tablet once daily
40931212|NCT06239818|DEVICE|Photobiomodulation therapy (PBMt)|Participants will be asked to use the photobiomodulation (PBM) device for 20 minutes, daily (e.g., Monday - Sunday) for a total of 30 days. The device will be preprogrammed and automatically switched off after 20 minutes.
41128809|NCT04436016|DRUG|Ivabradine|Ivabradine pills will be crushed and encapsulated for adequate dosing (0, 2.5mg, 5mg or 7.5 mg) and blinding.
41128810|NCT04436016|DRUG|Placebo|Mannitol will be encapsulated for adequate blinding.
41128811|NCT02568215|BIOLOGICAL|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
41128812|NCT02568215|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
41128813|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose|Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
41128814|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Medium Dose|Medium dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
41128815|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - High Dose|High dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
41128816|NCT04762914|OTHER|Prehabilitation|Prehabilitation is a multimodal and multidisciplinary person-centred perioperative approach involving supervised exercise training, nutritional education, management of polypharmacy and psychological advice.
41128817|NCT06449859|DRUG|TQC2938 Injection|TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
41128818|NCT06449859|DRUG|TQC2938 Placebo|TQC2938 Placebo is a placebo comparator
41128819|NCT02403375|DEVICE|Accu-Chek Insight Pump System|Continuous subcutaneous insulin infusion pump
41128820|NCT02260024|OTHER|High fat, high caloric meal|
40931213|NCT06239818|OTHER|Standard of Care|The patient is provided with verbal and written education including what a mild traumatic brain injury (mTBI) is, favorable expectations for recovery, and advice about how to manage specific symptoms. Relative rest for the first 24-48 hours after an mTBI is recommended as the main goal is to alleviate symptoms and reduce demands on the brain. After an initial period of relative rest and symptom stabilization, patients are encouraged to gradually resume normal daily activities as tolerated. Physical and cognitive activities can be progressively resumed at a pace that does not worse existing or create new symptoms. Education, return to activity advice, and symptom management are all reviewed in subsequent visits as needed.
40931214|NCT03479645|BEHAVIORAL|Serial text messages and mailed FIT kit|"1. Pre-alert SMS offering Opt-out of mailed FIT kit~2. Mailed home FIT kit~3. SMS A - Reciprocity message~4. SMS B - Offer for second FIT kit if lost/did not receive~   * Plus SMS A + C if second mailed FIT is requested.~5. SMS C - Salience message"
40931215|NCT05077917|DRUG|Cromolyn Sodium|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
40931216|NCT05077917|OTHER|Placebo|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
40931217|NCT05366010|DEVICE|Oscillation and Lung Expansion (OLE) therapy|Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
40931218|NCT03280927|DRUG|Jublia®|Jublia® topical solution
40931219|NCT04351061|DRUG|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 7 consecutive days.
40931220|NCT06064162|DRUG|ketamine|60mg (.5mg/kg over 40 minutes intravenously)
40931221|NCT01930331|DRUG|artemisinin/naphthoquine|"Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet))."
40931222|NCT01930331|DRUG|dihydroartemisinin/piperaquine phosphate|Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
40931223|NCT01767831|BEHAVIORAL|iBOLUSED|The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
40931224|NCT04820127|BEHAVIORAL|personalized care preceded by a standardized assessment|"* personalized intervention plan (PIP) proposed to the patient/caregiver dyad to correct potentially reversible causes of psycho-behavioral symptoms. This PIP will be re-evaluated and adapted at each visit by the nurse in close collaboration with the GP;~* PIP implementation will be based on a close follow-up during the 18 months follow-up coordinated by the nurse (3 memory consultation visits, 3 home visits (with the GP) and 6 phone calls). This follow up will be enhanced with the use of a web platform (allowing teleconsultation, tele-expertise and telemonitoring);~* specific training on psycho-behavioral symptoms for caregivers at baseline and during follow-up will be performed. On line training on psycho-behavioral symptoms management for GP will be available;"
40931225|NCT01063777|OTHER|A 12 week exercise therapy program and patient education.|"The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.~All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time."
41128821|NCT02260024|DRUG|Pramipexole IR tablets|
41128822|NCT02260024|DRUG|Pramipexole SR C|
41128823|NCT02260024|DRUG|Pramipexole SR C2|
41128824|NCT02260024|DRUG|Pramipexole SR C2A|
41128825|NCT02260024|DRUG|Pramipexole SR C2B|
41128826|NCT02213146|DRUG|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
41128827|NCT02213146|DRUG|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
41128828|NCT02213146|DRUG|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
41128829|NCT00139165|DRUG|Budesonide|Capsule. Oral 6 mg o.d. for 24 weeks
41128830|NCT00139165|PROCEDURE|sigmoidoscopy|Sigmoidoscopy performed 2 times during the study period.
41128831|NCT04010136|OTHER|Palliative care training|Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
41128832|NCT03489369|DRUG|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
41128833|NCT05080413|DEVICE|Laser shoes|Path Finder® is a device that is fixed to the noses of the patient's shoes using a rubber strap, and laser-marks the place to be stepped on the ground of the opposite foot when walking. It is installed on both feet to relieve the symptoms of freezing of gait.
41128834|NCT05080413|DEVICE|Metronome|The metronome, which makes a sound with a constant beat, is known to have an effect on the symptoms of Freezing of Gait in Parkinson's disease patients. At a rate of 80 beats per minute, the volume of sound that the patient can fully recognize is set to resolve the freezing of gait using the metronome sound.
41453465|NCT00285961|DEVICE|Cork splint materials (instead of plaster splint)|
41453466|NCT04508205|DRUG|CGB-400|BID application
40931226|NCT01063777|OTHER|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
40931227|NCT05415709|DRUG|Carboplatin|Given IV
40931228|NCT05415709|DRUG|Cisplatin|Given IV
40931229|NCT05415709|PROCEDURE|Cytoreductive Surgery|Undergo CRS
40931230|NCT05415709|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
40931231|NCT05415709|DRUG|Paclitaxel|Given IV
41128835|NCT04936386|BEHAVIORAL|Survey|The survey is composed of 4 different sections: the first section included questions about demographic data of participants; the second part evaluated responders' knowledge about FGM; the third section focused on participants' working experience with patients affected by FGM and personal attitude related to this topic.
41128836|NCT02436174|DEVICE|novel device|novel device being used to measure shivering
40755201|NCT05061095|OTHER|Assessment Surveys|Patients will complete surveys in three periods. An initial baseline survey, longitudinal assessments completed every 2 weeks over the course of the first three months on study (6 times maximum), and extended assessments that will happen every 3 months after the initial longitudinal period up to 2 years on the study (7 times maximum). Baseline questionnaire will collect demographic and background medical record information. Longitudinal assessments will consist of a BWS questionnaire (patients rate importance of 7 treatment goals), decisional conflict scales, EQ-5D-5L, distress thermometer, and items from PRO-CTCAE. Extended assessments will use same questionnaires as longitudinal assessments.
40755202|NCT05061095|OTHER|Qualitative Interviews|Patients will participate in 2 interviews (1 initial interview, 1 follow up). These will be cognitive interviews focusing on establishing content validity for BWS questionnaire. Will establish patient understanding of questions asked in BWS, understanding of how preferences affect treatment decisions, expected outcomes, and feedback from patients on other potentially important attributes not included in BWS.
40755203|NCT01520662|OTHER|Implementation of a secure web-based patient Wellness Portal|Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
40931232|NCT05415709|OTHER|Quality-of-Life Assessment|Ancillary studies
40931233|NCT05415709|OTHER|Questionnaire Administration|Ancillary studies
40931234|NCT06521099|BEHAVIORAL|Evaluative Conditioning with positive stimuli|In the pre-conditioning phase, participants will be exposed to pictures that vary in their emotional (negative, positive) and social (non-social, social) content. For each picture, they are required to indicate their immediate perceived valence (between negative to positive), degree of social engagement (between none to high), experiences of the scenes (never to always) on Likert-scales. In the conditioning phase, the most negative and most positive social pictures perceived by each participant in their pre-conditioning phase will be selected and paired with positive stimuli for trials in random order, for 6 sessions across 3 weeks. In the post-conditioning phase, participants will be asked to evaluate the valence of the stimuli again similar to that in pre-conditioning phase.
41128837|NCT04180683|OTHER|Battery of screening tests with semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria and an ID will be assigned to the participants that meet the criteria. Posteriorly, a clinical psychologist will administer the GDS-30, GDS-15, GDS-10 and GDS-5, the BDI-II and a semi-structured interview about depressive disorders according to the DSM-5 criteria. Participants with even ID's from each institution will be answer the instruments according to the order GDS-30, GDS-10, BDI-II, GDS-5 e GDS-15 and participants with odd ID's will answer the battery in the reverse order. The assessment session will take place in a single moment in time. After the assessment, the clinical psychologist will answer a questionnaire about which version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
41278583|NCT05519696|BEHAVIORAL|Intervention|Participants receiving the intervention will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting and includes a focus on cultural topics related to collectivism. Participants receive FitBits to track their physical activity and through the FitBit mobile app are connected to their group members to encourage communication and social support.
41453467|NCT02679729|DRUG|AZD5634 for inhalation|Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
40755204|NCT02998125|PROCEDURE|Total knee arthroplasty|prospective assessments for the functional outcome before and after the total knee arthroplasty
40931235|NCT06521099|BEHAVIORAL|Conditioning with neutral stimuli|In the pre-conditioning phase, participants will be exposed to pictures that vary in their emotional (negative, positive) and social (non-social, social) content. For each picture, they are required to indicate their immediate perceived valence (between negative to positive), degree of social engagement (between none to high), experiences of the scenes (never to always) on Likert-scales. In the conditioning phase, the most negative and most positive social pictures perceived by each participant in their pre-conditioning phase will be selected and paired with with neutral stimuli for trials in random order, for 6 sessions across 3 weeks. In the post-conditioning phase, participants will be asked to evaluate the valence of the stimuli again similar to that in pre-conditioning phase.
40931236|NCT03838783|DRUG|Insulin Degludec|50% of the patient's daily basal insulin dose delivered through once daily insulin degludec injected in the morning; 50% of the basal insulin to be delivered through previously established CSII
40931237|NCT04420754|BIOLOGICAL|AIC100 CAR T Cells|Autologous CAR T cells directed against ICAM-1
40931238|NCT02850081|DRUG|Statin|"Standard of care treatment (one of four):~* Simvastatin (to 40mg without amlodipine)~* Simvastatin (to 20 mg if currently on amlodipine)~* Atorvastatin (to 80mg)~* Rosuvastatin (to 20mg)"
40931239|NCT02850081|DRUG|Atorvastatin|"A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules"
40931240|NCT02850081|OTHER|Placebo|A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.
40931241|NCT00084591|DRUG|capecitabine|
40931242|NCT00084591|PROCEDURE|conventional surgery|
40931243|NCT00084591|PROCEDURE|neoadjuvant therapy|
40931244|NCT00084591|RADIATION|radiation therapy|
40931245|NCT02986880|DRUG|Botulinum toxin A|
40931246|NCT02986880|PROCEDURE|Placebo|Injection of sodium chloride (NaCl) 9/1000
40931247|NCT01768247|DRUG|HCG (human chorionic gonadotropin)|150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
40931248|NCT03191578|DRUG|RUTI®|Administration of RUTI®
41128838|NCT04180683|OTHER|Battery of screening tests without semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria an ID will be assigned to the participants that meet the criteria. Posteriorly, a psychologist will administer the GDS-30, GDS-15 and the BDI-II. Participants with even ID's from each institution will answer the instruments according to the order GDS-30, BDI-II and GDS-15 and participants with odd ID's the administration order will answer the battery in the reverse order. The assessment session will take place in a single moment in time.
41128839|NCT05224986|BEHAVIORAL|Fixed Schedule|Participants will be asked to maintain a fixed schedule for 12 weeks.
41128840|NCT05909670|BEHAVIORAL|Family Advice and Support Text and Telephone (FASTT) program|The Family Advice Support Text and Telephone (FASTT) service is a telehealth model that provides on-demand, evidence-based advice and support to reduce child behavior problems, address concerns about child development, and help manage stress for caregivers of children with DD. By using text and telephone, which are widely available without disparities in access by race, ethnicity, or socioeconomic status, FASTT overcomes barriers associated with videoconferencing which requires dependable Internet and familiarity with technology use. FASTT allows support to be delivered at times and locations that are convenient for the caregiver.
40931249|NCT03191578|DRUG|Placebo|Administration of placebo
40931250|NCT02477423|DRUG|Ampicillin|Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
40931251|NCT02477423|DRUG|Gentamicins|Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
40931252|NCT02477423|DRUG|Placebo|Normal saline will be given as placebo for those in the placebo comparator group.
40931253|NCT02533791|BIOLOGICAL|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)|one dose, 4×10\^10vp/1ml per dose
40931254|NCT02533791|BIOLOGICAL|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)|two doses, 0.8×10\^11vp/1ml per dose, with one dose to each arm at the same time
40931255|NCT02533791|BIOLOGICAL|placebo|
40931256|NCT04489901|OTHER|Olive oil|To apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
40931257|NCT01380938|DRUG|Peginterferon alpha-2a + Ribavirin|"Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight \< or \> 75 kg for 24 weeks (Arm A).~Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).~These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)"
40931258|NCT04945642|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR-BT
40931259|NCT04945642|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
40931260|NCT00688207|DRUG|Rosiglitazone (Extended Release)|open-label, single, oral, 4mg dose
41128841|NCT02695134|OTHER|Healing Touch|Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
41128842|NCT04257487|DRUG|Sulodexide|2 soft capsules of Vessel® 250 LSU BID for 12 months
41128843|NCT04257487|DRUG|Sulodexide and placebo|1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
41128844|NCT04257487|DRUG|Placebo|Sugar pill manufactured to mimic sulodexide 250 LSU
41128845|NCT01260870|DEVICE|Cotavance Paclitaxel Coated Balloon|
41128846|NCT01260870|DEVICE|Standard balloon angioplasty|
41128847|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
40931261|NCT03490162|DRUG|DM1157|DM1157 is a novel anti-malarial drug that is derived from chloroquine. DM1157 maintains the efficacy of chloroquine and has molecular features that overcome resistance to chloroquine.
40931262|NCT03490162|OTHER|Placebo|Placebo
41128848|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
40931263|NCT03965000|OTHER|Mixed-meal-tolerance-test|To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.
40931264|NCT01934543|OTHER|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
40931265|NCT01934543|OTHER|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
41128849|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
41449326|NCT04552990|DRUG|Jet injection of ALA|The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).
41449327|NCT04552990|PROCEDURE|Surgical excision|In the first 4 patients, the tumor will be excised according to national guidelines after 3h incubation (+/- 30 min is accepted).
41128850|NCT01206972|DRUG|Enoxaparin|daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
41449328|NCT04552990|PROCEDURE|Illumination|For patients 5-16,after 3h incubation (+/- 30 min), the tumor will be illuminated with red light corresponding to a dose of 75 J/cm2 570- 670 nm or equivalent dose of narrowband red light. The intervention will be repeated at after 14 days in patient 5-16. If the wound is not healed at two weeks, the treatment may be postponed to allow healing (patient 5-16).
41128851|NCT00255307|DRUG|CVT-E002 ginseng extract|
41128852|NCT01343459|RADIATION|HIOB|"IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)~* IOERT is performed on mobile or fixed linacs~* Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).~WBRT~* must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)~* In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.~* Single reference dose per fraction: 2,7 Gy (ICRU)~* Number of fractions: 15, Number of fractions per week: 5~* Total WBRT dose: 40,5 Gy"
40755205|NCT04948632|OTHER|Complete LeoMed application|Access to the complete LeoMed application on the participant's smartphone. The day before surgery, participants will receive notifications encouraging them to use the platform to help prepare for their surgery. Safety instructions will also be sent. Postoperatively, notifications will be sent to the participants every day during the first 4 days and on the 7th day. These notifications will direct them to online forms that aim to assess their condition. On the 15th and 30th postoperative day, the platform will send a follow-up form. The platform will collect this information and classify it for appropriate management of their condition.
40931266|NCT04351776|OTHER|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora application
40931267|NCT04351776|OTHER|VR-Distraction|Participants will be instructed to use one of three applications
40931268|NCT04351776|OTHER|360 Video|Participants will be instructed which video to view
41128853|NCT01784328|DEVICE|Peristeen Bowel Irrigation System|A complete system for bowel Irrigation to manage bowel dysfunction
41128854|NCT03205566|DRUG|Raltegravir 400Mg Tab|bd for 7 days
41128855|NCT03205566|DRUG|Lamivudine 150Mg Tablet|+ Raltegravir 400Mg tablet bd for 7 days
41128856|NCT03980613|OTHER|Triage|Emergency telephone calls from cases and controls are replayed and analyzed for symptom descriptions indicating spontaneous subarachnoid haemorrhage.
41128857|NCT00649805|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose applesauce
41128858|NCT00649805|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose applesauce
41128859|NCT06020352|DRUG|KN046 plus Axitinib|KN046 combined with axitinib as a neoadjuvant treatment regimen
41128860|NCT01286636|OTHER|computer model|Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.
41128861|NCT01286636|OTHER|Polysomnogram|Diagnosis of sleep apnea will rely on polysomnogram
41128862|NCT05508737|DRUG|Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)|Single arm: Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
41128863|NCT05879419|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (RZV)|RZV comprise 50 μg of recombinant VZV glycoprotein E and the liposome-based AS01B adjuvant system (which contains 50 μg of 3-O-desacyl-4'-monophosphoryl lipid A \[MPL\] and 50 μg of Quillaja saponaria Molina, fraction 21 (QS21, licensed by GSK from Antigenics, a subsidiary of Agenus)). Vaccine will be administered (0.5 ml) into the deltoid muscle at inclusion and 6 weeks (two doses).
41128864|NCT05879419|OTHER|MTX Discontinuation|Evaluation of discontinuation of the use of methotrexate (MTX) for 2 weeks after each vaccine dose in ARD patients: patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
41449329|NCT04552990|OTHER|Incubation|After injection of ALA, the tumor will be occluded with a light proof dressing and incubated for 3h (+/- 30 min).
41128865|NCT05879419|OTHER|MMF Discontinuation|Evaluation of discontinuation of the use of mycophenolate mofetil (MMF) for one week after each vaccine dose in ARD patients: patients using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for 2 weeks after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
40931269|NCT04632914|OTHER|trunk stabilizing exercise|trunk stabilizing exercise is a group of exercise which train the anterior thoracic cage and abdominal muscles in the form of static contraction of these muscles from a different position supine, sitting and standing.
40931270|NCT04632914|OTHER|cardiac rehabilitation programe|all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
40931271|NCT00804037|PROCEDURE|Injection Snoreplasty|Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
40931272|NCT03444532|BEHAVIORAL|12-week aerobic exercise and cognitive-behavioral therapy|12-week intervention of aerobic exercise training and four session of cognitive-behavioral therapy
41128866|NCT05879419|OTHER|Placebo|Patients with ARDs who received the placebo at study entry (P2). ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126.
41128867|NCT05879419|OTHER|MTX maintain|MTX dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MTX-withhold group.
41128868|NCT05879419|OTHER|MMF maintain|MMF dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MMF-withhold group.
41128869|NCT01186224|DRUG|Plerixafor and G-CSF|"G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.~The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily."
41128870|NCT02291094|DRUG|Lidocaine|Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
41128871|NCT02291094|DRUG|Remifentanil|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
41128872|NCT05746234|BEHAVIORAL|Emotion Regulation Course|"Each module contains a) the session outline, b) review of previous session's homework, c) theoretical background and module's rationale, d) skills activities, and e) homework assignment.~Each group will attend five 1.5-hour sessions with their allocated instructor. Participants in both groups will receive the same training modules in the same chronological order. For consistency across modalities, participants will receive an instructor's manual containing the core material for facilitating the ER4ALL training, and a companion students' workbook with supporting information and activities."
41128873|NCT02408887|PROCEDURE|Total Thyroidectomy (TT)|Total removal of thyroid
41128874|NCT02408887|PROCEDURE|Prophylactic central neck lymph node dissection (pCND)|Lymph node dissection
41128875|NCT05838781|DIAGNOSTIC_TEST|Risk prediction model|A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.
40931273|NCT01676597|DRUG|pentoxifylline and rifaximin|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
40931274|NCT01676597|DRUG|Pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
41128876|NCT05838781|DIAGNOSTIC_TEST|14-days continuous ECG monitoring|14-days continuous ECG monitoring with an ECG patch.
41128877|NCT00090519|DRUG|ruboxistaurin|32 mg once daily (QD) oral for up to 36 months
41128878|NCT00090519|DRUG|placebo|QD oral for up to 36 months
40931275|NCT04638504|OTHER|ultrasonography|vascular and adipose tissue measurement by ultrasonography
40931276|NCT04252833|DRUG|CT-044|CT-044 HCl is a reactive species decomposition accelerant
40931277|NCT05150444|OTHER|Cognitive and physical exercise training|"12 weeks (3 times a week): patients will cycle on an adapted ergometer during their dialysis procedure. The exercise program will be run by kinesiologists. Participants will start with 15 minutes of cycling and then gradually increase the time and intensity. After the physical exercise session, they will continue with cognitive training. This training will be done on a tablet computer on a CogniFit platform (\~30 minutes). The brain games on mentioned platform automatically adapt to individual cognitive abilities."
40931278|NCT05243550|DRUG|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
40931279|NCT02280083|DRUG|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
40931280|NCT02280083|DRUG|placebo|placebo
40931281|NCT06506071|DIAGNOSTIC_TEST|Spectral CT|Myocardial tissue characterization with Spectral CT
40931282|NCT05210764|DRUG|propofol|General anesthesia is induced and maintained mainly with propofol.
40931283|NCT05210764|DRUG|sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
40931284|NCT05210764|DRUG|S-ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
40755206|NCT04948632|OTHER|Basic LeoMed application|Access to a partial version of the LeoMed application on the patient's smartphone during a visit to the preoperative clinic. Before surgery, participants will receive a phone call to be summoned to the hospital and to remind them of the safety instructions. Postoperatively, their follow-up will not be standardized and will vary depending on their surgeon. On the 15th and 30th postoperative day, the platform will send a follow-up form. In the event of an emergency, they will receive the contact details of the CHUM Health Infoline to ensure the continuity of their care.
40931285|NCT02440412|OTHER|Massage Therapy|It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
40755207|NCT01748552|DRUG|Placebo|Administered orally as capsules
41449330|NCT01188863|DRUG|300 mg LX4211 (150 mg tablets)|Single oral dose of two 150 mg tablets LX4211
40755208|NCT01748552|DRUG|LY2922083|Administered orally as capsules
40755209|NCT05315778|BIOLOGICAL|autologous anti-BCMA chimeric antigen receptor T cells|Lymphoadenodepletion chemotherapy with FC (fludarabine 30mg/ m2 for 3 consecutive days and cyclophosphamide 300mg/m2 for 3 consecutive days) will be given at day -5, -4 and -3 before CAR T-cells infusion. A total of 1.0-2.0×10e7/Kg autologous anti-BCMA CAR T-cells will be infused by dose-escalation after the lymphoadenodepletion chemotherapy. Dose of CAR T-cells are allowed to be adjusted according to the severity of cytokine release syndrome.
40755210|NCT02537925|DRUG|Celecoxib|Celecoxib 200mg bid po, to the end of concurrent radiotherapy
40755211|NCT02537925|DRUG|Nedaplatin|40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
40931286|NCT02440412|OTHER|Rest in supine|It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
40931287|NCT04647487|DRUG|LY3484356|Administered orally.
40931288|NCT01209832|DRUG|Tasisulam|Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
40931289|NCT01209832|DRUG|Midazolam|1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
40931290|NCT01634178|DRUG|Apremilast|Tablet for oral administration
40931291|NCT02721186|DRUG|MDA with DHAp and SLD Primaquine|
40931292|NCT01872325|BEHAVIORAL|Education|An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
40931293|NCT03553030|DEVICE|coronary artery angiography|In all patients authors performed a coronary artery angiography for detection of coronary artery stenosis.
40931294|NCT02225392|PROCEDURE|Bronchial thermoplasty|Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.
40931295|NCT02225392|DEVICE|Alair system (Boston Scientific, USA)|The alair system consist of a controller and a bastket catheter.
40931296|NCT00203281|DRUG|tacrolimus|
40931297|NCT00203281|DRUG|mycophenolate mofetil|
40931298|NCT00203281|DRUG|daclizumab|
40931299|NCT00203281|DRUG|intravenous immune globulin|
40931300|NCT00203281|PROCEDURE|plasmapheresis|
40931301|NCT03742648|OTHER|Physiotherapy|Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
40931302|NCT04089215|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 be administered at dose level: 1 x 10\^8 CAR+T cells and 1.5 x 10\^8 CAR+T cells
40931303|NCT01489111|DRUG|turoctocog alfa pegol|Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
41449331|NCT01188863|DRUG|300 mg LX4211 (50 mg tablets)|Single oral dose of six 50 mg tablets LX4211
41449332|NCT01188863|DRUG|300 mg LX4211 (liquid)|Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
41453468|NCT02679729|DRUG|AZD5634 for infusion|Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
40755212|NCT02537925|RADIATION|Concurrent Radiotherapy|The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
40931304|NCT05937776|OTHER|Fludeoxyglucose F-18|Given IV
40931305|NCT05937776|OTHER|Gadoterate Meglumine|Given IV
40931306|NCT05937776|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo PET/contrast-enhanced MRI
40931307|NCT05937776|PROCEDURE|Positron Emission Tomography|Undergo PET/contrast-enhanced MRI
40931308|NCT01523470|DEVICE|BIPAP Synchrony|BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
40931309|NCT03784924|DIAGNOSTIC_TEST|MRI prostate|MRI and laboratory biomarkers
40931310|NCT04730414|DRUG|Full-spectrum hemp (0.018% THC)|Topical Application
40931311|NCT00739596|DRUG|Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
41453469|NCT02679729|OTHER|Placebo|inactive substance
41453470|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 1|
41453471|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 2|
41453472|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 3|
41453473|NCT01252758|OTHER|Placebo|
41453474|NCT01252758|DRUG|Albuterol|
41453475|NCT01252758|DRUG|Albuterol|
41449333|NCT05915858|OTHER|muscle energy technique|"Group 1: Group 2:~Muscle energy technique (Reciprocal inhibition) Stretching exercises Static stretching 2 weeks (twelve treatment session) patient supine, the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra-lateral knee (the leg on the side to be treated is crossed over the other, straight leg).~* The angle of hip flexion should not exceed 60 degree.~* The practitioner places one hand on the contra-lateral ASIS to prevent pelvis motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis for 7-10 seconds."
40931312|NCT00739596|DRUG|Amlodipine: 8 weeks|Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
40931313|NCT03021564|OTHER|cardiopulmonary resuscitation|Basic cardiopulmonary resuscitation : external electric shock, external cardiac massage, adrenaline injection ...
40931314|NCT03778775|DIAGNOSTIC_TEST|Liver sitffness measurement|Liver sitffness measurement is performed by FibroTouch, a new-generation of transient elastography with the tesing interval between liver sitffness measurement and esophagogastroduodenoscopy less than one week.
40931315|NCT00206076|DRUG|mycophenolate mofetil|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
40931316|NCT00206076|DRUG|mycophenolate mofetil|mycophenolate mofetil monotherapy
40931317|NCT00375375|DRUG|Lactulose|
40931318|NCT05765227|DEVICE|Lehfilcon A multifocal contact lenses|Investigational silicone hydrogel multifocal contact lenses
40931319|NCT05765227|DEVICE|Lotrafilcon B multifocal contact lenses|Commercially available silicone hydrogel multifocal contact lenses
40931320|NCT05765227|DEVICE|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
40931321|NCT01357200|OTHER|enteral formula|Complete feeding of study enteral formula, route and regime prescribed by the physician.
40931322|NCT01303003|DRUG|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
40931323|NCT01303003|PROCEDURE|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
40931324|NCT00907660|BEHAVIORAL|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
40931325|NCT00907660|DIETARY_SUPPLEMENT|Portion-Controlled Foods|"Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study."
40931326|NCT01133028|BEHAVIORAL|Behavioral contingency management|Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
40931327|NCT01133028|BEHAVIORAL|Tolerance training|Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
40931328|NCT03785743|PROCEDURE|TLPD Surgery|TLPD
40931329|NCT03785743|PROCEDURE|OPD Surgery|OPD
40931330|NCT04399174|DEVICE|US|
40931331|NCT06301243|OTHER|Inactivity|Low physical activity level prior to the exercise intervention.
40931332|NCT04440371|COMBINATION_PRODUCT|Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly|Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)
41128879|NCT00293397|DEVICE|Drug-eluting beads loaded with doxorubicin hydrochloride|Doxorubicin eluting beads
41128880|NCT02513667|DRUG|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
41128881|NCT02513667|RADIATION|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
41449334|NCT05915858|OTHER|stretching exercise|"Following the contraction the practitioner eases the treated side leg into adduction until a sense of resistance is noted; this is held for 10-30 seconds. 2 week (twelve treatment session) practitioner manual stretches the piriformis:~* The patient lies in supine position the affected leg is placed into flexion at hip and knee so that the foot rests on the table lateral to the contra-lateral knee.~* The practitioner places one hand over the contra-lateral ASIS to stabilize the pelvis during the exercise and passively abducts and internally rotates the hip medially till the pain is bearable.~* The process is repeated 3-5 times with a 30"
40931333|NCT04440371|COMBINATION_PRODUCT|Calcipotriol/Betamethasone ointment plus NBUVB|Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly
40931334|NCT03924271|DIAGNOSTIC_TEST|Iron deficiency testing|Blood sample for complete iron status
40931335|NCT05258669|BIOLOGICAL|BBV152|Each participant will receive 2 doses of the investigational product intramuscular injection of either 6 μg of BBV15 vaccine or placebo.
40931336|NCT02744937|DRUG|Aspirin|aspirin is continued by its regular dosing
40931337|NCT01165567|DRUG|sarpogrelate|sarpogrelate, 300mg/day,duration: 4 weeks
40931338|NCT05982951|PROCEDURE|Shoulder PENG block|Ultrasound guided insertion of a needle between subscapularis tendon and deltoid with injection of 10 mi 0.25% bupivacaine after confirming right plane of injection
40931339|NCT00197067|BIOLOGICAL|RTS,S/AS02D and RTS,S/AS02A|
40931340|NCT00708201|DRUG|Alvimopan|
40931341|NCT00708201|DRUG|Placebo|
40931342|NCT05304091|OTHER|Questionnaire on a smartphone application|Each day, the smartphone application will ask the patient if he or she is having an angioedema attack. It not, the questionnaire will stop. If the patient is having an attack, a series of 5 short questions is asked about the attack characteristics and the events that preceded it.
40931343|NCT02206243|DRUG|Embozene Microspheres|Intraarterial application
40931344|NCT04333043|DIAGNOSTIC_TEST|audiological test, cognitive questionnaires|administration of cognitive and quality of life questionnaires and audiological test
40931345|NCT02912143|OTHER|documentation only|
40931346|NCT03744143|PROCEDURE|longitudinal suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture
40931347|NCT03744143|PROCEDURE|transverse suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture
40931348|NCT03744143|PROCEDURE|Removal of vaginal endometriotic nodule|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
40931349|NCT02739737|OTHER|Blinded manuscript|Blinded version of sham manuscript
40931350|NCT02739737|OTHER|Unblinded manuscript|Unblinded version of sham manuscript
40931351|NCT00355277|DRUG|Amitriptyline|
40931352|NCT00463073|DRUG|Cetuximab|
40931353|NCT00463073|DRUG|Bevacizumab|
41449335|NCT05288972|DEVICE|Mattress 1|A mattress (M1) with the technical features suitable for scoliosis with supports the spine properly. The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
41449336|NCT05288972|DEVICE|Mattress 2|A mattress with standard technical features (M2). The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
40931354|NCT00463073|DRUG|Irinotecan|
40931355|NCT05002920|PROCEDURE|alveolar bone grafting|the surgery of alveolar bone graft for alveolar defect in cleft patients
40931356|NCT00971620|BIOLOGICAL|Botulinum toxin type A|Given as an intralesional injection.
40931357|NCT00971620|OTHER|Placebo|Given as an intralesional injection
41128882|NCT03752216|DRUG|Niraparib|"Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight \< 77 kg or a platelet count \<150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria."
41449337|NCT04963270|DRUG|Satralizumab|Satralizumab will be administered as a subcutaneous injection
41449338|NCT04963270|OTHER|Placebo|Satralizumab placebo will be administered as a subcutaneous injection
41449339|NCT06588634|DEVICE|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
41128883|NCT03926026|DRUG|Fluticasone Propionate|NCX 4251 Ophthalmic Suspension, 0.1%
41128884|NCT03926026|DRUG|Placebo|NCX 4251 Ophthalmic Suspension, 0%
41128885|NCT04383184|PROCEDURE|tracheoplasty|tracheoplasty and only left pulmonary artery transplantation
41449340|NCT06588634|PROCEDURE|Standard of Care|Standard of care treatment for pulmonary embolism
40931358|NCT05604053|BEHAVIORAL|Motivation Manipulation|On some trials, participants have lower motivation and on other trials participants have higher motivation.
40931359|NCT03413943|OTHER|gaze training|Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.
40931360|NCT00719433|DEVICE|robot therapy (ARMin)|therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
40931361|NCT00719433|OTHER|conventional therapy|physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
41449341|NCT05772702|DEVICE|Closed-loop tACS|Individual alpha tACS
41449342|NCT05016427|BIOLOGICAL|VT301|VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10\^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.
40931362|NCT02387255|DEVICE|Resoundant Driver System|This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
40931363|NCT00586326|DEVICE|MammoSite Radiation Therapy System|The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
40931364|NCT01214148|DEVICE|ORSIRO - Drug Eluting Coronary Stent|The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
40931365|NCT01180530|DEVICE|NovoPen Echo®|Prescribed insulin treatment delivered by NovoPen Echo®
40931366|NCT02519855|BIOLOGICAL|ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
40931367|NCT02519855|BIOLOGICAL|Placebo to ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
40931368|NCT02519855|BIOLOGICAL|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
40931369|NCT05300373|DIAGNOSTIC_TEST|ADENOSINE DEAMINASE TEST|ADENOSINE DEAMINASE DEFICIENCY TEST
40931370|NCT04691947|BIOLOGICAL|ERUCOV-VAC|Vaccination on Day 0 and Day 21
40931371|NCT04691947|OTHER|Placebo Vaccine|Placebo Vaccination on Day 0 and Day 21
40931372|NCT04425044|OTHER|Other|No Intervention
40931373|NCT04031677|PROCEDURE|Surgery|Large en-bloc curative-intent surgery
41128886|NCT02852252|DRUG|OTL38|Patients will be given imaging agent 2-3 hours before surgery to assist in imaging.
41128887|NCT02852252|DRUG|ICG|Patients will be given imaging agent 24 hours before surgery to assist in imaging.
41128888|NCT06452173|DIAGNOSTIC_TEST|Plasma|Plasma levels of metabolites and some proteins will be further determined
41128889|NCT06452173|DIAGNOSTIC_TEST|carotid high-resolution magnetic resonance imaging|Define plaque composition and morphological characteristics
41128890|NCT03973515|DRUG|glucokinase activator|PB-201 is a kind of dual and partial GKA
41128891|NCT03973515|DRUG|Placebo|Placebo oral tablet
41128892|NCT03355534|DRUG|Intravenous dexmedetomidine|drug is intravenously infused to patients
41278584|NCT05519696|BEHAVIORAL|Comparison|Participants receiving the comparison program will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, group walking program, and individual-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting only (and no focus on collectivism). Participants receive FitBits to track their physical activity, but are not connected to their group members on the mobile app.
40931374|NCT04031677|DRUG|Preoperative chemotherapy|"* High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks~* LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks~Note: the recommended dose of Doxorubicin (or Epirubicin) can be modified according to national/institutional guidelines, given that the minimal threshold must be Doxorubicin 60 mg/m2 per cycle (or the equivalent Epirubicin 95 mg/m2 per cycle); the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimal threshold must be 7.5 g/m2 per cycle; the recommended dose of Dacarbazine can be modified according to national/institutional guidelines, given that the minimal threshold must be 900 mg/m2 per cycle. The schedule of administration of above chemotherapies can be modified according to national/institutional guidelines provided that the minimal threshold of doses, and the treatment periods with chemotherapies remain the same."
40931375|NCT05287360|DRUG|Rivoceranib|Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
40931376|NCT05421650|RADIATION|CCRT|"1. Radiation: Extended field-external beam radiation therapy (EF-EBRT) + brachytherapy + lymph node boost.~2. Chemotherapy: Cisplatin 40mg/m2, every week, 4 to 6 cycles.~3. Radiation and chemotherapy are administered concurrently."
40931377|NCT05421650|PROCEDURE|Surgical debulking of bulky or multiple lymph nodes|"1. Open/minimally invasive method.~2. Surgical debulking of bulky or multiple lymph nodes.~3. Postoperative imaging evaluation to determine whether the lymph node has been successfully removed."
40931378|NCT05421650|RADIATION|CCRT|"1. Radiation: EBRT/EF-EBRT + brachytherapy + lymph node boost.~2. Chemotherapy: Cisplatin 40mg/m2, every week, 4 to 6 cycles.~3. Radiation and chemotherapy are administered concurrently."
40931379|NCT03271294|DEVICE|Exair Transvaginal Mesh|Exair transvaginal mesh system for the treatment of pelvic organ prolapse
40931380|NCT06520540|DRUG|HDM1002 100 mg QD 12weeks|Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)
41128893|NCT03355534|DRUG|nasal dexmedetomidine|drug is nasally given to patients
41128894|NCT03355534|DRUG|intravenous saline|saline is given to patients intravenously
41128895|NCT03355534|DRUG|nasal saline|normal saline is given to patients nasally
41128896|NCT05523869|DRUG|Intravitreal topotecan|Patients meeting all inclusion criteria and not meeting exclusion criteria will be assigned to receive pars plana vitrectomy with or without scleral buckle with intravitreal topotecan 8 µg/0.1mL, administered preoperatively within one week from surgery, intraoperatively during surgery, as well as postoperatively at 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks, for a total of 7 injections.
41128897|NCT05523869|PROCEDURE|Pars plana vitrectomy with or without scleral buckle|Standard three-port pars plana vitrectomy with or without scleral buckle.
41278585|NCT03754049|DRUG|TLC599|TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).
41278586|NCT03754049|DRUG|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
41278587|NCT03818035|DRUG|Guselkumab|Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
41278588|NCT03818035|DRUG|Placebo Injection|Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
41449343|NCT04122950|BEHAVIORAL|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of three times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
41449344|NCT04483921|OTHER|Acute exercise|Participants will complete a morning exercise bout at 70% of their individual maximal aerobic capacity to burn 200 kilocalories above their basal metabolic rate.
40931381|NCT06520540|DRUG|HDM1002 200 mg QD 12weeks|Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)
40931382|NCT06520540|DRUG|HDM1002 400 mg QD 12weeks，Q 2W for titration|Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration
41128898|NCT01218841|DIETARY_SUPPLEMENT|Fish oil lipid emulsion|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
41128899|NCT01218841|DIETARY_SUPPLEMENT|MCT/LCT|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
41128900|NCT05390905|DRUG|HSK21542 Injection|1μg/kg/dose
41128901|NCT05390905|DRUG|Tramadol hydrochloride|50mg/dose
41128902|NCT05390905|DRUG|placebo|placebo
41128903|NCT03422549|DEVICE|Drager VN500 Ventilator|This ventilator is capable of providing both CPAP and NHFOV support.
41128904|NCT05179187|BEHAVIORAL|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
41128905|NCT06231316|DRUG|Norepinephrine Injection|Norepinephrine is both a neurotransmitter and a hormone. It is essential vasopressor for rapid blood pressure support, crucial in maintaining hemodynamic stability
40931383|NCT06520540|DRUG|HDM1002 400 mg QD 12weeks，Q 3W for titration|Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration
40931384|NCT06520540|DEVICE|Placebo|Placebo
40931385|NCT02749955|BEHAVIORAL|PS-PrEP Intervention Group|This group will involve working with a PS-PrEP social worker to learn about PrEP. The PS-PrEP social worker will help subjects develop a care plan based on the subject's decision about whether or not to use PrEP. This may include referrals for PrEP, other services, and/or HIV testing. Personal contact will continue by way of phone calls, and messages in between visits.
40931386|NCT02749955|BEHAVIORAL|PrEPLine Control Group|This group follows routine department of public health care as a Linkage to Care Specialist from the PrEPLine provides subjects with PrEP education and the ability to schedule an initial PrEP appointment. In addition to this care, subjects will be referred for additional testing for STIs/HIV and subjects will be given information about programs available to prevent HIV infection, which include PrEP.
40931387|NCT03291418|DRUG|ATB-346 OR Placebo|Comparison of gastrointestinal effects
40931388|NCT03291418|DRUG|Naproxen sodium|Comparison of gastrointestinal effects
40931389|NCT05843773|PROCEDURE|Low Load Strength Training under Blood Flow Restriction|"The first training includes one initiation/warm up set and two sets of normal training. Every set lasts 60 seconds and the patient is asked to bend and stretch the knee with a standard speed of 20°/s.~From the second to the ninth training, the patient will have one warm up set plus three trainings sets. The speed of execution will be increased every training.~The 20-40% range of the 1RM will be applied according to the values of the theoretical maximal strength.~If no strength progression is observed in the three last training sessions, the speed of execution will automatically be increased by 15°/s.~In order to keep the training intensity low and to not overload the knee, participants will be instructed to control the intensity with the Borg CR10. The volunteers will have to keep their efforts between 2/10 and 4/10. They will also be asked to stay in the range defined thanks to the theoretical maximal strength shown by the screen."
40931390|NCT04074239|OTHER|Video triage|The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
40931391|NCT02565927|DEVICE|Traditional airway stent|process airway stenting
40931392|NCT02565927|DRUG|Iodine-125 seeds|process intraluminal brachytherapy
40931393|NCT06142526|DEVICE|DividPro film|DividPro Film is a sterile biodegradable translucent film that served as a physical barrier for preventing the adhesion between two adjacent layers of tissue in wound healing process.
40931394|NCT02904447|OTHER|x-ray and pedobar foot pressure mapping|
40931395|NCT01584570|DRUG|0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min|ECG monitoring for evaluation of QTc interval
40931396|NCT00156702|BEHAVIORAL|Feedback and Motivational Interviewing|
40931397|NCT00156702|BEHAVIORAL|Smoking Prevention Video|
40931398|NCT02914015|PROCEDURE|Continous QLB (quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major muscle with catheter insertion and continuous local infusion
40931399|NCT02914015|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
40931400|NCT02914015|DRUG|Ropivacaine|"* 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline given immediately after the correct position of the tip of the needle has been verified.~* followed with 0.2% ropivacaine infusion at a rate of 0.125ml/kg/h given through the catheter inserted in between the quadratus lumborum muscle and psoas major muscle."
40931401|NCT02914015|DRUG|Morphine given as IPCA|Bolus: 1-2mg, lock time: 10min, 1h limitation: 5-10mg. without background infusion.
40931402|NCT04422795|DEVICE|External thermomechanical device delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings frozen and the vibration mechanism switched on, delivering vibration and cold stimuli to the area for 30 seconds before the intramatricial injection and until needle withdrawal
40931403|NCT04422795|DEVICE|External thermomechanical device without delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings at unfrozen and the vibration mechanism switched off, for 30 seconds before the intramatricial injection and until needle withdrawal
40931404|NCT04422795|DRUG|Ethyl chloride skin refrigerant spray|Ethyl chloride skin refrigerant spray is applied to the area of injection for 3 seconds immediately before needle insertion
40931405|NCT04946227|DRUG|Pembrolizumab 200mg +Paclitaxel 80mg/m2|Pembrolizumab 200mg +Paclitaxel 80mg/m2
40931406|NCT00805233|DRUG|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
40931407|NCT00805233|DRUG|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
40931408|NCT06506305|DRUG|FB1001|Intravitreal (IVT) injection
40931409|NCT01050478|DRUG|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
41449345|NCT01920334|DRUG|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
41449346|NCT01920334|DRUG|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
41449347|NCT03300011|DEVICE|stent|PTCA or PCI
41453476|NCT03776344|DEVICE|Virtual Reality intervention - Oculus Rift HD|During the VR experience patients will have the opportunity to choose from different VR environments (VR application - Nature Treks VR) and explore them using Oculus Rift Device.
41453477|NCT02207764|BEHAVIORAL|Reiki|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
40931410|NCT01050478|DRUG|Benzodiazepine|Participants may receive the benzodiazepine lorazepam \[0-7.5 milligram (mg) per day\] as needed for sedation or rescue medication at the investigator's discretion.
40931411|NCT00433264|PROCEDURE|peritoneal dialysis|individualised
40931412|NCT01376557|DRUG|75 mg LX4211|Subjects will receive 75 mg LX4211 once daily
40931413|NCT01376557|DRUG|200 mg LX4211|Subjects will receive 200 mg LX4211 once daily.
40931414|NCT01376557|DRUG|400 mg LX4211|Subjects will receive 400 mg LX4211 once daily.
40931415|NCT01376557|DRUG|200 mg LX4211|Subjects will receive 200 mg LX4211 twice daily.
40931416|NCT01376557|DRUG|Placebo|Subjects will receive placebo once daily.
41449348|NCT06123689|DEVICE|AMT-Regenera activa|"Patient's preparation: is an ambulatory procedure, the sterility of the Micrograft and the method should be guaranteed during the whole procedure.~Punch biopsy extraction:~The punch should be obtained by the posterior auricular shell area. The zone cleaned with antiseptic solution. Anesthesia is applied in the posterior zone in the base area of the auricular shell. It should be applied superficially to separate the skin from the cartilage . Should be obtained by 3 dermic punches of 2,5mm diameter. The skin is separated from the perichondrium and cartilage.~1. Once the samples are obtained, they must be put on the metallic grid of the Rigeneracon~2. Afterwards, 4 ml of Saline solution are added in the inferior part of the Rigeneracon, then close the lid and then put it in the machine with the needed adaptors.~3. The samples are processed for 6 minutes~4. The Rigeneracon is extracted from the machine."
41449349|NCT06123689|DEVICE|Hyalubrix|"Patients randomized in Group 2 Sodim Hyaluronate (Hyalubrix 60 -1,5%-2ml vial). NOTE: For the infiltration in the medial knee compartment treatment, the use of intramuscular needle is recommended.~The care post-treatment The homeostasis of the donor's area is achieved by mechanical compression. Usually, there is no need of stitches.~Often it can be seen a bit of inflammation during the first 24-72 hours. The use of analgesic drugs is recommended, avoiding the NSAID, they can interfere in the function of micrografts. Apply intermittently cold on the area or a compressive bandage, if needed"
40931417|NCT05121571|PROCEDURE|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
40931418|NCT05121571|DRUG|Sorafenib|sorafenib 400mg bid
40931419|NCT03562871|BIOLOGICAL|IO102|test immunotherapy
40931420|NCT03562871|BIOLOGICAL|pembrolizumab (Keytruda)|anti-PD-1 immunotherapy
40931421|NCT03562871|DRUG|Carboplatin (Carboplatin Kabi)|chemotherapy
40931422|NCT03562871|DRUG|Pemetrexed (Pemetrexed Alvogen)|chemotherapy
40931423|NCT03346798|BEHAVIORAL|Food Photography|Participants will engage in food photography on their smart phones while eating
40931424|NCT03346798|BEHAVIORAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
40931425|NCT03346798|BEHAVIORAL|No Phone Use|Participants will not use their smart phones while eating
40931426|NCT05628688|DIAGNOSTIC_TEST|Insight Pro Device for Diagnosis|Insight Pro Device for Diagnosis of Lymphatic and Venous Disorders
40931427|NCT04616742|DRUG|[14C]SHR6390|Patients will receive single dose of orally \[14C\]SHR6390 on Day 1.
40931428|NCT01097083|DRUG|Coriolus Versicolor|
40931429|NCT06202651|DEVICE|Nd:YAG Laser|"Prior to Nd:YAG laser treatment, two drops of topical anesthetic will be administered to the study eye. The two most peripheral deposits that are of ca. 50 µm size will be located and used as the targets for the treatment. The Nd:YAG laser will then be administered to each one of the two deposits, beginning with the lowest energy setting (0.3 mJ) and increasing the energy levels up to to 3 mJ in increments of 0.5 mJ. Five single-burst shots will be performed per laser energy setting per opacity until a visible effect is seen.~After the procedure, the eye will be examined to assess the integrity of the corneal epithelium. If a defect is seen, the participant will be advised to administer topical antibiotic eye drops three times daily for a week as a precautionary measure."
40931430|NCT05456945|OTHER|acupressure application|Acupressure will be applied to the UB32 point
41449350|NCT00976443|DRUG|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
41449351|NCT00976443|DRUG|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
40931431|NCT05456945|DEVICE|Shotblocher|Shotblocher will be administered during injection
41128906|NCT00741650|BEHAVIORAL|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
41449352|NCT03056547|OTHER|Induced dyspnea|"Biological samples will be assessed during and after breathing discomfort induced by laboratory models of dyspnea (work/effort, air hunger)."
41128907|NCT00741650|BEHAVIORAL|Information, peer advisor and fast referral|"Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,"
41128908|NCT03707899|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
41128909|NCT03707899|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
41449353|NCT04293653|OTHER|Protocol for patients above 75 undergoing emergency laparotomy or laparoscopy|See above section
41128910|NCT03466931|OTHER|Milk|Meals containing Milk and Milk
40755213|NCT03295448|OTHER|Low carbohydrate diet|Diet low in carbohydrates (38%E), but higher in total and saturated fat.
40931432|NCT03603366|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
40931433|NCT00760084|DRUG|Decitabine|Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
40931434|NCT02963961|BEHAVIORAL|Preoperative Cognitive Training Battery|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
40931435|NCT03554265|DRUG|Somatropin|Genotropin given by injection
40931436|NCT02349308|DEVICE|CentrosFLO Long Term Hemodialysis Catheter|
40931437|NCT01957436|DRUG|abiraterone acetate|abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid
40931438|NCT01957436|RADIATION|radiotherapy|74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)
40931439|NCT01957436|OTHER|Androgen Deprivation Therapy|The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
40931440|NCT01957436|DRUG|Docetaxel|6 cycles at 75mg/m²/cycle, one cycle every 3 weeks
41128911|NCT06152900|DEVICE|Accufit|"Magnet-based and Direct muscle stimulation devices are commonly used to generate current flow through the muscles in order to activate the muscle. The Accufit Electrical Muscle Stimulation device is an FDA cleared device having a two-channel stimulator that provides up to 8 electrodes with waveforms of interferential and biphasic for muscle stimulation. The Accufit system is indicated for relaxation of muscles, muscle re-education, reduction of pain and increased local blood circulation.~Muscle stimulation technology has been around for many decades and has been shown to be safe and effective for a variety of clinical applications. The foundational basis for the technology revolves around electrical current flowing through the muscle can be used to activate the muscle."
41128912|NCT02280031|DRUG|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
41128913|NCT02280031|DRUG|Placebo|Capsule containing placebo pill with lactose
41128914|NCT04690738|DIAGNOSTIC_TEST|Fecal Elastase Concentration|Stool sample for fecal elastase-1 (FEC) analysis and microbiome for sequencing and analysis will be obtained pre- and post-transplant.
41128915|NCT03353636|DIETARY_SUPPLEMENT|Magnesium|150mg elemental magnesium
41128916|NCT03353636|DIETARY_SUPPLEMENT|Placebo|Rice flour
41128917|NCT05532072|DRUG|Rapamycin|Rapamycin plus Methylprednisolone
41128918|NCT05532072|DRUG|Methylprednisolone|Methylprednisolone Alone
41128919|NCT02148575|BEHAVIORAL|Self-Management Group|
41128920|NCT02148575|BEHAVIORAL|Symptom Management Group|
41128921|NCT02829931|RADIATION|Hypofractionated Stereotactic Irradiation|Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
41128922|NCT02829931|DRUG|Nivolumab|Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
41128923|NCT02829931|DRUG|Bevacizumab|Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination. Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
41128924|NCT02829931|DRUG|Ipilimumab|Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
41128925|NCT03675321|DEVICE|Active Auricular Neurostimulation|Active auricular neurostimulation for 4 weeks. Subjects in Active group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
41128926|NCT03675321|DEVICE|Sham Auricular Neurostimulation|"Sham auricular neurostimulation for 4 weeks with identical device as the active but lacking the electrical charge.~Subjects in Sham group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy."
41128927|NCT04713124|BEHAVIORAL|R2C-M|R2C-M comprises 12 modules addressing core practice elements and skills from evidence-based cognitive and behavioural interventions. Modules include: (i) self-monitoring, goal setting and behaviour change skills; (ii) identification of strengths and motivational enhancement; (iii) relapse prevention; (iv) psychoeducation and harm reduction; (v) emotion regulation skills; (vi) anger management skills; (vii) urges and cravings management skills; (viii) sleep hygiene skills; (ix) mindfulness skills; (x) interpersonal skills; (xi) anxiety management skills; (xii) depressed mood management skills. The R2C-M workbooks contain psychoeducation and intervention exercises, to facilitate counsellor-delivered exercises within sessions, and between-session practice.
41449354|NCT05496868|DRUG|Reparixin 600mg|Reparixin 600 mg tablets, administered crushed through nasogastric tube at the dose of 1200 mg TID (2 tablets TID administered approximately about every 8 hours) as add-on to the standard of care. After extubation and if the patient can swallow, reparixin may be administered orally. Total duration of the treatment: 14 days
41449355|NCT05496868|OTHER|Matching Placebo|"Placebo tablets. Administered crushed through nasogastric tube with the same schedule as reparixin as add-on to the standard of care. After extubation and if the patient can swallow placebo may be administered orally.~Total duration of the treatment: 14 days"
41449356|NCT00899951|DRUG|fentanyl citrate|
41449357|NCT00899951|OTHER|pharmacological study|
41128928|NCT04713124|OTHER|Self-help booklet|A booklet of information and self-help strategies for methamphetamine use problems.
41128929|NCT01185041|DIETARY_SUPPLEMENT|Watermelon Extract|6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
41128930|NCT04939909|DRUG|Botulinum toxin type A|Patients were treated with Botulinum toxin type A applications on the Orbicularis oculi and glabellar complex
41128931|NCT06046859|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
41128932|NCT06046859|DRUG|Placebo|When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
41128933|NCT04327752|OTHER|dermatological consultation|Dermatological consultation will be done on every children treated by biotherapy for chronic inflammatory disease in the Amiens hospital.
41128934|NCT00856700|DRUG|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
41128935|NCT01892176|DIETARY_SUPPLEMENT|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
41128936|NCT02009228|PROCEDURE|Ovarian cystectomy|
41128937|NCT03944694|DIAGNOSTIC_TEST|Delirium assessment.|Full blood count analysis.
41128938|NCT01691716|DRUG|Tendoactive|Food supplement containing mucopolysaccharides, type I collagen and vitamin C
41128939|NCT01691716|BEHAVIORAL|Eccentric training|Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
41128940|NCT00004840|DRUG|thyrotropin-releasing hormone|
41449358|NCT06623357|OTHER|Pilot Training Protocol|The pilot training protocol uses principles based on evidence-based research on factors that support caregiver learning of and adherence to home-therapy techniques/recommendations.
41449359|NCT06623357|OTHER|Standard Training Protocol|The standard training protocol uses the caregiver training methods that are currently used in our clinics.
41128941|NCT03980418|PROCEDURE|DaTSCAN SPECT/CT in VERITON-CT camera|the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
41128942|NCT01235806|RADIATION|MRI|MRI of the scaphoid bone fracture suspicion
41128943|NCT06455059|DRUG|Vosoritide|Subcutaneous injection of recommended dose of vosoritide based on weight-band dosing once daily.
41128944|NCT06455059|DRUG|Placebo|Subcutaneous injection of recommended dose of placebo
41128945|NCT03632876|DIETARY_SUPPLEMENT|retinyl palmitate|The intervention is a daily vitamin A supplement.
41128946|NCT00263549|BIOLOGICAL|House dust mite Novo Helisen Depot|
41278589|NCT03919240|BIOLOGICAL|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5\~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
41278590|NCT05805501|DRUG|Tobemstomig|Participants will receive IV tobemstomig Q3W.
41278591|NCT05805501|DRUG|Tiragolumab|Participants will receive IV tiragolumab Q3W.
41278592|NCT05805501|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W.
41278593|NCT05805501|DRUG|Axitinib|Participants will receive axitinib PO BID.
41278594|NCT02039557|GENETIC|NiCord®/CordIn™ (omidubicel)|
41278595|NCT01670500|DRUG|Cisplatin|administered intravenously every 3 weeks for 4 doses
41278596|NCT01670500|DRUG|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
41449360|NCT02385708|DRUG|2% Chlorohexidine Gluconate Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.
40755214|NCT03295448|OTHER|High carbohydrate, high sugar diet|Diet high in carbohydrates (53%E) and sugars, but low in wholegrain, rye and wheat fibre.
41128947|NCT03863587|BIOLOGICAL|HLX12|healthy volunters receive HLX12 (8mg/kg) once
41128948|NCT03863587|BIOLOGICAL|Cyramza (Ramucirumab)|healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
41128949|NCT04334005|DIETARY_SUPPLEMENT|Vitamin D|The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
41128950|NCT04172207|OTHER|Sampling|After periodontal parameters measured, smear samples were obtained from the buccal mucosa and keratinized gingiva, and then a gingival biopsy was performed from the upper premolars.
41128951|NCT00649272|DRUG|Oxybutynin Chloride Extended-Release Tablets, 15 mg|15mg, single dose fasting
41128952|NCT00649272|DRUG|Ditropan XL® Extended-release tablets, 15 mg|15mg, single dose fasting
41278597|NCT01670500|DRUG|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
41128953|NCT04523701|DRUG|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"
41278598|NCT05113940|DRUG|PF-07258669|PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
41278599|NCT05113940|DRUG|Placebo|Placebo will be administered as tablets; Q8H or Q12H over 14 days
41278600|NCT05113940|DRUG|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
41278601|NCT06500741|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
41278602|NCT06460350|DEVICE|NEUROCUPLE™ Patch|nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year.
41278603|NCT06460350|DEVICE|Placebo Patch|The placebo patch is identical to the active patch but with no active agents.
41278604|NCT05809687|DRUG|DKP21102_C|Placebo
40755215|NCT03295448|OTHER|High carbohydrate, low sugar diet|Diet high in carbohydrates (53%E), wholegrain, rye and wheat fibre, but low in sugars.
40755216|NCT04558853|DRUG|autologous NK cells|Autologous ex vivo expanded and activated NK cells
40755217|NCT05714228|PROCEDURE|Surgical Mitral Valve Repair|Mitral valve is repaired using open surgical approach
40755218|NCT05714228|PROCEDURE|Transcatheter Mitral Valve Repair|Mitral valve is repaired using Mitraclip transcatheter device
41128954|NCT01378416|DRUG|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m\^2 of decitabine.
41128955|NCT00894543|DRUG|Escitalopram|10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
41128956|NCT00894543|OTHER|Placebo|Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
41128957|NCT00156507|BEHAVIORAL|Asthma education for parents of very low birth weight infants|Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
41128958|NCT04910438|OTHER|STIs screening and care|"* Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).~* Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM."
41278605|NCT05809687|DRUG|DKP21102_B|Treatment
41278606|NCT05809687|DRUG|DKP21102_A|Active Control
41278607|NCT05218213|OTHER|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)"
41278608|NCT06171178|DRUG|ASP1012|Intravenous (IV) infusion
41278609|NCT06171178|DRUG|Pembrolizumab|IV infusion
41278610|NCT05970497|BIOLOGICAL|KB707|Genetically modified herpes simplex type 1 virus
41278611|NCT05004675|BIOLOGICAL|lerodalcibep|300 mg
41278612|NCT05004675|DRUG|Inclisiran|284 mg
40931441|NCT04037878|PROCEDURE|Transversus Abdominis Plane Block(TAP Block)|Under ultrasound guidance, a 22 gauge stimuplex needle will be used to approach the transversus abdominis plane and 20ml of 0.25% Bupivicaine will be infiltrated into the TAP space. This procedure will be performed on either sides once anesthesia is induced.
40931442|NCT04037878|PROCEDURE|Intra-peritoneal infiltration|Before skin closure, the surgeon will infiltrate the peritoneal cavity using a mixture of bupivicaine and epinephrine
40931443|NCT04037878|DRUG|PCIA Tramadol|All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
40931444|NCT00016900|DRUG|liposomal paclitaxel|
40931445|NCT02338336|DRUG|Nowarta110|Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
40931446|NCT02338336|DRUG|Placebo|Matching placebo liquid for topic administration.
40931447|NCT00872625|DRUG|cyclophosphamide|
40931448|NCT00872625|DRUG|docetaxel|
40931449|NCT00872625|DRUG|epirubicin hydrochloride|
40931450|NCT00872625|DRUG|fluorouracil|
40931451|NCT00872625|PROCEDURE|neoadjuvant therapy|
40931452|NCT00872625|PROCEDURE|therapeutic conventional surgery|
40931453|NCT00872625|RADIATION|hypofractionated radiation therapy|
40931454|NCT00872625|RADIATION|image-guided radiation therapy|
40931455|NCT00872625|RADIATION|radiation therapy|
40931456|NCT00872625|RADIATION|stereotactic radiosurgery|
40931457|NCT02326545|BEHAVIORAL|MindLight|MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.
40931458|NCT02326545|BEHAVIORAL|Online CBT|Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
40931459|NCT04524338|DEVICE|Transcranial Direct Current Stimulation|Brain Stimulation Devices attached to scalp
40931460|NCT00386971|DIETARY_SUPPLEMENT|L-carnitine|3 grams daily in liquid form by mouth
40931461|NCT00386971|OTHER|placebo|1 oz sweet tasting liquid daily by mouth
41278613|NCT06644989|PROCEDURE|Spencer Technique|Spencer technique on the hip
41278614|NCT06644989|OTHER|Sham (No Treatment)|Spencer technique position but no pressure
41278615|NCT03721068|BIOLOGICAL|iC9.GD2.CAR.IL-15 T-cells|Three dose levels are being evaluated: 0.5 x 10\^6, 1.0 x 10\^6, 1.5 x 10\^6
40931462|NCT02975583|DRUG|Vorapaxar|2.08 mg oral tablet daily
40931463|NCT02975583|DRUG|Placebos|Placebo oral tablet daily
40931464|NCT02696187|BEHAVIORAL|KOLwebben|KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
40931465|NCT05011279|OTHER|Move Together app/Garmin Activity Tracker|"* The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links.~* Garmin activity tracker in this study is for participants to track their steps and sedentary time."
40931466|NCT01652911|DEVICE|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
40931467|NCT03643614|PROCEDURE|Injection of autologous regenerative cells of adipose tissue|Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
41278616|NCT03721068|DRUG|Cyclophosphamide|500 mg/m\^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
41278617|NCT03721068|DRUG|Fludarabine|30 mg/m\^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
41278618|NCT05564403|DRUG|Binimetinib|Given PO
40755219|NCT01377311|PROCEDURE|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
40931468|NCT00958490|OTHER|Walking program|4 week physical activity walking program
40931469|NCT00569751|DEVICE|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
40931470|NCT03785275|RADIATION|gallium-68-exendin PET/CT|PET/CT scan after injection with gallium-68-exendin
40931471|NCT04256889|DEVICE|nfant(R) feeding system|Use of nfant(R) technology feeding system as an adjunct to visual assessment and cue-based feedings for infants born less than 30 weeks GA
40931472|NCT05125185|OTHER|The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation|To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation
40931473|NCT00675207|DRUG|Brimonidine purite 0.15%|A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
40931474|NCT00675207|DRUG|Dorzolamide 2%|A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
40931475|NCT00675207|DRUG|Brinzolamide 1%|A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
41278619|NCT05564403|PROCEDURE|Biopsy|Undergo biopsy
41278620|NCT05564403|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41278621|NCT05564403|PROCEDURE|Bone Scan|Undergo bone scan
41278622|NCT05564403|PROCEDURE|Computed Tomography|Undergo CT
41278623|NCT05564403|PROCEDURE|Echocardiography|Undergo ECHO
41278624|NCT05564403|DRUG|Fluorouracil|Given IV
40755220|NCT06051292|OTHER|Fast method|Fast decremental catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
40755221|NCT06051292|OTHER|Conventional method|Conventional catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
40755222|NCT03177915|DRUG|Hylase|median nerve hydro-dissection using Hyalase + 10 cc saline injection
40755223|NCT03177915|DRUG|Saline|median nerve hydro-dissection using 10 cc saline injection
40931476|NCT01113476|DRUG|Nab-paclitaxel|Starting dose of 50 mg/m\^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
40931477|NCT01113476|DRUG|Bevacizumab|Starting dose of 5 mg/m\^2 on Day 1 + 15 every 28 days (+/- 2 days)
40931478|NCT01113476|DRUG|Gemcitabine|1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
40931479|NCT05110001|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
40755224|NCT04566380|DRUG|ONO-4538|IV infusion over 30 minutes
40755225|NCT04566380|DRUG|oxaliplatin|IV infusion over 2 hours
40755226|NCT04566380|DRUG|S-1|Administered orally twice daily
40755227|NCT04566380|DRUG|capecitabine|Administered orally twice daily
40755228|NCT04566380|DRUG|bevacizumab|IV infusion over 30 minutes
40931480|NCT05110001|DRUG|Chlorhexidine Gluconate|Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.
40931481|NCT05110001|DRUG|Natamycin|Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.
40755229|NCT04566380|DRUG|temozolomide|Administered orally once daily for 5 days every 28 days
40755230|NCT02959892|DRUG|Amphetamine|Amphetamine tablets.
40755231|NCT02959892|DRUG|TAK -041|TAK-041 oral suspension.
40755232|NCT02959892|DRUG|[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)|\[11C\]PHNO injection.
40755233|NCT03109392|DRUG|Nebulized Lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
40755234|NCT03109392|DRUG|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
40931482|NCT05110001|DRUG|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
40931483|NCT05110001|OTHER|Placebo|Study participants receive sham RB-PDT within 48 hours of randomization. Participants will receive a 30-minute loading dose of topical balanced salt solution which will be applied in 5-minute intervals to the de-epithelialized cornea. A pen light covered with a green filter will be used for 15 minutes. Repeat cornea culture will be collected 30 minutes after the sham procedure.
40931484|NCT01251627|DRUG|Decitabine|Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles.
40931485|NCT00976508|DRUG|figitumumab|IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year
41128959|NCT03763682|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Six (6) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4, 5 and 6 month(s) after implantation
40931486|NCT00976508|DRUG|pegvisomant|growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
40931487|NCT02165176|DRUG|Oral cannabis|
40931488|NCT01348971|DIETARY_SUPPLEMENT|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
40931489|NCT01348971|OTHER|Sodium chloride|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
40931490|NCT02320903|DEVICE|VillageWhere App|
40931491|NCT00224627|PROCEDURE|Capsule GIVEN IMAGING LTD|
40931492|NCT00931346|DRUG|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
40931493|NCT00931346|DRUG|Placebo|Placebo
40931494|NCT01369485|DEVICE|(VERV™ System)|Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
40931495|NCT01369485|DEVICE|Sham version of (VERV™ System)|Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
40931496|NCT03312751|DRUG|Emapalumab|Emapalumab will be administered by intravenous infusion, twice weekly.
40931497|NCT00564538|DRUG|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
41128960|NCT02526576|BIOLOGICAL|Stromal Vasular Fraction|The stromal vascular fraction obtained from adipose tissue will be added to the graft
40931498|NCT00564538|DRUG|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
40931499|NCT05184751|OTHER|colonoscopy|
40931500|NCT02392715|DEVICE|Inspiratory muscle training with Threshold by respironics|"Inspiratory muscle training~15 minutes, 3x/weeks, 36 sessions~Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
40931501|NCT02392715|DEVICE|Sham Inspiratory muscle training|"with Threshold by respironics~15 minutes, 3x/weeks, 36 sessions~Intensity: 5 centimeters of water (cmH20)"
40931502|NCT03891667|DRUG|Disulfiram|Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
40931503|NCT01229462|DRUG|brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
40931504|NCT01229462|DRUG|brimonidine tartrate ophthalmic solution|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
41128961|NCT02526576|PROCEDURE|Biopsy|A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
41128962|NCT04291027|OTHER|Land Based Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
41128963|NCT04291027|OTHER|Aquatic Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
40931505|NCT01229462|DRUG|timolol ophthalmic solution|One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
40931506|NCT01229462|OTHER|fixed combination vehicle|Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
40931507|NCT02816164|DRUG|Neupogen|Subcutaneous injections
40931508|NCT05517460|OTHER|Auricular acupressure|The participant in Intervention period will receive acupressure on ear Shenmen point, ear Large intestine point, ear Rectumn point and ear San Jiao point.
40931509|NCT05517460|OTHER|health education|health education for self-care and medication adherence
40931510|NCT06450951|DIAGNOSTIC_TEST|Urinary EDC metabolite testing|Mail-in urine samples tested for metabolites of bisphenols, phthalates, parabens, and oxybenzone.
41128964|NCT01132560|GENETIC|RNA analysis|
41128965|NCT01132560|GENETIC|gene expression analysis|
41128966|NCT01132560|GENETIC|reverse transcriptase-polymerase chain reaction|
41128967|NCT01132560|OTHER|laboratory biomarker analysis|
41128968|NCT04502381|DRUG|Inhaled amp B deoxycholate+intravenous liposomal amp B|"Intravenous liposomal amphotericin B (beginning with 3mg/kg) along with inhaled amphotericin as below: Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited), will be dissolved in 10 mL distilled water. 2 mL of the reconstituted amphotericin B solution will be transferred into the drug chamber of a breath actuated nebulizer (Lupineb Ultra kit breath actuated nebulize which contains aeroclipse XL Reusable Breath Actuated Nebulizer and DeVilbiss 3655 compressor). 3 mL of distilled water is added to 2 mL of the reconstituted amphotericin B. The nebulization is continued till the chamber is emptied of the drug or the patient does not tolerate the therapy.~The first three doses of amphotericin B nebulization will be under the direct supervision of a physician. If tolerated, nebulization will be continued twice a day till tolerated or till response.The patient will complete a VAS score for cough after nebulization."
41128969|NCT04502381|DRUG|Intravenous liposomal amphotericin B alone|Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated
41278625|NCT05564403|DRUG|Leucovorin Calcium|Given IV
41278626|NCT05564403|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41278627|NCT05564403|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41278628|NCT05564403|DRUG|Oxaliplatin|Given IV
41278629|NCT04619420|DRUG|JNJ-63733657|JNJ-63733657 low or high dose will be administered by IV infusion.
40931511|NCT06450951|BEHAVIORAL|Educational curriculum|A self-directed online interactive curriculum of EDC material, with access to live coaches and an online forum.
40931512|NCT04929665|PROCEDURE|Two different block and combination of these two blocks|Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.
40931513|NCT01577810|DEVICE|Near Infrared Spectroscopy|Use of Near Infrared Spectroscopy in outpatient setting to determine global cardiac output
40755235|NCT03109392|DRUG|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
40755236|NCT06031051|DEVICE|Pillcam Crohn's Capsule Endoscopy|Patients with scheduled colonoscopy are invited to a previous exploration with capsule endoscopy
40755237|NCT06366958|PROCEDURE|excision of dorsal wrist ganglion|open and arthroscopic excision of dorsal wrist ganglion
40931514|NCT02923258|DRUG|Docetaxel|20mg/m2/w
40931515|NCT02923258|DRUG|Cisplatin|100mg/m2/q3w
40931516|NCT02923258|RADIATION|IMRT|a total dose of 60Gy in 30fractions over 6 weeks
40931517|NCT00649311|DRUG|eplerenone|Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
41128970|NCT02282657|DEVICE|ECCO2R will be initiated during the 2-hour run-in time|"A single (15.5 to 19 Fr) veno-venous ECCO2R catheter will be inserted percutaneously (jugular vein strongly suggested).~Catheters should be rinsed with heparinized saline solution before insertion Once the catheter has been inserted each line will be filled with an heparinized saline solution before its connection to the extracorporeal circuit The ECCO2R circuit will be connected to the catheter and blood flow set, depending on the device, up to 1000 mL/min.~Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device.~Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0X baseline. A bolus of heparin is suggested at the time of cannulation."
40755238|NCT02856373|PROCEDURE|RNS and RDN|The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
40755239|NCT03785132|PROCEDURE|Cardiac surgery|The relationship between performance measurement of blood pressure during cardiac surgery (before, during and after cardiopulmonary bypass) and postoperative mortality
40755240|NCT04063462|DRUG|Pyrotinib|pyrotinib, single agent, 400mg p.o once daily until disease progressed
40755241|NCT01936974|DRUG|Gemcitabine|Patient to receive gemzar
40755242|NCT01936974|DRUG|Bevacizumab|Patient to receive avastin
40755243|NCT01936974|DRUG|Carboplatin|Patient to receive carboplatin
40755244|NCT01936974|DRUG|Cisplatin|Patient to receive cisplatin
40755245|NCT01936974|DRUG|Oxaliplatin|Patient to receive Oxaliplatin
40755246|NCT03629002|BIOLOGICAL|Study of the gene expression profile|qPCR analysis
40755247|NCT01046669|DEVICE|TORAYMYXIN PMX-20R (PMX cartridge)|TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
40755248|NCT01046669|OTHER|Standard medical care for septic shock|Standard medical care for septic shock
40919430|NCT04590833|BEHAVIORAL|Supervised stretching exercise|Following baseline measures, a student will demonstrate the use of a pulse oximeter and stretching movements to these participants. Starting on week 3, participants will do the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise. Stretching will target all major muscle-tendon groups including shoulder, chest, neck, truck, lower back, hips, and legs. It will also involve a slow and constant motion that accounts for any physical limitations and physician-specified precautions
40931518|NCT00649311|DRUG|Losartan|Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
40931519|NCT02355600|OTHER|Oocyte retrieval|Tamoxifen given at a fixed dose for invasive breast cancer adjuvant hormonotherapy or for breast cancer prophylaxis.
40931520|NCT01432210|OTHER|Post-prandial Feeding Study|
40931521|NCT03256890|BEHAVIORAL|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
41278630|NCT04619420|DRUG|Placebo|Placebo matching to JNJ-63733657 will be administered by IV infusion.
41278631|NCT05817045|DEVICE|RD-X19|Investigational device that uses safe electromagnetic energy to target the oropharynx.
41278632|NCT05817045|DEVICE|Sham|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
41278633|NCT05255757|BEHAVIORAL|Script Intervention|This intervention provides language to participants to allow them to discuss kidney transplantation with their social network.
41128971|NCT02282657|OTHER|Neuromuscular blocking agents (NMBA)|Patients will receive NMBA starting in the run-in period and continued for the first 24 hours and thereafter will be directed by the attending physician
41128972|NCT02282657|DEVICE|Ventilation|Following the 2-hour run-in time, VT will be reduced gradually to 5 mL/kg. Sweep gas initiated then VT decreased to 4.5 then 4 mL/kg and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cm H2O.
41278634|NCT05255757|BEHAVIORAL|Search Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
41278635|NCT05898412|DRUG|Andexanet alfa|Patients treated with andexanet alfa
41278636|NCT04827355|DEVICE|External Upper Esophageal Sphincter (UES) Compression Device|External Upper Esophageal Sphincter (UES) Compression Device fit to manufacturer guidelines.
41128973|NCT02282657|OTHER|Level of carbon dioxide released at the end of expiration|EtCO2 will be monitored for safety purposes. Blood gases will be analyzed 20-30 minutes after each VT reduction
41128974|NCT02282657|OTHER|Respiratory Rate|RR will be kept what it was at baseline
41128975|NCT02282657|OTHER|Sweep gas flow|Sweep gas flow will be adapted to maintain the same EtCO2
41128976|NCT02282657|OTHER|Ventilation will be adapted|If PaCO2\> 75 mmHg and/or pH \< 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.
41128977|NCT02282657|OTHER|Respiratory rate will be adapted|If PaCO2 remains within the target range, respiratory rate will be progressively decreased to a minimum of 15/ min and facilitated by increases in sweep flow.
41128978|NCT00047190|DRUG|tipifarnib|Given PO
41128979|NCT00047190|OTHER|laboratory biomarker analysis|Correlative studies
41128980|NCT02765100|DRUG|Minocycline|Minocycline 100 mg twice a day
41128981|NCT01235936|DRUG|AKB-6548|Different dose levels
41128982|NCT00990600|OTHER|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
40931522|NCT03256890|OTHER|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
40931523|NCT04873271|DEVICE|Medtronic Implantable Tibial Neuromodulation (TNM) System|Tibial neuromodulation (TNM) devices are implantable devices that provide stimulation to the tibial nerve.
40931524|NCT03189381|RADIATION|Cohort A|Cohort A - WBRT dose = 25 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy
41278637|NCT04827355|DEVICE|Sham Device|External Upper Esophageal Sphincter (UES) Compression Device fit to pressure known not to provide treatment.
41278638|NCT05327114|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
41278639|NCT05327114|DRUG|Placebo|Placebo will be administered intravenously.
40755249|NCT05306015|COMBINATION_PRODUCT|Mindfulness meditation based on brain-computer interface|"Before surgery, The nurses will teach and explain the methods and significance of meditation training. Let the patient be familiar with the function and background of this method, and explain the use of the headband during the operation, so that the patient believes that meditation training can relieve pain.~In surgery, Wear a brain-computer interface headband for the patient to collect EEG, monitor the patient's psychological changes, and provide real-time feedback.~The patient wears a Bluetooth headset, according to the patient's preferences, different types of music are selected, and voice playback guides the patient to prepare, relax muscles and regulate breathing.~APP judges the patient's meditation state based on EEG signals, and adjusts music, voice guidance.~The nurse will give personalized guidance based on the patient's specific situation and the EEG displayed on the APP to help the patient achieve a state of meditation and relaxation."
40755250|NCT05306015|COMBINATION_PRODUCT|Routine care|Give routine treatment and care, and increase or decrease the dose or adjust according to the patient's condition in accordance with the doctor's advice. Before surgery, we will introduce the level of medical care involved in the surgery and the equipment of our hospital. Inform the patient of the surgical process and possible pain, and explain in detail the cause, location and characteristics of the pain, including the time when the pain will appear and last. Instruct patients to stabilize their emotions and maintain a calm state of mind. As far as possible to meet the patient's intraoperative care needs, give psychological care, wear a headband to collect EEG signals, but do not intervene in mindfulness meditation.
40755251|NCT02221297|DIETARY_SUPPLEMENT|Supplement product with plant stanol ester|2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
40931525|NCT03189381|RADIATION|Cohort B|Cohort B - WBRT dose = 20 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0 Gy
40931526|NCT03222492|BIOLOGICAL|Brentuximab Vedotin|Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
40931527|NCT03222492|BIOLOGICAL|Placebo|Placebo control for blinding (masking), 0.95% normal saline.
40931528|NCT01067547|DRUG|Iron Sucrose.|The total dose of iron sucrose given will be individualised by calculating their iron deficit.
40931529|NCT01067547|DRUG|Iron sucrose|300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
40931530|NCT01622283|DRUG|Levocetirizine|Levocetirizine
40931531|NCT01622283|DRUG|Cetirizine|Cetirizine
40931532|NCT01887743|DRUG|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
40931533|NCT04430205|PROCEDURE|Adhesive restoration protocol|"The canal walls were etched with 37% orthophosphoric acid for 30 seconds with use of a microbrush.~The primer was applied on the wet canal walls, with a microbrush several times, after checking by drying the canal, that the appearance of the dentine was shiny and not opaque or chalky.~The next step was the application of bonding with a microbrush, blowing in the fracture line to make sure it is not loaded with bonding.~Flow composite was used to make it penetrate the fracture line with the help of a 0.06 mm k-file.~The canals were filled with dual composite parts more deeply, light cured at the canal entrance and pulp chamber; the following phase was the coronal restoration with a sandwich technique, covering the cusp with composite."
40931534|NCT02976220|OTHER|Digital Education|Online videos, illustrations, and text materials designed to improve participants' awareness and understanding of kidney function, kidney disease, kidney failure options, peritoneal dialysis, home hemodialysis, in-center hemodialysis, kidney transplant, medical management, and treatment decision. Also includes online messaging system and discussion board designed to allow participants to message study nurse and peer mentor, as well as to engage in group discussion in an open forum and about specific scenarios.
40931535|NCT03170232|DRUG|Danirixin 35 mg tablets|Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
40931536|NCT03170232|DRUG|Placebo|Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
41449361|NCT02385708|DRUG|2% Chlorohexidine Gluconate Chin to Toe|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
40755252|NCT02037880|PROCEDURE|Lumbar puncture|
40755253|NCT02037880|DEVICE|Magnetic Resonance Imaging (MRI) of the brain|
40755254|NCT04118426|RADIATION|Cognitive testing|"Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI)."
40755255|NCT04535479|BEHAVIORAL|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
40755256|NCT04407117|BEHAVIORAL|Lock-down and social distancing|Lock-down and social distancing during COVID-19 pandemic
40755257|NCT00029900|DRUG|ADI PEG|
40755258|NCT03760666|DRUG|Brequinar/Brequinar + Ribavirin|The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.
40755259|NCT04238182|OTHER|wet cupping|This smoker group will receive single wet cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm . Cupping of BL 17 will be done bilaterally.
40755260|NCT04238182|OTHER|dry cupping|The smoker group will receive single dry cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm. Cupping of BL 17 will be done bilaterally.
40755261|NCT02569775|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
40755262|NCT04422132|RADIATION|5 days Radiation Therapy (32.5 Gy in 5 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
40755263|NCT04422132|RADIATION|20 days Radiation therapy (55 Gy in 20 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
40755264|NCT01893762|BIOLOGICAL|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
40755265|NCT01893762|BIOLOGICAL|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
40755266|NCT04635163|OTHER|None intervention|None intervention
40931537|NCT03170232|DEVICE|Metered dose inhaler (MDI) sensor device|MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
41128983|NCT06457516|COMBINATION_PRODUCT|Mirror Therapy|A mirror is used to create a reflective illusion of an affected limb in order to trick the brain into thinking movement has occurred without pain, or to create positive visual feedback of a limb movement. It involves placing the affected limb behind a mirror.
41128984|NCT06457516|OTHER|Music Therapy|Music therapy, an allied health profession, the clinical and evidence-based use of music interventions to accomplish individualized goals
41128985|NCT06444984|OTHER|Fasting Trial|Participants will report fasted and consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles) in the morning.
41128986|NCT06444984|OTHER|Fed Trial|Participants will report fasted and first consume a high-fat meal (Jimmy Deans) in the morning. After a three-hour break, participants will consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles).
41128987|NCT05605613|DRUG|PD-1 Antibody|PD-1 Antibody, an investigational humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1
40755267|NCT01652105|DIETARY_SUPPLEMENT|Standard diet versus standard VLCD (Prodimed)|
40755268|NCT04809467|DRUG|tafasitamab|tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.
40755269|NCT04809467|DRUG|parsaclisib|parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.
40755270|NCT04122495|DIETARY_SUPPLEMENT|Probiotic|Oral administration of B. lactis M8 at 10 log CFU/day for 4-weeks
40755271|NCT04122495|DIETARY_SUPPLEMENT|Placebo|Oral administration of maltodextrin daily for 4-weeks
40755272|NCT03996421|DIETARY_SUPPLEMENT|nutritional iron (14 mg) supplement in form of ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
40931538|NCT03170232|DRUG|Rescue medication|Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
40931539|NCT01663077|DRUG|Clozapine|A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
41128988|NCT05605613|DEVICE|BACE|Bronchial Arterial Chemoembolization
41128989|NCT05543044|BEHAVIORAL|Peer mentor intervention|Peer mentor delivered intervention for transitions to adult-oriented treatment for eating disorders
41128990|NCT03637036|OTHER|Communication intervention|The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.
41128991|NCT06075017|PROCEDURE|dental implant placement|Comparing the amount and type of biofilm on zirconia vs. titanium implants
41128992|NCT06238934|BIOLOGICAL|Bone marrow aspirate matrix|Bone marrow aspirate \* Hyaluronic acid
41128993|NCT06238934|BIOLOGICAL|Bone marrow aspirate|Bone marrow aspirate
41449362|NCT05887934|DEVICE|X-Ray Fluorescence Analyzer|The XRF analyzer (the ThermoFisher Niton XL3t GOLDD+) is a portable x-ray fluorescent analyzer specifically configured to measure low levels of metals, lead in particular, in bone. The device is designed to rapidly assess cumulative lead exposure, not to support or sustain human life.
41449363|NCT06628076|DIAGNOSTIC_TEST|Culture specific antibiotic therapy|Samples will be cultured on MacConkey agar. Morphological identifications of growth isolates by Gram staining, colony features and conventional biochemical tests. All isolates will be identified to species level using automated bacterial identification systems.
41449364|NCT06628076|DIAGNOSTIC_TEST|Antibiotic|Strains confirmed as A. baumannii will be examined for their different antibiotic susceptibility by modified Kirby Bauer\&#39;s disc diffusion method on Mueller Hinton Agar.
41128994|NCT06238934|DEVICE|Hyaluronic acid|Hyaluronic acid
41278640|NCT04222504|BEHAVIORAL|Provision of sexual health preventative services in the salon setting|"Participants at intervention salons will be offered a choice of receiving daily PrEP and/or contraceptives (oral and injectables). Participants that elect to receive at least PrEP or contraceptives will also be offered STI testing.~Follow-up visits will be planned for 3, 6, 9, and 12-months. Attendance at follow-up visits for monitoring and medication refill will be encouraged using text message reminders, WhatsApp support groups, and lottery-based incentives for free salon services."
41449365|NCT06628076|DIAGNOSTIC_TEST|Biofilm assessment|The biofilm formation activity of A. baumannii isolates will be tested using the microtitre plate technique
41278641|NCT04785287|BIOLOGICAL|Anti-CTLA4 Monoclonal Antibody BMS-986218|Given IV
41278642|NCT04785287|BIOLOGICAL|Nivolumab|Given IV
41449366|NCT06628076|DIAGNOSTIC_TEST|nanoparticle zinc oxide|Detection of the effect of ZnO NPs on the biofilm producer MDR A. baumannii strains using the same method
41128995|NCT00979459|DRUG|MK-1006 DFC|Each dry filled capsule contains 20 mg MK-1006
41278643|NCT04785287|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41449367|NCT06628076|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|- Evaluation the effect of ZnO NPs on the expression of some efflux pump genes, and biofilm related genes in MDR A. baumannii isolates using Real time PCR technology.
41449368|NCT04583423|DRUG|MK-3655|MK-3655 50, 100 or 300 dose for injection
41449369|NCT04583423|DRUG|Placebo|Matching placebo to MK-3655
41449370|NCT06627790|DRUG|Mouthwash preparation|Participants will be divided into two groups Group A and Group B Both the groups will receive thorough scaling and root planing at required sites. Use of mouthwash preparation is adviced for 8 weeks and discontinue after for 4 weeks. The Visual analogue scale Hypersensitivity will be assessed via Visual Analogue Scale at 4, 8 and 12 week interval
41449371|NCT01802112|DIETARY_SUPPLEMENT|Resistant maltodextrins|15 grams of Resistant maltodextrins per day dissolved in water during 21 days
41449372|NCT01802112|OTHER|placebo|15gr placebo
41449373|NCT01323491|DRUG|Nicotine replacement therapy|Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
41449374|NCT06162572|DRUG|S095018|Via IV infusion on Day 1 of each 21-day cycle
41449375|NCT06162572|DRUG|S095024|Via IV infusion on Day 1 of each 21-day cycle
41449376|NCT06162572|DRUG|S095029|Via IV infusion on Day 1 of each 21-day cycle
41449377|NCT06162572|DRUG|S095018 Recommended Dose Expansion (RDE)|Via IV infusion on Day 1 of each 21-day cycle
41449378|NCT06162572|DRUG|S095024 RDE|Via IV infusion on Day 1 of each 21-day cycle
41449379|NCT06162572|DRUG|S095029 RDE|Via IV infusion on Day 1 of each 21-day cycle
41449380|NCT06162572|DRUG|Cemiplimab|350 mg via IV infusion on Day 1 of each 21-day cycle
40755273|NCT03996421|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
41128996|NCT00979459|DRUG|MK-1006 FCT|Each film coated tablet contains 40 mg of MK-1006
41128997|NCT04230941|BEHAVIORAL|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.
41128998|NCT02561195|BIOLOGICAL|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
41128999|NCT02561195|BIOLOGICAL|Placebo|0.5 mL intramuscular injection
41129000|NCT02371395|OTHER|Realtime amplification (RealAmp)|Molecular assay for the diagnosis of malaria.
41129001|NCT00708045|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer to assess brain tumor metabolism
41449381|NCT01185158|DRUG|ZD1839 (IRESSA)|ZD1839: 250mg/day po or via g-tube Q 24 hours
41449382|NCT00470379|DRUG|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
41449383|NCT02005276|BEHAVIORAL|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
41449384|NCT02005276|BEHAVIORAL|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
41449385|NCT02005276|BEHAVIORAL|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
41449386|NCT01816230|DRUG|NiCord®|
41449387|NCT06529146|DRUG|BHV-4157|BHV-4157 (troriluzole) 200 mg QD
41449388|NCT04660864|DEVICE|Nasal cavity cooling device.|The RhinoChill® system cools by intranasal evaporation of a liquid coolant sprayed onto the surface of the nasal cavity. The RhinoChill® system is intended for use for the relief of pain and symptoms associated with acute migraine attack.
41449389|NCT01861535|DRUG|Imiquimod|
41449390|NCT01861535|PROCEDURE|Surgery|
41449391|NCT01398085|RADIATION|I131 1.1 GBq|Radio-iodine
40931540|NCT02550977|DRUG|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
40931541|NCT05466448|DRUG|RZL-012|concentration of injected formulation 50 mg/mL RZL-012 of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012
40931542|NCT01136200|OTHER|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
40931543|NCT02914587|DEVICE|ARTAS System|
40931544|NCT02914587|OTHER|Manual Implantation|
40931545|NCT00278915|DRUG|Fulvestrant|Participants will receive intramuscular injection of fulvestrant as stated in arm description.
40931546|NCT01007682|OTHER|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
40931547|NCT03199339|DRUG|TBA-7371|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
41449392|NCT05895435|DEVICE|radiofrequancy|"* Power of device: 150 W~* Duration of the session: 40 minutes~* Frequency: 2 sessions per week for 8 week.~* Heating temperature: According to patient tolerance."
41449393|NCT05895435|OTHER|aerobic exercise|The program include five minutes for warming-up in the form of range of motion and stretching exercises, thirty minutes of walking on treadmill with high speed (60-70% of maximum heart rate) and five minutes of cooling down (on treadmill with low speed and without inclination
41449394|NCT06422286|DEVICE|low-level laser|children will be allocated to the device then the gag reflex will be re-evaluated
40755274|NCT05890573|DRUG|Bailing capsule|6 Bailing capsules,po,tid,12 weeks
40931548|NCT03199339|DRUG|Placebo|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
40931549|NCT01076894|PROCEDURE|epidural anesthesia|In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.
40931550|NCT01076894|PROCEDURE|intercostal anesthesia|In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
40931551|NCT00910247|DRUG|Eslicarbazepine acetate|800 to 2400 mg once daily (QD)
40931552|NCT02125604|DRUG|dimethyl fumarate|capsules administered according to the prevailing product label
40931553|NCT00570479|DRUG|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
40931554|NCT06290245|DEVICE|PEP Buddy|It is a hands-free, oral PEP device (PEP buddy) which held by the patient's lips like a whistle and is attached to a necklace/lanyard. Different grades of PEP-buddy generate expiratory pressures of 5-17cm H2O
41449395|NCT06422286|BIOLOGICAL|microcurrent stimulation|children will be allocated to the device then the gag reflex will be re-evaluated
41449396|NCT06422286|DEVICE|placebo|children will be allocated to a deactivated meridian pen
41449397|NCT03886246|DRUG|Spesolimab|Solution for infusion
41129002|NCT05782699|DEVICE|BP monitoring during tilt testing|BP measure at various times during tilt testing
41129003|NCT05835934|DRUG|[14C]HSK21542|A single intravenous dose of 2 μg/0.212 μCi/kg \[14C\]HSK21542 in boluses within 2 minute after fasting for at least 10 hours.
41129004|NCT01895582|OTHER|Blood samples|"4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)"
41449398|NCT03886246|DRUG|Spesolimab|Solution for injection
41129005|NCT03373448|DEVICE|Labrida BioClean|The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline or commercially available and area-specific titanium curettes (Langer and Langer, Rønvig) for 2 minutes and thereafter irrigated with sterile saline. The treatment will be repeated every three months until the terminal examination after 24 months. Debridement is performed with local anaesthesia as needed. Healthy sites will not be retreated.
41129006|NCT03373448|OTHER|Titanium curettes|Peri-implant pockets will be debrided using titanium curettes.
40931555|NCT06290245|OTHER|aerobic exercise|Exercise training will start and finish with a 5-minute warm-up and cool-down on the cycle ergometers at (40% of PHR). The cycling active phase will last for 30 min. at 70% of HRmax (moderate-intensity continuous exercise).
41129007|NCT02022657|DRUG|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
40931556|NCT04367831|DRUG|Enoxaparin Prophylactic Dose|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~1. BMI \< 40 kg/m2: Enoxaparin 40 mg SC daily~2. BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~3. BMI \> 50 kg/m2: Enoxaparin 60 mg SC q12h"
40931557|NCT04367831|DRUG|Heparin Infusion|Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
40931558|NCT04367831|DRUG|Heparin SC|Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
40931559|NCT04367831|DRUG|Enoxaparin/Lovenox Intermediate Dose|If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.
41129008|NCT00056654|DRUG|Leuprolide acetate|45 mg Intramuscular injection 6 month depot formulation
41449399|NCT01968551|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
41449400|NCT01968551|DRUG|DRV|800 mg tablet administered orally once daily
41449401|NCT01968551|DRUG|Baseline DRV- containing ARV regimen|Participants will take their baseline DRV- containing ARV regimen as prescribed.
41453478|NCT01261949|DEVICE|Combined frontal and temporal rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
41449402|NCT05936996|DEVICE|MANTA Vascular Closure Device|The MANTA® Vascular Closure Device consists of a 14F or 18F MANTA® Closure Device, a 14F or 18F Sheath with Introducer, and an 8F Depth Locator. In the U.S. and Canada, the MANTA® Vascular Closure Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures.
41449403|NCT06301386|DRUG|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
40755275|NCT04822909|DRUG|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study"
40931560|NCT03139942|DEVICE|Optical spectral reflectance and autofluorescence imaging|When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
40931561|NCT06084598|DRUG|BMS-986446|Specified dose on specified days
40931562|NCT06084598|OTHER|Placebo|Specified dose on specified days
41129009|NCT05121636|DEVICE|MetaFix Collared Stem|Patients received the MetaFix Collared stem during there Total Hip Arthroplasty
41449404|NCT06301386|DRUG|PD-1|200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
40931563|NCT04972747|OTHER|skin care with sunflower oil|The application will be carried out twice a day during the maintenance hours of the service. In skin care applications, body baths are applied not more than three times a week, as it may cause hypothermia in preterm babies in the ward routine. In daily skin care, body cleaning with cotton, changing the fixation points such as orogastric probe, and changing the monitor probe locations are among the routine practices. In order to hydrate and moisturize the skin in preterm and term babies, baby oil in the service is used. Skin care applied in the service routine will be applied to the preterm babies included in the study, and only sunflower oil and coconut oil will be used as moisturizers.
40931564|NCT01433276|DRUG|Hyperosmolar sodium lactate|1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
41449405|NCT06080451|OTHER|Integrated Diabetes and Hypertension Primary Care Model|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators"
41449406|NCT06080451|OTHER|Integrated Diabetes and Hypertension Primary Care Model - Providers|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators~Health care providers will administer this intervention to patient participants and will report on their experience."
41449407|NCT06627530|DRUG|Darolutamide Oral Tablet|darolutamide 600 mg PO BID for 24 weeks
41449408|NCT06627530|DRUG|leuprorelin|leuprorelin depot 22.5 mg SC every 12 weeks
40931565|NCT01433276|DRUG|Ringer's lactate|1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
40931566|NCT05062993|PROCEDURE|caudal epidural pulse radio frequency|A needle is inserted into the caudal epidural space under ultrasound guidance and pulse radiofrequency is administered at 5 Hz using a 5. ms pulse width for 600 seconds at 55 V.
41129010|NCT01925365|DIETARY_SUPPLEMENT|wholegrain cereals oats (WGO)|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
41129011|NCT01925365|DIETARY_SUPPLEMENT|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
41129012|NCT00895609|DRUG|Sugammadex, Neostigmine, Saline|"Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)"
40755276|NCT01553500|DIETARY_SUPPLEMENT|glucomannan|glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
40931567|NCT03059446|DRUG|Cenicriviroc|Cenicriviroc immediate release tablets
40931568|NCT06217185|DRUG|Pyrotinib|Pyrotinib 400mg qd po continuously
40931569|NCT06217185|DRUG|Trastuzumab|For Trastuzumab, the loading dose for the first treatment cycle is 8 mg/kg, and for subsequent cycles, 6 mg/kg. It is to be used once every three weeks
40931570|NCT06217185|DRUG|Taxanes|Taxanes: Usual clinical dose is administered, in a 21-day cycle.
40931571|NCT06217185|DRUG|Capecitabine|Capecitabine: 650mg/m2 each time, given twice daily
40931572|NCT00464243|DRUG|volinanserin|oral administration
40931573|NCT00464243|DRUG|placebo|oral administration
40931574|NCT01145638|DRUG|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
40931575|NCT01145638|DRUG|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
40931576|NCT03095768|OTHER|Lifestyle Education and Cooking Demonstration|Participants will receive an interactive cooking demonstration as well as healthy lifestyle education
40931577|NCT01609478|DRUG|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
40931578|NCT01609478|DRUG|placebo|placebo delivered via Concept 1 inhaler
40931579|NCT01609478|DRUG|mometasone furoate|via Twisthaler inhaler
41449409|NCT05620862|DRUG|Mitoxantrone Hydrochloride Liposome|In phase Ia, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 . In phase Ib, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion of 24mg/m2. Up to 6 cycles (21 days per cycle)
41449410|NCT05620862|DRUG|Irinotecan|50mg/ m2，d1-5, 21 days per cycle
41449411|NCT05620862|DRUG|Vincristine|Vincristine 1.5mg/ m2，d1 , 21 days per cycle
41449412|NCT03946462|DRUG|NO gas delivered during cardiac surgery|intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
40931580|NCT02623231|DRUG|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
40931581|NCT02623231|DRUG|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
40931582|NCT06299423|DEVICE|Howdy Senior® device|Standard perioperative management plus three preoperative and twelve postoperative (until 90 days after surgery) HOWDY Senior® device assessments.
40931583|NCT01288976|DEVICE|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
40931584|NCT01288976|DRUG|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
40931585|NCT01288976|PROCEDURE|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
40931586|NCT03544788|DEVICE|Cirvo™ Therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).
40931587|NCT06256627|DRUG|recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine|"Patients in arm1 were randomly divided into two groups, namely the  interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count."
40931588|NCT00312754|DRUG|Atazanavir|
40931589|NCT04253509|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Sequencing|Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.
40931590|NCT04983303|OTHER|TICK-B group|These interventions will distract the child during venipuncture
40931591|NCT00609362|DRUG|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
40931592|NCT00609362|DRUG|Placebo pill|One encapsulated placebo pill a day for 14 weeks
41129013|NCT02675244|PROCEDURE|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
41129014|NCT02675244|PROCEDURE|MVS|MVS will be performed using standard surgical techniques
41129015|NCT05933499|DRUG|IV bimagrumab|IV bimagrumab (30mg/kg IV administered at 0, 4, 16, 28, and 40 weeks)
41129016|NCT05933499|DRUG|IV placebo|IV placebo (administered at 0, 4, 16, 28, and 40 weeks)
41129017|NCT05933499|DRUG|Semaglutide|Semaglutide 2.4mg SQ qweek
41129018|NCT05933499|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Elemental calcium 1200 mg + vitamin D3 800 IU PO daily
41129019|NCT05933499|BEHAVIORAL|Lifestyle and nutrition counseling|Lifestyle and nutrition counseling consistent with current guidelines for weight management
41129020|NCT00051584|DRUG|SGN-15 (cBR96-Doxorubicin Immunoconjugate)|
41129021|NCT00051584|DRUG|Gemzar (Gemcitabine)|
41129022|NCT05957510|DRUG|Serplulimab|serplulimab 300mg, d1, q3w, iv. etoposide 100 mg/m2, d1-3, q3w, iv. carboplatin AUC 5 (up to 750mg), d1, q3w, iv.
41129023|NCT05957510|DRUG|SOC|the treatment recommended by the investigator
41129024|NCT04278755|DRUG|Drospirenone-Ethinyl Estradiol Oral Tablet|3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
41129025|NCT02878616|DRUG|LFG316|LFG316 single dose
41449413|NCT03946462|OTHER|placebo gas delivered during cardiac surgery|placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.
41129026|NCT02878616|DRUG|IVIG|IVIG single dose
41129027|NCT03559205|OTHER|MSK-Tracker|"The intervention is not a treatment, but involves patients and clinicians engaging with the MSK-Tracker software which will facilitate a new care planning approach with the following distinct components:~* Pre-clinic preparation.~* Clinic dashboard.~* Summary action plan.~* Personal goal setting.~* Follow-up and monitoring."
41129028|NCT00051792|BEHAVIORAL|yoga|
41129029|NCT05395234|BEHAVIORAL|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura \& McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction \& flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
41129030|NCT03600844|BEHAVIORAL|Community distribution of SP for IPTp|SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
41129031|NCT00942487|DRUG|Nebilet|Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration
41278644|NCT06315010|DRUG|Repotrectinib|"Repotrectinib is administered orally in capsule form, with each capsule containing size 0 hard gelatin 40 mg of the active compound in bottles containing 30 capsules.~Repotrectinib is administered orally in the form of capsules. The capsules are taken by mouth and swallowed intact (without chewing, crushing, or opening) with water or another suitable liquid."
41278645|NCT05907759|DRUG|Daratumumab SC|Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses) followed by every 2 weeks for a total of 16 weeks (8 doses) followed by every 4 weeks for up to 96 weeks (24 doses)
41278646|NCT06603883|BIOLOGICAL|Fecal microbiota transplantation (FMT) by nasal jejunal tube|FMT was administered via a naso-jejunal tube to inject 50ml commercial intestinal bacterial suspension into the jejunum.
41278647|NCT03215914|DEVICE|MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.
41278648|NCT04985565|OTHER|Dietary Intervention|Participate in Mediterranean diet
41278649|NCT04985565|PROCEDURE|Radical Prostatectomy|Undergo standard of care radical prostatectomy
41278650|NCT05019456|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine (mRNA or J\&J)
41278651|NCT05946031|BEHAVIORAL|Reat ETM|Exclusive cigarette smokers will be recruited and will be exposed to the real ETM condition in which tobacco purchases are real and they receive products from one randomly selected trial.
41278652|NCT05946031|BEHAVIORAL|Hypothetical ETM|Exclusive cigarette smokers will be recruited and will be exposed to the hypothetical ETM condition in which tobacco purchases are hypothetical and they don't receive any products.
41278653|NCT01534598|DRUG|FdCyd + THU|Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown to be feasible in an expansion cohort of the previous trial.
41278654|NCT04109079|PROCEDURE|Axillary lymph node dissection|Participants will undergo removal of at least level I and II axillary lymph nodes.
41278655|NCT04109079|RADIATION|Axillary radiotherapy|Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
41278656|NCT04109079|RADIATION|Breast or chest wall radiotherapy|Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
41449414|NCT02363764|PROCEDURE|Nasal swab|"Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients"
41449415|NCT02363764|PROCEDURE|Cough swab|"Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients"
40755277|NCT01553500|BEHAVIORAL|lifestyle intervention|hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
41129032|NCT00942487|DRUG|Corvitol|Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
41129033|NCT04381949|PROCEDURE|positive pressure extubation|"Two arms:~the first with classic extubation with disconnection of the ventilator and the second with an extubation without disconnection of the respiratory positive pressure"
41129034|NCT00104741|DRUG|flutamide|
41129035|NCT00104741|DRUG|triptorelin|
41129036|NCT00104741|RADIATION|radiation therapy|
41129037|NCT06267300|DRUG|Hyperbaric oxygen|Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)
41129038|NCT01737749|DEVICE|Neurokeeper stroke detector|Electrophisoloigcal monitoring
41278657|NCT05524883|DRUG|DYNE-251|Administered by IV infusion
41278658|NCT05524883|DRUG|Placebo|Administered by IV infusion
41278659|NCT04273945|DRUG|Macitentan 10 mg|Participants will receive macitentan 10 mg film-coated tablets orally.
41278660|NCT04273945|DRUG|Macitentan 37.5 mg|Participants will receive macitentan 37.5 mg film-coated tablets orally.
41278661|NCT04273945|DRUG|Macitentan 75 mg|Participants will receive macitentan 75 mg film-coated tablets orally.
41278662|NCT04273945|DRUG|Placebo|Participants will receive matching placebo film-coated tablets orally.
41278663|NCT04490057|DRUG|Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler|Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.
41278664|NCT04490057|DRUG|Varenicline or bupropion|Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).
40755278|NCT03318419|DRUG|Cladribine|5mg/㎡ d1-5
41129039|NCT04777383|DRUG|Acetylcholine|Iontophoretic administration of 5 different concentrations of acetylcholine
41278665|NCT04490057|BEHAVIORAL|Contingency Management|Participants will be financially rewarded for abstinence to tobacco.
40931593|NCT03096041|DEVICE|Auriculotherapy for analgesic use|The ASP will be applied to specific pain points
40931594|NCT03096041|DEVICE|Placebo auriculotherapy|The ASP will be applied to placebo points (not specific to pain)
40931595|NCT00284076|DRUG|L-arginine|
40931596|NCT00652691|BIOLOGICAL|filgrastim|
41278666|NCT03517436|DEVICE|TAVR with CENTERA THV|TAVR with the Edwards CENTERA THV System
40931597|NCT00652691|DRUG|carboplatin|
40931598|NCT00652691|DRUG|cyclophosphamide|
40931599|NCT00652691|DRUG|topotecan hydrochloride|
40931600|NCT00652691|PROCEDURE|autologous hematopoietic stem cell transplantation|
40931601|NCT00652691|PROCEDURE|peripheral blood stem cell transplantation|
40931602|NCT05287542|OTHER|Hypnotic suggestion|The intervention group will receive four weekly 60 min. sessions with hypnosis treatment including induction followed by hypnotic suggestion.
40931603|NCT05287542|OTHER|Mindfulness|The active control group will receive four weekly 60 min. sessions of induction and mindfulness-based instructions.
40931604|NCT00454831|DEVICE|HEP-40 chitosan|Enzymatically Hydrolyzed Polychitosamine-40 kDa
40931605|NCT04128787|DRUG|AG881 Formulation 1|AG881 uncoated tablets
40931606|NCT04128787|DRUG|AG881 Formulation 2|AG881 film-coated tablets
40931607|NCT04128787|DRUG|Omeprazole|Omeprazole capsules
40931608|NCT04443751|DRUG|SHR-1702|SHR-1702 monotherapy, administered IV
40931609|NCT00590837|DRUG|Lomustine|"Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1."
40931610|NCT05635188|PROCEDURE|Intestinal ostomy confection|Surgical procedure for fecal diverting
40931611|NCT03841305|PROCEDURE|Liver preparation before major hepatectomy|Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.
40931612|NCT05171829|OTHER|Track U|Track U diary
40931613|NCT06209385|DRUG|YZJ-5053 tablets|YZJ-5053 tablets will be administrated orally QD for 21 days
40931614|NCT03449238|DRUG|Pembrolizumab|Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
41449416|NCT02363764|PROCEDURE|Spontaneous expectorated sputum|"Will be obtained by the physiotherapist in:~- Expectorating CF patients"
41449417|NCT02363764|PROCEDURE|Induced sputum|"Will be obtained by the physiotherapist in:~* Non-expectorating CF patients~* Bronchoscopy CF patients"
41449418|NCT02363764|PROCEDURE|Bronchoalveolar lavage|"Will be obtained by the pulmonologist in:~- Bronchoscopy CF patients"
41449419|NCT02363764|OTHER|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients \>6 years of age
40931615|NCT00188708|PROCEDURE|hypoxia measurement|transrectal oxygen measurement
40931616|NCT06520969|OTHER|Prevelance of Uterine Vein and Uterine Vein System Variations (anatomical study)|Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients
40931617|NCT00610584|PROCEDURE|acupuncture|arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
41278667|NCT04987203|DRUG|Tivozanib|Tivozanib will be administered orally.
41278668|NCT04987203|DRUG|Nivolumab|Nivolumab will be administered via intravenous infusion.
41278669|NCT02884635|DRUG|ASP1707|Oral
40755279|NCT03318419|DRUG|G-CSF|300ug d0-14
40755280|NCT03318419|DRUG|Cytarabine|10mg/㎡ q12h SC d1-14
40931618|NCT00610584|PROCEDURE|minimal (sham)acupuncture|arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
40931619|NCT00610584|DRUG|cetirizine dihydrochloride (rescue medication)|arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
40931620|NCT00733447|DEVICE|CardioWest temporary Total Artificial Heart (TAH-t) System|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) System is a pulsatile biventricular device that replaces a patient's native ventricles and valves, and pumps blood to both pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external pneumatic driver connected by drivelines.
40931621|NCT01787344|DRUG|Botulinum Toxin Type A(Botox®)|Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
40931622|NCT01787344|DRUG|Botulinum toxin type A(Botulax®)|Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
41129040|NCT04777383|DRUG|Norepinephrine|Iontophoretic administration of 5 different concentrations of norepinephrine
41129041|NCT04777383|DRUG|Phenylephrine|Iontophoretic administration of 5 different concentrations of phenylephrine
41129042|NCT04777383|DRUG|Atropine|Iontophoretic administration of 5 different concentrations of atropine
41129043|NCT04777383|DRUG|Neostigmine|Iontophoretic administration of 5 different concentrations of neostigmine
41449420|NCT00608322|DRUG|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
41449421|NCT00608322|OTHER|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
41129044|NCT04777383|DRUG|Sterile water|Iontophoretic administration of sterile water
41129045|NCT02191891|DRUG|BI 836845|Human monoclonal antibody. Two dose levels (high or low) depending on the dose cohort explored
41278670|NCT02884635|DRUG|Placebo|Oral
41129046|NCT02191891|DRUG|afatinib|Irreversible EGFR tyrosine kinase inhibitor. Two dose levels (30 mg, 40 mg) depending on the dose cohort explored or determined dose at part A
41129047|NCT05980507|DRUG|ICI201|ICI201 CAR-T cell injection
41278671|NCT02884635|DRUG|Methotrexate|Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
41278672|NCT05049798|DRUG|Guselkumab|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
41278673|NCT05049798|DRUG|IL-17i|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
41278674|NCT04681131|BIOLOGICAL|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
41278675|NCT04681131|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
41278676|NCT05488314|DRUG|Capmatinib|Capmatinib will be administered orally.
41449422|NCT04817722|DRUG|Intravenous Solution|Intraoperative hydration
41129048|NCT04755179|PROCEDURE|Laparoscopic appendectomy|"Laparoscopic appendectomy is performed according to daily practice but with the following standardized key points:~1. Conventional laparoscopy (three-trocar technique)~2. In case of purulent fluid: Suction and no peritoneal lavage procedure~3. Skelletizing of the mesoappendix (coagulation/clips according to routine practice locally)~4. Appendiceal stump closure: with two endoloops and dissected between the endoloops. In case of involvement of the appendiceal base, the use of endostapler is recommended.~5. Withdrawal of appendix: principle of abdominal wall protection is followed (trocar technique / endobag)~6. No drain placement, no nasogastric tube, and no urinary catheter routinely, only on indication.~7. Closure of wounds as appropriate"
41278677|NCT05488314|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
41449423|NCT06626906|DIAGNOSTIC_TEST|Echocardiography, Blood sampling for biomarker assays|
41449424|NCT04577651|DEVICE|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with 16-contact Directional Lead
41449425|NCT05373043|DIETARY_SUPPLEMENT|Mitoquinone|Mito-Q is a supplement that targets mitochondrial function. Linking a triphenyl-phosphonium cation to coenzyme-Q, to produce Mito-Q, results in a lipophilic compound, which, due to the large mitochondrial membrane potential, selectively accumulates within mitochondria. This targeted antioxidant approach results in 50- to 100-fold more Mito-Q accumulation compared to non-targeted antioxidant delivery.
41449426|NCT05373043|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
41449427|NCT02351700|DRUG|IV Caldolor|IV Caldolor (IV ibuprofen) intraoperatively and postoperatively
41278678|NCT02258412|DRUG|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
41278679|NCT02258412|DRUG|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
41278680|NCT05812716|BEHAVIORAL|resiLIR Healthcare Professionals|"Weeks 1 and 2: Theoretical part on stress, resilience, self-care, and self-compassion~Weeks 3 to 6: Training phase of a weekly introduced practical exercise (reflection on living with ease, self-compassionate body scan, planning of positive activities, self-compassionate letter). This phase additionally includes smartphone reminders to apply the exercises in everyday life."
41278681|NCT06048081|DRUG|zolbetuximab|"intravenous infusion~mFOLFOX6 or CAPOX (used at physician discretion) will be used in combination with zolbetuximab"
40755281|NCT03318419|DRUG|Pegaspargase|2500U/m2 im d1
40755282|NCT03854435|OTHER|Heart rate assessment (stethoscope)|Immediately after birth heart rate will be evaluated by auscultation
41278682|NCT05637112|OTHER|None (Observational study)|Not Applicable since Observational Study
41278683|NCT03842137|DEVICE|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
41449428|NCT02351700|DRUG|IV Placebo|IV Placebo intraoperatively and postoperatively
41449429|NCT06562296|OTHER|Amnion-Intermediate-Chorion|Dehydrated human placental multilayer allograft from derived donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
41449430|NCT06562296|OTHER|Amnion-Chorion-Amnion|Dehydrated human placental trilayer allograft derived from donated human tissue.
41449431|NCT06562296|PROCEDURE|Standard of Care|Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.
40755283|NCT03854435|OTHER|Heart assessment (umbilical cord palpation)|Immediately after birth heart rate will be evaluated by palpation of the umbilical cord
40755284|NCT03646188|DRUG|Placebo-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
40755285|NCT03646188|DRUG|25 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
40931623|NCT05506137|DRUG|Pilocarpine|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
41129049|NCT04755179|PROCEDURE|Open appendectomy|"Open appendectomy will be performed according to the following standardized key points:~1. Gridiron incision at the right lower quadrant. (McBurney's point)~2. After obtaining access to the abdominal cavity the principle of abdominal wall protection will be followed.~3. The appendiceal stump will be closed by ligation, not a purse string suture.~4. Closure of wounds as appropriate"
40931624|NCT05506137|OTHER|Placebo|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
40931625|NCT05438901|BIOLOGICAL|leech therapy|effects of medicinal leeches
40931626|NCT03195296|OTHER|No intervention|No intervention related to the study is foreseen
40931627|NCT00191087|DRUG|Duloxetine|
40931628|NCT06397521|PROCEDURE|Crown lengthening|Investigation of the three techniques for aesthetic crown lengthening
40931629|NCT05413278|BEHAVIORAL|Behavioral|Patient education, information and empowerment
40931630|NCT01947907|DRUG|ACP-001|Once weekly subcutaneous injection
41129050|NCT04755179|PROCEDURE|Non-operative treatment|"Non-operative treatment consisting of administration of intravenous antibiotics with or without drainage procedures (in case of an abscess), reserving an appendectomy for those not responding or with recurrent disease.~One of the two antibiotic regiments:~1. Combination A:~   1. Amoxicillin/clavulanic acid 25/2.5mg/kg 6 hourly (total 100/10 mg/kg daily. Maximum 6000/600mg a day) for children \<40 kg OR Amoxicillin/clavulanic acid 1000/200mg/kg 8 hourly (total 3000/6000 mg/kg daily) for children \> 40 kg~  2. Gentamicin 7mg/kg once daily~2. Combination B:~   1. Cefuroxim 25 mg/kg 6 hourly (total 100 mg/kg/day. Maximum 6gram/day)~  2. Metronidazole 10mg/kg 8hourly (total 30 mg/kg/day. Maximum 4000 mg/day) In case of peri-appendicular abscess the decision can be made to perform a drainage procedure either percutaneously or surgical."
41129051|NCT04755179|PROCEDURE|Direct appendectomy|laparoscopic or open appendectomy as described
41129052|NCT06417892|DRUG|PD-1inhibitor|PD-1 antibody was selected according to first-line drug use
41129053|NCT00131209|DIETARY_SUPPLEMENT|fortified spread (RUTF)|
41278684|NCT03842137|DEVICE|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
41278685|NCT06552130|OTHER|Spiroergometer test with intranasal insulin spray|Participants will undergo a 30 min bicycle spiroergometer test and intranasal insulin spray. Intranasal insulin will be administered 30 minutes prior to the start of the physical activity.
41278686|NCT06552130|OTHER|Spiroergometer test with intranasal placebo spray|Participants will undergo a 30 min bicycle spiroergometer test and intranasal placebo spray. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over 15 minutes 30 minutes prior to the start of the physical activity on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
41278687|NCT06656273|BEHAVIORAL|FT LCP|FT LCP is a behavior change software application, used as an adjunct to the standard National Diabetes Prevention Program
41278688|NCT05575310|PROCEDURE|Total Knee Arthroplasty|Articular knee surface replacement
41278689|NCT04919512|DRUG|TAR-200|TAR-200 will be administered.
41278690|NCT04919512|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
41449432|NCT02047305|DEVICE|Radiofrequency Ablation|Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
40931631|NCT01947907|DRUG|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone
40931632|NCT02230527|DRUG|Ticagrelor|90mg twice a day by mouth
40931633|NCT02230527|DRUG|Clopidogrel|75mg once a day by mouth
40931634|NCT01113047|DRUG|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ|Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg
40931635|NCT02528721|DEVICE|Dual Mode BreathID Hp System|The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device
40931636|NCT06281301|OTHER|education tool|Participants will have 15 minutes to review the single sided card and then the survey will be administered. Participants will then be surveyed again within 1-2 weeks after initial completion to assess how well information was retained.
40931637|NCT06281301|OTHER|no additional information|Survey will be administered without reviewing the single sided card
40931638|NCT01109056|DRUG|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
40931639|NCT01109056|DRUG|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
41129054|NCT00131209|DIETARY_SUPPLEMENT|maize and soy flour|
41129055|NCT03471585|DRUG|THC|A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.
41129056|NCT03471585|DRUG|Placebo oral capsule|A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
41278691|NCT01275677|DRUG|Cyclophosphamide|Given IV
41278692|NCT01275677|DRUG|Docetaxel|Given IV
41278693|NCT01275677|DRUG|Doxorubicin|Given IV
41278694|NCT01275677|DRUG|Doxorubicin Hydrochloride|Given IV
41278695|NCT01275677|OTHER|Laboratory Biomarker Analysis|Correlative studies
41278696|NCT01275677|DRUG|Paclitaxel|Given IV
41278697|NCT01275677|OTHER|Quality-of-Life Assessment|Ancillary studies
41278698|NCT01275677|BIOLOGICAL|Trastuzumab|Given IV
41278699|NCT06657222|DRUG|TUB-030|A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
41278700|NCT04714372|DRUG|Daratumumab/rHuPH20|Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
41278701|NCT04714372|DRUG|FT538|FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
41449433|NCT01808651|DRUG|Fluoxetine|Administered orally
41129057|NCT02910973|DEVICE|Vagus Nerve Stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
41129058|NCT02910973|DEVICE|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
41129059|NCT03680638|OTHER|Control (Lactated Ringer's)|This intervention is meant to serve as a control by which the experimental sites are compared to, to assess effectiveness.
41129060|NCT03680638|DRUG|Tempol|This intervention is meant to assess the impact of superoxide on vasodilator responses by scavenging available superoxide.
41129061|NCT03680638|DRUG|Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme NADPH oxidase.
41129062|NCT03680638|DRUG|Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme xanthine oxidase.
41129063|NCT04078607|BEHAVIORAL|Rapid Visual Information Processing task|A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.
41129064|NCT04078607|BEHAVIORAL|None or Control condition|Participant were instructed to eat at will during a 15-minute duration.
41129065|NCT03653364|DRUG|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age. Participants aged ≥ 3 months to \<12 months old received baloxavir marboxil, 2 milligrams per kilograms (mg/kg). Participants from birth to \< 4 weeks old and ≥ 4 weeks to \< 3 months old received baloxavir marboxil, 1 mg/kg.
41129066|NCT02261805|DRUG|Ganetespib|
41129067|NCT02261805|DRUG|Doxorubicin|
41129068|NCT00789542|DEVICE|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
41129069|NCT00789542|OTHER|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
41129070|NCT03071354|DIETARY_SUPPLEMENT|HMB protein supplement (3g)|HMB 3g/day or iso-nitrogenous control (discussed below) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward. The dose of HMB was chosen based on multiple studies revealing efficacy of 3g/day improving muscle mass and demonstrating an excellent safety profile. Feeding will be initiated as per local practice. Enrolled patients will be randomized to supplementation with HMB (3g) or control will begin within 72 hours of admission to ICU.
41129071|NCT03071354|DIETARY_SUPPLEMENT|Nutritional Supplement|Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward throughout the study. While the patient is intubated, the control nutritional supplement will be delivered via the enteral feeding tube. The participant will switch to oral administration once extubated
41129072|NCT03190850|OTHER|Intervention|The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength
41129073|NCT03190850|OTHER|Control|The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
41129074|NCT02731846|DRUG|Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
40755286|NCT03646188|DRUG|50 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
40931640|NCT04757454|DIAGNOSTIC_TEST|5-item SARC-F questionnaire|Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit
41129075|NCT02731846|DRUG|Fluticasone furoate 100 mcg + Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
41129076|NCT02731846|DRUG|Umeclidinium 62.5 mcg|Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
41129077|NCT02731846|DEVICE|Placebo ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
41129078|NCT02731846|DRUG|Albuterol/Salbutamol|Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
41129079|NCT01492049|BEHAVIORAL|CRCS patient decision aid (PtDA) video|Participant views PtDA program video in same room as research assistant who offers instruction as needed.
41449434|NCT06128967|DRUG|Fluvoxamine Maleate 100 MG|Fluvoxamine Maleate 100 mg each pills
40755287|NCT03646188|DRUG|100 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
40755288|NCT03646188|DRUG|200 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
40755289|NCT06253208|PROCEDURE|postoperative pain|Postoperative analgesia in laparoscopic sleeve gastrectomies: laparoscopic versus ultrasound-guided transversus abdominis plane block
40755290|NCT01491932|DRUG|AFQ056|AFQ056 will be supplied as oral capsules.
40931641|NCT06246279|BEHAVIORAL|Adaptation to Adolescence and Type 1 Diabetes Management Training Program|The content of the Training Program was created by researchers based on Transition Theory, in line with high-level research results and international guides. Then, the necessary arrangements were made by taking the opinions of 10 experts (child health and disease nursing faculty member, child and adolescent mental health specialist, child endocrinologist, child development specialist, nutrition and dietetics specialist, sports training specialist). The content was finalized in line with the comments received.
41278702|NCT04714372|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).
40931642|NCT03091777|DRUG|GDC-229|GDC-229 is a vaginal gel.
41278703|NCT04714372|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
41278704|NCT06519656|DRUG|Mazdutide|In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly. If well tolerated, the dosage is increased to 4mg once weekly for another 4 weeks. If still well tolerated, the dosage is further increased to 6mg once weekly and maintained for the ensuing 16 weeks.
41278705|NCT05895513|DRUG|Pimavanserin 34 mg|5HT-2a receptor antagonist
41278706|NCT05895513|DRUG|Placebo|Inactive Comparator
41278707|NCT05605574|BEHAVIORAL|Advance Care Planning conversations|In the first conversation, patients and caregivers are guided through conversations using a modified version of the Serious Illness Conversation Guide, which explores understanding of the AYA's illness and treatment plan, information preferences, goals, sources of support, fears and worries, and goals of care. In the second conversation, participants are introduced to and encouraged to complete portions of the advance care planning document, Voicing My CHOiCES. Participants are guided through a discussion of this experience and may share their perceptions of each other's preferences for care. In the third conversation, participants may discuss previous conversations or other new Advance Care Planning topics. At the end of each conversation, a summary of the conversation will be documented in the electronic medical record and the investigator will communicate directly any information requested by the patient or caregiver to be shared with specific members of the patient's care team.
41278708|NCT01085435|DEVICE|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.
41278709|NCT06096038|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/meter square IV
41278710|NCT06096038|DRUG|Fludarabine|fludarabine 30 mg/meter square IV × 3 days
41278711|NCT06096038|BIOLOGICAL|Cell Therapy|the autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen iC9-CAR.CSPG4 T cell infusion iC9-CAR.CSPG4 T cell infusion
41278712|NCT04116437|DRUG|Zanubrutinib|Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily or 320mg once daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
41278713|NCT06140836|DRUG|Repotrectinib|Specified dose on specified days
41278714|NCT06140836|DRUG|Crizotinib|Specified dose on specified days
40931643|NCT03091777|DRUG|Metronidazole Vaginal Gel 0.75%|Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
40931644|NCT03091777|DRUG|Placebo|Inactive arm of the study
40931645|NCT01444677|DRUG|MB12066|MB12066 300mg
40931646|NCT01444677|DRUG|MB12066|MB12066 400mg
40931647|NCT01444677|DRUG|MB12066|MB12066 100mg
40931648|NCT01444677|DRUG|MB12066|MB12066 200mg
40931649|NCT01444677|DRUG|Placebo|Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
40931650|NCT02707159|DRUG|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
41278715|NCT05754957|DRUG|Milvexian|Milvexian will be administered orally.
41278716|NCT05754957|OTHER|Placebo|Placebo will be administered orally.
41278717|NCT02743858|OTHER|Bilateral arm measurements|Pts treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder \& the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed before surgery, post-operatively \& at timepoints of 6,12,18, \& 24 months after surgery for 2 years will be obtained using the Perometer (Model 350 NT Perometer, Per-System) for bioimpedance measurements. Pts who have not yet developed lymphedema by 2 years, an additional measurement at approx 3 years post-surgery will be performed. If pt is diag with lymphedema at the 3-year visit, she will be asked to continue on study for an additional year. Pts treated with SLNB alone, following re-consent, a long-term follow-up volumetric arm measurement will be obtained using the perometer \& circumferential arm measurements at a minimum of 2 years post-surgery.
40931651|NCT03228199|OTHER|Intervention group|Will immediately receive a free pair of presbyopic glasses through the Clear Vision Workplace program. These glasses will correct the worker's vision at their usual working distance, and will not correct astigmatism.
40931652|NCT03228199|OTHER|Control Group|Will be deferred to receive spectacles as above, after the 12 week evaluation period.
40931653|NCT01895361|DRUG|SelG1|
40931654|NCT01895361|DRUG|Placebo|
40931655|NCT03657966|BIOLOGICAL|DCVAC/OvCa|activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy
40931656|NCT03657966|DRUG|Standard of Care Chemotherapy|either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
40931657|NCT02372214|PROCEDURE|Training|Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
40931658|NCT02002585|PROCEDURE|Renal denervation|Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
40931659|NCT01867073|OTHER|Biomarker|
40931660|NCT02927405|DRUG|Gabapentin|anticonvulsant drug that is used for neuropathic pain.
40931661|NCT02927405|PROCEDURE|TAP Block|a procedure done anesthetize the anterior abdominal wall
40931662|NCT06127537|BEHAVIORAL|Therapeutic Intervention Group|"The therapeutic group factors that are worked on in the group session with a psychologist are:~* Altruism.~* Cohesion: feeling of belonging and acceptance in a group.~* Universality: identification with the feelings, ideas or problems of the other group members.~* Interpersonal-internalisation learning: the patient understands himself/herself by sharing his/her experience with the group.~* Interpersonal-externalisation learning: the group offers the patient the possibility to express his own experience and to change his attitudes towards others.~* Counselling.~* Identification: assumption of behavioural patterns of other members as one's own.~* Reactualisation of the family experience.~* Understanding of one's own internal motivations.~* Reciprocal stimulation: the improvement of other members encourages them to solve or approach their problems in a more favourable way.~* Existential factors: empowerment of the individual."
41129080|NCT01492049|BEHAVIORAL|Questionnaires|Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
41129081|NCT01492049|BEHAVIORAL|Essential Hypertension video|Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
41129082|NCT00569634|PROCEDURE|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always \< 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
41278718|NCT02743858|OTHER|Body mass index (BMI)|Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. BMI will be correlated with the presence of inflammatory biomarkers in the tissue, as well as with lymphedema development.
41278719|NCT02743858|BEHAVIORAL|Quality of Life Questionnaire|
41449435|NCT06128967|DRUG|Placebo|Placebo talc pills of same shape, color, weight if compared with active comparator
41449436|NCT06128967|DRUG|Metformin Extended Release Oral Tablet|Metformin Extended release oral tablets of 750 mg each pill
41129083|NCT02595346|DRUG|Hydroxychloroquine|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
41129084|NCT02595346|DRUG|placebo|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
41278720|NCT02743858|OTHER|Blood draw|Patients enrolled in the translational study (Cohort 3) will undergo blood draws for serum collection preoperatively and 12-24 months postoperatively to test for FGF2, IL4, IL10, TGFB, Leptin, IL6, and CRP. At both timepoints, up to 20 mL of blood will be collected.
41449437|NCT04452786|PROCEDURE|Endoscopic sleeve gastroplasty|Four-hour solid mixed meal test
40931663|NCT01722227|DRUG|Liraglutide|
40931664|NCT01722227|DRUG|Placebo|
40931665|NCT03631355|DRUG|Tranexamic Acid|One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
40931666|NCT00432601|BEHAVIORAL|type of decision aid|We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
40931667|NCT03018665|DRUG|Exenatide|subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
40931668|NCT03018665|DRUG|BIAsp30|subcutaneous injection，fit dosage twice a day in three months
40931669|NCT03018665|DRUG|Metformin|oral，0.85g，twice a day in three months
40931670|NCT05519332|PROCEDURE|percutaneous vertebral-disc plasty|percutaneous vertebroplasty combined percutaneous cement discoplasty
40931671|NCT01527266|DIETARY_SUPPLEMENT|Carbohydrate drink|sucrose beverage
40931672|NCT01527266|DIETARY_SUPPLEMENT|Placebo mouth rinse|placebo; non-caloric sweetened beverage for use as a mouth rinse
40931673|NCT02646202|PROCEDURE|Sclerotherapy|Injection of varices
40931674|NCT02646202|PROCEDURE|Band ligation|endoscopic banding of varices
40931675|NCT02646202|PROCEDURE|Scleroligation|intra variceal endoscopic sclerotherapy combined with band ligation.
40931676|NCT05519293|DRUG|H002|Small molecule, Capsule
41449438|NCT04452786|PROCEDURE|Laparoscopic sleeve gastrectomy|Four-hour solid mixed meal test
41278721|NCT06235996|PROCEDURE|Office-based procedure indicated for chronic pain with music|Such procedure may include sacroiliac joint (SI) steroidal injections, SI radiofrequency ablations, peripheral nerve stimulator implantations, caudal and laminar epidural steroidal injections, lumbar medial branch blocks, lumbar medial branch nerve radiofrequency ablations, spinal cord implantation of electro stimulators.
41449439|NCT03599362|DRUG|Nivolumab + Cabiralizumab|Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.
41449440|NCT03599362|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.
40755291|NCT02466997|DRUG|tacrolimus|tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
40755292|NCT02466997|DRUG|Placebo|
41449441|NCT01302548|DEVICE|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
40931677|NCT06372743|OTHER|INTEGREAT-CKD Intervention|"The participant is reviewed once in 12 weeks by a CKD-trained APN, during a 30-minute timeslot, an extended duration compared to the timeslot of 10 to 15 minutes that routinely is designated for a recurrent review of a CKD patient in any restructured hospital in Singapore. The review consists of a 15-minute medical review centred on a discussion of the biochemical reports and clinical data relevant to CKD management, and educating on CKD knowledge and lifestyle modification.~Patients self-report the monitored parameters to a community-based nurse through a telehealth AI-based platform. The APN oversees monitoring the community-based parameters and titration of appropriate medications. The APNs have received a Master's in Nursing, with training that is primarily centred on generalist-led care, with additional clinical training in CKD management. They are supported with protocols to detect anomalies in blood pressure trends, glycemia ranges, and abnormalities in fluid status."
40931678|NCT00134784|DRUG|[123I]B-CIT SPECT imaging|To assess \[123I\]B-CIT SPECT imaging
40931679|NCT05694000|DEVICE|On-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is on."
40931680|NCT05694000|DEVICE|Off-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is off."
41129085|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Standard product (SP)|2 capsules - 200 mg total CoQ10
41129086|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP1)|2 softgels - 200 mg total CoQ10
41278722|NCT06235996|PROCEDURE|Office-based procedure indicated for chronic pain without music|Office-based procedure indicated for chronic pain without music
40931681|NCT03450980|OTHER|EyeTurn App|App software which analyzes the position of ocular surface reflections in a photograph to quantify eye misalignment (strabismus)
40931682|NCT01473927|OTHER|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
40931683|NCT01473927|OTHER|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
41129087|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP2)|2 softgels - 200 mg total CoQ10
41278723|NCT03049462|DRUG|Mirabegron|Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.
41278724|NCT03049462|OTHER|B Complex Plus Vitamin C Tablets|Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
41278725|NCT05021224|BEHAVIORAL|Rapidly prototype and test strategies|We will generate strategies for facilitating treatment initiation that address barriers and leverage facilitators, in partnership with a team of experts in behavioral science and implementation science. We will favor simple, established strategies with freely available resources (e.g., Caring Contacts templates) to promote scalability, but will also consider other potential strategies as indicated. We will explore both low- (e.g., manualized text messaging) and high-tech (e.g., electronic health record integrated patient messaging) strategies to maximize relevance across contexts. Next, prototype-strategy designs will be validated through rapid-cycle tests in this real world context and in a manner that is inexpensive and allows us to fail fast and learn quickly. After testing a given implementation strategy, the team will debrief and decide whether to refine or adjust it.
41278726|NCT05548634|DRUG|TAVO412|Biologic
41278727|NCT05908734|DRUG|Cetrelimab|Cetrelimab will be administered as IV infusion.
41278728|NCT05908734|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
41278729|NCT05957276|OTHER|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
40755293|NCT03966118|DRUG|Avelumab|Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle
40931684|NCT04653896|DEVICE|Keeogo|The Keeogo is the only commercially available (in Canada) robotic exoskeleton for a non-paralyzed population who can stand and initiate a stepping action, but have impaired mobility for functional tasks. Keeogo provides active assistance during stance and swing phases and assists users to perform functional mobility tasks including walking, stair climbing, sit-to-stand, bending, squatting, and kneeling.
40931685|NCT00471809|DRUG|Budesonide + Salmeterol + Azithromycin|
40931686|NCT00471809|DRUG|Budesonide + Salmeterol + Montelukast|
40931687|NCT00471809|DRUG|Budesonide + Salmeterol + Placebo|
41129088|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP3)|2 softgels - 200 mg total CoQ10
41129089|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP4)|2 capsules - 200 mg total CoQ10
41129090|NCT05157113|DRUG|Dropless Regimen|"Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops."
41129091|NCT05157113|DRUG|Standard Regimen|"Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
40755294|NCT03966118|DRUG|Ramucirumab|Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle
40931688|NCT05610410|OTHER|Laser speckle contrast analysis|Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT
41129092|NCT04696900|PROCEDURE|Exercise training|exercise training in an approved rehabilitation program
41129093|NCT04274881|PROCEDURE|Catheterization of internal jugular vein|"The right internal jugular vein will be cannulated under transesophageal echocardiographic (TEE) guidance in order to place the catheter tip in the mid-SVC.~The length of the catheter required to place the tip at the mid-SVC as guided by TEE will be regressed on the C-length or on the distance from the entry point to the surface point corresponding to the mid-SVC on the chest wall in order to obtain a predictive equation.~The accuracy of either equation will be assessed by estimation of the standard error of the estimate (SEest)."
41449442|NCT01302548|PROCEDURE|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
40931689|NCT03444987|GENETIC|Measurement of protein expression in tissues.|"The followings markers will be estimated in tissue~1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.~3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).~4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~5. Reduced glutathione, an antioxidant marker by a colorimetric method"
40931690|NCT05106790|BEHAVIORAL|Educational support with peer counseling|This group will receive peer counseling therapy sessions will be led by doctors who specialize in hypertension. Patients and their families will be the focus of the sessions. Face-to-face sessions will take roughly 25-30 minutes. Patients will receive spoken and written instructions based on their abilities during these sessions. The counseling sessions are geared toward overcoming both general and personal obstacles. The educational component will be delivered through smart booklets. Information on hypertension, blood pressure self-monitoring, and frequent systolic blood pressure (SBP) tests, as well as body weight and serum cholesterol values, are included in the instructional support. Food control, exercise therapy, and hypertension problems and their management will also be explored as non-pharmacological therapeutic approaches.
40931691|NCT05106790|BEHAVIORAL|mHealth intervention|"This group will receive mHealth intervention will include daily written and voice messages, and once weekly an educational-led video. This intervention module will be delivered through WhatsApp."
40931692|NCT05106790|BEHAVIORAL|mHealth intervention and Educational support with peer counseling|This group will receive both Educational support (Smart booklets) with peer counseling sessions on a monthly basis and mHealth intervention will include daily written and voice reminders, and once weekly an educational led video.
40931693|NCT05694221|DRUG|Supaglutide injection|Administered subcutaneously in the Supaglutide arms
41129094|NCT03486600|OTHER|Fluid Resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
41129095|NCT00507494|DRUG|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
40931694|NCT05694221|DRUG|Digoxin|Oral Administration
40931695|NCT05694221|DRUG|Metformin|Oral Administration
40931696|NCT00676221|DRUG|Myfortic|"Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.~Cellcept 1000mg bid = Myfortic 720mg bid"
40755295|NCT03966118|DRUG|Paclitaxel|Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle
40755296|NCT04553536|DRUG|Esketamine, Sulfentanil or/and Remifentanil|The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
40931697|NCT02296879|GENETIC|SAIT301|The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
41129096|NCT00143130|DRUG|Pregabalin|Pregabalin
41129097|NCT03478969|DEVICE|Accu-Chek® Solo micropump system|Medical device for subcutaneous delivery of insulin in a personalized way.
41129098|NCT03478969|DEVICE|mylife™ OmniPod® Insulin Management System|A patch pump system delivering insulin.
41129099|NCT03478969|OTHER|Multiple Daily Injections (MDI) therapy|Injecting insulin as per participant's need.
41129100|NCT03853538|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one hemiface.
41129101|NCT03853538|OTHER|Semisolid vaseline|Product is applied to one hemiface.
41129102|NCT05208034|DRUG|Methotrexate|Two-doses of intramuscular methotrexate as 50mg/m2.. One at at day-zero and 2nd at day 7.
41129103|NCT03923452|BEHAVIORAL|Mindfulness-based Stress Reduction|"Mindfulness-based stress reduction is a manualized mindfulness training protocol that has been researched for over 20 years. The original protocol will be used, with the exception of the prescribed home practice duration (i.e. 30 mins of practice). Rather, the program will be modified to set up participants for success by providing them with instruction to build on their meditation practice, beginning with 8 minutes a day."
41129104|NCT00104949|BIOLOGICAL|trastuzumab|
41129105|NCT03790215|DRUG|Dydrogesterone|The investigators give participants oral dydrogesterone(as described in arm description).After 3 cycles of treatment, the investigators evaluate the treatment effects.
41129106|NCT01183767|DRUG|Epigallocatechin-Gallate|EGCG in a dosage of up to 10mg/kg body weight
41129107|NCT01183767|DRUG|Placebo|
41129108|NCT00004559|BEHAVIORAL|dietary polyunsaturated fatty acid|
41129109|NCT00418652|DEVICE|No TMS intervention|"In the no TMS condition, no simulation was given and no coil placed near participants' heads."
41129110|NCT00418652|DEVICE|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
41449443|NCT05299463|DIAGNOSTIC_TEST|Exercise Testing|"* Tele-Six-minute walk test (T6MWT)~* 1 Minute Sit-to-stand test (STS)~* 2-minute symptom-limited Step test (ST)~* 3-metre Timed up and go test (TUG)."
41449444|NCT00270582|DRUG|Taxotere, Cisplatin, Gemcitabine|
41449445|NCT00193960|PROCEDURE|1) Intraocular pressure 2) visual acuity|
41449446|NCT01751087|OTHER|Mifepristone|oral mifepristone 200 mg on Day 1.
41449447|NCT01751087|DRUG|misoprostol|buccal misoprostol 400 mcg on Day 2
41449448|NCT01751087|DEVICE|Osmotic dilators|osmotic dilators on Day 1
41449449|NCT01751087|OTHER|placebo|placebo for mifepristone, on day 1
41129111|NCT00418652|DEVICE|TMS over the vertex|10Hz TMS for over vertex.
40931698|NCT03516474|DEVICE|MIMOSA Diagnostics|"The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing."
40931699|NCT04562753|PROCEDURE|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
40931700|NCT04562753|PROCEDURE|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
41129112|NCT02652585|DRUG|Naltrexone|
41129113|NCT02652585|DRUG|Placebo|capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
41129114|NCT05496374|DRUG|Placebo|Placebo-matching capsules will be administered orally.
41449450|NCT01751087|OTHER|placebo|placebo for misoprostol, on day 2
40931701|NCT02824861|BEHAVIORAL|Bemobile|
40931702|NCT00531674|DIETARY_SUPPLEMENT|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
40931703|NCT00531674|DIETARY_SUPPLEMENT|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
41449451|NCT06283667|DRUG|Semaglutide|Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
40931704|NCT00531674|DIETARY_SUPPLEMENT|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
40931705|NCT00531674|DIETARY_SUPPLEMENT|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
40931706|NCT00531674|DIETARY_SUPPLEMENT|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
40931707|NCT00531674|DIETARY_SUPPLEMENT|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
40931708|NCT01142128|DRUG|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
40931709|NCT01142128|DRUG|Placebo to Nexium|one capsule per day for one month
41129115|NCT05496374|DRUG|SPR720 500 mg|SPR720 500 mg (250 mg × 2 capsules) will be administered orally.
40931710|NCT01142128|DRUG|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
40931711|NCT01142128|DRUG|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
40931712|NCT03702296|OTHER|Ear plugs and eye masks|Patients in the intervention arm will be provided with ear plugs and eye masks and instructed on the use of these during sleep
40931713|NCT05678049|DIAGNOSTIC_TEST|Synovial fluid analysis|"For patients with knee under tension at the joint level, the symptomatology often requires evacuation by puncture under ultrasound guidance. The intervention will be performed only for patients for whom this therapeutic indication exists anyway by their physicians.~After making the evacuation we will want to use this liquid for Microscopic and Spectrophotometric evaluation"
41129116|NCT05496374|DRUG|SPR720 1000 mg|SPR720 500 mg (250 mg × 4 capsules) will be administered orally.
41129117|NCT01613053|DRUG|Glivec|800 mg per day
41129118|NCT03130894|OTHER|Plasma TMAO concentration|Plasma TMAO concentration
41129119|NCT01212744|DRUG|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
41129120|NCT04905004|PROCEDURE|Canine retraction|Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.
41129121|NCT00002235|DRUG|Indinavir sulfate|
41129122|NCT00002235|DRUG|Nelfinavir mesylate|
41449452|NCT06344130|RADIATION|Radiation Therapy|Radiation therapy will be administered via a linear accelerator using 6 megavoltage (MV) photons or greater.
41449453|NCT00945490|DRUG|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
41129123|NCT00002235|DRUG|Efavirenz|
41449454|NCT00945490|DRUG|Placebo|Single intraprostatic injection of placebo
41449455|NCT03602339|DRUG|Gadoterate (Dotarem/Clariscan)|Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
41449456|NCT03602339|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
40755297|NCT02082093|DEVICE|Telemedicine System|
41129124|NCT01596972|DEVICE|dBest semi-quantitative urine pregnancy test|The dBest® semi-quantitative urine pregnancy test (Figure 2) is a graduated urine pregnancy test with five different levels of sensitivity: 25 IU/L, 100 IU/L, 500 IU/L, 2000 IU/L, 10000 IU/L. The test detects the level of serum hCG that corresponds to the range between that level and the level above it, i.e. the test would be positive at 500 if the hCG was either 501 or 1999. The tool was validated in a US sample of 196 women, where there was a correlation of 69% between urine hCG and serum hCG. Furthermore, the test had a 10% false negative rate (i.e. recording a level two gradations below the serum level) and a 6% false positive rate (i.e. recording a level two gradations above the serum level)
41129125|NCT02761616|OTHER|eBC treated participants|No intervention administered in this retrospective observational study.
41129126|NCT02148185|DRUG|MT-1303|
41129127|NCT02730624|DRUG|Piperacillin-tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration
41129128|NCT00482742|DEVICE|CiTop(TM) Guidewire|
41129129|NCT01555138|DRUG|Indacaterol|Indacaterol is delivered via a SDDPI.
41129130|NCT01555138|DRUG|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
40931714|NCT03680469|BEHAVIORAL|standard early rehabilitation|The standard early rehabilitation program is an intervention regularly utilized in the stroke center of National Taiwan University Hospital. Activities performed in the standard early rehabilitation program within 24-72 hours of onset include(1) bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and facilitation techniques, and (2) functional training in which the patients are instructed to engage in the repetitive and systematic practice of tasks, such as rolling or sitting supported on the bed.
40931715|NCT03680469|BEHAVIORAL|adding early out-of-bed mobilization|Early mobilization treatment involving out-of-bed, task-specific activities including rolling and sitting up, sitting unsupported out of bed, and standing within 24-72 hours of onset and accounting for more than two thirds of the treatment time in early rehabilitation .
40931716|NCT01653782|BEHAVIORAL|Kundalini yoga|Guided training twice a week for six weeks. Self instructing cd for home practice
40931717|NCT01653782|BEHAVIORAL|Self care advice|"Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet The Back book"
40931718|NCT01653782|BEHAVIORAL|Exercise|"Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet The Back book"
40931719|NCT03425422|DEVICE|VITARIA System|Chronic stimulation of the right cervical vagus nerve
40931720|NCT02005198|OTHER|No treatment given|Subject will only fill out a questionnaire when entering the non-interventional study
40931721|NCT02732197|DRUG|Sedation|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
40931722|NCT02732197|DRUG|No sedation|Parturients did not receive any type of sedation after spinal anesthesia.
40931723|NCT01554631|DRUG|Acarbose (Glucobay ODT, BAYG5421)|
41449457|NCT05315063|OTHER|Eccentric Training|Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
40931724|NCT01554631|DRUG|Acarbose (Glucobay, BAYG5421)|
40931725|NCT03916107|PROCEDURE|Levator muscle and tarsus resection|Shortening the levator muscle with resection of tarsus to correct severe ptosis
40931726|NCT03916107|PROCEDURE|Frontalis flap|Using frontal muscle flap to correct severe ptosis
40931727|NCT01827358|DRUG|Mupirocin calcium|Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
40931728|NCT01827358|DRUG|Mupirocin calcium|Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
40931729|NCT05468736|BIOLOGICAL|Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) (or fractional dose if necessary) on Days 0 and 21 in the Initial Vaccination Period.
40931730|NCT05468736|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 201 and Day 229 for the participants originally randomized to placebo.
40931731|NCT05468736|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
40931732|NCT05468736|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in the Initial Vaccination Period or on Days 201 or Day 229 in the Booster Vaccination Period
40931733|NCT03083860|DEVICE|BEI|BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
40931734|NCT02339220|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|Constraint-Induced Movement Therapy (CIMT) is a form of physical rehabilitation based on basic research in behavioral psychology and behavioral neuroscience. The therapy will be given on an outpatient basis for 3.5 hours/day for 10 consecutive weekdays. This treatment has four components: 1. intensive training in use of the more-affected arm; 2. organization of this training following shaping principles, which involve frequent positive feedback and progressively increasing the demand of the task in small increments; 3. discouraging use of the less-affected arm by placing the hand in a padded safety mitt, and 4. a set of behavioral procedures, known as the Transfer Package, for transferring gains from the treatment to real-world setting. In this study, two forms of the Transfer Package, standard and enhanced, will be used and form a separate factor (see below).
40931735|NCT02339220|BEHAVIORAL|Lakeshore Enriched Fitness Training (LEFT)|This treatment will given on an outpatient basis for 3.5 hours per day for 10 consecutive weekdays. It will consist of the following components: general fitness exercises (largely lower extremity), sports and recreation (land and water-based); adapted Yoga; breathing exercises and postural control, movement to music, massage therapy, meditation and Progressive Muscle Relaxation (PMR).
41129131|NCT03849482|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging|Multiparametric MRI evaluation includes Conventional MRI, Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI
41129132|NCT03849482|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology|Ultrasound-Guided Fine Needle Aspiration Cytology
41129133|NCT03849482|DIAGNOSTIC_TEST|Clinical Evaluation|Patient's history and physical examination, reporting signs and symptoms suggestive of malignancy (pain, facial nerve weakness, fixation to skin and surrounding tissues, trismus, skin ulceration, lymphadenopathy, numbness, weight loss)
41129134|NCT03849482|DIAGNOSTIC_TEST|Final Histopathological Diagnosis|Final Diagnosis of the Disease from the Pathology Report after Surgical Resection of the Lesion
41449458|NCT05315063|OTHER|Muscle Energy Technique (PIR)|"The participant will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb.~On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch was applied and maintained for 30 seconds.3 repetitions of this process will be done"
41129135|NCT03768466|DRUG|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
41129136|NCT05352308|BEHAVIORAL|Common Sense Model Guided Narrative Video|The narrative video will address illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers
41129137|NCT02961075|OTHER|local surface anesthesia|Airway anesthesia for Bronchoscopy
41278730|NCT05217914|DRUG|Copanlisib (BAY80-6946)|Copanlisib for treatment of relapse/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL)
41449459|NCT00870129|PROCEDURE|MRI and advanced MRI sequences|This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
40931736|NCT02339220|BEHAVIORAL|standard Transfer Package (sTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
40931737|NCT02339220|BEHAVIORAL|enhanced Transfer Package (eTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
40931738|NCT02392832|BIOLOGICAL|Fourstar® granule, 90 day and 180 day briquettes Bti/Bs|"In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.~Starts from 2016, a total of 34 clusters in the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs."
40931739|NCT02577276|DEVICE|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
41129138|NCT02961075|DEVICE|Laryngeal tube|
41129139|NCT05758506|DEVICE|Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)|We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.
41129140|NCT02740231|DRUG|JTA-004 intra-articular injection|Each patient will undergo a single injection of JTA-004 into the knee joint
41449460|NCT05153304|BIOLOGICAL|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
41129141|NCT02740231|DEVICE|Reference product intra-articular injection|Each patient will undergo a single injection of Reference product into the knee joint
41129142|NCT06064669|DRUG|Metformin pretreatment before ovarian stimulation|The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
41129143|NCT06064669|DRUG|Placebo pretreatment before ovarian stimulation|The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
41129144|NCT06064669|DRUG|Metformin pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
41129145|NCT06064669|DRUG|Placebo pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
41278731|NCT05070858|DRUG|Pozelimab + Cemdisiran|Subcutaneous administration as described in the protocol
41278732|NCT05070858|DRUG|Cemdisiran|SC administration as described in the protocol
41278733|NCT05070858|OTHER|Placebo|SC administration as described in the protocol
41278734|NCT05070858|DRUG|Pozelimab|SC administration as described in the protocol
41278735|NCT05744921|DRUG|Pozelimab|Administered subcutaneously (SC) every 4 weeks (Q4W)
41278736|NCT05744921|DRUG|Cemdisiran|Administered SC Q4W
41278737|NCT04925570|DEVICE|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
41449461|NCT05153304|DRUG|Nivolumab|3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.
40931740|NCT01799382|OTHER|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
41129146|NCT05011955|BEHAVIORAL|Mindfulness, compassion and intercare based Intervention|"The mindfulness based intervention was a short version of the Mindfulness based intercare program (IBAP). The intervention consists of four synchronic group sessions via ZOOM of one hour each, one peer week and home practice. A total of four groups were conducted of 15 students each.~The IBAP program was inspired by first and second generation mindfulness based interventions, such as Mindfulness based cognitive training, Self-Compassion and Cognitive based Compassion training. Also compassionate communication, conservation of resource theory and habits theory.~Each module consists in meditation practices, inquiry and self or group reflections on different topics such as mindfulness, automatic pilot, mind wandering , acceptance, gratitude and compassion, care resources and intercare."
41129147|NCT05011955|BEHAVIORAL|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work base on psychoeducation about stress, anxiety, selfcare and effective communication. Plus general curricular intervention. Delivered by psychologist.
41129148|NCT05011955|OTHER|General curricular intervention|"All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams."
40755298|NCT01033370|DRUG|clevidipine.|Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes \& titrated to the desired BP lowering effect to SBP goal of \< 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
41129149|NCT01645124|DRUG|Hydroxyurea|
41129150|NCT01645124|PROCEDURE|Phlebotomy|
41449462|NCT06626789|BIOLOGICAL|Amygdala neurofeedback|Real-time fMRI neurofeedback from amygdala's blood oxygenation level dependent (BOLD) signal + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
41449463|NCT06626789|BEHAVIORAL|Sham neurofeedback|Recorded neurofeedback from a different participant + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
40755299|NCT03823885|OTHER|e-cigarette|use e-cig for 30 minutes
41449464|NCT06626581|DIETARY_SUPPLEMENT|Iodine excess|Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) ≥300μg/L
40755300|NCT03823885|OTHER|empty (-cigarette sham control)|use empty e-cig (sham control)
40755301|NCT01820104|DRUG|lansoprazole, 30 mg per day for 6 days|
40755302|NCT03261258|OTHER|Questionnaire|
40755303|NCT06277830|DEVICE|Wearable sensor|Participants will wear a pendant sensor for 7 days and then participate in an on-site examination with using a tablet designed to evaluate weakness in MG.
40755304|NCT04430621|DRUG|Follicle Stimulating Hormone|FSH will be administered s.c. in the morning to male healthy subjects
40755305|NCT01183182|DEVICE|ActiSight Needle Guidance System|Three different groups of patients defined per lesion size
40755306|NCT02051283|OTHER|RFA|RFA
40755307|NCT04570280|OTHER|Aerobic Exercises|Aerobic exercises with treadmill will be applied 3 times a week for 12 weeks.
40755308|NCT04570280|OTHER|Resistive Exercises|Resistive exercises with sandbag will be applied 3 times a week for 12 weeks.
40755309|NCT04570280|OTHER|Range of Motion Exercises|Range of Motion Exercises will be applied 3 times a week for 12 weeks.
40755310|NCT05775575|DRUG|TQB3909 tablets|TQB3909 is an inhibitor targeting BCL-2 protein
40755311|NCT05417386|DRUG|FOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
41449465|NCT06626581|DIETARY_SUPPLEMENT|Iodine suitable|Iodine suitable areas: water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
41449466|NCT05077449|DRUG|XZP-3287+Fulvestrant|XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
40755312|NCT05417386|DRUG|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
40755313|NCT05417386|DRUG|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
40755314|NCT05417386|DRUG|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
40755315|NCT05417386|DRUG|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
40755316|NCT05417386|DRUG|NIS793|Given by intravenous infusion
40755317|NCT05417386|RADIATION|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
40755318|NCT05417386|DRUG|Capecitabine|Taken Orally as part of Chemoradiation
40755319|NCT05417386|RADIATION|Radiation Therapy|Radiation Therapy as part of Chemoradiation
40755320|NCT05417386|PROCEDURE|Surgery|Surgical removal of tumor
40755321|NCT01903720|DRUG|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
40755322|NCT02058407|DRUG|GSK2793660 solution|Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
40755323|NCT02058407|DRUG|GSK2793660 capsule|Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
40755324|NCT02058407|DRUG|Placebo solution|Matching placebo to GSK2793660 solution
40755325|NCT02058407|DRUG|Placebo capsule|Matching placebo to GSK2793660 capsule
40755326|NCT04841876|OTHER|rugby matches|standard rugby-7s match
40755327|NCT06281002|DEVICE|conventional impression stone casts digitization|"Nine conventional physical open tray impressions will be poured into a hard dental stone to obtain nine definitive implant casts with conventional implant analogs to act as a reference comparator.~Impressions will be digitized to reference STL files."
40931741|NCT01799382|DEVICE|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
41129151|NCT03568175|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
41129152|NCT01292863|OTHER|Active Comparator: Conventional peritoneal dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
41449467|NCT05077449|DRUG|Placebo + Fulvestrant|Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
40755328|NCT06281002|DEVICE|digital scanning with coupled scanning aiding device|Nine optical impressions will be obtained while additional geometric scanning aids are coupled with the scan bodies to get nine CAD/CAM 3D-printed polymer casts with digital implant analogs.
41449468|NCT00070291|DRUG|cyclosporine|Cyclosporine doses will be based on actual body weight unless actual body weight is \> 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
41449469|NCT01852487|DIETARY_SUPPLEMENT|400mg /day during 6 months|
40755329|NCT06281002|DEVICE|Digital Implant Model assessment of accuracy|The nine STL files of optical scanning will serve as reference data for comparison with the digitized DIMs to evaluate the accuracy of representation of the actual position of implants in the software.
41129153|NCT01292863|OTHER|Experimental: Novel biocompatible dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
41129154|NCT02276599|PROCEDURE|Volume expansion|Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
41129155|NCT04759833|DRUG|Prucalopride|Prucalopride oral solution or oral tablets.
41449470|NCT05837832|DIETARY_SUPPLEMENT|Milk-based phospholipids|Powder based, fat-rich fraction of whey dissolved in water. Contains lactose.
41129156|NCT04759833|OTHER|Placebo|Prucalopride-matching placebo oral solution or oral tablets.
41129157|NCT03479411|DRUG|Itraconazole Powder|Itraconazole administered as a dry powder for inhalation (PUR1900)
41129158|NCT03479411|DRUG|Itraconazole 200 mg|Sporanox® Oral Solution
41129159|NCT06296407|OTHER|Standard metabolic integrated rehabilitation protocol - duration 3 weeks|Standard metabolic integrated rehabilitation protocol
41129160|NCT06296407|OTHER|Standard metabolic integrated rehabilitation protocol + respiratory exercises - duration 3 weeks|Standard metabolic integrated rehabilitation protocol + respiratory exercises (12 sessions \[5 sessions/week for 3 weeks\])
41129161|NCT01724996|OTHER|Clinical examination: chest wall tenderness|The physical examination includes the testing of chest wall tenderness: Palpation of chest wall tenderness in lying 30° elevation of chest position. Flat index with standardized pressure where spontaneous maximum pain is reported (reproducible vs. not reproducible pain vs. no pain). Negative control (right side of chest mid-clavicle intercostal 6/7), reproducible vs. not reproducible pain vs. no pain.
41129162|NCT05759260|OTHER|Observation|Observation
41129163|NCT02895659|PROCEDURE|perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)|Perioperative hemodynamic management will be performed according to a specified treatment protocol.
41129164|NCT05769413|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
41129165|NCT02079649|DRUG|AL-53817 Ophthalmic Solution, 0.1%|
41129166|NCT02079649|DRUG|AL-78843 Ophthalmic Solution, 0.03%|
41129167|NCT02079649|DRUG|Dexamethasone Ophthalmic Suspension, 0.1%|
41129168|NCT02079649|DRUG|AL-53817 Vehicle|Inactive ingredients used for masking purposes
41129169|NCT04724265|BIOLOGICAL|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in hearing loss.
41129170|NCT01532648|DRUG|Budesonide MMX®|Oral tablet taken daily in the morning after breakfast.
41129171|NCT01532648|DRUG|Placebo|Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
41129172|NCT01532648|DRUG|5-ASA|"Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g"
41129173|NCT04603508|DRUG|BERLIM 25/10 association|Berlim 25/10 association coated tablet.
41129174|NCT04603508|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
41129175|NCT04603508|DRUG|ROSUVASTATIN CALCIUM|Rosuvastatin 10 mg coated tablet.
41129176|NCT04603508|OTHER|BERLIM 25/10 ASSOCIATION PLACEBO|Berlim 25/10 association placebo coated tablet.
41129177|NCT04603508|OTHER|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
41129178|NCT04603508|OTHER|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin placebo coated tablet.
41129179|NCT02217514|DRUG|Midazolam|
41129180|NCT02217514|DRUG|BI 44370 low dose|
41129181|NCT02217514|DRUG|BI 44370 medium dose|
41129182|NCT02217514|DRUG|BI 44370 high dose|
41129183|NCT06108635|PROCEDURE|McKenzie Exercises|"These can be performed in sitting and the protocol includes,~1. Retraction and extension~2. Retraction and extension with rotation~3. Postural correction~There will be 2 sets of 5 repetitions in week 1 and 3 sets of 10 repetitions in week 2 followed by alternative days in a week. Each set is 30 seconds and each repetition is given in 2 seconds."
41129184|NCT06108635|PROCEDURE|Maitland mobilization|The grade I and II Maitland mobilizations are given in week 1 and then progressed to grade III and IV in week 2
41129185|NCT06108635|PROCEDURE|Heat Therapy|Moist heat therapy with hot pack.
40755330|NCT01260324|OTHER|No intervention given in this observational study|No intervention given in this observational study
40755331|NCT01260324|OTHER|No intervention given in this observational study|No intervention given in this observational study
40755332|NCT01187875|DIETARY_SUPPLEMENT|Placebo- Fiber free control|Dextrin control administered in a muffin treatment.
41129186|NCT04789759|DEVICE|Socket Preservation - Bond Apatite synthetic bone substitute|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth. If 1/3 of the buccal plate is missing, considered a class 2 alveolar socket.~Extraction of tooth and place 2/3 biphasic calcium sulfate cement matrix's with Hydroxyapatite (HA granules) , condensed , and covered with a resorbable membrane suture to the adjacent tissue.~At implant placement ,take bone for histological preparation and histomorphometric analysis of the healing pattern.~At T0, T1 and T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements, will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material.~Primary and secondary stability will be measured by ISQ units with a RFA machine, that will include the machine to measure and the magnetic tip to be screwed in the implant platform."
41129187|NCT04789759|PROCEDURE|Socket healing - No Filler|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth, at extraction day, no flap opening , atraumatic extraction, no biomaterial filler, At T0, T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements will include an intramural scanner from all the stages , we will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material."
41129188|NCT01510236|BEHAVIORAL|Self-help program|The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
41129189|NCT02909205|OTHER|sensitization / educational program|the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
41129190|NCT02909205|OTHER|training / sensitization program|diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
40755333|NCT01187875|DIETARY_SUPPLEMENT|Hi-maize resistant starch 9g|9g Hi-maize resistant starch administered in a muffin treatment.
40931742|NCT02366598|OTHER|Hemp shake|Hemp protein shake
41449471|NCT03850158|DRUG|Indocyanine Green|Indocyanine green is administered intra-venous after dilution with water in a peripheral vein at a dosage of 0.3mg/kg body weight as a bolus injection. The injection will take place during surgery. By using NIR fluorescence imaging ICG is made visible.
41129191|NCT02628106|DRUG|Lipo-PGE1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
41129192|NCT02799875|OTHER|Higher permissive hypercapnia|"* pCO2 ≥ 60mmHg with an upper limit ≤ 75mmHg;~* pH ≥ 7.20 from a capillary or arterial blood sample;"
41129193|NCT02799875|OTHER|Lower Permissive Hypercapnia|"* pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg;~* pH ≥ 7.25 from a capillary or arterial blood sample;"
41129194|NCT04220775|DRUG|Bintrafusp Alfa|Given IV
41129195|NCT04220775|OTHER|Quality-of-Life Assessment|Ancillary studies
41129196|NCT04220775|OTHER|Questionnaire Administration|Ancillary studies
41129197|NCT04220775|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41129198|NCT02072499|PROCEDURE|KTP Green Light Prostatectomy|
41129199|NCT02072499|DEVICE|Green Light|
41129200|NCT02072499|PROCEDURE|Open prostatectomy|
41129201|NCT01589341|OTHER|laboratory biomarker analysis|Correlative studies
41129202|NCT05559645|DRUG|DZD9008|Daily dosing of DZD9008 200mg
41129203|NCT05559645|DRUG|DZD9008|Daily dosing of DZD9008 300mg
41129204|NCT02492412|DRUG|HE 10|
41278738|NCT04925570|OTHER|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
41278739|NCT05811351|DRUG|JNJ-81201887|JNJ-81201887 will be administered as intravitreal injection.
41129205|NCT02492412|DRUG|Restasis|
41129206|NCT05460741|OTHER|integrated exercise approach|Integrated exercise plan will be given for 16 weeks with frequency of 3 times per week, with duration of session to be 50 minutes being 30 minutes of exercise in total and 10 minutes of rest and 10 min of warm up and cool down exercises.
41129207|NCT05460741|OTHER|educational program|educational program related to menstrual cycle will be given to females.
41129208|NCT01767467|BIOLOGICAL|Herpes zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
41129209|NCT01767467|DRUG|Placebo|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
41129210|NCT02220959|OTHER|walk test|patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
41278740|NCT05811351|DRUG|Prednisone|Prednisone will be administered as oral capsule.
41278741|NCT05811351|OTHER|Placebo|Prednisone matching placebo will be administered as oral capsule.
41278742|NCT05811351|DRUG|Triamcinolone|Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.
41278743|NCT05811351|OTHER|Sham Procedure|Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.
41278744|NCT06657170|PROCEDURE|Pulmunary veins reconnection plus hidden slow conduction ablation|"Ablation of pulmonary veins reconnections plus the search and ablation of hidden slow conductions sites (HSC) in the left atrium.~HSC sites are defined as EGMs showing highly fragmented or double electrograms in response atrial triple extrastimulus, presenting normal or fractionated electrogram in the sinus rhythm.~After checking for PV's conduction breakthroughs, point-by point ablation targeting HSC-EGMs will be performed.~The end point for HSC+ ablation will be reached with loss of local capture at a given lesion, pacing from the ablation catheter at high output (10V·2ms)."
41278745|NCT06657170|PROCEDURE|Pulmunary veins (PV) reconnection ablation only|Each vein will be re-assessed by observing PV potentials along the PV ostia and by pacing from the distal bipole of the ablation catheter (10mA at 2ms) within the lesion set with failed capture of the left atrium. In case of PVs reconnection touch-up applications will be performed at the earliest potential site, identified by comparing far-field atrial EGM to near-field local EGM timing, until isolation will be achieved (entrance and exit block).
41278746|NCT05083169|DRUG|Daratumumab|Daratumumab will be administered SC injection.
41278747|NCT05083169|DRUG|Pomalidomide|Pomalidomide will be administered orally.
41278748|NCT05083169|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously.
41278749|NCT05083169|DRUG|Bortezomib|Bortezomib will be administered SC injection.
41278750|NCT05083169|DRUG|Teclistamab|Teclistamab will be administered SC injection.
41278751|NCT04655976|BIOLOGICAL|Cobolimab|Cobolimab will be administered
41278752|NCT04655976|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered
41449472|NCT00599820|DRUG|Intravitreal Bevacizumab|
41449473|NCT02550535|GENETIC|Autologous WT1 TCR transduced T cells|Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
41449474|NCT06560502|OTHER|Standard of Care-DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
41129211|NCT06047535|DRUG|Naxitamab|"Naxitamab + GM-CSF:~Cycles 1-5: Patients will receive naxitamab IV at 3 mg/kg/infusion on Day 1, 3 and 5 and GM-CSF sc at 5 µg/kg/day on Days -4 to 0 and at 10 µg/kg/day on Days 1-5 for 5 cycles.~Isotretinoin:~Cycles 3-8: Patients will receive isotretinoin PO at 160 mg/m2/day divided into two daily doses on Days 15-28 for 6 cycles."
41278753|NCT04655976|DRUG|Docetaxel|Docetaxel will be administered
41278754|NCT04133636|DRUG|JNJ-68284528|Participants in Cohorts A,B,C, D, E, F, G, and H will receive JNJ-68284528 intravenously.
41278755|NCT04133636|DRUG|Lenalidomide|Some participants in Cohort D and all participants in Cohorts E, G, and H will also receive lenalidomide capsules orally.
41278756|NCT04133636|DRUG|Daratumumab|Participants in Cohorts E, G, and H will also receive daratumumab subcutaneous (SC) injection.
41278757|NCT04133636|DRUG|Bortezomib|Participants in Cohorts E and H will also receive bortezomib subcutaneously.
41278758|NCT04133636|DRUG|Dexamethasone|Participants in Cohorts E, G, and H will also receive dexamethasone orally or intravenously.
41278759|NCT03696784|BIOLOGICAL|iC9-CAR19 T cells|iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.
41278760|NCT03696784|DRUG|Bendamustine|70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.
41278761|NCT03696784|DRUG|Fludarabine|30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion
41278762|NCT03696784|DRUG|AP1903|"0.4 mg/kg of AP1903 as an IV infusion over 2 hrs for subjects who develop Grade 4 cytokine release syndrome (CRS) or grade ≥3 CRS that is unresponsive to standard of care interventions , subjects who develop grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) that does not improve to grade ≤1 within 72 hours with standard of care interventions, and subjects with grade 4 ICANS of any duration that have evidence of cerebral edema and/or generalized convulsive status epilepticus.~Subjects in the expansion cohort who experience ≥ grade 2 CRS or ICANS that remains ≥ grade 2, twenty-four hours after an initial dose of the standard of care treatment may be part of the sub-study of rimiducid. These subjects will receive one of two assigned dose levels. DL1 and DL2 doses are 0.05 mg/kg and 0.01 mg/kg for subjects and DL1: 0.1 mg/kg and DL2: 0.01 mg/kg for subjects with ICANS."
41129212|NCT02672891|DEVICE|condom balloon catheter|"The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.~(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed."
41278763|NCT03696784|DRUG|Cyclophosphamide|500 mg/m2/day administered by IV over 3 consecutive days
40755334|NCT01187875|DIETARY_SUPPLEMENT|Novalose 330 resistant starch 9g|9g Novalose 330 resistant starch administered in a muffin treatment.
41278764|NCT04936308|DRUG|Guselkumab|Participants will receive guselkumab as SC injection.
41278765|NCT04936308|DRUG|Placebo|Participants will receive matching placebo as SC injection.
41278766|NCT03417765|DRUG|FE 203799|GLP-2 analogue, once weekly, subcutaneous administration
41278767|NCT04497844|DRUG|Niraparib|Participants will receive Niraparib 200 mg once daily.
40755335|NCT01187875|DIETARY_SUPPLEMENT|4.5g Hi-maize resistant starch and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
40755336|NCT05123105|OTHER|1) cupping therapy|The participant lay on his front on a couch. The examiner applied a plastic cup on a pre-marked trigger point, suctioned it with a mechanical pump and left it for 2 minutes. This was a stationary application with medium suction force. Therapy was performed on both sides. Measurements were taken before and 2 minutes after the therapy.
40755337|NCT05123105|OTHER|2) control test (no intervention)|The participant lay on his front on a couch for 4 minutes without any activity and without anyy intervention. Measurements were taken before and after the session.
40755338|NCT05123105|OTHER|3) ischemic compression|The participant lay on his front on a couch. The researcher applied pressure to a pre-marked trigger point using the thumb for 2 minutes until tissue resistance was felt. This included 60-second compression and after a break of a few seconds, another 60 seconds of compression. Therapies were performed on each side. Measurements were taken before and 2 minutes after the therapy.
41129213|NCT02424474|DEVICE|Genetic NIPT|Both tests are realized in a population of pregnant women (with and without in vitro fertilisation (IVF)) concomitantly at the same time.
41129214|NCT02424474|BIOLOGICAL|Regular serum screening|
41129215|NCT02345174|DRUG|GSK2849330|GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
41129216|NCT02345174|DRUG|89Zr-GSK2849330|89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
41278768|NCT04497844|DRUG|Abiraterone acetate (AA)|Participants will receive AA 1000 mg once daily.
41278769|NCT04497844|DRUG|Prednisone|Participants will receive prednisone 5 mg once daily.
40755339|NCT04032327|DRUG|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed to be injected vaginally prior to the start of posterior colporrhaphy
40755340|NCT04032327|DRUG|Bupivacaine|20 mL of 0.25% plain bupivacaine to be injected vaginally prior to the start of posterior colporrhaphy
41278770|NCT04497844|DRUG|Placebo for Niraparib|Participants will receive matching placebo for Niraparib once daily.
41278771|NCT03155620|PROCEDURE|Biopsy|Undergo biopsy
40755341|NCT00595075|DRUG|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
40755342|NCT00595075|DRUG|placebo|placebo identical in appearance to active experimental drug x 1 dose
40755343|NCT04879485|BIOLOGICAL|Blood products|Compare two different transfusion strategies against standard transfusion regimen
40755344|NCT00511290|OTHER|no generic names|
40755345|NCT04057794|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
41129217|NCT01988402|DRUG|allopurinol|
41129218|NCT01988402|DRUG|Placebo (sugar pill)|
41129219|NCT02142751|DRUG|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
41278772|NCT03155620|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41278773|NCT03155620|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow and/or biopsy
41278774|NCT03155620|PROCEDURE|Bone Scan|Undergo a bone scan
41278775|NCT03155620|PROCEDURE|Computed Tomography|Undergo CT, PET/Ct, and/or CT/MRI
41278776|NCT03155620|DRUG|Ensartinib|Given PO
41278777|NCT03155620|DRUG|Erdafitinib|Given PO
41278778|NCT03155620|OTHER|Laboratory Biomarker Analysis|Undergo molecular analysis
41278779|NCT03155620|DRUG|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
41278780|NCT03155620|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
41129220|NCT02142751|DRUG|Meropenem intravenous|1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
41449475|NCT06560502|OTHER|AmnioCore - DFU|Participants will receive weekly applications of AmnioCore and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
41129221|NCT02142751|DRUG|Ceftriaxone intravenous|1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
41129222|NCT01310166|DRUG|Fingolimod|
41129223|NCT02299349|DRUG|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
41278781|NCT03155620|PROCEDURE|Mutation Carrier Screening|Undergo tumor tissue mutation screening
41278782|NCT03155620|DRUG|Olaparib|Given PO
41278783|NCT03155620|DRUG|Palbociclib|Given PO
41129224|NCT02299349|DRUG|concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL|Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
41129225|NCT04633148|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion for 3 days
41129226|NCT04633148|DRUG|Fludarabine (Non-IMP)|Intravenous infusion for 3 days
41278784|NCT03155620|OTHER|Pharmacological Study|Correlative studies
41278785|NCT03155620|PROCEDURE|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
41278786|NCT03155620|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
41278787|NCT03155620|DRUG|Samotolisib|Given PO
41278788|NCT03155620|DRUG|Selpercatinib|Given PO
41278789|NCT03155620|DRUG|Selumetinib Sulfate|Given PO
41278790|NCT03155620|DRUG|Tazemetostat|Given PO
41278791|NCT03155620|DRUG|Tipifarnib|Given PO or via nasogastric or gastric tube
41278792|NCT03155620|DRUG|Ulixertinib|Receive PO
41278793|NCT03155620|DRUG|Vemurafenib|Given PO
41278794|NCT03155620|PROCEDURE|X-Ray Imaging|Undergo an x-ray
41278795|NCT06122077|DIAGNOSTIC_TEST|blood draw|Subjects who provide informed consent and meet the eligibility criteria will have 50 ml of blood collected and sent to Freenome or Freenome's designee for processing, testing, and storage, and will then complete a standard-of-care screening LDCT.
41278796|NCT05217628|DRUG|Basimglurant|"Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability.~Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo.~OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1."
41278797|NCT05217628|OTHER|Placebo|Participant randomized to receive matching placebo once daily.
41278798|NCT06564974|DRUG|Vamorolone|"Patients on treatment with Vamorolone (AGAMREE®) Dosage: Oral Suspension: 40 mg/mL . Per package insert, the recommended dosage is 6 mg/kg taken orally once daily, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg.~Decrease dosage gradually when administered for more than one week."
41278799|NCT06166771|DEVICE|Alma system|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
41278800|NCT04636437|DRUG|Doravirine 100 Mg|Participants will receive 100 mg tablet by mouth daily with or without food.
41278801|NCT04636437|DRUG|Tenofovir alafenamide/emtricitabine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
41278802|NCT04636437|DRUG|tenofovir alafenamide/lamivudine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
41449476|NCT06560502|OTHER|Amnio Quad-Core - DFU|Participants will receive weekly applications of Amnio Quad-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
41278803|NCT04636437|DRUG|Integrase strand transfer inhibitors|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
41278804|NCT04636437|DRUG|tenofovir disproxil fumarate/emtricitabine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
41278805|NCT04636437|DRUG|tenofovir disproxil fumarate/lamivudine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
41278806|NCT06551623|DRUG|Midazolam|Midazolam Oral Solution 2 mg
41278807|NCT06551623|DRUG|Clarithromycin|Clarithromycin tablets 0.5 g
41278808|NCT06551623|DRUG|TNP-2198|TNP-2198 Capsules 400 mg
41278809|NCT05329194|DRUG|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab.
41278810|NCT05036785|OTHER|Timing of suture removal|Patients will either be randomized to have their sutures removed at 7 or 10 days post skin surgery
41278811|NCT04557059|RADIATION|Radiotherapy|Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.
41449477|NCT06560502|OTHER|Standard of Care-VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
41449478|NCT06560502|OTHER|Amnio Tri-Core - VLU|Participants will receive weekly applications of Amnio Tri-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
41449479|NCT06560502|OTHER|AmnioCore Pro|Participants will receive weekly applications of AmnioCore Pro and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
41449480|NCT06560502|OTHER|Amniocore Pro +|Participants will receive weekly applications of Amniocore Pro + and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
40755346|NCT04057794|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by centralized genetic counseling group at Indiana University.
41129227|NCT04633148|DRUG|UniCAR02-T-pPSMA|Intravenous Infusion for 21 days
41129228|NCT04633148|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
41129229|NCT00802126|DRUG|"Combination therapy IVB + rf-PDT"|low-fluence photodynamic therapy combined with intravitreal bevacizumab
40755347|NCT06211270|BEHAVIORAL|FRESH|FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration
40755348|NCT00538265|DRUG|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
40755349|NCT00538265|DRUG|tacrolimus, ATG|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)"
40755350|NCT00538265|DRUG|ATG+mycophénolate mofétil+tacrolimus|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months."
40755351|NCT02103946|PROCEDURE|Serratus Anterior Muscle Plane block (SAM block)|The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.
40755352|NCT02103946|PROCEDURE|Paravertebral Block|After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
40755353|NCT00050427|DRUG|ET743|580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
40755354|NCT00050427|DRUG|ET743|1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
40755355|NCT01234714|OTHER|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
40755356|NCT01234714|PROCEDURE|Major liver resection|Hepatectomy of \>= 3 liver segments
40755357|NCT00227955|DRUG|Imipramine|
40755358|NCT00227955|BEHAVIORAL|Interpersonal Psychotherapy|
40755359|NCT02810132|DRUG|Metformin|See above
40755360|NCT02810132|DRUG|Placebo|See above
40755361|NCT01666600|DRUG|BIBF 1120|BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
40755362|NCT01666600|RADIATION|radiotherapy|36 Gy, 2 Gy / fraction, 18 fractions
40755363|NCT03521609|BEHAVIORAL|Emotional intelligence intervention|Brief group intervention based on emotional intelligence
40755364|NCT06272929|DEVICE|doppler ultrasound|doppler US
41278812|NCT04557059|DRUG|LHRHa|Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.
41278813|NCT04557059|DRUG|Apalutamide|Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days.
41278814|NCT05612178|BIOLOGICAL|3BNC117-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
40755366|NCT00693732|DRUG|Escitalopram treatment|On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
40755367|NCT00693732|BEHAVIORAL|Quantitative sensory testing|Rectal Distention Stimulation
40931743|NCT02366598|OTHER|Soybean shake|Soybean protein shake
41278815|NCT05612178|BIOLOGICAL|10-1074-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10- 1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
41278816|NCT05612178|OTHER|Sterile Saline|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks, 20 and 40.
41453479|NCT01261949|DEVICE|Temporal low frequency rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
41449481|NCT06342830|DRUG|nanocurcumin gel|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5% between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of nanocurcumin gel until shown fill the canal under magnification and by using lentulospirals
41453480|NCT03703258|BEHAVIORAL|App-based intervention|A app-based cognitive-behavioral intervention to prevent the development of PTSD and high-risk drinking in recently-victimized adults
41129230|NCT02767765|DRUG|r-HuEPO|All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks.
40931744|NCT02366598|OTHER|Control|Non-protein shake
41129231|NCT00910338|DEVICE|PFMT with Extracorporeal Biofeedback|"Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks~* Twice a week for the first 4 weeks~* Once a week for the next 8 weeks"
41129232|NCT02767674|DRUG|Rituximab|375 mg/m2 IVD day0
41129233|NCT02767674|DRUG|Gemcitabine|Gemcitabine 1 g/m2 IVD day 1
41278817|NCT03095703|DRUG|Sirolimus|Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which will be given in 1mg tablets. On day 7 the first trough level is measured (using the LC-MS/MS method) and if not within the target range of 5-8ng/ml, dosing adjustments are made. In case of dosing adjustments, the next trough level is measured seven days later and this is repeated weekly until the target range is achieved. In case trough levels are within the target range, the next trough level measurement is at month 3, after which dosing adjustments are made if necessary, and at month 6. The maximum daily dose is 40mg. No placebo is given.
41129234|NCT02767674|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IVD day1
41129235|NCT02767674|DRUG|Cyclophosphamide|Cyclophosphamide 400 mg/m2 IVD d1
41129236|NCT02767674|DRUG|Epirubicin Injectable Product|Epirubicin 35 mg/m2 IVD d1
41129237|NCT02767674|DRUG|Vindesine|Vindesine 2 mg IVP d1
41129238|NCT02767674|DRUG|Prednisone|Prednisone 40mg/m2 PO d1-5
41129239|NCT03340909|DRUG|Prednisolone|Prednisolone tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
41278818|NCT06036875|OTHER|Non-Interventional Study|Non-interventional study
40931745|NCT02609997|PROCEDURE|Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
40931746|NCT02609997|PROCEDURE|Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
40931747|NCT02609997|DRUG|Subconjunctival dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
40931748|NCT02609997|DEVICE|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells
41129240|NCT03340909|OTHER|Placebo|Placebo tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
41129241|NCT01109498|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
41129242|NCT01109498|DRUG|Mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
41129243|NCT01109498|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
41129244|NCT01109498|DRUG|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
41129245|NCT02008669|PROCEDURE|Blood sampling|A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.
41129246|NCT02008669|OTHER|Gustatory sensitivity test using Taste strips|"16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.~Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)"
41129247|NCT02008669|OTHER|Questionnaires|"Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):~* Fatigue (EMIF-SEP)~* Dysphagia (DYMUS)~* Food intake (semi-structured questionnaire)~* Depression (BDI-II)~* Daily energy expenditure (NAP)~* Visual analog scale to study quality of sleep"
41129248|NCT01827839|BIOLOGICAL|Herpes Zoster vaccine (GSK1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
41129249|NCT04314375|DRUG|Low Dose Budesonide|3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
41278819|NCT06643728|DRUG|Bimagrumab|Administered SC
41129250|NCT04314375|DRUG|High Dose Budesonide|6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
41129251|NCT04314375|DRUG|Placebo|Matching placebo once daily.
41129252|NCT01137916|DRUG|Imatinib|800 mg
41129253|NCT02189759|OTHER|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
41129254|NCT02189759|OTHER|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
41129255|NCT02189759|OTHER|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
41129256|NCT02189759|OTHER|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
41129257|NCT01014299|OTHER|Recruitment maneuver|"Assigned interventions:~* No intervention after tracheal intubation (control group)~* Alveolar recruitment maneuver (RM group) immediately after intubation"
41129258|NCT06195813|DIETARY_SUPPLEMENT|Asparagus capsule|Asparagus capsule is categorized as dietary supplement.
41129259|NCT06195813|OTHER|Placebo capsule|Placebo capsule is categorized as other.
41129260|NCT06294223|DEVICE|Exercise follow up with near-infrared spectroscopy|Exercises will be followed by near-infrared spectroscopy. Fatigue protocol will be applied.
41129261|NCT05859113|DEVICE|Ziacom Galaxy dental implant with internal connical prosthetic connection|Placement and restoration of a single Ziacom Galaxy dental implant with internal connical prosthetic connection
41129262|NCT05859113|DEVICE|Ziacom Zinic dental implant with internal hexagonal prosthetic connection|Placement and restoration of a single Ziacom Zinic dental implant with internal hexagonal prosthetic connection
41129263|NCT03648190|DIAGNOSTIC_TEST|Flowcytometry analysis of platelets surface receptors|"BD FACSCalibur flowcytometry instrument.~Platelet flow cytometry is an emerging tool in diagnostic and therapeutic hematology. It is eminently suited to study the expression of platelet surface receptors both qualitatively as well as quantitatively.~Flow cytometry rapidly measures the specific characteristics of a large number of cells in suspension. Typically, the cells are labeled with fluorescently conjugated monoclonal antibodies (mAbs)."
41278820|NCT06643728|DRUG|Tirzepatide|Administered SC
41278821|NCT06643728|DRUG|Placebo|Administered SC
41278822|NCT06657742|OTHER|SCIM-SR|SCIM-SR was a self-reported scale that evaluated the independence of patients.
41278823|NCT05389423|DRUG|Vincristine|0.4 mg/m2/day administered by CIVI on days 1 to 4
41278824|NCT05389423|DRUG|Prednisone|60 mg/m2/day administered orally on days 1 to 5
41278825|NCT05389423|DRUG|Doxorubicin|10 mg/m2/day administered by CIVI on days 1 to 4
41278826|NCT05389423|DRUG|Etoposide|50 mg/m2/day administered by CIVI on days 1 to 4
41278827|NCT05389423|DRUG|Pomalidomide|An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.
41278828|NCT05389423|DRUG|Cyclophosphamide|750 mg/m2 administered IV on day 5
41278829|NCT05389423|DRUG|Rituximab|375 mg/m2 administered IV on day 1 (only for CD20+ tumors)
41278830|NCT04823663|DEVICE|Implant|In the scope of the CRM procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific CRM products/components and combination of those products/components with competitor product(s) per hospital's standard of care.
41278831|NCT04823663|PROCEDURE|Electrophysiologic procedure|In the scope of the EP procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific Electrophysiology products/components and capital equipment products and combination of those products/components with competitor product(s) per hospital's standard of care.
41453481|NCT05583162|BEHAVIORAL|Healthy Sport Project|2 interactive information lectures (given per class of 30 pupils), and 4 interactive workshops (given to sex-homogenous groups of 10 pupils). One per week, a total of 6 weeks with intervention.
41129264|NCT01057433|DRUG|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
40931749|NCT02609997|DRUG|proparacaine|0.5% proparacaine (Alcaine, Alcon Laboratories)
40931750|NCT02873403|DEVICE|KNEEMO knee brace|Bespoke knee brace made by additive manufacturing
40931751|NCT02873403|DEVICE|Popular knee brace|Customized knee brace used in the management of medial knee ostearthritis
40931752|NCT04703179|OTHER|Genetic test evaluation|Patients with rare and undiagnosed disease and their family members may be evaluated on a case by case basis. The research study may perform multi-omics testing to provide a diagnosis or to provide biomarker discovery.
40931753|NCT03518749|OTHER|1mA tDCS|transcranial direct current stimulation with the intensity of 1mA
40931754|NCT03518749|OTHER|2mA tDCS|transcranial direct current stimulation with the intensity of 2mA
40931755|NCT03518749|BEHAVIORAL|Cognitive control training|cognitive control training with the PASAT
41129265|NCT01057433|DRUG|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
41129266|NCT04880356|OTHER|collection of data|collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases
41129267|NCT03851367|PROCEDURE|Sling suspension using red cord|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
41129268|NCT03851367|PROCEDURE|Gym ball exercises|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
41129269|NCT00263159|PROCEDURE|Pharmaceutical care for asthma patients|
41129270|NCT03877198|DEVICE|Automated oxygen control by the CLiO2 algorithm|Automated oxygen control for 24 hours by the CLiO2 algorithm, preceded by a 1 hour wash-out period
41129271|NCT03877198|DEVICE|Automated oxygen control by the Oxygenie algorithm|Automated oxygen control for 24 hours by the Oxygenie algorithm, in case of switch in ventilator preceded by a 1-hour wash-out period.
41129272|NCT01954836|BEHAVIORAL|initial fasting|modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles
41278832|NCT05149196|OTHER|Targeted hemodynamic management|"During anesthesia, hemodynamic managements include active hydration (\>10 ml/kg/h), use of inotropes (dobutamine), and forced diuresis; the targets are to maintain pulse pressure variation \<9%, mean arterial pressure ≥85 mmHg, and urine output \>200 ml/h (3ml/kg/h).~During the first 48 hours after surgery, systolic blood pressure is maintained ≥110 mmHg or within 20% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or vasoactive infusion."
41278833|NCT05149196|OTHER|Routine care|"During anesthesia, hemodynamic managements are conducted according to routine practice and usually include fluid infusion at a rate of 6-8 ml/kg/h without inotropics; the targets are to maintain mean arterial pressure ≥60 mmHg and urine output \>0.5 ml/kg/h.~During the first 48 hours after surgery, hemodynamic management is performed according to routine practice."
41278834|NCT04925752|DRUG|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
41278835|NCT04925752|DRUG|F/TDF|Tablets administered orally
41278836|NCT04925752|DRUG|Sub-cutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
41449482|NCT06342830|DRUG|Curcumin Gel|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5% between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of curcumin gel until shown fill the canal under magnification and by using lentulospirals
41453482|NCT05451264|DIAGNOSTIC_TEST|blood pressure measurement|Completion of the physical activity and quality of life questionnaire (PedSQL adapted to the age of the child), measurement of weight and height; Measurement of VOP (Pulse wave velocity), AI (increase index) and ECG (electro cardiogram) collection at rest lying down; Stimulation test by slow breathing at 6 cycles/min for three minutes; Continuation of the measurements in a standing position for 5 minutes; Installation of blood pressure holter (MAPA) which will be kept for 24 hours and then returned by post.
41453483|NCT06393530|DRUG|0.9%sodium chloride|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,9% normal saline
41449483|NCT06342830|DRUG|Ciprofloxacin 500 mg +ibuprofen 400mg|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of ciprofloxacin + ibuprofen gel until fill the canal under magnification and by using lentulospirals
41278837|NCT04925752|DRUG|Placebo SC LEN|Administered via SC injections
41453484|NCT06393530|DRUG|0.2% ropivacaine|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,2% ropivacaine
40931756|NCT02982278|BEHAVIORAL|Community-based Intervention under Nurse Guidance after Stroke|CINGS is a 12-week nurse coordinated, Community Health Worker intervention structure. Intervention home visits will be conducted by the CHW and will include home-based training in self-care and self-management strategies alongside strategies to address risk of negative stroke outcomes that will be determined once these risk factors are identified and community-engaged approaches to their resolution derived. CHW efforts will be guided via televideo interactions with nurse coordinator. During home-visits, self-reported assessments will be collected via RedCap as well as assessments collected by the CHW and research nurse (weight, blood pressure, medication adherence). After baseline, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly for the other two months, conducted by the CHW. Additionally, there will be post-intervention follow-up assessments at 3, 6, and 12-month time intervals.
40931757|NCT03463876|DRUG|SHR 1210+apatinib|SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
40755368|NCT05999851|DEVICE|Arterial applanation tonometry|Arterial applanation tonometry will be performed at the carotid and femoral level by the PulsePen device (Software WPulsePen version 2.3.1, DiaTecne, Milan, Italy), while the subject is lying in the horizontal position and after 5 minutes of rest.
40755369|NCT05999851|DEVICE|In vivo endothelial glycocalyx measurement|The in vivo microscopy (GlycoCheck system) is performed in the sublingual capillaries during the morning, with the participant sitting on a chair. The sublingual capillaries are visualized using an SDF video microscope (Capiscope handheld, KK Research technology Ltd).
40931758|NCT00205829|DEVICE|battery-powered bion(R) microstimulator system|Stimulation on from initial activation and on.
40931759|NCT02937584|DRUG|GP MDI (PT001) 14.4 μg|Glycopyrronium
40931760|NCT02937584|DRUG|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
40931761|NCT01865071|PROCEDURE|loop ileostomi|
41129273|NCT01954836|BEHAVIORAL|Secondary fasting|modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
41129274|NCT03466242|DRUG|Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
41129275|NCT03466242|DRUG|Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine
41129276|NCT04823754|OTHER|Hospitalized patient with advanced hepatocellular carcinoma receiving systemic therapy.|"Administation of two surveys to included patients, about the perception of the disease and the expectations related to the treatment.~The physician will be asked to complete a survey on his or her perception of the prognosis and information received by the patient."
41129277|NCT00253890|DRUG|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
41129278|NCT00253890|DRUG|Placebo|1-3 at bedtime
41129279|NCT06440226|BEHAVIORAL|Eye Movement Technique|Participants were instructed to move their eyes as much as possible with their eyes closed just before falling asleep. This technique aimed to mimic the Rapid Eye Movement (REM) sleep phase, which is often associated with more vivid and memorable dreams.
41129280|NCT06440226|BEHAVIORAL|Memory Recall of Previous Night's Thoughts|Another intervention involved asking participants to recall and think about their thoughts or events from the previous night before going to sleep. This method engaged cognitive processes related to memory and reflection, potentially setting the stage for increased awareness during sleep.
41129281|NCT06440226|BEHAVIORAL|Recall of Previous Lucid Dreams|Participants were also asked to recall their lucid dreams from previous nights. This intervention seemed to activate memory and awareness related to dreaming, which significantly increased the likelihood of experiencing lucid dreams the following night.
41129282|NCT03484949|DIAGNOSTIC_TEST|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
41129283|NCT03452254|DEVICE|Active Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Active tDCS: The anodic electrode will be put on affected M1. The cathodic electrode will be put on contralateral M1. We will apply a constant current of 2mA of intensity during 20 minutes while the patient performs the occupational therapy session."
41129284|NCT03452254|DEVICE|Sham Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Sham tDCS: We will use the same place and parameters of stimulation applied for the active group, but the stimulator will deactivate after 30 seconds of stimulation. This will ensure that the patient will feel the initial tingling sensation at the beginning of the tDCS which is a requisite for blinding. The occupational therapy session will last one hour."
41278838|NCT04925752|DRUG|PTM F/TDF|Tablets administered orally
41278839|NCT04925752|DRUG|PTM Oral LEN|Tablets administered orally
41278840|NCT04925752|DRUG|F/TAF (for US participants only)|F/TAF tablets administered orally once daily
41129285|NCT03452254|OTHER|Modified Constraint Induced Movement Therapy|"Both groups will perform the mCIMT during a period of seven consecutive days. This protocol consists of two elements:~1. Restriction of the movements of the non-affected hand by wearing a mitt during six hours a day: we will use a mitt that limits the movement of the fingers but allows the free movements of the wrist, elbow, and shoulder.~2. Intensive and individualized training of the affected arm during 2 hours a day guided by an occupational therapist: the two hours training will be divided into two sessions of one hour each. Sessions will be organized in three blocks: preparation, activation, and function. In the third block, devoted to function, the patient has to choose one activity of daily living that he wants to improve."
41129286|NCT01356524|DRUG|Additional vaginal progesterone|The progesterone dose will be raised from 200 mg daily to 300 mg daily
41129287|NCT03879538|DRUG|Nitrous Oxide|A total of three inhalation treatments with 50% Nitrous Oxide plus 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
41129288|NCT03879538|DRUG|Oxygen|A total of three inhalation treatments with 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
41129289|NCT01426412|DRUG|LY3015014 IV|Administered IV over 30-90 minutes
41129290|NCT01426412|DRUG|Placebo IV|Administered IV only over 30-90 minutes
41449484|NCT06342830|DRUG|Metapaste [calcium hydroxide paste (control group)]|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of calcium hydroxide paste until fill the canal under magnification by using lentulospirals
41449485|NCT02587663|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo bilateral breast contrast enhanced MRI
40931762|NCT04130737|DEVICE|TORUS Stent Graft System|The TORUS Stent Graft is an intravascular prosthesis intended to improve blood flow in the area in which it is implanted and the TORUS Stent Graft Delivery System is a standard pin-and-pull delivery system used to implant the SG in the desired area. Use of the TORUS Stent Graft allows for improving blood flow in the peripheral vasculature.
40931763|NCT02973633|DEVICE|Diffusion Tensor MRI (DTI)|Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.
40931764|NCT02973633|DRUG|Gadolinium DOTA Meglumine|Late Gadolinium enhancement
40931765|NCT04022161|DRUG|Nitrogen Gas for Inhalation|See arm description
40931766|NCT04022161|OTHER|Blood withdrawal|Blood samples will be collected over four time-points: (I) baseline (before surgery) (II) end of the surgery, (III) end of 24 hours of gas delivery and (IV) 24 hours from the gas suspension.
40931767|NCT04022161|DRUG|Nitric Oxide|See arm description
40931768|NCT03541876|OTHER|Collection of data|"The following data will be collected by the physician :~sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control."
40931769|NCT04369924|BEHAVIORAL|Unidimensional Measurement-Based Care|Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
40931770|NCT04369924|BEHAVIORAL|Multidimensional Measurement-Based Care|Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
40931771|NCT00612729|PROCEDURE|Polylens Y30 intraocular lens|cataract surgery
41129291|NCT01426412|DRUG|LY3015014 SC|Administered SC
40931772|NCT00612729|PROCEDURE|Orange Series Model PC 440 Y intraocular lens|cataract surgery
41129292|NCT01426412|DRUG|Placebo SC|Administered SC
41449486|NCT02587663|PROCEDURE|Mammography|Undergo bilateral mammography
40931773|NCT05208307|BIOLOGICAL|Belantamab Mafodotin|Given IV
40931774|NCT05208307|DRUG|Dexamethasone|Given PO
40931775|NCT05208307|DRUG|Pomalidomide|Given PO
41129293|NCT00787969|BIOLOGICAL|rituximab|Give IV
41129294|NCT00787969|DRUG|cladribine|Give IV
41129295|NCT00787969|DRUG|temsirolimus|Give IV
41129296|NCT00787969|BIOLOGICAL|Filgrastim|Give SC
41129297|NCT00787969|BIOLOGICAL|Pegfilgrastim|
41129298|NCT04593238|DRUG|Double Antibiotic paste|Metronidazole and Ciprofloxacin
41129299|NCT04593238|DRUG|Calcium Hydroxide Paste - Non-Setting|Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
41129300|NCT00989469|DRUG|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
41129301|NCT01105234|DRUG|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.|
40931776|NCT01817517|DEVICE|Medtronic Activa Deep Brain Stimulation System|
40931777|NCT05577273|DRUG|Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)|single dose of P.O. Cefuroxime Axetil 500 mg. For penicillin allergy patients, single dose of P.O. Trimethoprim/Sulfamethoxazole 160mg/800mg
40931778|NCT01354054|PROCEDURE|High Frequency TENS|100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes
40755370|NCT05999851|DIAGNOSTIC_TEST|Serum markers of angiogenesis and endothelial dysfunction|ELISA assays to measure serum circulating markers of angiogenesis and endothelial dysfunction (ANG-1, ANG-2, ET-1, ICAM-1 and VCAM-1).
40931779|NCT01354054|PROCEDURE|Low frequency TENS|100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
40755371|NCT05999851|DIAGNOSTIC_TEST|Blood chemistry test|Immunochemistry analysis of serum levels of uric acid, total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, Lipoprotein (a)
40755372|NCT05999851|DIAGNOSTIC_TEST|Serum xanthine oxidase activity|Serum xanthine oxidase (XO) activity will be assessed in blood samples measuring the ability of XO to produce uric acid
40755373|NCT03690999|DIETARY_SUPPLEMENT|Placebo|Placebo product
40755374|NCT03690999|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic supplement
41129302|NCT02937493|BEHAVIORAL|Lunar phases|Observation if lunar phases had an influence on occurrence of IPV
40931780|NCT01354054|PROCEDURE|Placebo TENS|100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
40931781|NCT02202330|OTHER|Video Arm|"1. 5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~2. Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~3. Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
41129303|NCT03212638|DRUG|Baricitinib suspension|Administered orally
41129304|NCT03212638|DRUG|Baricitinib tablet|Administered orally
41129305|NCT01160588|DRUG|Sertraline|Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.
40931782|NCT06313021|OTHER|Reliability and Validity Study|Reliability and Validity Study
41129306|NCT02336958|DRUG|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
41129307|NCT02336958|DRUG|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
41129308|NCT02336958|DRUG|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
41129309|NCT02336958|DRUG|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
41129310|NCT03743649|DRUG|Haloperidol|Given IV
41129311|NCT03743649|DRUG|Lorazepam|Given IV
41129312|NCT03743649|OTHER|Placebo|Given IV
41129313|NCT03743649|OTHER|Quality-of-Life Assessment|Ancillary studies
41129314|NCT03743649|OTHER|Questionnaire Administration|Ancillary studies
41129315|NCT05435794|DEVICE|CPAP|Fixed-pressure CPAP device for the treatment of sleep apnea with optional humidification and heated circuit. This device is a Class II device. It has a remote monitoring function allowing service providers to track the use of the device.
41129316|NCT05435794|DEVICE|MAD|mandibular device orthosis made to measure from the dental impressions of patients, made by the specialist in the masticatory apparatus for the treatment of sleep apnea.
41129317|NCT00031720|DIETARY_SUPPLEMENT|soy protein|Given orally
41129318|NCT00031720|DIETARY_SUPPLEMENT|isoflavones|Given orally
41129319|NCT00031720|DRUG|Tamoxifen|
40755375|NCT02615496|BEHAVIORAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
40755376|NCT02615496|BEHAVIORAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|"Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet Your guide to EYLEA, patient information leaflet, and audio CD."
41129320|NCT00031720|OTHER|Placebo|Oral
41129321|NCT03745170|DRUG|Sintilimab|Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
41129322|NCT03745170|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
41129323|NCT03745170|DRUG|Capecitabine|1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
41129324|NCT03745170|DRUG|placebo|Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
41129325|NCT01769716|PROCEDURE|Umbilical cord blood transplantation|
41129326|NCT01765374|DEVICE|ESAOTE MyLab60|US evaluation at different time points
41129327|NCT01765374|DRUG|Rituximab|
41129328|NCT02918591|DRUG|Empagliflozine|All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
41129329|NCT00378300|DRUG|Oral Probiotics|
41129330|NCT03202992|DRUG|ABI-1968|Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
41129331|NCT02059538|OTHER|Adipose tissue biopsies (omental and subcutaneous) liver|
41129332|NCT02059538|RADIATION|CT-scan|
41129333|NCT02059538|OTHER|Stools sampling|
41129334|NCT02059538|OTHER|DNA sampling|
41129335|NCT02059538|OTHER|Blood sampling|
41129336|NCT02059538|OTHER|Urine sampling|
41129337|NCT02059538|RADIATION|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
41129338|NCT03842605|OTHER|Strength training|
41129339|NCT06515873|DEVICE|Virtual Reality Headset|The virtual reality headset, which will display one of the 3 available scenarios, will be placed on the patient head during a surgery under spinal anesthesia.
41129340|NCT04595474|DEVICE|Transient Elastography|Transient elastography is a noninvasive imaging modality used to assess NAFLD and advanced fibrosis
41129341|NCT05079126|DRUG|Trans Sodium Crocetinate|Single IV Bolus
41129342|NCT05079126|DRUG|Placebo|Single IV Bolus
41129343|NCT03214172|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
41129344|NCT04245995|DIAGNOSTIC_TEST|Feature Extraction Technology|The study´s aim was evaluation of the clinical applicability of the Feature Extraction Technology (FET) during a simulated blood loss scenario in comparison to visual estimation.
41129345|NCT00054938|DRUG|pravastatin|
41129346|NCT00054938|DRUG|aspirin|
41129347|NCT00054938|DRUG|ramipril|
41129348|NCT00054938|DRUG|Vitamins: B6, B12, and folate|
41129349|NCT00054938|BEHAVIORAL|heart health educational program|
41129350|NCT06510595|OTHER|Active Treatment Arm|"Electrotherapy:~Transcutaneous Electrical Nerve Stimulation (TENS) will be placed across the fracture segments. The setting will be adjusted to 2±0.4 Hz sinusoidal wave, with a pulse width set between 50-200 microseconds, and each session will last between 20-30 minutes.~Active Elbow Flexion Exercise:~Following the electrotherapy session, the child will perform active assisted elbow flexion exercises with the forearm in a neutral position. This exercise will consist of 3 sets of 15 repetitions to enhance the role of the horizontal components of the brachioradialis muscle force."
41129351|NCT06510595|OTHER|Control Treatment Arm|The child will wear a brace as a conservative treatment method.
40931783|NCT01283854|BEHAVIORAL|Supervised home-based exercise|"Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.~Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard)."
41129352|NCT04762238|OTHER|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
41129353|NCT04532450|DEVICE|Branched / fenestrated aortic stent graft|Endovascular repair of an aortic aneurysm with a branched/fenestrated stent graft to revascularise all visceral arteries together with exclusion of the aortic aneurysm.
40931784|NCT02305043|OTHER|non-interventional|non-interventional
40931785|NCT03190356|DEVICE|Soberlink Cellular Device|Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.
40931786|NCT03889301|BEHAVIORAL|E-E Video|The E-E video was developed by the research team and chronicles the story of Ana who while enjoying coffee with two family members, shares her challenges with depression and her successful outcome with therapy. The video utilizes the genre of the telenovela which creates an entertaining environment where the audience is captivated by the content and absorbs the messages portrayed.
40931787|NCT03889301|BEHAVIORAL|Discussion|Structured psychoeducation and pamphlet about anxiety and depression.
40931788|NCT02306733|DRUG|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).
40931789|NCT02306733|DRUG|Oxytocin|100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
40931790|NCT01852357|OTHER|Neurofeedback|The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
41129354|NCT05892562|OTHER|No intervention|As this study is purely observational, no intervention is involved.
41129355|NCT02304757|DRUG|99Tc-MDP|99Tc-MDP, H20000218
41129356|NCT02304757|DRUG|Fosamax|H20080172
41129357|NCT05671445|BIOLOGICAL|CM326|CM326 injection
41129358|NCT02955407|OTHER|no intervention|observational case-control study
41129359|NCT06034275|DRUG|VIP943|VIP943 will be administered by IV Infusion weekly
41129360|NCT05295342|BEHAVIORAL|No Means No intervention Girls' Curriculum|"The No Means No (NMN) Girls' Curriculum is a violence prevention program designed for adolescent girls and young women 10-20 years old. This curriculum has been designed specifically for safer implementation during the COVID-19 pandemic. NMN Girls' programming is deeply rooted in Empowerment Self-Defense, which is a uniquely holistic, survivor-centered, feminist approach to self-protection skills. Youth educators called Instructors deliver the curriculum to young people in schools. This 8-hour intervention is comprised of classes that teach young people mental, verbal and physical self-defense skills that can be used to prevent sexual assault and other forms of gender-based violence."
41129361|NCT05295342|BEHAVIORAL|No Means No intervention Boys' Curriculum|"The No Means No (NMN) Boys' Curriculum is a violence prevention curriculum that has been designed specifically for implementation during the COVID-19 pandemic. Designed for adolescent boys and young men age 10-20. Like the girls program it is delivered by youth educators called Instructors in schools. This 8-hour intervention is comprised of classes that teach young people gender equitable attitudes, skills to defend equality and how to avoid violence as a power paradigm."
41129362|NCT05295342|BEHAVIORAL|Active comparator: Life Orientation|The standard school-based Life Orientation curriculum
41129363|NCT00221559|PROCEDURE|Blood sampling for determination of serum Zn|
41449487|NCT02587663|PROCEDURE|Therapeutic Conventional Surgery|Undergo breast conserving surgery
41449488|NCT02587663|PROCEDURE|Ultrasonography|Undergo bilateral whole-breast ultrasound
41278841|NCT06221930|BEHAVIORAL|attexis|Participants will receive access to the digital health intervention attexis in addition to TAU.
41278842|NCT05885555|BIOLOGICAL|Ianalumab|Intravenous infusion, prepared from concentrate solution
41278843|NCT04933539|DRUG|Dexamethasone|Dexamethasone PO/IV (for Cycles 1-4: Dexamethasone 40 mg IV/PO on days 1, 8, 15, 22; for Cycles =5: Dexamethasone 20 mg IV/PO on days 1, 8, 15, 22); for up to 12 cycles
41278844|NCT04933539|DRUG|Carfilzomib|Carfilzomib IV (for Cycles 1-2: 20 mg/m2 IV on day 1, 56 mg/m2 IV on days 8, 15; Cycles =2: 56/m2 IV on days 1, 8, 15); for up to 12 cycles
41278845|NCT04933539|BIOLOGICAL|Daratumumab|Daratumumab SC 1800 mg (Cycles 1-2: Days 1, 8, 15, 22; Cycles 3-6: Days 1, 15; Cycles =7: Days 1 of the 28-day cycle); up to 36 cycles total
41278846|NCT04994717|DRUG|Blinatumomab|Continuous intravenous (cIV) infusion
41129364|NCT03916341|OTHER|EC with nicotine|Use an EC with nicotine for up to 30 minutes
41129365|NCT03916341|OTHER|EC without nicotine|Use an EC without nicotine for up to 30 minutes
41129366|NCT03916341|OTHER|control|sham control
41129367|NCT03916341|OTHER|TC with nicotine (own brand)|smoke a TC
41278847|NCT04994717|DRUG|Low-intensity chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
41278848|NCT04994717|DRUG|SOC chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
41278849|NCT04958785|DRUG|Magrolimab|Administered intravenously
41278850|NCT04958785|DRUG|Nab-Paclitaxel|Administered intravenously
41278851|NCT04958785|DRUG|Paclitaxel|Administered intravenously
40931791|NCT01852357|OTHER|Sham Neurofeedback|Feedback generated by data not associated with the current participant.
40931792|NCT06036147|BEHAVIORAL|Concussion-focused cognitive behavioral therapy|Youth randomized to receive this component will participate in six 30-minute sessions of cf-CBT. The intervention includes modular CBT targeting post-concussive, anxiety and depressive symptoms. In this CBT treatment, the adolescent can be taught coping skills, relaxation strategies, and cognitive strategies to manage their symptoms, while they are encouraged to increase appropriate activation, including pacing of activities. Six sessions from the CHIP Study Cognitive and Behavioral Skills for Concussion Recovery will be chosen by the interventionist based on the youth's goals in the Introduction Session.
41129368|NCT03916341|OTHER|research TC with very low level nicotine|smoke a research TC with very low level nicotine
41129369|NCT03352726|DRUG|DBV712 IHRP|DBV712 Solution for Skin Prick Test
41278852|NCT04958785|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
41278853|NCT04613206|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
41278854|NCT04613206|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
41278855|NCT04585685|BEHAVIORAL|Cognitive Processing Therapy|A 12-session cognitive behavioral therapy for posttraumatic stress disorder
41278856|NCT04585685|BEHAVIORAL|Self-Compassion Therapy|A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion
41278857|NCT05379595|DRUG|Amivantamab|Amivantamab will be administered as intravenous infusion.
41129370|NCT02724501|BEHAVIORAL|questionnaire|Using questionnaire to obtain patient's medical and family history of cancer.
41129371|NCT02724501|PROCEDURE|Blood sample-DNA testing / Tumour-genetic markers|Using Samples obtained to produce summary statistics on the tumour markers
41129372|NCT04400136|DRUG|Lansoprazole oral tablets 30 mg|Post operative prescription
41278858|NCT05379595|BIOLOGICAL|Fluorouracil|Fluorouracil will be administered as intravenous infusion.
41278859|NCT05379595|BIOLOGICAL|Leucovorin|Leucovorin will be administered as intravenous infusion.
41129373|NCT03491540|DRUG|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
41129374|NCT03491540|DRUG|Oral Gentamycin|"Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials"
41129375|NCT03491540|DRUG|Oral Ornidazole|"Oral ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
41129376|NCT03491540|DRUG|Oral Placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
41129377|NCT03491540|DRUG|Oral Placebo Ornidazole|"Placebo for oral ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablets per day) on day -2 and day -1"
41278860|NCT05379595|BIOLOGICAL|Oxaliplatin|Oxaliplatin will be administered as intravenous infusion.
41278861|NCT05379595|BIOLOGICAL|Irinotecan|Irinotecan will be administered as intravenous infusion.
41278862|NCT05086315|DRUG|SAR443579|Powder for solution for infusion; by IV infusion
41129378|NCT02071316|DRUG|Hexacapron( Tranexamic acid)|1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
41129379|NCT02071316|DRUG|esomeprazole|2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
41129380|NCT00596336|DRUG|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
41129381|NCT00596336|DRUG|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
41129382|NCT00012805|PROCEDURE|Telephone Monitoring|
41129383|NCT02022800|OTHER|PET 18FDOPA|contribution of PET 18FDOPAimagery in high level glioma diagnosis
41129384|NCT02369484|DRUG|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
41278863|NCT04776850|DRUG|Bortezomib|Given IV
40931793|NCT06036147|BEHAVIORAL|Parent skills training|The focus of the PST component is on the use of positive parenting skills as well as helping parents manage their own emotional distress. Parents are taught to set positive recovery expectations, and to use praise or attention to increase their teen's positive coping behaviors and decrease unhelpful coping behaviors. They are also taught positive communication skills to use with their teen, and guided to schedule pleasant events together in order to strengthen the relationship. In-vivo skills practice and feedback are provided to help parents generalize and use PST techniques. Parents randomized to receive this component will participate in six 30-minute sessions of PST, chosen from the CHIP Study Parent Support Skills Training for Concussion recovery based on the parent's goals in the Introduction Session.
40931794|NCT06036147|BEHAVIORAL|Care management|In the CM component, parents are provided support regarding advocating for their child's needs across different contexts in the healthcare system, school and athletic departments (including guidance regarding medication referrals), using applied problem-solving together with the skills coach to address emergent needs. Adolescents can also be involved in CM, if developmentally appropriate based on their age, independence, and interest. Of note, while the CM component engages youth and parents, treatment effects are hypothesized to result from facilitating access to supportive services including medication referrals at the organizational level. Families randomized to receive this component will participate in six 30-minute sessions of CM, following the guidelines in the CHIP Care Management Manual.
40931795|NCT01856283|DRUG|Nilotinib 300mg BID|Nilotinib
40931796|NCT02153476|DRUG|2.0mg of ALG-1001|
40931797|NCT02153476|DRUG|Balanced Salt Solution|
40931798|NCT05858840|OTHER|Urinary Artificial Sphincter (UAS) in Children|Patients aged under 18 years old with UAS
40931799|NCT00129298|DRUG|Tiagabine|The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
40931800|NCT03573102|DRUG|SGLT2 inhibitor|SGLT2 inhibitor 10 mg/day
40931801|NCT03573102|DRUG|ACE inhibitor|ACE inhibitor once daily
40931802|NCT04875247|DEVICE|IOLMaster 700 with central topography|The time needed to perform the measurement using the IOLMaster700 equipment with central topography will be recorded.
40931803|NCT04875247|DEVICE|IOLMaster 700 without central topography plus Cassini|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Cassini equipment will be recorded.
40931804|NCT04875247|DEVICE|IOLMaster 700 without central topography plus Pentacam|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Pentacam equipment will be recorded.
40931805|NCT00005934|DRUG|5-Azacytidine|
40931806|NCT05163873|PROCEDURE|Extra-peritoneal|Surgery procedure: a non-mesh prophylactic surgical technique to prevent PH
40931807|NCT01206387|DRUG|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
40931808|NCT01206387|DRUG|placebo comparator|Placebo administered to affected area twice a day for 28 days
40931809|NCT02113839|PROCEDURE|Spirometry|Before re-breathing (if the patient not performed one 6 months in advance).
40931810|NCT02113839|PROCEDURE|CO Exhaled breath|In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).
40931811|NCT02113839|PROCEDURE|P01|P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
40931812|NCT02113839|PROCEDURE|FeNO|The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.
40931813|NCT03457233|DRUG|Gonadotropins|1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
41129385|NCT04570358|OTHER|Static stretching|During the static stretching training for the calf muscles, the ankle joint is moved into maximal dorsiflexion until the point of discomfort is reached. The ankle joint is then held in this maximal position for 30 s followed by a rest period of 30 s. Afterwards, the procedure is repeated with the knee in flexed position to stretch the soleus muscle.
40931814|NCT03457233|DRUG|GNRH antagonist|cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
40931815|NCT03457233|DRUG|Human chorionic gonadotropin Chorimon|10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
40931816|NCT03457233|DRUG|Natural progesterone|400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
40931817|NCT00002967|DRUG|cyclophosphamide|
40931818|NCT00002967|DRUG|doxorubicin hydrochloride|
40931819|NCT00002967|DRUG|octreotide pamoate|
40931820|NCT00002967|DRUG|tamoxifen citrate|
40931821|NCT02960776|BEHAVIORAL|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
40931822|NCT00716950|DRUG|valsartan/amlodpine|tablets; 160mg/5mg; od; 4 weeks
40931823|NCT00716950|DRUG|losartan/amlodpine|tablets; 100mg/5mg; od; 4 weeks
40931824|NCT06239623|DRUG|JSI-1187|Use ERK inhibitor JSI-1187 to treat solid tumor
41278864|NCT04776850|DRUG|Busulfan|Given IV
41278865|NCT04776850|DRUG|Cyclophosphamide|Given IV
41278866|NCT04776850|DRUG|Dexamethasone|Given IV
41278867|NCT04776850|DRUG|Fludarabine Phosphate|Given IV
41278868|NCT04776850|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
41278869|NCT04776850|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
41278870|NCT04776850|DRUG|Mycophenolate Mofetil|Given IV or PO
41278871|NCT04776850|PROCEDURE|Plasmapheresis|Undergo plasmapheresis
41278872|NCT04776850|BIOLOGICAL|Rituximab|Given IV
41278873|NCT04776850|DRUG|Tacrolimus|Given IV or PO
41449489|NCT02587663|PROCEDURE|Ultrasonography|Undergo targeted breast ultrasound
41449490|NCT02587663|OTHER|Gadolinium|Contrast agent used in MRI
41449491|NCT04188509|DRUG|Voxelotor|All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a powder for oral suspension formulation (powder formulation packaged as stick packs).
41449492|NCT06624735|DIAGNOSTIC_TEST|psychometry|ADHD test and measurement of IQ level
41449493|NCT00250263|DRUG|(agent for immunotherapy) Staloral|"Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily"
41449494|NCT00250263|DRUG|Placebo|"Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily"
41449495|NCT05848908|OTHER|Telehealth Visit|telemedicine visit and follow-up surveys
41449496|NCT05730920|DRUG|Methadone|IV Methadone
41449497|NCT05730920|DRUG|Liposomal bupivacaine (LB, Exparel)|LB and bupivacaine hydrochloride via erector spinae plane blocks
40931825|NCT05260281|DEVICE|MONA algorithm|most artificial intelligence algorithms, like the MONA algorithm used in this study, are trained on 45-degree fundus photographs. In order to incorporate the use of the algorithm, the study intervention consists of taking 1 extra 45-degree fundus photograph per eye per patient using the Zeiss Cirrus Photo 800 system.
41129386|NCT04570358|OTHER|Proprioceptive neuromuscular facilitation stretching|During the proprioceptive neuromuscular facilitation stretching, the ankle joint is moved into maximal dorsiflexion. While the foot is kept in this position, the child will perform a (sub-) maximal isometric contraction of the plantar flexors against the resistance of their parents. Afterwards, the ankle joint will be moved further into greater dorsiflexion and is held there for the remaining seconds followed by 30 s of rest. Subsequently, the stretch will be applied with the knee flexed.
41129387|NCT05416827|PROCEDURE|slow-release dexamethasone implant|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
41129388|NCT04199338|OTHER|The Effect of Web Based Education Based on Self-Care Deficiency Theory on Self-Care Power and Self-Efficacy and Perceived Social Support in Patients Receiving Peritoneal Dialysis|"In the study, which will last for 3 months, the patients in the intervention group will receive pre-test Web-based training based on the Self-Care Deficiency Theory. And an intervention group will be expected to use the website weekly. Also weekly reminder messages will be sent regularly.~Following the final test, individuals in the enterprise group will be asked to evaluate their views on the website in writing with the WAMMI test."
41278874|NCT04358458|BIOLOGICAL|GEN3009|GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
41278875|NCT04358458|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
41278876|NCT06247995|DRUG|[68Ga]Ga-NeoB|68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.
41278877|NCT06247995|DRUG|[177Lu]Lu-NeoB|\[177Lu\]Lu-NeoB is a radioligand therapy drug.
41278878|NCT06247995|DRUG|Capecitabine|Capecitabine is a chemotherapy drug.
41278879|NCT02761057|PROCEDURE|Biospecimen Collection|Undergo collection of plasma and serum samples
41449498|NCT02054715|BEHAVIORAL|print educational intervention|print educational intervention
41278880|NCT02761057|PROCEDURE|Bone Scan|Undergo bone scan
41278881|NCT02761057|DRUG|Cabozantinib S-malate|Given PO
41278882|NCT02761057|PROCEDURE|Computed Tomography|Undergo CT
41278883|NCT02761057|DRUG|Crizotinib|Given PO
41278884|NCT02761057|DRUG|Savolitinib|Given PO
41278885|NCT02761057|DRUG|Sunitinib Malate|Given PO
41278886|NCT04914897|DRUG|THOR-707|Intravenous infusion: solution for infusion
41449499|NCT02054715|BEHAVIORAL|multimedia psychoeducational intervention|multimedia psychoeducational intervention
41449500|NCT00041015|DRUG|cisplatin|
41449501|NCT00041015|DRUG|etoposide|
41449502|NCT00041015|DRUG|topotecan hydrochloride|
41278887|NCT04914897|DRUG|Pembrolizumab|Intravenous infusion: solution for infusion
41278888|NCT04172675|DRUG|Erdafitinib|Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.
41278889|NCT04172675|DRUG|Investigator Choice (Gemcitabine)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
41278890|NCT04172675|DRUG|Investigator Choice (Mitomycin C)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
41449503|NCT03108235|BEHAVIORAL|HOM-HEMP|a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse.
41453485|NCT00314834|DRUG|Intradialytic parenteral nutrition|
41453486|NCT04364191|BEHAVIORAL|Multicomponent Behavioral Sleep Intervention for Insomnia|The MBSI-I will include a meaningful activity protocol during the day and ART therapy at night.
40931826|NCT01268371|DEVICE|Promus Element, Boston Scientific Corporation|Everolimus-eluting stent
40931827|NCT01268371|DEVICE|Nobori, Terumo Corporation (Japan)|Biolimus-eluting stent with biodegradable polymer
40931828|NCT04041791|DRUG|Benzyl penicillin|Benzyl penicillin is a penicillin antibiotic.
41278891|NCT06357221|DRUG|Cetaphil|Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.
41278892|NCT05746624|BEHAVIORAL|keypresses|benign behavioral intervention-- keypresses
41129389|NCT06145100|DIAGNOSTIC_TEST|Ultrasound including color doppler ultrasound|Patients with CVID receive color doppler ultrasound of the liver including assessment of portal vein diameter, portal vein flow velocity, hepatic vein diameter and assessment of arterial perfusion. Further liver and spleen stiffness measurement by transient elastography is performed.
41129390|NCT03927196|BEHAVIORAL|extended counseling|Patients are handed out information leaflets on the correction of risk factors, SMS reminders, extended statins counseling.
40931829|NCT04041791|DRUG|Gentamicin Sulfate|Gentamicin is an aminoglycoside antibiotic.
41129391|NCT05422846|OTHER|standard treatment|The control group will be provided with the necessary approaches for diabetic foot ulcer care and diaphragmatic breathing exercises.
41129392|NCT05422846|OTHER|aerobic exercise|The aerobic exercise group will be provided with the necessary approaches for diabetic foot ulcer care and in addition to diaphragmatic breathing exercises, they will be provided with aerobic exercise twice a week with a physiotherapist.
40931830|NCT04041791|DRUG|Ceftriaxone|Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.
40931831|NCT04041791|DRUG|Amoxicillin Clavulanate|Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.
40931832|NCT04041791|OTHER|Intravenous fluid|Maintenance fluids administered for at least 24 hours.
40931833|NCT04041791|OTHER|Nasogastric feeds|Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.
40931834|NCT04041791|DRUG|Ampicillin|Ampicillin is a penicillin-type antibiotic.
40931835|NCT00338975|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
40931836|NCT00338975|BEHAVIORAL|Goal-focused supportive contact (GFSC)|"There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills."
41278893|NCT04120493|GENETIC|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
41278894|NCT04120493|OTHER|Imitation (sham) surgery|Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull
41278895|NCT05047523|DRUG|ALXN1840|Administered as an oral tablet.
41278896|NCT05047523|DRUG|Standard of Care|Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
41453487|NCT04364191|BEHAVIORAL|Active Control|The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education.
40931837|NCT00338975|BEHAVIORAL|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
40931838|NCT00338975|BEHAVIORAL|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
41129393|NCT05422846|OTHER|exercise protocol|The protocol exercise group will be provided with the necessary approaches for diabetic foot ulcer care and exercises suitable for the physical condition of the wound and the patient, in addition to diaphragmatic breathing exercises. This group will also work with a physiotherapist twice a week.
41129394|NCT03217669|DRUG|Epacadostat|Epacadostat tablet: 100mg or 300mg
41129395|NCT03217669|DRUG|sirolimus|Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
41129396|NCT04929951|BIOLOGICAL|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
41129397|NCT04929951|BIOLOGICAL|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
41129398|NCT06192043|BEHAVIORAL|Behavioral Psychoeducational Intervention|Psychoeducational Program would be used as an intervention strategy for individuals with smoking cessation to provide understanding and insight to the participants about the problem. Furthermore, this program would deal with interventions like motivation, cognitive conceptualization, coping skills and training, craving management, and relapse prevention among individuals with smoking cessation
41449504|NCT03108235|BEHAVIORAL|HOM-HEMP with smartphone app|"a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse. In addition, participants will receive a smartphone app.~The smartphone will be used to monitor their health data (such as weight, and blood pressure). The data will be synchronized to a web-connected portal on a remote server. The research nurse would be able to access your data through the web-connected portal and provide consultation through scheduled tele or video conference."
41129399|NCT03819166|DEVICE|with deep touch pressure application|The deep touch pressure is applied by the weight loading devices, including but not limited to, weight blanket and weight vest.
41129400|NCT03819166|DEVICE|without deep touch pressure application|The deep touch pressure will not be applied.
41449505|NCT03108235|BEHAVIORAL|Standard Care|standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
41449506|NCT02659462|OTHER|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
41129401|NCT03069859|DRUG|TXA (1g)|1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
41129402|NCT03069859|DRUG|Placebo (0.9% saline)|0.9% saline (10 mL), diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
41129403|NCT04242212|BEHAVIORAL|Misoprostol sourced from clinics|One cohort of women using misoprostol sourced from clinics
41129404|NCT04242212|BEHAVIORAL|Misoprostol sourced from PMVs|One cohort of women using misoprostol sourced from PMVs
41129405|NCT03642106|BEHAVIORAL|Unidos Se Puede|The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
41129406|NCT05302076|DEVICE|Low-intensity electrical current (LIEC)|Each patient in the electrical group will be asked to wear a removable device containing a small electrical circuit that will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
41129407|NCT05302076|DEVICE|Traditional fixed orthodontic appliance|"The maxillary arch will be levelled and aligned. The rectangular stainless steel archwires (0.019 × 0.025) with anterior 8mm height soldered hooks distal to the canines will be inserted. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction."
41449507|NCT05625490|DRUG|Ga-68 Galmydar|Intravenous injections of the PET radiotracer \[68Ga\]Galmydar.
41449508|NCT05625490|DRUG|13N-ammonia|Two intravenous injections of PET radiotracer \[13N\]Ammonia.
41449509|NCT04948476|OTHER|Standardized Dialysis and Structured Discontinuation (S2D2)|"Prescription to minimize dialysis-induced ischemia~* Cool dialysate (35.0◦C)~* Dialysate sodium of 145mmol/L~* Dialysate calcium of 1.5mmol/L~* Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour)~  * Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable.~Structured dialysis discontinuation (all criteria met)~* Most recent pre-dialysis potassium \<6mmo/L and bicarbonate \>12mmol/L~* Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis \<1L/session~* If available, timed urine collection with result for mean creatinine and/or urea clearance \>12mL/min"
41453488|NCT03118687|OTHER|Biospecimen and survey collection|Blood, microbiota, surveys/questionnaires, electronic medical records.
41129408|NCT02656147|BIOLOGICAL|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
41129409|NCT05765331|DEVICE|Chatbot|The AI chatbot is a kind of artificial intelligence technology that can help increase knowledge and understanding of men's health issues. That interacts with subjects through literal text and provides educational resources, advice, and assistance related to lifestyle changes. The chatbot is a valuable aid to increase men's health by providing information about enlarged prostate with urination problems and erectile dysfunction.
41129410|NCT02988193|DEVICE|optima4BP Medication Management|A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
41129411|NCT01208116|OTHER|Cardiovascular events|"* Coronary intervention~* Infarction~* Congestive heart failure~* Stroke~* Cardiac death"
41129412|NCT04325711|DRUG|CSPCHA131|CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.
41129413|NCT01951807|BEHAVIORAL|Psychotherapy|
40931839|NCT06477809|DEVICE|ARIA Glasses ( Augmented Reality in Audio )|ARIA stands for Augmented Reality in Audio. The ARIA Device consists of Augmented Reality glasses connected by cord to a dedicated mobile phone that has the ARIA app installed. The glasses include cameras, speakers and an inertial measurement unit. The phone app uses artificial intelligence to convert camera vision from the glasses into a soundscape that includes words and unique sounds identifying specific objects nearby, and an audio rendering of depth that estimates the user's distance from solid matter. This soundscape is delivered to the user via an amplifier that enables volume control and switch-off. The soundscape is designed to augment rather than replace natural hearing, increasing the user's perceptual access to details in the nearby environment.
40931840|NCT06432881|DEVICE|RD SET Sensor|All subjects are enrolled into this arm and will have Sp02 measurements obtained.
40931841|NCT04585139|DEVICE|Phase 1- Introduction to Dexcom G6 CGM|Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy
40931842|NCT02312687|BIOLOGICAL|KRN23|solution for SC injection
40931843|NCT03687970|OTHER|Brief Pain Inventory|-A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
40931844|NCT03687970|OTHER|Hospital Anxiety and Depression Scale|"* 14 item scale with even of the items relating to anxiety and seven relating to depression~* Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression"
41129414|NCT02966652|DRUG|DITEST|Lipid formulation of native oral testosterone.
40931845|NCT03687970|OTHER|Neuropathic Pain Symptom Inventory|-The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia \[pain provoked by light touch\]). Each of the parameters includes recall of the past 24 hours
40931846|NCT03687970|PROCEDURE|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers"
41129415|NCT02966652|DRUG|Testosterone undecanoate|Generic treatment for patients with primary or secondary male hypogonadism
41129416|NCT00629096|PROCEDURE|Intracoronary infusion of autologous bone marrow cells|Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
41129417|NCT01141972|DIETARY_SUPPLEMENT|Vitamin D|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml \[≥75 nmol/L\]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.
41453489|NCT02265679|DRUG|BIIL 284 BS, low dose, pediatric patients|
41453490|NCT02265679|DRUG|BIIL 284 BS, medium dose, pediatric patients|
40931847|NCT03687970|PROCEDURE|Quantitative sensory testing|"* Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~* Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio"
40931848|NCT03687970|PROCEDURE|Conditioned pain modulation efficiency|-Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
40931849|NCT03687970|OTHER|Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)|"-The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain."
40931850|NCT06551103|BEHAVIORAL|Intervention group trained in line with the Health Promotion Model|A literature review was conducted by the researchers within the scope of Health Promotion Model and a educational material was prepared. With this educational material, the patients in the intervention group were trained in four sessions lasting 25 minutes each.
40931851|NCT00447200|PROCEDURE|Esophagus Doppler monitoring|
40931852|NCT00447200|PROCEDURE|Fluid optimization|
40931853|NCT06091072|OTHER|Image-guided navigation|A patient-specific 3D model will be created using an available pre-operative SPECT/CT scan. Pre-operatively, three electromagnetic patient trackers will be attached to the patients' skin, close to the pelvis, allowing tracking the patient's position during surgery. After anesthesia and before the skin disinfection procedure, the patient is placed in the final surgical position, where an intra-operative CBCT scan is performed required for the image-guided surgery workflow. During surgery, the preoperative images and 3D model will be visible for the surgeon together with a blunt-tip electromagnetic pointer enabling surgical navigation during robotic surgery. Anatomical structures will be used to validate the accuracy of the navigation. When the target is identified by the surgeon, the pointer is used to store the location digitally. Scheduled standard clinical 99mTc will be used as validation for target(s) identification.
40931854|NCT00316550|DRUG|AV608|
40931855|NCT00827931|DRUG|Tranexamic acid + Standard of Care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
40931856|NCT00827931|PROCEDURE|Standard of Care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
40931857|NCT05134532|DRUG|regorafenib|Regorafenib 160 mg orally every day for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off) plus best supportive care
40931858|NCT04491097|DEVICE|Panavia V5 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia V5 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
40931859|NCT04491097|DEVICE|Panavia F2.0 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia F2.0 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
40931860|NCT00000832|BIOLOGICAL|MF59|
40931861|NCT00000832|BIOLOGICAL|rgp120/HIV-1 SF-2|
40931862|NCT00717470|DRUG|Prograf®|oral
40931863|NCT00717470|DRUG|Advagraf®|oral
40931864|NCT00717470|DRUG|Mycophenolate Mofetil|oral
40931865|NCT00717470|DRUG|Simulect|oral
40931866|NCT00717470|DRUG|methylprednisolone / prednisone|oral
40931867|NCT00983398|DRUG|Carboplatin|Given IA
40931868|NCT00983398|DRUG|Mannitol|Given IA
40931869|NCT00983398|DRUG|Melphalan|Given IA
40931870|NCT00983398|OTHER|Quality-of-Life Assessment|Ancillary studies
40931871|NCT00983398|OTHER|Questionnaire Administration|Ancillary studies
40931872|NCT00983398|DRUG|Sodium Thiosulfate|Given IV
40931873|NCT04169347|DRUG|Oxaliplatin|2 week cycles
40931874|NCT05797545|DIAGNOSTIC_TEST|Breast MRI for Breast Cancer Detection|Comparison of diagnostic results of abbreviated breast MRI and full protocol MRI for secondary breast cancer surveillance
40931875|NCT03808103|BIOLOGICAL|Placebo|Orally, twice a day, for a period of fifteen days
40931876|NCT03808103|BIOLOGICAL|Bacteriophage preparation|Orally, twice a day, for a period of fifteen days
40931877|NCT00922701|DRUG|L-carnitine|Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
40931878|NCT05886517|DEVICE|Transfemoral transcatheter aortic valve implementation|ranscatheter aortic valve implantation, a percutaneous treatment for severe aortic valve stenosis, is increasingly performed worldwide. The pacemaker should be able to perform overdrive pacing which is essential to reduce cardiac output and transvalvular blood flow which are critical during balloon aortic valvuloplasty and valve deployment of the balloon- expandable valve. Minor adjustment may be needed for ideal positioning, but importantly this has to be done before valve implantation
40931879|NCT03790631|OTHER|The study is observational.|The study is observational.
40931880|NCT06020729|OTHER|General Exercises without occlusion training|General Exercises as bench press, squats , maximum sprint, leg power without occlusion training
40931881|NCT06020729|OTHER|Occlusion Training|In experimental sessions players will perform with occlusion training which is blood flow resistance training, 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time.This training will also improve and increase muscular strength as well as speed and physical performance in players.
40931882|NCT03684252|BEHAVIORAL|CBT-based intervention|Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.
40931883|NCT03684252|OTHER|Treatment as Usual|Participants' will receive treatment as usual.
41129418|NCT01141972|OTHER|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
41129419|NCT01337141|OTHER|Control|7 face-to-face visits.
41129420|NCT01337141|DEVICE|Telecare system|5 telematic visits and 2 face-to-face visits.
41278897|NCT06107829|DRUG|Valbenazine Oral Capsule|Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
41278898|NCT06640114|DEVICE|Efferon CT|"Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.~The duration of hemoperfusion is from 2 to 6 hours through peripheral venous access, followed by follow-up for 4 hours. The rate of hemoperfusion is from 60 to 80 ml/min. Anticoagulation is systemic (heparin)."
41449510|NCT04948476|OTHER|Usual Care|Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.
41449511|NCT06112626|BEHAVIORAL|CHG Skin Treatment Video|Short CHG skin treatment video that reviews the rationale/importance of CHG bathing, and the appropriate process for bathing
41449512|NCT01473173|DRUG|CJ-12420|
40931884|NCT04265768|PROCEDURE|Soft tissue augmentation surgery with CTG|"An epithelial-connective tissue graft of approximately 2-3 mm of thickness and adequate length will be taken from the palate or retromolar region of the patient and de-epithelialized with a scalpel (ideally a thickness of 1.5-2.0mm).~The connective tissue graft (CTG) obtained will then be positioned buccally to the dental implant and sutured to the internal side of the flap so to provide soft tissue bulk at the level of the neck of the implant and simulate a root prominence for the missing tooth."
40931885|NCT04265768|PROCEDURE|Soft tissue augmentation surgery with Fibro-Gide|Fibro-Gide will be used to obtain buccal soft tissue augmentation. Fibro-Gide will be trimmed with a scalpel and adjusted in size and thickness to better adapt to the area buccal to the implant. In particular, the graft will be shaped in order to obtain a graft of approximately 2-3 mm of thickness and adequate length. Fibro-Gide will then be sutured to the inner side of the buccal flap, before repositioning the flap and suturing it in a tension-free way.
40931886|NCT04265768|PROCEDURE|No soft tissue augmentation|During implant placement surgery, no soft tissue augmentation will be performed
40931887|NCT00999921|DRUG|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
40931888|NCT00999921|DRUG|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
40931889|NCT03464565|DEVICE|Penumbra System|Penumbra System
40931890|NCT03232073|DRUG|Ponesimod|Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
40931891|NCT01963052|DRUG|AGS15E|intravenous (IV) infusion
40931892|NCT00801307|DEVICE|spirometer|According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
40931893|NCT05743517|BEHAVIORAL|Fit4Treatment|This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.
41278899|NCT05286788|DRUG|Binimetinib Oral Tablet [Mektovi]|Binimetinib oral continuous dosing 32 mg/m2 PO BID for 4 weeks
41278900|NCT03808311|OTHER|Treatment strategy regarding different systolic BP goals|The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (\<120 mmHg in the intensive arm and \<140 mmHg in the standard arm).
40931894|NCT01280201|DRUG|Pazopanib|Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
41129421|NCT03749018|DRUG|Cyclophosphamide|Given IV
41278901|NCT03293680|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg, every 3 weeks
41278902|NCT04576156|DRUG|Imetelstat|Imetelstat will be given intravenously at 9.4 mg/kg every 21 days, until disease progression or unacceptable toxicity, treatment discontinuation or study end.
41278903|NCT04576156|DRUG|Best Available Therapy (BAT)|Non-JAK-inhibitor treatment will be given, which may include but is not limited to hydroxyurea, thalidomide or an analog of thalidomide, interferon, danazol, hypomethylating agents, chemotherapy or radiotherapy.
41278904|NCT05621668|DRUG|Cyclophosphamide|Given by IV (vein)
41449513|NCT01473173|DRUG|Esomeprazole 40mg|
41453491|NCT02265679|DRUG|BIIL 284 BS, high dose, pediatric patients|
41453492|NCT02265679|DRUG|BIIL 284 BS, low dose, adult patients|
41453493|NCT02265679|DRUG|BIIL 284 BS, medium dose, adult patients|
40931895|NCT02719873|OTHER|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
40931896|NCT02446743|BIOLOGICAL|rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)|One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
40931897|NCT01390220|DRUG|USL261|
40931898|NCT01390220|DRUG|Placebo|
40931899|NCT03036475|DEVICE|Sienna+ injection|Subcutaneous injection of Sienna+ in the morning of operation day
41129422|NCT03749018|DRUG|Doxorubicin Hydrochloride|Given IV
41129423|NCT03749018|DRUG|Etoposide|Given IV
41129424|NCT03749018|BIOLOGICAL|Nivolumab|Given IV
41129425|NCT03749018|DRUG|Prednisone|Given PO
41129426|NCT03749018|BIOLOGICAL|Rituximab|Given IV
41278905|NCT05621668|DRUG|attIL2-T cells|Given by IV (vein)
40755377|NCT04256837|DEVICE|Transcutaneous electrical auricular vagus nerve stimulation (VNS)|Electrical auricular stimulation is accomplished using a Roscoe Medical TENS 7000 that delivers a programmable electrical current density, frequency, and pulse width. The TENS 7000 will be connected to ear clip (or hand held) electrodes to transcutaneously stimulate the cymba conchae of the ear to activate the auricular branch of the vagus nerve (diagram above), also known as Arnold's nerve, which provides sensory innervation to the skin surrounding the ear canal. Through a neural reflex arc, activation of this sensory nerve sends a neural signal to the brainstem that then activates the efferent vagus nerve through the nucleus of the solitary tract (NTS). This is a well-described and clinically accepted neuromodulatory pathway, as transcutaneous electrical auricular stimulation has been studied to treat seizures, similarly to how invasive electrical vagus nerve stimulation has been approved by the FDA for the past two decades for the same indication.
40755378|NCT06000904|OTHER|Exergame-based balance training|For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute balance exercise, and 15-minute ground walking as a cool-down.
40931900|NCT01586273|DEVICE|MR-HIFU treatment for pain palliation of bone metastases|A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
40931901|NCT04388371|DRUG|Glutamine|Glutamine will be administered by IV injection prior to PET imaging.
40931902|NCT05869084|DIAGNOSTIC_TEST|pulmonary function tests|pulmonary function tests
40931903|NCT02273609|DRUG|Vitamin K antagonists (acenocoumarol or warfarin)|"INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.~No specific recommendation about treatment will be provided by sponsor."
40931904|NCT00413088|DRUG|bemiparin|
40931905|NCT00907062|DIETARY_SUPPLEMENT|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
40931906|NCT06177275|PROCEDURE|Placement of BLX implants 2 mm sub-crestal i|Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
40931907|NCT06177275|PROCEDURE|Placement of BLX implants equicrestal|Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
41278906|NCT06150157|DRUG|JNJ-88549968|JNJ-88549968 will be administered.
41278907|NCT06498921|OTHER|Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel|No treatment will be provided to participants in the study. The decision on initiation of darolutamide (Nubeqa, BAY1841788) in combination with ADT and doctaxel and duration of treatment is solely at the discretion of the treating physician, guided by the recommendations outlined in the local product information.
40931908|NCT06298344|DRUG|Thiamine|Daily Thiamine 100 mg in 28 days
41278908|NCT04206319|DRUG|Radium-223|an alpha particle-emitting drug, dose consists of 55 kBq/kg (1.49 microcurie/kg); administered every 4 days
41278909|NCT04206319|DRUG|18F Sodium Fluoride|18F-NaF (Sodium Fluoride) is a radio-pharmaceutical used to image skeletal pathology with positron emission tomography (PET) imaging
41278910|NCT04963231|DRUG|Setmelanotide|SC injection
41278911|NCT04963231|DRUG|Placebo|SC injection
41278912|NCT02390752|DRUG|TURALIO(R)|take oral drug daily for a 28 day cycle
41278913|NCT02315521|PROCEDURE|Fetal Intervention for LUTO|"Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves."
41278914|NCT04702737|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
41278915|NCT06568094|DRUG|HRS-5041 tablets|HRS-5041 tablets
41449514|NCT03764657|PROCEDURE|"In hot group 16 patients were treated by diathermy in Cold"|"In all interventions, the patients were placed in prone position on operating table with the gluteal line opened wide by adhesive patches; after skin disinfection, dimension and extension of cystic disease was studied by injection of hydrogen peroxide through superficial skin orifice. The same procedure was performed: an elliptical incision on midline around the sinus was made and the sinus was excided laterally and in depth on healthy tissue, down till the pre-sacral fascia: this common approach was made both using scalpel and electrosurgery in the two groups. During dissection and excision, in each group were measured and recorded the temperatures developing, both on the section surface using an infrared thermometer and thermal imaging camera, and deeper until 1 cm from the section frontline using a immersion thermometer sealed by a steri-drape to guarantee the sterility on surgical field. In this group excision was carried out with diatermocoagulation"
41449515|NCT03764657|PROCEDURE|"in Cold group 13 patients were treated by scalpel."|"the position and preparation of the patient on the operating table were the same as in the hot group, while the excision procedure performed with knife"
41449516|NCT05812638|OTHER|Mental imagery technique|Warm up Period Mental Imagery (Sit-stand task Static stance (30 seconds) Indoor walk on a leveled surface Walk indoor towards target Forward / Side Stepping) Walk outdoors
41449517|NCT05812638|OTHER|Virtual Reality technique|Virtual reality training (River rush, 20000 water leaks, reflex ridge.)
41449518|NCT00870558|DRUG|ethiodized oil|Given as an intra-arterial infusion
41449519|NCT00870558|RADIATION|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
41449520|NCT05428826|DRUG|Prednisone|Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
41449521|NCT04388722|DEVICE|Pulse CO-Oximeter Sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).
41449522|NCT05517304|DEVICE|tcVNS|active stimulation with transcutaneous Vagal Nerve Stimulation (tcVNS)
41449523|NCT05517304|DEVICE|sham|sham stimulation
41449524|NCT06035497|DRUG|BMS-986369|Specified dose on specified days
41449525|NCT05119504|BEHAVIORAL|Acceptance and Commitment|"During the 90-minute, one-on-one interventionist led session, participants will learn three inter-related acceptance-based techniques tailored for coping with physical discomfort and negative affect during physical activity. (1) cognitive defusion (i.e., disentangling physical sensations and thoughts from behavior), (2) acceptance (i.e., increasing willingness to experience unpleasant physical sensations/negative affect without trying to change or control them), and (3) valued action (i.e., evaluating the role of physical activity as a valued behavior). Participants will be taught these techniques via didactic instruction, metaphors, and experiential activities.~All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week."
41449526|NCT05119504|BEHAVIORAL|Multi-Health Behavior|The multi health behavior condition will include didactic material focused broadly on healthy lifestyle recommendations including physical activity. It will also emphasize that physical activity is one of several interconnected health behaviors including balanced diet, sleep, stress management. All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week.
41449527|NCT03278873|BIOLOGICAL|either AAV - CNGB3 or AAV - CNGA3|Comparison of different dosages of either AAV - CNGB3 or AAV - CNGA3
40755379|NCT06000904|OTHER|Upper limb and trunk training|For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute upper-limb and trunk exercise, and 15-minute ground walking as a cool-down.
40755380|NCT02690740|OTHER|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|"see information in arm/group descriptions"
40755381|NCT04721691|DRUG|Epidiolex 100 mg/mL Oral Solution|Epidiolex is a schedule 5 controlled substance that is a colorless to yellow oral liquid solution that is prepackaged into 100mL vials with 5mL syringes for use. It is typically used for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet Syndrome in patients 2 years of age and older.
40755382|NCT04721691|OTHER|Placebo|Placebo is composed of dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose.
40755383|NCT01872754|DRUG|1: Remifentanil|1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
40931909|NCT05918081|OTHER|Multi-Stage 20 m Shuttle Run Test|"The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test, their agility levels with the Pro Agility Test, their core muscle endurance with the McGill Trunk Extensor and Flexor Endurance test and their peripheral muscle strength with the MicroFET® 2 handheld dynamometer."
40931910|NCT00812643|DRUG|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
40931911|NCT00159562|BEHAVIORAL|individual education|individual sessions of psycho-education
40931912|NCT00159562|BEHAVIORAL|Group education|group psycho-education in 10 weekly sessions and then a session every third month for two years
40755384|NCT01872754|DRUG|2: Propofol|2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
40755385|NCT02920294|DIETARY_SUPPLEMENT|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments
41129427|NCT03749018|DRUG|Vincristine Sulfate|Give IV
40755386|NCT02920294|DIETARY_SUPPLEMENT|Probiotic 2|Fresh fermented dairy drink containing probiotic strain
41129428|NCT02266654|OTHER|IV fluids|Normal Saline 0.9%
40755387|NCT02920294|DIETARY_SUPPLEMENT|Placebo|Acidified dairy drink without ferments
40931913|NCT02793128|DRUG|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
40931914|NCT03377088|OTHER|Rose oil|Rose oil will be given as the intervention in this study, an over-the-counter agent that can be commonly found in retail stores. It will be delivered as 2 drops 50% rose oil in water on a cotton ball within 20 cm of the patient's face for 30 minutes.
41129429|NCT02266654|OTHER|Hospital Notification|Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
41129430|NCT03932513|DRUG|inarigivir soproxil|Inarigivir 200mg and 400mg oral tablets, once daily
41278916|NCT06568094|DRUG|Abiraterone Acetate tablets（II）|Abiraterone Acetate tablets（II）
41278917|NCT06568094|DRUG|Prednisone Acetate tablets|Prednisone Acetate tablets
40931915|NCT03377088|OTHER|Almond Oil|Almond Oil has been shown in limited studies to act as a placebo for pain control when compared to Rose Oil. This subtly sweet oil will be used to ensure the patient always receives a smell, and maintains blinding.
40931916|NCT05381337|PROCEDURE|sideburns mini incision|The investigators present a new method to calculate the shortest incision for zygomatic fracture, and use this method to calculate the sideburns mini incision for the surgical treatment of zygomatic arch fracture.
40931917|NCT05381337|PROCEDURE|coronal scalp incision|Coronal scalp incisions were used as control group.
40931918|NCT06246942|DEVICE|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, Bonn, Germany).
40931919|NCT06246942|DEVICE|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, Bonn, Germany).
41449528|NCT06624137|DRUG|Serotonergic Psychedelic|"Any serotonergic or classic psychedelic that exhibits mainly Serotonin 2A receptor (5-HT2AR) agonism and is judged to produce subjectively similar effects."
40931920|NCT06246942|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Structural, diffusion, and functional MRI with a 3-Tesla Siemens scanner
40931921|NCT06171490|OTHER|NP2-4mg|NP2-4 mg is a new product containing tobacco-derived nicotine.
40931922|NCT06171490|OTHER|NP2-6 mg|NP2-6 mg is a new product containing tobacco-derived nicotine.
40931923|NCT06171490|OTHER|Loz-4mg|The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
40931924|NCT06171490|OTHER|Gum-4mg|The Gum-4mg reference product is a commercially available 4mg nicotine gum.
40931925|NCT03513081|BEHAVIORAL|Educative session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
40931926|NCT05154370|DRUG|Intravenous steroid|This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
41449529|NCT06624137|DRUG|Placebo|Matched Placebo
41449530|NCT00170677|DRUG|Topotecan|Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.
40755388|NCT06385834|OTHER|Morning aerobic exercise|Patients were randomly assigned to morning aerobic exercise training for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week. Each class consists of 10 minutes of warm-up training, 40 minutes of aerobic training and 10 minutes of relaxation training. The intensity of aerobic exercise training will be personalized. According to the guidance of relevant guidelines, the exercise intensity of patients will be determined according to the results of their first cardiopulmonary exercise experiment, and the exercise load will be gradually increased according to the exercise program until the predetermined goal is reached. Patient fatigue levels will be monitored throughout the exercise using the borg scale.
40931927|NCT01385228|DRUG|Pazopanib|"Dose Level Xa - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg."
40931928|NCT01385228|DRUG|Docetaxel|Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
40931929|NCT01385228|DRUG|Pazopanib|"Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg."
40931930|NCT01385228|DRUG|Prednisone|5mg Prednisone given twice daily days 1-21.
41449531|NCT00170677|DRUG|Topotecan|Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
40931931|NCT01385228|DRUG|Pegfilgrastim|
40931932|NCT02718950|DRUG|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks
40931933|NCT05649839|OTHER|garment|patient randomized in the experimental arm will wear the specially designed garment
40931934|NCT04340427|DRUG|TQB3455|TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.
40931935|NCT03920072|DRUG|Burosumab|Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL
40931936|NCT01322308|DRUG|pioglitazone|30 mg tablet QD (taken once daily)
40931937|NCT01322308|DRUG|placebo|tablet taken once a day
40931938|NCT01687036|DEVICE|Cryoablation|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
40931939|NCT02528266|DEVICE|Nerve Capping Device|
41278918|NCT06568094|DRUG|Docetaxel Injection|Docetaxel Injection
41449532|NCT04268615|OTHER|Covert Saccades and Virtual Reality|During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
41453494|NCT02265679|DRUG|BIIL 284 BS, high dose, adult patients|
41453495|NCT02265679|DRUG|Placebo|
41278919|NCT06568094|DRUG|HRS-1167 tablets|HRS-1167 tablets
41278920|NCT06568094|DRUG|SHR2554 tablets|SHR2554 tablets
41278921|NCT06046560|DRUG|SGLT2 inhibitor, GLP-1 RA|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
41449533|NCT04268615|OTHER|Actives versus passives Head Impulses|Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
41449534|NCT04268615|OTHER|Visually guided saccades|Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
40931940|NCT01916967|DRUG|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
40931941|NCT01916967|DRUG|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
40931942|NCT04720261|DRUG|Caplacizumab|Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients
40931943|NCT04309071|OTHER|Dietary intervention|Salivary insulin responses to a standardized mixed meal
40931944|NCT00950261|RADIATION|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
40931945|NCT05540080|DEVICE|BTL-899|Treatment with applicators C4/C5 to the BTL-899 system.
40931946|NCT03080077|DRUG|Ricrolin+|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
40931947|NCT03080077|DRUG|Epi-Off|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
40931948|NCT01670578|BIOLOGICAL|PRP|
40931949|NCT01670578|DEVICE|Hyaluronic acid|
40931950|NCT04250311|DRUG|MMH-407|MMH-407: For oral use.
40931951|NCT04250311|DRUG|Placebo|Placebo: For oral use.
40931952|NCT02127060|DRUG|Vitamin C|for 1 month postoperative period, vitamin C was administered orally to the patients.
41129431|NCT04929106|DEVICE|mHealth support tool|The final app is named Active Leisure and consists of an advanced activity planner based on the platform developed by the ideal company Smart Cognition AS. The app offers different interface options (symbols only, easy to read text, plain text, and read aloud). The activity planner will mostly be used by the individual with IDs and a support person (caregiver or health care provider). After completing an activity, a simple reward is available (e.g., a smiling face or to share a picture with other users of the app). The use of tailored communication through personalization: the use of individuals first name in the activity planner, adaptation: individually chosen activities, adjusted communication (symbols, easy-to-read text or plain text), preparation and planning, and feedback: rewarding and positive feedback (after activities have been performed) is expected to increase motivation, and thereby lead to higher levels of PA.
41129432|NCT05661708|DRUG|Chitosan|Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect
41129433|NCT00548444|BIOLOGICAL|MVA85A|Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
41129434|NCT00548444|OTHER|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
41129435|NCT05477316|RADIATION|Radiation treatment|Radiation treatment of IMRT to the cerebellum and SRS to the cerebrum
41129436|NCT06445244|DIETARY_SUPPLEMENT|Alpha-ketoglutarate supplied as 1000mg capsule|AKG Double Wood® + lifestyle modification AKG Double Wood®: 500mg, qd, for one months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
41129437|NCT06445244|BEHAVIORAL|Behavioral: Lifestyle modification|Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
41129438|NCT02549807|DEVICE|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
41449535|NCT01597791|DEVICE|Foley catheter|Foley catheter placement after CSE.
40931953|NCT02127060|DRUG|Placebo drug|for 1 month postoperative period, placebo medication administered orally to the patients.
40931954|NCT04024384|DRUG|Daratumumab|Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
40931955|NCT05058495|OTHER|Mobile Lymphedema Self-Care Support Program|The Mobile Lymphedema Self-Care Support Program is composed of three section. First section includes the information about lymphedema and lymphedema self care. Second section includes the exercises videos which women can concurrently exercise with application and an alarm to remind to exercise. Last section is a social network form the women could chat and share anything with eachother. Patients will be told how to use the Mobile Lymphedema Self-Care Support Program and a contact number will be provided to ask questions about the program at any time.
40931956|NCT05058495|OTHER|standart lymphedema education|The control group will receive standard lymphedema education. The standard lymphedema education is an online education composed of information about lymphedema and lymphedema self-care.
40931957|NCT06089369|DRUG|Sintilimab (9 cycles)|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 9 cycles）
41278922|NCT06046560|BEHAVIORAL|Education-First|For the first 2-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 2 months, be invited to participate in the remote clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for therapy.
40931958|NCT06089369|DRUG|Sintilimab (18 cycles)|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles）
40931959|NCT06089369|OTHER|Active surveillance|Active surveillance
40931960|NCT04334109|BEHAVIORAL|Family Diabetes Self-Management Education and Support|Family Diabetes Self-Management Education and Support demonstrates the effectiveness of family-centered models of DSME that explicitly address diabetes self-management within a family context by educating both patients and family members and focusing on family motivational interviewing, family goal setting, understanding supportive and nonsupportive behaviors, and family behavioral changes.
40931961|NCT04334109|BEHAVIORAL|Standard Diabetes Self-Management Education and Support|Diabetes Self-Management Education and Support demonstrates the effectiveness of individual model DSMES that explicitly address diabetes self-management within an individual context by educating individual patients on individual motivational interviewing, individual goal setting, and individual behavioral changes.
40931962|NCT01606878|DRUG|Crizotinib|Given PO
40931963|NCT01606878|DRUG|Cyclophosphamide|Given IV
40931964|NCT01606878|DRUG|Dexrazoxane Hydrochloride|Given IV
40931965|NCT01606878|DRUG|Doxorubicin Hydrochloride|Given IV
41449536|NCT01597791|OTHER|No foley catheter|Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
40931966|NCT01606878|OTHER|Laboratory Biomarker Analysis|Correlative studies
40931967|NCT01606878|OTHER|Pharmacological Study|Correlative studies
40931968|NCT01606878|OTHER|Questionnaire Administration|Ancillary studies
40931969|NCT01606878|DRUG|Topotecan Hydrochloride|Given IV
40931970|NCT01606878|DRUG|Vincristine Sulfate|Given IV
40931971|NCT05301712|DRUG|Naloxone hydrochloride 5.0mg/5ml|"* Initial dose: 4mg, Intravenous injection~* Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4mg+8mg/day\*7=60mg"
41449537|NCT01591564|BEHAVIORAL|Interpersonal Psychotherapy for youth with SMD (IPT-SMD)|Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
41449538|NCT05519787|DEVICE|Central Veinous access devices' insertion|"Medical doctor should complete a questionnaire with medical history or any important clinical data that could help for the selection of the location of the port and catheter placement. The insertion will be planned only by a surgeon, interventional radiologist, or anaesthesiologist in the surgery block.~For the patient with a medical history of PICC line, PAC implantation, Central venous access device of any kind, or clinical risk of veinous compression (cervical or subclavian adenopathy, pelerine syndrome, mediastinal involvement...). An echo Doppler exam of the veinous cervical system is required before surgery. This exam should identify potential thrombosis that required a special treatment. It is important that the surgeon who will perform the device's insertion is aware of any history or risks of veinous thrombosis, stenosis, or phlebitis for the patient to avoid procedure's failure."
41449539|NCT00592969|DRUG|metformin|
41449540|NCT00592969|DRUG|biphasic insulin aspart|
41449541|NCT01545193|OTHER|Age and incidence of residual neuromuscular blockade|An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
41449542|NCT02856308|DEVICE|Hairstetics hair implant device|
40931972|NCT05301712|DRUG|Sodium Chloride 45mg/5ml|"* Initial dose: 4ml, Intravenous injection~* Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4ml+8ml/day\*7=60ml"
40931973|NCT00924170|DRUG|LMB-2|Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
40931974|NCT00924170|DRUG|Fludarabine|"Days 1-3:~Patients 1-7, 10-14, and \>18:25mg/m\^2/day Patients 8 - 9:30 mg/m\^2/day Patients 15- 17:20 mg/m\^2/day"
40931975|NCT00924170|DRUG|Cyclophosphamide|"Days 1-3:~Patients 1-7, 10 -14, and \>18:250 mg/m\^2/day Patients 8 - 9:300 mg/m\^2/day Patients 15-17:200 mg/m\^2/day"
40931976|NCT02780323|DRUG|CELBESTA®|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
41449543|NCT05638087|DRUG|Dexamethasone|Dexamethasone Oral Suspension
40931977|NCT02780323|DRUG|CELEBREX®|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
40931978|NCT02780323|DRUG|CELEBREX® placebo|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
40931979|NCT02780323|DRUG|CELBESTA® placebo|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
40931980|NCT04370483|DRUG|Leflunomide|Gievn PO
40931981|NCT04370483|OTHER|Quality-of-Life Assessment|Ancillary studies
40931982|NCT03103815|DRUG|Amivita|In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
40931983|NCT05024344|PROCEDURE|Erector Spinae Plane Block|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
40931984|NCT05024344|DRUG|Ropivacaine 0.5% Injectable Solution|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
40931985|NCT05024344|DRUG|Dexamethasone|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
40931986|NCT04341753|OTHER|pulmonary rehabilitation|"the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~- 2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
40931987|NCT01976988|DRUG|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
40931988|NCT06461429|DRUG|Erythromycin|Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
40931989|NCT06461429|DRUG|Amoxicillin and Erythromycin|Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
40931990|NCT06461429|DRUG|Azithromycin|Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
41278923|NCT05180812|DEVICE|ExoNet Tuned to Gravity Support|This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.
41278924|NCT04420884|DRUG|Dazostinag|Dazostinag intravenous infusion.
40931991|NCT06461429|DRUG|Caffeine citrate: Low dose|Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
41129439|NCT05141513|RADIATION|High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)|After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery.
41129440|NCT03926702|DRUG|Radiopharmaceuticals|All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
41129441|NCT03259516|DRUG|Nivolumab|1 mg/kg by vein on Days 1 and 15 of a 28 day cycle
41129442|NCT03259516|DRUG|Azacitidine|75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle
41129443|NCT03259516|DRUG|Fludarabine|25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.
41129444|NCT03259516|DRUG|Cyclophosphamide|300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
41129445|NCT03259516|DRUG|Cytarabine|10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle
41129446|NCT03259516|DRUG|all trans retinoic acid|45 mg/m2 per os daily during the whole course of treatment
41129447|NCT03259516|DRUG|Sildenafil|20 mg per os three times a day during the whole course of treatment
41129448|NCT03259516|DRUG|Melphalan|2 mg per os daily during the whole course of treatment
41129449|NCT03391024|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while navigated with clinically approved system.
41129450|NCT04611373|DRUG|Acetazolamide Levamisole|Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
41129451|NCT02189252|DRUG|Epanova|
41278925|NCT04420884|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
41129452|NCT02189252|DRUG|Lovaza|
41129453|NCT06109454|DRUG|Huaier granule|The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.
41129454|NCT06109454|OTHER|Control|The subjects received standard platinum dual drug chemotherapy.The subjects were treated with carboplatin injection (300mg/m2, intravenous injection, first day) combined with pemetrexed disodium (pathological type: adenocarcinoma, intravenous injection, 500mg/m2) or albumin bound paclitaxel (pathological type: squamous cell carcinoma, 260mg/m2, intravenous injection, first day) every three weeks, with a maximum of four cycles.
41278926|NCT04420884|DRUG|Platinum|Carboplatin or Cisplatin intravenous infusion
41278927|NCT04420884|DRUG|5-fluorouracil|5-fluorouracil intravenous infusion
41278928|NCT06179472|DEVICE|BALT GOLDBAL2 Balloon|Placement and retrieval of the GOLDBALLOON Detachable Balloon for severe CDH
41129455|NCT05397275|OTHER|progressive muscle relaxation+breathe exercises|progressive muscle relaxation+breathe exercises
41278929|NCT03871491|DRUG|Azithromycin|The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
41278930|NCT03871491|DRUG|Placebo|Identical appearing placebo, administered as a single oral dose directly after randomization.
41278931|NCT05878717|BIOLOGICAL|Belimumab|Belimumab will be administered.
40931992|NCT06461429|DRUG|Caffeine citrate: Medium dose|Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
40931993|NCT06461429|DRUG|Caffeine citrate: High dose|Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
40931994|NCT01360775|BEHAVIORAL|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
41129456|NCT05397275|OTHER|breathe exercises|breathe exercises
41129457|NCT05842382|DRUG|Active Ingredient|IV Vitamin C (12g/day)
41129458|NCT05842382|DRUG|Placebo|IV dextrose 5%
41278932|NCT05878717|OTHER|Placebo|.Placebo will be administered.
41278933|NCT06294028|OTHER|Adverse events collection|Collection of deaths from any cause, hospitalizations or emergency consultations for any event related to ventricular arrhythmia or its treatment (recurrence of ventricular tachycardia or complication linked to the defibrillator or crossover from one group to another)
41449544|NCT05638087|DRUG|Placebo Control|Placebo Oral Mix
41449545|NCT01861106|PROCEDURE|Allogeneic HSCT|Stem cell transplant
40755389|NCT06385834|OTHER|Evening aerobic exercise|Patients were randomly assigned to evening aerobic exercise training for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week. Each class consists of 10 minutes of warm-up training, 40 minutes of aerobic training and 10 minutes of relaxation training. The intensity of aerobic exercise training will be personalized. According to the guidance of relevant guidelines, the exercise intensity of patients will be determined according to the results of their first cardiopulmonary exercise experiment, and the exercise load will be gradually increased according to the exercise program until the predetermined goal is reached. Patient fatigue levels will be monitored throughout the exercise using the borg scale.
40755390|NCT03547232|DRUG|Indomethacin SR|Indomethacin SR 50mg given q12h from admission day 1 to day 7
40755391|NCT03547232|DRUG|Placebos|Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
40755392|NCT05639439|DEVICE|"Ventilation using the Fastrach intubating laryngeal mask airway and glottic view using fibrescope - Group A"|"Insertion of the intubating laryngeal airway device Fastrach, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
40755393|NCT05639439|DEVICE|"Ventilation using the Proseal laryngeal mask airway and glottic view using fibrescope- Group B"|"Insertion of the laryngeal airway device Proseal, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
40755394|NCT05639439|DEVICE|"Ventilation using the I-gel supraglottic airway device and glottic view using fibrescope- Group C"|"Insertion of the supraglottic airway device I-gel, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
40755395|NCT05639439|DEVICE|"Ventilation using the Protector laryngeal airway device and glottic view using fibrescope- Group D"|"Insertion of the laryngeal airway device Protector, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
40931995|NCT03608423|DEVICE|Minimally-invasive endoscopy-guided surgery|Surgery started within 8 hours of onset of spontaneous intracerebral hemorrhage.
41278934|NCT06294028|OTHER|Quality of life questionnaire EQ-5D-5L|"Questionnaire on the patient's quality of life and health in 6 questions: on mobility, the person's autonomy, current activities, pain, anxiety. Answers range from no problem to unable and 5 possible answers to each question.~The last question concerns the patient's health, the patient must rate his or her health on a scale of 0 to 100"
41278935|NCT06294028|OTHER|Medical-economic evaluation|"Collection of expenses incurred by the care of patients in each arm will be collected over a period of 36 months.~Direct medical and non-medical costs as well as costs related to absences from the workplace will be included in the analysis. Healthcare consumption will be collected using the National Health Data System (SNDS)."
41278936|NCT04119050|DRUG|M281|M281 injection administered as intravenous infusion
41278937|NCT04119050|DRUG|Placebo|Placebo administered as intravenous infusion
41278938|NCT05041335|OTHER|wet heparinzed suction|Needle flushed with 5000 Units in 10mL of heparin
41278939|NCT05041335|OTHER|Microsieve|A microsieve used for tissue preparation
41278940|NCT05041335|OTHER|No heparin flush|The needle not prepped
41278941|NCT05041335|OTHER|No microsieve|The tissue is placed into formalin
40931996|NCT02330328|OTHER|No Telemetry Monitoring|
41278942|NCT05018286|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
41278943|NCT06577441|PROCEDURE|Biospecimen Collection|Undergo buccal swab and blood sample collection
41278944|NCT06577441|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41278945|NCT06577441|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41278946|NCT06577441|DRUG|Decitabine and Cedazuridine|Given PO
41278947|NCT06577441|DRUG|Enasidenib|Given PO
41278948|NCT03282396|DRUG|Ibrutinib|Given PO
41278949|NCT05992467|BEHAVIORAL|Wellness Enhancement for Caregivers (WECARE)|WECARE behavioral intervention is guided by behavioral theories aimed to increase participants' caregiving mastery, enhance self-care, and improve psychosocial wellbeing. Participants will receive multimedia content on their WeChat account on cellphone or tablet, including short video clips, pictorial messages, short articles, and audio recordings 6 days a week, for 7 weeks.
41278950|NCT05888831|DRUG|BMS-986449|Specified dose on specified days
41449546|NCT01861106|DRUG|Busulfan Test dose|0.8 mg/kg IV infusion over 3 hours one time dose administered 5 to 14 days prior to start of preparative regimen (Days -11 to -20)
41453496|NCT00989053|DRUG|escitalopram|10 mg/d for a duration of 8 weeks
41278951|NCT05888831|DRUG|Nivolumab|Specified dose on specified days
41278952|NCT06411860|OTHER|Placebo|Participants will receive a subcutaneous (SC) injection of placebo.
41449547|NCT01861106|DRUG|Fludarabine (Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
41449548|NCT01861106|DRUG|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 3 hours once daily on Days -6, -5, -4 and -3 (weight based dosing). If in Arm B and if poor or very poor risk clonal chromosomal abnormalities, busulfan will also be given on day -2.
41449549|NCT01861106|DRUG|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing). For post-transplant, 50/kg IV once daily x2 doses on days +3 and +4
41449550|NCT01861106|PROCEDURE|Total Body Irradiation (TBI)|200 cGy on Day -1
41449551|NCT01861106|DRUG|Mycophenolate mofetil (MMF)|15mg/kg IV over 2 hours BID starting on day +5 will continue until day +35 (+/- 2 days)
40931997|NCT02330328|DEVICE|Telemetry Monitoring|
40931998|NCT03574324|DRUG|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy
40931999|NCT03574324|DRUG|CCRT+PF|Patients receive concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1-5 10:00-22:00) and 5-FU(800mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles
40932000|NCT00704275|DRUG|0.05% cyclosporin eye drop|bid dosage for 4 months
40932001|NCT06480162|PROCEDURE|Mechanical ventilation|After replacing the electrode, we'll monitor the EEG activity of the hippocampus and other cortex regions while weaning off mechanical ventilation.
40932002|NCT01422967|BEHAVIORAL|Balance and muscle strength|Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
40932003|NCT06432868|DIETARY_SUPPLEMENT|Solarplast (R)|Daily supplementation for 28 days prior to heavy resistance exercise.
40932004|NCT06432868|DIETARY_SUPPLEMENT|Placebo|Daily supplementation for 28 days prior to heavy resistance exercise.
40932005|NCT05238571|PROCEDURE|Re-surgery|Re-surgery with meshectomy and selective neurectomy
40932006|NCT05480774|DRUG|KRG hard capsule|Each subject was given orally 2 KRG hard capsules/day for 12 weeks
40932007|NCT05480774|DRUG|Placebo hard capsule|Each subject was given orally 2 placebo hard capsules/day for 12 weeks
40932008|NCT01505504|DRUG|mirtazapine|30 mg at bedtime
40932009|NCT03272269|DRUG|IMCY-0098|Small synthetic peptide for SC admin. Solvent: alum hydroxide
40932010|NCT03272269|OTHER|Placebo|Solvent: alum hydroxide
40932011|NCT05193357|DEVICE|home-based intermittent pneumatic compression (IPC) device|During the intervention, two programmed modes were used. The first mode, which mimics the MLD massage technique, begins with the inflation of the proximal chamber. After reaching the target pressure, the next chamber consecutively inflates while the initially inflated proximal chamber deflates. The inflation time of each chamber is 3 seconds with holding time of 1 second. The deflation and resting time of each chamber is 7 seconds (pressure setting: 40-60 mmHg). After 30 minutes of the first mode, the second mode, which is the conventional mode of sequential inflation from distal to proximal chambers while sustaining the pressure of the previously inflated chambers, was applied for 30 minutes (pressure setting: 80-100 mmHg, inflation time of each chamber: 6 seconds, holding time: 1 second, deflation time of each chamber: 7 seconds). Participants were instructed to use the IPC device with that 1-hour cycle twice a day for four weeks.
40932012|NCT05161351|DRUG|Baclofen|Baclofen is the only selective GABA-B agonist licensed for human use. Originally developed as a potential anti-epileptic in the 1920s, it was found to have anti-spastic effects and is currently used for the treatment of spastic movement, especially in instances of spinal cord injury, spastic diplegia, multiple sclerosis, and amyotrophic lateral sclerosis.
40932013|NCT05161351|DRUG|Vitamin D3|Placebo tablets will be vitamin D3, (colecalciferol).
40932014|NCT05029570|DEVICE|Conduction System Pacing (pacemaker implantation)|Conduction System Pacing (pacemaker implantation) and Atrioventricular node ablation
40932015|NCT04009083|DEVICE|Standard of Care MRI|Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies
41278953|NCT06411860|DRUG|Olpasiran|Participants will receive a SC injection of olpasiran at dose level 1 or 2.
41278954|NCT06411860|DRUG|Moxifloxacin|Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.
41278959|NCT06169124|PROCEDURE|Biospecimen Collection|Undergo archived tissue and blood sample collection
41278960|NCT06169124|PROCEDURE|Chest Radiography|Undergo chest x-ray
41278961|NCT06169124|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
41278962|NCT06169124|DRUG|Darolutamide|Given PO
41278963|NCT06169124|DRUG|Exemestane|Given PO
41278964|NCT06169124|DRUG|Leuprolide Acetate|Given IM
41278965|NCT06169124|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41449552|NCT01861106|DRUG|Tacrolimus|0.02mg/kg IV continuous infusion over 24 hours starting on day +5 until day +180
41449553|NCT01861106|BIOLOGICAL|Equine Anti-Thymocyte Globulin|(Deleted this intervention per amendment I): 30mg/kg IV (in the vein)once daily x 3 days on Days -6, -5, -4 (3 doses total)
41449554|NCT02856594|DRUG|Dexmedetomidine|Dexmedetomidine
41449555|NCT02856594|DRUG|Placebo|Placebo
41449556|NCT02179788|BEHAVIORAL|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
41453497|NCT00989053|DRUG|placebo|1 pill per day for 8 weeks
40932016|NCT04009083|OTHER|Fluciclovine PET scan added to MRI|18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
40932017|NCT05313152|DRUG|TAVO103A|TAVO103A single ascending dose IV infusion.
40932018|NCT05313152|OTHER|Placebo|Placebo single ascending dose IV infusion.
41278966|NCT06169124|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41278967|NCT05718102|OTHER|Population-health management|Population-health management
41278968|NCT06623981|BEHAVIORAL|Enhanced Brief Interpersonal Psychotherapy|Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual sessions carried out within an 8-12-week timeframe.
41449557|NCT02179788|DRUG|Metformin|"The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~* Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~* Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~* Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)"
41449558|NCT02179788|DRUG|Placebo|"The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~* Days 1-7, take 1 capsule with evening meal~* Days 8-14, take 3 capsules with evening meal~* Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
41449559|NCT03856320|BEHAVIORAL|Educational Video|An educational video describing obesity treatment options available in the VA.
40932019|NCT01373736|DRUG|123I-meta-iodobenzylguanidine|
41449560|NCT05674513|DRUG|Ulipristal acetate|Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
41449561|NCT00926887|DEVICE|Erchonia(R) EML Laser|Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
40932020|NCT02608333|BEHAVIORAL|ESDM-12|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
40932021|NCT02608333|BEHAVIORAL|control group|"heteregenous as usual community intervention"
40932022|NCT03652623|DRUG|TDF/FTC|In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
40932023|NCT04118582|OTHER|Body composition and resting metabolic rate analisys|
40932024|NCT03229460|OTHER|standard low flow therapy|In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
41129459|NCT01664806|DEVICE|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
40932025|NCT03229460|DEVICE|high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
41129460|NCT03516370|DRUG|Saccharomyces Boulardii 250 MG|all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
41278969|NCT06623981|BEHAVIORAL|Supplemented Usual Care|Usual care for caregivers with PHQ-9 scores 10-27 involves the asthma clinic physician discussing the PHQ-9 results with the caregiver, providing brief psychoeducation on depression and giving the caregiver a written list of mental health resources. Usual care will be supplemented by providing short-term care coordination. Care coordination will involve assisting the participant in calling a mental health clinic to make an appointment and one follow-up phone call within two weeks.
41278970|NCT05047172|DRUG|Ticagrelor + Aspirin|ticagrelor (180 mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
41278971|NCT05047172|DRUG|Rivaroxaban + Aspirin|low dose rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
41449562|NCT00926887|DEVICE|Placebo Laser|Inactive light
40755396|NCT03896932|OTHER|minipooled- Intravenous immunoglobulin(MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
40755397|NCT02202265|DIETARY_SUPPLEMENT|Olive oil|30ml a day of olive oil
41129461|NCT01837602|BIOLOGICAL|cMet RNA CAR T cells|
41129462|NCT06522737|DRUG|Duvelisib|oral capsules
41129463|NCT06522737|DRUG|Gemcitabine|solution for intravenous infusion
41129464|NCT06522737|DRUG|Bendamustine|solution for intravenous infusion
41129465|NCT03539952|DRUG|Penicillamine (D1-W12)|Penicillamine during baseline period (D1-W12)
41129466|NCT03539952|DRUG|TETA 4HCL (W12-60)|TETA 4HCL during post randomisation and 1st extension period (W12-W60)
41129467|NCT03539952|DRUG|Penicillamine (W12-W60)|Penicillamine during rondomisation and 1st extension period period (W12-W60)
41129468|NCT03539952|DRUG|TETA 4HCL (60-<W108)|TETA 4HCL during 2nd extension period (W60-\<W108)
41278972|NCT05047172|DRUG|Clopidogrel + Aspirin|clopidogrel (600mg loading dose, then 75mg daily) and aspirin (81mg daily)
41278973|NCT05047172|OTHER|Risk Factor Management|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.
41278974|NCT03977779|DEVICE|Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography|The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography
41449563|NCT02235922|OTHER|Dual task training|The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.
41129469|NCT03177941|OTHER|Eviderma Smart Phone Teledermatology Application (Eviderma)|First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.
41278975|NCT06621329|COMBINATION_PRODUCT|Transnasal sphenopalatine ganglion block|Transnasal sphenopalatine ganglion blocks will be performed using the Tx360 device. Medications used during the procedure include 0.75% bupivacaine with or without 1 mg of preservative free dexamethasone.
41449564|NCT02235922|OTHER|Conventional training|The conventional training consisted of individuals subjected to a multicomponent exercise program.
41449565|NCT04880616|DRUG|NBI-827104|Capsules for oral administration
41449566|NCT04880616|DRUG|Placebo|Capsules matching NBI-827104 for oral administration
41449567|NCT00873587|PROCEDURE|Chest tube pull on inspiration|Pull chest tube on Inspiration
41449568|NCT00873587|PROCEDURE|Expiration|Pull chest tube on Expiration
41449569|NCT00000653|DRUG|Zalcitabine|
41449570|NCT04856462|BEHAVIORAL|Education Support|Structured education is provided every other week (biweekly) to family caregivers over the course of 12 weeks, along with facilitated video-teleconferencing group meetings.
41129470|NCT00210106|DEVICE|Ablathermy|
41129471|NCT02860741|BEHAVIORAL|REJOICE|Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities
41278976|NCT05847881|BEHAVIORAL|Self-guided at home activities|After the kick-off meeting participants will complete the cultural probe kit for 3 weeks. This kit is a design research tool, to prompt participants to document, map, journal, and reflect on various aspects of daily lives. Following this, participants will attend a facilitated workshop and then complete the next at-home kits.
41278977|NCT06131372|DRUG|Cagrilintide|Participants will receive Cagrilintide subcutaneously.
41278978|NCT06131372|DRUG|Semaglutide|Participants will receive semaglutide subcutaneously.
41278979|NCT06131372|DRUG|Placebo|Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
41449571|NCT04856462|BEHAVIORAL|Phone Call|Participants will participate in an unstructored support group phone call
41449572|NCT03610542|BEHAVIORAL|Triggers for anxiety|Students learn about different triggers for anxiety, what the signs and indicators of anxiety are, and identify their own triggers for anxiety
41449573|NCT03610542|BEHAVIORAL|Identifying and challenging negative thoughts|Students learn about the types of unrealistic thoughts that underpin anxiety and how anxiety can be reduced with more realistic thoughts. Students identify their own unrealistic thoughts that contribute to anxiety and what more realistic thoughts can be used.
41449574|NCT03610542|BEHAVIORAL|Relaxation|Students are taught to relax through (1) breathing exercises, (2) progressive muscle relaxation, and (3) imagery. Student practice these techniques.
40755398|NCT02202265|DIETARY_SUPPLEMENT|Nuts|30g a day of nuts
41449575|NCT03610542|BEHAVIORAL|Goal Setting|Students learn how to set goals, monitor goal progress, and check when goals have been achieved. Students then identify their own goals.
41449576|NCT03610542|BEHAVIORAL|Overcoming avoidance|Students identify ways that they avoid anxiety-provoking situations (e.g., procrastinating exam study). Students develop plans for exposure to anxiety-provoking situations and learn study strategies to build confidence.
41449577|NCT05311072|PROCEDURE|pulmonary endarterectomy or balloon pulmonary angioplasty|A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
41449578|NCT05244720|DIAGNOSTIC_TEST|Fibroscan|A percutaneous scan, that measures shear wave velocity. It estimates liver stiffness.
40932026|NCT03229460|DEVICE|association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
40932027|NCT02753244|OTHER|Motion Based Cognitive Video Games Software|Intendu FBT motion based cognitive video games software
40932028|NCT02753244|OTHER|iPad Apps|Commercially available iPad game applications
40932029|NCT01967368|DRUG|Intanza|Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
40932030|NCT01967368|DRUG|Vaxigrip|Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
41278980|NCT06394193|BEHAVIORAL|Community-based participatory research intervention|Two training sessions (roughly two hours each) to train them in the intervention structure and curriculum
40932031|NCT01499862|DEVICE|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
40932032|NCT03817450|BEHAVIORAL|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention nursing homes.
40932033|NCT05054842|DRUG|Retagliptin phosphate tablets、metformin sustained-release tablets|Retagliptin phosphate tablets 100mg+ metformin sustained-release tablets 1500mg or 2000mg based on prior medication
40932034|NCT05054842|DRUG|Retagliptin phosphate placebo tablets、metformin sustained-release tablets|Retagliptin phosphate 100mg placebo tablets + metformin sustained-release tablets 1500mg or 2000mg based on prior medication
40932035|NCT01504061|OTHER|Mederma N&I|Topical gel applied three times a day for eight weeks.
40932036|NCT01504061|OTHER|Mederma Ultra Gel|Topical gel applied once daily for eight weeks.
40932037|NCT02008578|BIOLOGICAL|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|
40932038|NCT02008578|BIOLOGICAL|Placebo|
40932039|NCT02915328|DEVICE|Filterwire EZ™|
40932040|NCT02915328|DEVICE|MO.MA Ultra|
41449579|NCT05244720|DIAGNOSTIC_TEST|Blood samples|Blood samples to asses the function of liver, kidney and bone marrow, as well as nutrition/vitamin status.
40932041|NCT02915328|DEVICE|Stent Roadsaver®|
40932042|NCT02915328|DEVICE|Carotid Wallstent|
40932043|NCT04951739|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy involves an initial incision on the internal lining of the oesophagus. This permits entry of the endoscope to within the wall of the oesophagus, where the muscle will be exposed. The inner layer of the muscle near the lower oesophagal sphincter will be cut (this is termed myotomy). At the conclusion of the procedure, the oesophagal incision will be closed with standard endoscopic clips.
40932044|NCT03393533|PROCEDURE|Group I|Extraction third molar without the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
40932045|NCT03393533|PROCEDURE|Group II|Extraction third molar with the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
40932046|NCT04637009|DRUG|TAS1553|Form: tablet; Route of Administration: oral
40932047|NCT01623986|DEVICE|Mespere Venus 1000 System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)
40932048|NCT01623986|DEVICE|Echocardiography machine|Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
40932049|NCT00706069|DRUG|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
40932050|NCT00706069|DRUG|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
40932051|NCT03239561|DRUG|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of \[18F\]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
41449580|NCT00907387|DRUG|RT001|Dose A RT001
41449581|NCT00907387|DRUG|RT001|Dose B RT001
41449582|NCT00907387|OTHER|Placebo|Dose C Placebo
40932052|NCT00297024|PROCEDURE|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
40932053|NCT03560739|COMBINATION_PRODUCT|ofatumumab with PRF|ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)
40932054|NCT03560739|COMBINATION_PRODUCT|ofatumumab with AI|ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)
40932055|NCT02762851|OTHER|Sterile saline|0.5 ml dose injected intramuscularly
40932056|NCT02762851|DRUG|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
40932057|NCT05475782|PROCEDURE|Spyglass-guided lithotripsy|Spyglass-guided lithotripsy
40932058|NCT05475782|PROCEDURE|ESWL|ESWL+ERCP
40932059|NCT05954104|DRUG|Calcipotriol|To evaluate the efficacy of Calcipotriol on Alopecia Areata.
40932060|NCT04584307|DRUG|Elotuzumab|Elotuzumab 10-20mg/kg
40932061|NCT04584307|DRUG|Pomalidomide|Pomalidomide 2mg
40932062|NCT05757362|OTHER|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation (cq-HEPT)|An online application of the developed questionnaire form
40932063|NCT02029690|DRUG|ADI-PEG 20|
41449583|NCT02734511|DRUG|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
41449584|NCT06628258|OTHER|Moiz Cleansing Lotion|"Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry.~Frequency: Twice a Day Route of Administration: Topical."
41129472|NCT02860741|OTHER|Control|Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
41129473|NCT02380105|BEHAVIORAL|Counseling|Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
41129474|NCT02380105|DEVICE|Interocclusal Appliances|Patients were treated using interocclusal appliances
41129475|NCT05641506|DRUG|Yangzheng Xiaoji|Chinese patent medicine Yangzheng Xiaoji capsule， 0.36g\*4 tid，28 days as one cycle，up to 3 cycles.
41449585|NCT05979662|PROCEDURE|Endoscopic frontal sinus surgery grade 6(Draf III).|Patients will receive endoscopic frontal sinus surgery grade 6(Draf III).
41449586|NCT05979662|PROCEDURE|Endoscopic frontal sinus surgery grade 1-3(Draf I or IIa)|Patients will receive endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).
41449587|NCT06389448|DEVICE|pCLE-gastr|After identifying the location of the lesion through white light endoscopy, the pCLE operation is performed to acquire images from the specific gastric lesions, and finally the ESD routine is performed.
41449588|NCT04132115|DRUG|Piperacillin/tazobactam|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
41449589|NCT04132115|DRUG|Meropenem|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
40755399|NCT02202265|DIETARY_SUPPLEMENT|Control diet|Diet based on standard guidelines
40932064|NCT05648253|DEVICE|Hyivy Intravaginal Device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
41129476|NCT05641506|DRUG|Niraparib|"Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL."
41129477|NCT02941549|OTHER|Placebo capsules|
41129478|NCT02941549|DRUG|Epeleuton|
41129479|NCT05739370|OTHER|Problem-Solving Therapy for Older Adults|"Problem-Solving Therapy for Older Adults (Ger-iPST) is an 8-week online psychotherapy program with online therapist support delivered through the Online Psycho Therapy Tool (OPTT). Ger-iPST has several evidence-based elements tailored to the specific needs of older adults, including relevant content (e.g. aging-related examples); process adaptations (e.g. more repetition); and digital usability modifications (e.g. high-contrast text).~Ger-iPST contains therapy modules assigned weekly and accessible at any time during the week. Modules begin with a brief, guided mindfulness relaxation exercise, followed by approximately 20 slides taking, on an average 1 hour to complete. Each module highlights a different step of Psychotherapy (PST) and includes an overview of a new skill, interactive activities and examples. A homework exercise designed to guide participants in applying a new PST skill exercise is submitted through the platform, and a clinician will provide personalized feedback."
41129480|NCT01115036|DRUG|panobinostat|Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.
41129481|NCT01802424|BEHAVIORAL|The Friends program|The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
41129482|NCT06430021|BIOLOGICAL|blood sample|8 mL blood sample in EDTA tube
41129483|NCT00488566|DRUG|GSK drug|GSK drug
41129484|NCT00488566|OTHER|Placebo|Placebo
41129485|NCT00488566|OTHER|Lamictal|Positive control
41129486|NCT05662436|OTHER|Open Sky School program|Teachers lead students in 2 hours of outdoor activities per week for 12 weeks, as detailed in the arm description
41129487|NCT01340066|DRUG|UISH001|sublingual dosing, 1 drop 3 times a day
41129488|NCT01340066|DRUG|matching placebo|sublingual dosing,1 drop 3 times a day
41129489|NCT05986994|OTHER|Metabolic acidosis|Metabolic acidosis at birth with umbilical cord arterial pH at birth \< 7.12
41129490|NCT05986994|DIAGNOSTIC_TEST|microRNA|Evaluation of microRNA levels
41129491|NCT05986994|OTHER|Hypothermia|Therapeutic induced hypothermia refers to a lowering of the central body temperature for therapeutic purposes
41129492|NCT00982072|DRUG|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
41129493|NCT00982072|DRUG|prednisolone|Prednisolone 1mg/kg maximum 60mg od
40755400|NCT03594656|DRUG|Ganoderma|0.8g twice daily
40755401|NCT03594656|DRUG|Placebos|0.8g twice daily
40755402|NCT04744129|DRUG|NN414|To investigate the role of NN414 on cerebral hemodynamic in migraine patients
40755403|NCT04744129|DRUG|Saline|To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.
40755404|NCT03309111|BIOLOGICAL|ISB 1342|ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)
40755405|NCT01120444|DEVICE|BD Research Catheter with 34G x 1.5 mm needle|bolus injection of insulin given intradermal prior to standardized meal
40932065|NCT01211587|DRUG|safinamide|Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
40932066|NCT01211587|DRUG|placebo|Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
40932067|NCT04552262|DRUG|BAY2327949|Single dose of 90 mg BAY2327949
40932068|NCT04552262|DRUG|Placebo|Single dose of placebo to BAY 2327949
41129494|NCT05900505|OTHER|Social Navigator|The social navigator will assess patient/family needs and help them to access community resources (specific to their community) to address these, while promoting their engagement and self-efficacy.
41129495|NCT01644032|OTHER|Teleconsultation|Teleconsultation between paramedics and an EMS physician
41129496|NCT03836105|DRUG|cemiplimab|No investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions.
41129497|NCT02922088|DEVICE|DuraGraft|DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.
41129498|NCT02339259|OTHER|Observation|
41129499|NCT00667316|BEHAVIORAL|Set of questionnaires (respondent)|A set of questionnaires to determine risk factors for sick leave due to low back pain.
41129500|NCT05298371|BEHAVIORAL|Corrected Sitting postures|Change after being in Corrected Sitting postures
41129501|NCT05298371|BEHAVIORAL|Natural / relaxed sitting postures|Change after being in relaxed sitting postures
41129502|NCT05298371|BEHAVIORAL|Corrected Standing posture|Change after being in Corrected Standing posture
41129503|NCT05298371|BEHAVIORAL|Natural / relaxed standing postures|Change after being in relaxed standing postures
41129504|NCT02972359|DRUG|Neridronic acid|Neridronic acid administered as intravenous infusion.
41129505|NCT03282045|DRUG|Lysobact Complete Sprey|Inhaling spray
41129506|NCT03282045|DRUG|Tantum Verde® Spray|Inhaling spray
41278981|NCT06519929|PROCEDURE|ESP block with catheter using ropivacaine (bolus followed by continuous infusion)|A total of ropivacaine 75mg will be injected into the plane via the needle, followed by placement of a catheter 3-5 cm into the plane. A continuous infusion of ropivacaine 0.2% will be started at 8 mL/h and may be titrated up to a maximum of 10mL/h. Bolus doses of 5 mL using ropivacaine 0.2% will be permitted for breakthrough pain (pain score ≥ 7/10) and may be administered no more frequently than every 6 hours. Patients will be assessed for LAST twice daily by asking about tinnitus, perioral numbness, or metallic taste. Any patient who responds positively to these symptoms will have infusion stopped for 2 h and then restarted at a rate 2 mL/h lower. If the symptoms occur again, the catheter infusion will be stopped and the catheter removed. After the 72-hour study period the ESP catheter may remain in place if the patient has ongoing analgesia needs or if analgesia is controlled with oral medication the catheter may be removed at request of the treating team.
41278982|NCT06519929|DRUG|Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h|A bolus of 1 mg/kg based on ideal body weight will be given over 10 minutes with a physician present and infusions will be started at 1 mg/kg/h based on IBW. Infusions will run continuously for the first 72 h and can be continued beyond that at the discretion of the treating team if pain persists. Patients will be assessed for LAST twice daily. Any patient with suspected LAST will have lidocaine infusion stopped and a lidocaine plasma level will be sent. If symptoms resolve, the lidocaine infusion can be restarted at a rate 25% lower. If pain is refractory to the lidocaine infusion and multimodal adjuncts, the infusion may be increased to a maximum of 1.5 mg/kg/h (during first 24 h only). The actual duration of the infusion as well as total lidocaine dose given in mg will be recorded. Stopping criteria for lidocaine will include the occurrence of new EKG changes for which an alternative explanation is not more likely as well as LAST symptoms.
40932069|NCT05609812|DRUG|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
41129507|NCT03282045|DRUG|Pharyngal® Oromucosal Spray|Inhaling spray
41129508|NCT03282045|DRUG|Placebo|Inhaling spray
41129509|NCT01217866|PROCEDURE|Laparoscopic assisted vaginal hysterectomy|Surgical removal of uterus vaginally
41129510|NCT00415688|BEHAVIORAL|Low carbohydrate, ketogenic diet|
41129511|NCT00415688|BEHAVIORAL|Low glycemic index, reduced calorie diet|
41129512|NCT04539015|DEVICE|Prevena Plus|PREVENA Plus is a negative pressure wound therapy device intended for use on surgical incisions that continue to drain following sutured or stapled closures.
41129513|NCT02201888|BEHAVIORAL|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
41129514|NCT02201888|OTHER|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
41129515|NCT02201888|OTHER|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
41129516|NCT04755920|DRUG|SGM-101|Fluorescence-guided surgery
41129517|NCT02707666|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab every 21 days for three cycles
41129518|NCT02707666|DRUG|Cisplatin and Pemetrexed|Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
40932070|NCT05609812|DRUG|Placebo|placebo
41449590|NCT04132115|DRUG|Daptomycin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
41449591|NCT04132115|DRUG|Ceftobiprole|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
41449592|NCT04132115|DRUG|Linezolid|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
41449593|NCT04132115|DRUG|Vancomycin|Therapeutic drug monitoring(TDM) of this antibiotic plasma concentration
41449594|NCT04132115|DRUG|Fluconazol|Therapeutic drug monitoring (TDM) of this antifungal plasma concentration
41449595|NCT04132115|DRUG|Acyclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
41449596|NCT04132115|DRUG|Gentamicins|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
41449597|NCT04132115|DRUG|Amikacin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
41449598|NCT04132115|DRUG|Ganciclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
41449599|NCT02482922|OTHER|Exercise & Dietary Supplement|
41449600|NCT06078748|BEHAVIORAL|EX|"EX involves 2.5hrs of moderate intensity aerobic and resistance exercise per week. EX will be instructed by a clinical exercise physiologist (CEP) or registered kinesiologist (RKIN). The EX session will include a 5min warm-up, 20-30min of moderate intensity aerobic exercise, 20-30min of moderate intensity resistance training, and a 5min cool down. The virtual video session will be pre-recorded, have similar composition, and will be led by the same instructor as the group sessions. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on exercise in order to overcome barriers and increase maintenance of lifestyle changes."
41449601|NCT06078748|BEHAVIORAL|DIET|"DIET involves one session per week of diet education delivered by a Registered Dietitian. The DIET session will be 90 minutes during months 1-4, and 30 minutes in months 5 and 6. DIET was developed by our team, emphasizing foods identified as supporting executive function, memory, and other cognitive abilities. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on diet in order to overcome barriers and increase maintenance of lifestyle changes."
41449602|NCT06078748|BEHAVIORAL|STRETCH|STRETCH sessions will be time/frequency-matched to EX sessions (2.5hrs/week: 1.5hr in virtual group sessions; 1hr virtual video session) to control for social aspects and placebo effects of EX.Each STRETCH session will include a 5min warm-up, 5min of balance exercises, and 50min of stretching. Difficulty will not be progressed. STRETCH sessions will also be led by a CEP/RKIN instructor and video sessions will be pre-recorded by the same instructor.
41449603|NCT06078748|BEHAVIORAL|ED|ED sessions designed to be of equal intensity and social engagement to the DIET intervention. Participants will engage in group discussion and receive information on the brain and cognitive processes, the effect of age on cognition, and tips to promote healthy aging. This will include lectures, watching documentaries and participating in various games.
41449604|NCT06415903|DRUG|TQB3117 tablets|TQB3117 is a protein inhibitor.
40755406|NCT01120444|DEVICE|Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set|bolus delivery of insulin given subcutaneously prior to standardized meal
40755407|NCT02079285|PROCEDURE|EUS-FNA|
40755408|NCT02012777|DRUG|propranolol|Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
41449605|NCT02939703|OTHER|Diet|Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
41449606|NCT02452463|BIOLOGICAL|Durvalumab|Given IV
41449607|NCT02452463|DRUG|Nintedanib|Given PO
41449608|NCT02452463|OTHER|Placebo|Given PO
41449609|NCT02452463|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
41449610|NCT05251805|PROCEDURE|Blood, bone marrow and lung tumor tissue collection|"Blood sampling: 12ml of blood will be collected during the routine pre-operative blood collection~Bone marrow aspiration during thoracic surgery: following the surgical intervention, bone marrow aspiration will be performed through the incisions made for the thoracic procedure. The ribs lying directly above and below the trocar incision will be exposed. A bone marrow needle will be advanced into the periost until the needle tip reaches the bone marrow. After removing the stylet a 2ml syringe will be attached to the aspiration needle and 0.5ml to 2ml of bone marrow will be aspirated before removing the needle. This procedure will be repeated twice for every trocar site, for a maximum of 3 trocar sites, or until 5ml of bone marrow aspirate is obtained.~Lung tumor collection: all surgical samples will be analyzed by our anatomopathological department. Viable and fresh material, not used for the diagnostic purposes, will be sent to the LMCT."
41449611|NCT03097445|DRUG|Nicotine patch|mailed 5-week course of Habitrol® transdermal nicotine patches
40755409|NCT04124510|DRUG|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
40755410|NCT03031730|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40755411|NCT03031730|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
40755412|NCT03031730|DRUG|Carfilzomib|Given IV
40755413|NCT03031730|DRUG|Dexamethasone|Given PO
41449612|NCT04193241|PROCEDURE|Closure of chest tube wound|At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space
41449613|NCT05196347|DRUG|Dapagliflozin|In dapagliflozin arm, subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip \<20%.
41449614|NCT06365086|DEVICE|Personalized brain state-dependent single-pulse TMS|Single-pulse TMS will be applied to the right hemisphere during brain activity patterns associated with strong and weak corticospinal tract activation
41129519|NCT03926624|DRUG|DFP-10917|DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
41449615|NCT06094764|DEVICE|Group A|The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group A will be fitted with a cooling and bio-harness. At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.
41449616|NCT06094764|DEVICE|Group B|The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group B will wear a bio-harness and no cooling vest.At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.
41449617|NCT05291234|DRUG|ABBV-916|Intravenous administration
41449618|NCT05291234|DRUG|Placebo|Intravenous administration
41449619|NCT02518945|DRUG|Dapagliflozin|Dapagliflozin or Farxiga is a SGLT-2 inhibitor
41449620|NCT02518945|DRUG|Insulin|
41449621|NCT02518945|DRUG|Liraglutide|Victoza(Liraglutide) is a GLP-1 agent.
41449622|NCT02518945|DRUG|Dapagliflozin placebo|Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
41449623|NCT05878080|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
41449624|NCT01874535|DRUG|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
41449625|NCT01149057|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
41449626|NCT04516460|DEVICE|Interventional arm: endoscopic resection plus PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection of colorectal neoplastic lesions
41449627|NCT00879164|DRUG|bupivacaine hydrochloride|
41449628|NCT00879164|OTHER|questionnaire administration|
41449629|NCT01917227|BEHAVIORAL|Video|
41449630|NCT05244876|BEHAVIORAL|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
40932071|NCT00755911|BIOLOGICAL|Tissue Repair Cells (TRC)|30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
40932072|NCT00755911|DEVICE|Control|Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
40932073|NCT03575481|DIAGNOSTIC_TEST|The RAT and The TST|The RAT (ReoGo; Motorika Medical, Caesarea, Israel) The TST protocol included the conventional, repetitive, task-oriented training of the affected arm.
41129520|NCT03926624|DRUG|Cytarabine|cytosine arabinoside (ara-C)
41129521|NCT03926624|DRUG|Azacitidine|Azacitidine
41129522|NCT03926624|DRUG|Decitabine|Decitabine
41129523|NCT03926624|DRUG|Mitoxantrone|Mitoxantrone
41129524|NCT03926624|DRUG|Etoposide|Etoposide
41129525|NCT03926624|DRUG|Fludarabine|Fludarabine
41129526|NCT03926624|DRUG|Idarubicin|Idarubicin
41129527|NCT03926624|DRUG|Venetoclax|Venetoclax
41129528|NCT03926624|DRUG|Cladribine|Cladribine
41129529|NCT03197649|PROCEDURE|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
41129530|NCT03789071|DIAGNOSTIC_TEST|External ultrasound evaluation of the airway|Patients scheduled to have surgery under general anesthesia in whom tracheal intubation is planned, will have a clinical and ultrasound assessment of the airway before surgery. Information regarding laryngoscopy in the operating room will be recorded.
41129531|NCT03510052|BEHAVIORAL|Diet Modification Pilot Program (DPM)|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
41129532|NCT04366024|OTHER|other|clinical diagnosis
41129533|NCT02877641|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
41129534|NCT02877641|OTHER|Laboratory Biomarker Analysis|Correlative studies
41129535|NCT02877641|DIETARY_SUPPLEMENT|Multivitamin|Given PO
41129536|NCT02877641|OTHER|Placebo|Given PO
41129537|NCT02877641|OTHER|Questionnaire Administration|Ancillary studies
41129538|NCT00894894|DRUG|MP-470|escalating daily doses of amuvatinib
41129539|NCT00894894|DRUG|amuvatinib (MP-470)|escalating doses of daily amuvatinib
41449631|NCT04879381|OTHER|Sputum samples|During consultation, one expectoration will be performed.
41449632|NCT00637533|PROCEDURE|Lumbar sympathetic block with Botulinum Toxin type A|
41449633|NCT02901028|OTHER|Laboratory testing|Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
41449634|NCT02901028|OTHER|Blood and Urine Draws|subjects will have a blood draw and provide a urine sample
41449635|NCT06562101|PROCEDURE|Intra-articular Stromal Vascular Fraction Injection|Adipose tissue was harvested using the Q-graft system (Human Med®) from the abdominal subcutaneous fat of patients under local anesthesia. After concentration and resuspension in normal saline, 5 mL of the SVF suspension was injected into the knee joint cavity under sterile conditions.
41449636|NCT06560983|OTHER|The investigators are planning to do a observational cohort study, hence won't be doing any intervention.|The investigators won't be doing any intervention since this is an observational study.
40932077|NCT04954170|DIAGNOSTIC_TEST|IRRTM|IRRT at maximal 90° abduction and maximal external rotation is performed with the shoulder at maximal 90° rotation and the elbow flexed to 90° (Fig. 2). The patient is then asked to resist the external rotation force applied perpendicular to the forearm by the investigator. The test is considered positive if the patient could not hold the position or if he or she showed weakness of resisted internal rotation compared with the other side. It should be noted the maximal 90° abduction and maximal external rotation is active range of motion. Passive motion may affect the result of the test because of severe pain.
40932078|NCT04954170|DIAGNOSTIC_TEST|the lift-off test|The lift-off test is performed by placing the hand of the affected arm on the back (at the position of the midlumbar spine) and asking the patient to internally rotate the arm to lift the hand off the back \[9\]. The test is considered positive if the patient is unable to lift the arm posteriorly off the back or if he or she performs the lifting manoeuvre by extending the elbow or the shoulder. Weakness is also as a positive result.
40932079|NCT04954170|DIAGNOSTIC_TEST|the belly-press test|The belly-press test is performed with the arm at the side and the elbow flexed to 90°, by having the patient press the palm into his or her abdomen by internally rotating the shoulder \[3, 5\]. The test is considered positive (1) if the patient shows a weakness in comparison with the opposite shoulder or (2) the patient pushes the hand against the belly by wrist flexion, despite instruction to the contrary.
40932080|NCT04954170|DIAGNOSTIC_TEST|the IRLS test|IRLS test is evaluated with the affected arm of the patient was held by the examiner at maximum internal rotation \[10\]. The back of the hand is then passively lifted away from the body until almost full internal rotation is reached. Then, the patient is asked to actively maintain this position. The test is considered positive when the patient fails to maintain the position and the hand lagged.
40932081|NCT04954170|DIAGNOSTIC_TEST|the bear-hug test|The bear-hug test is performed with the palm of one side placed on the opposite shoulder and fingers extended and the elbow positioned anterior to the body \[3\]. The patient is then asked to hold that position when the examiner tried to pull the patient's hand from the shoulder with an external rotation force applied perpendicular to the forearm. The test is considered positive if the patient could not hold the hand against the shoulder or if he or she showed weakness compared with the other side.
40932082|NCT04954170|DIAGNOSTIC_TEST|IRRT 0°|IRRT at 0° abduction and 0° external rotation is performed with the arm at the side and the elbow flexed to 90° (Fig. 1). The patient is then asked to resist the external rotation force applied by the investigator. The test is considered positive if the patient could not hold the position at the side or if he or she showed weakness of resisted internal rotation compared with the other side. The test is negative if patients only complain of pain.
41129540|NCT00846222|PROCEDURE|Hypothermia|Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
40755414|NCT03031730|DRUG|Dexamethasone Sodium Phosphate|Given IV
40755415|NCT03031730|PROCEDURE|Echocardiography|Undergo echocardiography
40755416|NCT03031730|DRUG|Lenalidomide|Given PO
41129541|NCT00724399|BEHAVIORAL|Survey on womens health Issues.|Cardiovascular health.
40755417|NCT03031730|DRUG|Navtemadlin|Given PO
41129542|NCT03905642|DRUG|Arikayce™|Amikacin (aminoglycoside) in a liposomal formulation.
41449637|NCT00828321|DRUG|Ramipril 10 mg capsule|1 x 10 mg
41449638|NCT00828321|DRUG|Altace® 10 mg capsule|1 x 10 mg
40755418|NCT05624957|DRUG|Lidocaine epinephrine|Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
40755419|NCT05624957|DRUG|Epinephrin|0.25 mg epinephrine mixed with one litre of fluid irrigation
40755420|NCT03434301|DEVICE|ReliaTack™|Absorbable tack (ReliaTack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
40755421|NCT03434301|DEVICE|Protack™|Non-absorbable tack (Protack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
40932083|NCT04954170|DIAGNOSTIC_TEST|Diagnostic arthroscopy|At the time of surgery, general anaesthesia was administered and the patient was placed in beach-chair position. A complete arthroscopic exploration of the glenohumeral joint and the subacromial space was performed through a standard posterior portal. The senior author performed a complete arthroscopic exploration. Arthroscopic evaluation of the rotator cuff was considered the gold standard for making the definitive diagnosis. Evaluation of the SSC was carried out with both a 30° arthroscope and a 70° arthroscope.
40932084|NCT03472443|OTHER|acupuncture|Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
40932085|NCT02724670|RADIATION|IGRT|MR-based IGRT
40932086|NCT02355873|DEVICE|AN69ST hemofilter|
40932087|NCT02355873|DEVICE|AN69 hemofilter|
40932088|NCT06214494|OTHER|Blood Flow Restricted High Intensity Treadmill Training|Blood Flow Restricted High Intensity Treadmill Training at 70% limb occlusion (on hemiparetic limb only) 2x weekly for 16 Sessions totaling minimum of 75 minutes weekly.
40932089|NCT06214494|OTHER|HITT|High Intensity Treadmill Training 2x weekly for 16 Sessions totaling minimum of 75minutes weekly.
40932090|NCT00738621|DRUG|Aprepitant, Dexamethasone, Ondansetron|Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
40932091|NCT00738621|DRUG|Aprepitant, Dexamethasone, Placebo|Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
40932092|NCT01511666|DEVICE|Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS|ECLS states for extracorporeal life support.
40932093|NCT01511666|OTHER|Standard care|Standard care as per recent guidelines will be provided.
40932094|NCT04577339|PROCEDURE|Laparotomy or laparoscopy|"Laparotomy is the opening of the abdominal cavity usually through a midline incision.~Laparoscopy is using minimal access keyhole surgery to perform the surgery instead of laparotomy Interventional radiology is the use of imaging to perform a procedure on the abdomen without surgery, for example, using ultrasound to guide a needle to drain an abscess Best supportive care is usually end-of-life care concentration on relieving symptoms rather than treating the cause."
40932095|NCT01362595|DRUG|leucine|"Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day"
40932096|NCT02162576|DEVICE|Propeller Health intervention|The Propeller intervention works through the provision of information to patients and their providers. With the Propeller sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp and geographic location. Actuation data are then securely transmitted to Propeller Health where the information is also compiled into individual reports via mobile apps, online dashboards, email reports and text message reminders that are returned to the patient. This communication provides an ongoing assessment of their management based on the national guidelines, together with personalized information to help encourage and support self-management. Each participant was invited to share reports with his or her healthcare provider, but this was not required.
40932097|NCT03662243|BEHAVIORAL|Multicomponent reading and writing treatment|Intervention procedures incorporated into the program include drilling on sight words to improve immediate recognition of common words; engaging in Multiple Oral Reading procedures to increase reading fluency; practicing oral spelling of sight words to improve spelling accuracy; generating written sentences to improve accurate spelling and use of written conventions (e.g., punctuation, capitalization); and summarizing and subsequently writing sentences about read material to establish strategies to enhance reading comprehension and promote written expression.
40932098|NCT00800462|DRUG|Oxybutynin Cl|15 mg qd for 3 months
40932099|NCT00800462|DRUG|Trospium Cl|20mg bid for 3 months
40932100|NCT00800462|DRUG|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
40932101|NCT01476202|DRUG|nicotine|nicotine in the form of a mouth strip, lozenge and gum
40932102|NCT00821327|DRUG|Gemcitabine, Cisplatin, Sunitinib|"Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity."
40932103|NCT05623488|DRUG|huCART-meso cells|Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains
40932104|NCT05623488|DEVICE|Mesothelin Expression Testing|Laboratory Developed Test
41278983|NCT04341571|DIETARY_SUPPLEMENT|Probiotics|Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.
40755422|NCT03302936|DRUG|Phenazopyridine|to be given preoperatively
41449639|NCT03783663|BEHAVIORAL|Misfit Shine 2|The intervention group was given a Misfit Shine 2 to monitor sleep throughout the 12-week intervention period. Participants were instructed to wear the device on the wrist, which is better for capturing sleep than the other wear locations. Participants were instructed on how to self-monitor total sleep time and select a goal for that behavior. Further, participants were asked to view feedback on their sleep time daily on the Misfit smartphone app, which they used to monitor their progress toward achieving their behavioral goals.
40932105|NCT01736657|DEVICE|Red blood cell exchange in sickle cell|One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
40932106|NCT03375229|OTHER|Dry Needling|"It will be used acupuncture needles, individually packaged and sterilized, with 0.25 mm of thickness and 0.40 mm of length. The therapist will perform the grip in upper trapezius on the site of one of the two previously marked locations, according to the subject group allocation, and will insert the needle in the skin with help of a guide tube and will deepen the needle approximately 10 to 15 mm inside the trigger point. The needle will be moved up and down as in the fast-in and fast-out technique described by Hong and the movement will be repeated during 30 seconds in a cadence of approximately 1 Hz. The protocol will be the same for the groups that will receive the application directly on the trigger point and for the group that will receive the application away from the trigger point"
40932107|NCT03375229|DEVICE|Low-Level Laser Therapy|The laser protocol used the PainAway Laser™ cluster equipment composed of one pulsed infrared laser of 905 nm, four red LEDs of 640 nm, and four infrared LEDs of 875 nm, with full device aperture of 4 cm2, total delivered energy of 39,8 J, a magnetic field of 35 Mt and treatment time of 300 seconds. The equipment was turned on only for the DNP group and it remained in slight contact with the skin during 300 s for all groups.
40932108|NCT01041378|DRUG|dexamethasone|Intravenous dexamethasone (0.5mg/kg) before incision
40932109|NCT04564131|OTHER|Reflexology|"* Hands are washed.~* The individual is provided to be in a comfortable position to lie down or to be in a semi-sitting position.~* The toes of the patient are crossed and the patient's feet are placed at our chest level when we sit.~* Depending on the size of the foot, a slightly moisturizing amount of non-allergenic petroleum jelly is taken, and it is spread to provide slipperiness.~* Exercises to warm and relax the feet for five minutes.~* General massage is applied to the whole foot for five minutes.~* Reflexology massage is applied to the application areas for neuropathic pain.~* The individual is helped to take a comfortable position.~* Hands are washed."
40932110|NCT04564131|OTHER|Control|No intervention was performed to reduce pain in the control group
40932111|NCT02197455|DRUG|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
40932112|NCT03722043|BEHAVIORAL|Parenting Program|Parents will participate in a 5-week parenting program designed to uniquely work with veteran families. The program will target the following areas: mindful parenting strategies, emotional regulation, positive discipline, positive parenting/attachment, and sleep.
40932113|NCT00119873|BIOLOGICAL|VRC-HIVADV014-00-VP|
40932114|NCT00223236|DRUG|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
40932115|NCT00223236|DRUG|Placebo|Placebo matching active medication in all other aspects.
40932116|NCT03280043|PROCEDURE|Hematoma|Hematoma requiring return to operating room.
40932117|NCT02898584|OTHER|BP Track|
40932118|NCT00539097|DIETARY_SUPPLEMENT|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
40932119|NCT02249247|DRUG|Low dose of BIIL 284 BS tablets|
40932120|NCT02249247|DRUG|Medium dose of BIIL 284 BS tablets|
40932121|NCT02249247|DRUG|High dose of BIIL 284 BS tablets|
40932122|NCT02249247|DRUG|Placebo|
41129543|NCT03594305|BEHAVIORAL|Educational seminar|Religious leaders will be invited to participate in a one-day seminar led by Tanzanian religious leaders and physicians. The religious, cultural, and medical aspects of family planning will be discussed and seminar attendees will be given ample time for group discussions.
41129544|NCT03647358|DEVICE|PET/CT Scan|Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
41129545|NCT03647358|DRUG|Iodine-124|Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose.
41129546|NCT01368874|DEVICE|Ulthera® System treatment|Single treatment of focused ultrasound energy delivered below the surface of the skin.
41129547|NCT02234141|DRUG|Placebo|Tablet administered orally once daily
41129548|NCT02234141|DRUG|Selonsertib|Tablets administered orally once daily
41129549|NCT02108704|DRUG|Helicobacter pylori eradication therapy|
41129550|NCT02108704|DRUG|Placebo|
41129551|NCT02029469|DEVICE|Ascension HRA device|Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
41129552|NCT06133530|DIETARY_SUPPLEMENT|Human milk oligosaccharides|Prebiotic
41129553|NCT06133530|DIETARY_SUPPLEMENT|Maltose|Control
41129554|NCT06000800|OTHER|Group B|Umbilical cord clamping at 30 seconds
41129555|NCT06000800|OTHER|Group C|Umbilical cord clamping at 60 seconds
41129556|NCT06000800|OTHER|Group D|Umbilical cord clamping at 90 seconds
41129557|NCT06000800|OTHER|Group A|Umbilical cord clamping immediately after birth (5 second)
41129558|NCT00506844|DRUG|Cetuximab, Irinotecan, Capecitabine|
40932123|NCT05018936|DRUG|Hetrombopag|Hetrombopag starting at 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
40932124|NCT00477958|OTHER|questionnaire administration|Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.
41449640|NCT00726830|DRUG|methadone hydrochloride|Given orally
41449641|NCT00726830|DRUG|morphine sulfate|Given orally
40932125|NCT00477958|PROCEDURE|cognitive assessment|Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
40932126|NCT00477958|PROCEDURE|psychosocial assessment and care|Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
40932127|NCT04385927|BEHAVIORAL|e-Net for Parents of Neurodiverse Children|One-on-one distance coached intervention; approx. 12 sessions at 60-90 minutes.
40932128|NCT02150408|OTHER|PET-CT|
40932129|NCT01286831|DRUG|[14C]GW642444|Single 200μg dose of \[14C\]GW642444 given on Day 1.
40932130|NCT01445886|DRUG|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
40932131|NCT01445886|DRUG|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
41278984|NCT04341571|DRUG|Metformin|"Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks.~Homologated to the other intervention."
41278985|NCT05519475|DRUG|ALN-HSD|Administered by subcutaneous injection (SC)
41449642|NCT00726830|DRUG|oxycodone hydrochloride|Given orally
41449643|NCT01627431|DRUG|Acetylsalicylic acid|100 mg once per day
41449644|NCT01627431|DRUG|Clopidogrel|75 mg once per day
41449645|NCT02695472|DRUG|80 Milligrams NSI-189|Orally Administered
41449646|NCT02695472|DRUG|Placebo|Orally administered
41449647|NCT02695472|DRUG|40 Milligrams NSI-189|Orally Administered
40755423|NCT01451788|DEVICE|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
40755424|NCT00736476|BIOLOGICAL|H.pylori vaccines|1 dose of H.pylori vaccine at 0, 1, and 2 months
40932132|NCT02403687|DRUG|baclofen 2%|compound topical cream
40932133|NCT02403687|DRUG|Bupivacaine hydrochloride 1%|compound topical cream
40932134|NCT02403687|DRUG|Cyclobenzaprine hydrochloride 2%|compound topical cream
40932135|NCT02403687|DRUG|Diclofenac Sodium 3%|compound topical cream
40932136|NCT02403687|DRUG|Flurbiprofen 10%|compound topical cream
40932137|NCT02403687|DRUG|Gabapentin 6%|compound topical cream
40755425|NCT00736476|BIOLOGICAL|Placebo Vaccine|Placebo Vaccine at 0, 1, and 2 months
40932138|NCT02403687|DRUG|Ketamine 10%|compound topical cream
40932139|NCT02403687|DRUG|Lidocaine 2%|compound topical cream
40932140|NCT02403687|DRUG|Prilocaine 2.5%|compound topical cream
40932141|NCT02403687|DRUG|Meloxicam 0.09%|compound topical cream
40932142|NCT02403687|DRUG|Sumatriptan 5%|compound topical cream
40932143|NCT02403687|DRUG|Tizanidine 0.1%|compound topical cream
40932144|NCT02403687|DRUG|Topiramate 2.5%|compound topical cream
40932145|NCT02403687|DRUG|Capsaicin, USP 0.0375%|compound topical cream
40932146|NCT02403687|DRUG|Menthol, NF 5.00 %|compound topical cream
40932147|NCT02772198|BIOLOGICAL|CD19 CAR T cells|Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19
40932148|NCT04719832|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
40932149|NCT04719832|DRUG|Placebo|Matching placebo will be administered as a normal saline using a pre-filled syringe.
40932150|NCT06134271|DRUG|Rezvilutamide|Rezvilutamide 240mg qd
40932151|NCT06134271|DRUG|Rezvilutamide plus abiraterone|Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd
40932152|NCT06134271|DRUG|Continue previous treatment|Continue using the previous treatment regimen for treatment.
40932153|NCT06324916|RADIATION|Xray|X rays for ankle to see distal fibular remenant
41278986|NCT05519475|DRUG|Placebo|Administered by SC injection
41278987|NCT05627245|DRUG|Belinostat|Given IV
41278988|NCT05627245|PROCEDURE|Biopsy|Undergo biopsy
41278989|NCT05627245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41278990|NCT05627245|PROCEDURE|Computed Tomography|Undergo CT scan
41278991|NCT05627245|OTHER|Pharmacokinetic Study|Pharmacokinetic study
41278992|NCT05627245|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT
41278993|NCT05627245|DRUG|Tazemetostat|Given PO
41278994|NCT06521489|DEVICE|Asymmetrical High Flow Nasal Cannula Oxygenation|Asymmetrical High Flow Nasal Cannula Oxygenation will be implemented in this study group. (1st study group, 60l/min airflow, 60% fiO2)
41449648|NCT00471510|DRUG|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
41449649|NCT06626633|DRUG|CRD3874|CRD3874-SI is a STING agonist. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer.
41449650|NCT06320067|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|SABR is a way of giving focused high-dose radiotherapy. SABR given with a dose fractionation schedule of 30Gy in 3-5 fractions over 1-2 weeks to up to 5 metastatic lesions in the bone and/or non-regional (extra-pelvic) lymph nodes.
41449651|NCT06320067|OTHER|177Lu-PSMA-617|177Lu-PSMA-617 is a nuclear medicine therapy. Patients will receive 177Lu-PSMA-617 to a dose of 7.4GBq. Each cycle will consist of 2 doses, 1 week apart (on day 1 and day 8) and will last 6 weeks. Treatment will be given for up to 3 cycles (6 doses).
41449652|NCT06320067|DRUG|Niraparib and Abiraterone Acetate Dual Action Tablet DAT|Combination product containing Niraparib (PARP inhibitor) and Abiraterone Acetate (ARSI). The regular-strength dual-action tablet (DAT) contains 100 mg niraparib/500mg AA per tablet. Patients take 2 tablets a day and receive a of total dose 200 mg niraparib/1000 mg AA. A low-strength DAT tablet containing 50 mg niraparib/500 mg AA may be available for participants requiring a dose reduction of niraparib.
41449653|NCT06320067|DRUG|Abiraterone Acetate|Abiraterone Acetate is an ARSI. Single agent Abiraterone Acetate may be used in patients randomised to receive Niraparib and Abiraterone Acetate.
41449654|NCT06320067|DRUG|Apalutamide|Apalutamide is an ARSI administered as a 240mg oral dose (four tablets taken together at the same time every day) with or without food. It is given daily in 28-day cycles.
41449655|NCT06320067|DRUG|Androgen Deprivation Therapy (ADT)|Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.
40755426|NCT06479083|OTHER|New Intervention form including|The central element of the new form of care is the implementation of a tele medical evaluation and coordination function, which controls individualized treatment processes within the network. The individualized evaluation and coordination of treatment paths is carried out within the already existing Parkinson's network RheinMain+ by a non-physician medical specialist (APN) specially trained for the indication Parkinson's disease.
40755427|NCT06479083|OTHER|Standard treatment|The standard treatment which all compulsory insured patients get.
40755428|NCT05849376|BEHAVIORAL|Emergent Multi-Class Imitation Training|Sessions will be conducted in a room with minimal distractions containing a table, two chairs, a timer, and 3-4 highly preferred (HP) items identified by preference assessments.A minimum of 10 sessions per week will be distributed across at least 3 days per week. Each session will take 20-25 min to conduct. Each session will consist of the instructor presenting imitation training trials and probe trials. During baseline sessions, participants will not receive rewards for correct imitation. During training, participants will receive rewards for correct imitation and evidence-based teaching strategies that are commonly employed in applied behavior analysis therapy will be used to help participants learn how to imitate new responses. Novel probe trials will be embedded throughout all sessions to continuously evaluate the emergence of generalized imitation. When participants can consistently imitate novel probe responses, the intervention will conclude.
40755429|NCT02030639|DRUG|rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib (\[14C\]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
40932154|NCT00860977|DRUG|valacyclovir|oral valacyclovir 500mg twice daily
40932155|NCT00860977|DRUG|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
40932156|NCT03442764|DRUG|mavacamten|MYK-461
40932157|NCT03442764|DRUG|Placebo|Placebo
40932158|NCT06224920|DIAGNOSTIC_TEST|magnetic resonance imaging|MRI data acquisition was performed on a 3 Tesla MRI scanner with parallel transmission and reception technology (Skyra Magnetom, Siemens Healthcare, Erlangen, Germany). Imaging is performed with a maximum gradient strength of 45mT/m and a maximum slew rate of 200 T/m/s and a 64-element head coil.
40932159|NCT06224920|OTHER|electroencephalography|A 20-channel resting EEG (Brain Products, Gilching, Germany) is recorded as part of routine clinical diagnostics in the Department of Psychiatry and Psychotherapy at the LMU to rule out focal neurophysiological pathologies. Within the scope of the present study, an extended examination will be carried out, which includes a 64-channel EEG, including a passive visual paradigm. After completion of the clinical evaluation, the neurophysiological changes in resting activity will be scientifically analyzed in comparison to the MRI and PET data.
40932160|NCT06224920|DIAGNOSTIC_TEST|blood and CSF biomarker|Aβ1-42 and 1-40, total tau protein and phosphorylated tau protein 181 (p-Tau), apolipoprotein E (APOE), soluble TREM2 protein, neurofilament light chain and glial fibrillary protein (GFAP) will be determined.
40932161|NCT06224920|DIAGNOSTIC_TEST|positron emission tomography|According to an established and standardized protocol, PET scans are performed with the TSPO receptor ligand \[18F\]-GE-180, \[18F\]flutemetamol for assessment of fibrillar Aβ 162 accumulation and the Tau ligand \[18F\]-PI-2620. In brief, \[18F\]GE-180 TSPO PET images (mean dose: 177 ± 17 MBq) with an emission window of 60-80 min after injection will be acquired to measure the activation of glial cells. \[18F\]Flutemetamol Aβ PET images (average dose: 182 ± 11 MBq) are acquired with an emission window of 90-110 min after injection to assess fibrillar Aβ accumulation. Dynamic \[18F\]PI-2620 tau PET (average dose: 186 ± 14 MBq) with an emission window of 0-60 minutes after injection are performed for quantification of tau aggregation. Static images of the late phase (20-40 min) are reconstructed. These images are used for further processing and analysis.
40932162|NCT06224920|DIAGNOSTIC_TEST|neuropsychological test|Trained psychologists at the Memory Clinic of the LMU Hospital administered the CDR, CERAD-NB and Mini-Mental State Examination (MMSE). The CERAD-NB battery was used to generate a total score for the six subscales: semantic fluency (animals/60 s), modified Boston naming test, lexical items, construction practice, lexical items retrieval, and lexical items discrimination, with higher scores indicating better performance.
41129559|NCT05691842|OTHER|HIIT intervention|Patients will perform a muscle strength training circuit interspersed with resistance training circuit. The strength training circuit will consist of 10 strength exercises and resistance training circuit will consist of walking, jogging and running exercises. Each exercise will be performed for one minute, trying to reach maximum intensities adapted to each individual's condition.
41129560|NCT05691842|OTHER|Dual task intervention|Dual task training will consist of the progressive and specific assignment of primary motor tasks and secondary motor or cognitive tasks focused on: i) Primary tasks: static, dynamic balance and gait exercises; ii) Secondary tasks (motor or cognitive): verbal fluency, mathematical calculation, memory, visual-spatial planning, auditory discrimination, fine motor task, motor transport task.
41278995|NCT06521489|DEVICE|Conventional High Flow Nasal Cannula Oxygenation|Conventional High Flow Nasal Cannula Oxygenation will be implemented in this study group. (2nd study group, 60l/min airflow, 60% fiO2)
41278996|NCT02148029|OTHER|Exercise|Upper and Lower extremity exercise
41278997|NCT02148029|OTHER|Standard Care|anticoagulation, compression, and ad-lib ambulation
41278998|NCT06564454|OTHER|No intervention|Assessment of knowledge, attitude and practice of green Dentistry
41278999|NCT02607527|DEVICE|Mitral Valve IRIS Ring|Transcatheter implantation of the IRIS
41279000|NCT03969329|DRUG|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
41279001|NCT05281523|BIOLOGICAL|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) will be administered using a pre-filled syringe.
41279002|NCT05281523|DRUG|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
41449656|NCT06320067|DRUG|Androgen Receptor Signalling Inhibitor (ARSI)|"Second generation ARSI (Abiraterone Acetate and Prednisolone \[AA+P\], Enzalutamide, Apalutamide or Darolutamide). This will be given as standard of care as per local guidelines.~Abiraterone acetate will be administered as a single 1000mg once daily dose (4 tablets to be taken together once a day) with prednisolone 5mg once daily to prevent secondary mineralocorticoid excess.~Enzalutamide will be administered as a 160mg oral dose (four capsules taken together at the same time every day) with or without food. Enzalutamide is administered daily in 28-day cycles.~Apalutamide will be administered as 240mg oral dose (four tablets taken together at the same time every day) with or without food. Apalutamide is administered daily in 28-day cycles. Patients require thyroid function monitoring.~Darolutamide will be administered as 600mg oral dose (two 300mg tablets taken together) with or without food. Darolutamide is administered twice daily in 28-day cycles."
41449657|NCT06320067|RADIATION|Local Radiotherapy|Either 36.25Gy given in 5 fractions over 1-2 weeks to prostate or 60Gy in 20 fractions over 4 weeks to prostate (± 47Gy in 20 fractions to pelvic lymph nodes ± 51Gy in 20 fractions boost to involved nodes).
41449658|NCT06320067|DRUG|Prednisolone|Prednisolone should also be administered 5mg daily using local pharmacy prescribing.
41449659|NCT06320067|DRUG|Docetaxel|Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.
41449660|NCT06425757|DRUG|ciprofol|Patients who intended to undergo elective surgery under general anesthesia were induced by a single intravenous injection of 0.3mg/kg and ciprofol, and the experimental drug was manually injected by CVC within 30s. 2ml of venous blood was collected before and after administration 0.5min, 1min, 2min, 3min, 5min, 8min, 15min 30min, 1h, 2h and 4h respectively. The concentration of cyclopofol in blood was measured
41449661|NCT03812913|BEHAVIORAL|psychological evaluation|"* Neuropsychological and experimental tasks will assess cognitive and socio-cognitive functions.~* Questionnaires will assess psychoaffective aspects (depression, anxiety, self-esteem), and social and behavioral functioning."
40755430|NCT04065256|OTHER|Personalized music|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.
40932163|NCT03413176|DRUG|Cardiac complication induced by VEGF/VEGFR inhibitor|Case reported in the World Health Organization (WHO) of cardiac complication of patient treated by AAs, with a chronology compatible with the drug toxicity
41129561|NCT03280511|DRUG|PIPAC|PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
41129562|NCT02020694|DRUG|Vitamin D|
41129563|NCT02020694|DRUG|Placebo (for vitamin D)|
41279003|NCT06644157|DEVICE|Laser Néo Élite|One session of laser on one side of the face (randomly assigned for each patient for the duration of the study) will be performed every other week for 12 weeks for a total of 6 sessions. All the patients will apply the entire face a sunscreen of sun protection factor 50 with high UVA protection (UV Mune 400; La Roche Posay) during the entire study duration.
41279004|NCT03036930|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41279005|NCT03036930|PROCEDURE|HPV Self-Collection|Undergo self-collection of vaginal/cervical samples
41279006|NCT03036930|OTHER|Questionnaire Administration|Ancillary studies
41129564|NCT03333824|DRUG|CYP1A2 (caffeine)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
41129565|NCT03333824|DRUG|CYP2C19 (omeprazole)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
41129566|NCT03333824|DRUG|CYP3A (midazolam)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
41279007|NCT03036930|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
41449662|NCT05725499|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous stimulation of the spinal cord. Mapping will be performed to determine sites for optimal modulation of blood pressure. During each mapping day, with participants in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C5/6, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increased in 5 mA increments up to 100 mA. The frequency will be 2 or 30 Hz. Profiles will be established to guide selection of optimal site locations for blood pressure modulation. The profile chosen will be used during training and testing.~During testing, stimulation will be applied using the selected profile in order to normalize SBP to the range of 110-120 mmHg and stabilize it within this range during a 30-min tilt test.~On each session during the 2-week training-period, stimulation will be applied for 30 minutes using the selected profile, while the participant remains in a seated position."
41449663|NCT05725499|DIAGNOSTIC_TEST|Tilt-table orthostatic stress testing|"While lying supine, participants will be strapped to a Hi-Low tilt-table bed. The bed will gradually be tilted to a 70 degrees tilt, during which time continuous hemodynamic measures will be recorded. This position will be maintained for 30 minutes.~During some of the sessions, the tilt test will be accompanied by spinal stimulation."
40755431|NCT04065256|OTHER|Personalized music plus earplug|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
40755432|NCT04314180|DEVICE|Taking slit-lamp images|The participant only needs to take several slit-lamp images as usual.
41449664|NCT00472212|DEVICE|Spectacles|Hyperopic spectacle lenses
41449665|NCT00472212|DEVICE|Control|Plano (no power, control) spectacle lenses
40755433|NCT04102982|DRUG|Camrelizumab|Patients will be treated with camrelizumab alone.
40755434|NCT04102982|OTHER|Camrelizumab plus microwave ablation|In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
41279008|NCT06342310|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
41449666|NCT06058845|DIETARY_SUPPLEMENT|Tamarindus indica fruit juice_A|The participants will be exposed to 10% Tamarind pulp juice
41449667|NCT06058845|DIETARY_SUPPLEMENT|Tamarindus indica fruit juice_B|The participants will be exposed to 30% Tamarind pulp juice
41449668|NCT00948792|PROCEDURE|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
41449669|NCT00948792|PROCEDURE|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
41449670|NCT03694535|DRUG|bladder wall thermotherapy with Mitomycin-c|application of intravesical mitomycin-C with hyperthermia
41449671|NCT01769898|DRUG|Formoterol-budesonide|Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
41449672|NCT01769898|DRUG|Theophylline|Theophylline 0.1 Q12H
41449673|NCT01769898|DRUG|Placebo|Placebo for theophylline 0.1 Q12H
40755435|NCT00109070|DRUG|Avastin (bevacizumab)|
40755436|NCT01766843|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
40755437|NCT01766843|DRUG|Seretide Diskus|2 inhalations as a single dose
41449674|NCT04464005|DRUG|Magnesium sulfate 33% solution|Topical pads with cold magnesium sulfate 33% solution will be given 5 times/day for 15 minutes
40755438|NCT01766843|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
40755439|NCT01766843|DRUG|SF Easyhaler|2 inhalations as a single dose
40755440|NCT01401205|OTHER|upper airway ultrasonographic examination|upper airway ultrasonographic examination and cuff leak test
40755441|NCT06567301|COMBINATION_PRODUCT|Ultrasound therapy combined with Chitosan nanoparticles gel|Gymna - Belgian
41279009|NCT05495464|DRUG|Acalabrutinib|Given by PO
41279010|NCT05495464|DRUG|Rituximab|Given by IV (vein)
41279011|NCT05495464|OTHER|Brexucabtagene Autoleucel|Given by IV (vein)
41279012|NCT05495464|DRUG|Cyclophosphamide|Given by IV (vein)
41279013|NCT05495464|DRUG|Fludarabine Phosphate|Given by IV (vein)
41279014|NCT03808155|DRUG|Tamsulosin|The drug ist taken once a day per os five days prior to the operation and two days after the operation.
40932164|NCT05245279|DIAGNOSTIC_TEST|3 dimensional ultrasound investigation|Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.
40932165|NCT05245279|DIAGNOSTIC_TEST|2 dimensional ultrasound investigation|The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.
40932166|NCT06355674|BEHAVIORAL|Breastfeeding education provided with Lactation Simulation Model|The Lactation Simulation Model (LSM) is a high-fidelity simulator designed for interactive education, which educators can utilize for practical and wearable breastfeeding training. It is wearable like a shirt and is secured onto the chest by passing it over the shoulders and fastening it with a safety belt from the back. This allows the safety belt to be adjusted according to different body types and weights.
40932167|NCT00536861|DRUG|erlotinib|"Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity"
40932168|NCT00791232|DRUG|extended-release (ER) OROS paliperidone|
40932169|NCT00739271|OTHER|Early feeding|
40932170|NCT00739271|OTHER|late feeding after bowel sounds return|Traditional method
40932171|NCT01516333|OTHER|High GL 107|Three meals a day
40932172|NCT01516333|OTHER|Medium GL 76|Three meals a day
40932173|NCT01516333|OTHER|Medium GL 68|Three meals a day
40932174|NCT01516333|OTHER|Low GL 48|Three meals a day
40932175|NCT04597151|DIETARY_SUPPLEMENT|Dietary Intervention|Attend diet education sessions
40755442|NCT03240432|DEVICE|Dexcom CGM|CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
40932176|NCT04270903|DEVICE|EPR measurement|Subject put in a magnet, magnetic field sweeping around 40 mTesla. Irradiation with a wave with a frequency of 1.1 GHz. A resonator (surface coil) is put at the surface of the skin (arm). The EPR signal is recorded.
40932177|NCT02910128|BEHAVIORAL|chiquichefs|A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
40932178|NCT04500275|DRUG|Vancomycin Hydrochloride|Vancomycin will be spread on sternal edge immediately after sternotomy and before sternal closure
40932179|NCT04500275|OTHER|Normal Saline|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure
40932180|NCT05655806|DRUG|Aminophylline bolus then infusion|half an hour before discontinuation of isoflurane
40932181|NCT05655806|DRUG|aminophylline bolus|after discontinuation of isoflurane
40932182|NCT05655806|DRUG|normal saline|given as placebo
41129567|NCT03333824|DRUG|Kytril (granisetron)|Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water.
40932183|NCT00366340|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
40932184|NCT00366340|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
40932185|NCT05988697|DRUG|Combind asprin with Trametinib and Dabrafenib|Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD
40932186|NCT00182702|DRUG|ixabepilone|Given IV
40932187|NCT00182702|OTHER|laboratory biomarker analysis|Correlative studies
40932188|NCT04337177|DRUG|VAL-413|a flavored preparation of orally administered irinotecan
40932189|NCT04337177|DRUG|Temozolomide|alkylating oral chemotherapy agent used to treatment brain cancers
40932190|NCT00367770|DRUG|Tracleer®|Patients will receive up to 125 mg b.i.d. of Tracleer.
40932191|NCT02695212|DRUG|Apremilast|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
40932192|NCT03533686|DEVICE|Adhear Bone Conduction System|Non-invasive bone conduction hearing device using adhesive
40932193|NCT03533686|DEVICE|Bone anchored hearing aid (BAHA)|Non-invasive bone conduction hearing device using a headband
40932194|NCT03742440|BIOLOGICAL|GrafixPL PRIME|GrafixPL PRIME
40932195|NCT01687647|OTHER|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
40932196|NCT03036800|DRUG|Saxenda|standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
40932197|NCT03036800|OTHER|Specialist Obesity Management Services|Specialist Obesity Management Services standard of care
40932198|NCT05060523|DRUG|Tolvaptan Tablets|• Tolvaptan15 mg once a day for 7 days, stat with 7.5 mg and titrate to 15 mg in 24 hours max30 mg
40932199|NCT05060523|DRUG|Midodrine Oral Tablet|"• Midodrine 5 mg at 0 hours and then 5 mg every 8 hours to maintain Target MAP-80"
40932200|NCT05060523|OTHER|Placebo|Placebo of Midodrine
41449675|NCT04464005|OTHER|Cold water|Topical pads with cold water will be given 5 times/day for 15 minutes
40932201|NCT04449029|DRUG|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.
41449676|NCT00137644|BEHAVIORAL|Preventing AIDS Through Live Movement and Sound (PALMS)|
40755443|NCT04065854|BEHAVIORAL|Intervention|Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.
40932202|NCT04449029|DRUG|Placebo|Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
40932203|NCT04449029|DRUG|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.
40932204|NCT03792243|PROCEDURE|Complication|Readmission, reoperation
40932205|NCT03315052|DRUG|Budesonide|Oral steroid with high first-pass metabolism in liver
40932206|NCT03315052|DRUG|Tacrolimus（FK506）|Calcineurin immunosuppressant
40932207|NCT03315052|DRUG|Mycophenolate Mofetil|Immunosupressant
40932208|NCT03315052|DRUG|Prednisone|Immunosuppresant
40932209|NCT06523192|OTHER|Questionnaires|No intervention
40932210|NCT04319822|OTHER|blood sample and muscular biopsy|blood sample and muscular biopsy
40932211|NCT04441762|DRUG|Intravenous Ketorolac Tromethamine|30 mg ketorolac single dose
40932212|NCT04441762|DRUG|Intranasal Ketorolac Tromethamine|30 mg ketorolac single dose
40755444|NCT02584244|DRUG|LUM015|
40932213|NCT05112276|OTHER|Diet|A review has been undertaken to both identify specific bacteria associated with cardiometabolic risk factors and food items that have been shown to affect such bacteria in a beneficial direction. The intervention diet will include a variety of food items e.g. vegetables, fermented vegetables, fermented dairy products and cereal products. The control diet is based on a Swedish Average Diet
40932214|NCT05384704|BEHAVIORAL|Empower@Home|The intervention is a 9-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive weekly support from a trained research staff.
40932215|NCT00734760|BEHAVIORAL|education|face-to-face education and counseling intervention
41129568|NCT03333824|DRUG|Wee-1 kinase inhibitor AZD1775|Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
40932216|NCT03002376|DRUG|REGN2810|REGN2810 treatment
40932217|NCT00602745|DRUG|S-1|oral administration
40932218|NCT00602745|DRUG|5-Fluorouracil|intravenous bolus
40932219|NCT02138526|DRUG|pazopanib|pazopanib 800mg OD without food
40932220|NCT02138526|OTHER|continental breakfast|pazopanib 600mg OD with food
40932221|NCT06289621|BEHAVIORAL|False Safety Behavioral Elimination Treatment (FSET)|5-session transdiagnostic treatment for anxiety disorders and post-traumatic stress disorder (PTSD)
40932222|NCT06289621|BEHAVIORAL|Enhanced Standard Care|Participants in the enhanced standard care control group will receive treatment as usual and a list referrals.
40932223|NCT03932097|BEHAVIORAL|REAL Parenting|REAL Parenting digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
40932224|NCT03932097|OTHER|Active Control Materials|NIAAA materials on underage drinking for parents
40932225|NCT02203084|OTHER|Social Determinants Questionnaire|The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
40932226|NCT04417426|OTHER|Survey|A survey was conducted, which was filled voluntarily and completely anonymously; the demographic data asked were: sex, age, religion, and semester. We included questions about their sexual behavior: if they considered having enough knowledge about STDs, sexual intercourse onset, number of sexual partners in the last year, the total number of sexual partners, sexual orientation, the use of condoms and contraceptives, exclusive or non-exclusive sexual intercourses, frequency of STDs screening, and then if they know the location of STD testing centers.
40932227|NCT04895540|DIAGNOSTIC_TEST|ECG|All study subjects will undergo ECG recording.
40932228|NCT04895540|DIAGNOSTIC_TEST|Echocardiography|All study subjects will undergo transthoracic echocardiography
41449677|NCT04285268|DRUG|Bortezomib|Given IV or SC
41449678|NCT04285268|BIOLOGICAL|Rituximab|Given IV
40755445|NCT02584244|DEVICE|LUM 2.6 Imaging Device|
40755446|NCT00010907|DRUG|NPI-028|
40755447|NCT05324787|DEVICE|Grency venous stent system|Venous stent implantation during the index procedure
40932229|NCT04895540|DIAGNOSTIC_TEST|Cardiac MRI|All ACM patients and SCD survivors will undergo cardiac MRI testing.
40932230|NCT04895540|DIAGNOSTIC_TEST|Ambulatory ECG recording|All ACM patients and SCD survivors will undergo 24-hour ambulatory ECG recording
40932231|NCT04895540|DIAGNOSTIC_TEST|Cardiac EP study|ACM patients and SCD survivors will undergo diagnostic cardiac Electrophysiology testing.
41129569|NCT00989742|DRUG|Doxycycline|50mg od
41449679|NCT04285268|DRUG|Venetoclax|Given PO
41449680|NCT04515719|BIOLOGICAL|Belimumab|Belimumab 2mg/kg intravenously
41449681|NCT04515719|BIOLOGICAL|Placebo|Placebo intravenously
41449682|NCT05895383|DRUG|Nitrous oxide|Nitrous oxide administered at concentrations of minimal sedation (0-50%). Participants will be able to adjust the level of gas throughout the vasectomy using a handheld remote control.
40932232|NCT04895540|GENETIC|All study subjects will undergo sample collection for genetic testing.|Blood samples and buccal swab will be collected from study subjects for genetic testing.
40932233|NCT06282887|OTHER|Music therapy|The intervention has two parts. The first part is an approximately 15-minute music therapy session to induce relaxation and positive memories attached to the relaxing live music provided by a credentialed music therapist. The second part is music listening during the scanning process.
40932234|NCT00212017|DRUG|voglibose|
40932235|NCT00212017|BEHAVIORAL|diet and exercise therapy|
40932236|NCT03403387|DIETARY_SUPPLEMENT|GlutenShield|combination probiotic, prebiotic, and enzyme supplement
40932237|NCT03403387|OTHER|Placebo|Avicel (cellulose) and bentonite powder
40932238|NCT03121976|DEVICE|Ultrasound|Femoral catheter inserted using ultrasound only
40932239|NCT03121976|DEVICE|Ultrasound + Nerve Stimulation|Femoral catheter inserted using ultrasound and nerve stimulation
40932240|NCT02368925|DEVICE|Ultherapy™ System|The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200\~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
40932241|NCT05579600|BEHAVIORAL|Caring Contacts letters|Caring Contacts involves sending individuals at risk for suicide brief, non- demanding messages of care.
40932242|NCT05579600|BEHAVIORAL|Reports, re-engagement, and training|Behavioral health providers will receive training in reaching out to and re- engaging patients who pass through the justice system, as well as training in suicide risk assessment (the Columbia Suicide Severity Rating Scale; C-SSRS) and response (the Safety Planning Intervention; SPI).
40932243|NCT04113811|DEVICE|Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)|In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach
40932244|NCT05093790|DRUG|Ticagrelor|Specified dose on specified days
40932245|NCT05093790|DRUG|BMS-986141|Specified dose on specified days
40932246|NCT05093790|DRUG|Aspirin|Specified dose on specified days
40932247|NCT02648828|OTHER|Clinical deterioration|Patients at risk of clinical deterioration
40932248|NCT04499599|OTHER|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
40932249|NCT04499599|OTHER|Fasting|Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.
40932250|NCT04499599|OTHER|Study food|Study subjects will either continue to fast for 6 hours (Fast Group), consume either a breakfast (Breakfast Group) or a Fast Bar (Fast Bar Group).
40932251|NCT01837771|DEVICE|Diaphragmatic stimulation|
40932252|NCT05275660|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 will receive HFB30132A dose 2.
40932253|NCT05275660|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
40932254|NCT02013583|OTHER|No intervention|This is an observational registry. No interventions are required or provided.
40932255|NCT00384111|DRUG|Zevalin Therapeutic Regimen|Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
40932256|NCT00384111|DRUG|R-CVP|Standard R-CVP
40932257|NCT03088462|OTHER|Psychiatric management|Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.
40932258|NCT03088462|BEHAVIORAL|Psychosocial treatment|Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
40932259|NCT03088462|BEHAVIORAL|LiveWell Program|Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
40932260|NCT04106024|DRUG|Anlotinib|Anlotinib 12mg.qd ,taken for 2 weeks and discontinued for 1 week, namely 3 weeks (21 days).
40932261|NCT04272138|BEHAVIORAL|Calm Meditation|"The intervention will run for 4-weeks. Participants will complete the 30 day, How to Meditate meditation series that provides daily 10-minute meditations. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions participants and will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice ecological momentary assessment question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview."
40932262|NCT04272138|BEHAVIORAL|Educational Podcast Control|The intervention will run for 4-weeks. Control group participants will listen to daily 10-minute health education podcasts. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions and participants will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview.
41129570|NCT00989742|DRUG|Placebo|50mg od
41129571|NCT04587219|BIOLOGICAL|Gam-COVID-Vac|combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
41279015|NCT03808155|DRUG|Placebo Oral Tablet|The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
41279016|NCT06194448|DRUG|Osimertinib|80 mg daily (or 40 mg daily for dose reduction)
41129572|NCT00463229|OTHER|Interprofessional Team Approach|Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
41129573|NCT00109031|DRUG|palifermin|Administered as one daily intravenous bolus.
41129574|NCT00109031|RADIATION|Total Body Irradiation|To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
41129575|NCT00109031|DRUG|Cyclophosphamide|Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
41129576|NCT00109031|DRUG|Etoposide|Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
41129577|NCT00109031|DRUG|Placebo|Administered as one daily intravenous bolus.
41129578|NCT03547167|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
41129579|NCT03547167|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
41129580|NCT03547167|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
41129581|NCT01078909|BIOLOGICAL|Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)|Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
41129582|NCT00000587|PROCEDURE|erythropoietin, recombinant|
40932263|NCT02434601|PROCEDURE|Treatment of Dentin Surface|"* Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.~* Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.~Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate."
40932264|NCT02434601|PROCEDURE|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
40932265|NCT02434601|PROCEDURE|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
40932266|NCT03188172|DRUG|Cyclophosphamide|Chemotherapy
40932267|NCT03188172|DRUG|Bortezomib|Chemotherapy
40932268|NCT03188172|DRUG|Lenalidomide|Chemotherapy
41129583|NCT03392038|PROCEDURE|Thin ADM|Use of soft tissue allograft for root coverage
41129584|NCT03392038|PROCEDURE|Thick ADM|Periodontal surgical procedure to coronally position the tissue over the ADM allograft
41129585|NCT02132520|DEVICE|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
41129586|NCT02132520|BEHAVIORAL|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
41129587|NCT05782894|DRUG|Remimazolam besylate|0\~2.0mg/kg/h
41129588|NCT05782894|DRUG|Propofol|0.3\~4.0mg/kg/h
41129589|NCT05782894|DRUG|Remifentanil|1.5\~12μg/kg/h
41449683|NCT06015035|DRUG|Sintilimab and anlotinib in combination with chemotherapy|Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles. Surgical treatment was performed 4-6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) rate and safety.
41449684|NCT05280288|DEVICE|Bone@BC app|Participants in the intervention group will be asked to use the Bone@BC app daily it will take them 1-3 minutes to answer the daily questions in the app concerning symptoms and physical activity. They will have access to a Questionnaire Prompt List in the app Bone@BC.
41449685|NCT05361252|PROCEDURE|SVV-guided fluid management|fluid will be guided by value of stroke volume variation
40932269|NCT03188172|DRUG|Daratumumab|Chemotherapy
40932270|NCT03188172|DRUG|Dexamethasone|Chemotherapy
40932271|NCT03188172|DRUG|Melphalan|Chemotherapy
40932272|NCT03188172|DRUG|Filgrastim|Haematopoietic agent for the stem cell harvest
40932273|NCT01562067|DEVICE|ultrasound examination|ultrasound and doppler studies to evaluate size and vascularity of tumor during radiotherapy
40932274|NCT05711303|DIETARY_SUPPLEMENT|Superba Boost|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.
40932275|NCT05116072|PROCEDURE|total pancreatectomy|"The total pancreatectomy will be performed in two steps: The pancreatectomy will begin by a standard pancreaticoduodenectomy procedure.~The section margin will be sent for intraoperative histological analysis to confirm the absence of invasion of the left remnant pancreas.~When absence of tumor invasion is confirmed and the high-risk of postoperative pancreatic fistula is validated intraoperatively, the extended left distal pancreatectomy will be performed, with splenic preservation when possible.~Then, the left side of the pancreas will be resected and cooled (4-6°) in the preservation solution and shipped to Lille Biotherapy platform to perform islet isolation and purification. The reconstruction after total pancreatectomy will be done as usually performed by center expert surgeon."
41129590|NCT01673594|DRUG|SODAS MPH|Adults with ADHD will receive open-label SODAS MPH
41129591|NCT01673594|DRUG|Naltrexone|"Subjects randomized to the active double-blind group will receive Naltrexone HCl"
41449686|NCT05325515|DRUG|Conventional alendronate|Conventional alendronate 70mg weekly
40932276|NCT05116072|BIOLOGICAL|intraportal islet autotransplantation|The final islet preparation will be cultured and shipped 48 hours after total pancreatectomy from the Lille laboratory to the surgical center, and finally transplanted into the patient through a venous catheter placed in the portal trunk (91% of the total islet mass) and at the same time, a small fraction of the isolated islet (5% of the total islet mass) will be transplanted into the forearm muscle.
40932277|NCT01888003|DRUG|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
40932278|NCT01888003|DRUG|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
40932279|NCT01888003|OTHER|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb \< 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
40932280|NCT01064245|DRUG|high-dose methacholine challenge test|nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
40932281|NCT01064245|OTHER|mannitol challenge test|inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
40932282|NCT05064839|PROCEDURE|Bony scintigraphy|Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
40932283|NCT01089361|DRUG|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
40932284|NCT01089361|DRUG|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
40932285|NCT01501084|DRUG|Exenatide|10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
40932286|NCT01501084|DRUG|Normal saline .2cc subcutaneous injection|sterile saline injection
40932287|NCT03007069|OTHER|Mineralized plasmatic matrix (MPM).|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.
40932288|NCT03007069|OTHER|Autogenous bone graft (gold standard).|Exposed implant threads are to be covered with autogenous bone and collagen membrane.
40932289|NCT03831685|OTHER|Blood sample|Patients meeting the inclusion criteria and none of the non-inclusion criteria will benefit from 2 venous blood samples in order to precise the initial blood lactate level, e.g. at the first medical contact, and the final blood lactate level, e.g. at the hospital admission.
40932290|NCT04038632|OTHER|Decentralization of Childhood TB Diagnosis|The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
41129592|NCT05362942|DRUG|Venetoclax, Decitabine, Azacytidine, Cytarabine|Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
40932291|NCT05503927|OTHER|No Intervention|This is a non-interventional study, therefore no intervention is used.
40932292|NCT05856890|BIOLOGICAL|HepB mAb19|"HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg)."
40932293|NCT05856890|OTHER|Sterile Saline|Placebo will be normal sterile saline (NaCl 0.9%).
40932294|NCT05943743|OTHER|Google form|"* Self-administrated Questionnaire will be used for online survey. A pilot study was conducted on 30 sample size to check the reliability of questionnaire via statistical test.~* A Five-point Likert scale (strongly disagree, disagree somewhat, Neutral, agree somewhat, strongly agree)"
40932295|NCT01639508|DRUG|Cabozantinib|Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
40932296|NCT04259892|BIOLOGICAL|2019-nCoV PCR|Nasopharyngeal swabs
40932297|NCT00593580|DRUG|placebo|placebo
40932298|NCT00593580|DRUG|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
41129593|NCT05610566|DEVICE|the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System|The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a subannular implant (SAI), and their delivery systems and accessories. The TMV is a 28mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI), comprising a ring (made of polycarbonate urethane (PCU), nitinol, gold markers and polyester (Dacron) to be placed around the mitral valve apparatus to stabilize the position of the mitral valve implant.
41129594|NCT02765594|DRUG|Hydroxychloroquine Sulfate|200mg bid
41449687|NCT05325515|DRUG|Effervescent and buffered alendronate|Effervescent and buffered alendronate 70mg weekly
41449688|NCT00807495|DRUG|Alisertib|Alisertib capsules
41449689|NCT00615823|DRUG|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
41449690|NCT00615823|DRUG|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
41449691|NCT00387530|DRUG|oral sodium phenylbutyrate|
41449692|NCT00387530|DRUG|valganciclovir|
41449693|NCT00387530|GENETIC|polymerase chain reaction|
41449694|NCT00387530|GENETIC|protein expression analysis|
41449695|NCT00387530|PROCEDURE|biopsy|
40932299|NCT05982210|OTHER|Breathing Exercises and Manual Therapy of the Muscle Diaphragm and Ribs Protocol|The intervention consists on applying a protocol based on five different exercises, compound by breathing exercises and manual therapy of the muscle diaphragm and the ribs, applied by a physiotherapist.
40932300|NCT01403272|DEVICE|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
40932301|NCT02274038|DRUG|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
40932302|NCT02274038|DRUG|"Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare"|"FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare."
41449696|NCT04750239|DRUG|Nivatrotamab|Anti GD2×CD3 monoclonal bi-specific antibody
41129595|NCT02765594|DRUG|Valsartan|160mg qd
41129596|NCT03905512|DRUG|SEL-212|Administered as specified in the treatment arm
41129597|NCT03905512|DRUG|KRYSTEXXA®|Administered as specified in the treatment arm
41279017|NCT06194448|DRUG|Cisplatin or Carboplatin; Pemetrexed or Paclitaxel|Pemetrexed (500 mg/m2 to be administered on Day 1 of every 3-week cycle for 2 cycles) or Paclitaxel (175 mg/m2 on Day 1 of every 3-week cycle for 2 cycles) PLUS Cisplatin (75 mg/m2) or Carboplatin (AUC5) to be administered on Day 1 of every 3--week cycle for 2 cycles
41449697|NCT03090022|PROCEDURE|Strattice|Intra-abdominally Fixation
41449698|NCT03090022|PROCEDURE|Single running suture of abdominal fascia|Intra-abdominal suture
41449699|NCT02570828|DEVICE|Thermal Imaging|FLIR ONE attachment to an iPhone
41449700|NCT01225510|BIOLOGICAL|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
41449701|NCT01225510|BIOLOGICAL|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
41449702|NCT04207528|BEHAVIORAL|Writing|After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
41449703|NCT00070122|DRUG|oxaliplatin|Given IV
41279018|NCT06194448|DRUG|Radiation|"Patients must have received a total dose of radiation of 60 Gy ± 10% (54 to 66 Gy) as part of the chemoradiation therapy. It is recommended but not required that patients have a:~* Mean lung dose \< 20 Gy and/or V20 \< 35%~* Mean oesophagus dose \< 34 Gy~* Heart V50 \< 25%, V30 \< 50%, and V45 \< 35%"
40932303|NCT02274038|DRUG|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
40932304|NCT05854927|DIAGNOSTIC_TEST|3D T1 MRI sequences injected with fat saturation and black blood|3D T1 MRI sequences injected with fat saturation and black blood
40932305|NCT04661098|PROCEDURE|(Darwish hymenotomy technique)|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
41279019|NCT06046482|DRUG|Pembrolizumab|Given by IV (vein)
41279020|NCT06046482|DRUG|Magrolimab|Given by IV (vein)
41279021|NCT06046482|DRUG|cetuximab|Given by IV (vein)
41279022|NCT06046482|DRUG|Docetaxel|Given by IV (vein)
41279023|NCT04533711|BEHAVIORAL|OA-PCP Intervention|The OA-PCP intervention includes brief physical activity (PA) counseling delivered via phone by a PA Coach trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA Coach will ask participants about their current physical activity level and work with them to set physical activity goals. Then, after the first call, participants in this group will receive a call about two weeks later, then at about 3 months, 6 months, 9 months and 12 months later. During these calls, the PA coach will ask participants' about their progress toward PA goals and work with them to address any barriers or challenges. The coach will also help participants to identify any programs or resources that may help them to achieve their PA goals. Participants in this group will be asked to wear a wrist-worn monitor to help them track their PA during the intervention period. Also, if participants approve, the coach will use an online program to view their PA data.
41279024|NCT04533711|BEHAVIORAL|Attention Control|"This group will receive an intervention in the same dose (e.g., number and duration of phone calls and emails) as the OA-PCP group, but the content will not be PA-specific. During the first call, the Coach will discuss 2 topics, for which the amount of content parallels call #1 for the OA-PCP: What is OA? OA Diagnosis and OA Risk Factors. During the second call, the Coach will discuss the topic of Health Care Providers and Overview of OA Treatment Guidelines. Call topics for 3, 6, 9 and 12- month follow-up calls will be: Pain Medications, Mechanical Treatments (e.g., knee braces, footwear, joint protection), Complimentary and Alternative Therapies and discussion of OA and Mental Health, Sleep and Fatigue."
41279025|NCT06126224|DRUG|KarXT|KarXT 20/2 mg (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg (TDD 90/9 mg) KarXT 40/4 mg (TDD 120/12 mg) KarXT 50/5 mg (TDD 150/15 mg) KarXT 66.7/6.67 mg (TDD 200/20 mg)
40932306|NCT05172479|DIAGNOSTIC_TEST|Measurement of qSOFA score|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's qSOFA score.
40932307|NCT05172479|DIAGNOSTIC_TEST|Measurement of SIRS criteria|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's SIRS criteria.
40932308|NCT05172479|DIAGNOSTIC_TEST|Measurement of NEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS.
40932309|NCT05172479|DIAGNOSTIC_TEST|Measurement of NEWS2|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS2.
40932310|NCT05172479|DIAGNOSTIC_TEST|Measurement of MEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's MEWS.
40932311|NCT02203175|DRUG|saline|Before the anesthesia induction, 5 ml isotonic saline
40932312|NCT02203175|DRUG|fentanyl|before the anesthesia induction 50 mcgr fentanyl
40932313|NCT02203175|DRUG|propofol|during anesthesia 50 mg proposal with 50 mcgr fentanyl
40932314|NCT03085277|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.
41279026|NCT06126224|DRUG|Placebo|Placebo Capsules
41279027|NCT05635708|DRUG|Tislelizumab|Administered by intravenous infusion
41279028|NCT05635708|DRUG|BGB-A445|Administered by intravenous infusion
41279029|NCT05635708|DRUG|LBL-007|Administered by intravenous infusion
41279030|NCT05635708|DRUG|Carboplatin|Investigator's choice; administered by intravenous infusion
41279031|NCT05635708|DRUG|Cisplatin|Investigator's choice; administered by intravenous infusion
41279032|NCT05635708|DRUG|pemetrexed|Investigator's choice; administered by intravenous infusion
41279033|NCT05635708|DRUG|Paclitaxel|Investigator's choice; administered by intravenous infusion
41449704|NCT00070122|DRUG|leucovorin calcium|Given IV
41279034|NCT05635708|DRUG|Nab paclitaxel|Investigator's choice; administered by intravenous infusion
41279035|NCT05635708|DRUG|BGB-15025|Administered Orally
41279036|NCT05984927|GENETIC|NG101 AAV gene therapy|Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector
41279037|NCT05048290|OTHER|Communication Skills Training|Participate in communication workshops
41279038|NCT05048290|OTHER|Communication Skills Training|Participate in generic communication skills workshops
41279039|NCT05048290|OTHER|Educational Intervention|Develop a video
41279040|NCT05048290|OTHER|Survey Administration|Complete surveys
41449705|NCT00070122|DRUG|capecitabine|Given orally
41449706|NCT00070122|BIOLOGICAL|bevacizumab|Given IV
41449707|NCT00070122|DRUG|fluorouracil|Given IV
40932315|NCT03085277|DIETARY_SUPPLEMENT|Preterm Formula|Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
41129598|NCT06196749|PROCEDURE|Perform distal radial arterial cannulation using modified ultrasound-guided dynamic needle tip positioning technique|This study employs a modified ultrasound-guided dynamic needle tip positioning technique for distal radial arterial cannulation. The technique uses an ultrasound probe with two wires to create an acoustic shadow, improving needle tip visibility. Real-time dynamic tracking assists in precise needle placement within the distal radial artery through the nose-horn region. This method is used for coronary angiography and potential percutaneous coronary interventions, aiming to increase success rates and reduce complications like hematoma, nerve injury, and arterial spasm, thus enhancing safety and efficiency.
40932316|NCT06497036|DRUG|GP404141|subcutaneous injection
40932317|NCT06497036|DRUG|Nplate|subcutaneous injection
41129599|NCT06196749|PROCEDURE|Palpation guided puncture|Perform distal radial arterial cannulation under palpation guidance
41129600|NCT05501652|DEVICE|ALV1System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
41129601|NCT03056183|BEHAVIORAL|Depression Care Transitions (DCT)|DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
41129602|NCT03958773|DEVICE|Cardiovalve transfemoral Mitral valve system|Cardiovalve System, comprised of: 1) Cardiovalve Implant; 2) Cardiovalve Delivery System (DS); 3) Cardiovalve Accessories.
41129603|NCT03056313|BEHAVIORAL|Proactive support of labor|In case of delayed labor, active labor is defined at an earlier stage; labor support is given with 1 cm opening of the cervix and painful contractions. Labor support interventions are started then.
41129604|NCT03056313|BEHAVIORAL|support of labor as usual|In case of delayed labor, active labor start is defined as usual at 3-4 cm opening of the cervix and regular contractions. Labor support interventions are started then.
41129605|NCT04332094|DRUG|Tocilizumab|162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)
41129606|NCT04332094|DRUG|Hydroxychloroquine|400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)
41129607|NCT04332094|DRUG|Azithromycin|500 mg / day v.o. for 3 days
41129608|NCT01767688|DRUG|MK-3102|Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
41129609|NCT05829109|DRUG|Fecal Microbiota Transplant (FMT)|"The intervention consists of the following steps:~* Step 1: Vancomycin 125 mg orally every 6 hours and metronidazole 250 mg orally every 6 hours for 5 days.~* Step 2: Bowel preparation with 10 ounces of magnesium citrate.~* Step 3: Two FMT doses will be administered via enema one week apart using stool from donors with a durably healthy pouch."
41129610|NCT00767741|DEVICE|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
41129611|NCT02593149|DEVICE|ClearGuard HD End Cap|The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
41129612|NCT01065649|DRUG|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
41129613|NCT01065649|DRUG|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
41129614|NCT06510751|OTHER|CGRP level|CGRP and substance P levels will be analysed by ELISA method in CSF and blood materials.
41129615|NCT05259800|OTHER|Peppermint oil vapors|Subjects will be exposed to vapor of peppermint oil
41129616|NCT05259800|OTHER|Mineral Oil|Subjects will be exposed to vapor of placebo (mineral oil)
41129617|NCT06381700|OTHER|MySmile app|"The MySmile app contains several features:~A) Knowledge Hub~1. Do You Know section: This section consists of seven (7) topics where users can learn about oral health knowledge.~2. Quiz time section: In this section, school children can play games and challenge themselves.~B) Track yourself Brushing diary Diet diary~C) Get help~1. Ask an expert~2. Find your dentist~3. Friendly reminders"
41129618|NCT06381700|OTHER|Control|"This will receive the usual School Dental Service.~School Dental Service provide students who need dental treatment and will be called to be given treatment. Among the treatments given include:~* Dental filling~* Full mouth scaling~* Dental extraction~* Preventive treatment, such as topical fluoride application~All treatment is free of charge except for dentures, crown/bridge work and orthodontics. Treatment for school children is based on normative needs assessment as determined by the dentist. A child is defined as orally fit when all required treatment in the SDS has been completed and appropriate oral hygiene status is maintained."
41129619|NCT04363866|DRUG|Hydroxychloroquine|Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
41129620|NCT04363866|DRUG|Placebo|A placebo is a pill that looks like the study drug but has no real medicine in it.
41129621|NCT02036177|DEVICE|SCu300A IUB intrauterine device|Spherical copper IUD
41129622|NCT02036177|DEVICE|T380A IUD|T-shaped copper IUD
41129623|NCT02823574|BIOLOGICAL|Nivolumab|
41129624|NCT02823574|BIOLOGICAL|Ipilimumab|
41129625|NCT02823574|OTHER|Placebo|
41129626|NCT04649996|PROCEDURE|Appendectomy|comparison between operative and conservative treatment
41449708|NCT00070122|OTHER|laboratory biomarker analysis|Correlative studies
41449709|NCT05912127|DEVICE|implant supported fixed full arch prosthesis|the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.
41449710|NCT05644184|BIOLOGICAL|Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)|Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.
40932318|NCT02485678|OTHER|Proactive Telephone Toxicity Management|Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
40932319|NCT02485678|OTHER|Control Arm|Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
40932320|NCT02485678|OTHER|PRO Sub-Study|A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
40932321|NCT04334018|DEVICE|conventional CRT|"Conventional CRT or biventricular pacing resynchronizes left ventricular contraction by pacing the right and left ventricles (LV) simultaneously"
40932322|NCT04334018|DEVICE|MPP CRT|CRT with Multipoint pacing (MPP) where pacing can occur from more than one LV site simultaneously
41129627|NCT00982436|DRUG|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
41129628|NCT00982436|RADIATION|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
41129629|NCT00982436|DRUG|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
41129630|NCT02505191|DRUG|St. John's wort prolonged-release tablet 500 mg|
41129631|NCT02505191|DRUG|St. John's wort film coated tablets 250 mg|
41279041|NCT05272631|DEVICE|Retrograde Femoral Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with RFNA based on the surgeon's decision and the site's SOC.
41279042|NCT05272631|DEVICE|Tibial Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with TNA based on the surgeon's decision and the site's SOC.
41279043|NCT06581549|OTHER|Translation analysis|Bulk GEP analysis, Spatial whole transcriptome analysis, mIF analysis of tumors
41279044|NCT03579316|DRUG|Adavosertib|Given PO
41279045|NCT03579316|DRUG|Olaparib|Given PO
41279046|NCT03579316|DRUG|Ceralasertib|Given PO
41279047|NCT01176006|PROCEDURE|Reduced-intensity hematopoietic stem cell|stem cell transplant
41279048|NCT01176006|DRUG|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
41279049|NCT01176006|DRUG|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5
40932323|NCT03625271|DEVICE|The PEER Report|PEER Interactive references a subject's QEEG to a normative and then symptomatic database. By comparing a given subject's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER provides useful information regarding the response of neurophysiologically similar subjects to a wide number of medications - providing clinicians with useful information as to medication outcomes before a medication regime is started. Clinicians have also reported that negative findings (in which neurophysiologically similar subjects reported resistant outcomes for certain medications) can be extremely useful in reducing trial and error. It has also been used to help select the medication that best matches the QEEG brainwave pattern.
40932324|NCT06311552|OTHER|Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner|Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner
40932325|NCT03973801|OTHER|Auricular acupuncture|National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
40932326|NCT01382511|DRUG|Simvastatine|80 mg
41279050|NCT01176006|PROCEDURE|Total Body Irradiation (TBI)|200 cGy on Day -1
41279051|NCT01176006|DRUG|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 2 hours once daily on Days -6, -5, -4 and -3 (weight based dosing) or on days -4, -3 and -2
40932327|NCT03911843|DRUG|omega-3 supplementation|Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children
40932328|NCT03911843|DRUG|Vitamin D supplementation|Cholecalciferol 1000 IU/die
40932329|NCT03631797|PROCEDURE|Microvascular reactivity evaluation|Microcirculation will be evaluated for each patient before surgery with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of endothelium reactivity: Iontophoresis.
40932330|NCT03751774|BEHAVIORAL|MAMAACT|Post graduate training and health education materials
40932331|NCT02405936|PROCEDURE|Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.
40932332|NCT04144491|DIETARY_SUPPLEMENT|Probiotic|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.~100ml of yoghurt containing Lactobacillus rhamnosus yoba 2012 will be consumed 5 days per week, for 9 weeks."
40932333|NCT04144491|DIETARY_SUPPLEMENT|Placebo|100ml of custard will be consumed 5 days per week, for 9 weeks.
40932334|NCT05727384|DRUG|Clazakizumab|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
40932335|NCT05727384|DRUG|Placebo|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
40932336|NCT00829985|BIOLOGICAL|Glycerinated German Cockroach Allergenic Extract|Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
40932337|NCT00829985|BIOLOGICAL|Placebo|Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
40932338|NCT01383668|DRUG|sirolimus|Given PO
40932339|NCT01383668|DRUG|gold sodium thiomalate|Given IM
40932340|NCT01383668|OTHER|pharmacological study|Correlative studies
40932341|NCT01383668|GENETIC|RNA analysis|Correlative studies
40932342|NCT01383668|GENETIC|polymerase chain reaction|Correlative studies
40932343|NCT03249220|DEVICE|Placement of the CBMS Probe|Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
40932344|NCT00667446|DRUG|Leuprolide Acetate 3 Month Depot|
40932345|NCT04240353|OTHER|COPD digital support service|Use of COPD digital services to record patient symptoms, integrate physiology monitoring, communicate with the clinical team and track interaction
40932346|NCT01110070|DEVICE|ChonDux|Comparison of ChonDux plus microfracture to microfracture only
40932347|NCT01110070|DEVICE|ChonDux|single use device
40932348|NCT01355029|BEHAVIORAL|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
40932349|NCT00702572|DRUG|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which \<2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
40932350|NCT00702572|DRUG|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
40932351|NCT05030961|BEHAVIORAL|Virtual team-based clinic|Virtual team-based clinic will include consultation, counseling, and education from pediatric audiology, psychology, auditory verbal therapy, and education. Each session lasts approximately 30 minutes with a total of 3 sessions within the year.
41279052|NCT01176006|PROCEDURE|Donor peripheral blood stem cell mobiliation and collection|Donors undergo peripheral blood stem cell (PBSC) collection by apheresis will have their CD34 cells mobilized into the blood with filgrastim (Neupogen, Amgen)
41279053|NCT01176006|PROCEDURE|Bone Marrow Harvest Procedure|Bone marrow from haploidentical related donors, and, in some cases, matched related donors will be harvested under routine conditions in the operating room. General or spinal anesthesia will be employed.
41279054|NCT06004661|DRUG|AAA617|Administered intravenously once every cycles (1 cycle = 6 weeks)
41279055|NCT06004661|DRUG|68Ga-PSMA-11|Single intravenous dose of approximately 150 MBq
41279056|NCT05177796|DRUG|Carboplatin|Given IV
41279057|NCT05177796|DRUG|Cyclophosphamide|Given IV
41279058|NCT05177796|DRUG|Doxorubicin|Given IV
40932352|NCT05030961|BEHAVIORAL|Remote cochlear implant programming|Remote cochlear implant programming will be provided via Zoom on a study-provided encrypted laptop.
40932353|NCT01847911|OTHER|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
40932354|NCT01847911|OTHER|instructor training|a pre-validated OSCE neonatal resuscitation program
40932355|NCT00066144|DRUG|Cimicifuga racemosa|
40932356|NCT00066144|DRUG|Trifolium pratense|
40932357|NCT00066144|DRUG|Black cohosh|
40932358|NCT00066144|DRUG|Red clover|
40932359|NCT04110600|OTHER|Coffee effect on early gastric motility|this group 100ml coffee after two hours
40932360|NCT04110600|OTHER|Efficacy pepper mint oil on motility|This group 100me pepper mint oil after 2 hours
40932361|NCT04562272|PROCEDURE|LV mechanical unloading by Impella-CP|The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)
40932362|NCT01685346|BEHAVIORAL|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
40932363|NCT02981355|PROCEDURE|Microfracture treatment|Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.
40932364|NCT02981355|DEVICE|BST-CarGel|BST-CarGel is combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following microfracture arthroscopic surgery.
40932365|NCT03128151|BEHAVIORAL|Educational program for clinicians: implementation of a package of clinical prevention measures of NMB|Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
40932366|NCT05851001|OTHER|Progressive Muscle Relaxation exercise|This intervention consists of two parts. The first part (11 minutes) gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are 27 minutes of relaxation exercises accompanied by command with background music.
40932367|NCT05851001|OTHER|Muscle relaxation exercise|The participant was asked to listen to relaxation music for 30 minutes in a private room.
40932368|NCT00321087|DRUG|T2000|Dose escalation from 600 to 1000 mg
40932369|NCT00321087|DRUG|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
40932370|NCT00321087|DRUG|T2000|Placebo followed by dose escalation from 600 to 1000
40932371|NCT03231150|PROCEDURE|Local Steroid Injection into the plantar heel|Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.
40932372|NCT03231150|PROCEDURE|Ultrasound Guided Injection|Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach
40932373|NCT03231150|PROCEDURE|Anatomical Guided injection|Execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach.
40932374|NCT06275529|PROCEDURE|Transforaminal Epidural Steroid Injection|"Epidural injections have been used since about 1900 for the treatment of low back and lower extremity pain, with steroids added to local anesthetics in about 1950. The epidural space can be entered by 3 approaches: caudal, interlaminar, and transforaminal. Transforaminal Epidural Steroid Injections:~After the patient is monitored in pron position and asepsis is ensured, the epidural space is entered with the appropriate needle through the transforaminal space by giving the necessary angles to the fluoroscopy. Then the location is confirmed with radiopaque agent and steroid injection is performed. The procedure takes 15-20 minutes."
40932375|NCT00967928|DRUG|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
41279059|NCT05177796|DRUG|Paclitaxel|Given IV
40932376|NCT00967928|DRUG|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
40932377|NCT00967928|RADIATION|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
41279060|NCT05177796|BIOLOGICAL|Panitumumab|Given IV
41279061|NCT05177796|BIOLOGICAL|Pembrolizumab|Given IV
40932378|NCT00244842|DRUG|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
41279062|NCT02642042|DRUG|Docetaxel|Given IV
41279063|NCT02642042|OTHER|Laboratory Biomarker Analysis|Correlative studies
41279064|NCT02642042|DRUG|Trametinib|Given PO
40932379|NCT00244842|DRUG|Placebo|Placebo
41129632|NCT05124613|OTHER|Survey|"Information collected and stored in Survey:~* Type of knee surgery the patient is waitlisted for~* Demographics: age, sex, recent weight gain~* Validated and bespoke questions:~  1. EQ-5D survey (a validated questionnaire on health)~ 2. Bespoke questions on knee pain today~ 3. Bespoke questions on knee function today~ 4. Bespoke questions on change in knee pain since being waitlisted for surgery~ 5. Bespoke questions on change in knee function since being waitlisted for surgery~ 6. Bespoke questions on coping mechanisms patients use to manage symptoms~ 7. Bespoke questions on what support they would find beneficial whilst they wait for their surgery~ 8. Three bespoke questions about COVID-19 (Have they ever tested positive/Has the pandemic changed their mind about wanting surgery/Has the perception of their knee pain and function changed since the first lockdown was introduced?)"
41279065|NCT06352177|OTHER|Noom Weight Application|This commercially available program (Noom Weight) promotes clinically significant body weight loss and behavior change in multiple populations. The program is delivered through a smartphone application and includes self-monitoring and feedback features for diet, physical activity, and body weight, as well as digital access to a 1:1 behavior change coach, a support group facilitated by a health coach, and a curriculum delivered via daily articles focused on nutrition, physical activity, and sustainable behavioral change.
41129633|NCT04970511|BEHAVIORAL|BBAT (Basic Body Awareness Therapy)|The group I: BBAT Face-to-Face Training (60 min) will be provided.
41129634|NCT04970511|BEHAVIORAL|Online BBAT training|The group II: Online BBAT training (60 min) will be provided.
40932380|NCT05684731|BIOLOGICAL|KM1|Administer via intraperitoneal infusion for 3 or 6 doses Q3D.
40932381|NCT05684731|DRUG|Chemotherapy|"Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6."
41129635|NCT03275961|BEHAVIORAL|Stress Management and Resiliency Training|Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
40932382|NCT02764021|DIETARY_SUPPLEMENT|Carbohydrate-Restricted Diet|Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
40932383|NCT02764021|DIETARY_SUPPLEMENT|Standard Antidiabetic Diet|Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
40932384|NCT02820701|PROCEDURE|OMT|Osteopathic Manipulative Treatment to low back region
40932385|NCT05458726|DRUG|Osimertinib|Osimertinib or chemotherapy
41279073|NCT05423379|DEVICE|XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS)|XIENCE Skypoint Large Vessel EECSS is composed of a L-605 CoCr stent and coated with poly (n-butyl methacrylate) (PBMA) primer and a drug coating formulation of polymer of vinylidene fluoride and hexafluoropropylene (PVDF-HFP)/everolimus pre-mounted on a balloon catheter delivery system.
41279074|NCT04996797|DRUG|Tulisokibart|Administered by IV infusion
41279075|NCT04996797|DEVICE|Companion Diagnostic (CDx) Testing|PRA023 CDx Genotyping Assay
41279076|NCT04996797|OTHER|Placebo|Placebo administered by IV infusion
40932386|NCT02708303|OTHER|Mayo Clinic Foregut Surgery Report Card Questionnaire|"Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.~Data collected from the questionnaire will be entered into a database that will be maintained for future research."
40932387|NCT03409042|BEHAVIORAL|Caloric compensation|The investigators have adapted an established within-subject preload paradigm to assess infant's short term caloric compensation. At each studied age, the measure of caloric compensation required two visits at the laboratory on two non-consecutive days. On the first visit, the infants received a fixed amount of a food preload either low or high in energy density. The order of the two preloads was counterbalanced. After a delay (ranging from several hours in the 3-4 months old infants to 25 min in 10.5- and 14.5-month-old infants), the infants were served an ad libitum meal. Weight intakes (g) were assessed by weighing each bottle/bowl before and after consumption.
40932388|NCT01983150|BEHAVIORAL|Crush the Crave Application|Crush the Crave (CTC) allows users to customize a quit plan by choosing a quit date and then deciding whether to quit now or cut down the number of cigarettes they smoke every week up to the quit date. CTC reminds users of money saved and health improvements. Based on contingency reinforcement, rewards are provided, which smokers can then choose to share with their social network via Facebook. Supportive text messages tailored to their specific quit plan and where they are in the quitting experience are provided. CTC allows tracking of daily smoking habits and cravings as well as craving triggers or psychosocial determinants by recording when, where and why smoking occurred. Online distractions to help smokers deal with cravings are provided.
40932389|NCT01983150|BEHAVIORAL|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
40932390|NCT01323920|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 IV
40932391|NCT01323920|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg PO bid
40932392|NCT01323920|DRUG|Methotrexate|Methotrexate 15 mg/m\^2 IV
40932393|NCT05742178|BEHAVIORAL|Patient Navigation (PN) - More Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for cancer screening status and social needs and provide navigational support to cancer screening and social services.
40932394|NCT05742178|BEHAVIORAL|Educational Materials|Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.
40932395|NCT05742178|BEHAVIORAL|Patient Navigation (PN) - Less Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for social needs and provide navigational support to social services.
40932396|NCT04537221|BIOLOGICAL|Blood transfusion|Transfusion of red blood cells peri-operatively
40932397|NCT03500081|DEVICE|MRI Scan|The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.
40932398|NCT00507468|PROCEDURE|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
40932399|NCT02780674|BIOLOGICAL|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
40932400|NCT02780674|BIOLOGICAL|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
40932401|NCT00796354|DRUG|MOVICOL|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
40932402|NCT00796354|DRUG|Sugar Pill|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
40932403|NCT04241679|DEVICE|Auditory Nerve Test System|"The Auditory Nerve Test System provides an electrically-evoked signal from within the cochlea to facilitate intraoperative auditory nerve monitoring. The auditory nerve can be measured both at the root entry zone of the brainstem (eCNAP) and with scalp electrodes (eABR). Data on the health of the auditory nerve will be collected immediately prior to tumor dissection, during tumor dissection, and immediately after tumor dissection. The main purpose of this study is to determine feasibility of this novel intraoperative monitoring protocol.~Secondarily, if the auditory nerve is visually confirmed to be intact following tumor resection then the patients will receive a cochlear implant during the same surgery."
40932404|NCT03120455|BEHAVIORAL|Almond Group|Obese or overweight female adults will be randomly allocated to have almond as afternoon snacks, while they have a hypoenergetic diet.
40932405|NCT03120455|BEHAVIORAL|Pistachio Group|Obese or overweight female adults will be randomly allocated to have Pistachio as afternoon snacks, while they have a hypoenergetic diet.
40932406|NCT03120455|BEHAVIORAL|Nut free group|Obese or overweight female adults will be asked to avoid nuts, seeds and nut products, while they have a hypoenergetic diet.
40932407|NCT01936402|BEHAVIORAL|Education of chest compression depth|An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
41129636|NCT05860504|DIAGNOSTIC_TEST|Echocardiography|All patients in the study will be examined with echocardiography
41129637|NCT05860504|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
41129638|NCT05860504|DIAGNOSTIC_TEST|Coronary CT|Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
41129639|NCT02613403|DRUG|MK-3682B|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
40932408|NCT04259723|OTHER|VR during TAVI|Virtual Reality (VR) glasses
40932409|NCT00799773|DRUG|Rituximab|Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
40932410|NCT00799773|PROCEDURE|Plasma exchange|Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.
40932411|NCT00799773|DRUG|Corticosteroids|1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
40932412|NCT05111275|OTHER|Cognitive exercises|Exercises that stimulate and train memory, attention, executive functions, language and gnosis.
40932413|NCT00141570|DRUG|esterified estrogens 0.625 mg and methyltestosterone 1.25 mg|
40932414|NCT04052724|BEHAVIORAL|Intervention group LINGI|Intervention based on cognitive behavioural therapy principles and culturally adapted to Lithuanian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
40932415|NCT04700033|DEVICE|Somatic IVR (sIVR)|This intervention will consist of an IVR protocol that is focused on somatic interaction that encourages disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
40932416|NCT04700033|DEVICE|Distractive IVR (dIVR)|This intervention will consist of an IVR that is focused on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
40932417|NCT04700033|DEVICE|Control IVR (cIVR)|This intervention will consist of an IVR exposure to a black screen for 20 minutes. No light, images or scenery will be present in the IVR and it will serve as a control condition for the trial.
40932418|NCT00265928|DRUG|bortezomib|
40932419|NCT00265928|DRUG|rituximab|
40932420|NCT00265928|PROCEDURE|antibody therapy|
40932421|NCT00265928|PROCEDURE|biological therapy|
40932422|NCT00265928|PROCEDURE|enzyme inhibitor therapy|
40932423|NCT00265928|PROCEDURE|monoclonal antibody therapy|
40932424|NCT02592187|BEHAVIORAL|ReMemory-MCI training|
40932425|NCT02592187|BEHAVIORAL|Control intervention|
40932426|NCT00458874|BEHAVIORAL|CIMT results|"Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial."
40932427|NCT02918981|BEHAVIORAL|Resistance Exercise|Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
40932428|NCT02918981|DIETARY_SUPPLEMENT|14 g Whey protein|
40932429|NCT02918981|DIETARY_SUPPLEMENT|6.6 g Whey protein + 1.25 g leucine|
40932430|NCT02918981|DIETARY_SUPPLEMENT|4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides|
40932431|NCT02918981|DIETARY_SUPPLEMENT|6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline|
40932432|NCT02918981|OTHER|Water control|
40932433|NCT00809029|OTHER|GIP (glucose dependent insulinotropic peptide) infusion|an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.
40932434|NCT04510636|DRUG|Pembrolizumab|Pembrolizumab is a intravenously administered humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
40932435|NCT04510636|DRUG|Bendamustine Hydrochloride|Bendamustine is a unique alkylating agent with substantial activity in hematologic malignancies.
40932436|NCT02179138|DRUG|TFV 1% gel|
40932437|NCT00150644|DRUG|Asoprisnil|Asoprisnil 10mg Tablet, oral Daily for 12 weeks
40932438|NCT00150644|DRUG|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
40932439|NCT00150644|DRUG|Placebo|Placebo Tablet, oral Daily for 12 weeks
40932440|NCT03699384|DRUG|Azacitidine|AZA 75 mg/m\^2 SC or IV D 1-7 28 day cycle x 1
40932441|NCT03699384|DRUG|Avelumab|Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
40932442|NCT06327542|OTHER|Group Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
40932443|NCT06327542|OTHER|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90-120 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
40932444|NCT03774095|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil|Given 30 min prior to oral glucose tolerance test
40932445|NCT03774095|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil and olive oil|Given 30 min prior to oral glucose tolerance test
40932446|NCT03934814|DRUG|TJ011133|TJ011133 will be administered weekly.
40932447|NCT03934814|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks.
40932448|NCT03934814|DRUG|Rituximab|Rituximab will be administered weekly for 5 doses, then followed by monthly doses.
41129640|NCT02613403|DRUG|Ribavirin|Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
41129641|NCT01761487|DEVICE|Gentamicin and polymyxin E|
41279077|NCT02922764|DRUG|RGX-104|
41279078|NCT02922764|DRUG|Ipilimumab|
41279079|NCT02922764|DRUG|Docetaxel|
40932449|NCT02632838|DEVICE|iHealth BP7-Wireless Blood Pressure Wrist Monitor,|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor at home. This monitor is a fully automatic wrist cuff blood pressure monitor that uses the oscillometric principle to measure blood pressure and pulse rate. The monitor works with mobile devices to test, track and share vital blood pressure data. The Bluetooth sync system allows the monitor to send BP measures and pulse rate to patients' mobile devices. The free iHealth app automatically keeps a history of BP data and gives patient the option to share their blood pressure data with their provider. In addition to keep the data on the mobile device, patient also receive a free and secure cloud account. Vital data on the cloud allows patients to access from any computer and to share with their provider.
40932450|NCT00006487|DRUG|cisplatin|"During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
40932451|NCT00006487|DRUG|etoposide|"During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion~During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion."
40932452|NCT00006487|DRUG|tirapazamine|"During induction:~Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion~During consolidation:~330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
40932453|NCT00006487|RADIATION|radiation therapy|Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
40932454|NCT01975987|DEVICE|Bonfils fiberscope|
40932455|NCT04964284|BIOLOGICAL|rhTSH|rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH
41129642|NCT06116929|OTHER|Morphological and functional magnetic resonance imaging (MRI)|"Patients will undergo 3 morphological and functional MRI scans (during rest and activity) on the 3T MRI scanner at St Philibert Hospital (Lille, France) at 0 (M0), 6 (M6) and 12 (M12) months.~The controls will perform a single functional MRI on the 3T MRI."
41129643|NCT06116929|OTHER|Neuropsychological assessment|"3 neuropsychological assessments will be carried out at M0, M6 and M12, by the same neuropsychologist for all patients included.~Controls will undergo the same neuropsychological assessments, but only once."
41129644|NCT00329862|PROCEDURE|Laparoscopic Truncal Vagotomy|
41129645|NCT00076115|DRUG|Risperidone|
41129646|NCT05371951|DEVICE|Erchonia HLS|84 procedure administrations with the Erchonia® HLS™ administered by the subject at home: twice daily procedure administrations for 6 weeks.
41129647|NCT04015505|BEHAVIORAL|Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'|The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
41279080|NCT02922764|DRUG|Pembrolizumab|
41129648|NCT05193799|DEVICE|Investigational devices must be used 8 hours per day|During 3 consecutive days
41129649|NCT01170208|DEVICE|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
41129650|NCT03406169|DRUG|Sildenafil 25 MG Oral Tablet|twice a day dosing
41129651|NCT03406169|DRUG|Pentoxifylline|400mg twice a day
41129652|NCT03406169|OTHER|Placebo|placebo twice a day
41279081|NCT02922764|DRUG|Carboplatin|
41279082|NCT02922764|DRUG|Pemetrexed|
41279083|NCT03976089|BEHAVIORAL|Recipe 4 Success|"The Recipe 4 Success intervention consisted of 10 weekly lessons in which parents and toddlers prepared simple snacks or meals.~All Recipe 4 Success lessons started and ended with some evidence-based information for the parents about children's self-regulation skills or healthy eating habits. Most of each lesson in Recipe 4 Success was devoted to the snack or meal preparation activities. Each week, home visitors coached the parents as they worked with their toddlers to make increasingly challenging snacks and meals. During these activities, home visitors pointed out opportunities for parents to practice sensitive scaffolding strategies. At the same time, these meal and snack preparation activities allowed children to practice multiple age-appropriate self-regulation skills."
41279084|NCT03976089|BEHAVIORAL|Treatment as Usual Early Head Start|Treatment as Usual Early Head Start consisted of an evidence-based curriculum (usually Parents as Teachers) in which home visitors and parents worked with children on activities to support their physical, cognitive, and social-emotional development.
41129653|NCT00246805|DEVICE|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
41279085|NCT05609526|OTHER|Compression Therapy|6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.
41279086|NCT05609526|OTHER|Inspiratory muscle training|Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time per day will be 30 minutes.
40932456|NCT04964284|RADIATION|Radioiodine (131I)|Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).
41129654|NCT03019835|DRUG|Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery|
41129655|NCT03019835|OTHER|Spontaneous recovery|just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
41129656|NCT03577106|DEVICE|Transcranial magnetic stimulation (TMS)|Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
41129657|NCT01238042|DRUG|HPPH|3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
41129658|NCT03139331|DRUG|Pazopanib|Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.
41129659|NCT03139331|DRUG|Irinotecan|"Patients will be given irinotecan at a dose of 25 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 25 to 37.5 mg/m2/dose or orally at a dose of 45 to 67.5 mg/m2/dose on days 1-5 of a 21-day cycle.~Note that some patients enrolled on an earlier protocol version received 50 mg/m2/dose IV on days 1-5 of the first 21-day cycle and then either 50 mg/m2/dose IV or 90 mg/m2/dose orally for subsequent 21-day cycles. This higher dose level is no longer being given to newly enrolled subjects."
41129660|NCT03139331|DRUG|Temozolomide|Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
41129661|NCT01370928|DEVICE|Olympus PCF-Y0014-L|Screening colonoscopy with a prototype colonoscope
41129662|NCT01370928|DEVICE|Standard colonoscope|Screening colonoscopy
41129663|NCT02226159|DRUG|Lidocaine|
41129664|NCT02226159|DRUG|Lidocaine with Dexamethasone|
41129665|NCT00447837|DRUG|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
41129666|NCT02190149|BIOLOGICAL|ADVATE (Antihemophilic Factor [Recombinant])|
41129667|NCT02190149|BIOLOGICAL|RIXUBIS (Coagulation Factor IX [Recombinant])|
41129668|NCT03394105|DRUG|intrapleural docetaxel administration|intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer
41129669|NCT04806100|DEVICE|Malleo-Lok|The Malleo-Lok is a novel, low-profile carbon fiber device with two laterally positioned struts aligned in the sagittal plane.
41129670|NCT04690075|DIETARY_SUPPLEMENT|Nutrition Management and Dietary Fiber|Routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
41129671|NCT04690075|DIETARY_SUPPLEMENT|Nutrition Management|Routine nutrition management for 12 weeks.
41129672|NCT03640299|PROCEDURE|ERAS procedure|Optimized preoperative, intraoperative and postoperative procedures.
40932457|NCT06522191|OTHER|Physiotherapy Training (PT)|Both groups received the same therapist-led standardized PT for 5 days a week including 2 days of RR plus 3 days of conventional rehabilitation (CR) for 5 weeks. RR training will be given 40 min per session using an intelligent feedback robotic system. The system allows patients to move a cursor to targets on a monitor using a unilateral exoskeleton robotic arm and handle, which supports shoulder, elbow, forearm, and optionally multi-joint movements. The system provides visual and auditory feedback, offering exergame training with 1Dimension (D), 2D, and 3D options adjustable to three levels (low to high). Exergames and their parameters will be customized based on each patient's capacity. The CR protocol consists of joint range-of-motion, correct movement, stretching and balance exercises, gait training (walking on level surfaces, stairs), strengthening of antagonist muscle pattern will be provided. Each CR session will last 45 min of active treatment.
41129673|NCT01102699|DRUG|Filgrastim, hrG-CSF|Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
41129674|NCT06451770|DRUG|VERVE-201|Intravenous (IV) infusion
41129675|NCT03535272|DRUG|Bismuth subsalicylate|We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
41129676|NCT03535272|DRUG|Placebo Oral Tablet|Placebo manufactured to mimic pepto bismol
41129677|NCT01836445|BEHAVIORAL|Keep It Up!|
41129678|NCT01836445|BEHAVIORAL|HIV Knowledge Control|
41129679|NCT04175405|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser with a dose of 10J
41129680|NCT02455765|OTHER|Rice and Amino Acid mixtures|Rice and amino acid mixture
41129681|NCT02897206|DRUG|Imipenem|A wide-spectre antibiotic from the carbapenem group
41129682|NCT02897206|DRUG|Placebo|An imipenem-matching placebo
41129683|NCT05561231|PROCEDURE|Intubation with C blade|Intubation with C blade of CMAC videolaryngoscope
41129684|NCT05561231|PROCEDURE|Intubation with D blade|Intubation with D blade of CMAC videolaryngoscope
41129685|NCT01578941|OTHER|Diary|"Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (\>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM."
41129686|NCT02284113|DEVICE|iovera°|Use of iovera° device to administer treatment Focused Cold Therapy
41129687|NCT02284113|DEVICE|iovera° Sham|iovera° device used for sham treatment
41129688|NCT06396975|PROCEDURE|robotic surgery|robotic surgery
41129689|NCT03948542|OTHER|Outcome|"Nerve Recovery~* NCV~* Funcional assessment"
41129690|NCT03933800|DEVICE|High flow nasal cannula|High flow nasal cannula therapy
41129691|NCT03933800|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure therapy
41129692|NCT01358669|DRUG|Denosumab|60mg denosumab by injection as a single dose
40932458|NCT06522191|DEVICE|Cross-Education Intervention|Participants in the CE group will have the less affected upper extremity undergo game-based, unilateral, repetitive movement training using RR to enhance the effectiveness of the training to be provided to the affected side. Similar therapeutic games (exergames) planned for the more affected upper extremity will be selected through the unilateral exoskeleton RR device. As described in the PT section, upper extremity movements will be performed using the robotic arm and handle during the games. The difficulty level will be adjusted by the supervisor physiotherapist based on the grip threshold on the robotic handle, the game's difficulty level (low to high), workspace arrangement before each session, and suspension level according to the patient's needs. An approximately 20-minute program will be implemented, consisting of 8 games, each lasting about 2.5 minutes, tailored to the patient's capacity.
40932459|NCT06522191|OTHER|Control Intervention|The exercises to be administered in the control intervention will be selected based on the patient's level of impairment but will be planned without progression or intensity increase, and the involvement of the upper extremity will be kept to a minimum. The exercises will include lower limb joint range of motion exercises, weight bearing, weight shifting, and gait training.
40932460|NCT04623008|BEHAVIORAL|Goal-Oriented Episodic Future Thinking|Individuals in the intervention group will receive a 20-week web-based intervention and individual health coaching focused on stress management, healthy eating and physical activity.
40932461|NCT06206343|OTHER|TENS application, Tele-rehabilitation treatment program|Exercise training
40932462|NCT00469261|DRUG|Doxycycline|Doxycycline 100 mg bid for seven days after enrollment
40932463|NCT00469261|DRUG|Current medical therapy for AMI|Current medical therapy for AMI
40932464|NCT06228911|DRUG|steroid (triamcinolone)|triamcinolone is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions
40932465|NCT02065271|DIETARY_SUPPLEMENT|herbal supplement|
40932466|NCT02065271|OTHER|placebo supplement|
40932467|NCT00456807|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
40932468|NCT00456807|BIOLOGICAL|Cervarix TM|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
40932469|NCT05198700|DIETARY_SUPPLEMENT|Probiotic Formulation|Participants will be asked to take one sachet daily, containing 1 billion CFU of the probiotic formula. Sachets must be dissolved in warm water or mother's milk before consumption.
40932470|NCT05198700|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take one sachet containing the placebo daily. Sachets must be dissolved in warm water or mother's milk before consumption.
40932471|NCT02218632|OTHER|lactose-free diet|standard diet
40932472|NCT02218632|DIETARY_SUPPLEMENT|Temporary oral galactose supplements|galactose supplements in the range of physiological galactose production
40932473|NCT00821067|DIETARY_SUPPLEMENT|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
41129693|NCT01358669|OTHER|Placebo|Placebo by injection as a single dose
41279087|NCT05609526|OTHER|Calf muscle exercise training|A strengthening treatment program will be applied to the calf muscles.dorsiflexors and plantar flexors will consist of static stretching exercise, isotonic resistance exercise with elastic resistance bands, heel and toe raising in both feet, followed by toe raising and lowering without raising the heel.
41279088|NCT03436264|OTHER|MRI|fMRI
40932474|NCT00821067|DIETARY_SUPPLEMENT|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
40932475|NCT06341803|DEVICE|Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100|MagproX 100 and Axilium Cobot with Localite camera
40932476|NCT06335901|DRUG|Drug:Standard therapy|Percutaneous coronary Intervention
40932477|NCT04249609|OTHER|HCHO meals and exercise|Exercise will be conducted after high carbohydrate dinner and prior to high carbohydrate breakfast
40932478|NCT04249609|OTHER|LCHO meals and exercise|Exercise will be conducted after high fat dinner and prior to high fat breakfast
40932479|NCT03425227|OTHER|FRED EXERGAME|biofeedback with physiological constants as follows: systolic blood pressure, diastolic blood pressure, heart rate and blood oxygen saturation
40932480|NCT03067831|BIOLOGICAL|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
40932481|NCT01205178|DRUG|Chloroquine|The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.
40932482|NCT01205178|DRUG|Primaquine|Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment
40932483|NCT01205178|DRUG|Tafenoquine|Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
40932484|NCT01227564|BIOLOGICAL|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
41279089|NCT04034615|BIOLOGICAL|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
40932485|NCT01227564|BIOLOGICAL|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
40932486|NCT01227564|OTHER|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
40932487|NCT05191264|OTHER|EQ5D (EuroQol 5 Dimensions)|The evaluation of the quality of life was conducted with the EQ5D (EuroQol 5 Dimensions) score (min 0: bad health and max:100 good health).
40932488|NCT05191264|OTHER|Numerical Rating Scale (NRS)|the type and intensity of pain will be evaluated by Numerical Rating Scale (NRS) from 0 to 10 in different positions and in different activities (e.g. background pain, general maximum/minimum pain, pain of the site treated by the procedure, pain at rest, in lying position, in sitting position, in standing position, at bearing weight, in walking, description of painful irradiations, nocturnal awakenings).
40932489|NCT05191264|OTHER|evaluated the consumption of analgesics|the consumption of analgesics by step and by dosage will be evaluated.
40932490|NCT04036643|RADIATION|PET-MRI|Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
40932491|NCT01070147|OTHER|Computerized Asthma Management System|The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
40932492|NCT01698281|DRUG|AEZS-108|"AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity."
40932493|NCT01698281|DRUG|SCCC|"commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available."
40932494|NCT01698281|DRUG|Dexamethasone|Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
40932495|NCT03067233|OTHER|Polysomnography|Complete polysomnography with : Electroencephalogry, electro-oculography, surface electromyography (chin muscle, anterior tibial muscles), nasal pressure, respiratory movements (plethysmography of thoracic and abdominal inductance), pulse oximetry and electrocardiography.
40932496|NCT01804829|BIOLOGICAL|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
40932497|NCT00400114|DRUG|Irinotecan|Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
40932498|NCT00400114|DRUG|Cisplatin|Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
40932499|NCT00400114|PROCEDURE|Radiation|Radiation 50 Gy (weeks 4-9)
40932500|NCT00400114|PROCEDURE|Surgery|Esophagectomy
40932501|NCT00400114|DRUG|sunitinib (Sutent)|sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
40932502|NCT00003046|BIOLOGICAL|Recombinant Interleukin-12|Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
41449711|NCT05644184|BIOLOGICAL|Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
41449712|NCT00459407|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given orally
41449713|NCT00459407|DRUG|placebo|Given orally
41449714|NCT00459407|OTHER|immunohistochemistry staining method|Correlative studies
40932503|NCT03628261|DEVICE|Serious Game|Surface EMG detection for the myoelectric control of the EMG-based serious games and for the EMG assessment during gait will be performed with a wireless system.This device is composed of seven modules (sensor units), each detecting and transmitting two bipolar EMGs at 2 kilo Hertz (kHz). During the evaluation protocol EMGs will be detected from peroneus longus, gastrocnemius medialis, soleus and tibialis anterior muscles of both limbs using pre-gelled electrodes.
40932504|NCT03628261|OTHER|physical therapy|Children receive the regular rehabilitation for the treatment of ankle plantar flexor muscle overactivity and the paresis of ankle dorsal flexor muscle
40932505|NCT05629104|OTHER|There is no intervention since it is an observational study patients are treated according to clinical praxis|No intervention
40932506|NCT02829541|DRUG|BIIB068|Administered as specified in the treatment arm.
40932507|NCT02829541|DRUG|Placebo|Administered as specified in the treatment arm
40932508|NCT00939952|DRUG|ertapenem|500 mg IV once
40932509|NCT06381271|PROCEDURE|Transcatheter aortic valve replacement|A total of 500 consecutive patients with NAVR undergoing TAVR will be enrolled at 3-5 centers. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
40932510|NCT01166243|BIOLOGICAL|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
40932511|NCT01166243|PROCEDURE|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
40932512|NCT04330196|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participant ingests 75g of glucose
40932513|NCT04330196|DIAGNOSTIC_TEST|Ingestion of placebo|Participant ingests 700mg of aspartame
40932514|NCT00095680|DRUG|SCIO-469|two 30-mg capsules three times daily
41449715|NCT00459407|OTHER|immunoenzyme technique|Correlative studies
41449716|NCT00459407|OTHER|laboratory biomarker analysis|Correlative studies
41449717|NCT00459407|PROCEDURE|biopsy|Undergo biopsy
41449718|NCT00459407|OTHER|mass spectrometry|Correlative studies
41449719|NCT00459407|OTHER|high performance liquid chromatography|Correlative studies
41449720|NCT00673842|DEVICE|Implantable Cardioverter Defibrillator + Usual Care|Any Medtronic approved single chamber or dual chamber implantable cardioverter defibrillator (ICD)
41449721|NCT00673842|OTHER|Usual care|Usual post-MI care
41449722|NCT03068780|DRUG|Oleogel-S10|10% birch bark extract in 90% sunflower oil
41449723|NCT03068780|DRUG|Control gel|Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
41449724|NCT03612154|DRUG|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
40932515|NCT00095680|DRUG|SCIO-469 and bortezomib|The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
40932516|NCT06505967|DIETARY_SUPPLEMENT|Qualia NAD+|Qualia NAD+ is a novel dietary supplement, formulated to support the maintenance and enhancement of intracellular NAD levels.
40932517|NCT06505967|OTHER|Placebo|Rice flour
40932518|NCT00231374|PROCEDURE|Myelogram|
40932519|NCT03748043|DRUG|Lactoferrin|lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
40932520|NCT03748043|DRUG|Ferric Hydroxide Polymaltose|group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
40932521|NCT00466687|BIOLOGICAL|bevacizumab|10mg/kg, slow IV infusion, Days 1 and 14
40932522|NCT00466687|DRUG|erlotinib hydrochloride|150mg PO qd
40932523|NCT00466687|GENETIC|fluorescence in situ hybridization|Targeting multiple genetic aberrations in isolated tumor cells.
40932524|NCT00466687|GENETIC|gene expression analysis|gene expression analysis
40932525|NCT00466687|OTHER|immunologic technique|immunologic technique
40932526|NCT00466687|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
40932527|NCT00466687|PROCEDURE|biopsy|biopsy
41449725|NCT04435574|DRUG|Lactoferrin|Bovine Lactoferrin 100mg sachets.
41449726|NCT04435574|DRUG|Ferrous Sulfate|6mg/kg of ferrous sulfate.
40932528|NCT01490723|DRUG|Rituximab|250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
41129694|NCT06069700|OTHER|Non-pharmacological Individualized rehabilitative therapy|Treatments will be standardized but components of the treatments will be individualized to the participants based on what subgroup they're classified into at baseline based on their initial clinical examination and self-reported dominant impairment. \*Physiological group - Participants will receive supervised sub-symptom aerobic exercise 20-minutes twice per week and mindfulness-based training 20-minutes twice per week. \*Cervical group - Participants will receive physical therapy to the cervical spine. Physical therapy will include soft tissue therapy directed to the cervical myofascial tissues, and graded cervical spine facet mobilizations. \*Vestibulo-Ocular group - Patients classified to vestibulo-ocular subgroup will receive bi-weekly 30-minute individualized oculomotor, vestibular and balance exercises including adaptation exercises, gaze stability exercises, visual-vestibular integration exercises, habituation exercises, static and dynamic balance exercises.
41279090|NCT04034615|BIOLOGICAL|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
41279091|NCT04034615|BIOLOGICAL|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
41449727|NCT00382083|DRUG|1000 mg acetaminophen|
40932529|NCT01490723|DRUG|111In Ibritumomab|(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
40932530|NCT01490723|PROCEDURE|Planar Scintigraphy Imaging|Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
40932531|NCT01490723|DRUG|90Y IbritumomabTiuxetan|Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
40932532|NCT01490723|DRUG|Fludarabine|30 mg/m2 intravenously on Days -5, -4, and -3.
40932533|NCT01490723|DRUG|Bendamustine|130 mg/m2 intravenously on D-5, -4 and -3.
40932534|NCT01490723|DRUG|Thymoglobulin|1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
40932535|NCT01490723|DRUG|Tacrolimus|"Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.~For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present."
40932536|NCT01490723|DRUG|Methotrexate|5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
40932537|NCT01490723|DRUG|Mycophenolate|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
40932538|NCT01490723|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
40932539|NCT01490723|PROCEDURE|Stem Cell Transplantation|Stem Cell Transplantation on Day 0
41449728|NCT00382083|DRUG|800 mg ibuprofen|
41449729|NCT00382083|DRUG|1 oz 4% lidocaine gel|
41449730|NCT05716490|DEVICE|Incisional negative pressure wound therapy|Application of negative pressure wound therapy for prophylaxis of surgical site occurrences
41449731|NCT05716490|OTHER|Control group - standard wound dressing|Covering of surgical wound with standard wound dressing
41449732|NCT00161551|DEVICE|Vitatron T70 DR|
41449733|NCT04180969|DRUG|yohimbine + hydrocortisone|yohimbine 54mg + hydrocortisone 20mg oral
41449734|NCT04180969|DEVICE|medial prefrontal cortex rTMS|1 Hz mPFC rTMS
41449735|NCT04180969|DRUG|Placebo oral tablet|placebo stressor
41449736|NCT04180969|DEVICE|sham rTMS|sham mPFC rTMS
40932540|NCT05664854|DEVICE|Nerve cuff electrodes for spatially selective vagus nerve stimulation and electrical impedance tomography|Vagus nerve electrode cuffs will be placed on the exposed human vagus nerve during routine vagal nerve stimulator implantation surgery. These cuffs will then be used for spatially selective vagus nerve stimulation, with physiological readout, and electrical impedance tomography for the functional imaging of organ-specific regions in the nerve at cervical level.
40932541|NCT05779735|DIAGNOSTIC_TEST|Transperineal ultrasound measurements of AOP|The angle of progression (AOP) defined as the angle between the pubic bone axis and the leading part of the fetal head
40932542|NCT00102492|DRUG|GW679769|
40932543|NCT03790423|DRUG|Injection of 18F-ASIS|Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)
41129695|NCT06069700|OTHER|Non-pharmacological Usual care therapy|"All participants in the active control group will receive 'usual care', (twice a week for 6 weeks), which will consist of reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour. Additionally, participants will be afforded weekly 20-minute supervised progressive sub-symptom aerobic exercise sessions at the KITE clinic under the supervision of study coordinator NM. They will be instructed to also perform daily 20-minutes of subsymptom aerobic exercise outside the supervised exercise sessions."
40932544|NCT03790423|OTHER|PET/CT scan|Following one injection of 18F-ASIS the patients will be PET/CT scanned at 1 hour, 2 hours and 4 hours post-injection
40932545|NCT05956210|DEVICE|Evaluation of implementation regarding Philips Healthdot as monitoring device of hospitalized patients at one surgical ward|Hospitalized patients at one surgical ward will receive a Healthdot as monitoring device which will be used as primary monitoring after 3 months of preparation with education of hospital staff, improving infrastructure and training with application, activation and interpretation
40932546|NCT03624530|DRUG|Tyrosine kinase inhibitor (TKIs)|TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
40932547|NCT02480907|BEHAVIORAL|Workshop Group|Workshop support group
40932548|NCT02480907|BEHAVIORAL|Internet-based support group|Internet based support group with E-mail coaching
40932549|NCT04032574|COMBINATION_PRODUCT|Herbal Medicinal Product|
40932550|NCT04032574|OTHER|Placebo|
40932551|NCT00625703|DRUG|Linezolid|"Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid."
40932552|NCT01035450|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
40932553|NCT01035450|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent
40932554|NCT01449695|BEHAVIORAL|Life style counseling|A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.
40932555|NCT01449695|BEHAVIORAL|an individualized web portal|This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.
41129696|NCT04364867|DRUG|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
41129697|NCT04364867|DRUG|Pain Pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the PACU infusing at 4cc/hr. The patient will go home with that device until it runs out.
41129698|NCT04633941|OTHER|Standard Care|Standard Care
41279092|NCT05445193|BEHAVIORAL|PEaters Choice Module|There will be nine sessions conducted throughout the intervention period, which include module activity, assessment sessions and follow-up sessions. This module will have four primary sub modules (SM): SM1- An overview of picky eaters, SM2-Healthy eating for children, SM3-Parental Strategies and SM4- Sensory perception.
41449737|NCT05646823|DIETARY_SUPPLEMENT|Probiotic blend|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
41449738|NCT05646823|DIETARY_SUPPLEMENT|Placebo|vehicle only - Maltodextrin gluten free
41129699|NCT03380494|OTHER|Overhead perturbation training|A specifically chosen weight is attached to a 1m resistance band held above the head, hanging against gravity. The participant is encouraged to sustain a static position, where the weight and band provide variable magnitude perturbations to arm position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
41449739|NCT01306838|DIETARY_SUPPLEMENT|MicroLipid and fish oil|Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
41449740|NCT01306838|OTHER|Routine care|Routine care
41129700|NCT03380494|OTHER|Non-perturbed training|A weight is grasped by the participant and elevated above head to the same position as the OPT intervention. The participant is encouraged to sustain a static position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
41129701|NCT02540824|DRUG|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
41129702|NCT06395571|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Goat milk-based infant formula fed at age appropriate quantities for 24 weeks
41129703|NCT06395571|DIETARY_SUPPLEMENT|Cow's milk-based infant formula|Cow's milk-based infant formula formula fed at age appropriate quantities for 24 weeks
41129704|NCT01627561|BIOLOGICAL|Cervarix|2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6.
41129705|NCT01627561|BIOLOGICAL|Priorix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Day 0.
41129706|NCT01627561|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Month 6.
41129707|NCT03428698|DEVICE|Aminogam|A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.
41129708|NCT01467128|OTHER|Structured expert pharmacist review|The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
41129709|NCT01467128|OTHER|No Intervention|Normal hospital pharmaceutical care
41129710|NCT00455650|DRUG|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
41129711|NCT00455650|DRUG|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
41129712|NCT00455650|DRUG|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
41449741|NCT04170335|PROCEDURE|Bariatric surgery|Patients selected and consented for elective bariatric surgery will undergo standard of care preoperative mammogram, as well as inflammatory markers measurements and breast cancer risk score calculation. Post bariatric surgery the patients will have follow up mammogram, inflammatory markers, and breast cancer risk score calculation
41129713|NCT01718600|BEHAVIORAL|Neuropsychological testing|
41129714|NCT04688060|DIAGNOSTIC_TEST|Falls Efficacy Scale-International (FES-I)|The FES-1 was used to assess the fear of falling level of participants about falling during indoor or outdoor activities. It has 16 items scored on a four-point Likert scale. The Turkish validated version of the FES-I was used in this study. The total score (sum of the 16 responses) ranging from 16 to 64 points was used for data analysis. A higher score indicates better mobility performance. A cut-off score of 27 points on the 16- item FES-I was used to differentiate high concern for falling from low concern
41129715|NCT04570072|DIETARY_SUPPLEMENT|Probiotic|Patients receive the formula probiotic for consecutive 8 weeks ( one sachet per day ).
41129716|NCT04570072|DIETARY_SUPPLEMENT|Placebo|Patients receive the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
41449742|NCT02278757|OTHER|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
40932556|NCT01449695|BEHAVIORAL|individual and group consultations|group consultations with peers and a nurse individual consultation with a nurse
40932557|NCT04260243|OTHER|Experimental-Myofascial + Respiratory rehabilitation|6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
40932558|NCT04260243|OTHER|Sham Myofascial + Respiratory rehabilitation|6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
40932559|NCT04856475|DRUG|Neratinib|"As per investigator's choice, eligible subjects in all cohort will receive:~* Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~  * Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~ * Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~ * Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~* Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~  * T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)"
40932560|NCT05542277|DEVICE|ClearPlasma|ClearPlasma ClearPlasma™ is an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma™ is a non-pyrogenic, sterile, single-use medical device
40932561|NCT06438627|DRUG|TPC combined with Apatinib and Camrelizumab|Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab
40932562|NCT06438627|DRUG|GP Combined With Camrelizumab|Gemcitabine, Cisplatin regimen Combined With Camrelizumab
40932563|NCT04897139|DRUG|Flu-Bu-Mel-E|Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2
40932564|NCT05894122|DIAGNOSTIC_TEST|DM-DIV MITRA®|Comparison of phenylalanine concentrations in the new device with those in the current device (blotter).
40932565|NCT05860010|DRUG|Epinephrine injection|patients will be placed on left lateral position and drug will be given the caudal space
40932566|NCT05860010|DRUG|Dexmedetomidine|patients will be placed on left lateral position and drug will be given the caudal space
40932567|NCT05860010|DRUG|Bupivacaine|patients will be placed on left lateral position and drug will be given the caudal space
40932568|NCT04696497|DIAGNOSTIC_TEST|Ultrasound|"Ultrasound measurements of muscle thickness, using a linear probe (high frequency) on four muscle groups:~* Shoulder Side muscular compartment~* Anterior Arm muscular compartment~* Anterior thigh muscular compartment~* Antero-lateral leg muscular compartment"
40932569|NCT04696497|DIAGNOSTIC_TEST|Dynamometric muscular assessment|"The principle of electronic dynamometry is to measure an isometric force. To carry out these measurements, the examiner will stand on the side who has to be tested by exerting a pressure diametrically opposite to the patient's movement, thus preventing him/her from carrying out the movement. The patient will perform 3 tests for each movement, the best value will be collected by the examiner.~The reference position is :~Patient elbowed to the body bent at 90°, with trunk inclination at 30° in the resuscitation bed, lower limbs flat."
40932570|NCT04696497|DIAGNOSTIC_TEST|Manual muscular Assessment (MRC-SS)|Following the same positions as for the dynamometer, the examiner will evaluate the 12 motor functions according to the following 60-point rating. With the maximum quote of 5 point representing normal strength and 0 point the total absence of any muscular contraction
41449743|NCT02278757|OTHER|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
40932571|NCT00847171|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|"Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:~12 intradermal injections of a divided total dose of 5 x108 cells."
40932572|NCT00847171|BIOLOGICAL|trastuzumab|"Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.~Patient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg"
40932573|NCT00847171|DRUG|cyclophosphamide|Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
40932574|NCT00847171|OTHER|flow cytometry|Samples will be analyzed by flow cytometry using Cell Quest software
41449744|NCT03681977|DEVICE|Zimmer MP Persona|The medial pivot Persona® knee implant with a Medial Congruent™ Bearing
41449745|NCT03681977|DEVICE|Zimmer Persona Knee-PS|Persona the personalized knee system
40932575|NCT00847171|OTHER|immunoenzyme technique|
40932576|NCT00847171|OTHER|immunohistochemistry staining method|Measuring Immune Priming In Vivo By Vaccine Site Biopsies
41449746|NCT04697173|OTHER|Single consent|A single consent form for possible procedures the child may undergo while in the PICU
41449747|NCT00983996|DRUG|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
40932577|NCT00847171|OTHER|laboratory biomarker analysis|
40932578|NCT00847171|OTHER|pharmacological study|
40932579|NCT00847171|PROCEDURE|biopsy|skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only
41129717|NCT01220869|DRUG|Degarelix|Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
41129718|NCT04040296|OTHER|Kidney Action Team Recommendations|Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 30 minutes of AKI development. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
41129719|NCT01297894|DRUG|colistin|Colistimethate sodium 2.5-5mg/kg of colistin base
41449748|NCT00983996|DRUG|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
41129720|NCT01297894|DRUG|colistin plus fosfomycin|colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
41129721|NCT04124185|DIAGNOSTIC_TEST|Ocular assessments|Complete ocular examination, Axial length and corneal curvature, Optical Coherence Tomography, Visual acuity, Contrast sensitivity
41279093|NCT01526148|DRUG|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels \> 0.6mEq/L.
41279094|NCT01526148|DRUG|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
41279095|NCT04791943|DRUG|Melatonin 10 MG|3 melatonin 10mg capsules will be given to the treatment arm
41279096|NCT04791943|DRUG|Lactose pill|3 lactose pills will be provided to the control arm
41449749|NCT05275699|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
41449750|NCT01853722|DRUG|DCN01|Three serial applications per periocular region.
40932580|NCT03142061|PROCEDURE|Electrochemotherapy|Bleomycin plus local electroporation of cutan accessible tumor tissue in patients with advanced inoperable vulva carcinoma
40932581|NCT04215133|OTHER|exercise therapy|inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.
40932582|NCT02732743|DIETARY_SUPPLEMENT|Physiomanna® Baby|Dosage 1g/kg body, 2 cycles (if applicable)
40932583|NCT04512339|DRUG|Dupilumab|Dupilumab injections (blinded labels)
40932584|NCT04512339|DRUG|Placebo|Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance
40932585|NCT03304496|DRUG|Nitroglycerin 100 MCG/ML Injectable Solution|Previously described.
40932586|NCT03304496|DRUG|Saline Solution|Previously described.
40932587|NCT04573647|DRUG|Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]|Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
40932588|NCT05419479|DRUG|ZIMBERELIMAB|Via IV on two days per cycle, dosage per protocol
40932589|NCT05419479|DRUG|DOMVANALIMAB|Via IV on two days per cycle, dosage per protocol
40932590|NCT05419479|DRUG|APX005M|Via IV on two days per cycle, dosage per protocol
40932591|NCT05419479|DRUG|FOLFIRI|every two weeks through an infusion at a dose determined by physician
40932592|NCT04064567|BEHAVIORAL|PrEP-LINK|CHW will assist with healthcare and social service navigation and will utilize adherence counseling techniques. As per the model our intervention is based upon (the national Transitions Clinic Network \[TCN\]), our CHW has a history of incarceration. Participants randomized to the intervention group, the CHW will assist individuals with employment, housing (if needed), referrals to mental health or substance use treatment, keeping track of medical appointments and medication adherence.
40932593|NCT04064567|OTHER|Enhanced Standard of Care|Participants will receive education about PrEP and referral to a community PrEP provider which exceeds the standards of care these individuals would otherwise receive.
40932594|NCT01277042|BIOLOGICAL|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
40932595|NCT01277042|BIOLOGICAL|Engerix-BTM|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
41129722|NCT01083732|DRUG|dabigatran etexilate|Experimental dose chosen based on age and weight
41129723|NCT02502461|PROCEDURE|cuff palpation|Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
41279097|NCT01564979|DRUG|preseptal injection of botulinum toxin type A|botulinum toxin type A (Botox)2.5 units, 5 points
41279098|NCT01564979|DRUG|pretarsal injection of Botulinum toxin type A|Botulinum toxin type A 2,5 units, 5 points
40932596|NCT04665882|PROCEDURE|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
40932597|NCT00256282|DRUG|Vinorelbine|30 mg/m2 IV over 6-10 min every 14 days
40932598|NCT00256282|DRUG|Docetaxel|40mg/m2 IV over 1 hour every 14 days
40932599|NCT00256282|DRUG|Sargramostim|250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
41129724|NCT01437319|DEVICE|lotrafilcon A|To be used during run-in phase only.
41129725|NCT01437319|DEVICE|comfilcon A|To be assigned at randomization at phase 2 only.
41129726|NCT01437319|DEVICE|balafilcon A|To be assigned at randomization during phase 2 only.
41129727|NCT01437319|OTHER|etafilcon A|Assigned to Neophytes during Phase I for a 2-week period
41129728|NCT04174339|DRUG|Camrelizumab|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1
41129729|NCT04174339|DRUG|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID
41449751|NCT01853722|DRUG|Unisol|Three serial applications per periocular region.
41449752|NCT00955838|OTHER|Rehabilitation technique|12 therapy session
41449753|NCT02903407|DRUG|Midazolam|IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
41449754|NCT02903407|DRUG|Propofol|IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
41449755|NCT02903407|DRUG|Dexmedetomidine|IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
41279099|NCT06312306|DEVICE|transcranial direct current stimulation|Anodal tDCS applied using a direct current stimulator and two saline-soaked electrodes. The anode electrodes will be positioned approximately 2 cm anterior to Cz according to the International 10/20 EEG System. The cathode will be positioned over the inion. Stimulation intensity will be at 2.0 milliampere (as suggested to achieve excitation in the lower limb motor cortex areas)
41129730|NCT04174339|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
41449756|NCT04068818|DEVICE|ANTERION|Biometry images will be acquired on the ANTERION and the reference device and the image quality and the identification of abnormalities will be assessed by a reading center
40755448|NCT00576407|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Cultured thymus tissue for implantation (CTTI) (previously described as transplantation) is done using allogeneic cultured postnatal tissue from unrelated thymus donors. Thymus tissue, the thymus donor, \& thymus donor's birth mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were implanted into the recipient's quadriceps. Dose was number of grams of cultured thymus tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of CTTI, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-CTTI, subjects followed by routine research immune evaluations, using blood samples for approximately 2 years.
41129731|NCT04537741|PROCEDURE|Coronary CT angiography|all patients being included will undergo CCTA before invasive coronary angiography
41129732|NCT04537741|PROCEDURE|Invasive coronary angiography|all patients being included will undergo CCTA before invasive coronary angiography
41129733|NCT04038424|OTHER|Art therapy|Art therapy including coloring, painting and listening to music
41129734|NCT05623436|BEHAVIORAL|Nursing students will be trained through virtual reality.|Nursing students will be trained through virtual reality.
41129735|NCT00837954|DEVICE|Lyostypt® AND Surgicel®|"The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
41129736|NCT00837954|DEVICE|Lyostypt®|"The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII."
41449757|NCT05628103|DRUG|SEP-363856|SEP-363856 flexibly dosed
41279100|NCT06312306|OTHER|Pilates based core training|The Pilates training program will last 30 min per session, Each action in the training will be repeated eight times these actions are at beginner level, considering the characteristics of stroke patients. The selected exercises will be given to all patients and progressed week-wise.
41449758|NCT03600753|OTHER|culturomic|Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
40932600|NCT02360605|BEHAVIORAL|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
40932601|NCT02360605|BEHAVIORAL|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
40932602|NCT02360605|BEHAVIORAL|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
40932603|NCT00696475|DRUG|Diazoxide choline|
40932604|NCT00696475|DRUG|Diazoxide choline|
40932605|NCT00696475|DRUG|Diazoxide choline|
40932606|NCT00696475|DRUG|Placebo|
40932607|NCT04781660|DEVICE|Implantable Alginate Hydrogel|"Implantable Alginate Hydrogel is a single use, multiple component device. It is expected to be used as a space-occupying material implanted into the myocardium to affect the shape of the left ventricle and reduce the clinical symptoms of patients with left ventricular ischemia and non-ischemic cardiomyopathy.~The hydrogel serves as an artificial myocardial filler to stop the continuous expansion of the ventricle and restore it to a more favorable shape and size. The expected clinical effect of the Implanted Alginate Hydrogel is to reduce the clinical symptoms of patients and improve the quality of life by improving the structure and function of the failing heart."
40932608|NCT03687164|OTHER|Group Medical Visits|Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
40932609|NCT06107179|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|In MSOT, laser light is emitted into the target tissue via a handheld probe. Thermoelastic expansion of various molecules in the target area generates ultrasound waves that are detected by the transducer. The detected signals are reconstructed into images using algorithms. Spectral analysis of the optoacoustic signal at different wavelengths in the near-infrared range can detect individual chromophores, such as oxygenated and deoxygenated hemoglobin.
40932610|NCT03456609|DRUG|shenqifuzheng injection|500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
40932611|NCT03456609|DRUG|Sodium Chloride Injection 0.9%|500ml sodium chloride（0.9%）daily（at day 1-14 and day22-36）through intravenous infusion.
40932612|NCT01171833|DRUG|Sevoflurane|2.0 vol% prefilled in a corrugated circuit.
40932613|NCT01171833|DRUG|Desflurane|6.0 vol% prefilled in a corrugated circuit.
40932614|NCT01171833|DRUG|Isoflurane|1.2 vol% prefilled in a corrugated circuit.
40932615|NCT02942329|DRUG|apatinib|Apatinib was administered 250mg or 375mg orally daily. For gastric cancer patients, the dose would be 250mg or 375mg daily. For hepatocellular carcinoma patients, the dose would be 250mg daily.
40932616|NCT02942329|DRUG|SHR-1210|SHR-1210 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
41129737|NCT00837954|PROCEDURE|Surgicel®|"The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
41129738|NCT03524755|OTHER|Exercise|
41279101|NCT06312306|OTHER|conventional physiotherapy program|"Conventional physiotherapy program:~* Stretching Slow sustained stretching of spastic muscles (generally hip flexors and adductors, knee extensors or flexors and ankle plantar flexors)~* Strengthening Abdominals, lumbar spine extensors, hip flexors, extensors and abductors, knee extensors and flexors and ankle dorsi flexors~* Gait training In level surface and in stairs"
41279102|NCT01178021|DRUG|Chloroquine|Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2
41279103|NCT01178021|DRUG|Chloroquine/Primaquine|Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
41279104|NCT03315429|DIAGNOSTIC_TEST|stress echocardiography|stress testing of patients with functional mitral regurgitation
41279105|NCT00924989|DRUG|OSI-906|Administered orally
40932617|NCT05555771|BEHAVIORAL|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating three commonly recommended maneuvers of arm tensing, squatting, and leg crossing with arm tensing. Maneuvers should be held for 1-2 minutes, or until symptoms subside.
41129739|NCT03454113|DEVICE|Ellipsys Vascular Access|The Ellipsys Vascular Access System comprises the Ellipsys Catheter, Ellipsys Crossing Needle and Ellipsys Power Controller. The Ellipsys Crossing Needle is used to facilitate access between the artery and the vein. The Ellipsys Catheter is placed percutaneously into the selected vein in close proximity to the selected artery. The Ellipsys Catheter is actuated at the selected anastomosis site, and the vein and artery are approximated. Once the vessels are in the appropriate relative positions the catheter is connected to the Ellipsys Power Controller to create the anastomosis after which the Ellipsys Catheter is removed, and the access site is closed using standard percutaneous closure techniques.
41279106|NCT00924989|OTHER|Placebo|Matching placebo administered orally
40932618|NCT05555771|BEHAVIORAL|Usual Care|Participants will engage in behavioural interventions and avoidance measures that are commonly recommended as a part of usual care for recurrent syncope. This primarily includes recommendations such as staying hydrated, increasing salt intake, avoiding warm temperatures, avoiding standing for long periods of time, and engaging in regular physical activity. Some patients may be prescribed medication (Midodrine, Fludrocortisone), or other assistive interventions (e.g., compression stockings) at the discretion of their physician.
40932619|NCT03418571|BIOLOGICAL|ALX-0171 1.5 mg/kg|ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
40932620|NCT03418571|OTHER|Placebo|Placebo was administered via a single inhalation once daily for 3 consecutive days.
40932621|NCT05039827|OTHER|Mobilization with movement|Heating fermentation was done for 10 minutes as baseline treatment. MWM with wrist extension was given for alternative days in a week as per 3 sessions per week for 4 weeks.
40932622|NCT05039827|OTHER|Soft Tissue Mobilization|Heating fermentation was done for 10 minutes as baseline treatment. Parallel and longitudinal massage was given for alternative days in a week as per 3 sessions per week for 4 weeks
40932623|NCT05045066|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
40932624|NCT05045066|OTHER|Quality-of-Life Assessment|Ancillary studies
41279107|NCT02561897|DRUG|Edoxaban|
41279108|NCT02561897|DRUG|Warfarin|
41279109|NCT00592683|DRUG|Aripiprazole|tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
41279110|NCT00592683|DIETARY_SUPPLEMENT|fish oil|1600mg (4 capsules) daily for 12 weeks
41279111|NCT00592683|DRUG|Placebo|Placebo
40932625|NCT05045066|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40932626|NCT05728775|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia.
41449759|NCT03600753|OTHER|Metagenomic|Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
40932627|NCT05728775|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia.
40932628|NCT05124418|DIAGNOSTIC_TEST|palatal masticatory mucosa thickness measurement|Measure the thickness of palatal masticatory mucosa by a dynamic navigation system (Navident®, ClaroNav Inc., Toronto, Canada) and periodontal probe piercing.
40932629|NCT01640093|DRUG|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
40932630|NCT01640093|DRUG|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
40932631|NCT01640093|DRUG|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
40932632|NCT01640093|DRUG|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
40932633|NCT02259075|DRUG|Botulinum Toxin Type A|
40932634|NCT03809793|OTHER|Exercise Program|12-week walking based intervention (3 sessions per week)
40932635|NCT03809793|DIAGNOSTIC_TEST|DXA|Participants will undergo an assessment of body composition (DXA)
40932636|NCT03809793|DIAGNOSTIC_TEST|MRI|used to measure fat stored in the liver
40932637|NCT03809793|DIAGNOSTIC_TEST|Hyperinsulinaemic Euglycaemic Clamp|Participants will arrive at the laboratory after an overnight fast (\>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.
40932638|NCT03809793|DIAGNOSTIC_TEST|VO2 Max|Assessment of maximum aerobic capacity.
40932639|NCT03809793|DIAGNOSTIC_TEST|Continuous Glucose Monitor|CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.
41279112|NCT05911022|DRUG|Colchicine 0.5 MG|three times per day for three days and subsequently twice per day for four days
41279113|NCT05911022|DIETARY_SUPPLEMENT|Probiotic Formula|oral sachets once daily for two weeks
41449760|NCT03676634|BIOLOGICAL|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
41449761|NCT02736123|DRUG|Nivolumab - Arm A|Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).
41449762|NCT02736123|DRUG|Nivolumab + Ipilimumab - Arm B|Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
40932640|NCT03809793|PROCEDURE|Muscle Biopsies|Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
41279114|NCT05911022|OTHER|Standard protocol|the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks
41279115|NCT02424149|DRUG|Phenazopyridine|
40932641|NCT03809793|DRUG|Acipimox 250 MG|Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
40932642|NCT02843737|OTHER|Polysomnography under spontaneous breathing|Patient will come to the sleep laboratory to perform the polysomnography under spontaneous breathing prescribed by the clinician
40932643|NCT02651181|DEVICE|HLCL- Hybrid Logic Closed Loop System|All subjects wearing the HLCL System and using it with the closed loop algorithm
40932644|NCT05152914|DRUG|Cerliponase Alfa|Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
40932645|NCT02038374|PROCEDURE|biopsies|
40932646|NCT02454231|BIOLOGICAL|Transplantation of circulating CD14+CD34+cells|intramuscular injection of circulating EPC at leg level
40932647|NCT02454231|BIOLOGICAL|Transplantation of BM MNC|intramuscular injection of BM MNC at leg level
40932648|NCT03141645|OTHER|Fluid loading|Patients in the preoperative intravenous fluid loading group (group F) will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation.
40932649|NCT03141645|DRUG|Ondansetron|Patients in the ondansetron group (group O) will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation
40932650|NCT01637987|PROCEDURE|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
41279116|NCT06103110|DEVICE|Photobiomodulation|Laser therapy using low level laser
41279117|NCT00279747|DRUG|meloxicam 0.25 mg/kg|
41279118|NCT00279747|DRUG|meloxicam 0.125 mg/kg|
41279119|NCT00279747|DRUG|naproxen 10 mg/kg|
41449763|NCT03412058|PROCEDURE|Biopsy|To be performed prior to anti-PD1/PD-L1 treatment initiation
41449764|NCT03412058|PROCEDURE|Biopsy|To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients
41449765|NCT03412058|PROCEDURE|Biopsy|To be performed at disease progression if medically feasible
41449766|NCT02763345|OTHER|Supporting LIFE electronic Community Case Management|The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.
41449767|NCT02763345|OTHER|Standard care|
40932651|NCT01637987|PROCEDURE|Wee Sight® Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.
40932652|NCT01637987|PROCEDURE|VeinViewer® (Christie Digital Systems, Cypress, CA)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein \& surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
40932653|NCT02054481|DRUG|BI 655066|Medium dose
40755449|NCT00709345|BEHAVIORAL|Cognitive behavioral sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
40932654|NCT02054481|DRUG|BI 655066|High dose
40932655|NCT02054481|DRUG|Ustekinumab|
40932656|NCT02054481|DRUG|BI 655066|Low dose
40932657|NCT01043042|OTHER|No interventions will be used in this study|No interventions will be used in this study
40932658|NCT03540498|DIETARY_SUPPLEMENT|AB-DENTALAC [Probiotics (study)]|Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
40932659|NCT03540498|DIETARY_SUPPLEMENT|Placebo (control)|Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
40932660|NCT05377073|OTHER|Hatha Yoga|Patients in the yoga group performed warm-up exercises for 10 minutes, standing, sitting and supine positions of Hatha yoga (30 minutes), and relaxation and breathing exercises (20 minutes). The program consisted of one weekly session for a total of eight weeks.
40932661|NCT05377073|OTHER|Stretching|Patients in the stretching group performed warm-up activities (10 minutes), and analytic stretching exercises targeting the following muscles: sternocleidomastoid, splenius, trapeze, triceps, posterior shoulder capsule, paravertebralis, hamstrings, quadriceps, gastrocnemius, soleus and tibialis anterior (40 minutes). Two repetitions of 15 seconds of each stretch were performed, with a 15 seconds interval between repetitions. The sessions ended with diaphragmatic breathing exercises (10 minutes). The program consisted of one weekly session for a total of eight weeks.
40932662|NCT00533091|BIOLOGICAL|MEDI-545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
40932663|NCT00533091|OTHER|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks."
40932664|NCT04327960|DIAGNOSTIC_TEST|Cardiac troponin (cTn)|Cardiac troponin (cTn) will be measured with the Dimension RxL-HM analyzer .The one-step enzyme immunoassay is based on cTn specific monoclonal antibodies, performed on a separate module of the analyzer, assay-time is 17 minutes.
40932665|NCT04178083|DIAGNOSTIC_TEST|medical examination|medical examination
40932666|NCT02017600|DRUG|ND-420|ND-420 50 mg/m2 on day1
40932667|NCT02017600|PROCEDURE|Surgery|After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
40932668|NCT02017600|DRUG|Cisplatin|cisplatin 70 mg/m2 on day1
40932669|NCT02017600|DRUG|fluorouracil|fluorouracil 700 mg/m2 daily, day1 to day4
40932670|NCT03279627|OTHER|Diabetes Management Questionnaire|Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.
40932671|NCT00613197|DRUG|Epanova|4g/day in divided doses
40755450|NCT00709345|BEHAVIORAL|Time-matched attention control sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
40932672|NCT04088604|DRUG|LY01610 ( Irinotecan hydrochloride liposome injection )|Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;
40932673|NCT04088604|DRUG|LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）|Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;
40932674|NCT04088604|DRUG|Irinotecan Hydrochloride Injection（CAMPTO®）|Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study
40932675|NCT05486741|OTHER|Optical cehernce tomography|OCT macula and disc
40932676|NCT00352716|DRUG|Smecta (Diosmectite), duration of treatment - 7 days|
40932677|NCT04309747|PROCEDURE|nanosecond knife liver cancer ablation|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
41279120|NCT00440323|DRUG|SB-649868|SB-649868 tablets will be available with dose strength of 5 and 25 mg.
40932678|NCT05125887|OTHER|Questionnaire|Patients diagnosed positive for COVID on an outpatient basis will respond to a questionnaire by mail, at 24 month of diagnosis. This questionnaire will make it possible in particular to collect intercurrent events (hospitalization, emergencies, etc.).
40932679|NCT00461331|DRUG|Insulin Aspart|Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
40932680|NCT00461331|DRUG|Insulin Lispro|Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
40932681|NCT04136756|DRUG|NKTR-255|NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability
40932682|NCT04136756|DRUG|NKTR-255 Q21|NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability
40932683|NCT04136756|DRUG|Rituximab|Rituximab administered intravenously at specified dose on specified days
40932684|NCT04136756|DRUG|Daratumumab|Daratumumab administered subcutaneously at specified dose on specified days
40932685|NCT00735059|DEVICE|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, \> 3 hours
40932686|NCT00735059|DEVICE|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, \> 3 hours
40932687|NCT02155803|DRUG|ACTHAR Gel (adrenocorticotropic hormone)|ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
40932688|NCT04572516|DRUG|BTX A Topical|In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
40932689|NCT04572516|DRUG|BTX A Injection|In group B (injected group), 20 units of BTX_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
40932690|NCT04993222|DRUG|Amphotericin B liposome for injection|IV infusion
40932691|NCT04993222|DRUG|AmBisome®|IV infusion
41449768|NCT04263506|OTHER|Vignette with emphasis on supervisor's opinion|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).
41449769|NCT03578497|DRUG|IL-1 receptor antagonist Anakinra|IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
41449770|NCT05839262|OTHER|Conventional physical rehabilitation plus Active video games (CPR+AVG)|"In each session a routine of conventional physical rehabilitation and active video games is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR+AVG: Consists of conventional exercises (aerobic, muscle strengthening, postural balance and flexibility) added to a set of interactive video games available for the Nintendo Switch console."
40932692|NCT05911282|DRUG|N Acetylcysteine|"The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study."
40932693|NCT05911282|OTHER|Lemon juice|"The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number.~The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study."
40932694|NCT05465720|BEHAVIORAL|falls-prevention programs|Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.
40932695|NCT02048293|DRUG|Remifentanyl, Ultiva®|Anesthetic induction for orotracheal intubation. Group O
40932696|NCT02048293|DRUG|Remifentanil Laboratorios Chalver de Colombia S.A.|Anesthetic induction for orotracheal intubation. Group A
40932697|NCT02048293|DRUG|Fada Remifentanilo|Anesthetic induction for orotracheal intubation. Group B
40932698|NCT00827671|DRUG|cetuximab|cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment
40932699|NCT00827671|RADIATION|radiotherapy to oesophageal tumour|45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
40932700|NCT05500066|DEVICE|Aequalis Flex Revive Shoulder System|"The AEQUALIS FLEX REVIVE Shoulder System is intended for use as:~* A replacement of shoulder joints in primary anatomic or in primary reverse~* A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.~The system also allows for conversion from anatomic to reverse shoulder prosthesis in case of revision."
40932701|NCT01425775|DRUG|vitamin D 25(OH)D|2000IU/day for 12 months
40932702|NCT01425775|OTHER|Placebo|2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
40932703|NCT02663687|DRUG|Recombinant human C1 esterase inhibitor|Subjects will receive escalating doses I-IV as both IV and SC injections
40932704|NCT02663687|DRUG|Placebo|Subjects will receive matching placebo
40932705|NCT02663687|DRUG|SHP623|SHP623
40932706|NCT02663687|DRUG|Placebo|Placebo
40932707|NCT02963844|OTHER|Inspiratory Muscle Training|
40932708|NCT02963844|OTHER|Inspiratory Muscle Training Sham|
40932709|NCT02044497|DRUG|oral oxycodone|
40932710|NCT02345746|DRUG|Oxaliplatin|infusion over 12 hours via HAI
40932711|NCT02345746|DRUG|Folinic Acid|as a 2-hour infusion via HAI on day 2
40932712|NCT02345746|DRUG|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
40932713|NCT01784627|BEHAVIORAL|c-ASBI|Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
40932714|NCT05585281|DRUG|Fluzoparib|Fluzoparib Orally twice daily
40932715|NCT05585281|BIOLOGICAL|QL1101|Maintenance QL1101 7.5 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. QL1101 will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of QL1101 received with chemotherapy.
40755451|NCT03318874|DEVICE|Blephasteam|Steam delivery goggles, once daily
40932716|NCT00813176|DEVICE|Double Lumen Endotracheal Tube|
40932717|NCT00813176|DEVICE|Arndt Bronchial Blocker|
40932718|NCT04895800|DIETARY_SUPPLEMENT|Phytovive|Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
40932719|NCT04895800|DIETARY_SUPPLEMENT|Placebo|Natural Flavors \[Chocolate, Caramel, Vanilla Cream\], Silica, Inulin, Sucralose)
40932720|NCT04895800|DIETARY_SUPPLEMENT|Caffeine|Caffeine (Green tea caffeine extract (170 mg; to deliver 34 mg caffeine \[20% natural caf-feine\])
40932721|NCT00307879|DRUG|Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
40932722|NCT00307879|PROCEDURE|collection of mobilized peripheral blood stem cells|
40932723|NCT00307879|PROCEDURE|Intracoronary infusion of mobilized cells|
40932724|NCT01859104|BEHAVIORAL|Use of smartphone app|
40932725|NCT05165745|BEHAVIORAL|Individualized Feedback|Participants taking PrEP will receive questionnaires regarding self-reported weekly PrEP adherence; they will then receive individualized text-message or email feedback based on their self-reported adherence.
40932726|NCT05185336|DIAGNOSTIC_TEST|ultrasound assessment|gastric volume assessment by ultrasound
41279121|NCT00440323|DRUG|Zolpidem|Zolpidem capsules will be available with dose strength of 10 mg.
41449771|NCT05839262|OTHER|Conventional physical rehabilitation alone (CPR)|"In each session a routine of conventional exercises is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR: Conventional exercises (aerobic, muscle strengthening, postural balance and flexibility)."
41449772|NCT06626737|DRUG|Dapagliflozin (DAPA)|Participants will take Dapagliflozin 10mg every day in -1 to 14 days
40932727|NCT00266565|DRUG|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
40932728|NCT04175509|DRUG|Rectal acetaminophen|Rectal 1300mg
40932729|NCT04175509|DRUG|Intravenous acetaminophen|Intravenous 1000mg
40932730|NCT06135194|DRUG|T-DXd|Efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
40932731|NCT01687621|PROCEDURE|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
41279122|NCT00440323|DRUG|Placebo|Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
40755452|NCT03318874|DEVICE|THERA°PEARL Eye Mask|Heat delivery device, delivering heat to the eyelids, once daily
40932732|NCT03688425|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
40932733|NCT03688425|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
40932734|NCT06515028|PROCEDURE|Group GA|Anesthesia induction will be performed preoxygenation with 3 minutes of 80% FiO2 , followed by intravenosus propofol 2-2.5 mg/kg and fentanyl 2 µg/kg. Rocuronium 0.6 mg/kg will be administered for neuromuscular blockade, followed by endotracheal intubation after 2 minutes of mask ventilation. Anesthesia maintenance will be achieved with inhalation of 2.5-3.3% sevoflurane with 50% oxygen and 50% air mixture, along with infusion of remifentanil at 0.1 micrograms/kg/min. ventilation will be performed using a volume-controlled.
40932735|NCT06515028|PROCEDURE|Group IB|infraclavicular brachial plexus block will be performed in supine position with the arm adducted and flexed at 90 degrees. A mixture consisting of 15 ml of 0.5% Bupivacaine, 15 ml of 2% Lidocaine, and 30 ml of saline solution will be prepared, with equal concentrations distributed into three different syringes of 20 milliliters each. The clavicular notch will be palpated, and an ultrasound linear probe covered with a sterile sheath will be positioned in the lateral sagittal plane over this area to visualize the median, lateral, and posterior cords of the brachial plexus surrounding the axillary artery. A special Stimuplex A 22G, 100 mm needle will be used for plexus anesthesia. local anesthetic injection will be sequentially performed around the posterior, median, and lateral cords under ultrasound guidance. After confirming sensory and motor block, the operation will be commenced.
40932736|NCT02837484|OTHER|NuTech Affinity™ Membrane|NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
41279123|NCT06076044|DEVICE|toDCS 2mA 1Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 1Hz.
41449773|NCT03198923|BIOLOGICAL|natural killer and natural killer T cell|The eligible patients are infused with 10 doses of (2-2.5)x10\^9 NK and NKT cells in one course of treatment.
41449774|NCT00755313|BIOLOGICAL|trastuzumab|
41449775|NCT00755313|DRUG|aromatase inhibition therapy|
40755453|NCT03318874|DRUG|Hylo-comod|Tear substitute containing hyaluronic acid, four times daily
40932737|NCT02112955|BEHAVIORAL|Stroke self-management program|A nurse-led community-based self-efficacy enhancing stroke self-management program.
40932738|NCT02112955|BEHAVIORAL|Usual care|Usual care such as hospital-based or community-based health education or services.
40932739|NCT04285580|DRUG|Bimatoprost SR|Consists of 1 Bimatoprost SR administration in the study eye.
40932740|NCT04285580|DRUG|LUMIGAN|Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.
40932741|NCT00704522|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
40932742|NCT00704522|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
40932743|NCT00704522|BEHAVIORAL|Patient assistance program|"Assistance programs will be classified as follows:~1. Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~2. Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only."
40932744|NCT03969992|DRUG|AeroFact|Aerosolized SF-RI 1
40932745|NCT03969992|OTHER|nCPAP|nCPAP (nasal continuous positive airway pressure) alone
40932746|NCT06087198|DIAGNOSTIC_TEST|T-TAS 01 HD Assay|Disposable flow chamber microchip containing thrombogenic path to facilitate thrombus formation and occlusion
40932747|NCT00476047|COMBINATION_PRODUCT|Tositumomab and Iodine I 131 Tositumomab|Give IV
40932748|NCT00214500|DRUG|migalastat HCl|
40932749|NCT01555957|DRUG|intravenous lipid|intravenous given daily for 6 weeks
40932750|NCT05697744|DIAGNOSTIC_TEST|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
40932751|NCT03924466|DRUG|68GaNOTA-Anti-HER2 VHH1|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~A second injection of the IMP can be administered before or during standard-of-care treatment, depending on cohort."
40932752|NCT03914508|BEHAVIORAL|Memory + Behavioral Weight Loss|BWL and memory enhancement (M+BWL) will be integrated to capitalize on the strengths of both treatments. All participants will be taught general behavioral weight loss skills including to decrease caloric intake and increase physical activity, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss. The proposed M+BWL program provides memory interventions based on the literature, including eating attentively, memory of previous meal, memory skills for planning, effects of diet on memory and the relationship between memory and satiety. The M+BWL program will also utilize experiential learning during the group program such as practicing memory enhanced skills during eating.
40932753|NCT05011448|OTHER|Music Therapeutic Interaction and Verbal Interaction|"In both sessions (the Verbal Interaction and the Music Therapeutic Interaction) participants will be asked to perform three piano playing exercises in a fixed order: (1) playing a musical scale, (2) playing a short excerpt from a familiar song, and (3) free improvisation. Both sessions will also include a protocol of verbal instructions given by the therapist before each exercise. In session A ('Verbal Interaction') participants will perform these exercises alone while the therapist is only interacting with them verbally (asking them questions, commenting regarding their performance etc.). In session B ('Music Therapeutic Interaction') participants will perform these exercises while the therapist is interacting with them musically, using various music therapy techniques that are matched and attuned to each patient's playing dynamics and style. This is to reflect the dynamics of the music therapeutic interaction as it occurs in the real world of music therapy practice."
40932754|NCT00401895|DEVICE|TIPS created with 8 or 10 mm covered stent|creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
40932755|NCT00458497|DEVICE|Holofiber fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
40932756|NCT00458497|DEVICE|PET fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
40932757|NCT01117051|DRUG|placebo|placebo
40932758|NCT01117051|DRUG|prucalopride|1 or 2 mg prucalopride once daily before breakfast
40932759|NCT03239028|BEHAVIORAL|Observational|
40932760|NCT06184308|BEHAVIORAL|Home-based Physical Rehabilitation|Six out of seven days a week, gentle flexibility practice (upper arm and shoulder movements) that can be done seated or standing and two slow walking sessions focused on balance. In addition, complete a breathing practice focused on breathing in through the nose and exhaling through the mouth.
40932761|NCT06184308|BEHAVIORAL|Health Coaching|Study-trained nurse whom utilizes participant data to guide interactions in weekly calls.
41129740|NCT03293914|BEHAVIORAL|Lifestyle Redesign|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
40755454|NCT04364971|PROCEDURE|singleradius and multiradius total knee arthroplasty|singleradius and multiradius total knee arthroplasty
40755455|NCT06501170|OTHER|Retrospective Data Analysis of Emergency Abdominal Surgery Outcomes|Retrospective Data Analysis of Emergency Abdominal Surgery Outcomes
41129741|NCT02854241|PROCEDURE|Biannual ultrasonography|Biannual ultrasonography for HCC surveillance, performed by board-certified radiologists.
41279124|NCT06076044|DEVICE|toDCS 2mA 10Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 10Hz.
41279125|NCT06076044|DEVICE|tDCS 1mA|The subgroup treated by transcranial direct current stimulation of 1mA.
41449776|NCT00755313|DRUG|carboplatin|
40932762|NCT04787081|OTHER|Sleep Care Positioning Training Program GRP1|Video-based tutorial covering six nighttime postural care topic areas which contained narration and closed captioning. This 2-hour online training program was delivered in a University classroom via D2L Brightspace.
40932763|NCT04787081|OTHER|Sleep Care Positioning Training Program GRP2|Web-link based tutorial covering six nighttime postural care topic areas which contained mostly written content. This self-paced online training program was delivered in a University classroom via D2L Brightspace.
40932764|NCT02846376|DRUG|Nivolumab|Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.
40932765|NCT02846376|DRUG|Ipilimumab|Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
40932766|NCT00817687|DRUG|mycophenolate mofetil [CellCept]|As prescribed; + early biopsy
40932767|NCT00817687|DRUG|mycophenolate mofetil [CellCept]|As prescribed; + standard treatment
40932768|NCT05504720|DRUG|Pembrolizumab|200 mg flat dose, IV, over 30 minutes; day 1, 22, 43 (8 weeks) pre- and post-surgery, followed by post chemotherapy phase day 1 q3w for 11 cycles; max. 17 applications
40932769|NCT05504720|DRUG|Trastuzumab|loading dose 8 mg/kg IV over 90 min: day 1 pre- and post-surgery; maintenance dose 6 mg/kg IV over 30 min: Day 22, 43 pre- and post-surgery; followed by 6 mg/kg post chemotherapy phase, day 1 q3w for 11 cycles; max. 17 applications
40932770|NCT05504720|DRUG|FLOT|Docetaxel 50 mg/m² IV over 1 hour plus Oxaliplatin 85 mg/m² IV over 2 hours plus Folinic Acid 200 mg/m² IV over 1 hour plus 5-FU 2600 mg/m² IV over 24 hours every 2 weeks (day 1, 15, 29, 43) for 8 weeks pre- and 8 weeks post-surgery
40932771|NCT01381146|BEHAVIORAL|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
40932772|NCT01381146|BEHAVIORAL|TAU|have access to other jail programs and services
41279126|NCT06076044|DEVICE|sham|The subgroup treated by sham stimulation.
41279127|NCT00866437|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
41279128|NCT00866437|DRUG|Skin test panel|"Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1 mmol/L~3. Estrone 3 mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
41449777|NCT00755313|DRUG|cyclophosphamide|
40932773|NCT00489190|DRUG|Insulin Glulisine|
40932774|NCT05891964|DRUG|Secukinumab Injection|Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
40932775|NCT04539145|DEVICE|Chocolate PTA Balloon|Chocolate PTA Balloon
41449778|NCT00755313|DRUG|docetaxel|
40932776|NCT04539145|DEVICE|conventional balloon angioplasty|conventional bal-loon angioplasty
40932777|NCT00378079|OTHER|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
40932778|NCT00378079|DRUG|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
40932779|NCT00378079|DRUG|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
40932780|NCT03843710|DRUG|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
40932781|NCT03877081|BIOLOGICAL|Probiotics|Administration of oral probiotics with 2 doses a day
40932782|NCT03877081|OTHER|Placebo|Administration of oral placebo with 2 doses a day
40932783|NCT05067998|DIETARY_SUPPLEMENT|IV Vitamin Infused Therapy Treatment|Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals
40932784|NCT05067998|DRUG|Herbal medicine|Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
40932785|NCT02267642|BIOLOGICAL|AbGn-168H|monoclonal antibody
41129742|NCT02854241|PROCEDURE|Annual noncontrast liver MRI|"Annual noncontrast liver MRI consisted of T2WI, precontrast T1WI, dual-echo image, DWI (single shot, multishot) and T2 map.~DWI using multishot and T2 map are not included for initial MR reading."
41279129|NCT01739595|DRUG|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
41279130|NCT01739595|DRUG|Placebo|Oral capsule taken one time daily for 3 months
41449779|NCT00755313|DRUG|doxorubicin hydrochloride|
41449780|NCT00755313|OTHER|metabolic assessment|
41449781|NCT00755313|OTHER|questionnaire administration|
41449782|NCT00755313|OTHER|study of socioeconomic and demographic variables|
41449783|NCT00755313|PROCEDURE|cognitive assessment|
41449784|NCT00755313|PROCEDURE|positron emission tomography|
41449785|NCT00755313|RADIATION|fludeoxyglucose F 18|
41449786|NCT01309763|BIOLOGICAL|AFFITOPE AD03|s.c. injection
41449787|NCT01309763|BIOLOGICAL|AFFITOPE AD03 + Alum|s.c. injection
41449788|NCT00809705|DRUG|Placebo|sc once weekly for 12 weeks
41449789|NCT00809705|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
41449790|NCT00809705|DRUG|taspoglutide|10mg sc once weekly for 12 weeks
40932786|NCT01377285|DRUG|ARB|"Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan"
40932787|NCT01377285|DRUG|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
40932788|NCT01377285|DRUG|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
40932789|NCT02398409|BEHAVIORAL|ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths|"Randomized trial to evaluate the efficacy of the telephone intervention Acquiring New Skills While Enhancing Remaining Strengthsin informal caregivers of Veterans with stroke and TBI."
40932790|NCT02398409|OTHER|Control|8 week telephone usual care with education with nurse case manager
40932791|NCT04449471|DRUG|Naproxen tablet|For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
40932792|NCT03531073|DRUG|Methotrexate|This study is observational and patients will receive treatment for their psoriatic arthritis as clinically indicated. As per standard practice in this observational cohort, patients are most likely to be treated with methotrexate as the most common first line therapy in PsA. This cohort is the basis of a TWiCs (Trials Within Cohorts) study design and interventional studies will be nested within this in future. Whilst the cohort will receive treatment for their PsA as part of their routine clinical care, this treatment will be decided according to routine care and not protocolised.
40932793|NCT03518671|BEHAVIORAL|cognitive behavioral therapy, face to face|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via face-face delivery method
40932794|NCT03518671|BEHAVIORAL|cognitive behavioral therapy, telemedicine|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via tablet-based telemedicine platform
40932795|NCT01931176|BIOLOGICAL|rDEN2Δ30-7169 vaccine|Administered at a dose of 10\^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
40932796|NCT01931176|BIOLOGICAL|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm
40932797|NCT01689909|DRUG|Zolpidem-CR|Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
40932798|NCT01689909|DRUG|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
40932799|NCT00972647|PROCEDURE|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
41449791|NCT04741477|DRUG|CBD|CBD will be topically applied
40932800|NCT05037188|BIOLOGICAL|Low dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
41279131|NCT00525252|DRUG|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
41449792|NCT04741477|DRUG|THC|THC will be topically applied
41449793|NCT04741477|DRUG|Placebo|a placebo product (without cannabinoids) will be topically applied
40932801|NCT05037188|BIOLOGICAL|High dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
40932802|NCT05037188|BIOLOGICAL|Low dose or high dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
40932803|NCT05037188|OTHER|Placebo injection|Placebo injection
40932804|NCT05683431|BEHAVIORAL|Cognitive Control of Emotion (CCE) Training|Training consists of game-like exercises using a software program developed in collaboration with PositScience Corporation (using BrainHQ platform ) - which has exercises targeting cognition and social cognition. The CCE training program incorporates characteristics that optimize learning-induced neuroplasticity - most importantly, exercises are short \& rewarding, adapt to individual skill-level, and become increasingly difficult as performance improves. There are 5 CCE exercises that are organized in half-hour sessions and proceed in a predetermined sequence.
40932805|NCT03709732|OTHER|no intervention|observational study
40932806|NCT05857423|OTHER|Gentle Human Touch|"Gentle Human Touch procedure has 3 step as follows:~1. Mother/nurse must wash their hands with antimicrobial soap for 3 minutes before starting Gentle Human Touch procedure.~2. Next, mother/nurse must warm their hands.~3. Mother/nurse must place their one hand on the infant's head and the other hand on the lower abdomen that covers the waist and hips of the preterm infant, for 15 minute."
40932807|NCT05265377|DEVICE|Stelo|Use of Stelo exoskeleton in nine rehabilitation sessions
40932808|NCT01655108|DRUG|Minoxidil|Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
40932809|NCT01655108|DRUG|Saline|Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
40932810|NCT04132245|BEHAVIORAL|behavioral intervention|Families were randomized to a 14-week family based obesity prevention intervention or a 14-week general health intervention
40932811|NCT04132245|BEHAVIORAL|Obesity prevention intervention trial|Families were randomized to a 14-week obesity prevention intervention or a 14-week general health intervention
41279132|NCT00525252|DRUG|placebo|Placebo will be orally administered for 12 consecutive weeks
41279133|NCT00575679|BEHAVIORAL|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
41279134|NCT06090474|DRUG|NDC-002|Combination of NDC-002B and NDC-002C
41449794|NCT00918645|DRUG|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
41449795|NCT06003933|DRUG|Bupivacaine Hydrochloride|10 ml of 0.25% bupivacaine on each side of cervical region at C5
41449796|NCT06003933|DRUG|Lidocaine Hydrochloride|10ml xylocaine on each side of cervical region at C5
40932812|NCT05390190|DEVICE|Non ablative radiofrequency|Device
40932813|NCT01721707|DRUG|Latanoprost+Brinzolamide combination|1 drop in each eye, 1x/day, at 9PM
40932814|NCT01721707|DRUG|Latanoprost|1 drop in each eye, 1x/day, at 9PM
40932815|NCT00667420|DRUG|panitumumab, epirubicin, oxaliplatin, xeloda|pilot study
41449797|NCT06003933|DEVICE|Ultrasound|The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block.The five-layered posterior cervical muscles were identified at the level of C5 with a 6-15-MHz linear probe oriented in the transverse plane (SonoSite Edge, Bothell, Washington). The fifth cervical spine was counted from the C7 spinous process with the probe sliding cranially.
41449798|NCT06003933|DEVICE|Needle|the needle (22- G, 50-mm block needle (Visioplex, Vygon) was introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of bupivacaine 0.25% was injected5.
41449799|NCT01094457|DRUG|aspirin, clopidogrel|patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year
41449800|NCT01094457|DRUG|aspirin, clopidogrel, cilostazol|Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.
41449801|NCT01695239|DRUG|Ixekizumab|Administered SC
40932816|NCT04327479|DIAGNOSTIC_TEST|Assessment of cardiovascular diseases and cardiovascular risk factors|At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
40932817|NCT03899688|PROCEDURE|Maxillary sinus augmentation|Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
41449802|NCT01695239|DRUG|Placebo|Administered SC
41449803|NCT01695239|DRUG|Adalimumab|Administered SC
41449804|NCT01686438|BEHAVIORAL|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
41449805|NCT04179058|OTHER|Follow-up|Clinical data, radiological data and laboratory tests follow-up
41449806|NCT06543303|DRUG|BTV100 Low dose|1% Cevimeline Ophthalmic Solution
41449807|NCT06543303|DRUG|BTV100 Mid dose|2% Cevimeline Ophthalmic Solution
41449808|NCT06543303|DRUG|BTV100 High dose|4% Cevimeline Ophthalmic Solution
41449809|NCT06543303|DRUG|Placebo|Placebo
40932818|NCT03671590|DRUG|TG-1701|Oral daily dose
41449810|NCT02632253|PROCEDURE|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
41449811|NCT02632253|OTHER|MICE|MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
41449812|NCT05409651|BEHAVIORAL|Time restricted eating|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.
41449813|NCT06094023|OTHER|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
40932819|NCT03671590|DRUG|Umbralisib|Oral Daily Dose
40932820|NCT03671590|BIOLOGICAL|Ublituximab|IV infusion
40932821|NCT06268145|DRUG|ECC5004|A single dose tablet of 50 mg of the current tablet formulation (F1) or new tablet formulation (F2) administered orally.
40932822|NCT04581460|OTHER|Questionnaire|Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.
40932823|NCT04307745|OTHER|Primary prevention|The primary prevention that the 4 groups put in place for the upper limp athletes
40932824|NCT02597816|RADIATION|Three dimensional ultrasound|
40932825|NCT00474682|DRUG|Micronized dispersible ferric pyrophosphate|
40932826|NCT00833079|DRUG|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
40932827|NCT00833079|DRUG|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
40932828|NCT00833079|DRUG|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
40932829|NCT05909527|BIOLOGICAL|CD7 CAR-T|A single infusion of autologous CD7 CAR-T cells administered intravenously
40755456|NCT03570138|DEVICE|FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System|Specific therapeutic education for diabetes self management
40755457|NCT03570138|DEVICE|Usual self monitoring Blood Glucose device|Standard therapeutic education for diabetes self management
41129743|NCT02854241|PROCEDURE|Contrast enhanced liver CT|In patients without report of HCC during surveillance period, contrast CT is performed 6 months after the last MR scan.
41129744|NCT04051333|DEVICE|ALS Nutrition App (MyDataHelps platform)|We have designed a mobile health app to provide nutritional counseling and to measure disease outcomes both through self-reported questionnaires and through passive data collection.
41129745|NCT01447706|DRUG|MM-121|MM-121 (SAR256212) (IV)
41129746|NCT01447706|DRUG|Paclitaxel|Standard dosing Paclitaxel (IV)
41279135|NCT01561287|PROCEDURE|Dermal Autograft|Patients in the dermal autograft group will undergo harvest of a dermal autograft from the lower abdomen at the time of mastectomy, which will be used to cover the lower pole of the tissue expander.
41449814|NCT06094023|OTHER|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours.
41449815|NCT00656786|DRUG|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
40932830|NCT06392945|DEVICE|Cognitive Treadmill Walking Training with Rhythmic Auditory Cueing (CTW+RAC) group|Participants in the CTW+RAC group participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. To increase adaptability to rhythmic auditory cueing prior to cognitive treadmill walking training, participants are required to keep stepping on their feet while listening to the auditory cueing using a metronome program (Metronome APP) for 5 minutes of warm up. Then they start walking on a treadmill with a target speed and perform a cognitive task concurrently while listening rhythmic auditory cueing. According to previous research, the target treadmill speed at week 1, week 2, week 3, and week 4 is gradually increased from 90%, 100%, 110%, to 120% baseline walking speed of comfortable walking on the ground. The beat of rhythmic auditory cueing using the Metronome APP on the smartphone is set at 110% of baseline cadence of comfortable walking on the ground based on a previous study in individuals with stroke.
40932831|NCT06392945|DEVICE|Cognitive Treadmill Walking Training (CTW) group|Participants in the CTW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed and perform a cognitive task concurrently without rhythmic auditory cueing. Same cognitive training and target treadmill speed will be used as the CTW+RAC group during cognitive dual-task treadmill walking. Three cognitive training programs will be the verbal fluency, arithmetic, and visual distinguish tasks. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the 10 meters walk test at week 4.
40932832|NCT06392945|DEVICE|Treadmill Walking Training (TW)|Participants in the TW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed only, without concurrent performing a cognitive task and no listening rhythmic auditory cueing. Same target treadmill speed will be used as the other two groups during treadmill walking. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the ground.
40932833|NCT01593722|DRUG|Diethylcarbamazine|single dose
40932834|NCT01593722|DRUG|Ivermectin|single dose
40932835|NCT06325930|DRUG|[14C]-HU6|\[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects
40932836|NCT04144023|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|Given intradermally
40932837|NCT04144023|BIOLOGICAL|Multi-epitope HER2 Peptide Vaccine H2NVAC|Given intradermally
40932838|NCT04144023|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
40932839|NCT04144023|PROCEDURE|Echocardiography|Undergo ECHO
40932840|NCT04144023|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40932841|NCT04144023|PROCEDURE|Biopsy|Undergo biopsy
40932842|NCT05549427|OTHER|Ventilation|Ventilation in ICU
41449816|NCT00656786|DRUG|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
41449817|NCT05779527|BEHAVIORAL|Mindful Parenting Programme|Online Mindful Parenting Programme with group support sessions
41449818|NCT02253329|PROCEDURE|Dietary protein plus NMES during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
41449819|NCT02253329|PROCEDURE|Dietary protein plus NMES prior to sleep|Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
41449820|NCT06423014|BEHAVIORAL|Wearable devices only|self-monitoring
41449821|NCT06423014|BEHAVIORAL|Wearable devices with the 1st behavior change technique|reminder
41449822|NCT06423014|BEHAVIORAL|Wearable devices with the 2nd behavior change technique|social support
41449823|NCT06423014|BEHAVIORAL|Wearable devices with the 3rd behavior change technique|Competition
40932843|NCT03654430|OTHER|Echocardiography|Two echocardiographies will be performed in healthy newborns: The first between day 2 and day 5 of life, the second between day 60 and day 90 of life
40932844|NCT05346835|DRUG|Cilta-cel OOS Therapy|Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion.
40932845|NCT02835352|OTHER|Essential oils massages|
40932846|NCT02835352|OTHER|Oil massages|
40932847|NCT02573701|DRUG|Guideline treatment (Risperidone, administered orally)|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
40932848|NCT02573701|BEHAVIORAL|"Psychosocial treatment"|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
40932849|NCT02573701|DRUG|Treatment as Usual (any other antipsychotic)|Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
40932850|NCT03277079|DRUG|statin + ezetimibe|Combination of two drugs
41449824|NCT06423014|BEHAVIORAL|Wearable devices with the 4th behavior change technique|Goal-setting
41449825|NCT06423014|BEHAVIORAL|Wearable devices with the 5th behavior change technique|health coach
41449826|NCT06423014|BEHAVIORAL|Wearable devices with all behavior change techniques|Self-monitoring, health coach, goal-setting, competition, social support, and reminder
41449827|NCT03002935|DRUG|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
41449828|NCT06013163|DRUG|Xenical® vs EMP 22|Each participant will first use Xenical® TID for 9 days and then EMP22TID for 9 days (in total 27 doses of each drug).
41449829|NCT06013163|DRUG|EMP 22 vs Xenical®|Each participant will first use EMP22 TID for 9 days and then Xenical® TID for 9 days (in total 27 doses of each drug).
41449830|NCT06013163|DRUG|EMP 16 vs Xenical®|Each participant will receive a single dose of EMP16 and then a single dose of Xenical®.
41279136|NCT01561287|PROCEDURE|AlloDerm|The acellular dermal matrix used in our study is AlloDerm (LifeCell Corp., Branchburg, N.J.) The AlloDerm group will consist of patients without a suitable abdomen for autografting and those who declined the dermal autograft procedure. Patients in the dermal allograft group will have placement of AlloDerm over the lower pole of the tissue expander. Patients with a lower abdominal scar and sufficient abdominal laxity for autograft harvest will be offered this technique.
41449831|NCT03342846|DEVICE|rTMS|the first group received 20 Hz and the 2nd group received 1 Hz rTMS daily for 10 days 5 sessions every week on M1.
41449832|NCT02469363|DEVICE|Macintosh laryngoscope|Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)
41449833|NCT02469363|DEVICE|Mc-Coy laryngoscope|Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope
40755458|NCT05219344|PROCEDURE|Tissue flossing|After the standardized warm-up, participants will be instructed to stand still with their legs shoulder-width apart. The floss band (1.3 mm thick, 50 mm wide, 2 meters long, and strength level 3), consisting of a thick elastic latex band (COMPRE Floss, Sanctband), will be applied bilaterally around the distal third of the thigh. The applied pressure will be individualized by thigh circumferences, whereas low target pressure was chosen for this study, showing potential to elicit the most beneficial outcomes following flossing. The pressure will be monitored by the PicoPress device, which was placed at the middle distance of the application of the floss band to ensure that the entire surface of the pressure sensors was always completely covered. The flossing will be applied for 2 minutes with 2 minutes rest between sets. During flossing application subjects will be instructed to conduct 10 deep squats followed by 15 repetitions of knee extensions without added weight.
40755459|NCT04475939|DRUG|Niraparib|Niraparib will be administered
40755460|NCT04475939|DRUG|Pembrolizumab|Pembrolizumab will be administered
40755461|NCT04475939|DRUG|Placebo|Matching placebo will be administered
40755462|NCT00395512|DRUG|Alogliptin|Alogliptin tablets.
40755463|NCT00395512|DRUG|Pioglitazone|Pioglitazone tablets.
40755464|NCT00395512|DRUG|Placebo|Matching placebo tablets.
40755465|NCT04119336|DRUG|Nivolumab|Given intravenously once per cycle
40755466|NCT04119336|DRUG|Ixazomib|Given orally on days 1, 8, 15.
40755467|NCT04119336|DRUG|Dexamethasone|Given orally on days 1, 8, 15, 22
40755468|NCT04119336|DRUG|Cyclophosphamide|Given intravenously on days 1, 8, 15.
40755469|NCT03612895|BEHAVIORAL|Internal Care Coordination|This individual will primarily initiate, guide, and optimize adherence to the care that others deliver, rather than providing direct care his or herself. S/he will call the smoker to conduct a brief assessment of tobacco use and readiness to quit, offer brief counseling and motivational intervention, describe the available pharmacologic and behavioral options, help the smoker to choose among them, and link the smoker to chosen resources. The resources offered will include both internal (health care system based) and external (community based) tobacco cessation resources.
40755470|NCT03612895|BEHAVIORAL|External Community Referral|Massachusetts (MA) Helpline services include an assessment of smoking history and readiness to quit, advice to quit, self-help materials and telephone counseling. For smokers who set a quit date in the next 30 days, the Helpline offers up to 5 proactive telephone counseling calls with options for text messaging and web-based resources. It also provides eligible smokers 4 weeks of free nicotine patch or gum mailed to their home.
40755471|NCT03612895|BEHAVIORAL|Usual Care|Participants will be given the number to the MA Smokers Helpline and advised to contact their primary care provider for additional assistance in quitting smoking.
40755472|NCT03000166|BEHAVIORAL|Step-Up Intervention|Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
40755473|NCT04593329|DRUG|TIRADENTES ASSOCIATION|Tiradentes association tablet
40755474|NCT04593329|DRUG|DIPYRONE|Dipyrone 500 mg
40755475|NCT04593329|DRUG|TRAMADOL|Tramadol 50 mg
40755476|NCT04593329|OTHER|TIRADENTES ASSOCIATION PLACEBO|Tiradentes association placebo tablet
40755477|NCT04593329|OTHER|DIPYRONE PLACEBO|Dipyrone placebo tablet
40755478|NCT04593329|OTHER|TRAMADOL PLACEBO|Tramadol placebo capsule
40932851|NCT03277079|DRUG|statin + ezetimibe + Nutraceuticals|Combination of two grus plus nutraceuticals
40932852|NCT05369390|DRUG|NNC0487-0111 A|Participants will receive NNC0487-0111 A tablet once daily.
41279137|NCT06213389|DEVICE|EzVision® videolaryngoscopy|Patient will be intubated with EzVision® videolaryngoscopy
40932853|NCT05369390|DRUG|NNC0487-0111 B|Participants will receive NNC0487-0111 B tablet once daily.
40755479|NCT03083730|OTHER|Narrow band UVB treatment (NB-UVB)|NB-UVB light treatment NB-UVB light treatment for 3x/week for 12 weeks (36 visits)
40755480|NCT00664677|DRUG|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
40755481|NCT03817515|DRUG|ABI-009|Sirolimus Albumin-bound Nanoparticles
40755482|NCT04606966|OTHER|Therapeutic Horseback Riding|Horse therapy
40755483|NCT04606966|OTHER|Barn Activity|Horsemanship group
40755484|NCT04606966|OTHER|Hybrid|Ground and riding activities
40755485|NCT00007774|DRUG|Haloperidol|
40755486|NCT00007774|DRUG|Olanzapine|
40755487|NCT04952688|OTHER|OCT- Angiographie|Ophthalmological examinations
40755488|NCT06129682|OTHER|Self rehabilitation at home|6 week program of exercise at home of gradual intensity and duration
40932854|NCT05369390|OTHER|Placebo B (NNC0487-0111 B)|Participants will receive placebo matched to NNC0487-0111 B tablet once daily.
40932855|NCT05369390|OTHER|Placebo A (NNC0487-0111 A)|Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
40932856|NCT04976153|BIOLOGICAL|aSMDC|Autologous Muscle Derived Cells for injection into the external anal sphincter
41279138|NCT06213389|DEVICE|Macintosh Blade|Patient will be intubated with Macintosh Blade
41449834|NCT02469363|DEVICE|C-Mac videolaryngoscope|Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope
41449835|NCT02469363|DEVICE|McGrath videolaryngoscope|Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
40932857|NCT04976153|OTHER|Placebo|Placebo control is the vehicle solution used for the study product
40932858|NCT00003567|BIOLOGICAL|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
40932859|NCT00003567|BIOLOGICAL|sargramostim|Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
40932860|NCT00003567|BIOLOGICAL|therapeutic autologous lymphocytes|
40932861|NCT00003567|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
40932862|NCT00003567|DRUG|carmustine|Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
40932863|NCT00003567|DRUG|temozolomide|Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
40932864|NCT00003567|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
40932865|NCT05158647|OTHER|normal saline|10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
40932866|NCT05158647|DRUG|MgSo4|10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used
40755489|NCT01722643|BEHAVIORAL|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
40932867|NCT01233687|DRUG|AMG 102 and erlotinib|"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."
40932868|NCT04403490|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
40932869|NCT04403490|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
40932870|NCT02425527|BEHAVIORAL|The rehabilitation gaming|The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.
40932871|NCT02425527|BEHAVIORAL|The entertaining gaming|The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
40932872|NCT05341388|DIAGNOSTIC_TEST|MOCA cognitive evaluation test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
40932873|NCT05341388|DIAGNOSTIC_TEST|BDNF levels|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
40932874|NCT05341388|OTHER|SF-36 test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
40932875|NCT05341388|DIAGNOSTIC_TEST|Geriatric depression test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
40932876|NCT06455618|PROCEDURE|not Indwelling the ureteral stent|"Before the end of surgery, the urologist does not Indwell the ureteral stent in the patient's body. The ureteral stent is usually called Double-J Stent."
40932877|NCT06455618|PROCEDURE|Indwelling the ureteral stent|"Before the end of surgery, the urologist Indwell the ureteral stent in the patient's body. The ureteral stent is usually called Double-J Stent."
40932878|NCT02711345|DRUG|LTT462|ERK Inhibitor
40932879|NCT00003854|OTHER|immunohistochemistry staining method|
40932880|NCT00003854|PROCEDURE|lymphangiography|
41129747|NCT05379075|OTHER|26 styles of Chen Taichi training based on Relaxation guidelines|The arms and legs and the spine should rotate follow the arrow tips in order to cause a stretch reflex slightly. And then, the exerciser should use relaxation skills to eliminate the stretch reflex, such as exhaling, drop the control of body
41449836|NCT00003808|DRUG|theophylline|
40932881|NCT00003854|PROCEDURE|sentinel lymph node biopsy|
40932882|NCT00003854|PROCEDURE|therapeutic conventional surgery|
40932883|NCT00003854|RADIATION|whole breast irradiation|
40932884|NCT00002779|DRUG|fludarabine phosphate|
40932885|NCT00002779|DRUG|octreotide acetate|
40932886|NCT01486810|DRUG|Lisdexamfetamine|Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
40932887|NCT01486810|BEHAVIORAL|medication management|All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
40932888|NCT00375869|DRUG|Darbeopoetin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
40932889|NCT00375869|DRUG|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
40932890|NCT04461041|DRUG|Empagliflozin|Single oral tablet
40932891|NCT04461041|DRUG|Placebo|Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
40932892|NCT00072527|DRUG|carboplatin|IV
40932893|NCT00072527|DRUG|cisplatin|IV
40932894|NCT00072527|DRUG|etoposide|IV
41279139|NCT02693977|PROCEDURE|Sleep Endoscopy|Sleep endoscopy will be performed prior to the adenotonsillectomy, under the same general anesthetic. The endoscopy will be performed using a flexible fiber optic endoscope which will be advanced trans nasally into the pharynx down to the level of the hypopharynx. We will take note of any obvious septal deviation or nasal obstruction as well as adenoid hypertrophy, and dynamic collapse at the level of the velum, oropharynx/lateral walls, tongue base, epiglottis, and supraglottis. Relatively fixed structures such as the nasal airway and adenoids should require 1 minute to fully assess. The endoscope will then be held for 2 minutes of observation above each subsequent site of potential dynamic airway collapse (the velum, oropharynx/lateral walls, tongue base, epiglottis/supraglottis).
41279140|NCT04378777|PROCEDURE|Biological sample collection|During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study \[GWAS\]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
40932895|NCT00072527|DRUG|irinotecan hydrochloride|IV
40932896|NCT00072527|RADIATION|radiation therapy|
40932897|NCT00805376|DRUG|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
40932898|NCT00805376|PROCEDURE|Tumor Removal|Surgical Tumor Resection
40932899|NCT02518503|DRUG|Rosuvastatin (≥10 mg)|Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
40932900|NCT02518503|DRUG|Atorvastatin (≥20 mg)|Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
40932901|NCT02518503|DRUG|Simvastatin (≥40 mg)|Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
40932902|NCT02518503|DRUG|Fluvastatin|Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
40932903|NCT02518503|DRUG|Pravastatin|Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
40932904|NCT02518503|DRUG|Lovastatin|Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
40932905|NCT02518503|DRUG|Rosuvastatin (<10mg)|Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for \<10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
40932906|NCT02518503|DRUG|Atorvastatin (<20mg)|Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
40932907|NCT02518503|DRUG|Simvastatin (<40 mg)|Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
40932908|NCT06022484|OTHER|The present study does not contain any intervention|The present study does not contain any intervention
40932909|NCT02842905|OTHER|Fitting Audiologist completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the fitting Audiologist
40755490|NCT01722643|BEHAVIORAL|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
40932910|NCT02842905|OTHER|Participant's Physician completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the Participant's Physician
40932911|NCT04063527|DRUG|adjuvant chemotherapy|combination of paclitaxel and carboplatin
40932912|NCT04231591|DIAGNOSTIC_TEST|NT-proBNP|Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.
40932913|NCT00168987|DRUG|oral nutritional supplement rich in eicosapentanoic acid|
40932914|NCT00209651|DRUG|Campto, Topotesin|q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
40932915|NCT00209651|DRUG|TS-1|80 mg/m2, PO (oral) on day 1\~14 of each 28 day cycle.
40932916|NCT01611454|DEVICE|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
40932917|NCT01611454|DEVICE|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during the same type of comparator fluoroscopy guided interventions. Comparator arm uses same type of lead thyroid collar but the XPF under investigation.
40932918|NCT05976984|OTHER|Aim 1 (case-cohort study)|"* Cases: All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020~* Subcohort: A random sample of all Medicaid enrollees age 15 years or older irrespective of their stimulant overdose history during 2016-2020"
40932919|NCT05976984|OTHER|Aim 2 (case-crossover study)|"* Case period: 60 days before the date of stimulant overdose through the day before the date of stimulant overdose~* Control period: 179 days before the date of stimulant overdose through 120 days before the date of stimulant overdose~* Washout period: 119 days before the date of stimulant overdose through 61 days before the date of stimulant overdose"
40932920|NCT05976984|OTHER|Aim 3 (cohort study)|All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020
40932921|NCT01244360|DIETARY_SUPPLEMENT|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
40932922|NCT01244360|OTHER|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
40932923|NCT01727778|BIOLOGICAL|Anti-GRP78 monoclonal IgM antibody PAT-SM6|
40932924|NCT03295526|PROCEDURE|Lymph nodes debulking surgery.|Radical hysterectomy and selective enlarged lymph node dissection
40932925|NCT05896579|BEHAVIORAL|Exercise training|Exercise training will include supervised high-intensity interval training for \~35 minutes 3x/week on an upright stationary bicycle and unsupervised continuous aerobic exercise for \~30 minutes 2x/week.
40932926|NCT03783247|PROCEDURE|Pericapsular nerve group block|The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees (Figs. 2, 3). In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution (20ml of bupivacaine 0.25%) was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 30 mL
40932927|NCT03783247|PROCEDURE|Fascia Iliaca BLock|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
40932928|NCT04431089|DRUG|SHC014748M|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
40932929|NCT06032897|OTHER|Individualized music listening (IML)|The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The Individualized music listening (IML) were performed twice a week for four weeks, for a total of eight times.
40932930|NCT03448081|DRUG|SNA-120|SNA-120 (0.5%) active ointment
40932931|NCT03448081|DRUG|Placebo|Vehicle Ointment
40932932|NCT03448081|DRUG|Calcipotriene|Calcipotriene ointment (0.005%)
40932933|NCT02133443|DEVICE|PSV - pressure support ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Pressure support ventilator assistance to obtain a tidal volume of 6-8 ml/kg of ideal body weight.
40932934|NCT02133443|DEVICE|Neurally Adjusted Ventilatory Assist|"Partial ventilator support partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Stepwise implementation of the NAVA level (steps of 25% ), returning to the  optimal  level between each evaluation (PSV 100%, NAVA 100%, 75%, 50%, 125%, 150%)."
40932935|NCT01400438|OTHER|questionnaires|delivery of questionnaires and self-psychological interview
40932936|NCT01400438|OTHER|questionnaires|delivery of questionnaires and self-psychological interview
40932937|NCT01902771|BIOLOGICAL|Dendritic Cell Vaccine|Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
40932938|NCT01902771|BIOLOGICAL|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
40932939|NCT01902771|OTHER|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
40932940|NCT01902771|PROCEDURE|Leukapheresis|Baseline, post-surgery. Subjects will undergo leukapheresis procedure during baseline, after recovery from surgery to collect peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained, per study protocol.
40932941|NCT03981055|DEVICE|Active Comparator: Active tDCS and Active TUS|"Device: Transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
40932942|NCT03981055|DEVICE|Sham Comparator: Sham TDCS and Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
40932943|NCT03981055|OTHER|Physical Therapy|All subjects will enroll in a conventional PT balance and gait focused training program, and will receive PT 3x/week over the two weeks of stimulation for 45 minutes following the stimulation sessions when applicable. (And during the biweekly sessions for Phase II)
40932944|NCT06413173|COMBINATION_PRODUCT|Active tDCS and Cognitive Training Intervention|Cognitive training will occur concurrently with active tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
40932945|NCT06413173|COMBINATION_PRODUCT|Sham tDCS and Cognitive Training Intervention|Cognitive training will occur concurrently with sham tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
40932946|NCT01931670|OTHER|placebo|
41129748|NCT05379075|OTHER|26 styles of Chen Taichi training based on Coordination guidelines|"When the posture needs to open the arms should accompany with inhale and when the posture needs to close the arms should accompany with exhale. Similarly, if the arm is lifting should accompany with inhale, and the put down should accompany with exhale."
41129749|NCT02168998|BEHAVIORAL|Clown|Comparison of routine venipuncture with a distraction technique by a medical clown
41129750|NCT00171769|DRUG|Certoparin|
41129751|NCT05459350|DIAGNOSTIC_TEST|Safe Discharge Classification|Safe Discharge Classification
41129752|NCT03921866|DRUG|Palbociclib|Palbociclib
41449837|NCT01601405|DRUG|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
41449838|NCT01601405|DRUG|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
40755491|NCT03532490|DRUG|Roflumilast 500 Mcg Oral Tablet|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
40755492|NCT03532490|DRUG|Placebo oral capsule|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
41449839|NCT06454214|DEVICE|Multi-photon microscopy|To conduct 3D structural imaging on human breast tissues
41449840|NCT05603351|DIAGNOSTIC_TEST|magnetic resonance|biparametric MRI with protocol including anatomical T2 sequence and diffusion-weighted images (DWI), according to the standards
41449841|NCT05603351|DIAGNOSTIC_TEST|serum PSA examination|testing of prostate-specific antigen (PSA) in serum
41449842|NCT05603351|PROCEDURE|Biopsy|"Men with a positive MR test are planned for a targeted MRI/US fusion and systematic prostate biopsy.~Men with a positive blood marker (either PSA, PSAD, or PHI) are planned for a systematic 12 core biopsy. Positive test results are PSA ≥ 3, integrated marker PSAD ≥ 0.15, and PHI ≥ 35."
40755493|NCT04433026|DIAGNOSTIC_TEST|N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I|Biomarkers detected in the serum of patients
40755494|NCT01504542|BIOLOGICAL|HS110 vaccine|0.5ml to be administered twice weekly for 18 weeks (36 doses)
40755495|NCT01504542|BIOLOGICAL|Placebo|0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
40755496|NCT01504542|BIOLOGICAL|HS110 vaccine|0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
41279141|NCT04378777|PROCEDURE|Data Collection: Clinical Care Assessments|Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
40932947|NCT01931670|DRUG|Elagolix|
40932948|NCT04044027|BEHAVIORAL|S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring|S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
40932949|NCT04643171|DEVICE|high intensity elliptical training|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
40932950|NCT04643171|DEVICE|electrocaupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6 for 5 times per week, for 12 week
40932951|NCT00293488|DRUG|polyamine analogue PG11047|
40932952|NCT04485065|DRUG|IBI188+azacitidine|"Escalating and maintenance dose of IBI188 will be administered 30mg/kg, IV(intravenous infusion),Q4W~Drug:Azacitidine Azacitidine will be administered daily for 7 days, IH, Q4W"
40932953|NCT03076229|BEHAVIORAL|Healthy Marriage Program|Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
40932954|NCT05969327|DRUG|Vitamin D|oral supplementation of two different doses
40932955|NCT04111510|DRUG|Tumor infiltrating lymphocytes (TIL) LN-145|"The TIL autologous therapy with LN-145 is comprised of the following steps:~1. Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product;~2. LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility;~3. A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards);~4. Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization);~5. Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization)."
40932956|NCT04211233|DEVICE|invasive subdural grid electrode|A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.
40932957|NCT04211233|OTHER|Control arm|Standard Treatment based on Brain Trauma Foundation
40932958|NCT06111547|DRUG|TAK-279|TAK-279 oral tablet.
40932959|NCT06111547|DRUG|Placebo|TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.
40932960|NCT06403475|DEVICE|Transcutaneous Vagus Nerve Stimulation|"Transcutaneous auricular vagus nerve stimulation using the Nurosym (Parasym Ltd) device.~Stimulation parameters:~Pulse width: 250µs; Frequency: 25Hz; Intensity: Below pain threshold.~The active stimulation will be delivered to the left tragus. Participants will complete the intervention at home once they have received sufficient training on how to use the stimulation device."
40932961|NCT06403475|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|Stimulation will be delivered at the same parameters however, sham stimulation will be delivered to the left earlobe. Earlobe stimulation has been used as a sham in other studies as it is not thought to activate the vagus nerve.
40932962|NCT06403475|BEHAVIORAL|Computer Based Speech and Language Therapy (Step by Step)|Computer-based Speech and Language Therapy will be completed whilst wearing the stimulation device in all groups. The Step by Step programme uses an errorless learning approach to practice naming. All participants will practice a set of 30 meaningful words during the intervention. Participants will complete the SLT programme at home on an ipad, whilst using the stimulation device.
40932963|NCT00215579|DRUG|Depot Risperidone Microsphere (Consta)|
41279142|NCT01288768|PROCEDURE|Knee arthroscopy|Knee arthroscopy within 4 weeks.
41279143|NCT02910440|DRUG|DCL-101 vs Golytely|
40932964|NCT05877508|DRUG|AER002|Intravenous infusion of AER002
40932965|NCT05877508|OTHER|Placebo|Placebo infusion
40932966|NCT05281484|DRUG|CNM-Au8|"CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids).~Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm)."
41279144|NCT04657848|PROCEDURE|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
41279145|NCT03545282|BEHAVIORAL|Amigas Latinas Motivando el Alma (ALMA)|"In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions."
41279146|NCT00070447|BIOLOGICAL|rituximab|
41279147|NCT00070447|DRUG|cyclophosphamide|
40932967|NCT01376531|PROCEDURE|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
40932968|NCT03000127|DRUG|AndroGel 1 % Topical Gel|testosterone gel
40932969|NCT03000127|DRUG|Placebos|Placebo gel
41279148|NCT00070447|DRUG|doxorubicin hydrochloride|
40932970|NCT02571036|DRUG|DCC-2618|50 mg formulated tablets
40932971|NCT02571036|DRUG|DCC-2618|10 mg and 50 mg formulated tablets
40932972|NCT05832476|OTHER|No intervention|No intervention
41279149|NCT00070447|DRUG|prednisone|
41279150|NCT00070447|DRUG|vincristine sulfate|
41279151|NCT00070447|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
41279152|NCT05902585|BEHAVIORAL|Virtual reality|In the virtual reality group, patients will view a video with the virtual reality glasses from the beginning to the end of the venipuncture.
41279153|NCT03014648|DRUG|Atezolizumab|Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
40932973|NCT03264170|DIAGNOSTIC_TEST|Prediction of pregnancy outcome|The intervention group will receive the individualised prediction of their pregnancy (as a percentage). The prediction is calculated by a validated, accurate mathematical model using specific background information and ultrasound data for each participant.
41279154|NCT04205435|BIOLOGICAL|β-globin restored autologous HSC|gene edited autologous hematopoietic stem cells with β-globin restoration
41279155|NCT01011257|DRUG|Asprin|asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
41279156|NCT01011257|DRUG|Clopidogrel|clopidogrel 75 mg bid
40932974|NCT01607840|PROCEDURE|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
40932975|NCT02496676|DIETARY_SUPPLEMENT|Magnesium L-threonate|"In Part I, participants will receive 12 weeks of oral magnesium L-threonate; will be dose escalated based on weight.~In Part 2, participants will receive 24 weeks of oral magnesium L-threonate; will be dose escalated based on weight."
40932976|NCT02496676|OTHER|Placebo|In Part I, participants will receive 12 weeks of oral placebo; will be dose escalated based on weight.
41279157|NCT02039947|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules
41279158|NCT02039947|DRUG|Trametinib|Trametinib will be provided as 0.5 mg and 2.0 mg tablets
41279159|NCT04438655|DRUG|Oral antibiotic drugs|"Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon."
40932977|NCT02496676|DRUG|Intravenous (IV) magnesium sulfate (MgSO4)|In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).
40932978|NCT01326559|DRUG|Docetaxel, Cisplatin, 5-FU and Cetuximab|"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
41279160|NCT04438655|DRUG|Parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
40755497|NCT01389284|DRUG|Naproxen Sodium ER (BAYH6689)|660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
40755498|NCT01389284|DRUG|Naproxen Sodium IR (Aleve, BAYH6689)|220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
40755499|NCT01389284|DRUG|Naproxen Sodium ER Placebo|Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
40755500|NCT01389284|DRUG|Naproxen Sodium IR Placebo|Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
40932979|NCT02012673|DEVICE|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
40932980|NCT02414503|DRUG|8IU intranasal oxytocin|
41129753|NCT06292936|BEHAVIORAL|Acceptance-Based Behavioral Intervention|"Intervention will evaluate acceptance-based behavioral treatment (ABT) for individuals who are experiencing weight regain after bariatric surgery. ABT builds acceptance and mindfulness skills that increase the capacity to experience uncomfortable internal states (e.g., food cravings, hunger, negative affect). Online treatments include video modules demonstrating session content as well as interactive features. These interventions are particularly desirable, reduced participant burden, and are cost effective.~ABT provides patients unique skills that directly target causes of dietary non-adherence. ABT provides patients specialized skills to directly target causes of dietary nonadherence (rather that solely repeating behavioral strategies they received during preoperative medical weight management required by their third party payers and bariatric surgery programs)."
41129754|NCT06284564|DRUG|Evolocumab|Given by SC
41449843|NCT03541538|DEVICE|Global manipulation|The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.
41449844|NCT03541538|DEVICE|Especific manipulation|The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
40755501|NCT06025058|DEVICE|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
40755502|NCT00331149|DRUG|Ropinirole prolonged release|
40755503|NCT00331149|DRUG|ropinirole immediate release|
40755504|NCT04431778|DRUG|Ethosuximide|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
40932981|NCT02414503|DRUG|24IU intranasal oxytocin|
40932982|NCT02414503|DRUG|Placebo|
40932983|NCT02414503|DEVICE|OptiNose Breath Powered Bi|
40932984|NCT02025556|DRUG|LBR-101 High Dose|Subcutaneously Administered High Dose LBR-101 Monthly x 3
40932985|NCT02025556|DRUG|LBR-101 Low Dose|Subcutaneously Administered Low Dose LBR-101 Monthly x 3
40932986|NCT02025556|DRUG|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
40932987|NCT02126748|OTHER|inhalation 4ml hypertonic saline 3% 3x/day|
40932988|NCT02126748|DEVICE|Intrapulmonary Percussive Ventilation|
40932989|NCT02126748|PROCEDURE|Assisted Autogenic Drainage|
40932990|NCT04817852|OTHER|CBCT data of c-shaped canal in mandibular second molar.|Detection of variation in root canal morphology in mandibular second molar by using CBCT.
40932991|NCT06073990|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTi)|The intervention consists of four weeks of BBTi. During the first week, participants will receive face-to-face sleep assessments and sleep hygiene education. In the second week, a phone interview will be conducted to assess the patient's progress and provide appropriate relaxation techniques. Unsatisfactory responses to sleep restriction therapy or stimulation control methods will be addressed through face-to-face interviews in the third week. The fourth week will involve an overall review and evaluation conducted via a telephone interview.
40932992|NCT04674579|DEVICE|MRI|magnetic resonance imaging
40932993|NCT00865488|BIOLOGICAL|ADHEXIL|Adhesions prevention
40932994|NCT03612856|DRUG|AB023- Dose 1|Participants will receive a single dose of 0.25 mg/kg AB023.
40932995|NCT03612856|DRUG|AB023-Dose 2|Participants will receive a single dose of 0.5 mg/kg AB023.
40932996|NCT03612856|DRUG|placebo|Participants will receive a single dose of placebo.
40932997|NCT03901703|OTHER|Physiotherapy and Rehabilitation|The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.
40932998|NCT01251146|DRUG|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
40932999|NCT01251146|DRUG|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
40933000|NCT03566836|DEVICE|Garmin Smart Watch|Garmin Smart Watch
40933001|NCT03566836|DEVICE|Garmin Chest Band|Garmin Chest Band
40933002|NCT00278408|BIOLOGICAL|filgrastim|
40933003|NCT00278408|BIOLOGICAL|rituximab|
40755505|NCT04431778|DRUG|Placebo|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
40755506|NCT02143778|DEVICE|Methacetin Breath Test|13C labelled methacetin solution for breath test monitoring
40933004|NCT00278408|DRUG|cyclophosphamide|
40933005|NCT00278408|DRUG|doxorubicin hydrochloride|
40933006|NCT00278408|DRUG|prednisone|
40933007|NCT00278408|DRUG|vincristine sulfate|
40933008|NCT00278408|RADIATION|radiation therapy|
40933009|NCT05573815|DEVICE|BT-M01|Clinical decision support system for detecting brain metastasis
40933010|NCT00947050|OTHER|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
40933011|NCT03362307|DEVICE|Low-Level Laser and Light-Emitting Diodes|Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability
40933012|NCT03362307|DEVICE|Dental implant placement|A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible
40933013|NCT05644249|DRUG|Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy|Each course of combined treatment will start with PIPAC (a pressurized aerosol containing cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 diluted in NaCl 0.9% applied through the nebulizer inside the abdominal cavity during laparoscopy). Fourteen days afterward 2 cycles of systemic FOLFOX chemotherapy will be applied within 28 days. The interval between combined treatment courses will be 14 days.
40933014|NCT01280045|PROCEDURE|VAGINAL HYSTERECTOMY|GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
40933015|NCT00815724|BEHAVIORAL|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
40933016|NCT03442283|DIETARY_SUPPLEMENT|Vitamin mineral supplementation|supplementation with a vitamin or mineral: vitamin A, β-carotene, B1, B2, B3 (niacin), B6, B10 (folic acid), C, D and E, calcium, iron, zinc, magnesium and selenium. Also, multivitamins, antioxidants, B-complex and the combination of calcium and vitamin D.
40933017|NCT01993784|DRUG|nimotuzumab|
41129755|NCT06284564|DRUG|Nivolumab|Given by IV
41129756|NCT03642366|OTHER|Dornier Aries2 LiST Device + 5mg Tadalafil (1)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
41449845|NCT05374057|OTHER|Chiropractic spinal manipulative therapy (CSMT)|See study arm.
41449846|NCT05374057|OTHER|CSMT sham manipulation|See study arm.
40755507|NCT02594852|DEVICE|+ laser|Use of laser in the treatment
40755508|NCT04157582|OTHER|Pilates training|"1. Pilates warm-up training (5 minutes) consisted of Breathing, the Chest stretch, the Toy soldier, Upper extremity PNF patterns, and Roll down.~2. Pilates mat training performed in 5 different positions (30 minutes).~   1. One leg stretch, Hundreds, the Double leg stretch, Scissors, the Shoulder bridge, Oblique preparation, and the Hip twist were performed in the supine position(Fig.7).~  2. Clare, the Side kick, Arm openings, the Lower lift, Leg lifts, and the Side bend were performed in the side-lying position.~  3. Swan dive, the One leg kick, Swimming, the Breast stroke preparations, the Breast stroke performed in the prone position(Fig.8).~  4. Half roll back, Oblique roll up were performed in the sitting position.~  5. Swimming was performed in the kneeling position.~3. The Pilates cool down training (5 minutes) were the Spine stretch, Saw, Chest stretch, Toy soldier. (Cruz et al .,2011)"
40933018|NCT06517108|PROCEDURE|Chuna therapy|"The chuna therapy group will receive chuna therapy based on the degree of displacement of the lumbar, ilium, sacrum, and cervical vertebrae. The type of weight or treatment is selected based on the clinical judgment of the Korean medicine practitioner (HVLA: high-velocity low-amplitude thrust, drop table manipulation, muscle energy techniques, myofascial release, etc.). The area and number of treatments performed are recorded separately. Thermotherapy is applied as an adjuvant treatment.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement."
40933019|NCT06517108|PROCEDURE|Physical therapy|"The physical therapy group will receive transcutaneous electrical nerve stimulation (TENS) for about 10 to 15 minutes, and the area and number of times it was administered will be recorded. Thermotherapy is applied as an adjuvant treatment, and the area and number of times it is applied are recorded separately.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement."
40933020|NCT06346808|DRUG|Oncolytic virus Plus Anti-PD1 and Chemotherapy|Oncolytic virus，Camrelizumab ，AG（Gemcitabine +Capecitabine ）
40933021|NCT02026570|BEHAVIORAL|Internal Focus of Attention|Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
40933022|NCT02026570|BEHAVIORAL|External Focus of Attention|Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
40933023|NCT02974101|OTHER|registration of AdaptiveStim|
40933024|NCT04474353|DEVICE|Optune|Noninvasive, portable device which generates tumor treating fields (TTFields) manufactured by Novocure
40933025|NCT04474353|DRUG|Gadolinium|Gadolinium contrast medium
40933026|NCT04474353|DRUG|Temozolomide|Chemotherapy agent
40933027|NCT04474353|RADIATION|Stereotactic radiosurgery (SRS)|Standard of Care: SRS (35 Gy in 5 fractions of 7 Gy), 5-day treatment from Day 2
40933028|NCT02605044|DRUG|Masitinib (AB1010)|
40933029|NCT02605044|DRUG|FOLFIRI|
40933030|NCT03461679|PROCEDURE|Adductor canal block|Single shot block with 0.5% bupivacaine 10mls
40933031|NCT03461679|PROCEDURE|Femoral triangle block|Single shot block with 0.5% bupivacaine 10mls
40933032|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks|PCV10 1+1, 6 weeks \& 9 months
40933033|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks|PCV10 1+1, 14 weeks \& 9 months
40933034|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 2+1|PCV10 2+1, 6\&14 weeks \& 9 months
40933035|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks|PCV13 1+1, 6 weeks \& 9 months
40933036|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks|PCV13 1+1, 14 weeks \& 9 months
40933037|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 2+1|PCV13 2+1, 6\&14 weeks \& 9 months
40933038|NCT06520579|BEHAVIORAL|Proactive pharyngeal-laryngeal Exercise Program|This program consists of daily proactive pharyngeal-laryngeal exercises and weekly sessions with a speech-language pathologist post surgery. One week prior to surgery participants will begin daily proactive pharyngeal-laryngeal exercises and continue these daily exercises for 6 weeks post surgery. Beginning approximately one week after surgery, participants will meet with the speech-language pathologist. Sessions will occur weekly, for approximately 6 weeks, and will last approximately 45 minutes.
40933039|NCT06520579|DIETARY_SUPPLEMENT|Premier Protein Clear ® High Protein|Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink) 1 drink daily for 7 weeks.
41449847|NCT05374057|DRUG|Ibuprofen|See study arm.
41449848|NCT05374057|DRUG|Placebo medication|See study arm.
40933040|NCT06520579|BEHAVIORAL|Hydration Counseling|Daily hydration goals are based on recommended guidelines for adults, by gender, from The United States National Academy of Medicine (US NAM) and the European Food Safety Authority (ESFA) (\~2.0 L/day for women; \~2.5 L/day for men of fluid intake, accounting for 20% daily fluid intake from food sources). Patients will be required to track via paper log whether they met their hydration goals daily.
40933041|NCT04650646|OTHER|Exercise-related hypoglycaemia|Hypoglycaemia induced by intravenous insulin and exercise on a vertical cycle ergometer.
40933042|NCT04650646|OTHER|Hypoglycaemia under resting conditions|Hypoglycaemia induced by intravenous insulin during bed rest.
40933043|NCT00058539|DRUG|rhuMAb 2C4 (pertuzumab)|
40933044|NCT03513523|DIETARY_SUPPLEMENT|Group 1 NRPT|Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
41449849|NCT04750681|DIETARY_SUPPLEMENT|Placebo|Subjects orally ingested, with water, one capsule per day (in the evening)
41449850|NCT04750681|DIETARY_SUPPLEMENT|Saffron|Subjects orally ingested, with water, one capsule per day (in the evening)
41449851|NCT01715077|DRUG|Ipilimumab at 3 mg/kg dose|
41449852|NCT02761525|OTHER|silver nanoparticles|Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
41449853|NCT02761525|OTHER|placebo|Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
41279161|NCT06258278|PROCEDURE|Arthroscopic-assisted lower trapezius tendon transfer surgery|The procedure, conducted under general anesthesia, starts with diagnostic arthroscopy followed by excision of the posterior bursa and preparation of the rotator cuff footprint. Attention then shifts to harvesting the low trapezius tendon, accessed through a 10cm incision over the spina scapula. The tendon is detached, dissected, and released from adhesions, ensuring not to damage its pedicle. A fascia lata graft is harvested from the ipsilateral thigh and sutured to the low trapezius tendon in a continuous, locking manner to aid fixation on the humeral head. A subdeltoid tunnel is formed, and the graft is shuttled into the subacromial space and fixed at the bicipital groove and tuberculum majus with knotless anchors. The stability of fixation and mobility of the low trapezius muscle are verified, and the graft and tendon are sutured together with tension, with the arm held in 90° abduction and maximum external rotation.
41279162|NCT06230796|DEVICE|FES-cycling|30 minutes of active leg cycling with or without FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
41279163|NCT06230796|DEVICE|SHAM-cycling|30 minutes of active leg cycling with SHAM FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
41279164|NCT01485874|DRUG|Doxil (Pegylated Liposomal Doxorubicin)|Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
41279165|NCT01485874|DRUG|BIBF 1120|"Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle"
41279166|NCT04407377|DRUG|Tolperisone Hydrochloride|Study Drug
41279167|NCT04407377|DRUG|Cyclobenzaprine Hydrochloride 10 MG|Active Comparator
41279168|NCT04407377|OTHER|Placebo|Placebo Comparator
41279169|NCT05559814|DRUG|Intraluminal peppermint oil|Intraluminal flushing of peppermint oil solution through the scope channel during the scope withdrawal
41279170|NCT05559814|DRUG|Placebo|Intraluminal flushing of placebo solution through the scope during scope withdrawal
41279171|NCT01065935|DRUG|ALN-RSV01|Administered by nebulization once daily for 5 days
40755509|NCT04157582|OTHER|Conventional physical therapy|"1. Gentle manual stretching exercises for (elbow flexors, wrist flexors , hamstring and calf muscle).~2. Strengthening Exercises for ( elbow extensors, wrist extensors and dorsiflexors)~3. Balance training (Wobble board training) :~   * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror with hand support(with repetition 10times)~  * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror without hand support(with repetition 10times)."
40755510|NCT01951456|BEHAVIORAL|Resistance training|
41129757|NCT03642366|OTHER|Dornier Aries2 LiST Device + 5mg Tadalafil (2)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
41279172|NCT01065935|DRUG|Normal Saline|Administered by nebulization once daily for 5 days
41279173|NCT04549987|DEVICE|Space closure without changing working archwire monthly|Upper premolar space closure using the same 0.019X0.025 stainless steel archwire every month
41279174|NCT04549987|DEVICE|Space closure withchanging working archwire monthly|Upper premolar space closure using new 0.019X0.025 stainless steel archwire every month
41279175|NCT00326092|DRUG|Brinzolamide/Timolol|
41279176|NCT05564468|OTHER|Best Practice|Receive standard of care
41279177|NCT05564468|OTHER|Internet-Based Intervention|Receive Peacefully's end-of-life planning program
41279178|NCT05564468|OTHER|Questionnaire Administration|Ancillary studies
41279179|NCT03253640|OTHER|Exposure|Healthcare associated infection (HAI)
41279180|NCT01939795|OTHER|exercise training and/or CRT|Three 40-minute exercise sessions per week on a treadmill for four months
41279181|NCT05833880|BEHAVIORAL|Self-administered questionnaire|Self-administered questionnaire regarding complementary and alternative medicine use
41279182|NCT02094599|DRUG|Dronabinol 10 mg|Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
41279183|NCT02094599|DRUG|Dronabinol 30 mg|Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
41279184|NCT02094599|DRUG|Placebo|Matching placebo provided in capsules or as an oral solution in syringes.
40755511|NCT01951456|BEHAVIORAL|Health and Wellness|
40933045|NCT03513523|DIETARY_SUPPLEMENT|Group 2 NRPT|Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
40933046|NCT03513523|OTHER|Group 3 Placebo|Four placebo capsules will be taken once daily in the morning for 26 weeks.
41279185|NCT05144425|PROCEDURE|total knee arthroplasty with and without using pneumatic tourniquet|The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of\<8 g/dL or patient with symptomatic anemia.
41279186|NCT04435340|DIAGNOSTIC_TEST|Selective Sonography of the ventral abdominal hernia level|The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)
41279187|NCT03233048|DEVICE|ORBERA™ Intragastric Balloon|The balloon will be inserted into the stomach and inflated, and will remain in place for 6 months, after which the device will be removed.
41279188|NCT04180605|OTHER|Additional support for preoperative planning of LAA closure procedures|"The results of the computational simulations provided by FEops HEARTguideTM will be used in the computational simulation arm as an additional preoperative planning tool and their potential added value will be assessed by comparison to the standard of care arm."
41279189|NCT04180605|PROCEDURE|Left atrial appendage closure|Transcatheter device insertion to exclude the LAA from the cardiac circulation
41279190|NCT01729689|OTHER|counseling intervention|Undergo cognitive behavioral therapy
41279191|NCT01729689|OTHER|questionnaire administration|Ancillary studies
41279192|NCT01729689|PROCEDURE|quality-of-life assessment|Ancillary studies
41279193|NCT04232033|OTHER|Fibroblast growth factor 21 infusion|Infusion of Fibroblast growth factor 21
41279194|NCT04232033|OTHER|Placebo infusion (saline)|Infusion of Saline
41279195|NCT02562729|PROCEDURE|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
41279196|NCT06137352|OTHER|Follow up|Each subject was recruited in 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and followed up at 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, with a total of two follow-up visits. At enrollment and both follow-up visits, subjects were required to collect 2 tubes of peripheral venous blood each.
40933047|NCT04050917|DEVICE|real stimulation|The smartwatch generates imperceptible vibratory stimulation.
40755512|NCT03600103|BEHAVIORAL|Tech2Check|The intervention uses behaviors to improve HIV adherence and self-care. Investigators will use the Center for Disease Control (CDC) Partnership for Health (PfH) Medication Adherence.The CHN will administer PfH at all home/venue-based encounters, using communication styles that are more receptive to adolescents and young adults. Resources will be provided. At the end of the session, the participant will be able to state/demonstrate: goals of HIV care and adherence, meaning of CD4 and Viral Load (VL) measurements and the significance of their own measurements,signs of complications or problems for which participants need to seek additional care,understanding of optimal self-care.Further, CHNs will also provide tips to stay on schedule with taking their ART and problem-solve adherence barriers.
40755513|NCT04651374|DEVICE|geko T3|The device stimulates the peroneal nerve.It will be applied for the entire duration of ICU stay and replaced once every 24 hours.
40933048|NCT04050917|DEVICE|no stimulation|The smartwatch generates no stimulation.
40933049|NCT01437800|DRUG|Glimepiride / Extended release Metformin (4/850 mg).|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
40933050|NCT01973530|PROCEDURE|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
41279197|NCT02265328|DIETARY_SUPPLEMENT|Bovine colostrum|Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months
40933051|NCT01973530|PROCEDURE|femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
40933052|NCT02942576|DRUG|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.
40933053|NCT02942576|DRUG|VKA-Based Regimen|Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.
41279198|NCT02265328|DIETARY_SUPPLEMENT|Enteral Nutrition|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
41279199|NCT02265328|OTHER|prednisolone|Oral prednisolone 40mg/day × 4 weeks and tapered to \<40mg/day for next 4 weeks. (If Lilli score \> 0.45 after 7 days, then prednisolone would be stopped)
41279200|NCT02882477|DRUG|Deferiprone|
41279201|NCT02882477|DRUG|Acetylcysteine|
41279202|NCT02882477|DRUG|Sitagliptin and Metformin|
41279203|NCT01663441|DRUG|NL201|mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
40755514|NCT05531344|DEVICE|Composite Steep-pulse Treatment Device|Applying the Composite Steep-pulse Treatment Device to treat the patients with Benign Prostatic Hyperplasia
40755515|NCT05531344|DRUG|Tamsulosin Hydrochloride Capsules|Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia
40755516|NCT02424786|OTHER|STOPP/START criteria|Evaluation of medication lists
40755517|NCT01983904|DEVICE|deep brain stimulation with short & long pulse width|surgical implantation for bilateral electrodes and stimulation using short and long pulse width
40933054|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.
40933055|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in France.
40933056|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Spain.
40933057|NCT01716871|DEVICE|neurocryostimulation with Duo-cryo® device|organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
40933058|NCT01716871|DEVICE|cryotherapy with Cold pack® or ice-cubes pack|"Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.~The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group."
40933059|NCT01994499|DEVICE|Videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
41279204|NCT01663441|DRUG|NL201|mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
41279205|NCT01663441|DRUG|NL201|The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
40755518|NCT02503865|DRUG|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
40933060|NCT01994499|DRUG|Medical drainage|Medical pleural drainage
40933061|NCT05983783|DRUG|Docetaxel|This is Triple drug regimen for mHSPC
40755519|NCT02503865|DIETARY_SUPPLEMENT|"Analimentary detoxication"|Vegetable and salt diet
40933062|NCT05983783|DRUG|Rezvilutamide|This is doubling drug regimen for mHSPC
40755520|NCT05414747|DEVICE|ABV-1701|ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH)
40755521|NCT05414747|DEVICE|SF6 Gas|SF6 is a commercial gas tamponade as a vitreous substitute in pars-plana vitrectomy surgery (PPV)
40755522|NCT06393426|DRUG|Chinese Herb|Chinese herbal medicine
41279206|NCT01663441|DRUG|rhIL-11|rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
40933063|NCT03673761|OTHER|MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing|3.Dixon, T2 mapping MRI microRNAs
40933064|NCT04357691|BEHAVIORAL|Conventional training|Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model
40933065|NCT04357691|BEHAVIORAL|AI-led training|Participants will perform an AI-led training for 4 weeks
40933066|NCT04433143|DRUG|Minocycline hydrochloride capsules were taken orally|Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.
40933067|NCT00951782|DEVICE|High frequency TMS|deep TMS HADD coil
40933068|NCT00951782|DEVICE|Sham TMS|sham deep TMS HADD coil
40933069|NCT00951782|DEVICE|Low frequency TMS|Deep TMS - HADD coil
40933070|NCT02577783|DRUG|PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone|doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
40933071|NCT02577783|DRUG|PAD regimen: bortizomib, dexamethasone and doxorubicin|doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
40933072|NCT04450459|DIAGNOSTIC_TEST|ergospirometer test|ergospirometric test will be done before cardiac catheterisation and invasive measurement of FFR
40933073|NCT00599131|DRUG|Cisplatin|1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a \< 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, \> 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
40933074|NCT00599131|DRUG|Cetuximab|1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
40933075|NCT00599131|DRUG|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
40933076|NCT00599131|DRUG|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
40933077|NCT04330326|DRUG|Metabolic Cofactor Supplementation|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
40933078|NCT04330326|DRUG|Sorbitol|As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
40933079|NCT02992132|DRUG|Pimavanserin 34 mg|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
40933080|NCT02992132|DRUG|Pimavanserin 20 mg|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth
40933081|NCT02992132|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth
40933082|NCT05950139|BIOLOGICAL|Peptide vaccine|Peptide vaccine
40933083|NCT02364401|DEVICE|Ablation|Catheter ablation for atrial fibrillation
40933084|NCT04322201|DEVICE|continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care
40933085|NCT04322201|PROCEDURE|Ultrasound-guided intermittent large-volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter
40933086|NCT04783142|OTHER|High-fiber, low-protein diet|Diet will consist of at least 15g fiber above baseline and less than 10% of calories from protein.
40933087|NCT04783142|OTHER|Low-fiber, high-protein diet|Diet will consist of less than 15g fiber and greater than 18% of calories from protein
40933088|NCT03445182|PROCEDURE|Local anaesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anaesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
41279207|NCT00397150|BEHAVIORAL|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
40933089|NCT03445182|DEVICE|Local anaesthesia with conventional syringe + Dentalvibe|"Buccal infiltration in posterior maxillary region. The tip of the DentalVibe device is placed in the mucobuccal fold above the tooth to be anesthetized. The device is activated for 5 s. A 27 gauge short needle is inserted as close as possible to the inner side of the prong while the vibration is still on.~Local anaesthetic infiltration speed 1ml/min. After injection the needle is withdrawn and vibration continues for another 5 s.~Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
40933090|NCT06236191|DEVICE|transcranial pulsed current stimulation|A form of transcranial electrical stimulation that delivers unidirectional monophasic rectangular pulses of current.
40933091|NCT06236191|DRUG|Melatonin|Melatonin
40933092|NCT05025748|BEHAVIORAL|Behavioral Intervention|Complete questionnaires
40933093|NCT03037723|OTHER|CT simulation|
40933094|NCT06147973|BEHAVIORAL|Acceptance-based Treatment (ABT)|Participants will be provided with psycho-education, skill-builders, and other coaching to promote weight loss and healthy lifestyle changes.
40933095|NCT06147973|BEHAVIORAL|Health Education (HE) Comparison|Participants will be provided with psych-education and resources to promote weight loss and healthy lifestyle changes. They will not be provided with directives.
40933096|NCT00719797|BIOLOGICAL|bevacizumab|Given IV
40933097|NCT00719797|DRUG|fluorouracil|Given IV
40933098|NCT00719797|DRUG|irinotecan hydrochloride|Given IV
40933099|NCT00719797|DRUG|leucovorin calcium|Given IV
40933100|NCT00719797|DRUG|oxaliplatin|Given IV
40933101|NCT00287170|DRUG|Delayed Release 6MP or Calcitriol vs. Purinethol|
40933102|NCT04941443|DRUG|Methadone Pill|All participants will be given a 5mg methadone tablet to be taken immediately following the misoprostol dose.
40933103|NCT04941443|DRUG|Ibuprofen|All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.
40933104|NCT03230201|PROCEDURE|Lymph node dissection|Lymph node dissection during radical nephroureterectomy
40933105|NCT02353143|DRUG|MEN1112|"Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration)."
40755523|NCT05264584|DRUG|Isotonic saline|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
40755524|NCT05264584|DRUG|N-acetyl cysteine|all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .
40755525|NCT05264584|DRUG|Febuxostat 80 MG|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
40755526|NCT01637571|DRUG|Dexilant|60mg of Dexilant QD for 12 weeks
40755527|NCT01637571|DRUG|Dexilant Placebo|60mg of Dexilant placebo QD for 12 weeks
40755528|NCT06404554|OTHER|without any intervention|without any intervention
40755529|NCT00714363|PROCEDURE|LASIK|Refractive surgery
40755530|NCT00714363|PROCEDURE|SBK|Refractive surgery
40755531|NCT01454557|OTHER|Auditory Stimuli|Auditory Stimuli during rest and during physical activity
40755532|NCT02819544|DRUG|Sodium chloride administration|Sodium chloride administration
40755533|NCT02819544|DRUG|Ropivacaine administration|Ropivacaine administration
40755534|NCT03943992|DRUG|YYD601 40mg|Patients should take druges 30 minutes before breakfast.
40755535|NCT03943992|DRUG|Nexium 40mg|Patients should take druges 30 minutes before breakfast.
40755536|NCT03943992|DRUG|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
40755537|NCT02111356|DEVICE|Phinhole glasses|Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
40755538|NCT02645162|BEHAVIORAL|Community-based Preschool|"* Preschool sessions in community-based preschool~* Run by trained community youth leaders from the same village."
40933106|NCT05185011|DRUG|TPN171H|10 mg TPN171H tablets，single dose
40933107|NCT06119022|PROCEDURE|Invasive coronary angiography|Patients with positive myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to undergo invasive coronary angiography.
41279208|NCT04673383|DRUG|SPL026|Intravenous solution
41279209|NCT04673383|DRUG|Placebo|SPL026-matched placebo
41279210|NCT00281450|BEHAVIORAL|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
41279211|NCT03714893|DEVICE|Sensor wrist watch|Participants will wear a sensor wrist watch which will collect data
40755539|NCT00983957|DRUG|BMS-790052|Tablets, Oral, 60 mg, once daily, 10 days
40755540|NCT00983957|DRUG|Ortho Tri-Cyclen®|Tablets, Oral, once daily, 78 days
40755541|NCT04796220|DRUG|Gemcitabine|Gemcitabine (900 mg/m2) will be administered intravenously on day 1.
40755542|NCT04796220|DEVICE|Focused Ultrasound|Focused ultrasound will be applied to up to 2 breast lesions on day 8.
40755543|NCT04796220|OTHER|Gemcitabine and Focused Ultrasound|Gemcitabine (900 mg/m2) will be administered intravenously on day 1.Focused ultrasound will be applied to up to 2 breast lesions on day 8.
40755544|NCT05664646|DEVICE|DS8R|transcutaneous stimulation of the spinal cord.
40755545|NCT05664646|OTHER|Arm Ergometry|Study 1 will use the arm ergometry as a form of exercise.
40755546|NCT05664646|OTHER|Cool Environment|Study 2 will be completed in a cool environment setting.
40755547|NCT05811975|DRUG|KSX01-TCRT injection|individualization TCR-T cell injection
40755548|NCT04993768|DRUG|TPN-101, 100 mg/day|100 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
40755549|NCT04993768|DRUG|TPN-101, 200 mg/day|200 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
40755550|NCT04993768|DRUG|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
40755551|NCT04993768|DRUG|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
40755552|NCT03728231|OTHER|Complete blood count|taking blood sample from venous blood
40755553|NCT00592527|DRUG|insulin detemir|
40933108|NCT06119022|OTHER|routine medical treatment|Patients with negative myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to have routine medical therapy instead of invasive coronary angiography.
40933109|NCT03621345|PROCEDURE|Erector spinae plane block|Ultrasound guided bilateral erector spinae plane block will be administered. An intravenous patient control analgesia device with morphine will be given to patients.
41279212|NCT00146692|BEHAVIORAL|Free medical treatment|
41279213|NCT03677570|DIAGNOSTIC_TEST|postural stability|Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
40933110|NCT03621345|OTHER|sham block|A sham block will be applied. Skin will be infiltrated with local anesthetics, and 2 mL subcutaneous saline injection will be applied.An intravenous patient control analgesia device with morphine will be given to patients.
40933111|NCT05837143|BIOLOGICAL|JV001|JV001 (AAV9/modTERT) will be delivered by a percutaneous method in the catheter laboratory. Dose: 2×10\^11vg/kg，or 6×10\^11vg/kg.
40933112|NCT01451268|DRUG|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
40933113|NCT01451268|DRUG|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
40933114|NCT00762593|DEVICE|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
40933115|NCT00762593|DEVICE|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
40933116|NCT00482352|OTHER|laboratory biomarker analysis|Correlative studies
40933117|NCT03133988|BIOLOGICAL|Margetuximab|anti-HER2 monoclonal antibody
40933118|NCT06012643|OTHER|The purpose of this systematic review of case reports and case series was to evaluate the spectrum of subperiosteal implants for severely atrophied jaws using digital technology.|An electronic and manual search was conducted in the PubMed, Scopus, and Google Scholar databases. Publications of case reports and series written in English without data restrictions
40933119|NCT02779387|DRUG|Goserelin Acetate|
40933120|NCT05010642|DEVICE|Use of Eko DUO electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
40933121|NCT03517488|BIOLOGICAL|XmAb20717|Monoclonal bispecific antibody
40933122|NCT04560244|DRUG|SHR1701|PD-L1 / TGF-β RII double antibody
40933123|NCT01602133|PROCEDURE|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
40933124|NCT01879540|BIOLOGICAL|aTIV|Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
40933125|NCT03387475|DRUG|Deferasirox|iron chelation
40933126|NCT03918668|BEHAVIORAL|Women with recent diagnosis of breast cancer|To evaluate dietary habits of a group of women with pre and post-surgical breast cancer
40933127|NCT06336759|DEVICE|Restylane Defyne|Twenty (20) subjects with thin skin will be recruited and treated with Restylane Defyne.
40933128|NCT06336759|DEVICE|Restylane Lyft|Twenty (20) subjects with thick skin will be recruited and treated with Restylane Lyft.
40933129|NCT03505827|DIAGNOSTIC_TEST|24-2 SITA Standard Humphrey Visual Field Test|Patients participate in a 24-2 SITA Standard humphrey visual field test. This includes sitting in a dark room at a visual field machine. Stimulus test points of different intensity and size will be presented to the patient, as per SITA standard protocol. The patient will indicate by pressing a button when they see the visual stimulus.
41279214|NCT04101890|DRUG|Diaper care with Theraworx|Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
40933130|NCT00003395|DRUG|arsenic trioxide|
40933131|NCT00946400|OTHER|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
40933132|NCT00946400|OTHER|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
40933133|NCT00880165|DEVICE|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
40933134|NCT00969280|DEVICE|Standardized Acupuncture|"Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20\*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes."
40933135|NCT00969280|DEVICE|Non-acupuncture point shallow penetration acupuncture|"Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20\*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes."
40933136|NCT04999254|OTHER|Medical treatment|"Medical treatment will be based on functional treatment and the doctor will prescribe the RICE protocol. For this, the patient will have to :~* place an ice pack on the sprain~* apply sports rest for three weeks~* compress the sprain with a compression stocking when standing in order to prevent phlebitis. In addition, to avoid this complication, the doctor will prescribe an anticoagulant.~* raise the foot with crutches during the day~* elevate the foot at night or when doing an activity in a sitting position, using a cushion for example.~In addition, the doctor will prescribe anti-inflammatory drugs to ease the pain and physiotherapy to establish proprioception, muscle strength, joint range and dynamic postural balance of the sprain."
40933137|NCT04999254|OTHER|osteopathic treatment|Each patient will be treated as a whole and within a time limit of 45 minutes. The consultation will start with a medical history followed by medical tests. Then, the osteopath will perform osteopathic tests and manual treatment.
40933138|NCT05834595|DRUG|CKD-828, D064, D701|QD, PO
40933139|NCT02628769|DRUG|Solithromycin|
40933140|NCT02628769|DRUG|Placebo|
40933141|NCT00306111|DRUG|pegfilgrastim|Single dose (6mg) one day after chemotherapy
41279215|NCT04396977|PROCEDURE|Histamine 10 mg/ml skin prick|Skin prick through 5 µL histamine diHCl (10 mg/ml)
40933142|NCT05729802|DEVICE|HoloSIM Software via Hololens 2|Participants will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
40933143|NCT05729802|OTHER|Training by Mannequin Based Simulation|Participants will train a via traditional mannequin based medical crisis scenario
40933144|NCT01877733|OTHER|Maximal strength training|
40755554|NCT04759092|DEVICE|transcranial direct current stimulation (tDCS)|Apply 30min low dose (2mA) transcranial current stimulation on the scalp every day for four months.
40755555|NCT03077308|PROCEDURE|Auditory and Visual Event-related Potentials and EEG|Specifically, through up to three standardized sessions (i.e., annual \[every 10-14 months\]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
40755556|NCT03555097|PROCEDURE|incremental pressure support|Inspiratory positive airway pressure (IPAP) gradually increases from 10 to 24 cm water column (cmH2O) with 2 water column (cmH2O) increments. The expiratory positive airway pressure (EPAP) remains 4 water column (cmH2O), and each pressure level is maintained for 5 to 10 minutes.
40755557|NCT03954938|BEHAVIORAL|Craving Manipulation|Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
40755558|NCT03954938|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
40755559|NCT03954938|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
40755560|NCT04829214|DRUG|OTO-313|Single intratympanic injection
40755561|NCT04829214|DRUG|Placebo|Single intratympanic injection
40755562|NCT06500845|OTHER|Bevel marginal design endocrown for endodontically treated teeth|Bevel marginal design will be prepared for endodontically treated teeth and restores with Peek endocrown
40933145|NCT05148988|DIAGNOSTIC_TEST|EchoPIV|All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.
40933146|NCT05148988|DIAGNOSTIC_TEST|4D flow MRI|A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.
40933147|NCT04645485|BIOLOGICAL|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).|Participants received the investigational therapy through compressor (jet) nebulization, in two doses divided on Days 0 and 1. Each dose contains 10 mL of peripheral blood-derived stem cells CD45-/CD90+/CD133+.
40933148|NCT03656471|DEVICE|clear aligners or fixed appliances|Patients choose clear aligners or fixed appliances to treat their malocclusions
40755563|NCT06500845|OTHER|Butt marginal design endocrown for endodontically treated teeth|Butt marginal design will be prepared for endodontically treated teeth and restores with Peek endocrown
40755564|NCT02187081|PROCEDURE|radiofrequency ablation plus Sorafenib|To treat HCC with the combination of radiofrequency ablation and sorafenib
40755565|NCT02187081|PROCEDURE|Radiofrequency ablation|To treat HCC with radiofrequency ablation alone.
40755566|NCT02627638|OTHER|Ostheopathic treatment|Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
40755567|NCT03568071|DRUG|MOR 106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
40755568|NCT03568071|DRUG|Placebo|A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
40755569|NCT04826757|OTHER|Coordinated care|"Coordinated care between general practioners; physiotherapists and occupational health services.~Early contact with occupational health service by the general practioner and use of occupational retention tool Active physiotherapy (Individual active, intensive and regular rehabilitation program with 15 sessions of 1 hour, at a rate of 2 or 3 sessions per week)"
40933149|NCT06028100|PROCEDURE|sacral erector spinae plane block|espb from bilateral sacral level 2 with 20 ml %0,25 bupivacaine
40755570|NCT00984633|DRUG|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
40755571|NCT00984633|DRUG|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
40755572|NCT00984633|DRUG|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
40755573|NCT00984633|DRUG|Propofol|4-10 mg/kg/hr maintenance anesthesia
40755574|NCT04365270|DRUG|Glass Ionomer|Glass ionomer filling material would be modified accordingly or used as is
40933150|NCT02885168|DRUG|Recombinant Activated Protein C|24 μg/kg/h during 96 hours - intravenous injection
40933151|NCT02885168|DEVICE|Near-infrared spectroscopy (NIRS)|After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
40933152|NCT02885168|DRUG|Phenylephrine|"Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test."
40933153|NCT02885168|BIOLOGICAL|Blood sample|Analysis of inflammation and cellular adhesion markers and free radicals
40933154|NCT02739672|DRUG|TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once
40933155|NCT02739672|DRUG|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
40933156|NCT02739672|DRUG|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once
40933157|NCT00988767|BIOLOGICAL|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
40933158|NCT03906227|DEVICE|ENUMERATION OF CD5+ B Cells|A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
40933159|NCT05261776|OTHER|pilates exercise|"Pilates exercise for 40 minutes (5 minutes for warm-up and 30 minutes of pilates and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-A will get 40 minutes of session, Alternative three days/ week for 12 weeks."
40933160|NCT05261776|OTHER|brisk walk|"Brisk walk on treadmill for 40 minutes (5 minutes for warm-up and 30 minutes of brisk walk on treadmill and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-B of 40 minutes of session, Alternative three days/ week for 12 weeks."
40933161|NCT06021860|DRUG|Spironolactone Oral Suspension|"Spironolactone will be dosed on a mg/kg basis, with actual weight on Day 1 (pre-dose) determining the spironolactone suspension volume administered. Therefore, for a given patient, the dose administered on Day 1, based on the weight measured on Day 1, will be administered throughout their participation in the study.~Spironolactone will be administered as a single dose in the single-dose periods (Group 4, Parts 1 and 2), and as QD dosing in the multiple-dose periods (Groups 1 to 4, Parts 1 and 2).~The low and high doses to be administered during Part 2 of the study will be determined by the Safety Review Committee following their review of Part 1 data."
40933162|NCT05999539|DEVICE|Transtibial prosthesis|A transtibial prosthesis to be used for at least one year.
40933163|NCT01082640|DRUG|Febuxostat|Febuxostat capsules
40933164|NCT01082640|DRUG|Placebo|Febuxostat placebo-matching capsules
40933165|NCT03206957|DIAGNOSTIC_TEST|Funduscopic examination and retinal photography|A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.
40933166|NCT03206957|DIAGNOSTIC_TEST|Serum levels of endostatin and angiogenesis factors|Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed
40933167|NCT03206957|DIAGNOSTIC_TEST|Renal and low urinary tract Doppler ultrasound|"Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated.~Doppler ultrasound examination will assess renal arterial resistivity indexes"
40933168|NCT03206957|DIAGNOSTIC_TEST|Urinalysis|Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.
40933169|NCT03206957|DIAGNOSTIC_TEST|Anthropometric measures and vitals signs|weight, height and blood pressure will be assessed
40755575|NCT04365270|DRUG|Chitosan Low Molecular Weight (20-200 Mpa.S)|deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
40755576|NCT04365270|DRUG|Chlorhexidine Diacetate|Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
40933170|NCT03804073|RADIATION|standard treatment|3000 cGy in 10 daily fractions
40933171|NCT03804073|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
40933172|NCT04676555|DRUG|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
40933173|NCT04676555|DRUG|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
40933174|NCT06110975|OTHER|deprescribing-intervention|"The clinical guideline on Deprescribing drugs for OAB in The North Denmark Region serves as the basis for the intervention. The guideline provides recommended procedures for the deprescribing process. The guideline offers procedures for the deprescribing process and includes a deprescribing algorithm and a symptom questionnaire designed to evaluate the impact of medications utilized in the treatment of OAB."
40933175|NCT01926327|BIOLOGICAL|PRP injection|Injection of PRP in patients with knee osteoarthritis.
40933176|NCT01926327|BIOLOGICAL|Placebo|
40933177|NCT05999942|DRUG|Liposomal Amikacin for Inhalation|Administered via the Pari LC STAR™ nebulizer.
40933178|NCT03178695|OTHER|Autologous PRP injection into human ovarian tissue|Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.
40933179|NCT05969171|DRUG|Sofantinib、abraxane、gemcitabine|The combination of 3 weeks was a treatment cycle, and AG chemotherapy was defined as a maximum of 6 treatment cycles, and soantinib was continued until disease progression (PD, RECIST 1.1) or death (during patient treatment) or toxicity intolerance or other criteria for discontinuation of study therapy were met in the protocol.
40933180|NCT05969171|DRUG|Abraxane combined with gemcitabine|Abraxane combined with gemcitabine
41279216|NCT04396977|PROCEDURE|Placebo (saline) skin prick|Skin prick through 5 µL saline (0.9% NaCl)
40933181|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL
40933182|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine|Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL
40933183|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine|Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL
40933184|NCT04143061|BIOLOGICAL|Hepatitis A vaccine|Pharmaceutical form: Suspension for injection in prefilled syringe Route of administration: Intramuscular, 0.5 mL
40933185|NCT04143061|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine (MMR)|Pharmaceutical form: Lyophilized powder for injection Route of administration: Subcutaneous or Intramuscular, 0.5 mL
40933186|NCT04143061|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
40933187|NCT04143061|BIOLOGICAL|DTwP-HepB-Hib-IPV vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
40933188|NCT04143061|BIOLOGICAL|Varicella vaccine|"Pharmaceutical form: Sterile powder and diluent for injection in prefilled syringe Subcutaneous, 0.5 mL~Route of administration: Pharmaceutical form:"
40933189|NCT05762770|PROCEDURE|PICSI|Using HA-binding as a sperm selection tool, the intervention group will have sperm selected physiologically prior to ICSI using PICSI dishes, following ORIGIO recommended methods (CooperSurgical, 2021).
40933190|NCT04604067|DRUG|Acalabrutinib|"Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days"
40933191|NCT02486627|DRUG|plazomicin|
40933192|NCT02486627|DRUG|meropenem|
40933193|NCT02486627|DRUG|levofloxacin (oral)|
40933194|NCT03227341|OTHER|Exercise|8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions
40933195|NCT02219243|BEHAVIORAL|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
40933196|NCT02219243|BEHAVIORAL|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
40933197|NCT05614167|OTHER|correlation|A total of 97 children with CP between the ages of six and 12 years participated in the study. Muscle strength was measured with a handheld dynamometer. Motor function in children with CP was classified with the Gross Motor Function Classification System (GMFCS), graded with the Gross Motor Function Measure (GMFM)
40933198|NCT00661986|DIETARY_SUPPLEMENT|dark chocolate 6 g/day|dark chocolate 6 g/day
40933199|NCT00661986|DIETARY_SUPPLEMENT|dark chocolate 25 g/day|dark chocolate 25 g/day
40755577|NCT04365270|DRUG|Titanium Dioxide|Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), \>99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
40755578|NCT04082689|BEHAVIORAL|Assisted Infant Toilet Training|"The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The infant is held squatting over a potty or basin, while older children sit on the potty."
40755579|NCT03044288|OTHER|New adhesive strip|This is a strip made of a newly developed adhesive. This adhesive might in the future be part of an ostomy product.
40933200|NCT03783702|DRUG|OxyCODONE 5 Mg (milligram) Oral Tablet|Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
40933201|NCT03783702|DRUG|Ibuprofen 600 Mg (milligram) Oral Tablet|Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
40933202|NCT03783702|DRUG|Acetaminophen 650 MG (milligram) Oral Tablet|All patients will receive acetaminophen as the first-line analgesic.
40933203|NCT02822391|OTHER|observation|
40933204|NCT04955860|OTHER|Dental model analysis|No interventional treatment intervention will be made for individuals. Digital dental models taken for orthodontic recording will be examined.
40933205|NCT01646294|DRUG|YM178 modified release (OCAS)|oral
40933206|NCT01646294|DRUG|YM178 immediate release (IR)|oral
40933207|NCT01273376|DRUG|RX-10100|Extended-release tablet, taken twice daily for 8 weeks
40933208|NCT05757973|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
40933209|NCT02970370|OTHER|no intervention|
40933210|NCT06256575|COMBINATION_PRODUCT|Diosmin|A medical food of diosmin and alka4-complex
40933211|NCT06256575|OTHER|Placebo|Corn starch one (1) capsule twice daily
40933212|NCT04025476|DRUG|Steroids|IV and oral steroids
40933213|NCT01525173|DRUG|0.1% brimonidine tartrate ophthalmic solution|1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
40933214|NCT01525173|DRUG|0.01% bimatoprost ophthalmic solution|1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
40933215|NCT01525173|DRUG|0.2% hypromellose lubricant eye drops|1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
40933216|NCT01525173|DRUG|latanoprost 0.005% ophthalmic solution|1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
40933217|NCT01230775|DRUG|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range."
40933218|NCT01230775|DRUG|Placebo|"Week 1:~1. x1 tablet/d of placebo will be administered in week 1.~   Week 2~   Placebo:~2. x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/"
40933219|NCT05911594|DRUG|Solifenacin group|Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
40933220|NCT05911594|PROCEDURE|Percutaneous tibial nerve stimulation group|Patients in this group will receive Percutaneous tibial nerve stimulation after failure of medical therapy
40933221|NCT05911594|DRUG|Intradetrusor BOTOX group|Patients in this group will receive Intradetrusor BOTOX after failure of medical
40933222|NCT05911594|COMBINATION_PRODUCT|Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group|Patients in this group will receive Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation after failure of medical
40933223|NCT00321061|DRUG|VRC-HIVDNA016-00, VRC-HIVADV014-00|
40933224|NCT02793843|DRUG|Ondansetron (Zofran)|Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
40933225|NCT02793843|DRUG|Dexamethasone (Decadron)|Intravenous administration of 8 mg dexamethasone 15 minutes before spinal anesthesia
40933226|NCT02793843|OTHER|Spinal anesthesia|Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
40933227|NCT02914405|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.
40933228|NCT02914405|DRUG|Ch14.18/CHO|APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.
40933229|NCT04062318|DEVICE|Online active TMS|"One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold."
40933230|NCT02873520|DRUG|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
41279217|NCT03834948|DRUG|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
40755580|NCT03044288|OTHER|Standard adhesive strip|this is a standard adhesive strip (hydrocolloid). This adhesive is currently used in marketed ostomy devices.
40755581|NCT02650349|OTHER|fMRI|
40755582|NCT05004181|BIOLOGICAL|BNT162b2|Intramuscular (IM)
40755583|NCT05004181|BIOLOGICAL|BNT162b2 (B.1.1.7 + B.1.617.2)|Intramuscular (IM)
40933231|NCT02873520|BIOLOGICAL|Precision Cell Immunotherapy|DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
40933232|NCT00084773|BIOLOGICAL|cetuximab|
40933233|NCT00084773|DRUG|fluorouracil|
40933234|NCT00084773|PROCEDURE|neoadjuvant therapy|
40933235|NCT00084773|RADIATION|radiation therapy|
40933236|NCT04759183|OTHER|Survey Administration|Ancillary studies
40933237|NCT04759183|PROCEDURE|Virtual Reality Game|"Participate in VR Game Angry Birds"
40933238|NCT04759183|PROCEDURE|Virtual Reality Meditation|"Participate in VR Meditation TRIPP"
40933239|NCT00000506|DRUG|fenfluramine|
40933240|NCT00000506|DRUG|phentermine|
40933241|NCT02421003|PROCEDURE|heart surgery|
40933242|NCT06043284|DEVICE|Hyperbaric Oxygen Therapy|Subjects received 100% medical grade oxygen for 60 minutes at 2.0 ATA for 40 sessions in a hard-sided monoplace hyperbaric chamber
41279218|NCT03834948|DRUG|AO-176 + Paclitaxel|Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel
41279219|NCT03834948|DRUG|AO-176 + Pembrolizumab|Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab
41279220|NCT04519554|DEVICE|Endometrial sampling|Endometrial sampling with 2 different forceps
41279221|NCT02730702|DEVICE|LEBS - Low coherence enhanced backscattering|Unprepped patients will have the LEBS probe brought into contact with the rectal mucosa, upon which 10 random readings will be obtained.
41279222|NCT04267237|DRUG|Atezolizumab|Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.
41279223|NCT04267237|DRUG|RO7198457|RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
40933243|NCT00188331|BEHAVIORAL|Neuropsychological Testing|neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
40933244|NCT01649479|BIOLOGICAL|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
40933245|NCT01649479|BIOLOGICAL|Thrombophilia bloodwork|"Bloodwork will be drawn up for:~* antithrombin, protein C, protein S~* Factor V Leiden polymorphisms (F5 1691A)~* prothrombin 20210A gene polymorphism (F2 20210A)~* JAK2 617F Mutation~* Homocysteine~* Factor VIII"
40933246|NCT01649479|OTHER|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
40933247|NCT00996723|DRUG|vandetanib and dasatinib|Two oral investigational agents (vandetanib \[VEGFR2, RET, and EGFR inhibitor\] and dasatinib \[bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor\] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
40933248|NCT04698850|DRUG|Aflibercept 40 MG/ML [Eylea]|Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..
40933249|NCT04698850|DRUG|Brolucizumab-Dbll 120 MG/ML [Beovu]|Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.
40933250|NCT04698850|DRUG|Ranibizumab 6 MG/ML [Lucentis]|Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
40933251|NCT00921245|DRUG|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
40933252|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part a dose arm 1|Medium dose, expected to be approximately 10\^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
40933253|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part a dose arm 2|High dose, expected to be approximately 10\^7 TCID50/ mL (titer may be adjusted based on stock titer)
40933254|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part b dose 1|Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR Dose Arm 3
40933255|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part b dose 2|Addition of a 3rd dose, TBD depending on outcome of Part A
40933256|NCT01513369|DRUG|ferric carboxymaltose|Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
40933257|NCT01513369|DRUG|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
40933258|NCT06323343|OTHER|Video Intervention|Animated video delivered by text message to prepare parents to communicate with physicians at their upcoming appointment for a fetal anomaly concern.
40933259|NCT06323343|OTHER|Webpage links|Links to publicly available webpages about the fetal concerns clinic where the participants' appointments are scheduled.
40933260|NCT05547971|RADIATION|intensity-modulated radiation therapy|The patients got intensity-modulated radiation therapy during observation
40933261|NCT02284932|OTHER|No specific intervention for this study|No specific intervention for this study
40755584|NCT05004181|BIOLOGICAL|BNT162b2 (B.1.1.7)|Intramuscular (IM)
40755585|NCT05004181|BIOLOGICAL|BNT162b2 (B.1.617.2)|Intramuscular (IM)
40755586|NCT05004181|BIOLOGICAL|BNT162b2 (B.1.1.529.1)|Intramuscular (IM)
40755587|NCT05004181|OTHER|Observational|No vaccination within 3 months after Visit 1.
40933262|NCT04230720|DRUG|Systane Complete|1 drop 4 times a day for 14 days
40933263|NCT01991639|OTHER|Nutritional and physical activity intervention|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
40933264|NCT01271790|DRUG|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
40933265|NCT01271790|DRUG|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
40933266|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
40933267|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
40933268|NCT01271790|DRUG|GS-9451|GS-9451 tablet, 200 mg QD
40933269|NCT01271790|DRUG|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
40933270|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
40933271|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
40933272|NCT01271790|DRUG|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
40933273|NCT01271790|DRUG|GS-9451 placebo|placebo matching GS-9451 tablet QD
40933274|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
40933275|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
40933276|NCT04932187|DRUG|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
40933277|NCT04109898|DEVICE|Supraglottic airway device (I-gel) insertion|Modified I-gel insertion technique believed to be easier and non traumatic in anaesthetised patients.
40933278|NCT03050749|DEVICE|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
40933279|NCT01348009|DRUG|Tesetaxel-capecitabine-cisplatin|"Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1."
40933280|NCT00762424|DRUG|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
40933281|NCT00762424|DRUG|placebo|cornstarch
40933282|NCT02582255|BIOLOGICAL|Sabin mOPV2|"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
40933283|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine|200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
40933284|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine of Pasteur|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
40933285|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine of GSK|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
40933286|NCT05533476|BEHAVIORAL|Multi Sensory Stimulation and Priming|In the MuSSAP intervention group, the infant wears a multisensory stimulating wristband aiming at increasing attention for the affected upper limb and readiness to initiate a goal-directed movement. Parents are instructed to present a toy to their child if the child shows attention to the affected arm and hand. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
40933287|NCT05533476|BEHAVIORAL|Intensive Usual Care (Upper Limb)|The Intensive Usual Care (Upper Limb) intervention is a more intensive (in duration and frequency) version of standard Usual Care with focus on the motor development of the affected upper extremity. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
40933288|NCT04306679|OTHER|Animation clips|The first animation clip focuses on the importance of pain assessment introduce three pain scales (categorical, NPS and faces) followed by explanations on their properties and on the appropriate way to use them.The second movie was aimed to provide an opportunity to implement the new knowledge in case studies
40933289|NCT04306679|OTHER|Instructions|Routine preoperative preparations, which included a section on pain assessment instructions.
40933290|NCT00005646|DRUG|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
40933291|NCT05842473|DEVICE|Transcranial Magnetic Stimulation (active)|Theta-burst transcranial magnetic stimulation (active) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
40933292|NCT05842473|BEHAVIORAL|Language therapy|Language therapy immediately after each TMS session. Daily sessions for two weeks followed by 1 session per week.
41279224|NCT04788264|OTHER|Medical Device Usage and Evaluation|Receive Fitbit
40933293|NCT05842473|DEVICE|Transcranial Magnetic Stimulation (sham)|Theta-burst transcranial magnetic stimulation (sham) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
40933294|NCT03826576|BEHAVIORAL|Multicomponent intervention|"The multicomponent intervention will be consist of:~1. Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~2. Nutritional and food allergen analysis of the menu of the restaurant~3. Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~4. Marketing campaign about healthy and food allergen adapted menus in the restaurants"
40933295|NCT00600860|OTHER|No interventions|Only registration of clinical practice
40933296|NCT02378025|BEHAVIORAL|Yoga Group|A 10-week yoga course designed to treat pain.
40933297|NCT02378025|BEHAVIORAL|Pain Management Wellness Group|A 10-week behavioral therapy course designed to treat pain.
40933298|NCT01522885|DEVICE|KatGuide versus conventional method (forceps)|According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
40933299|NCT01522885|PROCEDURE|Chest tube insertion|The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
40933300|NCT00124397|DRUG|Atorvastatin|
40933301|NCT01146210|OTHER|laboratory biomarker analysis|Correlative studies
40933302|NCT05421403|PROCEDURE|adenotonsillectomy|all patients with adenoid or tonsillar or adenotonsillar hypertrophy of grade \>2 will undergo adenoidectomy, tonsillectomy or adenotonsillectomy (AT) according to the indication. Overweight or obese patients with mild or moderate OSAS will undergo 6-m trial of lifestyle intervention (LSI) and CPAP if indicated, responders will undergo more follow-up otherwise surgical interference was indicated
40933303|NCT05421403|BEHAVIORAL|Lifestyle intervention|After baseline testing, all subjects began a structured 6-month LSI consisting of dietary modification and exercise. Intensive dietary counseling was provided weekly for the first 4 weeks of the intervention, monthly subsequently until 6 months. A target caloric deficit of \~250.500 cal/d was recommended throughout dietary counseling. Dietary regimen consisted of diets composed of nutrients contributing to total energy as 55% carbohydrate, 15% protein, and 30% fat. Other lifestyle changes included calorie restriction depending on reduction of the frequency of snack consumption, ingestion of low-calorie and low-fat snacks, limiting sugar-based carbonated drinks and the duration of television watching or mobile games. Exercise sessions consisted of both aerobic and strength training three times weekly.
40933304|NCT03611842|OTHER|preservation of mucosal otitis media|Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum
40933305|NCT00597844|OTHER|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
40933306|NCT00597844|OTHER|undergo voice evaluation and fMRI prior|in approximately one month and six months
41279225|NCT04788264|OTHER|Consultation|Receive consultation from a physical therapist
40755588|NCT01431547|DRUG|dalotuzumab|For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m\^2, and escalated for successive cohorts of participants until MTD is found
40933307|NCT01440790|DIETARY_SUPPLEMENT|glucose bolus|50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
41279226|NCT04788264|OTHER|Exercise Intervention|Attend exercise training sessions
41279227|NCT04788264|BEHAVIORAL|Behavioral Intervention|Attend sessions with a behavioral therapist
41279228|NCT04788264|OTHER|Questionnaire Administration|Ancillary studies
41279229|NCT04788264|OTHER|Quality of Life Assessment|Ancillary studies
41279230|NCT06407856|OTHER|conventional therapy|The control group embarked on a conventional therapy regimen designed for patients with spastic diplegic cerebral palsy. This group will do 10reps of ROM exercises, 3 times stretching 30sec hold with 10sec rest and 5reps of strengthening exercises, standing , weight on one leg and raising the other leg to the side or behind, putting heel in front of your toe i.e., tandem stance, standing up and sitting down from a chair without using hands, walking while alternating knee lifts with each step.This group will do conventional therapy for 30 minutes a day, 3 times a week for 8 weeks
40933308|NCT01440790|DIETARY_SUPPLEMENT|Glucose sipping|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
41449854|NCT05949853|OTHER|the respiratory parameters (AHI) and time spent|interpret the recording will be evaluated for PSG, PV and PV+ASEEGA Apnea Hypopnea Index as assessed by PSG (respiratory signals + electro-encephalography + electro-oculography + chin electromyography), PV (respiratory signals) and PV+ASEEGA (respiratory signals + result of sleep stages and arousals scoring by ASEEGA algorithm based on automatic analysis of one EEG Cz-Pz channel)
41279231|NCT06407856|OTHER|Dual Task Training|Warming up exercise Supine Trunk and lower extremity ROM exercise Main exercise Sitting Base of support: balance cushion, ball Program: perform cognition task while maintaining balance (writing, drawing, puzzle etc.) Bench sitting (half ring P.) Base of support: balance pad Program: perform fine motor activities while maintaining balance (blocks assembly, scissoring, origami etc.) Standing Base of support: balance pad, balance cushion Program: perform eating while maintaining balance (drinking water, eat a snack etc.) Cool down exercise Supine Low extremity stretching \& deep breathing
40755589|NCT01431547|DRUG|dalotuzumab|For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
41449855|NCT04056585|PROCEDURE|Ultrasound guided axillary plexus block|Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml
41449856|NCT04056585|PROCEDURE|Intermittent pneumatic compression maneuver|Following ultrasound guided axillary plexus block, the pneumatic compression maneuver of upper arm is composed of 6 repeated inflation-deflation periods; inflation with a pressure of 200 mmHg for 30 seconds and deflation for 10 seconds each.
41449857|NCT04382963|OTHER|High Risk - intensive coaching|"The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.~Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis."
41449858|NCT04382963|OTHER|High Risk - standard care|The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.
40933309|NCT01440790|DIETARY_SUPPLEMENT|Glucose bolus plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
40933310|NCT01440790|DIETARY_SUPPLEMENT|Glucose sipping plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
40933311|NCT05882721|DEVICE|Sofwave|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Other Names:~SUPERB"
40933312|NCT03607643|DRUG|Cannabidiol|"* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal"
40933313|NCT03607643|DRUG|Bortezomib|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 \& 11 schedule to be repeated every 21 days.
40933314|NCT03607643|DRUG|Leucovorin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
41279232|NCT02195843|OTHER|Electrical optimization by RVLV Conduction Time with VectSelect|"VectSelect Quartet multivector testing is a programmer-based feature that provides centralized vector testing and programming with the flexibility to select the appropriate pacing vector to meet individual patient needs.~The Right ventricle - Left Ventricle (RV-LV) conduction time measurement will automatically identify the RV-LV conduction time for each LV electrode ."
41279233|NCT02195843|OTHER|Anatomical optimization of device and leads|Patients will be implanted with left ventricular leads which will be positioned most basal, most apical or midway in the left ventricle. This follows the physician's routine clinical practice and judgement.
41279234|NCT02195843|DEVICE|Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)|All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.
41279235|NCT05109312|DRUG|Bupivacaine Hydrochloride|100 mg
41279236|NCT05109312|DRUG|Bupivacaine Hydrochloride|125 mg
41279237|NCT05109312|DRUG|HTX-011|400 mg
41279238|NCT05109312|DEVICE|Luer lock applicator|Applicator for instillation
41279239|NCT05109312|DRUG|Ibuprofen|400 mg
41279240|NCT05109312|DRUG|Acetaminophen|1 g
41279241|NCT01360996|DRUG|3 mg DRSP/20 μg EE|1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
41279242|NCT05200988|DRUG|Ipilimumab + nivolumab|"Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~* Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~* Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy"
41279243|NCT05162157|DEVICE|NuvoAir platform|Nuvoair platform, consisting of a bluetooth spirometer, smartphone application and clinical portal
41279244|NCT04988373|DEVICE|Modified aligner appliance|Patients will be treated using a single aligner appliance with NiTi Springs in order to align their crowding teeth.
41279245|NCT04988373|DEVICE|Traditional fixed appliance|Patients will undergo typical orthodontic treatment using an MBT-prescription of metallic brackets.
41449859|NCT04382963|OTHER|Low Risk - control|Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.
41449860|NCT02313545|DRUG|IZN-6NVS Cream|"IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%"
41279246|NCT01130506|DRUG|Cytarabine|Given IV
41279247|NCT01130506|DRUG|Decitabine|Given IV
41279248|NCT01130506|OTHER|Laboratory Biomarker Analysis|Correlative studies
41279249|NCT01130506|OTHER|Pharmacological Study|Correlative studies
41279250|NCT01130506|DRUG|Vorinostat|Given PO
41279251|NCT00245232|BEHAVIORAL|Cognitive Therapy|
41449861|NCT00457067|DRUG|Ranibizumab|
41279252|NCT00245232|BEHAVIORAL|Cognitive Processing Therapy|
41449862|NCT02911701|DRUG|Acetaminophen|
41449863|NCT02911701|DRUG|Ibuprofen|
41449864|NCT04682327|OTHER|Response to anti-PD-1/PD-L1|Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
41449865|NCT04682327|OTHER|Non-response to anti-PD-1/PD-L1|Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
40933315|NCT03607643|DRUG|5-FU|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
40933316|NCT03607643|DRUG|Oxaliplatin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
40933317|NCT03607643|DRUG|Bevacizumab|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
40933318|NCT03607643|DRUG|Irinotecan|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
40933319|NCT03607643|DRUG|Gemcitabine|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
40933320|NCT03607643|DRUG|Temozolomide|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
40933321|NCT06421818|DRUG|Baitouweng Tang|Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.
40933322|NCT06421818|OTHER|Placebo|The same volume and color as Baitouweng Decoction.
40933323|NCT05818111|DRUG|steroid|triamcinolone 40mg 4cc
40933324|NCT05818111|DRUG|Xylocaine 2 % Injectable Solution|xylocaine 2% 4cc
40933325|NCT05818111|DRUG|Normal saline 2cc|normal saline 2cc
40933326|NCT05818111|DRUG|normal saline 12cc|normal saline 12cc
40933327|NCT05983146|DRUG|HRS-7053 Injection|HRS-7053 is administered by intravenous (IV) infusion once a week (QW) for one treatment cycle every 4 weeks
40933328|NCT02962375|DIETARY_SUPPLEMENT|Active|100% orange juice with orange pomace fiber
40933329|NCT02962375|DIETARY_SUPPLEMENT|Control|100% orange juice
40933330|NCT06312969|BEHAVIORAL|Video game based training|"Type of intervention: Cognitive training through 3 types of video games:~* Serious games or brain-training games.~* Exer-gaming~* Skill-training games~Method of administration: The patient will receive the treatment for a period of 12 weeks, in which they will commit to use the video games of the intervention with the following pattern:~* Brain-training game: sessions of 7-12 minutes with a frequency of 4 days a week.~* Exer-gaming: sessions of 15-20 minutes 2 days a week.~* Skill-training games: sessions of 15-20 minutes 2 days a week."
40933331|NCT05661201|DRUG|NEROFE|weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
40933332|NCT05661201|DRUG|Doxorubicin|weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
40933333|NCT05436340|DEVICE|The Effect Of Heel Protector In Intensive Care Units|In the experimental group, foot joint opening and heel pressure sore formation will be observed by using heel protector pad.
40933334|NCT05436340|DEVICE|Control group|Heel pads will not be used in the control group. Routine maintenance will be applied
41279253|NCT00245232|BEHAVIORAL|Written Exposure|
41279254|NCT02000843|PROCEDURE|tympanoplasty -- conchal cavum approach|Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
40933335|NCT01155479|DRUG|Preladenant 2 mg tablet|Preladenant 2 mg oral tablet taken twice daily
40933336|NCT01155479|DRUG|Preladenant 5 mg tablet|Preladenant 5 mg oral tablet taken twice daily
40933337|NCT01155479|DRUG|Preladenant 10 mg tablet|Preladenant 10 mg oral tablet taken twice daily
40933338|NCT01155479|DRUG|Rasagiline 1 mg capsule|Rasagiline 1 mg oral capsule taken once daily
40933339|NCT01155479|DRUG|Placebo for Rasagiline 1 mg capsule|Placebo for rasagiline 1 mg oral capsule taken once daily
40933340|NCT01155479|DRUG|Placebo for Preladenant|Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
40933341|NCT02820714|DRUG|BLI801 Laxative|BLI801 Laxative
40933342|NCT01642654|OTHER|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
40933343|NCT01642654|OTHER|Educational lectures|Educational lectures
40933344|NCT00121797|PROCEDURE|urine culture|
40933345|NCT00121797|DRUG|antibiotics according to culture|
40933346|NCT01337687|DRUG|Intranasal Oxytocin|Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
40933347|NCT01337687|DRUG|Placebo|Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
40933348|NCT04519177|BEHAVIORAL|Sleep Health Education Program (SHEP)|Sleep Health Education Program (SHEP) including screening for common sleep disorders
40933349|NCT06181045|DRUG|LY3410738|Administered orally.
40933350|NCT06181045|DRUG|Placebo|Administered orally.
40933351|NCT00000977|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
40933352|NCT06465212|DEVICE|TopCon Maestro 2 OCT|Ophthalmic Coherence Tomography
41279255|NCT00475163|BEHAVIORAL|Behavior modification|
41279256|NCT00004486|DRUG|fluoxetine|
41279257|NCT04792294|DEVICE|Extracorporeal photopheresis|ECP can be used as second-line treatment in patients unresponsive to azithromycin. ECP has been firstly developed for treatment of cutaneous T cell lymphomas and later used in a variety of other indications including solid organ transplantation. The process starts with leukapheresis, followed by incubation of the isolated cells with 8-methoxypsoralen (8-MOP) and subsequent activation of 8-MOP with ultraviolet A radiation. At the end, the cells are reinfused into the patient. 8-MOP is a biologically inert substance, but in the presence of UVA light it cross-links DNA by forming covalent bonds with pyrimidine bases and causes apoptosis.
41279258|NCT01841619|DRUG|IVIg|All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in \<25% subjects, the subjects will be re-treated by the standard protocol.
41449866|NCT06397339|OTHER|INTACT Program|"The INTACT Program has three components:~1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD,~2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia.~3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program"
41449867|NCT05282901|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution|Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor vascularization, thus allowing an increased infiltration of the tumor by immune cells and an improved immune response.
41449868|NCT02293928|PROCEDURE|Hybrid coronary revascularization|Hybrid coronary revascularization with standard double antiplatelet therapy
41449869|NCT00474058|DRUG|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h"
41449870|NCT00474058|OTHER|Placebo|Placebo transdermal patches
41449871|NCT03928405|OTHER|Exercises with Nintendo Wii virtual reality device|In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control. The patient was supported with verbal and physical feedback when the patient played incorrectly during the games in the next sessions. Games that require serious balance and coordination were considered as a difficult activity for the patient and were not used in this study. The difficulty of the games was set to the simplest level for each patient. As the patients were successful the games' difficulty level was upgraded. The difficulty of the games has been increased according to the classification determined by the Nintendo Wii device.
41449872|NCT05680272|BEHAVIORAL|empathic communication-based education|The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
41449873|NCT05717673|DEVICE|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph
41449874|NCT01704105|BEHAVIORAL|Water Quality|Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
41449875|NCT01704105|BEHAVIORAL|Sanitation|"Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound."
40933353|NCT00004229|BIOLOGICAL|recombinant human endostatin|
40933354|NCT01840839|DEVICE|brain stimulation|
40933355|NCT01840839|DEVICE|Sham Stimulation|
41279259|NCT04804215|PROCEDURE|Intraductal transanastomotic stent group|When bile duct anastomosis is performed, a intraductal transanastomotic stent is inserted into the bile duct.
41279260|NCT04804215|PROCEDURE|No stent group|Do not insert a stent into the bile duct during anastomosis of the bile duct.
41279261|NCT02053805|OTHER|PSA|PSA. Serum \& plasma will be stored for future investigations
40933356|NCT02017171|DRUG|Allopurinol|
40933357|NCT02017171|DRUG|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
40933358|NCT02757950|BIOLOGICAL|Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]|Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
41279262|NCT02053805|OTHER|IPSS questionnaire|the validated International Prostate Symptom Score
40933359|NCT00595777|BEHAVIORAL|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
40933360|NCT04699253|DEVICE|SanaCoach Heart failure|Patients will be using the SanaCoach heart failure for at least 6 months during the study period. SanaCoach heart failure is a web application that will be guiding the patient through a regular, systematic assessment of patient's health and wellbeing as well as regular education sessions. The assessment frequency ranges from daily to monthly, based on the settings provided by the health care provider. Furthermore, it provides a repository for patient's care plan to give insight into the course and treatment of the disorder and offers the possibility to contact the health care provider through the web application.
40933361|NCT00876603|PROCEDURE|ACDF|Anterior cervical decompression and fusion
40933362|NCT00876603|PROCEDURE|Cervical laminoplasty|Cervical laminoplasty
40933363|NCT01718912|DRUG|metronidazole-nystatin oral rinse|
40933364|NCT04728672|OTHER|Kinesio Tape|Kinesio Tape
40933365|NCT04728672|OTHER|Micropore Tape|Micropore Tape
40933366|NCT01954420|BEHAVIORAL|Cognitive-Behavioral Intervention|Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.
40933367|NCT01954420|OTHER|Attention Control|Standard care + Cancer education
40933368|NCT04470921|PROCEDURE|Opportunistic Salpingectomy|An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.
40933369|NCT00192686|PROCEDURE|culture a.m. Kamme-Lindberg|
40933370|NCT00849888|BIOLOGICAL|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects \>4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg \& serum free (SF) in other. After first 2 subjects \>10% naïve T cells, 3rd receives only SF thymus. After 3rd subject \>10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant \& thymus biopsy. Followed by immune evaluations.
41279263|NCT02053805|OTHER|DRE (Digital Rectal Examination )|physical examination for the prostate gland
41279264|NCT02053805|OTHER|urine flow and residual|The post void residual will be recorded by using ultrasound. Creatinine level will be checked.
41279265|NCT02053805|PROCEDURE|a multiparametric prostate MRI|The MRI will be reported on a 5 point Likert Scale
41279266|NCT02053805|PROCEDURE|trans-rectal ultra-sound guided prostate biopsy|12 core Trans-rectal prostatic biopsy for diagnostic purposes
41279267|NCT02807077|DRUG|Pacritinib|Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
41279268|NCT04837612|OTHER|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
41279269|NCT02951052|DRUG|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
41279270|NCT02951052|DRUG|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose"
41279271|NCT02951052|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
41279272|NCT02951052|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
41279273|NCT02951052|DRUG|2 NRTIs plus an INI, NNRTI, or PI|"Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~* INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~* NNRTI (either the initial or second cART regimen)~* Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)"
41279274|NCT03463330|BEHAVIORAL|Qigong exercise|The Qigong exercise is a series of mild exercise movements.
41279275|NCT03463330|BEHAVIORAL|Mild body exercise|Participants will be taught of series of similar movements to the Qigong exercise.
40933371|NCT00849888|OTHER|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg \& serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, \>10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject \>10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy \& skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
40933372|NCT04190303|OTHER|Pragmatic, multi-component package|This system-level intervention will be tailored to the needs and capacity of each hospital site, co-developed with policymakers and hospital staff
40933373|NCT00558376|DRUG|polyethylene glycol|Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
40755590|NCT01431547|DRUG|ridaforolimus|For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
40933374|NCT00558376|DRUG|Sodium phosphate|Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
41279276|NCT05929599|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
40933375|NCT06517797|DRUG|S1B-509|S1B-509 has multiple neurotransmitter activities
40933376|NCT02255578|DEVICE|Endobarrier treatment in PCOS|the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women
40933377|NCT02255578|DRUG|clomiphene citrate treatment|
40933378|NCT01203254|DRUG|Colesevelam|Colesevelam 625 mg tablet; 3 times daily 2 tablets
40933379|NCT01203254|DRUG|Placebo|Placebo tablet: 3 times daily 2 tablets
40933380|NCT04635670|DIETARY_SUPPLEMENT|Pro-/prebiotic Mix|Soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
40933381|NCT04635670|DIETARY_SUPPLEMENT|Placebo|Soluble powder for oral use twice daily.
40933382|NCT01392521|DRUG|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
40933383|NCT01392521|DRUG|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
40933384|NCT04601454|DEVICE|Spinal Cord Stimulation System|Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.
41279277|NCT05929599|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
40933385|NCT04532424|DEVICE|Transcranial magnetic stimulation|Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.
40933386|NCT00393640|PROCEDURE|Early and regular breast milk expression|Breast pump given to be used on regular intervals
40933387|NCT00068133|GENETIC|Plasmid based Gene Transfer product-VLTS-589|
41279278|NCT02291159|DEVICE|DNHS ® (Dry Needling for Hypertonia and Spasticity)|Dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
41279279|NCT02291159|DEVICE|Sham Dry Needling|Sham dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
41279280|NCT04243759|BEHAVIORAL|Control App Version|"The control version is a smartphone-compatible CGNG. The cued go/no-go (CGNG) tests ability to respond fast to go targets (activation) while withholding response to no-go targets (inhibition)."
40933388|NCT05160610|BEHAVIORAL|Multilevel intervention|Multilevel intervention based on AACTT theory
40933389|NCT05648656|DRUG|TXA Nebulization|Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days plus standard care of therapy
40933390|NCT05648656|OTHER|0.9% NS Nebulization|Nebulization with 0.9% normal saline (NS) 5mL 8 hourly for 2 days plus standard care of therapy
40933391|NCT03559426|DRUG|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
40933392|NCT03559426|DRUG|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
40933393|NCT02906462|OTHER|Early consideration of vulnerability|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
40755591|NCT04385836|DRUG|alpha one antitrypsin inhalation|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
40933394|NCT02906462|OTHER|Usual practices|the centres applies their usual practices
40933395|NCT03105544|OTHER|simulation-based training|As described under group descriptions
40933396|NCT02119676|DRUG|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
40933397|NCT02119676|DRUG|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
40933398|NCT02119676|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
40933399|NCT02208778|DRUG|Duloxetine|54 participants will be allocated for duloxetine treatment
40933400|NCT02208778|DRUG|Remifentanil|27 participants will be allocated to Remifentanil infusion
40933401|NCT02208778|DRUG|Placebo (for Remifentanil)|Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
40933402|NCT02208778|DRUG|Placebo (for Duloxetine)|Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
40933403|NCT06409455|BEHAVIORAL|Positive Dementia Caregiving in 30 Days|Based on an evidence-based face-to-face Benefit-Finding Intervention, a computer-delivered web-based program supporting 24/7 access without location restriction, is developed. It is a psychoeducation program with an emphasis on strengthening caregivers' coping capacity through skills training and developing a positive way of looking at caregiving challenges. The program consists of reading materials, illustrated texts, caregivers' testimonies, a chatbot, and several interactive apps to facilitate self-learning at the caregiver's own pace.
40933404|NCT06371820|OTHER|ESPRESSO [The study has no intervention]|This study has no interventions.
40933405|NCT05651568|OTHER|Periodized resistance training|"It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.~Frequency:~Three days in a week~Intensity:~60% intensity with one repetition maximum and 10% intensity were added each the two weeks.4 sets and 8-12 rep as per ACSM criteria. There will be rest of 60 second after every set and 120 seconds after every exercise.~Type:~8 types of resistance exercises were performed. There were 4 set of each exercise with 8 to 12 repetitions. These exercises are smith press, seated press, squat, lying dumbbell leg curls, leg extension, leg press, standing barbell, lying barbell and sit ups.~Time:~40 minutes per session."
41129758|NCT03642366|OTHER|Sham LiST Device + 5mg Tadalafil|Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
41129759|NCT00156845|PROCEDURE|AI-700 contrast-enhanced echocardiography|
41129760|NCT02736851|OTHER|Home-based telemedicine group|"All patients referring to the rehabilitation service as out-patients underwent in-hospital a specific exercise program for the neck. Patients are instructed individually by a physical therapist to perform several types of exercises and, from the first rehabilitation session, are encouraged to exercise regularly at home. Written and illustrated material reporting home exercises is provided to all patients.~At the end of out-rehabilitation program, according to a randomization list, patients are randomized in 2 groups and those included in a Home-Based Telemedicine (HBT) program are followed up by a nurse tutor at home for a 6-month period."
41129761|NCT03559413|BIOLOGICAL|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod|Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
41279281|NCT04243759|BEHAVIORAL|Standard App Version|The standard version is the same as the control version with the exception that information about performance (correct or incorrect) is displayed along with RT in ms for a correct response during each inter-trial interval.
41279282|NCT04243759|BEHAVIORAL|Experimental, Feedback App Version|The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.
41279283|NCT00961532|DRUG|DDAVP injection (desmopressin acetate)|0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
40933406|NCT05651568|OTHER|High intensity interval training|"It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30 to 35 minutes.~Active phase: Two weekly sessions of four times four minutes at 90-95% of individual heart rate maximum, separated by three minutes of active rest period and one weekly session of ten times one minute with maximal intensity, separated by one minute of active rest. The exercise mode will be treadmill or outdoor walking/running or cycling (self-selected)."
40933407|NCT05953714|OTHER|incision side cleaning with antiseptic products|A pilot study was conducted with six pregnant women to clarify the use of the data collection tools and the implementation plan during the study process. After that, the data collection forms were finalized. In the 6 operating room, two different solutions (PI and CG) were applied, according to the preference of the physician, to clean the surgical field. The study was carried out by adding a CG shower application to the physician's preferred solution (for a total of 3 groups). Pregnant women who were admitted to the obstetrics clinic were informed about the purpose, scope, duration, and method of the study by one of the researchers. Follow-up of the women was done for 7 day duration following postnatal to assess postoperative for comfort, pain, wound complications by the nurse researcher. At discharge, cultures were taken from the abdominal wounds of the participants
41279284|NCT02716376|DEVICE|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
41449876|NCT01704105|BEHAVIORAL|Handwashing|"Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces."
40933408|NCT05918198|DRUG|Ven+CAG|"100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day.~Ara-C 10mg/m2, ih, q12h × 14d； Acla 20mg/d × 4d； G-CSF 5ug/kg × 14d (WBC \> 30 × 10\^9/L pause)"
40933409|NCT06520475|PROCEDURE|genicular nerve block using bupivacaine and magnesium|The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of 10% magnesium sulfate
40933410|NCT06520475|PROCEDURE|genicular nerve block using bupivacaine and normal saline|The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of normal saline
40933411|NCT00212940|BEHAVIORAL|Supportive Therapy for Adherence to ART (behavior)|
40933412|NCT05504876|DRUG|Midazolam Syrup|Administered Midazolam Syrup 5 mg orally once daily in fed state;
40933413|NCT05504876|DRUG|HEC74647PA|Administered HEC74647PA 100 mg orally once daily in fed state;
41129762|NCT05968170|DEVICE|CliniMACS® device|CliniMACS TCR αβ+/CD19+ cell depletion for related or unrelated haploidentical/mismatched/matched hematopoietic stem cell transplant patients and/or high risk GVHD patients.
41129763|NCT04155905|PROCEDURE|fistulotomy and marsupialization of wound edges|after defining the fistulous track it was laid open (marsupialization) was done together with marsupialization of the wound edge with vicryl 3\\0 sutures
41129764|NCT04155905|PROCEDURE|fistulotomy|after defining the fistulous track it was laid open (marsupialization)
41129765|NCT05902936|PROCEDURE|Pulpotomy for mature permanent mandibular molars|Performing pulpotomy for mature teeth that involves removal of the coronal pulp tissue that is diseased or inflammed followed by placement of a biocompatible material with the intent of maintaining the vitality of the remaining radicular pulp tissue.
41129766|NCT06293066|DIAGNOSTIC_TEST|Ultrasound|Usefulness of transvaginal ultrasound
41129767|NCT01471691|DRUG|ranibizumab 0.5mg|Standard dose
41129768|NCT01471691|DRUG|ranibizumab 1.0mg|High dose
41129769|NCT03532165|DIAGNOSTIC_TEST|Lower extremity Ultrasound|One group may forego a CT angiogram of the chest if they have a positive lower extremity ultrasound. The other group with a negative ultrasound may still require CT angiogram imaging.
41279285|NCT03851861|OTHER|Mediterranean Diet|"Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consumption of ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fresh fruits (including natural juices); d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish or seafood (at least one serving of fatty fish); f) ≥3 weekly serving of nuts or seeds; g) select white instead of red meats or processed meats (burgers, sausages); h) cook at least twice a week with a tomato herb sauce.~Participants will be instructed to eliminate or limit the consumption of the following foods: cream, butter, margarine, cold meat, paté, duck, carbonated and/or sugared beverages, pastries, industrial bakery products and desserts, French fries or potato chips, and out-of-home pre-cooked cakes and sweets. For usual drinkers, the main source of alcohol should be wine."
40933414|NCT05504876|DRUG|HEC110114|Administered HEC110114 600 mg orally once daily in fed state;
40933415|NCT01047098|DIETARY_SUPPLEMENT|Iron|Iron as iron sulfate
41129770|NCT05751161|OTHER|conventional gait training|The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.
41129771|NCT04877340|DEVICE|needle punction|EUS-guided sampling of pancreatic solid lesions obtained with the 22-gauge
41129772|NCT01101594|DRUG|hLL1-DOX (the doxorubicin conjugate of milatuzumab)|hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 \& 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
41129773|NCT00188045|DRUG|Propranolol - Spironolactone|
41129774|NCT03959813|OTHER|Psychomotricity by touching and passive mobilizations|"The patient will have a first psychomotricity session. It will be carried out remotely from the drug catches to avoid bias induced by their administration having effects on the symptoms studied.~Before and after the session, two evaluations will be offered to the patient and performed by a nurse:~* A questionnaire, based on the physical experience,~* The ESAS scale will be administered to the patient to assess the importance of symptoms (pain, depression, anxiety, discomfort) During the session, a touch treatment will be offered to promote awareness of the body. Passive mobilizations at the level of the members and the axis will then be proposed, to promote the pleasure of being in motion. A touch treatment will be done again to promote relaxation.~A questionnaire can be offered to the patient after 4 sessions to assess his perception of psychomotricity."
41129775|NCT02195232|DRUG|Isoquercetin|
41279286|NCT02233842|BEHAVIORAL|Participant interview|People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
40933416|NCT01047098|DIETARY_SUPPLEMENT|Iron|Iron as iron sulfate
40933417|NCT01047098|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
40933418|NCT04695587|DIAGNOSTIC_TEST|123 MIBG scintigraphy testing|123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.
40933419|NCT04695587|DIAGNOSTIC_TEST|MSNA|MSNA in subacute phase and 12 months after the acute episode
40933420|NCT04695587|DIAGNOSTIC_TEST|ABPM|ABPM in subacute phase and 12 months after the acute episode
40933421|NCT04695587|DIAGNOSTIC_TEST|ECHO|ECHO in subacute phase and 12 months after the acute episode
40933422|NCT04695587|DIAGNOSTIC_TEST|24hour ECG|24hour ECG in subacute phase and 12 months after the acute episode
40933423|NCT04695587|DIAGNOSTIC_TEST|CMR|CMR in 12 months after the acute episode
40933424|NCT06518161|OTHER|Voluntary|Subjects undergoing scheduled surgery in the operating room at Nantes University Hospital, requiring general anesthesia with placement of an endotracheal intubation tube for invasive mechanical ventilation.
40933425|NCT03934697|BEHAVIORAL|imaginal exposure therapy|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
40933426|NCT01966692|DRUG|Fluticasone Propionate Formulation 1|Fluticasone Propionate dry powder inhaler Formulation 1
40933427|NCT01966692|DRUG|Fluticasone Propionate Formulation 2|Fluticasone Propionate dry powder inhaler Formulation 2
40933428|NCT01966692|DRUG|Fluticasone Propionate Formulation 3|Fluticasone Propionate dry powder inhaler Formulation 3
40933429|NCT01966692|DRUG|Fluticasone Propionate Formulation 3*|"Fluticasone Propionate dry powder inhaler Formulation 3\*~\*(The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation."
40933430|NCT02968589|BEHAVIORAL|Training|
40933431|NCT00572221|BEHAVIORAL|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
40933432|NCT00572221|BEHAVIORAL|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
40933433|NCT05949944|DRUG|Linperlisib in combination with CHOP|Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
40933434|NCT03277820|DIETARY_SUPPLEMENT|Probactiol Mini|6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
41129776|NCT00374959|DRUG|ceftriaxone|
41129777|NCT00374959|DEVICE|Endotracheal tube for aspiration of subglottic secretions.|
41279287|NCT01568216|DRUG|AMG 747|Three dose levels once-daily oral administration
41279288|NCT01568216|DRUG|Placebo|Once-daily oral administration
41279289|NCT03660878|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.
41279290|NCT03660878|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.
41279291|NCT03660878|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.
41279292|NCT00584974|DRUG|SEP-225289|0.5 mg SEP-225289
41279293|NCT00584974|DRUG|SEP-225289|2.0 mg SEP-225289
40933435|NCT00264862|PROCEDURE|DynaCT|
40933436|NCT04507880|DEVICE|Reverse Total Shoulder Arthroplasty|The RTSA (GLOBAL UNITE Reverse Fracture System) from DePuy Synthes.
40933437|NCT04507880|DEVICE|Hemiarthroplasty|The shoulder hemiarthroplasty
40933438|NCT01017575|DRUG|Daclatasvir|Tablets, Oral, 10 mg, daily, 24-48 weeks
40933439|NCT01017575|DRUG|Daclatasvir|Tablets, Oral, 60 mg, daily, 24-48 weeks
40933440|NCT01017575|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
40933441|NCT01017575|DRUG|Peginterferon alfa-2a|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
40933442|NCT01017575|DRUG|Ribavirin|Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
40933443|NCT05907343|DEVICE|Sham TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.
40933444|NCT05907343|DEVICE|Closed-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.
40933445|NCT05907343|DEVICE|Open-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
40933446|NCT03102840|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab will be performed in all participants
40933447|NCT03102840|DIAGNOSTIC_TEST|blood sampling|Blood sampling will be done by finger-prick in a sub-set of participants
40933448|NCT02625883|OTHER|Interview|Interview by validated Quality-of-life-questionnaire
40933449|NCT00020332|DRUG|alvocidib|
40933450|NCT00020332|DRUG|docetaxel|
40933451|NCT00607932|BEHAVIORAL|behavioral dietary intervention|
40933452|NCT00607932|DIETARY_SUPPLEMENT|Brassica vegetable|
40933453|NCT00607932|DRUG|indole-3-carbinol|follow up at 2,4,6 months post baseline.
40933454|NCT00607932|OTHER|counseling intervention|2, 4, 6 months post baseline
40933455|NCT00607932|OTHER|medical chart review|2,4,6 months post baseline
40933456|NCT00607932|OTHER|questionnaire administration|
40933457|NCT00607932|PROCEDURE|adjuvant therapy|
40933458|NCT01888887|OTHER|Cetaphil Daily Facial Cleanser|
40933459|NCT03647787|OTHER|observational study|This study is a longitudinal observational study
40933460|NCT00625482|BIOLOGICAL|OPV|
40933461|NCT00625482|BIOLOGICAL|OPV plus BCG|
40933462|NCT00625482|BIOLOGICAL|OPV|
40933463|NCT00625482|BIOLOGICAL|OPV plus BCG|
40933464|NCT01467245|PROCEDURE|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
41129778|NCT02313350|DEVICE|Chemonucleolysis with Discogel|Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes, each for single use which is stored at room temperature. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia .
41129779|NCT02313350|PROCEDURE|open discectomy|The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root.
41129780|NCT03331575|RADIATION|Arm1 (Hypofractionated radiotherapy)|hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
41279294|NCT00584974|DRUG|Venlafaxine|150 mg Venlafaxine
41279295|NCT00584974|DRUG|placebo|Placebo
41449877|NCT01704105|DIETARY_SUPPLEMENT|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
41449878|NCT00836862|OTHER|Biologic specimens|Banking of serum, DNA and tissue
40933465|NCT01467245|PROCEDURE|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
40933466|NCT05428982|PROCEDURE|Postoperative Modified Trendelenburg position|Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours at ward.
41449879|NCT03202927|DRUG|PEGFILGRASTIM|Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
41449880|NCT04887558|COMBINATION_PRODUCT|Smart-T Mental Health and NRT|Smart-Treatment Mental Health App and Nicotine Replacement Therapy
40933467|NCT05636488|OTHER|No intervention|There is no intervention group in this study
41449881|NCT04887558|COMBINATION_PRODUCT|Smart-T Mental Health+ and NRT|Smart-Treatment Mental Health App+NRT adherence messages and Nicotine Replacement Therapy
41449882|NCT04887558|COMBINATION_PRODUCT|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
40933468|NCT01992159|DRUG|Romosozumab|Administered by subcutaneous injection
40933469|NCT01992159|DRUG|Placebo|Administered by subcutaneous injection
40933470|NCT02862600|DRUG|Perhexiline|Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
40933471|NCT02862600|DEVICE|Use of bioanalytical assay to monitor plasma levels of perhexiline|The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
40933472|NCT03799172|DRUG|Echinocandin treatment|Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
41129781|NCT06225336|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
41129782|NCT02363049|PROCEDURE|Colectomy|
41129783|NCT02363049|DRUG|Chemotherapy|
41279296|NCT01172080|OTHER|protocol of reminders regarding due colonoscopy|Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
41449883|NCT02638428|PROCEDURE|CancerSCAN™|Targeted deep sequencing
41449884|NCT02638428|DRUG|Ifosfamide|
41449885|NCT02638428|DRUG|Carboplatin|
41449886|NCT02638428|DRUG|Etoposide|
41449887|NCT02638428|DRUG|Fludarabine|
41449888|NCT02638428|DRUG|Cytarabine|
40933473|NCT03799172|DRUG|Triazole treatment|"Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida."
41449889|NCT02638428|DRUG|Pazopanib|
41449890|NCT02638428|DRUG|Sorafenib|
41449891|NCT02638428|DRUG|Axitinib|
40933474|NCT01278654|BEHAVIORAL|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
40933475|NCT03865576|DIAGNOSTIC_TEST|Non-invasive ICP measurement|Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors
40933476|NCT04466345|BIOLOGICAL|Semaglutide|3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
40933477|NCT04466345|BIOLOGICAL|Placebo|Semaglutide placebo capsules
41129784|NCT01970553|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials
41129785|NCT01970553|DRUG|Gemcitabine|1000 mg vial, powder for injectable solution
41129786|NCT00746655|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
41129787|NCT00746655|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
41449892|NCT02638428|DRUG|Crizotinib|
41449893|NCT02638428|DRUG|Dasatinib|
41449894|NCT02638428|DRUG|Erlotinib|
41449895|NCT02638428|DRUG|Everolimus|
41449896|NCT02638428|DRUG|Imatinib|
41449897|NCT02638428|DRUG|Ruxolitinib|
41449898|NCT02638428|DRUG|Vandetanib|
41449899|NCT02638428|DRUG|Vemurafenib|
41449900|NCT02638428|DRUG|Trastuzumab|
41449901|NCT03018925|DRUG|Golimumab|The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
40933478|NCT01778179|DRUG|Tri-luma|"Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
40933479|NCT01778179|PROCEDURE|Cryotherapy (CRY-AC3® device)|Procedure performed at week 2.
40933480|NCT05371171|PROCEDURE|skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
40933481|NCT05371171|PROCEDURE|no skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
40933482|NCT04809636|OTHER|This is not an interventional study|While this is not an intervention, there will be separate participants for the survey study and for the other components of the study (focus groups, interviews, conjoint analysis, piloting the vignettes
40933483|NCT05144334|DRUG|BTX-1188|One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
40933484|NCT03042702|DRUG|Kevetrin|Kevetrin dose to associated cohort
40933485|NCT03042702|DRUG|Kevetrin|Kevetrin dose to associated cohort
41449902|NCT03814122|BEHAVIORAL|Action-based cognitive remediation|Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.
40933486|NCT05952271|OTHER|Hospitalization|Population of patients hospitalized for Herpes Zoster (ICD9-CM 053.xx)
40933487|NCT01685645|DEVICE|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
40933488|NCT05320497|DEVICE|Transparent cap|Add a self-made transparent cap (made by cutting a silicone drainage tube) to the end of the SpyGlass choledochoscope, and then perform routine choledochoscopy and biopsy operations
40933489|NCT01656174|DEVICE|Procleix Dengue Virus Assay|in vitro diagnostic assay
40933490|NCT05767801|PROCEDURE|Evaluation of subclinical inflammation|Minimally invasive synovial tissue biopsy for the semiquantitative and qualitative assessment of synovial immune and stromal cells; Peripheral blood collection for MBDA assessment and phenotyping of immune cells;
40933491|NCT00895011|DRUG|Placebo|One dose 30 minutes prior to initiation of sexual activity
40933492|NCT00895011|DRUG|Avanafil|One dose 30 minutes prior to initiation of sexual activity
40755592|NCT02155855|OTHER|Telemedicine|Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (\<70 mg/dL \> 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
40755593|NCT02155855|OTHER|Control|Routine care
40933493|NCT00895011|DRUG|Avanafil|One dose 30 minutes prior to initiation of sexual activity
40933494|NCT02274701|OTHER|Holistic Needs Assessment|An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
40933495|NCT02070471|DRUG|Placebo|Placebo
40933496|NCT02070471|DRUG|LC28-0126 Dose A|LC28-0126 Dose A
40933497|NCT02070471|DRUG|LC28-0126 Dose B|LC28-0126 Dose B
40933498|NCT02070471|DRUG|LC28-0126 Dose C|LC28-0126 Dose C
40933499|NCT04396184|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
40933500|NCT02895997|OTHER|Travel Telehealth Delivery|Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
40933501|NCT01733927|DEVICE|Rapid testing for HIV|The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
40933502|NCT02655146|DRUG|triptorelin 0.1|a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.
40933503|NCT02655146|DRUG|E2|Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
40933504|NCT02655146|DRUG|Progesterone|After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
40933505|NCT02655146|DRUG|triptorelin 3.75mg|as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
40933506|NCT03431272|DRUG|Lifitegrast|Eye drop
41449903|NCT03814122|OTHER|Waitlist Control Group|Receive treatment-as-usual through regular early psychosis programming.
41449904|NCT06626503|DRUG|Methadone based ERAS|Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision and 0.05 mg at the end of surgery) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
40933507|NCT00205400|PROCEDURE|medical care delivery model|
40933508|NCT03355664|DRUG|ACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24
40933509|NCT03355664|DRUG|TACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24
40933510|NCT01475071|DRUG|Metvix and natural daylight PDT|Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
40933511|NCT01475071|DRUG|Metvix and conventional PDT|Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
40933512|NCT04914039|COMBINATION_PRODUCT|Combination Product|Cases of brain death confirmed by the classic brain death confirmation test
40933513|NCT04914039|OTHER|NO CTA examination|NO CTA examination
40933514|NCT03372889|BEHAVIORAL|Patient educaiton materials - Print based|Print (paper) based materials
41449905|NCT06626503|DRUG|SOC non-methadone based group|Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
41449906|NCT02816996|PROCEDURE|Hand-holding|Subject will have their hand held.
40933515|NCT03372889|BEHAVIORAL|Patient educaiton materials - Media based|Media (electronic) based materials
40933516|NCT05791903|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Comfort-orientated care
40933517|NCT05405127|OTHER|traditional physical therapy|breathing exercises 10 repetitions, 1set, 3 days/week and targeted abdominal muscles. Total 6 sessions were given each consisting of 30 minutes.
40933518|NCT05405127|OTHER|core stability exercises|core stability along with breathing exercise 10 repetitions, 1set, 3 days/week and targeted core muscles. Total 6 sessions were given consisting of 30 minutes.
40933519|NCT03016676|OTHER|Spinal Manipulation|High velocity low amplitude thrust (HVLA) to the lumbar region of the spine between L1 and L5 vertebrae. The exact level thrust will be at the discretion of the treating practitioner determined by the level with the greatest perceivable motion restriction. The HVLA thrust will be performed with the patient side lying in a neutral.They take part in 12 treatment visits, 10 to 20 minutes sessions of SM over 2 weeks. Light soft tissue techniques (i.e., active and passive muscle stretching, and ischemic compression of tender points) may be used as needed to facilitate the manual therapy.
41449907|NCT02816996|PROCEDURE|Stress Ball|Subject will be given a stress ball to hold.
40933520|NCT03016676|OTHER|Exercise therapy|Self education, supervised exercise visits, and home exercise. The overall objectives are to help patient's mange their LBP and prevent future LBP recurrences. Total number of visits 12.Each visit starts with 10 minutes of self-care education to help patients establish and monitor goals aligned with the exercise program and enhance their understanding of LBP. Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
40933521|NCT02900144|BEHAVIORAL|Modified Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
40933522|NCT02900144|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
40933523|NCT04387383|DEVICE|Acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
40933524|NCT04387383|DEVICE|Sham-acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
40933525|NCT04080271|DEVICE|18F-FDG PET/CT|18F-fludeoxyglucose positron emission tomography/computed tomography
40933526|NCT04676971|DRUG|hzVSF-v13|Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
41129788|NCT05915000|DIAGNOSTIC_TEST|Lumbar CSF protein marker determination|The cerebrospinal fluid levels of the Aβ1-42 amyloid, h-tau and phospho-tau proteins will be assessed. The response of patients to the possible implantation of a ventricular peritoneal shunt will be assessed through neuropsychological, gait and ventricular size studies assessed through cerebral magnetic resonance studies.
40933527|NCT04676971|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
41449908|NCT04692155|DRUG|Ublituximab|Ublituximab (900mg) will be administered as an intravenous infusion through a dedicated line.
41449909|NCT04692155|DRUG|Umbralisib|Umbralisib(800mg)will be administered orally once daily within 30 minutes of starting a meal.
41279297|NCT04691258|BEHAVIORAL|Experimental: Complete Group|"The participants performed the squat and Stiff exercises with the maximum range of motion. In the squats, the knees were completely flirted, even if the participant could not perform the movement with neutral vertebral posture. The heels were also not supported to the ground in some participants due to lack of flexibility. It was instructed that the participants tried to perform the Squats and Stiff keeping the lumbar lordosis neutral, with the best posture they could in all training sessions, but all should perform the exercise with as much range of motion as possible.~The positioning of the feet was also carefully controlled, there was no hip rotation and the distance between the lateral edges of the heels was defined as the distance between the upper iliac spines (EIAS). The direction of the knees was oriented pointing in the direction of the tip of the feet parallel throughout the cycle of the movement."
40755594|NCT03240055|DRUG|spinal anesthesia|The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
40755595|NCT03240055|OTHER|etomidate|receive etomidate only
40755596|NCT00051142|DRUG|Travoprost|
40933528|NCT05235503|DRUG|Medicinal cannabis in combination with oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with oxycodon
40933529|NCT05235503|DRUG|Medicinal cannabis in combination with placebo oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with placebo oxycodon
40933530|NCT00375947|OTHER|Hand Exercise|
40933531|NCT00375947|OTHER|sham hand cream|placebo intervention
40933532|NCT01915927|DRUG|MSC-AFP|
40933533|NCT04132375|DRUG|INM004|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
40933534|NCT04132375|DRUG|Placebo|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
40933535|NCT01302015|BIOLOGICAL|RNL-Vascostem®|
40933536|NCT00968032|DEVICE|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
40933537|NCT00925743|DRUG|cabazitaxel (XRP6258)|"* administered by IV infusion~* in addition to cisplatin treatment"
40933538|NCT00119600|DRUG|AMG 114|
40933539|NCT00048841|DRUG|alendronate|
40933540|NCT03766282|DEVICE|ECMO|Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
41449910|NCT03196258|BEHAVIORAL|Cognitive behavioural therapy|Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
40755597|NCT00051142|DRUG|Latanoprost|
40933541|NCT00251160|PROCEDURE|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
40933542|NCT00251160|PROCEDURE|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
40933543|NCT05553054|OTHER|Quantification of IV drugs wastage|"Drugs are prescribed depending on physician discretion.~Specific collection bins are provided to ICU. Healthcare teams discard syringes labelled with name and dilution which have been used to prepare drugs into these bins. After 24 hours of collection, bins are analyzed by investigators."
40933544|NCT00548405|BIOLOGICAL|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
40933545|NCT00548405|BIOLOGICAL|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
40933546|NCT00548405|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
40933547|NCT04048161|DRUG|Tacrolimus|"The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is \< 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
40933548|NCT04048161|DRUG|Mycophenolate Mofetil|"The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20\~30mg/kg/day，BID. The concentration for MPA-AUC is 30\~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
40933549|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003892A (formulation 1)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
40933550|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003893A (formulation 2)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
40933551|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003895A (formulation 3)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
41449911|NCT05858333|OTHER|Extended culture for Group 2: (day 3-5 group)|To investigate thawing day three embryos and culturing them to be transferred as blastocyst that will improve pregnancy rate when compared to transfer thawed frozen blastocyst.
41449912|NCT01468623|OTHER|Pharmacokinetic 5-FU dose adjustment using OnDose® assay|OnDose is a commercially available assay to measure concentration of 5-FU exposure.
41449913|NCT01468623|OTHER|Standard of care|Patients' dose of 5-FU will be based on Body Surface Area (BSA).
41449914|NCT05473663|DEVICE|Radiofrequency Ablation|Genicular nerve RFA is a standard outpatient procedure using fluoroscopic guidance to ensure accurate placement of the radiofrequency cannula. After placement of the radiofrequency cannula, nerve stimulation is performed to confirm proper position and ensure that the cannula is not too close to motor fibers. One mL of 2% lidocaine is placed at each of the cannulas. The RFA treatment is then proceeded by rhizotomizing each genicular nerve at 80°C for 90 seconds with a 15-second ramp-up.
40933552|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003896A (formulation 4)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
40933553|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003898A (formulation 5)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
40933554|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003899A (formulation 6)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
40933555|NCT01905215|DRUG|Placebo comparator|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
40933556|NCT06482216|BIOLOGICAL|Varicella vaccine|lyophilized powder,subcutaneous injection
41449915|NCT05473663|DEVICE|Sham|Is performed identically to the active treatment but without the application of the RFA current
41449916|NCT05653934|BEHAVIORAL|Pre-operative use of virtual reality headset|Patient use the virtual reality headset the day before and / or the day of the surgery
41449917|NCT05653934|PROCEDURE|Standard surgery|Patient are operated as needed for treatment of colorectal cancer (usual care)
41449918|NCT05653934|BEHAVIORAL|Post-operative use of virtual reality headset|Patient use the virtual reality headset as many time as they want after the surgery during a maximum of 30 days
41449919|NCT02355730|PROCEDURE|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
41449920|NCT01311596|OTHER|Icons|Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
41449921|NCT01943045|BIOLOGICAL|NGM282|
41449922|NCT01943045|OTHER|Placebo|
41449923|NCT04554290|DIAGNOSTIC_TEST|temporal artery biopsy|description of temporal artery biopsy features, and its correlation with diagnosis of giant cell arteritis or other differential diagnoses.
40933557|NCT03160196|OTHER|Clinical Decision Support System|It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
40933558|NCT03160196|OTHER|Usual care based on clinical practice guideline|It is about usual care aligned with the diabetes guideline.
40933559|NCT05351398|DRUG|PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
40933560|NCT05351398|DRUG|Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
41449924|NCT05990894|DRUG|Methylprednisolone|In the steroid therapy group, patients received standard treatment plus steroid therapy. Steroid therapy protocol is as follows: 500 mg methylprednisolone once a day, intravenous drip for 3 days, then reduced to 80 mg once a day, intravenous drip for 5 days, and changed to oral methylprednisolone/prednisone 1 mg per kilogram body weight, gradually tapered off by a dose of 10 mg per week.
41449925|NCT05050851|DIETARY_SUPPLEMENT|Measurement of nutritional parameters in children with pneumonia|measurement of Body Mass Index, head circumference, weight, length
41449926|NCT05979311|DRUG|Dolutegravir|Dolutegravir will be administered once daily.
41449927|NCT05979311|DRUG|Lamivudine|Lamivudine will be administered once daily.
41449928|NCT05979311|DRUG|Bictegravir|Bictegravir will be administered once daily.
41449929|NCT05979311|DRUG|Emtricitabine|Emtricitabine will be administered once daily.
41449930|NCT05979311|DRUG|Tenofovir alafenamide|Tenofovir alafenamide will be administered once daily.
40933561|NCT04969003|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
40933562|NCT04197687|BIOLOGICAL|Multi-epitope HER2 Peptide Vaccine TPIV100|Given ID
40933563|NCT04197687|BIOLOGICAL|Pertuzumab|permitted at physician's discretion
40755598|NCT04356001|PROCEDURE|Socket preservation|'One-Piece' autologous tuberosity graft combining hard and soft tissue, harvested from the maxillary tuberosity, placed in extraction sockets.
40933564|NCT04197687|OTHER|Placebo Administration|Given ID
40933565|NCT04197687|BIOLOGICAL|Sargramostim|Given ID
40933566|NCT04197687|BIOLOGICAL|Trastuzumab|therapy are at the discretion of the treating physicians
40933567|NCT04197687|BIOLOGICAL|Trastuzumab Emtansine|at the discretion of the treating physicians.
40933568|NCT02551952|DEVICE|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
40933569|NCT00353028|DRUG|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
40933570|NCT00353028|DRUG|Placebo|Placebo
40755599|NCT06305858|PROCEDURE|Prosthetic Surgical Procedure|"The population consists of 48 patients divided into two groups:~24 patients Group A experimental group: partial denture surgical procedure~24 patients Group B control group: total denture surgical procedure with patellar resurfacing"
40933571|NCT05846477|DEVICE|MySpine|patient specific guide for screw positioning
40933572|NCT00590460|BIOLOGICAL|CAMPATH-1H|Given intravenous on days -8, -7, and -6
40933573|NCT00590460|BIOLOGICAL|Anti-CD45|"Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg"
40933574|NCT00590460|DRUG|Fludarabine|"Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2"
40933575|NCT00590460|PROCEDURE|Stem cell infusion|Stem cells are infused on day 0
40933576|NCT05185843|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
40933577|NCT00003930|DRUG|cisplatin|
40933578|NCT00003930|DRUG|gemcitabine hydrochloride|
40933579|NCT00003930|DRUG|paclitaxel|
40933580|NCT00003930|PROCEDURE|conventional surgery|
40933581|NCT00003930|RADIATION|radiation therapy|
40933582|NCT06212687|BEHAVIORAL|Digital pre-therapy patient education program (StartHjelp)|After randomization the intervention group receives access to a pre-therapy informational app, presenting information about the treatment process, options, patient rights, user organizations, and self-help while on waiting list before mental health outpatient treatment. The information is presented stepwise through video and text, while also providing links to additional information if needed. The videos are made available to the patients gradually, with more general information about the treatment process first, and more specific information as the first session approaches. The patient has the opportunity to rewatch the videos as they please.
40933583|NCT06212687|BEHAVIORAL|Comparator intervention|After randomization, while on waiting list, the control group gets sent all the same information as the intervention group in written form, by mail.
40933584|NCT01520831|DRUG|biphasic insulin aspart 30|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
40933585|NCT01520831|DRUG|biphasic insulin aspart 50|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
40933586|NCT01520831|DRUG|biphasic insulin aspart 70|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
40933587|NCT01520831|DRUG|insulin aspart|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
40933588|NCT01802970|DRUG|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m\^2 Intravenous on day 1,8 \&15 of a 28 day cycle), or capecitabine (1000mg/m\^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m\^2 intravenous on day 1 \& 8 of a 21 day cycle), or vinorelbine (25mg/m\^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
40933589|NCT03737071|BEHAVIORAL|Low Carbohydrate Diet|Ketogenic dietary intervention
40933590|NCT03737071|BEHAVIORAL|Simple Calorie Restriction Diet|Simple calorie restriction dietary intervention
40933591|NCT05557318|DEVICE|Vaginal swab for RT-PCR|Screening for Bacterial vaginosis (BV) / Trichomonas / Chlamydia trachomatis / Candida albicans
40933592|NCT05557318|DEVICE|Vaginal swab for culture|Screening for Group B streptococcus / Neisseria gonorrhoeae / Escherichia coli
40755600|NCT00779883|BIOLOGICAL|ISF35|Subjects participating in this study will receive a single dose of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells.
40755601|NCT00997191|PROCEDURE|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
40755602|NCT00997191|DRUG|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
41279298|NCT04691258|BEHAVIORAL|Active Comparator: Restricted Group|"The conventional movement technique of the squat exercise was used, in which the participants performed with the range of motion restricted to the neutral vertebral posture, approximately 90º of movement of the knee joint. may increase the range of motion if the lumbar posture did not rectify.~The positioning of the feet in this group was carefully controlled, the participants performed the exercise with the joints of the hips abducted and rotated laterally. Having markings on the ground as a reference, the feet went rotated at 21º and the lateral edge of the heels were moved away from each other, approximately with the biacromial distance. The direction of the knees was oriented pointing in the direction of the tip of the feet throughout the cycle of the movement, aligned to the lateral rotation of the hip. In the first training session, with the aid of a goniometer and metric tape, adhesive marks were placed on the floor to ensure this positioning of the support base."
41279299|NCT01503021|DRUG|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
41279300|NCT01503021|OTHER|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
41279301|NCT04283877|DRUG|Methylphenidate|3 x 10 mg oral tablets. Single acute dose for all participants
41279302|NCT04283877|DRUG|Placebo oral tablet|3 x 10 mg oral lactose tablet for all participants
41279303|NCT05038761|DEVICE|CGM System|"Following the manner of observational study, no intervention will be used for the study.~Participants will wear the CGM on abdomen or lower area for no longer than 14 days."
41279304|NCT05038761|PROCEDURE|Standard Venous Blood Glucose Test|Necessary venous blood glucose testing will be performed during the study as clinically required as comparator.
41279305|NCT04228419|PROCEDURE|Total Shoulder Arthroplasty|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components.
41279306|NCT04228419|PROCEDURE|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
41279307|NCT04725656|PROCEDURE|Smoking cessation counseling|Smoking cessation counseling at baseline, week 1, and week 4.
41279308|NCT04725656|OTHER|Open system vape device and nicotine salt e-liquids|Ad libitum use of nicotine salt e-liquids during three months.
41279309|NCT01814423|DRUG|Chloroquine-base 50 mg|
41279310|NCT01814423|DRUG|Chloroquine-base 70 mg|
41279311|NCT04863716|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered before the surgery.
41279312|NCT04863716|PROCEDURE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
41279313|NCT04513145|DRUG|Ropivacaine injection|Ropivacaine is a local anesthetic that is FDA approved for local anesthetic nerve block.
41279314|NCT04513145|DRUG|Saline Injection|Saline will be used as a placebo injection
41279315|NCT04513145|PROCEDURE|Total Knee Arthroplasty|All subjects participating in this study will undergo primary total knee arthroplasty
40755603|NCT00997191|DRUG|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
41449931|NCT05460520|BEHAVIORAL|VOR Readaptation|"The stimulus will be a combination of horizontal visual motion and a head maneuver. The subject will sit in a stationary chair, and a treatment provider will stand behind the subject. While the subject views the slow horizontal motion up to 10°/s of vertical stripes, the provider will gently hold the head of the subject above the ears and tilt the head in the roll (side-to-side) or pitch (up-down) plane by approximately ±20° at the frequency of 0.2 to 0.05 Hz for up to 10 min. The treatment will be repeated with breaks of approximately 5 min. A treatment session will last no longer 120 min including the breaks.~In Groups 1, 3, and 4, subjects will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius, and full-field visual motion will be generated with light projected on the wall of this chamber. In Group 2, visual motion will be presented on the screen of a VR headset. Unlike groups 3 and 4, groups 1 and 2 do not receive any complementary treatment."
40755604|NCT02620111|DIETARY_SUPPLEMENT|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
40755605|NCT02620111|DIETARY_SUPPLEMENT|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
40933593|NCT05557318|DEVICE|Metabolic gas signatures detected by Ainos Flora (operated by participant)|The participant operates the Ainos Flora to collect signatures of metabolic gases in the vagina by herself.
41279316|NCT00140803|DRUG|Visudyne|
41279317|NCT00140803|DRUG|Kenalog|
40755606|NCT01727427|DRUG|Heparin, fondaparinux, vitamin-K antagonists, aspirin|Parenteral or oral anticoagulant Antiplatelet agent
40755607|NCT02955550|DRUG|rhIL-2|Human recombinant Interleukin-2
40755608|NCT02955550|BIOLOGICAL|PNK-007|PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.
40755609|NCT03235492|DEVICE|SmartAlbu|"Plan:~1. Consent an individual~2. Measure and record temperature, blood pressure, heart rate, height and weight~3. Obtain two samples of saliva for the SmartAlbu portable salivary sensor~4. Take a venous blood sample for HbA1c and~5. Glycated albumin~6. Obtain blood sample from a finger stick for point of care HbA1c device"
41279318|NCT04536194|DRUG|norepinephrine|to treat hypotension under general anesthesia with norepinephrine
41279319|NCT04536194|DRUG|dopamine|to treat hypotension under general anesthesia with dopamine
41279320|NCT04681092|BIOLOGICAL|AKS-452|s.c. or i.m. vaccination
41279321|NCT02976506|BEHAVIORAL|Unsupervised exercise program|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
40933594|NCT05557318|DEVICE|Metabolic gas signatures detected by Ainos Flora (operated by medical staff)|The medical staff operates the Ainos Flora to collect signatures of metabolic gases in the participant's vagina.
40933595|NCT02881333|GENETIC|Blood samples|
40933596|NCT03447197|PROCEDURE|The use of extracorporeal circulation|The use or not of extracorporeal circulation during the coronary artery bypass procedure.
40933597|NCT01466140|OTHER|Writing down request for help|Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
40933598|NCT02166372|OTHER|Observation of natural course of Diabetes Mellitus Type 2|
40933599|NCT00002681|BIOLOGICAL|aldesleukin|
40933600|NCT00002681|BIOLOGICAL|daclizumab|
40933601|NCT03486145|DIETARY_SUPPLEMENT|fruit and vegetable juice supplement|"FVS was provided by Isagenix International LLC in identically sealed bottles labeled labeled B. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
40933602|NCT03486145|DIETARY_SUPPLEMENT|Placebo|"PRU was provided by Isagenix International LLC in identically sealed bottles labeled labeled A. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
40933603|NCT04513821|DRUG|Mino-Lok Therapy (MLT)|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok
40933604|NCT00266851|DRUG|Azithromycin|600 mg x 3 days, then 600 mg weekly x 11 weeks
40933605|NCT00266851|DRUG|Placebo|Matching placebo
40755610|NCT00857051|OTHER|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
40755611|NCT00857051|OTHER|Film|A DVD addressing common stressors in the early postpartum.
40755612|NCT05999552|OTHER|Eye exercises|The treatment will be applied in three sessions a week for eight weeks and each session will be approximately 20 minutes. Individuals will do each exercise shown at home as a home program on other days (days when the physiotherapist does not perform the exercise by video call).
40755613|NCT05229367|OTHER|Eccentric isokinetic training|Eccentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
40755614|NCT05229367|OTHER|Concentric isokinetic training|Concentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
40933606|NCT05987176|DRUG|Lutathera|"Dosage:~In total 14.8 GBq (400 mCi) 177Lu-DOTATATE administered in two equally divided doses. Each dose to be infused over 30 minutes.~Duration of treatment:~Two administrations of 177Lu-DOTATATE (each treatment 7.4 GBQ (200 mCi) at 8±1-week intervals, which can be extended to 16 weeks for resolving acute toxicity."
40933607|NCT04288232|DRUG|Aflibercept Injection [Eylea]|Intravitreal aflibercept Injection 2.0mg/0.05 ml
40933608|NCT05939011|BEHAVIORAL|Well-formulated Ketogenic Diet|1:1 ketogenic diet that is focused on intake of high-quality fats (nuts/seeds, fatty fish, avocado) and reduction in processed food.
40933609|NCT03281993|OTHER|CPAP AT|If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%; the CPAP apnea test (CPAP-AT) test was aborted.
40933610|NCT05443633|BEHAVIORAL|individualized speech-language training|Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
40933611|NCT05443633|BEHAVIORAL|standard language intervention|Participants will undergo standard speech-language naming therapy
40933612|NCT04461600|DRUG|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
40933613|NCT05578157|DIAGNOSTIC_TEST|Feeling Hot sensor|The Feeling Hot sensor is a proof-of-concept system, which can measure overnight penile, thigh and air temperature.
40933614|NCT03194490|OTHER|combined intervention group|The combined intervention group received the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).Stretching, cervical passive mobilization, and range of motion: The manual therapy was conducted by a physical therapist who has licensed from the California Board of Physical Therapy. The cervical passive mobilization were selected by the physical therapist based on the participant's condition. Stretching techniques were performed in the combined intervention group for 30 seconds and repeated 3 times twice a week in the following order on the following muscles: anterior, middle and posterior scalene, upper fibers of trapezius, pectoralis minor and interspinous muscles .AROM Exercise were performed 10 repetitions 3-4 times daily. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral.
40755615|NCT05389800|OTHER|Upper Extremity Aerobic Exercise|Using a cycle-ergometer (Monark 881E)
40933615|NCT03194490|OTHER|The standard intervention|"The standard intervention group will receive cervical mobilization and home program (ROM exercises).~Cervical mobilization and range of motion: The manual therapy was conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs). The nature of PAIVMs techniques was selected by the physical therapist based on the participant's condition.~Active Cervical Range of Motion Exercises (ACROM) were performed 10 repetitions 3-4 times daily. Subjects were advised to maintain their usual activity within the limits of pain. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral ."
40933616|NCT03931668|DRUG|TPN-672|single dose of TPN-672 maleate tablet
40933617|NCT02722096|DRUG|Axillary block anesthesia with Ropivacaine and Lidocaine|Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
40933618|NCT02722096|DRUG|Local anesthesia with Ropivacaine and Lidocaine|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
40933619|NCT01823510|DRUG|Ticagrelor + Aspirin|Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
40933620|NCT01823510|DRUG|Clopidogrel + Aspirin|Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
40933621|NCT02482207|DRUG|Rosuvastatin|
40933622|NCT02482207|BEHAVIORAL|Life style modification|
40933623|NCT04085367|DRUG|MAL 16.8% cream|Day light photodynamic therapy with MAL 16.8% cream
40933624|NCT04085367|DRUG|MAL Vehicle Cream|Day light photodynamic therapy with MAL vehicle cream
40933625|NCT01733797|DEVICE|Wooden spatula|Lollipop sticks placed between incisors
40933626|NCT01733797|DEVICE|Therabite|Hand held device placed in mouth that exercises the jaw
40933627|NCT00300079|DRUG|brinzolamide 1.0%|
41279322|NCT02976506|BEHAVIORAL|Physical fitness and quality of life|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
41279323|NCT01886664|DRUG|sevoflurane|
40933628|NCT04679545|DRUG|CBD|A water-soluble sublingual tablet containing 20 mg of CBD.
40933629|NCT04679545|DRUG|Placebo|An inactive compound.
40933630|NCT04389970|BEHAVIORAL|Time Restricted Feeding|Participants will eat all food within an 8 hour window each day. They will only consume water or black coffee during the remaining 16 hours.
40933631|NCT00899509|OTHER|laboratory biomarker analysis|correlative studies
40933632|NCT04291001|DEVICE|ENG implant|This is an FDA-approved contraceptive device
40933633|NCT04291001|DRUG|oral ulipristal acetate|This is an FDA-approved oral emergency contraceptive
40933634|NCT00647218|DRUG|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
40933635|NCT00647218|DRUG|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
40933636|NCT00647218|PROCEDURE|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
40933637|NCT00647218|RADIATION|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
41279324|NCT01886664|DRUG|Desflurane|
41279325|NCT01708226|BEHAVIORAL|Attention Modification Program|Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
41279326|NCT02145130|BIOLOGICAL|denovoDerm|Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
41279327|NCT02145130|BIOLOGICAL|denovoSkin|Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
41279328|NCT02544776|DRUG|Clomifene citrate ( clomid 50 mg )|
41279329|NCT02544776|DRUG|Amlodipine|
40933638|NCT00647218|DRUG|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
40933639|NCT05463627|DRUG|Metformin|All participants among the three groups were treated with metformin
40933640|NCT03046914|GENETIC|HLA-B*5801 test|Check whether a participant has HLA-B\*5801 allele or not, before administration of allopurinol
40933641|NCT01167985|DEVICE|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
41279330|NCT05319860|DRUG|Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)|Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.
41279331|NCT05319860|DRUG|Aromatherapy Care|An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
40933642|NCT01167985|DEVICE|IABN|patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.
40755616|NCT06458166|OTHER|Assessment of low frequency fatigue using low frequency eletrical stimulation|Pre-programmed muscle electrical stimuli will be applied via Myocene® software using 3 electrodes: 1 cathode (5 x 10 cm) placed transversely over the proximal quadriceps femoris, and 2 anodes (5 x 5 cm) over the distal vastus medialis and vastus lateralis. Sixteen sets of stimuli will be administered with 5 seconds between sets. Each set consists of a single pulse, a train of 5 stimuli at 20 Hz, and a train of 18 stimuli at 120 Hz, with 1-second intervals between. The stimulation intensity starts at 25 mA and increases by 1 mA per set, reaching 40 mA in the final set. The Myocene® software calculates the ratio of low- to high-frequency evoked forces within each set. The outcome (Powerdex) is the median value of these 16 ratios for each leg. This evaluation will be conducted on both legs, taking 2 minutes per leg.
40755617|NCT04153032|DRUG|Diltiazem|DTZ is a calcium channel blocker for the treatment of chronic anal fissure
40933643|NCT01167985|DEVICE|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
40933644|NCT00911378|PROCEDURE|Pressure support ventilation|These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.
40933645|NCT00911378|PROCEDURE|Spontaneous breathing trials|These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
40933646|NCT03295461|PROCEDURE|SRP+ 10% Emblica officinalis irrigation|
40933647|NCT03295461|PROCEDURE|SRP + 0.2% Chlorhexidine irrigation)|
40933648|NCT03295461|PROCEDURE|SRP + 0.9% Saline irrigation|
40933649|NCT03295461|PROCEDURE|SRP +10% E. officinalis gel application.|
40933650|NCT03295461|PROCEDURE|SRP+ placebo gel application.|
40933651|NCT06200194|DEVICE|MiyoSmart Spectacles|No power in the central optic zone of DIMS lens for premyopic children with normal vision. Before entering elementary school, eligible preschoolers are asked to wear the DIMS spectacles after kindergarten hours and during weekends and holidays. After entering elementary school, full-time mode wearing of DIMS spectacles is required.
40933652|NCT06200194|DRUG|0.01% atropine|daily use of non-preservative 0.01% atropine eye drop for each eye over the study period.
40933653|NCT00622739|DRUG|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
40933654|NCT00622739|DRUG|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
40933655|NCT03175055|DEVICE|Phoenix|The study to assess safety and efficacy of Phoenix medical exoskeleton.
40933656|NCT04763876|DRUG|Ketorolac Injection 15 mg|A single dose of 15 mg ketorolac administered intramuscularly.
40933657|NCT04763876|DRUG|Ketorolac Injection 60 mg|A single dose of 60 mg ketorolac administered intramuscularly.
40933658|NCT03900962|OTHER|Home-based resistance training|"Patients completed two home-based resistance training sessions each week on non-consecutive days for 12 weeks. The programme was delivered online via individual playlists on Youtube (YouTube, San Bruno, California, USA), with each playlist involving an individually-prescribed series of pre-recorded exercise videos. Each session involved a dynamic warm-up followed by 11 resistance exercises using body weight and resistance bands, and finished with static stretching. Participants completed 1-2 sets of 5-12 repetitions at 4-7 on a modified 10-point rating of perceived exertion scale, which corresponded to qualitative descriptors of moderate to hard. Resistance training stimuli were progressed weekly by increasing the external load, modifying the exercise selection, increasing the number of repetitions, and/or increasing the number of sets."
40933659|NCT03900962|OTHER|Walking intervention|After the initial baseline assessment, participants recorded the number of steps they walked daily for seven days using a waist-worn pedometer. Participants maintained their usual physical activity levels during this period. Participants were then encouraged to increase their total steps walked each day by 5% each week during the 12-week intervention.
40933660|NCT02385188|DRUG|Imiquimod|topical 5% imiquimod cream 3 times a week for 16 weeks.
40933661|NCT02385188|DRUG|paracetamol|
40933662|NCT02385188|DRUG|lidocaine in Vaseline ointment|
40933663|NCT04791527|BEHAVIORAL|Mind-body therapy|Online yoga, meditation, behavior change tips, and nutrition tips
40933664|NCT00782327|DRUG|Losartan|Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
40933665|NCT00782327|DRUG|Placebo|Daily placebo capsule
40933666|NCT06142227|OTHER|Reading a Pictorial Storybook|The pictorial storybook by children will be chosen by child psychologists. The book will be read to children by researcher. The researcher has a fairy tale therapy certificate. The pictorial storybook reading will start 15 minutes before the dental treatment process and will be completed before the treatment process begins.. The pictorial storybook will be read to children only one time.
41279332|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 5mg QD
41279333|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 15 mg QD
41279334|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
41279335|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 25 mg QD
41279336|NCT00917384|BIOLOGICAL|ramucirumab|Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
40933667|NCT00088998|BIOLOGICAL|bevacizumab|
40933668|NCT00088998|DRUG|capecitabine|
40933669|NCT00088998|DRUG|docetaxel|
40933670|NCT02127398|BIOLOGICAL|fecal microbiota|fecal microbiota in capsule form
40933671|NCT03112590|BIOLOGICAL|Interferon-gamma (IFN-γ)|Phase 1: IFN-γ 50 or 75 mcg/m\^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
40933672|NCT03112590|DRUG|Paclitaxel|Phase 1 and Phase 2: Paclitaxel 80 mg/m\^2/week, for 12 weeks.
40933673|NCT03112590|DRUG|Trastuzumab|Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
40933674|NCT03112590|OTHER|Pertuzumab|Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
40933675|NCT03112590|PROCEDURE|Post Therapy Surgery|Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
40933676|NCT06040242|OTHER|Exercise|Participants will perform 3 min of the different activities, followed by a 10-min recovery window.
40933677|NCT02666703|DEVICE|CytoSorb|CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.
40933678|NCT02666703|DRUG|Methylprednisolone|
40933679|NCT04615585|OTHER|Aloe vera after SRP|Subgingival administration of Aloe vera gel was preceded by flushing the area with saline to wash away any debris. Aloe vera (1cc) gel was applied subgingivally using atraumatic needle. Patients were instructed not to rinse or drink any liquid for at least 30 minutes. The application was performed at baseline and after 1 and 2 weeks.
40933680|NCT04615585|PROCEDURE|Scaling and root planing (SRP)|Removal of supragingival and sub-gingival calculus and debris was performed, followed by smoothing root surfaces and removing cementum or dentine that is impregnated with calculus and toxins.
40933681|NCT03004248|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular Injection
40933682|NCT06477224|OTHER|Scooter Board Activities|Participants in this arm engage in scooter board activities designed to improve neck control and address dysphagia. These activities include moving the scooter board in various directions using their hands or feet, maneuvering through obstacle courses, and engaging in playful tasks that require reaching or turning, which can enhance neck muscle strength and stability.
40933683|NCT06477224|OTHER|Routine Physical Therapy|Participants in this arm receive traditional physical therapy interventions, which might include range-of-motion exercises, muscle strengthening, stretching exercises, and postural control activities. These exercises are aimed at improving overall motor function, with a focus on neck stability and control. Standard physical therapy equipment such as therapy balls, balance boards, and resistance bands may also be used.
40933684|NCT01613196|OTHER|Positron Emission Tomography with 18F-Fluoro-deoxy-glucose|"2 or 3 FDG-PET scans will be performed in all patients : at inclusion\*, end of treatment and 6 months after completion of treatment in cases of persistent uptake~\*except if already done in the last 15 days."
40933685|NCT02575066|RADIATION|external beam radiotherapy|external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy
40933686|NCT02575066|DRUG|pazopanib|pazopanib QD 800 mg
40933687|NCT02164149|OTHER|Patients with primary colon cancer|CT scan two days after surgery
40933688|NCT06245187|OTHER|GWTG Atrial Fibrillation program|Evidence based recommended therapies and counseling prior to hospital discharge.
40755618|NCT04153032|DRUG|Mebo|Moist exposed burn ointment (MEBO) is a tropical Chinese medicine composed of sesame oil and herbal plants that is clinically used for the treatment of burn wound.
40755619|NCT01932424|DEVICE|Pelorus 1500|a bedside blood propofol measurement device
40755620|NCT01932424|DRUG|Propofol 2% (Diprivan 2%, Astra Zeneca UK)|
41279337|NCT00917384|DRUG|Placebo|Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
40755621|NCT01522547|DRUG|pomalidomide|Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
40755622|NCT00940511|BEHAVIORAL|Coordinated care|
40933689|NCT03505710|DRUG|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.
40933690|NCT00848003|DRUG|Bifidobacterium animalis subsp. lactis strain BB-12|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
40933691|NCT00848003|DRUG|Placebo|Strawberry flavored yogurt
40933692|NCT05130944|BEHAVIORAL|Entre Nosotras|"A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women."
40933693|NCT05130944|BEHAVIORAL|Doing What Matters in Times of Stress|The stress management components are derived from the World Health Organization Doing What Matters in Times of Stress illustrated guide for coping with adversity (World Health Organization, 2020). The illustrated guide and accompanying audio files are publicly available: https://www.who.int/publications/i/item/9789240003927. During five sessions, the intervention involves 15-20 minute exercises covering a range of stress management and coping skills.
40933694|NCT02376829|DEVICE|Invisalign System|The Invisalign® System is indicated for the alignment of teeth during orthodontic treatment of malocclusion
40933695|NCT00521001|DRUG|everolimus|
40933696|NCT00521001|DRUG|temozolomide|
40933697|NCT03891160|OTHER|3D model of heart|To assess if a 3D printed cardiac model improves visualization of VAD and cannula placement sites in CHD-HF patients as compared to 2D imaging. The investigators will prospectively enroll CHD-HF patients at multiple centers and randomize to group A (3D printed models will be used for pre-VAD planning) or Group B (controls).
40933698|NCT03588247|PROCEDURE|transcatheter aortic valve implantation|Patients with severe aortic valve stenosis undergo transcatheter aortic valve implantation
40933699|NCT00434239|DRUG|Lenalidomide + Ancestim|Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
40933700|NCT04652180|PROCEDURE|Esophagectomy|In this monocentre randomized controlled trial, we compare robot-assisted thoracic approach with conventional open transthoracic Ivor Lewis esophagectomy.
40933701|NCT02394145|DRUG|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
40933702|NCT02394145|DRUG|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
40933703|NCT02653261|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
40933704|NCT02653261|DRUG|Placebo|An equal volume of saline
40933705|NCT00806507|PROCEDURE|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
40933706|NCT00806507|PROCEDURE|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
40933707|NCT06454175|BIOLOGICAL|Placebo|immunization schedule：Month 0，Month 2，Month 6
40933708|NCT06454175|BIOLOGICAL|15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)|immunization schedule：Month 0，Month 2，Month 6
40933709|NCT01210287|DRUG|nucleoside analog reverse transcriptase inhibitor|tablets 100mg qd
40933710|NCT02318576|OTHER|Cognitive Training|Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
40933711|NCT02145507|DRUG|SOLX (Investigational)|SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
41279338|NCT00917384|OTHER|Best Supportive Care (BSC)|BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
40933712|NCT02145507|DRUG|AS-3 (Control)|AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
40933713|NCT03094039|PROCEDURE|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
41279339|NCT06001606|DRUG|Shingrix|Shingrix vaccination
40933714|NCT03094039|PROCEDURE|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
40933715|NCT00511225|DIETARY_SUPPLEMENT|cholecalciferol|10,000 IU weekly
41279340|NCT06001606|DRUG|Placebo|Placebo vaccination
41279341|NCT02284165|OTHER|retrospective analysis|Analysis of data for patients hospitalized in 2006-2008 with acute ischemic stroke, and successfully linked with Medicare claims through 2009
41279342|NCT03282747|BEHAVIORAL|no intervention|no intervention
41279343|NCT04259502|PROCEDURE|Rhomboid intercostal block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
41279344|NCT04259502|PROCEDURE|Erector spinae plane block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
41279345|NCT00543647|DRUG|Fenofibrate 160 mg tablet|
41279346|NCT00543647|DRUG|Placebo|
41279347|NCT06197126|RADIATION|Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .|The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.
41279348|NCT01501487|DRUG|TAC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
41279349|NCT01501487|DRUG|TC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
41279350|NCT01501487|DRUG|Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
41279351|NCT01501487|DRUG|TCH chemotherapy|Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
41279352|NCT01501487|DRUG|T + trastuzumab followed by CEF + trastuzumab|"Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.~Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr"
41279353|NCT01501487|DRUG|Dose dense AC followed by T + trastuzumab|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).~Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week."
41279354|NCT01501487|DRUG|Dose dense AC followed by T + trastuzumab + pertuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
41279355|NCT01501487|DRUG|PTH followed by dose dense AC of FEC|"Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel."
41279356|NCT03140826|DRUG|meropenem|Antibiotics to treat infections.
41279357|NCT02186392|DEVICE|Circadian Light luminaries|The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
40755623|NCT00831896|BIOLOGICAL|TAK-701|"Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy."
40755624|NCT05685407|DRUG|Caffeine|300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
41279358|NCT03830281|DRUG|Ultra-Rapid Lispro|Administered SC
41279359|NCT03830281|DRUG|Insulin Lispro|Administered SC
41453498|NCT06399445|PROCEDURE|conventional cold tonsillectomy and curettage adenoidectomy|After entering the operating room, the children will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths, then we will set 4 % concentration of Sevoflurane. After loss of consciousness, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, Fentanyl 1 mcg/kg iv. and Propofol 2 mg/kg. During stage III of anesthetic depth, we will perform orotracheal intubation.
40755625|NCT05685407|OTHER|Placebo|A placebo pill that matches in size, shape, and color will be administered to participants with female sexual arousal disorder.
41279360|NCT06069791|DRUG|Bupivacaine Injection|subcutaneous injection around bilateral greater occipital nerves
41279361|NCT01209858|DRUG|Perampanel and Microgynon-30|Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
40755626|NCT03005574|BEHAVIORAL|TSW-HP|TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
40755627|NCT03005574|BEHAVIORAL|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
40755628|NCT05889000|OTHER|questionnaire responses|questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
40933716|NCT00511225|DIETARY_SUPPLEMENT|placebo|placebo capsule
40933717|NCT03791827|DRUG|Corticosteroid|corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
40933718|NCT03791827|DRUG|Hydroxychloroquine|Hydroxychloroquine is recommended as the basic therapy for lupus nephritis
40933719|NCT03791827|DRUG|Cyclophosphamide|The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
40933720|NCT03791827|DRUG|Mycophenolate Mofetil|The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d
40933721|NCT03791827|DRUG|Azathioprine|The recommended dose of azathioprine is 1.5 to 2mg/kg/d
40933722|NCT03791827|DRUG|Tacrolimus|The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h
41279362|NCT01209858|DRUG|Perampanel and Microgynon-30|Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
41279363|NCT03226093|PROCEDURE|Stromal Vascular Fraction|The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
41453499|NCT06399445|DRUG|Rocuronium Bromide|After entering the operating room, chlidren will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths. After loss of consciousness, we will turn off Sevoflurane, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, 1 mcg/kg Fentanyl, 2.5 mg/kg Propofol and 0.6 mg/kg Rocuronium bromide (esmeron). After 2 min, orotracheal intubation will be performed.
40933723|NCT03791827|DRUG|Cyclosporine A|The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h
40933724|NCT03791827|DRUG|Rituximab|The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses
40933725|NCT00122733|DRUG|loxapine|
40933726|NCT04935450|DIAGNOSTIC_TEST|Bronchoalveolar lavage|Low volume Broncho alveolar lavage. During optic flexible bronchoscopy through the tracheal tube or the tracheostomy cannula a maximum of 4 aliquots of 20 ml normal saline will be instilled in a wedged position in the right medium lobe of the patients and then aspirated untill reaching a total of 25ml of fluid (BALF) for analysis
40933727|NCT01309893|DEVICE|Investigational Lens|Lenses worn on a daily wear basis for one week
40933728|NCT01309893|DEVICE|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
40933729|NCT01466595|DRUG|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
40933730|NCT04822584|DRUG|Baricitinib Oral Product|Baricitinib 4 mg/day orally for 36 weeks
41279364|NCT05844384|DEVICE|Nanodropper|Nanodropper delivers 1/5 of eye drop volume compared to regular droppers
41279365|NCT05844384|DEVICE|Regular dropper|Delivers full eye drop volume
40933731|NCT04822584|DRUG|Placebo|Placebo once a day orally for 36 weeks
40933732|NCT01115582|DRUG|Cholic acid|"The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child."
40933733|NCT03905447|DRUG|PC945|Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.
40933734|NCT03905447|DRUG|Standard of Care|Standard of Care antifungal medication
40933735|NCT02836600|DRUG|LY3039478|Administered orally
41279366|NCT05523180|DIETARY_SUPPLEMENT|Probiotic|"Active ingredients:~Lactobacillus plantarum RSB11, 5 Billion colony forming units (CFU) Lactobacillus acidophilus RSB12, 5 Billion CFU Lactobacillus rhamnosus RSB13, 5 Billion CFU Holy basil leaf extract, 42.0 mg Turmeric root extract, 30.0 mg Vasaka leaf extract, 48.0 mg~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
41279367|NCT05523180|OTHER|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
41279368|NCT02975128|DEVICE|BLES system and conventional lumpectomy|Each patient undergoes the same procedure. Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance. Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure.
40933736|NCT01631019|BEHAVIORAL|Mobile-phone-based Home Exercise Training Program|Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
41279369|NCT01146470|DIETARY_SUPPLEMENT|RGC|dosage of Red Grape Cells once a day, during 3 months
41279370|NCT01146470|DIETARY_SUPPLEMENT|Placebo|dosage of Placebo once a day, during 3 months
41453500|NCT01159873|DRUG|CEP-37251|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
40933737|NCT01631019|BEHAVIORAL|Home Exercise Training Program|all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
41279371|NCT04610255|OTHER|Assigned Interventions|"* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
40933738|NCT05908058|OTHER|Emotional Changes Investigation|Emotional Changes between Emergency and Intensive care unit and On-site Counter Staffs after COVID-19 Infection and Exploring The Impact of Personnel Emotional Adjustment
41453501|NCT01159873|DRUG|Placebo|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
40933739|NCT06283927|PROCEDURE|Re-resection|Resection of the recurrent tumor
40933740|NCT06283927|DRUG|Temozolomide|Re-challenge Temozolomide chemotherapy
40933741|NCT06283927|DRUG|Lomustine|Second line chemotherapy with Lomustine
40933742|NCT06283927|RADIATION|Re-irradiation|Re-irradiation with single dose, fractionated, or hypofractionated radiation of the recurrent tumor
40933743|NCT06283927|PROCEDURE|Experimental therapy|Experimental phase I therapy with oncolytic virotherapy or immunotherapy (this list is not exhaustive)
40933744|NCT06283927|OTHER|Best supportive care|Best supportive care, focused on alleviating symptoms
40933745|NCT01724320|DRUG|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
40933746|NCT03603327|DRUG|Direct acting anti-viral agents|Standard of care for Hepatitis C treatment
41449932|NCT05460520|BEHAVIORAL|VOR Habituation|The subject will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius. Physical motion will be generated by rotating the chair sinusoidally to the left and right, and full-field visual motion will be generated with light projected on the wall of this chamber. Velocity storage will be weakened by inducing a conflict between physical and visual motions. Subjects will be first treated with a stimulus with a peak speed of 5°/s. The stimulus speed will be gradually increased from 5°/s on Day 1 to 40°/s on Day 5. In total, the subjects are expected to undergo 200-280 min of treatment over the five days, broken up into several 10-20 min sessions per day with a 10-min break in between. If signs or symptoms of motion sickness are reported by the subject (nausea, sweating), the session will be immediately paused. Treatment may be continued after a short rest if the discomfort is alleviated or on the following day.
40933747|NCT02550769|PROCEDURE|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
40933748|NCT02550769|PROCEDURE|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
40933749|NCT05937464|OTHER|Exoskeleton ExoAthlet group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with exoskeleton ExoAthlet (ExoAtlet 1 model/2019, Russia). Participants were assessed at baseline and post-intervention.
40933750|NCT05937464|OTHER|Lokomat Free-D group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with Lokomat Free-D (Hocoma, Lokomat Pro Free-D model/2015, Switzerland). Participants were assessed at baseline and post-intervention.
40933751|NCT00116792|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
40933752|NCT04999774|DIAGNOSTIC_TEST|Different diagnostic tests|Each SAC will be tested with all tests
40933753|NCT04924803|BEHAVIORAL|No video|Weekly text messages
41279372|NCT04610255|OTHER|Dynamic myofascial release|"DMFR involves a manual application of low amplitude, long duration stretch to the fascia and muscle. Participants were instructed to relax as much as possible, and the therapist proceeded to smoothly move the joints in a diagonal or horizontal direction at a slow rate within the ROM. The therapist repeatedly pushed, pulled, or shook the joint area about three to five times for about 3 seconds with slight motion at the end of ROM.~Conventional therapy will includes~* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
41279373|NCT06275126|OTHER|CONSYDER decision aid|Web-based breast cancer surgery decision aid
41279374|NCT01087554|DRUG|Sirolimus|"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
41279375|NCT01087554|DRUG|Vorinostat|"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."
41279376|NCT01087554|DRUG|Everolimus|"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
40933754|NCT04924803|BEHAVIORAL|Video Text|Weekly text messages including links to intervention videos
40933755|NCT02718300|DRUG|Parsaclisib|Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
40933756|NCT02718300|DRUG|Parsaclisib|Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
40933757|NCT02718300|DRUG|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
40933758|NCT02718300|DRUG|Parsaclisib|20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
40933759|NCT02718300|DRUG|Parsaclisib|"2 dose strategies will be compared:~1. 5 mg parsaclisib beginning on Day 1 until end of treatment.~2. 20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily."
40933760|NCT00216164|DRUG|Rituximab|Rituximab 375 mg/m2, day 1 of 21 day cycle
40933761|NCT00216164|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
40933762|NCT03313908|PROCEDURE|detection of the tumor lesion|non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
40933763|NCT04767308|BIOLOGICAL|CT125A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT125A cells, during which cyclophosphamide and fludarabine will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT125A cells by intravenous (IV) infusion. The initial dose of 1×10\^6 CAR+ T cells/kg will be infused on day 0.
40933764|NCT04767308|DRUG|Cyclophosphamide, fludarabine|Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day on days -4, -3 and -2
40933765|NCT04824716|PROCEDURE|Postconditioning|The protocol of primary PCI followed by stenting is executed according to the descriptions according to the majority of relevant scientific literature on postconditioning studies and in accordance with the most recent guidelines. In the post conditioned group, after recanalization, the artery is occluded by inflation of stent balloon (4 times for 1-1 minute) followed by 1-1-minute reperfusion, repeatedly. Eight minutes after the start of examination, angiography is made in order to determine blood flow. Intervention is finished by the operator and another angiographic image is made (identical to initial standard projection).
40933766|NCT04824716|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention as per European Society of Cardiology guidelines.
40933767|NCT02800876|OTHER|CT-acquisition|
40933768|NCT01744912|DRUG|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
40933769|NCT01744912|DRUG|Lenalidomide|Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
40933770|NCT05945212|DEVICE|Vibration|The program will take place over 40 sessions : 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during the hospitalization in the department); this group will benefit from an effective vibration of a frequency of 100Hz
40933771|NCT05945212|DEVICE|Sham vibration|The program will take place over 40 sessions: 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during hospitalization in the department); this group will not benefit from effective vibration.
40933772|NCT05945212|OTHER|10 meters Walk Test|Short-distance ambulation speed is measurement between 2 markers on the ground 10 meters apart in a corridor with flat ground, the patient starting his walk 3 meters before to have a launched march disregarding markers, and ends 3 meters After. The stopwatch is started when the markers are crossed.
40933773|NCT05945212|OTHER|2 Minute Walk Test (2MWT)|Long-distance ambulation speed is measured from a standing start and the test involves asking the patient to walk as far as possible in 2 minutes.
40933774|NCT05945212|OTHER|Fugl-Meyer (FMA-LE)|The Fugl-Meyer (FMA-LE) assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination. Score from 0 to 34
40933775|NCT05945212|OTHER|Modified Ashworth scale|The modified Ashworth scale allows the measurement of spasticity, that is to say the measurement of muscle tone by mobilizing the segment of the lower limb and by evaluating the resistance to stretching of the muscles. Score from 0 to 4
40933776|NCT05945212|OTHER|ABILOCO questionnaire|The ABILOCO questionnaire evaluate the autonomy in the walking capacities of the patients (13-items)
40933777|NCT05945212|OTHER|Barthel index|The Barthel index measure autonomy in daily life.
40933778|NCT05945212|OTHER|isometric ergometer|Evaluate voluntary maximum force in isometric ankle dorsiflexion by Cybex isometric ergometer results.
40933779|NCT05945212|OTHER|Electromyograms (EMG)|Assessment of neuromuscular fatigue by electromyograms (EMG). Surface electrodes is place on the tibial muscle anterior to non-invasively collect electromyograms (EMG). The intensity of stimulation will be gradually increased until a plateau in mechanical (strength) and electromyograms (EMG) responses is obtained.
40933780|NCT05945212|OTHER|Traditional quantified gait analysis|Gait kinematics will be recorded on a force platform (90 x 90 cm, Model 9287C, Kistler, Winterthur, Switzerland) to determine: joint angles, net joint moments and powers at the ankle, knee and hip.
40933781|NCT05945212|OTHER|SPM - Statistical Parametric Mapping|Addition of a temporal component to the traditional quantified gait analysis, allowing the focus to be on time series parameters.
40933782|NCT05945212|OTHER|FACIT questionnaire (Functional Assessment of Chronic Illness Therapy)|A short questionnaire consisting of 13 questions to which the patient answers on a scale from 0 to 4. The scores are simply added up, inverting the scale for negative sentences, to give a result out of 52 points. The lower the score, the greater the fatigue.
40933783|NCT02669654|OTHER|Day-care management of Severe Pneumonia|Day-care management of Severe Pneumonia
40933784|NCT03504943|OTHER|Early Intradialytic Exercise|Timing of intradialytic exercise first half of HD
40933785|NCT03504943|OTHER|Late Intradialytic Exercise|Timing of intradialytic exercise second half of HD
41279377|NCT01087554|DRUG|Temsirolimus|"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
41279378|NCT00134914|DRUG|Buprenorphine|single doses given by sublingual and parenteral routes
41453502|NCT04738019|DIAGNOSTIC_TEST|Medical examination or treatment.|Medical examination or treatment when delayed on-set nodule or other side effects occur due to Y-Solution filler injection.
40755629|NCT06226415|BEHAVIORAL|Rehabilitation therapy|"The study lasted 14d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
40933786|NCT04047927|DEVICE|EpiFinder|The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
40933787|NCT02677727|OTHER|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20 is a 20-item chemotherapy-induced peripheral neuropathy-specific questionnaire which includes three scales assessing sensory (9 items: #31-36, 39, 40, 48), motor (8 items: #37, 38, 41-45, 49), and autonomic (3 items: #46, 47, 50) symptoms and functioning with each item measured on a 1-4 scale (1 - not at all; 4 - very much).
40933788|NCT02519673|DEVICE|Measurement of stromal tissue ablation|Stromal tissue consumption will be estimated preoperatively by WaveLight Allegretto EX-500 laser and central corneal thickness will be measured by Pentacam. One month after refractive surgery, during follow-up,central corneal thickness will be again measured by Pentacam.
40933789|NCT05725785|BEHAVIORAL|FOCUS participants|Participants using FOCUS will be given access to the FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
40933790|NCT01251471|DRUG|Escitalopram|10 mg/d; optional 20 mg/d after 2 weeks.
40933791|NCT05939362|OTHER|MRI follow-up|MRI follow-up for patient with early onset Alzheimer's disease
40933792|NCT05475340|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
40933793|NCT03722290|DRUG|Metformin|Oral administration of metformin 250mg (twice a day) for the 1st week followed by metformin 500mg (twice a day) for the next 8 weeks.
40933794|NCT00981773|DRUG|Maraviroc|Maraviroc 150 mg bid
40933795|NCT00981773|DRUG|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
40933796|NCT05916911|DIETARY_SUPPLEMENT|Glizigen|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 single doses of intravaginal use and 60 doses of oral solution should be given to each patient.~The intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
40933797|NCT05916911|OTHER|Placebo|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 placebo single doses of intravaginal use and 60 placebo doses of oral solution should be given to each patient.~The placebo intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The placebo oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
40933798|NCT02468011|OTHER|vibration|vibration will be applied at 35 Hz
40933799|NCT02388048|DRUG|Ibrutinib + ofatumumab|
40933800|NCT03291171|BEHAVIORAL|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
41279379|NCT01583348|PROCEDURE|Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy|During transvaginal rigid-hybrid NOTES cholecystectomy a intraoperative cholangiography is performed. After dissection of the Calot's triangle and distal clipping of the cystic duct, the cystic duct is incised and a regular cholangiography catheter is inserted. Contrast is injected and an image is obtained using an image-converter. After extraction of the catheter the cystic duct is clipped proximally. This intervention is performed in all patients included in the study.
41279380|NCT02593929|DRUG|ruxolitinib|
41279381|NCT00572481|PROCEDURE|Axillary Reverse Mapping|During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
41279382|NCT03448744|DRUG|Thymosin Alpha1|Thymosin Alpha1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
41279383|NCT03448744|DRUG|Entecavir|ETV (0.5 mg orally, daily) for 72 weeks
41279384|NCT03882918|DRUG|OV101|Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
40933801|NCT04841473|OTHER|TRAIN Concussion Education|Participants will receive the TRAIN concussion education module.
40933802|NCT04841473|OTHER|Standard Concussion Education|Participants will receive a standard concussion education module.
40933803|NCT01925989|BIOLOGICAL|LY2605541|Administered SQ
40933804|NCT01925989|BIOLOGICAL|Insulin Glargine|Administered SQ
40933805|NCT02282878|DIETARY_SUPPLEMENT|High/Low Sodium Diet|All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
40933806|NCT02948101|BIOLOGICAL|Anti-CSF1 Monoclonal Antibody PD-0360324|Given IV
41279385|NCT04748029|OTHER|Systemic immune inflammation index|The systemic immune inflammation index (SII) was calculated using the formula, SII = platelet count x neutrophil count / lymphocyte count. Systemic immune inflammation index (SII) is a new index related to systemic inflammation calculated by the numbers of lymphocytes, neutrophils and platelets in peripheral blood.
41279386|NCT03643692|DEVICE|ARISES|The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a novel mobile platform. Combining wearable sensors and smartphone technology, a range of biological, environmental and behavioural data will be analysed to provide real-time therapeutic and lifestyle decision support. Using Case-Based-Reasoning (CBR), the system will be adaptive and personalised with the ability to learn from previously encountered scenarios. Ultimately, ARISES aims to empower self-management of chronic illness and limit the complications associated suboptimal treatment.
40933807|NCT02948101|DRUG|Cyclophosphamide|Given PO
41279387|NCT02427165|DRUG|RPL554|A dual PDE3 and PDE4 inhibitor
40933808|NCT02948101|OTHER|Laboratory Biomarker Analysis|Correlative studies
40933809|NCT06382883|BEHAVIORAL|Individually tailored lifestyle and physical activity intervention|"Focus of the SEMC-protocol is on increasing PA gradually towards the national recommendations. Emphasis of counseling is on incidental exercise, endurance, and strength training. Techniques of motivational interviewing are utilized.~Baseline; MD+PT counseling, medical clearance, mapping lifestyle \& life situation, goal setting, measurements, questionnaires, feedback. weeks 1-6: guided group resistance training 1hr, 1x/week. 5-10-minute warm-up, 9 exercises with weight stack equipment on large muscle groups. 2-3 sets, 12-15 repetitions. Modified individually, e.g. according to musculoskeletal problems. Emphasis on learning the basics and safety aspects. After 6 weeks unsupervised training. 3-month: MD counseling and questionnaires. 6-month: MD+PT counseling, assessing safety of PA, measurements, questionnaires, feedback. 12-month: MD+PT counseling (feedback, ensuring continuity of lifestyle changes; redirecting to municipality/NGO activities), measurements, questionnaires, feedback"
40933810|NCT06382883|BEHAVIORAL|Individually tailored lifestyle and physical activity intervention combined with enhanced behavioral support -intervention (EBS)|"In addition to the SEMC-protocol, the participants will be contacted 3 times during the first 3 months (live / online as preferred). Themes:~Session 1: Motivation and illness perceptions. Exploring CPAP use, PA, and SB. Session 2: Self-regulation (feedback, goal setting, self-monitoring, action planning, problem solving), activating social support, prompts/cues, and preparatory behaviors. (Included BCTs from Michie et al 2013 taxonomy: 3.2, 12.2, 8.3,) Session 3: Assessing progress and agenda setting, self-regulation, maintenance of PA.~Measurements and questionnaires as with SEMC-protocol."
40933811|NCT06254196|PROCEDURE|Telenursing interventions for monitoring Supportive Care Needs|"Use of the Intelligence2health platform, data collection forms on Google Forms, and dedicated telephone line for telenursing remote nursing monitoring interventions.~Based on the data, nurses will be able to implement patient education interventions aimed at preventing and monitoring healthcare support needs related to treatment."
41279388|NCT02427165|DRUG|Salbutamol|a beta-2 receptor agonist
41279389|NCT02427165|DRUG|Placebo|RPL554 placebo containing no active ingredients
41279390|NCT03759275|OTHER|pMDT(Baseline Investigation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
40933812|NCT03673735|DRUG|Durvalumab|Durvalumab (one dose) before CRT and for 6 months Q4W after CRT
40933813|NCT03673735|RADIATION|radiotherapy|radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy
40933814|NCT03673735|DRUG|Placebo|placebo (one dose) before CRT and for 6 months Q4W after CRT
40933815|NCT03673735|DRUG|Cisplatin|Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
40933816|NCT01307605|BIOLOGICAL|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
40933817|NCT01307605|DRUG|lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
40933818|NCT00776685|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
40933819|NCT03368573|DEVICE|QbTest|QbTest is a computerised assessment which takes approximately 20mins. The test combines a continuous performance test alongside an infrared camera which measures the participant's movements. The infrared camera measures motor activity of the participant whilst they undertake the task. During the test, the participant is presented with continuously changing stimuli. Embedded within these stimuli is a given target. Participants have to respond by pressing a hand-held button only when the target appears. Attention is measured through omission errors and reaction time to response. Impulsivity is assessed through commission errors and anticipatory errors. Motor activity is measured through head movements during the task. The test is approved by the FDA (Ref: K133382) and CE marked.
40933820|NCT00179244|DRUG|Rispridone (drug) and Bupropion ER (drug)|
40933821|NCT03705273|DRUG|Dexamethasone IV for PO|Common pediatric emergency department practice
41279391|NCT03792958|DRUG|CM082|CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)
40933822|NCT03705273|DRUG|Dexamethasone crushed tablets|Alternative route of administration for patients unable to swallow tablet whole
40933823|NCT03465423|PROCEDURE|Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)|The patients of two cohort group will undergo general anesthesia in the same way and therefore there is no intervention in this study.
40933824|NCT00631761|OTHER|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
40933825|NCT00631761|OTHER|no intervention (usual resident activities)|usual activities
40933826|NCT01426789|DRUG|Placebo|Matching placebo to secukinumab I.V.
40933827|NCT01426789|DRUG|Secukinumab|In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
40933828|NCT05272644|BEHAVIORAL|surface electromyographic biofeedback assisted pelvic floor muscle training|participants will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
40933829|NCT05272644|BEHAVIORAL|surface electromyographic biofeedback and electrical stimulation|participants will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
40933830|NCT03034291|DIETARY_SUPPLEMENT|Cacao 70%|Consumption for 8 weeks of 50 grams of chocolate per day with 70% cocoa solids.
41129789|NCT05440812|BEHAVIORAL|Storytelling and Training to Advance Individual Recovery Skills (STAIRS)|STAIRS is a 8-week program, in which 8 different themes are addressed. Coverage of each theme starts with a group meeting guided by a professional and expert by experience. In these meetings different exercises are done (e.g., filling out an actual and desired week-schedule, role-playing a difficult situation), information is given and experiences are shared. Between meetings, participants can choose from a range of homework exercises to practice their desired skills in a tailored way. In addition, participants can share experiences with the other group members and exchange reactions using a private online community.
41129790|NCT05680649|OTHER|Breathing exercise|Diaphragmatic breathing exercises were taught to the individuals by the researcher and they were asked to start breathing exercises before starting PIVC. While the PIVC was being placed, the individuals continued the breathing exercise and the breathing exercise was terminated at the end of the application.
41129791|NCT00361205|DEVICE|Electronic Monitoring cap|
41129792|NCT01333605|DRUG|IGEV|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
41129793|NCT00412646|DRUG|TMC125|
41129794|NCT03488550|BIOLOGICAL|ANX007|Single ascending dose
41129795|NCT00973505|DRUG|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
41129796|NCT02963571|PROCEDURE|posterior percutaneous pedicle screw internal fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
41129797|NCT00993174|PROCEDURE|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
40755630|NCT06226415|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40755631|NCT06226415|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40933831|NCT03034291|DIETARY_SUPPLEMENT|White chocolate|
40933832|NCT02850133|OTHER|aerobic exercise training|aerobic exercise training for 36 sessions within 12-16 weeks
40933833|NCT03348787|BEHAVIORAL|Behavioral and Cognitive Therapies|"Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave Accept Voices applied to HAV"
40933834|NCT04306185|PROCEDURE|OVARIAN FRAGMENTATION|BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS
40933835|NCT02065362|BIOLOGICAL|DNR.NPC-specific T cells|"Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:~Dose Level 1:~Day 0: 2 x 10\^7 cells/m\^2~Day 14: 2 x 10\^7 cells/m\^2~The doses are calculated according to the total T cell number."
40933836|NCT02065362|BIOLOGICAL|DNR.NPC-specific T cells + cyclophosphamide + fludarabine|"Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.~Each patient will receive infusions according to the following dosing schedule:~Dose Level 2:~Cy/Flu on Days -4 to -2 and then 4 x 10\^7 cells/m\^2 on Day 0, Day 1 or Day 2~Dose Level 3:~Cy/Flu on Days -4 to -2 and then 1 x 10\^8 cells/m\^2 on Day 0, Day 1, or Day 2"
40933837|NCT01221454|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
40933838|NCT01221454|DRUG|Conserved therapy|Oral or intravenous administration
40933839|NCT05268211|DIAGNOSTIC_TEST|urinary oxygen partial pressure|measuring urinary oxygen partial pressure and measuring US Doppler renal resistive index
40933840|NCT04227054|DEVICE|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
40933841|NCT05880823|DEVICE|Synergy cervical disc system|motion preservation disc
40933842|NCT02849353|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
40933843|NCT02849353|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
40933844|NCT06391801|BEHAVIORAL|Neuroathletic training|Specific Neuroathletic training exercises were performed to improve balance ability of post stroke patients
40933845|NCT06391801|BEHAVIORAL|Traditional movement therapy in outpatient rehabilitation|Traditional movement therapy in outpatient rehabilitation
40933846|NCT02817477|DRUG|Ketamine Hydrochloride|Delivered intranasally using an atomizer
40933847|NCT02817477|DRUG|Morphine|Delivered either as an IM injection or a slow IV bolus
41129798|NCT00993174|PROCEDURE|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
40755632|NCT00425854|DRUG|BIBW 2992|high dose once daily
40933848|NCT02942589|OTHER|Meal portion size|
40933849|NCT02526329|BIOLOGICAL|donor regulatory T lymphocytes|Given IV
40933850|NCT02526329|OTHER|laboratory biomarker analysis|Correlative studies
40933851|NCT00475475|BEHAVIORAL|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
40933852|NCT00475475|BEHAVIORAL|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
40933853|NCT00475475|BEHAVIORAL|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
40933854|NCT00938964|DRUG|Lidocaine|Lidocaine versus placebo infusion for 48 hours
40933855|NCT00938964|DRUG|Placebo|Lidocaine versus placebo infusion for 48 hours
40933856|NCT00311480|BIOLOGICAL|Influenza vaccine surface antigen adjuvanted with MF59|
40933857|NCT02984072|DRUG|Menthol|Topical menthol in aqueous cream
40933858|NCT02984072|DRUG|Aqueous Cream|placebo
41129799|NCT01332175|DEVICE|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
41279392|NCT05410392|BEHAVIORAL|Physical exercise intervention|Home-based physical exercise with the use of a stationary recumbent style bike.
40933859|NCT00817479|DRUG|Dexamethasone|20 MG OF DEXAMETHASONE OR PLACEBO
40933860|NCT00817479|DRUG|Placebo|Placebo saline
40933861|NCT06067659|OTHER|Extracorporeal shock wave therapy|ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
41279393|NCT05410392|BEHAVIORAL|Cognitive exercise intervention|Home-based cognitive exercise with the use of smartphone to complete cognitive activities.
41279394|NCT05410392|BEHAVIORAL|Health education|Provision of general information about a variety of topics
40933862|NCT06067659|OTHER|Kinesiology taping|The material used in the taping will be 5 cm wide and 0.5 mm thick Kinesio® Tape. In practice, the patients were placed in the prone position and the ankle would be dorsiflexed at 10 degrees, and the band would be divided into 4 equal parts on the metatarsals of the 1/3 of the foot from the cruis, starting from the calcaneus. Then, taping will be performed from the medial to the lateral of the calcaneus, passing over the area where the pain is intense. Patients will be asked not to remove the applied tape for 3 days.
40933863|NCT06067659|OTHER|Extracorporeal shock wave therapy+Kinesiology taping|Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
40933864|NCT04610164|DRUG|Tranexamic acid|Prior to surgery, the patient will receive 1 gram of IV TXA
41129800|NCT01332175|DEVICE|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
41279395|NCT02153840|DRUG|PSORI-CM01（YXBCM01） granule|
41279396|NCT02153840|DRUG|placebo|
41279397|NCT04856761|DRUG|S-1|S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
41279398|NCT04856761|DRUG|Capecitabine|Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
41453503|NCT03431558|COMBINATION_PRODUCT|bLF (Bovine lactoferrin)|BLF administration in two different strengths (150 \& 300mg) will be given on the third day of life with a single daily dose mixed with milk for 1 month.
40755633|NCT05540600|DRUG|Digoxin 0.25 mg|Patients will have the dose of one tablet of 0.25mg per day
40933865|NCT06436300|BEHAVIORAL|Motivational text messaging|Intervention sends up to 4 motivational messages by text or email to Alaska Native men who are active patients and due for colorectal cancer screening. Incentive arms include promise of a $50 gift card or entry into a raffle for prize worth about $200 if they complete screening.
40933866|NCT02900001|PROCEDURE|early coronary angiography|Routine coronary angiography and revascularization if appropriate within 24 hours
40933867|NCT02900001|PROCEDURE|delayed coronary angiography|Routine coronary angiography and revascularization if appropriate after 72 hours
41129801|NCT01332175|PROCEDURE|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
40933868|NCT03194503|DEVICE|VL Coaching training using C-MAC video laryngoscope|"Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card)."
40933869|NCT02201342|DRUG|Udenafil|Drug
40933870|NCT02312427|DRUG|Suspending DPP-4 inhibitor, in outpatient service|After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
41449933|NCT05460520|BEHAVIORAL|Visual Motion Desensitization|The subject will be situated in darkness and view the movement of a visual pattern presented on a disk, sized 1 m in diameter and placed 1 m away from the subject with its center at the eye level. The disk will be rotated clockwise and counter-clockwise for up to 10 min at a fixed maximal speed within a treatment session but varying across sessions between 5 to 60°/s. Within a single session, the visual stimulus will be first presented with the subject sitting upright in a chair, and then the treatment will be repeated with the subject standing. The disk will be mounted on a vertical sled, so the center of rotation can be kept at the eye level when sitting and standing. A treatment session will be repeated or conducted with an increased visual motion speed up to 60°/s according to the subject's readiness. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions per day with a 10-min break in between
41449934|NCT05460520|BEHAVIORAL|Opposing visual motion stimulus|"The investigators characterize gravitational pull as a misaligned sense of upright in the velocity storage mechanism, and hypothesize that that this misalignment can be corrected with an opposing visual motion stimulus, e.g., backward pulling will be corrected with upward visual motion.~Patients in Group 5 will undergo view visual motion in a physical setting, and those in Group 6 under a VR setting. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions of 1-10 min per day with an approximately 5-min break in between."
40933871|NCT02312427|DRUG|Starting DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
40933872|NCT02312427|DRUG|Suspending DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
40933873|NCT03818984|BEHAVIORAL|Safer Conception for Men with At Risk Partners|CBT based safer conception counseling with longitudinal follow-up and booster sessions. The primary outcome will be HIV RNA suppression at 6 months. Secondary outcomes include early ART uptake, adherence, serostatus disclosure, couples HIV counseling and testing uptake, and limiting unprotected sex to peak fertility.
40933874|NCT05270161|PROCEDURE|Tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The incision was extended to the adjacent tooth on both sides of the multiple recessions. Dissection of the entire buccal aspect was performed as a partial-thickness flap using sharp tunnel elevators preserving the papillae. The flap was extended beyond the mucogingival junction and under each papilla allowing a tension-free flap mobilization in the coronal direction. The connective tissue graft was placed in the tunnel and was stabilized using absorbable suspensory sutures. The mobilized mucous flap was advanced coronally to the cemento enamel junction, and suspensory sutures were stitched.
40933875|NCT05270161|PROCEDURE|Laterally closed tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The tunnel elevators were mobilized apically beyond the mucogingival line and extended medially and distally from the recession defect by undermining the facial surface of the interdental papillae. The insertion of muscles and fibers must be removed until a tension-free flap is obtained in the mesial, apical and distal directions. The preparation of the flap will be done carefully to avoid rupture of the papillae and perforation of the flap. As a result of this procedure, the mesial and distal margins of the flap must be brought together without tension to cover the exposed part of the root surface. The connective tissue graft was placed in the tunnel and was fixed mesially and distally at the inner aspect of the flap. Margins of the flap were pulled together over the graft and sutured with interrupted sutures.
40933876|NCT05270161|PROCEDURE|Free gingival graft|In the recipient area, a marginal horizontal linear incision will be made in the mucogingival junction with a n°15 C blade, creating a partial thickness flap, keeping the periosteum intact. The horizontal dimension of the receiving area will be determined according to the mesiodistal extension of the area without keratinized gingiva. All mobile soft tissues, including epithelium, connective tissue and muscle fibers will be removed from the donor area using scissors to ensure stability in the recipient area. The connective tissue graft will be obtained by the free gingival graft technique and will be sutured in the recipient area.
41129802|NCT03709849|DRUG|experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo|the same as group description including dosage, frequency and duration
41129803|NCT03709849|DRUG|control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo|the same as group description including dosage, frequency and duration
41129804|NCT00054210|DRUG|carboplatin|
41129805|NCT00054210|DRUG|paclitaxel|
41129806|NCT00054210|DRUG|paclitaxel poliglumex|
41453504|NCT03431558|DRUG|Glucon-D 99.4% (Placebo)|This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
40933877|NCT05270161|PROCEDURE|Gingival graft - donor area|The connective tissue graft will be obtained by the free gingival graft technique for all groups (T1, T2, T3 and T4). The mold of the prepared receiving area will be performed using sterile aluminum foil. The mold will be transferred to the donor area on the palate and the edges of the mold delimited with a scalpel blade. Deeper incisions will be made on the edges with the scalpel perpendicular to the palate, aiming to obtain a graft approximately 1.5 mm thick. With the scalpel blade parallel, the graft will be removed (epithelium and connective graft) maintaining its uniform thickness. For T1 and T2, the free gingival graft will be de-epithelialized. In donor area, a hyaluronic acid gel and green tea will be applied by the participant 3 times a day for 7 days (gel group) or no material will be placed in the donor area and the clot will be kept in position by means of sutures (clot group).
40933878|NCT01776385|OTHER|Blood sampling|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
40933879|NCT01776385|OTHER|Control Group|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
40933880|NCT04950114|DRUG|GFB-887|GFB-887 is a potent, small molecule inhibitor of TRPC5.
40933881|NCT06245551|DRUG|Budesonide/albuterol metered-dose inhaler 160/180 μg|Budesonide/albuterol combination aerosol for inhalation, single dose (given as 2 actuations of 80/90 μg)
40933882|NCT06245551|DRUG|Placebo metered-dose inhaler|Placebo aerosol for inhalation, single dose (given as 2 actuations)
40933883|NCT00477074|PROCEDURE|bronchoalveolar lavage, blood analysis|
40933884|NCT04604691|DRUG|Blinatumomab for Injection|Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
40933885|NCT03119701|DRUG|Interferon Beta-1A|Lyophilisate for solution for injection.
40933886|NCT03119701|DRUG|Placebo|Lyophilisate for solution for injection as placebo.
40933887|NCT02749669|OTHER|Qualitative research|Semi-structured Interviews
40933888|NCT04481009|DRUG|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
40933889|NCT04481009|DRUG|Toripalimab|Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.
40933890|NCT04481009|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
40933891|NCT04481009|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
40933892|NCT01133327|DEVICE|Carotid Artery Stenting|"The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.~The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014 silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire."
40933893|NCT02717845|DEVICE|Ellipse|diagnostic CT scan imaging
40933894|NCT02717845|DEVICE|Tomofix|diagnostic CT scan imaging
40755634|NCT05540600|DRUG|Bisoprolol|Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization
40755635|NCT02759263|BEHAVIORAL|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
41279399|NCT02650011|OTHER|Acute deterioration of liver function|development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria) development of hepatic encephalopathy development of gastrointestinal hemorrhage development of jaundice (serum bilirubin greater than or equal to 3mg/dl) development of bacterial infection
40755636|NCT04861805|DEVICE|Vienna Aortic Valve SE System|Vienna Aortic Valve SE system for TAVI.
40755637|NCT03044912|DRUG|mirabegron|To evaluate the efficacy and safety of Mirabegron 50 mg vs 25 mg in Taiwanese patients with overactive bladder syndrome
40755638|NCT06440759|DEVICE|oXiris filter|"Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris.~The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared."
40755639|NCT06440759|DEVICE|M100 filter|Continuous Renal Replacement Therapy with the adsorption membrane filter M100. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.
40755640|NCT01407133|DEVICE|transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)|"The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic pseudo-dose on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months."
40755641|NCT01407133|DEVICE|Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)|Same sound level as active rTMS, but magnetic field strongly attenuated
40755642|NCT03876808|DEVICE|Bair Hugger™ Temperature Management Unit Model 750|Forced-air temperature management unit used for preoperative and intraoperative participant warming
40755643|NCT03876808|DEVICE|3M™ Bair Paws™ Flex Gown|Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
40755644|NCT04038658|BEHAVIORAL|Move-It|
40755645|NCT04250363|BIOLOGICAL|PfSPZ Challenge|Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.
40755646|NCT04250363|DRUG|Palcebo|Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
40755647|NCT04250363|DRUG|M5717 30 mg|Participants received 30 mg single oral dose of M5717 capsule on Day 1.
40755648|NCT04250363|DRUG|M5717 60 mg|Participants received 60 mg single oral dose of M5717 capsule on Day 1.
40755649|NCT04250363|DRUG|M5717 80 mg|Participants received 80 mg single oral dose of M5717 capsule on Day 1.
40755650|NCT04250363|DRUG|M5717 100 mg|Participants received 100 mg single oral dose of M5717 capsule on Day 1.
40755651|NCT04250363|DRUG|M5717 200 mg|Participants received 200 mg single oral dose of M5717 capsule on Day 1.
40755652|NCT04250363|DRUG|Placebo|Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
40755653|NCT04250363|DRUG|M5717 60 mg|Participants received 60 mg single oral dose of M5717 capsule on Day 5.
40755654|NCT04250363|DRUG|M5717 100 mg|Participants received 100 mg single oral dose of M5717 capsule on Day 5.
40755655|NCT04250363|DRUG|M5717 200 mg|Participants received 200 mg single oral dose of M5717 capsule on Day 5.
40755656|NCT06253728|DIETARY_SUPPLEMENT|High fiber and protein meal|In the intervention participants are assigned to eat high protein and fiber meal that differ in protein source or structure.
41279400|NCT02704104|DEVICE|AC5 Topical Hemostatic Device|Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
40755657|NCT06253728|DIETARY_SUPPLEMENT|Control|The control meal is low fiber and low protein meal.
40755658|NCT04579419|DRUG|Sodium Bicarbonate|Botulinum Toxin diluted in Sodium Bicarbonate
40755659|NCT04579419|DRUG|Normal Saline|0.9 NaCl
40755660|NCT01509456|DIETARY_SUPPLEMENT|Potassium Bicarbonate|90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
40755661|NCT06209086|DEVICE|skeletal anchored twin block|"This appliance was constructed as the modified Twin Block used for the first group in addition to the following modifications:~* Addition of mini-implants interdentally between the mandibular second premolar and mandibular first molar.~* Wire hooks: wire hook element in the lower part of the appliance was incorporated in the region of incisal capping with free end projecting at the canine region on both sides.~* Intra-oral elastics were attached from the mini-implant to the wire hook bilaterally."
40755662|NCT04309448|BEHAVIORAL|Perturbation-based balance training with functional electrical stimulation|The PBT program will consist of repetitive practice of reactive stepping for one hour. The participants will be equipped with the Odstock 2-Channel stimulator on one or both sides depending on their deficits. One channel of stimulation may be applied to the common fibular nerve to elicit a flexor withdraw reflex and elicit a step. The second channel of stimulation may be applied to the quadriceps muscles to assist with the supporting phase of the reactive step, as required. Participants will experience about 60 perturbations per session during balance exercises. To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness around the participant's trunk. Throughout the hour-long session, participants will complete challenging balance tasks, customized to their ability level, during standing and walking. The training will be supervised by a licensed physiotherapist and administered by a licensed physiotherapist or registered kinesiologist.
40755663|NCT03376412|DEVICE|Raindrop Near Vision Inlay|A maximum of 60 consecutive non-dominant eyes will be implanted with the Raindrop Near Vision Inlay.
40755664|NCT02205138|DRUG|ALLOB® cells with ceramic scaffold|Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
41279401|NCT05003362|BEHAVIORAL|ACT|mindfulness intervention for patients with pain/migraine
41449935|NCT03653299|DEVICE|Placebo or Active Phototherapy (MR4)|Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.
41449936|NCT01169272|DEVICE|CRT-SonR 9770|Active implantable defibrillator with capacity of cardiac resynchronization therapy
41449937|NCT02045108|BEHAVIORAL|Active Retraining|
41449938|NCT02045108|DEVICE|Sham TDCS|
41449939|NCT02045108|DEVICE|Active TDCS|
40755665|NCT04933058|DRUG|IV acetaminophen|Pain management
40755666|NCT04933058|DRUG|IV fentanyl|Pain management
40755667|NCT00563563|DRUG|NB32|All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
40755668|NCT00563563|BEHAVIORAL|Ancillary therapy|During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
40755669|NCT03238157|DRUG|Fluocinolone Acetonide (FA) implant|Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
41279402|NCT01152853|DRUG|PF00299804|PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
41449940|NCT02045108|BEHAVIORAL|Sham Retraining|
40755670|NCT00000665|DRUG|Foscarnet sodium|
40755671|NCT00000665|DRUG|Ganciclovir|
41129807|NCT01560494|OTHER|STAC curriculum|The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
41279403|NCT03941444|DRUG|ANAVEX2-73|Liquid oral solution
41449941|NCT05016986|OTHER|Standard clinical management|outcomes in GSW cardiac injuries
41449942|NCT05032963|BEHAVIORAL|Overnight polysomnography examinations|sleep lab for overnight polysomnography examinations
41449943|NCT06628154|DRUG|Losartan potassium 50mg|Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo
41449944|NCT06628154|OTHER|Placebo|Single tablet encapsulated identically to losartan
41279404|NCT03941444|DRUG|Placebo|Liquid oral solution
41449945|NCT02496104|BEHAVIORAL|Package n°1 of the APIB|
41449946|NCT03168035|DRUG|NC-4016|"Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
41449947|NCT03825198|PROCEDURE|Erector spinae plane block|Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
41449948|NCT03825198|DRUG|Levobupivacaine 0,25%|20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
41449949|NCT03825198|PROCEDURE|spine fusion|fusion of lumbar vertebral body on 1 or two levels
41449950|NCT03825198|DRUG|NaCL 0,9%|20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
41449951|NCT03825198|DRUG|Sufentanil|opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
41449952|NCT03825198|DRUG|propofol|induction agent for general anaesthesia ( 2-3 mg/kg)
41449953|NCT03825198|DRUG|Rocuronium Bromide|muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
41449954|NCT03825198|DRUG|sevoflurane|inhalation aesthetic used for the maintenance of general anaesthesia
41449955|NCT03825198|DRUG|paracetamol|postoperative drug for analgesia ( 1 gram 4/day)
40933895|NCT03857152|DIAGNOSTIC_TEST|Contrast enhanced spectral mammography (CESM)|"Contrast enhanced spectral mammography (CESM) will be undertaken in addition to routine practice.~CESM is a specialist mammography test that aims to 'highlight' areas of concern within the breast in more detail than a standard mammogram.~The difference between CESM and a standard mammogram (x-ray of the breast) is the use of a special dye (called contrast medium) that is injected into the veins before the mammogram images are taken. The contrast enhanced images give more detailed information to the breast radiologists (expert doctors trained to analyse breast imaging)."
40933896|NCT02140632|PROCEDURE|Local methylprednisolone acetate and lidnocaine injection|
40933897|NCT02140632|DEVICE|wrist splinting|
41129808|NCT01357694|BEHAVIORAL|psychotherapeutic contacts|psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
41129809|NCT03297138|PROCEDURE|FiLAC laser|The technique consists in applying in a radial way to 360 ° an energy laser in the fistulous route. This energy allows a thermal destruction by coagulation of the wall of the fistula and the fabrics of granulations in a circular and regular way as well as a shrinkage of neighbouring fabrics. The repair is made by a call of macrophages and fibroblasts of neighbouring healthy fabrics so ending in a closure of the fistulous route
41129810|NCT04816175|BEHAVIORAL|Acquire Therapy|This intervention is an operant conditioning based neurorehabilitation protocol for the promotion of psychomotor function
41129811|NCT06144749|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
41129812|NCT03689920|DEVICE|Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
41129813|NCT02404441|BIOLOGICAL|PDR001|anti-PD1 antibody
41129814|NCT05066022|BIOLOGICAL|CT0590 CAR T Cells|Dose-escalated CAR T cells infusion
41129815|NCT05980559|DRUG|Xeomin|50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally (15 Units per muscle applied with 2 injections in each masseter muscle) (10 Units per muscle applied with 2 injections in each temporalis muscle)
41129816|NCT06221137|PROCEDURE|conventional circumferential supracrestal fiberotomy|"The amount of tooth that need to be extruded will be measured Bonding brackets slot 0,022x0.028 Roth prescription on piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~• Fiberotomy After 2 days of bonding, local anaesthetic solution will be administrated. The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~supracrustal fibrotomy will be performed using 15 c blade (Carvalho, Bauer et al. 2006)"
41129817|NCT06221137|PROCEDURE|laser circumferential supracrestal fiberotomy|"* The amount of tooth that need to be extruded will be measured~* Bonding brackets slot 0,022x0.028 Roth prescription~* piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~  • Fiberotomy~* After 2 days of bonding, local anaesthetic solution will be administrated.~* The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~* A diode laser of 980 nm wavelength will be used The laser tip will be inserted, and incision will be extended around tooth circumference with the system configured to a continuous wave with the movement of the laser tip in an up and down stroking movement The laser tip will be moved in a circumferential manner taking care that all the fibers are lysed."
41279405|NCT03458169|DEVICE|Therapist LEAP session feedback|A standard therapy session is being performed with a participant with the LEAP body-weight support robot. Subsequently, the therapist is answering a questionnaire to assess the clinical applicability of the robot. An observer will assess with a questionnaire whether use errors occurred during the session.
41279406|NCT03458169|DEVICE|Participant LEAP session feedback|A standard therapy session is being performed with a participant inside the LEAP body-weight support robot. Subsequently, the participant is answering a questionnaire to assess the comfort of the robot.
41279407|NCT03458169|DEVICE|LEAP risk control validation|The therapist rates the risk control measurements of the LEAP robot with a questionnaire, during a session with a member of the investigational team.
41279408|NCT01543750|DRUG|4-Aminopyridine|
41279409|NCT01543750|DRUG|Placebo|Placebo
41279410|NCT00577187|DEVICE|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
41279411|NCT01126229|DIETARY_SUPPLEMENT|Placebo|2 capsules of placebo daily for 12 weeks
41279412|NCT01126229|DRUG|Low dose Resveratrol|2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient
41279413|NCT01126229|DRUG|High dose Resveratrol|2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
41279414|NCT01819792|OTHER|Multiplex respiratory viral PCR|
41279415|NCT04728945|PROCEDURE|lung recruitment|Automatic lung recruitment using the anesthetic machines (with PEEP 15 cmH2O for 30 seconds) will be performed every 30 minutes during laparoscopy.
41449956|NCT03825198|DRUG|Ketorolac|non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
41449957|NCT03825198|DRUG|morphine pca|postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
41449958|NCT03825198|DRUG|Dexamethasone|drug given during general anaesthesia to prevent postoperative nausea
40933898|NCT05523518|DEVICE|The Buzzy®|From one minute before the location of the catheter and until the end of the procedure, the researchers will place the Buzzy® device approximately 5cm above the area where the procedure will take place, with its wings under it. The gel in its wings will have been previously frozen solid in a refrigerator. In this way, vibration and cold will be applied, and immediately afterwards, vein entry will be performed. (For the children's safety, a piece of thin sterile gauze will be placed on the area in order to prevent direct contact between the ice wings and the skin.)
40933899|NCT05523518|DEVICE|The AccuVein®|In this group, the veins in the area where the entry is to be performed will be visualized with the AccuVein® infrared vein visualization device, and the standard catheter implementation will be performed in the vein which is decided on for entry.
40933900|NCT04123028|OTHER|observatory|observation for 1 year period
40933901|NCT04809077|OTHER|Reverse total shoulder replacement|Long-term radiographic and clinical data of patients who underwent a reverse shoulder replacement
40933902|NCT00025727|DRUG|Lopinavir/Ritonavir|
40755672|NCT04920123|DEVICE|Neuro-World|Neuro-World is a collection of six games that are developed for cognitive training that focuses on memory and attention.
40755673|NCT02390999|PROCEDURE|48 hours of therapeutic hypothermia|
40755674|NCT06548347|DRUG|Linperlisib|Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles
40755675|NCT06237907|OTHER|Patients underwent lymphedema surgery|Patients who have developed lymphedema and undergone lymphedema surgery.
40755676|NCT06237907|OTHER|Patients underwent surgery without LVA|For patients who have not experienced lymphedema but require surgery due to other disease such as cancer, trauma, chronic wounds, skin defects, etc.
40755677|NCT01124266|PROCEDURE|standard of care colonoscopy|Single inspection by endoscopist during colonoscopy
40933903|NCT00025727|DRUG|Ritonavir|
40755678|NCT01124266|PROCEDURE|standard of care colonoscopy|Dual inspection by both endoscopist and nurse during colonoscopy
40933904|NCT00025727|DRUG|GW433908|
40755679|NCT06366490|BIOLOGICAL|Innocell Autologous Cellular Immunotherapy|Innocell Autologous Cellular Immunotherapy
40933905|NCT01876433|DRUG|Mirabegron|
40933906|NCT01876433|DRUG|Placebo|
40933907|NCT00559182|DRUG|Comparator: MK-8033|"MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at \~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).~Enrollment in Parts A and B has been completed."
40933908|NCT00559182|DRUG|Comparator: MK-8033 +/- omeprazole|"Part C will occur at only one of the investigational sites.~In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.~Enrollment for Part C has been suspended."
40933909|NCT04676360|DRUG|Belantamab Mafodotin|Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.
40933910|NCT05312047|PROCEDURE|Pelvic organ prolapse surgery|Vaginal surgery of any compartment for pelvic organ prolapse
40755680|NCT04138082|OTHER|Exposition to high-dB soundtrack|Already stated
40755681|NCT02496312|BEHAVIORAL|Evaluation of Apathy Close to Real Life Situation|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
40755682|NCT00002135|DRUG|Ganciclovir|
40755683|NCT03154112|DEVICE|Measurement of oxygen consumption and caloric expenditure|This study will involve an \~1 hour, single point in time measurement of oxygen consumption, carbon dioxide production, resting energy expenditure, and respiratory quotient using two methods while patients are breathing an FiO2 of 40%. These measurements will be measured using the novel, responsive device and compared with gas collected simultaneously collected from a Douglas bag.
40755684|NCT03702374|DRUG|Combined antioxidant therapy|It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months
40755685|NCT03702374|OTHER|Placebo|It consists in a capsule with 100mg of magnesium oxide.
40755686|NCT04262427|DRUG|Cyclophosphamide 50mg|cytotoxic chemotherapy
40933911|NCT01005043|RADIATION|heavy ion radiotherapy (C12)|"Desired target of Heavy ion radiotherapy is 60 to 66 Cobalt Gray Equivalent (GyE), whenever possible. It is applied through 1 - 3 isocenter treatment portals. Dose distributions are calculated and dose volume histograms (DVH) are generated. A α/β-ratio of 2 is used for biological plan optimization. Fractionation is planned to be equivalent to 6 x 3 GyE / week. Dosage to organs at risk is minimized. Treatment continues for 20 to 22 days or until one of the following criteria applies:~Other illness that prevents further administration of treatment, Patient or legal guardian decides to withdraw from the study, or changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator."
40933912|NCT03754192|RADIATION|perfusion Computed Tomography|Will be carried before liver surgery
41449959|NCT03825198|DRUG|Morphine|loading dose morhine 0,1 mg/kg at the end of surgery
40755687|NCT04262427|DRUG|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|potent humanized immunoglobulin (Ig) G4 monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor
40933913|NCT05730088|OTHER|health education|Health Education: While they are still in the hospital, a 30-minute individually planned education about their disease will be given to patients using the COPD patient education booklet. step 1. Smoking cessation, step 2. Vaccination, step 3. Correct drug use, step 4. Regular exercise, step 5. Healthy eating, step 6. Coping with stress, step 7 Coping with attacks, step 8. Includes regular oxygen therapy. Let's learn nhaverug treatments in coping with COPD, under the title of pulmonary rehabilitation (Respiratory Rehabilitation), methods of coping with shortness of breath, indoor air pollution and outdoor air pollution subheadings.
40933914|NCT05730088|OTHER|Mobile application (Creating a WhatsApp group):|A group will be created through the WhatsApp application for participants in health education and visual and audio materials will be shared through this group every week. In the coming weeks, the researcher will provide consultancy services to those who have problems with the application.
40933915|NCT05730088|OTHER|Home visit:|Participants will be visited at home three times. During the home visit, any questions about their illness and the oxygen concentrator they use will be answered. During the home visits, the researcher will provide consultancy services.
40755688|NCT03967574|DEVICE|Transcranial direct current stimulation|"The tDCS anode was applied on the primary motor cortex area responsible for the control of the rotator cuff, as determined using transcranial magnetic stimulation and surface electromyography. The cathode was applied on the contralateral forehead, just above the eyebrow. The electrodes were soaked in saline solution to improve conductivity and the montage was secured with rubber bands and adhesive tape.~The tDCS device (Soterix Medical 1x1 tDCS device) was then gradually turned to an intensity of 2mA. This stimulation was continued for a total of 20 minutes, after which it was gradually stopped."
40933916|NCT05730088|OTHER|Telephone interview:|Participants will be called every month by the researcher and asked if there are any hospital visits in that month, especially if they are chest disease visits.
40933917|NCT02697110|BEHAVIORAL|Edutainment based intervention|Edutainment intervention package
41129818|NCT02821936|PROCEDURE|Parametric Imaging|2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
41129819|NCT02429115|OTHER|Mentoring|Six months of peer-mentoring.
41129820|NCT02766946|DEVICE|Ultrasound|An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
40755689|NCT05403515|OTHER|foot massage|foot massage
40755690|NCT05403515|OTHER|Foot massage +Aromatherapy group|foot massage and lavender oil inhalation
40755691|NCT01063803|DRUG|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
40755692|NCT01063803|DRUG|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
40755693|NCT00985192|DRUG|everolimus|
40755694|NCT00985192|OTHER|laboratory biomarker analysis|
41129821|NCT02766946|DEVICE|Ultrasound|An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
41129822|NCT02766946|OTHER|Neuromyopathy score|A neuromyopathy score will be assessed on the extubation day
41449960|NCT06561451|PROCEDURE|intracytoplasmic sperm injection and artificial oocyte activation|A single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.
41449961|NCT06561451|PROCEDURE|intracytoplasmic sperm injection|A single sperm will be injected within 4 hours after the follicular aspiration.
41449962|NCT04163588|DRUG|Metolazone|Study participants receive loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
41449963|NCT04163588|DRUG|Loop Diuretics|Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)
40933918|NCT03695874|OTHER|Phase 1 : fill out 1 scale|"Patients will be asked to complete questionnaires.~Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items).~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
40933919|NCT03695874|OTHER|Phase 2 : fill out 1 scale and 4 questionnaires|"Patients will be asked to complete questionnaires.~Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale.~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
40933920|NCT05673460|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD at dosage of 45 mg or 65 mg
40933921|NCT06391528|PROCEDURE|Transversalis Fascia Plane Block|application of local anesthetic between the transversus abdominis muscle and the transversalis fascia surrounding it from the inside, at the level of the posterior axillary line.
40933922|NCT02283151|DIETARY_SUPPLEMENT|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake \< 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (\<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
40933923|NCT02283151|OTHER|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
40933924|NCT03563144|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
40933925|NCT03563144|DRUG|Nab-paclitaxel|NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
41279416|NCT04728945|PROCEDURE|Standard ventilatory management|"After tracheal intubation, standard ventilatory management (metered ventilation) should be performed with the following initial settings, and rescue should be performed when hypoxemia occurs, if necessary.~\[initial setting\] PEEP 4cmH2O, FIO2 0.3 Ventilation rate: 6-8 ml/kg predicted body weight (PBW)"
41279417|NCT02101437|PROCEDURE|miRNA within 24hr|miRNA within 24hr
41279418|NCT02101437|PROCEDURE|miRNA after 1 week|miRNA after 1 week
41449964|NCT01426360|OTHER|control dentifrice|use the dentifrice to brush teeth twice a day for one minute for 3 days
41449965|NCT01426360|OTHER|strontium chloride/potassium nitrate dentifrice|use the dentifrice to brush teeth twice daily for 3 days
41449966|NCT03475251|BIOLOGICAL|CS1003|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.
40933926|NCT03563144|DRUG|Aldoxorubicin HCl|Albumin-binding prodrug of doxorubicin HCl
40933927|NCT03563144|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
40933928|NCT03563144|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
40933929|NCT03563144|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
40933930|NCT03563144|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
40933931|NCT03563144|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
40933932|NCT03563144|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
40933933|NCT03563144|BIOLOGICAL|GI-6207|CEA yeast vaccine
40933934|NCT03563144|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
40933935|NCT03563144|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\]
40933936|NCT03563144|DRUG|Avelumab|Avelumab
40933937|NCT03563144|DRUG|Bevacizumab|Bevacizumab
40933938|NCT03563144|DRUG|Capecitabine|Capecitabine
40933939|NCT03563144|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
40933940|NCT03563144|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
41279419|NCT02101437|PROCEDURE|miRNA after 1 month|miRNA after 1 month
41449967|NCT03475251|BIOLOGICAL|CS1003|CS1003 to be intravenously administered at the dose level determined during the dose escalation part
41449968|NCT03475251|DRUG|Regorafenib|Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle
41449969|NCT01747174|DRUG|IC Adenosine|IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
40933941|NCT03563144|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
40755695|NCT03291236|OTHER|Follow-up for death and recurrence of patients|All patients are follow-up to determine specific date of diagnosis, recurrence and death.
40755696|NCT00754559|DRUG|Tocilizumab|8mg/kg iv every 4 weeks
40755697|NCT05352113|DRUG|SSRIs|SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
40755698|NCT05352113|PROCEDURE|acupuncture|This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
40755699|NCT05352113|PROCEDURE|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
40755700|NCT05352113|DRUG|placebo|Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
40755701|NCT01204372|DRUG|Gemcitabine - Trastuzumab - Erlotinib|"Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.~* Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.~* Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.~* Erlotinib: oral route 100 mg/day from C1D1."
40755702|NCT03638271|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging and compare their results.
40755703|NCT06134895|DRUG|Tramadol with Ketamine|Tramadol with Ketamine is being provided randomly using prospective, double-blind
40755704|NCT06134895|DRUG|Tramadol|Tramadol alone is being provided randomly using prospective, double-blind
40755705|NCT02920567|DRUG|Octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
40933942|NCT03563144|DRUG|Oxaliplatin|Oxaliplatin
40933943|NCT05271708|DRUG|Fespixon cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
40933944|NCT05271708|DRUG|Placebo Cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
40755706|NCT02920567|DRUG|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
40755707|NCT00077012|DRUG|QLT0074|
40755708|NCT00077012|DRUG|Photodynamic therapy|
40755709|NCT03768674|OTHER|Assessment of diagnoses, functioning and health services|Systematic differential diagnostics, assessment of psychosocial and personality functioning and treatment/ health services
40755710|NCT05135780|OTHER|Osteopathic manual treatment|Between 5 and 8 sessions of osteopathy will be carried out, and the time interval between sessions may vary depending on the need and individual evolution of each child, assessed by the team of osteopaths.
40933945|NCT00761150|DRUG|ABT-712|ABT-712 extended-release tablet
40933946|NCT00761150|DRUG|Placebo|Placebo tablet
40933947|NCT03800472|DRUG|GLPG3312 IR|GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
40933948|NCT03800472|DRUG|Placebo|Placebo tablets
40933949|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).
40933950|NCT03800472|DRUG|GLPG3312 FE MR|GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.
40933951|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).
40933952|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR optimized film-coated tablets, up to 3 multiple ascending oral doses (Q, R, S).
40933953|NCT03800472|DRUG|Placebo|Placebo optimized tablets
40933954|NCT02551627|DIETARY_SUPPLEMENT|Test Product|MMN fortified beverage powder.
40933955|NCT02551627|DIETARY_SUPPLEMENT|Control|Isocaloric beverage powder without micronutrient fortification.
40933956|NCT05045378|DRUG|Midazolam (active placebo)|Arm1: Two 0.045mg/kg midazolam infusions at Day1 and Day3。
40933957|NCT05045378|DRUG|Ketamine and Midazolam (active placebo)|Arm2: First 0.045mg/kg midazolam infusion and Second 0.5mg/kg ketamine infusion。
40933958|NCT05045378|DRUG|Ketamine|Arm3: Two 0.5mg/kg ketamine infusions。
41129823|NCT02766946|OTHER|Respiratory performances|An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
40933959|NCT04409639|DRUG|Cobimetinib|Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
40933960|NCT04474548|OTHER|Ultrasound use|Ultrasound will be used to determine location of IUD after insertion.
40933961|NCT02770261|DRUG|DP-R208|DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
40933962|NCT02770261|DRUG|Candesartan32mg|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
40933963|NCT02770261|DRUG|Rosuvastatin 20mg|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
40933964|NCT02770261|DRUG|DP-R208 Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
40933965|NCT02770261|DRUG|Candesartan32mg Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
40933966|NCT02770261|DRUG|Rosuvastatin 20mg Placebo|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
40933967|NCT03627390|DRUG|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
40933968|NCT03627390|DRUG|BP-C2|BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
40933969|NCT02607839|BIOLOGICAL|glucose or normal saline|20% glucose solution or normal saline, intravenous infusion
40933970|NCT02673541|DEVICE|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
40933971|NCT02673541|DEVICE|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
40933972|NCT01548144|DRUG|Crizotinib (Xalkori)|"Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1."
40933973|NCT01548144|DRUG|Pazopanib|"Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1."
40933974|NCT01548144|DRUG|Pemetrexed|"Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1."
40933975|NCT00862108|DRUG|Methylphenidate|mg/kg dose: 0.7\~1.2mg/kg PO daily morning intake 8 weeks
40933976|NCT01445626|DRUG|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
40933977|NCT00718562|DRUG|AMN107|
40755711|NCT05135780|OTHER|Social education|"* Intervention in children:~  * During the school year there will be activities of two days per week with a duration of 2.5 hours per session in the afternoon.~ * The activities will focus on school reinforcement, facilitating snacks and having a recreational space.~ * Groups will be made by age ranges (from 4 to 6 and from 7 to 12) of maximum 10 children, due to the current COVID situation. The number could vary in the event of a change in measures at the institutional level.~* Family intervention:~  * Quarterly tutoring spaces between the coordinators and the team of social educators to evaluate needs, specify objectives and assess evolution.~ * Monthly group spaces for mothers managed by the team of educators where they will exchange experiences and create an informal support network.~ * Monthly spaces shared between parents and children accompanied by the educational team, where family ties will be worked through play."
40933978|NCT00993044|DRUG|Irinotecan|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
40933979|NCT00993044|DRUG|Vincristine|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
41129824|NCT03022968|DRUG|[18F]T807 PET|Imaging with \[18F\]T807 PET
41449970|NCT01747174|DRUG|IC Sodium nitroprusside (SNP)|IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
41449971|NCT01747174|PROCEDURE|Standard PCI|PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
41449972|NCT00072514|DRUG|gemcitabine hydrochloride|Given IV
41449973|NCT00072514|DRUG|carboplatin|Given IV
41449974|NCT00072514|DRUG|dexamethasone|Given PO
41449975|NCT00072514|BIOLOGICAL|rituximab|Given IV in CD20-POSITIVE LYMPHOMAS cases
41449976|NCT03369132|DEVICE|Angiflash|throat spray (20 ml) containing hypertonic seawater, vegetable glycerin, natural mint, acacia honey, propolis extract, essential oils of thyme linalool, ravintsara and wintergreen, natural lemon flavor.
41449977|NCT03369132|DEVICE|Placebo|water based throat spray matching Angiflash for posology, dispensed volume, shape and size.
41449978|NCT02075333|DIETARY_SUPPLEMENT|Ingestion of solution|Participants will ingest the solution
40933980|NCT00993044|DRUG|Temozolomide|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
40933981|NCT00993044|DRUG|Bevacizumab|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
40933982|NCT04589715|OTHER|electroacupuncture|the same as described in experimental arm.
40933983|NCT04589715|OTHER|sham electroacupuncture|the same as described in sham comparator.
40933984|NCT00920907|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
40933985|NCT00459979|DRUG|sunitinib malate|Sunitinib will be dosed at 50 mg p.o. daily
40933986|NCT00459979|PROCEDURE|conventional surgery|nephrectomy
40933987|NCT01580748|DRUG|Roflumilast|500 microgram once daily for 16 weeks
40933988|NCT02220127|RADIATION|GKR with a single shot of the 8 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.
40933989|NCT02220127|RADIATION|GKR with a single shot of the 4 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
41279420|NCT04722718|DRUG|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
40933990|NCT00476801|DEVICE|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
40755712|NCT04179162|DRUG|Bacillus Calmette-Guérin (BCG)|Patients will receive once-weekly intravesical BCG therapy (TICE strain, 50 mg) at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6(+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days).
40933991|NCT06322290|DIAGNOSTIC_TEST|assessment of pathogens in blood specimens|Molecular diagnosis of Invasive bacterial diseases due to Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae
40933992|NCT02048579|BEHAVIORAL|Behavior Therapy + Motivational Interviewing|
40933993|NCT03074942|DRUG|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
40933994|NCT04512287|DRUG|Autologous Platelet Rich Plasma|2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.
40933995|NCT04512287|OTHER|Saline Solution|2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.
40933996|NCT06086262|DEVICE|Hydraulic hand dynamometer (Jamar, Product model J00105, U.S.A)|"The hydraulic hand dynamometer is a reliable and valid an evaluation tool that's used to measure isometric grip force (hand grip strength) .~The hydraulic pinch gauge is a reliable and valid an evaluation tool that's used to measure isometric pinch force."
40933997|NCT05651204|DIAGNOSTIC_TEST|GABA Blood Level|Blood specimens will be collected by a registered phlebotomist according to hospital's specimen collection procedures.
40933998|NCT01198171|OTHER|Laboratory Biomarker Analysis|Correlative studies
40933999|NCT01198171|OTHER|Study of Socioeconomic and Demographic Variables|
40755713|NCT04179162|DRUG|Gemcitabine|Patients will receive gemcitabine at their specified dose level, given in a twice weekly fashion, with 72 to 96 h (+/- 1 day) between doses, at weeks 1, 4, 7, and 10.
40934000|NCT00669760|OTHER|non-interventional study|does not apply
40934001|NCT00546221|BEHAVIORAL|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
41279421|NCT01907685|DRUG|AVE8062|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
41279422|NCT01907685|DRUG|Docetaxel|"Pharmaceutical form: solution for infusion~Route of administration: Intravenous"
41279423|NCT02249715|DEVICE|Brainsway Multiway deep TMS device (two channels)|
41279424|NCT01042262|OTHER|Oxygen|100% Oxygen at a flow of 2 L/min
41279425|NCT01042262|OTHER|Placebo|No oxygen flow
41279426|NCT05428371|DIAGNOSTIC_TEST|Multiomic analyses of blood and surgical specimens|"The following items will be evaluated:~* cell free dna length and integrity~* presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples~* qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)"
40934002|NCT00546221|BEHAVIORAL|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
40934003|NCT03095547|DRUG|cyclosporine A|Pharmacokinetic assessment Area Under the plasma concentration: time Curve (AUC) 0-t
40934004|NCT03095547|DRUG|Posaconazole|Pharmacokinetic assessment AUC 0-tau
40934005|NCT03095547|DRUG|Pantoprazole|Pharmacokinetic assessment AUC 0-tau
40934006|NCT03095547|DRUG|F901318|Pharmacokinetic assessment AUC 0-tau
41279427|NCT00187590|BEHAVIORAL|Case manager phone call after an ER visit|
41279428|NCT06187506|DRUG|Disitamab vedotin|2.0 mg/kg, administered intravenously every three weeks
40934007|NCT03095547|DRUG|Tacrolimus|Pharmacokinetic assessment AUC 0-t
41279429|NCT06187506|DRUG|Bacillus Calmette Guerin Vaccine|Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
41279430|NCT02652000|OTHER|No intervention in this retrospective study|No Intervention in this retrospective Analysis.
41279431|NCT01610921|OTHER|Bronchial provocation test|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
41279432|NCT03120143|OTHER|Small-sided ball game training with high protein intake|In the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation high in protein consists of 18 g protein consumed immediately after and 3 h post exercise
41279433|NCT03120143|OTHER|Small-sided ball game training with low protein intake|n the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation low in protein consists of 3 g protein consumed immediately after and 3 h post exercise.
41279434|NCT03955367|RADIATION|Prophylactic extended-field Irradiation|CTV covers pelvis and para-aortic lymph nodes region.
41279435|NCT03955367|RADIATION|Pelvic irradiation|CTV covers pelvis.
40755714|NCT03788928|DIAGNOSTIC_TEST|serum mitochondrial DNA|serum mitochondrial DNA will be measured using RT-PCR within first 72 hours of symptoms of acute pancreatitis
40755715|NCT01284088|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
40934008|NCT02399618|DRUG|Fecal Microbiota Transplantation|Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
40934009|NCT05329571|BEHAVIORAL|Low-FODMAP diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
40934010|NCT05329571|BEHAVIORAL|Gluten-free Diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
40934011|NCT05329571|BEHAVIORAL|Control group|Patients of this group will have dietary consultation but will not change their regular diet for the period of the study.
40934012|NCT04995289|OTHER|Prone position on ECMO patient|blood gas analysis before and after PP
40934013|NCT03395132|DRUG|Fucicort® Lipid cream|The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.
40934014|NCT03395132|DRUG|Fucidin® cream|The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.
40934015|NCT03395132|DRUG|Fucicort® Lipid cream vehicle|The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.
40934016|NCT03395132|DRUG|betamethasone (Lianbang Beisong®) cream|The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.
40934017|NCT02598336|DEVICE|Structured Light Plethysmography|Non contact device that uses light to record displacement of the anterior thorax and abdomen region
40934018|NCT02598336|DEVICE|Pneumotachograph Spirometry|Device that measures airflow at the mouth using a mouthpiece
40934019|NCT04054570|OTHER|No intervention|No Intervention
41279436|NCT03955367|RADIATION|Intracavitary brachytherapy|The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.
41279437|NCT03955367|DRUG|Concurrent chemotherapy|Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.
41449979|NCT02075333|DIETARY_SUPPLEMENT|Rinising of solution|Participants rinse the solution in the oral cavity
40934020|NCT04859114|BEHAVIORAL|Format of outcome data presentation|Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.
40934021|NCT04859114|BEHAVIORAL|Displayed chance of survival|In the outcome data provided to participants, they view either a 30% or 60% chance of survival.
40934022|NCT03477929|DRUG|Ganirelix Acetate|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
40934023|NCT03477929|DRUG|Cetrorelix Acetate|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
40934024|NCT01039012|OTHER|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
40934025|NCT01039012|OTHER|Standard Care|Participant follow the standard care recommended by their physician.
40934026|NCT03867409|BEHAVIORAL|message delivered via virtual technology|The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.
40934027|NCT03540043|DRUG|Administration of Placebo|Botanical Drug Phase 2 clinical study
40934028|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.05%|Botanical Drug Phase 2 clinical study
40934029|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.1%|Botanical Drug Phase 2 clinical study
40934030|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.25%|Botanical Drug Phase 2 clinical study
40934031|NCT01325792|DEVICE|GORE® BIO-A® Tissue Reinforcement|Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
41279438|NCT00503191|BEHAVIORAL|NeuroModulation Technique|NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
41279439|NCT00454597|PROCEDURE|omentectomy|surgery omentectomy
40934034|NCT06423989|COMBINATION_PRODUCT|IVIG|treatment of subfertility
40934035|NCT01173887|DRUG|VCAP/AMP/VECP(mLSG15)|VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
40934036|NCT01173887|BIOLOGICAL|KW-0761|VCAP/AMP/VECP(mLSG15) + KW-0761
40934037|NCT05836779|DRUG|CBL-514 injection|CBL-514 will be administered at the raised area of cellulite.
40934038|NCT04279288|DEVICE|Hilotherm mask|a cooling mask used to treat localized swelling and bleeding
40934039|NCT04434378|DRUG|Tamsulosin|0.4 mg tamsulosin will be given to a randomized group of patients
40934040|NCT04434378|DRUG|Placebo|placebo will be given to a randomized group of patients
40934041|NCT05860374|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
40934042|NCT00291733|DRUG|Levetiracetam|500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
40755716|NCT01284088|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
40934043|NCT00291733|DRUG|Placebo|Placebo tabl
40934044|NCT01235871|DRUG|SB1578|JAK2 Inhibitor
40934045|NCT01235871|DRUG|Placebo|Control arm
40934046|NCT06303791|BEHAVIORAL|Digital Psychosocial intervention|The psychosocial program with digital support has been developed by combining different theoretical perspectives on intervention in children with ASD without intellectual disabilities and children with ADHD. The contents of the program are based on three main approaches, each of which has separately demonstrated evidence in the treatment of these neurodevelopmental disorders: psychoeducation and stress management, cognitive behavioral techniques, and techniques in social and communication skills (Dahl et al., 2020; DuPaul et al., 2020; Tan-MacNeill et al., 2021).
41279440|NCT02757495|DRUG|Dexmedetomidine|Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
40934047|NCT00121407|DRUG|Visudyne for injection|
40934048|NCT04732897|PROCEDURE|dynamic dressing|Dynamic dressing is made by bandages of the foot with gauze pad, stretchable adhesive tape and elastic compression band
40934049|NCT02902978|DRUG|E6130|
40934050|NCT02902978|DRUG|Placebo|E6130 matched placebo
40934051|NCT05814601|DRUG|norepinephrine|norepinephrine at a concentration of 5 mcg/ml is preemptively administered
40934052|NCT04589312|BIOLOGICAL|Standard of care vaccines|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)
40934053|NCT04589312|BIOLOGICAL|Boostagen, (BioNet-Asia)|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);
40934054|NCT01594437|BIOLOGICAL|TCN-202|Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
40934055|NCT01594437|BIOLOGICAL|Placebo|One or two doses administered by intravenous infusion.
40934056|NCT00057681|DRUG|Lithium carbonate|Titrated until blood level is 1.1 to 1.3 mEq/L
40934057|NCT00057681|DRUG|Valproate|Titrated until blood level is 111 to 125 ug/mL
40934058|NCT00057681|DRUG|Risperidone|Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
40934059|NCT05345327|DRUG|Dapagliflozin|SGLT2 inhibitor
40934060|NCT05345327|DRUG|Metformin|Metformin
40934061|NCT00882401|DRUG|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
40934062|NCT00882401|DRUG|Placebo|Matching placebo at same dose schedule as ergocalciferol
40934063|NCT01866553|DRUG|Nilotinib|300 mg capsule BID oral use
40934064|NCT01866553|DRUG|Pegylated interferon α-2b|25 - 40 microgram per week for subcutaneous use
40934065|NCT03961854|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
41279441|NCT02689700|OTHER|Blood samples|Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
40755717|NCT05055336|OTHER|Gastric emptying breath test|The gastric emptying breath test is used to diagnose gastroparesis. Participants ingest spirulina in a meal and samples are taken every 45 minutes for 4 hours.
40755718|NCT05055336|OTHER|Stomach ultrasound|Ultrasound of the fundus of the stomach will be done immediately after ingestion of the test meal, at 15 minutes, and at 30 minutes.
40755719|NCT00372515|DRUG|Gefitinib|On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
40755720|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with counter-displaced skin-subcutaneous fascial flaps after extralevatory abdominal-perineal extirpation of the rectum|Skin-subcutaneous fascial flap on the leg is cut out from one side of the perineal wound, and deepithelized, forming a diamond-shaped perineal wound. The cut flap is immersed in the aperture of the pelvis and fixed with single sutures to the remains of levators of the opposite side. The flap width should be 3-4 cm, sufficient to fill the pelvic aperture. On the opposite side of the wound, a skin-subcutaneous fascial flap is cut out on a triangular leg equal to the width of the previously formed diamond-shaped wound. The flap is moved to the center of the wound, additionally filling wound cavity with it, combining the vertex of the triangle with the vertex of the rhombus. The perineal wound is drained through the contraperture. The flap is fixed with separate nodal seams.
40934066|NCT03961854|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
40934067|NCT06516601|OTHER|no intervention|observational study, the patients received corticosteroids according to the physician on duty
41279442|NCT01563601|DRUG|Obatoclax Mesylate, Carboplatine and Etoposide|"Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles"
41449980|NCT06108557|DIAGNOSTIC_TEST|Serum Pararoxonase -1 level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
40934068|NCT03630276|DIAGNOSTIC_TEST|Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP|Lab
40934069|NCT05307939|DIAGNOSTIC_TEST|HPV ctDNA Assay|HPV ctDNA evaluation will be completed using NavDx which is a validated digital droplet PCR (ddPCR) assay that targets primers and hydrolysis probes to specifically detect amplicons within the E6 and E7 genes encoded by high-risk HPV strain 16, and the E7 gene for high-risk HPV strains: 18, 31, 33, and 35.
40934070|NCT05307939|DIAGNOSTIC_TEST|MRI Studies|Research MRI studies will be acquired at Memorial Sloan Kettering using a fast multi-phase spoiled gradient echo sequence. A Gadolinium-based agent will be used for DCE-MRI studies.
40934071|NCT05307939|BEHAVIORAL|EORTC QLQ H&N 35 and C30|The EORTC QLQ H\&N 35 s a validated 35-item site specific assessment tool. The module uses 7 multi-item scales to measure problems with swallowing, senses, speech, social eating and social contact. In addition, 11 single-item scales are utilized in assessing problems with teeth, mouth opening, dry mouth, sticky saliva, coughing, feeling ill, as well as use of analgesics, nutritional supplements, feeding tube and finally, weight gain and weight loss. All of the scales and single item measures range in score from 0 to 100. High scores for the Global Health Status/QoL scale represent high QoL, high scores for the functional scales represent high/healthy levels of functioning, but high scores for the symptom scales/items represent high levels of symptomatology/problems. Scoring the two instruments yields a total of 33 distinct scores and we will examine all of these scored.
40755721|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with local tissues|Simple layer-by-layer suturing of the sciatic-anal and subcutaneous adipose tissue is performed using nodular sutures. The skin was sewn up with nodular sutures at the discretion of surgeons. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon.
40934072|NCT05307939|BEHAVIORAL|MDADI-HN|The MDADI-HN is a questionnaire scored on a scale of 1 to 5, consisting of global, emotional, functional, and physical subscales. The MDADI-HN evaluates the effects of dysphagia on QOL.
40934073|NCT05307939|BEHAVIORAL|COST-FACIT|Comprehensive Score for financial Toxicity or COST survey is a validated screening tool to assess objective and subjective questions about treatment-related financial distress. It is scored from 0-44, where lower composite scores reflect greater risk of financial toxicity.
40934074|NCT05307939|RADIATION|Intensity-Modulated Radiation Therapy (Arm A)|59.4-60 Gy in 1.8-2 Gy fractions: CTV_primary, Involved/Adjacent to nodal levels. 50 Gy to this volume is allowed as per MSK institutional standards in patients with clear or close margins and 2-4 involved nodes. 45-50.4 Gy in 1.8-2 Gy fractions: Dissected node positive neck: uninvolved levels that are not adjacent to positive node - Dissected node negative neck
40934075|NCT05307939|COMBINATION_PRODUCT|Chemoradiation (Arm B)|30 Gy in 2 Gy fractions: CTV_primary, CTV_node-positive neck, CTV_node-negative neck, received de-escalated postoperative chemoradiation. Adjuvant radiation will be administered as previously outlined. Concurrent chemotherapy will be administered as per standard of care. Cisplatin will be administered concurrently with radiation. For non-cisplatin candidates, carboplatin/5fu will be administered. Reasons for using carboplatin/5FU instead of cisplatin need to be charted in the medical record, but the decision belongs to the treating physician. Cisplatin may be given up to 3 days before the scheduled dates, if necessary for medical or personal reasons
40934076|NCT01117792|DEVICE|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
40934077|NCT00060398|BIOLOGICAL|epoetin alfa|
40934078|NCT00060398|DRUG|dexamethasone|
40934079|NCT01046760|BEHAVIORAL|Language Assessment|Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
40934080|NCT03703570|DRUG|KW-6356|Oral administration
40934081|NCT03703570|DRUG|Placebo|Oral administration
40934082|NCT05346367|RADIATION|SRT|SRT
40934083|NCT05346367|RADIATION|fSRT|fSRT
40934084|NCT06523517|DRUG|Eliglustat Tartrate Capsules|The initial dose is 42 mg taken orally twice a day. After 2 weeks of treatment, if the blood trough concentration is less than 5 ng/mL, the dose will be increased to 84 mg taken orally twice daily.
40934085|NCT04841746|BEHAVIORAL|Physical therapy that include a standardized cycling training with functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the experimental group will received functional electrical stimulation administered to surface electrodes attached to lower limb muscles (quadriceps, hamstrings, gluteus maximus and triceps). Electrical stimulation will be delivered appropriately to the muscle during cycling regarding the angle of the pedal by a stimulator (Motimove-8 de 3Fit Fabricando Faber).
40934086|NCT04841746|BEHAVIORAL|Physical therapy that include a standardized cycling training with no additional functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the control group will received no additional functional electrical stimulation during cycling.
40934087|NCT01049399|DRUG|tideglusib|800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
40934088|NCT01049399|DRUG|tideglusib|600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
41279443|NCT01563601|DRUG|Carboplatin and Etoposide|"Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles"
40934089|NCT01049399|DRUG|placebo|powder for oral suspension administered once daily in fasting conditions for 52 weeks
40934090|NCT00936091|DRUG|vitamin A supplements|gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
40934091|NCT00936091|DRUG|Placebo|125 children received placebo capsules
40934092|NCT04475809|PROCEDURE|group C|laparoscopy will be performed with 14-16 mmHg intra-abdominal pressure. At the end of the procedure routine method for CO2 removal, passive exsufflation, will be used by applying gentle abdominal pressure to evacuate the residual gas through the port site.
40934093|NCT04475809|PROCEDURE|Group L|laparoscopy will be performed with 8-10 mmHg intra-abdominal pressure and routine passive exsufflation will be applied for CO2 removal at the end of the procedure.
40934094|NCT04475809|PROCEDURE|Group LR|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure pulmonary recruitment maneuver (PRM) will be done; which consists of five manual pulmonary inflations at a maximum pressure of 40 cm H2O and the fifth will be held for 5 seconds. During this procedure, the surgeon is instructed to keep the port sleeve valve fully opened to allow the CO2 to escape the abdominal cavity.
40934095|NCT04475809|PROCEDURE|Group LS|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure, intraperitoneal normal saline (IPS) will be infused for removal of the intra-abdominal CO2; in which we fill the upper part of the abdominal cavity evenly and bilaterally with isotonic normal saline (15-20 mL/kg body weight)
40934096|NCT06235242|BIOLOGICAL|GT201 injection in combination with teraplizumab injection|GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer
41279444|NCT02451956|DRUG|AZD5363|Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
41279445|NCT02451956|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
40934097|NCT06195761|PROCEDURE|computer guided modified ridge splitting technique in horizontal bone deficiency in posterior mandible|treatment plan includes harvesting and fixing the bone graft in posterior mandibular area using a computer-modified surgical guide
40934098|NCT06195761|PROCEDURE|free hand modified ridge splitting technique in horizontal bone deficiency in posterior mandible|treatment plan includes manually harvesting and fixing the bone graft in posterior mandibular area without a surgical guide.
40934099|NCT02859506|OTHER|Respiratory quotient|
40934100|NCT02859506|OTHER|Olfactory liking|
40934101|NCT00504582|DRUG|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
40934102|NCT02914821|BEHAVIORAL|Simulated tax via 3 cent per ounce price increase|For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
40934103|NCT02587325|DRUG|nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)|ABI-009
40934104|NCT05228457|DEVICE|Intensive intermittent theta-burst stimulation (iTBS)|Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.
40934105|NCT05060484|BIOLOGICAL|SCT1000|HPV vaccine
40934106|NCT05060484|BIOLOGICAL|Gardasil®9|HPV vaccine
40934107|NCT05060484|BIOLOGICAL|Gardasil®|HPV vaccine
40934108|NCT05060484|OTHER|placebo|adjuvent
40934109|NCT03335917|OTHER|Hypoxia|Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration
40934110|NCT03335917|OTHER|Exercise|Graded cycling exercise to volitional fatigue
40934111|NCT02848053|OTHER|no intervention|
41129825|NCT02957799|BEHAVIORAL|Accountable Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive ongoing monitoring and supervision. CHW will monitor mother's health and linkage to care; CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. CHW will also have a mobile phone to record information at each visit. CHW will log their home visits each day, rate the content and skills addressed on the mobile phone, weigh children, and report outcome achievements (e.g., receiving the child grant, immunizations, breastfeeding, and retention/ adherence to HIV care). The CHW in this arm will receive data-informed supervision. CHW will be monitored weekly with review of contact logs, recorded outcomes, and random site visits by supervising in-service training on a monthly basis. The Accountable Condition will last for two years (until the child is 24 months old).
41129826|NCT02957799|BEHAVIORAL|Control Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive supervision and monitoring consistent with local government practices. CHW will monitor mother's health and linkage to care. CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. The Control Condition will last for two years (until the child is 24 months old).
41129827|NCT04804566|OTHER|This is a non-interventional study|This is a non-interventional study
41129828|NCT00666419|OTHER|Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles
41129829|NCT01717066|DRUG|the ginsenoside Rg3|
41129830|NCT01717066|DRUG|Placebo|
41129831|NCT00495144|DRUG|TH-302|
40934112|NCT05438641|DRUG|BZDP-Sparing Protocol|BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants). Rescue with BZDP-based treatment allowed if there is symptomatic breakthrough- as measured by CIWA \> 15.
40934113|NCT05438641|DRUG|BZDP-Based Protocol|Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.
40934114|NCT03300648|OTHER|Mechanical ventilation|Intubation and mechanical ventilation for a maximum of 7 days
40934115|NCT03300648|DRUG|Hypertonic saline|Intravenous 3 percent hypertonic saline for a maximum of 7 days
40934116|NCT03494777|BEHAVIORAL|Incentivization based on high adherence|When a participant comes for a regular clinic visit, s/he will have the MEMS data extracted, and if adherence over the previous month \>=90%, will participate in a prize drawing.
40934117|NCT03494777|BEHAVIORAL|Incentivization based on timely clinic visit|When a participant comes for a regular clinic visit on the day s/he is scheduled, s/he will participate in a prize drawing.
40934118|NCT03494777|BEHAVIORAL|Annual adherence prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on the average adherence during that year.
40934119|NCT03494777|BEHAVIORAL|Annual viral suppression-based prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on showing viral suppression.
40934120|NCT03494777|BEHAVIORAL|Year 2 booster|Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.
40934121|NCT05205967|OTHER|MCED|Multi-cancer early detection (MCED) test
41129832|NCT00755144|DEVICE|LCS Knee|Cementless total knee arthroplasty with LCS Knee
41129833|NCT00755144|DEVICE|ROCC Knee|Cementless total knee arthroplasty with ROCC Knee
40934122|NCT05205967|OTHER|SOC|Standard of care cancer screening
40934123|NCT05993975|DRUG|Bupivacain 0.5%|Bupivacaine hydrochloride was given without any adjuvant
40934124|NCT05993975|DRUG|Dexmedetomidine Hydrochloride|Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride
40934125|NCT04231318|DRUG|Cingal|Single intra-articular injection of Cingal into the knee.
40934126|NCT04231318|DRUG|Triamcinolone Hexacetonide (TH)|Single intra-articular injection of TH into the knee.
40934127|NCT04231318|DRUG|Placebo|Single intra-articular injection Placebo (0.9% Saline) into the knee.
40934128|NCT03403842|DEVICE|Sublingual sufentanil tablet system|Administration of sublingual sufentanil with a PCA
40934129|NCT03403842|DEVICE|Peridural catheter|Positioning of a peridural catheter with a continuous infusion of ropivacaine 0,2% 99 ml+sufentanil 50 mcg
40934130|NCT03403842|DRUG|PCA Morphine|Administration of endovenous morphine with a PCA
40934131|NCT04050371|DRUG|200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate|All study participants received daily observed therapy with FTC/TDF.
40934132|NCT00906997|PROCEDURE|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
40934133|NCT00906997|PROCEDURE|Colonoscopy|Every 10 years, with sedation.
40934134|NCT03407339|OTHER|Shared Oral Care intervention|"One hour of teaching in oral hygiene and oral diseases to health care professionals at the intervention nursing homes.~The dentists will make an assessment of the elderly's oral hygiene at baseline, after three and six months using a mucosal and plaque score. During the six months, a dentist will be doing ward rounds at each nursing home in a specific time interval. In dialog with the resident and the healthcare professional, the dentist will present individual advice on how to perform oral care based on the resident's oral care routines, oral hygiene status, and the resident's physical and cognitive function level."
40934135|NCT04854642|DRUG|Ladarixin|A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.
40934136|NCT05868889|DRUG|Trabectedin and PLD|The main treatment observed in this study is trabectedin in combination with PLD in elderly patients with platinum-sensitive relapsed ovarian cancer, according to the SmPC.
40934137|NCT00621400|DRUG|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
40934138|NCT00621400|DRUG|Melphalan|0,18mg/Kg/day from day 1- 4
40934139|NCT00621400|DRUG|Dexamethasone|40mg/day from day 1- 4.
40934140|NCT02710643|DRUG|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
40934141|NCT04174950|OTHER|Routine nursing care|routine perioperative nursing intervention, including intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet. NPO after the dinner one day before operation. Patients are instructed to NPO 3 days after surgery and patients should stay on the bed for 3 days. Urinary catheter is always kept for 48 hours or more.
40934142|NCT04174950|OTHER|Perioperative Enhanced Recovery After Surgery (ERAS) Based Nursing Model|Establish ERAS nursing team and formulate ERAS nursing intervention. Nothing by mouth (NPO) 6 hours before operation and no water 4 hours before operation. Patients are given fluid food 24 hours after surgery. Urinary catheter is removed within 24 hours after surgery and encourage patient to mobile 24 hours after surgery. Give support to pain control and psychological support. Intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet were also given to patients.
40934143|NCT05091203|DRUG|Vitamin D|To investigate role of vitamin D in follicular maturation and number of mature follicles which help in the success of IVF procedure
40934144|NCT05596123|BEHAVIORAL|Therapeutic Chinese foot massage|Participants in the TCFM group will receive six weekly 25-minute TCFM sessions by a therapist. Each session will start with an assessment of the legs and toes of the affected extremity for broken skin and lesions, which the therapist will try to avoid. The participant will be positioned with support to their foot and legs, with the sole directed downward and the therapist directly in alignment with the soles of the foot. The therapist will sequentially perform the following four steps for each TCFM session.
40934145|NCT05596123|BEHAVIORAL|Placebo massage|The same therapist will give six weekly 25-minute placebo massage sessions to participants in the placebo massage group. These sessions will include assessing the affected extremity's legs and toes for lesions and broken skin in order to avoid them during the massage, as well as gentle foot and toe rubbing without any point stimulation or other TCFM techniques.
40934146|NCT03383705|DEVICE|VBeam Prima|Up to four treatments will be performed every 4-6 (±1) weeks.
40934147|NCT01010139|DRUG|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
40934148|NCT06516367|OTHER|Ain Shams University Screening Tool for Malnutrition, Sarcopenia, and Cachexia (ASUST-MSC)|25 items dichotomous questionnaire
40934149|NCT03843242|DEVICE|Pacemaker with Fixed long AV delay|Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.
41279446|NCT05695547|OTHER|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
41449981|NCT06108557|DIAGNOSTIC_TEST|Diagnostic Test: Serum pseudocholinesterase enzyme level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
40934150|NCT03843242|DEVICE|Pacemaker with VpS® algorithm on|"1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
40934151|NCT03843242|DEVICE|Pacemaker with IRSplus algorithm on|"1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
40934152|NCT00207571|BEHAVIORAL|Computer|
40934153|NCT02272387|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|
40934154|NCT02272387|OTHER|Placebo|
40934155|NCT02551250|DEVICE|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
40934156|NCT02551250|DEVICE|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
40934157|NCT04195737|PROCEDURE|Ossix volumax collagen matrix|Under LA horizontal incision is made.Split-full-split thickness flap is elevated.The remaining soft tissue of the anatomic interdental papillae deepithelialized.Coronal advancement of the flap obtained and closed using sling suture.
40934158|NCT04195737|PROCEDURE|Connective Tissue Graft|Under LA parallel incisions is made 1-2 mm first molar to canine.Graft incision 1 mm coronal to the horizontal flap incision.Through this incision designed graft thickness is obtained.The graft obtained between the two horizontal incisions has a 1 mm coronal strip that require depithelisation with a knife and closed using interrupted suture.
40934159|NCT06151184|PROCEDURE|Chiropractic adjustment|6 weeks of chiropractic care, with frequency and type of procedures determined by field clinician after initial examination.
40934160|NCT01690338|DRUG|Vecuronium Bromide|Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
40934161|NCT01690338|DRUG|Rocuronium|Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
40934162|NCT01690338|DRUG|Cisatracurium|Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
40934163|NCT02233946|BEHAVIORAL|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
40934164|NCT03490279|DIETARY_SUPPLEMENT|Lactoferrin CRX|Patients will be asked to take lactoferrin CRX as already mentioned (blindly).
40934165|NCT03490279|OTHER|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
40934166|NCT01232218|OTHER|Standard education/exercises for hemiplegic shoulder pain|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.
40934167|NCT01232218|OTHER|Three dimensional Scapular-Humeral Mobilizations|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
40934168|NCT01856023|DRUG|High Dose Interleukin-2|
40934169|NCT01856023|DRUG|Ipilimumab|
40934170|NCT04163731|OTHER|DASI questionnaire|All patients who accept to participate will undergo a self-questionnaire of 10 minutes. Medical data of their cardiac stress test and risk factor will be collected.
40934171|NCT01791556|OTHER|HIV-1 viral load testing|
40934172|NCT00208182|DRUG|Risperidone|
40934173|NCT05680740|DRUG|VTAMA® (tapinarof) Cream 1%|VTAMA® (tapinarof) Cream 1% applied topically once daily
40934174|NCT01727700|DRUG|Aripiprazole|Once-daily, tablet
40934175|NCT01727700|DRUG|Placebo|
40934176|NCT00252629|OTHER|Nasal CPAP treatment during sleep|After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
40934177|NCT00437970|DRUG|Pioglitazone|15mg of Pioglitazone taken orally twice a day
40934178|NCT00437970|DRUG|Metformin|500 mg of Metformin taken orally twice a day
40934179|NCT05478954|DRUG|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
40934180|NCT05478954|DRUG|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect. Adverse effect of amodiaquine includes abdominal discomfort and vomiting weakness and when used for prophylaxis it causes agranulocytosis. Amodiaquine is recommended as a partner drug in artemisinin based combination therapy."
41129834|NCT02933294|PROCEDURE|Triportal pulmonary resection surgery|Uniportal video-assisted thoracoscopic surgery
40934181|NCT02469038|DEVICE|AccuCath catheter|Ultrasound-guided insertion of an AccuCath catheter during a standard of care procedure.
40934182|NCT02469038|DEVICE|Control|Ultrasound-guided insertion of a conventional IV catheter during a standard of care procedure.
40934183|NCT05368454|BEHAVIORAL|Online Diabetes Self-Management Education and Support (DSMES) Program|An online program for Diabetes Self-Management, Education and Support (DSMES) that includes personal coaching by a certified Diabetes Care and Education Specialist (CDCES), tracking tools, and FreeStyle Libre CGMs, a wearable sensor with data scanning ability accessed through the smartphone app.
41129835|NCT02933294|PROCEDURE|Uniportal pulmonary resection surgery|Triportal video-assisted thoracoscopic surgery
41129836|NCT06161987|BEHAVIORAL|Early comprehensive rehabilitation|Patients randomized to the rehabilitation intervention group will be offered comprehensive rehabilitation plan containing 18 sessions of a structured outpatient-based exercise program over 6 weeks (3 times per week).
41129837|NCT05340452|DRUG|Klaribact 125mg/5ml Suspension|one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
40934184|NCT05368454|BEHAVIORAL|Standard of Care|All participants randomized to the standard of care/control arm will be asked to continue with their current care plan and care team for management of their diabetes.
40934185|NCT04176887|DRUG|Levetiracetam Injection|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
40934186|NCT04176887|DRUG|Phenytoin Injection|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
40934187|NCT00612898|DRUG|apricitabine|800mg BID apricitabine orally for 48 weeks
40934188|NCT00612898|DRUG|lamivudine|150mg BID lamivudine orally for 48 weeks
40934189|NCT01097798|DRUG|Aliviador|The study medication should be applied regimen of 8/8 hours over 2 days.
40934190|NCT01097798|DRUG|Gelol|The study medication should be applied regimen of 8/8 hours over 2 days.
40934191|NCT05868720|DRUG|Risperidone, Aripiprazole|The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.
40934192|NCT02531243|BEHAVIORAL|CALMS|Family Therapy; Multi-user Biofeedback Videogames
40934193|NCT04509739|BEHAVIORAL|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
40934194|NCT00146588|DRUG|Cyclophosphamide|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
40934195|NCT00146588|DRUG|Epirubicin|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
40934196|NCT00146588|DRUG|Capecitabine|Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
40934197|NCT06515067|OTHER|back massage|back massage
40934198|NCT06515067|OTHER|no ıntervention|no ıntervention
40934199|NCT02153710|BEHAVIORAL|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
40934200|NCT02153710|BEHAVIORAL|Phonomotor Therapy|Experimental therapy.
40934201|NCT04644783|DIAGNOSTIC_TEST|Blood test assay|Participants will have their blood drawn and be evaluated with a new blood assay that screens a large number of foods (more than 20) in a culture plate. Participants will be asked to eat the identified safe foods by the the blood assay.
40934202|NCT01633580|DRUG|corifollitropin alfa|long acting FSH
40934203|NCT04969796|OTHER|REACH Hope|REACH VA (Resources for Enhancing All Caregivers Health in Department of Veterans Affairs) and the DoD's Virtual Hope Box. For REACH Hope, as the caregiver and interventionist work on strategies one-on-one, these will be integrated into the Hope Box for the caregiver to use between and after sessions.
40934204|NCT01083927|PROCEDURE|Rotational Narrow Strip Conjunctival Graft|Surgical technique
40934205|NCT01083927|PROCEDURE|Full Conjunctival Graft|Surgical technique
41129838|NCT05340452|DRUG|Klaricid 125mg/5ml Suspension|one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
41129839|NCT02273999|DEVICE|RecoveryRx™|Appliance of the device after surgery
40934206|NCT00057122|DRUG|Isoniazid|300mg
40934207|NCT00057122|DRUG|Rifapentine|Rifapentine 900 mg
40934208|NCT00057122|DRUG|Rifampin|Rifampin 600 mg
40934209|NCT03520244|BEHAVIORAL|Exercise + Holistic Education|The exercise group will undertake a 12-week supervised progressive high intensity interval training program supplemented with 6 bi-weekly group-based holistic education sessions.
40934210|NCT02545231|DRUG|Pitavastatin 1mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
40934211|NCT02545231|DRUG|Pitavastatin 4mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
40934212|NCT02545231|DRUG|Placebo|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
40934213|NCT03498664|DEVICE|cap for mucosectomy|endoscopic mucosal resection of colonic lesions with a plastic cap for mucosectomy
40934214|NCT03498664|DEVICE|standard snare for polypectomy|endoscopic mucosal resection of colonic lesions with standard inject and cut mucosectomy
41129840|NCT06321952|DEVICE|ROSA robotic assist TKA|total knee replacement with ROSA robotic assist
41129841|NCT06321952|PROCEDURE|iassist TKA|total knee replacement with iassist
41129842|NCT00603954|DRUG|Conditioning regimen: TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
41129843|NCT00603954|DRUG|Conditioning regimen:TLI (8 Gy) + ATG|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
41129844|NCT01203293|BEHAVIORAL|Cognitive behavior based therapy|15-20 individual psychotherapy sessions
41279447|NCT02091440|DEVICE|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
40934215|NCT00558779|PROCEDURE|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
40934216|NCT00558779|PROCEDURE|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
40934217|NCT03729687|COMBINATION_PRODUCT|radiotherapy, capecitabine, oxaliplatin|5x5 Gy radiotherapy in 1 week, 4 cycles of CAPOX (capecitabine 1000 mg/m2 x2 d 1-14, oxaliplatin 130 mg/m2 d 1 every third week), surgery
40934218|NCT04661020|DRUG|CD19 CAR-T cells|Each subject receive CD19 CAR T-cells by intravenous infusion
40934219|NCT04307875|DIAGNOSTIC_TEST|Blood pressure measurement (sphygmomanometer)|measuring blood pressure with standard sphygmomanometer
40934220|NCT04307875|DIAGNOSTIC_TEST|Blood glucose measurement|measuring blood glucose using standard measurement devices
40934221|NCT04307875|OTHER|psychometric tests|WHODAS 2.0, PHQ-9, CAPS-5
40934222|NCT05260346|DIETARY_SUPPLEMENT|Cranberry juice|composition: Water, cranberry juice concentrate
41129845|NCT01203293|BEHAVIORAL|Treatment as usual|Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
41129846|NCT04492475|DRUG|Interferon beta-1a|Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.
41129847|NCT04492475|OTHER|Placebo|The interferon beta-1a placebo contains either 0.5 mL 0.9% normal saline or 0.5 mL sterile water for injection.
41129848|NCT04492475|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
41129849|NCT03148652|OTHER|Enhanced Intervention Condition|The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.
41279448|NCT03406962|DRUG|MGTA-456|Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.
41279449|NCT02762058|DEVICE|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy system using occulus rift as virtual headset and kinect as motion tracking sensor.
41279450|NCT02762058|PROCEDURE|Traditional Mirror Therapy|Traditional Mirror Therapy system consisting of a mirror in which patients view their healthy limb over the affected to trick brain during dual motion tasks. This therapy has been shown to improve upper extremity function in patients with acquired brain injury.
41279451|NCT01088425|OTHER|Observation|"Alberta infant motor scale~Griffiths test~Kauffmann ABC"
40934223|NCT05260346|DIETARY_SUPPLEMENT|Placebo|composition: Water, dextrose, citric acid, malic acid, fumaric acid, colorants, xanthan gum, natural flavor, emulsion
40934224|NCT03169751|DEVICE|Brain Sentinel Monitoring and Alerting System|The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
40934225|NCT03800303|BEHAVIORAL|Family-based treatment|2-week family-based treatment
40934226|NCT06143605|PROCEDURE|salvage treatment|salvage radical surgery or endoscopic resection
40934227|NCT03923478|DRUG|ABI-M201|Active Treatment
40934228|NCT03923478|DRUG|Placebo|Control Treatment
40934229|NCT04198818|DRUG|HH2710|HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
40934230|NCT04213573|DRUG|silver diamine fluoride|38% silver diamine fluoride liquid will be applied with a brush
40934231|NCT04213573|DRUG|MI Varnish|topical fluoride varnish with calcium and phosphate
40934232|NCT05276648|DIAGNOSTIC_TEST|CAM ICU test|CAM ICU for delirium
40934233|NCT05276648|DIAGNOSTIC_TEST|MOCA test|MOCA for cognitif disfonction
40934234|NCT05276648|DIAGNOSTIC_TEST|brief pain test|BRİEF PAİN for chronic pain
40934235|NCT05276648|DIAGNOSTIC_TEST|VAS scale|VAS scale for acute pain
40934236|NCT02670213|DRUG|recombinant factor XIII|No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.
40934237|NCT02313454|DEVICE|Intranasal Tear Neurostimulator|Neurostimulation applied intranasally and extranasally.
40934238|NCT05521776|PROCEDURE|First-trimester preeclampsia screening (FMF triple test)|"An algorithm assessing the risk of developing preeclampsia combining maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentrations.~For women in the screening group, a Doppler study of the uterine arteries and a blood test to quantify PlGF concentrations will be performed within 2 days of randomization, allowing the risk to be calculated according to the screening test. For women with a positive screening test (i.e. predicted risk\> 1/100), a treatment with aspirin will be prescribed at 160 mg/day, started as soon as possible and before 15 WG, and taken up to 36 WG, in the absence of contraindications. For women with negative screening, usual pregnancy monitoring without aspirin will be offered."
40934239|NCT03583242|DRUG|Antiangiogenic Agents|3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
40934240|NCT03583242|DRUG|Corticosteroid|1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
40934241|NCT01234818|DEVICE|Mirena (LNG-IUS)|* General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
40934242|NCT03103061|DRUG|Lexiscan|Coronary vasodilator
40934243|NCT04128332|RADIATION|Pre-operative stereotactic ablative body radiotherapy|Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
40934244|NCT00148551|DRUG|Triamcinolone Acetonide|
40934245|NCT00510952|DRUG|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
40934246|NCT00510952|DRUG|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
40934247|NCT03825471|PROCEDURE|electrotherapy|Cranial electrotherapy stimulation
40934248|NCT03825471|DRUG|Opioid Anesthetics|consumption of opioids during general anesthesia
40934249|NCT03825471|PROCEDURE|colon cancer surgery|laparoscopic colon cancer surgery
40934250|NCT06345664|OTHER|Diagnostics and intervention recommendations|All families get the same diagnostics and receive individual treatment recommendations.
40934251|NCT01795066|DEVICE|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
40934252|NCT01843478|OTHER|Self-Collected HPV Test|The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
41129850|NCT00710294|DEVICE|CVRx Rheos Baroreflex Hypertension Therapy System|"The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.~Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator."
41129851|NCT04720794|DEVICE|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
41129852|NCT05412017|DIAGNOSTIC_TEST|Hepatitis C Point of Care Testing and Treatment|Pharmacy led hepatitis C point of care testing
40934253|NCT01843478|OTHER|Usual Care|
40934254|NCT00081965|PROCEDURE|acupuncture therapy|
40934255|NCT00081965|PROCEDURE|hot flashes attenuation|
40934256|NCT00081965|PROCEDURE|management of therapy complications|
40934257|NCT02569827|DRUG|Celgosivir|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
40934258|NCT02569827|DRUG|Modipafant 50mg|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
40934259|NCT02569827|DRUG|Placebo|Placebo Q6H for 5 days
40934260|NCT02569827|DRUG|Modipafant 100mg|Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
40934261|NCT01347580|DRUG|Ticagrelor|Oral Ticagrelor loading dose (180 mg) followed by matching placebo
40934262|NCT01347580|DRUG|Placebo|Placebo followed by oral Ticagrelor loading dose (180 mg)
40934263|NCT02599948|OTHER|no intervention|
40934264|NCT02730897|PROCEDURE|Central/Peripheral|Central versus peripheral location of the primary tumor
40934265|NCT01383512|DEVICE|ARMEO Spring|Use of the device 1 hour per day, 5 days per week during 4 weeks
40934266|NCT01383512|OTHER|Self rehabilitation|Subject have to realised alone rehabilitation exercises 1 hour per day, 5 days per week during 4 weeks.
40934267|NCT05783882|DRUG|Prolgolimab|250 mg Q3W
40934268|NCT05034666|BEHAVIORAL|Before the education program|Before applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
40934269|NCT05034666|BEHAVIORAL|After the education program|After applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
40934270|NCT02346578|DRUG|Enzalutamide|
40934271|NCT02346578|DRUG|Flutamide|
40934272|NCT03906188|OTHER|LitEmotion|LitEmotion is a serious video game programmed for helping managing emotions. The experimental group will play during 3 weeks while the control group will not play. The sample will play during 21 days, one session daily, around 45 minutes. After the 21 sessions the group will stop playing during 3 weeks. Therefore, the scales are done three times. In the very beginning (before playing), 21 days after playing, and, finally, 21 days no playing.
40934273|NCT05805358|DRUG|Hyperpolarized 13C-Pyruvate injection|DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
40934274|NCT00399672|DRUG|Interferon injections and ribavirin|Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
40934275|NCT00399672|DRUG|Interferon injections and ribavirin|Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
40934276|NCT05962346|DEVICE|BALT GOLDBALL 2 detachable latex ballon|Inflated with fluid in the fetal trachea and provide with the occlusion necessary to promote lung growth.
40934277|NCT05962346|DEVICE|BALTACCIBDPE100 Microcatheter|Used to deliver the detachable balloon
40934278|NCT05962346|DEVICE|Storz fetoscopic operating sheath and miniature telescope/fetoscope|Used to percutaneously enter though the maternal abdominal wall, uterus and into the amniotic cavity, fetal mouth, pharynx, larynx, into the trachea where the delivery catheter will be used to deliver the detachable balloon that will provide with the tracheal occlusion.
40934279|NCT02596750|DEVICE|Microneedle Roller|200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller
40934280|NCT02596750|DEVICE|Sham microneedle Roller|Flat roller without microneedles
40934281|NCT03784287|DRUG|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
40934282|NCT04127812|BEHAVIORAL|Savor the Flavor|A series of five interactive classroom lessons focused on mindfulness in eating.
40934283|NCT02655393|DIETARY_SUPPLEMENT|Mitopure|
40934284|NCT02889562|DRUG|Apixaban|Study arm that patient can be randomized to. Apixaban is a novel, orally active, potent, direct selective inhibitor of coagulation FXa that directly and reversibly binds to the active site of FXa and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin.
41279452|NCT06322381|PROCEDURE|Reinsertion achilles tendon|Prone position, tourniquet over the thigh, direct midline incision, 2.0 cm proximal the insertion of the Achilles tendon up to 4.0 cm prolonged distal to the insertion is recommended. This is followed by a totally disinsertion of TA. At least a debridement of inflammatory or necrotic tissue as well as the removal of bony tissue is performed. tendon is re-inserted by 2-4 anchors.
41449982|NCT01355835|DEVICE|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
41449983|NCT00595153|DRUG|Pulmicort|inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
40934285|NCT02889562|DRUG|Warfarin|Study arm that patient can be randomized to. Warfarin therapy has been the mainstay of therapy for patients with POAF. While the duration of therapy is usually short (3-4 weeks), complications of anticoagulation do occur. Additionally, warfarin therapy for POAF is associated with increased length of stay, need for monitoring, and bleeding complications.
40934286|NCT01283243|DEVICE|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
40934287|NCT04539587|OTHER|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30 EORTC QLQ-BR23 EORTC SHQ-C22"
40934288|NCT01339026|DRUG|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
40934289|NCT01339026|DRUG|Plavix|Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
40934290|NCT00550251|DEVICE|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
40934291|NCT00550251|DEVICE|Placebo wristbands|Elasticated wrist bands without active bead.
40934292|NCT06309407|DEVICE|Hand Dosimeters|Participants were assigned to wear hand dosimeters in addition to the standard chest dosimeter worn by all participants
40934293|NCT06309407|DEVICE|Standard Practice|Participants only wore standard chest dosimeters
40934294|NCT02978131|OTHER|Histopathological study|
40934295|NCT02978131|OTHER|Molecular study (Polymerase chain reaction)|
40934296|NCT00002083|DRUG|Peptide T|
40934297|NCT05242315|DRUG|Envarsus Oral Product|as described in arm/group description
40934298|NCT05242315|DRUG|Prograf (SOC)|Prograf (SOC)
40934299|NCT01894815|DRUG|Escitalopram oxalate|The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
40934300|NCT01894815|DEVICE|transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
40934301|NCT01894815|OTHER|Sham tDCS + Placebo Pill|This group receives sham tDCS and placebo pill.
41129853|NCT01894217|GENETIC|Genetic testing and reporting for SLCO1B1*5 allele|Blood test for SLCO1B1\*5 allele; reporting of test results to provider and participant
41279453|NCT06322381|PROCEDURE|Zadek osteotomy|lateral position, under spinal anesthesia, tourniquet over the thigh, oblique lateral heel incision starting just anterior to the Achilles tendon, at a 45 angle to the long axis of the calcaneus posterior to the course of the sural nerve. A calcaneal osteotomy was then performed, two Kirschner wires, were then inserted from the posterior aspect of the calcaneus, over which cannulated screws were used for fixation of the osteotomy.
41279454|NCT05909891|OTHER|Patient training|"A training booklet will be created by scanning the literature on iron deficiency anemia. The training booklet will be evaluated in terms of content and readability, according to the DISCERN measurement tool, while obtaining expert opinion.~The training period will be at least 35-40 minutes, taking into account the educational status of the patient and explaining the importance of compliance with the treatment. After the training, when the patients come to the routine check-ups in the 1st and 2nd months, the level of compliance with the treatment and the fatigue of the patients will be evaluated."
41279455|NCT02111811|OTHER|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
41129854|NCT01596413|DRUG|Sancuso|granisetron transdermal system
41129855|NCT01596413|DRUG|IV granisetron|IV
41279456|NCT01133743|DRUG|Lenalidomide and Dexamethasone|Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
41279457|NCT06234904|BIOLOGICAL|IBR733 Cell Injection|The minimum initial dose is 5.0×10\^9 cells and then escalate to 7.5×10\^9 cells and 10.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
41279458|NCT05060861|OTHER|ChAdOx1 nCoV-19 vaccine|covid-19 vaccine
41279459|NCT05098184|BIOLOGICAL|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
41279460|NCT00445783|GENETIC|gene expression analysis|
41279461|NCT00445783|GENETIC|mutation analysis|
41279462|NCT00445783|OTHER|immunohistochemistry staining method|
41279463|NCT00445783|OTHER|laboratory biomarker analysis|
41279464|NCT00445783|PROCEDURE|examination|
41279465|NCT00445783|PROCEDURE|mutation carrier screening|
41279466|NCT00445783|PROCEDURE|study of high risk factors|
41279467|NCT04898114|DRUG|Magnesium sulfate|Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
40934302|NCT01276197|OTHER|Story-Telling DVD|DVD will contain both informational and story-telling components.
40934303|NCT01276197|OTHER|Non-Storytelling DVD|DVD will contain only informational component.
41129856|NCT04595305|DEVICE|Cardiac resynchronization therapy by CRT-P or CRT-D implantation|Clinically indicated implantation of a CRT-P or CRT-D device as per standard of care
41129857|NCT02741505|DEVICE|Actigraph|Participants will be asked to wear an actigraph
41129858|NCT05271994|PROCEDURE|endoscopic biliary drainage|endoscopic biliary drainage
41129859|NCT02426255|OTHER|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
41129860|NCT00081913|GENETIC|Cell Therapy - Autologous CD34 Positive Cells|
41129861|NCT04359017|DRUG|Lidocaine 1% Injectable Solution|The lidocaine will be injected into the fracture hematoma using buffered 1% lidocaine solution at a dose of 2.5 mg/kg (0.25 mL/kg), maximum dose 100 mg (10 mL). Using a 30-gauge needle to minimize pain, a small skin wheal of lidocaine will be injected over the fracture site. A 21-gauge needle will then be attached to the lidocaine filled syringe and passed through the skin wheal used to inject the lidocaine into the fracture hematoma. To confirm the needle is in the fracture hematoma, a small amount of blood from the hematoma will be aspirated into the syringe filled with lidocaine before injecting the lidocaine, as in standard practice.
41129862|NCT02246075|DRUG|EVP-6124|
41129863|NCT05917275|DRUG|Amlodipine|4 weeks of Amlodipine
41129864|NCT05917275|DRUG|Olmesartan|4 weeks of Olmesartan
41129865|NCT05917275|DRUG|Hydrochlorothiazide|4 weeks of Hydrochlorothiazide
41279468|NCT04898114|DRUG|Sildenafil Citrate|Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
41449984|NCT03210363|OTHER|Human Biological samples|Blood sample
41279469|NCT04898114|OTHER|Isotonic saline|Nebulized isotonic saline (4 ml) every 15 minutes
41279470|NCT03455543|DEVICE|Active Provant Therapy System|Treatment with active Provant Therapy System
41279471|NCT03455543|DEVICE|Inactive (sham) Provant Therapy System|Treatment with inactive Provant Therapy System
41279472|NCT06184438|DRUG|Micronized purified flavonoid fraction(Daflon 1000mg)|Received Micronized purified flavonoid fraction(Daflon 1000mg) BID after surgery from day to day 7
41279473|NCT06184438|DRUG|Placebo|Received placebo after surgery.
41279474|NCT06042140|DEVICE|NEOX Cord 1K applied fetoscopically|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (human umbilical cord) will be used for skin closure at the discretion of the Pediatric Neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
41279475|NCT06189820|DIAGNOSTIC_TEST|FAPI PET/CT|"In the department of Nuclear Medicine:~* Installation in a relax chair after weight and height control~* Placement of a venous line in the upper limb after which an infusion of 500ml of 0.9% NaCl is started.~* Intravenous injection of 3 MBq/kg (max 300 MBq) of 18F- FAPI 74 or of 2 MBq/kg 68Ga-FAPI46"
41279476|NCT01140087|PROCEDURE|Face Transplant|Transplantation of donor facial skin, tissue, muscle, and bone as needed
41129866|NCT05917275|DRUG|Amlodipine/Olmesartan|4 weeks of Amlodipine/Olmesartan
41279477|NCT06340711|DRUG|OBP-301|2×10(12) viral particles per injection given intratumorally every 2 weeks for a total of 4 injections starting on Day 1 of the study
41279478|NCT06340711|DRUG|Pembrolizumab|400 mg IV given every 6 weeks starting on day 4 of the study and given for up to 2 years
41279479|NCT04049279|PROCEDURE|BiMobile standard cement|BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
41279480|NCT04049279|PROCEDURE|BiMobile larger cement|BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
41279481|NCT04049279|PROCEDURE|Avantage standard cement|Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
41279482|NCT01978561|BIOLOGICAL|Post dosing with NT100|
41129867|NCT01023542|DRUG|delayed, low-dose CNI|immunosuppression
41129868|NCT01023542|DRUG|BU-CNI|Immunosuppression
41129869|NCT01023542|DRUG|BU-Everolimus|Immunosuppression
41129870|NCT04041219|DRUG|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.
41129871|NCT04041219|DRUG|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses
41129872|NCT05467813|OTHER|mirror therapy|The mirror therapy (MT) will be done with participants seated at a table. The affected upper-extremity (UE) will be placed behind the mirror and the unaffected UE in front of the mirror. Participants will be asked to do the same movements using both the unaffected and affected UE as possible. Each participant will practice two different MT protocols: unilateral mirror therapy (UMT) and bilateral mirror therapy (BMT). During UMT, the affected hand is static, while during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements, fine motor movements, and object manipulation.
41129873|NCT05467813|OTHER|augmented reality (AR)|The training program provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. To ensure safety, the investigators will place a handrail in front of the participant for support. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg), activities of daily living training (i.e., reaching), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
41129874|NCT05467813|OTHER|control therapy|The control intervention will include practice of upper limb activities, balance activities, activities of daily living, and cognitive enhancement tasks. The protocols of the conventional therapy will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their prioritized goals. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
41279483|NCT01978561|OTHER|Post dosing with Placebo|
41279484|NCT03547050|OTHER|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
41279485|NCT03547050|OTHER|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
41279486|NCT02284724|PROCEDURE|Dry Needling|
41279487|NCT02284724|PROCEDURE|Sham Needling|
41279488|NCT04938856|DRUG|Lamotrigine tablet|Lamotrigine 100 mg immediate release Tablet
41449985|NCT04599842|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block is performed by giving local anesthetic to the plan between the erector spinae muscle and the transverse process.
40934304|NCT05214846|BEHAVIORAL|Education and counseling|After obtaining informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher.The experimental group was given a telephone number where they could receive consultancy services for 12 hours a day. Pre-test was applied. One day later, the pregnant woman was called and encouraged to call for all her questions, and she was informed that she would be returned when she called.
40934305|NCT05435040|DEVICE|proprioceptive knee brace|the patient will perform the tests with the knee brace
40934306|NCT05435040|DEVICE|No knee brace|the patient will perform the tests without the knee brace
40934307|NCT00708071|BIOLOGICAL|Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)|Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
40934308|NCT01185431|DIETARY_SUPPLEMENT|Ficus carica (Fig paste)|Ficus carica paste 300g/day
40934309|NCT01185431|DIETARY_SUPPLEMENT|Placebo (Placebo paste)|Placebo composition 300g/day
40934310|NCT03152422|DIAGNOSTIC_TEST|Urinary proteomics|Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant
40934311|NCT02825407|DIETARY_SUPPLEMENT|Oral physiology|
40934312|NCT00003184|BIOLOGICAL|BCG vaccine|
40934313|NCT00003184|BIOLOGICAL|CD80 breast cancer vaccine|
40934314|NCT00003184|BIOLOGICAL|sargramostim|
40934315|NCT00842452|DRUG|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
40934316|NCT00842452|OTHER|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
40934317|NCT05386628|OTHER|conventional physiotherapy|"A basic physiotherapy program consisting of shoulder exercises will be applied to the participants.~content of the physiotherapy program~* Shoulder passive/active abduction, flexion, internal and external rotation exercises~* Posture exercises~* Neck stretching exercises~* Pectoralis major stretching exercises~* Shoulder capsule stretching exercises~* Scapular Mobilization exercises"
41129875|NCT00215787|DRUG|lansoprazole|Lansoprazole 30 mg BID for 1 year
41279489|NCT02095561|OTHER|HPV self testing|Community Health Workers instructed women about cervical cancer and HPV testing, advised them on how to seek screening at health centers, and offered them the option of self-testing, providing women with educational materials on how to perform it.
41279490|NCT05248997|DRUG|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
41279491|NCT05248997|DRUG|Matching placebo|One dose of matching placebo
41279492|NCT00668005|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
41279493|NCT00668005|DRUG|Placebo|Matching placebo
41279494|NCT00957853|DRUG|Cetuximab|First dose of 400 mg/m\^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m\^2 on week 2 and 3 (if applicable) given over 1 hour.
40934318|NCT05386628|OTHER|Manual lymphatic drainage|manual lymph drainage is a manual technique that is applied to the lymphatic system with a pressure of 40-50 mmHg and increases the working speed of lymphatic nodules/collectors. Manual lymph drainage will be made to the anterior axillar-axillar, posterior axillar-axillar and axilla-inguinal anastomosis collectors and the arm region (up to the elbow) lymph collectors.
40934319|NCT05386628|OTHER|Myofascial relasing|it will be done with the thumb or 3rd finger from the acu points of the superficial arm-anterior myofascial chain. 6-8 seconds with thumb to these points. pressure will be applied and vibration will be given clockwise.
40934320|NCT02829944|DRUG|Ropivacaine|
40934321|NCT02829944|DRUG|Ketorolac|
40934322|NCT02829944|DRUG|Placebo|
41279495|NCT00957853|DRUG|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
41279496|NCT00957853|PROCEDURE|Surgical tumor resection|Surgical tumor resection on Day 10.
40755722|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with mesh endoprosthesis|A mesh allograft with an adhesive coating is inserted into the bottom of the wound, positioned horizontally between the inner surfaces of the ischial bones and vertically between the sacrum and the vagina in women or between the sacrum and the prostate gland in men. The mesh was sewn from behind on both sides of the coccyx or sacrum. From the side, the mesh was attached to the remainder of the levator muscle and from the front to the transverse muscles of the perineum. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon. The sciatic-anal and subcutaneous fat are sutured using nodular sutures.
40934323|NCT03371771|BEHAVIORAL|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
40934324|NCT03371771|BEHAVIORAL|MSW-delivered Behavioral Activation|Behavioral Activation as delivered by trained MSWs
40934325|NCT00904410|OTHER|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
40934326|NCT00371761|BIOLOGICAL|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
41279497|NCT02473796|OTHER|Home based child care|HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight \<2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term \& weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
40934327|NCT00371761|DRUG|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
40934328|NCT03794960|BIOLOGICAL|TOL-3021|A plasmid expression vector containing the coding sequences for full-length human proinsulin.
40934329|NCT03794960|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
41129876|NCT04132141|OTHER|Virtual Reality Headset with curated content|clinicians will wear VR immersive headset for up to 15 minutes during their break
41279498|NCT05299892|DEVICE|Phonak Audeo P or Naida P hearing aid|"Commercially available hearing aid that has access to speech enhancer feature settings off, moderate and strong"
41279499|NCT05159193|DRUG|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m\^2, i.v., d1, q3w
41279500|NCT05159193|DRUG|cyclophosphamide (C)|cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q3w
40755723|NCT01561612|BEHAVIORAL|Breastfeeding promotion and support|Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
40755724|NCT03724097|OTHER|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
40755725|NCT03724097|OTHER|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
40934330|NCT00973570|BEHAVIORAL|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
40934331|NCT03348384|RADIATION|[C-11]|Radiolabel
40934332|NCT03348384|DRUG|NOP-1A|Tracer
40934333|NCT03276273|DEVICE|recording of Bispectral Index|recording of Bispectral Index
40934334|NCT03735173|PROCEDURE|ReUnion TSA, pegged design|ReUnion total shoulder arthroplasty system, pegged design
40934335|NCT03735173|PROCEDURE|ReUnion TSA, keeled design|ReUnion total shoulder arthroplasty system, keeled design
40934336|NCT00171678|DRUG|Diclofenac Topical Sodium Gel 1%|
40934337|NCT03981302|OTHER|Family nursing conversations|"The intervention is based on the concept family systems nursing developed by Wright \& Maureen. Family nursing aims to change restricting beliefs and alleviate illness suffering. The Illness Beliefs model and Calgarymodels are essential components. The illness beliefs model illuminates the family's different beliefs about their problems. The Calgary models consist of the Calgary family assessment model and the Calgary intervention model and aim to support change and help the family to find new ways to handle the illness. The use of the components cannot be standardised but must be tailored to match the needs of the specific family. The family nursing conversations in this intervention will last 1,5 hour. Every family will be offered three family nursing conversations with roughly three weeks interval. If the family after three conversations express a need for follow-up, they will be offered the fourth conversation."
40934338|NCT01298193|DRUG|Aprepitant|Efficacy phase (second cycle)
40934339|NCT03648385|DRUG|DHEA tablet|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.
40934340|NCT03648385|OTHER|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
40934341|NCT00660556|DEVICE|Archimedes Constant Flow Pump & System|Pump implanted in abdomen with intrathecal delivery (catheter) for pain.
40934342|NCT05753397|DRUG|Ropivacaine injection|We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)
40934343|NCT00358072|BEHAVIORAL|Postremission consolidation based on MRD status|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
40934344|NCT06468202|DRUG|Aspirin 81 mg|Participants will be assigned to 81mg Aspirin
40934345|NCT06468202|DRUG|Aspirin 162 mg|Participants will be assigned to 162mg Aspirin
40934346|NCT03031327|DEVICE|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
40934347|NCT03031327|DEVICE|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
40934348|NCT03031327|DEVICE|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
40934349|NCT01028378|DEVICE|T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser|
40934350|NCT03174899|RADIATION|Diffusion weighted magnetic resonance imaging|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient.
40934351|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
40934352|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
40934353|NCT00517803|DIETARY_SUPPLEMENT|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
40934354|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
40934355|NCT06070571|DRUG|Yarrow and moringa mixture|yarrow and moringa mixture nano particles loaded on buccal film
40934356|NCT03949907|OTHER|Nutritional counseling alone|"Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered.~In the presence of body weight loss \>10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition."
40934357|NCT03949907|OTHER|Early supplemental parenteral nutrition plus nutritional counseling|"Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.~Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated."
40755726|NCT03724097|DRUG|target drug with the score above 0,1|target drug with the score above 0,1
41279501|NCT05159193|DRUG|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
41279502|NCT05159193|DRUG|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
41449986|NCT05945472|OTHER|Positive reinforcement method|"A 30-minute talk based on mindfulness, positive thinking and teaching for the application of the cosmetic through positive messages (Ayuna method). Adapts the teachings of mindfulness to the field of beauty and stimulates the skin-brain connection through self-care. By applying cosmetics through intentional massages, with this technique is stimulated the brain in a positive positively in the general wellbeing.~The cosmetic is applied with a massage aimed at loving oneself, a ceremony for the skin and an invitation to enjoy the moment; positive messages are included during the application. In addition to favoring the penetration of the products, these maneuvers help to disconnect and achieve, in the long term, a healthier appearance. The technique consists of slow, intentional movements to create an ideal space to become aware of the present moment and draw a love story with oneself."
41449987|NCT05945472|OTHER|Standard method|"A 30-minute talk based on how to administer it according to the guidelines of general cosmetology, related to the use and application of the cream, following conventional techniques of the cosmetic industry, which focus on the application of the product in the areas of wrinkles or with more treatment needs: anti-aging anti-stain anti-sagging anti-sagging product, anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging product. rejuvenating results to try to reduce the skin years, reduce wrinkles, loss of firmness, flaccidity and spots."
41279503|NCT05159193|DRUG|docetaxel (T)|docetaxel (T) 90\~100 mg/m\^2, i.v., d1, q3w
41279504|NCT05159193|DRUG|docetaxel (T)|docetaxel (T) 75 mg/m\^2, i.v., d1, q3w
41279505|NCT05159193|DRUG|carboplatin (Cb)|carboplatin (Cb) AUC 6, i.v., d1, q3w
41449988|NCT05614453|DRUG|Tislelizumab|Tislelizumab is an investigational, humanised-IgG4 monoclonal antibody with high affinity/binding specificity for PD-1. It is engineered to minimise binding to FcγR on macrophages to abrogate antibody-dependent cellular phagocytosis.
41449989|NCT05614453|DRUG|Sitravatinib|Sitravatinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential anti-neoplastic activity.
41449990|NCT03749707|DIAGNOSTIC_TEST|HPV analysis|HPV analysis of SLNs
41449991|NCT02741895|BEHAVIORAL|Fitbit monitoring|Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
41449992|NCT03366428|DRUG|DS-8201a|DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion
41449993|NCT02654145|DRUG|Mepolizumab 100mg SC|At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
41449994|NCT02654145|DRUG|Albuterol/salbutamol MDIs|Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
41449995|NCT02654145|DRUG|Omalizumab|Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
41449996|NCT02927210|DRUG|Dimethandrolone Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
40934358|NCT04415060|DRUG|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
40934359|NCT04415060|DRUG|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
41279506|NCT05159193|DRUG|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
41279507|NCT05159193|DRUG|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
41449997|NCT02927210|DRUG|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
41449998|NCT00876265|DEVICE|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
40755727|NCT03724097|DRUG|target drug with the score equal or below 0,1|target drug with the score equal or below 0,1
40755728|NCT03724097|DRUG|non-target drug|non-target drug
40755729|NCT03724097|DRUG|palliative care|palliative care
40934360|NCT04581447|DRUG|Metformin|Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily
40934361|NCT04581447|OTHER|Standard Care|Standard Care
40934362|NCT04581447|DIETARY_SUPPLEMENT|Standardized meal|Measurements of metformin-induced enterohormones secretion will be done after standardized meal test in a subgroup of patients (ancillary study)
40934363|NCT00225043|DRUG|Epinephrine/phenylephrine|
40934364|NCT05314491|DEVICE|Multigen Plus CCK|Total Knee Arthroplasty
41279508|NCT02782715|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will be treated on study with a course of SBRT treatment by a radiation oncologist. Three SBRT dose levels targeting the primary tumor will be evaluated; level I: 6 Gy x 5 fractions (a common palliative dose), level II: 8 Gy x 5 fractions, and level III: 10 Gy x 5 fractions (a common definitive dose).
40934365|NCT05314491|DEVICE|AMF TT cones|To fill a proximal tibia or distal femur defect
40934366|NCT03844477|PROCEDURE|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified."
40934367|NCT03844477|PROCEDURE|Placebo control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified."
40934368|NCT02186366|OTHER|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
40934369|NCT02186366|DRUG|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
40934370|NCT04988633|BEHAVIORAL|Intervention CFG App|Online healthy lifestyle education through an App. The intervention will consist of viewing educational videos on diet and exercise through an App. Videos will be uploaded to the app on a weekly basis, lasting 2-3.
40934371|NCT04988633|BEHAVIORAL|Control Group|Standard tips for healthy lifestyles that are carried out in regular Primary Care practice. After day 1, where standard advice is received, follow-up visits are conducted at week 2, week 4, month 3, and month 6.
40934372|NCT06253676|BEHAVIORAL|Problem Management Plus (PM+)|Validated across multiple low- and middle-income country settings, PM+ is World Health Organization-developed, five-session task-sharing intervention for mild to moderate distress. Per the (manualized) intervention, trained non-specialist providers coach eligible clients to address practical problems and/or distress in their daily lives via the use of fundamental cognitive behavioral strategies (e.g., deep breathing and stress management, behavioral activation, strengthening of social support, etc.).
40934373|NCT00926588|DRUG|Stepped care|Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
40934374|NCT02022774|DRUG|Fimasartan|Fimasartan 60 \~ 120 mg/po take one tablet once a day
40934375|NCT02882373|DIETARY_SUPPLEMENT|Arginine|Given PO
40934376|NCT02882373|DRUG|Placebo|Given PO
40934377|NCT06197425|DRUG|"FOLFIRI cures"|(Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging
40934378|NCT06197425|DRUG|Trifluridine cures|Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging
40934379|NCT06197425|BIOLOGICAL|BIOLOGICAL ASSESSMENT|blood sample ACE markers
40934380|NCT06197425|OTHER|Questionnaires|Quality of life questionnaires (QLQ-C30 ; EQ-5D-5L ; GPAQ)
40934381|NCT06197425|OTHER|Thoracic-abdomino-pelvic scan or MRI|Thoracic-abdomino-pelvic scan or MRI
40934382|NCT04757740|BIOLOGICAL|intra-articular Platelet rich fibrin and lidocaine|intra-articular injection of 3.5 ml of 1% lidocaine and PRF mixture.
40934383|NCT04757740|DRUG|methylprednisolone acetate and lidocaine|intra-articular injection of Mixture of 40 mg of methylprednisolone acetate(1 ml) and 1% lidocaine (2.5 ml). intra-articular steroid
41129877|NCT06075082|DEVICE|LEFT smartwatch app|The LEFT smartwatch app is an app on the Apple Watch which measures body sleep position and gently vibrates when the body is in the right lateral decubitus position. In this way, patients with nocturnal gastroesophageal reflux symptoms learn to avoid the right lateral sleep position as they will avoid the annoying vibrations. Measurements while using the smartwatch app will be compared to measurements at baseline.
41129878|NCT04067219|PROCEDURE|DXA (dual-energy x-ray absorptiometric) measurement|DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).
41449999|NCT00876265|DEVICE|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
41129879|NCT00442637|DRUG|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
40934384|NCT00882492|BIOLOGICAL|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
40934385|NCT00882492|BIOLOGICAL|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
40934386|NCT04218123|DRUG|Venlafaxine|Daily oral intake 37.5 mg
40934387|NCT04218123|DRUG|Placebo oral tablet|Daily oral intake
40934388|NCT03192878|DRUG|Infliximab|infliximab biosimilar
40934389|NCT00210171|PROCEDURE|Toxicity : Time to progression, 1 and 2 years survival|
41129880|NCT00442637|OTHER|observation|observation after induction treatment
41129881|NCT05657821|DIETARY_SUPPLEMENT|Pumpkin seeds extract capsules|the intervention group was given pumpkin seed capsules for 12 weeks, and the intervention group was given iron tablets for 12 weeks
40934390|NCT06066801|PROCEDURE|Bedside blind bone biopsy procedure|It was performed in the patient's room under aseptic conditions. Pain relievers were given orally within the hour preceding the procedure. Superficial anesthesia was performed firstly subcutaneously and then on the periosteum, Inhaled anesthesia was started concomitantly. Following a short incision with a scalpel, the trocar inside a cannula was inserted through healthy skin at a minimum distance of 2 cm from the ulcer edge, close to the bone, preferentially on dorsal foot side. When the trocar was firmly inserted into the bone, it was pulled out from the cannula. Biopsy needle was then slipped into the cannula and twisted into the bone clockwise. Biopsy needle was then pulled out and the bone was pushed out with the ejector pin into a sterile surgical drape and divided in two parts.
40934391|NCT00249288|DRUG|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
40934392|NCT00249288|DRUG|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
40934393|NCT01752712|DRUG|CBSST + Oxytocin|The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
40934394|NCT01752712|DRUG|CBSST + Placebo|Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
40934395|NCT04652596|OTHER|Produce prescription program|A monthly $150 stipend will be provided to participants for 6 consecutive months to purchase fresh food items at mobile markets and independent farmers markets across Boston.
40934396|NCT04652596|OTHER|Grocery store gift cards|A monthly value of $150 in grocery store gift cards redeemable at conventional grocery stores will be provided to participants for 6 consecutive months.
40934397|NCT06356701|DIETARY_SUPPLEMENT|Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules)|"Medication for Research :~* Spirulina Bifidobacterium Capsules~* Fish Oil Grape Seed Blueberry Soft Capsules;~* Ganoderma Lucidum Sporoderm Oil Soft Capsules; oral administration. non-squamous cell carcinoma Drug: Pemetrexed+Cisplatin (or carboplatin)~  * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion squamous cell carcinoma Drug:Paclitaxel+ Cisplatin (or carboplatin)~ * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion"
40934398|NCT06515249|OTHER|Integrative medicine|Integrative medicine treatments including acupuncture, touch, movement, mind-body, as patient\&#39;s and staff\&#39;s choice
40934399|NCT00247533|PROCEDURE|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
40934400|NCT01417182|DRUG|18F-DCFBC|A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
40934401|NCT03654742|PROCEDURE|tonsillectomy|removal of tonsil tissue as described in the study arms
41129882|NCT04786275|DRUG|Fentanyl|Standard dose of 2 ug/kg after tetanic stimulation.
41129883|NCT04786275|OTHER|Tetanic stimulation|Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.
41129884|NCT06359548|PROCEDURE|Peeled ILM Reposition|"The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc) at a point away from the center of MH around one disc diameter in inferior quadrant of macular area. First, a horizontal ILM strip was peeled off with a width approximately 1.5 to 2.5 disc diameter. Then, the edge of the horizontal ILM strip was grasped and peeled from inferior to superior area continuously.Then the ILM roll was flattened back to peeled area assisted with approximately 1.0 mL of PFO (Perfluoron, Alcon Laboratories, Inc). The position of the fixed ILM flap was adjusted under PFO bubble using flute needle or forceps if required."
41129885|NCT06359548|PROCEDURE|ILM Peeling|The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc). The strand of ILM was peeled off radially from the foveal center to the vascular arcade. As a result, a round-shaped, 2.5-disk diameter to 3.5-disk diameter ILM-peeled area was created.
41129886|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)
41129887|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)|Intravenous infusion of autologous T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt
41129888|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (long spacer 2nd generation T cells)
41129889|NCT03088800|DRUG|Ibuprofen|Oral Ibuprofen at 10 mg/kg dose
40934402|NCT04756674|OTHER|No intervetion will be used|No intervention will be used
40934403|NCT05025540|DIAGNOSTIC_TEST|ultrasonic imaging|Two-dimensional ultrasound images of the patient's kidneys were obtained by ultrasound imaging.
40934404|NCT03342300|DRUG|pegylated liposomal doxorubicin|Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
40934405|NCT03342300|DRUG|pirarubicin|Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
40934406|NCT01171170|DRUG|carboplatin paclitaxel bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
40934407|NCT01171170|DRUG|Standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
40934408|NCT04810572|DIETARY_SUPPLEMENT|Composition with Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
40934409|NCT04810572|DIETARY_SUPPLEMENT|Low-mineral composition without Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
40934410|NCT05742347|DEVICE|DriGo Skin Protectant Textile|All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
40934411|NCT06046157|OTHER|Breast milk-scented PIOMI|"During PIOMI, the scent of breast milk will be provided through cotton soaked in breast milk placed 1.5 cm away from the babies.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
40934412|NCT06046157|OTHER|Breast milk-tasting PIOMI|"The finger used during PIOMI application will be performed by dipping it into breast milk. This will ensure that babies taste breast milk.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
40934413|NCT01439347|DRUG|Vincristine Sulfate Liposomes Injection (VSLI)|2.25 mg/m\^2 (without any dose cap) as an IV infusion over 60 minutes.
40934414|NCT01439347|DRUG|Vincristine Sulfate Injection (VSI)|1.4 mg/m\^2 with a 2 mg dose cap as an IV infusion over 10 minutes.
40934415|NCT05769543|PROCEDURE|WATSU application|20-minute application of WATSU
40934416|NCT05769543|OTHER|Lecture|20-minute lecture on WATSU technique
40934417|NCT04254042|DRUG|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
40934418|NCT04254042|DRUG|Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer|30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
40934419|NCT01858636|DEVICE|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
40934420|NCT02803515|BIOLOGICAL|peripheral venous blood samples|peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
40934421|NCT00013195|BEHAVIORAL|Telephone Care|
40934422|NCT03792984|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (Cholecalciferol) (6000 IU/daily). PO for 8 weeks.
40934423|NCT03792984|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate (1000 mg/daily). PO for 8 weeks.
40934424|NCT03792984|DRUG|Metformin|Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.
40934425|NCT03792984|DRUG|Placebo|PO for 8 weeks.
40934426|NCT02123628|DRUG|duration of the antibiotic therapy|
40934427|NCT00746447|DRUG|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
40934428|NCT00746447|DRUG|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
40934429|NCT00746447|DRUG|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
40934430|NCT03988959|PROCEDURE|resection of mucoeidermoid carcinoma|Surgical resection parotid with preservation of facial nerve
40934431|NCT06035055|DRUG|Ceftolozane/tazobactam|9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days
40934432|NCT02979327|DRUG|Adderall capsule|Amphetamine
40934433|NCT02979327|DRUG|Placebo capsule|Placebo capsule
40934434|NCT03173534|DEVICE|WATCHMAN|WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
40934435|NCT03173534|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
40934436|NCT02187874|PROCEDURE|delayed umbilical cord occlusion|
40934437|NCT02187874|PROCEDURE|early umbilical cord occlusion|
40934438|NCT02187874|DRUG|Oxytocin|
40934439|NCT01015001|PROCEDURE|Active rTMS x sham (placebo) rTMS|"Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations."
40934440|NCT01015001|PROCEDURE|sham rTMS|same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
40934441|NCT01015001|PROCEDURE|(1Hz) rTMS applied over the left temporoparietal cortex|20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
40934442|NCT06305871|PROCEDURE|Ablation therapy|Ablative treatment of hyperthyroidism
40934443|NCT01781169|DIETARY_SUPPLEMENT|Oral supplementation of vitamin D|Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.
40934444|NCT01639586|BEHAVIORAL|respite platform|Impact of the respite platform patient care on health profit
40934445|NCT01639586|BEHAVIORAL|Day care|Impact of the day care on health profit of patient
40934446|NCT01639586|BEHAVIORAL|No access to a respite structure|Control group without access to a respite structure
41279509|NCT02782715|PROCEDURE|Microwave Ablation (MWA)|Performed under sedation using ultrasound and computed tomography (CT) guidance for percutaneous antenna placement and confirmation. Depending on size and location of tumor, one to three antennas (Certus 140; NeuWave Medical) will be used. The system is an FDA-approved, high-powered third-generation MW device that uses CO2 gas cooling to prevent shaft heating. The gas cooling allows the probes to be stuck into tissue by creating a small ice ball at the tip using the Joule-Thomson method, similar to the tissue cooling mechanism of cryoablation systems. Probes are 17-gauge, and various ablation zone configurations are available depending on the probe selected. An ablation protocol using the 65W power setting for 5 minutes will be used for most patients. Ultrasound will be used for real-time monitoring of the extent of ablation to achieve a 5mm margin beyond tumor, and immediate post-procedure imaging performed using contrast-enhanced CT (CECT) for patients with adequate renal functions.
41279510|NCT04354454|OTHER|Fitbit|Participants will select a daily step goal and track their steps every day for 4.5 months.
40934447|NCT00278239|PROCEDURE|cognitive assessment|
40934448|NCT00278239|PROCEDURE|psychosocial assessment and care|
40934449|NCT00278239|PROCEDURE|quality-of-life assessment|
40934450|NCT04161300|OTHER|Foam Rolling (FR)|FR auto-massage will place the foam roller between their ischial tuberosity and a hard surface (i.e., the floor) with their legs held in an extended position, keeping their ankles relaxed and oriented upward. For FR in the lumbar region, participants use their weight to slide the FR through the erector of the lumbar and thoracic spine. The total approximate duration will be about 10-15 minutes.
40934451|NCT04161300|OTHER|Control Group (CG)|The CG did not receive any intervention.
40934452|NCT04161300|OTHER|Orthopaedic Manual Physical Therapy Group (OMPT)|Based on the protocol used by Espí-López et al.: a) Unspecific and bilateral lumbar thrust (L5-S1), one of each side were performed; b) Hip joint decompression, performing 25 repetitions c) Hip rotator stretch with hip and knee flexion, 15 repetitions; d) Femorotibial decompression, 25 reps. e) Quadriceps femoral muscle compression and traction, 25 repetitions; f) Opening of the internal and external femorotibial interline, 15 repetition; g) Ankle decompression, 3 repetitions; h) Posteroanterior and anteroposterior mobilization of head and base of fibula, 25 repetitions. The total duration will be approximately 10-15 minutes.
40934453|NCT00134537|DEVICE|Interspinous process and dynamic stabilization|Interspinous process and dynamic stabilization
40934454|NCT00134537|DEVICE|Conservative Care|Medication, exercise and spinal injections
40934455|NCT05776797|PROCEDURE|Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)|Ablation of the atrioventricular (AV) node is a procedure used to disrupt or break the electrical connection between the upper heart chambers (the atria) and the lower heart chambers (the ventricles).
40934456|NCT05776797|DRUG|Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)|Optimal medication therapy according to the prescription of the physician.
40934457|NCT04537260|BEHAVIORAL|Educational Video|Those in the intervention arm were asked to watch the 3-minute educational video prior to the knowledge questionnaire and meeting their provider (midwife or obstetrician). The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8.
40934458|NCT01268683|DRUG|Glyburide for Injection|Administered as specified in the treatment arm.
40934459|NCT03945175|DRUG|MYDAYIS|MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.
40934460|NCT03945175|DRUG|Placebo|During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
40934461|NCT01988480|PROCEDURE|Image-guided surgery|Placement on residual bone around the implant
40934462|NCT01988480|PROCEDURE|Sinus lift surgery|Allograft bone
40934463|NCT01066442|DRUG|BF2.649 (Pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
40934464|NCT00019110|BIOLOGICAL|human papillomavirus 16 E7 peptide|
40934465|NCT00019110|BIOLOGICAL|synthetic human papillomavirus 16 E6 peptide|
40934466|NCT02828891|DEVICE|Two-Dimensional Transcranial Doppler|Transcranial Doppler will be used to measure CSF pressure.
40934467|NCT04733443|DEVICE|Biolimus|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the Biolimus treatment group
40934468|NCT04733443|DEVICE|SeQuent® Please Neo|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the SeQuent® Please Neo treatment group
41129890|NCT03088800|DRUG|APAP|Oral APAP at 15mg/kg dose
40934470|NCT02730208|DRUG|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
40934471|NCT02730208|DRUG|Ivacaftor|IVA 150 mg tablet.
41279511|NCT04354454|OTHER|Fitbit + Game + Support from a Teammate|"Daily Fitbit tracking for 4.5 months, divided into 2 parts.~* 3 months on active intervention with Fitbit, a Game, and Support from a self-selected Teammate and pre-designed game.~* 1.5 month follow-up period with Fitbit and social support teammate only"
41450000|NCT04573569|BEHAVIORAL|Behavioral testing|Patients recruited for this study have already undergone surgical implantation of invasive electrodes for purpose of localizing and characterizing electrographic seizures as part of the second phase of surgical epilepsy evaluation. Patients who consent and complete enrollment will then be asked to complete cognitive and behavioral tasks on a portable computer or tablet PC while the invasive electrodes remain implanted. Tasks typically require the patient to think or act and then respond by interacting minimally with the portable computer. These tasks are performed at the will of each patient during their stay in the intensive care unit while surgical electrodes remain.
40755730|NCT01454063|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
40755731|NCT01454063|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
40755732|NCT05051410|PROCEDURE|intracanal cryotherapy using needle irrigation and EndoVac system|a cold saline will be used as final irrigant in two groups but with different irrigation systems.
40934472|NCT02730208|DRUG|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
40755733|NCT01745302|DRUG|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
40755734|NCT01745302|DRUG|EGFR-TKI|Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
40934473|NCT02730208|DRUG|Placebo|Placebo matched to IVA tablet.
40934474|NCT05451342|DIAGNOSTIC_TEST|Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling|Blood samples and BALD samples will be collected for further integrated transcriptomics, metabolomics, lipidomics analysis, and exosome extraction.
40934475|NCT01987947|DRUG|Placebo|Two administrations by subcutaneous injection
40934476|NCT01987947|DRUG|Quilizumab|Two administrations by subcutaneous injection
40934477|NCT03989726|PROCEDURE|AF ablation|AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
40934478|NCT04130867|PROCEDURE|pHRM|Pharyngeal high--resolution manometry (pHRM) provides direct and objective measurement of pressure changes in the pharynx that characterize basic mechanisms of swallowing.
40934479|NCT04130867|PROCEDURE|VFSS|Videofluoroscopic Swallow Study (VFSS) enables real-time visualization of bolus flow during swallow movement.
40934480|NCT00790257|DEVICE|"Encapsulated human islets in a Monolayer Cellular Device"|"The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation."
40934481|NCT03954327|DRUG|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)|Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
40934482|NCT03954327|DRUG|Raltegravir|Raltegravir (RTF) 600 mg two tablets by mouth once per day
41129891|NCT00860236|OTHER|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
41129892|NCT00860236|BEHAVIORAL|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
41129893|NCT00391898|DRUG|Levodopa/carbidopa/entacapone|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
41129894|NCT00391898|DRUG|Levodopa/carbidopa|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
41279512|NCT02420886|OTHER|Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media|
41279513|NCT02426307|PROCEDURE|TAVR|TAVR: Transcatheter Aortic Valve Replacement
41279514|NCT02426307|PROCEDURE|SAVR|SAVR: surgical Aortic Valve Replacement
41450001|NCT02835222|DRUG|Cytarabine|Given IV
40934483|NCT03954327|DRUG|Placebo Oral Capsule [CEBOCAP]|Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
40934484|NCT03027479|OTHER|Samples|Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample
40934485|NCT03268148|DEVICE|LaserPen|low level laser is used before heel-lancing for newborn screening
40934486|NCT05342532|DRUG|Amoxicillin|1 g
40934487|NCT05342532|DRUG|Omeprazole|40 mg. Patients were asked to take omeprazole one hour prior to food intake, while antibiotics were taken after meals.
40934488|NCT05342532|DRUG|Clarithromycin|500 mg twice daily
41450002|NCT02835222|DRUG|Daunorubicin Hydrochloride|Given IV
40934489|NCT04451642|PROCEDURE|Peripheral nerve block|Peripheral nerve block consists of the administration of a local anaesthetic into the nerves to inhibit nerve transmission in a specific part of the body. Ultrasound or Nerve stimulator could be used to locate the peripheral nerve. A needle is placed through the anatomical references to administer local anaesthetic around the peripheral nerve. Single-shot or continuous blocks are performed preoperatively and postoperatively as current practice in the surgery theatre. Using ultrasound, in-plane or out-plane approach could be performed. Peripheral nerve block provides excellent intraoperative and postoperative analgesia decreasing the need for intravenous pain drugs. Interscalene block, supraclavicular block, safene block, femoral block, BRILMA block are different kinds of peripheral nerve block using in the anaesthestic current practice.
40934490|NCT01497145|DRUG|KRN321|
40934491|NCT00740051|DRUG|Linagliptin|5mg once daily
40934492|NCT00740051|DRUG|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
40934493|NCT00740051|DRUG|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
40934494|NCT04729946|DEVICE|Pure-Vu Cleansing Device|The Pure-Vu device attaches to the colonoscope and provides colonic cleansing during urgent colonoscopy without the need for a bowel preparation
40934495|NCT01712321|DRUG|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth
40934496|NCT01712321|DRUG|Placebo|Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
40934497|NCT05166239|PROCEDURE|HAIC|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
40934498|NCT05166239|DRUG|Lenvatinib 1|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC.
40934499|NCT05166239|DRUG|PD-1 Inhibitors|PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
40934500|NCT05166239|DRUG|Lenvatinib 2|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily.
40934501|NCT05166239|DRUG|PD-1 inhibitors 2|PD-1 inhibitors injection intravenously or percutaneously every 4 week.
40934502|NCT04084678|DRUG|Ralinepag|Oral ralinepag
40934503|NCT04084678|DRUG|Placebo|Matching oral tablets
40934504|NCT00772070|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
40934505|NCT00772070|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
41129895|NCT02438007|DRUG|Galeterone|2550 mg galeterone tablets once daily PO
41129896|NCT02438007|DRUG|Enzalutamide|160 mg enzalutamide capsules once daily PO
41450003|NCT02835222|DRUG|Selinexor|Given PO
41450004|NCT05232539|DEVICE|Intraoperative Optical Coherence Tomography (iOCT)|The use of iOCT during surgery offers the advantage of a new view of the operating field, theoretically allows more precise performance and can also change decision-making mechanisms during surgery with more precise visual control of some surgical steps.
41450005|NCT04544033|DIAGNOSTIC_TEST|interleuken 6 level measurment|Detection of IL6 level using ELISA technique.
40934506|NCT05299788|OTHER|Active external warming|In this study, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for the control group. In addition to the cotton blankets and socks, electric blankets were used for the patients in the intervention group. In accordance with the literature, the temperature of the electric blanket was set at 38 °C (Celsius) at the beginning and increased to a maximum of 40-41 °C based on the patient's body temperature .
40934507|NCT05299788|OTHER|Ice application|In the intervention group, an ice pack was applied to the incision site for pain control in addition to active external warming. Ice packs at 0-5 °C with external dimensions of 160 × 91 × 34 mm and a filled weight of 363 g that were kept in the fridge were used for ice application. To prevent direct contact of the ice pack with the patient's skin, the ice pack was wrapped in a thin cotton sheath.
40934508|NCT05447221|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and pathologists|Pathologists and AI will assess the severity of intestinal metaplasia and judge the tumor area of whole slide images of gastric biopsy specimens independently. In addition, the pathologists can not see the diagnosis of AI.
40934509|NCT05459948|DEVICE|GMK SpheriKA|"The first objective is to study the FJS of patients who were implanted a GMK® SpheriKA knee prosthesis using the kinematic alignment technique"
40934510|NCT04729478|DEVICE|Drug-induced sleep endoscopy|An intravenous bolus injection of midazolam 1.5 mg will be used to induce sleep. Maintenance of sedated sleep will be obtained by a target-controlled infusion of propofol (2.0-3.0 µg/mL).
40934511|NCT04729478|DEVICE|Natural sleep endoscopy|Endoscopy during natural sleep.
40934512|NCT00844168|DRUG|sorafenib tosylate|Given orally
40934513|NCT00844168|OTHER|laboratory biomarker analysis|Correlative studies
40934514|NCT03064581|BEHAVIORAL|Intervention|The educational session consisted of a one-hour small group discussion (5-10 people). Gender-specific community health educators facilitated sessions for Pacific Islander women and for their spouses/significant others that included an educational video and other materials (brochure, calendar, and resource list). The video emphasized the importance of Pap testing for Pacific Islander women, and showed men supporting their women to get tested. Women's sessions provided basic information on cervical cancer and pap testing, and ended with verbal commitments and target screening dates by women to get screened. The men's education sessions contained similar information, with supplemental information on how to provide support for their wives to get tested and exercises on showing their support.
40934515|NCT03260439|DRUG|Tramadol|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
40934516|NCT03260439|DRUG|Placebo|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
40934517|NCT05871983|DEVICE|MUNICH TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM|"The replacement valve consists of a self-expanding, tri-leaflet, dry bovine -pericardial valve. The dry tissue allows the valve to be conveniently pre-loaded. The key characteristics of Munich valve are:~* Nitinol stent frame~* Bovine pericardium~* Polyester skirt~* Anchoring system allows anchoring the frame to the annulus~* Hooks are used to reduce the mobility of the native leaflets and decrease risk of embolization.~The Munich TMVR system design proposed for this clinical investigation represents a significant evolution from previous TMVR designs:~* Transfemoral / transseptal access~* Self-expanding~* Dry pericardium (can be pre-loaded)~* No anchors~* 27 Fr delivery catheter (~* Sizes: 40/48/55mm~* Height 30 mm The valve is available in 3 sizes with a 30mm profile and has been designed to reduce the complexity of implantation in comparison to other TMVR systems."
40934518|NCT05072327|PROCEDURE|Mohs surgery|Mohs surgery of eyelid
40934519|NCT05072327|PROCEDURE|cryotherapy|cryotherapy of eyelid
40934520|NCT03925168|BEHAVIORAL|Music therapy|Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
40934521|NCT04258137|GENETIC|Liquid biopsy|Liquid biopsy will be performed at cycle 1 day 1 and cycle 2 day of each line of systemic treatment, at each tumor evaluation by Imaging and at confirmation of progression
41129897|NCT01754051|DEVICE|PC 400 coils|
41129898|NCT00939510|BIOLOGICAL|sargramostim|All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
41450006|NCT04544033|DIAGNOSTIC_TEST|Interleukin-6 Gene-174C detection|The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
40934522|NCT05473182|OTHER|IndieTrainer system|The IndieTrainer system is comprised of the IndieGo device and video-game modules. The IndieGo device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. The video-game modules are integrated into the IndieGo device such that the video games can be played on a TV screen using the specific access method used to control the IndieGo (i.e., switch or joystick). The IndieTrainer system is designed to allow a child to practice power wheelchair skills as part of the video-game modules or as part of more traditional power wheelchair skills training activities wherein children are able to actively explore the environment and practice executing actual wheelchair skills.
40934523|NCT06234384|OTHER|Sarcoidosis diagnosis|Participants have been diagnosed with sarcoidosis.
40934524|NCT04282798|OTHER|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
40934525|NCT00955383|DRUG|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
40934526|NCT00955383|DRUG|Placebo|Matching placebo
40934527|NCT01633437|DRUG|CX157|CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.
40934528|NCT01633437|OTHER|Placebo|Placebo administered twice per day on study days 4-11 and in the morning of day 12.
40934529|NCT06519110|DRUG|Neratinib tablets|In the first week, take Neratinib tablets 120mg orally, in the second week take Neratinib tablets 160mg orally, and from the third week until the end of treatment, take Nilotinib tablets 240mg orally (from Cycle 1 Day 15 until the end of treatment).
40934530|NCT01765803|DRUG|Mellaril|Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. A second blood draw will occur at 24 hours post-treatment.
40934531|NCT05972603|PROCEDURE|1.0 g Vancomycin powder into the wound|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation and additional application 1.0 g Vancomycin powder into the wound
40934532|NCT05972603|PROCEDURE|0,35% povidone-iodine solution lavage|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation
41129899|NCT00939510|DRUG|lenalidomide|Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
41129900|NCT00939510|OTHER|laboratory biomarker analysis|Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
41129901|NCT05695469|DEVICE|Smart resuscitation glove (ResuGlove)|Participants will be randomly assigned into two equal groups using the online-based random number generator (https://www.random.org). Participants in the ResuGlove group will perform hand-only CPR wearing the ResuGlove with a running feedback program for 2 minutes.
41450007|NCT05463601|DRUG|Mecapegfilgrastim|Mecapegfilgrastim
41450008|NCT05463601|DRUG|dalpiciclib|dalpiciclib
41450009|NCT05463601|DRUG|exemestane, fulvestrant, letrozole, tamoxifen|endocrine therapy
41450010|NCT06549686|BIOLOGICAL|CLS2901C (human [allogeneic] chondrocyte sheets)|CLS2901C (human \[allogeneic\] chondrocyte sheets)
40934533|NCT05002153|OTHER|Fecal microbiota transplantation (FMT)|FMT is the process of transferring stool from a healthy donor to another.
40934534|NCT05002153|OTHER|Placebo|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
40934535|NCT00245583|DRUG|Topiramate|minimum does of 50mg/day
40934536|NCT00245583|DRUG|Placebo|matching tablet
41279515|NCT04401059|DRUG|Elemene plus first or third generation EGFR-TKIs|"Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label.~Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason.~First or third generation EGFR-TKIs: refer to the drug label."
40934537|NCT01395862|DRUG|Salmeterol and Fluticasone|
41129902|NCT05695469|OTHER|Traditional CPR|Participants in the traditional CPR group will perform hand-only CPR without the ResuGlove and feedback guidance for 2 minutes.
41279516|NCT04401059|DRUG|First or third generation EGFR-TKIs|refer to the drug label.
41279517|NCT02282761|DRUG|ITI-007|
41279518|NCT02282761|DRUG|Placebo|
41450011|NCT04431518|DRUG|JULUCA 50Mg-25Mg Tablet|One dose of JULUCA will be taken daily for up to 14 days
41450012|NCT06624267|DIAGNOSTIC_TEST|PET|PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Two 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. One 5-minute scan is conducted of the brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
41450013|NCT04637360|DRUG|Cinacalcet Tablets|All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.
41450014|NCT04637360|DRUG|calcitriol|All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.
41450015|NCT00538239|DRUG|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
41450016|NCT00538239|DRUG|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
41450017|NCT00476034|DRUG|lumiracoxib|
40934538|NCT02775903|DRUG|Azacitidine|Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
40934539|NCT02775903|BIOLOGICAL|Durvalumab|Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.
40934540|NCT02314143|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
40934541|NCT02314143|DRUG|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
40934542|NCT04494022|DIAGNOSTIC_TEST|contrast enhanced ultrasound|Perflubutane enhanced ultrasound for evaluating hepatic tumor
40934543|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task + action observation and motor imagery (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~1 hour, 3 times a week for six weeks."
41129903|NCT05346094|OTHER|No intervention|No intervention
40934544|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~1 hour, 3 times a week for six weeks."
40934545|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
41279519|NCT03619785|DRUG|Bupivacaine|Patient will be positioned supine or in the lateral decubitus position on the side contralateral to the fracture(s). A 3.5 in 20-gauge needle, extension tubing, and a 30 mL syringe loaded with 0.25% bupivacaine and 3 mL of 1% lidocaine loaded in a 5 mL syringe with a 27-gauge needle will be prepared. The ribs, teres minor, latissimus dorsi, and serratus anterior will be identified with bedside US and the site of entry marked along the lateral aspect of the 4th-5th rib. The skin will be sterilized and lidocaine placed at the site of entry. The needle will be introduced at a steep angle and advanced in-plane, under US-guidance, to the plane superficial to the serratus anterior muscle. A test dose of normal saline will confirm proper needle tip placement with opening of the intramuscular layer. Injection with aliquots of 3-5 mL after negative aspiration will continue until 30mL of 0.25% bupivacaine are administered.
41450018|NCT03721471|OTHER|Scoring of frailty|"1. Patients will be scored by the Clinical frailty Scale~2. Patients' hand-grip-strength will be measured by a dynamometer."
40934546|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task (twelve weeks: 6 +6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
40934547|NCT02297282|BEHAVIORAL|Behavioural Activation (BA)|Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
40934548|NCT03098771|PROCEDURE|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
40934549|NCT03098771|DRUG|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
40934550|NCT01484938|DEVICE|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
40934551|NCT01456273|PROCEDURE|Traditional Medical Consultation|Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole
40934552|NCT01456273|PROCEDURE|Therapeutic Encounter|"Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo."
40934553|NCT01574079|OTHER|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
40934554|NCT01574079|OTHER|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
40934555|NCT04144218|DRUG|Lacosamide|The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.
40934556|NCT04144218|DRUG|Placebo oral tablet|The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
40934557|NCT01191879|OTHER|Blood test|Blood test
40934558|NCT01165736|DRUG|PF-05186462|single intravenous infusion of 100 microgram
40934559|NCT01165736|DRUG|PF-05186462|single oral administration of 100 microgram
40934560|NCT01165736|DRUG|PF-05089771|single intravenous infusion of 100 microgram of PF-05089771
40934561|NCT01165736|DRUG|PF-05089771|single oral administration of 100 microgram PF-05089771
40934562|NCT01165736|DRUG|PF-05150122|single intravenous administration of 100 microgram PF-05150122
40934563|NCT01165736|DRUG|PF-05150122|single oral administration of 100 microgram PF-05150122
40934564|NCT01165736|DRUG|PF-05241328|single intravenous infusion of 100 microgram PF-05241328
41129904|NCT03689946|DRUG|Evolocumab|"Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector."
40934565|NCT01165736|DRUG|PF-05241328|single oral administration 100 microgram PF-05241328
41279520|NCT03619785|DRUG|Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen|Oral or IV pain medication as needed.
41279521|NCT02024776|BEHAVIORAL|Prehabilitation|Tailored exercise training program
41279522|NCT05189899|DEVICE|Virtual reality|One hemodialysis session with virtual reality and one other without it
40934566|NCT05963893|BEHAVIORAL|Uni4Move to sit less and move more|Co-create and implement an action plan to move more and sit less in the university context
40934567|NCT00218101|DRUG|Buprenorphine|
41279523|NCT06310369|RADIATION|radiation therapy|"Radiation therapy will be given in 20 fractions of 2.75 Gy covering the whole bladder over 4 weeks.~The use of a radiosensitizing agent is mandatory. Each recruiting center will have to choose 2 options of radiosensitizing agents."
41450019|NCT05597228|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
41450020|NCT03595254|BEHAVIORAL|Thrive|Computerized Cognitive Behavior Therapy program
40934568|NCT03937635|BIOLOGICAL|Daratumumab|Given IV
40934569|NCT03937635|DRUG|Dexamethasone|Given PO
40934570|NCT03937635|DRUG|Lenalidomide|Given PO
41450021|NCT02531620|OTHER|Physiatry Assessment|Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
41450022|NCT02531620|OTHER|Routine Care|Usual care for your disease process
41450023|NCT00154258|DRUG|Clozapine|
41450024|NCT01322321|DRUG|ACZ885|
40934571|NCT03937635|OTHER|Quality-of-Life Assessment|Ancillary studies
40934572|NCT03937635|OTHER|Questionnaire Administration|Ancillary studies
40934573|NCT02359162|DRUG|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
40934574|NCT02359162|DRUG|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
40934575|NCT02359162|DRUG|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
40934576|NCT02359162|DRUG|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
40934577|NCT02359162|DRUG|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
40934578|NCT02359162|DRUG|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
40934579|NCT02359162|DRUG|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
40934580|NCT02359162|DRUG|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
40934581|NCT02359162|RADIATION|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
40934582|NCT06002022|DEVICE|REBECCA system (smartwatch + mobile app use)|Patients will be trained in the use of the REBECCA system, which will provide in-depth information about their lifestyle (including physical activity levels, dietary habits, sleep quality and social mobility), as well as of their online behaviour (with outcome indicators of anxiety, PTSD and depression development) and self- or companion-reported measures of emotional state and quality of life. Based on the additional information, exploiting the enhanced monitoring capabilities of the REBECCA system, the supervising clinicians will be given the opportunity to continuously evaluate the progress of the patients, allowing them to schedule up to 3 phone-based consultation sessions in the first 12 months of treatment
40934583|NCT03052543|DEVICE|BIS™ Complete 2--Channel Monitor|monitor depth of anesthesia
40934584|NCT05578001|DRUG|Pilocarpine Ophthalmic|1 drop of Pilocarpine 1%
40934585|NCT00146107|BEHAVIORAL|Diet|10 percent weight loss through diet and behavioral modification
40934586|NCT00146107|OTHER|Exercise|Multicomponent (resistance, aerobic, balance) exercise three times a week
40934587|NCT00146107|OTHER|Weight Loss and Exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
40934588|NCT06259851|BEHAVIORAL|Dialectical behavioral therapy program|Dialectical behavioral therapy (DBT) program with all the standard DBT modules (individual therapy 1 hour per week, skills group 3 hours per week, phone coaching, and therapist consultation team 1,5 hour per week). The program takes 24 weeks in total comprising two 12-week runs of skills training. The program will be precluded with 4 individual sessions of pretreatment before the start of the main program part.
40934589|NCT06259851|DEVICE|Prefrontal rTMS treatment|rTMS will be performed by DuoMag XT with 70BF cool coil. Patients will undergo 15 daily stimulation sessions during a period of three weeks with one session each working day. Each session consists of 20 trains with 100 pulses (10 seconds for train). Inter-train interval will be 30 seconds. Gradual titration of the individual resting motor threshold (RMT) will apply, meaning probands will undergo first session with 90% RMT intensity, second session with 100% RMT intensity, third session with 110% RMT intensity. All the following sessions will use the final 120% RMT intensity. In case a session is left out because of any reason, the total duration of treatment will be prolonged by one day, so that the total number of sessions underwent is the same in all patients. Patients will receive 2000 pulses during one session (total 30000 pulses during the whole procedure) with 10 Hz frequency.
40934590|NCT06259851|DEVICE|Sham rTMS sessions|Sham TMS will be performed by sham coil that looks identical to DuoMag XT in the active group. Patients will undergo 15 daily sham stimulation sessions during a period of three weeks with one session each working day. Each session consists of 20 trains with 100 pulses (10 seconds for train). Inter-train interval will be 30 seconds.
40934591|NCT03096015|BEHAVIORAL|Intensive Comprehensive Aphasia Program|
40934592|NCT01036061|DRUG|GSK618334 Low Dose|GSK618334 low dose
40934593|NCT01036061|DRUG|GSK618334 PET subjects|PET subjects
40934594|NCT01036061|DRUG|GSK618334 Medium Dose|Medium Dose
40934595|NCT01036061|DRUG|GSK618334 High Dose|GSK618334 High Dose
40934596|NCT06051708|OTHER|standard AKI care bundle|AKI care bundle include use of iv fluids, diuretics, antihyperkalemic drugs, sodium bicarbonate, antibiotics in septic patients.
40934597|NCT06051708|OTHER|standard care for hospitalized patients|this includes iv fluids, diuretics, antibiotics in septic patients, other measures according to original disease
40934598|NCT03718299|DRUG|Injections of tildrakizumab|given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
40934599|NCT03956797|DEVICE|Recens Cooling Anesthesia Device|Application of cooling anesthesia device prior to intravitreal injection
40934600|NCT03272984|PROCEDURE|ERAS group|ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
40934601|NCT03272984|PROCEDURE|SC group|Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
40934602|NCT04041739|DIAGNOSTIC_TEST|fungal osteomyelitis culture and sensitivity|swabs from ulcer tissue and bone biopsy for culture and sensitivity test and blood sampling
40934603|NCT03498001|DRUG|GLP-1 agonists|Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg
40934604|NCT03498001|PROCEDURE|Cardiac MRI|T3 myocardial MRI (total acquisition time : 1h) performed before initiation of treatment and measuring the concentration of intramyocardial triglycerides (\[TG\] by NMR spectroscopy, parameters of cardiac morphology (myocardial mass, (epicardial fat surface, pericardial fat surface), function (LVEF, SV, TDV, PFR, TPFR) and tissue parameters (extracellular volume, left myocardial fibrosis volume).
40934605|NCT03498001|OTHER|Follow up by phone|at 2 and 4 mois
40934606|NCT01906879|DRUG|triple, quadruple, non-bismuth quadruple therapy|triple therapy, quadruple therapy, non-bismuth quadruple therapy
40934607|NCT00618839|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
40934608|NCT00618839|PROCEDURE|Cadaver allograft|The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
40934609|NCT04508764|OTHER|Families Accelerating Cascade Testing Toolkit|-Online family history assessment, video of Siteman Cancer Center genetic counselors, physicians and patients highlighting the importance of cascade genetic testing, reviewing and receiving a family letter and gene information sheet, reviewing websites/online resources, and offering a family visit with a genetic counselor
40934610|NCT03721679|BIOLOGICAL|Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months|Same as above
40934611|NCT00611871|DRUG|Propranolol|40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
40934612|NCT00611871|DRUG|Placebo|40mg placebo, followed 2 hrs after with 60mg placebo
40934613|NCT05513131|DRUG|Venetoclax；Azacitidine；Homoharringtonine|A cycle every 28 days Treatment with Venetoclax 100mg d1，200mg d2，400mg d3\~d14； Azacitidine 75mg/m2/d，d1\~d7 Homoharringtonine 2mg/d d1\~d7
41450025|NCT01322321|DRUG|Placebo|
40934614|NCT04841200|DRUG|Chinese medicine compound combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd.~Each type of granule will be given orally, twice a day, for 52 weeks."
40934615|NCT04841200|DRUG|Chinese medicine compound placebo combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 placebo Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules placebo for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules placebo for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules placebo for syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. The appearance, shape, color and packaging of Chinese medicine compound placebo are the same as those of drugs.~Each type of granule will be given orally, twice a day, for 52 weeks."
40934616|NCT00349271|PROCEDURE|Stem cell|Stem cell
40934617|NCT00349271|DRUG|Filgrastime (G-CSF)|Filgrastime (G-CSF)
40934618|NCT00349271|DRUG|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
40934619|NCT04019418|DIETARY_SUPPLEMENT|Maltodextrin (carbohydrate)|A drink containing 300ml of water and 75g of maltodextrin
40934620|NCT04019418|OTHER|Exercise|30 minutes on a cycle ergometer working at 75% VO2 max
40934621|NCT04019418|OTHER|Rest|30 minutes laying on a bed
40934622|NCT04019418|OTHER|Water|A drink containing 300ml of water
40934623|NCT02886156|DEVICE|CPAP|CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.
40934624|NCT02886156|DIETARY_SUPPLEMENT|BSC|BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
40934625|NCT02300727|DRUG|Curcumin-MTD|0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
40934626|NCT02300727|DRUG|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
40934627|NCT02300727|DRUG|Curcumin|After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
40934628|NCT05692973|BEHAVIORAL|Role of Knowledge Retrieval|Students will learn a new knowledge base to perfect mastery. Following the attainment of mastery students will read passages on the topic and answer questions that prompt the literal recall of key facts and the formation of inferences.
40934629|NCT05692973|BEHAVIORAL|Inference Intervention|The intervention will pre-teach students a set of 20 essential facts about Egypt. Students will interact with expository and narrative texts. Students will practice using a text clue strategy to activate and integrate prior knowledge, will make in-text connections, connections across the 3 intervention texts, and connections between text and knowledge, and will make inferences about character motives and author intent. The tutor will ask students to justify connections and evaluate how these connections enhance understanding. Students will answer inference questions that require using text and background knowledge. A simple graphic organizer will support and scaffold inferencing. Throughout the intervention, students will practice retrieving the 20 essential facts about Egypt from memory using flash cards, completed in pairs with students providing each other feedback.
40934630|NCT04352127|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
40934631|NCT02964403|DRUG|Cox-2|
40934632|NCT02964403|DRUG|Indomethacin|
40934633|NCT02393586|DRUG|Faropenem|Single oral dose
40934634|NCT02393586|DRUG|Amoxicillin/clavulanic acid 500mg/125mg|Single oral dose
40934635|NCT02393586|DRUG|Rifampicin|Single oral dose
40934636|NCT05409664|BEHAVIORAL|Physical activity adoption|webMFT will be delivered via a web-based platform. Coaches will be trained to deliver the intervention prior to being assigned a study participant. Upon successful completion of the informed consent for coaches and participants, coaches will be assigned a participant for their 3-month duration in the study. Coaches and participants will complete weekly phone calls focused on increasing the participants' MVPA up to the recommended 150 min/week.
40934637|NCT05409664|BEHAVIORAL|Self monitoring|Participants will be asked to gradually increase their activity up to the recommended 150 minutes of moderate-intensity/week during the 12-week intervention. Self-monitoring will be completed using a Fitbit tracker.
40934638|NCT04186689|OTHER|Routine Dental Examination|Routine dental examination for the pre-school children Questionnaire for their mothers
40934639|NCT05967897|DIETARY_SUPPLEMENT|Blueberries|22 g freeze-dried blueberry powder mixed with water
40934640|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Whey Protein|22 g freeze-dried blueberry powder mixed with whey protein and water
40934641|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Pea Protein|22 g freeze-dried blueberry powder mixed with pea protein and water
40934642|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Hemp Protein|22 g freeze-dried blueberry powder mixed with hemp protein and water
40934643|NCT04384588|BIOLOGICAL|Convalescent Plasma from COVID-19 donors|Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included
40934644|NCT02168426|PROCEDURE|Guardix|Applying 6g of guardix during abdominal surgery
40934645|NCT02168426|PROCEDURE|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
40934646|NCT04330820|DRUG|Venetoclax Oral Tablet|"This study will investigate the combination of a fixed maximum venetoclax dose with increasing cytarabine doses plus mitoxantrone in a fixed dose in phase I. In Phase II cytarabine will be given at MDT or RP2D that assessed in phase I.~The venetoclax dose of 400 mg will be reached by a ramp up over 3 days. Parallel chemotherapy with cytarabine and mitoxantrone will start on day 3."
40934647|NCT04628832|BEHAVIORAL|PMP Use Mandate Letter|A letter with reminders about the mandate to check the PMP when prescribing opioids.
40934648|NCT04628832|BEHAVIORAL|Prescribing Information Letter|A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
40934649|NCT04628832|BEHAVIORAL|Prescribing Information + PMP Use Mandate Letter|A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.
40934650|NCT06102460|DIETARY_SUPPLEMENT|Casein protein|40 grams of casein protein powder mixed with 8-10 fl. oz. of water.
40934651|NCT06102460|DIETARY_SUPPLEMENT|a-lactalbumin protein|40 grams of a-lactalbumin protein powder mixed with 8-10 fl. oz. of water.
40934652|NCT06102460|DIETARY_SUPPLEMENT|Carbohydrate|40 grams of a carbohydrate powder mixed with 8-10 fl. oz. of water.
40934653|NCT06102460|DIETARY_SUPPLEMENT|Placebo|Zero calorie, placebo powder mixed with 8-10 fl. oz. of water.
40934654|NCT01084096|BEHAVIORAL|Increasing use of Antenatal Corticosteroids (ACS)|"Intervention clusters:~* Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~* Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants."
40934655|NCT05897944|OTHER|COPD|A data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques.
40934656|NCT02063971|OTHER|Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)|
40934657|NCT01987531|OTHER|left ventricular epicardial pacing lead|
40934658|NCT02593045|BIOLOGICAL|IPH4102|
40934659|NCT01489371|OTHER|Laboratory Biomarker Analysis|Correlative studies
40934660|NCT01489371|BIOLOGICAL|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given IP
40934661|NCT01489371|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
40934662|NCT04169542|OTHER|Questionnaire Administration|Complete questionnaires
40934663|NCT05765981|DRUG|VGN-R09b|VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
40934664|NCT03501771|OTHER|Acupuncture|Disposable acupuncture needles will be inserted into acupoints (BL23, BL25, BL40) bilaterally for a depth of 10-30 mm
40934665|NCT01680549|DRUG|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
40934666|NCT04785690|DEVICE|CureSight|Subjects assigned to the binocular treatment group will be prescribed the CureSight treatment to watch for 90 minutes per day, 5 days a week for 16 weeks for the total of 120 hours. Parents of subjects will be instructed that the 90 minutes of daily treatment should be completed in a single 90-minute session, but if this is not possible for whatever reason, the treatment may be divided into two shorter sessions totaling 90 minutes per day
40934667|NCT04785690|DEVICE|Patching|"Subjects assigned to the patching group will wear an adhesive patch over the dominant eye for 2 hours per day, 7 days per week for 16 weeks. Parents of subjects will be instructed that the 2 hours of daily patching should be completed in a single 2-hour session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 2 hours.~Parents will be asked to complete a usage diary by manually recording the patch usage time on daily basis."
40934668|NCT00422318|DRUG|Benzbromarone (drug)|
40934669|NCT06174740|BEHAVIORAL|Music-cued audiovisual motor training|In addition to visual cues, music stimuli guide finger sequence movement both rhythmically (temporal component) and sonically (pitch-finger alignment).
40934670|NCT06174740|BEHAVIORAL|Visually-cued motor training|Visual cues guide finger sequence movement by indicating which finger to move in alignment with the position and of the visual cue.
40934671|NCT03808987|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|Child-Parent Psychotherapy (CPP) focuses on parent-infant relationships, increases efficacy for improved mother-child relationships, more sensitive parenting, healthier child development, and maltreatment prevention. A primary goal is to strengthen the parent-child relationship to improve family functioning and child security of attachment. Through respect, empathic concern, and positive regard, the therapeutic relationship provides mothers with corrective emotional experiences, through which they are able to differentiate current from past relationships, form positive internal representations of themselves and of themselves in relationship to others, particularly their children. Parents are encouraged to process their experiences of trauma and restore parental roles as protective shields, improve affective regulation capacities, enhance understanding of the meaning of behavior, acknowledge the impact of trauma, and support children in a more positive developmental trajectory.
40934672|NCT03808987|BEHAVIORAL|Community Health Worker (CHW) home visitation|Community Health Worker (CHW) home visitation includes assistance with concrete support needs, such as transportation to medical appointments, referrals for food, housing, and employment services, and attention to developmental needs of young children.
41129905|NCT03689946|DIAGNOSTIC_TEST|18F-NaF PET|18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.
41450026|NCT04186286|DRUG|Ivabradine 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
41279524|NCT05290467|BEHAVIORAL|Online antenatal care|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to both the experimental and control groups, using different delivery strategies. Participants in the control group will be scheduled for 12 routine ANC visits, and those in the experimental group will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Messages, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
41279525|NCT02591992|OTHER|Cardiac CT as the first diagnostic modality in suspected CAD|Performation of non-invasive cardiac CT angiogram
41279526|NCT02591992|OTHER|Invasive coronary angiography as indicated by the guidelines|Patient undergoes invasive coronary angiography
41279527|NCT00001515|DEVICE|virtual bronchoscopy|
41279528|NCT04281797|DIAGNOSTIC_TEST|Intestinal microbiome new generation sequencing|Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.
41279529|NCT00278629|BIOLOGICAL|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
41279530|NCT01047787|OTHER|Polysomnography|examination for sleep disorders
41279531|NCT03384056|DEVICE|Self Pressurized Airway Device with Blocker|used in adult low risk females undergoing elective gynecological operations
41279532|NCT03384056|DEVICE|Proseal Laryngeal Mask Airway|used in adult low risk females undergoing elective gynecological operations.
41279533|NCT03210844|PROCEDURE|Surgical approaches of total hip arthroplasty|Surgical approaches of total hip arthroplasty
41279534|NCT00509106|DRUG|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
41279535|NCT00509106|DRUG|Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
41279536|NCT00509106|DRUG|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
41279537|NCT06261788|DEVICE|Temporary pacing|Transvenous temporary cardiac pacing - right internal jugular insertion
41279538|NCT00586690|DEVICE|NK Cell infusion using CD56 monoclonal antibody|The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
41279539|NCT00586690|PROCEDURE|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for \>24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
41279540|NCT03237676|OTHER|Structured cognitive rehabilitation therapy|A computer-based cognitive rehabilitation therapy Therapy frequency is one hour session per week for three months.
40934673|NCT06400771|DRUG|DNP007|DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.
40934674|NCT00625573|DRUG|Abraxane|100mg/m2 every week X's 3
41279541|NCT03237676|OTHER|Patient-centred cognitive therapy|"Application of existing cognitive therapy at University Malaya Medical Centre, Malaysia. It is a patient-centred therapy approach over a period of three months, which include therapy session on symptoms management and coping strategies.~Clinical and treatment review are provided as part of routine outpatient rehabilitation clinic review."
41279542|NCT01440725|BIOLOGICAL|Autologous Platelet-rich plasma (PRP)|4-8cc, a single dose
41279543|NCT01440725|PROCEDURE|Evacuation of haematoma|Evacuation of the haematoma, a single procedure
41279544|NCT00157300|DRUG|Epoetin beta|intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
41279545|NCT04866472|DEVICE|video-laryngoscope and GlideRite Rigid Stylet|Once subject is in the operating room, standard monitoring will be instituted including nerve stimulator. Induction will follow standard practice.Once full muscle relaxation is confirmed with a train of four of 0/4 laryngoscopy will be preformed using a video-laryngoscope (VLS) with a #3 blade for women and a #4 blade men. Endotracheal intubation will be performed using a #7 endotracheal tube in women and # 8 in men using the GlideRite Rigid Stylet. The stylet will be shaped to the curvature of the blade of the VLS and lubricated with a water-based lubricant. After successful tracheal intubation the circuit will be connected and ventilation confirmed with capnography and auscultation.
41450027|NCT04186286|DRUG|Propranolol 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.
41279546|NCT04866472|DEVICE|video-laryngoscope and TCI Articulating Introducer Device|In the operating room, standard monitoring will be instituted including nerve simulator. Induction will follow standard practice. Once full muscle relaxation is achieved (train of four of 0/4) laryngoscopy will be performed using a video-laryngoscope (VLS) using a #3 blade in women and a #4 blade in men. A #7 endotracheal tube will be used for women and a #8 for men. Endotracheal intubation will be performed by placing the tube on the back of the TCI articulating introducer, after shaft is lubricated with a water based lubricant. The tip of the TCI articulating introducer will be maneuvered into the trachea and advanced until the green zone of the introducer shaft is adjacent to the glottis. The handle of the articulating introducer will then be removed and the ETT will be advanced over the articulating introducer and into the trachea via Seldinger's technique. Once in place the respiratory circuit will be connected and confirmed with capnography and auscultation.
41279547|NCT05123157|OTHER|NO intervention|"N/:~NO intervention"
41279548|NCT02811705|OTHER|Quality of life|Quality of life
40934675|NCT00623584|PROCEDURE|Corneal transplantation|Full thickness penetrating keratoplasty
40934676|NCT00623584|PROCEDURE|Corneal transplantation|Full thickness penetrating keratoplasty
40934677|NCT04033523|BEHAVIORAL|HIIT|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
40934678|NCT01011478|DRUG|rosuvastatin|
40934679|NCT01011478|OTHER|placebo|
40934680|NCT00008827|BEHAVIORAL|Behavioral weight loss|
40934681|NCT03052933|DRUG|Copanlisib|"For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level+0), or 60 mg/dose (level+1) of copanlisib. Maximal tolerated dose will be determined by modified 3+3 design including level-1 dose de-escalation.~For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15.~Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study."
40934682|NCT03052933|DRUG|Gemcitabine|For phase I/II study, participants will receive gemcitabine (in combination with copanlisib) IV infusion at fixed dose of 1,000 mg/m2 on Days 1 and 8 of each 28-day treatment cycle until maximum 6 cycles.
40934683|NCT02591771|DRUG|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
40934684|NCT02746003|OTHER|Managed Aquifer Recharge water|Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
40934685|NCT05469204|DRUG|Midazolam oral solution|2 mg single-dose before and during estradiol treatment.
40934686|NCT05469204|DRUG|Digoxin Oral Tablet|0.25 mg single-dose before and during estradiol treatment.
40934687|NCT05469204|DRUG|Acetaminophen Oral Tablet|500 mg single-dose before and during estradiol treatment.
40934688|NCT05469204|DRUG|Midazolam Injectable Solution|1 mg intravenous single-dose before and during estradiol treatment.
41279549|NCT03953105|DEVICE|ePER|usind the ePER for weight estimation and suggestion of the defined parameter
41279550|NCT03953105|DEVICE|BT|usind the BT for weight estimation and suggestion of the defined parameter
41279551|NCT00813995|DRUG|Comparator: Sitagliptin phosphate|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
41279552|NCT00813995|DRUG|Comparator: Placebo|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
41279553|NCT01509027|BEHAVIORAL|education by DVD|Information on detrimental conseqences of hyperphosphatemia is presented on DVD
40934689|NCT05004454|DIETARY_SUPPLEMENT|Bacillus subtilis BS50 spore preparation|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
40934690|NCT05004454|DIETARY_SUPPLEMENT|Maltodextrin|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
40934691|NCT03582644|OTHER|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
40934692|NCT03528395|OTHER|Semi-immersive virtual reality|Each participant will receive 24 additional sessions of semiinmersive virtual Reality therapy sessions on Monday, Wednesday and Friday, after realizing the conventional therapy sessions. The duration of each VR session will be gradually increased in time-intensity (5 minutes during the first week to 20 minutes during the last week) and motor requirements.
40934693|NCT03528395|OTHER|Conventional Rehabilitation|Conventional rehabilitation consisting of five weekly sessions of Physical therapy and Occupational Therapy, based on a task-oriented approach, lasting 45 minutes each.
40934694|NCT03351985|DEVICE|quantitative electroencephalogram (qEEG)|the patients receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
40934695|NCT01483586|DRUG|kanglaite gelcap|3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
40934696|NCT01483586|DRUG|Kanglaite gelcap|6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
40934697|NCT00390234|DRUG|ziv-aflibercept|Given IV
40934698|NCT04483687|DRUG|Filgotinib|Tablets administered orally once daily
40934699|NCT04483687|DRUG|Placebo to Match Filgotinib|Tablets administered orally once daily
40934700|NCT04199598|DRUG|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
40934701|NCT04199598|DRUG|Abediterol (4.8 μg)|4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
41279554|NCT01509027|BEHAVIORAL|Standard care|standard care
40934702|NCT04199598|DRUG|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
40934703|NCT04199598|DRUG|Abediterol (2.5 μg)|2.5 μg (nominal dose) abediterol via DPI, reference
40934704|NCT03249389|BIOLOGICAL|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
40934705|NCT02011893|DEVICE|Tonic Stimulation|Prodigy Neurostimulation System with associated components
40934706|NCT02011893|DEVICE|Burst Stimulation|Prodigy Neurostimulation System with associated components
40934707|NCT05684432|OTHER|No intervention|No intervention
40934708|NCT04932070|DIETARY_SUPPLEMENT|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
40934709|NCT00025805|DRUG|G-CSF|
40934710|NCT01815203|DRUG|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
40934711|NCT01815203|DRUG|Placebo|Administration of placebo with subsequent cognitive tasks and food test.
40934712|NCT00442884|BEHAVIORAL|Trier Social Stress Test (TSST)|
40934713|NCT04271280|OTHER|Non-interventional|This is a non-interventional study.
40934714|NCT06288789|OTHER|Social Frailty Index|Social Frailty Index will be applied twice, one week apart.
40934715|NCT01840644|OTHER|Walking on treadmill, different velocities and incline|Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
40934716|NCT06325475|PROCEDURE|labor with neuraxial labor analgesia|"Pregnant women in Group A will receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group A will receive 0.0625% bupivacaine via epidural route."
40934717|NCT06325475|PROCEDURE|labour without noroaxial labor analgesia|"Pregnant women in Group B will not receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group B will receive iboprufen and acetaminophen."
40934718|NCT03464695|DEVICE|O2matic|Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.
40934719|NCT04533477|PROCEDURE|Reconstructing forked corpus spongiosum (FCS)|During the routine standardized surgery, the FCS should be cut off along both sides of the middle urethral plate before dissecting the glans wings and then dissected along the penile tunica albuginea closely from the near to the far side of the penis until the top of the penis head was reached. The corpus spongiosum on both sides will be reserved for the two wings of the glans. The two wings of the glans should be carefully expanded to at least the 3 o'clock and 9 o'clock positions of the penis. Some cases of small glans should be dissected to the 2 o'clock and 10 o'clock positions to close the two wings of the glans with no tension when performing glansplasty. Additionally, the original FCS on both sides should be combined at the coronal sulcus, thereby covering the surface of the new urethra.
40934720|NCT04533477|PROCEDURE|Routine standardized surgery|When the urethral plate can be preserved after degloving, the investigators chose the surgical method according to the width of the urethral plate. If the width of the urethral plate is ≥6 mm, tubularized incised plate (TIP) urethroplasty will be performed, whereas if the width of the urethral plate is \<6 mm, the onlay island flap (ONLAY) technique will be performed. When the urethral plate can not be preserved after degloving, transverse preputial island flap urethroplasty (Duckett) will be performed.
40934721|NCT02000154|DRUG|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
40934722|NCT00259129|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
40934723|NCT03007108|OTHER|blood withdrawal|
40934724|NCT01227148|OTHER|Tightly glucose control|A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
41279555|NCT01509027|BEHAVIORAL|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
41279556|NCT03449888|PROCEDURE|Regadenoson myocardial perfusion imaging stress test|Best fit model of pharmacologic myocardial perfusion imaging data, including summed stress and difference scores, gated left ventricular ejection fraction, transient ischemic dilatation, and heart rate response to regadenoson data.
41279557|NCT03449888|PROCEDURE|Arm exercise electrocardiographic stress test|Published arm exercise score and best fit model of arm exercise ECG stress testing data.
40934725|NCT01227148|OTHER|Conventional glucose control|a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
40934726|NCT00756925|DRUG|Acthrel|1 ug/kg, i.v., 1 minute
40934727|NCT00171054|DRUG|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
40934728|NCT00171054|DRUG|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
40934729|NCT00171054|DRUG|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure \< 140 mmHg and Diastolic Blood Pressure \< 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
40934730|NCT02607566|BEHAVIORAL|Yoga|
40934731|NCT02607566|BEHAVIORAL|Standard Exercise Program|twice weekly aerobic exercise program, 60 minutes for 12 weeks
41279558|NCT03449888|PROCEDURE|Treadmill electrocardiographic stress test|Duke Treadmill Score and best fit model of treadmill exercise ECG stress testing data.
40934732|NCT05861531|BEHAVIORAL|Oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The oral stimulation program will be modeled after the protocol designed and studied for preterm infants and will be implemented for a goal of 10 consecutive days within a 14 day period. This includes 10 minutes of stroking the cheeks, lips, gums, and tongue, and the final 5 minutes consisting of mid tongue stroking, eliciting a suck with gloved finger, and sucking on a pacifier provided in the NICU. This will occur 15-30 minutes before a scheduled tube feeding when the infant is tolerating bolus enteral feeds of 120 ml/kg/day for at least 48 hours. This will occur behind a curtain to ensure blinding of staff and parents. Modifications will be made for infants that remain intubated and only 10 minutes of the stroking of the cheeks, lips, gums, and tongue will occur. Stimulation will cease if episodes of oxygen desaturation and/or apnea/bradycardia occur during the stimulation.
40934733|NCT05861531|BEHAVIORAL|Reading curriculum|Written packets with biweekly lessons. The first two lessons include how to begin to read and talk to their baby. The second two lessons include reading or talking about the day using infant directed speech. The final two lessons include continuing to engage with the baby through interactive reading.
40934734|NCT05861531|BEHAVIORAL|LENA recording|The LENA device provides 24 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
40934735|NCT05861531|BEHAVIORAL|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
40934736|NCT05861531|BEHAVIORAL|No oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The standard care group will not receive any stimulation but will have a study personnel present behind a curtain to ensure blinding of family, staff, and investigators. The study personnel will remain behind a curtain for 10-15 minutes prior to a feed for 10 days over a 14-day period beginning when the infant is tolerated 120 mL/kg/day for at least 48 hours.
40934737|NCT05331079|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
40934738|NCT02606695|DEVICE|NuvaMap O.R.|Clinical imaging software used to assess intraoperative spinal alignment
40934739|NCT02606695|DEVICE|NuvaMap|Clinical imaging software used to assess spinal alignment
40934740|NCT00894374|DRUG|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
40934741|NCT00894374|DRUG|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
40934742|NCT04005521|BEHAVIORAL|Preventive intervention|Preventive, structured exercise protocol
40934743|NCT02433158|DRUG|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses.
40934744|NCT00098982|DRUG|bortezomib|
40934745|NCT00098982|DRUG|fluorouracil|
40934746|NCT00098982|DRUG|leucovorin calcium|
40934747|NCT00098982|DRUG|oxaliplatin|
40934748|NCT02117414|DEVICE|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
40934749|NCT02117414|OTHER|Waiting Period Visit|Waiting period time will equate to 1 hour
40934750|NCT02448342|DEVICE|Remote Dielectric Sensing (ReDS) Wearable System|The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
40934751|NCT05489588|DEVICE|GORE® VIAFORT Vascular Stent|Treatment of unilateral symptomatic iliofemoral venous obstruction with the GORE® VIAFORT Vascular Stent.
40934752|NCT06286371|PROCEDURE|Laparoscopic Endometriosis Surgery|Laparoscopic Excision of Deep Endometriotic Nodule related to pelvic pain
40934753|NCT02317146|DRUG|Magnesium Sulfate|Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
40934754|NCT06114108|OTHER|Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)|The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.
40934755|NCT06114108|OTHER|Surgery|Surgery
40934756|NCT06114108|RADIATION|Radiotherapy|Radiotherapy
40934757|NCT04221243|DEVICE|3D printed space maintainer by NextDent Ortho Rigid|Biocompatible 3D printing material
40934758|NCT04221243|DEVICE|Conventional Band and Loop|metal space maintainer
40934759|NCT00070733|DRUG|testosterone enanthate|
40934760|NCT00070733|DRUG|duastride|
41129906|NCT03689946|DIAGNOSTIC_TEST|CCTA|CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.
41129907|NCT03689946|DRUG|Omnipaque|contrast agent for CCTA
41129908|NCT03689946|DRUG|Metoprolol|beta blocker to optimize heart rate during CCTA
41129909|NCT03689946|DRUG|Nitroglycerin|premedication for CCTA
41129910|NCT00156208|DRUG|Asoprisnil|10mg Tablet, oral Daily for 18 months
41129911|NCT00156208|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 18 months
40934761|NCT03029637|DEVICE|RBBs with no or minimal preparation of their abutment teeth|Placement of resin bonded bridges on teeth with no or minimal cutting of their supporting teeth
40934762|NCT03029637|DEVICE|RBBs with routine tooth preparation of their abutment teeth|Placement of resin bonded bridges on teeth after routine cutting of their supporting teeth
40934763|NCT00468767|DRUG|Vernakalant Injection 20 mg/mL|
40934764|NCT05419427|DRUG|Denosumab|Denosumab 60 MG/ML
40934765|NCT05419427|DRUG|Denosumab-Ref|Denosumab 60 MG/ML
40934766|NCT03571477|DEVICE|ApneaBand|Mesure of oxygen saturation (oximetry), pulse wave (photoplethysmography), electrodermal activity and movements (tri-axial accelerometer)
40934767|NCT02972762|DRUG|Diprivan|anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
40934768|NCT01479218|DEVICE|Occlutech PDA occluder|Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
40934769|NCT02160483|OTHER|Functional magnetic resonance imaging|3 Tesla magnetic resonance imaging
40934770|NCT00908011|DRUG|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
40934771|NCT00908011|DRUG|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
40934772|NCT00919841|OTHER|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
40934773|NCT01432509|OTHER|Prediabetes screening and prospective follow-up over 5 years|"The study period per patient is 5 years. The planned schedule of the study is as follows :~* Enrollment at visit V0 of subjects at high metabolic risk, based on a biological value (within the past 2 months) of moderate fasting hyperglycaemia (blood glucose ≥ 1,10 g/l and \< 1,26 g/l) or fasting blood glucose ≥ 1 g/l and \< 1,10 g/l with HbA1c ≥ 6,5%.~* First biological sample (B0) within 1 month following V0 (measuring fasting blood glucose + glycated hemoglobin HbA1c + lipid profile + creatinemia + liver function; and establishment of a biological sample collection to identify biomarkers).~* Annual follow-up for five years consisting in one blood sample (B1 to B5) measuring the same parameters as V0 + biological sample collection, and questionnaire on major health events or health events related to study procedures.~* End of study phone call"
40934774|NCT01951859|OTHER|Neuropathy/Ulcer Homeopathic topical cream|This is a GRAS topical agent containing homeopathic ingredients
40934775|NCT04375475|DIETARY_SUPPLEMENT|Bright Changyou probiotic flavored yogurt|Oral consumption of Bright Changyou probiotic flavored yogurt 100 g at a time and twice per day for 28 days. The experimental product has similar package and taste as the comparators.
40934776|NCT04375475|DIETARY_SUPPLEMENT|Bright Changyou lactobacillus flavored yogurt|Oral consumption of Bright Changyou lactobacillus flavored yogurt 100 g at a time and twice per day for 28 days.
40934777|NCT04375475|DIETARY_SUPPLEMENT|Bright flavored yogurt|Oral consumption of Bright flavored yogurt 100 g at a time and twice per day for 28 days.
40934778|NCT02330809|OTHER|Daily extra water intake|Amount of extra daily water intake to consume
40934779|NCT02330809|OTHER|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
41450028|NCT04186286|DRUG|Placebo 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
40934780|NCT04410770|BEHAVIORAL|Mood tracker ratings|The participant rates his/her emotional distress several times a week using a specially developed smart phone app. The participant receives support call to ensure that self-ratings are being completed.
40934781|NCT06516445|RADIATION|SCRT|5×5Gy，5Gy/d，QD，D1-D5
40934782|NCT06516445|DRUG|Camrelizumab|200mg, D1, ivgtt, Q3W, C1-4
40934783|NCT06516445|DRUG|Fluzoparib|100mg, BID, PO, Q3W, C1-4
40934784|NCT06516445|DRUG|CAPEOX|Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4
40934785|NCT06064526|OTHER|No intervention|Non-interventional study based on secondary use of hospital medical records
40934786|NCT00997542|DRUG|Allopurinol|
40934787|NCT00997542|DRUG|Placebo|
40934788|NCT03231020|OTHER|Interview|"The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (\< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period."
40934789|NCT04111952|DEVICE|CO2 laser|A single session of CO2 vaginal laser treatment
40934790|NCT04111952|DEVICE|Sham laser|A single session of sham laser treatment.
41129912|NCT03895515|DRUG|Fiasp®|Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.
41450029|NCT04895553|OTHER|Observation of ICH and VTE|The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.
41450030|NCT02840149|DRUG|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan
40934791|NCT04188171|PROCEDURE|Polidocanol foam sclerotherapy|"* Preparation of the foam is done according to the Tessari technique (2 disposable 20ml syringe, a three-way tap, reusable extender adapted to intravenous needle).~* Sclerosant applied according to the Blanchard technique through a disposable transparent anoscope (patient in knee-chest position).~* In each session, treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).~* During the intervention period the participants are observed at 3-week intervals. The required number of sessions (maximum of 3) is determined by clinical and anoscopic evaluation.~* After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
40934792|NCT06041776|DRUG|Befotertinib + Icotinib placebo|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis)~Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis)."
40934793|NCT06041776|DRUG|Icotinib + Befotertinib placebo|"Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).~The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis."
40934794|NCT03701737|OTHER|questionnaires|"* VAS on the feeling of hunger~* Evaluation of food wanting by the Finlayson test~* PREFQUEST Questionnaire~* 24-hour food recall~* Stunkard Questionnaire~* Measurement of daytime sleepiness by Epworth score"
40934795|NCT03701737|DEVICE|wrist actimeter|Actimeter delivery: it is worn on the wrist for 7 days, 24 hours a day.
40934796|NCT03701737|BIOLOGICAL|Blood samples|2 dry tubes of 7 ml of blood collected at each visit for plasma assays (ghrelin, leptin, FGF 21, amino acids including tryptophan, insulin resistance)
40934797|NCT05841121|DRUG|Dexamethasone|Antenatal dexamethasone will be given a course of four intramuscular injections of dexamethasone 6 mg (1.2 milliliter), 12 hours apart.
40934798|NCT01631656|DRUG|Azelaic acid|15% gel on half the face, twice daily, 6 weeks
40934799|NCT01631656|DEVICE|Nd:Yag laser|Treatment with Nd:Yag laser , once at Week 2.
40934800|NCT01056380|DRUG|Nitazoxanide|Tablet, 500 mg with food twice daily for 5 days
40934801|NCT01056380|DRUG|Placebo|Tablet, twice daily with food for 5 days
41279559|NCT03449888|PROCEDURE|Coronary artery calcium score and cardiac computed tomographic angiography|Coronary artery calcium score by Agatston criteria and severe obstructive coronary artery disease \> 70% by cardiac computed tomographic angiography or invasive coronary arteriography.
41279560|NCT03815890|DRUG|Nivolumab|2 courses 240 mg flat dose
40934802|NCT02481427|PROCEDURE|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
40934803|NCT02481427|PROCEDURE|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
40934804|NCT05143359|DIAGNOSTIC_TEST|Wharfe and Pederson difficulty index|Efficiency of Wharfe and Pederson Difficulty index in extraction of third molars.
40934805|NCT05143359|DIAGNOSTIC_TEST|Winters difficulty index|Efficiency of Winters Difficulty index in extraction of third molars.
40934806|NCT02448680|BIOLOGICAL|Coagulation FVIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
40934807|NCT00312403|PROCEDURE|Blood Sample|A single venous blood sample will be taken (10 ml).
40934808|NCT01254955|BIOLOGICAL|H1N1 vaccine Pandemrix|
41279561|NCT03815890|DRUG|Ipilimumab|single dose ipilimumab (1mg/kg) at day 1
41279562|NCT03815890|DRUG|Ipilimumab|two courses ipilimumab (1mg/kg) at day 1 and 21
40934809|NCT05446376|DRUG|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
41279563|NCT03445676|BEHAVIORAL|ABHR directly on gloves|HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
41279564|NCT05580289|OTHER|half-shower and hot pack|The patients in the experimental group will be given hot application and half shower applications and the pain levels of the patients and the development of bladder retention will be followed.
41279565|NCT01794780|DRUG|LABA based treatment: indacaterol|LABA based treatment: indacaterol
41279566|NCT01794780|DRUG|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
41279567|NCT01794780|DRUG|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
41279568|NCT01794780|DRUG|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
41279569|NCT01794780|DRUG|theophylline based treatment|theophylline based treatment
40934810|NCT01242397|DEVICE|CRT pacing|The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.
40934811|NCT01997385|PROCEDURE|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
40934812|NCT01997385|PROCEDURE|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
40934813|NCT00555139|DRUG|GSK561679 tablet|GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
40934814|NCT00555139|DRUG|GW876008 tablet|GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
40934815|NCT00555139|DRUG|alprazolam|Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
40934816|NCT00555139|DRUG|Placebo|GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
40934817|NCT01525901|DRUG|Insulin-Like Growth Factor-1 (IGF-1)|IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
40934818|NCT01525901|DRUG|Normal saline|Saline solution will be administered for three months subcutaneously.
40934819|NCT04647890|DRUG|FT011|Two x 100mg capsules once daily for 12 weeks
40934820|NCT04647890|DRUG|FT011|Two x 200mg capsules once daily for 12 weeks
40934821|NCT04647890|DRUG|Placebo|Two placebo capsules once daily for 12 weeks
40934822|NCT01172275|DRUG|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
40934823|NCT01172275|OTHER|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
40934824|NCT04356170|DRUG|Docetaxel|Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
40934825|NCT04356170|DRUG|Cisplatin|cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
40934826|NCT04356170|DRUG|Fluoro Uracil|750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)
41279570|NCT01794780|DRUG|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
41279571|NCT04844190|DIAGNOSTIC_TEST|EndoFLIP|During pre-G-POEM upper endoscopy, an EndoLIP catheter will be inserted through the patient's mouth into the stomach and across the pylorus. Once results of EndoFLIP are obtained, the catheter will be removed (5 minutes).
41279572|NCT04844190|DIAGNOSTIC_TEST|Antroduodenal Manometry|Following removal the EndoFLIP catheter, a manometry catheter will then be placed through the nose and advanced across the pylorus. Once catheter positioning is confirmed on endoscopy, the endoscope will be withdrawn. The manometry catheter will be taped to the nose and sedation stopped. The patient will be brought to the recovery area where they will wake-up with the catheter in place. In a private recovery room, the patient will have the catheter in place (no positioning or movement restrictions). When pyloric spasms are documented (0.5-4 hours), they will be given a standard small meal (water, toast/bread). Once motility is assessed with eating, the manometry catheter will be removed.
40934827|NCT06391931|DRUG|Cipepofol|0.6±0.2 mg/kg induce + 0.8 mg/kg/h maintain
40934828|NCT06391931|DRUG|Propofol|3.0 mg/kg induce + 5.0 mg/kg/h maintain
40934829|NCT00354900|DRUG|Aprotinin|
40934830|NCT01066676|DRUG|Dexibuprofen|400mg powder for oral suspension, daily dose 800mg
40934831|NCT01066676|DRUG|Ibuprofen|400mg, powder for oral suspension, daily dose 1600mg
40934832|NCT02386683|OTHER|lung-protective ventilation|mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
40934833|NCT01593462|PROCEDURE|MRE (magnetic resonance enterography)|The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.
40934834|NCT01593462|PROCEDURE|The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)|The US UEI will take about 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.
40934835|NCT01593462|BEHAVIORAL|Study Questionnaires|"The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.~A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. The study questionnaires should take no longer than 10 to 40 minutes to complete."
40934836|NCT01178996|BIOLOGICAL|Thymosin alpha 1|Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.
41279573|NCT02734563|OTHER|Collagen turnover|Type IV and V collagen synthesis and breakdown
41279574|NCT02835729|DRUG|Idarubicin|Chemotherapy
41279575|NCT02835729|DRUG|Cytarabine|Chemotherapy
41279576|NCT02835729|DRUG|Indoximod Freebase|IDO pathway inhibitor
40934837|NCT01178996|DRUG|Ribavirin|Ribavirin 1000 mg (\<75 kg) or 1200 mg (\>75 kg) daily with food divided in two doses orally for 48 weeks
40934838|NCT01178996|BIOLOGICAL|PEGinterferon alfa2a|180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
40934839|NCT01178996|DRUG|Placebo|Placebo
40934840|NCT05767476|DIAGNOSTIC_TEST|Clinical and instrumental neurological assessment|"Participants will be involved in serial assessment:~* Neonatal Cranial Ultrasonography~* Brain magnetic resonance imaging~* Neurological assessment~* Neurodevelopmental and cognitive assessment~* Electroencephalogram (EEG)~* Motor performance assessment"
40934841|NCT01541202|DRUG|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
40934842|NCT01541202|DRUG|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
40934843|NCT03986632|BEHAVIORAL|Tundra Gifts|Tundra Gifts is a home-focused intervention delivered by community health workers (CHW) that focuses on promoting healthy eating and an active lifestyle among 3-5 year olds through family and community partnerships. Primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a Facebook site.
40934844|NCT06148389|DRUG|STSA-1301 subcutaneous injection|Subjects will receive the administration dose on Day 0 following protocol requirements.
40934845|NCT06148389|DRUG|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements.
40934846|NCT02909803|OTHER|Lentil Variety|Participants will consume 8 varieties of lentils that are cooked by boiling
40934847|NCT02909803|OTHER|White Bread|Participants will consume white bread on at least two different test days
40934848|NCT06150417|DRUG|Androgen deprivation therapy (ADT)|Standard androgen deprivation therapy (ADT) will be administered at the discretion of treating physician.
40934849|NCT06150417|DRUG|Androgen receptor signaling inhibitor (ARSI)|Standard androgen receptor signaling inhibitors (ARSI) will be administered at the discretion of the treating physician.
41279577|NCT02835729|DRUG|Indoximod HCL F1|IDO pathway inhibitor
41279578|NCT02835729|DRUG|Indoximod HCL F2|IDO pathway inhibitor
41279579|NCT04379583|DEVICE|HairDx Sample Collection Kit|Saliva collection using FDA OTC cleared sample collection device
41279580|NCT00892437|DRUG|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
41279581|NCT00892437|DRUG|RTV|Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
41279582|NCT00892437|DRUG|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
41279583|NCT00892437|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
41279584|NCT00892437|DRUG|COBI placebo|Placebo to match COBI administered orally once daily
40934850|NCT06150417|OTHER|Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)|"Local therapy will either be radiotherapy (RT) or radical prostatectomy (RP).~* Prostate +/- pelvic nodal radiation~* Radical prostatectomy + pelvic lymph node dissection"
40934851|NCT06150417|RADIATION|Metastasis directed radiotherapy (MDRT)|In participants randomized to the MDRT arm, MDRT to all lesions will be performed by the end of Week 24. Selection of a particular regimen (the dose and fractionation) will based on the size and location of the participant's metastatic site and the surrounding normal tissue constraints.
40934852|NCT04396054|DEVICE|Lag Screws|Method of internal fixation
40934853|NCT04396054|DEVICE|double Y-shaped plates|Method of internal fixation
40934854|NCT02128360|DRUG|Letrozole, Gonadotropins|
41279585|NCT00892437|DRUG|RTV placebo|Placebo to match RTV administered orally once daily
40934855|NCT02128360|DRUG|Gonadotropins|
40934856|NCT00006157|DRUG|Desipramine|
40934857|NCT00006157|BEHAVIORAL|Cognitive Behavioral Treatment|
40934858|NCT02016547|PROCEDURE|abciximab IV and thrombectomy|
40934859|NCT02016547|DRUG|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)|
40934860|NCT01997710|DEVICE|all-ceramic inlay-retained RBFDP|Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
40934861|NCT01997710|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
40934862|NCT00381953|DRUG|Peginterferon alfa-2a|
40934863|NCT00381953|DRUG|Interferon alfa-2a|
40934864|NCT00381953|DRUG|Ribavirin|
40934865|NCT01535976|DRUG|Placebo|"Placebo Comparator: Placebo~.9 normal saline infusion"
40934866|NCT01535976|DRUG|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
40934867|NCT04457219|DEVICE|Haemostatic Dressing|A Hemostatic Dressing is applied at the radial access site, following a transradial angiographic procedure. This is a mineral-based dressing with a hydrophilic polymer that works independently of the clotting cascade to seal the site, by accelerating topical hemostasis.
40934868|NCT04457219|DEVICE|Conventional Dressing|A Conventional Absorbent Dressing is applied at the radial access site, following the transradial angiographic procedure.
41279586|NCT00189761|DRUG|Tacrolimus|
41279587|NCT01050621|DIETARY_SUPPLEMENT|vitamin C (ascorbic acid)|ascorbic acid 1.5 g/kg body weight infused over 90 to 120 minutes two or three times weekly concurrent with standard cytotoxic chemotherapy individually selected for each patient by the treating oncologist on the basis of best current clinical practice
41450031|NCT06158607|BEHAVIORAL|Addiction Clinic-Based PrEP Adherence Intervention for Women with Substance Use Disorders|Provision of PrEP information through 4 counseling sessions, prevention navigation, and nurse practitioner prescribed PrEP in an addiction treatment setting.
41450032|NCT06158607|OTHER|Standard of care treatment|Participants in substance use treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
41279588|NCT06263712|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The Attempted Suicide Short Intervention Program (ASSIP) is a specific therapy for patients with a suicide attempt in their biography. The brief therapy ASSIP consists of three to four sessions of approximately 50 minutes each.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her\*his personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
41279589|NCT06263712|BEHAVIORAL|Standard of care plus resource interview group (STAR)|The standard of care plus resource interview group (STAR) will be offered a clinical interview, a risk assessment, and a non-specific resource focused intervention over three face-to-face sessions. In this resource focused intervention, the patient is asked to name her\*his resources, describe them, and give examples.
41279590|NCT00064922|BEHAVIORAL|Behavior Therapy|
40934869|NCT04457219|DEVICE|120 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 2 hours. Prolonged time of compression may be required.
41279591|NCT04854655|OTHER|Conventional resin composite|nanofilled resin composite
41279592|NCT04854655|OTHER|Activa Presto|calcium and phosphate hybrid material
40934870|NCT04457219|DEVICE|60 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 1 hour. Prolonged time of compression may be required.
40934871|NCT01915628|DEVICE|BioMatrix Flex|Percutaneous coronary intervention
40934872|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Convenctional TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).
40934873|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Pseudo-acupuncture TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).
40934874|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Trabert ultrastimulation method)|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).
40934875|NCT04890743|OTHER|Kinesiotherapy combined with placebo electrotherapy|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
40934876|NCT04445116|DEVICE|Action Video Game Treatment|Endeavor™ is a digital, non-drug investigational treatment that is delivered through an action video game and is designed to target cognitive deficits in adolescence and young adults with pediatric onset MS.
40934877|NCT04173364|DRUG|Ropivacaine 0.5% Injectable Solution|Injectable solution of ropivacaine 0.5%
40934878|NCT04173364|DRUG|Ropivacaine 0.1% Injectable Solution|Dilution of ropivacaine to the concentration of 0.1%
40934879|NCT05994495|DIAGNOSTIC_TEST|nuclear acid amplification tests|The NAAT test will be performed with Bosch Vivalytic STI test. It is a qualitative Polymerase Chain Reaction-based assay for simultaneous detection of 10 common sexually transmitted pathogens: Herpes simplex virus 1 (HSV 1)- Herpes simplex virus 2 (HSV 2)- Chlamydia trachomatis (CT) - Haemophilus ducreyi (HD)- Mycoplasma genitalium (MG) - Mycoplasma hominis (MH) - Neisseria gonorrhoeae (NG) - Treponema pallidum (TP)- Ureaplasma urealyticum (UU) - Trichomonas vaginalis (TV)
40934880|NCT05994495|OTHER|Clinical Syndromic Approach|Physical examination
40934881|NCT06477328|PROCEDURE|Telemedicine|Video calls were made with the telemedicine group.
40934882|NCT03767803|OTHER|Non-interventional study|This is an observational, non-interventional study.
40934883|NCT02284971|BIOLOGICAL|CDX1127|
40934884|NCT02284971|RADIATION|SBRT|
40934885|NCT04563676|BIOLOGICAL|blood test|covid19 infected patient will have a blood test in order to make an autoimmune assessment (antinuclear antibodies, soluble nuclear anti-antigen, ANCA, antiphospholipid antibodies, FT3, FT4 , TSH, antithyroid antibodies, ACTH cortisol, and creation of a serotheque).
40934886|NCT06154200|DRUG|Testosterone gel 4.5%|Testosterone gel applied to eyelids twice per day
40934887|NCT06154200|DRUG|Vehicle gel|Vehicle gel applied to eyelids twice per day
40934888|NCT05853627|BEHAVIORAL|Memory reactivation procedures|In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.
40934889|NCT05853627|DRUG|Propranolol|Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
40934890|NCT04540939|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"There will be 8 sessions and these will be approximately 2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
40934891|NCT04540939|BEHAVIORAL|Muscle Relaxation Therapy|Each MR session is approximately 2 hours. Over the 8-weeks you will learn how to relax your body using a step-by-step process in which you alternate between squeezing and relaxing your muscles. You will learn about your body's natural response to stress and how to use muscle relaxation during your everyday life. Each session will also involve group discussion and feedback. You will be asked to practice these techniques at home, and keep a log of your mood, and stress ratings. You will receive audio files with exercises so you can practice at home between sessions.
40934892|NCT05447741|DIAGNOSTIC_TEST|Quantitative Ultrasound|Shear Wave Elastography acquisition. RF data acquisition (for HDK parameters calculation).
40934893|NCT04789018|OTHER|Educational Intervention|Attend virtual genetics board
40934894|NCT04789018|OTHER|Survey Administration|Complete survey
40934895|NCT04789018|OTHER|Interview|Complete interview
40934896|NCT06516341|PROCEDURE|CD patients|The study will involve the collection of mucosal brushes and collection of additional volume of blood and feces of patients at the time of surgery
40934897|NCT06516341|PROCEDURE|UC patients|The study will involve the collection of mucosal brushes and collection of additional volume of blood and feces of patients at the time of surgery
40934898|NCT03044639|DRUG|Lipid Emulsions, Intravenous|The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
40934899|NCT05352776|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
40934900|NCT01617148|DRUG|Aflibercept|Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
40934901|NCT06523374|PROCEDURE|Endoscopic brush cytology|A total of four brush samples will be taken during the endoscopy. Other minimally invasive interventions during this study are standard of care.
40934902|NCT05806671|DRUG|Dalpiciclib|Dalpiciclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off
40934903|NCT05806671|DRUG|Pyrotinib|Pyrotinib 320mg/day orally continuously
40934904|NCT05806671|DRUG|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle
40934905|NCT03593941|OTHER|Standard Diet|Participants will consume the standard diet provided in care home
40934906|NCT02385136|DRUG|Temozolomide|
40934907|NCT05929755|DRUG|Depo-Medrol|steroid
40934908|NCT05929755|DRUG|Gel-Flow NT|hemostatic agent
40934909|NCT06095622|DIETARY_SUPPLEMENT|Fenugreek Seeds and Indian Rennet|Food herbs like fenugreek Seeds and Indian rennet to formulate rice dish.
40934910|NCT01505647|BIOLOGICAL|Zoster Vaccine, Live (AMP)|One approximately 0.65-mL injection subcutaneously on Day 1
41450033|NCT05937451|OTHER|PRIME solution|The investigators will apply an AKI prediction model (PRIME solution) based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician.
40934911|NCT01505647|BIOLOGICAL|Zoster Vaccine, Live|One approximately 0.65-mL injection subcutaneously on Day 1
40934912|NCT03216031|BEHAVIORAL|Gardening programme|3 groups with up to 10 patients and 2-4 students/staff members each should meet once per week for about 1 hour to engage in gardening activities at the falls prevention growing site. Each participant will attend the programme 8 times.
40934913|NCT01958112|DRUG|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
40934914|NCT01958112|DRUG|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
40934915|NCT04149275|DRUG|Cabozantinib|Treatment with oral Cabozantinib once daily
40934916|NCT04149275|DRUG|Ipilimumab|IV administration of Ipilimumab on 21 day cycles
40934917|NCT04149275|DRUG|Nivolumab|IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles
40934918|NCT03705624|OTHER|Enhanced Community Case Management (CCM)|Enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with AL according to national guidelines
40934919|NCT03705624|OTHER|Monthly Screening and Treatment (MSAT)|Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
40934920|NCT04506762|PROCEDURE|Regional analgesia|Insertion of bilateral ESP catheters
40934921|NCT00321893|DRUG|Budesonide|Inhaled Budesonide 800 micrograms (ug) twice daily for one year.
40934922|NCT00321893|OTHER|Placebo|Inhaled placebo twice daily for one year.
40934923|NCT02172170|DRUG|BI 10773 single rising dose|
40934924|NCT02172170|DRUG|Placebo|
40934925|NCT01580371|DRUG|CKD-581|CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
40934926|NCT06518005|DRUG|Imlifidase|Imlifidase: single administration (dose is confidential), Lyophilized powder for concentrate for solution for infusion
40934927|NCT06518005|DRUG|GNT0003|GNT0003: single administration 5E+12 VG/kg, Sterile concentrate for solution for infusion
40934928|NCT01629706|DEVICE|Balafilcon A contact lens|Commercially marketed silicone hydrogel contact lens
41279593|NCT04854655|OTHER|Giomer|fluoride releasing hybrid material
40934929|NCT01629706|DEVICE|Habitual contact lenses|Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power
40934930|NCT01629706|DEVICE|Renu multi-purpose solution|Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
40934931|NCT01629706|DEVICE|ClearCare|Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses
40934932|NCT01629706|DEVICE|Habitual lens care|Lens care per habitual use
40934933|NCT01785095|DRUG|FSH (Follicle Stimulating Hormone)|
40934934|NCT02392845|DRUG|Combination of Docetaxel (DTX) and Epirubicin (EPI)|Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
41279594|NCT01962142|OTHER|Assessment of activity capacities|
41450034|NCT00058435|BIOLOGICAL|abagovomab|
41450035|NCT02241551|DRUG|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
40934935|NCT01367080|DRUG|DWETR10|Amitriptyline hydrochloride 10mg(DWETR10) single dose
40934936|NCT01367080|DRUG|DWETR25|Amitriptyline hydrochloride 25mg(DWETR25) single dose
40934937|NCT00332371|DEVICE|CPFA (Coupled Plasma Filtration Adsorption)|"CPFA is a specific method for the treatment of sepsis.~It consists of:~1. a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)~2. a hemofilter (polyethersulfone 1,4 m2)~3. a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)~The kit is lodged in the Bellco Lynda machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter."
40934938|NCT00453960|DIETARY_SUPPLEMENT|Genivis|54 mg/day daily for 6 months
40934939|NCT00453960|DRUG|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
40934940|NCT00453960|OTHER|placebo|tablets daily for 6 months
40934941|NCT03959228|DRUG|keto-analogs|The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).
40934942|NCT00238511|DRUG|SPM 927|
40934943|NCT02151136|DRUG|24% sucrose|
40934944|NCT02151136|DRUG|Sterile water|
40934945|NCT02151136|OTHER|Standard care|The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
41279595|NCT05973409|DEVICE|scleral lens|scleral lens with and without hydra-peg coating
41279596|NCT04265391|DIETARY_SUPPLEMENT|cookies|Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
41279597|NCT05766956|OTHER|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
41279598|NCT05766956|OTHER|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
41279599|NCT03840629|OTHER|No study intervention.|
41279600|NCT00204087|BEHAVIORAL|Cognitive behavioral therapy (CBT)|
41279601|NCT00204087|BEHAVIORAL|Supportive Counselling (SC)|
41279602|NCT00663130|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
41279603|NCT00663130|DRUG|Tadalafil|Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
41279604|NCT06118879|DEVICE|Transcutaneous electrical stimulation|sensory level stimulation, one-leg standing and Y-balance training
40934946|NCT06479395|OTHER|Pediatric Endurance and Limb Strengthening (PEDALS) program|Participants will perform pediatric endurance and limb strengthening (PEDALS) program. The stationary cycling intervention will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. The longer session duration is designed to allow adequate rest intervals between set (1-3 minutes). A generalized stretching program will be performed prior to cycling for mental relaxation for 6-7 minutes. Ankle-foot orthosis if used for walking. Each 60 minutes cycling session will be divided into 2 phases: (1) lower-extremity strengthening and (2) cardiorespiratory endurance.
40934947|NCT06479395|OTHER|Task-Oriented Training (TOT)|The experimental protocol consists of task-oriented training program (TOT) .it will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. Before each training session, there will be a warm-up period with 5 to 10 minutes of dynamic activities (e.g., jogging). After training, there will be a cool down period with 5 to 10 minutes of dynamic stretching exercises. In addition to rest intervals. after training session, there will be a 48-hour rest interval to prevent muscle fatigue and injury.
40934948|NCT03872414|BEHAVIORAL|Anterior cingulate cortex activation|"Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing."
40934949|NCT03872414|BEHAVIORAL|Primary auditory cortex activation|"Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as control/placebo condition in the current design (placebo comparator)."
40934950|NCT04686045|OTHER|observational study|observational study
40934951|NCT01261832|DRUG|antiplatelet therapy|Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
40934952|NCT04378985|DEVICE|Wearing a Wearable device (Fitbit inspire HR)|"'Wearing a wearable device (the smart watch) for 8 weeks~The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.'"
40934953|NCT05911425|DRUG|envolizumab , sovalteinib|Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
40934954|NCT01285687|DEVICE|acupuncture|Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
40934955|NCT04378452|BEHAVIORAL|COM-COVID anonimous survey|Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.
41129913|NCT04471441|DRUG|Everolimus Tab.|After first dose 1mg BID(total 2mg daily PO), check the blood concentration of everolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/mL.
41129914|NCT04471441|DRUG|Mycophenolate mofetil Tab./Cap.|Up to 1.5g BID(total 3g daily), PO
41129915|NCT00336505|DRUG|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
41129916|NCT00336505|DRUG|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
41279605|NCT06228755|BEHAVIORAL|Integrative Medicine Group Visit|Integrative Medicine Group Visit (IMGV) is a 9-week group visit series co-facilitated by a billing primary care provider and a trained co-facilitator (such as a behavioral health provider, mindfulness instructor, or yoga teacher). The IMGV will be delivered virtually over a secure telehealth platform for 2 hours weekly. The IMGV curriculum focuses on principles of mindfulness-based stress reduction, and includes patient education on pain, insomnia, nutrition, yoga, depression, self-massage, and self-acupressure.
41279606|NCT06228755|OTHER|Implementation Strategies|"Package includes:~* Patient strategies will include an orientation session to introduce patients to the IMGV model.~* Provider strategies include training in delivery of IMGV with continuing education credits. Training may be delivered on-line or in-person. Ongoing coaching in the first year of IMGV implementation will also be offered to providers leading IMGV, to increase self-efficacy to deliver the curriculum, and enhance fidelity."
41279607|NCT00443508|DRUG|adding Certican to therapy|
41279608|NCT00443508|DRUG|reducing Tacrolimus|
41279609|NCT06468371|DRUG|Dopamine Agonist (Ropinirole)|Ropinirole administration will start at 0.25 mg orally once daily, two hours before bedtime. The dose will be adjusted weekly based on symptoms, increasing by 0.5 mg increments, up to a maximum of 2.0 mg, which will be maintained for the remaining 12 weeks.
41450036|NCT02241551|DRUG|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
41450037|NCT02853019|OTHER|Electroencephalogram|electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli
41450038|NCT02853019|BEHAVIORAL|Cognitive tasks|- clinical scales and subjective assessments of emotional and motivational stimuli
41450039|NCT02853019|BEHAVIORAL|subjective evaluation scales|- clinical scales and subjective assessments of emotional and motivational stimuli
41450040|NCT05799677|OTHER|Reflexology|Additive reflexology treatment
40934956|NCT00421447|DRUG|Anastrozole|Group of women with breast cancer
40934957|NCT04503291|PROCEDURE|Metal stent placement|Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
40934958|NCT00213408|PROCEDURE|Radiofrequency catheter ablation of typical atrial flutter|
40934959|NCT06041971|DEVICE|AIDANET system|The study will involve testing a new AID system designed to enable full closed loop control and consisting of the following elements: the diabetes assistant (DiAs) prototyping platform (MAF 2019), connected to a Tandem t:AP research insulin pump and a Dexcom G6 CGM, and implementing the University of Virginia (UVA) AIDANET algorithm.
40934960|NCT05297435|DIAGNOSTIC_TEST|Questionnaires|Questionnaire study
40934961|NCT06260761|PROCEDURE|MIPO|minimal invasive surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
40934962|NCT06260761|PROCEDURE|Conventional|standard surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
40934963|NCT05363943|PROCEDURE|double plating|open reduction and internal fixation by using lateral and medial plates.
40934964|NCT05363943|PROCEDURE|Distal femoral replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
40934965|NCT05915559|PROCEDURE|Tonsillectomy|Tonsillectomy
40934966|NCT05915559|OTHER|daily follow-up|daily follow-up of clinical parameters (pain, feeding) and analgesia adapted to the pain
40934967|NCT01372982|DRUG|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
40934968|NCT06518694|DRUG|Βeta-Blockers discontinued (with tapering)|"The experimental group will undergo discontinuation of their beta-blockers treatment during the study period.~The tapering of beta-blocker will start on the day after randomisation and is based on a reduction by half-dose every 48 hours (1/2 maximally recommended dose for 48 hours, then ¼ maximally recommended dose for 48 hours) until reaching the minimal recommended dosage (1/8 maximally recommended dose) for 48 hours before complete interruption of treatment. Consequently, the tapering will not be needed in patients already receiving the minimal recommended dosage (i.e., 1/8 dose) at inclusion, and these patients will be instructed to stop taking beta-blockers the day after randomisation."
41279610|NCT06468371|OTHER|Excercise training|Exercise sessions will involve using a pedal bicycle twice a week for 12 weeks, integrated into the patients' hemodialysis schedule. Each session will last 20 minutes, scheduled between the second and third hours of dialysis. The first 5 minutes will be for warm-up with slow pedaling, followed by 10 minutes of intense pedaling, and concluding with a 5-minute cool-down period of slow pedaling to gradually reduce the heart rate.
40934969|NCT06164210|BEHAVIORAL|Snoezelen-Based Occupational Therapy Intervention Group|Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen-based interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.
40934970|NCT00498056|BIOLOGICAL|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
40934971|NCT00498056|BIOLOGICAL|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
41129917|NCT06463249|BEHAVIORAL|CORE Helpline|All participants will receive the Core Helpline program (CORE) for 2 months, which includes written weight loss material, use of a smartphone app, weekly text messages and email reminders and 1 optional participant-initiated coaching call per month.
41129918|NCT06463249|BEHAVIORAL|Extended Helpline|Those who achieved 2% weight loss at 2-month, will continue to Extended Helpline, where the participants can continue receiving all CORE resources including1-on-1 coaching through 1 optional participant-initiated call per month for 6 months.
40934972|NCT00498056|BIOLOGICAL|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
40934973|NCT00498056|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
40934974|NCT04186091|PROCEDURE|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction
40934975|NCT00201331|DRUG|leucovorin+5-FU|
40934976|NCT04581135|OTHER|COVID-19|Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
41129919|NCT06463249|BEHAVIORAL|Enhanced Helpline|Those who do not reach 2% weight loss at the end of 2 months will be randomized. Participants will continue to receive all CORE resources plus 1 optional participant-initiated call/month for 6 months. Additionally, the participants will receive 2 individualized coach-scripted feedback emails per month, and the option to receive daily text message reminders.
41279611|NCT03784378|DRUG|RXDX-105|RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
41279612|NCT01605474|OTHER|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
40934977|NCT00407290|DRUG|neostigmine|
41279613|NCT01605474|OTHER|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
40934978|NCT04727281|OTHER|Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form and Malnutrition-Inflammation Score|"Data about nutritional status using the Malnutrition-Inflammation Score, and Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form. Dialysis related data, The time needed for the patient to recover from a dialysis session (in minutes), Detailed history taking, Thorough physical examination, Laboratory Investigations:~• Hemoglobin , Serum sodium and potassium , Serum creatinine and blood urea , Serum phosphorus, serum calcium , Serum PTH level , Serum albumin ,CRP ,Total iron-binding capacity ."
40934979|NCT06280014|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was given mefenamic acid as a medication.
40934980|NCT06280014|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was dexketoprofen as a medication.
40934981|NCT01057901|DRUG|Flibanserin|Flibanserin 100mg administered at bedtime for 24 weeks
40934982|NCT01057901|DRUG|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
41129920|NCT06463249|BEHAVIORAL|Intensive Helpline|Those who do not reach 2% weight loss at the end of 2 months will be randomized. Participants will continue to receive all CORE resources plus 2 scheduled coaching calls/month for 6 months. Additionally, the participants will receive 2 individual coach-scripted feedback emails per month, and the option to receive daily text message reminders.
41129921|NCT03132688|DRUG|Propofol|Intravenous administration with dose of 100-200mcg/kg/min
40934985|NCT05806684|OTHER|ROP|Correlation between neonatal indirect bilirubin jaundice and ROP.
40934986|NCT02934529|DRUG|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
40934987|NCT02934529|DRUG|Folinic Acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
40934988|NCT02934529|DRUG|5-FU|5-FU 400 mg/m² bolus day 1, q d15
40934989|NCT02934529|DRUG|5-FU|5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
40934990|NCT02934529|DRUG|Cetuximab|cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
40934991|NCT02934529|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
40934992|NCT02934529|DRUG|Capecitabine|Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
40934993|NCT02934529|DRUG|regorafenib|160 mg per day (day 1-21) (repeated on day 28)
40934994|NCT02934529|DRUG|Irinotecan 125mg|Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
40934995|NCT02934529|DRUG|Cetuximab wkly|Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
40934996|NCT02879240|OTHER|Animated Cartoon|An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.
40934997|NCT02879240|OTHER|Black screen|A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.
40934998|NCT02937974|DRUG|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
40934999|NCT02937974|DRUG|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
40935000|NCT05029973|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
40935001|NCT05029973|DRUG|Sintilimab|200mg IV d1,Q3W
40935002|NCT05029973|DRUG|Bevacizumab Biosimilar|7.5mg/kg IV d1,Q3W
40935003|NCT00686998|DRUG|AZD2624|Oral Suspension
40935004|NCT00686998|DRUG|Olanzapine|PO BID
40935005|NCT00686998|DRUG|Placebo|
40935006|NCT06108986|OTHER|tabata training|this include tabata training thrice a week for six weeks
40935007|NCT06108986|OTHER|plyometric training|this include plyometric training thrice a week for six weeks
40935008|NCT05089201|BEHAVIORAL|Animal-assisted interaction|A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
40935009|NCT05089201|BEHAVIORAL|Conversational control|A handler alone will visit participants without a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
40935010|NCT00318227|PROCEDURE|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
40935011|NCT02689687|BEHAVIORAL|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
40935012|NCT02689687|BEHAVIORAL|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
40935013|NCT02689687|BEHAVIORAL|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
40935014|NCT02689687|BEHAVIORAL|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
40935015|NCT06150144|DRUG|5-Fluorouracil|The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.
40935016|NCT06150144|OTHER|SURGERY|Total excision of the lesion
40935017|NCT05151627|PROCEDURE|KINESIO TAPING|Kinesio taping The patient is in a supine position with full knee flexion. Prior to application, the skin surface was cleaned. This technique involved the use of two Y-cut strips and two I-cut strips.
40935018|NCT05151627|DEVICE|CONVENTIONAL PHYSICAL THERAPY|"Transcutaneous Electrical Nerve Stimulation TENS device settings, such as the frequency of 32-50 Hz, pulse width of 80 ms, and symmetrical biphasic waveform. The surface electrodes were placed on the medial and lateral superior borders of the patella, as well as the medial and lateral inferior borders of the patella.~Exercise therapy program The total duration of each exercise session was about 50 minutes, including warm-up-10 minutes, resistance exercise-20 minutes, balance and stability exercise-10 minutes, lower-limb stretching exercise-5 minutes, and cool-down exercise-5 minutes. The same assigned physical therapist supervised all of the sessions."
40935019|NCT05354154|PROCEDURE|endotracheal intubation|Consenting healthy patients of either sex will be endotracheally intubated under controlled environment
40935020|NCT04054427|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD L GF consisting of hydrophobic material
40935021|NCT05320627|DRUG|Edoxaban|Eligible patients will receive Edoxaban tablet once a day for 12 weeks
40935022|NCT04862858|OTHER|Educational Intervention|The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.
40935023|NCT06318962|BEHAVIORAL|Aviva|Digital phone app for BCBT
40935024|NCT05683184|DRUG|[11C]OMAR|For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
40935025|NCT00000203|DRUG|Buprenorphine|
40935026|NCT04862195|DEVICE|Attune™|Software as a medical device
40935027|NCT04862195|DEVICE|Cerena™|Software as a medical device
40935028|NCT01205581|BIOLOGICAL|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
40935029|NCT01205581|BIOLOGICAL|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
40935030|NCT06514443|OTHER|survey|survey exploring barriers and faciltiators for physical activity
40935031|NCT01773447|PROCEDURE|Set-back suture|
40935032|NCT01773447|PROCEDURE|Vertical mattress suture|
40935033|NCT02953158|OTHER|Haas Avocado|Hypocaloric weight loss diet
40935034|NCT02953158|BEHAVIORAL|Dietary Counseling|Dietary Counseling
40935035|NCT05503121|DIAGNOSTIC_TEST|3D motion analysis, muscle activation, biomarker analysis|Participants with nonspesific low back pain and control group will be analysed with 3D motion analysis sistem, sEMG and will be checked the biomarkers. Then the data will be compared.
40935036|NCT04690205|OTHER|End of Life (EOL) Care at at Home|Remote monitoring and home-based care designed for patients with advanced hematologic malignancies
40935037|NCT01840995|PROCEDURE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
40935038|NCT00097851|DRUG|docetaxel|
40935039|NCT00097851|DRUG|PI-88|
40935040|NCT02148146|DRUG|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
40935041|NCT05000333|OTHER|Self-questionnaire|The study will be proposed to caregivers who work at Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges, who agree to answer the questionnaire anonymously
40935042|NCT02235259|DRUG|XG-104|Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
40935043|NCT02235259|DRUG|Placebo|
40935044|NCT02599805|DEVICE|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
40935045|NCT04484168|PROCEDURE|Terminal Interruption of the Reflux Source|Foam Sclerotherapy of veins in the immediate vicinity of the venous ulcer
41129922|NCT01818180|DIETARY_SUPPLEMENT|URELL|
40935046|NCT04484168|PROCEDURE|Axial Ablation|Endovenous ablation of venous reflux in the main superficial veins of the leg
40935047|NCT01933815|DRUG|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
40935048|NCT01933815|DRUG|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
40935049|NCT05242861|RADIATION|Brachytherapy|Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
40935050|NCT02958384|BIOLOGICAL|Anti-LeY-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived LeY-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
40935051|NCT00242983|PROCEDURE|quality-of-life assessment|
41129923|NCT01818180|OTHER|Placebo|
40935052|NCT03882775|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute STEMI during emergency PCI operation.
40935053|NCT03882775|DRUG|Heparin|heparin with or without gpi during emergency PCI.
40935054|NCT03238846|OTHER|Three month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
40935055|NCT03238846|OTHER|Six month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
40935056|NCT04510571|OTHER|Evaluating Postoperative Pain After Root Canal Treatment with Protaper Next|Patients were randomly separated into two groups and root canal treatments were completed with Protaper Next file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
41279614|NCT05635565|OTHER|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
40935057|NCT04510571|OTHER|Evaluating Postoperative Pain After Root Canal Treatment with Reciproc Blue Files|Patients were randomly separated into two groups and root canal treatments were completed with Reciproc Blue file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
40935058|NCT00812487|DRUG|Intravenous insulin|Patients will receive continuous insulin infusion through the vein.
40935059|NCT00812487|DRUG|Subcutaneous insulin|4 injections of insulin/day
40935060|NCT02766842|PROCEDURE|EUS-FNB with ProCore needle|The use of the standard ProCore needle to acquire diagnostic tissue
40935061|NCT02766842|PROCEDURE|EUS-FNB with SharkCore needle|The use of new SharkCore needle to acquire diagnostic tissue
40935062|NCT02766842|DEVICE|ProCore needle|This is the standard needle used currently to procure tissue from lesions under endoscopic ultrasound guidance
40935063|NCT02766842|DEVICE|SharkCore needle|This is the new FDA approved needle for tissue procurement under endoscopic ultrasound guidance.
40935064|NCT00468039|DRUG|vildagliptin + metformin|
40935065|NCT00550056|BEHAVIORAL|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
40935066|NCT00550056|BEHAVIORAL|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
40935067|NCT00480974|OTHER|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
40935068|NCT04961970|DRUG|oxaliplatin , fluorouracil, and leucovorin|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
41129924|NCT06520306|DRUG|Ropivacaine combined with methylene blue for iliac fascia block|Ultrasound-guided fascia iliaca block using different concentrations of methylene blue combined with ropivacaine
40935069|NCT04961970|DRUG|gemcitabine and cisplatin|administration of gemcitabine and cisplatin via vein
40935070|NCT05685628|OTHER|Cinnamon dressing|"Use of CINESTEAM® as a non-occlusive secondary dressing~CE marked medical device class I, secondary, absorbent, non-adhesive and composed of:~* Anti-odor upper part, adsorbent containing cinnamon powder.~* Weakly absorbent lower part intended to absorb excess exudates."
40935071|NCT05685628|OTHER|Charcoal dressing|"Use of ACTISORB® as a non-occlusive secondary dressing~CE marked medical device class IIb, without adhesive, consisting of a non-woven nylon envelope containing a layer of activated carbon. ACTISORB® can be applied as a primary or secondary dressing."
40935072|NCT02117427|BIOLOGICAL|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
41129925|NCT03875066|OTHER|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
41279615|NCT05635565|OTHER|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
40935073|NCT02687659|DEVICE|TEMIS system|Wearing TEMIS system over the day during one week
40935074|NCT01957527|DEVICE|Peripheral arterial tonometry (EndoPAT)|
40935075|NCT05147779|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
40935076|NCT01692873|PROCEDURE|suspected pancreatic tumor|Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
40935077|NCT05958173|DIETARY_SUPPLEMENT|Capsaicin|Oral stimulation with natural TRPV1 agonist
40935078|NCT05958173|DIETARY_SUPPLEMENT|Piperine|Oral stimulation with natural TRPA1/V1 agonist
40935079|NCT05958173|DIETARY_SUPPLEMENT|Placebo|Oral stimulation with placebo solution
40935080|NCT06335147|DRUG|Serplulimab, mFOLFOX6|Serplulimab，200mg，iv，q2w，d1； mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）
40935081|NCT04620941|DIAGNOSTIC_TEST|reticulocyte/hemoglobin (Ret-He) ratio|Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.
40935082|NCT02414139|DRUG|Capmatinib|"Capmatinib was administered orally, at a dose of 400 mg on a continuous twice daily dosing schedule.~Capmatinib was administered to participants in Cohorts 1a, 1b, 2, 3, 4, 5a and 5b in a fasted state. For Cohorts 6.1. 6.2 and 7, capmatinib was administered either with or without food."
40935083|NCT02417844|DRUG|tamsulosin (Astellas)|
40935084|NCT02417844|DRUG|Tamsulosin HCL|
40935085|NCT00329940|DRUG|Letrozole|
40935086|NCT03209453|OTHER|family work shop|Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.
40935087|NCT01846520|OTHER|educational intervention|Receive FCPCI home education sessions
40935088|NCT01846520|BEHAVIORAL|telephone-based intervention|Receive FCPCI telephone support sessions and 24 hour telephone support
41129926|NCT03875066|OTHER|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
41129927|NCT01736475|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
41129928|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
40935089|NCT01846520|PROCEDURE|quality-of-life assessment|Ancillary studies
40935090|NCT01846520|OTHER|questionnaire administration|Ancillary studies
40935091|NCT05680259|OTHER|Maela connected follow-up|Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
40935092|NCT05680259|OTHER|traditional follow-up|medical recommendations and prescriptions at hospital discharge. Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
40935093|NCT00123968|BIOLOGICAL|VRC-HIVDNA016-00-VP|1x10\^11 per unit vaccine administered intramuscularly via Bioinjector
40935094|NCT00123968|BIOLOGICAL|VRC-HIVADV014-00-VP|4 mg administered intramuscularly via injection
40935095|NCT00123968|BIOLOGICAL|VRC-DILUENT013-DIL-VP|Administered intramuscularly via Bioinjector
40935096|NCT00123968|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|4 mg administered intramuscularly via injection
40935097|NCT06416995|DIAGNOSTIC_TEST|first trimester serum diagnostic test|First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes
40935098|NCT03047681|DIAGNOSTIC_TEST|venous blood withdrawl|patients will be asked for a venous blood sample
40935099|NCT02596282|PROCEDURE|Neonatal circumcision under topical anesthesia|"The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine \<1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care."
40935100|NCT05977478|DEVICE|SPECTRA IMDx™|In this study, SPECTRA IMDxTM system will be used to capture the Raman spectra to correlate to histopathology results and mass spectrometry profiling results.
40935101|NCT04029532|DEVICE|Respiratory exchange ratio|Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.
40935102|NCT04029532|DEVICE|Heart rate variability|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.
40935103|NCT04029532|DEVICE|Body composition|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.
40935104|NCT04029532|BEHAVIORAL|Eating behavior|Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).
40935105|NCT04029532|BEHAVIORAL|Physical activity recall|Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).
40935106|NCT04029532|BEHAVIORAL|Depression|Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).
40935107|NCT04029532|BEHAVIORAL|Body image|Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
41279616|NCT04948996|BEHAVIORAL|El Buen Consejo Móvil- Group (EBCM-G)|"1. Psycho-education and Information using a CBT toolbox approach.~2. Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~3. Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~4. Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol.~Additionally, participants in the Group Intervention will be able to communicate with and respond to one another through the group chat rooms within the app."
41453505|NCT03949296|BEHAVIORAL|Mindfulness Intervention|"10-session program~1. Introduction to mindfulness and its potential benefits~2. Introduction to mindful practices and yoga poses~3. Conditioned reactions to stress; integrating mindfulness into everyday life~4. Challenges and insights gained in practicing mindfulness~5. Using mindfulness to observe and reduce negative means of reacting to stress, and find more effective responses~6. Reacting vs. responding to stressors~7. Self-regulation and coping with stressors and communication challenges~8. Fostering continuity of moment-to-moment awareness while practicing different forms of mindfulness~9. Choosing and creating one's own blend of mindfulness practices~10. Maintaining momentum to practice mindfulness once the program ends"
40935108|NCT02961218|DRUG|ACZ885|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
40935109|NCT02961218|DRUG|Placebo|Monthly doses of placebo to match the administered dose of canakinumab s.c.
40935110|NCT01178255|DRUG|homeopathic q-potencies|individualised homeopathic medicines
40935111|NCT01178255|DRUG|Placebo|placebo
40935112|NCT01178255|OTHER|homeopathic case history taking type I|one special homeopathic technique for case history taking
40935113|NCT01178255|OTHER|homeopathic case history type II|another type of homeopathic case history taking
40935114|NCT02319356|DIETARY_SUPPLEMENT|Beetroot juice|(BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
40935115|NCT02319356|DIETARY_SUPPLEMENT|Placebo beetroot juice|(PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
40935116|NCT01871103|PROCEDURE|The dorsal homodigital island flap|The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
40935117|NCT02658097|DRUG|Pembrolizumab|200mg Pembrolizumab by IV infusion
40935118|NCT02658097|RADIATION|Single Fraction Radiation Therapy|8Gy radiation therapy will be given in a single fraction on the first day of treatment
40935119|NCT04173793|DRUG|AK102|Administered by subcutaneous injection
40935120|NCT04173793|DRUG|Placebo|Administered by subcutaneous injection
40935121|NCT04173793|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
40935122|NCT05629000|PROCEDURE|Carotid revascularization|All patients received carotid revascularization surgery at Peking Union Medical College Hospital.
40935123|NCT05629000|DIAGNOSTIC_TEST|MRI-PWI|Multi-modal MRI before and after surgery.
40935124|NCT05629000|DIAGNOSTIC_TEST|CTA|CTA before and after surgery.
40935125|NCT05629000|DIAGNOSTIC_TEST|PET/MRI|PET/MRI before surgery.
40935126|NCT05629000|DIAGNOSTIC_TEST|Ultrasound|Ultrasound before and after surgery.
40935127|NCT04656483|OTHER|Telemedicine Video Feedback Intervention|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
40935128|NCT04656483|OTHER|Psychoeducational Booklet Intervention|Mothers of this condition will receive an informative booklet addressing the same themes included in the experimental intervention (responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant status.
41279617|NCT04948996|BEHAVIORAL|El Buen Consejo Móvil- Individual (EBCM-I)|"1. Psycho-education and Information using a CBT toolbox approach.~2. Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~3. Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~4. Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol."
41279618|NCT02160418|BEHAVIORAL|Financial Incentives|
41279619|NCT02160418|BEHAVIORAL|Cognitive Incentives|
41279620|NCT02160418|BEHAVIORAL|Financial and Cognitive Incentives|
41279621|NCT04872725|BEHAVIORAL|Time management & participation & the leisure time activity|evaluated in terms of leisure time activities, time management and participation
41279622|NCT01218022|DRUG|Losartan Potassium Tablets|
41279623|NCT06332443|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed in the sitting or lateral position under sterile conditions. Spinal puncture will be performed at L2-L4 level using 50 mg of Clorotekal 1 or 2%. (intermediate-acting amide local anesthesia, commonly used) will be injected.
41279624|NCT06332443|PROCEDURE|Sedation epidural anesthesia|Sedation-EA will be performed in the sitting or lateral position under sterile conditions. Epidural puncture will be performed at the L2-L4 level and an epidural catheter will be inserted into the epidural space. 10 ml of 2% xylocaine without epinephrine will be injected through the catheter and the dose will be titrated (up to 20 mL) to achieve complete sensory block up to T12 dermatoma measured with a level to ice.
41279625|NCT05072405|DRUG|Simvastatin 20 mg (Zocor®, MSD)|Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.
41279626|NCT05072405|DRUG|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
41279627|NCT01810887|DRUG|Darunavir|Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
40935129|NCT00003950|DRUG|cyclosporine|
41279628|NCT01810887|DRUG|Ritonavir|Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
41279629|NCT01137435|BIOLOGICAL|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
41279630|NCT00003554|BIOLOGICAL|rituximab|
40935130|NCT00003950|DRUG|CPT-11|
40935131|NCT02316873|BEHAVIORAL|Music training|This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
40935132|NCT02316873|BEHAVIORAL|Visual arts|This program emphasized visual-spatial and hand skills as well as creativity.
41129929|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
41129930|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|On-demand treatment
41129931|NCT04140643|DEVICE|Ozonated water delivering device effects on the oral health of pregnant women|Oral Hygiene instructions and use of an ozonated water delivering device in pregnant women for a period of 75 days.
41129932|NCT04140643|BEHAVIORAL|Oral hygiene instructions|Oral Hygiene instructions
41279631|NCT00003554|DRUG|melphalan|
41279632|NCT00003554|DRUG|prednisone|
40935133|NCT05637593|BEHAVIORAL|Upper-limb movement training with the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
40935134|NCT05637593|BEHAVIORAL|Upper-limb movement training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
40935135|NCT02352584|BIOLOGICAL|GC3110A(Quadrivalent)|GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
40935136|NCT02352584|BIOLOGICAL|GC Flu(Trivalent)|GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
40935137|NCT02352584|BIOLOGICAL|GC3110A(Trivalent)|GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
40935138|NCT01284049|DRUG|Intralipid 20%®|Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
40935139|NCT01284049|DRUG|OMEGAVEN 10%®|OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
40935140|NCT02140775|BEHAVIORAL|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
40935141|NCT06484205|OTHER|WHO QualityRights e-training|WHO QualityRights training provides the necessary skills to support people with psychosocial disabilities in advocating for their rights. The QualityRights online course includes six main modules: 1) Human Rights; 2) Human rights, mental health and disability; 3) Legal capacity and the right to decide; 4) Stop coercion, violence and mistreatment; 5) Quality services and inclusion in the community; 6) Mental health, well-being and recovery and it will take approximately 8 hours for completion. QualityRights course modules can be completed at each participant's pace and needs. The training is considered concluded once the quizzes provided at the end of each of the six modules have been successfully completed and upon completion of the course it will be possible to download your official WHO certificate from the QR platform.
40935142|NCT06484205|OTHER|Emotional intelligence e-training|This course offers caregivers resources and knowledge so that they are able to manage their emotions and gain quality in the care they provide to others and in their own lives. The course duration is similar to that of the QualityRights online course and is intended for caregivers of people with disabilities and others interested
40935143|NCT06387433|BEHAVIORAL|mobile app use|The experimental group will use the mobile application while controlled group will not use mobile application. Investigators will assess the effectiveness of mobile application in ensuring medication adherence and self-management among diabetics in Pakistan
40935144|NCT02252276|PROCEDURE|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
40935145|NCT02252276|PROCEDURE|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
40935146|NCT01304784|DRUG|Cisplatin, Capecitabine, Trastuzumab and MM-111|Conventional chemotherapy
40935147|NCT01304784|DRUG|Lapatinib +/- Trastuzumab and MM-111|Conventional chemotherapy
40935148|NCT01304784|DRUG|Paclitaxel, Trastuzumab and MM-111|Conventional chemotherapy
40935149|NCT01304784|DRUG|Lapatinib, trastuzumab, paclitaxel, and MM-111|Conventional chemo
40935150|NCT01304784|DRUG|Docetaxel, trastuzumab and MM-111|Conventional chemotherapy
40935151|NCT03195842|OTHER|Recordable card|
40935152|NCT04319679|DEVICE|Extracorporeal shockwave therapy|6 times during 2 weeks
40935153|NCT04319679|DEVICE|Sham therapy|6 times during 2 weeks
40935154|NCT00718081|DRUG|Oral sufentanil|Oral dosage of sufentanil
40935155|NCT00718081|DRUG|Placebo|Oral dosage of placebo
40935156|NCT06482762|DEVICE|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
40935157|NCT05468853|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting medial prefrontal cortex
40935158|NCT05468853|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the inion
40935159|NCT00333892|PROCEDURE|leukapheresis|pack of cells as per protocol
40935160|NCT03585127|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
40935161|NCT03585127|BEHAVIORAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
40935162|NCT05671328|OTHER|Biological examinations performed on blood and BAL|Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL
41129933|NCT06348225|OTHER|Exercise or heat treatment|Interventions will be each of the four arms described previously, administered \~1 week apart in a randomized, counter-balanced fashion.
40935163|NCT02728778|DRUG|incobotulinumtoxin A|Application of botulinum toxin A into the forehead
40935164|NCT02728778|PROCEDURE|Acupuncture|Application of acupuncture into the forehead
40935165|NCT02480725|PROCEDURE|collect CSF (Cerebrospinal fluid) sample|collecting CSF samples for thrombin activity assay
40935166|NCT00322153|DRUG|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
40935167|NCT00322153|DRUG|Placebo|Matching placebo oral administration once daily.
41129934|NCT05121142|DRUG|Ruxolitinib|Ruxolitinib will be given by mouth or enteral tube (if applicable).
41129935|NCT01627314|BIOLOGICAL|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
41129936|NCT01627314|BIOLOGICAL|Untreated CB|Cord Blood
41129937|NCT05500170|DIETARY_SUPPLEMENT|Nicotinamide riboside|Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.
40935168|NCT04373668|BEHAVIORAL|Hypnotic Medication Review|A training programme focused providing guidance on the review and withdrawal process of hypnotic drugs.
40935169|NCT04373668|BEHAVIORAL|Structured Sleep Hygiene|Training module on the principle of good sleep hygiene
40935170|NCT04373668|BEHAVIORAL|Night Time Care Activities Programme|Training and support package to assist in the development of a personalised night time care plan and support the implementation and dissemination of information within the care home environment
40935171|NCT06192589|DRUG|Cannabidiol|Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.
40935172|NCT06192589|DRUG|Placebo|Placebo will be administered orally twice daily for 28 days in Part 1
40935173|NCT06192589|DRUG|Citalopram|Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13.
40935174|NCT06192589|DRUG|Morphine|Morphine will be administered once at 15 mg on days 1, 4, and 11.
40935175|NCT04394182|RADIATION|Ultra-Low-dose radiotherapy|The total dose to be administered was 0.8 Gy in an only single session including both whole-lungs extended 1cm isometric in all directions.
40935176|NCT04394182|DEVICE|ventilatory support with oxygen therapy|Oxygen Therapy: Nasal Cannula (NC); Ventimask (VMK) or VMK with reservoir
40935177|NCT04394182|DRUG|Lopinavir/ritonavir|100/400 mg/12h; 7-10 days
40935178|NCT04394182|DRUG|Hydroxychloroquine|200 mg/12h
40935179|NCT04394182|DRUG|Azithromycin|500 mg/24h, 3 days
40935180|NCT04394182|DRUG|Piperacillin/tazobactam|4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function
40935181|NCT04394182|DRUG|Low molecular weight heparin|prophylactic doses
40935182|NCT04394182|DRUG|Corticosteroid injection|250mg x 3 boluses
40935183|NCT04394182|DRUG|Tocilizumab|600mg single dose
41129938|NCT05500170|DIETARY_SUPPLEMENT|Placebo|The placebo pill will contain micro cellulose powder.
41129939|NCT04042298|OTHER|Arterial blood pressure|Measured using an automated non-invasive finger cuff that obtains beat-by-beat blood pressure measurements via finger photoplesmography. Briefly, changes in artery diameter are detected through infrared light in the finger cuff. (Finometer Pro, FMS, The Netherlands).
41129940|NCT04042298|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine and norepinepherine or phenylepherine via iontophoresis.
41129941|NCT04042298|OTHER|Brachial artery blood flow|A GE Ultrasound System will be used to non-invasively assess brachial artery blood flow prior to and following a standard flow mediated dilation protocol.
41129942|NCT04042298|OTHER|Venous blood draw|A venous blood sample from the antecubital vein or a vein in the back of the hand will be taken via venipuncure by a nurse or a certified phlebotomist at the beginning of the experimental visit. These blood samples will be analyzed for the presence of reactive oxygen species and inflammatory markers.
41129943|NCT02546531|BIOLOGICAL|Defactinib|
41279633|NCT03884634|DEVICE|Dabir Micropressure Overlay|"The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off."
40755735|NCT06500000|DIAGNOSTIC_TEST|liquid chromatography-mass spectrometry (LC/MS)|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography- mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and reproducibility.
40935185|NCT05095376|DRUG|Lomustine|Given PO
40935186|NCT05095376|RADIATION|Photon Beam Radiation Therapy|Undergo radiation therapy
41129944|NCT02546531|BIOLOGICAL|Pembrolizumab|
41129945|NCT02546531|DRUG|Gemcitabine|
41129946|NCT03085407|PROCEDURE|early cholecystectomy|cholecystectomy was done within 48 after admission
41279634|NCT01386671|DRUG|Metformin glycinate|Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
41129947|NCT03085407|PROCEDURE|delayed cholecystectomy|cholecystectomy was done after 30 days after randomization
41129948|NCT01730456|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
41129949|NCT02522312|OTHER|No Intervention|No drug is administered in this study
41129950|NCT03646266|DRUG|Rocuronium Bromide|Titration with rocuronium bromide until tidal volume 6ml/kg PBW
40755736|NCT06471517|DEVICE|Somatosensory feedback|Performing different mobility tasks in 10 separate sessions while the device is providing or not somatotopic sensations through non-invasive electrical stimulation. Benefits connected to the stimulation of sensory nerves will be assessed.
40755737|NCT04704921|GENETIC|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
41129951|NCT01360918|DEVICE|Epicardial pulmonary vein isolation|After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
40755738|NCT04704921|GENETIC|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
40755739|NCT04704921|BIOLOGICAL|Ranibizumab (LUCENTIS®)|0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
41129952|NCT01360918|OTHER|Usual care|Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
41129953|NCT02374736|DRUG|Privigen (Human normal immunoglobulin G (IgG > 98 % purity))|"Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL."
41279635|NCT01386671|DRUG|Metformin hydrochloride|12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
40935187|NCT05095376|OTHER|Quality-of-Life Assessment|Ancillary studies
40935188|NCT05095376|OTHER|Questionnaire Administration|Ancillary studies
40935189|NCT05095376|DRUG|Temozolomide|Given PO
40935190|NCT00521911|BEHAVIORAL|Cognitive Behavioural Therapy|
40935191|NCT05828771|PROCEDURE|THIN FREE FLAP|Flap design will be performed on the basis of the preoperative perforator mapping. Freestyle flap elevation will be performed under loupe magnification from one of the incisions until the perforators are reached
40935192|NCT01264627|BEHAVIORAL|Mindful Breathing (MB) Intervention|"The Mindful Breathing (MB)intervention is based on MBSR developed by Jon Kabat-Zinn. Participants will attend 8 individual weekly MB sessions. MB consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, from a non-evaluative or judgmental perspective. As attention wanders to concerns or thoughts, participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing. Participants in MB will have their breathing rate and PetCO2 monitored during the 8 training sessions with a breathing monitor."
40935193|NCT01264627|BEHAVIORAL|Usual Care (UC) Control Condition|"This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and (Blood Pressure) BP, and completion of questionnaires. Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition. UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online Healthy Lifestyle Programs. We will assess the extent to which participants in both MB and UC used these resources."
40935194|NCT05054244|OTHER|standard wound treatment|Standard treatment includes dressings, debridement, antibiotics, and bacterial load relief. The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with formed granulation tissue. The progression of the wound and the need for specific treatment will be evaluated weekly by dermatologist and vascular surgeon specializing in wound care, and appropriate treatment conducted according to wound assessment (antibiotics, bandage, dressing change, debridement, amputations).
40935195|NCT05054244|PROCEDURE|Hyperbaric oxygenation (HBOT)|The HBOT sessions will be performed 5 days a week, in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2 with effective treatment lasting for 90 min. The sessions will be supervised by doctors trained in hyperbaric medicine.
40935196|NCT05583669|DRUG|DS-2325a|Subcutaneous injection (starting dose 300 mg)
40935197|NCT05583669|DRUG|Placebo|Subcutaneous injection
40935198|NCT02340273|DEVICE|Therapeutic ultrasound|Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
40935199|NCT02340273|DEVICE|Placebo therapeutic ultrasound|"Patients receive sham therapeutic ultrasound daily for 4 hours."
41129954|NCT04624139|BEHAVIORAL|Internet-based cognitive behavioral therapy + physiotherapy|"Combined intervention of stress reducing I-CBT and physiotherapy. The intervention consists of two components; I-CBT and physiotherapy aiming to reduce symptoms of stress.~I-CBT: Designed to reduce stress, during 8 weeks. Physiotherapy: A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
40935200|NCT00442468|OTHER|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
40935201|NCT00566644|DEVICE|levonorgestrel-releasing intrauterine system|
40935202|NCT00566644|OTHER|questionnaire administration|
40935203|NCT00566644|PROCEDURE|observation|
40935204|NCT04823416|PROCEDURE|Resection|Left hemicolectomy
40935205|NCT04823416|PROCEDURE|Stoma|Colostomy
40935206|NCT02492737|DRUG|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
40935207|NCT05840029|PROCEDURE|VIDEO-ASSISTED THORACOSCOPIC SURGERY|A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.
40935208|NCT03303482|BEHAVIORAL|Enhancing Trauma Awareness (Diane Wagenhals, MEd-Lakeside Global Institute)|The trauma awareness professional development course is delivered in a small group (up to 16 participants; 2.5 hours every other week over 12 weeks). The course provides an environment for professionals to explore in depth the complex nature of trauma, while also recognizing and emphasizing the highly sensitive nature of trauma that is essential to becoming trauma-informed. The course facilitates a heightened awareness and appreciation for trauma-related behaviors and consequences that influence relationships and systems and that persist across generations.
40935209|NCT04205097|DRUG|Neostigmine + glycopyrate|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
40935210|NCT04205097|DRUG|Sugammadex|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg
40935211|NCT04293627|BEHAVIORAL|ATTAIN|ATTAIN is an 8-step model to identify co-occurring mental health conditions and facilitate linkage to mental health services for youth with an existing autism spectrum disorder diagnosis.
40935212|NCT01124630|DRUG|CS-1008|CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
40935213|NCT01124630|DRUG|FOLFIRI|The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
40935214|NCT04444427|DRUG|GLR2007|Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
40935215|NCT03302520|DEVICE|NovoMax, BioAlpha Inc, Seong-nam, Korea|CaO-SiO2-P2O5-B2O3 glass ceramics spacer
40935216|NCT03302520|DEVICE|PEEK cage|PEEK cage
40935217|NCT04490330|OTHER|questionnaire|AUDIT questionnaire (alcohol use disorders identification test)
40935218|NCT05303272|DRUG|Abatacept Prefilled Syringe|Abatacept (Orencia) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product. Combined with standard of care prednisone 10-40mg qd
40935219|NCT05303272|DRUG|Mycophenolate Mofetil 500Mg Tab|MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
40935220|NCT03127956|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
40935221|NCT04618887|PROCEDURE|pallidotomy|deep brain nuclei lesion of GPi
40935222|NCT04618887|PROCEDURE|deep brain stimulation|deep brain stimulation of GPi
40935223|NCT01680510|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil|
40935224|NCT01680510|OTHER|Placebo (starch)|
40935225|NCT03790007|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
40935226|NCT02809261|PROCEDURE|Ultrasound-guided perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
40935227|NCT02809261|PROCEDURE|Ultrasound-guided perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
40935228|NCT02809261|DRUG|Normal Saline|Normal saline is safe for perineural injection.
40935229|NCT02809261|DRUG|5% Dextrose|5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
40935230|NCT02634476|BEHAVIORAL|Alcohol approach/avoidance task|The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).
40935231|NCT02634476|BEHAVIORAL|Sham approach/avoidance task|The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
40935232|NCT00194675|DRUG|Dutasteride|Dutasteride 0.5 mg orally daily
40935233|NCT00194675|DRUG|Testosterone gel|Testosterone gel 7.5 g daily topical
40935234|NCT00194675|DRUG|Placebo dutasteride|placebo dutasteride orally daily
40935235|NCT00304369|DRUG|Metronidazole|
41279636|NCT03615092|PROCEDURE|Root coverage with extended flap technique and acelular dermal matrix|At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
41279637|NCT04339504|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
41279638|NCT04339504|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
41279639|NCT04339504|BIOLOGICAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
40935236|NCT05314985|OTHER|Prehab intervention|Individual training program containing strengthening, sensori-motor, joint mobilisation and endurance exercises as well as educational inputs concerning perioperative procedure and instructions on e.g. how to walk with crutches.
40935237|NCT01673282|DRUG|Lacosamide|Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
40935238|NCT03859206|OTHER|Medical thoracoscopy|• With the closed biopsy forceps, step by step, fibrinous septae were perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken \& If no lesion, biopsy from parietal pleura was obtained from any sites.
40935239|NCT03475875|DEVICE|senofilcon A TEST Lens|senofilcon A with new UV blocker investigational process
40935240|NCT03475875|DEVICE|senofilcon A CONTROL Lens|senofilcon A with new UV blocker standard process
40935241|NCT03549351|OTHER|Measurable residual disease measured by flow cytometry|Measurable residual disease measured by flow cytometry
40935242|NCT04782960|DRUG|Iocal anaesthetic bupivacaine|Local anaesthetic Subconjunctival bupivacaine
40935243|NCT04782960|DRUG|Placebo|0.9 saline
40935244|NCT06163469|DEVICE|Bladder instillation with Irrisept|9 months of bladder instillations (3 months of saline and 6 months of chlorohexidine gluconate)
40935245|NCT00404703|DRUG|bevacizumab [Avastin]|15mg iv on day 1 of each 3 week cycle
40935246|NCT00404703|DRUG|Platinum-based chemotherapy|As prescribed
40935247|NCT05751616|OTHER|Laminate veneers with speed sintering|Zirconia specimens will be sintered using speed sintering cycle in a conventional furnace according to the manufacturer instructions.
40935248|NCT05751616|OTHER|Laminate veneers with conventional sintering|Zirconia specimens will be sintered using conventional sintering cycle in a conventional furnace according to the manufacturer instructions.
40935249|NCT01645722|PROCEDURE|Procedure/Surgery: Enriched Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
40935250|NCT04587180|PROCEDURE|Arthroscopic suture-bridge rotator cuff repair|Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.
41129955|NCT04624139|BEHAVIORAL|Physiotherapy only|"A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
40935251|NCT00246688|DRUG|Sagopilone (BAY86-5302 , ZK219477)|10.5 mg lyophilized sagopilone per vial
40935252|NCT03555838|OTHER|transcranial direct current stimulation|Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
41129956|NCT05075421|PROCEDURE|Gastrectomy|Any type of gastrectomy for gastric cancer
41129957|NCT00009932|DRUG|cisplatin|
41129958|NCT00009932|DRUG|fenretinide|
41129959|NCT00009932|DRUG|paclitaxel|
40935253|NCT03555838|OTHER|sham transcranial direct current stimulation|an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
40935254|NCT04452929|DRUG|Erenumab|Subcutaneous injection of 140 mg erenumab.
40935255|NCT04452929|DRUG|Placebo|Subcutaneous injection of saline placebo.
40935256|NCT04452929|DRUG|Calcitonin gene-related peptide|Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.
40935257|NCT04452929|DRUG|Cilostazol|Oral intake of 200 mg cilostazol.
40935258|NCT03810404|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|"Interventions:~The experimental procedure for each athlete included an acute SB supplementation in a different-dose regimen in order to assess whether the dose affects the actual physical and exercise capacity (doses: 0.15-, 0.25-, 0.35- and 0.50 g/kgFFM (0.12-, 0.20-, 0.28- and 0.40 g/kgBM), respectively). SB (Alkala, SANUM, Poland) will be administered as dissolved form in a 750 ml of fluid (water + fruit juice). On testing days the SB will be taken before physical and exercise capacity tests session.~Between the SB and PLA or a PLA and SB treatments, a minimum 7-day washout period will be introduced."
41129960|NCT02432274|DRUG|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
41129961|NCT02432274|DRUG|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
40755740|NCT03306290|DRUG|Serum dosage of antibiotic prophylaxis CEFOXITIN|"Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.~1. Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (\~30 min), 1 tube (5 ml) of blood will be withdrawn~2. Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)~3. Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn"
40755741|NCT03921437|RADIATION|decision support intervention|CKD Guardian is the decision-maker and uses the e-book software to develop medical decision-assist tools, and applies this tool and decision-directed mode to introduce and select. The implementation steps include team discussion, option discussion and decision-making. The group is introduced with traditional care instructions for routine care.
40755742|NCT06344377|DIETARY_SUPPLEMENT|Betaine|Betaine supplemented for 8 weeks
40755743|NCT06344377|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation for 8 weeks
40755744|NCT00819832|PROCEDURE|Kyphoplasty|A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.
40755745|NCT00819832|PROCEDURE|Vertebroplasty|Medical cement will be injected into broken back bone.
40755746|NCT00819832|DEVICE|Cavity SpineWand|Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
40755747|NCT03335566|DRUG|Sonazoid™|Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
40755748|NCT03335566|DRUG|SonoVue®|Single Dose of SonoVue® 2.4 mL as I.V. injection.
40755749|NCT05675293|DEVICE|IONTOPHORESIS|The process of increasing the penetration of drugs into the skin by application of an electric current
41129962|NCT02432274|DRUG|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
41129963|NCT02432274|DRUG|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose). Lenvatinib dose can be escalated to the RD from Cohort 1 or de-escalated to 40 and 60% lower than the RD from Cohort 1.
41129964|NCT02432274|DRUG|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
41129965|NCT02432274|DRUG|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Ifosfamide dose can be de-escalated to 2400 mg/m2/day and 1800 mg/m2/day.
41129966|NCT02432274|DRUG|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Etoposide dose can be de-escalated to 80 mg/m2/day and 60 mg/m2/day.
41129967|NCT02432274|DRUG|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
41129968|NCT02432274|DRUG|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
41129969|NCT00100698|DRUG|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
41129970|NCT00100698|DRUG|placebo|placebo subcutaneously once a day, 18 months
41129971|NCT04389385|BIOLOGICAL|COVID-19 Specific T Cell derived exosomes (CSTC-Exo)|The virus-specific T-cells (VSTs) are body's natural immune defense against various disease-causing viruses. Donor originated COVID-19 specific T-cells (CSTC) are in vitro activated and expanded by exposing to viral peptide fragments in the presence of natural immune stimulant proteins called cytokines. These Covid-19 specific fragment peptides activate specific T-cells and stimulate the secretion of potent mediators including IFN gamma in forms of exosomes. We propose treatment of Covid-19 patients -who are at early stages of pulmonary disease- with CSTC-exomes to control disease progression.
41129972|NCT00353691|DRUG|glimepiride|
41129973|NCT00353691|DRUG|metformin|
41129974|NCT02463994|DRUG|MPDL3280A|Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
41129975|NCT02463994|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Image-Guided Radiotherapy (HIGRT)
41129976|NCT01223924|OTHER|placebo|placebo
41129977|NCT01223924|DRUG|M2ES|M2ES IV 7.5mg-90mg
41129978|NCT02928250|DIETARY_SUPPLEMENT|Carnosine|Patients in intervention group received carnosine capsules orally daily
41129979|NCT02928250|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
41279640|NCT05385562|DRUG|Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate|formulated with sodium hyaluronate and chondroitin sulfate
41279641|NCT05385562|DRUG|Triamcinolone Acetonide alone|Triamcinolone Acetonide alone
41279642|NCT03397836|OTHER|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers who will collect information electronically using a tablet computer. The volunteers will collect information about the client's health goals, health risks, and needs using a specifically designed application (TAP-App). Once the data is gathered, it is summarized into a report (TAP-report) which is securely and electronically sent to the health care clinic (TAP huddle). The team can leverage clinic supports and/or community supports as they deem appropriate to help clients reach their health goals and address any needs and risks which were reported during the volunteer visits.
41279643|NCT03397836|OTHER|Usual Care|Usual care while waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
41279644|NCT01841151|BEHAVIORAL|SCP training|
41279645|NCT01841151|BEHAVIORAL|Live Z-score training|
41279646|NCT01841151|BEHAVIORAL|WM training|
41279647|NCT05647993|DRUG|Azithromycin Injection [Zithromax]|Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
41279648|NCT05647993|DRUG|Cefazolin|All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
41279649|NCT05647993|DRUG|Sodium Chloride 0.9% Intravenous Solution|For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
41279650|NCT03158402|OTHER|Prehabilitation with inspiratory muscle training|3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
41279651|NCT04219371|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
41279652|NCT00688688|DRUG|Mirabegron|Tablets
41279653|NCT00688688|DRUG|Tolterodine|Extended release capsules
41450041|NCT04921631|BEHAVIORAL|Early Integration of Specialty Palliative Care with Critical Care|The PC team will visit the patient within 24 hours of randomization and the consultation will address the following domains of PC: illness understanding and goals of care conversations with patients/surrogates; symptom assessment and management; spiritual needs; patient and family coping and support; and care coordination and transitions. The initial family meeting will be scheduled to occur within two days of randomization. Follow-up visits will be conducted by the PC MD/APP every weekday. During this time, the ICU and PC team will be in daily communication. The PC team will continue to follow the patient in the hospital once discharged from ICU. Prior to discharge, the PC team will document patient goals and preferences for future treatment, coordinate appropriate PC services in the home and/or outpatient clinic settings and contact the patient's primary physician to provide an update on the patient's hospital stay.
41450042|NCT00011063|DRUG|Ginkgo Biloba|
41450043|NCT02284035|DRUG|Raltegravir/3TC|MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
41450044|NCT02284035|DRUG|EFV/TDF/FTC|standard combination therapy
41450045|NCT02284035|DRUG|ATV/r + TDF/FTC or DRV/r + TDF/FTC|
41450046|NCT02284035|DRUG|DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC|
41450047|NCT02284035|DRUG|EFV plus ABC/3TC or RPV/TDF/FTC|
41450048|NCT02284035|DRUG|ATV/r plus ABC/3TC|
41279654|NCT00688688|DRUG|Placebo to Mirabegron|Matching mirabegron placebo tablets.
41279655|NCT00688688|DRUG|Placebo to Tolterodine|Matching tolterodine placebo capsules.
41279656|NCT03015532|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), via instillation
41450049|NCT02284035|DRUG|DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC|
41450050|NCT02284035|DRUG|RAL plus ABC/3TC|
41450051|NCT02284035|DRUG|Other ART regimens|
41129980|NCT06046196|DRUG|Sarpogrelate SR|Sarpogrelate SR 300mg, once a daily, for 24weeks
41129981|NCT06046196|DRUG|Sarpogrelate|Sarpogrelate 100mg, 3 times a day, for 24weeks
41450052|NCT01808716|DEVICE|Low-level laser therapy (808nm) and exercise|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
40755750|NCT05675293|DRUG|ORAL ANTIBIOTIC|Oral Antibiotic
41129982|NCT00008242|DRUG|dexamethasone|
41129983|NCT00008242|DRUG|doxorubicin hydrochloride|
41129984|NCT00008242|DRUG|thalidomide|
41129985|NCT02185794|DRUG|Voxilaprevir|Voxilaprevir tablets administered orally once daily
41129986|NCT02185794|DRUG|Placebo to match voxilaprevir|Placebo to match voxilaprevir tablets administered orally once daily
41129987|NCT02185794|DRUG|SOF/VEL|400 mg/100 mg FDC tablet administered orally once daily
41279657|NCT03015532|DRUG|Saline Placebo|Saline placebo via injection
41279658|NCT03015532|DRUG|Bupivicaine HCl|Bupivacaine HCl without epinephrine
41279659|NCT03015532|DRUG|Ropivacaine|Ropivacaine, via injection
41279660|NCT05452564|DRUG|Baricitinib 2 MG Oral Tablet|Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
41453506|NCT03949296|BEHAVIORAL|Sleep Hygiene|"Session includes a handout with15 sleep hygiene tips:~1. Maintain a regular sleep pattern~2. Only try to sleep when feeling tired or sleepy~3. If unable to sleep, do something calm until feeling tired and returning to bed~4. Avoid caffeine \& nicotine for 4-6 hours before going to bed~5. Avoid alcohol for 4-6 hours before going to bed~6. Use the bed only for sleeping and sex~7. Avoid naps during the day~8. Develop rituals to get relaxed and ready to sleep~9. Try a hot bath prior to bedtime~10. Avoid checking the clock during the night~11. Use a sleep diary for a few weeks to track progress~12. Avoid strenuous exercise before bedtime~13. Avoid a heavy meal before bedtime~14. Create a sleep environment that is quiet, comfortable, and dark~15. Maintain a regular daytime routine"
40755751|NCT04810858|OTHER|Multimodal, multi-parametric MRI|The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.
40755752|NCT04810858|OTHER|Immune and cytokine profiling|Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.
41453507|NCT02791594|DRUG|Pembrolizumab|
41453508|NCT00603967|PROCEDURE|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
41129988|NCT00811941|DRUG|Placebo|as-needed use, tablets, orally, 52 weeks
41129989|NCT00811941|DRUG|Nalmefene|18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
41279661|NCT05452564|DRUG|Placebo|Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
41453509|NCT00603967|PROCEDURE|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
41279662|NCT00372918|PROCEDURE|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
41279663|NCT01613612|PROCEDURE|core decompression|minimal surgical invention to drill a core to the femoral head to release pressure
40755753|NCT04810858|BEHAVIORAL|Neuropsychological testing|Participants will have neuropsychological testing three times over 2 years.
40755754|NCT03499665|BEHAVIORAL|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|For Group 1 (n:20), the PNF, myofascial releasing and home exercises were used to decrease pain, jaw restriction and improve functional mobility on the masseter, lateral and medial pterygoid, buccinator, temporalis, orbicularis oris, orbicularis oculi, upper side of trapezius muscle, splenius, scalenous, and cervical extensor muscle in 20 patients with bruxism, for 2 and 6 weeks after pre-evaluation. PNF, myofascial releasing and home exercises were administered for 2 weeks, followed by 3 sets of 10 repeat home exercises and 6 weeks under physiotherapist control.
40755755|NCT03499665|BEHAVIORAL|Myofascial Releasing Maneuvers and Home Exercises Group|In Group 2 (n:15), as myofascial releasing and home exercise group,final evaluation was made with 10 sets of myofascial releasing and home exercises for 2 and 6 weeks.
40755756|NCT03499665|BEHAVIORAL|Control Group|In Group 3 (n:17), as the control group, no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
40755757|NCT04174820|OTHER|Functional Magnetic Resonance Imaging (fMRI)|list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests
40755758|NCT04557345|DIAGNOSTIC_TEST|Determination of cytokines|Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
40755759|NCT04557345|DIAGNOSTIC_TEST|Two-dimensional transthoracic echocardiogram|With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.
40755760|NCT05866601|OTHER|Role-playing for learning the clinical interview|"Thirty-one first-year physiotherapy students will carry out the role-playing methodology to learn how to take a clinical history in physiotherapy.~Before and after the realization, they will be measured by means of a validated questionnaire in Spanish, the language in which they study, the variable of empathy and anxiety."
40755761|NCT01414829|PROCEDURE|Gastroscopy|The reason for gastroscopy will be not related to the study
40755762|NCT05483400|DRUG|Tiragolumab and atezolizumab|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.
40755763|NCT05318560|DRUG|Lidocaine 2% Injectable Solution|for MPS
41129990|NCT05460910|OTHER|core stability exercises with treadmill|swiss ball use patient is lying in supine position with 15 repitations and 3 sets.
41129991|NCT05460910|OTHER|core stability exercise without treadmill|technique used to improve stability
41129992|NCT03106259|DRUG|FURESTEM-RA Inj.|Non-interventional observational study
41129993|NCT04874649|OTHER|Balloon-blowing breathing|Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
41129994|NCT04874649|OTHER|Sustained maximal inspiration breathing|Participant sit on a chair. Inhale through their nose fully and hold for 3 seconds for a full breath, Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
41279664|NCT01613612|PROCEDURE|Enriched BMCs implantation combined with core decompression|Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
41279665|NCT00364260|DRUG|epoetin alfa|
40755764|NCT05318560|DRUG|Ozone|for MPS
41279666|NCT03557021|DIAGNOSTIC_TEST|HIV Drug resistance testing|HIV Drug resistance testing by HIV pro DNA sanger sequencing
41279667|NCT03265691|OTHER|Early detection and treatment of hyponatremia|In the experimental group, hyponatremia will be diagnosed and treated early. Therefore, the researchers will review the patients' sodium levels at admission and throughout their stay.
41279668|NCT03265691|OTHER|No Intervention (SOC)|Usual pattern of work will be performed in all patients who enter in Hospital.
41279669|NCT04392414|BIOLOGICAL|COVID-19 convalescent hyperimmune plasma|Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
41279670|NCT04392414|BIOLOGICAL|Non-convalescent fresh frozen plasma (Standard plasma)|Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
40935259|NCT03810404|DIETARY_SUPPLEMENT|Placebo treatment|"Interventions:~The experimental procedure for each athlete will be included an PLA supplementation. Placebo will be administered in a form of 750 ml of fluid (water + fruit juice). On testing days the PLA will be taken before physical and exercise capacity tests session.~Between the PLA and SB or a SB and PLA treatments, a minimum 7-day washout period will be introduced."
40935260|NCT04545944|DRUG|Vonoprazan|20 mg tablets administered orally
41129995|NCT00650104|DRUG|Ropinirole XL (formerly CR)|Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
41279671|NCT05784090|OTHER|blood and saliva sample and lumbar puncture diagnostic for specific neurological diseases|"Saliva was collected using Salivettes (Sarsted, Newton, NC, USA) in dim light. CSF was obtained in the morning after overnight fasting by lumbar puncture at the L3/L4 or L4/L5 interspace.~Blood samples were drawn in fasting conditions. Plasma was separated by centrifugation."
41279672|NCT00006122|DRUG|cytarabine|
41279673|NCT00006122|DRUG|etoposide|
41279674|NCT00006122|DRUG|gemtuzumab ozogamicin|
40935261|NCT04545944|DRUG|Midazolam|2 mg syrup administered orally
41279675|NCT00006122|DRUG|idarubicin|
41279676|NCT00006122|DRUG|mitoxantrone hydrochloride|
41279677|NCT03295305|BEHAVIORAL|Action-Based Cognitive Remediation|
40935262|NCT00827580|DRUG|Eniluracil|
40935263|NCT05650567|DRUG|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks.
40935264|NCT05650567|DRUG|Placebo|Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
40935265|NCT00674778|PROCEDURE|Any percutaneous cardiovascular procedure|
40935266|NCT02415855|DRUG|Dabigatran|
40935267|NCT03582228|BEHAVIORAL|Virtual Envrionment for Social Communication|"Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~* 15 minutes- Social support group (guided discussion of experiences related to weekly topic)~* 20 minutes- Didactic instruction~* 15 minutes- Role playing~* 10 minutes- Debriefing and group feedback"
40935268|NCT02265601|OTHER|computer-based decision aid|Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.
40935269|NCT02265601|OTHER|standard care|paper/pencil living will form
41279678|NCT03295305|BEHAVIORAL|Unstructured support group|
41279679|NCT00507715|DRUG|Plantago ovata husk|5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
41279680|NCT00507715|OTHER|hemicellulose crystalline|5g effervescent powder t.id. during 14 days
40935270|NCT01479985|OTHER|CDM Tool|Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
40935271|NCT00401141|PROCEDURE|Blood samples|
40755765|NCT05318560|OTHER|stretching exercise|for MPS
40755766|NCT05690191|DRUG|Chidamide|Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
40935272|NCT03289364|DEVICE|Penguin Cold Caps|Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
40935273|NCT01084447|DEVICE|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
40935274|NCT01084447|DEVICE|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
40935275|NCT00924625|OTHER|Neuromuscular electrical stimulation|Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.
40935276|NCT00924625|OTHER|Volitional exercises|The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
40935277|NCT04099251|BIOLOGICAL|Nivolumab|Specified dose on specified days
40935278|NCT04099251|OTHER|Placebo|Specified dose on specified days
40935279|NCT05068895|OTHER|liquid chromatography-mass spectrometry|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography-mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and repro- ducibility.
41279681|NCT02704429|DRUG|PRN1008|"Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks."
41279682|NCT03013595|BEHAVIORAL|TRAM feedback|
40755767|NCT05690191|DRUG|Lenalidomide|Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
40935280|NCT00310453|BIOLOGICAL|ALK Grass tablet|
40935281|NCT00457964|DRUG|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
40935282|NCT00488878|PROCEDURE|Biospecimen Collection|Patients' residual tissue samples are collected
40935283|NCT00488878|OTHER|Electronic Health Record Review|Medical records are reviewed
40935284|NCT02069288|DRUG|Fludrocortisone|50 µg of fludrocortisone per os
40935285|NCT02069288|DRUG|Placebo|1 tablet of placebo per os
40935286|NCT02855515|PROCEDURE|Short-time diagnostic anaesthesia|Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
40935287|NCT06423729|DRUG|Nicorandil 10 MG|Patients will receive oral Nicorandil 10 MG twice daily in addition to 2nd generation sulfonylureas , for 3 months.
41279683|NCT00187083|DRUG|Topotecan, dexamethasone, vincristine|See Detailed Description section for details of treatment interventions.
41279684|NCT00187083|DRUG|E. coli Asparaginase, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
41279685|NCT00187083|DRUG|erwinia asparaginase|See Detailed Description section for details of treatment interventions.
41279686|NCT00187083|DRUG|fludarabine, methotrexate, mercaptopurine|See Detailed Description section for details of treatment interventions.
41279687|NCT00187083|DRUG|idarubicin, etoposide, cytarbine, teniposide|See Detailed Description section for details of treatment interventions.
41279688|NCT00187083|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
41279689|NCT05646550|DRUG|CC-1 Infusion|Short term (3h) infusion of CC-1
41279690|NCT03751202|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg|2 inhalations of Test and Reference product in each study period
41279691|NCT03751202|DRUG|ADVAIR DISKUS|2 inhalations of Test and Reference product in each study period
41279692|NCT03828292|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered as an intravenous infusion.
40755768|NCT05690191|DRUG|Rituximab|Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
40755769|NCT00678574|DRUG|fluoxetine|Fluoxetine 20 mg daily by mouth for 2-3 months.
40755770|NCT03095976|PROCEDURE|Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
40755771|NCT06256874|BEHAVIORAL|Myofascial Release Training|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
40755772|NCT00969085|DRUG|Curcumin (Turmeric)|"Chew then swallow 2 sticks per day for up to 6 months.~2 sticks = 1 packet of curcumin = 8 grams"
40755773|NCT00969085|BEHAVIORAL|Questionnaires|Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
40755774|NCT00969085|OTHER|Photos|Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
40755775|NCT03340935|OTHER|Fasting mimicking diet|Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (600 Kcal on day 1, followed by 300 KCal/day on days 2 to 5), low-protein, low carbohydrate diet
40755776|NCT03704974|BEHAVIORAL|Video-Based Parent Training Program|An18-20 week evidence-based social cognitive theory-based parenting program where parents see brief video vignettes of effective and less effective parenting and develop concepts to modify their child's behavior.
40935288|NCT05635058|OTHER|The Reminisence Therapy|Reminiscence sessions were held in a meeting room in the nursing home and arranged in accordance with the interviews. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. The materials to be used in the reminiscence sessions were determined in accordance with the education level and cultural characteristics of the participants. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher, the following weeks topic was determined and the interview was concluded.
40935289|NCT01594385|BIOLOGICAL|Seprafilm|"Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:~* Two Seprafilm pieces between the liver and the anterior abdominal wall~* Four pieces over the exposed bowel surfaces anteriorly~* Two slightly staggered pieces of Seprafilm in each colic gutter~* Two pieces in the pelvic area.~* If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair."
41279693|NCT03828292|DRUG|Bortezomib|Bortezomib solution for injection will be administered subcutaneously.
41279694|NCT03828292|DRUG|Dexamethasone|Dexamethasone tablets will be administered orally.
41279695|NCT03828292|DRUG|Pomalidomide|Pomalidomide capsules will be administered orally.
41279696|NCT05241587|OTHER|Gum Group:|"Gum Group:~Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010)."
41279697|NCT05241587|OTHER|Mouth Spray Group:|"Mouth Spray Group:~The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request."
41279698|NCT02862795|PROCEDURE|HPV detection in anal canal samples|Additional anal taking during the colonoscopy with cytobrush
41279699|NCT02248376|DRUG|Gel|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
40755777|NCT04716309|PROCEDURE|Open reduction and volar locking plate and closed reduction and K-wires.|DVR Anatomic Plate, K-wires
40755778|NCT00493558|DEVICE|Trabecular Metal Intervertebral Cage with RSA beads|Roentgen Stereophotogrammetric Analysis beads will be inserted at time of implant of the Trabecular Metal Intervertebral Cage.
40935290|NCT05262959|DRUG|Donafenib, PD-1|Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.
40935291|NCT05262959|PROCEDURE|TACE|TACE will be performed by the investigator based on the patient's tumor status.
40935292|NCT03143491|DRUG|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
40755779|NCT05610761|BEHAVIORAL|Core stabilization exercises with Kegel exercises|Core stabilization exercise program consists of two phases: teaching the basic movement (contraction of the Transversus abdominis and other muscles with diaphragmatic breathing) and incremental exercises added to the basic movement. The basic movement will be studied before each exercise and then the specified exercises will be added. The physiatrist will teach the exercise program to the patients. The first 6 of the 12 exercises classified according to the degree of difficulty will be performed for 5 weeks, and the next 5 weeks will be moved to the other 6 exercises. The exercises will be performed at least 3 days a week, with 10 repetitions of each movement, and the program will last for 10 weeks. Compliance with the exercise program will be questioned over the phone, and patients will be evaluated with a follow-up form before the study, at the 10th week, and at the 20th week. In addition, the Kegel exercise program specified in the other group will be applied.
40935293|NCT01049477|OTHER|Music group|The patients randomized to the music group of the study will listen to music 30 minutes in the holding room prior to their c/s. They will then listen to music after their c/s for 30 minutes. They will complete the STAI before and after their c/s.
40935294|NCT01049477|OTHER|Non music group|Patients randomized to the non music group will complete the STAI before and after their c/s, but not listen to music.
40935295|NCT05065775|DEVICE|Dexmedetomidine|Single intranasal dexmedetomidine dose of 100 µg. Intranasal dexmedetomidine will be administered shortly after induction of anesthesia using a mucosal atomization devise (LMA MAD Nasal™)
41279700|NCT02986451|DRUG|clarithromycin|Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
41279701|NCT02986451|DRUG|Lenalidomide|Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
41279702|NCT02986451|DRUG|Dexamethasone|Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
41279703|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
40935296|NCT01740505|BEHAVIORAL|Timing and Coordination|This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
40935297|NCT01740505|BEHAVIORAL|Aerobic Walking|Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
41279704|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
41279705|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
41279706|NCT05124275|DRUG|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
41279707|NCT01982630|DRUG|MK-8521|
41279708|NCT01982630|DRUG|Liraglutide|
40935298|NCT01740505|BEHAVIORAL|Stretching and Relaxation|Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
40935299|NCT04141644|DRUG|Ipilimumab|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
40935300|NCT04141644|DRUG|Osimertinib|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
40935301|NCT04592263|OTHER|EPD Questionnaire|A 44 items questionnaire (4 point likert scale) was distributed. Included dimensions where: experience with your physician, provision of care, barriers, outcomes of care, symptoms, patient engagement, health literacy and patient empowerment.
41279709|NCT01982630|DRUG|Placebo|
41279710|NCT00893711|OTHER|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
41279711|NCT00893711|OTHER|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
41279712|NCT00893711|DIETARY_SUPPLEMENT|L.reuteri + Vit D|
41279713|NCT00893711|DIETARY_SUPPLEMENT|Vit D placebo|
41279714|NCT05176678|DIETARY_SUPPLEMENT|1 gram of a protein hydrolysate|After 1 gram of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
41279715|NCT05176678|DIETARY_SUPPLEMENT|2 grams of a protein hydrolysate|After 2 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
41279716|NCT05176678|DIETARY_SUPPLEMENT|4 grams of a protein hydrolysate|After 4 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
40935302|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 0:1 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
40935303|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:6 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
40935304|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:4 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:4 means there will be one degree of motion in the transverse plane for every four degrees of motion in the sagittal plane.
40935305|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:3 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:3 means there will be one degree of motion in the transverse plane for every three degrees of motion in the sagittal plane.
40935306|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:2 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:2 means there will be one degree of motion in the transverse plane for every two degrees of motion in the sagittal plane.
40935307|NCT04228575|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
40935308|NCT04220853|DIAGNOSTIC_TEST|Rhinomanometry in patients after septoplasty and/or turbinoplasty|Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.
41453510|NCT00603967|BEHAVIORAL|Questionnaire|"Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline"
41279717|NCT05176678|DIETARY_SUPPLEMENT|8 grams of a protein hydrolysate|After 8 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
41279718|NCT01449825|DRUG|Pazopanib use|Treatment with pazopanib
41279719|NCT01449825|DRUG|Use of sunitinib, bevacizumab, or sorafenib|Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
41453511|NCT02618460|DEVICE|Non contrast-enhanced magnetic resonance imaging|
41453512|NCT02766257|PROCEDURE|Anesthesia for ambulatory paediatric surgery|
41453513|NCT05779943|DRUG|Furosemide|Given IV
41453514|NCT05779943|OTHER|F18-rhPSMA-7.3|Given IV
41453515|NCT05779943|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
40935309|NCT04220853|DIAGNOSTIC_TEST|Acoustic rhinometry in patients after septoplasty and/or turbinoplasty|Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.
40935310|NCT00768469|DRUG|Neratinib|Administered orally, continuous, once daily.
40935311|NCT00768469|DRUG|Paclitaxel|Administered IV, on days 1, 8, 15 of 28 day cycle.
40935312|NCT03600688|DEVICE|Edwards Cardioband System|Transcatheter mitral valve repair
40935313|NCT00583479|OTHER|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
40935314|NCT00583479|OTHER|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
40935315|NCT04768985|DRUG|Treatment A: Acalabrutinib tablet|Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
40935316|NCT04768985|DRUG|Treatment B: Acalabrutinib capsule|Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
40935317|NCT01150331|DRUG|Levetiracetam/Clonazepam|Association of two anti-epileptic drugs in first line
40935318|NCT01150331|DRUG|Clonazepam/Placebo levetiracetam IV|Association of placebo to an active comparator (clonazepam)
41450053|NCT06492109|BEHAVIORAL|Experimental sleep deprivation|Cognitive assessment of subjects: This study will collect the Mini-Mental State Examination (MMSE) results as a supplement to the Montreal Cognitive Assessment (MoCA). The sleep status of subjects will be screened using the Morningness-Eveningness Questionnaire (MEQ), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). Subjects must maintain regular sleep and diet before sample collection. Peripheral blood samples will be taken the day before, the day of, and the day after acute sleep deprivation, whether voluntary or involuntary, along with anxiety and depression assessments. For chronic sleep deprivation (≥7 days), blood samples will be collected before and after the deprivation period, with anxiety, depression, and cognitive assessments. Voluntary sleep deprivation occurs under experimental conditions, while involuntary deprivation is due to factors like age or shift work.
40935319|NCT05974501|DRUG|Dexamethasone|Dexamethasone 10mg administered via IV once postoperatively within 24 hours for pain and swelling
40935320|NCT05974501|DRUG|Acetaminophen|1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively
41129996|NCT05911867|OTHER|combination of mobilization with movement and muscle energy techniques|"The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range."
41129997|NCT05911867|OTHER|muscle energy techniques Interventions:|The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applied manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.
41129998|NCT05911867|OTHER|mobilization with movement|Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range.
41129999|NCT01389921|OTHER|Electroencephalography|Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
41130000|NCT03307694|DIAGNOSTIC_TEST|Ultrasound|All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.
41450054|NCT00714051|BEHAVIORAL|fall prevention training|Training on a specialized treadmill that produced trip-simulating perturbations (movements.
41450055|NCT00714051|BEHAVIORAL|Attention Control|Participants walked on a treadmill at a self-selected speed once per week for four weeks.
41450056|NCT00754455|BIOLOGICAL|Influenza VLP Vaccine (recombinant)|Single injection Day 0; 0.5mL
40935321|NCT05974501|DRUG|Lyrica|Administered via tablet 75mg nightly for pain during the first 1-2 weeks postoperatively
40935322|NCT05974501|DRUG|Celebrex|200mg administered via tablet twice a day for pain and swelling during the first 1-2 weeks postoperatively
40935323|NCT05974501|DRUG|Meloxicam|30mg administered via IV once postoperatively within 24 hours for pain and swelling
40935324|NCT05974501|DRUG|Oxycodone|5mg administered via tablet every 4 hours as needed for pain during the first 1-2 weeks postoperatively
40935325|NCT05974501|DRUG|Ropivacaine|20 milliliters Ropivacaine 0.2% administered via injection perioperatively.
40935326|NCT01739400|DRUG|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
40935327|NCT00277641|DRUG|Lamotrigine|25 mg or 100 mg
40935328|NCT00277641|DRUG|placebo|identical tablets to study drug
40935329|NCT03176758|DRUG|Spinal Block|Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
40935330|NCT03176758|DRUG|General anesthetic|1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
40935331|NCT03176758|DEVICE|Total knee replacement|A total knee arthroplasty surgery, which is not the intervention of interest
40935332|NCT04816201|OTHER|Electroacupuncture|Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
40935333|NCT01844479|DEVICE|diabetic foot orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
40935334|NCT01844479|OTHER|Standard innersole|
40935335|NCT04167371|BEHAVIORAL|Biofeedback|Three sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
40935336|NCT04167371|DIETARY_SUPPLEMENT|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
40935337|NCT04498494|DEVICE|ECG|12-lead ECG
40935338|NCT06361992|OTHER|Blue Cap Foam|Application regimen: Blue Cap foam 100 ml, Activated Piroctone Olamine (Foam, label 100 ml), Catalysis S.L. Madrid must be applied twice a day on all affected areas. The application is to be continued for 30 days, after which the patients stop using the foam until the final assessment at day 45.
41130001|NCT03307694|DIAGNOSTIC_TEST|Shear wave elasticity imaging|"Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue."
41130002|NCT03307694|DIAGNOSTIC_TEST|Multi-angle compound shear wave elasticity imaging|The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
40935339|NCT05557435|OTHER|breast milk odor|"The intervention of the experimental group was to stimulate the odor of breast milk. The researchers informed the mothers of premature infants in advance on the day before the experiment, and collected the breast milk samples in the morning before eating on the day of the experiment (excluding the influence of the odor of breast milk by diet). The researchers took a clean cotton ball so that the breast milk was completely absorbed by the cotton ball, and placed the cotton ball that absorbed breast milk at a distance of 5cm next to the mouth and nose of the premature infant, so that the premature infant could receive the smell of breast milk.~The intervention of the control group was to stimulate the smell of distilled water."
40935340|NCT05557435|OTHER|Placebo|Placebo
40935341|NCT00141583|DRUG|Enalapril 20 mg bd|
40935342|NCT00141583|DRUG|Candesartan 8 mg bd|
41130003|NCT05057936|BIOLOGICAL|COVID vaccine|The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study. All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
41130004|NCT01141803|DIETARY_SUPPLEMENT|Apples|550g of apples/day
41130005|NCT01141803|DIETARY_SUPPLEMENT|Apple pomace|22g apple pomace/day
41130006|NCT03820050|DEVICE|Freestyle LIbre Flash Glucose Monitoring System|System Performance will be characterized with respect to YSI reference venous plasma measurements
41279720|NCT04295187|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
41279721|NCT04295187|OTHER|Physical development and General Health|Physical development and General health examination
41279722|NCT04295187|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
40935343|NCT04969367|OTHER|Medical Device Usage and Evaluation|Wear activity monitor (Fitbit)
40935344|NCT04969367|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40935345|NCT04969367|OTHER|Questionnaire Administration|Complete questionnaires
40935346|NCT04969367|OTHER|Quality-of-Life Assessment|Complete questionnaires
40935347|NCT05222490|DEVICE|Thermal Camera images acquisition - FeetSee|Thermal images will be collected according to the instructions for use of the Feetsee device.
40935348|NCT05222490|DEVICE|Thermal Camera images acquisition - Reference|After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer
40935349|NCT05072470|DEVICE|Roger microphone|Commercially available transmitter microphone which sends distant speech signals to a receiver that is attached/embedded into hearing aids.
40935350|NCT05072470|DEVICE|Phonak Audeo hearing aid|Commercially available receiver-in-canal hearing aid
40935351|NCT00354185|DRUG|tanespimycin|Given IV
40935352|NCT00354185|DRUG|belinostat|Given IV
40935353|NCT00354185|OTHER|laboratory biomarker analysis|Correlative studies
40935354|NCT00354185|OTHER|pharmacological study|Correlative studies
40935355|NCT05409820|PROCEDURE|use of different spinal anesthesia techniques|Comparison of spinal anesthesia with 5 mg hypobaric bupivacaine and 5 mg hyperbaric bupivacaine in outpatients
41279723|NCT03116113|BIOLOGICAL|BIIB112|Administered as specified in the treatment arm.
41279724|NCT06062888|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Standard of Care + 2 units (400-500 ml) of fresh frozen plasma
41450057|NCT00754455|BIOLOGICAL|Placebo|Placebo as a single injection of 0.5 mL.
41450058|NCT00538031|DRUG|cyclophosphamide|Given orally
41450059|NCT00538031|DRUG|celecoxib|Given orally
41450060|NCT03065751|DEVICE|Plasmaexchange|TPE against fresh frozen plasma
41453516|NCT05779943|PROCEDURE|Computed Tomography|Undergo PET/CT scan
40935356|NCT03440177|DRUG|Ramipril|Patients are tested for their normal prescription ramipril medication
40935357|NCT04743518|OTHER|Aortic pulse wave velocity|Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness
40935358|NCT04743518|OTHER|carotid intima media thickness (CIMT)|carotid intima media thickness (CIMT)
40935359|NCT00815516|DRUG|micafungin|Administered by intravenous infusion
40935360|NCT00815516|DRUG|amphotericin B deoxycholate|Administered by intravenous infusion
40935361|NCT04143529|BEHAVIORAL|Personalized acceptance-based mindfulness exercise|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
40935362|NCT04143529|BEHAVIORAL|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 seconds
40935363|NCT04735718|DEVICE|Cerviron|"Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.~Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations."
40935364|NCT02800954|BIOLOGICAL|blood samples|
40935365|NCT02800954|BIOLOGICAL|Bone marow samples|
40935366|NCT01771185|PROCEDURE|Duodenal jejunal bypass plus sleeve gastrectomy|Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
40935367|NCT01771185|DRUG|Best medical treatment (Metformin ; gliclazide)|Metformin 2 g/day; gliclazide 30 mg
40935368|NCT06459141|PROCEDURE|acute normovolemic hemodilution|The ANH was conducted with more than 8 ml/kg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g/dL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.
40935369|NCT00660283|DRUG|Temozolomide|"(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.~7. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles."
40935370|NCT03338309|OTHER|Instantaneous wave-free ratio measurement|Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
40935371|NCT02656212|DRUG|epicatechin|30 mg (+)-epicatechin, taken orally, one pill/day in the morning
40935372|NCT02656212|DRUG|Placebo|Placebo pill, taken orally, one pill/day in the morning
40935373|NCT02789579|DRUG|levofloxacin|There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
40935374|NCT02789579|DRUG|Nitrofurantoin|There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
40935375|NCT02789579|DRUG|cefuroxime|There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
41450061|NCT04301258|OTHER|Articular cartilage repair|Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
41450062|NCT02535936|PROCEDURE|3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia|2 post-operative MRI's at 2 months and 12 months
41453517|NCT06343792|DRUG|RLS-0071|RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.
41453518|NCT01872507|OTHER|Biofeedback training|usual treatment +12 biofeedback training
40935376|NCT03012568|DEVICE|SJM Implantable cardiac devices|SJM implantable devices undergoing MRI scan
40935377|NCT02497976|BIOLOGICAL|Certolizumab pegol|400 mg
40935378|NCT02497976|DRUG|Placebo|Normal saline
40935379|NCT02424214|OTHER|Artificial Oocyte activation|
40935380|NCT02424214|DRUG|Ca Ionophore|
40935381|NCT02424214|DRUG|Strontium Chloride|
40935382|NCT02590302|OTHER|Implementation Phase|"Core Components of the implementation intervention include:~* Hospital and CMHA project commitment~* Site champion teams (from hospital and CMHA)~* Memorandum of Agreement between Hospital and CMHA~* Pre-intervention site visits~* Education sessions~* Posters/reminders~* Instructional videos (HEADS ED video)~Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site."
40935383|NCT03030118|DRUG|Hydroxychloroquine|Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
40935384|NCT03030118|DRUG|Placebo Oral Capsule|An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
40935385|NCT06004687|DRUG|acetaminophen mannitol|Intravenous acetaminophen was administered 30 minutes before anesthesia
40935386|NCT06004687|DRUG|Normal saline|Intravenous acetaminophen was administered 30 minutes before anesthesia
40935387|NCT01609101|DEVICE|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
40935388|NCT01609101|DEVICE|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
40935389|NCT01609101|DEVICE|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
40935390|NCT01609101|DEVICE|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
40935391|NCT01609101|DEVICE|King Vision® videolaryngoscope|King Vision® videolaryngoscope
40935392|NCT01609101|DEVICE|Venner® videolaryngoscope|Venner® videolaryngoscope
40935393|NCT01609101|DEVICE|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
40935394|NCT02116478|PROCEDURE|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
40935395|NCT05784961|DEVICE|tDCS|"tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.~The stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6."
40935396|NCT02102971|PROCEDURE|Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
41130007|NCT01119651|DRUG|Tazarotene (Patch application in Challenge Phase)|There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated \& will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
40935397|NCT03917498|RADIATION|Single Pre-Operative Radiation Therapy - with Delayed Surgery|Single Pre-Operative Radiation Therapy - with Delayed Surgery
40935398|NCT05769127|OTHER|Diabetes Prevention Program (DPP), Diabetes Self-Management Training (DSMT)|DPP lifestyle intervention program DSMT education on diabetes and lifestyle changes
40935399|NCT00003959|BIOLOGICAL|ras peptide cancer vaccine|
40935400|NCT00003959|BIOLOGICAL|sargramostim|
40935401|NCT04650854|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
40935402|NCT01897376|PROCEDURE|Pfannenstiel incision|Pfannenstiel incision at time of cesarean section
40935403|NCT01897376|PROCEDURE|vertical skin incision|vertical skin incision at time of cesarean section
40935404|NCT03636711|OTHER|antibiotic protocol, according to a syndromic approach|Description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols
40935405|NCT06097780|GENETIC|NestaCell®|Human Dental Pulp Stem Cells (hDPSCs).
40935406|NCT04401644|DIAGNOSTIC_TEST|Novel laser inferometry test for CORONA virus|detection of virus particles by light absorbtion patterns.
40935407|NCT06404346|DIAGNOSTIC_TEST|High Velocity Thrust|Group A Participants assigned to the HVT will receive manual therapy sessions consisting of specific manipulative techniques targeting the sacroiliac joint and surrounding structures. participant lying on your side or on your stomach, depending on which SI joint needs to be manipulated.The physiotherapist will stabilize body to isolate the specific SI joint that needs adjustment. This may involve holding certain parts of your body in place or using props like a belt or cushion.With precise control and speed, the physiotherapist will apply a sudden thrust to the targeted SI joint. This thrust aims to mobilize the joint and restore its normal function. This procedure will perform in 3 sessions per week for 2 weeks
40935408|NCT06404346|OTHER|Bowen therapy|participants will undergo sessions involving gentle, rolling movements over muscles, tendons, and ligaments in sacroiliac joint . participant lie comfortably on a treatment bed fully clothed, typically face down or on your side. The physiotherapist will perform a series of gentle, rolling movements with their fingers and thumbs over specific points on your body, including the lower back, hips, and buttocks. These moves are designed to stimulate the nervous system and promote relaxation and healing in the affected area.
41130008|NCT05168306|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.
41450063|NCT06627036|DEVICE|Dermatoscope|For participants in the dermoscopy group, the marking will also be done preoperatively with a marker pen, but the lesion borders will be determined using a dermatoscope. A peripheral margin based on BAD guidelines will be marked similarly.
40755780|NCT05610761|BEHAVIORAL|Kegel exercises|"Kegel Exercises The exercise will start as 2 sets of 10 repetitions in the morning and evening, and after getting used to it, it will be increased to 3 sets of 10 repetitions per day.~The patient, lying on his back with his knees bent, feet slightly apart from each other, will try to lift the breech, urinary tract opening and vagina on the pelvic floor by counting to 5, and should not tighten your abdominal and leg muscles, and should not hold your breath while doing this exercise.~In this way, he will count up to 5 while contracting, then he will relax by counting to 10 (after getting used to it, the holding time will be increased to 10 seconds)."
40755781|NCT05672537|DRUG|Durvalumab|1500mg intravenous injection for 21d cycle
40935409|NCT04733391|OTHER|Quality of life questionnaire|"Quality of life will be evaluated using the child version of the VSP-A questionnaire, for patients aged 8-10 years and the adolescent version for those aged 11-17 years."
40935410|NCT05715801|PROCEDURE|hyperbaric oxygen therapy|The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
40935411|NCT05715801|PROCEDURE|conventional oxygen therapy|Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
40935412|NCT05719987|OTHER|Biodentine|After the endodontic procedure, Biodentine will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
40935413|NCT05719987|OTHER|MTA|After the endodontic procedure, MTA will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
40935414|NCT02172053|OTHER|Compensatory Workplace Exercise (CWE) - Comparative Group|The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
40935415|NCT02172053|OTHER|Individual Resistance Exercise (IRE) - Intervention Group|Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
40935416|NCT04025671|DEVICE|Nasal Spray Naloxone|Nasal spray naloxone device.
40935417|NCT04025671|DEVICE|Intramuscular Naloxone|A vial of simulated naloxone and syringe with attached needle.
40935418|NCT04025671|DEVICE|Improvised Nasal Atomizer|A naloxone bristoject dose and nasal atomizer device.
40935419|NCT03099070|BEHAVIORAL|Stress|Trier Social Stress Test
40935420|NCT03099070|OTHER|Fasting|12-hour fasting prior to study visit
40935421|NCT02876640|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
40935422|NCT02876640|DRUG|Retinoid 9cUAB30|Given PO
40935423|NCT02876640|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection surgery
40935424|NCT02537574|DRUG|NTX/BUP|Daily doses
41450064|NCT04789434|DRUG|PD-1 Inhibitor Tislelizumab maintenance therapy|PD-1 Inhibitor Tislelizumab maintenance therapy, 200mg, every 2 months, 12 times
40935425|NCT02537574|DRUG|NTX/PBO-B|Daily doses
40935426|NCT02537574|DRUG|PBO-N/PBO-B|Daily doses
40935427|NCT05607836|DEVICE|IntuBrite intubation|Use of new laryngoscope IntuBrite for intubation in patients with cardiopulmonary arrest and during resuscitation
41130009|NCT06106100|PROCEDURE|Antireflux mucosal ablation|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed, followed by mucosa markings with straight-fire APC catheter (ERBE Electromedizin, Tübingen, Germany) in forced coagulation mode (VIO300D, ERBE Electromedizin, Tübingen, Germany, 20W). The marking site at 1-cm and 2-cm distal to squamocolumnar junction at anterior-posterior and lesser curvature site, respectively, sparing the greater curvature site of cardia, is done. After marking, mucosal ablation (forced coagulation mode, 1L/min, 80W) is performed at marking site in a hoarse-shoe shape. Adequate ablation depth is defined as reaching the submucosal layer with blackish discolored tissue with carbonization
40935428|NCT05607836|DEVICE|Macintosh laryngoscope|Use of standard Macintosh blade laryngoscope for intubation in patients with cardiac arrest and requiring cardiopulmonary resuscitation
40935429|NCT01631955|DRUG|Ciprobay|Ciprobay (250mg, bid, oral)
40935430|NCT04455243|DRUG|N-Acetyl cysteine|150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
40935431|NCT04455243|DRUG|Placebo|Matching placebo administered in the same schedule and volume as NAC
40935432|NCT06387160|DRUG|as per institutional protocol|This is an observational study. Treatment will be given to the patients as per institutional protocol
40935433|NCT03150667|DRUG|Ticagrelor|Ticagrelor in patients with CKD presenting with ACS.
40935434|NCT03150667|DRUG|Clopidogrel|Clopidogrel in patients with CKD presenting with ACS.
40935435|NCT01296243|DRUG|Tesetaxel|Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.
40935436|NCT05366673|OTHER|massage|Perform a 10-minute back massage every day for a week
40935437|NCT04985188|DIAGNOSTIC_TEST|Quantitative ultrasound (QUS) technique|Measurement of quantitative ultrasound parameter using clinical US machine (RS85)
40935438|NCT03778944|PROCEDURE|Mannitol infusion|Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
40935439|NCT03778944|PROCEDURE|Dopamine infusion|Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.
40935440|NCT03778944|PROCEDURE|Adequate hydration|Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.
40935441|NCT03792425|PROCEDURE|Connective tissue graft and implant placement|Augmenting soft tissue with connective tissue graft
40935442|NCT02484625|OTHER|Potato chips|Commercially available potato chips, 180 kcal
40935443|NCT02484625|OTHER|Greek yogurt|Commercially available Greek yogurt, 180 kcal
40935444|NCT02484625|OTHER|Cookies|Commercially available cookies, 180 kcal
40935445|NCT02484625|OTHER|Cheese|Commercially available cheese, 180 kcal
40935446|NCT02484625|OTHER|Milk|Commercially available milk, 180 kcal
40935447|NCT03005171|DRUG|Bupivacaine|Thoracic epidural bupivacaine infusion
40935448|NCT03005171|DRUG|Lidocaine|Intravenous lidocaine infusion
40935449|NCT03406923|OTHER|Health literacy-psychosocial support|The intervention is based upon enhancing patient health literacy-related attributes by (1) addressing the barriers to patients' self-efficacy by working with the patient to minimize the barriers (2) clarifying the patient beliefs about diabetes and diabetes medications, and (3) developing personalized action plans. We will tailor the intervention to each patient, so, the details of the content of each session will depend on the individual's self-efficacy, beliefs in illness and medicines, and health literacy level obtained at baseline. In addition to the 45-minute scheduled sessions, patients will be able to call the clinical pharmacist on the phone during the 6-week session at their discretion, for patient-driven support for self-management of goals and skills.
40935450|NCT00510874|BIOLOGICAL|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
40935451|NCT00510874|BIOLOGICAL|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
40935452|NCT02752555|OTHER|Antioxidant (l-cratinine) + modifiable lifestyle factors|All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
40935453|NCT04049227|DRUG|Abemaciclib|Given PO
40935454|NCT04049227|DRUG|Letrozole|Given PO
41279725|NCT03873597|BEHAVIORAL|Tele-coaching + Usual Care|The tele-coaching intervention will be delivered for 3 months following discharge from hospital. This consists of: 1) An interview discussing motivational issues, favourite daily activities and strategies to become more physically active; 2) a step counter 3) a smart phone with tele-coaching application providing activity goals (daily steps), feedback and educational tips on a daily basis. Patients' targets will be automatically revised on a weekly basis, based on performance in the preceding week; (4) a booklet containing home exercises; (5) weekly activity proposals; (6) tele-phone contacts triggered in the case of non-compliance, failure to transmit data or difficulty to progress.
40755782|NCT05672537|PROCEDURE|Surgery|Surgery
40935455|NCT04049227|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care hysterectomy
40935456|NCT02948218|DEVICE|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
40935457|NCT00623116|DRUG|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
40935458|NCT00300118|DRUG|budesonide|9 mg
41279726|NCT06010667|DRUG|Envafolimab|With or without Envafolimab
41130010|NCT06106100|PROCEDURE|Sham procedure|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed. Using the straight-fire APC catheter to touch the marking sites similar to the treatment group without electrocauterization is performed.
40935459|NCT00300118|DRUG|mesalazine|4.5 g
41130011|NCT03611075|OTHER|No Intervention|No interventions are administered in this study
41130012|NCT05605925|DRUG|Artemether/lumefantrine|4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
40755783|NCT05672537|DRUG|Gemcitabine|gemcitabine 1000mg/m2, D1\&D8, 21d cycle.
40755784|NCT05672537|DRUG|Cisplatin|cisplatin 25mg/m2, D1\&D8, 21d cycle.
40935460|NCT05646472|DIAGNOSTIC_TEST|Frailty multidimensional assessment|"Each Centre will administer SUNFRAIL frailty assessment tool to the enrolled older adults and, according to the specific alerts triggered by the answers provided, older adults will be subjected (at the same time or subsequently) to one or more validated in-depth tests (already included in the SUNFRAIL+ platform) in order to perform further diagnostic or dimensional evaluations.~During the observation phase, subjects will be given different health promotion activities, depending on the assessment.~During the follow-up phase, 6 months after enrolment, SUNFRAIL tool and in-depth tests will be administered again. In addition, during the follow up, the extent to which exposure to interventions has influenced the quality of life of older adults will be measured and the number of users enrolled by territorial services, based on user care needs. In addition, the level of satisfaction and usability of the SUNFRAIL+ solution by health and social care professionals will be measured."
40935461|NCT00848575|DEVICE|Flexible Endoscope|
40935462|NCT04739865|DRUG|Psilocybin|Open label
40935463|NCT06010875|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
40935464|NCT06010875|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
40935465|NCT02312882|DRUG|Tofacitinib|Tofacitinib 5 mg tablet taken by mouth twice a day.
40935466|NCT01222403|BIOLOGICAL|Fluad_MF59-adjuvanted trivalent influenza subunit vaccine|
40935467|NCT01222403|BIOLOGICAL|Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine|
40935468|NCT04801316|BEHAVIORAL|Steady Feet exercise programme|"Steady Feet (SF) is a 6-month community-based structured exercise programme aimed at improving physical strength and balance among older adults (aged 60 years and above) who are at high risk of falls.~This exercise programme was developed by Changi General Hospital's physiotherapists and exercise physiologist from evidence found in the literature."
40935469|NCT04801316|BEHAVIORAL|Steady Feet Video|About an hour-long video showcasing the exercise steps of the Steady Feet exercise programme
40935470|NCT01949285|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
40935471|NCT05057910|DIAGNOSTIC_TEST|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: \< 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
40935472|NCT03706222|DRUG|elbasvir/grazoprevir|Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
40935473|NCT01043900|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
40935474|NCT04535167|DRUG|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
40935475|NCT04535167|DRUG|Placebo|Placebo will be formulated for intravenous delivery
40935476|NCT00054171|DRUG|aminolevulinic acid hydrochloride|
40935477|NCT05448976|OTHER|Saliva and serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis.
40935478|NCT00937781|GENETIC|RNA analysis|
40935479|NCT00937781|GENETIC|gene expression analysis|
40935480|NCT00937781|GENETIC|microarray analysis|
40935481|NCT00937781|GENETIC|polymerase chain reaction|
40935482|NCT00937781|OTHER|immunohistochemistry staining method|
40935483|NCT00937781|OTHER|laboratory biomarker analysis|
40935484|NCT02808572|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
40935485|NCT02808572|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
40935486|NCT02808572|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by multidetection computerized tomography
41130013|NCT05605925|DRUG|Ivermectin|IVN 600 mcg/kg/day for 3 days
41279727|NCT04321343|DRUG|PXL065|PXL065 oral tablet
41279728|NCT04321343|DRUG|Placebo oral tablet|Placebo oral tablet
40935487|NCT02376283|DRUG|Prasugrel|
40935488|NCT02376283|DRUG|Clopidogrel|
40935489|NCT02376283|DRUG|ticagrelor|
40935490|NCT05945680|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
40935491|NCT05945680|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
40935492|NCT03598634|PROCEDURE|administration of riboflavin for epi-off cross-linking|riboflavin 0.1% in 20% dextran solution
40935493|NCT03598634|PROCEDURE|administration of riboflavin for epi-on cross-linking|riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid
40935494|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
40935495|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
40935496|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
40935497|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
41130014|NCT03387540|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
41130015|NCT05310968|DRUG|Tirofiban hydrochloride sodium chloride injection|Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.
41130016|NCT05310968|DRUG|Tirofiban hydrochloride sodium chloride injection placebo|Day 1: Tirofiban placebo will be injected at the same rate with experimental group.
41130017|NCT05310968|DRUG|Aspirin|Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day
40755785|NCT01189227|PROCEDURE|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
40935498|NCT01566760|DRUG|fesoterodine fumarate|one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
40935499|NCT03616171|BEHAVIORAL|SLEEP-Extend intervention|"1. One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~2. Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later"
40935500|NCT03616171|OTHER|Control|Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
40935501|NCT03730454|DEVICE|Transanastomotic Tube (5FR)|5FR tube left in place for 5 days after completion of esophageal anastomosis.
40935502|NCT03730454|OTHER|No Transanastomotic Tube|No transanastomotic tube used during repair
40935503|NCT04817527|DRUG|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
40935504|NCT02199327|DRUG|Mitomycin C|Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
40935505|NCT02199327|DRUG|Interferon Alfa-2b|Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
40935506|NCT01108289|OTHER|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
40935507|NCT03784365|DRUG|One dose of Cefo-perazone Sulbactum|Antibiotic
40935508|NCT05588804|DRUG|Broncho-munal®|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
40935509|NCT05588804|DRUG|Placebo|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
40935510|NCT00911742|DRUG|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
40935511|NCT00911742|DRUG|Zytram|1 Zytram 200 mg tablet as a single dose
40935512|NCT05980793|PROCEDURE|PIP joint denervation|Surgical denervation of the PIP joint
41130018|NCT02139813|PROCEDURE|Laparoscopic Mini-gastric bypass|"The laparoscopic Omega Loop Bypass will consist of:~* a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His~* a narrow gastric tube will be calibrated to be approximately 1.5 cm wide~* an Omega loop of 200 cm~* a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler"
41130019|NCT02139813|PROCEDURE|Procedure of reference in bariatric surgery|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects"
41130020|NCT03875313|DRUG|CB-839|CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
41130021|NCT03875313|DRUG|Talazoparib|Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
41130022|NCT01786876|DRUG|Radiolabeled SPD557|A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
40935513|NCT05980793|PROCEDURE|Patient education plus exercise|An education plus exercise program
41450065|NCT04127292|BEHAVIORAL|Emotional Self Awareness (ESA) Individual Feedback|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
40935514|NCT01192243|DRUG|Gefitinib|250mg qd po d3-16
40755786|NCT01189227|PROCEDURE|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
40935515|NCT01192243|DRUG|Pemetrexed|500mg/m2 venous infusion,D1,q3w
40935516|NCT01192243|DRUG|Cisplatin or carboplatin|Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w
40935517|NCT03353389|OTHER|No AKI|Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.
40935518|NCT03353389|OTHER|CA-AKI|"CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
40935519|NCT03353389|OTHER|HA-AKI|"HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
40935520|NCT01680237|BEHAVIORAL|Cognitive behavior therapy|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises as well as identification and correction of maladaptive thoughts about anxiety and its consequences.
40755787|NCT03173508|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
40755788|NCT03173508|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
40935521|NCT01680237|BEHAVIORAL|Exposure in-vivo|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises.
40935522|NCT03083431|DRUG|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)
40935523|NCT03083431|DRUG|Placebo|Oral solution containing the same excipients as propranolol solution
40935524|NCT02410733|BIOLOGICAL|Lipo-MERIT|vaccination
41130023|NCT01988935|BEHAVIORAL|Prolonged Exposure|Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
41130024|NCT01988935|BEHAVIORAL|Smoking Cessation|Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
41130025|NCT05673746|PROCEDURE|Acupuncture|acupuncture administration
41130026|NCT05673746|DRUG|treatment of physician choice, according to the standard of care|treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
41130027|NCT06463041|OTHER|Experimental, comparator and control|How does implementing a GetUp Assist device in addition to a daily low-intensity functional or traditional training program affect Norwegian female office workers' physical health after 12 weeks?
41130028|NCT01044888|DRUG|Heparin|150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
41130029|NCT01672333|DRUG|TOX|oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
41130030|NCT05494866|DRUG|Cobicistat Oral Tablet|Cobicistat Oral Tablet
41130031|NCT05494866|DRUG|Gemcitabin|Gemcitabin
41130032|NCT05494866|DRUG|Nab paclitaxel|nab-Paclitaxel
41130033|NCT00002748|BIOLOGICAL|gene-modified tumor cell vaccine therapy|
41130034|NCT00002748|BIOLOGICAL|interleukin-2 gene|
41130035|NCT03241706|DRUG|Low Fructose|IV fructose (1.3 mg/kg/min)
41130036|NCT03241706|DRUG|Saline|Saline given as a comparison to fructose.
41450066|NCT05216562|DRUG|Exosome-MSC Intravenous injection|Intravenous injection of Exosome-MSC
41450067|NCT05216562|DRUG|Placebo Intravenous Injection|Intravenous injection of Placebo
41450068|NCT05216562|DRUG|COVID-19 Standard Treatment|Specific drugs considered standard treatment for COVID-10 by each location may vary
41450069|NCT03562182|OTHER|blood draw|Blood draw (2.5mL) to assess mRNA LPCAT1 levels
41450070|NCT02943343|OTHER|No intervention|
41130037|NCT03241706|DRUG|Somatostatin|IV infusion of somatostatin (60 ng/kg/min)
41130038|NCT03241706|DRUG|Insulin|IV infusion of insulin between 20-60 mU/m2/min.
41130039|NCT03241706|DRUG|Glucagon|IV glucagon (0.65 ng/kg/min).
41450071|NCT06555939|BEHAVIORAL|Collaborative Care Model|The interprofessional team will meet weekly to review survey scores, endorsed psychological and physical health needs, as well as other concerns. They will conduct assessments as a group that may include referrals for additional support.
41130040|NCT03241706|DRUG|Dextrose solution|IV dextrose to clamp the plasma glucose at the desired level.
41130041|NCT03241706|DRUG|High Fructose|IV-fructose (6.5 mg/kg/min)
41130042|NCT02349516|DRUG|Squalamine Lactate Ophthalmic Solution 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
40755789|NCT05537857|OTHER|High dietary salt|Controlled feeding study that varies in salt content.
40755790|NCT00601016|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
40755791|NCT01743703|OTHER|diagnostic whole body MRI|diagnostic whole body MRI, both STIR and diffusion weighted
40755792|NCT01515254|BEHAVIORAL|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
40755793|NCT04898309|DRUG|GNR-038, 50 МЕ/ kg|A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.
40755794|NCT04898309|DRUG|GNR-038, 100 МЕ/ kg|A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.
40755795|NCT04898309|DRUG|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
40755796|NCT04898309|DRUG|Placebo|A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
40755797|NCT04898309|DRUG|GNR-038. The dose will be selected according to results of stage 1 clinical trial.|A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
40755798|NCT04898309|DRUG|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
40755799|NCT03269786|DIAGNOSTIC_TEST|Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC)|Liver function tests will be assessed after endoscopic varisceal treatment for 6 monthes
40755800|NCT03269786|DEVICE|biannual ultrasonography|portal vein diameter , portal vein velocity and flow direction, volume flow in portal vein , congetive index, spleen size.will be assessed after endoscopic varisceal treatment by using biannual ultrasonography for 6 monthes
40755801|NCT02262273|OTHER|Data Collection|Colleciton of data from medical records only
40755802|NCT01371565|DRUG|Mifepristone|mifepristone at doses from 300mg/day up to 1200mg/day
40755803|NCT00600704|PROCEDURE|Fluid Restriction Policy|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
40755804|NCT00600704|PROCEDURE|Free fluid infusion|Free fluid infusion unless Hb\< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
40755805|NCT00005078|DRUG|carboplatin|
40755806|NCT00005078|DRUG|paclitaxel|
40755807|NCT00005078|DRUG|tirapazamine|
40755808|NCT01579305|DEVICE|Juvéderm® Volbella with Lidocaine|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
40755809|NCT01579305|DEVICE|Restylane-L®|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
40755810|NCT01812018|DRUG|Endostar|Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
40755811|NCT01812018|DRUG|Gemcitabine|Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
40755812|NCT01812018|DRUG|Docetaxel|Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
40755813|NCT01290354|DRUG|Lapatinib|Unlabelled, administered orally
40755814|NCT01290354|DRUG|[11C] lapatinib|Radiolabelled, administered intravenously
40935525|NCT03462290|DRUG|botulinum toxin type A|Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide
40935526|NCT03462290|DRUG|placebo|solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
40935527|NCT03149393|DRUG|Qizhi Weitong Granules|Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
40935528|NCT03149393|DRUG|Mosapride Citrate Tablets|Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
41130043|NCT03616015|BIOLOGICAL|blood samples|20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
41130044|NCT03616015|BIOLOGICAL|fecal samples|1 g of feces (D-8, D0, D15, D30, D90)
41450072|NCT06555939|BEHAVIORAL|Promoting Resilience in Stress Management|PRISM targets 4 resilience resources: stress management, goal-setting, cognitive reframing and meaning-making. It is delivered one-on-one by trained coaches in English or Spanish via HIPAA compliant video-conference or in-person. Sessions are delivered every 1-2 weeks based on patient preference. To facilitate practice between sessions, all participants 13 or older have access to the digital PRISM app.
40755815|NCT05882331|PROCEDURE|Extracorporeal photopheresis|ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes \~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.
40755816|NCT00008333|DRUG|vinorelbine tartrate|
40755817|NCT04191733|DEVICE|KINCISE(TM) Surgical Automated System|Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
40755818|NCT06269601|DIAGNOSTIC_TEST|Upper Limb Rotation Test|The athletes were instructed to perform a 90° abduction and 90° external rotation of the shoulder, accompanied by trunk rotation for a duration of 15 seconds. The number of repetitions was recorded. The tested side was the upper extremity in which the closed kinetic chain position was maintained. The test was repeated three times, and the average of the results was calculated.
40755819|NCT03570515|BEHAVIORAL|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days, recording their practice on a yoga homework log provided to them.
40755820|NCT03570515|BEHAVIORAL|Educational film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
40755821|NCT00127543|BEHAVIORAL|Medication Education for Children|
40755822|NCT06436521|BEHAVIORAL|Positive Cognitive Behavioral Therapy|Positive CBT integrates brief Solution-Focused Brief Therapy with Positive Psychology techniques, within a cognitive-behavioral framework. It is considered a competency and strengths-based model.
40755823|NCT06436521|BEHAVIORAL|Traditional Cognitive Behavioral Therapy|Traditional cognitive behavioral therapy is a form of psychological treatment that emphasizes that psychological problems are based on faulty or unhelpful ways of thinking and the focus is to change thinking patterns.
40755824|NCT05624632|OTHER|Remote cognitive testing|Remote cognitive testing
40755825|NCT04499053|DRUG|Durvalumab|durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)
40755826|NCT04499053|DRUG|Tremelimumab|tremelimumab 75 mg, intravenous, every 3 weeks for 4 cycles. A dose of tremelimumab 75 mg will be given at week 16.
40755827|NCT05041582|DEVICE|tDCS|dual tDCS with ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1 cathodal stimulation, 2 weeks after SSRI treatment
40755828|NCT05041582|DRUG|Citalopram|total 3 months, since 2-4 weeks after stroke
40755829|NCT05041582|BEHAVIORAL|Rehabilitation|hospitalized rehabilitation, 3 hours daily
40755830|NCT05983900|PROCEDURE|BRIX3000|chemo-mechanical caries removal agent
40755831|NCT05983900|PROCEDURE|papacarie|chemo-mechanical caries removal agent
40755832|NCT05983900|PROCEDURE|hand excavation|mechanical caries removal
40755833|NCT04605588|DRUG|Nitazoxanide|Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
40755834|NCT04605588|DRUG|Placebo Nitazoxanide|Placebo Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
40755835|NCT04605588|DRUG|Ribavirin|Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
41279729|NCT04358757|PROCEDURE|Elective cesarean delivery|scheduled cesarean delivery for maternal / obstetric indications
41279730|NCT04358393|DRUG|APG-115|APG-115 given once daily on day 1-5 of every 28 day cycle
41279731|NCT04358393|DRUG|5-azacitidine|5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days
41279732|NCT02086773|BIOLOGICAL|Red blood cell transfusion|
41279733|NCT00040157|DRUG|ACH126-443 (Beta-L-Fd4C)|
41450073|NCT01910038|DRUG|corticoids+ tocilizumab 8mg/Kg/4 weeks|
41450074|NCT01932021|PROCEDURE|adipose tissue grafting|
41453519|NCT03317067|DRUG|Dexmedetomidine|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
40935529|NCT02874768|DRUG|Dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 \~ 0.7 mcg/kg/h)
40935530|NCT02874768|DRUG|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 \~ 1.6 mg/kg/h)
40935531|NCT01206673|OTHER|Blood sampling|One blood sampling is required for the research
40935532|NCT05408468|BEHAVIORAL|FAMCOPE-ICU|(1) FAMCOPE-ICU is a digital eHealth emotion regulation and coping intervention. FAMCOPE-ICU contains three digital modules representing the three interventional doses. Corresponding with Gross's Extended Process Model of Emotion Regulation, the three respective doses entail assessments, adaptive feedback, and interactive activities pertaining to understanding their affective experiences, learning strategies to regulate emotions and stress, and practicing these skills in a virtual decision-making task. Each dose of the intervention is expected to last 10-15 minutes
40935533|NCT01689961|BEHAVIORAL|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
40935534|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
40935535|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
40935536|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
40935537|NCT00624702|DRUG|Placebo|
41279734|NCT03946267|DEVICE|Inverted inner limiting membrane flap technique for large full thickness macular holes|The ILM, stained with IFCG or BBG, is peeled off with ILM forceps, usually beginning near the inferotemporal vascular arcade, at least 2 disk diameters from the macular hole, in a circular manner. The peeling is extended up to the edges of the macular hole, the wide ILM flap obtained reduced by trimming with the vitreous cutter, and the annular remnant of ILM hinged to the hole's edge gently inverted upside down facing the RPE. Therefore, the hole is covered with usually more layers of inverted ILM. Attention is paid to avoid insertion and filling of the hole volume with ILM.
41279735|NCT00466505|BIOLOGICAL|cetuximab|400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
40755836|NCT04605588|DRUG|Placebo Ribavirin|Placebo Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
40755837|NCT04605588|DRUG|Hydroxychloroquine|Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
40755838|NCT04605588|DRUG|Placebo Hydroxychloroquine|Placebo Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
40935538|NCT03201627|DRUG|Lithium Carbonate|To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1
40935539|NCT04853303|DEVICE|Hypnosis VR|Children will be required to wear a VR gadget for hypnosis when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain. The duration is 15 minutes.
40935540|NCT06422754|DEVICE|Becure GmbH|Becure Balance System
40935541|NCT01215864|DRUG|TCD-717|"Patients will receive TCD-717 at the following dose levels:~2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m\^2"
40935542|NCT03121339|BIOLOGICAL|VXA-A1.1 H1 Tablet Vaccine (small)|Tableted oral H1 vaccine (\~140 mg tablet)
40935543|NCT03121339|BIOLOGICAL|VXA-A1.1 H1 Tablet Vaccine (large)|Tableted oral H1 vaccine (\~275 mg tablet)
40935544|NCT02005328|DEVICE|Tested product : DC161-DP0291|Application of product in the mouth twice daily
40755839|NCT05174702|RADIATION|Irradiation collected at the end of the operation on the active dosimeter|Mesure of the irradiation collected at the end of the operation on the active dosimeter for the surgeon, the patient and the operating team
40755840|NCT06125379|BEHAVIORAL|brief mindfulness|The mindfulness intervention protocol in this study is an adaptation of the Mindfulness Based Stress Reduction (MBSR) protocol with the cultural adaptation suits Indonesia population with addition of Islamic elements (i.e., a series of spiritual approaches) to improve emotional regulation, make sense of their life, be grateful and feel closer to God.
40755841|NCT02642679|DEVICE|Opticell Ag|Opticell Ag+ applied to STSG donor site
40935545|NCT02005328|DEVICE|Tested product : DC161-DP0292|Application of product in the mouth twice daily
40935546|NCT02005328|DEVICE|Tested product : DC161-DP0293|Application of product in the mouth twice daily
40935547|NCT02005328|DEVICE|Reference product: solution for oromucosal sprays|Application of product in the mouth twice daily
41279736|NCT00466505|DRUG|celecoxib|200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
41279737|NCT00466505|GENETIC|proteomic profiling|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
41279738|NCT00466505|OTHER|immunohistochemistry staining method|phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
41453520|NCT03317067|OTHER|Placebo|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
41453521|NCT01791062|DEVICE|HYTOP®|HYTOP® will be implanted once during surgery.
40755842|NCT01470820|OTHER|Phototherapy with blue light|The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
40755843|NCT04482621|DRUG|Decitabine|"Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants.~Decitabine will be administered via Intravenous Administration 10/mg/m\^2/day Dosage: 10mg/m\^2/day IV day x 5 days (1 cycle only)"
40755844|NCT04482621|OTHER|Placebo Saline|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m\^2/day IV day x 5 days (1 cycle only)
40755845|NCT02167685|DRUG|CMX001|
40755846|NCT05645185|DIAGNOSTIC_TEST|Diagnosis test|Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.
40755847|NCT05826470|DEVICE|"TRANBERG®|Thermal Therapy System"|Focal laser ablation.
40755848|NCT01342042|BIOLOGICAL|rExenatide-4|This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 \[glucagon-like peptide-1\] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
40755849|NCT03535519|DRUG|Methotrexate|standard of care treatment with methotrexate
40755850|NCT00558207|DRUG|ARQ 197|120 mg capsule administered twice daily for 240 mg total daily dose
40755851|NCT00558207|DRUG|gemcitabine|1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
40755852|NCT04938674|DEVICE|ultrasonic guidance|Standard process for blood collection using Ultrasonic Guided puncture
40755853|NCT00406731|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6 mg/kg over 5 minutes followed by a continuous intravenous infusion of 60 µg/kg/min over 12 minutes; twice on 1 study day
40755854|NCT00406731|DRUG|Endothelin-1 (ET-1)|5 ng/kg/min intravenous infusion over 17 minutes; twice on 1 study day
40755855|NCT00406731|DRUG|Physiologic saline solution (placebo control)|intravenous infusion over 20 minutes; twice on 1 study day
40755856|NCT00406731|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
40755857|NCT00406731|DEVICE|Goldmann applanation tonometer|Intraocular pressure measurements
40755858|NCT00406731|DEVICE|HP-CMS patient monitor|blood pressure and pulse rate measurements
40755859|NCT00406731|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
40755860|NCT02687165|DRUG|Milnacipran and D-cycloserine|Milnacipran augmented by D-cycloserine
40755861|NCT04693715|DRUG|RNS60|RNS60 injection solution
40755862|NCT04693715|DRUG|Placebo|Placebo injection solution
40935548|NCT05200741|BIOLOGICAL|DelNS1-2019-nCoV-RBD-OPT1|Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray
40935549|NCT05200741|BIOLOGICAL|Matching placebo|Solution for Intranasal Spray
41453522|NCT02408653|DEVICE|EEG|
41279739|NCT00466505|OTHER|laboratory biomarker analysis|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
41279740|NCT00466505|OTHER|mass spectrometry|We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
40935550|NCT04349293|PROCEDURE|Tissue sampling|Collection of a sample of tumor tissue and a sample of adjacent or counter lateral healthy tissue (if possible) from the surgical room
40935551|NCT04349293|PROCEDURE|Blood sampling|Collection of a 30mL peripheral blood sample in heparin at several times: during surgical and medical treatment (before surgery, before the start of mAbs and after mAbs)
40935552|NCT02573038|DRUG|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
40935553|NCT04308811|BIOLOGICAL|platelet rich plasma|Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions
40935554|NCT04308811|COMBINATION_PRODUCT|amniotic membrane graft group|amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions
40935555|NCT04308811|DEVICE|Intrauterine balloon|intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions
41130045|NCT03616015|BEHAVIORAL|Anxiety test|Test of Spielberger
41279741|NCT03219125|DEVICE|Dixon Magnetic Resonance Imaging|MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.
41279742|NCT03219125|DEVICE|dual-energy X-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
41450075|NCT03022643|BEHAVIORAL|Interpersonal Social Rhythms Psychotherapy|The treatment involves 8-weeks of individual psychotherapy. Weekly sessions will be 60-minute long and will take place at the Pain Research Center. The treatment focuses on 1) the link between life events, pain severity, sleep disturbances, fatigue, and mood, 2) social and behavioral rhythms and sleep-wake disturbances, 3) identification and management of rhythm dysregulation and the triggers for it, 4) allowing and facilitating the mourning of the loss healthy self, 5) identification and appropriate management of symptoms.
40935556|NCT00773383|DRUG|RG1507|iv 9mg/kg weekly
40935557|NCT00773383|DRUG|erlotinib [Tarceva]|150mg oral daily
40935558|NCT02997267|PROCEDURE|Closure of the ileostomy|Surgical closure of the protective ileostomy (reconnection of intestinal loops)
41130046|NCT03616015|BEHAVIORAL|Stress test|Test of Cohen
41279743|NCT01309516|BEHAVIORAL|Complex Intervention|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
41279744|NCT04604327|DRUG|Bemiparin sodium|Prophilactic vs full-dose for 10 days
40935559|NCT02054871|PROCEDURE|RIPC|A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
40935560|NCT00579007|BEHAVIORAL|telephone interviews|Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
40935561|NCT04086875|BEHAVIORAL|Focus Group|Participate in focus group
40935562|NCT04086875|OTHER|Text Message|Receive text messages
41279745|NCT05321186|PROCEDURE|minimally invasive spinopelvic fixation|"Bilateral percutaneous L4 and L5 pedicle screws will be placed under fluoroscopic guidance with Jamshidi needles, and these were will also be used the iliac fixation via percutaneous S2 alar iliac screws.~Cases presenting with significant instability, minimally invasive Transforaminal lumbar interbody fusion (MIS-TLIF) will be performed. Additionally, in cases with neurological deficit, posterior decompression will be performed."
41279746|NCT01053676|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
41279747|NCT01053676|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
41450076|NCT03022643|OTHER|Bright Light Device|All patients will be provided with a bright light device (Re-Timer) and will be instructed to use it in the first 2-hours of the day (for a minimum of 30 minutes) throughout the 8-week treatment period.
41450077|NCT06150807|DEVICE|ultrasound and doppler|Ultrasound examinations of the liver and spleen including color Doppler imaging of the portal veins, hepatic veins, splenic vein, and superior mesenteric vein will done in the Department of Pediatric
41450078|NCT00611676|DRUG|Venlafaxine|Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
40935563|NCT04086875|OTHER|Best Practice|Receive usual care
40935564|NCT04086875|OTHER|Questionnaire Administration|Ancillary studies
40935565|NCT01306877|DEVICE|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
40935566|NCT01306877|DEVICE|Endosurgery Proximate PPH03 Stapling Set|Surgical device
40935567|NCT04571515|DRUG|MR-107A-01|Oral tablet
40935568|NCT04571515|DRUG|Placebo|Oral tablet
41130047|NCT02717819|DIETARY_SUPPLEMENT|Protein|Daily intake of supplement
41130048|NCT02717819|DIETARY_SUPPLEMENT|Placebo|Daily intake of supplement
41130049|NCT02717819|OTHER|Resistance training|Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
41130050|NCT02717819|DIETARY_SUPPLEMENT|Vitamin D|Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
41130051|NCT02238041|DEVICE|GlucoClear System|
40935569|NCT00761748|DEVICE|Convatec Uro 2-piece|"Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.~The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look."
40935570|NCT00761748|DEVICE|SenSura Uro 2-piece|SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
40935571|NCT03686644|PROCEDURE|Wearing of night splint ankle foot orthoses (phase A)|"Children wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
40935572|NCT03686644|PROCEDURE|No wearing of night splint ankle foot orthoses (phase B)|"Children no wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
40935573|NCT02571400|OTHER|Continued use of opioid analgesics >90 days post-surgery|Exposure of interest: continued use of opioid analgesics \>90 days post-surgery
40935574|NCT06278909|DEVICE|Trigeminal Nerve Stimulation|Active trigeminal nerve stimulation
40935575|NCT04746872|DIAGNOSTIC_TEST|Alinity m HR HPV|A qualitative in vitro test that amplifies and detects HR HPV DNA in cervical tissue samples.
40935576|NCT03695276|BEHAVIORAL|PushCon Model|Pulmonary specialist consultation facilitated by a trained health coach, who will gather information from the patient and medical record prior to the consultation and will using health coaching skills to support implementation of recommended care.
40935577|NCT03695276|BEHAVIORAL|Usual care|The standard of care, which usually means management within primary care.
40935578|NCT00176722|OTHER|table tilt|One group randomized to table tilt. One group will be flat.
40935579|NCT04900168|DEVICE|Intracranial pressure monitoring|An invasive method to monitor the intracranial pressure of patient
40935580|NCT04016740|DRUG|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
40935581|NCT04016740|DRUG|Ketamine|Intraoperative infusion
40935582|NCT04016740|DRUG|Remifentanil|Intraoperative infusion
41130052|NCT03329482|OTHER|PULSE ULTRASOUND|For group A, The PUS group received pulse mode of ultrasound (sonoplus 490s), with frequency of 1MHZ and intensity of 1.5w/cm according to Ebadi et al 10). Grey's formula was used to estimate the duration of ultrasound (US) for each patient 21). The average local exposure time was one minute and the effective radiating area of the transducer head was 5 cm2. For a patient with an area of low back pain of 40 cm2, the required total treatment time was: 1 min × (40 cm2/5 cm2) = 8 minutes. US was applied using slow circular movements, with the transducer head placed over the painful paravertebral low back region and Lofnac gel used as coupling medium.
40935583|NCT04016740|DRUG|Dexmedetomidine|Intraoperative infusion
41130053|NCT03329482|OTHER|KNEADING MASSAGE|Kneading massage was done with the two hands maintaining a slow circular compression of soft tissues against underlying bone. Pressure was applied as the hands moved proximally, continuously maintaining a contact with the skin, according to Goat22). Lofnac gel was used as a coupling medium for the massage. This was done for an approximately ten and 12 minutes.
41130054|NCT03090711|DEVICE|Transcranial Magnetic Stimulation (TMS)|The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.
41279748|NCT05045040|BEHAVIORAL|Mobile-based empathetic communication support program to promote ACP discussion|Patients in the intervention group are provided a mobile-based empathic communication support program-an app on a mobile phone. The app comprises a QPL (46 questions in eight categories) and questions about the patient's preferred treatment and end-of-life care based on their values and goals. Then, they proceed with the content themselves, at home or anywhere, at any time. Between app registration and the next outpatient visit, the patient is interviewed (by phone or in person) by a nurse or a clinical psychologist, who helps them prepare for the discussion with the physician and asks questions based on the patient's app responses for 30 minutes to an hour. During the outpatient visit, feedback is provided to patients and their physicians based on the interview. The duration between the start of app use and the next consultation is a minimum of one week and a maximum of four weeks.
40935584|NCT04016740|DRUG|Rocuronium|Intraoperative intermittent bolus
40935585|NCT04016740|DRUG|Propofol|Intraoperative infusion
40935586|NCT04016740|DRUG|Sevoflurane|Intraoperative inhaled as needed
40935587|NCT04016740|DRUG|Dexmedetomidine|Post-operative infusion
40935588|NCT04016740|DRUG|Propofol|Post-operative infusion
40935589|NCT04016740|DEVICE|EEG monitoring|Perioperative monitoring
40935590|NCT02043379|DRUG|IVIG|Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
40935591|NCT02043379|OTHER|Placebo|If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
40935592|NCT04936464|DEVICE|transcutaneous tibial nerve stimulation (TTNS)|TTNS is a non-invasive, surface electrode therapeutic stimulation technique available for home administration that has been proposed as a treatment for overactive bladder.
40935593|NCT04936464|DEVICE|transcutaneous electrical stimulation (TENS)|The sham intervention is designed to appear almost identical to the TTNS intervention.
40755863|NCT04845542|BEHAVIORAL|ReStoreD|ReStoreD is a remotely-administered behavioral intervention in which couples coping with stroke learn and practice goal-setting, communication strategies, and positive psychology activities, such as expressing gratitude, finding meaning, and fostering connections. Participants are provided with 8 weekly modules, each featuring two components: 1) psychoeducational materials, such as an informational video and resources/links about a general topic related to resilience, coping, and/or overall well-being of the individual and couple, and 2) examples of positive psychology activities that relate to the week's theme or topic. Participants are asked to complete at least two positive psychology activities alone and two together each week.
40935594|NCT04255797|BEHAVIORAL|baby massage|The steps are as follows:1. Monitor the physiological indicators before massage, 2. Assist premature babies to lie on prone, take off their clothes and diapers, and then apply the baby's massage oil to the hands of both parents to warm them. 3. In the incubator, slight pressure touch the baby's body with warm palms and fingers.
40935595|NCT04988828|DEVICE|Whole body vibration|vertical vibration platform with the frequency of 30Hz, amplitude of 4mm. The intervention will last for 5 weeks, twice /week.
40935596|NCT06152471|DRUG|SPC-flakes|Aktive drug
40935597|NCT06152471|DRUG|Salovum|Active drug
40935598|NCT06152471|DRUG|Placebo|Placebo drugs
40935599|NCT06215664|BEHAVIORAL|Singularities Game|Singularities is a theory-based, community-informed, web-accessible, roleplaying game-based intervention incorporating 4 primary components: fostering healthy identity development in a safe environment; encouraging help-seeking behaviors; encouraging use of productive coping; alcohol-harm reduction; and encouraging healthy internet and social media use.
40935600|NCT06215664|BEHAVIORAL|Psychosocial Education|Psychoeducational core components of the Singularities intervention delivered in an instructional text format to participants through a Qualtrics-based training program.
40935601|NCT05160987|DRUG|Remimazolam|Remimazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
40935602|NCT05160987|DRUG|Midazolam|Midazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
40935603|NCT01603238|DRUG|[14C]-LC15-0444|A single oral administration of \[14C\]-LC15-0444 50 mg, containing 4.9 MBq \[14C\]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
40935604|NCT05606718|DRUG|Dapagliflozin|dapagliflozin 10mg once daily for 3 months after randomization
40935605|NCT05606718|OTHER|guideline-directed medical therapy (GDMT)|guideline-directed medical therapy (GDMT)
40935606|NCT04073303|BIOLOGICAL|Botulinum Toxin Type A|Day 1 Administration of bilateral intramuscular injections into the masseter
40935607|NCT04073303|OTHER|Placebo|Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
41279749|NCT01349738|DRUG|Antibiotic|Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
41279750|NCT05714371|DRUG|Nivolumab|Patients receiving nivolumab
40935608|NCT05532787|OTHER|Application of acute chest pain risk stratification scores (HEART and EDACS)|Collection of data elements for the HEART Pathway and EDACS-ADP assessments and calculation of scores to risk stratify patients into low risk or high risk
40935609|NCT04070976|RADIATION|Hypofractionated therapy|All patients will be treated with an external beam of 37.5 Gray in 15 fractions (2.5 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using the anterior/posterior field and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
40935610|NCT04070976|RADIATION|Standard therapy|All patients will be treated with external beam radiotherapy with 50 Gray in 25 fractions (1.8-2 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using anterior/posterior fields and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
40935611|NCT01058265|OTHER|Integrative|Integrative Medicine medical evaluation.
41130055|NCT03090711|DEVICE|Transcranial Alternating Current Stimulation (tACS)|TACS stimulation involves two electrodes placed on either side of the desired site of cortical stimulation. The mode of stimulation used in this experiment is identical to previous studies using tACS in sleep ( Marshall et al., 2006; Prehn-Kristensen et al., 2014 ). Stimulation follows a sinusoidal pattern from 0 to 260 μA. This pattern is delivered at 0.75 Hz and is repeated for 225 cycles; a total of 5 minutes of stimulation. This 5 minute pattern is again repeated 5 times, with a minute of no stimulation between each; thus for a total of 30 minutes.
41130056|NCT03090711|DEVICE|sham Transcranial Magnetic Stimulation (TMS)|Sham coil will be used to exclude possible nonspecific effects of the TMS. The sham coil is shielded i.e., the magnetic field output is weakened and therefore insufficiently powerful to stimulate the cortex.
41279751|NCT05714371|DRUG|Ipilimumab + nivolumab|Patients receiving ipilimumab + nivolumab
41279752|NCT05714371|DRUG|Pembrolizumab|Patients receiving pembrolizumab
41279753|NCT05714371|DRUG|Dabrafenib + trametinib|Dabrafenib + trametinib
41450079|NCT04345640|OTHER|no intervention|no intervention
40935612|NCT01058265|OTHER|Standard|Standard general medical evaluation.
41279754|NCT00473694|DRUG|sugammadex|Administered as an intravenous (IV) infusion
41279755|NCT00473694|DRUG|neostigmine|Administered as an IV infusion
41279756|NCT00473694|DRUG|vecuronium|Administered as an IV infusion
41279757|NCT00473694|DRUG|rocuronium|Administered as an IV infusion
41279758|NCT00473694|DRUG|glycopyrrolate|Administered as an IV infusion
41279759|NCT02085577|DRUG|(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml|Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
41279760|NCT02085577|DRUG|Isotonic sodium chloride 0.9 percent|Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
41279761|NCT02085577|DRUG|Paracetamol 1 g|Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
41279762|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
41450080|NCT06000579|OTHER|EFT|Each student will be asked to voluntarily give their phone number and last menstrual cycle date, and the day will be determined for the first session. Then, the first EFT session will be made by the researchers by calling 14 days before the menstruation date. In the 2nd and 3rd sessions, a total of 3 sessions of EFT will be applied face-to-face by the researchers 14 days before menstruation. After each student completes three menstrual cycles, the researchers will meet with the student and PMSS will be applied as a post-test.
41279763|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
41279764|NCT02085577|DRUG|Ondansetron 2 mg/ml|Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
40935613|NCT04544969|DRUG|cisplatin-based chemotherapy|"GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge."
40935614|NCT04706416|DIETARY_SUPPLEMENT|N-acetyl glucosamine (NAG)|Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.
40935615|NCT04706416|OTHER|Control|Patients do not receive treatment with N-Acetylglucosamine. They may receive other treatments at the discretion of the treating physician, as with the treatment group.
40935616|NCT05088655|DRUG|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
40935617|NCT03926546|BEHAVIORAL|ERP for Individuals|Comparing Group vs. Individual ERP for OCD
40935618|NCT00818675|DRUG|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
40935619|NCT00818675|DRUG|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
40935620|NCT00818675|DRUG|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
40935621|NCT04545203|OTHER|Slow-stroke back massage|Slow-stroke back massage was performed to the breast cancer patients in intervention group. The SSBM sessions were administered 10 minutes before and after chemotherapy treatment.The SSBM was applied for 20 minutes in total, on each cycle. The intervention group received 20-minute SSBM sessions 3 chemotherapy cycle in addition to the routine care.
40935622|NCT02794740|DRUG|X0002|External Spray
40935623|NCT02794740|DRUG|Placebo|External Spray
40935624|NCT03787563|DRUG|Herbal Tea|All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.
40935625|NCT03787563|DRUG|Placebo Tea|Similar looking inert placebo tea.
40935626|NCT06330844|BEHAVIORAL|Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI)|RBSEF-CCT-MCI differs from ME-CCT in that this intervention integrates psychoeducation and strategies for processing and coping with race/ethnicity-related stressors, as part of the larger conversation in ME-CCT regarding stress, and how stress interferes with attention, learning, and subsequently one's subjective sense of memory.
40935627|NCT06330844|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT)|"ME-CCT focuses on:~1. Cognitive training, psychotherapeutic, and lifestyle techniques.~2. Incorporates CCT techniques designed to help patients manage problems with memory, attention, and executive functions (i.e., organization, planning, decision-making, and problem-solving).~3. Includes mindfulness-based stress reduction practice which has been shown to improve cognitive and neuropsychiatric function in various populations."
40935628|NCT05648071|DRUG|Sintilimab|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus Bevacizumab until disease progression or intolerable toxicity.
40935629|NCT01646060|DEVICE|CM-1500|Blood Volume Monitor
40935630|NCT00084461|DRUG|romidepsin|Given IV
41279765|NCT02085577|DRUG|Usual daily opioids|The patients usual daily opioid consumption are administered during the study period
41279766|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
41279767|NCT02085577|DRUG|Sufentanil 5 microgram/ml|Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
41450081|NCT00996697|DRUG|Budesonide/formoterol and tiotropium|Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
40935631|NCT00084461|OTHER|laboratory biomarker analysis|Correlative studies
40935632|NCT05811533|OTHER|Spencer's MET with conventional therapy|Patients will be asked to lie in a side lying position with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand provided force into the restrictive barrier of shoulder in 7 different movements. During all the movements, patients will ask to use their muscle energy 20% against the slight resistance offered by the therapist for 3-5 seconds. The patient then asks to relax and exhale after that shoulder joint will move beyond the barrier to achieve the next barrier. After 20 sec of rest, this technique will be repeated 3-5 times
41279768|NCT04543448|OTHER|Traditional Rehabilitation for multiple sclerosis|Traditional rehabilitation program include strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs.
41279769|NCT04543448|OTHER|Cervical mobilization for multiple sclerosis|Cervical mobilization program include myofascial relaxation techniques and mobilization to cervical spine in addition to traditional program.
41279770|NCT05006443|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|a non-invasive assessment to determine severity of tricuspid regurgitation
41279771|NCT03226418|DRUG|Cytarabine|Given IV
41279772|NCT03226418|DRUG|Decitabine|Given IV
41279773|NCT03226418|DRUG|Idarubicin|Given IV
41279774|NCT03226418|OTHER|Laboratory Biomarker Analysis|Correlative studies
41279775|NCT03226418|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
41279776|NCT03226418|OTHER|Quality-of-Life Assessment|Ancillary studies
41450082|NCT00996697|DRUG|Budesonide/formoterol and placebo|Symbicort 200/6 2puff bid and placebo
41279777|NCT03226418|OTHER|Questionnaire Administration|Ancillary studies
40935633|NCT05811533|OTHER|Post-Facilitation Stretch with conventional therapy|Muscle Energy Technique \[Post Facilitation Stretch)\] for the shoulder joint will be applied with 3 repetitions per set, 1 session per day. Patient will be instructed to perform a full strength contraction of the muscle to be stretch for 10 seconds. The muscle is then allow to fully relax, whereupon a rapid stretch of the affected muscle will be performed and will held in position by the physician for 15 sec. Patient will be asked to relax and whole cycle will be repeated
41279778|NCT03226418|DRUG|Azacitidine|Given by infusion
40935634|NCT01604109|DRUG|10 % w/v CPP-ACP paste|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch
41279779|NCT03226418|DRUG|Venetoclax|oral tablet
41279780|NCT03226418|DRUG|glasdegib|oral tablet
41279781|NCT03792503|DRUG|Apatinib|Apatinib 500 mg Po qd
40935635|NCT01604109|DRUG|the paste without CPP-ACP|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch.
40935636|NCT01728948|DRUG|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator
41279782|NCT03792503|DRUG|Pemetrexed|Pemetrexe 500 mg/m2 d1×q3w
41279783|NCT03149835|OTHER|Non-invasive ventilation|NIV was provided by BiPAP-Vision™ ventilator (Philips Respironics Inc, Murrysville, PA, USA) set at the BIPAP mode and applied by a nasal mask, with room air, for 60 minutes. Volunteers were studied during the application of NIV (inspiratory pressure of 14cmH2O and expiratory pressure of 4cmH2O), with a pressure support of 10cmH2O and without oxygen support (FIO2 0.21). These pressure levels were chosen based on the current practice of NIV in the intensive care setting.
40935637|NCT03062410|OTHER|Electronic PRO in daily clinical practice|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
40755864|NCT05214027|OTHER|Treadmill-Based Exercise (60% VO2 Max for 60 minutes)|"Each participant will undergo a single 60-minute treadmill-based exercise intervention in a randomised order.~Treadmill settings are generated based on settings which correspond to participants exercising at 60% VO2 max from their maximal exercise test on visit 2. To confirm that participants are exercising at 60% during the hour session, 1 minute samples of expired air are taken at 15 minute intervals and immediately analysed to check % VO2 max. Participants heart rate and RPE measures are also taken at 15 minute intervals throughout the exercise session and cross-checked against predicted values at 60% VO2 Max."
40755865|NCT05214027|OTHER|Rest (60 minutes)|Each participant will undergo a 60-minute rest period in a randomised order.
40935638|NCT04308798|PROCEDURE|Surgical glove changing|Changing surgical glove after draping and before cementation during total knee arthroplasty
40935639|NCT01203176|PROCEDURE|Hysteroscopic polypectomy|Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
40935640|NCT05551637|DIETARY_SUPPLEMENT|Kazu Gain Gold|"Kazu Gain Gold is an Oral Nutritional Supplementation made by AIWAIDO Food Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~User Manual: Mix 6 spoons of Kazu Gain Gold (equal to 49,2 grams) with 180 ml of warm water (The energy density reaches 1kal/ml). Consume 2 glasses per day or follow the directions from the medical staff. The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
40935641|NCT00003171|DRUG|bryostatin 1|
41453523|NCT03218787|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
41130057|NCT03090711|DEVICE|sham Transcranial Alternating Current Stimulation (tACS)|Sham stimulation will be used to exclude possible nonspecific effects of the tACS. Sham tACS stimulation will involve actual stimulation for the first 30 seconds of the ramp-up period (stimulation power is gradually increased until its final level), and then immediately gradually decreased until zero (without the intermediate 4 minutes of actual stimulation). This procedure will be repeated 5 times every 6 minutes and shall induce similar cutaneous sensations as real stimulation.
40935642|NCT03189771|PROCEDURE|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
40755866|NCT00890097|DRUG|AL-8309B Ophthalmic Solution|
40755867|NCT00890097|DRUG|AL-8309B Vehicle|Inactive ingredients used as placebo comparator
40935643|NCT02723253|RADIATION|Radiotherapy|Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement \> 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.
40935644|NCT02723253|DRUG|Tom-OX|The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
40935645|NCT02354482|BEHAVIORAL|Patient Communication and Care Management|"Received the following Transitional Care strategies:~1. Helpful Health Care Contact OR Symptom Management~2. Post-discharge Care Consultation~3. Patient Goal/Preference Assessment~4. Plain Language Communication in Hospital~5. Plain Language Communication at Home~6. Transition Summary for Patients and Family Caregivers"
40935646|NCT02354482|BEHAVIORAL|Home-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~1. Transition Team~2. Home visits~3. Plain Language Communication at Home~4. Promote Trust at Home~5. Referral to Community Services~6. Follow-up Appointment"
40935647|NCT02354482|BEHAVIORAL|Hospital-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Identify High-Risk Patients and Intervene~3. Medication Reconciliation~4. Plain Language Communication in Hospital~5. Promote Trust in the Hospital~6. Transition Summary for Patients and Family Caregivers"
40935648|NCT02354482|BEHAVIORAL|Patient/Caregiver Assessment and Provider Information Exchange|"Received the following Transitional Care Strategies:~1. Patient Goal/Preference Assessment~2. Identify High-Risk Patients and Intervene~3. Timely Exchange of Critical Patient Information among Providers~4. Patient/Family Caregiver Transitional Care Needs Assessment"
40935649|NCT02354482|BEHAVIORAL|Assessment and Teach Back|"Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Language Assessment~3. Teach Back for Information and Skills"
40935650|NCT02354482|OTHER|Standard of Care (Reference)|No specific Transitional Care Strategy
41130058|NCT04720612|BIOLOGICAL|Omalizumab|Single subcutaneous dose of 375mg of omalizumab and standard of care.
41130059|NCT04720612|OTHER|Placebo|Single subcutaneous dose of normal saline in a syringe identical to that of the omalizumab arm and standard of care.
41130060|NCT00552253|DRUG|Levothyroxin treatment|Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1\~0.3 mU/L. It will be discontinued for 3 months. Then
41279784|NCT00784407|DEVICE|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
41450083|NCT00845637|DRUG|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
40755868|NCT03822819|DIETARY_SUPPLEMENT|probiotic cocktail capsules|Daily uptake of probiotic cocktail for three weeks
40755869|NCT03822819|DIETARY_SUPPLEMENT|placebo capsules|Daily uptake of placebo capsule for three weeks
40755870|NCT00231465|DRUG|docetaxel (Taxotere®)|Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
40755871|NCT00231465|DRUG|ZD1839|ZD1839 will be continued until progression, or until trial closure, whichever comes first.
40755872|NCT02284854|DRUG|BIA 2-093|
40755873|NCT02284854|DRUG|Carbamazepine|
40755874|NCT01341990|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
40755875|NCT01341990|DEVICE|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
40755876|NCT01341990|DEVICE|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
40935651|NCT03589547|DRUG|Durvalumab|Durvalumab10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)
40935652|NCT03589547|RADIATION|SBRT|"SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab.~The dose will consist of 20Gy (2 fractions of 10Gy)~\*3 fractions are allowed for centrally located tumors"
40935653|NCT03474315|DIAGNOSTIC_TEST|Multivariate assessment|Patient's status assessment according to clinical evaluation and data acquired from the implanted device.
40935654|NCT04516044|BEHAVIORAL|Video games|See arm description
40935655|NCT04590742|DRUG|melatonin 6mg|6 weeks of melatonin (6mg) given to patient
41279785|NCT04108767|BEHAVIORAL|Answer to standardized questionnaires in quality of life, health, lifestyle and behaviors|"The cross-sectional study will be conducted in all students in health sciences in 3rd year enrolled at the University Claude Bernard Lyon 1 (UCBL) and participating at the required medical consultation at the college Health Department of UCBL, over a period of 9 months.~The self-questionnaires will be completed by the students during the mandatory medical preventive visit at the university health center.~All dimensions investigated by the questionnaire are usually questioned by the caregivers during the consultation as part of the usual follow-up of students."
41279786|NCT04925115|OTHER|Brisk walking|"* Warm up and cool down (10 minutes before physical activity)~* Brisk walking ( 30 minutes each session for 5 days in a week)"
40935656|NCT04590742|DRUG|Placebo|Patient given 6 weeks of placebo tablet
40935657|NCT03241069|OTHER|Reference position|patient is put in a 30 degree supine position during 5 minutes
40935658|NCT03241069|OTHER|sitting position|patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured
40935659|NCT03241069|OTHER|Valsalva maneuver|patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.
40935660|NCT03241069|OTHER|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.)
40935661|NCT04008043|DRUG|Vicodin|In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
40935662|NCT04008043|DRUG|Dexamethasone|In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
40935663|NCT05443971|BIOLOGICAL|Durvalumab|Given IV
40935664|NCT05443971|RADIATION|Radiation Therapy|Undergo grid therapy
40935665|NCT05443971|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40935666|NCT04080076|DRUG|Acthar 80 UNT/ML Injectable Solution|ACTHar 80 Units SQ 1042 x Week
41130061|NCT01237067|DRUG|Carboplatin|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
41130062|NCT01237067|DRUG|Olaparib|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
41130063|NCT00678925|DIETARY_SUPPLEMENT|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
41130064|NCT00678925|DIETARY_SUPPLEMENT|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
41130065|NCT01695954|DRUG|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
41130066|NCT01695954|DRUG|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
41130067|NCT01695954|DRUG|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
40935667|NCT04080076|DRUG|Oral Tab Tacrolimus|Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
40935668|NCT04781777|DRUG|insulin|sonar guided insulin combined with dexamethasone and local anesthetics
40935669|NCT02886689|DRUG|TNF-alpha antagonist and other biotherapy|
41279787|NCT01724606|RADIATION|Whole Brain Radiotherapy (WBRT)|WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
41450084|NCT00845637|DRUG|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
41450085|NCT02024048|OTHER|OCT|Optical coherence tomography in enhanced depth imaging mode
41450086|NCT02112123|DRUG|Icariin|
41450087|NCT02112123|DIETARY_SUPPLEMENT|Matching placebo|
40935670|NCT05523440|DRUG|Bevacizumab|Bevacizumab infusion.
40935671|NCT05523440|DRUG|Niraparib|Niraparib oral capsule.
40935672|NCT02157207|DIETARY_SUPPLEMENT|Antioxidant|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
41130068|NCT01695954|DRUG|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
41130069|NCT04737291|DEVICE|drug coated balloon|use of drug coated balloon in treatment of critical limb ischemia
41450088|NCT05347953|DEVICE|Single night downgraded home polygraphy|All patients will be outfitted with the ambulatory downgraded polygraphy device (Nox A1, Nox Medical Global, Reykjavik) for 24 hour monitoring. The data exported by the polygraphy device is in European Data Format and will be filtered and annotated using custom MATLAB-software.
40935673|NCT02157207|OTHER|Placebo|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
40935674|NCT05016284|OTHER|JW-100|Cosmetic CBD cream (JW-100)
40935675|NCT05016284|DRUG|Eucrisa|Topical EUCRISA®, Pfizer
40935676|NCT01315236|DRUG|Liposomal amikacin for inhalation (LAI)|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension."
40935677|NCT01315236|DRUG|placebo|"* Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
40935678|NCT03503851|DEVICE|MitraClip implantation|Device to approximate the mitral valve leaflets
40935679|NCT05445323|GENETIC|Low dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
40935680|NCT05445323|GENETIC|Mid Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
40935681|NCT05445323|GENETIC|High Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
40935682|NCT02744001|OTHER|Low Added Sugar Diet|1-week intake of Low Added Sugar Diet 3 day rotating menu
40935683|NCT04694456|OTHER|cytokines dosage|Mesure of cytokines concentration in serum
40935684|NCT04694456|PROCEDURE|test of walk|patient must walk during 6 minutes on a flat surface
40935685|NCT04694456|PROCEDURE|Manual muscular test|test performed to evaluate the patient muscular weakness
40935686|NCT04694456|PROCEDURE|Motrice fonction mesurement|scale allowing the evaluation of patient posture and upper body movements
40935687|NCT02909179|OTHER|mCARE-II|mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
41450089|NCT02495207|DEVICE|Piezosurgery|This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
40755877|NCT01716195|RADIATION|Induction Chemotherapy followed by Response Adapted Chemoradiation|All patients receive induction chemotherapy with 2 cycles of paclitaxel and carboplatin followed by response adapted, de-escalated chemoradiation. Patients with a complete or partial response will receive 54 Gy with concurrent paclitaxel and patients with stable disease will receive 60 Gy with concurrent paclitaxel.
40935688|NCT03312699|BIOLOGICAL|Fluzone® quadrivalent|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
40935689|NCT03312699|BIOLOGICAL|Fluzone High Dose|High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
40935690|NCT03312699|BIOLOGICAL|Fluad|Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
40935691|NCT03312699|BIOLOGICAL|Vaqta|Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
41450090|NCT06103097|OTHER|No interventions done (obervational)|Observational study
41450091|NCT01945450|DRUG|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams\*4, Gentamycin 240 mg\*1, Clindamycin 600 mg\*3
41450092|NCT01945450|DRUG|Ampicillin|
40755878|NCT00906750|BIOLOGICAL|FluMist|FluMist is a live attenuated intranasal influenza vaccine
40935692|NCT03312699|BIOLOGICAL|Typhim Vi|Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
40755879|NCT00906750|BIOLOGICAL|Inactivated influenza vaccine|Inactivated influenza vaccine
40755880|NCT05527314|DRUG|Remimazolam|Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.
40755881|NCT05527314|DRUG|Sevoflurane|Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.
40755882|NCT05527314|DRUG|Fentanyl|Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
40935693|NCT03312699|BIOLOGICAL|Vivotif|One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm \[temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)\] drink on alternate days, e.g., days 1, 3, 5 and 7.
40755883|NCT05527314|DRUG|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.
40755884|NCT05527314|DRUG|Remifentanil|After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
40755885|NCT04695782|RADIATION|Pencil beam proton radiotherapy|Doseescalated pencil beam proton Therapy
40755886|NCT01431573|BEHAVIORAL|Wake Therapy|Maintaining wakefulness on alternating nights over 7 days, with continued sleep deprivation the next day.
40755887|NCT01431573|DEVICE|light box|use of a lightbox titrated between 15-60 minutes (typically 30 minutes), timed according to chronotype score on the Morningness-Eveningness Questionnaire
40755888|NCT01431573|DRUG|Lithium|For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
40755889|NCT02920554|PROCEDURE|wedge resection|The extent of hepatic resection is wedge resection of liver including gallbladder fossa
40755890|NCT02920554|PROCEDURE|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy of liver
40755891|NCT02829957|DRUG|Apixaban|10mg BID for 7 days, then 5mg BID for three months
40755892|NCT02829957|DRUG|Rivaroxaban|15mg BID for 7 days, then 20mg daily for three months
40755893|NCT06397066|PROCEDURE|White light endoscopy group|White light endoscopy observe the characteristics of mucosa under white light
40755894|NCT06397066|PROCEDURE|Magnifying endoscopy group|NBI+ME to observe the non atrophic area of the gastric fundus gland. The results depend on the ratio of gastric fundus gland.
41450093|NCT01945450|DRUG|Gentamycin|
41450094|NCT01945450|DRUG|Clindamycin|
41130070|NCT00836498|BIOLOGICAL|Comparator: RotaTeq|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
41130071|NCT00836498|BIOLOGICAL|Comparator: Placebo|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
41130072|NCT00836498|BIOLOGICAL|Comparator: RotaTeq + Placebo|One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
41130073|NCT05915715|OTHER|McGill stabilization exercise|"McGill Curl Up Lie down on your back.~The Side Bridge Lie on your side.~The Bird Dog."
41279788|NCT01724606|DRUG|Sorafenib|The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
40935699|NCT04551144|DRUG|testosterone cypionate|intramuscular injection every 2 weeks. Dose will be titrated based on blood levels
40935700|NCT04551144|DRUG|Estradiol Valerate|intramuscular injection every week. Dose will be titrated based on blood levels
40935701|NCT02764125|DRUG|Stalevo|levodopa/carbidopa/entacapone
40935702|NCT02764125|DRUG|levodopa MR|levodopa MR/carbidopa/ODM-104
40935703|NCT03777735|PROCEDURE|human bone graft screw|All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
40935704|NCT05380999|DIAGNOSTIC_TEST|Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)|Up to 15 ml of peripheral blood will be collected from each subject, and the blood specimen will be processed to isolate mature red blood cells and extract the DNA and RNA from RBCs. DNA and RNA methylation will be tested by next-generation sequencing (NGS).
40935705|NCT05041530|DEVICE|REBUILD Bioabsorbable|REBUILD is an investigational medical device designed to be used with third-party suture to distribute suture tension in abdominal wall closures.
40935706|NCT02403388|OTHER|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
40935707|NCT00005665|DRUG|interferon alpha|
40755895|NCT06091605|PROCEDURE|Soft tissue augmentation around dental implants.|Soft tissue augmentation around dental implants using Omega roll envelope flap (OREF) technique.
40755896|NCT02898610|DRUG|Colchicine|
40755897|NCT04007874|DRUG|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
40935708|NCT03574480|BEHAVIORAL|Intervention (training in use of a Smartphone application)|The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.
40935709|NCT03574480|BEHAVIORAL|Control (Advice on healthy diet and physical activity recommendations)|Advice on healthy diet and physical activity recommendations
40935710|NCT05947643|DRUG|theophylline|capsules dissolved in intranasal irrigation
40935711|NCT05947643|DRUG|Placebo|identical-appearing lactose capsules dissolved in intranasal irrigation
40935712|NCT03504579|OTHER|rt-fMRI neurofeedback|use of real time fMRI neurofeedback to achieve targeted brain changes
41279789|NCT01647763|PROCEDURE|Hemorrhoidal artery ligation with rectoanal repair|"Hemorrhoidal arteries will be detected using an ultrasound Doppler probe. The arteries will be sutured with at least 4 Z-sutures.~In the area with the 3 largest knots a purse string suture will be placed."
41279790|NCT01647763|PROCEDURE|Stapled hemorrhoidopexy|A purse string suture will be placed just below the hemorrhoidal cushion. Fixing the suture around the shaft of a circular PPH 03 stapler (Ethicon Endo-Surgery). Hemorrhoids will be removed by firing the stapler. Sufficiency of the stapler line will be examined through a proctoscope. Eventual sources of bleeding will be sutured.
41279791|NCT02624648|BEHAVIORAL|The Female Sexual Function Index (FSFI)|The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function
41279792|NCT02624648|BEHAVIORAL|The Female Intervention Efficacy Index (FIEI)|The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function
41279793|NCT02624648|BEHAVIORAL|The Beck Depression Inventory II|The Beck Depression Inventory II will be used to evaluate or ward off depression
41279794|NCT02624648|DRUG|Lepidium Meyenii Walp|They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
41279795|NCT02624648|DRUG|Placebo|They will receive a capsule of Placebo twice a day for 120 days
41279796|NCT04681326|DEVICE|biological prosthesis|retro-muscular positioning of a swine dermal collagen prosthesis
40755898|NCT04007874|DRUG|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
40755899|NCT01746069|BEHAVIORAL|Quit smoking combined cessation programme|Support sms messages to patient's mobile phone and health advice
40755900|NCT01746069|BEHAVIORAL|health advice|routine clinical practice
40935713|NCT01212133|DRUG|liraglutide|Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
40935714|NCT01455376|DRUG|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
40935715|NCT06004908|DEVICE|MRI|a type of scan that uses strong magnetic field sand radio waves to produce detailed images of the inside of the body
40935716|NCT04075370|OTHER|Neuropsychological Testing|Measure cognition function and cognitive reserve in patients before, during and after radiation therapy using cumulative scores of Hollingshead Index, North American Adult Reading Test, HVLT-R, TMT A\&B and COWA over time.
40935717|NCT06246721|BEHAVIORAL|Self-management of vaginal pessary|Self-management of vaginal pessary
40935718|NCT04707352|DRUG|Dapagliflozin|All eligible subjects will receive Dapagliflozin 10 mg each day. The study treatment will be provided for the duration of the trial from baseline (Day 1) through last visit (Day 180).
40935719|NCT03010761|DRUG|escitalopram|antidepressant use for the betel-quid abstinence
40935720|NCT03010761|DRUG|Moclobemide|antidepressant use for the betel-quid abstinence
40935721|NCT03010761|DRUG|Placebo - Cap|Placebo - Cap
40935722|NCT03969966|OTHER|renal replacement therapy as clinically indicated|Continuous renal replacement therapy
40935723|NCT01915264|DRUG|Acarbose/Metformin (Glucobay M, BAY81-9783)|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
40935724|NCT03568084|OTHER|MEFAP|multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
40935725|NCT03568084|OTHER|control usual practice|Individuals allocated to this arm, will be look after as usual in their health Centers.
40935726|NCT05313100|DRUG|sugammadex|At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
40935727|NCT03583515|BEHAVIORAL|Alcohol-Specific Personalized Normative Feedback|Participants will receive personalized normative feedback about drinking.
41450095|NCT01443195|DRUG|Iron preparation|"Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~1. Before starting iron supplementation (maximum one week before).~2. At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~3. Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation)."
41450096|NCT06139133|DRUG|Placebo supplementation|Placebo
40935728|NCT03583515|BEHAVIORAL|Social Media Personalized Normative Feedback|Participants will receive personalized normative feedback about social media use.
40935729|NCT01255787|DRUG|Vortioxetine|Vortioxetine tablets
40935730|NCT01255787|DRUG|Placebo|Vortioxetine placebo-matching tablets
40935731|NCT04541160|DIAGNOSTIC_TEST|CR|Lung imaging evaluation performed with CR
40935732|NCT04541160|DIAGNOSTIC_TEST|ULDCT|Lung imaging evaluation performed with ULDCT
40935733|NCT05956379|OTHER|exercise|Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, \>=3 cardio workouts per week. The form of aerobic exercise can be carried out in the form of treadmill walking, walking, jogging, cycling, aerobic dance, ball games, swimming, rope skipping, stepping exercises, etc. When the exercise reaches the target intensity, we will adjust the training intensity process according to personal ability. The physical therapist will again adjust the content of the aerobic exercise program at week 12 based on the reassessment of the exercise capacity.
40935734|NCT04041700|DEVICE|Osia 2 system|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound processor.
40935735|NCT01575288|DRUG|Placebo|100g maltose 1/day
40935736|NCT01575288|DRUG|High-dose trehalose|100g 1/day
40935737|NCT01954147|DRUG|GLP-1|GLP-1 therapy
40935738|NCT01954147|BIOLOGICAL|SC|Stem cell infusion
40935739|NCT01954147|OTHER|Standard Medical Treatment|Standard Medical Treatment
40935740|NCT02891005|DEVICE|paclitaxel controlled release balloon catheter (VasoguardTM)|paclitaxel controlled release balloon catheter implantation for small vessel lesion
40935741|NCT02891005|DEVICE|common balloon catheter (Maverick2)|common balloon catheter implantation for small vessel lesion
40935742|NCT02326311|DRUG|imatinib|Tyrosin kinase inhibitor
41450097|NCT06139133|DRUG|Vitamin D supplementation|Vitamin D3 supplementation (2 00,000 IU/Week)
41450098|NCT04919005|OTHER|Virtual Environment|The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.
40935743|NCT02326311|DRUG|nilotinib|Tyrosin kinase inhibitor
40935744|NCT02326311|DRUG|dasatinib|Tyrosin kinase inhibitor
40935745|NCT02734433|DRUG|Pexidartinib|
40935746|NCT01960387|DRUG|Clofarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
40935747|NCT01960387|DRUG|Cytarabine|Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
40935748|NCT00548106|DIETARY_SUPPLEMENT|partially hydrolyzed whey|Total infant feeding by study formula.
40935749|NCT00548106|DIETARY_SUPPLEMENT|Nan HA|Total infant diet by study formula.
40935750|NCT00792831|DRUG|ITF2357|Histone-Deacetylase Inhibitor
40935751|NCT06179433|PROCEDURE|Root canal treatment|Two-visit root canal treatment will be performed.
40935752|NCT06179433|PROCEDURE|Regenerative endodontic procedure|Regenerative endodontic procedure with i-PRF and blood clot induction will be performed.
40935753|NCT01278303|DEVICE|Treatment of Aortic Wall Injury|A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
40935754|NCT01409759|PROCEDURE|Perforator based interposition flap|The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
41279797|NCT03271710|DEVICE|peripheral balloon angioplasty|Percutaneous transluminal angioplasty (PTA) of the lower extremities
41279798|NCT00520026|DRUG|lithium|
41279799|NCT00520026|DRUG|placebo|
41450099|NCT03707587|DRUG|M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
41450100|NCT04598763|OTHER|smell the odors of the olfactory rehabilitation kit according to the classic or intensive method|regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.
41450101|NCT00137735|DRUG|Gabapentin|300mg tds
40935755|NCT05000372|DRUG|68Ga-grazytracer|68Ga-grazytracer PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Biograph mCT Flow 64 scanner or Total-body PET/CT uEXPLORER scanner will be applied, and the scan range will be from the top of the head to 1/3 of the upper thigh.
41279800|NCT00451087|PROCEDURE|leg press training|quadriceps muscle strengthening. 30min/ 3times/ week
41279801|NCT00451087|PROCEDURE|isokinetic training|quadriceps muscle training. 30 min/ 3 times/ week
41279802|NCT06150209|DEVICE|Vendaje|Dehydrated Human Amniotic Membrane
41279803|NCT05034679|BIOLOGICAL|Vcinated|Patients who were vacinated.
41279804|NCT00312013|DRUG|Nadroparin|Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
41279805|NCT02573116|PROCEDURE|scaling and root planing|full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia
41279806|NCT04512261|DRUG|Tucatinib|Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
41279807|NCT04512261|DRUG|Pembrolizumab|Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
41279808|NCT04512261|DRUG|Trastuzumab|Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
41279809|NCT03463317|DEVICE|CE-mark approved LAA closure devices|LAA closure with post procedure treatment
41279810|NCT03463317|DRUG|Acetylsalicylic acid|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
41279811|NCT03463317|DRUG|Clopidogrel|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
41279812|NCT03463317|DRUG|Dabigatran|Patients allocated to the best medical care group receive either NOAC therapy or VKA
41279813|NCT03463317|DRUG|Rivaroxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
41279814|NCT03463317|DRUG|Apixaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
41279815|NCT03463317|DRUG|Edoxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
41279816|NCT03463317|DRUG|Phenprocoumon|Patients allocated to the best medical care group receive either NOAC therapy or VKA
41279817|NCT03463317|DRUG|Warfarin|Patients allocated to the best medical care group receive either NOAC therapy or VKA
41279818|NCT06338787|OTHER|FeSC|Iron/yeast complex
41279819|NCT05952414|BEHAVIORAL|self-efficacy-based interventions|The intervention aims at increasing self-efficacy and consists of Cognitive Behavioural Therapy (CBT)-based exercises related to sources of self-efficacy beliefs: 1) mastery experiences, 2) vicarious experiences, 3) verbal persuasions, and 4) emotional and physiological states.
41279820|NCT04015765|PROCEDURE|Hybrid Argon Plasma Coagulation and EMR procedure|Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications
41279821|NCT02043574|BEHAVIORAL|Treadmill Exercise|Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
41279822|NCT02043574|BEHAVIORAL|Stretching (control)|Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
41279823|NCT06404684|BEHAVIORAL|Cognitive behavioral therapy (CBT)|se above
41279824|NCT05213169|DRUG|Apomorphine Hydrochloride 5mg/ml|Product administered using an external continuous subcutaneous infusion pump.
41279825|NCT05213169|OTHER|Sodium chloride 9mg/ml|Product administered using an external continuous subcutaneous infusion pump.
41279826|NCT01243593|PROCEDURE|Transversus Abdominis Plane Block|A block needle will be advanced in a medial to lateral direction until the tip is visualized in the transversus abdominis plane. After negative aspiration 0.4 ml/kg of bupivacaine 0.25% with 1:200 000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
41279827|NCT01243593|PROCEDURE|Standard Anesthesia|Local field infiltration with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg before skin incision.
41279828|NCT00345111|PROCEDURE|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
41279829|NCT00015548|DRUG|Olanzapine|
41279830|NCT00015548|DRUG|Quetiapine|
41450102|NCT00137735|OTHER|placebo|tds
40935756|NCT04872530|DIETARY_SUPPLEMENT|Pea-protein concentrate|Pea-protein concentrate
41279831|NCT00015548|DRUG|Risperidone|
41279832|NCT00015548|DRUG|Citalopram|
41130074|NCT05915715|OTHER|Proprioceptive neuromuscular facilitation technique|. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively.
40935757|NCT04872530|DIETARY_SUPPLEMENT|Fava-bean protein concentrate|Fava-bean protein concentrate
41279833|NCT02354950|DRUG|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
40935758|NCT04872530|DIETARY_SUPPLEMENT|Chickpea protein concentrate|Chickpea protein concentrate
40935759|NCT04872530|DIETARY_SUPPLEMENT|Red lentil protein concentrate|Red lentil protein concentrate
41279834|NCT05696340|OTHER|semi-structured interview|"Subjects will be recruited in a purposive, non-randomized manner. Data will be collected to obtain a sufficient diversity of perspectives on the topic, while maintaining sufficient homogeneity for analysis.~The number of participants cannot be determined in advance; it will be determined after data saturation."
41279835|NCT06270225|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
41279836|NCT06270225|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
41279837|NCT06270225|DRUG|Colchicine 0.5 mg|Subjects will receive 0.5mg/d Colchicine for 12 weeks.
41279838|NCT03783156|PROCEDURE|hot snare|polypectomy with hot snare
41279839|NCT03783156|PROCEDURE|cold snare|polypectomy with cold snare
41279840|NCT02717507|DRUG|Carvedilol|Given PO
41279841|NCT02717507|OTHER|Laboratory Biomarker Analysis|Correlative studies
40935760|NCT04872530|DIETARY_SUPPLEMENT|Non-essential amino acid blend|Non-essential amino acid blend
40935761|NCT04872530|DIETARY_SUPPLEMENT|Whey protein concentrate|Whey protein concentrate
40935762|NCT04274478|DEVICE|Auditive cueing|Based on gait measurement, auditive cueing is generated automatically to check its impact on patients with Freezing Of Gait.
40935763|NCT05638477|BEHAVIORAL|Free-viewing eye tracking|Participants will watch 20 minutes of video clips while their eye movements, pupil size and blink rate are recorded
40935764|NCT03809923|DRUG|lidocaine and dexmedetomidine infusion|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
41130075|NCT05838469|OTHER|Pediatric Strip Crown and High Viscosity Glass Ionomer Cement|"Following the decision on the appropriate size of celluloid strip crown, the tooth will be isolated using roll cottons and the cavity conditioner (GC, Japan) will be applied to all surfaces for 10 seconds, washed away and dried with cotton pellets. The selected celluloid strip crown will be filled with a fluoride-releasing bulk fill hybrid glass ionomer cement (EQUIA Forte, GC, Japan) prepared by mixing for 10 seconds in an automatic mixer and placed on the tooth with light pressure. The excess material on the crown margins will be removed with a hand instrument, and the celluloid strip crown will be removed from the tooth. If necessary, the restoration will be polished using a polishing discs. After the crown surface is washed and dried, a nano-filled surface sealant (EQUIA Forte Coat, GC, Tokyo, Japan) will be applied for 10 seconds with a micro-tipped applicator and light cured for 20 seconds."
41279842|NCT02717507|OTHER|Pharmacogenomic Study|Correlative studies
41279843|NCT02717507|OTHER|Pharmacological Study|Correlative studies
41279844|NCT02717507|OTHER|Placebo Administration|Given PO
41279845|NCT02717507|OTHER|Quality-of-Life Assessment|Ancillary studies
41279846|NCT02717507|OTHER|Questionnaire Administration|Ancillary studies
41279847|NCT05374941|DEVICE|Injectable and wearable neurostimulator for the hypoglossal nerve|Temporary placement of injectable and wearable neurostimulator for the hypoglossal nerve
41279848|NCT02682810|DEVICE|DNA PCR HIV diagnostic test|standard of care
41279849|NCT02682810|DEVICE|Alere Q|POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
41279850|NCT04920981|OTHER|atezolizumab|observational
41279851|NCT02676258|DEVICE|Si-Hy (olifilcon B)|Wear Si-Hy silicone hydrgel soft contact lens for 3 months
41279852|NCT02676258|DEVICE|Vistakon (narafilcon A)|Wear Vistakon soft contact lens for 3 months
41279853|NCT04017403|DRUG|Bifidobacterium triple live capsule|Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
41279854|NCT04017403|DRUG|Placebos|Placebos were administrated as same as the bifidobacterium live capsule
41279855|NCT05712824|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
40755901|NCT01011231|PROCEDURE|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
40935765|NCT03809923|DRUG|Saline infusion|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
41279856|NCT04242030|OTHER|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
41279857|NCT04242030|DEVICE|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena for the Heart meridian and Lung meridians.
41450103|NCT06560307|DEVICE|Enterra Therapy System|The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
41450104|NCT04411680|DRUG|Sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). Dosage for inhaled sargramostim: 125 mcg twice a day. Dosage for intravenous sargramostim: 125mcg/m2/day given over a 4 hour period.
40755902|NCT02783963|DEVICE|OCT and CMR imaging|"OCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings."
40755903|NCT02813512|DRUG|ADSCs|Autologous ADSCs
41130076|NCT05141136|PROCEDURE|Ultrasound probe sagittal group|Place the ultrasound probe vertically against the patient's spine and insert the needle in-plane. The width of insertion of the needle is usually approximately 5 cm from the midline. After the needle penetrates the superior costovertebral ligament and pops, when it reaches the thoracic paravertebral space, perform aspiration and inject 10 mL of 1% lidocaine. At this time, it can be observed in real time as the infusion fluid pushes the bright pleura away from the needle.
40935766|NCT03809923|DRUG|Lidocaine infusion|patients received an IV bolus infusion of lidocaine (2%) 1.5 mg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg made up to 20ml and 20ml normal saline every hour until 30 min before the end of operation, respectively.
41130077|NCT05141136|PROCEDURE|Ultrasound probe transverse group|Place the ultrasound probe transverse to the spine and insert the needle in-plane. The reflection of a transverse process is a common landmark. The needle goes in from lateral to in plane. The goal is a triangle between the parietal pleura anteriorly and the internal intercostal membrane and intercostal muscle posteriorly. The final point of the needle is the transition zone from the intercostal to the thoracic paraspinal space, just anterior to the transverse process. When it is confirmed that the tip of the needle has reached the paravertebral space, 10 mL of 1% lidocaine is injected after checking the negative pressure, and after confirming the spread of the drug in real time with ultrasound.
41130078|NCT00683800|DRUG|desvenlafaxine succinate (DVS) SR|Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
41130079|NCT00683800|DRUG|Placebo|Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
41130080|NCT02031185|BEHAVIORAL|FitBit only|Participants will use the FitBit device
41130081|NCT02031185|BEHAVIORAL|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
41130082|NCT02138994|DEVICE|Next Science Wound Gel|
41130083|NCT02138994|DRUG|Triple Antibiotic Ointment Neosporin|"Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~* Subject may continue the application of Neosporin until wound closure or~* Subject may cross over to the treatment group for 3 months"
41130084|NCT00900341|GENETIC|DNA analysis|
41130085|NCT00900341|GENETIC|gene expression analysis|
41130086|NCT00900341|GENETIC|protein expression analysis|
41130087|NCT00900341|GENETIC|reverse transcriptase-polymerase chain reaction|
41130088|NCT00900341|GENETIC|western blotting|
41130089|NCT00900341|OTHER|immunohistochemistry staining method|
41130090|NCT00900341|OTHER|laboratory biomarker analysis|
41130091|NCT06408077|OTHER|Water administration|Intravenous administration of water (Aqua ad injectabilia) until a decrease of plasma sodium of 5 to 8 mmol/l has been achieved
41130092|NCT06408077|OTHER|NaCl-Administration|Intravenous administration of NaCl 3% until an increase of plasma sodium of 5 to 8 mmol/l has been achieved
41130093|NCT03960957|BIOLOGICAL|AbobotulinumtoxinA|Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
41450105|NCT04411680|DRUG|Standard of care|Standard of care for COVID-19
41450106|NCT01378962|DRUG|erlotinib|150 mg orally once a day for 12 months
41130094|NCT03960957|OTHER|Placebo|Treatment of glabellar facial lines with placebo
41130095|NCT02789020|DRUG|Rasagiline|Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.
41130096|NCT02789020|OTHER|Placebo|A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.
41130097|NCT02789020|DEVICE|Magnetic Resonance Imaging|This test will be performed at baseline and one year.
41130098|NCT02789020|DEVICE|functional Magnetic Resonance Imaging|This test will be performed at baseline and one year.
41130099|NCT02789020|OTHER|Physical Function Performance Test|This test will be performed at baseline and one year.
41450107|NCT04904094|OTHER|Casting of the lower limb and homebased stretching exercise program.|Lower leg casting in combination with removable upper leg casts for approximately 2 weeks and stretching exercises during casting and 4 weeks after casting.
41279858|NCT01979107|BEHAVIORAL|Proactive action by the general practitioner|"Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.~At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results."
41279859|NCT02351115|DRUG|A=Placebo|
41279860|NCT02351115|DRUG|B=Inhaled Alprazolam 0.5 mg|
41279861|NCT02351115|DRUG|C=Inhaled Alprazolam 1 m|
41279862|NCT02351115|DRUG|D= Inhaled Alprazolam 2 mg|
41279863|NCT02351115|DRUG|E=Placebo|
41450108|NCT06193213|PROCEDURE|measurement of train of four ratio (TOFR) to assess residual neuromuscolar block|Upon arrival of the spontaneously breathing patient in the Post-Anesthesia Care Unit, a researcher will evaluate the TOFR to detect any residual neuromuscular block using the acceleromyographic method at the level of thumb adductor.2 TOFR measurements will be performed 30 seconds apart. If the difference between the two measurements will be ≤ 0.1, the average value will be considered for the purposes of the analysis. In case of a difference \> 0.1, a third measurement will be taken and the average of the two closest results will be considered. If a residual block is detected sugammadex will be administered (2 mg/kg in the case of at least 2 contraction responses to TOF stimulation or 4 mg/kg in the case of no contraction response) to restore normal neuromuscular function , assessed by subsequent TOFR measurement.
41450109|NCT03332082|PROCEDURE|Tooth positioner|Orthodontic Tooth positioners treatment have been used in the Orthodontic Industry for many years. These positioners are used for small minor movements to complete the final smile. These positioners are made from a biocompatible and FDA approved clear silicone material after the teeth have been set to the final position.
41450110|NCT03415308|OTHER|Focus Groups|Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.
40755904|NCT00262613|DRUG|sodium pyruvate in 0.9% sodium chloride solution|
40935767|NCT03809923|DRUG|Dexmedetomidine infusion|Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.
40935768|NCT03977428|OTHER|standard of care|No intervention, this a patient registry and is purely an observational study
40935769|NCT04835467|DEVICE|Dual-modal OCT-FLIm|Intracoronary imaging using dual-modal OCT-FLIm catheter
40935770|NCT01364675|DRUG|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
40935771|NCT01364675|DRUG|Placebo tablet|Identical Placebo Tablet
41130100|NCT00570388|DRUG|Prometa Treatment Program|"Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol."
41130101|NCT00093353|DRUG|cefixime|
41130102|NCT00093353|DRUG|irinotecan hydrochloride|
40755905|NCT06428474|OTHER|Health education|Oral health education program designed for orphans children
40755906|NCT01694186|DRUG|FAI insert|
40755907|NCT01694186|DRUG|Sham injection|
40755908|NCT00108563|DRUG|Citalopram or Placebo|
40755909|NCT02539407|OTHER|Pharmacokinetics|
41279864|NCT02859038|PROCEDURE|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5
41279865|NCT02859038|PROCEDURE|Interval debulking surgery|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy
41279866|NCT06389695|DRUG|68Ga-NYM032 injection|The radiation dose is about 3-6 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM032 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
40935772|NCT03839927|OTHER|Validity and reliability of Life-Space Assesment|Life-Space Assesment and SF-36 surveys will be applied. The reliability and validity of the results will be analyzed.
40935773|NCT02929784|DEVICE|Intervention|Device: neuroConn_CE_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
40935774|NCT02929784|DEVICE|Sham|no meaningful stimulation will be given.
40935775|NCT06347679|OTHER|Aroma diffuser with single-note sweet orange essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note sweet orange essential oil into the aroma diffuser reservoir containing 120 ml of water.
41130103|NCT00093353|DRUG|temozolomide|
41130104|NCT04043169|DIAGNOSTIC_TEST|Clearblue pregnancy test|Urine pregnancy test
41130105|NCT02426996|PROCEDURE|Scan of shoulder|A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
40935776|NCT06347679|OTHER|Aroma diffuser with single-note tea tree essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note tea tree essential oil into the aroma diffuser reservoir containing 120 ml of water.
40935777|NCT06347679|OTHER|Aroma diffuser with water|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of water.
41279867|NCT04937023|DRUG|Ursodeoxycholic acid gel|Following scaling and root planing in intrabony defects UDCA gel will be injected
41279868|NCT02369783|OTHER|Questionnaire and interview|The aim is to detect social fragility.
41279869|NCT03233399|DEVICE|Sham TMS3 stimulation|half of the subjects will receive sham stimulation first
40935778|NCT04048811|DRUG|HSK3486|The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
40935779|NCT04048811|DRUG|Propofol|The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
40935780|NCT04048811|DRUG|Propofol HSK3486|The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
40935781|NCT03960021|RADIATION|RFA interventions|Each patient is treated with 2 RFA interventions. Abiopsy of one metastasis is done at each RF session. Histological samples are sent to the Bio-pathology department of Institut Bergonié for tumor infiltrating lymphocytes counting. Primary outcome results from this counting (stromal TILs ≥ 20% is considered as a significant level, a comparative measurement before and after RF will be performed). In parallel blood samples are performed before and after RFA to analyze the kinetics of peripheral blood T lymphocytes subsets, tumoral circulating cells and tumoral DNA.
40935782|NCT01859585|DRUG|Parecoxib|Parecoxib 40 mg intravenous
40935783|NCT01859585|DRUG|Ketorolac|Ketorolac 30 mg intravenous
40935784|NCT03858439|OTHER|Dietary|Low sodium, low protein dietary recommendation
41130106|NCT05181475|DRUG|Sodium Oligomannate Capsules (GV-971)|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
41130107|NCT00644566|OTHER|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
41130108|NCT04061759|OTHER|Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.|Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
41130109|NCT00068458|DIETARY_SUPPLEMENT|Calcium-Rich Diet|1,200 - 2,500 mg/day. 6 month intervention
41130110|NCT00068458|OTHER|Arm 2: Exercise + Calcium-Rich Diet|Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
41130111|NCT00068458|OTHER|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|1,200 - 2,500 Calcium intake per day. 6 month intervention period.
41130112|NCT03155100|DRUG|Carfilzomib for Inj 60 milligram (MG)|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
41130113|NCT03155100|DRUG|Elotuzumab 400 MG|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
41130114|NCT03155100|DRUG|Dexamethasone|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
41130115|NCT06510790|DEVICE|Double J stent|Double J ureteral catheter has been used to prevent upper urinary tract obstructions or strictures and to facilitate stone clearance after procedures such as percutaneous nephrolithotomy (PCNL), retrograde intrarenal surgery (RIRS), and ureteroscopic lithotripsy (URSL).
41279870|NCT03233399|DEVICE|rTMS of left or right angular gyrus (AG) or frontal cortex (FC)|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
41279871|NCT03233399|DEVICE|Anodal tDCS of left or right AG or FC|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
41279872|NCT01123889|BIOLOGICAL|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
41279873|NCT01123889|DRUG|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
40935785|NCT04014673|BEHAVIORAL|Behavioral : Characterization|Behavioral scales and neuropsychological tests; MRI, SPECT/PET
40935786|NCT03750422|DEVICE|Picoway|1064/532nm picosecond laser
40935787|NCT03750422|OTHER|Stratacel|a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties
40935788|NCT03750422|OTHER|Aquasonic|clear ultrasound gel
40935789|NCT03704701|DIAGNOSTIC_TEST|Cardiac MRI and contrast-enhanced cardiac CT|Cardiac MRI Contrast-enhanced cardiac CT
40935790|NCT03650296|DEVICE|ePER vs PS vs PaedER|see detailed description of methods
40935791|NCT01410552|DEVICE|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
40935792|NCT03055858|DEVICE|ADO II AS (PDA closure)|Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).
40935793|NCT05817279|DIAGNOSTIC_TEST|Optical coherence tomography|"Optical coherence tomography: OCT is a non-invasive CE-certified diagnostic modality based on light interferometry. An OCT scan visualizes an area with a diameter of 6mm thereby revealing the skin and adnexal structures with a depth of approximately 1.5mm.~3mm punch biopsy: the patients included in this study underwent a 3mm punch biopsy conform regular care. The subsequent histopathological examination of the biopsy specimen serves as ground truth diagnosis of the lesions (gold standard)"
40935794|NCT01525121|OTHER|Expiratory Rib Cage Compression|The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
41130116|NCT02310152|BEHAVIORAL|Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Supportive Parenting for Anxious Childhood Emotions
41130117|NCT02310152|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
41279874|NCT05975229|OTHER|Knitting and education (pamphlet)|Pamphlet and knitting program (-8-week duration). The knitting program has two components: bi-weekly 20-minute group knitting sessions and 20-minute home daily knitting on the 5 remaining weekdays.
41279875|NCT05975229|OTHER|Education (pamphlet)|Receive only the pamphlet, not the knitting program.
41279876|NCT04143022|DEVICE|acupuncture press needle|Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
41279877|NCT04884087|BEHAVIORAL|Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day|Participants receive 3 EMA survey prompts daily for the duration of the study.
41279878|NCT04884087|BEHAVIORAL|Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day|Participants receive 6 EMA survey prompts daily for the duration of the study.
41279879|NCT04884087|BEHAVIORAL|Incentive Structure - fixed|"Those assigned to the fixed incentive condition will earn a fixed bonus based on EMA completion (50-74%=$3; 75-89%=$5; ≥90%=$10) each week."
41279880|NCT04884087|BEHAVIORAL|Incentive Structure - prize based|"Those assigned to the prize-based incentive will be rewarded for high survey completion with increasing numbers of draws depending on their level of response to EMA prompts each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws). For each draw, individuals will use the EMA app to spin the wheel to see which prize amount they earn. Out of a total of 500 total draws, 50% will be $1, 43.6% will be $3, 6% will be medium prizes ($5), and 0.4% will be a jumbo prize ($90)."
41130118|NCT04402112|DRUG|Pitavastatin|1mg, 2mg, or 4mg, Once a day, at least 8 weeks
41130119|NCT04694014|BEHAVIORAL|EI Open ended Pre-Survey and Semi Structured Interview|Provide Interview questions via online survey with informed consent to the participants then contact a 60 minute member checking interview in person or virtually via recorded Zoom sessions for each participant
41130120|NCT04694014|BEHAVIORAL|Behavioral and Cognitive Assessment|Use Predictive index for both cognitive and behavioral assessment of the paticipants
41130121|NCT04694014|BEHAVIORAL|Geneva Emotional Competence Test (GECO)|Administer the Geneva Emotional Competence Test to each participant
41130122|NCT00756405|BEHAVIORAL|Antioxidant diet|Participants were asked to increase antioxidant-rich food intake to approximately double their daily habitual intake and take a placebo pill.
41130123|NCT00756405|DIETARY_SUPPLEMENT|Antioxidant supplement|Participants were asked to consume their usual diet and take a supplement containing carotenoids, mixed tocopherols, vitamin C and selenium, designed to approximately double their daily habitual intake.
41130124|NCT00756405|DIETARY_SUPPLEMENT|Placebo|Participants were asked to consume their usual diet and take a placebo pill.
40935795|NCT06489379|DEVICE|high flow nasal cannula|humidified and heated oxygen
40935796|NCT06489379|OTHER|standard oxygen|oxygen delivery through Venturi mask
40935797|NCT02195284|DEVICE|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate
40935798|NCT02195284|DEVICE|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
41130125|NCT06229730|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
41130126|NCT06229730|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
41279881|NCT05931770|PROCEDURE|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by the child. will be determined by children preference
40935799|NCT02195284|DEVICE|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)
40935800|NCT02195284|DEVICE|TURBUHALER|Placebo inhaler containing lactose monohydrate.
40935801|NCT00589784|DRUG|Sunitinib|The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
40935802|NCT03488823|DIETARY_SUPPLEMENT|with Flavanol|Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
40935803|NCT03488823|DIETARY_SUPPLEMENT|without Flavanol|Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
40935804|NCT06045169|PROCEDURE|Post Isometric Relaxation|Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
40935805|NCT02615925|OTHER|Psychiatry Consultation|Psychiatry Consultation
40935806|NCT06287567|DRUG|Lusutrombopag Oral Tablet|Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and doses are adjusted based on platelet counts during week 5-12. If a subject's platelet count remains \< 50x10\^9 /L, the dose could have been increased up to a maximum dose of 6 mg（2 tablets).If a subject's platelet count reaches ≥ 250x10\^9 /L during the first 4 weeks, treatment is stopped and participants are allowed to enter into Titration Study in advance when platelet count drops to ≥100x10\^9 /L.
40935807|NCT03401853|OTHER|Laboratory Biomarker Analysis|Correlative studies
40935808|NCT03401853|BIOLOGICAL|Pembrolizumab|Given IV
40935809|NCT03401853|BIOLOGICAL|Rituximab|Given IV
40935810|NCT03401853|BIOLOGICAL|Obinutuzumab|Given IV
40935811|NCT05599919|DRUG|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
40935812|NCT03462069|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
40935813|NCT03462069|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
40935814|NCT03462069|DRUG|Empagliflozin|"Pharmaceutical form: capsule~Route of administration: oral"
40935815|NCT03462069|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
40935816|NCT01627171|DRUG|Bisacodyl 10mg|Given at the start of the bowel preparation the day before colonoscopy
40935817|NCT01627171|DRUG|Polyethelene Glycol|280g reconstituted in 4 liters of water
40935818|NCT01627171|DRUG|Picosulfate sodium|Two sachets, Each sachet has 10mg dose
40935819|NCT03797001|DRUG|Anakinra|100 mg subcutaneous injection, daily for 24 weeks
40935820|NCT03797001|DRUG|Placebo|subcutaneous injection, daily for 24 weeks
40935821|NCT06060821|OTHER|No intervention|No intervention
41279882|NCT05931770|PROCEDURE|Parent (mother or father) selection according to parents' preference|Accompanying parentwho will accompany during the perioperative period will be determined by the parents. to be determined by
40935822|NCT04626466|OTHER|Biological investigations|(complete blood count, platelet count, renal function evaluation)
40935823|NCT05249777|DRUG|TD0069 hard capsule|TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.
40935824|NCT05249777|DRUG|TD0069 Placebo|TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
40935825|NCT00235001|DRUG|trandolapril/verapamil|180/2 mg QD
40935826|NCT02931266|DEVICE|PASS MIS®|Posterior mini-invasive osteosynthesis
40935827|NCT01459848|BEHAVIORAL|block play|30 minutes of block play
40935828|NCT01459848|BEHAVIORAL|baby dvd|30 minutes of dvd viewing
40935829|NCT01277081|DRUG|Paracetamol hot drink|Hot drink containing paracetamol
40935830|NCT01277081|DRUG|Paracetamol tablets|Paracetamol tablets
40935831|NCT06517680|OTHER|tight control management|Patients will be seen every month for the first 3 months of follow-up During these consultations, shoulder pain and function will be assessed. Treatment adjustments (steroid injections, drugs and physiotherapy) will be proposed in line with predefined objectives.
40935832|NCT06517680|OTHER|standard follow-up|Patients are monitored according to standard practice
40935833|NCT03203525|BIOLOGICAL|Bevacizumab|Given IV
40935834|NCT03203525|DRUG|Fluorouracil|Given via pump
40935835|NCT03203525|DRUG|Leucovorin|Given via pump
40935836|NCT03203525|DRUG|Oxaliplatin|Given via pump
40935837|NCT03203525|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
40935838|NCT03203525|DRUG|Temsirolimus|Given IV
40935839|NCT03203525|PROCEDURE|Tumor Treating Fields Therapy|Use NovoTTF-100L(P) system
40935840|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
40935841|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
40935842|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
40935843|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
41279883|NCT04439578|DRUG|SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin|600 mg rifampicin was administered in the morning.
40935844|NCT01920555|DRUG|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
40935845|NCT02895633|OTHER|Ecography|Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
40935846|NCT02895633|OTHER|CT scan|With injection of Iomeron 400
40935847|NCT02895633|OTHER|MRI|With injection of gadolinium (Multihance)
40935848|NCT01795378|BIOLOGICAL|donor natural killer cell infusion|"* Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.~* The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).~* For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.~* The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg."
40935849|NCT01858584|DRUG|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~* Infants weighing \<5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~* Infants weighing\> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
40935850|NCT01858584|DIETARY_SUPPLEMENT|thickened milk|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
41130127|NCT06229730|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
41130128|NCT06229730|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
41279884|NCT05591833|PROCEDURE|SASI|Single-Anastomosis Sleeve ileal (SASI) Bypass
41279885|NCT05591833|PROCEDURE|SAS-J|Single-Anastomosis Sleeve Jejunal (SAS-J) Bypass
40935851|NCT03007901|BEHAVIORAL|Mindful Climate Action|Educational and Behavioral Training Curriculum: An article describing our proposed program was recently published in Sustainability (1) and is summarized here. Experienced instructors from the UW Integrative Medicine Mindfulness Program will teach the 8-week program. Classes will meet weekly for 2½ hours, with a 6 hour weekend retreat. Twenty to 45 minutes of daily home practice will be guided by audio recordings leading participants through body scan, sitting meditations, breath awareness, and mindful movement. Each of the 2½ hour weekly classes includes topics (\~30 min) relating to climate change, energy use, and carbon footprint.
40935852|NCT05324176|RADIATION|diaphragmatic ultrasound|diaphragmatic thickness will be measured on both sides during a deep breath in inspiration and during expiration.
40935853|NCT05536505|GENETIC|Adjuvant treatment for MRD positivity|The MRD positive group would receive icotinib as adjuvant treatment. When the peripheral blood MRD turned negative, the subjects entered the drug withdrawal observation period. When the MRD turned positive again, the subjects resumed icotinib treatment. If EGFR T790M mutation was found, researchers would resume medication and choose osimertinib therapy.
40935854|NCT00689091|DEVICE|Bispectral Index Monitor|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
40935855|NCT00689091|DEVICE|Electronic MAC alert|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
40935856|NCT02231047|DIETARY_SUPPLEMENT|64N Nutraceutical|40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)
40935857|NCT02231047|OTHER|No 64N Nutraceutical|12 ounce warm drink daily for 1 week (7 days)
40935858|NCT04459767|DRUG|Vupanorsen|80 mg subcutaneous injection
40935859|NCT04459767|DRUG|Placebo|Subcutaneous injection
40935860|NCT01616134|OTHER|Korea red ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
40935861|NCT01616134|OTHER|Placebo|The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
40935862|NCT00890188|DRUG|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
40935863|NCT00095927|DRUG|Amifostine|Given subcutaneously
40935864|NCT00095927|DRUG|Carboplatin|Given IV
40935865|NCT00095927|DRUG|Paclitaxel|Given IV
40935866|NCT00095927|RADIATION|radiation|Given once daily for 4 weeks and then twice daily for 2 weeks.
41279886|NCT02372617|PROCEDURE|periacetabular osteotomy|
41279887|NCT03746730|DEVICE|ultrasound|gray scale and doppler ultrasound
40935867|NCT04737057|PROCEDURE|SDF|Apply this topical medication through : 1)Dry with a gentle flow of compressed air to decayed tooth surfaces. 2) Bend micro sponge brush to remove excess liquid before application apply SDF directly to only the affected tooth surface. 3) Apply the SDF material 4)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
40935868|NCT04737057|PROCEDURE|Hall technique|this technique is performed through :1) Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up to (but not through) the contact points and the PMC has been filled with a Riva self-cure capsule cement, extruded cement is quickly wiped away and the child is asked to keep biting on the crown for two minutes, until the cement is set, to prevent 'spring back' of the PMC from the fully seated position
40935869|NCT04914416|DIETARY_SUPPLEMENT|Verum T1|Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
40935870|NCT04914416|DIETARY_SUPPLEMENT|Verum T2|Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
40935871|NCT04914416|DIETARY_SUPPLEMENT|Verum T3|Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
40935872|NCT04914416|DIETARY_SUPPLEMENT|Verum T4|Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
40935873|NCT04914416|DIETARY_SUPPLEMENT|Verum T5|Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
40935874|NCT04914416|DIETARY_SUPPLEMENT|Verum T6|Verum T6 is a 34200AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
40935875|NCT04914416|DIETARY_SUPPLEMENT|Verum T7|Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
40935876|NCT04914416|DIETARY_SUPPLEMENT|Verum T8|Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
40935877|NCT04914416|DIETARY_SUPPLEMENT|Verum T9|Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
40935878|NCT04914416|DIETARY_SUPPLEMENT|Verum T10|Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
40935879|NCT04914416|DIETARY_SUPPLEMENT|Verum T11|Verum T11 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 900 mg in 3 capsules
40935880|NCT04914416|DIETARY_SUPPLEMENT|Verum T12|Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
40935881|NCT04914416|DIETARY_SUPPLEMENT|Verum T13|Verum T13 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
40935882|NCT04914416|DIETARY_SUPPLEMENT|Verum T14|Verum T14 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 900 mg in 3 capsules.
40935883|NCT04914416|DIETARY_SUPPLEMENT|Verum T15|Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.
40935884|NCT04914416|DIETARY_SUPPLEMENT|Verum T16|Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.
40935885|NCT04914416|DIETARY_SUPPLEMENT|Verum T17|Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
41279888|NCT05307744|DIETARY_SUPPLEMENT|PS128|Each PS128 capsule contained \>3 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.
40935886|NCT04746716|OTHER|Phone call|Phone call to the patient to complete quality of life scales
40935887|NCT01742247|OTHER|Physiogel|Application of moisturizer on laser-treated area
40935888|NCT01742247|OTHER|Moisturizer|Application of moisturizer on laser-treated area
40935889|NCT00082927|DRUG|ibandronate sodium|
40935890|NCT03254368|DRUG|ZGN-1061|ZGN-1061 is a methionine aminopeptidase 2 inhibitor
40935891|NCT03254368|DRUG|Placebo|Placebo has the same excipients and appearance as ZGN-1061
40935892|NCT04812678|PROCEDURE|Fasciatherapy|Fasciatherapy, with manual therapy and/or gestual therapy.
40935893|NCT04812678|PROCEDURE|Physiotherapy|Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.
40935894|NCT04908020|OTHER|Follow-up patients|The intervention consists in the assessment of some psychological aspects (post traumatic stress symptoms and coping) of cancer patients in follow-up care, through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
40935895|NCT03159702|DRUG|Evomela|140 mg/m\^2/day IV on Day -6 for patients who are \< 60 years of age. 70 mg/m\^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of \>3
41279889|NCT05307744|OTHER|Placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
41279890|NCT01665638|DRUG|Canagliflozin 300 mg|Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
41279891|NCT01665638|DRUG|Placebo|Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
41279892|NCT01665638|DRUG|Somatostatin|A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
40935896|NCT03159702|DRUG|Fludarabine|40 mg/ m\^2/day intravenous on Days: -5 -4, -3, -2
40935897|NCT03159702|RADIATION|Total Body Irradiation|200 cGy on Day: -1
40935898|NCT02741388|DRUG|selinexor|
40935899|NCT02741388|DRUG|Rituximab|
40935900|NCT02741388|DRUG|Dexamethasone|
40935901|NCT02741388|DRUG|Oxaliplatin|
40935902|NCT02741388|DRUG|Cisplatin|
40935903|NCT02741388|DRUG|Cytarabine|
40935904|NCT02741388|DRUG|Gemcitabine|
40935905|NCT05424237|BEHAVIORAL|App intervention|usual care plus app ussage with the aim of promote healthy behaviors (diet, physical activity and weight)
40935906|NCT00929812|DRUG|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
40935907|NCT00929812|DRUG|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
40935908|NCT05072886|DRUG|AT193|Topical applied to affected areas daily
40935909|NCT00415571|DRUG|Fispemifene (once daily for 8 weeks)|
40935910|NCT01016561|RADIATION|intracavitary balloon brachytherapy|
40935911|NCT01016561|RADIATION|external beam radiation therapy|
40935912|NCT01016561|RADIATION|intensity-modulated radiation therapy|
40935913|NCT01016561|RADIATION|radiation therapy treatment planning/simulation|
40935914|NCT01016561|RADIATION|3-dimensional conformal radiation therapy|
40935915|NCT01016561|DRUG|Cisplatin|
40935916|NCT00939757|DRUG|mirabegron|oral tablet
40935917|NCT02039440|OTHER|Blood draw|One-time blood draw
40935918|NCT02284672|DRUG|Dexmedetomidine|
40935919|NCT02284672|DRUG|Normal saline|
40935920|NCT05598827|OTHER|Tik Tok|The enrolled patients were encouraged to watch Tik Tok without limit starting 24 days before chemotherapy and continuing until the seventh day after chemotherapy.
41450111|NCT03415308|OTHER|Cognitive Interviews|To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability
41130129|NCT06229730|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21-item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
41450112|NCT03415308|OTHER|Pilot Testing of Implicit Bias Training|Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
41450113|NCT01783535|DRUG|vincristine|Given via minibag/gravity flow.
41450114|NCT01783535|DRUG|topotecan|Given IV over 30 minutes.
40935921|NCT05644782|OTHER|Open wheat challenge|Patients randomized to intervention diet group will have to follow a diet with elimination of wheat and cow's milk products for 2 months; after that they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
40935922|NCT05644782|OTHER|Placebo challenge|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
40935923|NCT05162040|DEVICE|Use of PedaleoVR|"All participants must undergo an evaluation of their motor skills through the application of physical assessment metrics performed by the physician. The metrics are the Timed Up-and-Go Test (TUG) and the 6-minute walk test.~Next, they must perform a pedaling exercise on a bicycle or stationary pedaling station synchronizing the physical activity with the visual feedback from the virtual reality application. Two pedalling sets of 10 minutes each are performed, with 5 minutes of rest between sets. Finally, the participant is asked to rate the usability: System Usability Rating Scale (SUS), activity credibility (Credibility and Expectancy Questionnaire, CEQ) and intrinsic motivation (Intrinsic Motivation Inventory, IMI) of the virtual reality application."
41130130|NCT04820049|DRUG|F573|F573 for injection
41130131|NCT04820049|OTHER|Placebo|Water for injection
41130132|NCT01600482|DEVICE|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
41130133|NCT05370287|OTHER|oxygen inhalation|Subjects will breath 100% oxygen through a mask.
40935924|NCT03949491|PROCEDURE|3D medical models|Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease both operative time and dissection time. This will also allow for the proposal of incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes, decrease donor site complications and improve patient satisfaction
40935925|NCT00900601|PROCEDURE|Arthrodesis to the sacroiliac joint and symphysis|"Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery."
40935926|NCT02577432|DRUG|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
40935927|NCT02577432|DRUG|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
40935928|NCT02577432|DRUG|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
40935929|NCT02577432|DRUG|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
40935930|NCT03350984|DRUG|NPH insulin|NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL.
40935931|NCT03350984|DRUG|Glargine and Lispro insulin|Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
40935932|NCT01590992|BEHAVIORAL|Exposure-based psychotherapy for somatic symptoms|Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
40935933|NCT01590992|BEHAVIORAL|Relaxation therapy|Progressive muscle relaxation (Jacobson)
41279893|NCT01665638|DRUG|C-peptide|Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
40935934|NCT03360786|OTHER|Specific intervention|Series of progressive exercises targeted at balance, adaptation, dividing attention, head on neck control, visual + education on concussion identification and concussion education
40935935|NCT03360786|OTHER|Control intervention|Education on concussion and concussion identification in addition to typical cardiovascular warmups
40935936|NCT04968054|DRUG|Arm I (Propofol)|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
40935937|NCT04968054|DRUG|Arm II (Remimazolam)|Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
41450115|NCT01783535|DRUG|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is \>2,000/µL on one occasion after the expected nadir.
40935938|NCT03895242|BEHAVIORAL|Group 1:Supine-Prone|After the infants were treated and fed, supine position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in supine position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the supine positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the prone position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the prone position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
41130134|NCT05370287|DEVICE|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
41130135|NCT05254392|DEVICE|Digital BP monitor (Chidalex®)|Interventions were provided in groups of 4 - 10 participants after data collection at baseline while reinforcing individualized interventions were provided during subsequent visits to the research clinic for follow-up at 6 months and 12 months. Medication reminder text messages were delivered to each participant biweekly.
41130136|NCT05701059|PROCEDURE|Cervical arthroplasty|A joint replacement procedure administered by inserting an artificial disc between the vertebrae to replace a natural spinal disc after it has been removed.
41130137|NCT05701059|DEVICE|Semi-Constrained Nuvasive Simplify|This weight-bearing implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile zirconia toughened alumina (ZTA) ceramic core will be administered by cervical arthroplasty into the specified single-level cervical region.
41450116|NCT01783535|DRUG|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is \>2,000/µL on one occasion after the expected nadir.
40935939|NCT03895242|BEHAVIORAL|Group 2:Prone-Supine|After the infants were treated and fed, prone position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in prone position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the supine position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the supine position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
40935940|NCT02309866|GENETIC|Genetic testing|Genetic testing for mutations in known and novel genes underlying RP and allied diseases
40935941|NCT05561179|PROCEDURE|Hyaluronic acid injection|"Patients with confirmed diagnosis of GERD will be treated with HA injections in the lower esophageal portion. HA + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
40935942|NCT05561179|PROCEDURE|Sodium chloride injection (control group)|"Patients with a confirmed diagnosis of GERD will be treated with sodium chloride injection in the lower esophageal portion. Sodium chloride + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
40935943|NCT02651714|DRUG|Tradipitant|
40935944|NCT02651714|DRUG|Placebo|
40935945|NCT00983788|DRUG|Bezafibrate|3 x 200 mg/ day
40935946|NCT00983788|OTHER|Placebo|Placebo
40935947|NCT05740995|DRUG|neoadjuvant anti-PD-1 plus chemotherapy|"Patients will be given preoperative treatment as below once recruited:~1. Chemotherapy is delivered and composed of two cycles of Nab-paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 3 weeks;~2. PD-1 antibody is delivered 200 mg (iv, in 30 minutes) every 3 weeks;~3. After neoadjuvant therapy of 3-4 cycles, esophagectomy is performed. We advise starting 4 cycles of identical chemoimmunotherapy in 6w after surgery."
40935948|NCT05437835|DRUG|Ropivacaine|Ropivacaine 20 ml injection into the subparaneural space of sciatic nerve
40935949|NCT03557827|DRUG|Photodynamic Therapy with indocyanine green and diode laser|mechanical debridement by periodontal curets plus Indocyanine green solution activated by diode laser. The diode laser is classified as a Class I medical device according to the Directive 93/42/EEC
40935950|NCT03557827|PROCEDURE|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
40935951|NCT00381381|DRUG|Donepezil|2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
40935952|NCT01375426|DRUG|Oral amoxicillin|
40935953|NCT00423696|BIOLOGICAL|bevacizumab|
40935954|NCT00423696|DRUG|capecitabine|
40935955|NCT00423696|DRUG|fluorouracil|
40935956|NCT00423696|DRUG|irinotecan hydrochloride|
41130138|NCT05701059|DEVICE|Unconstrained Biomet Zimmer Mobi-C|This unconstrained, three-piece implant will be administered by cervical arthroplasty into the specified single-level cervical region.
41130139|NCT00539812|BEHAVIORAL|Standard Care|Standard 40 hour state mandated batterer intervention program
41450117|NCT01783535|DRUG|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
41450118|NCT01783535|OTHER|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
41450119|NCT01783535|DRUG|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
40755910|NCT03087123|BEHAVIORAL|P-Mobile App|The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
40755911|NCT03574779|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
40755912|NCT03574779|BIOLOGICAL|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to Programmed cell death protein 1 (PD-1) resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
40935957|NCT00423696|DRUG|leucovorin calcium|
40935958|NCT05501262|DEVICE|Cryoablation|Image (ultrasound and fluoroscopic guided) cryoablation will be performed of the Morton's neuroma after nerve block.
40935959|NCT05501262|PROCEDURE|Nerve block|Ultrasound and fluoroscopic guided nerve block.
40935960|NCT05562271|RADIATION|low-dose radiation therapy|low-dose radiation therapy to involved knee joint
40935961|NCT05562271|RADIATION|sham radiation therapy|sham radiation therapy to involved knee joint
40935962|NCT00568490|PROCEDURE|Tumor biopsy|For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
40935963|NCT00568490|PROCEDURE|Phlebotomy|Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
41130140|NCT00539812|BEHAVIORAL|Brief Alcohol Intervention combined with standard care|Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
40935964|NCT04586361|COMBINATION_PRODUCT|RegenLab PRP|PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit.
40935965|NCT04586361|COMBINATION_PRODUCT|hyaluronic acid|Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life.
41450120|NCT01783535|DRUG|cyclophosphamide|Given IV.
41130141|NCT05499663|BEHAVIORAL|POSTHOC app|The POSTHOC app is a smartphone application that will deliver the Survivorship Care Plan and promote healthy lifestyle behaviors consistent with the individual's Care Plan
41130142|NCT01971112|DIETARY_SUPPLEMENT|Multivitamins and minerals|Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
41130143|NCT03347396|DRUG|BIVV009|Sutimlimab was administered as intravenous (IV) infusion.
41130144|NCT01759862|DRUG|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
41130145|NCT01759862|OTHER|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
41130146|NCT01759862|DRUG|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
41279894|NCT06503198|BEHAVIORAL|Virtual care|"Through Cloud DX, intervention group participants will receive:~Remote Automated Monitoring: measurement of: blood pressure, heart rate, respiratory rate, oxygen saturation, temperature and weight.~Frailty-tailored daily symptom survey: The recovery survey consists of questions related to infection, bleeding, pain, appetite, dehydration, appetite, syncope and falls.~The tablet will prompt the participant to complete a Katz Index of Independence in Activities of Daily Living (IADL) survey. The FAM-CAM survey will also be pushed by Cloud DX to be completed.~Virtual RN assessment: a virtual RN assessment will be scheduled at a minimum of every 2 days for the first 7 days. The virtual RN will also perform the 4AT Delirium Assessment.~Medications: the virtual RN will undertake medication review and reconciliation. In addition, they will provide counselling regarding analgesic support and monitor for drug interactions."
41279895|NCT00195351|DRUG|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
41450121|NCT01783535|DRUG|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
40755913|NCT03574779|BIOLOGICAL|Bevacizumab|Bevacizumab is an Food Drug and Administration (FDA) approved antiangiogenic recombinant humanized monoclonal Immunoglobulin (Ig) G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.
40755914|NCT03574779|DRUG|Carboplatin|Carboplatin will be infused intravenously over 60 minutes at the prescribed dose of area under the concentration versus time curve of 5 to 6 mg/milliliters (mL) per minute on Day 1 of every 21-day cycle
40755915|NCT03574779|DRUG|Paclitaxel|Paclitaxel will be administered intravenously over 180 minutes at the prescribed dose of 175 mg/meter square (m\^2) on Day 1 of every 21-day cycle
40755916|NCT00141193|DRUG|Celecoxib|
40935966|NCT04586361|OTHER|normal saline|In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient.
40935967|NCT04847089|DEVICE|Motor imagery BCI training|Motor Imagery (MI)-BCI training, 2-3 hours, 3 times/week for 4 weeks.
40935968|NCT02180724|DRUG|Acalabrutinib (ACP-196)|
40935969|NCT02180724|DRUG|Acalabrutinib (ACP-196)|
40935970|NCT03026088|DRUG|Bisoprolol|Participants received Bisoprolol orally, once daily at a dose of 1.25 milligram (mg) up to Weeks 3, and then it was up-titrated to 2.5 mg up to Week 6, 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18 and 10 mg up to Week 26.
40935971|NCT01280955|DRUG|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
40935972|NCT00876798|DRUG|Lixivaptan|Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.
40935973|NCT00876798|DRUG|Placebo|Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
40935974|NCT06024733|DRUG|Sevoflurane|patient recieve propofol for induction and sevoflurane for maintenance
40935975|NCT06024733|DRUG|Target Controlled Infusion|target controlled infusion of propofol
41130147|NCT05660434|OTHER|Aroma Inhaler with Bergamot essential oil|The intervention group will receive an aroma inhaler and logbook to use three times a day for 7 days and complete pre and post surveys for comfort, ease, and stress.
41130148|NCT05926674|OTHER|Myofascial Release|Myofascial release is a manual therapy technique commonly used by clinicians and bodyworkers to provide effects such as decreased pain, improvement in flexibility, ROM, and quality of life. It combines non-gliding fascial traction with varying amounts of stretching to produce a tensional force on the muscle and its associated fascia resulting in viscoelastic lengthening and deformation.
41130149|NCT05926674|OTHER|Light Touch Contact|The sham treatment of light touch will be applied to the lumbar spine and this form of contact is not therapeutic. It is only meant to only mimic a manual therapy technique.
41450122|NCT01783535|DRUG|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
41450123|NCT01783535|PROCEDURE|enucleation|Eye removal due to advanced disease in Strata C and D participants.
40935976|NCT06024733|DRUG|Target Controlled Infusion and lidocaine|patients will receive total intravenous anesthesia with propofol Target Controlled Infusion. At the induction of anesthesia, the patients will receive a bolus of lidocaine 1% 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure.
40935977|NCT04216914|DEVICE|Hand outline|A simple outline of a hand, to which the child tried to match their own hand on order to improve positioning.
41279896|NCT00195351|DRUG|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
41279897|NCT06059885|DRUG|Tislelizumab plus tyrosine kinase inhibitor|Lenvatinib, tyrosine kinase inhibitor (TKIs)
41279898|NCT06023212|DRUG|Tranexamic Acid|"IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery；~1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery."
41279899|NCT06023212|DRUG|stroke-physiological saline solution (SPSS)|IV drip of 2 bottles of saline before making incision during surgery； saline soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.
41279900|NCT02498652|DRUG|RDEA3170 2.5 mg|"Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets)."
40755917|NCT02099123|DRUG|Atorvastatin|Atorvastatin 20 mg tablet
40935978|NCT02632903|DRUG|Zoledronic acid|
40935979|NCT02721979|DRUG|Apalutamide|Given PO
41279901|NCT02498652|DRUG|allopurinol 300 mg|allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
41279902|NCT05346302|DRUG|Pneumovax 23|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
41279903|NCT05346302|DRUG|Typhim VI|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
41279904|NCT05346302|OTHER|Saline|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
41279905|NCT04007614|OTHER|Questionnaire|Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
41279906|NCT04355286|DRUG|Bemotrizinol|Market-image topical sunscreen formulation containing BEMT (6%)
41279907|NCT02593370|DRUG|Lidocaine-epinephrine added gadoterate meglumine|
41279908|NCT01154101|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
41279909|NCT01154101|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
41279910|NCT02528344|BEHAVIORAL|HIIT|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
41279911|NCT00267241|OTHER|Mechanical Ventilation|Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
40755918|NCT02099123|DRUG|Placebo (for Atorvastatin)|Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
40755919|NCT00002101|DRUG|Ethambutol hydrochloride|
40755920|NCT00002101|DRUG|Clarithromycin|
40935980|NCT02721979|OTHER|Laboratory Biomarker Analysis|Correlative studies
40935981|NCT02721979|OTHER|Quality-of-Life Assessment|Ancillary studies
40935982|NCT02721979|OTHER|Questionnaire Administration|Ancillary studies
40755921|NCT00002101|DRUG|Rifabutin|
40755922|NCT01788774|DRUG|Risperidone ISM 50 mg|
40935983|NCT01725412|DIETARY_SUPPLEMENT|Thiamine 300mg PO once daily|
40935984|NCT01725412|DIETARY_SUPPLEMENT|placebo|
40935985|NCT05440071|DEVICE|JX- XFINE lead|Pacemaker subjects implanted with one JX - XFINE passive pacing lead
41279912|NCT02631161|OTHER|Equia Forte|Restoration of cavities with a Glasshybrid material (Equia Forte)
40935986|NCT04639037|DEVICE|Automated adjustment of vasopressor|The objective of this randomized controlled superiority study is to demonstrate that, in patients admitted to intensive care after a major surgery, tight control of MAP using a closed-loop system for vasopressor administration will result in MAP being more often within a MAP range of 80-90 mmHg compared to the same management without this automated closed-loop system (nurse adjustment of vasopressor administration)
40935987|NCT04639037|DEVICE|Manual adjustment of vasopressor|Fluid and vasopressor will be delivered as standard of care (manual adjustment of both fluid and vasopressor infusion rate by the nurse)
40935988|NCT03932968|PROCEDURE|pH-metry during 24 hours|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry will be performed
40935989|NCT04551391|OTHER|Blood and urine sampling|Retinal OCT is a novel, non-invasive method for cross-sectionally imaging the eye's retina and choroid
40935990|NCT03080974|DRUG|Nivolumab|Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
40935991|NCT03080974|PROCEDURE|Irreversible Electroporation|Non-thermal ablation of tumor
40935992|NCT04149392|DEVICE|Continuous Glucose Monitor|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge. The participants will go home with the device and keep it for 6-14 days until they return to clinic for follow up visit. At this time the device will be removed, the information regarding glucose levels during those days will be downloaded and based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
40935993|NCT03237871|BEHAVIORAL|Text-message survey and informational text messages|Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
40935994|NCT03813823|BEHAVIORAL|Fear tasks|All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.
40935995|NCT06210308|PROCEDURE|Data collection from gastric ultrasound|observational study
40935996|NCT02902796|DEVICE|Spinal cord stimulator|Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
40935997|NCT02480712|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
40935998|NCT02001025|DEVICE|Absorb scaffold|
40935999|NCT02001025|DEVICE|Xience stent|
40936000|NCT04374968|DEVICE|Blood flood restriction cuff|Blood flow restriction cuffs will be used as an augment to physical therapy
40936001|NCT01992978|PROCEDURE|Radiofrequency-assisted Hepatectomy|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
40936002|NCT01992978|PROCEDURE|Conventional Hepatectomy|Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
40936003|NCT03155360|OTHER|Non interventional study|Non interventional study
40936004|NCT05774977|OTHER|Aviation Noise Only (AN)|The aviation noise (AN) night will expose subjects to a pre-programmed recording of aviation noise during sleep from 2300-0700.
41130150|NCT05225376|OTHER|Physical activity sessions for pregnant women|"The physical activity sessions will take place once a week at the Estaing UHC, in the room used for the childbirth and parenting preparation classes of the outpatient obstetrics-gynecology clinic; and twice a week on Zoom. These sessions will be supervised by an APA professional (degree in STAPS and APA).~The measurement of the women's physical conditions will make it possible to adapt and individualize the PA sessions to each woman's level."
41130151|NCT02520674|OTHER|optic nerve head ophthalmoscopy|Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
41130152|NCT03440996|OTHER|Clinpro™ 5000|Clinpro™ 5000 with 1.1% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
41130153|NCT03440996|OTHER|Clinpro™ Tooth Crème|Clinpro™ Tooth Crème with 0.21% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
41130154|NCT03440996|OTHER|MI-Paste Plus|MI-Paste Plus is a widely used anti-cavity toothpaste on the market and it is used as a control group in this study.
41130155|NCT02620449|OTHER|Diet|Participants will be fed a low-additive diet as the primary intervention
40936005|NCT05774977|OTHER|Pink noise, 50 dBA only (BN50)|The BN50 night will consist of exposure to continuous pink noise throughout the sleep period at a level of 50 A-weighted decibels (dBA).
40936006|NCT05774977|OTHER|Aviation noise plus earplugs (AN+EP)|The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.
40936007|NCT05774977|OTHER|Aviation noise plus white noise 40 dBA (AN+BN40)|The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.
40936008|NCT05774977|OTHER|Aviation noise plus white noise 50 dBA (AN+BN50)|The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.
40936009|NCT05774977|OTHER|Control Night (CTRL)|Control night (CTRL) without noise exposure and without earplugs.
40936010|NCT00282542|PROCEDURE|Hepatocyte Infusion|
40936011|NCT04079569|BEHAVIORAL|Tobacco|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
40936012|NCT04079569|BEHAVIORAL|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
40936013|NCT00043121|DRUG|oxaliplatin|Given IV
40936014|NCT00043121|DRUG|leucovorin calcium|Given IV
40936015|NCT00043121|DRUG|fluorouracil|Given IV
40936016|NCT00043121|DRUG|capecitabine|Given orally
40936017|NCT00043121|OTHER|pharmacological study|Correlative studies
40936018|NCT06398795|PROCEDURE|Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS).|An innovative surgical approach, Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS), presents a unique dual-port endoscopic technique for thyroidectomy. DTS significantly reduces postoperative hospital stay, emphasizing its potential for accelerated patient recovery compared to COT.
40936019|NCT06398795|PROCEDURE|Conventional open thyroidectomy (COT)|open thyroidectomy with traditional collar incisions
40936020|NCT02581839|DRUG|Eribulin Mesylate|Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
41130156|NCT03661463|DRUG|Aspirin|Drug
41130157|NCT02490956|BIOLOGICAL|Verorab® (PVRV; Purified Vero Cell Vaccine)|"* Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
40936021|NCT02581839|DEVICE|MRI|An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
40936022|NCT02581839|DRUG|Pre-Medication: Zofran|Zofran at 8mg orally. Given at the discretion of the treating physician
40936023|NCT02581839|DRUG|Pre-Medication: Decadron|decadron at 8mg orally. Given at the discretion of the treating physician
40936024|NCT05373615|DRUG|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
40936025|NCT04365062|DEVICE|Excimer laser and drug coated balloon|Excimer laser and drug coated balloon
40936026|NCT04365062|DEVICE|Excimer laser and plain balloon|Excimer laser and plain balloon
40755923|NCT01788774|DRUG|Risperidone ISM 75 mg|
40755924|NCT01788774|DRUG|Risperidone ISM 100 mg|
40936027|NCT04365062|DEVICE|plain balloon and drug coated balloon|plain balloon and drug coated balloon
40936028|NCT02806193|PROCEDURE|Cardiovascular Magnetic Resonance Imaging|"Cardiac magnetic resonance imaging (CMR) has emerged as both a remarkably powerful diagnostic and prognostic tool for the assessment of cardiovascular disease. The high spatial resolution of CMR and the ability to characterize soft tissue provides the opportunity for unique diagnostic assessment of a myriad of cardiac pathology, including ischemic heart disease (IHD), preoperative assessment, intra- cardiac mass and thrombus, pericardial disease, valvular heart disease, and cardiomyopathy evaluation.~Between individual CMR programs, GCMR will offer information useful in assessing the differences in protocol, performance, and clinical adaptation by varying geographic regions, institutional environments, and expertise. Such an assessment is critical for uncovering possible reasons for disparities in performance and obtaining opportunities for advancement."
40936029|NCT00333203|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
40936030|NCT00333203|OTHER|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
41130158|NCT03021512|PROCEDURE|Phaco with Restor|Phacoemulsification with bilateral bifocal intraocular lenses implantation
41130159|NCT03021512|PROCEDURE|Phaco with Panoptix|Phacoemulsification with bilateral trifocal intraocular lenses implantation
41130160|NCT00023400|DRUG|Nelfinavir|
41130161|NCT00023400|DRUG|Rifabutin|
41130162|NCT00087256|DRUG|Celecoxib|
41130163|NCT00087256|OTHER|placebo|
41130164|NCT04627896|DEVICE|Katty focal therapy|Microwave ablation with TATO3 generator (Katty system) under guidance of ultrasound/mpMRI fusion image device Trinity
41130165|NCT05328258|DRUG|Triptorelin Embonate|"11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug.~3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug."
41130166|NCT05328258|DRUG|Sodium Chloride solution 0.9%|One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
41130167|NCT02307396|DRUG|Olanzapine|
41130168|NCT02307396|DRUG|Amisulpride|
41130169|NCT02307396|DRUG|Risperidone|
41130170|NCT02307396|DRUG|Haloperidol|
40936031|NCT02075970|DRUG|Epoetin Alpha|"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1."
40936032|NCT02075970|DRUG|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
41130171|NCT02307396|DRUG|Quetiapine|
41130172|NCT02307396|DRUG|Perphenazine|
41130173|NCT02307396|DRUG|Sulpiride|
41130174|NCT02307396|DRUG|bromperidol|
41130175|NCT02307396|DRUG|Zuclopenthixol|
40936033|NCT00003548|DRUG|aminocamptothecin colloidal dispersion|
41130176|NCT02307396|DRUG|Thioridazine|
41130177|NCT02307396|DRUG|Paliperidone|
41130178|NCT02307396|DRUG|Ziprasidone|
41130179|NCT02307396|DRUG|Benperidol|
41130180|NCT02307396|DRUG|Fluspirilene|
40936034|NCT02602977|OTHER|Multiple-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days."
40936035|NCT02602977|OTHER|Single-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Single-dose RIPC consists of 1 dose of RIPC as described above"
40936036|NCT02602977|BIOLOGICAL|LPS infusion|To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group \[n=10\], single-dose RIPC group \[n=10\] and control group \[n=10\]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
41130181|NCT02307396|DRUG|Pimozide|
41130182|NCT02307396|DRUG|Perazine|
41130183|NCT02307396|DRUG|Fluphenazine|
41130184|NCT02307396|DRUG|Flupentixole|
41130185|NCT02307396|DRUG|Sertindole|
41130186|NCT02095366|DRUG|Morphine|"Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
41130187|NCT02095366|DRUG|Sufentanil|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
41130188|NCT02095366|DRUG|Placebo|"Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
41130189|NCT02095366|DRUG|Placebo|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
41130190|NCT05510700|DEVICE|Acupuncture|All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.
41130191|NCT05510700|DEVICE|Sham acupuncture|"The placebo needles selected for this study are flat-tipped needles without a tip that cannot be pierced into the skin. Also, an external patch device will hold the needles in place and these needles are visually pierced into the skin. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needles being pulled out."
41279913|NCT02631161|OTHER|Filtek Supreme XT/Clearfil SE Bond|Restoration of cavities with a composite resin based material after placing an adhesive
40755925|NCT06395714|OTHER|Personnalized physiotherapy|"Following completion of the ankle go test, patients in experimental group will receive specific instructions for continuing their rehabilitation, which will be passed on to the physiotherapist responsible for the rehabilitation."
40936037|NCT02891616|DRUG|fludeoxyglucose F 18|
40936038|NCT02891616|DEVICE|Positron emission tomography-computed tomography|
40936039|NCT02891616|DRUG|18F-fluorothymidine|
40936040|NCT02891616|DEVICE|Positron emission tomography-magnetic resonance imaging|
41450124|NCT01783535|RADIATION|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
41450125|NCT03243591|OTHER|Livionex gel|Brushing area of mucositis with gel
41450126|NCT03243591|OTHER|Aquafresh gel|Aquafresh gel
41450127|NCT05308186|BEHAVIORAL|Auditory stimulation|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report) through headphones. In case no report is given, nature (brook) sounds will be streamed.
41450128|NCT05308186|BEHAVIORAL|Auditory and tactile stimulations|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report, otherwise nature (brook) music will be streamed) through headphones combined with deep tissue massage will be given on the upper limbs.
40936041|NCT04437849|DEVICE|Home Telemonitoring System|Home Telemonitoring System (HTS) The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
40936042|NCT06007859|OTHER|section orientation|The patient was placed in a decubitus supine head back extension position to fully expose the cervical thyroid examination site. The instrument was adjusted appropriately to achieve optimal imaging quality, the suspicious nodule was located in conventional ultrasound mode, the SWE option in VT mode was selected, and the patient was instructed to hold his/her breath to minimize the effect of respiration, and elastograms of the nodule in transverse and longitudinal sections were obtained.
40936043|NCT00749554|DEVICE|Disc biacuplasty|The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
40936044|NCT00749554|DEVICE|Sham biacuplasty|Probes not inserted into disc, no RF electricity applied.
40936045|NCT05152264|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
40936046|NCT05152264|OTHER|Conventional analgesic treatment|Conventional analgesic treatment. Conventional analgesic treatment may include no pharmacological treatment if the patient does not use any analgesics.
40936047|NCT01258270|PROCEDURE|Postop Dressing|The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
40936048|NCT01258270|PROCEDURE|Postop Dressing|A standard island dressing consists of adhesive tape and gauze.
40936049|NCT05034445|DIAGNOSTIC_TEST|Next generation sequencing|Extract DNA from sputum sample, minimum DNA amount should be over 50ng.
40936050|NCT00655135|DRUG|LDP-02|Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
40936051|NCT00655135|DRUG|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
40936052|NCT05521529|OTHER|no intervention, as this is an observational study|no intervention
40936053|NCT00603421|OTHER|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
40936054|NCT00603421|OTHER|treatment as usual|Treatment as usual
40936055|NCT02034422|DIETARY_SUPPLEMENT|Oral Antioxidant|Consisting of vitamins C, E and alpha lipoic acid.
40936056|NCT02034422|OTHER|Exercise rehabilitation|8 weeks of exercise rehabilitation
40936057|NCT01545843|BEHAVIORAL|Sleep scheduling|8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
40936058|NCT01545843|DRUG|Fluoxetine|20-40 mg fluoxetine daily for 8 weeks
40936059|NCT00582283|DRUG|I124-NM404|I-124-NM404
40936060|NCT03024437|DRUG|Atezolizumab|Atezolizumab will be given intravenously every 3 weeks at 1200 mg.
40936061|NCT03024437|DRUG|Bevacizumab|Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.
40936062|NCT03024437|DRUG|Entinostat|Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).
40936063|NCT00337350|DRUG|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
41450129|NCT05666960|DRUG|R-3750|Probiotic
40936064|NCT00337350|DRUG|placebo|matched placebo for rosiglitazone 4mg/day
40936065|NCT03522753|DEVICE|Metal skin staples|Routine closure methods/material for surgical wounds
40936066|NCT03522753|DEVICE|Nylon sutures|Routine closure methods/material for surgical wounds
40936067|NCT02048189|DRUG|LEVEMIR|
41450130|NCT06219031|OTHER|no intervention|no intervention
41450131|NCT01937182|DRUG|Citalopram|Citalopram 10-40 mg per day administered orally
41450132|NCT01937182|DRUG|Placebo|1/2-2 tablets per day with no intrinsic drug activity
40936068|NCT02048189|DRUG|APIDRA|
40936069|NCT05796778|PROCEDURE|subomohyoid plane block|The block needle was inserted in line with the probe in a lateral-to-medial orientation toward the suprascapular nerve. Local anesthetic solution was then injected after negative aspiration for blood to achieve circumferential spread around the neurovascular bundle
40936070|NCT05796778|PROCEDURE|Interscalene brachial plexus block|The block needle is usually advanced in plane in a lateral-to-medial direction through the middle scalene muscle to contact the nerve roots and inject local anesthetic around them.
40936071|NCT05803980|PROCEDURE|Fecal microbiota transplantation (FMT)|Single FMT infusion via colonoscopy
40936072|NCT05832827|DRUG|MK-3475|Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.
41130192|NCT04319549|OTHER|Ketorolac Tromethamine irrigant|Ketorolac tromethamine, a potent NSAID available in both oral and injectable forms, is over 400 times more potent as a selective inhibitor of COX-1 over COX-2 than many other drugs. When ketorolac tromethamine was used as an intracanal medicament in teeth with irreversible pulpitis undergoing root canal treatment, it contributed to significant post operative pain relief.
41279914|NCT02812511|PROCEDURE|Biopsy|Skin biopsy is performed at the arm with a punch of 3 mm in diameter or a scalpel under local anesthesia, and then preserved in low glucose DMEM at room temperature.
41279915|NCT04224623|BEHAVIORAL|Raising Well at Home|The Raising Well at Home intervention was delivered via 3 core home visits designed to be delivered every 4-6 weeks, with additional support via text or phone over 6 months. The home visits were designed to engage the whole family, build skills, and promote changes in the home environment to support lifestyle behavior change. These essential behaviors focused on reducing sugary beverage intake, promoting appropriate portion sizes, improving fruit and vegetable intake, increasing walking and reducing screen time/sedentary activity.
41279916|NCT04084392|OTHER|Bridge Clinic|Referral to the Bridge Clinic for temporary outpatient addiction treatment while the bridge clinic identifies an outpatient addiction treatment provider to accept the patient for long term treatment.
41279917|NCT04084392|OTHER|Usual Care|Referral to an outpatient provider for addiction treatment.
41279918|NCT05343390|BEHAVIORAL|Enhanced implementation package|Individual training with teaching and modeling (tablet-guided, \~8 hours) Small group training with practice and feedback (tablet-guided, \~16 hours) Ongoing continuous quality improvement sessions (tablet-guided, \~2 hours/month)
41279919|NCT05343390|BEHAVIORAL|Standard implementation package|Individual training with teaching (facilitator-guided, \~2 hours) Small group practice (facilitator-guided, \~1 hour) Ongoing clinic support (facilitator-guided, \~30 minutes/month)
41279920|NCT01671904|DRUG|Bendamustine|Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter \[mg/m\^2\]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
41279921|NCT01671904|DRUG|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams \[mg\]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
40936073|NCT05832827|DRUG|Lenvatinib|Lenvatinib will be administered at a dose of 8 mg orally QD every 21 days (3 weeks) for up to 4 cycles in the induction phase, followed by 20 mg QD for up to 31 cycles in the maintenance phase. Then, further maintenance therapy with lenvatinib will be allowed until progression or unacceptable adverse events.
40936074|NCT05832827|DRUG|Carboplatin|Carboplatin will be administered at a dose of AUC 5 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
40936075|NCT05832827|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m\^2 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
40936076|NCT02992561|BEHAVIORAL|FORNET (adapted version)|
41130193|NCT04319549|OTHER|sodium hypochlorite irrigant|NaOCl is the gold standard and the most commonly used root canal irrigant. NaOCl is able to dissolve the organic tissues inside root canal due to its alkalinity (pH11), which causes amino acid degradation and hydrolysis through the production of chloramine molecules. In addition, it possesses highly antibacterial effect and its low cost makes it the most frequently used root canal irrigant. Dual rinse is considered an effective time saving root canal irrigant with a better antibacterial property in comparison to NaOCl alone. In addition to its effectiveness on smear layer removal and reduction in the debris accumulation during root canal instrumentation.
41130194|NCT00663819|DEVICE|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement|Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
41130195|NCT00663819|PROCEDURE|Staple line without reinforcement|colorectal and coloanal anastomotic staple line without reinforcement
41130196|NCT06114615|DEVICE|LiveCare|Patient use LiveCare device to monitor their blood pressure and data is transmitted to dashboard.
41130197|NCT06114615|BEHAVIORAL|Text Messages|Patients also receive text messages after their PCI procedure for follow up appointment reminders, enrollment in cardiac rehab, and diet and exercise counseling.
41130198|NCT06114615|OTHER|Conventional Care|No digital monitoring with LiveCare device and no text messages.
41130199|NCT01072045|DRUG|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
41279922|NCT01671904|DRUG|Rituximab|Participants will receive IV infusion of rituximab (375 mg/m\^2) on Day 1 of Cycle 1 and 500 mg/m\^2 administered on Day 1 of Cycles 2-6.
41279923|NCT01671904|DRUG|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
41130200|NCT01072045|DRUG|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
41130201|NCT01323790|DRUG|NKTR-118|12.5 mg oral tablet once daily
41130202|NCT01323790|DRUG|NKTR-118|25 mg oral tablet once daily
41130203|NCT01323790|DRUG|Placebo|Placebo to NKTR-118
41130204|NCT01046136|DRUG|guaifenesin (Mucinex)|bid 7 days
41130205|NCT01046136|DRUG|placebo|bid 7 days
41130206|NCT00125905|BEHAVIORAL|Advice|
41130207|NCT00125905|BEHAVIORAL|Motivational Interviewing|
41130208|NCT00125905|DRUG|Nicotine Gum and Patch|
41130209|NCT00125905|DRUG|Bupropion|
41130210|NCT00777049|DRUG|Panobinostat|Hard gelatine capsule - 5mg and 20mg
41130211|NCT05377918|OTHER|Diary|spiritual diary group and diary gruop will write a diary
41279924|NCT05393154|DEVICE|Biopsy Adequacy Evaluation by Aquyre Biopsy Scanner|Microscopic viewing and imaging of Bronchoscopic Biopsy Specimens using Full Field Optical Coherence Tomography and Dynamic Cell Imaging
41279925|NCT05123287|DRUG|PD-1 immune checkpoint blockades|intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months
41279926|NCT06448793|DRUG|Approved Non-small Cell Lung Cancer (NSCLC) therapies|As prescribed by treating physician
41279927|NCT06392490|OTHER|Technology Based Asthma Program|Evaluate the impact of peer-led and adult-based technology-based education on the quality of life, asthma control, asthma knowledge and self-efficacy in adolescents diagnosed with asthma.
41279928|NCT04702230|DIAGNOSTIC_TEST|MRI|Baseline and follow-up MRI at 1 and 3 months post-TAE or post-TARE
41279929|NCT00603005|DEVICE|Use of TravAlert dosing aid with or without drop guider|Each patient will use a dosing aid and/or drop guider for 6 months
40744325|NCT04144764|OTHER|Workplace-based exercise|Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.
41130212|NCT03440645|OTHER|Family-oriented primary cardiovascular prevention|An initial screening visit including a targeted history, physical exam, and investigations as per the Canadian Cardiovascular Society's recommendations for cardiovascular primary prevention. Counselling and informational handouts on improved cardiovascular risk factor and lifestyle habits. All family and household members, as well as the cardiovascular disease proband, are encouraged to attend and participate in all healthcare visits.
40936079|NCT06290973|PROCEDURE|surgery of varicose veins|including ablation with radiofrequency, phlebectomy and saphenectomy.
40936080|NCT03895762|DRUG|Abstral Oral Disintegrating Tablet (ODT)|Opioid(Fentanyl)
40936081|NCT05038904|DRUG|Acalabrutinib|100 mg oral capsule
40936082|NCT02810678|OTHER|Latent Tuberculosis Infection program evaluation & diagnosis|
40936083|NCT00991068|DRUG|Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch|Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
40936084|NCT01860573|DRUG|Amino acids|
40936085|NCT06338761|BEHAVIORAL|Smoking cessation|Stop smoking
40936086|NCT06338761|BEHAVIORAL|Switching to E-cigarette|Switching to E-cigarette
40936087|NCT01462786|DRUG|ATX-101|2 mg/cm2 ATX-101
40936088|NCT00284622|PROCEDURE|Arthroscopy|HTO with pre-scope
40936089|NCT04621357|RADIATION|Brain MRI|Brain MRI will include differents sequences.
40936090|NCT04621357|BIOLOGICAL|Biological biomarkers|Biological biomarkers will include a set of systemic inflammatory markers
40936091|NCT05920928|RADIATION|Short course radiotherapy with concurrent capecitabine(825mg/m2)|Compared to conventional treatments, short-term radiotherapy has lower fraction numbers but higher radiation doses per fraction. capecitabine is given during treatment time (825mg/m2)
40936092|NCT05920928|RADIATION|Long course radiotherapy with concurrent capecitabine(825mg/m2)|Long-term radiation is administered in conjunction with concomitant capecitabine (825mg/m2)
40936093|NCT00745615|DRUG|Laquinimod|Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.
40936094|NCT00745615|DRUG|Placebo|Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
40755926|NCT06395714|OTHER|Usual physiotherapy|"Following completion of the ankle go test, patients in active comparator group will receive usual physiotherapy"
40755927|NCT01216085|DRUG|high-dose imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
40936095|NCT03157323|BEHAVIORAL|Low Glycemic Index Diet|The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.
40936096|NCT01541345|DEVICE|Autogenous bone graft|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
40936097|NCT01541345|DRUG|InductOs|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
40936098|NCT01541345|PROCEDURE|Augmentation surgery|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
41130213|NCT02236611|DRUG|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
41279930|NCT05465135|DRUG|Dihydroartemisinin|Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
41279931|NCT03240081|DRUG|50mcg estradiol cream|Use of study drug nightly applied to vulvar vestibule
41279932|NCT03240081|DRUG|100mcg estradiol cream|Use of study drug nightly
40936099|NCT01880047|DRUG|Eltrombopag|Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (\> 50,000 and increase by \> 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (\> 50,000 and \> 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
40936100|NCT01880047|DRUG|Placebo|
40936101|NCT01070862|DRUG|Thalidomide, Dexamethasone|Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
40936102|NCT01070862|DRUG|Vincristin , Adriamycin, Dexamethasone = VAD|Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
40936103|NCT01070862|DRUG|Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
40936104|NCT01070862|DRUG|melphalan, endoxan, dexamethasone (MCDex)|melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
40936105|NCT01070862|DRUG|Thalidomide, Dexamethasone|Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
40936106|NCT03763227|DRUG|Intravitreal ranibizumab (IVR) injection|Intravitreal ranibizumab (IVR) injection in patients with retinal dystrophy and macular cysts who have not responded to treatment with carbonic anhydrase inhibitors
40936107|NCT03763227|DRUG|Carbonic Anhydrase Inhibitor (CAI) therapy|Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts
40936108|NCT04167722|PROCEDURE|Robotic Radical Prostatectomy|Routine NHS Radical Prostatectomy
40936109|NCT02499458|OTHER|None- observational study|
40936110|NCT00617643|DRUG|Nevirapine without dose escalation|Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
40936111|NCT00617643|DRUG|Nevirapine initiation with dose escalation|Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
40936112|NCT00062673|DRUG|Duloxetine|
40936113|NCT00062673|DRUG|Placebo|
40936114|NCT02581943|DRUG|Carboplatin|Given IV
40936115|NCT02581943|OTHER|Laboratory Biomarker Analysis|Correlative studies
40936116|NCT02581943|DRUG|Paclitaxel|Given IV
40936117|NCT02581943|BIOLOGICAL|Pembrolizumab|Given IV
40936118|NCT02581943|OTHER|Quality-of-Life Assessment|Ancillary studies
40936119|NCT03395925|DEVICE|Celon Pro Surge|bipolar coagulation electrode intended for tissue heating
41450133|NCT04277793|BEHAVIORAL|Monitored self-guided problem solving|Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
40936120|NCT00270829|DRUG|nesiritide|Drug given intrarenally or placebo
40936121|NCT01314157|OTHER|Isostretching|12 interventions (two times per week) for 45 minutes
40936122|NCT06274905|DRUG|EMLA|EMLA cream
40936123|NCT06274905|DRUG|Ethyl chloride|Ethyl chloride
40936124|NCT06274905|DRUG|Aqueous cream BP|Aqueous cream
40936125|NCT03334708|DIAGNOSTIC_TEST|Blood Draw|"If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:~Patients and controls weighing 50kg or more~* For draw amounts up to 50mL, there is no required hemoglobin threshold.~* For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period.~Patients and controls weighing \< 50kg~* For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time."
40936126|NCT03334708|DIAGNOSTIC_TEST|Tumor Tissue Collection|Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
40936127|NCT03334708|DIAGNOSTIC_TEST|Cyst Fluid|Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
40936128|NCT01453192|DRUG|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
40936129|NCT06159101|DRUG|HLX13|A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.
40936130|NCT06159101|DRUG|CN-sourced ipilimumab|A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.
40936131|NCT06159101|DRUG|EU-sourced ipilimumab group|A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.
40936132|NCT06159101|DRUG|US-sourced ipilimumab group|A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.
41130214|NCT02236611|DRUG|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
41279933|NCT05797129|DEVICE|CEDM|Women underwent CEDM screening
41450134|NCT05702905|DRUG|Metformin Hydrochloride 500 MG|Metformin oral tablet (500mg per tablet) will be administered in a dose increasing mode: the initial dose will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
41450135|NCT05702905|DRUG|Semaglutide, 1.34 mg/mL|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and increased to 1.0mg QW after another 4 weeks, and then maintained 1.0mg until the end of treatment in total 12 weeks.
40936133|NCT05789108|DIAGNOSTIC_TEST|Blood sample and Ultrasound examination|"The ultrasound examination is a non-invasive procedure with no risks, adverse reactions, or discomforts associated with the examination. The study blood samples are mostly obtained at the same time as clinical blood sample collection in order to avoid unnecessary complications.~The inclusion and ultrasound examiniation is performed by the patient responsible physician at the Emergency Department. Blood samples during the study period are performed by trained study staff."
41130215|NCT00748982|DRUG|AZD1305|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
41130216|NCT00748982|DRUG|Placebo|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
41130217|NCT04441775|OTHER|AI-assisted RT modelling|Artificial Intelligence assisted Radiation Treatment
41130218|NCT01634165|DRUG|LY2963016|Administered subcutaneously
41130219|NCT01634165|DRUG|Lantus|Administered subcutaneously
41130220|NCT00241618|DRUG|Pegylated interferon alpha 2|
40936134|NCT00912665|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
40936135|NCT00912665|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
40936136|NCT00912665|OTHER|squatting|Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
40936137|NCT00912665|DEVICE|Suction cup|Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
40936138|NCT02024438|DRUG|monosialotetrahexosylganglioside Sodium|it is extracted from pig's brain,shenjie is the brand name
40936139|NCT02024438|OTHER|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
40936140|NCT02102360|DEVICE|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
40936141|NCT02102360|DEVICE|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
40936142|NCT02710500|DRUG|rAAVrh74.MHCK7.DYSF.DV|Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.
40936143|NCT03156361|DRUG|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
40936144|NCT03156361|DRUG|Insulin Lispro 100 Units/mL|Sterile Water for Injection added to commercial insulin lispro
40936145|NCT04148833|DRUG|LDE-Paclitaxel|LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks
40936146|NCT04148833|DRUG|LDE-Placebo|LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
40936147|NCT00290979|DRUG|insulin glulisine|
40936148|NCT02605837|DRUG|Oral Budesonide Suspension (OBS)|Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
40936149|NCT02605837|DRUG|Placebo|Oral dose of 10 ml of placebo matched with the experimental drug.
41130221|NCT00241618|DRUG|Ribavirin|
40936150|NCT00586196|DRUG|donepezil|5 mg each day for 30 days
40936151|NCT00586196|DRUG|Placebo|Encapsulated cornstarch One capsule daily for 30 days
40936152|NCT00121888|BEHAVIORAL|Prolonged Exposure Therapy|
40936153|NCT00121888|DRUG|Paroxetine-CR|
40936154|NCT03775161|DEVICE|V-LAP™ System|Delivery of the V-LAP™ implant via a catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
40936155|NCT05867342|DRUG|Epinephrin|Topical application of 2 pieces of Epinephrin (1:1,000)-soaked cottonoid in nasal cavity
40936156|NCT05867342|DRUG|1% lidocaine with epinephrin 1:100,000|4 ml intranasal infiltration of 1% lidocaine with epinephrine (1:100,000) at 2 sites (2 ml infiltration at each site)
40936157|NCT05867342|DRUG|Saline|4 ml intranasal infiltration of saline at 2 sites (2 ml infiltration at each site)
40936158|NCT02771587|DIETARY_SUPPLEMENT|Alcohol and energy drink|Multiple oral dose of alcohol Multiple oral dose of energy drink
40936159|NCT02771587|DIETARY_SUPPLEMENT|Alcohol|Multiple oral dose of alcohol
40936160|NCT02771587|DIETARY_SUPPLEMENT|Energy drink|Multiple oral dose of energy drink
40936161|NCT02771587|DIETARY_SUPPLEMENT|Placebo|Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
40936162|NCT00450112|DEVICE|Gel-200|Single Intra-articular Injection
40936163|NCT02699216|DEVICE|Electrical Stimulation of the Retina|Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
40936164|NCT00590629|DRUG|Niaspan|1500 mg Niaspan for 16 weeks
40936165|NCT06240780|OTHER|Activated Incrediwear Products|Activated Incrediwear products incorporates semiconductor elements within the fabric that releases negative ions when stimulated by body heat. The negative ions activate cellular vibrations that increase blood flow and circulation.
40936166|NCT06240780|OTHER|Sham Incrediwear Products|Simple fabric Incrediwear products that do not include the semiconductor elements within the fabric.
40936167|NCT05091502|DIAGNOSTIC_TEST|Personalised musculoskeletal modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop personalised musculoskeletal models
40936168|NCT01076075|DRUG|Sitagliptin phosphate|Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
40936169|NCT01076075|DRUG|Comparator: placebo to pioglitazone|Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
41130222|NCT04142255|BIOLOGICAL|FMT|FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
41130223|NCT02739100|DRUG|Triferic|
41130224|NCT05157048|OTHER|Cigarette A|Participants will be smoke a first type of blinded commercially available cigarette.
41130225|NCT05157048|OTHER|Cigarette B|Participants will smoke a second type of blinded commercially available cigarette.
41279934|NCT00968734|DIETARY_SUPPLEMENT|colecalciferol|50.000UI single oral dose
41279935|NCT02265913|DRUG|Acyclovir 5 percent (Perrigo)|
41279936|NCT02265913|DRUG|Acyclovir 5 percent (Reference)|
41279937|NCT02265913|DRUG|Placebo cream|
40936170|NCT01076075|DRUG|Comparator: placebo to Sitagliptin|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
40936171|NCT01076075|DRUG|Comparator: pioglitazone|Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
40936172|NCT01076075|DRUG|Glimepiride or gliclazide|Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
40936173|NCT01076075|DRUG|Metformin|"Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin"
40936174|NCT01076075|DRUG|Pioglitazone rescue therapy|Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
40936175|NCT03269461|DEVICE|Angiography and Optical Coherence Tomography evaluations|coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
40936176|NCT06243744|DEVICE|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
40936177|NCT00198796|BIOLOGICAL|H10407|The primary objective of the proposed clinical investigation is to validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea
40936178|NCT05783986|OTHER|randomly divided|500 patients of our hospital were randomly divided into testing group and internal validation group, and 100 patients in collabrative hospital were external validation group.
40936179|NCT04618770|DEVICE|Triathlon PSR Tibial Insert|The Triathlon PSR Tibial Insert is intended to be used as a component in primary TKA and is designed to reduce rotational constraint at deep flexion.
41279938|NCT06112925|OTHER|Medication Therapy Management|The medication therapy management intervention was delivered via the five (5) core components which include medication therapy review, personal medication record, medication-related action plan, intervention, and documentation and follow-up. The interventions was also given via educating patients about diabetes, hypertension, complications of diabetes and hypertension, impact of having diabetes and hypertension, antidiabetes and antihypertensive medications, goals of therapy for diabetes and hypertension, health promoting behaviours (healthy diet, regular exercise, salt reduction, \& smoking cessation), drug adherence, and self-monitoring of the diseases.
41279939|NCT03893292|PROCEDURE|Total knee replacement|Patients will undergo total knee replacement surgery.
40744326|NCT04144764|OTHER|Ergonomic advice and education|Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
40936180|NCT03117088|OTHER|Checklist ISBAR3|"Checklist ISBAR 3~Use of an online based checklist for handovers with the following items:~Identification Situation Background Assessment Recommendation Read- back Risk~Established Checklist as communication tool"
40936181|NCT03117088|OTHER|Checklist VICUR|"Checklist Vicur~Use of an online based alternative checklist for handovers with the following items:~Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?~alternative checklist missing communication tool"
40936182|NCT00823342|DRUG|CLEVUDINE + TENOFOVIR PLACEBO|30 MG
40936183|NCT00823342|DRUG|CLEVUDINE IN ASSOCIATION TENOFOVIR|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
40936184|NCT00823342|DRUG|TENOFOVIR + CLEVUDINE PLACEBO|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
40936185|NCT01393015|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
40936186|NCT01393015|DEVICE|Manual settings with FreeO2 system in collection mode|Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
41130226|NCT04959669|OTHER|DeSSBack|The DeSSBack (Decision Support System for Low Back Pain) is a decision support tool developed in the University of Malaya Medical Centre's (UMMC) electronic medical record system by adopting and re-packaging the STaRT system to suit the local context. It stratifies patients with low back pain to low, medium or high risk, which are then managed differently. The DeSSBack has also been incorporated the local clinical practice guidelines and feedback from local experts.
41130227|NCT03421249|OTHER|Exercises|Muscle strengthening exercises of the hip and knee muscles
41130228|NCT03421249|OTHER|Electromagnetic field therapy|Electromagnetic field therapy with Magnetron®
41130229|NCT04618250|OTHER|SOFIA model|A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan
41130230|NCT05080036|OTHER|Medio-lateral imbalance|Thrust on the pelvis in the medio-lateral direction in order to create a balance perturbation
41130231|NCT00204685|DRUG|dornase alfa|
41279940|NCT03893292|DEVICE|COOLIEF|The superior lateral genicular nerve, superior medial genicular nerve, and inferior medial geniculate nerve will be ablated.
41450136|NCT05702905|DRUG|Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG|Both Semaglutide injection and Metformin oral tablet will be administered as described above.
40744327|NCT05124782|OTHER|Rheumatoid Arthritis Impact of Disease questionnaire|Rheumatoid Arthritis Impact of Disease questionnaire
41130232|NCT05134103|BEHAVIORAL|Mindbeacon Therapist Guided, Internet Cognitive Behavioral Therapy for Depression|"The treatment consists of 11 depression modules delivered approximately once per week (at therapists' discretion) over a period of 12 weeks. Additionally, the therapist typically tailors treatment to client's individual needs by including supplementary modules for a variety of issues such as generalized anxiety, panic, social anxiety, post-traumatic stress, insomnia, pain, and relationships etc. Clients can complete the readings, exercises, and worksheets at any convenient time, using their web-enabled smartphone, tablet, or computer. Access to the modules and all messaging is provided through the secure platform. Messaging is asynchronous meaning participants can message their therapist as often as they choose and expect a response within 1-2 business days. After 12 weeks of active treatment, they will have unguided access (without therapist support) to the treatment materials that were covered for an additional 40 weeks."
41279941|NCT05219565|DEVICE|Attractive Targeted Sugar Bait (ATSB)|An ATSB is a A4-sized panel containing thickened fruit syrup laced with a neonicotinoid insecticide, dinotefuran. The syrup-insecticide mixture is covered with a protective membrane that allows mosquitoes to feed through the membrane while preventing non-target organisms from feeding. This device is designed to attract and kill mosquitoes.
41130233|NCT05134103|OTHER|Waitlist Control Group|Participants assigned to this arm will wait for 12 weeks before receiving active treatment condition
41130234|NCT02553889|DRUG|ISIS 416858|subcutaneous injection
41130235|NCT02553889|DRUG|Placebo|subcutaneous injection
41130236|NCT02620306|DRUG|Fimsartan 60mg~120mg|Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
41130237|NCT02620306|DRUG|Fimsartan 60mg~120mg|Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
41130238|NCT02620306|DRUG|Losartan 50mg~100mg|Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
41130239|NCT02620306|DRUG|Losartan 50mg~100mg|Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
41130240|NCT01397006|DRUG|Pregabalin|Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
41130241|NCT05400161|BEHAVIORAL|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. Investigators will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
41279942|NCT04621747|OTHER|Battery of neurophysiological explorations|"Visit 1: Biometry collection: gender, age, weight, height, eye colour.~* Questionnaires : the State and Trait Anxiety Inventory and the Pain Sensitivity~* Threshold of unpleasant light brightness, mechanical sensitivity threshold (von Frey hair).~* Training to estimate unpleasantness Under nociceptive and tickling stimuli, to use the handgrip.~* Mechanical pain threshold (electronic von Frey), heat pain threshold (Medoc Pathway).~* 48 stimulations applied to the back skin, following a predetermined plan with 12 different pathways, imbricated with 4 different speeds of movement.~Visit 2 (1 to 8 days later) :~* 42 stimulations applied to the back skin, to test the effect of stimulation intensity, the side of application, continuity break of the contact, and distraction by other cutaneous stimuli. The stimuli will follow the best paradigm as identified at the previous visit.~* 12 stimulations applied to forearm, cheeks, lower limbs, also testing the effect of hairiness."
41279943|NCT00476138|DRUG|Epigallocatechin-gallate|
41279944|NCT02832271|DRUG|SUNPHENON EGCg|SUNPHENON EGCg Oral, 400mg, twice per day
41279945|NCT02832271|DRUG|Placebo|Placebo
40936187|NCT03935620|BEHAVIORAL|Enhanced Milieu teaching|"Enhanced Milieu Teaching (EMT) an evidence-based, naturalistic language intervention that has been optimized to address the specific language and communication deficits associated with DS. EMT is a parent-implemented intervention that involves home-visits during which clinicians teach parents to support their child learning language during typical parent-child interactions at home (play with toys, music, book reading, and snack time). Clinicians follow an evidence-based instructional framework called Teach-Model-Coach-Review to teach parents language support strategies."
40936188|NCT02394002|DRUG|Propofol|
40936189|NCT03403270|OTHER|ENCOURAGE App|Users will have an opportunity to engage with the app as described for the duration of the study period.
41279946|NCT03392233|RADIATION|Stereotactic Body Radiation Therapy|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time
41279947|NCT04670705|OTHER|patients' characteristics|There was no intervention.
40755928|NCT02589912|DEVICE|Nucleus Profile ABI541 Auditory Brainstem Implant|
40936190|NCT04005989|BIOLOGICAL|Stromal Cells Injection|Adipose stromal cell
40936191|NCT05427955|PROCEDURE|One-level Erector Spinae Plane Block|One-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 30 ml of 0.25% bupivacaine will be injected at the T5 level.
40936192|NCT05427955|PROCEDURE|Bi-level Erector Spinae Plane Block|Bi-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 15 ml of 0.25% bupivacaine at T4 level and 15 ml of 0.25% bupivacaine at T6 level will be injected.
40936193|NCT04024878|DRUG|Nivolumab|Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
40936194|NCT04024878|BIOLOGICAL|NeoVax|"The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity"
40936195|NCT04024878|PROCEDURE|Core Needle Biopsy|Surgical procedure
40936196|NCT04243421|DEVICE|Implantation|Soft tissue aesthetics, marginal bone level on CBCT
40936197|NCT03945292|DRUG|Fazisiran Injection|solution for subcutaneous (sc) injection
40936198|NCT03945292|OTHER|Placebo|sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
40936199|NCT03242824|DRUG|Fluorine F 18 Fluorodopa|Contrast used in PET
40936200|NCT03242824|RADIATION|Intensity-Modulated Radiation Therapy|Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor
40936201|NCT03242824|PROCEDURE|Positron Emission Tomography|imaging test
40936202|NCT00622076|PROCEDURE|postoperative catheterization|postoperative catheterization after anterior colporrhaphy for five days versus two days.
40936203|NCT00107367|PROCEDURE|conventional surgery|
40936204|NCT00107367|RADIATION|intraoperative radiation therapy|
40936205|NCT04639115|DRUG|Ozanimod|Ozanimod
40936206|NCT02943252|DRUG|Apatinib|apatinib 500 mg in tablet once daily
40936207|NCT02943252|DRUG|S1|S-1 40-60mg bid, days 1-14 , every 3 weeks
40936208|NCT02086279|DRUG|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured."
40936209|NCT01424202|DEVICE|Mechanical Insufflation Exsufflation|"After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.~On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.~The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse."
40936210|NCT03893331|DEVICE|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
40936211|NCT02149615|OTHER|Retinal nerve fibre layer measurement|Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
40936212|NCT01184131|OTHER|Mentor Training|Four 2 hour sessions of Mentor Training
40936213|NCT02818647|PROCEDURE|Tonsillectomy|Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.
40936214|NCT03737851|DRUG|elezanumab|solution for infusion
40936215|NCT03737851|DRUG|placebo|solution for infusion
40936216|NCT04873128|GENETIC|Multi-OMICS|Measurement of gene expression in immune cells (Human Peripheral Blood Mononuclear Cell (PBMCs) or total blood) using functional genomics, proteomics, metabolomics and lipidomics tools and compare the dynamics of immune response before and after vaccination against COVID-19.
40936217|NCT05875103|DIAGNOSTIC_TEST|linguistic processes|"Linguistic processes are assessed by performance score on the following tests:~* naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)~* vocabulary test (Mill Hill - Deltour, 1993),~* repetition tests (Gremots - Bézy et al., 2016),~* articulatory speed (Majerus, 2014 ; Roussel et al., 2012)~* semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),~* semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),~* phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)"
41279948|NCT03681717|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
41279949|NCT00986349|DEVICE|EndoBarrier Liner|52 week treatment of EnoBarrier Liner
40936218|NCT01721577|DRUG|AXL1717|IGF-1 receptor inhibitor
40936219|NCT00608543|DRUG|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
40936220|NCT06366022|DEVICE|The tunnel technique for root coverage with CTG with inner side of the graft|Procedure: The tunnel technique for root coverage with CTG with inner side of the graft
40936221|NCT06366022|DEVICE|The tunnel technique for root coverage with CTG with outer side of the graft|The tunnel technique for root coverage with CTG with outer side of the graft
40936222|NCT01230125|DRUG|Mapracorat|Instill study medication into study eye per dosing instructions for 14 days
40936223|NCT01230125|DRUG|Vehicle|Instill study medication into the study eye per dosing instructions for 14 days
40936224|NCT03762538|DRUG|Propofol|Patients will be induced to unconsciousness using propofol intravenously.
40936225|NCT01949337|DRUG|enzalutamide|Enzalutamide 160 mg daily, orally
40936226|NCT01949337|DRUG|abiraterone|abiraterone 1000 mg daily, orally
41450137|NCT05702905|BEHAVIORAL|calorie-restricted diet|All subjects after randomization will be reviewed and evaluated by a nutritionist, and then will receive diet guidance. The clinical nutritionist will develop a written nutrition plan for each subject. The nutrition plan of this study adopted the method of calorie restriction diet (CRD) to develop a diet, which required 83.68 kJ/kg of energy per day, 1.2 g/kg of protein per day, 40%\~55% of carbohydrate energy supply ratio, and 20%\~30% of fat energy supply ratio, to ensure the intake of vegetables, fruits and other rich dietary fiber, and drinking more than 1.5 L per day. The nutritionist will explain the method of food exchange in detail to enrich the food types of patients. The diet diary will be distributed to each subject, and the subjects will be required to make a return visit once every four weeks, return the diet diary each time, and receive guidance according to their compliance.
41453524|NCT03218787|DRUG|DAPT|"3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care."
40936227|NCT01949337|DRUG|prednisone|prednisone 5 mg twice daily, orally
40936228|NCT00260078|DRUG|Atazanavir|200 mg to 400 mg orally daily
40936229|NCT00260078|DRUG|Darunavir|300 mg or 600 mg orally twice daily
40936230|NCT00260078|DRUG|Efavirenz|Dosage dependent on participant
40936231|NCT00260078|DRUG|Nevirapine|Dosage dependent on participant
40936232|NCT00260078|DRUG|Ritonavir|50 mg or 100 mg orally twice daily
40936233|NCT00260078|DRUG|Tenofovir disoproxil fumarate|300 mg orally daily
40936234|NCT00260078|PROCEDURE|Pharmacokinetic Study|Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
40936235|NCT01007253|DRUG|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
40936236|NCT01007253|DRUG|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
40936237|NCT01007253|DRUG|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
40936238|NCT01007253|DRUG|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
40936239|NCT00491426|DRUG|Ampicillin|Drug prescribed per routine medical care.
40936240|NCT00491426|DRUG|Metronidazole|Drug prescribed per routine medical care.
40936241|NCT00491426|DRUG|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
40936242|NCT00491426|DRUG|Acyclovir|Drug prescribed per routine medical care.
40936243|NCT00491426|DRUG|Amphotericin B|Drug prescribed per routine medical care.
40936244|NCT00491426|DRUG|Ambisome|Drug prescribed per routine medical care.
40936245|NCT00491426|DRUG|Anidulafungin|Drug prescribed per routine medical care.
40936246|NCT00491426|DRUG|Caspofungin|Drug prescribed per routine medical care.
40936247|NCT01350518|DIETARY_SUPPLEMENT|Benefiber|"Benefiber® powder will be used as our dietary supplement intervention. Benefiber® powder contains wheat dextrin, a 100% natural fiber. Participants in the intervention arm will receive 3 supplement packets to be consumed per day.~Each active dietary supplement packet contains 8 grams of Benefiber® powder and 3 grams of TRUE® lemon flavoring, a 100% natural with no artificial ingredients or sweeteners, preservatives, sodium or gluten."
40936248|NCT01350518|DIETARY_SUPPLEMENT|TrueLemon|Each placebo dietary supplement packet contains 8 grams of Splenda and 3 grams of TRUE® Lemon sweetener. Each packet is designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid ounces.
40936249|NCT00396448|DRUG|CP-945,598 Treatment B|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
40936250|NCT00396448|DRUG|CP-945,598 Treatment A|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
40936251|NCT00396448|DRUG|Placebo|Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
41130242|NCT05400161|BEHAVIORAL|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. Investigators will organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily and provides feedback to participants. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed and counts of sessions viewed and comments posted. Participants randomized to the intervention will also have the option to take part in a preliminary virtual session through a secure video platform (e.g. BlueJeans) and will receive weekly engagement text messages. Women in the intervention group will be enrolled in the online depression treatment program, MoodGym.
40936252|NCT04385407|DRUG|Sofosbuvir + Simeprevir + Ribavirin|
40936253|NCT02586402|DRUG|pegol-Sihematide|
40936254|NCT02586402|DRUG|Epoetin Alfa|
40936255|NCT02610959|OTHER|Intervention group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
40936256|NCT02610959|OTHER|Control group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
40936257|NCT01554969|DRUG|capecitabine + ganetespib|"Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily."
40936258|NCT05920915|OTHER|non-interventional clinical research|This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain
40936259|NCT03262402|PROCEDURE|Basic periodontal treatment|Basic periodontal treatment consists of scaling and root planing performed with manual curettes or ultrasonic instruments.
40936260|NCT03320603|OTHER|Expert eCRF|An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.
40936261|NCT03320603|OTHER|Prothrombin Complex Concentrate|Prothrombin Complex Concentrate given as standard of care
40936262|NCT00728767|OTHER|Brief intervention|"The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.~The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.~The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.~Employees had been instructed to ask these questions during the intervention: What are you already doing to restrain your drinking? And What can you do more?"
40936263|NCT00728767|OTHER|Control group|The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
40936264|NCT04124718|GENETIC|high caries experience|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
40936265|NCT06422273|DRUG|Tranexamic Acid|Endobronchial (topical) tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients
40936266|NCT06422273|OTHER|Saline (placebo)|Topical Saline (placebo) administered as endobronchial topical application prior to performing transbronchial biopsies in lung transplant recipients.
40936267|NCT00002664|BIOLOGICAL|edrecolomab|
40936268|NCT00002664|BIOLOGICAL|sargramostim|
40936269|NCT06488105|DRUG|Statin (rosuvastatin 10 or 40 mg daily, depending on risk)|moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)
40936270|NCT06488105|BEHAVIORAL|Healthy Lifestyle Counseling|Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework
40936271|NCT06488105|OTHER|Outpatient Followup|Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral
40936272|NCT05702853|DRUG|Cyclophosphamide injection|500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
40936273|NCT05702853|DRUG|Fludarabine Injection|30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
41279950|NCT01620125|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
41279951|NCT03038022|DRUG|MGL-3196|Oral
41279952|NCT03038022|DRUG|Placebo|Oral
41453525|NCT02195401|OTHER|Cleanroom|Cleanroom with air the quality of the pre-industrial age
40936274|NCT05702853|BIOLOGICAL|CD19-CD34t metabolically programmed CAR transduced T-cells|Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping
40936275|NCT02598570|DRUG|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
40936276|NCT06071936|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
40936277|NCT06071936|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
40936278|NCT00633620|DEVICE|Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)|colonoscopy withdrawal with NBI mode
40936279|NCT04441866|DIAGNOSTIC_TEST|Automated algorithms|Automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
40936280|NCT04441866|DIAGNOSTIC_TEST|Standard technique|Standard ultrasound examination without use of automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
40936281|NCT02317783|DRUG|[18F]Flutemetamol|Brain scan with imaging tracer that binds to amyloid plaques
40936282|NCT02317783|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
40936283|NCT02317783|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Brain scan to assess regions of abnormal volume and density
40936284|NCT00879931|DRUG|Methylprednisolone|Methylprednisolone
40936285|NCT00879931|DRUG|Placebo|Placebo (NaCl 0.9%)
40936286|NCT03919877|OTHER|Dietary|Dietary counseling based on results of CGM analyses.
40936287|NCT00810927|PROCEDURE|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
41279953|NCT02234037|DRUG|Decitabine|Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
40936288|NCT00810927|PROCEDURE|Laser Doppler flowmetry|Measurement of choroidal blood flow
40936289|NCT00810927|PROCEDURE|Measurement of intraocular pressure|
40936290|NCT03332550|PROCEDURE|Laparoscopic lavage|Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3
40936291|NCT03332550|PROCEDURE|Colon resection|Operation with colon resection for perforated diverticulitis Hinchey 4
41279954|NCT02234037|BEHAVIORAL|Exercise|Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise \> 10 minutes of muscle strengthening, \> 10 minutes of aerobic exercise (treadmill walking or cycling), \> 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
41279955|NCT05634603|DIETARY_SUPPLEMENT|Lactose-free milk formula (Frisolac LF ®)|Following the initial rehydration phase, children were alternately assigned to receive 100 ml/kg/day of either lactose-free or lactose-containing formula
41279956|NCT00082082|DRUG|Thymalfasin (thymosin alpha-1)|
40936292|NCT00000523|BEHAVIORAL|exercise|
41279957|NCT00082082|PROCEDURE|Trans arterial chemoembolization (TACE)|
41279958|NCT00444184|DRUG|Travoprost/timolol fixed combination, travoprost|
40936293|NCT05969418|DIAGNOSTIC_TEST|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment
40936294|NCT01834482|DIETARY_SUPPLEMENT|Modified Atkins diet|Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
40936295|NCT01834482|DIETARY_SUPPLEMENT|KetoCal|Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
40936296|NCT03649867|OTHER|Semi-structured interviews|Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
40936297|NCT06265480|OTHER|FallFitness intervention group|Eight week group-based fallprevention intervention. A total of eight session (1-hour once a week).
40936298|NCT05952076|DIETARY_SUPPLEMENT|B. infantis Bi-26|A once-daily oral dose of Bi-26 will be provided to infants for 28 days.
41279959|NCT03698734|DRUG|Evening primrose oil(EPO)|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of EPO( 1000mg) in addition to misopristol
41279960|NCT03698734|DRUG|Placebo - Cap|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
41453526|NCT02979132|DRUG|Eisensulfat LOMAPHARM 50 mg|oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
40936299|NCT05952076|DIETARY_SUPPLEMENT|Placebo|A once-daily oral dose of placebo maltodextrin will be provided to infants for 28 days
40936300|NCT04485429|DRUG|Methylprednisolone|Methylprednisolone 0.5 mg/kg every 12 hours intravenously for the first 14 days; followed by 0.5 mg/kg/day from day 15 to day 21; followed by 0.25mg/kg/day from day 22 to day 25; followed by 0.125 mg/kg/day, from day 26 to day 28 of treatment.
40936301|NCT04485429|DRUG|Heparin|Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.
40936302|NCT02309463|DRUG|Endothelin receptor antagonist therapy|
40936303|NCT04099771|DRUG|Ketamine|Ketamine infusion
41453527|NCT02979132|DRUG|Ferinject(R)|Single-dose Ferinject(R) administration
41453528|NCT02979132|DIETARY_SUPPLEMENT|iron fortified biscuits|consumption of an iron-fortfied biscuit every morning for 90 days
41453529|NCT02083809|DRUG|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
41453530|NCT02083809|DRUG|Intravenous Fluids and Electrolytes|500 ml of inert IV fluid
40936304|NCT01622127|DEVICE|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
41453531|NCT01235260|OTHER|Becaplermin nonusers|A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
40936305|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT)."
40936306|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
40936307|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
40936308|NCT01856764|DRUG|0.5% Roflumilast Cream|Roflumilast 0.5% cream
40936309|NCT01856764|DRUG|Vehicle Cream|Roflumilast formulation vehicle
40936310|NCT01729247|DEVICE|NIOX MINO® Instrument (09-1100)|
40936311|NCT04421807|OTHER|Scapulatoracic stabilization exercises|Scapulatoracic stabilization exercises consisted of 3 phases; the warming phase which consists of mobility and stretching; exercise phase consisting of static, dynamic and functional phase; the cooling phase consisting of mobility and stretching. Scapulatoracic stabilization exercises additionally applied to CDT were performed 3 days a week for 8 weeks. These exercises were specially planned for the patients and applied gradually
40936312|NCT04421807|OTHER|Complex decongestive therapy (CDT)|In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.
40936313|NCT03642093|COMBINATION_PRODUCT|Nutritional Intervention|Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency
40936314|NCT03642093|BEHAVIORAL|Physical Activity Intervention|Walking and Inspiratory Muscle Training
40936315|NCT00117286|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
40936316|NCT04507854|OTHER|Strength, range of motion and functional tests + Questionnaire|Patients undergoing instability surgery will perform amplitude, strength, functional tests and a questionnaire at 6 months of the operation. Then they will be contacted at 12, 18 and 24 months to find out if they have regained their performance level or if they have injured their shoulder again.
40936317|NCT05908318|BEHAVIORAL|olfactory training|In this group, patients were performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
40936318|NCT02503345|DRUG|ALLN-177 low dose|ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
40936319|NCT02503345|DRUG|ALLN-177 mid dose|ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
40936320|NCT02503345|DRUG|ALLN-177 high dose|ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
40936321|NCT02503345|DRUG|Placebo|Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
40936322|NCT03927599|OTHER|Data Collection|Colleciton of data from medical records only
40936323|NCT05295797|BEHAVIORAL|Dance Program|Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
40936324|NCT02217540|OTHER|Standard protocol|Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
41130243|NCT03185936|PROCEDURE|pars plana vitrectomy with internal limiting membrane (ILM) peeling|pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.
41130244|NCT04631445|OTHER|Ketogenic Diet|Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to \< 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).
41453532|NCT01235260|DRUG|Becaplermin users|A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
41453533|NCT00272441|DRUG|inhaled corticosteroids|
41453534|NCT01942135|DRUG|Palbociclib|Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
41450138|NCT05702905|BEHAVIORAL|physical exercise|All subjects after randomization will be reviewed and evaluated by a trainer, and then will receive guidance of physical exercise.The trainer will formulate an exercise plan for each subject. The exercise plan consists of 30 minutes of moderate and low intensity continuous aerobic exercise every day, with a frequency of 5-7 days/week. The form of exercise can be determined according to personal hobbies, such as fast walking, jogging, climbing, swimming, etc. The exercise diary will be distributed to each subject, and the subjects are required to make a return visit once every four weeks, return the exercise diary each time, and the trainer will provide guidance to the subjects according to their compliance.
41453535|NCT01942135|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
41453536|NCT01942135|DRUG|Placebo|Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
40936325|NCT02217540|OTHER|Mulligan Concept Mobilisation with Movement|The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
40936326|NCT04995796|OTHER|Surveys for Research Purposes|"VISIT #1:~1. Pre-Testing:~   * Pre Knowledge Test~  * Pre SURE (decisional conflict) test~2. Independent DSI/DA Interaction~3. Post-Testing:~   * Post Knowledge Test~  * Post SURE (decisional conflict) Test~  * Acceptability Index~  * Modified Single Item Literacy Screen~  * Additional Demographics~VISIT #2: Check-In Call 1 week later:~After viewing the DSI/DA and completing the post-test components above, the subjects will also complete a 5 minute debrief interview about 1 week later via phone or video conference with a team member to give feedback on their experience using the DSI/DA, including its strengths and weaknesses. This will allow for further improvement and refinement of the DSI."
40936327|NCT03115580|DEVICE|Rotational atherectomy|"Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect."
40936328|NCT03115580|DEVICE|Cutting Balloon Angioplasty|Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
40936329|NCT04646772|PROCEDURE|Multivisceral resection|Multivisceral resection for locally advanced colon cancer.
40936330|NCT03823378|DRUG|Elsubrutinib|Elsubrutinib capsule will be administered orally.
40936331|NCT03823378|DRUG|Upadacitinib|Upadacitinib tablet will be administered orally.
40936332|NCT03823378|DRUG|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
40936333|NCT03823378|DRUG|Placebo for upadacitinib|Upadacitinib placebo tablet will be administered orally.
40936334|NCT01936727|PROCEDURE|cataract surgery|
40936335|NCT03370289|BIOLOGICAL|BLB-750 Vaccine (Qinghai RG strain)|BLB-750 Injection
40936336|NCT03665415|BEHAVIORAL|NDGameSquad|The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
40936337|NCT02637128|DRUG|artemether-lumefantrine (AL)|Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
40936338|NCT02637128|DRUG|artesunate-amodiaquine (ASAQ)|Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
40936339|NCT03636737|OTHER|pathology associated|list of pathology associated to Pyoderma gangrenosum
40936340|NCT05984849|BEHAVIORAL|vaccination games|Brief health games to promote two different vaccines among youth
40936341|NCT00312637|PROCEDURE|Magnetic Resonance Spectroscopy|
40936342|NCT03734744|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health
40936343|NCT05402020|DRUG|Tiotropium (Tio)|Tiotropium (Tio)
40936344|NCT05402020|DRUG|Inhaled corticosteroids (ICS)|Inhaled corticosteroids (ICS)
40936345|NCT05402020|DRUG|Olodaterol (Olo)|Olodaterol (Olo)
40936346|NCT05402020|DRUG|Long-acting β2-agonists (LABA)|Long-acting β2-agonists (LABA)
40936347|NCT04812080|DEVICE|EXPLORER PET/CT|FDG PET Scans on the total body EXPLORER PET/CT scanner
40936348|NCT02912988|DRUG|Letrozole|Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.
40936349|NCT02337348|OTHER|Optical coherence tomography|Preintervention imaging
40936350|NCT02337348|RADIATION|Coronary angiography|Conventional coronary intervention
40936351|NCT04864080|BEHAVIORAL|Computer game/task|N-back, COGED, PacMan game, Bandit task, Websurf task.
40936352|NCT04864080|BEHAVIORAL|Health surveys online|Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
40936353|NCT05463939|DRUG|Teclistamab|Teclistamab will be administered subcutaneously (SC).
40936354|NCT06260527|DRUG|ARTS-011|Single ascending dose (SAD): 3mg, 10mg, 20mg, 40mg, and 60mg. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Food effect study: single dose of ARTS-011 under the fasting and high-fat meal.
40936355|NCT06260527|DRUG|Placebo|Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days.
40755929|NCT05719389|DRUG|CT-P13|CT-P13 is a biosimilar of infliximab approved by EMA since 2015, and it is administered intravenously (i.v.) at a standard dose of 5 mg/kg at week 0, 2, 6 and then every 8 weeks, although the scheduled maintenance regimen can be optimized by administering the drug every 4-6 weeks or increasing the dose up to 10 mg/kg2.The safety profile of CT-P13 SC was comparable to that of CT-P13 i.v.; There were also fewer patients with positive anti-drug antibodies with CT-P13 SC than with CT-P13 i.v.3 At the moment, no data are available on the effectiveness, safety and immunogenicity in a real-world population of patients who have been switched from i.v. to s.c. infliximab.
40755930|NCT01534715|DRUG|IMGN529|
40755931|NCT00122863|DRUG|Duloxetine Hydrochloride|
40755932|NCT00122863|DRUG|placebo|
40755933|NCT01277731|DRUG|Methylprednisolone|Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
40755934|NCT06212739|PROCEDURE|Laser|Diode laser used to effect closure of the anal fistula tract
40755935|NCT06212739|PROCEDURE|LIFT|The intersphincteric portion of the fistula is excised and ligated.
40755936|NCT06067971|DEVICE|Laparoscopic surgery with augmented reality device|Gynecological laparoscopic surgery with augmented reality device.
40755937|NCT02674256|DRUG|CRH|100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute
40755938|NCT02674256|OTHER|Placebo|1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
40755939|NCT04652999|BEHAVIORAL|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot). The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds. The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
40755940|NCT04652999|BEHAVIORAL|Neutral Guided Imagery|This placebo consists on neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, be it positive or negative, which occurred before patient has the current DFU. Then, questions are asked which allow a more detailed reconstruction of the event and the patient is asked to imagine according only to the instructions given. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered in each of the questions given.
40755941|NCT03471286|DRUG|Epacadostat|Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.
40755942|NCT04444297|OTHER|3D Telemedicine|A consultation performed with a 3D form of telemedicine
40755943|NCT04444297|OTHER|2D Telemedicine|A consultation performed with 2D (standard) telemedicine
40755944|NCT00002835|BIOLOGICAL|Bleomycin Sulfate (BLM)|
40936356|NCT06523751|DIAGNOSTIC_TEST|Trabeculopuncture|Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.
40936357|NCT02003339|OTHER|Additional RMIs|
40936358|NCT03894592|OTHER|Virtual reality|Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol
40936359|NCT02037152|BEHAVIORAL|Body scan exercise|"The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions."
40755945|NCT00002835|BIOLOGICAL|Filgrastim (G-CSF)|Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
40755946|NCT00002835|BIOLOGICAL|Recombinant Interferon Alfa|
40936360|NCT02064075|DRUG|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
40936361|NCT02064075|DRUG|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
40936362|NCT00560378|DRUG|Tacrolimus ointment 0.1%|Topical
40936363|NCT02830269|DEVICE|Transcranial Doppler ultrasonography measurements|Third ventricle diameter measurements with standard method (CT) and Transcranial Doppler ultrasonography
40936364|NCT00397566|DRUG|HIV Integrase Inhibitor (BMS-707035)|
40936365|NCT03310320|DRUG|AZD0284 oral solution 2.5 mg/mL|AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
40936366|NCT03310320|DRUG|Placebo|Placebo for AZD0284 oral solution, twice daily for 4 weeks
40755947|NCT00002835|DRUG|Carmustine|Arm 1, Course 3, IV over 1 hour on day -6.
41130245|NCT04694066|BEHAVIORAL|Qigong|Qigong Baduanjin, comprising eight standardized movements, will be adopted in the study. It is practiced as a combination of body movements, breath control, and mindful meditation.
41453537|NCT01942135|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
40755948|NCT00002835|DRUG|Cisplatin (CDDP)|
40755949|NCT00002835|DRUG|Cyclophosphamide|
40755950|NCT00002835|DRUG|Cytarabine (ARA-C)|Arm 1, Course 3, every 12 hours on days -5 to -2.
40755951|NCT00002835|DRUG|Etoposide (VP-16)|Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
40755952|NCT00002835|DRUG|Idarubicin|
40936367|NCT03744000|PROCEDURE|Immediate stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
40936368|NCT03744000|PROCEDURE|Deferred stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 3 to 7 days after TIMI Ⅲ flow has achieved.
40936369|NCT06271499|OTHER|Radial artery catheterization with USG|Radial artery catheterization with USG The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with the high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
40936370|NCT06271499|OTHER|Radial artery catheterization with smart glasses integrated UGG|The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). Before the study, as practitioners had no previous experience with smart glasses, they performed 5 catheterizations with smart glasses integrated USG on model. The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with smart glasses integrated high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
40936371|NCT00079131|BIOLOGICAL|oblimersen sodium|Given IV
40936372|NCT00079131|OTHER|pharmacological study|Correlative studies
40936373|NCT00079131|OTHER|laboratory biomarker analysis|Correlative studies
40936374|NCT00728078|DRUG|thalidomide|thalidomide 50mg tid for 6 months
40936375|NCT01599832|DRUG|pazopanib hydrochloride|Given PO
40936376|NCT01599832|OTHER|laboratory biomarker analysis|Correlative studies
40936377|NCT01599832|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo dynamic contrast-enhanced magnetic resonance imaging
40936378|NCT01599832|OTHER|pharmacogenomic studies|Correlative studies
40936379|NCT05009082|DRUG|Carboplatin|Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
40936380|NCT05009082|DRUG|Paclitaxel|175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
40936381|NCT05009082|DRUG|Bevacizumab|7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year
40936382|NCT05009082|DRUG|Niraparib|200 or 300 mg capsules once daily for up to a total of 3 years
40936383|NCT05606146|DEVICE|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
40936384|NCT01082380|DRUG|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066
40936385|NCT01179035|OTHER|Transitions Clinic - parolee-targeted care|Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
40936386|NCT01179035|OTHER|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
40936387|NCT03953118|DRUG|Azithromycin Oral Product|Oral azithromycin dosed at 1 gram per week for 3 weeks
40936388|NCT03953118|DRUG|Placebo Oral|Oral placebo tablet
41450139|NCT04870333|DRUG|Niclosamide|140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
40755953|NCT00002835|DRUG|Ifosfamide|During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
40755954|NCT00002835|DRUG|Leucovorin Calcium|
40936389|NCT00982696|BIOLOGICAL|Opioid Growth Factor|250ug per kilogram weekly IV infusions
41130246|NCT04694066|BEHAVIORAL|Light flexibility exercise|The supervised sessions will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
41130247|NCT01939691|DRUG|Difluprednate|Difluprednate 0.05% - corticosteroid eyedrop
41130248|NCT01939691|DRUG|Nepafenac|Nepafenac 0.1% - NSAID eyedrop
41130249|NCT01939691|DRUG|Prednisolone acetate|prednisolone acetate 1% - corticosteroid eyedrop
41450140|NCT04870333|DRUG|Placebo|140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
40755955|NCT00002835|DRUG|Melphalan|
40755956|NCT00002835|DRUG|Methotrexate|
40755957|NCT00002835|DRUG|Methylprednisolone|
40755958|NCT00002835|DRUG|mitoxantrone hydrochloride (DHAD)|Arm 1, Course 2, IV on day 1.
40755959|NCT00002835|DRUG|Vincristine Sulfate|
41450141|NCT04870333|DRUG|Ciclesonide|"Participants will be prescribed ciclesonide once daily, administered as follows:~Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
40936390|NCT06447493|OTHER|Osteopathic Manipulative Treatment-Spencer's Technique (Modified)|Combination OMT approach utilizing Muscle Energy Technique (MET), Articulatory Technique (ART), and Myofascial Release (MFR). It is a series of direct OMT addressing the barrier of somatic dysfunction (SD) with the goal of restoring neurovascular balance and improved motion of the shoulder girdle and glenohumeral joint. Utilizing these three OMT techniques, the practitioner attempts restoration of glenohumeral joint motion using shoulder extension, flexion, circumduction with compression, circumduction with distraction, abduction, adduction, external rotation, internal rotation, and distraction in abduction. The study uses a modified version of the Spencer technique, done in the seated position for patient comfort, as well as adding to the treatment sequence: latissimus dorsi, pectoralis minor-major, serratus anterior, and rhomboid major-minor. Adding these muscles into treatment will help to address and correct sternoclavicular joint SD, acromioclavicular joint SD, and scapular SD.
40936391|NCT06447493|OTHER|Rest|10 minute rest period.
40936392|NCT01683227|BEHAVIORAL|Screening/motivational drug intervention|Screening and brief motivational intervention delivered in the ER to reduce drug use
40936393|NCT01683227|BEHAVIORAL|Motivational placebo intervention|Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
40936394|NCT02142114|DEVICE|Eye injection by 30 or 32 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
40936395|NCT06468969|OTHER|Enhanced Follow-up|"Participants will receive comprehensive follow-up care starting from the 4th week post-surgery. Every 3 weeks, they will undergo a thorough assessment that includes:~Symptom Assessment Nutritional Assessment (using NRS 2002 and PG-SGA) Psychological Assessment (using DT, GAD-7, FCR-7, ISI, PHQ-9)"
40936396|NCT00289718|BIOLOGICAL|Twinrix™ adult|Intramuscular administration
40936397|NCT03972930|RADIATION|Hypofractionated Radiotherapy|Hypofractionated radiation is delivered using highly conformal technique, allowing for a high dose of radiation to be delivered precisely.
40936398|NCT03663153|OTHER|SEMA4C high value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
40936399|NCT03663153|OTHER|SEMA4C low value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
40936400|NCT06476964|PROCEDURE|skin biopsies|Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin
40936401|NCT04417543|DRUG|Memantine Hydrochloride|Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
40936402|NCT04417543|DRUG|Placebo|Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
40936403|NCT01182779|RADIATION|Carbon ion|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
40936404|NCT01182779|RADIATION|Protons|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
40936405|NCT00843726|RADIATION|Arm 1 stereotactic body radiation therapy|Patients undergo 1 high-dose fraction
40936406|NCT00843726|RADIATION|Arm II stereotactic body radiation therapy|Patients undergo 3 high-dose fractions
40936407|NCT05123599|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
40936408|NCT05123599|BIOLOGICAL|JNJ-64300535|JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.
40936409|NCT05123599|DRUG|ETV monohydrate|ETV monohydrate film-coated tablets will be administered orally.
40936410|NCT05123599|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
40936411|NCT05123599|DRUG|TAF|TAF film-coated tablets will be administered orally.
40936412|NCT05043285|BIOLOGICAL|SCTV01C|intramuscular injection
40936413|NCT05043285|OTHER|Placebo|Intramuscular injection
41450142|NCT04870333|DRUG|Placebo|"Matched placebo: two puffs inhaled via mouth sequentially and one puff inhaled via nose.~Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
40936414|NCT04869020|DEVICE|Otoband|Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.
41130250|NCT00293761|DRUG|Travoprost, Investigational|One drop in study eye once daily for 13 days
41450143|NCT04870333|DRUG|Sotrovimab|"There will be a single infusion of sotrovimab administered at the beginning of the study.~500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter. Four vials will be required for a 2000 mg dose."
41450144|NCT04870333|DRUG|Placebo|There will be a single infusion placebo, in the form of 100mL 0.9% sodium chloride, administered at the beginning of the study.
40755960|NCT00002835|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
40936415|NCT04869020|DEVICE|Sham A|Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.
40936416|NCT04869020|DEVICE|Sham B|Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.
40936418|NCT01825954|DEVICE|RINCE|The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
40936419|NCT00455910|DRUG|Thalidomide|
40936420|NCT05715879|DIAGNOSTIC_TEST|covid infection|patients with covid infection which was proved with positive test
40936421|NCT05715879|BIOLOGICAL|admission to hispital|patients with sever covid disease, who was admitted in hospital
40936422|NCT01927302|BEHAVIORAL|Treatment Focusing on Naming Objects|Treatment will be administered from week 0 until week 12.
40936423|NCT01927302|BEHAVIORAL|Treatment Focusing on Improving Spelling Abilities|Treatment will be administered from week 0 until week 12.
40936424|NCT01927302|BEHAVIORAL|Treatment Focusing on Improving Sentence Processing|Treatment will be administered from week 0 until week 12.
40936425|NCT01927302|BEHAVIORAL|No Treatment|No treatment will be administered.
40936426|NCT01812590|BEHAVIORAL|Exercise|
40936427|NCT05469685|DRUG|Vonoprazan|Potassium-competitive acid blocker
40936428|NCT05469685|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
40936429|NCT03512015|OTHER|The Lung Cancer App - LuCApp|The Intervention Arm receiving LuCApp (The Lung Cancer App) in addition to standard care
40936430|NCT03512015|OTHER|Standard care|The Standard-of-Care patients receiving following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
40936431|NCT02374047|DRUG|CAT-2054|
40936432|NCT02374047|DRUG|Placebo|
40936433|NCT02374047|DRUG|CAT-2054-C|
40936434|NCT02374047|DRUG|Atorvastatin|
40936435|NCT01739855|DRUG|Calciferol, calcium carbonate|
40936436|NCT03673410|PROCEDURE|Robotic bariatric surgery - revisional|Using robotic techniques during any revesional bariatric surgery
40936437|NCT03673410|PROCEDURE|Laparoscopic bariatric surgery - revisional|Using laparoscopic techniques during any revesional bariatric surgery
40936438|NCT02142985|DRUG|Sodium Chloride 0.9% Intravenous|vascular filling with 500 ml of crystalloid solution (sodium chloride 0.9%) over 30 minutes
40936439|NCT00453388|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
40936440|NCT00453388|DRUG|Cyclophosphamide|Given IV
41450145|NCT03324139|DRUG|Low molecular weight heparin|Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
40936441|NCT00453388|DRUG|Cyclosporine|Given IV or PO
40936442|NCT00453388|DRUG|Fludarabine Phosphate|Given IV
40936443|NCT00453388|OTHER|Laboratory Biomarker Analysis|Correlative studies
40936444|NCT00453388|DRUG|Mycophenolate Mofetil|Given PO
40936445|NCT00453388|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
41450146|NCT03324139|DRUG|Placebos|Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
40755961|NCT00002835|RADIATION|Radiation Therapy|
40755962|NCT01707446|DEVICE|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)|In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
40936446|NCT00453388|RADIATION|Total-Body Irradiation|Undergo TBI
40936447|NCT04746742|PROCEDURE|Tunneled Femoral Catheter (TFC) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
40936448|NCT04746742|PROCEDURE|Femoro-femoral Arteriovenous graft (FF-AVG) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
40936449|NCT01247181|OTHER|Mobile phone text message|Weekly message with motivational content
40936450|NCT01247181|OTHER|Usual care|Usual care provided at clinic
41130251|NCT00293761|DRUG|Travoprost (TRAVATAN)|One drop in study eye once daily for 13 days
41130252|NCT04527094|DIAGNOSTIC_TEST|Prediction of postoperative respiratory failure using a machine learning|The performance of a machine learning model to predict postoperative respiratory failure after general anesthesia within postoperative day 7 was tested prospectively.
41450147|NCT04210947|OTHER|30 rolls per minute(30RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 2 secs. Then comeback from insertion to origin with 2 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
41450148|NCT04210947|OTHER|15 rolls per minute(15RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 4 secs. Then comeback from insertion to origin with 4 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
41450149|NCT04210947|OTHER|self-determined|Participants will start using foam roller from muscle origin to insertion with self determined-speed. Then comeback from insertion to origin with same pace. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
41450150|NCT04474405|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), single dose
41450151|NCT04474405|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).
41130253|NCT06509412|DEVICE|LANAP surgical protocol using ND:YAG 1064 laser|A free running pulsed, 1064 nm wavelength-specific ND:YAG laser (Light walker AT)\* with an attached 320 µm diameter optical glass fiber attached to a metallic hand piece with a flexible tip, which will be set at 3:4 -watt average power, 20 HZ, and a 100-600 µs pulse duration
41450152|NCT04474405|PROCEDURE|Whole body PET scan|positron emission tomography (PET) scan of the body from the vertex of the head to the thighs starting immediately following injection and repeated over 6 hours
41450153|NCT04474405|DRUG|Florbetapir F 18|IV injection, 370 MBq (10 mCi), single dose
41450154|NCT04474405|PROCEDURE|Brain MRI|Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain
41450155|NCT02153203|BEHAVIORAL|Prevent-Teach-Reinforce Model|Implementation of the model once to twice per week over a period of 8 weeks
41450156|NCT02153203|OTHER|Individual Parent Training Session|One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
40936451|NCT05956184|DEVICE|Intrauterine Device Insertion|All womens will be placed in a gynecological position and underwent a bimanual examination to better determine whether the uterus was in the anteverted or retroverted position. Subsequently, a speculum will be inserted, and the cervix will be disinfected with betadine. In the conventional method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and after entering the uterine cavity with a hysterometry the IUD is inserted. In the direct method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and without using hysterometry the IUD is directly inserted. The strings will be cut approximately 2-3 cm after the cervix, and the Pozzi forceps and speculum will be removed. The accuracy of the IUD placement will be confirmed using pelvic ultrasound. The process will take about five minutes.
40936452|NCT04063098|OTHER|Oral glucose tolerance test|Oral glucose tolerance test (OGTT) after a 72-hours standardized diet. OGTT will be performed 1 month prior to as well as 1, 3, 6, and 12 months after endoscopic sleeve gastroplasty
40936453|NCT05156476|PROCEDURE|Genicular nerve block-iPACK group|Group 1: Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
40936454|NCT05156476|PROCEDURE|Femoral triangle block-iPACK group|Group 2: Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
40936455|NCT05156476|PROCEDURE|Local infiltration analgesia|Group 3: LIA (performed by surgeon) Method: Blind injection Drug: a total of 200ml of 0.2% ropivacaine will be used (400mg). Of this, 150ml of ropivacaine 0.2% will be mixed with 1mg of adrenaline.
40936456|NCT03412071|DRUG|Oral Tinidazole|Please see description under arms
40936457|NCT03412071|DRUG|Topical metronidazole|Please see description under arms
40936458|NCT03412071|DRUG|Topical Clindamycin|Please see description under arms
40936459|NCT03412071|DRUG|Topical Hydrogen Peroxide|Please see description under arms
40936460|NCT00048711|DRUG|N-acetylgalactosamine 4-sulfatase|
40936461|NCT00259675|DRUG|carboplatin/gemcitabine, carboplatin/taxol|
41279961|NCT00608140|PROCEDURE|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
40936462|NCT02599675|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
41279962|NCT00608140|DRUG|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
40936463|NCT02599675|DIETARY_SUPPLEMENT|Placebo|Olive oil, encapsuled
40936464|NCT01249118|DRUG|GDC-0973 IV Infusion|IV infusion.
40936465|NCT01249118|DRUG|GDC-0973 Oral Capsules|Oral dose.
40936466|NCT02428985|DRUG|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information
40936467|NCT05050682|DRUG|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
40936468|NCT04266938|BEHAVIORAL|Rapid start of antiretrovirals|Utilize health navigators to link patients with newly diagnosed HIV into care and treatment within 7 days
41130254|NCT06509412|DEVICE|LANAP surgical protocol using diode 940 laser|Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm was attached with a power average set at 0.5-1 watt, in continuous mode, and 20 HZ
41130255|NCT06509412|PROCEDURE|Scaling and root planing (SRP)|Scaling and root planing (SRP) using ultrasonic device (Woodpecker USD-P Led Ultrasonic Scaler Ende) at moderate setting and with appropriate tips and also hand curettes will be used for root planning.
41450157|NCT01354886|DRUG|FSH-GEX™|single dose
41450158|NCT01354886|DRUG|Gonal-f|150 IU single dose
41450159|NCT01354886|DRUG|Bravelle|150 IU single dose
40936469|NCT04266938|BEHAVIORAL|Retrospective analysis|Review historical standard of care relative to time to start antiretrovirals and impact on retention in care.
40936470|NCT04266938|BEHAVIORAL|Non- RAPID start|Review of patients who failed to establish care and start ART within 7 days of HIV diagnosis and analyze impact on retention in care.
40936471|NCT02125643|DRUG|Caffeine|
41450160|NCT01354886|DRUG|Placebo|single dose
41450161|NCT06154096|OTHER|Acute glucagon infusion|All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
41450162|NCT05201235|DEVICE|MAEVAD|"MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into le Royaume d'Adelia, a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character."
41453538|NCT00263458|OTHER|Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting|Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
40936472|NCT02125643|OTHER|Flour|Flour will be administered as the placebo.
40936473|NCT03373799|OTHER|Video-Based Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. A video record was made by the physiotherapist to a patient where each exercise was described in detail and the patient correctly performed the exercises according to the verbal and visual commands of the physiotherapist. This video record watched by the patients who come to the clinic and patients were asked to do the exercises in the video. Patients did the exercises under control of the physiotherapist in the clinic.
40936474|NCT03373799|OTHER|Physiotherapist-Supervised Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. Program was carried out by teaching the same exercises individually by the physiotherapist.
40936475|NCT00320723|DRUG|bupropion, transdermal nicotine patch|
40936476|NCT01486485|DRUG|heparinized saline priming group|
40936477|NCT01486485|DRUG|nafamostat infusion after heparinized saline priming|
40936478|NCT02985970|OTHER|questionnaire|The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
40936479|NCT03252184|DEVICE|Low level laser therapy - 1|In the phase 1, the low level laser therapy will be performed with the Fluence device (HTM, Brasil) and the probe from the same manufacturer. For the interventions in groups G1, G2 and G3 (photobiomodulation) will be used, respectively, the energy doses of 18J, 36J and 54J. A 658nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
40936480|NCT03252184|DEVICE|Low level laser therapy - 2|In the phase 2, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Group 3 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
40936481|NCT03252184|DEVICE|Low level laser therapy - 3|In the phase 3, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
40936482|NCT01563146|OTHER|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
40936483|NCT02404532|DEVICE|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
40936484|NCT03845465|BEHAVIORAL|Positive Affect + Education|Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.
40936485|NCT03845465|BEHAVIORAL|Education|Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
41130256|NCT02531841|DRUG|Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|"Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~* Rituximab 375 mg/m²/d i.v. (d0)~* Dexamethasone 40 mg/d i.v. (d1-3)~* Etoposide 100 mg/m²/d i.v. (d1-3)~* Ifosfamide 1500 mg/m²/d i.v. (d1-3)~* Carboplatin 300 mg/m² i.v. (d1)"
40936486|NCT05090358|DIETARY_SUPPLEMENT|Ketogenic Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
40936487|NCT05090358|DIETARY_SUPPLEMENT|Low Carbohydrate Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
40936488|NCT05090358|DRUG|Alpelisib|The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
40936489|NCT05090358|DRUG|Fulvestrant|"The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter."
40936490|NCT05090358|DRUG|Canagliflozin|Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
40936491|NCT05570201|OTHER|Control group|No intervention was applied to the women in the control group, only the questionnaires (pre-test, post-test) were filled out. Filling the questionnaires lasted 10-15 minutes on average in all groups
40936492|NCT02808091|DRUG|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for 4 cycles
40936493|NCT02808091|DRUG|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
40936494|NCT02808091|RADIATION|IMRT|a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)
40936495|NCT03741127|DRUG|Rimiducid may be administered as indicated|Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
40936496|NCT00470912|DRUG|sunscreen RV 2547C|
40936497|NCT02723578|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
40936498|NCT02723578|DRUG|Erlotinib|Erlotinib 150 mg PO once daily on days 1-21 every 21 days
40936499|NCT02759978|OTHER|diagnostic workup|Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.
40936500|NCT05809739|DEVICE|STYLAGE Hydro|3 sessions of injections (J0, J14 and J28)
40936501|NCT03832075|DIAGNOSTIC_TEST|Berg Balance Scale|Berg Balance Scale is 14 item scale for detecting balance disorder.
41453539|NCT05073523|OTHER|Diet|All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.
40936502|NCT03832075|DIAGNOSTIC_TEST|Timed Up and Go Test|Timed Up and Go Test assesses mobility, balance, walking ability, and fall risk in older adults.
40936503|NCT03832075|DIAGNOSTIC_TEST|Korebalance Balance System|"Korebalance Balance System evaluates the balance and stability using objective neuro-sensory balance assessment. Static Test requires standing steady \& balancing on the platform, keeping the crosshairs of cursor in the center of the test pattern. The Score indicates the deviation of user's center of gravity from the center of the pattern. Dynamic Test offers a moving cursor that the user follows. Four patterns are offered: Circle, Square, Infinity and Random. Each pattern is available in three dimensions: Small, Medium and Large; five speeds; Clockwise and Counterclockwise directions."
41279963|NCT03088501|BEHAVIORAL|Interactive voice response system|IVR allows the pregnant women, their family members to interact with a computer system using a telephone.Through IVR, women receive a 2-3 minute call that reminds them of lab test, their next follow-up visit and also provides information on child care attendance, breastfeeding, introduction of solid foods, motor development, and sleep.
40755963|NCT01707446|OTHER|An alarm threshold at 75% of the baseline rSO2 value|If the threshold of \< 75% from baseline is reached for \> 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
40755964|NCT01289535|PROCEDURE|Blood sample|Blood sample of 7 ml
40755965|NCT00636337|BEHAVIORAL|Attention Training|Computer program training for attention difficulties.
40755966|NCT00636337|BEHAVIORAL|Placebo|Comparison computer program
40936504|NCT06156475|PROCEDURE|Proprioception exercises|Patients trained for proprioception exercises.
41279964|NCT03088501|BEHAVIORAL|Mother and baby affairs workshop|Mother and baby affairs workshop will involve antenatal workshop and counseling for parents. The intervention will involve brief talk by health professionals, quiz activities, role-plays on personal hygiene, nutritional food, institutional delivery, precautions at the time of delivery, caring for the baby, feeding of colostrum, homemade baby food, immunization, and family planning measures.
41279965|NCT01462513|BIOLOGICAL|L-BLP25|Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
41279966|NCT01462513|BIOLOGICAL|Placebo|Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
41279967|NCT04030195|GENETIC|PBCAR20A|"Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied."
40755967|NCT00281853|PROCEDURE|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
41450163|NCT05201235|DEVICE|DeCaLigne|"DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the royaume d'Adelia in order to control the motivational effect of the serious game."
40936505|NCT06156475|PROCEDURE|Proprioception exercises with Electromyographic Biofeedback|Patients trained for Proprioception exercises with Electromyographic Biofeedback
40936506|NCT06156475|PROCEDURE|Wand Exercise|Patients were educated with wand exercises.
40936507|NCT00179127|DRUG|glargine|0.3u/kg of glargine, subcutaneously, once
40936508|NCT00179127|DRUG|saline|0.3u/kg of saline, subcutaneously, once
40936509|NCT03833947|DRUG|lignocaine+bicarbonate|ETT cuff was filled with mixture of 2% lignocaine with bicarbonate
40936510|NCT03833947|DRUG|lignocaine+dexamethasone|ETT cuff was filled with mixture of 2% lignocaine with dexamethasone
40936511|NCT05559333|PROCEDURE|class I restoration placement|zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.
40936512|NCT02177578|DRUG|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
40936513|NCT02177578|RADIATION|Subventricular Zone radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
40936514|NCT02177578|RADIATION|Neural Progenitor Cell Sparing radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
40936515|NCT04448782|DIAGNOSTIC_TEST|Asynchronies detection|Asycnhronies detection
40936516|NCT02530567|PROCEDURE|Intervention|All patients performing the biopsy will have an MRI to carry out the necessary measures.
40936517|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions of 5g/1litter of water, 3drinks a day, daily for 1week (7 days) (current recommendation).
40936518|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions of 5g/500ml of water, 2drinks a day, daily for 1week (7 days) (increase concentration and decrease dose frequency).
40936519|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions,5g/1liter of water, 3drinkss a day, weekly for 4weeks (decrease dose frequency and increase length of treatment).
40936520|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions, 5g/1liter of water, 3drinks a day, daily for1week (7 days) (current treatment with improved taste).
41450164|NCT00002562|DRUG|paclitaxel|
41450165|NCT03896594|DRUG|HL237|Experimental
41450166|NCT03896594|DRUG|Placebo Oral Tablet|placebo with same properties except for active ingredient
41450167|NCT04042415|OTHER|Caloric restriction|Patients will be treated with a diet regimen of mild caloric restriction (15-20% caloric restriction)
40936521|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions, 5g/500ml of water, 2drinks a day, daily for 1 week (7 days) (improved taste, increase concentration and decrease dose frequency).
40936522|NCT05440773|OTHER|Artemisia afra tea infusions|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, weekly for 4weeks (improved taste, decrease dose frequency and increase length of treatment).
40936523|NCT05440773|OTHER|Flavored placebo infusions|Flavored placebo infusions, 5g/liter of water, 3drinks a day, daily for 1week (7 days) (improved taste with no active molecule)
40936524|NCT05440773|OTHER|Regular tea placebo|Regular tea placebo taken as desired, daily for 1 week (7 days) (Regular tea with no active molecule).
40936525|NCT05871996|OTHER|Palliative Care and Oncology Survey on Terminology (POST)|Each group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.
40936526|NCT06110520|DEVICE|Violet Light Lamp|Medical grade lamps with Violet LEDs enabled
40936527|NCT06110520|DEVICE|White Light Lamp|Standard bedside lamp with standard 4000K LED light bulb.
40936528|NCT04291378|RADIATION|Proton versus photon radiation therapy|The intervention is proton radiation therapy versus photon radiation therapy
40936529|NCT02901639|OTHER|counseling|
40936530|NCT04105829|OTHER|Bond-a braid|Stainless steel lingual retainer application
40936531|NCT04105829|OTHER|EverStick-Ortho|Fiber reinforced lingual retainer
41279968|NCT04030195|DRUG|Fludarabine|Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).
40936532|NCT04105829|OTHER|Ribbond|Fiber reinforced lingual retainer
40936533|NCT03954522|OTHER|interview|"Child = A clinical interview (recorded, duration approximately 30 min) and a scale of acute stress (IES child) will be performed at 2 times (during the 7 days following the first visit of hospitalized kin and 1 month after the kin was discharged from ICU)~Accompanying parent/kin = Semi-directive interviews (recorded - duration approximately 30 min) will be performed at the same time as those of the child and will be recorded. The parent/kin will also complete a socio-demographic questionnaire of the family group and a depression anxiety scale (HADS)~Nursing staff = A semi-directive interview (recorded - duration approximately 30 min) will be performed only once (during the 7 days following the first visit to the hospitalized kin). The caregiver will also complete a socio-demographic questionnaire and a Moral Distress Scale (MDS-R)~Hospitalized parent = One month after ICU discharge, a depression anxiety scale (HADS) and an acute stress scale (IES) will be performed"
40936534|NCT06420128|OTHER|Primary care team|Patients whose general practitioner is a member of a primary care team since at least 12 months
41279969|NCT04030195|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
41279970|NCT01740336|DRUG|GDC-0941|GDC-0941 will be administered QD orally for 5 consecutive days each week.
41279971|NCT01740336|DRUG|Placebo|Placebo matching to GDC-0941
40936535|NCT01055496|DRUG|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|"Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total."
40936536|NCT01055496|DRUG|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|"Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total."
40936537|NCT02388282|DEVICE|diaphragm ecography|recording of diaphragm ecography
40936538|NCT04028245|DRUG|Spartalizumab|Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion
40936539|NCT04028245|DRUG|Canakinumab|Canakinumab 300 mg IV Q4 weeks x 2 doses prior to radical nephrectomy Infusion
40936540|NCT03901118|DRUG|chiauranib|in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily
40936541|NCT03901118|DRUG|etoposide|50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most
40936542|NCT03901118|DRUG|paclitaxel|60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most
40936543|NCT03954652|GENETIC|WGS-Diagnostic|Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.
40936544|NCT03494348|DEVICE|Medial Congruent Polyethylene (MC)|One group receives the conventional CR surface and the other the new MC articular surface
40936545|NCT01048281|PROCEDURE|Blood draw|
40936546|NCT01048281|PROCEDURE|Tissue tumor biopsy|
40936547|NCT05611177|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.
40936548|NCT06326970|DIAGNOSTIC_TEST|99mTc-FAPI SPECT imaging|99mTc radionuclide is labeled to a HYINC-FAPI-04 probe as a tracer. SPECT imaging was performed 2 hours after 99mTc-FAPI intravenous injection into the subject, and image processing and quantitative analysis were performed using the Q.Volumetrix MI System software package.
40936549|NCT00712556|RADIATION|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
41279972|NCT01740336|DRUG|Paclitaxel|Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
41279973|NCT01670201|DEVICE|Mepilex Transfer Ag|Silver dressing
41279974|NCT05841472|DRUG|Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin|"* 200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~* Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~* Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles."
41450168|NCT04042415|OTHER|Caloric restriction without cow's milk and gluten|Patients will be treated with mild caloric restriction (15-20% caloric restriction) plus excluding from diet cow's milk, its derivatives and gluten.
40936550|NCT00473746|DRUG|Abiraterone acetate|The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
41450169|NCT06212492|DRUG|NMBAs|Early and systematic use of NMBAs
40936551|NCT00473746|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
40936552|NCT00473746|DRUG|prednisone/prednisolone or dexamethasone|prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
41279975|NCT02224950|DEVICE|Non-medicated Emollient plus Lyocell/Chitosan Sleeve|
41279976|NCT02224950|OTHER|Non-medicated Emollient plus Cotton Sleeve|
41279977|NCT02224950|OTHER|Placebo Sleeve|
41279978|NCT01191593|PROCEDURE|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
41279979|NCT01191593|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
41279980|NCT05239689|BIOLOGICAL|CD38 CAR T-cells|Drug: CD38 CAR T-cells Each subject receive CD38 CAR T-cells by intravenous infusion Other Name: CD38 CAR T-cells injection
41279981|NCT04331301|PROCEDURE|Bipolar Vapo-Enucleation of the prostate|group A: Patient will be subjected to bipolar endoscopic enucleation of the prostate by vaporization electrode (vapoenucleation).
40936553|NCT00331253|PROCEDURE|Indocyanine Green-Mediated Photothrombosis|
40936554|NCT05789394|BIOLOGICAL|Allogeneic Adipose-derived Mesenchymal Stem Cells|Receive IT
40936555|NCT05789394|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
40936556|NCT05789394|PROCEDURE|Craniotomy|Undergo craniotomy
40936557|NCT05789394|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40936558|NCT05789394|PROCEDURE|Ommaya Reservoir Tap|Undergo Ommaya reservoir placement for collection of CSF
40936559|NCT05993182|DRUG|Ephedrine 5mg|Patients received 5mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
40936560|NCT05993182|DRUG|Ephedrine 10mg|Patients received 10mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
41279982|NCT04331301|PROCEDURE|Bipolar Needlescopic Enucleation of the prostate|group B: Patient will be subjected to bipolar endoscopic enucleation of the prostate by hot knife electrode (Needlescopic Enucleation ).
41279983|NCT02786641|DRUG|Docetaxel|Docetaxel 65mg/m2 in induction chemotherapy
41279984|NCT02786641|DRUG|Cisplatin 1|Cisplatin 75mg/m2 in induction chemotherapy
41450170|NCT06212492|OTHER|Prone positioning|Early and systematic use of prone positioning
41450171|NCT06562920|DRUG|adebrelimab and chemotherapy|3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment.
40936561|NCT05993182|DRUG|Ephedrine 15mg|Patients received 15mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
41279985|NCT02786641|DRUG|Xeloda|Xeloda 2000mg/m2 D1-14 in induction chemotherapy
41279986|NCT02786641|RADIATION|IMRT|IMRT for all patients
41279987|NCT02786641|DRUG|Cisplatin 2|Cisplatin 100mg/m2 in concurrent chemotherapy
41279988|NCT01041092|DRUG|raloxifene|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
41279989|NCT06143384|DEVICE|Telemonitoring AirView (ResMed company)|Introduction of AirView telemonitoring of HMV, during a 6-months period.
41279990|NCT01860170|DRUG|Cohort 1-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
41279991|NCT01860170|DRUG|Cohort 2-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
41279992|NCT01860170|DRUG|Cohort 3-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
41279993|NCT02397252|DEVICE|Eve Medical self-collection system©|The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.
41279994|NCT02397252|DEVICE|cobas® PCR Female swab self-sampling|Regular polyester swab for collection of vaginal cells.
41279995|NCT02397252|PROCEDURE|Physician-collected sampling|Routine colposcopy sample collected by a physician.
41279996|NCT06037876|DRUG|IVM (200 µg/kg) + ALB (400 mg)|World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
40936562|NCT03878186|OTHER|Usual Care (UC)|Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt
40936563|NCT03878186|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT): Usual Care + Cognitive-behavioral therapy program intervention (AppraHIV). This intervention involves 7 in-person weekly sessions based on Adjuvant Psychological Therapy centered in three areas: cognitive appraisal, affect and adherence and self-care, everyone with different techniques: cognitive techniques, diaphragmatic breathing, scheduling pleasurable activities, use of pillbox, solving problems, planning for the future, etc. The intervention was manualized (according to Template for Intervention Description and Replication TIDieR), piloted and validated.
40936564|NCT05719727|DIAGNOSTIC_TEST|colonoscopy|lower colonoscopy
40936565|NCT01857310|DIETARY_SUPPLEMENT|5 mg folic acid and 30 mg elemental zinc|
40936566|NCT01857310|DRUG|Placebo Comparator: Placebo|
41279997|NCT06037876|DRUG|ALB (400mg)|Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
41450172|NCT06596889|PROCEDURE|Successful airway management|"* Types of equipment: Traditional oral airways, new airways, etc.~* Professional experience of the airway management practitioner (in years).~* If advanced, type of airway complication (bleeding, dental damage, mucosal damage, etc.), number of attempts~will be recorded separately for each patient."
41450173|NCT03406598|OTHER|Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
41450174|NCT03867071|OTHER|recombinant erythropoietin injection|Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).
40936567|NCT05240586|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
40936568|NCT05240586|PROCEDURE|acupuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and number of acupuncture therapy according to participants' conditions.
40936569|NCT05240586|PROCEDURE|physical therapy, medication(prn)|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
41279998|NCT05135364|DRUG|Camrelizumab|Each infusion is 30 min (not less than 20 min, not more than 60 min), once every 3 weeks
40936570|NCT06383676|OTHER|Functional reaction balance training|The interventions will carried out two days a week and 40 minutes, for eight weeks.
40936571|NCT06383676|OTHER|Functional balance training|The interventions will carried out two days a week and 40 minutes, for eight weeks.
40936572|NCT05675605|DRUG|TY-1091|TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg
40936573|NCT02691962|DEVICE|Xen Matrix AB|Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
40936574|NCT03125291|BEHAVIORAL|Bridges 4-week Program|Participants receive 4, 2-hour sessions over a 6-week period.
41450175|NCT03867071|OTHER|placebo injection|Intravenous injection 0,9% saline solution.
40936575|NCT01514370|DRUG|IFN beta 1a 44 mcg TIW|Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
40936576|NCT01514370|DRUG|Curcumin|Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
40936577|NCT01514370|DRUG|Placebo|Subjects received placebo matched to curcumin orally twice a day for 24 months.
40936578|NCT02878824|OTHER|Ethnicity|"As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek \& Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr \& Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong)."
40936579|NCT02878824|OTHER|Environment|The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray \& Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
40936580|NCT04568343|DEVICE|Capsule endoscopy|We use two capsule endoscopy for evaluation their diagnostic yield. Patient will recieve different capsule endoscopy:The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule
40936581|NCT04235010|DEVICE|Genius toothbrush|Patients brushed their teeth twice a day for 2 minutes. An integral timer was used in the genius toothbrush group.
40936582|NCT04235010|DEVICE|Manual toothbrush|Patients brushed their teeth twice a day for 2 minutes. During brushing, patients in manual group assigned to use their brushes were provided with a digital timer.
40936583|NCT01369654|BEHAVIORAL|Computerized decision aid with 1 type of value clarification|Women will be instructed to view a computerized BSO decision support guide.
40936584|NCT06463678|DRUG|IVIEW-1201|Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
40936585|NCT06463678|DRUG|NATACYN®|Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
40936586|NCT04920227|PROCEDURE|phacoemulsification;|Group A: class combined with phacoemulsification
41279999|NCT05135364|DRUG|HAIC|A chemotherapy regimen perfused through the tumor supplying artery, d1-2 administration, perfused every 4 weeks
41450176|NCT01341951|DRUG|Granulocyte colony stimulating factor|300 I.U twice daily for 5 days
41280000|NCT05135364|DRUG|TKI|Lenvatinib or Regorafenib
41450177|NCT03721718|BIOLOGICAL|GLS-5300|\[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)
40936587|NCT01179997|DEVICE|Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves|
40936588|NCT01179997|DEVICE|Electrocardiographic optimization of the interventricular pacing delay according to QRS width|
40936589|NCT04577352|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
40936590|NCT04577352|DRUG|Placebo|Placebo will be administered per schedule specified in the arm.
40936591|NCT05141825|RADIATION|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
40936592|NCT05110547|BIOLOGICAL|blood collection|2 additional 5ml EDTA tubes, with assays for the following markers: 24S and 27 hydroxycholesterol (gas chromatography-mass spectrometry, GC-MS), Neurofilaments (SIMOA), oxydative phosphorylation (OXPHOS) and quantitative measurement of intracellular ATP (ELISA), Very long chain fatty acids (GC-MS), Octanoyl CoA (HPLC), Uric acid, MDA assay (TBAR assay kit), and Lipid panel.
40936593|NCT00972855|DRUG|Bicalutamide|50 mg Tablet
40936594|NCT00972855|DRUG|Casodex®|50 mg Tablet
40936595|NCT06423417|BEHAVIORAL|LifeHack|See arm description
41280001|NCT00000312|DRUG|M-CPP|
41450178|NCT03721718|DEVICE|Cellectra 2000 Electroporation|GLS-5300 administered ID followed by Cellectra 2000 Electroporation
41450179|NCT05701163|OTHER|Abstinence followed by semen sample collection.|Abstinence is the intervention. Semen samples will be collected after abstinence periods.
41450180|NCT05448209|BEHAVIORAL|walking exercise|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
41450181|NCT05701384|DRUG|Lazertinib|160mg po qd
41450182|NCT02114788|OTHER|Internet-based|
41450183|NCT02889107|OTHER|personal frequency modulated systems|patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
40936596|NCT02398227|BEHAVIORAL|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
40936597|NCT02398227|BEHAVIORAL|PCT|Present Centered Therapy for PTSD
40936598|NCT06087614|RADIATION|DE-HyART|The HSV delineation will be done for patients in arm 3 using baseline FMISO. The HSV will be contoured and adjusted according to the second FMISO scan done between the 4th - the 5th week of radiation treatment. A planning CT will also be repeated at the time for adjusting the HSV to account for temporal changes. The Biological Target Volume thus generated after adequate margins will be prescribed 30 Gy in 10 fractions over and above the standard fractination.
40936599|NCT06087614|RADIATION|Standard Arm|The prescribed radiotherapy dose will be 70 Gy in 2 Gy per fraction daily. The elective volume will be treated with 50 Gy in 2 Gy per fraction daily till the first 5 weeks. The entire treatment will be delivered in a phased mannered using sequential planning.
40936600|NCT06087614|DRUG|Cisplatin injection|Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated
40936601|NCT06087614|RADIATION|Standard fractionation (Radiation Oncology preference)|Standard institutional practice is detailed before starting the patient. Doses 66-70 Gy over 6-7 weeks
41130257|NCT02531841|DRUG|Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)|"4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~* Carmustine\* 400 mg/m² i.v. (d-6)~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)~  \* if carmustine is not available at the investigation site, busulfan can be administered instead:~* Busulfan 3,2 mg/kg/d (d-8-(-7))~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)"
41130258|NCT06112600|PROCEDURE|VR|Virtual reality glasses were used as a distraction method for children during vaccination.
41130259|NCT06112600|PROCEDURE|Kaleidoscope|Kaleidoscope toys were used as a distraction method for children during vaccination.
41130260|NCT00528320|DEVICE|Ovatio CRT|
41130261|NCT05407272|OTHER|Health Education Manual|A health education manual based on a shared model
41130262|NCT05407272|OTHER|manual|routine care
41130263|NCT05017454|DRUG|the optimized sodium valproate-loaded nanospanlastic dispersion|participants will apply the optimized sodium valproate-loaded nanospanlastic dispersion twice daily, on the affected areas of the scalp for 3 months
41130264|NCT05017454|DRUG|mometasone furoate lotion|participants will apply marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
41130265|NCT03513692|DEVICE|Fill-Up composite resin|2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite
41130266|NCT04178213|DEVICE|Implantation of ADAPT 3D ALR|The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.
41130267|NCT06082115|OTHER|Selected Physical and Occupational Therapy Program|"The selected physical and occupational therapy program include:- A-Physical therapy program contains neurodevelopmental technique for U.L \& L.L (U.L \& L.L approximation, U.L \& L.L weight bearing exercises), stretching exercises for U.L \& L.L muscles, strengthening exercises for antispastic group of U.L \& L.L muscles, facilitation of postural reactions, facilitation of gait training and, ascending and descending stairs.~B-Occupational therapy program contains transfer cube from one hand to hand, reaching to mouth (eating lollipop), throwing and catching ball and, clapping with both hands."
41130268|NCT06082115|OTHER|Mirror Therapy|The mirror therapy program include tasks of manipulative and grasping skills that performed by the non-affected hand in-front of mirror while the affected hand behind the mirror. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
40936602|NCT05807633|DEVICE|Novosyn®|Novosyn® for uterus closure in patients undergoing cesarian section
40936603|NCT05522387|DRUG|XPro1595|Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
40936604|NCT06372379|OTHER|no intervention|no intervention
41130269|NCT06082115|OTHER|Task-Oriented Training|The task-oriented training program include tasks of manipulative and grasping skills that performed by the affected hand based on repetition practice. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
40936605|NCT00494845|BEHAVIORAL|Mindfulness|8-week mindfulness program will be compared to an education control group.
40936606|NCT00494845|BEHAVIORAL|Control: Health Education Class|8-week education program
40936607|NCT00129818|DRUG|Famciclovir|
40936608|NCT04983953|DEVICE|cHS|Clinical decision support system for diagnosing intracranial haemorrhage
40936609|NCT05221827|DIAGNOSTIC_TEST|C2i Test|The C2i-Test, a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS)-based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD).
40936610|NCT00957385|DRUG|Revlimid|10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
40936611|NCT06385990|DRUG|UTD1|UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
40936612|NCT04687618|DEVICE|High Flow Nasal Cannula withAutomatic control of FiO2 using OAM|The target oxygen saturation (SpO2) value will to be determined and set by the clinician according to specific patient needs. The target SpO2 in preterm infants is 90-95% with alarm limits at 89-96%. In automatic control of oxygen, the OAM automatically increases or decreases the FiO2 (oxygen delivery) setting on the Vapotherm Precision Flow based on pulse oximetry readings of the OAM. The target saturation will be set at 93% and the FiO2 will be adjusted by OAM to maintain the target saturation. The automated FiO2 setting can be overridden for a clinician pre-set period of time (30-120 sec) by simply manually adjusting the FiO2 on the Precision Flow. Automated control resumes after the clinicians pre-set period of time (30-120 sec) based on the current SpO2 and FiO2. The OAM utilizes a feedback control algorithm that receives a patient's oxygen saturation value from a build in pulse oximetry device (Masimo SET OEM - normal sensitivity, averaging time window set at 8 seconds).
40936613|NCT04687618|DEVICE|High Flow Nasal Cannula with manual control of FiO2|In manual control of oxygen all FiO2 adjustments will be done by the clinical staff to maintain saturations between 90-95%. The alarm limits will be 89-96%.
40936614|NCT02425644|DRUG|ponesimod|film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
40936615|NCT02425644|DRUG|teriflunomide|film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
40936616|NCT05262231|BEHAVIORAL|Online Breastfeeding Education|Breastfeeding education will be announced with a poster on social media. At the same time, mothers will be informed about the training in the institution where the institution permission is obtained. Postpartum period 4-8. A single-blind randomization method will be used per week. Pre-test will be applied to the mothers in the experimental and control groups. After the pre-test, online breastfeeding training will be given to the experimental group. The training consists of a single session. It will take about 40-60 minutes. The content of the training includes the benefits of breastfeeding for the mother, baby and society, breast problems and solutions, causes and solutions of breast rejection, breastfeeding positions, etc. consists of topics. After the training experimental group, the post-test will be applied. At the same time, the post-test will be applied to the control group who did not receive the training.
40936617|NCT00801671|PROCEDURE|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
40936618|NCT00056498|DRUG|Placebo|Placebo capsule daily for 16 weeks
40936619|NCT00056498|DRUG|Risperdal|Risperdal 4 mg per day for 16 weeks
40936620|NCT03504670|PROCEDURE|Early Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed prior to the cervix being dilated 4cm.
40936621|NCT03504670|PROCEDURE|Late Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed once the cervix is at least 4cm dilated.
40936622|NCT03580304|BEHAVIORAL|Industrial work|Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.
40936623|NCT03580304|BEHAVIORAL|Physical load|The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
40936624|NCT03580304|BEHAVIORAL|Cognitive load|The cognitive load of an industrial task will be simulated in this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
41130270|NCT00427440|DRUG|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
41130271|NCT00427440|DRUG|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
40936625|NCT00005851|DRUG|fludarabine phosphate|Given IV
40936626|NCT00005851|RADIATION|total-body irradiation|Undergo TBI
40936627|NCT00005851|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
40936628|NCT00005851|DRUG|cyclosporine|Given PO or IV
40936629|NCT00005851|DRUG|mycophenolate mofetil|Given PO or IV
41130272|NCT06270524|PROCEDURE|Blood sampling|Blood sampling will be taken for further analysis
41130273|NCT02873559|DRUG|testosterone|Testosterone supplemented in 5 months
41130274|NCT02873559|OTHER|Progressive muscle training|Progressive muscle training during 4 months
41130275|NCT04352517|OTHER|Online Survey|Online survey completion through google app.
41130276|NCT00843050|DRUG|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
41130277|NCT04195477|BEHAVIORAL|vDPP|virtual Diabetes Prevention Program
40755968|NCT02416388|DRUG|Idarubicin|"Induction chemotherapy :~Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)~+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
41280002|NCT06404190|COMBINATION_PRODUCT|Diode laser and 3% hydrogen peroxide|"Hydrogen peroxide due to its super radicals has a local antimicrobial effect. Since hydrogen peroxide can be easily available in a clinical setting and is cost-effective. It could be used for photo disinfection along with lasers.~The diode lasers that belong to the 655-980 nm spectrum could represent a safer alternative. Because of the transmission or scattering effect on hydroxyapatite, diode lasers have no effect on hard tissues and deposits. The photoactivation procedure uses photolysis of hydrogen peroxide with 810nm laser.~Hydrogen peroxide acts as an endogenous dye, which can increase the laser effect at this level and also generate ROS. Thus the combination of 3% H2O2 and laser light generate hydroxyl radicals as a result of photoactivation.~Therefore, the diode laser stimulation of 3%hydrogen peroxide has been utilized adjunctive to SRP to optimize clinical outcomes."
41280003|NCT06457126|BEHAVIORAL|Attention Training Technique|"Phase 1: Non-concurrent multiple baseline design A-B design where the ATT (B) is introduced sequentially across participants. ATT and baseline (A) will be alternated on a weekly basis.~Phase 2: Alternating treatment design where an active (B) and passive (C) version of the ATT are rapidly and frequently alternative within the same participant on a weekly basis (e.g., A-B-A-C-A or A-C-A-B-A)."
41280004|NCT03025412|PROCEDURE|endoscopic surgery|Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
41280005|NCT03025412|BEHAVIORAL|physiotherapy and exercise|Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
41280006|NCT03427073|DRUG|ALM201|Drug: ALM201 administered subcutaneously
41280007|NCT00528229|RADIATION|Computer Tomography|
41280008|NCT05280561|DIETARY_SUPPLEMENT|DHM|DHM is a positive modulator of GABA. We hypothesize the DHM could reduce stress/anxiety induced insomnia during the pandemic
41280009|NCT05280561|DIETARY_SUPPLEMENT|Placebo|Excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
41280010|NCT00396396|DRUG|Acetylcysteine|
41280011|NCT00000889|DRUG|Aldesleukin|
41280012|NCT05090241|DIAGNOSTIC_TEST|Instrumental measurement of balance and gait|The balance measurement was performed on a force platform. The walk test was carried out using sensors to analyze and retrieve data from the participant's walk (gait speed, step length, duration of the double support phase).
41280013|NCT05992077|DRUG|Sofosbuvir/Daclatasvir|Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.
41450184|NCT03603990|PROCEDURE|Vitrectomy|"During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
41450185|NCT03603990|PROCEDURE|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
41130278|NCT03451695|DRUG|Morphine|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
41280014|NCT00934609|BEHAVIORAL|Endurance training|45 min ergometer cycling at the ventilatory anaerobic threshold 4 times per week for 12 weeks
41280015|NCT04302272|DEVICE|Spiration Valve System (SVS)|Spiration Valves are one-way endobronchial valves indicated for adult patients with shortness of breath and hyperinflation associated with severe emphysema in regions of the lung that have evidence of low collateral ventilation. The Spiration Valve is loaded in the deployment catheter, then passed through the channel of a flexible bronchoscope and deployed at the intended target location. The SVS device is designed to relieve the symptoms of shortness of breath and hyperinflation associated with severe emphysema without surgery.
41280016|NCT06481735|BIOLOGICAL|TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2 : dose of RP2D.
40936630|NCT00005851|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
41450186|NCT04081558|DEVICE|Electronic patient reported outcomes tool|Electronic patient reported outcomes
41450187|NCT03922490|DEVICE|Lipogems Device PLUS debridement|Lipogems is the name of the technology used to obtain stem cells from the abdomen, which will then be injected into the knee after knee arthroscopy.
41450188|NCT03922490|PROCEDURE|Debridement only|Patients will undergo knee arthroscopy as a standard treatment for their condition but will not receive the fat-derived stem cell treatment nor will undergo any additional procedures.
41450189|NCT03313895|BEHAVIORAL|Aerobic & Cognitive Training (ACT)|ACT stands for combined aerobic exercise and cognitive training.
41450190|NCT03313895|BEHAVIORAL|Cycling Only|Cycling on a recumbent stationary cycle
41450191|NCT03313895|BEHAVIORAL|Cognitive Training Only|Engage in cognitive training on a computer
40936631|NCT00005851|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
40936632|NCT00005851|OTHER|laboratory biomarker analysis|Correlative studies
40936633|NCT02383225|BEHAVIORAL|Lakota Language enhancement|This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.
40936634|NCT02383225|BEHAVIORAL|Facebook Supplement|This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.
41130279|NCT03451695|DRUG|Placebo|Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
41130280|NCT04250636|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30mg/kg
41130281|NCT04250636|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 30mg/kg
41130282|NCT04163237|DRUG|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti- autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
41130283|NCT04163237|DRUG|Sorafenib|Sorafenib tosylate is a novel multi- target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet- derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
41130284|NCT06268782|BEHAVIORAL|Rehabilitate your core|The intervention was an online exercise program \&#34;Rehabilitate your core,\&#34; designed for postpartum women by a company called Nordic Fit Mama. Its primary goal is to fortify the core and pelvic floor muscles to enhance the recovery process after childbirth, while also emphasizing overall well-being. The program is accessible through a website and is intended to be completed independently over a span of 6 weeks. Each week focuses on a specific theme, encompassing six to seven subtopics. The regimen follows a progressive structure, starting with the identification of pelvic floor and core muscles and gradually advancing to exercises aimed at strengthening them. The exercises, which last around 10 minutes each, are tailored to integrate seamlessly into daily life. Comprising 25 instructional exercise videos and 13 guidance videos, the program only necessitates access to a device for logging into the platform.
41130285|NCT01532999|BEHAVIORAL|Mindfulness Based Stress Reduction|MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
41130286|NCT01532999|BEHAVIORAL|Present Centered Group Therapy|The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
41130287|NCT01296815|DRUG|Bevacizumab|Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
41130288|NCT03770520|PROCEDURE|QFR-guided CABG|CABG surgery based on CAG and QFR
41130289|NCT03770520|PROCEDURE|Angio-guided CABG|CABG surgery based on heart team discussion of CAG
41130290|NCT04378205|PROCEDURE|0.014-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.014-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
41130291|NCT04378205|PROCEDURE|0.016-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.016-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
41130292|NCT00238485|DRUG|Licarbazepine|
41130293|NCT02322424|PROCEDURE|pancreaticoduodenectomy|
41130294|NCT05967858|OTHER|observation|no intervention
41130295|NCT00977249|BEHAVIORAL|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
41130296|NCT00977249|DRUG|varenicline|
41130297|NCT00977249|DRUG|placebo|
41280017|NCT06481735|DRUG|Fludarabine|Intravenous fludarabine 25\~30 mg/m\^2/day on days -5, -4, and -3.
41280018|NCT06481735|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
41450192|NCT03313895|BEHAVIORAL|Stretching and Mental Stimulating Activities|Stretching exercises and mental stimulating activities on a computer
41130298|NCT01026207|DEVICE|Polysomnography|Sleep study polysomnography compared with portable monitoring
41453540|NCT05065528|DIETARY_SUPPLEMENT|Magnesium|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with 400 mg supplemental magnesium twice daily for 3 days
41280019|NCT05714930|OTHER|Treat-to-target as a new treatment concept|After trial initiation, the study personnel in the intervention centers will receive a training on T2T and shared decision making (SDM). Patients in the intervention centers will receive 6-weekly visits for at least 24 weeks with therapeutic adjustments to achieve remission. In case of stable remission for 6 weeks at week 24, the patients switch to 12-weekly visits until the end of the trial at week 120. In case of flare, the patient switches to 6-weekly visits for 24 consecutive weeks. Pharmaceutical treatment decisions will be guided by current treatment standards and will be taken in accordance with SDM between patients and treating physicians.
41280020|NCT03736044|DRUG|TNF-blockers suspension in patients with rheumatoid arthritis|in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
41280021|NCT04087499|DEVICE|Acupuncture|acupuncture treatment on selected acupoint
41280022|NCT04751500|PROCEDURE|Outpatient hysteroscopy|Direct visualisation and careful extraction of retained pregnancy tissue using a specific hysteroscopic technology known as a hysteroscopic tissue retrieval system.
41280023|NCT04751500|BEHAVIORAL|Expectant management|Leaving the retained pregnancy tissue alone to pass by itself
41280024|NCT04751500|DRUG|Medical management|Giving medications to contract the womb to pass the retained pregnancy tissue
41280025|NCT04751500|DRUG|Antibiotic|Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself
41280026|NCT04751500|PROCEDURE|Surgical management|Passing a small cannula/catheter/currette into the womb and mechanically scraping the womb lining to remove the retained pregnancy tissue
41280027|NCT06201143|OTHER|BREATHING EXERCISE AND MOBILIZATION TRAINING|After cesarean mobilization and breathing exercise training, the number of breathing exercises performed and the duration of mobilization will be recorded. Thus, the effectiveness of the training will be examined in detail.
41280028|NCT06201143|OTHER|KINESIOLOGICAL TAPING + BREATHING EXERCISE AND MOBILIZATION TRAINING|It will be the first study to use kinesiotaping, breathing exercise and mobilization training together.
41280029|NCT03823729|DEVICE|Elosan Cabin|The Elosan Cabin is a closed, electrically insulated, biocompatible cabin for the short-term application of electrostatic high voltage. Patients assigned to the Group A will have 8 sessions in the Elosan cabin, with an interval of 3 to 4 days between sessions.
41280030|NCT01144273|PROCEDURE|Transversus abdominis plane block|"This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity."
41280031|NCT04932889|OTHER|Survey|A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease...), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc..., treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
41280032|NCT04932889|OTHER|Laboratory parameters|The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.
41280033|NCT04932889|OTHER|chest computed tomography|Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
41280034|NCT02714530|DRUG|Erlotinib|Tarceva daily during radiotherapy course
41280035|NCT02714530|RADIATION|Radiation|Radiotherapy
41280036|NCT05221190|PROCEDURE|Single buccal infiltration|injecting local anaesthetic solution into the soft tissues of the buccal sulcus adjacent to the target tooth.
41280037|NCT05221190|PROCEDURE|Inferior alveolar nerve block|Injection of local anesthetic solution into the pterygomandibular space to access the inferior alveolar nerve before it enters the mandible.
41280038|NCT01857895|DRUG|Exenatide|Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
41280039|NCT02515240|BIOLOGICAL|PPV23|23 valent pneumococcal polysaccharide vaccine in Healthy adults.
41280040|NCT02803034|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number- SR15-60-Z15-030).
41280041|NCT01333189|OTHER|Weight-bearing biofeedback exercise|"Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.~Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games."
41280042|NCT01333189|OTHER|Standard of care exercise|Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
41280043|NCT04227691|DEVICE|Long-pulsed Nd Yag laser treatment|One treatment of the assigned axilla with long-pulsed Nd YAG laser treatment in ten patients
40936635|NCT02383225|BEHAVIORAL|Substance Use Resistance Skills|This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
40936636|NCT06536231|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
41280044|NCT04227691|DEVICE|IPL treatment|One treatment of the assigned axilla with IPL treatment in ten patients
41280045|NCT01856673|BEHAVIORAL|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
41280046|NCT01856673|BEHAVIORAL|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
41280047|NCT01856673|OTHER|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
41280048|NCT00994617|DRUG|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
41280049|NCT00994617|DRUG|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
41280050|NCT04622852|DEVICE|Open reduction internal fixation (ORIF) with an angular stable plate|Operative treatment of proximal humeral fracture
41280051|NCT04661696|DRUG|Paclitaxel (albumin-bound)|The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.
41280052|NCT02085655|DRUG|pegaspargase|pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
41280053|NCT02085655|DRUG|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
41280054|NCT02085655|DRUG|Oxaliplatin|100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
41280055|NCT02085655|DRUG|Methotrexate|3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
40936637|NCT02189954|PROCEDURE|The placement according to the manufacturer's instructions|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience
41280056|NCT02085655|DRUG|Dexamethasone|40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
41280057|NCT02085655|DRUG|Thalidomide|100-200mg, PO, after chemotherapy
41280058|NCT06335121|BEHAVIORAL|POWER Up strategies -|Clinics will implement adapted POWER Up intervention strategies when a patient is flagged as PrEP eligible.
41280059|NCT02732951|DRUG|BI 1026706|
41280060|NCT02732951|DRUG|Placebo|
41280061|NCT02711371|OTHER|fMRI|
41280062|NCT05207150|DEVICE|LINQII/Apple Watch Series 6|LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear an Apple Watch Series 6 for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (Apple Watch) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
41453541|NCT05065528|DRUG|Placebo|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
41453542|NCT00109512|DRUG|NBI-56418 (GnRH antagonist)|
41453543|NCT00109512|DRUG|placebo|
41280063|NCT05207150|DEVICE|LINQII/SkyLabs CART-I ring|LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear a SkyLabs CART-I ring for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (CART-I ring) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
40936638|NCT02189954|PROCEDURE|Cuff inner pressure was held below 44 mmHg|cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
40936639|NCT01384643|DRUG|Propofol|Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
40936640|NCT04257097|DEVICE|RPM - Osteogenics Lubbock Texas USA|25 patients will undergo bone regeneration with a reinforced PTFE mesh, manually shaped and modelled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption
40936641|NCT04257097|DEVICE|Yxoss CBR - Reoss Filderstadt Germany|25 patients undergo bone regeneration with a custom-made titanium mesh, digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption
41130299|NCT02540031|DRUG|"Additional oral preparation (3L of PEG+Asc, Coolprep®)"|"The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
41130300|NCT02540031|DRUG|"Standard oral preparation (2L of PEG+Asc, Coolprep®)"|"The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
41130301|NCT05528549|OTHER|Exercise|The investigators are looking at how blood flow and blood pressure are regulated in individuals with Down syndrome, who have a reduced ability to do work. This study will compare individuals with Down syndrome to a control group without Down syndrome.
41130302|NCT00401479|DRUG|Placebo|
41130303|NCT00401479|DRUG|Solabegron (GW427353)|
41130304|NCT00853580|DRUG|Lovastatin ™|Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
41130305|NCT00853580|DEVICE|placebo|Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
41130306|NCT03784469|OTHER|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
41130307|NCT04161716|DEVICE|NIRS recording|Patient has a NIRS module during their urodynamic exam.
41130308|NCT03739866|DRUG|Lenacapavir|Administered subcutaneously in the abdomen
41130309|NCT03739866|DRUG|Placebo|Administered subcutaneously in the abdomen
41130310|NCT03739866|DRUG|B/F/TAF|50/200/25 mg tablets administered orally once daily
41130311|NCT03739866|DRUG|TAF|Tablets administered orally
41130312|NCT02605850|OTHER|Water|All subjects will consume ground beef patty meal with water at the baseline visit.
41130313|NCT02605850|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate Juice will be taken 1/day for 4 weeks.
41130314|NCT02605850|DIETARY_SUPPLEMENT|Pomegranate extract|Pomegranate extract will be taken 1/day for 4 weeks.
41130315|NCT04759794|DIAGNOSTIC_TEST|Cytology staining|"Two stainings will be performed in cytology specimens obtained from the same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using the antibody of aminoacyl-tRNA synthetases"
41130316|NCT02260154|DRUG|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
41130317|NCT00227175|BEHAVIORAL|Semi-structured, open ended interview|
41130318|NCT03230006|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The UP will be conducted in a standardized fashion, over 16 sessions, following the published therapist guide with minor refinements for application in the proposed comorbid population.
41130319|NCT03230006|BEHAVIORAL|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
41130320|NCT04108403|OTHER|Pain Inducing Massage|A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.
41130321|NCT04108403|OTHER|Pain Free Massage|A pain free massage (pain intensity = 0/100) will be applied for 60 seconds, 4 times.
41130322|NCT04108403|OTHER|Positive Expectation Instructional Set|Participants will be instructed that the massage is effective for some people with neck pain.
41130323|NCT04108403|OTHER|Negative Expectation Instructional Set|Participants will be instructed that the massage is ineffective for some people with neck pain.
41453544|NCT03419403|DRUG|Steroid eye drops|Solution, eye drop
41130324|NCT03281603|DEVICE|CAD/CAM complete denture|complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
41130325|NCT01462149|DRUG|Neoadjuvant chemotherapy|Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
41130326|NCT01462149|DRUG|Carboplatin|Carboplatin AUC 5, q 3 weeks, 3 cycles
41453545|NCT03419403|DRUG|Vasoconstrictor eye drops|Solution, eye drop
41453546|NCT03419403|OTHER|Cold compress|Cold compress
40936642|NCT00733889|DRUG|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|"Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36"
40936643|NCT01757691|DRUG|Fingolimod 0.5mg/daily|
40936644|NCT01757691|DRUG|Placebo|
40936645|NCT05453266|PROCEDURE|Application of Tranexamic acid in arthroscopic irrigation solution|Application of Tranexamic acid in arthroscopic irrigation solution
40936646|NCT05453266|PROCEDURE|No application of Tranexamic acid in arthroscopic irrigation solution|No application of Tranexamic acid in arthroscopic irrigation solution
40936647|NCT00099645|DRUG|Mifepristone|
40936648|NCT00873860|OTHER|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
40936649|NCT00873860|BIOLOGICAL|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
40936650|NCT00873860|BIOLOGICAL|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
40936651|NCT00873860|BIOLOGICAL|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
40936652|NCT05737771|DRUG|DWC202213|DWC202213
40936653|NCT05737771|DRUG|DWJ1563|DWJ1563
40936654|NCT05737771|DRUG|DWP16001|DWP16001
41130327|NCT01584466|DRUG|Paliperidone|"The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.~Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary."
41130328|NCT03958019|OTHER|RESTORE II Program|Detailed in arm description
41130329|NCT03898505|DIETARY_SUPPLEMENT|AvoMax (Low Dose)|AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
41280064|NCT05742386|BEHAVIORAL|Communication training|Clinics will host an AAT workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
41280065|NCT05742386|BEHAVIORAL|Communication training enhanced with standing orders optimization|"Clinics will host an AAT workshop, as in the other trial arm.~Clinic representatives will attend working meetings on putting HPV vaccine standing orders into clinic workflow. Clinics will then orient their staff to the standing orders. Finally, clinic representatives will discuss their use of standing orders in a learning collaborative."
41280066|NCT03669393|DRUG|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
40936655|NCT04179890|DRUG|Afatinib (Gi(l)otrif®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
40936656|NCT04179890|DRUG|Erlotinib (Tarceva®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
40936657|NCT04179890|DRUG|Gefitinib (IRESSA®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
40936658|NCT04179890|DRUG|Osimertinib (Tagrisso®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
40936659|NCT04179890|DRUG|Afatinib (Gi(l)otrif®)|As first line therapy.
40936660|NCT04179890|DRUG|Osimertinib (Tagrisso®)|In the case the T790M resistance mutation was developed (second line therapy).
40936661|NCT01542671|BEHAVIORAL|Intervention|"* Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.~* Monthly Motivational phone calls with Lifestyle Counselor for the first year~* 4 informational DVDs over the two year period~* Feedback on submitted food and exercise journals"
40936662|NCT01542671|BEHAVIORAL|Control|"* Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* 5 informational NIDDK mailings over the two year period"
40936663|NCT03435640|DRUG|NKTR-262|"During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262."
40936664|NCT03435640|DRUG|bempegaldesleukin|"During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.~During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles."
40936665|NCT03435640|DRUG|nivolumab|During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
40936666|NCT03137576|PROCEDURE|Paravertebral Block (PVB)|PVB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%) in the paravertebral space (defined by the anterior aspect of the ribs, the vertebral body and the parietal pleura. The space is identified under ultrasonographic guidance by a dedicated Anesthesiologist.
41130330|NCT03898505|DIETARY_SUPPLEMENT|AvoMax (High Dose)|AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
41450193|NCT06435793|PROCEDURE|MEP measurement - Surface EMG - IOPI|"Participants will undergo serial expiratory maneuvers using variously-sized circular mouthpieces and a reference ovoid-shaped mouthpiece.~At each maneuver, the maximal expiratory mouth pressure at total lung capacity will be measured, alongside with the degree of neuromuscular activation of the internal oblique and transverse abdominal muscles using surface electromyography.~The Orbicularis Oris strength will also be measured using the Iowa Oral Performance Instrument."
41450194|NCT06082102|DRUG|Orelabrutinib|Orelabrutinib Tablets
41280067|NCT05182736|BEHAVIORAL|TRAIL intervention|The TRAIL program is comprised of a multi-tier system of strategies: Universal strategies impact the entire school via a school-wide social norms marketing campaign and school-climate change activities. School staff trainings and professional development activities focus on enhancing protective factors for students to reduce the effects of stressful life events and trauma, improving classroom management, linking students to resources, and improving the overall school climate for students and staff. Targeted strategies include an in-school curriculum and service learning component, which impact all ninth grade students at the intervention high schools and all eighth grade students at the intervention middle schools. Intensive strategies are intended for a subset of youth and their caregivers with identified increased risk-factors, and they include peer mentoring, after-school running/positive youth development programming, summer programming, and parent workshop support.
41280068|NCT02950506|DEVICE|transcranial direct current stimulation|The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
40936667|NCT03137576|PROCEDURE|Erector Spinae Plane Block (ESPB)|ESPB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%), in the anatomical plane between the Erector Spinae muscles and deeper surface of Rhomboid muscle. The space is identified under ecographic guidance, laterally to the spinous process of T5. The diffusion of the anesthetic solution along the space can be echographically appreciated.
40936668|NCT06331845|DRUG|Gemcitabine|1000 mg/m2 on Days 1 and 8
40936669|NCT06331845|DRUG|Cisplatin|a total of 80-100 mg/m2 for d1-3
41280069|NCT02950506|OTHER|Cognitive Remediation Therapy|The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
41280070|NCT01848314|PROCEDURE|Renal Denervation|Flowmeasurements will be performed before and after renal denervation
41280071|NCT03591887|BIOLOGICAL|ABY-035|ABY-035 solution for injection
40936670|NCT06331845|DRUG|Paclitaxel protein-bound|260 mg/m2 on Day 1
40936671|NCT06331845|DRUG|Capecitabine|a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle
41130331|NCT03898505|OTHER|Placebo|Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.
41280072|NCT03591887|BIOLOGICAL|Placebo|Placebo to ABY-035 solution for injection
41450195|NCT06082102|DRUG|Lenalidomide|Lenalidomide Capsules
41450196|NCT06082102|DRUG|Rituximab|Rituximab Injection
40936672|NCT06331845|DRUG|Tislelizumab|200 mg on Day 1
40936673|NCT01198379|DRUG|aspirin|aspirin 100 mg qd for 3 years
40936674|NCT01198379|DRUG|Placebo|
40936675|NCT06417073|BEHAVIORAL|Face-To-Face Task-orianted Training|In this study, face-to-face task-oriented station training is provided by trained occupational therapists to elderly nursing home residents. Each session involves structured activities that simulate real-world challenges designed to improve cognitive and hand functions. These include exercises to enhance fine motor skills, hand strength, coordination, and cognitive tasks such as problem-solving and memory exercises.
40936676|NCT06417073|BEHAVIORAL|Tele-Rehabilitation Task-orianted Training|This intervention utilizes video-conferencing technology to deliver task-oriented training to elderly nursing home residents, focusing on cognitive and hand function improvements.
41130332|NCT03081013|BEHAVIORAL|Social information|Social comparison information will be provided to the study participants weekly via SMS
41130333|NCT03081013|DEVICE|Fitbit|Fitbit is a wireless pedometer that tracks steps of participants and will be offered in conjunction with a tailored website with customised information for participants.
41130334|NCT03865004|DRUG|Paracetamol+Morphine|1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously
41130335|NCT03865004|DRUG|Dexketoprofen plus Morphine|Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
41130336|NCT03865004|DRUG|Placebo plus Morphine|100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously
41280073|NCT04002687|DRUG|ATV-PG 1000-400 mg + AQ 612 mg|The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
41280074|NCT01937312|DRUG|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
41280075|NCT01937312|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
41280076|NCT01937312|DRUG|Prostaglandin analogue|
41450197|NCT06082102|DRUG|Orelabrutinib Placebo|Orelabrutinib Placebo Tablets
41450198|NCT00730691|DRUG|Placebo|Placebo-matching capsules
41450199|NCT00730691|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
41450200|NCT00730691|DRUG|Duloxetine|Overencapsulated duloxetine capsules
41450201|NCT01943877|PROCEDURE|scaling root planing|scaling root planing
41450202|NCT01943877|DRUG|Propolis|experimental
41450203|NCT05137054|DRUG|Linvoseltamab|Linvoseltamab is administered by intravenous (IV) infusion
41450204|NCT05137054|DRUG|Daratumumab|Daratumumab is administered by IV infusion and/or subcutaneous (SC) injection; SC injection may be used after a minimum of 2 cycles of IV administration at the investigator's discretion.
41450205|NCT05137054|DRUG|Carfilzomib|Carfilzomib is administered by IV infusion
41450206|NCT05137054|DRUG|Lenalidomide|Lenalidomide is administered by mouth (PO) as a capsule
40936677|NCT06417073|BEHAVIORAL|Home-based Task-orianted Training|"Home-Based Task-Oriented Training Intervention Description:~This home-based intervention involves a series of task-oriented activities specifically designed to improve cognitive and hand functions for elderly residents in nursing homes. Participants carry out prescribed activities independently, based on detailed guides provided by occupational therapists. The activities are tailored to stimulate cognitive processes and enhance fine motor skills, including tasks like sorting, assembling, and manipulative exercises that replicate daily challenges. Each participant follows a structured program of daily 45-minute sessions for two weeks, with periodic remote check-ins by therapists to assess progress and adjust the difficulty of tasks as needed. This format allows participants to engage in rehabilitation at their own pace, within the comfort of their own living spaces, fostering greater autonomy and adherence to the intervention."
40936678|NCT03223636|DEVICE|TMS|We will use TMS with paired-pulse technique to activate corticospinal neurons in the primary motor cortex and motorneurons in the brainstem, respectively (Hallett 2007; Ugawa et al. 1991; Ugawa et al.1994). Two stimulations will be separated with various interstimulus intervals to produce collision on nerve fibers with different conduction velocity in the corticospinal tract. The conduction time on nerve fibers in the corticospinal tract with different conduction velocity will be identified and the distribution of these fibers will be calculated.
40936679|NCT03223636|DEVICE|MRI|MRI exams will consist of several sessions including calibration, anatomic, and diffusion MRI scanning (Avram et al. 2013; Avram et al. 2016; Pierpaoli et al. 1996). Data in each exam will be acquired in the left or right forearm (PNS).
40936680|NCT06053008|OTHER|The relationship between pain perception, temporomandibular joint disorder severity and spine health|The relationship between pain perception, temporomandibular joint disorder severity and spine health
41280077|NCT01612234|DIETARY_SUPPLEMENT|High palmitate or high oleate diet.|High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
41280078|NCT00938548|DRUG|Pregabalin|Pregabalin 75 mg orally
41280079|NCT00938548|DRUG|Vitamin Complex (placebo)|Vitamin Complex orally
41280080|NCT01091350|DEVICE|Diprifusor (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
41280081|NCT01091350|DEVICE|Orchestra (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
41280082|NCT02898012|DRUG|Temozolomide|Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.
41280083|NCT02898012|DRUG|Bevacizumab|Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage \> grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
41280084|NCT01035151|BEHAVIORAL|Experimental|Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)
41280085|NCT01035151|BEHAVIORAL|Control|Written Cessation Materials
41280086|NCT05762341|OTHER|PRESSURE INJURY PREVENTION TRAINING|PREVENTION OF PRESSURE INJURY TO FACE TO FACE TRAINING
41280087|NCT01695369|DEVICE|Senofilcon A; Comfilcon A|Senofilcon A; Comfilcon A
41280088|NCT01695369|DEVICE|Comfilcon A; Senofilcon A|Comfilcon A; Senofilcon A
41280089|NCT00826748|DRUG|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
40755969|NCT02416388|DRUG|Daunorubicin|"Induction chemotherapy :~Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)~+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
40755970|NCT02416388|DRUG|HD Cytarabine|"Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
41280090|NCT03723447|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.
41450207|NCT05137054|DRUG|Bortezomib|Bortezomib is administered by IV infusion or SC injection
41450208|NCT05137054|DRUG|Pomalidomide|Pomalidomide is administered by mouth (PO) as a capsule
41450209|NCT05137054|DRUG|Isatuximab|Isatuximab is administered by IV infusion
41450210|NCT05137054|DRUG|Fianlimab|Fianlimab is administered by IV infusion
40755971|NCT02416388|DRUG|Cyclosporine|"GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100"
40755972|NCT02416388|DRUG|Methotrexate|"GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11"
41280091|NCT03723447|DRUG|Bupivacaine/epinephrine/dexamethasone|Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
41280092|NCT02848547|BEHAVIORAL|Text Messaging via Short Message Service|
41280093|NCT02870673|DRUG|SHINCORT|triamcinolone Acetonide (10mg/ml) 0.5 ml
41280094|NCT02870673|DRUG|XYLOCAINE|xylocaine(20mg/ml) 0.5 ml
41450211|NCT05137054|DRUG|Cemiplimab|Cemiplimab is administered by IV infusion
41450212|NCT05137054|DRUG|Nirogacestat|Nirogacestat is administered by mouth (PO) as a tablet
41453547|NCT03419403|DRUG|Ophthalmic steroid ointment|Ointment
41453548|NCT03419403|DRUG|Depatuxizumab mafodotin|During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.
40936681|NCT04648501|OTHER|Dual-task training|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
40936682|NCT03268473|OTHER|Experimental|Experimental: Non-surgical periodontal therapy in patient with OSAS and Periodontitis
40936683|NCT03268473|OTHER|Control|Control: Non-surgical periodontal therapy in Periodontitis
40936684|NCT01747018|BIOLOGICAL|Platelet-rich Plasma|
40936685|NCT03565471|DIAGNOSTIC_TEST|Echocardiography|Standard echocardiography.
40936686|NCT03565471|DIAGNOSTIC_TEST|Right side catheterization|Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.
40936687|NCT03565471|DIAGNOSTIC_TEST|Exercise test|Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.
40936688|NCT03565471|DIAGNOSTIC_TEST|Holter monitor|Holter monitor worn for 2 whole days registering heart rate.
40936689|NCT01915966|DIETARY_SUPPLEMENT|Cardamom, ginger and orange juice gelatin|Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
40936690|NCT01915966|DIETARY_SUPPLEMENT|Camomile infusion with lemon juice|Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
40936691|NCT06330688|PROCEDURE|percutaneous cholecystostomy|PC is a minimally invasive, nonsurgical, image-guided intervention that aims to drain and decompress the gallbladder by placing a pigtail catheter through the abdominal wall into the gallbladder lumen.
40936692|NCT00808431|BEHAVIORAL|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
40936693|NCT00088036|DRUG|Olanzapine|
40936694|NCT03504930|OTHER|Impact of biotherapy on postoperative morbidity in ulcerative colitis|Impact of biotherapy on postoperative morbidity, quality of life, sexual function, sexual health in ulcerative colitis
40936695|NCT06194201|DRUG|HRS9432|Dosing frequency: intravenously once week
41450213|NCT06471504|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their caregiver's lap and will face a computer monitor. After a sticker is applied to the child's forehead and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
41450214|NCT01632215|DRUG|Gabapentine|Gabapentine 600 mg 01 dose
41450215|NCT01632215|OTHER|Sugar pill|Sugar pill 01 dose
40936696|NCT06194201|DRUG|Caspofungin Acetate for Injection|Dosing frequency: D1 70mg，followed by 50mg intravenously once daily
40936697|NCT02633852|DRUG|Aflibercept|
41280095|NCT02870673|DEVICE|sham electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
40936698|NCT01673750|OTHER|Questionnaire|The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
41280096|NCT02870673|DEVICE|electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
41450216|NCT02172781|DRUG|Ipratropium - unit dose vial|
41450217|NCT02172781|DRUG|Tiotropium - inhalation capsule|
40936699|NCT03310827|BEHAVIORAL|Personalized Nutrition|Diet plan based on nutrition-related gene test results
40936700|NCT03492775|DRUG|Obinutuzumab|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
40936701|NCT03492775|DRUG|Bendamustine|Bendamustine belongs formally to the alkylators, but has been shown to have a unique mechanism of action. The dose limiting toxicity of bendamustine is its reversible suppression of bone marrow function with drops in leukocyte and thromobocyte counts.
41450218|NCT02172781|DRUG|Placebo matching tiotropium|
41450219|NCT02172781|DRUG|Placebo matching ipratropium|
41450220|NCT04313764|DRUG|Bupivacaine Hcl 0.25% ESP block|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
40936702|NCT00842764|PROCEDURE|Holmium: YAG laser|Minimally Invasive Holmium:YAG laser Blepharoplasty
40936703|NCT05656989|OTHER|Periodontal clinical measurements and GCF sampling|Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
41280097|NCT04269408|DRUG|Nicardipine|10 NicaPlant® implants releasing 4 mg nicardipine each.
41280098|NCT04269408|OTHER|Standard of care|Both arms receive the usual standard of care.
41280099|NCT03099759|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D2/D3
40936704|NCT04148872|OTHER|Neuromuscular Retraining Therapy (4 months)|Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.
40936705|NCT04148872|DRUG|Chemodenervation (4 months)|A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
40936706|NCT04148872|OTHER|Neuromuscular Retraining + Chemodenervation|Participants will receive both interventions for the last 4 months of their time on study.
40936707|NCT02935374|DRUG|Amoxicillin|The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
40936708|NCT02935374|DRUG|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
40936709|NCT02935374|DRUG|Macrolide|The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
40936710|NCT01213550|DRUG|Chlorhexidine gluconate|
41130337|NCT03964740|OTHER|Mobile App intervention|The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations
41130338|NCT05645068|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography
41130339|NCT05645068|OTHER|multidisciplinary care program|multidisciplinary care program including sports activity
41450221|NCT04313764|DRUG|Bupivacaine Hcl 0.25% infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
40755973|NCT02416388|DRUG|Mycophenolic acid (MPA)|"GvHD prophylaxis post allogeneic SCT :~* 720 mg BID from D0 to D+28 for HLA-identical siblings~* 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors"
40755974|NCT02416388|DRUG|vosaroxin|"Consolidation chemotherapy course (s) :~-70 mg/m² on D1 and D4"
41130340|NCT04769141|COMBINATION_PRODUCT|CURATE.AI|"CURATE.AI is one example of an artificial intelligence guided dosing decision tool. It is customized to each individual and can be applicable across many different conditions, as it is disease agnostic.~This platform has already demonstrated initial success in cancer and transplant populations but yet to be applied to chronic disease patients."
41130341|NCT06509607|OTHER|Concentric Lower Limb Training Program|A specially designed 30-minute concentric lower limb training program (squats, lunges and leg extensions) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the coach, 2 days per week for 8 weeks.
41130342|NCT06509607|OTHER|Eccentric Lower Limb Training Program|A specially designed 30-minute eccentric lower limb training program (wall sit, sitting straddle single leg and full squat) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the same coach, 2 days per week for 6 weeks.
40755975|NCT02416388|DRUG|ID cytarabine|"Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
40755976|NCT02416388|DRUG|Dexamethasone|"Consolidation chemotherapy course (s) :~-10 mg/12h on D1, D3 and D5"
40936711|NCT01213550|DRUG|Placebo mouthrinse|
40936712|NCT01898494|PROCEDURE|Transoral surgery|Undergo transoral surgical resection
40936713|NCT01898494|RADIATION|intensity-modulated radiation therapy|Undergo standard-dose or low-dose IMRT
40936714|NCT01898494|DRUG|cisplatin|Given IV
40936715|NCT01898494|DRUG|carboplatin|Given IV
40936716|NCT01469104|OTHER|3 day fast|Subjects will fast for 72 hours
40936717|NCT01469104|OTHER|3 day CHO-free diet|Subjects will receive a carbohydrate-free diet for 72 hours
40936718|NCT02982785|BEHAVIORAL|Standard post-operative rehabilitation|
40936719|NCT05022446|OTHER|Survey Administration|Complete survey
40936720|NCT01736332|DRUG|Vicks VapoInhaler|2 inhalations each nostril every 2 hours for 6 doses on day 1, one dose on morning of day 2
40936721|NCT01736332|OTHER|Poppy seeds|45 g in liquid at 9 am and 5 pm on day 1
40936722|NCT02273518|DRUG|Asasantin ER, new formulation I|
40936723|NCT02273518|DRUG|Asasantin ER, new formulation II|
40936724|NCT02273518|DRUG|Asasantin ER, present commercial formulation|
40936725|NCT02582762|DRUG|Nail gel|apply nail gel on affected nails twice daily for 2 months
41280100|NCT01881555|PROCEDURE|invasive coronary angiography|
41280101|NCT01881555|PROCEDURE|Functional testing by fractional flow reserve measurement|Functional testing by fractional flow reserve measurement
41280102|NCT03628157|OTHER|Geistlich Bio-Oss® bovine bone alone|Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
41450222|NCT00483743|DRUG|TPI 1020|250 mcg/caps 2 caps BID x 42 days
41450223|NCT00483743|DRUG|Budesonide|400mcg mcg capsules- 2 capsules BID
41450224|NCT00483743|DRUG|Placebo|2 caps BID x42 days
40936726|NCT02827565|OTHER|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|10 ml blood sample
40936727|NCT05202470|OTHER|TE|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
40936728|NCT05202470|OTHER|CE|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
40936729|NCT04661553|DEVICE|"Mueller's polarimetric colposcopy Group 1"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population with a low-risk premature birth. This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for a normal pregnancy and, therefore, to monitor the regular advancement of the gestation."
40936730|NCT04661553|DEVICE|"Mueller's polarimetric colposcopy Group 2"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population at high-risk of preterm birth.~This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for an abnormal pregnancy and, therefore, to predict premature childbirth."
40936731|NCT01608854|OTHER|Antibiotic Protocol|Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
40936732|NCT04596553|DIETARY_SUPPLEMENT|Essential Amino Acid|Immediately following the exercise intervention participants will consume their assigned essential amino acid supplement
40936733|NCT04596553|DIETARY_SUPPLEMENT|Collagen Peptide|Immediately following the exercise intervention participants will consume their assigned collagen peptide supplement
40936734|NCT04596553|DIETARY_SUPPLEMENT|Maltodextrin Placebo|Immediately following the exercise intervention participants will consume their assigned maltodextrin supplement
40936735|NCT04148677|DIETARY_SUPPLEMENT|Protoves M1®|A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)
40936736|NCT05606653|OTHER|Measurement of critical airway closing pressure|Measurement of critical airway closing pressure
40936737|NCT05606653|OTHER|Respiratory function tests|CO2 response test
40936738|NCT05606653|OTHER|pharyngometry|measure of the pharyngometry
40936739|NCT01165190|OTHER|pioglitazone|
40936740|NCT04706117|DEVICE|Self-retaining bicanalicular intubation stent|self-retaining bicanaliculs intubation setII(SRSII) which is the latest innovation in the field as these silicone stent segments traverse both canaliculi till the lacrimal sac. In which each end of this semicircular device has 2 stout angulated wings/flanges which pose no resistance while proceeding forward into the canaliculus, but once they get into open cavity (lacrimal sac), the flanges open up and give resistance to their removal against the common canalicular opening
40936741|NCT02815774|DRUG|SP2086|all subjects were given SP2086 50mg only one time.
40936742|NCT04935437|OTHER|Supervised rehabilitation program.|The program includes aerobic exercise, strengthening exercises, physiotherapy, psychological support and dietary advice.
40936743|NCT00383773|PROCEDURE|Retinal endo vascular surgery|
40936744|NCT02278471|DRUG|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
40936745|NCT02828527|OTHER|Observational|
40936746|NCT01148797|DRUG|Canakinumab|
40936747|NCT00151853|DRUG|PPSB-SD|
40936748|NCT04211805|DRUG|Tenofovir Alafenamide 25 MG for arm (A)|Tenofovir Alafenamide (TAF) will be provided, 25 mg Per Oral daily.
40936749|NCT04211805|DRUG|Tenofovir Disoproxil Fumarate 300mg for arm (B)|Tenofovir Disoproxil Fumarate (TDF) will be provided, 300 mg Per Oral daily.
40936750|NCT00076024|DRUG|Placebo|5 mg twice daily \[bid\] continuous dosing
40936751|NCT00076024|DRUG|Docetaxel|Standard of care drug administration
40936752|NCT00076024|DRUG|AG-013736 (axitinib)|5mg twice daily \[bid\] continuous dosing
40936753|NCT00076024|DRUG|Docetaxel|Standard of care drug administration
40936754|NCT02923544|PROCEDURE|YUMI manipulator|
40936755|NCT05272215|PROCEDURE|Bariatric surgery|Pre- and post-bariatric surgery (3, 6, 12 months postoperative and yearly)
40936756|NCT05272215|PROCEDURE|Body contouring surgery|Pre- and post body contouring surgery (3, 6, 12 months postoperative and yearly)
40936757|NCT01709578|DRUG|Sarilumab|Pharmaceutical form:solution Route of administration: subcutaneous
40936758|NCT01709578|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
41130343|NCT00949364|DRUG|Pomalidomide|"Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles)."
41130344|NCT04263610|DRUG|Dimethyl fumarate (DMF) standard scheme|Participants will receive DMF gastro-resistant tablet orally from baseline to Week 16, at a dose of 30 milligrams (mg) once daily, twice daily, thrice daily in Week 1, Week 2, Week 3 respectively, 120 mg only once in Week 4. Participants will increase DMF dose by 120 mg tablet per week for the subsequent 5 weeks. Participants achieving Psoriasis area and severity Index (PASI) 50-75 (partial responder) or 75 (responder) will continue the DMF treatment until Week 40. The maximum daily dose taken by a participant will be 720 mg.
40936759|NCT01709578|DRUG|hydroxychloroquine|Dispensed according to the local practice.
40936760|NCT01709578|DRUG|methotrexate|Dispensed according to the local practice.
40936761|NCT01709578|DRUG|sulfasalazine|Dispensed according to the local practice.
40936762|NCT01709578|DRUG|leflunomide|Dispensed according to the local practice.
40936763|NCT01030627|DEVICE|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4\*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
40936764|NCT02380820|DEVICE|Airsoft Duo mattress|A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
40936765|NCT02380820|DEVICE|Softform Premier mattress (in static mode)|A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
40936766|NCT05718544|DRUG|Esketamine|Esketamine 50 mg is included in the mixture for patient-controlled analgesia.
40936767|NCT05718544|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
40936768|NCT05718544|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
40936769|NCT06265779|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
40936770|NCT06265779|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
41450225|NCT01993186|DRUG|UX007|oral liquid
40755977|NCT02416388|DRUG|Venetoclax|"Consolidation chemotherapy course (s) :~Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:~* 100 mg/d on D1 to D8 (selection phase dose level 1)~* or 200 mg/d on D1 to D8 (selection phase dose level 2)~* or 400 mg/d on D1 to D8 (selection phase dose level 3)~* or 400 mg/d on D1 to D14 (selection phase dose level 4)"
40936771|NCT06265779|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
40755978|NCT02934217|DRUG|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
40755979|NCT02934217|DRUG|Placebo|One single intravenous bolus injection of Placebo
40755980|NCT02934217|PROCEDURE|Echocardiography|3 years after AMI
40755981|NCT04621279|PROCEDURE|Normothermia|Usual care for first 72 hours for neonates with mild encephalopathy maintaining core temperature (36.5°C ± 1 C).
40755982|NCT04621279|PROCEDURE|Whole body therapeutic hypothermia|Whole-body therapeutic hypothermia (33.5°C ± 0.5°C) for 72 hours began by 6 hours of age for neonates with mild encephalopathy per site standard of care practice.
40936772|NCT03671278|OTHER|STarT Back Screening Tool Approach|Patients classified as low risk of persistent pain will be educated about their condition and how to manage their back pain by targeting modifiable prognostic factors. Patients classified as medium risk will receive evidence-based physical therapy. Patients classified as high risk will receive evidence-based physical therapy as well as individualized psychological intervention.
40936773|NCT01999101|DRUG|Px-104|28 days treatment
40936774|NCT04290390|DRUG|Segesterone Acetate and Ethinyl Estradiol|Contraceptive Vaginal System
40936775|NCT04290390|DRUG|Rifampin|CYP3A inducer
40755983|NCT06074185|DRUG|Ipratropium Bromide|The study intervention involves implementing a treatment bundle that includes inhaled ipratropium bromide and dexamethasone.
40755984|NCT06021223|DIETARY_SUPPLEMENT|Chicken extract supplement (high-dose)|140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
40936776|NCT04290390|DRUG|Itraconazole|CYP3A inhibitor
40936777|NCT05696860|DEVICE|Capnography Monitoring|Capnography monitoring
40936778|NCT02886065|DRUG|Hiltonol|Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration
40936779|NCT02886065|DRUG|Citarinostat|Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.
40755985|NCT06021223|DIETARY_SUPPLEMENT|Chicken extract supplement (low-dose)|140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
40755986|NCT06021223|OTHER|Placebo|140ml of placebo to be consumed daily for 2 weeks
40755987|NCT03401580|DRUG|Viena II 160/10|once daily
40755988|NCT03401580|DRUG|Viena II 190/10|once daily
40936780|NCT02886065|DRUG|Lenalidomide|Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.
40936781|NCT02886065|BIOLOGICAL|PVX-410|PVX-410 Biweekly (0.8 mg) via subcutaneous injection
40936782|NCT03124238|OTHER|Massage|Massage therapy localized to the back of the individuals for a duration of 30 minutes
41450226|NCT01993186|DRUG|Placebo|oral liquid
41450227|NCT06627062|PROCEDURE|moderate and severe subluxated lens extraction|A double-strand polypropylene suture (9-0 or 8-0) was looped and tied to one end of the preloaded CTR, which was then implanted into the capsular bag. The needle was inserted through the main incision, traversed the anterior chamber, under the posterior iris, and exited 2.0 mm behind the limbus at the central zonular weakness. The CTR was secured to the sclera using the knotless Z-suture technique to center the capsular bag, allowing safe insertion of the intraocular lens (IOL).
41450228|NCT04404439|DRUG|Nortriptyline + topiramate|Treatment group 1
41450229|NCT04404439|DRUG|Verapamil + paroxetine|Treatment group 2
40755989|NCT03401580|DRUG|Viena II 160/12|once daily
40755990|NCT03401580|DRUG|Viena II 190/12|once daily
40755991|NCT00489476|DRUG|Staccato Loxapine|
40755992|NCT00489476|DRUG|Staccato Placebo|Placebo aerosol inhalation (0mg)
40936783|NCT01976078|DRUG|Midazolam/Ranitidine/Esomeprazole|Each of the three drugs will be given at 10% of their usual doses for age/weight.
40936784|NCT05620641|DRUG|Ondansetron 8mg|50 patients will receive intravenous ondansetron 8 mg before the end of surgery.
40936785|NCT05620641|DRUG|Gabapentin|50 patients will receive 600 mg oral gabapentin 1 h before anesthesia.
40936786|NCT01562873|DRUG|Ruxolitinib|
40936787|NCT03463031|DRUG|GSP 301 NS|1 spray in each nostril twice daily for 14 days
40936788|NCT03463031|DRUG|GSP 301 Placebo NS|1 spray in each nostril twice daily for 14 days
40936789|NCT03762915|DRUG|minocycline HCl microspheres|Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
40936790|NCT00730262|DRUG|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
40936791|NCT02772484|DEVICE|HS-1000|
40936792|NCT04658173|DRUG|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
40936793|NCT04658173|DRUG|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1 mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs，and alfentanil 5ug/kg when additional analgesia is needed
40936794|NCT04688879|PROCEDURE|intra-arterial urokinase thrombolysis|Under local anaesthesia, the right femoral artery was punctured in accordance with the Seldinger technique, and a 6-Fr sheath, 10 cm in length, was implanted. Selective catheterization of the SMA was performed with 4-Fr catheter. The SMA angiography was performed to identify the filling defect. Thrombolysis was performed using a 5-Fr multiple-sideport infusion catheter (100cm with sideport of 7cm, 14 ports or 100cm with sideport of 15cm, 30 ports, Cook, Bloomington, IN, U.S.A). The tip of the microcatheter was embedded in the thromboembolism, which was fragmented at the time of thrombolysis. Thrombolysis was performed locally in the SMA with a bolus of urokinase
40936795|NCT01515007|DRUG|Ciprofloxacin dispersion for inhalation|
40936796|NCT01515007|DRUG|Placebo|
41280103|NCT01193335|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
41450230|NCT04404439|OTHER|Placebo|Placebo comparator
40755993|NCT01299532|DEVICE|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
40936797|NCT05012787|BIOLOGICAL|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Participants will receive 1 intramuscular (IM) injection of 30 microgram (mcg) SCB-2019 with CpG 1018/Alum adjuvant on Day 1 and on Day 22.
40936798|NCT05012787|BIOLOGICAL|Havrix|Participants will receive Havrix (Hepatitis A vaccine) containing 1440 Enzyme-linked Immunosorbent Assay (ELISA) units (EL.U.) in 1.0 mL dose on Day 1.
40936799|NCT05012787|OTHER|Placebo; 0.9% saline|Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 22.
41280104|NCT01193335|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
41280105|NCT06035718|DRUG|Probiotic Blend Capsule|By a probiotic blend capsule a specific product is intended which contains the following: Lactobacillus rhamnosus Lactobacillus plantarum Lactobacillus casei Lactobacillus helveticus Lactobacillus acidophilus Lactobacillus bulgaricus Lactobacillus gasseri Bifidobacterium bifidum Bifidobacterium lactis Bifidobacterium breve Bifidobacterium longum Streptococcus thermophile Fructooligosaccharides (FOS).
40755994|NCT01362530|DRUG|Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
40936800|NCT03624296|DEVICE|MRI 7T|MRI 7T
40936801|NCT03624296|OTHER|TEST EDSS|EDSS - Expanded Disability Status Scale
40936802|NCT03624296|OTHER|TEST MSFC|MSFC - Multiple Sclerosis Functional Composite
40936803|NCT00633867|DEVICE|McGrath|Tracheal intubation, using Mcgrath video-laryngoscope
40936804|NCT00633867|DEVICE|Tracheal intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
40936805|NCT04867434|DRUG|RZL-012|small synthetic molecule for submental fat reduction
40936806|NCT04867434|DRUG|Placebo|Placebo
41280106|NCT06035718|DEVICE|tDCS|Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp.
40755995|NCT01362530|DRUG|Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
41280107|NCT06035718|DEVICE|Sham tDCS|Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp. At this arm the electric current will be applied for a very short time (30 s) after which the device will turn off, thus providing the initial tingling sensation over the scalp but not interfering with the ongoing brain activity.
40936807|NCT03930160|OTHER|Logistic Organ Dysfunction System Score|Variables of logistic organ dysfunction system score, including: GCS; heart rate; systolic BP; blood urea; serum creatinine; urine output; leucocyte count; platelet count; PaO2/FiO2; serum bilirubin; prothrombin time.
40936808|NCT05251428|PROCEDURE|Excision of the A1 pulley|Participants will undergo excision of the A1 pulley. Wounds will then be irrigated and closed in the standard fashion.
40936809|NCT05251428|PROCEDURE|Incision of the A1 pulley in the standard fashion|Participants will undergo incision of the A1 pulley in the standard fashion. Wounds will then be irrigated and closed in the standard fashion.
40936810|NCT02516735|DEVICE|I-scan with magnification|
40936811|NCT02516735|DEVICE|Standard endoscopy|
40936812|NCT01452009|DRUG|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|Travoprost Ophthalmic Solution, 0.004% given one drop once daily
40936813|NCT01452009|DRUG|TRAVATAN®|TRAVATAN® administered one drop once daily
40936814|NCT03718325|DEVICE|Burst-SCS|The treatment arm used in the study is clinically-effective burst spinal cord stimulation (Burst-SCS). The device used to deliver Burst-SCS is the St. Jude Medical Invisible Trial System.
40936815|NCT03718325|DEVICE|Sham SCS|The placebo control arm used in the study is sham spinal cord stimulation (sham SCS). The device used to deliver sham SCS is the St. Jude Medical Invisible Trial System.
40936816|NCT05530512|OTHER|electroacupuncture|acupuncture needling and stimulation are applied for 30 min
40936817|NCT04426903|OTHER|webFitForAll|PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)
40936818|NCT04426903|OTHER|BrainHQ|CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)
40755996|NCT01362530|DRUG|Aprepitant powder for suspension (PFS)|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
40755997|NCT01362530|DRUG|Ondansetron|Day 1: Administered according to product label for pediatric usage or local standard of care
40936819|NCT04710277|OTHER|Opioid-sparing multimodal pain management|Ice pack applied to abdominal incisions for 20 minutes every 2 to 3 hours for 24 hours after surgery and scheduled acetaminophen and NSAID for 96 hours after surgery. Narcotic pain medication for severe breakthrough pain.
40936820|NCT04710277|OTHER|Usual care|Scheduled acetaminophen and NSAID for 24 hours after surgery. Narcotic pain medication for severe breakthrough pain.
40936821|NCT05930704|DRUG|SHR-2017 injection|Randomized participants of multiple dose cohorts will receive a single subcutaneous dose of SHR-2017 injection.
40936822|NCT05930704|DRUG|Placebo|Randomized participants will receive a single SC injection dose of matching placebo.
40936823|NCT03063671|DRUG|Ketamine, bupivacine,dexmedetomidine|thoracic epidural catheter insertion at T4-5
40755998|NCT01362530|DRUG|Placebo for Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
40936824|NCT01469117|OTHER|enteral formula|Complete feeding of study enteral formula, route and regimen prescribed by the physician
40936825|NCT00434395|DRUG|MOA-728|
40936826|NCT04853381|OTHER|dietary treatment (low FODMAP)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
40936827|NCT04853381|OTHER|dietary treatment (gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
40936828|NCT04853381|OTHER|dietary treatment (low FODMAP+gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
40755999|NCT01362530|DRUG|Placebo for Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
40936829|NCT04853381|OTHER|dietary treatment (Traditional diet recommendations)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
40936830|NCT06115837|PROCEDURE|multivisceral resection|The prognostic factors were analyzed for pT4bN0M0 colorectal cancer after multivisceral resection
41280108|NCT02537860|OTHER|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
41280109|NCT02537860|OTHER|Placebo at T11 and L3|Two injections that contain saline are performed
41280110|NCT02537860|OTHER|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
41280111|NCT02537860|PROCEDURE|Herniorrhaphy|Unilateral inguinal hernia repair
41280112|NCT02537860|DRUG|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
40936831|NCT05167110|DIETARY_SUPPLEMENT|Placebo|Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
40936832|NCT05167110|DIETARY_SUPPLEMENT|Probiotic|Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
40936833|NCT03486717|DEVICE|Virtual reality goggles|Patients will act as their own control over two different dental appointments. One appointment will consist of wearing the virtual reality googles, the other appointment will be conducted without them. The goggles have a small screen inside of them along with headphones. This device will play an a movie or cartoon that will immerse the patient during treatment.
41450231|NCT06022107|BEHAVIORAL|LDART|LDART is a newly developed web-based social support intervention that can be accessed by smartphone or computer. Each night, the participant sets a recovery goal for the next day (e.g., drink less than usual, go to a support group meeting). The next night, they log on to LDART to indicate whether they reached their goal for the day. Depending on their response, they will be shown either a celebratory or encouraging message from someone in the addiction recovery community, along with specific information on that person's recovery organization.
41450232|NCT06363617|OTHER|FLI|Health professionals will use the FLI test in their clinical practice
41450233|NCT00364559|DRUG|Rosuvastatin|20 mg 10 days daily
41450234|NCT01205035|DRUG|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
40936834|NCT05998928|DRUG|Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells|"fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 both on three consecutive days during D-7 to D-3~BCMA-GPRC5D CAR-T Cells on day 0"
40936835|NCT00306332|PROCEDURE|T-cell and B-cell depletion|
40936836|NCT06219551|OTHER|Mobile messages via What's App|The information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic.
40936837|NCT04534465|DRUG|Polyethylene glycol (MiraLAX, BAY81-8430)|Oral solution, 17g polyethylene glycol, one time
40936838|NCT04534465|DRUG|Mannitol|Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
41130345|NCT04263610|DRUG|Dimethyl fumarate (DMF) simplified scheme|Participants will receive DMF gastro-resistant tablet orally at a dose of 60, 120, 180, 240, 360 mg daily in Week 1, Week 2, Week 3, Week 4, Week 5 respectively, and 480 mg daily from Week 6 to Week 8. If a PASI is greater than or equal to (\>=) 30% at Week 8, no dose increase will be done and if PASI is less than (\<) 30% at Week 8, participants will receive 600 mg daily in Week 9 and 720 mg from the Week 10 onwards.
41130346|NCT04263610|DRUG|Tildrakizumab|Participants who achieve PASI less than (\<) 50 (non-responders) at Week 16 will receive Tildrakizumab subcutaneous injection at a dose of either 100 or 200 mg \[(as per the Summary of Product Characteristics (SmPC)\] at Weeks 16, 20 and 32 up to Week 40.
41450235|NCT06052839|DRUG|Pembrolizumab|Immunotherapy that works by helping the immune system to kill cancer cells by targeting and blocking a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
41450236|NCT06052839|DRUG|Carboplatin|A chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
41450237|NCT06052839|DRUG|Paclitaxel|A chemotherapeutic agent used as a treatment for various cancers; paclitaxel is a mitotic inhibitor.
41450238|NCT00983099|DRUG|Neramexane|single and multiple dose, tablets, oral
40756000|NCT01362530|DRUG|Placebo for Aprepitant PFS|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
40936839|NCT03042273|DIETARY_SUPPLEMENT|High Strength Cranberry|Softgel capsule
40936840|NCT03042273|DIETARY_SUPPLEMENT|Placebo|Soy oil to match High Strength Cranberry Softgel Capsule
40936841|NCT04336644|DEVICE|BodyGuardian Mini Plus|The BodyGuardian Mini Plus attaches to the upper chest of the patient through the use of an adhesive patch. ECG tracings are recorded continuously and sent to the linked smartphone and subsequently to a cloud server.
41450239|NCT00937664|DRUG|AZD7762|solution, intravenous, weekly
41450240|NCT00937664|DRUG|gemcitabine|intravenous, weekly
40936842|NCT05278637|DRUG|Aspirin|Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
40936843|NCT05278637|DRUG|Ticagrelor|Ticagrelor 90mg BID x 4 weeks
41130347|NCT02246946|DEVICE|Positive Airway Pressure|To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
41130348|NCT02246946|OTHER|Conventional Chest Physiotherapy|To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
41130349|NCT02246946|PROCEDURE|Control group|to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
41130350|NCT05440058|DEVICE|Bispectral Index (BIS) monitoring system|Left and right sensors to record EEG activity and muscle reaction to anesthesia utilized in the operating room by anesthesia providers to assess the depth of sedation in patients with anesthesia.
41130351|NCT02931396|DEVICE|FES|
41450241|NCT05474079|OTHER|Moderate intensity exercise training|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
40936844|NCT03565965|BEHAVIORAL|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
40936845|NCT03565965|BEHAVIORAL|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
40936846|NCT00814125|DRUG|Anastrozole (Arimidex)|1mg, orally, once daily
40936847|NCT00814125|DRUG|Tamoxifen (Nolvadex)|20mg, orally, once daily
40936848|NCT00814125|DRUG|Nolvadex placebo|
40936849|NCT00814125|DRUG|Arimidex placebo|
40936850|NCT00417482|DRUG|risperidone|Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
40936851|NCT05930041|PROCEDURE|Experimental CSP|Either CSP is performed for 10-19 mm nonpedunculated colorectal polyps.
40936852|NCT05930041|PROCEDURE|Active Comparator HS-EMR|Either HS-EMR is performed for 10-19 mm nonpedunculated colorectal polyps.
40936853|NCT05852600|BEHAVIORAL|Parents and Adolescents Talking about Healthy Sexuality (PATHS)|"PATHS is an intervention delivered to parents of AMSM that aims to increase parent communication about sexuality and HIV, as well as other parent behaviors supportive of sexual risk reduction. PATHS can all be accessed online, is self-paced, and typically takes parents 40-60 minutes to complete. The toolkit is comprised of 7 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. One month later parents complete a refresher module that queries them about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact."
40936854|NCT05852600|BEHAVIORAL|Lead with Love (LWL)|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance. One month after watching LWL, parents return to the website to review refresher materials that summarize the most important lessons from the film."
40936855|NCT00812344|DRUG|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
40936856|NCT00812344|DRUG|Ketoconazole|tablets, orally, once daily for 3 days
40936857|NCT00812344|DRUG|ketoconazole|dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
40936858|NCT02925325|BEHAVIORAL|Music therapy|Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
40936859|NCT02925325|OTHER|Usual Treatment|It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
41130352|NCT04162457|DIETARY_SUPPLEMENT|Stevia|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
41130353|NCT04162457|DIETARY_SUPPLEMENT|Glucose|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
41130354|NCT04162457|DIETARY_SUPPLEMENT|Maltodextrin|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
41130355|NCT04162457|DIETARY_SUPPLEMENT|Water|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
41450242|NCT00965757|DRUG|T-614|T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
41450243|NCT00965757|DRUG|Placebo|Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
41130356|NCT04876495|DIETARY_SUPPLEMENT|Whey protein isolate|"Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the whey protein shake:~* Tropicana Trop50 Orange Juice 207mL~* Water 43 mL~* Sucralose 0.5g~The total energy 233.47Kcal.~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
41280113|NCT02537860|DRUG|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
40936860|NCT05526209|PROCEDURE|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
40936861|NCT04661969|PROCEDURE|Surgery|(group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
40936862|NCT01299701|DRUG|ASA404|(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
40936863|NCT03551483|DEVICE|ArtontheBrain|The ArtontheBrain intervention has three activities focused on a user selected artwork. The activities promote an in-depth analysis of the artwork and are organized into three activity categories; learn, play, and mingle. In 'learn', the options are to read and/or listen to the curatorial description of the artwork. In 'play', the options are to engage in a word search game, to engage in a visual puzzle game, or to engage in a storytelling game whereby a reminiscence or imaged story can be written. In 'mingle' the options involve social communications about the artwork that include seeing what other comments and seeing how the artwork has been rated by others. The mingle option permits the user to engage only with a select circle of users or to engage with a group of public users.
40936864|NCT03551483|DEVICE|Seniors Online Victoria|The active control group will use a freely available website, which is updated daily with online games for seniors through an organization called Seniors Online Victoria (https://www.seniorsonline.vic.gov.au/services-information/games).
40936865|NCT06072027|DIAGNOSTIC_TEST|cytology|Conventional cytology will be performed in parallel with VISIOCYT cytology in order to compare the two results.
40936866|NCT04965558|OTHER|No intervention|No intervention
40936867|NCT04951232|DRUG|Cinepazide Maleate|The experimental group: guipiprazitel maleate injection (klingo): 320mg (4), dissolved in 500ml of normal saline, and injected in a medium vein at a rate of 100ml/h, once a day, and administered for 14 days.
40936868|NCT04951232|OTHER|Placebo|Placebo: 4 pieces, dissolved in normal saline 500ml, intravenous drip, the speed is 100ml / h, once a day, continuous administration for 14 days
40936869|NCT03856775|DEVICE|Quantitative EEG and Seizure detector|Paediatric intensive care unit nurses, residents or fellows will perform hourly review of a bedside graphical display of the previous hour's epoch of quantitative EEG for seizure patterns. One page of quantitative EEG data represents one hour of recording. The graphical display will include a seizure-detection marker, seizure probability indicator, bilateral rhythmicity spectrogram and bilateral amplitude integrated EEG.
40936870|NCT01408329|DEVICE|CVAC Device (Cyclic Variations in Altitude Conditioning)|A hypobaric hypoxia chamber
40936871|NCT05829187|DRUG|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
40936872|NCT05829187|DRUG|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
40936873|NCT05829187|DRUG|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
40936874|NCT05829187|DRUG|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
40936875|NCT06048614|PROCEDURE|Saline Enema (SE)|"infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds~Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm"
40936876|NCT06048614|DRUG|Glycerin Suppository|"Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned."
40936877|NCT00193193|DRUG|Paclitaxel|
40936878|NCT00193193|DRUG|Estramustine|
40936879|NCT00193193|DRUG|Carboplatin|
41130357|NCT04876495|DIETARY_SUPPLEMENT|Potato protein isolate|"Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake.~Other ingredients in the potato protein shake:~* Tropicana Trop50 Orange Juice 250mL~* Sucralose 0.5g~The total energy 233.46Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
40756001|NCT01362530|DRUG|Emetogenic chemotherapy|"Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."
40756002|NCT00385489|DRUG|LXR-623|
40936880|NCT05760118|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
40936881|NCT05082532|OTHER|Interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) .|we here conduct a prospective study to evaluate the efficacy and safety of self- expandable nitinol stent especially interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) in femoropoliteal complex occlusive lesions.
40936882|NCT03454321|OTHER|Infiltration|The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.
41280114|NCT01568411|DRUG|TD-1211|Period 1
40936883|NCT04669288|DRUG|Azithromycin|"oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging."
40936884|NCT04669288|DRUG|Placebo|"oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging."
40936885|NCT00924417|BEHAVIORAL|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
40936886|NCT00924417|BEHAVIORAL|Distraction|"Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement."
40936887|NCT04094077|DRUG|AGuIX|2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
40936888|NCT01807702|DRUG|13C-Pyruvate 13C-lactate and dichloroacetate|Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
40936889|NCT01488968|RADIATION|Standard Radiation Treatment|39 radiation treatments
40936890|NCT01488968|RADIATION|Hypofractionated radiation treatment|25 radiation treatments
40936891|NCT02935543|BIOLOGICAL|CART 19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10\^7 CART19 cells, Day 2, 30% fraction: 3x10\^7-1.5x10\^8 CART19 cells, Day 3, 60% fraction: 6x10\^7-3x10\^8 CART19 cells
40936892|NCT04804501|DEVICE|Blue Light Glasses|Participants will be randomized into an experimental group (blue light glasses) or a control group (no glasses). Participants will perform a computer reading task while either wearing, or not wearing the glasses.
40936893|NCT04804501|OTHER|Computer Reading Task|Participants will read on a computer until concussion symptoms increase by a score of 3 or more (reading task termination criteria). One or more points will be assigned for each increase in symptom severity, and one point will be assigned for each new symptom that appears.
40936894|NCT03431311|BIOLOGICAL|Adoptive Cell Therapy (ACT)|T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting mutant transforming growth factor beta receptor type II (TGFβII)
40936895|NCT00640835|DRUG|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
40936896|NCT00640835|DRUG|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
40936897|NCT01911637|DRUG|VBY-036|Study drug VBY-036
40936898|NCT01911637|DRUG|Placebo|Placebo
40936899|NCT00912379|BIOLOGICAL|hemoglobin determination|laboratory and non invasive hemoglobin determinations
40936900|NCT03486704|BEHAVIORAL|Face to Face VRRS and telerehabilitation|"Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.~The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
40936901|NCT03486704|BEHAVIORAL|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
40936902|NCT03486704|BEHAVIORAL|FTF VRRS plus unstructured CS|"Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation.~Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week."
40936903|NCT03486704|BEHAVIORAL|Face to Face VRRS plus active tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
41130358|NCT04876495|DIETARY_SUPPLEMENT|Rice protein isolate|"Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the rice protein shake:~* Tropicana Trop50 Orange Juice 183mL~* Water 67mL~* Sucralose 0.5g~The total energy 233.43Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
41130359|NCT05452525|DRUG|CKD-379 I|1 tablet administration under fed condition
41130360|NCT05452525|DRUG|CKD-379 II|1 tablet administration under fed condition
41130361|NCT05452525|DRUG|D759+D745+D150|3 tablet coadministration under fed condition
41130362|NCT02686398|BIOLOGICAL|Fluad|
41130363|NCT02686398|BIOLOGICAL|Agrippal|
40756003|NCT01081938|DRUG|INSULIN GLARGINE|"Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine"
41130364|NCT01243814|DEVICE|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
41130365|NCT01243814|DEVICE|placebo injection|joint injection with saline solution for placebo
41130366|NCT06221215|PROCEDURE|trauma|The main purpose of this study is to observe whether the early hormone changes and trends in the two groups of patients with or without trauma.
41280115|NCT01568411|DRUG|TD-1211+ itraconazole|Period 2
41280116|NCT01449838|DRUG|Colistimethate sodium|active
41280117|NCT01449838|DRUG|Saline|placebo
40936904|NCT03486704|BEHAVIORAL|Face to Face VRRS plus placebo tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
40936905|NCT04204785|BEHAVIORAL|Noise Reduction Education|OR staff will be offered education regarding the importance of minimizing noise in the OR. There will also be reminder signs and posters for the duration of the post-education period.
40936906|NCT01578564|DRUG|SOR-C13|Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
40936907|NCT05031598|OTHER|Long-term fasting according to the Buchinger Wilhelmi fasting program|the participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision
40936908|NCT01231230|DRUG|fluticasone|220- mcg once
40936909|NCT01231230|DRUG|placebo inhalation|placebo inhalation once
40936910|NCT01231230|DRUG|Salmeterol|50 mcg salmeterol once
40936911|NCT01231230|DRUG|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
40936912|NCT00511212|DRUG|intravenous immunoglobulin|
40936913|NCT03361579|OTHER|Education|c.p. intervention description
40936914|NCT05695664|DRUG|Ibuprofen 800 mg|Intravenous injection of ibuprofen 800 mg
40936915|NCT05695664|DRUG|Ketorolac Injection|Intravenous injection of Ketorolac 30 mg
40936916|NCT04255927|DRUG|Coated Vicryl plus|Vicryl plus (Coated Polyglactin 910 with Triclosan)
40936917|NCT04255927|DRUG|Coated vicryl|Vicryl (Coated Polyglactin 910 without Triclosan)
40936918|NCT03961074|OTHER|Iron deficiency anemia in Chinese pregnant women|Iron deficiency anemia exists in Chinese pregnant women during pregnancy
40936919|NCT00177476|BEHAVIORAL|behavioral weight loss|
41130367|NCT04839185|DRUG|Ferumoxytol infusion|"Ferumoxytol will be administered intravenously, by infusion, over 30 minutes. It will be used a contrast agent for MRI imaging to detect placental lesions in fetal growth restriction.~Dose will be 255 mg in 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Ferumoxytol/Feraheme will be administered only once, in one infusion of 255 mg to each subject."
41130368|NCT04839185|PROCEDURE|MRI scan|The MRI scanning procedure will last for approximately 60 minutes.
41130369|NCT04263051|DRUG|UCPVax + Nivolumab|"UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care."
41130370|NCT04263051|DRUG|standard chemotherapy|Second line chemotherapy at the choice of the investigator
41130371|NCT05097001|OTHER|DBS programming|DBS readjustment based on COMPUTER or CLINICAL program
41130372|NCT01237496|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
41130373|NCT05485818|DRUG|Low Dose|12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
41130374|NCT05485818|DRUG|Middle Dose|12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
41130375|NCT05485818|DRUG|High Dose|12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
41130376|NCT05485818|OTHER|Placebo|15 subjects will be randomly assigned to the placebo for 7 days
40936920|NCT01164384|DRUG|Baminercept|
40936921|NCT04797897|DEVICE|CORI|unicondylar knee arthroplasty (UKA) treated with CORI
40936922|NCT04797897|DEVICE|Conventional|unicondylar knee arthroplasty (UKA) treated with conventional approach with conventional manual instrumentation
40936923|NCT02284178|OTHER|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
40936924|NCT02284178|OTHER|Usual Care|Oral suction with suction swab every 4 hours
40936925|NCT03626571|OTHER|18F-FDG|Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
40936926|NCT02960997|DRUG|Sirolimus, 2%|
40936927|NCT02960997|DRUG|Vehicle|
40936928|NCT00898378|GENETIC|gene expression analysis|gene expression analysis
40936929|NCT00898378|GENETIC|polymerase chain reaction|polymerase chain reaction
40936930|NCT00898378|GENETIC|polymorphism analysis|polymorphism analysis
40936931|NCT00898378|GENETIC|protein expression analysis|protein expression analysis
40936932|NCT00898378|GENETIC|proteomic profiling|proteomic profiling
40936933|NCT00898378|OTHER|gas chromatography|gas chromatography
40936934|NCT00898378|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
40936935|NCT00898378|OTHER|liquid chromatography|liquid chromatography
40936936|NCT00898378|OTHER|mass spectrometry|mass spectrometry
40936937|NCT00898378|OTHER|questionnaire administration|questionnaire administration
40936938|NCT00046111|DRUG|topotecan|A topoisomerase I inhibitor used for ovarian and lung cancer treatment
40936939|NCT04798807|DIAGNOSTIC_TEST|Nutritional screening|
40936940|NCT00814801|DRUG|Placebo|Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
40936941|NCT00814801|DRUG|Galantamine 16 mg/day|Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
40936942|NCT00814801|DRUG|Galantamine 24 mg/day|Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
40936943|NCT00970866|DIETARY_SUPPLEMENT|Iron and Folic Acid (IFA)|Pregnant women will receive one (1) Iron (60 mg) and Folic Acid (400 mcg) (IFA) tablet daily during pregnancy, and a tablet containing calcium (Ca) only (akin to a placebo) during lactation; there will be no supplementation for infants born to the women. The Fe/FA tablets will be taken each day with water after meals
40936944|NCT00970866|DIETARY_SUPPLEMENT|Multiple Micronutrient (MMN) group|Pregnant women will receive one (1) Multiple Micronutrient tablet daily during pregnancy and the first 6 months of lactation; there will be no supplementation for infants born to the women. The MMN tablets will be taken each day with water after meals
40936945|NCT00970866|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplements (LNS) group|"Pregnant women will receive 20 g of LNS-P\&L daily during pregnancy and the first 6 months of lactation, whilst infants born to the women will receive 20 g of LNS-20gM daily from 6 to 18 mo of age.~The LNS products (LNS-P\&L and LNS-20gM) will be consumed by being added to prepared food (usually mixed with complementary foods, for the child). Mothers will consume the full sachet of LNS (20 g/day) at one meal each day. Dosage and directions for use of the LNS product for children will be as follows: 20 g (\~4 teaspoons) per day divided into 2 portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion of the supplement to be consumed with 2-3 tablespoons of the already prepared food (as done previously in our study in Ghana (1)), and eat the mixture before eating the rest of the food. Do not cook food with the supplement. Store supplement at room temperature. There is no need for refrigeration."
40936946|NCT04998682|PROCEDURE|Axillary Dissection|A surgical procedure that opens the armpit (axilla) to identify, examine, or remove lymph nodes. Axillary dissection will be performed during SoC breast cancer surgery.
40936947|NCT02130726|PROCEDURE|Minimally-invasive gastrectomy|Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.
40936948|NCT02130726|PROCEDURE|Open Gastrectomy|patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
40936949|NCT03986762|DRUG|Clavulanic Acid|\~10 days of Clavulanic Acid
40936950|NCT05086068|DEVICE|Arthrosamid|Intra-articular hydrogel injection comprising of water and cross-linked polyacrylamide.
40936951|NCT06017544|PROCEDURE|PCI|The T2DM affected by AMI will be referred for receiving PCI.
40936952|NCT05328115|BIOLOGICAL|ALZ-101|Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.
40936953|NCT05328115|OTHER|Placebo|Intramuscular injections of adjuvanted placebo.
41280118|NCT04350203|PROCEDURE|Laparoscopic right colectomy with intracorporeal anastomosis (IA)|First, the right colon dissection was completed by laparoscopy. An isoperistaltic side-to-side ileocolonic mechanical anastomosis was then performed by using a linear cutting stapler. The enterotomy used to enter the stapler was closed with a running suture (3-0 absorbable monofilament or a 3-0 barbed suture). Finally, the specimen was extracted through a Pfannenstiel mini-laparotomy (4-5 cm).
40756004|NCT01081938|DRUG|INSULIN GLULISINE|"Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine"
40756005|NCT04799119|BEHAVIORAL|Do As I Do (DAID) dog training|Children and their family dog will participate in this dog training program.
40936954|NCT01948310|DRUG|Ranolazine|Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
40936955|NCT01948310|BEHAVIORAL|Aerobic Exercise|Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
40936956|NCT01948310|DRUG|Placebo|Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
41130377|NCT04304937|OTHER|patient reported outcome measure|2 questionnaires are tested against each other
41130378|NCT01530334|DRUG|Gefitinib 250mg|Gefitinib 250mg once daily
41130379|NCT05022615|DIAGNOSTIC_TEST|Topcon Camera|Standard 7 field imaging
40756006|NCT03307824|DEVICE|Synthetic glue IfabondTM|Use of the synthetic glue IfabondTM
40756007|NCT03307824|PROCEDURE|Glue-Free Suture Technique|Suture Technique
40756008|NCT03816826|OTHER|physical therapy|both are physical therapy intervention technique used to treat the soft tissue acute injuries
40936957|NCT01697358|DEVICE|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
40936958|NCT01697358|DRUG|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
41130380|NCT05022615|DIAGNOSTIC_TEST|Optos Camera|Ultrawide field imaging
41130381|NCT05022615|DIAGNOSTIC_TEST|Clarus Camera|Ultrawide field imaging
41130382|NCT04749784|DIETARY_SUPPLEMENT|High Dose Arterin Cholesterol|240mg active ingredient daily
41130383|NCT04749784|DIETARY_SUPPLEMENT|Low Dose Arterin Cholesterol|120mg active ingredient daily
41130384|NCT04749784|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
41280119|NCT04350203|PROCEDURE|Laparoscopic right colectomy with extracorporeal anastomosis (EA)|First, the right colon was widely mobilized. A small laparotomy was performed in the mid/upper abdomen to exteriorize the colon and to perform a side-to-side mechanical anastomosis, using a linear cutting stapler (GIA). The bowel opening was closed either with a manual suture or by a second firing of the GIA.
41450244|NCT05205096|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (CoronaVac), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
40936959|NCT04654884|OTHER|Auricular acupuncture (AA)|The add-on treatment will be administered at the treatment sessions with their caregiver (i.e. registered nurse, psychologist, curator), and at each session the participants receive 5 sterile stainless needles in each outer ear. The needling is standardised according to the NADA-protocol. The needles will remain in the outer ears for approximately 45 minutes, and will be removed by the care giver.
40936960|NCT04246736|BEHAVIORAL|Bädda för Kvalitet|"A group-administered preventive programme focusing on beneficial strategies for sleep and recuperation, in relation to work related stress and shift work. The intervention was based on knowledge from previous research on sleep, stress and work hours, as well as on cognitive behavioural therapy (CBT) techniques for sleep and stress management, modified for shift workers. Participants were encouraged to discuss and reflect on personal habits related to sleep and recovery. As homework between sessions, the participants were encouraged to try possibly beneficial strategies for sleep and recuperation. All participants got written material covering the content of the session, during each sessions. In addition, an adapted version of a biomathematical model (ArturNurse) was used to give participants an estimation of expected sleep lengths and fatigue levels together with tips of possible strategies to optimise sleep in relation to different shifts."
40936961|NCT05917509|DRUG|DTG/3TC|DTG/3TC FDC will be administered as an oral once daily tablet.
40936962|NCT05917509|DRUG|Cabotegravir (CAB) LA|CAB LA will be administered as a gluteal intramuscular injection once every 2 months in combination with RPV LA.
40936963|NCT05917509|DRUG|Rilpivirine (RPV) LA|RPV LA will be administered as a gluteal intramuscular injection once every 2 months in combination with CAB LA.
40936964|NCT05731531|DEVICE|ELECTROGASTROGRAPHY|Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.
40936965|NCT00436930|BIOLOGICAL|autologous tumor cell vaccine|Given subcutaneously
41280120|NCT05865327|PROCEDURE|Cryoneurolysis|Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
41280121|NCT05865327|PROCEDURE|Sham Cryoneurolysis|Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
41280122|NCT02568436|RADIATION|low level laser therapy|low level laser therapy is intended to accelerate tooth movement
41280123|NCT03950986|OTHER|Modified clinical reminders|Clinical reminders for the vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
41450245|NCT03636386|DEVICE|Percutaneous microelectrolysis|284/5000 Application of Direct Current through an acupuncture needle with intensities in microamps (μA) in the PGm of the upper trapezius muscle. The acupuncture needle will correspond to the negative electrode or cathode. The intensity of work will be 610μA at the myofascial trigger point.
41450246|NCT03636386|DEVICE|Ultrasound therapy|Application of conventional ultrasound (US) on PGm with a frequency of treatment 1MHz, intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
41450247|NCT04173858|DRUG|Naloxegol|25 mg oral naloxegol once daily.
41450248|NCT03103360|DEVICE|videopupillometer|Measure of pupillary diameter and pupillary pain index via an infrared camera Each measure lasts approximately 20 seconds
41450249|NCT03103360|PROCEDURE|skin incision|performed under general anesthesia by the surgeon, at the beginning of an elective or emergency surgery.
41450250|NCT06442956|OTHER|Rapid Heat Condition|The heat condition is the intervention. Personal protective equipment will be used to create the rapid heat stress condition, resulting in a rapid rise in core temperature. This will be in combination with the physiological heat produced by the treadmill protocol.
40936966|NCT00436930|BIOLOGICAL|sargramostim|Given subcutaneously
41450251|NCT06442956|OTHER|Gradual Heat Condition|The gradual heat condition is the control. Physiological heat will be produced by exercise on a treadmill, and light exercise clothing will help moderate the rise in core temperature.
41450252|NCT06230692|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
40936967|NCT00436930|BIOLOGICAL|therapeutic autologous dendritic cells|Given subcutaneously
40936968|NCT03621618|DIAGNOSTIC_TEST|dobutamine|evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure
40936969|NCT03621618|DIAGNOSTIC_TEST|norepinephrine|evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis
40936970|NCT02700087|DRUG|ranitidine or famotidine|Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
41280124|NCT01225354|DRUG|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
41450253|NCT03665194|DRUG|Cortexolone 17α-propionate solution|Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.
40936971|NCT02700087|DRUG|Placebo|Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
40936972|NCT00167466|DEVICE|Soladey-3 toothbrush|subject to brush with experimental Soladey-3 brush for 4 week
40936973|NCT00167466|DEVICE|Placebo Soladey-3 toothbrush|subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
40936974|NCT04477239|BEHAVIORAL|Gluten (behaviour)|Gluten is a protein normally present in the daily diet of healthy volunteers not suffering from gluten related disorders, in far greater quantities (10-20 g/day) than those used in this study (10 mg-1 g/day).
40936975|NCT04477239|BEHAVIORAL|Placebo (behaviour)|Placebo is composed of pregelatinized maize starch Ph.Eur. 97.5%; magnesium stearate Ph.Eur. 1.5%; micronized silica Ph.Eur. 0.5%; Micronized talc Ph.Eur. 0.5% (NOT containing preservatives, colorings, or gluten).
40936976|NCT02029339|DEVICE|Continuous topical triple-tube irrigation and suction|"The triple-tube device was continuous operated: instilled the topical solution through the washing tube, delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of sleeve tubes through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China)."
40936977|NCT02029339|DEVICE|SOC|Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
40936978|NCT04756180|DRUG|Omega-3-acid ethyl ester or Placebo|Omega-3-acid ethyl ester 2 gm/day for first 4 week followed by 4gm/day for 8 week
40936979|NCT02259790|DRUG|Telmisartan/amlodipine fixed-dose combination tablet|
40936980|NCT02259790|DRUG|Telmisartan|
41130385|NCT05652075|PROCEDURE|pericapsular nerve group and lateral femoral cutaneous nerve block|Will undergo pericapsular nerve group block (PENG) combined with lateral femoral cutaneous nerve under ultrasound guided block with 20 mL of 0.25% bupivacaine.
41130386|NCT05652075|PROCEDURE|lumbar plexus block|Will undergo Lumbar plexus block (LPB) under ultrasound guided block with 20 mL of 0.25 % bupivacaine.
41130387|NCT06163300|DIAGNOSTIC_TEST|MRI advanced techniques|Participants will be submitted to MRI studies at diagnosis, during disease evolution and after treatment. Data collected will be analysed by two different neuroradiologists using advanced techniques.
41130388|NCT03580200|OTHER|Trigger Point Dry Needling|For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
41450254|NCT03665194|DRUG|Placebo|matching placebo
41280125|NCT05811195|DEVICE|Diode Semiconductor, Duo|Intraoral photobiomodulation therapy (660nm, 3s/point, 10J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
40936981|NCT02259790|DRUG|Amlodipine|
40936982|NCT04974918|PROCEDURE|Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of large Lip defects post traumatic or post tumor resection.|A perforator near the defect was selected to accomplish a sufficient arc of rotation without tension. The flap was designed to cover the defect based on one perforator and to hide the donor site in the nasolabial fold. An incision on one side of the flap was made to the subcutaneous tissue. Undermining of the flap until the perforators were identified. After the perforators were identified, the flap was redesigned and an incision was made circumferentially. Dissection of the pedicle was performed until tension-free transposition was done to cover the defect, and the distal perforators were sacrificed to help flap movement.
41450255|NCT03444883|DRUG|Ilaprazole|10mgx2 tablet once daily for weeks
41450256|NCT02202057|OTHER|Respiratory resistive load on inhalation|"The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in."
40936983|NCT04633343|OTHER|Small volume breath and fast breathing rate for 5 minutes|Small volume breath and fast breathing rate delivered via mechanical ventilator.
40936984|NCT04633343|OTHER|Large volume breath and slow breathing rate for 5 minutes|Large volume breath and slow breathing rate delivered via mechanical ventilator.
40936985|NCT04807478|DRUG|Omegaven® (fish oil triglycerides) Injectable Emulsion|Dose, frequency and duration is a decision of the Investigator
40936986|NCT03345342|DRUG|PP6M|Participants will receive intramuscular injection of PP6M.
40936987|NCT03345342|DRUG|PP3M 350 mg eq.|Participants will receive intramuscular injection of PP3M 350 mg eq.
40936988|NCT03345342|DRUG|PP3M 525 mg eq.|Participants will receive intramuscular injection of PP3M 525 mg eq.
41450257|NCT02202057|OTHER|Fluoroscopic swallowing evaluation|Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
40936989|NCT03345342|DRUG|PP1M|Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
40936990|NCT03345342|OTHER|Placebo|Participants will receive matching placebo.
41450258|NCT04966403|OTHER|Standard physical therapy|building strength, enhancing developmental skills, boosting balance, coordination, and postural control
40756009|NCT02321150|PROCEDURE|Cautery|"* Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Relaxing incisions placed at the corners of the recipient site.~* Graft is slid into place~* Graft / host interface is gently dried with a Qtip~* Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.~  * Power setting: 25.~ * Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.~* Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off~* Cautery is applied at the 4 apices of the graft then in between these points."
40756010|NCT02321150|PROCEDURE|Sutures|"* Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures"
40756011|NCT02633527|DRUG|Placebo|Placebo was administered once daily
40756012|NCT02633527|DRUG|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
40756013|NCT02633527|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
40756014|NCT02633527|DRUG|300mg SPN-812|300mg SPN-812 was administered once daily and compared to placebo
40756015|NCT02633527|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
40756016|NCT04452162|DIAGNOSTIC_TEST|MRI|You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
40756017|NCT03345810|DRUG|Durvalumab|Induction: (1125 mg) cycle Q3W Maintenance: (1500 mg) cycle Q4W
40756018|NCT03345810|DRUG|Vinorelbine|(30 mg/m2 D1 + D8 as infusion) cycle Q3W
40756019|NCT03345810|DRUG|Gemcitabine|(1000 mg/m2 D1 + D8 as infusion) cycle Q3W
40756020|NCT03345810|DRUG|nab-Paclitaxel|(100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W
40756021|NCT03345810|DRUG|Carboplatin|(AUC = 5 mg•min/mL on Day 1) cycle Q3W
40936991|NCT02531334|DIETARY_SUPPLEMENT|TA-65|2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
41450259|NCT04966403|OTHER|trampoline-based stretch-shortening cycle exercises|muscle strength
40756022|NCT04791020|DRUG|Lidocain topical + paracervical blockade|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade
40756023|NCT04791020|DRUG|Lidocaine topical|5mL of lidocaine gel applied topically to cervix previous to clamping, No paracervical blockade will be applied.
40756024|NCT05750004|PROCEDURE|computer guided immediate implant placement|Atraumatic extraction followed by immediate implant placement using safe angle position computer guided surgical stents, followed by customized healing abutments. after 3 months, Impressions for final prosthesis will be done
40756025|NCT00674843|RADIATION|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
40756026|NCT03055078|BIOLOGICAL|mesenchymal stem cells|Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
40756027|NCT03445442|PROCEDURE|SCP|Sacrocolpopexy (SCP) aims to secure the anterior vaginal wall, the uterus more or less the posterior vaginal wall using polypropylene prostheses and to secure them to the presacral ligament to restore the patient's anatomical features and improve pelvic symptoms
40756028|NCT03445442|PROCEDURE|NTR|Native tissue repair surgery (NTR) consist of site-specific surgical repair of the existing defect (anterior and/or posterior) using non-absorbable sutures. Specifically, anterior and/or posterior colporrhaphy for cystocele and rectocele respectively after adequate hydrodissection of the vesicovaginal or rectovaginal space.
40756029|NCT03445442|PROCEDURE|VMR|Vaginal mesh repair surgery (VMR) is performed using a single-incision mesh system. A single vertical incision is made in the anterior and/or posterior vaginal wall. A full-thickness dissection is performed laterally and apically to the ischial spine.
40756030|NCT05095441|BIOLOGICAL|C5252|A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.
41450260|NCT02177617|DRUG|Botox injection|Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms
40936992|NCT05369260|OTHER|Telerehabilitation-based cervical and scapular stabilization exercises|Telerehabilitation based cervical and scapular stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
40936993|NCT05369260|OTHER|Telerehabilitation-based cervical and core stabilization exercises|Telerehabilitation based cervical and core stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
41450261|NCT02177617|BEHAVIORAL|Physical Therapy|Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.
41453549|NCT03419403|DRUG|Temozolomide|Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.
40936994|NCT06521840|DEVICE|Masimo RAD 67|This is an observational study of a non-invasive hemoglobin measurement device in a pregnant patient population. The current standard of care for anemia screening during pregnancy involves performing invasive venipuncture at two separate visits throughout the course of the pregnancy. The purpose of this research study is to compare the device performance with the gold standard hemoglobin measurement (venipuncture). The research team will use the Masimo Rad-67 handheld co-oximeter which has a reusable finger-tip sensor that enables spot-check monitoring measurements of both oxygen saturation and non-invasive hemoglobin measurement. At the time of a blood draw, the research team will place the pulse oximeter on the participant's finger. The devices requires 1-3 minutes for an accurate measurement. After the measurement is complete, the participant will be asked 2 questions on their satisfaction and comfortability with the device and 1 question regarding their skin tone.
40936995|NCT02554851|DRUG|recombinant human Epidermal Growth Factor (rhEGF)|The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local application (intralesional) with the therapeutic potential to promote granulation and wound healing of DFU. The rhEGF is a polypeptide of 53 amino acids and has the ability to stimulate fibroblasts, keratinocytes and vascular endothelial cells proliferation. Then it contributes to its properties in scar tissue formation. The action mechanism is based on the interaction with specific receptors located on specifics cell membranes. The rhEGF was developed through recombinant DNA technology and it has been produced by biotechnological methods in Saccharomyces cerevisiae yeast line.
40936996|NCT02554851|OTHER|Placebo|This group will receive the standard medication and the placebo drug. The placebo drug has the same formulation, except for the fact that it does not contain the recombinant human Epidermal Growth Factor (rhEGF).
40756031|NCT02364895|OTHER|Males control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
40936997|NCT06338605|OTHER|no intervention, observational study of AKI under CDK4/6 inhibitor treatment|no intervention
40936998|NCT04219462|DEVICE|active extracorporeal shock wave|Ultrasound gel was used as a coupling agent, and the applicator of extracorpral shock wave therapy (ESWT) will be held perpendicular to the treatment surface throughout the treatment. Men in this group (n= 20) men receive ESWT twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura + 5 mg sildnafil once daily for 3 months
40936999|NCT04219462|DEVICE|sham extracorporeal shock wave|twenty men will receive sham treatment underwent identical therapy with ESWT application with a similar appearance and sound as the active extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
40937000|NCT06142890|OTHER|No cooling (control)|Participants are exposed to 31°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure.
40937001|NCT06142890|OTHER|Cooling with ceiling fan|Participants are exposed to 31°C, 45% relative humidity for 8 hours. Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure. Participants will remain under a commercially available ceiling fan generating a standard air flow throughout the duration of exposure.
40937002|NCT00945854|OTHER|Wholegrain cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
40937003|NCT00945854|OTHER|Refined cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
40756032|NCT02364895|OTHER|Males Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
40937004|NCT04758845|DIETARY_SUPPLEMENT|Cocktail|Subjects will consume 2B CFU once daily containing .5B CFU DE111, .5B CFU MIT411, .5B CFU CGI314, and .5B CFU CSI08 for 45 days.
41130389|NCT03039296|PROCEDURE|Endoscopic rhizotomy|Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.
41453550|NCT03419403|RADIATION|Radiation|Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.
41453551|NCT04647825|OTHER|Collection of data from non-invasive epilepsy monitoring|Creation of a large long-term EEG database for seizure detection/prediction
40756033|NCT02364895|OTHER|Males Group 2: New letter with neutral gender content|Unisex letter
40756034|NCT02364895|OTHER|Males Group 3: New letter with male-specific content|New letter tailored for men
40756035|NCT02364895|OTHER|Females control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
40756036|NCT02364895|OTHER|Females Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
40756037|NCT02364895|OTHER|Females Group 2: New letter with neutral gender content|Unisex letter
41280126|NCT05811195|DEVICE|Gemini laser|Extraoral photobiomodulation therapy (810 + 980 nm, 20s/point, 4.07J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
41280127|NCT03139292|DEVICE|ProSeal Laryngeal Mask Airway|ProSeal Laryngeal Mask Airway was used as the supraglottic device
41280128|NCT03139292|DEVICE|AmbuAuraGain Laryngeal Mask Airway|AmbuAuraGain Laryngeal Mask Airway was used as the supraglottic device
41280129|NCT06269523|OTHER|Kinesio taping, Lymphatic drainage|Kinesio tape, is an elastic cotton strip with an acrylic adhesive that is purported to ease pain and disability from athletic injuries and a variety of other physical disorders. The application of Kinesio Tex Tape facilitates the opening of microvalves due to a dynamic pressure variation due to alteration in skin density. This decompression activates lymphatics in the dermis and improves lymphatic flow. The end result is a tissue inflammation and swelling reduction.It has been applied at the end over every session after lymphatic dreinage (see below).
41280130|NCT06269523|OTHER|Lymphatic drainage|Lymphatic drainage is a type of manual manipulation of the skin based on the hypothesis that it will encourage the natural drainage of the lymph, which carries waste products away from the tissues back toward the heart. The lymph system depends on intrinsic contractions of the smooth muscle cells in the walls of lymph vessels (peristalsis) and the movement of skeletal muscles to propel lymph through the vessels to lymph nodes and then to the lymph ducts, which return lymph to the cardiovascular system. Manual lymph drainage uses a specific amount of pressure and rhythmic circular movements to stimulate lymph flow.
41280131|NCT01591980|DRUG|Pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
41453552|NCT01202253|DRUG|anidulafungin|A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
40756038|NCT05073757|DEVICE|Personalized guides and plates|Patients will be included in the study and then followed clinically according to the routine care of orthognathic surgery with personalized guides and plates. The only specific act this study is the completion of an OQLQ quality of life questionnaire by patients preoperatively and between 8 to 12 months postoperatively.
40756039|NCT03992430|DRUG|Eteplirsen|Solution for intravenous (IV) infusion.
40756040|NCT03881878|DRUG|TAHP and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (420mg, IV)"
40756041|NCT03881878|DRUG|TAHP plus AC and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~* Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~* Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
40756042|NCT00043680|DRUG|Celecoxib|
40756043|NCT00917020|DRUG|Nasal CO2|As-Needed during the 14 day Treatment Period
40756044|NCT00917020|DRUG|Inactive Placebo Gas|Placebo
40756045|NCT03041337|DIAGNOSTIC_TEST|stress echocardiography|"stress echocardiography will be performed in accordance with the current guidelines on a variable load 45° cycle ergometer with an incremental workload of 25 W every 2 minutes up to the symptom-limited maximal tolerated workload. Echocardiographic measurements will be acquired at baseline, at peak exercise and during recovery of 5 minutes.~The electrocardiogram and blood pressure will be monitored at each workload. Termination criteria and / or positive test criteria for inducible myocardial ischemia will follow the current recommendations"
40756046|NCT01952262|OTHER|diaphragm ultrasound|we'll perform diaphragm ultrasound in ICU critically ill patients
40756047|NCT06500468|DEVICE|PillSense System|"The PillSense System consists of the PillSense Capsule, a small single use capsule that is safe for human consumption and PillSense Receiver, an external real-time monitor for data display. The PillSense Capsule is a minimally invasive, single use medical device designed to detect the presence of bleeding in the upper digestive tract, to aid with patient care. The PillSense Receiver collects and displays real-time information gathered by the PillSense Capsule within 10 minutes. The PillSense Receiver interprets the data and displays a result message Blood detected or No blood detected."
41280132|NCT01591980|DRUG|pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
41280133|NCT01591980|DRUG|placebo|Identical placebo capsules will be administered in the same way.
41280134|NCT01158612|DRUG|Growth Hormone|infusion of Growth hormone in the patella tendon.
41280135|NCT05290220|DRUG|HLX07|1500 mg
41280136|NCT05290220|DRUG|HLX10|300 mg
41450262|NCT02177617|PROCEDURE|Transcranial magnetic stimulation (TMS)|For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
41450263|NCT01731977|BEHAVIORAL|Strengths-based family psychoeducation|Family psychoeducation in a group setting is performed every two weeks for eight weeks.
41450264|NCT06627244|DRUG|Tebentafusp|Tebentafusp will be administered intravenously to participants at or within 28 days of their first Y-90 TARE procedure. This 28-day period includes the 14- to 28-day Y-90 TARE Recovery Period. For administrative purposes, one cycle of tebentafusp treatment is 28 days in length. Tebentafusp will be administered on a dose escalation schedule for Cycle 1 starting at 20 mcg on Day 1, increasing to 30 mcg on Day 8, and a final dose of 68 mcg on Day 15, which will be administered once per week until unacceptable toxicity develops, disease progression, or withdrawal of consent, whichever occurs first.
41450265|NCT06627244|RADIATION|TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization|Participants will undergo radiographic and 99mTC-labeled macroaggregated albumin (99mTc-MAA) assessment for suitability prior to Y-90 absorbed glass microsphere treatment per institutional procedures. Y-90 trans-arterial radioembolization (TARE) is a standard of care treatment for intrahepatic metastases of uveal melanoma as indicated in the National Comprehensive Cancer Network (NCCN) consensus guidelines (NCCN Guidelines®, 2023). Y-90 absorbed glass microspheres will be administered at least one time prior to initiating Tebentafusp treatment. After the Y90-TARE procedure, participants will have a 14- to 28-day Y-90 TARE Recovery Period.
41450266|NCT03621046|DRUG|Zolpidem|Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.
41450267|NCT03621046|OTHER|Placebo|Placebo
41450268|NCT06491342|DIETARY_SUPPLEMENT|Probiotic|Probiotic-Lactobacillus Zeae and Lactobacillus reuteri
41450269|NCT06491342|DIETARY_SUPPLEMENT|Placebo|placebo
41450270|NCT03007706|PROCEDURE|Women undergo cesarean section delivery|
41450271|NCT03680313|PROCEDURE|Hypertension outpatient treatment|Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
41450272|NCT02647853|DRUG|TAT4 Gel concentration A|
41450273|NCT02647853|DRUG|TAT4 Gel concentration B|
41450274|NCT02647853|DRUG|Placebo|
41450275|NCT05946486|DRUG|immunomodulatory treatment by rituximab|1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days)
41280137|NCT05290220|DRUG|HLX04|15mg/kg
41280138|NCT05290220|DRUG|lenvatinib|12 mg (BW≥60 kg) or 8 mg (BW \<60 kg)
41280139|NCT00012610|PROCEDURE|Telepsychiatry|
41450276|NCT00921674|DRUG|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
40756048|NCT05640635|PROCEDURE|Ventilator weaning first|Ventilator weaning initiated and completed before start of ECMO weaning.
41280140|NCT00222079|DRUG|Esomeprazole (Nexium)|
41280141|NCT05911997|DRUG|MTC 01|Slurry to be administered via colonoscopy
41280142|NCT05911997|DRUG|Fecal Microbiota Transplantation (FMT)|Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
41450277|NCT06298877|OTHER|Frailty and Quality of Life evaluation|Frailty and Quality of Life evaluation after surgery
41280143|NCT02281812|PROCEDURE|Radiofrequency ablation|After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H\&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
41280144|NCT04460703|OTHER|Control message|2/15 of the sample will be assigned to the pure control group, which is a passage on the costs and benefits of bird feeding.
41280145|NCT04460703|OTHER|Baseline message|3/15 of the sample will be assigned to a control group with a message about the effectiveness and safety of vaccines.
41280146|NCT04460703|OTHER|Personal freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting people's personal freedom and by working together to get enough people vaccinated society can preserve its personal freedom.
41450278|NCT05574036|DRUG|Febuxostat 80 MG Oral Tablet|Febuxostat used as 80 mg oral tablet once daily for 6 months
40756049|NCT05640635|PROCEDURE|ECMO weaning first|ECMO weaning initiated and completed before start of ventilator weaning.
41280147|NCT04460703|OTHER|Economic freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting peoples's economic freedom and by working together to get enough people vaccinated society can preserve its economic freedom.
41280148|NCT04460703|OTHER|Self-interest message|1/15 of the sample will be assigned to this intervention, which is a message that COVID-19 presents a real danger to one's health, even if one is young and healthy. Getting vaccinated against COVID-19 is the best way to prevent oneself from getting sick.
40937005|NCT04758845|DIETARY_SUPPLEMENT|CGI314|Subjects will consume 1B CFU of CGI314 once daily for 45 days.
40937006|NCT04758845|DIETARY_SUPPLEMENT|CSI08|Subjects will consume 1B CFU of CSI08 once daily for 45 days.
41280149|NCT04460703|OTHER|Community interest message|1/15 of the sample will be assigned to this intervention, which is a message about the dangers of COVID-19 to the health of loved ones. The more people who get vaccinated against COVID-19, the lower the risk that one's loved ones will get sick. Society must work together and all get vaccinated.
41450279|NCT05574036|DRUG|vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
41450280|NCT03774329|OTHER|Usual care|Patients included in the control group will not benefit from the intervention in adapted physical activity. However, this will not affect their support. Patients will be seen by their specialist doctor as part of the usual management of their IBD.
40937007|NCT04758845|DIETARY_SUPPLEMENT|MIT411|Subjects will consume 1B CFU of MIT411 once daily for 45 days.
40937008|NCT02865343|DEVICE|Non-invasive Ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
41130390|NCT04921488|DEVICE|screening colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
41130391|NCT05770427|BEHAVIORAL|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by parents and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching parents to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
41130392|NCT01185600|BIOLOGICAL|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
41130393|NCT01185600|BIOLOGICAL|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
41130394|NCT04981600|DEVICE|Radiofrequency ablation|Patients in the RF group will be first examined under anesthesia at the beginning of the procedure in lithotomy position. Approximately 3-6 ml of 20 mg/ml Lidocaine (Jetokaine, Adeka İlaç Sanayi, Samsun) solution will be injected between the cushion and the internal anal sphincter to minimize heat conduction to the surrounding tissues during the procedure. The HPR45i probe (F Care Systems, Antwerpen, Belgium) connected to the Rafaelo ® EVRF machine (F Care Systems, Antwerpen, Belgium) will be placed inside the cushion and 25 watts of RF energy will be transmitted. Care will be taken by not exceeding the dentate line caudally. The recommended Joule value for each operation is 1200-3000 J. Then cold is applied on the cushion, reducing the temperature of the tissue and preventing damage to the surrounding tissues. The same procedure will be performed for other pathologic cushions as well.
41280150|NCT04460703|OTHER|Economic benefit message|1/15 of the sample will be assigned to this group, which is a message about how COVID-19 is wreaking havoc on the economy and the only way to strengthen the economy is to work together to get enough people vaccinated.
41280151|NCT04460703|OTHER|Guilt message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and society must work together to get enough people vaccinated. Then it asks the participant to imagine the guilt they will feel if they don't get vaccinated and spread the disease.
40937009|NCT02865343|DEVICE|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
40937010|NCT06321627|RADIATION|Radiation therapy as curative treatment|Radiation therapy as curative treatment (exclusive, post-operative, with or without chemotherapy) for HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus
40937011|NCT00775385|DRUG|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
40937012|NCT00775385|DRUG|Customized Treatment|"Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~* ERCC1 high : no treatment~* ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)"
40937013|NCT05090462|DEVICE|PICO dressing|Negative Pressure Wound Therapy device
41280152|NCT04460703|OTHER|Embarrassment message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the embarrassment they will feel if they don't get vaccinated and spread the disease.
41280153|NCT04460703|OTHER|Anger message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the anger they will feel if they don't get vaccinated and spread the disease.
41280154|NCT04460703|OTHER|Trust in science message|1/15 of the sample will be assigned to this message about how getting vaccinated against COVID-19 is the most effective way of protecting one's community. Vaccination is backed by science. If one doesn't get vaccinated that means that one doesn't understand how infections are spread or who ignores science.
41280155|NCT04460703|OTHER|Not bravery message|1/15 of the sample will be assigned to this message which describes how firefighters, doctors, and front line medical workers are brave. Those who choose not to get vaccinated against COVID-19 are not brave.
40756050|NCT01497093|DRUG|Pomalidomide|Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle
41280156|NCT02339714|OTHER|acupuncture combined moxibustion|"Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).~Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether."
41130395|NCT04981600|DEVICE|Laser|"The same preoperative preparations will be done for the laser group as well. The NeoV 1470 (neoLaser, Israel) device will be used in this group. Following routine placement of the patient in lithotomy position and determining the cushion to be treated, a 12 W laser beam with a wavelength of 1470nm will be inserted into the cushion above the dentate line and advanced to the apex and approximately 3 laser shots are delivered throughout the course caudally, the number of which can be altered according to the size targeted cushion. Finally the procedure will be completed after gentle cold application.~An enema will be given to the patients in both study groups in the morning of the operation and patients will be discharged with analgesics on the same day."
41280157|NCT02339714|DRUG|Loratadine|Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
41280158|NCT03285815|DEVICE|Proton Therapy|
41280159|NCT01587963|DRUG|Ascorbic Acid|66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
40756051|NCT01497093|DRUG|Bortezomib|Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression
41130396|NCT00327119|DRUG|ABX-EGF (panitumumab)|
41130397|NCT03665792|DEVICE|nociception index qNOX|non-invasive, real time, monitoring for nociception stimulation
41130398|NCT04987801|OTHER|Drug Toxicity|Patients who took over dose of Drugs
41130399|NCT00537212|OTHER|The South Beach Diet|"Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet."
41130400|NCT00537212|OTHER|The Ornish Diet|"Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book."
41130401|NCT00537212|OTHER|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
41130402|NCT02788994|DEVICE|Endovis BA2 nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~* stable fracture synthesis for fast rehabilitation and early mobilization~* an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)"
40756052|NCT01497093|DRUG|Dexamethasone|Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
41280160|NCT01587963|OTHER|Ringers Lactate or Normal Saline|Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
41280161|NCT01346800|DRUG|Prasugrel|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
41280162|NCT01346800|DRUG|Ritonavir|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
41453553|NCT04919616|DRUG|TILs（Tumor Infiltrating Lymphocytes）|10e9, 10e10, 10e11 dose range of TILs, 3+3 dose escalation
41453554|NCT02733211|DEVICE|MD- Logic Closed Loop System|Closed Loop System
41130403|NCT02788994|DEVICE|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
41130404|NCT05909072|DRUG|Hyaluronic acid combined with tranexamic acid microneedling|1 ml of TXA, available as a 500 mg/5 ml ampoule, will be applied on the right side of the face after microneedeling and left to dry
41130405|NCT05909072|DRUG|tranexamic acid microneedling|On the left side of face, 0.5 ml of HA 3.5% will be used 1st followed by microneedling then 1 ml of TXA will be applied
40756053|NCT03203603|OTHER|No active intervention|This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
40756054|NCT01775410|DEVICE|Wolverine System to perform atherectomy|
40937014|NCT00817284|DRUG|bevacizumab and Irinotecan and radiotherapy|"* Bevacizumab 10 mg/kg is administered on days 1 and 15.~* Irinotecan:~* Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~* Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~* During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
41130406|NCT05794659|BIOLOGICAL|AST-201|i.d. (3-week interval, 3 cycles in total)
41130407|NCT05794659|DRUG|Paclitaxel|3-week interval, 6 cycles in total
41130408|NCT05794659|DRUG|Carboplatin|3-week interval, 6 cycles in total
41130409|NCT05794659|DRUG|Placebo|i.d. (3-week interval, 3 cycles in total)
41130410|NCT05794659|DRUG|rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)|i.d. (3-week interval, 3 cycles in total)
41280163|NCT00353977|BIOLOGICAL|ALVAC-CMV (vCP260)|"ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.~Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.~Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)"
41280164|NCT02850796|BEHAVIORAL|Kg-Free|Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities
41280165|NCT02850796|OTHER|Treatment as Usual|Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
41280166|NCT02350543|DRUG|Aspirin|
41280167|NCT06049316|OTHER|Scapular stabilization exercises|"In Scapular stabilization exercise, following treatment protocol will involve.~* In supine position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree. After this patient will raise his hand overhead with 90 degree flexion and elbow extension and also perform scapular retraction. (10 sec hold, 10 reps, 20 sec break).~* In quadrupled position with 120 degree flexion and shoulder abduction patient will lifted his hands. (10 sec hold, 10 reps, 20 sec break) TYI exercises will be administered~* T shape: Place both arms horizontal with thumbs up. (10 times, 5 sec hold, 3 sets)~* Y-shape: In prone lying place arms in 45 degree. (10 times, 5 sec hold, 3 sets)~* I-shape: In prone position patients will place his both arms overhead. (10 times, 5 sec hold, 3 sets).~These above exercises will perform 3 times a week for eight weeks."
41450281|NCT03774329|OTHER|adapted physical activity|Patients in the experimental group will have, in addition to their usual follow-up with their specialist doctor, an intervention in adapted physical activity at home, at the rate of 3 sessions (of a duration of 10 to 20 minutes) per week during 9 consecutive months.
41450282|NCT04283851|DIAGNOSTIC_TEST|testing functional haemodynamic parameters for preload assessment|dynamic testing of preload responsivity plus echocardiography
41450283|NCT00533507|BIOLOGICAL|Synflorix|Intramuscular injection, 3 doses.
40756058|NCT06032975|OTHER|Questionnaires|The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer
41130411|NCT00111683|DRUG|MK0457|
41130412|NCT00004149|DRUG|arsenic trioxide|
41130413|NCT01193205|BEHAVIORAL|Skills Training|20 weeks of Dialectical Behaviour Therapy Skills Training
41130414|NCT01982994|BEHAVIORAL|Education/Daily Planning|"In this study, we will use educational materials delivered at the initial enrollment session and in daily facts of the day presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)"
41130415|NCT02614235|DEVICE|Pocket-ECG III system|Continuous cardiac telemetry until diagnosis or a maximum of two months
41450284|NCT00533507|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses.
41450285|NCT00533507|BIOLOGICAL|Rotarix|Oral, 2 doses.
41450286|NCT02128308|DRUG|Levofloxacin and Streptomycin added|
41450287|NCT02128308|DRUG|Moxifloxacin and Kanamycin added|
41450288|NCT04013763|OTHER|wheat containing skin care products|stop or continue using wheat containing skin care products
40756059|NCT04619849|DIAGNOSTIC_TEST|EMG|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
40756060|NCT04619849|DIAGNOSTIC_TEST|Palmaris Longus Test|Schaffer test will be done to understand the presence of palmaris longus. 4 different tests will be done to prove its absence.
40756061|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 50mg BID, once daily, 24 weeks.
41130416|NCT03901781|COMBINATION_PRODUCT|ST266 via Intranasal Delivery|ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.
40756062|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
40756063|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 90mg BID, once daily, 24 weeks.
40756064|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
40756065|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
41130417|NCT02189772|DRUG|Metadoxine extended release|MG01CI
41130418|NCT02189772|DRUG|Placebo|Inactive drug
41130419|NCT05206058|PROCEDURE|venipuncture|Plan to enroll 240 health people who are 20-35 years of age. People with received veinpuncture. Blood will be collected at time and drawn into Heparin-coated tube.
41450289|NCT03522532|PROCEDURE|Amalgam placement|Before the Amg was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
41450290|NCT03522532|PROCEDURE|Tetric EvoCeram placement|Before the TEC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
41450291|NCT03522532|PROCEDURE|Beautifil placement|Before the BF was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
41450292|NCT03522532|PROCEDURE|Zinc phosphate cement placement|Before the ZPhC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
41450293|NCT03522532|PROCEDURE|Zinc polycarboxylate cement placement|Before the ZPoC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
41450294|NCT03522532|PROCEDURE|Glass ionomer cement placement|Before the GIC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
41450295|NCT02795663|DEVICE|NIRS EEG HR recording|NIRS EEG HR recording
41450296|NCT03220958|DRUG|Metoclopramide|Metoclopramide 20mg
41450297|NCT03220958|DRUG|Diphenhydramine|Diphenhydramine 25mg
41450298|NCT03220958|DRUG|Normal saline|100ml normal saline
41450299|NCT06627335|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
41450300|NCT06627335|DRUG|TCS|Topical corticosteroid
41450301|NCT02473393|DRUG|OPS-2071 tablet|
41450302|NCT03245658|DRUG|THC and CBD Mixture|Individually titrated doses on daily basis
41450303|NCT05069480|DEVICE|Virtual reality-based training equipment.|It is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The equipment facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
40756066|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
40756067|NCT05274035|DRUG|Perampanel|"For children ≥4 years old, the initial dose is 2 mg per day, the titration interval is ≥2 weeks, the daily dose is increased by 2 mg each time (based on clinical response and tolerability), and the maintenance dose is ≥4 mg per day, up to a maximum dose of 12 mg per day.~For children \<4 years old, the initial dose is 0.04 mg/kg per day, the titration interval is ≥ 2 weeks, the daily dose is increased by 0.04 mg/kg each time (based on clinical response and tolerability), and the maintenance dose is ≥ 0.08 mg/day per day kg, the highest dose is 0.24 mg/kg per day.~According to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
40937015|NCT00817284|DRUG|Bevacizumab and Temozolomide and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
40937016|NCT00414427|PROCEDURE|Intraarticular steroids|
40937017|NCT01466777|PROCEDURE|Traditional surgery type|Traditional laparoscopic surgery for endometrial cancer
40937018|NCT01466777|PROCEDURE|Robotic assisted laparoscopic surgery|Robotic assisted laparoscopic surgery for endometrial cancer
40937019|NCT00745225|DRUG|Pioglitazone|pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
40937020|NCT00745225|DRUG|placebo comparator|1 capsule daily, 96 weeks.
40937021|NCT03832244|DIAGNOSTIC_TEST|Sub-mental ultrasonography|Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries
40937022|NCT03455764|DRUG|MCS110|MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
40937023|NCT03455764|DRUG|Dabrafenib|Dabrafenib attack different proteins that promote the growth of cancerous cells
40937024|NCT03455764|DRUG|Trametinib|Trametinib attack different proteins that promote the growth of cancerous cells
40937025|NCT05354804|DIAGNOSTIC_TEST|Troponin I (Siemens VTli) 0/1 hour algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
40937026|NCT05354804|DIAGNOSTIC_TEST|Troponin T (Roche Diagnostics) 0/1 hour ESC algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
40937027|NCT01683773|BIOLOGICAL|AERAS-402|Intramuscular needle injection 1x10\^11 vp
40937028|NCT01683773|BIOLOGICAL|MVA85A|Intradermal needle injection 1x10\^8 pfu
40937029|NCT03316534|DRUG|Aspirin|Aspirin (100 mg once a day)
40937030|NCT00260611|DRUG|Oxaliplatin|
40937031|NCT00260611|DRUG|Taxotere|
40937032|NCT04465162|OTHER|Radiation Therapy|Undergo radiation therapy
40937033|NCT06271174|DRUG|Carbocaine|"After general anesthesia and before incision, patients will receive loco-regional analgesia.~Carbocaïne will be injected around the nerve responsible of the innervation of the operated area by echography guidance."
40937034|NCT06271174|DRUG|Profofol and/or Suxaméthonium and/or Sévoflurane|"General anesthesia~Anesthetic induction is performed on a full stomach using :~* Intravenous hypnotic Propofol 2-5 mg/kg~* A rapid-acting intravenous curare Suxamethonium 1 mg/kg~On an empty stomach :~- An intravenous hypnotic Propofol 2 to 5 mg/kg or/and an inhalatory hypnotic, Sevoflurane, as anesthetic co-induction by these 2 agents is generally used in pediatrics."
40937035|NCT04722653|DRUG|NNC0194-0499|1 single dose administered subcutaneously (s.c. - under the skin)
40937036|NCT04722653|DRUG|Placebo (NNC0194-0499 )|1 single dose administered subcutaneously (s.c. - under the skin).
40937037|NCT02704910|BEHAVIORAL|Subthalamic stimulation|Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
40937038|NCT01653028|DRUG|Alisertib|Given PO
40937039|NCT01653028|OTHER|Laboratory Biomarker Analysis|Correlative studies
40937040|NCT02044328|DRUG|Icotinib|Icotinib is administered 125 mg three times per day.
40937041|NCT03708627|DRUG|Bimatoprost Ophthalmic|Bimatoprost, aka Lumigan, one drop in one eye nightly
40937042|NCT04073329|OTHER|post operative measure of reduction|measurement was used to grade quality of reduction according to Matta's system . In accordance with prior studies, adequate (or anatomic) reductions with 0-1 mm of displacement were compared to inadequate (imperfect or poor) reductions with \> 1 mm displacement . For the CT-based method, postoperative pre-digital (prior to 2000) and digital CT images were independently assessed in the axial, sagittal, and coronal planes, and residual gap and step displacement were measured along the articular surface at the level of the weight-bearing dome. Adequate reductions on postoperative CT were defined as \< 1 mm step and \< 5 mm gap displacement and inadequate reductions as ≥ 1 mm step and/or ≥ 5 mm gap displacement.
41450304|NCT05069480|OTHER|Traditional physical therapy program|The traditional physical therapy program aimed for inhibition of spasticity, facilitation of muscle action, and improving the motor functions of the involved upper limbs.
41453555|NCT02733211|DEVICE|sensor augmented pump therapy|Sensor augmented pump therapy
41453556|NCT01696305|DEVICE|Hyalobarrier|
41453557|NCT01696305|DEVICE|Guardix-SG|
41453558|NCT01146223|OTHER|laboratory biomarker analysis|Correlative studies
41453559|NCT04076007|DIETARY_SUPPLEMENT|Beetroot juice|
40937043|NCT04910373|OTHER|Experimental Extensively Hydrolyzed Formula|experimental powder formula
40937044|NCT04910373|OTHER|Placebo Extensively Hydrolyzed Formula|placebo powder formula
40937045|NCT00056056|DRUG|bexarotene|The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
40937046|NCT00056056|DRUG|methoxypsoralen|The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
40937047|NCT00056056|PROCEDURE|UV light therapy|Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
40937048|NCT02457273|DRUG|TLC 388|40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
40756068|NCT02605538|BIOLOGICAL|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
40756069|NCT03203707|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
41130420|NCT03700034|OTHER|mHealth Integrated Model of Antenatal Care|"In the intervention facilities, antenatal care (ANC) will be provided to all pregnant women using the mIRA electronic decision support system (EDSS) by ANMs (Auxiliary Nurse Midwife), Staff nurses, or Medical Officers (MOs). These frontline healthcare workers (FHWs) will be trained to use the EDSS and will also be provided refresher training on the guideline-recommended processes of ANC. This training will enable them to use the mIRA EDSS in the provision of ANC. Non-physician FHWs (ANMs and staff nurses) will screen, detect, and refer PIH, GDM, and severe anemia cases. They will not prescribe treatments, but will carry out all other duties including diagnosis, referral to the MO to prescribe drugs, provide lifestyle advice, follow-up, and subsequently support adherence to management plans."
41130421|NCT02611609|BIOLOGICAL|MultiStem|
41450305|NCT01930409|BEHAVIORAL|Telephone Support and Coaching|"The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:~* Health Status~* Medication Management~* Activity/Exercise Prescription and Goal-Setting~* Falls Prevention~* Clarification of Appointments~* Coordination of Post-Discharge Home Services~* What To Do If a Problem Arises"
41450306|NCT01930409|BEHAVIORAL|Education Only|An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
41453560|NCT04076007|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|
40756070|NCT01275937|DRUG|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
40756071|NCT01275937|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
40937049|NCT04006782|DEVICE|Narrow dental implants|Insertion of narrow dental implants in multiple fixed prosthesis
40937050|NCT05280379|OTHER|no intervention will take place|no intervention will take place
41130422|NCT02611609|BIOLOGICAL|MultiStem|
40937051|NCT02194608|DEVICE|Home telehealth system|Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB.
40937052|NCT04738929|OTHER|Extra virgin coconut oil or extra virgin olive oil|"Subjects consumed standard breakfast meals containing extra virgin coconut oil or extra virgin olive oil"
40937053|NCT00156572|PROCEDURE|Sodium supplementation|
40937054|NCT00156572|PROCEDURE|Fluid restriction|
40937055|NCT05751096|DEVICE|Low-intensity Focused Ultrasound (LIFU)|repeat pulse application of low intensity focused ultrasound using a single element transducer to a selected neurological target for neuromodulation.
40937056|NCT05751096|DEVICE|Sham Low-intensity focused ultrasound (LIFU)|Sham application of LIFU.
40937057|NCT02636842|DRUG|Aripiprazole Lauroxil|Intramuscular (IM) injection, single dose
40937058|NCT00254774|DRUG|quetiapine fumarate or valproate|
40937059|NCT01946906|DRUG|Rifaximin|
40937060|NCT04414332|OTHER|Data collection only|This registry is to capture high quality patient safety and effectiveness data on use of the Angiovac device for 3 separate, but overlapping conditions; a) Iliofemoral and Caval DVT, b) Right heart masses, and c) PE. The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the angiovac catheter deployed into the vascular system.
40937061|NCT00817583|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
40937062|NCT00817583|RADIATION|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
40937063|NCT06516159|DIAGNOSTIC_TEST|MBI-C Scale in French|"The original version has 34 items, divided into 5 areas:~* a reduction in motivation, interests and initiative~* the appearance of mood disorders~* dysregulation of impulse management~* loss of conventions and societal norms~* the abnormal development of strongly held beliefs and sensory experiences~The items are rated based on the occurrence of the severity of the disorders in the previous six months on a scale of 0 to 3.~This scale is completed by a member of the healthcare team on the basis of information collected from the relative (informant) either in person but also by telephone The score varies between 0 and 102. The higher the score, the more psychological and behavioral symptoms are present.~The test lasts 10 minutes."
40937064|NCT06132828|DRUG|DR30206|Subjects receive DR30206 intravenously
40937065|NCT00045721|DRUG|O6-benzylguanine|
40937066|NCT00045721|DRUG|polifeprosan 20 with carmustine implant|
40937067|NCT00045721|PROCEDURE|adjuvant therapy|
40937068|NCT00045721|PROCEDURE|conventional surgery|
40937069|NCT00045721|PROCEDURE|neoadjuvant therapy|
40937070|NCT01095471|BIOLOGICAL|PCV13|Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
40937071|NCT01872234|DEVICE|Two-lead CRT-P|The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
40937072|NCT01810965|PROCEDURE|First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)|
41130423|NCT02611609|BIOLOGICAL|Placebo|
41130424|NCT03039244|OTHER|Photodynamic therapy|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
41130425|NCT03039244|OTHER|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
41130426|NCT03039244|DEVICE|Diode Laser|
41130427|NCT06180070|DRUG|Ibuprofen/ Paracetamol tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
40937073|NCT04834765|OTHER|Mindfulness-based art therapy|The researchers developed a novel MBAT intervention consisting of 10 easily reproducible, clay-based MBAT directives, administered through an online platform delivery strategy. By developing an MBAT intervention that uses an online delivery strategy, the researchers realized it may have the potential of decreasing demands placed on counseling centers.
41130428|NCT06180070|DRUG|Nuromol® tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
40937074|NCT04834765|OTHER|Art-only|The AO modules consist of an open-ended art-making exercise, with minimal direction. The AO intervention is designed as an 'art for art's sake' intervention with the focus on the art-making and less on outcome or product. Participants are asked to pull their ball of clay out and spend ten minutes creating a form from the clay to visually express their experience in the present moment.
40937075|NCT04834765|OTHER|Mindfulness-only|The MO modules consist of only the mindfulness practices from the ABM intervention. The participants to follow along with a five-minute light yoga sequence, where asanas (yoga postures) are cued with breath. Yoga, for the purposes of the study, is explicitly defined to participants as the unity of breath with body movement. Poses were chosen based on their accessibility to a variety of body types and abilities, and chosen because they are documented to aid in grounding, increased haptic awareness, lowered levels of stress and anxiety, and restoration.
40937076|NCT02592811|PROCEDURE|ERCP|Common bile duct cannulation with a cannulation catheter
41450307|NCT05759715|OTHER|Iris Color Measurement , LF/HF Measurement|Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)
41450308|NCT03678363|OTHER|Tai chi chuan|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
41450309|NCT03249844|DRUG|Methylprednisolone + prednisolone|"The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~* week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~* week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),"
41450310|NCT06241976|OTHER|Glucose drink|75g glucose in 300 ml water (281 kcal) used for oral glucose tolerance test (OGTT)
41450311|NCT06241976|OTHER|Pure orange juice|300ml pure orange juice (OJ, Tesco 100% Pure Squeezed Orange Juice Smooth containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) from Tesco supermarket
41450312|NCT00614861|OTHER|Non-cancer pain management survey|Non-cancer pain management survey
41450313|NCT02518360|OTHER|Osteopathic|Body adjustment in three sessions (20 minutes/session).
41450314|NCT02518360|OTHER|Auto Stretching|The patients realize auto stretching in three sessions (20 minutes/session).
41450315|NCT00254280|PROCEDURE|Intense Pulsed Light + paring versus paring alone|
41450316|NCT03973489|BEHAVIORAL|Magnetic resonance imaging (MRI)|On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
41450317|NCT03973489|DRUG|Methamphetamine Hydrochloride Tablets|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
41450318|NCT03973489|DRUG|Placebo oral tablet|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
41450319|NCT01943435|DRUG|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
40756072|NCT03542357|DRUG|Calcitonin Gene Related Peptide|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
40756073|NCT03542357|DRUG|Sumatriptan 50 mg|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
40756074|NCT03542357|DRUG|Placebo Oral Tablet|CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
40937077|NCT02592811|PROCEDURE|Endoscopic Sphincterotomy|Endoscopic large sphincterotomy
40937078|NCT02592811|DEVICE|Large Balloon Dilatation of Oddi Sphincter|Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
41450320|NCT01943435|PROCEDURE|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
40937079|NCT02592811|PROCEDURE|Stone extraction|After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
40937080|NCT06518902|DRUG|mesenchymal stem cells (umbilical cord) injection|Patients receive mesenchymal stem cells (umbilical cord) injection once or once a week for three consecutive weeks
40937081|NCT02786524|BEHAVIORAL|Specialized Symptom Management and Supportive Care|Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
40937082|NCT04195126|DEVICE|CytoSorb haemadsorption device|CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device.
41130429|NCT03526406|DIETARY_SUPPLEMENT|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
40937083|NCT03794921|OTHER|Every Step Counts|Pedometer coupled to a website that provides step-count goals, feedback, education, motivation, and social support.
40937084|NCT02417948|OTHER|Written Educational Brochure|Receive brochure with skin cancer education and preventative information
40937085|NCT02417948|OTHER|Online educational video|Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
40937086|NCT03714737|BIOLOGICAL|experimental vaccine|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
40937087|NCT03714737|BIOLOGICAL|Positive control vaccine 1|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
40937088|NCT03714737|BIOLOGICAL|Positive control vaccine 2|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
40937089|NCT01473056|DRUG|JTK-853|Tablets, twice a day for 3 days
41130430|NCT03526406|DIETARY_SUPPLEMENT|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
41450321|NCT01943435|OTHER|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
41450322|NCT01943435|OTHER|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
40756075|NCT00107614|DRUG|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with \< 50% response to induction) OR MEL-DT PACE (Patients with \> 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
40756076|NCT04992741|OTHER|education and motivational interview|The control group will remain subject to the routine process without any intervention.
40756077|NCT03177070|DRUG|Methylene Blue|As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
40756078|NCT00225602|BEHAVIORAL|Assertive Community Treatment|
40756079|NCT00225602|BEHAVIORAL|Treatment in Community Mental Health Center|
40756080|NCT01793571|PROCEDURE|TAP block|2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
40937090|NCT01473056|DRUG|Dose 2 JTK-853|Tablets, twice a day for 3 days
40937091|NCT01473056|DRUG|Dose 3 JTK-853|Tablets, three times a day for 3 days
40937092|NCT01473056|DRUG|Dose 4 JTK-853|Tablets, twice a day for 3 days
40937093|NCT01473056|DRUG|Placebo|Tablets, twice a day or three times a day for 3 days
40937094|NCT05669001|BIOLOGICAL|TCD601|Investigational Product
40937095|NCT05669001|BIOLOGICAL|belatacept|Study Product
41130431|NCT00599469|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
41130432|NCT02631369|DEVICE|Heidelberg Spectralis OCT device|
41130433|NCT00786513|OTHER|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
41130434|NCT00786513|OTHER|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
40937096|NCT05669001|DRUG|ATG|Comparator
40937097|NCT05669001|DRUG|TAC|Comparator
40937098|NCT05669001|DRUG|MPA|Immunosuppression Therapy
40937099|NCT05669001|DRUG|Corticosteroids|Immunosuppression Therapy
40937100|NCT01919840|PROCEDURE|Group ROTEM|"10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.~If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected."
40937101|NCT01919840|OTHER|Group C|"10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.~If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result."
40937102|NCT03802747|DRUG|Durvalumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.
40937103|NCT03802747|DRUG|Durvalumab and Tremelimumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.
40937104|NCT03802747|DRUG|Y-90 Selective Internal Radiation Therapy (SIRT)|Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.
40937105|NCT03802747|DRUG|Stereotactic Body Radiation Therapy (SBRT)|High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
40937106|NCT02139800|PROCEDURE|Sustained Inflation|The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
40937107|NCT02139800|PROCEDURE|Standard of Care|Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
40937108|NCT03420027|OTHER|questionnaire to be filled in by investigators|A simple seven-item questionnaire will be filled in by the investigator before performing urgent tracheal intubation. This intubation, which will be performed as done in routine care, does not constitute a study specific intervention
40937109|NCT04432220|DRUG|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
40937110|NCT01568307|DRUG|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
40937111|NCT04923165|DEVICE|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
40937112|NCT04923165|DIAGNOSTIC_TEST|biochemical analyses|ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;
40756081|NCT03346746|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention was a diet that provided participants with three meals with a low GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
40756082|NCT03346746|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention was a diet that provided participants with three meals with a high GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
40937113|NCT04923165|DEVICE|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip
40937114|NCT04923165|DIAGNOSTIC_TEST|nutritional assessment, MNA|nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection
40937115|NCT03176875|OTHER|ALICALM (75% of daily caloric requirements)|PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
40937116|NCT03176875|OTHER|ALICALM (100% of daily caloric requirements)|EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
40937117|NCT05563480|DRUG|TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
40937118|NCT05563480|DRUG|Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
40937119|NCT05563480|DRUG|TQB2618 injection; Penpulimab injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
41450323|NCT01943435|OTHER|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
40756083|NCT06249477|DEVICE|Wrist activity tracker and scale|Wrist activity tracker used to evaluate number of steps, heart rate, and frequency of usage of the devices to monitor activity. Scale used to record a patient's weight value.
40756084|NCT06249477|BEHAVIORAL|Nutritional Coaching group sessions|Nutritional coaching group sessions held via zoom and performed by a certified clinical nutritionist regarding nutrition, and physical activity specific for weight loss.
40756085|NCT03167398|BIOLOGICAL|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
40937120|NCT02125773|BEHAVIORAL|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
40937121|NCT05558917|PROCEDURE|PECS BLOCK 2|With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.
40937122|NCT05558917|PROCEDURE|ESP BLOCK|Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.
40937123|NCT00731432|DRUG|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
40937124|NCT00731432|DRUG|Placebo Patch|Identical in shape and texture to treatment patch
40937125|NCT01368718|PROCEDURE|Active CPAP is compared with sham CPAP as a control intervention.|Patients are randomized into active or control arm. After the first treatment, a washout period is installed,after which therapy is switched according to the cross-over protocol. A CPAP device consists of a unit that generates airflow, which is directed to the airway via a mask. With active CPAP, the generated airflow creates a positive pressure and prevents upper airway collapse. With sham CPAP, the generated airflow creates a very low pressure.
40937126|NCT04369170|DEVICE|prosthesis connected directly to the implants|dental prostheses connected directly to the dental implants
41450324|NCT04562935|OTHER|admission to pediatric intensive care with mechanical ventilation|admission to pediatric intensive care with mechanical ventilation
41450325|NCT04589286|BEHAVIORAL|Pack Health's Digital Life Coaching (DLC)|Pack Health smartphone-based DLC platform
40937127|NCT04369170|DEVICE|Intermediate abutment|dental prostheses connected with an intermediate abutment to the implant
40937128|NCT00543855|DRUG|3 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
41450326|NCT04589286|OTHER|Electronic Handouts|Generic wellness-related electronic handouts
41450327|NCT02173886|DRUG|Bupropion SR and XL|
41450328|NCT00265226|BIOLOGICAL|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
41450329|NCT01602328|BIOLOGICAL|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
41450330|NCT01602328|BIOLOGICAL|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
41450331|NCT03706508|PROCEDURE|Robot-assisted laparoscopic radical prostatectomy|Patients with localized prostate cancer underwent transperitoneal robot-assisted laparoscopic radical prostatectomy
41450332|NCT01236287|DRUG|Voclosporin|Subjects will receive voclosporin capsules, twice daily
41450333|NCT05374850|PROCEDURE|Cervical Interlaminar Epidural Steroid Injection|This intervention is applied mostly for cervical disc herniation.The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then combined local anesthetics and glucocorticoids is delivered to the epidural space.
41450334|NCT03090321|BEHAVIORAL|Stand Prompt|The participant will receive a notification asking them to stand or walk if they have been sitting for longer than 60 minutes
41450335|NCT03090321|BEHAVIORAL|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
41450336|NCT03090321|BEHAVIORAL|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study
41450337|NCT03090321|BEHAVIORAL|Read AHA website|Daily reminder to read the newsfeed from the American Heart Association (AHA) website, this is a control arm
41450338|NCT02995135|DRUG|BAY987517|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-094)"
41450339|NCT02995135|DRUG|SFP Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
41450340|NCT04511039|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
41450341|NCT04511039|DRUG|Talazoparib Tosylate|Given PO
41450342|NCT00078923|DIETARY_SUPPLEMENT|soy isoflavones|
41450343|NCT00078923|PROCEDURE|neoadjuvant therapy|Prostatectomy or Brachytherapy
41450344|NCT00078923|OTHER|Placebo|Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
41450345|NCT02275143|RADIATION|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
41450346|NCT05877274|OTHER|Sodium channel mutation|Mutation of the genes SCN9A and SCN10A, which encode for Sodium channel 1.7 and 1.8.
40756086|NCT03863301|RADIATION|MR-guided single dose preoperative PBI|A single dose of 20Gy to the gross tumor volume (GTV) is prescribed, to the clinical target volume (GTV + 20mm margin) 15Gy is prescribed.
41280168|NCT06049316|OTHER|Scapular functional exercises|"In Scapular functional exercises, following treatment protocol will involve~* Press-up (in a chair).~* Push-up plus, Grade 1, in oblique position exercise will be performed with the support of a table. After progression perform this in horizontal plane.~* Lateral pull down~* Horizontal pull apart~* Prone flexion: in prone position on plinth. Both arms placed overhead, and then raise arms towards ceiling.~* Prone rows: in prone position, with elbow straight, slowly raise arms towards ceiling while bending the elbows.~These all above exercises will perform by holding dumbbells in hands (20RM at first week, 10RM at last week) with 3 sets, 3 times a week for eight weeks."
40937129|NCT00543855|DRUG|5 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks)."
40937130|NCT00543855|DRUG|10 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).~Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks)."
40937131|NCT00543855|DRUG|Placebo|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
40937132|NCT03549403|BEHAVIORAL|Patient-centered telephone education|The intervention will be carried out in accordance with the guidelines and the contents of the patient-centered telephone education intervention in the same way with every patient. The education call duration is approximately 15 to 30 minutes.
40937133|NCT02716896|RADIATION|Radiation and chemoradiation|Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
40937134|NCT02716896|PROCEDURE|Radical cystectomy|Radical cystectomy will be performed on those who are randomized to this group.
41130435|NCT05749224|DIAGNOSTIC_TEST|Helkimo Index|Helkimo Index is comprised of five items, with each assessment having three possible answers, scored as 0, 1 or 5. The first item is related to the limitation in the range of jaw movement. The second item evaluates the alterations of joint function that produce deviations, sounds and/or joint locks or blockages; the third item evaluates the presence of pain when performing some movements; the fourth item evaluates muscular pain in the masticatory muscles; and the fifth item evaluates the presence of discomfort or pain in the prearticular area of the temporomandibular joint (TMJ) through palpation. From the sum of the 5 items, we identify no TMJ involvement if the score is 0, mild TMJ involvement when the score ranges from 1 to 9, moderate TMJ involvement if the score ranges between 10 and 19 and severe TMJ involvement for a score between 20 and 25.
41130436|NCT03363984|DRUG|Midazolam|Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times
41130437|NCT03363984|DRUG|ID-082|Administration of ID-082 under fasted conditions/outside of meal times
41130438|NCT01780675|RADIATION|Radiation Prophylactic Cranial Irradiation|
41130439|NCT01780675|RADIATION|Radiation Hippocampal Avoidance PCI|
41130440|NCT02912247|DRUG|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
41130441|NCT02912247|DRUG|adalimumab|adalimumab, 40mg,subcutaneous injection,once
41130442|NCT00002900|PROCEDURE|management of therapy complications|
41130443|NCT04863677|BEHAVIORAL|High Intensity Interval Training(HIIT）|Last 12 weeks (3 sessions per week)
41130444|NCT04863677|BEHAVIORAL|Moderate Intensity Continuous Training(MICT）|Moderate Intensity Continuous Training(MICT）
41130445|NCT02538900|BEHAVIORAL|Exercise|Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.
41280169|NCT03520049|DRUG|Oseltamivir|
41280170|NCT03520049|DRUG|Placebo|
41280171|NCT05269355|DRUG|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm description.
41280172|NCT05269355|DRUG|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm description.
40756087|NCT06272682|PROCEDURE|Systemic bethametasone injection|betamethasone intramuscular injection in the treatment of carpal tunnel syndrome
40756088|NCT06272682|PROCEDURE|Local bethametasone injection|Local betamethasone injection under ultrasound in the carpal tunnel, in the treatment of carpal tunnel syndrome
40756089|NCT01903733|DRUG|bosutinib|The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
40756090|NCT01923974|DRUG|Melatonin 10 mg|
40756091|NCT01923974|DRUG|Melatonin 100 mg|
40756092|NCT01923974|DRUG|Placebo|
41280173|NCT05269355|OTHER|Placebo|Placebo will be administered as per the schedule specified in the arm description.
41280174|NCT01064089|DRUG|HSP990|
41280175|NCT05305716|OTHER|Online Pilates Training|The group that received telerehabilitation and telerehabilitation-based pilates training.
41280176|NCT05305716|OTHER|Control group|The group who received breathing and relaxation exercises with a home program.
40937135|NCT02894632|DEVICE|MRI compatible motion sensor (MARMOT)|MRI with motion control (several motion sensors placed on the volunteer's body)
40937136|NCT06208930|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.
40937137|NCT05637658|OTHER|Exercise|aerobic exercise
40937138|NCT01070797|BIOLOGICAL|Multi-virus Specific T cells|"Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10\^6 rCTLs/m2~Level Two: 1 x 10\^7 rCTLs/m2~Level Three: 2 x 10\^7 rCTLs/m2~Level Four: 5 x 10\^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days."
40937139|NCT05888571|PROCEDURE|prepectoral breast reconstruction|Patients receive immediate prepectoral breast reconstruction
40937140|NCT05888571|PROCEDURE|Tiloop Mesh implantation|Patients receive immediate prepectoral breast reconstruction with Tiloop Mesh
40937141|NCT06329115|OTHER|Exercise training|Within the physical activity program, an aerobic training program will be applied to students for a total of 150 minutes per week for 8 weeks. Aerobic training includes moderate-intensity walking exercise. The concept of moderate walking will be explained to individuals at the beginning of the study. Maximal and submaximal heart rate calculations will be made with the formulas (220-age) / (220-age X 0.6) and this heart rate will be maintained throughout the training. Students will have a pedometer application installed on their phones and their step counts and exercise minute data will be recorded. At the same time, in order for students to use their respiratory functions properly during regular walking, diaphragmatic breathing and alternating nose breathing breathing exercises will be taught and they will be instructed to do them once a day with 5 repetitions.
40937142|NCT00730028|DRUG|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child \> 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child \< 40 kg dose). Study drug will be administered for 10 days.
40937143|NCT00730028|OTHER|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
40937144|NCT00730028|DRUG|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
40937145|NCT03319290|GENETIC|BRCA1 and BRCA2|Genetic breast and ovarian cancer testing
40937146|NCT03705078|PROCEDURE|Transjugular Portosytemic Shunt (TIPS)|The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.
40937147|NCT03705078|PROCEDURE|glue obliteration|The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
40937148|NCT06033508|OTHER|exercise with whole body vibration device|exercise with whole body vibration device
40937149|NCT06033508|OTHER|placebo exercise|exercise without vibration on land
40937150|NCT03433027|DRUG|BB-401|BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks
40937151|NCT05904990|DEVICE|traditional exercise therapy only|50-minute program included a 10-minute warm-up phase (treadmill walking at a comfortable speed), 30 minutes of stretching exercises for (glutei, paraspinal muscles, hamstring, pectoralis, scalenus, intercostal muscles, and trapezius), and a 10-minute cool-down involving self-stretching and respiratory exercises
41130446|NCT02538900|OTHER|Attention control|Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
41130447|NCT04531059|DRUG|Esomeprazole|Proton pump inhibitor
41280177|NCT04712175|DIAGNOSTIC_TEST|Nasopharyngeal sampling|Swabs will be taken of nasopharyngeal samples for RT-PCR
41280178|NCT04712175|DIAGNOSTIC_TEST|Saliva sampling|A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR
41280179|NCT02764619|DRUG|Spironolactone|
41280180|NCT02764619|DRUG|Placebo|
40937152|NCT05904990|DEVICE|HILT alongside traditional exercise therapy|YAG laser device (HIRO 3.0; ASA Laser, Arcugnano, Italy). This equipment delivers pulsed laser light at a wavelength of 1,064 nm, with a very high peak power of 3 kW and energy density ranging from 360 to 1,780 mJ/cm2. It operates with short pulse durations between 120 and 150 μs, at low frequencies of 10 to 40 Hz, and has a duty cycle of about 0.1%.
40937153|NCT03116347|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
40937154|NCT03116347|BIOLOGICAL|KIOVIG|100 mg/ml solution for Immune Globulin Intravenous Infusion
41130448|NCT04531059|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
40937155|NCT03116347|BIOLOGICAL|Cuvitru|200 mg/ml solution for Immune Globulin Subcutaneous Injection
40937156|NCT03439527|OTHER|Muscle Precursor Cells (MPCs), ATMP|The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.
40937157|NCT00542451|DRUG|Paclitaxel|Every week for 12 weeks
41130449|NCT04531059|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
41130450|NCT04531059|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
41130451|NCT04044859|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 alone or in combination with either nivolumab 480 mg IV every four weeks or pembrolizumab 400mg IV every 6 weeks
41130452|NCT01432769|DIETARY_SUPPLEMENT|dietary supplement high in energy and protein|"patients in the standardized diet will receive extra 500 kcal from the dietary supplement"
41130453|NCT00389194|DRUG|continuing AZT+3TC or switching AZT+3TC to TDF+ FTC|
41130454|NCT03172871|DRUG|Aripiprazole IM Depot|Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
41280181|NCT02698410|DRUG|Lanreotide (Autogel formulation) and Temozolomide|
40937158|NCT00542451|DRUG|Trastuzumab|Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
40937159|NCT00568685|DRUG|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
40937160|NCT00568685|DRUG|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
40937161|NCT00568685|DRUG|Atomoxetine hydrochloride|"Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days"
40937162|NCT06130306|PROCEDURE|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 45 minutes targeted the pudendal nerve, thrice weekly for a minimum of 8 weeks. The treatment plan remains ongoing until the patient opts to discontinue voluntarily.
41130455|NCT03172871|DRUG|Aripiprazole tablet|Oral aripiprazole tablets 10 to 20 mg daily
41280182|NCT00468715|DRUG|bicalutamide|
41280183|NCT00468715|OTHER|diagnostic laboratory biomarker analysis|
41280184|NCT00468715|OTHER|immunohistochemistry staining method|
41280185|NCT01646710|BEHAVIORAL|Pretesting food based recommendations|
41280186|NCT04223089|DIAGNOSTIC_TEST|Near Infrared Spectroscopy|"The Kent Camera is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of the following in superficial tissue:~* oxygen saturation (StO2),~* relative oxyhemoglobin level (HbO2), and~* relative deoxyhemoglobin (Hb) level~The Kent Camera displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. The Kent Camera is indicated for use to determine oxygenation levels in superficial tissues."
40937163|NCT06130306|PROCEDURE|pelvic floor muscle training combined with transanal electrical stimulation|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system \[AM1000B; Shenzhen Creative Industry Co. Ltd, China\]) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB 4, Electronic Concept Lignon Innovation, France)) at a current intensity of \< 60 mA (as high as possible to get a PFM contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients also conducted 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks. If the patient is willing, the treatment plan can continue until the patient voluntarily decides to stop.
40937164|NCT00846170|DRUG|co-biotic|give probiotic 2 t/day
40937165|NCT00846170|DRUG|placebo 2T/day|cross over of patients from study arm to placebo arm
40937166|NCT00065364|BEHAVIORAL|Newborn Individualized Developmental Care Assessment Program|
40937167|NCT01910571|DRUG|P7435|
40937168|NCT01910571|OTHER|Placebo|
41450347|NCT04763161|PROCEDURE|Decompressive hemicraniectomy|Decompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident
40756093|NCT02631031|DRUG|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
40756094|NCT03486470|DIAGNOSTIC_TEST|Ultrasound examination of radial arteries|Measuring the diameter and the depth of two radial segments on both arms
40756095|NCT00131742|DRUG|telbivudine|
40937169|NCT06240507|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
40937170|NCT06240507|PROCEDURE|fluoroscopy-guided intralesional radiofrequency thermocoagulation|The painful heel and calcaneal spur were visualized under lateral fluoroscopy. A 22-gauge, 10-cm radiofrequency cannula was inserted and advanced until the needle tip reached the calcaneal spur tip. When the needle tip contacted the spur, local anesthetic was administered through the cannula and radiofrequency ablation was performed at 80°C for 90 s.
40937171|NCT04337385|BEHAVIORAL|Interrupting 3 hours of prolonged sitting with high intensity interval exercise|Breaking up a prolonged bout of sitting in adolescents using high intensity interval exercise
40937172|NCT04337385|BEHAVIORAL|3 hours of prolonged sitting|Participants will be asked to remain seated for 3 hours and refrain from moving their lower limbs
40937173|NCT01879527|DRUG|Amiloride hydrochlorothiazide|Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
40937174|NCT01879527|DRUG|Sugar pill|containing placebo
40937175|NCT02041442|PROCEDURE|Electrical mapping of the urinary bladder|
41130456|NCT05398224|DRUG|Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab|"Induction therapy: Zanubrutinib will be given as 160mg bid orally between days 1 and 14 of each 14-day cycle; rituximab will be given at 375mg/m2 intravenously on day 1 of each cycle; methotrexate at 3.5g/m2 for patients ≤65 or 1.5g/m2 for patients \>65 (standard hydration/leucovorin support) will be given intravenously on day 2 of each 14-day cycle; for 6 cycles.~Consolidation therapy: For patients ≤65, autologous hematopoietic stem cell transplantation (ASCT with a conditioning regimen of thiotepa/carmustine) will be given as consolidation treatment after induction therapy.~Maintenance therapy:Drug: zanubrutinib. Zanubrutinib will be given as 160mg bid orally continuously until progression of the disease (PD), intolerable toxicity, death, or patient/investigator discretion."
41450348|NCT04763161|PROCEDURE|neurosurgical operation|neurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.
40937176|NCT06400927|OTHER|HF-guided VA|VA guided recommendation
40937177|NCT06400927|OTHER|Standard-of-care|Standard-of-care
41450349|NCT03121716|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
41450350|NCT03121716|DRUG|Gemcitabine|gemcitabine
40937178|NCT00384527|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
41450351|NCT03121716|DRUG|cis-platinum|cis-platinum
41453561|NCT05946239|OTHER|Manage My Pain App|This digital application helps patients measure, track, and manage chronic pain, functionality, and medication use. MMP can also be used to share patient pain experiences with their circle of care via reports and offers educational resources for patients.
41453562|NCT02818790|BEHAVIORAL|Intervention 1|Bodyguard + Precious App. Short onsite training session on how to use the system.
40756096|NCT00131742|DRUG|lamivudine|
40756097|NCT04846257|OTHER|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is the acquisition of sequential images during the passage of a contrast agent within a tissue of interest.
40756098|NCT01687205|DRUG|1% Tenofovir Gel|
40756099|NCT03098407|DRUG|Buprenorphine|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
40756100|NCT03098407|DRUG|Methadone|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
40756101|NCT05730660|DIETARY_SUPPLEMENT|Quercetin group|2 capsules a day of Quercetin Fitosoma® of 250 mg each
40937179|NCT00384527|DRUG|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
40937180|NCT02477137|DEVICE|smartphone or tablet|Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
40937181|NCT04448873|DRUG|Sirolimus|After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.
40937182|NCT04223648|DRUG|tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy|"Subjects will receive 1 cycle of tremelimumab/durvalumab~* Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s~* TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.~Subjects will receive 3 cycles of ipilimumab/nivolumab~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy."
40937183|NCT01275547|DRUG|s-ketamine & midazolam|s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
40937184|NCT01275547|DRUG|Morphine PCA|2 mg Morphine i.v. all 12 minutes as a patient controlled system
40937185|NCT04896021|DIAGNOSTIC_TEST|Cardiovascular disease risk assessment|Intervention in which the addition of guideline-recommended absolute cardiovascular disease risk assessment is embedded into point-of-care blood collection services for cholesterol measurement and results (including risk score) are reported to referring doctors.
40937186|NCT04896021|DIAGNOSTIC_TEST|Usual care assessment|Usual care in which blood cholesterol results are reported to referring doctors
40937187|NCT01661985|DRUG|Azithromycin|In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
40937188|NCT01661985|DRUG|Doxycycline|Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
40937189|NCT01661985|DRUG|lymecycline|Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
40937190|NCT04934631|OTHER|Recording of CBT-ED session.|Therapists will deliver treatment as usual (CBT-ED) to eating disorder patients. Therapy session will be audio recorded.
41130457|NCT04407975|OTHER|Betamethasone|A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
41130458|NCT04407975|OTHER|Placebo|A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
41130459|NCT01088841|DIETARY_SUPPLEMENT|lactisole|lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
41130460|NCT05185245|PROCEDURE|Liver Transplantation|Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
41130461|NCT06284213|OTHER|No interventions|This is an observational study with no interventions.
41130462|NCT00588406|DRUG|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
41130463|NCT00588406|DRUG|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
41130464|NCT00588406|DRUG|Ipratropium bromide|2.5 mg, one dose
41130465|NCT00588406|DRUG|Prednisone|60mg PO
40937191|NCT04934631|OTHER|Assessment of CBT-ED clinician competence.|Independent raters will assess CBT-ED competence using the Cognitive-Behavioural Therapy Scale for Eating Disorders (CBTS-ED).
40937192|NCT02583243|BEHAVIORAL|MET/CBT based individualized counseling|Manualized counseling with the first four week being MET followed by 8 weeks of CBT
40937193|NCT02583243|DRUG|Buprenorphine|Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
40937194|NCT02890290|DIETARY_SUPPLEMENT|Marine Protein hydrolysate|The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.
41130466|NCT04852315|DIETARY_SUPPLEMENT|Caffeine|Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
41130467|NCT04852315|DIETARY_SUPPLEMENT|Placebo|Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
41130468|NCT06101875|OTHER|Health Coach (Health coaching)|Patients will be assigned a health coach and be eligible to 8 times, 1 hour sessions over a 12 week period. The health coach will use techniques to increase their ability to self-manage, motivation levels and commitment to change their behaviour.
41130469|NCT06101875|OTHER|Digital Toolkit (Control)|This is an online website, unsupervised, 12-week self-management programme.
41130470|NCT02842957|BEHAVIORAL|Lifestyle Intervention|Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
41130471|NCT00810849|DRUG|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
41280187|NCT03414879|DRUG|Ketamine|While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..
41280188|NCT03414879|DRUG|Lidocaine|While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
41130472|NCT00810849|BIOLOGICAL|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
41130473|NCT05966012|DRUG|Tranexamic acid|Recent data suggests that antifibrinolytics like tranexamic acid (TXA) might be able to lessen the inflammation of the nervous system caused by surgery and CPB through the inhibition of plasmin production, thereby stabilising the blood brain barrier.
41130474|NCT01094626|DRUG|Secretin|Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
41130475|NCT04650191|OTHER|Identification of genetic variants|DNA will be extracted from whole blood from study subjects
41130476|NCT06294756|OTHER|Inhalation of Sulfurous Thermal Water|Active Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a conventional thermal water aerosolization Faset™system (Faset Spa, Trezzano sul Naviglio, Milan, Italy) delivering particles of TW with a diameter between 0.6 µm \<MMAD \< 5 µm. Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs.
41130477|NCT06294756|OTHER|Inhalation of Sterile Distilled non-pyrogenic Water|Placebo Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a modified thermal water aerosolization Faset™system, previously disconnected from the hydraulic circuit that supplied TW and connected to non-pyrogenic sterile water reservoirs (Highly depurated water- Pharmaceutical grade FU-for external and internal use, Makeitlab, Canosa di Puglia, BT, Italy). Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs delivering particles of SDW with a diameter between 0.6 µm \<MMAD \< 5 µm.
40756102|NCT05730660|DIETARY_SUPPLEMENT|Placebo group|2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.
41130478|NCT05063045|BEHAVIORAL|smart-cloth assisted home nursing care|Older persons with dementia or hip fracture were asked to wear a smart vest, which contained a coin-size monitor in a hidden inner pocket. Sensors were installed in bedrooms and living areas to receive signals from the smart clothing. The home care nurses then gave feedback from the sensor signals to family caregivers.
41130479|NCT05940740|OTHER|Colorectal-Mobile application|The use of Colorectal-Mobile application by the patients on a daily basis by the researcher will be monitored remotely via the management platform of the usage status of the mobile health application.
40756103|NCT02350998|DRUG|OTO-201|
40756104|NCT01514435|DEVICE|Electroconvulsive therapy|treatment for major depression
40937195|NCT02890290|DIETARY_SUPPLEMENT|Placebo|Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.
41130480|NCT04693949|OTHER|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
41130481|NCT04693949|OTHER|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
41130482|NCT03892317|BEHAVIORAL|Pharmacist led medication adherence interventions|Medication adherence interventions which will be tailored to individual patient need
41130483|NCT02847520|BEHAVIORAL|Canadian Index Excessive Game|self-administered questionnaire Canadian Index Excessive Game
41130484|NCT01064999|DRUG|Oxaliplatin|CRT:50mg/m2,IV,weekly\*5 cycle CT: 130mg/m2,IV,d1,q 21 day
41130485|NCT01064999|DRUG|Capecitabine|CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
41130486|NCT01064999|RADIATION|Radiotherapy|High intensity group:55Gy Low intensity group:50Gy
41130487|NCT01064999|PROCEDURE|Surgery|Lower anterior resection or abdominoperineal resection
41280189|NCT01167127|DRUG|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release|OXN Tablet, oral, BID, flexible dose design
41280190|NCT00730093|DIETARY_SUPPLEMENT|B12 vitamin (Cyanocobalamin)|Arm A: B12 vitamin (Cyanocobalamin)
40756105|NCT01514435|DEVICE|18-Fluoro-desoxy-glucose positron emission tomography|"intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.~It´s a neuroimaging technique."
40756106|NCT05684614|OTHER|Negative mood induction procedure|"The negative mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce negative mood: 1) Velten's tasks, consisting of interactive phrase formulations with negative thoughts and beliefs about the self (e.g., I don't have any future); 2) visualizing International Affective Pictures; and 3) recalling a negative autobiographical memory related to a significant loss (e.g., a person, a pet)."
40756107|NCT05684614|OTHER|Spontaneous emotion regulation task|Participants are instructed to use whatever strategy they want by doing, saying, and/or thinking whatever they want to feel better for 2 min
40756108|NCT05684614|OTHER|Positive mood induction procedure|"The positive mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce positive mood: 1) Velten's tasks, consisting of interactive phrase formulations with positive thoughts and beliefs (e.g., Life is wonderful); 2) visualizing International Affective Pictures; and 3) recalling a positive autobiographical memory"
41450352|NCT01442051|PROCEDURE|Acute Normovolemic Hemodilution|A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB \< 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB \<7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
41453563|NCT02818790|BEHAVIORAL|Intervention 2|Bodyguard + Precious App + Motivational Interviewing. Face to face counseling session followed by a short onsite training session on how to use the system.
41453564|NCT04671147|PROCEDURE|Preoperative traction|Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)
41130488|NCT05454059|PROCEDURE|Non-surgical periodontal treatment|Routine non-surgical periodontal treatment will be applied to patients with periodontitis. The main aim of non-surgical periodontal treatment is to protect, heal and maintain the existing dentition. For this purpose, using manual, sonic or ultrasonic instruments, microbial dental plaque and calculus are removed by tooth surface cleaning and root surface straightening.
41130489|NCT05454059|DIAGNOSTIC_TEST|ELISA Test|C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
41130490|NCT05454059|OTHER|Periodontal Examination|All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
41130491|NCT05454059|OTHER|Saliva Sample Collection|Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
41130492|NCT05454059|DIAGNOSTIC_TEST|HbA1c Level|Measurement of HbA1c levels from blood tests
41130493|NCT02260726|PROCEDURE|Magnetic resonance imaging|
41130494|NCT02260726|PROCEDURE|Ultrasound|
41130495|NCT04295642|DRUG|CVL-751|Oral tablet
41130496|NCT05473117|DIAGNOSTIC_TEST|Coronary Magnetic Resonance Angiography (CMRA)|A highly optimised CMRA protocol integrating advanced, automated software for detection of coronary artery stenosis
41450353|NCT02010060|BEHAVIORAL|Aerobic Exercise Training|Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week \[KKW\]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits
40937196|NCT03207334|DRUG|Midostaurin|"Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase~Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant."
40937197|NCT03207334|DRUG|Cytarabine|"Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.~Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle."
41130497|NCT04237909|BIOLOGICAL|PRP injection into at least one ovary|The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.
41130498|NCT00380250|DRUG|Lubiprostone|
41130499|NCT00380250|DRUG|Placebo|
41453565|NCT02519153|DRUG|Sildenafil|placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks
40937198|NCT01926665|DRUG|Carfilzomib|Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.
41130500|NCT05972252|DEVICE|Cerebrovascular Interventional Procedural Control System|The Cerebrovascular Interventional Procedural Control System is intended for use in the remote delivery and manipulation of guidewires and rapid deliver stent catheters, and remote manipulation of guide catheters during cerebrovascular intervention procedures.
41130501|NCT05419232|OTHER|Short Message Service (SMS) + Website Link Strategy|The intervention we are evaluating is the effectiveness of a participant receiving a SMS + Website Link as a vaccine uptake strategy
41130502|NCT05419232|OTHER|Phone Call with Peer Strategy|The intervention we are evaluating is the effectiveness of a participant having a phone call with a peer as a vaccine uptake strategy
41130503|NCT03925389|PROCEDURE|External septorhinoplasty|A surgical procedure to repair defects or deformities of both the nasal septum and the external nasal pyramid through an external incision at the columella.
41453566|NCT03684928|DEVICE|Comfilcon A (test)|Daily wear contact lenses
41453567|NCT03684928|DEVICE|Senofilcon C (control)|Daily wear contact lenses
41130504|NCT05912374|BEHAVIORAL|standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|CHRP-BB is an evidence-informed behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. CHRP-BB consists of 4 weekly 50- minute sessions.
41130505|NCT05912374|BEHAVIORAL|enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|The enhanced version of CHRP-BB is an adapted behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. This intervention consists of 4 weekly 50- minute sessions that include cognitive dysfunction accommodation strategies.
41130506|NCT04693741|PROCEDURE|secondary alveolar bone graft|"Under general anesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will be injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will be made on both sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will be dissected. Next, the bone particles will be implanted into the bone defect.~Then, The cleft site will be closed without tension by the advancement of the gingival flaps."
41130507|NCT04693741|PROCEDURE|Harvesting of the autogenous bone graft|Under general anaesthesia ,the soft tissue in the superior iliac crest will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. The cancellous bone will harvested with an osteotome and then cut into small bone granules.
41130508|NCT04693741|PROCEDURE|Preparation of PRP|10 ml of blood will be collected in vacuum tubes without anticoagulants which are then immediately centrifuged at a rate of 3000 rpm for 10 min. After centrifugation, the resultant product consists of three layers. The topmost layer consisting of acellular PPP (platelet poor plasma), PRF clot in the middle and RBCs at the bottom of the test tube. The attached red blood cells scraped off from it and discarded. The discarded PRF is then mixed with xenograft and placed inside the alveolar defect.
41450354|NCT02010060|BEHAVIORAL|Aerobic Exercise+ Physical Activity|The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
41450355|NCT02727725|OTHER|Traminer MRI Sequence|The Traminer MRI sequence will be added to the standard IR Turbo-Flash sequence and last 2-5 minutes.
41450356|NCT05015595|DRUG|Memantine Oral Tablet|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
41130509|NCT02455557|OTHER|Laboratory Biomarker Analysis|Correlative studies
41130510|NCT02455557|DRUG|Montanide ISA 51 VG|Given SC
41450357|NCT05015595|DRUG|Placebo|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
41450358|NCT03086460|DRUG|CHF 1531 pMDI|Dose Response: Test one of five different doses of CHF 1531
41130511|NCT02455557|BIOLOGICAL|Sargramostim|Given SC
41130512|NCT02455557|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
41450359|NCT03086460|DRUG|Formoterol Inhalation Solution|Active Control
41450360|NCT03086460|DRUG|Placebo pMDI|Matched Placebo
41450361|NCT05738421|DIAGNOSTIC_TEST|fiberoptic endoscopic evaluation of swallowing|Questionnaire, FEES, OPES
41130513|NCT02455557|DRUG|Temozolomide|Given PO or IV
41130514|NCT02021396|PROCEDURE|Embolization|this arm of the study was interventional (splenic artery embolization)
41280191|NCT03509506|BEHAVIORAL|App Group|"The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~* The vital signs show undesired readings~* The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent."
41280192|NCT00942409|BIOLOGICAL|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
41280193|NCT02473406|DRUG|Thymosin Alpha 1|In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
41280194|NCT02473406|DRUG|normal saline|Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
41450362|NCT04604938|DRUG|Losartan|administration of losartan (50 mg) (oral)
41450363|NCT04604938|DRUG|Placebo oral tablet|administration of placebo (oral)
40937199|NCT01926665|DRUG|Dexamethasone|4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
40937200|NCT03523000|OTHER|Continuous intrathecal prognostic infusion test|The patient is infused with solution through the percutaneous intrathecal catheter at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
40937201|NCT03523000|DRUG|Bupivacaine|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
40937202|NCT03523000|DRUG|Fentanyl|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
40937203|NCT03523000|DRUG|Placebo|Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
40937204|NCT03523000|DEVICE|Intrathecal Drug Delivery System (IDDS)|40-mL IDDS containing a solution of fentanyl 50 mcg/mL with bupivacaine 30 mg/mL
40937205|NCT00841373|PROCEDURE|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
40937206|NCT00841373|PROCEDURE|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
40937207|NCT00877474|DRUG|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
40937208|NCT00120354|PROCEDURE|Blood Testing|
40937209|NCT00120354|PROCEDURE|Percutaneous Liver Biopsy|
40937210|NCT00120354|PROCEDURE|Lamivudine Therapy|
40937211|NCT00396747|DRUG|Infliximab, methylprednisolone, methotrexate|
40937212|NCT00396747|DRUG|Methotrexate|
40937213|NCT00396747|DRUG|Methotrexate + Methylprednisolone|
40937214|NCT00396747|DRUG|Methotrexate + Infliximab|
40937215|NCT00413478|DRUG|5-Azacytidine|Starting dose level: 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
40937216|NCT00500305|PROCEDURE|Withhold standard INDO dose if BNP < 100 pg/ml|
40937217|NCT06542263|DEVICE|CPAP|For the non-CPAP group, the intervention includes catheter ablation and conventional treatment for AF combined with OSA; For the CPAP group, the intervention includes catheter ablation and CPAP treatment for AF combined with OSA
41130515|NCT05845970|OTHER|Pamprin Botanicals|Participants will take Pamprin Botanicals only. Participants will take 450mg of Pamprin Botanicals two days before their predicted period and then take it every day during their period. Participants can also take Pamprin Botanicals two days after the bleeding has concluded.
41130516|NCT05845970|COMBINATION_PRODUCT|Pamprin Botanicals + Pamprin Menstrual Pain Relief|Participants will repeat taking Pamprin Botanicals two days before their second predicted period and continue to take it each day during their period. However, during the second period, participants will also take Pamprin Menstrual Pain Relief per the over-the-counter directions (2 tablets every 6 hours with water).
41130517|NCT00043966|DRUG|Lopinavir/ritonavir|
40937218|NCT00184873|BEHAVIORAL|Health Counseling|
40937219|NCT03772860|OTHER|Pain stimulation|Pain will be simulated with an electric shock 25 mlAMP over the median nerve
40937220|NCT03772860|OTHER|Visual stimulation|Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds
40937221|NCT03772860|OTHER|Auditory stimulation|Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds
41130518|NCT00043966|DRUG|Tenofovir DF|
41280195|NCT03214835|DEVICE|Endo CDx Brush biopsy|In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
40937222|NCT03772860|OTHER|Mental stress|A mathematical challenge will be displayed on a computer screen that must be quickly solved
40937223|NCT06314620|DRUG|Heparin saline lock|Participants with intercostal chest catheter who underwent normal saline flushing with heparin saline lock
40937224|NCT06314620|OTHER|Without heparin saline lock|Participants with intercostal chest catheter who underwent normal saline flushing without heparin saline lock
40937225|NCT02812407|DEVICE|Mucosal Impedance|"During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.~* The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second~* At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds~* And at 20 cm"
40937226|NCT05120843|BEHAVIORAL|Care coordination and motivational interviewing|Interventionist will engage participants in care planning, health education, health care navigation, screening for unmet health needs or social needs, and motivational interviewing. The final intervention is expected to be six months in duration. However during this single-arm open testing phase, some participants may receive only key components of the intervention in order to assess feasibility, reach, adoption, and fidelity of those components.
40937227|NCT00421291|BEHAVIORAL|Education|
40937228|NCT04784104|DRUG|Bupivacaine HCl 0.5% Injectable Solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
40937229|NCT04784104|DRUG|Prilocaine HCl 2% Injectable solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
40937230|NCT04784104|DRUG|Adrenaline amp. 0.5 mg|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
40937231|NCT04784104|PROCEDURE|Ultrasound guided supraclavicular block with coronal oblique method|The blocks will be performed by an experienced anesthesiologist with a USG guidence.
41130519|NCT00043966|DRUG|Emtricitabine|
41130520|NCT01616888|DEVICE|PTA with drug eluting balloon with paclitaxel|Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
41280196|NCT05374343|DRUG|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule orally (by mouth) on Day 1
41130521|NCT02807857|PROCEDURE|Standard care|Patients will receive the treatment that their primary care physician has decided to prescribe for their disease
41130522|NCT00968695|DRUG|Albumin|The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
41130523|NCT00978588|DRUG|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
41130524|NCT04070963|OTHER|HbA1C|To take additional blood test of HbA1C once patient consented to the study
40937232|NCT04784104|PROCEDURE|Ultrasound guided lateral sagittal infraclavicular block|The blocks will be performed by an experienced anesthesiologist with USG guidence.
41130525|NCT00442104|DRUG|Ganaxolone|
41130526|NCT05206240|OTHER|Radial extracorporeal shock wave therapy and conventional physical therapy|"The conventional physical therapy program will consist of verticalization strategies, range of motion exercises, muscle stretching and strengthening exercises, stance and balance training, core stability exercises, gait training, functional training, cryotherapy or local heat for 1h/day, 5 days/week for 2 weeks.~Regarding the rESWT delivery, 2000 shots will be applied on the triceps surae myotendinous junction with a frequency of 10 Hz and an energy density of 60 mJ, 7 min/session, 1 session/week for 2 weeks."
41280197|NCT01440101|DRUG|Natalizumab (BG00002)|
41280198|NCT01440101|DRUG|Placebo|
41450364|NCT03207152|BIOLOGICAL|Influenza A/California/04/09|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
40756109|NCT00663195|DRUG|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
41130527|NCT05150873|OTHER|CTA evaluation|Any pre-operattive CTA of the patients of the cohort will be carefully evaluated to determine the theoric anatomical feasibility of an off the shelf Endograft, particularly in patients with an angulated and short aortic neck
41130528|NCT01229904|BEHAVIORAL|music therapy with guitar lessons|The treatment is a 6 week music therapy intervention. Subjects receive 1 hour individual lesson and a 1 hour group session weekly for 6 weeks. they are given a guitar following completion of the study
41130529|NCT05267769|DRUG|AP707|Preparation of Cannabis flowers (Cannabis flos)
41130530|NCT03315065|DRUG|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, \< 1 hour
40937233|NCT04325984|DRUG|Dexamethasone|To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
40937234|NCT00766961|PROCEDURE|Trans-catheter arterial embolization|Trans-catheter arterial embolization
41130531|NCT06041165|DRUG|JS401|Single dose of JS401 by subcutaneous (sc) injections
41130532|NCT06041165|DRUG|Placebo|Calculated volume to match active treatment
41130533|NCT05328466|DEVICE|The engineer-built system, video-game based Kinect sensor|The games were developed by the researcher team.
41130534|NCT01223274|DEVICE|CPAP/PEEP|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
41130535|NCT01223274|DEVICE|Standard management practices|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
41130536|NCT05211232|DRUG|Tislelizumab|GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
41130537|NCT05211232|DRUG|Placebo|GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
41130538|NCT00084435|DRUG|cisplatin|75 mg/m2 IV, Day 1, q 21 days for 3 cycles
41130539|NCT00084435|DRUG|docetaxel|15 mg/m2 IV, Day 1, 1 7 days for 6 doses
41450365|NCT04982523|BEHAVIORAL|Online Mental Health Program|The proposed program consisted of eight sessions conducted twice per week, consisting of 5 minutes of introductory material, 12-15 minutes of main content, and 5 minutes of concluding content. The main content intended to improve the control processes and each of the four adaptive modes of the RAM. The eight sessions were uploaded on the web. Links and passwords for each session were provided to the participants through SNS. The program was accessible from any electronic device with Internet access
40937235|NCT00766961|PROCEDURE|Surgery|Surgery
40937236|NCT05739864|BIOLOGICAL|FMT|This intervention is represented by the administration, in the recipients' gut, of super - donor microbiota through FMT
41130540|NCT00084435|RADIATION|radiation therapy|200 cGy/day, Days 1-5, q week for 6 weeks
41130541|NCT00526994|OTHER|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
41130542|NCT00526994|BEHAVIORAL|universal education|receives referral information
41130543|NCT04407884|DEVICE|Soovu Labs Inc. Pain Relief System|Longnitual follow-up
41130544|NCT02766296|BEHAVIORAL|Active Emotional Working Memory Training|This training regimen has adapted the existing n-back paradigm, which has been widely used in the field. Training requires participants to shift between visual and auditory information while continually updating their working memory.
41130545|NCT02766296|BEHAVIORAL|Control Working Memory Training|This training utilized a fixed dual 1-back training paradigm.
41130546|NCT04148560|OTHER|Tests of the validity of the RFPM and SmartIntake app.|Participants who enroll will be trained in using the RFPM/SmartIntake app and a food record and will complete the Food Intake Assessment Preference Survey. They will also use both methods to estimate intake during a simulated lab-based meal (they will not eat during this simulated meal). They will be dosed with DLW at this visit and will use the RFPM for the subsequent 1-2 days to get accustomed to using the method, with the following three days comprising the data collection period.
41130547|NCT02376309|BEHAVIORAL|Inactivity|Inactivity
41130548|NCT02376309|DRUG|ND|1 nandrolone decanoate injection
40937237|NCT05739864|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
41130549|NCT02376309|DIETARY_SUPPLEMENT|Leu|Leucine supplements
41130550|NCT00766909|DRUG|cyclosporine|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days."
41450366|NCT02095613|OTHER|traditional food|
41450367|NCT02095613|OTHER|food that is nutrient dense|
40937238|NCT01604759|DEVICE|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
40937239|NCT04686487|PROCEDURE|stereotactic ablative radiotherapy|stereotactic ablative radiotherapy by targeting high energy heavy ion beams at a specific area of the body
40937240|NCT03931343|PROCEDURE|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance|Thoracolumbar interfascial plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
41130551|NCT00766909|DRUG|tacrolimus|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days."
41130552|NCT00766909|OTHER|Capsules and isotonic saline|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.~For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days."
41130553|NCT00538759|DEVICE|External beam radiation therapy|Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty
41130554|NCT00538759|OTHER|Sham Control|
41130555|NCT00491894|DRUG|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
41130556|NCT05948449|DRUG|S-1, Oxaliplatin, Cadonilimab|3 cycles of neoadjuvant therapy will be administered: S-1: 40\~60mg Bid，d1\~14, q3w Oxaliplatin：130mg/m2，iv drip，d1, q3w Cadonilimab（AK104）:10mg/Kg,iv drip,d1,q3w
41130557|NCT00237120|DRUG|Imatinib|
41450368|NCT03363555|DRUG|SHR-1210|A humanized monoclonal immunoglobulin.
41450369|NCT03193567|BIOLOGICAL|HEKT cell|3 cycles of HEKT cell treatment
41450370|NCT03684330|DIETARY_SUPPLEMENT|Vitamin D|a dose once a week
41450371|NCT03684330|OTHER|whole body vibration (WBV)|03 months of WBV training three times per week
41130558|NCT02631668|DRUG|ferrous succinate and vitamin C|As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
41130559|NCT02631668|DRUG|ferrous succinate|As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
41130560|NCT02631668|DRUG|ferrous succinate|As another active comparator, patients take the tablets of ferrous succinate with double dosage
41280199|NCT04652362|BEHAVIORAL|Growth Mindset Online Single-Session Intervention|During the self-administered single session intervention participants are provided with basic information about the brain and are introduced to the concept of neuroplasticity. The concept of neuroplasticity is applied to personal traits, such as shyness, anxiety and sadness, and young people are taught that these traits are the result of thoughts and feelings in our brain and are amenable to change. Participants are presented with scientific information and research evidence to support the idea that people have the potential to change and are given vignettes from older children detailing how they have used a growth mindset to overcome difficulties. The intervention takes approximately 20-30 minutes to complete.
41450372|NCT06020430|RADIATION|CTV omitted or delineated|Patients who responded to the induction therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radical radiotherapy group or CTV-delineated radiotherapy group.
41450373|NCT04069936|BIOLOGICAL|MILs™ - NSCLC|To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC
41450374|NCT04069936|BIOLOGICAL|nivolumab|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC
40756110|NCT06570603|BEHAVIORAL|Self-Efficacy|Brief skills based psychotherapy session to increase perceived self-efficacy for withstanding distress, giving participants increased beliefs that they \*can\* do it.
40756111|NCT06570603|BEHAVIORAL|Willingness|Brief skills based psychotherapy session to increase perceived willingness to engage with distress for withstanding distress, giving participants increased motivation to try.
41450375|NCT04069936|DRUG|tadalafil|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC
41450376|NCT05359965|DEVICE|Positive Airway Pressure|Gentle and steady pressure (with or without supplemental oxygen) delivered to the airways of the lungs while subjects are sleeping.
41450377|NCT00735176|PROCEDURE|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
41450378|NCT00735176|PROCEDURE|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
41450379|NCT05878015|DRUG|Acetaminophen|1000mg intravenous every 6 hours on day 1 and day 2. 1000mg intravenous every 8 hours on day 3 as needed.
41450380|NCT03917758|DRUG|SGLT2 inhibitor|Start of the treatment with SGLT2i.
41450381|NCT00834613|DRUG|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fed
41450382|NCT00834613|DRUG|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fed
40756112|NCT06570603|BEHAVIORAL|Psychoeducation|Psychoeducation about the components and functions of emotion.
40756113|NCT00419432|OTHER|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
41280200|NCT04652362|BEHAVIORAL|Supportive Therapy Online Single-Session Intervention (Control)|The single session supportive therapy intervention was designed to be structurally comparable to the growth mindset intervention, including the same number of reading and writing activities. Participants were provided with information about emotions and the benefits of expressing emotions. Vignettes from older children described times they had shared their emotions with friends and family members.
41280201|NCT01490593|BEHAVIORAL|Public Health strategies|It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
41450383|NCT00942838|DRUG|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
41450384|NCT00942838|RADIATION|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
40756114|NCT00419432|OTHER|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
41280202|NCT02331264|OTHER|Exposure to metal debris|The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
41450385|NCT01325935|DRUG|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
41450386|NCT04792723|DRUG|Sublingual aspirin|Vita Green Health Products sublingual aspirin 80 mg tablet
41450387|NCT04792723|DRUG|Oral aspirin|Synco (HK) oral aspirin 80mg tablet
41450388|NCT02458664|GENETIC|Genetic analysis on tumor kept in tumor bank|
41450389|NCT00866476|BIOLOGICAL|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.
40756115|NCT04796818|PROCEDURE|Diffusion Weighted Imaging|Undergo IVIM DWI
41280203|NCT00197860|BIOLOGICAL|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate-pulsed dendritic cells i.d. 1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week and from the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
41280204|NCT03025581|OTHER|Nipple stimulation|For the intervention group participants will be instructed to gently massage alternate breasts, especially around the nipples for 15 minutes every 6 hours until the appearance of regular contractions but not more than 24 hours. Moist cloth or lubricating or moisturizing cream will be offered to facilitate the procedure according to individual preferences. In the control group all participants will be asked to avoid any breast stimulation during the study period.
41280205|NCT03314168|OTHER|Combined training|Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
41280206|NCT03314168|OTHER|Control group|The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
41280207|NCT04285918|PROCEDURE|Percutaneous device closure|If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.
41280208|NCT02639676|OTHER|Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections|
41280209|NCT05260411|BIOLOGICAL|AK102|Administered AK102 450 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
41280210|NCT05260411|BIOLOGICAL|AK102|Administered AK102 600 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
41280211|NCT05260411|DRUG|Placebo|Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
41450390|NCT00866476|OTHER|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
41450391|NCT01164657|DEVICE|"BirthRite"|Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
41450392|NCT01440179|DRUG|SAR3419|Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
41450393|NCT05450549|DRUG|DNL919|Single doses
41450394|NCT05450549|DRUG|Placebo|Single doses
41450395|NCT05869136|PROCEDURE|microneedling and hyaluronic acid for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered.~Hyaluronic acid:~HA will be injected in the attached gingiva and MN will be carried out 1mm below the gingival margin on the keratinized gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles in the test group."
41280212|NCT00655720|OTHER|infant formula|"1. hydrolyzed infant formula without probiotics~2. hydrolyzed infant formula with probiotics~3. hydrolyzed infant formula with probiotics"
41450396|NCT05869136|PROCEDURE|microneedling for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered and microneedling alone will be performed in control group"
41450397|NCT03172286|DEVICE|Radiofrequencer|Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
41450398|NCT01816360|OTHER|Olfactory aromatherapy|Inhalation of essential oils.
41450399|NCT01816360|OTHER|Yogatherapy|Yogatherapy respiratory exercises.
41450400|NCT01032213|DRUG|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
41450401|NCT01032213|DRUG|normal saline|Group S received the same volume of isotonic saline as same method.
41450402|NCT00396929|DRUG|local intracoronary dosis of Paclitaxel|
41280213|NCT01581190|DIETARY_SUPPLEMENT|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
41280214|NCT04740957|OTHER|Distal limb reintroduction of ileostomy effluent|"Patients will undergo water soluble contrast enema to confirm anastomotic healing 8 weeks post operatively as per standard practice at Imperial.~Patients will be educated in how to reintroduce ileostomy output to the distal (downstream) loop of their ileostomy. They will be asked to reintroduce 50ml of ileostomy output using a conventional long-tipped bladder syringe daily until surgery to close the stoma."
41280215|NCT01851096|DRUG|SNX-5422|Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
41280216|NCT00337051|DRUG|Sevoflurane|General anesthesia using Sevoflurane (inhalation) as hypnotic
41280217|NCT00337051|DRUG|Propofol|General anesthesia with propofol TCI
41450403|NCT01825694|BEHAVIORAL|Trauma-focused Substance Abuse Intervention|An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
41450404|NCT00081653|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 years
41450405|NCT00081653|DRUG|ibandronate [Bonviva/Boniva]|100mg po monthly for 3 years
41450406|NCT04936529|DIETARY_SUPPLEMENT|β-glucan|"Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).~Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14).~Group 3 participants will be treated as in Group 1."
41450407|NCT04936529|DRUG|GM-CSF|"Group 1 participants will not receive GM-CSF.~Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14.~Group 3 participants will be treated as in Group 1."
41450408|NCT04936529|BIOLOGICAL|OPT-821|Vaccine injections must occur a minimum of 6 days apart. After the first four vaccine injections, vaccines can be administered up to two weeks earlier or later than indicated without representing a protocol violation.
41450409|NCT05497986|DEVICE|High flow nasal cannula|HFNC with the maximum tolerated flow (up to 60 L/min). Titration of supplemental oxygen to a SpO2 between 88 - 92%.
41280218|NCT04288245|DEVICE|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper extremity rehabilitation. VNS stimulation as described in the current study consists of 0.5 s trains of 0.8 mA 100 µs biphasic pulses delivered at 30 Hz. Stimulation trains are delivered only during rehabilitation.
41280219|NCT04288245|DEVICE|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
41280220|NCT06453694|DRUG|Efgartigimod Alfa|"2,016 mg will be administered subcutaneously by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."
41280221|NCT06453694|DRUG|Placebo|"Subcutaneous injection of placebo will be administered by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."
41280222|NCT00954785|DEVICE|Ankle brace|Sports Stirrup ankle brace (Aircast)
41280223|NCT00954785|DRUG|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
41130561|NCT04890899|PROCEDURE|Cystic enculation of spleen hydatid|Preoperative preparation did according to the general condition of the patient and fitness for anaesthesia. Laparotomy did under general anaesthesia, supine position, the abdomen opened either by midline or left subcostal incision. Identification of splenic hydatid cyst. Exploration of the peritoneal cavity for undetected hepatic or peritoneal hydatid preoperatively. Isolation of operative field by packs socked with hypertonic solution (20 -30 % hypertonic saline). Aspiration of the cyst fluid. Injection of suitable amount about 5 ml of (1 % of cetramid) solution and waiting for at least 5 minutes and then re-aspiration. The spleen is not needed to mobilize. Extraction of the endocyst and washing of the cavity with normal saline. Occupying the cystic cavity intracystic drain. Perioperative and postoperative close observation of the patient for an anaphylactic reaction or any other complication. Follow-up of the patient until discharge from hospital on (3th - 5th) days.
41450410|NCT05497986|DEVICE|Conventional low flow oxygenation|Conventional oxygenation through nasal prongs or a facemask, with supplemental oxygen titrated to a SpO2 between 88 - 92%.
40937241|NCT03931343|PROCEDURE|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance|Erector spinae plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
40937242|NCT03481660|DRUG|Brolucizumab|Intravitreal injection
41280224|NCT00954785|DRUG|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
40937243|NCT03481660|DRUG|Aflibercept|Intravitreal injection
41130562|NCT03986359|DEVICE|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
40756116|NCT04210076|BEHAVIORAL|MBAT-T|The MBAT-Team program builds on the basic 4-week, 8-hour MBAT-Soldier program. In addition to the basic program, MBAT-Team includes exercises promoting the cultivation of attention and emotion regulation in the service of effective team interactions (e.g., mindful communication and listening; monitoring and attention to the activities and emotional states of others, and additional practices to promote collective mindfulness).
40756117|NCT04210076|BEHAVIORAL|MBAT-I|The MBAT-Individual program is based on the basic 4-week, 8-hour MBAT-Soldier curriculum.
40937244|NCT03978715|OTHER|No intervention-retrospective study|This is a retrospective study. No intervention
40937245|NCT05292404|DRUG|alirocumab|In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab,75mg) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months
40937246|NCT05292404|OTHER|conventional treatment|conventional treatment were given according to international uniformguidelines
40937247|NCT02648321|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
40937248|NCT02648321|BEHAVIORAL|Health Education|General education about healthy lifestyle and diet.
40937249|NCT03583203|DEVICE|personalized information about lung damage|Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months
40937250|NCT01736384|PROCEDURE|Gastric bypass or cholecystectomy|
41130563|NCT00371345|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)
41130564|NCT00371345|DRUG|Dasatinib 100 mg|Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)
41280225|NCT05230043|OTHER|Algometer test|The computerized pressure algometer, AlgoMed (Medoc, Ramat Yishai, Israel), will be used for mechanical pain stimulation to assess information about pain threshold and tolerance. A constant rate of pressure is delivered by the examiner, and the pressure is recorded in Kilopascal (kPa). The stimulation will be applied between the medial and distal joints of the phalanges of the dominant hand.
41450411|NCT03677960|DRUG|Topical ABI-1968 cream|Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
41450412|NCT01002963|DRUG|PF-04418948|solution, 30 mg, single
41450413|NCT01002963|DRUG|PF-04418948|solution, 100 mg, single
41450414|NCT01002963|DRUG|PF-04418948|solution, 300 mg, single
41450415|NCT01002963|DRUG|PF-04418948|solution, 1000 mg, single
41450416|NCT01002963|DRUG|PF-04418948|solution, 3000 mg, single
41450417|NCT01002963|DRUG|PF-04418948|solution, 4500 mg, single
41450418|NCT01002963|DRUG|PF-04418948|solution, 6000 mg, single
40937251|NCT05544981|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice containing \~5 mmol of inorganic nitrate
40937252|NCT05544981|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
40937253|NCT06111391|DEVICE|Osstell® device (Integration Diagnostics Ltd.).|After trans-mucosal abutments were removed and the smart pegs were attached to the fixtures, resonance frequency analysis was done to assess implant stability.The implant stability quotient (ISQ) was used to quantify stability via the Osstell® device (Integration Diagnostics Ltd.).
40937254|NCT03742908|DRUG|Cefazolin/clindamycin|Local implant immersion and/or breast pocket irrigation
40937255|NCT02857595|BEHAVIORAL|Online Behavioral Weight Loss program|
40937256|NCT02857595|BEHAVIORAL|Weight Loss Nomogram|
40937257|NCT02857595|BEHAVIORAL|Bite Counter|
40937258|NCT04907461|PROCEDURE|LAPTAP|Laparoscopic guided Transverse Abdominus Plane block
40937259|NCT03663738|BEHAVIORAL|mobile app NOVAME|The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
41280226|NCT05230043|OTHER|functional MRI|"* Two 8s sequences of spin echo field map with phase encoding AP and PA~* A 12:00min bold sequence for resting-state~* A 15:12min bold sequence for gambling task thickness=2mm, Matrix Size = 105×105, FOV=210×210mm2;~* A 6:38min T1w MPR sequence~* A 7:40min T1w MPR sequence~* A 5:57min T2w SPC sequence~* A 8:24min T2w SPC sequence~* A 8:32min FLAIR T2w sequence~* Two 8:26min Multi-echo GRE sequence~* A 8:29min high resolution multi-echo GRE sequence~* Two 6:46min multi-echo GRE sequence with and without magnetic transfer contrast~* Two 6:03min diffusion weighted images with phase encoding AP and PA"
40937260|NCT05135312|DRUG|Etanercept|TNF-alpha inhibitors improve nail psoriasis.
40937261|NCT05135312|DEVICE|OCT|Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
40937262|NCT06518889|PROCEDURE|Selective Dorsal Rhizotomy|Selective Dorsal Rhizotomy (SDR) is an irreversible neurosurgical procedure where 50-70% of the sensory nerve roots are cut at the spinal level. The procedure is used to reduce lower limb spasticity permanently and is augmented by intensive rehabilitation for at least two years after surgery to optimise outcomes.
41280227|NCT05546489|BEHAVIORAL|Lymfit intervention|Wearable activity trackers (Fitbit) were given to participants as a motivational tool and for data collection purposes. Participants received a personalized exercise prescription designed by a kinesiologist. Physiologic metrics were collected by the Fitbit monitors and were stored in the Lymfit database. Self-reported questionnaires measuring health outcomes were collected at baseline and post-intervention.
41280228|NCT02353949|DRUG|Flutemetamol (Vizamyl)|PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
41280229|NCT02256358|DRUG|Midazolam|preoperatively injected intravenous 0.1 mg/kg midazolam
40937263|NCT05925218|RADIATION|Radiotherapy as per standard of care|Adjuvant Radiotherapy +/- systemic therapy as per standard of care
40937264|NCT04447872|PROCEDURE|Timing of injectable gonadotropins|Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)
40937265|NCT03213353|DRUG|Tablet paracetamol, guaifenesin and phenylephrine HCL|Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
40937266|NCT03213353|DRUG|Vicks Active SymptoMax Plus powder for oral solution|Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
40937267|NCT02789332|DRUG|PwO|paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
40937268|NCT02789332|DRUG|PwCb|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
40937269|NCT02789332|DRUG|EC|both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
40937270|NCT02789332|PROCEDURE|Surgery after neoadjuvant Therapy|In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.
41450419|NCT00774540|DRUG|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
41130565|NCT03987698|BIOLOGICAL|SHR-1210|SHR-1210 injection
41130566|NCT03987698|BIOLOGICAL|CIK cells|CIK cells injection
41130567|NCT05381090|DIAGNOSTIC_TEST|Venous blood collection|Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.
41130568|NCT05811273|OTHER|physical readiness training|Bend and Reach:5 repetitions, Rear Lunge:5 repetitions per leg, High Jumper:5 repetitions, Rower:5 repetitions, Squat Bender:5 repetitions, Windmill:5 repetitions, Forward Lunge:5 repetitions per leg, Prone Row:5 repetitions, Bent-Leg Body Twist:5 repetitions per side, Push-Up:5 repetitions.
41280230|NCT02256358|DRUG|Ketamine|Preoperatively injected intravenous 1mg/kg ketamine
41450420|NCT00774540|DRUG|Placebo|Saline
41450421|NCT06209749|OTHER|Sensory-based intervention module|Consists of sensory-based activities (Set A-F) with six weeks of individual sessions and six weeks of group sessions
40937271|NCT02789332|OTHER|Stratification|Hormone-receptor status (HR+ vs HR-) Age \< 40 years vs \>= 40 years
41450422|NCT05859984|DRUG|recombinant human interferon ω spray|8 ml/bottle（contain 2 million IU recombinant human interferon ω）
41450423|NCT04698473|OTHER|NCPAP|NCPAP infants will be randomized into two different non invasive ventilation groups
40937272|NCT04804020|PROCEDURE|NC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
40937273|NCT04804020|PROCEDURE|mNC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
41130569|NCT05811273|OTHER|Control group|general exercises
41450424|NCT04698473|OTHER|NIPPV|NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups
41130570|NCT01619410|BIOLOGICAL|Linezolid|Linezolid 600 mg every 12 hours for 7 days
41280231|NCT05718401|DEVICE|NMR|nuclear magnetic resonance in genomics
41280232|NCT04068883|OTHER|Q collar|An externally-worn medical device that applies mild jugular compression
41450425|NCT06452030|BEHAVIORAL|Specific sensorimotor control training|Participants allocated to the specific motor control group will receive sensorimotor training of the multifidus muscle.
41450426|NCT06452030|BEHAVIORAL|Aspecific extension training|Participants allocated to the aspecific group will receive spinal extension exercises.
41280233|NCT02503891|DEVICE|MP-1 Polymer on Ceramic Articulation system|MP-1 Polymer liner on Ceramic head
41450427|NCT06452030|BEHAVIORAL|Fascia training|Participants allocated to the fascia group will receive general movement exercises.
41450428|NCT03948854|OTHER|Registered dietitian|Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet
41450429|NCT03948854|OTHER|On-line video program|Education on low FODMAP diet is provided by an on-line program via a link sent through email
41130571|NCT01619410|BIOLOGICAL|Clindamycin|Clindamycin 300 mg po every 6 hours for 7 days
41450430|NCT03948854|OTHER|Printed handout|Education on low FODMAP diet is provided through printed handout material at the initial visit.
41450431|NCT03948854|OTHER|Dietitian-led group|Education on low FODMAP diet is provided in a dietitian-led group setting
41450432|NCT06370104|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Suicide Prevention|see arm description
41130572|NCT01744808|DRUG|EB-1020 IR|Immediate release
41130573|NCT01744808|DRUG|EB-1020 SR1|sustained release
41130574|NCT01744808|DRUG|EB-1020 SR2|Sustained release
41130575|NCT01744808|DRUG|EB-1020 SR3|Sustained release
41450433|NCT06370104|BEHAVIORAL|Living under control|see arm description
41130576|NCT01744808|OTHER|Placebo|Placebo formulation
41130577|NCT04775810|DEVICE|The device is an algorithm designed to enhance speech intelligibility of speech-in-noise signals|Normal-hearing and hearing-impaired subjects will listen to speech-in-noise audio files that are either unprocessed or processed in order to increase speech intelligibility.
41130578|NCT03294967|DIETARY_SUPPLEMENT|Caffeine|As in group descriptions
41130579|NCT03294967|DIETARY_SUPPLEMENT|Vitamin E|As in group descriptions
41130580|NCT00062660|DRUG|Tipranavir|Tipranavir 250 mg soft elastic capsules
41280234|NCT03614390|BEHAVIORAL|mindfulness based cognitive therapy (MBCT)|a well described and structured intervention, which is published previously. The psychoeducation materials in the MBCT will be titrated to discuss about low mood and burnout
41280235|NCT00659438|DRUG|ZD6474 (Vandetanib)|300mg orally, once daily
41280236|NCT00659438|DRUG|Bicalutamide|150mg orally, once daily
41280237|NCT00659438|DRUG|Placebo|orally, once daily
41450434|NCT00425308|DRUG|Everolimus + Cyclosporine|
41450435|NCT00425308|DRUG|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
41450436|NCT00425308|DRUG|Steroids|
41450437|NCT05965908|DRUG|liraglutide|glucagon-like peptide 1 receptor agonist
41450438|NCT05965908|DRUG|Metformin|biguanide antihyperglycemic
41450439|NCT00408304|DRUG|omega-3 fatty acid|
41450440|NCT00295490|DRUG|Devil Claw|Dose ranging study so will elucidate dose Frequency is four times daily
41450441|NCT00295490|DRUG|Placebo|Placebo has same dosing freq as for active intervention and for same time period
41450442|NCT00627016|DRUG|Dexlansoprazole|30 mg capsule, orally, once daily for 4 weeks
41450443|NCT00627016|DRUG|Placebo|1 capsule, orally, once daily for 4 weeks
41280238|NCT05023889|DRUG|patisiran|"Patients will receive 0.3 mg/kg patisiran once every 21 days administered as an IV infusion over 70 minutes (approximately 1 mL/minute for the first 15 minutes followed by approximately 3 mL/minute for the remainder of the infusion) by a controlled infusion device.~All patients in this study will be premedicated prior to dosing with patisiran. Study drug supplied for this study must not be used for any purpose other than the present study and must not be administered to any person not enrolled in the study.~The first dose of study drug (week 1) will be administered under the supervision of site personnel. After the first dose of patisiran, patients should return to the site for patisiran dosing once every 21 days or receive the patisiran infusions at a local infusion center by a healthcare professional trained on the Protocol, administration of premedication, and patisiran infusion. Patient must receive a dose of interventional drug within the dosing window (±3 days)."
41450444|NCT04940494|OTHER|collection of data|collection of data for all Obstetrical Anal Sphincter Injury women (score of quality of life, experimenting anal incontinence...)
40937274|NCT04804020|PROCEDURE|AC|The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
41130581|NCT04185181|OTHER|virtual reality|wii video game based exercise
41130582|NCT04185181|OTHER|proprioceptive neuromuscular facilitation|PNF with breathing
41450445|NCT00000950|DRUG|Ethambutol hydrochloride|
41450446|NCT00000950|DRUG|Isoniazid|
41450447|NCT00000950|DRUG|Pyrazinamide|
41450448|NCT00000950|DRUG|Pyridoxine hydrochloride|
41130583|NCT04185181|OTHER|complete decogestive therapy|pneumatic compression, manual lymph drainage, skin care and home exercise program
41130584|NCT02570100|PROCEDURE|Biological collection|"Collection of blood samples and tumor specimens :~Biological collection before treatment :~* 1 tumor specimen (under echographic control)~* 4 blood collections~Biological collection during treatment :~* 1 tumor specimen after 3 cycles~* 4 blood collections after 3 and 6 cycles"
41280239|NCT02160067|DRUG|Second generation BTDS patch|
41280240|NCT02160067|DRUG|First generation BuTrans patch|
41280241|NCT04693871|DEVICE|Transesophageal ultrasound|Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.
41280242|NCT06443086|PROCEDURE|Radical operation and perioperative therapy|Surgical intervention, particularly radical excision, was performed for each patient, including the extent of resection and lymph node dissection. Information on adjuvant therapies, such as chemotherapy and radiotherapy, was also recorded, specifying the regimens and durations.
41280243|NCT01122329|DIETARY_SUPPLEMENT|caprylidene|Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days
41280244|NCT01122329|DIETARY_SUPPLEMENT|Placebo|
40937275|NCT05012436|DRUG|YHD1119 75mg|A single oral dose
41130585|NCT03314636|DRUG|Carfilzomib|See in arm description
41280245|NCT01929252|DRUG|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
41450449|NCT00000950|DRUG|Rifampin|
41450450|NCT02940457|DEVICE|Verum tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA
41450451|NCT02940457|DEVICE|Sham tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
41450452|NCT03513185|DRUG|Deanxit, SSRI or SRNI|After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
41450453|NCT02466490|DRUG|Fimasartan|Fimasartan tablets
41450454|NCT02466490|DRUG|Fimasartan; Hydrochlorothiazide|Fimasartan plus hydrochlorothiazide fixed dose combination tablets
41450455|NCT06115317|OTHER|Prism|Prism
41450456|NCT06115317|OTHER|Sham|Sham
41130586|NCT03314636|DRUG|Lenalidomide|See in arm description
41130587|NCT03314636|DEVICE|PET-CT|See in arm description
41130588|NCT03314636|DRUG|Dexamethasone|See in arm description
41130589|NCT02195856|DIETARY_SUPPLEMENT|Beetroot juice|140mL concentrated Beetroot juice or placebo juice
41130590|NCT02195856|DIETARY_SUPPLEMENT|Placebo|
41130591|NCT00144040|BEHAVIORAL|Physician & patient education on appropriate antibiotic use|
41130592|NCT00144040|PROCEDURE|Rapid C-reactive protein testing to guide antibiotic treatment|
41130593|NCT06175871|OTHER|OTAGO exercises|Exercices for improvement postural control and mobility and decrease falls risks
41130594|NCT06175871|OTHER|Conventional therapy|Exercice and education from physical therapy practice conventional from Hospital.
41130595|NCT00188305|BEHAVIORAL|General health counselling and risk information|General health counselling and risk information
41130596|NCT02399449|DRUG|Brand sodium ferric gluconate|brand product
41130597|NCT02399449|DRUG|Generic sodium ferric gluconate|generic product
41130598|NCT03292692|BEHAVIORAL|OurRelationship|Online intervention with coach support
41130599|NCT02221505|DRUG|LOP628|
41130600|NCT02325466|DRUG|Aspirin|Aspirin 81mg
41130601|NCT02325466|DRUG|Ticagrelor|ticagrelor 90 mg
41130602|NCT02325466|DRUG|Aspirin Placebo|
41130603|NCT02325466|DRUG|Ticagrelor Placebo|
41130604|NCT02433587|DRUG|Aspirin|Patients will take Aspirin 81 mg
41130605|NCT02433587|DRUG|Clopidogrel|Patients will take Clopidogrel 75 mg
40937276|NCT00655460|PROCEDURE|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
41130606|NCT03580551|BEHAVIORAL|Intervention Group|"Intervention group participants will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. Participants will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. During the first 6 weeks, the intervention group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end of week 6, the intervention group will be contacted to schedule a post-assessment for the end of week 8, which will include repeating all health measures, except for health status."
41280246|NCT01929252|DRUG|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
41280247|NCT00659295|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
41280248|NCT03319550|DIETARY_SUPPLEMENT|Casein|see experimental description
41280249|NCT03319550|DIETARY_SUPPLEMENT|Whey|see experimental description
41280250|NCT03319550|DIETARY_SUPPLEMENT|Leucine-enriched whey|see experimental description
41280251|NCT00125034|BIOLOGICAL|Cetuximab|"Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m\^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
41280252|NCT00125034|DRUG|Oxaliplatin|"Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m\^2/day IV over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
41450457|NCT03921879|DRUG|OT-82 Dose Escalation|The starting OT-82 dose level will be16.5mg/m2 given orally as an oral suspension once daily on Days 1-3, 8-10, and 15-17 of each successive 28-day cycle. Dose escalation will follow a modified 3+3 design. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
41453568|NCT02861560|OTHER|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
40937277|NCT01082731|DRUG|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
40937278|NCT01082731|DRUG|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
41280253|NCT00230763|PROCEDURE|GSS questionnaire|D0, D30 and D84
41280254|NCT00230763|PROCEDURE|IOP|D0, D30 and D84
40756118|NCT02542579|GENETIC|16S rRNA pyrosequencing analysis|Next generation sequencing analysis will be done for 16S rRNA V1,2 hypervariable regions at Biocore (Seoul, Korea).
41450458|NCT03921879|DRUG|OT-82 Dose Expansion|A total of 25 patients evaluable for disease response will be treated with OT-82 on Days 1-3, 8-10, and 15-17 of the 28-day cycle at the MTD or maximum tested dose determined from Stage 1. This may include patients treated at that dose in Stage 1 plus expansion at that dose during Stage 2. Evaluability for disease response requires that patients receive at least one dose of OT-82. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
41130607|NCT03580551|BEHAVIORAL|Waitlist Control Group|"At week 8, waitlist control group will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. The waitlist control group will complete a post-assessment at the end of week 8, which will include all health status measures, except health status. Waitlist control group will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. Waitlist control group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end 14 weeks, waitlist control group will be contacted to schedule a final meeting, and to collect the adherence logs and satisfaction survey. At 16 weeks, the waitlist control group will not receive an additional post-assessment."
41130608|NCT02926794|BEHAVIORAL|SA and II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
41130609|NCT02926794|BEHAVIORAL|SA and No II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
41130610|NCT02926794|BEHAVIORAL|No SA and II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
41130611|NCT02926794|BEHAVIORAL|No SA and No II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
41280255|NCT00230763|DRUG|LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION|in the evening during 84 days
41280256|NCT00230763|PROCEDURE|Visual acuity|D0 and D84
40756119|NCT05289453|PROCEDURE|lens extraction by phacoemulsification|lens extraction by phacoemulsification
40756120|NCT02786511|DRUG|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
41280257|NCT01752283|PROCEDURE|video-assisted thyroidectomy|Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
40756121|NCT05232305|DIETARY_SUPPLEMENT|Pomegranate Peel|Standard bread and test breads (with added pomegranate peel) to be used in the study will be produced by Asst. Prof. Özlem ÖZPAK AKKUŞ in the Nutrition Principles Laboratory of Toros University. For standard bread, 900 ml of water, 42 fresh yeast, 12 g of salt and 12 g of sunflower oil will be added to 1000 g of sifted whole wheat flour and the prepared bread mixture will be divided into 40 equal parts. To make bread with pomegranate peel added, 1000 g of sifted whole wheat flour, 20 g of pomegranate peel powder, 914 ml of water, 42 g of fresh yeast, 12 g of salt and 12 g of sunflower oil will be added and the prepared bread mixture is divided into 40 equal parts with 500 mg of pomegranate peel powder in each piece).
41280258|NCT01752283|PROCEDURE|Video-assisted thyroidectomy|video-assisted thyroidectomy under general anesthesia
41280259|NCT05828901|OTHER|S1PR analysis on immune cells|S1P receptor 1 and 5 expression will be measured on immune cells
41280260|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: hesperidin and flaxseed|2 capsules hesperidin and 30 g flaxseed
41280261|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: hesperidin|2 capsules hesperidin
41280262|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: flaxseed|30 g flaxseed
41280263|NCT03734510|OTHER|control|no supplementation
41280264|NCT02896478|OTHER|No intervention. Only observational study|
41280265|NCT04001686|OTHER|incidence aplastic anemia|Ambispective chart review
41280266|NCT02038062|PROCEDURE|Sevoflurane preconditioning|Preconditioning by transient application of sevoflurane
41450459|NCT02775994|DRUG|Canakinumab|interleukin beta (IL-1) antagonist
41450460|NCT03866265|DIETARY_SUPPLEMENT|Food Grade Extract of Salmon Polar Lipids (FGE-Salmon-PLs)|Each participant will be administered per day a capsule of the FGE-Salmon-PLs food supplement (containing 0.125 g of FGE-Salmon-PLs) for a period of 28 days in a double blind randomized, crossover and placebo-controlled design.
41280267|NCT04847986|BEHAVIORAL|acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
41280268|NCT04847986|BEHAVIORAL|Control group|The control group will receive care as usual with psychoeducation materials provided.
41280269|NCT02384720|OTHER|Age: 20-40years|
41280270|NCT02384720|OTHER|Age: 41-64years|
41280271|NCT02384720|OTHER|Age: ≥65years|
41450461|NCT03866265|OTHER|Placebo|Each participant will be administered per day a placebo capsule (containing 0.125 g of glycerin) for a period of 28 days in a double blind randomized, crossover design.
40937279|NCT04686123|OTHER|Active Stretching or Self-stretching exercises|Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks
40937280|NCT04686123|OTHER|Active strengthening Or Self-Strengthening exercises|Lower trapezius muscle was strengthened under the supervision of a physiotherapist as follows: -2 sets of 5-rep./session/day, for 5 consecutive days in 1st week, progressed to 10 and 20 reps./session/day for 2 weeks and 3 weeks respectively.
40937281|NCT02122731|DRUG|Amiloride|5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
40937282|NCT03364907|OTHER|HIPEC with flushing afterwards|flushing with saline fluid after HIPEC
41130612|NCT06304051|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
41280272|NCT05278390|RADIATION|Thoracic CT scan|Automated quantitative analysis of altered pulmonary volume
41450462|NCT05824897|OTHER|Serum levels of vitamin D|Subjects in this study are grouped according to baseline serum levels of 25(OH)D. The serum level of total 25(OH)D ≥30ng/ml (75nM) is sufficient, 20-30ng/ml (50-75 nm) is insufficient, and less than 20ng/ml (50nM) is deficient.
40937283|NCT03364907|OTHER|HIPEC without flushing afterwards|NO flushing with saline fluid after HIPEC
40937284|NCT05062278|DRUG|Vinblastine|Single-dose of intravenous vinblastine at 6mg/m2 (maximum 10mg).
41280273|NCT00319163|DRUG|levonorgestrel/ethinyl estradiol|
41280274|NCT04827238|DIAGNOSTIC_TEST|Standardized Invasive Hemodynamics|The SIH technique is a standardized, reproducible and efficient way of obtaining hemodynamic measurements.
41280275|NCT00448461|DRUG|heparin|comparison between heparin and bivalirudin
41450463|NCT00959790|DIETARY_SUPPLEMENT|Vegetables|200 or 50 grams of vegetables daily for four weeks
40937285|NCT05062278|DRUG|Hydroxyurea capsules|Oral hydroxyurea at a dose of 50mg/kg/day until the administration of induction chemotherapy.
41280276|NCT00448461|DRUG|bivalirudin|comparison between heparin and bivalirudin
41280277|NCT04551443|BIOLOGICAL|Intravenous infusion placebo|Intravenous infusion placebo or WJMSCs in patients with AMI
41280278|NCT04551443|BIOLOGICAL|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with AMI
41280279|NCT03220412|BEHAVIORAL|Movies with Guns|Participants in this arm viewed movies (National Treasure, The Rocketeer) without guns. The movies, rated PG, were edited to remove guns from the scenes
41280280|NCT05466435|OTHER|Heavy Slow Resistance|Heavy slow resistance exercise will be given twice a week for 12 weeks along with traditional physical therapy program
41280281|NCT05466435|OTHER|Control group|Traditional physical therapy program only will be given twice a week for 12 weeks
41280282|NCT00241267|DEVICE|Dedicated ultrasonographic probe during bronchoscopy|
41280283|NCT06346405|OTHER|Subthreshold Micropulse Laser Treatment|Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.
41280284|NCT00763893|DRUG|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
41280285|NCT00763893|DRUG|Losartan|50 mg/day if \< weight 50 kg 100 mg/day if weight \> 50 kg
41450464|NCT00959790|DIETARY_SUPPLEMENT|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
41450465|NCT02923336|DRUG|non selective beta blocker|"the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time"
41450466|NCT01969123|DRUG|Drug: EVP-6124|
41450467|NCT01969123|DRUG|Placebo|
40937286|NCT00112697|DRUG|cisplatin|
40937287|NCT00112697|DRUG|docetaxel|
40937288|NCT00112697|DRUG|fluorouracil|
40937289|NCT00112697|RADIATION|radiation therapy|
40937290|NCT06480981|DRUG|Noribogaine|Noribogaine capsules
41280286|NCT02500550|BIOLOGICAL|ATIR101|T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).
41450468|NCT00164684|BEHAVIORAL|Father Friendly Initiative|
41450469|NCT02266095|DEVICE|Oval-8 Splint|Splinting with Oval-8
40937291|NCT00660621|DRUG|Temozolomide and Bevacizumab|"Between 14 and 28 days after surgery, all subjects will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin with concomitant temozolomide at a daily dose of 75 mg/m2 (7 days/week).~No later than 45 days after date of completion of radiation therapy, all subjects will begin dose dense temozolomide at dose of 150 mg/m2 on Days 1-7 and 15-21 of a 28 day cycle with concomitant bevacizumab 10mg/kg administered intravenously every other week."
41130613|NCT06304051|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, the investigators made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
41130614|NCT02562937|BEHAVIORAL|text messages related to sedentary behaviour|texts sent twice daily encouraging reduced sedentary behaviour
41130615|NCT04044781|DRUG|BPN14770, T2310|Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
41130616|NCT03154736|OTHER|Interview|Individual interview and group interview Socio-economic questionnaire
41130617|NCT05543109|DRUG|Fentanyl|1 mic/kg during induction of anesthesia
41130618|NCT05543109|DRUG|Propofol|3mg/kg during induction of anesthesia
41130619|NCT05543109|DRUG|Rocuronium|0.9 mg/kg during induction of anesthesia
41130620|NCT05543109|DRUG|Sevoflurane|2-3% during maintanance of anesthesia
41130621|NCT05543109|DRUG|Ropivacaine|0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.
41130622|NCT03998059|PROCEDURE|splenectomy|These patients should fail to have sustained response to multiple first- and second-line treatments of ITP and agree to have splenectomy.Before splenectomy, these patients will be reassessed and still diagnosed with ITP.Their platelet level will be raised to a safe state before surgery, and the laparoscopic splenectomy will be performed in Tianjin People's Hospital.
40937292|NCT03889171|BEHAVIORAL|Behaviour|Comparison to psychological, medical and emotional Influencing communication and achievement factors to Oncogenetics tests
40937293|NCT04691388|DRUG|Amlotinib+Sindili|All patients will receive Sindelizumab combined with Antinib Hydrochloride capsule every 3 weeks
40937294|NCT00752544|DRUG|TMC435350|
41130623|NCT03408041|OTHER|Medical file data extraction|Medical file data extraction
41130624|NCT04535856|DRUG|allogeneic mesenchymal stem cell|"Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)"
41280287|NCT02500550|PROCEDURE|Haploidentical hematopoietic stem cell transplantation (HSCT)|"CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:~* Total Body Irradiation (TBI) regime~* Non-TBI regime~(See below for details)"
41130625|NCT04535856|OTHER|Placebo|Control group (placebo)
41130626|NCT05011292|BEHAVIORAL|Educational Video about SCB|3-4 minutes video about SCB.
41280288|NCT02500550|PROCEDURE|TBI regime|"* Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)~* Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
41280289|NCT02500550|PROCEDURE|Non-TBI regime|"* Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1~* ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
41280290|NCT00193843|PROCEDURE|Post-operative chemoradiotherapy / accelerated radiotherapy|
41280291|NCT05718362|BEHAVIORAL|Ayres Sensory Integration Therapy|It is an intervention method whose effectiveness is questioned. It is a therapy program applied according to Ayres Sensory Integration Fidelity Measure.
41280292|NCT05718362|BEHAVIORAL|Home Program|These are the activities created for the participants (both intervention and control groups) and to be done in the home environment.
41280293|NCT03409302|BEHAVIORAL|ALGEApp (Brief iACT intervention)|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The i-ACT intervention participants will be encouraged to login the website platform with their credentials and to complete 4 weekly sessions (1 session per week) which lasts about 1 hour each. Participants will be guided by a 3D- animated Avatar who adopts the role of a facilitator.
41450470|NCT02266095|DEVICE|Tee Pee Splint|Splinting with Tee Pee
41450471|NCT02266095|DEVICE|Forearm Based Splint|Splinting with Forearm based
41280294|NCT03409302|BEHAVIORAL|Active control group|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The active control group will have access, through the same platform. only to limited online psycho-educational information regarding pain. Active control group will complete pre-treatment and post-treatment questionnaires in parallel with the intervention group.
41280295|NCT04476264|PROCEDURE|Novel use of an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection|The present study serves to describe a novel approach to utilizing a single adjustable 8-0 polypropylene suture for scleral fixation without conjunctival dissection and to evaluate safety and efficacy outcomes associated with this technique.
41280296|NCT02888626|DEVICE|Microlens Array|Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
40937295|NCT05333783|BEHAVIORAL|Augmented Reality Exposure Therapy Based on ExposXR software|The ExposXR software is developed by The Stress Trauma Anxiety Research Clinic at Wayne State University, U.S.A. When it is used inside a Augmented Reality hardware such as Hololens, it renders artificial phobic objects into what the participants see. The treatment consist of a one-session treatment for cynophobia using Augmented Reality.
41450472|NCT02561845|DRUG|rosuvastatin|5mg, 10mg, 20mg
41450473|NCT01742403|RADIATION|R/T gating kV intrafraction monitoring|This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
40937296|NCT04499547|BEHAVIORAL|YouTube-delivered aerobic and muscle-strengthening physical activity intervention|Participants in the intervention group will receive two YouTube-delivered videos each week, for 8 weeks. In detail, on Monday, participants will receive an aerobic-based physical activity video with information and a workout to complete and on Thursdays, the participants will receive a video with muscle-strengthening physical activity information and a workout to complete.
40937297|NCT03395054|OTHER|cervical stabilization exercises|cervical stabilization exercises
40937298|NCT03395054|OTHER|conventional exercises|conventional exercises
41130627|NCT05011292|BEHAVIORAL|Survey on child feeding and related knowledge and practices|Short survey about infant feeding practices (3-4 minutes). No identifying information will be collected. The general scope of topics covered in the surveys will be attitudes toward the sugar-containing beverage reduction (SCB) videos played at the clinic as well as SCB knowledge and practices of parents and their children.
41130628|NCT05011292|BEHAVIORAL|Educational Video other than SCB|Educational video about a topic other than infant SCB consumption.
40937299|NCT01807832|OTHER|capsaicin challenge|
41130629|NCT01266369|DRUG|masitinib|
41280297|NCT02884180|DRUG|Dexamethasone|A dose of 24 mg dexamethasone given after start of anaesthesia
41280298|NCT02884180|DRUG|Saline isotonic|A dose of 6 ml of isotonic saline given after start of anaesthesia
41280299|NCT06279923|BIOLOGICAL|CD19-BAFF Targeted CAR T-cells|Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
41280300|NCT03065530|DRUG|Normal Saline|Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
41280301|NCT03065530|DRUG|Dexmedetomidine 0.03ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
41280302|NCT03065530|DRUG|Dexmedetomidine 0.05ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
41280303|NCT03065530|DRUG|Dexmedetomidine 0.08ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
41280304|NCT00765765|DRUG|hydroxychloroquine|Dose escalation from 200 mg po qd to 200 mg po bid.
41280305|NCT00765765|DRUG|ixabepilone|Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
41280306|NCT03150940|DIAGNOSTIC_TEST|ECG|12 lead electrocardiogram used to demonstrate cardiac function
41280307|NCT03150940|DIAGNOSTIC_TEST|bedside cardiac ultrasound|bedside cardiac ultrasound to see 2D images of each participants heart. Without the use of radiation.
41280308|NCT04560127|DRUG|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
41130630|NCT00145587|PROCEDURE|Stem Cell Transplantation|An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
41130631|NCT00145587|DEVICE|Miltenyi Biotec CliniMACS|Stem cell selection device
41450474|NCT00120887|DRUG|Atorvastatin|
41450475|NCT01418573|OTHER|Palaeolithic meal 1|Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
41450476|NCT01418573|OTHER|Palaeolithic meal 2|Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
41450477|NCT01418573|OTHER|Reference meal|Based on WHO dietary guidelines for protein, fat and carbohydrate.
41450478|NCT04026048|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia (CBT-I)|CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
41450479|NCT04200872|OTHER|biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
41450480|NCT04200872|OTHER|no biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
41453569|NCT02977416|OTHER|anti-TNFα|
41453570|NCT04999423|DEVICE|LVIS EVO and HydroCoil Embolic System|Stent assisted Coiling
40937300|NCT02729675|OTHER|Access Intervention|The 7 worksites in this arm received year-round, weekly mobile F\&V markets (Fresh To You - FTY) selling local and non-local fresh produce at or below local supermarket prices. The markets carried 50 to 70 different produce items and were held both indoors and outdoors depending on the weather and worksite preference. When held indoors, F\&V were sold in a cafeteria or other highly trafficked area. In good weather, the markets were held outside on the worksite property in a retrofitted a car trailer. Each market lasted two hours. On average, FTY prices were 15% to 25% lower than local retail supermarket prices. Signs, posters, email blasts and flyers advertised the markets. The FTY intervention at each worksite began with a Kick-Off event, which included the first FTY market. Each employee who attended the first market received a large, reusable shopping bag with the FTY logo on it and a freezer pack to keep F\&V fresh.
41280309|NCT03431012|OTHER|Agency Assignment framing|Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch...') or the pandemic flu virus itself (VA: 'It can infect you when you touch...')
41280310|NCT03431012|OTHER|Attribute framing|Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
41280311|NCT02119715|DRUG|Pegylated rhG-CSF 100μg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
41280312|NCT02119715|DRUG|Pegylated rhG-CSF:150 μg/kg|Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
41450481|NCT05928247|BEHAVIORAL|Functional Communication Training (FCT)|During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. For participants with challenging behavior determined to be maintained by social-positive reinforcement (attention and/or tangible), the investigators also will typically recommend using a multiple schedule FCT (mult-FCT) to signal when reinforcement is available and to thin the schedule of reinforcement to render the treatment more practical for caregivers to implement. For participants with challenging behavior determined to be maintained by social-negative reinforcement (escape), the investigators will recommend using a chained schedule FCT (chained-FCT).
41450482|NCT05928247|BEHAVIORAL|Non-Contingent Reinforcement (NCR)|During NCR, the investigators will deliver the functional and competing reinforcers on time-based schedules and use multiple and chained schedules to signal when noncontingent reinforcement is available (similar to multiple- and chained-FCT).
41453571|NCT03164460|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT/IMPT
40937301|NCT02729675|BEHAVIORAL|Enhanced Intervention|The 7 worksites in this arm received the Access intervention described above as well as set of educational/behavioral interventions. At the Kick-Off, employees received the first month's newsletter and an educational digital video disk (DVD) in the reusable shopping bag. They also received a chef-run cooking demonstration/taste-testing along with recipes and information about the upcoming intervention activities. Intervention activities included two 6-week campaigns (Just Add Two and Choose Color, Choose Health); a 90 minute DVD with cooking demonstrations about preparing quick, healthy inexpensive meals and unusual F\&V; a two-page, full-color newsletter distributed monthly; Food demonstrations/tastings delivered once a month by chefs including an easy to prepare, F\&V-based recipe; a total of 12 recipe handouts that correlated with the monthly cooking demonstration; a Good to Go website; and a project bulletin board.
40937302|NCT02729675|BEHAVIORAL|Comparison Behavioral Intervention|Brown University contracted with the Greater Providence Young Men's Christian Association (YMCA) to provide a physical activity and stress reduction intervention at the 7 worksites in the comparison group. Two, six-week campaigns were developed jointly by the Brown study team and YMCA staff. These campaigns followed the same format as the enhanced intervention group campaigns and were provided during the same time periods as those at the enhanced intervention sites. Everyone who participated in the campaigns also received a free, 6-week membership to the YMCA.
40937303|NCT04447612|DRUG|Durvalumab|Intravenous infusion of durvalumab 1500mg every 4 weeks for 13 cycles (1 year), starting 1 week before start of induction chemotherapy
40937304|NCT04447612|DRUG|Cisplatin|Induction phase: cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles Concurrent phase: cisplatin 100mg/m2 starting on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles
40937305|NCT04447612|DRUG|Gemcitabine|Induction phase: gemcitabine 1000mg/m2 on day 1 and day 8 via intravenous infusion every 3 weeks for 3 cycles
40937306|NCT04387760|DRUG|Hydroxychloroquine|"400mg BID PO day 1 then 200mg BID PO from day 2 to day 10.~In addition to Hydroxychloroquine all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
40937307|NCT04387760|DRUG|Favipiravir|"1600mg BID PO day 1600mg BID PO day 2 to day 10.~In addition to Favipiravir all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
40937308|NCT04387760|OTHER|Routine care for COVID-19 patients|Supportive care according to local guidelines
40937309|NCT04934280|DIAGNOSTIC_TEST|sonohysterography|saline infusion transvaginally followed by 2D transvaginal ultrasound imaging
40937310|NCT03800082|BEHAVIORAL|at heart (changed from HEARTPA♀N during usability testing)|An integrated smartphone and web-based intervention (at heart) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with heart disease. The intervention for participants randomized to the treatment group will consist of regular use of a progressive WebApp that is managed by a Chatbot named 'Holly', in addition to usual care, for a period of 3 months.
40937311|NCT00276081|DRUG|Gabapentin, Estrogen and placebo administration|
41453572|NCT03164460|RADIATION|Proton Radiation|Undergo IMRT/IMPT
41453573|NCT03164460|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41450483|NCT05928247|BEHAVIORAL|Competing Items and Response Blocking|The investigators will conduct a competing stimulus assessment (CSA) to identify items that produce at least an 80% reduction in challenging behavior when the participant is engaged with them. The investigators will evaluate conditions in which participants have free access to the item(s), when engagement with the item(s) is prompted, and when challenging behavior is physically blocked. Treatment will include one or more of the following components: non-contingent reinforcement informed by the CSA, reinforcing adaptive behavior, and blocking challenging behavior. The investigators will also use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of the this treatment. The ending duration of the S-delta component will be based on input from caregivers and the participant's school personnel.
41450484|NCT05928247|BEHAVIORAL|Research Units in Behavioral Intervention (RUBI) protocol|Caregivers of participants with mild challenging behavior will receive training on a variety of topics, such as prevention strategies and functional communication training, throughout implementation of the RUBI protocol.
41450485|NCT03480230|DRUG|Compound 121564|Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
40756122|NCT02470871|BIOLOGICAL|Eptacog alfa (activated) or pdFVII|"Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.~Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study."
40756123|NCT02470871|BIOLOGICAL|CSL689|Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
40937312|NCT02948283|OTHER|Laboratory Biomarker Analysis|Correlative studies
40937313|NCT02948283|DRUG|Metformin Hydrochloride|Given PO
40937314|NCT02948283|OTHER|Pharmacological Study|Correlative studies
41450486|NCT05046340|OTHER|Passive leg raising|We perform the PLR test by adjusting the bed and not by manually raising the patient's legs. Bronchial secretions must be carefully aspirated before PLR. If awake, the patient should be informed of what the test involves. And measure the cardiac output by using certain devices at the bedside. The end-expiratory occlusion consists in interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output.
41450487|NCT02994147|DRUG|Placebo|Placebo-only control study medication is the same formulation as active treatment without active ingredient
41450488|NCT02994147|DRUG|AC-201CR|The investigational product is formulated as controlled-release (CR) tablets
41450489|NCT03905967|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of each center.
41450490|NCT03905967|DRUG|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients \>60kg)
41450491|NCT04454307|DRUG|Tramadol|tramadol 100 mg twice daily for 10 days
41450492|NCT04454307|OTHER|Standard care delivered in the isolation hospitals.|Oxygen ventilation.
41450493|NCT06054984|DRUG|TCR-T Cells Injection（GB3010 Cells Injection）|The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced to express a T-cell Receptor that recognizes the RAS/TP53.Patients were sequentially enrolled into 3 dose escalation groups(dose level 1-3) :5×10\^8±20%,5×10\^9±20%,5×10\^10±20%.
41450494|NCT01301794|DIETARY_SUPPLEMENT|Omega 3 fatty acid (Lovaza)|Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).
41450495|NCT00196963|BIOLOGICAL|Meningococcal (vaccine)|
41450496|NCT02275962|DRUG|K-877|
41450497|NCT02275962|DRUG|Rifampin|
41450498|NCT06626867|DIETARY_SUPPLEMENT|Dietary Fiber Supplementation|Each participant ingested either dietary fiber or placebo. The dietary fiber is indi-gestible dextrin (The WiseMan\&#39;s Dining, KING CAR OTSUKA CO., Taipei, Taiwan). The dosage of contents in each package is 6 grams, 3 packs a day, with a total dose of 18 grams.
41450499|NCT06626867|OTHER|Placebo|The placebo was a colored capsule with 5 grams of maltodextrin, which is taken once a day.
41453574|NCT05691153|DRUG|ThisCART19A with Dose Level 1|ThisCART19A，2×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
40756124|NCT00052715|DRUG|poly ICLC|
40756125|NCT03106402|DRUG|topical bromfenac sodium hydrate|
40756126|NCT00417287|DRUG|PX-12|3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
40756127|NCT05604157|OTHER|Use of Tourniquet|Application of tourniquet or not in adults undergoing a primary total knee replacement.
40937315|NCT02948283|DRUG|Ritonavir|Given PO
40937316|NCT02948283|OTHER|Quality-of-Life|Ancillary studies
40937317|NCT02948283|OTHER|Questionnaire|Ancillary studies
41453575|NCT05691153|DRUG|ThisCART19A with Dose Level 2|ThisCART19A，3×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
40756128|NCT03871504|OTHER|Submaximal isometric exercise|The exercise is a submaximal isometric contraction
40756129|NCT02610062|DRUG|AGS67E|Intravenous (IV) infusion
40756130|NCT01126398|PROCEDURE|ankle or distal tibia surgery|internal fixation for ankle or distal tibia fracture
40937318|NCT04144465|DRUG|NORADRENALIN|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
40937319|NCT04144465|DRUG|PHENYLEPHRINE|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
40937320|NCT05235464|OTHER|Standard meal|Standard meal
40937321|NCT05235464|OTHER|High animal protein meal|Meal with high animal protein content
40937322|NCT05235464|OTHER|High plant protein meal|Meal with high plant protein content
40937323|NCT05235464|OTHER|High plant protein meal with additional leucine|Meal with high plant protein content and additional leucine
41453576|NCT05020444|DRUG|TriPRIL CAR T Cells|Intravenous infusion
41450500|NCT05561088|OTHER|Scalp Acupuncture|mplementation plan of head needle: The middle frontal line (MS1), the middle parietal line (MS5) and the back parietal and temporal oblique line (MS7) in the International Standardization Program for the Name of the first needle Point in 1989 were selected, and the needles were inserted along the shape of each section. One needle was inserted into the middle frontal line and the middle parietal line, and two needles were inserted into the back parietal and temporal oblique line. The KWD-808I pulse electrotherapy instrument produced by Changzhou Wujin Great Wall Medical Equipment Co., Ltd. is used on the needle handle after lifting, inserting and twisting. The continuous waveform was used, the voltage was 2-4 V, the frequency was 60-80 times /min, the intensity was tolerated by the patient, the needle was kept for 30min, and the treatment was performed once a day.
41280313|NCT02119715|DRUG|rhG-CSF 5 μg/kg/day|Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
41280314|NCT00805415|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
41280315|NCT00805415|DRUG|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
41450501|NCT05561088|OTHER|The treatment recommended in the guidelines for acute ischemic stroke was administered|The treatment recommended in the guidelines for acute ischemic stroke was administered
40937324|NCT05337930|DEVICE|Happyr App|"The Happyr app offers three main areas:~(A) A mood diary in which a user can keep track of emotional wellbeing by answering three short questions.~(B) A pain diary in which a user and supporter can record headache attacks by answering a set of predefined questions whenever a user experiences or has experienced a headache attack.~(C) An overview section in which entries from the mood and pain diary are visualized for the user. In this section, a PDF document can also be exported with a summary of data from the symptom diary that can be taken to the clinician.~A standardized notification is sent to each user at 6pm local time to remind them about logging their mood and symptoms of a headache attack."
41280316|NCT00495027|BEHAVIORAL|Internet-delivered Stress Innoculation Training|
41280317|NCT02032524|DRUG|Avalglucosidase Alfa|Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
41280318|NCT04492410|OTHER|rapid serological test|screening using a rapid serological test with a drop of blood from a finger prick
41130632|NCT00145587|DRUG|Systemic chemotherapy and antibodies|"Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease~Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis."
41280319|NCT03156530|DEVICE|Auricular acupunture|Evaluation of balance before, during and after applying of auricular acupuncture.
41450502|NCT06152796|DRUG|Paracetamol|Anti_inflammatory drug
41450503|NCT06152796|DRUG|Ibuprofen|Non steroidal anti_inflammatory drug
41450504|NCT05452707|OTHER|Observation and questionnaire of active therapy|There will be an observation of the usual care; no intervention will be added.
41450505|NCT03354338|DRUG|Amoxicillin|Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
41280320|NCT03156530|OTHER|Control|Not receive stimulation.
41280321|NCT00460928|DRUG|intravenous immune globulin (IVIG)|
41280322|NCT05878028|COMBINATION_PRODUCT|L-TIL, Tislelizumab, Docetaxel|PD1 positive lymphocytes were collect, isolated, and expanded from peripheral blood, then infused back into the patient's body. Besides this, Tislelizumab and Docetaxel were used as combination therapy.
40937325|NCT04984603|PROCEDURE|PLR in patients under VA-ECMO|After securing the VA-ECMO tubing, PLR is realized using an automatic bed elevation technique. The lower limbs are raised to a 45° angle while the patient's trunk is lowered in supine position
40937326|NCT00766441|DRUG|Sitagliptin|tablet, 100mg, once daily, 4 weeks
41280323|NCT03982667|DIAGNOSTIC_TEST|PCT-guided group|In the PCT-guided group, the study protocol encourages to stop the prescribed antibiotics if PCT concentration decrease by 80% or more of its peak value (or if PCT concentration is ≥0·25 and \<0·5 μg/L), and strongly encourage to stop the prescribed antibiotics when it reaches a value of \< 0·25 μg/L. The attending physician is free to decide whether to continue antibiotic treatment in patients who reach these thresholds. Reasons for non-adherence will be recorded. Antibiotics in the standard-of-care group will be stopped according to local or national guidelines and according to the discretion of attending physicians. Patients will be followed-up until hospital discharge.
41280324|NCT03080987|DRUG|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.
41280325|NCT03080987|DRUG|JNJ-64179375 1.0 mg/kg|JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
41280326|NCT03080987|DRUG|JNJ-64179375 2.5 mg/kg|JNJ-64179375 2.5 mg/kg IV infusion on Day 1.
41450506|NCT03354338|OTHER|Placebo|Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
41450507|NCT02455947|OTHER|Inquiry Based Stress Reduction (IBSR)|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
41450508|NCT02611687|DRUG|pitolisant|Tablet
41450509|NCT02611687|DRUG|Placebo|Tablet
41450510|NCT01181635|BEHAVIORAL|Psychotherapy|Standard psychotherapy for psychiatric disorders.
41450511|NCT05586880|OTHER|Experimental: EnXtra 300 mg/ capsule|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
41450512|NCT05586880|OTHER|Microcrystalline cellulose (MCC) 300mg|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
40937327|NCT00766441|DRUG|sulphonylurea|sulphonylurea, variable, od or bd, during ramadan
40937328|NCT01175837|OTHER|questionnaire administration|Ancillary studies: Pre- and post-fasting side effect questionnaires
41130633|NCT03507972|RADIATION|ankle ultrasound|Ankle ultrasound performed during emergencies visit.
41130634|NCT03507972|RADIATION|Member MRI|Member MRI (without injection of contrast product) performed within 7 days following the trauma
41130635|NCT06027970|DRUG|Terlipressin|After successful Endoscopic variceal ligation (EVL) The treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days
41130636|NCT06027970|OTHER|0.9% normal saline (NS)|After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days
41130637|NCT03908606|PROCEDURE|Scaling and root planing|Supra and subgingival scaling and root planing.
41130638|NCT01928459|DRUG|BGJ398|BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.
41130639|NCT01928459|DRUG|BYL719|BYL719 will be administered orally once daily on each day of the 28-day cycle.
41130640|NCT05089266|DRUG|CAR T cells|αPD1-MSLN-CAR T Cells
41130641|NCT04617574|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
41130642|NCT04617574|DEVICE|Endo GIA Reloads with Tri-Staple Technology|Surgery with Endo GIA Reloads with Tri-Staple Technology
41130643|NCT04149119|DEVICE|Attractive Target Sugar Baits (ATSB)|Within the intervention area, a total of four ATSB station will be deployed (external wall). ATSB stations will be monitored by community health workers through weekly visit and all stations will be replaced 6months after deployment.
41130644|NCT05219526|DIAGNOSTIC_TEST|blood glucose measurement: BGM|measurement of blood glucose concentration using different BGM
41130645|NCT05219526|DIAGNOSTIC_TEST|blood glucose measurement: reference method|measurement of blood glucose concentration using reference Method
41130646|NCT03041233|OTHER|Observation / Data Collection|"The following data will be reviewed / collected:~Baseline Visit: Patient demographics; Atrial fibrillation History; Cardiovascular history; Cardiac medical history.~Ablation Procedure: Devices used; Ablation parameters; Ablation success definition and result; Operator feedback (Device combination chosen, device maneuverability, ease of use in combination with other device); Number, experience and type of attending personnel; Definition of standard of care (follow-up procedures and occurrence).~6- and 12-month follow-up (+/- 30 DAYS): Recurrence of atrial arrhythmias: list of atrial arrhythmias since last visit, classify episodes, duration of the episodes; Changes in therapy; In case of Repeat Ablation Procedures, reconnections and new ablations will be recorded."
41130647|NCT01513616|OTHER|Pulmonary rehabilitation|8-week program, 3 supervised session per week
41130648|NCT01513616|OTHER|Usual care|An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
41130649|NCT03477305|BEHAVIORAL|Blackberry Consumption|Measures of biomedical and behavioral changes resulting from the consumption of blackberries.
41130650|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (Low - Dose 435 mg/day)|Plant protein hydrolysate
41130651|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (Mid - Dose 870 mg/day)|Plant protein hydrolysate
41130652|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (High - Dose 2610 mg/day)|Plant protein hydrolysate
41130653|NCT06440213|DIETARY_SUPPLEMENT|Placebo Microcrystalline Cellulose|Placebo MCC micro-crystalline cellulose
41450513|NCT05559736|DEVICE|Artemis Proximal Femoral Nail (PFN) implant|Artemis Proximal Femoral Nail (PFN) implant
41130654|NCT04257799|OTHER|Structured Light Imaging (SLI) System|Investigation of SLI and Tomographic Imaging to see if they will identify cancer cells at the edge of tissue specimens removed during the operation.
41450514|NCT04410380|BEHAVIORAL|Electronic tablet provision with teaching|Spanish-speaking parents are provided with an electronic tablet and taught how to use it to access health information for their children.
41130655|NCT06081738|DRUG|Neostigmine|a combination of 0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously at the reappearance of a second twitch of TOF after the last dose of rocuronium
41130656|NCT06081738|DRUG|Sugammadex|2-4 mg/kg sugammadex intravenously upon the reappearance of a post-tetanic count 1-2 or a second twitch of TOF after the last dose of rocuronium
41130657|NCT03938337|DRUG|Cohort 1 Not Previously Treated|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
41130658|NCT03938337|DRUG|Cohort 2 Treated Previously|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
41130659|NCT02810600|OTHER|Gallium-68 DOTA TATE PET scan|One PET/CT scan using Gallium-68 DOTA TATE
41130660|NCT02108574|DEVICE|Placebo Filter|
41130661|NCT02108574|DEVICE|Rhinix Nasal Filter|
41130662|NCT00196521|DEVICE|Tension-free vaginal tape obturator system|
41130663|NCT05758584|OTHER|Intervention|Vibrating tourniquet
41130664|NCT05758584|OTHER|Distraction card|Distraction card
41130665|NCT02018900|DIETARY_SUPPLEMENT|Ecologic 825/scFOS|
40937329|NCT01175837|OTHER|preventative dietary intervention|24, 36, or 48 hour fast prior to chemotherapy
40937330|NCT01175837|OTHER|laboratory biomarker analysis|Correlative studies
40937331|NCT00107952|DRUG|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days.
40937332|NCT00107952|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 21 days
40937333|NCT01269788|DRUG|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
40937334|NCT01269788|DRUG|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
40937335|NCT01269788|DRUG|placebo|oral , daily 30 mins before breakfast, for 6 weeks
40937336|NCT01269788|DRUG|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
40937337|NCT01269788|DRUG|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
40937338|NCT01269788|DRUG|placebo|oral , daily 30 mins before breakfast, for 6 weeks
41130666|NCT02018900|DIETARY_SUPPLEMENT|Placebo|
41280327|NCT03080987|OTHER|Placebo|Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
41450515|NCT01572051|BEHAVIORAL|Educational Course|2 Educational courses
41450516|NCT01572051|BEHAVIORAL|Phone Calls|Phone Calls
41450517|NCT01572051|BEHAVIORAL|Printed Material|Printed Material
40937339|NCT01250288|OTHER|Personal Health Management System|BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients \& their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
40937340|NCT06479876|OTHER|HBCR|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
40937341|NCT03895021|BEHAVIORAL|Pisando Fuerte|"Pisando Fuerte, a linguistically and culturally appropriate version for Spanish speakers of an evidence-based fall prevention program (Stepping On \[SO\])."
40937342|NCT05611125|OTHER|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in our study.
41130667|NCT05095974|DEVICE|ultrasonography|Ultrasound assessment will performed with parturient in the supine position using Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz). A C60x 5-2 MHz convex transducer will used for lung ultrasound (Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz).The Echo Comet Score (ECS) will obtained by the 28-rib interspaces technique dividing the chest wall in 12 areas on the left side (from the second to the fourth intercostal space) and 16 (from the second to the fifth intercostal space) on the right anterior and lateral hemithorax.
41280328|NCT03080987|DRUG|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined).
40937343|NCT06522412|DIETARY_SUPPLEMENT|JING SI HERBAL TEA LIQUID PACKETS|JING SI HERBAL TEA LIQUID PACKETS contains: eight herbal ingredients, primarily including dwarf lilyturf, houttuynia, balloon flower, siegesbeckia, licorice, mugwort, perilla leaf, and chrysanthemum. These eight Taiwanese native herbs are known for their abilities to moisturize, disperse cold, relieve lung congestion, dissolve phlegm, remove dampness, and clear heat.
40937344|NCT06522412|DIETARY_SUPPLEMENT|JING SI HERBAL TANG HENG POWDER DRINK|JING SI HERBAL TANG HENG POWDER DRINK contains: Based on the eight herbal ingredients of Jingsi Herbal Drink Concentrate, this drink additionally includes pumpkin powder and bitter melon extract powder. (Ingredients: siegesbeckia, Jingsi complex herbal powder (dextrin fiber, herbal extracts (mugwort, siegesbeckia, dwarf lilyturf, houttuynia, balloon flower, licorice, perilla leaf, chrysanthemum)), pumpkin powder, bitter melon extract powder (bitter melon extract (containing bitter melon peptides), maltodextrin), black pepper, chromium nicotinate complex (chromium nicotinate, sodium chloride)).
41130668|NCT05095974|DEVICE|echocardiography|MHz cardiac transducer for echocardiography with two-dimensional, M-mode, color-flow, continuous, pulsed wave and tissue Doppler imaging.
41280329|NCT06360393|DEVICE|Smart spacer|Participants' inhalation medication adherence and inhalation technique will be monitored using a smart spacer. Their usual medication regime will be continued and they will not receive information about their adherence or inhalation technique measured by the spacer during the follow-up year (except for any interventions that will be done in standard care).
41450518|NCT05699538|BEHAVIORAL|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
41280330|NCT03075839|OTHER|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of two weeks
41280331|NCT06286423|DRUG|Colchicine 0.6 mg|Colchicine treated subjects will take 0.6mg of drug 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of drug 1x per day (or every other day if kidney disease is present) for 76 +/1 days.
41280332|NCT06286423|DRUG|Control/Placebo group|Placebo treated subjects will take 0.6mg of placebo 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of placebo1x per day (or every other day if kidney disease is present) for 76 +/1 days.
41450519|NCT00767260|DRUG|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
41450520|NCT00767260|DRUG|BM-MNC|Autologous Bone Marrow Mononuclear cell Infusion
41450521|NCT00767260|DEVICE|HOT|Hyperbaric Oxygen Therapy
41280333|NCT05587881|BIOLOGICAL|COVID-19 vaccine(donor)|Donor received COVID-19 vaccine before stem cells collection.
41450522|NCT00767260|DRUG|SMT|hypoglycemic drugs or exogenous insulin
41450523|NCT00521573|OTHER|Dark chocolate|
41453577|NCT05020444|DRUG|Cyclophosphamide|Intravenous infusion
41453578|NCT05020444|DRUG|Fludarabine|Intravenous infusion
41453579|NCT04366960|DRUG|Enoxaparin|Subcutaneous enoxaparin
41453580|NCT05485064|DRUG|fentanyl|The investigator 1 use fentanyl to sedate patients coordinate with remimazolam
41280334|NCT05587881|BIOLOGICAL|COVID-19 vaccine(patient)|Patient received COVID-19 vaccine before allo-HSCT.
41280335|NCT04093830|DEVICE|hearing aid|hearing aid can be used in their non- implanted ear with residual hearing
41280336|NCT03903471|DEVICE|22G-ProCore Endobronchial Ultrasound Needle|EchoTip Procore® Endobronchial HD Ultrasound Biopsy Needle, COOK
41450524|NCT02120677|DRUG|Itraconazole|Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
41450525|NCT00557050|OTHER|Training|10-week eccentric hamstring muscle training
41450526|NCT03119077|DRUG|BAY1161116|Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
41450527|NCT03119077|DRUG|Placebo|Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
41450528|NCT03119077|DRUG|Itraconazole|Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
40756131|NCT01065805|BIOLOGICAL|18F-FLT|"Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient"
40756132|NCT05838313|BEHAVIORAL|Elective Induction of Labor Decision Support Tool|Decision support tool for people having their first baby and planning vaginal delivery without a medical indication for induction of labor
40937345|NCT01744418|DEVICE|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
41280337|NCT03903471|DEVICE|22G-Standard Endobronchial Ultrasound Needle|EchoTip® Ultra Endobronchial High Definition Ultrasound Needle, COOK
41280338|NCT00093236|PROCEDURE|Early Periodontal Treatment|Subjects will receive scaling and root planing at baseline. Three weeks after initiation of the study, they will return and be re-evaluated for the need for periodontal surgery. If indicated, they will then receive definitive periodontal surgery over the next 4 weeks. At the 12-week time point, periodontal surgery will be reevaluated and further therapy provided as needed and make repeated visits as needed to achieve periodontal health.comprehensive periodontal treatment
41280339|NCT00093236|PROCEDURE|Usual Dental Hygiene|Subjects will receive routine oral hygiene visits at the 3 and 12-week time points. After a 12-week period (24 week time point) to allow healing and resolution of a systemic inflammatory state, patients will return for follow-up measurements of periodontal parameters, vascular function and inflammation.
40756133|NCT04615013|DRUG|Capecitabine|Not applicable to this study
40756134|NCT04615013|DRUG|Carboplatin|Not applicable to this study
40756135|NCT04615013|DRUG|Docetaxel|Not applicable to this study
40756136|NCT04615013|DRUG|Fluorouracil|Not applicable to this study
40756137|NCT04615013|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or IN
40756138|NCT04615013|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40756139|NCT04615013|DRUG|Leucovorin|Not applicable to this study
40756140|NCT04615013|DRUG|Oxaliplatin|Not applicable to this study
40756141|NCT04615013|DRUG|Paclitaxel|Not applicable to this study
40756142|NCT05312892|DRUG|Amlodipine|Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
40756143|NCT05312892|DRUG|Moxonidine|Moxonidine
40756144|NCT05312892|DRUG|Placebo|Placebo
40756151|NCT05835557|OTHER|BFR-ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Blood flow restriction will be applied for 2 mins during the passive rest at 80% of limb occlusion pressure.
41130669|NCT05095974|DEVICE|thoracic electrical bioimpedence|EC ICONR monitor (Osypka Medical, Inc., La Jolla, California and Berlin) will be applied to the patients through four ECG electrodes. The electrodes will be placed over the bare skin of patients at the following sites: (1) on the left neck below the ear; (2) directly superior to the midpoint of the left clavicle; (3) along the left mid-axillary line at the level of the xiphoid process; (4) two-inches caudad from the third electrode.
41130670|NCT02067819|DEVICE|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
41130671|NCT02067819|DEVICE|Placebo Oral Orthotic Treatment|After two weeks, this treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
40756152|NCT05835557|OTHER|ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Cycling will be conducted in an environmental chamber and participants informed that the altitude is set to 2500m - actual altitude will be sea level.
40756153|NCT02598999|DRUG|ALX-009|Solution for inhalation administered through nebulization
40756154|NCT02598999|DRUG|OSCN-|Solution for inhalation administered through nebulization
40756155|NCT02598999|DRUG|bLF|Solution for inhalation administered through nebulization
40756156|NCT02598999|DRUG|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
40756157|NCT06232031|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
40756158|NCT03643588|DEVICE|HYAJOINT Plus|Single-injection, 60 mg / 3 ml (2%) cross-linked hyaluronan
40756159|NCT03643588|DEVICE|Hyalgan|Three-injection, 20 mg / 2 ml (1%) linear hyaluronan
40756160|NCT04086615|DEVICE|NMES and exercise supplemented with high BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 80% of LOP, the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
40756161|NCT04086615|DEVICE|NMES and exercise supplemented with low BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 20mmHG venous pressure (no blood flow restricted), the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
40756162|NCT04656028|GENETIC|Genetic Testing|DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database \<0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).
40756163|NCT04656028|BEHAVIORAL|Motivational Counseling|"Motivational counseling will be carried out during Visit 2 and in one month after Visit 2 by certified psychologist with taking into account the results of the psychodiagnostic survey conducted at the first and second visits.~The goals of motivational counseling:~1. Increasing motivation for a healthy lifestyle;~2. Increasing adherence to treatment;~3. Increased motivation to invite relatives for cascade screening. Motivational counseling will be carried out using methods of motivational interviewing, transtheoretical model of changes, cognitive-behavioral therapy, extended preventive counseling."
40756164|NCT04656028|DIAGNOSTIC_TEST|Lipid analysis|Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.
40937346|NCT03924531|BEHAVIORAL|Mindful Awareness Program|2-hour mindfulness training for 6 weeks.
40937347|NCT03924531|BEHAVIORAL|Health Promotion Program|Health Promotion Program
40937348|NCT04856865|BIOLOGICAL|Low dose ADP101|Active powder formulation
40937349|NCT04856865|BIOLOGICAL|High dose ADP101|Active powder formulation.
41130672|NCT04544319|DRUG|Zemiglo 50mg and Forxiga 10mg|Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD
40937350|NCT04856865|BIOLOGICAL|Pooled Placebo|Placebo powder
41450529|NCT04423835|PROCEDURE|Paley's Principle osteotomy|. The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs. An isosceles triangle template was used for osteotomy, and the medial cortex was left intact. K-wires were used to fix the osteotomy laterally.
41450530|NCT05600699|DEVICE|Cardiac pacemaker and Select Secure lead|model 3830, 69cm, Medtronic, Inc., Minneapolis, MN, USA
40756165|NCT04656028|OTHER|Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)|All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
40756166|NCT04656028|OTHER|Visit 1|"Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
40756167|NCT04656028|OTHER|Visit 2|"Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days"
40756168|NCT04656028|OTHER|Visit 3|"Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
40756169|NCT04656028|OTHER|Visit 4|"Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
40756170|NCT06255938|DIAGNOSTIC_TEST|smears|PCR smears for HPV testing will be performed
40756171|NCT04503421|OTHER|Blood Flow Restriction Therapy|Use of a tourniquet set to 50% of limb occlusion pressure while performing post operative physical therapy
40756172|NCT02832505|OTHER|No intervention but only observational|This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.
40756173|NCT03721965|DRUG|Itacitinib|Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.
40756174|NCT03721965|DRUG|Corticosteroids|Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
40756175|NCT04170075|BEHAVIORAL|Whole Body Vibration|Undergo WBV
40756176|NCT02719366|DEVICE|comfilcon A Extended Range test lens|contact lenses
40756177|NCT02719366|DEVICE|comfilcon A control lens|contact lenses
40756178|NCT00043784|DRUG|enoxaparin|
40937351|NCT04697381|BIOLOGICAL|somatropin - GH naïve pediatric cohort|somatropin 0.245 mg/kg/week
40937352|NCT04697381|BIOLOGICAL|somatropin - GH treated cohort|somatropin 0.084 mg/kg/week
40937353|NCT04697381|BIOLOGICAL|somatropin - adult cohort|somatropin 0.084 mg/kg/week
40937354|NCT06115031|DRUG|Remimazolam|General anesthesia will be induced and maintained using continuous infusion of intravenous remimazolam.
40937355|NCT06115031|DRUG|Propofol|General anesthesia will be induced and maintained using target-controlled infusion of intravenous propofol.
41130673|NCT04544319|DRUG|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD
41130674|NCT01748864|DRUG|Etarfolatide (EC20)|
41450531|NCT01215721|DRUG|Vesicare|5 mg daily
41450532|NCT01484912|DRUG|STA-2|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
41450533|NCT01484912|DRUG|Placebo|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
41450534|NCT06183788|BEHAVIORAL|Remote cognitive rehabilitation program|Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
40937356|NCT01669707|DRUG|Endostar -Continued Pumping into+GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2\*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
40937357|NCT01669707|DRUG|Endostar -injecting into +GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
40937358|NCT02057627|BEHAVIORAL|Perinatal Dyadic Psychotherapy|8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months
40937359|NCT02057627|BEHAVIORAL|Placebo Comparator|Standard care plus depression monitoring by phone
40937360|NCT04491253|BEHAVIORAL|Social support for diabetes self-management|Four individualized intervention sessions, every two weeks with a duration of 40 minutes.
40937361|NCT02906969|OTHER|Colonoscopy Educational Video|Brief Video utilization to assess comprehension and evaluation bowel preparation quality
41130675|NCT05722912|DRUG|Ruxolitinib|Ruxolitinib Cream
41130676|NCT00968903|DRUG|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
41130677|NCT03758391|OTHER|Flipped Classroom education|Fellows will receive GI/Bilirubin education in a flipped classroom format.
41130678|NCT00943969|PROCEDURE|gastric bypass|gastric bypass combines restrictive and malabsorptive procedures
41130679|NCT05067101|PROCEDURE|Capsule Sparing Cystectomy (CSC)|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
41130680|NCT05067101|PROCEDURE|Conventional Radical Cystoprostatectomy (CRC)|According to the consensus standard program, remove the accessory tissues including the bladder, prostate and seminal vesicles
40744328|NCT04137536|DRUG|anti-EGFR-bispecific antibody armed activated T-cells|"Phase I:~* First 3 participants, twice weekly infusions of 10\^10 EGFR BATs infusions~* If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10\^10.~* If \>/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10\^9 per infusion~* If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~- 8 infusions of 7.5 x 10\^9 or 10\^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)"
40756179|NCT02100644|DRUG|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG\&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
40937362|NCT02906969|OTHER|Placebo Educational Video|Brief Video utilization to provide placebo information and evaluation bowel preparation quality
40937363|NCT02436642|DEVICE|AVERT Plus System|
40937364|NCT02469376|DRUG|[18F]-GP1|Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
40937365|NCT02391896|DEVICE|Dual energy and tomosynthesis xray|
40937366|NCT02038452|DRUG|Depo-Medrone|Steroid Injection
41130681|NCT00898521|DRUG|DGD|"DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area."
41130682|NCT06509165|PROCEDURE|Modified coronally advanced flap technique|Subepithelial connective tissue graft was applied to the relevant areas with a modified coronally placed flap technique to cover the gingival recession.
41130683|NCT06509165|PROCEDURE|Tunnel technique|Subepithelial connective tissue graft was applied to the relevant areas with the tunnel technique to cover the gingival recession.
41130684|NCT04681794|OTHER|exercise-based intervention|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, jumping/hopping, and movement-based mindfulness.
41130685|NCT05277454|DRUG|HMPL-653|"Dose-escalation Stage:~Several dose levels will be evaluated for HMPL-653. The participants will receive oral HMPL-653 single-dose evaluation and oral HMPL-653 QD continuously treatment in a therapeutic cycle of 28 days until reaching the criteria for the end of treatment.~Dose-expansion Stage:~The participants will receive HMPL-653 treatment （RP2D）until reaching the criteria for the end of treatment."
40756180|NCT03149380|BEHAVIORAL|Web-based education|The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
40937367|NCT02038452|DEVICE|Wrist Splint|Simple wrist splint
40937368|NCT04323722|PROCEDURE|Empty Bladder planning CT scan and CBCTs|Patient will receive a Planning CT scan, 3 CBCTs on the first week and once a week during radiotherapy treatment with an Empty Bladder
40937369|NCT01293500|PROCEDURE|Goal-directed Therapeutic Protocol|A 10 month period of data collection for transport patients with SIRS (Systemic Inflammatory Response Syndrome) will be followed by training and institution of a goal-directed resuscitation protocol. A second 10 month data collection period will then commence. Groups will be compared with respect to outcome measures at the end of the study. All subjects will be monitored with NIRS cerebral and somatic oximetry.
41130686|NCT06326788|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|"Participants will start soleus pushups in sitting positions. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and the feet will be placed flat on the ground.~Participants will then move their heels up and down continuously. Soleus push-ups will be performed with moderate intensity using weights which will be placed on their laps.~Participants will perform this activity till 60-70% of their maximum heart rate is achieved and maintained."
41280340|NCT05155098|OTHER|secukinumab|Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study.
41280341|NCT06124703|DRUG|Prednisone tablet|Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided
41280342|NCT06124703|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.
41450535|NCT05646251|DEVICE|Heart Ultrasound|A wand is placed on the chest to use soundwaves to make a picture of the heart and shows how the muscle and valves work. This helps with device placement.
40937370|NCT00200551|DRUG|Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.|
41450536|NCT04604262|DEVICE|Waterpik|Waterpik dental water jet
41450537|NCT04233060|DRUG|CS3005|CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
41450538|NCT04957979|OTHER|Nursing/Medical Model of Care Coordination|"No social worker on the clinic's care coordination team.~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Referrals for continuing care~* Referral to community resources~* Referral to mental health services if needed or requested~* Referral to interventional counseling for behavioral health issues"
40937371|NCT00200551|DRUG|Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.|
40937372|NCT00002898|BIOLOGICAL|dactinomycin|
41453581|NCT05485064|PROCEDURE|eletroacupuncture(transcutaneous electrical acupuncture point stimulation )|The investigator 1 use electroacupunture(transcutaneous electrical acupuncture point stimulation )to coordinate with remimazolam
41453582|NCT05485064|DRUG|placebo needle|The investigator 1 use placebo needle to sedate patients coordinate with remimazolam
40937373|NCT00002898|DRUG|carboplatin|
41130687|NCT06326788|BEHAVIORAL|SUSTAINED SOLEUS PUSH-UPS|"Participants will start soles push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and the feet will be placed flat on the ground.~Participants will then move their heels up and down continuously. Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum 4-minute break time after every 90 mins intervention. In the meantime, their blood sample will be collected."
41130688|NCT01852006|DEVICE|Abdominal Binder|Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
41453583|NCT05485064|DRUG|remimazolam|The investigator 1 use remimazolam to sedate patients coordinate with eletroacupuncture(transcutaneous electrical acupuncture point stimulation )or placebo needle
40937374|NCT00002898|DRUG|cyclophosphamide|
40937375|NCT00002898|DRUG|epirubicin hydrochloride|
40937376|NCT00002898|DRUG|etoposide|
40937377|NCT00002898|DRUG|ifosfamide|
40937378|NCT00002898|DRUG|vincristine sulfate|
40937379|NCT00002898|PROCEDURE|adjuvant therapy|
40937380|NCT00002898|PROCEDURE|conventional surgery|
40937381|NCT00002898|PROCEDURE|neoadjuvant therapy|
40937382|NCT00002898|RADIATION|brachytherapy|
40937383|NCT00002898|RADIATION|radiation therapy|
40937384|NCT02789228|BIOLOGICAL|Tumor associated antigen lymphocytes (TAA-CTL)|"This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2"
40937385|NCT04991428|OTHER|Transcranial direct current stimulation|tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.
40937386|NCT03538678|OTHER|Kwit smartphone app|Kwit smarphone app
40937387|NCT04805827|DRUG|Gabapentin|1 tablet contains 600 mg Gabapentin
40937388|NCT04805827|DRUG|Neurontin|2 capsule contains 2\*300 = 600 mg Gabapentin
40937389|NCT02091219|DRUG|Vitamin D|2400 IU/day by mouth for 16 weeks
40937390|NCT02091219|DRUG|25(OH)D3|20 micrograms/day by mouth for 16 weeks
41130689|NCT01602185|DRUG|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
41130690|NCT01602185|DRUG|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
41130691|NCT01602185|DRUG|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
41450539|NCT04957979|OTHER|Medical/Social Model of Care Coordination|"Social worker is part of the clinic's care coordination team.~* Need not be licensed as a social worker~* Must have time dedicated to care coordination for a specific clinic or clinics~* Must interact with individual patients to provide them with services~* Must interact with individual clinicians about their individual patients in care coordination~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Assistance with referrals for continuing care~* Assessment and plan to address social and resource needs including housing, transportation or financial needs; Assist patient in locating and obtaining needed community resources~* Assistance with identifying and addressing psychological/emotional issues and referrals as needed~* Interventional counseling for behavioral health issues or referrals to interventional counseling, depending on licensure"
40937391|NCT04671173|DEVICE|Measurement of the Intra-Compartmental Pressure with the MY01 device|"All Participants will be monitored for clinical signs of symptoms of ACS, including the 7 Ps at a minimum of every 4-6 hours.~The Intra-Compartmental Pressure of the anterior compartment of the leg will be monitored with the MY01 device. The device should be inserted five centimeters (5 cm) from the fracture, if possible, in the muscle belly. The affected limb will then be splinted in a standard U-slab with no pressure on the monitored device."
40937392|NCT01129570|DRUG|Silybin|4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
40937393|NCT00925171|BEHAVIORAL|Pulmonary Intervention|Maintenance programme of 2 hours duration, every 3 months. During the first hour patients will describe the extent to which they have been able to continue with their exercises at home on an individual basis and ways of enhancing adherence to this training will be discussed. Positive re-enforcement will be provided. Patients with suspected depression or social isolation will be referred to their GP for additional management. Patients will be advised on dyspnoea management strategies, especially controlled breathing combined with supervised activity exertion on activities relevant to their daily living. This will be followed by 1 hour of supervised strength and endurance training including walking, cycling, standing from sitting, arm exercises using dumbbells and step-ups. Patients will receive a written report on their progress by their physician and copied to their GP. This will be in addition to the standard advice given to the control group.
40937394|NCT04703218|OTHER|olfactory rehabilitation|Olfactory rehabilitation consists of smelling 4 scents twice a day using scent sticks, for 12 weeks
40937395|NCT00135044|PROCEDURE|intravenous taurine in nutritional supplement|
40937396|NCT06084728|DIAGNOSTIC_TEST|Color Doppler ultrasonography|in a longitudinal plane, the dorsal clitoral artery, which is sampled on the outer surface of the clitoral body as previously described. With the same longitudinal approach, the terminal branch of the posterior labial artery (a branch of the internal pudendal artery) was visualized posterolaterally to the labia majora
40937397|NCT00916214|OTHER|Pharmaceutical care program|The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
40937398|NCT05053542|PROCEDURE|Enema|Patients in the PBP group underwent a cleansing enema procedure with a solution of monosodium phosphate and disodium phosphate (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before hemorrhoidectomy, whereas patients in the non-PBP group skipped the procedure.
40937399|NCT01314911|DRUG|Oseltamivir|Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
40937400|NCT01314911|DRUG|Placebo|Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
40937401|NCT05581875|DRUG|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
40937402|NCT05581875|DRUG|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
40937403|NCT05581875|DRUG|Pomalidomide|Pomalidomide will be administered per os.
40937404|NCT05581875|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
40937405|NCT00000574|DRUG|ibuprofen|
40937406|NCT06198764|DRUG|Colistimethate sodium for injection|Colistimethate Sodium for Injection is the Prodrug of Polymyxin E, which is hydrolyzed into Polymyxin E after entering the human body to play a bactericidal role.Polymyxin selectively acts on gram-negative aerobic bacteria with hydrophobic outer membrane, leading to cell death by destroying the cell membrane.
41450540|NCT04548258|DEVICE|electric intraoral weilding|weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally
41450541|NCT04548258|DEVICE|casting|casting metal framework
41450542|NCT04231643|DRUG|Dronabinol|one-time oral administration of 5 mg dronabinol
41450543|NCT04231643|DRUG|Epidiolex|one-time oral administration of 600 mg Epidiolex
40937407|NCT06198764|DRUG|Meropenem for Injection|Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.
40937408|NCT06198764|DRUG|Coly Mycin M Injectable Product|Coly Mycin M is the originally marketed colistimethate sodium for injection.
40937409|NCT02769676|OTHER|3-week visit|The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
40937410|NCT02769676|OTHER|usual care|Participants in the usual care arm will receive no additional interventions.
41280343|NCT03853694|DRUG|50 mcg Duramorph+ EXPAREL + multi-modal pain regimen|Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
40937411|NCT04165811|OTHER|Exercise treatment|A program consisting of aerobic dance based exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
40937412|NCT04165811|OTHER|Counselling|Only physical activity counseling will be given to the subjects in this group.
40937413|NCT04980573|OTHER|Aromatherapy|The aromatherapy intervention consists of inhaling a fragrant oil extracted from citrus peels, plant resins, and leaves.
40937414|NCT04980573|OTHER|Placebo|The placebo intervention consists of inhaling an oil extracted from inert plant matter.
40937415|NCT00272753|DRUG|budesonide/formoterol Turbuhaler|
40937416|NCT00272753|DRUG|formoterol Turbuhaler|
40937417|NCT00272753|DRUG|salbutamol|
40937418|NCT00808678|DRUG|ABT-143|once, see arm description for more information
41280344|NCT03853694|DRUG|150 mcg Duramorph + multi-modal pain regimen|Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
41450544|NCT04231643|DRUG|Placebos|one-time oral administration of placebo
41130692|NCT06341959|PROCEDURE|Oral screening|The participants in the intervention group will receive an oral examination. Subsequently, information about any identified problem will be given. Lastly, participants will receive a referral letter for their dentist and a report for the general practitioner. If the participants don't have a regular dentist, they will also be given a list with contact information of dentists in the area.
40937419|NCT00808678|DRUG|ABT-335|once, see arm description for more information
41130693|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET|amlodipine/atorvastatin (5/20mg tablet) once a day
41130694|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|amlodipine/atorvastatin (5/10mg tablet) once a day
41130695|NCT04111419|DRUG|Allisartan Isoproxil|allisartan (240mg/tablet) once a day
41130696|NCT01540305|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
41130697|NCT01540305|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
41130698|NCT02579915|BEHAVIORAL|FaceAnxiety|Computerized treatment targeting mental habits and primary care linkage.
41130699|NCT02579915|BEHAVIORAL|Symptom Tracking|Weekly self-assessment with validated questionnaires and primary care linkage
41130700|NCT00609869|DRUG|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
41130701|NCT00609869|DRUG|Rituximab|Rituximab was administered at 375 mg/m\^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
41130702|NCT02359916|OTHER|Time delays on delivery of less healthy snacks|
41130703|NCT02359916|OTHER|25%/$0.25 discount on healthy snacks|
41130704|NCT02359916|OTHER|25%/$0.25 tax on less healthy snacks|
41130705|NCT01940107|OTHER|evaluations|Only evaluations
41130706|NCT01940107|PROCEDURE|Protocol of physiotherapy exercises|Oriented domiciliary physiotherapeutic exercises
41280345|NCT03853694|DRUG|Exparel TAP + multi-modal pain regimen|EXPAREL administered via TAP infiltration + multi-modal pain regimen.
41280346|NCT00742781|DIETARY_SUPPLEMENT|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
41280347|NCT03991247|BEHAVIORAL|Computerized behavioral therapy program delivered by internet for insomnia management|"The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm)."
41280348|NCT03991247|OTHER|Spa treatment|"Spa treatment is harmonized in the different stations. It consists in:~* a medical thermal follow-up: weekly medical consultation of 15 minutes during the 3 weeks spa treatment.~* an institutional follow-up: support, help and monitoring of patients during spa treatment~* Crenotherapy: 18 baths of 10 minutes in running water, 18 spa showers of 3 minutes, 9 massages under water of 20 minutes, 18 baths of 10 minutes in pool. Water temperature of pool is between 31°C and 33°C. Water temperature for other care is 35°C and 38°C."
41280349|NCT00630032|DRUG|cyclophosphamide|500 mg/m² every 3 weeks
41280350|NCT00630032|DRUG|Docetaxel|100 mg/m² every 3 weeks
41280351|NCT00630032|DRUG|epirubicin hydrochloride|100 mg/m² every 3 weeks
40937420|NCT00808678|DRUG|rosuvastatin|once, see arm description for more detail
41130707|NCT03651934|DIETARY_SUPPLEMENT|Normal iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
41130708|NCT03651934|DIETARY_SUPPLEMENT|Weak iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
41280352|NCT00630032|DRUG|fluorouracil|500 mg/m² every 3 weeks
41280353|NCT00630032|DRUG|ixabepilone|40 mg/m² every 3 weeks
41450545|NCT03986463|OTHER|Circulating tumour DNA (ctDNA)|Circulating tumour DNA (ctDNA) will be isolated from blood samples
41450546|NCT01011413|DRUG|Efavirenz 600mg|3 x EFV 200 milligram (mg) tablets once daily
40937421|NCT04177238|DIETARY_SUPPLEMENT|Fruit concentrate - either cherry or blueberry|Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).
40937422|NCT00267618|BEHAVIORAL|FHP Pain|Evidence-based psychological and behavioural Intervention
40937423|NCT00559936|DRUG|Topical Avastin 1%|Avastin (bevacizumab) 1%
41450547|NCT01011413|DRUG|Efavirenz 400mg|2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily
41450548|NCT03001596|PROCEDURE|Neoadjuvant Chemoradiotherapy|Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
40937424|NCT04115540|DEVICE|TENS penile nerve stimulation|The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum) to stimulate the penile nerves.
40937425|NCT00336180|BEHAVIORAL|HealthWise South Africa curriculum|18 classroom lessons
41450549|NCT03001596|PROCEDURE|Neoadjuvant Chemotherapy|Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
41130709|NCT03651934|DIETARY_SUPPLEMENT|Normal selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
41130710|NCT03651934|DIETARY_SUPPLEMENT|Weak selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
41130711|NCT01553487|OTHER|Forearm vibration|All cases will be trained by forearm vibration device 5 times a week for six weeks period.
41130712|NCT06341946|DEVICE|Endoscopic third ventriculostomy|role of endoscopic third ventriculostomy in management of malfunctioning ventriculoperitoneal shunt
41130713|NCT02198417|DRUG|Metformin ER|Treatment with metformin ER for 12 weeks
41130714|NCT00345046|DRUG|Pred Forte|Four drops daily decreasing to once daily over four weeks.
41130715|NCT00345046|DRUG|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
41130716|NCT00345046|DRUG|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
41130717|NCT04338451|OTHER|Music during the first part of ESWL|Music listening during first part of ESWL
41130718|NCT04338451|OTHER|Music during the second part of ESWL|Music listening during second part of ESWL
41130719|NCT03375424|BIOLOGICAL|vedolizumab|duration of disease and kind of therapy
41130720|NCT05604755|DRUG|HQP1351( Olverembatinib dimesylate)|HQP1351 was initiated at a dose of 40mg every two days
41130721|NCT03389789|OTHER|Oral glucose solution + maternal holding|Infant will receive both the oral glucose solution and the contact with the mother
41130722|NCT03389789|OTHER|Breastfeeding|Infants will be breastfed
41130723|NCT03389789|OTHER|Oral glucose solution|Infant will receive only oral glucose solution without contact with the mother
41130724|NCT03389789|OTHER|Oral expressed breastmilk|Infant will receive only oral expressed breast milk without contact with the mother
41130725|NCT03288688|OTHER|Exercise program and education|"The exercise program comprises warm-ups, exercises and cool-downs and aims to improve recruitment, strength and endurance of postural muscle groups that are key to the work of a musician. Basic activation exercises progress to dynamic and resisted exercises as well as functional musical movements. There is a series of six exercises of increasing difficulty for each of the following bodily regions: hips, back, neck, shoulders and abdominals.~Topics to be discussed in the educational presentation and e-mails include healthy practice habits, activity dosage, the importance of physical activity, how the body adapts to workload and physical stressors, and instructions pertaining to the exercise program."
41130726|NCT04810975|DEVICE|Muscle Strength Training|Strength training occurring specific exercise regimens using Exercise Equipment A or B
41130727|NCT00750477|DIETARY_SUPPLEMENT|NEM|see Treatment Arms
41130728|NCT00750477|DIETARY_SUPPLEMENT|Placebo|Placebo comparator containing inactives
41280354|NCT02712502|DRUG|Levofloxacin|"* Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~* Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
41280355|NCT02712502|DRUG|Amoxicillin-Potassium Clavulanate Combination|"Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
41280356|NCT03744689|PROCEDURE|Erector Spinae Plane block|Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride
41280357|NCT03744689|PROCEDURE|Sham block|Sham block will be done with serum physiologic.
41450550|NCT03001596|PROCEDURE|Minimally Invasive Esophagectomy|After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
41450551|NCT00113958|DRUG|Cinacalcet|
41450552|NCT00525213|DRUG|Rob 803|two capsules per day during 12 weeks
41450553|NCT00525213|DRUG|Placebo|two capsules per day during 12 weeks
41450554|NCT03637764|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
41450555|NCT03637764|DRUG|Atezolizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
40937426|NCT02866487|PROCEDURE|Bronchoscopy|A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
40937427|NCT02567552|DRUG|Subcutaneous progesterone|subcutaneous progesterone 25 mg/day
40937428|NCT02567552|DRUG|Intramuscular progesterone|intramuscular progesterone 50 mg/day
40937429|NCT03691324|OTHER|Inhalation technique training and discharge service|Patient drug counselling one-to-one, focusing on inhalation drugs and technique
40937430|NCT01358071|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
40937431|NCT01358071|DRUG|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
40937432|NCT01358071|DRUG|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
40937433|NCT03531034|OTHER|Combined Exercise Training|The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.
40937434|NCT03325699|DEVICE|SMART4MD Health Application|"SMART4MD is a general health application which has been adapted specifically for people with mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal carers. The application is optimized for tablet devices running on Android operating system (OS). Participants will be provided with a tablet with the SMART4MD health application.~The core functionalities of the application are based on reminders (medication, appointments with healthcare providers), brain supporting activities (clock, calendar, brain games, photos) and optional status and health information sharing with family and informal carers (including daily feeling status, specific health problems, and quality of life). An important feature of SMART4MD is its personalization facility: main users (PWD and informal carers) will be able to switch off/on various features and information sharing possibilities."
40937435|NCT05321160|DRUG|Esketamine|0.25 mg/kg esketamine for induction and 0.25 mg/kg esketamine at the beginning of surgery
40937436|NCT05321160|DRUG|Sevoflurane|4% sevoflurane for induction and 2-4% sevoflurane for maintain
40937437|NCT03590197|DRUG|Melatonin 3 mg|Melatonin 3 mg/ day with Valproate
41130729|NCT05715632|DRUG|Carrelizumab combined with XELOX|Before surgery, the patient received standard dose of carrelizumab combined with XELOX regimen for 4 courses of treatment, and within 3-4 weeks after the completion of the fourth administration, preoperative imaging examination was conducted to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, and to receive radical hand surgery for gastric cancer
41130730|NCT00944541|DRUG|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
41280358|NCT03744689|DRUG|Bupivacaine Hydrochloride|20 ml 0,25% Bupivacaine will be used for block performances
41280359|NCT03744689|DEVICE|PCA|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
41280360|NCT05928143|PROCEDURE|Traditional corticotomy|A flap covering the alveolar process will be elevated. Perforations will be done using surgical burs, and then the flap will be returned, and sutures will be performed.
41280361|NCT05928143|PROCEDURE|Flapless corticotomy|Some incisions will be made in the mucosa of the alveolar process. Then these incisions will allow the working head of the piezotome to cut the bone in grooves. The whole procedure will not require flap elevation and replacement.
41130731|NCT06157554|OTHER|Breathing Exercises|During the exercise sessions, participants will be seated in a chair. In the first five and last five minutes of the session, they will be instructed to focus on their breathing and the sensations produced in the body while sitting comfortably in a relaxed position with all joints in the chairs with their eyes closed. After the initial 5 minutes of relaxed breathing, participants will be instructed to perform diaphragmatic and costal breathing for 10 minutes. After 5 minutes of diaphragmatic breathing, the patient will be rested for 1 minute and then 5 minutes of costal breathing will be performed. While doing coastal breathing, patients will be asked to place their hands on their costas, take a deep breath and inflate the bottom of their hands; then they will be asked to exhale the breath they take in a longer (1:2) time.
41280362|NCT00488631|BIOLOGICAL|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
41280363|NCT00488631|BIOLOGICAL|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
41453584|NCT01380613|BEHAVIORAL|Workshop|10 session intervention
41453585|NCT01380613|BEHAVIORAL|Workshop control|1 session intervention on standard HIV/STD information
40937438|NCT03590197|OTHER|Placebo|Placebo with Valproate
40937439|NCT00462371|DEVICE|Insulin pump (CSII)|
40937440|NCT01285960|DEVICE|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
40937441|NCT04354727|DRUG|APG-1252|infusion once weekly
40937442|NCT04354727|DRUG|Ruxolitinib|taken orally twice a day
40937443|NCT00579436|DRUG|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
40937444|NCT00579436|DRUG|placebo|4 inert capsules daily by mouth for 12 weeks.
40937445|NCT04867239|OTHER|A two-day education progra|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise.
40937446|NCT01323842|PROCEDURE|EDTU|bedside ultrasound imaging by the treating emergency physician
40937447|NCT01796496|OTHER|Manipulative Therapy Techniques|"* Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.~* Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.~* Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction."
40937448|NCT01796496|OTHER|Functional Technique|The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
40937449|NCT01419821|DRUG|Vitamin D|800IU (4gtt/d) once a day for 2 years once a day.
40937450|NCT01419821|OTHER|Placebo (for Vitamin D)|4gtt/d for the placebo for two years.
40937451|NCT06295978|DIAGNOSTIC_TEST|Biochemical marker assays|DOSAGE BIOMARKERS
40937452|NCT04145479|BEHAVIORAL|physical activity|exercise
40937453|NCT05872932|PROCEDURE|gastric balloon implantation|After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed
40937454|NCT05872932|PROCEDURE|botulinum toxin A injection|After diagnostic endoscopy if there is no any gastric pathology that would be contraindication Botox injection and balloon placement, 200 U of Botox A will be injected to antrum and fundus. And 1 week later gastric balloon will be implanted
40937455|NCT05250089|OTHER|Simulation|Each simulation will focus on a trauma case deemed to be complex, that is to say one involving difficult decision-making. Each simulation session lasts approximately thirty minutes. It includes a time to complete the questionnaires necessary for carrying out the study, before and / or after the simulated practice depending on the type of questionnaire, a brief briefing on the simulation scenario, and the time for the simulated practice.
40937456|NCT04914507|DEVICE|Anterior Vertebral Body Tethering|Subject will receive anterior vertebral body tethering surgery.
41130732|NCT06157554|OTHER|Conventional treatment|Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
41130733|NCT00773500|OTHER|Electronic prescribing|Implementation of a commercially available electronic prescribing system with clinical decision support
41130734|NCT02024217|RADIATION|S1，oxaliplatin，radiation|Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
41130735|NCT05944224|DRUG|SPH4336|SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle
40937457|NCT03340428|BEHAVIORAL|Transition Community Adherence Club (TCAC)|A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
41130736|NCT05944224|DRUG|Cadonilimab|Intravenous infusion, 6mg/Kg,28 days/cycle
41130737|NCT03588832|DIAGNOSTIC_TEST|Evaluation Upper Extremity patterns.|The procedure involves evaluating subjects who meet the eligibility criteria and agree to participate in the study by signing informed consent. The study includes a measurement, applying a registration form, the Barthel scale and the FIM scale.
41130738|NCT01401790|DEVICE|Telehomecare (Intelligent Distance Patient Monitoring)|"Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for~* Automatic download of blood glucose levels~* Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team~* Changes in treatment plan by the diabetes professionals~* E mail exchanges between families and health care professionals~* Reinforcement of teaching program"
41130739|NCT01401790|OTHER|Standard education and follow up at diabetes clinic|Patients allocated to the control branch receive standard diabetes teaching and care.
41130740|NCT05600387|DRUG|Empagliflozin 10 MG|subjects in Empagliflozin group take 10mg Empagliflozin per day
41130741|NCT05558124|DRUG|Vyxeos|Fixed dose of Vyxeos (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) (Day 1, 3, and 5) in combination with various dose schedules of Gemtuzumab Ozogamicin (GO)
41130742|NCT05558124|DRUG|Gemtuzumab Ozogamicin|"Participants will be treated at the following dose levels:~Dose Level 1 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 Dose Level 2 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 and 4 Dose Level 3 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1, 4, 7"
41130743|NCT03733275|DRUG|Lidocaine|for experimental arm, lidocaine spray and lidocaine bupivacine mixture-soaked nasal packing vs. for placebo arm, normal saline spray and packing
40937458|NCT05464329|DRUG|Mosunetuzumab|Provided by Genentech.
41130744|NCT02387645|PROCEDURE|Lavage of the Uterus|The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
40937459|NCT05464329|DRUG|DHAX|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
40937460|NCT05464329|DRUG|ICE|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
40937461|NCT04759027|OTHER|subacromial distance measurement|distance between acromion and humerus
40937462|NCT03576222|DEVICE|PICO DRESSING|USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM
40937463|NCT03576222|DEVICE|MEPORE dressing|MEPORE dressing
40937464|NCT05198778|DRUG|URC102|tablet
40937465|NCT05198778|DRUG|URC102|tablet
41130745|NCT02440438|BIOLOGICAL|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
41280364|NCT00488631|BIOLOGICAL|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
41280365|NCT00488631|BIOLOGICAL|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
41280366|NCT03754153|DEVICE|Balanced Binocular Viewing (BBV)|The dose of BBV therapy will be one hour a day or 2x30 min/day (depending on child's attention span and/or need to implement the treatment around the family daily routine).
41280367|NCT03754153|OTHER|Standard Therapy - Occlusion (patching) or blurring (atropine)|The prescribed dose of occlusion treatment / patching (parental choice) will depend on the severity of amblyopia, as by current clinical practice based on PEDIG studies
41280368|NCT02028949|DRUG|Zavedos®|
41280369|NCT02028949|OTHER|Blood samples|
41280370|NCT04518384|PROCEDURE|colon or rectum resection|surgical procedure to resect the colon or rectum
40937466|NCT02182648|DRUG|etomidate|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of etomidate at 2 minutes before anesthesia induction"
40937467|NCT02182648|DRUG|propofol|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of propofol at 2 minutes before anesthesia induction"
40937468|NCT02182648|DRUG|sevoflurane|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. inhale sevoflurane for anesthesia induction and maintenance"
40937469|NCT00564720|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
40937470|NCT00564720|DRUG|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
40937471|NCT00564720|DRUG|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
40937472|NCT00564720|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
41280371|NCT05144061|DRUG|HRS2398 Tablets|Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
41280372|NCT06488196|BEHAVIORAL|Motivational Interviewing|Motivational interviewing (MI) is a person-centered, goal-oriented psychotherapeutic intervention designed to enhance the recipient's motivation for and commitment to a target behavior or behavior change. MI's core action mechanisms include strengthening the recipient's change talk (e.g., assertions about desire and commitment toward the target behavior) and softening the recipient's sustain talk (e.g., statements about barriers). MI clinicians achieve these goals using specific micro-skills (e.g., reflective listening) that reflect MI's fundamental spirits (i.e. collaboration, acceptance, compassion, evocation.
41280373|NCT06488196|OTHER|Treatment As Usual|TAU included the opportunity for mothers to meet with a NICU psychologist or psychology trainee at least once-per-week for supportive care.
40937473|NCT03300518|DRUG|Follitropin Beta;MSD|Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
40937474|NCT03300518|DRUG|Ganirelix|A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
40937475|NCT03300518|DRUG|hCG|Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
40937476|NCT03300518|DRUG|estradiol valerate|Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
40937477|NCT04326075|DEVICE|CPAP treatment|CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.
40937478|NCT04616027|DRUG|PF-06882961 20 mg|PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
40937479|NCT01933789|BEHAVIORAL|Communication Feedback Form for Patients with Serious Illness|"The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately."
40937480|NCT01411930|DRUG|Intramuscular olanzapine, aripiprazole|"1. 1st clamp: single intramuscular 10.0 mg dose of olanzapine~2. 2nd clamp: single intramuscular 9.75 mg dose of aripiprazole"
40937481|NCT01411930|DRUG|Intramuscular aripiprazole, olanzapine|"1. 1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2. 2nd clamp: single intramuscular 10.0 mg dose of olanzapine"
40937482|NCT01464983|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
40937483|NCT01464983|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
40937484|NCT01464983|DRUG|Ibuprofen|Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
40937485|NCT01464983|DRUG|Ibuprofen|Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
40937486|NCT01464983|DRUG|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
40937487|NCT06082271|DEVICE|Class III medical Hydrolyzed Collagen Peptides PEP-52 (Peptys)|Anti-inflammatory and regenerative effect, 5 mg/ml
40937488|NCT06082271|DRUG|Cortisone|DEPO-MEDROL 40 mg/ml + 1 cc di NAROPINA 0,75% 7,5 mg/ml
40937489|NCT06179368|DIAGNOSTIC_TEST|hypothroidism|throid fuction will be evaluated on admission of hepatic failure patients, and the hypothyroid patients will be enroled in this group.
40937490|NCT06179368|DIAGNOSTIC_TEST|euothyroid|throid fuction will be evaluated on admission of hepatic failure patients, and the euothyroid patients will be enroled in this group.
40937491|NCT00847639|DRUG|lenalidomide|"Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.~Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.~The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days)."
40937492|NCT02355977|DRUG|minocycline|Periocline dental ointment
40937493|NCT02355977|PROCEDURE|surface and root planning|surface and root planning
40937494|NCT02460458|DRUG|Von Willebrand Factor|Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.
40937495|NCT01861171|DIETARY_SUPPLEMENT|Green Tea|Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
40937496|NCT00071266|DRUG|Niacin Extended Release and Lovastatin Tablets|
40937497|NCT02642874|DRUG|Methocarbamol|Methocarbamol twice daily
40937498|NCT02642874|DRUG|Calcium Carbonate|Calcium carbonate twice daily
40937499|NCT04975529|BEHAVIORAL|Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education|Two-group quasi experimental intervention with schools assigned to intervention or comparison.
40937500|NCT03882008|DRUG|Abatacept|All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks
40937501|NCT00147420|DRUG|Zhi Byed 11|
40937502|NCT06349070|BEHAVIORAL|Low Touch - Text Messaging Implementation Strategy|The low touch strategy is designed as a tool to distill and organize the most important information from the Starting Early Program (StEP) original evidenced-based intervention curriculum. Video links are sent to pregnant subjects via automated SMS messaging. Subjects will receive videos (20 videos total) at least weekly lasting 17 to 31 weeks and the duration is based upon the gestational age at enrollment into the study. Subjects will also receive SMS messages in between videos at least weekly to keep them engaged and reinforce the video content delivered. The StEP curriculum is guideline concordant and includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management, enhance prenatal breastfeeding support, and build social support. The StEP curriculum was adapted into brief videos (\<5 minutes), and an additional module on Sleep Health was added.
41280374|NCT05742945|PROCEDURE|Immediate lymphatic reconstruction|Breast cancer patients receive axillary lymph node dissection and immediate lymphatic reconstruction
41280375|NCT03394950|DRUG|Butyphthalide combined with rtPA|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
40744329|NCT03906994|OTHER|Video game Mario Kart Wii|Subjects will place a patch over the better-seeing eye and play the video game Mario Kart Wii for a total of 40 hours over a 1 month perior
40937503|NCT06349070|BEHAVIORAL|High Touch - Community Health Worker (CHW) Implementation Strategy|The curriculum will be delivered by CHWs. Each subject will be asked to participate in 1-hour live sessions with a CHW. During the sessions, videos are interspersed with open-ended questions and pauses to discuss these open-ended questions. This results in an interactive session that employs principles of active learning. The curriculum includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management during pregnancy, enhance prenatal breastfeeding support, and build social support and are anchored by the same brief videos developed for the low touch strategy.
40937504|NCT04730167|OTHER|Neurological and neuropsychological assessments / MRI / PET scan / Video-oculography.|Essential data for this study are those collected during the concussion assessment, carried out as part of routine care at Princess Grace Hospital (medical background; history of sports practice and history of concussions; data extracted from clinical and neuropsychological evaluations, from imaging exams (MRI and PET-Scan) and from eye-tracking evaluation).
40937505|NCT00562744|OTHER|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
40937506|NCT01515540|DRUG|lidocaine|5% lidoderm patch
40937507|NCT01515540|DRUG|placebo|placebo
40937508|NCT02801344|DIETARY_SUPPLEMENT|Normal|test drink which contains low amount of amino acids (0.14 g/kg/day)
40937509|NCT02801344|DIETARY_SUPPLEMENT|Moderate|test drink which contains moderate amount of amino acids (0.40 g/kg/day)
40937510|NCT02801344|DIETARY_SUPPLEMENT|High|test drink which contains high amount of amino acids (1.03 g/kg/day)
40937511|NCT02801344|OTHER|Controlled-diet|the diet containing 0.8 g protein /kg/day
40756181|NCT02192476|OTHER|conventional neuro rehabilitation programme|All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
40937512|NCT01799577|PROCEDURE|Laparoscopic surgery|Two methods will be compare
40937513|NCT02506569|DEVICE|Implantable Cardioverter Defibrillator therapy|Tachycardia Fast Heart Beat
40937514|NCT02506569|OTHER|Magnetic Resonance Imaging (MRI)|MRI scan of the head and lower body parts
40937515|NCT05621551|DRUG|Dapagliflozin|The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.
40937516|NCT06433570|GENETIC|multiplex PCR|Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients using multiplex PCR
40937517|NCT00003301|DRUG|irinotecan hydrochloride|
40937518|NCT03506867|BEHAVIORAL|Life skills, training, education and work/volunteer opportunities|Intervention arm will receive proactive and sustained access to enhanced education and socio-economic supports (e.g. volunteer and/or work opportunities).
40937519|NCT03506867|BEHAVIORAL|Standard Care|Usual care will receive information on locally available services.
40937520|NCT03601000|DRUG|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.
40937521|NCT03601000|DRUG|Placebo|Placebo granules 5g given three times a day for up to 16 weeks.
40937522|NCT06275581|DEVICE|Ketac Universal Aplicap Glass Ionomer Restorative (3M) (test group)|Ketac Universal Aplicap Glass Ionomer Restorative (test group) was applied in one cavity of the patient, randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth. This material does not require a cavity conditioning step prior to restoration placement.
40937523|NCT06275581|DEVICE|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group)|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group) was applied in the other cavity of the patient,randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth.
40937524|NCT01225536|DRUG|ARQ 736|Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
40937525|NCT03292211|BEHAVIORAL|early mobilization|early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.
40937526|NCT03292211|BEHAVIORAL|early standard intervention|Conventional early in-bed activities within three days after stroke
40937527|NCT02201511|DRUG|3 mg PF-06412562 MR tablets_Fasted|A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
41280376|NCT03394950|DRUG|rtPA|Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
41280377|NCT03067220|OTHER|Virtual outpatient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
41280378|NCT03067220|OTHER|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
40937528|NCT02201511|DRUG|2 x 15 mg PF-06412562 MR tablets_Fasted|Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
40937529|NCT02201511|DRUG|2 x 15 mg PF-06412562 MR tablets_Fed|Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
40937530|NCT02201511|DRUG|10 mg PF-06412562 IR tablets|a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
40937531|NCT03679585|OTHER|Internet-Based Intervention|Undergo Talking Pictures social media intervention
40937532|NCT03679585|OTHER|Quality-of-Life Assessment|Ancillary studies
40937533|NCT03679585|OTHER|Questionnaire Administration|Ancillary studies
40937534|NCT05808283|OTHER|preoperative anemia frequency|patients who applied to the outpatient clinic prospectively for 3 months
40937535|NCT06424418|DEVICE|Robotic Scope Cleaner|The device is used to clean the scope when it visualization becomes obstructed during a surgical procedure.
40937536|NCT04344288|DRUG|Prednisone|The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)
40937537|NCT04344288|OTHER|Control group|The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.
40937538|NCT06332248|DIETARY_SUPPLEMENT|Magnesium|The dietary supplement magnesium (375 mg) was given daily for up to 3 months (oral intake).
41130746|NCT03041090|DEVICE|Lucerno ID (identification) System|The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
41130747|NCT01833455|DRUG|PVC Suppression using Flecainide|Flecainide will be administered to result in a reduction in PVC burden.
41130748|NCT01833455|DRUG|No PVC Suppression using Placebo|Placebo (sugar pills) will be given to result in no alteration in PVC burden.
41130749|NCT05888805|OTHER|DIMS spectacle lens|DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.
41130750|NCT05282966|DIAGNOSTIC_TEST|QSant-TM Urine Test|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
41130751|NCT05323032|DEVICE|Multifocal electroretinogram (mf-ERG) by electroretinogram device|Measurement of mf-ERG parameters with 61 stimulus elements to asses amplitude of waves in nano volt/degree square (nv/deg2) and latency in millisecond (msec) as measured by electroretinogram device.
41130752|NCT00547066|BIOLOGICAL|veltuzumab|hA20 will be administered intravenously in two doses over two weeks
41130753|NCT00692120|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|50,000 IU once monthly for 12 months
41130754|NCT00692120|DIETARY_SUPPLEMENT|Ergocalciferol (vitamin D2)|oral capsule 50,000 IU once monthly for 12 months
41130755|NCT00692120|DIETARY_SUPPLEMENT|Ergocalciferol (vitamin D2)|oral capsule 1600 IU once daily for 12 months
41130756|NCT00692120|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|oral capsule 1600 IU once daily for 12 months
41130757|NCT00692120|DIETARY_SUPPLEMENT|Placebo|oral placebo capsule once daily for 12 months
41130758|NCT00529204|DRUG|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
40937539|NCT06332248|DIETARY_SUPPLEMENT|Placebo|Placebo tablet, oral intake once a day for up to three months.
40937540|NCT05774548|OTHER|In-depth interviews (IDI)|In-depth interviews (IDI) 20 MSM,20 TGW, current, previous PrEP users will assess which attributes are relevant each population. Posters will be used to recruit for IDIs. Self-reported HIV-negative who either report interest in current or past PrEP use will be eligible to participate in IDI. IDI will be conducted by a study by in-person, on-line interviews.
41130759|NCT03254472|DIAGNOSTIC_TEST|Measured concentrations of biomarkers|
41130760|NCT02394613|DRUG|ANX776|Single intravenous injection
41130761|NCT02776982|PROCEDURE|Confocal endomicroscopy|Confocal endomicroscopy will be performed during clinically indicated endoscopy.
41130762|NCT02776982|PROCEDURE|Mucosal impedance|Mucosal impedance will be performed at the time of clinically indicated endoscopy.
41130763|NCT02776982|PROCEDURE|Research biopsies|Research biopsies will be obtained during clinically indicated endoscopy.
41130764|NCT02776982|PROCEDURE|Bravo ambulatory pH monitor|Bravo ambulatory pH capsule will be placed during clinically indicated endoscopy.
41130765|NCT04756440|BEHAVIORAL|Education Program and Music Therapy|After the intervention, it is expected that their awareness of Romana cervical cancer will increase, their perception of obstacle towards screening tests will decrease and they will be tested.
41130766|NCT03411174|RADIATION|hypofractionated partial breast irradiation|deliver 40Gy/15Fx to tumor bed areas
41130767|NCT01262963|DRUG|GSK2118436|A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
41130768|NCT04487249|OTHER|Vision Therapy|20 consecutive weeks of office-based vision therapy with home therapy that aim to improve the participant's vergence skills, accommodative skills, and sensory fusion.
41130769|NCT02899312|DRUG|PSMA PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
40937541|NCT05774548|OTHER|Focus group discussion (FGD)|Focus group discussion (FGD) will discuss a interested information from IDIs. IDIs will be informed, invited to a FGD. FGD recruit 6-10 IDI. 10 random number will be generated using statistical if more 10 individuals show interest in participating in a FGD. If there are less than 6 accepted participants for a FGD, the backup list or new participant will be invited. Study will perform FGD by in-person, on-line conference. Data obtained during a process will be used to create a list of attributes for each population, their levels to include in the choice tasks, ensuring that a choices are plausible, exchangeable.
41130770|NCT04543838|DIAGNOSTIC_TEST|Intervention|Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP) intraoperative monitoring
41130771|NCT04543838|OTHER|Standard of Care BP management|If blood pressure (BP) control is determined to be necessary, standard of care practices to manage it will be implemented
41130772|NCT04205669|DRUG|Benzyl Benzoate 25% Topical Application Lotion|Applied to skin for the treatment of scabies
41130773|NCT06459284|OTHER|retrospective data analysis|Surgical video-documentation including continous iOCT will ne reviewed for Instrument tissue interactions at the grasp site of the starting point of Membrane peeling
40937542|NCT05538819|DRUG|Glimepiride|Glimepiride 1-4 mg/day
40937543|NCT04285099|DEVICE|Application of dual system in frequency A|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
40937544|NCT04285099|DEVICE|Application of dual system in frequency B|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
40937545|NCT02636374|BEHAVIORAL|Guided Imagery|A fifteen minute recording of gentle music together with soft talking to guide relaxation.
40937546|NCT01314612|BEHAVIORAL|Cognitive-Behavioral Insomnia and Nightmare Group|Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
40937547|NCT04924179|DRUG|Tislelizumab plus Fruquintinib and SBRT|Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
40937548|NCT02841527|PROCEDURE|Gastric Band|Surgical intervention in which a band is inserted around the top of the stomach to reduce its size.
40937549|NCT02841527|PROCEDURE|Gastric Bypass|Surgical intervention where a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
40937550|NCT02841527|PROCEDURE|Sleeve Gastrectomy|Surgical intervention which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach.
40937551|NCT03355118|OTHER|General anaesthesia and major surgery|The effect of general anaesthesia and surgery on oxygen transport and how it relates to outcome
40937552|NCT01181648|BEHAVIORAL|questionnaire and semi-structured interviews|Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
40937553|NCT05673564|PROCEDURE|Anatomical Resection|Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
40937554|NCT05968365|DEVICE|electronic Vision-aid Device|Electronic blind aid is a non-invasive electronic aid product for the visually impaired. The product converts visual signals into tactile signals. The Vision Pro is designed for people with poor or no visual perception. The product does not change the previous travel mode of the visually impaired, and provides additional external information for the visually impaired on the basis of their existing cognition. The product can provide the visually impaired person with additional external information based on the cognition in front of them. The product can feedback the environmental information within 2.52.5 meters in front of the visually impaired person in the form of electrical stimulation to the visually impaired person. The visually impaired person can be stimulated by the tongue current to help them identify obstacles and give early warning. Avoid obstacles and give early warning.
40937555|NCT05630300|DIAGNOSTIC_TEST|PMC Sure Status COVID-19 Antigen Test|COVID-19 professional use kit in out-patient departments
40937556|NCT05630300|DIAGNOSTIC_TEST|Acon Flowflex COVID-19 Antigen Home Test|COVID-19 self-test kits
40937557|NCT03405636|DEVICE|Xeltis Pulmonary Valved Conduit|RVOT reconstruction
40937558|NCT02135939|BEHAVIORAL|Diet|Whole foods plant based vegan diet vs the American Heart Association-recommended diet
41280379|NCT05293067|DIAGNOSTIC_TEST|high-sensitive troponin|Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.
40937559|NCT02663583|BEHAVIORAL|Symptom Questionnaires|"Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months."
40937560|NCT02663583|BEHAVIORAL|Dysphagia Inventory Questionnaire|"Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months."
40937561|NCT02663583|BEHAVIORAL|Activity Bands|Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.
41130774|NCT04810390|DRUG|Bilastine|Ophthalmic solution 0.6%
41130775|NCT04810390|DRUG|Placebo|Ophthalmic solution
41280380|NCT00454233|DRUG|YM543|Oral
41280381|NCT00454233|DRUG|Metformin|Oral
41280382|NCT00454233|DRUG|Placebo|oral
41280383|NCT03643887|DRUG|FMT Capsule DE|30 capsule one-time oral dose
41280384|NCT03643887|DRUG|Placebo oral capsule|30 capsule one-time oral dose
41280385|NCT02909868|DEVICE|BackBeat-PHC|A conductance catheter will be used to obtain PV loops prior to a Moderato pacemaker implant procedure.
41280386|NCT01564784|DRUG|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m\^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
41280387|NCT01564784|DRUG|FLAG (fludarabine, cytarabine and G-CSF)|Dose: cytarabine 2.0 g/m\^2/day IV days 1-6 fludarabine30 mg/m\^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4
41280388|NCT01564784|DRUG|HIDAC (high dose cytarabine)|cytarabine 3 g/m\^2 IV every 12 hours for up to 12 times
40937562|NCT03894137|DIETARY_SUPPLEMENT|Grains of Paradise (Aframomum Melegueta)|This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
40937563|NCT03973073|COMBINATION_PRODUCT|CapulinTM|camouflage
40937564|NCT03973073|OTHER|topical applications and NB-UVB|combination therapy of vitiligo
40937565|NCT02049671|DRUG|Growth Hormone Therapy|
40937566|NCT02641483|OTHER|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
40937567|NCT00554112|BEHAVIORAL|Exercise|Exercise
40937568|NCT02554188|BIOLOGICAL|Seasonal influenza (flu) vaccine|"Seasonal influenza (flu) vaccine~* Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~* Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older"
40937569|NCT02554188|OTHER|Diet|A 5-day low calorie fasting-mimicking diet
40937570|NCT03380936|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level \> 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.
40937571|NCT03380936|OTHER|Plasma Exchange and IVIG (Intravenous Immunoglobulin )|Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
40937572|NCT02780219|OTHER|stable amino acid infusion|stable isotopes Such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
40937573|NCT02780219|OTHER|acute exercise with amino acid infusion|resistance exercise of each limb (i.e., leg (right/left); arm (right/left) on an isokinetic exercise machine allowing control of velocity, force, etc. with stable isotopes such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
40937574|NCT02780219|OTHER|24-hour post exercise amino acid infusion|stable isotopes such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
40937575|NCT00426231|BEHAVIORAL|Navigation by a health worker|Help provided by health worker to navigate medication access programs
40937576|NCT00426231|BEHAVIORAL|Information control|Information about medication access programs provided to the participant and their healthcare provider
40937577|NCT04455984|OTHER|Date collection|Retrospective data analysis
40937578|NCT01577654|DRUG|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
40937579|NCT01577654|DRUG|EC145 + Docetaxel|"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +~Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"
40937580|NCT01577654|DRUG|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
40937581|NCT01577654|DRUG|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
40937582|NCT03915522|PROCEDURE|Single adductor canal block|The operated leg is slightly externally rotated and prepared for a block with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and after a subcutaneous injection of 2 ml of 1% lidocaine a total of 20 ml of 0'5% ropivacaine is injected into the canal using a 22 gauge ultrasound-visible needle. In the end, a sterile apposite is placed at the puncture site
41130776|NCT02955199|BEHAVIORAL|Mothering From the Inside Out (MIO)|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
41280389|NCT01564784|DRUG|cytarabine and mitoxantrone|mitoxantrone 12 mg/m\^2 IV days 1-3 cytarabine 200 mg/m\^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
41280390|NCT00919659|DIETARY_SUPPLEMENT|parenteral nutrition|25kcal/kg bw with parenteral nutrition
40756182|NCT02192476|OTHER|California tri-pull taping (CTPT)|"Two types of tape was used, a self-adhesive 1.5 cotton undercover tape and a 1 rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape."
41130777|NCT02955199|BEHAVIORAL|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
40937583|NCT03915522|PROCEDURE|Simulated adductor canal block|The operated leg is slightly externally rotated and prepared with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and at this leve a subcutaneous injection of 2 ml of 1% lidocaine . After, a sterile apposite is placed at the puncture site.
41130778|NCT05162339|OTHER|No intervention was made|No intervention was made
41130779|NCT05077670|PROCEDURE|Pulmonary vein electrical isolation|Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy.
41130780|NCT05077670|DEVICE|Atrial substrate mapping|Electro-anatomical maps will be performed with CARTO navigation system with multi-electrode catheters.
41130781|NCT01815359|PROCEDURE|Cytoreductive Surgery|Optimal Surgical Debulking
41130782|NCT01815359|DRUG|HIPEC with Mitomycin-C|
41130783|NCT01815359|DRUG|EPIC with FUDR and Leucovorin|
41130784|NCT06294834|OTHER|Part 1 of intervention A - Wheelchair skills training modules|"Clinicians will review a suite of training videos in a prescribed order that discuss motor learning principles, safe spotting, and how to complete 15 intermediate and advanced skills:~1. Opening/closing doors~2. getting over a gap~3. getting over a threshold~4. ascending a low curb~5. descending a low curb~6. ascending a high curb~7. descending a high curb~8. performing a stationary wheelie~9. descending a high curb in a wheelie position~10. descending a steep incline in a wheelie position and stopping~11. ascending stairs~12. descending stairs~13. completing a floor-to-chair transfer~14. car transfers~15. folding and unfolding wheelchair"
41280391|NCT03792009|DEVICE|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
41280392|NCT03792009|DRUG|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
41280393|NCT03792009|DRUG|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
40937584|NCT00350454|DEVICE|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
40937585|NCT00350454|DEVICE|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
41130785|NCT06294834|OTHER|Part 2 of intervention A - Asynchronous feedback from a remote trainer|Participants will practice of wheelchair skills paired with remote feedback. Participants will be reminded to practice once per week. The participant will practice any number of the 15 skills for a self-selected duration. Following each practice session, the participant will upload video(s) of the skills practiced and a session log, indicating any difficulties they encountered. The remote trainer will then review the video-recordings and reply to the participant with feedback.
41130786|NCT06294834|OTHER|Intervention B: Education on wheelchair provision|Participants will be provided with access to web-based wheelchair provision education modules. When the content is viewed will be self-selected by participants. Participants will be asked to complete a feedback survey at the end of the modules. Participants will receive weekly reminders to complete the intervention until a feedback survey completed.
41130787|NCT03520036|DRUG|MT-7117 low dose|MT-7117 low dose QD, oral, 16 weeks
41130788|NCT03520036|DRUG|MT-7117 high dose|MT-7117 high dose QD, oral, 16 weeks
41130789|NCT03520036|DRUG|Placebo|Placebo QD, oral, 16 weeks
41280394|NCT05794529|OTHER|There are no interventions in the present study|There are no interventions in the present study
40937586|NCT00350454|DEVICE|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
40937587|NCT06278220|DEVICE|placido-based topographer (wavelight allegro topolyzer vario) and scheimpflug -based (Oculus Pentacam )|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo pentacam and topolyzer examination to asses corneal high order aberrations before LASIK procedure.~Patients will be assigned to undergo LASIK. Follow up pentacam and topolyzer examination will be done 3 months after LASIK."
40937588|NCT02515032|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|2 daily for 12 weeks
41130790|NCT06356532|BEHAVIORAL|intensive care unit diary|The intensive care unit diary is a notebook provided to patients during their stay in the intensive care unit, allowing them to record all events that occur during this period. Patients are encouraged to freely write about their experiences, which may include details about their treatment progress, daily activities, visits from family members, and other relevant aspects of their stay.
41130791|NCT01957163|DRUG|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
41130792|NCT01957163|DRUG|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
41130793|NCT01957163|DRUG|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
40937589|NCT02515032|DIETARY_SUPPLEMENT|Isocaloric placebo|2 daily for 12 weeks
40937590|NCT06023524|DEVICE|Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. Dose 4 Joule at the acupuncture body points and 1 Joule at the ear points
41130794|NCT01957163|DRUG|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
41130795|NCT05474313|BEHAVIORAL|PrEP-3D package|A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.
40937591|NCT06023524|DEVICE|Sham Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. The laser is turned on but not activated
40937592|NCT05222243|DRUG|Direct pulp capping with calcium hydroxide|Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide
41130796|NCT05474313|BEHAVIORAL|Standard of Care|Participants are given local standard of care navigation for initiation of PrEP
41130797|NCT02235298|DRUG|Dapagliflozin|5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.
41130798|NCT02235298|DRUG|Metformin|500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL
41130799|NCT02235298|DRUG|Placebo|Placebo pill taken once daily to mimic Dapagliflozin
41130800|NCT03862469|PROCEDURE|Individualized laboratory test|Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.
41130801|NCT00894218|PROCEDURE|Arthroplasty|Hip or knee arthroplasty
40937593|NCT05222243|DRUG|Direct pulp capping with MTA|Capping exposed dental pulps during cavity preparation in primary teeth with MTA
40937594|NCT05222243|DRUG|Direct pulp capping with Formocresol|Capping exposed dental pulps during cavity preparation in primary teeth with zinc oxide eugenol after medication with formocresol
40937595|NCT03484260|DRUG|Testosterone Product|Men used testosterone product following prescription
40937596|NCT00330798|DRUG|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
40937597|NCT00330798|OTHER|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
40937598|NCT03786614|OTHER|Discontinuation of serotonergic antidepressants|Discontinuation of serotonergic antidepressants and possibly shift to other antidepressant categories that were proven to be effective in treating depression such as pramipexole, bupropion, quetiapine, lurasidone, brexpipazole. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
40937599|NCT03786614|OTHER|Continuation of serotonergic medications|Continuation of serotonergic medications which is the standard care of treatment. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
40937600|NCT01020539|DRUG|Fludarabine|Conditioning Regimen
40937601|NCT01020539|DRUG|Busulfan|Conditioning Regimen
41130802|NCT03512782|OTHER|CARDIOENF|The patients listed in interventional group will have access to software Cardioenf that is a app used in a device (cel phone, tablet) to monitoring signs and symptoms of the heart failure patients after discharge from hospital. In this software, their signs and symptoms will be inserted in three moments during the first 30 days after discharge. Nurses will monitor these data in the follow-up period.
41130803|NCT01022125|DRUG|TMC435|
41130804|NCT01399450|DRUG|paliperidone|paliperidone augmenting on ongoing medication
41130805|NCT04999072|PROCEDURE|Colectomy for colon cancer|Segmental or total colectomy was performed for colorectal cancer.
41130806|NCT03413826|BEHAVIORAL|Exercise|The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.
41130807|NCT03636854|OTHER|Concentric exercises|Resistance concentric straight leg raise and knee extension will be done.
41130808|NCT03636854|OTHER|Eccentric exercises|Resistance eccentric straight leg raise and knee extension will be done.
41130809|NCT05240794|DEVICE|ABM-01|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT)
41130810|NCT05240794|DEVICE|Digital Control|Placebo control for ABM-01
41130811|NCT02357472|DRUG|dehydroepiandrosterone|high dose group treatment represent for 50mg t.i.d and standard dose group represents for normal treatment with 25mg t.i.d. Each patients in these two group will take one capsule each time and three times a day for three months before entering into IVF cycles.
40937602|NCT01020539|DRUG|GVHD Prophylaxis|Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
40937603|NCT01020539|DRUG|Gemtuzumab Ozogamicin|Dose Escalation
40937604|NCT01020539|DRUG|Anti-Thymocyte Globulin|Unrelated Donors only
41130812|NCT03914885|GENETIC|ATLCAR.CD30|Administered at a dose of 2 x 10\^8 cells/m2
41130813|NCT03914885|DRUG|Bendamustine|Administered as a dose of 70mg/m2/day over 3 consecutive days; maybe dose reduced per treating physician discretion based on prior toxicities and the patient's clinical status
41130814|NCT03914885|DRUG|Fludarabine|Administered at a dose of 30mg/m2/day over 3 consecutive days; given concomitantly with bendamustine
41130815|NCT06494566|DIETARY_SUPPLEMENT|Omega-3|Omega-3 capsule
41450556|NCT05835804|DRUG|GCP intratumoral catheter|After local anaesthesia, intratumoral catheter will be place (one or several depending tumour criteria).The catheter placement could be guided by radiological imaging. Gemcitabine (200mg/l), carboplatin (100mg/l) and paclitaxel (20mg/l) will be each diluted in each in 160ml of NaCl0.9%. GCP will be administered successively for 8hours, at 20ml/h with a total duration of 24hours. The ITC will be done every 28 days for 6 times maximum in case of good response and tolerance. Nivolumab 240 mg IV will be started 1 to 7 days before the first intratumoral infusion and every 15 days, until progression or 2 until years in case of partial response, complete response or stabilization. Evaluation of tumour size will be done by CT-scan, or MRI 2every 2 months and PET-FDG every 3 months.
40937605|NCT01020539|DRUG|Isotretinoin|JMML patients only
40937606|NCT02480985|OTHER|Pituitary function evaluation|"Pituitary function evaluation performed at hospital discharge, 6 and 12 months~* Thyroid-stimulating hormone, free T4 and T3~* Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone~* Adrenocorticotropic hormone stimulation test~* Glucagon test (growth hormone deficit)~Risk factors evaluation of pituitary dysfunction~* Demographic data~* Daily data (clinical exam, secondary brain injuries)~* Hormone levels on day 1, 3 and 7~* Biomarkers on day 1, 3 and 7~* Brain CT-Scan on day 1~* Pituitary MRI on day 7~Outcome measures at 6 and 12 months~* Neurological recovery (GOSe)~* Independent functioning (FIM)~* Quality of life (EQ-5D-5L)~* Life satisfaction (LISAT-11)~* Depression (PHQ-9)"
41130816|NCT06494566|DIETARY_SUPPLEMENT|Mineral Oil|Mineral Oil Capsule
41130817|NCT00223756|OTHER|Low Vision Intervention - Outpatient Training Program|Patients receive LV therapy as outpatients
41130818|NCT02529449|DRUG|Placebo|Oral
41130819|NCT02529449|DRUG|ASP1941|Oral
41450557|NCT04917419|OTHER|Luminotherapy and /or Psychoeducation Program|TO complete
40744330|NCT01899885|PROCEDURE|AHA (Acute Highrisk Abdominalsurgery): Optimized Course|"optimized course: Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~1. standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~2. GDT-LiDCO fluid management pre-, per- and postoperative~3. Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~4. Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
40937607|NCT04522908|DRUG|Cabozantinib Oral Tablet|Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards
40937608|NCT02216825|DIETARY_SUPPLEMENT|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
40937609|NCT02216825|DIETARY_SUPPLEMENT|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
40937610|NCT05976438|DRUG|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the study drugs the patients will receive.
40937611|NCT05976438|DRUG|Chlortalidone|Chlortalidone 25mg will be one of the study drugs the patients will receive.
40937612|NCT00470184|DRUG|capecitabine|Oral
40937613|NCT00470184|DRUG|oxaliplatin|IV
41130820|NCT03506945|BEHAVIORAL|mPEP|Behavioral Activation Therapy
41450558|NCT00452920|DRUG|docetaxel|
41450559|NCT00452920|RADIATION|cesium Cs 137|
41450560|NCT00452920|RADIATION|radiation therapy|
40937614|NCT00470184|GENETIC|gene expression analysis|Correlative Study
41130821|NCT03506945|BEHAVIORAL|Bibliotherapy|Provide educational material on coping strategies pertinent to caregivers
41450561|NCT04927416|DRUG|68-Gallium-DOTATATE-PET/CT|68Ga-DOTATATE is administered one-time via intravenous injection of 5 mCi in a volume of 3-5 ml containing up to 50 mcg \[68Ga\] DOTATATE.
40937615|NCT00470184|GENETIC|microarray analysis|Correlative Study
40937616|NCT00470184|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative Study
40937617|NCT00470184|PROCEDURE|adjuvant therapy|Metastatic growth control
40937618|NCT00470184|PROCEDURE|biopsy|Examination of tissue type
40937619|NCT00470184|PROCEDURE|conventional surgery|Tissue removal
40937620|NCT00470184|PROCEDURE|neoadjuvant therapy|Tumor shrinkage
41450562|NCT05163886|DRUG|LAM-002A|LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.
40937621|NCT00470184|PROCEDURE|quality-of-life assessment|Correlative Study
40937622|NCT00470184|RADIATION|radiation therapy|Undergoing radiation therapy
40937623|NCT01732731|OTHER|treadmill training|Home-based treadmill training will be administered to the children in the experimental group
40937624|NCT03257176|BEHAVIORAL|Stepping Stones and Creating Futures|21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
41130822|NCT01935063|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
41130823|NCT01935063|OTHER|Topical Lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
41450563|NCT05163886|OTHER|Placebo|Microcrystalline cellulose in Swedish orange, size 0 capsules.
41450564|NCT01305109|BIOLOGICAL|ORV 116E|Oral Rotavirus Vaccine 116E (ORV 116E), 10\^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals
40937625|NCT06515041|OTHER|brain well-being|Each volunteers will be subjected to an evaluation of his well-being using a previously well established well-being scale, through a list of questions, prior, during and after the visit to the museum. All volunteers will be also equipped with a non invasive NIRS system to measure their emotions (measure of tissus oxygenenation), with a non invasive system of eye tracking glasses to measure where their eyes are looking and with a non invasive system to measure their heart rate.
40937626|NCT06087315|OTHER|Multi-faceted oxygen systems strengthening interventions (different for each country)|The specific approaches are different in each country but broadly include efforts to: (1) strengthening policies, strategies, and governance of medical oxygen production, distribution, maintenance, and use; (2) building capacity of healthcare workers and technicians to use and maintain oxygen well, and (3) strengthening oxygen-related data acquisition and use for forecasting, budgeting, and monitoring.
40937627|NCT03534453|DRUG|Olaparib 300mg tablets|300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
41130824|NCT06497920|DEVICE|Active rTMS to the motor cortex|Active bilateral repetitive transcranial magnetic stimulation to the motor cortex
41450565|NCT01305109|BIOLOGICAL|Placebo|3 doses of 0.5 mL at 4 week intervals
41450566|NCT02081105|OTHER|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
41450567|NCT04891276|OTHER|Data collection|Data collection on the national PMSI database
41450568|NCT04878263|OTHER|Conventional hospitalization|Conventional care pathway : patients will be hospitalized as long as necessary and then followed according to High Health Authorities recommendations and usual practices.
40937628|NCT03639571|DRUG|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
40937629|NCT03639571|OTHER|Placebo TEPI Plaster|Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
40937630|NCT01142518|DRUG|Interferon beta 1a|Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.
40937631|NCT03329781|DIETARY_SUPPLEMENT|BCM-95|Consuming 1 capsule of BCM-95 per day.
40937632|NCT03329781|DIETARY_SUPPLEMENT|Placebo|Consuming 1 placebo capsule per day
40937633|NCT05931588|OTHER|Pilates excercises, streching and breathing|international group receive Pilates exercises, stretching and breathing two times a week (30 min per session) perform 3 to 5 reps of Pilates exercises under supervision
40937634|NCT05931588|OTHER|stretching and breathing|control group guided with stretching and breathing home based program both group till 8 week both groups
40937635|NCT05293509|DRUG|Fludarabine|40 mg/m2/day i.v.- by vein
40937636|NCT05293509|DRUG|Dexamethasone|25 mg/m2/day i.v.-by vein
40937637|NCT05293509|DRUG|Cyclophosphamide|100 mg/m2 IV-by vein
40937638|NCT05293509|DRUG|Bortezomib|Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
40937639|NCT05293509|DRUG|Rituximab|Four doses of rituximab at a dose of 375 mg/m2- by vein
40937640|NCT05293509|DRUG|Busulfan|110 mg/m2 i.v-by vein
41130825|NCT06497920|DEVICE|Sham rTMS to the motor cortex|Sham bilateral repetitive transcranial magnetic stimulation to the motor cortex
41130826|NCT04815720|DRUG|pepinemab + pembrolizumab|The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.
41280395|NCT05170737|DRUG|AEF0217|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD."
41280396|NCT05170737|DRUG|Placebo|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort."
41450569|NCT04878263|OTHER|FIL-EAS ic care pathway|Organized care pathway with a maximum 4 working day long conventional hospitalization followed by hospitalization at home with a follow up combining hospital and private practice competences.
41130827|NCT00105846|PROCEDURE|Home care telemedicine|
41130828|NCT04957277|OTHER|load modulation|Adding body weight (BW) up to 20% BW and subtracting body weight down to -20% BW
41450570|NCT04635020|PROCEDURE|iStent|2 trabecular Stent injected at the end of the cataract surgery to the trabecular meshwork
41450571|NCT04635020|PROCEDURE|SLT-laser|1 month after cataract surgery laser treatment to the trabecular meshwork (100 applications, 360 degrees)
40937641|NCT05293509|DRUG|Cyclophosphamide (Cy)|by vein
40937642|NCT05293509|DRUG|Tacrolimus (or cyclosporine)|by vein
40937643|NCT05293509|DRUG|Mycophenolate mofetil (MMF)|given by PO
40937644|NCT05293509|DRUG|Rabbit ATG|by vein
40937645|NCT04732156|BIOLOGICAL|Blood sample|Measurement of PHI Index
40937646|NCT04732156|OTHER|Follow up questionnaire|3 years after inclusion
40937647|NCT04732156|DIAGNOSTIC_TEST|Human reading of prostate MR images (PI-RADSv2.1).|The PI-RADSv2.1 score will be compared to systematic and targeted biopsy findings (primary objective) and 3-year follow-up (secondary objective)
40937648|NCT02370771|PROCEDURE|Biological sampling|Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis
41130829|NCT06375759|PROCEDURE|Subarachnoid-Subarachnoid (S-S) Bypass|"The dura was widely exposed beyond the level of trauma, and then a midline dural opening was made under an operative microscope. When dura and arachnoid were adhered because of an expansion of arachnoiditis, they had to be released with great care to place the bypass tubes. During this procedure, S-S bypass was not usually needed to performed arachnoid lysis. This exposure had to reach the normal arachnoid mater free from arachnoiditis and adhesion, with normal CSF circulation.~After dissections of the normal arachnoid mater at the cephalic and caudal sites, 1 or 2 tubes made of medical grade silicone (ventricular drainage tube; internal diameter 1.5-2.0 mm, external diameter 2.5-3.3 mm) were inserted into the cephalic and caudal ends of the normal subarachnoid space. The part of the tube inserted into the subarachnoid space was approximately 2 cm long."
41130830|NCT06375759|PROCEDURE|Intradural Adhesion Lysis|Intradural spinal cord Adhesion Lysis
41130831|NCT02089529|DRUG|Ibuprofen|Ibuprofen/Ibumetin with no information, positive information and neutral information
41130832|NCT02089529|DRUG|Placebo|Placebo with no information, positive information and neutral information
41130833|NCT01756599|BIOLOGICAL|blood samples|
40937649|NCT02370771|DEVICE|Radiographic evaluation|Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
40937650|NCT00226629|PROCEDURE|Endovascular vs Open Repair|
40937651|NCT02660398|PROCEDURE|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
40937652|NCT03020290|DEVICE|Endovascular treatment for PAD during medical care (SuperA stent (Abbott))|Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
40937653|NCT01759888|DRUG|18F-DTBZ|"Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
41130834|NCT05948059|DRUG|SHR-2106 injection or placebo|starting dose from 50 mg
40937654|NCT05186428|OTHER|carrying out standard care|The adaptation of the diuretic treatment will be made according to the possible diuresis records and the weighing of the patient every 2 days.
40937655|NCT05186428|OTHER|adult diaper|the diuresis which will be calculated by making the difference between the weight of the soiled protection weighed and the weight of the dry protection
40937656|NCT04424524|OTHER|Direct-to-pharmacy oral PrEP refill visits|Programmatic direct-to-pharmacy oral PrEP refill visits supported with client HIV self-testing
40937657|NCT03690323|PROCEDURE|Radiofrequency ablation (RFA)|RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.
40937658|NCT03690323|DRUG|FOLFIRINOX|Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
40937659|NCT03690323|DRUG|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
40937660|NCT03690323|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
40937661|NCT03723200|OTHER|Fibrinogen and blood products|Fibrinogen and blood products
40937662|NCT03163810|DEVICE|Erchonia Verju Laser|The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
40937663|NCT03163810|DEVICE|Erchonia EVRL Laser|The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
41130835|NCT05948059|DRUG|SHR-2106 injection or placebo|starting dose from 300 mg
41130836|NCT00012259|DRUG|troxacitabine|
40937664|NCT03609580|DRUG|Tamsulosin - 1 week|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
40937665|NCT03609580|DRUG|Tamsulosin - 3 days|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 3 days), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
40937666|NCT03701321|DRUG|Bortezomib|Given SC
40937667|NCT03701321|BIOLOGICAL|Daratumumab|Given IV
40937668|NCT03701321|DRUG|Dexamethasone|Given PO
40937669|NCT03701321|DRUG|Venetoclax|Given PO
41280397|NCT02693223|OTHER|GWTG Stroke program|Evidence based recommended therapies and counseling prior to hospital discharge.
41280398|NCT03944837|OTHER|Oxygen gas|Transient maternal oxygen administration during echocardiographic and MRI imaging
40937670|NCT03632343|OTHER|Pain Squad+ with Nurse Support|Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain \>3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
40937671|NCT03632343|OTHER|Pain Squad+|Pain Squad+ smartphone app with algorithm-driven pain management advice without RN-initiated pain support.
40937672|NCT05497635|DRUG|STSA-1002 Injection|Intravenous injection
40937673|NCT05497635|DRUG|Placebo|Intravenous injection
40937674|NCT00959335|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
40937675|NCT00959335|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
40937676|NCT02775201|PROCEDURE|Plantaris release under ultrasound guidance|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
40937677|NCT02775201|PROCEDURE|Plantaris excision surgically|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
40937678|NCT00708565|DRUG|iloprost|Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
40937679|NCT02875925|OTHER|MTM|Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
40937680|NCT06010732|DRUG|0 ppm F (placebo, negative control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
40937681|NCT06010732|DRUG|1100 ppm F as sodium fluoride (positive control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
40937682|NCT06010732|DRUG|1100 ppm F as sodium fluoride Test Product|• Each subject will use this product during one of the three treatment periods in the crossover study design.
40937683|NCT01654861|DRUG|Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)|Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose \>90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
40937684|NCT06145906|PROCEDURE|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
41280399|NCT00522860|PROCEDURE|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
40937685|NCT06145906|PROCEDURE|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
40937686|NCT00050687|DRUG|Gallium maltolate|
40937687|NCT05961644|DRUG|Cladribine Subcutaneous Injection|Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)
40937688|NCT05961644|DRUG|0.9% Chloride Injection Sodium|0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
40937689|NCT00000328|DRUG|Opioid-Related Disorders|
40937690|NCT01411072|DRUG|gemcitabine|Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
40937691|NCT01411072|DRUG|5-fluorouracil|5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
40937692|NCT03518931|DIAGNOSTIC_TEST|Fitness testing|The intervention in this study was measuring cardiorespiratory fitness and muscular strength and providing normative data to subjects.
40937693|NCT02750943|DRUG|Stannous Fluoride|Dentifrice containing 0.454% w/w stannous fluoride
41130837|NCT03312621|BEHAVIORAL|Health Care Transition Care Coordination|These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
41450572|NCT04635020|PROCEDURE|Cataract surgery|Conventional cataract surgery
40937694|NCT02750943|DRUG|Sodium Monofluorophosphate|Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
40937695|NCT06222359|DEVICE|COMPASS|Digital CBT to treat psychological distress in Multiple Sclerosis (MS)
40937696|NCT01019811|PROCEDURE|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
41130838|NCT01711294|DEVICE|19 G Flex Needle|Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
41130839|NCT01711294|DEVICE|22 G Needle|Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
41130840|NCT01711294|DEVICE|19 G Needle|Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
41280400|NCT00522860|PROCEDURE|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
41280401|NCT03139370|DRUG|KITE-718|A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
41280402|NCT03139370|DRUG|Cyclophosphamide|Administered intravenously
40937697|NCT03491943|PROCEDURE|ultrasound-assisted midline approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via midline approach.
40937698|NCT03491943|PROCEDURE|ultrasound-assisted paramedian approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
40937699|NCT01706679|DRUG|ATX-101 (10 mg/ml)|
40937700|NCT01706679|DRUG|ATX-101 (20 mg/ml)|
41280403|NCT03139370|DRUG|Fludarabine|Administered intravenously
40937701|NCT01706679|DRUG|Moxifloxacin (400 mg)|
41280404|NCT03139370|DEVICE|MAGE - A3/A6 Screening Test|A screening test for MAGE-A3/A6+ tumors
41280405|NCT03404505|BEHAVIORAL|Infant Achievements|Play-based intervention for caregivers and infants. The efficacy of the Infant Achievements intervention for improving communication and social behavior in infants who are at risk for communication, social, or developmental delay.
40937702|NCT01706679|DRUG|Placebo vehicle (PBS)|
40937703|NCT05530876|OTHER|Telerehabilitation with virtual game|It will be applied 10 sessions of remote rehabilitation in women with and without breast cancer, in order to promote physical activity.
40937704|NCT05788978|OTHER|Scale development|Scale development
40937705|NCT05819684|DRUG|SHR-4602 for injection|be administered via intravenous (IV) infusion
40937706|NCT04938479|BIOLOGICAL|blood sample|D-dimer measurement in blood sample
40937707|NCT00046891|DRUG|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
41280406|NCT03404505|BEHAVIORAL|Caregiver Education (CE)|Parents in the CE group will be taught about child development and well-being in their home, weekly, with a weekly follow-up phone call by trained research staff.
40937708|NCT00046891|OTHER|Placebo|Patients will take 1 tablet BID
40937709|NCT02722486|DEVICE|Vestibular Rehabilitation/Balance Belt|With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.
40937710|NCT02722486|OTHER|Standard Vestibular Rehabilitation|This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
40937711|NCT05199727|DEVICE|LI-ESWT|Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)
40937712|NCT05199727|DRUG|Tadalafil 20Mg Oral Tablet|Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
40937713|NCT00079534|BEHAVIORAL|Non-local/distant healing or prayer|
40937714|NCT05906238|BEHAVIORAL|STEREOBES Workshops|These workshops are designed to help patients develop appropriate behaviors to deal with stigmatizing situations. They will focus on three main areas: adapted physical activities, nutrition and mental well-being. They will include sessions on developing self-esteem, improving body image and managing emotions. The aim will be to deconstruct the myths and stereotypes surrounding obesity.
40937715|NCT05906238|BEHAVIORAL|Un Poids en moins|"Standard intervention proposed by La Vie la Santé"
40937716|NCT03023046|DRUG|Cyclophosphamide|Given IV
40937717|NCT03023046|DRUG|Dasatinib|Given PO
40937718|NCT03023046|DRUG|Doxorubicin|Given IV
40937719|NCT03023046|DRUG|Etoposide|Given IV
40937720|NCT03023046|DRUG|Imatinib Mesylate|Given PO
40937721|NCT03023046|OTHER|Laboratory Biomarker Analysis|Correlative studies
40937722|NCT03023046|DRUG|Prednisone|Given PO
41280407|NCT00428363|DEVICE|Cataract surgery with implantation of an intraocular lens|
41280408|NCT01225406|DRUG|Tenofovir|
41280409|NCT06255886|DRUG|Protein pump inhibitor. Continuing nutrition containing cows' milk protein.|1 mg/kg /day
40937723|NCT03023046|BIOLOGICAL|Rituximab|Given IV
40937724|NCT03023046|DRUG|Vincristine Sulfate|Given IV
40937725|NCT05765656|BEHAVIORAL|GP - pharmacist collaboration and pharmacist motivational interviewing|"1. Patients in the GP-CP clusters randomized to the intervention arm will be offered a joint GP-CP deprescribing intervention by their GP.~2. After the encounter, the patients will go to the pharmacy to get their medication dispensed. They will be given education materials. The pharmacist will plan with the patients 3 Motivational Interviews which will address the risks of using BZDR, and the benefits and modalities of stopping them. The pharmacists will receive a 2-day training course in MI. They will be given guidelines on BZDR deprescribing. If required, the pharmacists will be supported in their first MI.~3. Following each interview, the pharmacist will inform the GP by means of a formalized report of the points discussed. The pharmacist will inform the GP of the patient's choice or not to get involved in a deprescribing process and of the protocol followed. The objective of this exchange is to formalize the joint GP-CP intervention and to secure the deprescribing of BZDR."
40937726|NCT04600310|DEVICE|ULTRAPREP|ULTRAPREP device for reducing OR prep times.
41280410|NCT06255886|BEHAVIORAL|Mother or infant diet|Mother on cow milk protein diet or infant on hypoallergenic formula in case of bottle fed
41280411|NCT06255886|DRUG|Placebo|Placebo medicine (appearing substantially like Omeprazole) 1mg/ ml, and continuing nutrition containing cows' milk protein
40937727|NCT04600310|DEVICE|No Intervention|Conventional skin preparation technique
40937728|NCT04059198|DRUG|Inarigivir soproxil|Inarigivir soproxil 400 mg tablets
40937729|NCT04059198|DRUG|Tenofovir alafenamide fumarate (TAF)|Tenofovir alafenamide fumarate 25 mg tablet
40937730|NCT04827121|PROCEDURE|Fascial iliac compartment block|Patients will recieve supra-inguinal approach of fascial iliac compartment block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
40937731|NCT04827121|PROCEDURE|Quadratus lumborum block|Patients will recieve transmuscular approach of quadratus lumborum block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
40937732|NCT05263947|DRUG|Bevacizumab and Icotinib|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
40937733|NCT01218633|DRUG|saline infusion|saline infused at 30ml/hour
40937734|NCT01218633|DRUG|GLP-1-9,36 infusion|infused @ 1.2pmol/kg/min
40937735|NCT01218633|DRUG|Exendin-9,39 at low dose|infused at 30pmol/kg/min
40937736|NCT01218633|DRUG|Exendin-9,39 at high dose|infused @ 300pmol/kg/min
40937737|NCT00768937|DRUG|Sorafenib|All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
40937738|NCT00768937|PROCEDURE|Transarterial chemoembolisation (TACE)|TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
41280412|NCT01240070|OTHER|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
40937739|NCT04849325|DEVICE|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with IBS Titan™.
40937740|NCT04849325|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Subjects in this arm will be treated with PTA device.
41280413|NCT02427061|BEHAVIORAL|Intervention Program (Manhood 2.0)|
41280414|NCT02427061|BEHAVIORAL|Control Program (Job Skills Training)|
41280415|NCT01536444|DEVICE|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
41130841|NCT01026805|DEVICE|Interlace Medical 1st Generation Hysteroscopic Morcellator|The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
41130842|NCT05202366|DRUG|CGB-400 Topical Gel|CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
41130843|NCT03378791|DRUG|Iron bisglycinate Oral Tablet|
41280416|NCT00537719|DRUG|GSK716155|albiglutide subcutaneous injection
41280417|NCT00537719|DRUG|Placebo|placebo injection
41130844|NCT03378791|DRUG|Ferrous Fumarate Oral Tablet|
41130845|NCT02892591|DRUG|Cannabis|vaporized plant material
41130846|NCT02892591|DRUG|Oxycodone|oral capsule
41130847|NCT02892591|DRUG|Placebo for Cannabis|vaporized placebo plant material
41130848|NCT02892591|DRUG|Placebo for Oxycodone|oral placebo capsule
41130849|NCT00344916|DRUG|Ng-monomethyl-L-arginine (drug)|
41130850|NCT04256148|BIOLOGICAL|ALXN1830|Administered via intravenous (IV) infusion
41280418|NCT01400646|DRUG|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
41280419|NCT01400646|DRUG|Warfarin|Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
41130851|NCT04256148|OTHER|Placebo|Matching placebo (sterile liquid diluent) administered via IV infusion
41130852|NCT00143806|DRUG|Transitioning patients from cyclosporine to alefacept|
41130853|NCT02944123|DRUG|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
41130854|NCT02944123|DRUG|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
41130855|NCT02944123|DRUG|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
41130856|NCT05292066|DRUG|Duloxetine Tablets,|"Duloxetine is an FDA-approved medication used to treat the major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. It is taken by mouth. It is a serotonin-norepinephrine reuptake inhibitor.~Pregabalin is an FDA approved, sold under the brand name Lyrica. it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,"
41130857|NCT05292066|DRUG|Pregabalin Tablets|Pregabalin is an FDA approved, it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,
41130858|NCT00667017|BIOLOGICAL|RFT5-dgA immunotoxin|
41130859|NCT00667017|OTHER|fluorescence activated cell sorting|
41130860|NCT00667017|OTHER|immunohistochemistry staining method|
41130861|NCT04131257|BEHAVIORAL|Nurse-led Continuum of Care|This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
41130862|NCT04003259|BEHAVIORAL|Lifestyle management programme|The programme consisted of 1) the initiation phase (1-3 months), 2) the establishment phase (3-6 months), and 3) the maintenance phase (7-12 months). Guidance was given altogether on 25 separate occasions with special emphasis on the motivation and education. The goal for weight loss was 5-10 %. The programme included four visits by medical doctor, an educational lecture by medical doctor and personal trainer, five sessions by registered dietician, two cooking classes by professional chef, two group discussions, and exercise as follows: personalized exercise program tailored by personal trainer, one-year gym access with four guided group sessions, and two guided group Nordic walking sessions, and three individual exercise sessions by personal trainer.
41130863|NCT05731206|OTHER|Hydrolyzed protein infant formula|Hydrolyzed protein infant formula
41130864|NCT05731206|OTHER|commercially available hypoallergenic infant formula|commercially available hypoallergenic infant formula
41280420|NCT01400646|DRUG|Vitamin K|Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
41280421|NCT01400646|DRUG|Vitamin K|Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
41280422|NCT01400646|DRUG|Warfarin|Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
41280423|NCT01400646|DRUG|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
41280424|NCT01400646|DRUG|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
41130865|NCT02116075|PROCEDURE|Epidural Prolotherapy|caudal injection of 10mL 5% dextrose
41130866|NCT02116075|PROCEDURE|Epidural Steroid|caudal injection of 1mL 80mg depo-medrol with 9ml of 1% lidocaine
41280425|NCT04578210|BIOLOGICAL|T memory cells and NK cells|Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).
41280426|NCT00827489|DRUG|HTC-867|
41130867|NCT04031365|PROCEDURE|Acupuncture|Use of sterile, disposable needles in acupuncture
41130868|NCT04031365|BEHAVIORAL|Cognitive Behavioral Therapy|psychotherapy
41130869|NCT04301206|BEHAVIORAL|Intervention Group|Empowerment of parents. When calling the medical helpline 1813 the parents will be offered to access the new material about sick children, compared to not getting this possibility.
41130870|NCT02589457|DRUG|CKD-390|Tenofovir Disoproxil Aspartate 1T PO
41130871|NCT02589457|DRUG|Viread® tablet|Tenofovir Disoproxil Fumarate 1T PO
41130872|NCT01888744|DRUG|GnRH agonist|
41130873|NCT01888744|DRUG|GnRH antagonist|
41130874|NCT01888744|DRUG|hP-hMG|
41130875|NCT01888744|DRUG|Human chorionic gonadotropin|induction of final oocyte maturation
41130876|NCT01888744|DRUG|Progesterone|
41130877|NCT05516745|DEVICE|AioCare spirometer|In the first part of the trial, all participants from arms 1 and 2 will receive the AioCare spirometer (Healtup, Poland) to home-based monitoring pulmonary function. Hospital spirometry examinations (Jaeger, Germany) evaluating disease progression will be performed periodically. There are to be follow-up visits after 3 months and after 6 months. The end-point visit is planned for 12 months.
41130878|NCT05516745|OTHER|telerehabiliation of the respiratory system|A major component of respiratory dysfunction seems to be a decline of respiratory muscle weakness. The proposition is respiratory telerehabilitation to improve the function of respiratory muscles. Telerehabilitation includes breathing exercises for use at home. The participants will be trained in the hospital and will receive video presentations to support the exercises at home.
41130879|NCT00268723|DRUG|Levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
41130880|NCT00268723|DRUG|Placebo|Placebo MDI QID
41130881|NCT01669356|OTHER|Parenteral supplement with enteral nutrition for patients after esophagectomy|
41130882|NCT01669356|OTHER|Enteral Nutrition alone for patients after esophagectomy|
41130883|NCT06026800|BIOLOGICAL|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
41130884|NCT00892541|DRUG|ER OROS paliperidone|
41130885|NCT01087437|DIETARY_SUPPLEMENT|gastrolith calcium|
41130886|NCT05004207|DIAGNOSTIC_TEST|99mTc Scintigraphy|"After fasting for at least 8 to 12 hours, standardized meal mixed with 99mTc-sulfur colloid radiolabeled test will be administered as quickly as possible, optimally within 10 min. Imaging will be obtained with Siemens SYMBIA E dual head (SPECT) scanner in a format of at least 128 x 128 pixels. Anterior and posterior planar images (or a single left anterior oblique image) with the distal esophagus, stomach, and proximal small bowel in the field of view will be obtained for 1 min immediately after ingestion of the test meal and repeated images will be obtained in the same projections with 2 min static images at hourly intervals up to 6 h and at 24 hours as was used for the initial images.~Next day LHBT will be performed after at least 12 hours of fasting. Following administration of test substrate (Lactulose 10 grams) with one cup of water, breath samples will be analyzed for hydrogen every 15 minutes for 1 hour followed by every half hour for next 2 hour with LACTOFEN 2 device."
41130887|NCT04352400|DRUG|Nafamostat Mesilate|administered intravenously as a continuous infusion
41130888|NCT04352400|DRUG|Placebo|administered intravenously as a continuous infusion
41280427|NCT00827489|OTHER|Placebo|
41280428|NCT02801175|PROCEDURE|Pulmonary vein isolation|
41280429|NCT03386240|DRUG|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)|The intervention consists of using Plus group (Triclosan-coated Sutures)
41280430|NCT03386240|OTHER|Vicryl, monocryl, PDS (not coated with triclosan)|Consists of equivalent sutures (not coated with triclosan) during cesarean delivery.
41130889|NCT00047528|DRUG|Alcon Investigational Agent|
41130890|NCT05316766|OTHER|Physical rehabilitation|Exercises to rehabilitate upper limb strength, coordination and range of movement, based on conventional therapy
41130891|NCT05316766|OTHER|Physical rehabilitation interactive table|Exercises to rehabilitate upper limb strength, coordination and range of movement, based on multi-user touch surface
41130892|NCT02080585|BEHAVIORAL|Physical Activity advice.|Subjects receive advice regarding physical activities.
41130893|NCT02172560|DRUG|Tiotropium|
41280431|NCT01106638|BEHAVIORAL|Positively Smoke Free|An eight session, group therapy intervention targeting smokers living with HIV/AIDS
41280432|NCT01106638|BEHAVIORAL|Standard care|Advice to quit, smoking cessation brochure, and offer of nicotine patches
41280433|NCT02911987|OTHER|high intensity training (HIT) program|The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.
41280434|NCT02911987|OTHER|moderate intensity training (MIT) exercise therapy|MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
41280435|NCT02070432|DRUG|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
41280436|NCT00003937|DRUG|cisplatin|
40756183|NCT03749174|PROCEDURE|Long acting Supraclivicular block vs Short acting Supraclavicular block|"Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block"
40756184|NCT03956108|DIAGNOSTIC_TEST|MRI+targeted biopsies+Stockholm3-test|MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.
40756185|NCT03956108|DIAGNOSTIC_TEST|PSA + systematic biopsies|Systematic biopsies and PSA test
40756186|NCT05521282|DRUG|Treatment group|Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
40756187|NCT02594956|DEVICE|no nasogastric tube|
41280437|NCT00003937|DRUG|dexrazoxane hydrochloride|
41280438|NCT00003937|DRUG|doxorubicin hydrochloride|
41280439|NCT00003937|DRUG|etoposide|
40937741|NCT01866722|BEHAVIORAL|Usual care|Participants will get a brief (\<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
40937742|NCT01866722|BEHAVIORAL|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
40937743|NCT01866722|BEHAVIORAL|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
40756188|NCT02594956|DEVICE|nasogastric tube|
40937744|NCT00652639|DRUG|Clonazepam|Tablets, 1 mg, single-dose
40937745|NCT00652639|DRUG|Klonopin|tablets, 1 mg, single-dose
40937746|NCT04061473|DRUG|Sitagliptin 100mg|"2 tablets of sitagliptin 100 mg.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
40937747|NCT04061473|DRUG|Empagliflozin 25 MG|2 tablets of empagliflozin 25 mg.
40937748|NCT04061473|OTHER|Placebo tablet|"2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
40937749|NCT06166030|DIETARY_SUPPLEMENT|Nutritional blend (ImmuneRecov).|Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.
40937750|NCT03723603|DEVICE|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
41280440|NCT00003937|DRUG|ifosfamide|
41280441|NCT00003937|DRUG|methotrexate|
40744331|NCT05331924|PROCEDURE|IPL therapy|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
40744332|NCT05331924|PROCEDURE|Punctal plugs|Silicone punctal plugs are small pieces of silicone designed to block tear drainage through occluding the lacrimal punctum.
40744333|NCT04050605|DEVICE|somofilcon A toric contact lens|Contact Lens
40744334|NCT04050605|DEVICE|fanfilcon A toric contact lens|Contact Lens
40744335|NCT04938947|DEVICE|Blood Flow Restriction Cuffs|This intervention consists of inflatable cuffs that are designed to partially occlude veinous blood return from the lower extremities during resistance training.
40756189|NCT05109559|BIOLOGICAL|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
40937751|NCT04564118|DRUG|Retrospective analysis of assigned treatment|analysis of treatment assigned by physicians within routine clinical practice
40937752|NCT01616082|BEHAVIORAL|Low Calorie Diet (LCD)|A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.
40937753|NCT01616082|DRUG|Phentermine|"Individuals not on track to achieve their target weight by four weeks received the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects were given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~* Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~* Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated."
40937754|NCT04171427|OTHER|Lithium liposome|Cosmetic product
40937755|NCT04171427|OTHER|Placebo|Cosmetic product vehicle
40937756|NCT05641675|DIAGNOSTIC_TEST|right heart catheterization|Connect to a heart monitor to record heart rate, blood pressure and blood oxygen levels Place sterile sheets on chest and neck (or groin area) Clean the skin over the neck or groin Give local anaesthetic to numb the area (this may sting a little when it is given) Gently pass a catheter into a vein to the heart Record pressure readings from the heart chambers and lungs Give medication, depending on heart's pressure readings Remove the catheter and apply pressure where it was inserted
40937757|NCT01658618|BIOLOGICAL|HP802-247|
40937758|NCT05876572|DRUG|intradermal naloxone|One time 8 mg/0.1 mL dose of naloxone to be administered intradermally
40937759|NCT05876572|DEVICE|microneedle injection|Intradermal delivery of naloxone using microneedle
40937760|NCT02331875|DRUG|IPH2201|The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
40937761|NCT02331875|PROCEDURE|Standard Surgery|After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
41280442|NCT00003937|PROCEDURE|conventional surgery|
41280443|NCT02886104|PROCEDURE|CRLM resection group|Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
41130894|NCT03258866|DRUG|Rituximab|given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
40756190|NCT05109559|BIOLOGICAL|Half dose of Ad26.COV2. 2.5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
40756191|NCT05109559|BIOLOGICAL|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
41130895|NCT03258866|DRUG|Rituximab|given with a single dose of 375mg/m2
41130896|NCT04747418|PROCEDURE|Diagnostic Hysteroscopy|Collection of first 5 cc of normal saline from the output port during diagnostic hysteroscopy
40756192|NCT04738669|OTHER|mHealth|The mHealth intervention includes telephonic call and SMS.
40756193|NCT04738669|BEHAVIORAL|Teach-back|While the teach-back includes counselling session related to discharge instruction including medication adherence.
40756194|NCT03048019|DRUG|Tirofiban|Patients will receive Tirofiban during the PCI procedure
40756195|NCT03048019|DRUG|Cangrelor|Patients will receive Cangrelor during the PCI procedure
40756196|NCT04634331|BEHAVIORAL|Augmented Reality Multi-Modal Training|Training administered via an augmented reality headset.
40756197|NCT04634331|BEHAVIORAL|Traditional Multi-Modal Training|Training administered via a 1:1 physical therapy session
40756198|NCT01991886|DEVICE|Vapotherm Precision Flow|Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
41130897|NCT04747418|PROCEDURE|Trans-vaginal ultrasound|Trans vaginal ultrasound performed immediately following the diagnostic hysteroscopy ( as sonohysterography)
41130898|NCT05035329|OTHER|Outcome measurements|Outcome measurements were applied.
41280444|NCT02886104|DEVICE|CRLM ablation group|Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
41130899|NCT03907306|PROCEDURE|Wound healing|The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
41130900|NCT02747394|OTHER|Working Memory Training|
41280445|NCT02601417|OTHER|Ignoring result of bile culture|the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group
41280446|NCT04247048|OTHER|infusion of tracer [5,5,5-2H3] -L-leucine|A bolus of 6ml of \[5,5,5-2H3\] -L-leucine tracers will be performed followed by an infusion of 90 ml of \[5,5,5-2H3\] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.
41280447|NCT00009672|DRUG|Nortriptyline|
41280448|NCT00009672|DRUG|Morphine|
41280449|NCT01021111|DEVICE|Activity Training with Feedback|The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
41280450|NCT01945892|DRUG|Ozurdex|"- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior."
41280451|NCT01379625|DRUG|Triheptanoin|Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
41280452|NCT05282940|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Investigational Medicinal Product
41280453|NCT05282940|DRUG|Microgynon CD|Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug
41280454|NCT05076422|DRUG|BI 3006337|BI 3006337
41280455|NCT05076422|DRUG|Placebo|Placebo
41280456|NCT00075881|DRUG|bortezomib|Given IV
41280457|NCT00075881|OTHER|laboratory biomarker analysis|Optional correlative studies
41130901|NCT02720432|OTHER|CIMT|Constraint-induced movement therapy
41130902|NCT02720432|OTHER|HABIT|hand-arm bimanual intensive training
41130903|NCT02720432|OTHER|baby-massage|instructions for baby-massage
41130904|NCT04090632|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
41130905|NCT01155206|DRUG|glucagon|glucagon 3ng/kg/min
41130906|NCT01779050|DRUG|Doxorubicin|
41130907|NCT01779050|BIOLOGICAL|Trastuzumab|
41130908|NCT01779050|DRUG|Cyclophosphamide|
41130909|NCT01779050|DRUG|Paclitaxel|
41280458|NCT03415230|OTHER|Therapeutic massage|Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.
41280459|NCT03415230|OTHER|Sham massage|Sham massage involves only light touch massage in a non systematic way
40756199|NCT01045265|OTHER|Seminal plasma pharmacokinetics|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
41130910|NCT01779050|DRUG|Epirubicin|
41130911|NCT01779050|DRUG|Docetaxel|
41130912|NCT01779050|DRUG|Carboplatin|
41280460|NCT04820192|OTHER|Craniosacral Therapy|The Upledger method of applying both specific and non-specific manual therapy of gentle, sustained, non-invasive stretch to soft tissues of fascia, meninges and osseous attachments. Fluid exchange is also believed to be a resulting result of CST. Treatment is applied to myofascial and osseous sites over the entire body, tending to specific and unique constellation of tissue restrictions and osseous compressions of soft tissue.
41280461|NCT03068962|OTHER|beetroot Juice|Beetroot Juice
41280462|NCT03068962|OTHER|Buxton water|natural mineral water
41130913|NCT01779050|DRUG|Fluorouracil|
40756200|NCT01460537|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 as 30-minutes IV infusion
40756201|NCT01460537|DRUG|BAY80-6946|Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
40756202|NCT01460537|DRUG|Cisplatin|1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
40756203|NCT01460537|DRUG|NaCl|Infusion of 500 ml of 0.9% NaCl over 30-minutes
41130914|NCT02146469|BIOLOGICAL|2 doses with an 3 months interval|varicella vaccination
41130915|NCT02146469|BIOLOGICAL|A second dose with an 1 year interval|varicella vaccine
41130916|NCT02146469|BIOLOGICAL|A second dose with an 3 year interval|varicella vaccine
41130917|NCT02146469|BIOLOGICAL|A second dose with an 5 year interval|varicella vaccine
41130918|NCT02146469|BIOLOGICAL|1 dose Varicella vaccine and 1 dose MMR given at the same time|varicella vaccine and MMR
40937762|NCT02331875|RADIATION|Postsurgical Adjuvant Therapy|After the standard surgery, according to standard recommendations in the relevant country
41130919|NCT02146469|BIOLOGICAL|1 dose MMR|MMR
41130920|NCT03402854|DEVICE|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during the first 20 min of bimanual training.
41280463|NCT03068962|OTHER|antiseptic mouthwash then beetroot juice|Chlorhexidine glocunate
41280464|NCT05290870|DEVICE|Posterior-chamber intraocular lens|Implantation of a posterior-chamber intraocular lens to correct aphakia after removal of the crystalline lens
41280465|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 1 gram|after a blood draw 1 gram of vitamin c will be consumed followed by 3 additional blood draws
41280466|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 2 grams|after a blood draw 2 grams of vitamin c will be consumed followed by 3 additional blood draws
40756204|NCT01460537|DRUG|BAY80-6964 fixed dose|BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. \[If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.\]
40756205|NCT02837952|DRUG|FDC IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
40937763|NCT04131218|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
41130921|NCT03402854|BEHAVIORAL|bimanual training|Participants will engage in movements that use both hands, by playing with toys and games.
41130922|NCT02777541|DIETARY_SUPPLEMENT|Resumption of feeding 3 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
41130923|NCT02777541|DIETARY_SUPPLEMENT|Resumption of feeding 8 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
41130924|NCT06387550|PROCEDURE|Eccentric Training|Warm up phase that include hip circles and shoulder rolls(1 sets of 5 reps), participants are trained on bicycle ergometer for 15 minutes on 2-3 times a week and its duration is increased according to patient tolerance, after that they will be pass through exercise phase that include squating, lunges and leg press (8-10 reps of 3 sets) after that cool down phase begin that include cat cow stretch and oblique stretch (5 reps of 1 set)
41130925|NCT02507869|BEHAVIORAL|Positive affective response|Participants adjust the intensity of their exercise to maintain a pleasant affective response.
41130926|NCT02507869|BEHAVIORAL|Moderate-intensity heart rate|Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
41130927|NCT02460549|BEHAVIORAL|therapeutic education program|
41280467|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 5 grams|after a blood draw 5 grams of vitamin c will be consumed followed by 3 additional blood draws
41280468|NCT04463030|DIETARY_SUPPLEMENT|Placebo|after a blood draw placebo will be consumed followed by 3 additional blood draws
41280469|NCT02466256|PROCEDURE|Intraocular lens implantation|Intraocular lens implantation
40937764|NCT05864573|BIOLOGICAL|ZGGS15|ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.
41280470|NCT02466256|DEVICE|Autosert Injector|Motorised injection device for intraocular lens implantation
41280471|NCT02466256|DEVICE|Royale Injector|Manual, plunger type injection device for intraocular lens implantation
41280472|NCT02466256|DEVICE|Monarch III Injector|Manual, screw type injection device for intraocular lens implantation
41280473|NCT05383820|DRUG|Ketorolac|The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
41280474|NCT00170976|DRUG|valsartan + amlodipine|
41280475|NCT06349551|BIOLOGICAL|Patients of intensive care unit|Patients of intensive care unit having an arterial catheter undergoing arterial blood sampling
41280476|NCT04255134|DRUG|Abatacept Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
41280477|NCT04255134|DRUG|Adalimumab Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
40756206|NCT02837952|DRUG|Placebo|Placebo
40756207|NCT06114641|DRUG|Enoxaparin sodium injection|Originator Enoxaparin with a trade name is Lovenox.
40756208|NCT01786109|DRUG|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
40756209|NCT01786109|DRUG|Placebo|Placebo will match study drug; taken as one dose orally with water.
40756210|NCT03159442|DRUG|AZD8871|Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
41130928|NCT01218009|DRUG|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
40756211|NCT03159442|DRUG|Placebo|Powder for inhalation administered via single dose DPI
40756212|NCT03997734|DRUG|AB001|single and repeated dosing
41280478|NCT04548310|OTHER|Muscles Fatigue|An exhaustion protocol that reduces knee joint flexor and extensor torque will be applied.
40756213|NCT03997734|DRUG|oral capsule|single dose
40937765|NCT03458663|DEVICE|Prevena™ og ACTIV.A.C™ Therapy System.|A vacuum assisted (negative pressure) system, Prevena ™ and ACTIV.A.C ™ therapy system have been developed to maintain drainage on closed incisions. The system also works by altering the cytokine profile locally so that it functions anti-inflammatory, by increasing local growth factors and promoting angiogenesis19. Negative pressure wound management (NPWM) such as Prevena ™ and ACTIV.AC ™ is a widely used tool with many different variations, but the evidence of effect remains sparse and more studies are required20. We believe that in a dry and closed incision such as the one after BCL surgery, in an area exposed to stretching during healing, it must be an advantage of maintaining drainage, reducing the anti-inflammatory response and increasing angiogenesis.
41280479|NCT00779168|DRUG|white button mushroom extract|For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
41280480|NCT00779168|OTHER|flow cytometry|Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
41280481|NCT00779168|OTHER|immunologic technique|Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
41280482|NCT00779168|OTHER|laboratory biomarker analysis|Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.
41280483|NCT00779168|OTHER|gas chromatography-mass spectrometry|Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
41280484|NCT00779168|OTHER|pharmacological study|Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
41450573|NCT00013390|PROCEDURE|Tinnitus Masking|"Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or covering up (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle)."
41130929|NCT01218009|DRUG|Albuterol Spiromax|"Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN)."
41130930|NCT04912765|BIOLOGICAL|Neoantigen Dendritic Cell Vaccine|10 doses of the vaccine will be administered via intra-dermal injection concurrently with adjuvant nivolumab.
41130931|NCT04912765|DRUG|Nivolumab|9 doses of 240mg IV nivolumab as a 30 minutes infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of 10 doses of NA DC vaccine, 480mg IV nivolumab will be administered as a 30 minutes infusion for a maximum of 9 doses.
41130932|NCT04553549|DEVICE|Transradial approach|"Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
41130933|NCT03572803|OTHER|Group of Dry Needling|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
40937766|NCT05269251|DEVICE|Near Infrared Spectroscopy (NIRS)|After the brachial plexus block, the regional oxygen saturation (rSO2) was monitored for 30 minutes with the Regional Oximetry System (O3™, Masimo, Irvine, CA) and the radial artery diameter with ultrasound in the same period.
40937767|NCT01362751|OTHER|No intervention|This study is an observational cohort study \> no interventions
40937768|NCT02050971|BIOLOGICAL|Umbilical Cord Blood Infusion|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
41130934|NCT03572803|OTHER|Group of Electrolysis|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
41130935|NCT03572803|OTHER|Control Group|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
41130936|NCT01856569|OTHER|no intervention|in real life of drug,dosage,frequency and duration
41130937|NCT03934567|DRUG|Abexinostat|Abexinostat tablets
41130938|NCT05389618|OTHER|Diagnostic Tests|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
41130939|NCT01588093|DRUG|Increlex|Increlex 120 micrograms/kg body weight single subcutaneous injection
41130940|NCT01588093|DRUG|0.9% Saline|Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
41130941|NCT03865875|BEHAVIORAL|Exercise Program|Participants will start the exercise program within 2 weeks of enrollment and will continue until surgery. This program will consist of twice weekly individualized sessions with a trainer.
41130942|NCT03865875|BEHAVIORAL|Nutrition Program|Each patient enrolled will undergo nutritional assessment at their initial post-enrollment visit to develop an individualized nutrition plan to be implemented up until when the patient undergoes surgery.
41130943|NCT06134349|DEVICE|lithium MRSI|lithium magnetic resonance spectroscopy imaging
41130944|NCT02919748|OTHER|Choral Singing|Weekly sessions at 1 hour of choral singing.
41453586|NCT05305495|DRUG|Empagliflozin 25 MG|Patients who fulfill the inclusion criteria will receive an intravenous dose of 1.0-1.5 mg/kg of furosemide (≤120 mg) and urine output will be monitored for three hours. Those with a urine output \< 300 ml in the first two hours post furosemide administration will receive a single oral dose of 25 mg of empagliflozin. Two hours after taking empagliflozin, patients will receive a second intravenous dose of 1.0-1.5 mg/kg of furosemide with another timed urine collection at three hours. Empagliflozin will then be continued daily for five days or until hospital discharge, unless the treating physician considers this not to be clinically appropriate.
40937769|NCT02050971|BIOLOGICAL|Intravenous Infusion of Peripheral Blood or its Components|Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
40937770|NCT00847119|BIOLOGICAL|Bevacizumab|Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
41130945|NCT02919748|OTHER|Health Education Program|Weekly session at 1 hour of health education talk and group activities
41130946|NCT03614663|DRUG|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
41130947|NCT03614663|OTHER|Placebo Transdermal Gel|Placebo formulated as a clear gel (transdermal delivery)
41130948|NCT05359536|BEHAVIORAL|Training Early Childhood educators in PA|The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
40937771|NCT00847119|DRUG|capecitabine (Xeloda)|Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
40937772|NCT00847119|RADIATION|Rectal Radiotherapy|Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
40937773|NCT04248803|OTHER|GLUMA (Kulzer GmbH, Germany) desensitizing agent|GLUMA desensitizer is used to reduce tooth sensitivity
40937774|NCT03210987|PROCEDURE|patient case presentation bedside|Patient case presentation in absence or presence of Patient at bedside.
40937775|NCT03210987|PROCEDURE|patient case presentation Outside-the-room|Patient case presentation Outside-the-room.
41280485|NCT05738863|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.~rTMS application Magventure MagPro R30 device is planned to provide magnetic stimulation with its stimulator. The stimulation pattern was shaped according to the protocols used in previous studies.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
41280486|NCT05738863|DEVICE|Sham rTMS Protocol|"It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
41280487|NCT00223340|BEHAVIORAL|Patient Activation and Diabetes Registry|
41280488|NCT00849550|DRUG|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
41280489|NCT01575912|OTHER|experimental pain tests|
41280490|NCT01209715|DRUG|Placebo|participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
41280491|NCT01209715|DRUG|Fluticasone /salmeterol|Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
41280492|NCT04032366|DRUG|inhaled nitric oxide|using of inhaled nitric oxide
41280493|NCT04032366|DEVICE|PEEP|increasing PEEP or decreasing PEEP
41280494|NCT04322708|OTHER|Placebo|Placebo
41280495|NCT04322708|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
41280496|NCT05886998|DRUG|Heparin|Heparin sodium (Generic, 5000 IU/ml ampoules)
41280497|NCT05886998|OTHER|Normal Saline|0.9% sodium chloride solution (normal saline)
41280498|NCT02113293|DRUG|CyclASol®|Cyclosporine A Solution
41280499|NCT02113293|DRUG|Placebo (vehicle)|Vehicle Solution
41280500|NCT04946318|DRUG|CSJ117|CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.
41280501|NCT04946318|DRUG|Placebo|Placebo inhaled once daily for 12 or 24 weeks. Delivered via Concept1 device.
41280502|NCT00407355|DRUG|Intravitreal injection of ranibizumab .3 dose|PRN every 30 days withing retreatment criteria
41280503|NCT00407355|DRUG|Intravitreal injection of Ranibizumab .5 dose|Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria
40756214|NCT03997734|DRUG|positive comparative patch|single and repeated dosing
40756215|NCT03997734|DRUG|Placebos|single and repeated dosing
40937776|NCT02359851|BIOLOGICAL|Pembrolizumab|Given IV
40937777|NCT02359851|OTHER|Laboratory Biomarker Analysis|Correlative studies
40937778|NCT00976573|BIOLOGICAL|bevacizumab|Given IV
40937779|NCT00976573|DRUG|carboplatin|Given IV
40937780|NCT00976573|DRUG|everolimus|Given orally
40937781|NCT00976573|DRUG|paclitaxel|Given IV
40937782|NCT01871857|DRUG|Hypertonic saline and epinephrine|
40937783|NCT01871857|DRUG|Normal saline and epinephrine|
40937784|NCT05075057|BIOLOGICAL|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
40937785|NCT01589627|DEVICE|Wrist Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
40937786|NCT00644748|DRUG|gabapentin|"Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg"
40937787|NCT00145600|DRUG|12 Week Stanford V Chemotherapy|12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children
41280504|NCT02420457|PROCEDURE|Epidural injection|After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.
41280505|NCT02420457|DRUG|Epidural steroid injection as determined by routine care provider|Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
40937788|NCT00145600|DRUG|4 cycles of VAMP chemotherapy|4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
40937789|NCT00145600|DRUG|2 alternating cycles of VAMP/COP chemotherapy|2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
40937790|NCT00145600|DRUG|3 alternating cycles of VAMP/COP chemotherapy|3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
40937791|NCT00391261|DRUG|Metformin|open-label, flexible dosing
40937792|NCT05961878|DIETARY_SUPPLEMENT|mediterranean diet with adequate protein intake|balanced mediterranean diet with 1.1 g/kg die protein intake
40937793|NCT00896636|PROCEDURE|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
40937794|NCT00896636|OTHER|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
40937795|NCT03001388|PROCEDURE|Transient Elastography (TE)|Participants enrolled in Cystic Fibrosis Liver Disease Network (CFLD NET)Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) study in longitudinal follow up at centers with Fibroscan available (currently 8/11 centers)
40937796|NCT02616471|DIETARY_SUPPLEMENT|High-fat cheese|
40937797|NCT02616471|DIETARY_SUPPLEMENT|Low-fat cheese|
40937798|NCT02616471|DIETARY_SUPPLEMENT|No-cheese/carbohydrate|
40937799|NCT02861989|OTHER|qualitative study|
40937800|NCT06107231|OTHER|Honey|Honey representing 7% of total energy (kilocalorie) needs (40-70 grams)
40937801|NCT06107231|OTHER|Sucrose|Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams)
40937802|NCT06107231|OTHER|Honey plus almonds|Honey representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
40937803|NCT06107231|OTHER|Sucrose plus almonds|Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
40937804|NCT00596180|DRUG|HBOT|total body exposure to greater than atmospheric pressure oxygen
40937805|NCT05587218|BEHAVIORAL|Self-production|After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
41130949|NCT05960994|OTHER|Intervention period|"During the intervention period, three interventions will be implemented through telemedicine.~1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.~2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.~3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety."
41130950|NCT04664998|DIAGNOSTIC_TEST|Diagnostic test for NG/CT|All participants will receive diagnostic testing for NG/CT at each quarterly visit.
41130951|NCT04664998|DIAGNOSTIC_TEST|HIV testing|All participants will receive diagnostic testing for NG/CT at each quarterly visit.
41130952|NCT01581216|OTHER|10 minute walk|Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
41130953|NCT01581216|OTHER|20 minute walk|Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
40937806|NCT02669277|DRUG|IVIG prepared by minipool technology|Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
40937807|NCT02669277|DRUG|standard IVIG product|to compare efficacy and safety with the minipool IVIG
40937808|NCT00723203|DRUG|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
40937809|NCT00723203|GENETIC|gene expression analysis|Day 1 and day 28 samples
40937810|NCT00723203|GENETIC|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
41130954|NCT01581216|OTHER|30 minute walk|Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
41130955|NCT03697603|DRUG|Brexpiprazole|Tablets, Oral, once daily, 14 weeks
41130956|NCT03697603|DRUG|Placebo|Tablets, Oral, once daily, 14 weeks
40756216|NCT01468961|BEHAVIORAL|Internet-based CBT|10 weeks of internet-based CBT with online therapist contact
40937811|NCT00723203|OTHER|laboratory biomarker analysis|Day 1 and day 28 samples
40937812|NCT03158714|BEHAVIORAL|Couples Connecting Mindfully|
40937813|NCT03158714|BEHAVIORAL|ELEVATE|
40937814|NCT05935722|BEHAVIORAL|Parenting Young Children|PYC is a home-based intervention programme involving weekly, one-hour sessions over a period of at least six months. The programme has two core modules (1) Parent-Child Interaction and (2) Child Care Skills and Safety. The Parent-Child Interaction module focuses on the parent-child relationship and interaction skills such as parents' responsiveness to the child's signals, giving the child attention and encouragement, and supporting prosocial behaviour. The Child Care Skills and Safety module targets safety at home and the parent's caring skills (e.g. food, health, and hygiene). Checklists are adapted to each parent in order to support the PYC practitioner and the parent. The programme is compiled in a manual that includes work tasks, instructions for how to perform the tasks, and teaching materials.
41130957|NCT04243915|OTHER|Percutaneous neuromuscular electrical stimulation (PNMES) plus motor control exercise program|The technique consists of a muscular stimulation of the deep lumbar multifidus by means of a TENS current applied through four dry needling or acupuncture needles introduced by ultrasound guidance in said muscle 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
41280506|NCT04449861|DRUG|Durvalumab plus chemotherapy|"Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria.~Drug: Carboplatin 4-6 cycles every 3 weeks~Drug: Cisplatin 4-6 cycles every 3 weeks~Drug: Etoposide 4-6 cycles every 3 weeks"
40937815|NCT05935722|BEHAVIORAL|Treatment as Usual|TAU consists of a variety of interventions from the social services. The support will be logged and classified in accordance with the Swedish National Board of Health and Welfare's guidelines for classifications of its activities. TAU will be divided into the following five categories: 1) conversation counselling or emotional support, 2) practical support, 3) skills training, 4) compensatory strategies, and 5) other support. Support will also be classified based on whether it is home-based or given outside the home and whether it is individualised or in a group setting.
40937816|NCT03258177|OTHER|Virtual Visit|Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
41280507|NCT01073943|DRUG|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
40937817|NCT03347708|BIOLOGICAL|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
41280508|NCT01073943|DRUG|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
41130958|NCT04243915|OTHER|Sham PNMES (introducing the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
41280509|NCT01073943|DRUG|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
41130959|NCT04243915|OTHER|TENS plus motor control exercise program|Transcutaneous electrical nerve stimulation will be applied through 4 patches / adhesives placed in your lower back for 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
41130960|NCT04243915|OTHER|Sham PNMES (without inserting the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the needle will not be inserted and the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
41130961|NCT03674515|DEVICE|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
41130962|NCT03674515|DEVICE|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
41130963|NCT03170882|DRUG|Ixazomib|Ixazomib capsules
41130964|NCT03170882|DRUG|Pomalidomide|Pomalidomide capsules
41130965|NCT03170882|DRUG|Dexamethasone|Dexamethasone tablets
41130966|NCT00467272|DRUG|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
41130967|NCT04004494|OTHER|3D reconstruction|3-dimensional computed tomography reconstruction guided VATS segmentectomy
41130968|NCT05769816|DRUG|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
40744336|NCT04938947|OTHER|Low-Intensity Resistance Training|This intervention consists of performing low-intensity bilateral (both legs at the same time) leg extensions using 30% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
40937818|NCT03347708|DRUG|Saline Solution|Sodium Chloride Solution
40937819|NCT03347708|DRUG|Sodium Hyaluronate|Sodium Hyaluronate Vehicle
40937820|NCT04213521|OTHER|Multisensory balance exercise|Multisensory balance training describes a balance exercise incorporating individual sensory manipulation of vision, vestibular, proprioception and sensory integration.
40937821|NCT04213521|OTHER|Conventional balance exercise|such as static and dynamic standing balance without altered sensory inputs.
40937822|NCT04428437|DRUG|Lenvatinib|Prescribed by physician.
41130969|NCT05769816|DRUG|NAs|Once/day, 1 capsule/time, oral
41130970|NCT04080232|DEVICE|lung MRI|lung MRI (1.5T Siemens Aera) using the following sequences: 3D Fast gradient-echo pulse sequences with ultra-short echo time (UTE), acquisitions at end-inspiration breath hold, end-expiration breath hold, and free-breathing using an echonavigator positioned on the diaphragm, acquisitions using routine pulse sequences (SSFP, T2FSE) and the administration of oxygen during the MRI: O2 will be administered at 15L/min during 6 minutes.
41130971|NCT06406426|DRUG|Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin|Cadonilimab : 6mg/kg (≤375mg) d1,15 s.c. Q4W; Fruquintinib: 3mg p.o. Q.d d1-21,Q4W.; Paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
41130972|NCT00306475|DRUG|divalproex sodium ER|divalproex sodium ER1000 mg
41130973|NCT00306475|DRUG|placebo|placebo identical in appearance to active comparator
41130974|NCT01584752|PROCEDURE|Gore-BioA Fistula Plug|Gore-BioA Fistula Plug
41130975|NCT05508607|OTHER|CDI-risk Classification Tool|This tool will focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.
41130976|NCT01809275|DRUG|QBECO|
41130977|NCT01809275|DRUG|Placebo|
40937823|NCT05550610|BEHAVIORAL|Mindfulness Based Attention Training (MBAT) and Yoga|Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Participants also completed 15 minutes of group mindfulness practice 6 days/week and received information on embedded practice during the duty day. Yoga was delivered 6 days/week, 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
40937824|NCT03096145|BEHAVIORAL|Telephone counseling 1 session|1 call coaching session for nonsmokers that will be piloted and adapted in this study
40937825|NCT03096145|BEHAVIORAL|Mobile texting|nonsmokers will receive 3-5 text messages for 4 weeks
40937826|NCT03096145|BEHAVIORAL|Health incentive|Smokers receive a $25 gift card if they call the quitline
40937827|NCT03204786|DRUG|Vasopressin (USP) Injectable Solution [Vasostrict]|Nasal Spray
40937828|NCT03204786|DRUG|Placebo|Placebo Nasal Spray
40937829|NCT00321724|DRUG|cediranib maleate|Given orally
40937830|NCT00321724|OTHER|laboratory biomarker analysis|Correlative studies
40937831|NCT03671473|DEVICE|Extracorporeal shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
40937832|NCT04916782|OTHER|Quality of life Questionnaire|Quality of life questionnaire
40937833|NCT05650554|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5413|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
40937834|NCT05650554|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
40937835|NCT05650554|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
40937836|NCT05650554|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
40937837|NCT05129891|DRUG|Semaglutide D|Tablet given orally
40937838|NCT05129891|DRUG|Semaglutide G|Tablet given orally
40937839|NCT05129891|DRUG|Semaglutide H|Tablet given orally
40937840|NCT05129891|DRUG|Semaglutide I|Tablet given orally
40937841|NCT05129891|DRUG|NNC0385-0434 B|Tablet given orally
41280510|NCT01689558|DRUG|Recombine Endostatin|Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
41280511|NCT00987415|DRUG|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
41280512|NCT00987415|DRUG|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
41453587|NCT01150422|OTHER|Alternative follow-up|After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
41453588|NCT00131417|DRUG|ready-to-use therapeutic food|
40937842|NCT05129891|DRUG|NNC0385-0434 C|Tablet given orally
40937843|NCT05129891|DRUG|NNC0385-0434 D|Tablet given orally
40937844|NCT05129891|DRUG|NNC0385-0434 E|Tablet given orally
40937845|NCT02808871|DRUG|Pirfenidone|Pirfenidone three times daily (2403 mg) for 52 weeks
40937846|NCT02808871|DRUG|Placebo|Placebo three times daily for 52 weeks
40937847|NCT03149510|BEHAVIORAL|Mobile Application|Participants will use the mobile application daily to assess heart failure symptoms.
40937848|NCT01362868|DEVICE|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
40937849|NCT04617535|DRUG|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
40937850|NCT05712876|DRUG|CK-0045|Interleukin-22 agonist
40937851|NCT05712876|DRUG|Placebo|Matching placebo
40937852|NCT02435069|DRUG|Dose Response - NS and USP Glycerin - First Intervention|This trial used a repeated measures, single subjects alternating treatments A-B-C-B'-C'-B1' withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.
40937853|NCT02435069|DRUG|Effectiveness - NS and USP Glycerin - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase B'-C'-B1' of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
40937854|NCT01759485|DRUG|Vitamin D3|once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
40937855|NCT01759485|DRUG|placebo|
40937856|NCT04526990|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
40937857|NCT04526990|BIOLOGICAL|Placebo|Intramuscular administration
40937858|NCT00095628|DRUG|ispinesib|Given IV
40937859|NCT00095628|OTHER|laboratory biomarker analysis|Correlative studies
40937860|NCT00095628|OTHER|pharmacological study|Correlative studies
40937861|NCT05542134|DIAGNOSTIC_TEST|P2Y12 Platelet Aggregation Inhibitor|Verify now PRU test
40937862|NCT01778777|DEVICE|Universe Reverse Prosthesis|Implantation of an universe reverse prosthesis
40937863|NCT00295828|OTHER|Pegaptanib Sodium Injection/Panretinal Photocoagulation|Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
40937864|NCT00295828|PROCEDURE|Panretinal Photocoagulation (PRP)|Ocular Laser Procedure
40937865|NCT00253500|BIOLOGICAL|pegfilgrastim|6 mg in a syringe
40937866|NCT00253500|DRUG|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
40937867|NCT00253500|PROCEDURE|conventional surgery|to remove small piece of cancer
40937868|NCT04638673|DEVICE|Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.
40937869|NCT04638673|DEVICE|Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group|Participants will receive sham taVNS stimulation for weeks 1\&2 and active stimulation for weeks 3\&4 of the stimulation portion of this study.
40937870|NCT00553865|DRUG|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
40937871|NCT05350735|BEHAVIORAL|Intervention arm: SMS text reminders and medical card|This study arm will assess compliance with anti-rabies vaccine regimen by participants in the presence of SMS text reminders as compared to without the SMS reminder.
40937872|NCT04473625|OTHER|Stool Sample Collection|Subjects participating in the study will provide a stool sample within 30 days of enrollment.
40937873|NCT00650234|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
41453589|NCT02803827|OTHER|Rapid diagnostics|Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
40937874|NCT00650234|DRUG|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
40756217|NCT01978015|DRUG|travoprost and timolol maleate fixed combination|travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
40937875|NCT06404424|DEVICE|Efferon LPS|"Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of sepsis to improve hemodynamic function and abrogate septic shock.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption"
40937876|NCT06404424|DEVICE|Efferon CT|"Efferon CT, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that adsorbs excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of cytokine storm syndrome in the course of severe SARS-CoV-2.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption"
40937877|NCT04025281|OTHER|Extra Virgin Olive Oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
41130978|NCT05568381|DEVICE|digital CBT-I|Sleepio is a digital cognitive behavioral therapy (CBT) program designed to treat insomnia. The program is fully automated, and its underlying algorithms drive the delivery of information, support, and advice.
41130979|NCT05568381|OTHER|Online Sleep Health Education package|Wait-listed control participants will have full access to three online modules for the duration of the study. The information in these modules will provide non-tailored basic sleep information and content will contain text and basic images but will not be personalised to the individual participant.
41453590|NCT02803827|BIOLOGICAL|Probiotic|The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
41453591|NCT02803827|OTHER|Placebo|The placebo will be the vegetable oil vehicle and look identical to the probiotic.
41453592|NCT00075608|BIOLOGICAL|filgrastim|16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
41453593|NCT00075608|DRUG|melphalan|140-200 mcg/kg IV over two days
40756218|NCT01978015|DRUG|latanoprost and maleate timolol fixed combination|Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
40756219|NCT01978015|DRUG|bimatoprost and timolol maleate fixed combination|bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
40756220|NCT01978015|DRUG|dextran and hypromellose|Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
40756221|NCT06494371|BIOLOGICAL|LCAR-HL30 cells|Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
40937878|NCT04025281|OTHER|Refined Olive Oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
40937879|NCT05261451|OTHER|Workshop|Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops
40937880|NCT02856893|DRUG|Osimertinib|Osimertinib 60 or 40 mg daily until progression
40937881|NCT02856893|DRUG|Gefitinib|Gefitinib 250mg daily until progression
40937882|NCT01272284|DEVICE|Altis® Single Incision Sling System (SIS)|The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
40937883|NCT01387399|PROCEDURE|Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion|"Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)"
40937884|NCT03857906|DEVICE|Intra-Aortic Ballon Pump insertion|The IABP (Ultraflex IAB 7.5F, 2.5mm; Arrow International, Reading, PA) was inserted percutaneously through the right femoral artery in the previous 1 - 6 hours before the scheduled surgery. Positioning of the IABP was guided by radioscopy. The balloon size was based on the patient's height (30, 40 or 50 cc). Transesophageal echocardiography was used to confirm correct IABP placement before and after CABG
41130980|NCT06162702|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
41130981|NCT04518813|DEVICE|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
41130982|NCT01974258|DRUG|Cobimetinib|Escalating dose
40937885|NCT01816841|PROCEDURE|fluorescence imaging|Undergo DVFE
41130983|NCT01974258|DRUG|Cobimetinib|Orally administered once daily for 21 consecutive days, followed by 7 days off.
41130984|NCT01974258|DRUG|Onartuzumab|Administered by IV infusion every 2 weeks
41280513|NCT05824910|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions
40937886|NCT01816841|PROCEDURE|biopsy|Undergo scalpel biopsy
41130985|NCT01974258|DRUG|Vemurafenib|Orally administered twice daily
41130986|NCT03470805|DRUG|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
41280514|NCT01409317|DEVICE|Deep Transcranial Magnetic Stimulation|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
40937887|NCT01816841|PROCEDURE|examination|Undergo COE
40937888|NCT01816841|PROCEDURE|Comparison of surgical margins by COE vs. DVFE|Surgical margin determination using DVFE
40937889|NCT00164229|BEHAVIORAL|math|
40937890|NCT00164229|BEHAVIORAL|behavior regulation|
40937891|NCT04119154|DIAGNOSTIC_TEST|Contrast Microhalography (CEM)|Fine needle aspirates evaluated by CEM device
40937892|NCT04205994|DRUG|Tolcapone 200 MG|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in randomized, double-blind, counterbalanced fashion with a placebo.
40937893|NCT04205994|OTHER|Functional Magnetic Resonance Imaging (fMRI)|FMRI provides an indirect and noninvasive measure of brain activity.
40937894|NCT00630474|DRUG|xylometazoline|xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
40937895|NCT06427915|OTHER|OLIPOP prebiotic soda|12oz serving containing Carbonated Water, OLISMART(TM) (Cassava Root Fiber, Acacia Fiber, Guar Fiber, Nopal Cactus\*, Marshmallow Root\*, Calendula Flower\*, Kudzu Root\*), Cassava Root Syrup, Apple Juice Concentrate, Lime Juice, Natural Cola Flavor, Alpinia Galanga Root\*, Stevia Leaf\*, Himalayan Pink Salt, Green Tea Caffeine\*, Natural Caramel Flavor, Natural Vanilla Flavor, Cinnamon\* (\*Extract)
40937896|NCT06427915|OTHER|Traditional sugar-sweetened cola|12oz serving containing carbonated water, high fructose corn syrup, caramel color, phosphoric acid, natural flavors, caffeine
40937897|NCT05983887|OTHER|Therapeutic Climbing|The protocol consists of using an in-door climbing wall as an complementary therapeutic intervention model.
40937898|NCT01440062|DRUG|Verum arm receiving Vitamin D oil|oil: 20000 IU/g tablet: 400 IU/g every second day
40937899|NCT01440062|DRUG|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day|neutral oil and a low dose of vitamin D
40937900|NCT03729973|DRUG|Ketamine|Patients nebulized ketamine by compressor nebulizing for 15 minutes.
40937901|NCT03729973|DRUG|Magnesium Sulfate|Patients nebulized magnesium sulfate 250mg (3ml)plus 2ml normal saline by compressor nebulizing for 15 minutes.
40937902|NCT03729973|DRUG|Lidocaine|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized lidocaine 5ml by compressor nebulizing for 15 minutes."
41280515|NCT01409317|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
41280516|NCT02646475|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
41280517|NCT02646475|DRUG|Saline|Normal saline will be used as a placebo comparator.
41453594|NCT00075608|PROCEDURE|autologous stem cell transplantation|infusion of previously collected stem cells on Day 0
40937903|NCT03729973|DRUG|Normal saline|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes."
40937904|NCT03470571|DIAGNOSTIC_TEST|CMR|Outcome analysis of CMR features in suspected myocarditis patients
40937905|NCT00558571|DRUG|BI 10773 low dose|
40937906|NCT00558571|DRUG|placebo to BI 10773|
40937907|NCT00558571|DRUG|BI 10773 medium dose|
40937908|NCT00558571|DRUG|BI 10773 high dose|
40937909|NCT01875003|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at high or low dose Q4W.
40937910|NCT01875003|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection Q4W.
40937911|NCT01875003|DRUG|Standard of Care|Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
40937912|NCT01159977|BEHAVIORAL|Facilitated small groups|1 hour sessions every 2 weeks for small groups of 9 participants, 19 sessions over 9 months.
40937913|NCT01159977|BEHAVIORAL|Unstructured time.|1 protected hour every 2 weeks for 9 months, without small group structure.
40937914|NCT01159977|BEHAVIORAL|Usual practice|No protected time provided.
40937915|NCT04705038|BEHAVIORAL|Patient Education|Brief educational session on surgical castration as an alternative to lifelong ADT for prostate cancer.
40937916|NCT03641885|BEHAVIORAL|mothers and adolescents|The intervention package will be sent to mothers and adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
40937917|NCT03641885|BEHAVIORAL|adolescents|The intervention package will be sent to only adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
40937918|NCT03641885|BEHAVIORAL|active control|The active control group receives an information sheet regarding recommendations on oral health behavior via telegram. There will be 3 assessment points in time, with 1 month and six months in between.
40937919|NCT00225303|DRUG|TMC125|
40937920|NCT00745576|DRUG|SAM-531|
40937921|NCT03986515|DRUG|apatinib plus SHR-1210|apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w
40937922|NCT01600508|OTHER|Videoconference stoma care|Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
40937923|NCT04680676|DRUG|BI 730357|BI 730357
40937924|NCT04680676|DRUG|Placebo|Placebo
40937925|NCT03858231|DRUG|Norco 5Mg-325Mg Tablet|1 tablet up to 4 times per day for 7 days
40937926|NCT03858231|DRUG|Ibuprofen 600 mg|1 tablet up to 4 times per day for 7 days
40937927|NCT03858231|DRUG|Acetaminophen 325Mg Tab|1 tablet up to 4 times per day for 7 days
40937928|NCT01753804|OTHER|Observational study|There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
40937929|NCT00411931|DRUG|Multihance|0.5M administered as a single injection
40937930|NCT02016339|BEHAVIORAL|Standard care|24-h consultation telephone line to the sleep nurses to answer questions regarding CPAP usage. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic by the nurse. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy.
40937931|NCT02016339|BEHAVIORAL|Intensive care|Standard group care plus: Involvement of the patient's partner or family necessary. Extra education on sleep apnea and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses after CPAP titration study. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence
40937932|NCT03455049|OTHER|Andrographis Paniculata Ext|Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
40937933|NCT01467583|DRUG|Fondaparinux|2.5 mg every 48 hours
40937934|NCT06424665|DRUG|FZ-AD005|Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
41280518|NCT03263806|DIAGNOSTIC_TEST|CTFFR-Guided Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results will be communicated to the provider who will use CTFFR interpretation to guide care pathway.
40937935|NCT05592834|BEHAVIORAL|positive deviance hearth strategy|"The PD-program is run for 3-months with 2 weeks (12 days) of nutrition education and rehabilitation sessions (NERS) conducted in each month. Each day session includes an half hour education session and a one and half hour peer led cooking session. Caretakers learn how to rehabilitate their malnourished children under the supervision and the support of caregivers who have well-nourished children (positive deviants). Children are nutritionally assessed by trained nutrition assistants or clinician on the 1st day of the NERS sessions and after three months.~During the rehabilitation sessions, caregivers learn how to prepare nutrient-rich meals for their children from locally available food identified during the positive deviance-inquiry, and actively practice good feeding and hygiene practices. Caregivers together prepare food menus based on the PD-inquiry good foods or what they can conveniently access but of equal nutritional value."
40937936|NCT05592834|BEHAVIORAL|Parent facilitator trainings|Primary caregivers of children with CP residing in the study setting are trained as parent facilitators by expert physical rehabilitation therapist . Trained parent facilitators then hold fellow caregiver workshops each lasting approximately two hours long and includes between 6-10 caregivers. To ensure quality and consistency of the workshops, the Parent Facilitators follow a detailed manual adapted from the Carer-2-Carer Programme translated into Lusoga, the local language. No expert therapists is involved in the parent facilitator training workshops. Parent facilitator training workshops involve 7 sessions that expose caregivers to understanding CP and how to improve body functioning: session1: what is CP? session2: CP as a way of life, Session 3: Getting my child's body ready to move, Session 4: Eating and drinking a healthy diet, Session 5: communication, Session 6: Play, and Session 7: Central visual impairment.
40937937|NCT05592834|OTHER|Control|This group will receive neither the PD nor the PFT interventions but care as usual
40937938|NCT06206070|BEHAVIORAL|The Hong Kong version of Westmead Feeling Program 2|Westmead Feelings Program (WFP) is a manualized emotion-based learning intervention for children on the autism spectrum. WFP teaches autistic children how to understand their own and other's emotions, solve problems, and regulate emotions through the implementation of transactional support. In doing so, parents and teachers are also trained to develop their emotional coaching skills to support children in everyday settings. Its impact on improving emotional competence in primary school-aged children on the autism spectrum has been established in 41 mainstream schools in Australia.
40937939|NCT05857228|PROCEDURE|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery for removal of nasal polyps and sinus tissue.
40937940|NCT04245371|DRUG|Lidocaine 1.8%|Topical Patch
40937941|NCT04245371|DRUG|Placebo|Matching Placebo Patch
40937942|NCT05730634|DRUG|Atorvastatin 40 Mg Oral Tablet|Atorvastatin 40mg once daily for three months
41280519|NCT03263806|DIAGNOSTIC_TEST|SOC Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results are NOT communicated to the provider who will dictate patient management according to their own clinical judgment
41280520|NCT04881838|DRUG|P regimen|Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1
41280521|NCT04881838|DRUG|Course A1 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
41450574|NCT00013390|PROCEDURE|Tinnitus Retraining Therapy|"Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at retraining brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus signal to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted."
41450575|NCT03399539|DRUG|Dexamethasone|Given PO
41450576|NCT03399539|DRUG|Ixazomib Citrate|Given PO
40937943|NCT00883844|DRUG|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
40937944|NCT00883844|DRUG|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
40937945|NCT03249493|OTHER|Blood sample on DBS|"We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.~HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results \> 1000 cp/mL"
40937946|NCT06402084|DIAGNOSTIC_TEST|abdominal ultrasound|abdominal ultrasound and lipid profile will be done
40937947|NCT00272727|BEHAVIORAL|Dialog tool for caregivers|
40937948|NCT00995865|BIOLOGICAL|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10\^8 VE/0.5mL and Mid dose = 2.2 x 10\^7 VE/0.5mL
40937949|NCT00995865|BIOLOGICAL|Placebo|NaCl Injectable 0.9%
40937950|NCT01236118|DRUG|LY2439821|Administered subcutaneously
40937951|NCT02186132|DRUG|Atropine 0.6 mg|Atropine 0.6 mg intravenous
40937952|NCT02186132|DRUG|Atropine 1.2 mg|Atropine 1.2 mg intravenous
40937953|NCT06329089|PROCEDURE|Reoperative Sentinel Lymph Node Biopsy|Reoperative sentinel lymph node biopsy refers to a surgical procedure performed when there is a need to re-examine the sentinel lymph nodes (SLNs) in patients who have previously undergone breast cancer surgery. The sentinel lymph nodes are the first lymph nodes to which cancer cells are likely to spread from the primary tumor. During the procedure, the surgeon locates and removes the previously identified sentinel lymph nodes using techniques such as lymphatic mapping and injection of a radiotracer or dye. The removed lymph nodes are then examined by a pathologist to determine if there is any evidence of cancer spread.
40937954|NCT01230710|DRUG|Erlotinib|Erlotinib was supplied as tablets.
40937955|NCT03415854|DRUG|Paricalcitol (Zemplar)|combination therapy
40937956|NCT01507454|DRUG|estradiol, 25 mcg|Vaginal tablets for 6-12 weeks according to product labelling
40937957|NCT01056328|DEVICE|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
40937958|NCT01056328|DEVICE|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
40937959|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation A|Memantine HCl MR capsule formulation will be administered orally in a single dose
40937960|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation B|Memantine HCl MR capsule formulation will be administered orally in a single dose
40937961|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation C|Memantine HCl MR capsule formulation will be administered orally in a single dose
40937962|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation D|Memantine HCl MR capsule formulation will be administered orally in a single dose
40937963|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation E|Memantine HCl MR capsule formulation will be administered orally in a single dose
40937964|NCT03468543|PROCEDURE|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
40937965|NCT06083935|DRUG|Daflon|Daflon; two film coated tablets 500 mg daily
40937966|NCT06083935|DRUG|Combined oral contraceptive|Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily
40937967|NCT06083935|DRUG|Metformin|Glucophage ® 500 tablets twice daily
40937968|NCT02812355|DRUG|Heparin|
40937969|NCT00084838|BIOLOGICAL|filgrastim|
41450577|NCT03399539|OTHER|Laboratory Biomarker Analysis|Correlative studies
40937970|NCT00084838|DRUG|cisplatin|
40937971|NCT00084838|DRUG|cyclophosphamide|
41450578|NCT03399539|DRUG|Venetoclax|Given PO
40937972|NCT00084838|DRUG|cytarabine|
40937973|NCT00084838|DRUG|dexrazoxane hydrochloride|
40937974|NCT00084838|DRUG|doxorubicin hydrochloride|
40937975|NCT00084838|DRUG|etoposide|
40937976|NCT00084838|DRUG|leucovorin calcium|
40937977|NCT00084838|DRUG|methotrexate|
40937978|NCT00084838|DRUG|temozolomide|
40937979|NCT00084838|DRUG|therapeutic hydrocortisone|
40937980|NCT00084838|DRUG|vincristine sulfate|
40937981|NCT00084838|RADIATION|radiation therapy|
40937982|NCT00084838|DRUG|Dactinomycin|
40937983|NCT06515522|OTHER|differential diagnosis|this is a retrospective observational study. no intervention has been or will be performed
40937984|NCT04151342|DRUG|Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.|Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
40937985|NCT04151342|OTHER|Patient-reported outcomes (PROs)|Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
40937986|NCT00773916|DRUG|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
40937987|NCT02514473|DRUG|VX-809|
40937988|NCT02514473|DRUG|Placebo|
40937989|NCT02514473|DRUG|VX-770|
40937990|NCT05407753|DIETARY_SUPPLEMENT|Ketone ester|Subjects receive the ketone ester at the following timepoints: 25g before ultrarun, 12.5g every 30 min during race, 25g immediately after race, 25g before sleep, 3 x 25g on day after race.
40937991|NCT05407753|DIETARY_SUPPLEMENT|Placebo|Subjects receive a non-caloric taste-matched placebo (water with sucrose octaacetate)
40937992|NCT00219167|DRUG|aliskiren|
40937993|NCT02524210|DRUG|Dabigatran|dabigatran etexilate 150 mg/day (1 day)
40937994|NCT02524210|DRUG|Rabeprazole and Dabigatran|rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
40937995|NCT02524210|DRUG|Omeprazole and Dabigatran|omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
41450579|NCT00592579|DRUG|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
41450580|NCT05361941|DEVICE|EP Granules with Tobramycin|EP Granules with Tobramycin is a Ca-salt resorbable intended for orthopedic applications as a bone void filler for bone gaps or voids and in cases where risk of post-operative infection is high, such as the first stage of a two-stage revision of an infected total joint.
41450581|NCT05361941|DEVICE|empty voids|Voids are left empty
41450582|NCT01847235|DRUG|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
41450583|NCT03544216|DEVICE|Multifocal Contact Lens|The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks
41453595|NCT00075608|PROCEDURE|stem cell infusion|infusion of previously collected stem cells on Day 0
41130987|NCT05320874|BIOLOGICAL|KM257 Bispecific antibody|"Part 1a dose escalation:~There will be 3 increasing dose levels (3mg/kg,6mg/kg,12mg/kg). Patients will be intravenously administrated with one dose of KM257, QW for continuous cycles of 21 consecutive days for each cycle. The dosing interval may be adjusted during the study based on emerging data from this trial.~Part 1b dose expansion:~Part1b:For cohort 1 and cohort2, KM257 will be given at the RP2D identified in Part1a;~For cohort 3 to 7:KM257 will be given combined with one of the following selected drug combination:~Drug: Capecitabine Combination therapy with KM257 - Cohort 3~Drug: Paclitaxel or Docetaxel or Irinotecan Combination therapy with KM257 - Cohort 4~Drug: Gemcitabine+Cisplatin Combination therapy with KM257 - Cohort 5~Drug: Gemcitabine+Cisplatin or Carboplatin Combination therapy with KM257 - Cohort 6~Drug:Carboplatin+Paclitaxel Combination therapy with KM257 - Cohort 7"
41130988|NCT05438992|DRUG|Bupivacaine 0.25% Preservative-Free Injectable Solution|local anesthetic drug injection for postoperative pain
41130989|NCT05144984|DRUG|NNC0480-0389|A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.
41130990|NCT05144984|DRUG|Semaglutide|A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.
41130991|NCT05144984|DRUG|Placebo (NNC080-0389)|A weekly dose of placebo (NNC0480-0389). The study will last for about 41weeks.
41450584|NCT03544216|DEVICE|Single Vision Contact Lens|The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks
41450585|NCT00629304|DEVICE|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
41450586|NCT00629304|DEVICE|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
41450587|NCT00629304|DEVICE|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
41450588|NCT01960296|DRUG|Clopidogrel|Continue home dose of clopidogrel into surgery
41130992|NCT05144984|DRUG|Placebo (semaglutide)|A weekly dose of placebo (semaglutide). The study will last for about 41weeks.
41130993|NCT02696200|DEVICE|Q Collar|The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
41450589|NCT01960296|DRUG|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
41450590|NCT03708133|DRUG|Nifurtimox (Lampit, BAYA2502)_Test|Orally intake of 1 \*120mg new formulation tablet as test treatment
41450591|NCT03708133|DRUG|Nifurtimox (Lampit, BAYA2502)_Reference|Orally intake of 1 \*120mg current clinical formulation tablet as reference treatment
41453596|NCT06272877|OTHER|Fluidotherapy|Fluidotherapy is a dry environment created by mobilizing solid particles using heated air flow. Fluidotherapy will be applied 20 minutes a day, 5 days a week for 4 weeks.
41450592|NCT04060251|DEVICE|CyMedica e-vive™ System; CY-1000|"All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical."
41130994|NCT01670474|DRUG|rt-PA (2mg/2mL) actilysis|At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
41130995|NCT01670474|DRUG|rt-PA|At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
41130996|NCT02845466|BIOLOGICAL|Becaplermin|0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
41130997|NCT02845466|DEVICE|Promagran Dressing|44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.
41130998|NCT02845466|DEVICE|Placebo Dressing|Inactive wound dressing.
41130999|NCT03711084|DIETARY_SUPPLEMENT|Natural high potency sweetener from leaf extract|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
41131000|NCT03711084|DIETARY_SUPPLEMENT|Glucose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
41131001|NCT03711084|DIETARY_SUPPLEMENT|Sucrose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
41280522|NCT04881838|DRUG|Course B1 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
41450593|NCT04060251|OTHER|iGetBetter telemedicine physical therapy|Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
41450594|NCT03153605|OTHER|Common toothpaste|different toothpaste
40937996|NCT05965297|DEVICE|DeltaFil|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using DeltaFil conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (DeltaFil). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
40937997|NCT05965297|DEVICE|Riva Self Cure HV|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using Riva conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (Riva Self Cure HV). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
40937998|NCT00185770|BEHAVIORAL|Reducing television and other screen time (SMART curriculum)|
40937999|NCT00569829|BEHAVIORAL|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
41450595|NCT06595342|OTHER|No intervention|no intervention
40938000|NCT00785967|BIOLOGICAL|Various vaccines|VAQTA: 1.0ml IM at weeks 24 \& 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
40938001|NCT01668927|DRUG|Proton Pump Inhibitor|
40938002|NCT01668927|DRUG|Bismuth|
40938003|NCT01668927|DRUG|Metronidazole|
40938004|NCT01668927|DRUG|Tetracycline|
40938005|NCT01668927|DRUG|Furazolidone|
40938006|NCT01668927|DRUG|Amoxicillin|
40938007|NCT04017247|DRUG|Oxytocin|Intermittent oxytocin Infusion
40938008|NCT04017247|DRUG|Oxytocin|Continous oxytocin Infusion for 16 hours
40938009|NCT00744458|OTHER|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
41131002|NCT03711084|DIETARY_SUPPLEMENT|Maltodextrin|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
41280523|NCT04881838|DRUG|Course A2 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
40756222|NCT04727827|OTHER|Pharmacogenomic-guided supportive care|Patients undergoing hematopoietic stem cell transplantation will be genotyped and supportive care therapies tailored to identified drug-gene pairs and guideline recommendations
40756223|NCT04859686|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR program included weekly 2.5-hour sessions in a group format over eight weeks, plus a 1-day retreat. Formal practices included several types of meditation, such as mindful breathing, sitting meditation, walking meditation, gentle hatha yoga, body scan, and mindful awareness. Participants were asked to practice at home for 20 minutes daily, six days a week.
40756224|NCT04859686|PROCEDURE|Acupuncture Treatment|"Participants received two treatments per week over eight weeks, 35-40 minutes each.~At each treatment, participants were treated with 10 body and two ear points: seven major points on either the front or back of the body. The treatment position alternated between sessions, such that the first session was on the back, with the next session on the front, unless a physical limitation prevented alternation."
41131003|NCT03711084|DIETARY_SUPPLEMENT|Water|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
41131004|NCT00192218|BIOLOGICAL|FluMist|0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
41131005|NCT05082636|OTHER|Observational Study ( Tissue Biopsy )|control study includes a total of 90 subjects. Of them 54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital, besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).obtained by fiberoptic bronchoscopy
41131006|NCT01006538|DEVICE|Epimacular Brachytherapy|Strontium-90. The device delivers 24 Gray of beta radiation to the choroidal neovascular membrane (CNV) lesion. Each device is calibrated for a set duration.
41131007|NCT01006538|DRUG|Ranibizumab|intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
41131008|NCT04411888|OTHER|observation|observation
41131009|NCT04233905|BEHAVIORAL|Psychometric questionnaire study|Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.
41131010|NCT06251336|OTHER|UroialTM Plus|Nutraceutical
41131011|NCT06251336|OTHER|Placebo|Placebo sachet
41131012|NCT00532116|DRUG|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
41131013|NCT00532116|DRUG|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
41280524|NCT04881838|DRUG|Course B2 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
41450596|NCT02802852|DEVICE|Pneumatic calf compression|Application of a pneumatic calf compression device for two hours per day, every day for 30 days.
41450597|NCT02802852|DRUG|Filgrastim|Administration of Filgrastim 10 mcg/kg every 3rd day for 30 days
40756225|NCT03623490|OTHER|managment of oral therapy|Initial consultation with a trio oncologist / pharmacist / nurse
40756226|NCT06220253|PROCEDURE|vaginal hysterectomy by bipolar vessels sealing|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be coagulated and cut by a bipolar vessel sealing instrument
40756227|NCT06220253|PROCEDURE|vaginal hysterectomy by traditional technique|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be sutured by absorbable threads
40756228|NCT05725525|BEHAVIORAL|Remote PCIT augmented with wearable devices|Participants will be enrolled in remote PCIT and be asked to wear a Garmin watch throughout the course of the study in order to measure biometric fluctuations
40756229|NCT03889015|DIETARY_SUPPLEMENT|Probiotic yogurt|Probiotics are found in different dairy products including yoghurt, that are known as carriers of probiotics. These products can be easily integrated in daily meals to reduce cariogenic streptococcus mutans bacteria in dental biofilm
41450598|NCT04626440|PROCEDURE|Diagnostic stage or the Clinical outcome|After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.
41453597|NCT06272877|OTHER|conventional rehabilitation program|The conventional rehabilitation program determined before the study will be implemented by a physiotherapist in the hospital for 6 weeks.
41453598|NCT01287351|DRUG|extra-fine hydrofluoroalkane beclometasone dipropionate|
40744337|NCT04938947|OTHER|High-Intensity Resistance Training|This intervention consists of performing high-intensity bilateral (both legs at the same time) leg extensions using 80% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
40744338|NCT03447145|DRUG|TQ-B3203|dose escalation, 2/4/6/10/14/18mg/m2
40744339|NCT06359522|DEVICE|NIRS monitor|NIRS monitoring data will be collected to determine organ perfusion.
40938010|NCT00744458|OTHER|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
40938011|NCT00744458|OTHER|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
40938012|NCT04735458|OTHER|Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
40938013|NCT00696683|OTHER|None, this is an observational study|
40938014|NCT02280473|DRUG|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
40938015|NCT02280473|DRUG|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
40938016|NCT00505882|DRUG|Pramlintide|Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.
40938017|NCT00505882|DRUG|Glargine|
40938018|NCT00505882|DRUG|Lispro|
40938019|NCT00505882|DRUG|Aspart|
40938020|NCT05791370|DIETARY_SUPPLEMENT|A 12-week parallel dietary intervention|Subjects consumed 3 isocaloric meals prepared with the 3 oils for a duration of 12 weeks. The test meals were given for 5-day a week and contained 27-30% energy fat, with 2/3 (20% energy fat) replaced by experimental fat.
40938021|NCT05585788|DEVICE|Addinex Device (ADX-27)|"The device operates without the use of any electronics, wireless or firmware requirements. This is achieved through its mechanical system which uses a different randomized passcode for each dose that is loaded into a circular drum inside the device. The passcodes are provided by an online server through either a mobile app, web app, text service or call in service. The online server provides passcodes on a request basis, while following instructions set by the treating physicians."
40938022|NCT02325856|DEVICE|Bioimpedance Spectroscopy|Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.
40938023|NCT02325856|BEHAVIORAL|Clinical judgement|
40756230|NCT03889015|DIETARY_SUPPLEMENT|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
40938024|NCT06059118|DRUG|DFMO|Each 119 day cycle, Days 1-7 patient will take 1000 mg by mouth (PO) twice a day (bid), and then on Day 8 - 63 patient will take 1000 mg PO bid while receiving high dose testosterone IM on Day 8 and Day 36 of cycle.
40938025|NCT06059118|DRUG|testosterone cypionate|On Day 8 and Day 36 of each 119 day cycle, patient will receive high dose testosterone at 400 mg through intramuscular (IM) injection.
40938026|NCT06059118|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Patients who have progressive disease after treatment with Abiraterone (Abi) will continue with androgen depravation therapy (ADT) with LHRH analogue (LHRH agonist drug (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist drug (Degarelix or Relugolix)). Dosing instructions will vary between the different LHRH analogues. Patients should follow the dosing instructions as directed by their physician.
40938027|NCT06059118|DRUG|Enzalutamide|Each 119 day cycle, Days 64-119 patient will take 160 mg by mouth (PO) once a day (qd).
40938028|NCT02854410|DIETARY_SUPPLEMENT|Sodium nitrate|Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid
40938029|NCT02854410|DIETARY_SUPPLEMENT|sodium chloride|Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid
40938030|NCT02399007|DEVICE|Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)|SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
41280525|NCT04881838|DRUG|Course A3 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
41280526|NCT04881838|DRUG|Course B3 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
41280527|NCT04881838|DRUG|Maintenance therapy|Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
41280528|NCT04630054|DEVICE|Face mask|Intervention individuals will be given cloth or surgical face masks.
41280529|NCT04630054|BEHAVIORAL|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
41280530|NCT05293418|OTHER|data collection|data collection from medical records and the microbiological surveillance system of the enrolled patients
41280531|NCT04351659|OTHER|Blood donation from convalescent donor|Donation of 1 unit of blood or leukapheresis
41280532|NCT02426866|DRUG|Efavirenz|
41280533|NCT03183570|DRUG|[18F]FP-R01-MG-F2|7mCi (range 6-9mCi) \[18F\]FP-R01-MG-F2 will be administered
41280534|NCT05502289|DEVICE|TEST LENS|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
41280535|NCT05502289|DEVICE|CONTROL LENS|PRECISION1™ for Astigmatism Contact Lenses (P1fA)
41280536|NCT03617926|DEVICE|X92001666|the X92001666 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
41453599|NCT01287351|DRUG|Fluticasone propionate|
41131014|NCT03961451|DEVICE|Podometer|Patients will be equipped with pedometers for 8 weeks, all day and must complete the number of steps each day. They will have to complete online evaluation questionnaires regularly. The main objective is to correlate the level of physical activity with the level of fatigue, quality of life and well-being weekly during an anticancer treatment.
41131015|NCT02379000|DRUG|Triamcinolone Acetonide|Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
41131016|NCT02379000|PROCEDURE|Transpupillary thermotherapy|We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
41131017|NCT00309036|BIOLOGICAL|Recombinant grass pollen|
41131018|NCT01357512|DEVICE|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
41131019|NCT00877305|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
41131020|NCT00877305|OTHER|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
41131021|NCT00649857|DRUG|Cetirizine HCl Tablets 10 mg|10mg, single dose fed
41131022|NCT00649857|DRUG|Zyrtec® 10 mg|10mg, single dose fed
41131023|NCT03670121|DEVICE|Bronchoscopic Thermal Vapor Ablation (BTVA)|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
41131024|NCT02428556|OTHER|Facts only|Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
41131025|NCT02428556|OTHER|promising language|"Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)"
41131026|NCT02428556|OTHER|breakthrough only|Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
41131027|NCT02428556|OTHER|"breakthrough with may warning"|"Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials"
41131028|NCT02428556|OTHER|"breakthrough with is warning"|"Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials."
41131029|NCT00944593|DIETARY_SUPPLEMENT|Jejunal Feed|Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)
41131030|NCT00944593|DIETARY_SUPPLEMENT|Normal Saline|200ml Normal Saline 0.9%
41131031|NCT04124887|DRUG|Sodium Fluoride|Sodium Fluoride varnish was applied to the targeted teeth at baseline, one and three months.
41131032|NCT04124887|DRUG|Tricalcium Phosphate|Varnish with Tricalcium Phosphate was applied to the targeted teeth at baseline, one and three months.
41131033|NCT04124887|DRUG|Xylitol-coated calcium and phosphate|Varnish with Xylitol-coated calcium and phosphate was applied to the targeted teeth at baseline, one and three months.
41450599|NCT01880476|OTHER|Home visits and group program|Participants will receive up to three home visits by a Registered Nurse and two home visits by a Registered Dietitian over the 6-month intervention period. Participants will also be invited to attend a monthly Diabetes Wellness Day group program which will include diabetes education, interaction with peer volunteers, group exercise, and a meal. The Registered Nurse will coordinate care to help participants access necessary community supports and services and lead monthly interprofessional case conferences to develop a client-centred plan of care for each study participant.
41131034|NCT04124887|DRUG|Casein phosphopeptide amorphous calcium phosphate|Varnish with Casein phosphopeptide amorphous calcium phosphate was applied to the targeted teeth at baseline, one and three months.
41131035|NCT05028933|DRUG|EPCAM CAR-T|Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion
40938031|NCT02399007|DEVICE|Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)|Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
41131036|NCT05562102|BIOLOGICAL|Typbar-TCV, Bharat Biotech|Typhoid conjugate vaccine
41131037|NCT01583868|DEVICE|B&L RD2135-01 lens C|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
41131038|NCT01583868|DEVICE|B&L RD2135-01 lens D|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
41131039|NCT01583868|DEVICE|PureVision2|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
41450600|NCT05391451|PROCEDURE|efficacy of quadratus lumborum block in post-operative analgesia in kidney transplant surgery|no premedication for anxiolytic purposes before surgery. Cimetidin 200mg can be administrated for Mendelson syndrome prevention. After general anesthesia induction, echo-guided quadratus lumborum block is performed by applying 20ml of levobupivacaine
41131040|NCT01583868|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
41131041|NCT05274321|DEVICE|Nanodropper|Device used for administering eye drops
41131042|NCT05274321|DEVICE|Standard Eye Dropper|Standard Eye Dropper used for administering eye drops
41131043|NCT02282709|DRUG|Daclatasvir|60 mg once daily
41131044|NCT02282709|DRUG|asunaprevir|100 mg BID
41131045|NCT01020266|PROCEDURE|non electroacupuncture stimulation|The same procedure as electroacupuncture except stimulation
41131046|NCT01020266|PROCEDURE|Electroacupuncture pretreatment|According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
41280537|NCT03617926|OTHER|RID shampoo|Active Comparator: RID shampoo The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
40744340|NCT04285411|DEVICE|Accuracy of the VitalDetect™ pulse oximetry system|The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
41131047|NCT05937269|COMBINATION_PRODUCT|Near-infrared fluorescence lymphatic imaging|All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.
41131048|NCT05937269|DEVICE|advanced pneumatic compression therapy|The advanced pneumatic compression device (APCD) mimics manual lymphatic drainage, a light massage that stimulates lymphatic uptake and function and frequently prescribed for lymphedema therapy.
41131049|NCT04528498|OTHER|Preimplantation Genetic Testing|Embryo biopsies will undergo preimplantation genetic testing for aneuploidies as per standard of care, and polygenic disease risk (PGT-P) will be computed for these samples.
41131050|NCT02097394|DRUG|Combizym|Combizym( 1 tablet, po, tid)
41131051|NCT02097394|DRUG|Bifidobacteri|Bifidobacteri (2 tablet, po, tid)
41131052|NCT02097394|DRUG|Combizym + Bifidobacteri|Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
41131053|NCT04644887|OTHER|Dietary intervention: Healthy diet|Dietary guidance in the intervention group is based on the Nordic and Finnish nutrition recommendations with an emphasis on the quality of dietary fat. The aims for the intake of fatty acids will be SFA \< 10 % of energy intake (E%) and mono- and polyunsaturated fatty acids (UFA) \>2/3 of the total fat intake. The key food products such as vegetable oil-based spread, liquid margarine and canola oil are provided to the participants. The participants are recommended to use fat free (e.g. milk, sourdough milk and yogurt) and low fat (e.g. cheese ≤ 17%) dairy products and low-fat meat, poultry, and fish as well as natural nuts and seeds.
41280538|NCT00597649|DRUG|Bicifadine|SR dosage form of 400 mg bid or tid for one year
41280539|NCT04771715|DRUG|Regorafenib|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
41280540|NCT04771715|DRUG|Nivolumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
41280541|NCT04771715|DRUG|Pembrolizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
41280542|NCT04771715|DRUG|Camrelizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
41280543|NCT04771715|DRUG|Sintilimab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
41280544|NCT04771715|DRUG|Toripalimab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
41280545|NCT04771715|DRUG|Tislelizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
41280546|NCT05859958|OTHER|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups
41280547|NCT00775021|DEVICE|etafilcon A|Contact Lens
41280548|NCT00775021|DEVICE|nelfilcon A|Contact Lens
41450601|NCT05391451|PROCEDURE|general anesthesia|general anesthesia is the current technique for kidney transplant surgery. The protocol involves the combination of several drugs: Propofol, Remifentanil, Ketamin, Atracurium or Cisatracurium. Curarization monitoring is systematic.
41131054|NCT04644887|OTHER|Dietary intervention: Control diet|The control diet corresponds to the average nutrient intake in the Nordic countries, i.e. the intake of SFA about 15 E% and the proportion of UFA about 50 % of total fat intake. The participants of the control group will get butter-based spread for bread and cooking. They are recommended to use semi-skimmed milk (1,5 %), normal fat yogurt (\~2%), normal fat cheese (\~24-35 %) and avoid consumption of vegetable oils. They are allowed to eat a portion of fish and nuts once a week.
40938032|NCT02455141|DRUG|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4
40938033|NCT02455141|DRUG|Taxanes|Paclitaxel: 80mg/m2, d1, qw\*12 or Docetaxel: 80-100mg/m2,d1,q3w\*4
41131055|NCT00291694|DRUG|celecoxib|Celecoxib 400 mg BID
41131056|NCT00291694|OTHER|placebo|placebo
41131057|NCT04276506|OTHER|music group|to reduce anxiety, some selected music pieces will have patients listened by headset.
41280549|NCT01264003|DRUG|sefazolin|In prophylaxis
41131058|NCT04276506|OTHER|information group|A visual information booklet which is prepared by the researchers will be used
41131059|NCT02903875|OTHER|Patient therapeutic education (PTE) programme|
41131060|NCT04798534|BEHAVIORAL|Service decentralization facilitation intervention|The intervention CHW will participate in three 60-minute intervention weekly sessions. During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients. The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently. Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving. In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients. The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
41280550|NCT05772364|OTHER|Loading of low-calcium water first, then high-calcium water|All cohort subjects are asked to consume water with less than 5 mg/L of calcium first, then are asked to consume water with at least 400 mg/L of calcium
41280551|NCT00257036|DRUG|levofloxacin|
41280552|NCT04942548|OTHER|Ketogenic Diet|Ketogenic diet intervention that is high in fat and low in carbohydrates, causing the body to induce a state of metabolic ketosis, whereby fat is broken down into ketones to provide an energy source for the body.
41450602|NCT06081634|BEHAVIORAL|Enhancing cognitive reserve|Intervention in group format (6-8 patients) consisting of 12 weekly sessions, each lasting approximately 60 minutes. The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning. Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support. Technological resources such as the use of the Internet and some telephone applications will also be used in some sessions. For those sessions in which the practice of mindfulness techniques will be promoted, a virtual reality device will be used per patient.
40756231|NCT01300520|DEVICE|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
40938034|NCT02455141|DRUG|Taxanes plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w\*4 Carboplatin AUC=2, d1,d8,d15, q4w\*4 or Docetaxel: 75mg/m2,d1,q3w\*4 plus Carboplatin AUC=5-6, d1, q3w\*4
40938035|NCT04426578|DRUG|Perhexiline|"All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count."
41131061|NCT03243006|DRUG|Paracetamol|2 tablets of 500mg of paracetamol
41131062|NCT03243006|DRUG|Tramadol/Paracetamol combination|2 tablets of tramadol/paracetamol combination (32.5mg/325mg)
41131063|NCT03243006|DRUG|Placebo Oral Tablet|2 tablets of placebo
41280553|NCT04437264|DIETARY_SUPPLEMENT|Intermittent feed participant|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
41450603|NCT06081634|OTHER|Treatment as Usual|The group will only receive the pharmacoloical treatment according to the based guidelines.
40756232|NCT05853939|DEVICE|repetitive transcranial magnetic stimulation|Repetitive TMS targeted by neuronavigation to left lower visual field of primary visual cortex. Randomized to 10 Hz or 1 Hz on different treatment days. Stimulation at 110% of phosphene threshold, or 110% resting motor threshold if phosphenes not detectable. 1 Hz: 1000 pulses total over 1000 seconds. 10 Hz: 1000 pulses over 10 10 second pulse trains, with 50 second intertrain intervals
40756233|NCT00005775|DRUG|Glutamine|Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
41131064|NCT04150042|DRUG|Melphalan|Intravenous melphalan (to be given in conjunction with the other listed drugs).
41131065|NCT04150042|DRUG|BCNU|Intravenous BCNU (to be given in conjunction with the other listed drugs).
41131066|NCT04150042|DRUG|Vitamin B12B|Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).
41131067|NCT04150042|DRUG|Vitamin C|Intravenous vitamin C (to be given in conjunction with the other listed drugs).
41131068|NCT04150042|DRUG|Ethanol|Intravenous ethanol (to be given in conjunction with the other listed drugs).
41131069|NCT04150042|DEVICE|Autologous Hematopoietic Stem Cells|After each cycle of chemotherapy, participants will receive an autologous hematopoietic stem cell infusion.
41131070|NCT05856656|BEHAVIORAL|Music therapy|Music therapy is a technique of care, accompaniment and support, which aims to improve health and well-being.
41280554|NCT04437264|DIETARY_SUPPLEMENT|Continuous feeds participant|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
41280555|NCT04770103|BEHAVIORAL|Balance recovery|"Balance recovery by stepping ascertains the capability of the participant to recover when subjected to a loss of balance in the forward direction.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability."
41450604|NCT02255149|DEVICE|Bone/Mesh|A titanium mesh (Ti-Mesh) that is more porous than other materials will be placed in order to hold a spot for the bone particles to grow.
41450605|NCT05328908|DRUG|Nivolumab-relatlimab FDC|Specified dose on specified days
41450606|NCT05328908|DRUG|Regorafenib|Specified dose on specified days
41450607|NCT05328908|DRUG|TAS-102|Specified dose on specified days
40756234|NCT00005775|DRUG|Placebo|TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
40938036|NCT04426578|OTHER|Placebo|"All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count."
40938037|NCT00964132|DRUG|NRX194204|Once Daily, Oral
40938038|NCT00955227|DIETARY_SUPPLEMENT|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
40938039|NCT00955227|DRUG|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
40938040|NCT02821910|DRUG|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
40938041|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
40938042|NCT02821910|DRUG|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
40938043|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
40938044|NCT02821910|DRUG|Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
40938045|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
40938046|NCT00246779|PROCEDURE|Modified ultrafiltration|
41131071|NCT00244673|BIOLOGICAL|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
41131072|NCT04864782|DRUG|QL1604|Intravenous Infusion
41131073|NCT04864782|DRUG|Paclitaxel injection|Intravenous Infusion
41131074|NCT04864782|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
41131075|NCT04187066|BEHAVIORAL|mindset induction|induction of a health mindset to measure changes in cue-dependent and goal-directed behavior
41280556|NCT04770103|BEHAVIORAL|Postural Sway|"Postural sway is a pseudo-static measure of postural control that evaluates a participants balance recovery ability when the perturbation does not require a dynamic step recovery.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability."
41280557|NCT01697345|DRUG|Testosterone|
41450608|NCT02606032|DRUG|Metronidazole|active comparator
40938047|NCT00359697|DRUG|Hypertonic Saline, Mannitol|
40938048|NCT06011031|DEVICE|Novaloc attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
40938049|NCT06011031|DEVICE|Locator attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
40938050|NCT06483074|DRUG|Empagliflozin 10 MG|empagliflozin oral 10mg daily for 6 months
40938051|NCT06515509|PROCEDURE|immediate implant placement with or without loading|immediate implant placement with or without loading
40938052|NCT01151098|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
40938053|NCT05104554|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|IFA: Weekly regimen of one tablet containing iron (60 mg) and folic acid (2800 μg)
40938054|NCT05104554|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS)|MMS: Daily regimen of one multiple micronutrient tablet containing fifteen micronutrients in the United Nations International Multiple Micronutrient Preparation (UNIMMAP) preparation. Composition includes vitamin A (800 ug), vitamin D (5 ug), vitamin E (10 mg), vitamin C (70 mg), vitamin B1 (1.4 mg), vitamin B2 (1.4 mg), niacin (18 mg), vitamin B6 (1.9 mg), vitamin B12 (2.6 ug), folic acid (400 ug), iron (30 mg), zinc (15 mg), copper (2 mg), selenium (65 ug), and iodine (150 ug).
40938055|NCT05425589|PROCEDURE|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
40938056|NCT01522729|DRUG|Fentanyl|Single-dose of intrathecal fentanyl \[25ug\] Duration of fentanyl : 3.5 hours
41131076|NCT02224469|DEVICE|ECoG (electrocorticography) sensing|Implant electrodes and sensing device and use for control of Assistive Technology
41131077|NCT03230903|OTHER|Home telerehabilitation|Patients will receive an individualized exercise plan sent to a computer at their home. Patients will have daily access to a physical therapist and exercise physiologist.
41131078|NCT03230903|OTHER|Usual Care|Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
41280558|NCT04619407|DIAGNOSTIC_TEST|Nasopharyngeal swab|SARS-CoV-2 PCR
41280559|NCT04619407|DIAGNOSTIC_TEST|Serum testing|Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)
41280560|NCT03550690|DEVICE|Large Volume Paracentesis|Insertion of a plastic tube into the abdomen and draining off ascitic fluid under local anaesthetic, removing the drain afterwards
41280561|NCT03550690|DEVICE|Rocket Indwelling Pleural Catheter|A small plastic tube under the skin which is left in place so that the fluid can be drained if it builds up again
41280562|NCT00104130|DRUG|KOS-862|
41280563|NCT02635230|DRUG|Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.|
41280564|NCT04133324|DIAGNOSTIC_TEST|C-reactive protein|C-reactive protein at postoperative days four and two.
41280565|NCT04575129|OTHER|No intervention will be applied|No intervention will be applied
41450609|NCT02606032|DRUG|Doxycycline|active comparator
41450610|NCT02606032|DRUG|Terbinafine|active comparator
41450611|NCT02606032|DRUG|Placebo|identical placebos to all antibiotics
41450612|NCT03195595|DEVICE|mitral valve replacement|early postoperative outcome regarding pain in minimal invasive technique
40938057|NCT01522729|DRUG|Placebo comparator|placebo \[NaCl\]
40938058|NCT05395273|DEVICE|Game Ready cryocompression|Cryotherapy on the coldest tolerable level and intermittend compression on the knee
40938059|NCT00419679|PROCEDURE|x-ray diffraction of human hair|
40938060|NCT03150485|DEVICE|JJVC Fitting Guides|Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
40938061|NCT03467607|PROCEDURE|tidal volume ventilation|low tidal volume ventilation
40938062|NCT02774733|DEVICE|spirometer;Intraocular pressure;Color doppler imaging|
40938063|NCT00476359|DRUG|Lopinavir/r plus saquinavir|lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
40938064|NCT02929251|DRUG|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
40938065|NCT02929251|DRUG|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
40938066|NCT02929251|DRUG|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
40938067|NCT02640040|DEVICE|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
40938068|NCT02640040|DEVICE|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
41131079|NCT03773549|OTHER|Virtual reality experience|Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.
41280566|NCT04382508|OTHER|Questionnaire|A weekly questionnaire will be filled in
40938069|NCT02640040|PROCEDURE|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
40938070|NCT02905656|BEHAVIORAL|Brief Advice|Psychoeducation
40938071|NCT02905656|BEHAVIORAL|Motivational Interviewing|Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
40938072|NCT02905656|BEHAVIORAL|Rate Reduction|Reducing the number of cigarettes consumed.
40938073|NCT02905656|DRUG|Pharmacological|Nicotine Replacement Therapy in the form of gum.
40938074|NCT02905656|BEHAVIORAL|MI+RR|Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
40938075|NCT00033072|DRUG|Selegiline|
40938076|NCT00002398|DRUG|Levocarnitine|
40938077|NCT00002398|DRUG|Adefovir dipivoxil|
40938078|NCT00478699|DRUG|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
40938079|NCT00478699|DRUG|Docetaxel|Docetaxel 75 mg/m2 day 1, 4 cycles
40938080|NCT00478699|DRUG|Gemcitabine/Cisplatin|Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
40938081|NCT00478699|DRUG|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
40938082|NCT05509946|DRUG|Single dose of celecoxib 400 mg and pregabalin 150 mg|Single dose of celecoxib 400 mg and pregabalin 150 mg
40938083|NCT05509946|DRUG|Repeated dose of celecoxib 200 mg and pregabalin 75 mg|Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery
40938084|NCT05509946|DRUG|Placebo|Placebo
41131080|NCT04688684|BEHAVIORAL|Family-based diet and exercise intervention|The participants will meet together weekly as a family unit to receive education and planning to implement diet and lifestyle changes under the supervision of a health coach. This coach will also be available during the week by telephone or messaging for additional individualized support if needed.
41131081|NCT02334215|DRUG|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
41131082|NCT02334215|BEHAVIORAL|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
41280567|NCT04449692|DRUG|Dasiglucagon|Abdominal s.c. administration
41280568|NCT04449692|OTHER|Carbohydrate (dextrose tablets)|Oral administration
41450613|NCT03195595|DEVICE|conventional mitral valve replacement|early postoperative outcome regarding pain in conventional median sternotomy
41131083|NCT02334215|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
41131084|NCT03132298|OTHER|Implicit Theories of Personality Program|This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
41131085|NCT03132298|OTHER|Control Program|This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
41131086|NCT03664011|DRUG|BI 730357 mixed with [C-14]BI 730357 BS|Oral Solution
41280569|NCT02649634|BEHAVIORAL|Motivational Interviewing|The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
41450614|NCT05108935|DRUG|Suboxone|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
41131087|NCT05543005|OTHER|maternal voice intervention|maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time after routine care period
40938085|NCT01678937|PROCEDURE|Blood Draw - Rapamycin|Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
40938086|NCT01678937|PROCEDURE|Blood Draw from Control Subjects|"Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
40938087|NCT01678937|PROCEDURE|Blood Draw - CyA|"Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
41450615|NCT05108935|DRUG|Truvada|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
40938088|NCT01678937|PROCEDURE|Blood Draw - Tacrolimus|"Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
40938089|NCT01678937|PROCEDURE|Blood Draw - MMF|"Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
40938090|NCT01678937|PROCEDURE|Blood Draw - Rapamycin|"Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
40938091|NCT00400530|DRUG|MK0217, alendronate sodium / Duration of Treatment: 1 Month|
40938092|NCT00400530|DRUG|Comparator: Alendronate-Teva / Duration of Treatment: 1 Month|
40938093|NCT04387825|DRUG|ADSVF application in the right hand|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
40938094|NCT05041946|DRUG|Methylphenidate|Given PO
40938095|NCT05041946|OTHER|Placebo (Sugar Pill)|Given PO
40938096|NCT03442387|OTHER|Frame of numerical information|Each group received only one frame of information.
40938097|NCT01764035|BEHAVIORAL|Body Scan (BS) Meditation Intervention|This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
41450616|NCT05108935|DRUG|Mavyret|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
41450617|NCT01521780|PROCEDURE|MRI|Participants undergo volumetric \& diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
41450618|NCT01521780|PROCEDURE|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
40938098|NCT01764035|BEHAVIORAL|Brief Supportive Psychotherapy (SP)|SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
40938099|NCT00085124|BIOLOGICAL|oblimersen sodium|Given IV
40938100|NCT00085124|DRUG|cytarabine|Given IV
41450619|NCT01521780|PROCEDURE|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
41450620|NCT01521780|PROCEDURE|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
41450621|NCT03167606|BEHAVIORAL|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
40938101|NCT00085124|DRUG|daunorubicin hydrochloride|Given IV
40938102|NCT00085124|OTHER|laboratory biomarker analysis|Correlative studies
41131088|NCT03476772|DRUG|Nalbuphine|Children will be randomly assigned into 2 groups of 30 patients each. They will receive caudal anesthesia using bupivacaine 0.25% 1ml/kg plus 2 ml normal saline in the control group, bupivacaine 0.25% 1ml/kg plus nalbuphine 0.1 mg/kg in 2 ml solution in the nalbuphine group.
41131089|NCT00612209|DRUG|ARQ 197|Treatment with ARQ 197
40938103|NCT05220800|DRUG|Iron(III)isomaltoside|Weight-dependent dosage of iron(III)isomaltoside. See group descriptions
40938104|NCT05220800|DRUG|Placebo|Isoton saline infusion
40938105|NCT02163122|PROCEDURE|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
40938106|NCT02163122|OTHER|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
40938107|NCT02163122|BIOLOGICAL|Cat allergen (FelD1)|
40938108|NCT00882219|DEVICE|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
40938109|NCT04108676|DRUG|Fluzoparib|PARP inhibitor
41131090|NCT02340013|DRUG|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
41131091|NCT00804219|BIOLOGICAL|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
40938110|NCT04108676|DRUG|Omeprazole|proton pump inhibitor
40938111|NCT00028275|DRUG|Gamma Interferon 1b|
40938112|NCT04224883|PROCEDURE|Continuously feeding|Daily amount of feeding were continuously pumped for 24 hours. EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours. If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200mL were considered markers of good tolerance.Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
40756235|NCT04117087|DRUG|KRAS peptide vaccine|"1. KRAS peptide vaccine will be administered on cycle 1 (days 1, 8, 15) and R-Cycle 2 Day 1 (R-C2D1). Boost vaccinations with will be administered every 28 days at Reinduction cycle 5, 7, 9, 13. Extended vaccinations will be administered on Reinduction cycles 15 to 18, 19 and beyond (180 days ± 30 days for a total of 5 years on study.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
40756236|NCT04117087|DRUG|Nivolumab|"1. Nivolumab will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of each 21 day cycle. Boost Phase will be administered every 28 days on cycles 5 thru 14.~2. Drug: 3mg/kg IV, 480 mg IV"
40756237|NCT04117087|DRUG|Ipilimumab|"1. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of Cycles 1 and 3 of the study.~2. Drug: 1mg/kg IV"
40756238|NCT01258699|DRUG|Thiocacid HR Tab 600mg|600mg for 1 day
40756239|NCT01258699|DRUG|BK-C-0701 320mg|320mg for 1 day
40756240|NCT01258699|DRUG|BK-C-0701 480mg|480mg for 1 day
40756241|NCT03104920|PROCEDURE|ERAS Program|An ERAS pathway comprises of optimized management of diet, mobilization, multimodal perioperative analgesia and GI function recovery modalities.
40756242|NCT03104920|PROCEDURE|Traditional treatment|A traditional perioperative management for HCC.
40756243|NCT02577302|DEVICE|CAN-Stim - Protect CAN-Stim System|CAN-Stim subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the CAN-Stim System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will continue therapy and followed for a total of 12 months.
40756244|NCT02577302|DEVICE|SNS - InterStim® System|"Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study.Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will receive a full implant and followed for a total of 12 months."
40756245|NCT03721367|OTHER|Diagnostic Ultrasound|All individuals will undergo a blood draw for measurement of biomarkers of liver disease and an ultrasound with shear-wave elastography.
40756246|NCT05192031|BEHAVIORAL|Smoking cessation support|Training healthcare professionals to deliver smoking cessation support as part of hospital-based lung cancer workup.
40756247|NCT04253678|DRUG|Vortioxetine|Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
40756248|NCT00003192|DRUG|aminocamptothecin|
41280570|NCT02649634|BEHAVIORAL|Attention Control|The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
40756249|NCT06076538|DIAGNOSTIC_TEST|2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging|PET/MR scan utilizing FDG Radiopharmaceutical
40756250|NCT02124005|DRUG|Bupivacaine|
40756251|NCT00236197|DRUG|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
40756252|NCT00236197|DRUG|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
40756253|NCT04291885|DRUG|Avelumab|Avelumab IV infusion
40756254|NCT04291885|DRUG|Placebo|Placebo IV infusion
40756255|NCT04100603|OTHER|No Intervention|There is no intervention for this study
40756256|NCT02694055|OTHER|Proactive Community Case Management|CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package.
40756257|NCT02694055|OTHER|Integrated Community Case Management|CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package to patients that visit them at their work post.
40756258|NCT02694055|OTHER|Removal of point-of-care user fees|User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
40756259|NCT02694055|OTHER|Infrastructure improvements at primary health centre|Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
40938113|NCT04224883|PROCEDURE|16-hours feeding|Daily amount of feeding were continuously pumped for 16 hours.EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
40938114|NCT04224883|PROCEDURE|intermittent feeding|Daily amount of feeding were divided into four meals, each meal are pumped within 60mins or 120mins through stomach tube. EN preparation pumping scheme was as follows: If the volume of each meal is less than or equal to 250ml(≤250ml), pump in within 60min, if volume is greater than 250ml(\>250ml), pump in within 120min and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
40938115|NCT05580510|DRUG|Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator."
40938116|NCT05580510|DRUG|Empagliflozin 10 MG OD|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug."
40938117|NCT00599781|GENETIC|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
40938118|NCT00777205|BEHAVIORAL|Telephone-based peer support|Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
40938119|NCT00777205|BEHAVIORAL|Enhanced Usual Care|Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
40938120|NCT01805271|DRUG|Everolimus|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
40938121|NCT01805271|DRUG|Placebo|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
40938122|NCT04113031|BEHAVIORAL|Flywheel squats versus free weight high load squats for explosive actions in football|Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (\~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.
40938123|NCT02958189|BEHAVIORAL|Tweet4Wellness|A daily, behavior change theory-based intervention message is sent to a private, 25-person online Twitter-support group to prompt peer-to-peer discussion. Participants receive individual text messages to encourage group participation (e.g. 'thank you for participating' or 'please participate tomorrow'). Participants also receive weekly individual messages giving them daily step goals for the week based on their previous week's daily step average, recorded from Fitbit.
40938124|NCT02958189|BEHAVIORAL|Self-monitoring|A Fitbit is provided to the group which tracks participants' daily steps.
40938125|NCT03181373|OTHER|Cognitive rehabilitation program|Rehabilitation
40938126|NCT02631356|DRUG|Ringer's lactate solution|
40938127|NCT02631356|DRUG|Succinylated gelatin|
40938128|NCT01302379|DRUG|Metformin|Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
41131092|NCT06182475|BEHAVIORAL|EPPComm Provider Training|A curriculum will be developed to educate patients about LDKT and promote the search of potential living donors while supporting patients' values and cultural preferences. The curriculum will consist of two components: didactic education and skills-based communication. The didactic component provides evidence of the impact of patient-provider communication and LDKT process outcomes for Black and Caucasian patients. The skills-based component will build communication confidence leading discussions about LDKT. It provides instructions for the key communication skills needed to confidently assuage patients' concerns about LDKT/live donation and motivates patients to search for living donor. The following will be covered: providing LDKT information/answering questions, highlighting LDKT benefits, refuting live donation misinformation, and encouraging patients to seek living donors.
40938129|NCT01302379|DRUG|Placebo|Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
40938130|NCT01302379|BEHAVIORAL|Lifestyle intervention|Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
40938131|NCT01302379|BEHAVIORAL|Standard printed dietary guidelines|Set of standard health education materials provided to participants at single time point (immediately after randomization)
40938132|NCT03913325|OTHER|PREVSAM model|A person-centred rehabilitation plan, including coordinated measures within primary health care as well as in collaboration with participants' employers, and when relevant the Swedish Public Employment Agency
40938133|NCT03913325|OTHER|Treatment as usual (standard treatment)|Treatment as usual (ordinary/standard) treatment. Can include unimodal or multimodal treatment of physiotherapy solely and/or occupational therapy
40938134|NCT01543373|DEVICE|Amphilimus Eluting Stent|Sirolimus formulated coronary eluting stent
40938135|NCT01543373|DEVICE|Bare Metal Stent|Bare metal coronary stent
40938136|NCT02129218|OTHER|questionnaire administration|Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
40938137|NCT02129218|OTHER|laboratory biomarker analysis|Correlative studies
40938138|NCT02129218|BEHAVIORAL|Standard Dietary Intervention|Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).
41131093|NCT04572867|DEVICE|Aquapheresis|The Aquadex FlexFlow® Fluid Removal System (from CHF Solutions™, Minneapolis, MN) is an FDA approved device that provides mechanical isosmotic fluid removal in volume-overloaded CHF patients via veno-venous ultrafiltration, and has been used in patients with congestive heart failure refractory to diuretics, it should be considered standard of care also. This study is using it in a randomized, controlled study in the Outpatient setting. The Aquadex FlexFlow® Fluid Removal System is a dual rotary pump device used with a sterile, single-use UF 500 Blood Circuit Set. Blood withdrawal is usually from a peripheral arm vein (such as the antecubital vein), using a 16 or 18- gauge, 3.5 cm catheter (similar to a standard IV catheter). A similar IV catheter is used for blood return via a second peripheral vein (typically in the forearm).
41131094|NCT04572867|DRUG|IV Diuretics|Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR\< 2.0, or 5mg PO if Cr \> 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
41280571|NCT03217760|PROCEDURE|Endodontic treatment|Endodontic treatment or root canal therapy is a sequence of treatment for the infected pulp of a tooth which results in the elimination of infection and the protection of the decontaminated tooth from future microbial invasion.
41280572|NCT03217760|OTHER|VAS of stress|The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)
41280573|NCT03217760|OTHER|CORAH scale|At the beginning of the treatment (T1), the patient is asked to complete a French version of the Corah Dental Anxiety scale (DAS).
41280574|NCT03217760|OTHER|HAD Scale|At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.
41450622|NCT05959187|DIAGNOSTIC_TEST|pharmacogenomic testing|Pharmacogenomic testing has emerged as a promising diagnostic tool, allowing clinicians to guide the selection and dosage of antidepressant medications. In theory, pharmacogenomic testing may provide improved drug selection and dosing strategies for patients with genetic alterations related to drug response
41450623|NCT03373968|DRUG|Givinostat|suspension of givinostat (10 mg/mL)
41450624|NCT04379739|DRUG|Camrelizumab|camrelizumab 200mg, q3w, i.v., 2-4 cycles;
41450625|NCT05198622|PROCEDURE|Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be completely preserved during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
41131095|NCT05746741|BEHAVIORAL|Telehealth solution|Video conferencing
41131096|NCT01797354|BEHAVIORAL|Cognitive-behavioral therapy and hypnosis group|
41131097|NCT01797354|BEHAVIORAL|Support group|
41280575|NCT03217760|OTHER|Cardiovascular Parameters|For each subject, the physiological indicators of stress (ie, heart rate \[HR\], systolic blood pressure \[SBP\], and diastolic blood pressure \[DBP\]) are monitored during each of the 6 steps.
41280576|NCT03217760|OTHER|Cortisol Measurements|Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .
41280577|NCT03217760|OTHER|Discomfort and Pain Experienced During Treatment|Patients were asked to report the levels of discomfort and pain experienced during the 6 steps using the VAS and at the next visit for the final restoration.
41280578|NCT03217760|OTHER|Patient's preferences.|After the completion of each treatment patients will have to report whether they thought that they would have experienced as much pain, stress, or discomfort if they had received premedication before treatment.
41450626|NCT05198622|PROCEDURE|Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be sacrificed during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
40744341|NCT01132755|PROCEDURE|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
40938139|NCT02129218|BEHAVIORAL|Intensified Dietary Intervention|Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
40938140|NCT02129218|BEHAVIORAL|Low glycemic load|
40938141|NCT02129218|BEHAVIORAL|Medium Glycemic Load|
40938142|NCT04967612|OTHER|Virtual implantation|Temporary placement of virtual optical lens in the crystalline lens plane.
40938143|NCT04663919|PROCEDURE|Bariatric surgery-RYGB|"After the creation of a 15-25-cc gastric pouch from the upper stomach, transection of proximal jejunum 70 cm from Treitz ligament also called alimentary tract and anastomosis of the distal end of jejunum to the gastric pouch, and thereafter, anastomosis of the proximal end of transected jejunum to the distal part of the jejunum at 150 cm below the site of transection (jejunoileal anastomosis)."
40938144|NCT04663919|BEHAVIORAL|Dietary intervention|High-calorie medical nutrition program to ensure weight gain
40938145|NCT05268107|DRUG|Dupilumab|"Patients will be treated with dupilumab for 4 months (standard FDA-approved dosing of 600 mg subcutaneously at baseline/week 0, followed by 300 mg every 2 weeks).~Skin biopsies will be assessed at baseline (lesional and non-lesional), week 2 (lesional), and week 16 (lesional). In addition, blood will be obtained at baseline and week 16."
40938146|NCT03282565|OTHER|Functional Resistance Training with Brace|A brace will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
40938147|NCT03282565|OTHER|Control|A brace will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
40938148|NCT03282565|OTHER|Functional Resistance Training with Elastic Band|An elastic band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
40938149|NCT05785104|OTHER|Myofascial release|Is Facilitation of mechanical and neurological adaptive capacity as integrated through the Myofascial system
40938150|NCT05785104|OTHER|Muscle energy technique|Is manual therapy procedure that involves alternating periods of resisted muscle contraction and assisted stretching
40938151|NCT01772511|BEHAVIORAL|Questionnaire|All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
40938152|NCT00910468|PROCEDURE|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
40938153|NCT01511185|DRUG|liraglutide|A single dose of 7.5 mcg/kg administered subcutaneously in random order
40938154|NCT01511185|DRUG|placebo|A single dose administered subcutaneously in random order
40938155|NCT02693392|DRUG|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents"
40938156|NCT02693392|DIETARY_SUPPLEMENT|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
40938157|NCT05973396|OTHER|Physical Fatiguing Task only|Control group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] without mentally fatiguing task during low intensity effort pace
40938158|NCT05973396|OTHER|Physical and Mental Fatiguing Task|Experimental group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] with mentally fatiguing task during low intensity effort pace (which includes: stroop test)
40938159|NCT06165627|DEVICE|Lehfilcon A toric contact lenses|Commercially available soft contact lenses worn as indicated
40938160|NCT06165627|DEVICE|Comfilcon A toric contact lenses|Commercially available soft contact lenses) worn as indicated
40938161|NCT06165627|DEVICE|CLEAR CARE|Commercially available hydrogen peroxide-based solution for daily cleaning and disinfection of contact lenses used as indicated
40938162|NCT00606827|DRUG|Sodium Bicarbonate|Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure
40938163|NCT00606827|DRUG|Isotonic Saline|Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
40938164|NCT05863338|BEHAVIORAL|NURSING FOLLOW-UP BY PHONE|The training was carried out in the form of individual training and as a single session.The training,which lasted about 30 minutes,was carried out in the training room of the polyclinic with the support of Barco vision.In the training session,lecture,question-answer methods were used and at the end of the training session,a booklet containing the training content was given to the patients.The researcher phoned the patients once a week for 24 weeks,conveyed how they were doing,whether there was anything they wanted to ask or learn,and provided counseling to the patients in line with their needs.The next week's plan was also determined in the phone calls made in the following weeks.Patient follow-ups as stated were continued for 24 weeks.At the 12th and 24th weeks of the telephone nursing follow-up, the patients filled out the scales again.
41131098|NCT02470169|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
41131099|NCT02470169|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
41131100|NCT02470169|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
41131101|NCT02470169|DEVICE|shepherd catheter|
41131102|NCT02470169|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
41131103|NCT04433780|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC
41450627|NCT06416241|DRUG|EYLEA 2 MG in 0.05 ML Injection|Intravitreal injection
40938165|NCT00769574|OTHER|Biological analysis of biomarkers|Biological analysis of biomarkers
41280579|NCT03217760|OTHER|student preferences.|"When the treatment is complete the students are asked to report:~1. his/her level of satisfaction with the course of treatment,~2. whether he/she felt awkward faced with the patient's manifestations of stress, discomfort, or pain during the session~3. whether he/she would have preferred that the patient had received sedative medication before the endodontic treatment."
41280580|NCT02491541|BIOLOGICAL|Changchun Werersai|"A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.~1.0 ml experimental vaccine on day 0,3,7,14,28"
41280581|NCT02491541|BIOLOGICAL|Jilin Maifeng|"A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.~1.0 ml comparator vaccine on day 0,3,7,14,28"
41450628|NCT05570539|DRUG|BLU-5937 IR|Each subject will receive two single and multiple administrations of Immediate Release reference formulation
40938166|NCT00769574|OTHER|Biological analysis of biomarkers|Biological analysis of biomarkers
40938167|NCT01949454|DRUG|Fluorometholone 0.1% ophthalmic solution|
40938168|NCT01949454|OTHER|Artificial tears (Placebo)|Artificial tears (Placebo)
40938169|NCT04698265|BIOLOGICAL|Human amniotic suspension allograft (ASA)|Human amniotic suspension allograft (ASA) intra-articular injection.
40938170|NCT04160728|OTHER|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
40938171|NCT04160728|OTHER|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work
40938172|NCT04160728|OTHER|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts
40938173|NCT04160728|OTHER|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
40938174|NCT04160728|OTHER|Business as usual scenario|No interference with the usual work day of the participants
40938175|NCT04160728|OTHER|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment
40938176|NCT03280095|DRUG|co-codamol 15mg/500mg capsule|
40938177|NCT03280095|DRUG|co-codamol 30mg/500mg tablet|
40938178|NCT06008834|PROCEDURE|First-day discharge protocol|Enhance Recovery after Surgery (ERAS) protocol consisting in perioperative mesures and first-day hospital discharge with domiciliary follow-up
41131104|NCT04586348|COMBINATION_PRODUCT|Low Iodine Supplement|Multivitamin and mineral supplement with reduced iodine
41131105|NCT04586348|COMBINATION_PRODUCT|Standard Iodine Supplement|Multivitamin and mineral supplement with standard amount of iodine to match current leading brands of prenatal supplements
41280582|NCT00373074|OTHER|Epidural Blood Patch|Use 15 cc of blood
41280583|NCT00373074|OTHER|Epidural Blood Patch|Inject 20 cc of blood into epidural space
41280584|NCT00373074|OTHER|Epidural Blood Patch|Inject 30 cc of autologous blood
41280585|NCT05241652|OTHER|Inspiratory Muscle Training with an intensity of 50% MIP|Patients received IMT exercise program at a 50% MIP intensity for 12 weeks
41280586|NCT05241652|OTHER|Inspiratory Muscle Training with an intensity of 10% MIP|Patients received IMT exercise program at a 10% MIP intensity for 12 weeks
41280587|NCT02332252|DEVICE|Scalpel|Skin incision performed with a scalpel during cesarean section.
41280588|NCT02332252|DEVICE|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
41280589|NCT02332252|PROCEDURE|Skin incision|
41280590|NCT00987844|DRUG|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
41280591|NCT05337124|DRUG|LUPKYNIS|LUPKYNIS treatment per the approved US Prescribing Information
40938179|NCT04805944|DRUG|Dolutegravir|Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.
40938180|NCT04805944|DRUG|Bictegravir|Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
40938181|NCT04805944|DRUG|Dolutegravir|Patient having discontinued dolutegravir will be included and samples (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
40938182|NCT04805944|DRUG|Dolutegravir|Patients starting dolutegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of dolutegravir
41131106|NCT00849485|DRUG|Levetiracetam|750 mg Tablet
41131107|NCT00849485|DRUG|Keppra®|750 mg Tablet
41131108|NCT01051271|DRUG|midazolam|midazolam 1.5 mg
41131109|NCT05620472|DRUG|Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1|One single intravenous injection of \[99mTc\]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
41131110|NCT05136794|OTHER|Data collection|complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay
41280592|NCT03224962|DEVICE|fluorescence camera|drug - diagnostic test
41280593|NCT06225817|DIETARY_SUPPLEMENT|Open-label placebo pills|The placebo pills in this study are empty capsules without any ingredients inside. The capsules are made of microcrystalline cellulose.
41280594|NCT00054470|BIOLOGICAL|trastuzumab|
41280595|NCT00054470|DRUG|tipifarnib|
41280596|NCT02541630|BEHAVIORAL|Big Mind|mindfulness based intervention
41450629|NCT05570539|DRUG|BLU-5937 ER|Each subject will receive single and multiple oral administrations of Extended Release formulation
41450630|NCT01803594|DIETARY_SUPPLEMENT|Krill Oil|Neptune Krill Oil Gold
41450631|NCT01803594|DIETARY_SUPPLEMENT|Lutein|Jarrow Formulas
41450632|NCT01803594|DIETARY_SUPPLEMENT|Nicotinic acid|Natures Way
41450633|NCT01803594|DIETARY_SUPPLEMENT|Dairy phospholipids|PC700 manufactured by Fonterra
41450634|NCT01803594|OTHER|Control|Control shake without dietary supplements
40938183|NCT04805944|DRUG|Bictegravir|Patients starting bictegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of bictegravir
40938184|NCT05628961|DRUG|HOPO 14-1|HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
40938185|NCT02745067|BEHAVIORAL|enhanced cognitive behavioral therapy|
40938186|NCT00832390|DRUG|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
40938187|NCT03911310|DIAGNOSTIC_TEST|[18F]PSMA-11|\[18F\]PSMA-11 PET/CT
40938188|NCT03911310|DIAGNOSTIC_TEST|[68Ga]PSMA-11|\[68Ga\]PSMA-11 PET/CT
40938189|NCT03136731|DIAGNOSTIC_TEST|Celiac disease antibody screening|Observational parameters
40938190|NCT00920829|DRUG|Naltrexone 50 Mg|Naltrexone 25 or 50 mg per titration schedule
40938191|NCT00920829|DRUG|Placebo|placebo
40938192|NCT06409403|DEVICE|clinical application of robotic technique|effect of various surgical technique on clinical efficacy of TME
40938193|NCT02555241|BEHAVIORAL|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
40938194|NCT02555241|BEHAVIORAL|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
40938195|NCT02555241|BEHAVIORAL|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
40938196|NCT04147572|DRUG|Placebo Tiotropium inhalation powder type A|Placebo inhalation from inhaler A
40938197|NCT04147572|DRUG|Placebo Spiriva capsule|Placebo inhalation from HandiHaler
40938198|NCT04147572|DRUG|Placebo Tiotropium inhalation powder type B|Placebo inhalation from inhaler B
40938199|NCT04147572|DEVICE|Substudy Placebo Tiotropium Easyhaler|Substudy placebo inhalation
40938200|NCT04147572|DEVICE|Substudy Placebo Spiriva® via HandiHaler|Substudy placebo inhalation
40938201|NCT03850288|OTHER|Neuropsychological assessment : Stroop task|"Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive."
41131111|NCT03473717|DEVICE|classic method|"* Put the Pozzi forceps to draw the uterus by the cervix to horizontalize it and align uterine cavity in the direct axis of cervix.~* Insert the hysterometer to measure the uterus depth.~* Locate the uterine depth on the inserter tube."
40938202|NCT03850288|OTHER|Neuropsychological assessment : Go No Go task|"Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive."
40938203|NCT06415851|DRUG|mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody|This study is a single-arm intervention study. All subjects in this study will be treated with this study protocol, that is, after mFOLFOX6 protocol and bevacizumab induction therapy, combined with slulimumab treatment.
40938204|NCT02916238|DRUG|Fluoxetine|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
40938205|NCT02916238|BEHAVIORAL|Enhanced Usual Care|Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.
40938206|NCT00018070|PROCEDURE|Angiography|
40938207|NCT00018070|PROCEDURE|Laser Treatment|
40938208|NCT04638192|DEVICE|tACS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
40938209|NCT01571024|DRUG|BKM120|BKM120 40 mg, orally, once daily.
40938210|NCT01571024|DRUG|mFOLFOX6|mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
40938211|NCT02732080|DEVICE|deferred coronary stenting|Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)
40938212|NCT02732080|DEVICE|immediate stenting|Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
40938213|NCT04455360|OTHER|Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol|EMDR is a form of psychotherapy treatment whereby the client verbally relates a narrative of a traumatic episode or emotionally disturbing material in brief sequential doses while simultaneously focusing on an external stimulus. The EMDR Recent-Traumatic Events protocol (R-TEP) aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR R-TEP should be delivered within 3-months of the onset of a traumatic event.
40938214|NCT04928339|DRUG|Bupivacaine Injection|10mL of 0.25% bupivacaine
40938215|NCT04928339|DRUG|Liposomal bupivacaine|15mL of 133mg liposomal bupivacaine
40938216|NCT04928339|OTHER|Saline|25mL saline control
40938217|NCT00522964|BEHAVIORAL|behavioral intervention|The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
40938218|NCT05796336|DEVICE|Lip taping|Steri strip tape and passive baby feeding plate Two methods of lip taping will be used with passive baby feeding plate. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
41131112|NCT03473717|DEVICE|direct method|"* Place the ring on the inserter tube 3 to 4 cm from the end as a marker.~* Insert the tube into the cervix until you feel the passage of the internal orifice of the cervix or until the ring is in contact with the external orifice of the cervix, the tube does not enter the uterine cavity"
40938219|NCT01163032|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
40938220|NCT01163032|DRUG|Placebo|Placebo capsules, PO daily for 6 months
41280597|NCT03668132|OTHER|ischemic brain damage|Have or not have the ischemic brain damage and the location of the damage
41280598|NCT04112914|BEHAVIORAL|Post-concussion education for families|An educational intervention for families will be developed based on the CDC guidelines for returning to daily activities, school, and sports, adapted with stakeholder feedback to meet the learning needs of low health literacy parents.
41280599|NCT02820857|DRUG|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
41450635|NCT04264221|BEHAVIORAL|New management mode|"* New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use"
41450636|NCT02213705|BIOLOGICAL|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
41450637|NCT03102385|BEHAVIORAL|Motivational Interview|A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
41450638|NCT03102385|BEHAVIORAL|Knowledge Interview|A web-based interview that includes open-ended questions regarding blood donation knowledge.
40756260|NCT02694055|OTHER|Training of primary health centre staff|"Health center staff will receive targeted training in~* Integrated management of childhood illness~* Diagnosis and treatment of simple and severe cases of malaria~* Helping babies breathe~* Managing post-partum haemorrhage~* Gestational dating using frontal height, last menstrual period and ultrasound~* Family planning counselling and administration of long-acting contraceptives~* Pharmacy stock management~* Health center management"
40756261|NCT03232892|DRUG|Trametinib|Trametinib 2mg, once daily, PO, 28-day cycles
41131113|NCT05383989|BEHAVIORAL|UniVenture Hopelessness manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Hopelessness (HOP) personality traits on the Substance Use Risk Profile Scale (SURPS).
41131114|NCT05383989|BEHAVIORAL|UniVenture Anxiety Sensitivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Anxiety Sensitivity (AS) personality traits on the Substance Use Risk Profile Scale (SURPS).
41131115|NCT05383989|BEHAVIORAL|UniVenture Sensation Seeking manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Sensation Seeking (SS) personality traits on the Substance Use Risk Profile Scale (SURPS)
41131116|NCT05383989|BEHAVIORAL|UniVenture Impulsivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Impulsivity (IMP) personality traits on the Substance Use Risk Profile Scale (SURPS).
41131117|NCT05383989|BEHAVIORAL|Service as usual provided by the University|It is the regular university-provided well-being services.
41131118|NCT05609786|BEHAVIORAL|Personalized safety planning tool|The myPlan Kenya app is a web-based safety planning tool that is secure, private, free and personalized to the user. The app includes multiple, evidence-based modules: Strategies (safety strategies tailored to the user's needs and violence experience); Resources (referrals to local health, safety and justice resources and services); About You (questionnaires that help the user assess their relationship safety and tailor their Strategies, including My Relationship, Red Flags, My Safety, My Priorities); Understanding (knowledge sections that share information on relationships and violence, including Healthy Relationships, Harmful Beliefs About Abuse, About Violence).
41131119|NCT06303674|BEHAVIORAL|Physical activity with engaging cognitively|"This experimental condition will follow the following structure: involving 10 consecutive, 30 second-blocks of physical activity. This experimental condition will focus on aerobic metabolism. The total exercise time commitment is 10 minutes (30 seconds of working - 30 seconds of executing an engaging cognitive task, 1:1 work-to-rest ratio), plus 5 minutes of warm-ups and 5 minutes of cool-down activities. The cognitive task consists of solving various tangrams."
41131120|NCT06303674|BEHAVIORAL|Physical activity without engaging cognitively|This experimental condition will replicate the structure of the preceding one. Participants will engage in physical activity, guided by video observation and imitation. However, during the rest periods, they will refrain from engaging in cognitive tasks
41280600|NCT02820857|DRUG|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
41280601|NCT00509886|DRUG|Drysol|20% aluminum chloride hexahydrate
41280602|NCT00509886|DRUG|Drioff|1% aluminum acetate
41280603|NCT04538404|PROCEDURE|Colon Surgery|Right, left colon surgery, transverse colon surgery, multiple colon surgery in open and minimally invasive surgert
41280604|NCT00862602|BEHAVIORAL|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet \& nutrition and prevention.
41280605|NCT01147783|OTHER|CT, MRI|
41280606|NCT03022461|OTHER|Long term follow-up|
41280607|NCT06456710|BEHAVIORAL|Conventional IBS Health Education|Patients were provided with IBS related knowledge (e.g., the pathogenesis of IBS and the reasons affecting the treatment effect), exercise guidance, drug guidance and dietary management precautions; and timely answers to patients' clinical problems and psychological support.
41450639|NCT00052286|DRUG|modafinil|
41450640|NCT05418374|PROCEDURE|Continous Spinal Anestheisa|Continuous spinal anesthesia (CSA) describes subarachnoid blockade maintained by local anesthetics administered through an indwelling spinal catheter. CSA provides fewer episodes of hypotension and no severe hypotension versus single dose bupivacaine also it offers the ability to titrate the dose of local anesthetics needed while maintaining hemodynamic stability.
41450641|NCT04182126|OTHER|Regular long-lasting insecticidal nets|Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn
41450642|NCT04182126|OTHER|LLIN plus Piperonyl butoxide-treated LLIN|Olyset Plus: containing 2% permethrin and 1% PBO
41450643|NCT04182126|OTHER|Long-lasting microbial larvicide|Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet
40938221|NCT05315856|BIOLOGICAL|either BNT162b2 or ChAdOx1 vaccine|Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
40938222|NCT04819022|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
41131121|NCT02441374|DEVICE|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
41131122|NCT02441374|OTHER|Classical kinesiotherapy.|Applying classical kinesiotherapy in upper limb post stroke.
41131123|NCT00715351|DRUG|insulin detemir|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
40938223|NCT04819022|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
40938224|NCT04819022|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
40938225|NCT05445934|DRUG|FB2001|FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.
40938226|NCT05445934|DRUG|FB2001 placebo|Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
40938227|NCT02514317|PROCEDURE|percutaneous treatment|
40938228|NCT02514317|DEVICE|Ultrasound|
40938229|NCT01905111|DRUG|BI 853520|BI 853520 once daily in a dose escalation schedule
41131124|NCT00715351|DRUG|insulin NPH|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
41131125|NCT04950920|DRUG|Y-2 sublingual tablets|30mg Edaravone+6mg d-borneo OR， Bid
41131126|NCT04950920|DRUG|d-borneol|60 μg d-borneol OR， Bid
41131127|NCT02575365|DRUG|0,5 mg Fingolimod|0.5 mg p.o fingolimod daily
41131128|NCT04012970|OTHER|Manual spinal mobilisations|
41131129|NCT04064359|DRUG|OBT076, a CD205-directed antibody-drug conjugate|Intravenous (IV) infusion of OBT076 every 3 weeks.
41131130|NCT00716170|BIOLOGICAL|Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)|"Day A: Oral glucose tolerance test (50g glucose)~Day B: Isoglycemic intravenous (iv) glucose infusion~Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)~Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)~Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)~Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E."
41131131|NCT02646618|BEHAVIORAL|Get Social|Online-delivered weight loss intervention
41131132|NCT02646618|BEHAVIORAL|Traditional|Group-delivered weight loss intervention
41131133|NCT02646618|DEVICE|Smartphone|A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
40744342|NCT01003626|PROCEDURE|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
40744343|NCT01003626|DEVICE|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
40756262|NCT05704699|BEHAVIORAL|eTRE|eating between 0800h and 1600h daily
41131134|NCT05820763|DRUG|Selinexor|Selinexor is administered by mouth on Days 1, 8, 15, and 22 at a dose of 60 mg during the four cycles of consolidation. Selinexor is then decreased to 40 mg and administered by mouth on Days 1, 8, 15, and 22 for up to 8 cycles of maintenance therapy.
41131135|NCT05820763|DRUG|Lenalidomide|"Lenalidomide is administered by mouth daily on Days 1 to 21 at a dose of 10 mg during the first three cycles of consolidation, and then titrated up to 15 mg on Days 1 to 21 for the fourth cycle of consolidation. Lenalidomide 15 mg by mouth daily on Days 1 to 21 can be continued for up to 8 cycles of maintenance therapy.~For patients with baseline renal dysfunction, the starting dose of lenalidomide will be 2.5 mg or 5 mg by mouth daily on Days 1 to 21. Patients may titrate up per physician discretion."
41131136|NCT05820763|DRUG|Dexamethasone|Dexamethasone is administered by mouth on Days 1, 8, 15, and 22 at a dose of 20 mg during all four cycles of consolidation only.
41131137|NCT00822900|DRUG|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
41131138|NCT00822900|DRUG|Placebo|"Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours."
40744344|NCT05249751|DIAGNOSTIC_TEST|Assessement of serum copeptin by ELISA technique|Assessement of serum copeptin by ELISA technique
40938230|NCT03816670|DRUG|Corifollitropin Alfa|late start (day 4) vs. corifollitropin-alfa standard start (day 2)
40938231|NCT03578770|DEVICE|Hot Axios stent|Hot Axios stent
40938232|NCT06168227|DRUG|Disitamb Vedotin|RC48-ADC based therapy
40938233|NCT00825851|DRUG|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
41131139|NCT04902066|OTHER|Cognitive Behavioural Virtual Reality Therapy.|Cognitive Behavioural Therapy augmented with Virtual Reality.
41131140|NCT04902066|OTHER|Traditional Cognitive Behavioural Therapy|Traditional Cognitive Behavioural Therapy for psychosis.
41131141|NCT01942915|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cells|Participants will be transplanted with umbilical cord blood mononuclear cells.
41280608|NCT06456710|BEHAVIORAL|Based on ACT Theory of Psychological Intervention|"On the basis of the control group, the stigma intervention program of college students with IBS based on ACT theory was implemented. The duration of intervention was 40 to 50 minutes for 6 times, once a week for 6 weeks.~Week1: established relationships; introduced the core contents of ACT, the treatment process, and the effects of application.~Week2: encouraged to express negative emotions and behaviors; made patients accept the disease.~Week3: explained the importance of coping with negative emotions; instructed to separate negative thoughts from reality through cognitive dissociation exercises.~Week4: changed the concept of self and actively accepted IBS; guided to focus on the current life and true self.~Week5: introduced the values in ACT; helped clarify the values; guided to build confidence and focused on the core values.~Week6: introduced the importance of commitment to action; developed goals and plans together; encouraged to strengthen the use of ACT."
41280609|NCT05970887|BIOLOGICAL|bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine|The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.
41280610|NCT05970887|BIOLOGICAL|quadrivalent influenza vaccine|The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season
41280611|NCT04745442|DRUG|Antithrombin + best available treatment|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
41280612|NCT04745442|DRUG|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
41280613|NCT00836940|DRUG|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
41280614|NCT01682044|BIOLOGICAL|pegfilgrastim|Given SC
41280615|NCT01682044|BIOLOGICAL|rituximab|Given IV
41280616|NCT01682044|OTHER|flow cytometry|Correlative studies
41280617|NCT01682044|PROCEDURE|biopsy|Correlative studies
41280618|NCT01682044|OTHER|immunohistochemistry staining method|Correlative studies
41280619|NCT01682044|GENETIC|western blotting|Correlative studies
41280620|NCT03716791|DIETARY_SUPPLEMENT|methylsulfonylmethane|3g per day
41280621|NCT03716791|DIETARY_SUPPLEMENT|placebo|white rice flour
41280622|NCT02288637|OTHER|Olyset Plus LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
41280623|NCT02288637|OTHER|Conventional Olyset LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
41280624|NCT02288637|OTHER|IRS|Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
41280625|NCT03121690|DRUG|Prednisone|prednisone 40 mg/day for 7 days
40756263|NCT05704699|BEHAVIORAL|eTRE with BISC|eating between 0800h and 1600h daily and completing 3 sessions of BISC per week of study duration
41280626|NCT03121690|DRUG|placebo|5ml saline / day for 7 days
40756264|NCT04031768|OTHER|Timing of rest prior to blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.
40938234|NCT00825851|DRUG|Placebo patch|
40938235|NCT00825851|BEHAVIORAL|Smoking cessation|
40938236|NCT00825851|BEHAVIORAL|Continuous smoking|subjects smoke 20 cigarettes per day
40938237|NCT00589485|DEVICE|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
40938238|NCT00589485|DEVICE|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
40938239|NCT00117065|DRUG|Aranesp®|
40938240|NCT05045833|DRUG|SYN-020 Delayed Release Capsule|Oral administration (by mouth)
40938241|NCT00493376|PROCEDURE|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
40938242|NCT00493376|PROCEDURE|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
40938243|NCT00493376|PROCEDURE|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
40938244|NCT00493376|PROCEDURE|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
41131142|NCT00047125|RADIATION|radiation therapy|
41131143|NCT04990388|BIOLOGICAL|UX053|mRNA-based biologic
41131144|NCT04990388|OTHER|Placebo|consists of the same components as the formulation buffer for UX053
41131145|NCT04990388|DRUG|Antipyretic|participants will receive oral premedication prior to infusion
41131146|NCT04990388|DRUG|H2 Blocker|participants will receive oral premedication prior to infusion
41131147|NCT04990388|DRUG|H1 Blocker|participants will receive oral premedication prior to infusion
41131148|NCT04809376|DRUG|Pentosan Polysulfate Sodium twice weekly|Subcutaneous Injection, 1.5mg/kg Ideal body Weight (IBW)
41131149|NCT04809376|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
41280627|NCT00904254|RADIATION|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
41280628|NCT02900092|DRUG|Ganaxolone|Participants received ganaxolone
41280629|NCT02677584|DRUG|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
41280630|NCT02677584|DRUG|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
41450644|NCT04182126|OTHER|Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides|Each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl at the recommended dosage of 1g/m² and at the recommended frequency of once a year or twice a year. Other insecticides may be used to replace the Actellic 300 CS depends on Kenya government policy, current policy requires rotating different insecticides annually.
41131150|NCT04809376|DRUG|Pentosan Polysulfate Sodium Fixed Dose|Subcutaneous Injection, 100/150/180 mg if \<65kg/ ≥ 65 kg and ≤ 90kg/ \>90 kg IBW
41280631|NCT04894383|DEVICE|Aetrex L420 Compete Orthotic|An orthotic insole to be inserted into shoes. Orthotic for low arches to flat feet with no forefoot pain, featuring a posted heel to control over-pronation and provide balance. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia.
41280632|NCT04894383|DEVICE|Aetrex indoor comfort sandal with built-in arch support|An indoor comfort sandal with built-in arch support to be used at home. Provides extreme cushioning, shock absorption and durability. Arch support helps to stabilize and align feet and also helps to relieve common foot pain \& plantar fasciitis.
41131151|NCT04809376|DRUG|Pentosan Polysulfate Sodium once weekly|Subcutaneous Injection, 2.0mg/kg Ideal body Weight (IBW)
41131152|NCT00864006|DRUG|Divalproex Sodium|
41131153|NCT00864006|DRUG|Depakote DR Tablets|
41131154|NCT05741450|DEVICE|Lens 1 (monthly replacement)|Monthly replacement spherical silicone hydrogel contact lens for 15 minutes
41131155|NCT05741450|DEVICE|Lens 2 (daily disposable)|Daily disposable spherical silicone hydrogel contact lens for 15 minutes
41280633|NCT03597906|PROCEDURE|topography guided ablation|using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
41280634|NCT03597906|PROCEDURE|manifest refraction|using for ablation the exact manifest refraction
41131156|NCT05898126|PROCEDURE|Renin-guided hemodynamic management|If normalization of renin levels is achieved (values within the normal laboratory range), we will continue with usual care according to local protocols.
41131157|NCT05898126|PROCEDURE|Usual care|Standard of care
41131158|NCT02616926|PROCEDURE|Hepatic resection|Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
41131159|NCT02616926|PROCEDURE|TACE|TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed
41131160|NCT02616926|PROCEDURE|RFA|RFA will be performed 1 week after TACE.
40938245|NCT05368532|OTHER|Temperature|The temperature will be reduced for approximately one hour.
40938246|NCT03824028|DEVICE|Clareon® IOL AutonoMe™ automated preloaded delivery system|Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
40938247|NCT05831631|DIAGNOSTIC_TEST|Circulating leukocytes immunophenotype|Blood samples will be tested with flow cytometry in order to characterize leukocyte subpopulations and to evaluate the circulating immunophenotype
40938248|NCT05831631|DIAGNOSTIC_TEST|Tumor sampling|Immunohistochemical analysis will be performed on tumor samples in order to characterize immune T cells distribution within the tumor.
40938249|NCT00287079|DRUG|Rebif®|44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
40938250|NCT00287079|OTHER|No Treatment|No treatment for 96 weeks
40938251|NCT05086744|DRUG|Iptacopan|Iptacopan 200 mg BID
40938252|NCT05704296|PROCEDURE|Y-composite grafting|Saphenous vein is used as a Y-composite graft during coronary artery bypass grafting
41280635|NCT03597906|PROCEDURE|full topography modified refraction|full topography modified refraction means changing both sphere and cylinder power in the ablation profile
40756265|NCT00860431|DRUG|AST-120|6g/day (3 times a day)
40756266|NCT05791149|DIAGNOSTIC_TEST|saliva tube|1 tube of saliva (\~2 ml) will be collected from all patients enrolled in the study. For operated OSCC patients a second tube will be collected during the routine hospital visit 4 weeks after surgery
40938253|NCT05704296|PROCEDURE|Aortocoronary grafting|Saphenous vein is used as an aortocoronary graft during coronary artery bypass grafting
40938254|NCT02037581|BEHAVIORAL|Early detection and Integrated Care|Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)
40938255|NCT02037581|BEHAVIORAL|Standard Care|Standard care as being offered by private psychiatrists
40938256|NCT05660798|BEHAVIORAL|heated tobacco - lifestyle intervention|Patients unable (unwilling) to stop smoking will be randomized to either combustion (C) or heated (H) tobacco groups.
40938257|NCT00438438|BEHAVIORAL|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
40938258|NCT04134351|OTHER|Bronchial challenge test|Bronchial challenge test with sphingosine-1-phosphate
40938259|NCT05323565|DRUG|Dexmedetomidine|adjuvants to 0.25 bupivacaine in TAB block.
40938260|NCT06331676|PROCEDURE|Tissue collection|Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling
40938261|NCT06331676|OTHER|Data collection|Questionnaire on menstrual health and history of hormone treatments for the research purpose
40938262|NCT04805320|PROCEDURE|Dental Extraction|Extraction
40938263|NCT02352922|DRUG|Liposomal Bupivacaine|pre-incision infiltration with liposomal bupivacaine
40938264|NCT02352922|DRUG|Bupivacaine HCl|pre-incision infiltration with bupivacaine HCl
40938265|NCT02394548|RADIATION|Contralateral Esophageal Sparing Technique (CEST)|Determine whether CEST decreases rate of severe acute esophagitis
41280636|NCT03597906|PROCEDURE|partial topography modified refraction|partial topography modified refraction means changing only cylinder power and axis in the ablation profile
40938266|NCT01612728|OTHER|Women without Arthralgia|For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine \& Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.
40938267|NCT01612728|DRUG|Women with Arthralgia|
40938268|NCT05023798|DEVICE|ATD (device test)|Medical device test (no intervention)
40938269|NCT00715169|DRUG|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
40938270|NCT00715169|OTHER|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
40938271|NCT01487473|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
40938272|NCT02811601|PROCEDURE|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
41280637|NCT04929639|OTHER|measurment of intraabdominal surgery|Immediately after intubation, while the patient is lying in the supine position, an intra-abdominal measurement will be made from the bladder catheter and recorded. Then, after the surgical site antisepsis, when the trocar required for the operation is placed by the general surgeon, another measurement will be made from the trocar port. Measurements will be recorded.
40938273|NCT01208831|DRUG|LDE225|
40938274|NCT00006389|DRUG|bryostatin 1|Given IV
40938275|NCT00006389|DRUG|cisplatin|Given IV
40938276|NCT00006389|OTHER|laboratory biomarker analysis|Correlative studies
40938277|NCT06004453|OTHER|Heart Failure medications|There is no treatment allocation. Patients are allocated to the respective cohort based on the treating physician enrolling them in the study. Patients are treated according to the local prescribing information and routine medical practice.
40938278|NCT02812303|OTHER|Centralized support for population health management activities|
40938279|NCT01546064|DEVICE|Choledocho-choledochostomy with T-tube|In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
40938280|NCT01546064|DEVICE|Choledocho-choledochostomy without T-tube|The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
40938281|NCT01129674|DRUG|LY2140023|Administered orally, twice daily for 104 weeks
41280638|NCT00124306|DRUG|Amitriptyline|Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.
41280639|NCT00124306|OTHER|Placebo|Placebo will be dosed exactly as active arm.
41280640|NCT03184870|DRUG|BMS-813160|Specified dose on specified days
41280641|NCT03184870|BIOLOGICAL|Nivolumab|Specified dose on specified days
41280642|NCT03184870|DRUG|Nab-paclitaxel|Specified dose on specified days
41280643|NCT03184870|DRUG|Gemcitabine|Specified dose on specified days
40938282|NCT01129674|DRUG|Olanzapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
40938283|NCT01129674|DRUG|Aripiprazole|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
40938284|NCT01129674|DRUG|Risperidone|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
40938285|NCT01129674|DRUG|Quetiapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
40938286|NCT05274659|DRUG|KJ103|Recombinant Immunoglobulin G Cleaving Enzyme
40938287|NCT05274659|DRUG|Placebo|Placebo
40938288|NCT02147002|DIETARY_SUPPLEMENT|Gold omega 3|At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
40938289|NCT04405427|PROCEDURE|head acupoints acupuncture|The participants will undergo GV20, EX-HN-1, GV21, GV22, GV23, GV24, GV29, and GB13 head acupoints aupunture treatment 3 times/ 1 week for 4 weeks.
40938290|NCT04405427|PROCEDURE|body acupoints acupuncture|The participants will undergo HT7, PC6, SP6, ST36, KI3, and LR3 body acupoints acupunture treatment 3 time/1 week for 4 weeks.
40938291|NCT04733612|OTHER|Informative messages|"In addition to their standard treatments, an informative SMS (text message) on diabetes was sent to the intervention group three to four times a week for six months.~The short messages were in the form of a short sentence for the subject and the predicate. The messages sent have been prepared in such a way that they do not exceed 1 SMS quota and are less than 160 characters on mobile phones."
40938292|NCT00450775|DRUG|Dermatix Q|Dermatix Q applied twice daily
40938293|NCT00695578|DRUG|Biafine|Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
40938294|NCT00695578|DRUG|Polysporin|over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
40938295|NCT00116662|DRUG|Resiquimod|
40938296|NCT00926068|DRUG|HO/03/03 10µg|
40938297|NCT00926068|DRUG|Placebo|
40938298|NCT01402895|OTHER|Exercise|Transversus abdominus exercise
40938299|NCT01402895|OTHER|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
41280644|NCT03184870|DRUG|5-fluorouracil (5-FU)|Specified dose on specified days
41280645|NCT03184870|DRUG|Leucovorin|Specified dose on specified days
41450645|NCT06241222|DRUG|Probiotic Blend Oral Tablet|In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
40756267|NCT02524899|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.
40756268|NCT02524899|DRUG|Guanfacine|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
40756269|NCT02524899|DRUG|Placebo|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
40756270|NCT04065841|DRUG|Tropifexor|100mcg+30mcg+10mcg capsules of tropifexor taken orally every day until the 140 mcg capsule of tropifexor taken orally every day is produced, then patients will switch to the single 140mcg capsule taken orally every day
40938300|NCT00484718|DRUG|celecoxib|oral, 100 mg bid
41280646|NCT03184870|DRUG|Irinotecan|Specified dose on specified days
41450646|NCT05718687|DRUG|GBT021601|Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601
41450647|NCT05212350|PROCEDURE|Total pancreatectomy|Patients randomized to receive total pancreatectomy at the time of transection of the pancreas will undergo completion total pancreatectomy according to each Institution's operative standards.
40938301|NCT00484718|DRUG|Oxycodone|oral, 20 mg bid
40938302|NCT00484718|DRUG|placebo|oral bid
40938303|NCT03144024|DEVICE|band implantation|
40938304|NCT03144024|DEVICE|rigid ring implantation|
41280647|NCT04372264|DRUG|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
41280648|NCT04372264|DRUG|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
41280649|NCT04372264|DRUG|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
40938305|NCT02325661|OTHER|cognitive interviewing|"For the individual cognitive interviews we are using the two techniques to think aloud and the verbal probing. To think aloud means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the verbal probing technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation."
40938306|NCT04807140|DRUG|Toripalimab, nab-paclitaxel, carboplatin|"Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
40938307|NCT04807140|DRUG|Toripalimab|"Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
40938308|NCT04807140|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
40938309|NCT00611039|DRUG|Darunavir 900mg + ritonavir 100 mg once a day|Darunavir 900mg + ritonavir 100 mg once a day
40938310|NCT00611039|DRUG|Darunavir 600mg + ritonavir 100mg twice day|Darunavir 600mg + ritonavir 100mg twice day
40938311|NCT05866627|DRUG|Famotidine|Specified dose on specified days
40938312|NCT05866627|DRUG|Afimetoran|Specified dose on specified days
40938313|NCT05590221|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
40938314|NCT05590221|DRUG|Fludarabine|Administered according to package insert
40938315|NCT05590221|DRUG|Cyclophosphamide|Administered according to package insert
40938316|NCT02770469|BEHAVIORAL|Linguistically and Culturally Tailored Information|Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.
40938317|NCT02770469|BEHAVIORAL|Cognitive-Behavioral Stress Management|Participants learned and practiced skills related to mindfulness, relaxation, stress reduction, rational thinking, improving coping, enhancing social support, anger management, and assertiveness training.
40938318|NCT04594954|DIETARY_SUPPLEMENT|Diet|A high-protein low carbohydrate diet (HPLC) diet would be prescribed to the patients. HPLC (high-protein low carbohydrate) diet would comprise of energy as 20-25 Kcal/Kg IBW/day (amounting to 700- 800 Kcal less than the usual dietary intake), Protein as 1.2-1.5 gm/Kg IBW/day i.e. 30% of the total calories as proteins, 52% of carbohydrates 18% of fats with dietary fiber as 25 g/day. The protein requirements would be met with modular high protein, low calorie supplements.
40938319|NCT04594954|OTHER|FMT|"Stool Administration Procedure (ILBS FMT Protocol)~* 500 mL filtrates will be delivered through the UGI Endoscopy into proximal jejunum \[(2 to 3 minutes per 50 ml).\]~* The recipient will be kept nil per oral for at least 4 hours prior to the stool instillation.~* 100 mL freshly thawed sample will be given once in 15 days for 3 doses~* Non-absorbable antibiotics will be avoided in the patient from the time of enrollment into the study and therapy initiation.~* Intravenous antibiotics will be continued as per institutional protocol in the event of active sepsis based on culture and sensitivity.~* The patient will be allowed to consume liquid diet two hours after the procedure."
40938320|NCT04594954|OTHER|Physical Activity|"Physical Activity:~The exercise program would consist of brisk walking. Brisk walking is defined as the walking intensity of 60-70% of their respective age-predicted maximum heart rate (target heart rate) 27,28. Speed of 5- 6 kmph considered as a brisk walking in most of the studies preferably on a treadmill for a duration of 30-45 minutes30 or brisk walking (walking faster than normal pace, measure 5000 steps continuously by pedometer). Same amount of physical activity would be prescribed to both the groups for 5 days a week for 30 -45 min."
40938321|NCT00430430|PROCEDURE|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
40938322|NCT00430430|PROCEDURE|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
40938323|NCT05594043|DRUG|MK-6598|Oral tablet
40938324|NCT05594043|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
40938325|NCT05616715|DEVICE|Peek device|Participants with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
40938326|NCT05616715|OTHER|Crown lengthening/gingivectomy|Participante with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
41131161|NCT06318559|PROCEDURE|3D Robot-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy|"The operation is performed using the Da Vinci HD robotic system which allows the use of laparoscopic instruments, with greater mobility and the possibility of easier and more precise control of movements in three dimensions. Furthermore, the system allows the surgeon a three-dimensional view of the operating field. The surgery is performed under general anesthesia. Six or more trocars are positioned, into which the instruments operated by the robot or directly by the surgical assistants are inserted.~Then a radical prostatectomy is performed."
41131162|NCT04347733|DRUG|Triamcinolone Acetonide 40mg/mL|We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
41131163|NCT04347733|DRUG|Hyaluronidase Injection|We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
41131164|NCT00070694|DRUG|MDL100.907|
41450648|NCT05212350|PROCEDURE|Pancreatic anastomosis|Patients randomized to receive pancreatic anastomosis at the time of transection of the pancreas will undergo pancreatico-jejunosomy or pancreatico-gastrostomy according to each Institution's operative standards.
40756271|NCT04065841|DRUG|Licogliflozin|30mg tablet of licoglifozin taken orally every day
40938327|NCT01952470|DRUG|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
40938328|NCT01952470|DRUG|Isotonic Saline.|Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
40938329|NCT06336161|DRUG|Fentanyl|to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.
40938330|NCT02670343|DRUG|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
40938331|NCT05214378|DEVICE|Finetech-Brindley Sacral Anterior Roots Stimulation System|Electrodes implanted on sacral roots connected to implanted induction coil. External controller box administers stimulation via induction through skin to electrodes. Stimulation activates nerves to modulate bladder, bowel, and sexual functions.
40938332|NCT04653532|BEHAVIORAL|Exercise Programme and Counselling|A 6 month exercise and physical activity programme supported by an exercise specialist
40938333|NCT04653532|DEVICE|Polar Ignite and App|A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
40756272|NCT04065841|OTHER|Placebo|licogliflozin placebo + tropifexor placebo
40938334|NCT05143190|DRUG|PTR-01|Intravenous recombinant collagen 7
40938335|NCT04335422|DEVICE|Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)|"Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games.~Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given."
40938336|NCT04335422|BEHAVIORAL|Control group (routine physical and rehabilitation medicine program)|Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
40938337|NCT00122278|DRUG|Dexamethasone|Dexamethasone 10mg IV
40938338|NCT00122278|OTHER|Placebo|Placebo Dexamethasone 10mg IV
41450649|NCT05721794|OTHER|A multicentric prospective observational longitudinal cohort study.|Observational study on the accuracy of TPUS and MRI in the investigation of perianal fistulae in CD patients.
40938339|NCT02185846|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
40938340|NCT02185846|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
41450650|NCT01573663|DRUG|Ambroxol and Levodropropizine|Ambroxol HCl 30mg \& Levodropropizine 60mg, PO, Single dose
40938341|NCT01607268|PROCEDURE|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy \[1H-MRS\] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
40938342|NCT02487823|DRUG|BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide|BKM 120, LH-RH agonists and Bicalutamide
40938343|NCT05569811|DRUG|Patritumab deruxtecan|HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
41450651|NCT01573663|DRUG|Ambroxol|Ambroxol HCl 30mg, PO, single dose
41450652|NCT01573663|DRUG|Levodropropizine|Levodropropizine 60mg, PO, single dose
40756273|NCT00032331|PROCEDURE|PET Imaging|
40756274|NCT00032331|PROCEDURE|CT scan|
40938344|NCT05569811|DRUG|Chemotherapy|Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
41280650|NCT03389672|PROCEDURE|spinal anesthesia|For conventional spinal anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
41280651|NCT03389672|PROCEDURE|epidural anesthesia|For conventional epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
40938345|NCT05569811|DRUG|Letrozole|Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
40938346|NCT01863810|DRUG|KW21052|1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
40938347|NCT01863810|DRUG|Lyrica|1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
40938348|NCT01863810|DRUG|Lyrica (low dose)|1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
40938349|NCT01863810|DRUG|Placebo of KW21052|Oral,once a day, for 8 weeks
40938350|NCT01863810|DRUG|Placebo of Lyrica|Oral, twice a day, for 8 weeks.
40938351|NCT01071473|OTHER|12 Week Exercise Intervention|Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
41131165|NCT02329704|PROCEDURE|Diff-Quik staining for morphology evaluation|"Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).~Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm."
41131166|NCT02329704|PROCEDURE|Motility Evaluation for grade A and B|"The better separation method will insure more progressive sperms after processing.~Grading using A and B scale scored by (WHO 2010) references."
41280652|NCT03389672|PROCEDURE|combined spinal-epidural anesthesia|For conventional combined spinal-epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
41450653|NCT05911321|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle.
41450654|NCT05911321|DRUG|Pomalidomide|Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle.
40744345|NCT04529408|DEVICE|EarSats Pulse Oximeter Probe|Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test
40938352|NCT03256188|BEHAVIORAL|Active classroom|30 minutes of moderate-to-vigorous physical activity
40938353|NCT01737450|DRUG|BKM120|
40938354|NCT03888131|DRUG|CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo|Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
41131167|NCT02329704|PROCEDURE|Concentration (mil/ml)|count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
41131168|NCT02329704|PROCEDURE|24 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
41131169|NCT02329704|PROCEDURE|48 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
40938355|NCT03888131|DRUG|Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
40938356|NCT02301988|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
40938357|NCT02301988|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion QW for 3 cycles.
40938358|NCT02301988|DRUG|Placebo|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
40938359|NCT02283177|DRUG|crenolanib|
40938360|NCT02283177|DRUG|cytarabine|
40938361|NCT02283177|DRUG|daunorubicin|
40938362|NCT02283177|DRUG|idarubicin|
40938363|NCT00470158|DIETARY_SUPPLEMENT|iron and zinc combined|Children \>= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
40938364|NCT00470158|DIETARY_SUPPLEMENT|iron and zinc on separate days|Children \>= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
40938365|NCT00470158|DIETARY_SUPPLEMENT|iron|Children \>= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
40938366|NCT00470158|DIETARY_SUPPLEMENT|Zinc|Children \>= 12 months received an average of 5mg zinc/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
40938367|NCT00470158|DIETARY_SUPPLEMENT|placebo|Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
40938368|NCT02025517|OTHER|Cognitive Tasks.|The Experimental Group underwent treadmill gait training simultaneously to a protocol of cognitive tasks created specifically for this study, based on cognitive activities proposed in previous studies. The training sessions lasted 20 minutes. The first three minutes allowed subjects to familiarize themselves with the treadmill. From the 4th minute onward, the volunteer walked for 1 minute while performing cognitive tasks, and in the following minute, only walked. Thus, the 17 remaining minutes on the treadmill alternated between one minute of treadmill training combined with a cognitive task and the following minute only treadmill training. Treadmill gait speed was that reported by the patient as the fastest possible speed while maintaining a suitable comfort level.
40938369|NCT01713387|DRUG|Gemcitabine, S-1|Dose of gemcitabine and S-1 and treatment schedule
40938370|NCT00596362|DRUG|AVASTIN|a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
40938371|NCT00005863|BIOLOGICAL|filgrastim|
41131170|NCT02329704|PROCEDURE|HBA Testing|"The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).~By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm."
41131171|NCT02329704|BIOLOGICAL|Bacterial contamination|Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
41450655|NCT05911321|DRUG|Dexamethasone|Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week.
41450656|NCT03993145|BEHAVIORAL|Web-based lifestyle intervention|Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
40938372|NCT00005863|DRUG|cytarabine|
40938373|NCT00005863|DRUG|daunorubicin hydrochloride|
41280653|NCT00775164|DRUG|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
41280654|NCT00775164|DRUG|Metformin|Metformin XR; 1000 mg once daily
41450657|NCT02619253|DRUG|Pembrolizumab|
41450658|NCT02619253|DRUG|Vorinostat|
41450659|NCT03574805|DRUG|PRS-060|Study drug
41450660|NCT03574805|DRUG|Placebo|Inhalant designed to mimic PRS-060
41450661|NCT02042560|OTHER|Blood samples|
41450662|NCT02042560|OTHER|Spleen samples|
41280655|NCT02088034|BEHAVIORAL|Promotora-led Intervention|Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
41280656|NCT02088034|DRUG|Metformin Therapy|Participants in this group will receive metformin 850 mg bid for one year.
41280657|NCT02088034|OTHER|Usual Care|Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
41280658|NCT05088148|OTHER|. Pesticide and Pharmaceutical analysis|Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.
41450663|NCT02479763|PROCEDURE|Waveform-confirmed loss-of-resistance|Using waveform analysis to confirm thoracic epidural space
41450664|NCT00239005|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
41450665|NCT00239005|DRUG|Mycophenolate Mofetil (MMF)|
41280659|NCT02114190|BEHAVIORAL|Adolescent Mindful Eating Group|Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
41450666|NCT00680940|DRUG|Paclitaxel & Cisplatin|Chemotherapeutic agent
41450667|NCT00680940|BIOLOGICAL|Mycobacterium w.|Immunomodulator
41450668|NCT03649763|DRUG|Lidocaine|lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
41450669|NCT03649763|DRUG|Bupivacaine|Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
41280660|NCT02114190|BEHAVIORAL|Parent Integrated Group|Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
41280661|NCT04489238|OTHER|Risk Factor Questionnaire|Participants, both cases and controls, will complete the CYOC risk factor questionnaire, preferably at the time of first visit
41450670|NCT03649763|DRUG|Lidocaine|lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
41450671|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative|0.25 mL, Intramuscular
41450672|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative|0.5 mL, Intramuscular
41450673|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative|0.5 mL, Intramuscular
41450674|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative|0.5 mL, Intramuscular
41450675|NCT04431505|OTHER|apoptosis|study of apoptotic changes due to anaesthesia
41450676|NCT04124354|BEHAVIORAL|Physical Activity|Participants will attend 3 treadmill walking sessions/week for 8 weeks (24 total)-exercising at 60-75% of their heart rate (HR) reserve monitored using Polar FT1 HR monitors. All walking sessions will take place using treadmills within the West Bank Office Building on the UMN-Twin Cities campus. Each walking session will be 30 min long during intervention weeks 1-4 and 45 min each during weeks 5-8. This exercise dose is equivalent to that employed in the only two human studies of exercise and the gut microbiome in addition to the dosage observed necessary to yield meaningful cardiometabolic changes. After the 4th- and 8th-weeks of the intervention, participants in both study groups will again undergo outcome assessments
40744346|NCT00368550|DRUG|Sertraline|Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
40938374|NCT00005863|DRUG|etoposide|
41280662|NCT03010189|DEVICE|Actigraphy|A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.
41450677|NCT05567003|PROCEDURE|Percutaneous transhepatic cholangioscopic (PTCS) laser incision|Infrared percutaneous transhepatic cholangioscopic guided holmium laser incision for treatment of benign biliary strictures.
41280663|NCT03010189|DEVICE|Heart-rate variability monitoring|A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.
40938375|NCT00005863|DRUG|fludarabine phosphate|
40938376|NCT00005863|DRUG|tretinoin|
40938377|NCT02445391|DRUG|Capecitabine|Given PO
41131172|NCT03872063|OTHER|Experimental|The intervention by myofascial induction will consist of the application of two techniques: global technique of myofascial induction of the pectoralis major muscle (once the tissue is placed in tension, the direction of fascia release in that region should be followed and as a result of the release, the caudal hand can move to the pelvis in any direction, to the right or to the left) and telescopic technique for the upper extremity of the subject's dominant arm (gently tractioning the upper limb of the subject, making a slight external rotation, so slow and progressive). The subjects will then perform the eccentric exercises, which will also be done by control group subjects
41280664|NCT03010189|DEVICE|Pupillometry|A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.
41280665|NCT05842343|OTHER|Stool sample|Purification by affinity of the IgA coated bacteria from a fecal solution. Genomic analysis of the bacteria for diversity and richness
41450678|NCT01446770|DEVICE|Hydrogel scaffold (MF-4181)|Following surgical removal of the ear keloid, the incision will be treated with MF-4181.
41450679|NCT01572857|BIOLOGICAL|urinary excretion of FLC immunoglobulin|"First phase :~Collection of four urine samples daily for 2 days:~* Of the 24-hour urine~* at 8 AM~* at 12 AM~* at 4 PM~On each of these urine samples, the following analysis will be performed:~* Proteinuria~* Albuminuria~* Urinary FLC (Freelite ™)~* Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row."
41450680|NCT00353457|DRUG|Capecitabine, Oxaliplatin and Cetuximab|Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
41450681|NCT00353457|RADIATION|Radiation|45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
40938378|NCT02445391|DRUG|Carboplatin|Given IV
40938379|NCT02445391|DRUG|Cisplatin|Given IV
40938380|NCT04165642|OTHER|Laser ballon ablation for Pulmonary vein isolation|The patients indicated to AF ablation procedure will be treated with laser balloon ablation without verification of electrical isolation of pulmonary veins using implantable loop recorder and/or Holter monitoring
40938381|NCT00869843|PROCEDURE|RF Ablation|
40938382|NCT01386112|DRUG|EUR-1100|Active oral medication
40938383|NCT01386112|DRUG|placebo|matching placebo
41280666|NCT05842343|OTHER|Food intake evaluation|Measure (by survey) of food group intake for : lipids /proteins / fibers / carbohydrates
41450682|NCT05978791|PROCEDURE|collection of venous blood or arterial blood|"1. Partial CAD patients were collected 20 mL arterial blood samples 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor. The blood samples were divided into 2 mL centrifuge tubes, with each containing 1.0 mL (for preparation of blood clots).~2. Partial CAD patients were collected 40 mL blood samples into sodium citrate anticoagulant tubes 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor (for preparation of platelet-poor plasma, PPP).~3. Healthy volunteer (group 1) collected 40 mL blood samples into sodium citrate anticoagulant tubes (for preparation of PPP).~4. Healthy volunteer (group 2) collected 9 mL venous blood samples (for platelet aggregation assay)."
41131173|NCT03872063|OTHER|Control|The intervention by eccentric exercises will consist of two exercises using an elastic band. In the supine position, with the elastic band on the contralateral side attached to a fixed body perpendicular to the subject's hand performing a slow and constant movement of external rotation against resistance in an approximately 45 degree arc; holding for 5 seconds and relaxing slowly (perform 3 sets of 12 repetitions). The second exercise, with the elbow in 90 degrees of flexion and a shoulder abduction also of 90 degrees, with the elastic band in front of the subject, executing a movement against resistance performing an external rotation.
41131174|NCT03737487|PROCEDURE|Multidisciplinary fall risk and geriatric comprehensive assessment|"* Complete blood count, serum electrolytes, C-Reactive Protein, transaminases and gamma-glutamyl transferase, thyroid-stimulating hormone, and 25OH vitamin D.~* Calculation of BMI~* A 40-min assessment of balance, walking speed, muscle strength, activity, and functional status by a physiotherapist~* A 40-min assessment by an occupational therapist, including a detailed questionnaire on social support, living situation and home environment, fear of falling, and cognitive function~* A 20-min assessment by a podiatrist including an examination of the patient's feet and footwear.~* A 60-min assessment by a geriatrician including assessment of circumstances of the previous fall(s), review of current medications and medical history, and an in-depth examination of the patient to detect possible contributors or risk factors for falling~* A 20-min review meeting with the 4 healthcare professionals in order to prioritize recommendations to be provided."
41280667|NCT06030011|BEHAVIORAL|NYU Electronic Patient Visit Assessment (ePVA)|The NYU Electronic Patient Visit Assessment (ePVA) for head and neck cancer is a digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. Patients access the ePVA through a web link and complete the survey questions within 10 minutes on digital devices (e.g., smart phones, laptops, or digital devices provided by the clinic).
40938384|NCT03220529|DEVICE|Brillouin Ocular Scanner|
41450683|NCT03822754|BIOLOGICAL|sIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
41131175|NCT01808352|DRUG|FTC/TDF|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
41450684|NCT03822754|BIOLOGICAL|wIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
40938385|NCT02054468|DRUG|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
40938386|NCT02054468|DRUG|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
40938387|NCT02054468|DRUG|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
40938388|NCT02054468|DRUG|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
40938389|NCT02054468|DRUG|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
40938390|NCT02054468|DRUG|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
40938391|NCT02054468|DRUG|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
41450685|NCT04183335|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
40938392|NCT02054468|DRUG|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
41131176|NCT04658667|BIOLOGICAL|IHV01|IHV01 consists of the Full-Length Single Chain (FLSC) gp120-CD4 chimera subunit HIV-1 vaccine formulated in aluminum phosphate adjuvant. It is encoded by a synthetic gene, which contains a human codon-optimized HIV (BaL) gp120 sequence followed by human CD4D1D2, with a flexible 20-amino acid linker.
41131177|NCT04658667|BIOLOGICAL|A244|A244 consists of the gp120 envelope glycoprotein HIV-1 subtype CRF_01AE A244 derived from the CM244 CRF_01AE. The A244 gp120 envelope has an 11 amino N-terminal deletion, similar to the A244 protein used in AIDSVAX B/E. The aluminum hydroxide fluid gel (AHFG) adjuvant that is mixed with A244 consists of Rehydragel HPA that is diluted with sterile water for injection to a concentration of 5 + /- 1mg/mL.
41131178|NCT04658667|BIOLOGICAL|ALFQ|ALFQ (Army Liposomal Formulation) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA) with the addition of QS-21.
41450686|NCT04183335|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
41450687|NCT04183335|DRUG|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
41450688|NCT04183335|DRUG|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
41450689|NCT04183335|DRUG|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
40938393|NCT02054468|DRUG|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
40938394|NCT03901898|BEHAVIORAL|Training, audit, and reminders|Briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter), and re-audit at 6 months.
40938395|NCT03901898|BEHAVIORAL|Intervention after 6 months (wait list)|After 6 months, practices receive the intervention: briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter).
40938396|NCT04315935|DRUG|Butorphanol and Propofol|The two groups were given propofol for sedation, BG for butorphanol for analgesia and FG for fentanyl for analgesia
40938397|NCT04315935|DRUG|Fentanyl and Propofol|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
40938398|NCT04518202|DRUG|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
41131179|NCT04658667|OTHER|Placebo|Normal saline (Sodium Chloride for injection USP, 0.9%) will be used as placebo.
41131180|NCT00369902|PROCEDURE|acupuncture|
41450690|NCT06462976|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
41450691|NCT04238715|DRUG|E7090|E7090 tablets orally.
41450692|NCT01366963|BEHAVIORAL|Seated Measurements|"The following measurements will take place in a seated position:~Ruff 1 \& 7 (visual search and attention processes) Trails A \& B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)"
41450693|NCT01366963|BEHAVIORAL|Standing Measurements|"The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test"
41450694|NCT01366963|BEHAVIORAL|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
41280668|NCT06030011|BEHAVIORAL|Usual Care|Usual care encompasses pre-treatment, on treatment, and post-treatment care. Pre-treatment care includes education of patients on the treatment plan. On-treatment care includes daily monitoring by a nurse in the radiation therapy (RT) department, weekly on-treatment visits with the RT nurse practitioner and radiation oncologist, and weekly visits with medical oncology nurse practitioners and medical oncologists for patients receiving RT plus chemotherapy. Post-treatment care includes follow-up visits with HNC clinicians (i.e., surgeon, medical oncologist, oral maxillofacial surgeons, and radiation oncologist) to assess the patient's cancer status and identify the patient's acute and long-term symptoms. The clinician's decisions on radiologic exams and referrals to appropriate specialist services, including dental care, are based on the patient's cancer status and symptoms.
41280669|NCT06196502|OTHER|Gentle Human Touch (GHT)|Gentle touch is a touch technique that provides a kind of relaxation in premature babies, reduces behavioral stress and motor activities of babies and is effective in their positive behavior. GHT Hepatitis-B vaccine will start 5 minutes before the application and continue during and after the procedure. It is planned to take 10 minutes in total. The researcher will place one hand on the baby's head and the other hand on the baby's lower abdomen, covering the waist and hips, for 10 minutes.
41280670|NCT06196502|OTHER|Kangaroo Care|"Kangaroo care will be provided to randomly selected volunteer moms in their own gynecological ward rooms, where they will have skin-to-skin contact with their babies while maintaining their privacy. Kangaroo care is a strategy that promotes bonding and engagement between a mother and her infant by allowing skin-to-skin contact with the newborn's face facing the mother and only the diaper remaining.~The infant is positioned such that his or her shoulders are totally on the mother's chest, ensuring the baby's airway is open. To avoid heat loss while the baby is in skin-to-skin contact with his mother, a tiny blanket will be placed on his back and a beanie will be placed on his head. Kangaroo care will begin 5 minutes before the Hepatitis-B vaccine is administered and will continue throughout the operation. It is estimated that it will take 10 minutes in total."
41280671|NCT06196502|OTHER|Lactation|Breastfeeding will become standard medical practice. Breastfeeding will start as soon as the baby is given the vaccination and continue throughout the process.
41280672|NCT05281315|OTHER|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.
41280673|NCT01706913|OTHER|Dermatology consult|
41280674|NCT05934214|DRUG|Immune checkpoint inhibitor|"Reports associated with an an Immune checkpoint inhibitor with a status of Suspect or Interacting~ICI will include the following list of FDA-apporved ICIs:~nivolumab, pembrolizumab, cemiplimab, dostarlimab, durvalumab, atezolizumab, avelumab, ipilimumab, tremelimumab, relatlimab"
40938399|NCT04518202|DRUG|Sham patch|Sham patch containing no study medication applied at 6 hours before the scheduled office hysteroscopy.
40938400|NCT03053765|OTHER|training in IPT|Follow-up training in IPT to determine which best enhances fidelity
40938401|NCT01799031|OTHER|internet-based intervention|Receive access to the WISE web-based educational intervention
41450695|NCT05297227|PROCEDURE|Non surgical periodontal Therapy|Non-surgical periodontal therapy comprising oral hygiene instruction and motivation, professional mechanical plaque removal, and subgingival instrumentation will be performed. It consists in the use of an ultrasuond (piezoeletric device) and manual curettes.
41450696|NCT05154890|DRUG|Pegtarviliase IV|Administered IV
41450697|NCT05154890|DRUG|Pegtarviliase SC|Administered SC
41450698|NCT00068731|DIETARY_SUPPLEMENT|lycopene|
41450699|NCT01665404|DRUG|Fluvoxamine|Multiple doses of fluvoxamine
41450700|NCT01665404|DRUG|RO4917523|Single dose of RO4917523
41450701|NCT03531645|DRUG|Fulvestrant|"Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days."
41450702|NCT03531645|DRUG|Abemaciclib|"Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days."
41450703|NCT00192257|BIOLOGICAL|CAIV-T and TIV|
41450704|NCT01394419|DRUG|N-acetylcysteine|N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
41450705|NCT01394419|DRUG|Saline|Equal volume of normal saline
41450706|NCT03007563|DEVICE|bilirubin concentration estimation from smartphone pictures|pictures taken of the skin covering the breast bone
41450707|NCT03007563|PROCEDURE|bilirubin concentration measured in standard blood samples|
40938402|NCT01799031|PROCEDURE|management of therapy complications|Receive standard of care
40938403|NCT01799031|OTHER|educational intervention|Receive access to the WISE web-based educational intervention
41450708|NCT03007563|DEVICE|bilirubin concentration measured by transcutaneous device|
40938404|NCT01799031|OTHER|questionnaire administration|Ancillary studies
40938405|NCT01799031|PROCEDURE|quality-of-life assessment|Ancillary studies
41450709|NCT01394094|BEHAVIORAL|Gum chewing|Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
41280675|NCT01400737|DRUG|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
40938406|NCT02234856|PROCEDURE|Laparoscopic Hysterectomy trainer|In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
41280676|NCT01400737|DRUG|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
41280677|NCT00587223|DEVICE|Apligraf|Up to 3 applications: Day 0, Month 1, Month 2.
41280678|NCT00587223|OTHER|Standard dressing regimen|Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
41280679|NCT04751643|OTHER|Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)|"Therapeutic plasma exchange (TPE) ; 3 sessions in 3 consecutive days (Day 1 to Day 3) in intensive care unit in addition to usual treatments.~Plasma removed is replaced by thawed fresh frozen plasma. Plasma blood volume exchanged : 1.2 Apheresis type: centrifugation"
41450710|NCT03013413|PROCEDURE|Shear Wave Elastography|Undergo ultrasound-based elastography imaging using the Aixplorer system
41450711|NCT03013413|PROCEDURE|Ultrasound Elasticity Imaging|Undergo ultrasound-based elastography imaging using the Aixplorer system
41450712|NCT03013413|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo standard of care ultrasound-guided prostate biopsy
41450713|NCT06628310|DRUG|ABBV-400|Intravenous (IV) Infusion
41450714|NCT06628310|DRUG|Budigalimab|IV Infusion
41450715|NCT06628310|DRUG|Fluorouracil|IV Infusion; IV Injection
41450716|NCT06628310|DRUG|Leucovorin|IV Infusion; IV Injection
41450717|NCT06628310|DRUG|Oxaliplatin|IV Infusion
41450718|NCT03227939|PROCEDURE|Laparoscopic sleeve gastrectomy（LSG）|LSG：All these operations were performed by the same surgeon team. Dissect the greater omentum alongside the greater gastric curvature, make sure that the greater gastric curvature and fundus of stomach were completely made free from pancreas and spleen.Fully Exposed left and right diaphragm angle and taking care not to injure the esophagus. Resection was started 2 to 4 cm from pylorus and alongside a 40Fr tube up to the esophagogastric junction and created a 60 to 80ml gastric lumen, removed the fundus of stomach thoroughly and take care of the esophagus and preventriculus. Repaired the hiatal hernia if it was exsit.
41450719|NCT03227939|PROCEDURE|Uvulopalatopharyngoplasty(UPPP) and Adenoidectomy/Tonsillectomy|UPPP：PPP is typically administered to patients with obstructive sleep apnea in isolation. It is administered as a stand-alone procedure in the hope that the tissue which obstructs the patient's airway is localized in the back of the throat. The rationale is that, by removing the tissue, the patient's airway will be wider and breathing will become easier.
41450720|NCT03414151|OTHER|Observation|No intervention administered.
41450721|NCT01103713|DRUG|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
40744347|NCT00368550|DRUG|Placebo|Placebo for 14-week treatment period
40938407|NCT03119207|BEHAVIORAL|Naptime Protocol|Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
41450722|NCT05274022|OTHER|Standard of Care Physical Therapy Program|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits. As part of the study, all patients will receive the same exercise program. Exercises will include lower extremity strengthening, balance, and mobility exercises with the use of modalities as needed
40938408|NCT03407300|DRUG|Docetaxel|To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients
40938409|NCT03407300|DRUG|Chinese traditional medicine XH1|To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
41131181|NCT04402736|BEHAVIORAL|The modified Barthel Index-based rehabilitation nursing program|The intervention with the program based on the MBI classified function of patients into five levels, with every 20 points as a level, Each level corresponds to different training items. Training items included self-care training and training in transfer activities, sitting balance, walking, and sit-to-stand, etc. Each training session lasting at least 30 minutes, two sessions per day, for seven continuous days. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
41131182|NCT04402736|BEHAVIORAL|Usual care|Patients in the control group received clinical usual care including the activities of daily living assessment, early mobilization guide and health education. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
41131183|NCT01763853|DRUG|4% albumin|
41131184|NCT02767999|DRUG|Fluoxetine|20 mg of fluoxetine capsule per day from D0 to D90
41131185|NCT02767999|DRUG|Placebo|cellulose placebo per day from D0 to D90
41131186|NCT02767999|RADIATION|fMRI|functional resting state MRI
41131187|NCT02328144|DRUG|Metronidazole|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days
41131188|NCT02328144|DRUG|Placebo|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
41131189|NCT02386098|DRUG|BMS-955176|HIV Maturation Inhibitor
41131190|NCT02386098|DRUG|Atazanavir (ATV)|Atazanavir
41131191|NCT02386098|DRUG|Ritonavir (RTV)|Ritonavir
41131192|NCT02386098|DRUG|Dolutegravir (DTG)|Dolutegravir
41131193|NCT02386098|DRUG|Tenofovir (TDF)|Tenofovir
41450723|NCT05274022|OTHER|Speed Walking Intervention|The 4-6 week program will consist of a warm up of active stretching. Following the warm up, subjects will perform a 2 minute warm up followed by 1 minute of walking at their fastest comfortable speed followed by 2 minutes of active recovery where they will walk at a speed of their choosing for 4cycles and then a 2 minute cool down. The program will be performed 12 visits over 4-6 weeks.
40938410|NCT02378675|OTHER|Blood draw|During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
40938411|NCT03892473|OTHER|Community mental health teams (CMHT)|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
40938412|NCT03892473|OTHER|Care as usual (CAU)|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
40938413|NCT02097537|DRUG|Methacholine Chloride (SK-1211)|
41131194|NCT03417700|DIETARY_SUPPLEMENT|NW training|NW training
41131195|NCT03417700|DIETARY_SUPPLEMENT|Placebo|training with placebo
41131196|NCT03417700|DIETARY_SUPPLEMENT|HICT|Training and vitamin D
41131197|NCT05522023|PROCEDURE|group treated with aromatic solution|The aromatic solution applied in the experimental group will be obtained by mixing lavender oil and ginger oil into cold drinking water. For this, lavender and ginger oil approved by the Ministry of Agriculture will be used. 3 drops of lavender oil and 3 drops of ginger oil will be mixed into each 100 ml of drinking water, and it will be applied by spraying 4 times in the oral cavity and throat by shaking to ensure homogeneous distribution before each use. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
41131198|NCT05522023|PROCEDURE|group treated with drinking water|In the placebo group, drinking water will be sprayed 4 times in the oral cavity and throat of the patients after the surgery. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
41131199|NCT04653246|DRUG|Isatuximab|Via IV at predetermined dosage and predetermined days during each cycle
41131200|NCT04653246|DRUG|Lenalidomide|Oral, predetermined dosage and predetermined days during each cycle
41131201|NCT04653246|DRUG|Bortezomib Injection|SQ Oral, predetermined dosage and predetermined days during each cycle
41131202|NCT04653246|DRUG|Dexamethasone|IV or Oral predetermined dosage and predetermined days during each cycle
40938414|NCT06088381|OTHER|Experimental Observation|Patients on the experimental arm will be under observation only.
41131203|NCT03258398|DRUG|eFT508|eFT508 will be taken orally (PO) twice a day (bid).
41450724|NCT04169815|DIAGNOSTIC_TEST|Access Immunodiagnostic Products|Access Natriuretic Peptide Assay
41131204|NCT03258398|DRUG|Avelumab|Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
41131205|NCT05186688|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
41131206|NCT02861820|DEVICE|MRI: Brain Imaging Data Collection|This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
41450725|NCT03720444|OTHER|MDT (mechanical diagnosis and therapy) method|The intervention consists of a first session to carry out an assessment, followed by 4 reassessment sessions
41280680|NCT04751643|OTHER|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
41280681|NCT04075643|DRUG|Reference drug|D935 Cap. 1 Cap., single oral administration under fasting condition
41450726|NCT04306068|OTHER|Plyometric protocol|"Each session will last 20 minutes, with 2 sessions a week, over a period of 5 weeks. The intervention will last 20 minutes, which consists of a 4-station circuit.~Exercise 1: jump on the rope, with your feet together at a moderate pace. Exercise 2: In standing with hands on the hip and hip flexion (one foot in front). Knee flexion and dorsal ankle flexion, with straight trunk. Alternate legs.~Exercise 3: box jump (jump on the box with both feet at the same time). Exercise 4: depth jumps from box to antoher box (jump on the box with both feet at the same time and when falling, immediately jump to the other box).~1 minute with 30 seconds between sets."
41450727|NCT05954663|OTHER|Basic demographic information|"Basic demographic information: age, sex, weight, height, BMI. Comorbidities: history of major bleeding, cardiovascular comorbidities, diabetes mellitus, renal failure, smoking, hormone therapy Anticoagulant and antiplatelet therapy (molecule, duration and indication, before and after intervention) Procedure data: number and type of stents implanted, diameters and lengths, name of stented venous segments Postoperative complications: bleeding complications, pelvic pain, early thrombosis, early pulmonary embolism~* Clinical examination carried out 1 month after the operation and more than 6 months after the operation~* Data from the control ultrasound performed 1 month after the operation and more than 6 months after the operation"
40756275|NCT00233168|BEHAVIORAL|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
40938415|NCT06088381|OTHER|Observation per Standard of Care|The low-risk group of patients will be observed per standard of care.
40938416|NCT06088381|RADIATION|Adjuvant Treatment per Standard of Care|The high-risk group of patients will receive adjuvant treatment per standard of care (Radiation with or without chemotherapy)
40938417|NCT06088381|DIAGNOSTIC_TEST|Circulating Tumor DNA test (ctDNA test)|Blood test for diagnostic and surveillance purposes measuring expression of Cell free HPV tumor DNA (ctDNA) in the blood. Patients will undergo ctDNA within 90 days pre-transoral robotic surgery(TORS), 2-14 days post TORS, then every 3 months (except for at 21 months) for 2 year post completion of initial therapy or salvage therapy.
40938418|NCT01536288|DRUG|Rhodiola crenulata|Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
41131207|NCT05554549|OTHER|Dietary pattern observed|Dietary pattern: regular meat-eater, occasional meat-eater, pescatarian, and vegetarian. There are no interventions in this observational cohort.
41131208|NCT01616472|DRUG|Cumulative corticosteroid exposure|Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
41280682|NCT04075643|DRUG|Test drug|CKD-385 Tab. 1 Tab., single oral administration under fasting condition
41280683|NCT02012010|PROCEDURE|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
41280684|NCT02012010|PROCEDURE|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
41450728|NCT04090021|DRUG|Esomeprazole 40mg|Use in a drug combination for H. pylori eradication
41450729|NCT04090021|DRUG|Clarithromycin 500mg|Use in a drug combination for H. pylori eradication
41450730|NCT04090021|DRUG|Metronidazole 500 mg|Use in a drug combination for H. pylori eradication
41450731|NCT04090021|DRUG|Amoxicillin 1000 MG|Use in a drug combination for H. pylori eradication
41450732|NCT04090021|DRUG|Levofloxacin 500mg|Use in a drug combination for H. pylori eradication
41450733|NCT04090021|DRUG|Rifabutin 150 MG|Use in a drug combination for H. pylori eradication
41450734|NCT02007863|PROCEDURE|Umbilical Cord Blood Transfusion|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
41450735|NCT02007863|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
41280685|NCT04297007|OTHER|PECS block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
41131209|NCT05521906|BEHAVIORAL|Promoting Resilient Youth with Strong Hearts and Minds (PRYSHM)|The intervention focuses on psycho-education (provision of accurate information about LGBTQIA2S+ people, education about the effects of alcohol), fostering positive identity development for LGBTQIA2S+ youth (e.g., fostering pride in identity, exposure to positive adult role models), teaching of alcohol use and sexual refusal skills, correction of inaccurate social norms about alcohol use and dating violence, teaching assertive communication skills, teaching emotion coping skills, mindfulness and grounding skills, and teaching bystander intervention skills related to dating/sexual violence and alcohol use..
41131210|NCT00010088|DRUG|fluorouracil|
41280686|NCT04297007|OTHER|Rhomboid intercostal block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
41280687|NCT00006072|DRUG|Rituxan|
41131211|NCT00010088|DRUG|gemcitabine hydrochloride|
41450736|NCT02007863|DRUG|Busulfan|Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
41450737|NCT02007863|DRUG|Melphalan|Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
40938419|NCT01536288|DRUG|placebo|Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
40938420|NCT02923427|DEVICE|Laryngeal mask Supreme Evaluation|Evaluation of clinical performance in terms of Insertion, ventilation and complications
41131212|NCT00010088|DRUG|leucovorin calcium|
41131213|NCT00010088|PROCEDURE|conventional surgery|
41131214|NCT00010088|RADIATION|radiation therapy|
41280688|NCT01779609|DRUG|Bosentan|
41131215|NCT01372085|DRUG|LY2584702 Reference Formulation|Administered orally
41131216|NCT01372085|DRUG|LY2584702 Test Formulation|Administered orally
41280689|NCT01779609|DRUG|Placebo|
41280690|NCT01779609|BEHAVIORAL|Exercise|Supervised exercise training program of 8 weeks, for 3x/week
41450738|NCT05842135|PROCEDURE|Laparoscopic approach to small bowel obstrcuction|Bowel viability assessment by indocyanine green fluorescent angiography during laparoscopic approach to small bowel obstruction
41450739|NCT06415760|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
40938421|NCT02923427|DEVICE|i-gel Evaluation|Evaluation of clinical performance in terms of Insertion,ventilation and complications
41131217|NCT01372085|DRUG|Placebo|Administered orally
41131218|NCT05436275|BIOLOGICAL|CM310|300 mg every two weeks
41131219|NCT05436275|BIOLOGICAL|Placebo|once every two weeks
41131220|NCT01814839|DRUG|ALN-TTRSC (revusiran)|Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
41131221|NCT01814839|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
41131222|NCT01928875|DEVICE|AoA Monitoring|Monitoring with Entropy and SPI parameters during surgery
41450740|NCT02091713|OTHER|Functional movement screen|The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
40938422|NCT03614767|DIAGNOSTIC_TEST|urodynamics|Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.
41450741|NCT00393250|OTHER|Hypnosis|Subjects receive hypnosis (experimental intervention) during 4 weeks of face-to-face encounters with a physician trained in hypnosis. For 6 weeks following the instruction period, the participants will perform daily self- hypnosis using customizable digital media.
41131223|NCT01928875|DEVICE|Routine (Standard) Anesthesia Monitoring|Standard of care monitoring
41280691|NCT01818544|DRUG|BAY85-8501|BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
41280692|NCT01818544|DRUG|Placebo|Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
41280693|NCT00318955|DRUG|Dexmedetomidine|
41280694|NCT00318955|DRUG|Propofol|
41450742|NCT00393250|OTHER|Control|Subjects in the control arm of the study will receive face-to-face education regarding sickle cell disease for the same length and frequency as the treatment group hypnosis encounters before crossing over to the experimental intervention arm of the study
41450743|NCT00754858|DRUG|belotecan hydrochloride|
40938423|NCT00630695|DRUG|Lanreotide LP 90|Lanreotide LP 90
40938424|NCT00630695|DRUG|Placebo lanreotide|Placebo
40938425|NCT00301821|BIOLOGICAL|epratuzumab|
40938426|NCT00301821|BIOLOGICAL|rituximab|
40938427|NCT00301821|DRUG|cyclophosphamide|
40938428|NCT00301821|DRUG|doxorubicin hydrochloride|
40938429|NCT00301821|DRUG|prednisone|
40938430|NCT00301821|DRUG|vincristine sulfate|
41131224|NCT03018067|DRUG|RDX227675|
41131225|NCT03018067|DRUG|Placebo|
41131226|NCT05010772|DRUG|Decitabine and Cedazuridine|Given PO
41131227|NCT05010772|DRUG|Enasidenib|Given PO
41131228|NCT05010772|DRUG|Gilteritinib|Given PO
41131229|NCT05010772|DRUG|Ivosidenib|Given PO
41131230|NCT05010772|DRUG|Venetoclax|Given PO
41131231|NCT02587052|DRUG|Generic tacrolimus|Generic tacrolimus
41131232|NCT02587052|DRUG|Prograf|Prograf, the original tacrolimus
41280695|NCT00275080|DRUG|vorinostat|Given orally
41280696|NCT00275080|DRUG|decitabine|Given IV
41280697|NCT05244772|OTHER|Remote monitoring|Remote monitoring with a smartphone application of pain and nausea after day care surgery
41280698|NCT06002685|BEHAVIORAL|Attachment and Biobehavioral Catch-Up|The ABC program consists of 10 one-hour home-based sessions delivered by a trained parent coach. Each session includes the mother and her child together and addresses a specific topic. Principal intervention activities include a discussion of basic attachment principles, guided practice of new parenting behaviors, and a review of video clips from previous sessions to help reinforce parenting targets. The parent coach promotes (a) nurturance, especially in response to distress; (b) following the child's lead with delight; and (c) avoiding frightening caregiving behavior. As specified by the ABC protocol, any/all other family members will be invited to observe or participate in each ABC session Each full-time ABC parent coach will serve 8 to 10 families at a time (i.e., complete 8-10 hourly ABC visits per week).
41280699|NCT06002685|OTHER|Home-Based Book-of-the-Week|The HBOW program is an active control condition developed by PI Berlin. It consists of 10 English/Spanish developmentally appropriate books hand-delivered weekly to the mothers. During each of the 10 weeks, a trained RA will visit each HBOW mother to drop off the book and to ask briefly about the mother's and child's well-being (using a standard set of questions). Thus, this condition will parallel the intervention condition in duration (number of weeks) and structure, although it will be less intensive in terms of participant contact time per visit.
41280700|NCT00753636|DRUG|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
41280701|NCT05698186|DRUG|Thero2-01S22|Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
41280702|NCT05698186|DRUG|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
41280703|NCT05698186|DRUG|Thero2-01S22|Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
41450744|NCT00754858|DRUG|cisplatin|
41450745|NCT00994604|DRUG|broccoli sprout extract|consumption of broccoli sprout extract for 2 weeks
40938431|NCT02824172|OTHER|cast immobilization group|Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.
41280704|NCT05698186|DRUG|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
40756276|NCT00233168|BEHAVIORAL|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
40756277|NCT03426852|OTHER|No intervention|No intervention
40756278|NCT00337597|OTHER|Glucose 5%|
40756279|NCT00337597|OTHER|NaCl 0.9%|
40938432|NCT02824172|OTHER|complete sport rest.|Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .
40938433|NCT01030328|DRUG|Placebo|2 sugar pills by mouth once a day.
40938434|NCT01030328|DRUG|TriLipix|135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
40938435|NCT03827837|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
40938436|NCT03827837|DRUG|Famitinib|a small-molecule multikinase inhibitor
40756280|NCT00002656|DRUG|pyrazoloacridine|"Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.~Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)"
40756281|NCT01008046|DRUG|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
40756282|NCT01008046|DRUG|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
40756283|NCT00101400|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
41131233|NCT05127967|OTHER|Skin biopsy|A skin biopsy involves taking a piece of skin to obtain cells (fibroblasts). Skin biopsy is a minimally invasive examination and a technically simple procedure performed with a 3mm diameter punch, or with a scalpel under local anesthesia (Lidocaine patch). The procedure can be done in a consultation office with strict asepsis. It lasts 15 minutes in total + the time to reach between putting on the lidocaine patch and performing the procedure. This biopsy will usually be done on the inside of the arm. In the majority of cases, it is not helpful to close the scar with stitches.
41131234|NCT00219791|DRUG|glucarpidase (50 Units/kg)|
41131235|NCT00366249|DRUG|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
41131236|NCT00366249|DRUG|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
40756284|NCT06427642|BIOLOGICAL|Mononuclear cells|UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation
40756285|NCT06427642|DEVICE|Mild hypothermia therapy|Mild hypothermia therapy via hypothermia therapy apparatus
40938437|NCT00989573|DRUG|Placebo|oral administration of placebo once-daily for 8 weeks
41450746|NCT03512483|BEHAVIORAL|Virtual Atrial Fibrillation Clinic|Participants in the intervention group will receive usual GP care plus the vAFC which consists of telehealth appointments with Nurse Practitioner/Cardiologist and access to an AF specific educational website. It is anticipated the vAFC, as with the onsite clinic, will include a maximum of four scheduled telehealth appointments: an initial appointment following randomization, at 4-6 weeks, 3 months, and 6 months.
40756286|NCT06427642|DEVICE|Breathing support technique|Breathing support via ventilator
40756287|NCT06427642|PROCEDURE|Total parenteral nutrition|Liquid nutrition injected directly into the bloodstream
40756288|NCT03907202|DRUG|Daily injection of KBP/placebo for up to 28 days|Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
40756289|NCT01346592|BIOLOGICAL|Trivalent split influenza vaccine (TIV)|
40756290|NCT01346592|BIOLOGICAL|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
40756291|NCT01346592|BIOLOGICAL|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
40756292|NCT03884920|DIETARY_SUPPLEMENT|Polyherbal formulation|Test candidate will be administered per oral before / with meal in two divided doses
40756293|NCT01242384|DEVICE|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
40756294|NCT06405347|BEHAVIORAL|Inpatient Whole Health Bundle|Hospitalized patients on the intervention units will be offered participation in the Inpatient Whole Health Bundle, which is comprised of a variety of offerings aimed at improving the wellbeing of the patient. They can choose to use any or none of the bundle elements.
40756295|NCT04121871|OTHER|No intervention|Not required
40756296|NCT05444088|DRUG|Adebrelimab|intravenous infusion
40756297|NCT05444088|DRUG|Bevacizumab|intravenous infusion
40756298|NCT05444088|DRUG|SHR-8068|intravenous infusion
40756299|NCT06147245|BEHAVIORAL|Person-centred culturally sensitive course of treatment|12-month person-centred and culturally sensitive intervention: Participants will attend 6 visits at SDCC including visits with a diabetes nurse, physician and dietitian. The course of treatment is focusing on extended time in consultations, use of technology for diabetes monitoring, meeting the same healthcare professionals, awareness of language barriers and use of accurate communication and dialogue tools in participants native language.
40756300|NCT00085020|BIOLOGICAL|trastuzumab|
40756301|NCT00085020|DRUG|lapatinib ditosylate|
40756302|NCT02098486|DRUG|Moxifloxacin|
40756303|NCT02098486|DRUG|ceftriaxone|
40756304|NCT03367351|BEHAVIORAL|Web-Based Education|Completion of a CGM specific web-based educational intervention that includes a series of online learning modules.
40756305|NCT03367351|BEHAVIORAL|Social Support|Engagement in peer-led CGM specific discussion boards
40756306|NCT03367351|BEHAVIORAL|Standard of Care|Standard of Care - serves as the control group for the treatment arm
40756307|NCT02511743|OTHER|physicians|physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
40938438|NCT00989573|DRUG|OPC-6535|oral administration of OPC-6535 25 mg once-daily for 8 weeks
41131237|NCT00556478|DRUG|PSD502, contains a mixture of lidocaine and prilocaine|"PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
40756308|NCT04201405|DRUG|Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene|Autologous CD34+ haematopoietic stem cells from MPS IIIA patients will be genetically modified ex vivo using CD11b.SGSH Lentiviral vector (LV), a self-inactivating LV expressing the SGSH gene codon optimized for human use and regulated by a human CD11b myeloid-specific promoter. Cells will be cryopreserved prior to patient administration.
40756309|NCT06234475|BEHAVIORAL|Mobile health support|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months"
40756310|NCT06234475|BEHAVIORAL|Financial incentive|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
40756311|NCT06234475|BEHAVIORAL|Combine intervention|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months~7. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
40938439|NCT00989573|DRUG|OPC-6535|oral administration of OPC-6535 50 mg once-daily for 8 weeks
40938440|NCT02517970|BEHAVIORAL|Technology distraction|Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
41280705|NCT02998502|DEVICE|Freespira Breathing System|Over an 8-week period the efficacy of the FBS system in youth will be tested, with those in the randomized active device group. The control group will not receive the device until completion of the 8 week baseline.
41280706|NCT03165396|DRUG|Propofol|Propofol is the most common clinical anesthetics.
41280707|NCT03165396|DRUG|Sevoflurane|Sevoflurane is the most common clinical anesthetics.
41280708|NCT05914766|BEHAVIORAL|PATHWAYS|The PATHWAYS intervention is a psychoeducational intervention comprised of three components.
41450747|NCT02116595|OTHER|high or low acid diet|high or low acid diets
41450748|NCT04085861|BEHAVIORAL|Mental health literacy in dancers|Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.
40938441|NCT04631302|BEHAVIORAL|Be Mindful|"Be mindful is an online course run by the Mental Health Foundation and Wellmind Media. It was developed together with British mindfulness instructors and offers access to its course materials and instructional videos through a website (http://www.bemindfulonline.com).~The course consists of 11 sessions led by two mindfulness teachers, one female, one male. Using a variety of media (videos, assignments, audio tracks and e-mails), participants are taught to use formal as well as informal mindfulness techniques. The course lasts 4 weeks. For each week, participants are asked to do a daily formal mediation practice (up to 30 minutes but it varies from week to week) and one or two informal exercises."
41450749|NCT04085861|BEHAVIORAL|Mental health literacy in dance teachers|Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
41450750|NCT05439707|DEVICE|transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
41280709|NCT05914766|OTHER|Enhanced usual care|The enhanced usual care condition consists of an information resource guide.
40938442|NCT04631302|BEHAVIORAL|Light exercise course|"The control condition involves light physical exercises aimed at increasing mobility, reducing stiffness, improving circulation, and avoiding pain or repetitive strain injuries that may result from sedentary or repetitive tasks common in office environments. The exercises will include simple whole-body slightly aerobic exercises such as rotation of limbs and stretching. The course was developed by Dr Julieta Galante, a public health doctor, together with an expert in body posture re-education and body techniques.~The course is designed to match with the mindfulness intervention condition in duration and media (length of videos, amount of written instructions). It also replicates the encouraged use of short breaks (of seconds or minutes) throughout the workday to focus on wellbeing, as occurs in mindfulness."
40938443|NCT02129660|DRUG|Dose 1 of glycopyrrolate, 2.0% QD|Dose 1 of glycopyrrolate Topical Wipes
40938444|NCT02129660|DRUG|Dose 2 of glycopyrrolate, 3.0% QD|Dose 2 of glycopyrrolate Topical Wipes
40938445|NCT02129660|DRUG|Dose 1 of glycopyrronium, 2.5% QD|Dose 1 of glycopyrronium Topical Wipes
40938446|NCT02129660|DRUG|Dose 2 of glycopyrronium, 3.75% QD|Dose 2 of glycopyrronium Topical Wipes
40938447|NCT02129660|OTHER|Vehicle|Vehicle Topical Wipes
40938448|NCT05497700|DRUG|Ephedrine|Bolus injection of 6 mg ephedrine to keep mean arterial blood pressure above 65 mm Hg
40938449|NCT05497700|DRUG|Norepinephrine|Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg
40938450|NCT04597372|DRUG|Tamsulosin|Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.
40938451|NCT04597372|DRUG|Placebo|Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.
40938452|NCT01795820|DRUG|loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
41280710|NCT00609609|PROCEDURE|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
40938453|NCT01795820|DRUG|no loading with Ticagrelor|"Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.~In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor."
40938454|NCT01557894|OTHER|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
41131238|NCT00556478|DRUG|Placebo|"The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
41131239|NCT01663454|BEHAVIORAL|Cogmed Robomemo working memory training|The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
41131240|NCT02575924|DRUG|sequential medium|administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
41131241|NCT02575924|DRUG|1-step medium|administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
41131242|NCT01749319|DRUG|Oral baclofen|Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.
41131243|NCT01749319|DRUG|Intervenous baclofen|
41131244|NCT04989842|BEHAVIORAL|Curriculum Hannover|The methodology uses a natural variation design within the Dr. Becker Clinical Group. The interventions consist of a face-to-face or a digital psychosomatic aftercare basing upon the concept of the Curriculum Hanover. A control group is included that does not receive these two interventions (but receives a similar rehabilitation treatment to the intervention groups).
41131245|NCT00743574|DIETARY_SUPPLEMENT|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
41131246|NCT00743574|DRUG|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
41131247|NCT00743574|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
41131248|NCT00743574|DIETARY_SUPPLEMENT|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
41131249|NCT04555668|OTHER|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch The lying posture with flexion of the legs aimed to stretch the posterior chain (upper trapezius, levator scapulae, sub occipital, erector spinae, gluteus maximus, ischio-tibial, triceps surae, and foot intrinsic muscles). The initial position will lying with the hip flexed and progression consisted of increasing hip flexion, knee extension, and dorsiflexion of the ankle All above exercises will be given and to be held for 15 minutes each. 40 min/session, 3 times/week for 6 weeks
41131250|NCT04555668|OTHER|Hamstring Stretch Program|Hamstring Stretch Program 3 times for 30 seconds hold, subjects rested for 15 seconds between stretches. Knee -flexor eccentric training to prevent hamstring muscle strain 10-15 rep 40 min/session, 3 times/week for 6 weeks
41131251|NCT05049941|DIAGNOSTIC_TEST|lactat and blood gases|observational
41131252|NCT04870775|BEHAVIORAL|Mindfulness Training Program|Mindfulness training program to reduce psychotropathological symptoms in hospital workers
41131253|NCT03222934|DEVICE|multislice computed tomography|radiological diagnosis of the status and variations in the sphenoid sinus
41131254|NCT02275416|DRUG|Ipilimumab|
40938455|NCT05320302|DRUG|[11C]-Lu AF88370|PET ligand in a single intravenous bolus injection
40938456|NCT03126877|DRUG|Mitomycin C|The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
41131255|NCT02275416|BIOLOGICAL|UV1 vaccine|
41131256|NCT02275416|BIOLOGICAL|GM-CSF|
41131257|NCT02954289|BEHAVIORAL|Dietary intervention|"Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets"
41131258|NCT02173288|DRUG|Standard medical therapy|
41131259|NCT02173288|DRUG|Tolvaptan|
41131260|NCT02173288|DRUG|Midodrine|
41131261|NCT01318694|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
41131262|NCT01318694|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
41131263|NCT01318694|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
41131264|NCT01318694|DRUG|ALV Placebo|ALV placebo soft gel capsules administered orally
41131265|NCT03959384|DRUG|Curosurf 80Mg/Ml Intratracheal Suspension|CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.
41131266|NCT03959384|OTHER|Ambient Air|Ambient air aspirated in sterile syringes
41131267|NCT02605174|DRUG|Lasmiditan 50 mg|One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
41131268|NCT02605174|DRUG|Lasmiditan 100 mg|One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
41131269|NCT02605174|DRUG|Lasmiditan 200 mg|One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
41450751|NCT05439707|DEVICE|fake transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
41131270|NCT02605174|DRUG|Placebo|Two placebo tablets to match lasmiditan doses.
41131271|NCT02641912|OTHER|Biotene mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
41280711|NCT00609609|DRUG|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
41450752|NCT04869995|OTHER|Interview|An individual semi-structured interview per surgeon, according to an interview guide.
41450753|NCT03071562|OTHER|Yoga-mindfulness|"Sample class:~Warm-up~(15 minutes) Standing poses~(15 minutes) Balance poses~(15 minutes) Abdominals \& back bends (10 minutes) Cool-down~(5 minutes) Seated meditation Alternate nostril breathing Bellows breath Shoulder/neck stretches Cat-cow Forward fold Sun salutations Warrior 1 Warrior 2 Triangle Extended side angle Reverse warrior High lunge with twist Tree pose Standing holding knee Modified warrior 3 (chair support) Half moon~Bird-dog Side plank Bridge Cobra Sphinx Corpse pose Side-lying Seated om~Every month, a smudging ceremony will take place with an Aboriginal Elder for 5-10 minutes at the start of the class."
40938457|NCT03126877|DEVICE|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominante eye for the improvement of uncorrected near vision.
40938458|NCT02068339|DRUG|Oltipraz 1 (90mg)|
41280712|NCT06070363|OTHER|Manual Acupuncture|Acupuncture Needle Insertion
41280713|NCT01938183|PROCEDURE|Full-mouth periodontal debridement|full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
41280714|NCT01938183|DRUG|Metronidazole tablet|750 mg metronidazole tablets
41280715|NCT01938183|DRUG|placebo gel|semi-solid suspension containing carbopol
41280716|NCT01938183|DRUG|Metronidazole benzoate gel|15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
41280717|NCT02765841|DRUG|Lomitapide|
41280718|NCT02625961|BIOLOGICAL|Pembrolizumab|Participants with CIS with or without papillary tumors (Cohort A) and participants with papillary tumors only, without CIS (Cohort B) receive pembrolizumab 200mg via IV infusion once every 3 weeks for up to 35 administrations
41280719|NCT02625961|BIOLOGICAL|Pembrolizumab/vibostolimab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion once every 3 weeks for up to 35 administrations
40938459|NCT02068339|DRUG|Placebo|
40938460|NCT02068339|DRUG|Oltipraz 2 (120mg)|
40938461|NCT05860231|DEVICE|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
41280720|NCT02625961|BIOLOGICAL|Favezelimab/pembrolizumab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive favezelimab/pembrolizumab (coformulation of 800mg favezelimab and 200 mg pembrolizumab) via IV infusion once every 3 weeks for up to 35 administrations
41280721|NCT02240706|PROCEDURE|Best Supportive Care|At Discretion of the Investigator (Transfusions)
41280722|NCT02240706|DRUG|BI 836858|Monotherapy with BI 836858
41280723|NCT00606515|DRUG|Liposomal paclitaxel|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
41280724|NCT00606515|DRUG|Paclitaxel|Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
41280725|NCT03926143|DRUG|BAY94-9343 (Anetumab ravtansine)|BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies
41280726|NCT00011115|BEHAVIORAL|Weight loss motivations|
41280727|NCT04654507|DRUG|Dexamethasone Oral|Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days
41280728|NCT04654507|DRUG|Placebo|Placebo
41280729|NCT02570451|OTHER|Patient Survey|This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
41280730|NCT02570451|OTHER|Mini Cog|The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
41131272|NCT02641912|OTHER|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
41131273|NCT01105975|DRUG|LY2484595|Administered daily by mouth for 12 weeks
41131274|NCT01105975|DRUG|Atorvastatin|Administered daily by mouth for 12 weeks
41131275|NCT01105975|DRUG|Simvastatin|Administered daily by mouth for 12 weeks
41131276|NCT01105975|DRUG|Rosuvastatin|Administered daily by mouth for 12 weeks
41131277|NCT01105975|DRUG|Placebo for LY2484595|Administered daily by mouth for 12 weeks
41131278|NCT01105975|DRUG|Placebo for Statins|Administered daily by mouth for 12 weeks
41131279|NCT03398798|DEVICE|".014"|".014 CuNiTi orthodontic arch wire"
40744348|NCT04027309|DRUG|Gilteritinib|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
41131280|NCT03398798|DEVICE|".016"|".016 CuNiTi orthodontic arch wire"
41131281|NCT03398798|DEVICE|Twin brackets|Ormco Insignia Metal Twin brackets
41131282|NCT03398798|DEVICE|Self-ligating brackets|Ormco Insignia SL brackets
41131283|NCT06509048|OTHER|STN-DBS Theta Gamma Stimulation|Standard STN-DBS stimulation with addiction of bilateral theta frequency stimulation of ventral contacts
41131284|NCT05985590|DRUG|BMS-986278|Specified dose on specified days
41131285|NCT05985590|DRUG|Drospirenone/Ethinyl Estradiol|Specified dose on specified days
41131286|NCT01611337|OTHER|insight variation measure|insight variation between the firt week of hospitalization and 1 month later
41450754|NCT03510923|OTHER|Inspection and palpation of the appendix|The removed appendix will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The appendix will not be opened. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the appendix, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
41131287|NCT05381532|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.
41131288|NCT05834452|PROCEDURE|The Epley Maneuver|"5 step procedure where the patient:~1. Sits upright in a neutral position~2. Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~3. Rotated 90° towards the unaffected side around the yaw axis~4. Rotate a further 90° toward the unaffected side around the yaw axis~5. Rotates back to an upright position with a 135° backward rotation around the pitch axis."
41280731|NCT02570451|OTHER|Independent Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
41450755|NCT03510923|OTHER|Inspection and palpation of the gallbladder|The removed gallbladder will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The gallbladder is opened in its length, without cutting the cystic duct, and is inspected and palpated. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the gallbladder, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
41450756|NCT02555137|OTHER|'prediction score' and 'rule-out criteria'|The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
41450757|NCT01069536|DRUG|metoclopramide 10 mg|
40756312|NCT06234475|BEHAVIORAL|Control group|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months for those without abstinence at 12-month follow-up after follow-ups ending~6. Acceptance and Commitment Therapy based rear-time Chat-based support for 3 months for those without abstinence at 12-month follow-up after follow-ups ending"
41131289|NCT05834452|PROCEDURE|The 360 Degree Maneuver|"5 step procedure where the patient:~1. Sits upright in a neutral position~2. Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~3. Rotate a further 90° backward around the pitch axis (total 225°)~4. Rotate a further 90° backward around the pitch axis (total 315°)~5. Rotate back to an upright position with an additional 45° backward rota-tion around the pitch axis (total 360°)."
41131290|NCT05834452|DEVICE|Mechanical rotational chair|TRV chair
40756313|NCT00265642|DRUG|Irbesartan|one tablet of 150 mg/d during 2 years
40756314|NCT00265642|DRUG|placebo|one tablet per day during 2 years
40938462|NCT05860231|DEVICE|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
41450758|NCT06561542|DRUG|LX22001 for Injeciton|single dose: 25mg,50mg,100mg,200mg ,intravenous infusion. repeat doses: 50mg,100mg , intravenous infusion,once daily for 3 days.
41450759|NCT06561542|DRUG|Tegoprazan tablet|50mg,oral,single dose
40938463|NCT04250714|DEVICE|Boston Scientific Cardiac Cryoablation System|cryoablation of atrial fibrillation consisting in electrical isolation of the pulmonary veins
41450760|NCT06561542|DRUG|Esomeprazole sodium for injection|80 mg intravenous infusion for 30 min followed by a continuous infusion of 8 mg/h for 71.5h
41450761|NCT04426851|DRUG|BI 1358894|BI 1358894
41450762|NCT03485118|DRUG|HS006+CHOP|"Drug:HS006 HS006 375 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
41450763|NCT03485118|DRUG|HS006+CHOP|"Drug:HS006 HS006 500 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle."
41450764|NCT03485118|DRUG|Rituximab+CHOP|"Drug:Rituxan Rituxan 375 mg per square metre (mg/m\^2), administered by intravenous (IV) on Day 1 of each 21-day cycle.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
41131291|NCT00201045|OTHER|Physician/Pharmacist Collaborative Teams|The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
41131292|NCT03795688|OTHER|Pregnancy|Peripartum transition from pregnant to postpartum state
40756315|NCT06085638|DRUG|Azacitidine|Given by SC (under the skin) or IV (vein)
40756316|NCT06085638|DRUG|Tamibarotene|Given by PO
41280732|NCT02570451|OTHER|Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
41280733|NCT02570451|OTHER|Geriatric Depression Scale Short Form|Questionnaire used to measure self-reported mood
40938464|NCT03771547|DIAGNOSTIC_TEST|ERCP|
40938465|NCT03193125|DIETARY_SUPPLEMENT|L-Carnitine|500 mg tablets of L-Carnitine taken 3 times daily before meals.
40938466|NCT03193125|DIETARY_SUPPLEMENT|Placebo|500 mg tablets of L-Carnitine taken 3 times daily before meals.
41131293|NCT05943132|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC-CBO is a year-long semi-structured, manualized video-feedback caregiver intervention that targets key components in caregiver-child interactions known to improve caregiving quality and child outcomes. These components include emotional and cognitive components shown to improve socio-emotional and cognitive developmental outcomes in children.
40938468|NCT04082832|DRUG|Cu(II)ATSM|oral suspension
40938469|NCT04082832|DRUG|Placebos|oral suspension
41131294|NCT05943132|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes general support for children in homework and nutrition.
41450765|NCT03821675|DEVICE|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
40756317|NCT06085638|DRUG|Venetoclax|"Given by PO~TAMIBAROTENE Azacitidine Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine Venetoclax ABT-199, GDC-0199, Venetoclax"
40756318|NCT01048359|BEHAVIORAL|Brief advice|The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
40756319|NCT01048359|BEHAVIORAL|Brief Intervention plus Booster|A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
40938470|NCT04850898|BIOLOGICAL|SAB-176|Treatment of influenza
40938471|NCT04850898|OTHER|Placebo|Placebo Control
40938472|NCT00546468|PROCEDURE|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
40938473|NCT00546468|PROCEDURE|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
40938474|NCT04020575|BIOLOGICAL|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
40938475|NCT04020575|BIOLOGICAL|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
41131295|NCT01149759|DRUG|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
41131296|NCT03476798|DRUG|Rucaparib|Rucaparib 600mg PO BID daily
41131297|NCT03476798|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV on day 1 of each cycle
41131298|NCT03150875|DRUG|IBI308|Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.
41131299|NCT03150875|DRUG|Docetaxel|As 2nd line treatment to subjects with squamous NSCLC
41450766|NCT03821675|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
41450767|NCT01522820|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intranodally
41450768|NCT01522820|OTHER|Laboratory Biomarker Analysis|Correlative studies
41450769|NCT01522820|OTHER|Pharmacological Study|Correlative studies
41450770|NCT01522820|DRUG|Sirolimus|Given PO or PEG
41450771|NCT03801707|DRUG|Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C
41450772|NCT03801707|DRUG|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]|Three tablets once a day for 12 weeks for treatment of hepatitis C
41450773|NCT03461380|DIETARY_SUPPLEMENT|Menopause Relief EP-40|Fixed combination of black cohosh and Rhodiola rosea
41450774|NCT03461380|DIETARY_SUPPLEMENT|Low Dose Black Cohosh|6.5 mg black cohosh
40938476|NCT04673084|DEVICE|negative pleural suction|by comparing the effect of water seal alone of chest tube in one groups of trauma patients and the effect of both water seal and suction in other group
40938477|NCT02301585|PROCEDURE|Passive Leg Raising Test|Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
41450775|NCT03461380|DIETARY_SUPPLEMENT|High Dose Black Cohosh|500 mg black cohosh
40938478|NCT02301585|PROCEDURE|Standard of care|Patients are treated according to Surviving Sepsis Guidelines
40938479|NCT03810820|DEVICE|mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS)|A wearable cardiac monitoring device is provided to patients pre- and post-TAVI. The monitor transmits cardiac data in real time to the m-CARDs team. Cardiac abnormalities are reported to the clinical team who then assess the abnormality and intervene as clinically necessary.
41450776|NCT03461380|DIETARY_SUPPLEMENT|Placebo|600 mg excipient
40938480|NCT01973543|BIOLOGICAL|VY-AADC01|Neurosurgical delivery of VY-AADC01 to the brain.
40938481|NCT02288143|DRUG|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~* Oral clomiphene citrate: 100 mg/day until the day of the triggering.~* Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~* hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~* 1-2 days after the identification of one follicle ≥ 17 mm~* 0-1 days after the identification of one follicle ≥ 19 mm."
40938482|NCT03245229|DRUG|Aprocitentan|Capsule for oral administration
41450777|NCT04051307|DRUG|PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL|Peptide vaccination
41450778|NCT04051307|DRUG|Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL|Peptide vaccination
40938483|NCT03245229|DRUG|Rosuvastatin|Tablet for oral administration
40938484|NCT01477203|DRUG|Escitalopram|2-4 weeks, 5-10mg, max 20mg
40938485|NCT01012076|BEHAVIORAL|Active Control vs Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
41280734|NCT02570451|OTHER|Confusion Assessment Method (CAM)|This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
40938486|NCT04348890|DRUG|Vamorolone 4% suspension for oral dosing|vamorolone 6 mg/kg/day orally once daily for 8 weeks.
40938487|NCT00063375|BEHAVIORAL|Computer Based Cognitive Behavioral Therapy|
40938488|NCT06156540|OTHER|virtual reality glasses|Using virtual reality glasses, caregivers in the experimental group were shown 360-degree VR relaxing videos.
40938489|NCT06386731|OTHER|Intermittent Phototherapy|2-hour phototherapy application in the intervention group
40938490|NCT01180166|DRUG|nimotuzumab|200 milligram (mg) of nimotuzumab per week during radiation period
41280735|NCT02570451|OTHER|RAND 36-Item Short Form Health Survey|This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
41280736|NCT02570451|OTHER|Grip Strength|Measured using the JAMAR dynamometer
41280737|NCT02883699|BEHAVIORAL|Standard endurance training|Continuous vigorous training 2 x per week on a cycle ergometer
41453600|NCT01460628|DRUG|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
40938491|NCT04777838|DRUG|Citalopram 10 MG|10 mg of citalopram every day
40938492|NCT04777838|DRUG|Amitriptyline|25mg of Amitriptyline every
40938493|NCT04777838|DEVICE|Bite Splint|Night use of occlusal splint
40938494|NCT02467335|DRUG|BMS-663068|BMS-663068
40938495|NCT06133738|OTHER|Standardized Exercise Program|"Participants will be asked to attend to the department for 8 supervised physiotherapy sessions designed to strengthen lower limb muscles. Eight sessions were chosen as this number should be able to achieve improvements in pain and function. Standardized exercises sessions will be held once weekly in the health center and will be supervised by the researcher. In addition, participants will be requested to perform the prescribed exercises 3 times per week at home, with 1-2 days rest interval between the exercise's sessions.~The program is comprised of a minimum of 4 and a maximum of 6 individualized lower limb exercises to be performed 4 times per week (once in the health center and 3 times at home). All exercise programs will include at least 2 knee extensor strengthening exercises, 1 hip abductor strengthening exercise, 1 hamstring strengthening exercise, 1 calf strengthening exercise, and 1 other exercise will be chosen based on assessment findings."
40938496|NCT06133738|OTHER|Internet based Cognitive Behavioral Therapy|"This intervention will be given to participants in intervention group. This is a link to access pre-recorded online sessions of CBT.~The iCBT link contained eight 35- to 45-minute sessions, designed to be completed weekly, each provided an explanation of a cognitive or behavioural pain coping skill. Session 1 provided an overview, including a therapeutic rationale of CBT, followed by training in progressive muscle relaxation. Sessions 2 through 7 taught brief relaxation skills, activity-rest cycling, pleasant activity scheduling, cognitive restructuring, pleasant imagery, and problem-solving. Session 8 consolidated the learnt and taught strategies for long-term skill use. Each session has to be completed within the same week where the physiotherapy session is given.~The researcher has developed a website that contained all the CBT materials."
40938497|NCT06133738|OTHER|Educational Materials|All participants will receive a link to access online educational material about chronic knee pain. This is a YouTube link that consists of 5 sessions, with each lasting for 5-7 minutes, and is comprised of general information about the following: healthy eating, osteoarthritis and X-Ray, physical activity, the full pain experience, and proper footwear. Participants will be encouraged to access the educational material at their own leisure and pace.
40938498|NCT03491189|DEVICE|Lag screw fixation|surgical fixation
40938499|NCT03491189|DEVICE|Helical blade fixation|surgical fixation
40938500|NCT04210323|DEVICE|ShotBlocker®|The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
40938501|NCT04210323|DEVICE|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
41280738|NCT02883699|BEHAVIORAL|Polarized endurance training|Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
41280739|NCT02883699|BEHAVIORAL|Standard resistance training|Machine based hypertrophy training 2 x per week
41280740|NCT02883699|BEHAVIORAL|Daily undulating periodization resistance training|Machine based daily undulating periodization resistance training 1 x per week
41280741|NCT03666767|OTHER|Comparisons will be made between LMICs and HICs|Countries will be defined as low, middle or high-income using the World Bank classification.
41450779|NCT05846282|BEHAVIORAL|STRIVE|The STRIVE intervention will include all activities and BREATHE skill training components of L2B with content framed within the needs of high achieving college-bound BIPOC students who can benefit from health promoting practices to offset the costs of resilience. The intervention will include twelve 60-minute group sessions, with two sessions on each of the six core themes. Each session will include an opening mindful movement, short didactic presentation of the topic or theme of that week, group activities that illustrate the theme, guided discussion about the activity, and in-session group mindfulness meditation practice.
40938502|NCT00508768|DRUG|Oral SCIO-469 capsule|
40938503|NCT04870736|PROCEDURE|Mout-to-mouth ventilation|Chest rising during basic life support will be recorded as No breath (no visible chest rising) and Breath (chest rising) by the observer.
40938504|NCT04870736|PROCEDURE|Mout-to-mouth ventilation with quantitative analysis|Chest rising during basic life support will be recorded and evaluated (breath by breath) in QCPR Skill Reporter software
40938505|NCT03186885|BEHAVIORAL|Healthy Frio In-Person Family-focused Intervention|Participants learn about energy balance behaviors, skills to support health behavior change, managing personal wellness, and parenting strategies. Sessions use interactive learning strategies to elicit knowledge and experience of participating families to encourage families to learn from each other. YMCA staff members lead a 50-minute group exercise session after each health education session to help participants meet their commitment of engaging in PA at least 3 times/week.
40938506|NCT03186885|BEHAVIORAL|Healthy Frio Remote Technology Family-focused Intervention|Tablet computers will be used as the platform to deliver the health education content for the FI-RT. Each session will present the class content and guide the participants to complete class activities. Videos of health education and class activities (e.g., cooking demonstrations, exercise demonstrations) will be embedded in the lesson. Interactive assessment questions with feedback will be presented throughout the session to check for understanding of the content. Viewing time and responses to the assessment questions will be recorded to evaluate progress and comprehension. Participants will view the health education sessions at home as a family and discuss the content as prompted by lesson instructions.
40938507|NCT03186885|BEHAVIORAL|Control|Participants receive standard of care
40938508|NCT04258189|DRUG|JNJ-64417184|Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
40938509|NCT03551340|DIAGNOSTIC_TEST|Gastro-intestinal panel by PCR|The study will evaluate the change in medical management with the replacement of traditional stool investigations (microscopy and culture) by the new gastrointestinal multiplex PCR panels
40938510|NCT04456010|OTHER|Questionnaire|Eligible patients will be selected from our electronical database and invited via email to participate.
41131300|NCT04439500|BEHAVIORAL|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
40938511|NCT02922491|DIETARY_SUPPLEMENT|vitamin E|daily intake of vitamin E
40938512|NCT02922491|DIETARY_SUPPLEMENT|starch|daily intake of starch (control)
41131301|NCT04439500|BEHAVIORAL|Brain Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
41131302|NCT06261437|OTHER|CCAR|The CCAR will be consumed as the sole source of nutrition during a 7-day military training exercise.
41131303|NCT06261437|OTHER|FSR|The FSR will be consumed as the sole source of nutrition during a 7-day military training exercise.
41131304|NCT05093062|OTHER|Tian Jiu Therapy|
41131305|NCT01727570|DIETARY_SUPPLEMENT|Whey Protein (Immunocal®)|The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
41280742|NCT01576081|DEVICE|HEPHAISTOS|HEPHAISTOS unloading orthotic
41450780|NCT05846282|BEHAVIORAL|Study Skills|The sessions will focus on goal setting (4 sessions), organization and time management (3 sessions), and study skills for reading comprehension, writing papers, note-taking, and test-taking (4 sessions). Parallel to the final L2B session, the last meeting will include activities to share and reflect on how students plan to incorporate and sustain new skills.
41450781|NCT03385135|DRUG|Allopurinol|300 mg for 4 weeks then 600 mg for 4 weeks in the active group
41450782|NCT02312154|DEVICE|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
41450783|NCT04221958|DEVICE|Electrocardiogram|"An electrocardiogram measures the electrical activity of the heartbeat. This intervention will be used on healthy adult volunteers whom are part of the staff at the institution."
41450784|NCT02828631|DEVICE|Macintosh laryngoscope|
41280743|NCT02049567|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
41280744|NCT02049567|PROCEDURE|Cataract Surgery|Performed using standard microsurgical techniques
41450785|NCT02828631|DEVICE|McGrath videolaryngoscope|
40938513|NCT01729260|DRUG|Mebendazole|The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
40938514|NCT04276454|DEVICE|Flexitouch Plus system|A single treatment for external lymphedema using the FDA-approved Flexitouch Plus device.
40938515|NCT04353414|PROCEDURE|Transmuscular Quadratus Lumborum Block|Transmuscular Quadratus Lumborum Block (TQLB) is a relatively new block that targets thoracic and lumbar nerves. The decrease in sensation means a decrease in pain. The TQL block will be preformed in addition to an incision-site injection (on hip), called pericapsular injection. The potential risks associated with the Transmuscular Quadratus Lumborum Block (TQLB) include nerve damage and infection at injection site. In addition, there can be temporary sensory and motor loss, depending on the dosage, site of injection and duration of the nerve block. However, the amount (30mL) used in this study meets FDA dosage-regulations for this medication.
40938516|NCT04353414|PROCEDURE|Pericapsular injection|Pericapsular injection (PCI) of 20 mL of 0.25% Bupivacaine HCL (numbing medication) into the incision-site (hip portal sites) to decrease sensation. The potential risks associated with the pericapsular injection include bleeding, infection at injection site and local anesthetic toxicity however, the likelihood is low due to the expertise of the surgeon preforming the injection and the sterile environment and good clinical practice from clinicians, which reduces the likelihood of infection.
40938517|NCT04353414|DRUG|Bupivacaine Hydrochloride|Bupivacaine used for this study is the standard of care for both TQLB and PCI. Pericapsular injection (PCI) contains 10 mL of 0.25% Bupivacaine HCL which will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
40938518|NCT03210181|OTHER|Superficial cervical plexus block|A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.
41131306|NCT03555175|OTHER|Eccentric exercise|The group make hamstring eccentric exercise. The participants have to do 12 serie of 6 repeats
41131307|NCT03555175|OTHER|Proprioception|The group have to do three kinds of exercise in a inestable area during 15 second in 2 repeats for each one
41131308|NCT03555175|OTHER|Control group|Any exercise
41131309|NCT05951972|OTHER|nutritional|participants will receive 2 pairs of food items to consume - pair A - Bananas and Apples, pair B - cucumbers and peanuts.
41131310|NCT01489774|DRUG|Placebo|single and multiple dose
41131311|NCT01489774|DRUG|CJ-12406|single and multiple dose
41131312|NCT05247437|BEHAVIORAL|Digital Intensive Lifestyle Intervention|The FitD consists of 8 digital lessons on how to improve dietary and exercise habits using self-monitoring, goal-setting, cognitive restructuring, and other behavioral and cognitive strategies. The FitD app offers a virtual coach that guides the participant to complete the treatment.
41450786|NCT02828631|DEVICE|Pentax videolaryngoscope|
40938519|NCT03210181|OTHER|Placebo|Patients will receive an equivalent volume of normal saline
40938520|NCT01273285|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
40938521|NCT03845049|OTHER|Inclusion examinations|Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
40938522|NCT03845049|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection of aflibercept at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
41131313|NCT05247437|BEHAVIORAL|Digital Self-Help Control Condition|The digital self-help control condition consists of educational materials related to diet and exercise. The materials are open for access all at once. There is no guidance by a virtual coach or digital lessons.
41131314|NCT06322121|OTHER|MRI|Assessment of vascular reactivity and CAA/SVD MRI markers
41131315|NCT05515146|DIAGNOSTIC_TEST|near infra red fluorescence lymphatic imaging|ICG (0.2 ml from 25mg of ICG diluted by 5.0 ml of aqua ad injectabilia) was injected intradermally at the basis of the tattooed cutaneous area and at one point chosen so that the tracer had to flow under this area directly towards the root of the limb
41280745|NCT00200057|DEVICE|InterStim Sacral Nerve Stimulation Therapy|Open label study. All subjects that qualify for the study will be implanted.
41280746|NCT01013727|RADIATION|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
41280747|NCT03030040|BEHAVIORAL|The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.|Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
41280748|NCT02195830|OTHER|Ultrasound of the inferior vena cava|B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
41450787|NCT06507553|BIOLOGICAL|Trivalent-Darwin influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
41450788|NCT06507553|BIOLOGICAL|Augment-Tasmania influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
41450789|NCT06507553|BIOLOGICAL|TIV-2X Darwin influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
41450790|NCT06507553|BIOLOGICAL|Trivalent-Tasmania influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
41450791|NCT00827164|BEHAVIORAL|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
40744349|NCT04027309|DRUG|Midostaurin|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
40756320|NCT01048359|BEHAVIORAL|Brief Intervention|A brief drug use intervention based on motivational interviewing is provided to participants at baseline
40756321|NCT02122185|DRUG|metformin hydrochloride|Given PO
41131316|NCT04422405|PROCEDURE|One Anastomosis Gastric Bypass (OAGB)|"The procedure is performed laparoscopically. The GIA stapler divides the stomach at the junction of the body and antrum. An Ewald tube, roughly the diameter of the esophagus, is passed by the anesthetist and held against the lesser curvature. The division of the stomach against the tube is completed, with 5- 6 lines of staples. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 200 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to perform the anastomosis between the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel."
41131317|NCT01171976|DRUG|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
41450792|NCT00827164|BEHAVIORAL|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
41450793|NCT04031690|OTHER|Caregiver Quality of Life Questionnaires|Measurement of quality of life at D0, M6 and M12 via SF-36, CarGOQoL and the one-dimensional Zarit score
40938523|NCT03845049|DRUG|SHAM injection|Intravitreal injection of SHAM at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
40938524|NCT03845049|OTHER|Examinations during study (every month)|visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
40938525|NCT03333733|BEHAVIORAL|HENRY|"HENRY is an 8-week programme delivered in Children's Centres, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. It is currently delivered in \~ 35 local areas across England and Wales by trained health and community practitioners. Training includes:~Centre Level Training: to equip staff with knowledge and skills to promote and provide healthy nutrition within early years settings and support parents to provide healthy family lifestyles and nutrition for their families. The theoretical underpinning combines proven models of behaviour change including the Family Partnership Model, motivational interviewing and solution-focused support.~Practitioner Level Training: to deliver the 8-week HENRY programme, which aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition for their young children."
40938526|NCT00440778|DRUG|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
40938527|NCT04877223|OTHER|No intervention|No intervention
40938528|NCT00920205|DRUG|MPC-3100 (an Hsp90 inhibitor)|oral daily dose for 21 days in a 28-day cycle
40938529|NCT06190353|BEHAVIORAL|An internet-based self-help program with minimal telephone support utilizing Acceptance and Commitment Therapy for alleviating burnout among healthcare workers.|An eight module self help program
41131318|NCT04235998|DIAGNOSTIC_TEST|Systematic lung ultrasound|"Patients will undergo a systematic lung ultrasound including review of:~* Sonographic characteristic of effusion~* Parietal, diaphragmatic and visceral pleura~* Pleural nodules~* Lung parenchyma~* Extra pulmonary findings: Hepatic pathology, enlarged lymph nodes of the neck and a cardiac assessment."
41131319|NCT00367874|DRUG|Buprenorphine|
41131320|NCT00367874|DRUG|Valproate|
41131321|NCT05705323|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (iCBT)|This CBT is specifically adapted for individuals experiencing tinnitus
41131322|NCT05705323|BEHAVIORAL|Internet-delivered mindfulness-based tinnitus stress reduction (iMBTSR)|This is a mindfulness-based intervention specifically adapted for individuals experiencing tinnitus
41131323|NCT04983615|DRUG|fentanyl-based sedation|fentanyl-based sedation instead of midazolam-based sedation in ventilated patients
41131324|NCT04983615|DRUG|midazolam-based sedation|midazolam-based sedation
41131325|NCT05063864|OTHER|Nursing Support Program|"Within the scope of the nursing support program, counselling services were provided to women by making regular phone calls that lasted 15-20 minutes once a week. Within the scope of the support program, two training booklets titled Life After Hysterectomy Surgery and Women's Health During Menopause were prepared by reviewing the literature."
41131326|NCT06079242|DEVICE|Resin microspheres containing yttrium-90 (Y-90)|SIR-Spheres Y-90 resin microspheres are permanent implant and for single use only
41450794|NCT04031690|OTHER|Patient Quality of Life Questionnaires|Quality of life measurement at D0, M6 and M12 via the SF-36
41450795|NCT02538627|DRUG|MM-151|MM-151
40938530|NCT02474680|GENETIC|Pharmacogenetic testing|Psychotropic genotyping panel
41131327|NCT01224613|BIOLOGICAL|Intanza|0.1 mL of Intanza intradermally at visit # 1
41131328|NCT01224613|BIOLOGICAL|Intanza|0.1 mL of Intanza intradermally at visit #1
41450796|NCT02538627|DRUG|MM-121|MM-121
41450797|NCT02538627|DRUG|MM-141|MM-141
41450798|NCT02538627|DRUG|trametinib|trametininb
41450799|NCT00466167|DRUG|Pramipexol Extended Release|
41450800|NCT00466167|DRUG|Pramipexol Immediate Release|
41450801|NCT00466167|DRUG|Placebo|
41450802|NCT06562374|DEVICE|Low Frequency Ultrasound Therapy|The ultrasound will be delivered at a frequency of 33 kHz at power levels of 4-10 Pascals with a program of 1.6 seconds on and 1.6 seconds off. The generators will be encased in epoxy within the Osteoarthritis baths. The intervention will be repeated on every second or third day to allow time for healing
40756322|NCT02122185|DRUG|placebo|Given PO
41450803|NCT06212479|DIAGNOSTIC_TEST|MRI Scan|Whole Body MRI Scan
40938531|NCT05074173|BEHAVIORAL|Text|These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure.
41450804|NCT03552484|BEHAVIORAL|Home Visit Program|Informed consent discussion, documentation; UPDRS I-IV, medical history, vitals, medication reconciliation, patient medical history and comorbidities; home safety assessment; psychosocial assessment of dyad, resource utilization questionnaire, caregiver medical history and comorbidities, MCSI; patient and caregiver short MoCA, satisfaction surveys, EQ5D; counseling, summarizing plan of care
41453601|NCT05922306|DRUG|PEGylated recombinant human interferon alpha-2b injection|Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.
40938532|NCT06438146|DRUG|Liraglutide|"Dosing regimen: In this study protocol, liraglutide dosing will be implemented as follows: Liraglutide will be started at a dose of 0.6 mg per day. Participants will be taught to use the injection pen and will be observed giving the first injection. The dose will then be increased by 0.6 mg each week to a maximum dosage of 3.0 mg per day at the end of 4 weeks.~This corresponds to the following dosing schedule:~Week 1: 0.6 mg per day for one week Week 2: 1.2 mg per day for one week Week 3: 1.8 mg per day for one week Week 4: 2.4 mg per day for one week Week 5-12: 3.0 mg per day for 8 weeks Week 13-24: No drug administration"
40938533|NCT06302738|DIAGNOSTIC_TEST|polysomnography|patients will undergo a home sleep study to evaluate the presence of sleep disorders
40938534|NCT01681797|DEVICE|Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)|Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
40938535|NCT05718050|DIAGNOSTIC_TEST|Mandibular flexure evaluation|A mandibular silicon impression was taken, and a vacuum molded thermoplastic stent with radiopaque fiducial markers (steel ball bearings) on the facial side of the canines and molars was fabricated for each patient. Two Cone Beam Computed Tomographs (CBCTs) were made per patient with their radiographic stent in the mouth at the OVD and MO positions at the University Advanced Digital Diagnostic Center. The CBCT examination was performed without any stitching procedure using a computed tomography (SCANORA 3DX; Dexis LLC) set up at 90 kV, 4 mA and a field of view (FOV) of 140 and 100 mm in height and width respectively, to decrease the radiation dose without affecting the quality of the examination.
41131329|NCT00808496|OTHER|MRI|"Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported."
41131330|NCT00808496|OTHER|Radiography|"Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported."
41450805|NCT03552484|BEHAVIORAL|Usual Care/Online Survey|Patients and caregivers, if available, will be asked to complete an online survey that asks about demographics, disease history, resource utilization, and unmet needs. The will be asked to complete a follow-up survey 12 months after completion of the initial survey.
40938536|NCT00048087|DRUG|ZD1839|250 mg by mouth daily each day for 4 weeks.
40938537|NCT00048087|DRUG|Docetaxel|30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
41450806|NCT03683667|DRUG|Azithromycin Oral Product|Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age
41450807|NCT03683667|DRUG|Placebos|Contain inert excipients only
41450808|NCT03683667|DIETARY_SUPPLEMENT|Protein Supplement|Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age
41131331|NCT00808496|OTHER|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
41131332|NCT00259142|DRUG|Chloroquine, sulphadoxine-pyrimethamine|
41280749|NCT04203173|BEHAVIORAL|FINANCE-DM|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session. Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
41450809|NCT03683667|DIETARY_SUPPLEMENT|Isocaloric Supplement|Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age
41450810|NCT03683667|DIETARY_SUPPLEMENT|Egg|Egg provided daily to infants from 6-12 months of age
41450811|NCT03683667|BEHAVIORAL|Nutrition Education|Monthly messaging on infant and young child feeding
41450812|NCT00367133|PROCEDURE|Standard of Care Group|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
41453602|NCT05922306|DRUG|PEGylated recombinant human interferon alpha-2b injection|Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.
40938538|NCT02069418|RADIATION|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
40938539|NCT02069418|RADIATION|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
40938540|NCT02687178|DRUG|Canrenone 50 vs canrenone 100 mg|
41280750|NCT04203173|BEHAVIORAL|Active Comparator|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
41280751|NCT00815789|BEHAVIORAL|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
40938541|NCT05693844|BIOLOGICAL|Pan-T booster co-expressing MSLN CAR T cell|Starting Dose: 1×10\^6 cells/kg
40938542|NCT05693844|DRUG|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
40938543|NCT05693844|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2
40938544|NCT05693844|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2
40938545|NCT01295931|DRUG|Indocyanine Green (IC-Green)|5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.
40938546|NCT01295931|PROCEDURE|Imaging|Nonradioactive optical imaging with indocyanine green as a fluorescent contrast agent prior to sentinel lymph node biopsy or lymph node surgery.
41280752|NCT01295125|DEVICE|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
41280753|NCT01295125|PROCEDURE|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
41280754|NCT03301857|DRUG|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
41280755|NCT03312218|BEHAVIORAL|Spaced educational intervention|A spaced educational intervention will be provided to participants
41131333|NCT01752699|DRUG|Methadone|patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
41131334|NCT01752699|DRUG|Placebo|patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
40938547|NCT05022875|DEVICE|Healthcare CEO app- for experimental app intervention|The app content was designed based on the results of previous qualitative and Delphi studies (Chiang et al., 2021; Chiang et al., 2020) and consists of 11 interfaces: CEO's profile, Health Tracking, CEO Knowledge Base, Barrier-free Communication, See Here: Diet and Exercise, Help Me, Detective!, CEO Chatroom, CEO's Secretary, Who's the Best CEO, SOS Calls, and Q\&A
40938548|NCT05022875|DEVICE|Healthcare CEO app-for control app intervention|consists of 2 interfaces: CEO's profile, Health Tracking.
40938549|NCT05998278|PROCEDURE|Personalized Optimization of Systematic Prostate Biopsy|Login the model based on our previous study (https://daringsky.shinyapps.io/prediction_v2/) allows for input of age, BMI, serum PSA, size and location of suspicious lesions, PIRADS - V2 score, and prostate volume to generate an individualized needle distribution map,then targeted biopsy combined personalized optimization of systematic prostate biopsy was performed.
40938550|NCT02898116|DRUG|Ensartinib|Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).
40938551|NCT02898116|DRUG|Durvalumab|During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
40938552|NCT02131532|BEHAVIORAL|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
41450813|NCT00367133|DRUG|1mg triamcinolone acetonide|Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
40938553|NCT06115148|OTHER|Feeding|Nutrition beverages will be provided to meet the nutrient needs described in the Feeding Arm.
41280756|NCT03492164|DRUG|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
41280757|NCT02940964|BEHAVIORAL|Count on me Singapore (COMS) CPR|Using the song as a mental metronome to guide CPR.
41450814|NCT00367133|DRUG|4mg triamcinolone acetonide|4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
41450815|NCT03115697|DRUG|Lactulose|Lactulose 20 mL
41450816|NCT03115697|DRUG|Rifaximin|Rifaximin 550 BD
41450817|NCT03115697|BIOLOGICAL|Plasmapheresis|Plasmapheresis 8 hrly duration
40938554|NCT06115148|OTHER|Fasting|Water will be consumed as described during the Fasting Arm.
40938555|NCT00576212|BEHAVIORAL|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
40938556|NCT03937869|DRUG|Secnidazole|One dose
40938557|NCT01173861|BEHAVIORAL|Physical activity counseling|20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
40938558|NCT00557401|DRUG|XP19986 SR3, 20 mg QD|XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
40938559|NCT00557401|DRUG|XP19986 SR3, 40 mg QD|XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
41280758|NCT02940964|BEHAVIORAL|Standard CPR|"Standard CPR with one-and-two-and-three.... counting"
41280759|NCT05408858|BEHAVIORAL|LGBTQ-affirmative cognitive behavioral group therapy|10 sessions of supportive, LGBTQ-affirmative psychotherapy
41280760|NCT04470895|DIAGNOSTIC_TEST|Failure Track patients analysis|"The nurse coordinator of the Fracture Track first comes to give the patient a written information note. She answers the patient's questions and obtains his or her non-opposition. The patient must be given sufficient time for reflection to make his decision in order to participate in the study. His non opposition will be traced in the computerized medical record. Each enrolling patient in the study can simultaneously participate in another research. There is no exclusion period in the protocol.~Once the patient is included, a semi-directed interview is conducted. The name of the patient's usual pharmacy will be collected. Data from the computerised medical record concerning the patient's stay are also analysed.~The patient's usual pharmacy or the nurse in charge of the patient will then be questioned in order to carry out a drug reconciliation interview."
41450818|NCT02161263|OTHER|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
41280761|NCT01161225|BEHAVIORAL|Peer-assisted asthma self-management program|Intervention group: An asthma self-management program (Power Breathing™) was implemented by trained peer leaders at an asthma day camp. The program consisted of 3 sessions (appx. 45-60 min/session): basic asthma education (pathophysiology, triggers); psychosocial issues of asthma; and asthma self-management (peak flow monitoring and medication). The program was delivered by trained peer leaders paired for each small group of 6-8 teens. Group activities involved discussion, strategic thinking, knowledge-testing games and role plays.
40938560|NCT00557401|DRUG|XP19986 SR3, 60 mg QD|XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
40938561|NCT00557401|DRUG|XP19986 SR3, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
40938562|NCT00557401|DRUG|Placebo|Placebo tablet taken orally for approximately 32 days with titration and taper periods.
40938563|NCT01231308|PROCEDURE|Roux-en-Y-Gastric Bypass|Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
40938564|NCT01231308|BEHAVIORAL|Intensive lifestyle modification and Optimal medical Therapy|Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
40938565|NCT03758326|OTHER|Body App|Participants will indicate areas of concern on a virtual manikin using an electronic online interface. Body measurements will also be collected.
40938566|NCT00470665|DRUG|Rapamune|
40938567|NCT05396703|PROCEDURE|TOETVA|Completed procedure.
40938568|NCT03700879|RADIATION|MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler|Patients presented with clinical picture and radiography suggestive of acute ischemic stroke will be subjected to a comprehensive evaluation with MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler
40938569|NCT00351546|DRUG|Vildagliptin|
41280762|NCT01161225|BEHAVIORAL|Adult-led asthma self-management program|Control group: The group attended an adult-led day camp where 2 NPs and a MD offered didactic asthma education based on the Power Breathing™ program.
41280763|NCT05763407|DEVICE|FIRE1 System|FIRE1 System
40938570|NCT01176344|DRUG|Vitamin D|50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years
40938571|NCT01176344|DRUG|Placebo|Inert placebo capsules once monthly for 2 years.
40938572|NCT03706898|DRUG|Elpida®|Elpida® capsules, 20mg
40938573|NCT03706898|DRUG|Dolutegravir|Dolutegravir, film-coated tablets, 50mg
41280764|NCT00083538|DRUG|Dexamethasone|
41280765|NCT00083538|DRUG|Thalidomide|
41280766|NCT00083538|DRUG|Cisplatinum|
41280767|NCT00083538|DRUG|Adriamycin|
41280768|NCT00083538|DRUG|Cyclophosphamide|
41280769|NCT00083538|DRUG|Etoposide|
41280770|NCT01593982|OTHER|repetitive Transcranial Magnetic Stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
41280771|NCT05264337|OTHER|Self-reported lymphedema|Lymphedema as reported by LymQOL questionnaire.
41453603|NCT05646316|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40938574|NCT03706898|DRUG|Sofosbuvir|Sofosbuvir, film-coated tablets, 400mg
40938575|NCT03706898|DRUG|Daclatasvir|Daclatasvir, film-coated tablets, 60mg
40938576|NCT03015883|RADIATION|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
40938577|NCT00145678|BEHAVIORAL|Psychodynamic Therapy|Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.
40938578|NCT00145678|BEHAVIORAL|Optimized Community Care|individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
40938579|NCT03862040|DRUG|Cefiderocol|Administered intravenously, at a dosage determined based on renal function.
40938580|NCT03862040|DRUG|Standard of Care Antibiotic|Standard of care antibiotic treatment for pneumonia
40938581|NCT00015938|BIOLOGICAL|filgrastim|
40938582|NCT00015938|DRUG|docetaxel|
40938583|NCT00015938|DRUG|vinorelbine|
40938584|NCT05929820|BEHAVIORAL|Protect Your Colon™|Protect Your Colon™ is an online decision aid focused on CRC screening. The site will first educate patients on the importance of CRC screening and offer information on the advantages and disadvantages of the available test options. Protect Your Colon™ will then present an interactive conjoint analysis-a quantitative survey technique that elucidates how individuals make complex decisions-to precisely determine individuals' latent preferences regarding CRC screening options. Afterwards, the app will generate a personalized report that rank orders the importance of each test attribute (e.g., accuracy, invasiveness, test frequency) in patients' decision making and identifies the screening modality that best matches their preferences. The report will also be shareable with physicians, enabling patients and providers to engage in shared decision making surrounding CRC screening in the clinic.
40938585|NCT02959164|DRUG|Decitabine|"Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level"
41131335|NCT03388840|BIOLOGICAL|Adipose derived stem cells suspention|application of adipose derived stem cells to the engrafted hair in hair transplantation surgery
41280772|NCT05264337|OTHER|Dielectric constant ratio|Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.
41453604|NCT05646316|PROCEDURE|Diagnostic Imaging|Undergo imaging
41280773|NCT05264337|OTHER|Limb volume|Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.
41280774|NCT01497392|DRUG|dovitinib lactate|Given PO
41280775|NCT01497392|DRUG|gemcitabine hydrochloride|Given IV
41280776|NCT01497392|DRUG|capecitabine|Given PO
41280777|NCT01497392|OTHER|laboratory biomarker analysis|Correlative studies
41450819|NCT04693533|DRUG|Fremanezumab Prefilled Syringe [Ajovy]|The treatment is 225 mg (dissolved in 1.5 ml saline) fremanezumab. Fremanezumab (Ajovy) is a month-long-acting anti-CGRP injection that patients are taught to self-administer at home.
41450820|NCT03609762|BEHAVIORAL|EQ-5D-5L HRQOL results be available to the attending doctor|all subjects attending the intervention clinics will complete the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
41450821|NCT03125408|DIAGNOSTIC_TEST|HCV Assay|Molecular diagnostic test to detect Hepatitus C
41280778|NCT01497392|OTHER|enzyme-linked immunosorbent assay|Correlative studies
41280779|NCT01497392|OTHER|pharmacological study|Correlative studies
41280780|NCT01802944|DRUG|Intranasal Insulin|
41280781|NCT01802944|DRUG|Placebos|
41280782|NCT06025344|DRUG|PanCytoVir™ 100 mg/mL oral suspension|Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
41280783|NCT06025344|DRUG|Probenecid 500 mg|Single oral dose of 1000 mg under fasted conditions
41280784|NCT05664633|DRUG|Sugammadex|Sugammadex or G/N will be given at the end of the procedure once the surgeon communicates with the anesthesiologist. The surgeon will typically do this at the time of putting the closing sutures.
41280785|NCT00976430|PROCEDURE|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
41280786|NCT03860506|DRUG|PSI-697|
41450822|NCT00932763|DRUG|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
41450823|NCT00932763|DRUG|Norvasc|10 mg dose (Pfizer, USA)
40756323|NCT02122185|DRUG|Chemotherapy|Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
41131336|NCT03388840|BIOLOGICAL|Platelet rich plasma|application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
41131337|NCT02934932|DRUG|Brexpiprazole|Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
41280787|NCT03860506|DRUG|Placebo|
41280788|NCT05483127|DEVICE|Verofilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
41280789|NCT05483127|DEVICE|Stenfilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
41280790|NCT03283215|DIAGNOSTIC_TEST|complete blood count , electrolytes|it is a labarotory test to assess hemoglobin white blood count plate let
41280791|NCT01733329|DRUG|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
41280792|NCT01733329|DRUG|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
41280793|NCT03059290|DEVICE|neolix file|first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
41450824|NCT05028140|DRUG|PIEMONTE|Piemonte association 1 coated tablet once a day
41450825|NCT05028140|OTHER|PIEMONTE PLACEBO|Placebo of Piemonte association 1 coated tablet once a day
41450826|NCT05028140|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg 1 coated tablet once a day
41450827|NCT05028140|OTHER|PLACEBO EMPAGLIFLOZIN|Placebo of empagliflozin 25 mg 1 coated tablet once a day
41450828|NCT05028140|DRUG|PIOGLITAZONE|Pioglitazone 30 mg 1 tablet once a day
41450829|NCT05028140|OTHER|PLACEBO PIOGLITAZONE|Placebo of pioglitazone 30 mg 1 tablet once a day
41450830|NCT06433739|OTHER|standardized algorithm|standardized algorithm for the correct selection of peripheral venous catheters
41453605|NCT05646316|PROCEDURE|Excisional Biopsy|Undergo sentinel lymph node excision
41280794|NCT00661765|DRUG|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
41280795|NCT00661765|DRUG|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
41280796|NCT03437187|PROCEDURE|Cholecystectomy|Laparoscopic technique
41280797|NCT06346795|OTHER|High-filling flowable dental composite|Class II restorations will be performed with G-aenial Universal Injectable, Grandio Flow, and Clearfil Majesty Flow high-filling flowable composites.
40756324|NCT04480580|DIAGNOSTIC_TEST|SARS-CoV-2 Ab|Patient test for specific antibodies for SARS-CoV-2
41131338|NCT05430087|DRUG|Observe the clinical outcome and inflammatory cytokines levels in patients with systemic lupus erythematosus (SLE) after being supplemented with Cholecalciferol (Vitamin D3) and Curcumin-Piperine.|All patients and physicians were blinded to group assignment and treatment allocation. All subjects received the tablets for three months. All subjects were still required to consume their routine medications during the supplementation according to the disease activity. Patients were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters. Adherence to therapy was assessed by monthly pill counts of returned tablets and biweekly phone calls to the patients.
41131339|NCT04638738|DEVICE|SensiumVitals wearable patch sensor|Wearable sensor which measures heart rate, respiratory rate, and temperature continuously.
41131340|NCT01692769|DRUG|Normal Saline|Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
40756325|NCT04923997|BEHAVIORAL|Health Coaching|6 months of integrative health coaching, goal setting, survey administration and physical assessments.
41131341|NCT01692769|DRUG|Ringer's Lactate|Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
41450831|NCT03199196|DEVICE|Activity Tracker|"Group 1 - Intervention: Participants given an accelerometer at each visit. Participant wears the accelerometer for 7 days.~Group 2 - Newsletters: After completing the 16 week visit, participant given an activity tracker."
41450832|NCT03199196|DEVICE|Smartphone Application|"Group 1 - Intervention: Participant given smartphone application baseline visit to track physical activity, connect with participant's partner to share information about participant's physical activity, and provide support to partner to be more physically active.~Group 2 - Newsletters: After completing the 16 week visit, participant given instruction in the use of a smartphone application."
40756326|NCT04652765|DRUG|Camostat Mesilate|Camostat 600mg by mouth four times a day, for a total of 7 days
40756327|NCT04652765|DRUG|Bicalutamide 150 mg|Bicalutamide 150mg by mouth once daily, for a total of 7 days
40756328|NCT06067893|DRUG|Dexmedetomidine|Patient receives dexmedetomidine for 48 hours post-operatively
40756329|NCT06067893|DRUG|Normal Saline|Patient receives normal saline for 48 hours post-operatively
41131342|NCT05325541|DEVICE|Visual Biofeedback Therapy|Visual Biofeedback intervention will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
41131343|NCT05325541|BEHAVIORAL|Conventional Balance exercise|Conventional Balance exercises will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
41131344|NCT02697305|DIETARY_SUPPLEMENT|IV BCAA|in total dose of 0,4 g/kg in a 2 h intravenous infusion
41131345|NCT02697305|DIETARY_SUPPLEMENT|ORAL BCAA|single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
41131346|NCT02697305|OTHER|ORAL Placebo|single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
41131347|NCT00512252|DRUG|AMD3100|
41131348|NCT00512252|DRUG|Mitoxantrone|
41131349|NCT00512252|DRUG|Etoposide|
41131350|NCT00512252|DRUG|Cytarabine|
41450833|NCT03199196|BEHAVIORAL|Questionnaires|Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.
41450834|NCT03199196|BEHAVIORAL|Focus Group|Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.
41131351|NCT05435859|BEHAVIORAL|Speech Tasks|Listen to 25-minutes of speech sounds in English.
41131352|NCT06396338|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
41131353|NCT01898754|OTHER|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
41131354|NCT01025128|DRUG|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
41131355|NCT02278666|PROCEDURE|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
41131356|NCT02278666|DEVICE|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
41131357|NCT02278666|DEVICE|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
41450835|NCT03199196|BEHAVIORAL|Electronic Newsletters|Participant emailed electronic newsletters to read that may help participant be more physically active.
41450836|NCT03199196|BEHAVIORAL|Telephone Counseling|Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
41450837|NCT04580784|RADIATION|Weekly hypofractionation for early breast cancer|Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks
41450838|NCT00848536|DRUG|Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
41450839|NCT00848536|DRUG|Travoprost 0.004% (BAK-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
41131358|NCT03177590|OTHER|Recordings of facial and vocal emotional productions|"Children are asked to perform three tasks:~1. an emotional production on imitation (the child with autism or TED will imitate the emotion expressed by an animated avatar)~2. an emotional production by mime of the emotion on command (oral and written) without visualizing the model of imitation~3. Emotional production in context: the child with autism or EFD will describe images forming the story of Frog and as it is read, will produce the appropriate facial and vocal emotions in the context."
40938586|NCT02959164|DRUG|Gemcitabine|"Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level"
40938587|NCT00285467|DRUG|doxercalciferol|form of vitamin D that is already in active form.
41131359|NCT01359150|DRUG|CP-690,550|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
41131360|NCT01359150|DRUG|placebo|Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
41280798|NCT01014884|OTHER|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
41280799|NCT01014884|OTHER|Multidisciplinary team bimonthly visits either in person or via telephone.|
41280800|NCT01014884|OTHER|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
41280801|NCT01870492|DRUG|Activase|Patients treated with Activase
41280802|NCT01870492|DEVICE|Endovascular therapy|Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
41280803|NCT03629509|BEHAVIORAL|BEFORE decision aid|Implementation of the BEFORE decision aid in clinical practice
40938588|NCT00285467|DRUG|Cholecalciferol|from of vitamin D that requires cells in the body to make active
41280804|NCT03629509|BEHAVIORAL|BEFORE decision aid|Implementation of the BEFORE decision aid on RUBY communication portals
41280805|NCT03629509|BEHAVIORAL|BEFORE decision aid|Review impact of BEFORE decision aid implementation in clinical practice
41280806|NCT06260787|PROCEDURE|In Vitro Fertilisation|Assisted reproductive technology in the form of in vitro fertilisation
41280807|NCT05265650|DRUG|BO-112 in combination with ablative radiotherapy (SABR) and nivolumab|Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.
41280808|NCT05265650|PROCEDURE|Tissue Biopsies|Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.
40938589|NCT01918722|DRUG|ICH-1(herbal medicine with Hirudo, Tabanus)|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
40938590|NCT01918722|DRUG|placebo|placebo herbal medicine, one dose,bid, for 10 days
40938591|NCT01918722|DRUG|ICH-2(herbal medicine without Hirudo, Tabanus)|(6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
40938592|NCT01216267|DRUG|Lansoprazole|lansoprazole 30 mg HS x 7 days
40938593|NCT01216267|DRUG|lansoprazole|lanzoprazole 30 mg HS for 7 days
40938594|NCT02594540|DEVICE|Mechanical Peripheral Stimulation (GONDOLA)|
40938595|NCT00423748|DRUG|ambrisentan|
40938596|NCT05770531|PROCEDURE|Biospecimen Collection|Undergo blood sample collection for banking
40938597|NCT05770531|PROCEDURE|Computed Tomography|Undergo CT
40938598|NCT05770531|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40938599|NCT05770531|PROCEDURE|Biospecimen Collection|Undergo blood sample collection for ctDNA evaluation
40938600|NCT05770531|BIOLOGICAL|Sacituzumab Govitecan|Given by IV
40938601|NCT02351986|PROCEDURE|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
41131361|NCT04006834|OTHER|No intervention involved|No intervention involved
41131362|NCT04614805|BEHAVIORAL|Mobilizing clinical leaders|Clinical leaders and clinical personnel will regularly receive feedback regarding performance of their own hospital as well as other providers in the regional health trust of North Norway.
41131363|NCT02180815|DEVICE|ReVENT Sleep Apnea System|
41131364|NCT03937765|PROCEDURE|PRP harvest and preparation|"The PRP harvest and preparation will be done in the operating room with the help of the hospital blood bank. The skin graft surgery will be completed by Dr. Jason Lowe and/or one of the Orthopaedic Surgery residents. Follow up will also be completed by Dr. Lowe or one of the residents. Data analysis will be done by Drs. Lowe and Manoharan.~Each patient that will be undergoing a skin graft surgery will be randomized into either the PRP (intervention) group or the control group. Follow up and dressing changes will be the same for both groups. Each group will be prescribed a multi-modal pain regimen to reduce narcotic usage."
41131365|NCT04924296|DRUG|SHR-1314|SHR-1314 s.c. + Steroids
41131366|NCT04924296|DRUG|Placebo|Placebo s.c. + Steroids
41280809|NCT03633331|DRUG|Palbociclib|Given PO
41280810|NCT03633331|DRUG|Letrozole|Given PO
41280811|NCT03633331|DRUG|Fulvestrant|Given IM
41280812|NCT03633331|OTHER|Questionnaire Administration|Ancillary studies
41280813|NCT03633331|OTHER|Quality-of-Life Assessment|Ancillary studies
41453606|NCT05646316|DRUG|Indocyanine Green Solution|Given via injection
41280814|NCT06203431|DRUG|ET-26|freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.
41280815|NCT06203431|DRUG|Etomidate Injectable Emulsion|lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
41280816|NCT01061489|OTHER|auditory discrimination training|10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home
41280817|NCT01061489|OTHER|physical movement training|10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
41280818|NCT05478915|PROCEDURE|discectomy of the TMJ disc|removal of the TMJ disc
41280819|NCT05478915|PROCEDURE|TMJ discopexy|fixation of the TMJ disc
40938602|NCT02351986|OTHER|ice pack|
40938603|NCT01654796|DEVICE|Low Field Magnetic Stimulation (LFMS)|The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.
40938604|NCT01654796|DEVICE|Sham LFMS|Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
41131367|NCT04047407|DEVICE|Suprathreshold pain stimulation|"Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized."
41131368|NCT02534285|DEVICE|hearing protection|Attenuation of hearing during surgery
41131369|NCT02841449|BEHAVIORAL|Hypohydrated|Participants remain hypohydrated after the heat tent procedure
41131370|NCT02841449|BEHAVIORAL|Rehydrated|Participants rehydrate after the heat tent procedure
41280820|NCT01122927|DRUG|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
41280821|NCT02868892|DRUG|Pemetrexed|Pemetrexed 500 mg/m2
41280822|NCT06368947|BEHAVIORAL|Therapeutic Play|Therapeutic play sessions will be organized twice a week for 4 weeks during chemotherapy treatment for children diagnosed with acute lymphoblastic leukemia in the intervention group.
41450840|NCT05029726|DRUG|Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine|Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB
40938605|NCT06295081|OTHER|Exercise exposure|"Exercise is NOT part of our study protocol. Participants will voluntarily participate in a mass-participation exercise event (i.e. walking, cycling or running). Participation in this exercise event is voluntary and independent from participation in this study (i.e. participants would also take part in the exercise event if they did not participate in our study). Therefore, we do not consider the performed exercise an intervention or part of our study protocol. Hence, we consider our study design to be observational.~Participants will perform exercise during a mass-participation exercise event, stratified for type of exercise (walking versus running versus cycling; n=500 each).~The mass-participation exercise events have a sport-specific minimum distance of:~a mass-participation exercise event with a:~* Walking distance ≥20 km~* Cycling distance ≥100 km~* Running distance ≥15 km"
41280823|NCT02514538|DRUG|Non- effervescent Paracetamol kern|1g
41280824|NCT02514538|DRUG|Effervescent paracetamol termalgin|1 g
41131371|NCT05170620|PROCEDURE|laser ablation|Laser ablation will be done for the squamous intraepithelial lesions of the lower anogenital tracts.
41131372|NCT04551651|DEVICE|ApplTree|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
41280825|NCT03103399|DRUG|Comtan®|200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
41280826|NCT03103399|DRUG|Nebicapone|50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
41131373|NCT04551651|DEVICE|Google Calendar|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
41280827|NCT03103399|DRUG|Levodopa/DDCI|"Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients."
41450841|NCT05029726|DRUG|normal saline|normal saline in 30cc syringes administered using ESPB technique
41450842|NCT05208892|PROCEDURE|SZMN block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally
41450843|NCT05208892|PROCEDURE|SZMN block with Dexmedetomidine|Suprazygomatic Maxillary Nerve (SZMN) Blocks with local anesthetic and Dexmedetomidine bilaterally
41450844|NCT06627816|DRUG|Nefopam|efficacy of 3 drugs in preventing post-spinal anesthesia shivering
41453607|NCT05646316|PROCEDURE|Minimally Invasive Surgery|Undergo minimally invasive hysterectomy
40756330|NCT05689736|BEHAVIORAL|Motivational Enhancement|"Motivational Enhancements (ME) will include three features:~1. Personalized change plan. Parents will describe their intervention goals, motivation for participation, steps they are willing to take to meet those goals, as well as potential barriers to engagement and strategies to try to overcome such barriers. We will display the change plan to remind parents of their personalized responses. ME will also integrate participants' change plan responses into intervention content.~2. Assessment feedback. We will provide norm-referenced feedback for each selected parenting measure after the week 1 assessment. For simplicity, feedback will graphically categorize the parent or child in 3 categories per outcome: red (≥90th %ile), yellow (70-89th %ile), and green (\<70th %ile).~3. Modified, personalized SMS text nudges. Parents will receive 2 weekly personalized SMS messages based on their change plan responses."
40756331|NCT05689736|BEHAVIORAL|Simplification|We will follow recommendations of research on improving the readability of patient-directed text (e.g., fewer, shorter, less complex words, minimizing colons, semicolons, and decimal points). We will employ the Dale-Chall Readability (DCRI) score, which was developed for health education materials and, compared to other readability metrics, has higher correlations with comprehension. The target DCR score is 7 (8th grade reading level). We will avoid lower DCR scores because moderate levels of complexity enhance, attention, absorption, satisfaction, and ultimately engagement.
40756332|NCT05689736|BEHAVIORAL|Gamification|"Gamification will include four features:~1. Game-like graphical environment (e.g., avatars to represent the participant).~2. Digital rewards. Parents will receive points and badges for completing intervention activities.~3. Leaderboard. A leaderboard will be used to activate competitive motives and social referencing. The leaderboard will display the points/badges of the participant relative to 4 other actual or simulated anonymized parents who are at a similar point in the intervention; their number of points and badges will be determined by those of the participant.~4. Modified, personalized SMS text nudges. SMS text nudges will alternate between Core content (e.g., reminder to complete a module) and reminders about game features such as badges and standings."
40756333|NCT05689736|BEHAVIORAL|Low Engagement Nudges|SMS text nudges will be sent to participants who have fallen behind in completing specific intervention tasks within a given time window; e.g., failing to log-in to the next module by a predetermined date, timed to program enrollment or in a prespecified number of days since completing the previous module.
40756334|NCT05689736|BEHAVIORAL|Essentials for Parenting Toddlers and Pre-schoolers (EFP)|"All parents will receive the Core intervention content, including text, demonstrations (videos and vignettes), and interactive activities (e.g., skill-building), and comprising five modules: Communicating with Your Child; (2) Giving Directions; (3) Creating Structure; (4) Using Discipline and Consequences; and (5) Using Time-out. The Core intervention will be augmented with more prescriptive behavioral skills practice exercises and SMS text nudges to remind participants to complete intervention modules.~All conditions will be housed on Westat servers accessible through any device that can use the Internet, including computers, tablets, and smartphones. Westat has extensive technical capacities for web programming/hosting."
40938606|NCT04774120|DRUG|Propofol|Propofol will be started at a rate of 15-20 mg/kg/hr in patients \>65 years and 20-25 mg/kg/hr in younger patients (\<65 years) until a suppression rate (SR) is achieved. If not, can be increased by 5 mg/kg/hr every 5 minutes up to 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group or after 15 minutes have passed. When the SR appears, propofol infusion will be stopped. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
40938607|NCT00034749|DRUG|Risperidone|
40938608|NCT01759134|OTHER|Post discharge formula|Babies will be given either materna sensitive or similac neosure
40938609|NCT02700022|DRUG|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
41131374|NCT01091168|DRUG|vinflunine|280 mg/m2 on day 1 of each cycle every 3 weeks
41280828|NCT03103399|DRUG|Placebo|Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
41453608|NCT05646316|PROCEDURE|Pelvic Lymphadenectomy|Undergo pelvic lymphadenectomy
41280829|NCT02484261|DRUG|Bortezomib|1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
41280830|NCT02484261|DRUG|Pravastatin|10 mg for age \< 8 years, 20 mg for age 8-\<13 years, 40 mg for ages \>14 years
41280831|NCT05289661|DRUG|Topical Ripasudil|To determine the effect of rho-kinase inhibitors on endothelial cell loss
41280832|NCT05289661|DRUG|Topical Placebo|topical Placebo
41280833|NCT05200767|OTHER|completing surveys|"The level of usual physical activity before the disease ( COVID-19- coronavirus disease 2019) will be analysed based on the IPAQ ( International Physical Activity Questionnaire) results."
41280834|NCT02993237|DRUG|DRV/COBI FDC placebo tablet|Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
41280835|NCT02993237|DRUG|D/C/F/TAF FDC placebo tablets|Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
41131375|NCT01091168|DRUG|Alkylating agent of physician choice registered in cancer|cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
41131376|NCT05841407|DIETARY_SUPPLEMENT|High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
41131377|NCT05841407|DIETARY_SUPPLEMENT|No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
41131378|NCT00790699|DEVICE|I-PORT|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
41131379|NCT00790699|OTHER|standard injections|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
41131380|NCT05254912|DRUG|6% Bemotrizinol in sunscreen formulation|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)
41131381|NCT05254912|DRUG|6% Bemotrizinol in petrolatum|6% Bemotrizinol (BEMT) as a dispersion in petrolatum (SU-E-101413-82)
41131382|NCT05254912|OTHER|Vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (SU E 101413 91)
41131383|NCT03567616|DRUG|Venetoclax|Tablet; oral
41131384|NCT03567616|DRUG|Pomalidomide|Capsule; oral
41131385|NCT03567616|DRUG|Dexamethasone|Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]
41131386|NCT05505851|OTHER|Control|Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
41131387|NCT05505851|OTHER|Sequential Core Stability Corrective Exercise Approach|"1. Corrective Exercises~2. Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~3. Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~4. Core Stability exercises~   1. Beginning~  2. Progressing~  3. Advanced"
41280836|NCT03716726|BEHAVIORAL|WE CARE SDoH Screening Survey|The survey will be given at all visits by the front desk staff to all parents of SCA patients. It consists of 12 questions designed to: (1) briefly identify 6 unmet material needs (e.g., childcare, employment, food security, household heat, housing inadequate education) by self-report and (2) using a family-centered approach, determine whether parents would like assistance with each problem Parents wanting help will receive a resource referral. Clinical team members will be trained to review the WE CARE SDoH survey at visits and to provide community resource information sheets to parents with needs. Completed surveys will be scanned into the EHR
41280837|NCT03716726|BEHAVIORAL|Family Resource Book|The Family Resource book will contain one-page information sheets listing community resources (e.g., food pantries) and their contact information (i.e. telephone number) for each specific material need (e.g., food insecurity). Information sheets will be specific to each site and written at, or below, the 8th grade level. For parents with an identified need, providers will be instructed to give an information sheet. The book will contain six separate tabs, one for each unmet need, and will contain multiple copies of the information sheets. The Family Resource Book will be made available in each exam room. The investigators will work with each practice to create a Family Resource Book prior to study initiation.
41280838|NCT03716726|OTHER|Standard of care|Usual outpatient care for pediatric patients with sickle cell anemia will be provided.
41453609|NCT05646316|OTHER|Questionnaire Administration|Ancillary studies
40744350|NCT06111625|DRUG|blinatumomab|Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion.
41131388|NCT00236652|DRUG|levofloxacin|
41131389|NCT01009424|DRUG|R7103|escalating inhaled dose
41131390|NCT02419300|DEVICE|ultrasoungraphy|pelvic ultrasonography and Doppler
41131391|NCT05868304|DEVICE|BFR|Exercises may involve warm up on a stationary bike for 5 minutes, application of a BFR cuff (a cuff that often uses air to inflate around a limb) on the selected extremity, and exercise sets (e.g. banded squats, step ups, Romanian dead lifts). We will record metrics on an iPad. Testing will be done with ForceDecks and ForceFrames (system for measuring muscle strength and imbalance).
41131392|NCT05868304|OTHER|Stanard strengthening program.|"The exercise program will be completed 3 times per week Participants will warm up on a stationary bike for 5 minutes~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
41131393|NCT00031941|DRUG|lenalidomide|
41131394|NCT03131128|BEHAVIORAL|Mindfulness-based Intervention|"1. Keeping mindful when selecting food.~2. Be aware of hunger and satiety by the body clues.~3. Understanding how stress affect diet and life, and learn how to cope with stress in life.~4. Learning to identify overeating caused by mood, social stress and specific food."
40938610|NCT04352231|DIETARY_SUPPLEMENT|High Fiber Diet Intervention|Plant-based diet with a targeted quantity of 35 g of dietary fiber per day, from a variety of fiber types. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
40938611|NCT04352231|DIETARY_SUPPLEMENT|Low Fiber Diet Intervention|Animal based diet (meat, dairy) with a targeted quantity of 10 g of dietary fiber per day. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
40938612|NCT03918681|OTHER|Therapeutic Intervention|Instruction for all participants in the experimental group will begin with transitioning foot strike pattern from a rearfoot strike to a non-rearfoot strike running pattern (NRFS) and increasing preferred step rate by 5-10%. Each participant program thereafter will be progressed individually according to the clinical investigators follow up assessments of running mechanics and participant pain and function with running. Intervention gait retraining sessions will include drills for reinforcement to include soft landing single leg bounding, adequate time to practice, and pre-class and post-class video assessment with feedback.
40938613|NCT01100736|DRUG|Bosentan|Bosentan 125mg tablets, orally, twice daily for 7 days
40938614|NCT01100736|DRUG|Sitaxsentan|Sitaxsentan 100mg tablets, orally, once daily for 7 days
40938615|NCT01100736|DRUG|Placebo|Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
40938616|NCT01100736|BIOLOGICAL|Endothelin-3|5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
40938617|NCT03486431|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|A minimum of thirty patients will be included for each dose level. An interval of at least 24 weeks from the first patient treatment to the next patient treatment at each dose level will be respected. In the meantime, more patients will be included in the previous dose level, in an effort to establish the secondary endpoints. In case 1-5 patients present with dose-limiting toxicity (DLT) at 6 months after SABR, thirty additional patients will be included at the same dose level. The maximal tolerated dose will be defined as the dose level below which at least 10 patients present with a dose-limiting toxicity at 6 months after SABR.
40938618|NCT06000176|DEVICE|Optical coherence tomography angiography|diagnostic test OCTA macula and ONH
40938619|NCT06343883|DEVICE|low-intensity focused ultrasound - low pressure|low-intensity focused ultrasound applied to the S1.
41280839|NCT05760495|OTHER|blood sampling|Blood sampling for evaluation of oxidative stress markers
40938620|NCT06343883|DEVICE|low-intensity focused ultrasound - medium pressure|low-intensity focused ultrasound applied to the S1.
40938621|NCT06343883|DEVICE|low-intensity focused ultrasound - high pressure|low-intensity focused ultrasound applied to the S1.
40938622|NCT04542538|OTHER|No intervention, observational study|
40938623|NCT04538196|OTHER|Resident education on documentation and coding|Surgery residents will receive education on documentation and coding at the beginning of a particular surgical rotation vs the control group who will receive no education on documentation
40938624|NCT06168760|DIAGNOSTIC_TEST|Anthropometric Measurements|Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
40938625|NCT03039972|DIAGNOSTIC_TEST|No intervention|No intervention
41131395|NCT03131128|BEHAVIORAL|Health Education Intervention|"1. Identifying improper diet patterns and attitudes~2. Understanding the impact of irrational cognition and attitudes on dietary behavior~3. Training coping skills for stresses in real life and preventing the recurrence of bulimia."
41131396|NCT02208414|PROCEDURE|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
41131397|NCT02208414|PROCEDURE|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding water vial
41131398|NCT05784259|BEHAVIORAL|Transdiagnostic single-session treatment|Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
41280840|NCT06546592|DEVICE|AI assisted contouring|Initial are generated automatically using software powered by artificial intelligence
41453610|NCT05646316|PROCEDURE|Sentinel Lymph Node Mapping|Undergo sentinel lymph node mapping
40744351|NCT03044561|DRUG|Sildenafil Citrate|25 mg orally, 4 times per day for 21 days
40744352|NCT03044561|DRUG|matching placebo|orally, 4 times per day for 21 days
41280841|NCT06007612|BEHAVIORAL|Context Sensitivity in Emotion Regulation|Context Sensitivity of affective intensities and its association to Emotion Regulation Flexibility Selection
41280842|NCT02441530|DIETARY_SUPPLEMENT|Vitamin D|
41280843|NCT02441530|DIETARY_SUPPLEMENT|Vitamin E|
41280844|NCT02441530|DRUG|Ibuprofen|
40938626|NCT03929484|DEVICE|Nasal reservoir cannula|The experimental oxygen mask (nasal reservoir cannula) fits over a standard nasal cannula. The system is designed to reduce administered oxygen to deliver an equal or higher fraction of inspired oxygen (FiO2) per oxygen delivered (L/min) compared with a standard nasal cannula alone.
40938627|NCT04570267|BIOLOGICAL|CSL324|Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection
40938628|NCT04570267|DRUG|Placebo|Sterile solution of CSL324 formulation buffer for injection
40938629|NCT04067583|OTHER|Physician questionnaire|This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
40938630|NCT05274139|DRUG|HD-MTX-Ara-C regimen|"HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles"
40938631|NCT05274139|DRUG|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
40938632|NCT05266274|DRUG|CD47 monoclonal antibody|patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation
41131399|NCT02509858|DRUG|thyroxine|treatment with 50μg of thyroxine once daily for two months.
41131400|NCT02509858|DRUG|Placebo|treatment with 50μg of placebo, once daily, for two months.
41131401|NCT02509858|OTHER|A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)|
41131402|NCT05155358|DIAGNOSTIC_TEST|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
41131403|NCT01159236|DRUG|Paclitaxel|80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
41131404|NCT01159236|DRUG|Fluorouracil|500 mg/m2 for 4 courses (once every 7 days)
41131405|NCT01159236|DRUG|Doxorubicin|50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
41280845|NCT00358163|DRUG|PTK787/ZK 222584|Taken in tablet form daily
41280846|NCT00358163|DRUG|paclitaxel|Given as a 3-hour infusion once every 21 days
40938633|NCT00679055|DRUG|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
40938634|NCT00679055|DRUG|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
40938635|NCT03639532|PROCEDURE|COC THA|standard total hip arthroplasty is done, with ceramic on ceramic for the bearing.
40938636|NCT03639532|PROCEDURE|COP THA|standard total hip arthroplasty is done, with ceramic on highly cross linked polyethylene for the bearing.
41131406|NCT01159236|DRUG|Epirubicin|100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
41131407|NCT01159236|DRUG|Cyclophosphamide|500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
41131408|NCT01159236|DRUG|Bevacizumab|10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
41131409|NCT02103166|DRUG|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
41280847|NCT00227357|DRUG|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
40938637|NCT00133393|DRUG|Pentoxifylline|
40938638|NCT05348135|OTHER|functional strength training|children in this group received FST. Each training session started with 10 minutes dynamic warm-up period and ended with 5 minutes cool down in the form of muscle stretching and aerobics. The warm up was followed by gait training in addition to 4 functional lower limb exercises; sit to stand exercise, forward/ lateral step-up exercise, half knee rise exercise, and bridging exercise.
41131410|NCT02103166|DRUG|Physiological serum|100 ml of physiological serum (0.9% NaCl).
41131411|NCT04580433|BEHAVIORAL|Time-Restricted Feeding|"The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.~Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day."
41131412|NCT03777566|DIAGNOSTIC_TEST|sonohysterography|sonohysterography with measuring the uterine cavity volume
41131413|NCT00621673|DRUG|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
41131414|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Scheduled|VSTs will be infused into stem cell transplant recipients on schedule.
41131415|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Treatment|VSTs will be infused into stem cell transplant recipients only if viremia is detected.
41280848|NCT00227357|DRUG|Off-site - methadone or no agonist|
41450845|NCT03067987|DEVICE|Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~."
41450846|NCT01827787|DRUG|Eribulin|
41450847|NCT03890237|BEHAVIORAL|Her Spaces|Her Spaces will comprise a set of activities leveraging the Her Spaces curriculum and program model which includes curriculum-based sessions for 11-13 year old girls, with 40 sessions delivered weekly over the course of 10 months
41450848|NCT03890237|BEHAVIORAL|Act With Her|Act With Her was designed to facilitate adolescent transitions to adulthood via improvements across the six GAGE domains (education, bodily integrity, health, psychosocial well-being, voice and agency, and economic empowerment). Project activities fall into three main categories: curriculum-based programming with adolescent girls and boys, community transformation, and systems strengthening. Act With Her will work with 10-13 year old girls and boys for 10 months and implement community-level and high-level system strengthening work up to 24 months (in rural and pastoralist areas).
40938639|NCT05348135|OTHER|cognitive training|Children in this group received cognitive training by RehaCom cognitive rehabilitation software. Training was applied for four cognitive domains of function; attention / concentration, figural memory, reaction behavior and logical reasoning.
40938640|NCT05348135|OTHER|conventional physical therapy|including reinforcement of normal motor development, reflex inhibiting patterns, balance exercises, stretching exercises and gait training
40938641|NCT01522586|DRUG|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
40938642|NCT01522586|DRUG|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
40938643|NCT05049733|DRUG|CBD 1mg/Kg|Participants will ingest soft gel tablets containing CBD 1mg/Kg
40938644|NCT05049733|DRUG|CBD 2mg/Kg|Participants will ingest soft gel tablets containing CBD 2mg/Kg
41280849|NCT01558687|DRUG|Drug (including placebo)|"Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide."
41280850|NCT01558687|OTHER|Standard therapy|In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
41450849|NCT03890237|BEHAVIORAL|Act With Her + Asset Transfer|This arm will implement the Act With Her program described above, using program curricula with 10-13-year-old girls and boys over 10 months and conducting community-level systems strengthening up to 24 months. Additionally, the girls participating in this arm will receive one of three asset transfer options. The packages will be of equal value (115 USD) - one will include school supplies, one will include hygiene supplies, and will be a combination of both. Each adolescent girl will choose which package she would like to receive and will receive components of the package at 3 timepoints over the course of the first 10 months of the project.
40938645|NCT05049733|DRUG|CBD 4mg/Kg|Participants will ingest soft gel tablets containing CBD 4mg/Kg
40938646|NCT05049733|DRUG|Placebo CBD|Participants will ingest soft gel tablets containing placebo for CBD
40938647|NCT04146298|DRUG|Cyclophosphamide|Cyclophosphamide will be administered prior to cell infusion.
40938648|NCT04146298|DRUG|Fludarabine|Fludarabine will be administered prior to cell infusion.
40938649|NCT04146298|BIOLOGICAL|Mutant KRAS G12V-specific TCR transduced autologous T cells|After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.
40938650|NCT04146298|DRUG|Anti-PD-1 monoclonal antibody|During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
40938651|NCT01011023|OTHER|Non application of nasogastric tube in the experimental group|Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
40938652|NCT04689438|DIAGNOSTIC_TEST|gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
41280851|NCT00003248|BIOLOGICAL|rituximab|
41280852|NCT00003248|DRUG|fludarabine phosphate|
40938653|NCT06086626|DRUG|Cefiderocol|Administered via intravenous (IV) infusion
40938654|NCT06086626|DRUG|Standard of Care|Antibiotics selected by the investigator based on the participant's symptoms, in accordance with local standards
40938655|NCT00474838|DRUG|intensive insulin group|Once daily long acting insulin and preprandial rapid acting insulin injection
40938656|NCT00474838|DRUG|Oral AntiDiabetic Drug (glimepiride and metformin)|glimepiride and metformin combined therapy
40938657|NCT02207660|DRUG|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
40938658|NCT03686826|PROCEDURE|Acquisition of MEP und SSEP|Acquisition of MEP und SSEP at two different time points within 1 to 30 days
40938659|NCT00190944|DRUG|Teriparatide|
40938660|NCT00190944|DRUG|placebo|
40938661|NCT00124488|DEVICE|Tomotherapy Treatment Planning|
40938662|NCT01164540|DRUG|Rosuvastatin (AZD4522)|Oral dose (od) 20 mg
40938663|NCT01164540|DRUG|Placebo|Oral dose (od)
41131416|NCT05113810|DRUG|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
40938664|NCT00636883|DRUG|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
40938665|NCT02285556|BEHAVIORAL|psychological rehabilitation training|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
40938666|NCT02285556|BEHAVIORAL|physical and neurological rehabilitation training|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
40938667|NCT02285556|RADIATION|rTMS 10HZ high frequency stimulation|Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
40938668|NCT02285556|RADIATION|fake rTMS 10HZ high frequency stimulation|Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
40938669|NCT03293511|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
40938670|NCT03293511|DRUG|intranasal placebo|24 IU of of placebo nasal spray will be applied to each subject.
40938671|NCT02986971|DEVICE|New IMD|The contraceptive implants of the subjects in this arm are removed by the new IMD.
40938672|NCT02561910|DEVICE|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
40938673|NCT01199900|DRUG|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
40938674|NCT01199900|DRUG|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
40938675|NCT01199900|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
40938676|NCT01199900|DRUG|PF-04171327|3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
40938677|NCT01199900|DRUG|PF-04171327|10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
40938678|NCT01199900|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
40938679|NCT01199900|DRUG|Prednisone|5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
40938680|NCT04167956|DEVICE|ultrasound and CT|Experimental: ultrasound combined with CT guided Active Comparator: CT guided
40938681|NCT03071198|PROCEDURE|TME|"1. Find the hypogastric nerve trunk in front of sacral promontory and protect it,be careful to use electrocautery hemostasis biased toward the side of rectal when handle lateral ligament of rectum and middle rectal artery and avoid to damage the pelvic plexus.~2. At least a 2-cm margin to the lower edge of the tumor is adequate for distal bowel resection. Resect 5cm length distal rectal or all of the mesorectum.Check the integrity of the mesorectum in postoperative routine examination. Double stapling method is used for all low anastomosis operations."
40938682|NCT03071198|RADIATION|Concurrent chemo-radiotherapy|Three-dimensional conformal radiotherapy as following: CTV 44Gy/22 times＋GTV1 6Gy/3 times(2Gy/time/day，5 days a week，totally 5 weeks),if rectal tumors do not regress obviously, additional GTV2 is necessary, 5.4Gy/3 times (1.8Gy/time/day). At the same time, Capecitabine (850mg/m2, two times every day) will be taken on radiotherapy day
41131417|NCT05113810|OTHER|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
41453611|NCT05941390|DEVICE|VR without positive psychology|Using VR goggles showing relaxing short videos without sound
41450850|NCT03890237|BEHAVIORAL|Act With Her (simple)|This arm will implement the Act With Her curricula described above with 10-13 year old girls and boys over 10 months. The adolescent groups will follow the same model (near-peer, same-sex mentors, 40 weekly meetings for girls, 18 meetings for boys, 4 of which are joint sessions for boys and girls, 6 sessions for parents), but will not include community-level systems strengthening activities
40938683|NCT03071198|DRUG|neoadjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
40938684|NCT03071198|DRUG|adjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
40938685|NCT01196039|DRUG|MEMP1972A|Intravenous repeating dose
40938686|NCT01196039|DRUG|placebo|Intravenous repeating dose
40938687|NCT02240290|DRUG|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
41131418|NCT01238874|DEVICE|Cardiac Resynchronization Therapy|All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
41450851|NCT03390790|DRUG|Lidocaine gel 2%|If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.
40938688|NCT02240290|DRUG|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
40938689|NCT01323738|BEHAVIORAL|Psychoeducation|Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
40938690|NCT00728052|DRUG|GSK598809|GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
40938691|NCT00728052|DRUG|Placebo|Placebo capsules will be administered orally with water.
40938692|NCT00664469|DRUG|ezetimibe|ezetimibe 10 mg/day over a 6-week course of treatment.
40938693|NCT00664469|DRUG|Comparator: Simvastatin 20, 40 and 80 mg|Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
41131419|NCT04813224|BEHAVIORAL|TRAUMA CENTERED EMDR-BASED TREATMENT and TRAUMA-FOCUSED CBT-BASED TREATMENT|Psychological evidence-based intervention for the reduction of the impact of childhood sexual abuse.
41131420|NCT04210258|DEVICE|Etermis 3|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling facial moderate wrinkles (marionette lines) and/or to increase lip volume
41131421|NCT04210258|DEVICE|Etermis 4|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling deep and severe volume loss (nasolabial folds and/or marionette lines) and/or to increase lip volume
41131422|NCT04783441|DEVICE|Dexcom G6|access to continuous glucose monitoring in the Dexcom G6 arm 24/7
41450852|NCT03390790|OTHER|Standard lubricant gel|If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.
40938694|NCT00664469|DRUG|Comparator: Atorvastatin|Atorvastatin 20, 40 \& 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
40938695|NCT00664469|DRUG|Comparator: Rosuvastatin|Rosuvastatin 10, 20 \& 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
40938696|NCT01253330|OTHER|Text Message Reminders|During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
41131423|NCT04783441|DEVICE|Dexcom G6 blinded sensor|retrospective access to continuous glucose profile after 10 days of wear
41280853|NCT03270722|DEVICE|FLIP topography|During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
41280854|NCT03270722|PROCEDURE|Upper Endoscopy|A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
41450853|NCT03913676|BEHAVIORAL|Velibra|"Velibra is grounded in a cognitive-behavioral theoretical orientation and consists of six treatment modules representing different skills and therapeutic techniques. Each of the first five modules is followed by a training session, and contains activities related to training attention biases (CBM-I). All sessions plus trainings are designed to be completed in 1 - 2 hours, depending on the user's reading speed, interest, motivation, and individual path through the program. The modules cover a variety of therapeutic content that is broadly consistent with a cognitive-behavioral perspective. The modules' content draws from therapeutic strategies: (1) Cognitive Modification, (2) Mindfulness, Acceptance, and Relaxation techniques (4) Exposure, (5) Interpersonal Skills, (6) Psychoeducation and Relapse Prevention."
41450854|NCT02132910|OTHER|RESTORE Intervention|
40756335|NCT00005819|DRUG|cisplatin|Patients receive cisplatin IV over 30 minutes on day 7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
40756336|NCT00005819|DRUG|fenretinide|Patients receive oral fenretinide twice daily for 7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
40756337|NCT00005819|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
41131424|NCT02821299|OTHER|Laryngeal transplantation|Laryngeal transplantation
41131425|NCT00895245|DRUG|fosaprepitant dimeglumine|Given IV
41280855|NCT00378729|DRUG|Metformin and FSHr|treatment for infertility
41280856|NCT00378729|PROCEDURE|Ovarian drilling by FERTILOSCOPY|surgical ovarian drilling
41450855|NCT05759663|PROCEDURE|MIRRAD|Repair of the diastasis with MIRRAD technique
41450856|NCT05759663|PROCEDURE|Plication of the entire diastasis arm|Plication of the entire diastasis
40756338|NCT01810172|DEVICE|Digital pleural drainage system|Reusable device with disposable collection system for digital monitoring of air leak.
40756339|NCT01810172|DEVICE|Dry suction pleura drainage device|Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
40756340|NCT05530707|OTHER|Moisturizer containing saccharide isomerate and niacinamide|Moisturizer containing saccharide isomerate and niacinamide
40756341|NCT04740879|BEHAVIORAL|Be Mindful|The online 4-week Be Mindful intervention was designed to follow the same outline as typical in-person 8-week MBCT courses. Week 1 and Week 2 introduce the topic of mindfulness and encourage its daily use, whereas Week 3 and Week 4 teach the individual to decenter from thoughts and utilize mindfulness when coping with stressors. Each week focuses on a separate mindfulness topic, which is initially presented to the individual in a short (under 5 minute) video containing didactic information and an overview of the experiential activities that will be introduced in subsequent videos. The intervention is provided entirely through audio, video, and text provided on the Be Mindful website (BeMindfulOnline.com).
40756342|NCT06391333|DEVICE|laryngeal mask airway and endotracheal tube|The two most commonly used devices for mechanical ventilation.
40756343|NCT06190275|BIOLOGICAL|GT201 in combination with PD-1 inhibitors|GT201 in combination with a PD-1 inhibitor for advanced (HNSCC)
40756344|NCT00569998|DEVICE|NovoPen™ 4|
40756345|NCT00569998|DEVICE|NovoPen® 3|
40938697|NCT04291261|DRUG|Uvadex|Extracorporeal photopheresis (ECP) with Uvadex is scheduled 3x/week in weeks 1+2, 2x/week thereafter till day 28 and 1x/week till day 56
40938698|NCT04152980|DRUG|Pentoxifylline|The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
40938699|NCT03676985|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
40938700|NCT03676985|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
41131426|NCT00895245|DRUG|cisplatin|Given IV
40938701|NCT03676985|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
40938702|NCT04856202|BEHAVIORAL|Advance Care Planning interview|The facilitator will clarify the patients' preferences, asking specific questions regarding personal goals, including religious and cultural beliefs. The facilitator will discuss life supporting treatments that might be applicable to the patient and encourage the patient to weigh up personal benefits and burdens. Treatments may include: invasive therapy (such as chemotherapy or dialysis), hospitalization, resuscitation, ventilation, artificial nutrition or hydration and administration of antibiotics. The patient will also be encouraged to identify specific situations that are likely to improve or diminish his or her quality of life. The facilitator will assist the patient in documenting their wishes, including the assignment of a health care proxy.
40938703|NCT04397627|PROCEDURE|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
40938704|NCT00355901|DRUG|Visilizumab (Nuvion®; HuM291)|
40938705|NCT05637671|DRUG|oxybutynin ER|One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.
40938706|NCT05637671|DRUG|Paroxetine CR|the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks.
40938707|NCT00238537|DRUG|Alteplase t-PA|
40938708|NCT05658003|DRUG|[177Lu]Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
40938709|NCT05658003|DRUG|ARDT|administered orally on a continuous basis, as per package insert and guidelines
40938710|NCT05658003|DRUG|[68Ga]Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
40938711|NCT05658003|OTHER|Best supportive care|Best supportive/best standard of care as defined by the local investigator
40938712|NCT00398489|BIOLOGICAL|trastuzumab|
40938713|NCT00398489|DRUG|anastrozole|
40938714|NCT00398489|DRUG|cyclophosphamide|
40938715|NCT00398489|DRUG|docetaxel|
41450857|NCT06315387|DRUG|4-MUST, 1 tablet|4-methylumbelliferyl trimebutine sulfate, 128 mg
41450858|NCT06315387|DRUG|4-MUST, 2 tablets|4-methylumbelliferyl trimebutine sulfate, 256 mg
41450859|NCT06315387|DRUG|4-MUST, 3 tablets|4-methylumbelliferyl trimebutine sulfate, 384 mg
40756346|NCT01749293|PROCEDURE|Haploidentical Transplant|Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
40756347|NCT01749293|DRUG|Fludarabine|Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.
40938716|NCT00398489|DRUG|epirubicin hydrochloride|
40938717|NCT00398489|DRUG|goserelin acetate|
40938718|NCT00398489|DRUG|tamoxifen citrate|
40938719|NCT00398489|PROCEDURE|adjuvant therapy|
40938720|NCT00398489|PROCEDURE|conventional surgery|
40938721|NCT00398489|PROCEDURE|neoadjuvant therapy|
40938722|NCT00398489|RADIATION|radiation therapy|
40938723|NCT03871335|DIAGNOSTIC_TEST|Investigation of the work-related musculoskeletal disorders|Structured questionnaires will be used to determine the prevalence of the work-related musculoskeletal disorders and work-related factor. Photogrammetric method will be used to evaluate working posture.
40938724|NCT03247803|DEVICE|air-Q® SP|air-Q SP placement for airway maintenance,
41131427|NCT00895245|DRUG|palonosetron hydrochloride|Given IV
41131428|NCT00895245|DRUG|dexamethasone|Given IV and orally
40938725|NCT03247803|DEVICE|Williams Airway Intubator (WA)|WA is placed in subject's oropharynx. If the vocal cords are not in view at the end of the WA, the operator may ask an assistant to perform an airway maneuver (e.g., jaw thrust, anterior jaw lift, or lingual traction) to attempt to bring the vocal cords into view
40938726|NCT05631288|GENETIC|Sampe collection|Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).
41131429|NCT00895245|OTHER|Functional Living Index-Emesis Questionnaire|Ancillary studies
41131430|NCT00895245|BEHAVIORAL|Emesis Diary|Ancillary studies
41131431|NCT00895245|RADIATION|Radiotherapy|Undergo radiotherapy
41450860|NCT00736658|DRUG|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
41450861|NCT00736658|DRUG|Placebo|Oral admin. of doses at 11 days through a 12 days period.
41450862|NCT04494607|DIETARY_SUPPLEMENT|lowest Glycemic Index for a selected type fo cereal product|determination of lowest Glycemic Index for a selected type fo cereal product
41450863|NCT02956681|BEHAVIORAL|Intervention Group|Callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that a genetic counselor will call them back to offer them a free genetic counseling appointment and that a brochure will be sent. A UCSF/SFGH genetic counseling assistant will call them back within a few days to offer them a free genetic counseling appointment at SFGH.
41280857|NCT01012661|DEVICE|Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)
41131432|NCT02085772|OTHER|Blood samples at 37-38 Weeks of amenorrhea|
40756348|NCT01749293|DRUG|Busulfan|Subjects in this trial will receive Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.
41131433|NCT02085772|OTHER|Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy|
41131434|NCT02085772|OTHER|Blood samples at the time of delivery|
41131435|NCT00000492|DRUG|propranolol|
41131436|NCT01005849|DIETARY_SUPPLEMENT|Protecflor|1 Capsule to be taken once a day during the entire study period
41131437|NCT01005849|DIETARY_SUPPLEMENT|Placebo|1 Capsule to be taken once a day during the entire study period
41131438|NCT02498145|OTHER|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
41131439|NCT02498145|OTHER|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
41131440|NCT00352599|DRUG|Lovastatin|
41131441|NCT00352599|DRUG|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
41131442|NCT00352599|DRUG|placebo pill|
41131443|NCT00158483|DRUG|Acyclovir (ACV)|
41131444|NCT06509308|OTHER|Psychological Questionnaires|Patients will be asked to complete a series of questionnaires regarding disease expectations, cognitions, and representations of their health status. Additionally, sociodemographic data and clinical variables will be collected from medical records.
41131445|NCT06314932|OTHER|MD high in UPF|A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of UPF, as defined by the NOVA system (e.g., flavored yogurt, breakfast cereals with added sugar, processed meat).
41131446|NCT06314932|OTHER|MD low in UPF|A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of products from the same food group, but non-UPF (e.g., plain yogurt, breakfast cereals with no added sugar, unprocessed meat)
41131447|NCT02988713|DEVICE|Programming|Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
41131448|NCT05795088|DEVICE|Continuous theta burst stimulation|Two sessions of continuous theta burst stimulation over primary motor cortex to explore synaptic plasticity in Patients with Parkinson's disease
41131449|NCT01450163|DRUG|Pregabalin, Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
41131450|NCT01450163|DRUG|Placebo , Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
41131451|NCT00582972|DRUG|Omeprazole|40 mg po qAM one-half hour before breakfast for 30 days
41131452|NCT02334917|PROCEDURE|Surgical wound closure with superficial absorbable sutures|Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
41280858|NCT01012661|DEVICE|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
41280859|NCT02809248|DEVICE|ZES|stent implantation (zotarolimus eluting stent)
41280860|NCT02809248|DEVICE|BMS|stent implantation (bare metal stent)
41280861|NCT00652587|PROCEDURE|hepatectomy and transcatheter arterial chemoembolization|partial hepatectomy with adjuvant transcatheter arterial chemoembolization
41453612|NCT05941390|DEVICE|VR with positive psychology|Using VR goggles showing relaxing short videos with positive psychological messages
41453613|NCT01360437|DRUG|Prasugrel|Prasugrel 10mg/day
40756349|NCT01749293|RADIATION|Total Body Irradiation|Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.
41131453|NCT05179265|DRUG|recombinant human serum albumin|10 g/bottle (20%, 50 mL)
41131454|NCT05179265|DRUG|Human serum albumin|10 g/bottle (20%, 50 mL)
41131455|NCT05099419|DEVICE|Repetitive Transcranial Magnetic Stimulation|"rTMS uses pulses of magnetic energy to non-invasively stimulate the brain. The rTMS device to be used in this study is the Magstim Rapid2 Plus1. The rTMS device is connected to an active figure-of-eight coil which rests against the scalp and delivers the magnetic energy to the brain. The rTMS protocol is specified by the parameters of pulse frequency, duration of continuous pulse delivery, intensity, and stimulation location.~Each participant will receive two different standard rTMS protocols that have been used in past research studies for modulation of pelvic floor tone delivered over the motor cortex in an area that is known to control pelvic floor muscles."
41131456|NCT02925988|DEVICE|EEG monitoring|Neonates will receive their amplitude-integrated EEG monitoring as soon as the indication for monitoring is established, and conventional EEG electrodes will be applied in parallel.
41280862|NCT00652587|PROCEDURE|hepatectomy|hepatectomy alone
41453614|NCT01360437|DRUG|Ticagrelor|Ticagrelor 90mg twice a day
40756350|NCT01749293|DRUG|Cyclophosphamide|Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
40938727|NCT05889572|DRUG|MaaT033|MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.
40938728|NCT00079014|DRUG|triapine|Given IV
41280863|NCT04936932|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
41280864|NCT04936932|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
41280865|NCT02209766|DRUG|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
41280866|NCT02209766|DRUG|Placebo|"1. st cohort: Dose 1(2g) D5884(n=3) in Japanese~2. nd cohort: Dose 2(4g) D5884(n=3) in Japanese"
41280867|NCT01595217|DEVICE|3T MRI|diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
41280868|NCT00345891|BEHAVIORAL|Coping-focused counseling telephone calls|
41280869|NCT05854134|DIAGNOSTIC_TEST|Closed Chain|Effectiveness of Closed Chain for Strengthening and Improving Quality of Life in Post Stroke Patients
40938729|NCT00079014|DRUG|doxorubicin hydrochloride|Given IV
41131457|NCT05981352|PROCEDURE|mineral trioxide aggregate pulpotomy|"* After achieving hemostats, Mineral trioxide aggregate powder will be mixed with saline.~* Then Mineral trioxide aggregate will be placed directly on the pulp stumps."
41131458|NCT05981352|PROCEDURE|Dehydrated amniotic membrane pulpotomy|"* After achieving haemostasis, a double layer of sterile processed human allograft tis¬sue (dehydrated dual-layer dental amni¬on patch) will be trimed and soaked in saline for a minute.~* Dehydrated amniotic membrane will be Placed directly on the pup stumps using sterile tweezers and adjust¬ed to the entire floor of the pulp chamber."
41280870|NCT05854134|DIAGNOSTIC_TEST|Aerobic Exercise|Effectiveness of Aerobic Exercise for Strengthening and Improving Quality of Life in Post Stroke Patients
41280871|NCT04659993|BEHAVIORAL|Telemental Health Sessions, Support Groups and Questionnaires|Participants will complete initial online questionnaires lasting about 25-30 minutes as well as attend weekly support group meetings online. After 4 weeks, participants will complete seven online follow-up questionnaires that should take no longer than 30 minutes and again at the end of the study.
41280872|NCT02579603|DRUG|Nintedanib|Nintedanib 150mg bid
41131459|NCT05981352|PROCEDURE|Hyaluronic acid pulpotomy|"* After achieving haemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder with consistency (1:1 ratio by volume) .~* The cavities of all pulpotomy molars will be sealed with a layer of reinforced zinc oxide and eugenol ."
41280873|NCT02579603|DRUG|Pirfenidone|
41280874|NCT04209738|OTHER|This is an observational study being conducted as a substudy of another trial.|This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.
41280875|NCT06006078|DEVICE|Endoscopic Patient Facemask|A commonly used endoscopic patient facemask that is normally used for oxygen delivery during endoscopy will be tested in this trial as a potential intervention for decreasing particle aerosolization
41131460|NCT01475266|DRUG|EO9 (Apaziquone)|4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
41131461|NCT01475266|DRUG|Placebo|40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
41131462|NCT05609149|PROCEDURE|total mesorectal excision|patients must underwent total mesorectal excision
41131463|NCT02999763|DEVICE|SlimShape|SlimShape radiofrequency treatment to the abdomen
41131464|NCT02159352|DRUG|Daclatasvir|
41131465|NCT02159352|DRUG|Darunavir|
41131466|NCT02159352|DRUG|Ritonavir|
41131467|NCT02159352|DRUG|Lopinavir/Ritonavir|
41131468|NCT05381519|BIOLOGICAL|DXP604|1800mg，IVgtt
41280876|NCT03401749|DRUG|Chlorhexidine Gluconate 2% Wipe|Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
41280877|NCT03401749|OTHER|Theraworx Bath Wipes|Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
41280878|NCT06136858|DEVICE|Cuirass ventilation|We will fit the Cuirass Shell and start Biphasic Cuirass Ventilation on all participants.
41280879|NCT00040534|DRUG|Farnesyl Protein Transferase Inhibitor|
41450864|NCT02956681|BEHAVIORAL|Delayed Intervention Group|This is a randomized delayed intervention control trial in which eligible callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that they are eligible to speak to a genetic counselor who is available at no charge at SFGH and that they will be sent a brochure with information on where to call.
40938730|NCT00079014|OTHER|laboratory biomarker analysis|Correlative studies
40938731|NCT00079014|OTHER|pharmacological study|Correlative studies
40938732|NCT01565837|DRUG|Ipilimumab|Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
41131469|NCT02795884|DRUG|intercalation therapy using pemetrexed, cisplatin and erlotinib|During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
41450865|NCT06559527|DRUG|NNC0487-0111|Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.
41131470|NCT02795884|DRUG|Vinorelbine, cisplatin|Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
41131471|NCT04874259|PROCEDURE|Living donor liver transplantation|Living donor liver transplantation
41131472|NCT02674841|OTHER|Feedback on TUT|Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
41131473|NCT02674841|OTHER|No feedback on TUT|Access only to live visual feedback on pulling force from an application on an iPad.
41131474|NCT02674841|OTHER|Exercise|3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
41131475|NCT00312806|DRUG|Pantoprazole|Pantoprazole 40 mg o.d.
41131476|NCT03232398|DRUG|Apixaban Oral Tablet [Eliquis]|Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
41131477|NCT03232398|DRUG|Warfarin|Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
41131478|NCT05073224|DIAGNOSTIC_TEST|Active Straight Leg Raise Test|The ASLR test is a well-established clinical test that assesses stability of the lumbar spine/pelvis, posterior pelvic pain severity, and ability to activate the abdominal muscles. It is performed in supine. Participants are instructed to raise one leg, with the knee straight, to a heel height of 20 cm. The leg is held at the top for 5 seconds, then slowly lowered to the ground. The participant is asked to report perceived difficulty to raise the leg on a 0 to 5 scale (0=not at all difficult; 5=unable to lift leg) and pain on a 0 to 10 scale (0=no pain; 10=worst possible pain). If difficulty or pain are rated at a 1 or higher, the test is repeated with the researcher providing external compression of the pelvis. If perceived difficulty or reported pain are lower with compression, the test is considered positive for lumbopelvic instability. The test is then repeated on the opposite limb.
41131479|NCT05073224|OTHER|Active Straight Leg Raise Fatigue Task|The protocol is similar to the ASLR test, except that the participant is instructed to maintain the elevated leg off the ground for as long as possible. A biofeedback air cuff will be placed under the participant's lumbopelvic region to assess movement of the spine/pelvis. The cuff will be inflated to 40 mm Hg, and the participant instructed to keep the needle as close to 40 mm Hg as possible throughout the test; no information will be provided on how to affect cuff pressure, but visual feedback of cuff pressure will be provided throughout the task. Ratings of perceived exertion (RPE) and pain will be obtained from participants every 30-60 seconds. Task failure will be defined as a heel height ≤10 cm or a change in cuff pressure ≥20 mm Hg. Both limbs will be tested, but in different sessions. The order of limb testing (dominant vs non-dominant) will be randomized and counter-balanced. Limb dominance will be self-reported.
41131480|NCT05073224|OTHER|Lower Extremity Strength Testing|"A straight leg raise maximal voluntary contraction (MVC) of each lower extremity an MVC of the hip extensors of the grounded limb will be performed in supine before and within 2 minutes of completing the ASLR fatigue task. The straight leg raise MVC will be performed with a custom-made load cell instrumented strength testing device, which consists of a rigid platform on which the participant will lie. At the foot of the device is a tower that houses 2 load cells connected to a lightly padded push plate.~The hip extension MVC will be performed on a force plate. Before the ASLR fatigue task, a minimum of 3 MVC trials will be performed for each muscle group, with a minimum of 1 minute rest between trials; the highest peak force will be considered the MVC. Only 1 MVC trial per muscle group will be performed following the ASLR Fatigue Task."
41131481|NCT05073224|DIAGNOSTIC_TEST|Ultrasound imaging of abdominal wall|Real time ultrasound will be used to assess inter-recti distance above and below the umbilicus. Participants will be assessed with B Mode images in supine at rest, in supine while lifting their head, and in supine while performing a straight leg raise. The Principle Investigator has training and experience in musculoskeletal ultrasound.
41131482|NCT05276999|OTHER|Healthcare provider education|Mix of training and educational activities within the district continuing medical education system targeting community health workers and frontline providers focused on the importance of sore throat and it's link to RHD, clinical guidelines to differentiate patients at high or low risk for GAS pharyngitis and guideline based care for treating GAS pharyngitis
41131483|NCT05276999|OTHER|Community Awareness campaign|A district wide public health campaign to increase community awareness of sore throat, including school based education, VHT community sensitization, education of parents and patients, radio messaging, posters, signs and billboards.
41131484|NCT05925699|OTHER|Collection of clinical, radiological, and biological data from patients' medical records|Collection of clinical, radiological, and biological data from patients' medical records
41131485|NCT01025167|DIETARY_SUPPLEMENT|Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|500 ml per day / treatment period 11-14 weeks
41450866|NCT02480660|BEHAVIORAL|Educational Video|The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
41131486|NCT01025167|DIETARY_SUPPLEMENT|Fresubin(R)|500 ml/a nutritionally complete enteral standard feed (isoenergetic)
41131487|NCT00989196|BIOLOGICAL|Human-cl rhFVIII|50 IU/kg for PK dose
41131488|NCT00989196|BIOLOGICAL|Kogenate FS|50 IU/kg for PK dose
41131489|NCT01896843|DRUG|STX107|
41450867|NCT01438203|PROCEDURE|Thrust manipulation|Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
40756351|NCT05544344|BEHAVIORAL|Healthy ReStart|In addition to receiving mental health services as usual, subjects receive services from health coaches over a four-month period to assist them in creating a Restart plan and attaining related life goals.
40756352|NCT05544344|OTHER|Services as Usual|Subjects receive mental health services as usual.
40756353|NCT06327711|OTHER|Control: CHO Blend|2 servings as a snack or between meals morning and evening
40756354|NCT06327711|OTHER|Experimental: CHO Blend plus AN100|2 servings as a snack or between meals morning and evening
41131490|NCT05923190|DRUG|Enfortumab vedotin|EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
41131491|NCT05923190|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of a 21-day cycle
41131492|NCT03488719|DRUG|Metoprolol Succinate 25 MG|A single dose of 25 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
41131493|NCT03488719|DRUG|Metoprolol Succinate 50 MG|A single dose of 50 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
41131494|NCT03488719|DRUG|Metoprolol Succinate 100 MG|A single dose of 100 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21, approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
41131495|NCT00449774|DRUG|Lamotrigine IR tablets|Lamotrigine IR tablets will be available in dose strength of 200 mg.
41131496|NCT00449774|DRUG|Lamotrigine ODT tablets|Lamotrigine ODT tablets will be available in dose strength of 200 mg.
41131497|NCT02727634|OTHER|Comparison cardiac power and cardiac power output at different time points in the perioperative period|The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
41131498|NCT05856682|PROCEDURE|Laparoscopic-assisted TAP block(LATAP) and Rectus Sheath block|Laparoscopic -assisted TAP and rectus sheath block will be performed after insertion of optical port By Surgeon /surgery trainee. • Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be anterior to the midaxillary line between the costal margin and iliac crest bilaterally.
41131499|NCT05120336|DEVICE|transcutaneous vagus nerve stimulation|Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
41131500|NCT05120336|DEVICE|sham stimulation|Sham procedure for active transcutaneous vagus nerve stimulation
41131501|NCT05815628|DIAGNOSTIC_TEST|DISQVER|NGS based infection diagnosis
41131502|NCT01702259|DEVICE|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
41131503|NCT01702259|DEVICE|Placebo device|Inactive Erchonia GLS.
41131504|NCT04023175|OTHER|Telemedicine preoperative counseling|The telemedicine visit will be completed using an Atrium Health approved virtual visit platform.
41131505|NCT04023175|OTHER|In office preoperative counseling|This includes our standard preoperative counseling located at the Women's Center for Pelvic Health
41131506|NCT00610558|DEVICE|Arm 1: Juvenile Myoclonic Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
41131507|NCT00610558|DEVICE|Arm 2: Frontal Lobe Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
41131508|NCT00610558|DEVICE|Arm 3: Normal Controls|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
41131509|NCT05229952|DIETARY_SUPPLEMENT|Low-oxalate controlled diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium for 5 days. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
41131510|NCT05229952|OTHER|Primed, continuous intravenous infusion of 13C2-oxalate|Participants will receive a continuous intravenous administration of carbon-13 oxalate, a naturally occurring form of oxalate, over the course of several hours until steady-state is achieved, using an IV catheter, while remaining fasting.
41131511|NCT02874534|BEHAVIORAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
41131512|NCT02874534|BEHAVIORAL|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
40756355|NCT03093246|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
41131513|NCT06038942|BEHAVIORAL|Formal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The formal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught formal mindfulness practices (e.g., sitting meditation, body scan, thought meditation, loving-kindness meditation) during the group sessions and will be asked to commit to practicing the strategies independently throughout the project period."
41131514|NCT06038942|BEHAVIORAL|Informal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The informal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught how to integrate informal mindfulness into their daily routine and will be guided through a series of demonstrations within the group sessions. Participants will be asked to commit to practicing informal mindfulness independently throughout the project period."
41131515|NCT04612868|DEVICE|AEYE Software Device|"Eligible participants will undergo the following procedures:~* Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis.~* Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis.~* All study subjects will have their pupils dilated using dilation drops."
41131516|NCT05996315|OTHER|Hematoma block|A patient who presents to the emergency department with a suspected distal end radius fracture , will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give hematoma block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
41131517|NCT05996315|OTHER|Supracondylar radial nerve block|A patient who presents to the emergency department with a suspected distal end radius fracture will be assessed with a baseline NRS score1 and given analgesics if needed. Further they will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give supracondylar radial nerve block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
41131518|NCT00309751|DRUG|Pitavastatin|Pitavastatin 4 mg QD
41131519|NCT00309751|DRUG|Atorvastatin|Atorvastatin 20 mg
41131520|NCT04255316|PROCEDURE|Modified method of eversion carotid endarterectomy|Mini approach for CCA bifurcation - Clamping ICA, ECA and CCA - ICA is cut off with a scalpel at the mouth itself - Dissection of the ICA and ECA in the distal direction to the distal border of the atherosclerotic plaque - Endarterectomy - Performing of a new bifurcation of the CCA with prolene 7/0
41131521|NCT04255316|PROCEDURE|Standard method of eversion carotid endarterectomy|standard eversion technic
41450868|NCT01438203|PROCEDURE|Non-thrust manipulation|Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
41450869|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order A-B|Research participants will be assigned to day shift condition and Diet A-B order condition.
41450870|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order B-A|Research participants will be assigned to day shift condition and Diet B-A order condition.
40756356|NCT03093246|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
40756357|NCT03093246|OTHER|Placebo|Placebo pills over a period of 180 days
40756358|NCT03093246|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
40756359|NCT00288561|DRUG|ranibizumab|
40756360|NCT00779610|PROCEDURE|Vibration with flexion|Vibration with forearm flexion (active contraction)
41280880|NCT06377189|OTHER|Intervention arm - Consultation-Liaison (CL) brief psychiatric intervention in primary care settings|"The CL brief psychiatric intervention (2 months) in the primary setting will consist of 3 different phases:~1. A direct referral of their PCP to the practice's CL psychiatrist will be held directly after the inclusion of the patient to the intervention arm, by conducting a clinical exchange (by oral or by mail) with the latter.~2. The CL psychiatrist will organize rapidly (in a delay of 1-2 weeks) a first session and will perform 1 to 4 psychiatric sessions, depending on the participant's needs. These sessions will take place in his/her consultation room, located in the referring PCP's practice, and will be completed in less than 2 months. No intervention guide will be provided to perform these sessions.~3. A joint feedback session between the PCP, the participant, and the CL psychiatrist will be organized (2 months after the first psychiatric session), during which the CL psychiatrist will make restitution of his/her proposals, from a biopsychosocial perspective."
41280881|NCT06377189|OTHER|Control Arm - Treatment As Usual (TAU)|PCPs will explain to the participants that they will treat their psychological suffering, by providing the usual care for patients with psychiatric co-morbidities. Treatment as usual (TAU) by the PCP may involve supportive care (psychoeducation, psychotherapeutic support, social interventions, etc.), referral to a mental health provider (psychotherapist, psychiatrist, psychiatric nurse, etc.), treatment with psychotropic drugs, hypnosis, acupuncture, relaxation, etc. So as to facilitate their task, PCPs participating in this study will be provided with a list of mental health workers that they could contact.
41450871|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order A-B|Research participants will be assigned to simulated night shift condition and Diet A-B order condition.
40938733|NCT01565837|RADIATION|Stereotactic Ablative Radiosurgery (SART)|Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
41450872|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order B-A|Research participants will be assigned to simulated night shift condition and Diet B-A order condition.
40938734|NCT05547152|OTHER|massages|The experimental rehabilitation protocol includes massages
40938735|NCT05547152|OTHER|motor stimulation and stretching|motor stimulation and stretching
40938736|NCT05547152|OTHER|virtual reality|Patient watches an avatar of his face performing different movements on a screen, and will have to imagine performing these movements without actually doing them.
41131522|NCT05225012|OTHER|Acceptance and Commitment Therapy|Participants will then commence the intervention for the next 4 weeks. They will be sent the workbook via post. This will not be a standalone self-help intervention; participants will progress through the workbook alongside weekly emotional support sessions. These will either be over the phone or using an online video-call software, depending on participants preference. The first session will be an hour long to set-up the workbook, answer questions and go through goal setting. The following three weekly sessions will be half an hour to revisit exercises in the workbook, answer questions and review how the workbook progress is going. All sessions will be delivered by a trainee clinical psychologist who will receive standardised training and ongoing supervision from an experienced clinical psychologist.
41131523|NCT04464031|OTHER|electronic alert|The e-alert system was developed by the divisions of Nephrology and Information Management of Guangdong Provincial People's Hospital (Patent Application 201610001950.5). The alert system made a diagnosis of acute kidney injury according to Kidney Disease: Improving Global Outcomes criteria. Then, the doctor receives an alert of acute kidney injury.
41450873|NCT05278221|DEVICE|Software EstimLT|Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested
41450874|NCT02153645|DRUG|240mg Amantadine HCl ER tablets|
41450875|NCT02153645|DRUG|Placebo tablets|
41450876|NCT02153645|DRUG|320mg Amantadine HCl ER tablets|
40938737|NCT02843308|BEHAVIORAL|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
40938738|NCT05155137|DRUG|Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)|Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
40938739|NCT05155137|BEHAVIORAL|Stroke Riskometer|the primary care units will be randomized to use Stroke Riskometer App together with health community workers to help in the lifestyle modifications
40938740|NCT05814497|OTHER|Multisensory Task|Reversing checkerboard, tones, and finger opposition.
40938741|NCT05814497|OTHER|Graphesthesia|Trace numbers on skin.
40938742|NCT05814497|OTHER|Divided attention|Divide attention between two noxious stimuli.
41131524|NCT03540524|DRUG|GLPG2451 dose regimen A|GLPG2451 oral suspension, daily.
41131525|NCT03540524|DRUG|GLPG2451 dose regimen B|GLPG2451 oral suspension, daily.
41131526|NCT03540524|DRUG|GLPG2222|GLPG2222 tablet for oral use, daily.
41131527|NCT03540524|DRUG|GLPG2737|GLPG2737 capsules for oral use, daily.
41131528|NCT01307800|DRUG|LY2140023|Administered orally
41131529|NCT01307800|DRUG|Placebo|Administered orally
41131530|NCT00004805|BEHAVIORAL|CPR instruction|
41131531|NCT05558072|GENETIC|Toll-like receptor 4|Toll-like receptor 4
41131532|NCT01760382|DEVICE|Primary PCI|mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
41453615|NCT02959879|DRUG|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
41453616|NCT02959879|DRUG|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
41280882|NCT01173653|OTHER|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
41280883|NCT01173653|OTHER|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
40938743|NCT06138288|BEHAVIORAL|acupressure|The acupressure points to be used in the research are located on the inner side of the lower leg, 4 fingers above the ankle and on the spleen meridian behind the tibia (SP6), which was previously effective in reducing pain, and located three fingers above the wrist (in the middle of the 2nd metacarpal bone, on the dorsum of the hand, adjacent The points determined as P6 (located between the metacarpal bones) and LI4 located in the space between the thumb and index finger (between the 1st and 2nd metacarpal bones of the hand, in the middle of the 2nd metacarpal bone on the radial side) were applied by a certified researcher to women in the acupressure group. will be done
40938744|NCT06482918|BEHAVIORAL|Cognitive Remediation|Computer-assisted top-down or bottom-up cognitive remediation using tablets
40938745|NCT05060887|BIOLOGICAL|OVX836-003|One single administration intramuscularly at Day 1.
40938746|NCT05060887|BIOLOGICAL|Saline solution|One single administration intramuscularly at Day 1.
40938747|NCT05344638|DRUG|AGS (Experimental)|tid
40938748|NCT05344638|DRUG|AGU (Active Comparator)|tid
40938749|NCT01818960|PROCEDURE|IRA-PCI|IRA only PCI at the time of Primary PCI
40938750|NCT01818960|PROCEDURE|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
40938751|NCT03577171|DRUG|ABI-H0731|Participants will receive 300mg QD of ABI-H0731 tablets orally.
40938752|NCT03577171|DRUG|SOC ETV|Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
41131533|NCT02408913|BIOLOGICAL|VRC-EBOMVA079-00-VP (MVA-EbolaZ)|Ebola Modified Vaccinia Virus Ankara Vaccine
41280884|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 1|Step 1 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 25% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
40938753|NCT03577171|DRUG|Placebo Oral Tablet|Participants will receive matching QD placebo tablets orally.
41280885|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 2|Step 2 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 50% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
41131534|NCT02408913|BIOLOGICAL|VRC-EBOADC069-00-VP (cAd3-EBO)|Ebola Chimpanzee Adenovirus Vector Vaccine
41131535|NCT00869934|OTHER|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
41131536|NCT00869934|OTHER|Behavior Therapy|Sleep restriction and stimulus control
41131537|NCT00869934|OTHER|Cognitive Therapy|Cognitive restructuring therapy
41131538|NCT04574466|BEHAVIORAL|Problem Management Plus|Problem Management Plus (PM+) is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
41131539|NCT03234959|DEVICE|CareToy intervention|Infants will perform goal directed activities inside the CareToy System
41131540|NCT03234959|OTHER|Infant Massage|Infants will received IM by their parents
41280886|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 3|Step 3 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 75% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
40938754|NCT05350176|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
40938755|NCT05350176|DIETARY_SUPPLEMENT|Placebo|Capsules containing dextrose (1 capsule per day)
41280887|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 4|Step 4 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 100% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
41280888|NCT00484354|DRUG|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
41280889|NCT00484354|OTHER|Normal saline|IV Normal saline with volume given determined by patient weight
40938756|NCT06415734|DEVICE|rTMS|LF-rTMS of M1 contralateral to the brain lesion for 20 min, 1200 pulses, 120% RMT, treatment cycle of 5 days
40938757|NCT01552473|BEHAVIORAL|Brain Training Program 1|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.
40938758|NCT01552473|BEHAVIORAL|Brain Training Program 2|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
40938759|NCT04526301|DEVICE|Tablo Hemodialysis System|Home hemodialysis treatments \~4 times a week.
40938760|NCT00349427|DRUG|Rosiglitazone 4 mg|
40938761|NCT01186497|DRUG|Rabeprazole sodium: Treatment E|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.
41131541|NCT04149132|DEVICE|pulse photoplethysmography (PPG)|PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
41131542|NCT04149132|DIAGNOSTIC_TEST|Measurements of nitric oxide (NO) and malondialdehyde (MDA)|On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
41131543|NCT01561300|OTHER|Nutrition intervention study with a black tea extract|"Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
41131544|NCT01561300|OTHER|Nutrition intervention study with a control|"Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
41131545|NCT04373694|PROCEDURE|vaginoscopy|vaginal distension with hysteroscope for hysteroscopy morcellation (without speculum or tenaculum forceps)
41131546|NCT04373694|PROCEDURE|standard hysteroscopy|speculum, paracervical block before hysteroscopy morcellation
41131547|NCT01035372|DIETARY_SUPPLEMENT|dried plum powder|subjects will have 25% of their diet substituted by dried plum powder
41131548|NCT05031923|PROCEDURE|SMV and antimicrobial photodynamic therapy|Application of SMV and antimicrobial photodynamic therapy in intrabony defects
41131549|NCT05031923|PROCEDURE|SMV application|Application of SMV without antimicrobial photodynamic therapy in intrabony defects
41131550|NCT06251674|OTHER|long-axis needle release|The participants received one session of ultrasound-guided long-axis TCL needle release.
41131551|NCT06251674|OTHER|short-axis needle release|The participants received one session of ultrasound-guided long-axis TCL needle release.
41131552|NCT02305511|DEVICE|Peripheral venous catheterization|Cannulation using standard method
41131553|NCT02305511|DEVICE|Jamshidi|intraosseous access using the Jamshidi device
41131554|NCT02305511|DEVICE|BIG|intraosseous access using the BIG device
41131555|NCT02305511|DEVICE|Cook|intraosseous access using the Cook device
41131556|NCT02305511|DEVICE|EZIO|intraosseous access using the EZIO device
41280890|NCT00484354|OTHER|Bicarbonate|IV bicarbonate, dosed by weight
40938762|NCT01186497|DRUG|Rabeprazole sodium: Treatment C|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.
41280891|NCT00484354|OTHER|Placebo|Normal saline, with volume given based on patient weight
41280892|NCT06001580|DRUG|BR101|BR101 injection was administered once for 28 days observation period and then weekly until the subject experienced unacceptable toxicity, disease progression, poor compliance, pregnancy, informed withdrawal, death, study interruption, and withdrawal from the study
41280893|NCT00972608|OTHER|Anatomic Reconstruction and Surgical Planning|Standard of care patient-images will be acquired and used to construct a model of the patient anatomy. The model will then be used to simulate surgical options and allow the surgeon to visually evaluate the optimal approach.
41450877|NCT04542746|PROCEDURE|Minimally invasive surgical technique|After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.
40938763|NCT01186497|DRUG|Rabeprazole sodium: Treatment D|The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.
40938764|NCT01186497|DRUG|Rabeprazole sodium: Treatment A|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.
40938765|NCT01186497|DRUG|Rabeprazole sodium: Treatment B|The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
40938766|NCT05990998|DRUG|68Ga-DOTATATE and 68Ga-FAPI|Each patient receive a single intravenous injection of 68Ga-FAPI or 68Ga-DOTATATE (2-4mCi) , and undergo PET/CT scan at 40-60 min post injection.
40938767|NCT04488107|DRUG|FCN-437c|- FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
40938768|NCT04488107|DRUG|Letrozole 2.5mg|"* Letrozole is the latest generation of aromatase inhibitor. Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.~* Letrozole is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years."
40938769|NCT02561624|BEHAVIORAL|Behaviour change communication via text message|
40938770|NCT06434818|COMBINATION_PRODUCT|EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)|EDITOR includes a user-friendly cloud portal synced with the main device, providing a comprehensive training program for the orbitofrontal cortex (OFC). The main device stimulates the orbitofrontal cortex intensely, preventing habituation to smells and improving adaptability. This enhances neurobehavioral plasticity, benefiting Substance Use Disorder (SUD) outcomes. The device also features a 60% beta-caryophyllene scent for addressing issues like Alcohol Use Disorder and stimulant use disorders. With ten digital enhancements, it enables remote treatment and data collection, seamlessly transmitting information to healthcare providers through a secure, HIPAA-compliant portal.
40938771|NCT06434818|COMBINATION_PRODUCT|CBOT with olfactory stimulants & OFC tasks|The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
40938772|NCT06434818|COMBINATION_PRODUCT|CBOT Sham|CBOT Sham uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks
40938773|NCT01736020|DRUG|Dexmedetomidine|A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
40938774|NCT01736020|DRUG|Propofol|A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
40938775|NCT01736020|DRUG|Ketamine|A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
40938776|NCT01736020|DRUG|Nitrous Oxide|A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
40938777|NCT01736020|DRUG|Placebo|Placebo
40938778|NCT01002482|DEVICE|CGAO-based Glucose Control|"Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.~CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a human-in-the-loop approach.~The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control."
40938779|NCT01002482|DEVICE|Standard-Care Glucose Control|"Patients in the control group will receive conventional insulin therapy using the usual care protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl)."
40938780|NCT01764425|DRUG|P7435|It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
40938781|NCT03517124|OTHER|Ceramic tooth restoration|Dental restorations
40938782|NCT00990275|OTHER|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
40938783|NCT00526877|DRUG|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
40938784|NCT02804529|DEVICE|Veress needle|
40938785|NCT01715714|DRUG|Statin Recapture Therapy|Given 12h and 2h before CABG
40938786|NCT01715714|DRUG|Placebo|Given 12h and 2h before CABG.
40938787|NCT00566501|DRUG|Donepezil|Donepezil SR 23 mg once daily orally.
40756361|NCT00779610|PROCEDURE|Vibration without flexion|Vibration without forearm flexion (passive)
40756362|NCT02006615|DEVICE|Functional near infrared spectroscopy|Using high-sensitivity infrared to detect the active brain areas
40756363|NCT02006615|DEVICE|rTMS|To modulate brain cortex
40756364|NCT01391494|BIOLOGICAL|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
40756365|NCT01391494|BIOLOGICAL|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
41131557|NCT00564421|DRUG|epinastine nasal spray, low concentration, low dose volume|2 sprays in each nostril, dosed twice a day
41131558|NCT00564421|OTHER|placebo nasal spray|2 sprays in each nostril, dosed twice a day
41131559|NCT00564421|DRUG|epinastine nasal spray, low concentration, high dose volume|2 sprays in each nostril, dosed twice a day
41131560|NCT00564421|DRUG|epinastine nasal spray, high concentration, low dose volume|2 sprays in each nostril, dosed twice a day
41131561|NCT00564421|DRUG|epinastine nasal spray, high concentration, high dose volume|2 sprays in each nostril, dosed twice a day
41131562|NCT03204032|DRUG|Tegafur|Tegafur 40-60mg po bid(d1-d14);
41131563|NCT03204032|DRUG|Temozolomide|200mg po qd(d10-d14)
41131564|NCT03204032|DRUG|Thalidomide|Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
41131565|NCT01476241|PROCEDURE|PEG tube placement|Percutaneous endoscopic gastrostomy
41131566|NCT03650465|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT)
41131567|NCT03809949|DRUG|Fentanyl Opioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
41131568|NCT03809949|DRUG|Saline Nonopioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
41131569|NCT06510140|BEHAVIORAL|Detection of the Post-operative delirium (POD)|Detection of the early Post-operative delirium (POD) to assess the performance of a new composite score with pre-operative frailty, and per-operative ElectroEncephaloGram (EEG).
41131570|NCT06190132|DRUG|Omega 3 fatty acid, gabapentin|To study the effect of omega 3 fatty acids on uremic pruritus in prevalent hemodialysis patients versus the effect of gabapentin
41131571|NCT02018549|DEVICE|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
40938788|NCT01967758|BIOLOGICAL|Cohort 1|Four doses of IV ADU-623 at a dose of 3 x 10\^7cfu
40938789|NCT01967758|BIOLOGICAL|Cohort 2|Four doses of IV ADU-623 at a dose of 3 x 10\^8cfu
40938790|NCT01967758|BIOLOGICAL|Cohort 3|Four doses of IV ADU-623 at a dose of 3 x 10\^9cfu
40938791|NCT01967758|DRUG|Antibiotics|A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
40938792|NCT00107926|DRUG|Licarbazepine|
40938793|NCT00107926|DRUG|Placebo|
40938794|NCT04509765|RADIATION|Linac Based VMAT TBI|Use of linac based Volumetric Arc Therapy (VMAT) to deliver Total Body Irradiation (TBI). The study intervention is a VMAT based delivery technique using a 6 MV photon beam from a Varian TrueBeam® (Palo Alto, CA) equipped with a Millennium multi-leaf collimation (MLC) system3. TBI will be delivered using a Varian TrueBeam linear accelerator with photon beam VMAT capability. VMAT is a radiation technique combining dynamic photon fluence modulation using multi-leaf collimation (MLC) with gantry rotation to deliver a highly conformal dose distribution with improved target coverage and sparing of organs at risk (OARs).
40938795|NCT02135159|DRUG|TDM1|administration of the TDM1 by IV perfusion
40938796|NCT02135159|RADIATION|Brain Sequential RT|local RT
40938797|NCT04590079|DEVICE|Conventional pain treatment with daily sessions with innovative medical device, Remedee One, for pain management by Millimeter Band Radiation|Conventional pain treatement with daily sessions with innovative medical device for pain management (radiation in millimeter band) at the rate of 1 to 3 sessions by day of 40 minutes for 3 months.
40938798|NCT01912963|DRUG|Pertuzumab|
40938799|NCT01912963|DRUG|Trastuzumab|
40938800|NCT01912963|DRUG|eribulin|
41131572|NCT00392899|DRUG|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
40756366|NCT01391494|BIOLOGICAL|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
40756367|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in 12 adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
40938801|NCT04391413|DEVICE|Use of OCT to guide the angioplasty procedure|OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.
40938802|NCT01221103|DRUG|Combination of dexamethasone, ofatumumab and bendamustine|"* Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle~* Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity~* Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)"
40938803|NCT01943708|DEVICE|SPAP|Novel Auto-algorithm for Auto-CPAP device
40938804|NCT01943708|DEVICE|CPAP|Standard CPAP therapy
40938805|NCT03913546|PROCEDURE|Spinal manipulative therapy|Participants in the actual spinal manipulative therapy group will be assessed through the activator basic method protocol. SMT will be performed with an Activator IV (Activator Methods International, Phoenix, AZ) setting the force at level 3 for the low thoracic spine (T7-T12), and level 4 for the lumbar spine and pelvis.
40938806|NCT03913546|OTHER|Sham spinal manipulative therapy|Participants in the sham SMT group will undergo a protocol identical to the actual one, with the exception that a sham mechanical thrust (force set at level 0) will be delivered to the targeted areas. In the force level 0 no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition
40756368|NCT01391494|BIOLOGICAL|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
40938807|NCT04884776|DIETARY_SUPPLEMENT|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3 Bifidobacteria, 10 billion CFU per sachet)
40938808|NCT04884776|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains active vitamin
40938809|NCT04609475|PROCEDURE|Osseodensification technique|Implant bed preparation will be performed according to the manufacturer's guidelines, densifying burs (Densah® Burs) will be used sequentially in densifying mode (counterclockwise drill speed 800-1500 rpm with copious irrigation) to achieve the planned osteotomy diameter and desired ridge expansion. The implant will be then placed in the prepared osteotomy
40938810|NCT04609475|PROCEDURE|Motor driven expanders' technique|The technique consisted of preparing the implant bed by progressively increasing the size of the osteotomes until the desired expansion will be achieved. At the planned implant site, a pilot drill 1000 rpm with irrigation until the desired length, then expansion with the series of ridge spreaders and finally using the final drill. The implant will be then placed in the prepared osteotomy.
40938811|NCT02644200|DEVICE|Gelatin tannate|
40938812|NCT05570617|BEHAVIORAL|Transition Coach Intervention|The Transition Coach Intervention will include 8, 1-hour sessions over 6-months. The transition coach will independently meet one-on-one with each youth using an individualized, patient-centred approach beginning with an introductory session, followed by 5 sessions covering each topic in the Youth Transition Roadmap. These topics include: Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. The clinical psychologist will lead 2 sessions beginning with the Patient Health Questionnaire for Anxiety and Depression as a screening tool. The clinical psychologist will discuss psychological and social well-being in the context of their disease covering personally relevant issues/concerns.
41450878|NCT02097160|OTHER|Vitamin D fortified yogurt and cheese products|
41280894|NCT02688569|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Widespread Pain|CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
40938813|NCT05570617|BEHAVIORAL|Standard of Care- Youth Transition Roadmap|All participants will receive the Youth Transition Roadmap (standard of care) which discusses 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. This is an informational pamphlet and will not require any additional meetings with the patient beyond their normal healthcare interactions
40938814|NCT04123665|DRUG|Stannous fluoride|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
40938815|NCT04123665|DRUG|Sodium monofluorophosphate|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as SMFP to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
40938816|NCT04838197|OTHER|Questionnaires and Surveys|Quantitative questionnaires will measure and quantify the importance of the various factors (e.g., intensity of dependence, duration of care, health literacy, physical well-being, emotional well-being, social well-being, and financial well-being) that contribute to caregiver burden both preoperatively and postoperatively at 48 hours, 1 week, 2 weeks, and 1 month.
40938817|NCT03489551|DRUG|Haldol|
40938818|NCT04830644|DRUG|Iguratimod|Iguratimod orally twice a day
40938819|NCT04830644|DRUG|Placebo|Placebo orally twice a day
40938820|NCT06520202|DRUG|rhPRG4 (450 µg/mL)|1-2 drops of rhPRG4 450 µg/mL solution in both eyes
40938821|NCT06520202|DRUG|Vehicle|Sterile isotonic aqueous solution for ocular administration containing 0.01% polysorbate 20.
40938822|NCT05503316|OTHER|Dynamic balance training|Participants will receive dynamic balance training while walking on the GRAIL device.
40938823|NCT05503316|OTHER|Traditional gait rehabilitation|Participants will receive traditional gait rehabilitation that also includes balance training while walking but not on the GRAIL device.
40938824|NCT01755273|PROCEDURE|Pancreaticoduodenectomy with more distal enteral bypass|Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
40938825|NCT04824183|OTHER|Music intervention|Three WhatsApp sessions will be delivered before the surgery. In the first session, participants will describe their experience with the diagnosis of breast cancer and acceptance. In the second session, participants will be educated on anxiety before their surgery, how anxiety is being managed in the hospital and self-care strategies for anxiety like MI, how to report preoperative anxiety. The third session will include postoperative pain education. The pain education will include information about the type of pain to expect after surgery, medications, pain reporting and MI for pain management. Telephone session; on the day of surgery and at 24 and 48 hours after surgery, a reminder will be sent to the participants by WhatsApp group chat. Face-to-face; MI delivery will involve the delivery of the MP3 to participants and monitoring of their use for 30 minutes both on the day of surgery and 24 and 48 hours after surgery.
40938826|NCT02794792|DRUG|Ipragliflozin L-proline|Oral
41280895|NCT01420575|BEHAVIORAL|Visual Decision Aid and Shared Decision Making Model|Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
41280896|NCT01420575|BEHAVIORAL|Usual Care|Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
41280897|NCT05733455|DRUG|Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)|Participants will ingest two overencapsulated tablets of alpelisib at 23:00, along with a saltine cracker.
41280898|NCT05733455|DRUG|Placebo (microcrystalline cellulose), 2 capsules|Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.
40938827|NCT02794792|DRUG|Metformin|Oral
41280899|NCT05733455|DEVICE|FreeStyle Libre Pro|Continuous glucose monitoring for 24 hours (double blinded)
41280900|NCT05733455|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT) with Trutol glucose beverage|Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.
41280901|NCT05733455|DIETARY_SUPPLEMENT|BOOST Plus nutritional beverage|Participants will consume a quantity of BOOST Plus calculated to match their daily caloric needs, divided over three liquid meals.
41450879|NCT02097160|OTHER|Control Group 1|
40756369|NCT01391494|BIOLOGICAL|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
40938828|NCT02794792|DRUG|Placebo|Oral
40938829|NCT01361854|DEVICE|polysomnography|home-based polysomnography with hook-up performed ar at home or in the hospital
40938830|NCT01955980|DRUG|Budesonide|Inhalation
40938831|NCT01955980|DRUG|Budesonide|Nasal Spray
41450880|NCT01943695|BEHAVIORAL|Aerobic Training|
41450881|NCT01943695|BEHAVIORAL|Educational Information|Subjects will be given material regarding cancer and it's impact.
40938832|NCT02568982|OTHER|Exams and questionnaires|Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
41280902|NCT05196893|BEHAVIORAL|Link Intervention|Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.
40938833|NCT03318718|DRUG|Anesthesia with non-depolarizing NMBA Rocuronium|Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.
40756370|NCT01391494|BIOLOGICAL|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
40938834|NCT03318718|DIAGNOSTIC_TEST|TOF measurement|TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus
41280903|NCT05718115|DIAGNOSTIC_TEST|CT scan|Biphasic CT scan including arterial phase and portal venous phase after intravenous injection of 80-100 mL of non-ionic iodinated contrast at rate of 4ml/s using pressure injector.
40938835|NCT03318718|DIAGNOSTIC_TEST|MEP measurement|MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
40938836|NCT02374086|BEHAVIORAL|Exercise training|
40938837|NCT00835822|DRUG|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
40938838|NCT00835822|DRUG|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
40938839|NCT02884843|DEVICE|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction
40938840|NCT02884843|DEVICE|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
40938841|NCT02119091|DRUG|Moxifloxacin|
40938842|NCT03918889|DRUG|Dexmedetomidine Injectable Product|dexmedetomidine infusion at 0.5 µg•kg-1 for 10 min before tracheotomy then adjusted to 0.3µg•kg-1•h-1
41280904|NCT03001544|BIOLOGICAL|TS23|comparison of different doses
41453617|NCT02959879|PROCEDURE|curative surgery for resectable pancreatic duct adenocarcinoma|curative surgery for resectable pancreatic duct adenocarcinoma
40938843|NCT03918889|DRUG|Midazolam injection|midazolam infusion at 0.05 mg•kg-1 ten minutes before tracheotomy then adjusted to 0.02mg•kg-1•h-1
40938844|NCT00812747|OTHER|observation|
40938845|NCT05022264|DIAGNOSTIC_TEST|RIA-VS|Measuring vital signs with a new contactless camera technique
40938846|NCT04862286|DRUG|Risankizumab|Subcutaneous (SC) injection.
40938847|NCT01247038|DEVICE|Metal on ceramic articulation|Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup
40938848|NCT01247038|DEVICE|Metal-on-Metal|Metal on Metal articulation
40938849|NCT06352333|PROCEDURE|supraclavicular ultrasound guided brachial plexus block|two approaches of ultrasound guided supraclavicular brachial plexus block in upper limb surgery : the cornerpocket supraclavicular brachial plexus block and parasagittal supraclavicular brachial plexus block
40938850|NCT01429038|BIOLOGICAL|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
40938851|NCT05876260|BEHAVIORAL|Greek yogurt|Following 2 days of controlled diet, participants will consume greek yogurt following high-intensity interval exercise
40938852|NCT05876260|BEHAVIORAL|Carbohydrate-based study supplement|Following 2 days of controlled diet, participants will consume a carbohydrate-based study supplement following high-intensity interval exercise
40938853|NCT05876260|BEHAVIORAL|Exercise|Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
40938854|NCT00439465|BIOLOGICAL|Ex-vivo expanded effector cells|This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
40938855|NCT01400685|DRUG|Lenalidomide|Lenalidomide will be dose escalated until the maximum tolerated dose is reached. The starting dose is 2.5mg, followed by 5mg, followed by 10mg.
40938856|NCT01400685|DRUG|Bendamustine|90 mg/m\^2 IV days 1-2 of each cycle for 6 cycles
40938857|NCT01400685|DRUG|Rituximab|375 mg/m\^2 IV day 1 (cycle 1), 500 mg/m\^2 day 1 (cycles 2-6)
40938858|NCT04912011|DRUG|Canrenoate Potassium|Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
40938859|NCT04912011|DRUG|Normal Saline|Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
40938860|NCT03137771|RADIATION|3-Dimensional Conformal Radiation Therapy (3D-CRT)|Undergo 3DCRT
40938861|NCT03137771|DRUG|Docetaxel|Given IV
40938862|NCT03137771|DRUG|Gemcitabine|Given IV
40938863|NCT03137771|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
40938864|NCT03137771|DRUG|Pemetrexed Disodium|Given IV
40938865|NCT03137771|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
40938866|NCT03137771|DRUG|Erlotinib Hydrochloride|Given PO
40938867|NCT03137771|DRUG|Pembrolizumab|Given IV
40938868|NCT02787551|DRUG|Insulin glargine/lixisenatide fixed ratio combination|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40938869|NCT02787551|DRUG|liraglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40938870|NCT02787551|DRUG|exenatide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40938871|NCT02787551|DRUG|exenatide extended-release|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40938872|NCT02787551|DRUG|albiglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40938873|NCT02787551|DRUG|dulaglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40938874|NCT02787551|DRUG|Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)|Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
40938875|NCT03251677|PROCEDURE|Surgical procedure, Hysterectomy|Surgical removal of the uterus
40938876|NCT00014027|DRUG|Docosahexaenoic acid (DHA)|
40938877|NCT00014027|DRUG|Eicosapentaenoic acid|
40938878|NCT05218265|DIAGNOSTIC_TEST|routine laboratory tests|Complete blood count (CBC), coagulation profile, serum biochemical tests (including renal and liver function, and electrolytes), laboratory investigation to assess severity of COVID-19: lactate dehydrogenase (LDH), myocardial enzymes (CPK-MB), serum ferritin, D dimer and arterial blood gases analysis
40938879|NCT00023192|DRUG|T-Cell Depleted & CD34+Select/w/StemCell Enriched Product|
40938880|NCT03950037|DRUG|Albendazole|Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.
40938881|NCT05095493|DIETARY_SUPPLEMENT|Zinc Acetate|50 mg tablet
40938882|NCT05095493|DIETARY_SUPPLEMENT|Placebo|Zinc Acetate matched placebo tablet
40938883|NCT02250027|DRUG|HL301 300mg capsule|2 capsules at once, 3 times a day, for 7 days
40938884|NCT02250027|DRUG|Placebo|2 capsules at once, 3 times a day, for 7 days
40938885|NCT01009281|DRUG|AIN457|
40938886|NCT05246904|OTHER|Fitting algorithm|The best fitting algorithm will be selected by the audiologist (arm 1) or software.
40756371|NCT01391494|BIOLOGICAL|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
40938887|NCT04186481|DEVICE|MINITAC Ti 2.0 suture anchor|The MINITAC◊ Ti 2.0 Suture Anchor is intended to provide secure reattachment of soft tissue to bone in the foot and ankle as well as elbow, wrist and hand.
40938888|NCT02781519|DRUG|THC|Active THC (0.015mg/kg) administered over 10 minutes
40938889|NCT02781519|DRUG|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
40938890|NCT02602847|BIOLOGICAL|cccDNA assay on liver biopsy|cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
40938891|NCT00002178|DRUG|Ritonavir|
40938892|NCT00002178|DRUG|Nelfinavir mesylate|
40938893|NCT00002178|DRUG|Saquinavir|
40938894|NCT00002178|DRUG|Delavirdine mesylate|
40938895|NCT03812432|DEVICE|Near-infrared fluorescence cholecystocholangiography|Device: Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
40938896|NCT02990156|DEVICE|Coil Embolization System|deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.
40938897|NCT02990156|DEVICE|Cotrol device from Medronic|Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
40938898|NCT05319093|DRUG|Ozanimod|Three-months, longitudinal observational period
40938899|NCT03294473|BEHAVIORAL|R/R - Autodialers|Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
40938900|NCT03294473|BEHAVIORAL|R/R - Texting|Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
40938901|NCT03294473|BEHAVIORAL|R/R - mailed postcard|Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
40938902|NCT00023244|DRUG|Basiliximab|Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
40938903|NCT00023244|DRUG|Cyclosporine|Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
40938904|NCT00023244|DRUG|Tacrolimus|Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
40938905|NCT00023244|DRUG|Sirolimus|Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
41131573|NCT00405184|DRUG|IntragamP|IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
40938906|NCT00023244|DRUG|Methylprednisolone|Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
40938907|NCT00023244|DRUG|Prednisone|Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
40938908|NCT00023244|DRUG|Bactrim|All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
41453618|NCT02959879|DRUG|Standard adjuvant chemotherapy|12 cycles of standard adjuvant chemotherapy are administrated
41453619|NCT02959879|DRUG|adjuvant chemotherapy|8 cycles of standard adjuvant chemotherapy are administrated
40756372|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
40756373|NCT01391494|BIOLOGICAL|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
40938909|NCT05682248|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
40938910|NCT05682248|DEVICE|Sham Transcranial magnetic stimulation|Sham Transcranial magnetic stimulation
40938911|NCT04431427|DEVICE|Biliary drainage with PC-SEMS|partially covered metallic biliary stent insertion during ERCP
41131574|NCT00405184|DRUG|Ig NextGen 10%|Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
40756374|NCT01391494|BIOLOGICAL|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
40938912|NCT04431427|DEVICE|Biliary drainage with U-SEMS|Uncovered metallic biliary stent insertion during ERCP
40938913|NCT00560469|OTHER|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
40938914|NCT02085915|OTHER|strip Peri Screen|
40938915|NCT05391971|DRUG|Bupivacaine|At the C6 level, a total of 7cc of 0.5% bupivacaine will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of 0.5% bupivacaine.
40938916|NCT05391971|DRUG|Saline|At the C6 level, a total of 7cc of saline control will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of saline control.
40938917|NCT03637179|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
40938918|NCT03637179|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
40938919|NCT03570879|DEVICE|Power morcellation|Power morcellation of surgical specimens after laparoscopic myomectomy.
40938920|NCT03570879|PROCEDURE|Transvaginal extraction|Transvaginal extraction of surgical specimens after laparoscopic myomectomy.
40938921|NCT05571579|BIOLOGICAL|blood and/or csf collection|"blood and/or collection~Only once :~* 1 tube of blood of 4 mL on dry tube with or without gel,~* 2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection."
40938922|NCT03013127|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy.
40938923|NCT04243785|DRUG|BTX-A51|Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.
40938924|NCT04243785|DRUG|Azacitidine|Azacitidine will be administered IV or SC 75 mg/m2 QD on Days 1-7 of each 28-day cycle.
40938925|NCT04292912|DRUG|GSK2798745|GSK2798745 will be administered.
40938926|NCT04623385|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"1. The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~2. The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
40938927|NCT04623385|DRUG|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
40938928|NCT02594241|DRUG|Methyl-Prednisolone|Single-shot 125 mg infusion given immediately after induction of anesthesia.
40938929|NCT02594241|DRUG|Physiological saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
40938930|NCT00137865|GENETIC|EGEN-001 (phIL-12-005/PPC)|
41131575|NCT05078775|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
40938931|NCT00434343|OTHER|Global Therapeutic Massage (GTM)|
40938932|NCT00434343|OTHER|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
40938933|NCT02684318|DRUG|PM01183 + olaparib|
40938934|NCT06353230|PROCEDURE|injection 5% phenol in almond oil|Group A were given 5% phenol in almond oil
40938935|NCT06353230|PROCEDURE|injection 15% hypertonic saline|Group B were given hypertonic saline
40938936|NCT06353230|PROCEDURE|injection 50% dextrose water|group C were given 50% dextrose water
40938937|NCT04356976|DEVICE|Ventralex|Repair of hernia using Ventralex patch in sublay position
40938938|NCT04356976|OTHER|Stratafix|Repair of hernia without mesh. Defect closed with Stratafix suture.
41453620|NCT05966922|PROCEDURE|Transcutaneous Electrical Stimulation|Electrical Stimulation and a sham will be administered through the skin in random consecutive sessions in a study group. A single monophasic square electrical pulse and transcutaneous electrical nerve stimulation will be applied to the forearm volar aspect.
40756375|NCT01391494|BIOLOGICAL|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
40756376|NCT01391494|BIOLOGICAL|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
40938939|NCT06199037|DRUG|SHR-1707|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection
40938940|NCT06199037|DRUG|SHR-1707 placebo|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection
40938941|NCT00803218|DRUG|Fluticasone Propionate 0.005% Ointment-Reference Product|Small amount applied and evaluated over the course of one day
40938942|NCT00803218|DRUG|Fluticasone Propionate 0.005% Ointment-Test product|Small amount applied and evaluated over the course of one day
41131576|NCT03658109|DRUG|Lidocaine Bolus Infusion|Patients will undergo Lidocaine Bolus infusion.
41131577|NCT03658109|PROCEDURE|QL block|Patients will undergo a posterior QL block pre-operatively
41131578|NCT03658109|DRUG|Saline Bolus Infusion|Patients will undergo Saline Bolus infusion.
41131579|NCT03658109|PROCEDURE|Simulated QL block|Patients will undergo a simulated posterior QL block pre-operatively.
41131580|NCT00003087|DRUG|cisplatin|
41131581|NCT00003087|DRUG|paclitaxel|
41131582|NCT00003087|PROCEDURE|surgical procedure|
41131583|NCT00003087|RADIATION|radiation therapy|
41131584|NCT01540318|PROCEDURE|Abdominal Ultrasound (FAST examination)|Use of FAST abdominal ultrasound exam
41453621|NCT02798458|DEVICE|Smartpill|The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.
40938943|NCT04457973|DEVICE|Active tDCS|tDCS with a constant current intensity of 2 milliampere (mA) will be applied for 20 minutes per session daily for 5 days via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and 5x7 cm saline-soaked surface sponge electrodes.
40938944|NCT04457973|DEVICE|Sham tDCS|The electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
40938945|NCT02759354|OTHER|Blood Sample|Blood sample at approx. 4 years of age
40938946|NCT06135168|DRUG|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
40938947|NCT06135168|DRUG|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
40938948|NCT04490824|DEVICE|KELEA Excellerated Water|Water with increased kinetic activity as assessed by published methods of the PI
40938949|NCT04490824|DEVICE|Water Without an Elevated Level of KELEA|Bottled water without an elevated level of KELEA, as shown by proprietary testing will be provided as a control.
40938950|NCT01610271|DEVICE|Air Barrier System|ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
40938951|NCT05710848|DRUG|STM-416|STM-416 monotherapy
40938952|NCT01657929|BIOLOGICAL|H5-VLP + GLA-AF|H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
40938953|NCT01657929|BIOLOGICAL|H5-VLP alone|H5-VLP antigen alone. 2 injections at Days 0, and 21.
40938954|NCT01657929|BIOLOGICAL|H5-VLP + Alhydrogel(R)|H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
40938955|NCT01657929|BIOLOGICAL|Licensed H5N1 vaccine|Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
40938956|NCT03480035|PROCEDURE|lightwand intubation|intubation using lightwand
40938957|NCT05027893|DRUG|Moxifloxacin 400 mg Oral Tablet|All used film-coated tablets (400 mg moxifloxacin) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
40938958|NCT05027893|DRUG|Cefixime 400 mg Oral Tablet|All used film-coated tablets (400 mg cefixime) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
40938959|NCT05027893|OTHER|Placebo|All used film-coated placebo-tablets were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
40938960|NCT03324529|DEVICE|Tako Breath|Device guided breathing. A medical device with a computerized control unit, a breathing sensor and a set of earphones with audio-prompts to guide breathing at a slow rate (\<10 breaths/min) with prolonged exhalation.
40938961|NCT03668366|DRUG|S-1|The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
40938962|NCT02492581|DRUG|Nalmefene|No intervention on the use of Selincro. The physician will prescribe Selincro following its usual practice.
40938963|NCT05024318|DRUG|Pembrolizumab|Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles
40938964|NCT05024318|RADIATION|Stereotactic Ablative Radiotherapy|42Gy delivered in 3 fractions
40938965|NCT05024318|PROCEDURE|Nephrectomy|Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab
40938966|NCT02783885|DRUG|immunotherapy|
40938967|NCT00377975|DRUG|Ephedrine|
40938968|NCT00377975|DRUG|Pioglitazone|
40938969|NCT00377975|DRUG|Caffeine|
40938970|NCT04360863|OTHER|Telephone survey|Participants will be asked to respond to a survey regarding their knowledge about the relationship between smoking and COVID-19, their smoking behaviors and readiness to quit during the pandemic.
40938971|NCT02272543|DIETARY_SUPPLEMENT|Fish surimi peptide|
40938972|NCT03606395|DRUG|NV-5138|single ascending dose
40938973|NCT03606395|DRUG|Placebos|Placebo liquid solution to mimic NV-5138
40938974|NCT03342521|DIAGNOSTIC_TEST|optical coherence tomography and VerifyNow|optical coherence tomography Imaging P2Y12 and Aspirin reaction units quantification by the VerifyNow
40938975|NCT04383899|OTHER|Questionnaire|All patients testing positively for COVID-19, with completed questionnaires. As appropriate, the duration of the study will be at least the time to complete the questionnaire for non-hospitalized patients, and for those who are hospitalized, they will be followed until hospital discharge or death to ascertain outcome.
40938976|NCT03611010|DRUG|Atorvastatin injection|statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection
40938977|NCT05684939|BEHAVIORAL|Questionnaire (patient reported outcome)|Online self-administered questionnaire exploring substance use, pain, chemotherapy-induced peripheral neuropathy, health-related quality of life, anxiety, depression, social and material deprivation, patients and oncological charactericitcs, and intercurrent pathologies
40938978|NCT03488927|BEHAVIORAL|Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)|The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
40938979|NCT05716503|DEVICE|Negative Pressure Wound Therapy (NPWT)|Patients Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.
40938980|NCT05716503|OTHER|Ordinary dressings with antibiotic ointment and gauze|Patients will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
41131585|NCT05879276|DRUG|Empagliflozin 10 MG|Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks.
40938981|NCT01490788|DRUG|Treatment A|TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
40938982|NCT01490788|DRUG|Treatment B|Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
41131586|NCT02290158|OTHER|Finishing Protocol|Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
40938983|NCT01490788|DRUG|Treatment C|TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
40938984|NCT01725308|DRUG|FK949E|Taken by mouth (orally).
40938985|NCT01725308|DRUG|Placebo|Taken by mouth (orally).
40938986|NCT04758078|OTHER|Inhaled corticosteroids|Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
40938987|NCT04758078|OTHER|Placebo|Nebulized 0.9% saline will be given four times per day
40938988|NCT05455385|OTHER|standard 12-week rehabilitation program|The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
40938989|NCT05455385|OTHER|extra session hydrotherapy|The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.
40938990|NCT05455385|OTHER|extra session ground exercises|The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
40938991|NCT01806727|BEHAVIORAL|Community Lifestyle Weight Loss (LWL)|Changing dietary and physical activity behavior to promote weight loss
40938992|NCT01806727|BEHAVIORAL|Diabetes Self Management (DSM)|Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
40938993|NCT03469388|DIAGNOSTIC_TEST|Pulse wave analyses; central blood presaure parameters|Pulse wave analyses; central blood presaure parameters
40938994|NCT03139318|RADIATION|GRID radiotherapy|Patients will be treated with GRID radiotherapy
40938995|NCT05760573|BEHAVIORAL|Family Wellness Program (FWP)|The FWP will consist of the following general format: (1) 8 weekly 60-minute summer workshops; (2) 4 booster workshops throughout the year; and (3) 2-3 outreach text messages per week for 10 months.
40938996|NCT03324672|PROCEDURE|TRIGGER|only TRIGGER point will be included for the manual therapy
40938997|NCT03324672|PROCEDURE|TRIGGER+CURETAPE|TRIGGER point will be included for the manual therapy with kinesio-taping
40938998|NCT02826135|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output or decreased central venous pressure, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
40938999|NCT05428098|OTHER|education|Oral and written education according to the life model
40939000|NCT02169973|DRUG|JNJ-42165279|Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
40939001|NCT02169973|DRUG|11C-MK-3168|Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
40939002|NCT00606944|BEHAVIORAL|fast-track rehabilitation|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
40939003|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 10 mg IV every 8 weeks
40939004|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 5mg IV every 8 weeks
41131587|NCT05456334|DEVICE|Pulsed-dye laser|Comparance of pulsed-dye laser-mediated and conventional photodynamic therapy in a split-head design
41131588|NCT05456334|DEVICE|Fractional CO2-laser|Comparance of fractional CO2-laser-mediated or plain daylight photodynamic therapy in a split-head design
41131589|NCT05456334|DRUG|Metvix cream|Metvix-cream was used for photodynamic therapy in all experimental arms
40939005|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 2.5 mg IV every 8 weeks.
40939006|NCT00744471|BIOLOGICAL|Placebo|Placebo to match tanezumab IV every 8 weeks
40939007|NCT05210231|OTHER|Transcranial Direct Current Stimulation|The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
40939008|NCT06293456|OTHER|Dignity Therapy|A trained research staff member will conduct the DT interview virtually. The interview will occur or by phone only if the participant lacks access to technology for videoconferencing. The interviewer asks a series of open-ended questions that encourages patients to talk about their lives and what matters most to them.
40939009|NCT04037358|DRUG|Radium-223|Radium-223 plus SABR will be within two weeks.
40939010|NCT04037358|RADIATION|stereotactic ablative radiotherapy (SABR)|SABR 1-5 fractions
40939011|NCT05542186|PROCEDURE|Kinesiotaping|Biomechanical correction for discogenic low back pain using kinesiotaping
40939012|NCT00218725|BEHAVIORAL|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
40939013|NCT00218725|OTHER|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
41131590|NCT00940069|DRUG|pemetrexed|"'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.~'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks."
40939014|NCT06455839|BEHAVIORAL|Guided Resipiration Mindfulness Therapy (GRMT)|GRMT provides training in respiratory regulation, mindfulness and relaxation. The GRMT training will begin with a 15-minute introduction to the treatment model, followed by an hour of therapist-guided respiration (i.e., continuous rhythmic expansion of the chest, and relaxed exhalation involving release of all respiratory and peripheral musculature). The final 45 minutes will be used to discuss participant experiences during the GRMT training. GRMT training sessions will occur in-person and in a small group format (\<5 participants each).
41280905|NCT04980547|DEVICE|ACUMED® Scapholunate Repair System Group|To address the technical difficulties associated with the RASL procedure, Dr. Mel Rosenwasser developed an external over-the-top jig that in theory enables accurate and easy scapholunate-axis screw placement. The Acumed Scapholunate Repair System was designed treat patients with acute or chronic, static or dynamic scapholunate instability in the absence of significant capitolunate osteoarthritis, scapholunate ligament repair, scapholunate reduction, lunotriquetral ligament repair, lunotriquetral reduction, and carpal instability. This new Scapholunate Repair System features a targeting guide designed to enable the surgeon to reproducibly place the implant in optimal position. The implant allows physiologic intercarpal scapholunate rotation by means of a free rotation design. The procedure can forestall progressive osteoarthritis and the need for secondary salvage procedures.
41280906|NCT00706732|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
40939015|NCT00132561|DRUG|Sulfadoxine/pyrimethamine and artesunate|
40939016|NCT04235803|OTHER|Telemedicine follow-up|A telemedicine follow-up form based in REDCap that collects information from the patient including: history, photographs, vision measurement, and questions.
40939017|NCT00208299|DRUG|Regadenoson|0.4 mg, bolus intravenous injection
40939018|NCT00208299|DRUG|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
40939019|NCT02992080|OTHER|miRNAs isolation from blood samples of patients and control|Blood sample collection in specific PAXGene tubes
40939020|NCT05323578|OTHER|Survey|Prevalence of safe caffeine consumption among anesthetists
40939021|NCT05152563|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8
40939022|NCT05152563|OTHER|Placebo|Placebo
40939023|NCT04597918|DRUG|Faricimab|A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
40939024|NCT02030054|DRUG|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
40939025|NCT02030054|DRUG|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
40939026|NCT04814901|PROCEDURE|Curing small and medium sized oronasal fistula|"* Flap will be marked medial to the duct, which limits posterior extent of flap. Anterior flap marking starts 1cm posterior to oral commissure.~* Width of flap was kept to about 2-2.5cm.~* An initial incision will be made 1cm posterior to oral commissure.~* Incision will be deepened through buccal mucosa, submucosa, \& underlying muscles into layer of buccal fat.~* Flap will be dissected in a retrograde or antegrade manner depending on fistula site, maintaining vessels in a central position in the flap.~* Once completely raised, flap inserted \& sutured in place while donor site be closed primarily with 4-0 polyglactin (Vicryl) interrupted sutures.~* Patient's comparator group will be treated by raising a palatal pedicled flap.~* Flap will be outlined extending from palatal mucosa against permanent 2nd molar till permanent canine anteriorly.~* It is rotated towards oronasal fistula \& secured in place using 4 -0 Vicryl interrupted sutures."
40939027|NCT01244698|DRUG|Cefadroxil discontinued early|All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
40939028|NCT01244698|DRUG|Cefadroxil until drain removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
40939029|NCT01455467|DEVICE|One iStent|Implantation of one iStent in conjunction with cataract surgery
40939030|NCT01455467|DEVICE|Two iStent|Implantation of two iStent in conjunction with cataract surgery
41280907|NCT00706732|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
41280908|NCT00706732|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the IM route
41280909|NCT00706732|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the SC route
41280910|NCT02580162|BEHAVIORAL|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
41280911|NCT02580162|BEHAVIORAL|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
40756377|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
40756378|NCT01391494|BIOLOGICAL|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
40939031|NCT02207673|PROCEDURE|Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery|
40939032|NCT03315182|BIOLOGICAL|rAAV9.CMV.hNAGLU|Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
40939033|NCT03000270|DEVICE|Impella unloading prior to PPCI|Impella unloading prior to PPCI
40939034|NCT04253964|DRUG|Pembrolizumab|ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.
40939035|NCT04253964|DRUG|Carboplatin|FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
40939036|NCT04253964|DRUG|Paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
40939037|NCT04253964|DRUG|Nab paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.
40939038|NCT04253964|OTHER|Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)|The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
40939039|NCT04253964|OTHER|QLQ-C30 Global Health/Quality of Life Questionnaire|30 item questionnaire - Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures
40939040|NCT04253964|OTHER|COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes|Dyspnea scale scores in patients with respiratory disease (particularly COPD) to establish baseline functional dyspnea burden (taken pre-study at Week 0 and Post Treatment at week 13)
40939041|NCT04253964|DRUG|Pemetrexed|FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
40939042|NCT03069118|BEHAVIORAL|Treatment - Workit Health Online Program|"The Workit Health program is an adaptive recovery in your pocket harm reduction and sobriety solution that provides 24-hour access to adaptive lessons, mentorship, written and audio driven therapeutic exercises and tools, and peer-to-peer coaching. Users access our online site and enter an initial 90-day program that takes a holistic approach to recovery by addressing the physical, mental, emotional, and social aspects of addiction. As they advance, they move through successive levels that include lessons, activities, and assignments. Bonus materials, such as meditations and suggested reading, give users timely opportunities to dive deeper into a problem they are struggling with that day. Workit Health implements evidence-based strategies such as CBT, DBT, and MI."
40939043|NCT03069118|BEHAVIORAL|Control - Resource List|Tailored list of resources.
40939044|NCT04429360|PROCEDURE|pelvic reconstructive surgery|Pelvic reconstructive surgery
40939045|NCT02009007|DRUG|dopamine|continuous infusion during operation
40939046|NCT02009007|DRUG|phenylephrine|continuous infusion of phenylephrine during operation
40939047|NCT05799183|DRUG|SHR-1210|Subjects will receive treatment SHR-1210 before process changes 20 mg
40939048|NCT05799183|DRUG|SHR-1210|Subjects will receive treatment SHR-1210 after process changes 20 mg
40939049|NCT05020912|DRUG|ALA|At first visit, ALA applied to one BCC lesion
40939050|NCT05020912|PROCEDURE|PDT|PDT with blue light (for 30 min (\~20 mJ/cm2))
40939051|NCT04073368|DIETARY_SUPPLEMENT|AXA1957|Amino acids, food study
40939052|NCT04073368|DIETARY_SUPPLEMENT|AXA1125|Amino acids, food study
40939053|NCT04073368|DIETARY_SUPPLEMENT|Placebo|Amino acids, food study
40939054|NCT04997590|BIOLOGICAL|Umbilical cord blood mononuclear cells|injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.
41280912|NCT02580162|BEHAVIORAL|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
41280913|NCT01925521|DRUG|Part1 : OPS-2071|single oral dose under fasted condition
40939055|NCT04997590|DRUG|Staphylococcal Enterotoxin C|injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.
40939056|NCT04322214|DRUG|Cobicistat 150 MG|once daily cobicistat (150 mg QD) for 5 days
40939057|NCT04322214|DRUG|Placebo|once daily lactose capsules (as aspect cobicistat capsules)
40939058|NCT04322214|DRUG|GHB|single oral dose of GHB (25 mg/kg) on days 5 and 17
40939059|NCT01727908|OTHER|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
40939060|NCT02433327|OTHER|PEWS - trigger tool|PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
40939061|NCT02433327|OTHER|RM - trigger tool|RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
41280914|NCT01925521|DRUG|Part1 : Placebo of OPS-2071|single oral dose under fasted condition
41280915|NCT01925521|DRUG|Part2 : OPS-2071|multiple twice-daily oral dosing for 5-7days
41280916|NCT01925521|DRUG|Part2 : Placebo of OPS-2071|multiple twice-daily oral dosing for 5-7days
40939062|NCT05521568|DIAGNOSTIC_TEST|Index test: Abbott ID NOW STREP A 2|The test under evaluation ('index test') is the rapid molecular test for Group A streptococcus Abbott ID NOW STREP A 2 (performed on saliva samples instead of throat swabs). This test was chosen because of its ease of use and several previous evaluations showing high diagnostic accuracy on throat swabs. The test gives a result after 2 to 6 minutes and will be performed by primary care practitioners participating in the study, in their office, using salivary swabs instead of throat swabs. Investigators will receive one session of specific training prior to the study. Saliva samples will be collected using the cotton swab that comes within the test packages. Index test results will not be used for patient management. Clinicians performing the rapid saliva test will not be blinded to clinical information.
40939063|NCT05521568|DIAGNOSTIC_TEST|Reference standard test: Composite of culture and PCR-based tests based on a throat swab|"Throat samples will be obtained by use of a double-swab collection-transportation system :~* Swab #1 will be used to perform the rapid antigen detection test (see below)~* Swab #2 will be held at ambient temperature and sent within 72 hours to Robert Debre Hospital microbiology laboratory. Throat swabs will be used to perform throat cultures using standard techniques (PMID: 22768060). Throat swabs will also be used to perform a PCR specific for Group A streptococcus (PMID: 23465407). Samples with a positive culture and/or a positive PCR test result will be classified as reference-standard-positives. Samples with a negative culture and a negative PCR will be classified as reference-standard-negatives. Investigators will be blinded to clinical data, including the result of the rapid antigen detection test and the rapid saliva test."
40939064|NCT05521568|DIAGNOSTIC_TEST|Comparator test: Rapid antigen detection test (usual care)|As per usual care, all children will undergo a rapid antigen detection test (StreptAtest, Biosynex), using Swab#1 (see above). This rapid antigen detection test is the one used in France and is the only commercial kit that is officially recommended by the National Health Insurance system. It detects Lancefield's Group A antigen, which is specific to Group A Streptococcus. The test will be performed by investigators, during consultation time. Clinicians performing the rapid antigen detection test will not be blinded to clinical information.
40939065|NCT00761579|DRUG|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
40939066|NCT05468138|DRUG|SOX|"Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.~Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1."
40939067|NCT05468138|DRUG|XELOX|Drug: Capecitabine 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W. Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
40939068|NCT05468138|OTHER|Observation|follow up and Observation alone. Abdomen/chest CT scan will be performed every 6 months after surgery.
40939069|NCT05468138|DRUG|PD-1 antibody|Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles
40939070|NCT02490410|DIETARY_SUPPLEMENT|protein supplement|
40939071|NCT00072176|DRUG|temsirolimus|Given IV
40939072|NCT00072176|OTHER|laboratory biomarker analysis|Correlative studies
40939073|NCT03453411|OTHER|Non interventional study|Non interventional study
40939074|NCT04166227|PROCEDURE|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
40939075|NCT04166227|PROCEDURE|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
40939076|NCT04896775|BEHAVIORAL|NiteCAPP CARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.
40939077|NCT04896775|BEHAVIORAL|NiteCAPP SHARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.
40939078|NCT01902251|DRUG|Enzalutamide tablet|Oral
40939079|NCT01902251|DRUG|Enzalutamide capsule|Oral
40939080|NCT03912896|BEHAVIORAL|Taekwondo|Children will participate in a 7-week taekwondo program.
41131591|NCT03504904|BEHAVIORAL|Internet-Delivered ACT and CFT|An 8-week internet-based intervention focused on acceptance and compassion. Psychological intervention based on Acceptance and commitment therapy and compassion focused therapy
41131592|NCT03813472|DEVICE|Hydration Sensor|This device includes a hydration sensor embedded within silicone and applied to the skin with a medical grade adhesive.
40939081|NCT06040879|PROCEDURE|PERICAPSULAR NERVE GROUP BLOCK COMBINED WITH LATERAL FEMORAL CUTANEOUS NERVE BLOCK|During and after the surgery, a group of patients received intravenous morphine analgesia via PCA (concentration 1mg/ml, bolus dose of 1mg, lock time 10 minutes, maximum dose 10mg/4 hours). The remaining group of patients receive pain relief by PENG block and LFCN block. In this group, the ultrasound probe was placed horizontally from the anterior superior iliac spine, and was moved along the femoral arc defining the pubic spine. Then, the transducer was rotated 45 degrees, moved parallel to the femoral arch identifying the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE) and inferior lumbosacral head. The ultrasound probe was moved lightly until the upper end of the femoral head was identified. Next, a 120 mm Tuohy 18G anesthetic needle was used under ultrasound guidance, which was moved lateral to medial in the plane between the ultrasound transducer and the superior tip of the femoral head. Then, 10 mL of ropivacaine 0.25% was injected through the anesthetic needle tip
40939082|NCT01266941|DRUG|Inhaled FF 200mcg/GW642444M 25mcg|All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
40939083|NCT02765776|OTHER|Observational retrospective cohort to describe RAL data|"This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens the investigators mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies. Data will be collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months."
40939084|NCT01711879|DRUG|Aflibercept|Details covered in arm description
40939085|NCT02173184|BIOLOGICAL|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
40939086|NCT02173184|BIOLOGICAL|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
40939087|NCT00181623|DRUG|Recombinant Human Prolactin|
40939088|NCT04870034|DRUG|Binimetinib|Given PO
40939089|NCT04870034|DRUG|Palbociclib|Given PO
40939090|NCT04870034|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40939091|NCT01825603|DRUG|ADH-1|Given IV
40939092|NCT01825603|DRUG|Cisplatin|Given IV
40939093|NCT01825603|DRUG|Gemcitabine Hydrochloride|Given IV
40939094|NCT01825603|OTHER|Laboratory Biomarker Analysis|Correlative studies
40939095|NCT04376892|OTHER|Quality of life measurement|Quality of life measurement by St. George Respiratory questionnaire
40939096|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
40939097|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
40939098|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
40939099|NCT04300374|OTHER|The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively|routine remifentanil infusion during general anesthesia
40939100|NCT02294773|PROCEDURE|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
40939101|NCT02294773|DRUG|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
40939102|NCT02294773|DRUG|Letrozole|Patient is to take letrozole during cycle days 3-7.
40939103|NCT01598168|DRUG|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
40939104|NCT04664244|COMBINATION_PRODUCT|Combination of nimotuzumab and radiotherapy|Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.
41131593|NCT02457806|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Active Spray with deliverable volume of 0.1 mL
41280917|NCT03433066|PROCEDURE|Advanced platelet-rich fibrin mixed with biphasic alloplast|mucoperiosteal flaps will be reflected to expose the defects , which will be debrided properly and finally filled with the freshly prepared Advanced platelet-rich fibrin mixed with the biphasic alloplast.
41280918|NCT03433066|PROCEDURE|Biphasic alloplast mixed with saline|mucoperiosteal flap will be reflected to expose and clean the intrabony defect ,then it will be filled with biphasic alloplast mixed with saline.
40939105|NCT01120834|DRUG|azacytidine|"* Dose level 1: azacitidine 55 mg/m2 on days 1-5~* Dose level 2: azacitidine 75 mg/m2 on days 1-5~* Dose level 3: azacitidine 55 mg/m2 on days 1-5~* Dose level 4: azacitidine 75 mg/m2 on days 1-5~Each cycle = 28 days. Subjects may receive up to 6 cycles."
40939106|NCT01120834|DRUG|vorinostat|"* Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.~* Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.~* Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.~* Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.~Each cycle = 28 days. Subjects receive up to 6 cycles."
41131594|NCT02457806|DRUG|Placebo spray|Aqueous solution to deliver 0.1 mL per unit
41131595|NCT04351932|BIOLOGICAL|bone marrow mesenchymal stem cells|intrarticular bone marrow mesenchymal stem cells injection
41131596|NCT04351932|BIOLOGICAL|Adipose Mesenchymal stem cells|intrarticular adipose mesenchymal stem cells injection
41131597|NCT04351932|BIOLOGICAL|bone marrow & adipose mesenchymal stem cells injection|intrarticular bone marrow and adipose stem cells injection.
41131598|NCT00734578|DRUG|SPD503-AM|SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
41131599|NCT00734578|DRUG|SPD503-PM|SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
41131600|NCT00734578|DRUG|Placebo|Placebo matched to Guanfacine Hydrochloride Extended Release
40939107|NCT05592522|OTHER|External oblique intercostal block|EOI block:Under guidance of the linear high frequency transducer, sagittal plane between anterior axillary line and midclavicular line at the level of the 6th rib, In-plane approach between external oblique and intercostal muscles Hydrodissection with 30 ml of 0.25% bupivacaine hydrochloride .
40939108|NCT05592522|OTHER|Oblique subcostal TAP block|OSTAP block: The needle was inserted in plane through the rectus adjacent to costal margin Once the tip of the needle was visualized in between the rectus muscle and transversus abdominus muscle and negative pressure aspiration was demonstrated, 30 ml bupivacaine 0.25% was deposited within the plane and hydrodissection was noted.
40939109|NCT05592522|OTHER|Posterior Rectus sheath block|Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.
40939110|NCT02059005|BEHAVIORAL|Specialized Community Disease Management|Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.
40939111|NCT02059005|BEHAVIORAL|Treatment As Usual|Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
40939112|NCT05642078|BIOLOGICAL|Investigational Vaccine(0.25ml/vial)|Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
40939113|NCT05642078|BIOLOGICAL|Investigational Vaccine(0.5ml/vial)|Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
40939114|NCT05642078|BIOLOGICAL|Active compared Vaccine|Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
40939115|NCT01024218|DEVICE|NovoFine® needle 8 mm|
40939116|NCT01024218|DEVICE|autocover needle|
40939117|NCT06288477|DRUG|A cotton pellet moistened with full-strength FC|A cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM (Intermediate Restorative Material).
40939118|NCT06288477|DRUG|Neo-Putty|Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).
40939119|NCT00427960|BEHAVIORAL|Dietary advice|
40939120|NCT00427960|DRUG|rosuvastatin|rosuvastatin 5 mg
40939121|NCT00427960|DRUG|atorvastatin|atorvastatin 10 mg
40939122|NCT04163718|DRUG|Umbralisib|800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
40939123|NCT05932784|DEVICE|transesophageal echocardiography|Utilizing transesophageal echocardiography (TEE) during resuscitation allows medical professionals to determine if a patient's aortic valve is being compressed while receiving chest compressions, providing valuable insight to optimize the resuscitation process.
40939124|NCT06181279|PROCEDURE|Individualized PEEP group|Individualized PEEP group: Recruitment Maneuver (RM) is performed first. In pressure control mode, PEEP and airway plateau pressure are increased to 20 cmH2O and 35 cmH2O at a rate of 5 cmH2O every 30s, and driving pressure is maintained at 15 cmH2O throughout. Subsequently, in volume-controlled ventilation mode, PEEP decreases from 20 cmH2O to 4 cmH2O at gradient of 2 cmH2O, and each PEEP level is maintained for 30s. The PEEP corresponding to the lowest driving pressure is the individualized PEEP we need. If multiple PEEP levels showed the same lowest driving pressure, the lowest PEEP value as the individualized PEEP. The above procedures are performed three times during the surgery (5 minutes after intubation,5 minutes after the beginning of pneumoperitoneum, and 5 minutes after the end of pneumoperitoneum).
40939125|NCT06181279|PROCEDURE|Fixed PEEP group|After the same RM, PEEP is fixed at 8 cmH2O.
40939126|NCT05395663|BEHAVIORAL|Community health worker|A trained navigator (e.g. OSU Extension staff) will have 3 meetings with the participants in Arm 2. These meetings will be held in person, on the phone, or in zoom.
40939127|NCT01076816|DRUG|dexmedetomidine|"dexmedetomidine will be given max 48h. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated patient (assessed by regular Comfort scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
40939128|NCT01076816|PROCEDURE|Vital signs|systolic and diastolic blood pressure, heart rate, respiratory rate,oxygen saturation, temperature are assessed baseline and at least per hour reassessed after starting the dexmedetomidine.
40939129|NCT01076816|PROCEDURE|blood sampling|Blood sampling for pharmacokinetic modelling is limited to a maximum of 1,8 ml/kg (in line with the EMEA guidelines on maximum blood sampling in children). Pharmacokinetic parameters and influence of covariates on these parameters will be assessed by a population pharmacokinetic approach.
40939130|NCT03114059|DIAGNOSTIC_TEST|Glaucoma diagnostics|Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
41280919|NCT03190343|PROCEDURE|cholangio-pancreatoscopy|
40756379|NCT05899868|DEVICE|Time to Intubation using FASTER device|Time from fiberoptic placement onto airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
40939131|NCT02962154|RADIATION|Coronary CT Angiography|The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
40939132|NCT02962154|OTHER|Mood Symptom Scale|"Some or all of the following questionnaires will be conducted to assess mood symptoms:~Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale"
40939133|NCT02962154|OTHER|Anxiety Symptom Scale|"Some or all of the following questionnaires will be conducted to assess anxiety symptoms:~Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)"
40939134|NCT02962154|OTHER|Chronic Stress Inventories|"Some of all of the following questionnaires will be conducted to assess chronic stress:~Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist"
40939135|NCT02962154|OTHER|Psychosocial Function Questionnaires|"Some of all of the following questionnaires will be conducted to assess psychosocial function:~Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)"
40939136|NCT02962154|OTHER|General Health and quality of life questionnaires|"Some of all of the following questionnaires will be conducted to assess quality of life:~EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire"
40939137|NCT02962154|OTHER|Magnetic Resonance Imaging|First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
40939138|NCT00240227|DRUG|Prazosin|FDA approved medication for hypertension
41280920|NCT05628844|PROCEDURE|Continuous enteral feeding|Enteral nutrition by continuous infusion for 10 hrs at a dose corresponding to 25 kcal/kg body weight/day
40939139|NCT00240227|DRUG|placebo|
40939140|NCT03037268|DEVICE|Lytro Plenoptic Camera and 28D lens|"* visual acuity measured, intraocular pressure obtained, eyes dilated as part of a standard exam for intended patient visit~* screened and consented for study~* subjected to bilateral plenoptic ophthalmoscopy~* mydriatic, single-field fundus images obtained~* images reviewed for quality and diagnostic utility by a masked grader"
40939141|NCT05293015|OTHER|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
40939142|NCT05829200|DEVICE|Transcranial Doppler (TCD)|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
40939143|NCT04644445|DIETARY_SUPPLEMENT|Bariatric Full Liquid Diet|Patient's will receive a Bariatric Full Liquid Diet (standard bariatric clear liquid diet + protein shakes) to be started 4 hours after surgery
40939144|NCT02389075|PROCEDURE|Pinch biopsies|Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
40939145|NCT02389075|PROCEDURE|Flexible sigmoidoscopy|Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
40939146|NCT03456440|DIAGNOSTIC_TEST|MRI|MRI scan of the patients liver with DWI and acquisition of ADC value.
41280921|NCT00661375|DRUG|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
41280922|NCT06509061|OTHER|Physical Activity Self-Definition|6 week behavioural change program designed to increase PASD and PA
41280923|NCT06509061|OTHER|Control|6 week program designed to as an attention control, delivering content on general health behaviour.
41280924|NCT03019549|DRUG|Lanabecestat|Administered orally
41280925|NCT03019549|DRUG|Rosuvastatin|Administered orally
41450882|NCT01943695|BEHAVIORAL|Supervised Home Based Training|Patients that elect supervised home based training platform or plan to complete unsupervised training sessions will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements. The study kit will be given to the patient upon completion of their baseline testing. The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group. The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym. A member of Ex Onc will provide an orientation session for the patient to set up all study kit items. If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.
40939147|NCT05625620|DEVICE|Active Transcranial Pulse Current Stimulation|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes.
40939148|NCT05625620|DEVICE|Sham Transcranial Pulse Current Stimulation|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes. Electric Current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
40939149|NCT02835560|DRUG|Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy|Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid
41131601|NCT01440166|DRUG|Drug|Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
41280926|NCT01419990|DRUG|GLPG0634|GLPG0634 300 mg oral capsules, qd, 10 days
41280927|NCT01419990|DRUG|GLPG0634|GLPG0634 450 mg oral capsules, qd, 10 days
41280928|NCT01419990|DRUG|Placebo|Placebo oral capsules, qd, 10 days
41280929|NCT02984462|PROCEDURE|percutaneous Akin osteotomy|The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
41450883|NCT05192057|DEVICE|Hypertonic Saline inhalation|Hypertonic Saline inhalation is thought to increase mucociliary clearance of the airways
40939150|NCT02835560|DRUG|Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
41280930|NCT00909272|PROCEDURE|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
41280931|NCT00909272|PROCEDURE|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
40939151|NCT02012582|DRUG|VAS203|i.v. infusion
40939152|NCT02012582|DRUG|Saline|i.v. infusion
40939153|NCT03551353|OTHER|Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
40939154|NCT03551353|OTHER|Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
40939155|NCT00800748|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
40939156|NCT00800748|DRUG|Ribavirin|Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
41280932|NCT05707130|OTHER|gaze stabilization exercises|patients will perform gaze stabilization exercise, Static neck exercise, and Habituation exercise. Neck isometric exercises like isometric flexion, extension, lateral bending will be performed.
41280933|NCT05707130|OTHER|neck isometrics|Patients in Conventional group will get neck isometric exercises like isometric flexion, extension, lateral bending.
41280934|NCT01904487|RADIATION|[11C]flumazenil|\[11C\]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
40939157|NCT00195871|DRUG|Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide|coventional dosages
40939158|NCT00195871|PROCEDURE|hematopoietic stem cell allograft|conventional procedures
40939159|NCT01187719|DRUG|phenytoin|phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
40939160|NCT00286611|PROCEDURE|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
40939161|NCT03335111|OTHER|Remote Ischemic Conditioning Equipment|BAIPC is admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation) for one week.
40939162|NCT03335111|PROCEDURE|Intravenous blood collection|Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
40939163|NCT02169193|RADIATION|99mTc-Rhenium Sulfide Nanocolloid|12 MBq of NanoCis added to 500 ml of enteral feeding
40939164|NCT00845780|DRUG|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
40939165|NCT03385161|PROCEDURE|Botulinum toxin A|
40939166|NCT03385161|PROCEDURE|Ethanol|
40939167|NCT00174291|DRUG|Somatropin|Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
40939168|NCT00221312|DRUG|Fosamax|
40939169|NCT00637871|DRUG|Casodex|150mg once daily
40939170|NCT00637871|DRUG|Tamoxifen|
40939171|NCT03282851|DRUG|MSB11456|Subjects will receive a single injection of MSB11456 on Day 1.
40939172|NCT03282851|DRUG|US-licensed Actemra|Subjects will receive a single injection of US-licensed actemra on Day 1.
40939173|NCT03282851|DRUG|EU-approved RoActemra|Subjects will receive a single injection of EU-approved RoActemra on Day 1.
40939174|NCT02158260|BEHAVIORAL|Position changing|
40939175|NCT00751621|BIOLOGICAL|IgPro20|
41131602|NCT01440166|OTHER|Placebo|Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
41131603|NCT06510361|DRUG|Epcoritamab|Humanized IgG1 bispecific antibody, 5 or 60 mL vial, via subcutaneous (under the skin) injection per protocol.
41280935|NCT01904487|DRUG|Tiagabine|Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
41280936|NCT00968266|BEHAVIORAL|Patient-centered group intervention|"Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent."
41280937|NCT03950323|RADIATION|MRI with Facial nerve tractography|MRI with Facial nerve tractography in addition to T1 imaging, T1 gadolinium imaging and T2 imaging.
41280938|NCT02972827|DEVICE|NICOM/FloTrac|Use of noninvasive cardiac output and minimally invasive cardiac output monitors
41280939|NCT02972827|OTHER|Crystalloid Fluid Challenge|500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
40939176|NCT03979430|OTHER|Home spirometry|Patients will receive a tablet and a spirometer for daily home spirometry. Each patient is supposed to do the home spirometry at the same time every morning. The spirometer and the tablet are connected via Bluetooth. Data will be transferred to a webpage, which team members have access to. Alerts will be automatically send to team members, if the FVC-value decreases about 5% or more within three consecutive days or if the patient does not do the measurement on three consecutive days. Study period is one year. Patients will also conduct a survey to measure health related quality of life (K-BILD). This questionnaire, as well as a phone interview to record changes in medication and condition will be conducted at baseline and every 4 weeks. At baseline and after 3, 6, 9, and 12 months, patients will conduct a 6 minutes walking test, lung function test, blood will be drawn for biomarker analysis, and sputum, nasal swab, and urine samples will be collected and analyzed.
40939177|NCT00062322|DRUG|cisplatin|
40939178|NCT00062322|DRUG|irinotecan hydrochloride|
40939179|NCT00062322|PROCEDURE|conventional surgery|
40939180|NCT00062322|PROCEDURE|neoadjuvant therapy|
40939181|NCT00062322|RADIATION|radiation therapy|
40939182|NCT03841838|OTHER|Energy drink|Two 12 oz bottles of commercially available energy drink
40939183|NCT03841838|OTHER|Placebo drink|Two 12 oz bottles placebo drink. Placebo drink will contain carbonated water, lime juice, and cherry flavoring.
40939184|NCT06309537|DIAGNOSTIC_TEST|chemoreflex evaluation|the ventilatory response to carbon dioxide and hypoxia will be assessed in study participants
40939185|NCT01530347|DEVICE|Easy Check|Collection of paired measurements of capillary blood glucose using reference method and data generated by the non invasive study device. Samples will be obtained at specific time points during 4 hours: at fasting, and after consuming standard liquid meal at 60, 120, 180 and 240 minutes.
40939186|NCT00433654|DEVICE|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
40939187|NCT00433654|OTHER|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
40939188|NCT02106039|PROCEDURE|intensive monitoring|
40939189|NCT00894127|DEVICE|CyPath|CyPath diagnostic assay for the early detection of lung cancer using sputum
41280940|NCT01183494|DRUG|FOLFIRI, Avastin, Irinotecan|Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1\*1/\*1 and UGT1A1\*1/\*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.
41280941|NCT03008551|DRUG|Empagliflozin|Each participant will receive empagliflozin 25mg daily for 3 months.
41280942|NCT03008551|DRUG|Metformin|Each participant will receive metformin 1500mg daily for 3 months.
41280943|NCT03883061|OTHER|regular medical treatment|regular medical treatment
41280944|NCT03006783|PROCEDURE|Cross-face nerve graft|connecting the healthy facial nerve to the affected facial nerve
41280945|NCT01011686|BIOLOGICAL|ANT-SM|autologous adipose-derived stem cell
40939190|NCT06212427|DIETARY_SUPPLEMENT|HMO supplement|Liquid supplement containing 2 specific HMOs. Supplement will be given 3-4 times a day, not mixed with any feeding.
40939191|NCT00831350|DRUG|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
40939192|NCT02207985|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|
40939193|NCT04672330|DRUG|Tislelizumab|Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
40939194|NCT05461807|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
40939195|NCT05461807|DRUG|Apixaban|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
40939196|NCT04621565|DRUG|Normal saline|No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
41131604|NCT02977832|DIETARY_SUPPLEMENT|Odyliresin|Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)
41131605|NCT02977832|DRUG|Alfuzosin|10Mg Oral Tablet, Extended Release
41131606|NCT03677037|OTHER|Short-term MBT|Short-term mentalization-based therapy
41280946|NCT03206502|DEVICE|Embrace + Alert App|Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.
41280947|NCT04756544|DIETARY_SUPPLEMENT|Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175|probiotic
41280948|NCT04756544|OTHER|placebo|placebo
41280949|NCT04986501|DEVICE|MucoPEG|Experimental
41280950|NCT04986501|DEVICE|Biotene|Active Comparator
40939197|NCT04621565|DRUG|Hydrocortisone|"Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 \& 100mg at 2000), the postoperative day 1 (100mg at 0800 \& 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program."
40939198|NCT02597634|DRUG|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
40939199|NCT02597634|DRUG|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
40939200|NCT04949685|PROCEDURE|plantar plate repair|surgical repair via dorsal approach of lesser metatarsophalangeal joint general anesthesia
40939201|NCT03128645|DEVICE|Abdominal Corset|The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.
40939202|NCT04956770|PROCEDURE|Implantation surgery|"The intervention involves the implantation of:~* a neurostimulator: the Activa® RC from Medtronic~* a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic"
40939203|NCT00135070|DRUG|Detemir|
40939204|NCT02675101|OTHER|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
40939205|NCT02675101|OTHER|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
40939206|NCT02675101|OTHER|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
40939207|NCT02799979|DEVICE|3D right ventricular imaging echocardiographic|Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
40939208|NCT05144204|BEHAVIORAL|Low FODMAP diet|Low FODMAP diet instruction to irritable bowel syndrome patients.
40939209|NCT05684523|DRUG|Valerian-Hop Extract|herbal drug
40939210|NCT05684523|DRUG|Placebo|Placebo
41131607|NCT03677037|OTHER|Long-term MBT|Long-term mentalization-based therapy
41131608|NCT03468634|DIAGNOSTIC_TEST|endoscopy|Oesophageal endoscopy with biopsy
41131609|NCT04801199|DRUG|CPL-2009-0031 140 mg|Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
41131610|NCT04801199|DRUG|Sitagliptin 100mg|Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
41131611|NCT03065049|BEHAVIORAL|Peer-Facilitated Counseling|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
41131612|NCT03065049|BEHAVIORAL|Fitbit activity tracker|Participants will be given a Fitbit activity tracker to monitor physical activity.
41131613|NCT01576796|RADIATION|Radiotherapy|"No additional dose (patients negative F-miso)~* Radiation therapy is conducted under standard conditions of conformal radiotherapy:~* The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week~With additional dose (patients positive for F-miso)~The dose in the PTVmiso increased until the maximum tolerable radiation by the lung."
41131614|NCT03398876|DRUG|Oromucosal Nicotine Spray (ONS)|Participants will receive oral dose of oromucosal nicotine spray (ONS).
41131615|NCT03398876|DRUG|Nicotine Gum|Participants will chew nicotine gum for 30 minutes.
41131616|NCT03398876|OTHER|Cigarette|Participants will smoke one cigarette as 10 puffs for 3 minutes.
41131617|NCT00562614|DRUG|SLx-2101|
41266941|NCT03394560|DEVICE|Sham High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
40939211|NCT00400790|DRUG|propofol|Propofol used as the primary anaesthetic agent
40939212|NCT00400790|DRUG|desflurane|Desflurane used as the primary anaesthetic
40939213|NCT06443073|OTHER|Patient-reported outcomes for speech disorders: positive|The Communicative Participation Item Bank (CPIB) aims to assess communication participation in all kinds of communication disorders. The Voice Self-Efficacy Questionnaire (VSEQ) monitors self-efficacy in individuals with self-declared voice problems before and after interventions. The Vocal Fatigue Handicap Questionnaire (VFHQ) and the Vocal Fatigue Index (VFI) aim at reflecting vocal fatigue. Both have been adapted to reflect purely positive wording.
40939214|NCT03526731|OTHER|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block for post operative pain control after unilateral inguinal hernia repair.
40939215|NCT02917473|BEHAVIORAL|In-person counseling|"In-person counseling~Sun protection"
40939216|NCT02917473|BEHAVIORAL|Written advice|Written advice
40939217|NCT02917473|BEHAVIORAL|Medical skin screening|Medical skin screening
40939218|NCT03548571|BIOLOGICAL|Dendritic cell immunization|Intradermal injection
40939219|NCT03548571|DRUG|Adjuvant temozolomide|After a 4-week break, patients were then to receive up to six cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days at 150 mg per square meter for the first cycle and thereafter increase to 200 mg per square meter beginning with the second cycle.
40939220|NCT01384071|DEVICE|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
40939221|NCT01384071|DEVICE|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
40939222|NCT04333771|DRUG|SHR0302|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
41131618|NCT06409897|OTHER|Sequencial increasing of head of the bed elevation and alveolar recruitment maneuver followed by a PEEP titration with 10° of head of the elevation|Patients will be sequentially positioned at 0, 10, 20, 30, and 40 degrees of head-of-bed elevation. An alveolar recruitment maneuver will be performed. For patients with body mass index ≤ 30 kg/m\^2, the maneuver will be conducted in pressure control mode, pressure control = 15 cmH2O, respiratory rate = 20 breaths per minute, and the PEEP will be increased in steps of 5 up to 30 cmH2O. For patients with body mass index \> 30, the PEEP will be increased up to 35. Then, a PEEP titration will be performed, tidal volume = 5 mL/Kg, respiratory rate = 25 breaths per minute, and the PEEP will be decreased from 24 down to 4 cmH2O in steps of 2 cmH2O with 30 seconds in each PEEP level. The PEEP titration software of Enlight 2100 will be used to determine the ideal PEEP, defined as the PEEP level with a collapse less than 5%. The alveolar recruitment maneuver will be performed again to reopen the lungs. Then, data will be collected, as with the 0 and 40-degree steps, with ideal PEEP.
40939223|NCT04333771|DRUG|Placebo|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
40939224|NCT01427322|DRUG|Lapatinib|given orally 2-4 hours before first fraction of radiation therapy
41131619|NCT03627637|DIETARY_SUPPLEMENT|Soy nuts|Study volunteers will receive daily 70 g of soy nuts (roasted soybeans containing approximately 100 mg isoflavones). The amount of soy protein provided by the nuts equals the FDA recommended daily intake of 25-30 g.
41131620|NCT03060317|BEHAVIORAL|Examination with neurological scales.|Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
41131621|NCT04433637|DIETARY_SUPPLEMENT|Cake + fruit juice|Cake+fruit juice experiment group, pregnant were allowed to consume fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST.
41131622|NCT04433637|OTHER|Video group|Music with motivational video experimental group, pregnant women were provided with fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST. During this waiting period, the researchers were informed about the development and changes in the body and the fetus specific to the gestational week and NST. Later, NST was applied, and during the procedure, the pregnant women were watched with music that provides relaxation with the video regarding the fetal development appropriate for the gestational week and changes in the mother.
41131623|NCT04788524|BEHAVIORAL|Computer Task Manipulation|Participants will complete computer tasks.
41131624|NCT00004361|DRUG|calcium gluconate|
41131625|NCT00004361|DRUG|sodium citrate|
41131626|NCT01766206|BIOLOGICAL|MenACWY-CRM (Menveo)|One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
41131627|NCT05081804|DIETARY_SUPPLEMENT|Carbohydrate Preoperative Drink|Patients randomized to the intervention will drink the preoperative drink two hours prior to surgery
41131628|NCT02788019|DRUG|Ropivacaine|Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
41131629|NCT02383043|DRUG|Cocaine|
41131630|NCT02383043|DRUG|Sustained Release d-Amphetamine|
41131631|NCT01094106|DRUG|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
41131632|NCT01094106|DRUG|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
41131633|NCT00780806|BIOLOGICAL|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
40939225|NCT01427322|RADIATION|Radiation therapy|Standard radiation therapy
40939226|NCT05293964|DRUG|SIM0270|SIM0270 is an oral, selective estrogen receptor degrader (SERD)
40939227|NCT05293964|DRUG|Palbociclib|palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
40939228|NCT05293964|DRUG|everolimus|Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
40939229|NCT02776371|DRUG|Modified non-clarithromycin triple therapy|H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
40939230|NCT02776371|DRUG|Sequential therapy|H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
40939231|NCT01456390|DEVICE|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
41131634|NCT00780806|PROCEDURE|Blood draw|Blood draw
41131635|NCT01754636|OTHER|No intervention|
40939232|NCT01903525|DRUG|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
40939233|NCT01903525|DRUG|Placebo|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
40939234|NCT05612100|OTHER|Electronic Health Record Review|Ancillary studies
40939235|NCT05612100|OTHER|Questionnaire Administration|Complete alopecia questionnaires
40939236|NCT05612100|OTHER|Survey Administration|Complete alopecia surveys
40939237|NCT01695200|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
40939238|NCT03051646|DRUG|Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
40939239|NCT03051646|DRUG|Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit|Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
40939240|NCT01784393|RADIATION|chemoradiation|
40939241|NCT00965510|BEHAVIORAL|care coordination|patients receive care coordination to improve their type II diabetes
40939242|NCT03660631|BEHAVIORAL|CVRS Intervention|"1. Evaluate gaps in therapy~2. Contact patients regularly by email, phone and/or text message~3. Assess and counsel for medication adherence, side effects, life-style behaviors~4. Develop an action plan and send recommendations to provider"
40939243|NCT02298985|DRUG|Curcumin|3 g/day (3 capsules/day) for 6 months
40939244|NCT02298985|DRUG|placebo|3 g/day (3 capsules/day) for 6 months
40939245|NCT03224546|BEHAVIORAL|Contingency Management|Subjects will receive payments for providing cocaine negative urine samples.
40939246|NCT01661816|BEHAVIORAL|interview|psychological, emotional, family and social parameters
40939247|NCT00366015|PROCEDURE|Robotic-assisted Coronary Surgical Revascularization|Robotic assistance of coronary artery bypass grafting using the DaVinci surgical robotic console
40939248|NCT00366015|PROCEDURE|PCI- Drug Eluting Stents|Drug eluting stents performed by cardiologist within the same operating theatre following robotic assisted coronary artery bypass surgery
40939249|NCT00010127|BIOLOGICAL|therapeutic autologous dendritic cells|
40939250|NCT00162721|DRUG|doxorubicin, ifosfamide, cisplatin|
40939251|NCT03733340|DRUG|Imipenem|Imipenem: A wide-spectre antibiotic from the carbapenem group Other name: Imipenem-cilastatin
40939252|NCT04349085|DEVICE|Effective PBMT/sMF|A cluster with 20 diodes, manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used: 4 diodes of 905 nm (1.25 average power, 50 W of peak power for each diode), 8 diodes of 850 nm (40 mW of average power for each diode) and 4 diodes of 633 nm (25 mW average power for each diode). Effective PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The effective PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 270 J for knee extensors/hip flexors, 180 J for knee flexors/hip extensors, and 60 J for plantar flexors.
40939253|NCT04349085|DEVICE|Placebo PBMT/sMF|A cluster manufactured by Multi Radiance Medical® (Solon, OH, USA) with 20 diodes will be used: Placebo PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The placebo PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
40939254|NCT00071578|BEHAVIORAL|Group Psychotherapy-Negative Emotion Focus|20 weekly sessions, 2 hours, group format
40939255|NCT00071578|BEHAVIORAL|Group Psychotherapy- Self-Esteem Focus|20 weekly sessions, 2 hours, group format
40939256|NCT02285660|PROCEDURE|4D PET-CT Scan|
40939257|NCT02285660|OTHER|No intervention|
40939258|NCT04867031|DIETARY_SUPPLEMENT|Milk|One portion of semi-skimmed cow's milk (approx. 450mL), providing \~140µg of iodine.
40939259|NCT04867031|DIETARY_SUPPLEMENT|Fish|One portion of cod (approx. 130g), providing \~140µg of iodine.
40939260|NCT04867031|DIETARY_SUPPLEMENT|Seaweed|One portion of dried seaweed sheets (approx. 6g), providing \~140µg of iodine.
40939261|NCT01931202|DRUG|Escitalopram|Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
40939262|NCT01931202|DRUG|Placebo oral tablet|Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
40939263|NCT04942353|BEHAVIORAL|Home-based Exercise Rehabilitation.|Based on physical therapist or exercise physiologist assessment, subjects will receive an individualized exercise prescription for frequency, duration, and intensity of walking and strength training (including exercises using light-weight hand-weights and upper and lower body exercises using resistance bands). Research team will provide updated exercise prescription based on Garmin watch/Datos app activity data and Datos app data (including Borg scale).
40939264|NCT04942353|BEHAVIORAL|Usual Care|Patients receive a standardized recommendation to increase their walking activity to 30 minutes 5 days/week.
40939265|NCT04048200|DRUG|Fentanyl|Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
40939266|NCT04048200|DRUG|Dexmedetomidine Ketamine|No opioid will be used in induction of anesthesia. A combination of dexmedetomidine and ketamine will be infused. Sevoflurane will be used for maintenance of anesthesia.
41280951|NCT02247869|DRUG|dose dense ABVD|"dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~* Doxorubicin 25 mg/m2 i.v. day 1 and 8~* Bleomycin 10 mg/m2 i.v. day 1 and 8~* Vinblastine 6 mg/m2 i.v. day 1 and 8~* Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14"
41131636|NCT00452452|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
41131637|NCT01972776|DRUG|QBM076|Supplied in 25 mg and 75 mg capsules
41131638|NCT01972776|DRUG|Placebo|Matching placebo capsules
41131639|NCT01673399|DRUG|Atosiban|Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
41280952|NCT04462237|PROCEDURE|Root coverage procedures|Treatment of multiple adjacent gingival recession using a coronally advanced flap
41450884|NCT01718704|DEVICE|Viberect device|Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
40756380|NCT03138382|DEVICE|Vestibular Nerve Stimulator|Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.
40939267|NCT01216995|BIOLOGICAL|Dose A|ADRC Dose A
40939268|NCT01216995|BIOLOGICAL|Placebo|Placebo Comparator
40756381|NCT03138382|DEVICE|Sham stimulator|Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
40756382|NCT01877278|DEVICE|Wearable pulsed electromagnetic fields|
40756383|NCT03139253|DRUG|amoxicillin|amoxicillin 1000 mg bid. for 14 days
40756384|NCT03139253|DRUG|clarithromycin|clarithromycin 500 mg bid. for 14 days.
40939269|NCT00997438|DIETARY_SUPPLEMENT|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
40939270|NCT03793218|DEVICE|Latera Device|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
40939271|NCT03793218|PROCEDURE|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
41280953|NCT04082247|BEHAVIORAL|The education and training of early childhood educators and their intervention on children|"A 24-week cluster randomized trial will be developed, with the childcare being the randomization unit. Training sessions will be conducted for all early childhood educators in the intervention group. The control group will receive the Portuguese standard education and at the end of the intervention this group will also receive the initial training given to the intervention group, so that they can later also implement the intervention. At the end of the intervention, all early childhood educators and parents/guardians will have access to the intervention outcomes."
41280954|NCT01193764|DIETARY_SUPPLEMENT|100% cocoa powder|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
41450885|NCT03675633|DIAGNOSTIC_TEST|FEUrea|FEUrea in decompansated liver cirrhosis
41450886|NCT05272813|DRUG|MS-553|MS-553
40939272|NCT01775462|DRUG|EDI200|3 or 10 mg/kg of EDI200
40939273|NCT04561674|OTHER|Implementation of web-based patient education|Web-Based Patient Education on Colostomy and Ileostomy (WBPECI) was developed in accordance with the principles of the ADDIE instructional design. The web-based education was designed in line with these learning objectives determined. The content of the website was developed in light of the opinions sought from five subject experts. The WBPECI content includes a total of 7 videos, 1 animation with sound, 1 forum and 1 consultation page
40939274|NCT03221075|OTHER|Registry|There is no intervention.
40939275|NCT05875467|OTHER|SE3 Game|A prototype online game designed to increase environmental health literacy
40939276|NCT03122301|DRUG|Stellate Ganglion Block injection with bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
40939277|NCT03122301|DRUG|Saline|sham injection with saline
40939278|NCT02240173|DIETARY_SUPPLEMENT|Jobelyn|Jobelyn is a dietary supplement made from Sorghum bicolor
40939279|NCT02240173|DRUG|Haloperidol|Conventional drug normally used for psychotic problems
41131640|NCT01673399|DRUG|placebo|
41131641|NCT01064466|DRUG|ETOPOSIDE - Usual|Etoposide Injection
40939280|NCT04132882|DRUG|Sodium Thiosulfate (STS)|
40939281|NCT02474225|DRUG|Intravitreal injection (bevacizumab or ranibizumab)|The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
40939282|NCT05916144|BEHAVIORAL|Interaction-Based Early Education Program|The intervention program will be created based on the ETEÇOM model which is the Turkish adaptation of the Responsive Teaching Program developed in the United States. In this program, by improving the interactive behaviors of experts/educators or parents, the aim is for the child to acquire or develop 15 core behavior. Each session is planned to last between 60-90 minutes on average and will be conducted in a group format, consisting of 5 sessions, and can be conducted face-to-face or online.
40939283|NCT02763761|DRUG|Infliximab + Prednisone|Prednisone dose will be decreased every 3 days for 18 days
40939284|NCT02763761|DRUG|Methylprednisolone + Prednisone|Prednisone dose will be decreased every 4 days for 40 days
40939285|NCT02722525|PROCEDURE|Magnetic Resonance Imaging|Undergo treadmill stress CMR
40939286|NCT02722525|BEHAVIORAL|Exercise Intervention|Complete treadmill exercise
40939287|NCT02722525|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo gadopentetate dimeglumine perfusion MRI
41131642|NCT01064466|DRUG|ETOPOSIDE - Study|Etoposide Capsule
41131643|NCT01793779|PROCEDURE|cold water immersion|
41131644|NCT01793779|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)|
41131645|NCT01793779|DIETARY_SUPPLEMENT|Placebo|
41131646|NCT06380309|BIOLOGICAL|IDOV-SAFE|Intravenous injection of oncolytic virus every 3 weeks until tumor progression
41131647|NCT01500200|DRUG|ALKS 5461|Two active tablets, given daily
41131648|NCT01500200|DRUG|Placebo|Two placebo tablets, given daily
41280955|NCT01193764|DIETARY_SUPPLEMENT|gelatin (Gelita)|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
41280956|NCT03547141|DRUG|MBA-P01|injection of MBA-P01 into the muscle of each contralateral foot in equal doses
41280957|NCT03547141|DRUG|BOTOX|injection of BOTOX into the muscle of each contralateral foot in equal doses
41280958|NCT03251690|DRUG|Tenofovir/Emtricitabine/Rilpivirine|Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression
40744353|NCT01838811|BEHAVIORAL|Speed of Process Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself. These training tasks are tailored to each individual's ability by the trainer.
40744354|NCT00727064|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
40744355|NCT00727064|DRUG|Venlafaxine Extended Release (VEN ER)|
40744356|NCT01196611|BEHAVIORAL|Voice Amplification|Behavioral: Voice Amplification. Patients use VA over a course of 6 weeks Control group. No treatment over a course of 6 weeks.
40939288|NCT02722525|BEHAVIORAL|Exercise Intervention|Complete resistive lower extremity exercise
40939289|NCT02722525|PROCEDURE|Spectroscopy|Undergo skeletal muscle PMRS
40939290|NCT02722525|OTHER|Laboratory Biomarker Analysis|Correlative studies
40939291|NCT05288699|BEHAVIORAL|Aliento|Aliento is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety delivered via a mobile application.
40939292|NCT03830112|BEHAVIORAL|Pilates exercise with Theraband|The experimental group will perform all the exercises with Theraband® in the same manner than active comparator group.
41131649|NCT01870830|OTHER|Altitude exposure|Stay at different altitudes: 490, 1650, 2590 m
41131650|NCT06270862|BEHAVIORAL|Resilience training|Receive mini course on what is resilience and how to use different exercises to be more resilient in life.
41131651|NCT06270862|BEHAVIORAL|cognitive training|Play games that trains attention, memory and planning using the services provided by CogniFit.
41280959|NCT03251690|DRUG|Tenofovir/Emtricitabine/Efavirenz|as a active comparator
41280960|NCT03328819|OTHER|Acupuncture|The following depression-specific acupoints: Baihui (Du-20), Yintang (EX-HN3), Sishencong (EX-HN1), bilateral Cuanzhu (BL2), bilateral Toulinqi (GB15), bilateral Neiguan (PC6), bilateral Shenmen (HT7), bilateral Sanyinjiao (SP6), and bilateral Taichong (LR3). These depression-specific acupoints could raise up the qi, calm the mind, smooth liver qi stagnation, promote blood circulation, remove blood stasis, and nourish yin. The following pain-specific acupoints: bilateral Fengchi (GB20), bilateral Jianjing (GB21), bilateral Quchi (LI11), bilateral Shousanli (LI10), bilateral Hegu (LI4), bilateral Wangu (SI4), bilateral Shenshu (BL23), bilateral Huantiao (GB30), bilateral Weizhong (BL40), bilateral Feiyang (BL58), bilateral Yanglingquan (GB34), bilateral Yinlingquan (SP9), and bilateral Taixi (KI3). These pain-specific acupoints could eliminate wind, relax muscles, promote blood circulation, and supplement the kidney.
41280961|NCT00310310|BEHAVIORAL|Sleep Apnea Self-Management Program|Sleep apnea self-management program - 4 sessions, group-based.
41280962|NCT00310310|BEHAVIORAL|Usual care|Usual sleep apnea and cpap care
41280963|NCT02512796|DRUG|Gadolinium contrast dye|Gadolinium contrast dye administered during MRI
40939293|NCT03830112|BEHAVIORAL|Pilates exercise|The active comparator group will perform all the exercises without Theraband®
40939294|NCT00625742|BEHAVIORAL|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
40939295|NCT00625742|BEHAVIORAL|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
40939296|NCT00625742|DRUG|Melatonin|20 mg by mouth (PO) Daily
40939297|NCT00625742|DIETARY_SUPPLEMENT|Juven|90 calories of Juven, twice a day.
40939298|NCT00625742|DRUG|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate \>110 beats/min) or resting energy expenditure (REE) \> 110% of predicted.
40939299|NCT00625742|DRUG|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
40939300|NCT04493879|OTHER|Bioptron Light Therapy (BLT)|BLT for 30 days 10 minutes every day. The treatment points displayed were: one point in the right jugal mucosa, one point in the left jugal mucosa, one point in the lower lip 's inner mucosa, analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections)
40939301|NCT02653885|OTHER|Red red cell distribution width|Results from hemogram
40939302|NCT00002311|DRUG|Wobenzym|
40939303|NCT04766372|OTHER|Behaviour change|Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.
40939304|NCT02847468|OTHER|FDG Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
40939305|NCT02847468|OTHER|FCH Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
40939306|NCT03824067|DIAGNOSTIC_TEST|Point of Care Early Infant Diagnosis|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
41280964|NCT00561353|DRUG|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
41280965|NCT00561353|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
41280966|NCT00561353|DRUG|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
41280967|NCT00561353|DRUG|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
41280968|NCT02979314|DEVICE|Galvanic Vestibular Stimulation|The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
41280969|NCT01590329|DEVICE|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
41280970|NCT02833311|BEHAVIORAL|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
41280971|NCT02833311|BEHAVIORAL|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
41280972|NCT02833311|BEHAVIORAL|Contact Control Group|Participants are prescribed an exercise program and given information on healthy eating.
41280973|NCT05430867|DRUG|Memantine Oral Tablet|Memantine 20mg once-daily
41280974|NCT05430867|DRUG|GV-971 capsule|GV-971 450mg twice a day
41280975|NCT01748383|PROCEDURE|Transplantation of BMMCs|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
40939307|NCT03824067|DIAGNOSTIC_TEST|Standard of Care Early Infant Diagnosis|Conventional laboratory based EID testing
40939308|NCT03415100|BIOLOGICAL|CAR-NK cells targeting NKG2D ligands|The infusion of CAR-NK cells will be performed in the Third Affiliated Hospital of Guangzhou Medical University. Following infusion of CAR-NK cells, interleukin-2 (IL-2) will be injected subcutaneously into some patients to support the in vivo survival of CAR-NK cells. The subject will be observed for any side effects during this time and all the adverse events will be recorded.
40756385|NCT03139253|DRUG|tinidazole|tinidazole 500 mg bid. for 14 days.
40939309|NCT01740843|DEVICE|transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)|The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
40939310|NCT06313879|OTHER|online education|Description of hydrocephalus disease, treatment methods and ventriculoperitoneal shunt care training will be given.
41131652|NCT06270862|BEHAVIORAL|physical exercise|Engage in age-appropriate physical exercises.
41131653|NCT06270862|BEHAVIORAL|social interaction|Engage in social discussion with peers in the group.
41131654|NCT06270862|BEHAVIORAL|workshop series|Watch a series of workshops targeting the older adult population.
41280976|NCT01748383|PROCEDURE|Transplantation of CD 133+ cells|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
41280977|NCT01748383|PROCEDURE|stenting of IRA|The only stent implantation
41280978|NCT04723095|OTHER|Follow-Up|Receive follow up
41280979|NCT04723095|OTHER|Medical Chart Review|Review of medical records
41280980|NCT02980614|DEVICE|4D flow imaging|To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
41280981|NCT01517438|BEHAVIORAL|agitation|agitation score after desflurane anesthesia
41280982|NCT03161418|DRUG|KSP-910638G, 0.4 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)
41280983|NCT03161418|DRUG|KSP-910638G, 1.2 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
41280984|NCT02456220|DEVICE|Herbst appliance|Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
40756386|NCT03139253|DRUG|levofloxacin|levofloxacin 500 mg qd. for 14 days.
40939311|NCT03544476|BEHAVIORAL|Mobile phone TB treatment support app plus usual care|The behavioral intervention is delivered through a mobile phone TB support app. The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report. The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app. The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.
40939312|NCT03544476|OTHER|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
40939313|NCT00249158|DRUG|Risperidone|
40939314|NCT04022343|DRUG|Cabozantinib|Given PO
41266942|NCT03952338|OTHER|Food coupons|Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
41266943|NCT03952338|OTHER|Nutrition skill-building|Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
41266944|NCT03975998|PROCEDURE|Mitral valve repair|Minimally invasive repair of severe organic mitral regurgiation
41266945|NCT03972631|BEHAVIORAL|Lifestyle education|Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.
41266946|NCT03972631|BEHAVIORAL|Intensive lifestyle intervention|One to one intensive lifestyle intervention according to the diet and activity plan
41266947|NCT03972631|BEHAVIORAL|Hypocaloric low-carbohydrate diet plan|A diet plan with restricted calorie and carbohydrate intake
41266948|NCT00292084|DRUG|Celgosivir|
41266949|NCT03598907|OTHER|Fresh frozen plasma|Fresh frozen plasma will be used according to anaesthetist ,,blind,, decision
41266950|NCT00330707|DRUG|Bacillus Calmette Guerin and interferon alpha|
41266951|NCT01340521|DRUG|Clomiphene Citrate|0, 25, 50 or 100 milligrams daily. Will be taken orally days five through nine of the menstrual cycle.
41266952|NCT04627909|OTHER|Robot|The patient interacts with a robot
41266953|NCT04627909|OTHER|Medical Personnel|The patient interacts with medical personnel
41266954|NCT04627909|OTHER|Caregiver|The patient interacts with the caregiver
41266955|NCT05200260|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
41266956|NCT05200260|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
41266957|NCT05200260|DRUG|PARP inhibitor|For patients with CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors. In this trial, Niraparib 200mg po qd is suggested after the front-line therapy.
41266958|NCT01239407|BEHAVIORAL|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
41266959|NCT04850183|BEHAVIORAL|Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis|The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.
41266960|NCT02555163|DEVICE|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
41266961|NCT02555163|DEVICE|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
41266962|NCT02750202|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
41266963|NCT02750202|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
41266964|NCT06309056|DEVICE|VitalStim|VitalStim is a device that provides neuromuscular electrical stimulation. It will be applied on muscles related to swallowing to stimulate muscle contraction.
40939315|NCT01292785|DRUG|Hormones|"FtM will receive~* 1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~* if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~* 50mg cyproterone acetate daily (Androcur®)~* estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is \> 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is \< 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~* 2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss."
40939316|NCT00749580|DRUG|Switch NRTIs as a Backbone to Raltegravir|This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA \<75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
40939317|NCT02622750|PROCEDURE|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
40939318|NCT02622750|PROCEDURE|four-branched Dacron graft|"The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the open aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft."
40939319|NCT00451139|DRUG|artemether/lumefantrine|
40939320|NCT00451139|DRUG|quinine|
40939321|NCT00451139|DRUG|atovaquone/proguanil|
40939322|NCT03911154|DEVICE|Philips SmartSleep Technology--Continuous Fixed Interval modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
40939323|NCT03911154|DEVICE|Philips SmartSleep Technology--Block modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
40939324|NCT03911154|DEVICE|Philips SmartSleep Technology--In-Phase Adjustable modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
40939325|NCT04350346|DRUG|Motilitone|"1. Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~2. Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~3. Pharmacological action:~   * It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~     * Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor."
40939326|NCT04350346|DRUG|Gasmotin|"1. Ingredient and content: mosapride citrate dihydrate 5.29mg (5mg as active ingredient)~2. Dosage method: Usually, an adult is orally administered 1 tablet 3 times a day before meals.~3. Pharmacological action: mosapride is a selective serotonin-4 (5-HT4) receptor agonist with gastrointestinal stimulating activity, contracting smooth muscle"
40939327|NCT00988325|DRUG|Tamiflu|oral repeating dose
40939328|NCT03962309|OTHER|Health self-assessment questionnaire|The health self-assessment questionnaire includes questions covering anthropometric, sociodemographics, personal and family health history, life style habits and aspects of the behavioral domain. The questionnaire will be administered as paper format or web-based electronic format according to participants' preferences.
40939329|NCT03665831|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
40939330|NCT01237964|DRUG|Xiaflex (FDA approved collagenase)|0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
41280985|NCT06389370|OTHER|HU-DBI questionnaire|a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.
40939331|NCT06197399|PROCEDURE|Detethering Surgery|Detethering surgery, or cord untethering, is a conventional surgical approach for treating tethered cord syndrome (TCS). It involves releasing the spinal cord from its abnormal attachment. During the surgical procedure, once the tethered area is identified, careful microsurgical techniques are used to separate the spinal cord from the surrounding abnormal tissue. This operation aims to alleviate the symptoms of TCS by removing the cause of tension on the spinal cord.
41280986|NCT04038840|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
41280987|NCT04038840|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
41280988|NCT06273163|OTHER|Medically tailored meals|Medically tailored meals are nutritious meals formulated for weight wellness.
40756387|NCT03139253|DRUG|furazolidone|furazolidone 100 mg bid. for 14 days.
40939332|NCT06197399|PROCEDURE|Spinal Column Shortening Surgery|"Spinal column shortening surgery is an innovative surgical approach that involves reducing the tension on the spinal cord by shortening the spinal column, effectively untethering the spinal cord indirectly. The procedure primarily involves the thoracolumbar region.The choice of this region for intervention offers several advantages: it is a safe distance from the previous detethering surgery area; it is closer to the conus medullaris of the spinal cord, ensuring better treatment effectiveness; and the impact on spinal mobility is minimal after internal fixation at this region. This technique is designed to alleviate TCS symptoms while minimizing the risk of postoperative cerebrospinal fluid (CSF) leakage, which is a common complication in direct untethering procedures for recurrent cases. All procedures will be conducted by trained and experienced neurosurgeons following standardized protocols."
40939333|NCT05170568|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 106, 2.0 × 106 and 4.0 × 106 CAR-T/kg groups in order of sequence. And the subjects will be administered once.
40939334|NCT00882700|DRUG|Cefdinir 300 mg Capsule (Sandoz, Austria)|
40939335|NCT00882700|DRUG|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
40939336|NCT04463511|OTHER|Polyethylene bag before the umbilical cord is clamped|"11 x 16 (279mm x 406mm) sterile resealable PB (Resealable Polybag, Helapet Ltd, Bedfordshire, UK)"
40939337|NCT00348244|DRUG|Ketorolac, Prednisolone Acetate|
40939338|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 14mg once daily|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
40939339|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 25mg once daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
41280989|NCT06273163|BEHAVIORAL|Noom®|Noom® is a subscription-based mobile application used to support healthy eating and exercise behavior change.
41280990|NCT06273163|OTHER|Usual care|Care is provided at the discretion of the individual provider (e.g., usual care).
41280991|NCT05917886|OTHER|Auditory beat stimulation: 8Hz monaural beat stimulation|Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
41280992|NCT01567436|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of scissors is used to remove the inner ring, and a bandage or gauze dressing is applied.
41280993|NCT04348903|BEHAVIORAL|Virtual Reality Distraction|The researchers will prepare the VR device. The researches will explain the aim of using VR and adopt tell-show-do technique in introducing VR Glasses. Once VR device headset will be adapted to the child's head size and adjusted in front of his/her eyes, the selected 3D cartoon movie will be played in the waiting room and throughout the procedure of dental LA injection. After ensuring that the child is fully immersed in the cartoon movie, a needle of local anesthetic agent will be prepared and injected after explanation of the procedure.
41280994|NCT04348903|BEHAVIORAL|Positive Pre-Visit Imagery Intervention|Short narrative visual information regarding the dental chair, environment and equipment will be provided. It will be done through showing children an interactive book that contained photographs of A4 size, depicting three children model aged 4 - 6 years who are smiling while sitting in the dental chair and cooperative with the dentist. Benefit of LA in alleviating pain will be explained. The researchers also will explore the children's reflection of the children model and allow them ask questions relevant to LA injection.
41280995|NCT05716919|DRUG|Ivaltinostat|Ivaltinostat capsule
41450887|NCT02266407|PROCEDURE|Aquamantys System|The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
41450888|NCT03442530|BEHAVIORAL|ToPIC|Expanded tobacco cessation counseling for pregnant women.
40939340|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 25mg twice daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily
41450889|NCT03442530|BEHAVIORAL|Tobacco Treatment As Usual (TTAU)|Standard of care tobacco cessation counseling for pregnant women
40939341|NCT02753218|DRUG|Midazolam|
40939342|NCT02753218|DRUG|LEO 32731|
40939343|NCT02788474|DRUG|nintedanib|
40939344|NCT02788474|DRUG|placebo|
40939345|NCT00571376|OTHER|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
40939346|NCT05940584|DEVICE|Tele-Reha provided with EvoPads|Exercises and cognitive training provided on an EvoPad
40939347|NCT05940584|OTHER|Paper-based exercises with option to do tele-reha afterwards|Similar exercises and cognitive training as Group 1 provided on paper. Patients receive the Tele-Reha afterwards
40939348|NCT05940584|OTHER|Only paper-based exercises|Same exercises and cognitive training as Group 2 provided on paper only.
40939349|NCT04172662|BEHAVIORAL|Facilitated Music Listening|The patient gets a preparatory session with the music therapist one day before the invasive procedure, where individual assessment is made based on a biopsychosocial approach. Sequences of facilitated Music listening is provided during the pre-, peri and postoperative phase, and a closing dialog performed postoperatively. Patient-preferred music is chosen from a limited set of playlists provided on the app The Music Star.
40939350|NCT04731961|PROCEDURE|Standard of care (15 Botox injections)|The controls will be given the standard of care of 15 Botox injections.
40939351|NCT04731961|PROCEDURE|Experimental Arm (5 Botox injections)|5 Botox injections will be given, with each injection containing three times the amount of Botox than each of the 15 injections given in the standard of care arm.
41280996|NCT05716919|OTHER|Placebo|Placebo capsule
41280997|NCT01938625|DRUG|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
41280998|NCT01938625|DRUG|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
41280999|NCT01938625|DRUG|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
41450890|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Rockwood Clinical Frailty Scale
41450891|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Frail NonDisabled Questionnaire (FiND)
41450892|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Clinician's subjective 'end-of-bed' test
41450893|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Healthcare Improvement Scotland FRAIL Scale
41450894|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|11-item modified Frailty Index (mFI-11)
41450895|NCT00464594|BEHAVIORAL|Standard lifestyle guidance|
41450896|NCT00464594|DRUG|Lifestyle guidance and monotherapy with acarbose|
40939352|NCT00938223|BIOLOGICAL|4-peptide and 12-peptide melanoma vaccines|"Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN)."
40939353|NCT05817071|PROCEDURE|Arthroscopic massive rotator cuff repair|Arthroscopic massive rotator cuff repair without biceps tendon augmentation either partial or complete repair.
40939354|NCT05817071|PROCEDURE|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon .
40939355|NCT00267189|DRUG|Everolimus|1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
40939356|NCT00267189|DRUG|Calcineurin inhibitors (CNI)|
40939357|NCT00267189|DRUG|Mycophenolate acid (MPA)/ Azathioprine (AZA)|
40939358|NCT00267189|DRUG|Steroids|
40939359|NCT00200096|PROCEDURE|Acupuncture and questionnaires|"Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation."
40939360|NCT00200096|PROCEDURE|placebo acupuncture|"During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure."
41131655|NCT04125901|OTHER|Pain Neuroscience Education and Exercise|The incorporation of the exercise in this group will be gradual, in order to decrease the education component and increase the exercise component (up to 45/60 minutes). The 1st session will be only PNE and will last approximately 45 minutes. In the 2nd session, there will be 30 minutes of PNE and the remaining 15 minutes of exercise. In the following 4th and 6th sessions, 15 minutes of each session will be used to clarify doubts and emphasize PNE concepts and strategies. The 8th session will include exercises only. In WhatsApp sessions, in addition to the video with the exercises, participants will receive activities about the PNE.
41131656|NCT04125901|OTHER|Exercise|The exercise group will perform exercises in all sessions (45 minutes of exercise in face-to-face sessions). In WhatsApp sessions, participants will receive a video with exercises to perform at home.
41281000|NCT01938625|DRUG|Cyclosporine|Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
41281001|NCT01938625|DRUG|Tacrolimus|Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
41281002|NCT03119649|DRUG|GLPG2222 50 mg|Oral tablet(s) containing GLPG2222
41281003|NCT03119649|DRUG|GLPG2222 100 mg|Oral tablet(s) containing GLPG2222
41281004|NCT03119649|DRUG|Placebo|Matching oral tablet(s) containing placebo
41131657|NCT04510324|OTHER|Red meat patties group|"1. Baseline Visit: day -7 before randomization~* Clinical history~* Refrain from seafood, eggs, fish or meat, for 7-day (washout) prior to Day 1. 2. Day 1 Randomization~* Randomization to 1 of 2 interventions: plant-based or meat burgers~* 6 days-worth of burgers will be delivered to the participant's house 3. Day 1-6:~* The participant will be asked to eat a specific randomized diet for 6 days 5. Days 7~* Physical exam (weight, BP, HR)~* Food questionnaire~* Blood draw: Circulating TMAO, Total, LDL, and HDL cholesterol, Creatinine, High-sensitivity c-reactive protein~* Urine Collection - TMAO 6. Day 7-14: Washout 7. Day 14: Patties delivery 8. Day 14-20: Assigned diet for 6 days 9. Days 20: Same as day 7"
41131658|NCT04510324|OTHER|Plant-based patties group|Same as above
41131659|NCT01331499|DEVICE|Bipolar Sealer (Aquamantys)|Standard of care blood sparing techniques along with the use of bipolar sealer
41281005|NCT03119649|DRUG|GLPG2222 200 mg|Oral tablet(s) containing GLPG2222
41281006|NCT03119649|DRUG|GLPG2222 400 mg|Oral tablet(s) containing GLPG2222
41450897|NCT00464594|DRUG|Lifestyle guidance and monotherapy with metformin|
41450898|NCT00464594|DRUG|Lifestyle guidance and monotherapy with gliclazide|
41453622|NCT02798458|PROCEDURE|Endoscopic Mucosal Resection|a Sigmoidoscopy is an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed.
40939361|NCT02532530|DEVICE|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
41131660|NCT01331499|PROCEDURE|Standard of Care|Standard of care blood sparing techniques without the useof bipolar sealer
41131661|NCT01233934|DRUG|Dexchlorpheniramine 1% Gel|Small amount applied over the lesion twice a day for 7 days.
41281007|NCT06133543|PROCEDURE|Robot-assisted ICG-guided sentinel lymph node biopsy|The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.
41281008|NCT04899648|BEHAVIORAL|Behavioral Intervention Group|Behavioral intervention: (a) form groups and choose peer leaders; (b) train peer leaders on 16 core classes based on diabetes prevention program curriculum; (c) support and motivate peer leaders to lead intervention in their group; (d) monitoring of the interventions.
41281009|NCT06016712|DEVICE|SENSIMED Triggerfish Eye Lenses|Contact lenses used for measuring intraocular pressure.
41281010|NCT04939493|OTHER|Rhythmic Auditory Cueing|"Patients will perform the same movement sequence in time with the metronome beat. The frequency of the rhythmic auditory stimulation will be matched to the participants preferred movement speed, which will be assessed prior to the start of the trial, and participants typically started moving after they had heard the metronome beat two to three times. Participants will be given sufficient practice trials to ensure full understanding before the actual recording of data, and will be given 3-minutes break between trials.~On the 3rd and 5th week, the rhythm frequency was increased by 5%."
41281011|NCT04939493|OTHER|Bilateral arm training|Training will consist of 20 minutes of bilateral arm training In each session, patients will be seated comfortably at a table in the following limb positions: ankles in neutral dorsiflexion, knees and hips placed at 90°, shoulders in 0° flexion, elbows in 60° flexion, and wrists in neutral position of flexion/extension
41281012|NCT04939493|OTHER|Conventional physical therapy program|Scapular mobilization. Thoracic spine mobilization. Mechanical assisted (active and passive) exercises. Therapeutic positioning as weight bearing on the paretic arm. Opening and closing closed fist. Strengthening exercise. Stretching of spastic muscles.
41281013|NCT04873687|DEVICE|External Counter Pulsation (ECP) therapy|ECP therapy consist of 36 session, each session @1 hour/day, five days a week with initial pressure of 300mmHg
41281014|NCT02617355|DEVICE|Prototype surgical magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
41281015|NCT02617355|DEVICE|Green Covidien Magnetic Drape|Green Covidien Magnetic Drape applied to the patient's thorax
41281016|NCT02617355|DEVICE|Jac-Cell Medic Reusable Magnetic Pad|Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
41450899|NCT00391365|PROCEDURE|Gait analysis|Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.
41450900|NCT05210647|DEVICE|robotic surgery|by da Vinci Xi
41450901|NCT04670107|DRUG|Anlotinib in combination with Immune checkpoint inhibitors|Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following instructions, iv.)
41450902|NCT06391372|DRUG|estriol cream|1 g intravaginal estriol via applicator twice a week before going to bed for 4 weeks
41450903|NCT05231603|DRUG|Ivermectin|0.4 mg/kg/day-maximum dose is 24 mg.
41450904|NCT05231603|OTHER|Placebo|Similar to drug in term of tablets
41450905|NCT01516762|DRUG|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
40939362|NCT06091787|DRUG|Ursodeoxycholic acid|Tablet Ursodeoxycholic acid 450mg per orally twice daily from Post operative day 1 to post operative day 10.
40939363|NCT06091787|OTHER|Standard Medical Treatment|Standard Medical Treatment
40939364|NCT04496310|PROCEDURE|Telemedicine|Telemedicine versus usual care (face to face visit)
40939365|NCT03503071|PROCEDURE|Cytoreductive surgery and intraperitoneal chemotherapy|Cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer or pseudomyxoma peritonei. Either early postoperative intraperitoneal chemotherapy (EPIC) or hyperthermic intraperitoneal chemotherapy (HIPEC) is used for intraperitoneal chemotherapy.
41131662|NCT01233934|DRUG|Dexchlorpheniramine 1% Cream|Small amount applied over the lesion twice a day for 7 days.
41131663|NCT03066609|DRUG|Secukinumab 150 mg s.c.|150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
41131664|NCT03066609|DRUG|Secukinumab 300 mg s.c.|300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
41131665|NCT03066609|DRUG|Placebo|Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
41131666|NCT03500549|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
41131667|NCT03500549|DRUG|Soliris|Complement (C5) Inhibitor
40939366|NCT06463574|OTHER|self-adhesive resin restoration|Light cured, hybrid resin composite material which contains polymerization modulator that lessens its degree of polymerization shrinkage
40939367|NCT06087003|DRUG|Basiliximab Injection|As an induction treatment for kidney transplantation
40939368|NCT06087003|DRUG|rabbit ATG|As an induction treatment for kidney transplantation
40939369|NCT06184399|DRUG|Ivermectin 1.5 mg ODT|Oro-dispersible tablets of 1.5 mg ivermectin
40939370|NCT06184399|DRUG|Ivermectin 3 mg Oral Tablet|Tablets of 3 mg ivermectin
40939371|NCT06184399|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
40939372|NCT06184399|DRUG|Placebo IVM ODT|Placebo for ivermectin ODT
40939373|NCT05455762|OTHER|Exercise|The intervention consists of 8 week of combined resistance and aerobic exercise. Patients will exercise 6 days a week;3 days aerobic ones and 3 days resistance ones. The aerobic exercise include 20 minutes of walking divided into three parts. In the first five minute the patients walks slowly to warm up, in the next 10 minutes the patient will speedup to reach the intensity described by the physiotherapist. In the last 5 minutes the patient walks like the first five minutes. The middle 10 minutes may be increased or not based on patient's weekly report. The resistance training consists of 5 exercise; hip abduction, shoulder abduction, bridging, elbow flexion and knee extension. each of these exercises is done in 3 set of 10 repetition with one minute break between each set. Based on patients' weekly report a 0.5 kilogram weight might be added.
40939374|NCT00775944|BEHAVIORAL|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
40939375|NCT00775944|BEHAVIORAL|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
40939376|NCT00775944|DRUG|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
40939377|NCT03287583|BEHAVIORAL|SBIRT for Gambing|The SBIRT intervention uses a brief gambling screening assessment to determine whether or not a participant is at risk for problem gambling. This is followed by a structured short brief intervention to assist people in better understanding their risk for gambling and what they can do to limit that risk.
40939378|NCT03287583|OTHER|Enhanced Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
40939379|NCT05061745|DEVICE|Guided Meditation VR for Wellness|"Selected Modules of Commercially Available Guided Meditation VR presented on Valve Index Headset"
40939380|NCT05061745|DEVICE|Accelerated Transcranial Magnetic Stimulation: Treatment A|Either MagVenture Transcranial Magnetic Stimulation (Treatment Coil Cool B70 AP) or The NeuroStar® System will be used.
41281017|NCT02617355|DEVICE|"DeRoyal Magnetic Pad size 20 x 16"|"Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax"
41281018|NCT02617355|DEVICE|"DeRoyal Magnetic Pad size 10 x 16"|"Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax"
41281019|NCT06392815|DIAGNOSTIC_TEST|Cu DOTATATE PET|The primary endpoint of the study is diagnostic performance for detecting LNB by 64Cu-DOTATATE-PET/CT/MRI measured as the difference in uptake between patients with definite LNB and patients without LNB. The primary read-out from 64Cu-DOTATATE-PET/CT/MRI is SUV in CNS and reference organs
40939381|NCT05061745|DEVICE|Accelerated Transcranial Magnetic Stimulation: Treatment B|Either MagVenture Transcranial Magnetic Stimulation (Cool D-B80 AP) or The NeuroStar® System will be used.
40939382|NCT05192915|DEVICE|Modular customized AFO|Walks better at self selected speed with a modular customized AFO than with a conventional AFO.
41131668|NCT05945316|BEHAVIORAL|Accessing Confidence levels of Nursing students|Three mock CODE BLUE training events for Spring, Summer, and Fall Nursing Residents and Nursing Fellows are scheduled for 2022 followed by an actively participated CODE BLUE event. The PI plan to collect data from all new residents meeting the inclusion/exclusion criteria with voluntary participation to complete.
41281020|NCT00125333|DRUG|NF-kappaB Decoy|
41281021|NCT05611138|DIETARY_SUPPLEMENT|Protein supplementation|Participants will be instructed to dissolve the protein powder in liquids (such as water) or on their food (e.g., yoghurt, oat porridge). A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge, where they will receive the daily protein portion as breakfast.
41281022|NCT04518371|OTHER|Reinforced composite for the fabrication of permanent, indirect restorations using a CAD/CAM grinding process.|Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments
40939383|NCT06025929|OTHER|Maitland's mobilization technique|Maitland's mobilization technique was performed on the patients with its all components, such as 1. Distraction 2. Anteroposterior glides 3. Posteroanterior glides 4. Medial glides and 5. Lateral glides.
40939384|NCT06025929|OTHER|Mulligan's mobilization techniques|Mulligan's mobilization technique was performed on the patients with its all components using a therapeutic belt, such as 1. Medial mobilization with movement (MWM) for Knee flexion 2. Medial mobilization with movement (MWM) for Knee extension 3. Lateral mobilization with movement (MWM) for Knee flexion 4. Lateral mobilization with movement (MWM) for Knee extension.
40939385|NCT06025929|OTHER|Interferential Therapy (IFT)|Interferential Therapy was performed on the patients with the following parameters: career frequency 4000Hz; waveform: rectangular; sweep time: 1 second rise and fall and 5 second stay; Treatment duration: 10 minutes; sweep frequency: 10 to 130 Hz. The current intensity was adjusted until the subject reported feeling a strong tingling sensation without causing muscle contraction. A aquatic gel was applied before straping the electopads over treatment area for smooth electrical conduction.
40939386|NCT06169631|DEVICE|Gen0b|The ultrasound will be administered to the brain region of interest.
41131669|NCT00866619|BIOLOGICAL|Malaria Vaccine 257049|administered intramuscularly into the left deltoid.
41131670|NCT00866619|BIOLOGICAL|Meningococcal C Conjugate Vaccine|administered intramuscularly into the left deltoid.
41131671|NCT00866619|BIOLOGICAL|Cell-culture rabies vaccine|administered intramuscularly into the left deltoid.
41131672|NCT00866619|BIOLOGICAL|TritanrixHepB/Hib|administered intramuscularly into the left deltoid.
40939387|NCT04520373|OTHER|Best Medical Management: Occupational and Physical Therapy|Observation while undergoing Occupational and Physical Therapy for 6 months
40939388|NCT04520373|BIOLOGICAL|Autologous, Adipose Derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.
40939389|NCT06484673|DRUG|Bosentan Dispersible Tablets|1 tablet of 32 mg Bosentan
40939390|NCT06484673|DRUG|Tracleer Tablet for Oral Suspension|1 tablet of 32 mg Bosentan
40939391|NCT00002585|DRUG|pyrazoloacridine|
40939392|NCT01765660|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
40939393|NCT01765660|BIOLOGICAL|Non-mesenchymal stem cells|Other second line drugs are taken.
40939394|NCT01041729|DRUG|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
40939395|NCT01041729|DRUG|Standard Medical Treatment|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment."
41281023|NCT05627466|DRUG|Magrolimab|Administered intravenously
41281024|NCT02418494|OTHER|Concept Elicitation|Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
41281025|NCT02418494|OTHER|Comprehension Assessment|Comprehension assessment of draft quality of life assessment
41281026|NCT06545604|OTHER|Yoga Therapy for Nutritional, Physical, and Psychosocial Prehabilitation|Usual care supportive services including nutrition counseling per usual care
41281027|NCT02582515|DRUG|D-cycloserine|
41281028|NCT02582515|DRUG|Placebo|
40939396|NCT05010408|OTHER|Flavored carbonated soft drink (CSD) at different sweetness levels|Beverage
41131673|NCT00866619|BIOLOGICAL|Polio Sabin Oral Polio Vaccine (GSK)|administered orally.
41131674|NCT02871661|DRUG|Amitriptyline|Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
41131675|NCT02871661|OTHER|Kinesiotherapy|Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
41131676|NCT02871661|DEVICE|IC (Quark)|Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
41281029|NCT03473873|OTHER|Measures of muscle function|The participants will be assessed with various measures of muscle function at baseline and at follow up including: Isokinetic knee muscle strength, Isometric strength of trunk and lower extremity, single-leg hop for distance (SLHD), side hop, postural orientation errors (single leg-squat, stair descending, forward lunge, SLHD), hip and ankle range of motion, and muscular activation patterns.
41281030|NCT04903860|DEVICE|total hip replacement with single use ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
41281031|NCT04903860|DEVICE|total hip replacement with conventional ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
41281032|NCT05980026|DRUG|oral omega-3 fatty acids supplementation|oral omega-3 fatty acids supplementation
41281033|NCT05980026|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.
40939397|NCT04396496|DRUG|Daratumumab Injection|"DARA is a human monoclonal antibody that specifically recognizes the CD38 molecule that is expressed at a high level in a variety of hematological malignancies, including myeloma cells.~DARA injection will be given with oral lenalidomide for up to 12 four week cycles."
40939398|NCT03206255|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
40939399|NCT03206255|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
40939400|NCT02707809|DRUG|Dexmedetomidine|Dexmedetomidine infusion
40939401|NCT01954732|DRUG|metformin hydrochloride|Given PO
40939402|NCT01954732|OTHER|pharmacological study|Correlative studies
40939403|NCT05573386|DRUG|Filgrastim|human granulocyte colony-stimulating factor (G-CSF) protein obtained from the bacterial fermentation of a strain of E. coli. transformed with a genetically engineered plasmid containing the human G-CSF gene; administered via syringe
40939404|NCT05573386|DRUG|Pegfilgrastim|long-acting covalent conjugate of recombinant methionyl human filgrastim and monomethoxypolyethylene glycol (PEG); administered via syringe
40939405|NCT05515471|DRUG|SHR8058 eye drops|SHR8058 eye drops
40939406|NCT05515471|DRUG|saline eye drops.|saline eye drops.
40939407|NCT00573196|RADIATION|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
41281034|NCT04756934|DRUG|HX008|HX008: 200mg, Q3W
41281035|NCT04756934|DRUG|LP002|LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W
41281036|NCT00964418|DRUG|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
41281037|NCT00964418|DRUG|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
40756388|NCT03139253|DRUG|tetracycline|tetracycline 750 mg bid. for 14 days.
41281038|NCT03240640|PROCEDURE|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
40939408|NCT03265327|DIETARY_SUPPLEMENT|Oral supplement containing omega-3 and omega-6|An oral supplement containing omega-3 and omega-6
41281039|NCT03240640|PROCEDURE|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
40756389|NCT03139253|DRUG|Ilaprazole|Ilaprazole 5 mg bid. for 14 days.
40756390|NCT00653705|OTHER|Yogurt drink with probiotic bacteria BB12|Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
40756391|NCT00653705|OTHER|Placebo|Vanilla flavored dairy drink. One bottle a day for 16 weeks.
40939409|NCT03265327|DIETARY_SUPPLEMENT|Oral supplement containing coconut and olive oil|An oral supplement containing coconut oil and olive oil
40939410|NCT05937074|OTHER|Weight loss (%)|Change in body weight from cancer diagnosis to study enrollment
40939411|NCT04927000|DRUG|Tofacitinib|in tofacitinib treatment group，we added tofacitinib 5mg/BID in the basic treatment in all subjects.
40939412|NCT05766254|DEVICE|Active 10-Hz TMS to the DLPFC|The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
41131677|NCT03188341|OTHER|vascular surgery procedure|"* an elective open vascular surgery procedure~* ECG Holter recording during the procedure and 24 hours after operation (continuous electrocardiographic tracing (digital Holter ECG monitor)"
41131678|NCT00557284|DRUG|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
40756392|NCT02442531|DRUG|CriPec® docetaxel|-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
40756393|NCT03191734|DEVICE|AQUABEAM System|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
40939413|NCT05766254|DEVICE|Sham TMS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
40939414|NCT00446589|DRUG|ibandronate|iv 1mg ibandronate monthly for one year
40939415|NCT00446589|DRUG|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
40939416|NCT03385083|BEHAVIORAL|Step count monitoring with consulting|Subject counseled on step counts at initial visit and 2 and 4 weeks
40939417|NCT03385083|BEHAVIORAL|Step count monitoring without consultation|Subject counseled on step counts at initial visit
40939418|NCT03385083|DEVICE|Fitbit tracker|Fitbit tracker given to participant
41131679|NCT00557284|DRUG|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
41131680|NCT01180231|DRUG|Moxonidine (Physiotens)|Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
41131681|NCT01180231|OTHER|Dietary intervention|Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
41131682|NCT05656066|BEHAVIORAL|The Vibration Intervention|The vibration frequency of the massager, which accelerates blood circulation, is 6000 / min, it works with a 1.5 volt battery. Can be used easily with one hand. The vibration simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
41131683|NCT05656066|BEHAVIORAL|The Pressure Intervention|Pressure was placed in the ıntramuscular area properly 30 seconds before injection. Then the injection process was completed.
41131684|NCT04714346|OTHER|no interventions|there is no intervention
41131685|NCT02927249|OTHER|Placebo|Given PO
41131686|NCT02927249|DRUG|Aspirin|Given PO
41131687|NCT02113267|DRUG|Mometasone furoate|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
40939419|NCT05622370|DRUG|Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)|"Brivaracetam tablets (trade name: Briviact) Specification: 50mg/ piece Batch number: 34244 Content: 100.0% Date of purchase: September 2022~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.~Expiry date: April 2025 Storage conditions: sealed, stored at 20-25℃, allowing short-term temperature deviation of 15-30℃ Manufacturer: Union Chimique Belge Pharm, UCB Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd."
40939420|NCT05622370|DRUG|Brivaracetam sustained-release tablets 100mg|"Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
41131688|NCT02113267|DRUG|Placebo|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
41131689|NCT02930954|DRUG|Gefitinib|Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
41131690|NCT02930954|DRUG|pemetrexed or gemcitabine plus carboplatin,|doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks
41131691|NCT02930954|DRUG|bevacizumab|bevacizumab 7.5mg/kg intravenously per 3 weeks
41131692|NCT06159959|DRUG|Carbetocin|To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.
41131693|NCT02198300|PROCEDURE|Coronary angioplasty with stent implantation|
41131694|NCT02198300|DRUG|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
41131695|NCT01190852|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
41131696|NCT01190852|DRUG|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
41131697|NCT01190852|DRUG|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
41131698|NCT03454256|DEVICE|Virtual Reality|Virtual Reality Rehabilitation System
41131699|NCT00562094|DRUG|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
41131700|NCT02593760|OTHER|Placebo|Placebo will be administered PO QD for up to 48 weeks.
41131701|NCT02593760|DRUG|Ruxolitinib|Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
41281040|NCT03451448|DIAGNOSTIC_TEST|PET/MRI|PET/MRI with USPIO contrast
41131702|NCT02593760|DRUG|Vismodegib|Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
41131703|NCT01298076|DRUG|bevacizumab|Anti-VEGF drug for intravitreal injection
41131704|NCT01298076|DRUG|dexamethasone|Slow-release steroid formulation for intravitreal injection
41131705|NCT05946213|RADIATION|External Beam Radiation Therapy|Undergo EBRT
41131706|NCT05946213|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41131707|NCT02432300|BEHAVIORAL|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
41131708|NCT00857766|DRUG|ADVAIR DISKUS™ 250/50mcg|ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
41131709|NCT00857766|OTHER|Placebo|COPD subjects-Placebo DISKUS
41131710|NCT02680262|BEHAVIORAL|HPV self-sampling kit mailed directly|Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.
41131711|NCT02680262|BEHAVIORAL|HPV self-sampling kit on demand|"Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.~The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure)."
41131712|NCT02680262|BEHAVIORAL|Second reminder|The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
41131713|NCT06135220|DIAGNOSTIC_TEST|New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.|The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.
41281041|NCT03451448|DIAGNOSTIC_TEST|MRI|MRI with USPIO contrast
41281042|NCT03815175|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
40939421|NCT05622370|DRUG|Brivaracetam sustained-release tablets 50mg|"Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
40939422|NCT04298372|DRUG|Lenalidomide 25mg|"As single arm study, patients will be treated as follows:~* Lenalidomide : D1\~D21 daily oral administration, starting dose 15mg, with an increase of 5mg every cycle, if tolerated, up to 25mg.~* Dexamethasone : D1\~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old) Patients will be treated every 4 weeks as one cycle, and up to 12 cycles of treatment will be conducted."
40939423|NCT04913766|BEHAVIORAL|Problem Management Plus|Five session psychological intervention focusing on problem management skills.
40939424|NCT04913766|BEHAVIORAL|Services as Usual|Mental health services provided by a mental health specialists according to their standard practices of care
40939425|NCT01111409|DEVICE|VFIX Device|Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor
40939426|NCT01678027|DRUG|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
40939427|NCT01678027|DRUG|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
40939428|NCT04466228|DEVICE|non-invasive transcranial electrical stimulation|Non-invasive transcranial electrical stimulation across the prefrontal cortex.
40939429|NCT03396393|DRUG|Dihydroartemisinin tablet|DHA tablet
40939430|NCT03396393|DRUG|Placebo tablet|Placebo tablet
40939431|NCT03246984|DEVICE|VasQ|VasQ device implantation in patients with a new brachiocephalic or radiocephalic fistula creation.
40939432|NCT00405327|BIOLOGICAL|Tumor lysate-pulsed dendritic cell (DC) vaccine|Tumor lysate-pulsed dendritic cell vaccine
40939433|NCT00405327|OTHER|Hematopoietic stem cell transplantation (HSCT)|Hematopoietic stem cell transplantation (HSCT)
41131714|NCT02115659|DRUG|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
41131715|NCT02115659|DRUG|Placebo|Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
41131716|NCT05679479|BIOLOGICAL|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
41131717|NCT05679479|OTHER|Normal saline|0.9% normal saline
41131718|NCT00086359|DRUG|Abacavir sulfate, lamivudine, and zidovudine|one pill twice daily
41131719|NCT00086359|DRUG|Lamivudine/zidovudine|one pill twice daily
41131720|NCT00086359|DRUG|Lopinavir/ritonavir|four pills twice daily
41131721|NCT04063124|DRUG|Dasatinib + Quercetin|Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
41131722|NCT05803109|OTHER|AVIVA-PURE-CocoPull-Organic-made in USA|virgin cold pressed coconut oil with Peppermint essential oil
41281043|NCT03815175|DRUG|DAPT (aspirin and/or P2Y12 receptor inhibitor)|"1-month clear subjects (pooled from Xience 28 USA study and Xience 28 Global study) will receive 1 month of DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days and will discontinue P2Y12 receptor inhibitor as early as 28 days and will continue with aspirin monotherapy through 12-month follow-up."
40939434|NCT02133521|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
40939435|NCT02133521|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
40939436|NCT00844818|BEHAVIORAL|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
40939437|NCT01309308|PROCEDURE|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
40939438|NCT01309308|OTHER|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
40939439|NCT03052764|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injection into the bladder.
40939440|NCT03052764|DRUG|Placebo (saline)|Placebo (saline) injection into the bladder.
40939441|NCT05447039|DRUG|Montelukast Sodium Tablets|intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days
41131723|NCT01054287|OTHER|Multifactorial falls prevention program|
41131724|NCT01054287|OTHER|No falls prevention intervention|
41131725|NCT03760653|OTHER|Physical Exercise and probiotic group|The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of \~ 60 min duration (aerobic and strength combined training). The exercise sessions will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a authorized fitness center and it will be supervised and individualized for each subject by expert professionals.The probiotic will be taken (3 capsules/day) for 12 weeks. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
41281044|NCT05877677|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
41281045|NCT05877677|DIETARY_SUPPLEMENT|Polygonatum kingianum extract drink|consume 1 bottle per day
40939442|NCT01600807|DRUG|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
40939443|NCT01600807|DRUG|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
40939444|NCT03609151|PROCEDURE|laparoscopic hepatectomy (surgery)|Patients receive laparoscopic hepatectomy.
40939445|NCT03609151|RADIATION|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy(SBRT)
41281046|NCT01898663|BIOLOGICAL|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DC vaccine plus CIK cells
40939446|NCT06135415|DRUG|Tirbanibulin|Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.
41281047|NCT04960891|DRUG|Tebentafusp|Concentrate solution for intravenous infusion
41281048|NCT00548912|DRUG|Spironolactone|
41453623|NCT06089395|DRUG|Jiajian Guishen granules|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
40939447|NCT06135415|OTHER|Vehicle ointment|Participants will apply vehicle ointment topically on the face or balding scalp with AK.
40939448|NCT03535376|DRUG|Valsartan|Patients are tested for their normal prescription valsartan medication
40939449|NCT00925990|DRUG|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
40939450|NCT00925990|DRUG|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
40939451|NCT00925990|DRUG|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
40939452|NCT04194346|PROCEDURE|Lung ultrasound|Healthy volunteers will have lung ultrasonography at 15 predetermined sites for a common volume continuum between 5 and 15 cc/kg. For each volume, 3 respiratory cycles will be recorded.
40939453|NCT05500547|OTHER|"US Public Health Service USPSH criteria for assessment of success of resin composite restorations"|"US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months."
41281049|NCT01152099|OTHER|Compression Bandaging|"Group A or Control Group: ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
41281050|NCT01152099|OTHER|Manual Lymph Drainage (MLD) and Compression Bandaging|"Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
41281051|NCT05334979|OTHER|Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic|"Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic~Subjects in both arms will be asked to partake in the same activities, as follows: The day before presenting to the research clinic subjects will collect urine at home. Subjects will will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains oxalate, and they will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect urine and blood throughout the day. While at the clinic, subjects will also receive specially prepared snacks."
41281052|NCT01261676|OTHER|Implementation aids|An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)
41281053|NCT04947137|DRUG|Tc99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
41281054|NCT03180996|DEVICE|Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System|Fenestrated Endovascular Aortic Repair (FEVAR)
41281055|NCT00683943|DRUG|Lithium Carbonate|
41450906|NCT05366582|DEVICE|Macintosh Laryngoscope|"After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal carbon dioxide (CO2). Failed intubation will be considered if not achieved within 2 minutes"
40939454|NCT00586846|DRUG|Cisplatin|Cisplatin 120 mg/m\^2
40939455|NCT00586846|DRUG|Doxorubicin|75mg/m\^2
40939456|NCT00586846|DRUG|Methotrexate|Methotrexate 12g/m\^2
40939457|NCT04376177|DIAGNOSTIC_TEST|Ultrasound|Echodoppler imaging of upper limbs performed by trained operators at rest and during provocative maneuvers for TOS diagnosis.
40939458|NCT04376177|DIAGNOSTIC_TEST|angiography|Angiography (arterial and/or venous) of upper limbs performed by trained operators at rest and during provocative maneuvers such for TOS diagnosis.
40939459|NCT04376177|DIAGNOSTIC_TEST|questionnaires|Use of standard questionnaires (MASC, DASH, SF36) for the evaluation of upper limb symptoms self-completed by the patients at admission.
40939460|NCT04376177|DIAGNOSTIC_TEST|Transcutaneous oximetry|Mesurement of transcutaneuos oxygen pressure on both forearms performed at rest and during provocative maneuversfor TOS diagnosis.
40939461|NCT04376177|DIAGNOSTIC_TEST|plethysmography|Photoplethysmography of the forearms or fingers performed at rest and during provocative maneuvers for TOS diagnosis
40939462|NCT04376177|DIAGNOSTIC_TEST|Electromyogram|Electromyography of the upper limbs with encoding of the physician for the presence or abnsence of signs of plexis compression (impairment of the response on C8 T1 erea
41131726|NCT03760653|DIETARY_SUPPLEMENT|Probiotic group|Probiotic supplementation (3 capsules/day) will be taken before bedtime for 12 weeks.Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
41131727|NCT03760653|DIETARY_SUPPLEMENT|Placebo group|Subjects will take 3 capsules/day of placebo capsules (maltodextrin) for 12 weeks
41131728|NCT06137898|BIOLOGICAL|biological check-up|Blood sampling
41131729|NCT04886466|PROCEDURE|core stability in a sitting position and while walking in one place|The intervention consisted of checking how the active tension of the multisection and transverse abdominal muscles affects the pattern of the trunk movement (in the sitting position) and the work of the lower limbs and the speed of movement while walking in a place.
41131730|NCT00077935|DRUG|Civamide|Cream 0.075%, TID for 52 weeks
41281056|NCT05006612|PROCEDURE|Serratus Anterior Plane Block|"SAPB Technique; U/S probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, Then, using U/S guidance, A 38-mm 22-gauge regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid IV injection 30ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle.~SAPB combined with Modified Pectoral Nerve Block :~SAPB with injection of 20 ml levobupivacaine 0.25% as discussed before. Modified Pectoral Nerve Block:After identification of the axillary vessels, the U/S probe will turned inferolaterally till the serratus anterior and the two pectoralis muscles are detected in one plane. 10 ml of levobupivacaine 0.25%was injected between the two pectoralis muscles. After that,10 mL of levobupivacaine 0.25%is injected above this muscle."
41281057|NCT01093495|DEVICE|CPAP|CPAP
41281058|NCT01093495|DEVICE|Nasal Cannula|Nasal Cannula
41281059|NCT05418712|DRUG|Placebo|Placebo matched to VX-150 for oral administration.
41281060|NCT05418712|DRUG|VX-150|Solution or Suspension for oral administration.
41450907|NCT05366582|DEVICE|Video Laryngoscope|"After the induction, laryngoscopy will be performed with a Video laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2. Failed intubation will be considered if not achieved within 2 minutes"
41450908|NCT06626672|BEHAVIORAL|Digital Health Intervention|Access to a digital platform including weekly workout videos, live workouts, recipes, study summaries, and a consultation hour.
40939463|NCT04376177|DIAGNOSTIC_TEST|Standard X-Ray|Standard X-Ray performed for the research of apophysomegaly or additionnal cervical rib.
41453624|NCT06089395|DRUG|coenzyme Q10|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
41453625|NCT00147563|DRUG|Eplerenone|
40939464|NCT01178073|DRUG|ambrisentan|ambrisentan (target dose: 10mg)
40939465|NCT01178073|DRUG|tadalafil|tadalafil (target dose: 40mg)
40939466|NCT00963677|PROCEDURE|Nasotracheal Intubation through seeing optical stylet (SOS)|Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
40939467|NCT01982058|OTHER|communication intervention|
40939468|NCT01982058|OTHER|counseling intervention|
40939469|NCT01982058|OTHER|nutrition intervention|
40939470|NCT01982058|OTHER|questionnaire administration|
40939471|NCT01388920|DRUG|Tesamorelin|
40939472|NCT01388920|DRUG|Placebo|
40939473|NCT06156124|DIAGNOSTIC_TEST|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning of adolescents (including occurrence of internalizing and externalizing problems, coping with adolescent crisis), family functioning (siblings relations, parental attitudes, parentification), functioning at school (school achievement, extracurricular activities), relations with peers (time spending with peers, number of friends, quality of relations). Further, the sociodemographic variables will be also measured.
40939474|NCT02616432|DEVICE|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
40939475|NCT00930982|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
40939476|NCT00930982|DRUG|Placebo|Inhalation of matching placebo twice a day
40939477|NCT03381573|DRUG|Roflumilast|Roflumilast
40939478|NCT01741012|DRUG|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
40939479|NCT00410228|DRUG|AHT956|
40939480|NCT03640767|BEHAVIORAL|Message-based lifestyle intervention|Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160. Both intervention and control groups will receive face-to-face lifestyle adherence counseling and booklets at baseline. The intervention group will receive 4 mobile phone messages per week for 24 weeks. The messages are motivational advice to support lifestyle behavioral modification in various stages of behavioral changes.
40939481|NCT05553951|BEHAVIORAL|Controlgroup|The control group and intervention group will receive daily text message reminders twice a week to take their medications and to rinse their nose.
40939482|NCT05553951|BEHAVIORAL|Intervention|Patients in the intervention group will receive systematic and structured nursing guidance regarding their adherence, which includes proper use of nasal irrigation once or twice daily, nasal steroid/drops, use of inhaled medications, follow-up of smoking status. The intervention group will receive guidance videos which have been prepared prior to the study and will be standard for the intervention group. Guidance videos will cover the correct use of nasal irrigation, inhalation steroid, and nasal steroid/drops.
40939483|NCT04838392|DEVICE|RIGHTEST Continuous Glucose Monitoring System|RIGHTEST Continuous Glucose Monitoring System
40939484|NCT05537090|DRUG|BV100|Rifabutin for Infusion
40939485|NCT05537090|DRUG|Midazolam|Syrup for oral administration
40939486|NCT02525315|DEVICE|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
40939487|NCT05305027|BEHAVIORAL|Prompt diagnois pregnancy outcome|
40939488|NCT01194427|DRUG|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
40939489|NCT02291536|DRUG|tetrahydrocannabinol|
40939490|NCT02291536|DRUG|cannabidiol|
40939491|NCT02291536|OTHER|placebo|
40939492|NCT00691067|DRUG|mifepristone|200 mg po per day x 6 weeks
40939493|NCT00691067|DRUG|Placebos|placebo
40939494|NCT00662220|DRUG|ribavirin|25-29 mg/kg/day
40939495|NCT00662220|DRUG|ribavirin|12-15 mg/kg/day
40939496|NCT05610085|DRUG|Levetiracetam Injection|Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital
40939497|NCT05610085|DRUG|Phenobarbital Sodium Injection|Standard of care for neonatal seizures
40939498|NCT05572190|DRUG|ETR028, ETR029, [ETR028 + ETR029] or HCBT|Hydrocodone prodrugs
40939499|NCT01570868|DRUG|Ponatinib|Starting dose: 45 mg by mouth once daily.
41131731|NCT02760654|DEVICE|Proactive Self Management Program for Effects of Cancer Treatment|
40744357|NCT01196611|BEHAVIORAL|Function Voice Exercises|Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
40744358|NCT00128427|DRUG|Colchicine (for 1 month)|
40939500|NCT01063712|DEVICE|Nit-Occlud® PDA-R|"Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.~The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure."
40939501|NCT02462174|DRUG|Ketamine|0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
40939502|NCT02462174|DRUG|Ketamine|0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
40939503|NCT02462174|DRUG|Bupivacaine|1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
40939504|NCT02462174|DRUG|Bupivacaine|0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
40939505|NCT00953381|DRUG|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
40939506|NCT00953381|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
40939507|NCT00953381|DRUG|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
40939508|NCT00953381|DRUG|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
40939509|NCT05400915|DRUG|Variltinib, Paclitaxel|Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest period of 1 week.
40939510|NCT03654027|DRUG|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
40939511|NCT03654027|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1)
40939512|NCT00048451|DRUG|paricalcitol|
41281061|NCT05194319|OTHER|All assessments of children (Demographic information, upper extremity skills, quality of life and participation levels)|The researcher will fill out the personal information form containing the descriptive characteristics of the parents and children. GMFCS to assess children's functional levels, Manual Ability Classification System (MACS) to assess hand skills, Modified Ashworth Scale for upper extremity muscle spasticity, for upper extremity functional skills; Jebson Taylor Test, Abilhand Kids scale, for Quality of Life; The Quality of Life Scale for Children (PedsQL), PODCI criterion for participation levels will be administered by a physiotherapist who has 2 years of experience in the profession and works in the field of pediatric rehabilitation. The Jebson Taylor test and spasticity classification will be applied directly to the child by the physiotherapist, but other scales will be filled in by the parents under the supervision of the physiotherapist. .
40939513|NCT02908893|BEHAVIORAL|In-app and push notification mobile messages|Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
41281062|NCT06489418|OTHER|Dew Restore Barrier Repair Cream|"Wash the face with the gentle cleanser to remove dirt, and oil and pat dry with the towel\| tissue paper. Afterwards take the pea side amount of the test product you finger tips, apply it over the face by small dotes and massage it in circular motion until it absorbed.~Frequency: Twice a Day Route of Administration: Topical"
41281063|NCT03578406|DRUG|HPV E6-specific TCR-T cells|Patients were infused with HPV E6-specific TCR-T cells
41281064|NCT04438421|DRUG|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
41281065|NCT04438421|DRUG|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.2%mouthwash, as an active comparator, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
41281066|NCT04438421|DRUG|Placebo|Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
41281067|NCT04885738|OTHER|no intervention|"For Chronic Cough，follow《Guidelines for the diagnosis and treatment of cough》(2015).~For Asthma, follow GINA For COPD, follow GOLD."
41281068|NCT06229509|DEVICE|Effective noninvasive ventilation|Noninvasive ventilation set to alleviate dyspnea Inspiratory aid set according to a preliminary test (aiming for a diminution of 2 points in Borg score)
41281069|NCT06229509|DEVICE|Sham noninvasive ventilation|Noninvasive ventilation set with an insufficient inspiratory aid to alleviate dyspnea
41281070|NCT01773824|BEHAVIORAL|Antibiotic prescription feedback|Monthly postal and electronic feedback on antibiotic prescription rates
41281071|NCT01773824|BEHAVIORAL|No Feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
41281072|NCT05918887|DEVICE|NJOY ACE commercial e-cigarette|"The NJOY ACE is the commercial version of the Standardized Research E-Cigarette (SREC), which was developed by NIDA with NJOY for research purposes.~Nicotine pods:~* Sealed, pre-filled, non-refillable~* 1.9 mL e-liquid with 5% w/w nicotine~* Approx 300 (280-330) puffs/pod~Nicotine liquid characteristics:~* Volume of liquid per pod 1.9 mL~* Active (nicotine USP 5% wt/wt)~* Propylene Glycol USP \& Vegetable Glycerin USP - PG/VG Ratio 0.77~* Lactic Acid USP~Battery characteristics:~* USB Rechargeable~* Storage Capacity \~ 400 mAh~* Approx 200 (3s) puffs / charge~* 300 charge cycles to \> 80% initial capacity~* Time to full charge 75 - 85 min~* Voltage / Temperature settings not user adjustable"
41281073|NCT05343195|OTHER|Task-oriented exercise|Task-oriented exercise program for patients after total hip replacement.
41281074|NCT05343195|OTHER|Control|Control intervention: conventional physiotherapy after hip replacement
41450909|NCT05757830|DEVICE|UANGO suite exoskeleton|"Each subject will perform 3 experimental conditions (Condition 1: Walking without exoskeleton; Condition 2: Walking with exoskeleton; Condition 3: Walking with exoskeleton and walker).~Each condition includes 5 triasl (Trial 1 - Sitting: 5 minutes, sitting at rest in comfortable position; Trial 2 - Standing: 5 minutes, with assistance; Trial 3 - Comfortable speed Walking (100% assisted): 4 min during back-and-forth locomotion on a 20-m length linear flat path; Trial 4 - Comfortable speed Walking (75% assistance): 4 min during back-and-forth locomotion on a 20-m length linear flat path, Trial 4 is not available in condition 1; Trial 5 - 1 minute Sit to stand test). Nasa TLX and RPE will be requested at the end of each trial. Usability questionnaires will be fullfilled at the end of condition 2 and condition 3."
41450910|NCT04863560|OTHER|Auditory Cueing|Metronome beat to step in time with
41450911|NCT04863560|OTHER|Visual Cueing|Lines on the floor to step over
41450912|NCT04863560|OTHER|tactile Cueing|Vibration to step in time with (metronome like)
41450913|NCT03860987|DRUG|goserelin|Goserelin will be administered SC at 10.8 mg every 12 weeks
40939514|NCT04545359|BEHAVIORAL|Alpha-based neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
40744359|NCT04905290|DEVICE|Left ventricular coronary sinus configuration|For subjects with a pacemaker, pacing of the left ventricular coronary sinus only. For subjects with a defibrillator, biventricular pacing of the left ventricular coronary sinus and the right ventricle.
40744360|NCT04905290|DEVICE|Conduction system pacing-only configuration|Conduction system pacing (CSP) of the left bundle branch.
40939515|NCT04545359|BEHAVIORAL|Sham neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
40939516|NCT05670353|DRUG|Cannabis Derivatives|CBD 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
41450914|NCT03860987|DRUG|Enzalutamide|Enzalutamide will be given orally at 160mg once daily
41450915|NCT03860987|DRUG|Abiraterone|Abiraterone will be taken orally at 1000 mg once daily
41450916|NCT03860987|DRUG|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
41450917|NCT03860987|DRUG|Prednisone|Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart
40939517|NCT05670353|DRUG|Placebo|Placebo 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
41450918|NCT03860987|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy
41450919|NCT00506831|DRUG|Imatinib mesylate|100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
41450920|NCT06307288|DRUG|minocycline|The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.
41450921|NCT06307288|DRUG|tranilast|The patient was treated with oral tranilast, 0.1g each time, three times a day, for 12 weeks.
41453626|NCT03967262|BEHAVIORAL|Brief Motivational Intervention|The objective of motivational intervention is to make the patient aware of the relationship between the consumption of alcohol and other drugs and the accident, and induce them to carry out a change in habits.
41453627|NCT00109057|DRUG|Avastin (bevacizumab)|
40939518|NCT05670353|DRUG|Hormonal Contraceptive Agents|All participants will be given hormonal contraceptive.
40939519|NCT02701920|DEVICE|HeartLight hat|HeartLight hat will be worn for up to 1 hour.
40939520|NCT02701920|DEVICE|The HeartLight hat with in-built sensor|The HeartLight hat with in-built sensor will be worn.
40939521|NCT02701920|DEVICE|HeartLight|Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat
40939522|NCT02701920|DEVICE|HeartLight device|HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope
40939523|NCT02701920|OTHER|parental feedback|Questionnaire
40939524|NCT02701920|OTHER|healthcare provider feedback|Questionnaire
40939525|NCT05958732|OTHER|Somato-sensorial exercises therapy|It includes exercises, which is already mentioned in the arm description.
41131732|NCT03335488|DRUG|RAVICTI|RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose
41131733|NCT03335488|DRUG|NaPBA|"* NaPBA in patients weighing \< 20 Kg - 600 mg/Kg, maximum total daily dose~* NaPBA in patients weighing \> 20 Kg - 13 g/m2, maximum total daily dose"
41131734|NCT01905800|DEVICE|Biaxial rotational chair|This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
41131735|NCT01178372|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
40939526|NCT05958732|OTHER|Conventional Therapy|It Includes routine exercises for the stroke patient the detail is already given in the arm description.
41131736|NCT01178372|DRUG|Probiotics(VSL#3)|will receive VSL#3 (110 billion CFU)three times a day
41131737|NCT04758949|DRUG|FL-101|200 mg administered intravenously every 2 weeks prior to surgery.
41131738|NCT04758949|DRUG|Nivolumab|240 mg administered intravenously every 2 weeks prior to surgery.
41131739|NCT04758949|DRUG|Placebo|200 mg administered intravenously every 2 weeks prior to surgery.
41131740|NCT04767815|DRUG|Diet A group|Fasting + DWN12088 200 mg
41131741|NCT04767815|DRUG|Diet B group|30 minutes after a high-fat meal + DWN12088 200 mg
41131742|NCT04767815|DRUG|Diet C group|2 hours after a high-fat meal + DWN12088 200 mg
41131743|NCT03855293|PROCEDURE|Rhexis protection shield|In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation
41131744|NCT03569774|PROCEDURE|One-lung ventilation with individualized PEEP|During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
41131745|NCT03569774|PROCEDURE|One-lung ventilation with low PEEP|Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
41131746|NCT01575015|DEVICE|Continuous renal replacement therapy (CRRT)|Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
41131747|NCT01575015|PROCEDURE|Standard intraoperative support|Patients allocated to standard intraoperative support will receive usual care (no CRRT).
41131748|NCT04863339|DRUG|Tranexamic acid|Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.
41131749|NCT04863339|DRUG|Placebo|Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
41131750|NCT00918333|DRUG|panobinostat|Given PO
41131751|NCT00918333|DRUG|everolimus|Given PO
41131752|NCT00918333|OTHER|laboratory biomarker analysis|Correlative studies
41131753|NCT00918333|OTHER|pharmacological study|Correlative studies
41131754|NCT00849238|DRUG|mycophenolate mofetil|
41131755|NCT03440086|DEVICE|abdominal Jackson-Pratt drain|One-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
41131756|NCT01970007|DEVICE|Zilver Vena Venous Self-Expanding Stent|stenting
41131757|NCT03516032|BEHAVIORAL|exercises|
41131758|NCT01493882|DRUG|Placebo|Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
41131759|NCT01493882|DRUG|JNJ-39758979 30 mg/d|Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
41131760|NCT01493882|DRUG|JNJ-39758979 100 mg/d|Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
41131761|NCT01493882|DRUG|JNJ-39758979 300 mg/d|Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
41131762|NCT00385606|DRUG|gemcitabine|
41131763|NCT00385606|DRUG|prolonged continuous infusion gemcitabine|
41131764|NCT00385606|DRUG|cisplatin|
40939527|NCT02793193|DIETARY_SUPPLEMENT|Probiotic|Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
40939528|NCT02793193|DIETARY_SUPPLEMENT|Placebo for antibiotic|The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
40939529|NCT02793193|DRUG|Antibiotic|Antibiotic Xifaxan ® will be 200mg per tablet
40939530|NCT02793193|DIETARY_SUPPLEMENT|Placebo for probiotic|The placebo identical-looking to the probiotic B.longum 1714
40939531|NCT01732003|DIETARY_SUPPLEMENT|Omega-3 Complete|
40939532|NCT01732003|DIETARY_SUPPLEMENT|Placebo Pill|
40939533|NCT00413166|DRUG|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
40939534|NCT00413166|DRUG|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
41281075|NCT06056284|BEHAVIORAL|Progressive relaxation exercises and sleep hygiene training|Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the patients in the experimental group in the first week of the 7-week study. Data will be collected by face-to-face interviews with the patients. After seven weeks, an appointment will be given for the post-test. In the second week, those in the experimental group will be taught progressive relaxation exercise using a compact disc (CD) prepared by the Turkish Psychological Association in the hospital and after the sleep hygiene training, progressive relaxation exercise brochure and sleep hygiene training brochure will be distributed. Starting from the second week, the individuals in the experimental group will be expected to apply the trainings given in the hospital accompanied by the researcher two days a week for six weeks and to apply the trainings given to the individuals at home on the other days of the week.
41281076|NCT01719757|DRUG|Oxycodone/Naloxone|Twice daily
41281077|NCT02081963|DRUG|Amikacin|Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
40939535|NCT00413166|DRUG|Idarubicin|"1. 12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~2. If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date."
40939536|NCT00413166|DRUG|Gemtuzumab Ozogamicin|Induction: 9 mg/m2 on day 1 of induction
40939537|NCT01257802|DRUG|depot leuprolide acetate 3.75 mg|Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
40939538|NCT01257802|DRUG|Placebo|Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
40939539|NCT05151601|DIETARY_SUPPLEMENT|Experimental|2 x sachets per day
40939540|NCT05151601|OTHER|Placebo|2 x sachets per day
40939541|NCT00073073|DRUG|Exemestane|exemestane 25 mg by mouth (PO) every day for two years
40939542|NCT00073073|DIETARY_SUPPLEMENT|Calcium carbonate|calcium carbonate 1200 mg PO every day x 2 years
40939543|NCT00073073|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 400 international units PO every day x 2 years
41131765|NCT00385606|DRUG|rofecoxib|
40939544|NCT02933580|DRUG|JNJ-56136379|Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
40939545|NCT02933580|OTHER|Placebo|Participants will receive matching placebo tablets on Day 1.
40939546|NCT00604305|DEVICE|Acrysof|Monofocal IOL
40939547|NCT00604305|DEVICE|Acuity's AIOL|Accommodating IOL
40939548|NCT03599401|OTHER|Scaling and root planing|"Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~."
41131766|NCT01898299|DEVICE|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
41281078|NCT02081963|DRUG|Normal saline|Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
41281079|NCT04381234|DEVICE|dialyzer|Asymmetric triacetate dialyzer
41281080|NCT04381234|COMBINATION_PRODUCT|hemodialysis with citrate-containing dialysate|acetate-free dialysate
41281081|NCT04381234|OTHER|predilution hemodiafiltration|predilution hemodiafiltration
41281082|NCT04177836|BEHAVIORAL|Mindfulness intervention|Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
41281083|NCT01783665|OTHER|aerobic exercise|
41281084|NCT01783665|OTHER|home exercise program|
41281085|NCT05363007|DRUG|nanoliposomal irinotecan|"Upfront SI (Arm A): Upfront nanoliposomal irinotecan (80 mg/m2, day 1) + 5-FU/leucovorin (2400 mg/m2, 400 mg/m2) plus SI~Add-on SI (Arm B): Add-on SI following limited progression to prior nanoliposomal irinotecan (last dose used) + 5-FU/leucovorin (last dose used)"
41281086|NCT05363007|RADIATION|spleen irradiation|"Upfront SI (Arm A): upfront spleen irradiation (1 Gy/fx, day 1-4) in cycle 2~Add-on SI (Arm B): add-on spleen irradiation (1 Gy/fx, day 1-4) in cycle 1 following limited progression to prior nanoliposomal irinotecan + 5-FU/leucovorin"
41450922|NCT03413423|BEHAVIORAL|BAT-CS|All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
41450923|NCT03413423|BEHAVIORAL|Smoking Cessation and Health & Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
41450924|NCT05364177|DRUG|68Ga-Pentixather|After intravenous injection of 68Ga-pentixather, PET/CT scan will be performed.
41450925|NCT05364177|DRUG|68Ga-Pentixafor|After intravenous injection of 68Ga-pentixafor, PET/CT scan will be performed.
41450926|NCT04074707|DIETARY_SUPPLEMENT|Labeled iron solution (60mg and 120mg Ferrous Fumarate)|3 doses of 60mg iron as ferrous fumarate are given on one consecutive day and one alternate day (e.g., days 1, 2, 4); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 200ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with 60mg iron daily vs alternate day dosing, 120mg daily vs alternate day dosing or 120mg daily vs every-third day dosing.
41450927|NCT06627543|DIAGNOSTIC_TEST|echo|echocardiographic
40744361|NCT04905290|DEVICE|Conduction System Pacing Optimized Therapy (CSPOT) configuration|A combination of left ventricle (LV) pacing and conduction system pacing (CSP) of the left bundle branch.
41131767|NCT01898299|DEVICE|Sham tDCS|Sham (inactive) tDCS treatment
41131768|NCT04068506|DRUG|Gabapentin 600 mg Tab|Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
41131769|NCT02983266|DEVICE|InTENsity MicroCombo|An electrotherapy device.
41131770|NCT01450657|DIETARY_SUPPLEMENT|Kibow Biotics/Renadyl|Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 \& 4, three capsules three times daily (270 CFU's). Months 5 \& 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 \& 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
41131771|NCT05319041|DRUG|Wei's Qi Ju Gan Lu Formula|"The formulation, Wei's Qi Ju Gan Lu Formula, is initiated by the senior TCM collaborator, Prof Wei QP, is formulated to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
41131772|NCT05319041|DRUG|Placebo|0.5g maltodextrin without any herbs medicine
41281087|NCT01875497|DIETARY_SUPPLEMENT|grape fruit (vitis vinifera) extract in capsule with 205 mg|Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
41281088|NCT02415725|DRUG|Indocyanine Green|visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
41281089|NCT01818349|OTHER|isokinetic lower-limb training|concentric training of the affected plantarflexors, hip flexors and hip extensors
41281090|NCT01818349|OTHER|isokinetic upper-limb training|concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
41131773|NCT03042741|BIOLOGICAL|atherosclerosis vaccine|Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue
41131774|NCT03042741|BIOLOGICAL|Placebo pills|Half of the patients will be randomly assigned to receive placebo pill
41131775|NCT05085418|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
41131776|NCT06298266|BIOLOGICAL|infusion of GPRC5D-CD19 CAR T injection|Infusion of GPRC5D-CD19 CAR T cells injection by dose of 1.0×10\^6 /kg±20 % CAR-T ，3.0×10\^6 /kg±20%、6.0×10\^6 /kg±20%. Administration method: intravenous infusion. Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
40939549|NCT02734420|DRUG|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
41131777|NCT01484743|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
41450928|NCT06146959|DEVICE|Corrective Kinesiology taping|corrective kinesiology tape is a form of biomechanical tape that is used with specific tension to get a corrective effect
41450929|NCT06146959|DEVICE|Non corrective kinesiology tape|Non-corrective kinesiology tape is a form of biomechanical tape that is used without any tension
41131778|NCT01660659|DEVICE|Biomass Briquettes and Rocket stove|Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
41131779|NCT02994407|DRUG|turoctocog alfa pegol|"Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months."
41450930|NCT06146959|OTHER|Home exercise program|Intrinsic foot strengthening and stretching exercises
41450931|NCT06558487|OTHER|Cancer Admission Score Prediction Model|A prediction model that calculates the chance for a patient to be admitted after triage and after first blood results
41131780|NCT06477679|PROCEDURE|• Furlow with buccinators myomucosal flap|• Furlow with buccinators myomucosal flap. Two opposing Z-plasties were designed on the oral and nasal mucosal surface. The posterior based flap on each surface was composed of muscle and mucosa, and the anterior surface was composed of mucosa only. BMFs were raised from the donor site, and immediately transferred to the recipient site to repair the defect. The flaps were sutured to the recipient site. The donor site was also closed primarily
41450932|NCT04842435|DRUG|COVID-globulin|"In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study."
41281091|NCT05041738|PROCEDURE|Intraoral Cryotherapy|small ice packs wrapped in sterile gauze placed in the mouth on the vestibular surface of the treated tooth
41453628|NCT02994836|BIOLOGICAL|Anti-TNF: Infliximab (Infusion)|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
41453629|NCT02994836|DRUG|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
41281092|NCT05041738|PROCEDURE|Intracanal Cryotherapy|Intracanal cryotherapy technique using 2.5°C cold saline irrigation as final irrigant
40744362|NCT06330025|OTHER|Children between 2 and 8 years, without medical treatments or pathologies impacting food intake and his parents|The group comprises 102 children aged between 2 and 8 years, hospitalized for at least 48 hours and their parents. The children's pathologies and medical treatments should not influence their food intake.
40744363|NCT03411538|OTHER|Collect data on clinical history|Collect data on clinical history, clinical manifestation, comorbidity, admission data, use of invasive medical intervention, history of antibiotic treatment and antibiotic susceptibility test results
41453630|NCT02994836|BIOLOGICAL|Anti-TNF:Adalimumab (Subcutaneus)|Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
41281093|NCT03560362|DRUG|Bupivacaine liposome|
41281094|NCT03560362|DRUG|Bupivacaine / Epinephrine|
41281095|NCT05449353|BEHAVIORAL|Trauma-informed Cognitive Behaviour Therapy (TiCBT)|Group: Experimental (n=24 participants) will receive the TiCBT which consists of a total of 8-group integrated sessions lasting approximately 60 minutes per session every 3 days interval with 24 persons in the single group.
41281096|NCT02912871|OTHER|MRIgHIFU unilateral subthalamotomy|High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
41281097|NCT01329757|DRUG|GH|Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
41131781|NCT06477679|PROCEDURE|• Two flap palatoplasty as von langenbeck technique|• Two flap palatoplasty as von langenbeck technique, Upper left: Medial incisions design. Upper right: Lateral relaxing incisions and nasal mucosa closure using the anterior triangular flap and lateral nasal mucosa flaps. Release of the abnormal muscular insertion is performed. But two flap palatoplasty can lengthen the soft palate by push-back
41131782|NCT00580866|DEVICE|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
41281098|NCT01329757|DRUG|Placebo|Administration of a subcutaneously injected daily dose of placebo for 1 year
41131783|NCT03212885|DEVICE|Deep Brain Stimulation|Electrode that provides electrical stimulation to deep brain structures for relief of Parkinson's Disease symptoms.
41281099|NCT02437669|DRUG|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
41281100|NCT01773473|DRUG|Insulin Lispro Mix25|Administered SC
41281101|NCT01773473|DRUG|Insulin Lispro Mix50|Administered SC
41131784|NCT05486494|OTHER|Treatment (non- surgical/surgical)|Treatment Outcome based on different aspects
41281102|NCT01994343|OTHER|Global posture reeducation|An assessment of the women is performed using global posture reeducation.
41281103|NCT03979729|OTHER|Routine Screening Mammogram (3D + 2D)|Subjects that have undergone a routine screening mammogram (3D + 2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
41453631|NCT02994836|DRUG|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
40756394|NCT02628145|BEHAVIORAL|Resistance Training Intervention|The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
40756395|NCT02628145|BEHAVIORAL|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
40939550|NCT02734420|DRUG|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
40939551|NCT02734420|DEVICE|Laser|
41453632|NCT03368209|DEVICE|WM3.4|Investigational Medical Device collecting spectral raman data from tissue.
40939553|NCT00891111|BEHAVIORAL|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
41453633|NCT04474587|OTHER|Indirect calorimetry|Measurements of REE by indirect calorimetry
41453634|NCT02512328|DEVICE|APP supported colonoscopy preparation|additional usage of an app for colonoscopy preparation
40939554|NCT00891111|BEHAVIORAL|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
40939555|NCT00678340|DEVICE|WACA and PVI|Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
40939556|NCT00678340|DEVICE|PVAC|Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
40939557|NCT03970213|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|IV TXA given during surgery
40939558|NCT03970213|DRUG|Normal Saline 0.9% Infusion Solution Bag|IV saline given during surgery
40939559|NCT03955380|DRUG|Contraloid|Oral administration of capsules, drug substance or placebo without any exipients.
40939560|NCT03858465|DRUG|Ephedrine|intravenous 25 mg of ephedrine
40939561|NCT03858465|DRUG|Phenylephrine|intravenous 0,3 mg of phenylephrine
40939562|NCT04585373|OTHER|kinesio-taping with conventional therapy 24 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
41281104|NCT03979729|OTHER|Routine Screening Mammogram (2D)|Subjects that have undergone a routine screening mammogram (2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
40756396|NCT04402814|DIAGNOSTIC_TEST|Clungene rapid test cassette|Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.
41131785|NCT05316259|DRUG|BPI-16350|Administered orally
41131786|NCT06151106|DRUG|Chidamide combined with Duvillisib|Specified dose on specified days
40939563|NCT04585373|OTHER|kinesio-taping with conventional therapy 48 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
40939564|NCT04585373|OTHER|kinesio-taping with conventional therapy 72 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
40939565|NCT00055471|DRUG|ZD4054 10 mg|1 x 10 mg oral tablets once daily
41281105|NCT03979729|OTHER|No Screening Mammogram|Subjects will participate in a one-time facilitated focus group.
41281106|NCT02602067|COMBINATION_PRODUCT|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
41281107|NCT01241786|DRUG|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and \< 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
41281108|NCT01241786|DRUG|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
41281109|NCT00378846|PROCEDURE|infrared thermography|
41281110|NCT00023322|DRUG|Peginterferon Alpha-2a|Treatment
41281111|NCT05755789|DRUG|Loading bolus of cefoxitin|Cefoxitin \[2g\] before incision
40756400|NCT03468127|OTHER|Soy foods|Isolated soy protein, soy protein, soybean products, soy milk
40756401|NCT01003964|DRUG|IP|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
40756402|NCT01003964|DRUG|GP|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
40756403|NCT00235625|DRUG|Curcuminoids C3 Complex®|
40756404|NCT05968937|DRUG|20 mg baclofen vaginal suppository daily per vagina|20 mg baclofen vaginal suppository in Supposibase F daily per vagina - to be compounded by The Louisville Compounding Pharmacy
40756405|NCT05968937|DRUG|Placebo|Vaginal suppository composed of Supposibase F daily per vagina
40756406|NCT03335267|DRUG|CPX-351|Cytarabine:Daunorubicin Liposome Injection
40939566|NCT00055471|DRUG|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
40939567|NCT00055471|DRUG|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
41131787|NCT06466512|BEHAVIORAL|Midwifery-embodied care|The midwife will provide ANC, delivery and PNC. The Community Healthcare Provider, Health Assistants will act as auxillary staff. Local transports will be integrated into the system. Coordination committee will see through that the interventions are carried out properly.
40756407|NCT01825252|BEHAVIORAL|Social Network Intervention|Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
40756408|NCT01825252|BEHAVIORAL|Counsel, Test, and Treat|People receive standard-of-care HIV/STD counseling, testing, and treatment
40756409|NCT03180138|BEHAVIORAL|Reminders alone|Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
40756410|NCT03180138|BEHAVIORAL|Compliance-linked incentives|Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
40756411|NCT04298333|DRUG|BP-C1|"BP-C1, 0.05% solution for injection, will be administered intramuscularly once per day. The cumulative dose range will be 0.64-1.12 mg/kg body weight depending on design level (design level 1-3). The daily dose range will be 0.02-0.035 mg/kg body weight (0.04-0.07 mL/kg) depending on design level (design level 1-3).~Dose level 1: 0.02 mg/kg body weight (0.04 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 2: 0.03 mg/kg body weight (0.06 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 3: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days.~Changes in the cumulative dose of BP-C1 between patients in the sequence are predefined and will be adjusted by escalation/deescalation rules based on changes in toxicity observed in the previous design level.~The duration of BP-C1 treatment will be 32 days."
40756412|NCT05975775|PROCEDURE|Laparoscopic radical prostatectomy|Prostate cancer may require laparoscopic radical prostatectomy, a surgical procedure performed under general anaesthetic.
40756413|NCT06361446|DRUG|Zonisamide 50 MG|"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. all patients received zonisamide 100 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."
40756414|NCT06361446|DRUG|Propranolol|"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients received propranolol 160 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."
40756415|NCT04308993|PROCEDURE|percutaneous transhepatic choledochoscopy|percutaneous transhepatic choledochoscopy
40756416|NCT03014505|BIOLOGICAL|FMT|Fecal Microbiota Transplantation and the traditional treatments for Decompensated Cirrhosis in part 1
40756417|NCT03014505|OTHER|traditional treatments|traditional treatments for Decompensated Cirrhosis in part 2
40756418|NCT01311011|PROCEDURE|SCT|SCT
41131788|NCT06509763|DEVICE|ECGI system during LBBP implant|ECGI system to create non-invasive ventricular maps during the screwing steps of the LBBP electrode
41131789|NCT01046292|DRUG|Ginkgo biloba|The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
41131790|NCT01888991|OTHER|Glucose Preload and Exercise Intervention|A glucose preload and exercise were administered to examine the modulate substrate oxidation
41131791|NCT02859844|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS)|
41281112|NCT05755789|DRUG|Intermittent cefoxitin|Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure
41281113|NCT05755789|DRUG|Continuous infusion of placebo|Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure
41281114|NCT05755789|DRUG|Continuous infusion of cefoxitin|Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure
41281115|NCT05755789|DRUG|Intermittent placebo|Additional bolus of placebo every 2 hours until the end of surgical closure
41131792|NCT05985408|DEVICE|left ventricular septal pacing|For left bundle branch pacing (LBBP) failure cases, use left ventricular septal pacing instead of LBBP; others were same as traditional CRT.
41131793|NCT05985408|DEVICE|right ventricular apical pacing|For left bundle branch pacing (LBBP) failure cases, use right ventricular apical pacing instead of LBBP; others were same as traditional CRT.
41131794|NCT02586272|DEVICE|Daifert|
41131795|NCT02586272|PROCEDURE|Control Group|
40756419|NCT03976726|DEVICE|Comparison of physcial parameters|Increasement of weight, volume expansion and decrease of density are measured.
40756420|NCT01272622|RADIATION|Radiation|Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
40756421|NCT01272622|OTHER|wait and watch|wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
40939568|NCT01327911|BIOLOGICAL|NT-501 implant|Ciliary neurotrophic factor (CNTF) implant
41131796|NCT03813524|DEVICE|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
41131797|NCT02220452|OTHER|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
41281116|NCT04674943|OTHER|Breathing exercises|Breathing exercises as well as Buteyko technique and Papworth relaxation method was performed as relaxation technique. All exercises were performed 15rep 3 sets for 15 min.
41281117|NCT04930939|OTHER|Aerobic training cardiac rehabilitation program|Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
41281118|NCT05839561|DRUG|Letrozole as monotherapy|Letrozole 5 mg daily orally for 10 days from day 0
41281119|NCT05839561|DRUG|MTX as monotherapy|MTX in a single dose of 100 mg intravenously on day 0
41281120|NCT04114981|RADIATION|Single Fraction Stereotactic Radiosurgery|Undergo SSRS
41281121|NCT04114981|RADIATION|Fractionated Stereotactic Radiosurgery|Undergo FSRS
41281122|NCT04114981|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
41281123|NCT04114981|OTHER|Questionnaire Administration|Ancillary studies
41450933|NCT04842435|DRUG|Placebo|"In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose."
41450934|NCT01427062|OTHER|experimental|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
41450935|NCT01427062|OTHER|control|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
41450936|NCT03121898|DEVICE|Platelet function test|Measurement of P2Y12 and PAR-dependent platelet function activity before and after cardiac surgery by ADPtest and TRAPtest
41450937|NCT05115357|PROCEDURE|Pecto-Intercostal Fascial Block|A high-frequency (7-12 Mhz) linear ultrasound transducer will be placed approximately 2 cm lateral to sternal edge in the 4th or 5th intercostal space. A 22-gauge, 50-mm needle will be inserted in-plane under ultrasound guidance. The needle will be advanced through the pectoralis major muscle, and the drug will be deposited in the pecto-intercostal fascial plane located between the pectoralis major muscle and the external intercostal muscles. The separation of the fascial plane and the spread of the drug could be observed on the ultrasound image .The procedure will be repeated on the other side of sternotomy to achieve bilateral blockade.
41450938|NCT05115357|PROCEDURE|Transversus Thoracis Muscle Plane Block|The ultrasound probe will be placed in the longitudinal plane 1 cm lateral to the sterna border. the T4-T5 intercostal space will be identified under US. A parasternal sagittal view of the internal intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib will be visualized above the pleura. A 22-gauge, 50-mm needle will be inserted inplane until the tip of the needle is located in the transversus thoracis muscle plane between the internal intercostal and transversus thoracis muscles . After excluding intravascular and intrapleural placement, local anesthetic will be administered in 5mL aliquots with intermittent aspiration.
41450939|NCT06378190|BIOLOGICAL|CAR-T cells therapy|CAR-T cells therapy
41450940|NCT02160613|PROCEDURE|Open flap debridement|an access flap
41450941|NCT02105272|DRUG|OPC-1085EL ophthalmic solution|
40939569|NCT03712254|DRUG|Fosphenytoin|Patients with trigeminal neuralgia that due to acute exacerbations of trigeminal neuralgia pain are admitted for fosphenytoin loading are the subjects of interest.
41281124|NCT06498388|OTHER|Stiffness measurement by visco-elastography|Participant will be asked to put on the study's bra with the help of a female member of the team if necessary and to complete the examination process.
41281125|NCT04317807|DRUG|Levetiracetam Pill|Levetiracetam is an anticonvulsant that is frequently used to treat epilepsy in children and adults due to its superior tolerability, ease of use and excellent safety profile. It is rapidly absorbed and rapidly crosses the blood-brain barrier. Levetiracetam does not affect metabolism of antipsychotic drugs and may normalize hippocampal hyperactivity by decreasing excessive glutamatergic and dopaminergic transmission, thereby making it an ideal agent to test the hypothesis that reducing excessive hippocampal activity may enhance treatment of early psychosis and prevent antipsychotic toxicity. Levetiracetam will be administered in 500 mg capsules twice a day.
41450942|NCT02105272|DRUG|Latanoprost ophthalmic solution|
41450943|NCT02358538|DRUG|Ganaxolone|oral suspension or capsules
41450944|NCT06625021|PROCEDURE|Chiropractic manipulation|"Chiropractic manipulation: Lower cervical chiropractic manipulation is a technique used to increase mobility and relieve pain in the lower vertebrae of the neck. However, such procedures should only be performed by trained chiropractors; if done incorrectly, they can lead to serious problems. The patient should be placed in a comfortable position. The supine or side-lying position is usually preferred. Contact is established with the transverse processes of the lower cervical vertebrae. High-velocity, Low-amplitude thrust is applied within anatomical limits.~As a graduate of Bahcesehir University Chiropractic Masters Degree, I applied chiropractic twice a week for 3 weeks."
40756422|NCT03847818|DRUG|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|"Drug: Pyrotinib Pyrotinib: 400mg orally daily~Drug: Trastuzumab Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;~Drug: Docetaxel Docetaxel: 75mg/m2 for a total of 6 cycles~Drug: Carboplatin Carboplatin: AUC=5 or 6 for a total of 6 cycles"
40756423|NCT05542901|DIAGNOSTIC_TEST|Joint Position Sense Analysis|The Xsens DOT Motion Capture System will be used to analyze joint position sense.
40756424|NCT06304896|DRUG|Carvedilol|Carvedilol 6.25 mg oral tablets. Prescribed: Twice daily PO with 200 mL of water.
40756425|NCT06304896|DRUG|Ramipril|Ramipril 2.5 mg oral capsules. Prescribed: Once daily PO with 200 mL of water.
41281126|NCT04317807|OTHER|Placebo|The placebo pill (sugar pill) will look just like the levetiracetam pill but does not contain levetiracetam. Placebo will be taken along with optimal antipsychotic medication selected by either the outpatient provider or the hospital staff responsible for the participant's care. Participants will be instructed to take the placebo pill twice daily for 12 weeks.
41281127|NCT04466124|RADIATION|Liver Cancer Patients Treated With Proton Beam Therapy|Proton Beam Therapy
41281128|NCT05576220|DEVICE|IDION iTempShield|Subject is being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
40756426|NCT06304896|DRUG|Rosuvastatin|Rosuvastatin 20 mg oral tablets. Prescribed: Once daily PO with 200 mL of water.
41281129|NCT03021902|DRUG|IV amino acids|IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.
41281130|NCT03021902|DEVICE|In-bed cycle ergometry exercise|"In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling.~Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay."
41281131|NCT03752905|DRUG|PTR-01|Recombinant human collagen 7 (rC7)
41281132|NCT03752905|DRUG|Normal saline|Saline control
41281133|NCT06167161|DEVICE|Hearing aid|The hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and through a dedicated smartphone application
41281134|NCT04292938|DIETARY_SUPPLEMENT|Low carbohydrate ketogenic diet|Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
41281135|NCT04146688|OTHER|Music Balance Board|The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
41281136|NCT03421548|DEVICE|EyeMate|Patients will undergo implantation BKPro with concomitant implantation of the EyeMate pressure sensor. The surgical approach will involve a trephination of the central recipient cornea of adequate size. In subjects with adequate capsular support, the sensor device will be placed in the sulcus space by grasping the sensor's silicone sleeve at approximately the 3 and 9 o'clock positions and sliding it into the sulcus space. In subjects in whom capsular support is inadequate, the Eyemate implant will be sutured to the sclera. This is performed by placing an 8-O Gortex suture or 9-O prolene on CIF-4 needles around the antenna at the 2 and 7 o'clock positions and suturing the device to the sclera using an ab-interno technique.
41281137|NCT01561131|DIETARY_SUPPLEMENT|Whey protein|45g protein/d; Dosage 3x15g protein daily
41281138|NCT01561131|DIETARY_SUPPLEMENT|Whey protein enriched with calcium|45g protein/d + 1000mg calcium/d; dosage: 15g protein + 333mg calcium x 3 daily
41281139|NCT01561131|DIETARY_SUPPLEMENT|Soy protein|45g soy protein/d; dosage 15g soy protein x 3 daily
41281140|NCT01561131|DIETARY_SUPPLEMENT|Maltodextrin|48g carbohydrate/d; dosage: 16g carbohydrate x 3 daily
41281141|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
41281142|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
41450945|NCT06625021|PROCEDURE|Exercises to be done for neck pain of mechanical origin|Conservative treatment, which is frequently used in the treatment of mechanical neck pain, was planned. A warm-up period was defined with stretching exercises in all areas of neck movement. Again, isometric exercise should be 10 seconds in all directions. In addition to neck and shoulder mobility exercises, neck region posture exercises were included. It was planned to do these exercises for 4 weeks, 5 days a week, in all 4 groups.
40756427|NCT06304896|DRUG|Colchicine|Colchicine 0.6 mg oral tablets/capsules. Prescribed: Once daily PO with 200 mL of water.
40756428|NCT06304896|DRUG|Placebo|Placebo oral capsules. Prescribed: Once daily PO with 200 mL of water.
40756429|NCT05571163|DRUG|AMG 510|Tablets
40756430|NCT03844412|DRUG|5% lidocaine/5 mg/ml 0.02% estradiol compound cream|Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
40939570|NCT05598931|DEVICE|Transcranial Magnetic Stimulation|Subjects will participate in an on-line neuro-navigation session in which 6 TMS coil positions will be recorded.
41281143|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 2|Participants will use their Radicle GI Health Placebo Control Form 2 as directed for a period of 6 weeks.
41281144|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
41281145|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.2 Usage|Participants will use their Radicle GI Health Active Study Product 2.2 as directed for a period of 6 weeks.
41281146|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 3|Participants will use their Radicle GI Health Placebo Control Form 3 as directed for a period of 6 weeks.
41281147|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
41281148|NCT04746040|DRUG|Test|2 inhalations of Test and Reference product in each study period
41281149|NCT04746040|DRUG|Reference|2 inhalations of Test and Reference product in each study period
41281150|NCT01783834|DRUG|Gefitinib|compare progression free survivla rate and safety to both drugs
41281151|NCT01783834|DRUG|Pemetrexed|compare PFS rate, safety to both drugs
41281152|NCT04454814|OTHER|Protaper Universal instruments|Root canal treatment using Protaper Universal instruments
41131798|NCT02220452|OTHER|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
41131799|NCT01122914|DRUG|Anakinra|
41131800|NCT00343408|DRUG|cediranib maleate|
41131801|NCT00343408|DRUG|cisplatin|
41131802|NCT00343408|DRUG|fluorouracil|
41131803|NCT00343408|DRUG|gemcitabine hydrochloride|
41131804|NCT00343408|DRUG|leucovorin calcium|
41131805|NCT00343408|DRUG|oxaliplatin|
41131806|NCT02591056|DEVICE|Erchonia® Verju™ Laser|There are 12 procedure administrations with the Erchonia® Verju™ Laser across 6 weeks: 2 procedures per week. For each procedure administration, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes to the front and 15 minutes to the back. All subjects receive the active Erchonia Verju Laser treatment for all 12 procedure administrations.
41131807|NCT02591056|DEVICE|Green PRESS 8|There are 12 procedure administrations with the Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration, the Green PRESS 8 is applied to the midsection for 30 minutes. All subjects receive the active Green PRESS 8 treatment for all 12 procedure administrations. Each Green PRESS 8 procedure administration occurs right after each procedure administration with the Erchonia Verju Laser.
41131808|NCT02541318|BEHAVIORAL|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
41131809|NCT02493166|OTHER|dual task cost (cognitive-motor interference)|comparing single versus dual task performance (on both motor and cognitive task)
41131810|NCT02423642|PROCEDURE|Continuous renal replacement therapy with regional citrate anticoagulation|"CRRT with anticoagulant : regional citrate anticoagulation~Filter : AQUAMAX™ (Edwards Lifesciences)"
41131811|NCT02423642|PROCEDURE|Continuous renal replacement therapy with no anticoagulation or heparin|CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
41131812|NCT01016457|DEVICE|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
41131813|NCT00653172|DRUG|NXL103|600mg orally twice daily
41131814|NCT00653172|DRUG|comparator|comparator twice daily
41281153|NCT04454814|OTHER|Reciproc Blue instruments|Root canal treatment using Reciproc Blue instruments
41281154|NCT01750918|DRUG|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
40939571|NCT06025851|DRUG|Anti-human CCL24 monoclonal antibody (CM-101)|Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)
40939572|NCT06025851|DRUG|Placebo|Placebo Comparator
41131815|NCT00653172|DRUG|NXL103|500mg orally twice daily
41131816|NCT02683174|DEVICE|Novel ambulatory patch (ZIO® XT Patch)|All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)
41131817|NCT02683174|BIOLOGICAL|BNP and hs-troponin I at 0 and 3 hours post ED attendance|All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
41131818|NCT01267643|DRUG|Alefacept|"Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly"
41131819|NCT05295706|BEHAVIORAL|Counterfactual Intervention|"The intervention occurs during the third study visit. This is a counterfactual intervention, which will involve asking the subjects to think of an alternative reality that might have been based on the concurrency of their glucose readings and the meals they ate."
41131820|NCT04253951|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)-monitored feeding trial|LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
41131821|NCT06509243|BIOLOGICAL|tablets Acarizax|sublingual immunotherapy to house dust mites
41281155|NCT01750918|DRUG|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
41131822|NCT06509243|BIOLOGICAL|dupilumab|dupilumab - biologic therapy for atopic dermatitis
41131823|NCT06509243|DRUG|cyclosporine|cyclosporine used in atopic dermatitis
41131824|NCT04178421|OTHER|Computerized training program|Eye-gaze fixation computer based training program
41131825|NCT04178421|OTHER|Placebo|Pac-Man, Zookeeper, Tetris
41131826|NCT04653688|DEVICE|The FeetMe® Evaluation|The FeetMe® Evaluation device is a medical device (class Im CE 0459) for ambulatory gait analysis, consisting of a pair of connected insoles and an Android mobile application.
41131827|NCT04653688|DEVICE|the PKG® Watch,|The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® system consists of a wrist-worn movement recording device known as the PKG® Watch,
41131828|NCT04653688|RADIATION|MRI|"* an anatomical 3D T1-weigthed gradient-echo sequence (1mm isotropic):~* anatomical registration~* automated segmentation~* volumetric~* texture analysis"
41131829|NCT04653688|RADIATION|DaTSCAN|"* quantify nigrostriatal dopaminergic depletion~* correlate its impact on the type and severity of gait disorders in Parkinson's disease."
41131830|NCT01319838|DRUG|Isotretinoin|\>12 kg: 160 mg/m2/day, given PO, divided BID \<=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
41131831|NCT03950206|OTHER|Indocyanine green angiography|Intravenous ICG (PULSION Medical Systems SE, Feldkirchen, Germany) will be used for the intraoperative evaluation of ureteral vascularization. Twenty-five milligrams of indocyanine green will be diluted in 10 ml of soluble water, and a bolus of 0.25 mg/Kg will be injected through a peripheral vein. During laparoscopy, a NIR camera-head (KARL STORZ Gesellschaft Mit Beschränkter Haftung\&amp; Co., Tuttlingen, Germany) will be used to visualize the ureteral vascularization.
41131832|NCT05348603|OTHER|Traditional Letter|Patients receive a traditional letter.
41131833|NCT05348603|OTHER|Direct to Patient Message|Patients receive a direct to patient message via the portal.
41131834|NCT05348603|OTHER|Chatbot|Patients are contacted by a chatbot via the portal.
41131835|NCT05348603|OTHER|Banner|Patients are exposed to a banner ad via the portal.
41131836|NCT00042965|DRUG|capecitabine|
41131837|NCT00042965|DRUG|gemcitabine hydrochloride|
41131838|NCT01697891|DEVICE|Codetron ALTENS|ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
41131839|NCT02073500|OTHER|Observational study.|"Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease."
41131840|NCT06272591|OTHER|Preliminary search in the patient's file|"Details of the information previously sought in the patient's file :~age profession gender/parity physiological or pathological pregnancy indication for induction of labour gestational age at time of induction"
41131841|NCT06272591|OTHER|A posteriori research in the patient's file|Data on maternal and foetal morbidity and mortality following childbirth will be collected.
41131842|NCT06272591|OTHER|First questionnaire : choice of induction method reason for choice|Given on arrival at the maternity unit to begin induction.
41131843|NCT06272591|OTHER|Second questionnaire : experience of induction|Given post-partum in the maternity unit.
41131844|NCT01998958|DRUG|Esketamine 14 mg|1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
41131845|NCT01998958|DRUG|Esketamine 28 mg|1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
41131846|NCT01998958|DRUG|Esketamine 56 mg|1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
41131847|NCT01998958|DRUG|Esketamine 84 mg|1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
41131848|NCT01998958|DRUG|Placebo|1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
41131849|NCT02262299|DRUG|Pirfenidone|Receive tablets with pirfenidone
41131850|NCT02262299|DRUG|Placebo|Recieve tablets with placebo
41131851|NCT06100198|OTHER|nutrition and exercise program|Nutrition courses include understanding malnutrition and sarcopenia; understanding the six major food categories and their requirements; and understanding protein-rich food sources. Exercise courses include understanding exercise types, flexibility exercises, and muscle strength training exercises.
41266965|NCT01412957|OTHER|Best Supportive Care (BSC)|BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.
41266966|NCT01412957|DRUG|Panitumumab|Administered intravenously
41266967|NCT00873002|DRUG|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
41266968|NCT00873002|DRUG|sorafenib tosylate|400 mg PO BID
40744364|NCT05122819|PROCEDURE|Mandibular Molar Extraction Under Local Anesthesia|"Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS)."
40744365|NCT00855478|DEVICE|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
40744366|NCT05869747|BEHAVIORAL|Blood Donation|Participants asked to donate whole blood at a donation facility from a list provided by the study.
41281156|NCT01750918|DRUG|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
41131852|NCT04310514|DIETARY_SUPPLEMENT|Fructose/glucose/xylitol/saccharose|"1. Intervention: rehydration with glucose solution. Glucose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~2. Intervention: rehydration with fructose solution. Fructose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~3. Intervention: rehydration with xylitol solution. Xylitol will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~4. Intervention: rehydration with sucrose solution Saccharose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m."
41281157|NCT01750918|DEVICE|5-fluorouracil|5-fluorouracil-based chemotherapy
41281158|NCT01733706|DEVICE|No nicotine electronic cigarette|"The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine."
41281159|NCT01733706|OTHER|Standard counseling|standard counseling
41281160|NCT03540823|BIOLOGICAL|Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)|Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
41281161|NCT05415579|OTHER|Traditional Chinese medicine (TCM)|TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.
41131853|NCT02134106|DRUG|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
41131854|NCT02134106|DRUG|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
41281162|NCT02101008|DRUG|disulfiram and chelated zinc|
41281163|NCT01215630|BEHAVIORAL|Aerobic Interval Training|One interval training session
41281164|NCT02468193|DRUG|Osilodrostat|Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.
41281165|NCT06487351|BEHAVIORAL|The adapted PHBI|The adapted intervention is expected to be an online 60-minute video with an educational part about implicit racial bias, its consequences in healthcare inequalities, how to mitigate it, and seven case scenarios (5 minutes each) to train pharmacy interns on aspects related to cultural competency and how and when to use IBMS to reduce the impact of bias on prescribing PrEP for people of color.
41281166|NCT06487351|BEHAVIORAL|The NIH Implicit Bias course|The NIH Implicit Bias course consists of three modules designed to teach users what bias is, how to recognize it, and how to minimize its impact
41281167|NCT02111369|DRUG|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
41281168|NCT02111369|PROCEDURE|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
41281169|NCT03395522|DEVICE|iTind|device implanted for 5-7 days
41281170|NCT03202654|OTHER|Corn Oil|4 tablespoons/day of corn oil for 4-week treatment period.
41281171|NCT03202654|OTHER|Coconut Oil|4 tablespoons/day of coconut oil for 4-week treatment period.
41281172|NCT00833859|DRUG|GTX (gemcitabine, docetaxel and capecitabine)|GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
41281173|NCT00833859|RADIATION|stereotactic body radiation therapy|stereotactic body radiation therapy (SBRT) 25
41281174|NCT00601978|DRUG|carbidopa/levodopa|
41281175|NCT00601978|DRUG|Carbidopa/Levodopa/Entacapone|
41281176|NCT02659449|DEVICE|made to measure compression gloves|Patients achieve tests with compression glove
41281177|NCT02659449|DEVICE|Compression bandaging|Patients achieve tests with compression bandaging
41281178|NCT02659449|OTHER|Free Hands|Patients achieve tests without device
41281179|NCT04988230|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
41281180|NCT04988230|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
41281181|NCT01947270|OTHER|" Optimisation de la Prescription MEDicamenteuse  (Optimization of drug prescribing)"|"The multidisciplinary intervention program include:~* Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.~* Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis"
41281182|NCT04705454|BIOLOGICAL|Loncastuximab Tesirine|
41281183|NCT02291341|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
41281184|NCT02291341|DRUG|Cymbalta®|60 mg capsule of Eli Lilly and Company
41281185|NCT02053688|DEVICE|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
41281186|NCT02053688|DEVICE|Toric Soft Contact Lenses|astigmatism correction using toric optics
40939573|NCT02758756|OTHER|Massage|Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
41131855|NCT03317652|OTHER|Hyperventilation|The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.
41281187|NCT02677740|DEVICE|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention.
41281188|NCT02677740|DEVICE|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention.
41281189|NCT01310738|DRUG|Antimoniate of N-methylglucamine|Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.
41131856|NCT03317652|OTHER|6% CO2 breathing|The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.
40744367|NCT05869747|BEHAVIORAL|Plasma Donation|Participants asked to donate plasma at a donation facility from a list provided by the study.
41281190|NCT01310738|DRUG|amphotericin B deoxycholate|1mg/kg/d, I.V. for 14 consecutive days.
40744368|NCT05869747|BEHAVIORAL|Zone 2 Training|Participants asked to work out in their custom Zone 2 heart range 4 times a week for 45 to 60 minutes.
40744369|NCT05869747|BEHAVIORAL|Intermittent Fasting|Participants asked to engage in an intermittent fasting routine of a 16 hour fast followed by an 8 hour eating period at least 4 times a week.
40744370|NCT05869747|BEHAVIORAL|Surveys|Participants were asked to complete surveys throughout the study to monitor intervention progress and to collect baseline and end-of-study data.
40744371|NCT01297790|OTHER|Cough Challenge Tests|Inhalational cough challenge tests with capsaicin, bradykinin, Citric acid and prostaglandin E2
40744372|NCT01297790|OTHER|ambulatory cough recording|Cough recording with a portable device to capture cough sounds
41281191|NCT01310738|DRUG|Liposomal amphotericin B|3mg/kg/d, I.V. for 7 consecutive days.
40756431|NCT03844412|DRUG|Nortriptyline|Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
40939574|NCT02758756|OTHER|Reiki|Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
40939575|NCT05307731|DRUG|Fingolimod|0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
40939576|NCT05307731|DRUG|guideline-based treatment for DM|guideline-based treatment for DM
40939577|NCT06523699|DRUG|Recombinant glycosylated human interleukin-7|Provided by RevImmune
40939578|NCT06523699|DRUG|Melphalan|Standard of care
40939579|NCT06523699|PROCEDURE|Autologous hematopoietic cell transplant|Standard of care
40939580|NCT01435317|DEVICE|ANM T30 CR®-System|Stimulation for 4-6h/day for a time of 1 year
40939581|NCT03759288|DRUG|Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
40939582|NCT03759288|DRUG|Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
40939583|NCT03759288|DRUG|Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
40939584|NCT03759288|DRUG|Placebo|Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
40939585|NCT05420727|DRUG|Ga-68-PSMA-11 PET/CT|Ga-68-PSMA-11 PET/CT imaging
40939586|NCT05420727|DRUG|Lu-177-ITG-PSMA-1|Lu-177-ITG-PSMA-1 treatment
40939587|NCT06033716|OTHER|Measurement correlation variable|resilience and anxiety and depression
41281192|NCT01310738|DRUG|Liposomal amphotericin B|10mg/kg/d, I.V. single dose.
41281193|NCT01310738|DRUG|Antimoniate of N-methylglucamine|20mg/kg/d of pentavalent antimonial I.V. for 10 days
41450946|NCT06625021|PROCEDURE|Classic Hand-Wrist Exercises|The participants of this group will be subjected to wrist range of motion (ROM), stretching and strengthening exercises. Measurements will be made in all axes of motion of the wrist, which are extension, flexion, ulnar and radial deviation. ROM exercises and stretching exercises were applied passively to all axes of motion within anatomical limits. At the last angles of the movement, the individual was forced and stretched without causing discomfort and waited at the last angles for a short time. Stretching exercises were performed five times for each movement. Strengthening exercises for all axes of movement of the wrist will be performed using dumbbells weighing 1 and 2 kilograms and an exercise band suitable for the persons endurance and strength. In exercises performed with dumbbells, all movements of the wrist will be performed against gravity. All applications were applied to the classical hand-wrist exercise group for at least half an hour every day for 4 weeks.
40756432|NCT03844412|DRUG|Placebo cream|The comparison treatment will be an identical-appearing placebo Moisturel™ cream
40939588|NCT01490970|OTHER|Database|Database
40939589|NCT04158791|PROCEDURE|pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling|25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
40939590|NCT03012516|BEHAVIORAL|PAP-treatment by physiotherapist|
40939591|NCT03012516|BEHAVIORAL|Ordinary PAP-treatment at the health care center|
40939592|NCT05633225|OTHER|Submax exercise test on a bicycle ergometer|"To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.~If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard)."
40939593|NCT04490031|DRUG|Ketamine Hydrochloride|patient in Ketamine group will be given Ketamine as sedative agent
40939594|NCT03219918|DEVICE|EndoRings II Distal Attachment|Colonoscopy cap
40939595|NCT05598047|BEHAVIORAL|Executive Functioning Training|Those in the Executive Functioning Training Group will engage in exercises requiring one to set shift; that is, to maintain at least two sets of rules and decide which is appropriate to determine the response. In using these training exercises in the TOPS study, the effects size was quite large (d=-0.89). Dosage of 20 hours of training is considered an upper range on how much training is needed to produce an optimal therapeutic effect.
40939596|NCT06130007|DRUG|Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy|Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
41281194|NCT04285723|OTHER|alpelisib|Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate.
41281195|NCT02175550|DEVICE|NR CC|
41281196|NCT04176510|BEHAVIORAL|Health Coach Intervention|A structured, manualized coaching intervention by a lay Health Coach that employs a standardized positive affect/self-affirmation intervention, not tied to specific chronic diseases, to help motivate patients to learn to implement self-management by setting life goals.
41281197|NCT02904564|DRUG|MMP with 5-FU|MMP with 5-FU using tattoo device
41281198|NCT02904564|DRUG|MMP with Saline infusion|MMP with saline infusion using tattoo device
40939597|NCT00882973|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
40939598|NCT03183778|DRUG|Patiromer|Patiromer dosing will be determined based on fasting potassium concentrations measured at the end of each week, factoring in both the absolute concentration, as well as the rate of change. The baseline dose of patiromer will correspond to the study by Weir et al. (2015); 8.4-g once per day for participants with a baseline serum potassium of greater than or equal to 5.1 mEq/L.
40939599|NCT03183778|DIETARY_SUPPLEMENT|Research Diet Menu|During the study, participants will be asked to consume only the foods provided in the research diet
41281199|NCT03650504|PROCEDURE|Above Artery Catheter Placement|Nerve catheter placed between superficial femoral artery and sartorial muscle
40756433|NCT03844412|DRUG|Placebo pill|The comparison treatment will be an identical-appearing placebo pill
41281200|NCT03650504|PROCEDURE|Between Artery and Vein Placement|Nerve catheter placed between superficial femoral artery and femoral vein
40744373|NCT01297790|OTHER|Cough questionnaires|Questionnaires designed to study cough. These include Leicester cough questionnaire, cough visual analogue score and cough quality of life questionnaire.
40744374|NCT00207428|DRUG|Carbamazepine|
41281201|NCT03442803|DEVICE|Target-Controlled Infusion|Propofol Target-Controlled Infusion
40939600|NCT02013869|DEVICE|Flow-I, a modern anaesthetic machine without a bag/below/gas reservoir for compression of insufflation gas|Desflurane Dialed setting 18 % on the machine gas vaporized
41281202|NCT03040024|DRUG|Ketamine|Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
40939601|NCT02013869|DEVICE|Asys, a anaesthetic machine with a bag/bellow for compression of gas to be insufflated|Desflurane dialed 18% on the machine gas vaporized
41281203|NCT03040024|DRUG|Placebo|Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
41281204|NCT03040024|DEVICE|Electroencephalogram (EEG)|A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
41281205|NCT03690791|DRUG|MediCabilis CBD Oil|50 mg of CBD: \<2mg of THC in one ml. The cannabis oil consists of CBD extract in MCT oil.
40939602|NCT01135576|DIETARY_SUPPLEMENT|non-fortified fruit juices consumed as part of the usual diet|
41281206|NCT03690791|DRUG|Placebo Oil|Placebo will contain only hemp seed oil.
41281207|NCT00813475|DRUG|Basal bolus insulin regimen (tight glucose control)|Basal bolus insulin regimen
41281208|NCT00813475|DRUG|Basal bolus insulin regimen (standard control)|basal bolus insulin regimen
41281209|NCT02670304|DRUG|letrozole|letrozole from the day of oocyte retrieval for 5 days
41281210|NCT02670304|DRUG|Aspirin|aspirin from the day of oocyte retrieval for 5 days
41281211|NCT01399346|DRUG|Insulin aspart|Application of 18 IU insulin aspart as one bolus at one injection site
41450947|NCT06625021|PROCEDURE|Proprioceptive exercise group|Similar to the classical wrist exercise group, the participants in this group were applied joint range of motion, stretching and strengthening exercises as well as proprioceptive exercises such as joint approximation, traction and mobilization. In addition to all axes of motion of the wrist, active and passive stretching exercises were applied to the forearm flexor and extensor muscles five times each. The resistance and repetition number were gradually increased according to the wrist strength and endurance of the individuals to at least 10 repetitions. Repetitive contraction and rhythmic stabilization techniques were used from proprioceptive neuromuscular facilitation methods. Joint approximation technique and taping of forearm flexor and extensor muscles were used to increase the level of contraction and stimulation of joint receptors. External stabilization and perturbation exercises were performed with an exercise ball against the wall at different angles of the upper extremity.
40756434|NCT03672981|BEHAVIORAL|Exercise Intervention|Undergo resistance training program and cardiovascular exercise
40756435|NCT03672981|OTHER|Quality-of-Life Assessment|Ancillary studies
41131857|NCT03317652|DRUG|Infusion of sodium nitroprusside|Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
41131858|NCT00065000|BEHAVIORAL|Water, Cafeteria and Staff Health Promotion|
41131859|NCT05563571|DRUG|Methylprednisolon, Lidocaine|Intra-articular cortisone injection
41131860|NCT05563571|OTHER|Pulsed radiofrequency, Lidocaine|pulsed radiofrequency of shoulder joint and suprascapular nerve
41281212|NCT01399346|DRUG|Insulin aspart|Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
41281213|NCT01531725|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
41281214|NCT00003029|DRUG|cisplatin|
40756436|NCT03672981|OTHER|Questionnaire Administration|Ancillary studies
40756437|NCT03672981|BEHAVIORAL|Telephone-Based Intervention|Participate in phone calls with exercise physiologist
40756438|NCT03173378|OTHER|Questionnaires|Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
40756439|NCT03434899|BEHAVIORAL|Physical exercise and online support|Person-centered design of a health care plan including individually adjusted physical exercise. Online support for management of health care plan.
40756440|NCT03434899|BEHAVIORAL|Physical exercise|Person-centered design of health care plan individually adjusted physical exercise.
40939603|NCT01135576|DIETARY_SUPPLEMENT|Iron fortified fruit juice|Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet
41131861|NCT02160119|OTHER|MRI-based techniques|fMRI, DTI
41131862|NCT02160119|OTHER|EEG|ERP
41131863|NCT00714207|BEHAVIORAL|NOT program|Students in this arm of the study received the reformatted NOT intervention
41131864|NCT00714207|BEHAVIORAL|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
41131865|NCT00714207|BEHAVIORAL|Kicking Butts intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
41131866|NCT00714207|BEHAVIORAL|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
41131867|NCT00002437|DRUG|Cidofovir|
41281215|NCT00003029|DRUG|fluorouracil|
41281216|NCT00631319|DRUG|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
41281217|NCT00631319|DRUG|Placebo|Placebo
41281218|NCT05917743|OTHER|Mat Pilates|Duration: 50 minutes per session Repetitions: 8-12 repetitions per exercise Sets: 2-3 sets per exercise Rests: 30-60 seconds rest between sets Frequency: 3 times per week for 4 weeks Exercises: A series of Mat Pilates exercises targeting core strength, flexibility, and muscle control
41131868|NCT00002437|DRUG|Probenecid|
41131869|NCT02044809|DRUG|Cannabidiol|
41131870|NCT02044809|DRUG|Placebo|
41131871|NCT00690131|BEHAVIORAL|BTSCS|BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
41131872|NCT03225625|PROCEDURE|Paraspinal|BMSC provided by paraspinal injection, intravenous and intranasal
41131873|NCT03225625|PROCEDURE|Paraspinal EX|BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
41131874|NCT03225625|PROCEDURE|Paraspinal VR|BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
41131875|NCT03543059|DRUG|GnRH analogue|gonadotrophin releasing hormone analogue
41131876|NCT00502294|DRUG|Visilizumab (HuM291; Nuvion®)|
41131877|NCT05230264|OTHER|Elective AAA Repair|Elective AAA Repair - Observation of Stress Response
40939604|NCT02546115|DEVICE|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
41131878|NCT03434587|PROCEDURE|Syndactyly|Syndactyly
41131879|NCT03434587|PROCEDURE|Reduction and inmobilization|Closed reduction and inmobilization with splint
41131880|NCT00890591|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
41131881|NCT04675684|BEHAVIORAL|Recovery-group|The complex intervention are instructions in ruminations-therapy and mindfulness, advice in healthy diets, physical - and social activities and sleep hygiene, and support in smoking cessation, alcohol counseling and medication adherence.
41131882|NCT06497699|DRUG|Dexycu|single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
40744375|NCT00672009|DRUG|Ixabepilone|Ixabepilone 35 mg/m\^2 intravenously over 3 hours every 21 days for 4 cycles.
40744376|NCT04924491|BIOLOGICAL|Autologous thyTreg|Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
40744377|NCT05413460|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
40939605|NCT02546115|OTHER|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
41131883|NCT05851495|PROCEDURE|physiotherapist-led groups, home-based follow up groups|The group involved in physiotherapists-led groups was shown the exercises in practice and under the supervision of the physiotherapist, the patients applied their exercises throughout their treatment. Home-based follow up groups, after the exercise training was given to the patients with a physiotherapist, daily text messages (SMS) were sent to the patients and the patients were reminded to do the exercises
41131884|NCT04121715|DEVICE|Fastigial Nucleus Stimulation|Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation
41131885|NCT04121715|DRUG|Standard treatment|"Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition"
41131886|NCT02867956|DRUG|Apatinib|Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
41131887|NCT02867956|DRUG|Etoposide|Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
41281219|NCT05917743|OTHER|General Exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
41281220|NCT04942639|DEVICE|JOE|Audiovisual support by the robot when taking maintenance treatments at home.
41281221|NCT03250741|DRUG|Rotigotine transdermal patch|Rotigotine transdermal patches 4mg/24hr
41281222|NCT03250741|OTHER|Placebo|Placebo transdermal patches of the same size as for Rotigotine transdermal patches
40939606|NCT02992210|GENETIC|4SCAR-GD2|
41131888|NCT00127582|PROCEDURE|Electrophysiological study|
41281223|NCT04246554|DRUG|Ketorolac|Oral ketorolac for pain control following ACL reconstruction surgery
41281224|NCT04246554|DRUG|Oxycodone-Acetaminophen|Oral oxycodone-acetaminophen for post-operative pain control
41281225|NCT05147246|BEHAVIORAL|ParentCorps-Professional Development (PD)|PD is a school-based evidence-based-intervention (EBI) and preventive service provision model that supports teachers and school personnel to apply EBI strategies to promot young children's medical health in impoverished areas. Teachers and PTAs will participate in a 4-day training before the 1st school term. Teachers in the intervention condition will also receive 8 sessions (8 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
41281226|NCT06489288|OTHER|ERAS protocol|The ERAS process mainly includes removing the urethral catheter before the recovery of anesthesia, removing the abdominal drainage tube within 3 days after surgery, removing the nasogastric feeding tu
41450948|NCT05441592|DRUG|Tranexamic acid injection|The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
41450949|NCT05441592|OTHER|No additional irrigation|There will be no additional irrigation after the standard surgical procedure.
41450950|NCT00452023|DRUG|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
41450951|NCT03369496|OTHER|Social capital; Neighborhood environment|Observational study examining the relationship among neighborhood environment, social capital and health among Montreal adults
40939607|NCT01771575|OTHER|Placebo device|Placebo device
40939608|NCT01771575|DEVICE|PoNS™ device|The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance \& gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
40939609|NCT01158508|PROCEDURE|Remote ischemic preconditioning|Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
40939610|NCT02898155|OTHER|measure of access to primary care and of the Interface Between Primary ans Secondary Care|
40939611|NCT02104973|BEHAVIORAL|Lifestyle counseling|We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
41131889|NCT00127582|DEVICE|pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant|
41131890|NCT04932018|BEHAVIORAL|Virtual Community of Support|The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.
41131891|NCT04932018|BEHAVIORAL|Mentorship Incubator|The 6-month incubator intervention will consist of monthly interactive time with an assigned study facilitator/farmer mentor.
41281227|NCT05137938|DRUG|Intranasal Ketamine (IN)|A sterile form of ketamine will be administered intranasally twice weekly for four weeks. Dosing schedule will be determined based on patient's weight using a specialized formula. Patients will be started at the lowest dose during the first treatment session. Dose will be titrated further to therapeutic dose in the following sessions. The dose will be adjusted if patients do not tolerate full therapeutic doses. After receiving the second treatment of each week, participants will be seen by a study physician to determine dosing for the following week. Patients will be monitored by trained personnel for the full duration of the 2 hour supervision period. Vital signs and physical symptoms will be monitored consistently and measurements taken every 30 minutes. Appropriate medications will be provided to manage treatment-related side effects and any adverse events. Labetalol will be used in the management of treatment-related transient hypertension as needed.
41281228|NCT06225362|DEVICE|Quatera 700|Phacoemulsification device
41281229|NCT06225362|DEVICE|Centurion|Phacoemulsification device
41281230|NCT03927040|DEVICE|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. The device provides global treatment to forebrain. For each of the 120 days of in-home treatment, a single 1-hour treatment will be administered by the subject's caregiver, who will position the device on the patient's head and monitor treatment.
41281231|NCT03957083|DRUG|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
41281232|NCT06236217|OTHER|Carotid Ultrasound|The carotid artery corrected flow time (FTc) was used in patients to optimize the volume status before performing spinal anesthesia.
41281233|NCT06236217|OTHER|Electrical cardiometry|Stroke volume variation (SVV) measured by electrical cardiometry (EC) was used to optimize the volume status before performing spinal anesthesia.
41281234|NCT04964401|PROCEDURE|Thoracic paravertebral block vs Erector spinae plane block|Thoracic paravertebral block and erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
40756441|NCT06522529|OTHER|Multifaceted implementation strategy|The multifaceted implementation strategy consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local context analysis, identifying barriers to improvements in clinical practice, and developing and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
40756442|NCT00966446|DRUG|Unsupervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
40939612|NCT05273970|OTHER|Behavioral testing under intracranial monitoring|After standard of care surgery to implant the electrodes is complete and patients have have recovered satisfactorily from the procedure, they will be asked to perform some computer based tasks to answer questions about pretend financial decisions, pay attention to certain images, watch videos, look at images, listen to sounds, or move a joystick.
40939613|NCT00687232|DRUG|AZD4818|Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
40939614|NCT00687232|DRUG|Placebo|
41131892|NCT01685268|DRUG|AT13387|Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.
41131893|NCT01685268|DRUG|abiraterone acetate|1000 mg PO daily.
41131894|NCT01685268|DRUG|Prednisone|5 mg PO twice daily.
41131895|NCT04009291|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
41131896|NCT04009291|COMBINATION_PRODUCT|Placebo for TransCon PTH|Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
41131897|NCT01917994|BEHAVIORAL|Text Messages|The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
41131898|NCT01917994|BEHAVIORAL|Appointment Reminders|
41131899|NCT03492021|OTHER|Diet Intervention_AP-CPT|Adequate Protein_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .
41281235|NCT00159484|DRUG|EPO906, celecoxib|EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
40939615|NCT02262052|OTHER|MRDTI|MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
41131900|NCT03492021|OTHER|Diet Intervention_PP-PPT|Optimal Protein_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
41281236|NCT00644579|DRUG|bLAC|bLAC high and low dose and placebo
41281237|NCT00644579|DRUG|Placebo|Placebo
41281238|NCT02330991|DRUG|Temozolomide|
41281239|NCT00662870|BIOLOGICAL|DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)|0.5 mL, Intramuscular
41281240|NCT00662870|BIOLOGICAL|Pentacel: DTaP-IPV/Hib|0.5 mL, Intramuscular
41281241|NCT04783155|DEVICE|POWERBreathe Plus®|Commercially available pressure-threshold device
40939616|NCT03660488|DRUG|Cefixime 400 milligram Oral Capsule [Suprax]|The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days
40939617|NCT03660488|DRUG|Benzathine Penicillin G|The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
40939618|NCT05340907|DEVICE|Virtual Reality Device|A virtual reality headset is a heads-up display (HUD) that allows users to interact with simulated environments and experience a first-person view (FPV). VR headsets replace the user's natural environment with virtual reality content, such as a movie, a game or a pre-recorded 360-degree VR environment that allows the user to turn and look around, just as in the physical world. Patient undergoing bronchoscopy will be given the device before and during the procedure.
40939619|NCT05938179|DRUG|HS-10353 30mg oral capsules|HS-10353 30mg oral capsules
40939620|NCT05938179|DRUG|HS-10353 50mg oral capsules|HS-10353 50mg oral capsules
40939621|NCT05938179|DRUG|Placebo for HS-10353 30mg capsules|Placebo for HS-10353 30mg capsules
40939622|NCT05938179|DRUG|Placebo for HS-10353 50mg capsules|Placebo for HS-10353 50mg capsules
40939623|NCT00344240|BEHAVIORAL|Functional circuit training with lifestyle behavior|
41281242|NCT04783155|OTHER|Cardiopulmonary rehabilitation post lung transplant|Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
41281243|NCT02528695|RADIATION|18F-FDG PET/CT|18F-FDG PET/CT
41281244|NCT02528695|DEVICE|euglycemic clamp|euglycemic clamp
41281245|NCT02528695|DEVICE|hypoglycemic clamp|hypoglycemic clamp
41281246|NCT01715025|DRUG|E2Nomac|Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
41281247|NCT02894073|DEVICE|skin transilluminator|VeinViewer
41281248|NCT03222661|DIAGNOSTIC_TEST|Refraction|Refractive error measurement
41281249|NCT02997930|BEHAVIORAL|fMRI|fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.
41281250|NCT02997930|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|A measure of general cognition
41281251|NCT02997930|BEHAVIORAL|Digital Clock Drawing Test Command and Copy|A measure of current cognition using digital pen technology
41281252|NCT02997930|BEHAVIORAL|Wide Range Achievement Test reading subtest|A measure of premorbid intellectual estimate
40939624|NCT04295655|OTHER|Global Exercise intervention|The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises
40939625|NCT04295655|OTHER|Functional Electrostimulation Group|"The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
40939626|NCT04295655|OTHER|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
40939627|NCT00070655|DRUG|SR34006 (idraparinux sodium) Injection|
40939628|NCT00070655|DRUG|vitamin K antagonist (warfarin or acenocoumarol) tablets|
41281253|NCT02997930|BEHAVIORAL|Hopkins Verbal Learning Test (HVLT)|A measure of declarative memory
40939629|NCT05078502|DIETARY_SUPPLEMENT|Vitamin D3|One capsule of vitamin D3(40000IU) weekly for 8 weeks
40939630|NCT02474888|OTHER|blood specimen|blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
40939631|NCT04387721|OTHER|Kind of trifocal IOL|Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D
41266969|NCT00721487|DRUG|Fluconazole|Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
41266970|NCT01067131|BIOLOGICAL|PEV7C1|capsule intravaginal application contains antigen coupled to virosomes
41266971|NCT01067131|BIOLOGICAL|PEV7C9|capsule intravaginal application contains excipient only
41266972|NCT01067131|BIOLOGICAL|PEV7B2|reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes
41281254|NCT02997930|BEHAVIORAL|General Depression Scale (GDS)|A measure of the of presence of depression.
41281255|NCT04632979|PROCEDURE|Backwards running on a Treadmil with a negative slope|Running backward on a treadmill with a negative slope
41281256|NCT03146312|DIETARY_SUPPLEMENT|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 4 weeks
41281257|NCT03146312|DIETARY_SUPPLEMENT|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
41281258|NCT05330520|PROCEDURE|"Butterfly Medical Prostatic Retraction Device (the Butterfly device) removal/replacement"|when necessary, the device may be removed or replaced easily through the urethra due to its minimal surface and easy release from the mucosa covering it.
41281259|NCT01215539|DRUG|panitumumab|Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
41281260|NCT00276289|DRUG|Spironolactone|
41281261|NCT02309710|DEVICE|ShangRing|ShangRing administered to males seeking medical male circumcision
41281262|NCT02795234|OTHER|Blood samples|
40939632|NCT06344182|OTHER|Step Up and Down Test|Step Up and Down Test In the StUD test, the patient completes maximum number of step-up-down repetitions in 15 seconds. Starting from a standing position, the participant took a full step up, leading with the test leg, then the non-testing leg, until both knees were fully extended and both hips were at least in neutral extension. In order to stress the testing limb concentrically and eccentrically, the participant stepped off the step first with the non-testing limb, then the testing limb. The patient was asked to repeat for 15 seconds as quickly as possible. The physical therapist stood to the side of the step for safety and so that he/she could observe the technique and ensure that the participant came to a full step up and down during the test.
40939633|NCT00002065|DRUG|Disulfiram|
40939634|NCT04476823|OTHER|Activity|The questionnaire had requested information on the biosafety organization, impact of the COVID-19 crisis on the clinical and molecular pathology and the biobanking activity in thoracic pathology, on the research activity associated with the COVID-19, and on the educational and training organization. It requested the different needs planned by the different laboratories following the COVID-19 crisis and finally the consequence of this latter on the health and virological status of the staff members.
40939635|NCT00780390|OTHER|Autonomic Function Assessment|
40939636|NCT00216554|DRUG|risperidone|
40939637|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
40939638|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
40939639|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
40939640|NCT01545453|DRUG|placebo|subcutaneous dose every 4 weeks
40939641|NCT00417573|DRUG|IV Gamunex 10%|
40939642|NCT05730816|DRUG|Magnesium sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
40939643|NCT05730816|DRUG|Normal Saline|Intravenous infusion of normal saline.
40939644|NCT00494065|OTHER|Home exercise|Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.
40939645|NCT00494065|OTHER|Chiropractic Spinal Manipulative Therapy + Home exercise|The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
40939646|NCT02809521|OTHER|Activity Liking|
40939647|NCT00477581|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
40939648|NCT00477581|DRUG|sitagliptin|oral administration (100mg), once a day in the morning
40939649|NCT06552247|DIAGNOSTIC_TEST|Fundus Picture AI testing|G-Risk AI algorithm will assess the optic disc centered fundus picture and determine whether or not there is a need for referrable based on a pre-determined threshold (\>=0.73)
40939650|NCT04647071|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
40939651|NCT04647071|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose
40939652|NCT03964844|OTHER|No intervention|No intervention
40939653|NCT04529473|DIETARY_SUPPLEMENT|Eubacterium hallii|Eubacterium hallii, ≥ 1x10\^9 live bacterial cells (per capsule)
41131901|NCT04536766|BEHAVIORAL|Enhanced Sleep Health Education|The intervention comprehensively addresses poor sleep health behaviors. Personalized sleep health education will be delivered in two telephone sessions by Beds for Kids staff members. Sleep health information will consist of the following evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a family bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs. Personalization will be accomplished via direct questions to families during the education phone call related to their own barriers to achieving healthy sleep habits and goals for optimal sleep.
41131902|NCT04536766|BEHAVIORAL|Beds for Kids Standard Program|The Beds for Kids program provides beds, bedding, and written healthy sleep education to families living at or below 100% of the federal poverty line and without an individual child bed to sleep in.
41131903|NCT05416476|DRUG|Anisodine Hydrobromide|Anisodine Hydrobromide 1 mg oral tablet, twice times a day
41131904|NCT05416476|DRUG|Anisodine Hydrobromide placebo|Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day
41131905|NCT00661336|DRUG|buthionine sulfoximine|
41131906|NCT00661336|DRUG|melphalan|
41131907|NCT00661336|GENETIC|microarray analysis|
40939654|NCT04529473|OTHER|Placebo|Placebo capsules are identical to the active treatment
40939655|NCT00004017|PROCEDURE|conventional surgery|
40939656|NCT00004017|RADIATION|iodine I 131 monoclonal antibody TNT-1/B|
40939657|NCT06411600|DRUG|Encorafenib|Encorafenib is administered orally at a daily dose of 300 mg, typically in the form of four 75 mg capsules taken together.
40939658|NCT06411600|DRUG|Cetuximab|Cetuximab is administered intravenously every two weeks at a dose of 500 mg/m².
40939659|NCT06411600|DRUG|Bevacizumab|Bevacizumab is administered intravenously every two weeks at a dose of 5 mg/kg.
40939660|NCT04601922|OTHER|Semi-structured interview|The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways
40939661|NCT00992329|DRUG|ciprofloxacin|ciprofloxacin 200mg tablet (single dose)
40939662|NCT03785288|RADIATION|HDR vaginal brachytherapy|HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions
40939663|NCT01717144|BEHAVIORAL|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
40939664|NCT02341105|PROCEDURE|Catheter ablation|Pulmonary vein isolation by catheter ablation
41131908|NCT00661336|OTHER|high performance liquid chromatography|
41131909|NCT00661336|OTHER|laboratory biomarker analysis|
41131910|NCT00661336|OTHER|pharmacological study|
41131911|NCT00661336|PROCEDURE|biopsy|
40939665|NCT02341105|DRUG|Amiodarone|antiarrhythmic therapy using Amiodarone
41266973|NCT01067131|BIOLOGICAL|PEV7B1|reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
40939668|NCT02266043|DEVICE|Pre-epiglottic baton plate (PEBP)|"modified acrylic palatal plate in which a velar extension resembling a spur or baton shifts the base of the tongue forward.~This treatment is the standard care for infants with Pierre-Robin-Like Phenotype in the participating study centers and not assigned by protocol."
40939669|NCT02034071|DRUG|DCCR|
40939670|NCT02034071|DRUG|Placebo|
40939671|NCT01484132|PROCEDURE|Restoration of dental caries with dental composite|Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
40939672|NCT01242683|BEHAVIORAL|Vivamos Activos Fair Oaks Program|"Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms."
40939673|NCT02676466|DIETARY_SUPPLEMENT|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
40939674|NCT02676466|DRUG|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
40939675|NCT02676466|OTHER|Corn Oil (Fish oil Placebo)|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
40939676|NCT02676466|OTHER|Cellulose Based (Losartan Placebo)|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
40939677|NCT05252065|OTHER|Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging|Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.
40939678|NCT02572193|PROCEDURE|POEM|To determine the feasibility of same-day discharge following a POEM procedure
40939679|NCT02752971|DRUG|Bupivacaine|
41281263|NCT05821543|DRUG|metformin+sibutramine|1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)
40756443|NCT00966446|DRUG|Supervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
40939680|NCT02752971|DRUG|Sodium diclofenac|
40939681|NCT05868668|DEVICE|Focused shockwave|Storz Duolith SD-1 (Storz Medical, Tagerwilen, Switzerland)
40939682|NCT05868668|DEVICE|Radial wave|Zimmer enPuls Pro (Zimmer MedizinSysteme GmbH, Neu-Ulm, Germany)
40939683|NCT05868668|DEVICE|Sham treatment|Handheld sham probe
40939684|NCT03952754|BEHAVIORAL|Hip Hop Nutrition-Math Curriculum|This program teaches children skills needed to understand restaurant-menu boards, how to make healthy food choices, while reinforcing the common core math concepts they are learning in school. The program consists of: 2 lessons a week, of about 1 hour each lesson, for a total of 20 lessons.
41281264|NCT05821543|DRUG|sibutramine+ microcrystalline cellulose|1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)
41281265|NCT06244576|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as anorexia nervosa, autism spectrum disorder, refractory depression, cluster c personality disorders, and mood disorders.
41281266|NCT01657123|OTHER|ergometry|ergometry measurements
41281267|NCT01657123|OTHER|ergometry|Ergometry measurements
41281268|NCT02942498|DRUG|Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|
41281269|NCT02942498|DRUG|Placebo|Placebo
41281270|NCT06403852|COMBINATION_PRODUCT|Functional Magnetic Resonance Imaging (fMRI) with propofol|Three 16-min sessions in wakeful baseline, light sedation, and recovery will be conducted (Fig. 2). Light sedation will be achieved by IV infusion of propofol to achieve effect-site concentrations of 1.0 μg/ml. Infusion rate will be manually controlled. An initial bolus dose (525 µg/kg) and subsequent infusion rate (82 µg/kg/min) for each participant
41281271|NCT01645761|DRUG|Endonase|PPI- based triple therapy with endonase
41281272|NCT01029561|DEVICE|CPAP|Treatment with Continuous Positive Airway Pressure
41281273|NCT01029561|BEHAVIORAL|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
41281274|NCT03373786|DRUG|RG012|RG012 in 0.3% sodium chloride
41281275|NCT03486236|DRUG|VX-440|VX-440 was administered in TC with TEZ and IVA.
41281276|NCT03486236|DRUG|TEZ|TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
41281277|NCT03486236|DRUG|IVA|IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet
41281278|NCT03486236|DRUG|Matched Placebos|Placebos matched to VX-440, TEZ, and IVA.
41281279|NCT05972187|OTHER|Temperature and Humidity|Temperature and Humidity of room changed
41281280|NCT03487224|DEVICE|MRI with fMRI frequency|Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
41281281|NCT00893607|DRUG|NRL001|10mg NRL001 was administered as a slow release suppository
41281282|NCT02585544|PROCEDURE|day-care surgery|day-care surgery
41281283|NCT01662089|DRUG|15 mg Chelate zinc supplement|15 mg Chelate zinc additional to standard 5% minoxidil
41281284|NCT01662089|DRUG|Placebo drug supplement|Placebo drug instead of Zinc supplement
41281285|NCT02803216|DRUG|standard triple region|ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
40756444|NCT05182476|DRUG|Placebo|Oral tablets
40756445|NCT05182476|DRUG|Luvadaxistat|Oral tablets
40939685|NCT03952754|BEHAVIORAL|Food Explorers Program|"After-school program Food Explorers will represent Usual Care. This program comprises food and exploration activities, familiarizing children with diverse foods, nutrition concepts, tasty recipes and physical activity."
40939686|NCT02966041|DRUG|Ondansetron|Ondansetron/Zofran is an antiemetic drug used to prevent and treat nausea and vomiting.
41281286|NCT02803216|DRUG|2-week Xiang-sha-liu-jun decoction|2-week Xiang-sha-liu-jun decoction, bid.
41281287|NCT02803216|DRUG|4-week Xiang-sha-liu-jun decoction|4-week Xiang-sha-liu-jun decoction, bid.
41281288|NCT05671653|DRUG|PF-07081532|Experimental oral GLP-1 drug
41281289|NCT05671653|DRUG|Semaglutide|Approved and marketed GLP-1 drug for subcutaneous injection.
41281290|NCT06246682|PROCEDURE|Transcanal Endoscopic removal of atticoantral cholesteatoma|removal of the cholesteatoma presented in the atticoantral region by otoendoscope
41281291|NCT00296439|BEHAVIORAL|Behavior|
41281292|NCT05741203|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound
41281293|NCT01826214|DRUG|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
41281294|NCT01217749|DRUG|PCI-32765|420 mg PO daily
41281295|NCT01217749|DRUG|ofatumumab|per package insert as an IV infusion
41281296|NCT04909567|BEHAVIORAL|Optimisation|Defined optimisation
41281297|NCT05893134|OTHER|Risk Assessment|A probabilistic risk model will be generated based on the variables of different natures used and maps will be built to identify the areas of greatest risk for dengue transmission in the study area
41281298|NCT04874740|OTHER|No intervention|No intervention
41281299|NCT02450357|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
41281300|NCT02450357|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
41281301|NCT03319199|DIETARY_SUPPLEMENT|"SLIM WATER"|2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks
40939687|NCT02966041|DRUG|Saline|Normal saline is salt water and is acting as a placebo in this study. A placebo is an inactive substance that looks identical to the test drug, but it contains no therapeutic ingredient.
40939688|NCT05337293|BEHAVIORAL|COPE-HF Partnership Intervention|Participants were trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems experienced in the home over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention was to move HF patients toward a positive problem orientation and use of rational problem-solving strategies that support greater HF self-care and reduce depression. The COPE-HF Partnership Intervention consisted of 1 home visit and 7 follow-up telehealth sessions led by a registered nurse interventionist.
40939689|NCT05337293|OTHER|Attention|Participants in the attention group received a sham intervention that consisted of scheduled telephone calls consistent with the timing of that received by the intervention group. During these calls, basic information was gathered on key areas of heart failure self-care management and the frequency of healthcare usage. No intervention or education was provided.
40939690|NCT00519298|DRUG|SAM-531|dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
40939691|NCT00519298|OTHER|placebo|placebo
40939692|NCT00519298|DRUG|Donepezil|dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
40939693|NCT02640469|OTHER|Chlorhexidine with water rinse|"This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute"
40939694|NCT02640469|OTHER|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
40939695|NCT02640469|OTHER|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
41450952|NCT04605835|DIAGNOSTIC_TEST|ULTRASONIC VISUALIZATION OF OBSTRUCTIVE UROPATHIES IN CHILDREN.|The purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using Doppler ultrasound. Based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.
41450953|NCT00728754|DEVICE|Dental implant Osseotite Prevail|Root form titanium dental implant
41131912|NCT03930940|DEVICE|remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.
41131913|NCT03930940|OTHER|Regular treatment|Regular treatment is based on associated guidelines for ICH.
41450954|NCT00728754|DEVICE|Dental implant Osseotite|root form titanium dental implant
41450955|NCT01852799|DRUG|PAD Followed by ASCT|"Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
41450956|NCT03892343|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.
41450957|NCT00673010|RADIATION|131 I-iodine (131-I), 124 I-iodine (124-I)|Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
41450958|NCT00197249|BIOLOGICAL|Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix|
41450959|NCT01089530|BEHAVIORAL|Lifestyle intensive group|hipocaloric diet smoking cessation physical exercise
40939696|NCT03028350|DRUG|Ifetroban Oral Capsule|Subjects will be treated with oral ifetroban daily for 8 weeks
41131914|NCT03295409|BEHAVIORAL|Self-affirmation|Participants are asked to complete a standard questionnaire and on the last page they are asked to form a self-affirming implementation intention by copying out a sentence.
41131915|NCT00002236|DRUG|Indinavir sulfate|
41131916|NCT00002236|DRUG|Delavirdine mesylate|
41131917|NCT00002236|DRUG|Zidovudine|
41266974|NCT01694043|OTHER|Healthy Foods|While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
41266975|NCT01694043|OTHER|Unhealthy Snack Foods|While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
41281302|NCT03319199|OTHER|Placebo - water|for a duration of 16 weeks
40939697|NCT03028350|DRUG|Placebo Oral Capsule|Subjects will be treated with oral placebo daily for 8 weeks
40939698|NCT00764491|DEVICE|Structural Allograft Spacer|Following disc space preparation the spacer is placed in accordance with cleared labeling and supplemental instrumentation is provided as an adjunct to fixation.
40939699|NCT00764491|DEVICE|OptiMesh 1500S|Following disc space preparation the OptiMesh is deployed and filled in accordance with study surgical technique and supplemental instrumentation is provided as an adjunct to fixation.
40939700|NCT05116358|DEVICE|Phototherapy device|The active phototherapy device will emit light
40939701|NCT00425633|DRUG|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
40939702|NCT01721473|OTHER|positron emission tomography scan|2-FA positron emission tomography scan
40939703|NCT05753631|PROCEDURE|non surgical periodontal treatment|"scaling and root planning were applied for non-surgical periodontal treatment i-PRF application: Intravenous blood sample taken from the antecubital vein of the patients was collected in a 10 ml tube and centrifuged at 700 rpm for 3 minutes in a PRF centrifuge device. The PRF obtained from the upper liquid layer formed in the tube was injected subgingival into the deepest point of the pocket after SRP treatment.~Clinical periodontal measurements: plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing, and gingival recession were calculated.~gingival crevicular fluid: Perio papers were placed in the deepest part of the sulcus and left for 30 seconds. After 30 seconds, the paper strips were placed in the periotron device and the volume was calculated."
40939704|NCT05921318|COMBINATION_PRODUCT|Beijing protocol|"For patients \<55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)~For patients ≥ 55 years or HCI-CI\>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)."
40939705|NCT06424327|OTHER|Patient-Reported Outcomes Measurement Information System|Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)
41131918|NCT05063006|OTHER|Cardiopulmonary exercise tests with maintained baseline optimal pump speed settings.|Optimal resting LVAD speed settings is defined as periodic aortic valve opening while maintaining the central position of the intraventricular septum, minimizing mitral regurgitation, and preserving the mean systemic blood pressure above 65 mmHg. The aim is to achieve an aortic valve opening ratio of around 25-33% by changing the pump speed at resting conditions.
41266976|NCT02604264|DEVICE|ClearGuard HD end cap|The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub
41266977|NCT01052857|PROCEDURE|acupuncture|acupuncture application
41266978|NCT03023904|BIOLOGICAL|Nivolumab|Given IV
41266979|NCT03023904|OTHER|Laboratory Biomarker Analysis|Correlative studies
41266980|NCT02269358|DRUG|METHOTREXATE|Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
41266981|NCT00381407|BEHAVIORAL|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
41266982|NCT00381407|BEHAVIORAL|Contingency management (CM)|"Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal."
41266983|NCT03992144|DRUG|Amoxicillin 500 Mg|Amoxicillin 500mg an hour before tooth extraction
41266984|NCT03992144|DRUG|metronidazole 400mg|400mg of metronidazole an hour before extraction
41266985|NCT03992144|DRUG|metronidazol 400mg and amoxicillin 500mg|400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
40939706|NCT03311620|PROCEDURE|Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)|Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
41450960|NCT04516096|DRUG|AMX0035|Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day
41450961|NCT02278302|DRUG|Aggrenox®|
41450962|NCT02278302|DRUG|Placebo|
41450963|NCT02278302|OTHER|Ethanol|
41450964|NCT03904095|PROCEDURE|Psoas Compartment Block Group (GROUP I)|Psoas Compartment Block will perform preoperative to all patients in Group I. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
41450965|NCT03904095|PROCEDURE|Erector Spinae Plane block ( Group II)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
41450966|NCT03904095|PROCEDURE|Control Group (GROUP III)|Control group will receive no intervention. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
41450967|NCT03575351|DRUG|Standard of Care|Standard of Care
41450968|NCT03575351|GENETIC|JCAR017|JCAR017
41450969|NCT03972696|RADIATION|Irradiation|BA3S versus BA2 irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
41450970|NCT00056433|DRUG|Hydroxyurea|
41450971|NCT00056433|DRUG|L-Arginine|
41450972|NCT00056433|DRUG|Sildenafil|
41450973|NCT00926835|DRUG|paroxetine|6 weeks, 20-50mg/day
40939707|NCT03866031|OTHER|implant-supported mandibular overdenture|The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.
40939708|NCT05778851|DEVICE|EsoGuard result|Education slide-set EsoGuard and patient cases including EsoGuard result
41281303|NCT05059353|DEVICE|Digitally based multidomain intervention|"Education (5-10 mins). This session is to educate patients on instrumental activities of daily living such as the importance of companionship, medication, finance, home, travel, and kitchen safety. The content will be delivered using video and text-based material in English.~Physical Activity (10 mins). This session includes activities such as brisk walking and yoga. Participants will be allowed to choose their preferred exercise option from the menu.~Reminiscence Therapy (20 mins). This session includes recollection of events using directed questions, and a collection of photos from the past. Participants will be asked to share about any aspect related to the given topics using text or audio.~Cognitive Games (20 mins). Participants will be asked to play games using their fingers to control characters on the screen to achieve goals. These games are designed to train different cognitive abilities, including attention, memory, executive functioning, and processing speed."
41281304|NCT00844883|DRUG|sorafenib|sorafenib: given 400 mg twice per day for as long as it is beneficial
41281305|NCT00844883|PROCEDURE|LC Bead-TACE|"LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period"
41281306|NCT02919293|BIOLOGICAL|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)|30μg /dose, Intramuscular
41281307|NCT02919293|BIOLOGICAL|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)|0.5ml /dose, Intramuscular
41281308|NCT05026073|BEHAVIORAL|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia|age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
41450974|NCT00926835|DRUG|Escitalopram|10-20mg/day for 6 weeks
41450975|NCT00926835|DRUG|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
41450976|NCT00926835|DRUG|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
41450977|NCT00926835|DRUG|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
41450978|NCT00926835|DRUG|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
41450979|NCT00926835|DRUG|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
41450980|NCT00926835|DRUG|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
41450981|NCT00926835|DRUG|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
41450982|NCT00731939|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
41450983|NCT02744287|BIOLOGICAL|BPX-601|Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain
41450984|NCT02744287|DRUG|Rimiducid|Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence
41450985|NCT04002648|PROCEDURE|Right minithoracotomy|Incision of the right chest between 3rd and 4th or 4th and 5th intercostal space
41450986|NCT04002648|PROCEDURE|Sternotomy|Longitudinal resection of the sternum
41450987|NCT05717790|DRUG|Nimotuzumab|"Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT ."
40939709|NCT05411133|DRUG|Cabotamig (ARB202)|Cabotamig (ARB202), Atezolizumab
40939710|NCT00266773|BEHAVIORAL|Chronic pain therapeutic interactive voice response (TIVR) system|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
40939711|NCT06271655|DEVICE|SPOTFIRE R Panel|The intervention involves the use of a rapid point-of-care multiplex PCR test (Spotfire) to identify etiology of patients with ARI. Specimen samples will be collected by research staff at the time of ED presentation. Upon collection, the sample will be promptly prepared for testing on the SPOTFIRE R Panel device. The device will be in the ED to facilitate testing and accelerate delivery of diagnostic results to clinicians. The time when the provider receives the results will be recorded to evaluate the incorporation of results in clinical decision making.
40939712|NCT02136108|OTHER|OPENtext|Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
40939713|NCT02136108|OTHER|OPENnav|Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
40939714|NCT03490968|BEHAVIORAL|Supervised Exercise|Subjects will have 3 visits per week for 12 weeks.
40939715|NCT03490968|BEHAVIORAL|Vascular Assessment|"Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated."
40939716|NCT03711266|BEHAVIORAL|PE-PC|PE-PC treatment will follow the PE-PC manual and patient workbook. Treatment content for PE-PC is drawn from the PE model and condensed so as to deliver the most efficacious components of PE. PE-PC consists of four, 30-minute appointments scheduled approximately once a week over 4-6 weeks
40939717|NCT02818491|DRUG|Placebo|Normal saline 0.9% in 2 mls
40939718|NCT02818491|DRUG|Dexamethasone 1 mg|Dexamethasone 1 mg in 2 mls
40939719|NCT02818491|DRUG|Dexamethasone 2 mg|Dexamethasone 2 mg in 2 mls
40939720|NCT02818491|DRUG|Dexamethasone 3 mg|Dexamethasone 3 mg in 2 mls
40939721|NCT02818491|DRUG|Dexamethasone 4 mg|Dexamethasone 4 mg in 2 mls
40939722|NCT02818491|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% 20 mls
40939723|NCT02273531|DRUG|Asasantin ER, new formulation|
40939724|NCT02273531|DRUG|Asasantin ER, present commercial formulation|
40939725|NCT03722173|DRUG|Itraconazole|Oral solution
40939726|NCT03722173|DRUG|BI 894416|Tablet
40939727|NCT00430651|DRUG|Docetaxel|Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
40939728|NCT00430651|DRUG|Carboplatin|Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15
40939729|NCT06275607|BEHAVIORAL|Cognitive Behavioral Affective Therapy|Active training in regulating anger.
40939730|NCT06275607|BEHAVIORAL|Emotional Discussion|General discussion of emotions; no therapy or training is offered.
40939731|NCT02758977|PROCEDURE|ALPPS|For detailed information please refer to description of experimental arm
40939732|NCT02758977|PROCEDURE|TWO STAGE HEPATECTOMY|For detailed information please refer to description of active comparator arm
40939733|NCT03751228|DRUG|BMS-986165|Swish and expectorate after tasting
40939734|NCT03751228|DRUG|Active Pharmaceutical Ingredient|Swish and expectorate after tasting
40939735|NCT05743621|DRUG|TVB-2640|TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
40939736|NCT05743621|DRUG|Enzalutamide|160 mg daily PO
40939737|NCT01654627|DEVICE|Regenecure AMCA GBR Dental Membrane|Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane
40939738|NCT01654627|DEVICE|Geistlich Bio-Gide® collagen membrane|The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
40939739|NCT06038474|DRUG|Descartes-08|Autologous T-cells expressing a chimeric antigen receptor directed to BCMA
41450988|NCT05717790|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
40939740|NCT04076527|DRUG|UDCA|Routine data is collected for UDCA therapy.
40939741|NCT04076527|DRUG|Ocaliva|Routine data is collected for OCA therapy.
40939742|NCT03508427|OTHER|Daily self-monitoring|Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
40939743|NCT06326489|DEVICE|Switching to the Medtronic 780G insulin pump|Patients using a Medtronic 740G insulin pump will receive the 780G model for three months
40939744|NCT05373771|OTHER|Care pathway|Implementation of care pathway as part of hybrid type 2 implementation effectiveness study
40939745|NCT06077708|DIETARY_SUPPLEMENT|Vitamin D3K2|Non-surgical periodontal treatment was applied to all individuals included in the study. 2 drops of the preparation containing 25 µg D3 \[1000 IU\] and 11.25 µg K2 in each drop were given per day to participants in the test group.
40939746|NCT06077708|OTHER|Saline Solution|Non-surgical periodontal treatment was applied to all individuals included in the study and saline solution (0.9% NaCl) was given as placebo, 2 drops per day to particiapants in the control group.
40939747|NCT05616806|BEHAVIORAL|iENDURE|"Two delivery modes: computer and text message. The intervention provides introductory strategies for managing physical and emotional distress associated with Long COVID through a computer-delivered session followed by 4-weeks of theoretically-informed text messages intended to promote distress tolerance (DT).~Computer - the initial intervention will be delivered online via the Qualtrics survey tool following informed consent. The intervention provides strategies to better tolerate emotional and physical discomfort to persist with behavioral goals. Text Message - The text message intervention will be delivered using Marigold Health (a HIPAA compliant platform for secure text messaging). Participants will receive daily text messages that focus on emphasizing adaptive strategies for tolerating physical and emotional discomfort in order to work toward behavioral goals. The text messages will be personalized and offer skills training (reminders of previously learned DT skills)."
40939748|NCT00941382|DRUG|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
41450989|NCT05717790|DRUG|Cisplatin|"Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles."
41450990|NCT05717790|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
41450991|NCT01750073|DRUG|Cyclophosphamide|Given IV
41450992|NCT01750073|DRUG|Doxorubicin Hydrochloride|Given IV
41450993|NCT01750073|OTHER|Laboratory Biomarker Analysis|Correlative studies
41450994|NCT01750073|DRUG|Paclitaxel|Given IV
41450995|NCT01750073|RADIATION|Radiation Therapy|Undergo RT
41450996|NCT01750073|PROCEDURE|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
40939749|NCT00941382|DRUG|Sibutramine|15 mg per day for 180 days
40939750|NCT00941382|DRUG|Metformin|Metformin 850 mg per day for 180 days
41281309|NCT05026073|PROCEDURE|Blood and endometrial tissue sampling|"* All women will undergo planned hysterectomy.~* Venous blood sample will be collected prior to surgery.~* Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~* Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation."
41281310|NCT05026073|PROCEDURE|Lymph node sampling|"Lymph nodes will be excised if recommended as part of the standard treatment for endometrial cancer.~Each node will be cut in half or in quarters, depending on size, to expose the core. Wet and dry spectral analysis will be performed, followed by staining for histopathological confirmation."
41281311|NCT04359966|DRUG|Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,|First line therapy
41281312|NCT04359966|DRUG|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|First line therapy second arm
41281313|NCT04359966|DRUG|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|Second line therapy for Helicobacter pylori infection
40939751|NCT01091727|DRUG|Botulinum toxin A|Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
41281314|NCT04359966|DRUG|Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg|Second line therapy for Helicobacter pylori infection second arm
41281315|NCT01627704|DRUG|Fluoroestradiol (18F)|2-4 MBq/kg body mass, one single IV injection
41281316|NCT03062917|DIAGNOSTIC_TEST|Nasal and Bronchial Sampling|Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
41450997|NCT01750073|BIOLOGICAL|Trastuzumab|Given IV
40939752|NCT05302661|BEHAVIORAL|re-education|Contact patients by phone or wechat and guide them
41450998|NCT01127113|OTHER|Infusion of investigational product|The investigational product will be delivered via intravenous infusion
41450999|NCT01127113|OTHER|Cardiac magnetic resonance imaging|Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
41451000|NCT00794794|DRUG|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
41451001|NCT00794794|DRUG|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
41451002|NCT01490190|DRUG|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
41451003|NCT06249113|DRUG|NaCl 0.9%|NaCl 0.9% continous intravenous on tumor craniotomy surgery
41451004|NCT06249113|DRUG|Adjuvant lidocaine continous|Adjuvant lidocaine continous intravenous on tumor craniotomy surgery
41451005|NCT00001058|DRUG|Indinavir sulfate|
41451006|NCT00001058|DRUG|Ritonavir|
41451007|NCT00001058|DRUG|Ethambutol hydrochloride|
41451008|NCT00001058|DRUG|Clarithromycin|
41451009|NCT00001058|DRUG|Rifabutin|
41451010|NCT01062490|DRUG|Treosulfan|14 g/m2/d, day -6 to -4
41451011|NCT00521586|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
41451012|NCT00521586|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
41451013|NCT01492439|BEHAVIORAL|Cognitive Remediation|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness. In addition to the supports available to all RTE students, this group will receive a total of twenty 45 minute computer-based cognitive exercise sessions held twice a week using COGPACK (Ver 6.0,www.cogpack.de). This program facilitates practice across a range of cognitive functions, including attention,psychomotor speed,memory, and executive functions. Participants will also take part in 10 weekly group discussion sessions,approximately 60 minutes in duration, focusing on strategies for management of symptoms and other cognitive deficits in an academic setting.
41281317|NCT00142506|DRUG|sildenafil citrate and questionaires|"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
40939753|NCT02772679|BIOLOGICAL|PolyTregs+IL-2|PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10\^6 cells. The second cohort will receive 20x10\^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
40939754|NCT01476644|OTHER|Clinical evaluation|Biomicroscopy (look at front of eye), ophthalmoscopy (look at back of eye), visual acuity, visual fields, intraocular pressure, spectral domain optical coherence tomography, Pelli-Robson and the Spaeth-Richman Contrast Sensitivity tests
40939755|NCT01476644|OTHER|Performance based measures|Compressed Assessment of Ability Related to Vision (CAARV) items include: 1) computerized motion detection; 2) recognizing facial expressions; 3) reading street signs; and 4) finding objects in a room
40939756|NCT01476644|OTHER|Subjective measures of vision-related quality of life|National Eye Institute Visual Functioning Questionnaire 25 (NEI-VFQ-25) includes a series of questions pertaining to vision or feelings about a vision condition and the Modified Glaucoma Symptom Scale (MGSS) includes a series of questions pertaining to eye comfort.
40939757|NCT00953459|DRUG|sunitinib malate|
40939758|NCT00953459|OTHER|laboratory biomarker analysis|
40939759|NCT00953459|RADIATION|fludeoxyglucose F 18|
41281318|NCT00142506|DRUG|placebo tablets and questionaires|"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
41281319|NCT05297565|BIOLOGICAL|Nivolumab/rHuPH20|Specified dose on specified days
41281320|NCT05297565|BIOLOGICAL|Nivolumab|Specified dose on specified days
41281321|NCT04109040|DEVICE|slit lamp|diagnostice device to examine anterior segment of the eye and for fundus examination
41281322|NCT05194436|DEVICE|AeviceMD|The AeviceMD will be placed on the patient to detect wheeze and perform auscultation.
41281323|NCT00840463|DRUG|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
41281324|NCT00840463|OTHER|Placebo|Sugar pill
41281325|NCT01838057|DEVICE|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
40939760|NCT04082039|OTHER|convetional PCA method unsing only 1-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
41281326|NCT01838057|OTHER|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
40756446|NCT04349371|DRUG|Chloroquine|Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.
41451014|NCT01492439|BEHAVIORAL|Supported Education|Students enroll in credit courses, such as communications, computer skills, and the psychology of human relations which can lead to eligibility for post-secondary programs. Remedial skills in English, supervised study skills classes and other non-credit courses are included. Vocational testing is offered to help students determine their interests and aptitudes and students try out possible careers as well as their readiness to return to work by engaging in volunteer and work placements. Counsellors are also available to assist students in areas such as learning difficulties and coping with the stresses of school. The overarching goal of this program is to help students explore valued non-illness identities, build confidence, and re-engage with their communities.
41451015|NCT06470243|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41281327|NCT03216629|BEHAVIORAL|"Saying sorry"|"The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?"
41281328|NCT01651923|DRUG|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
41281329|NCT05475873|DRUG|normal saline|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
41281330|NCT05475873|DRUG|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
41281331|NCT05475873|DRUG|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
41281332|NCT00005037|DRUG|temozolomide|
40756447|NCT04349371|DRUG|Placebo oral tablet|Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
40756448|NCT00781664|OTHER|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
40756449|NCT00781664|DRUG|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
40939761|NCT04082039|OTHER|utilizing 2-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
41281333|NCT00005037|DRUG|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
41281334|NCT06483828|BEHAVIORAL|Dental Anxiety Coping Module|Dental tour where participants will be introduced to the dental clinic setting while Expressive Art Therapy, participants will engage with activity of making collage and finger painting.
41451016|NCT06470243|PROCEDURE|Bone Scan|Undergo bone scan
40756450|NCT00781664|DRUG|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
40756451|NCT00781664|OTHER|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
40756452|NCT00781664|DRUG|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
40939762|NCT01331941|DRUG|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m\^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
41281335|NCT02655861|OTHER|Observation|
41451017|NCT06470243|DRUG|Cabazitaxel|Given IV
41451018|NCT06470243|DRUG|Carboplatin|Given IV
41451019|NCT06470243|PROCEDURE|Chest Radiography|Undergo chest x-ray
41451020|NCT06470243|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41281336|NCT06411626|OTHER|PNH-relevant therapies|This is an observational study. There is no treatment allocation. The decision to initiate PNH-relevant therapies (such as eculizumab, ravulizumab, pegcetacoplan, iptacopan, and others) will be based solely on clinical judgement.
41281337|NCT03128463|DRUG|Intravitreal injection of conbercept|We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
41281338|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
40939763|NCT01331941|DRUG|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
41281339|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
41281340|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
41281341|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
41451021|NCT06470243|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41451022|NCT06470243|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40939764|NCT01704898|DRUG|Efavirenz 600 Test-Stocrin 600 Reference|
41281342|NCT00847613|DRUG|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
41281343|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
41281344|NCT00847613|DRUG|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
41281345|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
41281346|NCT06489145|DEVICE|Technology-enhanced Rehabilitation|"Based on their individualized rehabilitation project, patients will undergo robot-assisted therapy (RAT) and/or virtual reality (VR)-based treatment.~RAT will consist of the use exoskeleton devices intended for the treatment of upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™) impairments.~VR-based rehabilitation will be conducted non-immersive VR devices: the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), and the Walker View™ (TechnoBody SRL, Italy).~Technology-enhanced treatment duration (number of sessions, minutes of use) will strictly depend on patients' rehabilitation needs and individualized rehabilitation program. Overall, part of the duration of the whole treatment will be dedicated to the use of the technological device, resulting in the same amount of rehabilitation for all participants."
41281347|NCT06489145|OTHER|Multidisciplinary Traditional Rehabiltiation|Patients will receive traditional treatment consisting of two daily one-hour session (4 weeks, 20 sessions) and including rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
41451023|NCT06470243|DRUG|Prednisone|Given PO
41451024|NCT03151577|PROCEDURE|XEN® Gel Stent implantation|Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.
41451025|NCT05206838|PROCEDURE|Surgical reconstruction of gluteus medius with Achilles tendon allograft|Achilles tendon allograft i fixed between the gluteus medius muscle and the greater trochanter
41451026|NCT01883713|DEVICE|Brain Oximetry|Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
40939765|NCT01704898|DRUG|Stocrin 600 Reference-Efavirenz 600 Test|
41451027|NCT04733313|PROCEDURE|ultrasound guıded quadratus lumborum block|Administering local aneshtetic agent with a block needle using the in-plane technique, bilaterally. Lumbar interfascial triangle, where the middle lumbar fascia joins the deep lamina of the posterior layer on the lateral border of the erector spinae was targeted as the optimal point of injection.
41451028|NCT03010657|OTHER|Intervention|Subjects will be asked to consume certain foods during chemotherapy treatment.
40756453|NCT00781664|DRUG|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
41131919|NCT05063006|OTHER|Cardiopulmonary exercise test with gradually increased pump speed depending on live echocardiographic imaging.|During the modified speed exercise, when the aortic valve opening ratio rises above 50%, the pump speed is increased by 100 revolutions per minute (RPM). As the aortic valve remains closed the RPM is lowered by 100. Speed increment is not greater than 100 RPM per 45 seconds to enable an echocardiographic analysis of resulting changes and prevent suction events. There is no determined target speed, neither per time period nor maximal.
41281348|NCT03335501|DEVICE|Insulin pump|The participant's insulin pump will be used to infuse insulin
41281349|NCT03335501|DEVICE|Continuous glucose monitoring system|The Dexcom G4 Platinum will be used to measure glucose levels
41281350|NCT03335501|OTHER|11-hour intervention with the single-hormone artificial pancreas|"Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.~At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.~Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes."
40939766|NCT05916430|DIAGNOSTIC_TEST|EarliPoint Investigational Device|Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.
41281351|NCT06070415|DEVICE|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
41281352|NCT06070415|OTHER|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
41281353|NCT06070415|OTHER|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
41281354|NCT03332888|DRUG|Rituximab|Rituximab will be studied in patients with HFrEF, and verify the patients safety.
41281355|NCT01455727|OTHER|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
40939767|NCT03267732|BIOLOGICAL|Pegilodecakin|Pegilodecakin Alone
41281356|NCT01455727|OTHER|Usual care|Control patients received usual care directed by their physician.
41281357|NCT04819828|PROCEDURE|Extracorporeal shock wave lithotripsy|A single session of extracorporeal shock wave lithotripsy: the session will be finished upon reaching a maximum of 4,000 shocks or if a complete fragmentation of the kidney stone is observed.
41281358|NCT04819828|DRUG|Diclofenac|Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.
41451029|NCT01736007|DEVICE|308-nm excimer laser to alopecia patch|MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
41451030|NCT01736007|DEVICE|Liquid light guide tip on laser|Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
40939768|NCT03317132|BEHAVIORAL|IPS|One year of IPS Support
40939769|NCT02269826|DEVICE|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
40939770|NCT02269826|DEVICE|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
40939771|NCT03702686|DEVICE|FEEDBACK System|Smart Nipple Shield and Monitor Unit
40939772|NCT06260098|BEHAVIORAL|Yoga with High Breath work & meditation; Low movement/postures|Participants will engage in an 8 week asynchronous yoga class focused on the internal and cognitive experience within the practice using breathing and meditation focused techniques.
41281359|NCT04819828|DRUG|Tamsulosin|Oral tamsulosin (0.4 mg/day) for eight weeks.
41281360|NCT05817721|DRUG|Proton pump inhibitor|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not
41281361|NCT05817721|DEVICE|LAMS-implantation|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis
41281362|NCT03954171|OTHER|Patients treated with platinum based-chemotherapy|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~* before treatment initiation (blood sample),~* during hospitalisation for surgery (blood sample),~* during follow-up consultations (blood sample).~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study."
41281363|NCT02363205|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
41281364|NCT04824989|BEHAVIORAL|Sleep Health in Preschoolers (SHIP)|SHIP is an 8 session home visiting intervention to reduce child sleep problems using a framework that draws from motivational interviewing and social cognitive theory, and effectively improves sleep timing, duration, and quality. Following ecological assessment of child sleep and sleep routines, feedback is provided on family strengths and challenges in the child sleep domain, with motivational interviewing to increase parent knowledge of sleep, correct misperceptions, and raise outcomes expectations. The remaining sessions are targeted modules that give tailored feedback and education, and coach the parent in setting manageable goals, identifying action steps, anticipating barriers, and supporting positive behaviors. Targets: bedtime scheduling, consistency, and routines; media use, independent sleep onset, nightmares and fears, night wakings, and early waking; sleep location, nap issues, engaging other caregivers.
41451031|NCT03757195|PROCEDURE|Augmentation|combination product
41281365|NCT04824989|BEHAVIORAL|Family Check-Up (FCU)|FCU is an 8 session home visiting intervention to reduce behavior problems for children through improved parenting. Over 30 years of research establishes its efficacy in reducing behavioral and emotional problems, including in low income toddlers. Following ecological assessment of behavior management and child behavior, family receives feedback on family strengths and challenges within the behavioral domain via a motivational interviewing approach. The remaining sessions are targeted modules drawn from the Everyday Parenting curriculum, individualized based on parent goals and identified challenge areas. Each session begins by establishing a collaborative skill set, involves teaching the rationale for a skill, teaching and modeling effective use of the skill, and then role play and experiential practice to coach the parent to success. Targets can include Positive Behavior Support, Limit Setting and Monitoring, Family Routines, Communication, and Problem Solving.
41281366|NCT04824989|BEHAVIORAL|Oral Health, Child Safety, and Environmental Health Intervention (Active Control)|This intervention serves as an active control condition to ensure that observed effects are due to the intervention content, rather than to study processes, staff attention, or general support and problem solving. The intervention is designed to be comparable to SHIP and FCU in intensity, personal contact, session structure and approach, but focused on Oral Health, Child Safety, and Environmental Health, domains which should not immediately affect study outcomes.
41281367|NCT04990570|OTHER|Telemedicine in the form Virtual clinic via video consultation|"Pediatric patients, with age ranging from 1 month-14 years, with surgical problems, encountered during the era of Covid-19 pandemic.~Some of them seen at the OPD clinic, while the majority failed to attend because of Covid-19 associated lock-down and Curfew, thus, rendering their approach to the service.~Telemedicine, in the form of Virtual clinic, was utilized to address the distressing problem of difficult approach of patients to the pedia surgery OPD because of Covid-19 pandemic restrictive regulatory precautions, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship \& encounter."
40939773|NCT06260098|BEHAVIORAL|Yoga with Low Breath work & meditation; High movement/postures|Participants will engage in an 8 week asynchronous yoga class with a emphasis on the physicality and movements of the practice.
41281368|NCT05069779|DRUG|Diazepam|Oral administration of 10 mg of diazepam
41281369|NCT00189826|DRUG|tacrolimus|immunosuppression
41281370|NCT01854177|DRUG|Aprepitant|
41281371|NCT01854177|DRUG|Placebo|
41281372|NCT04046302|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.
41281373|NCT04046302|DRUG|placebo|one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
41451032|NCT03795012|DRUG|Eribulin|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
41451033|NCT03717701|DRUG|metformin|Patients will take metformin single dose of 1000 mg orally once a day
41451034|NCT03717701|DRUG|esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day
41451035|NCT03717701|DRUG|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
41451036|NCT01843179|DRUG|Cytarabine|Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
40939774|NCT00869427|DRUG|vitamin C|vitamin C 1g bid for 1 year
40939775|NCT04121416|DRUG|Oxycodone 10mg|induction with 0.3mg/kg of oxycodone in general anesthesia
40939776|NCT04121416|DRUG|Sufentanil|induction with 0.3 µg/kg of Sufentanil in general anesthesia
41131920|NCT04152824|BEHAVIORAL|Resilience-Supportive Leadership Training (RESULT)|Leaders will receive a training addressing supportive supervisor behaviors and resilience
41131921|NCT02205515|DRUG|Everolimus|Everolimus is a novel derivative of rapamycin.
41451037|NCT01843179|DRUG|Sulindac|Taken orally twice per day at home for 12 months
41451038|NCT03133260|DIAGNOSTIC_TEST|Troponin|Troponin will be measured before surgery and postoperative at days 1,2 and 3.
41451039|NCT03133260|DRUG|Acetylsalicylic acid|100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
41451040|NCT03133260|DRUG|Statin|40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
41451041|NCT00005873|DRUG|rubitecan|
41451042|NCT04953520|PROCEDURE|ultrasound-CT fusion imaging|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
41451043|NCT04953520|PROCEDURE|pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
41451044|NCT01698554|DRUG|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
41451045|NCT01698554|DRUG|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
41451046|NCT01698554|DRUG|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
41131922|NCT02879942|OTHER|Ultrasound study of the placenta|The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.
40939777|NCT04766827|DRUG|albumin-bound paclitaxel|Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
40939778|NCT05128773|DRUG|Amcenestrant|tablet, oral
40939779|NCT05128773|DRUG|Tamoxifen|tablet, oral
40939780|NCT05128773|DRUG|Amcenestrant-matching placebo|tablet, oral
40939781|NCT05128773|DRUG|Tamoxifen-matching placebo|tablet, oral
40939782|NCT00209508|DRUG|GPI 1485|
40939783|NCT03492411|OTHER|eHealth Breastfeeding Co-parenting Resource|The eHealth breastfeeding co-parenting resource was designed using a participatory model in partnership with the target population. It contains extensive information about breastfeeding and co-parenting. The topics include not only the importance of breastfeeding and technique but also information on how to manage common issues during breastfeeding establishment as well as over the child's first years, since breastfeeding is recommended to two years and beyond. Interactive learning elements, videos, and links to additional resources are included in the resources.
40939784|NCT01094639|PROCEDURE|Scaling root planing|Deep gum cleaning with local anesthesia
40939785|NCT01094639|PROCEDURE|Supragingival Prophylaxis|Plaque removal
41281374|NCT05361096|OTHER|Educational approach (Flipped learning)|"In the intervention group, the out-of-class stage started one week before the in-class stage of the relevant week. The researchers covered the topic of the week asynchronously in the virtual classroom in the learning management system. Students have been able to log into the system at anytime and anywhere and study the course video and other course materials repeatedly.~The in-class stage is the session in which the students in the intervention group come together with the researcher synchronously and conduct an online lesson. It was conducted one session per week for four weeks. The course was carried out synchronously on the Zoom platform during the in-class stage."
40939786|NCT05793437|BEHAVIORAL|permissive hypercapnia|Tidal volume (6-8ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:45～55mmHg
40939787|NCT05793437|BEHAVIORAL|normocapnia|Tidal volume (8-10ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:35～45mmHg
40939788|NCT06360341|BEHAVIORAL|Emergency Department Digital Pain Self-Management Intervention (EDPSI)|The EDPSI is a developed supplemental digital video for patients presenting to the emergency department with acute low back pain (aLBP). The content consists of self-management approaches for diverse adult patient preferences including biopsychosocial contributors to pain and clinical practice guidelines to self-management options. Highlights of the discharge instructions summary include follow-up with provider, red flag warnings, and medication safety. Actor demonstration of ergonomics and range of motion movements provide application of Physical Therapy (PT)-based preventative strategies. Combination therapies including PT counseling, complementary alternative medicine (acupuncture, massage, yoga, or Pilates), and use of and safety with ice or heat thermal therapies. Active participation, stress management, and involvement of support systems are addressed.
40939789|NCT06360341|OTHER|Routine Discharge Care|Routine Discharge Care
40939790|NCT01236014|DRUG|Eltrombopag|Eltrombopag \& standard of care
40939791|NCT01236014|DRUG|Romiplostim|Romiplostim \& standard of care
41281375|NCT05793567|DIAGNOSTIC_TEST|Coronary angiogram with coronary reactivity testing (CRT)|CRT is an angiography procedure (using X-ray) to examine the small blood vessels in the heart and how they respond to three drugs (adenosine, acetylcholine and nitroglycerin) as per clinical protocol.
41281376|NCT04012255|DRUG|Semaglutide (administered by DV3396 pen)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 21 weeks
41281377|NCT04012255|DRUG|Semaglutide (administered by PDS290 pen)|Increasing doses of semaglutide given sc in the stomach for 21 weeks
40939792|NCT01236014|DRUG|Placebo|Placebo \& standard of care
41281378|NCT01725763|OTHER|Cardiac MRI|
41451047|NCT01698554|DRUG|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
40756454|NCT00781664|DRUG|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
40939793|NCT03813771|DRUG|Benepali|Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
40939794|NCT03813771|DRUG|Sulfasalazine|Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
40939795|NCT03813771|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
40939796|NCT03813771|DRUG|Hydroxychloroquine|Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
40939797|NCT00002576|DRUG|cyclophosphamide|
40939798|NCT00002576|DRUG|doxorubicin hydrochloride|
40939799|NCT00002576|DRUG|mitoxantrone hydrochloride|
40939800|NCT00002576|DRUG|prednisolone|
40939801|NCT00002576|DRUG|vincristine sulfate|
40939802|NCT00851760|PROCEDURE|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
40939803|NCT00851760|PROCEDURE|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
40939804|NCT01158664|DEVICE|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
40939805|NCT01158664|DEVICE|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
41281379|NCT00826514|DRUG|Tanezumab|Intravenous, 20 mg, single dose.
41281380|NCT00826514|DRUG|Placebo|Intravenous placebo, single dose
41281381|NCT02017444|DRUG|AZD4017|
41281382|NCT02017444|OTHER|Placebo|Matched placebo (matched to AZD4017 arm)
41281383|NCT00538681|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression
41281384|NCT00538681|DRUG|pemetrexed|500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
41281385|NCT00538681|DRUG|cisplatin|75 mg/m², IV, every 21 days, for each 21-day cycle
41281386|NCT00538681|DRUG|placebo|po, QD
41281387|NCT04752787|OTHER|Online breastfeeding training|Online breastfeeding training will be provided to pregnant women expecting twin babies.
41281388|NCT04752787|OTHER|QR code supported online breastfeeding training|QR code supported online breastfeeding training will be given to pregnant women who are expecting twin babies.
41281389|NCT00782080|DRUG|Sedariston|St. John´s Wort (100 mg) Valerian Extract (50 mg)
41281390|NCT00782080|DRUG|Placebo|Placebo
40756455|NCT00781664|DRUG|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
41281391|NCT02320578|PROCEDURE|3D Laparoscopy|3D Laparoscopy approach
41281392|NCT02320578|PROCEDURE|Standard Laparoscopy|Standard laparoscopy approach
41281393|NCT02016807|DEVICE|ProThelial|August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
41281394|NCT00144170|DRUG|Tipranavir (with low dose ritonavir)|
41281395|NCT00144170|DRUG|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
41281396|NCT00784758|DEVICE|Fenzian Device|Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
41281397|NCT00784758|DEVICE|Sham Device|Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
41281398|NCT06337201|DEVICE|Test of the application Min Memoria|Focus group interviews will be conducted to reach healthcare professionals' experiences using a written life story in daily care. Then, the information from the written life story will be transferred to the application, and the healthcare professionals will test a digital life story (the application) in daily care instead. Observation studies will be conducted to observe the use of the digital life story. What can be seen in the communication and the interaction, and in what situations is the digital life story used?
41281399|NCT05366608|DIAGNOSTIC_TEST|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.
40756456|NCT00781664|OTHER|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
40756457|NCT02252510|OTHER|HALOSPERM|
40756458|NCT02942407|DRUG|apixaban|oral anticoagulant
40756459|NCT02942407|DRUG|warfarin|oral anticoagulant
40756460|NCT00677300|DRUG|Raltegravir|400mg P.O. (orally) twice daily for 48 weeks
41281400|NCT01901744|PROCEDURE|Cataract Surgery|
41281401|NCT00896519|BIOLOGICAL|rituximab|
41281402|NCT00896519|BIOLOGICAL|sargramostim|
41281403|NCT00896519|DRUG|cyclophosphamide|
41281404|NCT00896519|DRUG|doxorubicin hydrochloride|
41281405|NCT00896519|DRUG|prednisone|
41451048|NCT06627855|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
40756461|NCT00677300|DRUG|Darunavir|800 mg P.O. (orally) once daily
40756462|NCT00677300|DRUG|Ritonavir|100mg once daily
40756463|NCT00677300|DRUG|Tenofovir/Emtricitabine|300 mg/200 mg P.O. (orally) once daily
40756464|NCT04589624|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
41281406|NCT00896519|DRUG|vincristine sulfate|
41281407|NCT00896519|GENETIC|gene expression analysis|
41281408|NCT00896519|GENETIC|gene rearrangement analysis|
41281409|NCT00896519|GENETIC|polymerase chain reaction|
41281410|NCT00896519|OTHER|R-CHOP regimen|
41281411|NCT00896519|OTHER|laboratory biomarker analysis|
41281412|NCT02462161|DRUG|Insulin aspart|Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.
40939806|NCT06259201|DEVICE|Vagus Nerve Stimulation|Vagal nerve stimulation (VNS) involves the use of a device to stimulate the vagus nerve with electrical impulses twice per day (AM \& PM) for two minutes each. It is an approved treatment for treatment resistant epilepsy and depression.
41281413|NCT02462161|DRUG|Placebo|Participants will administer placebo two times per day with an intranasal delivery device.
41281414|NCT03211247|BIOLOGICAL|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
41281415|NCT03211247|BIOLOGICAL|Viaskin Peanut 100 mcg|Viaskin Peanut 100 mcg, once daily
41281416|NCT03211247|BIOLOGICAL|Placebo|Placebo patch, once daily
41281417|NCT02560454|BEHAVIORAL|Cogmed|"Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance's"
41451049|NCT06627855|PROCEDURE|Sham treatment|The techniques in the therapy will be applied by imitating the techniques in the therapy for the fascial distortions determined according to the Manual Therapy Based on the Fascial Distortion Model.
41451050|NCT04405479|BEHAVIORAL|Examination of tremor and upper hand functions|Participants will be only examined. They will not undergo any intervention.
41451051|NCT06588738|DRUG|ESK-001|ESK-001
41451052|NCT06588738|DRUG|Placebo|Placebo
41451053|NCT06588738|DRUG|Apremilast|Apremilast
41451054|NCT00096655|DRUG|Infliximab|
41451055|NCT02108639|DRUG|DCV 3DAA FDC|
40939807|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|2.5mg po daily
40939808|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
40939809|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
40939810|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|150mg po monthly
40939811|NCT00048061|DIETARY_SUPPLEMENT|Calcium|500 mg/day
40939812|NCT00048061|DIETARY_SUPPLEMENT|Vitamin D|400 IU/day
41451056|NCT02108639|DRUG|BMS-791325|
41451057|NCT00290927|DRUG|insulin glulisine|
41451058|NCT01933282|DRUG|MESA chemotherapy|Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
41451059|NCT01933282|DRUG|MESA|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
41281418|NCT02560454|BEHAVIORAL|Presco|"Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances."
41281419|NCT03926403|OTHER|"State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire)"|"Patients will be given, a State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire) that will be collected on the same day. Each patient's initial anxiety score will be calculated so as to select only patients who are at least lightly anxious about their management (score ≥ 36)."
41281420|NCT03926403|PROCEDURE|hypnosis techniques|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
41281421|NCT03926403|PROCEDURE|local anaesthesia|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
41281422|NCT06075056|OTHER|No Intervention|No intervention is planned as part of this study, this is a feasibility/pilot study
41281423|NCT02852369|BEHAVIORAL|Task Oriented Treatment|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
41281424|NCT05182164|DRUG|Association of pembrolizumab + cabozantinib|"A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis."
41281425|NCT01656642|DRUG|Atezolizumab|Atezolizumab will be administered q3w or q2w.
41281426|NCT01656642|DRUG|Cobimetinib|Oral repeating dose
41281427|NCT01656642|DRUG|Vemurafenib|Oral repeating dose, depending on arm/cohort
41281428|NCT00121225|DRUG|vorinostat|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
41281429|NCT04153630|BIOLOGICAL|mesenchymal stem cells derived from bone marrow (BM-MSCs)|Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
41281430|NCT05495607|DEVICE|CARPEDIEN|Continuous renal replacement therapy
41281431|NCT01444716|BIOLOGICAL|Ofatumumab|Given IV
41281432|NCT01491958|DRUG|atorvastatin|"donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first."
41281433|NCT01491958|DRUG|Tacrolimus|beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
40756465|NCT04589624|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40756466|NCT04589624|PROCEDURE|Magnetic Resonance Imaging|Undergo hpMRI
40756467|NCT03004131|DRUG|Azelastine hydrochloride + fluticasone propionate nasal spray|
40756468|NCT03004131|DRUG|Placebos|
41281434|NCT01491958|DRUG|methotrexate|Day +1, +3, and +6 and +11
41281435|NCT01000103|DEVICE|Real rTMS|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
41281436|NCT01000103|DEVICE|Sham rTMS|"two TMS coils will be used: a passive one which is placed flat on top of the actively targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations"
41281437|NCT02362607|BEHAVIORAL|Integrated Diabetes Management Protocol|
41281438|NCT02362607|BEHAVIORAL|Standard Diabetes Management Protocol|
41281439|NCT01639183|DEVICE|Rotating-oscillating Power Toothbrush|A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
41281440|NCT01639183|OTHER|Standard Care|Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
40756469|NCT03004131|DRUG|fluticasone propionate nasal spray + loratadine|
40756470|NCT02868879|OTHER|Quantitative multiparametric and functional MRI|"Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2\*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks."
40756471|NCT02118415|OTHER|Hsp70-peptide TKD/IL-2 activated, autologous NK cells|Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
41281441|NCT04219267|BEHAVIORAL|character strengths-based intervention|"Character strengths-based intervention (CSI) is one kind of positive psychology interventions. It specifically focuses on character strengths, related activities and exercises assisting individuals to reconnect with their characters and promote self-conceptualization.~The researcher will develop an education module on CSI based on the previous literatures conducted in China and other countries. Before the RCT, this module will be adapted to Chinese participants. During the intervention, participants in the intervention group will be offered the educational module to learn about strengths, comments around the definition of character strengths and examples of specific strengths."
41281442|NCT04219267|BEHAVIORAL|early memories|In early memories, participants will be instructed to write down something from their early memories every day. The memories could be the things happened several days or many years before the writing day. The memories could be participant' travel experiences or food for a day. There are no strict restrictions on the timing or content of these early events.
41281443|NCT05614011|DIAGNOSTIC_TEST|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test. A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's Instructions For Use (IFU) in one nostril.
41451060|NCT02777307|OTHER|Hemopatch Sealing Hemostat|Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
41451061|NCT02282124|BEHAVIORAL|Self-management program with monthly sessions|Patients participate in 9 sessions during the first 8th month after transplantaiton
41451062|NCT02282124|BEHAVIORAL|Usual Care, containing one session|Session takes place within the first three months after transplantation
41451063|NCT05853653|BEHAVIORAL|Using dolls in breastfeeding education|Using dolls in breastfeeding education
40756472|NCT06334354|OTHER|Assessments|Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment
40756473|NCT06334354|OTHER|Assessment (Survivors Only)|\*Tumor/Treatment Variables (Survivors Only)
40756474|NCT06334354|OTHER|APOE and DNA Isolation|Biospecimens procurement and processing
40939813|NCT05050552|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
41281444|NCT05614011|DIAGNOSTIC_TEST|Real-time PCR Test|Mid-turbinate nasal swab samples will be taken from the opposite nostril that was not swabbed for the comparator sample using Copan FLOQ swabs and placed into MSwab buffer. In instances where opposite nostrils cannot be swabbed for both the comparator and the candidate tests, a 15-minute waiting period to allow for viral reloading will occur before collecting the candidate test sample.
41281445|NCT03679221|OTHER|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
41281446|NCT01844076|DRUG|Quinacrine and Capecitabine|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
41281447|NCT02215265|DRUG|Cisplatin|Chemotherapy
41281448|NCT02215265|RADIATION|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
41281449|NCT00584662|DRUG|Oxymetazoline Hydrochloride|Oxymetazoline Hydrochloride TWO SPRAYS BID
41281450|NCT02894515|DRUG|Idalopirdine commercial tablet (test)|single dose, 10 mg, oral
40939814|NCT06193577|DIETARY_SUPPLEMENT|Phaseolus Vulgaris L. Dry Extract|Extracts of Phaseolus vulgaris (beans) in association with a balanced diet are known to reduce glycaemia and food intake in rodents and humans thus promoting weight loss.
41281451|NCT02894515|DRUG|Idalopirdine clinical tablet (reference)|single dose, 10 mg, oral
40939815|NCT06193577|DIETARY_SUPPLEMENT|Placebo|The placebo control does not contain active ingredients.
41281452|NCT05187169|DRUG|VS-6766|Dual RAF/MEK inhibitor
41281453|NCT02389881|DRUG|TAK-058|TAK-058 Solution
41281454|NCT02389881|DRUG|TAK-058 Placebo|TAK-058 placebo-matching solution
41281455|NCT04020432|BEHAVIORAL|questionary|"A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
41281456|NCT02561156|DRUG|TAK-653 Placebo|TAK-653 placebo-matching tablets.
41281457|NCT02561156|DRUG|TAK-653|TAK-653 tablets.
41281458|NCT00396578|DRUG|aerosolized vancomycin or gentamicin|
41281459|NCT04519528|OTHER|DENVER scale (under 2 years old) or Pediatric Cerebral Performance Category (PCPC) score (over 2 years old)|"The DENVER II is a measure of developmental problems in young children. It was designed to assess child performance on various age-appropriate tasks and compares a given child's performance to the performance of other children the same age. The instrument consists of 125 tasks, which broadly reflect the following areas: personal-social, fine motor-adaptive, language, and gross motor.~The target population corresponds to infants and pre-school age children.~The POPC and PCPC are global scales based on observer impressions. Scores include 1 for good, 2 for mild disability, 3 for moderate disability, 4 for severe disability, and 5 for vegetative state or coma (6 indicates death)."
41281460|NCT04519528|OTHER|Pediatric Quality of Life Inventory™ (PedsQL)|"The PedsQL questionnaire is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Measurement Model integrates seamlessly both generic core scales and disease-specific modules into one measurement system. Twenty-three items divided into different functional areas are evaluated: physical (8 items), emotional (5 items), social (5 items) and school (5 items over 4 years old; 3 items before 4 y.o).~Child self-report and parent proxy report formats of the questionnaire allows self-assessment of child over 5 years old and parents' evaluations. Items can be reverse and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0) with higher scores indicating better quality of life."
41281461|NCT02139410|PROCEDURE|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
41281462|NCT01151072|DRUG|insulin degludec|Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
41281463|NCT05596981|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
40939816|NCT05625893|RADIATION|PBT and atezolizumab/bevacizumab|"Atezolizumab 1200 mg and bevacizumab 15 mg/Kg is administered IV infusion every 3 weeks.~Proton beam therapy 30 - 50 Gy/5 fractions to portal vein tumor thrombosis with or without main primary tumor after 1 week (+/- 7 days) of 2nd cycle of atezolizumab and bevacizumab~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
41131923|NCT02879942|OTHER|Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test|
41281464|NCT03746197|DEVICE|Project EVO Multi- Treatment|The EVO platform assesses perceptual discrimination while single-and multi-tasking. Visuomotor tracking involves navigating a character through a dynamically moving environment while avoiding obstacles. EVO uses adaptive algorithms to change game difficulty on a trial by trial and patient by patient basis for the tracking task and discrimination task with real-time feedback.
41281465|NCT05957081|DRUG|PMC-309 monotherapy|PMC-309 will be administered intravenously.
40939817|NCT05585164|BEHAVIORAL|Engage & Connect (E&C)|"Engage \& Connect, is a remotely-delivered extension of Engage psychotherapy. It is aimed to increase engagement in rewarding social activities and in turn, reduce postpartum depression. In each session, the therapist will work with the patient to develop action plans to pursue rewarding social activities of their choice with the goal of reducing social isolation."
41281466|NCT05957081|DRUG|PMC-309 Dose Escalation in Combination with Pembrolizumab|Both PMC-309 and pembrolizumab will be administered intravenously. At the time of the combination therapy (Week 1/Day 1 of each cycle), participants will be dosed with pembrolizumab first, administered over 0.5 hours (± 10 minutes). Following an interval of 1 hour (± 15 minutes), participants will be dosed with PMC-309 administered over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration.
41281467|NCT05957081|DRUG|PMC-309 Dose Expansion|"Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts:~* Cohort A: PMC-309 monotherapy therapy~  - PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A~* Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab"
41281468|NCT00759577|DRUG|Solifenacin|5mg and 10 mg, oral once daily
41281469|NCT04914338|OTHER|Health Promotion|Participate in MDT-intervention
41281470|NCT04914338|OTHER|Quality-of-Life Assessment|Ancillary studies
41281471|NCT04914338|OTHER|Questionnaire Administration|Ancillary studies
41281472|NCT04057170|OTHER|accelerated protocol and mulligan method|manual therapy technic
41281473|NCT04305392|DRUG|SHR4640|orally SHR4640
41281474|NCT01916772|OTHER|no interventions|no interventions
41281475|NCT02379858|DRUG|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
41281476|NCT02379858|DRUG|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
41281477|NCT02624700|DRUG|Experimental Arm A: Pemetrexed|Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
41281478|NCT02624700|DRUG|Experimental Arm A: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.
41281479|NCT02624700|DRUG|Experimental Arm B: Pemetrexed|Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
41131924|NCT04580459|BEHAVIORAL|CARE Parenting Group Treatment|The CARE parenting group treatment is a 12-session, 60-minute group mentalizing-focused intervention with 3 monthly parent-child sessions.
41281480|NCT02624700|DRUG|Experimental Arm B: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
40756475|NCT06514729|PROCEDURE|Adopting different ventilation modes during the operation|The ventilation side adopts different ventilation modes combined with continuous positive pressure ventilation on the surgical side.
41281481|NCT02413658|DRUG|Phenytoin|Topical use of phenytoin solution on dressings of split thickness skin graft sites.
41281482|NCT02413658|DRUG|Sugar solution|
40756476|NCT04156100|DRUG|AGEN1223|AGEN1223 is a bispecific antibody.
40756477|NCT04156100|DRUG|AGEN1223 and balstilimab|AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.
41281483|NCT04236453|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
41281484|NCT04236453|DRUG|Darunavir|Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.
41281485|NCT04236453|DRUG|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
41281486|NCT04236453|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally on Day 1.
41281487|NCT00390832|DRUG|Erythropoietin|33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
41281488|NCT00390832|OTHER|Placebo|Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
41281489|NCT06082336|DIAGNOSTIC_TEST|MagIA IBC test in capillary blood|After a finger prick, patients will be taken a drop of capillary drop. This drop will be used to perform the MagIA IBC test.
41281490|NCT06082336|DIAGNOSTIC_TEST|MagIA IBC test in other matrices|Blood samples will be taken and used to perform the MagIA IBC in veinous blood, serum and plasma.
41281491|NCT05493514|DEVICE|Robotic Assisted Gait Training with G-EO system|Robotic-assisted gait training is a rehabilitation treatment that applies robotic technologies to improve mobility of patients with stroke or other neurological disorders. In this study, participants will use the G-EO system robotic device according to the daily clinical practice of the Don Gnocchi Foundation.
41281492|NCT03306537|DEVICE|RespiraSense Respiratory Rate Monitor|RespiraSense device will be attached at the same time as the capnograph (gold standard) and both will measure simultaneously for one hour
41281493|NCT03740022|PROCEDURE|ACL plasty|standard ligamentoplasty by Kenneth Jones
41281494|NCT03740022|PROCEDURE|ACL + ALL plasty|standard ligamentoplasty and anterolateral plasty
41281495|NCT00004980|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site
41281496|NCT00004980|DEVICE|sham stimulation|"132 minutes of stimulation given at 80% motor threshold with coil tilted single wing 45 degrees away from scalp deliverd to TP3 site"
41281497|NCT05505058|BEHAVIORAL|Audio-visual material|Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.
41281498|NCT05771571|OTHER|Functional olive oil, enhanced with orange peel extract|The functional olive oil was enriched with 10% w/w orange peel extract
41281499|NCT05771571|OTHER|Control|Refined olive oil
41281500|NCT04516902|DRUG|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
41281501|NCT04516902|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
41281502|NCT04516902|OTHER|LSD Placebo|Pure alcohol instead of an alcoholic solution containing LSD
41281503|NCT04516902|OTHER|MDMA Placebo|Mannitol capsules instead of capsules containing MDMA
40756478|NCT02096965|DRUG|Tolvaptan|Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).
40756479|NCT02096965|DRUG|Placebo|Patients will receive daily dose at 8 AM and at 4 PM.
40756480|NCT04634175|BEHAVIORAL|Mind-body intervention|The mind-body intervention is composed of kundalini yoga techniques.
40756481|NCT04634175|BEHAVIORAL|Sham intervention|The sham intervention is composed of stretching and muscle flexion techniques.
41281504|NCT05459597|DRUG|antiepileptic drugs|phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
41281505|NCT04847271|BEHAVIORAL|Physical activity on prescription (PAP)|The intervention in this study will comprise the 3 PAP components. Participants will take part in all components and perform one or several physical activities of their choice in accordance to the written prescription, at the prescribed frequency and duration, for a period of 4 months.
41281506|NCT01400828|DRUG|Bilastine|20 mg (encapsulated) tablets QD/14 days
41281507|NCT01400828|DRUG|Desloratadine|5 mg (encapsulated) tablets QD/14 days
41281508|NCT01400828|DRUG|Placebo|(encapsulated) Tablets QD/14 days
41281509|NCT04783207|DIETARY_SUPPLEMENT|Mitopure|Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily
41281510|NCT04783207|DIETARY_SUPPLEMENT|Placebo|Softgel containing only excipients. 4 soft-gels to be taken daily
41281511|NCT04526158|BEHAVIORAL|Mobile+Group LAMP Mindfulness-Based Intervention|The Mobile+Group LAMP Mindfulness-Based Intervention (MBI) condition consists of eight 90-minute weekly group sessions, delivered via secure video-conferencing. The first session is preceded by a 90-minute technical session introducing the video-conference system and other logistics. The program consists of educational and instructional videos presented by a trained mindfulness instructor interspersed with workbook reflections and group discussions, and daily practice exercises that participants do on their own. A trained facilitator (who is not required to be an expert in mindfulness) leads the group. Participants also have access to a mobile app and a study website, with the same educational and instructional videos that are presented in the group sessions, and the accompanying workbook.
41451064|NCT01195233|DRUG|bioxtra|spray /mouth rinse
41451065|NCT02336087|DRUG|Gemcitabine Hydrochloride|Given IV
41451066|NCT02336087|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
41281512|NCT04526158|BEHAVIORAL|Mobile LAMP Mindfulness-Based Intervention|The Mobile LAMP MBI consists of 8 self-paced, 30- to 60-minute weekly sessions, delivered on a mobile app and available on the study website, with an accompanying workbook. The program consists of educational and instructional videos presented by a trained mindfulness instructor, with workbook reflections and daily practice exercises that participants do on their own (the same content used in Mobile+Group LAMP). Participants also participate in 3 engagement phone calls with a facilitator. The 1st call (45-60 minutes), held at the beginning of the program, includes technical and logistical information on engaging with mobile app, website, and workbook; and discussion of goals, challenges and plans for practice. The 2nd (middle of program) and 3rd call (end of program) are 25-45 minutes long and address technical/logistical issues and discussion of goals, progress, plans for practice and strategies to address challenges.
41281513|NCT05308108|PROCEDURE|(Adeno)tonsillectomy|registration of PORC in children with OSAS after (adeno)tonsillectomy
41281514|NCT00599768|OTHER|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
41281515|NCT04808687|DRUG|Nab paclitaxel and S-1|Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area \< 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 \< 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
41281516|NCT01697332|DRUG|Hyperpolarized 129Xe gas|800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
41281517|NCT02603575|DRUG|caspofungin|70mg ivdrip the first day, then 50mg ivdrip qd
41281518|NCT02603575|DRUG|corticosteroids|40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
41281519|NCT02603575|DRUG|Sulfanilamides|1.92g q8h
41281520|NCT00658229|BEHAVIORAL|Strength training group|After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
41281521|NCT02493179|DRUG|Serodase 5 mg|Serodase 5mg two tablets three times per day
41281522|NCT02493179|DRUG|Placebo|Placebo two tablets three times per day
41281523|NCT04966221|DIAGNOSTIC_TEST|Lung MRI scan|Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
41281524|NCT04232449|DRUG|PREDNISON Galepharm Tabl. 20 mg|5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone
41281525|NCT04232449|DRUG|placebo tablets|5 daily- doses of placebo (2 tablets)
41281526|NCT00201201|OTHER|Education Intervention|Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
41281527|NCT00201201|OTHER|Control|Control group receiving care as usual after interfacing with the surveys on the PEP-NG
41281528|NCT00035893|DRUG|poly I-poly C12U|200-400 mg IV infusions 2x/week for 64 weeks
41281529|NCT03949673|DRUG|Fasinumab|Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
41281530|NCT03949673|DRUG|Naproxen|Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
41281531|NCT03949673|DRUG|Diclofenac|Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
41281532|NCT03949673|DRUG|Celecoxib|Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
41281533|NCT03949673|DRUG|Placebo|Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
41281534|NCT04045912|OTHER|AGYW-Friendly Services|"Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW."
41281535|NCT04045912|OTHER|HIVST|Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
41281536|NCT00605826|DEVICE|NASHA/Dx (Solesta) Gel|Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
41281537|NCT00605826|DEVICE|Sham Injection|Sham injection at the start of the blinded phase.
41281538|NCT00206570|DRUG|Estradiol|
41281539|NCT03481530|DEVICE|Continuing Glucose Monitor System|glucose monitoring
41281540|NCT04284644|DRUG|Induction using propofol|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, a dose of 1.5 mg/kg of propofol slowly over 2 minutes.
41281541|NCT04284644|DRUG|Induction using sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 8% inhalational sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen.
41281542|NCT04284644|DRUG|Induction using propofol and sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 4% sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
41281543|NCT01656239|DRUG|fedovapagon 1 mg|
41281544|NCT01656239|DRUG|fedovapagon 2 mg|
41281545|NCT01656239|DRUG|fedovapagon 4 mg|
41281546|NCT01656239|DRUG|Placebo ( sugar pill)|
41281547|NCT05222802|DRUG|ERAS-801|Administered orally
41281548|NCT00731029|BIOLOGICAL|Thiomersal free trivalent influenza split vaccine 2002/2003|Single dose, intramuscular injection
41281549|NCT00731029|BIOLOGICAL|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003|Single dose, intramuscular injection
41451067|NCT02336087|DRUG|Metformin Hydrochloride|Given PO
41281550|NCT04861038|DEVICE|aerSleep II|Continuous negative external pressure (cNEP) system that maintains an open airway by applying negative pressure to the anterior neck via a soft silicone collar
41281551|NCT06189443|OTHER|Group administered to individual telemedicine|A brochure containing incontinence patient information will be prepared and given, web-based training will be implemented, and informative/reminder messages will be sent via short messages every day.
41281552|NCT00664170|DRUG|ANX-514|75 mg/m\^2
41281553|NCT00664170|DRUG|docetaxel|75 mg/m\^2
41281554|NCT02826057|OTHER|Targeted temperature management (33 degree Celsius)|
41281555|NCT04708912|OTHER|Observation|The study parameters will be obtained at the time of recuirement (Basal)
41281556|NCT05659732|DRUG|PEP07|PEP07 is a selective Chk1 inhibitor maleate drug which is supplied as a hard gelatin capsule. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
41281557|NCT04754373|DIETARY_SUPPLEMENT|GFA-918|Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.
41281558|NCT04754373|OTHER|Placebo|Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
41281559|NCT00648986|DRUG|Tazorac|All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
41281560|NCT00932464|DRUG|Neratinib|240-mg oral tablet; single dose under fasted conditions
41281561|NCT00932464|DRUG|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
41281562|NCT04609748|DRUG|Cannabidiol Oil|Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.
41281563|NCT04609748|DRUG|Nimesulide|Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
41281564|NCT02902809|BIOLOGICAL|Tralokinumab open-label|Subcutaneous injection; fixed dose; 300 mg
41281565|NCT01320228|DIETARY_SUPPLEMENT|Control|Alli treatment plus placebo (rice flour)
41451068|NCT02336087|DIETARY_SUPPLEMENT|Therapeutic Dietary Intervention|Given PO
41451069|NCT02336087|OTHER|Laboratory Biomarker Analysis|Correlative studies
41451070|NCT02336087|OTHER|Quality-of-Life Assessment|Ancillary studies
41451071|NCT05191238|OTHER|IUD self-removal education|Two part educational intervention (watching IUD self-removal video and practicing IUD removal on two simulation models)
41451072|NCT02885909|DEVICE|CONTINUE GLUCOSE MONITOR|Continue glucose monitor
41451073|NCT02885909|PROCEDURE|Insulin protocal|Using insulin protocal based on glucose monitor
41281566|NCT01320228|DIETARY_SUPPLEMENT|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
41281567|NCT01320228|DIETARY_SUPPLEMENT|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
41281568|NCT01320228|DIETARY_SUPPLEMENT|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
41281569|NCT03308630|BEHAVIORAL|Yoga based Energy Alignment and Mantra|"Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated."
41281570|NCT03360929|DRUG|AZD3759|Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
41281571|NCT02485392|DEVICE|Da Vinci Single Site Robot-Assisted Cholecystectomy|
41281572|NCT02485392|DEVICE|Single Incision Laparoscopic Cholecystectomy|
41281573|NCT00198705|BEHAVIORAL|Improved management of severe neonatal infections|
41281574|NCT03114761|RADIATION|CT angiography|Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
41281575|NCT01823562|DRUG|lyophilized black raspberry confection|Given PO
41281576|NCT01823562|OTHER|laboratory biomarker analysis|Correlative studies
41281577|NCT01823562|DIETARY_SUPPLEMENT|dietary intervention|Follow a low polyphenol diet
41281578|NCT01823562|DIETARY_SUPPLEMENT|dietary intervention|Follow a low ellagitannin diet
41281579|NCT01823562|PROCEDURE|quality-of-life assessment|Ancillary studies
41281580|NCT01823562|OTHER|questionnaire administration|Ancillary studies
41281581|NCT01442584|PROCEDURE|ovarian transplantation|ovarian transplantation
41281582|NCT03489213|OTHER|Dietary Intervention|Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.
41281583|NCT03489213|BEHAVIORAL|Exercise Intervention|Participants will wear a FitBit every day and monitor daily physical activity.
41281584|NCT03489213|OTHER|Laboratory Biomarker Analysis|Correlative studies
41281585|NCT03489213|DIETARY_SUPPLEMENT|Nutritional Intervention|Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.
41281586|NCT03489213|OTHER|Questionnaire Administration|Ancillary studies
41281587|NCT03028493|BEHAVIORAL|Original SAFE Intervention|A CDC recommended, evidence-based falls prevention intervention.
41281588|NCT03028493|BEHAVIORAL|Adapted SAFE Intervention|An adapted version of the SAFE intervention meant to target older adults with low vision.
41281589|NCT03431389|DEVICE|Tracheostomy tube|Tracheostomy done to all patients by open surgical technique and was done in ICUs without need to transfer to theatre.
41281590|NCT04866836|COMBINATION_PRODUCT|Radiotherapy|Patients who meet the criteria for enrollment first receive radiotherapy, either IMRT or SBRT, and the relative biological effect dose is\> 40Gy. On the 7th day (±3 days) after radiotherapy, start to give tislelizumab 200 mg, IVD, q3w, and continue the treatment until disease progression, unacceptable toxic radiotherapy, death or meet the description in the protocol Any discontinuation criteria shall be subject to whichever occurs firs
41281591|NCT00904124|DIETARY_SUPPLEMENT|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
41281592|NCT01948752|OTHER|Nutrition information on menus|
41281593|NCT00998738|DRUG|Calcium Gluconate|Given IV
41281594|NCT00998738|DRUG|Magnesium Sulfate|Given IV
41281595|NCT00998738|OTHER|Placebo|Given IV
41281596|NCT00998738|OTHER|Quality-of-Life Assessment|Ancillary studies
41281597|NCT00998738|OTHER|Questionnaire Administration|Ancillary studies
41281598|NCT00998738|DRUG|Ixabepilone|Given IV
41281599|NCT02290210|DRUG|URC102 0.25mg|
41281600|NCT02290210|DRUG|URC102 0.5mg|
41281601|NCT02290210|DRUG|URC102 1.0mg|
41281602|NCT02290210|DRUG|URC102 2.0mg|
41281603|NCT02290210|DRUG|placebo|
41281604|NCT03304808|DEVICE|Exercise Programme +device+ lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
40939818|NCT05585164|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|SPR is a remotely-delivered intervention aimed to increase knowledge of postpartum depression and monitor mental health changes. In each session, the therapist will review the participant's symptoms and discuss information related to postpartum depression and changes after birth.
40939819|NCT03593434|DRUG|hyperpolarized Xenon gas|This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.
41281605|NCT03304808|BEHAVIORAL|Exercise Programme + lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
41281606|NCT03037216|OTHER|Exercise Intervention|10 Week aerobic exercise training
41281607|NCT02132221|BEHAVIORAL|Cognitive Behavioral Therapy|10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
41281608|NCT04705480|DRUG|Pregabalin 50mg|Patients will receive 50 mg every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
41281609|NCT04705480|DRUG|Gabapentin 300mg|Patients will receive 300 mg PO every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
41281610|NCT04705480|DRUG|Neither Pregabalin nor Gabapentin|Patients will receive neither Pregabalin nor Gabapentin.
41281611|NCT04541069|BEHAVIORAL|Social Communication and Emotional Skill Development (SCESD) module|The intervention, Social Communication and Emotional Skill Development (SCESD) module, is based on the basics of the neuroscience of child development. The module has focused on these basic behaviors of infants, and has incorporated strategies to enhance the five basic behaviors i.e. eye contact, attention to others, joint attention, imitation and non-verbal communication.
41451074|NCT04020796|DIETARY_SUPPLEMENT|Beetroot juice|Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.
41451075|NCT02828449|BEHAVIORAL|therapeutic education program|
41451076|NCT01566435|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
41451077|NCT01566435|DRUG|Cisplatin|
40939820|NCT00246415|DRUG|Memantine|
41451078|NCT01566435|DRUG|Fluorouracil|
41451079|NCT01566435|RADIATION|Intensity modulated radiation therapy|
41451080|NCT01566435|DRUG|Cetuximab|
41451081|NCT01566435|PROCEDURE|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
41451082|NCT05255393|OTHER|Questionnaires|"A 13-item questionnaire specific to LEL, developed and validated by investigators at the Mayo Clinic.~The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients.~The EORTC Quality of Life - Cervical Cancer Module."
40939821|NCT01626638|PROCEDURE|Confocal Micro Endoscopy|
40939822|NCT06437990|PROCEDURE|Arteriovenous loop graft|Using saphenous vein graft to create an arteriovenous loop from the common carotid artery to the external jugular vein, providing vascular supply for a free functional gracilis muscle flap in patients with late-onset brachial plexus injury with concomitant subclavian or axillary artery injury.
40939823|NCT06379425|DRUG|Acetaminophen|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
40939824|NCT06379425|DRUG|Celecoxib|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
40939825|NCT06379425|DRUG|Gabapentin|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
41281612|NCT01671670|OTHER|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
40756482|NCT05812144|OTHER|Remote monitoring program|Remote program is composed of some questionnaires and physical exercises performed at home and at hospital (depending on the concerned visit)
40756483|NCT04178863|DEVICE|CATS Tonometer|latanoprost vs. timolol
41281613|NCT01671670|OTHER|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
41281614|NCT04468672|BEHAVIORAL|Portion size|The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.
41281615|NCT05000320|DIAGNOSTIC_TEST|Neuronal Injury Panel|A panel of neuronal and astroglial assays that may be a marker of brain injury.
41281616|NCT02863848|DIETARY_SUPPLEMENT|OraftiR inulin-type fructans|
41281617|NCT02863848|DIETARY_SUPPLEMENT|Placebo|maltodextrin
41281618|NCT05700214|DRUG|Ropivacaine injection|30ml of 0.375% ropivacaine
41281619|NCT05700214|DRUG|Lidocaine IV|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
41281620|NCT05283733|PROCEDURE|reverse conversion technique|converting open appendectomy to laparoscopic technique for proper control of intraabdominal sepsis
41281621|NCT02362373|DRUG|levonorgestrel IUS|placement of levonorgestrel intrauterine system
41281622|NCT02082561|BEHAVIORAL|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
41281623|NCT04876339|DEVICE|"Gait rehabilitation with sonification"|The sonification system is composed by 2 inertial sensors, a computer and a pair of bluetooth headphones connected with the computer. The sensors will be placed one per leg at the ankle and connected with Matlab software. An home-made ad-hoc software associates patient's movements with music patterns. The patient's natural rhythm is detected and used at the beginning of the intervention. The first part of each exercise is supported by a pre-recorded chord progression with a click on the background. In the second part (sonification approach) the software notices and records the contact of the heel with the ground. Each contact activates musical stimuli listened to via headphones. The steps succession will build a regular and predictable musical progression in relation to the correct sequence of steps. The exercises planned in this intervention are the same as those planned in the gait standard rehabilitation (see below).
41451083|NCT06254560|DRUG|Rituximab|Rituximab is administered at a dose of 100mg per week, a total of 4 times. Cyclosporin is administered at a dose of 3-5mg/kg per day.
40756484|NCT04178863|DRUG|Latanoprost|latanoprost IOP reduction
41451084|NCT03939364|DRUG|SBS-101|Isotretinoin Oral-Adhesive Film
40939826|NCT00446342|DRUG|SNS-032 Injection|"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
40939827|NCT01631812|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
41451085|NCT03939364|DRUG|Placebo|Placebo
41451086|NCT04915339|BEHAVIORAL|Physical activity|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables...) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation...).
41451087|NCT04915339|BEHAVIORAL|cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables...) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation...).
41451088|NCT04915339|BEHAVIORAL|combined physical and cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables...) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation...).
41451089|NCT06563232|DEVICE|FNA group|Fine-needle-aspiration (22G EchoTip Ultra Echo-3-22)
41451090|NCT06563232|DEVICE|Adapt FNB group|Fine-needle-biopsy (22G Adapt Aspiration)
41451091|NCT01344031|DRUG|Akt Inhibitor MK2206|Given PO
40939828|NCT03887403|BEHAVIORAL|Multimodal Intervention|
40939829|NCT03887403|OTHER|Usual care|
40939830|NCT03480906|DRUG|Latanoprost|Latanoprost ophthalmic solution administered as a microdose spray
41451092|NCT01344031|DRUG|Anastrozole|Given PO
41451093|NCT01344031|DRUG|Fulvestrant|Given IM
41451094|NCT01344031|OTHER|Laboratory Biomarker Analysis|Correlative studies
41451095|NCT04628663|DRUG|Dexmedetomidine|Administration
41281624|NCT04876339|OTHER|Standard gait rehabilitation (without sonification)|"The training will be carried out without any musical support. Exercises I Phase~1. Load shift in anteroposterior standing in tandem position, left foot forward (3 minutes exercise with a short break in the middle)~2. Load shift in anteroposterior standing in tandem position, right foot forward (3 minutes exercise with a short break in the middle)~3. Left foot swing (3 minutes exercise with a short break in the middle)~4. Right foot swing (3 minutes exercise with a short break in the middle)~5. March in place (3 minutes exercise with a short break in the middle) Exercises II phase (15 minutes): the patient will perform 14 minutes of walking with a 1 minute of break in the middle (7 minutes of walking, 1 minute rest, 7 minutes of walking). In the second part of walking the patient will be asked to slightly increase the pace of the step up to the maximum possible speed."
41281625|NCT05416892|OTHER|Pharmaclass® software|Clinical decision support tool via artificial intelligence in order to improve the patient's medication management.
40744378|NCT02214810|DRUG|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
41281626|NCT04177030|BEHAVIORAL|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
41281627|NCT04177030|BEHAVIORAL|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
41281628|NCT05080829|DIAGNOSTIC_TEST|Myeloid mutations measurement|Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done
41281629|NCT03064282|OTHER|Placebo|observation of skin changes if any
41281630|NCT03064282|DRUG|papaverine|observation of symptoms
41281631|NCT02278978|DRUG|BIBF1120|BIBF1120 200 mg two times per day orally
41281632|NCT03817918|PROCEDURE|Lung ultrasonography|Patients undergoing thoracic surgery under general anesthesia using one-lung ventilation will have lung ultrasonography at 2 predetermined sites at four different time points
41281633|NCT02198144|OTHER|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
41281634|NCT03648450|OTHER|Propeller EMD|Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
41281635|NCT02363400|DRUG|MEP|Adjuvant Chemotherapy
41281636|NCT05272514|OTHER|Hypoxia|Individuals will be exposed to varying levels of hypoxia according to the protocol detailed above.
41281637|NCT06085066|PROCEDURE|Conventional Ultrafiltration alone on Cardiopulmonary bypass|Conventional Ultrafiltration was used on Cardiopulmonary bypass for patients who underwent open heart surgery
41281638|NCT06085066|PROCEDURE|Conventional Ultrafiltration followed by Modified Ultrafitration on Cardiopulmonary bypass|Modified Ultrafiltration was used following the Conventional Ultrafiltration on Cardiopulmonary bypass for patients who underwent open heart surgery
41281639|NCT05366829|DRUG|Tislelizumab|Tislelizumab (also known as BGB A317) is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against programmed cell death protein-1 (PD-1) under clinical development for the treatment of several human malignancies. Tislelizumab consolidation therapy after radiation therapy can capitalize on the immunomodulatory effect of radiotherapy and improve tumor responses and patient outcomes.
41281640|NCT03069339|DRUG|Carvedilol|Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min
41281641|NCT03069339|PROCEDURE|Endoscopic Variceal Ligation|EVL will be done every 3 weeks till eradication
41281642|NCT02449330|DRUG|Teneligliptin|
41281643|NCT04062812|OTHER|the same citrate dosification in both types|match concentrated and dilute citrate protocol
41281644|NCT04510259|PROCEDURE|Selective Brachial plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1: 200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
41451096|NCT04628663|OTHER|Normal Saline|Administration
41451097|NCT00163319|DRUG|Ciclesonide|
41451098|NCT03336580|DRUG|PRX004|"PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)"
41451099|NCT02805764|DEVICE|Homeoblock|A removable, functional dental appliance to be worn nightly for 1 year Pending 510(k) clearance for the use of reducing snoring and mild to moderate obstructive sleep apnea in adults. A class II medical device.
41281645|NCT00583401|DEVICE|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
40939831|NCT03480906|DRUG|Latanoprost|Latanoprost ophthalmic solution administered as an eyedrop
40939832|NCT02889276|OTHER|Functional Resistance Training|Supervised group-based Functional Resistance Training
41281646|NCT06289049|OTHER|Experimental|"Three primary exercises will be included in the exercise sessions for participants randomized to this group: barbell back squat, bench press, and dead lift~The weight will be progressively increased overtime based on participants' perceived exertion and repetitions in reserve. Number of repetitions performed for each exercise will begin at 10 repetitions in weeks 1-2, with gradual progression to lifting heavier loads of 3-5 sets of 1-5 repetitions between weeks 6-12."
40939833|NCT02889276|BEHAVIORAL|Unsupervised activity|General activity to meet 150 minutes of moderate intensity activity per week
40939834|NCT01514500|DRUG|somapacitan|Administered s.c. (subcutaneously, under the skin)
40939835|NCT01514500|DRUG|placebo (somapacitan)|Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
40939836|NCT00883584|DRUG|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
40939837|NCT00883584|DRUG|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
40744379|NCT03116815|OTHER|Direct input of home blood pressure readings via MyChart|Participants will record home blood pressure readings directly into the electronic health record via the MyChart application
40939838|NCT04968379|DRUG|Ferric carboxymaltose|Intravenous
40939839|NCT00040261|DRUG|Memantine HCL|
40939840|NCT03376438|OTHER|Prospective observational cohorts|Patients with AF or SVT that is significant enough to consider prenatal treatment are eligible for enrollment. Management decisions are made at each patient encounter by the primary physician based on clinical findings and may include: 1) no antiarrhythmic treatment; 2) transplacental antiarrhythmic treatment; 3) direct fetal antiarrhythmic treatment; 4) delivery. Patients enrolled in the FAST Registry will be followed from the time of enrollment until the baby is discharged after birth.
40939841|NCT03913442|DRUG|Colchicine 0.8 mg or 0.6 mg orally once daily|Colchicine 0.8 mg orally once daily for 1.5 months, and then 0.6 mg once daily for the remainder of the time (1.5 months)
40939842|NCT03913442|DRUG|Placebo oral capsule|Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
40939843|NCT04733378|PROCEDURE|Peri-operative neurological monitoring|Pre- and post-operative cerebral MRI, standardized neurological examinations at 4, 12, 24 months and neuropsychological evaluation with a Bayley III test (Bayley Scale of Infant and Toddler Development, Third Edition) at 24 months.
40939844|NCT01168960|BEHAVIORAL|Cognitive behavioral therapy for alcohol dependence|12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
40939845|NCT03508531|PROCEDURE|ESP Block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
40939846|NCT03508531|PROCEDURE|OSTAP block|The bilateral OSTAP will be performed at the end of the surgery. A total of 40 ml local anesthetic mixture (Bupivacaine and lidocaine) will be injected bilaterally with interfascial plane between the external oblique and transversus abdominis muscles
41131925|NCT04580459|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual (TAU) involves typical child outpatient mental health services, such as individual child appointments and medication management.
41131926|NCT04530032|OTHER|ketogenic/modified Atkins diet|ketogenic/modified Atkins diet use
41131927|NCT04530032|OTHER|Standard diet|standard (normal) diet use
41131928|NCT02873533|OTHER|geriatric care and longitudinal follow up|geriatric care and longitudinal follow up
41281647|NCT00184990|DRUG|Aminoguanidine|
41281648|NCT00184990|DRUG|endotoxin|
41281649|NCT04222985|BIOLOGICAL|HSV 2 Formulation 1|Route of administration: Intramuscular
41281650|NCT04222985|BIOLOGICAL|HSV 2 Formulation 2|Route of administration: Intramuscular
41281651|NCT04222985|BIOLOGICAL|HSV 2 Formulation 3|Route of administration: Intramuscular
41281652|NCT04222985|BIOLOGICAL|HSV 2 Formulation 4|Route of administration: Intramuscular
41281653|NCT04222985|BIOLOGICAL|HSV 2 Formulation 5|Route of administration: Intramuscular
41281654|NCT04222985|BIOLOGICAL|HSV 2 Formulation 6|Route of administration: Intramuscular
41131929|NCT03609099|DRUG|Moxifloxacin|400 mg / day once a day oral treatment during 3 days.
41281655|NCT04222985|BIOLOGICAL|Sodium Chloride 0.9%|Route of administration: Intramuscular
41281656|NCT01316094|DRUG|ASP1941|oral
41281657|NCT01316094|DRUG|placebo|oral
41281658|NCT05169671|DRUG|ATH-1020|ATH-1020 in oral capsule form
41281659|NCT05169671|DRUG|Placebo|Placebo in oral capsule form
41281660|NCT05723146|BEHAVIORAL|Spatial cognition assessment|The intervention will be composed of tasks assessing spatial cognition in a real environment (cancellation task, line bisection and baking tray task) and in a virtual environment (cancellation task, line bisection, baking tray task and localization tasks).The Catherine Bergego Scale (questionnaire) will also be used.
41281661|NCT04444570|DEVICE|Continuous glycemia measuring device (Dexcom) implantation into the subcutaneous tissue|14 days before the date of the surgery and after the surgery patient will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
41281662|NCT01874483|DRUG|Placebo|placebo
41281663|NCT01874483|DRUG|BI 187004|BI 187004, dose 2
41281664|NCT01874483|DRUG|BI 187004|BI 187004, dose 4
41281665|NCT01874483|DRUG|BI 187004|BI 187004, dose 5
41281666|NCT01874483|DRUG|BI 187004|BI 187004, dose 6
41281667|NCT01874483|DRUG|BI 187004|BI 187004, dose 7
41281668|NCT01874483|DRUG|BI 187004|BI 187004, dose 1
41281669|NCT01874483|DRUG|BI 187004|BI 187004, dose 3
41281670|NCT01090557|OTHER|Collection of exhaled breath|balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
41281671|NCT05745727|DRUG|PRX-115|Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 8
41281672|NCT05745727|DRUG|Placebo|Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8
41281673|NCT05415280|BEHAVIORAL|Mindfulness Based stress reduction|The aim of the psychological intervention to reduce the mental health problems of the participants.
41281674|NCT05294900|DRUG|paclitaxel/carboplatin|"Induction chemotherapy : total 2 cycle every 3weeks as below:~* Paclitaxel 175mg/m2~* Carboplatin AUC5"
41281675|NCT03806244|OTHER|Intraoperative acquisition (robotic c-Arm) of images|"Conventional laparoscopic colorectal oncologic resection is performed. During the procedure, the operator will identify previously defined anatomical landmarks, point them with an instrument tracked by the navigation system and the accuracy of the stereotactic navigation system will be calculated by comparing the surgical anatomical point and its correspondent on the images of the navigation platform."
41281676|NCT00744289|OTHER|Incentive condition|Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
41281677|NCT06216886|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
41281678|NCT06216886|DRUG|Sodium Chloride 0.9% for Injection, Preservative Free|intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
41281679|NCT04549012|DRUG|Tranexamic acid|comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
41451100|NCT05994066|OTHER|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).
40744381|NCT01182961|OTHER|gait training|subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device
41281680|NCT04549012|DRUG|Oxytocin|Oxytocin
41281681|NCT03808207|OTHER|Dietary counseling and DHA dietary increase in breastfeeding mothers|Specific dietary advices in order to increase the daily/weekly intake of docosahexaenoic acid of breastfeeding mothers for the first 3 months after delivery
41281682|NCT01664026|BEHAVIORAL|Web-based lifestyle modification|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
41281683|NCT01664026|BEHAVIORAL|Web-based lifestyle modification +|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
41281684|NCT05159180|DEVICE|cardioz mapping|Patients will be submitted to mapping of both voltage and tissue impedance.
40939847|NCT03508531|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
40939848|NCT04356365|OTHER|Cross-sectional study investigating the association of NPIs with mental health|Cross-sectional study investigating the association of NPIs with mental health
40939849|NCT04399031|DRUG|E-cigarette e-liquid|Participants will self-administer an experimenter-provided e-cigarette.
40939850|NCT00626054|DRUG|PEG solution in a single dose of 3 liters|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
40939851|NCT00626054|DRUG|PEG solution|PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
40939852|NCT03049527|BEHAVIORAL|Education, Incentives and Feedback|The study participants will receive additional educational activities, including low-literacy fact sheets on liquid intake guidelines, cards with instructions on how to self-monitor urine color and volume, and flyers and posters placed throughout the worksite. All consenting study participants will be offered incentives to start the work day hydrated and then to maintain or improve their hydration status over the work shift. Participants who do not meet hydration goals will receive additional coaching and feedback on ways to improve hydration.Feedback will also be provided to all groups about their productivity level to help participants recognize the connection between improved health and function.
41451101|NCT05936645|PROCEDURE|A temporary sub-placental Uterine Tourniquet in management of Placenta Accreta Spectrum disorder by a retrograde cesarean hysterectomy (Bladder Last)|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
40756485|NCT04122690|BEHAVIORAL|PDAE|Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
40756486|NCT04122690|BEHAVIORAL|WAE|The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
40756487|NCT06127901|PROCEDURE|Any surgery under any type of anaesthesia.|Any surgery under any type of anaesthesia.
40756488|NCT00204581|DRUG|Interleukin-2 (Proleukin)|6-12 MIE/d 3times a week
40756489|NCT06548672|DRUG|BC3195|BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).
40939853|NCT01828515|DRUG|Vilazodone|Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
40939854|NCT01828515|DRUG|Placebo|
40939855|NCT01828515|DRUG|Hydrocortisone|Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment
40939856|NCT03046173|OTHER|concentrated growth factors|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
41131930|NCT03609099|DRUG|Placebo|once a day oral treatment during 3 days.
41281685|NCT03577990|BEHAVIORAL|Interactive Technology Enhanced Coaching (ITEC)|As participants wear the activity tracker, take their BP and weight, along with input of food intake and medication-taking, data is transmitted in real time via Bluetooth Smart technology to the Fitbit Plus dashboard. All data is tracked, analyzed, and transparently displayed for participants to view and better understand their condition, and actively engage in self-care. Staff monitor data and communicate with participants to encourage active engagement in action plans by sending tailored coaching messages (ITEC) via the Fitbit Plus dashboard to the treatment arm weekly for 3 months, and biweekly for 3 months to motivate and support (BP control, medication adherence, and lifestyle modifications). After 6 months, the treatment arm will be monitored an additional 3 months with no tailored coaching for sustainability.
41281686|NCT03577990|BEHAVIORAL|Interactive Technology-No Coaching (IT)|After receiving usual care for 3 months, the control arm will receive the same electronic monitoring as the treatment arm and data will be captured in the same manner with the Fitbit Plus dashboard. Participants will be expected to use the information from the dashboard and the CDSMP workshop as a guide to self-care without coaching (IT). Staff will only monitor data. Control participants will not be contacted between repeated measures data collection periods, except to send reminders if they are not participating daily.
41281687|NCT00754390|DIETARY_SUPPLEMENT|Moderate Calcium, Low phytate Diet|Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
41281688|NCT00754390|DIETARY_SUPPLEMENT|Moderate Calcium, High Phytate Diet|Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
40939857|NCT03046173|OTHER|hydroxyapatite and autogenous bone|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
41281689|NCT00754390|DIETARY_SUPPLEMENT|High Calcium, Low Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks
41281690|NCT00754390|DIETARY_SUPPLEMENT|High Calcium, High Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
41281691|NCT02108730|PROCEDURE|restrictive pancreatic resection|Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
41281692|NCT04036565|BEHAVIORAL|sunlight therapy|Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
41281693|NCT04074486|DEVICE|BrainScope Ahead 300iP-O|BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.
41281694|NCT04074486|DIAGNOSTIC_TEST|SCAT5|Sports Concussion Assessment Tool 5
40939858|NCT02945787|BEHAVIORAL|Spanish-Language Version of the Stop Smoking for Good|Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.
41281695|NCT04074486|DIAGNOSTIC_TEST|Near Point Convergence|Manual ocular function measurement conducted only if electronic version on device fails
41281696|NCT02039154|BEHAVIORAL|Aerobic and strength training group|A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.
41281697|NCT02039154|BEHAVIORAL|Balance and flexibility group|For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
41281698|NCT03815292|DRUG|MMH-MAP|Oral administration
41281699|NCT03815292|DRUG|Placebo|Oral administration
41281700|NCT05427630|DRUG|THC ~2.5%|Cannabis flower containing THC \~2.5%
41281701|NCT05427630|DRUG|THC ~5%|Cannabis flower containing THC \~5%
40939859|NCT02945787|BEHAVIORAL|NCI-Produced Spanish-language Self-help Booklet|Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet.
40939860|NCT02793466|DRUG|Durvalumab; MEDI4736|IV Infusion every 2 weeks for a maximum of 26
41281702|NCT05427630|DRUG|THC ~10%|Cannabis flower containing THC \~5%
41281703|NCT05427630|DRUG|Sham Cannabis|Cannabis flower from which the THC and CBD have been extracted
41281704|NCT02216565|OTHER|Hospitalization in specialized neuro-vascular unit|
41281705|NCT02216565|DRUG|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
41281706|NCT02216565|OTHER|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
41281707|NCT02216565|PROCEDURE|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
41281708|NCT04871815|DRUG|sodium pyruvate nasal spray|Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
41281709|NCT01421368|DRUG|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
41281710|NCT01421368|DRUG|Depo-medroxyprogesterone acetate (DMPA)|DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
41281711|NCT01421368|DRUG|Oral contraceptive: LNG 150 mcg and EE 30 mcg|Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
41281712|NCT05040204|DIETARY_SUPPLEMENT|Monosaccharide Powder|Monosaccharide powder dissolved in water.
41281713|NCT05040204|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo (glucose powder)
41451102|NCT05936645|PROCEDURE|Retrograde cesarean hysterectomy (Bladder Last) for management of Placenta Accreta Spectrum disorder|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
40756490|NCT00144508|DRUG|MRA (Tocilizumab)|8mg /kg /4week for 52 weeks
40756491|NCT00144508|OTHER|current treatment|continue current treatment
40756492|NCT01401075|DRUG|mistletoe extract|subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
40756493|NCT01401075|DRUG|doxifluridine|600 - 900 mg per day orally, depending on weight and status of the patient
40756494|NCT01385995|DEVICE|Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
40756495|NCT01385995|DEVICE|Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
41281714|NCT05986656|PROCEDURE|Atlas-Standard method|Hardware acupressure of the suboccipital muscles according to the Atlas-Standard method for the reduction of chronic subluxation of the first cervical vertebra.
41281715|NCT05051618|BEHAVIORAL|POWER-MS|"The POWER-MS intervention includes both aerobic exercise and resistance exercise:~Aerobic Exercise:~The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention.~Resistance Exercise:~Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level."
40756496|NCT00752219|DRUG|ceftazidime/NXL104 + metronidazole|IV TID
40756497|NCT00752219|DRUG|meropenem|IV TID
40756498|NCT04704128|OTHER|Salivic sample|Collection of total saliva not stimulated
40756499|NCT00456911|BEHAVIORAL|Fat and carbohydrate controlled diet|
40756500|NCT05136521|DRUG|Trazodone HCl - new polymer|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
41281716|NCT05051618|BEHAVIORAL|FLEX-MS|The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
41281717|NCT04919564|DRUG|Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL)|Furosemide 2 mg/hour infusion for 12 hours since induction
41281718|NCT04919564|DRUG|NaCl 0.9%|NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
41281719|NCT04429750|PROCEDURE|Immediate umbilical cord clamping|"In the immediate cord clamping group, the umbilical cord will be clamped within the first 20 seconds after birth and the infant will be transferred to the resuscitation room. The newborn infant will be intubated and mechanically ventilated as quickly as possible on the resuscitation table as recommended in the French Programme National de Soins.~After cardiorespiratory stabilization (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%), the infant will be transferred to the neonatal intensive care unit (NICU). Oxytocin is infused to the mother as recommended in the local protocol (usually just after birth or cord clamping)."
41451103|NCT03595787|PROCEDURE|Coaching and Habilitation|nutritional support, adapted physical activity and coaching
41451104|NCT05471947|DRUG|15% Trichloroacetic acid + 3% glycolic acid|Treatment of the hand with an over-the-counter chemical peel containing 15% trichloroacetic acid + 3% glycolic acid
41451105|NCT03980522|DRUG|KPL-914|"KPL-914 (rilonacept) will be provided in its commercially available formulation as a lyophilized powder to be reconstituted for SC administration.~Adult participants (≥ 18 years of age) KPL-914 will be administered as an initial loading dose of 320 mg SC, delivered as 2 subcutaneous injections of 160 mg SC each on Day 0, then 160 mg SC dosed once weekly for 5 subsequent weeks.~Pediatric participants (6 to \<18 years of age) KPL-914 will be administered with an initial loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as 2 subcutaneous injections of 2.2 mg/kg each with a maximum single-injection volume of 2 mL.~Participants considered to be 'treatment responders' will be offered participation in an optional 18-week extension period (EP) in which KPL-914 can be continued for a total duration of KPL-914 treatment of up to 24 weeks."
41451106|NCT05062564|DEVICE|LipiFlow Thermal pulsation system|Single treatment with LipiFlow thermal pulsation system on the eyelids within two months before surgery
40756501|NCT05136521|DRUG|Trazodone HCl - Contramid®|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
40756502|NCT03796221|BEHAVIORAL|Parenting videos|Brief online videos, featuring families of children with obesity of diverse backgrounds, to provide education on parenting skills and motivate families to adopt healthy lifestyle behaviors as a family. Videos will be delivered monthly for three months in between pediatric obesity clinic visits.
41451107|NCT05062564|PROCEDURE|Eyelid warm compresses plus massages|Eyelid warm compresses plus massages twice a day for the preoperative month
41451108|NCT05168163|BIOLOGICAL|Atezolizumab|Given IV
41451109|NCT05168163|DRUG|Cabozantinib|Given PO
41451110|NCT05168163|DRUG|Lenvatinib|Given PO
40939861|NCT06182280|BEHAVIORAL|PrEP4T|PrEP4T is an individualized TMSM-specific intervention adapted from The Fenway Model. PrEP4T consists of online one-on-one sessions between a peer and a participant using a strengths-based case management manualized curriculum. Peer navigators (PNs) share transmasculine community membership with participants and are trained to provide linkages. They use an individualized approach to navigate barriers, apply an assets-based frame to promote resiliencies, and pragmatically leverage these to improve biomedical HIV prevention outcomes. PNs utilize techniques from established behavior change models (e.g., Motivational Interviewing; Transtheoretical Model) in PrEP decision-making.
40939862|NCT06182280|BEHAVIORAL|LS4TM|LS4TM is a theory-based peer-delivered small group-based behavioral intervention to reduce HIV risk and address mental health-related effects of stigma for TMSM. Groups will be led by trained peer navigator staff and comprise no more than 10 participants per cohort.
40939863|NCT03231982|DRUG|Group I|Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
40939864|NCT03231982|DRUG|Group II|Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
40939865|NCT03033446|RADIATION|Y-90 Radioembolization|Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
40939866|NCT03033446|DRUG|Nivolumab|21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
40939867|NCT02314390|BEHAVIORAL|Group-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
40939868|NCT02314390|BEHAVIORAL|Individual-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
40939869|NCT02987660|PROCEDURE|Topography Guided LASIK|Corneal surgery for refractive error correction
40939870|NCT02987660|PROCEDURE|Small Incision Lenticular Extraction|Refractive surgical procedure for the correction of myopia with or without astigmatism
40939871|NCT02987660|DEVICE|WaveLight EX500 Excimer Laser System|As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
40939872|NCT02987660|DEVICE|VisuMax Surgical Laser|As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
40756503|NCT03796221|BEHAVIORAL|Standard pediatric obesity treatment|Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
40756504|NCT06199999|PROCEDURE|Erector Spinae Block|General anesthesia with Erector Spinae Plane Block
40939873|NCT03960554|DRUG|Denosumab Inj 60 mg/ml|Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.
40756505|NCT06199999|PROCEDURE|Local infiltration with local anesthetic|General anesthesia with local infiltration of local anesthetic:
40756506|NCT02718482|DRUG|Gemcitabine and Docetaxel|Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle
40756507|NCT02718482|DRUG|Ifosfamide|Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
40756508|NCT01713829|OTHER|Cranberry Beverage|8 oz cranberry beverage consumed daily for 12 weeks
40756509|NCT01713829|OTHER|Placebo Beverage|8 oz placebo beverage consumed daily for 12 weeks
40756510|NCT00601185|PROCEDURE|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
40756511|NCT01638299|DEVICE|Hypo-Hyper Minimizer (HHM) System|Adjustment of Insulin dosing during meal time
40939874|NCT03960554|OTHER|Placebo|Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.
40939875|NCT02276573|BIOLOGICAL|buccal cavity sample|
40939876|NCT05572554|OTHER|Foot Bath Group|The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks.
40939877|NCT06448182|DIETARY_SUPPLEMENT|Postbiotic|1 capsule of postbiotic daily in the morning
40939878|NCT06448182|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo daily in the morning
40939879|NCT00704912|DRUG|Orlistat/Meal Replacement/Lifestyle Modification|Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
40939880|NCT00704912|DRUG|Loestrin 1/20|Patients will be started on a low dose containing OCP for a continuous 4 month period.
40939881|NCT00704912|DRUG|Combination of treatments|Medications will be administered as described for the other 2 arms.
40939882|NCT04643821|DRUG|N-acetylcysteine, NAC, and calcitriol|iv administration of antioxidant and active vitamin D
41451111|NCT00746850|PROCEDURE|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
40939883|NCT04941781|DRUG|PIPE-307|"Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307.~Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging."
40939884|NCT01043510|DRUG|insulin degludec|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
40939885|NCT01043510|DRUG|insulin detemir|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
40939886|NCT04138888|DRUG|Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use|Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
40756512|NCT02661815|DRUG|Paclitaxel|Please see arm/group description.
40756513|NCT02661815|DRUG|Ricolinostat|Please see arm/group description.
40756514|NCT02661815|DRUG|Bevacizumab|Please see arm/group description.
40756515|NCT05995665|DEVICE|EsoGLOVE with Trigno Biofeedback (EMG sensors)|The dose is referred to the stay of inpatient setting. The stroke patients will be transferred to community hospital when medically stable. The average of stay in community hospital is 3 weeks. The stroke patients will receive intensive stroke rehabilitation during the stay, which will be daily physiotherapy and occupational therapy. The subjects will receive EsoGLOVETM with Trigno Biofeedback (EMG sensors) training on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day. A total of 15 sessions (5 session per week for a total of 3 weeks) of a minimum of 30 mins. This is similar to the dose in a similar trial (DSRB 2017/00312, Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture).
40939887|NCT04138888|DRUG|Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use|Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
40744382|NCT01182961|OTHER|gait training 2|subjects will walk on a treadmill under a progressive intensive gait protocol
40744383|NCT01182961|OTHER|exercise group|standard of care exercise group to improve strength and balance
40744384|NCT03637829|OTHER|Control|Water
40744385|NCT03637829|OTHER|White chocolate|Experimental snack treatment
40744386|NCT03637829|OTHER|Dark chocolate 1|Experimental snack treatment
40744387|NCT03637829|OTHER|Dark chocolate 2|Experimental snack treatment
40744388|NCT00800514|DRUG|amantadine|amantadine twice daily
40744389|NCT00800514|DRUG|amantadine|amantadine 100 mg twice daily
40744390|NCT03232944|DEVICE|Cardiac Resynchronization Therapy - MPP|The multiple point pacing feature (MPP) is designed to allow pacing from 2 LV electrodes.
40939888|NCT01640626|OTHER|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
40939889|NCT01374711|DRUG|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
40939890|NCT01374711|DRUG|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
40939891|NCT01374711|OTHER|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
40939892|NCT03425019|DEVICE|Soterix 1x1 tDCS mini-CT Stimulator device|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
40939893|NCT01229397|BIOLOGICAL|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
40939894|NCT01229397|BIOLOGICAL|Inflexal V|Inflexal V 0.5 mL administrated once only
40939895|NCT06079528|DEVICE|Electromagnetic device|"Health wave's generator (Manufactured with Simeds S.r.l. by Machiavelli, Italy, with serial number 11492.) with two separate emission channels and asynchronous operation was employed, along with 100 saved and storable programs that could be altered by the user (intensity, frequency and phase time). The different associated applicators are recognized automatically. Magnetic field strength up to 100 Gauss and output frequency from (1 - 100) Hertz are programmable."
40939896|NCT06079528|OTHER|visceral manipulation therapy|for the pelvic reproductive organs and their related structures (ligaments and fasciae) was applied one session/week for 12 weeks. Each patient was was advised to evacuate her bladder before starting the treatment session, mobility and motility testing of pelvic organs, together with the assessment of fascial tension, was then performed, with detecting restrictions, treatment was applied according to Hebgen
40939897|NCT06079528|OTHER|General advice|were directed for both groups in term of the following: Perform pelvic floor exercises regularly ; avoid constipation and straining; treat the cause of any chronic cough and infection of urethra or bladder; stop smoking; maintain a healthy weight; drinking sufficient amounts of healthy fluids (water); decrease the caffeine intake; and decrease the amount of acidic and spicy foods.
40939898|NCT06079528|OTHER|pelvic floor muscle training|consisted of 24 sessions of 45-60 min each, twice a week, for 12 weeks. The PFMT was divided into four phases. Proprioceptive (3 weeks): where the woman has gained adequate perception of PFM and performed fast and slow contractions; Simple (3 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (3 week): where the exercise evolved into functional exercises of greater amplitude; and Power (3 week): where the maximum voluntary contraction of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and fast fibers
41281720|NCT04429750|PROCEDURE|intact cord resuscitation|The umbilical cord will be kept intact during the initial phase of the resuscitation. The infant will be placed on a specifically designed compact trolley with a warmed platform, suitable for commencing resuscitation between the mother's legs in case of vaginal birth or near the operating table beside the mother in case of cesarean section. This trolley will be fully equipped for resuscitation, including a suction device, gas flowmeter/blender, ventilatory support, and monitoring system. Its height can be adjusted in order to position the infant close to the maternal perineum. The infant will be intubated and mechanically ventilated on this trolley. The cord will be clamped once cardiorespiratory stabilization will be obtained (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%) or in case of spontaneous placental expulsion. The infant will be then transferred to the neonatal intensive care unit (NICU).
41281721|NCT00527202|DRUG|botulinum toxin A|Botulinum toxin A versus saline in parallel groups
41451112|NCT00746850|PROCEDURE|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
40939899|NCT02049320|DRUG|Remifentanil|
40939900|NCT06400979|DEVICE|Elequil aromatab|Aromatherapy impregnated tab utilized to dispense inhaled scent for the study
40939901|NCT05771168|DEVICE|Artificial urinary sphincter|Implantation of peri-urethral artificial urinary sphincter
40744391|NCT02639533|DRUG|Pregabalin|Pregabalin 150 mg PO, single dose.
40744392|NCT02639533|OTHER|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
40939902|NCT05771168|DEVICE|Male sling|Retrourethral implantation of male sling
40744393|NCT05728229|DRUG|Supplement with SiderAl® Med|Nutritional supplementation with special purpose food
40744394|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
40744395|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
40939903|NCT03137030|DRUG|GRT7014 - Abuse Deterrend Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
40939904|NCT03137030|DRUG|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
41281722|NCT05574192|BEHAVIORAL|Social Engagement Intervention|"The intervention includes social visiting with women affected by violence. Social visiting is carried out by trained peer-workers. Peers are women who share life histories with the target study population. Peer-workers will establish a visiting schedule (day/time) and provide a detailed list of activities in two categories:~1. arts-based activities.~2. physical activities.~The peer will meet with the participant at the scheduled place and times to accompany the participant and engage in the activities with the participant.~Participation in scheduled social activities that target the interest and ability of women affected by violence is considered to improve social connectedness by increasing the quality and quantity of a woman's social interactions with a supportive, trained person who shares life experiences. Shared, consistent and reliable social activities also are hypothesized to reduce loneliness by contributing to a sense of belonging and sense of being cared for."
40756516|NCT05995665|OTHER|Graded Repetitive Arm Supplementary Program (GRASP)|Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.
41281723|NCT04619576|BEHAVIORAL|Occupational health workers|Questionnaire online
41281724|NCT02162979|DRUG|sildenafil|sildenafil 50mg BID for 2 weeks
41281725|NCT02162979|DRUG|Placebo|
41451113|NCT01275664|PROCEDURE|Adjuvant Therapy|Ancillary studies
41451114|NCT01275664|DRUG|Aprepitant|Given IV and PO
41451115|NCT01275664|DRUG|Carboplatin|Given IP
40756517|NCT05362175|DEVICE|Obstetric ultrasound|ultrasound measurement of the cross sectional area of umbilical cord within 1 cm from the cord insertion in to fetal abdomen and the standard Hadlock's formula
40756518|NCT01179620|DRUG|Certoparin|Certoparin
40756519|NCT02209909|DRUG|aspirin continuation|Patients are randomized to continue aspirin before OPCAB surgery.
40756520|NCT02209909|DRUG|aspirin discontinuation|Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
40756521|NCT06298864|BEHAVIORAL|Internet-CBT|"* Common reactions following ACS. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation, i.e., labeling. General lifestyle advice on e.g., physical activity, diet.~* Identifying life areas impaired by ACS-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Gradual exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms.~* Gradual exposure to avoided situations, activities and increase in physical activity.~* Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
40939905|NCT04738734|DEVICE|CellFX System Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
40939906|NCT04738734|DEVICE|Cryosurgery Liquid Nitrogen Sprayer|Cryosurgery will be standardized across all investigational sites using the Brymill Cry-Ac spray canister with standard cryoprobe.
40939907|NCT06104371|DEVICE|Magtrace|Sentinel lymph node tracer and metastatic lymph node clip
40939908|NCT00021671|DRUG|Erythromycin|
40939909|NCT00021671|DRUG|Nevirapine|
40939910|NCT00021671|DRUG|Ampicillin sodium|
40939911|NCT00021671|DRUG|Metronidazole|
40939912|NCT02430506|BIOLOGICAL|Placebo|This is the identical buffer solution in which AERAS-402 is formulated.
41451116|NCT01275664|DRUG|Cisplatin|Given IP
41451117|NCT01275664|DRUG|Dexamethasone|Given PO
41451118|NCT01275664|DRUG|Granisetron Transdermal Patch|Apply one patch to upper arm
41451119|NCT01275664|PROCEDURE|Management of Therapy Complications|Ancillary studies
41451120|NCT01275664|OTHER|Questionnaire Administration|Ancillary studies
41451121|NCT06468839|BEHAVIORAL|digital addiction management model|The experimental group will implement a digital addiction model. No intervention will be made to the control group.
41451122|NCT01218360|DRUG|Physician standard-of-care|Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
41451123|NCT01024855|DEVICE|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
41451124|NCT01677338|DRUG|13C-uracil|PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
41451125|NCT01677338|DRUG|99mTc sulfur colloid|PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
41451126|NCT02341690|OTHER|Interval walking training|"Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger"
41451127|NCT02341690|OTHER|control|Standard care at the promotion centre in the municipality
41451128|NCT01620840|DRUG|Lacosamide 10mg/ml|intravenous administration up to 10 days
41451129|NCT00672373|DRUG|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
41451130|NCT00672373|DRUG|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
41451131|NCT06628232|OTHER|pacifier with breast milk|swaddling in the mother\&#39;s lap together with giving a pacifier dipped in breast milk
41451132|NCT06628232|OTHER|heel heating|swaddling in the mother\&#39;s lap together with local dry heat application
41451133|NCT06628232|OTHER|interventions combined|swaddling in the mother\&#39;s lap together with giving a pacifier dipped in breast milk and heel heating
41451134|NCT06628232|OTHER|Control|swaddling the baby in the mother\&#39;s lap
41451135|NCT01243983|DRUG|LX211|"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks"
41451136|NCT04633863|DEVICE|Artificial tear MDI - 101|Medical device CE marked - artificial tears containing arabinogalactan, trehalose and hyaluronic acid - 10 weeks treatment
41451137|NCT00779519|DRUG|TTP435|
41451138|NCT00779519|DRUG|Placebo|
41451139|NCT02044731|BEHAVIORAL|Active and Healthy Families|A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
41451140|NCT05798884|DEVICE|Acupuncture|Disposable acupuncture needles (0.25 mm in diameter and 25 mm in length) are straightly into body acupuncture points (he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10)). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occur due to Capecitabine (Xeloda). Electrical stimulation will be delivered with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument. The needles will be retained in position for 25 minutes.
41451141|NCT05798884|DEVICE|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
41451142|NCT02424435|DRUG|Methylprednisolone|Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescription bottle of 25 tablets (standard quantity) and will self-administer 21 tablets over a 28-day dosing cycle.
41451143|NCT00630253|BIOLOGICAL|Anti-Thymocyte Globulin|30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
41451144|NCT00630253|DRUG|Cyclophosphamide|5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
41451145|NCT00630253|DRUG|Fludarabine|35 mg/m\^2 intravenously (IV) on days -6 through -2.
41451146|NCT00630253|PROCEDURE|Hematopoietic Stem Cell Transplantation|Bone marrow or umbilical cord blood infusion on day 0.
41451147|NCT00630253|DRUG|Methylprednisolone|Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
41451148|NCT00630253|DRUG|Filgrastim|5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count \> or = 2.5 x 10\^9/L
41451149|NCT00630253|DRUG|Cyclosporine|Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.
41451150|NCT00630253|DRUG|Mycophenolate Mofetil|Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
41451151|NCT04341337|OTHER|interview|questionnaire about ethics in surgery
41451152|NCT02768974|DRUG|OPRX-106|Oral delivery, once daily.
41451153|NCT02940444|DRUG|Heparin|
41451154|NCT04340063|DEVICE|Gait training performed on a treadmill|Participants randomized to the Control group will complete high intensity gait training on a treadmill.
41281726|NCT03572374|OTHER|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
40939913|NCT02430506|BIOLOGICAL|AERAS-402|Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
41281727|NCT03572374|OTHER|Information Booklet|Participants in the control arm will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
41281728|NCT01021943|DRUG|spironolactone|Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
41281729|NCT01021943|DRUG|Placebo|Half of the subjects will be assigned to receive placebo for 6 months
41281730|NCT03358628|OTHER|Molecular Profiling & In Vivo drug testing in PDX|Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.
40744396|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
40744397|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
40756522|NCT06298864|BEHAVIORAL|Internet-CL|"* Education on ACS, risk factors, its treatments and medication.~* Education and advice promoting healthy habits regarding diet, alcohol and tobacco.~* Education and advice regarding physical activity and the beneficial effects on health.~* Education regarding common emotional reactions following ACS.~* Prevention of relapse and plan forward to maintain a healthy lifestyle."
41281731|NCT03265587|OTHER|No intervention|No intervention
41281732|NCT01855230|DRUG|ASM-024|ASM-024 b.i.d for 14 days
41281733|NCT01855230|DRUG|Placebo|Placebo b.i.d. for 14 days
41281734|NCT06421324|BEHAVIORAL|Health reccommendations|Patients are given recommendations according to their risk group, based on the model which already predicted health indicators. This information will be sent to the patient's treating physician so that treatment and recommendations are aligned with the clinical care practice based on the European Code of Cancer guidelines, the H. pylori best practices guidelines and European GIM guidelines
41281735|NCT05347823|DIAGNOSTIC_TEST|Hair analysis for drug concentration|Sample collection for the determination of treatment adherence
41281736|NCT04116671|DEVICE|Neuromechanical Gait Assist|A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
41281737|NCT04938466|DRUG|Long-Acting Growth Hormone (LAGH)|Long-acting growth hormone (LAGH) treatment
41281738|NCT00686127|DRUG|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
41281739|NCT00686127|DRUG|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
41281740|NCT03193905|PROCEDURE|Bairhugger Full Access Underbody Blanket|30 patients undergo new procedure with a Bairhugger Full Access Underbody Blanket
40939914|NCT02471976|OTHER|strategy promoting early consideration and collegiate vulnerability of patients|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
40939915|NCT02395510|DRUG|Vortioxetine|Vortioxetine 5-20mg
41281741|NCT03193905|PROCEDURE|Cotton blanket - control group|30 patients undergo standard procedure with a cotton blanket
40939916|NCT01139840|DIETARY_SUPPLEMENT|vitamin D2|Study Supplement
41281742|NCT05651087|DRUG|LACUDY|LACUDY:Insert 2mL twice a week for 4 weeks before going to bed
41281743|NCT04101812|DRUG|pegylated liposomal doxorubicin (PLD)|PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
41281744|NCT04101812|DRUG|PD-1|PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
40939917|NCT01139840|DIETARY_SUPPLEMENT|vitamin D3|Study Supplement
40939918|NCT03243266|DIAGNOSTIC_TEST|CBC/Diff Reference Interval|Results will not be used to manage patients
40939919|NCT00127595|DRUG|gemcitabine, oxaliplatin|
40939920|NCT03500679|BIOLOGICAL|ExPEC4V|Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.
40939921|NCT03500679|BIOLOGICAL|Placebo|Participants will receive placebo as an IM injection on Days 1 and 181.
41281745|NCT04881539|DIETARY_SUPPLEMENT|Cannabidiol (CBD)|This group will receive an oral dose of CBD (Six Degrees Wellness).
41451155|NCT04340063|DEVICE|Gait training performed in a Movement Amplification Environment|The Experimental group will perform all gait training within the movement amplification environment. To create the movement amplification environment, the investigators have constructed a cable-driven robot, the Agility Trainer. The Agility Trainer applies small forces to the pelvis that increase the difficulty to maintain forward walking
40756523|NCT02191995|BEHAVIORAL|yoga|
40756524|NCT05810649|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.
40756525|NCT04194619|OTHER|Questionnaire|Interview of women with a rare vascular disease through a phone questionnaire about severe and specific obstetrical complications during and after pregnancy.
40939922|NCT03198039|BEHAVIORAL|Meditation|Isha Kriya (IK) meditation approximately 12 minutes, twice a day
40939923|NCT04552730|DRUG|Cenegermin-Bkbj|Topical Cenegermin-bkbj 6 times per day for 8 weeks.
40939924|NCT05507827|DRUG|Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)|CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration
40939925|NCT05507827|DRUG|Treg CD34+HSPC (Orca-T)|Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
41281746|NCT03457298|DEVICE|Ossix Volumax|Ossix Volumax is intended to be used for Lateral ridge augmentation
41281747|NCT03457298|DEVICE|FDBA with collagen membrane|freeze-dried bone allograft (FDBA) with collagen membrane
41281748|NCT03215277|DRUG|Bimekizumab|One bimekizumab dose will be administered.
40756526|NCT02572687|DRUG|Ramucirumab|Administered IV
40939926|NCT02524977|BEHAVIORAL|Decision Support|Provision of recommended antithrombotic therapy based on atrial fibrillation decision support tool that uses both stroke and bleeding risk
40939927|NCT02524977|BEHAVIORAL|Educational Intervention Only|Educational conference series
40939928|NCT01016704|BEHAVIORAL|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
40939929|NCT00666796|DRUG|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
40939930|NCT00666796|DRUG|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
40939931|NCT00666796|DRUG|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
40939932|NCT00666796|DRUG|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
41281749|NCT03215277|DRUG|Certolizumab pegol|Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
41281750|NCT03215277|OTHER|Placebo|Placebo will be provided to maintain the blinding.
41281751|NCT02058121|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is provided in 12 weekly two hour long sessions in a group setting
41281752|NCT02058121|BEHAVIORAL|Treatment as usual|Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a physician, dietician and/or physiotherapist.
41281753|NCT03542214|COMBINATION_PRODUCT|Calcium electroporation|Patients with inoperable colorectal cancer will be treated with calcium electroporation
41451156|NCT05444647|PROCEDURE|stool and blood collection|Patients will collect fecal and blood samples prior to treatment and at the time of response evaluation, and completion of therapy using a standard stool-collection-kit. At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
41451157|NCT06627621|PROCEDURE|Alveolar Ridge Reconstruction|scaffold guided alveolar bone regeneration
41451158|NCT01096329|DRUG|Testosterone Spray 5% and 1%|Testosterone Spray 5% 2x90uL for 14 days Testosterone Spray 1% 2x90uL for 14 days
41281754|NCT04180592|PROCEDURE|CT Fusion + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
41281755|NCT04585763|DEVICE|Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)|The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.
41281756|NCT00356915|DRUG|Itraconazole 100mg capsules|Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
41281757|NCT00356915|DRUG|Itraconazole 200mg tablets|Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
41281758|NCT00356915|DRUG|Placebo tablets|Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
41451159|NCT01096329|DRUG|Intrinsa® Patch and Testosterone Spray 5%|Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days
41451160|NCT01096329|DRUG|Intrinsa® Patch and Testosterone Spray 1%|Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
40939933|NCT00666796|DRUG|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
41281759|NCT01288183|PROCEDURE|sham tDCS|"sham condition as delivered by the stimulator study mode (2mA during 40s and brief current pulses until the end of the stimulation) 20 minutes, 10 sessions, 2 per day"
40756527|NCT02572687|DRUG|MEDI4736|Administered IV
40756528|NCT03692026|PROCEDURE|Immediate implant placement|implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.
40756529|NCT03692026|DRUG|Hyaluronic acid and Melatonin Mixture|a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
41451161|NCT05474651|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, the Fagerstrom Test of Nicotine Dependence,Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, smoking hazard questionnaire, motivation to quit smoking sheet, ability to quit smoking sheet, alcohol consumption, International Physical Activity Questionnaire.
40939934|NCT00666796|DRUG|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
40939935|NCT00666796|DRUG|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
40939936|NCT00666796|DRUG|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
40939937|NCT00495131|DRUG|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 24 weeks
40939938|NCT00495131|DRUG|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 48 weeks
40939939|NCT04376879|OTHER|Data monitoring for 48h within the first 24 hours of admission for COVID-19|The admission variables and those constituting the predictive score (blood pressure, temperature, oxygenotherapy, biological analysis...) will be collected for 48 hours after enrolment (i.e within the first 24 hours of admission )
40939940|NCT04957095|DRUG|Apomorphine Injectable Solution|Apomorphine injected for therapeutic relief
40939941|NCT04957095|OTHER|Subcortical Stimulation|Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
40939942|NCT04243109|DRUG|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~* Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started. Dose reductions will be made based on the evaluation of hematological and non-hematological toxicity.~* Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~* Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles. In patients older than 75 years the dose will be reduced to 20 mg / day in the same previous schedule.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
40939943|NCT00945555|DRUG|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
40939944|NCT04549246|RADIATION|Spatially Fractionated Radiation (GRID) Therapy|Grid therapy allows for high doses of radiation to be delivered over several spatially distinct, small regions. This permits regions of very high dose to a large tumor away from critical structures, which could be beneficial in both palliative and definitive treatments. Additionally, allowing for high doses to be delivered could pose a benefit for radioresistant histologies.
40939945|NCT00160966|DRUG|Ciclosporin and Mycophenolate-mofetil|according to the Giessen protocol
41281760|NCT01288183|PROCEDURE|active tDCS|anodal tDCS applied over the right DLPFC 2mA, 20minutes, 10 sessions, 2 per day
41281761|NCT04642235|OTHER|Nature Nook|The Nature Nook intervention will take place on lots that already have the standard greening intervention. In addition, design elements will be added such as a simple path and benches to explicitly invite people into the space. An additional difference is the exclusive use of larger, corner lots, rather than smaller mid-block spaces, to maximize visibility.
40939946|NCT00160966|DRUG|Tacrolimus and Mycophenolate-mofetil|according to Giessen protocol
40939947|NCT00160966|DRUG|Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus|according to Giessen protocol
40939948|NCT04012918|DRUG|Capecitabine plus aromatase inhibitor|Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
40939949|NCT04012918|DRUG|A.I.|aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor
40939950|NCT05538598|PROCEDURE|Intramuscular Dry Needling|The insertion of thin monofilament needles (without injectate) into a tight band of muscle. The needles will be inserted into the muscle for \~10 seconds.
40939951|NCT03642743|OTHER|postoperative follow up appointment|Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone
40939952|NCT05169073|PROCEDURE|Virtual Reality training|In the Virtual Reality (VR) study arm, a VR software (Specto VRTM, version 4.0, Diffuse Ltd, Heimberg, Switzerland) will be used to display volumetric MRCP data using a tethered head-mounted display (HMD) prior to the operation. Specto uses volume rendering at 180 frames/sec to visualize the medical data in an immersive fashion in the VR environment and allows for viewing of the 3D reconstructed 3D imaging with 360° free movement. Each participant will perform a procedure with VR training and one with conventional preparation (MRCP).
40939953|NCT05169073|PROCEDURE|Conventional training|In the conventional study arm, the participants will view the preoperative MRCP.
40939954|NCT00457366|DRUG|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD
40939955|NCT00457366|DRUG|Haloperidol|given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary
41451162|NCT05196334|OTHER|No intervention|No intervention
40939956|NCT00457366|DRUG|Lorazepam|given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.
40939957|NCT00457366|DRUG|Cogentin|given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
41451163|NCT05605652|PROCEDURE|microosteoperforations|"Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire."
40756530|NCT04410133|DRUG|18F fluciclovine|18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
40939958|NCT02803762|DRUG|Pacritinib|400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
40939959|NCT01596673|DRUG|45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|"Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet."
40939960|NCT01596673|DRUG|Placebo|Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
40939961|NCT05821101|DEVICE|Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.|Bilateral implantation of IOLs such that dominant eye is corrected for distance vision while the non-dominant eye is corrected with a small amount of nearsightedness (-0.5 diopters).
40939962|NCT06282848|DRUG|Atropine 0.05%|Topical application
40939963|NCT06282848|DEVICE|DIMS lens|Spectacle wear
40939964|NCT00000434|BEHAVIORAL|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
40939965|NCT02411760|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Assessment of the performance of DWI/ADC measurements alone, and as an adjunct to dynamic contrast enhanced (DCE) MRI in diagnosing/characterizing breast cancer.
40939966|NCT01110655|OTHER|Intravenous hypertonic Saline|Intravenous 100mL bolus of 3% saline
40939967|NCT01110655|OTHER|Oral hypertonic saline|Oral 100mL bolus of 3% saline
40939968|NCT00083096|DRUG|lonafarnib|
40939969|NCT00083096|DRUG|temozolomide|
41281762|NCT04642235|BEHAVIORAL|Nature Coach|"The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.~Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
40939970|NCT03162731|BIOLOGICAL|Nivolumab|Given IV
41281763|NCT04642235|OTHER|Nature Nook + Nature Coach|The combined intervention will involve the installation of Nature Nooks to blighted vacant lots followed by the delivery of the Nature Coach intervention to people living in the immediate surrounding blocks. The intervention will be tailored to explicitly direct participants to use the Nature Nook.
41281764|NCT01023529|RADIATION|Palliative pelvic soft-tissue radiation (external beam)|3 Gy x 10-13 (range 30 - 39 Gy total)
41451164|NCT05173350|OTHER|RETAIN KY|The experimental group receives a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Services offered by the project include individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support. The project provides training on SAW/RTW best practices and RETAIN, as well as financial incentives to health care professionals. The treatment group is eligible to receive the full set of RETAIN intervention activities.
41451165|NCT05173350|OTHER|Active Comparator|Those in the active comparator arm continue to receive medical services. A RTW coordinator creates a RTW plan with the enrollee and refers them to existing resources. The RTW coordinator works with enrollees for 2.5 hours total.
41451166|NCT04547309|RADIATION|68Ga/18F-HER2 Affibody PET/CT scan|HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.
41451167|NCT00867360|DRUG|Mifepristone (RU-486)|
41451168|NCT00867360|DRUG|Placebo|Placebo medication
40939971|NCT03162731|BIOLOGICAL|Ipilimumab|Given IV
40939972|NCT03162731|RADIATION|Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Undergo simultaneous integrated boost integrated modulated radiation therapy
40939973|NCT03162731|RADIATION|Volume Modulated Arc Therapy|Undergo volumetric modulated arc therapy
41281765|NCT01154413|BEHAVIORAL|Intensive education of the doctor/nursing team on the protocol|
41451169|NCT06175364|OTHER|Health Professionals in the Field of Orthotics Prosthetics|Three data collection tools will be used as data collection methods for the research. These data collection tools; demographic information form, Health Sciences Evidence-Based Practice Survey and Information Literacy Self-Efficacy Scale.
41451170|NCT00004398|DRUG|heme arginate|
41451171|NCT00004398|DRUG|tin mesoporphyrin|
41451172|NCT02991196|DRUG|DS-8273a + nivolumab|Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered \[90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions\] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
40939974|NCT00727831|DRUG|glucarpidase|
40939975|NCT00727831|DRUG|leucovorin calcium|
40939976|NCT00727831|DRUG|methotrexate|
40939977|NCT00727831|OTHER|laboratory biomarker analysis|
40939978|NCT00727831|PROCEDURE|quality-of-life assessment|
40939979|NCT00727831|RADIATION|radiation therapy|
41281766|NCT03529487|DRUG|Oxymetazoline|Oxymetazoline gel applied intra-analy
41281767|NCT03446677|OTHER|Postural Stability Testing|Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks. Data of center of pressure, antero-posterior sways and medial-lateral sways were collected in each of the conditions. Each task took 30 seconds to be performed. The first 4 tasks were performed with the mat on the hard surface of the floor. These 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving head upward and downward, and standing with eyes closed and the head actively moving upward and downward. The subjects were asked to perform four more tasks while standing on a thick piece of balance foam that was placed on top of the MatScan®. The remaining 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving the head upward and downward, and standing with eyes closed with head actively moving upward and downward.
41281768|NCT00472303|DRUG|Tapentadol Extended Release|Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
41281769|NCT00472303|DRUG|Matching Placebo after Tapentadol in the Titration Phase.|Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
41281770|NCT00472303|DRUG|Morphine Sulphate Controlled Release|Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
41281771|NCT04352829|OTHER|VIDEO-TRAINING-SESSION ABOUT MDI USE|The steps were demonstrated with the brochure that illustrated correct inhalation techniques and were prepared by Turkish Respiratory Research Society-Inhalation Treatment Study Group in line with the literature and were described with a video that was designed by Turkish National Society of Allergy and Clinical Immunology (25). The video is provided with a free access on the webpage of Turkish National Society of Allergy and Clinical Immunology.The video included images that explained the steps about what to do before MDI use, how to use the device and the issues to which attention should be paid during the use of the device and focused on the skill-steps that should gradually be performed about MDI use.
41281772|NCT04520477|DIAGNOSTIC_TEST|Bio Impedance assesement (BIA)|BIA every 5 minutes od the test protocol. Patients stood up for 5 minutes, laid down for 70 minutes, followed by 5 minutes in a seated position and ending with 30 minutes standing. BIA was done every 5 minutes.
41281773|NCT04520477|DIAGNOSTIC_TEST|Blood and salava sample|Blood Samples were done at the initation of the protocol, and every 10 minutes after ingestion of the deutarated water
41451173|NCT01152645|DRUG|ARQ 197|Orally twice daily administration of ARQ 197
41451174|NCT03066479|DEVICE|Fitbit|Wearable activity \& sleep tracker.
41451175|NCT03066479|OTHER|OSA questionnaire|Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
41451176|NCT03066479|DIAGNOSTIC_TEST|Polysomnography|All participants will be undergoing a sleep study as part of their clinical care.
41451177|NCT05877326|DRUG|General anesthesia with propofol or sevoflurane|General anesthesia
41451178|NCT05877326|BEHAVIORAL|CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative|The presence of mental confusion will be determined by CAM-ICU at J3 post intervention.
40756531|NCT06007157|BEHAVIORAL|Hypersodic/Hyposodic diet|Participants will undergo a dietary intervention consisting of a week of high-sodium diet (4800 mg/day), followed by a week of low-sodium diet (1200 mg/day).
40939980|NCT03092024|OTHER|SPIN-HAND program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
40939981|NCT03095443|OTHER|Music Therapy - Personalized Playlist|Participant receives personalized playlist.
40939982|NCT03095443|OTHER|Music Therapy - Standard Playlist|Participant receives a standard low beats per minute playlist.
41281774|NCT04520477|DIETARY_SUPPLEMENT|Ingestion of deuterated water|15 minutes after the intiation of the test protocol, participants drink an amount of deuterated water corresponding with 0.25% of their TBW calculated using the Watson Formula
41281775|NCT04520477|DIAGNOSTIC_TEST|Urine sample|A urine sample is taken at the initiation and after termination of the protocol.
41281776|NCT02303587|DRUG|methylprednisolone|
41281777|NCT02104180|DEVICE|Urgotul|sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
41281778|NCT02104180|DEVICE|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
41281779|NCT01439958|DRUG|Inhalation|Twice daily inhalation for a maximum of three years.
41281780|NCT00249561|BEHAVIORAL|Recovery by Choice|"The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive."
41281781|NCT00249561|BEHAVIORAL|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg \& Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
41281782|NCT06283251|BEHAVIORAL|PediRISE Resource Program|A centrally administered, income-poverty targeted intervention that includes twice-monthly direct provision of unrestricted cash transfers along with benefits counseling to mitigate the risk of loss of means-tested benefits. Funds will be dispersed to families via provided debit card or through personal banking, PayPal, or Venmo.
41281783|NCT05957640|COMBINATION_PRODUCT|Yttrium-90 carbon microspheres SIRT|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
40939983|NCT03095443|OTHER|Attention Control|Participant receives an audio-book.
40939984|NCT00806871|DRUG|Methylprednisolone 40 mg|"Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use~1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline"
40939985|NCT00806871|DRUG|Methylprednisolone 80 mg|"Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.~2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine"
40939986|NCT00806871|DRUG|Sodium chloride|"Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline"
40939987|NCT06048250|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40939988|NCT06048250|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40939989|NCT06048250|PROCEDURE|Computed Tomography|Undergo CT
40939990|NCT06048250|BIOLOGICAL|Mezigdomide|Receive PO
41451179|NCT04303208|PROCEDURE|Blood sample|Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum . Separated serum will be stored at \< - 20c ( avoid repeated freeze - thaw cycles ) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
41281784|NCT01401140|DRUG|St Thomas|Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
40939991|NCT06048250|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40939992|NCT05270421|DRUG|Furosemide 40 mg|Standard ESWL + Furosemide 40 mg
40939993|NCT05270421|OTHER|Conventional Treatment|Standard ESWL
40939994|NCT01791010|OTHER|Inspiratory muscle training|
40939995|NCT01791010|OTHER|Training sham|Conducting fake training with the aim of blind the control group
40939996|NCT01325623|DEVICE|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
41281785|NCT01401140|DRUG|Custodiol|Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
41287292|NCT01620996|BEHAVIORAL|Motivational Interviewing|"Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:~FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism~These mediators/ingredients are delivered by the clinician using the following principles:~Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy"
40939997|NCT03657693|DIAGNOSTIC_TEST|NICU MRI|MRI device that is not FDA approved.
40939998|NCT03657693|DIAGNOSTIC_TEST|Polysomnography|Polysomnography to better determine obstruction index in the airway.
40939999|NCT00244166|DRUG|prednisolone|
40940000|NCT03470974|BEHAVIORAL|Self-titration strategy|The self-titration strategy allows patients or medical professionals to adjust their medicine (additional, maintain, or decrease dose) depending on a bespoke plan. The bespoke plan for hypertensive patients involves setting target blood pressure, self-monitoring blood pressure, recording blood pressure readings and constructing a medication titration schedule. Each medication titration step is conducted based on the average home BP measurement readings.
40940001|NCT03869892|DRUG|Trifluridine/tipiracil hydrochloride (S95005)|Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
40940002|NCT03869892|DRUG|Capecitabine|Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
40940003|NCT03869892|BIOLOGICAL|Bevacizumab experimental|Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
40940004|NCT03869892|BIOLOGICAL|Bevacizumab control|Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
40940005|NCT04613453|DRUG|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
40940006|NCT04613453|DRUG|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
40940007|NCT04177927|DEVICE|Capnostream 20p / Coviden|The special nasal canule is used for detection carbondioxide from breathe of patients
40940008|NCT04177927|DEVICE|Rutine monitoring|peripheric Oxygen saturation is monitored.
40940009|NCT06518525|OTHER|pilates-based tele-exercises|pilates-based tele-exercises
40940010|NCT04226534|OTHER|Maximal effort test|Performing a maximal effort test on the treadmill
40940011|NCT05307978|DRUG|ALXN1910|Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
40940012|NCT05307978|DRUG|Placebo|Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
40940013|NCT01794182|DRUG|Glyburide for Injection|Administered as specified in the treatment arm.
40940014|NCT01794182|DRUG|Placebo|Administered as specified in the treatment arm.
40940015|NCT04824729|PROCEDURE|Lower limb revascularization|French population of patients with lower-extremity peripheral artery disease who have undergone lower limb revascularization.
40940016|NCT04824729|PROCEDURE|Lower limb revascularization|French population of patients matching the VOYAGER PAD exclusion criteria resembling a subgroup of the PAD revascularized population.
40940017|NCT03258138|BEHAVIORAL|Health and wellness learning sessions|The health and wellness learning sessions provide a platform for concepts from a variety of health behaviour theories and CBT to be combined with evidence- and practice-based recommendations for healthy lifestyles. They provide the basis for participants' development of an individualized action plan. The sessions will last one hour and participants will receive them in a group setting, 18 times throughout the duration of the program. Specifically, the sessions will be delivered during weeks: 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48.
40940018|NCT03258138|BEHAVIORAL|Brainstorming group sessions|The brainstorming group sessions allow for facilitated discussions where individuals explore barriers and facilitators to achieving their goals and provide an interpersonal component to the program through the building of social interactions. Participants will also receive help in finding community programs to support healthy lifestyles. These sessions will last one hour and participants will receive them in a group setting, 30 times throughout the duration of the program. Specifically, these sessions will be delivered during weeks: 9-11, 13-15, 17-19, 21-23, 25-27, 29-31, 33-35, 37-39, 41-43, 45-47.
40940019|NCT03258138|BEHAVIORAL|Individual sessions with a multidisciplinary health team|Monthly individual sessions with a family physician trained in medical CBT, a dietician and a physical therapist help individuals tailor their action plans and recommendations to their particular circumstances and provide supports based on their needs. The initial session will last 3 hours and occur at baseline. The follow-up sessions will last 1 hour.
40940020|NCT03258138|BEHAVIORAL|Health goal development|Participants in both arms will develop health goals. Several components of these goals will be measured throughout the study, including the stage of change, self-efficacy and actual goal achievement. In the more intensive program arm, participants will develop health goals and learn about how to meet those goals through the group and individual sessions. In the less intensive program arm, participants will receive support in developing health goals from a research assistant trained in theories of health behaviour and in goal setting at baseline, 3 months, 6 months, 9 months and 12 months. The initial goal setting session will be provided within a time period of 2 hours, and the follow-up sessions will be provided within one hour time periods.
40940021|NCT03258138|BEHAVIORAL|Physical activity and nutrition journals|Participants in both arm will be asked to maintain a physical activity journal and a nutrition journal for a week each every three months. These journals help participants reflect on current behaviours and areas for change.
40940022|NCT00336583|DRUG|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
40940023|NCT04652232|OTHER|RV3466F lotion|"Code: RV3466F Formula: MF5354~Application modalities:~3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.~Shampoo should be avoided within the 2 hours after application"
40940024|NCT04652232|OTHER|Shampoo|"Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application"
40940025|NCT06202417|DRUG|Fruquintinib|an oral tyrosine kinase inhibitor (TKI)
40940026|NCT03804034|DEVICE|Block of resin|
40940027|NCT03804034|DEVICE|Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire|
40940028|NCT02072239|DEVICE|Angioshield|The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
41451180|NCT03960801|DRUG|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
40756532|NCT05467228|DEVICE|vibro-tactile stimulation (VTS)|To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (\~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second
40756533|NCT03723525|COMBINATION_PRODUCT|Package of HIV care|"A. Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI). Detail information mentioned in the manual (refer to uploaded protocol).~B. Rapid ART Initiation~1. PLHIV without suspicion or active OI: Initiate ART within seven days or same day after HIV serology disclosure~2. PLHIV with suspicion or active OI: Defer initiation if clinical symptoms suggest tuberculosis or cryptococcal meningitis. Detail information mentioned in the manual (refer to uploaded protocol).~C. Enhanced Adherence/Retention Support: mHealth: Receive text messages in mobile regarding appointment reminder (pill pick up, CD4 test, viral load test, early infant diagnosis (EID) test etc.) and general awareness messages (positive prevention, the importance of regular health check-up etc.). PLHIV with advanced HIV disease will also receive weekly/biweekly home-based adherence/ retention support linked to community care centre and community home-based care."
40756534|NCT03723525|COMBINATION_PRODUCT|Standard HIV care|Standard of HIV care includes screening and management of OI (OI- tuberculosis (TB), bacterial pneumonia, herpes, and candidiasis), baseline assessment (CD4 and other blood tests- complete blood count, hemoglobin, platelets, liver function test, renal function test, urine for albumin, chest x-ray), at 6 months CD4 test, viral load (twice a year) and then on a yearly basis, additional lab test at 3 months, 6 months, antiretroviral (ARV) toxicity monitoring like hemoglobin (Zidovudine), Serum Glutamic-Pyruvic Transaminase (Nevirapine/Efavirenz), Creatinine (Tenofovir), prophylaxis (Co-trimoxazole preventive therapy CD4\<350 and WHO stage III and IV and Isoniazid preventive therapy if eligible) and ART / follow up (generally monthly/ bimonthly).
40756535|NCT01071785|DIETARY_SUPPLEMENT|guar gum|guar gum 10g/day for six weeks
40756536|NCT02268305|DRUG|MSM 1000mg twice a day (6000 mgs)|MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
41451181|NCT03960801|DRUG|neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
41451182|NCT04225715|DRUG|Nucleos(t)ide (NUC)|Nucleos(t)ide (NUC) will be administered orally
41451183|NCT04225715|DRUG|CpAM (RO7049389)|CpAM (RO7049389) will be administered orally
41451184|NCT04225715|DRUG|TLR7 (RO7020531)|TLR7 (RO7020531) will be administered orally
41451185|NCT04225715|DRUG|siRNA (RO7445482)|siRNA (RO7445482) will be administered subcutaneously
41451186|NCT04225715|DRUG|PEG-IFN|PEG-IFN will be administered subcutaneously
41451187|NCT04225715|DRUG|PD-L1 LNA (RO7191863)|PD-L1 LNA (RO7191863) will be administered subcutaneously
41451188|NCT03911635|PROCEDURE|URAGPI technique|the Urethral Advancement, Glanuloplasty and Preputioplasty
40756537|NCT02268305|OTHER|Placebo capsules twice a day|Placebo is a capsule filled with rice flour.
40756538|NCT03955185|PROCEDURE|minimally invasive surgery|Laparoscopic or robotic assisted radical hysterectomy
40756539|NCT03955185|PROCEDURE|open abdominal surgery|Traditional open abdominal radical hysterectomy
40756540|NCT04831619|DRUG|PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)|A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
40940029|NCT00170963|DRUG|valsartan/amlodipine|
40940030|NCT05334511|OTHER|Functional Electrical Stimulation|functional electrical stimulation with Frequency 20 pps with Pulse width of 300 msec.
40940031|NCT02985203|DRUG|Vinorelbine Oral|Oral vinorelbine plus cisplatin Followed by Metronomic oral Vinorelbine
41451189|NCT01647321|BEHAVIORAL|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
41451190|NCT01647321|BEHAVIORAL|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
41451191|NCT03824691|DRUG|Cabozantinib|cabozantinib 40 mg orally once daily
40940032|NCT02852772|BEHAVIORAL|Cognitive function tests|
41451192|NCT03824691|DRUG|Durvalumab|1500 mg durvalumab (MEDI4736) IV infusion every 28 days
41451193|NCT00415935|DRUG|methotrexate|
41451194|NCT02131220|DRUG|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
40756541|NCT05218161|DRUG|Dexmedetomidine alone|All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
41281786|NCT05957874|OTHER|Combined package program|"Combined package program content:~* Training: A one-week sleep hygiene training will be given to the experimental group. The training will take an average of 30 minutes for three consecutive days and a training booklet will be provided. In addition, two posters will be prepared to hang in the classroom. In one of the posters, a sleep hygiene rule will be placed at each hour using the clock order. In the other poster, good and bad sleep habits will be placed in the form of do-do.~* Task Flower: Tasks that will facilitate the transition to weekly sleep will be given to the children of the experimental group. Tasks are applications to be done within 30-60 minutes before going to bed. After the tasks, the children will perform their daily sleep routine and go to sleep.~* Notifications: As part of using technology positively, reminders will be sent to families every day for two weeks via a social media tool. These warnings will include sleep hygiene principles."
41281787|NCT05510986|DRUG|Fentanyl group|Dilute fentanyl hydrochloride injection (1ml:0.1mg) with 0.9% normal saline to 10μg/ml, 1μg/kg fentanyl is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
41451195|NCT02131220|DRUG|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
41281788|NCT05510986|DRUG|Oxycodone Hydrochloride group|"Dilute Oxycodone Hydrochloride injection (1ml:10mg) with 0.9% normal saline to~1mg/ml, 0.1mg/kg Oxycodone Hydrochloride is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes."
41281789|NCT03803215|DRUG|Theophylline|Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
41281790|NCT04520789|DIAGNOSTIC_TEST|RPE cell collection and single cell heterogeneity study|Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.
41451196|NCT02131220|DRUG|normal saline|intracoronary bolus infusion using selective catheter during PCI
41281791|NCT04520789|PROCEDURE|Postoperative intervention|Early local steroids drug intervention in patients with severe postoperative PVR
41281792|NCT04520789|PROCEDURE|Conventional Surgery for Retinal Detachment|Conventional Surgery for Retinal Detachment
41451197|NCT03169816|DRUG|Lorcaserin|Lorcaserin 10mg, twice daily
41451198|NCT03169816|DRUG|Placebo|Matched placebo for lorcaserin condition dosed twice daily
41281793|NCT00794287|OTHER|Taking blood samples|No intervention is done. Only blood samples are taken.
41451199|NCT04970836|BIOLOGICAL|recombinant hepatitis B vaccine|Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.
41451200|NCT00748722|DEVICE|CT Angiography|Injection of contrast material (iodine)
41281794|NCT06498037|DRUG|Fentanyl|Administration of subcutaneously administered fentanyl loading boluses
41281795|NCT05750914|DEVICE|Broadband Light|Broadband Light treatment using standard protocol
41281796|NCT04880317|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|All enrolled patients will undergo a contrast-enhanced CMR examination for the assessment of extracellular volume
41451201|NCT05031858|OTHER|Respiratory physiotherapy|Respiratory physiotherapy
41281797|NCT04880317|DIAGNOSTIC_TEST|Additional CT acquisition|All enrolled patients will undergo an additional CT scan at 5 minutes post-contrast injection to evaluate myocardial relative enhancement
41281798|NCT04880317|DIAGNOSTIC_TEST|Blood tests|Patients will undergo blood tests to review hematocrit, Sars-CoV-2 antibody status and cardiac fibrosis biomarkers
41451202|NCT00902538|DRUG|Olmesartan medoxomil 40 mg - Amlodipine 10 mg|Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily
41451203|NCT00902538|DRUG|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
41451204|NCT00902538|DRUG|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
41451205|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
41451206|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
41281799|NCT05631951|PROCEDURE|bone transport through induced membrane|Debridement done followed by external fixator and cement application to be followed by removal of cement (after 6 weeks) and start bone transport
41281800|NCT05631951|PROCEDURE|bone transport|Debridement done then external fixator was applied then bone transport started.
41281801|NCT02357992|RADIATION|Stereotactic Body Radiotherapy (SABR)|SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
41281802|NCT04637451|PROCEDURE|Root coverage treatment|Gingival unit graft Connective tissue graft
41281803|NCT00903084|DRUG|Tenofovir Disoproxil Fumarate|300-mg tablet
41281804|NCT05391893|DRUG|Oral|Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
41281805|NCT05391893|DRUG|Intravenous drug|these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
41281806|NCT01748760|BEHAVIORAL|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
41281807|NCT01748760|OTHER|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
41281808|NCT06499207|DIAGNOSTIC_TEST|Photon-counting detector computed tomography (PCD-CT)|Patients undergoing follow-up coronary angiography with IVI after percutaneous coronary intervention (PCI) as part of routine clinical practice will additionally receive coronary computed tomography angiography (CCTA) with PCD as part of this study.
41281809|NCT05384730|OTHER|Group nutrition and exercise support|Weekly group nutrition and exercise support delivered online through trained volunteers
41281810|NCT04297644|OTHER|There is no intervention|There is no intervention
41281811|NCT04299529|DIAGNOSTIC_TEST|In-vitro urinary diagnostic test|Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
41281812|NCT05988645|DEVICE|MiWEndo System|"All colonoscopies will be performed with high-definition technology. The MiWEndo System will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. The MiWEndo Analyzer will be managed by the assistant.~At the beginning of the extubation, the MiWEndo System will be turned on and the endoscopist will put music headphones on (blind to the results of MiWEndo).~In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
41451207|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
41451208|NCT04419935|PROCEDURE|lymphadenectomy|Lymphadenctomy according with ESTS guidelines
41451209|NCT02243982|OTHER|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
41451210|NCT06174753|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg daily X 7 days
41451211|NCT06174753|DIAGNOSTIC_TEST|CMR|CMR 3-5 days post randomization
41451212|NCT00660660|DRUG|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
41451213|NCT00660660|DRUG|Placebo|once daily
41451214|NCT03331458|BEHAVIORAL|exrecise intervention|Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures
41451215|NCT00757419|DRUG|AZD3355|capsules, oral, single or twice daily dose
40756542|NCT06524648|DIAGNOSTIC_TEST|niPGT-A|"Embryos will be cultured, from oocyte fertilization up to day 6/7 of development, in a time lapse system following the standard practice. On day 6/7, embryos will be vitrified and the embryos's media will be collected for niPGT-A analysis.~Patients will undergo a single embryo transfer (SET) following the niPGT-A report indications. In the event of 1 or more embryos with the same niPGT-A score, the embryo for transfer will be determined by the site standard practice (morphology or time-lapse score).~Patients who do not achieve a pregnancy after a niPGT-A guided SET can undergo as many niPGT-A guided SET or COS+niPGT-A cycles as they need to get pregnant, while the study recruitment phase is active."
41281813|NCT01817257|DRUG|Low Molecular Weight Heparin (LMWH)|Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
41281814|NCT01403077|DEVICE|480 Biomedical Bioresorbable Scaffold System|480 Biomedical Bioresorbable Scaffold System
41281815|NCT04915521|OTHER|erector spina plane block (ESPB) group|"An experienced anesthesiologist performed ESPB in all patients in sitting position bilaterally.~A linear ultrasound probe (6-13 MHz) was used for ultrasound guidance. Injection was done using in-plane technique. A 22G block needle (100mm, B-Braun, Germany) was inserted 3- cm lateral to the T9 spinous process and advanced in cranio-caudal direction. To separate erector spina muscle from the transverse process, initially 1-2 ml saline was injected; then 20 ml 0.5% bupivacaine and 5 ml 0.2% lidocaine were injected following separation. Diffusion of the drugs in erector spina plane at cranio-caudal line was ensured. No analgesic or sedative was used during the procedure."
40756543|NCT05388825|DRUG|TPN171H 2.5mg|TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
40756544|NCT05388825|DRUG|TPN171H 5mg|TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
40756545|NCT05388825|DRUG|TPN171H 10mg|TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
40756546|NCT05388825|DRUG|Placebo 5mg|Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
40940033|NCT02845518|PROCEDURE|Cardiac magnetic resonance imaging (cMRI)|"Right ventricular contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~A self-administered questionnaire made up of 2 Likert scales will be given to all patients on visits V1, V2 or V3 and V9.~To constitute a biobank for diagnosis and prognosis purposes blood samples will be taken at visits V1, V2 or V3 and V9."
40756547|NCT05388825|DRUG|Placebo 10mg|Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
40940034|NCT00008554|DRUG|Abacavir sulfate|
40940035|NCT00008554|DRUG|Nelfinavir mesylate|
40940036|NCT00008554|DRUG|Lamivudine|
40940037|NCT00008554|DRUG|GW433908|
40940038|NCT03095274|DRUG|Durvalumab|Durvalumab, 1500 mg Q4W for 12 months.
40940039|NCT03095274|DRUG|Tremelimumab|Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
40940040|NCT03709329|DEVICE|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
40940041|NCT03709329|DEVICE|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
41281816|NCT06117514|DRUG|Sudapyridine 30mg|Sudapyridine capsule 30mg, orally, single dose
41281817|NCT06117514|DRUG|Sudapyridine 100mg SAD|Sudapyridine tablet, 100mg orally, single dose
41281818|NCT06117514|DRUG|Sudapyridine 200mg SAD|Sudapyridine tablet, 200mg orally, single dose
41281819|NCT06117514|DRUG|Sudapyridine 200mg MAD|Sudapyridine tablet, 200mg orally once a day for 14 days
41281820|NCT06117514|DRUG|Sudapyridine 300mg MAD|Sudapyridine tablet, 300mg orally once a day for 14 days
41281821|NCT06117514|OTHER|Placebo tablet SAD|Placebo tablet, 100mg orally, single dose
41281822|NCT06117514|OTHER|Placebo 200mg SAD|Placebo tablet, 200mg orally, single dose
41281823|NCT06117514|OTHER|Placebo tablet MAD|Placebo tablet, 200mg orally once a day for 14 days
41281824|NCT06117514|OTHER|Placebo tablet MAD|Placebo tablet, 300mg orally once a day for 14 days
41281825|NCT00693186|BIOLOGICAL|HBVaxPRO® 5 µg / 0.5 mL|5 µg / 0.5 mL
41281826|NCT00693186|BIOLOGICAL|Engerix B® 10 µg / 0.5 mL|10 µg
41281827|NCT01878565|DRUG|Drug|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
41281828|NCT01878565|DRUG|GM-CSF control|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
41281829|NCT02844738|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Days 7 and 14 \[PRP\]
41281830|NCT06013787|BEHAVIORAL|"Nuestras Historias"|"Nuestras Historias is a digital story curriculum that is displayed on a small solar-powered tablet. The curriculum is a collection of 7 digital stories used to discuss health issues during pregnancy that the community identified as important. The digital stories are short videos that combine local photos and local voices sharing real-life narratives about experiences during pregnancy. The videos were made in collaboration with community health workers and local mothers."
41281831|NCT06071312|BIOLOGICAL|single FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through a single infusion of FMT
41281832|NCT06071312|BIOLOGICAL|sequential FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through multiple infusions of FMT (sequential approach)
41281833|NCT03586804|OTHER|dual task|mental and motor tasks will be performed while standing. Motor task: holding mini blocks Mental task: Counting the numbers from 200 to 1
41281834|NCT00968344|DIETARY_SUPPLEMENT|Leucine|3-4g Leucine added to daily meals
41281835|NCT00968344|DIETARY_SUPPLEMENT|Alanine|Powered amino acid
40940042|NCT04163822|OTHER|no intervention|no intervention, only observation
40940043|NCT04263454|DRUG|Endotoxin, Escherichia Coli|Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.
40940044|NCT04263454|PROCEDURE|Magnetic Resonance Spectroscopy|MRI is a non-invasive imaging technique and does not utilize ionizing radiation.
40940045|NCT01155219|DRUG|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
40940046|NCT01155219|DRUG|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
40940047|NCT05588648|DRUG|Vactosertib|Vactosertib is given twice a day, five days on and two days off in four-week cycles. Vactosertib is a transforming growth factor-beta (TGF-β) type 1 receptor inhibitor.
40940048|NCT05023876|OTHER|IASTM+respiratory Exercise|Instrument assisted soft tissue mobilization
40940049|NCT05023876|OTHER|Respiratory Exercise|Respiratory Exercise
41281836|NCT06153862|DIAGNOSTIC_TEST|Immuno analytical assay|The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.
41281837|NCT05838417|BEHAVIORAL|REDS survey|R - Reactance, E - self-Exemption, D - Disbelief, S - Source derogation
41451216|NCT00757419|DRUG|Placebo|To match dosing of AZD3355
41451217|NCT00582387|GENETIC|specimen samples|blood, urine and tissue
40940050|NCT05152316|OTHER|Observational study|This is an observational study and no additional interventions will be done except for those that are standard care. Blood and tracheal aspirates will be taken to assess the surfactant protein levels and inflammatory markers including cell counts and cytokine levels.
40940051|NCT03487679|OTHER|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water-only fasting and final day of habitual eating consuming the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
40940052|NCT04183517|DRUG|PXS-5382A|Orally once daily or twice daily
40756548|NCT01435746|BEHAVIORAL|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
40756549|NCT03023683|BIOLOGICAL|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
40756550|NCT05681585|OTHER|Implementation support program|"The intervention consists of:~I Implementation strategies:~1.1 Ensuring leadership commitment 1.2 Responsive evaluation 1.3 Whole ward approach 1.4 Train the trainer model 1.5 Sustainability after the study~II Implementation interventions 2.1 Implementation team 2.2 ACP coordinator 2.3 Training and supervision: Kick-off, training of resource persons and health care personnel including practical exercises, network conferences 2.4 Toolkit and shared resources: ACP guideline, teaching material, information leaflets, documentation templates etc. 2.5 Structured fidelity measurements of the implementation level of a) the implementation interventions and b) the clinical intervention, with tailored feedback and supervision~III Clinical intervention: Advance Care Planning 3.1 Routine information and invitation to Advance Care Planning to all eligible patients 3.2 Written information to patients and relatives 3.3 Documentation and collaboration with other health care levels"
40756551|NCT04514276|OTHER|consecutive fetoneonatal healthcare pathway|(1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
40756552|NCT01153542|DRUG|VX-770|In period 1, subjects will receive a single oral dose of desipramine on Day 1.
40756553|NCT01153542|DRUG|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
40756554|NCT03855839|DEVICE|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort.
40756555|NCT03855839|DEVICE|Compression shirt|Compression shirts are designed for recreational sport activities and can be bought in any local sports store
40756556|NCT05168124|BEHAVIORAL|Acceptance Commitment Therapy for chronic fatigue|ACT was originally developed for the treatment of depression and anxiety. Recently, a single study investigated ACT as a therapeutic approach in CFS/ME and showed no negative effects on disease progression. ACT is characterized by acceptance- and mindfulness-based techniques, serves to promote acceptance and the development of new value goals, and can thereby open up new perspectives on life, which would be promising in terms of a reduction of symptom focus that seems to be a crucial effective factor for an improvement in exhaustion states. The intervention involves psychoeducation and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for anxiety disorders is adapted to the needs of patients with CFS, the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms.
40940053|NCT01195077|OTHER|seaweed, spirulina, seaweed + spirulina|"Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day."
40940054|NCT02125474|RADIATION|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
40940055|NCT02416310|DEVICE|TEAS|According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
40940056|NCT04891731|DRUG|AI or TAM|This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.
40940057|NCT00403403|DRUG|Bevacizumab|Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
40940058|NCT00403403|DRUG|Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
40940059|NCT00403403|DRUG|Placebo|Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
41451218|NCT00582387|BEHAVIORAL|questionnaires|
41281838|NCT01561638|PROCEDURE|Conventional Radiofrequency|pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
40756557|NCT05168124|BEHAVIORAL|Micro breaks in everyday life for chronic fatigue|"In terms of break design in the work context, research in recent years has increasingly focused on so-called micro breaks (MB) - mini breaks of one to five minutes in length. Transferred to mini breaks in everyday life (MBEL), there have been found fundamentally positive effects in terms of performance, vitality and well-being, which could also have a positive impact on the clinical picture of CFS/ME. However, practically no research results are yet available with regard to the implementation of MB in everyday life of patients with CFS/ME. The effects of MB, on the other hand, have been tested several times in everyday work settings and showed desirable effects on mood, attention, fatigue, vitality, performance, and well-being."
40940060|NCT03736707|DEVICE|Selective HFOV|Selective HFOV will only be provided with piston/membrane oscillators able to provide a real oscillatory pressure with active expiratory phase
41281839|NCT01561638|PROCEDURE|Pulsed Dose Radiofrequency|pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
41281840|NCT01561638|PROCEDURE|Sham|will receive puncture for 4 minutes
40756558|NCT02890160|DEVICE|Firesorb|Sirolimus Target Eluting Bioresorbable Vascular Scaffold
40756559|NCT02890160|DEVICE|XIENCE|Everolimus Eluting Coronary Stent System
40940061|NCT03736707|DEVICE|CMV|CMV was delivered by time-cycled, pressure-limited ventilators
40940062|NCT05661214|OTHER|Teaching|The intervention in this study is teaching. Researchers, will create a pressure injury teaching content and assess this effectiveness and also, intervention groups will use Clinical Decision Support System (CDSS) as a tool to plan nursing interventions.
41281841|NCT05450068|OTHER|Mulligan's Mobilization with movement|The Mulligan's technique will be performed as described by Brian Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets.
41281842|NCT05450068|OTHER|Spencer's muscle energy technique|Muscle energy technique that is composed of 7 stages repeated on after the other will be performed. Each movement will be repeated 10 times with 1 minute rest between each set.
41281843|NCT05450068|OTHER|Conventional Therapy|Electrotherapy-Ultrasound (5-10 mins), Exercise therapy program (isometric, capsular stretching, pectoral stretch and scapular stabilization exercises)
41281844|NCT06098014|DRUG|Thalidomide Capsules|To see safety and efficacy of Thalidomide in Transfusion depended thalassemia
41281845|NCT06098014|DRUG|Placebo|compare with Thalidomide
41281846|NCT02064764|DEVICE|Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter|
41281847|NCT02064764|DEVICE|Arctic Front Advance™ Cardiac Cryoablation System|
40940063|NCT04884932|DEVICE|30 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 30 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
40940064|NCT04884932|DEVICE|Sham stimulation (Myomed 932, Enraf-Nonius)|Sham stimulation will be delivered at a frequency of 30 kHz only during the first 30 seconds.
40940065|NCT00229918|DRUG|triamcinolone acetonide|
40940066|NCT00395538|DRUG|PTH 1-34|Given twice daily by subcutaneous
40940067|NCT05122676|BEHAVIORAL|More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)|"This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits.~The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains."
40940068|NCT01520454|DRUG|Saline|IV saline at 0.83 mL/kg/hr for six hours
40940069|NCT01520454|DRUG|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
40940070|NCT01520454|DIETARY_SUPPLEMENT|Water|Water by mouth
40940071|NCT01520454|DIETARY_SUPPLEMENT|oral fat|Soybean oil by mouth at 1.25 g/kg x 2 doses
40940072|NCT01520454|DRUG|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
40940073|NCT00597337|BEHAVIORAL|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
40940074|NCT02640716|BEHAVIORAL|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
40940075|NCT02640716|BEHAVIORAL|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
40940076|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
40940077|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
40940078|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
40940079|NCT03248843|DRUG|KN035|Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
40940080|NCT00934258|DRUG|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
40940081|NCT00934258|GENETIC|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
40940082|NCT01467427|DRUG|nonacog beta pegol|A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
40940083|NCT00291538|DRUG|bortezomib|
40940084|NCT05310188|DIAGNOSTIC_TEST|pseudocholinesterease|blood samples
41281848|NCT03369847|DRUG|budesonide, beclomethasone|The inhaled corticosteroids we are using for this study are budesonide nebulized solution and beclomethasone metered-dose inhaler. Low-doses for these medications are 0.5mg/day for budesonide and 160 mcg/day for beclomethasone. Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer. Budesonide is FDA approved for children under 5 years of age. Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer. Beclomethasone is FDA approved for children 5 years and older.
40940085|NCT05752981|DEVICE|multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS)|Participants will be monitored during surgery using the multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS). This study is observational in nature and no intervention will be applied based on the results of the tr-fNIRS device.
40940086|NCT00186329|DRUG|Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo|
40940087|NCT01539317|DRUG|Topical liquid lidocaine|active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
40940088|NCT01539317|DRUG|Topical saline|saline applied to the vestibule mucosa will not reverse the local tenderness
40940089|NCT00116428|DEVICE|NAVISTAR® THERMOCOOL® Catheter|The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
40940090|NCT00116428|DRUG|Antiarrhythmic drug|Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
40940091|NCT04592744|DRUG|Angiotensin II|Angiotensin II infusion for Intraoperative management during liver transplantation
40940092|NCT04592744|DRUG|Norepinephrine|Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
40940093|NCT05868018|BEHAVIORAL|Education|This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.
40940094|NCT03593161|BEHAVIORAL|Humor therapy|Clown visits
40940095|NCT02187770|DEVICE|IMED-4|Non invasive recording electrode used to assess lung fluid
40940096|NCT01423149|DRUG|Combretastatin A-4 Phosphate|Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
40940097|NCT04471597|DRUG|normal saline 0.9%|5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
40940098|NCT04471597|DRUG|Bupivacaine Hydrochloride|5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
40940099|NCT00479895|DRUG|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
41281849|NCT05726695|DIAGNOSTIC_TEST|microRNA test|Laboratory analysis for the detection of microRNA in blood samples.
41281850|NCT05726695|DIAGNOSTIC_TEST|Heart ultrasound examination|Heart ultrasound examination will be performed as a standard cardiology examination.
41281851|NCT01901224|DRUG|Metformin 1000 mg|
41281852|NCT01901224|DRUG|Placebo|
41281853|NCT03829761|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.
41281854|NCT03829761|DEVICE|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.
41281855|NCT03244371|OTHER|blood draw|4 blood draws of 25 mls of blood will be performed at 4 differents time points (before treatment, 4 weeks later, at the end of the treatment and 6 months after the end of the treatment)
41281856|NCT00653315|DRUG|Tramadol APAP|Tablets, 37.5mg/325mg, single dose
41281857|NCT00653315|DRUG|Ultracet|Tablets, 37.5mg/325mg
41281858|NCT05128240|DIETARY_SUPPLEMENT|Placebo|1g corn oil capsules
41281859|NCT05128240|DIETARY_SUPPLEMENT|Ceto 10|1g capsules containing oil broad spectrum marine oil from north atlantic fish
41281860|NCT06031753|BEHAVIORAL|Time restricted eating|Only eating windows were determined to an 6 hour period, starting at 12:00hrs and ending at 18:00hrs. After that, patients in group 1 and 2 were indicated not to consume any calories. The composition of their diet was not modified, it was assessed by performing a 24-hour recall to make sure there were no significant changes in diet composition throughout the study.
41281861|NCT05129540|DEVICE|Custom-made foot orthosis|The foot orthoses for group A will be custom made using phenolic foam molds of the feet. They consist of a polypropylene layer of 3 mm from heel to just proximal to the metatarsal heads, and an upper sheet of 30 Shore A polyethylene foam.
41281862|NCT05129540|DEVICE|Placebo orthosis|"A flat insole made of the same material as the upper layer of the custom-made foot orthoses used for group custom-made foot orthosis."
41281863|NCT02948894|DEVICE|Mandibular advancement device|an oral appliance (a dental device) for obstructive sleep apnea
41281864|NCT03344835|OTHER|No intervention|
41281865|NCT00155402|DRUG|tissue fibrin glue application (Tisseel)|Apply several droplets within several seconds to several minutes
41451219|NCT06467344|DRUG|ACDN-01|ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
41451220|NCT00975494|DRUG|Sildenafil|
41451221|NCT00975494|DRUG|Placebo|
40940100|NCT04877106|DRUG|Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg)|The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®, 50mg/850mg)
40940101|NCT04877106|DRUG|Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)|The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
40940102|NCT04476550|DRUG|Filgrastim|5 days of daily sub-cutaneous administration of 10mcg/kg filgrastim
40940103|NCT00478881|DRUG|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
40940104|NCT00478881|DRUG|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
40940105|NCT03740867|OTHER|Pulmonary rehabilitation|Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components.
40940106|NCT01418027|OTHER|Intensive exercise|Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
40940107|NCT01418027|OTHER|Conventional exercise|Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
40940108|NCT00281073|DEVICE|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
40940109|NCT00281073|DEVICE|Intracardiac Echo|Intracardiac Echo Viewmate
40940110|NCT00281073|DEVICE|ICE|ICE or TEE
40940111|NCT04713657|OTHER|N-thymidine|15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.
40940112|NCT04713657|OTHER|Urine Collection|Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.
40940113|NCT04713657|PROCEDURE|Echocardiogram|On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in ToF/PS and is non-invasive.
40940114|NCT04713657|PROCEDURE|Cardiac MRI|"A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this feed, swaddle, and sleep technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle."
40940115|NCT04713657|DRUG|Propranolol Hydrochloride|For patients who are randomized to receive propranolol, The target dose for this study will be 4 mg/kg/day divided in 4 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 4 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
40940116|NCT04713657|DRUG|Placebo|For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 4 doses per day. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
40940117|NCT04713657|PROCEDURE|Physical Exam|On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.
40940118|NCT04713657|OTHER|Specimen Collection|On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.
40940119|NCT01511393|OTHER|No treatment given|None. Non-interventional study.
40940120|NCT04520893|PROCEDURE|ventilator setting vcv with pause|ventilator setting vcv with pause
41451222|NCT00448825|DRUG|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
41451223|NCT00448825|DRUG|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
40756560|NCT03151603|DRUG|Arctuvan|application of a herbal drug
40756561|NCT03151603|DRUG|Fosfomycin|application of an antibiotic drug
40940121|NCT04520893|PROCEDURE|ventilator setting vcv|ventilator setting vcv without pause
40940122|NCT04520893|PROCEDURE|ventilator setting pcv-vg|ventilator setting with pcv-vg
40940123|NCT01278160|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
40940124|NCT01278160|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
40940125|NCT01278160|DRUG|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
40940126|NCT05087849|BIOLOGICAL|nonavalent human papillomavirus vaccine|Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks
40940127|NCT04014023|DRUG|DWP16001|DWP16001 tablets
40940128|NCT04014023|DRUG|Placebo|DWP16001 placebo-matching tablets
41281866|NCT03337659|OTHER|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
41451224|NCT03323450|BEHAVIORAL|CogMed®|"It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.~Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):~1. Baseline before the participant is introduced to the CogMed® training program~2. Within 2 weeks of completion of the CogMed® program~3. At 3 months of completion of the CogMed® program to establish maintenance of gains~4. At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains"
41451225|NCT06013150|DRUG|Epinephrine|Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.
41451226|NCT06013150|DRUG|Placebo|Participant in Part 1 of the study will receive matching doses of placebo
40756562|NCT03151603|DRUG|Placebo to Arctuvan|application of Placebo to Arctuvan
40756563|NCT03151603|DRUG|Placebo to Fosfomycin|application of Placebo to Fosfomycin
40756564|NCT06451926|OTHER|Escape room game|Educational escape rooms are live action games where teams use content knowledge to complete tasks and puzzles to reach a final goal, such as escaping from a room or completing a final puzzle
40756565|NCT00467467|DRUG|Alfuzosin Hydrochloride|
40940129|NCT02938845|BEHAVIORAL|Spielberger's State-Trait Anxiety Inventory(STAI )|State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
40940130|NCT02938845|PROCEDURE|total laparoscopic hysterectomy(TLH)|
41451227|NCT04385251|OTHER|Data Collection|"DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 \& 28:~Vital and hospitalization status; Symptoms and health status"
41451228|NCT05319054|DEVICE|Sacral NeuroModulation|Sacral Neuromodulation group will include up-to 20 patients with major LARS. Medtronic Interstim system will be used, including 2 week trial device.
41451229|NCT05319054|DEVICE|Trans-Anal Irrigation|Trans-Anal irrigation group will include up-to 20 patients with major LARS. Specific system will be agreed with the patient, depending on eligibility and preference.
41451230|NCT05319054|OTHER|Optimised Conservative Management|Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.
40756566|NCT05091450|BEHAVIORAL|Couple-based I-BMS intervention for infertility|It is based on the previous I-BMS intervention for women undergoing IVF treatment, and aims to improve fertility quality of life and couple flourishing by (1) increasing awareness of the interconnectedness between physical and psychosocial well-being, (2) practicing body-mind-spirit techniques, (3) facilitating personal growth and partner empathy and compassion, and (3) creating the shared meaning of life, family, children. As a strength-focused and meaning-oriented approach, it utilizes experiential and self-reflective exercises to help participants reconstruct the meaning behind their ordeal and rediscover the strengths that keep them going.
40756567|NCT01744366|DRUG|Degarelix|
40756568|NCT01744366|DRUG|Goserelin|
40940131|NCT02938845|PROCEDURE|total abdominal hysterectomy(TAH)|
40940132|NCT03068598|DEVICE|PulseOn watch/Suunto Spartan Ultra watch|The Watch (PulseOn or Suunto Spartan Ultra) and a smartphone will be given to the patient after discharge. After a brief training on how to use the sleep tracker, patient will monitor his sleep with watch during the five nights following the discharge. All data will be transmitted directly to the smartphone. Each morning, the patient will complete a questionnaire to assess the quality of his sleep and on day 5, during a standart follow up visit, he will complete a questionnaire evaluating the acceptability of the sleep recording device.
40940133|NCT05695534|OTHER|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
40940134|NCT01753739|DRUG|Bepotastine besilate|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
40940135|NCT01753739|DRUG|Placebo|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
40940136|NCT00414921|DRUG|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
40940137|NCT00414921|DRUG|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
40940138|NCT00414921|OTHER|placebo|inactive substance
40940139|NCT01107418|DRUG|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
40940140|NCT01107418|DRUG|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
40940141|NCT01107418|DRUG|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
40940142|NCT01107418|DRUG|RO5185426|960 mg orally twice daily, from day 22 onward
40940143|NCT01107418|DRUG|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
40940144|NCT01867112|BEHAVIORAL|Physical Activity|Physical activity either by individualized program or general guidelines
40940145|NCT05091671|OTHER|Free From Pain Exercise Programme Variation 1|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets.
40940146|NCT05091671|OTHER|Free From Pain Exercise Programme Variation 2|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets, and the 12 Zoom online sessions.
40940147|NCT04411524|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody After neo-CRT: 3 cycles of PD-1 antibody
40940148|NCT04411524|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
40940149|NCT04411524|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
40940150|NCT04411524|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
40940151|NCT05333081|OTHER|Consumption of rice for evaluation of the glycemic index|The test of each food was carried out for a maximum time of 120 minutes, by carrying out repeated measurements of the glycaemia of all subjects at a distance of 0, 15, 30, 45, 60, 90 and 120 minutes from the administration of the sample in order to obtain a glycemic curve for each sample considered.
41281867|NCT00404443|DEVICE|Acupuncture|Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
40940152|NCT02343081|DRUG|Temozolomide|
40940153|NCT02343081|DRUG|Temozolomide|
40940154|NCT00478374|DRUG|Sorafenib|Sorafenib 400mg bid
40940155|NCT00478374|PROCEDURE|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
40940156|NCT01598675|OTHER|Same Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Control-Dual-belted treadmill belts respond to encourage symmetric gait
41281868|NCT02910778|DRUG|Atorvastatin|Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.
41281869|NCT02910778|DRUG|Placebo|Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
41281870|NCT02910778|DRUG|Ticagrelor|
41281871|NCT04632849|BEHAVIORAL|GEM + CGM|Participants follow the GEM guidebook for 4 months (1 month of intervention and 3 months of maintenance) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM to provide feedback about activity and blood glucose. The GEM guidebook covers Routine choices, Recovering from blood glucose excursions, Reducing blood glucose excursions, and Maintenance.
40940157|NCT01598675|OTHER|Different Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.
40940158|NCT01606254|DRUG|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
40940159|NCT02123043|BEHAVIORAL|Motor learning-based training|The motor learning-based training will focus on some of the core concepts in the field of motor learning. The key concepts will include variable practice with respect to speed, feedback (both intrinsic and extrinsic but focusing on extrinsic), feedback focusing on three main variables (wheeling pattern, speed of hand when contacting push rim, push angle), sequential learning (specifically relating to wheeling pattern), and mental imagery (during the rest breaks).
40940160|NCT02123043|BEHAVIORAL|Practice wheeling|The practice wheeling will consist of the same amount of wheeling exposure compared to the motor learning-based training group, however no feedback regarding an individuals's wheeling will be provided. Participants randomized to this group will wheel for two 5-minute trials/ visit for 6 visits for a total of 60 minutes of wheeling exposure.
40940161|NCT04246255|DRUG|Xylocaine 10% Oral|"50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
40940162|NCT04246255|DRUG|Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul|"50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
40940163|NCT02732717|OTHER|ultrasound (observation)|"Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.~Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave)."
41451231|NCT00691470|DRUG|ATI-5923|Dose Adjusted based on INR.
40940164|NCT06178328|BEHAVIORAL|Things You Do Course|Participants receiving the brief psychological intervention ('Things You Do' Course) will have access to a single online lesson that includes course materials and printable materials (i.e., an activity guide and planner) that can be retained for longer-term use. The course materials include an introduction to the purpose and content of the course, education about factors that impact mental health, and information about the 'Big Five' things participants can do to improve their mental health. Participants will also receive automated no-reply emails (5 days/week) through the intervention platform to remind them to practice the skills from the course.
40940165|NCT05541068|DEVICE|Bioimpedance analysis|Bioimpedance analysis to achieve assessments of fluid status, especially dry-weight, was performed with the portable Biomasc touch i8 (MaltronInternationl, Essex, UK).
40940166|NCT03766685|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
40940167|NCT01859143|BIOLOGICAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
40940168|NCT01859143|OTHER|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
40940169|NCT02698059|DEVICE|iNAP® Sleep Therapy System (iNAP)|The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
40940170|NCT05708027|PROCEDURE|Thoracoscopic surgical ablation|Thoracoscopic surgical ablation is a minimally invasive procedure used to treat atrial fibrillation by creation Box Lesion Set using Radio Frequency Energy. Pulmonary veins isolation was performed using ablation clamps, whereas isolation of the posterior left atrium (box) was performed using a clamping Medtronic or a linear nonclamping AtriCure device.
40940171|NCT00188799|PROCEDURE|daily Xray volume imaging for planning radiotherapy|
40940172|NCT00237185|DRUG|Imatinib mesylate|Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
40940173|NCT02653404|OTHER|IGRA test (QTF-GIT)|blood sample for QFT-GIT will be taken together with other routine blood samples
40940174|NCT03580148|DRUG|Cortisone|Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection
40940175|NCT03580148|BIOLOGICAL|Bone Marrow Aspirate|Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
40940176|NCT02178683|DRUG|Tacrolimus and MMF.|First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
40940177|NCT05653258|OTHER|Lifestyle Intervention|"1. Exercise: Subjects will undergo a combined aerobic and resistance exercise intervention. The investigators propose a multi-modal training program because they improve metabolic outcomes and adding resistance training reduces the risk of muscle loss during weight loss. Subjects will exercise in the gym for three sessions per week for 10 weeks under supervision of an exercise physiologist. On each session, aerobic exercise will be followed by resistance exercise.~2. Diet: The aim of the dietary intervention is to reduce caloric intake sufficient to result in 8-10% weight loss, while incorporating behavioral and dietary strategies to maximize adherence and to minimize risk of muscle and bone loss. Subjects will attend small-group sessions led by a dietitian for changing their dietary composition to follow American Heart Association (AHA)/American College of Cardiology (ACC) guidelines."
40940178|NCT05653258|DRUG|Dasatinib 100 MG|100 mg of dasatinib (D) daily for 3 consecutive days plus quercetin (Q) for the same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
40940179|NCT05653258|DRUG|Quercetin 1000mg|Quercetin (Q) (4) 250 mg capsules daily (total 1000 mg daily) plus dasatinib (D) same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
40940180|NCT05653258|DRUG|Placebo|Subjects will receive a placebo (methylcellulose) to provide a similar mass, number of tablets/ capsules, and frequency as the senolytic arm.
40940181|NCT05653258|PROCEDURE|Abdominal adipose tissue biopsy|All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq
40940182|NCT03676335|DRUG|CsA eye gel|The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
41281872|NCT00816803|PROCEDURE|Autologous bone marrow transplant|
40940183|NCT03676335|DRUG|CsA for eye emulsion|The CsA for eye emulsion of 0.4 ml: 0.2 mg
40940184|NCT03676335|DRUG|Hypromellose Eye Drops|Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop
40940185|NCT02922933|DRUG|entinostat|HDAC (histone deacetylase inhibitor)
41281873|NCT00816803|PROCEDURE|Physical therapy|
41281874|NCT00370344|PROCEDURE|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
41281875|NCT00370344|PROCEDURE|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
40940186|NCT02922933|DIETARY_SUPPLEMENT|Omeprazole|Proton pump inhibitor
41451232|NCT00691470|DRUG|Coumadin (warfarin)|Dose adjusted based on INR.
41451233|NCT06057558|BIOLOGICAL|Probiotic throat spray|Throat spray containing Lacticaseibacillus casei AMBR2
40940187|NCT02922933|DIETARY_SUPPLEMENT|Famotidine|Histamine-2 blocker
40940188|NCT06217601|BEHAVIORAL|Digital intervention through Tablet|Web-based multi-domain lifestyle training intervention will be conducted to promoted and focus three lifestyles: nutritional advice, exercise and cognitive training; chat communication with research team, and personalized agenda on daily activities and an information library.
40940189|NCT04195139|DRUG|Nivolumab|Participants will receive Nivolumab intravenous infusions (240 mg days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6).
40940190|NCT04195139|DRUG|Temozolomide|Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.
40940191|NCT05266027|DRUG|Nalbuphine Sebacate (Naldebain)|Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.
41281876|NCT00805207|DRUG|Progesterone|Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.
41281877|NCT00805207|DRUG|testosterone|Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
41281878|NCT00805207|DRUG|glucocorticoid|Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
40756569|NCT05529420|OTHER|measurement of the depth of neuromuscular blockade|time of TOF 1 measurement (= clinical effect, stimulation of the ulnar nerve - adductor pollicis muscle tension) will be documented in the CRF and if there is no need to add further doses of the muscle relaxant, TOF 2, TOF 3, TOF 4, and TOF-R ≥ 0,9 (= time to full recovery from the effect of the non-depolarizing muscle relaxant) will also be registered.
40756570|NCT00379379|DEVICE|electroacupuncture|
40756571|NCT02243826|DRUG|50:50 mixture of nitrous oxide/oxygen|
40756572|NCT02887352|OTHER|assessment of problem-solving ability|
40756573|NCT00002046|DRUG|Zidovudine|
40756574|NCT05127200|DEVICE|Starstim (Neuroelectrics)|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
41281879|NCT00805207|DEVICE|continuous positive airway pressure|Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.
41451234|NCT04273971|OTHER|Plyometric exercises|Plyometric exercises will be composed of vertical jumps, box jumps, half squat jumps, high straight jumps, bounding jumps, drop jumps and 10-m sprint.
41281880|NCT00805207|DRUG|Estrogen|Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.
41451235|NCT03903796|DRUG|HS-10234|Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
40756575|NCT04105725|BEHAVIORAL|Brief Motivational Intervention+Substance-Free Activity Session|A dialogue with the individual of their own experiences with alcohol use and related problems, as well as academic/career goals and personal interests.
40756576|NCT04105725|OTHER|Alcohol + Nutrition Education Session|Education on alcohol, alcohol metabolism in the body, and alcohol overdose, as well as education on food groups and recommendations for a balanced diet.
40940192|NCT05266027|DRUG|Placebo medication|Placebo medication, Nalbuphine Sebacate not contained
40940193|NCT02040285|DRUG|Bisacodyl & PEG-CS|"the day before the CTC:~* low fiber diet~* at 15.00: 2 tablets of bisacodyl (5 mg)~* at 17.00: 1 litre of PEG-CS~* liquid diet~the day of the exam:~* at home: 2 tablets of bisacodyl (5 mg)~* at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water~* at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im"
40940194|NCT02040285|DRUG|Iopamidol|"the day before CTC:~* low fiber diet~* at 15.00: 90 ml of Iopamidol in 250 ml of water~* at 17.00: 90 ml of Iopamidol in 250 ml of water~* at 20.00: start liquid diet"
40940195|NCT02931591|DRUG|Metformin|Metformin is administered as an oral solution
40940196|NCT02931591|DRUG|Growth Hormone|Growth Hormone- no specific band
40940197|NCT02931591|DRUG|Placebo|
40940198|NCT02557438|PROCEDURE|Roux-en-Y Gastric Bypass|Determination of the kind of surgery will be made by the participant's providers and not by study staff
40940199|NCT02557438|PROCEDURE|Vertical Sleeve Gastrectomy|Determination of the kind of surgery will be made by the participant's providers and not by study staff
40940200|NCT01367119|DRUG|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.
40940201|NCT01367119|DRUG|methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
40940202|NCT02914847|BEHAVIORAL|Functional Imagery Training (FIT)|Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
40940203|NCT05276947|OTHER|position with peanut ball|The experimental group will be positioned with the peanut ball until the end of the active phase of labor.
40940204|NCT01551537|OTHER|Cervarix data collection|Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
40940205|NCT01551537|OTHER|Data Collection|All adverse events will be recorded by diary card, follow-up visit or telephone contact.
40940206|NCT00542568|BIOLOGICAL|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
40940207|NCT02800902|DRUG|placebo|Oral prophylaxis followed by placement of placebo gel
40940208|NCT02800902|DRUG|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
40940209|NCT02800902|DRUG|Atorvastatin|Oral prophylaxis followed by placement of atorvastatin gel
40940210|NCT04510974|OTHER|Spinal Cord Injury|Spinal Cord Injury
40940211|NCT03977454|PROCEDURE|Nerve Block|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~1. QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~2. LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA"
40940212|NCT03977454|PROCEDURE|Periarticular Injection (PAI)|"Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA"
40940213|NCT03977454|DRUG|Ropivacaine|60 ml 0.2% ropivacaine
41451236|NCT03903796|DRUG|TDF|Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
40940214|NCT03977454|DRUG|Dex|10 mg DEX/ 80 mg MPA
40940215|NCT03902106|DRUG|salbutamol|subjects ingest salbutamol
40940216|NCT03902106|OTHER|exercise|subjects undergo 6 weeks of endurance training (3 times weekly)
40940217|NCT01504568|OTHER|Treatment|Adults: ≥40 kg:250mg every eight hours Children: \<40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
40940218|NCT06150469|COMBINATION_PRODUCT|"Blend of ginger and lemon essential oils, Neutral oil"|Patients will be given aromasticks to inhale the blend of essential oils.
40940219|NCT04559360|DEVICE|PRESTOapp|The intervention group will be asked to use the app for a period of 2 months.
40940220|NCT01350154|DRUG|Sildenafil|20 mg in gelatine capsules, oral, three times daily
40940221|NCT01350154|DRUG|Placebo|Lactose monohydrate oral in gelatine capsules, 3 times daily
40940222|NCT01780532|PROCEDURE|Photoacoustic Imaging (PAI)|Standard of Care
40940223|NCT02495103|DRUG|Vandetanib|PHASE I: Vandetanib by mouth (PO) daily at 300mg in combination with escalating doses of metformin.
40940224|NCT02495103|DRUG|Metformin|Phase I: Metformin starting dose 250mg by mouth (PO) daily in combination with Vandetanib
40940225|NCT02495103|DRUG|Vandetanib/Metformin|Phase II: Vandetanib and metformin by mouth (PO) daily at determined maximum tolerated dose (MTD).
41281881|NCT00805207|OTHER|Control|No treatment with studies performed 31 to 72 days apart
41281882|NCT02605577|PROCEDURE|new systemic nutrition management protocol|a new established systemic nutrition management protocol
41451237|NCT02225457|OTHER|Hypercaloric diet|"Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet."
41451238|NCT02225457|DIETARY_SUPPLEMENT|polyphenols|Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
41451239|NCT02225457|DIETARY_SUPPLEMENT|placebo (for polyphenols)|Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
41281883|NCT04643041|BEHAVIORAL|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3w) therapy and start watch and wait.
41281884|NCT02224430|DEVICE|schizophrenia/schizoaffective disorder.|Participants with schizophrenia/schizoaffective disorder will be observed remotely and at weekly/biweekly laboratory visits over a period of 16 weeks or until relapse occurs.
41281885|NCT01671410|DRUG|oral morphine|Oral morphine for the treatment of neonatal abstinence syndrome
40940226|NCT01351246|BEHAVIORAL|CBT Based Self-help Workbook + Counseling Telephone|"Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation and is based on the therapy manual Therapy program for children with hyperactive and oppositional problem behavior THOP (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006). Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet."
41281886|NCT01671410|DRUG|sublingual buprenorphine|Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
41281887|NCT02251743|DEVICE|Neurofeedback treatment|"Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~1. The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~2. Average voltage of theta waves~3. Average voltage of beta~4. Average ratio of theta to beta power (TBR)"
40940227|NCT04776044|DRUG|ATR-002|150mg tablets for oral intake
41281888|NCT03560076|OTHER|SBIRT Training and Implementation Strategies|A train-the-trainer approach will be used to train site coordinators on the SBIRT process and implementation strategies.
41281889|NCT04714112|DRUG|dexamethasone|Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
41281890|NCT04459962|DIAGNOSTIC_TEST|Breath Test & Cheek Swab|Breath Sample and Cheek Swab of participants will be used for machine learning (NBT - Nanobiotechnology Biomarkers Tagging) system to develop a profile which can be used later on for Covid-19 Diagnosis.
41281891|NCT00013806|DRUG|131I-MIBG|
41281892|NCT01676116|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
41281893|NCT01676116|DRUG|liraglutide|Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
41281894|NCT01676116|DRUG|exenatide|Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
41281895|NCT04833439|OTHER|Fasting Mimicking Diet|Low-caloric, low-protein, plant-based diet regiment for 3 days
41281896|NCT06133010|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
41281897|NCT06133010|BIOLOGICAL|Placebo|Sterile liquid for injection
41281898|NCT01331161|BIOLOGICAL|ZOSTAVAX|shingles vaccine, one dose
41281899|NCT05349461|PROCEDURE|Complete patellofemoral articular contact|The patellofemoral condition is in constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
40940228|NCT04776044|DRUG|Placebo|matching tablets for oral intake
40940229|NCT00649415|DRUG|piroxicam|piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
40940230|NCT00649415|DRUG|valdecoxib|valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
40940231|NCT06469398|DEVICE|Cutera Laser System|Subjects will receive up to 6 laser treatments
41281900|NCT05349461|PROCEDURE|Incomplete patellofemoral articular contact|The patellofemoral condition is in no constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
41281901|NCT00761215|DRUG|TR-701 200 mg|oral TR-701 200 mg for 5 to 7 days
41281902|NCT00761215|DRUG|TR-701 300 mg|oral TR-701 300 mg for 5 to 7 days
41281903|NCT00761215|DRUG|TR-701 400 mg|TR-701 400 mg for 5 to 7 days
41281904|NCT05593601|DRUG|Neomycin|Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
40940232|NCT03645018|DIAGNOSTIC_TEST|diagnosis with tomosynthesis|Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
40940233|NCT01630785|DEVICE|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
40940234|NCT01272661|BEHAVIORAL|Enhanced Curriculum|Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
40940235|NCT01272661|BEHAVIORAL|Enhanced Curriculum+Breastfeeding Doula|In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
40940236|NCT01272661|BEHAVIORAL|Enhanced Curriculum +Father Support|In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
40940237|NCT06134609|BEHAVIORAL|Sexual intercourse|Sexual intercourse without barrier contraceptive at the evening/night after the embryo transfer
41281905|NCT04501640|DRUG|mirabegron|Oral adminstration
41281906|NCT06033443|OTHER|Collaborative Learning Group|The experimental group is the group that receives nursing education based on collaborative learning.
41281907|NCT00257127|BIOLOGICAL|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
41281908|NCT00257127|BIOLOGICAL|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
40756577|NCT02071654|DEVICE|Venus P-valve transcatheter implantation|Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
40940238|NCT03703596|DRUG|Anlotinib Hydrochloride|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
40940239|NCT03703596|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
40940240|NCT03230253|BEHAVIORAL|Sequential training|The participant will cycle on a stationary bike for 30 minutes, which includes a 3-min warm-up phase followed by the aerobic training components (25 minutes), then a 2-min cool-down phase. The target heart rate during the aerobic training phase will be 40 to 70% of maximal heart rate (HRmax). After cycling, the participant will engage in a 30-minute of computer-based cognitive training program using BrainHQ (Posit Science Inc., San Francisco, CA, USA). The following are the areas of training: visuospatial processing, attention, memory, language, and logical thinking.
40940241|NCT03230253|BEHAVIORAL|Dual training|The dual-task training group will cycling concurrently with the computer-based cognitive training. The training principle of cycling and cognitive training is similar to the SEQ group; however, the training intensity will be adjusted according to each participant's ability.
40940242|NCT03230253|BEHAVIORAL|Control training|The control participants will receive 60 minutes of health-related rehabilitation programs which involves non-aerobic physical exercise (e.g., muscle stretching, range of motion exercises, relaxation techniques) and unstructured cognitive related rehabilitation programs (e.g., watch health-related videos or read newspapers or magazines and then answer the content-related questions raised by the therapist).
40940243|NCT02889692|DRUG|YiQiFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable."
40756578|NCT05200780|DEVICE|ultrasound|All subjects will undergo the tests with the same machine. Transverse ultrasound images were obtained using the Philips HD with a 4-12 MHz probe. in neurosonology unit in neurology department.
40756579|NCT02842385|OTHER|Implant|One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement
40940244|NCT02889692|DRUG|YangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable."
40940245|NCT02889692|DRUG|YiQiYangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable."
40940246|NCT02889692|DRUG|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
40940247|NCT02889692|DRUG|Erlotinib®|"Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops."
41281909|NCT00257127|BIOLOGICAL|Hepatitis B vaccine|0.5 mL administered intramuscularly
41281910|NCT00257127|BIOLOGICAL|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
41281911|NCT00315302|DRUG|Atropine|Atropine 1% once each weekend day
41281912|NCT00315302|DEVICE|Plano Lens|Plano lens for the sound eye
41281913|NCT02270177|OTHER|Telemedicine, videoconsultation|We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
41281914|NCT01305915|BEHAVIORAL|Getting Back on Track|The intervention, entitled Getting Back on Track, is two hours in duration and delivered by a multidisciplinary team representing nursing, radiation therapy, social work, rehabilitation services, and nutrition from the Breast Cancer Clinic at Princess Margaret Hospital. Relying on the content of the Getting Back on Track booklet, clinical experience and the principles of adult education, this team developed scripts for each component of the class.
41281915|NCT03062501|DRUG|Hydroxyurea|Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
41451240|NCT05462548|DRUG|Luspatercept Injectable Product|1-1.25mg/kg every 3 weeks subcutaneous injection
40940248|NCT02889692|DRUG|Gefitinib®|"Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops."
40940249|NCT02889692|DRUG|Icotinib®|"Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops."
40940250|NCT01177332|OTHER|exercise|2 hours cycling exercise at 50 % of maximal power output
40940251|NCT05319769|PROCEDURE|Atrial fibrillation ablation|Pulmonary vein isolation
40940252|NCT03911219|OTHER|eHealth system support for symptom management via CANKADO|Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.
40940253|NCT02831374|DRUG|Local anesthesia|The surgical extraction under local anesthesia (2% Lignocaine and 1:100000 Adrenaline) procedure was the same in all patients.
40940254|NCT02831374|PROCEDURE|surgical extraction of impacted third molar|After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
40940255|NCT02831374|BIOLOGICAL|Preparation of PRP gel|Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
40940256|NCT02831374|PROCEDURE|Placing platelet Rich plasma and suturing|Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
40940257|NCT02831374|PROCEDURE|Suturing|Wound closure was done using simple interrupted 3.0 black silk sutures.
40940258|NCT02831374|DRUG|Postoperative medication|Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
40940259|NCT04840576|OTHER|Regular waterproof sterile dressing.|Waterproof sterile dressing OPSITE Post-Op Visible, Smith \& Nephew, UK
40940260|NCT04840576|OTHER|Prophylactic Negative Pressure Dressing|Negative wound pressure dressing: PICO-7, Smith \& Nephew, UK
40940261|NCT03408002|BEHAVIORAL|Psychological intervention|"The intervention aims to increase self-efficacy perception in managing pre-operative anxiety. The intervention is based on one single psychological consultation adopting the Four elements technique elaborated by Shapiro"
40940262|NCT06063707|OTHER|Taking peripheral blood|Taking peripheral blood of no more than 3ml
40940263|NCT00003800|OTHER|immunohistochemistry staining method|
40940264|NCT00003800|OTHER|laboratory biomarker analysis|
40940265|NCT00003800|PROCEDURE|radionuclide imaging|
40940266|NCT00004347|BEHAVIORAL|diet|
40940267|NCT03613610|RADIATION|Radio-frequency ablation of genicular nerves|Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
40940268|NCT03505671|PROCEDURE|Acupuncture Therapy|Undergo acupuncture therapy
40940269|NCT03505671|OTHER|Best Practice|Receive usual care
41131931|NCT03738709|BEHAVIORAL|Falls prevention and education giving a demonstration of the usage of technical assistance.|"* Ecological trail to work on balance and walking.~* Technical assistance presentation and try-outs within the therapeutic apartment.~* Discussion on the perceived feelings over the exercises and the technical assistance submitted.~* Falls Education and prevention, screening of the dangerous activities and education on the safe behaviours."
41281916|NCT04710108|OTHER|Health Communication|Spoken word poem set to video images performed by author. Comic book was transformed from the video that was equivalent in content to the video.
41281917|NCT00430534|BIOLOGICAL|EBV vaccine (268664)|
41281918|NCT01769521|DEVICE|Sensimed Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
40940270|NCT03505671|OTHER|Quality-of-Life Assessment|Ancillary studies
40940271|NCT03505671|OTHER|Questionnaire Administration|Ancillary studies
40940272|NCT02552615|OTHER|body awareness therapy|
40940273|NCT02552615|OTHER|core stabilization exercises|
40940274|NCT02552615|OTHER|traditional exercises|
40940275|NCT01336569|DRUG|Travoprost 0.004%/timolol maleate 0.5% fixed combination|
40940276|NCT04153071|DEVICE|OPUS system|Each subject will have a single cutaneous treatment of their lower abdomen, with variable treatment parameters. Punch biopsies will be obtained from each treatment section, for in-vivo histological evaluations.
41131932|NCT04388865|BEHAVIORAL|Control|Subjects will engage with their providers as is standard of care.
41131933|NCT04388865|BEHAVIORAL|Text-based Clinical Hovering|Subjects will receive remote monitoring via text messaging of clinical symptoms and medication adherence reminders with feedback to social support.
41131934|NCT06264583|OTHER|HDV screening|1. Analyze the rate of HDV-testing and evaluate the prevalence of HDV-infection by testing.
41131935|NCT03941665|DEVICE|Gelronate|Gel for topical use
41131936|NCT03941665|OTHER|Aloevera|Gel for topical use
41131937|NCT04480385|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch
41131938|NCT01113736|BIOLOGICAL|AlloMEM™|To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
41451241|NCT03835468|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria
40940277|NCT04350398|OTHER|Hippotherapy|The horse is an excellent collaborator in situations of physical and mental disability, whether temporary or consolidated. It provides support to humans towards an impairment (anatomical or physiological), a disability, or a restriction of participation as defined by the WHO in 2001. Hippotherapy has a direct action on the sensorimotor capacities of the individual but also on their cognitive capacities, such as attention, memory, psychomotricity, emotions, perceptions, the sequencing of complex movements, or the experience of oneself and the functions of time. Overall, the strong demand from the sensitive, sensory and motor spheres promotes and interacts with the mechanisms linked to the execution of tasks in the cognitive domain (memory, attention, executive functions, speed of information processing, etc.) through the interactions of several neural networks.
40940278|NCT04350398|OTHER|Conventional therapy|Personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
40940279|NCT00006169|BEHAVIORAL|Behavioral Treatment|
40940280|NCT03658707|OTHER|questionnaire|Shoulder questionnaire
40940281|NCT05992571|OTHER|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 90 minutes of rest.
40940282|NCT05992571|DIETARY_SUPPLEMENT|β-OHB|Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 90 minutes of rest.
40940283|NCT02579928|DRUG|Ketamine|A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
40940284|NCT02579928|DRUG|Midazolam|A single dose of 0.045mg/kg of Midazolam will be administered intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
40940285|NCT06448585|DRUG|Specific immunotherapy (SIT) treatment|Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.
40940286|NCT06448585|DIETARY_SUPPLEMENT|Dietary Supplement: ABB C1|"Ingredients: betaglucanos, levadura Saccharomyces cerevisiae, selenio y zinc.~1 sachet/day; contains 3 grams"
40940287|NCT06448585|DIETARY_SUPPLEMENT|Mini-tablets with pork extract|Mini-tablets with pork extract containing the diamine oxidase enzyme (3 mini-tablets/day)
40940288|NCT01337271|PROCEDURE|SBT- PSV|An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
40940289|NCT01337271|PROCEDURE|SBT - NAVA|An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
40940290|NCT04536831|DRUG|Vitamin D|Vitamin D will be given to group A selected by Lottery method
40940291|NCT04536831|DRUG|Normal saline|Vitamin D will be given to group B slected by Lottery method
40940292|NCT06199232|DRUG|HAIC+targeted therapy+PD-1 inhibitor|"HAIC regimen: doublet or triplet regimen based on the response and adverse events occurred in the previous standard treatment (depended on the decision of researchers)-oxaliplatin (85 mg/m2, split into d1 and d2, 0-2h,) and 5-fluorouracial (2g/m2, split into d1 and d2, 2-24h)/ oxaliplatin (65 mg/m2, 0-2h, d1), irinotecan (100 mg/m2, 0-2h, d2), and 5-fluorouracial (2g/m2, split in d1 and d2, 2-24h), repeated every 4 weeks; drug-eluting TACE will be performed at 3rd-4th cycles if the lesions in liver is abundant with blood supply.~Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.~Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.~Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w."
40940293|NCT04564885|DEVICE|BAGUERA®C Cervical Disc Prosthesis|surgery
40940294|NCT04564885|DEVICE|Mobi-C Cervical Disc|surgery
40940295|NCT04322981|BEHAVIORAL|Pharmacist-Led care|Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led
40940296|NCT04322981|BEHAVIORAL|Standard of Care (Hepatology)|Rapid testing in a community pharmacy, with standard of care referral to academic hepatology
40940297|NCT01389518|DRUG|Active|1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
40940298|NCT01389518|DRUG|Placebo|1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
40940299|NCT00075673|DRUG|celecoxib|Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
40940300|NCT00075673|DRUG|vinorelbine ditartrate|Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
40940301|NCT06016062|DRUG|RC148|RC148 is a bispecific antibody, targeting programmed death-1(PD-1) and Vascular endothelial growth factor(VEGF).
40940302|NCT05997472|DIAGNOSTIC_TEST|evaluation af mobility and balance|evaluation af mobility and balance Timed Up and Go Test Berg Balance Scale
40940303|NCT02829983|DRUG|Clarithromycin|Use of 500mg of Clarithromycin twice a day for 3 days
40940304|NCT02829983|DRUG|Placebo|Use of placebo tablets twice a day for 3 days.
40940305|NCT02829983|OTHER|One-stage full-mouth ultrasonic debridement (FMUD)|One session of Periodontal debridement using ultrasonic device.
40940306|NCT05236153|DIAGNOSTIC_TEST|Electroanatomic substrate mapping|Participants will undergo a sinus rhythm RV substrate map using the HD Grid catheter (Abbott) and the Ensite X electroanatomic mapping system (Abbott) prior to TPVR.
40940307|NCT00526045|DRUG|AUY922 2 mg/m2|
40940308|NCT02438527|BEHAVIORAL|Chart for CPR guidance|
40940309|NCT02098824|DRUG|Galantamine|Single administration of capsule containing 16 mg of Galantamine
40940310|NCT02098824|DRUG|Methylphenidate|Single administration of capsule containing 10 mg of Methylphenidate
40940311|NCT02098824|DRUG|Placebo|Single administration of capsule containing placebo
40940312|NCT01643603|DRUG|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
40940313|NCT01643603|OTHER|laboratory biomarker analysis|Correlative studies
40940314|NCT01962922|DRUG|LCP-Tacro|once-daily extended release tablet
40940315|NCT01962922|DRUG|Tacrolimus -IR|twice daily capsules
41451242|NCT03835468|DIETARY_SUPPLEMENT|Maltodextrin|sugar based placebo
40940316|NCT00701376|OTHER|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
41131939|NCT01583920|RADIATION|focal salvage HDR prostate brachytherapy|Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
40940317|NCT01419639|DRUG|Everolimus (RAD001) , Afinitor®|Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
40940318|NCT05838235|OTHER|Adapted Physical Activity program|The Adaptated Physical Activity program will consist of a Personalized Training Program
40940319|NCT02942420|DRUG|Bucillamine|Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
40940320|NCT00739492|BEHAVIORAL|financial incentives|financial incentives based on attaining weight loss goals
40940321|NCT05659056|DRUG|Pyrotinib, trastuzumab, paclitaxel-albumin|pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
40940322|NCT01125501|DIETARY_SUPPLEMENT|Protandim|The product Protandim used in this study have ingredients derived from five botanical sources \[Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)\].
40940323|NCT04779931|BEHAVIORAL|Convoy-Pal|12 week mobile self-management intervention with palliative care resources.
40940324|NCT05100095|DRUG|Radiation therapy|Hypofractionated radiation therapy to the primary tumor and/or lymph nodes
40940325|NCT02015702|OTHER|One-on-one physician training|Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
41131940|NCT04382313|PROCEDURE|the adequate hydration group guided by Vigileo|If the patient is mechanically ventilated, the following scheme is adopted: if SVV≤10%, then adjust the rehydration speed to 1 ml/kg/h; if 10%\<SVV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if SVV≥15%, then adjust the rehydration speed to 3 ml/kg/h. The hydration lasts 24 hours after operation, and the rehydration speed is changed according to the SVV. If the patient does not use mechanical ventilation, the following scheme is adopted: 250ml normal saline is administered within 10 minutes after direct PCI, and the rehydration volume changes to 125ml in patients with mild-to-moderate congestive heart failure. If the increment of SV≥15%, then adjust the rehydration speed to 3 ml/kg/h; if 10%≤the increment of SV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if the increment of SV\<10%, then adjust the rehydration speed to 1 ml/kg/h. Reassessed every 1 hour until SV is stable，and the hydration also lasts 24 hours after operation.
41131941|NCT01291212|DRUG|Testosterone and FSHr-LHr|75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
41131942|NCT01291212|DRUG|testosterone and FSHr alone|FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
41131943|NCT01458600|DRUG|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
41131944|NCT01458600|DRUG|Methimazole|T Methimazole 5 mg 3x2 for 18 months
41131945|NCT01458600|DRUG|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
41131946|NCT01458600|DRUG|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
41131947|NCT01458600|DRUG|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
40940326|NCT02015702|OTHER|Usual training|Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.
40940327|NCT00952627|DIETARY_SUPPLEMENT|Pycnogenol|50 mg tablet, 200 mg/day, 4 tablets/day
41281919|NCT03245879|BEHAVIORAL|Program 1|Program 1 hospitals received a basic curriculum and tools for implementation of basic antibiotic stewardship interventions. Hospitals required an indication for every antibiotic order. A daily email was sent to a designated email account when a patient had been on an antibiotic for \>48 hours. Curriculum included implementing antibiotic time-outs, IV to PO conversion, indications, evaluating for bug-drug mismatches, and recommendations on when to call the Infectious Diseases (ID) hotline. A daily antibiotic stewardship check list was created. All materials were provided to all pharmacists and remained on-site. Clinicians had access to an ID telephone hotline to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter.
41281920|NCT03245879|BEHAVIORAL|Program 2|Program 2 hospitals received all the interventions of Program 1. In addition, Program 2 hospitals received more intense antibiotic stewardship education. Educational topics included audit and feedback, antibiotic de-escalation, the need for antibiotics targeting anaerobic bacteria, antibiotic allergy verification, and antibiotic restrictions. Pharmacists in Program 2 hospitals reviewed patients on vancomycin, piperacillin/tazobactam, imipenem, meropenem, and cefepime. For patients receiving one of these antibiotics, pharmacists reviewed the patients' microbiology data to identify opportunities for antibiotic de-escalation, IV to PO conversion, bug-drug mismatches, and/or indications for calling the ID hotline. Program 2 hospitals also restricted daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold active antifungals. In Program 2 hospitals, the local pharmacy staff pre-authorized restricted antibiotics based on defined criteria.
41281921|NCT03245879|BEHAVIORAL|Program 3|Program 3 hospitals received all the interventions of Program 1 and Program 2. In addition, pharmacists in program 3 hospitals reviewed an expanded list of antibiotics for audit and feedback. These antibiotics included: Vancomycin, piperacillin/tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and fluoroquinolones. Program 3 hospitals implemented the same antibiotic restrictions as Program 2 but ID pharmacists controlled pre-authorization of restricted antibiotics. In addition, an ID physician reviewed pre-specified positive cultures (e.g. all positive blood cultures, cultures with highly resistant Enterobacteraciae) and contacted providers with recommendations as needed. ID physician review occurred Monday through Friday and alerts were batched daily at 6am.
41281922|NCT00783640|DRUG|Lactic Acid|Drug: Lactic Acid (Dermacyd Femina)
41281923|NCT01287117|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
41281924|NCT01287117|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
41281925|NCT00738738|DRUG|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
41281926|NCT01613092|DRUG|Incremental|Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
41281927|NCT01613092|DRUG|Cefazolin|Preoperative antibiotic
40756580|NCT05274698|BEHAVIORAL|muscle energy technique|It is a manual treatment in which a patient produces a contraction in a precisely controlled position and direction against a counterforce applied by a manual therapist .Muscle energy techniques (MET) were originally developed to treat soft tissue, mobilize joints, stretch tight muscles and fascia, reduce pain and to improve circulation and lymphatic drainage.
40756581|NCT05274698|BEHAVIORAL|conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.|"Joint mobilization, specifically glenohumeral joint distraction, glenohumeral joint caudal glide, glenohumeral joint posterior glide, and glenohumeral joint anterior glide, will be applied with patients.~Posterior capsule stretching will be applied with patients in side lying position. The scapula will be stabilized at the lateral side with the arm at 90° flexion. Stretching will be applied from the elbow with a downward force. The stretch will be repeated 10 times for 20 s each. A 30-s break will be given between each stretching .~Range of motion exercises:~Codman/ pendulum exercise ,Wall climbing exercise and Shoulder wheel exercise Circumduction of the shoulder joint clockwise and anticlockwise using shoulder wheel"
40756582|NCT03015948|DRUG|SHR4640|a single dose of SHR4640 (n=8) for each dose cohort
40940328|NCT00952627|DIETARY_SUPPLEMENT|Placebo|
40940329|NCT05436223|DRUG|Human CD19Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
40940330|NCT03480867|DRUG|Temozolomide|Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.
40756583|NCT03015948|DRUG|Placebo|a single dose of placebo (n=2) for each dose cohort .
40756584|NCT01105832|DRUG|Teriparatide|Teriparatide (Forsteo) 20 micrograms daily during four weeks
40940331|NCT03480867|RADIATION|Pre-Operative Radiation|Radiation is given with Temozolomide for 7 days before surgery
40940332|NCT05344885|BEHAVIORAL|DPT-Standard|The parent training intervention includes 7 modules, recommended to be completed within 7- to 10-weeks period. Module's content includes videos and texts guiding the parent through the training process; interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials, and a Q\&A section that contains frequently asked questions.
41451243|NCT01533038|DEVICE|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
41451244|NCT01533038|PROCEDURE|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
41451245|NCT06353139|DEVICE|Modified olfactory training device|Conduct olfactory training in patients with olfactory disorders
40756585|NCT00000726|DRUG|Foscarnet sodium|
40756586|NCT05102461|DIETARY_SUPPLEMENT|Florajen Digestion Supplementation|Subjects will take the placebo starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
40940333|NCT05344885|BEHAVIORAL|DPT-Enhanced|DPT-Enhanced will include all the ingredients of DPT-Standard, but with additional features. The program itself is based on pre-defined decision rules that are either event or time based based on evidence based practice in promoting effective parental engagement. Each component includes a short learning phase, followed by a 1-2 week focusing phase. The focusing phase is designed to encourage and help parents to practice and acquire learned skills in their day-to-day lives, by making these skills more salient in their mind.
41281928|NCT04810273|BEHAVIORAL|Early progressive mobilization|The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 7 days).
41281929|NCT00679861|BEHAVIORAL|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
41281930|NCT00679861|BEHAVIORAL|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
41451246|NCT05120388|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil Addition|Daily dietary addition of olive oil (three tablespoons)
41281931|NCT00302692|DRUG|Esmolol|
41281932|NCT00302692|DRUG|Metoprolol|
40940334|NCT00001443|DRUG|indinavir (MK-0639)|
40940335|NCT03206073|DRUG|Durvalumab|1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria
41281933|NCT03707561|DIAGNOSTIC_TEST|Right Heart Catheterization (RHC)|RHC at the enrollment and every 12 months
40756587|NCT05102461|DIETARY_SUPPLEMENT|Placebo Supplementation|Subjects will take Florajen Digestion starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
40756588|NCT01509209|DRUG|Pseudoephedrine / Levocetirizine|tablet, BID everyday
40756589|NCT02303483|DIETARY_SUPPLEMENT|Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )|
40756590|NCT02303483|DIETARY_SUPPLEMENT|Placebo|
41451247|NCT04175158|BIOLOGICAL|GB222|Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
41451248|NCT04175158|BIOLOGICAL|Bevacizumab|Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
41451249|NCT00837564|OTHER|CBASP psychotherapy|specific psychotherapy for chronic depression
41451250|NCT00837564|DRUG|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
41451251|NCT00115869|BEHAVIORAL|Social-influences|grades 3-10, school-based social influences tobacco use prevention curriculum
41451252|NCT05399446|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
41451253|NCT05399446|BEHAVIORAL|Educational Group|We selected a T1D management/Eating disorder psychoeducational comparison condition to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
41451254|NCT01030796|BEHAVIORAL|Caffeine abstinence|Brief instruction on beginning and maintaining caffeine abstinence.
41451255|NCT05644106|DEVICE|personal sound amplification product, hearing aid|the device for hearing gain in sensorineural hearing loss
41451256|NCT05345249|DRUG|Ropivacaine Hydrochloride Injection|Investigating the effectiveness of erector spinae plane block with ropivacaine for lumbar spinal fusion surgery versus placebo.
41451257|NCT05345249|DRUG|Sodium chloride|Placebo comparator
41451258|NCT06626542|OTHER|resistance and aerobic training exercises|resistance and aerobic training exercises
41451259|NCT00844922|DRUG|SCH 900636|"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."
41451260|NCT00844922|DRUG|Placebo|Placebo
41451261|NCT04574960|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, IV infusion on days 1 and 8 of each 3-week cycle
41451262|NCT04574960|DRUG|Cisplatin|Cisplatin 70 mg/m\^2, IV infusion on day 1 of each 3-week cycle
41451263|NCT04574960|DRUG|Carboplatin|Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
41451264|NCT03899935|PROCEDURE|Laparoscopy|Laparoscopy for endometriosis
41451265|NCT01528735|DRUG|BI 207127 NA|one fix dose
41451266|NCT01528735|DRUG|peginterferon|per package insert
41451267|NCT01528735|DRUG|Ribavirin|per weight BID
41451268|NCT01528735|DRUG|Ribavirin|per weight BID
41451269|NCT01528735|DRUG|BI 207127 NA|one fix dose
41451270|NCT01528735|DRUG|BI 201335 NA|high dose
41451271|NCT01528735|DRUG|BI 201335 NA|low dose
40756591|NCT03071302|OTHER|EVALUATION OF VSX1, SOD1, and TIMP3 genes|Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
41451272|NCT01528735|DRUG|peginterferon|per package insert
41451273|NCT01183884|BIOLOGICAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|"3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in \> or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2."
41451274|NCT03798457|OTHER|No intervention|In this study there is no intervention
41451275|NCT03088007|OTHER|Cognitive, adaptive, behavioral and academic assessment|Cognitive, adaptive, behavioral and academic assessment will be performed if not available in the records, using WISC-IV, VABS, GECEN and an academic skills rating form.
41451276|NCT01819064|DRUG|Atropine|intravenous atropine affect on heart rate
41451277|NCT00949819|OTHER|Active surveillance|Serial, long term data collection and active surveillance
41451278|NCT04691960|OTHER|Ketogenic Diet|Ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis. The diet will begin at an approximately 3:1 fat to carbohydrate + protein ratio for 5 days. If the patient does not show urine ketosis (1.5 mmol/L or 27.0 mg/dL), the ketosis diet will be advanced to approximately 4:1 ratio for 5 days. If the patient still does not attain ketosis a 24 hour fast will be done to promote ketosis. The diet will encourage at least 30 ml per day of Medium Chain Triglycerides (MCT) oil to enhance ketosis.
41451279|NCT04691960|DRUG|Metformin|Metformin will be administered as a single 850 mg dose P.O. at Week 8, then titrated up to 850 mg P.O. BID at Week 10, and then 850 mg T.I.D. at Week 12, as tolerated.
41451280|NCT03931616|PROCEDURE|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure management (choice of drug at discretion of treating physician), use of telemedicine for image transfer as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
40940336|NCT03206073|DRUG|Tremelimumab|300 mg of tremelimumab via intravenous (IV) infusion on Day 1 of cycle 1
41281934|NCT02542995|OTHER|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
41281935|NCT04763525|BEHAVIORAL|Pythagorean Self-Awareness Intervention(PSAI)|The PSAI is a mental, stress-management technique that promotes self-awareness, cognitive reconstruction and self-improvement based on the Golden Verses moral framework of the ancient Greek philosopher Pythagoras. The individual must practice the technique twice daily( at bed-time and in the morning, every day, at home) and through a 3-stage internal dialogue (recall of daily events, inspection of related thoughts and emotions and self-appraisal)is encouraged to detect wrong choices and unhealthy behaviours and initiate self-correction towards a healthier lifestyle.
41281936|NCT00000899|DRUG|Nelfinavir mesylate|
41281937|NCT00000899|DRUG|Lamivudine|
41281938|NCT00000899|DRUG|Filgrastim|
41281939|NCT00000899|DRUG|Stavudine|
41281940|NCT00000899|DRUG|Cyclophosphamide|
41281941|NCT03531229|DRUG|Placebo|Placebo to Lu AF76432 oral solution
40756592|NCT06366919|DIAGNOSTIC_TEST|Alexander Technique (AT)|The AT arm of study will involve participants receiving indivisual sessions. These sessions will typically focus on non specific neck pain management improving posture , movement coordination and body awareness through gentle hands on guidance
40756593|NCT06366919|DIAGNOSTIC_TEST|Feldenkrais Technique (FT)|The FT arm of study will involve participants recieving individual sessions. These sessions will typically focus on pain improvement, maintaining alignment, reducing muscle tension and promoting ease of movement.
41281942|NCT03531229|DRUG|Lu AF76432|Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
41281943|NCT01655407|DRUG|Autologous Engineered Skin Substitute|"The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place."
41281944|NCT01655407|DRUG|Split-Thickness Autograft (AG)|"The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin."
41451281|NCT03931616|PROCEDURE|Regular care|A regular ambulance, the comparator, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
41451282|NCT01743898|DRUG|Rivaroxaban|Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
40756594|NCT03715829|DRUG|PF-06651600|Induction dose 1. Oral tablet taken QD
40756595|NCT03715829|DRUG|PF-06651600|Induction dose 2. Oral tablet taken QD
40756596|NCT03715829|DRUG|PF-06651600|Maintenance dose A. Oral tablet taken QD
41281945|NCT00800072|DEVICE|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
41281946|NCT06380244|OTHER|anesthesia without opioids|Opioid free general anesthesia
41281947|NCT04373525|OTHER|Genome analysis|Venous blood will be obtained for later genome analysis
41281948|NCT01626040|DRUG|polyethylene glycol powder|A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
41281949|NCT00499915|BEHAVIORAL|Secondhand Smoke Reduction and Smoking Cessation Counseling|A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.
41281950|NCT00499915|BEHAVIORAL|Asthma Education|Asthma education will be provided at NICU discharge.
41281951|NCT06394622|COMBINATION_PRODUCT|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.
41281952|NCT04776343|OTHER|telemedecine follow-up|weekly home-based follow-up of visual acuity on electronic tablet
41281953|NCT00308620|DRUG|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
41281954|NCT00308620|DRUG|Placebo|Placebo once daily for 8 weeks
41281955|NCT03291379|DRUG|BTG-002814|BTG-002814 containing 100 mg vandetanib
41281956|NCT00206141|DRUG|Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)|
41281957|NCT04603378|OTHER|KB195|KB195 is a novel glycan
41281958|NCT04603378|OTHER|Polydextrose|Polydextrose is an oligosaccharide
41281959|NCT04603378|OTHER|Pullulan|Pullulan is an oligosaccharide
41281960|NCT04603378|OTHER|Maltodextrin|Maltodextrin is a digestible carbohydrate
41281961|NCT04265612|PROCEDURE|"Pico® negative pressure dressing"|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy.The dressing will remain on for 7 days without waking up, unless it is saturated, in which case only the dressing will be changed"
41281962|NCT04265612|PROCEDURE|"Aquacel Surgical® hydrogel dressing"|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
41281963|NCT01477450|DEVICE|Pulse-dose oxygen|Pulsed-dose oxygen delivery from an oxygen concentrator
41281964|NCT01477450|DEVICE|Cylinder oxygen delivery|Oxygen delivery from an oxygen cylinder
41281965|NCT05850377|DRUG|5-Aminolevulinic Acid (5-ALA) Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials and is administered orally three hours (range 2-4 hours) before anaesthesia. One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). The recommended dose is 20 mg 5-ALA HCl per kilogram body weight. One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl.
41281966|NCT05850377|PROCEDURE|Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)|During the surgical exploration of the glioma, the neurosurgeon will attempt to identify the mass. The location of the tumor will be assessed using the blue-light filtered microscope. A biopsy of the fluorescent region will be taken to confirm the glioma subtype. The tumor will then be maximally resected.
41451283|NCT01743898|OTHER|no anticoagulation|
40756597|NCT03715829|DRUG|PF-06651600|Maintenance Dose B. Oral tablet taken QD
40756598|NCT03715829|DRUG|PF-06651600|Maintenance Dose C. Oral tablet taken QD
40940337|NCT03206073|BIOLOGICAL|Pexa-Vec|3 x 10E\^8 plaque-forming unit (pfu) (Dose Level (DL) 1) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
41281967|NCT02957708|OTHER|mCIMT + SR|"Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance."
41281968|NCT02957708|OTHER|Control|A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
41281969|NCT05758038|PROCEDURE|Radiofrequency ablation/Microwave ablation|thermal ablation by radiofrequency and Microwave
41451284|NCT06060353|BEHAVIORAL|Regulation Focused Psychotherapy (RFP-C)|Regulation-focused psychotherapy for children (RFP-C; Hoffman, Rice, \& Prout, 2016) is a manualized, psychodynamic play therapy. Through 20 sessions (16 with the child and four parent meetings), RFP-C allows the child to understand the ways distressing affects are avoided and to explore alternative ways of coping with unpleasant affect. The clinician works to increase the child's understanding that all behavior, especially oppositional and disruptive behavior, has meaning in the service of emotional and behavioral regulation. This work is also done with the parents to better support the child in achieving symptom reduction and increased emotion regulation.
40756599|NCT03715829|DRUG|placebo|placebo
40756600|NCT03715829|DRUG|PF06700841|Oral tablet taken QD
40756601|NCT03715829|DEVICE|narrow-band UVB phototherapy|Phototherapy will be combined with PF-06651600
40940338|NCT03206073|BIOLOGICAL|Pexa-Vec|1 x 10E\^9 pfu (DL 2) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
40940339|NCT01693302|OTHER|Insulin|The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
40940340|NCT04428775|DRUG|ALZT-OP1a (cromolyn)|"1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory"
41281970|NCT04807491|OTHER|Kabat Technique's|"As with all cranial nerves, some specific techniques can also be applied on the facial nerve to enhance responses and improve recovery; the most important are: The rhythmic start: shows and guides the subject into the movements and the scheme; agonist investigation utilizes sequential concentric and eccentric contractions; The inversion of the antagonist: reinforces responses through the induction phenomenon; Repeated contractions: calls for a response with repeated stretching that briefly enables movement; Isometric contractions: for stabilizing and reinforcing the response.~Conventional therapy exercises"
40940341|NCT00541463|DRUG|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
40940342|NCT00541463|DRUG|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
40940343|NCT01464723|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
40940344|NCT05922553|BEHAVIORAL|Active Ingredient Mukbang|Mukbang videos include the items which can truly improve the appetite of children with cancer, such as food images, eating sound and interactivity.
40940345|NCT05922553|BEHAVIORAL|Common Mukbang|Common Mukbang videos made and uploaded by the famous Mukbang makers.
40940346|NCT05922553|BEHAVIORAL|General short videos|Short videos that don't contain any food cues.
41131948|NCT05935046|BEHAVIORAL|Walk test and meal test|"The subjects will perform a treadmill walking test at increasing speed from 2 to 6km.h-1 in 5min increments.~During the second experimental visit, subjects will be required to consume a test meal containing 590kcal (12% protein, 35% fat, 53% carbohydrate) (Duhita et al 2017).~The composition of the test meal will be developed based on the food preferences and habits questionnaires completed during the inclusion visit. Foods indicated as preferred by participants will not be offered during these sessions to avoid any influence of their palatable nature on participants' consumption."
40756602|NCT03531567|BEHAVIORAL|Virtual Reality Mystic Isle Game|8 week virtual reality based exercise program
40756603|NCT03531567|BEHAVIORAL|Standard Home Exercise Program|8 week standard occupational therapy home exercise program
40756604|NCT04389463|OTHER|No intervention|No description
40756605|NCT01674361|DRUG|Bitopertin|Bitopertin once daily orally.
40756606|NCT01674361|DRUG|Placebo|Placebo matched to bitopertin once daily orally.
40940347|NCT01171508|DEVICE|Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA|Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.
40940348|NCT01171508|DEVICE|Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)|Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).
40940349|NCT01171508|DEVICE|Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)|Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.
40940350|NCT01171508|PROCEDURE|Urine 6-sulphatoxymelatonin (aMT6s)|Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.
40940351|NCT01171508|OTHER|Karolinska Sleepiness Scale|Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.
40940352|NCT01171508|OTHER|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.
40940353|NCT01171508|OTHER|Sleep-diary|Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
40756607|NCT01674361|DRUG|SSRI|Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
40756608|NCT02004275|DRUG|pomalidomide|given PO
40756609|NCT02004275|DRUG|ixazomib|given PO
40756610|NCT02004275|DRUG|dexamethasone|given PO
40756611|NCT03344705|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.
40756612|NCT03344705|DRUG|Fludarabine|Two days before cell infusion,all patients will be treated with fludarabine for 3 days
41281971|NCT04807491|OTHER|Neuromuscular Re-Education|"After the baseline assessment, the participant in the control will receive Neuromuscular Re-Education. The duration of session will be 45 minutes.Neuromuscular Re-Education: For initiation (acute phase): Active-assisted exercise,Massage and stretch for affected side.For Facilitation ,Active-assisted exercise.For Movement control:Massage and stretching for facial retraction,Assisted and active exercises on involved side.~For Relaxation,Thermotherapy,Relaxation exercises,Alternating rhythmic movements.~Conventional therapy exercises"
41281972|NCT02638012|DRUG|Floseal|Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
41281973|NCT02638012|OTHER|Packing|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
41281974|NCT01420133|OTHER|Regimen|regimen normal in salt and sugar
41281975|NCT01420133|OTHER|Standard regimen|with diet low in salt and sugar
41281976|NCT04938648|BEHAVIORAL|Pharmacist-led deprescribing intervention|1) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
41281977|NCT02509962|DIETARY_SUPPLEMENT|Slow sodium tablets|6 g sodium chloride per day over 14 days
41281978|NCT06329388|DIETARY_SUPPLEMENT|TruHeight Growth Protein Shake|Participants will be administered two scoops of TruHeight Growth Protein Shake, mixed with 12-16 fluid ounces of water, once daily, five times per week for six months. The supplement is intended to support growth patterns in children by providing essential nutrients that contribute to bone development and overall growth.
41281979|NCT06075615|DRUG|dacomitnib|patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
41281980|NCT05176210|DRUG|PS1|PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
41281981|NCT05176210|DRUG|Placebo|Placebo will be provided as a 120 mg tablet.
41281982|NCT05736315|OTHER|Placebo dairy beverage|Placebo dairy beverage (placebo) is a sweetened dairy beverage.
41281983|NCT02636309|BEHAVIORAL|physical therapy at work|gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
41281984|NCT04457440|BEHAVIORAL|Intensive Lifestyle Intervention|This intervention is an abbreviated version of the Diabetes Prevention Program, which has been shown to be effective in reducing the risk of developing type 2 diabetes.
41281985|NCT04457440|BEHAVIORAL|Intensive Lifestyle Intervention enhanced with Cognitive Behavioral Sleep Intervention|This intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session. The additional sleep components will include (a) psychoeducation about the importance of sleep in weight control and glycemic control, (b) sleep hygiene, (c) stimulus control, (d) modifying maladaptive beliefs about sleep, (e) and, setting individualized sleep schedule and reviewing sleep schedule.
40756613|NCT03344705|DRUG|Cyclophosphamide|Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
40756614|NCT06002698|PROCEDURE|Root canal treatment (Control)|Root canal treatment - Removal of the inflamed pulp tissues from the whole root canals of the tooth.
40756615|NCT06002698|PROCEDURE|Full pulpotomy (Experimental)|Full pulpotomy - Removal of the inflamed coronal pulp tissues from the crown of the tooth.
40756616|NCT00684554|DRUG|Buprenorphine|Dose is determined according to the participants' individual need.
41281986|NCT04721873|DRUG|Phentermine-Topiramate|Patients will be randomized to either once-daily, oral phentermine-topiramate 15-92mg or placebo, in a 1:1 fashion, for 22 weeks, with clinic visits with an obesity medicine specialist, for intensive counseling for diet and lifestyle intervention. All patients will be dose-titrated within the first 4 weeks, starting at phentermine-topiramate 3.75-23mg, or placebo. Dose titration will be performed as follows 3.75-23mg x 1 week --\> 7.5-46mg x 1 week --\> 11.25-69mg x 1 week --\> 15-92mg. Patients who experience side effects would undergo slower titration, and dose would be down-titrated and capped at highest tolerated dose.
41281987|NCT04721873|DRUG|Placebo|Matching placebo, titrated as active intervention
41281988|NCT03909815|DEVICE|Dual mobility cup|Patients with a displaced femoral neck fracture eligible for THA receive a dual mobility cup, as opposed to a standard cup in the control group.
41281989|NCT03909815|DEVICE|Standard cup|Patients with a displaced femoral neck fracture eligible for THA receive a standard cup, as opposed to a dual mobility cup in the experimental group.
41281990|NCT03638011|DRUG|Exparel|Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
41281991|NCT02858479|OTHER|stimulation on painful area (area allodynic)|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
41281992|NCT02858479|OTHER|same stimulation on non-painful area|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
41281993|NCT02858479|RADIATION|MRI scan|"2 sessions for 10 minutes :~* 11 controls stimulations for 6 s each spaced 20 s without stimulation.~* 11 allodynic stimulations for 6 s each spaced 20 s without stimulation."
41281994|NCT05802329|DRUG|OCU200 Low Dose|Intravitreal Injection
41281995|NCT05802329|DRUG|OCU200 Medium Dose|Intravitreal Injection
41281996|NCT05802329|DRUG|OCU200 High Dose|Intravitreal Injection
41281997|NCT05856864|DRUG|Cadonilimab Injection|Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,
41281998|NCT05856864|DRUG|Ramucirumab Injection|Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,
41281999|NCT06188832|DIETARY_SUPPLEMENT|glucomannan, inulin, and psyllium|the subjects recieved fiber supplement containing glucomannan, inulin, and psyllium
41282000|NCT06188832|OTHER|placebo|the subjects recieved placebo
41282001|NCT03723096|DRUG|CC-4047|CC-4047 will be administered orally
41282002|NCT01816087|OTHER|brief geriatric assessment|All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
41282003|NCT05773456|OTHER|Sushi and wakame salad|One serving of mixed sushi and wakame salad
41282004|NCT00730236|DRUG|AEGR-733|5-80 mg daily by mouth for 1.5 yrs
41282005|NCT05867940|BEHAVIORAL|Physical activity on prescription|"Physical activity on prescription (PAP) is a well-established method to enhance physical activity in adults in primary care. The prescribed activity should lead to moderate increase of the pulse, such as walking, cycling, swimming, or gardening, and should be performed over a longer period of time in order to achieve a change towards a more active lifestyle. The activity may be prescribed by a physiotherapist, physician, nurse, or other health professional. PAP has shown to be feasible to increase participation in physical activity and to reduce sedentary behaviour in children with cerebral palsy.~Motivational interviewing is used for our PAP with participants with disabilities. During PAP-period, the participants are asked to fill in an activity logbook."
41282006|NCT05344547|DIAGNOSTIC_TEST|Cardiac risk ratio (CRR)|Cardiac risk ratio (CRR) was calculated according to Genest et al. (23) as serum total cholesterol (TC) level divided by serum high-density lipoprotein-cholesterol (HDL-c) level and woman with CRR at ≥3.5 was considered at risk of cardiac disease (24).
41282007|NCT03501576|BIOLOGICAL|Inactivated Influenza Vaccine|Given seasonal inactivated influenza vaccine IM
41282008|NCT02421874|BEHAVIORAL|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
40756617|NCT00449800|DRUG|ceftriaxone|
40756618|NCT05920616|OTHER|Magnetic Resonance Imaging|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
40756619|NCT05920616|OTHER|Ultra-High Resolution Computed Tomography (CT) Scan|Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.
40756620|NCT00952562|DIETARY_SUPPLEMENT|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
40756621|NCT00952562|DIETARY_SUPPLEMENT|placebo|Empty capsules, 3 capsules per day for 16 weeks
40756622|NCT02683798|DIETARY_SUPPLEMENT|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
41282009|NCT02421874|BEHAVIORAL|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
41451285|NCT06060353|BEHAVIORAL|Parental Awareness and Child Social Skills Group|Parental awareness and child social skills group is a manualized group psychotherapy that involves twelve parallel sessions conducted separately with parents and children. The parent group involves modules related to psycho-education, role-play and awareness building activities on child needs \& rights, child temperament, praise \& acceptance, child play, limit setting, anger management, transmission of parenting styles through genograms and family trees. With children, the groups involve psycho-education and play based activities to build awareness on children's rights, temperament, feelings, play \& relationship skills, empathy \& praise, anger management.
40756623|NCT02683798|DIETARY_SUPPLEMENT|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
40756624|NCT03424980|COMBINATION_PRODUCT|Tyrosine kinase inhibitors|Tyrosine kinase inhibitors only or combinations therapies of tyrosine kinase inhibitors
41282010|NCT05750940|DIAGNOSTIC_TEST|31Phosphor Magnetic Resonance Spectroscopy|Measurement of skeletal oxidative metabolism with 31phosphor magnetic resonance spectroscopy
41282011|NCT01966731|DRUG|Hydroxyurea|Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
41282012|NCT00714142|DRUG|62Cu-ethylglyoxal bis(thiosemicarbazone)|15-25 mCi, IV
41282013|NCT00714142|DRUG|15O-water|10-20 mCi, IV
41282014|NCT00714142|PROCEDURE|Positron Emission Tomography|PET Scan
41282015|NCT03268798|DEVICE|Unilateral wrist extension training|Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
41451286|NCT02653664|BEHAVIORAL|PsychoEducation|Condition #1
41451287|NCT02653664|BEHAVIORAL|Self-Hypnosis Training|Condition #2
41451288|NCT02653664|BEHAVIORAL|Mindfulness Meditation|Condition #3
40756625|NCT01623427|PROCEDURE|Application of vacuum|The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
41282016|NCT02936895|DRUG|Vitamin D3|vitamin D at a dose of 50,000 IU per day for 2 days
41282017|NCT02936895|DRUG|Placebo|Placebo for 2 days
41451289|NCT06627348|DEVICE|Hilotherm ChemoCare|Hilotherapy
41451290|NCT04153539|BEHAVIORAL|Walking along a busy road|The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
41451291|NCT04153539|BEHAVIORAL|Walking in a traffic-free park|The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
41451292|NCT04001062|PROCEDURE|Surgical Fixation|For both scissoring and non-scissoring injuries surgical fixation by either pinning, dorsal plate, or lag screws will be considered. This will be determined by surgeon expertise at the time of surgical fixation. Postoperative, a volar short arm splint and immediate AROM at full range with buddy taping to adjacent digit will be indicated. Transition to removable short arm splint at week 2 after suture removal. No strengthening until clinical union.
40756626|NCT01623427|PROCEDURE|No vacuum|Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
40756627|NCT00005880|DRUG|budesonide|
41282018|NCT05890703|DRUG|IMP2 (lidocaine-23%-tetracaine-7% gel)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
41282019|NCT05890703|DRUG|IMP1 (EMLA 5% cream)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
41282020|NCT01113528|OTHER|Regenerative therapy (omega 3 PUFA plus low dose aspirin)|Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin
41282021|NCT01113528|DRUG|Sugar pill|3 times daily
41282022|NCT02120417|DRUG|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)"
40940354|NCT05196178|PROCEDURE|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565;Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
41282023|NCT02120417|DRUG|Capecitabine|Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
41282024|NCT02120417|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
40940355|NCT03739840|DRUG|Padsevonil|Padsevonil in different dosages.
41131949|NCT02117310|DRUG|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
41451293|NCT04001062|OTHER|Non-Operative Management|"1. For non-scissoring injuries: Placement of short-arm cast; immediate AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union.~2. For scissoring injuries: Closed reduction in clinic/ER and placement of short-arm cast; immediate full range AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union"
41282025|NCT00337389|DRUG|5- Fluorouracil (5-FU)|
41451294|NCT05697679|BEHAVIORAL|Treatment group|WeChat groups will be set up, and once a week on Monday, articles on physical exercise and once a week on Wednesday, 3-minute films about health education will be shared. For the duration of the 3-month intervention period, the following technologies will be used to deliver the GAT-pap: (1) Short Messaging Service (SMS) text (batch messaging); (2) WeChat (e.g., physical activity guidelines, group chats); and (3) monthly face-to-face interviews (behaviour change promotion, risk factor management). Although not essential, participants will be urged to register their daily exercise in the group chat. In order to determine if they are accomplishing their goals and what objectives they should be pursuing, the researchers will develop customised training regimens for each participant.
41451295|NCT05697679|BEHAVIORAL|Contral group|One or two times each week, participants in the control group will get general lifestyle advice through SMS. They will not participate in the intervention's fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group's complaints or questions will always be answered with basic health information and suggestions. Researchers won't ask for individual advice or comments from other professionals.
41451296|NCT00318188|PROCEDURE|standardized reeducation and readaptation program|
41451297|NCT00292929|DRUG|Intravenous artesunate|
41451298|NCT03123094|DRUG|Spesolimab|single dose
41451299|NCT03123094|DRUG|Placebo|single dose
41451300|NCT00487695|DEVICE|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
41451301|NCT00487695|DEVICE|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
41451302|NCT01756885|DRUG|Varenicline|Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
41451303|NCT01756885|DRUG|Placebo|On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
40940356|NCT03739840|DRUG|Placebo|Placebo will be provided matching padsevonil.
40940357|NCT05490238|PROCEDURE|Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)|Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
40940358|NCT01733849|OTHER|Stool sample|Samples will be tested to determine the presence or absence of rotavirus.
40940359|NCT01733849|OTHER|Data collection|Log books
41131950|NCT04376775|OTHER|Transplant patient|Surveys will be distributed via an email sent by transplant centres or patient's associations. A link to a secure survey platform will be given. A questionnaire will completed by patients. Patients, who agreed to fill the survey, will be offered the possibility to be contacted for a second survey over a 6 months period.
41282026|NCT00337389|DRUG|bevacizumab (Avastin)|
41282027|NCT00337389|DRUG|Leucovorin|
41282028|NCT00337389|DRUG|CoFactor (ANX-510)|
40940360|NCT02922400|BEHAVIORAL|Social Cognition Assessment and Training|The study includes an assessment and treatment phase: The assessment phase will test the efficacy and feasibility of a battery of measures evaluating social cognition and behavior. Functional magnetic resonance imaging (fMRI) will also be used to investigate functional differences in regions of the brain associated with social cognition and differences in cognitive progressing. The treatment phase will assess the efficacy and feasibility of a strategy-based social skills treatment using a virtual reality platform.
40940361|NCT03022227|OTHER|telemedicine|telemedicine applied to adult cochlear implant users' follow-up
41282029|NCT04445662|BEHAVIORAL|Financial incentives|Escalating financial rewards for saliva cotinine levels \<30 ng/mL, assessed 10 times over 12 weeks
41282030|NCT04445662|DRUG|Varenicline|"* Day 1 - 3: 0.5 mg daily~* Day 4 - 7: 0.5 mg twice daily~* Day 8 - Week 12: 1 mg twice daily~* Dose/schedule may be adjusted based on medical history and clinician judgement"
41282031|NCT04445662|BEHAVIORAL|Tobacco coaching|5 one-on-one tobacco cessation coaching sessions over 12 weeks
41282032|NCT01325493|DRUG|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
41282033|NCT01325493|DRUG|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
41282034|NCT03754985|DEVICE|Hyperbaric oxygen therapy|"The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session."
41282035|NCT03166800|DRUG|Mitoquinone|This arm of the intervention the study subject will be administered 40mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
41282036|NCT03166800|DRUG|Mitoquinone|This arm of the intervention the study subject will be administered 20mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
41282037|NCT03166800|DRUG|Placebo|This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.
41131951|NCT00210275|BEHAVIORAL|Printed Educational Message|Three forms of printed educational materials (short or long educational messages and patient reminder notes)
41131952|NCT00274417|DRUG|dutasteride|
41282038|NCT00004829|DRUG|tobramycin|
41282039|NCT05881993|DRUG|CBP-4888|siRNA therapeutic
41282040|NCT05881993|OTHER|Placebo|Normal Saline
41282041|NCT02424487|PROCEDURE|Intracuff pressure measurement in one-lung ventilation during thoracic surgery|
41282042|NCT04603248|DRUG|Nivolumab|Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
41282043|NCT03455387|DIAGNOSTIC_TEST|sampling of the serum marker sFlt1 and PlGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
41282044|NCT03554239|GENETIC|genotyping|Blood sample
41282045|NCT05125653|PROCEDURE|Indocyanine Green Fluorescent Laparoscopic Cholangiography|Indocyanine Green Fluorescent Cholangiography
41282046|NCT05125653|PROCEDURE|White Light|Performing the laparoscopic cholecystectomy and identifying the biliary structures under the conventional white light
41282047|NCT04967690|DRUG|SI-053|SI-053 will be used as an add-on to SoC for newly diagnosed GBM.In conjunction with surgical resection, SI-053 will be applied intracranially (i.c.) into the cavity that is formed after tumor resection. Post-operative chemoradiotherapy (including concomitant and adjuvant TMZ or following the CeTeG protocol) will be initiated at least 21 and no later than 35 days after SI-053 administration.
41282048|NCT02408250|PROCEDURE|Exercise program|Exercise program in intensive care unit established from a decisional algorithm and applied to the critical care unit patients
41282049|NCT04696549|BEHAVIORAL|Virtual visual art experience guided by Visual Thinking Strategies|All study dyads (where study dyad consists of a participant with dementia and his/her care-partner) will participate in 3 scheduled virtual visual art sessions via Zoom. Each session will last about an hour and will include a guided discussion of pre-selected visual art using the Visual Thinking Strategies approach. It is anticipated that two pieces of art will be shown during each art session. The three sessions will be scheduled one month apart.
41131953|NCT01299194|DRUG|ATORVASTATIN|80mg once daily for 3 months
41131954|NCT04250623|OTHER|Health care product (gel)|hyaluronic acid intimate moisturizing gel (to be applied on the subject's skin)
41131955|NCT03473041|PROCEDURE|Hybrid sling|sling formed of surgeon tailored autologous rectus sheath and polypropylene arms
41282050|NCT03343964|DIAGNOSTIC_TEST|Amplitude-integrated electroencephalography|Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
40940362|NCT03497793|OTHER|SNUBY|Following written informed consent, mother will be issued with an appropriate sized SNUBY® for her use only. The infant will be placed in skin-to-skin in SNUBY®, infant chest to mother's chest whilst the mother is seated on a reclining chair, allowing the infant to be further stabilised by gravity. Monitor wires, IV lines and/or ventilation tube will be secured using the ties on the SNUBY®. The infant's temperature, pulse and SaO2 will be recorded prior to skin-to-skin, repeated as required for the infant's clinical condition or at 30min intervals for the duration of skin-to-skin. Maternal and infant behaviour will be recorded, including spontaneous breastfeeding. The time taken to put the infant into skin-to-skin care, time in skin-to-skin care and time to return to cot will be recorded.
40940363|NCT01756300|DEVICE|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
40940364|NCT03431103|BEHAVIORAL|Exercise|12 week home exercise program
40940365|NCT00000762|BIOLOGICAL|rgp120/HIV-1MN|
40940366|NCT00000762|BIOLOGICAL|rgp120/HIV-1 SF-2|
40940367|NCT00000762|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
40940368|NCT04026581|BEHAVIORAL|Speech generating device (SGD) evaluation including BCI access|At the initial evaluation the participants will review the full range of AAC options and speech generating devices (SGDs) and complete a speech and language evaluation. The second evaluation date will involve a trial of SGDs matched to the participant's assessment results. The third visit is the trial of an AAC system with BCI access. Should the dry electrode headgear for BCI access prove ineffective, then the gel electrode cap will be offered to the participant for trial. At the end of the third visit, the evaluation results will be discussed with participant and family, and they will be asked to select the preferred SGD.
41131956|NCT03473041|PROCEDURE|TVT-O|midurethral transobturator vaginal tape
41282051|NCT04544267|BIOLOGICAL|Quadrivalent influenza vaccine, high-dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
41282052|NCT04544267|BIOLOGICAL|Quadrivalent influenza vaccine, standard dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
41282053|NCT02830425|OTHER|No intervention|
41282054|NCT01368068|DRUG|Tibolone|2.5mg/oral/daily
41282055|NCT01368068|DRUG|Escitalopram|10mg/oral/daily
41282056|NCT01368068|DRUG|Natvia|serving size: 0.09g per tablet
41282057|NCT06178640|DRUG|Simvastatin 40 mg film-coated tablet|Simvastatin 40 mg film-coated tablet
41451304|NCT01756885|BEHAVIORAL|Smoking Cessation Counseling|"Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial."
41282058|NCT06178640|DRUG|Zocor 40 mg film-coated tablet|Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)
41282059|NCT00226642|DRUG|Sertralin|
41451305|NCT03388905|DEVICE|Life Vest Wearable defibrilator|The LifeVest is a cardioverter defibrillator worn by a patient at risk for sudden cardiac arrest (SCA). It monitors the patient's heart continuously and, if the patient goes into a life-threatening arrhythmia, can deliver a shock treatment to restore the patient's heart to normal rhythm.
41131957|NCT01012063|DRUG|iron sucrose, erythropoietin-β|The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
41131958|NCT01012063|DRUG|normal saline|100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
41131959|NCT04060212|OTHER|Tuna fish|Six meals of tunafish (\~200gms) will be consumed. Three meals will be consumed in a period of 14 days, and a subsequent 3 meals will be consumed within a 14 day period six month after the first 3 meals.
41131960|NCT04060212|DIETARY_SUPPLEMENT|prebiotic|Prebiotin brand prebiotic will be consumed at 8grms/day for a period of 75 days. The prebiotic administration will begin with the second grouping of 3 fish meals.
41131961|NCT04730206|DRUG|Camostat|100 milligram tablets
41131962|NCT04730206|DRUG|Placebo|oral tablets, identical in size and shape
41131963|NCT04730206|DRUG|Molnupiravir|200 milligram tablets
41131964|NCT00010049|DRUG|imatinib mesylate|
41131965|NCT01801800|PROCEDURE|Echocardiography|Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
41282060|NCT00226642|BEHAVIORAL|Cognitive-behavioral therapy|
41282061|NCT00226642|DRUG|Placebo|
41282062|NCT00226642|BEHAVIORAL|Non-specific supporting group therapy|
41282063|NCT00847717|PROCEDURE|Selective neck dissection|Level IIb preserving neck dissection
41282064|NCT00847717|PROCEDURE|Conventional Neck dissection|Conventional neck dissection (MRND type III or Supraomohyoid)
41282065|NCT03306147|BEHAVIORAL|Pain education with follow up encounters|Patient pain review, counseling and education by pharmacists and physicians in follow up encounters
40940369|NCT04026581|BEHAVIORAL|Training and treatment|Participants receive training on the selected SGD followed by monthly treatment sessions from the SLP who monitors performance. In some cases the participants' SGD will be an AAC system with BCI access. In this case training will also include an identified system support person. Use of the SGD is monitored on a monthly basis through home visits and/or tele-practice sessions, when requested. Technical support for the SGD is provided on an as needed basis or when requested by the participant or support person.
40940370|NCT04640181|DRUG|Enoxaparin|Subcutaneous enoxaparin While hospitalized only.
40940371|NCT04640181|DRUG|Rivaroxaban|Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.
40940372|NCT06231836|DEVICE|High flow nasal cannula (HFNO)|O2 is administered by HFNO with flow 70L/min and the FiO2 is set at 40%,
40940373|NCT06231836|DEVICE|nasal cannula|O2 is administered by nasal cannula at 6L/min
40940374|NCT00560885|DEVICE|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
40940375|NCT03682575|OTHER|Enrollment|All infants whose families consent will be enrolled and will all receive the same treatment which included measurements of work of breathing.
40940376|NCT02369562|PROCEDURE|Evaluation of the failure rate of dental implants|Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
40940377|NCT03599635|DRUG|liposomal bupivacaine|Experimental
40940378|NCT03599635|DRUG|Bupivacaine|Active Comparator
40940379|NCT03625206|BEHAVIORAL|Cognitive bias modification training|These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways
40940380|NCT03625206|BEHAVIORAL|Control training|These exercises are matched to the task demands of the modules of cognitive bias modification training
41131966|NCT02227706|BIOLOGICAL|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
41282066|NCT02189265|OTHER|Smoke-free legislation|The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
41282067|NCT04711681|BEHAVIORAL|Positive Behavior Supports in Middle Schools|"2-4 days SWPBS training for school team and 1-2 days for whole staff training (SW and Classroom Management). Use staff release days for whole staff training.~Schedule up to four meetings with the PBS team~1K/School is to fund part or whole day training meeting with PBS team Schedule whole staff training per school year staff release days Enhanced Intervention Family Support Universal -- parent education and invitation Selective -- Family Check up School Intervention ACT for teachers PBS Calendar Kernel Recipes (Treatment) Reminder Emails Brochures Weekly phone contact (Treatment)"
41131967|NCT02227706|DEVICE|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
40940381|NCT00679744|DRUG|Pyrimethamine|Pyrimethamine will be given PO once daily for 8 consecutive weeks.
40940382|NCT03680430|RADIATION|Adaptive radiation therapy|Patients will be treated by preoperative or definitive radiotherapy for a limb STS, using an intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7 consecutive weeks. The total dose delivered will be of 50 Gray (preoperative RadioTherapy), or 60 to 70 Gray (exclusive RadioTherapy).
40940383|NCT00586729|DEVICE|Vashe|Antimicrobial irrigant
40940384|NCT00586729|DRUG|Mafenide acetate|Antimicrobial solution
40940385|NCT00145171|DRUG|apomorphine HCl injection|
40940386|NCT02314234|DRUG|sugammadex (Bridion)|single dose of sugammadex at skin incision
40940387|NCT02680899|BEHAVIORAL|Curricular Intervention|The intervention is a novel grades 7 and 8 InSciEd Out curriculum in mental health and addiction called My Mind, My Body.
40940388|NCT03251664|DIETARY_SUPPLEMENT|Food groups consumed|
40940389|NCT05332691|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
40940390|NCT01461278|DEVICE|iStent supra|Cataract surgery and implantation of one iStent supra
40940391|NCT01461278|PROCEDURE|Cataract surgery|Cataract surgery alone
41282068|NCT04711681|BEHAVIORAL|Positive Behavior Supports in Middle Schools|1 days PBS training for school team and informational presentation to whole staff Attend 2-3 PBS team meetings (coaching) Data-based feedback (limited)
41282069|NCT04752280|RADIATION|Proton irradiation|proton irradiation applied as follows: 30 x 2 Gy(RBE) 33 x 1,8 Gy (RBE), or 15 x 2,67 Gy (RBE)
40940392|NCT05596396|BEHAVIORAL|LifeHack|Participants assigned to LifeHack will follow a six week-guided online intervention with a fixed structure where the themes are delivered in a predefined order, and the contents get unlocked sequentially. The first mandatory module is the introduction module which also functions as a goal-setting module. Following this, students complete one mandatory module per week (and the optional modules if they choose to do so) delivered sequentially, starting with the theme of mood, studies, social life and finally, self-esteem. Students complete the themes one by one and the consecutive themes (and modules) are unlocked only after completing the main module of the assigned theme.
40940393|NCT05596396|BEHAVIORAL|LifeHack-C|Participants assigned to LifeHack-C will receive the same guided online intervention, but they can choose what theme they would like to start with, when to work on it and how many modules they wish to complete. After completing the introduction module, the participants will be advised to complete two modules per week and at least four in total. Therefore, the program's duration will be approximately two and six weeks. However, participants can follow the program at their own pace.
40940394|NCT00620789|DRUG|Escitalopram + CBT-I|"* Escitalopram, 10 mg daily for the duration of the study (6 months)~* CBT-I, four biweekly sessions during eight week Treatment phase."
41282070|NCT04752280|RADIATION|Photon irradiation|proton irradiation applied as follows: 30 x 2 Gy 33 x 1,8 Gy, or 15 x 2,67 Gy
41282071|NCT06411444|DEVICE|Grape Design Nasal Stent|Grape Design Nasal Stent
41282072|NCT05085210|DEVICE|transcranial random noise stimulation (tRNS)|noninvasive current stimulation for 20 - 30 minutes stimulation on visual cortex (electrodes on surface of scalp, positioned O1 / O2 on EEG cap). 1mA max amplitude noise stimulation, frequencies from 100 Hz - 640 Hz.
41282073|NCT05085210|BEHAVIORAL|Computer Based Visual Training|Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center of screen during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
41282074|NCT05085210|DEVICE|Sham stimulation|20-30 minutes sham stimulation on visual cortex. Participants receive identical setup to real stimulation. The device provides a short ramp on period to simulate the feeling of real stimulation at the start but no current is delivered otherwise.
41282075|NCT05085210|BEHAVIORAL|Virtual Reality Based Visual Training|• Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center point within the VR headset during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
41282076|NCT02260011|DRUG|Ipratropium bromide HFA-134a inhalation aerosol|
40940395|NCT00620789|BEHAVIORAL|CBT-I plus placebo antidepressant medication|"* CBT-I, 4 biweekly sessions, eight week Treatment phase.~* Placebo,daily for duration of study(6 months)."
40940396|NCT00620789|DRUG|Escitalopram|"* Escitalopram, 10 mg daily for the duration of the study (6 months)~* SH, four biweekly sessions during eight week Treatment phase"
41282077|NCT02260011|DRUG|Atrovent® CFC inhalation aerosol|
41282078|NCT02260011|DRUG|Placebo|
40940397|NCT03548090|OTHER|Skateboard exercise at an incline angle of 0 degrees and 50% body weight|Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
41282079|NCT03394222|DRUG|preoperative budesonide inhalation|
41282080|NCT03394222|DRUG|preoperative normal saline inhalation|
41282081|NCT02850198|DEVICE|scalp electroacupuncture|
41282082|NCT02850198|DEVICE|sham scalp electroacupuncture|
41282083|NCT05157633|OTHER|Controls|questionnaire food scale: HME data collection of food survey
41282084|NCT02053974|DRUG|Spironolactone|Spironolactone
41282085|NCT02053974|OTHER|Placebo|Placebo
41282086|NCT01598181|DEVICE|tDCS NeuroConn DC-stimulator plus|Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
41451306|NCT01767753|DEVICE|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
40744398|NCT05563974|OTHER|Family led postnatal care|"Family-led Postnatal Care-FPNC A midwife involves families and uses a visual checklist to assess and counsel. The midwife then gives families the checklist and guides them how to retrieve a home care kit that has a blood pressure machine, infrared thermometer, and health education booklet.~At home, families assess the health of postnatal mothers and newborns for 6 days, and then return the completed checklist and home care kit to the community location."
41282087|NCT01598181|DEVICE|sham tDCS|similar montage and time as active. Stimulation fades out after 20 sec.
41131968|NCT02893969|BEHAVIORAL|Physical Activity|After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
41131969|NCT02893969|BEHAVIORAL|Rest|Complete physical rest until asymptomatic.
40940398|NCT03548090|OTHER|Skateboard exercise at an incline angle of 5 degrees and 50% body weight|Participants will stand on a specified incline angle (5 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
41131970|NCT01747304|DEVICE|DXA Se femur scans (previously called IVA femur)|Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
41131971|NCT01887275|DEVICE|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
41131972|NCT01887275|DRUG|conventional interferon-α|Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
41131973|NCT03035942|DRUG|Dexamethasone|Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
41131974|NCT03035942|DRUG|Ondansetron|Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
41131975|NCT03035942|DRUG|Saline|Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
41131976|NCT05292521|OTHER|Best Practice|Receive usual care
41131977|NCT05292521|OTHER|Informational Intervention|Receive QOL fact sheet
41131978|NCT05292521|OTHER|Questionnaire Administration|Ancillary studies
41131979|NCT04909333|DRUG|Exenatide|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously."
41451307|NCT03406845|BEHAVIORAL|Chair-side mindfulness intervention|"Tailored mindfulness intervention to chair-side type, based from Mindfulness Based Cognitive Therapy (MBCT).~Health promotion based on the Health Enhancement Program (HEP)."
41451308|NCT02193022|DRUG|Miltefosine|
41451309|NCT02462837|DRUG|Mirabegron|
41451310|NCT02462837|DRUG|Placebo|
41451311|NCT02557464|BEHAVIORAL|An eye tracking experiment|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
41282088|NCT04648371|OTHER|Cognitive Remediation and Transcranial Direct Current Stimulation|"Cognitive Remediation (CR) is a well-established psychosocial group intervention that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.~Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation method that can be safely administered to awake outpatients. It does not require general anesthesia or surgical implantation. It utilizes low intensity electrical current (e.g., 2 mA) either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode."
41282089|NCT04878783|DIAGNOSTIC_TEST|CT scan|Patients undergoing CT scan staging for gastric and EJ junction cancer + perioperative chemotherapy (FLOT regimen) , CT scan re-staging and radical gastrectomy or esophagogastrectomy will be enrolled in the study
41282090|NCT03890055|DRUG|Anlotinib Hydrochloride|Best supportive care
41282091|NCT03007277|OTHER|PANJO|PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
41282092|NCT04387279|OTHER|Interview|Surveys on medical use patterns and patient's perceptions about COVID-19
41282093|NCT00002523|DRUG|fluorouracil|
41282094|NCT00002523|DRUG|leucovorin calcium|
41282095|NCT00002523|PROCEDURE|conventional surgery|
41282096|NCT00002523|RADIATION|radiation therapy|
40940399|NCT03548090|OTHER|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
41282097|NCT05434546|DRUG|Sepranolone|Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
41282098|NCT04773769|DIETARY_SUPPLEMENT|Tea Made of Graviola Leaves|"Graviola leaves will be supplied to the patient with instructions on how to prepare the tea which will consist of 10 guanabana leaves which the patient will boil in 1 liter of water for 3 minutes. Once boiled, the formulation will be stores in the refrigerator and once cool enough the patient will start drinking 100 cc two times per day.~The Treatment Period begins with Cycle 1 Day 1 dosing. Patients will take the tea continuously during a 28-day cycles, until there is an indication for treatment change based on response assessment."
41282099|NCT05595525|DEVICE|1064NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
41282100|NCT05595525|DEVICE|755NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
41282101|NCT02609399|DRUG|Oseltamivir|Oral
41282102|NCT02609399|DRUG|Peramivir|"IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician."
41282103|NCT02225886|DRUG|Ascorbic Acid|300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
41451312|NCT02557464|BEHAVIORAL|A neuropsychological evaluation|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
41451313|NCT04566497|OTHER|No stress testing|No stress testing during the patient follow up (up to 48 months) if the patient remains asymptomatic
41282104|NCT00364793|DRUG|Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)|"Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)"
41282105|NCT05127486|DRUG|Galcanezumab|Administered SC.
41282106|NCT05127486|DRUG|Rimegepant|Administered orally.
41282107|NCT05127486|DRUG|Placebo|Administered orally.
40940400|NCT03548090|OTHER|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (90%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
40940401|NCT03548090|OTHER|Control 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The control group will perform three sets of ten repetitions of the following 4 exercises, for a total of 120 repetitions: 1) standing hip abduction against green theraband resistance with upper extremity support, 2) sit to stands from chair with no upper extremity support, 3) bilateral calf raises with upper extremity support, and 4) right and left weight shifting exercises using a wobble board with upper extremity support available if needed.
41282108|NCT05127486|DRUG|Placebo|Administered SC.
41282109|NCT04252417|DRUG|MD1003|Single oral dose administration of MD1003 at Day 1
41282110|NCT04614792|DEVICE|Transcranial direct current stimulation|Non-invasive brain stimulation or neuromodulation.
41282111|NCT05878509|OTHER|conducting questionnaires|The patients were administered TSK, Pain Catastrophizing Scale (PCS), Beck Anxiety Inventory (BAI) by face to face interview technique.
41282112|NCT05878509|OTHER|assesment of the severity and pain|The Modified Hand Injury Scoring System (MHISS) to determine the severity of the injury, and Visual Analog Scale (VAS) to evaluate perceived pain levels were used.
41282113|NCT05835401|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (800mg). Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
41282114|NCT05835401|DIETARY_SUPPLEMENT|Beetroot juice depleted in nitrate|The participant will intake beetroot juice depleted in NO3. Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
41282115|NCT03921112|DEVICE|lung ultrasound|bedside lung ultrasound will be done for patients
41282116|NCT03921112|OTHER|routine tools|chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
41282117|NCT00003956|DRUG|fluorouracil|
41131980|NCT04909333|DRUG|0.9% saline solution|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously."
41282118|NCT00003956|DRUG|leucovorin calcium|
41282119|NCT00003956|DRUG|lonafarnib|
41282120|NCT01152138|DEVICE|Open cells stent|Cobalt Chromium Stent with open cell design
41282121|NCT01152138|DEVICE|Closed Cells Stent|Cobalt Chromium stent with closed cell design
41451314|NCT04566497|PROCEDURE|stress testing|Systematic annual stress testing during the patient follow up (up to 48 months)
41451315|NCT02427919|DRUG|G-CSF|Comparison of the effect of G-CSF use
41282122|NCT05888259|OTHER|foot insole|The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.
40940402|NCT03548090|OTHER|Experimental 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
41282123|NCT00551707|DRUG|CRx-102 (2.7/180)|prednisolone 2.7 mg plus dipyridamole 180 mg
41282124|NCT00551707|DRUG|prednisolone|prednisolone (2.7 mg)
40940403|NCT03548090|OTHER|Over-ground multi-directional gait training|In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
40940404|NCT03548090|OTHER|Home exercise|Home exercise consists of three sets of ten repetitions of the following three exercises to be performed on non-therapy days over the four weeks of phase 3: 1) sit to stands from chair with no upper extremity support, 2) bilateral calf raises with hand support, and 3) resisted side stepping to the non-paretic side using a green theraband with upper extremity support.
41282125|NCT00551707|DRUG|dipyridamole|dipyridamole 360 mg
41282126|NCT00551707|DRUG|placebo|placebo
41282127|NCT00551707|DRUG|CRx-102 (2.7/360)|Prednisolone 2.7 mg plus Dipyridamole 360 mg
41282128|NCT01658800|BIOLOGICAL|VAX161C vaccine|Recombinant H5 influenza vaccine, VAX161C
41282129|NCT02957773|BEHAVIORAL|Qigong and art activities|Participants join a 90-minute session of integrated Qigong and art activity consisting of 30 minutes Qigong followed by 60 minutes art activity.
41282130|NCT02957773|BEHAVIORAL|Art activities|Participants join a 90-minute session that consists of 60-minute art activities followed by 30 minutes daily activities.
41282131|NCT02957773|BEHAVIORAL|Qigong|Participants join a 90-minute session that consists of 30-minutes Qigong exercise followed by 60 minutes daily activities (watching television, reading or sitting together).
40940405|NCT00292318|BEHAVIORAL|Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study|Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
40940406|NCT00292318|BEHAVIORAL|control group|Medical counseling and ano-sphinctal exercises.
40940407|NCT03843112|DRUG|Vivag Plus|Contains two lactobacilli strains; l. gasseri and l. rhamnosus
41282132|NCT02957773|BEHAVIORAL|Daily activities|Participants do their daily activities routine for 90-minutes, such as watching television, reading and sitting together or participants can do free individual activities on their own.
41282133|NCT01826669|PROCEDURE|Stretching|Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
41282134|NCT02680288|DRUG|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
41282135|NCT02680288|DRUG|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
40756628|NCT02739880|DEVICE|DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)|"Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule~The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .~Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total."
41282136|NCT02680288|OTHER|Oral Placebo|Oral inert treatment
40756629|NCT03814629|DRUG|Weifuchun|The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
40756630|NCT00338000|DRUG|Epoetin alfa|
41282137|NCT00023348|DRUG|Isoniazid|
40756631|NCT02317042|DEVICE|Juno|Juno device set to ST mode with participant's current therapy settings.
41282138|NCT00023348|DRUG|Rifabutin|
41282139|NCT00789126|DRUG|VX-509|
40756632|NCT02317042|DEVICE|Juno|Juno device set to AutoEPAP iVAPS mode.
40756633|NCT02317042|DEVICE|Juno|Juno device set to Fixed EPAP iVAPS mode.
40756634|NCT02536339|DRUG|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
40756635|NCT02536339|DRUG|Trastuzumab|Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
40756636|NCT04934683|PROCEDURE|Routine blood pressure control|Routine blood pressure control.
41451316|NCT04613167|DRUG|Alirocumab|The first group will receive alirocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
40756637|NCT04934683|PROCEDURE|Tight blood pressure control|Tight blood pressure control.
40940408|NCT03843112|DRUG|Placebo - Cap|Vaginal supplements
40940409|NCT03718182|DIETARY_SUPPLEMENT|Cholecalciferol|vitamin D3 daily oral supplement
40756638|NCT04934683|DRUG|Etomidate|Anesthetic induction with etomidate.
40756639|NCT04934683|DRUG|Propofol|Anesthetic induction with propofol.
40756640|NCT00495781|PROCEDURE|%-hypo (laboratory parameter, functional iron deficiency)|
40756641|NCT00495781|PROCEDURE|CHr (laboratory parameter, functional iron deficiency)|
40756642|NCT00495781|PROCEDURE|RET-HE (laboratory parameter, functional iron deficiency)|
40756643|NCT03851666|DIETARY_SUPPLEMENT|12 weeks daily administration Cereal 1|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
40940410|NCT01812772|DEVICE|Double J-stent with a long tether|Patients will receive a double-J stent placement with a long tether following ureteroscopy.
40940411|NCT01812772|DEVICE|Double J-stent without a long tether|Patients will receive a double-J stent placement without a long tether following ureteroscopy.
40940412|NCT01843595|BEHAVIORAL|REFIT Intervention|The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
40940413|NCT01721070|DRUG|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
40940414|NCT01721070|DRUG|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
40940415|NCT05223335|DRUG|Clopidogrel|75 mg/day
40940416|NCT05223335|DRUG|Prasugrel|60 mg bolus then 10 mg daily
40940417|NCT05223335|DRUG|Tricagrelor|180 mg bolus then 90 mg twice daily
41282140|NCT02375776|OTHER|"CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
41282141|NCT04168086|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
41282142|NCT04168086|OTHER|Sham|The investigators will simulate focused ultrasound stimulation similar to the experimental groups but without stimulation.
41282143|NCT05809310|PROCEDURE|Percutaneous intervention (stent) for PA stenosis|Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries
41282144|NCT00650923|DRUG|ziv-aflibercept|Given IV
41282145|NCT00650923|PROCEDURE|radiation therapy|Undergo RT
41282146|NCT00650923|DRUG|temozolomide|Given PO
41451317|NCT04613167|DRUG|Evolocumab|The second group will receive evolocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
40940418|NCT03301974|PROCEDURE|conjunctival autograft with fibrin glue|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).
40756644|NCT03851666|DIETARY_SUPPLEMENT|12 weeks daily administration Cereal 2|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
40756645|NCT03851666|OTHER|12 weeks daily administration Placebo|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of placebo.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation."
40756646|NCT06296030|BEHAVIORAL|POOF ACT program|The goal of this study is to test this culturally tailored intervention (POOF) against classic ACT, to discover if POOF does better at decreasing race-based trauma in African Americans.Guided by the cultural humility framework and social determinants of health model, we examine POOF, a culturally-tailored ACT model for use with anxious African Americans. The POOF approach builds on research on ACT for the general population, an evidence-based intervention, by tailoring the language of ACT while retaining the fidelity of the ACT model. Our hypotheses examine acceptability and attitudes toward treatment, treatment outcomes for psychological symptoms (i.e., anxiety) and an ACT-related outcome (i.e., psychological flexibility), and a possible underlying mechanism of change (i.e., race-based stress).
40756647|NCT06296030|BEHAVIORAL|Classic ACT program|This protocol is for a classic, non-adapted ACT intervention.
40756648|NCT02226653|DRUG|Evacetrapib|Administered orally
40756649|NCT03582397|DEVICE|Virtual Reality Mirror Therapy|Virtual reality mirror therapy (WiseMind) developed by Realiteer and delivered via Oculus Rift virtual reality platform.
40940419|NCT03301974|PROCEDURE|sutured conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).
40940420|NCT03301974|PROCEDURE|sutureless and glue-free conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)
40940421|NCT04526327|OTHER|exercise|the combination of aerobic and resistive exercise, three time a week
40940422|NCT03388515|BIOLOGICAL|SSS11|IV infusion for 60 min.
40940423|NCT03388515|OTHER|placebo|IV infusion for 60 min.
40940424|NCT00600535|DRUG|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
40940425|NCT00600535|DRUG|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
40940426|NCT00600535|DRUG|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
40940427|NCT00600535|DRUG|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
40940428|NCT00600535|DRUG|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
41282147|NCT00650923|PROCEDURE|pharmacological study|Correlative studies
41282148|NCT00650923|PROCEDURE|laboratory biomarker analysis|Correlative studies
41282149|NCT01144754|DRUG|Rituximab|Calculated per patient
40940429|NCT00600535|DRUG|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
41282150|NCT01091129|DEVICE|miraDry System (treatment with energy)|Treatment with microwave energy delivery device as specified by manufacturer's instructions
41282151|NCT03438422|DIETARY_SUPPLEMENT|Pollen extract|1 tablet a day
40940430|NCT00600535|DRUG|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
40940431|NCT04005170|DRUG|Toripalimab|Patients received toripalimab 240 mg on days 1 and 22 during radiotherapy followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
40940432|NCT04005170|DRUG|Paclitaxel/Cisplatin|Patients received 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 during radiotherapy.
40940433|NCT04005170|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
40940434|NCT05439642|OTHER|Evaluation of health related quality of life|Evaluation of health related quality of life of boys with hemophilia with the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool and the Pediatric Inventory of Quality of Life
40940435|NCT04365257|DRUG|Prazosin|Participants in this arm will receive the study drug as outlined in the arm description.
40940436|NCT04365257|OTHER|Standard of care|Participants in this arm will receive standard of care.
40940437|NCT05242523|OTHER|Bergamot scent|The scent of bergamot is fruity and citrusy, with floral hints and spice notes.
40940438|NCT05242523|OTHER|Natural wood scent|Wood notes tend to be rich and warm, often forming the base of a scent due to their aromatic weight.
40940439|NCT01600742|DRUG|Vorinostat|"Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
40940440|NCT01600742|DRUG|Placebo|"Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
40940441|NCT04107259|DIAGNOSTIC_TEST|Blood sample|Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.
40940442|NCT04343729|DRUG|Methylprednisolone Sodium Succinate|injectable solution at a dose of 0.5mg/kg
40940443|NCT04343729|DRUG|Placebo solution|injectable saline solution
40940444|NCT00364130|DEVICE|Low magnitude mechanical stimulus|10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
40940445|NCT00364130|DEVICE|Placebo (inactive) low magnitude mechanical stimulus|10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
40940446|NCT02686528|OTHER|Hip Precautions|Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
40940447|NCT02686528|OTHER|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
40940448|NCT00757107|DEVICE|Taperloc Microplasty|primary total hip arthroplasty
40940449|NCT00757107|DEVICE|Taperloc standard|primary total hip arthroplasty
40940450|NCT02028871|DRUG|Intranasal Insulin|
41266986|NCT05222321|OTHER|Sensory-Play Based (SenPlay) Intervention|SenPlay is a sensory-play based intervention that includes deep tactile pressure, vestibular and proprioceptive input as a therapeutic medium to facilitate optimal arousal through sensory-play based activities such as pushing, pulling, climbing, jumping, crashing, and swinging. These activities are designed to facilitate changes in the child's arousal through providing sensory input to ensure the child is reaching a threshold of moderate to vigorous physical activity. Completed at three time points, once weekly for three weeks.
41282152|NCT00346515|DEVICE|FiberNet Emboli Protection System|
40940451|NCT02028871|DRUG|Placebo|
40940456|NCT01672736|DRUG|ASP7487, Velcade, Dexamethasone|ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
40940457|NCT00138411|DRUG|Ciprofloxacin 500 mg|
40940458|NCT00138411|DRUG|ETI-204 (Anthim)|
40940459|NCT02080858|DRUG|Ticagrelor + Apixaban + ASA|
40940460|NCT02080858|DRUG|Ticagrelor + Apixaban|
40940461|NCT04558281|DRUG|Active ropivacaine 0.3% erector spinae plane perineural administration|Ropivacaine 0.3% administration via an erector spinae plane perineural catheter
40940462|NCT04558281|DRUG|Placebo erector spinae plane perineural administration|Normal saline administration via an erector spinae plane perineural catheter
40940463|NCT04274283|OTHER|Matched Tumour and Blood Sample - Research Pathway|"For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples.~Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites"
41266987|NCT05222321|OTHER|Spontaneous, Free Play|Participant engages in spontaneous, free play with the investigator supervising only for safety within the sensorimotor gym for 15 minutes. Completed at three time points, once weekly for three weeks.
41266988|NCT01286857|DEVICE|External Suction Interface and a Silicon Film|Evaluate the function of a new silicon cover film and an on-top suction device to be used in a NPWT system in the treatment of acute and chronic wounds.
41266989|NCT04268719|DIAGNOSTIC_TEST|wireless pH capsule recording|wireless pH capsule recording for up to 96 hours
41266990|NCT00124345|DEVICE|MR730|humidity measurement inside the helmet by a capacitative hygrometer and evaluation of patients' comfort
41266991|NCT05079789|DRUG|Amiloride|Treatment with amiloride, start dose 5 mg
41266992|NCT05079789|DRUG|Furosemide|Treatment with furosemide, start dose 40 mg
41266993|NCT06126640|DRUG|SHR-A1811|Lyophilized powder injection, 100mg / bottle, intravenous drip
41266994|NCT06126640|DRUG|Trastuzumab Emtansine|Lyophilized powder injection, 160mg / bottle, 100mg / bottle, intravenous drip
41266995|NCT04014829|DIAGNOSTIC_TEST|Pain-Pressure Threshold|Performed on bilateral trapezius muscles. Pressure will be applied at 90 degrees downward with an algometer, with the speed of pressure increase approximately 1kgf/s. Upon the sensation of pain, the patient will vocalize or raise her hand to terminate the test, and the highest reading will be recorded (up to maximum 6kgf). If two values are recorded within 0.2kgf of each other, the mean value will be recorded. If two values are greater than 0.2kgf of each other, a third test will be performed and the mean obtained.
41266996|NCT04014829|DIAGNOSTIC_TEST|Mechanical Temporal Summation|"Pinprick hyperalgesia will be evoked using a Von Frey filament, applied to the volar aspect of the dominant forearm. Participants will report using the numerical rating scale the intensity of pain from the first stimulus. Subsequently, ten repetitive stimuli one second apart will be applied with the same filament within an area of 1cm diameter of the same forearm. Subjects will report the rate the pain intensity of the tenth stimulus. The magnitude of MTS is calculated as the difference between the last to the first pain scores. The investigators will classify the participants according to evoked MTS if the last stimulus is rated higher than the first, or no MTS if the last stimulus is rated equal or lower than the first. The research team administering the test will follow a set script."
41266997|NCT04014829|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Standardized questionnaire to determine the level of anxiety and depression.
41266998|NCT04014829|DIAGNOSTIC_TEST|Pain Catastrophizing Scale|Standardized questionnaire to determine the level of pain catastrophizing.
41266999|NCT04014829|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization.
41267000|NCT04014829|DIAGNOSTIC_TEST|Fear-Avoidance Component Score|Standardized questionnaire to determine the level of fear and avoidance.
41267001|NCT04014829|DIAGNOSTIC_TEST|EQ-5D|Standardized questionnaire to assess generic health-related quality of life.
41267002|NCT04014829|DIAGNOSTIC_TEST|heart rate variability|Heart rate variability will be determined from the R-to-R intervals obtained from a 5-minute ECG recording.
41267003|NCT04014829|DIAGNOSTIC_TEST|Anxiety, anticipated pain, anticipated analgesia|Preoperative anxiety (0 to 100), anticipated pain (0 to 100), and anticipated analgesia requirement (0 to 5).
41451318|NCT04613167|DRUG|Control group|The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
40940464|NCT04274283|OTHER|Matched Tumour and Blood Sample - NHS GMS pathway|Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.
40940465|NCT02854176|PROCEDURE|Somatosensory electrical stimulation|
40940466|NCT02854176|PROCEDURE|Control|
40940467|NCT05289531|PROCEDURE|Rectal Resection Patients|Patients who have had low anterior resection of rectum was categorized for their quality of life related to surgery
41267004|NCT04014829|DIAGNOSTIC_TEST|State-trait anxiety inventory|Standardized questionnaire to assess anxiety.
40940468|NCT02547285|OTHER|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
40940469|NCT05977361|PROCEDURE|Resiting Epidural Catheter|After a UDP has occurred, epidural catheter will be re-sited in a different intervertebral space. Analgesia will be then maintained according to internal protocol, using PIEB (Programmed Intermittent Epidural Bolus) system. Catheter will be left in place for the first 24-36 hours.
41267005|NCT04014829|DIAGNOSTIC_TEST|Beck's Depression Inventory|Standardized questionnaire to assess depressive symptoms.
41267006|NCT01279057|DRUG|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
41267007|NCT01279057|DRUG|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
41267008|NCT01279057|DRUG|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
41267009|NCT01944085|DRUG|Acetaminophen|Syrup
41267010|NCT01944085|DRUG|Ibuprofen|Syrup
41267011|NCT01944085|OTHER|Vitamin C|Syrup
41267012|NCT05451719|DRUG|Fruquintinib Plus Capecitabine|Fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W). Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
41267013|NCT05451719|DRUG|Capecitabine|Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
41267014|NCT04590001|DEVICE|MobiusHD|The MobiusHD device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
41267015|NCT02421250|DEVICE|Radical-7 Noninvasive Hgb Monitor|
40940470|NCT05977361|PROCEDURE|Intrathecal Catheter Placement|After a UDP has occurred, an intrathecal catheter will be placed through the dural tap. Analgesia will be then maintained according to internal protocol, using PISB (Programmed Intermittent Subarachnoid Bolus) system. Catheter will be left in place for the first 24-36 hours. During this time, a continuous infusion of sterile saline at a rate of 2 mL/h will be maintained. Before removal, an additional bolus of 10 mL of sterile saline will be administered in the intrathecal catheter.
40940471|NCT04682873|DRUG|Enisamium Iodide|"Capsule formulations of the active product (enisamium iodide 500 mg; Investigational medicinal product 1 \[IMP-1\]).~1 capsule Amizon® Max contains: enisamium iodide 500 mg.~Amizon® Max (active ingredient: enisamium iodide; IMP-1 will be administered as 1 capsule 4 times a day, every 6 hours (total dose 2,000 mg per day). Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-1 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
40940472|NCT04682873|DRUG|Placebo|"Capsule formulations of the reference product placebo Amizon® Max (IMP-2), will be identical in appearance (size, shape, and color), taste, and smell as the active formulation capsule.~1 capsule placebo Amizon® Max contains: placebo (no active substance).~Amizon® Max placebo (IMP-2), will be administered as 1 capsule 4 times a day every 6 hours. Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-2 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
40940473|NCT00597701|DRUG|Baclofen|Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
40940474|NCT00597701|DRUG|Placebo|Placebo
41282153|NCT04978623|OTHER|high frequency ultrasound|high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome
41282154|NCT01548638|DRUG|Galantamine ER|"The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER."
41282155|NCT03771625|RADIATION|radiotherapy|whole brain with/without spinal cord
41282156|NCT01896232|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
41282157|NCT01896232|DRUG|Cinacalcet|Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
41282158|NCT01896232|DRUG|Oral Placebo|Administered orally once a day.
41282159|NCT01896232|DRUG|Intravenous Placebo|Administered intravenously (IV) three times per week.
41282160|NCT03663244|BEHAVIORAL|MBSR|Standardised stress reduction programme with established efficacy
41282161|NCT03663244|BEHAVIORAL|LSR|Existing stress reduction programme in a Danish municipality
41282162|NCT02594592|OTHER|questionaire|Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
41282163|NCT06084780|PROCEDURE|Intestinal, Multivisceral or Modified Multivisceral Transplantation|"Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for:~* Isolated small bowel transplant (SBT): transplantation of the donor small intestine~* Modified multivisceral tran I lant (MMVT): transplantation of the donor pancreas and small intestine, with or without stomach~* Multivisceral transplant (MVT): transplantation of the donor pancreas, small intestine, and liver, with or without stomach"
41282164|NCT06084780|DRUG|Alemtuzumab|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
41282165|NCT06084780|DRUG|Tacrolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
41282166|NCT06084780|DRUG|Sirolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
41282167|NCT03285529|DEVICE|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
41282168|NCT03285529|DEVICE|VICRYL|Vicryl #1
40940475|NCT00597701|DRUG|Lorazepam|"Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms."
40940476|NCT04601337|PROCEDURE|Infrared Neural Stimulation|We will stimulate nerves identified for transfer or grafting over a range of simulation parameters (pulse width, spot size, energy per unit area, etc) to determine the stimulation threshold. Only portions of the nerve that are no longer functionally required will be stimulated optically. Successful INS events will be determined by visual muscle contractions. Stimulation thresholds will be determined by fitting the data to a cumulative distribution function. Stimulation sites on the nerve will be harvested and histologically examined for evidence of INS-induced damage.
40940477|NCT04948567|OTHER|split-dose of Magnesium Sulfate solution|purgative for bowel preparation
40940478|NCT04948567|OTHER|split-dose of PEG|purgative for bowel preparation
40940479|NCT02193451|PROCEDURE|Urodynamics|Diagnostic test for urinary storage and voiding function
40940480|NCT02193451|PROCEDURE|Usual care|
40940481|NCT00004637|DRUG|Vitamin E|
40940482|NCT06329843|DEVICE|Picterus Jaundice Pro (JP)|"Picterus Jaundice Pro photos will be obtained of enrolled subjects each time the patient has a serum bilirubin level obtained. Up to five paired measurements will be obtained per enrolled subject. The study nurse will place the proprietary calibration card over the subject's sternum and take six Picterus Jaundice Pro photos using a study iPhone within one hour of the serum bilirubin draw. This process takes less than one minute. After the study photos are obtained, the study nurse will record the serum and Picterus Jaundice Pro values in the data-recording log.~In the event an enrolled infant requires phototherapy, a light occlusive adhesive patch will be placed over the center of the chest before phototherapy initiation. When a serum bilirubin level is obtained, the research nurse will remove the patch for a brief moment to take Picterus Jaundice Pro pictures (within one hour of the serum value draw)."
40940483|NCT03753490|OTHER|ABC score guided therapy|In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.
40940484|NCT03753490|OTHER|Standard care|In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.
40940485|NCT03693170|DRUG|encorafenib|300 mg administered orally once daily (QD)
40940486|NCT03693170|DRUG|Binimetinib|Binimetinib 45 mg administered orally twice daily (BID)
40940487|NCT03693170|DRUG|Cetuximab|"Standard of care for the 28 first weeks(\*) and then every 2 weeks (\*\*) :~(\*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (\*\*) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward.~Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic."
40940488|NCT04327310|DRUG|Meplazumab for Injection|humanized mAb against CD147
40940489|NCT04327310|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
40940490|NCT05465746|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring (ABPM)|Using a WatchBPO3 AFIB device (Microlife) placed around the left upper arm, BP measurements will be recorded every twenty minutes during the day and every thirty minutes at night, over a twenty-four-hour period. The device will automatically calculate the BP and the twenty-four-hour average BP, day, night, and cumulative BP load
40940491|NCT05465746|DIAGNOSTIC_TEST|Three-dimensional transthoracic echocardiography|Using an EPIQ CVx (Philips) echocardiograph with an ultrasound sector transducer, 3D-TTE will be performed to assess the LVM index.
40940492|NCT04087928|DEVICE|FMV_flex|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to flexor muscles of the upper limb (brachial biceps and carpal flexors).
40940493|NCT04087928|DEVICE|FMV_ext|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to extensors muscles of the upper limb (triceps brachial and carpus extensors).
40940494|NCT00700570|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle.
40940495|NCT00700570|DRUG|capecitabine [Xeloda]|1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
40940496|NCT00700570|DRUG|oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
40940497|NCT05989347|DRUG|Dapagliflozin 10mg|10 mg tablets for oral administration daily throughout chemotherapy treatment
41267016|NCT02520986|DEVICE|Carbon dioxide Laser ablation|surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage
41267017|NCT02520986|DEVICE|Electrocoagulation|surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage
41267018|NCT01356004|DRUG|live attenuated chicken pox vaccine|Each immunizing dose was given subcutaneously (SC) in the form of 0.5 ml reconstituted vaccine which contains not less than 1033 plaque forming units (PFU) of the attenuated varicella-zoster-virus (VZV), which meets the World Health Organization (WHO) requirements for biological substances and for varicella vaccines. Doses were given 3 weeks apart for a total duration of 12 weeks (3 months).
41267019|NCT01356004|DRUG|saline, efficacy|4 doses of SC saline (0.5 ml) -as a placebo- in the same pattern as group A patients
41282169|NCT03932955|BIOLOGICAL|MC-19PD1 CAR-T cells|T cells purified from the PBMC of subjects, transduced with anti-CD19 CAR and PD1/CD28 chimera lentiviral vector, expanded in vitro for future administration.
41282170|NCT00367809|BEHAVIORAL|Mindfulness-Based Stress Reduction (MSBR)|Mindfulness-Based Stress Reduction (MBSR) is the intervention of primary interest. It is a psycho-educational program of 8-weekly classes, 2.5 hours long taught by a trained instructor. Over the course of the program participants receive training in several formal meditation techniques: a body-scan meditation, sitting meditation, walking meditation and mindful Hatha yoga that involves simple stretches and movements. Participants are requested to practice meditation at home and to integrate informal mindfulness practices into their daily lives. The content of MBSR is described in the book Full Catastrophe Living by Jon Kabat-Zinn.
41282171|NCT00367809|BEHAVIORAL|Health Education (HE)|The active control condition was a peer-led chronic disease self-management program comprised of 8 weekly, 2.5 hour meetings. Led by trained peer-leaders, groups of participants discussed health challenges and problem-solved using a technique called action-planning. The curriculum described by Lorig and colleagues in the book Living a Health Life was the core of this program, and transplant-specific issues were covered in two meetings to match MBSR for time and attention.
41282172|NCT00367809|BEHAVIORAL|Delayed Intervention|A temporary wait-list control group; after 6 months, those in the Delayed Intervention were randomized a second time, to one of the active treatment arms (MBSR or HE).
41282173|NCT04840667|DRUG|REPLAGAL|Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
41282174|NCT00594399|BEHAVIORAL|Physical Activity Counseling|Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
41282175|NCT02001740|DRUG|Triamcinalone (steroid) and lidocaine|receive once
41282176|NCT02001740|OTHER|Lidocaine|receive once
41282177|NCT04037085|DRUG|Ketamine|Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
41282178|NCT00670111|DEVICE|Insignia Plus / Ultra (Guidant/Boston Scientific)|Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
41282179|NCT04155879|DRUG|Colchicine Tablets|Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
41282180|NCT04155879|PROCEDURE|Cardioversion|Electrical or pharmacologic restoration of sinus rhythm
41282181|NCT00704106|DRUG|Entecavir|0.5 or 1 mg dose qd
41282182|NCT02035384|DRUG|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.
41282183|NCT01051739|PROCEDURE|Comparison of four visual field testing strategies|We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
41282184|NCT00963807|DRUG|Cisplatin|Given IV
41282185|NCT00963807|PROCEDURE|CT|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
41282186|NCT00963807|DRUG|Docetaxel|Given IV
41282187|NCT00963807|DRUG|FDG|Undergo FDG PET/CT
41282188|NCT00963807|DRUG|FLT|Undergo FLT PET/CT
41282189|NCT00963807|PROCEDURE|PET/CT|Undergo FDG PET/CT and FLT PET/CT
41282190|NCT00963807|PROCEDURE|Surgery|Undergo surgery
41282191|NCT03018015|DRUG|Ibuprofen 400 mg oral powder|
41282192|NCT03018015|DRUG|Ibuprofen 400 mg film-coated tablet|
41282193|NCT03018015|DRUG|Ibuprofen 400 mg soft capsule|
41282194|NCT05662644|PROCEDURE|Minimally Invasive Surgery for Esophageal Cancer|Assessment of minimally Invasive Surgery for Esophageal Cancer
41282195|NCT01958567|OTHER|Optical Coherence Tomography|
41282196|NCT05079438|DRUG|Dendrobium Huoshanense Suppository|1.7g rectal administration per day for 5 weeks
41282197|NCT06374810|BEHAVIORAL|Conscious Connected Breathwork|Participants were taught the Conscious Connected Breathwork Technique. 2 facilitators were monitoring and coaching the participants to ensure adherence to the technique
41282198|NCT06374810|OTHER|Placebo waitlist|Participants were told the study was full and that they were placed on a waiting list until the 1st cohort had completed the breathwork program
41282199|NCT01523444|BEHAVIORAL|computer-assisted Screening & Brief Advice|"The computer-facilitated screening and brief advice (cSBA) intervention is a self-administered, computer-facilitated screening that asks about lifetime and past-12-month use of substances followed by scientific information about how substance use affects health and true-life stories illustrating the health risks of substance use. The cSBA program prints out a Report Form with the screening results, risk level, and talking points designed to prompt a 2 to 3-minute provider/teen conversation about the health effects of substance use, which recommends abstinence."
41282200|NCT01523444|BEHAVIORAL|computer-assisted Screening & Brief Advice Plus|The cSBA+ intervention contains cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider. In the first session of this intervention, youth should be encouraged to think about: (1) The role alcohol and drugs play in his/her life; (2) His/her personal goals for changing alcohol and drug use; (3) Strategies for reaching and maintaining goals. The goal at the end of the session is positive movement in the direction of abstinence or change. The aim of the second session is reinforcement of goals set forth in the prior meeting with the BHC.
41282201|NCT00294593|DRUG|folinic acid|
41282202|NCT06510283|DRUG|Taitacept|Taitacept
41282203|NCT03026387|BEHAVIORAL|Neuropsychological battery tests|"The neuropsychological battery tests is composed with: Continuous Performance Test, Iowa Gambling Test, Verbal fluency (animals), Emotional stroop, Self-injury implicit association test and N-back test.~The neuropsychological battery assesses domains heavily involved in suicidal behavior: impulsivity, affective dysregulation, alterations in decision-making (risky choices), selective attention,verbal fluidity and working memory."
41282204|NCT00002103|DRUG|Trimetrexate glucuronate|
41282205|NCT00002103|DRUG|Leucovorin calcium|
41282206|NCT05440825|DEVICE|VRelax|Virtual Relaxation relaxation, VRelax, includes a collection of high quality 360° degrees videos of nature environments with 3D audio and interactive elements, created for relaxation, stress-reduction and improving sleep. When activated, the participant can choose specific 360° videos from a menu. The 360° videos include among other things a coral reef with an interactive game element of popping air bubbles, a scuba diving experience with dolphins, a mountain meadow with cows, and a session of Tibetan sound bowls.
41282207|NCT05440825|OTHER|Relaxation exercises|Relaxation exercises consisting of audio-guided breathing exercises, muscle relaxation exercises, and body scan exercises
41282208|NCT06301399|DRUG|Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy|Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.
41282209|NCT03605901|DRUG|Standard dosing of methadone|Subject will receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
40756650|NCT05613179|PROCEDURE|Group1 (lever positioning manipulation)|The specific lever positioning manipulation is as follows: the patient lies prone at the mouth-open position with muscles relaxed, waist exposed, knees and hips bent, and ankle joints crossed. The practitioner uses the right elbow olecranon to point at the lumbar vertebrae, then hold the patient's two ankle joints in both hands to cause the lumbar vertebra to make hyperextension and flexion movements through the arms and pull the patient backward and upwards hard. When pulling upwards to the trigger point, the practitioner pulls wit lever quickly with a technique and then senses a clatter or looseness at the positioning point. When the practitioner pulls with lever manipulation, the patient is asked to exhale and then inhale at the end of the manipulation.
40940498|NCT05729230|BEHAVIORAL|Questionnaire|"Physician/data nurse and the patients will complete a questionnaire. The physician or data nurse must complete a descriptive form including the patient's age and gender as well as some information about the tumour and the underlying liver disease.~Based on the 4 open questions, patient will be classified into 2 groups after assessment of his answers by a group of digestive oncologists and psychologists. Group A includes patients with an accurate perception of the disease whereas group B will gather patients with unrealistic expectations. Psychosocial aspect, quality of the physician's communication, comprehension of the disease and treatment expectations are assessed by multiple-choice questions (Liker scale evaluation). Depression and anxiety were evaluated by the Hospital Anxiety and Depression Scale (HADS) that has been validated as a good scale with a high sensitivity and specificity for depression and anxiety for cancer patients."
41282210|NCT03605901|DRUG|Aliquots of methadone titrated to apnea|Subjects will receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 5-10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals.
40940499|NCT03862859|DRUG|Warfarin|Dose adjusted Warfarin targeting an international normalized ratio of 2-3.
40940500|NCT06458426|DEVICE|shock-absorbing prosthesis|the intervention will test the difference between rigid and shock-absorbing pylons, while the same prosthetic foot is applied in each condition.
40940501|NCT04490239|DRUG|Intranasal heparin sodium (porcine)|Intranasal heparin sodium
40940502|NCT01596543|OTHER|partial and complete sleep deprivation|The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
40940503|NCT03234777|BEHAVIORAL|Whiteboard animation video|Developed via qualitative research with parents of children with acute gastroenteritis.
40940504|NCT03234777|BEHAVIORAL|Regular video|Developed by CDC
40940505|NCT05588271|OTHER|Exposures|This study is an observational study.Exposure factors is patients with pressure injury.
41282211|NCT00101361|DRUG|Oxandrolone|Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.
41282212|NCT00101361|DRUG|Placebo|Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
41282213|NCT00811226|DRUG|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
41282214|NCT00565422|DRUG|Escitalopram|10 mg/day
41282215|NCT04636918|DRUG|Cyclosporine Ophthalmic|Prospective interventional study (single arm)
41282216|NCT05918510|DIAGNOSTIC_TEST|Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx|The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.
41282217|NCT05437796|DEVICE|Hypnotic virtual reality support using hypnosis software Hypno-VR®|Hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
41282218|NCT05437796|DEVICE|No Hypnotic virtual reality|Group without Hypnotic virtual reality
41282219|NCT03864965|OTHER|Advance Care Planning|The provider will guide advance care planning conversations with patients identified with mild or moderate dementia during their third office visit, approximately three months after the first visit.
41282220|NCT05048472|DIAGNOSTIC_TEST|Abbott HIV-1/2 VL Point of care Device|Point of care viral load monitoring
41282221|NCT02852629|OTHER|observational study|
41282222|NCT01753492|DEVICE|Ologen|
41282223|NCT02122289|DEVICE|Application of Smartphone|Weekly questionnaire on smartphone
41282224|NCT02122289|OTHER|No application Smartphone|No weekly questionnaire on smartphone
41282225|NCT01106261|PROCEDURE|Metastasectomy|Pulmonary Metastasectomy
41282226|NCT01106261|PROCEDURE|Active monitoring|Active monitoring
41282227|NCT06388057|DIAGNOSTIC_TEST|Intraoperative Small Bowel Ultrasonography|An intraoperative ultrasound study will be performed on the intestinal segment identified as the resection site
41282228|NCT04554576|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish|"The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)"
41282229|NCT04554576|BEHAVIORAL|Remote feedback active group|After the 6-week self management program, half the participants will be randomized to an every 6 weeks for 6 months phone or video visit from a health care provider, in Spanish. The phone or video sessions will include: review previous action-plans (goals) and provide support in forming new action-plans (goals)
41282230|NCT04554576|BEHAVIORAL|Remote feedback control group|After the 6-week self-management program, half the participants will be randomized to a control group for 6 months.
41282231|NCT00160927|DEVICE|local heating|
41282232|NCT00160927|DEVICE|iontophoresis|
41282233|NCT00160927|DRUG|actylcholine|
41282234|NCT00160927|DRUG|sodium nitroprusside|
41282235|NCT03843580|DEVICE|optiflow|we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
41282236|NCT04291157|OTHER|CVD risk estimation incorporating the PRS and guideline based preventive interventions.|Total CVD risk estimation using SCORE plus PRS and European Society of Cardiology (ESC) CVD prevention guideline based interventions.
41282237|NCT04291157|OTHER|Standard GP care|Usual GP care (opportunistic CVD prevention)
41282238|NCT05702021|BEHAVIORAL|Science to Service Laboratory|The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).
41282239|NCT01047410|OTHER|Exercise intervention|Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
41451319|NCT01395017|DRUG|dasatinib|GEM 1000 mg/m2 by intravenous \[IV\] infusion weekly for 3 weeks of a 4-week cycle plus dasatinib 100 mg (or matched placebo) by mouth once daily (QD). Subjects will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
41451320|NCT01395017|DRUG|Placebo|Matching Placebo
41451321|NCT04945096|DRUG|decitabine|Decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen)
41282240|NCT01047410|OTHER|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
41282241|NCT00604578|DRUG|Pioglitazone Hydrochloride|
41282242|NCT06482879|DEVICE|Oxygen delivery|Oxygen is delivered with high flow nasal canula or simple nasal canula to prevent hypoxia during procedures under deep sedation.
41282243|NCT02236624|BEHAVIORAL|Aerobic exercise|
41282244|NCT06272214|RADIATION|Adjuvant radiotherapy|"The start time for radiotherapy is 4-6 weeks after surgery, typically not exceeding 8 weeks. Intensity-modulated radiation therapy (IMRT) will be used, with a total dose of 45Gy administered in 25 fractions, five times per week.~The recommended target delineation for radiotherapy is based on the Chinese guidelines for radiation therapy of esophageal cancer, which mainly covers the high-risk lymph node area."
40940506|NCT05090540|DEVICE|Trancatheter Edge to Edge Repair|TEER is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of prolapsed MV. The patient may be under conscious sedation or general anesthesia, depending on hospital standard practice. The procedure is performed through femoral venous access and the inter-atrial septum is crossed using standard techniques. Trans-septal puncture allows MitraClip Steerable Guide Catheter (Guide) to advance so that the guide is positioned over the mitral valve. The MitraClip delivery catheter is advanced to the MitraClip device and emerges from the tip of the guide into the left atrium. The MitraClip device can now be opened and advanced through the MV in the LV. Once in the LV, it is pulled back to grasp the leaflets. Two-dimensional and/or 3-dimensional echocardiography and color Doppler are useful for evaluating the anatomical features of the mitral valve and directing the procedure until the double orifice is formed alongside evaluating residual mitral regurgitation
40940507|NCT05090540|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement is performed using mechanical or biological prosthesis while preserving the subvalvular apparatus to avoid dilation of the left ventricle over time.
41282245|NCT06272214|OTHER|Observation|Patients receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by active survillance and maintenance therapy with PD1/PDL1 inhibitors for up to 1 year or until tumor progression.
41282246|NCT03390829|OTHER|semi-directed interviews|semi-directed interviews
41282247|NCT01358110|OTHER|Early palliative care consultation|Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.
41282248|NCT01358110|OTHER|Care as usual|Standard care as usual which may or may not include palliative care consultation
41282249|NCT02814773|OTHER|questionnaires|
41282250|NCT00555945|PROCEDURE|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
41282251|NCT00555945|PROCEDURE|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
41451322|NCT04945096|DRUG|Acetylcysteine|Acetylcysteine: 1.2g twice a day, oral administration, from day -10 to day 365 after HSCT.
41451323|NCT04945096|DRUG|Semustine|Semustine: 250 mg/m2/day on day -9.
41451324|NCT04945096|DRUG|Cytarabine|Cytarabine: 2 g/m2 every 12 hours on day -8.
40940508|NCT05090540|PROCEDURE|Restrictive Mitral Annuloplastie|Mitral valve repair consists of a restrictive mitral annuloplasty (RMA) using a prosthetic ring
40940509|NCT05090540|PROCEDURE|Restrictive Mitral Annuloplastie/Subvalvular Repair|RMA may be associated with the use of a subvalvular repair (SR). The SR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation.
40940510|NCT01516229|DRUG|somatropin|Prescription of somatropin at the discretion of the physician
40940511|NCT02296944|OTHER|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery|
41282252|NCT01018407|BEHAVIORAL|Discrete Trial Training|"UCLA model, developed by Lovaas and colleagues (Smith, Groen \& Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program."
41451325|NCT04945096|DRUG|Busulfan|Busulfan: 3.2mg/kg/day on day -7 to -5.
41451326|NCT04945096|DRUG|Cyclophosphamide|Cyclophosphamide: 1.8g/m2/day on day -4 to -3.
41451327|NCT04945096|DRUG|Cyclosporin A|Cyclosporin A: 3mg/kg/d from day -8.
41451328|NCT04945096|DRUG|Anti-thymocyte globulin|Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.
41451329|NCT04945096|DRUG|Mycophenolate|Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.
41451330|NCT01902719|BEHAVIORAL|Community Health Worker (CHW) Intervention|Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
41451331|NCT01902719|BEHAVIORAL|Communication Skills Training|"Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training."
41451332|NCT01902719|BEHAVIORAL|Problem Solving Skills Training|Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
40756651|NCT05613179|PROCEDURE|Group2 (placebo group)|The specific sham lever positioning manipulation is as follows: the patient lies prone with his mouth open, muscles relaxed, waist exposed, knees bent at the hip and ankles crossed. The practitioner points to the lumbar spine with the right elbow olecranon, and then holds the patient's two ankles in both hands, so that the lumbar spine through the arm for overextension and flexion, and forcefully pulls the patient back and up. When pulling up to the trigger point, maintain this movement for a short period of time, depending on the patient's endurance, about 1-5 minutes. After finishing, ask the patient to rest in prone position.
40756652|NCT00310843|DRUG|Nevirapine|Patients with HIV-1 infection who have taken or are currently taking nevirapine
40940512|NCT03896685|DRUG|Bedaquiline 100 MG|Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
41282253|NCT01018407|BEHAVIORAL|Interpersonal Developmental Approach|"Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities."
41282254|NCT00861185|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
40940513|NCT03896685|DRUG|Delamanid 50 MG Oral Tablet|Delamanid: 100 mg BID
40940514|NCT03896685|DRUG|Clofazimine 100 MG Oral Capsule|Clofazimine: 100 mg QD
41282255|NCT00861185|DRUG|Placebo|Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
41451333|NCT03276767|OTHER|Endre|"The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt."
41451334|NCT02000388|DRUG|Ketorolac Tromethamine|
41451335|NCT02000388|OTHER|Standard of Care|
41451336|NCT02294305|DRUG|Vortioxetine|
41451337|NCT02294305|DRUG|Placebo|
41451338|NCT05123885|OTHER|Study on Data|Study on Data
41451339|NCT00728351|DRUG|vildagliptin + metformin|
41451340|NCT00728351|DRUG|metformin|1000 bid metformin
41451341|NCT05173792|DRUG|AK119|Subjects will receive AK119 intravenously.
41451342|NCT05869162|DRUG|SY-3505|A Third-generation ALK TKI
41451343|NCT00199654|PROCEDURE|PET|
40940515|NCT03896685|DRUG|Linezolid 600Mg Tab|Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
40940516|NCT03896685|DRUG|Control arm MDR-TB regimen, designed according to latest WHO guidelines|Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
40940517|NCT05912452|OTHER|Percussion Massage Therapy|Individuals who receive percussion massage therapy will be treated with a 5-minute medium-frequency percussion massage on the deltoid muscle group every other day. Percussion massage therapy will be applied in a total of 10 sessions and will be completed in 20 days.
40940518|NCT05912452|OTHER|Kinesiotaping|the Kinesiotape group; Kinesiotape banding will be done with 25% tension by applying a Y band to the deltoid muscle group. After the application, the Kinesio band will stay on the participant for 2 days. The next day, the participant will rest. This cycle will be repeated for 20 days.
40940519|NCT05912452|OTHER|Dynamic stretching|Dynamic stretching exercises will be applied to the shoulder flexor and abductor muscle groups in the Dynamic Stretching Group with 10 repetitions. As in percussion massage therapy, these exercises will be performed under the supervision of a physiotherapist every other day. The application will continue for 20 days.
41282256|NCT06487910|DEVICE|3D scan measurment|"patients included in the study will undergo a 3D scan measurement of on or more burn scars. This measurement will then be digitally modified in preparation for the manufacture of the differential pressure distribution orthosis. The orthosis will then be manufactured using a 3D printing process."
41451344|NCT01499043|DRUG|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
41451345|NCT00320307|DRUG|abacavir|
41282257|NCT00825071|DRUG|Dexamethasone|8 mg, Intravenous
41282258|NCT00825071|DRUG|Ondansetron|4 mg, intravenously
41282259|NCT00825071|DRUG|normal saline|2 ml, intravenously
41282260|NCT00262704|BEHAVIORAL|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
41282261|NCT00262704|BEHAVIORAL|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
41282262|NCT00077987|DRUG|SU011248|
41282263|NCT01617486|BEHAVIORAL|BALANCE|The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
41282264|NCT00202540|DRUG|S18986|
41282265|NCT03552783|BEHAVIORAL|FFL + Cognitive Behavioral Therapy|Participants in the intervention arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime in addition to 12 weekly, one-hour, group CBT sessions, and three (3), one-hour, one-on-one therapy sessions throughout the 12-week FFL program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum.
40940520|NCT04447378|DRUG|Fondaparinux 2.5Mg/0.5Ml Inj Syr|post natal thromboprophylaxis
40940521|NCT01200849|OTHER|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
41451346|NCT04385485|PROCEDURE|Active mobilisation|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
41451347|NCT04385485|PROCEDURE|Passive mobilisation with place and hold|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
41451348|NCT02364531|OTHER|Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
40940522|NCT05294536|DRUG|Liraglutide injection,RD12014|single dose, s.c. injection
40940523|NCT05294536|DRUG|Liraglutide injection,Victoza|single dose, s.c. injection
40940524|NCT02393690|RADIATION|Iodine I-131|Given PO
40940525|NCT02393690|OTHER|Placebo Administration|Given PO
40940526|NCT02393690|DRUG|Selumetinib|Given PO
40940527|NCT01137318|BEHAVIORAL|Cognitive remediation and Parent Training|Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
40940528|NCT01087697|DEVICE|Neo-Urinary Conduit|Implantation with the autologous Neo-Urinary Conduit
40940529|NCT04985370|OTHER|Pain neuroscience education|Three sessions of pain neuroscience education based on explaining patients: characteristics of acute versus chronic pain, function of acute pain, how acute pain is originated within the nervous system, how acute pain progress to chronic pain, and factors that contribute to central sensitization (e.g., emotions, stress, disease and pain beliefs, behaviors regarding pain...). All the explanations will be conducted using easy-understandable examples and metaphors.
40940530|NCT04985370|OTHER|Exercise|Progressive resistance exercise program based on isometric, concentric, eccentric, and pliometric contractions.
40940531|NCT06182579|DRUG|RiMO-401|• Single intratumoral injection of RiMO-401 followed by palliative radiotherapy
40940532|NCT05715671|DRUG|esketamine|The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.
40940533|NCT03200665|DIAGNOSTIC_TEST|Ultrasound 35-36 (6 / 7 days weeks)|An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
40940534|NCT01145612|DRUG|Losartan|Losartán dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
40940535|NCT01145612|DRUG|Atenolol|Atenolol dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
40940536|NCT02038829|DRUG|Placebo|Placebo
40940537|NCT02038829|DRUG|SUN101 3 mcg|SUN-101 3 mcg bid
40940538|NCT02038829|DRUG|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
40940539|NCT02038829|DRUG|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
40940540|NCT02038829|DRUG|SUN-101 50 mcg|SUN-101 50 mcg bid
40940541|NCT02038829|DRUG|Aclidinium|Aclidinium 400 mcg bid
40940542|NCT05352490|DIAGNOSTIC_TEST|calculate LUS score|calculate LUS score
40940543|NCT03524079|DRUG|Ajmaline 17-(Chloroacetate) Monohydrochloride|Ajmaline 17-(Chloroacetate) Monohydrochloride(1mg/kg in 5 minutes)
40940544|NCT01143207|DRUG|Medroxyprogesterone acetate|Injectable hormonal contraceptive
40940545|NCT03219879|BEHAVIORAL|Telephone-administered continuation therapy|The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
41282266|NCT03552783|BEHAVIORAL|Fathers for a Lifetime (FFL) only|"The participants in the comparison arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime. The curriculum is broken into three categories:~1. Personal responsibility~2. Personal responsibility to your child~3. Responsibility to your family and community"
41282267|NCT06052462|DRUG|[14C]-LY3556050|Administered orally
40940546|NCT03219879|OTHER|Usual care|Usual care without any study-related intervention
40940547|NCT04160481|DIETARY_SUPPLEMENT|FruitFlow|300mg tomato extract
40940548|NCT04160481|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
40940549|NCT03576365|BEHAVIORAL|VOICE Intervention Arm|"Introductory and background information about voice problems and psychosocial distress~* Examples of concerns raised by patients with voice problems (e.g., I feel left out of conversations because of my voice problem)~* Information about perceived control and how improving perceived control can lead to decreased distress~* Examples of strategies that have helped patients identify controllable and uncontrollable aspects of their voice problems (e.g., I learned to plan to take breaks to rest my voice between teaching classes)~* Self-guided exercises designed to help improve perceived control and develop better management skills for voice problem symptoms"
40940550|NCT03576365|BEHAVIORAL|Information-Only Arm|"General introduction of the program and background on voice related information in an interactive manner~* Examples of what patients want to learn more about the voice (e.g., I would like to learn more about how the voice works when it is healthy)~* Information on the anatomy of the voice and how the voice works~* Educational materials to help understand voice physiology and function~* Self-guided learning exercises (e.g., what are some things about vocal function that you would like to learn more about?)"
41282268|NCT03543371|DIAGNOSTIC_TEST|Neuropsychological assessment|Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A \& B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
41282269|NCT03846362|OTHER|HSCT|allogenic HSCT from 5-8 HLA-MM family donor as a first choice for patients with initial high risk of relapse and for patients with MRD2\>0,1% and initial intermediate risk
41282270|NCT04237649|DRUG|KAZ954|KAZ954 will be administered in every arm.
41282271|NCT04237649|DRUG|PDR001|KAZ954 + PDR001
41282272|NCT04237649|DRUG|NIR178|KAZ954 + NIR178
41282273|NCT04237649|DRUG|NZV930|KAZ954 + NZV930
41282274|NCT03795350|DRUG|Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide|single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
41282275|NCT02176486|DRUG|Ixazomib|Ixazomib capsules.
41282276|NCT02176486|DRUG|Placebo|Ixazomib placebo-matching capsules.
41282277|NCT05422300|BEHAVIORAL|Fed|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13C\]-leucine.
41282278|NCT05422300|BEHAVIORAL|Ex-Fed|"Participants will be subjected to a full-body resistance exercise protocol, consisting of an upper and lower body circuit. The upper body circuit will be a chest press and dumbbell row superset, whereas the lower body circuit will be leg press and leg extension (4 sets of 10 repetitions @ 75% of their 1 repetition max, respectively). The inter-set rest period will be 90 seconds.~Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13C\]-leucine."
41282279|NCT01772134|DRUG|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
41282280|NCT01772134|DRUG|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
41282281|NCT01772134|DRUG|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
40940551|NCT06520670|DIAGNOSTIC_TEST|Urinary galectin-3 binding protein|Investigate urinary galectin-3 binding protein (G3BP) as a biomarker for lupus nephritis and indicator for disease activity.
41282282|NCT01772134|DRUG|Placebo|Inhalation Powder, Placebo
41282283|NCT00186602|BEHAVIORAL|Peer counseling|
41282284|NCT03163342|BIOLOGICAL|Licensed seasonal influenza vaccine|20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
41282285|NCT03751384|DIETARY_SUPPLEMENT|Möllers Omega-3 Ekstra Sterk|
41282286|NCT03751384|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|
41451349|NCT04987216|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
41451350|NCT00408577|DRUG|L-arginine|
41451351|NCT02751437|DIETARY_SUPPLEMENT|Arginine|
40940552|NCT02090868|OTHER|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
41282287|NCT05902793|DEVICE|Experimental: Investigational device: V.A.C. VERAFLO™ Dressing Kit|"Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation. The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit."
41282288|NCT05902793|DEVICE|Active Comparator: Dressing Name: Negative pressure wound drainage material|"Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation. The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit."
41282289|NCT00004081|DRUG|docetaxel|
41282290|NCT00138840|DRUG|STA-5326 mesylate|
40940553|NCT02323932|BEHAVIORAL|Perception of correct intonation identification|The amount of change in the fundamental frequency that was required in order to identify a question
41282291|NCT00168012|DRUG|Immunoglobulins Intravenous (Human)|
40940554|NCT06468215|DRUG|Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.|Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.
40940555|NCT00664027|DRUG|RTA 402 (Bardoxolone Methyl)|Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
40940556|NCT00894023|DRUG|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
40940557|NCT00894023|DRUG|IV abciximab|IV abciximab + infusion
40940558|NCT03346707|DEVICE|10.5 Tesla|10.5Tesla MR scan
40940559|NCT02702063|OTHER|passive leg raising test|Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
40756653|NCT04377256|PROCEDURE|Ridge preservation: Tooth extration and immediat bone grafting in the socket|Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate
40756654|NCT00000810|DRUG|Delavirdine mesylate|
40756655|NCT00000810|DRUG|Zidovudine|
40756656|NCT00000810|DRUG|Didanosine|
40940560|NCT02702063|PROCEDURE|right heart catheterisation|CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC
41282292|NCT05086237|OTHER|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who missed their well child visits.
40940561|NCT02702063|OTHER|TTE vs. EC + calibration group|Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
40940562|NCT01588249|DIETARY_SUPPLEMENT|Pasteurized maple syrup|
41282293|NCT06448156|DIAGNOSTIC_TEST|"cardiac arrest and sudden death"|"Selection of cases with a secondary diagnosis containing the diagnostic keywords cardiac arrest and sudden death.cardiac arrest and sudden death.The incidence rate is then calculated"
41282294|NCT05029622|DRUG|Triptorelin Pamoate|Triptorelin 6-month formulation for IM on day 1 and Month 6.
41282295|NCT03669133|DRUG|Vitamin E|Vitamin E 800 IU/daily
40940563|NCT01588249|DIETARY_SUPPLEMENT|Placebo|
40940564|NCT03081221|DIAGNOSTIC_TEST|USG|
40940565|NCT02439879|DRUG|Alpha lipoic acid|Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased \>3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
41282296|NCT03669133|DRUG|Placebo|Matching placebo daily
41282297|NCT05942690|PROCEDURE|manual osteopathic intervention|The subject sits on the examination table for the manual osteopathic intervention. The expert osteopath, having no report from the sonographers, will manually test breathing diaphragmatic and will bring osteopathic manual treatment to the area of mobility restriction
41282298|NCT04188158|COMBINATION_PRODUCT|CAPECITABINE AND OXALIPLATIN|Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
41282299|NCT03995771|OTHER|Questionnaire delivery|A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
41282300|NCT03744234|PROCEDURE|PRP|Autologous platelet-rich plasma
41282301|NCT03744234|PROCEDURE|Steroid Injection|Steroid injection
41282302|NCT03212261|BEHAVIORAL|3RP-Lymphoma|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
41282303|NCT05626777|DRUG|Pre-filled syringe, mepolizumab 100 mg/month|Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
41451352|NCT04020458|PROCEDURE|dental intervention|"Dental intervention plan for Group 1 and 3 subjects with periodontitis only, i) Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
41282304|NCT05626777|DRUG|Auto-injector pen, mepolizumab 100 mg/month|Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
41282305|NCT04418440|DIETARY_SUPPLEMENT|Souvenaid oral nutritional supplement (Nutricia)|Daily dose of a commercially available oral nutritional supplement based around the active compound recipe Fortasyn Connect, produced by Nutricia, Danone.
41282306|NCT04166396|DRUG|Resveratrol|500 mg resveratrol, BID
41282307|NCT04166396|DRUG|NR|500 mg NR BID
41282308|NCT04166396|DIETARY_SUPPLEMENT|Placebo|Placebo
41282309|NCT04698408|OTHER|high-protein, carbohydrate-reduced diet|the high-protein, carbohydrate-reduced diet will consist of 1.2-1.4 g/kg/d protein, 26-20en% carbohydrates and +/- 50en% fatty acids, with mainly unsaturated fatty acids. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
41451353|NCT03946995|OTHER|Dry Needling Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed. Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points.~The treatment will be continued for 2 weeks with 2 sessions per week."
40940566|NCT00596856|BEHAVIORAL|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
40940567|NCT01450111|DRUG|Lacosamide|Lacosamide 50 mg, tablet, once in the morning on Day 1
40940568|NCT01450111|DRUG|Lacosamide|Lacosamide 100 mg, tablet, once in the morning on Day 1 Lacosamide 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
41282310|NCT04698408|OTHER|Dutch Nutritional Guidelines|the diet according to the Dutch Nutritional Guidelines will consist of a protein intake of 0.8-1.0 g/kg/d and 50-60en% carbohydrates, and +/-30en% fatty acids, with restriction of saturated fatty acids \<10en%. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
41282311|NCT06097806|OTHER|low and high flow|low and high flow anesthesia are both being used. The effects of different gas flows will be evaluated.
41282312|NCT01959360|PROCEDURE|Direct lateral|Total hip replacement; direct lateral approach
41282313|NCT01959360|PROCEDURE|minimal invasive|Total hip replacement; minimal invasive approach
41282314|NCT01959360|PROCEDURE|modified minimal invasive|Total hip replacement; modified minimal invasive approach
41282315|NCT05374356|DRUG|Intrathecal bupivacaine and morphine|Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).
41282316|NCT03847311|DRUG|Sulfasalazine|This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
41282317|NCT03847311|DRUG|Placebos|This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
41282318|NCT02778698|DIETARY_SUPPLEMENT|Omegaven|
41282319|NCT00636818|DRUG|Atomoxetine|Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
41282320|NCT04824261|DRUG|Clotrimazol solution 1%|50 otomycosis randomized patients will receive Clotrimazol solution 1% The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
41282321|NCT04824261|DRUG|4%boric acid in distilled water|50 otomycosis randomized patients will receive 4%boric acid in distilled water The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
41282322|NCT00424307|DEVICE|HiResolution Bionic Ear System|
41282323|NCT00082823|BIOLOGICAL|ziv-aflibercept|
41282324|NCT00524303|DRUG|Trastuzumab|4mg/kg IV loading dose followed by 2mg/kg IV weekly
41282325|NCT00524303|DRUG|Paclitaxel|80mg/m2 IV weekly for 4 (21 day) cycles
41282326|NCT00524303|DRUG|FEC75|5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
41282327|NCT00524303|DRUG|Lapatinib|1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
41282328|NCT06370247|DIAGNOSTIC_TEST|HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K|HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K will measure
41282329|NCT01457248|DEVICE|Endotracheal tube TaperGuard|Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)
41282330|NCT01457248|DEVICE|Endotracheal tube Hi-Contour Brandt|Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
41282331|NCT05651646|OTHER|Intervention Arm (STIMFIX)|This is a single-arm prospective multicenter clinical study recruiting 50 subjects who are already undergoing a spinal cord stimulator trial for chronic back pain secondary to failed back surgical syndrome. Each patient who is recruited for spinal cord stimulator trial for their low back pain is informed about the traditional method of managing the leads and the trail lead anchoring system. If the patient agrees for the Stimfix trail lead anchoring clips StimfixTM, then informed consent is taken for anchoring clips usage during the spinal cord stimulator trail.
40940569|NCT01450111|DRUG|Lacosamide|Lacosamide 200 mg, tablet, once in the morning on Day 1 Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
40940570|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 50 mg tablet once in the morning on day 1.
40940571|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 100 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamode 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
40940572|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 200 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
40940573|NCT05005520|DRUG|DTRI-031|Investigational drug
40940574|NCT05005520|DRUG|Placebo|Matching placebo to DTRI-031
40940575|NCT03472066|OTHER|Previous conization|a group of women who have been conized,
40940576|NCT03472066|OTHER|no previous conization|group with asymptomatic patients on routine second trimester echography
40940577|NCT03381105|DIAGNOSTIC_TEST|PSA and Stockholm3|The new Stockholm3 test and traditional PSA test
40940578|NCT00002567|BIOLOGICAL|filgrastim|
40940579|NCT00002567|DRUG|etoposide|
40940580|NCT00002567|PROCEDURE|peripheral blood stem cell transplantation|
40940581|NCT00002567|RADIATION|low-LET electron therapy|
40940582|NCT00002567|RADIATION|low-LET photon therapy|
40940583|NCT02066220|RADIATION|Radiotherapy without Carboplatin|"Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks~LR Arm after Amendment (Protocol version 11- 17 Nov 2014):~Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks"
41267020|NCT03624257|DEVICE|Laser treatment|The participants in the laser group are treated by a combination of scaling and root planning (SRP) and 445 nm diode laser. The peri-implant pocket will be radiated with the 445 nm laser, removing bacteria, diseased epithelium and granulation tissue. The Power setting on the laser will be 0.7 W continuous wave and will be used at maximum 20 s Before cooling water is applied. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
41267021|NCT03624257|PROCEDURE|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, in combination with scaling and root planning (SRP), and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
41267022|NCT04357106|BIOLOGICAL|Convalescent plasma|Convalescent plasma obtained by aphaeresis from recovered patients.
41267023|NCT03871114|DRUG|Triamcinolone Acetonide in orabase|treatment of OLP with topical steroid
41267024|NCT03882424|BIOLOGICAL|TRS003|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
41267025|NCT03882424|BIOLOGICAL|China-approved Bevacizumab|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
41267026|NCT03882424|BIOLOGICAL|US-licensed Avastin|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
41267027|NCT05612919|OTHER|Red blood cell from umbilical cord blood|"Patients will receive a volume of 15-20 ml/kg of red blood cell from umbilical cord blood (UCB-RBC). The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient. The UCB-RBC bags will contain a minimum volume of 20 mL of RBC, with a haematocrit of about 60% and an acceptable residual leucocyte content of \<106/mm3.~Product validation is currently under development."
41267028|NCT05612919|OTHER|Red blood cell from adult donor|"Patients will receive a volume of 15-20 ml/kg of red blood cell from adult donor according to standard guidelines.~The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient.~Blood samples are irradiated according to standard practise."
41267029|NCT05808257|DEVICE|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
41267030|NCT05808257|DEVICE|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
40940584|NCT02066220|DRUG|Reduced-intensity maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2."
40940585|NCT02066220|RADIATION|Radiotherapy with Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
40940586|NCT02066220|DRUG|Maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients)."
40940587|NCT02066220|RADIATION|WNT-HR < 16 years|Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Boost to macroscopic metastases - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
40940588|NCT02066220|RADIATION|WNT-HR >= 16 years|Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 14.4 Gy in 8 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 50.4 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
40940589|NCT02066220|DRUG|Induction Chemotherapy|Doxorubicin 37,5mg/m² in 24h-infusion, days 1 and 2 (If administration of doxorubicin is not deemed appropriate, doxorubicin can be substituted by carboplatin 200mg/m²) VCR 1,5mg/m² (max. dose 2mg) in short infusion, days 1, 15, 29, 43 HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin) Carboplatin 200mg/m² in 1h-infusion, days 43, 44, and 45 MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46
40940590|NCT02066220|RADIATION|SHH-TP53 M0|"* with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks~* clinical target volume (CTV): safety margin along typical spread 10 mm: 23.4.Gy in 13 fractions to CTV.~* focal RT boost to tumour bed and residual tumour (GTV) (boost: 30.6 Gy in 17 daily fractions of 1.8 Gy)"
40940591|NCT02066220|RADIATION|SHH-TP53 M+ (germline)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (cranial) - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (spinal) - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
41131981|NCT05987774|DEVICE|AI Modules for Improving Social Conversation|"The application if the modules will be delivered using software. These modules have been developed to provide feedback on specific areas following voice or text input (user preference will be recorded in case this effects the results).~The investigators currently have developed AI modules for common social communication challenges exhibited by individuals with ASD. Examples include:~Empathy (general and in the work setting), Asking Relevant Questions, Listen and Respond, Talking the right amount, giving the right amount of personal information, Tactful Responses, Giving compliments, and Staying on topic during Conversation. These are all areas that can be challenging for individuals diagnosed with autism spectrum disorder.~AI modules consist of thousands of total training examples. Participants may access the modules on their phones or computers."
41131982|NCT00694889|BEHAVIORAL|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
41282332|NCT01774448|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
41282333|NCT03061708|DRUG|AZD2014|mTOR inhibitor
41282334|NCT04998006|DRUG|Alcohol and Cannabis vs. Alcohol only|Self-directed (ad-libitum) cannabis and alcohol vs. self-direct (ad-libitum) alcohol
41282335|NCT02693964|OTHER|Bone density and carotid ultrasound|All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
41282336|NCT05307471|OTHER|Thoracotomy/scopy|
41451354|NCT03946995|OTHER|Graston Technique Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed.~Later, lubricant will be applied to the skin, and Graston technique will be applied using instrument over the active myofascial trigger points in upper trapezius.~The treatment will be continued for 2 weeks with 2 sessions per week."
40940592|NCT02066220|RADIATION|SHH-TP53 (somatic)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45 Gy in 25 daily fractions of 1.80 Gy
41131983|NCT00694889|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
41131984|NCT04587505|PROCEDURE|Epidural anesthesia with light general anesthesia|Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ ml and fentanyl 8.3 μg/ml. Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.
41451355|NCT02575651|DRUG|Fluzoparib|Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
41451356|NCT01325740|DRUG|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
41451357|NCT04902963|DEVICE|PE tube|Gelatin mixed with antibiotic and steroid ear drop to create a rigid device that maintains a lumen, acting as an intermediate-duration bioabsorbable ear tube.
40940593|NCT02066220|DRUG|Vinblastin Maintenance|Weekly VBL (5mg/m², max. 10mg/dose) for 24 weeks
40940594|NCT01061632|PROCEDURE|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
40940595|NCT01061632|PROCEDURE|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
40940596|NCT05564793|DEVICE|Pre-implantation planning|ECGi mapping using the CE marked Amycard 01C device and a contrast enhanced CT
41451358|NCT05261191|BIOLOGICAL|MGD020|MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
41451359|NCT05261191|BIOLOGICAL|MGD014|MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.
41451360|NCT01140438|DRUG|metformin+ NPH insulin|Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
41451361|NCT01140438|DRUG|metformin + sitagliptin +/- repaglinide|Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
41451362|NCT01904162|DRUG|400 mg finafloxacin (2 x 200 mg tablets)|
41451363|NCT01986647|BEHAVIORAL|On the Move exercise - exercise leader|exercise physiologists
41451364|NCT01986647|BEHAVIORAL|Standard program - exercise leader|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by research staff who are PTs, PTAs, or exercise physiologists
41451365|NCT01986647|BEHAVIORAL|On the Move exercise - staff activity personnel|this is a group exercise program focusing on the timing and coordination of walking. The program is taught by a person from the facility that the research team trained.
41451366|NCT01986647|BEHAVIORAL|Standard program - staff activity personnel|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by a member of the facility that the research staff trained.
41451367|NCT02277093|DRUG|Pacritinib|
41451368|NCT01277835|DRUG|Lidocaine Infusion|Infusion of lidocaine 3mg/min or 2mg/min during surgery
40940597|NCT05564793|DEVICE|Post-implantation assessment|ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT
41131985|NCT04587505|DRUG|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
41451369|NCT01277835|DRUG|Placebo|Saline Infusion at same rate as experimental arm
41267031|NCT02006771|OTHER|Southern Chinese meal|White rice (1 bowl), stir fried choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
41267032|NCT02006771|OTHER|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
41267033|NCT02006771|OTHER|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil and Coca-cola classic (21 fluid ounces)
41267034|NCT02006771|OTHER|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
41267035|NCT03005626|OTHER|Therapeutic education|
41267036|NCT03005626|OTHER|Standard follow-up|
41267037|NCT05389488|DEVICE|OsciPulse system|The OsciPulse system is a pneumatic compression system designed to provide intermittent compression to the limbs to augment venous blood flow.
41267038|NCT05389488|DEVICE|Flowtron ACS900|The Arjo Flowtron ACS900 intermittent pneumatic compression system provides compression the calf to augment venous blood flow.
41267039|NCT04942392|DEVICE|Digital dance for PD|The digital dance class was held via Zoom. The class was scheduled once a week for 60 min and consisted of 10 sessions. A professional, certified Dance for PD and experienced dance instructor was teaching the dance class. The dance classes followed the Dance for PD protocol yet was adjusted to fit the digital zoom format.
41267040|NCT01099969|DEVICE|Glidescope videolaryngoscope|
41267041|NCT01099969|DEVICE|McGrath videolaryngoscope|
41267042|NCT01099969|DEVICE|Non-styletted Endotrol endotracheal tube (ETT)|
41267043|NCT01099969|DEVICE|Regular endotracheal tube (ETT) with Gliderite stylet|
41267044|NCT01124565|DRUG|RT001|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
41131986|NCT04587505|PROCEDURE|General anesthesia|Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1. Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.
40940598|NCT02738632|DRUG|Telmisartan/Amlodipine+Hydrochlorothiazide|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD"
41131987|NCT04587505|DRUG|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
41131988|NCT01624493|DRUG|Carboplatin|Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
41131989|NCT01624493|DRUG|Gemcitabine|Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
41131990|NCT01624493|DRUG|Carboplatin|Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
41131991|NCT01624493|DRUG|Gemcitabine|Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
41131992|NCT01624493|DRUG|BNC105P|BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
41131993|NCT00361907|PROCEDURE|Effect of Pulsatile IV insulin on diabetic pt blood markers|Diabetic patients are given pulsatile intravenous insulin on a weekly basis determined by weekly physician order based on pt response and insulin resistance.
41131994|NCT00361907|PROCEDURE|Effect of Pulsatile IV Insulin on blood markers|Circulating blood markers are performed at baseline and every twelve months to compare and measure against diabetic patients receiving pulsatile intravenous insulin.
41131995|NCT00361907|PROCEDURE|Effect of Pulsatile IV insulin on diabetic pt blood markers|Blood markers will be performed on diabetic patients enrolled as control patients at baseline and every twelve months to measure and compare against diabetic patients treated with Pulsatile intravenous insulin therapy
41131996|NCT04363112|BEHAVIORAL|Mini Kid II|Mini Kid II (Mini International Neuropsychiatric Interview ) is a standardised, hetero mental health questionary for children, according to DSM IV. Mini Kid II will be administered to children between day 3 and 7 during the study.
41131997|NCT00808834|DEVICE|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
41131998|NCT00808834|DEVICE|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
41131999|NCT05139784|OTHER|Biosampling|Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.
41132000|NCT00845364|DRUG|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
41267045|NCT02620904|DRUG|Mifepristone|
41267046|NCT02620904|DRUG|placebo|
41267047|NCT06411093|COMBINATION_PRODUCT|Kinesiology tape wrapping|Place Kinesiology tape between the nail plate and the inflamed periungual granulation tissue in addition to conventional treatment for 3 months
41267048|NCT06411093|DRUG|Conventional treatment including silver nitrate cauterization|Conventional treatment including silver nitrate cauterization, with or without topical antiseptics, topical steroids, topical beta-blockers, short-term systemic antibiotics, systemic steroids for 3 months
41267049|NCT04068857|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
41267050|NCT01275014|DRUG|Dexamethasone|1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
41267051|NCT01275014|DRUG|Isotonic saline|1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
41267052|NCT04802473|PROCEDURE|Mucogingival surgery|In brief description, Tunnel+acellular dermal matrix treatment will be performed by starting initial sulcular incisions, tunneling knives will be used to elevate the buccal gingiva by means of a full-thickness flap elevation. Flap preparation will be extended beyond the MGJ. The exposed root surfaces will be treated with pre-conditioning EDTA (Straumann PrefGel®) for 2 minutes. ADM (OrACELL, LifeNet Helth, Virginia Beach, VA, USA) of 1.25-1.75mm in thickness will be cut to the exact size of the defect, and will be inserted into the tunnel, and subsequently covered advancing the flap by means of sling sutures to stabilize the flap in a coronal position (6-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA). Sutures will be removed after 14 days. Two weeks after surgery, patients will resume mechanical tooth cleaning with a soft toothbrush. Patients will be recalled at 1, 3 and 6 months for professional oral hygiene procedures.
41267053|NCT00000257|DRUG|0% N2O and 10% N2O|
41267054|NCT00000257|DRUG|0% N2O and 20% N2O|
41267055|NCT00000257|DRUG|0% N2O and 30% N2O|
41267056|NCT00000257|DRUG|0% N2O and 40% N2O|
41282337|NCT05998343|BEHAVIORAL|Intergenerational HOW R U?|1-on-1 discussion over telephone with a trained volunteer aged 19-39 years old who has received training to provide strength-based support sessions weekly for 12 weeks.
41282338|NCT05998343|BEHAVIORAL|Same-Generation Peer Support HOW R U?|1-on-1 discussion over telephone with a trained volunteer aged 60 years or older who has received training to provide strength-based support sessions weekly for 12 weeks.
41282339|NCT03895138|OTHER|Standard Glucommander Protocol (SGP)|Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.
41282340|NCT03895138|OTHER|Optimized Glucommander (OGM)|The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.
41282341|NCT01962454|DRUG|Deuterated Water|D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
41282342|NCT01962454|DRUG|Testosterone enanthate|Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).
41282343|NCT01962454|DRUG|Placebo to match testosterone enanthate|Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
41282344|NCT03379350|PROCEDURE|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
41282345|NCT05288088|DIAGNOSTIC_TEST|No intervention|This is an observational study
41282346|NCT01812161|OTHER|acupuncture protocol 1|Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
41282347|NCT01812161|OTHER|Acupuncture protocol 2|Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of \<5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
41132001|NCT00845364|DRUG|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
41132002|NCT06161259|DRUG|Leritrelvir(Ray1216)|Participants receive Leritrelvir orally.
41282348|NCT04837911|DEVICE|Spirobank Smart|Patients using the Spirobank Smart
41282349|NCT00575796|DRUG|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
41282350|NCT05064241|OTHER|Access to Genetic Counselor for answering questions|A genetic counselor answers questions posed by participants in the intervention arm on how to access genetic medicine. At the end of the study, the number of participants who were able to access genetic medicine will be assessed
41282351|NCT03273621|PROCEDURE|Bariatic surgery|One of two different types of surgery: sleeve gastrectomy and Roux-en-Y gastric by-pass.
41282352|NCT06346275|PROCEDURE|Acupuncture|Acupoints: Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20), Taixi (KI3), Zusanli (ST36), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7).
41451370|NCT04002024|OTHER|Moisturizer with active ingredients|Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day
41451371|NCT04002024|OTHER|Placebo|Placebo: 1 fingertip unit to cover one side of the face twice a day
41451372|NCT02962180|DEVICE|Dermabrasion with dermaroller|o The dermaroller is passed on the treated depigmented area. This technique is based on tiny microwounds performed using 540 microneedles (0.2mm length) which should allow the penetration of the suspension cells into the epidermis to obtain a good repigmentation.
41132003|NCT01544907|DEVICE|Conventional PTA|Use of conventional balloon for angioplasty only
41132004|NCT01544907|DEVICE|Drug Eluting Balloon (DEB)|Use of DEB after conventional balloon angioplasty
41132005|NCT01292213|PROCEDURE|Cough swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
41132006|NCT01292213|PROCEDURE|Oropharyngeal swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
41132007|NCT01292213|PROCEDURE|Nasopharyngeal swabs|Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
41282353|NCT05584826|DRUG|MDMA|On 2 separate treatment visits, participants will receive dosing of 100 mg MDMA HCl (\~84 mg MDMA) + 40 mg MDMA HCl (\~34 mg MDMA) supplement unless tolerability issues arise from the first dose or the participant declines
41282354|NCT00725738|GENETIC|Stem Cell Transplantation|"1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes."
41282355|NCT04112758|OTHER|High-intensity interval training|2 times weekly for 5 weeks Circuit training with 4 stations
40940599|NCT02738632|DRUG|Telmisartan/Amlodipine|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD"
40940600|NCT02738632|DRUG|Placebo for Hydrochlorothiazide|
40940601|NCT04811573|DRUG|EU-sourced Otezla®|Test product
40940602|NCT04811573|DRUG|US-sourced Otezla®|Reference product 1
40940603|NCT04811573|DRUG|Japan-sourced Otezla®|Reference product 2
40940604|NCT00415454|GENETIC|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
40940605|NCT05473884|DEVICE|lesion preparation devices|successful recanalization of femoropopliteal artery occlusion and then followed by lesion preparation devices and plain old balloon angioplasty
40940606|NCT05473884|DEVICE|conventional balloon|Lumen gain is achieved by plain old balloon angioplasty under working inflation pressure.
40940607|NCT02609698|DEVICE|Coroflex ISAR|This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
40940608|NCT02609698|DRUG|3 months DAPT|
40940609|NCT02609698|DRUG|6 months DAPT|
40940610|NCT04215588|DEVICE|Hemostasis Management System Plus|Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.
40940611|NCT04215588|DEVICE|Activated Coagulation Timer System Plus|The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.
40940612|NCT03361267|DIAGNOSTIC_TEST|Helicobacter pylori PCR test|Clarithromycin resistance (-) Triple therapy (rabeprazole 20 mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid) for 7 days Clarithromycin resistance (+) Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 500 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) for 7 days
41282356|NCT01334073|DRUG|Axitinib plus everolimus|Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
41282357|NCT01940718|DRUG|Transdermal Androgel|T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (\~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
41451373|NCT03306758|DRUG|Sodium Bicarbonate|Sodium Bicarbonate was given 1g tid for one month
40940613|NCT03361267|DIAGNOSTIC_TEST|CLO test|CLO test : negative --\> drop out CLO test : postive --\> bismuth containing quadruple therapy
40940614|NCT05386485|OTHER|None intervation|Observational Study
40940615|NCT00859183|DRUG|Sirolimus|cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
40940616|NCT00859183|DRUG|Sirolimus|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
40940617|NCT00859183|DRUG|Placebo|Placebo oral
40940618|NCT00741962|DIETARY_SUPPLEMENT|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
40940619|NCT00741962|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
41132008|NCT01292213|PROCEDURE|Blood sample|Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
41451374|NCT04072003|DEVICE|intravascular ultrasound (IVUS)|use IVUS in the procedure
41451375|NCT04072003|OTHER|coronary angiography|Coronary angiography is required for all PCI procedure.
40940620|NCT01500512|OTHER|Clinical Observation|Undergo observation
40940621|NCT04300621|DRUG|OTF 1|Participants will receive (S)-ketamine administered sublingually through OTF 1.
40940622|NCT04300621|DRUG|OTF 2|Participants will receive (S)-ketamine administered sublingually through OTF 2.
40940623|NCT04300621|DRUG|OTF 3|Participants will receive (S)-ketamine administered sublingually through OTF 3.
40940624|NCT04300621|DRUG|OTF 4|Participants will receive (S)-ketamine administered sublingually through OTF 4.
40940625|NCT00498524|DEVICE|ICD|Received an ICD
40940626|NCT00498524|DEVICE|ICD|Have not received an ICD
41132009|NCT01292213|PROCEDURE|Bronchoscopy/ bronchoalveolar lavage samples|Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
41132010|NCT01292213|OTHER|Data collection|Questionnaire completion.
41132011|NCT02711332|OTHER|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
41132012|NCT02711332|OTHER|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
41132013|NCT00211549|DRUG|IDEA-033|
41132014|NCT01023698|PROCEDURE|laser photocoagulation|Laser photocoagulation
41267057|NCT01568203|DRUG|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
41267058|NCT01568203|DRUG|Placebo|Matching placebo control for AMG 579 at each dose level
41451376|NCT04096547|DRUG|Rivaroxaban|rivaroxaban for stroke prevention of atrial fibrillation
41451377|NCT03123874|DEVICE|Sterile pump set-up|Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
40940627|NCT05132868|OTHER|Educational video and pamphlet|The primary intervention in this study is watching the video or reading the pamphlet in advance of the genetic counseling session, which overview the same information that we currently provide in-person/via telehealth during the genetic counseling session.
40940628|NCT05132868|OTHER|Traditional genetic counseling|Patients will receive traditional genetic counseling
40940629|NCT01210573|DEVICE|adjustment of LVAD or pacemaker|"For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.~For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide."
40940630|NCT05288413|DEVICE|3-compression Ultrasound scan with AutoDVT software integrated Ultrasound probe|The study coordinator, Miss Kerstin Saupe will perform a three-point compression ultrasound scan (USS) of the upper leg with the AutoDVT software. The AutoDVT software will store the results of the scan for retroperspective analysis and review. Effectiveness of AutoDVT as diagnostic tool will be evaluated in perspective to different patient groups, eg. patients with adipositas or maligner disease,
40940631|NCT05546918|OTHER|survey, interviews and focus groups|"The 2 groups of participants will be invited to:~* complete an anonymous online survey~* participate in individual semi-structured interviews and 2 focus groups"
40940632|NCT03127787|DIAGNOSTIC_TEST|CMV Assay|Molecular diagnostic test to detect CMV
40940633|NCT01539798|OTHER|Oral saline|Ingestion of 2 L of 0.9% saline solution over 1h
40940634|NCT01539798|OTHER|Intravenous saline|Infusion of 2L of 0.9% saline solution over 1h
40940635|NCT01762046|DRUG|Glipizide|
40940636|NCT01762046|DRUG|Metformin|
40940637|NCT01762046|OTHER|Oral Glucose Tolerance Test|
40940638|NCT02903212|BIOLOGICAL|Autologous apoptotic cells injection|cells injection
40940639|NCT02746367|OTHER|Diagnostic test (LDT)|Proteomic assay
40940640|NCT06333821|BIOLOGICAL|Nimotuzumab|Nimotuzumab 400mg
40940641|NCT06333821|DRUG|Cisplatin|Cisplatin 40mg/m\^2
40940642|NCT06333821|RADIATION|External Beam Radiotherapy (EBRT)|External Beam Radiotherapy (EBRT)
40940643|NCT06333821|RADIATION|Brachytherapy|Brachytherapy
40940644|NCT06333821|DRUG|placebo for Nimotuzumab|placebo for Nimotuzumab 400mg
40940645|NCT02531100|DEVICE|BonyPid 500TM implantation concomitantly to SOC treatment|BonyPid 500TM implantation concomitantly to SOC treatment
40940646|NCT02531100|OTHER|SOC treatment only|Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
40940647|NCT01600118|DEVICE|Extracorporeal shockwave therapy|1000 impulses
40940648|NCT01600118|DEVICE|No extracorporeal shockwave|0 impulses, acoustic effect
40940649|NCT00398333|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched nutritional supplement|Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
40940650|NCT05331027|DRUG|Desflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
40940651|NCT05331027|DRUG|Sevoflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
40940652|NCT03613597|DRUG|etoposide plus lobaplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin
40940653|NCT03613597|DRUG|etoposide plus cisplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin
40940654|NCT05442775|DRUG|Reldesemtiv|Oral tablet
40940655|NCT05928871|DRUG|Misoprostol 200mcg Tab|60 women: will receive preoperative 600 microgram of misoprostol ( 3 tablets ) rectally after spinal anaesthesia and urinary catheterization and postoperative placebo (3 tablets). (as per WHO dose recommendation)
40940656|NCT05928871|DRUG|Misoprostol Pill|"60 women: will receive preoperative placebo 3 tablets and postoperative 600 microgram of misoprostol  3 tablets at operating theatre (as per WHO dose recommendation)."
40940657|NCT00234910|DRUG|Tenofovir DF|TDF 300mg QD for 72 wks
40940658|NCT00234910|DRUG|lopinavir/ritonavir with 2 Nucleoside RTIs|LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
40940659|NCT06255210|DRUG|Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)|When the Ki67% index of the tumor is ≥ 25%, patients were treated with the GP regimen for induction chemotherapy; When the Ki67% index of the tumor is \< 25%, patients were treated with the CEP regimen for induction chemotherapy.
40940660|NCT01468103|PROCEDURE|Surgical Iridectomy|Surgical Iridectomy is now widely used in our clinical.
40940661|NCT01468103|PROCEDURE|Laser Iridotomy|alternative choice to surgical iridectomy
40940662|NCT03998813|DRUG|Ropivacaine|Locoregional analgesia by femoral triangle catheterization
40940663|NCT03998813|DRUG|Ropivacaine|Tissue infiltration
40940664|NCT02210468|DEVICE|APIC-CF, 4 cc|
40940665|NCT02210468|DEVICE|APIC-CF, 2 cc|
40940666|NCT02210468|OTHER|Placebo Comparator: Saline|Placebo Comparator: Saline
40940667|NCT03438318|DRUG|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
40940668|NCT03438318|DRUG|Atezolizumab|Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
40940669|NCT03438318|RADIATION|Radiation Therapy|Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
40940670|NCT00378586|PROCEDURE|Rectal biopsy|Rectal biopsy.
40940671|NCT00378586|PROCEDURE|Measurement of inflammatory markers in the rectal mucosa|IL-6, TNF-alfa.
41282358|NCT04057443|OTHER|Nutritional support|Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.
41282359|NCT04057443|OTHER|Physical exercise|The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.
41282360|NCT04057443|DRUG|Hematologic Drug|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
41282361|NCT05243771|PROCEDURE|Rectal resection with diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created
41282362|NCT05243771|PROCEDURE|Rectal resection without diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created
41282363|NCT05243771|PROCEDURE|Rectal resection with permanent colostomy|Patients in this group will receive a rectal resection and a permanent colostomy will be created
41282364|NCT04793776|BEHAVIORAL|Manage Emotions to Reduce Aggression|MERA begins with education about the adaptive nature of emotions, how childhood and military experiences can influence emotion regulation, and how combat requires different emotion regulation strategies than most civilian environments. MERA use modeling and practice with feedback to teach cognitive-behavioral and acceptance-based emotion regulation skills.
41282365|NCT04793776|BEHAVIORAL|Present Centered Psychotherapy|PCT will serve as the comparison group. PCT assists Veterans in understanding and coping with current difficulties, such as aggression, but does not provide systematic training in emotion regulation skills.
41282366|NCT00292773|PROCEDURE|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
41282367|NCT01317849|DRUG|Folic Acid|0.8mg
41282368|NCT01317849|DRUG|Vitamin B6|10mg
41282369|NCT01317849|DRUG|Vitamin B12|500ug
41282370|NCT01317849|DRUG|placebo|0.8 mg
40940672|NCT00378586|PROCEDURE|Measurement of rectal lactic acid|Equilibrium dialysis.
41282371|NCT01317849|DRUG|placebo|10mg
40940673|NCT04104529|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before and during treatment.
40940674|NCT04104529|OTHER|tumor collection|Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
40940675|NCT03862716|DRUG|IDegLira|Dose is titrated to achieve fasting normoglycemia
40940676|NCT03862716|DRUG|insulin degludec|In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
41282372|NCT01317849|DRUG|placebo|500ug
41282373|NCT04060992|DRUG|Elagolix 200 MG Oral Tablet [Orilissa]|oral tablet given twice daily
41282374|NCT00368173|DRUG|rhIGF-I/rhIGFBP-3|
41282375|NCT05187117|BEHAVIORAL|CAPABLE Family - Open Label Pilot|"As in CAPABLE (NA_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations for cognitive decline will be made on a per-client basis as part of the open-label pilot. Topics of adaptations include problem areas addresses, care partner involvement, length/frequency of visits, types of assessments and questions asked, and brainstorming/action planning structure."
41282376|NCT05187117|BEHAVIORAL|CAPABLE Family - Randomized Control Trial|As in CAPABLE (NA_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
41282377|NCT05666154|OTHER|Real diet|Diet excluding either trigger nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger)
41282378|NCT05666154|OTHER|Sham diet|Diet excluding either sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
41282379|NCT05666154|OTHER|Wheat exclusion diet|Diet excluding wheat in a blinded crossover fashion (CLE negative individuals without identified trigger)
41282380|NCT05666154|OTHER|Soy exclusion diet|Diet excluding soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
40756657|NCT06549127|DEVICE|Soft Wearable Robot|This study aims to enroll 20 participants who will receive assistance in flexion and extension of the knee and hip during overground walking adaptation training. Following the initial assessment, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered hip assistive device over two weeks. After completing these sessions, Post-intervention Assessment 1 will be conducted. Then, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered knee assistive device over two weeks, followed by Post-intervention Assessment 2. Each participant will have a total of nine visits, including three functional assessments and six adaptation training sessions. The first visit will involve scheduling subsequent visits. The familiarization process will occur two to three times per week, adjustable for participants' convenience, with each set of three visits completed within three weeks.
40940677|NCT03862716|DRUG|Metformin|Dose is titrated to 2000 mg per day or maximal tolerated dose
41282381|NCT01004107|DEVICE|Radiesse Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
41282382|NCT00397956|DRUG|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
41451378|NCT03123874|DEVICE|Mother's Own pump set-up|Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
41282383|NCT02141061|DRUG|Telapristone Acetate, Proellex 12 mg Formulation A|
41282384|NCT02141061|DRUG|Telapristone Acetate, Proellex 12 mg Formulation B|
41282385|NCT01576471|BIOLOGICAL|Trichuris suis ova (TSO)|TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
41282386|NCT01576471|BIOLOGICAL|Placebo|Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
41451379|NCT00532012|DRUG|RhuDex®|
41451380|NCT04345107|DRUG|SY-009|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
41451381|NCT04345107|DRUG|SY-009 matching placebo|SY-009 matching placebo
41451382|NCT05341154|DRUG|Ketamine Hcl 50Mg/Ml Inj|Patients will be given the active comparator or placebo only once right before the induction of anesthesia.
40756658|NCT02375711|BIOLOGICAL|Blood sample|A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
40756659|NCT01800110|DIETARY_SUPPLEMENT|pomegranate juice|
40940678|NCT03862716|BEHAVIORAL|Lifestyle Therapy|Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
40940679|NCT04704284|DIAGNOSTIC_TEST|Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)|Magnetic Resonance Imaging (MRI) with zero echo-time (ZTE) that uses proton density differences rather than T2 relaxation time differences to achieve contrast.
41267059|NCT03254173|DRUG|Mirtazapine 30 mg oral tablets|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks
40940680|NCT02233062|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition Therapy|
40940681|NCT00096954|DRUG|omalizumab (Xolair)|Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
41267060|NCT03254173|DRUG|Placebo oral tablets|Placebo oral tablets , half tablet daily before sleep for 8 weeks
41267061|NCT00073840|DRUG|levalbuterol|"* Levalbuterol 90 ųg QID (manufacturing sites A or B);~* Racemic Albuterol 180 ųg QID;~* Placebo QID"
41267062|NCT04388501|DRUG|Milvexian|Participants will receive milvexian capsules orally qd for 5 days as per the assigned treatment sequence.
41267063|NCT04388501|DRUG|Atorvastatin|Participants will receive atorvastatin tablets orally qd for 5 days as per the assigned treatment sequence.
41267064|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
41267065|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX (PG)|5.0 grams of PGX
41267066|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX|7.5 grams of PGX
41267067|NCT00801814|DIETARY_SUPPLEMENT|Control|0g of PGX
41267068|NCT00801814|DIETARY_SUPPLEMENT|Second Control|0g of PGX
41267069|NCT05947240|OTHER|aerobic exercises|The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist.
41267070|NCT05947240|OTHER|active alternating movements for the upper limbs|The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks.
41267071|NCT04786067|DRUG|Belatacept|Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.
41267072|NCT05533749|DEVICE|GILL eHealth|The aim of the successfully pilot-tested GILL eHealth intervention is to support mental health nurses and clinical nurse specialists in structured somatic screening and lifestyle promotion. The GILL eHealth intervention consists of two parts. Part one is OurGILL which focuses on systematic somatic screening and provides an overview of all somatic abnormalities. It promotes the prevention, early recognition and treatment of somatic problems. The second part is MyGILL. It provides the basis for drawing up a personalized lifestyle plan. The result of MyGILL is an overview of the performance of patients in different lifestyle areas. The eHealth intervention consists of an individual internet environment and is also supported by an app for mobile devices.
41267073|NCT04140214|DRUG|Hypertonic saline|Nebulized hypertonic saline solution (6%)
41267074|NCT04140214|DRUG|Carbocysteine 750 MG|Carbocisteine tablet
41267075|NCT05717348|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
41267076|NCT05333094|OTHER|Brackets|"Levelling and alignment for the bonded teeth through following the wire sequence: 0.014 NiTi, 16 NiTi, 0.016×0.022 NiTi and 0.017×0.025 StSt. (Wires from American Orthodontics)~• After levelling and aligning is completed the patient will be referred for the uptake of post intervention records; a standardized dental photograph and CBCT after 6- 9 months)"
41267077|NCT02521701|DRUG|NFL101|"Level 1: 100 µg~* 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~* 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
41267078|NCT06449586|DRUG|Letermovir|letermovir stops when CMI\>1.5
41267079|NCT00490542|DRUG|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
40940682|NCT00096954|DRUG|placebo|The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
40940683|NCT05830903|BEHAVIORAL|VR-assisted occupational training|VR-assisted occupational training
41282387|NCT06187818|DRUG|Crocin|According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group \[experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period\]
41282388|NCT00688038|PROCEDURE|Laser Ablation|Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.
41282389|NCT00688038|PROCEDURE|Magnetic Resonance Thermal Imaging|MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
41282390|NCT02001012|DRUG|Artemether-lumefantrine combination|
41451383|NCT02471807|DEVICE|Edwards FORMA Tricuspid Transcatheter Repair System|
40940684|NCT04708119|PROCEDURE|The follicular tissues were also excised after tooth extraction.|The follicular tissues were also excised after tooth extraction. Soft tissue samples taken during surgical removal of ILTM were evaluated in the department of pathology.
40940685|NCT00255801|DRUG|Targretin® (bexarotene)|
40940686|NCT00255801|DRUG|pegylated liposomal doxorubicin hydrochloride|
40940687|NCT05577871|DRUG|Dexmedetomidine|infusion of dexmedetomidine during the off pump coronary artery bypass grafting surgery
40940688|NCT05577871|DRUG|normal saline|infusion of normal saline during the off pump coronary artery bypass grafting surgery
40940689|NCT05471700|DRUG|Azacitidine|Subjects will receive Azacitidine 75 mg/m2 on days 1-7.Each course is 28 days long.
41282391|NCT02001012|DRUG|Chloroquine|
41282392|NCT00532259|DRUG|CT-011|IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
41282393|NCT00193505|DRUG|Ifosfamide|
41282394|NCT00193505|DRUG|Carboplatin|
41282395|NCT00193505|DRUG|Etoposide|
41282396|NCT00193505|DRUG|Rituximab|
40756660|NCT04275869|OTHER|Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
40940690|NCT05471700|DRUG|Venetoclax|Subjects would receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. Each course is 28 days long.
40940691|NCT05346432|DIETARY_SUPPLEMENT|PS23|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
40940692|NCT02634710|RADIATION|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
40940693|NCT02730520|OTHER|Retrospective analysis of patient files|The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
40940694|NCT04533880|DEVICE|DBM|Demineralized bone matrix (Allosync, CDMB Putty, Arthrex, Naples, FL)
41282397|NCT00193505|DRUG|90Y Zevalin|
41282398|NCT00215254|DRUG|quetiapine|
40756661|NCT03178890|DEVICE|OHMG|Device will be implanted in all enrolled patients.
40940695|NCT04533880|DEVICE|Calcium phosphate cement|Quickset, Arthrex, Naples, FL
40940696|NCT04533880|OTHER|Autologous bone graft|Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft
40940697|NCT05773703|DRUG|PSMA-Targeted [In-111]-Labeled Trillium Compound|Radiotracer
40940698|NCT05773703|DRUG|PTI-122|Cytoprotective agent
40940699|NCT03092804|PROCEDURE|ventriculo-peritoneal shunting|A mainstream therapy for NPH. It involves the device of CSF flow control of shunts and accessories(CFDA(I)20143665605)
40940700|NCT00239902|DRUG|FTY720|
41282399|NCT05531656|DRUG|CT1812|Study Drug
41282400|NCT05531656|DRUG|Placebo|Non-active study drug
41282401|NCT02654925|PROCEDURE|Adipose Tissue Biopsy|
41282402|NCT03590457|DEVICE|Airvo 2; High-Flow nasal cannula system|Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
41282403|NCT04734873|DRUG|CPI-006 2 mg/kg + SOC|IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care
41282404|NCT04734873|DRUG|CPI-006 1 mg/kg + SOC|IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care
41282405|NCT04734873|DRUG|Placebo + SOC|IV placebo plus standard of care
41282406|NCT06122584|DRUG|[18F]PSMA-1007|Diagnostic radiopharmaceutical for PET scan
41282407|NCT00367471|DRUG|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
41282408|NCT00367471|DRUG|carboplatin|An alkylating agent used in the treatment of some cancers
41282409|NCT00367471|DRUG|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
41282410|NCT00367471|DRUG|paclitaxel|A mitotic inhibitor used in cancer treatment
41282411|NCT04902287|BEHAVIORAL|Training Intervention for the Engagement of Families (TIES)|This intervention involves training service personnel in a method of communication that elicits a person's intrinsic motivation for change.
41282412|NCT05751005|DIETARY_SUPPLEMENT|Collagen Peptides vs. Placebo|Participants were randomized into one of three treatment groups.
40940701|NCT02172066|BEHAVIORAL|Narrative Exposure Therapy (NET)|
40940702|NCT04461249|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
40940703|NCT04461249|DRUG|Travoprost 0.004% ophthalmic solution|Travoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
40940704|NCT04461249|DRUG|Tafluprost Ophthalmic 0.0015% Ophthalmic Solution|Tafluprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
40940705|NCT02435329|OTHER|Baseline comparison of microcirculation and bone metabolism|Baseline comparison of microcirculation and bone metabolism among the 5 different groups
40940706|NCT01982331|BIOLOGICAL|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
40940707|NCT01982331|OTHER|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
40940708|NCT01496768|DIETARY_SUPPLEMENT|Leucine|7,2 g/day during 3 months
40940709|NCT01496768|DIETARY_SUPPLEMENT|Alanine|7,2 g/day during 3 months
40940710|NCT03423134|OTHER|New adhesive strip|This is a strip made of a newly developed adhesive
40940711|NCT00069433|PROCEDURE|Social skills and symptom management training|
40940712|NCT05036369|DEVICE|Vibrant capsule|Vibrant capsule - Administered twice a week (Monday and Thursday).
40940713|NCT05036369|DEVICE|Placebo capsule|Placebo Capsule administered twice a week (Monday and Thursday)
40940714|NCT03956056|BIOLOGICAL|Neoantigen Peptide Vaccine|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
40940715|NCT03956056|DRUG|Poly ICLC|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
40940716|NCT03956056|PROCEDURE|Blood for immune monitoring|-Baseline, day 1, day 22, day 50, day 78, week 25, and week 73
40940717|NCT03779958|OTHER|Mobile App|a mobile app that demonstrates hand therapy exercises
41451384|NCT04388787|DEVICE|Stochastic resonance (SR) wraps|SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
40940718|NCT02775604|BEHAVIORAL|Video based/Therapists' rating of comprehensive-home-fall-hazard-checklist (vt-CHFHC)|The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
40940719|NCT02775604|BEHAVIORAL|Paper based/Patient self-rating of comprehensive-home-fall-hazard-checklist (pp-CHFHC)|A paper version of CHFHC and other self-reported documents will be completed by the participants in their homes based on standardized verbal instruction provided by the research staff.
40940720|NCT01459237|DRUG|Acthrel|Ovine Corticorelin
40940721|NCT02171702|DRUG|BIBW 2992|
40940722|NCT00989690|DRUG|docetaxel|
40940723|NCT00989690|DRUG|erlotinib hydrochloride|
40940724|NCT00989690|DRUG|pemetrexed disodium|
40940725|NCT00989690|GENETIC|fluorescence in situ hybridization|
40940726|NCT00989690|GENETIC|mutation analysis|
40940727|NCT00989690|GENETIC|proteomic profiling|
40940728|NCT00989690|OTHER|immunohistochemistry staining method|
40940729|NCT00989690|OTHER|laboratory biomarker analysis|
40940730|NCT00989690|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
40940731|NCT00989690|PROCEDURE|breath test|
40940732|NCT05512364|DRUG|Elacestrant|400mg QD orally on a continuous dosing schedule
40940733|NCT05512364|DRUG|Tamoxifen|20 mg QD orally on a continuous dosing schedule
40940734|NCT05512364|DRUG|Letrozole 2.5mg|2.5 mg QD orally on a continuous dosing schedule
40940735|NCT05512364|DRUG|Anastrozole 1mg|1 mg QD orally on a continuous dosing schedule
40940736|NCT05512364|DRUG|Exemestane 25 MG|25 mg QD orally on a continuous dosing schedule
40940737|NCT02147912|OTHER|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
40940738|NCT06418893|DRUG|Target control infusion propofol|target control infusion of propofol for target plasma concentration 2.5mcg/ml and BIS 40-60
40940739|NCT06418893|DRUG|Inhalational isoflurane|Inhalational Isoflurane at concentration 1-2%
40940740|NCT00289484|DRUG|Omega-3 Polyunsaturated Fatty Acids|
40940741|NCT04406285|OTHER|Standard protocol Leukemia|"* Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets)."
41267080|NCT00490542|DRUG|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
41267081|NCT04909905|DIETARY_SUPPLEMENT|Standard enteral nutrition|Standard enteral nutrition according to ICU nutrition protocol for 7 days
41267082|NCT04909905|COMBINATION_PRODUCT|Glutamine|Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days
40940742|NCT04406285|OTHER|Periodic Resistance Training Program Leukemia|"* Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels."
40940743|NCT04406285|OTHER|Standard protocol Lymphoma|"* Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets)."
40940744|NCT04406285|OTHER|Periodic Resistance Training Program Lymphoma|"* Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels."
40940745|NCT03358537|DIETARY_SUPPLEMENT|Clear Liquid Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
40940746|NCT03358537|DIETARY_SUPPLEMENT|Low-residue Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
40940747|NCT01328171|DRUG|FOLFOXIRI + Panitumumab|irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
40940748|NCT01328171|DRUG|FOLFOXIRI|irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
40940749|NCT02998216|PROCEDURE|Bilateral sacrospinous fixation|Bilateral sacrospinous vaginal suspension
40940750|NCT03139695|DIAGNOSTIC_TEST|Ultrasound|High resolution Ultrasound of the Diaphragm and Intercostal muscles
40940751|NCT01490554|PROCEDURE|autologous fibroblasts grafts|Autologous cultured fibroblasts will be grafted in facial skin
40940752|NCT01008631|DRUG|Sodium thiosulfate|6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
40940753|NCT02942875|OTHER|mirror therapy|"During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.~The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced."
41451385|NCT01327976|DEVICE|vBloc (Active Device)|Active device will deliver vBloc Therapy
41451386|NCT01327976|DEVICE|Sham (Non-active Device)|Functional non-active control device will deliver no vBloc Therapy
40940754|NCT02942875|OTHER|control therapy|Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
40940755|NCT03516708|DRUG|Epacadostat|Patients will receive epacadostat at the designated dose level starting the day of radiation therapy, throughout the chemotherapy, and until the day of surgery. If the patient dose not proceed with the surgery, epacadostat will be discontinued after the last biopsy is performed, and after the investigator confirms non-operative management plans.
40940756|NCT03516708|RADIATION|Short-course radiation|Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
40940757|NCT03516708|DRUG|CAPOX chemotherapy|CAPOX is typically capecitabine at 1000 mg/m2 PO BID (Days 1-14 of each 3-week cycle) and oxaliplatin 130 mg/m2 IV Q3W. The second cycle of epacadostat will begin when CAPOX starts. Patient will receive a total of 6 cycles of CAPOX chemotherapy.
40940758|NCT03359239|DRUG|Atezolizumab|1200 mg administered by IV infusion every 3 weeks (21 \[+/-2\] days) for up to 12 months in the adjuvant setting and up to 24 months in the metastatic setting.
41267083|NCT02146339|OTHER|Cheese n°1- cheese n°2 - cheese n°3|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
41267084|NCT02146339|OTHER|Cheese n°1- cheese n°3 - cheese n°2|"Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
41267085|NCT02146339|OTHER|cheese n°2 - cheese n°1- cheese n°3|"Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
41267086|NCT02146339|OTHER|Cheese n°2- cheese n°3 - cheese n°1|"Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
41267087|NCT02146339|OTHER|Cheese n°3 - cheese n°1- cheese n°2|"Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
41267088|NCT02146339|OTHER|Cheese n°3- cheese n°2 - cheese n°1|"Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
41267089|NCT04939688|RADIATION|Conventional dose AND ultra low-dose CT scanning in the search for cranial lesions|As well as undergoing the usual, conventional radiation dose CT scan, these patients will also undergo ultra low-dose CT scanning in the search for cranial lesions.
41282413|NCT02660554|OTHER|Polymerase Chain Reaction (PCR)|Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
41282414|NCT06127212|DRUG|Dapagliflozin 10 mg film-coated tablet|One tablet of the test drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
41282415|NCT06127212|DRUG|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia|One tablet of the reference drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
41451387|NCT06143202|DEVICE|Freestyle Libre 3 Continuous Glucose Monitor|Pediatric participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.
40940759|NCT03359239|BIOLOGICAL|PGV001|"PGV001: up to ten total doses of PGV001with helper peptides. The product is prepared within the ISMMS . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.~A dose of PGV001 consists of the following:~Up to ten synthetic peptides - 100μg (0.01 mL, 10 mg/mL) per peptide. One tetanus helper peptide - 100μg (0.01 mL, 10 mg/mL)"
40940760|NCT03359239|DRUG|Poly ICLC|1.4 mg (0.7 mL, 2 mg/mL)
40940761|NCT03359239|DRUG|Normal saline|0.19 mL
41451388|NCT03764592|OTHER|radiofrequency ablation|Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
41282416|NCT03715543|PROCEDURE|Surgical Resection of the Greater Splanchnic Nerve|"Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated."
41282417|NCT02623361|DRUG|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
41282418|NCT02623361|DRUG|Sham Block|Sham Block by saline injection
41282419|NCT05786170|DIAGNOSTIC_TEST|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging
41282420|NCT05432570|PROCEDURE|Group A - Muscle Relaxants Used|Induction will be achieved with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium stored at 4 degrees. After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
41282421|NCT05432570|PROCEDURE|Group B - No Muscle Relaxants|Induction will be provided with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol. After ventilation, vocal cords will be seen with a Macintosh laryngoscope, and 2cc of 2% lidocaine will be applied to the vocal cords as a spray with the help of a 5 ml injector. After ventilation, laryngoscopy will be performed with a Macintosh laryngoscope by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
41282422|NCT06380998|DIETARY_SUPPLEMENT|whey protien|Whey, the supernatant of yogurt and a byproduct of cheese, is rich in protein and consists of β-lactalbumin, α-lactoglobulin, immunogloblin, bovine serum albumin, and other minor proteins. Whey protein is a globally consumed food material and is well known for its health benefits
41282423|NCT02680067|DRUG|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
41282424|NCT02680067|DEVICE|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
41282425|NCT01305369|DRUG|Prasugrel|"Patients will be blindly and randomly allocated to treatment A (prasugrel 10 mg daily) or B (placebo) for 15 days. After a 15-day wash-out period, patients who had initially been allocated to treatment A will be allocated to treatment B, and vice versa."
41282426|NCT06123156|DRUG|Sildenafil|Sildénafil during 10 months (50mg daily), start 30 days after surgery
41282427|NCT06123156|OTHER|Placebo|1 platelet during 10 months (daily), start 30 days after surgery
41282428|NCT06278259|OTHER|Telerehabilitation program bases aerobic and Baduanjin exercises|It is an interventional study in which 60 stroke patients estimated to enrol according to random allocation and divided into two groups. The study group participants involve in Telerehabilitation sessions is based on low-impact rhythmic movements, guided by video, according to the protocol of (Schachter et al., 2003). The telerehabilitation program is moderately intense aerobic exercise 3 times per week and included 3 parts: warm-up, central part, and cool-down. Each session : 30 min, 3 sessions/ week for 3 months.With the Baduanjin exercise program is delivered individually, at each patient's home, through telerehabilitation, with direct remote supervision by a physiotherapist
40756662|NCT03673228|BEHAVIORAL|Comprehensive Relapse Prevention Intervention|"This intervention consists of 4 components:~1. Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling~2. Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit~3. Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit~4. Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations"
40756663|NCT03673228|BEHAVIORAL|Standard Treatment Counseling|Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge
41282429|NCT06278259|OTHER|Telerehabilitation program bases aerobic exercises|The telerehabilitation program is moderately intense aerobic exercise 3 times per week and included 3 parts: warm-up, central part, and cool-down. Each session : 30 min, 3 sessions/ week for 3 months.
41451389|NCT05652257|DRUG|[14C]-brensocatib|Oral solution.
41451390|NCT05539937|OTHER|Quality of life questionnaire|Before TAVI, 30 days, 6 months and twelve months after TAVI, patients will answer TASQ questionnaire,
41451391|NCT02143726|DRUG|sorafenib|Given PO
41451392|NCT02143726|DRUG|everolimus|Given PO
41451393|NCT02355847|OTHER|Lectures|Lectures
40940762|NCT01032902|DEVICE|In Vitro Diagnostic Device|For the detection of antibodies to HIV in serum, plasma, blood and oral fluid
40940763|NCT05639465|BEHAVIORAL|JoH-C19|Journey of Hope- COVID 19 (JoH-C19) includes eight, 1-hour consecutive sessions delivered in groups of 8 children during the school day and in after school settings. The 1.5 hour JoH-C19 caregiver workshop is delivered with groups of 8 parents prior to the child JoH-C19 curriculum
40756664|NCT03673228|DRUG|Nicotine Replacement Therapy (NRT)|Patients in both arms will be encouraged to receive NRT
40756665|NCT00641212|DRUG|Budesonide|
40756666|NCT00641212|DRUG|Placebo|
41282430|NCT03918512|OTHER|nine online self-administered questionnaires|"patients will be invited to complete the following nine online self-administered questionnaires at baseline, 7 days and 3 months:~* Demographical and clinical characteristics at baseline~* Consolidated version of the CSS-48 questionnaire~* Lumbar pain numeric rating scale (NRS)~* Radicular pain NRS~* Zurich Claudication Questionnaire (ZCQ) (physical function subscale)~* Oswestry Disability Index (ODI)~* Fukushima LSS Scale 25 (FLS-25)~* 12-Item Short Form Health Survey (SF-12)~* Anchoring questions : 1 anchoring question about patient acceptable symptom state (at baseline, 7 days and 3 month) and 1 anchoring question about patient minimal clinically important difference (at 3 months)."
41282431|NCT02947750|DRUG|6R-BH4|Participants will receive 200 mg of 6R-BH4 twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
41451394|NCT00869713|BIOLOGICAL|Inactivated, Dried (TSI-GSD 200), RVF Vaccine|All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 \& 14, \& once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer \<1:40. Initial non-responders: Individual who has a PRNT80 titer \<1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 \<1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of \<1:40.
40756667|NCT02729012|DRUG|hypertonic saline solution (NACL 3%+NAHCO3)|Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
40756668|NCT02729012|OTHER|Saline Solution (NACL 0,9%)|Treatment with nebulized Saline Solution (NACL 0,9%)
41451395|NCT05821608|OTHER|Message variation 1|Message before call letting member know they will be called (variation 1)
40940764|NCT05639465|BEHAVIORAL|Switch off Get Active|Switch off Get Active covers 4 topics, and its eight, 1- hour sessions are delivered in groups of 8 children. The 1.5 hour Switch Off Get Active caregiver workshop is delivered with groups of 8 parents prior to the Switch off Get Active child curriculum
40940765|NCT05560035|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
40940766|NCT05560035|OTHER|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
41282432|NCT02947750|OTHER|6R-BH4 placebo|Participants will receive a placebo that is identical to 200 mg of 6R-BH4. The placebo will be taken twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
41282433|NCT02947750|DIETARY_SUPPLEMENT|Folic acid|Participants will take 1 mg of folic acid daily for 12 weeks. Folic acid is given because it enhances the binding affinity of BH4 to nitric oxide synthase (NOS), and also enhances the regeneration of BH4 from inactive BH2
41282434|NCT02947750|OTHER|Exercise training|Participants will exercise 3 times a week on a stationary ergometer. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) calculated utilizing the Karvonen method. Briefly, target exercise heart rate (HR) is calculated by subtracting the persons age from 220. Resting heart rate is then subtracted from this number. The answer is then multiplied by the target percent (50% for example) and the product is added back to resting heart rate to provide the target exercise session heart rate. Intensity will be increased by 5% every week (as tolerated by the participant) to a maximum of 80% of maximal heart rate. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week.
41451396|NCT05821608|OTHER|Message variation 2|Message before call letting member know they will be called (variation 2)
41451397|NCT02331108|DRUG|Selection of anesthetic induction technique|Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
41451398|NCT04149691|DRUG|CPL304110|CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
41451399|NCT05448235|OTHER|conventional treatment|the patient will be asked to make pursed lip breathing (Breathe in for 2 seconds through his nose and Breathe out for 4 seconds through pursed lips)for 5-10 min ,3-4 times , 8-10 rep each cycle then asked to make diaphragmatic breathing exercise (Lie on his/her back and Inhale deeply through his/her nose for a count of three)for 5-10 min , 3-4 times , 8-10 repetition then postural drainage , furthermore the patient takes different position (prone to make percussion on lower lobes, side lying on anterior basal segment then sitting position on the upper lobe). After that a vibration on the chest (place a flat hand firmly atop the lung segment to be drained., and should apply light pressure and create a rapid, shaking movement) 1 min inhale and 5 time of repetition at the exhale and finally asked the patient to make productive cough for 5 times to get out the sputum.
40756669|NCT05654519|DRUG|PENG/LFCN and QL Blocks|Bupivacaine 0.25% injection
40756670|NCT00707304|DRUG|Talactoferrin|Oral, 1.5 grams twice per day
40756671|NCT00707304|DRUG|Placebo|Oral, twice per day
40940767|NCT06016192|BEHAVIORAL|Aerobic Exercise Training|Physical activity performed as controlled aerobic exercise training on ergometer
41132015|NCT00765544|DEVICE|Anklebot|The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
40756672|NCT02980900|DIETARY_SUPPLEMENT|Post exercise protein-polyphenol supplement|Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
41132016|NCT00765544|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
40947883|NCT04507100|BEHAVIORAL|World Health Organization Health Promoting Schools|"Healthy eating: regulation and monitoring of food sold in school cafeterias, healthy eating behavior change campaign, provision of healthy breakfasts.~Physical activity: hourly active breaks during classes, quality physical education, active recess, and extra-curricular leisure activities and tournaments.~Healthy hydration: access to water fountains and regular monitoring of water safety, regulation and monitoring of beverages sold in the school, and social marketing campaign promoting drinking plain water.~Other cross-sectional activities: Referral of children identified as living with underweight, overweight, or obesity, training for school directors, teachers and parents, establishment of school objectives to become a health promoting school, monitoring progress, and publicly acknowledging school progress in becoming a health promoting school."
41282435|NCT02947750|OTHER|Stretching|Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.
41282436|NCT02947750|DIETARY_SUPPLEMENT|Histidine and beta-alanine supplementation|Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes. Participants randomized to this study arm will receive combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
41282437|NCT02947750|OTHER|Histidine and beta-alanine placebo|Participants randomized to this study arm will receive a placebo to match combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
41282438|NCT00504257|DRUG|Avastin|Day 1, every 21 day cycle
41282439|NCT00504257|DRUG|Docetaxel|Day 1, 8, every 21 day cycle
41282440|NCT01684826|RADIATION|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
41282441|NCT01684826|RADIATION|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
41282442|NCT06185920|OTHER|Description of severe infection|Description of severe infections treated with bacteriophage in the Hospices Civils de Lyon from 2015 to 2033.
41282443|NCT03280329|OTHER|Generalized Music therapy|Patients will receive broadcasted music via speakers in their room from 7am to 11pm, from admission to discharge
41282444|NCT03280329|OTHER|Personalized Music therapy|Patients will receive music via earphones after specific music therapist advice, for 2 hours per day, from admission to discharge
41132017|NCT02300467|DRUG|NOV120401|5 to 45 mg/day PO for 5 consecutive days and 2 days off
41132018|NCT02966249|DRUG|Levobupivacaine|3 ml Levobupivacaine 0.5% (15mg) given intrathecally
41132019|NCT02966249|DRUG|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
41282445|NCT03138915|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
41282446|NCT03138915|PROCEDURE|CTA|Radiomic features were extracted from CTA images.
41282447|NCT03940885|PROCEDURE|Erector spinea plane block group|Which will receive ultrasound-guided erector spinea plane block bilaterally and the local anesthetic injected will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
41132020|NCT02966249|DRUG|Normal Saline added intrathecally|Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
41132021|NCT02966249|DRUG|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
41132022|NCT02966249|DRUG|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
41132023|NCT02966249|DRUG|Dexmetomidine intrathecally|5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
41132024|NCT05520359|DEVICE|Mobility Device|Use of mobility device during session.
41282448|NCT03940885|PROCEDURE|Transversus abdominis plane block|Which will receive ultrasound-guided Transversus Abdominis plane block bilaterally and the local anesthetic used will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
40940768|NCT04796571|BEHAVIORAL|Proactive Symptom Monitoring and Care Coordination|Patients randomized to the intervention arm were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care. Symptom monitoring was facilitated through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. The IBD-focused care coordinator made two attempts to reach each participant using portal messaging, followed by a phone call to reduce non-response. PRO questionnaires were reviewed by the care coordinator and out of range scores triggered algorithm-based recommendations to the IBD specialist including stricter monitoring of disease activity, behavioral and medication adherence counseling, facilitation of expedited follow-up with treating providers, and referrals to social work, mental health, and gastroenterology-specific behavioral health services.
40756673|NCT02980900|DIETARY_SUPPLEMENT|Post exercise placebo supplement|Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
40940769|NCT00234403|DRUG|gefitinib and fulvestrant|
40940770|NCT03708848|DRUG|Esomeprazole|Proton pump inhibitor
41282449|NCT03940885|PROCEDURE|Control group|this group will receive only standard general anesthesia
41282450|NCT01252966|BEHAVIORAL|Cognitive Training|The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
41282451|NCT01252966|BEHAVIORAL|Control training|The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
41282452|NCT05167201|DEVICE|Nasal High Flow|High flow nasal cannula (NHF) is a device that delivers warmed and humid air through a high air flow rate, through the nose. It is used as a non-invasive ventilatory approach, which is relatively comfortable, in the management of respiratory failure and has been investigated in several studies evaluating the outcomes as domiciliary treatment in patients with COPD.
41282453|NCT04630314|DEVICE|Percutaneus Coronary Intervention|Covered Stent
41282454|NCT02756871|OTHER|online guided self-help intervention for perfectionism|"CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony"
40756674|NCT02980900|DIETARY_SUPPLEMENT|Pre bed protein-polyphenol supplement|Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
40756675|NCT02980900|DIETARY_SUPPLEMENT|Pre bed placebo supplement|Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
40756676|NCT01104298|DRUG|Doxorubicin|A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
40756677|NCT01104298|DRUG|Trabectedin|A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
40756678|NCT02242903|DRUG|LY3079514|Administered SC
40756679|NCT02242903|DRUG|LY3079514|Administered IV
40756680|NCT02242903|DRUG|Placebo|Administered SC
40940771|NCT03708848|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
40940772|NCT03708848|DRUG|Clarithromycin|antibiotic for H. pylori eradication
40940773|NCT03708848|DRUG|Metronidazole|antibiotic for H. pylori eradication
40940774|NCT03708848|DRUG|Levofloxacin|antibiotic for H. pylori eradication
40940775|NCT03708848|DRUG|Tetracycline|antibiotic for H. pylori eradication
40940776|NCT01880216|DRUG|Bemiparin sodium|subcutaneous application daily for 7±2 days
40940777|NCT01880216|DRUG|Enoxaparin sodium|subcutaneous for 7±2 days
40940778|NCT02887573|DRUG|Free-residue nutrients|This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
40940779|NCT02887573|DRUG|Low fiber diet|Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
40940780|NCT02887573|PROCEDURE|Colon capsule endoscopy|In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
40940781|NCT02887573|DRUG|2L PEG|2L PEG are laxatives for experiment group.
40940782|NCT02887573|DRUG|4L PEG|4L PEG are laxatives in the control group.
40940783|NCT02887573|DRUG|PEG|These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
40940784|NCT02887573|DRUG|Mosapride citrate|5mg mosapride citrate are used to promote gastric motivity.
40940785|NCT00645684|PROCEDURE|Gastrointestinal Anastomosis|Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
40940786|NCT00381251|DRUG|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
41451400|NCT05448235|OTHER|thoracic mobilization|we will use A SNAG to mobilization using type 3 oscillatory and sustain for 90 second, at first put the patient in 3 position (side lying to make mobilization of upper 6 ribs in downward direction then make on lower 6 ribs ,furthermore flexion of the thoracic and next rotation toward the midline then ask the patient to transfer to supine lying position and mobilize the sternum in downward direction the next mobilize the clavicle and ask the patient to take sitting position and put his hand on his head in adduction position and make extension on the thoracic vertebrae with inward mobilize with the investigator knees ,take each 4 vertebrae along the 12 thoracic vertebrae.
40940787|NCT00560274|DRUG|Pegasys|As prescribed
40940788|NCT00560274|DRUG|Ribavirin|As prescribed
40940789|NCT00560274|DRUG|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
40756681|NCT02242903|DRUG|Placebo|Administered IV
40940790|NCT05953376|DRUG|Calcium Gluconate|There will be 2 study arms, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion.
40940791|NCT03037801|DEVICE|Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)|IPV physiotherapy 3 times a day
40940792|NCT01248481|DRUG|Acarbose (Glucobay, BAYG5421)|Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
40940793|NCT03110744|DRUG|Palbociclib|application on 21 consecutive days of a 28 days cycle
40940794|NCT02165709|PROCEDURE|Salpingectomy|
40940795|NCT02165709|PROCEDURE|Traditional sterilization|
40940796|NCT01511965|OTHER|autologous (cellular therapy)|The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
40940797|NCT00518973|DRUG|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
40940798|NCT00518973|DRUG|Placebo|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
40756682|NCT02702999|DEVICE|Clinically-indicated ultrasound|Routine third trimester care with clinically-indicated ultrasound (control)
40940799|NCT01922674|PROCEDURE|Standard open tension-free inguinal hernia repair with mesh|
40940800|NCT03815617|DIETARY_SUPPLEMENT|Zircombi|Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs ± 11 SD) were enrolled and randomized to treatment or placebo in a a crossover randomized double-blind two-block placebo-controlled trial. Abdominal pain and bloating, intestinal habits, severity of disease, intestinal permeability, and intestinal microbiota were performed at the different time points.
40940801|NCT03815617|DIETARY_SUPPLEMENT|Placebo|Given as comparable packets. Same duration.
40940802|NCT01135290|DRUG|Aquaphor|
40940803|NCT01135290|DRUG|HP828-101|
40940804|NCT00561769|DRUG|Norditropin pen|12 IU per day
40940805|NCT06374771|DRUG|Melatonin 10 MG|10 mg of Melatonin will be given orally pre and post-operative
40940806|NCT06374771|DRUG|Vitamin C|1 gm of Vitamin C will be given orally pre and post-operative
40940807|NCT05360368|DRUG|HLX07|A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle
40940808|NCT04329442|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|30 day supply of 200mg tablets
40940809|NCT01348607|DRUG|methylphenidate hydrochloride|Given orally
40940810|NCT01348607|DRUG|modafinil|Given orally
40940811|NCT01348607|DRUG|placebo|Given orally
40940812|NCT00902161|DRUG|MK0893|Single dose of MK0893 1000 mg (ten 100 mg tablets)
40940813|NCT00902161|DRUG|MK0893-matched Placebo|Single dose of placebo to MK0893 (ten tablets)
40940814|NCT00902161|DRUG|Propranolol Hydrochloride (HCL)|Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
40940815|NCT00575250|BEHAVIORAL|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
40940816|NCT00575250|BEHAVIORAL|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
40940817|NCT01763671|DRUG|Docetaxel|75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
40940818|NCT01763671|DRUG|Paclitaxel|90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
41282455|NCT02271490|OTHER|Acrosome Reaction induction|
41282456|NCT02271490|OTHER|capacitation in incubation medium prior to ICSI|
41282457|NCT01576211|GENETIC|DNA methylation analysis|
41282458|NCT01576211|GENETIC|RNA analysis|
41282459|NCT01576211|GENETIC|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
41282460|NCT01576211|GENETIC|gene expression analysis|
40940819|NCT01763671|DRUG|Bevacizumab|10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
40940820|NCT04095390|DRUG|Pyrotinib|400 mg
40940821|NCT04095390|DRUG|SHR6390|125mg
40940822|NCT04095390|DRUG|Letrozole|2.5mg
40940823|NCT04095390|DRUG|Capecitabine|500mg
40940824|NCT02224092|DIETARY_SUPPLEMENT|multivitamin multimineral with phytonutrient supplementation|"The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo."
40940825|NCT04208568|PROCEDURE|Laparoscopic cholecystectomy|Four ports laparoscopic cholecystectomy under general anaesthesia
40940826|NCT01163266|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
41282461|NCT01576211|GENETIC|nucleic acid sequencing|
41282462|NCT01576211|GENETIC|polymorphism analysis|
41282463|NCT01576211|OTHER|laboratory biomarker analysis|
41282464|NCT04884828|DEVICE|external gas during NIV|The procedure was performed in the patient's room during his or her hospital stay to avoid additional visits for study participation. The patient was placed in the supine position, and the usual ventilator interface was placed in a single-limb system, along with the commercial ventilator to be studied. The ventilator model were evaluated at bedside in random order. The parameters of the ventilator were the same as those that the patients used at home (that is, unlike the bench study, the sensitivity of the trigger was not modified). A external polygraph was used to moritor the study, with the incorporation of thoracic and abdominal bands and parasternal electromyography, to better evaluate asynchronies, in addition to pulse oximetry control. The ventilation periods were 1 minute (without gas, gas, without gas). This sequence was performed twice in each group of established conditions.
41282465|NCT02172118|DRUG|BI 1774 CL|
41451401|NCT04432636|OTHER|Data collection of environmental factors|- Data collection of environmental factors (including maternal nutrition and social level, mode of delivery, birth weight, mode of infant feeding, antibiotic treatments) at the recruitment
41282466|NCT05836961|OTHER|Benazir Nashonuma Program (BNP)|"Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy (1/4 of daily energy requirements for children in this age range)~Conditional Cash Transfers (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
41282467|NCT05326919|OTHER|Biobanking|For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.
40756683|NCT02702999|DEVICE|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
40756684|NCT03024411|OTHER|iPod (Music/video games)|Experimental patients will be given an iPod to enjoy music/video games during induction of labor.
41282468|NCT05059197|DIETARY_SUPPLEMENT|AP collagen peptide|Health functional food
41282469|NCT05059197|DIETARY_SUPPLEMENT|Placebo|placebo
41451402|NCT04432636|OTHER|Collection of maternal feces|- Collection of maternal feces: the first sample after delivery and once a week during the period of hospitalization of their infant (i.e. 5 to 8 samples per mother)
40756685|NCT00635466|PROCEDURE|laparoscopic surgery for rectal carcinoma|Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (\<8 cm).
41132025|NCT05520359|DEVICE|Spinal Stimulation|A stimulator will be used non-invasively stimulate the spine at the neck and/or lower back (cervical and/or lum
41282470|NCT06231043|DRUG|Diclofenac/Tramadol|"Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse."
41282471|NCT04000035|OTHER|Health and work environment information and processes|see arm/group description
41282472|NCT01458769|DRUG|C-10276|C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose
41282473|NCT01458769|DRUG|C-10276|C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose
41282474|NCT01458769|DRUG|C-10297|C-10297 200 mg, oral, single dose
41282475|NCT01458769|DRUG|C-10299|C-10299 200 mg, oral, single dose
41282476|NCT01458769|DRUG|C-10297|C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose
41282477|NCT01458769|DRUG|C-10299|C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose
41282478|NCT01458769|DRUG|C-10276|C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose
40756686|NCT06548620|DRUG|RD06-04 cell infusion|CAR T Cells
40756687|NCT02986438|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.~Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold."
41132026|NCT03624335|PROCEDURE|ECC|Early clamping of the umbilical cord
41132027|NCT03624335|PROCEDURE|DCC|Delayed clamping of the umbilical cord
41282479|NCT01458769|DRUG|Reyataz®|Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
41282480|NCT01179295|DRUG|BAY86-9766|BAY86-9766 30 mg twice a day (bid).
41282481|NCT01179295|DRUG|BAY86-9766|BAY86-9766 50 mg twice a day (bid).
41282482|NCT01179295|DRUG|BAY86-9766|BAY86-9766 100 mg once a day (od)
41282483|NCT01179295|DRUG|BAY86-9766|BAY86-9766 60 mg once a day (od)
41282484|NCT03943381|DEVICE|Duplex US|Duplex US (Caliper, wave forms...)in evaluation of Pelvic Veins (namely left ovarian vein). in pelvic congestion syndrome
41282485|NCT02296346|DRUG|SoluMedrol|Infusion of drug subcutaneously, once a month.
41282486|NCT02296346|DEVICE|Extracorporeal Photopheresis|This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
41282487|NCT01967225|DRUG|Tedizolid Phosphate (Sivextro, BAY1192631)|BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
41282488|NCT01967225|DRUG|Linezolid|Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
41282489|NCT01720771|DIETARY_SUPPLEMENT|probiotic tablet|Intake of one probiotic lozenge tablet per day
41282490|NCT01720771|DIETARY_SUPPLEMENT|sugar pill|one tablet daily
40940827|NCT01163266|DRUG|Placebo|Vortioxetine placebo-matching capsules
40940828|NCT05427591|PROCEDURE|"The chemomechanical caries removal agent BRIX3000® in group (1A)"|"In group(1A), the chemomechanical caries removal agent BRIX3000® was used for caries removal in primary molars."
40940829|NCT05427591|PROCEDURE|The traditional surgical treatment in group (1C)|In group(1C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
40940830|NCT05427591|PROCEDURE|"The chemomechanical caries removal agent Carie-CareTM in group (2B)"|"In group(2B), the chemomechanical caries removal agent Carie-CareTM was used for caries removal in primary molars."
40940831|NCT05427591|PROCEDURE|The traditional surgical treatment in group (2C)|In group(2C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
40940832|NCT01512056|DRUG|AdimFlu-S|All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
40940833|NCT03300310|OTHER|nursing visit|nursing visit at patient home
40940834|NCT03300310|OTHER|no nursing visit|the patient take his treatment without nursing visit
40940835|NCT02983396|DEVICE|Diagnostic accuracy of Mini Relf Device|Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty
40940836|NCT01147588|DRUG|lansoprazole|60 mg (2x30-mg capsule), once daily
40940837|NCT01147588|DRUG|omeprazole|80 mg (2x40-mg capsule), once daily
40940838|NCT01147588|DRUG|esomeprazole|40 mg (1x40-mg capsule), once daily
40940839|NCT01147588|DRUG|clopidogrel|300 mg loading dose on Day 1 then 75 mg daily for 28 days
40940840|NCT03304418|DRUG|Radium Ra 223 Dichloride|Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals
40940841|NCT03304418|RADIATION|Radiation|"All external beam radiations oligometastatic sites will commence after cycle 1 of Radium-223 but prior to cycle 2 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation.~Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2:~* Single fraction: 16 Gy total at 16 Gy per fraction (SBRT)~* Three fractions: 24 Gy total at 8 Gy per fraction (SBRT)~* Five fractions: 30 Gy total at 6Gy per fraction (SBRT).When using five fractions, can reduce to 25 Gy total at 5 Gy per fraction (SBRT) or to a minimum of 20 Gy total at 4 Gy per fraction (SBRT), per treating investigator.~* Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)"
40940842|NCT02946320|DEVICE|Predilatation with non-compliant balloon|Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
40940843|NCT02946320|DEVICE|Predilatation with scoring balloon (Scoroflex)|Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
40940844|NCT02946320|DEVICE|Predilatation with cutting balloon (Flextome)|Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
40940845|NCT00731016|DRUG|Zoledronic acid, pravastatin|"Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~* injection 1, S1: 0.0125 mg/kg of zoledronic acid~* injection 2, S6: 0.025 mg/kg of zoledronic acid~* injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid"
40940846|NCT01833546|DRUG|Evofosfamide|Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m\^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
40940847|NCT01833546|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
40940848|NCT03014492|DEVICE|Q Collar|Collar designed to mitigate slosh in the brain
40940849|NCT04494360|OTHER|No intervention|No investigational medicinal product will be administered as a part of this study.
41282491|NCT01377493|DIETARY_SUPPLEMENT|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
40940850|NCT00904397|DRUG|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
40947884|NCT03001882|BIOLOGICAL|Nivolumab|Specified dose on specified days
40947885|NCT03001882|BIOLOGICAL|Ipilimumab|Specified dose on specified days
41132028|NCT03624335|PROCEDURE|Blood Test 6hours|Blood Test 6hours
41132029|NCT03624335|PROCEDURE|Blood Test 24hours|Blood Test 24hours
41132030|NCT03624335|PROCEDURE|Blood Test 48hours|Blood Test 48hours
41132031|NCT03624335|PROCEDURE|Blood Test 28days|Blood Test 28days
40940851|NCT00904397|DRUG|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
40940852|NCT03439943|DRUG|Lixisenatide|Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day
40940853|NCT03439943|DRUG|placebo|Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).
41282492|NCT06114043|OTHER|Conservative treatment with orthopedic aid/wide shoe for participants with mild to moderate hallux valgus|60 participants will receive conservative treatment with orthopedic aid/wide shoe. Participants will be followed for 2 years.
41282493|NCT06114043|OTHER|Operation for mild to moderate hallux valgus|60 participants will receive the traditional operative treatment for the deformity. Participants will be followed for 2 years.
41282494|NCT06261814|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
41282495|NCT06261814|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
41282496|NCT06261814|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
41282497|NCT06261814|OTHER|Medical Chart Review|Ancillary studies
41282498|NCT00212914|BEHAVIORAL|Reminder letter|
41282499|NCT03876587|DRUG|Pyrotinib Maleate combine with Docetaxel|Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
41282500|NCT04410302|PROCEDURE|Biospecimen Collection|Undergo collection of tumor tissue, blood, saliva, and urine samples
41282501|NCT04557904|OTHER|Craniocervical flexion exercises|Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible. Subject has to slightly raise his/he skull a few centimeters. Fingers should be touching the cranium but not supporting it. Subject had to respire and hold the position. Subject has the move out the chin. Stop exercise and restart again. Perform this exercise for 10 times by holding this position for 20 sec at the start of the exercise, increasing it by 10 seconds every session commonly underwent pectoralis minor stretching before every session of exercise of 4 sets with 30 second's hold
41282502|NCT04557904|OTHER|Scapular stabilization exercises|The scapular stabilization exercises were made up of four stages: (1) In supine position, the patient was commanded to deep respire for the sake of relaxation by maintain the cervical and shoulder in relaxing position to take a deep breath to relax the body while holding her shoulders and neck in relaxing position. (2) The patient then flex her knees and placed her feet flat on the plinth, and maintain the pose without any cervical movement. Then the patient asked to raise her dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. This position was sustained for 10 seconds before going to initial position. Three laps of 10 repetitions with one-minute interval in between were performed. (3) In quadruped position, the patient raise her arms alternatively with shoulder abduction and 120 ° flexion. That posture was held for 10 seconds before returning to the starting position. (4) In sitting position
41282503|NCT02499952|DRUG|Pembrolizumab|200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
41282504|NCT02463942|DRUG|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
41282505|NCT02463942|DRUG|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
41282506|NCT02463942|OTHER|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
40940854|NCT04284852|DRUG|Niraparib|PARP inhibitor
40940855|NCT05346250|BEHAVIORAL|Non-exercise control|12 month lifestyle education
40940856|NCT05346250|BEHAVIORAL|Moderate intensity exercise|12 month moderate intensity exercise by brisk walk 30 min per day and more than 5 days per week.
40940857|NCT05346250|BEHAVIORAL|Vigorous intensity exercise|6 month vigorous intensity exercise on treadmill for 30 min per day and more than 5 days per week, and subsequent 6 month moderate exercise by brisk walk 30 min per day and more than 5 days per week.
40940858|NCT00402142|BIOLOGICAL|Dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
40940859|NCT00402142|BIOLOGICAL|non pulsed dendritic cell untreated patients|107 DC subcutaneous 3 doses every 2 weeks
40940860|NCT00402142|BIOLOGICAL|pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
41282507|NCT04535063|BIOLOGICAL|COVID19 convalescent plasma infusion|intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott)
41282508|NCT00215150|DRUG|Ziprasidone|Sertraline augmentation with ziprasidone
41282509|NCT00215150|DRUG|Sertraline|Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
41451403|NCT04432636|OTHER|Collection of infant feces|- Collection of infant feces: the first sample after birth and once a week during the period of hospitalization of the baby (i.e. 5 to 8 samples per mother) and a sample collected at the corrected age of 1 year and 2 years (i.e. 8 to 10 samples per infant)
41451404|NCT04432636|OTHER|food questionnaire|- A food questionnaire completed by the mother the week after delivery,
41282510|NCT04118361|DIAGNOSTIC_TEST|HINTS Test|"The HINTS test is a clinical test composed of 3 oculomotor examinations:~* Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~* Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~* Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging."
41282511|NCT04118361|DIAGNOSTIC_TEST|STANDING Algorithm|The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
40756688|NCT02986438|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).~This condition will only last two weeks."
40756689|NCT04845555|OTHER|Observation of the association between clotting factor level and risk of bleeding whilst physical activity|"The participants of this study will be monitored for a period of twelve months regarding individual clotting factor level, bleeding episodes as well as type and intensity of physical activity. By doing so, bleeding events, factor consumption as well as the course of the individual factor clotting factor level will be documented via the mobile application myPKFiT. This individual factor treatment regime will be compared with the retrospective treatment outcome in the last twelve months before the first study visit."
40756690|NCT01554709|DEVICE|Aortic Cannulas (CardioGard)|Comparison of aortic cannulas during by pass surgery
40940861|NCT00402142|BIOLOGICAL|dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
40940862|NCT00402142|BIOLOGICAL|non pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
40940863|NCT06325904|PROCEDURE|Uniportal VATS|"* single port video-assisted thoracoscopic surgery in the 5th intercostal space~* performed under general anesthesia.~* pleural fluid/pus was drained~* pleural adhesions was removed"
40940864|NCT06325904|PROCEDURE|Tube thoracostomy|"* Chest tube is inserted in 5th mid-axillary line~* performed under local anaesthesia"
41282512|NCT03883893|DRUG|Intravenous acetaminophen|Intravenous acetaminophen will be given in the OR.
41282513|NCT03883893|OTHER|Normal saline|Normal saline will given if randomized to this group.
41282514|NCT01713062|DEVICE|Vitelene|THA
40756691|NCT03236805|DRUG|Ketamine|Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care
40756692|NCT03236805|DRUG|Morphine|Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
40756693|NCT01093573|DRUG|midostaurin|Given orally
40756694|NCT01093573|DRUG|azacitidine|Given IV
40940865|NCT05221307|OTHER|exercises|Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
40940866|NCT03709641|DEVICE|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL
40940867|NCT01216124|DRUG|docetaxel oxaliplatin|"docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2~1 cycle=21 days DO\*6"
40940868|NCT02826850|PROCEDURE|Saphenous Nerve|Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
40940869|NCT02826850|PROCEDURE|Genicular nerves|Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
41282515|NCT01713062|DEVICE|XLPE|THA
41451405|NCT04432636|OTHER|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year
40756695|NCT01093573|OTHER|bone marrow aspiration|Correlative study: Pretreatment bone marrow aspirates or blood \[(3 ml in EDTA tube (purple top)\] will be analyzed according to local institution guidelines to determine whether blasts contain wild type Flt3, ITD, or Flt 3 mutations.
40756696|NCT01093573|OTHER|mutation analysis|Correlative study
40756697|NCT01093573|OTHER|Pharmacokinetic study|Correlative study: Concentrations of unchanged midostaurin and its major metabolites, CGP52421 and CGP62221 in plasma samples will be determined using a validated liquid chromatography / mass spectrometry method.
40756698|NCT01545310|DRUG|SLV354|One dose of ABT-354
40756699|NCT00974597|DEVICE|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
40756700|NCT00069953|BIOLOGICAL|filgrastim|During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients \>70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
40940870|NCT02350673|DRUG|Atezolizumab|Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
40940871|NCT02350673|DRUG|Cergutuzumab Amunaleukin|Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
40940872|NCT03875118|BEHAVIORAL|The mouth-opening training with follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
40947886|NCT03800173|DRUG|galidesivir|galidesivir IV infusion
40947887|NCT03800173|DRUG|placebo|placebo IV infusion
41282516|NCT06286618|BEHAVIORAL|Psychosocial Intervention|Psychosocial intervention is an intensive behavioral therapy intervention to address dietary behaviors. Each intervention session is a one-on-one interaction that focuses on setting individualized dietary goals and following up on them and is delivered by trained personnel. Sessions are delivered in 3 modalities which include face-to-face, phone call, and telehealth delivery. Each participant is randomly assigned to receive 4 weeks of each modality in one of the following orders: 1) Face-to-face; Telehealth; Phone Call 2) Telehealth; Phone Call; Face-to-face 3) Phone call; Face-to-face; Telehealth.
40940873|NCT03875118|BEHAVIORAL|The mouth-opening training without follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
41451406|NCT04432636|OTHER|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years
41451407|NCT04432636|OTHER|Sample of milk|A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day (if not possible between the 7th and the 10th postnatal days).
41451408|NCT04432636|OTHER|The 'Ages and Stages Questionnaire' ASQ|- The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up
41451409|NCT00232687|DRUG|Aripiprazole|Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
41451410|NCT00232687|DRUG|Aripiprazole|Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
41451411|NCT01441349|DRUG|IP chemotherapy|"Irinotecan/cisplatin (IP) chemotherapy~* Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8.~* Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 \& 8~* Every 21 days"
41451412|NCT01441349|DRUG|IP chemotherapy plus simvastatin|"* Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8~* Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1\& 8.~* Every 21days.~* Simvastatin 40 mg per day orally D1of cycle 1"
41451413|NCT03328364|DRUG|enzalutamide|oral
41451414|NCT03328364|DRUG|docetaxel|intravenous infusion
41451415|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 50 mg QD
41451416|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 100 mg QD
40940874|NCT02438657|PROCEDURE|median nerve block|
41451417|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 300 mg QD
41451418|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
41451419|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
41451420|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
41451421|NCT01316237|DRUG|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
40940875|NCT02861131|DRUG|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
41451422|NCT01316237|DRUG|GS-6620 tablet|GS-6620 tablet, 900mg , BID
41451423|NCT01316237|DRUG|GS-6620 tablet|GS-6620 tablet, 900 mg
41451424|NCT02702635|PROCEDURE|DCE MRI of the brain|An MRI of the brain including a DCE sequence
41451425|NCT06174558|DEVICE|Sleep Tracking Devices|Observational Study, Smartwatches and home sleep device for sleep and respiratory monitoring
41451426|NCT05343676|DEVICE|ultrasonography|"* For assessment of LNS ( cervical , axillary and inguinal LNS ), The choice of transducer is an important consideration when evaluating lymph nodes as higher frequencies provide better resolution for superficial structures~* For color Doppler assessment of the lymph nodes, scanning will be done using the slow frame rate, low pulse repetition frequency~* Assessment features including lymph node location, size, shape, border, echogenicity, calcifications, necrosis or cystic change, and adjacent soft tissue edema"
41451427|NCT00867763|PROCEDURE|In vitro maturation and in vitro fertilization|No gonadotropin, eggs harvested early
41451428|NCT00867763|PROCEDURE|Low doses of gonadotropin stimulation.|Gonadotropin followed by conventional IVF
41451429|NCT02607826|PROCEDURE|Starvation|Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
41451430|NCT05264896|DRUG|5-FU, Leucovorin, Oxaliplatin, Docetaxel|FLOT 4 cycles pre and post radical gastrectomy
41451431|NCT05264896|DRUG|XELOX|XELOX 8 cycles post radical gastrectomy
41451432|NCT05779358|OTHER|Expectancy and gluten|Effect of expectancy to receive gluten and/or actual gluten intake
41451433|NCT04234568|PROCEDURE|Biospecimen Collection|Correlative studies
41451434|NCT04234568|PROCEDURE|Computed Tomography|Undergo CT
41451435|NCT04234568|DRUG|Lutetium Lu 177 Dotatate|Given IV
41451436|NCT04234568|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41451437|NCT04234568|DRUG|Triapine|Given PO
41451438|NCT03701945|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
41451439|NCT02677558|OTHER|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
41451440|NCT01715779|DRUG|Eltrombopag|Eltrombopag exposure
41282517|NCT06286618|OTHER|Structural Intervention|The structural intervention is designed to supplement the diet with food resources via three modalities: voucher-based or F/V prescription, home meal delivery, or food bank box program. The voucher-based model includes a weekly $50 gift card with a prescription for having to eat more fruits and vegetables. The home meal delivery model includes a meal subscription that supplements the diet with two meals for two people each week (four total servings worth $65 including shipping). The food bank box program consists of participants picking up a box of food weekly from a food pantry located in the outpatient clinic. Each participant is randomly assigned to receive 4 weeks of each modality in one of the following orders: 1) Voucher; Meal Delivery; Food Box 2) Meal Delivery; Food Box; Voucher 3) Food Box; Voucher; Meal Delivery.
41282518|NCT06286618|OTHER|Traditional Psychosocial+Structural|Participants will receive a combination of psychosocial and structural intervention, based on the most feasible selections from the preparation phase of the study. The intervention will initiate in a referral-based fashion in which participants will receive referral at enrollment visit.
41451441|NCT03087162|DRUG|Dexlansoprazole 60 mg once daily|Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
41451442|NCT04506918|OTHER|IVR survey|Participants will receive an IVR survey
41451443|NCT04506918|OTHER|SMS survey|Participants will receive a SMS survey
41451444|NCT06065280|DRUG|Empagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
40940876|NCT02861131|DRUG|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
40940877|NCT01514331|OTHER|SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
41451445|NCT06065280|DRUG|Dapagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
41451446|NCT06331572|DIAGNOSTIC_TEST|17-HAMD|Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
40940878|NCT01514331|OTHER|PSV+VG (pressure support ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with PSV+VG
40940879|NCT01699932|DRUG|Glimepiride+metformin (Amaryl M®) - HOE4900|"Pharmaceutical form:tablet~Route of administration: oral"
40940880|NCT02045173|OTHER|Apneascan TM|Autoscoring algorithms with automatical detection of sleep apnea by the Apneascan TM
40940881|NCT02045173|DEVICE|Polysomnography/polygraphy|1 night polysomnography/polygraphy
40940882|NCT00046514|DRUG|ABI-007|
40940883|NCT04814732|DRUG|Surufatinib|HMP-012
40940884|NCT00121264|DRUG|sorafenib tosylate|Given orally
40940885|NCT00121264|DRUG|tanespimycin|Given IV
40940886|NCT00121264|OTHER|laboratory biomarker analysis|Correlative studies
40940887|NCT00121264|OTHER|pharmacological study|Correlative studies
40940888|NCT00121264|PROCEDURE|magnetic resonance imaging|Correlative studies
40940889|NCT01675427|OTHER|Interleukin 28B testing|Blood sampling for ILB28 genotyping
40940890|NCT03819673|BEHAVIORAL|Intervention Group Care|children's assessment, setting weight management goals, provision of personalised meal plans, personalised diet and lifestyle optimization advice recommendations to children and their families, periodic re-evaluation every 3 or 6 months
41451447|NCT05539157|DRUG|JCXH-211|JCXH-211 administered once every 28 days
41451448|NCT02902601|DRUG|JNJ-54175446, 600 mg|Participants will receive JNJ-54175446, 600 mg as an oral suspension.
41451449|NCT02902601|DRUG|JNJ-54175446, 150 mg|Participants will receive JNJ-54175446, 150 mg as an oral suspension.
41451450|NCT02902601|OTHER|Placebo|Matching placebo to JNJ-54175446
41451451|NCT03672240|DRUG|APL-1202|To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
41451452|NCT02501863|DRUG|Femoral nerve block with ropivacaine+fentanyl|Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
41451453|NCT02501863|DRUG|Femoral nerve block with ropivacaine|Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
41451454|NCT04737239|OTHER|Corticosteroid injections for CTS treatment|Treatment of carpel tunnel syndrome with corticosteroid injections for EMG mild and EMG negative patients
40940891|NCT05153473|DEVICE|Total Hip Arthroplasty Revision|Hip revision surgery is performed to repair an artificial hip joint (prosthesis) that has been damaged over time due to an infection, or due to normal wear and tear of the prosthetic hip. Revision surgery helps to correct the problem so the hip can function normally again.
40940892|NCT01583543|DRUG|Olaparib|400mg PO BID Continuous
40940893|NCT00563420|PROCEDURE|Bronchoscopy|
40940894|NCT03092271|BEHAVIORAL|Stepped Care for Suicide Prevention|ZSQI plus Stepped Care for Suicide Prevention
40940895|NCT03092271|BEHAVIORAL|Zero Suicide Quality Improvement|ZSQI
40940896|NCT05358015|PROCEDURE|vascularized bone graft for scaphois nonunion|vascularized bone graft for scaphois nonunion
40940897|NCT02874287|DRUG|Hydroxychloroquine Sulfate Tablets|Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
40940898|NCT02874287|DRUG|Placebo Tablets|Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
40940899|NCT05812079|DIAGNOSTIC_TEST|skin biopsy examined by ELISA technique|skin biopsy examined by ELISA technique
40940900|NCT06265051|DRUG|Tirofiban|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
40940901|NCT06265051|DRUG|Saline placebo|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.
40940902|NCT05299723|BEHAVIORAL|BLT Intervention|BLT will be administered via a Luminette 3 light therapy visor. The Luminette 3 is a visor worn above the eyes containing light emitting diode (LEDs) emitting a blue-enriched white light reflecting to the retina at 1,000 lux via a holographic system in order to ensure correct penetration into the eye without impeding vision. This range of light and intensity is sufficient to synchronize the circadian clock.
40940903|NCT05299723|BEHAVIORAL|BLB Intervention|BLB will be administered via orange lenses that filter out short-wavelength blue light, while allowing the other visible spectrum light to pass. The BLB lenses result in a reduction in melanopic irradiance (i.e., the light that affects sleep) of about 85%. The BLB lenses only make the overall light environment about 30% dimmer. Therefore, the BLB lenses are effective in blocking out most of the blue light in the visible environment that impacts sleep, but do not result in drastic overall dimming/darkening of the light environment.
40940904|NCT05299723|BEHAVIORAL|Sleep Hygiene Education|The sleep hygiene education will consist of watching a sleep education video (background on the regulation of sleep, the impacts of insufficient sleep on mental and physical health, etc.) and a sleep hygiene video (providing overview of sleep hygiene approaches).
40940905|NCT00002121|DRUG|Diethylhomospermine|
40940906|NCT06237647|DIETARY_SUPPLEMENT|Hyaluronic acid, HA|improve tissue repair
40940907|NCT05174845|DRUG|1L PEG + ASCORBIC ACID|"* 2-Day Split-Dosing: The patient has taken the product in the evening before the scheduled colonoscopy and mandatory additional clear fluid. The patient has taken the second dose with mandatory additional clear fluids on the morning of the colonoscopy.~* Same Day: The patient has taken the first dose of the product on the day of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break, the patient has taken a second dose plus additional clear mandatory fluid."
41282519|NCT06286618|OTHER|Integrated Psychosocial+Structural|Participants will receive a combination of psychosocial and structural intervention, based on the most feasible selections from the preparation phase of the study. The intervention will initiate in an integrated fashion in which participants will receive immediate onboard at enrollment visit.
41282520|NCT03243903|DEVICE|QS-M insulin-free injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
41282521|NCT03243903|DEVICE|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
41282522|NCT04427085|OTHER|Ultrasound assessment of optic nerve sheath diameter|Using ultrasonography, optic nerve sheath diameter is measured during perioperative period.
41282523|NCT04372238|BEHAVIORAL|RAPIDS Intervention|RAPIDS intervention combines a behavioral intervention along with hands-on training to use fentanyl test strips.
40940908|NCT02289001|BEHAVIORAL|Education on SBAR worksheet|The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
40940909|NCT01397812|DEVICE|BreathScanner 1.0|For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
40940910|NCT01397812|DEVICE|BreathLink|The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
40940911|NCT02276404|BEHAVIORAL|relaxation training|"The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes."
41451455|NCT04044573|PROCEDURE|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
41451456|NCT03077451|OTHER|Laboratory Biomarker Analysis|Correlative studies
41451457|NCT03077451|DRUG|Nelfinavir Mesylate|Given PO
41451458|NCT03949062|DRUG|Ibrutinib|Ibrutinib 560mg per day administered orally on Day 1-21 of each 21-day cycle for 6 cycles
41451459|NCT03949062|DRUG|Lenalidomide|Lenalidomide 25mg per day administered orally on Day 1-10 of each 21-day cycle for 6 cycles
41282524|NCT04372238|BEHAVIORAL|Standard OEND|In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
41282525|NCT03002506|DRUG|Ceftolozane/tazobactam|Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
41451460|NCT03949062|DRUG|Rituximab|Rituximab 375mg/m2 per day administered intraveneously on Day 1 of each 21-day cycle for 6 cycles
41451461|NCT04584541|BIOLOGICAL|blood tests|Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)
41451462|NCT04584541|BIOLOGICAL|Nasopharyngeal swabs|SarS-Cov-2 viral load assessment
41451463|NCT04584541|BIOLOGICAL|Stools|SarS-Cov-2 viral load assessment
41451464|NCT03889639|DRUG|SAR442168|Pharmaceutical form: Film coated tablet; Route of administration: Oral
41451465|NCT03889639|DRUG|Placebo|Pharmaceutical form: Film coated tablet; Route of administration: Oral
41282526|NCT05386914|DRUG|Sirolimus|1 mg of Sirolimus taken orally once a day for 4 weeks.
41282527|NCT02719054|BEHAVIORAL|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|"A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum."
41451466|NCT03889639|DRUG|Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
41451467|NCT04739735|PROCEDURE|Dental Local Anaesthesia|lower primary molar teeth indicated for extraction will be given a local anaesthetic injection according to the random allocation to one of the two arms mentioned previously
41451468|NCT01949324|BIOLOGICAL|Ciliary neurotrophic factor (CNTF)|Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
41451469|NCT01949324|PROCEDURE|Sham procedure|Sham surgery for Sham arm
41451470|NCT01949324|DEVICE|NT-501 Implant|NT-501 encapsulated cell implant
41451471|NCT01949324|PROCEDURE|NT-501 Implant procedure|Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
41451472|NCT02956096|DEVICE|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.
41451473|NCT02956096|DEVICE|training on the running belt|The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
41451474|NCT04322513|DIAGNOSTIC_TEST|Biomarkers expression|Evaluation in biomarkers expression between 2 groups
41451475|NCT03893617|DRUG|Propranolol|A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.
41451476|NCT03893617|DRUG|Placebo oral capsule|A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
41451477|NCT03893617|BEHAVIORAL|Acute stress task|Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.
41451478|NCT03893617|BEHAVIORAL|No stress task|Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
40756701|NCT00069953|BIOLOGICAL|pegfilgrastim|During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
41282528|NCT05381961|DEVICE|Bioimpedance spectroscopy (BIS) measurement, SOZO device|All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.
41282529|NCT03681860|BIOLOGICAL|ChAdOx185A|ChAdOx1 85A is an adenoviral vaccine based on a vector that is a chimpanzee adenovirus isolate Y25 expressing the M.tb antigen 85A. Adenoviruses are attractive candidates for use as viral vectors and have been used as vaccine vectors for a number of conditions; however, the use has been limited by the high level of anti-vector immunity present in humans in whom adenovirus is a ubiquitous infection. This has led to the consideration of simian adenoviruses, which are not known to cause pathology or illness in humans and to which the prevalence of anti-vector antibodies is low. The ChAdOx1 vector has been developed by the University of Oxford and been used with different inserts for vaccination, for example the vaccine ChAdOx1 NP+M1 has demonstrated an excellent safety profile in the Influenza trial FLU004. A BCG - ChAdOx1 85A - MVA85A prime boost regime is more protective than BCG alone in mice.
41282530|NCT03681860|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly-attenuated strain of vaccinia virus which cannot replicate in human cells. It is known to be highly immunogenic in UK adults but has been less immunogenic in African children and infants. It is suitable for use as a viral vector in a prime-boost regime in new vaccine development. It has an excellent safety record as it was administered intradermally to approximately 120,000 people during the smallpox eradication campaign, and has since been used in numerous clinical trials of candidate vaccines against viral, mycobacterial and protozoal infections.
41282531|NCT03681860|BIOLOGICAL|BCG|BCG is the only vaccine currently approved for use against Tuberculosis.
41282532|NCT00235157|DEVICE|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
41282533|NCT02286102|DEVICE|OrthoPAT|OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
41282534|NCT02286102|DEVICE|Constavac|Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
41282535|NCT01836315|OTHER|Observational Study|
41282536|NCT01815398|BEHAVIORAL|Cognitive Remediation|Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
41282537|NCT01815398|BEHAVIORAL|Computer Skills Training|Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
41282538|NCT00996840|DRUG|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
41282539|NCT00996840|DRUG|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
41282540|NCT00996840|DRUG|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
41282541|NCT00996840|DRUG|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
41282542|NCT00996840|OTHER|Placebo|Placebo to match intervention
41282543|NCT05304208|BIOLOGICAL|Mesopher|autologous monocyte-derived DCs loaded with PheraLys (tumor cell lysate)
41282544|NCT00412529|DRUG|Entecavir|Entecavir 0.5 mg once daily for 12 weeks.
41282545|NCT00412529|DRUG|Telbivudine|Telbivudine 600 mg once daily for 12 weeks.
41282546|NCT01071070|DRUG|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
41282547|NCT04900701|OTHER|Energy status|Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
41282548|NCT03904615|DIETARY_SUPPLEMENT|Whey Protein|30 g of whey protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
41451479|NCT02588144|PROCEDURE|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
40756702|NCT00069953|DRUG|cisplatin|During induction therapy, patients receive 15 mg/m\^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m\^2/day by IV over 1 hour beginning on days 57-61.
41282549|NCT03904615|DIETARY_SUPPLEMENT|Collagen Protein|30 g of collagen protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
41282550|NCT03904615|DIETARY_SUPPLEMENT|Placebo|30 g of maltodextrin in flavored water, twice daily, during hospitalization and for 30 days post-discharge
41451480|NCT02588144|PROCEDURE|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
41451481|NCT05250960|DEVICE|SCD|Patient will receive 1L of LR and have SCDs applied 15 minutes before epidural placement and will be removed 1 hour after epidural placement
41282551|NCT04075227|DRUG|0.2% loteprednol etabonate|Use topical 0.2% loteprednol etabonate eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
40940912|NCT02276404|OTHER|acupuncture|The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
40940913|NCT04744038|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
40940914|NCT04808284|DEVICE|Transcranial direct-current stimulation|A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
40940915|NCT04808284|DEVICE|Transcranial direct-current stimulation|A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
40940916|NCT04808284|DEVICE|Sham Transcranial direct-current stimulation|A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.
40940917|NCT04562493|PROCEDURE|Transforaminal Epidural injection|Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
40940918|NCT00460369|DRUG|sulfadoxine-pyrimethamine|"tablets 1,25/25 mg~1 tablet per 20 kg of body weight Single drug intake"
40940919|NCT00460369|DRUG|artemether-lumefantrine|"tablets 20/120 mg~* 1 tablet twice daily for 3 days below 15 kg of bodyweight~* 2 tablets twice daily for 3 days below 24 kg of bodyweight~* 3 tablets twice daily for 3 days below 35 kg of bodyweight"
41282552|NCT04075227|DRUG|0.1% dexamethasone|Use topical 0.1% dexamethasone eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
41282553|NCT06297304|BEHAVIORAL|Sedentary and physical activity behaviors|The intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: Week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators related to sedentary behaviors and the physical activity levels will be recorded to assess the progress of each student.
40940920|NCT00460369|DRUG|amodiaquine-artesunate coformulation|"one 25mg/67,5mg tablet, once daily for 3 days below 9 kg~one 50/135mg tablet, once daily for 3 days below 18 kg"
40940921|NCT04671485|OTHER|Standard care|Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
41282554|NCT00251797|DRUG|Irinotecan|Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
41282555|NCT00251797|DRUG|Thalidomide|Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
41282556|NCT01237470|PROCEDURE|Desarda technique|no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal
41282557|NCT01237470|PROCEDURE|Lichtenstein technique|hernioplasty with the usage of plain polypropylene mesh
41282558|NCT02365428|BEHAVIORAL|Physical activity text messages|
41282559|NCT01025635|DRUG|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
41282560|NCT01025635|DRUG|Vehicle foam|Applied topically twice daily for 12 weeks
41282561|NCT01519726|DRUG|Midazolam|
41451482|NCT04823832|PROCEDURE|pancreaticoduodenectomy|resection of the head of pancreas and the duodenum followed by triple anastomosis
41451483|NCT04874428|DRUG|Rivaroxaban 10 mg Oral Tablet|Administration of one single dose of rivaroxaban (10 mg) in tablet form.
41451484|NCT04874428|DRUG|Apixaban 2.5 mg Oral Tablet|Administration of one single dose of apixaban (2.5 mg) in tablet form.
41451485|NCT02169323|OTHER|Step-down|Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
41451486|NCT04837469|PROCEDURE|fissure sealant application|fissure sealants were placed after differnt adhesive strategies used
41451487|NCT02997176|DRUG|Talazoparib|Daily oral doses of talazoparib 0.5 mg
41451488|NCT02934620|DEVICE|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
41451489|NCT02934620|DEVICE|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
40756703|NCT00069953|DRUG|fluorouracil|During induction therapy, patients receive 650 mg/m\^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m\^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
40940922|NCT04671485|OTHER|Autohypnosis|"The patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
40940923|NCT04671485|OTHER|Musicotherapy|"the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
40940924|NCT01037322|DRUG|cannabidiol|cannabidiol given in olive oil drops, 5 mg twice daily
40940925|NCT01037322|DRUG|placebo in drops|olive oil containing no drug given in drops twice daily
40940926|NCT04007211|DEVICE|ABT13107|Dose: 3mL, maximum 10mL
40940927|NCT04007211|DEVICE|Hyalobarrier|Dose: 10mL
40940928|NCT06023225|BEHAVIORAL|Pain|Postoperative pain levels
40940929|NCT06023225|BEHAVIORAL|Opioid use|Postoperative opioid use
40940930|NCT03539354|DEVICE|Temporary spinal cord stimulation|Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.
40940931|NCT03539354|PROCEDURE|Coronary artery bypass grafting|Standart coronary artery bypass grafting procedure.
40940932|NCT03539354|DRUG|B-blockers|Standart b-blocker therapy will be administered in each group for AF prophylactics
40940933|NCT03901456|BEHAVIORAL|Care to Plan|Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. Caregivers will complete the tool with the guidance of a CtP interventionist (Senior Care Navigator/Riverside Health System staff). The interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a recommended support service if so desired.
40940934|NCT03901456|BEHAVIORAL|Usual Care|"Receive care as usual.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
40940935|NCT04960410|COMBINATION_PRODUCT|Types and exposure of different air pollutants|Types and exposure of different air pollutants in COPD patients' living and working environment
40940936|NCT00017238|DRUG|KRN5500|Given IV
40940937|NCT00017238|OTHER|pharmacological study|Correlative studies
40940938|NCT05136131|PROCEDURE|Electrical cardioversion|"Shocks are delivered as per the Ottawa Cardioversion Protocol in the shock arm. 1) 200J shock delivered using self-adhesive electrodes in an anteroposterior configuration. 2) 200J shock delivered using self-adhesive electrodes in an anterolateral configuration while applying pressure over the electrodes with disconnected standard handheld paddles. 3) 360J shock delivered using the same technique as in (2). 4) As per the treating physician's discretion."
41451490|NCT02934620|BEHAVIORAL|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
40756704|NCT00069953|DRUG|paclitaxel|During induction therapy, patients receive 200 mg/m\^2/day by IV over 2 hours on days 1 and 29.
40940939|NCT05136131|OTHER|Sham electrical cardioversion|No shock is delivered in the sham procedure arm.
40940940|NCT04926727|OTHER|Survey|Observational study
40940941|NCT04499976|DRUG|Isonicotinic Acid|Drug: Isonicotinic Acid then misoprostol Drug: Isonicotinic Acid 300mg total dose 900 mg per day for 3 days
40940942|NCT04499976|DRUG|Placebo|Drug: placebo then misoprostol Drug: Placebo placebo for 3 days
40940943|NCT04499976|DRUG|Misoprostol|Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
40940944|NCT00674167|DRUG|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
40940945|NCT00674167|DRUG|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
40940946|NCT00674167|DRUG|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
40940947|NCT03910959|OTHER|Animal-assisted therapy|Therapy in the presence and with interaction with an animal. Involved animals can be all species that live at REHAB Basel and are part of the AAT program. All animals are trained for the specific service with vulnerable patients.
40940948|NCT03910959|OTHER|Conventional therapy|Parallelled conventional therapy sessions (treatment as usual)
40940949|NCT05910177|DRUG|Karelizumab combined with etoposide and cisplatin|Karelizumab：200 mg，ivgtt，D1，q3w； Cisplatin：75 mg/m2，ivgtt，D1，q3w； Etoposide：100 mg/m2，ivgtt，D1\~3，q3w
40940950|NCT00979069|BEHAVIORAL|Aerobic group|12 weeks of aerobic exercise 3 times a week
40940951|NCT05161871|DEVICE|Cathodal transcranial direct current stimulation|The cathodal transcranial direct current stimulation protocol will consist in five daily sessions, each lasting 20 min. The montage will provide a bilateral stimulation on occipital areas, with the reference anodal electrodes positioned on the M1 areas. The stimulation will be applied via 4 conductive-rubber square electrodes (5x5 cm) placed in sponges saturated with high conductivity gel and connected to a battery-operated stimulator system. Direct current with maximal intensity of 1.5 mA with be provided for 20 minutes.
40940952|NCT05161871|DEVICE|Sham cathodal transcranial direct current stimulation|Sham stimulation will be performed by the same protocol as active stimulation; however, the device will be switched off 30 seconds after the beginning of stimulation. This way, the patient will experience the same sensations as with active stimulation without receiving actual stimulation.
40940953|NCT02504710|DEVICE|Kinematic Real Time Feedback|
40940954|NCT02504710|OTHER|Traditional systems of manual therapy teaching|
40940955|NCT05468151|OTHER|Cold acclimation|The cold water immersions will last 30-60 minutes per day and the volunteers will undergo 2-3 cold immersions per week.
40940956|NCT05468151|OTHER|Intervention Control group - volunteers with obesity|Participants with obesity in the control group will undergo PET/CT scans at baseline and 12 weeks after the first scan.
40940957|NCT05468151|OTHER|Acute cold exposure|All participants (lean and with obesity) will undergo PET/scans after 2 hours of cold exposure to investigate BAT perfusion and BAT glucose uptake.
40940958|NCT03332771|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
40940959|NCT03332771|DRUG|Glimepiride|"Pharmaceutical form: capsule~Route of administration: oral"
40940960|NCT03332771|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
40940961|NCT03332771|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
40940962|NCT03332771|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
40940963|NCT03391310|OTHER|Honey (medicated)|Honey (medicated) dressing will be used in the experimental group
40940964|NCT04256096|DEVICE|Thrombectomy|Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
40940965|NCT03644680|DIAGNOSTIC_TEST|Nasal Provocation with Birch Extract|Nasal spray containing birch extract from Allergopharma
40940966|NCT03644680|OTHER|Nasal Provocation with NaCl 0.9%|Nasal spray containing sterile sodium chloride 0.9%
40940967|NCT00446420|DRUG|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
40940968|NCT01091337|DRUG|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
40940969|NCT01091337|DRUG|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
40940970|NCT04547790|DIETARY_SUPPLEMENT|Psyllium|One level scoop (12.5mL) of 5.1g of psyllium fiber twice a day with 8 ounces water
40940971|NCT04547790|DIETARY_SUPPLEMENT|Wheat Dextrin|One level scoop (12.5 mL) of 1.7g wheat dextrin fiber twice a day with 8 ounces water
40940972|NCT05732987|OTHER|Analysis of samples|DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;
40940973|NCT05732987|OTHER|Analysis of samples|RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.
40940974|NCT05732987|OTHER|Analysis of samples|Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.
40940975|NCT05732987|OTHER|Analysis of samples|Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).
40940976|NCT05110443|OTHER|D-WB PET/CT|"Instead of the usual procedure of having the injection of the radiotracer in the waiting room and having to wait 60 minutes before being moved to the scanner room for imaging, the study participants will be injected with the radiotracer already laying on the scanner bed and the scan will commence immediately.~Therefore, in this study the patients are still only being scanned once, but we are gathering PET information in a different way."
40940977|NCT01297998|DRUG|gemcitabine , cisplatin|Dose of gemcitabine and cisplatin and treatment schedule
40940978|NCT04840173|BEHAVIORAL|Music|During attendance at a one hour, 6-week psychosocial classroom or virtual training, caregivers will learn to use singing and other music-based interventions, implementing them each week before the informational session.
40940979|NCT04901546|OTHER|Patient's own saliva|Infants with esophageal atresia will be given their own saliva
40940980|NCT00514423|OTHER|Psychoeducation by professonals|
40940981|NCT00514423|OTHER|Psychoeducation by peer-moderators|
40940982|NCT00514423|OTHER|Video-education|
40940983|NCT00514423|OTHER|Noneducational video group (control group)|
41282562|NCT04664491|BEHAVIORAL|Standardized COPD management|"In standardized management group, patients will receive a multifaceted and integrated disease management that follows recommendations in GOLD 2020 and China Guideline on COPD care. It contains the components below.~1. Maintenance therapy after initial treatment. In this study, patients' initial therapy is the prescribed inhalers at baseline. Maintenance therapy is the medications (LABA, LAMA, or ICS) prescribed for regular or long-term use after initial therapy.~2. Long-term follow-up and routine monitoring of symptoms measured by CAT, mMRC and SGRQ.~3. Regular pulmonary function testing for lung function monitoring~4. Strengthened COPD education~5. Behavioral modification, eg. encouragement of influenza/pneumococcal vaccination, providing smoking cessation counseling and pulmonary rehabilitation."
40940984|NCT00116168|BIOLOGICAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
40940985|NCT00116168|BIOLOGICAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
40940986|NCT00116168|BIOLOGICAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
40940987|NCT00116168|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
40940988|NCT02922595|DEVICE|Intubation through ILMA®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
40940989|NCT02922595|DEVICE|Intubation through ILTS®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
40940990|NCT05826184|BEHAVIORAL|Time restircted eating|8 hour time restricted eating alone
40940991|NCT05826184|BEHAVIORAL|Time restricted eating + prebiotic|8 hour TRE with a prebiotic supplement
40940992|NCT04568889|BEHAVIORAL|A $10 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
40940993|NCT04568889|BEHAVIORAL|A $20 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
40940994|NCT04568889|BEHAVIORAL|Emphasis of Government Involvement|Individuals see a message emphasizing the involvement of the government in the study,
41282563|NCT04664491|OTHER|Routine COPD management|Patients will undergo usual care according to current clinical practice in study sites. Usual care is the routine care provided to patients. Prescription and dispense of medicine for COPD initial and maintenance therapy will be at the discretion of doctors.
41282564|NCT02286960|DRUG|Steroid|A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
41282565|NCT02286960|DIETARY_SUPPLEMENT|Lactose Pills|4 day course 2 x 20mg per da
41282566|NCT01633060|DRUG|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
40940995|NCT04568889|BEHAVIORAL|Emphasis of Academic Researchers Involvement|Individuals see a message emphasizing the involvement of academic researchers in the study,
41282567|NCT01633060|DRUG|BKM120|BKM120 100 mg once daily
41282568|NCT01633060|DRUG|BKM120 matching placebo|BKM120 matching placebo, once daily
40940996|NCT04568889|BEHAVIORAL|Cost-Benefit Frame|Individuals will see messaging that emphasizes the public health benefits of answering the survey questions in the baseline survey (cost-benefit frame).
40940997|NCT04568889|BEHAVIORAL|Duty Frame|Individuals will see messaging that emphasizes an individual's responsibility to their community in the baseline survey (duty frame),
40940998|NCT04568889|BEHAVIORAL|Racial/Ethnic Frame|Individuals will see messaging that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups in the baseline survey.
40940999|NCT04568889|BEHAVIORAL|No Messaging|Individuals will see no messaging in the baseline survey.
40941000|NCT05154214|PROCEDURE|Adenotonsillectomy|Removal of tonsils and adenoids
40941001|NCT05154214|PROCEDURE|Drug-induced sleep endoscopy directed surgery|Surgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep
40941002|NCT05403333|DRUG|utidelone|Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days
40941003|NCT05123911|OTHER|Investigational Shampoo|Parent/LAR will bathe the child participant with the investigational shampoo at least 3 times a week for up to 28 days.
41282569|NCT05632172|PROCEDURE|implant insertion|bone level dental implant insertion
41282570|NCT01046149|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
40941004|NCT05123911|OTHER|Investigational Conditioner|Parent/LAR will bathe the child participant with the investigational conditioner at least 3 times a week for up to 28 days.
40941005|NCT05123911|OTHER|Investigational Combing Cream|Parent/LAR will apply investigational combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
41282571|NCT01046149|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
41282572|NCT03456479|DIAGNOSTIC_TEST|skin prick test - specific serum IgE|The study will assess the diagnosis of Cow's milk protein allergy (CMPA) among infant and children in Assiut University Children Hospital using skin prick test and specificserumIgE
41282573|NCT02691000|DEVICE|LiteBook|Light therapy using a Bright White Light Litebook for 1 hour each morning for 8 weeks. This is the experimental intervention.
41282574|NCT02691000|DEVICE|LiteBook|Light therapy using a Dim Red Light Litebook for 1 hour each morning for 8 weeks. This is the control.
41282575|NCT04345549|OTHER|Individualised Ayurveda|Saline warm water gargle, Steam, Paracetamol for body temperature and plenty fluid and rest, Food and herbs recommendation as per individual Ayurveda constitution, Using Ginger/ lemon/ turmeric/ honey recommended as per individual, Yoga breathing
41282576|NCT01777633|RADIATION|Palliative re-irradiation for progressive DIPG in children|
40756705|NCT00069953|PROCEDURE|conventional surgery|Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
41282577|NCT02107664|RADIATION|Palliative RT for bone cancer pain|
41451491|NCT03601403|DEVICE|inhaler technique|The first day of the intervention consisted primarily of ventilatory re-education. During the realization of the technique, he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
41451492|NCT00452738|BEHAVIORAL|Therapy dog|
41451493|NCT00452738|BEHAVIORAL|Costumed character|
40941006|NCT06025643|OTHER|TENS - Cervical stimulation group|TENS will be applied bilaterally through self-adhesive electrodes in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes.
40941007|NCT06025643|OTHER|TENS - Plus cervical stimulation group|TENS will be applied bilaterally in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes, on the earlobe, on the wrists and ankles simultaneously.
41282578|NCT06233292|BIOLOGICAL|ZG005 Powder for Injection|The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.
40941008|NCT06025643|OTHER|TENS - Renal stimulation group|TENS will be applied through self-adhesive electrodes in the abdomen (anatomical region corresponding to the kidneys) and dorsal region at the level of the 10th thoracic vertebra.
40941009|NCT00041821|PROCEDURE|Nasal irritation thresholds and irritant provocation|
40941010|NCT00992303|OTHER|biologic sample preservation procedure|
40941011|NCT00992303|OTHER|medical chart review|
41451494|NCT00452738|BEHAVIORAL|Parents-only|
41451495|NCT04413799|COMBINATION_PRODUCT|lidocaine, ketamine intravenous infusion|"Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to lidocaine/ketamine group, the anesthesiologist led Acute Pain Service (APS) will prescribe lidocaine/ ketamine infusion, which will be monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups"
40756706|NCT00069953|RADIATION|radiation therapy|External beam radiotherapy with megavoltage linear accelerators (\> 6 MV) will be used to deliver multiple (\> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
40756707|NCT01400152|DEVICE|Additional active warming|Chemical heat pad applied to the upper torso
40756708|NCT03751748|DEVICE|AFR implantation|Implantation of atrial flow regulator (AFR) device
40756709|NCT03751748|DEVICE|Sham procedure|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
40941012|NCT00992303|OTHER|questionnaire administration|
40941013|NCT04064385|DEVICE|FES Cycling|Stimulation parameters will be 450μs, 40Hz, and up to 140mA, these values will be changed if needed based on individual response. For example, stimulation to the gluteal muscles often may to be decreased to prevent autonomic dysreflexia. To receive correct stimulation parameters, stimulation intensity will be chosen to ensure a palpable muscle contraction and sensor tolerance. Each session will include a 2-minute warm-up and 2-minute cool-down of passive cycling. The unit automatically delivers enough stimulation to maintain a speed of 30 rotations per minute (rpm). Where this is not achieved, the leg cycle will assist the stimulated movement to maintain a speed of 30 rpm.
40941014|NCT02520128|RADIATION|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
40941015|NCT04802070|DRUG|Autologous CIK|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
40941016|NCT04944095|OTHER|Change in SARS-CoV-2 Antibody Levels|Changes in plasma antibody levels over 12 months will be determine post-vaccination with one of the authorized SARS-CoV-2 vaccines.
40941017|NCT02171572|DRUG|Dabigatran etexilate low|
40941018|NCT02171572|DRUG|Dabigatran etexilate high|
40941019|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using CIMBI-36 tracer|This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
40941020|NCT05516732|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
41282579|NCT06233292|BIOLOGICAL|ZG005 Powder for Injection|Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.
41282580|NCT04741464|DRUG|Tinzaparin|"Tinzaparin 20 000 anti-Xa IU/mL dispensed in graduated syringes of 0.5 mL, 0.7 mL and 0.9 mL at the dose of 175IU/Kg/d.~Strategy: Tinzaparin 175 UI/Kg/d for 21 days After this time the physician will continue the treatment of his choice to treat DVT."
40941021|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using DASB tracer|To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
41282581|NCT00533000|PROCEDURE|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
41282582|NCT02986373|BIOLOGICAL|risankizumab|Risankizumab administered by subcutaneous injection.
40941022|NCT05516732|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
40941023|NCT05516732|OTHER|Lumbar puncture|A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
40941024|NCT05419531|OTHER|prospective observational study - screening and follow up colonoscopy|Involves two visits and a colonoscopy. The first visit will be prior to the colonoscopy. 4-35 days after the colonoscopy, there will be a one time appointment to go over the results of the colonoscopy.
40941025|NCT04637906|DIETARY_SUPPLEMENT|Bioarginina®|Food supplement based on 1,66 grams of L-arginine
40941026|NCT02851186|DEVICE|Acupuncture|
40941027|NCT02851186|DEVICE|Sham acupuncture|
40941028|NCT04524169|DRUG|Thymosin Alpha1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
40941029|NCT00892918|DRUG|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
40941030|NCT05884710|OTHER|Foot core exercises|2 groups; First group is an intervention group who has contain foot core exercises and the other group is a control group.
40941031|NCT05884710|OTHER|Conventional Physiotherapy|Electrotherapeutic modalities and range of motion exercises
40941032|NCT00000671|DRUG|Zidovudine|
40941033|NCT00000671|DRUG|Didanosine|
40941034|NCT05245253|RADIATION|Positron Emission tomography|Patients will be tested with PET-examination at 3 weeks, 3 months and 1 year after the trauma
40941035|NCT02809326|BEHAVIORAL|17 week Exposure Therapy Control Arm|15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
40941036|NCT02809326|BEHAVIORAL|Trauma Management Therapy|TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
40941037|NCT02809326|BEHAVIORAL|Intensive 3-Week Trauma Management Therapy|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
41282583|NCT03678883|DRUG|9-ING-41|Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.
41282584|NCT03678883|DRUG|Gemcitabine - 21 day cycle|Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle
41282585|NCT03678883|DRUG|Doxorubicin.|Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
41282586|NCT03678883|DRUG|Lomustine|Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.
41282587|NCT03678883|DRUG|Carboplatin.|Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.
41282588|NCT03678883|DRUG|Nab paclitaxel.|Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle
41282589|NCT03678883|DRUG|Paclitaxel.|Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.
40941038|NCT02939079|DRUG|Fingolimod|Produced by Osveh ® Pharm Company in Iran
40756710|NCT06087510|DRUG|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative analgesia.
40756711|NCT05379725|OTHER|Mediterranean Dietary Pattern|The Mediterranean dietary pattern includes whole or minimally processed foods with a high intake of vegetables, fruits, whole grains, fish, and olive oil.
40941039|NCT02939079|DIETARY_SUPPLEMENT|Fish Oil|produced by Zahravi ® Pharm Company in Iran
40941040|NCT02939079|DRUG|Placebo (for Fish Oil)|placebo capsules to mimic Fish Oil 1 g capsules
40941041|NCT04981821|BEHAVIORAL|GO-EXCAP Mobile App|A mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©®) is a progressive walking and resistance exercise program
40941042|NCT04981821|BEHAVIORAL|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
40941043|NCT06256198|OTHER|measurement of serum lactate and procalcitonin and PCO2 gap|measurement of serum lactate, procalcitonin and PCO2 gap
41282590|NCT03678883|DRUG|Gemcitabine - 28 day cycle|Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle
41282591|NCT03678883|DRUG|Irinotecan|Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle
41282592|NCT05286294|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
41282593|NCT01636037|DRUG|levodopa/carbidopa (generic version of Sinemet)|Oral levodopa 900mg daily as tolerated.
41282594|NCT04329949|DRUG|Relacorilant, 100 mg and 25 mg|Relacorilant is supplied as capsules for oral dosing.
40941044|NCT03300531|BIOLOGICAL|Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Pure platelet-rich plasma will be injected into the tendon.Once a week for three times.
40941045|NCT03300531|BIOLOGICAL|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Platelet-rich plasma will be injected into the tendon.Once a week for three times.
40941046|NCT03300531|DRUG|Ultrasound-guided Compound betamethasone injection|Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
40941047|NCT04319991|DIETARY_SUPPLEMENT|Probiotics product|This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
40941048|NCT06203574|RADIATION|[68Ga]Ga-NOTA-T4 or [18F]AlF-RESCA-T4|The dose of \[68Ga\]Ga-NOTA-T4 or \[18F\]AlF-RESCA-T4 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 mCi\]/kg, and the method of administration was intravenous push, with one single imaging administration.
40941049|NCT02921360|DRUG|acetylsalicylic acid|
41282595|NCT04329949|DRUG|Nab-paclitaxel|Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
41282596|NCT04227444|DIAGNOSTIC_TEST|Hologram|"Patient undergoing elective anatomical resection for lung cancer will receive standard preoperative CT scan of the chest (as usual); CT images will be subsequently elaborated by a Holographic computer to generate 3D images (holograms).Two radiologists and two thoracic surgeons will analyze CT images in a standard modality and report number of artery and vein branches for the lobe to be resected, moreover they will report every anatomical variation, according to the normal anatomy.~After that, the same two radiologists and thoracic surgeons will analyze 3D images by the use of Microsoft Hololens and perform the same analysis as quoted above.~For each review of the exam performed will be written a digitally signed clinical report to certify the timing of the evaluation and to be able to trace the analysis and any subsequent modifications of the interpretation of the CT images results."
41282597|NCT02748369|DRUG|Somatostatin|Somatostatin infusion to create a low insulin state.
40756712|NCT05379725|OTHER|High Fermented Food Dietary Pattern|Fermented foods such as yogurt, kefir, fermented cottage cheese, fermented vegetables, vegetable brine drinks, kombucha, other fermented non-alcoholic drinks, and other foods will be recommended.
41282598|NCT02748369|DRUG|Glucagon|Glucagon infusion in the setting of ongoing somatostatin.
41282599|NCT00497224|DRUG|Erlotinib|Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
41282600|NCT03631329|DIAGNOSTIC_TEST|Doppler sonographic measurement|First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
41282601|NCT02318004|OTHER|Home Monitoring|Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
41282602|NCT04194177|OTHER|mechanical ventilation during robotic surgery|protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg
41453635|NCT05198973|BEHAVIORAL|Bumblebee Breath|"Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face.~this will applied half an hour daily for ( 1 month)"
41453636|NCT06065735|DRUG|Paroxetine|Paroxetine will be administered
40756713|NCT05463471|DRUG|Compound sodium acetate ringer injection|Quickly infuse 500ml of compound sodium acetate ringer injection for volume expansion within 20-30 minutes
40756714|NCT05463471|DRUG|Albumin|Quickly infuse 500ml of albumin for volume expansion within 20-30 minutes
40941050|NCT05173480|OTHER|Conventional rehabilitation|Exercise therapy through conventional rehabilitation training made by physiotherapists.
40941051|NCT05173480|DEVICE|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS).
40941052|NCT05173480|DEVICE|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS) with sensors not connected.
40941053|NCT00815269|DRUG|Halothane|Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
40941054|NCT00815269|DRUG|Isoflurane|Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
40941055|NCT00815269|DRUG|Sevoflurane|Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
40941056|NCT00815269|DRUG|Desflurane|Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
40941057|NCT00815269|DRUG|Enflurane|Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
40941058|NCT03953183|OTHER|P3P-1mg|P3P-1mg (P3P product containing 1mg of nicotine.)
40941059|NCT03953183|OTHER|P3P-2mg|P3P-2mg (P3P product containing 2mg of nicotine.)
40941060|NCT02963831|BIOLOGICAL|ONCOS-102|ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.
41282603|NCT02783781|PROCEDURE|Cardiac surgery (extracorporeal circulation; beating heart)|"Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.~Blood sample collection Urine sample collection"
41282604|NCT02490852|OTHER|Investigational infant formula|fed ad libitum
41282605|NCT02490852|OTHER|Active Comparator: Commercially available Infant formula|fed ad libitum
41282606|NCT02490852|OTHER|Active Comparator: Human milk|fed ad libitum
41282607|NCT05332444|DRUG|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
41282608|NCT05332444|DRUG|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
41282609|NCT03456492|DIAGNOSTIC_TEST|serum sodium|Serum sodium will be measured on admission, assesment of mental status by Modified Mini-Mental score and measurement of glutamate in CSF sample taken while dripling during spinal anathesia for surgical intervention.
41282610|NCT05059132|BEHAVIORAL|Tele-rehabilitation|The tele-rehabilitation intervention will include education, inspiratory muscle training, and behavioral support to promote walking.
41282611|NCT05059132|OTHER|Education only|The education only arm will receive information on the importance of general exercise following lung cancer treatment.
41282612|NCT03728244|DRUG|MEBO ointment|The pharmacological effects of MEBO are attributable to beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensi, Beeswax and sesame oil (Zhang et al., 2005).
41282613|NCT03728244|DRUG|Hyaluronic Acid gel|Hyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints. The hyaluronic acid that is used as medicine is extracted from rooster combs or made by bacteria in the laboratory.
41282614|NCT05133986|OTHER|Onion Feeding|The intervention includes feeding individuals a 120g portion of onions (experimental condition).
41282615|NCT05133986|OTHER|Couscous Feeding|The intervention includes feeding individuals a 120g portion of couscous (control condition).
41282616|NCT05133986|OTHER|Onion Supplementation Period|Three 4-day supplementation periods separated by two 3-day washout periods. Supplementation periods will provide participants with a daily portion of onions to be consumed with their evening meals. The daily quantity of onion supplementation, low (40g), medium, (80g) and high (160g), will remain constant throughout each 4-day period, and the order will be individually randomised.
41282617|NCT00427414|DRUG|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
41282618|NCT03759652|BEHAVIORAL|before-after study|The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).
41282619|NCT06393751|BIOLOGICAL|Bevacizumab|Given IV
41282620|NCT06393751|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41282621|NCT06393751|PROCEDURE|Computed Tomography|Undergo CT
41282622|NCT06393751|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41282623|NCT06393751|DRUG|Paclitaxel|Given IV
40756715|NCT04353661|DRUG|Azithromycin|Azithromycin will be administered orally.
40941061|NCT02963831|DRUG|Durvalumab|Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.
41282624|NCT06393751|DRUG|Tolinapant|Given PO
40756716|NCT04353661|OTHER|HP xenon (¹²⁹XE)|HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds
40756717|NCT02051387|DRUG|Cannabidiol CR|
40756718|NCT02051387|DRUG|Cannabidiol|
40756719|NCT02051387|DRUG|Amisulpride|
40756720|NCT02051387|DRUG|Olanzapine|
40941062|NCT02963831|DRUG|Cyclophosphamide|A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
40941063|NCT05493618|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
40941064|NCT05493618|DRUG|Belantamab mafodotin|Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
40941065|NCT05493618|DRUG|Dexamethasone|Dexamethasone 40 mg IV q3 weeks (20 mg if patient \>75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
40941066|NCT01994590|DRUG|Dovitinib|Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.
40756721|NCT02051387|DRUG|Quetiapine|
40756722|NCT02051387|DRUG|Risperidone|
40756723|NCT02051387|DRUG|Placebo|
40941067|NCT01994590|DRUG|Abiraterone Acetate|4 tablets (250 mg each) by mouth daily.
40941068|NCT01994590|DRUG|Prednisone|5 mg by mouth twice daily.
41282625|NCT01960686|BIOLOGICAL|Low dose RSV F Antigen|
41282626|NCT01960686|BIOLOGICAL|High dose RSV F Antigen|
41282627|NCT01960686|BIOLOGICAL|Dose 1 of Aluminum Adjuvant|
41282628|NCT01960686|BIOLOGICAL|Dose 2 of Aluminum Adjuvant|
41282629|NCT01960686|BIOLOGICAL|Dose 3 of Aluminum Adjuvant|
41282630|NCT01960686|BIOLOGICAL|Dose 4 of Aluminum Adjuvant|
41282631|NCT01960686|BIOLOGICAL|Placebo|
41282632|NCT02363829|DRUG|Nelfinavir|
41282633|NCT02363829|BIOLOGICAL|Cisplatin|
41282634|NCT03514147|OTHER|Experimental|"1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
41282635|NCT03514147|OTHER|Control|"1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
41282636|NCT00098059|DRUG|Famciclovir|Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle
41282637|NCT01357239|DRUG|AFQ056|
41282638|NCT01357239|DRUG|Placebo|
41282639|NCT00980083|DRUG|Saline|
41282640|NCT00980083|DRUG|Exendin(9-39)amide|
41282641|NCT01095861|DEVICE|FlexTip ETT (Parker FlexTip/GlideScope FlexTip)|FlexTip ETT used for endotracheal intubation
41282642|NCT01095861|DEVICE|Control - standard flexible ETT (Mallinckrodt)|"Control - standard flexible ETT~Mallinckrodt Hi-Lo cuffed tracheal tube, Catalog # 86114, Mallinckrodt, ST. Louis, MO, 63134"
41282643|NCT00094120|DRUG|MSI-1256F (Squalamine Lactate)|
41282644|NCT05674773|PROCEDURE|Endoscopic or surgical resection|endoscopic or surgical (partial, (sub)total, proctocolectomy) resection
41282645|NCT03808961|DIETARY_SUPPLEMENT|Niacin|100mg tablets twice daily
41282646|NCT03808961|DIETARY_SUPPLEMENT|Niacinamide|100mg tablets twice daily
41282647|NCT03808961|OTHER|Placebo|Placebo tablet twice daily
41282648|NCT05500989|OTHER|Venepuncture|The only invasive procedure is a venepuncture where 100 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
41282649|NCT00824564|DRUG|Tranexamic Acid plus standard of care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
41282650|NCT00824564|PROCEDURE|Standard of care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
41282651|NCT03530163|DEVICE|Respiratory Muscle Training|Subjects will breathe through a custom isocapnic Respiratory Muscle Training method developed in-house. The initial breathing frequency will be 30 breaths per minute. Subsequent sessions will begin with 20 minutes of breathing at the highest rate attained on the previous training day. During the last 10 minutes of each session, breathing rate will increase by 1-2 breaths/min.
41282652|NCT03530163|DEVICE|Sham Breathing Training|Each subject in the sham group will be prompted to hold his breath for 10 seconds every 30 seconds (two times each minute) while breathing on a circuit visibly identical to that used in Respiratory Muscle Training. The subject will breathe ambient air normally after each breath hold. Each sham session will last 30 minutes total.
41282653|NCT04924725|PROCEDURE|Endoscopic ultrasound-guided fine needle biopsy|Endoscopic ultrasound-guided fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions
41282654|NCT02183389|DRUG|Warfarin|
41282655|NCT02183389|DRUG|BI 1356|
41282656|NCT05011461|OTHER|Almond Oil|Almond Oil Pressed Cold
41282657|NCT03836144|DIETARY_SUPPLEMENT|Potassium citrate|
40756724|NCT03956082|DEVICE|Ultravision™ Visual Field Clearing System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation
40941069|NCT01484054|DEVICE|etafilcon A with print and PVP for dark eyes (EAPVPDE)|A daily disposable contact lens
40941070|NCT01484054|DEVICE|etafilcon A control lens (EADE)|A marketed daily disposable contact lens
41282658|NCT05004012|DEVICE|Magnetically Controlled Capsule Endoscopy|This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
41282659|NCT02534909|BIOLOGICAL|LFG316|"LFG316 will be administered to all patients enrolled in the study~LFG316: Treatment periods 1-3 and first 4 weeks of period 4. LNP023: Treatment Period 4"
41282660|NCT02534909|DRUG|LNP023|LNP023 will be administered in period 4 to patients who participate in period 3 of this study and are willing to join long term extension study with LNP023.
41282661|NCT00658333|DRUG|Enteric-coated Mycophenolate Acid (EC-MPA)|
41282662|NCT00658333|DRUG|Mycophenolate Mofetil (MMF)|
41282663|NCT00658333|DRUG|Placebo MMF|
41282664|NCT00658333|DRUG|Placebo EC-MPA|
41282665|NCT00135421|DRUG|Pexacerfont|Tablets \& Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
41282666|NCT00135421|DRUG|Escitalopram|Tablets \& Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
41282667|NCT00135421|DRUG|Placebo|Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
41282668|NCT06217991|PROCEDURE|PTST(parachute-tunnel-style technique)for esophagogastrostomy|Suture the gastric remnant at the mark on the back wall of the esophagus.(Don't tighten the suture); Pull the esophageal stump out of the tunnel meanwhile tighten the suture and the gastric stump to close the back wall of the esophagus and the gastric stump together;Cut the back esophageal wall close to the esophageal stump,cut the front gastric wall along line B. Suture the back esophageal wall and the upper edge of the front gastric wall incision from right to left;Remove residual esophageal nail, and suture the back esophageal wall and the lower edge of the gastric incision from right to left. Suture the anterior wall of the stomach at the lower edge of the tunnel with the serosa layer at the lower edge of the front wall of the esophagus stomach anastomosis;Suture the upper edge of the tunnel with the front wall of the esophagus and the left and right lateral walls at the gastric stump suture of the original posterior wall of the esophagus. (all use 3-0 barbed suture continuously)
41282669|NCT04778761|BEHAVIORAL|Home ACP Video|A video focused on Advance Care Planning and Hospice for patients with serious illness
41282670|NCT02299934|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI sequences for visualisation of the blood supply of liver without contrast agent.
41453637|NCT04443998|DEVICE|Bone reducion forceps|Repositioning forceps provide a more accurate anatomical reduction and higher pre-compression can be achieved compared to IMF or manual reduction
40941071|NCT04743349|PROCEDURE|Steam inhalations|Exposure of airway mucosae to humidified steam through steam inhalation for at least 20 min (4 cycles of 5 min) daily, for 10 days.
40941072|NCT00614328|DRUG|Naltrexone, Baclofen, Placebo and Behavior Therapy|Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
40941073|NCT04946461|DRUG|Dexamfetamine Sulfate 5 Mg Oral Tablet|The dosage is set based on the recommendation of the practitioner. Dexamphetamine is administered twice a day, with an interval of 4 hours.
40941074|NCT04946461|DRUG|Lisdexamfetamine Dimesylate|The dosage is set based on the recommendation of the practitioner. Lisdexamphetamine is only administered once a day.
40941075|NCT04946461|BIOLOGICAL|blood samples|The blood samples will be taken at set times: 0, 2, 4, 6, 9 and 12 (hours)
40941076|NCT01054807|DEVICE|Galyfilcon A Habitual Lens|Comparison of three soft contact lens designs.
40941077|NCT01054807|DEVICE|Galyfilcon A 8.7 BC (Investigational)|Comparison of three soft contact lens designs.
40941078|NCT01054807|DEVICE|Galyfilcon A 8.3 BC (Investigational)|Comparison of three soft contact lens designs
40756725|NCT03956082|DEVICE|Ultravision Ionwand™|The Ionwand™ is introduced into the abdomen through either the Ultravision™ 5mm Trocar or a 2.5 mm percutaneous catheter. The Ionwand™ provides the source of electrons that create the negative ions that transiently charge the surgical smoke particles and accelerate their sedimentation.
40941079|NCT06304038|DRUG|Flu Vaccine|Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra
40941080|NCT02394678|DEVICE|AngioJet Thrombectomy System|Mechanical removal of blood, using a pressurised jet of water, from ventricles of patients suffering from intraventricular haemorrhage
40941081|NCT02592122|DRUG|Salbutamol Aerosol|
40941082|NCT02592122|DRUG|No drugs|
40941083|NCT01564771|OTHER|Non Intervention|This Is A Non Interventional Study
40941084|NCT02477267|DRUG|SL spray|
40941085|NCT02477267|DRUG|SL film|
40941086|NCT02029599|DRUG|Fang yi qing feng shi granule|10g, Oral,Three each time, 3 times a day,for 3 months;
41282671|NCT02299934|DIAGNOSTIC_TEST|Compurtized Tomgraphy (CT)|CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
41282672|NCT05191212|PROCEDURE|indocyanine green|Cervical indocyanine green injection for the detection of sentinel lymph node
41282673|NCT03411070|DEVICE|Implanted Medical Device|Undergo SCOUT reflector placement
41282674|NCT03411070|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40756726|NCT05845814|BIOLOGICAL|Coformulated favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion
40756727|NCT05845814|BIOLOGICAL|Coformulated vibostolimab/pembrolizumab|Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion
40756728|NCT05845814|COMBINATION_PRODUCT|EV|1.25 mg/kg IV infusion
40756729|NCT05845814|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
40756730|NCT02921282|GENETIC|Genotype dopamine|Laboratory investigations of nicotine reinforcement
40756731|NCT02921282|GENETIC|Genotype cannabinoids|Laboratory investigations of nicotine reinforcement
40941087|NCT02029599|DRUG|placebo|10g, Oral,Three each time, 3 times a day,for 3 months
40941088|NCT02029599|DRUG|Methotrexate|7.5-15mg per week，All patients should be used
40941089|NCT02029599|DRUG|Acetaminophen tablets|Oral,0.5g, 1\~2 times a day, when vas=10
40941090|NCT03427112|DEVICE|Xin1 Humerus System|"Retrospective assessment of the surgical handling and performance of the X-ray-based tracking and navigation system Xin1 Humerus system evaluated from 10 proximal humerus plate fixations"
40941091|NCT04348643|BIOLOGICAL|CEA CAR-T cells|CEA-CAR-T cells will be administered intravenously.
40941092|NCT01869725|DRUG|gallium Ga 68-edotreotide|Given IV
40941093|NCT01869725|PROCEDURE|positron emission tomography/computed tomography|Undergo gallium Ga 68-edotreotide PET/CT scan
40941094|NCT01869725|RADIATION|indium In 111 pentetreotide|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
40941095|NCT01869725|PROCEDURE|computed tomography|Undergo indium In 111 pentetreotide contrast-enhanced CT scan
40941096|NCT01869725|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
40941097|NCT01669564|OTHER|Will use HIT patient feedback to activate patients.|"After completing the FAST, GIMO patients seeing a participating provider will receive(or not receive)HIT patient feedback, based on their providers' study group assignment. Feedback for each PRI will be personalized based on the medical history, family history, and other PRI reported on the FAST. A discussion of potential treatment options will be presented along with possible general referral resources. The patient will be encouraged to discuss the PRI with his or her physician.~Patients will be provided with a list of resources, customized to their study-designated PRI, that includes ongoing programs available both in the community and GIMO to help them with behavior change and mental HRQoL."
40941098|NCT01669564|OTHER|Patients will not receive HIT patient feedback.|After completing the FAST (standard of care in GIMO) GIMO patients seeing a participating provider will receive (or not receive) HIT patient feedback, based on their providers' study group assignment.
41282675|NCT02629705|DIETARY_SUPPLEMENT|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
41282676|NCT02629705|DIETARY_SUPPLEMENT|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
41282677|NCT02051101|OTHER|Biopsy sample from Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
41282678|NCT06418542|DEVICE|use of florescein|Fluorescein, an organic contrast agent, is used in FFA to detect retinal pathologies.
41282679|NCT02760628|BEHAVIORAL|The First Twenty (TF20)|TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.
41282680|NCT02760628|BEHAVIORAL|Life Simple 7 (LS7)|LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
41282681|NCT03270787|DRUG|Placebo|Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
41282682|NCT03270787|DRUG|Compound danshen dripping pills|Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
41453638|NCT01211951|DRUG|KCT-0809|
41453639|NCT01211951|DRUG|KCT-0809|
40756732|NCT02844712|OTHER|Evaluation of reexposure to a negatively tested betalactam|
40756733|NCT06114472|DRUG|aromatherapy blend containing Lavender|hree drops of aromatherapy blend containing Lavender essence 10% were poured on cotton in cast containers, and the patient was asked to inhale it for 5 minutes from a distance of 10 cm
40756734|NCT05806190|DEVICE|Continuous Glucose Monitoring|Continuous Glucose Monitoring using a Dexcom G6 Continuous Glucose Monitoring Device
40756735|NCT02999997|BEHAVIORAL|Ronnie Gardiner Method (RGM)|RGM includes functional exercises consisting of cognitively challenging multi-task exercises. The exercises are performed sitting down or standing up with weight shifting exercises. The practitioner projects unique symbols shaped as red or blue hands and feet on the wall in specific 'choreoscores' of 2-8 bars. Red symbolizes left side of the body, blue the right side. Each symbol is accompanied with a certain movement and sound code. To the sound of rhythmical music the participants follow the symbols beat by beat, performing the movements and pronouncing the word. The exercises are progressed by increasing the tempo of the music, or by using more symbols. The practitioner uses a shirt with the color red on one side, and blue on the other side, in order to facilitate for the participants.
40756736|NCT05227365|DEVICE|Lenire|The sound stimulus of PS6 is comprised of sequences of tones and is spectrally modified according to the participant's hearing thresholds so that different components of the sound stimulus can be sufficiently heard by the participant irrespective of their hearing characteristics (audiological profile). The tongue stimulus of PS6 is delivered by an array of electrical signals via 32 transmucosal electrodes contacting the anterodorsal surface of the tongue. The sound and tongue stimulus parameters are presented with certain stimulus rates and timing relationships between modalities.
40756737|NCT03470883|OTHER|Evaluation of the long-term complete remission rate (> 12 months)|Evaluation of the long-term complete remission rate (\> 12 months)
40756738|NCT00205634|DRUG|Biaxin ( clarithromycin)|
41132032|NCT06502132|OTHER|Patient Education Group|Patients whose surgery has been postponed will be educated by the researcher through a booklet regarding the waiting process. The education includes information such as anxiety management, pain management, and re-surgery planning. The booklet consists of 22 pages and a copy is given to each patient in this group. The education lasts between 15-20 minutes and the patients' questions are answered. It is applied in a single session.
41132033|NCT06502132|OTHER|Therapeutic Touch Group|Therapeutic touch application is applied as a single session and lasts approximately 20-25 minutes. The therapeutic touch that emerges from the artistic aspect of nursing is an energybased practice that does not involve physical contact. Therapeutic touch is a conscious and compassionate effort to direct the flow of one's universal life energy to healing by influencing this energy.
41282683|NCT00087295|DRUG|Depsipeptide|Depsipeptide wil be given 13 mg/m\^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
41282684|NCT04093219|DRUG|IV acetaminophen|use of IV tylenol for pain
41132034|NCT02432898|DEVICE|3D OCT-1|Spectral Domain OCT Device
40756739|NCT02674763|DRUG|IMGN779|
40756740|NCT02928835|DEVICE|Knee flexion Dynasplint orthosis|Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
40756741|NCT01933516|DRUG|GP2013|GP2013
41132035|NCT02432898|DEVICE|3D OCT-2000|Spectral Domain OCT Device
40941099|NCT01638819|BIOLOGICAL|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
40941100|NCT01638819|BIOLOGICAL|Placebo|Saline
40941101|NCT04211571|DEVICE|Theranova 400 dialyzer|Hemodialysis using Theranova 400 dialyzer
41282685|NCT04093219|OTHER|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
40941102|NCT04211571|DEVICE|High-flux dialyzer|Hemodialysis using high-flux dialyzer
41132036|NCT02432898|DEVICE|DRI OCT-1|Swept Source OCT Device
41132037|NCT02432898|DEVICE|NW-300|Fundus Camera
41132038|NCT02432898|DEVICE|CT-1P|Tonometry
41282686|NCT06163235|OTHER|Obemar platform|Online platform for education and follow-up
41282687|NCT04884243|DRUG|CBT-006|ophthalmic solution
41282688|NCT01415388|DIETARY_SUPPLEMENT|Krill Oil|4 Capsules twice daily providing 0 (placebo), 0.5, 1.0, 2.0, or 4.0 g krill oil/day for a period of 12 weeks
41282689|NCT00391976|DRUG|Tobramycin solution for inhalation 300 mg|Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
41453640|NCT01211951|DRUG|KCT-0809|
41453641|NCT01211951|DRUG|Placebo|
40941103|NCT02047149|DRUG|Zileuton (Zyflo®) Dasatinib (Sprycel®)|To determine the maximum dose of zileuton/dasatinib in subjects with CML
40941104|NCT02047149|DRUG|Dosing with Zileuton/Dasatinib in CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
40941105|NCT02047149|DRUG|Daily dosing of Zileuton/Dasatinib|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
40941106|NCT02047149|DRUG|Daily dosing with Zileuton/Dasatinib for CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
40941107|NCT01840618|DEVICE|Nasal Continuous positive airway pressure (CPAP)|We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
40941108|NCT05658666|BEHAVIORAL|Video feedback intervention (in Dutch: Video Interventie Ouderenzorg)|The video feedback trainer assesses the interaction between the person with dementia and the caregiver and acquires agreement from the caregiver on the goals of the intervention. Caregivers are trained during several feedback sessions using personal video footage of interaction between the person with dementia and the caregiver. The feedback focuses on basic interaction and attunement principles, and the team feeling competent. Recording starts with a nondemanding situation, enabling the caregiver to become aware of the principles they already apply and to learn how these principles can be used in more demanding situations. Subsequently, video footage is recorded in 1 to 3 situations, depending on the progress, of increasing difficulty, with about 4 weeks between 2 recordings. After each recording, a 1-hour feedback session is held. The intervention concludes with separate, 30-minute sessions for the formal and informal caregivers evaluating the intervention.
40941109|NCT02493582|BIOLOGICAL|Cytokine-Induced Killer Cells|CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
40941110|NCT02493582|DRUG|Apatinib|Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
40941111|NCT06415318|DRUG|Paclitaxel + Ifosfamide + Cisplatin & Toripalimab|Paclitaxel + Ifosfamide + Cisplatin \& Toripalimab
40941112|NCT03775291|DIAGNOSTIC_TEST|Simultaneous assessment of sleep apnea by polysomnogram and wearable device|Characterization of sleep apnea by lab-based polysomnogram
40941113|NCT05607771|DEVICE|Manual Vitrification|Oocytes will be prepared for vitrification using the manual protocol
41282690|NCT02919306|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
41282691|NCT02919306|BIOLOGICAL|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
40941114|NCT05607771|DEVICE|Automated Vitrification|Oocytes will be prepared for vitrification using the DaVitri device
40941115|NCT04437953|DRUG|Avatrombopag|"Patients will receive an initial dose of Avatrombopag 60 mg on Day 1. Starting on Day 2, the dose will be Avatrombopag 20 mg daily. Once a patient has reached a platelet target of \> 100,000/mcL patients can initiate systemic cancer therapy. Avatrombopag will be continued as maintenance (subscript m) and titrated weekly with a goal to maintain a platelet count of ≥ 100,000/mcL during administration of systemic cancer therapy. Duration of maintenance therapy will be at least 12 weeks (indicated by Week 1m, Week 2m, ... 12m) starting from time of platelet correction and resumption of systemic cancer therapy. End of Treatment (EOT) is up to 15 weeks on study Week 12m."
40941116|NCT02546635|DRUG|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
40941117|NCT02546635|DRUG|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
40941118|NCT01770652|DRUG|Deferiprone|Oral iron chelator
40941119|NCT06316115|OTHER|In Patıents Wıth Dıabetıc Foot Ulcer, Effect On Paın And Anxıety Of Stress Ball Use Durıng Sharp Debrıdement|Patients in this group participating in the study will be given a stress ball and asked to use it before the debridement procedure, and each patient will be debrided by the same person throughout the procedure. The patient's pain and anxiety will be evaluated by a nurse independent of the research before and after the debridement procedure.
41132039|NCT02432898|DEVICE|TRK-2P|Tonometry, Corneal Topography
41132040|NCT02432898|DEVICE|SP-1P|Specular Microscopy
41132041|NCT02432898|DEVICE|SL-D701|Slit Lamp Imaging
41132042|NCT02432898|DEVICE|MC-4S|Visual Acuity Testing
41132043|NCT02199626|DEVICE|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
41132044|NCT03699410|RADIATION|Neoadjuvant radiotherapy|Radiotherapy with total dose of at least 50 Gy on the tumor (cT) and the involved nodes (cN+) and with standard fractionation (1.8 Gy/fraction), 5 days/week.
41282692|NCT02919306|DRUG|Placebo|Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
40941120|NCT04638296|OTHER|Interviews|The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.
40941121|NCT02208700|OTHER|Oxepa|Therapeutic nutrition with EPA, GLA\< and antioxidants
40941122|NCT02208700|OTHER|Jevity 1.5|Complete balanced nutrition with a unique fiber blend
40941123|NCT00586131|DRUG|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
40941124|NCT00586131|DRUG|Sodium citrate/citratic acid|dictated by pH
40941125|NCT00111878|DRUG|MEDI-534|
40941126|NCT04208581|DRUG|Yiqi Huoxue Huatan granule|Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
40941127|NCT04208581|DRUG|Placebo Yiqi Huoxue Huatan granule|Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
40941128|NCT00881478|OTHER|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
40941129|NCT00881478|OTHER|Nutrition counseling|Nutrition counseling with registered dietician
40941130|NCT00168402|DRUG|Botulinum Toxin Type A|
40941131|NCT01854931|BEHAVIORAL|Tai Ji Quan|single aim intervention
40941132|NCT00275964|DRUG|TMN-1|
40941133|NCT02160353|DRUG|Abiraterone acetate, Prednisolone|
40941134|NCT00003976|DRUG|indisulam|
40941135|NCT05449769|BEHAVIORAL|eNutriCardio personalised nutrition advice|eNutriCardio is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutriCardio Team, including a registered dietitian and registered nutritionist, are in line with UK dietary guidelines (primarily the EatWell Guide), and promote a Mediterranean-style diet (in line with NICE guidance). Therefore, the advice builds on the generalised advice given during the usual NHS CR programme.
40941136|NCT05523297|DRUG|Octaplex|Prothrombin complex concentrate
40941137|NCT05523297|DRUG|Frozen Plasma Product, Human|If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma
40941138|NCT04256954|BEHAVIORAL|Peer navigation intervention|A peer navigator will assist those assigned to the intervention group access community mental health, medical care and substance use services. Peer navigators will help create linkages to services
41132045|NCT03699410|DRUG|Neoadjuvant chemotherapy|Oral Capecitabine, at the standard dose of 825 mg/m2 twice daily, concomitant to radiotherapy.
41132046|NCT03699410|PROCEDURE|Radical surgery|The time point of surgery is usually dependent on surgeon's and institutional habits and lies within 6 to 12 weeks after the end of nCRT. Surgeons participating in this study will be asked to operate patients on the 10th week after the end of nCRT.
40941139|NCT01822704|DEVICE|Low intensity whole body vibration|
40941140|NCT01822704|DEVICE|High intensity whole body vibration|
40941141|NCT01822704|BEHAVIORAL|Leg exercises|
40941142|NCT03560830|OTHER|2 submaximal exercise stress tests|
40941143|NCT03645031|OTHER|Acute Intermittent Hypoxia|AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.
40941144|NCT03645031|OTHER|Sham Acute Intermittent Hypoxia|Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
40941145|NCT06488313|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).
40941146|NCT02818231|OTHER|Brushing of the olfactory cleft|Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
40941147|NCT04630639|DEVICE|Sparkle|The Sparkle device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
41132047|NCT02401932|OTHER|Hemophagocytosis|Best supportive care and immunosuppressive treatments
41132048|NCT02347332|DRUG|Vinflunine|
41132049|NCT02347332|DRUG|Methotrexate|
40941148|NCT02518412|OTHER|tDCS|Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
40941149|NCT02518412|OTHER|Placebo tDCS|Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
40941150|NCT00739050|DRUG|simvastatin|simvastatin 20mg daily at nights for 12 weeks. Tablets
40941151|NCT00739050|DRUG|Comparator: Placebo|placebo daily at nights for 12 weeks. Tablets
41282693|NCT02580058|BIOLOGICAL|avelumab|10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
41282694|NCT02580058|DRUG|PLD|PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
41282695|NCT01565486|DEVICE|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
41282696|NCT01565486|DEVICE|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
41282697|NCT02261623|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures
41282698|NCT02261623|DEVICE|WallFlex™ Biliary RX Partially Covered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
41282699|NCT02261623|DEVICE|WallFlex™ Biliary RX Uncovered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
41282700|NCT01870635|DRUG|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
41282701|NCT01870635|DRUG|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
41282702|NCT03169283|OTHER|Cereal with B glucan|A cereal high in viscous dietary fiber B glucan
41282703|NCT03169283|OTHER|Cereal without B glucan|Cereal without B glucan
40941152|NCT02160782|DRUG|LUM001 (Maralixibat)|LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
40941153|NCT02160782|DRUG|Placebo|Placebo will be administered orally once daily during randomized withdrawal period
41132050|NCT01351376|DEVICE|Low Level Laser Therapy|Placebo LLL combined with CDT
41132051|NCT01351376|DEVICE|Low Level Laser|Active LLL combined with CDT
41132052|NCT00354237|OTHER|Conventional antidiabetic treatment|No intensive treatment
41132053|NCT00354237|OTHER|Intensive insulin treatment|Intensive insulin treatment
41132054|NCT00001752|DRUG|L-arginine|
41282704|NCT02112968|PROCEDURE|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
41282705|NCT02112968|PROCEDURE|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
41282706|NCT02112968|PROCEDURE|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
40941154|NCT03589014|DRUG|Propranolol|Patients randomized to the experimental arm will receive propranolol on top of standard recommended treatment for CCM. Initial oral dose of 40 mg bid will be uptitrated to 80 mg bid in the absence of excessive bradycardia or hypotension. Doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
40941155|NCT00736879|DRUG|Dapagliflozin|Tablets, Oral, Once Daily, Up to 24 weeks
40941156|NCT00736879|DRUG|Placebo|Tablets, Oral, Once Daily, Up to 24 weeks
40941157|NCT04019431|DIETARY_SUPPLEMENT|Whey protein, vegetable protein or animal protein|meal replacements or animal protein
40941158|NCT00154492|DRUG|activated recombinant human factor VII|
40941159|NCT02913040|OTHER|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
40941160|NCT02913040|OTHER|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
40941161|NCT04941963|DIAGNOSTIC_TEST|Chest ultrasound|Patients will undergo chest ultrasound scanning after obtaining parent's consent. each enrolled patient will have one chest ultrasound to assess diaphragmatic function and lung ultrasound severity score.
41132055|NCT00001752|DRUG|Estrogen|
41132056|NCT03067857|BIOLOGICAL|Stem Cells|Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.
41132057|NCT04454476|DRUG|Trametinib treatment|1 mg taken by mouth once a day for 14 days
41132058|NCT04454476|PROCEDURE|Endoscopy|A tiny camera on the end of a long, flexible tube will be used to examine the stomach and take biopsies.
41132059|NCT04037020|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (extreme dark (90%), dark (70%), milk (38%), and white (0%)).
41282707|NCT04298411|DEVICE|Falcon|The Falcon contains a selection of 25+ games that require wrist extension and challenges children to grasp the controller with their affected hand. As children progress, they may advance to more difficult games that challenge the child to work against a resistance and/or apply greater grip forces. Therapists will be trained on the system, games, and given a guide summarizing the available games and the motor function areas targeted in the game. Using this guide, therapists can choose the games that are most suited to the child's abilities and goals. As multiple games will target many of the same motor function areas, children will have the option of choosing the games they like best to maximize motivational value. While this introduces some variability in the intervention, this flexibility is required to ensure that the therapy is targeting the specific interests, needs and goals of each individual child and is reflective of how ICP is used in a clinic setting.
41282708|NCT02189382|DEVICE|Potassium Oxalate|
41132060|NCT03593642|DRUG|Continuous infusion of ropivacain in ESP catheter|administration of ropivacaine in ESP catheter to provide regional analgesia after surgery
41132061|NCT03593642|DRUG|Continuous infusion of Iso Saline in ESP catheter|administration of Iso Saline in ESP catheter to be the control group
41282709|NCT02189382|OTHER|Water|
41282710|NCT05367661|DRUG|CHK336|Tablet
41282711|NCT05367661|DRUG|Placebo|Tablet
41282712|NCT01059812|DRUG|insulin degludec/insulin aspart|Injected subcutaneously twice daily. Dose was individually adjusted.
41282713|NCT01059812|DRUG|biphasic insulin aspart 30|Injected subcutaneously twice daily. Dose was individually adjusted.
41282714|NCT02511210|BEHAVIORAL|regional anesthesia|preoperative anxiety
41282715|NCT02511210|BEHAVIORAL|general anesthesia|preoperative anxiety
41282716|NCT05432544|DRUG|SHR-1918|Ascending dose
41282717|NCT05432544|DRUG|SHR-1918 placebo|Ascending dose
41282718|NCT03770143|OTHER|Feeding with palm olein formula|
41282719|NCT02277171|DEVICE|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
41282720|NCT04527757|PROCEDURE|Inhalation induction|For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
40756742|NCT01641666|DRUG|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
41282721|NCT04527757|PROCEDURE|Intravenous induction|For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
41282722|NCT05541315|DRUG|JNJ-88260237|JNJ-88260237 will be administered orally.
41282723|NCT05541315|DRUG|Placebo|Matching placebo will be administered orally.
41282724|NCT00673855|OTHER|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye 1 time
41282725|NCT00673855|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops
41282726|NCT00206518|DRUG|Taxotere/Docetaxel|Taxotere
40941162|NCT06212310|OTHER|Telephone genetic counseling|genetic counseling service delivered audio-only
40941163|NCT02002611|DRUG|Lobeglitazone|
40941164|NCT02002611|DRUG|Warfarin|
40941165|NCT05479773|DEVICE|Standard NIV mask|The hospital standered NIV mask
40941166|NCT05479773|DEVICE|Lumena NIV mask|aerosol-reducing mask
40941167|NCT06086691|OTHER|Strength Training with Caffeine|"The intervention protocol consists of 5 types of strength training exercises. The following exercises will be performed for the strength training group:~1. bench press (3 sets of 10 reps)~2. biceps curl (3 sets of 10 reps)~3. triceps pushdown (3 sets of 10 reps)~4. leg press (3 sets of 10 reps)~5. leg extension (3 sets of 10 reps)~Strength training would be performed in 3 sets of 10 repetitions with 2 minutes of rest between each exercise. This protocol will be performed in a 30-40-minute session. 10-15 minutes of light warm-up activities will be performed before the start of each exercise session. The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions."
40941168|NCT06086691|OTHER|Endurance Training with Caffeine|"The intervention protocol consists of 3 types of endurance training exercises. The following exercises will be performed by this group:~1. Cycling (15 min)~2. Running (20 min)~3. Rowing (10 min)~The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions."
41132062|NCT05403359|DRUG|Steroids|"Description of the intervention in each of the work packages:~* WP1A admission: Steroid dose \>6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~* WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (\> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~* WP2 ICU admission: High-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~* WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) or no steroids up to day 28."
41132063|NCT00686595|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV infusion.
41132064|NCT02179359|DRUG|Reduced Toxicity Ablative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Stem Cell Infusion Day 0"
41282727|NCT00206518|DRUG|Adriamycin/Cytoxan|Adriamycin/Cytoxan
41282728|NCT00206518|DRUG|doxorubicin|AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
41282729|NCT01416311|DRUG|Eltrombopag|
41282730|NCT02171715|DRUG|BIBW 2992 MA2|film-coated immediate release tablet - final formulation
41282731|NCT02171715|DRUG|BIBW 2992 MA2|film-coated immediate release tablet - trial formulation II
41282732|NCT02171715|DRUG|BIBW 2992 MA2|powder for oral solution
41282733|NCT04713319|DRUG|Panavital|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
40941169|NCT06143111|DEVICE|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
40941170|NCT06143111|DEVICE|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
40941171|NCT00978432|DRUG|RAD001|10 mg/day for Part 1 of the trial
40941172|NCT00978432|DRUG|LBH589|40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
40941173|NCT00978432|DRUG|Doublet (RAD001 and LBH589)|RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
40941174|NCT01571297|DRUG|RM-131|Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
40941175|NCT01571297|DRUG|Placebo|Placebo given subcutaneously for 35 days
40941176|NCT02306499|PROCEDURE|ICSI|Intracytoplasmic Sperm Injection
40941177|NCT02515812|DRUG|I-123-MIBG|
40941178|NCT02515812|DEVICE|CZT Camera (D-SPECT)|
40941179|NCT02515812|DEVICE|Anger Camera|
40941180|NCT01684020|BIOLOGICAL|ARTISS human fibrin sealant|
40941181|NCT04505397|DRUG|SKL24741|An inhibitor of voltage-gated sodium channels and a possible activator of Big Potassium channels. Administered as an oral dose in the form of a capsule or tablet.
40941182|NCT04505397|DRUG|Placebo|Sugar pill manufactured to mimic SKL24741
40941183|NCT00326794|PROCEDURE|mobilisation (rehabilitation)|
40941184|NCT02791399|BEHAVIORAL|ISOP Intervention with the Nurse Care Manager|A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
40941185|NCT03905473|BEHAVIORAL|Accelerometer measurements|To validate the questionnaires about physical activity, some patients will be wearing an accelerometer for one week. An accelerometer is a little device worn in a belt around the hip, which can measure intensity of the patient's activity level. The accelerometer is worn 24 hours a day for one week and is only removed when bathing.
40941186|NCT06517563|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
40941187|NCT06517563|DRUG|Rivaroxaban|FXa Inhibitor
41282734|NCT04713319|OTHER|Placebo|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
41282735|NCT00900432|OTHER|immunoenzyme technique|
41282736|NCT00900432|OTHER|laboratory biomarker analysis|
41282737|NCT00366236|DRUG|Nitazoxanide|
41282738|NCT02082691|DRUG|G-202|Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
41282739|NCT06221111|DRUG|Rimegepant 75 MG [Nurtec]|placebo controlled trial
41451496|NCT04413799|DRUG|paravertebral block with ropivicaine|"Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to PVB, the anesthesiologist led Acute Pain Service (APS) will place a paravertebral block catheter. Ropivacaine infusion will be started, monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups"
40941188|NCT06517563|DRUG|UFH|Unfractionated Heparin
41282740|NCT03405103|BEHAVIORAL|Striving|
41282741|NCT03405103|BEHAVIORAL|Boning-Up|
41282742|NCT03405103|BEHAVIORAL|Personal Choice|
41282743|NCT05837754|OTHER|C8-C12|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
41282744|NCT05837754|OTHER|Placebo|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
41282745|NCT04029337|DEVICE|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
40941189|NCT06517563|DRUG|Enoxaparin|Low Molecular Weight Heparin
40941190|NCT05869565|DRUG|Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1|Patients will be enrolled in the study and randomized into one of four arms
40941191|NCT00443612|DRUG|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
40941192|NCT00443612|DRUG|Irbesartan|Administration of irbesartan 150 mg/day
40941193|NCT05617443|DEVICE|stackable guide|different types of stackable guide
40941194|NCT02386969|DEVICE|active rTMS then sham rTMS|A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
40941195|NCT02386969|DEVICE|sham rTMS then active rTMS|A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
40941196|NCT00092690|DRUG|MK0653A, ezetimibe (+) simvastatin|
40941197|NCT00092690|DRUG|Comparator: atorvastatin|
40941198|NCT04095273|DRUG|Elimusertib (BAY1895344)|Study drugs will be administered as scheduled
40941199|NCT04095273|DRUG|Pembrolizumab (Keytruda®)|Study drugs will be administered as scheduled
40941200|NCT01157156|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
40941201|NCT02519387|DRUG|Buprenorphine Transdermal Patch|
40941202|NCT00471146|DRUG|AG-013736|oral administration, starting dose 5 mg twice daily \[BID\] every day until unacceptable toxicity or tumor progression.
41282746|NCT04427657|PROCEDURE|autologous microfragmented lipoaspirate tissue (Lipogems®).|patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
41282747|NCT04427657|PROCEDURE|arthroscopic debridment|patient in supine position. Under sedation is perform an arthroscopic debridement
41282748|NCT00201539|DRUG|single dose Morphine|
41282749|NCT00201539|DRUG|double dose Morphine|
41282750|NCT00201539|DRUG|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
41282751|NCT00540215|OTHER|Glucagonlike peptide|450 nmol native form, synthetic
41282752|NCT05330468|DEVICE|Abbott Mechanical Heart Valve (MHV) Regent™|SJM Regent™- Standard cuff (Model number AGN-751); SJM Regent™- FlexCuff™ (Model number AGFN-756)
40941203|NCT00471146|DRUG|Gemcitabine|intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
41282753|NCT00489762|PROCEDURE|Installation of an energy efficient heater|
41282754|NCT05071339|DRUG|Ganirelix Acetate, Cetrolix Acetate|3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.
40941204|NCT00471146|DRUG|Gemcitabine|intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
40941205|NCT00471146|DRUG|placebo|placebo
40941206|NCT00573365|DEVICE|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
40941207|NCT00573365|RADIATION|Radiation|Weekly radiation treatment
40941208|NCT00573365|RADIATION|Radiation|Weekly radiation treatment
40941209|NCT03416374|DRUG|Ixazomib|Ixazomib capsules
40941210|NCT03416374|DRUG|Bortezomib|Bortezomib injections
40941211|NCT03416374|DRUG|Carfilzomib|Carfilzomib intravenous infusions
40941212|NCT03416374|DRUG|Lenalidomide|Lenalidomide capsules
40941213|NCT03416374|DRUG|Dexamethasone|Dexamethasone tablets
40941214|NCT00923936|DRUG|Liposomal Doxorubicin|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles.
40941215|NCT00923936|DRUG|Bevacizumab|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
40941216|NCT06202456|DRUG|Huazhi Rougan granule|Huazhi Rougan granule
40941217|NCT02645721|BEHAVIORAL|Extended self-help program with guidance|See arm description for Experimental
40941218|NCT02645721|BEHAVIORAL|Briefer Self-help program, no guidance|See arm description for Active Comparator
40941219|NCT02645721|BEHAVIORAL|WL: Extended self-help program, choice of guidance intensity|See arm description for Waiting list.
40941220|NCT00932737|DRUG|Placebo|1-5 tablets per episode
40941221|NCT00932737|DRUG|HBB 20 mg|Active drug, one to five tablets per episode
41282755|NCT00793585|DRUG|allopurinol|Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level \< 6mg/dl , the dosage changed to 200mg/d.
41282756|NCT00793585|OTHER|continue their usual therapy|Patients will receive lifestyle modification and continue their usual therapy.
41451497|NCT06428305|OTHER|Providing hygiene education based on the method of teaching what has been learned in the context of a genital hygiene guide|As shown in the Flow Chart of the study, research data were collected from pregnant women who were in the control group at the December intervals with the experimental group. After the completion of the study, this group will also be given an education and training booklet.
40941222|NCT04448054|OTHER|MRI|"Case 1: Routine care protocol not requiring injection~* Realization of the non-injected MRI protocol adapted to the indication~* + Addition of a 3D bFFE-Xd sequence (+ 2 min) The protocol will last the examination time usually provided by the current treatment according to the indication + 2 min of complementary sequence Case 2: Routine treatment protocol requiring an injection~* Realization of the injected MRI protocol adapted to the indication~* Before gadolinium injection:~* Addition of a 3D bFFE-Xd sequence (+ 2 min) before injection~* After gadolinium injection:~* Option 1: if olfaction disorder, addition of DCE perfusion sequence (T1-WI) which will be the 1st post injection sequence (+ 4 min 30)~* FABIR 0.9 3D sequence (+ 4 min)~* 3D sequence T1 TSE 0.7 (+ 2 min 30)~* FLAIR HR coronal sequence (+ 3 min 30)~* Option 2: if hearing / balance disorder, adding 3D FLAIR labyrinth sequence (+ 6min) which will be the 1st post injection sequence"
40941223|NCT03538431|DRUG|Buspirone|Buspirone is an atypical anxiolytic medication.
40941224|NCT01242059|DIETARY_SUPPLEMENT|yellow pea protein|Served in a tomato soup
40941225|NCT01242059|OTHER|yellow pea fiber|Served in a tomato soup
40941226|NCT01242059|DIETARY_SUPPLEMENT|Control|Served in a tomato soup
40941227|NCT03161093|DRUG|Fasinumab|Solution for injection in pre-filled syringe
40941228|NCT03161093|DRUG|Naproxen|Pharmaceutical form: Capsule
40941229|NCT03161093|DRUG|Fasinumab-matching placebo|Solution for injection in pre-filled syringe
40941230|NCT03161093|DRUG|Naproxen-matching placebo|Capsule
40941231|NCT04292392|OTHER|preop ACB, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
40941232|NCT04292392|OTHER|preop ACB+IPACK block|Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block
40941233|NCT04292392|OTHER|preop ACB+IPACK block, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
40941234|NCT01371370|OTHER|Resistance exercise training|The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.
40941235|NCT01371370|OTHER|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
40941236|NCT01371370|OTHER|Resistance exercise training & diet|Combination of low intensity resistance exercise training and hypocaloric diet
40941237|NCT03388437|DEVICE|NI-NAVA|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
41451498|NCT05072535|DRUG|HA121-28 tablet B|HA121-28 tablet B 200 mg
41451499|NCT05072535|DRUG|HA121-28 tablet A|HA121-28 tablet A 200 mg
41451500|NCT00967135|DRUG|Pregabalin|150 mg oral dose of pregabalin twice daily for 5 consecutive days.
40941238|NCT03388437|DEVICE|NIPPV|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
40941239|NCT01900639|BEHAVIORAL|change time of intake of aspirin|
40941240|NCT00928798|DRUG|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
40941241|NCT00928798|DRUG|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
41451501|NCT00967135|DRUG|Placebo|Matching oral placebo twice daily for 5 consecutive days.
41451502|NCT03724890|DRUG|M3814|Participants will receive M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.
41451503|NCT03724890|DRUG|M3814|Participants will receive M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.
41451504|NCT03724890|DRUG|Avelumab|Participants will receive avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.
40941242|NCT02355496|OTHER|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
40941243|NCT05844709|OTHER|IVH care Bundle|"The experimental group received bundle nursing care within 3 days after birth in addition to routine nursing care after consent was given and the informed consent form was signed.~IVH care Bundle: 1. Maintaining midline head position 2. Avoid prone, place in supine or side-lying position 3. Incubator tilted 15-30 degrees 4. Slow withdrawal and flushing for UAC, UVC, and PAL."
41282757|NCT05077514|BEHAVIORAL|Experimental: Cognitive Behavior Therapy|Participants assigned to Group A were asked to participate in a talking session with a psychologist regarding thoughts about treatment. This session is designed to explore thoughts about behavioral health therapy for suicidality. The session was administered by phone, initially and again one month later. Participants discussed current functioning and their thoughts about seeking help with the goal of modifying thoughts about treatment. This phone session lasted approximately 45 to 60 minutes.
40941244|NCT04373174|DEVICE|Regional oximetry probe|Regional oximetry probe will be placed in the frontal area of the head
40941245|NCT04373174|PROCEDURE|Thoracic Epidural block|Thoracic epidural block will be applied to the patients before the operation begins
40941246|NCT05868473|DIAGNOSTIC_TEST|Mobilization With Movement|Mobilization With Movement Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
41282758|NCT05077514|BEHAVIORAL|Active comparator: National Crisis Line|Participants assigned to Group B received information about the VA's National Crisis Line.
41282759|NCT04278573|DRUG|Vitamin D3|Intralesional injection of 0.3 ml 40,000 IU/ml vitamin D3 into one wart
41282760|NCT04278573|DRUG|Placebo|0.3 ml injection of sterilized sesame oil with no active study ingredient
41282761|NCT06075940|DEVICE|MAGNITUDE BRS|Treatment with the MAGNITUDE Scaffold
41282762|NCT02111538|OTHER|Dietary advice|Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
40941247|NCT05868473|DIAGNOSTIC_TEST|Kinesotaping|Kinesotaping Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
40941248|NCT01439568|DRUG|LY2510924|Administered subcutaneous injection
40941249|NCT01439568|DRUG|Carboplatin|Administered intravenously
40941250|NCT01439568|DRUG|Etoposide|Administered intravenously
41282763|NCT04165395|DEVICE|Five-layer foam dressing|Five-layer foam dressing applied on the sacrum within 48 hours of spinal surgery
40941251|NCT03858478|DRUG|Biktarvy arm|BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
40941252|NCT03261180|OTHER|Best Practice|Receive regular diet
40941253|NCT03261180|OTHER|Laboratory Biomarker Analysis|Correlative studies
40941254|NCT03261180|DIETARY_SUPPLEMENT|Nutritional Intervention|Receive Nestle Impact AR
40941255|NCT03845374|DEVICE|Hyper-CL™ lens|Use of the Hyper-CL™
41282764|NCT04165395|DEVICE|Heelmedix boot|Heelmedix boot will be installed alternately from one foot to the other.
41282765|NCT03530449|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
41282766|NCT03530449|DEVICE|Color Fundus Photography|Non-contact white light photography
41282767|NCT03530449|DEVICE|Optical Coherence Tomography|Two and Three dimensional cross sectional imaging of the back of the eye to look at vascular structures and is an aid in the detection and management of various ocular diseases.
41282768|NCT03731793|BIOLOGICAL|Non-Animal Chondroitin Sulphate|Mythocondro® is an ichthyic-like chondroitin sulfate produced by chemical sulfation of a non-sulfated chondroitin backbone obtained by thermo-acid hydrolysis of the capsular polysaccharide naturally produced by an Escherichia coli strain.
41282769|NCT03731793|OTHER|Placebo|Placebo
41282770|NCT00602407|DRUG|Cilostazol|
41282771|NCT01859351|DRUG|WX-037|
41282772|NCT01859351|DRUG|WX-554|
41282773|NCT01687673|DRUG|Temsirolimus|10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
41282774|NCT01687673|DRUG|Sorafenib:|200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
41282775|NCT01538615|BEHAVIORAL|HOME Plus intervention|The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
41282776|NCT06313216|PROCEDURE|duoteck membrane|the dehisced bone defect will be covered with duoteck membrane
41282777|NCT06313216|PROCEDURE|autogenous demineralized tooth graft|the dehisced bone defect will be covered with autogenous demineralized tooth graft
40941256|NCT01053949|DRUG|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
40941257|NCT01053949|DRUG|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
40941258|NCT00704808|PROCEDURE|Primary surgical treatment|Primary surgery for tumor resection.
40941259|NCT00704808|RADIATION|Radiotherapy|Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
40941260|NCT00704808|DRUG|Temozolomide|Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
40941261|NCT00193388|DRUG|Topotecan|
40941262|NCT03391531|PROCEDURE|Bilateral subcostal TAP block|Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle
40941263|NCT03861611|DRUG|Ketorolac|Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed
40941264|NCT03861611|DRUG|Ibuprofen|Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed
40941265|NCT03861611|DRUG|Diclofenac|Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed
40941266|NCT03861611|BEHAVIORAL|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
40941267|NCT02869997|DEVICE|Aspect BIS XP (A-2000) Bispectral Index Patient Monitor|
40941268|NCT00797342|DRUG|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
40941269|NCT00797342|DRUG|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
40941270|NCT00797342|DRUG|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
40941271|NCT04879121|DRUG|Larotrectinib Sulfate|Given PO
40941272|NCT03264313|DEVICE|Deep Transcranial Magnetic Stimulation|Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
40941273|NCT00764504|DEVICE|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
40941274|NCT00764504|DEVICE|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
40941275|NCT05970718|DRUG|REGN7544|Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
40941276|NCT05970718|DRUG|Matching Placebo|Solution for single ascending IV or SC administration per the protocol
40941277|NCT02370277|OTHER|Cytology Specimen Collection Procedure|Undergo collection of stool samples
40941278|NCT02370277|OTHER|Laboratory Biomarker Analysis|Correlative studies
41451505|NCT03724890|RADIATION|Radiotherapy|Participants will receive radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.
40941279|NCT02370277|OTHER|Questionnaire Administration|Ancillary studies
40941280|NCT04007432|OTHER|pulse oxymeter|Nocturnal oxymetry data will be continuously collected during nighttime by a pulse oxymeter, covering for 1 to 3 nights.
40941281|NCT05982431|OTHER|Traditional physical therapy program|60-minutes exercise program, three times a week on alternate days for 12 successive weeks
40941282|NCT05982431|OTHER|Kinsio taping|One full strip of kinesiology taping tape and one half-length strip were needed for the kinesiology taping application
40941283|NCT05982431|OTHER|placebo Kinsio taping|One full strip of kinesiology taping tape and one half-length strip were needed for the placebo kinesiology taping application
40941284|NCT02780609|DRUG|Selinexor|Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.
40941285|NCT02780609|DRUG|Melphalan|Melphalan 100 mg/m\^2 IV over 30-45 minutes.
40941286|NCT02780609|DRUG|Dexamethasone|Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).
40941287|NCT02780609|PROCEDURE|Autologous Hematopoietic Cell Transplantation (HCT)|Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.
40941288|NCT02780609|DRUG|Fosaprepitant|Fosaprepitant at 150 mg IV on days -3 and -2.
40941289|NCT04842422|DRUG|Imiquimod 3.75% Cream|Imiquimod 3.75% Cream
40941290|NCT00005093|DRUG|gemcitabine hydrochloride|
40941291|NCT00005093|DRUG|tacedinaline|
40941292|NCT05855070|DRUG|Intralesional treatment with Hyaluronic acid|Patients will receive intralesional treatment with Hyaluronic acid (0.8% highly purified sodium salt Hyaluronic acid16 mg/2 mL; Sinovial, IBSA, Lodi, Italy) weekly for 12 weeks.
40941293|NCT05855070|DRUG|Intralesional treatment with Verapamil|Patients will receive intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks.
40941294|NCT00089323|PROCEDURE|Bone Marrow Aspiration|
40941295|NCT04072575|DRUG|PP6M injection Dose 1|Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
40941296|NCT04072575|DRUG|PP6M injection Dose 2|Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
40941297|NCT01483690|DRUG|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
40941298|NCT01483690|DRUG|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
40941299|NCT01483690|DRUG|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
40941300|NCT01483690|DRUG|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
40941301|NCT01483690|DRUG|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
40941302|NCT01483690|DRUG|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
40941303|NCT01483690|DRUG|Methotrexate|"Given intrathecally to all patients the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35"
40941304|NCT04092569|BEHAVIORAL|Pre-medical consultation structured diabetes self-care education programme|"The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki."
40941305|NCT02935101|DRUG|Prednisolone|formulated for oral administration. encapsulated.
40941306|NCT02935101|DRUG|Placebo (for Prednisolone)|Sugar pill manufactured to mimic Prednisolon 10mg capsules
40941307|NCT01698112|DIETARY_SUPPLEMENT|Flaxseed High Dose|26 gram flaxseed intervention
40756743|NCT01641666|DRUG|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
40941308|NCT01698112|DIETARY_SUPPLEMENT|Flaxseed Low Dose|13 grams flaxseed
40941309|NCT00732797|BEHAVIORAL|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
40941310|NCT00732797|BEHAVIORAL|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
40941311|NCT00006367|BIOLOGICAL|filgrastim|
40941312|NCT00006367|DRUG|busulfan|
40941313|NCT00006367|DRUG|cytarabine|
40941314|NCT00006367|DRUG|idarubicin|
40941315|NCT00006367|PROCEDURE|peripheral blood stem cell transplantation|
40941316|NCT02457481|DEVICE|Embryo Culture medium|Two step sequential embryo culture medium system
40941317|NCT00753779|DRUG|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
40941318|NCT00753779|DRUG|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
40941319|NCT06229782|DIAGNOSTIC_TEST|Orbital Doppler ultrasonography|During measurement, Doppler settings were adjusted to detect low flow and the smallest available Doppler gate was used for all ODUS examinations. The imaging probe position for ODUS was used transversely and axially, and mean values were recorded. ODUS 10-18 MHz linear probe was used.
40941320|NCT06229782|DIAGNOSTIC_TEST|Transcranial Doppler ultrasonography|"During the measurement, Doppler settings were adjusted to detect low flow, and the minor available Doppler gate was used for all TDUS examinations. For TDUS, a temporal window was used approximately 1 cm above the midpoint of the line joining the lateral palpebral fissure and the external auditory meatus.~Transcranial Doppler ultrasonography ( TDUS) 3-5 MHz convex array probe was used."
40941321|NCT06229782|DIAGNOSTIC_TEST|Computed Tomography Angiography|Cranial Computed Tomography Angiography
40941322|NCT03217981|OTHER|Sepsis protocol|Adherence to the sepsis protocol
40941323|NCT04030455|DRUG|Carboplatin|Given IV
40941324|NCT04030455|DRUG|Cisplatin|Given IV
40941325|NCT04030455|DRUG|Docetaxel|Given IV
40941326|NCT04030455|BIOLOGICAL|Pembrolizumab|Given IV
40941327|NCT02653027|DRUG|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
40941328|NCT02653027|OTHER|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
41282778|NCT06313216|PROCEDURE|autogenous demineralized tooth graft and plate|the dehisced bone defect will be covered with autogenous demineralized tooth graft combined with autogenous demineralized tooth plate
41282779|NCT01471327|BIOLOGICAL|SB-240563|10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
41282780|NCT01471327|OTHER|Placebo|Saline IV, single dose at Day 1
41282781|NCT04665102|OTHER|Image classification using deep learning algorithm|Image classification using deep learning algorithm
41282782|NCT04702711|OTHER|No intervention|No intervention
40941329|NCT03364530|DRUG|Gemcitabine-Oxaliplatin Regimen|"Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity."
40941330|NCT03364530|PROCEDURE|Hepatic intra arterial chemotherapy|"The implantation of a hepatic arterial catheter has now been mastered by interventional radiologists and makes it possible to increase the intra-tumoral concentration of the drugs and probably to limit their systemic toxicity.~Very recently, we have reported that this combination in progressive IHC following systemic gemcitabine/oxaliplatin has led to partial responses and allowed certain patients to benefit from curative treatment.~This suggests that the intra-arterial approach increases the efficacy of these 2 drugs. For locally-advanced IHC, such a loco-regional approach is worth exploring in this poor-prognosis tumor."
40941331|NCT00814151|OTHER|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|"In vitro diagnostic: The MicroPhage Intervention was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The Intervention results were not made available to the patient or their physician."
41132065|NCT02179359|DRUG|Reduced Intensity Preparative Regimen|"* Alemtuzumab~* Cyclophosphamide~* Fludarabine~* Total Body Irradiation (TBI)~* Stem Cell Infusion Day 0"
41132066|NCT02179359|DRUG|Myeloablative Preparative Regimen|"* Alemtuzumab~* Cyclophosphamide~* Busulfan~* Stem Cell Infusion Day 0"
41132067|NCT05305508|DRUG|Calcium Dobesilate|The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
41282783|NCT04599426|BIOLOGICAL|Allogeneic NK cell regimen group|"10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15 ."
41282784|NCT06488118|DRUG|R848|Inhaled R848 dose ranging from 0.1 to 100 μg/mL
41282785|NCT06488118|DRUG|Saline|Inhaled Saline control
41132068|NCT05305508|DRUG|Mannitol|The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
41132069|NCT05964907|DEVICE|Light Source B: Visible Light solar simulator (VL + UVA1)|Patients will be radiated with light source B (Visible light solar simulator)
41282786|NCT05796661|OTHER|Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration|"Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow."
40941332|NCT05748665|DRUG|Remimazolam besylate|Using remimazolam for induction of general anesthesia
40941333|NCT05748665|DRUG|etomidate|Using etomidate for induction of general anesthesia
40941334|NCT06145607|DRUG|ABBV-CLS-7262|ABBV-CLS-7262
41132070|NCT05964907|DEVICE|Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)|Patients will be radiated with light source A (Visible light solar simulator closer match to sunlight)
41132071|NCT00545311|DRUG|NVA237|
41132072|NCT00545311|DRUG|NVA237|
41132073|NCT00545311|DRUG|NVA237|
41132074|NCT00545311|DRUG|NVA237|
41132075|NCT00545311|DRUG|Placebo|
41282787|NCT01160731|DRUG|cisplatin|
41282788|NCT01160731|DRUG|etoposide phosphate|
41282789|NCT01160731|DRUG|panobinostat|
41282790|NCT01160731|OTHER|laboratory biomarker analysis|
41282791|NCT01160731|OTHER|pharmacological study|
41282792|NCT06219538|DEVICE|DAISY Uterine Drain|Insertion of the DAISY Uterine Drain and connection to wall suction in women who have undergone a Caesarean Delivery.
41282793|NCT03846947|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes total and will be added before and after the standard MRI sequence.
41282794|NCT05637450|DIETARY_SUPPLEMENT|Blue Whiting Protein Hydrolysate|25g Blue Whiting Protein Hydrolysates mixed with an everyday food / drink product daily for 6 weeks
41282795|NCT05637450|DIETARY_SUPPLEMENT|Placebo|Isocalorific maltodextrin citrus flavoured powder mixed with an everyday food / drink product for 6 weeks
40941335|NCT00954304|DRUG|HM30181AK 1mg|HM30181AK 1mg tablet
41282796|NCT04642144|OTHER|Yerba mate infusion|"Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate."
40941336|NCT00954304|DRUG|HM30181AK 5mg|HM30181AK 5mg tablet
40941337|NCT00954304|DRUG|HM30181AK 15mg|HM30181AK 15mg tablet
40941338|NCT00954304|DRUG|HM30181AK 60mg|HM30181AK 60mg tablet
41282797|NCT04642144|OTHER|Carbohydrate meal|Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.
41282798|NCT03227926|DRUG|Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
41282799|NCT03227926|DIAGNOSTIC_TEST|Molecular Screening|Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
41282800|NCT03528681|DRUG|Sodium Zirconium Cyclosilicate 5g|Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
40941339|NCT00954304|DRUG|Loperamide 2mg|Loperamide 2mg capsule
40941340|NCT01549470|BIOLOGICAL|VRC-HIVDNA009-00-VP|Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
40941341|NCT01549470|BIOLOGICAL|Placebo vaccine|Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
40941342|NCT04723901|BIOLOGICAL|Dual target CAR-T cell therapy|CD19/CD22 dual target CAR-T cell therapy
41282801|NCT03528681|DRUG|Sodium Zirconium Cyclosilicate 10g|Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
41282802|NCT03528681|DRUG|Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
41282803|NCT06010810|DRUG|3 % Topical Tranexamic Acid|Patient will be given 3% Topical Tranexamic Acid, on half of the face, twice a day for 2 months
41282804|NCT06010810|DRUG|4% Topical Hidroquinone|Patient will be given 4% Topical Hidroquinone, on half of the face, twice a day for 2 months
41282805|NCT00006061|DRUG|phosphatidylcholine|
41282806|NCT01078753|DRUG|Desmopressin|Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
40941343|NCT00688727|BEHAVIORAL|CBT|CBT, up to 12 sessions.
40941344|NCT00688727|BEHAVIORAL|Standard Care|Routine review by neuropsychiatrist in outpatient clinic
40941345|NCT05683223|BEHAVIORAL|Group CBT for Social Anxiety Disorder|Initial CBT will consist of 12 weekly, 2.5-hour group sessions. Later sessions (after session 7) become more individualized as the exposure practices are tailored to the individual participant's concerns. Most often, the exposures are completed outside the group environment. Session content includes various cognitive behavioral strategies tailored to SAD, such as psychoeducation, examining and challenging cognitive distortions, and exposure exercises.
40941346|NCT05683223|DRUG|Sertraline|Non-responders will initiate sertraline at baseline (week 0) with 25 mg/day followed by a dose increase to 50 mg/day at week 1, 100 mg at week 4, 150 mg at week 6, and 200 mg at week 8. Upward dose titration may be slowed and the dose decreased if necessary due to side effects, but the clinician will attempt to titrate all symptomatic participants up to 200 mg/day if tolerated by week 8, with the last dose increase allowed at week 10. Participants will be assessed at each visit by the study psychiatrist for purposes of dose titration and monitoring. Symptomatic participants unable to reach 200 mg/day of sertraline due to side effects will be maintained in the trial if they are on at least 50 mg/day by week 8; all symptomatic participants will be titrated to their maximally tolerated dose (\< 200 mg/day sertraline). Any participant unable to tolerate sertraline will be discontinued and referred for clinical treatment.
40941347|NCT05683223|BEHAVIORAL|Individual CBT for Social Anxiety Disorder|Participants who show no or only partial response to the initial group CBT will continue with an individual, tailored form of CBT plus adjunctive SSRI. The format of CBT will include
41282807|NCT01078753|DRUG|Placebo|Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
41282808|NCT04358978|PROCEDURE|laparoscopic sacral colpopexy with posterior mesh no attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with no attachement of posterior mesh
41282809|NCT04358978|PROCEDURE|laparoscopic sacral colpopexy with posterior mesh attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with the attachement of posterior mesh to vagina
40756744|NCT01641666|DRUG|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
40756745|NCT01724385|DRUG|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
40756746|NCT01678365|DRUG|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
40941348|NCT02068456|DRUG|Roflumilast|
40941349|NCT01050127|DRUG|ABT-436|See Arm Description for details.
41282810|NCT01759303|DRUG|pazopanib|"For subjects \> 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA \< 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
40941350|NCT01050127|DRUG|Placebo|See Arm Description for details.
40941351|NCT01665612|DEVICE|Contact lens care solution|Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
40941352|NCT05374668|BEHAVIORAL|Video-based Yoga Exercises|They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants
41282811|NCT00795730|DRUG|NSA-789|
41282812|NCT00795730|OTHER|placebo|
41282813|NCT00708396|DRUG|Escitalopram|First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
41282814|NCT06388369|RADIATION|[177Lu]Lu-PSMA-617|2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals
40756747|NCT04332770|OTHER|levothyroxine withdrawal|All participants of this study are decided to get radioactive iodine therapy using levothyroxine withdrawal or human recombinant TSH injection prior to the study enrollment. That decision is independent with this study protocol. This study just collect continuous bio signals using wearable devices in the patients undergoing two different preparation methods for radioactive iodine therapy. That is why this study is an observational cohort study.
41282815|NCT06388369|DRUG|Ipilimumab|4 cycles of Ipilimumab 3mg/kg at 3 weeks intervals
41282816|NCT05631028|DRUG|Dexmedetomidine|Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.
41282817|NCT05631028|DRUG|Remimazolam tosilate|Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
41282818|NCT00291343|BIOLOGICAL|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
40756748|NCT01386645|OTHER|low glycemic index (LGI) diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index \<35) for 4 weeks with all food provided by the Human Nutrition Lab
40941353|NCT02260531|DRUG|Cabozantinib|
40941354|NCT02260531|DRUG|Trastuzumab|
40941355|NCT00423670|DRUG|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
40941356|NCT00423670|DRUG|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
40941357|NCT00423670|DRUG|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
40941358|NCT00423670|DRUG|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
40941359|NCT01234207|DEVICE|Standard, non-free-form, non-customized PAL spectacles|Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
40941360|NCT01234207|DEVICE|Individually customized free-form surfaced PAL spectacles|Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
40941361|NCT04543825|DEVICE|Cardiopulmonary exercise testing|Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath. We will also do impedance cardiography, an FDA-approved test to check how the heart functions during exercise. For this test we will attach 6 electrodes (total) to the chest and back (similar to an EKG), so that we can measure the quantity of blood coming out of the heart on every heartbeat. Each evaluation will also include cardiac testing looking for coronary artery disease (CAD).
40941362|NCT01070043|DRUG|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
40941363|NCT01070043|DRUG|Valsartan|"For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks"
40941364|NCT05250128|PROCEDURE|Catheterization|Right heart catheterization, using the Swan-Ganz standard technique, to measure mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance
40941365|NCT01781533|PROCEDURE|algorithm|
41282819|NCT00291343|BIOLOGICAL|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
41282820|NCT00291343|BIOLOGICAL|Mencevax™ ACWY|One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months
41282821|NCT04837560|DEVICE|ElastiMed's SACS 2.0|A wearable medical device that improve circulation using smart materials
41282822|NCT00954577|BEHAVIORAL|Nutrition, health, and exercise education|The classroom intervention is part of the routine science curriculum and consists of 14 sessions taught by the investigators. Topics covered include the development of type 2 diabetes, nutrition education, exercise education, and overall healthy lifestyle education (both at home and in school). The intervention is offered in each year to all grades and to all students, regardless of whether or not they are enrolled in the study. The exercise intervention is optional and consists of 2-3 sessions per week of aerobic exercise (dancing) taught by pediatric trainers and offered in lieu of regular gym classes.
41282823|NCT02063529|DRUG|FOLFOXIRI + Cetuximab|Cetuximab 500mg/m² + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
41282824|NCT02063529|DRUG|FOLFOXIRI|Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
41282825|NCT05654415|OTHER|Melatonin|Each enrolled patient will be subjected to two nap EEG recordings receiving in one occasion the melatonin-based solution under study at a dosage of 5 mg
41282826|NCT05654415|OTHER|Deprivation|Each enrolled patient will be subjected to two nap EEG recordings,in one they will be subjected to sleep deprivation
41282827|NCT00260000|DRUG|5,6,7,8-tetrahydrobiopterin|
41282828|NCT03554512|OTHER|Telehealth virtual appointment|Appointment with NICU clinician via telehealth equipment.
41282829|NCT00631462|DRUG|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
41282830|NCT05990439|BEHAVIORAL|Baby-Feed|The Baby-Feed web application was developed by the researchers of this application at Florida International University. It was designed based on a validated infant food frequency questionnaire (FFQ) developed by our group. The Social Cognitive Theory (SCT) and the Health Self-Empowerment Theory (HSET) were used in the development of the different components. The main intervention component is showing automatic results on how well parents are feeding their infants, upon completion of the infant FFQ, showing results on which food groups are consumed at the recommended level, which are consumed above and which are consumed below. It also shows a growth chart showing how the baby is progressing when they add their baby's weight and length. The website also includes a tracking system with short questions asking about their weekly progress and the recommendations to review frequently, if needed.
41282831|NCT05990439|BEHAVIORAL|Limited access to the Baby-Feed web application|Limited access to the Baby-Feed web application, with only the options of completing the FFQ and inputing their baby's weight and length.
41282832|NCT00337532|DRUG|Paclitaxel|Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
41282833|NCT00337532|DRUG|cisplatin|solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
41282834|NCT03880396|RADIATION|hypofractionated Rth with platinol|hypofractionated Rth with weekly cisplatin 40mg/m2
41282835|NCT04968834|GENETIC|Genomic profiling|Genomic profiling using CLIA assay
41282836|NCT05309083|BEHAVIORAL|Mindfulness Based Walking Therapy (MBWT)|MBWT will be a modified form of the typical Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking meditations and is acceptable for people with Parkinson disease and freezing of gait.
41451506|NCT06095180|OTHER|corticosteroid injection|In the steroid group, 4 mL lidocaine 2% + 1 mL betamethasone injection will be administered under ultrasound guidance and conventional treatment will be given (conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
41451507|NCT06095180|OTHER|dry needling|In the dry needling group, a total of 3 sessions of dry needling will be performed once a week using a 0.60×100 mm sterile needle under ultrasound guidance and conventional treatment will be given ((conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
40941366|NCT05129423|DRUG|MTPS9579A|MTPS9579A will be administered.
41132076|NCT05935969|PROCEDURE|ERCP(Endoscopic retrograde choangiopancreatography), ETGBD(endoscopic transpapillary gallbladder drainage)|For transpapillary gallbladder drainage, biliary cannulation was performed with a duodenoscope (JF-260V or TJF-260V; Olympus Optical). After successful deep cannulation of the CBD, we checked the cholangiogram, performed endoscopic sphincterotomy, and removed the CBD stone using a memory basket and/or retrieval balloon. Cholangiography was then performed again to locate the cystic duct orifice, and a guide wire (Jagwire; Boston Scientific, Marlborough, Massachusetts, USA or Visiglide; Olympus, Tokyo, Japan) was inserted into the gallbladder with different types of catheters (standard catheter, pull-sphincterotome, or rotating sphincterotome) under fluoroscopic guidance. After placement of the guide wire into the gallbladder, contrast dye was injected to confirm good entry into the gallbladder. Once the gallbladder was selected and the guidewire was coiled in the GB, a 7Fr 12-15cm double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Winston-Salem, NC) was inserted into the GB.
41132077|NCT06522919|BIOLOGICAL|Autologous Dendritic Cell (DC) Vaccine|Induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.
41132078|NCT02381470|DRUG|Faropenem|Faropenem 600mg
41451508|NCT06095180|OTHER|exercise|The conventional treatment group (control group) will be given piriformis stretching exercises including hip and knee flexion, hip abduction and external rotation in the supine position. It will be stated that patients should do 2 sets a day and each set should be 10 repetitions.
41132079|NCT02381470|DRUG|Amoxicillin/clavulanic acid|Amoxicillin 500mg/ clavulanic acid 125mg
41132080|NCT02381470|DRUG|Cefadroxil|Cefadroxil 1g
41282837|NCT06143410|DRUG|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
41282838|NCT06143410|DRUG|Saline administration as placebo|administration of a bolus of saline solution as a placebo
41451509|NCT05333107|DRUG|NNC0385-0434 G|Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
40941367|NCT05129423|DRUG|Placebo|Placebo matched with MTPS9579A will be administered.
40941368|NCT00737464|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.
40941369|NCT02713204|DRUG|REGN910-3|
40941370|NCT02713204|DRUG|Intravitreal Aflibercept Injection (IAI)|
40941371|NCT03460600|OTHER|Optical Coherence Tomography (OCT)|Optical Coherence Tomography is a fairly new imaging technique in ophthalmology
40941372|NCT03024697|PROCEDURE|Pectoral Plane Block|
40941373|NCT03024697|PROCEDURE|Local Anaesthetic Wound Infusion Catheter|Levobupivicaine 0.1% @10ml/hr via a wound infusion catheter
40941374|NCT05603663|GENETIC|Informing study subjects about their high CVD polygenic risk score|During a visit, the family physician will announce the value of the subject's polygenic risk for CVD (either at the start or end of the trial, depending on the group) and discuss what it means, calculate the subject's overall risk for CVD using the Kardiokompass tool, advise the subject on weight loss and physical activity, and, if necessary, commence preventive treatment. Between visits, a mobile application will be utilized to collect data about the subjects' level of physical activity and body weight as well as to send reminders to the subjects every two weeks regarding exercise and healthy lifestyle choices.
40941375|NCT06207968|DEVICE|Knee surgery with FH Ortho devices|"This clinical investigation is a real-life observatory designed to collect long-term clinical data on patients who have undergone knee joint replacement or knee ligament reconstruction.~In this type of intervention, one or more medical devices distributed by FH ORTHO SAS may be used by surgeons."
40941376|NCT00977808|DEVICE|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
40941377|NCT00977808|DEVICE|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
40941378|NCT05036720|BEHAVIORAL|LTP+Dads|"LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
40941379|NCT05036720|BEHAVIORAL|LTP+ Optional mother component|LTP+ is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP+ is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
40941380|NCT03086278|DRUG|AST-008|AST-008 is a toll-like receptor 9 agonist.
40941381|NCT00721266|DRUG|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
40941382|NCT01149811|DRUG|Fipamezole ODT|Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
40941383|NCT01149811|DRUG|Fipamezole ODT Cohort 2|Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
40941384|NCT02526173|PROCEDURE|RALP using full nerve sparing technique|RALP using full nerve sparing technique
41282839|NCT06143410|DRUG|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol using target controlled infusion (TCI)
41282840|NCT06143410|PROCEDURE|gastroscopy|esogastroduodenoscopy
41282841|NCT00519077|DRUG|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
41282842|NCT04653662|DEVICE|Earol|Treated with Earol on both ears and subsequent removal after 6 days of application
41282843|NCT04554368|PROCEDURE|intra-arterial contrast enhanced Flat Detector CT|After femoral artery puncture, FDCT scan (if necessary) and IA-CEFDCT scan were performed on a single flat-detector angiography system (Allura Xper FD20, Philips Medical systems, Best, the Netherlands), respectively. FDCT was acquired with the following acquisition parameters: 20s rotation, 220° rotation, 617 single frames at a frame rate of 30/s, 48cm detector field of view, 1024 acquisition matrix. Images were reconstructed using a soft-tissue kernel with an isotropic voxel size of 0.9 × 0.9 × 0.9 mm on a dedicated workstation for FPCT data (XperCT Dual 3.2.0). For image analysis, these isotropic FDCT data were viewed in the axial plane with 5 mm slice thickness.
41451510|NCT05333107|DRUG|NNC0385-0434 F|Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
41451511|NCT05333107|DRUG|NNC0385-0434 B|Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
41282844|NCT04847128|BEHAVIORAL|Chronic aerobic exercise|Participants in the experimental group will exercise more than 30 minutes each time and 3 times weekly for 8 weeks. The chronic aerobic exercise in the present trial is running. The heart rate is required to 60% -85% of the maximum heart rate during exercise. Maximum heart rate = 220 - age.
41282845|NCT00553787|DRUG|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
41282846|NCT00553787|DRUG|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
41282847|NCT00553787|DRUG|VI-0521|placebo
41282848|NCT02587494|PROCEDURE|Cardiac catheterization|Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
41282849|NCT01275404|BEHAVIORAL|Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls|"Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patients success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2)."
41282850|NCT01275404|BEHAVIORAL|Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction|Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
41282851|NCT01919307|OTHER|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
41282852|NCT01451515|DRUG|Prednisone|Given orally (PO).
41282853|NCT01451515|DRUG|Vincristine|Given intravenously (IV).
41282854|NCT01451515|DRUG|Daunorubicin|Given IV.
41282855|NCT01451515|DRUG|PEG-asparaginase|Given intramuscularly (IM) or IV.
41282856|NCT01451515|DRUG|Erwinia asparaginase|Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
41451512|NCT06398522|DIETARY_SUPPLEMENT|Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3|Food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3
41282857|NCT01451515|DRUG|Doxorubicin|Given IV.
40941385|NCT02526173|OTHER|dHACM Application|2x12 sheet of dHACM applied to the neurovascular bundle
40941386|NCT04990336|COMBINATION_PRODUCT|Dachaihu decoction compound|Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.
40941387|NCT04990336|DRUG|Rhubarb single medicine|Rhubarb single medicine
40941388|NCT04990336|COMBINATION_PRODUCT|Regular therapies|Regular therapies, such as fluid therapy, for acute pancreatitis
41282858|NCT01451515|DRUG|Cyclophosphamide|Given IV.
41282859|NCT01451515|DRUG|Cytarabine|Given IV or IT.
41451513|NCT06398522|OTHER|Placebo|Placebo
40756749|NCT01386645|OTHER|high glycemic index (HGI) diet plus placebo (PLAC)|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
40941389|NCT02425072|DEVICE|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
40941390|NCT05806879|OTHER|Maternity Napkin|"Use of maternity napkin with the following specifications (followed for 4.5 months)~* Length is 230-240mm, to be able to provide adequate coverage.~* Width is 150-155mm with wings.~* Thickness is 3-5mm.~* The maternity napkin is curved to prevent leakage on the sides, has wings for secure attachment to the underwear and able to absorb 30-40 ml per minute."
40941391|NCT04071587|DEVICE|Brain Computer Interface training|Training with RecoveriX system.
40941392|NCT04071587|BEHAVIORAL|Control|Standard physiotherapy and occupational therapy according to clinical routines.
41282860|NCT01451515|DRUG|Thioguanine|Given PO.
41282861|NCT01451515|DRUG|Clofarabine|Given IV.
41282862|NCT01451515|DRUG|Methotrexate|Given IV, IM or IT.
41282863|NCT01451515|DRUG|Mercaptopurine|Given PO.
41282864|NCT01451515|DRUG|Dexamethasone|Given PO or IV.
41282865|NCT01451515|DRUG|Hydrocortisone|Given IT.
41282866|NCT01451515|DRUG|Etoposide|Given IV.
41282867|NCT04036760|BEHAVIORAL|Research transitional care coordination|Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
41282868|NCT04335825|PROCEDURE|phacotrabeculectomy|combined antiglaucoma procedure: trabeculectomy with phacoemulsification
40941393|NCT03238742|DRUG|Xuebijing Injection|100ml Xuebijing Injection every 12 hours for 5 days
40941394|NCT03238742|DRUG|normal saline|200ml normal saline every 12 hours for 5 days
41282869|NCT04335825|PROCEDURE|ExPress antiglaucoma surgery combined with phacoemulsification|combined antiglaucoma procedure: ExPress device implantation with phacoemulsification
41451514|NCT03817151|PROCEDURE|posterior chamber intraocular lens implantation|patients who underwent transscleral sutured posterior chamber intraocular lens implantation
41451515|NCT02965261|DRUG|Torrent's Fluoxetine Tablets|
40941395|NCT03927807|DRUG|Misoprostol|"This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.~Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.~Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity."
40941396|NCT00452478|DRUG|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
40941397|NCT00689598|DRUG|Spironolactone|25 mg po qd 25 mg po bid
40941398|NCT00689598|DRUG|Placebo|Spironolactone 25 mg po qd
40941399|NCT02406950|DRUG|Sitagliptin|The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
40941400|NCT03882788|DRUG|Isoflurane|Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management.
40941401|NCT03882788|DRUG|Fentanyl (high dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
40941402|NCT03882788|DRUG|Fentanyl (low dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
40941403|NCT04768673|DRUG|CKD-393 formulation I|single, oral administration of 2 tablets under fed condition
40941404|NCT04768673|DRUG|CKD-393 formulation II|single, oral administration of 2 tablets under fed condition
40941405|NCT04768673|DRUG|D501, D759, H053|single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
40941406|NCT04840069|DRUG|Fluciclovine PET guided Radiotherapy|PET+MRI Based There is no GTV_5400. The GTV_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV_5400 will include the GTV_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV_5400 must also include the entirety of the GTV_6000. There is no CTV_6000. PTV_5400 is the CTV_5400 plus a geometric 3 mm expansion in all dimensions; PTV_6000 is GTV_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV_5400 must contain the PTV_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV_6000. PTV_6000 will be defined as GTV_6000 plus a geometric 3 mm expansion in all dimensions.
40941407|NCT06428682|DRUG|Tranexamic acid|Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.
40941408|NCT06428682|DRUG|Placebo|Control group will receive same volume equivalent of saline intravenously at the time of their surgery.
40941409|NCT04856891|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
40941410|NCT04856891|OTHER|Placebo|Placebo
40941411|NCT05495087|DEVICE|IHT Treatment|IHT Treatment: IH exposure to 10% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
40941412|NCT05495087|OTHER|Sham-IHT Control|Sham-IHT Control: Exposure to 21% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
40941413|NCT05235139|DEVICE|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
40941414|NCT05235139|DEVICE|IOL implantation active comparator (Acrysof Vivity)|Implantation of EDOF IOL Acrysof Vivity
40941415|NCT00968318|PROCEDURE|Excision of strip of deep fascia|operative technique to excise deep fascia.
40941416|NCT04925271|DEVICE|X-Tack|The mucosal or submucosal defect is closed with X-Tack.
40941417|NCT04925271|DEVICE|Overstitch|The mucosal or submucosal defect is closed with Overstitch.
40941418|NCT01993251|DRUG|melatonin|one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
40941419|NCT01993251|DRUG|Melatonin|one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
40941420|NCT01993251|DRUG|Melatonin|one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
40941421|NCT01993251|DRUG|placebo|one capsule, placebo, oral, once a day, 30 minutes before bedtime
40941422|NCT05454904|BEHAVIORAL|Low fat diet|The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the following criteria: 1) \<3 teaspoons/day of olive or Canola oil and \<3 units/week of avocado, 2) removal of visible fat from meats before cooking or from cooked dishes before intake, 3) ≤1 serving per week fat-rich meats, hamburger, commercial ground meat, sausage, cured ham, bacon and salami, 4) daily consumption of low fat dairy products, 5) ≤1 serving/week of butter, margarine, lard, mayonnaise, milk cream, or milk- based ice cream, 6) ≤1 time/week intake of fatty fish or seafood, 7) ≤1 serving per week of commercial sweets or industrial bakery products (not homemade), and 8) ≤1 time/week consumption of nuts (including peanuts), potato chips, French fries, or commercial snacks. This intervention arm will be supplemented with powdered low fat milk (3 kgs/month) for daily use.
41132081|NCT02381470|DRUG|Rifampicin|Rifampicin 10mg/kg
41282870|NCT05367531|DEVICE|Autoinjector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
41451516|NCT02965261|DRUG|Warner Chilcott LLC Sarafem Tablets|
41451517|NCT04168307|DEVICE|Ankle trainer device|The ankle trainer provides passive stretch in dorsal flexion of the ankle as well as active plantar flexion.
40941423|NCT05454904|BEHAVIORAL|Mediterranean diet|The Mediterranean diet group will receive dietary recommendations as follows: 1) use of olive oil (\>3 teaspoons/day), 2) Canola oil as second fat source for cooking and dressing or \>3 units/week of avocado; 3) ≥3 daily servings of vegetables (at least one of them as fresh vegetables in a salad), 4) ≥2 daily servings of fresh fruits; 5) ≥2 weekly servings of legumes; 6) \>2 weekly servings of fresh, canned or frozen fish (at least one serving of oily fish)/seafood; 7) ≥2 weekly servings of nuts/seeds; 8) 4-8 servings/week of white meats (poultry or turkey without skin) instead of 9) fatty or processed meats (\<1 serving/week), 10) ≥2 daily servings of whole grains, 11) ≥1 daily/serving of low fat and fermented dairy products, 12) \<1 daily/serving of whole fat dairy products, 13) ≤1 daily/serving of sugary snacks, drinks or juices and \<4 teaspoons/daily of sugar, and 14) moderate (1-2 drinks/day) wine consumption with meals.
41282871|NCT05367531|DEVICE|Standard Injector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
41282872|NCT05367531|DEVICE|Prefilled|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
41282873|NCT02452359|DEVICE|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
41282874|NCT02411123|GENETIC|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
41451518|NCT04168307|OTHER|Conventional physiotherapy|The patients were instructed in stretching exercises using a non-elastic band
40941424|NCT05454904|BEHAVIORAL|Mediterranean diet plus psychological well-being support|This group will be subjected to the same Mediterranean diet pattern indicated previously as well as to a psychological well-being intervention that will include a variety of components/activities, embracing values, purpose, self-acceptance, character strengths, emotional regulation, dealing with negativity, goal-setting, mindfulness, savoring, gratitude, autonomy, relationships, social interactions, and prosocial behavior.
40941425|NCT02438306|BIOLOGICAL|Autologous cell therapy|Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.
40941426|NCT02438306|OTHER|Sham|An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.
41451519|NCT04939363|COMBINATION_PRODUCT|Obinutuzumab with Ibrutinib and Venetoclax|"1. Obinutuzumab intravenous infusion:~2. Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~3. Venetoclax with an accelerated ramp-up and close inpatient Tumor Lysis Syndromes (TLS) monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:"
41451520|NCT06026657|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41451521|NCT06026657|PROCEDURE|Computed Tomography|Undergo CT scan
41451522|NCT06026657|DRUG|Gemcitabine|Given IV
40941427|NCT05080127|COMBINATION_PRODUCT|application of the allergenic food|a small amount of the allergenic fresh food will be placed on the forearm using a patch test sticker for 15 minutes. the skin reaction will be measured.
40941428|NCT01655680|DRUG|ABT-126|ABT-126 Middle Dose
40941429|NCT01655680|DRUG|ABT-126|ABT-126 Low Dose
41451523|NCT06026657|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41451524|NCT06026657|BIOLOGICAL|Naxitamab|Given IV
41451525|NCT06026657|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given IV
40941430|NCT01655680|DRUG|ABT-126|ABT-126 High Dose
41451526|NCT02086838|DRUG|Theragran Hematinic|
41451527|NCT02086838|DRUG|low molecular weight iron dextran|
41451528|NCT02404753|DRUG|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
41451529|NCT02404753|PROCEDURE|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
41451530|NCT02404753|PROCEDURE|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
40941431|NCT01655680|DRUG|Placebo|Placebo
40941432|NCT01932073|DEVICE|Low-Level Laser Therapy|Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
40941433|NCT04323605|OTHER|"Outpatient assistance program for transplant patients (AMA-ALLO) based on a navigation nurse"|"Integration of a post-transplant navigation nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)"
40941434|NCT05613803|DRUG|Fish oil|6g of EPA and DHA in a 1.3:1 ratio as six Omacor capsules manufactured by Provona Biocare (Olso Norway), or generic equivalent, taken once daily, or in divided doses, with food.
40941435|NCT05613803|OTHER|Placebo|Six capsules containing palm oil and soybean oil on an 8:2 ratio taken once daily, or in divided doses, with food.
40941436|NCT06256757|PROCEDURE|fenestration|Thoracic EndoVascular Aortic Repair (TEVAR) with fenestrations
40941437|NCT02800759|DIETARY_SUPPLEMENT|JOINTRUS®|100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
40941438|NCT02800759|DIETARY_SUPPLEMENT|80% dose of JOINTRUS®|80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
40941439|NCT02800759|DIETARY_SUPPLEMENT|62.4% dose of JOINTRUS®|62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
40941440|NCT02800759|DIETARY_SUPPLEMENT|Starch 100%|0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
40941441|NCT00371501|DRUG|Rosuvastatin|10mg/day
41282875|NCT05752266|DIETARY_SUPPLEMENT|AMILI Probiotic pills|AMILI (AMILI Pte Ltd) will analyze stool samples provided by participants, and assign each participant a type of probiotic pill from the 5 different types of probiotic pills commercially available in AMILI retail store.
41282876|NCT05752266|DIETARY_SUPPLEMENT|Placebo pills|Placebo pills contaning maltodextrin with similar appearance to Probiotic pills will be provided to participants allocated to the Placebo Arm.
41451531|NCT02404753|DRUG|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
41451532|NCT04996316|OTHER|Electronic Health Record Review|Health record reviewed
41451533|NCT04996316|OTHER|Interview|Participate in interview
40941442|NCT00371501|DRUG|placebo|one tablet/day
40941443|NCT00371501|DRUG|aspirin|80mg/day
40941444|NCT00371501|DRUG|placebo|placebo
40941445|NCT04367883|DRUG|Antihistamine|No intervention is performed. We propose an observational study.
41451534|NCT04996316|OTHER|Media Intervention|Use MammoScreen
41451535|NCT04996316|OTHER|Survey Administration|Complete survey
41451536|NCT04996316|OTHER|Training and Education|Undergo training
41451537|NCT04951778|DRUG|CC-91633|Administered orally according to the assigned treatment schedule
41451538|NCT01046084|DRUG|Lansoprazole|30 mg Delayed-Release Capsule
41451539|NCT01046084|DRUG|Prevacid®|30 mg Delayed-Release Capsule
40941446|NCT04367883|DRUG|Amantadine|No intervention is performed. We propose an observational study
40941447|NCT04367883|DRUG|ACEI|No intervention is performed. We propose an observational study.
40941448|NCT04367883|DRUG|ARB|No intervention is performed. We propose an observational study.
40941449|NCT04367883|OTHER|Influenza vaccine and COVID|No intervention is performed. We propose an observational study.
40941450|NCT01232205|DIETARY_SUPPLEMENT|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
40941451|NCT01232205|DIETARY_SUPPLEMENT|Control|supplementation with milk
41451540|NCT00473772|DEVICE|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
40941452|NCT04973696|BEHAVIORAL|Toolkit for Optimal Recovery after Orthopedic Injury|The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
40941453|NCT04973696|OTHER|Minimally Enhanced Usual Care (MEUC)|The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
41132082|NCT05108363|BEHAVIORAL|Lifestyle modification program|Participants will attend dietary consultation sessions weekly in the first 4 months during the intensive phase , and monthly in the subsequent 8 months in the maintenance phase of LMP either face-to-face or via telephone. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The diet will aim for a calorie reduction of 10-20%, at least 10% body weight reduction or body mass index less than 23 kg/m2.Participants will see an exercise instructor a minimum of four times starting at the 2nd month. The exercise instructor will design a suitable exercise regime. Participants will first be advised to increase daily physical activities or to do moderate intensity aerobic exercise, with the goal of 30 minutes for 3 to 5 days a week.
41282877|NCT02610283|DRUG|QPI-1002|IV injection
41282878|NCT02610283|DRUG|Placebo|isotonic saline
41451541|NCT05274763|OTHER|Quality-of-Life Assessment|Ancillary studies
41451542|NCT05274763|OTHER|Questionnaire Administration|Ancillary studies
41451543|NCT05274763|PROCEDURE|Spiritual Therapy|Deliver or undergo Compassion Centered Spiritual Health (CCSH) session
41451544|NCT01129986|DEVICE|DermaStream|Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
41451545|NCT04777305|OTHER|Physical activity training|Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.
41451546|NCT00425841|DRUG|gemcitabine hydrochloride|
41451547|NCT00425841|DRUG|oxaliplatin|
41451548|NCT00425841|PROCEDURE|adjuvant therapy|
41451549|NCT00425841|PROCEDURE|neoadjuvant therapy|
41451550|NCT00425841|RADIATION|hypofractionated radiation therapy|
40941454|NCT02526836|PROCEDURE|Conventional Surgery|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
40941455|NCT02526836|PROCEDURE|Complete mesocolic excision with central vascular ligation|excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
40941456|NCT03589781|DIETARY_SUPPLEMENT|Mikei Red Reishi Essence EX|Dosage is 490 mg per capsule, 3 capsules twice a day with food or water. Total of 6 capsules per day.
40941457|NCT03589781|DIETARY_SUPPLEMENT|Placebo|Matching placebo. Consume 3 capsules twice a day with food or water. Total of 6 capsules per day.
40941458|NCT01889940|BEHAVIORAL|Training for professionals (Spinal Cord Injury Unit staff).|"Prior to the training, separate focus groups for professionals, patients \& families are conducted to determine each party's needs and worries.~Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.~Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period."
40941459|NCT03036605|DRUG|Bupivacaine|%0.5 bupivacaine
40941460|NCT03036605|DRUG|Dexamethasone|8 mg Dexamethasone
40941461|NCT00365144|BIOLOGICAL|bevacizumab|
40941462|NCT00365144|DRUG|erlotinib hydrochloride|
40941463|NCT00365144|OTHER|laboratory biomarker analysis|
40941464|NCT02179775|DRUG|propranolol|
40941465|NCT02179775|DRUG|Quince's oxymel|
40941466|NCT02179775|DRUG|placebo|
40941467|NCT03585348|OTHER|Neuromuscular blocking agents|Neuromuscular blocking agent ED95 equivalent dose by provider
40941468|NCT04228783|BIOLOGICAL|Ad26.ZEBOV|Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).
40941469|NCT04228783|BIOLOGICAL|MVA-BN-Filo|Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.
40941470|NCT04228783|BIOLOGICAL|Placebo|Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).
40941471|NCT04953052|DRUG|Imatinib Mesylate|An isotonic sterile solution of imatinib.
40941472|NCT04953052|DRUG|Placebo|An isotonic sterile solution
40941473|NCT05689944|BEHAVIORAL|Dance-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 15 mn of body warm-up with taught contemporary dance exercises~* 15 mn of creative research based on dance improvisation on a given theme~* 15 mn of sharing for the elaboration of a choreography~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session if he/she wishes (e.g. think of a choreography, remember what was done etc. ....) in order to encourage the commitment to care. These sessions will be based on contemporary dance and dance improvisation techniques."
40941474|NCT05689944|BEHAVIORAL|Art-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 10 mn of discovery of a new technique (acrylic painting or collage).~* 35 mn of practice in a project fixed beforehand~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session (e.g. collecting plants for collage....) in order to encourage commitment to the treatment. The sessions will be based on acrylic painting or collage techniques."
40941475|NCT05689944|BEHAVIORAL|Yoga|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn welcome~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 50 mn of Vinyasa type yoga (warm-up, breathing, balance, strength and flexibility, relaxation)~* 5 mn of closing of the session~* At the end of the session, 5mn of self-evaluation of the pain thanks, the thymia, the fatigue and the level of appreciation of the session (VNS).~These sessions engage the body without entering into a therapy protocol turned towards art as in the two previous interventions."
40941476|NCT03890952|DRUG|Nivolumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
40941477|NCT03890952|DRUG|Bevacizumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
40941478|NCT03051854|BEHAVIORAL|Interaction Competencies with children - for teachers|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
40941479|NCT00004834|DRUG|imipramine|
40941480|NCT00004834|BEHAVIORAL|cognitive-behavioral therapy|
40941481|NCT00296803|DRUG|clopidogrel|
40941482|NCT04375618|DRUG|RhEGF|The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.
41451551|NCT00425841|RADIATION|stereotactic radiosurgery|
40941483|NCT04375618|DRUG|Plain Collagen|A collagen membrane without FGF-2 will be used.
40941484|NCT05550844|RADIATION|Chest HRCT|A chest HRCT to identify emphysema
40941485|NCT05550844|GENETIC|blood analysis|If emphysema is identified, a blood analysis will be performed to exclude known causes of emphysema (Alpha-1 antitrypsin deficiency, PTPN6 mutation)
40941486|NCT05550844|OTHER|Lung function tests|Lung function tests will be performed in accordance with ATS/ERS technical standard
40941487|NCT04233463|DIETARY_SUPPLEMENT|Modulen|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
40941488|NCT04233463|DRUG|Budesonide|Standard treatment for mild Crohn Disease patients
40941489|NCT01243671|BIOLOGICAL|Adalimumab|
40941490|NCT02237911|OTHER|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
40941491|NCT02237911|OTHER|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
40941492|NCT01119560|OTHER|Cytology Specimen Collection Procedure|Correlative studies
40941493|NCT01119560|OTHER|Laboratory Biomarker Analysis|Correlative studies
40941494|NCT01119560|OTHER|Questionnaire Administration|Ancillary studies
40941495|NCT06187675|BEHAVIORAL|Nutrition and Exercise Lifestyle Intervention Program|Nutrition and Exercise components for pregnancy
40941496|NCT06248411|DRUG|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
40941497|NCT06248411|DRUG|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
40941498|NCT03768570|DRUG|Durvalumab|1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
40941499|NCT03508271|OTHER|Non-Interventional|Non-Interventional
40941500|NCT04084327|OTHER|stastical analysis|1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results
40941501|NCT06306053|COMBINATION_PRODUCT|tDCS+EuleriaLab|Home based: Non invasive Neuromodulation treatment + Motor Training
40941502|NCT06306053|DEVICE|tDCS|Non invasive brain stimulation
40941503|NCT06306053|OTHER|EuleriaLab|Home Motor Training
40941504|NCT03354975|BEHAVIORAL|Experiential Training|Participants in the experiential training will be provided with information about using exposure therapy to treat patients with anxiety via lecture-style teaching. Then, they will themselves undergo a one-session phobia treatment for spiders.
40941505|NCT03354975|BEHAVIORAL|Training-As-Usual|The training-as-usual condition will incorporate passive and active learning components. The first half of the training will include lecture-style teaching about using exposure therapy to treat patients with anxiety. The second half of training will incorporate active learning components (e.g., role plays) to reinforce concepts discussed in the first half of training.
40941506|NCT02929173|OTHER|Allceram|Pressed E-max coping veneered with E-max veneering system
40941507|NCT02929173|OTHER|hybrid crown|pressed Bio HPP coping veneered with visolign veneering system
40941508|NCT02793011|DRUG|Dexamethasone|Oral dexamethasone elixir (0.5mg/ml or 4 mg/ml) mixed with Ora-sweet or simple syrup to mask the taste. Or 1 mg or 4 mg dexamethasone capsules if age appropriate
40941509|NCT02793011|DRUG|Placebo|Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
40941510|NCT05535231|DIETARY_SUPPLEMENT|Turmeric test product|2 capsules of 490 mg Turmeric are taken with water once
40941511|NCT05535231|DIETARY_SUPPLEMENT|Turmeric comparator|2 capsules of 200 mg Turmeric are taken with water once
40941512|NCT04732169|DRUG|Active study drug ( oral CBD)|CBD in single dose syringes
40941513|NCT04732169|DRUG|matching placebo|Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes
40941514|NCT03828773|DRUG|Posaconazole|Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients \>18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
40941515|NCT03828773|DRUG|Fluconazole|Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
41282879|NCT05572099|DIAGNOSTIC_TEST|ExoDx Prostate|Observational only.
40941516|NCT04738851|OTHER|Therapy Mirror task|"The protocol has 3 conditions:~* A virtual TM task (TMV~* A classic TM task (TMC)~* A control task (TC)~The order of the 3 conditions will then be randomized to avoid potential biases linked to the sequence of conditions."
40941517|NCT02872571|DRUG|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
40941518|NCT00377000|DRUG|clindamycin 1% / benzoyl peroxide 5% gel pump|
40941519|NCT00377000|DRUG|clindamycin 1% / benzoyl peroxide 5% tube|
40941520|NCT00412568|PROCEDURE|Photorefractive Keratectomy (PRK)|vision correction with PRK
40941521|NCT03226873|BEHAVIORAL|Peer Navigation|Peer education, counseling, and facilitation of PrEP care
40941522|NCT02353754|DRUG|Intrathecal morphine injection|0.2 mg
40941523|NCT02353754|DRUG|EXPAREL|266 mg
40941524|NCT00233428|PROCEDURE|Blood Draw|
40941525|NCT05456919|OTHER|SFQ28 Questionnaire|SFQ28 Questionnaire
40941526|NCT02563132|PROCEDURE|Carbon dioxide insufflation|Carbon dioxide insufflation during diagnostic colonoscopy
40941527|NCT04115644|DRUG|Ketorolac|Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
40941528|NCT04115644|DRUG|Marcaine (placebo)|Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
40941529|NCT04115644|DRUG|Kenalog|Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
40941530|NCT04528771|DRUG|SNO|Six-hour SNO treatment by inhalation at a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr. Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
40941531|NCT04528771|DRUG|Nitrogen gas|Six-hour nitrogen gas treatment by inhalation.Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
41282880|NCT02127762|BEHAVIORAL|Mindfulness Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
41282881|NCT01389128|OTHER|Non-pharmacological resources|"A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Pelvic mobility on the exercise ball oriented and accompanied by the researcher for 40 minutes;~* Lumbosacral massage for a period of 40 minutes, when dilation was between 5 and 6 cm. During the procedure, the woman in labor was allowed to freely choose the most comfortable position; and,~* Warm shower with the water flow directed to the lower-back of the woman in labor, for 40 minutes, when uterine cervical dilation was equal to or higher than 7cm."
41282882|NCT01389128|OTHER|Routine care|Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
41282883|NCT01241539|DRUG|Dabigatran etexilate|150 mg capsule
40941532|NCT00901927|DRUG|Bendamustine|Starting dose 90 mg/m\^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
40941533|NCT00901927|DRUG|Mitoxantrone|10 mg/m\^2 by vein over 15 minutes on Day 2 of each cycle.
40941534|NCT00901927|DRUG|Rituximab|375 mg/m\^2 by vein over several hours on Day 1 of each cycle.
40941535|NCT03205137|DRUG|subjects treated with telmisartan/hydrochlorothiazide|subjects treated with telmisartan/hydrochlorothiazide
40941536|NCT03205137|DRUG|Subjects treated with Telmisartan and amlodipine|Subjects treated with Telmisartan and amlodipine
40941537|NCT03205137|DRUG|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
41132083|NCT03184987|DRUG|FF/UMEC/VI 100/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
41282884|NCT01241539|DRUG|Dabigatran etexilate|75 mg capsule
40941538|NCT03205137|DRUG|subjects treated with telmisartan+amlodipine double pill|subjects treated with telmisartan+amlodipine double pill
40941539|NCT02343133|BIOLOGICAL|HemaMax|
40941540|NCT02343133|DRUG|Placebo|
40941541|NCT05854199|BEHAVIORAL|Telehealth solution|Telehealth nutrition education platform
40941542|NCT01991106|BEHAVIORAL|High intensity interval training|Twelve weeks of 2-3 supervised training sessions each week.
40941543|NCT01991106|BEHAVIORAL|Moderate intensity continuous training|Twelve weeks of 2-3 supervised training sessions each week.
40941544|NCT01991106|DIETARY_SUPPLEMENT|Nutritional advice|healthy food choices, portion sizes and regular mealtimes
40941545|NCT02524964|DRUG|sodium tanshinone IIA sulfonate|eligible participants were randomized to receive sodium tanshinone IIA sulfonate injection (drip 80 mg/day for 7 days immediately after PCI)
40941546|NCT02524964|OTHER|control|equivalent volume of sodium chloride solution
40941547|NCT00089856|BIOLOGICAL|Immunotherapy with allogeneic prostate vaccine|Immunotherapy with allogeneic prostate vaccine
40941548|NCT00089856|DRUG|Chemotherapy (Taxotere and prednisone)|Chemotherapy (Taxotere and prednisone)
40941549|NCT06429007|DRUG|Metformin|Infants in the study will receive 50% of the target dose (12.5mg/kg) for the first 6 weeks of participation. At the 6 week visit, the patient will be assessed and if found still eligible, will receive the full dose (25mg/kg) for the remaining 6 weeks of participation.
40941550|NCT00674427|BIOLOGICAL|CD3/CD28 Activated T cells|Subjects who are not in CR will receive one infusion of high dose aDLI
41132084|NCT03184987|DRUG|FF/UMEC/VI 200/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
40941551|NCT00674427|BIOLOGICAL|CD3/CD28 Activated T cells|Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
40941552|NCT01480128|PROCEDURE|Single-port|Single-port laparoscopic colon resection
40941553|NCT01480128|PROCEDURE|Multi-port|Multi-port laparoscopic colon resection
40941554|NCT04319731|BIOLOGICAL|Human Amniotic Fluid|Administration of amniotic fluid in SARS-CoV-2 positive patients
40941555|NCT03402659|DRUG|neflamapimod|40 mg neflamapimod capsule
40941556|NCT03402659|OTHER|placebo|matching placebo capsule
40941557|NCT04771884|DRUG|meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid|The use of antimicrobial agents depends on the clinical practice
40941558|NCT01836224|DRUG|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) \>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
40941559|NCT01836224|DRUG|Noradrenaline|Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)\>65
40941560|NCT05515666|DIAGNOSTIC_TEST|Wearable electrocardiogram|All participants will have their ECG monitored at home using a wearable ECG, and then be hospitalized for coronary angiography and quantitative flow fraction to confirm the presence of coronary artery disease.
41282885|NCT01241539|DRUG|Dabigatran etexilate|110 mg capsule
41282886|NCT05914883|DIAGNOSTIC_TEST|Long-term continuous ECG monitoring|Long-term continuous ECG monitoring with ECG247 Smart Heart Sensor
41282887|NCT02306278|DRUG|gabapentin|gabapentin capsules 0.3g
41282888|NCT02306278|DRUG|vitamin capsules|vitamin B
41282889|NCT02985801|DRUG|Pancrelipase|Lipase 16,000 United States Pharmacopoeia (USP) units, protease 57,500 USP units, and amylase 60,500 USP units
41282890|NCT02985801|DRUG|Placebo Oral Capsule|Placebo Oral Capsule
41282891|NCT03747952|PROCEDURE|Tibiotalocalcaneal arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
41282892|NCT03747952|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
40941561|NCT02091973|DRUG|Everolimus|Everolimus dosing to target tough level 6-10 mg/ml
40941562|NCT02091973|DRUG|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
40941563|NCT03211962|OTHER|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest
40941564|NCT05220410|DRUG|Psilocybin|Open-Label
41132085|NCT03184987|DRUG|Salbutamol|Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
41132086|NCT03184987|OTHER|ACQ-7|ACQ-7 will be used for the assessment of control status of asthma.
41132087|NCT02436694|DRUG|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
41282893|NCT02262637|DRUG|Micardis®|
41282894|NCT02262637|DRUG|MicardisPlus®|
41282895|NCT00743886|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
41282896|NCT00743886|DRUG|saline|injection of 6 cc of saline into injured area
41282897|NCT03486314|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
41282898|NCT03486314|DRUG|Rifampin|Rifampin capsules.
41282899|NCT03486314|DRUG|Docetaxel|Docetaxel intravenous infusion.
41282900|NCT03486314|DRUG|Carboplatin|Carboplatin intravenous infusion.
41282901|NCT03486314|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
41282902|NCT05417321|DRUG|HB0036|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).
41282903|NCT01983865|OTHER|Exposure to birch pollen|
41282904|NCT05401071|OTHER|Short Regimen with Rifapentine 10mg/kg|rifapentine 10mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
41282905|NCT05401071|COMBINATION_PRODUCT|Standardized Regimen|"During the intensive phase, rifampicin ≤55kg 450mg daily, 55-71kg 600mg daily, \>71kg 750mg daily; isoniazid ≤55kg 225mg daily, 55-71kg 300mg daily, \>71kg 375mg daily; pyrazinamide ≤55kg 900mg daily, 55-71kg 1200mg daily, \>71kg 1600mg daily; ethambutol ≤55kg 825mg daily, 55-71kg 1100mg daily, \>71kg 1375mg daily; All treatment is taken orally.~During the continuation phase, rifampicin ≤50kg 450mg daily, \>50kg 600mg daily; isoniazid 300mg daily; All treatment is taken orally."
40941575|NCT05927324|BEHAVIORAL|CAVEAT|Brief psychotherapy with mothers of infants and young children, to which infants and young children attend many but not all sessions with mother
41132088|NCT02436694|DRUG|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
41132089|NCT04969666|DRUG|IPED2015|Active treatment
41132090|NCT04969666|DRUG|Placebo|Placebo
41282906|NCT05401071|OTHER|Short Regimen with Rifapentine 15mg/kg|rifapentine 15mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
41282907|NCT05401071|OTHER|Short Regimen with Rifapentine 20mg/kg|rifapentine 20mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
41282908|NCT04373083|DRUG|Cemiplimab|Administered in 3-week intervals
41282909|NCT04373083|RADIATION|Involved-site radiotherapy (IS-RT)|Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
41282910|NCT01420185|GENETIC|RNA analysis|
41282911|NCT01420185|GENETIC|gene expression analysis|
41282912|NCT01420185|GENETIC|microarray analysis|
41282913|NCT01420185|GENETIC|reverse transcriptase-polymerase chain reaction|
41282914|NCT01420185|OTHER|laboratory biomarker analysis|
41282915|NCT03183921|OTHER|No intervention|No Interventions
40941576|NCT05191979|OTHER|Exercise regiment (aerobic exercise on bike)|Subjects participating in the current study will be trained progressively and intensively for 12 months primarily on bike indoors and outdoors
40941577|NCT01086423|BIOLOGICAL|Infanrix-IPV/Hib™|Intramuscular, three doses
40941578|NCT01086423|BIOLOGICAL|Infanrix Hib™|Intramuscular, three doses
40941579|NCT01086423|BIOLOGICAL|Poliorix™|Intramuscular, three doses
40941580|NCT06183190|OTHER|No intervention|No intervention
40941581|NCT02756065|OTHER|no intervention|no intervention is used
40941582|NCT05841901|DRUG|Huang-long Zhi-xiao Granule|The experimental group was given Huang-long Zhi-xiao Granule.1 dose per day, oral in 2 divided doses, 1 course every 4 weeks, for a total of 8 weeks of treatment.
40941583|NCT05841901|DRUG|Huang-long Zhi-xiao Granule placebo|The toncral group was given placebo Huang-long Zhi-xiao Granule.The course of treatment was the same as that of the experimental group.
40941584|NCT00144027|BEHAVIORAL|Antipsychotic medication adherence intervention|The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
40941585|NCT03771053|DRUG|Ezetimibe with simvastatin|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
41282916|NCT01770184|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|
41451552|NCT04823936|OTHER|core stability training|core stability training program for 30 minutes including Supine abdominal draw in Abdominal draw in with double knee to chest Trunk twist while sitting on medical ball Lying supine on the medical ball and rotating the trunk to the sides Contracting abdominal muscles while lying in a supine position and pulling the limbs upward with arms and legs kept close Bringing up the arms and legs simultaneously in the prone position Bridging with head on medical ball hold this position for 3-5 s then slowly relaxes Bridging while shoulders and hands are on the floor and one leg is raised Lying supine on the medical ball and holding the abdomen in and bringing with one leg up
41451553|NCT00416780|OTHER|counseling intervention|
41451554|NCT00416780|OTHER|educational intervention|
41451555|NCT00416780|PROCEDURE|psychosocial assessment and care|
40941586|NCT03771053|DRUG|Simvastatin|simvastatin 40mg everyday for 12 months after PCI
40941587|NCT03053271|DRUG|ATR-101|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
40941588|NCT03053271|DRUG|Placebo|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
40941589|NCT03368963|DRUG|Nanoliposomal Irinotecan|Given IV
40941590|NCT03368963|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
40941591|NCT01248845|OTHER|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
40941592|NCT02999009|DEVICE|Trident II Tritanium Acetabular Shell|A hemispherical acetabular shell indicated for cementless application.
40941593|NCT04478331|BEHAVIORAL|Technology-based physical activity interventions|The technology groups will receive a PA program for 12 weeks. These PA programs will be given twice a week and include: 5-10 minutes of warm-up, 20-40 minutes of aerobic exercise and muscle strengthening via circuit training composed of 8-10 exercises with 8-12 repetitions per exercise for 2-3 series, and 5-10 minutes of stretching. In addition, advice and counseling will be given about walking activities to achieve the recommendations.
41282917|NCT01663649|BEHAVIORAL|Deprexis|web-based treatment program for depression
40941594|NCT01165333|DRUG|Cilengitide dose escalation|"Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.~The Cilengitide dose (mg/m²/infusion)levels are as follows :~* 240~* 480~* 720~* 1200~* 1800"
41282918|NCT01663649|BEHAVIORAL|Wait-list|the wait-list group receives Deprexis after 6 month
41282919|NCT03959189|DRUG|ERX-963|Active medicine
41282920|NCT03959189|DRUG|Placebo|Comparator
41282921|NCT04789681|DRUG|Canakinumab|Given SC
41282922|NCT04789681|OTHER|Quality-of-Life Assessment|Ancillary studies
41282923|NCT02489630|DRUG|Ketamine|0.1mg/kg ketamine IV
41282924|NCT02489630|DRUG|Normal Saline|1ml/kg normal saline placebo
41282925|NCT02489630|DRUG|opiate analgesic|0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
41282926|NCT05822856|OTHER|Blood sampling and others interventions|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
41282927|NCT05678998|DRUG|WTX-330|Investigation Product
40941595|NCT01165333|DRUG|Cilengitide|Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
41282928|NCT04057183|DIAGNOSTIC_TEST|Carotid Stenotic Scan|Noninvasive determination of presence or absence of carotid artery stenosis
41282929|NCT00469508|DRUG|Modafinil|400mg pills taken orally daily for 12 wks.
41282930|NCT00469508|DRUG|Placebo|400mg pills taken orally daily for 12 wks
41282931|NCT02329925|DEVICE|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
41282932|NCT04767880|DIETARY_SUPPLEMENT|Whey|Doses of 10, 15, 20 and 30 gram protein of a regular whey protein compound (whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients))
41282933|NCT04767880|DIETARY_SUPPLEMENT|Placebo|The placebo contains \<1 kcal and 0 g protein
41282934|NCT00098631|DRUG|lapatinib ditosylate|Given orally
41282935|NCT00098631|OTHER|laboratory biomarker analysis|Correlative studies
41282936|NCT04481100|DRUG|itraconazole|Oral administration of itraconazole twice daily concurrent with chemoradiation
41282937|NCT03478683|DRUG|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
41282938|NCT03478683|DRUG|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
40941596|NCT01165333|RADIATION|Concomitant radiotherapy|1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
40941597|NCT01165333|BIOLOGICAL|Pharmacokinetic|A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
40941598|NCT01165333|BIOLOGICAL|Pharmacogenetic|For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
40941599|NCT01165333|BIOLOGICAL|Exploratory investigation|Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
40941600|NCT02827916|DEVICE|Assessment of neuropathic pain with theThermotest device|Measure of painful neuropathy with thermotest
40941601|NCT02827916|DEVICE|Assessment of neuropathic pain with SUDOSCAN device|Measure of painful neuropathy with sudoscan Devices
41282939|NCT03478683|DRUG|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
41132091|NCT01402518|PROCEDURE|Per-oral enodscopic myotomy|
41282940|NCT03478683|DRUG|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
41282941|NCT03478683|DRUG|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
41282942|NCT03478683|DRUG|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
41282943|NCT03478683|DRUG|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
41282944|NCT03478683|DEVICE|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
41282945|NCT03478683|DEVICE|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
41282946|NCT03478683|DEVICE|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
41282947|NCT01985321|DRUG|ethanol/glycolic acid solution|ethanol/glycolic acid solution
41282948|NCT01985321|DRUG|Placebo/Ethanol|ethanol solution
41282949|NCT03322683|PROCEDURE|Physiotherapy treatment with physium device.|This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 45 minutes.
41282950|NCT03322683|PROCEDURE|Conventional physiotherapy treatmen|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
41282951|NCT02588456|BIOLOGICAL|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
41282952|NCT04896177|DEVICE|Sirolimus drug-eluting coronary balloon catheter|Patients in experimental group will undergo PCI, using sirolimus drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
41282953|NCT04896177|DEVICE|Paclitaxel drug-eluting coronary balloon catheter|Patients in control group will undergo PCI, using paclitaxel drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
41282954|NCT03590561|OTHER|High caloric diet|After dietary counseling, subjects will receive high caloric snacks for five days.
41282955|NCT06069063|DRUG|Zafirlukast|Oral zafirlukast is approved to treat asthma and been shown in previous trials to be effective in blocking or mitigating the symptoms of people allergic to cat dander
41282956|NCT04987593|DIETARY_SUPPLEMENT|Probiotics|Once a day daily intake of probiotics, at least for 28 consecutive days before giving birth and for at least 28 consecutive days after giving birth
41451556|NCT04976179|DRUG|Ferric carboxymaltose|Ferric carboxymaltose to be given as an intravenous infusion
40941602|NCT02827916|DEVICE|Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.|Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
40941603|NCT00232089|DRUG|Tegaserod|
40941604|NCT01820156|DEVICE|Home Respiratory Polygraphy|
40941605|NCT01820156|DEVICE|Standard Polysomnography|
40941606|NCT06336083|PROCEDURE|Doppler ultrasound|Participants will receive doppler ultrasound of the carotid arteries, and no other interventions studied
40941607|NCT02595970|DRUG|Secukinumab|weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.
40941608|NCT05055453|DEVICE|MyPhonak Junior App|The app is an accessory to the hearing aids which allows the user to make adjustments to their hearing aid in real-time. The hearing aid does not require the use of the app, but the objective of this study is to evaluate the effects of the user adjustments made via the app on the participant's speech intelligibility with the hearing aid.
41282957|NCT00167622|PROCEDURE|mechanical ventilation|Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
41282958|NCT00167622|PROCEDURE|physiotherapy and oxygen if needed|oxygen will be delivered via facial mask whenever needed and physiotherapy
41282959|NCT01153490|BEHAVIORAL|Behavioral Intervention|Substance-related
40941609|NCT05055453|DEVICE|Phonak Sky hearing aid|A Behind-The-Ear hearing aid (BTE) fit to hearing impaired persons with mild to severe hearing loss.
40941610|NCT06421051|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation
40941611|NCT05262725|BEHAVIORAL|Values-based Behavioral Activation|Initially, patients complete a values assessment in which they identify personal values in various life domains. With the assistance of a clinician, patients set incremental behavior goals to move their daily actions to better align with their self-reported values. Goal completion allows the patient to achieve outcomes consistent with recovery, and they potentially experience enjoyment, self-efficacy, and confidence as they progress through the treatment.
41282960|NCT04201431|BIOLOGICAL|PvDBPII/Matrix-M1|50ug PvDBPII in 50ug Matrix M1
41282961|NCT01530490|DRUG|Cabergoline and Hydroxyethyl Starch|0.5mg
40941612|NCT01773772|DRUG|Progesterone|Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls \< 42kg and 50 mg given to those or = to 42 kg.
40941613|NCT01773772|DRUG|Placebo|Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
40941614|NCT01941043|DRUG|CERC-301|
40941615|NCT01941043|OTHER|Placebo|
40941616|NCT05892861|BEHAVIORAL|cognitive stimulation|video education, board games, and 24-hour dietary recall record
40941617|NCT05892861|OTHER|as usual care|history taking, explain data, and discuss how to control healthy condition
41282962|NCT01530490|DRUG|Hydroxyethyl Starch|0.5 mg cabergoline administration 8 days
40941618|NCT00371007|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks|
40941619|NCT00371007|DRUG|Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks|
40941620|NCT02305888|DRUG|LEO 43204|Treatment of actinic keratosis
40941621|NCT01474369|DRUG|TAK-438|TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
40941622|NCT01474369|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
40941623|NCT01474369|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
40941624|NCT01384279|DRUG|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
40941625|NCT02911571|DEVICE|MMprofiler SKY92 gene signature|"MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis"
40941626|NCT00765024|DRUG|Ivermectin|single dose of 200 mcg/kg
40941627|NCT00765024|DRUG|ivermectin|two single dose of 200mcg/kg in 2 weeks
40941628|NCT00765024|DRUG|Albendazole|Albendazole 7 days
40941629|NCT02386306|DRUG|GC021109|
40941630|NCT02386306|OTHER|Placebo|
41282963|NCT04264104|OTHER|neural mobilization|This is a type of mobilization that uses a specific combination of joint movements
41282964|NCT05467085|DEVICE|BX Pulsar 1002|Imaging-Guided Low Intensity Focused Ultrasound Pulsation (LIFU) device
41282965|NCT04562363|PROCEDURE|Suturing of a laparotomic wound with modified methods|Suturing the white line of the abdomen with the help of developed techniques aimed at preventing hernias and eventrations
41282966|NCT00820105|DRUG|ADX10059|oral administration
41282967|NCT00820105|DRUG|ADX10059|Oral administration
41282968|NCT00820105|DRUG|ADX10059|Oral administration
41282969|NCT00820105|DRUG|ADX10059 Matching Placebo|Oral administration
41282970|NCT01195025|DRUG|acetated Ringers|Infusion of Ringer acetate 20 ml/kg over 30 min
41282971|NCT01195025|DRUG|colloid|Infusion of starch 10 ml/kg over 30 min
41282972|NCT01195025|DRUG|colloid+acetated Ringer|Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
41282973|NCT01195025|DEVICE|Non-invasive hemoglobin with pulse-oximeter (SpHb)|Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
41282974|NCT04025840|OTHER|Epidural block|Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.
41451557|NCT04976179|DRUG|Ferrous sulfate|Ferrous sulphate tablet to be taken orally
41451558|NCT00377039|DRUG|AD 337|
41451559|NCT05515458|DRUG|Chiglitazar|Oral single dose 48 mg
41451560|NCT05444296|OTHER|Superficial Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
41282975|NCT04025840|DRUG|Dexamethasone|Dexamethasone (10 mg) is administered intravenously before anesthesia induction.
41282976|NCT05279378|RADIATION|lung ultrasonography versus CT|"chest CT will be done before admission and LUS within first 24 h from admission into the quarantine sector. In addition to 2 weeks after admission.~CT images will be reviewed by chest radiologist expert, who will calculate a CT severity score based on extension and distribution of GGOs and consolidations.~All CT scans will be performed in supine position at end inspiration without intravenous administration of contrast media.~Within 24 h from admission and CT scanning, bedside LUS will be performed by clinician who will be blind to chest CT findings.~Examinations will be performed with the patient in the sitting position, systematically scanning the front and the back side of each hemithorax.~Blood sample will be collected into 4 mL Vacuette containing EDTA. Samples will be stored on ice, processed within 30 min and plasma will be isolated by centrifugation at 2000g for 20 min at 4 °C. Plasma will be immediately frozen at - 80 °C in several aliquots."
41282977|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
41282978|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
41282979|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
40941631|NCT06317376|OTHER|MICT with Aerobic exercise on treadmill|MICT 3 session per week with Aerobic exercise on treadmill for 30 minute with moderate intensity.
41282980|NCT01612910|DRUG|oral microencapsulated diindolylmethane|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
41282981|NCT01612910|OTHER|laboratory biomarker analysis|Correlative studies
41282982|NCT05880914|PROCEDURE|miRNAseq analysis|Identify miRNA in serum and prepare a miRNA sequencing library for novel analysis.
41282983|NCT05880914|DRUG|Standard treatment for bone disorder|Participants will be prescribed a clinically indicated bone-targeted treatment for osteoporosis or bone disorder related to CKD. (non-experimental)
41282984|NCT05740787|OTHER|No intervention|Observation only
41282985|NCT01242111|DRUG|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
41282986|NCT05457140|GENETIC|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
41282987|NCT05457140|DIAGNOSTIC_TEST|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
41282988|NCT00430040|DRUG|Carvedilol Controlled Release (CR)|"lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study.~Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at least 2 weeks to achieve target blood pressure sSBP \<130 and sDBP \< 80"
41282989|NCT00430040|DRUG|lisinopril|lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study
41282990|NCT05951127|PROCEDURE|Esophagectomy|Esophagectomy for esophageal cancer and regional lymph nodes dissection.
41282991|NCT05994651|BEHAVIORAL|Tidal Model improvement model|"1. st interview Pre-assessment Application of measurement tools~2. nd meeting Orientation Concept of recovery, change phase of the individual, Holistic Evaluation, Creation of Personal Safety Plan 3. Interview Process planning Setting goals, Starting One-on-One Sessions~4th meeting Healing is possible, accepting his illness, overcoming change, emphasizing his strengths, instilling hope 5.-6. interview Empowerment Coping with crisis, reducing anxiety, relaxation exercises, individual roles, assertiveness, strengthening self-esteem 7.-8. Interview Maintaining control of life, taking responsibility for behavior, appropriate expression of anger, feeling, thinking and Taking responsibility for recovery, discovering behaviors 9th interview Creating a supportive environment Increasing new interactions, relationships, social skills 10th meeting Evaluation Finalizing the personal security plan, using new knowledge and behaviors in the healing journey, evaluation of the process"
41282992|NCT05939284|DRUG|Injection of Cetrorelix|Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day.
41282993|NCT05939284|DRUG|Oral insertion of dydrogeserone|Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day
41282994|NCT05116969|DRUG|PTX-35|PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody
41282995|NCT02863263|DEVICE|Foam Dressing|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device on its own. Subjects are randomised to one of 2 arms.
41282996|NCT02863263|DEVICE|Foam Dressing with Povidone Iodine|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device own. Subjects are randomised to one of 2 arms.
41282997|NCT01998607|OTHER|Physician Survey|Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
41282998|NCT01585649|DRUG|Lipegfilgrastim|Lipegfilgrastim 100ug/kg
41282999|NCT00608088|BEHAVIORAL|Usual Care|"The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls."
40941632|NCT06317376|OTHER|standard hospital protocol|standard hospital protocol
40941633|NCT03120442|DRUG|Propofol|target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4
40941634|NCT03120442|DRUG|Dexmedetomidine|Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4
41451561|NCT05444296|OTHER|Non-thrust Mobilizations only|Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.
40941635|NCT03120442|DRUG|Fentanyl|0.25 mcg fo Fentanyl for anxiolysis
40941636|NCT03002207|DEVICE|Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
41132092|NCT00372775|DRUG|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
41132093|NCT00655499|DRUG|Panitumumab|6 mg/kg
41132094|NCT00655499|DRUG|Irinotecan hydrochloride|180 mg/kg
41132095|NCT00655499|GENETIC|Chromogenic in situ hybridization|
41132096|NCT00655499|GENETIC|Fluorescence in situ hybridization|
41132097|NCT00655499|GENETIC|Gene expression analysis|
41132098|NCT00655499|OTHER|Laboratory biomarker analysis|
41132099|NCT01214031|DEVICE|Confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy
41132100|NCT01333449|DRUG|Decitabine|20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
41132101|NCT00722046|BIOLOGICAL|PF-04360365 0.1 mg/kg|0.1 mg/kg every 60 days (10 doses total)
41132102|NCT00722046|BIOLOGICAL|PF-04360365 0.5 mg/kg|0.5 mg/kg every 60 days (10 doses total)
41132103|NCT00722046|BIOLOGICAL|PF-04360365 1 mg/kg|1 mg/kg every 60 days (10 doses total)
41132104|NCT00722046|DRUG|Placebo|Placebo every 60 days (10 doses total)
41132105|NCT00722046|BIOLOGICAL|PF-04360365 3 mg/kg|3 mg/kg every 60 days (10 doses total)
41132106|NCT00722046|BIOLOGICAL|PF-04360365 8.5 mg/kg|8.5 mg/kg every 60 days (10 doses total)
41132107|NCT03473249|DRUG|Contrast-Enhanced Ultrasound using Lumason|Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound
41132108|NCT06002035|DIETARY_SUPPLEMENT|Binom Vitamin D drops|Take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added
41132109|NCT00309166|BIOLOGICAL|Cervarix vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
41132110|NCT00309166|BIOLOGICAL|Engerix-B vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
41132111|NCT01902914|PROCEDURE|Hearing Aids Evaluation|Functional Gain Sound field Speech Audiometry
41132112|NCT05785728|DRUG|DB-1202|Administered I.V.
41132113|NCT00255372|DRUG|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
41132114|NCT00255372|DRUG|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
41132115|NCT06147466|DEVICE|Dexcom Continuous Glucose Monitoring|A continuous glucose monitor (CGM) is a wearable device that tracks blood glucose (sugar) every few minutes, throughout the day and night. The readings are relayed in real time to a device which can be read by the patient, caregiver or health-care provider, even remotely
41132116|NCT02310581|DRUG|Buprenorphine Sublingual Spray|Buprenorphine sublingual spray delivered via single 100 μL spray
41132117|NCT02310581|DRUG|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
41132118|NCT02387866|DRUG|AG-221|
41132119|NCT06356922|DRUG|Experimental drug [177Lu]Lu-PentixaTher|Injection of \[177Lu\]Lu-PentixaTher
41132120|NCT00162253|DRUG|BMS 587101|
41132121|NCT03566901|DEVICE|G-EO System|The G-EO Systems can reproduce the gait pattern and realistically simulates the ability to carry out stairs up and stairs down. It provides real-time feedback on the patient's movements with the Visual Scenario and offers the possibility to experience augmented reality further enhance the effectiveness of each therapy session. An intelligent control (G-EO System Evolution) reacts and adapts to each patient's individual capability by either supporting the patient - active assistive mode - or increasing resistance - active mode. The G-EO Systems rehabilitation robot allows to secure the subjects with a harness while they stood on the foot plates of the machine. The foot plates has 3 DoF each, allowing to control the length and the height of the steps and the foot plate angles. The maximum step length corresponded to 550 mm, the maximum achievable height of the steps is 400 mm, the maximum angles is ±90°. The maximum speed of the foot plates is 2,3 km/h.
41132122|NCT03566901|OTHER|Conventional Physiotherapy|Overground walking training including real stair climbing up/down and lower limb mobilization and stretching exercises.
41132123|NCT04246866|BIOLOGICAL|GEM103|GEM103
41132124|NCT00571649|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
41132125|NCT00571649|DRUG|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
41132126|NCT00571649|DRUG|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
41132127|NCT00571649|DRUG|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
41132128|NCT00273052|DRUG|Carvedilol Phosphate modified release formulation|
41132129|NCT00273052|DRUG|metoprolol succinate|
41132130|NCT02551237|RADIATION|50 Gy|radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
40941637|NCT03002207|PROCEDURE|The defect is sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.
40941638|NCT04497207|OTHER|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterir and posterior surfaces of the cornea to obtain corneal tomographic maps.
40941639|NCT02896374|BEHAVIORAL|Theory of mind without visual cues|Theory of mind stimulation without visual reinforcement while performing EEG recordings
40941640|NCT02896374|BEHAVIORAL|Theory of mind without visual cues|Theory of mind stimulation with visual reinforcement while performing EEG recordings
40941641|NCT06403631|OTHER|observational|Data will be gathered longitudinally from participants newly diagnosed with multiple sclerosis. Participants will fill in online questionnaires measuring flow, mindfulness, positive mental health, anxiety and depression. The questionnaires, including both scaled and open-ended questions, will be proposed at the project start (T1) and 6 months later (T2).
40941642|NCT05043558|DRUG|beprostaglandin sodium|beprostaglandin sodium
41283000|NCT00608088|BEHAVIORAL|Community Health Nurse/Peer Councelor Team|"Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.~The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months."
41283001|NCT02609477|DRUG|Istradefylline|Istradefylline 40, 80, 160 mg
41283002|NCT02609477|DRUG|Phentermine 45 mg|Phentermine 45 or 90 mg
41283003|NCT02609477|OTHER|Placebo|Placebo
41283004|NCT05981950|DIAGNOSTIC_TEST|artificial intelligence algorithm|Retinal diseases diagnosed by artificial intelligence algorithm
41283005|NCT05215522|DEVICE|The BCI-FES Intervention|To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.
41283006|NCT04319094|BEHAVIORAL|PEERS|Peer mentors deliver depression care that include social support and coping skills, focused on goal setting and small behavioral changes.
41283007|NCT04319094|OTHER|Social interaction|Study staff will provide a combination of 8 social interaction visits and phone calls to the participants randomized to this condition.
41283008|NCT00065910|BEHAVIORAL|Caregiver joint attention intervention|
40941643|NCT02744469|OTHER|No intervention (observational study)|
40941644|NCT00585390|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"* Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams~* Docosahexaenoic acid fish oil concentrate at 1.6 grams"
40941645|NCT00585390|OTHER|Olive oil placebo|Olive oil capsules, 8 capsules per day
40941646|NCT00585390|DIETARY_SUPPLEMENT|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
40941647|NCT00585390|DRUG|Placebo|Olive oil capsule
40941648|NCT02966873|DRUG|N-Acetylcysteine (NAC) Treatment|Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
40941649|NCT02966873|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
40941650|NCT02966873|DRUG|Inactive Placebo Oral Capsule|Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
40941651|NCT02966873|OTHER|Functional magnetic resonance imaging (fMRI)|Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).
40941652|NCT02966873|OTHER|Proton magnetic resonance spectroscopy (MRS) Imaging|Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).
40941653|NCT02705027|DEVICE|Freka®-Trilumina versus Freka®-EasyIn|Direct placement of probe via endoscope
40941654|NCT00625794|DRUG|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
40941655|NCT00625794|BEHAVIORAL|Smoking cessation counseling|8 weeks or counseling
40941656|NCT01754909|DRUG|Enalapril|Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
40941657|NCT01754909|DRUG|placebo|Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
40941658|NCT02957565|BEHAVIORAL|Baseline Questionnaires|Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
41283009|NCT00715715|DRUG|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
41283010|NCT06037655|DRUG|Total Neoadjuvant Treatment|Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously
41283011|NCT05232955|DEVICE|PET/MR scanner|Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
41283012|NCT05267028|OTHER|AD-TAR|12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
40941659|NCT02957565|OTHER|Videos|Participant watches 2 short videos that show actors playing doctor and patient roles, discussing different cancer-related symptom treatment options. Each video is about 4 minutes long and discusses the same content, but setting of each video is different.
41132131|NCT02551237|DRUG|Capecitabine|oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
41283013|NCT05267028|OTHER|AD-Cognitive Stimulation|12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
41283014|NCT04385108|BIOLOGICAL|Blood collection on admission and longitudinally|33 mL of blood collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
41283015|NCT04385108|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|33 mL of blood collected on their first consultation and 10 to 14 days later
41283016|NCT02045199|DEVICE|Tested product : V0111 cream|Application twice a day during 28 days
41283017|NCT02045199|DEVICE|Placebo|Application twice a day during 28 days
41283018|NCT05057728|BEHAVIORAL|Social-Emotional Prevention Program enhanced version|The intervention is provided for all children for whom parental consent is obtained. The intervention includes a classroom curriculum, teacher training and parent training.
41283019|NCT01776268|OTHER|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
41283020|NCT01674764|PROCEDURE|Early surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
41283021|NCT01674764|PROCEDURE|Late surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
41283022|NCT06495151|DIAGNOSTIC_TEST|Mannose-binding lectin-associated serine protease-3 (MASP-3) Level|Measurement of venous blood serum and peritoneal fluid levels of MASP-3 level by ELISA method.
41283023|NCT06495151|DIAGNOSTIC_TEST|Adipsin Level|Measurement of venous blood serum and peritoneal fluid levels of adipsin level by ELISA method.
41283024|NCT06495151|DIAGNOSTIC_TEST|Properdin Level|Measurement of venous blood serum and peritoneal fluid levels of properdin level by ELISA method.
41283025|NCT06495151|DIAGNOSTIC_TEST|Complement Factor H (CFH) Level|Measurement of venous blood serum and peritoneal fluid levels of CFH level by ELISA method.
41283026|NCT06495151|DIAGNOSTIC_TEST|Cancer Antigen 125 (CA-125) Level|Measurement of venous blood serum level of CA-125 level by ELISA method.
41283027|NCT00847561|BEHAVIORAL|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
41283028|NCT00847561|BEHAVIORAL|Information Monitoring|Packet providing information on strategies for coping with anxiety
41283029|NCT06478836|OTHER|planter pressure|no intervention
41283030|NCT00290472|DRUG|temsirolimus|
41283031|NCT02240134|BEHAVIORAL|Education Intervention (Tx1)|The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
41283032|NCT02240134|DEVICE|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency."
41283033|NCT02240134|DEVICE|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
41283034|NCT01403129|PROCEDURE|Artemis Ultrasound Exam|Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
41283035|NCT01403129|PROCEDURE|Optical Coherence Tomography (OCT) Exam|OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
41283036|NCT00002208|DRUG|Indinavir sulfate|
41283037|NCT00002208|DRUG|Lamivudine|
41283038|NCT00002208|DRUG|Stavudine|
41283039|NCT00002208|DRUG|Zidovudine|
41283040|NCT05565924|OTHER|Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
41283041|NCT05565924|OTHER|Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
41283042|NCT05565924|OTHER|Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
41132132|NCT02551237|RADIATION|25 Gy|radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
41132133|NCT05075499|BIOLOGICAL|COVID-19 vaccination|Blood sample obtained before, 1 , 3 and 6 months after the intervention
41283043|NCT05565924|OTHER|Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
41283044|NCT05565924|OTHER|Group- E; Control group|"Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study."
41283045|NCT05426343|BIOLOGICAL|MVC-COV1901|Approximately 125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
41283046|NCT05426343|BIOLOGICAL|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
41283047|NCT02117089|DEVICE|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20-session device assisted upper limb training with an intensity of 3 to 5 sessions/week, which will be finished within 7 consecutive weeks. In each session, the subjects will conduct the system assisted and task-oriented upper limb training for 1.5 hours.
41283048|NCT00863954|DEVICE|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
41283049|NCT04905862|DIAGNOSTIC_TEST|Immune response|"1. Venous blood samples will be collected at seven-time points: before dose 1 of vaccine, 21 days after dose 1, within 14-21 days after dose 2 and 3,6,9,12 months after vaccination. From the volume of about 8 ml of the patient's peripheral blood, a fraction of PBMC (peripheral blood mononuclear cells) will be isolated.~2. The level of antibodies against the SARS-CoV-2 nucleocapsid (N) antigen will be detected in serum using the Abbot Architect™SARS-CoV-2 IgG test.~3. The level of neutralizing IgG and IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S) will be detected in serum using the DiaSorin LIAISON®SARS-CoV-2 S1/S2 IgG serology COVID-19 S-Protein (S1RBD) Human IgA ELISA Kit respectively.~4. The cellular component of the immune response will be tested using the ELISPOT method, which involves testing the amount of INF-γ and IL-2 released from leukocyte cells."
41283050|NCT04905862|OTHER|Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events|The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials. Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination. Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
41283051|NCT01691118|DRUG|Fimasartan|
41283052|NCT01691118|DRUG|Antihypertensive treatment|
41283053|NCT01052064|DEVICE|Transcranial Magnetic Stimulation|rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
41283054|NCT03361670|OTHER|Observational Study|
41283055|NCT00957372|DRUG|eslicarbazepine acetate|oral tablet, 800 mg or 1200 mg once daily
40941660|NCT02957565|BEHAVIORAL|Assessment Questionnaires|"After viewing first video, participant completes assessment questionnaire to evaluate their opinion of the physicians behavior. These questionnaires should take about 5 minutes to complete.~After viewing second video, participant completes the same 3 assessment questionnaires. Participant also completes 2 additional questionnaires asking which physician participant would prefer as a primary physician and the satisfaction with health information technology use in their care."
41283056|NCT00957372|DRUG|placebo (Part I)|once daily placebo comparator
40941661|NCT05577468|DRUG|Tegoprazan|tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;
40941662|NCT01291433|DRUG|Pentoxifylline placebo|Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
40941663|NCT01291433|DRUG|Pentoxifylline|Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
40941664|NCT01291433|DRUG|Tocopherol acetate|Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
40941665|NCT01291433|DRUG|Clodronic Acid|Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
40941666|NCT01291433|DRUG|Tocopherol placebo|Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
40941667|NCT01291433|DRUG|Clodronate placebo|Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
40941668|NCT00042367|DRUG|Induction therapy (Regimen 1, Course 1, Cycle A1|"2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.~12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.~Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.~3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.~Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)"
41283057|NCT00957372|DRUG|ESL - Open-label Extension (Part II)|Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
41283058|NCT00868387|OTHER|energy-restricted, CHO-restricted diet|carbohydrate content of the diet \< 40% Frequency: daily Duration: 12 months
41283059|NCT00868387|OTHER|energy-restricted, CHO-rich diet|carbohydrate content of diet \> 55% Frequency: daily Duration: 12 months
41283060|NCT02015819|BIOLOGICAL|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
41283061|NCT02015819|DRUG|flucytosine|Given orally
41283062|NCT02015819|DRUG|leucovorin calcium|Given orally
41283063|NCT02015819|OTHER|pharmacological study|Correlative studies
41283064|NCT02015819|OTHER|laboratory biomarker analysis|Correlative studies
41283065|NCT02515695|DRUG|Interferon beta-1a|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution
40941669|NCT00042367|DRUG|Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
40941670|NCT00042367|DRUG|Cycle B|"Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.~Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.~Monitor weekly CBC/diff/plt. If ANC \< 500/mm3 or platelets (unsupported) \< 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.~Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1."
40941671|NCT00042367|DRUG|Regimen 1, Course 2|6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
40941672|NCT00042367|DRUG|Intrathecal Mafosfamide|Regimen 1, Course 1 Mafosfamide, 14 mg, is given two times/week during Cycle A1 and Cycle A2 of Course 1, for 12 total doses during days 1-41. The first dose of Cycles A1 and A2 should be given, if possible, on the same day as the first I.V. cyclophosphamide dose and the second dose 3 to 4 days later. The assigned dose is given one time/week during Cycle B, Course 1 for 3 total doses during days 43 - 63.
40941673|NCT00042367|DRUG|Regimen 1 Course 2, IT mafosfamide|"Regimen 1, Course 2 The assigned dose is administered once with IV cyclophosphamide during each of Cycle A1 and Cycle A2, and day 1 of Cycle B for a total of 3 doses during Course 2.~Patients with an initially abnormal flow study, who show no evidence of obstructive hydrocephalus or compartmentalization on the repeat study, may begin intrathecal mafosfamide administration with the initiation of Regimen 1, Course 2. The frequency of intrathecal mafosfamide administration, for such patients, will be as outlined in Regimen 1, Course~1."
40941674|NCT00042367|DRUG|Regimen 2, Course 1|"Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is \< 1.012.~0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl~(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is \> 2000 on two consecutive days, post ANC nadir."
41283066|NCT00201799|DRUG|Infliximab|"A total of 6 doses of Infliximab will be administered as follows:~Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42"
40941675|NCT00042367|DRUG|Regimen 2, Course, 1, Cycle C1|"Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.~Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2."
41283067|NCT01006356|DRUG|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
41283068|NCT03576027|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
41283069|NCT00049764|DRUG|Drotrecogin alfa (activated)|
41451562|NCT04125862|DIAGNOSTIC_TEST|MRI-based Neuroimaging|During evoked pain fMRI, noxious pressure and heat stimuli will be applied in the two anatomical sites noted above. During fMRI data acquisition, a total of 5 pressure stimulations and 5 heat stimulations will be delivered. Both types of pain stimuli will be applied in a 36/17-sec off/on cycle. The off-condition will correspond to a baseline temperature of 35C and the on condition will match the subject-specific and site-specific 7/10 pressure and heat pain thresholds defined during QST procedures. VAS pain ratings associated with evoked pain stimulation will be collected at the end of each scan. The investigators will also explore the structural properties of the CNS by implementing high-resolution anatomical MRI (gray matter volumes) and diffusion tensor imaging (white matter pathway integrity). All CNS imaging will take approximately 50-60 minutes to complete
40941676|NCT00042367|DRUG|Regimen 2, Course 2|Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
41283070|NCT00049764|DRUG|Placebo|
41283071|NCT01447693|PROCEDURE|application of ointment (olive-omega 3 ointment)|
41283072|NCT04935736|DEVICE|root canal sealer : CORTISOMOL SP|The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.
41283073|NCT04935736|DEVICE|root canal sealer : SEALITE REGULAR|The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.
41283074|NCT01187225|DRUG|Fibrinogen concentrate|In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
41283075|NCT01187225|DRUG|Cryoprecipitate|In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
41451563|NCT04125862|DIAGNOSTIC_TEST|Non-contrast MRI|Musculoskeletal imaging of the affected lower extremity. Patients will be allowed to watch a movie during data acquisition. The following MRI procedures will be completed in order to identify soft tissue lesions in active or painful regions. Fast spin echo (FSE) T2 fat saturated, T1 weighted MRI, FSE proton density MRI, Short-TI Inversion Recovery (STIR), Diffusion weighted MRI (DW-MRI) and 3D Double Echo Steady State (DESS) will be collected. All musculoskeletal MRI will take approximately 30 minutes to complete.
40941677|NCT00042367|RADIATION|radiation therapy|"Conformal Irradiation Patients who are initially M0 with a CR, PR, or SD to Regimen 1 induction chemotherapy (with or without second surgery) will receive local irradiation using conformal techniques. Treatment will commence within 2 weeks of completing Regimen 1 or second surgery. Treatment planning and technique may involve 3D conformal,IMRT, or proton planning and delivery, provided the guidelines regarding volume, dose,and normal tissue restrictions are honored.~8.3.1 Fraction Size 180 cGy fractions will be used for all target volumes. 8.3.2 Fractionation Conventional fractionation will be used. Treatments will be given once daily, 5 days/week except for necessary interruptions secondary to medical or administrative reasons."
40941678|NCT00002988|DRUG|carmustine|
40941679|NCT00002988|DRUG|irinotecan hydrochloride|
40941680|NCT05290545|OTHER|PBSCs|PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10\^8 total nucleated cells/kg recipient ideal body weight.
40941681|NCT05290545|OTHER|Cord|The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10\^8 nucleated cells/kg and 0.15×10\^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.
40941682|NCT05290545|OTHER|BMSCs|BMSCs of donor will be collected and infused at least 0.5×10\^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.
40941683|NCT05618431|OTHER|NIPT|This research aims to develop and validate a new method for non-invasive prenatal testing
40941684|NCT02670174|OTHER|Traditional training|
40941685|NCT02670174|OTHER|Separate kinetic chain training|
40941686|NCT02670174|OTHER|Integrated kinetic chain training|
40941687|NCT05345054|OTHER|no intervention|This study will not involve an intervention of any sort. Participants will either take a survey or undergo an interview, and those taking the survey will have clinical data captured.
40941688|NCT04534803|DRUG|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
40941689|NCT04534803|OTHER|Placebo|.1 nL of diluent (saline) given intradermally at baseline
40941690|NCT03143543|DRUG|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
40941691|NCT03143543|DRUG|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
40941692|NCT03143543|OTHER|Group B Parallel Placebo|Oral placebo vs 10 mg lorcaserin
40941693|NCT03143543|OTHER|Group B2 Parallel Placebo|Oral placebo vs 20 mg lorcaserin
40941694|NCT03458793|BEHAVIORAL|Group walking and group educational workshops|"The experimental group will take part in 12 week intervention consisting of group walking and group educational workshops.~Group walking sessions will run once weekly for up to 45 minutes each in small groups (up to 8-9 people per group) and will be delivered by a trained walk leader once weekly for duration up to 45 minutes per session.~Group educational workshops will be delivered in the form of a group presentation once weekly for up to 45 minutes by the research team (i.e. the PhD student) on a variety of topics focused on the healthy ageing, such as eye hygiene, mental health and well-being, preventing falls, social support, nutritional guides, physical activity recommendations for older adults and other topics"
40941695|NCT04211168|DRUG|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle.~Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, orally, day 2, 6 weeks a cycle. Dose reduction to 4mg/d or dose termination is allowed according to adverse events.~Number of cycle: until progression or unacceptable toxicity events develop."
40941696|NCT01057771|BEHAVIORAL|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
40941697|NCT01057771|BEHAVIORAL|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
40941698|NCT05472454|OTHER|Ready-to-eat meals|Participant group to consume ready-to-eat meals in accordance with the DASH diet for a period of 4 weeks.
40941699|NCT00006324|DRUG|Ethinyl estradiol/levonorgestrel|
40941700|NCT00006324|DRUG|Medroxyprogesterone acetate|
41283076|NCT01774942|PROCEDURE|Procedure/Surgery|All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
40941701|NCT02593201|DRUG|Extended antibiotics (cefazolin or ceftazidime)|To continue with the existing effective antibiotic therapy for one extra week
40941702|NCT02593201|DRUG|Usual antibiotics (cefazolin or ceftazidime)|Usual duration of effective antibiotic therapy therapy
40941703|NCT04660253|BEHAVIORAL|LTP Plus Dads|
40941704|NCT05788601|DRUG|Dapiglutide|GLP-1/GLP-2 receptor agonism
40941705|NCT05788601|DRUG|Placebo|Placebo
40941706|NCT05482542|OTHER|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
40941707|NCT05482542|DRUG|Cyclophosphamide/ATG|Cyclophosphamide/ATG
40941708|NCT05482542|DRUG|Cyclophosphamide/Rituximab|Cyclophosphamide/Rituximab
40941709|NCT01632137|DRUG|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
40941710|NCT01632137|DRUG|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
40941711|NCT06317441|DIETARY_SUPPLEMENT|Probiotic|The intervention consists of a probiotic either with a low or high dosage
41283077|NCT02988648|RADIATION|Radioiodide (131I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
41283078|NCT04814537|DRUG|Bupivacaine Hydrochloride|Local Anesthetic Agent
41283079|NCT05252520|DRUG|JNJ-77474462|JNJ-77474462 will be administered subcutaneously.
40941712|NCT00346944|PROCEDURE|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
41283080|NCT05011552|BEHAVIORAL|Self-Compassion, Health, and Empowerment (SHE)|The SHE intervention includes 8 weekly sessions and 24-hour access to the intervener for any additional support needed. The first and last sessions will be delivered over the phone with the woman based on a brochure. The brochure describes the four major components: a) IPV information, b) Danger Assessment, c) Safety Planning, and d) Resources. It will be discussed with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Session 2-7 focus on providing mental health self-care resources, which are deep breathing, progressive muscle relaxation, visualization, general introduction and overview of self-compassion, mindfulness, and loving-kindness.
41283081|NCT05011552|BEHAVIORAL|The Control Condition|Women randomized to the control group will be provided with the same brochure and mental health care resources.
41283082|NCT06066879|DRUG|Ketamine Hydrochloride|Pre-Operative Ketamine infusion
41283083|NCT06469294|PROCEDURE|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anestesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and scaling and root planing in recurrent periodontal pockets, will be performed with ultrasound (Dabi Atlante, Rio de Janeiro, RJ, Brazil) complemented with Gracey curettes (Golgran, São Caetano do Sul, SP, Brazil) on each patient under local anesthesia. The maintenance therapy will be include every 30 days, until 3 months, when the periodontal parameters will be reassessed."
41283084|NCT06469294|PROCEDURE|Periodontal procedure|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anestesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and scaling and root planing in recurrent periodontal pockets, will be performed with ultrasound (Dabi Atlante, Rio de Janeiro, RJ, Brazil) complemented with Gracey curettes (Golgran, São Caetano do Sul, SP, Brazil) on each patient under local anesthesia. The maintenance therapy will be include every 30 days, until 3 months, when the periodontal parameters will be reassessed."
41283085|NCT06469294|PROCEDURE|Oral treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anestesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and scaling and root planing in recurrent periodontal pockets, will be performed with ultrasound (Dabi Atlante, Rio de Janeiro, RJ, Brazil) complemented with Gracey curettes (Golgran, São Caetano do Sul, SP, Brazil) on each patient under local anesthesia. The maintenance therapy will be include every 30 days, until 3 months, when the periodontal parameters will be reassessed."
41283086|NCT00576914|DRUG|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
41283087|NCT02182037|DRUG|Single rising doses of BIBT 1011 BS|
41283088|NCT02182037|DRUG|BIBT 1011 BS placebo|
41283089|NCT00934895|DRUG|everolimus|Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
41283090|NCT00934895|DRUG|abraxane|Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
41283091|NCT03016611|DRUG|Chewing Ticagrelor LD|180 mg Chewing Ticagrelor
41283092|NCT03016611|DRUG|Chewing Prasugrel LD|60 mg Chewing Prasugrel
41283093|NCT03818815|COMBINATION_PRODUCT|OP0201|OP0201 20mg per day in two divided doses for 10 days
41283094|NCT03818815|COMBINATION_PRODUCT|Placebo|Placebo 0mg per day in two divided doses for 10 days
41283095|NCT03818815|DRUG|Amoxicillin-clavulanate|Oral Amoxicillin-clavulanate in two divided doses for 10 days
41283096|NCT00921921|DRUG|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
41283097|NCT00921921|DRUG|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
41283098|NCT05480514|DEVICE|TEST LENS|etafilcon A with cosmetic pattern
41283099|NCT05480514|DEVICE|CONTROL LENS|Acuvue 1-Day Define Fresh Honey
41283100|NCT01926886|DRUG|Trastuzumab|Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
41283101|NCT04447547|BIOLOGICAL|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
41283102|NCT06254274|DRUG|RAY1225|Administered SC
41283103|NCT06254274|DRUG|Placebo|Administered SC
41283104|NCT04652934|OTHER|Neurodynamic|The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
41451564|NCT04125862|DIAGNOSTIC_TEST|18F-FDG-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-FDG with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be \~3-4 mSv.
40941713|NCT03485469|BEHAVIORAL|Hypnosis|"There ar 10 hypnosis sessions :~* 1st session of hypnosis : relaxation and orientation towards emotional cleansing.~* 2nd session of hypnosis: oriented towards digestion, physical and psychological~* 3rd session of hypnosis: oriented towards the feeling of security.~* 4th session of hypnosis: self-esteem oriented.~* 5th hypnosis session: oriented towards emotional management.~* 6th hypnosis session: oriented towards self-confidence.~* 7th hypnosis session: oriented towards the completion of the projects.~* 8th, 9th and 10th sessions: concern the learning of self-hypnosis and autonomy. A USB key containing the induction of a session of autohypnosis will be given to the subject to promote the continuation of home-made auto-hypnosis."
40941714|NCT03485469|BEHAVIORAL|Standard Care|The dietary advice given during these dietary consultations is part of the standard care adapted to patients who have undergone bariatric surgery while increasing the frequency of consultations (Fractionation of meals, Volume of meals, Taking meals, Drinks, Food diversity)
40941715|NCT01702831|DRUG|Busulfan|Once daily intravenous (IV) busulfan at a dose of 3.2 mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -5 to -3), option 1 OR Once daily intravenous (IV) busulfan at a dose of 3.2mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -6 to -4), option 2.
40941716|NCT01702831|DRUG|Melphalan|"I.V. reduced dose of melphalan (140mg/m2) on day -2, followed by an autologous stem cell transplant on day 0 (day -1 will be a rest day) - this is referred to as Option 1 dosing schema OR I.V. reduced dose of melphalan (140mg/m2) on day -3 followed by autologous stem cell transplant on day 0 (days -2 and -1 will be rest days). This is referred to as Option 2"
40941717|NCT01702831|DRUG|Lenalidomide|Oral lenalidomide 10mg per day (on all 28 days of a 28 day cycle) for the first three cycles and then escalated to 15 mg daily if clinically appropriate to do so. The lenalidomide maintenance will start on day 100 post ASCT and continue till disease progression.
40941718|NCT00920231|DEVICE|initial system|The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
40941719|NCT00920231|DEVICE|modified system|The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
40941720|NCT05591742|DIETARY_SUPPLEMENT|FEMIDUR®|"Femidur® consist of 2 vaginal lactobacillis; Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®. One tablet a day.~Placebo Z Cap V-3 Pla; mainly maltodextrin"
40941721|NCT05591742|OTHER|Placebo Z Cap V-3 Pla|Consist mainly of maltodextrin. One tablet a day.
40941722|NCT02313324|DEVICE|Extracorporeal shock wave therapy (ESWT)|The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
40941723|NCT02313324|DEVICE|SWD combined IFC|The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
41283105|NCT04652934|OTHER|Mimic group|The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
41283106|NCT04627350|OTHER|Response to pulmonary finding (nodule, mass)|Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax
41283107|NCT02875210|PROCEDURE|Laximeter measurement|
41283108|NCT02075164|DIETARY_SUPPLEMENT|Fructose|High oral Fructose challenge (150g per day for 56 days)
41283109|NCT02075164|DIETARY_SUPPLEMENT|Glucose|Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
41283110|NCT01905956|DIETARY_SUPPLEMENT|IQP-AK-102|IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.
41283111|NCT01905956|DIETARY_SUPPLEMENT|Placebo|The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
41283112|NCT05668156|OTHER|Consensus Decision Making|Consensus-based decision-making process, where experts are asked to comment definitions of terms used for fasting interventions
41283113|NCT03980093|BEHAVIORAL|Education|Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
41283114|NCT03980093|BEHAVIORAL|Values|An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
41283115|NCT05671900|DRUG|Gemcitabine 1000 mg, Docetaxel 37.5g|6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.
41283116|NCT04373603|DRUG|Tranexamic acid|TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
41283117|NCT04373603|OTHER|Saline|sodium chloride and water for use as control
41283118|NCT04373603|DRUG|Hyaluronic acid|Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
40941724|NCT06223035|OTHER|Exercise|Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
40941725|NCT04038931|OTHER|Liver biopsy collection|Liver biopsy collection to Confirm suitability of T1DM, total or partial pancreatectomy patient's liver cells to be used as future personalized cell replacement therapy.
40941726|NCT03795610|DRUG|IPI-549|40mg by mouth (PO) every day (QD) for at least 14 days
40941727|NCT02617784|DRUG|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
40941728|NCT00557427|DRUG|hypericum|250mg tablets twice daily for 8 weeks
40941729|NCT00557427|DRUG|fluoxetine|20mg - 40mg daily for 8 weeks
40941730|NCT00426998|DRUG|Verteporfin|
40941731|NCT00426998|DRUG|Bevacizumab|
40941732|NCT00261118|DRUG|Rituximab|Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
40941733|NCT05693727|DIAGNOSTIC_TEST|pleural markers|Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}
40941734|NCT04140136|DIETARY_SUPPLEMENT|Tocotrienols|Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response
41267090|NCT06192433|DEVICE|High-frequency repetitive transcranial magnetic stimulation (40Hz)|Participants in this group receive high-frequency TMS at 40 Hz. The TMS intervention is applied to the bilateral dorsolateral prefrontal cortex (DLPFC). Each patient undergoes this TMS treatment for a course of 10 consecutive working days. The specific parameters for TMS include pulses at 40 Hz with an intensity set at 40% of the maximum intensity. Each pulse lasts for 2 seconds, followed by a 58-second rest period. On each treatment day, patients receive 30 sets of stimulation, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
41283119|NCT03868553|OTHER|No intervention|observational study
40756750|NCT01386645|DRUG|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
40756751|NCT03410771|DRUG|Monitor antibiotic exposure (PK profile)|several plasma samples to measure drug exposure
40756752|NCT03410771|DEVICE|Bioelectrical impedance analysis to measure body composition|non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.
40941735|NCT04140136|DIETARY_SUPPLEMENT|Placebo|The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
40941736|NCT00190515|DRUG|5FU+l-leucovorin|5FU+l-leucovorin
40941737|NCT00190515|DRUG|UFT+Leucovorin|UFT+Leucovorin
40941738|NCT03668769|OTHER|Internet Mobile Technology|Use Quitting Schedule mobile smartphone app
40941739|NCT03668769|OTHER|Interview|Ancillary studies
40941740|NCT03668769|OTHER|Questionnaire Administration|Ancillary studies
40941741|NCT03668769|BEHAVIORAL|Smoking Cessation Intervention|Participate in individual smoking cessation program
40941742|NCT05227144|DRUG|ORIC-533|ORIC-533 once daily in consecutive 28-day cycles
40941743|NCT03088215|DEVICE|shock-waves|Application of shock-waves (radial and focused)
40941744|NCT04360590|DEVICE|pressure support ventilation versus neurally adjusted ventilatory assist|All patients underwent three mechanical ventilation modes, lasting 1 hour each: pressure support mode, neurally adjusted ventilatory assist and again pressure support ventilation
40941745|NCT05574166|DRUG|SP-8356|SP-8356 demonstrates anti-atherosclerotic and anti-ischaemic activity as a novel CD147 inhibitor.
40941746|NCT05574166|DRUG|Placebo|Placebo for SP-8356 powder
40941747|NCT01128751|PROCEDURE|Embol-X intra-aortic emboli filter|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
40941748|NCT01128751|PROCEDURE|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
40941749|NCT01128751|PROCEDURE|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
40941750|NCT03238196|DRUG|Erdafitinib|4mg - 8mg
40941751|NCT03238196|DRUG|Palbociclib|125 mg
40941752|NCT03238196|DRUG|Fulvestrant|500 mg
40941753|NCT03384693|DRUG|Defibrotide|Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.
40941754|NCT00182871|DRUG|testosterone|
40941755|NCT02521571|BEHAVIORAL|Resiliance Alliance|"The intervention is 6 months long \& is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs \& Supervisors/Managers separately.~Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week."
40941756|NCT02521571|BEHAVIORAL|Secondary traumatic stress training|"These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a summary version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent treatment as usual, as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff."
40941757|NCT02962947|DRUG|Propranolol|80 mgR propranolol once daily
40941758|NCT02962947|DRUG|Placebo|placebo once daily
40941759|NCT04702854|DIAGNOSTIC_TEST|Ultrasound Biomicroscopy|Measure of cutaneous melanomas by ultrasound Biomicroscopy
40941760|NCT05462470|PROCEDURE|Repeat Liver Surgery|repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)
40941761|NCT05462470|PROCEDURE|Non-Repeat Liver Surgery|Systemic palliative chemotherapy
40941762|NCT03967678|DIETARY_SUPPLEMENT|Three portions per week (690g beef (raw weight)) for 5 weeks|Lunches served in Human Intervention Studies Unit
40941763|NCT03550651|OTHER|Licorice|Licorice, since years is known for its anti-inflammatory, antimicrobial, antiviral, antiprotozoal, antioxidative, hepatoprotective, cardioprotective, immunomodulatory and antitumour activity. Licorice can be beneficial for oral health. Glycyrrhizin, the sweet component of licorice root has antiplaque property. Pterocarpenes isolated from G. uralensis root extract exerts an antibacterial activity against Streptococcus mutans.
40941764|NCT03550651|OTHER|Hypertonic salt solution|The antiseptic and bactericidal qualities of salt help in removing plaque which is a cause of gingivitis and caries. Warming water with a pinch of table salt can reduce or even be an alternative to anti-inflammatory drugs intra-orally. Its high osmolality reduces inflammation and can be microbicidal. Moreover, efficacy of luke warm hypertonic salt solution has shown antimicrobial, anti-inflammatory and immunomodulatory properties.
41283120|NCT00452621|PROCEDURE|blood draw|
40941765|NCT03550651|OTHER|Essential oil|Essential oils have a wide application in folk medicine, food flavoring and preservation as well as in fragrance industries. The antimicrobial properties of essential oils have been known for many centuries. In recent years, a large number of essential oils and their constituents have been investigated for their antimicrobial properties against some bacteria and fungi. Essential oils have the potential to be used as therapeutic agents for chronic gingivitis and periodontitis conditions that have both bacterial and inflammatory components.
40941766|NCT03550651|OTHER|Chlorhexidine Gluconate|Chlorhexidine is a symmetrical bisbiguanide synthetic antiseptic. It is available in three forms, digluconate, acetate and hydrochloride salts. Which have broad spectrum antimicrobial activity; it is effective against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes, yeasts, fungi and lipid enveloped viruses. Chlorhexidine is considered to be the most effective plaque inhibitor against which other antiplaque agents are measured.
40941767|NCT03550651|OTHER|Distilled water|Distilled water is commonly placebo in various research projects and it is also useful in as placebo treatment.
40941768|NCT03548233|BIOLOGICAL|bcg vaccine|live attenuated vaccine
40941769|NCT03630367|DRUG|Dexamethasone|Intramuscular injection 8 mg
40941770|NCT03630367|DRUG|L-Carnitine 1G/5mL Injection|slow intravenous injection
40941771|NCT00867477|PROCEDURE|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
40941772|NCT00867477|BEHAVIORAL|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
40941773|NCT00867477|PROCEDURE|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
41283121|NCT02764866|OTHER|Sleep testing|Home sleep testing
41283122|NCT00262106|DRUG|PRO 2000/5|Gel
40941774|NCT02545140|OTHER|No intervention|
40941775|NCT03810144|GENETIC|Vectra MBDA Test|Vectra Guided versus Usual Care
40941776|NCT00326573|BEHAVIORAL|Motivational Interviewing|
40941777|NCT00003254|DRUG|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
40941778|NCT00003254|DRUG|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
40941779|NCT06369623|OTHER|Monetary Incentive Delay Task|The Monetary Incentive Delay functional Magnetic Resonance Imaging task is well-characterized and commonly utilized in research settings to measure neural activation between win and loss conditions, as well as between phases of anticipation and consummation/outcome. A recent meta-analysis indicates that the task has been used in over 80 studies and 5,000 subjects as of Year 2022. The task is also valid and appropriate for use in children and adolescents, as demonstrated by its inclusion in National Institute on Drug Abuse ABCD study. The task is utilized for its short-lived, reversible, and/or benign effects on brain activation (e.g., brief processing of a reward cue).
41283123|NCT00262106|DRUG|Placebo|Placebo
41283124|NCT05710874|OTHER|CPP-ACP paste|Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
41283125|NCT05710874|OTHER|CPP-ACPF paste|Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoridepaste) (MI Paste Plus®) in addition to twice daily use of conventional toothpaste.
41283126|NCT05710874|OTHER|1.25% fluoride gel|Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
41283127|NCT05710874|OTHER|Conventional|Twice daily use of conventional toothpaste.
41283128|NCT06402773|DEVICE|The Signati Separo™ Vessel Sealing System|Vessel Sealing System
41283129|NCT00588679|OTHER|Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging|All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
41283130|NCT02146781|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intradermal injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe."
41283131|NCT02146781|OTHER|Saline Control|The subjects in Cohort 1 will receive four doses of saline control 14 days apart, beginning Day 0. Each dose will be delivered as four separate injections of 0.200 mL volumes administered Intradermally (ID) using the needless Biojector 2000 device in separate skin sites. The use of the four 0.200 mL volumes is necessitated in order to compare the skin test sites to the number of sites in Cohorts 2 (4 sites per dose) and Cohort 3 (2 sites per dose). The multiple intradermal administration sites per dose are because of the dilute vaccine material (2.7 mg/mL).
41283132|NCT00243737|DRUG|Artesunate-Mefloquine|
41283133|NCT02152969|DRUG|Telmisartan|
41283134|NCT02152969|DRUG|Amlodipine|
41283135|NCT02152969|DRUG|Chlorthalidone|
40941780|NCT01858311|DIETARY_SUPPLEMENT|Tocotrienol Capsules|Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
41283136|NCT00001737|DRUG|Cyclosporin A Implant|
41283137|NCT03983941|DRUG|Ropivacaine injection|Total dose not to exceed 3 mg/kg of ropivacaine.
41283138|NCT06433115|OTHER|Lean (93%) Grass-Fed Beef|The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
41283139|NCT06433115|OTHER|Lean (93%) Grain-Fed Beef|The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
41283140|NCT06433115|OTHER|Plant-Based Meat|Plant-based meat would be macronutrient matched to the same quantities of meat prescribed for a given energy level.
41283141|NCT01613105|DRUG|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
41283142|NCT01079767|DRUG|temsirolimus|
41283143|NCT00000790|DRUG|Thalidomide|
41283144|NCT00839111|DRUG|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
41283145|NCT00839111|DRUG|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
41283146|NCT06407518|DRUG|Midazolam oral solution|Each individual administers the midazolam oral solution nightly from enrollment to the surgry.
41283147|NCT06407518|OTHER|Placebo|Each individual administers placebo solution nightly from enrollment to the surgry.
41283148|NCT05277012|DRUG|Etrumadenant|Etrumadenant capsule and tablet formulations
41283149|NCT03304457|DRUG|Olanzapine|Olanzapine 10mg once daily orally for 6 weeks
41283150|NCT03304457|DRUG|Lurasidone|Lurasidone 80mg once daily orally for 6 weeks
41283151|NCT05004467|OTHER|Mobilization With Movement Technique|The researcher explains cervical movements to the patient to be done while the technique is performed. This movements will be the painful and limited movements detected in goniometric intervention before the treatment and movements done actively and in all range of motion.
41283152|NCT03331211|DRUG|TKIs|Dasatinib combined with Chematherapy
41283153|NCT06482060|DEVICE|Stabilization splint|Stabilization splint application is a treatment that improves the function of TMJ and masticatory muscles by creating a balanced, stable occlusion to reduce the effects of occlusal interference and parafunctional habits and eliminate associated pain.
41283154|NCT01363050|DRUG|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
41283155|NCT06487884|OTHER|escape games|A suitable day and time will be determined in the curriculum of the students in the intervention group and escape games consisting of various games involving intravenous drug administration will be played. Games will be played within the determined game guidelines. Each group will play the games at the stations respectively and get a clue at the end of each game. After completing the last game, the time it takes to find the password and complete the game will be recorded. After all groups complete the game, the group that completes the games in the shortest time will win the game and receive the prize in the chest.
41283156|NCT00459927|DEVICE|Floseal tonsillectomy|
41283157|NCT00459927|DEVICE|Coblation tonsillectomy|
41283158|NCT00937235|DRUG|Varenicline|1 mg tablets, orally, twice daily x 12 weeks
41283159|NCT00937235|BEHAVIORAL|Medication Management Counseling|15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
40756753|NCT00359398|PROCEDURE|Platelet rich plasma sequestration|Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
40756754|NCT02596893|DRUG|GED-0301|
40941781|NCT01858311|OTHER|Placebo Vehicle|Placebo capsules per day (2 in the morning and 2 in the evening)
40941782|NCT01887301|DRUG|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
41283160|NCT00937235|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
41283161|NCT00148239|BEHAVIORAL|Caregiver Only Intervention|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
41283162|NCT00148239|BEHAVIORAL|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
41283163|NCT00148239|BEHAVIORAL|Control|Participants given written educational materials at beginning of study; no treatment beyond this
41283164|NCT00756002|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
41283165|NCT00756002|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
41283166|NCT02592564|BEHAVIORAL|Internet-delivered cognitive behavior therapy|Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
40941783|NCT05984368|DRUG|BG136|Subjects injected with BG136 in Part 1 and Part 2
40941784|NCT05984368|DRUG|Placebo|Subjects injected with Placebo in Part 1 and Part 2
40941785|NCT05064904|DRUG|never received RAAS blockers or received RAAS blockers before AKI.|"Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).~All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, \<130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge."
40941786|NCT05070169|PROCEDURE|Early Surgical Fixation vs. Delayed Surgical Fixation|Evaluation of the reduction of the peri-operative blood loss in patients undergoing early surgical fixation (within 24 hours) of an intertrochanteric fracture under DOAC therapy compared to a retrospectively enrolled group of patients who underwent delayed surgical fixation (≥48 hours) of an intertrochanteric fracture under DOAC therapy.
40941787|NCT05337436|BIOLOGICAL|Lymphatic drainage|Biological determination in plasma:
40941788|NCT05337436|BIOLOGICAL|Total and ionized magnesium|Total and ionized magnesium
40941789|NCT05337436|BIOLOGICAL|Total and ionized calcium|Total and ionized calcium
40941790|NCT04926454|DRUG|Dexmedetomidine|"Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously.~patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia"
40941791|NCT05407610|PROCEDURE|Conventional Radiofrequency ablation of the genicular nerves|Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.
40941792|NCT05407610|PROCEDURE|Cooled Radiofrequency ablation of the genicular nerves|Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.
40941793|NCT05407610|PROCEDURE|Sham procedure|Sham procedure with placing of needles subcutaneously.
40941794|NCT05777018|PROCEDURE|conventional recruitment maneuvers|"The recruitment maneuver will be performed at 3 predefined time points: 5 minutes after induction of GA (T2), 5 minutes after insufflation of the capnoperitoneum (T3), After the end of surgery and before recovery from anesthesia (T4).~by pressure controlled mode starting with an airway pressure of 15 cmH2O the subsquently changed ( decrease or increase) to provide targeted tidal volume according to each patient, maintaining end-tidal carbon dioxide between 35 to 45 mmHg with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 s. The peak airway pressure will be maintained for 10 s or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings"
40941795|NCT05777018|PROCEDURE|ultrasound-guided recruitment maneuvers|"* Ultrasound guided maneuver will be performed at T2, T3 and T4.~* The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area is visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit will be 40 cmH2O. The Recruitment maneuvers (RM) will be started searching the pressure level at which the consolidation pattern disappears and progressive lung re-aeration is observed and will be recorded for all patients (the lung's opening pressure).(14) Lung ultrasound examination will be performed every 5 cmH2O increments in PEEP to detect the lung's opening pressure."
40941796|NCT05825261|OTHER|voice sampling|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
40941797|NCT05825261|OTHER|capnometry|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
40941798|NCT02142010|DRUG|paclitaxel liposome injection plus cisplatin|Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
40941799|NCT05202132|DIAGNOSTIC_TEST|Questionnaire|A 3 item validated questionnaire assessing masticatory function
40941800|NCT05202132|DIAGNOSTIC_TEST|Chewing gum test|The test is based on the ability of a subject of mixing a two colour chewing gum with 20 masticatory cycles. Mixing of the two colour chewing gum will be assessed as variance of hue in a scanned image of the flattened chewing gum. The method has been validated in independent studies.
40941801|NCT01400815|DRUG|X-22 Smoking Cessation Product|"The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
40941802|NCT01400815|DRUG|Active Control Cigarettes|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
40941803|NCT05078918|OTHER|Comprehensive care program|Comprehensive care program includes education and re-evaluation process. Education using video-materials to help patients adapt to the new normal before and after surgery. And re-evaluation patient's needs 1 month after surgery and arrangement resources.
40941804|NCT05078918|OTHER|Usual care|Usual care includes encouraging deep breathing and exercise using inspirometer, postoperative early ambulation, giving information at discharge and follow up 1 month after surgery.
40947888|NCT04693117|OTHER|Interval Training|All individual of interventional group participated in an interval training program, which comprised of 3 days/week for twelve weeks. A booklet was given to each participant containing instructions and guideline about interval training. The interval training program was introduced as prescribed previously.17 After the workout, a cool down period of 5 minutes was given during which they perform paddling with low speed. All training program was supervised by a qualified physical therapist.
40941805|NCT05753527|BEHAVIORAL|Progressive Relaxation Exercises|Deep abdominal breathing will be done three times and the breath will be given slowly. The fists will be clenched, keep the fists clenched in this way for 7-10 seconds, and then release them for 15-20 seconds. By opening the arms to the side and locking the elbows, the triceps muscle will be stretched and relaxed. The forehead muscles by raising the eyebrows The eyes will be closed and relaxed. The mouth will be opened and closed. The head will be stretched back and relaxed. The shoulders will be lifted and relaxed. Both hips will be tightened and relaxed by bringing them closer together. The thigh muscles will be tightened and relaxed.
40941806|NCT01394718|DRUG|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
40941807|NCT01394718|OTHER|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
40941808|NCT02547714|DRUG|Secukinumab (AIN457)|Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
40941809|NCT02695875|PROCEDURE|Aquatic therapy|"Pool material is contributed by Maria José Jove Foundation. The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
40941810|NCT02695875|PROCEDURE|Land-based therapy|"The material is contributed by Faculty of Physiotherapy at University of A Coruña.~The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
41283167|NCT05075642|OTHER|Initial management of the urinary disorder/s identified during the screening phase|Intervention can be defined as the initial management of the LUTS identified during the screening phase; management lasts at least three months. As observation of routine clinical practice, no specific intervention is included, but any counseling/drug/rehabilitation included as first line management.
41283168|NCT05319964|BEHAVIORAL|Anti-gravity treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~Participants were provided 30 minutes anti-gravity treadmill sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks"
41283169|NCT05319964|BEHAVIORAL|Conventional treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period."
41283170|NCT05319964|BEHAVIORAL|Control|Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.
41283171|NCT03742427|DIAGNOSTIC_TEST|ultrasonography|optic nerve sheath diameter measurement will be done by ultrasonography on both eyes
41451565|NCT04125862|DIAGNOSTIC_TEST|18F-NaF-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-NaF with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be \~3-4 mSv.
40941811|NCT06130527|PROCEDURE|Nicardipine|Following the intubation, the infusion was initiated by using an infusion device (Orchestra Base Primea, Fresenius Kabi) with an i.v. dose of 1.0 µg/kg/min iv in Group N. The targeted MAP was determined as 50-65 mmHg and drug doses were increased until the targeted MAP was achieved In Group N. Nicardipine infusion will be increased by titration in groups with MAP above 65 mm/Hg for more than 5 minutes.
40947889|NCT03311529|BEHAVIORAL|Applied Relaxation|10 training sessions (90 min. each) in Applied Relaxation (group format)
41267091|NCT06192433|DEVICE|Moderately high-frequency repetitive transcranial magnetic stimulation (10Hz)|Participants in this group receive moderately high-frequency TMS at 10 Hz. Similar to the high-frequency group, the TMS intervention targets the bilateral dorsolateral prefrontal cortex (DLPFC) and is administered for a course of 10 consecutive working days. The TMS parameters for this group involve pulses at 10 Hz with an intensity set at 90% of the maximum intensity. Each pulse lasts for 4 seconds, followed by a 56-second rest period. As in the high-frequency group, patients in this group also receive 30 sets of stimulation per treatment day, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
41267092|NCT05231083|DEVICE|Genital Nerves Stimulation|Transcutaneous electrical stimulation of the genital nerves using a TENS device and skin adhesive surface electrodes
41283172|NCT06346912|BIOLOGICAL|CD19-BAFF Targeted CAR T-cells|Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
41451566|NCT04207333|BEHAVIORAL|Mental Arithmetic Test|The researcher will call out a four-digit number and ask the participant to subtract either 7 or 13. Each minute, a new four-digit number will be called out and the participant must subtract the 7 or 13 from the number. The test will last approximately 5 minutes
41451567|NCT05815667|BEHAVIORAL|Individualised Active Communication Education (I-ACE)|The swedish I-ACE consists of five modules with different themes, all with sections of information alternated with reflective tasks. The participants are assigned one module each week and provided with weekly feedback from a health care professional on their work, before being assigned the next module.
40756755|NCT02596893|DRUG|Placebo|
40756756|NCT02176759|OTHER|Administration of rice fortified with regular FePP|
40756757|NCT02176759|OTHER|Administration of rice fortified with regular FePP with citrate added during extrusion|
40756758|NCT02176759|OTHER|Administration of rice fortified with regular FePP and citrate added at consumption|
40756759|NCT02176759|OTHER|Administration of rice fortified with ferrous sulphate|
40756760|NCT00558480|DRUG|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
40756761|NCT00558480|DRUG|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
40756762|NCT04384497|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.
40756763|NCT03382171|OTHER|FoodforCare at home|Five small protein rich meals that will be delivered twice a week for 3 weeks.
41283173|NCT02031900|DEVICE|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
41283174|NCT01673061|DRUG|Lidocaine|See associated Arm Description
41283175|NCT01673061|DRUG|Vapocoolant|See associated Arm Description
41283176|NCT02140125|DRUG|ASP2408|subcutaneous administration
41283177|NCT02140125|DRUG|Placebo|subcutaneous administration
41283178|NCT01655511|DRUG|Tafamidis|240 mg, solution, single dose
40756764|NCT02242656|DRUG|Opium Tincture USP Deodorized|Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
40756765|NCT02242656|DRUG|Opium Tincture USP Deodorized|Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
40756766|NCT02462629|DRUG|BLZ-100|
40941812|NCT06130527|PROCEDURE|Remifentanil|Infusion was administered i.v. using an infusion device (Orchestra Base Primea, Fresenius Kabi). In Group R, the dose will start at 0.05 µg/kg/min following intubation. The target MAP was determined as 50-65 mmHg and drug doses will be increased until the target MAP is reached. HR more than 120 seconds and less than 45 beats/min will be considered as bradycardia and the remifentanil dose will be reduced. If response is unsatisfactory, 0.5 mg Atropine i.v. will be implemented. Nicardipine and Remifentanil infusions in groups will be increased by titration if MAP rises above 65 mm/Hg for more than 5 minutes.
40941813|NCT01753102|DRUG|Estradiol|one tablet will be inserted daily for 14 days
40941814|NCT02126358|DRUG|Gemigliptin and/or Rosuvastatin|
40941815|NCT03521219|DRUG|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
40941816|NCT00174811|DRUG|telithromycin (HMR3647)|
41283179|NCT01655511|DRUG|Tafamidis|480 mg, solution, single dose
41451568|NCT03810937|OTHER|head position|head positioning in sniffing or flat position
40941817|NCT04728867|OTHER|to compare the educational effectiveness of various educational tools|This prospective, randomized, blinded study is designed to compare the educational effectiveness of various educational tools including the surgical textbook, animation, and cadaveric videos in laparoscopic rectal surgery among board-certificated surgeons.
40941818|NCT01225107|DIETARY_SUPPLEMENT|Cranberry Extract|500mg TID
40941819|NCT01225107|DRUG|Inert Placebo Capsule|Inert substance, 3 times per day in capsule form
40941820|NCT00069966|BIOLOGICAL|filgrastim|
40941821|NCT00069966|BIOLOGICAL|rituximab|
40941822|NCT00069966|DRUG|cisplatin|
40941823|NCT00069966|DRUG|cytarabine|
40941824|NCT00069966|DRUG|methylprednisolone|
40941825|NCT00069966|DRUG|pixantrone dimaleate|
40941826|NCT00069966|PROCEDURE|autologous bone marrow transplantation|
40941827|NCT00069966|PROCEDURE|peripheral blood stem cell transplantation|
40941828|NCT04689815|DRUG|Oral Arsenic Trioxide Formulation|Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
41267093|NCT04345419|DRUG|Remdesivir|Remdesivir as antiviral drug
41267094|NCT04345419|OTHER|Standard of care treatment|Standard of care treatment
41267095|NCT04133077|BIOLOGICAL|blood samples collection|Serology and genetic analyses will be performed in patients blood samples
41267096|NCT02595034|DRUG|Clindamycin and Benzoyl Peroxide Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
41267097|NCT02595034|DRUG|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
41267098|NCT02595034|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
41267099|NCT01286493|BIOLOGICAL|rabies vaccines on day 0 and 3|All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,30,90,180,360
41267100|NCT01511757|DRUG|Fluconazole|Fluconazole Tablets, 200 mg
41267101|NCT01511757|DRUG|Fluconazole|fluconazole 200 mg
41267102|NCT04523974|PROCEDURE|Preemptive Surgical Intervention and Precise Efficacy Evaluation of CKD-SHPT|"1. Preemptive surgical intervention for CKD-SHPT patients with poor calcium and phosphorus metabolism controlled by drugs;~2. Rapid immunoreactive parathyroid hormone detection technology during peri-operative period."
41267103|NCT01424592|DEVICE|Testing with a portable sleep apnea monitor .|Portable sleep apnea testing will performed on referred patients.
41267104|NCT04819906|DRUG|Estetrol 20 mg|One estetrol monohydrate (E4) 20 mg tablet plus four matching placebo tablets orally once
41267105|NCT04819906|DRUG|Estetrol 100 mg|Five estetrol monohydrate (E4) 20 mg tablets orally once
41267106|NCT04819906|DRUG|Placebo|Five placebo tablets orally once
41267107|NCT04819906|DRUG|Moxifloxacin 400 mg|One moxifloxacin 400 mg tablet orally once (open-label)
41267108|NCT00594217|DRUG|oral micronized progesterone suspension|oral micronized progesterone suspension, single 100 mg oral dose
41267109|NCT00594217|OTHER|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
40941829|NCT02260674|DRUG|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
40941830|NCT02260674|DRUG|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
40941831|NCT02260674|DRUG|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
40941832|NCT04572802|PROCEDURE|Coronary angiography|Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus
40941833|NCT00881101|DRUG|Liposomal paclitaxel|All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
40941834|NCT00813033|OTHER|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
40941835|NCT05352399|OTHER|NeuViCare application|Intervention arm participants will engage with NeuViCare AI, including all variations of its 5 components: 1) NeuViCare Planner - enables review of ordered tests and external resources recommended by the care provider; 2) NeuViCare Task-Support Service - provides context-sensitive, personalized text-based assistance to help patients' complete care plan captured in the NeuViCare Planner; 3) NeuViCare Resource Advisor - presents trusted, unbiased advice to locate nearby resources listed within their care plan; 4) NeuViCare Advisor - educates and trains Persons Living With Dementia (PLWD) and their care partners at the moment of need; and 5) NeuViCare Community Hub - a safe virtual space which enables care partners to interact with other peer care partners to gain their experiential knowledge and emotional support.
40941836|NCT05979285|DEVICE|N1-Headache App (by Curelator)|Digital application allowing patients to monitor their migraines, and to identify triggers and/or protectors for their migraines.
40941837|NCT00961766|DRUG|BG00010 (Neublastin)|Single dose, weight-based IV administration
40941838|NCT00961766|DRUG|Placebo|Single dose IV matched placebo
40941839|NCT04368273|DRUG|PD-1 antibody|a new treatment drug combined radical radiotherapy concurrent chemotharpy
40941840|NCT05274165|DEVICE|Lyric Hearing Aid- Experimental Design|Extended wear hearing aid with a fitting modification that is currently not available
40941841|NCT05274165|DEVICE|Lyric Hearing Aid- Commercially Available|Extended wear hearing aid that is currently available
40941842|NCT00752115|DRUG|sildenafil|50mg, day1,8 and 15 in each cycle
40941843|NCT00752115|DRUG|placebo|1 tab, day 1,8 and 15 in each cycle.
40941844|NCT00752115|DRUG|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
40941845|NCT00752115|DRUG|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
40941846|NCT03525093|BEHAVIORAL|Hypnosis|"5 session of group hypnosis, each 90 minutes, to reduce subjective levels of stress, improve coping with stress. Additional audiotapes of hypnosis sessions as homework.~Participants receive a health education booklet on improving coping with stress."
40941847|NCT03525093|BEHAVIORAL|Health education|Participants receive a health education booklet on improving coping with stress.
40941848|NCT05675982|OTHER|CAR-T cells monitoring|monitoring of circulating DNA by blood sample
40941849|NCT00856648|DEVICE|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
40941850|NCT06157060|DIAGNOSTIC_TEST|circulating tumor DNA|blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
40941851|NCT01553032|DRUG|Erbitux®|400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
40941852|NCT01553032|RADIATION|Fractionated Radiotherapy|30-35 fractions of radiotherapy (6-7 weeks)
40941853|NCT01554228|OTHER|Observation|Observational study to examine changes in cognition following bariatric surgery after one year.
40941854|NCT01682668|PROCEDURE|Bilateral subthalamic stimulation|
40941855|NCT02819661|DEVICE|SOMNOTOUCH RESP|Ventilatory effort recorder
40941856|NCT02819661|PROCEDURE|Caesarean section|Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
40941857|NCT02819661|DRUG|Spinal anesthesia with intrathecal morphine|is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
41267110|NCT00295945|DRUG|fentanyl citrate|
40941858|NCT04157621|DEVICE|Active taVNS|Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus
40941859|NCT04157621|DEVICE|Sham Stimulation|Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.
40941860|NCT00001431|DRUG|gemcitabine|
40941861|NCT04996641|PROCEDURE|Root canal treatment and crown|Pre-radiation one day root canal treatment and CAD/CAM chair side fabricated crowns for head and neck cancer patients
40941862|NCT00730197|DRUG|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
40941863|NCT00730197|DRUG|VoSpire® ER Tablets 8 mg|8mg, single dose fed
40941864|NCT01830075|BEHAVIORAL|Consultations|The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
41267111|NCT00295945|DRUG|hydromorphone hydrochloride|
41267112|NCT00295945|DRUG|ropivacaine hydrochloride|
41267113|NCT06014944|DRUG|Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody|neoadjuvant therapy for short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody for PMMR / MSS type middle and low locally advanced rectal cancer.
41267114|NCT00608855|OTHER|questionnaire administration|
41267115|NCT00608855|PROCEDURE|cryosurgery|
41267116|NCT00608855|PROCEDURE|pain therapy|
41267117|NCT00608855|PROCEDURE|quality-of-life assessment|
41267118|NCT01662648|DRUG|Paliperidone ER|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
41267119|NCT05435820|DEVICE|Near-infrared Transcranial Laser Therapy|The treatment consists in exposing bilaterally the frontal brain to Transcranial Laser Therapy, which may enhance ATP production in depressed subjects.
40941865|NCT04163679|PROCEDURE|Vaginal Preparation|"One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick."
40941866|NCT03015545|DEVICE|paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
40941867|NCT03015545|DEVICE|paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
40941868|NCT03015545|DEVICE|non-paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
40941869|NCT03015545|DEVICE|non-paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
40941870|NCT00710437|DRUG|Dexmedetomidine|Steady state infusion 0.007 mcg/kg/min
40941871|NCT01387373|DRUG|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
41267120|NCT01774422|DEVICE|Extracorporeal CO2 removal device|
41267121|NCT02835885|DEVICE|Digitmer High Voltage Stimulator model DS7A TENS unit|
41267122|NCT05388747|DRUG|Cefuroxime|Population pharmacokinetics, effectiveness, and safety of cefuroxime
40941872|NCT03004222|DRUG|Bupivacaine|20 ml of 0.5% Bupivacaine
40941873|NCT03004222|DRUG|Placebos|
40941874|NCT02715479|DRUG|Dolutegravir|Dolutegravir
40941875|NCT02715479|DRUG|BMS955176|BMS955176
40941876|NCT02414672|BEHAVIORAL|CareSTEPS|Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
40941877|NCT03461510|PROCEDURE|Hyperglycemic clamp|Subjects with T2D will receive IV Dextrose infusion to maintain plasma glucose at \~250 mg/dL during fMRI.
40941878|NCT03461510|PROCEDURE|Hyperinsulinemic Euglycemic clamp|Subjects with T2D will receive IV Dextrose and Insulin infusion to maintain plasma glucose at approximately 90 mg/dL during fMRI.
41267123|NCT02406846|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
41267124|NCT02406846|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
41267125|NCT04067765|BEHAVIORAL|Alcohol cue|Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of alcohol beverages (beer, wine, or liquor)
41267126|NCT04067765|BEHAVIORAL|Neutral cue|Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of neutral beverages (water).
41267127|NCT04753892|OTHER|3SM2-G-CRM197 with squalene adjuvant|Immune challenge agent
41267128|NCT00936624|DRUG|SOTB07|SOTB07 100mg
41267129|NCT00936624|DRUG|SOTB07|SOTB07 200mg
41267130|NCT00936624|DRUG|placebo|placebo
41267131|NCT00936624|DRUG|montelukast|montelukast 10mg po, bid, 12week
41267132|NCT05502497|OTHER|Observational|No application will be made to the control group.
41267133|NCT05502497|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
41267134|NCT00955058|DRUG|OCP|Daily For 3 months
41267135|NCT05560737|BEHAVIORAL|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consists of:~* Automated digital counselling resources (educational pages, videos, tools, and trackers)~* Chatrooms available 24/7~* Weekly 30-minute presentations and discussions led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4 and 8, and study completion (up to 16 months)."
41267136|NCT01672931|OTHER|Oocyte Measurement|
41267137|NCT01032629|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily
41267138|NCT01032629|DRUG|Canagliflozin (JNJ-28431754) 100 mg|One 100 mg capsule taken orally (by mouth) once daily
41267139|NCT01032629|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg capsule taken orally (by mouth) once daily
41267140|NCT05935384|DIAGNOSTIC_TEST|Guardant360|Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.
41267141|NCT02984592|BEHAVIORAL|physical exercise|regular exercise programs in the previous 6 months.
41267142|NCT04182867|OTHER|Dietary intervention|Dietary modification (provision of diet).
41267143|NCT01214486|DRUG|Raltegravir|Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA \< 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
41267144|NCT01499173|BEHAVIORAL|Stroke Preparedness Intervention|A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
41267145|NCT03611439|DIETARY_SUPPLEMENT|ReBuilder|8-component botanical dietary supplement
40941879|NCT01850264|DEVICE|Application of quadripolar / bipolar LV electrodes|
40941880|NCT00242073|PROCEDURE|MRI Prostate|
40941881|NCT01712646|DRUG|Intranasal Oxytocin|
40941882|NCT04575844|DRUG|Liraglutide|24 weeks of Liraglutide
40941883|NCT04575844|OTHER|Exercise training|24 weeks of Exercise training
40941884|NCT04575844|DRUG|Liraglutide + Exercise training|24 weeks of Liraglutide + Exercise training
40941885|NCT01067976|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
40941886|NCT04758910|DEVICE|High Flow Oxygen Therapy|A 30-minute spontaneous breathing trial using high flow oxygen therapy via tracheostomy.
40941887|NCT04758910|DEVICE|T-piece|A 30-minute spontaneous breathing trial using T-piece via tracheostomy.
40941888|NCT03111069|PROCEDURE|Abdominal Surgery|"Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).~Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor."
40941889|NCT03111069|DRUG|Doxorubicin|"Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation."
40941890|NCT03111069|RADIATION|Intra-Operative Radiation|Standard dose brachytherapy delivered to the residual pelvic tumor sites.
40941891|NCT05819606|OTHER|Immunohistochemistry (IHC) analysis|Setting of the percentage amount of PSMA expression on the primary tumor cell surface on post-surgical samples by the Immunohistochemistry method (IHC)
40941894|NCT04793061|OTHER|blood sample collection|Blood is samples from peripheral vein during routine care
40941895|NCT04265469|OTHER|Diabetic foot education|Give Diabetic foot education via mobile phone
40941896|NCT00126607|BIOLOGICAL|trastuzumab|Given IV
40941897|NCT00126607|OTHER|laboratory biomarker analysis|Correlative studies
40941898|NCT05834413|DRUG|chemotherapy plus TCM 1&ICIs plusTCM2 placebo|"In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
40941899|NCT05834413|DRUG|chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo|"Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
40941900|NCT04240470|PROCEDURE|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
40941901|NCT03923985|DIETARY_SUPPLEMENT|Probiotic containing Lactobacillus Crispatus|1 tablet / day of probiotic (275 mg of live probiotic lactic ferments: 10 Mld L. fermentum (SGL 10), 10 Mld L. gasseri, 10 Mld L. casei, 10 Mld L. acidophilus, 10 Mld L. crispatus) during 2 months.
40941902|NCT00218127|DRUG|Levoacetyl Methadol|WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
40941903|NCT00218127|DRUG|Levoacetyl Methadol|MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
40941904|NCT00218127|DRUG|Levoacetyl Methadol|LAAM Fixed Dose evaluation up to 48 mg 48 mg
41267146|NCT03611439|DIETARY_SUPPLEMENT|Placebo|Inactive Placebo Capsule
41267147|NCT02379325|BEHAVIORAL|Lets Quit|"Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling."
40941905|NCT01025765|DRUG|Pioglitazone|Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
41267148|NCT02379325|BEHAVIORAL|pamphlets material|Given pamphlets material on smoking and complication
41267149|NCT01245647|DRUG|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
41267150|NCT01245647|OTHER|Sugar pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
41267151|NCT06030180|DEVICE|EsoGuard|EsoGuard is a set of genetic assays and algorithms for the assessment of specific methylation patterns of DNA encoding the genes vimentin (VIM) and cyclin A1 (CCNA1)
41267152|NCT00215930|DRUG|Vinorelbine|Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
41267153|NCT00215930|DRUG|Docetaxel|"RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days."
40941906|NCT01025765|DRUG|Acarbose|Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
40941907|NCT01025765|DRUG|Metformin|Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
40941908|NCT06166602|DRUG|PENG block with 0.25% bupivacaine.|Peng block will be applied to the same side as the surgery, using 0.25% bupivacaine at the same concentration in different volumes.
40941909|NCT04570722|OTHER|Ipsilateral peripheral IV insertion|Patients with successful ipsilateral intravenous access will be provided a patient education sheet describing signs and symptoms that should be reported to the study team. All participants will be contacted by the study team at twelve week intervals for 12 months after their radiology encounter for completion of symptom assessments. If a subject reports new signs or symptoms of lymphedema during follow-up, a clinic appointment for volumetric measurements and thorough evaluation will occur
40941910|NCT04623398|DRUG|Lithium Carbonate|The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials.
40941911|NCT04623398|DRUG|Placebo|Placebo
41283180|NCT01655511|DRUG|Tafamidis|TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.
41283181|NCT04055649|DRUG|Akt/ERK Inhibitor ONC201|Given orally (PO)
41283182|NCT04055649|DRUG|Paclitaxel|Given IV
41283183|NCT04055649|OTHER|Questionnaire Administration|Ancillary studies
41283184|NCT02129764|DRUG|Prednisone|
41283185|NCT02129764|DRUG|Allopurinol|
41283186|NCT00248677|BEHAVIORAL|Behavioral Family-Based Intervention|Behavioral family intervention
41283187|NCT00248677|BEHAVIORAL|Behavioral Parent-Based Intervention|Behavioral Parent-Only Intervention
41283188|NCT05394077|DIAGNOSTIC_TEST|Active Release Technique|Using Active Release Technique
41283189|NCT05394077|DIAGNOSTIC_TEST|Abdominal Drawing-Maneuver|Using Abdominal Drawing-Maneuver Technique
41283190|NCT02062086|DIETARY_SUPPLEMENT|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
41283191|NCT05178134|BIOLOGICAL|Etvax|"Preparation of complete Wet formulation. The vaccine supplied as a liquid, is mixed with the 150 ml of sodium bicarbonate buffer solution on the day of preparation for use on dosing day.~Just prior to administration 10 µg of dmLT is added by pipette (50 µl)."
41283192|NCT05178134|BIOLOGICAL|Etvax|Preparation of partially dry formulation. The partially dry formulation of vaccine is prepared by adding the effervescent powder containing the dmLT and LCTBA to 150 ml of water. After mixing, the content of the vaccine vial is added to the mixture and the vaccine is administered to the volunteer within 30 minutes after adding the buffer powder to the water.
41283193|NCT03359603|DEVICE|Electro-acupuncture|"Patients will be treated by use of 5 obligatory and 3 customized acupoints. Obligatory points (ST35, EX-LE5, LR8, GB33 and Ashi) will be used in all patients. Other 3 customized acupoints should be chosen by the physicians on the basis of traditional Chinese medicine diagnosis for acupuncture channels related to the individual pain area, with the intent of optimizing efficacy. ST34, ST36, ST32, ST40 and EX-LE2 will be used for pain at stomach meridian. GB31, GB36, GB34, GB39 and GB41 will be used for pain at gallbladder meridian. BL39, BL40, BL57 and BL60 will be used for pain at bladder meridian. LR7, SP9, SP10, KI10, SP4, SP6, LR3 and KI3 will be used for pain at three yin meridians of foot. Needles will be stimulated manually for 10 seconds to achieveDe Qi. Paired alligator clips will be attached transversely to the needle holders at LR8-GB33 and two other customized acupoints. Other needles will be manipulated for 10 seconds during the treatments."
41283194|NCT03977077|DRUG|Albumin binding taxol|125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
41283195|NCT04090723|BEHAVIORAL|CBI-CC with peer navigation|Computer delivered brief alcohol intervention enhanced with information of HIV infection, HIV risk, and comorbid mental health disorders
40941912|NCT02457585|DRUG|remicade (anti tumor necrosis factor inhibitor)|single arm:remicade treatment group
40941913|NCT06173141|OTHER|low- to moderate-continuous intensity cycling exercises:|"aerobic exercise during dialysis using Pedal machine at low- to moderate continuous intensity rating from 11 to 13 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
40941914|NCT06173141|OTHER|moderate- to high-interval intensity cycling exercises|"aerobic exercise during dialysis using Pedal machine at moderate-to-high interval intensity rating from 12 to 15 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
41283196|NCT03088150|PROCEDURE|Thermal ablation|Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).
41283197|NCT03088150|PROCEDURE|Surgical resection|In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
41283198|NCT00217438|DRUG|melphalan|Given IV
41283199|NCT00217438|DRUG|amifostine trihydrate|Given IV
41283200|NCT00217438|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
41283201|NCT00217438|GENETIC|fluorescence in situ hybridization|Correlative study
41283202|NCT00217438|PROCEDURE|bone marrow ablation with stem cell support|Undergo transplant
41283203|NCT04538950|DIAGNOSTIC_TEST|PET/CT|Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.
41283204|NCT04538950|DRUG|radioactive drug (tracer)|A radioactive drug (tracer) is used in the PET scan.
41451569|NCT03671954|BEHAVIORAL|Home Strengthening Exercises|The intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy, while the control group will receive standard physical therapy alone.
41451570|NCT03671954|OTHER|Standard Physical Therapy|Physician determined standard of care for individual TKA patients.
40941915|NCT06173141|OTHER|hemodialysis sessions only|hemodialysis sessions only
40941916|NCT00539669|DRUG|Docetaxel|
40941917|NCT02366858|PROCEDURE|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
40941918|NCT02366858|PROCEDURE|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
40941919|NCT05774275|DRUG|Pegylated Liposomal Doxorubicin|In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
40941920|NCT05774275|DRUG|Doxorubicin|75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
40941921|NCT05774275|DRUG|Anti-PD-1 monoclonal antibody|200 mg, d1, q3w
40941922|NCT05774275|RADIATION|Radiotherapy|BED=50-60Gy(α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
40941923|NCT01575886|OTHER|Teachable Moment Communication Process|The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
40941924|NCT05204732|OTHER|Intonation training|The participants will receive intonation training (1h/week) for four weeks, aiming for more gender congruent intonation patterns.
40941925|NCT05204732|OTHER|Sham therapy + intonation training|The participants will first receive four weeks of sham therapy (with no expected effect on speech), during which information on voice functioning, voice surgery, voice hygiene, and transgender health care will be provided. In addition, during sham therapy, active intervention will be given around nonverbal communication. After four weeks of sham therapy, for ethical reasons, subjects in this group will also receive four weeks of intonation training (aiming for more gender congruent intonation patterns).
40941926|NCT01887093|BEHAVIORAL|walking|Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
40941927|NCT04282512|OTHER|Sodium bicarbonate-rich mineral water|St-Yorre, a sodium bicarbonate-rich mineral water, is a commercial mineral water that contains 4368 mg/l sodium bicarbonate. The study intends to evaluate the effect on blood pressure of the sodium bicarbonate intake due to this mineral water consumption.
40941928|NCT05082831|BIOLOGICAL|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery. The primary purpose of the study is to compare the two groups: microfracture surgery + HST003 as compared to the microfracture surgery only group.
40941929|NCT04061382|PROCEDURE|Venepuncture|"One study visit will be conducted by research study staff and blood sampling will be carried out.~Up to three follow-up visits will be conducted for a percentage of participants, where additional blood samples will be collected. The blood sample will initially focus on looking at population immunity to diphtheria, group C invasive meningococcal disease and SARS-CoV-2."
40941930|NCT04061382|PROCEDURE|Oral fluid swab|Saliva sampling will be collected during the follow-up visits. This swab will be collected either by the participant or the participants parent/guardian on the day of the visit. The saliva sampling will primarily be analysed for SARS-CoV-2 antibodies.
40941931|NCT00169884|BEHAVIORAL|cognitive-behavioural therapy|
40941932|NCT04406610|BIOLOGICAL|GD2 CAR-T immunotherapy|Antigen-specific T cell therapy
40941933|NCT06387537|PROCEDURE|Conventional physical therapy|Patients in this group will recieve hot pack, ROM exercises, strengthening exercises and Kaltenborn mobilizations. A total of 12 sessions, 3 sessions per week for 4 consecutive weeks. Sets and repetitions will be increased progressively.
40941934|NCT06387537|PROCEDURE|Scapular mobilization.|Scapular Mobilizations: Glides- superior, inferior, distraction, upward and downward rotation (5 sets, 10 reps, 30 sec break in 1 session).Every session will be given for 30 minutes and a total of 12 sessions would be conducted over a period of 4 consecutive weeks.
40941935|NCT05032430|BEHAVIORAL|CCC|A mix of mindfulness-based stress reduction, mindful eating, and mindful parenting strategies.
40941936|NCT05032430|BEHAVIORAL|Enhanced Usual Care|Consists of strategies meant to enhance health and well-being (e.g., health education, strategies to get more physical activity) but does not include mindfulness as an active ingredient.
40941937|NCT00063323|DRUG|Bupropion|
40941938|NCT05605431|DIAGNOSTIC_TEST|Polysomnography|over nightSleep study
40941939|NCT03121001|DRUG|ATG|0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
41267154|NCT00215930|DRUG|Gemcitabine|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days."
41267155|NCT00215930|DRUG|Carboplatin|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days."
41267156|NCT02799862|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
41267157|NCT02799862|DRUG|Carboplatin|Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.
41283205|NCT03794986|BEHAVIORAL|Trauma-informed SGM affirmative care|"All SGM male survivors who meet inclusion criteria, including significant emotional distress, will complete pre-test measures and be randomized to 6-week Motivational Interviewing (MI) delivered by peers in online groups or 6-week MI with trauma-informed, SGM affirmative care delivered by peers in online groups.~Participants will complete pre-intervention (baseline), end of the 6-week intervention, 60- and 120-days follow-up assessments via an online survey platform, to determine if there was an increase in formal treatment engagement, and any significant changes in mental health symptomology (i.e., PTSD, depression, high-risk drinking, and illicit substance use)."
41283206|NCT03794986|BEHAVIORAL|Motivational Interviewing|"Major principles and tenets of Motivational Interviewing (MI) group include: Non-confrontational nature of group; environment is one of respect, safety, and encouragement of all group members; purpose is to learn about members' personal thoughts and choices and not to push an agenda"
41283207|NCT04590612|DRUG|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|25mg-100mg tablets to be taken orally three times a day on an empty stomach
41283208|NCT04590612|DRUG|Citalopram|20 mg tablet to be taken orally once and at the same time of the day, daily.
41283209|NCT06017323|DRUG|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15every 28 days (1 cycle)
41283210|NCT06017323|DRUG|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15every 28 days (1 cycle)
41283211|NCT06017323|DRUG|Proglumide Dose level 1|Daily dose of 1200 mg orally given as400 mg orally (PO), three times a day(TID) (dose level 1)
41283212|NCT06017323|DRUG|Proglumide Dose level 2|Daily dose of 1600 mg orally given as800 mg orally (PO) twice a day (BID)(dose level 2).
41283213|NCT00181298|DRUG|Memantine|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
41283214|NCT00181298|DRUG|Placebo|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
41451571|NCT03671954|OTHER|Preoperative Assessments|"Assessments will include:~* TUG (timed up and go test) \>12 sec indicates increased fall risk~* Tandem balance test \< 10 sec indicates increased fall risk~* Sit to Stand test (age based norms)~* Knee Range Of Motion (ROM)~* Quadriceps and hamstring strength (MMT or hand held dynamometer)~* Lower Extremity Functional Score (LEFS questionnaire)"
41451572|NCT01670890|DRUG|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
41451573|NCT01670890|DRUG|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
40941940|NCT03121001|DRUG|fludarabine|30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
41283215|NCT01233726|DIETARY_SUPPLEMENT|T-Diet plus Diabet IR|Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
41283216|NCT01233726|DIETARY_SUPPLEMENT|ISOSOURCE PROTEIN FIBRE|Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
41283217|NCT01233726|DIETARY_SUPPLEMENT|GLUCERNA SELECT|Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
41283218|NCT03466762|OTHER|Non applicable|Non applicable
41283219|NCT00870493|DRUG|Aliskiren|Aliskiren 300 mg daily oral
41283220|NCT00870493|DRUG|Placebo|starch tablet, 300 mg/day
41451574|NCT04800718|OTHER|Intervention Arm|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
40941941|NCT03121001|DRUG|cyclophosphamide|14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
41451575|NCT01216865|BIOLOGICAL|umbilical cord mesenchymal stem cells|5\*10/7 per ischemic limb
41451576|NCT01216865|DRUG|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
41451577|NCT01063244|DEVICE|foley balloon only|place foley balloon only in cervix
41451578|NCT01063244|DEVICE|foley balloon with weight attached|foley balloon with 1000cc IV bag attached
41451579|NCT02827682|DEVICE|Angel-6000D Multiparameter Anesthesia Monitor (IoC)|The Angel-6000D Multiparameter Anesthesia Monitor, Shenzhen Weihaokang Medical Technology Co., Ltd, Guangdong, China
40941942|NCT03121001|RADIATION|Total body irradiation|3 Gy on day -1
41283221|NCT03783910|DRUG|GRT9906|One prolonged-release tablet containing 40 mg of GRT9906
41283222|NCT03783910|DRUG|Placebo|Placebo matching GRT9906 tablets
41283223|NCT03868722|DRUG|Acalabrutinib|Acalabrutinib 100 mg BID from cycle 1 day 1 for 3 cycles of 28 days.
41283224|NCT03868722|DRUG|Venetoclax|Venetoclax, ramp up during the first five weeks starting cycle 1 day 1, 7 days treatment on each dose level (20-50-100-200-400 mg), thereafter 400 mg once daily for a total of 3 cycles of 28 days.
41283225|NCT06148610|DEVICE|NewSpringForMe digital solution|Follow-up of transplanted patients for hematological diseases using the NewSpringForMe device as support of quality of life
41283226|NCT06264453|DRUG|KH001|topical applications of KH001
41283227|NCT06264453|DRUG|Placebo|topical applications of Water for Injection
41283228|NCT05936086|DRUG|Cytoxan|Cytoxan 40mg/kg iv qd x 2days (day 1 and 2);
41283229|NCT05936086|DRUG|Etoposide|etoposide(VP16):150 mg/m2, twice a week, 1-2 weeks; 150mg/m2, once a week for the 3rd to 6th week.
41283230|NCT05936086|DRUG|Dexamethasone|Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.
41283231|NCT05936086|DRUG|Cyclosporine (CSA)|Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).
41283232|NCT01887834|DIETARY_SUPPLEMENT|Kyodophilus multi-strain probiotic capsules|
41283233|NCT01887834|DIETARY_SUPPLEMENT|Kyodophilus Matching Placebo Capsules|
41451580|NCT02827682|DEVICE|BIS VISTA Monitor (BIS)|BIS VISTA Monitor, Covidien, Changchun city shi jia trade co., Ltd, Changchun, China
41451581|NCT00834353|DRUG|ATT|
41451582|NCT01654419|DEVICE|Class II elastics and Sliding Jig|Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
41451583|NCT01654419|DEVICE|Class II elastic alone|Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
40941943|NCT03121001|PROCEDURE|Stem cell infusion|Stem cell product infused according to BMT unit policy on day 0.
40941944|NCT03121001|DRUG|Sirolimus|loading dose of 15 mg followed by 5 mg per day on day +5
40941945|NCT03121001|DRUG|mycophenolate mofetil|1 g every 8 h (until day 35) will be started on day 5
40941946|NCT06170203|OTHER|Personalised Follow-up Pathway|Discharge from routine oncology Follow-Up 2 years following radical treatment for a head and neck cancer
40941947|NCT03491306|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
40941948|NCT03491306|OTHER|Breflex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
40941949|NCT04461288|BEHAVIORAL|Social media-based education, counseling, and support|This six-month intervention is culturally-tailored to sexual and gender minority cigarette smokers. The intervention is group-based and includes daily posts and weekly live sessions during the initial three months. Posts and group sessions focus on tobacco use education, developing a quit plan, as well as managing stress, negative thinking, social support, exercise, as techniques to support cessation.
40941950|NCT04461288|OTHER|Nicotine replacement therapies (NRT)|"Participants will have access to up to six months of nicotine patch therapy. Participants will start on either 21, 14, or 7 mg patches based on manufacturers recommendations based on smoking behaviors.~In addition to nicotine patch, participants will have access to a choice of 2 mg. nicotine lozenges or nicotine gum as an adjunct to patch treatment. Participants will be encouraged to use up to 5 pieces daily to address situational urges and cravings for a cigarette."
41283234|NCT01158950|DRUG|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
41283235|NCT01158950|OTHER|Placebo|Placebo (200mg) administered at study visit
40941951|NCT04461288|OTHER|Gamification|Gaming elements designed to encourage participation in the program and behavior change.
40941952|NCT05547022|PROCEDURE|Endovascular revascularisation|Peripheral vascular angioplasty or stenting
40941953|NCT04169100|DRUG|Prednisone|We propose to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
41283236|NCT04494165|OTHER|massage with frankincense and myyrh essential oil|In addition to the standard physical therapy session, 30 patients in aromatherapy group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
40941954|NCT05887648|BEHAVIORAL|SinDance|"One face-to-face briefing session (20 min) will be offered to participants in the SinDance group as part of promoting physical activity and safe exercise for older adults.~Participants will be asked to engage in SinDance 3 times a week for 6 weeks. Each session will last for about 30-40 mins, including 5 mins warm up exercise before the game and 5 mins cool down exercise afterwards.~All the game play sessions will be conducted in LB centres. Each participant will play the game individually.~To play the game, participants will dance to the dance moves shown on the screen (on the external monitor or the projected screen) and as they get each move right, they will be awarded points. The more accurate their moves are, the more points they get in the game.~During the gameplay, the participants will be instructed to stop and rest if they are tired. A RN/RA will be on site to observe the safety of exergaming and to help resolve technical issues as they arise."
41283237|NCT04494165|OTHER|massage with carrier oil|In addition to the standard physical therapy session, 31 patients in placebo group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
41283238|NCT00986960|DRUG|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
41283239|NCT00986960|DRUG|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
40941955|NCT05805488|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
40941956|NCT05805488|DIETARY_SUPPLEMENT|TCI904 sachet|consume 1 sachet per day
40941957|NCT00005110|DRUG|Salmeterol|
40941958|NCT00005110|DRUG|Albuterol|
40941959|NCT01199107|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
40941960|NCT01199107|BEHAVIORAL|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
41283240|NCT05741021|DRUG|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
41283241|NCT05741021|DRUG|Pemetrexed|A chemotherapy medication used to treat a number of types of cancer.
40941961|NCT01199107|BEHAVIORAL|Wellness Intervention|30 minutes of wellness education prior to Prolonged Exposure
40941962|NCT03773380|COMBINATION_PRODUCT|Breathe Anew Survivorship Program|The feasibility will be tested of the Breathe Anew Survivorship Program
40941963|NCT05685654|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
40941964|NCT03031236|BEHAVIORAL|Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice|The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
40941965|NCT02666534|DRUG|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
40941966|NCT02666534|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
40941967|NCT02666534|DRUG|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
40941968|NCT02666534|DEVICE|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
40941969|NCT00504036|DEVICE|inflatable intra-gastric balloon|inflatable intra-gastric balloon
40941970|NCT03936322|DEVICE|Minimally invasive fetoscopic repair of MMC|Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.
40941971|NCT00121173|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|recombinant DNA vaccine
40941972|NCT06210581|OTHER|Supervised Exercise Program Group|The exercise programs will performed with the physiotherapist. The treatment programs of the patients will start with warm-up exercises and continue with aerobic exercises. Strengthening exercises will be performed in lying, sitting and standing positions. Body weight or free weight will be used for strengthening exercises. Balance exercises will be performed in sitting and standing positions and will be performed with or without support according to the patients conditions. The treatment sessions will be terminated by performing relaxation exercises combined with stretching and breathing exercises.
40941973|NCT06210581|OTHER|Internet Based Exercise Program Group|"Patients who are in the internet-based exercise program group will register cite ''https://www.telenororehab.com /'' which is web- based physiotherapy program for exercises. After the first evaluation patients will be given a username and password to log in to the system.~Before starting the exercise programs, the pages on how patients can log in to the system, how they can reach the physiotherapist through the system and how they can find individual exercise programs will be shown before the study. After logging in to their own pages, patients will be able to access video-based exercise programs that have been specially prepared for them. Patients in the Internet-based exercise program group will also be given the same exercise programs as the supervised exercise program group. The entry-exit times of patients to the system and the duration of maintaining exercise programs will be controlled from the administrator section on the system."
40941974|NCT00139061|DRUG|Torcetrapib/Atorvastatin|
40941975|NCT00139061|DRUG|Fenofibrate|
40941976|NCT00486174|DRUG|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
40941977|NCT04627337|DRUG|Saccharomyces Boulardii 250 MG|Probiotic yeast in capsules
40941978|NCT04627337|BEHAVIORAL|Dietary advice following a low fermentation diet|Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
40941979|NCT02484287|DEVICE|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
40941980|NCT02484287|DEVICE|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
40941981|NCT02484287|DEVICE|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
40941982|NCT05120609|DEVICE|Parkinson's Application|The application delivers at-home, tailored allied health exercises (physiotherapy, speech and language therapy, and occupational therapy) for the gait, speech, and manual dexterity symptoms associated with Parkinson's disease.
41283242|NCT05741021|DRUG|Carboplatin|A chemotherapy medication used to treat a number of types of cancer.
41283243|NCT05741021|DRUG|Paclitaxel|A chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).
41451584|NCT00218322|DRUG|Atomoxetine hydrochloride|Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
41451585|NCT00218322|DRUG|Placebo|Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
41451586|NCT02586350|DRUG|Anlotinib|
41451587|NCT02586350|DRUG|Placebo|Placebo p.o. qd
41451588|NCT03921762|PROCEDURE|Cataract surgery with Artis Active IOLs|Patients will be implanted with the Artis Active IOLs during cataract surgery
40941983|NCT05120609|DEVICE|Digital Placebo Application|The application is designed to provide a method of capturing outcome measures without providing access to the therapy exercises.
40941984|NCT06216834|OTHER|No intervention|No intervention
40941985|NCT00600444|PROCEDURE|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
40941986|NCT00600444|PROCEDURE|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
40941987|NCT04245462|OTHER|No intervention|Cross-sectional
40941988|NCT02973607|PROCEDURE|Nephrectomy|This is observational in design.
40941989|NCT01788176|DRUG|Zoledronic acid|One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
40941990|NCT01788176|DRUG|Placebo|one single intravenous infusion of 100ml of saline.
40941991|NCT00290212|DRUG|Natto capsules (food suppl.) cont. 360 microg. vit K2/day|
40941992|NCT00290212|DRUG|Placebo capsules|
40941993|NCT02315573|PROCEDURE|Wrist block anesthesia|The carpal tunnel release surgery will be performed under wrist block anesthesia. Group 1 will have the wrist block performed with Lidocaine and epinephrine, while Group 2 with Bupivacaine and epinephrine.
41451589|NCT03921762|PROCEDURE|Cataract surgery with AT Lara IOLs|Patients will be implanted with the AT Lara IOLs during cataract surgery
41451590|NCT02438735|PROCEDURE|laparoscopic endometrioma excision|
40941994|NCT03557554|OTHER|Massage|A 20 minute massage protocol will be administered in a chair by a licensed massage therapist no more than 24 hours prior to each paclitaxel infusion.
40941995|NCT04426708|DRUG|HMS5552|single dose of HMS5552 25mg
40941996|NCT03896867|DEVICE|Anapod™ Humi-Therm Heated Humidification System Breathing Circuit|"For the Anapod™ group, the BairHugger™ blanket will be connected, but the unit will not be turned on. The Anapod™ will be used with a starting circuit temperature set at the standard 45°C (note, this is temperature at the unit - NOT the temperature of the gas reaching the trachea). In the event that the patient's rectal temperature falls below 35.6C, the BairHugger™ warming system will be activated (Hypothermic Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the Anapod system will be turned off - and the BairHugger turned on with the warming unit set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
40941997|NCT03896867|DEVICE|Bair Hugger™ Warming Blanket|"For the BairHugger™ group, the blanket will be used with a starting temperature set at HIGH. The BairHugger™ unit will be attached to the warming unit and started as soon as possible. In the event that the patient's rectal temperature falls below 35.6C, the Anapod™ warming system will be activated (Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the BairHugger™ warming unit will be set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
40941998|NCT05994560|OTHER|With temporary occlusion|at the time of surgery the randomization table was consulted and if it was in the occlusion arm was performed
41451591|NCT02438735|OTHER|Conservative follow up|
41451592|NCT03517319|DRUG|Normal Saline 0.9% 1.2 ml|
41451593|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U|
40941999|NCT05389046|DRUG|Escitalopram|Escitalopram
40942000|NCT05389046|DRUG|Escitalopram+Aripiprazole|Escitalopram+Aripiprazole
40942001|NCT05389046|DRUG|Escitalopram+omega-3 PUFAs|Escitalopram+omega-3 PUFAs
41132134|NCT04881305|DIAGNOSTIC_TEST|questionnaires and neuropsychological assessment|Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
41132135|NCT00240175|OTHER|No Intervention|No Intervention
41132136|NCT01981603|OTHER|navigator|
41132137|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
41132138|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
41451594|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U|
40942002|NCT05389046|DRUG|Escitalopram+Aripiprazole+omega-3 PUFAs|Escitalopram+Aripiprazole+omega-3 PUFAs
40942003|NCT02570841|DRUG|Topical High dose Capsaicin|Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
40942004|NCT02570841|DRUG|Topical Placebo|Placebo exposure within an area of 3x3 cm for 60 minutes
40942005|NCT04824365|DRUG|Sodium Pyruvate|Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
40942006|NCT04824365|OTHER|Saline|Subjects will use a saline nasal spray 3x daily for 14 days.
40942007|NCT04864847|DIAGNOSTIC_TEST|RENISCHEM L-FABP POC Test|Point-of-care test cassette with quantitative reader used for the measurement of L-type fatty acid binding protein (L-FABP) in human urine specimens.
40942008|NCT00232167|DRUG|Indiplon|
40942009|NCT00232167|DRUG|Sertraline|
40942010|NCT03718871|BEHAVIORAL|HIV testing at traditional healer practices|HIV 1/2 antigen-antibody POC test (Oraquick©) will be administered to those participants who agree to test. Pre-test counseling will be performed before results are delivered. Clients with positive tests will be provided with detailed contact information for the MUST ISS clinic, and given specific instructions to present to the clinic as soon as possible for confirmatory testing and linkage to care.
40942011|NCT03182803|BIOLOGICAL|CTLA-4/PD-1 antibodies expressing mesoCAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing mesothelin-targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
40942012|NCT04966052|OTHER|No intervention|No intervention
40942013|NCT03961373|PROCEDURE|Gastrectomy with D2 lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.
40942014|NCT03961373|PROCEDURE|Gastrectomy with D2plus lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
40942015|NCT02968511|BIOLOGICAL|fecal microbiota transplant|Fecal microbiota transplant for the treatment of severe, complicated C. difficile infection
40942016|NCT00603785|DRUG|Placebo|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive placebo treatment for 6 months.
40942017|NCT00603785|DRUG|Xolair|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive Xolair treatment for 6 months.
40942018|NCT01546012|DEVICE|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
40942019|NCT01546012|DEVICE|HYLO-COMOD®|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
40942020|NCT05266534|DRUG|Terlipressin|the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
40942021|NCT05266534|DRUG|Carbetocin|the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
40942022|NCT05266534|DRUG|Saline|the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
40942023|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 6 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 8 stimuli (the Fully Learned stimuli). Each of the 8 Fully Learned stimuli will be produced 60 times over the 6 training sessions.
40942024|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 1 training session|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During the training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 60 times.
40942025|NCT05437159|BEHAVIORAL|Learning of novel multisyllabic nonwords|Each trial of the training sessions (total of 6 training sessions over 2 days) will follow a simple reaction time protocol in which a nonword stimulus formed by 2 or 3 syllables that are legal in American English is presented auditorily to the participant, who then produces the stimulus as quickly and accurately as possible. During training, each participant will repeatedly produce 6 nonwords, with each nonword produced a total of 60 times over the 6 training sessions.
40942026|NCT05437159|DEVICE|Anodal tDCS|Continuous anodal tDCS is delivered to a speech processing area of the brain during a 19-minute speech training session. The tDCS stimulation will ramp up to its maximum value (2 milliamperes) in the minute prior to the training session and maintained at that level throughout the session.
40942027|NCT05437159|DEVICE|Sham tDCS|Sham tDCS stimulation is delivered to a speech processing area of the brain during a 19-minute speech training session. During the minute prior to training onset, the tDCS stimulator is ramped up to 2 milliamperes and then back down to 0.
40942028|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 8 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 120 times over the 8 training sessions.
40942029|NCT02025062|OTHER|CGA and geriatric follow-up|The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
40942030|NCT04684290|PROCEDURE|Alcohol Septal Ablation|Participants will be treated with alcohol septal ablation.
40942031|NCT04684290|PROCEDURE|Surgical Septal Myectomy|Participants will be treated with surgical septal myectomy.
40942032|NCT01369615|DRUG|Oxycodone hydrochloride controlled-release tablets|Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
41132139|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
41451595|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U|
41451596|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U|
41451597|NCT00606658|PROCEDURE|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
41451598|NCT01412827|RADIATION|1/2 dose of 99mTc OR 201Tl tracers|"Rest: Imaging will occur 30 to 60 minutes after injection of tracer.~Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer."
41451599|NCT04425941|OTHER|artificial intelligence diagnosis|artificial intelligence prediction of colorectal polyp histology
41451600|NCT01916915|DRUG|Tramadol infusion via wound catheter|
41283244|NCT05596825|DEVICE|Mandibular Advancement Device|"To analyze the phenotypic characteristics of different subgroups of patients with obstructive sleep apnea syndrome who respond better (complete responders) or worse (partial responders or non-responders) to treatment with mandibular advancement devices.~Responders will be defined as a post-treatment AHI of less than 10/h and at least a 50 percent reduction in their AHI. Partial responders will be defined as a post-treatment AHI greater than 10/hour but at least a 50 percent reduction in AHI, and non-responders as less than a 50 percent reduction compared to baseline."
41283245|NCT00001081|DRUG|Nitazoxanide|
41451601|NCT01916915|DRUG|Levobupivacaine|
41283246|NCT02612714|DRUG|Rosuvastatin|All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
41451602|NCT06628271|DIAGNOSTIC_TEST|Guidelines|Participant with typical spells will be investigated according to our guidelines. These include that participants with heredity for or signs and symptoms of cardiac disease will be subjected to an ECG and participants with two or more spells should be subjected to blood tests for anemia and iron deficiency
41451603|NCT00531180|PROCEDURE|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
40942033|NCT00372203|PROCEDURE|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
41451604|NCT00531180|PROCEDURE|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
41451605|NCT02224144|DRUG|Vitamin D3|Vitamin D3 1000 IU per day for 12 months
41451606|NCT02224144|DRUG|Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
41451607|NCT02224144|DRUG|Placebo|Placebo (sugar pill) 1 pill per day for 12 months
40942034|NCT01847001|DRUG|Propranolol|Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.
40942035|NCT01847001|OTHER|DOT imaging|(Non-experimental) During the baseline visit, you will undergo DOT evaluation of your tumor for determination of blood, fat, and water content in the affected and unaffected breast. DOT readings will be obtained at 4 additional time points: after paclitaxel week #3, before AC week #1, before AC week #3, and prior to surgery.
41132140|NCT04243200|OTHER|Hypos can strike twice|"The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover."
41283247|NCT05951582|OTHER|Plyometric Exercises|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics were performed.~1. Horizontal jumps over hurdle.~2. Standing long jump~3. Front cone hops~4. Forward-backward run~5. Double leg horizontal jump~6. Lateral jump over hurdle~7. Side to side sprint~8. Jumps over low hurdles~9. Split squat jump~10. Cone hops with change of sprint direction~11. Lateral jump over hurdle~12. Side to side slide and hops.~13. Lateral and horizontal jump~14. Cone hops with 180o turn~15. Vertical, Lateral, and horizontal jump~16. Lateral cone jump~17. Single leg lateral jump~18. Diagonal Jumps.~19. Standing long jump with diagonal sprint.~20. Single leg vertical jump~21. Cone hop with 1800 turn~22. Skipping over cone"
41283248|NCT05951582|OTHER|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises were performed.~1. Single Leg Squat/ Lunges~2. Modified Box Step Ups~3. Press Ups~4. Box Jumps~5. Shoulder Press~6. Standing Band Row~7. Band Butterfly Pills"
41283249|NCT04457921|OTHER|deep tissue massage|DTM was applied to participants in the experimental group twice (at the 10th and 22nd h) after cesarean
41283250|NCT02571413|OTHER|score before teaching|score the check-point of correct INCS usage before teaching
41283251|NCT02571413|OTHER|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
41283252|NCT02571413|OTHER|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
41283253|NCT02626338|DRUG|Crenolanib|
41283254|NCT02626338|DRUG|Mitoxantrone|
41451608|NCT00120783|DRUG|Indinavir|
41451609|NCT00120783|DRUG|Lamivudine|
41451610|NCT00120783|DRUG|Ritonavir|
41451611|NCT02521103|DEVICE|Triathlon Tritanium Cone Augments|The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
41283255|NCT02626338|DRUG|Cytarabine|
41283256|NCT02626338|DRUG|Etoposide|
41451612|NCT01905605|DRUG|phosphatidylcholine supplementation|phosphatidylcholine concentrate 700 mg twice per day
41451613|NCT01905605|DRUG|placebo|placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
41451614|NCT01261663|OTHER|oral nutritional energy and protein enriched supplement (NOS)|
41283257|NCT02626338|DRUG|Fludarabine|
41283258|NCT02626338|DRUG|G-CSF|
41451615|NCT06048848|PROCEDURE|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
41451616|NCT06048848|DRUG|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
41283259|NCT02626338|DRUG|Idarubicin|
41283260|NCT01906840|DRUG|Turmeric|
41283261|NCT01906840|DRUG|placebo|
41283262|NCT03551509|BIOLOGICAL|ArthroFLEX ECM scaffold graft|In patients receiving a graft, thru mini open technique the lateral portal incision will be extended vertically approximately 5-6 cm. A standard, deltoid-splitting, mini-open approach will then be performed, leaving the deltoid attachment to the acromion intact. For arthroscopic technique same method of fixation will be used below. The dermis graft will be sized and cut so as to cover the entire repair site in both medial-lateral and anterior-posterior dimensions.
41451617|NCT06048848|DRUG|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
41451618|NCT04728750|PROCEDURE|Enucleation of a tumor of the pancreas|Enucleation of a tumor in the pancreas is feasible and safe, as it offers a minimally invasive approach, and morbidities are fewer than open or conventional approach
41451619|NCT06476015|OTHER|Therapeutic exercise|Duration: 30 minutes. Frequency: Once a week. Type of excercise: Cardiovascular, strengthening and balance. Supervised by a health professional.
41451620|NCT06627556|DRUG|H021|H021 oral tablet.
41451621|NCT06627556|DRUG|H021 Placebo|H021 placebo oral tablet.
41451622|NCT02754076|DRUG|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
41451623|NCT01667822|BEHAVIORAL|Continued self help CBT|After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.
41451624|NCT01667822|BEHAVIORAL|Individual CBT|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
41451625|NCT02722798|DRUG|KRN23|Doses may be titrated to achieve the target peak serum phosphorus range
41451626|NCT01167439|PROCEDURE|Upper esophageal sphincter myotomy|Upper esophageal sphincter release operation to allow better swallowing. The intervention is done under GA and by extra-mucosal approach.
41451627|NCT04948619|BIOLOGICAL|Vaccine|Patients will have lab evaluations for immune function at baseline, 3, 6, 12, and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.
41132141|NCT04236700|OTHER|Oral clinical exam|Detailed anamnesis, with information regarding the time of sun exposure, protection measures, medical history and application of questionnaires will be carried out. Dental dental and tissue examination should be performed
41132142|NCT03705663|BEHAVIORAL|PrEP initiation|Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
41132143|NCT03183349|PROCEDURE|deprotienized bovine bone (tutogen)|
41132144|NCT03183349|PROCEDURE|platelet rich fibrin|
41132145|NCT05018156|BEHAVIORAL|Default Genetics Referral Process|Patients and their oncology providers will be notified of their eligibility for a cancer genetics referral, with an option to opt out if they are not interested in proceeding. Everyone else will be automatically referred to their local hospital's cancer genetics program for contact and scheduling. Standard genetic counseling, testing, and results disclosure will take place, including usual methods of payment and insurance coverage for testing.
41132146|NCT03398668|DEVICE|Relievion device- Treatment stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
41132147|NCT03398668|DEVICE|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
41132148|NCT02509715|PROCEDURE|Intraoperative nerve monitoring|Intraoperative nerve monitoring during thyroid surgery
41132149|NCT02251301|DIETARY_SUPPLEMENT|Skim Milk|250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
41132150|NCT02251301|BEHAVIORAL|High intensity interval training|All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
41132151|NCT02251301|OTHER|Placebo|250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
41132152|NCT02251301|DIETARY_SUPPLEMENT|Macronutrient isoenergetic control|250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
41132153|NCT06487286|OTHER|observational study|observational study
41132154|NCT00224432|DRUG|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
41132155|NCT06033352|DEVICE|KTP laser|Treatment with KTP 532 nm laser. Laser fluence depends on erythema intensity and ranges from 7.0 J/cm2 to 11 J/cm2 with a 4-11 mm spot size and 8-12 ms pulse duration.
41132156|NCT06033352|DRUG|Ivermectin 1% cream|Application of ivermectin 1% cream 1x/day. Interruption for 4 days in case of irritation/redness.
41132157|NCT02732990|BEHAVIORAL|Exercise training|All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)
41132158|NCT03831698|DRUG|Omega-3 fatty acid ethyl esters (2 gram)|Omega-3 fatty acid ethyl esters (2 gram)
41283263|NCT03551509|PROCEDURE|Control|This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.
41283264|NCT03551509|BIOLOGICAL|Crossover|Patients randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
41451628|NCT04863144|OTHER|Blood samples|Plasma concentrations of paclitaxel and its metabolites will be obtained during the first treatment cycle. The samples for paclitaxel analysis will be collected in ethylenediamine tetraacetic acid tubes at 7-time points: just before infusion, in the middle of the infusion, at the end of infusion, at 1, 2, 4 and 6 hours post-infusion.
41451629|NCT00935805|DRUG|Metformin|850 mg TID
41451630|NCT00935805|DRUG|Glybenclamide|10 mg BID
41451631|NCT00935805|DRUG|NPH insulin|Variable SC dose
40942036|NCT01847001|DRUG|Paclitaxel|(Non-experimental) given as a one-hour intravenous infusion (IV) every week for a total of 12 weeks; the first dose of paclitaxel may be given over 90 minutes, per the discretion of your treating doctor. The dose will be given in 80 mg/m2 based on individual body surface area (BSA). This drug is given through a vein in the arm or a catheter (eg. Infusaport, Portacath).
40942037|NCT01847001|DRUG|Nab-paclitaxel|(Non-experimental) In the event paclitaxel is not available due to manufacturing and supply shortages, nab-paclitaxel will be substituted for paclitaxel. The dose is 100 mg/m2 IV infusion over 30 minutes weekly (or institutional standard). No premedications are given with nab-paclitaxel.
40942038|NCT01847001|DRUG|Trastuzumab|(Non-experimental) (only if HER2-positive): Trastuzumab is given as an IV infusion initially over 90 minutes for the first dose, then 30-60 minutes every 3 weeks in subsequent doses if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
40942039|NCT01847001|DRUG|Pertuzumab|(Non-experimental) (only if HER2-positive): Pertuzumab is given as an IV infusion over 60 minutes on the first dose, then 30-60 minutes every 3 weeks if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
40942040|NCT01847001|DRUG|Doxorubicin|(Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.
40942041|NCT01847001|DRUG|Cyclophosphamide|(Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
40942042|NCT01847001|PROCEDURE|Surgery|After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor if your doctor feels that it is medically appropriate (if you have had a good response to the treatment) - lumpectomy/mastectomy.
40942043|NCT01847001|DRUG|Premedication|As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
40942044|NCT01847001|DRUG|Anti-nausea therapy|In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
41283265|NCT01274897|BIOLOGICAL|Novartis MenACWY-CRM|All subjects had blood drawn at Day 1 and Day 29.
41283266|NCT01274897|BIOLOGICAL|Saline Placebo|All subjects had blood drawn at Day 1 and Day 29.
41283267|NCT04307966|BEHAVIORAL|The CIrCLE of Life Initiative|HIV and obesity prevention programme delivered directly to Grade 6 preadolescents and indirectly to their parents.
41283268|NCT01524289|DRUG|Anacetrapib|One oral tablet, orally once daily for 52 weeks
40942045|NCT01847001|DRUG|Pegfilgrastim|When you receive the AC chemotherapy, you will also receive treatment with a drug called pegfilgrastim (Neulasta). Neulasta is a commercially available drug. It stimulates the production of white blood cells and reduces the likelihood of developing a low white blood cell count and fever after chemotherapy. It will be given as an injection under the skin on the day after each chemotherapy treatment (day 2).
41283269|NCT01524289|DRUG|Placebo|One oral tablet once daily for 52 weeks
41283270|NCT02047552|DRUG|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
41283271|NCT02047552|DRUG|Oxandrolone|10 mg PO Q12 hours for seven days
41283272|NCT02047552|DRUG|IV iron placebo|100 mL normal saline
41283273|NCT02047552|DRUG|Oxandrolone placebo|similar color and size sugar pill
41283274|NCT02981472|DRUG|Apixaban|Specified dose on specified days
41283275|NCT02981472|DRUG|Vitamin K Antagonist (VKA)|Specified dose on specified days
41283276|NCT02981472|DRUG|Low Molecular Weight Heparin (LMWH)|Specified dose on specified days
41283277|NCT03797287|DEVICE|Tensor Tunnler|Create the bone tunnels during the arthroscopic rotator cuff repair procedure
41283278|NCT03797287|PROCEDURE|Anchor Rotator Cuff Repair|The suture anchors (Smith and Nephew PEEK Helicoil Anchor) are inserted in bone and the sutures are then used to sew the tendons to bone arthroscopically.
41283279|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
41283280|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
41283281|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
41283282|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
41283283|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
41451632|NCT00935805|DRUG|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
41283284|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
41451633|NCT00935805|DRUG|Propranolol|40 mg BID
41451634|NCT00935805|DRUG|Captopril|50 mg TID
41451635|NCT00935805|DRUG|Amlodipine|10 mg QD
41451636|NCT05570955|BEHAVIORAL|Text reminder|weekly text to remind use of drug
41451637|NCT06082505|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include 1 hour breast and cervical cancer prevention education session delivered with support of electronic presentations. For phone education, trained project staff or Community Health Workers (CHWs) will deliver telephone-based education as an alternative to group education session for women who missed scheduled session twice (education materials would be printed and mailed).
41451638|NCT06082505|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
41283285|NCT03086850|BEHAVIORAL|Promotion of daily physical activity with a pedometer|"Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:~* \<6000 steps/day: increase by 3000 steps/day~* 6000 - 10000 steps/day: reach 10000 steps/day~* \> 10000 steps/day: maintain or increase steps"
41283286|NCT03086850|OTHER|Conventional treatment|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
41283287|NCT04992026|PROCEDURE|robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection|Robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection will be performed.
41283288|NCT04992026|DRUG|1.Abiraterone Acetate Tablets|1000mg(4 tablets, 250mg per tablet) daily for 6 cycles
41283289|NCT04992026|DRUG|Prednisone Acetate Tablets|5 mg oral low dose prednisone taken along with Abiraterone Acetate Tablets
41283290|NCT04992026|DRUG|Luteinizing Hormone-Releasing Hormone Analog|Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.
41283291|NCT03069638|DRUG|Dexmedetomidine|Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
41283292|NCT03069638|DRUG|Sedatives/Hypnotics,Other|Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
41283293|NCT03540095|DRUG|Erector Spinae Plane Block|See arm description
41283294|NCT03540095|DRUG|Paravertebral Nerve Block|See arm description
41283295|NCT00853905|DRUG|Triesence|At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound.
41451639|NCT03825562|BEHAVIORAL|acceptance and commitment therapy, ACT|
41451640|NCT03155893|DRUG|ODV Placebo (Matching 25 mg ODV)|Participants will receive ODV placebo (matching 25 \[mg\] ODV \[1\*25 mg tablet\]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.
41283296|NCT00853905|DRUG|balanced salt solution BSS|At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
41283297|NCT02517879|OTHER|Community point distribution|Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
41283298|NCT02517879|OTHER|Community health worker hang-up visit|CHWs visited households to take stock of how many ITNs that were distributed during the distribution were hung and to hang any unhung ITNs.
41283299|NCT04615871|DRUG|semaglutide|semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
41283300|NCT02455115|OTHER|Alternating mean arterial pressure|In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.
41283301|NCT02455115|DRUG|Norepinephrine|Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
41283302|NCT02455115|DRUG|Chromium ethylenediaminetetraacetic acid|Extraction of 51Cr-EDTA measured for FF and GFR
41283303|NCT05084547|OTHER|No intervention|No intervention
41283304|NCT02997124|PROCEDURE|local infiltration and TAP block|Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done
41283305|NCT02997124|PROCEDURE|local infiltration only|Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
41283306|NCT01282814|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
41283307|NCT01282814|DRUG|Effexor® XR|150 mg Extended-Release Capsule
41283308|NCT00117078|DRUG|Aranesp®|
41283309|NCT01845025|DRUG|Formoterol 12 mcg|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
41283310|NCT01845025|DRUG|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
41283311|NCT01845025|DRUG|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
41283312|NCT01845025|DRUG|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
41451641|NCT03155893|DRUG|ODV Placebo (Matching 200 mg ODV)|Participants will receive ODV placebo (matching 200 mg ODV \[4\*50 mg tablets\]) on Days 1 and 2 in Treatment E.
41451642|NCT03155893|DRUG|ODV Placebo (Matching 125 mg ODV)|Participants will receive ODV placebo (matching 125 mg ODV \[2\*50 mg tablets + 1\*25 mg tablets\]) orally once daily on Days 3 to 7 in Treatment E.
40942046|NCT06421207|DEVICE|ellacor® Micro-Coring procedure|ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
41283313|NCT01845025|DRUG|Placebo|Placebo to match formoterol one inhalation twice daily via dry powder inhaler
41283314|NCT05057988|BEHAVIORAL|Empowered Relief class|The participants will attend the Empowered Relief class online via Zoom. The class includes pain neuroscience education, as well as cognition, emotion, and physiologic self-regulation for people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
41283315|NCT00946270|DRUG|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
41283316|NCT00946270|DRUG|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
41283317|NCT00946270|DRUG|CC-4047|3.0 mg capsules daily by mouth day 1 through 21.
41283318|NCT02372162|OTHER|Image Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
41283319|NCT02372162|OTHER|Molecular Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
41283320|NCT05485103|DRUG|Polyethylene Glycols|Take asol as total enteral nutrition, and take polyethylene glycols and glycerin enema as bowel preparations
41283321|NCT04054713|DIAGNOSTIC_TEST|Acetic acid chromoendoscopy|Acetic acid is prepared at a concentration of 2.5% in a 20ml syringe, it will be applied with a 7 french spray catheter compatible with a working channel 2.8mm onwards, starting the proximal application When distally performing a uniform application on the area of intestinal metaplasia and the timed time for mucous visualization in search of areas of loss of acetowhitening begins, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal or abnormal, once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
41283322|NCT04054713|DIAGNOSTIC_TEST|Seattle protocol|Take random biopsies by quadrants every 2 centimeters. Biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction will be initiated, taking tissue every 2cm from the four quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
41283323|NCT06193148|DRUG|Jaktinib|Participants will receive Jaktinib orally for single dose
41283324|NCT06193148|DRUG|Placebo|Participants will receive Placebo orally for single dose
41283325|NCT03877406|DRUG|Empagliflozin 10 MG|addition of empagliflozin 10 MG
41283326|NCT03877406|DRUG|Hypoglycemics Oral|dose escalation of hypoglycemics oral
41283327|NCT00203567|DRUG|carbamazepine ER|Active study drug, no comparator
41283328|NCT00991900|DEVICE|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
41283329|NCT06365359|OTHER|Blood sample for analysis of plasma of organochlorine pesticides concentration|A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the analysis of chlordecone and the following organochlorine compounds: p,p'-DDE, βHCH, γHCH, PCB 153. This analysis will be carried out at the Institut Pasteur of Guadeloupe (IPG).
41283330|NCT06365359|OTHER|Blood sample for cell collection|"A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the cell collection which will be kept at the CeRBiM.~This collection will be used for subsequent studies on the immunotoxicity of chlordecone, by studying the cytokine, apoptotic and autoreactive functions of PBMC (Peripheral Blood Mononuclear Cells)."
41283331|NCT00233779|DEVICE|SIROLIMUS-ELUTING, HEPARIN-COATED CoCr BALLOON-EXPANDABLE STENT|
41283332|NCT01450540|DEVICE|REMstar Auto A-Flex|Standard CPAP
41283333|NCT01450540|DEVICE|modified REMstar Auto A-Flex with AGPAP|Modified device -Software upgrade to GP 12
41283334|NCT03247400|DRUG|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb
41283335|NCT03247400|DRUG|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb
41283336|NCT03038724|DIAGNOSTIC_TEST|Rapid HIV test|
41283337|NCT00440401|DRUG|fibrinogen (human) + thrombin (human)|
41283338|NCT00440401|DRUG|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
41283339|NCT00546351|DRUG|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
41283340|NCT00104507|DRUG|APD356|
41283341|NCT04015557|DRUG|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
41283342|NCT04015557|DRUG|N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
40942047|NCT06354257|DRUG|EE/LNG|One dose of EE and LNG is administered on Day 1 of treatment period 1 and one dose of EE/LNG co-administered with GSK3036656 DL 2 is given on Day 15 of treatment period 3.
40942048|NCT06354257|DRUG|GSK3036656 Dose Level 1|A loading dose of GSK3036656 with DL 1 is administered on Day 4 of treatment period 2.
41283343|NCT04024696|DRUG|Abexinostat|Abexinostat Tosylate Tablets
41451643|NCT03155893|DRUG|ODV Placebo (Matching 100 mg ODV)|Participants will receive ODV placebo (matching 100 mg ODV \[2\*50 mg tablets\] orally once daily on Days 8 to 14 in Treatment E.
41283344|NCT05962307|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
41283345|NCT01593748|DRUG|Gemcitabine and Pazopanib|Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
41283346|NCT01593748|DRUG|Gemcitabine and Docetaxel|Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
41283347|NCT02514057|OTHER|Questionnaire|Form filling only
41451644|NCT03155893|DRUG|SMV Placebo (Matching 150 mg SMV)|Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
41451645|NCT03155893|DRUG|AL-335 Placebo (matching 1200 mg AL-335)|Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 \[3\*400 mg tablets\]) administered orally on Day 15 in Treatment A and B.
41451646|NCT03155893|DRUG|Moxifloxacin Placebo (matching 400 mg moxifloxacin)|Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.
41283348|NCT04074993|DRUG|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
41283349|NCT03984526|DRUG|normal saline|intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
41283350|NCT03984526|DRUG|atropine 0.5mg|intravenous atropine 0.5mg pretreatment at the onset of dexmedetomidine infusion
41283351|NCT03984526|DRUG|ephedrine 8mg|intravenous ephedrine 8mg pretreatment at the onset of dexmedetomidine infusion
41283352|NCT02364817|BEHAVIORAL|cognitive and psychiatric assessment|"Administered at baseline:~* Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)~* hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)~* psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)~* cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)~* impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)~* alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.~* administered at week 12: ASRS"
41283353|NCT01690962|OTHER|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
41283354|NCT01690962|DIETARY_SUPPLEMENT|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
41283355|NCT02818634|PROCEDURE|Harvesting rib cartilage|
41283356|NCT00242879|DRUG|Physician determined comparator PI + ritonavir|
41283357|NCT00242879|DRUG|GW640385 + ritonavir|
41283358|NCT03603132|DRUG|Hetrombopag Olamine|7.5mg in each cycle
41451647|NCT03155893|DRUG|ODV 25 mg|Participants will receive ODV 25 mg orally once daily administered on Days 2 to 16 in Treatment C.
41451648|NCT03155893|DRUG|ODV 200 mg|Participants will receive ODV 200 mg (4\*50 mg tablets) orally once daily will be administered on Days 1 and 2 in Treatment F.
41451649|NCT03155893|DRUG|ODV 125 mg|Participants will receive ODV 125 mg (2\*50 mg tablets + 1\*25 mg tablets) once daily administered on Days 3 to 7 in Treatment F.
41451650|NCT03155893|DRUG|ODV 100 mg|Participants will receive ODV 100 mg (2\*50 mg tablets) orally once daily administered on Days 8 to 14 in Treatment F.
41451651|NCT03155893|DRUG|SMV 150 mg|Participants will receive SMV 150 mg (2\*75 mg capsules) orally once daily administered on Days 2 to 16 in Treatment C.
41451652|NCT03155893|DRUG|AL-335 1200 mg|Participants will receive a single oral dose of AL-335 1200 mg (3\*400 mg tablets) administered on Day 15 in Treatment C.
41451653|NCT05572996|DRUG|Inhaled Treprostinil|
40756767|NCT04674319|BEHAVIORAL|external cues and cogntive movement strategies|"external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing).~In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task.~During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section."
40756768|NCT02822690|OTHER|Hospice care at UMCG|introduction of hospice care facilities on the wards at the UMCG
41283359|NCT00989703|DRUG|placebo|oral solution, daily for 14 days
41283360|NCT00989703|DRUG|GLPG0259|oral solution
41283361|NCT00989703|DRUG|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
41283362|NCT03170284|DRUG|Bevacizumab|Bevacizumab is prescribed by physicians as per SPC.
41283363|NCT03205787|DIETARY_SUPPLEMENT|Trifolium pratense|Red Clover extract standardized to isoflavone content.
41283364|NCT06221644|DIAGNOSTIC_TEST|[18F]SynVesT-1 PET/CT|60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent \[18F\]SynVesT-1 PET/CT for synaptic density assessment
40942049|NCT06354257|DRUG|GSK3036656 Dose Level 2|One dose of GSK3036656 DL 2 is administered once a day from Day 5 to Day 14 of treatment period 2. In treatment period 3 a single dose of GSK3036656 DL 2 co-administered with EE/LNG is given on Day 15, then GSK3036656 DL 2 once a day from Day 16 to Day 17.
40942050|NCT00295971|BIOLOGICAL|anti-thymocyte globulin|
40942051|NCT00295971|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40942052|NCT00295971|DRUG|fludarabine phosphate|
40942053|NCT00295971|DRUG|thiotepa|
40942054|NCT00295971|PROCEDURE|allogeneic bone marrow transplantation|
40942055|NCT00295971|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40942056|NCT00295971|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
40942057|NCT00295971|RADIATION|total-body irradiation|
40942058|NCT04559919|OTHER|Seizure status|We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.
41283365|NCT00336362|DRUG|Hydroxyurea|"Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis."
40756769|NCT04439357|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
40942059|NCT04559919|DIAGNOSTIC_TEST|Tests|We will collect results from imaging, electroencephalogram, and laboratory tests.
40942060|NCT04559919|OTHER|Epilepsy|We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.
40942061|NCT04559919|OTHER|Demographics and psychosocial|We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.
40942062|NCT04559919|OTHER|Health care|We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs
40942063|NCT02834377|OTHER|Treatment algorithm targeting individual cardiac output|
40942064|NCT03278782|BIOLOGICAL|Pembrolizumab|Given IV
40942065|NCT03278782|DRUG|Romidepsin|Given IV
40942066|NCT06550271|DRUG|Rapamycin|Rapamycin in 2 different dosage forms (compounded and generic)
40942067|NCT05272449|DEVICE|Sleep apnea diagnosis|Split-night
41283366|NCT05749588|DRUG|A1: SHR-A1811|A1: an anti-HER2 antibody-drug conjugate (ADC)
40942068|NCT00315354|OTHER|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
40942069|NCT00315354|OTHER|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
40942070|NCT00315354|OTHER|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
40942071|NCT02712255|BEHAVIORAL|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
40942072|NCT02712255|BEHAVIORAL|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad: the patient."
40942073|NCT02712255|BEHAVIORAL|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (the patient and the partner) and include some plans for joint physical activity."
40942074|NCT02712255|BEHAVIORAL|Education|CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
40942075|NCT03799211|BEHAVIORAL|Motivational Interviewing|Phone call using motivational interviewing technique
40942076|NCT03799211|BEHAVIORAL|Treatment as Usual|will receive a regular study phone call after three months
40756770|NCT00504556|DRUG|Edoxaban (DU-176b)|30mg tablet once daily
40756771|NCT00504556|DRUG|Edoxaban (DU-176b)|60mg tablet once daily
41283367|NCT05749588|DRUG|A2: SHR-A1811 with Camrelizumab|"A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
40942077|NCT05237271|OTHER|Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)|Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.
40942078|NCT05237271|OTHER|Educational Materials on the CVD-T2D and Bundled Metabolic Panel|Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.
40942079|NCT04595344|OTHER|Listening to Pure Binaural Beats|"The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves."
40942080|NCT04595344|OTHER|Listening to classical music|The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.
40942081|NCT04595344|OTHER|No audio only headphone|The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing
40942082|NCT04924205|DEVICE|FM2 Knee Brace|Participants in this group will use the FM2 Knee Brace for their post-TKA physical therapy.
40942083|NCT03511118|DRUG|Tranexamic acid (TXA)|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942084|NCT03511118|DRUG|labetalol|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942085|NCT03511118|DRUG|metformin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942086|NCT03511118|DRUG|nifedipine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942087|NCT03511118|DRUG|clindamycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942088|NCT03511118|DRUG|oxycodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942089|NCT03511118|DRUG|azithromycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
41283368|NCT05749588|DRUG|B1: TROP2 ADC|B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
40756772|NCT00504556|DRUG|Edoxaban (DU-176b)|30mg tablet two times a day
40942090|NCT03511118|DRUG|escitalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942091|NCT03511118|DRUG|sertraline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942092|NCT03511118|DRUG|ondansetron|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942093|NCT03511118|DRUG|Ciprofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942094|NCT03511118|DRUG|Doxycycline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942095|NCT03511118|DRUG|Levofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942096|NCT03511118|DRUG|Methylphenidate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
41283369|NCT05749588|DRUG|B2: TROP2 ADC with Camrelizumab|"B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
40942097|NCT03511118|DRUG|Sumatriptan|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942098|NCT03511118|DRUG|Citalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942099|NCT03511118|DRUG|Cyclobenzaprine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
41283370|NCT05749588|DRUG|C1: SHR-A1811|C1: an anti-HER2 antibody-drug conjugate (ADC)
41283371|NCT05749588|DRUG|C2: SHR-A1811 with BP102|"C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
41283372|NCT05749588|DRUG|D1: TROP2 ADC|D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
40942100|NCT03511118|DRUG|Furosemide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942101|NCT03511118|DRUG|Gabapentin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942102|NCT03511118|DRUG|Hydrochlorothiazide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942103|NCT03511118|DRUG|Hydroxyurea|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942104|NCT03511118|DRUG|Rosuvastatin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942105|NCT03511118|DRUG|Topiramate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40756773|NCT00504556|DRUG|Edoxaban (DU-176b)|60mg tablet two times a day
40756774|NCT00504556|DRUG|warfarin|warfarin tablets
41283373|NCT05749588|DRUG|D2: TROP2 ADC with BP102|"D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
41283374|NCT05749588|DRUG|E1: SHR-A1811|E1: an anti-HER2 antibody-drug conjugate (ADC)
40756775|NCT05240924|BEHAVIORAL|Exposure and Response Prevention|ERP is a specialized cognitive behavioral intervention conducted over the course of 8-16 therapy sessions. ERP is based upon exposure principles and the idea that people can habituate to the distress caused by OCD triggers and learn to cope with anxiety about feared consequences without engaging in compulsive behaviors to 'neutralize' the obsession. ERP begins with psychoeducation about OCD and exposure, followed by construction of a hierarchy, or list, of situations that are feared, avoided, or trigger OCD rituals such as washing or checking. Then, the therapist and client begin in-session exposures to hierarchy items utilizing response or ritual prevention techniques to avoid reinforcing the ritual. Exposures can be in vivo, such as touching a contaminated item, or imaginal, such as visualizing a feared consequence happening.
41283375|NCT05749588|DRUG|F1: TROP2 ADC|F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
41283376|NCT05749588|DRUG|G1: SHR-A1811|G1: an anti-HER2 antibody-drug conjugate (ADC)
41283377|NCT05749588|DRUG|H1: TROP2 ADC|H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
41283378|NCT02916446|BIOLOGICAL|Viaskin Peanut 250 mcg|
41283379|NCT02916446|BIOLOGICAL|Placebo|
41283380|NCT01293669|DRUG|TC-6987|TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
41283381|NCT01293669|DRUG|Placebo|Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
41283382|NCT04732377|PROCEDURE|erector spinae block with bupivacaine|"Group (A) (control group):~Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5."
41283383|NCT04732377|PROCEDURE|erector spinae block with bupivacaine and dexmedetomidine|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
41283384|NCT02449564|DRUG|sirolimus|sirolimus 1mg daily
41283385|NCT04031014|DEVICE|BTL EMSELLA Active treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 100% for active treatment
41283386|NCT04031014|DEVICE|BTL EMSELLA Sham Treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 5% for sham treatment
41283387|NCT00705900|DRUG|LCD|2 applications / day for 12 weeks
41283388|NCT00705900|DRUG|calcipotriol|2 applications / day for 12 weeks
41283389|NCT01258439|DRUG|raltegravir plus truvada|raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
41283390|NCT01258439|DRUG|Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)|Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
41283391|NCT03413644|DIAGNOSTIC_TEST|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer
41283392|NCT05282212|DIAGNOSTIC_TEST|Ultrasound Scan|Within 90 days before the revision surgery, a calibrated examiner will ultrasonically scan the implants. The ultrasound device has been validated for its usability and design on human subjects in our recent clinical study (the University of Michigan Institutional Review Board under the number HUM00139630 and was registered with the National Institutes of Health U.S. National Library of Medicine database for clinical trials (clinicaltrials.gov) under the following identifier: NCT03558282) Coupling will be achieved with commercially available sterilized US gel (Sterile Aquasonic, Fairfield, NJ). The US probe will be mounted on an adjustable arm attached to a fixed stand. The probe is navigated by a calibrated examiner at the implant of interest and then will execute a total ±5 mm linear mesio-distal and coronal-apical translations to create 3D cross-sectional and transverse volumes, respectively and stored as an imageframe series, i.e., a DICOM format cineloop.
40942106|NCT03511118|DRUG|Trazodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
41283393|NCT04957355|DEVICE|Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)|"Stance and Walk-Perturbation Training Protocol ActiveStep and Surefooted Protocol: Perturbation training protocol with and without FES Participants will be asked to perform a postural disturbance protocol in the stance position and walk in the form of 7 slips and 7 trips with two retention trials after the training using the ActiveStep treadmill system while fitted in a safety harness. All perturbations will be delivered at each participant's comfortable walking speed. Similar slip and trip training in walking will be conducted on the surefooted platform with and without FES.~Gait Training Protocol and Surefooted protocol Participants will be asked to perform a 10m walking test (walking for a distance of 45 feet) in a laboratory environment six times (three times with and without FES) and in an outdoor environment located in the parking lot of the Applied Health Science building (1919 W. Taylor St., Chicago, IL)"
41283394|NCT04220892|DRUG|Pembrolizumab|200 mg intravenous (IV) every 3 weeks
41283395|NCT04220892|DRUG|Pemetrexed|900 mg/m\^2 IV every 3 weeks. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
41283396|NCT04220892|DRUG|Abemaciclib|150 mg twice a day, by mouth.
41283397|NCT00025649|BIOLOGICAL|filgrastim|
41283398|NCT00025649|DRUG|busulfan|
41283399|NCT00025649|DRUG|carboplatin|
41283400|NCT00025649|DRUG|cyclophosphamide|
41283401|NCT00025649|DRUG|doxorubicin hydrochloride|
41283402|NCT00025649|DRUG|etoposide|
40942107|NCT03511118|DRUG|Valganciclovir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
41283403|NCT00025649|DRUG|melphalan|
41283404|NCT00025649|DRUG|vincristine sulfate|
41283405|NCT00025649|PROCEDURE|autologous bone marrow transplantation|
41283406|NCT00025649|PROCEDURE|conventional surgery|
41283407|NCT00025649|PROCEDURE|peripheral blood stem cell transplantation|
41283408|NCT05006053|OTHER|Interviews/Focus groups|Qualitative study (no intervention delivered)
41283409|NCT00471380|DRUG|travoprost 0.004% and brinzolamide 1%|Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
41283410|NCT00471380|DRUG|fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle|group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
41283411|NCT05431608|BIOLOGICAL|MCARH125|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
41283412|NCT05431608|BIOLOGICAL|MCARH109|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
41283413|NCT00515125|BEHAVIORAL|Dietary Advice|Dietary Advice sheet
41283414|NCT00515125|DIETARY_SUPPLEMENT|Oral Nutritional Supplements (Fortisip)|"These products are classified as non-medicinal, borderline substances, foods for special medical purposes.~A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period."
41451654|NCT05397977|DEVICE|mechanical traction group|"In the mechanical traction group, 26 people with cervicogenic headache will be traction with the Chattanooga Tru Trac traction device, 6 days a week for 2 weeks.~Persons to be mechanically traction will be placed on their backs on the treatment bed with their necks on the neck collar of the device. After the patients are fixed to the head, the pulling force of the device will start with 10% of the patient's body weight, the device will be set as 60 seconds of pulling force and 20 seconds of relaxation. In subsequent sessions, the pulling force will be gradually adjusted based on the patient's previous traction therapy, tolerance, and symptom response. Each session will take 15 minutes.~Participants will be given 20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound, and the exercise will be given as a home program."
41283415|NCT02987673|PROCEDURE|MGB/OAGB|
41283416|NCT02987673|PROCEDURE|LSG|
41283417|NCT03877744|BEHAVIORAL|interactive virtual presence|parents will install car seat through remote guidance via interactive virtual presence
41283418|NCT03877744|BEHAVIORAL|live technician|parents will install car seat through guidance from a live certified technician who is present
41283419|NCT04237883|BEHAVIORAL|Standard communication email|This is the base communication that all physicians will receive.
41283420|NCT04237883|BEHAVIORAL|Social comparison Intervention|The social comparison is added onto the standard communication email to provide some peer comparison between the physicians.
41283421|NCT04237883|BEHAVIORAL|Leadership Training|Clinic and Physician leads will be provided with a clinic leadership training seminars in leadership, quality improvement, and support from the Quality Improvement team at UCLA Health.
41132159|NCT04613713|OTHER|Somatocognitive physiotherapy|"The main intervention areas include:~1. education about the PVD, healthy vulvo-vaginal and sexual behaviors, nature of chronic pain and factors influencing pain intensity~2. bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension and respiration pattern in different situations~3. techniques to cope with emotions and thoughts related to bodily experiences and to PVD~4. structured homework assignments promoting application of the learned techniques in daily situations and gradual exposure of the patient to activities associated with pain.~Participants will be offered maximally 15 treatment sessions. No minimal number of sessions is set. Treatment will be conducted by female physiotherapists experienced in treating long-standing pain conditions."
41283422|NCT06176703|DEVICE|mobile application|using mobile application along with standard treatment of diabetes mellitus
41283423|NCT05953064|OTHER|DHA-NAT|Endogenous metabolite of omega-3 fatty acid docosahexaenoic acid
41283424|NCT05953064|OTHER|Placebo|Vehicle control (H2O) for the intervention used in the experimental arm (DHA-NAT).
41283425|NCT01211691|DRUG|KB004, Monoclonal Antibody|
40942108|NCT03511118|DRUG|Venlafaxine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
41283426|NCT04906005|DRUG|gadopiclenol|administration by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a saline flush of at least 5 mL at the same rate to ensure complete injection of the contrast agent.The gadopiclenol administration is performed by power injecto
41283427|NCT04906005|DRUG|Placebo|intravenous (IV) bolus injection at 2 mL/s, followed by a saline flush of at least 5 mL to be in the same conditions as for gadopiclenol administration.The gadopiclenol administration is performed by power injector
41283428|NCT02287246|DRUG|Extended-Release liposomal bupivacaine (Exparel)|20mL
41283429|NCT02287246|DRUG|Normal saline|20mL
41283430|NCT06261528|DEVICE|Light therapy|Light therapy aimed at alleviating fatigue through circadian rhythm synchronization
41283431|NCT05511922|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
41283432|NCT04471220|DEVICE|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
41283433|NCT05139524|OTHER|Evidence of past or recent RVF exposure|Detection of RVF exposure.
41283434|NCT00458471|DEVICE|Insertion of a urinary catheter coated with benign E. coli|
41283435|NCT01910506|DRUG|RDEA3170 10 mg|
40942109|NCT03511118|DRUG|Verapamil|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942110|NCT03511118|DRUG|Remdesivir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942111|NCT03511118|DRUG|Anakinra|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942112|NCT03511118|DRUG|Tocilizumab|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942113|NCT03511118|DRUG|Fluvoxamine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942114|NCT03511118|DRUG|Amoxicillin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942115|NCT03511118|DRUG|Bupropion|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942116|NCT03511118|DRUG|Duloxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942117|NCT03511118|DRUG|Hydrocodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942118|NCT03511118|DRUG|Levetiracetam|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942119|NCT03511118|DRUG|Paroxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942120|NCT03511118|DRUG|Buprenorphine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
40942121|NCT06239636|BIOLOGICAL|UP421|Intramuscular transplantation with the ATMP UP421 composed of genetically modified human pancreatic islet cells
40942122|NCT02672280|DEVICE|Medical Collagen Membrane with MSC|
40942123|NCT02672280|DEVICE|Medical Collagen Membrane|
40942124|NCT00089284|DRUG|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
40942125|NCT00089284|DRUG|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
40942126|NCT00089284|DRUG|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
40942127|NCT01497327|DRUG|PSI-352938|PSI-352938 300mg once daily (QD) for seven days
40942128|NCT01497327|DRUG|PSI-7977|PSI-7977 400mg QD for seven days
40942129|NCT06350773|DRUG|tadalafil 20 mg then 40 mg if tolerated|Patients will receive tadalafil for 12 week follow up period, in addition to the conventional anti failure therapy.
40942130|NCT03398161|OTHER|Quality-of-Life Assessment|Ancillary studies
40942131|NCT03398161|OTHER|Questionnaire Administration|Ancillary studies
40942132|NCT03398161|RADIATION|Radiation Therapy|Undergo ultra low dose radiation therapy
41132160|NCT04613713|OTHER|Treatment as usual|The participants will follow the current treatment advice as recommended by the Vulva Clinic at OUH, a tertiary health care center specialized in treatment of vulvar disorders. Advice include guidance about the management of PVD as a condition, use of medication, physiotherapy, sexologist and psychological counseling, usage of internet resources (vulva.no) and others. Participants will be free to pursue treatment options of their choice. The type of treatment, number of treatments and medication usage will be monitored by bi-weekly electronic forms during the whole study period.
41132161|NCT02940249|DIETARY_SUPPLEMENT|Apple polyphenols|Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
41132162|NCT02940249|DIETARY_SUPPLEMENT|Placebo|
41283436|NCT00227461|DRUG|Wait first, then levetiracetam|Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
40942133|NCT00003307|DRUG|amifostine trihydrate|
40942134|NCT00003307|RADIATION|radiation therapy|
40942135|NCT04598464|OTHER|Home based exercise|The home-based training program included posture and stretching exercises, strengthening exercises, balance training, and a walking regimen 3 days per week for 3 months.
41283437|NCT00227461|DRUG|Levetiracetam first, then wait|subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
40942136|NCT02405754|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
41283438|NCT03448835|DRUG|Atezolizumab|atezolizumab 1200 mg 5 cycles
41283439|NCT03448835|DRUG|Capecitabine|capecitabine 850 mg /m2 4 cycles
41283440|NCT03448835|DRUG|Oxaliplatin|oxaliplatin 100 mg/m2 4 cycles
41283441|NCT03448835|DRUG|Docetaxel|docetaxel 50 mg/m2 4 cycles
41283442|NCT00562419|DRUG|CT-322|IV solution, weekly
41283443|NCT00562419|DRUG|irinotecan hydrochloride|IV solution, biweekly
41283444|NCT01101074|OTHER|This is non-intervention observational study|This is non-intervention observational study
41283445|NCT00101088|DRUG|imatinib mesylate|Given orally
41283446|NCT00101088|DRUG|temsirolimus|Given IV
41283447|NCT00101088|OTHER|laboratory biomarker analysis|Correlative studies
41283448|NCT01962662|OTHER|EMG biofeedback training|EMG biofeedback assisted tibialis anterial force level control
41283449|NCT01962662|OTHER|U/E exercise|strengthening and stretching
41283450|NCT00602628|OTHER|questionnaire administration|
41283451|NCT00602628|PROCEDURE|adjuvant therapy|
41283452|NCT00602628|PROCEDURE|biopsy|
41283453|NCT00602628|PROCEDURE|computed tomography|
41283454|NCT00602628|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
41283455|NCT00602628|PROCEDURE|magnetic resonance imaging|
41283456|NCT00602628|PROCEDURE|therapeutic conventional surgery|
41283457|NCT00602628|PROCEDURE|ultrasound imaging|
41283458|NCT00602628|RADIATION|radiation therapy|
40942137|NCT04741698|DRUG|Propranolol|Propranolol 2mg IV
40942138|NCT03512990|PROCEDURE|Bupivacaine - Superior Trunk Block|It will be performed the superior trunk approach with local anesthestic in patients and methylene blue in cadavers.
40942139|NCT04408131|BIOLOGICAL|Blood sample|virological test
40942140|NCT04408131|BIOLOGICAL|Blood sample|serological test
40942141|NCT00957112|PROCEDURE|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
40942142|NCT00957112|PROCEDURE|standard follow-up care|Patients receive standard care
40942143|NCT06252298|BIOLOGICAL|SCTC21C|SCTC21C is injected to the participants subcutaneously and is tentatively scheduled to be administered weekly for the first two cycles, once every 2weeks for cycle3-6, and once every 4 weeks thereafter until the occurrence of progressive disease
40942144|NCT05591846|BEHAVIORAL|Face-to-face training|Face-to-face training
40942145|NCT05591846|BEHAVIORAL|web-based training|web-based training
40942146|NCT00837928|DRUG|bendamustine|40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
41283459|NCT05720312|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Patterned pulsed magnetic stimulation delivered using an electromagnet. We will use a MagVenture rTMS device and a Cool-B65 coil.
41283460|NCT02924792|DEVICE|Reinfusion - Sternal IO needle|
41283461|NCT02924792|DEVICE|Reinfusion - Intravenous needle|
41283462|NCT05041764|OTHER|NO INTERVENTION|No INTERVENTION
41283463|NCT03636815|OTHER|physical therapy|Cardiopulmonary rehabilitation for patients who receive left ventricle assist device
41283464|NCT01318616|OTHER|Strength training of the hip adductors|Adductor strength training
41283465|NCT00960557|DRUG|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
41283466|NCT05667519|PROCEDURE|Additional guidance of lead implantation by transesophageal echocardiography|Transesophageal echocardiography guidance of lead implantation targeting a stable lead position in a tricuspid valve commissure (preferentially postero-septal) and an apical ventricular lead position
41283467|NCT02406664|PROCEDURE|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
41283468|NCT00755001|DEVICE|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
41283469|NCT00755001|DEVICE|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
41283470|NCT04348721|OTHER|online survey|"An online survey including 8 case-vignettes was sent to international liver transplant surgeons who had published on liver transplantation. The first part is related to surgeon's own experience. In the second part, the surgeons were asked to rate the difficulty of various situations in liver transplantation on a scale of 1 to 10 (level 1 was labeled as easier, and level 10 was labeled as difficult). In the third part, 8 case-vignettes corresponding to 8 clinical real-life situations are submitted to experts"
41283471|NCT02012816|OTHER|Peer-referral incentive program to increase VMMC uptake|The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
41283472|NCT03232112|DRUG|Exenatide 2 MG Injection|Subcutaneous injection once-weekly
41283473|NCT03232112|DRUG|BD PosiFlush (saline)|Subcutaneous injection once-weekly
41283474|NCT01975025|PROCEDURE|Short daily dialysis for 2 weeks|
41283475|NCT05574543|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
41283476|NCT05574543|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
41283477|NCT06180577|DEVICE|Nerivio|Nerivio is a prescribed Remote Electrical Neuromodulation (REN) device for treatment of migraine
41283478|NCT05751408|PROCEDURE|gait analysis using 3D (Vicon) and IMU (Movella)|Subjects are measured using Vicon 3D analysis, combined with IMU-sensors
41283479|NCT04631718|RADIATION|Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)|"MRI-based QSM methods estimate the susceptibility of tissues based on measuring the magnetic field distortion produced by the tissues themselves.~Upon successful validation, MRI-based abdominal QSM will provide accurate, repeatable, and reproducible quantification of Liver iron concentration (LIC) that is independent of the distribution of iron and does not require calibration."
41283480|NCT02801357|DRUG|lofexidine administration in subjects seeking buprenorphine dose reduction|
41283481|NCT02257606|OTHER|I-TRAVLE training|
41283482|NCT03398772|BEHAVIORAL|Comprehensive Health Coaching Program|Comprehensive Health Coaching Program: included physical activity and motivational interviewing techniques, participants were encouraged to set goals with decision-making, self-management and self-monitor their progress, and received support from researcher.
41283483|NCT01609283|BIOLOGICAL|autologous mesenchymal stem cells|"There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~* Group 1: single intrathecal dose of 1 x 107 cells~* Group 2: single intrathecal dose of 5 x 107 cells~* Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~* Group 4: single intrathecal dose of 1 x 108 cells~* Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells"
41283484|NCT00775567|DIETARY_SUPPLEMENT|Fructose powder|30g in 250ml water twice a day
41283485|NCT04121910|DRUG|Savolitinib|On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast
41283486|NCT04121910|DRUG|Itraconazole|Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
40942147|NCT00837928|OTHER|laboratory biomarker analysis|samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
40942148|NCT00837928|PROCEDURE|Surgical Resection of Brain Metastases|Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
41283487|NCT03032744|OTHER|Asthma Assessment & Management|Asthma Assessment \& Management based on NAEPP-EPR3 guidelines
41283488|NCT03032744|OTHER|Asthma Education|Asthma education on medications
41283489|NCT03032744|OTHER|Controller medication at school|Students will receive the morning dose of their daily preventive asthma medication at school on school days.
41283490|NCT03400293|OTHER|Functional Assessment of HIV Infection|Functional Assessment of HIV Infection will be used to assess HRQoL of subjects. This will include 47 items.
41283491|NCT03400293|OTHER|Patient Satisfaction Questionnaire|Patient Satisfaction Questionnaire will be used to assess burden and HRQoL in subjects. This will include 18 items.
41283492|NCT03400293|OTHER|Symptom Distress Module|Symptom Distress Module will be used to assess burden and HRQoL in subjects. This will include 20 items.
41283493|NCT03400293|OTHER|Patient Health Questionnaire|Patient Health Questionnaire will be used to assess burden and HRQoL in subjects. This will include 2 items.
41283494|NCT03400293|OTHER|Internalized Stigma of AIDS Tool|Internalized Stigma of AIDS Tool will be used to assess burden and HRQoL in subjects. This will include 10 items.
41283495|NCT03400293|OTHER|Medication adherence visual analogue scale|Medication adherence visual analogue scale will be used to assess burden and HRQoL in subjects. This will include 1 item.
41283496|NCT04446585|DEVICE|Automated External Defibrillator (AED)|Deployment of AEDs
41283497|NCT04446585|OTHER|Training in cardiopulmonary resuscitation and AED use|Residents will undergo 30-minute courses at study start and if needed during the trial period. During the course they will also be recruited as citizen responders
41283498|NCT04446585|OTHER|Activation of citizen responders|Citizen responders will be activated in case of suspected cardiac arrest through the heart runner app.
41283499|NCT01513915|OTHER|Group cognitive behavioral intervention|A Group cognitive behavioral intervention _based on parent training component of FRIENDS program_ was performed.The program protocol was translated to Persian, using the back translation method.The intervention was delivered in 6 two-hour weekly sessions. Two intervention groups ran, each group included 10 parents.The therapy was provided by an attending board certified child and adolescent psychiatrist and co lead by a fellow of child and adolescent psychiatry who distributed psychometric procedures and completed treatment adherence ratings.
41283500|NCT05444244|OTHER|Relational Research Recruitment and Engagement Intervention|"* Specified recruiter/point of contact~* Flexibility in study time, place, method of recruitment (preferred participant email, phone), and follow-up (in registry, if participant calls back at all restart 3 failed phone contacts)~* Resource matching (financial, transportation constraints)"
41283501|NCT02849769|DEVICE|Implant of an MR-conditional Tachy device system|
40942149|NCT00837928|RADIATION|Stereotactic body radiation therapy|Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
41132163|NCT02850939|BEHAVIORAL|Mobile phone app + patient navigation|The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
41132164|NCT05240300|BIOLOGICAL|BX005-A|phage gel
41132165|NCT05240300|OTHER|Placebo|vehicle gel
41132166|NCT03622710|OTHER|Rehabilitation therapy|Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.
41132167|NCT00933270|DEVICE|SUPERA® Nitinol Stent System|Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
40942150|NCT03860142|BEHAVIORAL|Archet scale|Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale
40942151|NCT00003173|BIOLOGICAL|filgrastim|
40942152|NCT00003173|DRUG|thiotepa|
40942153|NCT00003173|PROCEDURE|autologous bone marrow transplantation|
41283502|NCT00388739|DRUG|Intervention: Budesonide|Patients 1-5 years of age who are randomly assigned to the treatment arm will be given a one month supply as well as a prescription (for a 6 month supply) for Pulmicort respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
40942154|NCT00003173|PROCEDURE|peripheral blood stem cell transplantation|
40942155|NCT03657862|DEVICE|application of 38% silver diamine fluoride solution|SDF solution was painted onto the surface of the carious lesion of the tooth
40942156|NCT03657862|OTHER|application of a placebo (tonic water)|tonic water was painted onto the surface of the carious lesion of the tooth
40942157|NCT05080660|DRUG|LY3526318|Administered orally.
40942158|NCT05080660|DRUG|Placebo|Administered orally.
40942159|NCT05213000|BEHAVIORAL|Exercise|90 minute exercise session
40942160|NCT01222858|BEHAVIORAL|Diet and Activity Education|Education about behavioral modification of eating and activity habits for weight loss.
40942161|NCT01222858|BEHAVIORAL|Self-monitoring with Feedback|Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
40942162|NCT00397410|DEVICE|Hip protectors|
40942163|NCT01716325|OTHER|Self-management weight loss plan endorsement.|Self-management weight loss plan endorsement.
40942164|NCT01716325|OTHER|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
41132168|NCT03871439|DRUG|PF-05221304 Formulation A|50mg
41283503|NCT00388739|DRUG|Usual care: albuterol + systemic steroids|All children (control and treatment arm) will be given a burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day) at discharge from the ED. All children 1-5 years of age will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor.
41283504|NCT05321953|OTHER|Standard Physical Therapy Care|Standard physical therapy care. Six to eight, one hour sessions over the course of 4-6 weeks. For individuals with chronic constipation that includes biofeedback therapy, breathing techniques on the toilet, manual therapy to the abdominal wall, and education on toileting posture and favorable lifestyle habits for gut health.
41283505|NCT05321953|OTHER|Aerobic and Inspiratory Muscle Training|The exercise-based 3 times per week for 8 weeks intervention will consist of aerobic interval training and inspiratory muscle training (IMT) for a total duration of 30 minutes. Aerobic-based intervals will be performed at a moderate intensity. Aerobic modes of exercise will include upper extremity ergometer, treadmill, bike, or elliptical.
41283506|NCT06102161|PROCEDURE|Wedge resection|Wedge resection is a surgical procedure that is done to remove a wedge-shaped section of lung tissue, usually for treating lung cancer. A wedge resection is less invasive than some of the other surgical options used to remove lung cancer.
41451655|NCT05397977|OTHER|manuel traction group|"Manual traction, one of Cyriax's neck mobilization techniques, will be applied to the MTG. Vertebrobasilar artery test will be applied to the patients before starting the treatment, and manual traction will be applied to the patients in case the vertebrobasilar artery test is negative. Manual traction technique will be applied to the cervical region for 15 minutes. While applying manual traction, the patient will be placed on his back with his head hanging off the bed. Grasp the occiput with one hand and under the chin with the other. Manual traction will be applied by keeping the neck neutral and the occiput slightly extended. After applying traction for a few seconds, it will be slowly released and returned to the starting position, and the application will be made for 15 minutes.~20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound will be applied to the participants, and the exercise will be given as a home program."
40942165|NCT05718999|DIAGNOSTIC_TEST|Not intervention|Not having intervention is an observational study
40942166|NCT04576624|BEHAVIORAL|Lifestyle Intervention|A combined approach of a lifestyle structuring intervention to improve the general health and quality of life of persons with cognitive impairments. The investigators propose to combine a multi-modal cognitive intervention and lifestyle redesign approach to improve the cognitive health of older persons with cognitive impairments.
40942167|NCT04576624|BEHAVIORAL|social activity|24 social gathering events
40942168|NCT03364790|PROCEDURE|PLIF|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
40942169|NCT03364790|PROCEDURE|TKA|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
40942170|NCT02682407|BIOLOGICAL|OMS721 (narsoplimab)|Biological: OMS721 (narsoplimab)
40942171|NCT01437878|DRUG|Iloprost|5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks
40942172|NCT01437878|DRUG|Placebo|matching placebo
40942173|NCT04351997|PROCEDURE|Cord clamping|Umbilical cord clamping after delivery.
40942174|NCT04179851|DIAGNOSTIC_TEST|Thermal imaging of neck veins|Thermal imaging of neck veins
40942175|NCT01131767|DRUG|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
40942176|NCT05260970|PROCEDURE|Rectus muscle reapproximation at cesarean section|Rectus muscle reapproximation: Continuous Suturing of rectus muscles with 2.0 Vicryl (Ethicon) at Cesarean section.
40942177|NCT04769856|OTHER|State-Trait Anxiety Inventory (STAI) scale|State-Trait Anxiety Inventory (STAI) scale
40942178|NCT04769856|OTHER|Satisfaction scale|Satisfaction scale
40942179|NCT04416308|DIAGNOSTIC_TEST|NG test|rapid diagnosis Covid 19
40942180|NCT04416308|DIAGNOSTIC_TEST|Blood test|sample
40942181|NCT04416308|BEHAVIORAL|Self-questionnary|behavioral survey
40942182|NCT05324618|DRUG|Tacrolimus|0.03% topical tacrolimus ointment applied on the affected areas twice daily for 4 months.
41451656|NCT01080820|DRUG|CMX157|One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
41451657|NCT01080820|DRUG|Placebo|One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
41451658|NCT01080820|DRUG|Viread|One single oral dose of 300mg Viread.
40942183|NCT05324618|DRUG|Hydrocortisone|1% hydrocortisone cream applied on the affected areas twice daily for 4 months.
40942184|NCT01462227|DRUG|Naltrexone High Dose|Naltrexone 100mg for two administrations.
40942185|NCT01462227|DRUG|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
41132169|NCT03871439|DRUG|PF-05221304 Formulation B|50mg
41132170|NCT02803749|DRUG|Buspirone|
41132171|NCT02803749|DRUG|Placebo|
41283507|NCT05568745|DEVICE|Balloon for cervical ripening (Teleflex French Dufour catheter CH20 reference 174000)|Balloon catheter is inserted by a resident or a physician under visual control. The expected volume injected in the balloon probe is 60 mL. No traction is performed on the catheter. The catheter is left in place for a maximum of 12 hours.
41283508|NCT05568745|DRUG|Oxytocin|Intravenous oxytocin addition (preceded or followed by epidural analgesia on patient's request) will be performed 6 hours after insertion of balloon catheter. Oxytocin is administered as an intravenous infusion (5 IU of oxytocin in 49 mL of 5% glucose\*) at the lowest possible dose with the aim of achieving a maximum of three to four contractions per ten minutes. After appropriate uterine activity has been achieved, the rate of the oxytocin infusion is decreased or stopped.
41283509|NCT05568745|DRUG|Misoprostol Oral Tablet|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
41283510|NCT04411238|OTHER|interview|interview
41451659|NCT01198938|OTHER|Melatonin|Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
41132172|NCT03522259|DRUG|Rivaroxaban 10 MG Oral Tablet [Xarelto]|Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
41132173|NCT00002801|DRUG|leucovorin calcium|
41132174|NCT00002801|DRUG|tegafur-uracil|
41132175|NCT00002801|RADIATION|radiation therapy|
41283511|NCT03034941|DRUG|Metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks
40942186|NCT06199050|OTHER|Questionnaire: SPIRIT|"T0: Before the first intake at Maastro, the Trialpoli (TP) contacts a patient via phone to inform whether or not he is interested in participating in this study. If the patient shows interest in participating in the study, he will be invited for a consultation with the Trialpoli. This consultation takes place on the day of intake at Maastro. After consent, the patient is randomized to fill out T0 before or after the intake.~T1: After filling out T0, the patient receives the ENGAGE information card with the url en QR code to the VR-movie. After watching the VR movie and before start RT the patient is asked to fill in T1. This questionnaire is distributed with instructions by the TP.~T2: Between the 5th and the 15th radiation treatment, patients will be asked to fill in the questionnaires for the third and last time. The Patient Information Form (PIF) and Informed Consent (IC) are added in a separate document."
41283512|NCT03034941|DRUG|Liraglutide + metformin|In the COMBI group the initial dose of metformin was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg twice per day. Liraglutide 1.2 mg once per day s.c. was added after first two weeks of monotherapy with metformin.
41283513|NCT06123416|BEHAVIORAL|Expressive Writing|Caregivers complete three 20-min writing sessions in which they write about an assigned topic - emotional or non-emotional.
41283514|NCT05308147|DIETARY_SUPPLEMENT|First Reference product|Dextrose (containing 25 grams of carbohydrates)
40942187|NCT06199050|OTHER|Questionnaire: HADS|Hospital Anxiety and Depression Scale, 14 questions likert scale
40942188|NCT06199050|OTHER|Questionnaire: QSC-R23|Dutch version of the Questionnaire on stress symptoms, 23 questions likert scale
41283515|NCT05308147|DIETARY_SUPPLEMENT|Second Reference product|Dextrose (containing 25 grams of carbohydrates)
40942189|NCT06199050|OTHER|General questions|"* Education level~* Marietal status~* Medication use (in order to assess influence on fear)~* Previous cancer diagnosis~* Acquired information on treatment~* Expected fear and anxiety mitigation strategies~* Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~* PROM at baseline"
40942190|NCT06199050|OTHER|Clinical data collected|"Clinical data in HIX:~* Age~* Gender~* Cancer type~* WHO status~* TNM"
40942191|NCT02667327|DRUG|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
40942192|NCT02667327|OTHER|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
40942193|NCT02669238|DEVICE|Nexplanon®|Subcutaneous implant (Nexplanon®) containing etonogestrel 68 mg
40942194|NCT02669238|DRUG|Minidril®/Leeloo®|continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
41283516|NCT05308147|DIETARY_SUPPLEMENT|Third Reference product|Dextrose (containing 25 grams of carbohydrates)
41283517|NCT05308147|DIETARY_SUPPLEMENT|First Concept product|Infant Formula (containing 25 grams of carbohydrates)
41283518|NCT05308147|DIETARY_SUPPLEMENT|Second Concept product|Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
41283519|NCT05308147|DIETARY_SUPPLEMENT|Third Concept product|Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
41283520|NCT02817607|PROCEDURE|Sensory testing and Biopsy|"Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.~A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit."
41283521|NCT02803502|DEVICE|Chronometric method|Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)
41283522|NCT02803502|DEVICE|Chromogenic method|"Chromogenic FVIII assay method ( BIOPHEN FVIII: C and BIOPHEN Factor IX of the firm Hyphen BioMed)"
40942195|NCT02761291|DRUG|Gemcitabine|Gemcitabine will be administrated 600\~1250 mg/m\^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m\^2. If no subject suffered the dose limit toxicity, 1000 mg/m\^2 and even 1250 mg/m\^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m\^2, the 600 mg/m\^2 will be started.
40942196|NCT02761291|DRUG|Valproic acid|Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
40942197|NCT02761291|DRUG|Valganciclovir|Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and \< 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
40942198|NCT04878887|PROCEDURE|IP-DRA vs IP- PRA|Catetherization approach in plane : distal radial artery VS proximal radial artery
40942199|NCT03031535|DRUG|Intranasal octreotide acetate|Intranasal spray of octreotide acetate
41283523|NCT02803502|DEVICE|Thrombin generation test (TGT)|"Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent PPP-reagent Low respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used."
41283524|NCT01701700|PROCEDURE|portable electronic magnifier|
41283525|NCT01701700|PROCEDURE|optical aids|
41283526|NCT03244098|BEHAVIORAL|Transition Assistance Program|TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
41283527|NCT01586728|OTHER|Air - oxygen|"1. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)~2. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%."
41283528|NCT01586728|OTHER|Oxygen - Air|"1. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~2. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%."
41283529|NCT06023914|OTHER|STRENGTH EVALUATION WITH ELECTROSTIMULATOR|Evaluation of isometric strength using an electrostimulator.
41283530|NCT06023914|OTHER|STRENGTH EVALUATION WITHOUT ELECTROSTIMULATOR|Evaluation of isometric strength not using an electrostimulator.
40942200|NCT03031535|DRUG|Subcutaneous octreotide acetate|Subcutaneous injectable solution of octreotide acetate
41283531|NCT01099345|PROCEDURE|cystometry (CMG)|recording device measuring pressures though catheters placed in bladder and rectum
40942201|NCT03031535|DIAGNOSTIC_TEST|Growth hormone-releasing hormone|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
40942202|NCT03031535|DIAGNOSTIC_TEST|Arginine hydrochloride|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
40942203|NCT00841971|DRUG|Anidulafungin|200 mg IV loading dose followed by 100 mg qd for 21 days
41283532|NCT01099345|PROCEDURE|polysomnography (PSG)|Recording device measuring sleep activity through electrodes attached to the subject
41283533|NCT05893082|DEVICE|F2 Filter and Delivery System|Placement of F2 device in aorta to cover the great cerebral vessels.
41283534|NCT05817201|DRUG|Toripalimab|Toripalimab 240mg day7 and day 28，every 3 weeks 1month after radiotherapy，until progression or 1 years or intolerant.
41283535|NCT05817201|DRUG|Tegafur|Tegafur 70mg/m2/day day 1 to day 14，and day 29 to day42.
41283536|NCT05817201|RADIATION|IMRT|PGTV 54Gy/2.16Gy/25F/5W, PTV 45Gy/1.8Gy/25F/5W
41283537|NCT04632147|OTHER|Ujjayi pranayama, Nadi-Shodhana pranayama, Sukha pranayama|Ujjayi pranayama:It is a pranayamic application that is performed by slightly twisting the throat and breathing through the nose. Nadi shodhana pranayama is breathing alternately through the right and left nostrils.Sukha pranayama is inhaled through the nose for 5 seconds, then given through the nose for 5 seconds. Thus, 6 times of inspiration and expiration is done per minute.
41283538|NCT03443024|BIOLOGICAL|Lebrikizumab|Sterile liquid solution administered subcutaneously.
41283539|NCT03443024|DRUG|Placebo|Solution administered subcutaneously.
41283540|NCT00542347|DRUG|Esomeprazole first|"* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
41283541|NCT00542347|DRUG|Generic omeprazole first|"* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
41283542|NCT00884507|DRUG|Placebo|po daily for 24 weeks
41283543|NCT00884507|DRUG|RO5313534|1mg po daily for 24 weeks
41283544|NCT00884507|DRUG|RO5313534|5mg po daily for 24 weeks
41283545|NCT00884507|DRUG|RO5313534|15mg po daily for 24 weeks
40942204|NCT00841971|DRUG|Fluconazole|400 mg IV for 21 days
40942205|NCT03131453|DRUG|CNP520 50mg|50 mg capsule
40942206|NCT03131453|DRUG|CNP520 15mg|15 mg capsule
40942207|NCT03131453|OTHER|Matching placebo|Matching placebo for 15 and 50 mg capsules
40942208|NCT00287651|PROCEDURE|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
40942209|NCT00287651|PROCEDURE|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
41283546|NCT06049732|DEVICE|PainChek®|Both PainChek® and the Abbey Pain Scale are observational pain assessment tools which have been designed to assist healthcare professionals and profession caregivers assess pain in people who cannot self-report their pain
41283547|NCT03550950|DRUG|JNJ-64232025 IV|JNJ-64232025 will be administered as IV infusion.
41283548|NCT03550950|DRUG|JNJ-64232025 SC|JNJ-64232025 will be administered as SC injection.
41283549|NCT03550950|DRUG|Placebo|Matching placebo will be administered as IV infusion or SC injection.
41283550|NCT03167619|DRUG|Olaparib Oral Product|olaparib 300mg twice daily
40756776|NCT05240924|OTHER|Stress Management Training|The stress management training intervention will be based on that delivered by Simpson in an ERP trial. It will be delivered by PhD and Master's level therapists from each site's clinics. The stress management training intervention will begin with an introductory session providing psychoeducation about OCD, followed by 15 sessions covering stress management skills such as deep breathing progressive muscle relaxation, positive imagery, assertiveness training, and problem solving. Each session will contain an extended practice of the selected skill and will end with homework assignments to practice the stress management skills and monitor symptoms.
40756777|NCT06232993|OTHER|Kinesio taping|Kinesio taping is a technique that involves the application of a special elastic tape to the skin to provide support to muscles and joints without restricting the body's range of motion. This method is designed to facilitate the body's natural healing process and improve muscle function while providing support and stability to muscles and joints. Kinesio tape is believed to help reduce pain, support muscles during movement, and aid in rehabilitation. It is commonly used in sports medicine and physical therapy to address a variety of musculoskeletal conditions and injuries.
41283551|NCT03167619|DRUG|Olaparib Oral Product in combination with Durvalumab|olaparib 300mg twice daily plus intravenous durvalumab every 28 days
41283552|NCT03952364|OTHER|PredictSURE IBD™|To evaluate a test called PredictSURE IBD™ in the US population
41283553|NCT05425771|PROCEDURE|Anti Reflux Mucosa Ablation|Mucosa ablation with Argon plasma coagulation performed in inversion at the gastroesophageal junction in a crescent or horseshoe shape over a width of 1.5 - 2 cm in patients with refractory reflux symptoms
41283554|NCT04678544|DEVICE|Scalp cooling system 2|The investigational device which will be used in this study is the Paxman Scalp Cooling System 2. This device is manufactured by: Paxman Coolers Limited. This is a free-standing, electrically-powered, mobile refrigeration unit which circulates a refrigerated liquid coolant, at a pre-set temperature and flow rate, through a cooling cap which is attached to, and covers, the top of the patient's head. The Paxman Scalp Cooling System is intended to be used for scalp cooling of patients who are receiving chemotherapy for the treatment of solid tumors, in order to reduce the risk of chemotherapy-induced alopecia.
41283555|NCT05324215|PROCEDURE|Transversalis fascia plane block and rectus sheath block|Transversalis fascia plane block and rectus sheath block will be administered after the surgery.
41283556|NCT05324215|DEVICE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
41283557|NCT00133744|DIETARY_SUPPLEMENT|folic acid|pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid
41283558|NCT00133744|DIETARY_SUPPLEMENT|folic acid plus iron|pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe
41283559|NCT00133744|DIETARY_SUPPLEMENT|supplements with multiple vitamins and minerals|pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg
41283560|NCT05947019|DEVICE|Myopic amblyopia comprehensive treatment instrument|Myopic amblyopia comprehensive treatment instrument is produced by Suzhou Industrial Park Zuoguan Medical Equipment Co., LTD.
41283561|NCT05947019|DEVICE|Glasses|Optometry with glasses as a routine treatment
40942210|NCT00287651|PROCEDURE|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
41283562|NCT06158698|DRUG|Colchicine|Colchicine 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
41283563|NCT06158698|OTHER|Placebo|Placebo 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
41283564|NCT01946009|DRUG|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.|
41451660|NCT02697682|BIOLOGICAL|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
41451661|NCT01640743|DRUG|Tacrolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
41451662|NCT01640743|DRUG|Tacrolimus + Everolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
40756778|NCT06232993|OTHER|Occlusal Splinting|Occlusal splinting, also known as a bite guard or night guard, is a removable dental appliance typically made of plastic that is custom-fitted to a patient's upper or lower teeth. It is primarily used to address issues related to teeth grinding (bruxism) or temporomandibular joint (TMJ) disorders. The splint is designed to fit over the teeth, creating a barrier between the upper and lower teeth to prevent grinding and clenching during sleep. Occlusal splints aim to reduce the impact of bruxism on the teeth and jaw, alleviate associated pain, protect the teeth from wear, and promote relaxation of the jaw muscles.
41283565|NCT01676961|BIOLOGICAL|romiplostim|Given SC
41283566|NCT05742620|DRUG|anlotinib+CAPEOX/SOX|"Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1."
40942211|NCT01902433|PROCEDURE|Astym|
40942212|NCT05291026|OTHER|mobile phone-based health information|health education and follow-up messaging, randomly assigned to each participant in the intervention arm using a randomization software, delivered once daily, as short message service (sms)
41283567|NCT02454114|OTHER|HOMEFIRST|HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.
41283568|NCT02454114|OTHER|Standard Hospital Care|"No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team.~SF-12 (physical and mental function) \[performed twice in total\] - at recruitment (day 0) and 6 weeks~CAP-SYM \[performed 3 times in total\] - at recruitment day 0 (twice including day minus 30) and 6 weeks~Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor."
41283569|NCT03659435|DRUG|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
41283570|NCT03659435|DRUG|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
41283571|NCT00131443|DRUG|Topiramate|
41283572|NCT01172171|DRUG|Melatonin, N-acetyl-5-methoxytryptamine|The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
41283573|NCT01172171|DRUG|Isotonic saline, Natrium chloride|The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
41283574|NCT03177252|DRUG|Lidocaine|-2% lidocaine will be given
41283575|NCT03177252|DRUG|Sodium chloride|-Normal saline will be given
41283576|NCT03177252|DRUG|Bupivacaine|-0.5% bupivacaine will be given
41283577|NCT04170621|DEVICE|Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
41283578|NCT05015712|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training was scheduled 3 times per week for 3 months. Every sessions included warm-up (\<50% target intensity for 2 min then gradually increasing load 1-10 W/min up to 100% target intensity for 5-10 min), exercise phase (100% target intensity (heart rate at anaerobic threshold±5) starting with 20 min and gradually lengthening up to 45 min in the 1 month as well as 45 min in another 2 months), cool down with gradual reduction of load within 3 min. The target intensity will be determined by the heart rate at anaerobic threshold measured by cardiopulmonary exercise test (CPET). The intensity will be adjusted after implementation of CPET and will keep at a minimum intensity, gradually increasing to the maximum intensity every month. Moreover, patients will be instructed to complete 2 supervised sessions and 1 home-based session during the 1 month and then to continue 3 home-based session for a further 2 months.
41283579|NCT03879590|DRUG|Doxophylline|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
41451663|NCT02417428|DIETARY_SUPPLEMENT|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
41451664|NCT02417428|OTHER|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
40756779|NCT06232993|OTHER|Exercises|For patients with bruxism, exercises can be beneficial in managing symptoms and promoting relaxation of the jaw muscles. These exercises aim to reduce the frequency and intensity of bruxism, alleviate associated pain, and improve overall jaw function and comfort. It's important for patients to consult with healthcare professionals to determine the most appropriate exercises for their individual needs.
40942213|NCT02537782|DEVICE|Cardiac resynchronisation therapy|
40942214|NCT02537782|OTHER|Echocardiography|
41283580|NCT03879590|DRUG|Budesonide|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
41283581|NCT03309670|OTHER|Psychiatric future|Former young psychiatric patients are contacted to determine their psychiatric outcome.
41283582|NCT06435715|OTHER|10 Repetitions of Deep Breathing Exercise|Respondents in the intervention group performed 10 repetitions of deep breathing exercises every 3 hours for 3 days.
41283583|NCT06435715|OTHER|3 Repetitions of Deep Breathing Exercise|Respondents in the control group performed 3 repetitions of deep breathing exercises for 3 days.
41283584|NCT05275413|BEHAVIORAL|family-based mHealth Intervention|The intervention consists of three versions: mother, father, and grandparent. The app consists of health information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos. Each versions have their unique features, such as a platform to ask questions in mother version, a quiz game to promote fathers' knowledge related to father's involvement, educational materials tailored for grandparents. An obstetrician and a social worker will respond to the questions. Details please refer to the proposal.
41451665|NCT02417428|BEHAVIORAL|Exercise|Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
41451666|NCT02417428|OTHER|without exercise|No exercise program will be assigned to participants.
40942215|NCT02537782|OTHER|Magnetic Resonance Imaging|
40942216|NCT02537782|OTHER|Positron Emission Tomography|
41283585|NCT05275413|BEHAVIORAL|mother-only mHealth Intervention|The expectant mothers in this group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app. The expectant mothers will also have access to a platform in the smartphone app to ask questions about their pregnancy. An obstetrician will respond to the questions.
40756780|NCT02339675|OTHER|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
40756781|NCT03161262|BEHAVIORAL|SMS-based reminders|The SMS-based reminders consist of sending messages to participants assigned to this study arm reminding them to take their medication and prompting participants to complete surveys. Medication reminders are sent as per the participant's prescribed frequency and weekly surveys allow participants to report their pain level as well as send an image of their surgical site. Beyond pre-determined reminders and surveys sent to patients, the Memora Health platform is interactive and allows patients to text in questions they may have regarding their medications, care, or condition. Participants will receive the messages for 3 months.
40756782|NCT05630365|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Rapid Panel device, hereafter referred to as the Panbio™ Rapid Panel, is a visual lateral flow assay for the rapid immuno-chromatographic qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in mid-turbinate nasal swabs
41283586|NCT05275413|OTHER|Health education|The expectant mothers in the control group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app.
41283587|NCT06156202|OTHER|Comprehensive Rehabilitation|Subjects will be given the option to undergo the comprehensive rehabilitation program including speech therapy and physical therapy. Progression through the rehabilitation program will be personalized and designed based on impairments identified during the comprehensive baseline assessment and previous sessions. Subjects will undergo 12 one- hour sessions over the course of six weeks. The exercise program will be graded and targeted to the person's physical capacity with the goal of slowly advancing the exercise duration or intensity to effect physiological strengthening and increased physical function.
40756783|NCT05477641|PROCEDURE|Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block|Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule
41283588|NCT06156202|OTHER|Augmented Usual Care|"Following randomization, subjects in the augmented usual care group will be given the results of their in-person baseline assessment as well as the WHO Guide Support for Rehabilitation Self-Management after COVID-19 Related Illness. This guide consists of ways to manage: breathlessness, difficulty with voice, eating, drinking and swallowing; problems with attention, memory and thinking clearly; limitations in activities of daily living, manage stress and mood dysfunction and advice for when to contact healthcare professionals. Follow-up interviews will assess process measures, including use of outpatient rehabilitation clinics, to examine possible contamination effects"
40756784|NCT05477641|PROCEDURE|Fascia Iliaca Compartment Block|Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.
40756785|NCT04214444|BIOLOGICAL|Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma|The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).
40756786|NCT00736151|DRUG|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
40756787|NCT01277185|DIETARY_SUPPLEMENT|Low Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.
40756788|NCT01277185|DIETARY_SUPPLEMENT|High Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
40756789|NCT06256484|DRUG|ATA3219|ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.
40756790|NCT06243250|DIAGNOSTIC_TEST|Hyperpolarized 13C-MRI|Metabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.
40756791|NCT04701983|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
40756792|NCT04701983|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
40756793|NCT01713322|BEHAVIORAL|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
41283589|NCT01683500|DEVICE|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
41283590|NCT04710030|DRUG|Valacyclovir hydrochloride 500mg caplet|Active Comparator
41283591|NCT04710030|DRUG|Placebo sugar pill caplet|Placebo Comparator
41283592|NCT05126108|PROCEDURE|Thyroid and parathyroid surgery|Thyroid and parathyroid surgery
40756794|NCT01713322|BEHAVIORAL|No pain management education|Control - parents receive general information about childhood immunization.
40756795|NCT05301972|DRUG|BET Inhibitor|Bromodomain and Extra-Terminal Inhibitor
40942217|NCT06498505|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
40942218|NCT06498505|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
40942219|NCT05548309|DEVICE|HFNC|High flow nasal cannula (HFNC) was inserted through specific medium/large nasal prongs . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) connected to the HFNC. Starting flow 35 L/min, temperature 31oc. The flow was titrated up to 60L/min with a target SpO2 of ≥94%.
40942220|NCT05548309|DEVICE|Oxygen face mask|Oxygen face mask was applied to patients postoperatively with starting flow 8L/min and titration of flow up to 10 L/min with target SpO2 of ≥94%
40942221|NCT00717444|BEHAVIORAL|contingency management|"contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors"
40756796|NCT02518698|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
40756797|NCT00100750|DRUG|Gemcitabine Hydrochloride|Given IV
40756798|NCT00100750|DRUG|Tipifarnib|Given PO
40756799|NCT00100750|OTHER|Laboratory Biomarker Analysis|Correlative studies
40756800|NCT02244957|DEVICE|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations \<88% while on stable bi-level settings.
40942222|NCT00717444|BEHAVIORAL|contingency management|"contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors"
40942223|NCT06259708|DEVICE|Low intensity focused ultrasound|Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).
40942224|NCT02035501|DRUG|L-Tyrosine|
40942225|NCT02035501|DRUG|Placebo|
41267158|NCT00793351|PROCEDURE|Reduced-intensity allogeneic hematopoietic stem cell transplantation|"Treatment Scheme~* Enrollment - Pre-RIST treatment - RIST~* 4 cycles of conventional chemotherapy will be given prior to RIST.~* Surgery will be done whenever possible prior to RIST.~* Local radiotherapy will be applied whenever possible prior to RIST.~* topotecan + cyclophosphamide) regimen will be used for pre-RIST conventional chemotherapy.~* Cyclophosphamide/Fludarabine (CyFlu) regimen will be used as conditioning regimen for matched related or unrelated SCT. CyFlu-ATG regimen will be used as conditioning regimen for mismatched related SCT."
40756801|NCT02244957|DRUG|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
41283593|NCT05126108|OTHER|Recurrent nerves monitoring|Recurrent nerves monitoring
41283594|NCT04289883|COMBINATION_PRODUCT|Nano-particulated whey protein vs non-particulated whey protein (control)|Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.
40756802|NCT01346917|DRUG|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
41283595|NCT04289883|COMBINATION_PRODUCT|High molecular weight whey protein-alginate coacervates vs calcium alginate (control)|Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.
41283596|NCT03595293|DEVICE|fNIRs-based Neurofeedback|Patients receive fNIRs-based neurofeedback from the rDLPFC to allow them to modify activation within this area.
41283597|NCT03595293|DEVICE|Sham feedback|Patients receive fNIRs-based sham feedback from the left zygomatic area to allow them to modify activation within this area.
41283598|NCT06206876|PROCEDURE|Biopsy|Undergo biopsy
40756803|NCT01346917|DRUG|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
40756804|NCT04325607|PROCEDURE|Excision of HS followed by NPWTi|The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
40756805|NCT04325607|PROCEDURE|Excision of HS followed by NPWT|The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
40756806|NCT00047580|DRUG|tizanidine hydrochloride capsule|
40756807|NCT04743063|DRUG|sacubitril/valsartan|Initiation of sacubitril/valsartan, identified using prescription fill in pharmacy claims
40756808|NCT04743063|DRUG|Angiotensin II Receptor Blockers|Initiation of ARBs, identified using prescription fill in pharmacy claims
40756809|NCT05305703|OTHER|cervical stretching|Heating therapy for 10 minutes Passive stretching of neck muscles including Sub-occipital muscles, Trapezius upper boarder and Sternocleidomastoid muscle with 10 reps each
40756810|NCT05305703|OTHER|soft tissue mobilization|Heating therapy for 10 minutes Soft tissue mobilization for 8 minutes and trigger point release of sub-occiptal muscles with 5 repetitions each.
40756811|NCT06110871|OTHER|inhaled lavender|They will be asked to inhale deeply 10 times. Then, a total of 30 minutes in the waiting room where aromastone is located and in the IA application room.
41283599|NCT06206876|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41283600|NCT06206876|PROCEDURE|Computed Tomography|Undergo CT
41283601|NCT06206876|DRUG|DDX5 Degrader FL118|Given PO
41283602|NCT06206876|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41283603|NCT02687308|PROCEDURE|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
41283604|NCT02687308|PROCEDURE|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
41283605|NCT04507815|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
41283606|NCT04507815|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
41283607|NCT01645930|DRUG|Ixazomib|Ixazomib capsules
41283608|NCT01645930|DRUG|Lenalidomide|Lenalidomide capsules
41283609|NCT01645930|DRUG|Dexamethasone|Dexamethasone tablets
41283610|NCT05446675|PROCEDURE|Endoscopic eTEP|Endoscopic extended view totally extraperitoneal prosthesis repair.
40756812|NCT06110871|OTHER|Working Group 2: Focusing|During IUD application
40756813|NCT06110871|OTHER|Working Group 3 music|for a total of 30 minutes
40756814|NCT05518838|DRUG|OKN-007|OKN-007 is an intravenously administrated drug being developed as a novel anti-cancer therapy against gliomas.
40756815|NCT03849235|DIETARY_SUPPLEMENT|Standardised meal or glucagon|Standardised meal (Nutridrink, Nutricia, 300 kcal, 18.4 g carbohydrates, 5.8 g fat, 12 g protein) or 1mg glucagon
40756816|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 0.5 mg/kg Q2W
40756817|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 2 mg/kg Q2W
40756818|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 5 mg/kg Q2W
40756819|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 10 mg/kg Q2W
40756820|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 200 mg Q2W
40756821|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 300 mg Q3W
40756822|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 300 mg Q2W
40756823|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 200mg Q2W
40756824|NCT02636335|DEVICE|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
40756825|NCT01908387|DRUG|Oral azacitidine|100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
41283611|NCT05446675|PROCEDURE|Open Rives-Stoppa|Open Rives-Stoppa repair with retromuscular mesh placement.
41283612|NCT06459752|OTHER|visceral manipulation and noble technique|"First, the patient will lie face-up on a massage or exam table. Physiotherapists feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles. Physiotherapist manual poking, pressing, and massage actions do three things:~1. Reveals visceral adhesions.~2. Find tender spots.~3. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that makeup fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely.~Minor adhesions may resolve after one session. Tough, stubborn adhesions may require several sessions plus self-manipulation between sessions"
40756826|NCT03419624|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg tablet once daily
41283613|NCT06459752|OTHER|noble technique|The patient is positioned in supine with both knees bent and feet flat on a firm surface. The patient then places her crossed hands over her abdomen to support and pull the rectus abdominis muscles towards the midline. Finally, the patient is asked to slowly raise her head until a slight contraction is felt in the abdomen, holding for 20 seconds and repeating the exercise up to 20 times a day
41283614|NCT00607750|DRUG|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
40756827|NCT03419624|DRUG|Exenatide 2 mg [Bydureon]|Exenatide 2 mg injection once weekly
40756828|NCT03419624|DRUG|Placebo Oral Tablet|Placebo oral tablet once daily
41283615|NCT00607750|DRUG|Placebo|Placebo eyedrops, BID, 48 weeks
41283616|NCT04063683|DRUG|Anlotinib Hydrochloride, Paclitaxel, cisplatin|"* anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~* Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~* Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle."
41283617|NCT04677270|BEHAVIORAL|Digital problem solving tool|Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic
41283618|NCT00241111|DRUG|zoledronic acid|
41451667|NCT04330547|DRUG|Analgesic administration|"* Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~* Level 2: Tramadol 50mg.~* Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~* Increase of a prior level 3 medication :~  1. 1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~ 2. If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)"
41451668|NCT04330547|DRUG|Placebo administration|Folavit (folic acid, 0.4 mg)
41451669|NCT02092857|DIETARY_SUPPLEMENT|Arachidonic acid (25 mg/100 kcal )|
41451670|NCT02092857|DIETARY_SUPPLEMENT|Arachidonic acid (34 mg/100 kcal)|
40756829|NCT03419624|DRUG|Placebo injection|Placebo injection once weekly
40756830|NCT03419624|DRUG|Insulin|daily Insulin injections
40756831|NCT03419624|DRUG|Metformin, if taken before|If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
40756832|NCT03902210|BEHAVIORAL|Online Yoga|60 minutes per week of online yoga through Udaya.com
40756833|NCT03902210|BEHAVIORAL|Podcast|60 minutes per week of podcasts
41283619|NCT00666185|DRUG|Micafungin|IV
41283620|NCT00666185|DRUG|Fluconazole|IV
41283621|NCT05284110|BEHAVIORAL|Physical activity|Multiple bouts of 3-min brisk walking, every 30 min, for 4 hours.
41451671|NCT02092857|DIETARY_SUPPLEMENT|Placebo|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
41451672|NCT01878864|DRUG|Bupivacaine lozenge|
41451673|NCT01878864|DRUG|Lidocaine-adrenalin injection|
41451674|NCT02244190|DRUG|Tipranavir|New oral solution (back up) formulation
40942226|NCT00877110|DRUG|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight\<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
40947890|NCT05014217|BEHAVIORAL|Mentalization-based Treatment|An empirically-validated intervention for personality disorders based on the attachment theory and on knowledge from developmental psychology and cognitive neuroscience (Bateman and Fonagy, 2004). Patients assist psychoeducative group meetings beforehand, along with a pretreatment of four to six individual meetings (over four to eight weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts two years. Patients have an assessment meeting with their individual therapist and one of the group therapists at the end of each session. Psychiatric follow-up appointments are on an as-needed basis and every patient has a treatment contract with specific and measurable treatment objectives.
41283622|NCT01710761|DIETARY_SUPPLEMENT|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
41283623|NCT01710761|DIETARY_SUPPLEMENT|Nitrate supplement with caffeine|Lozenge consisting of beetroot and 75 mg caffeine
41283624|NCT03328611|DEVICE|Hip and Knee Joint Replacement|Hip and Knee Joint Replacement
41451675|NCT02244190|DRUG|Tipranavir|
41451676|NCT02244190|DRUG|Ritonavir|
41283625|NCT05968950|DEVICE|Thoracic ultrasound|The use of ultrasound to count ribs in order to surface mark the corresponding spinal level
41283626|NCT05597267|DEVICE|MIRIA Laser|4-6 experimental treatments at 4-6 weeks intervals
41283627|NCT04711421|DEVICE|4 VIVOFIT-|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
41283628|NCT04477122|OTHER|Manual therapy and extracorporeal radial shock waves therapy|25 minutes of manual therapy, 5 minutes of temporomandibular joint mobilization and 3 minutes of extracorporeal radial shock waves therapy (real or placebo)
41283629|NCT02570815|DRUG|indocyanine green|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
41451677|NCT00433745|DRUG|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
41451678|NCT05711901|DEVICE|Efferon LPS|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 12h immediately following admission to the intensive care unit
41283630|NCT03906877|PROCEDURE|Acid hyaluronic injection laryngoplasty|Hyaluronic acid is injected into the paralyzed vocal fold
41283631|NCT03906877|BEHAVIORAL|Voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises"
41283632|NCT03906877|OTHER|Sham of injection|Injection of physiological saline under the skin of the neck (sham of injection).
41283633|NCT03906877|OTHER|Sham of voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture."
41283634|NCT00584064|DEVICE|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
41283635|NCT02707757|DRUG|Iron sucrose|1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
41283636|NCT02707757|DRUG|Erythopoietin stimulating agent|Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
41283637|NCT02039388|PROCEDURE|Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle|
41283638|NCT02032628|BEHAVIORAL|Exercise|The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
41451679|NCT02578277|DRUG|CYP and transporter probe substrates|Cocktail of CYP (cytochrome P450) and transporter probe substrates
41283639|NCT03913910|PROCEDURE|Lipogems|Autologous micro-fragmented adipose tissue is injected in the internal orifice, mucosal, submucosal and muscular layer, then in the fistula tract and external orifice in addition to anal flap.
41283640|NCT04306042|DRUG|Nivolumab or Pembrolizumab|Nivolumab or Pembrolizumab
41283641|NCT01738035|DRUG|NEFECON|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
41283642|NCT01738035|OTHER|Placebo|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
41283643|NCT01521845|DRUG|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
41283644|NCT01245712|RADIATION|Accelerated Partial Breast Irradiation|Undergo APBI delivered with proton radiation
41283645|NCT01245712|RADIATION|Proton Beam Radiation Therapy|Undergo APBI delivered with proton radiation
41283646|NCT01245712|OTHER|Quality-of-Life Assessment|Ancillary studies
41283647|NCT06011070|BEHAVIORAL|Gambling Personalised Feedback|The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
41283648|NCT02448550|DRUG|Bivalirudin|
41283649|NCT02448550|DRUG|Unfractionated heparin|
41283650|NCT03317808|DIAGNOSTIC_TEST|Different exercise|Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
41283651|NCT05996744|DRUG|Obeldesivir|Tablet administered orally with or without food
41283652|NCT03951987|DRUG|4 ml CG5503|4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).
41283653|NCT03951987|DRUG|5 g charcoal powder|Oral administration of 5 g charcoal powder suspended in 100 ml tap water.
41451680|NCT02578277|DRUG|BMS-955176|BMS-955176
41451681|NCT02578277|DRUG|BMS-955176 plus CYP and transporter probe substrates|BMS-955176 plus the cocktail of CYP and transporter probe substrates
41451682|NCT03248128|DRUG|FF/VI via ELLIPTA DPI|ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
41451683|NCT03248128|DRUG|FF via ELLIPTA DPI|ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
41451684|NCT04434716|DEVICE|Feasibility of wearing a Readiband to monitor Sleep and Fatigue|On day one of the study participants will complete a demographic survey. On day one, every seventh day and at the end of the study each participant will complete all the scales; The Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Self-Care of Heart Failure Index will be completed on day one and day 60. At the end of the intervention an Interview will be conducted to assess participants experiences using the Readiband: On a scale of 0-10, how would you rate your digital literacy? 2) Why that number? 3) Tell me about a day using the readiband? 4) Were there any challenges to wearing the band, forgetting to wear it, level of comfort wearing the band? Anything else etc..? 5) How did the digital tools enhance your health? 6) Did the use of digital tools cause you to take a proactive approach rather than a reactive approach to your health? 7) As I use the readiband in a next study, what suggestions do you have for me?
41283654|NCT00231478|DRUG|granisetron|20 micrograms intravenously (iv) 15 min prior to end of surgery
41283655|NCT00231478|DRUG|granisetron|40 micrograms intravenously (iv) 15 min prior to end of surgery
41451685|NCT03723733|BEHAVIORAL|screen high and low triat subjects|use a range of questionniares to screen screen high and low triat subjects (eg. Autism, Anxiety, Depression traits and social network size)
40942227|NCT05392517|OTHER|self-mobilization technique along with conventional therapy|"Group A will be treated with self-mobilization technique of thoracic spine with the frequency of 2 sets of 10 repetitions thrice per week for a total of six weeks and conventional treatment.~Self-mobilization technique will be comprised of self-mobilization technique using tennis balls and foam roller. The participant will be supine with knees in 90-degree flexion.~* Mobilization Technique 1: Cross your arms over your chest so that you are in slight flexion and then slowly begin to move your shoulders and head closer to the floor placing the mid back into extension over the balls joined to make mobilization device. Hold this position for 3 seconds and then return to the flexed position.~* Mobilization Technique 2: Lying lengthwise on the foam roller, clasp your hands together in front of you, above your chest with arms straight. Slowly move your arms above your head until you feel a good stretch. This exercise should be pain free. Hold stretch for 30- 60 seconds."
40942228|NCT05392517|OTHER|conventional therapy|Group B will be treated with the conventional treatment (heating pad, ultrasound, thoracic strengthening exercises
40942229|NCT00964080|DRUG|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
40942230|NCT05691439|BEHAVIORAL|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
40942231|NCT05691439|BEHAVIORAL|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
40942232|NCT05800873|DRUG|EVER001|A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
40942233|NCT03656835|PROCEDURE|Molecular Nanotechnology|Undergo ILN biochip testing
40942234|NCT01739673|OTHER|Ultraviolet-A and riboflavin|
40942235|NCT03277521|OTHER|Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
41132176|NCT06523478|PROCEDURE|Intratonsillar immunotherapy (ITIT)|During injection, the operator needs to gently shake the injection bottle about 20 times, the drug must be mixed to ensure the consistency of allergen concentration, and carefully check the patient's name and concentration on the bottle. Allergy extracts should not be injected intravenously, so the syringe will be aspirated to avoid inadvertent intravascular injection. Before each injection, after inserting the needle into the selected tonsil, before injecting the dose, the investigator will slightly pull the plunger of the syringe. If blood returns from the syringe, the syringe, and its contents will be discarded. The other tonsil will be selected and a new syringe will be prepared.
41283656|NCT04591288|OTHER|Functional Electrical Stimulation protocol|FES-assisted treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age-predicted maximum heart rate. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Each treadmill bout consists of alternating one- minute intervals of FES on and FES off. For the last walking bout, the first three minutes will be FES-assisted on the treadmill and the last three minutes will be overground walking without FES assistance to promote carryover effects. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
41283657|NCT04591288|OTHER|Treadmill only protocol|We will implement a 12-wk Treadmill training protocol consisting of treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
41283658|NCT00152256|DRUG|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for 6 months
41283659|NCT00152256|DRUG|Asoprisnil|Asoprisnil 25mg Tablet, oral Daily for 6 months
41283660|NCT00152256|DRUG|Placebo|Placebo Tablet, oral Daily for 6 months
41283661|NCT01820910|DRUG|Doxycycline|All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
40756834|NCT05112926|DEVICE|Embosphere Microspheres|Embosphere Microspheres are 100-300μm small, compressible, hydrophilic, biocompatible spheres made of acrylic polymer and porcine-derived gelatin used for embolization of geniculate artery.
40942236|NCT05899010|DRUG|Vaginal progesterone 600mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
40942237|NCT05899010|DRUG|Vaginal progesterone 800mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
41283662|NCT05946330|BEHAVIORAL|NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).|The intervention group will receive educational actions in individual nutrition with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up
41283663|NCT00104104|DRUG|zoledronic acid|4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
40942238|NCT02321631|DIETARY_SUPPLEMENT|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
41451686|NCT03921801|OTHER|Gait retraining|"Gait retraining using real-time electromyography biofeedback performed once per week for eight weeks.~During the gait retraining session the participant is walking on a treadmill while receiving information on calf muscle activation. A single session includes five bouts of walking each lasting for 5 minutes. During the first bout, the participant is receiving feedback (visual and auditive) on soleus muscle activation with the aim to increase it by 20% from their normal walking. During the second bout, the participant is receiving feedback (visual and auditive) on medial gastrocnemius muscle activation with the aim to decrease it by 20% from their normal walking. During the last three bouts, the participant is receiving feedback (visual and auditive) on the soleus to medial gastrocnemius muscle activation ratio with the aim to increase it by 20% from their normal walking. If hitting the target, the aim is increased by 5% for the subsequent bout."
40942239|NCT02321631|DIETARY_SUPPLEMENT|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
41283664|NCT02519231|DRUG|Naproxen|Naproxen 440mg 1x pid
40942240|NCT03276819|PROCEDURE|Samples collection|OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples
41283665|NCT02519231|DRUG|Placebo|Placebo tablet 440mg 1x pid
41283666|NCT05899725|DRUG|Corticosteroids|Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence
41451687|NCT03921801|OTHER|Gait retraining + strength training|"Gait retraining using real-time electromyography biofeedback performed once per week and home-based calf muscle strength training performed three times per week for eight weeks.~The gait retraining is identical to the one intervention described for the intervention group Gait retraining.~The strength training is performed three times per week except for the first week in which it is performed two times. The session contained a warm-up (3x10 repetitions of two-legged heel raises) and maximal isometric calf muscle contractions. The maximal contractions are performed using a custom device with the ankle in dorsiflexion and the knee flexed by 100-120 degrees. Three sets of 10 repetitions (3-second contraction and 3-second rest) are performed with both legs and with maximal effort and 1-minute rest between the sets."
41451688|NCT04218994|OTHER|Flossing technique|Subjects instructed on flossing technique
41283667|NCT05899725|DRUG|Corticosteroids and Ruxolitinib|Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib
41283668|NCT04375878|DRUG|MS1819|MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
41451689|NCT03181620|OTHER|Intermittent Dosing of Medication|Typical sedative/narcotic medication administered for sedation while mechanically ventilated is given in an intravenous intermittent bolus fashion rather than a continuous intravenous drip.
41451690|NCT03736577|OTHER|Drug reviews with NorGeP-NH|Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts
40942241|NCT03276819|BEHAVIORAL|Psychological and Sociological evaluation|Cohort B ....
41283669|NCT04375878|DRUG|Porcine PERT|Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.
40942242|NCT03276819|BEHAVIORAL|Intensive and sustained smoking cessation program|Evaluation of efficacy of the smoking cessation program (intensive and sustained versus minimal)
41283670|NCT04248010|DEVICE|neuroConn DC-Stimulator MR|standard tDCS, active \& sham
40942243|NCT03276819|BEHAVIORAL|Tobacco and alcohol status follow-up|Evaluation of the tobacco and alcohol status all along the study (questionnaires)
40942244|NCT00683085|BIOLOGICAL|HLA-A*02:01-restricted VEGFR1-derived peptide vaccination|VEGFR1-derived HLA-A\*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m\^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the feasibility and efficacy of this type of peptide.
40942245|NCT00635791|DRUG|Sorafenib|Given by mouth
40942246|NCT00635791|DRUG|Vorinostat|Given by mouth
41283671|NCT04248010|DEVICE|Soterix MxN HD-tES|HD-tDCS, active \& sham
41283672|NCT04853329|DRUG|CPO107|CD20-CD47 Bispecific Fusion Protein
41283673|NCT00486980|DRUG|Peramivir 150mg|
41283674|NCT00486980|DRUG|Peramivir 300mg|
41283675|NCT02437838|OTHER|No Intervention|No Intervention
40942247|NCT05385185|DRUG|Camrelizumab or envafolimab|combine Camrelizumab or envafolimab with Recombinant human vascular endostatin
40942248|NCT04200859|OTHER|Cold application|cold application using ice pack/gel pad in the control of pain experienced during chest tube removal
40942249|NCT05034133|DRUG|Durvalumab|Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles
41283676|NCT05263843|DIAGNOSTIC_TEST|Biological markers of myocardial fibrosis|Blood sample for measurements of NET activation and collagen biomarkers
40942250|NCT00001095|DRUG|Indinavir sulfate|
40942251|NCT00001095|DRUG|Amprenavir|
40942252|NCT00001095|DRUG|Nevirapine|
40942253|NCT00001095|DRUG|Lamivudine|
40942254|NCT00001095|DRUG|Stavudine|
40942255|NCT00001095|DRUG|Zidovudine|
40942256|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention A|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.
40942257|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention B|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.
40942258|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention C|Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.
41283677|NCT06396481|BIOLOGICAL|Vγ9Vδ2 T cell|The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.
41283678|NCT00786240|DRUG|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
41283679|NCT00786240|DRUG|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
41283680|NCT03118843|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
41283681|NCT05446597|PROCEDURE|Symptom-specific Headache Treatment|Greater Occipital Nerve Block
41283682|NCT05446597|OTHER|Symptom-specific Dizziness &/or Neck Pain Treatment|Cervicovestibular Physiotherapy Treatment
41283683|NCT05446597|BEHAVIORAL|Multimodal Concussion Treatment|Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
41283684|NCT01953315|BIOLOGICAL|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
41283685|NCT00982605|PROCEDURE|EBUS_TBNA|EBUS during bronchoscopy
41283686|NCT03946176|DIETARY_SUPPLEMENT|Symbiotic|HD patients follow a 8-weeks oral administration of the symbiotic supplement (2 bags/day)
41283687|NCT03946176|DIETARY_SUPPLEMENT|Placebo|HD patients follow a 8-weeks oral administration of the placebo (2 bags/day)
40942259|NCT05086952|DRUG|Vericiguat (Verquvo, BAY1021189) - Intervention D|Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.
40942260|NCT04232306|DRUG|Liposomal bupivacaine|Bupivacaine liposome injectable suspension
40942261|NCT04232306|DRUG|Bupivacaine HCl|Bupivacaine HCl surgical-site incision infiltration
40942262|NCT02675712|OTHER|African drumming|Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
40942263|NCT04608942|DEVICE|Jett Plasma Medical Lift|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
40942264|NCT04608942|PROCEDURE|Mechanical Debridement|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
40942265|NCT03555773|PROCEDURE|Lipogems|After local surgical drainage of the perianal disease, micro-fragmented adipose tissue is injected circumferentially into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract.
40942266|NCT01482351|BEHAVIORAL|CPAP adherence intervention|Critical factors were (1) OSA education, treatment expectations, and ways to minimize barriers and facilitate CPAP use; (2) promotion of a positive initial CPAP experience; (3) motivational interviewing to reinforce participants' health-related goals and CPAP self-efficacy; (4) anticipatory guidance and follow-up of common CPAP problems; and (5) social support by a study partner. Trained project staff provided the intervention by phone and face to face for a total of 12-14 hours over the 1 year project.
40942267|NCT01482351|BEHAVIORAL|Attention control intervention|This intervention, provided by phone and face to face by project staff, provided equal time and attention. Critical factors were (1) education about OSA and risks, (2) education about memory, and other health topics of interest to the participants; (3) motivational interviewing to reinforce participants' health-related goals; (4) building rapport, and (5) social support by a study partner.
40942268|NCT05377203|DRUG|Quadruple combination of half doses therapy→Dual combination of standard dose therapy|"Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.~Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day."
40942269|NCT05377203|DRUG|Dual combination of standard dose therapy→ Quadruple combination of half doses therapy|"Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.~Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day."
40942270|NCT03114488|DEVICE|tDCS|Transcranial electrical stimulator
40942271|NCT00229151|BEHAVIORAL|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
40942272|NCT00229151|OTHER|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
40942273|NCT03695887|DRUG|Nitrous Oxide Inhalant Product|Nitrous Oxide Inhalant Product
40942274|NCT03695887|DRUG|Placebo|Inactive comparator
40942275|NCT04749667|OTHER|MSCs|Autologous bone-marrow derived mesenchymal stem cells
40942276|NCT04749667|DRUG|Saline|Isotonic saline
40942277|NCT05497518|OTHER|Observational study - registry|The Network is a longitudinal observational cohort study that collaborates with health systems to obtain both electronic healthcare records (EHR) and patient-entered data. Eligible people with a diagnosis of chronic kidney disease at any stage, age 18 years and above, are identified through EHR data review, referral by a provider, or are recruited through the NKF's outreach campaign. Patients self-enroll into the online registry and share their experiences and health data through a secure portal where they can also find education, tips, and support. Research partners can view aggregate data through a collaboration portal.
40942278|NCT00467610|DRUG|Panhematin|
40942279|NCT04118933|DRUG|JS001|JS001 240mg, Q3W
41451691|NCT04185857|DRUG|canrenone 50-100 mg orally once a day|After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.
40942280|NCT03903601|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.
40942281|NCT03903601|DIAGNOSTIC_TEST|Blood samples collection|Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.
41283688|NCT03946176|DEVICE|DVB cartridge|On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge
41283689|NCT02334969|DRUG|Naoxintong Capsule|This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
41283690|NCT02334969|DRUG|Placebo|placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
41283691|NCT00745030|DRUG|Rozerem|Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
41451692|NCT04185857|DRUG|olmesartan 10-20 mg orally once a day|"After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone."
41451693|NCT06428162|OTHER|questionner|three sections questioner including: demographics, reported cases, unreported cases
41451694|NCT00924053|DRUG|EGT0001474|Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
41451695|NCT00924053|DRUG|Placebo|Placebo capsules to match EGT0001474
41451696|NCT02649335|DRUG|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study
41451697|NCT02649335|PROCEDURE|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
41451698|NCT03246503|DEVICE|BiliCam estimated bilirubin (BCB)|Images will be obtained using the BiliCam app installed on a commercial smartphone and used to calculated a BCB level. The BCB levels will be used for study purposes only and not used for clinical care
41451699|NCT03389113|DEVICE|Whole body vibration|Whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
41451700|NCT03389113|OTHER|Exersice|Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.
41451701|NCT00677872|DRUG|PRX-08066|
41451702|NCT01872676|OTHER|Spine manipulation|
41451703|NCT01872676|OTHER|Manipulation sham|
41451704|NCT06550869|PROCEDURE|Anterior Quadratus Lumborum Block at the lateral supra-arcuate ligament under laparoscopic direct vision|The urologists find the inner arcuate ligament. The scalp needle is inserted from the midpoint of the lower edge of the inner or outer arcuate ligament towards the head to the dorsal side of the diaphragm. After withdrawing without blood, air, or cerebrospinal fluid, 2 ml of normal saline is first administered to observe the fluid spreading towards the head Then, 20 ml of 0.375% ropivacaine hydrochloride injection is administered.
41451705|NCT06550869|PROCEDURE|Local infiltration anesthesia|The urologists give local infiltration anesthesia with 20 ml of 0.375% ropivacaine hydrochloride injection.
41451706|NCT00107263|DRUG|letrozole|
41451707|NCT00107263|DRUG|zoledronic acid|
41451708|NCT05823662|PROCEDURE|DJ stent|A 5 Fr DJ stent will be inserted and then removed after three weeks.
41451709|NCT05823662|DRUG|Silodosin|Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
41451710|NCT05282693|DIETARY_SUPPLEMENT|ReMag|300 mg of ReMag dissolved in lemon flavor liquid
41451711|NCT05282693|DIETARY_SUPPLEMENT|Placebo|Lemon flavored liquid
41451712|NCT00134485|DRUG|torcetrapib/atorvastatin|
41451713|NCT00134485|DRUG|atorvastatin|
41451714|NCT01545349|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
41451715|NCT01545349|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
41451716|NCT01545349|BIOLOGICAL|Live attenuated influenza vaccine|0.2 mL pre-filled, single use intranasal spray
40942282|NCT03903601|DIAGNOSTIC_TEST|Neuropsychological tests|Cognitive functions assessment
41451717|NCT05368480|OTHER|Senior Companion Program|Receives a companion to socialize with them, help with daily tasks, etc.
41451718|NCT02942082|OTHER|ACP oral care gel|a desensitizing agent will be applied on tooth before and/or after bleaching
41451719|NCT02942082|OTHER|glycrin|glycrin will be applied on tooth surface before and/or after bleaching
41451720|NCT05773222|DRUG|Apixaban|Single Group Assignment
41451721|NCT04892953|DRUG|Carboplatin|Given IV
41451722|NCT04892953|BIOLOGICAL|Durvalumab|Given IV
41451723|NCT04892953|DRUG|Gemcitabine|Given IV
41451724|NCT04892953|PROCEDURE|Local Consolidation Therapy|Undergo LCT
41451725|NCT04892953|DRUG|Nab-paclitaxel|Given IV
41451726|NCT04892953|DRUG|Paclitaxel|Given IV
41451727|NCT04892953|DRUG|Pemetrexed|Given IV
41451728|NCT04892953|OTHER|Quality-of-Life Assessment|Complete questionnaire
41451729|NCT04892953|OTHER|Questionnaire Administration|Complete questionnaire
41451730|NCT04646603|DRUG|MRG-001|Subjects will receive subcutaneous MRG-001 injections.
41451731|NCT04646603|DRUG|Placebo|Subjects will receive subcutaneous placebo injections.
41451732|NCT04964687|PROCEDURE|Liver transplantation|Liver transplantation
41451733|NCT01408654|BEHAVIORAL|Peer Companionship|Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
41451734|NCT01158118|DRUG|Sargramostim|
41451735|NCT01158118|DRUG|Plerixafor|
41451736|NCT00564031|DRUG|Femanest|2mg/day
41451737|NCT00564031|DRUG|gestapuran|5mg/day
41283692|NCT00745030|DRUG|Placebo|Placebo 8 mg tablets
41283693|NCT02843711|GENETIC|Sequencing|Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.
41283694|NCT04014907|PROCEDURE|Frozen Elephant Trunk Technique|Endovascular technique forTAA repair
41283695|NCT03935854|OTHER|LCHF, Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
41283696|NCT01809366|PROCEDURE|seminal plasma insemination|
41283697|NCT04704076|OTHER|ESVS|Breastfeeding with up to 59-mL formula daily for the first 30 days, followed by exclusive breastfeeding through 6 months of age
41283698|NCT04704076|OTHER|Exclusive breastfeeding|Breastfeeding exclusively without any other food or fluid except vitamins, minerals and medications through 6 months of age
41283699|NCT03689738|OTHER|Potato (Resistant Starch)|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
41283700|NCT03689738|OTHER|CHO-matched (Low-fiber, RS-free)|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
41283701|NCT05691062|DEVICE|Titanium Fusion Device|Titanium fusion device will be utilized for one-level lumbar fusion.
41283702|NCT05691062|DEVICE|PEEK Fusion Device|PEEK fusion device will be utilized for one-level lumbar fusion.
41283703|NCT05715346|DRUG|LEV102 1.0%|Oxymetazoline ophthalmic gel
41283704|NCT05715346|DRUG|LEV102 2.0%|Oxymetazoline ophthalmic gel
41283705|NCT05715346|DRUG|Vehicle|Vehicle ophthalmic gel
41283706|NCT00989326|OTHER|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
41283707|NCT05839132|PROCEDURE|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
41283708|NCT05413681|DIAGNOSTIC_TEST|a supra-maximal exercise test on a cycloergometer.|10 blood samples will be taken: before, during and during recovery from exercise: before the exercise test on the cycloergometer, 2 samples during exercise on the cycloergometer (middle of the threshold and peak of the exercise), 2 samples during recovery from exercise on the cycloergometer (at 2 and 10 minutes), and 1 sample at 24 hours.
41283709|NCT05413681|DIAGNOSTIC_TEST|handgrip muscle activity test.|2 bloods samples : at rest, after the 3 maximum contractions of the forearm, at 5 minute's recovery from the 30-second contraction of the grip test,
41283710|NCT04862416|BIOLOGICAL|R0.6C transmission blocking vaccine|Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.
41283711|NCT02786862|OTHER|independent ventilation|comparison conventional and independent 1:1 ventilation
41451738|NCT00564031|DRUG|placebo|daily
40942283|NCT04512170|DRUG|HEC585|single or Mulltiple doses up to 10 days
40942284|NCT04512170|DRUG|placebo|single or Mulltiple doses up to 10 days
41283712|NCT00095121|DRUG|Placebo (PLB)|Matching placebo
41283713|NCT00095121|DRUG|Adefovir Dipivoxil (ADV)|10-mg tablet or 2-mg/mL oral suspension
41283714|NCT00095121|DRUG|Lamivudine|100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration \>= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained \>= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
41283715|NCT05154851|BIOLOGICAL|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
41283716|NCT02607215|DRUG|Vinorelbine|25 mg/m2, D1, D8
41283717|NCT02607215|DRUG|DDP|75 mg/m2, D1
41283718|NCT01186432|DRUG|PDS 1.0|
41283719|NCT00984451|BIOLOGICAL|Plasma collection following infection or vaccination with influenza A|High titer influenza A plasma collection for use as therapeutic plasma in influenza treatment studies.
41283720|NCT06117592|OTHER|Education, training and assessment intervention|Staff competence assessment documents for acute oncology knowledge and skills
41283721|NCT03607227|DRUG|Levobupivacaine|Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
41283722|NCT03607227|DRUG|Saline Solution|Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
41283723|NCT01652196|BIOLOGICAL|aflibercept|4 mg/kg as a 1-hour IV(intervenous) infusion
41283724|NCT01652196|DRUG|oxaliplatin|85 mg/m2 IV infused over 2 hours
41283725|NCT01652196|DRUG|leucovorin|200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
41283726|NCT01652196|DRUG|fluorouracil|400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
41283727|NCT01652196|OTHER|Correlative Studies|Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
41451739|NCT00564031|DRUG|Femanest plus Gestapuran|combined daily
41451740|NCT00197938|PROCEDURE|Measurement of rectal lactic acid.|
41451741|NCT04423380|DRUG|SH3051 capsule treatment|Starting dose 20mg,oral administered twice daily.If tolerated subsequent cohorts will test increasing doses (40mg,60mg,80mg,100mg) of SH3051.
40942285|NCT03206437|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
40942286|NCT03206437|BEHAVIORAL|Waitlist|This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
40942287|NCT04676217|PROCEDURE|Postoperative positioning advice|The postoperative positioning advice until 3 am the same day.
40942288|NCT03606629|DEVICE|Endoprosthesis implantation|Endoprosthesis implantation by Percutaneous Angioplasty
40942289|NCT05305339|OTHER|Placental and Umbilical cord biopsy|After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
40942290|NCT02354183|BEHAVIORAL|DBT Skills Training|Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
40942291|NCT01641510|DRUG|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
40942292|NCT01641510|DRUG|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
40942293|NCT00931736|DRUG|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
40942294|NCT00931736|DRUG|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
40942295|NCT03309644|OTHER|Peripheral nerve blockade|Participants who receive a peripheral nerve block identified through the medical chart.
40942296|NCT03309644|OTHER|No peripheral nerve blockade|Participants who did not receive a peripheral nerve block identified through the medical chart.
40942297|NCT06150755|PROCEDURE|implant supported overdenture by ball|overdenture supported by two implant with ball attachment
40942298|NCT06150755|PROCEDURE|implant supported overdenture by bar|overdenture supported by two implant splinted by intraoral welding titanuim bar
40942299|NCT02586285|DRUG|S-Adenosyl Methionine|500mg-1000mg,iv,qd
40942300|NCT04460456|DRUG|SBT6050|Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2
40942301|NCT04460456|DRUG|pembrolizumab|400 mg IV
40942302|NCT04460456|DRUG|Cemiplimab|350 mg IV
40942303|NCT00187759|DRUG|cephalexin|
40942304|NCT03003611|PROCEDURE|hypnose sedation|Patient will be anesthetized with an hypnose sedation and a complement with light anesthesia
40942305|NCT03003611|PROCEDURE|general anesthesia|Patient will be anesthetized with a classical general anesthesia
40942306|NCT00846287|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
40942307|NCT00846287|DRUG|Placebo|Subject will inhale a placebo (nebulized saline) with no drug.
40942308|NCT00846287|DRUG|Aformoterol|Subjects will receive the drug arformoterol prior to scanning
40942309|NCT04866329|OTHER|Blood sample|Additional blood sampling at the end of ovarian stimulation monitoring (the eve of the oocyte pick-up)
40942310|NCT04866329|OTHER|Urine sample|Collection of the first urine in the morning on the day of the oocyte pick-up
40942311|NCT04866329|OTHER|Follicular fluid and granulosa cells sample|Collection of follicular fluid and granulosa cells during oocyte pick-up.
40942312|NCT01370668|BEHAVIORAL|Functional remediation|"The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management."
40942313|NCT01370668|BEHAVIORAL|Psychoeducation|Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.
40942314|NCT01370668|BEHAVIORAL|Treatment as usual|The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
40942315|NCT00092768|DRUG|MK0663, etoricoxib|
40942316|NCT00092768|DRUG|Comparator: celecoxib|
40942317|NCT05658536|BEHAVIORAL|6-Week Self-Management Group|The goal of the 6-session group-based intervention for patients with Post-COVID is to teach patients behavioral strategies known to be helpful in managing several common Post-COVID symptoms, including fatigue, memory and attention issues, poor sleep, breathlessness, coping with anxiety and uncertainty, and stress management. It is currently available to patients who are seen in the Post-COVID-19 Rehabilitation and Recovery Clinic at UW and the Post-COVID-19 Clinic in VAPSHCS Rehabilitation Care Services.
41267159|NCT01111266|DEVICE|xevonta|"Patients will be treated with 3 different sizes of xevonta (2 weeks each size) for determination of in vivo KUF following FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers. In addition blood samples will be collected for determination of removal rates of different small molecules and protein."
41267160|NCT02397473|DRUG|Galcanezumab|Administered SC
41451742|NCT06024980|PROCEDURE|Open partial horizontal laryngectomy(OPHL), Type I-III|An open partial horizontal laryngectomy(OPHL) was performed for patients with T2 supraglottic and glottic carcinoma, according to the American Joint Committee on Cancer(AJCC) criteria. Type I OPHL: Entails the resection of the supraglottis, including the pre-epiglottic space and the upper half of the thyroid cartilage. Type II OPHL: Entails the resection of the entire thyroid cartilage, with the inferior limit represented by the upper edge of the cricoid ring. Type III OPHL: Entails the resection of the entire supraglottic, glottic, and part of the subglottic sites, sparing both or at least one functioning crico-arytenoid unit.
40942318|NCT05184556|BEHAVIORAL|Family-based treatment (FBT)|FBT is a structured behavioral treatment focused on empowering caregivers to take charge of the adolescent's eating behavior and return him/her to a normative weight and developmental trajectory. FBT involves three consecutive phases: 1) caregivers are fully in control of the adolescent's eating; 2) control of eating is gradually returned to the adolescent; and 3) developmental issues are explored. In the current study, FBT is adapted for delivery in the home setting in the following ways: intensified dose of treatment (2-6 hours of therapy per week over 10 - 32 weeks); use of clinician as an additional support to the family; multiple family meals in the home and community; sociocultural tailoring; and inclusion of supplemental individual work with the adolescent to improve emotion regulation/distress tolerance.
41451743|NCT06024980|PROCEDURE|Transoral endoscopic laser cordectomy|"For patients with T1 glottic laryngeal carcinoma, according to the criteria of the American Joint Committee on Cancer(AJCC), transoral endoscopic CO2 laser(2-40Watts) cordectomy was performed. The classification comprises eight types of cordectomies:~* A subepithelial cordectomy (type I) is a resection of the epithelium of the vocal fold.~* A subligamental cordectomy (type II) is a resection of the epithelium, Reinke's space, and vocal ligament.~* Transmuscular cordectomy (type III), which proceeds through the vocalis muscle.~* Total cordectomy (type IV).~* Extended cordectomy encompasses the contralateral vocal fold and the anterior commissure (type Va).~* Extended cordectomy, which includes the arytenoid (type Vb).~* Extended cordectomy, which encompasses the subglottis (type Vc).~* Extended cordectomy, which consists of the ventricle (type Vd)."
41451744|NCT01663662|DRUG|Tolvaptan|
41451745|NCT01663662|DRUG|placebo|
41451746|NCT00611650|DRUG|defined green tea catechin extract|Given orally
41451747|NCT00611650|OTHER|placebo|Given orally
41451748|NCT04223349|DRUG|JNJ-70033093|JNJ-70033093 capsules will be administered orally .
41451749|NCT04223349|DRUG|Placebo|Matching placebo in capsule will be administered orally.
41267161|NCT02397473|DRUG|Placebo|Administered SC
41267162|NCT00177515|BEHAVIORAL|"video doctor, computer module"|computerized counseling about emergency contraception and peri-conception folate
41267163|NCT02002702|DRUG|Serelaxin|Intravenous infusion
41267164|NCT02002702|DRUG|Placebo|Placebo
41267165|NCT05503355|DRUG|BST-236|"In part 1: During the induction (in combination with venetoclax), the BST-236 doses are:~In cohort 1 - 2.3 g/m2/d X6 days In cohort 2 - 2.3 g/m2/d X6 days In cohort 3 - 4.5 g/m2/d X6 days In cohort 4 - 4.5 g/m2/d X6 days In cohort 5 - 4.5 g/m2/d X6 days In part 1: During maintenances (for responding patients) the BST-236 dose- 4.5 g/m2/d X6 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
41267166|NCT05503355|DRUG|venetoclax|"In part 1: During the induction (in combination with BST-236), the venetoclax doses are:~In cohort 1 - 200 mg QD X 7 days In cohort 2 - 400 mg QD X 7 days In cohort 3 - 200 mg QD X 7 days In cohort 4 - 400 mg QD X 7 days In cohort 5 - 200 mg QD X 14 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
41267167|NCT04206878|DIAGNOSTIC_TEST|Point-of-care birth test|Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers
41267168|NCT00130338|DRUG|Rivastigmine|
41267169|NCT02766660|DEVICE|Optical Coherence Tomography|All groups were measured by optical coherence tomography.
41267170|NCT04639323|DIAGNOSTIC_TEST|Endoscopic ruler|"Endoscopic ruler for varices in portal hypertension~Product uses: measuring the diameter of the veins under the endoscopy for the assessment of the risk of variceal haemorrhage in patients with portal hypertension~Black and white measuring rule is highly recognizable under the endoscopy~The width of each cell is 1 mm, and the measuring range is 0-10 mm~With smooth edge, safe and reliable"
41267171|NCT04947527|DRUG|Test varnish|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
41267172|NCT04947527|DRUG|Placebo|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
41267173|NCT04426695|DRUG|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
41267174|NCT04426695|DRUG|Placebo|Placebo IV Single Dose
41267175|NCT01082484|DRUG|treprostinil|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
41267176|NCT01082484|DRUG|iloprost|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
41267177|NCT01082484|DRUG|NaCl 0.9%|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
41267178|NCT03696992|PROCEDURE|Tandem colonoscopy|Tandem colonoscopy with different image modalities
41267179|NCT05210504|DRUG|L-Lysine|5g L-lysine in 50ml water, administered orally
41267180|NCT05210504|DRUG|Normal Saline|Normal (0.9%) Saline
41267181|NCT02773966|RADIATION|Kypho-IORT|During kyphoplasty/vertebroplasty a intraoperative radiotherapy of the affected vertebrae is done with a miniature X-ray generator (INTRABEAM®, Carl Zeiss, Surgical, Oberkochen, Germany). The prescription dose will be 8 Gy in a distance of 13 mm from the isocenter of the radiation source. IORT will take about five minutes. After radiation the applicator will be removed and the operation will be finished as usual.
41267182|NCT02773966|RADIATION|EBRT|The external beam radiotherapy will be usually carried out as an outpatient procedure. All patients will receive a planning CT before the first irradiation. EBRT will be performed with 30 Gy, added in 3 Gy per fraction or 8 Gy single dose (only for international study centers, not permitted in Germany) on a conventional linear accelerator (LINAC).
41267183|NCT06075823|DEVICE|TEER|transcatheter edge-to-edge mitral valve repair for significant mitral regurgitation
41283728|NCT01652196|PROCEDURE|DCE MRI|Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
41283729|NCT01652196|RADIATION|f18FDG-PET|18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
41283730|NCT01652196|PROCEDURE|PET (positron emission tomography)|Correlative studies
41283731|NCT04327648|DEVICE|Social interaction treatment|Children in social interaction treatment group will have 30min social interaction each day for 3 months.
41283732|NCT04327648|DEVICE|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months.
41283733|NCT04327648|OTHER|Routine treatment|Children in routine treatment group will keep the same initial treatment.
41283734|NCT03195140|DEVICE|Predictive Low Glucose Suspend|Application of Predictive Low Glucose Suspend
41283735|NCT03364218|DRUG|N-Acetyl Cysteine|Nebulized N-Acetyl Cysteine administered every 12 hours
41283736|NCT06214728|PROCEDURE|Hyaluronic acid gel application|HA gel was applied to the periodontal pockets where the intraosseous defect was located using a sterile injector with a plastic needle. The gel was applied until it overflowed from the gingival sulcus. Patients were instructed not to eat, drink or brush their teeth for at least one hour. Subgingival application of HA was repeated 4 weeks after the first session.
41283737|NCT06214728|PROCEDURE|Placebo gel application|The control group received placebo HA gel probe without rinsing. Placebo application was repeated 4 weeks after the first session.
41283738|NCT02327650|PROCEDURE|The examinations for bones in joints of OA and RA patients|
41283739|NCT06109909|DEVICE|Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation|The EEG interface device is a J\&J Engineering 1-330 C2 box. The software used to determine LIP-tES feedback patterns was developed by Neurogen High Performance Neurofeedback. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+,A-,B+,B-), with respect to the Common Neck Reference. During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scale to record EEG signals. All four (A+,A-,B+,B-) electrodes are involved in applying weak electrical pulses back to the brain (feedback process). The brief feedback pulse (\~100mV) is adaptive and determined based on the offset of the frequency spectrum recorded across the left and right hemisphere (A vs. B) electrodes in the time window immediately prior to stimulation.
41283740|NCT00736229|DRUG|Exenatide|0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
41283741|NCT04207710|DRUG|Gebauer's Pain Ease Top Aerosol Mist Spray|Topical refrigerant spray
41283742|NCT04207710|DRUG|Gebauer's Ethyl Chloride|Topical refrigerant spray
41283744|NCT03085069|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
41283745|NCT00843986|DRUG|conivaptan|Premix bag
41283746|NCT00843986|DRUG|placebo|Premix bag
41283747|NCT01923064|DRUG|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
41283748|NCT01923064|DRUG|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
41283749|NCT05766735|BEHAVIORAL|Routine Care + Glycemic Excursion Minimization (RC+GEM)|In addition to receiving routine care, participants will receive GEM, a structured, self-directed, and personalized program that will allow participants with pre-diabetes to improve their metabolic status by illustrating the effects of their routine food and physical activity choices on their blood glucose levels and variability.
41283750|NCT05766735|OTHER|Routine Care (RC)|RC participants will meet with their primary care provider to determine the best diabetes medication and proper dose. The participant will be allowed to change medications, or use a combination of medications, that is best suited for their care during the duration of the study. The study team will not influence these decisions.
41283751|NCT02139189|DEVICE|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
41283752|NCT01374698|DRUG|Aspirin|Aspirin 325 mg
41283753|NCT06028815|BEHAVIORAL|Group music therapy|Music therapy intervention using active and receptive techniques, focusing on the technique of songwriting.
41283754|NCT06146114|DIAGNOSTIC_TEST|Collect HER2 expression in prostate cancer patients|HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023
41451750|NCT06312462|BEHAVIORAL|health education|In the intervention group, we provide schistosomiasis health education to students once a month through community health volunteers for a duration of six months. After that, the community health volunteers no longer visit the school for health education until the completion of a one-year follow-up period.
41451751|NCT04084795|BEHAVIORAL|Eye Movement Desensitization and Reprocessing therapy|"EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation."
41451752|NCT04084795|OTHER|Multifocal transcranial Current Stimulation|MtCS represents a promising intervention option, given its capacity to modulate cerebral excitability in a simple, safe manner. F3 anodal; AF3, FC1, FC3, FC5, F5, return montage will be used with the anode over the left DLPFC. Half of the patients will receive active stimulation and the other half sham stimulation. Active stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions. The same protocol and montage will be used for sham stimulation.
41451753|NCT03122522|DRUG|ipilimumab|ipilimumab 3mg/kg
41283755|NCT02237027|BIOLOGICAL|TasP using ART regimen as per Benin guidelines|Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
41283756|NCT02237027|BIOLOGICAL|PrEP using Truvada|Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
41283757|NCT03322137|DRUG|SNA-120|Pegcantratinib ointment
41283758|NCT03322137|DRUG|Vehicle|Placebo ointment to mimic Pegcantratinib ointment
41283759|NCT05316363|OTHER|OMT|"Suboccipital Release - Finger pads are placed onto suboccipital musculature and a smooth, gentle, and rhythmic laterocephalad traction is applied to reduce muscle tension.~Paraspinal Inhibition - Hands are placed under the patient's thoracolumbar spine and contract the erector spinae tissue to draw the thoracolumbar spine into extension and hold until relaxation is felt.~Rib Raising - Hands are placed under the subject's thorax and contact the rib angles with finger pads. Fingers are flexed while adding an anteriolateral traction directed at the rib angle while maintaining neutral wrists. Arms are used as a lever by leaning forward thus creating a fulcrum with the treatment table with a smooth, rhythmic motion. This motion is repeated several times throughout the entire thoracic region, unilaterally and then switch sides.~Diaphragm Release - Hands apply a gentle pressure until a barrier or point of ease of the fascia is felt and hold that position until tissue response is felt."
41283760|NCT00482846|BIOLOGICAL|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is \>40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
41283761|NCT00482846|DRUG|melphalan|"Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. \<60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
41451754|NCT03122522|DRUG|nivolumab|nivolumab 1mg/kg
40756835|NCT01485367|DRUG|adapalene gel 0.3%|A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand \& extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand \& extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right \& left forearms.
41283762|NCT00482846|OTHER|questionnaire administration|Day -5 to Day +28
41283763|NCT00482846|PROCEDURE|autologous peripheral blood stem cell transplantation|Day 0
41283764|NCT00482846|OTHER|quality-of-life assessment|Day -5 to Day +28
41283765|NCT05462093|DEVICE|Liver Multiscan sequences|Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.
41283766|NCT05462093|DEVICE|Liver Multiscan analysis|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
41283767|NCT05462093|DEVICE|MRCP+|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
41283768|NCT05606705|DIETARY_SUPPLEMENT|Baked Milk|Participants to regularly eat a baked milk muffin for 6 weeks
41283769|NCT01096667|DRUG|Placebo to Ertuglilflozin 1 or 5 mg|Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
41283770|NCT01096667|DRUG|Ertugliflozin 1 mg|Ertugliflozin tablet 1 mg once daily for 28 days
41283771|NCT01096667|DRUG|Ertugliflozin 5 mg|Ertugliflozin tablet 5 mg once daily for 28 days
41283772|NCT01096667|DRUG|Ertugliflozin 25 mg|Ertugliflozin tablet 25 mg once daily for 28 days
41283773|NCT01096667|DRUG|HCTZ 12.5mg|Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
41283774|NCT01096667|DRUG|Placebo to HCTZ|Placebo to HCTZ 12.5 mg capsule once daily for 28 days
41283775|NCT01096667|DRUG|Placebo to ertuglilflozin 25 mg|Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
41283776|NCT01917331|DRUG|Beclometasone/Formoterol/Glycopyrrolate|Active drug tested
41283777|NCT01917331|DRUG|Beclometasone/Formoterol|Active comparator
41283778|NCT00377962|DRUG|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
41283779|NCT00377962|DRUG|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
41283780|NCT00377962|DRUG|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
41283781|NCT00377962|DRUG|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
41267184|NCT06075823|OTHER|Optimal Medical Therapy|optimal heart failure management of ATTR-CM
41267185|NCT05733377|DIAGNOSTIC_TEST|Arrow Test|It consists of taking the widest measurement between the rope of a plumb bob on her upper and lower back.
41267186|NCT05733377|DIAGNOSTIC_TEST|Angle measurement by imaging device|First, three anatomical landmarks are located, and a sticker is placed on each of them: the 12th thoracic vertebra at its intersection with the midline descending from the axilla, the greater trochanter, and the anterior superior iliac spine. After this, the woman will be asked to stand in a normal position facing forward with her hands crossed over her shoulders, and a picture will be taken and pixelated with anything that could identify her. The angle formed by the three stickers will be measured with this image and the software.
41267187|NCT06146894|PROCEDURE|Single obturation technique (Bioceramic Sealer)|Root canal will be obturated using single cone technique using Bioceramic Sealer
41267188|NCT06146894|PROCEDURE|lateral condensation technique (Bioceramic Sealer)|Root canal will be obturated using lateral condensation technique using Bioceramic Sealer
41267189|NCT06146894|PROCEDURE|Warm Vertical condensation technique (Bioceramic Sealer)|Root canal will be obturated using vertical condensation technique using Bioceramic Sealer
41267190|NCT06146894|PROCEDURE|lateral condensation technique (AH Plus Sealer)|Root canal will be obturated using lateral condensation technique using AH plus Sealer
41267191|NCT06146894|PROCEDURE|Warm Vertical condensation technique (AH plus Sealer)|Root canal will be obturated using vertical condensation technique using AH plus Sealer
41267192|NCT00691665|DRUG|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
41267193|NCT00691665|DRUG|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
41267194|NCT00699179|DRUG|biphasic insulin aspart 30|There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
41267195|NCT01142414|BIOLOGICAL|panitumumab|
41267196|NCT01142414|DRUG|cisplatin|
41267197|NCT01142414|DRUG|fluorouracil|
41267198|NCT01142414|OTHER|laboratory biomarker analysis|
41267199|NCT01142414|PROCEDURE|adjuvant therapy|
41267200|NCT01142414|PROCEDURE|quality-of-life assessment|
41267201|NCT01142414|RADIATION|3-dimensional conformal radiation therapy|
41267202|NCT01142414|RADIATION|intensity-modulated radiation therapy|
41267203|NCT03894345|DRUG|Prazosin|Competitive alpha-1 adrenergic receptor blocker which has been used to treat PTSD and Benign Prostatic Hypertrophy
41267204|NCT03623919|OTHER|FallSensing multiplayer games|"FallSensing multiplayer games is a technological solution based on an interactive (exer)game.~Players will wear a strap on the lower limbs contaning an inertial sensor. This device enables movement identification on the characterization in real time, triggering actions in the game.~The exercise games are based on a validated fall prevention exercise plan - the Otago Exercise Programme. The exercises were designed to promote mobility and improve muscle strength and balance."
41267205|NCT02495948|DEVICE|Lotrafilcon B contact lenses|
41267206|NCT02495948|DEVICE|Samfilcon A contact lenses|
41267207|NCT02495948|DEVICE|Hydrogen peroxide solution|Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
41267208|NCT02495948|DEVICE|Saline solution|Used for rinsing contact lenses, as needed
41267209|NCT03543085|DEVICE|GiMer Medical MN 1000 External Stimulator|Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
41283782|NCT00228371|DEVICE|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
41283783|NCT04273984|DRUG|Misoprostol|Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.
41283784|NCT02240628|DEVICE|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
41283785|NCT02240628|DRUG|Saline|Patients in arm 2 will receive Saline with the Propofol.
41283786|NCT02240628|DRUG|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
40942319|NCT05184556|BEHAVIORAL|Integrative family therapy|The integrated family therapy approach includes psychoeducation, supportive family therapy, and elements of cognitive-behavioral interventions. Families may be referred for additional nutritional counseling and prescribed a meal plan as indicated. Typical strategies include educating families on the presentation and prognosis of adolescent AN; identifying dysfunctional family structures/alliances and communication patterns; using reflective listening to engage and validate family members; challenging maladaptive beliefs about eating and weight; and supporting families in developing strategies for management of both general and eating disorder-specific distress. Treatment is generally non-directive.
41283787|NCT03952650|DRUG|Chloroquine Phosphate|Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
40942320|NCT02580903|RADIATION|Radiology|Only a small subsample will require CT and right heart catherisation
40942321|NCT02149875|DRUG|Dl-3-n-butylphthalide|Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
41283788|NCT03952650|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
41283789|NCT03952650|DRUG|Pyrimethamine|"Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses."
41283790|NCT03952650|DRUG|Coartem|Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
41283791|NCT03952650|DRUG|ibuprofen|Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
41283792|NCT03246438|BEHAVIORAL|Colonoscopy only|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
41283793|NCT03246438|BEHAVIORAL|Colonoscopy outreach + mailed FIT follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
40942322|NCT02149875|DRUG|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
41283794|NCT03246438|BEHAVIORAL|Colonoscopy + Mailed FIT outreach and follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
41451755|NCT04710290|DIETARY_SUPPLEMENT|Beta-Glucan|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
40942323|NCT02149875|DRUG|Placebo|100 ml saline intravenous infusion once daily for 10 days.
41132177|NCT06523478|PROCEDURE|Subcutaneous immunotherapy (SCIT)|Injection requires shaking bottle 20x to mix drug for consistency. Verify patient name \& concentration. Use 1 ml skin test syringe for deep subcutaneous injection at 45° angle, 1 cm into outer upper arm. Lift skin folds for deeper injection, avoid subcutaneous, muscular or intravascular. Inject slowly, 1 min for 1 ml. Avoid shallow injections which may cause local side effects. Alternate between left \& right arm for 5 min after injection for compression.
41132178|NCT02757469|DRUG|Drospirenone and ethinyl estradiol combination (Yasmin)|Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
41132179|NCT01218659|DRUG|migalastat hydrochloride|150-mg capsule administered orally QOD
41132180|NCT01218659|BIOLOGICAL|agalsidase|Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
41132181|NCT01619059|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
41451756|NCT04710290|DIETARY_SUPPLEMENT|Glutamine|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
40942324|NCT01295229|PROCEDURE|laparoscopic Roux-en-Y gastric bypass (RYGB) procedure|The laparoscopic Roux-en-Y gastric bypass (RYGB) procedure is the most commonly performed bariatric procedure in the United States. Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons, using a 90-cm alimentary limb, 50-cm biliopancreatic limb, antecolic/antegastric approach, and totally stapled technique.
40942325|NCT01295229|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention includes behavior-modification skills counseling combined with training in diet and exercise change. The focus of the exercise intervention is a gradual increase in brisk walking or other activities of similar moderate aerobic intensity. The exercise prescription will consist of at least 45 minutes of exercise, 5 days per week for 12 months. The diet intervention will be conducted by a research dietician with training in behavior modification, with supervision by Dr. Foster-Schubert. In week 1 the dietician will meet for a 60-minute individual session with participants at the FHCRC Prevention Center. Over the next 23 weeks the dietician will conduct one 30-minute group session per week.
40942326|NCT01885871|DEVICE|Picosecond QS Nd:YAG Laser|Up to 2 laser treatments delivered 6 weeks apart
41451757|NCT04710290|DIETARY_SUPPLEMENT|Immunoglobuin|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
41451758|NCT04710290|DIETARY_SUPPLEMENT|Corn starch|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
41451759|NCT05040737|DEVICE|PS membrane versus PMMA membrane,|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
40756836|NCT03678857|DIETARY_SUPPLEMENT|Creatine|"Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes)."
40942327|NCT00608972|DRUG|Doxil|Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
40942328|NCT00608972|DRUG|Carboplatin|Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
40942329|NCT00608972|DRUG|Bevacizumab|Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
41132182|NCT01619059|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
41132183|NCT01619059|DRUG|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
41132184|NCT01619059|DRUG|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
41267210|NCT01779284|DRUG|Travoprost/timolol therapy|Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
41267211|NCT01779284|DRUG|Latanoprost/Timolol therapy|Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
41267212|NCT04508907|DRUG|Mavyret|Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients
41267213|NCT02113787|PROCEDURE|Pharmacokinetic study|Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
41267214|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Bicruciate retaining|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
41267215|NCT04334304|PROCEDURE|Robot-assisted Total Knee Arthroplasty|A total knee arthroplasty will be performed with robot-assistance (NAVIO).
41267216|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Posterior Stabilized|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
41267217|NCT02412280|OTHER|retrospecive observational|
41267218|NCT05123235|BEHAVIORAL|Physical Activity|the participants will be encouraged to set their own physical activity goals weekly and using behavioral strategies work towards meeting those goals. The behavioral strategies will be discussed weekly for 30 minutes a telehealth method.
41267219|NCT00714779|DRUG|Fluoxetine|20-40 mg / day orally
41267220|NCT00714779|BEHAVIORAL|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
41267221|NCT01268293|DRUG|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
41267222|NCT02914509|DRUG|Travoprost|
41267223|NCT02914509|OTHER|Placebo Vehicle|
41267224|NCT05163704|DRUG|Dexmedetomidine|Dexmedetomidine is a beneficial sedative for children. It provides a sedation equivalent to a natural deep sleep with negligible respiratory effects. Administration via the nose provides better absorption and faster impact effect. The drug does not taste and does not sting when administered.
41267225|NCT01002508|BIOLOGICAL|Influenza vaccine|One dose of influenza vaccine
41267226|NCT03312192|DEVICE|Interbody Cage|Anterior cervical discectomy and fusion with interbody cage placement
40942330|NCT05235243|OTHER|Online therapeutic intervention for maladaptive daydreaming based on mindfulness and self-monitoring|An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
40942331|NCT05235243|OTHER|Online therapeutic intervention for maladaptive daydreaming based on mindfulness|An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
40942332|NCT01285453|DRUG|vadimezan|
40942333|NCT04965051|DRUG|insulin degludec/insulin aspart (IDegAsp)|To evaluate the efficacy and safety of the IDegAsp in T1DM
41283795|NCT05968274|DEVICE|Rebox-Physio 4 (real stimulation)|Rebox-Physio 4 is a CE-certified medical device class IIa. The device is a voltage-controlled generator of specific DC electric pulses with voltage amplitude 0-21 V, current intensity up to 200 uA, rectangular pulse shape, pulse frequency 3000 Hz and pulse duration 0.25 ms. Rebox currents are applied locally at the site of pain non-invasively transcutaneously with a touch of a flexible pin active treatment electrode (cathode) while the patient holds a cylindrical electrode (anode) to close electric circuit. Stimulation time in one point is 3-5 seconds until the current intensity reaches stable target values of 140-160 uA. During one session, total 20-50 points are systematically treated at a mutual distance of approx. 2 cm over the target region.
41451760|NCT04922957|DRUG|ALLOCETRA-OTS|The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
41451761|NCT04922957|OTHER|Placebo|Ringer's lactate solution
41451762|NCT03314857|DEVICE|SAPIEN XT THV with the NovaFlex+ delivery system|Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
40942334|NCT04965051|DRUG|basal insulin plus pre-prandial insulin|To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM
40942335|NCT02876744|OTHER|ophthalmologic examination|ophthalmologic examination including optical coherent tomography with angiography module
40942336|NCT01863238|OTHER|Ophthalmologic examinations|Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
40942337|NCT01863238|DRUG|Ivacaftor Exposed|
40942338|NCT02525276|BEHAVIORAL|exercise|The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.
41132185|NCT04169776|DEVICE|Transcutaneous Auricular Vagus Nerve (taVNS) stimulation|Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
41132186|NCT01341132|PROCEDURE|MRI Scan of the Liver enhanced with Eovist|10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
40942339|NCT02525276|DRUG|Hormone treatment|"Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat"
40942340|NCT01420653|DRUG|Maxigesic 325|Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
40942341|NCT01420653|DRUG|Acetaminophen|Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
40942342|NCT01420653|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
40942343|NCT01420653|DRUG|Placebo|placebo, three tablets four times a day, with food for 48 hours
41283796|NCT05968274|DEVICE|Rebox-Physio 4 (sham stimulation)|"In the sham stimulation, the comparator will be a visually identical sham version of the real Rebox-Physio 4.The sham device has a resistor installed at the output generating current of negligible intensity (maximum 1 uA) assuming no relevant physiological effect. The application procedure will be identical to the real device. When applied to the patient, the sham device displays false voltage and current intensity values and responds to the operator´s actions in real time mimicking the real stimulation. The operator is therefore blinded."
41283797|NCT00768378|DEVICE|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
41283798|NCT05190835|DEVICE|Optical scanner|During the visits (Day 0 before surgery, Day 8, Day 21, Day 45, Month 3 and Month 6 after surgery), a measurement of the volume and the perimeter of the patient's two feet is carried out (operated foot and control foot). The edema is measured by a non-invasive method using an optical scanner (camera + laser scanning). The image processing software accompanying this tool has an automatic calculation of the volumes and the different perimeters of the foot. The measurement time by the scanner is less than 4 seconds.
41283799|NCT02764879|DIETARY_SUPPLEMENT|Omega 3 fatty acids|omega3 received 2 times daily-for 6 months
41283800|NCT02764879|PROCEDURE|scaling and root planing|
41283801|NCT02764879|OTHER|placebo soft gelatin capsules|placebo soft gelatin capsules received 2 times daily-for 6 months
41283802|NCT01057264|DRUG|HAI Abraxane|Starting dose: 120 mg/m\^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
41283803|NCT01057264|DRUG|Gemcitabine|Starting dose: 600 mg/m\^2 by IV on Days 1 and 8 of 21 day cycle
41283804|NCT01057264|DRUG|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
41283805|NCT01057264|DRUG|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
41283806|NCT03497689|DRUG|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)
41283807|NCT00995371|DEVICE|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
41283808|NCT00995371|DRUG|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
41283809|NCT00526201|BEHAVIORAL|12-weeks EnhanceFitness|EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
41283810|NCT00526201|BEHAVIORAL|Control|Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
41283811|NCT00465569|DRUG|cow's milk powder|Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
41283812|NCT00465569|OTHER|Placebo|
41283813|NCT04439734|DEVICE|Electromyostimulation|WB-EMS once per week 20 min for 16 weeks
41283814|NCT02305433|OTHER|Home-based physiotherapy (physical exercise)|Each physiotherapy (physical exercise) session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
41283815|NCT01519843|DEVICE|transcranial direct current stimulation tDCS|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
41283816|NCT01519843|DEVICE|transcranial magnetic stimulation TMS|TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
41283817|NCT02691273|BEHAVIORAL|cellular application treating diabetes using breathing technique|
41283818|NCT04775043|DIAGNOSTIC_TEST|HFRDIS questionnaire completion|HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
41283819|NCT03340350|DRUG|Minocycline|Minocycline capsule
41283820|NCT04300725|OTHER|Video Counseling|Patients in the other study arm receive verbal + video counseling prior to their induction of labor.
41283821|NCT00728338|DIETARY_SUPPLEMENT|Docosahexenoic acid (DHA)|The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
41283822|NCT00728338|DIETARY_SUPPLEMENT|Olive oil|7.5 g olive oil/day
41132187|NCT05599815|DRUG|ADX-629|ADX-629 (250 milligrams) administered twice daily
41132188|NCT02305498|OTHER|Vigorous yoga practice|
41132189|NCT02305498|OTHER|Restorative (gentle) yoga practice|
41132190|NCT04508777|BEHAVIORAL|Saliva-based testing|Participants will take part in a voluntary COVID-19 screening program that includes bi-weekly saliva-based testing.
41132191|NCT04288167|DIAGNOSTIC_TEST|Sample collection|Samples of urine and saliva will be collected from participants using customary sample collection means.
41132192|NCT01989052|DRUG|CTO|
41132193|NCT01989052|DRUG|Lomustine|
41132194|NCT00605306|DRUG|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
41132195|NCT00605306|DRUG|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
41132196|NCT04157894|OTHER|Standard long-lasting insecticidal net|Interceptor® (BASF) contains a pyrethroid insecticide
41132197|NCT04157894|OTHER|Chlorfenapyr insecticide treated net|Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
41132198|NCT04157894|OTHER|Piperonyl butoxide long-lasting insecticidal net|PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
41132199|NCT05089487|PROCEDURE|Nocturnal rest (sleep study)|Proportion of patients free of severe hypoxemia without oxygen therapy during nocturnal rest .
41132200|NCT01411566|BEHAVIORAL|Skills trainig for patients with dual diagnosis|Skills trainig for patients with dual diagnosis
40942344|NCT04000230|BEHAVIORAL|TCIT|"TCIT consists of the following:~* CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~* CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~* TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~* TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks."
41283823|NCT02180386|BEHAVIORAL|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.|videogame can be considered as a method of distraction.
41451763|NCT01135784|DIETARY_SUPPLEMENT|MIGRA-ZEN RELIEF PLUS|one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
41451764|NCT01135784|DIETARY_SUPPLEMENT|Placebo for Migrazen relief plus|2 capsule dose per 24 hours for 90 days
40942345|NCT04000230|BEHAVIORAL|Booster|Teachers in the Intervention group will receive additional booster sessions during the second half of the school year. Booster sessions consist of coaching teachers in CDI and TDI skills. Teachers receive 4-8 booster sessions.
40942346|NCT03578757|BEHAVIORAL|21-day residential program|"Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes...). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up."
41283824|NCT01594723|DRUG|120 mg LY2784544|Administered orally
40942347|NCT00392821|DRUG|Sorafenib|Sorafenib
40942348|NCT00392821|DRUG|RAD001|RAD001
40942349|NCT03374631|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks and self-report measures to assess paranoid ideation
41132201|NCT01411566|BEHAVIORAL|regular treatment|regular treatment
41132202|NCT00474799|DRUG|MNS075|MNS075 7.5mg q1h MNS075 15mg q3h
41283825|NCT00385021|DRUG|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
41283826|NCT04369339|OTHER|Colposcopy|
41283827|NCT04655586|DRUG|rNAPc2|two dose levels of rNAPc2
41283828|NCT04655586|DRUG|Heparin|standard of care heparin per institution (therapeutic or prophylactic regimen)
41283829|NCT00408681|DRUG|lithium carbonate|Given orally
41451765|NCT03385863|DRUG|Surfactant, Pulmonary，Curosurf|All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
41451766|NCT03385863|OTHER|Perinatal risk factors of NRDS|Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.
41451767|NCT05098223|BEHAVIORAL|Intervention to remove price promotions on unhealthy foods when online shopping|Removal of price promotions on unhealthy foods
41451768|NCT06448390|BEHAVIORAL|Physical training|The patients are randomized to either walking 30 minutes 3 times a week or lifting the body to a tip toe position three times a day until pain in the claves and then add another five liftings before ending the session
41451769|NCT00603499|DIETARY_SUPPLEMENT|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
41451770|NCT00603499|OTHER|Placebo|Subjects in the control group received inert placebo once per day during 4 months
41451771|NCT03304223|DIAGNOSTIC_TEST|[18F]FB-IL2 PET scan|\[18F\]FB-IL2 PET scan procedure
41451772|NCT01099007|BEHAVIORAL|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
41451773|NCT01099007|BEHAVIORAL|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
41132203|NCT00916409|DEVICE|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
41132204|NCT00916409|DRUG|Temozolomide|"maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles."
41283830|NCT00408681|OTHER|laboratory biomarker analysis|Correlative studies
41451774|NCT02225782|DRUG|Alteplase|Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
40942350|NCT03374631|DEVICE|sham tDCS|sham tDCS with behavioral tasks and self-report measures to assess paranoid ideation
40942351|NCT00051389|DRUG|Fosinopril|
40942352|NCT00976170|DRUG|GC33(RO5137382)|IV administration at 6 escalating dose levels.
40942353|NCT00976170|DRUG|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
40942354|NCT00503516|DRUG|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
40942355|NCT00503516|DRUG|Placebo|1 sachet of 160 mg of placebo b.i.d.
40942356|NCT03659786|OTHER|CC-Test|Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
40942357|NCT00992927|PROCEDURE|Capsule-Preserving Intra-articular Hydraulic Distension|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
40942358|NCT00992927|PROCEDURE|Capsule-Rupturing Intra-articular Hydraulic Distension|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
40942359|NCT00251355|DRUG|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
40942360|NCT00251355|DRUG|5-Fluorouracil|5-FU via continuous IV infusion.
40942361|NCT00251355|PROCEDURE|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
40942362|NCT03447184|DRUG|Androgen priming|"Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor"
40942363|NCT02245204|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
40942364|NCT02620007|DRUG|Ciprofloxacin|oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks
40942365|NCT02620007|DRUG|Rifaximin|oral Rifaximin 800 mg bid for 12 weeks
41283831|NCT03426046|PROCEDURE|Partial Pulpotomy|Partial removal of inflamed pulp tissue in cariously exposed teeth
41283832|NCT03426046|DRUG|Pulp Capping Agents|Biocompatible materials
41283833|NCT02625038|DEVICE|EUDAMED CIV-14-03-011940|
41283834|NCT00640783|BEHAVIORAL|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
41283835|NCT00640783|BEHAVIORAL|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, \<30%).
41283836|NCT03456115|DEVICE|Mechanical nasal dilator|Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
41283837|NCT03414125|OTHER|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
41451775|NCT03521362|DEVICE|MyT1DHero|MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.
40942366|NCT02620007|DRUG|Ciprofloxacin Placebo|a placebo of Ciprofloxacin bid for 12 weeks
40942367|NCT02620007|DRUG|Rifaximin Placebo|a placebo of Rifaximin bid for 12 weeks
40942368|NCT06090357|OTHER|Plantar pressure|Biomechanical functional assessments investigate specific variables: gait analysis, stabilometry, kinematics and kinetics of joint movements, activation, and strength of specific muscle groups.
40942369|NCT00950495|DEVICE|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
40942370|NCT00950495|DEVICE|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
40942371|NCT00950495|DEVICE|placebo|as a placebo, a thin (\< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
40942372|NCT04426201|DRUG|CYT107|IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
40942373|NCT04426201|DRUG|Placebo|Same number, volume and frequency of IM administration of saline
41451776|NCT03521362|DEVICE|Other T1D Mobile App|A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
41451777|NCT06363799|OTHER|4th ventricle compression technique|"For the CV4 the mediator's hands assume a specific position: one on top of the other, with the tips of the thumbs joined together in a V shape, positioned approximately on the process spinous between the patient's second and third cervical vertebrae, pointing downwards."
41451778|NCT06363799|OTHER|Sham Technique|The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 5 minutes.
41451779|NCT06363799|OTHER|Diaphragmatic breathing technique|For the diaphragmatic breathing the participant will place one hand on their chest and the other over their abdomen. Both of their hands will be overlapped by the mediator's, so it is easier to feel the correct breathing movements to be performed.
40942374|NCT05398926|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
40942375|NCT03436810|PROCEDURE|Motor imagery|Motor imagery (MI) will be trained for the individuals by imagination of the movement. Program of MI includes 1) body relaxation and awareness 2) visual imagery 3) kinesthetic imagery and 4) refocusing of body and environment.
40942376|NCT03436810|PROCEDURE|Health education|Topic of Health education (HE) consists of 1) Changes caused by stroke 2) Complications after stroke 3) Emotional changes after stroke 4) Living at home after stroke 5) High blood pressure and stroke and 6) Preventing recurrent stroke.
40942377|NCT03436810|PROCEDURE|Task-Oriented Circuit Class Training|Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.
40942378|NCT03048461|DEVICE|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to an area of alopecia
40942379|NCT03048461|DRUG|Placebo|intradermal injections to an area of alopecia
40942380|NCT02297243|DEVICE|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
40942381|NCT05631665|OTHER|Survey results before and after laser treatment|Determination of sexual activity rates as points with a questionnaire before and after laser treatment for patients with postmenopausal sexual function problems.
40942382|NCT04418284|OTHER|survey|online survey
40942383|NCT01749774|BEHAVIORAL|Physical activity counseling|
40942384|NCT00154726|DRUG|Paclitaxel-HDFL|
41267227|NCT03312192|DEVICE|Interbody Cage and Anterior Plating|Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
41267228|NCT04375306|PROCEDURE|RFR guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.
41267229|NCT04375306|PROCEDURE|Angio guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
41267230|NCT03478241|DEVICE|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
41267231|NCT03478241|DEVICE|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
41267232|NCT03478241|DEVICE|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
41267233|NCT05651945|OTHER|Cardiac rehabilitation program|The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.
41267234|NCT02522767|DRUG|Mesalamine|
41267235|NCT02522767|DRUG|Placebo|
41267236|NCT00937222|DIETARY_SUPPLEMENT|Peanuts and peanut butter|Peanuts and peanut butter
41267237|NCT02611401|BEHAVIORAL|Mindfulness|"The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.~The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life."
40942385|NCT04624438|OTHER|Isometric training with electromyostimulation|"Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The force intensity was determined individually during pretest where EMS was delivered at maximal tolerable dose. Electrical stimulation was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Stimulation characteristics were selected among the Compex commercially available strength programs. The stimulation intensity was monitored on-line and determined by the subject at the start of each EMS session according to his/her pain threshold to produce a force corresponding to at least 60% of the pretest MVC score."
40942386|NCT04624438|OTHER|Isometric training with voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). Participants were required to reach the proscribed force level only through voluntary activation of QF. To attain the same contraction/rest ratio as in EMS, automated audible signals were delivered in accordance with the contraction-rest pattern produced by the muscle stimulation device. To ensure participants produced 60% of individual MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
41283838|NCT03414125|OTHER|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences. Outreach includes: 1) invitation letter, 2) choice grid 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
41283839|NCT06476080|PROCEDURE|ultrasound guided erector spine block|Ultrasound guided thoracic erector spinae block
41283840|NCT06476080|PROCEDURE|Serratus anterior block|Ultrasound guided serratus anterior block
41283841|NCT04135781|DRUG|nab paclitaxel|nab paclitaxel （120mg/m2；iv；d1，8）
41283842|NCT04135781|DRUG|Tegafur|S-1 （\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）
40942387|NCT04624438|OTHER|Isometric training with combination of electromyostimulation and voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The proscribed force level was reached by the simultaneous action of EMS and VOLUNTARY. Each contraction was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Electrical stimulation corresponded to 30% of MVC, while the remaining 30% was achieved through voluntary muscle activation. To ensure participants produced a force corresponding to 60% of MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
40942388|NCT04223232|DRUG|[14C]-MD1003|single oral dose of 100mg \[14C\]-MD1003
40942389|NCT00567593|DRUG|Rosiglitazone|8mg tablet once a day for 14 days
40942390|NCT05386576|DRUG|Venetoclax|"During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42."
41132205|NCT01211106|BEHAVIORAL|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
41132206|NCT01211106|BEHAVIORAL|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
41283843|NCT04135781|DRUG|Oxaliplatin|Oxaliplatin（130mg/m2 , iv, d1）
41283844|NCT04135781|DRUG|Capecitabine|Capetabine（1000 mg/m2 po, d1-14 bid ）
41283845|NCT01413269|RADIATION|radiotherapy|"one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week."
41283846|NCT04609384|DEVICE|Alcohol rub timer device|A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence
41132207|NCT01800305|DRUG|Pegylated rhEPO|
41132208|NCT01800305|DRUG|EPIAO®|
41283847|NCT01928979|OTHER|no drug|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
41283848|NCT03607370|PROCEDURE|Surgery after 12 weeks of delay after chemoradiotherapy.|Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.
41283849|NCT01690832|DRUG|standard saline infusion|i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
41283850|NCT01690832|DRUG|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
41283851|NCT04847115|PROCEDURE|Operative|Intramedullary screw fixation
41283852|NCT04847115|OTHER|Walking boot orthosis|Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.
40942391|NCT03686514|BIOLOGICAL|FLUARIX QUADRIVALENT|The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.
40942392|NCT01171664|DRUG|Placebo|Tablet, one BID
40942393|NCT01171664|DRUG|STAHIST|STAHIST in tablet form dosed one BID
40942394|NCT04259554|DEVICE|OFC rTMS|repetitive transcranial magnetic stimulation over right orbito-frontal cortex with 1Hz (360 pulses in 6 trains á 60 pulses with 30s intertrain-interval)
40942395|NCT05284877|OTHER|No intervention|The study is an observational study without intervention.
40942396|NCT02063880|OTHER|Urgent ART|Children will be started on HAART \<48 hours after enrollment.
40942397|NCT02063880|OTHER|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
40942398|NCT04841915|DIETARY_SUPPLEMENT|High-Protein Diet|Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet
40942399|NCT04841915|BEHAVIORAL|Clinical dietician|Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
40942400|NCT04841915|BEHAVIORAL|Weight loss|4 weeks eucaloric diet \~13 MJ/day followed by, 20 weeks hypocaloric diet \~9 MJ/day until 5% weight loss is achieved.
40942401|NCT01516528|PROCEDURE|Spirometry|Assessment of lung function by spirometry
40942402|NCT00788398|PROCEDURE|Saline Solution|Irrigation with Saline
40942403|NCT00788398|PROCEDURE|Soap solution|Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
40942404|NCT00788398|PROCEDURE|Gravity Flow Irrigation|Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
40942405|NCT00788398|PROCEDURE|Low Pressure Irrigation|"Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.~Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i."
40942406|NCT00788398|PROCEDURE|High Pressure|"Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.~Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i."
40942407|NCT00797368|OTHER|Manual Therapy and Exercise|Manual Therapy and Exercise
40942408|NCT00797368|OTHER|Home exercises|Home exercises
40942409|NCT00537784|BIOLOGICAL|Autologous platelets|Local injection 10mL, about 2.5 x 10E10 platelets.
40942410|NCT00537784|BIOLOGICAL|no injection|
40942411|NCT02783846|OTHER|normal saline|receive equal volume of normal saline
40942412|NCT02783846|DRUG|dexmedetomidine 0.5 µg/kg|receive dexmedetomidine 0.5 µg/kg
40942413|NCT02783846|DRUG|dexmedetomidine 1.0 µg/kg|receive dexmedetomidine 1.0 µg/kg
40942414|NCT00074438|DRUG|methotrexate|Oral or parenteral repeating dose
40942415|NCT00074438|DRUG|rituximab|Intravenous repeating dose
40942416|NCT00074438|DRUG|corticosteroids|Intravenous repeating dose
40942417|NCT00074438|DRUG|placebo|Intravenous repeating dose
40942418|NCT02495012|DRUG|placebo|Freeze-dried powder without snake venom will be dissovled in saline
40942419|NCT02495012|DRUG|Anfibatide|Freeze-dried powder with snake venom will be dissovled in saline
40942420|NCT01621503|DEVICE|NT-530P|intraocular pressure and central corneal thickness measurement
40942421|NCT02806973|DRUG|Nasal Glucagon|Administered intranasally.
40942422|NCT05237297|DRUG|Ilaprazole|Ilaprazole 10mg
40942423|NCT05237297|DRUG|Naproxen|Naproxen 500mg
40942424|NCT05237297|DRUG|Aceclofenac|Aceclofenac 100mg
40942425|NCT05237297|DRUG|Celecoxib|Celecoxib 200mg
40942426|NCT04185870|DIAGNOSTIC_TEST|3D scan|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum.
40942427|NCT04185870|DIAGNOSTIC_TEST|Standard photography|All participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
40942428|NCT02778971|DRUG|[18F]Flutemetamol|amyloid PET imaging with \[18F\]Flutemetamol and subsequent modification of diagnosis and management
40942429|NCT03179761|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine given intramuscularly
40942430|NCT03179761|OTHER|Laboratory Biomarker Analysis|Correlative studies
40942431|NCT03179761|BIOLOGICAL|Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine given intramuscularly
40942432|NCT04691401|DEVICE|Artificial Intelligence System (CAD EYE, Fujifilm Co.)|A dedicated CNN-based AI system (CAD EYE, Fujifilm Co, Tokyo, Japan) has been recently developed. The Computer-aided diagnosis (CAD) CAD EYE system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.
40942433|NCT01147172|DEVICE|Elevess|Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
40942434|NCT02534220|DEVICE|Manual Toothbrush|Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter \& Gamble, Cincinnati, OH
40942435|NCT02534220|DEVICE|Oscillating-rotating toothbrush|Triumph 5000, Oral-B, Procter \& Gamble, Cincinnati, OH
40942436|NCT03512899|PROCEDURE|Right internal jugular access.|Implantation using percutaneous puncture.
40942437|NCT03512899|PROCEDURE|Left internal jugular access.|Implantation using percutaneous puncture.
40942438|NCT03512899|PROCEDURE|Right axillary vein access.|Implantation using percutaneous puncture.
40942439|NCT03512899|PROCEDURE|Left axillary vein access.|Implantation using percutaneous puncture.
40942440|NCT01848197|DRUG|paclitaxel|
40942441|NCT03698331|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
40942442|NCT03698331|DRUG|Placebo oral capsule|non-active dosage form
40942443|NCT00634400|DRUG|Candesartan|
40942444|NCT00634400|DRUG|Placebo|
40942445|NCT04040868|DEVICE|the TiRobot system|The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach
40942446|NCT04040868|DEVICE|Freehand|conventional fluoroscopy-assisted
40942447|NCT00352443|DRUG|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
40942448|NCT00352443|DRUG|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
40942449|NCT01924624|DRUG|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
40942450|NCT03011619|BEHAVIORAL|Usual Standard of Care|medication management, group therapy, and individual therapy.
40942451|NCT03011619|BEHAVIORAL|Cognitive Behavioral Therapy Condition (CBT)|CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
40942452|NCT01614600|DEVICE|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
40942453|NCT04490811|OTHER|no intervention. observational cohort study|blood sampling is part of care
40942454|NCT02896244|OTHER|no intervention|
40942455|NCT00504985|BEHAVIORAL|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
40942456|NCT01556737|DIETARY_SUPPLEMENT|High daidzein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
40942457|NCT01556737|DIETARY_SUPPLEMENT|High genistein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
40942458|NCT01724411|OTHER|Resistant Starch type 3|Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
40942459|NCT03235843|DEVICE|AAIR pacing|Rate adaptive pacing using a MV sensor.
40942460|NCT03235843|DEVICE|DDI-pacing|Rate adaptive pacing OFF
40942461|NCT01338142|OTHER|CCC|"600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.~1.5 mg of 42Ca labeled CaCl2 through IV injection"
40942462|NCT01338142|OTHER|ACC|600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection
40942463|NCT03913403|PROCEDURE|ECHO|Echocardiogram at baseline and 24 hours later
41132209|NCT06466616|OTHER|Real stretching|Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks stretching of plantar fascia, gastrocnemius and hamstring muscle.
41132210|NCT06466616|OTHER|Placebo stretching|Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks placebo stretching of plantar fascia, gastrocnemius and hamstring muscle.
41451780|NCT02742558|BIOLOGICAL|Cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
41451781|NCT02742558|BIOLOGICAL|Shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
41451782|NCT02583698|DRUG|Carvedilol|
41451783|NCT02583698|DRUG|Placebo|
40942464|NCT03913403|PROCEDURE|Blood Draw|Blood Draw for Troponin Levels - 5ml at baseline and 24 hours later
40942465|NCT01720212|DRUG|YM178|oral
40942466|NCT02979717|DIETARY_SUPPLEMENT|High protein, high fiber dietary supplement|
40942467|NCT02979717|OTHER|Low protein, low fiber comparator|
40942468|NCT00147758|DRUG|Colesevelam hydrochloride|
40942469|NCT02128828|DRUG|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
40942470|NCT00905216|DRUG|heparin sodium - Bergamo|5.000 UI/mL
40942471|NCT00905216|DRUG|heparin sodium - APP|5.000 USP
40942472|NCT00003099|DRUG|Fenretinide|Daily for 14-28 days.
40942473|NCT00003099|DRUG|Tamoxifen Citrate|Daily for 14-28 days.
40942474|NCT00003099|OTHER|Placebo|Daily for 14-28 days
40942475|NCT05870293|BEHAVIORAL|nurse coaching|2 sessions of nurse coaching including the Walt Disney method will be applied to the participants.
40942476|NCT03923738|DRUG|Tocilizumab|TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.
40942477|NCT03225274|OTHER|Breathing Exercises as Therapeutic Play|"On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.~On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.~On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day."
41451784|NCT02671058|DRUG|Cortenema|Hydrocortisone Administered as a Liquid Enema
41451785|NCT02671058|DRUG|Hydrocortisone Acetate|Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
41451786|NCT01592240|DRUG|PBO|Placebo Q28d
41451787|NCT01592240|DRUG|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
41451788|NCT01592240|DRUG|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
41451789|NCT01592240|DRUG|PBO|Placebo, Q14d
41451790|NCT01592240|DRUG|PF-04950615|PF-04950615 50mg, Q14d
41451791|NCT01592240|DRUG|PF-04950615|PF-04950615 100 mg, Q14d
40942478|NCT02577562|DEVICE|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
40942479|NCT03376906|PROCEDURE|HIIE 1|In the HIIE 1 session, all the subjects performed 10 stimuli of 1 min at high intensity (92% of VO2Max) with passive recovery (without exercise) of 1 min.
40942480|NCT03376906|PROCEDURE|HIIE 3|In the HIIE 3 session, the subjects performed the same stimulus of the HIIE1, but with passive recovery of 3 min. Both protocols started with a warm-up of 5 min at 50% of the VO2Peak performed on a T2-100 GE Healthcare® treadmill (Lynn Medical, Wixon, Michigan, USA).
40942481|NCT03376906|PROCEDURE|Control|In the control session, participants remained seated for 30 min. During HIIE 1 and 2, HR and RPE were assessed immediately after stimulus intervals (ten measurements at each HIIE). In all sessions, the subjects remained in supine position to obtain hemodynamic measurements which were obtained before and at 10 min, 30 min and 60 min after the HIIE and control sessions.
41451792|NCT01592240|DRUG|PF-04950615|PF-04950615 150mg, Q14d
41451793|NCT04005222|DRUG|SELENIUM|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
41451794|NCT04005222|DRUG|MELATONIN|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
40756837|NCT03263390|PROCEDURE|Bariatric Surgery|Sleeve gastrectomy or Roux-en-Y Gastric Bypass
40942482|NCT02646254|OTHER|blood cardioplegia|
40942483|NCT02646254|OTHER|del nido cardioplegia|
40942484|NCT05802875|BEHAVIORAL|RASMUS Resilience Training|"RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course."
41132211|NCT03343184|PROCEDURE|SEE Strategy and Incremental Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
41132212|NCT03343184|PROCEDURE|SEE Strategy and Bulk Fill Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
41132213|NCT03343184|PROCEDURE|SET Strategy and Incremental Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
41132214|NCT03343184|PROCEDURE|SET Strategy and Bulk Fill Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
41132215|NCT01595451|PROCEDURE|Acupuncture|A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
41132216|NCT01829646|OTHER|functional MRI|Functional MRI on day 22 of the chemoradiotherapy treatment. Parameters of these images will be later on correlated with outcome.
41132217|NCT01829646|OTHER|Hypoxia gene expression profile.|Tumour biopsies will be obtained as part of the staging procedure (standard). On this biopsies we will conduct a hypoxia gene expression profile (15 genes on PCR that can be analyzed individually or as a group through one binary variable). Hypoxia will be a parameter in our prognostic/predictive model.
41132218|NCT01829646|OTHER|Functional MRI before start of treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with outcome.
41132219|NCT03180541|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
41132220|NCT01015872|DEVICE|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
41132221|NCT00570999|DRUG|Palifermin|60 mg/kg/day
41132222|NCT00570999|OTHER|Placebo|1,2 mL once daily
40942485|NCT05802875|BEHAVIORAL|Progressive Muscle Relaxation|"Progressive Muscle Relaxation is a representative relaxation technique used in a wide scope of disorders. Developed by the American physician E.Jacobson in the late 1920s, it is based on the finding that anxiety states are usually accompanied by increased muscle tension, while in resting states the muscles are relaxed. By applying this technique, an individual learns how to relax several muscle groups in the body.~In the context of the current project, PMR is chosen as the active control condition because it is a broadly accepted and easy-to-implement relaxation exercise that can be offered as a (group) online course and does not include specific contents of RASMUS."
40942486|NCT03965208|DRUG|Bivalirudin|titrated continuous infusion
41283853|NCT05070338|BEHAVIORAL|Guideline-Based (Injunctive Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amounts recommended by safety guidelines for these procedures.~For patient safety, Sutter Health recommends prescribing within the ranges below for these procedures. Doing so will also meet best-practice safety guidelines for post-operative opioid prescribing.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]"
41283854|NCT05070338|BEHAVIORAL|Peer-Based (Social Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amount prescribed by YY% of your peers for these procedures.~YY% of \[specialty\] surgeons at Sutter Health prescribe within the ranges below for these procedures.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]~The ranges of 5mg oxycodone tablets displayed will be the same as the ranges stipulated by the prescribing guidelines, but this nudge will not mention guidelines."
41283855|NCT04901897|DEVICE|kalifilcon A|kalifilcon A daily disposable contact lens
41451795|NCT02667769|OTHER|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose \<55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
41451796|NCT01487720|DRUG|GEMOX|Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
41451797|NCT03273751|PROCEDURE|Remote Ischemic Preconditioning|After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
41283856|NCT04901897|DEVICE|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
41283857|NCT04901897|DEVICE|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
40942487|NCT03965208|DRUG|Unfractionated heparin|titrated continuous infusion
40942488|NCT01061983|DEVICE|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
40942489|NCT00542971|DRUG|Idarubicin|12 mg/m\^2 IV over 1 hour daily (days 1-3)
41451798|NCT03273751|PROCEDURE|Sham control|After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
41451799|NCT01257633|PROCEDURE|Transoral robot-assisted tumor resection using the da Vinci robot|Transoral robot-assisted tumor resection using the da Vinci robot
41451800|NCT06077786|DRUG|Lu AG06474|Oral solution
41451801|NCT06077786|DRUG|Placebo to Lu AG06474|Oral solution
40942490|NCT00542971|DRUG|Sorafenib|Starting dose 400 mg by mouth for 7 days
40942491|NCT00542971|DRUG|Ara-C|1.5 g/m\^2 IV over 24 hours daily (days 1-4)
40942492|NCT03302195|DRUG|Heparin|Based on patient body weight (UI/kg)
40942493|NCT03302195|PROCEDURE|cardiopulmonary bypass pump flow rate|Based on patient body weight (L/min/m2)
41132223|NCT03376659|DRUG|Durvalumab|750mg IV q2 weeks
41451802|NCT06077786|DRUG|Ibuprofen|Capsule
41451803|NCT06077786|DRUG|Pregabalin|Capsule
41451804|NCT06077786|DRUG|Placebo|Capsule
41451805|NCT05109104|DRUG|CAP UnScented|Sunscreen lip balm.
41451806|NCT05109104|DRUG|CAP Herbal Mint|Sunscreen lip balm.
41451807|NCT05109104|DRUG|CAP Mountain Berry|Sunscreen lip balm.
41451808|NCT05109104|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
41451809|NCT05277402|DRUG|ADG116|IV infusion
41283858|NCT01475201|BEHAVIORAL|Step count prescription|Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (\<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.
41283859|NCT01475201|BEHAVIORAL|Usual care|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
41283860|NCT00274430|DRUG|dexamethasone 8 mg bid|
41283861|NCT00274430|DRUG|tadalafil 10mg bid|
41283862|NCT02724033|PROCEDURE|regional nerve block|regional nerve block
41283863|NCT02724033|DRUG|Antiemetic|Antiemetic
41283864|NCT02638181|PROCEDURE|trabeculectomy|
41283865|NCT03088579|DEVICE|GammaTile seed loader|Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
41283866|NCT02884115|DRUG|benzathine penicillin|
41283867|NCT00041899|DRUG|CDB-2914|
41283868|NCT00041899|DRUG|COB-2914|
41283869|NCT02509546|DRUG|8-Chloroadenosine|Given IV
41283870|NCT02509546|OTHER|Laboratory Biomarker Analysis|Correlative studies
41283871|NCT02509546|OTHER|Pharmacological Study|Correlative studies
41132224|NCT03376659|BIOLOGICAL|CV301|"MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c."
41132225|NCT03376659|DRUG|Capecitabine|1000mg orally twice a day, Monday - Friday Weekly
41132226|NCT03376659|DRUG|Bevacizumab|5mg/kg IV q2weeks
41283872|NCT01068561|BIOLOGICAL|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
41283873|NCT01843322|PROCEDURE|endoleak repair procedure (navigation technology )|
41283874|NCT02978014|DEVICE|ProSpare|A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
41283875|NCT03553173|OTHER|So-Lo-Mo|So-Lo-Mo is an innovative intervention based on mobile technologies and its capacity to trigger behavioral changes. In this sense, the App is a complement to pharmacological therapies to quit smoking providing personalised motivational messages, physical activity monitoring, lifestyle advices and distractions (mini-games) to help pass the cravings. The main objective of this App is to improve patient's adherence to the smoking cessation process making use of behavioral techniques in the form of motivational messages and/or Short Message Service (SMS).
41283876|NCT03553173|BEHAVIORAL|Psychological advice|Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
41283877|NCT03553173|DRUG|Bupropion Pill|Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.
41283878|NCT03553173|DRUG|Varenicline Pill|Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.
41451810|NCT02589366|DRUG|Lymphoseek plus Vital Blue Dye|intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
41451811|NCT03801876|DRUG|Carboplatin|Given IV
40756838|NCT03263390|DRUG|Anti Obesity Drugs|Response to FDA approved anti obesity medications
40756839|NCT05447663|DRUG|Siremadlin|30-40 mg QD siremadlin capsules, orally (1-5 days of 28 or 42 days cycle)
40942494|NCT04581759|DEVICE|RIPC device (IPC-906X)|Patients in the RIPC group will have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm twice a day after Mechanical Thrombectomy.
40942495|NCT04581759|DRUG|foundational treatment|foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
40942496|NCT04604158|BEHAVIORAL|Elly Mobile Phone Application|The Elly mobile phone application delivers daily audio recording aimed at reducing anxiety, stress, loneliness, and social isolation.
41283879|NCT01450137|DRUG|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
41451812|NCT03801876|PROCEDURE|Esophagectomy|Undergo esophagectomy
40756840|NCT01337310|DRUG|Tesetaxel|The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
40942497|NCT00629174|BEHAVIORAL|Exercise|Endurance and resistence training, 90 minutes, 3 times weekly
40942498|NCT00629174|BEHAVIORAL|Mental activity|Participation at computer lessons, 3 times weekly, 90 minutes each
41451813|NCT03801876|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40942499|NCT00276913|DRUG|STA-5312|
40756841|NCT05966727|DRUG|Cholestyramine Powder|Bile salt chelating resin, used as a lipid-lowering treatment.
40756842|NCT01668199|DRUG|TZP-101|
40756843|NCT01292993|DRUG|400 mg LX4211|400 mg of LX4211 given as a solid oral dose form
40942500|NCT00880685|DRUG|Memantine|10-30mg, daily for 8 weeks
41132227|NCT03987646|PROCEDURE|Non-staged vestibular fresh socket therapy|a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
41451814|NCT03801876|DRUG|Paclitaxel|Given IV
41132228|NCT06470386|DRUG|Alverine|180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
41132229|NCT06470386|DRUG|Carvedilol|taken orally, starting dose of 6.25 mg once a day, gradually adjusted according to heart rate to 6.25 mg twice a day, 12.5 mg in the morning and 6.25 mg in the evening, 12.5 mg twice a day, or adjusted to the maximum tolerated dose (heart rate greater than 55 beats/min and systolic blood pressure greater than 90 mmHg), taken continuously for 24 weeks.
41132230|NCT03723031|DRUG|Misoprostol|400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.
41283880|NCT01450137|DRUG|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
41451815|NCT03801876|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
41451816|NCT03801876|OTHER|Quality-of-Life Assessment|Ancillary studies
41451817|NCT03801876|OTHER|Questionnaire Administration|Ancillary studies
41451818|NCT03801876|DRUG|FOLFOX regimen|Folinic acid, flurouracil and oxaliplatin
41451819|NCT03801876|DRUG|CAPOX regimen|Capecitabine combined with oxaliplatin
40942501|NCT04844775|BIOLOGICAL|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"1. Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelope have been replaced by the sequences encoding HIV-1 gp140 (96ZM651) antigen.~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
41283881|NCT03078361|OTHER|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Both intervention groups will receive an I-FOBT kit (by study coordinator) with verbal and written instructions in Spanish on how to complete the stool sampling at home within 1 week, and mail the completed kit in the pre-addressed, postage paid mailer. Patients with abnormal results will receive a call explaining the meaning of an abnormal I-FOBT and encouraging them to take specific next steps.
41283882|NCT03078361|BEHAVIORAL|LATINOS CARES Toolkit|DVD + photonovella booklet), about colorectal cancer screening (CRCS) targeted for a Latino medically underserved population.
41283883|NCT03078361|BEHAVIORAL|Standard Intervention|Standard intervention (CDC brochure) on colorectal cancer screening in community health clinics.
41283884|NCT02211339|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
41283885|NCT02211339|OTHER|Usual care|Staff-led social activity
41283886|NCT01046318|DRUG|OPC-262|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
41283887|NCT02035943|DIETARY_SUPPLEMENT|Insulin separated|separate continuos infusion of insulin
40942502|NCT04844775|BIOLOGICAL|DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)|"1. Drep-HIV-PT1 1mg (see above)~2. Drep-HIV-PT1 1mg (see above)"
40942503|NCT04844775|BIOLOGICAL|DNA-HIV-PT123 4mg and CN54gp140/MPLA-L|"1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef~2. CN54gp140/MPLA-L Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
41283888|NCT02035943|DIETARY_SUPPLEMENT|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
41283889|NCT00850512|DRUG|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
41283890|NCT00850512|DRUG|Zevalin|12-week safety period for Zevalin
41283891|NCT03185130|DRUG|Normal Saline 5mL|Control arm subjects will receive Normal Saline 5 mL IV over 1 hour
41283892|NCT03185130|DRUG|Normal Saline 20mL/kg|Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
40942504|NCT01329484|BEHAVIORAL|Reminiscence therapy|Personalized reminiscence therapy using a computerized system
40942505|NCT01329484|BEHAVIORAL|Cognitive training|Cognitive training using a computerized system
40942506|NCT01329484|OTHER|No treatment|Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
41283893|NCT03185130|DRUG|Prochlorperazine 0.15 mg/kg up to 10 mg IV|Standard Treatment Arm and Study Arm will receive prochlorperazine 0.15 mg/kg up to 10mg IV slow push
41283894|NCT03185130|DRUG|Diphenhydramine 1 mg/kg up to 50 mg IV|Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
41283895|NCT05814029|OTHER|Mobilization with movement for Ankle|The participant will assume a lunge position on a rigid serving table with the relevant extremity in a weight-bearing stance and the foot in a neutral position. An inelastic belt will be placed around the clinician's waist, flush with the lower edge of the medial malleolus, around the distal tibia and fibula. The clinician will stabilize the talus and forefoot with the web spacing of the hands and pressure dimensions on the talus and forefoot, and maintain posterior to anterior sliding of the tibia over the talus using the arch. The clinician will continue to apply pressure while the person is reporting discomfort and/or while the lunge moves, which will continue until the end of the range of motion. Mobilization will be performed as a 3 set of 10 repetitions.
41283896|NCT05387330|DIAGNOSTIC_TEST|ELISA kit|Sandwich ELISA kit for the accurate quantitative detection of sCD62L and SPARC in human plasma and serum samples.
41283897|NCT01584024|DEVICE|Resin infiltration|"Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062"
41283898|NCT01584024|DEVICE|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
41283899|NCT04718090|PROCEDURE|PENG Block|Pericapsular nerve group block in shoulder surgery.
41451820|NCT03801876|DRUG|Docetaxel|Chemotherapy
40756844|NCT01292993|DRUG|1000 mg metformin|1000 mg metformin given as a solid oral dose form
40756845|NCT02510742|DEVICE|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
41283900|NCT05732129|DRUG|Fluzoparib|150mg,orally, bid (days 1-7) every 2 weeks
40756846|NCT02510742|DEVICE|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
41283901|NCT05732129|DRUG|Irinotecan|30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
40756847|NCT03621215|DIETARY_SUPPLEMENT|Tart cherry juice|30 mL tart cherry juice concentrate (CherryActive, UK), diluted with water to 250 mL. This is consumed daily by participants, with breakfast, for 12 months.
41283902|NCT03392129|OTHER|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week 40 minutes each session) of treatment with the Ai Chi Method, and educational intervention in relation to asthma.
41451821|NCT03801876|DRUG|5FU|Chemotherapy
41451822|NCT01193972|OTHER|Decision aid|Decision aid to assist patients in making a decision about smoking during the perioperative period
40942507|NCT00048763|DRUG|Pletal|
40942508|NCT04949971|BEHAVIORAL|High volume group|Thea High tidal volume of the exposed group was 10ml/kg ideal body weight
40942509|NCT00000631|BIOLOGICAL|HIVAC-1e|
40942510|NCT00000631|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
40942511|NCT00315159|PROCEDURE|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
40942512|NCT01317381|PROCEDURE|Observational|Blood draw
41283903|NCT03392129|OTHER|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
41283904|NCT02320331|BEHAVIORAL|PILI Lifestyle Program|A 12-week Individual-focused Behavioral Weight Loss Intervention. Our 12-week intervention is modeled after the Diabetes Prevention Program's (DPP) Lifestyle Intervention. Each of the 8 lessons of this 12-week intervention will be done in a group classroom setting via trained community peer educators for a total of 8 group meetings as outlined above. Lesson 1 through 4 will be done every week, once a week, for 4 weeks followed by every other week for the remaining 4 lessons (lessons 5 through 8). Each group meeting will have between 12 to 15 people and take 1 to 1 ½ hours to complete. After completing the 12-week behavioral weight loss intervention, participants will participate in an additional 6 lessons. A lesson will be done once-a-month. These 6 lessons will teach participants how to involve their family and friends in their healthy lifestyle changes.
40942513|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 1|0.5 mL, Intramuscular (Low dose)
41283905|NCT04954677|OTHER|AI-box|Automatic quality-control system（AI-box）could real-time measure endoscopic inspection completeness, evaluate gastric cleanliness.
41283906|NCT04579861|OTHER|Prospective data collection following gynaecological oncology surgery|Prospective data collection and entry on database following gynaecological oncology surgery
41283907|NCT00949338|PROCEDURE|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
41283908|NCT02058381|DRUG|alpelisib (BYL719)|BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
41283909|NCT02058381|DRUG|buparlisib (BKM120)|BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
41283910|NCT02567695|DRUG|GBT440|Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
41283911|NCT05121740|DRUG|Plitidepsin 1.5 mg / day|Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
41283912|NCT05121740|DRUG|Plitidepsin 2.0 mg / day|Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
41283913|NCT05121740|DRUG|Plitidepsin 2.5 mg / day|Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
41451823|NCT05795621|BIOLOGICAL|IBI311|10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
40942514|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 2|0.5 mL, Intramuscular (Middle dose)
40942515|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 3|0.5 mL, Intramuscular (High dose)
40942516|NCT01444352|BIOLOGICAL|Placebo|0.5 mL, Intramuscular
40942517|NCT02616848|DRUG|Everolimus|
40942518|NCT02616848|DRUG|Eribulin|
41451824|NCT05795621|BIOLOGICAL|placebo|4 does of placebo for phase II; 8 does of placebo for phase III.
41132231|NCT05309200|DRUG|OCE-205|The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.
40942520|NCT02044835|DRUG|Fu-zheng-qu-zhuo oral liquid|Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
40942521|NCT01296360|BIOLOGICAL|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
40942522|NCT01296360|BIOLOGICAL|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
41451825|NCT03296956|DIETARY_SUPPLEMENT|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in day-5 postpartum women.
40942523|NCT05240287|DIAGNOSTIC_TEST|Navicular Drop Test|The researchers will measure the distance between the navicular tuberosity and the ground with a caliper with non-weight bearing in sitting. After that, the distance between the ground and the navicular tuberosity will be measured in standing while weight-bearing. The researchers will evaluate both sides and record the value in mm. According to Navicular Drop Test, the difference between weighted and unweighted measurements is considered normal (neutral) if it is between 5 and 9 mm, pronation (pes planus) if it is 10 mm or more, and supination (pes cavus) if it is 4 mm or less. In our study, individuals with a difference of 10 mm or more in both feet will be included in the pes planus, and individuals with a difference between 5-9 mm will be included in the control group.
41132232|NCT05309200|DRUG|Placebo|Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.
41132233|NCT05703698|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
41283914|NCT04731064|PROCEDURE|HAL (Hemorrhoidal Artery Ligation) - RAR (Recto-Anal Repair)|The patient is operated on in the first perineal position, under general anesthesia or under locoregional or even local anesthesia, after rectal preparation by simple enema. The HAL equipment included a disposable transparent rectoscope fitted near its end with a centimeter window through which wire stitch ligatures will be made. A light source facilitating the exposure of the internal face of the rectum and a Doppler transducer secured to the base of the rectoscope containing the Doppler system. Everything is connected to a generator which transmits Doppler noises to the surgeon. A printer on the generator makes it possible to map ligatures and note the depth of linked arteries. Equipment includes needle holder, knot pusher, scissors and dissecting forceps. The material for HAL is identical, except for the disposable rectoscope which is more indented at its end and on one side.
41283915|NCT04837885|PROCEDURE|Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection|Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
41283916|NCT04837885|PROCEDURE|Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection|intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
41451826|NCT03296956|OTHER|Placebo|Matching placebo for appearance, taste
41451827|NCT03253354|DEVICE|repetitive magnetic stimulation|Neurostimulation
40942524|NCT05240287|DIAGNOSTIC_TEST|Foot Posture Index|The index consists of six items in which the foot is evaluated observationally. In the evaluation, the individual is asked to stand in a comfortable and relaxed position. The researcher observes the medial longitudinal arch structure, the structure of the talonavicular joint region, the degree of abduction/adduction in the forefoot relative to the hindfoot in the front part of the foot. In the back foot, inversion/eversion of the calcaneus, talus head position, and curvatures above and below the lateral malleolus are evaluated. The total score is reached by scoring each criterion between -2 and +2 values. 0; neutral position, (+) values; pronation (pes planus), (-) values indicate supination (pes cavus). Individuals with +6 to +12 points from this index will be included in our study.
40942525|NCT05240287|DIAGNOSTIC_TEST|Balance|Static and dynamic balance and stability limit values of individuals will be evaluated with the HUR Smart Balance (SME Inc, USA) balance measurement device. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals will be asked to place their feet on the marked places on the platform. The researchers will evaluate the balance in four different situations, 30 seconds each. In the first test, individuals keep the balance on firm ground with their eyes open. The second test performed on the firm ground with eyes closed, in the third test, on the soft ground with eyes open, and in the fourth test, on the soft ground with eyes closed. For dynamic balance, individuals will be asked to extend their body weight to the front, back, and sides with their feet in 4 different directions for 8 seconds.
40942526|NCT05240287|DIAGNOSTIC_TEST|Plantar Pressure Analysis|Plantar pressure analysis of individuals will be evaluated by measuring with the DIERS Pedoscan DICAM 3 v3.10.8 (2019) device. DIERS Pedoscan is a system integrated into the treadmill that measures the pressure distribution on the sole during stance. As a result of this evaluation, right-left and anterior-posterior weight transfer, left-right foot rotation, lateral mobility, the center of gravity movement, and swing area data will be recorded.
40942527|NCT05240287|DIAGNOSTIC_TEST|Gait Analysis|Gait analysis of individuals will be evaluated with the DIERS Leg Axis DICAM 3 v3.10.8 (2019) system. The system consists of a treadmill, computer, and cameras. Before the measurement, colored markers will be placed on the knee and ankle joints of the individual. For gait assessment, individuals will walk at their preferred comfortable walking speed. In the evaluation, joint angles, walking speed, step lengths are recorded. Evaluation time is approximately 5 minutes.
40942528|NCT03843827|DEVICE|Laryngeal Mask Airway|The aim of this study is to compare between cLMA and I gel regarding insertion success rate, the time of insertion, leaking pressure, assessment of position by fiber optic, hemodynamic, Spo2 for each device during insertion and maintenance of general anaesthesia and postoperative complications in obese patients
40942529|NCT03843827|DEVICE|I gel Airway|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage
40942530|NCT04449887|DRUG|Xiangsha Liujunzi granules|A traditional Chinese medicine compound, taken three times a day, one bag at a time, for a total of 28 days
40942531|NCT06143800|BEHAVIORAL|reactivation|During the retrieval phase, cues are presented to participants to reactivate their memories; participants in the non-retrieval group go directly to cognitive reappraisal phase.
40942532|NCT06143800|BEHAVIORAL|cognitive reappraisal intervention|"Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it."
40942533|NCT06383767|DRUG|ESG401|IV infusion on day 1,8, and 15 of each 28 day cycle
40942534|NCT06383767|DRUG|Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)|Eribulin, capecitabine, gemcitabine or vinorelbine
40942535|NCT01942473|DEVICE|Automated FiO2 Control|Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
40942536|NCT02138422|BIOLOGICAL|Xilonix|
40942537|NCT02138422|BIOLOGICAL|Placebo|
40942538|NCT03208595|DIAGNOSTIC_TEST|Endometrial sampling of a Typical Embryo transfer catheter|no intervention no additional change from unit protocol
40942539|NCT00150540|DRUG|Lanthanum carbonate|
40942540|NCT05682235|OTHER|Therapeutic exercise AND pain neurophysiology education|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group and talks on healthy habits to the placebo group participants.
40942541|NCT05682235|OTHER|Sham|Talk about healthy habits
41451828|NCT01814904|DRUG|colestilan-L|body surface area equivalent (BSAeq) 3 g/day
40756848|NCT03621215|OTHER|Fruit-flavoured placebo drink|Consumed daily by participants, with breakfast, for 12 months.
41451829|NCT01814904|DRUG|colestilan-M|BSAeq 6 g/day
41451830|NCT01814904|DRUG|colestilan-H|BSAeq 9 g/day
40756849|NCT03275831|DEVICE|PluroGel|Surfactant based gel
40756850|NCT03275831|DEVICE|Intrasite gel|Hydrogel
40942542|NCT02684487|DRUG|vitamin D3|Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
40942543|NCT02684487|DRUG|Placebo|Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
40942544|NCT04615897|PROCEDURE|new tecnology intervention|"The intervention consists of 16 sessions, performed with a frequency of twice a week, the final evaluation was made within three days after the end of the last treatment session. It is used for the motor task, the Fishing Under Zero exercise, included within the balance modality and the so-called Step Plus located in the aerobic exercise folder. Each subject carried out the training taking into account the following methodology: 3 cycles of the Fishing under zero exercise, one cycle of the Step Plus exercise and 3 cycles of the Fishing under zero exercise, the approximate duration of the task being about 30 minutes."
41451831|NCT01814904|DRUG|CBPB|
41451832|NCT04491422|COMBINATION_PRODUCT|Integrated Next Steps Counseling with Real-Time Drug Level Feedback|Integrated next steps counseling with real-time drug level feedback using point-of-care urine tenofovir testing at quarterly visits
40942545|NCT05584371|DIETARY_SUPPLEMENT|Free Beta-hydroxybutyrate|Participants will be asked to ingest 10 grams of beta-hydroxybutyrate, diluted in water and sweetened with Stevia, every morning between 9:00 and 11:00 for four weeks.
40942546|NCT05209178|DIAGNOSTIC_TEST|Collection of nasal and oropharyngeal specimen for COVID19 antigen test|Regarding two independent sampling procedures from the anterior part of the nose and the oropharynx, participants are randomized to either perform the sampling by themselves with written instructions or having the procedure performed by trained personnel. The specimen is meant for a rapid antigen test for COVID-19 infection.
40942547|NCT04155489|PROCEDURE|blood transfusion|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started. in the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
40942548|NCT01607671|DRUG|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
40942549|NCT01409395|DRUG|Metformin and nizatidine|Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
40942550|NCT01409395|DRUG|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
40942551|NCT00509392|DEVICE|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation \& ClosureFAST catheter
40942552|NCT00509392|DEVICE|Endovenous Laser|laser catheter
40942553|NCT02517216|OTHER|parabolic flight|
40942554|NCT02517216|DEVICE|MRI|
40942555|NCT01790776|RADIATION|Urografin 30%|"Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).~The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled."
40942556|NCT01790776|RADIATION|NaCl 0,9 % in aqua|The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
40942557|NCT05318339|DRUG|Trastuzumab|"A loading dose of trastuzumab 8mg/kg IV over 90 minutes will be administrated on day 1 of week 1.~For all subsequent doses, trastuzumab 6mg/kg IV over 30 minutes will be administrated every three weeks.~Pyrotinib 400mg PO daily will be administrated at the same time."
40942558|NCT05736783|OTHER|plyometric exercises|"1. st week Wall touches 3x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4conesx10~2. nd week Wall touches 4x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4 cones x 30~3. rd week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30~4. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (20)~5. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (30)~6. th week Wall touches 6x30 s Split squat jumps 2x70 Lateral cone jumps 2x60 Cone hops with 180 turn 4 cones x 40 Drop jump 45.72 cm (40)"
40942559|NCT05736783|OTHER|strenghtening of quadriceps and hamstring|1st to 3rd week l 4th to 6th week Squat 2x12 3x8 l 3x10 4x6 Knee extension 3x12 3x8 l 2x10 2x6 Nordic hamstring 3x3 3x3 l 3x4 3x4
40942560|NCT04288271|BEHAVIORAL|Adherence Intervention|"Intervention:~* Adherence Support Team (patient, parent or a significant other, Coach)~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Identification of adherence barriers, self-efficacy for medication-taking, and allocation of treatment responsibility~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~Device:~* Electronic pillbox monitoring with text message and/or audio/visual dose reminders and access to e-pillbox website~* Feedback of electronic monitoring data at increasing intervals between initiation of the intervention at 4-week and exit at 14-week."
40942561|NCT04288271|OTHER|Healthy living education intervention|"Intervention:~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Healthy living topic discussion at increasing intervals between 4-wk and 14-wk visits~* 'Action-Focused Problem-Solving' to address barriers on healthy living topic selected by the patient~Device:~• Electronic adherence monitoring without dose reminders or feedback (enrollment to 14w)"
40942562|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 20 mg once daily (od) for 12 weeks
40942563|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 30 mg od for 12 weeks
41451833|NCT00834314|PROCEDURE|Vacuum-Pack-technique for temporary abdominal closure|"Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations)."
40942564|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 40 mg od for 12 weeks
40942565|NCT00395772|DRUG|(LMW) Heparin + Vitamin K Antagonist|Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
40942566|NCT02869061|PROCEDURE|Liposuction|
40942567|NCT02869061|PROCEDURE|Transurethral bladder neck resection.|
40942568|NCT02869061|BIOLOGICAL|ADRC|Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.
40942569|NCT02869061|OTHER|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
41451834|NCT00834314|PROCEDURE|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
40942570|NCT01969643|DRUG|ladiratuzumab vedotin|LV will be given into the vein (IV; intravenously)
40942571|NCT01969643|DRUG|Trastuzumab|Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
40942572|NCT00443027|DEVICE|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
40942573|NCT05922956|OTHER|Facial emotion recognition test|Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
41451835|NCT00991796|DRUG|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
41451836|NCT00991796|DRUG|Placebo|Placebo
41451837|NCT00991796|DRUG|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
40942574|NCT02138435|OTHER|MRI exercise test|Measuring cardiac output with MRI during exercise on an ergometer bicycle.
40756851|NCT03630510|OTHER|Ventilator hyperinflation|The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
40942575|NCT02138435|OTHER|Gas-exchange exercise test|Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
40942576|NCT06083857|DRUG|Amivantamab|Given by IV (vein)
40942577|NCT06083857|DRUG|Tepotinib|Given by PO
40942578|NCT04723758|DEVICE|GI Genius-assisted diagnostic colonoscopy|Participants will undergo diagnostic colonoscopy, which will be identical to the normal standard of care at the unit where they are undergoing their procedure, except that GI Genius will be turned on during the procedure.
41267238|NCT02611401|BEHAVIORAL|Psychoeducation|"The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.~This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session."
41451838|NCT00991796|DRUG|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
40942579|NCT04723758|DIAGNOSTIC_TEST|Diagnostic Colonoscopy|Diagnostic colonoscopy will be performed as per the standard of care for the unit where the patient is having their procedure.
41451839|NCT03262051|DIAGNOSTIC_TEST|CYP phenotyping|Phenotyping using a simplified version of the Geneva cocktail
41451840|NCT04567329|DRUG|NOV03|100% perfluorohexyloctane
41451841|NCT04567329|DRUG|Saline Solution|0.6% sodium chloride solution
40942580|NCT01526122|DRUG|G0041(75/100mg)|G0041(75/100mg) 2 capsules(Clopidogrel 75mg \& Aspirin 100mg in 1 capsule), PO
40942581|NCT01526122|DRUG|Clopidogrel & Aspirin|Clopidogrel 75mg 2 tablets \& Aspirin 100mg 2 capsules, PO
41451842|NCT05089903|BEHAVIORAL|Bulk Order|A mammogram order will be placed using bulk order technology in the EHR in advance of outreach for all patients.
41451843|NCT05089903|BEHAVIORAL|Texting|In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.
41451844|NCT05089903|BEHAVIORAL|Clinician Endorsement|Outreach informing patients that they are overdue for a mammogram will be signed by the patient's primary care provider.
41451845|NCT05089903|BEHAVIORAL|No Bulk Order|The outreach will ask patients to contact their PCP's office in order to have a mammogram order placed on their behalf.
41451846|NCT05089903|BEHAVIORAL|Standard Endorsement|Patient's will receive outreach from the practice informing them that they are overdue for a mammogram.
41451847|NCT04224584|DRUG|Duloxetine|Duloxetine will be administrated with a two weeks up titration followed by a 10 weeks full treatment (60 mg/daily) and finalized by a two weeks discontinuation.
40942582|NCT05030324|DRUG|XC221 100 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
40942583|NCT05030324|DRUG|XC221 200 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
40942584|NCT05030324|DRUG|Placebo|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
40942585|NCT02002390|DRUG|Fingolimod|A sphingosine-1-phosphate receptor regulator
40942586|NCT00447317|BEHAVIORAL|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
40942587|NCT00447317|BEHAVIORAL|Attention control|Standard peritoneal dialysis dietary education
40942588|NCT00215202|DRUG|Iressa (ZD1839)|
40942589|NCT02891811|DRUG|Carfilzomib|Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
40942590|NCT02891811|DRUG|Thalidomide|100mg orally on days 1-28 in patients \<75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
40942591|NCT02891811|DRUG|Lenalidomide|25mg p.o. on days 1-21 of each cycle
40942592|NCT02891811|DRUG|Dexamethasone|40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients \<75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
40942593|NCT00130273|BEHAVIORAL|Managed problem solving|Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
40942594|NCT00130273|BEHAVIORAL|Standard care|Participants will receive standard of care for 12 months.
41132234|NCT04399772|BEHAVIORAL|Cognitive Functional Therapy+ pathway|"The CFT+ intervention comprises 4 main components: (1) making sense of pain: context-based patient education focusing on the multidimensional nature of pain and disability, while reducing the threat of structural damage and correcting unhelpful beliefs; (2) exposure with control: graded exposure to painful, feared, or avoided activities with body relaxation; (3) lifestyle changes: encouraged to perform physical activity based on preference and taught strategies to manage stress and poor sleep, (4) focus on coping strategies in life and how these strategies influence the current situation.~After CFT+, patients can be offered the comparator pathway should that be clinically indicated from these criteria: the patient does not feel ready to stop treatment AND Analgesic treatment is inappropriate OR Social situation is problematic OR Significantly psychological distress that requires further treatment by psychologist. This decision is based on a multidisciplinary team conference."
41451848|NCT04224584|DRUG|Placebo oral tablet|Placebo will act as a control for duloxetine.
41451849|NCT00210223|PROCEDURE|Radiofrequency|
40756852|NCT04334681|PROCEDURE|Un-roofing curettage method|In this method, the roof of the pilonidal cyst is opened, and the inside is cleaned, and curettage is performed. The wound is closed with a dressing after hemostasis.
40942595|NCT04012125|DEVICE|flexible thoracolumbar brace|Subjects would wear the flexible thoracolumbar brace over 18 hours a day
40942596|NCT04793698|OTHER|Compassion meditation|10 week meditation course taught in 90-minute groups
40942597|NCT04793698|BEHAVIORAL|Applied relaxation|10 week applied relaxation course taught in 90-minute groups
41132235|NCT04399772|BEHAVIORAL|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Individualized combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects), (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs."
41267239|NCT04116099|OTHER|Conservative care|May include graduated compression, MLD performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
41267240|NCT04116099|DEVICE|Flexitouch Plus|Flexitouch Plus treatment.
41267241|NCT03358914|OTHER|No intervention|Completion of surveys
41267242|NCT03554044|DRUG|Anastrozole|Given PO
41267243|NCT03554044|DRUG|Exemestane|Given PO
41267244|NCT03554044|DRUG|Fulvestrant|Given IM
41267245|NCT03554044|DRUG|Letrozole|Given PO
41267246|NCT03554044|DRUG|Paclitaxel|Given IV
41267247|NCT03554044|BIOLOGICAL|Talimogene Laherparepvec|Given IT
41267248|NCT03554044|DRUG|Tamoxifen|Given PO
41267249|NCT03554044|DRUG|Nab paclitaxel|Given IV
41267250|NCT03554044|DRUG|Gemcitabine|Given IV
41267251|NCT03554044|DRUG|Carboplatin|Given IV
41267252|NCT06373874|BEHAVIORAL|Heel blood collection in a newborn simulation model|"The person who will take heel blood in the newborn simulation model can prepare the materials.~Firstly, the blood sample can fill in all the information on the filter paper. Knows where the baby's face should be. It can determine the area where a heel blood sample can be taken.It can gently warm the heel area for a few minutes. The area can be cleaned with alcoholic preparation (cotton/swab, etc.). He can squeeze the heel with his thumb and index finger in front. The other 3 fingers can be rubbed at the back. May stroke the heel three times. The heel can be pierced once with a lancet at a suitable location. He can relax his hand. He can wipe away the first drop of blood. It can create a large thick drop of blood to be collected on filter paper. It can make the drop fill the entire ring on the filter paper with one touch. After the procedure is completed, the heel can be pressed."
41267253|NCT00313924|DRUG|DETRUSITOL|
41267254|NCT04126824|DRUG|Triamcinolone|40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)
41267255|NCT04126824|DRUG|Bupivacaine|0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).
41267256|NCT04126824|OTHER|Iohexol contrast|The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.
41267257|NCT01837693|PROCEDURE|Experimental: immediate colposcopy|A immediate colposcopy in this arm may detect potentially spontaneous regressive cervical lesions, so may determine an over diagnosis and over treatment, which the study want to estimate
41267258|NCT04273074|RADIATION|sonographic assessment|preoperative sonographic assessment to airway
41267259|NCT03152240|OTHER|Non intervention|Non intervention
41267260|NCT04042194|PROCEDURE|Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF|A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.
41283917|NCT04837885|DRUG|LUTATHERA® by intra-arterial hepatic (IAH) injection|"One treatment dose of LUTATHERA® by IAH injection for the 10 first patients with an PET/CT ratio greater then 3.~The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations"
40942598|NCT02169284|DRUG|Erlotinib Hydrochloride|Given PO
40942599|NCT02169284|OTHER|Laboratory Biomarker Analysis|Correlative studies
41451850|NCT01601353|DEVICE|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
41283918|NCT04837885|PROCEDURE|Scan|Scans after completion of LUTATHERA® treatment injection
41283919|NCT00722605|PROCEDURE|cone-beam CT|"You will have the following CT scans along with the standard weekly portal images:Before treatment you will have a CT scan (a respiratory-correlated CT scan) at the time of the radiation planning, or simulation planning.During the first week of treatment - you will have 5 cone-beam CT scans at days 1 through 5 of your radiation treatment schedule.~* During the remaining weeks of treatment - you will have a cone-beam CT scan every week. Depending on the number of treatments that your study doctor has prescribed for you, the number of weekly scans can be between 3 and 7.~* For all scans, an external monitor will be used to record your breathing.~* If needed, you will be repositioned by adjusting the radiation machine's treatment couch position."
41283920|NCT04453644|OTHER|Muscle static stretching|On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).
41283921|NCT00462423|DRUG|Avastin|Avastin 10 mg/kg IV every 2 weeks (without rest period).
41283922|NCT00462423|DRUG|Abraxane|Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
41283923|NCT04113629|DEVICE|HCV point of care machine|Xpert HCV Assay performed on the GeneXpert point of care machine
41283924|NCT01075425|DRUG|bortezomib|Given IV
41283925|NCT01075425|DRUG|belinostat|Given IV
41283926|NCT01075425|OTHER|laboratory biomarker analysis|Correlative studies
41283927|NCT01075425|GENETIC|western blotting|Correlative studies
41283928|NCT01075425|OTHER|pharmacological study|Correlative studies
41283929|NCT01075425|OTHER|flow cytometry|Correlative studies
41283930|NCT05178537|OTHER|AAS users|no intervention
41283931|NCT02629393|DRUG|ORGN001 (formerly ALXN1101)|
41283932|NCT01815437|DIETARY_SUPPLEMENT|Mushroom Vitamin D2|2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
41451851|NCT05484908|OTHER|DPMAS+LPE|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times in two weeks. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
41451852|NCT05484908|OTHER|PE|Patients will receive treatment of plasma exchange (PE) for three times in two weeks. The volume of fresh frozen plasma used in PE is 2000 millilitre.
41451853|NCT05484908|OTHER|Comprehensive internal medical treatment|Patients will receive comprehensive internal medical treatment.
41451854|NCT01252953|DRUG|Anacetrapib|tablet, 100mg daily
41451855|NCT01252953|DRUG|Placebo anacetrapib|tablet, 1 tablet daily
41283933|NCT01815437|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU crystalline cholecalciferol once/day for 12 weeks
41283934|NCT01815437|DIETARY_SUPPLEMENT|Vitamin D2 - Ergocalciferol|2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
41283935|NCT01815437|DIETARY_SUPPLEMENT|Mushroom Extract|Same quantity of mushroom extract in a capsule
41451856|NCT01749553|OTHER|Sleeper Stretch|Posterior shoulder stretch technique
40942600|NCT02169284|OTHER|Pharmacological Study|Correlative studies
40942601|NCT02169284|OTHER|Placebo|Given PO
41283936|NCT03928470|DRUG|EsoDuo Tab. 20/800mg|Nexium Tab. 20mg
41283937|NCT02502929|BEHAVIORAL|Social Services|
41283938|NCT02502929|BEHAVIORAL|Lifestyle|
41283939|NCT02502929|BEHAVIORAL|Lifestyle Plus Medication Therapy Management|
41451857|NCT04203667|DEVICE|EndoRotor Resection|"The EndoRotor® is a powered cutting cannula for the removal of alimentary tract mucosa. Cutting is performed by aspirating tissue into a rotating cutting window. The resected tissue is immediately aspirated away from the resection site and collected in the EndoRotor Specimen Trap. The tissue can then be sent for pathological examination using standard methods.~The system consists of a power console, foot control, specimen trap with pre-loaded filter and the applied part, which is the single-use catheter."
41451858|NCT05210608|BEHAVIORAL|Working Memory Training (Active Intervention) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Working Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
41283940|NCT02696083|DEVICE|Provant Therapy System|
41283941|NCT04937387|DRUG|FF/VI|FF/VI will be administered.
41451859|NCT05210608|BEHAVIORAL|Control Training (CT) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Control Condition Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
41451860|NCT00970788|BEHAVIORAL|Video intervention|Video of goals of care
41451861|NCT02805166|DRUG|PEG-rhG-CSF|
40942602|NCT02169284|OTHER|Quality-of-Life Assessment|Ancillary studies
40942603|NCT02169284|PROCEDURE|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
40942604|NCT05803629|DIAGNOSTIC_TEST|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq(2-4 mCi) 68Ga-FAPI.
41283942|NCT04937387|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered.
41283943|NCT04937387|DEVICE|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
41283944|NCT02375022|DRUG|Endostar and icotinib|Endostar and icotinib are used as combination therapy.
41283945|NCT00986778|DRUG|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
41283946|NCT00986778|DRUG|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
41283947|NCT00986778|DRUG|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
41283948|NCT03548428|DRUG|Atezolizumab|1200mg IV every 3 weeks for 4 months
41283949|NCT03548428|RADIATION|SBRT|3 to 5 fractions depending on tumor size
41283950|NCT00467844|DRUG|GTx-024|1 mg GTx 024
40942605|NCT05803629|DIAGNOSTIC_TEST|18F-FDG|Intravenous injection of one dosage of 7.4MBq/kg(0.2mCi/kg) 18F-FDG. 18F-FDG PET/CT is performed within one week from 68Ga-FAPI PET/CT scan.
40942606|NCT06426433|OTHER|Proprioceptive Exercises|In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Proprioceptive exercises aim to restore muscle balances, unconscious joint control with reactive muscle activations and feedforward joint control.
40942607|NCT06426433|OTHER|Upper Extremity Exercises|In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Upper extremity exercises are traditional rehabilitation exercises for strength, endurance and range of motion.
40942608|NCT03054753|BEHAVIORAL|Abduction brace wearing time analysis|To evaluate the patient´s abduction brace wearing time a sensor = Orthotimer® (Rollerwerk, 72336 Balingen, Germany, www.orthotimer.com) is implanted in the abduction brace. The sensor measures the body temperature of the patient. Through that the wearing time can be evaluated.
40942609|NCT05276154|OTHER|thermoviscous bulkfill composite (Viscalor)|a relatively new product of composite resin which is transformed from high viscosity to low viscosity by the action of head produced by a heating device.
41283951|NCT00467844|DRUG|GTx-024|3 mg GTx-024
41283952|NCT00467844|DRUG|Placebo|Matching Placebo
40756853|NCT04334681|PROCEDURE|Modified Limberg Flap Group|In this method, the pilonidal cyst is excised with a rhomboid incision and closed with the modified Limberg flap method.
41283953|NCT06027801|OTHER|Iron-fortified cookies|Study cookies fortified with ferrous fumarate, providing 15 mg of elemental iron in each portion.
41283954|NCT06027801|BIOLOGICAL|Japanese encephalitis (JE) vaccine|All participants will be administered the live attenuated JE vaccine
41283955|NCT06027801|BIOLOGICAL|Typhoid Vi polysaccharide (Vi-PS) vaccine|All participants will be administered the typhoid Vi-PS vaccine
40942610|NCT06293079|OTHER|Exercise Program|Structured rehabilitation program of the groups; Patient education consists of aerobic and strengthening exercises. An information brochure will be given to patients after the first evaluation about the program to be implemented.
40942611|NCT02092272|BEHAVIORAL|instructional exercise video source|instructional exercise video source
40942612|NCT03903653|DRUG|Botulinum toxin type A|"Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
40942613|NCT03903653|DEVICE|Serial Casting|"Using Serial Casting in conjunction with Botox injection for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
41283956|NCT06027801|OTHER|non-fortified cookies|Study cookies containing no iron
41283957|NCT05954754|OTHER|Diaphragmatic Breathing Exercises|Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
40942614|NCT04920682|DRUG|Reversal of moderate neuromuscular blockade|Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)\> 0.4
40942615|NCT04920682|DRUG|Reversal of superficial neuromuscular blockade|Neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
40942616|NCT04920682|DRUG|Two-step reversal|Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
40942617|NCT04920682|DRUG|Placebo|0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)\> 0.4
40942618|NCT03654443|DIAGNOSTIC_TEST|Critical care pain observation tool|The CPOT tool is administered in a crossover manner by two study observers
40942619|NCT00959712|BEHAVIORAL|ECA Interaction|The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
40942620|NCT04704843|DRUG|Guselkumab|Guselkumab will be administered as IV infusion (induction dose) and SC injection.
40942621|NCT04704843|DRUG|Placebo|Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
40942622|NCT01130103|DRUG|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
40942623|NCT01130103|BEHAVIORAL|Prolonged Exposure Therapy|Weekly for 10 weeks
40942624|NCT01352468|OTHER|Multifaceted cognitive training|Four computerized training tasks
40942625|NCT05345873|BIOLOGICAL|SCTV01E|one dose of SCTV01E on D0, intramuscular
40942626|NCT05345873|BIOLOGICAL|mRNA-1273|one dose of mRNA-1273 on D0, intramuscular
40942627|NCT02720237|BEHAVIORAL|Brief Intervention|In-person individual sessions (occurring one month apart) and booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.
40942628|NCT02720237|BEHAVIORAL|Motivational Enhancement Therapy (MET) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
40942629|NCT02720237|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
40942630|NCT01736124|OTHER|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
40942631|NCT01736124|OTHER|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
40942632|NCT01674634|BIOLOGICAL|XIAFLEX / XIAPEX|injection (0.58 mg after reconstitution with sterile diluent \[0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride\])
40942633|NCT05821673|PROCEDURE|Argon plasma pre-treated abutment insertion|abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.
40942634|NCT05821673|PROCEDURE|abutment insertion|the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment
40942635|NCT06403670|DRUG|Dexmedetomidine|Group DP received 0.5 mcg/kg of dexmedetomidine IV for 30 seconds, then dexmedetomidine infusion was started at 0.1-0.7 mcg/kg/h. Propofol 1 mg/kg was administered after waiting for 5 minutes for adequate sedation to develop due to dexmedetomidine's delayed onset of action.
40942636|NCT06403670|DRUG|Remifentanil|Group RP received remifentanil 0.1 mcg/kg intravenously for 30 seconds, then remifentanil infusion was started at 0.01-0.1 mcg/kg/min. After waiting 2 minutes to develop a sufficient sedation level, 1 mg/kg of propofol was given.
40942637|NCT03397173|DRUG|Azacitidine|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, allowing interruptions for weekends and holidays within each 28-day cycle. No dose modifications will be permitted during the treatment period.
40942638|NCT03397173|DRUG|Ascorbic acid|Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
40942639|NCT03561753|DRUG|Group A (the standard 2HRZE/4HR regimen）|The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
41283958|NCT01501344|DIETARY_SUPPLEMENT|200 g yogurt with fortified calcium content and MBP 80 mg|Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
41283959|NCT05370157|BEHAVIORAL|TeamTRACS|TeamTRACS is a team training intervention adapted from TeamSTEPPS (Team Strategies and Tools to Enhance Performance and Patient Safety), a widely used evidence-based team training developed by the Agency for Healthcare Research and Quality. TeamTRACS targets knowledge, skills, and attitudes related to team member roles, shared awareness, communication, mutual support, and goal-setting. TeamTRACS is structured, easy to use, flexible in length and intensity, and requires few resources. It incorporates didactic instruction, discussion, and interactive activities and can be delivered virtually or in-person.
41283960|NCT00232037|DRUG|Tegaserod|
41283961|NCT05109390|DRUG|Danicopan|Oral tablet.
41283962|NCT05109390|DRUG|Cyclosporine|Oral capsule.
41283963|NCT05109390|DRUG|Tacrolimus|Oral capsule.
40942640|NCT03561753|DRUG|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
40942641|NCT02422316|OTHER|Non-contrast Cardiac CT scan|
41283964|NCT05109390|DRUG|Calcium Carbonate|Chewable tablet.
41283965|NCT05109390|DRUG|Aluminum/Magnesium Hydroxide/Simethicone|Chewable tablet.
41283966|NCT05109390|DRUG|Omeprazole|Oral, delayed-release capsule.
41283967|NCT02599389|DEVICE|Drug-coated balloons|
41283968|NCT02599389|DEVICE|Excimer Laser|
41283969|NCT00025038|DRUG|tipifarnib|Given orally
41132236|NCT04128670|DEVICE|Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
41283970|NCT00025038|DRUG|isotretinoin|Given orally
41283971|NCT00025038|DRUG|fludarabine phosphate|Given IV
40942642|NCT03361254|BIOLOGICAL|cryopreservation|cryopreservation to every patient with an indication of ECP for acute or chronic GVHD in Nancy Hospital for 18 months
41283972|NCT00025038|DRUG|cytarabine|Given IV
41283973|NCT00025038|RADIATION|radiation therapy|Undergo total body irradiation
40942643|NCT00004076|DRUG|mureletecan|
40942644|NCT05663268|BIOLOGICAL|Infliximab-dyyb biosimilar|Remsima for subcutaneous injection is a biosimilar monoclonal antibody of infliximab-dyyb that inhibits the activity of tumour necrosis factor (TNF)-alpha.
40942645|NCT02185755|OTHER|Internet-Based Glucose Monitoring System|
40942646|NCT02185755|DRUG|Normal Medication Positive Control|
41132237|NCT02098837|DRUG|Dolutegravir|Dolutegravir 50mg once daily
41132238|NCT00973999|DRUG|Botulinum Toxin|"Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.~Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle."
41283974|NCT00025038|DRUG|cyclophosphamide|Given IV
41283975|NCT00025038|BIOLOGICAL|anti-thymocyte globulin|Given IV
41283976|NCT00025038|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplant
41283977|NCT00025038|PROCEDURE|double-unit umbilical cord blood transplantation|
41283978|NCT00025038|PROCEDURE|umbilical cord blood transplantation|Undergo allogeneic cord blood transplant
41283979|NCT00025038|OTHER|laboratory biomarker analysis|Correlative studies
41283980|NCT00679107|DEVICE|Use of OP-1 Putty in Uninstrumented posterolateral fusion|Use of OP-1 Putty in Uninstrumented posterolateral fusion
41283981|NCT04292600|DIAGNOSTIC_TEST|POCKiT diagnostics' algorithm for LVO detection|Measurement of blood biomarkers and integration within Pockit diagnostics' algorithm for LVO detection
41132239|NCT06132594|PROCEDURE|Conventional arthrocentesis followed by I-PRF injection|An auriculotemporal nerve block using Mebacaine 0.5% was administered near the mandible's neck. The patient sat at a 45° angle with their head turned. The posterior entry point was 10 mm from the midtragus and 2 mm below the line, while the anterior entry point was marked 20 mm from the midtragus and 10 mm below the line. A biting block kept the mouth open. 2-3 ml of Ringer lactate was injected with an 18-gauge needle to enlarge the joint space. A second needle allowed the solution to flow freely. After lavaging the joint, 1 ml of I-PRF was injected into the upper joint space. Jaw manipulation was done to address adhesions and improve disc mobility.
41267261|NCT04042194|PROCEDURE|Placement of Implants and Thickening Peri-Implant Mucosa with CTG|The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
41267262|NCT05202457|PROCEDURE|Elective surgery|Patient undergoing elective or urgent surgery
41267263|NCT05567523|DRUG|Dexmedetomidine|In dexmedetomidine groups, patients will be pumped 0.1ml/kg of dexmedetomidine (contained dexmedetomidine 0.25/0.5/0.75µg/kg in Group D0.25/D0.5/D0.75) for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation.
41267264|NCT05567523|DRUG|Normal saline|normal saline
41267265|NCT05567523|DRUG|Midazolam|midazolam
41267266|NCT03311256|DIAGNOSTIC_TEST|Tissue Transit Time|Determination of Tissue Transit Time as a prognostic and diagnostic factor
41267267|NCT01091636|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
41267268|NCT05850845|DEVICE|Microscopic hyperspectral imaging system|CTX for idiopathic membranous nephropathy
41267269|NCT00961987|OTHER|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
41267270|NCT00961987|OTHER|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
41267271|NCT05332119|DEVICE|VR glasses|Patients will watch a virtual world in VR glasses during the painful procedure. They will be able to choose between 3 VR content based on their preferences.
41267272|NCT05332119|OTHER|Control group|Patients will not receive distraction during chest drain removal
41267273|NCT02151344|BIOLOGICAL|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
41267274|NCT02151344|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
41267275|NCT02562547|DEVICE|Hem-Avert Perianal Stabilizer|The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
41267276|NCT02058732|OTHER|MRI|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
40942647|NCT02312921|OTHER|PREDICT|Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
40942648|NCT04117139|DIAGNOSTIC_TEST|PET/MRI|A PET/MRI of the Head and Neck region is done for all patients included in the project.
40942649|NCT01451580|DRUG|Lipo-Dox|
40942650|NCT02145988|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
41283982|NCT06499636|OTHER|other|other
41283983|NCT03885921|DRUG|Ezetimibe|oral tablet
41283984|NCT03885921|DRUG|Atorvastatin|oral tablet
41283985|NCT03885921|DRUG|Simvastatin|oral tablet
41283986|NCT00638846|DEVICE|senofilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
41283987|NCT00638846|DEVICE|balafilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
41283988|NCT04226352|DRUG|Dextromethorphan|Dextromethorphan will be administered and its tolerability evaluated.
41283989|NCT05055908|DRUG|Pemetrexed plus Pembrolizumab|Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
41283990|NCT05055908|DRUG|Pembrolizumab|Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
41283991|NCT05055908|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
41283992|NCT00059761|DRUG|cisplatin|
41283993|NCT00059761|DRUG|irinotecan hydrochloride|
41283994|NCT00059761|RADIATION|radiation therapy|
41283995|NCT02838030|DRUG|L-arginine|3 gr per day
40942651|NCT02145988|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
40942652|NCT00969254|DRUG|Pílulas de Lussen|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pílulas de Lussen®~\*\* Drug B: placebo."
40942653|NCT00969254|DRUG|Pyridium®|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pyridium®~\*\* Drug B: placebo."
40942654|NCT02464917|DEVICE|Device: simple facemask to administer supplemental oxygen|
40942655|NCT02459652|DRUG|S-1|S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
40942656|NCT02459652|RADIATION|Radiation Therapy|Radiation therapy is delivered with \>6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
41132240|NCT06132594|PROCEDURE|3d surgical guided Arthrocentesis followed by I-PRF injection|Patients underwent arthrocentesis with Ringer lactate, followed by I-PRF injection in the TMJ's superior space using a CT-planned 3D-printed guide. Positioned at a 45° angle, patients were comfortably seated, and disinfection was performed. The patient-specific guide, fitting over maxillary teeth and the face, was employed unilaterally or bilaterally with a biting block for mouth opening maintenance. An 18-gauge needle administered 2-3 ml of Ringer lactate, widening the joint space, followed by a second needle allowing free solution flow (80-90 ml) to flush the superior joint space. Post-arthrocentesis, 1 ml of I-PRF was injected. To enhance joint mobility and free the disc, gentle manipulation of the lower jaw was performed after removing the needles and guide.
41132241|NCT03537326|DRUG|Budesonide|Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
41132242|NCT02063659|DRUG|Telotristat etiprate|Telotristat etiprate tablets
41132243|NCT02063659|DRUG|Placebo|Placebo-matching telotristat etiprate tablets
41132244|NCT01988649|DRUG|Intranasal Oxytocin|Administration of intranasal Oxytocin
41132245|NCT01988649|DRUG|Placebo (saline)|Administration of normal saline intranasally.
41132246|NCT03496558|OTHER|Variability of the lipid profile in pregnant women|"The women participants will be divided into two groups. Group 1 comprised of healthy women and group 2 by pregnant women with a history of risk. A personal, family history and a detailed medical history will be taken in each group. We will proceed to see all possible variables that influence the level of biomarkers (lipids and prolactin).~At least 60 healthy pregnant women and 60 pregnant women with a history of risk (20 for each risk) x 2 series (three years) will be tried, a total of 240-300 women to whom 5 analytical tests would have to be performed."
41132247|NCT00003412|BIOLOGICAL|recombinant interleukin-12|
41132248|NCT02176577|DRUG|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
41132249|NCT03221881|DRUG|Pegylated Liposomal Doxorubicin and docetaxel|
41132250|NCT00880074|DRUG|Fluorothymidine F-18|Undergo fluorine F-18 fluorothymidine PET
41132251|NCT00880074|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41132252|NCT00880074|PROCEDURE|Positron Emission Tomography|Undergo fluorine F-18 fluorothymidine PET
41283996|NCT02838030|DRUG|Placebo (for L-arginine)|3 gr per day
41283997|NCT02838030|DRUG|acetylsalicylic acid|3 gr per day
41283998|NCT05914363|OTHER|Sealed washable floor plus behaviour change|Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling
41283999|NCT05914363|BEHAVIORAL|Behaviour change intervention|Support for behaviour change through 'floor clubs' and the provision of printed guides
41284000|NCT05914363|DRUG|Routine deworming|Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)
41284001|NCT05914363|PROCEDURE|treatment for tungiasis|Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county Department of Health recommendations
41284002|NCT03616743|BEHAVIORAL|Psychoeducation|Psychoeducation about the links between smoking and chronic pain.
40942657|NCT04648709|DIAGNOSTIC_TEST|ELISPOT|measure of immune response by ELISPOT
40942658|NCT04648709|DIAGNOSTIC_TEST|QUANTIFERON|measure of immune response by QUANTIFERON
40942659|NCT05290207|DIAGNOSTIC_TEST|The hyperinsulinaemic hypoglycaemic clamp|Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
40942660|NCT04171284|DRUG|SCT-I10|200 mg, Q3W, maximum treatment up to six cycles
40942661|NCT04171284|DRUG|Docetaxel|70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles
41284003|NCT03616743|BEHAVIORAL|Brief smoking control arm|Psychoeducation about the general adverse effects of smoking.
40942662|NCT04171284|DRUG|Placebo|200 mg, Q3W, maximum treatment up to six cycles
40942663|NCT05215990|DRUG|MetFORMIN 500 Mg Oral Tablet|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive metformin with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
40942664|NCT05215990|DRUG|Placebo|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive placebo drug with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
40942665|NCT02545595|DRUG|Sugammadex 1 mg/kg|
40942666|NCT02545595|DRUG|Sugammadex 2 mg/kg|
40942667|NCT02545595|DRUG|Sugammadex 4 mg/kg|
40942668|NCT06409351|BEHAVIORAL|Intervention group|Please refer to arm descriptions
40942669|NCT03500471|PROCEDURE|Robotic-assisted Total Gastrectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
40942670|NCT03500471|PROCEDURE|Laparoscopic-assisted Total Gastrectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
40942671|NCT05077735|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
40942672|NCT05077735|OTHER|Questionnaire Administration|Ancillary studies
40942673|NCT05077735|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40942674|NCT05077735|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
40942675|NCT03530566|OTHER|PnK® Method|A multidisciplinary program of weight loss based on diet (initially very low ketogenic diet), physical activity and emotional support
40942676|NCT03530566|OTHER|standard diet|standard low calorie diet for weight loss
40942677|NCT01924507|DEVICE|CPAP|CPAP - continuous positive air pressure in patients with sleep apnea
40942678|NCT03253458|DEVICE|Confocal Laser Endomicroscopy|Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
40942679|NCT01466179|BIOLOGICAL|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
40942680|NCT00882466|DRUG|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
40942681|NCT00729599|DRUG|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
40942682|NCT04810663|RADIATION|Radiotherapy|Adjuvant Radiotherapy in operated gastric cancer
40942683|NCT04766710|OTHER|Community-based ART delivery (CAD)|The frontline workers to implement the CAD model intervention will be people living with HIV recruited from the community who will plays roles as CAWs. The CAWs will receive intensive training, coaching, and mentoring from their respective ART clinics and implementing partners' field staff on ARV dispensing, drug storage, patient's vital sign assessment and recording, HIV education and counseling, medication adherence, referral systems, mental health, stigma and discrimination, and sexual and reproductive health of people living with HIV. To closely monitor the work of the CAWs, a respective ART clinic team, consisting of an ART counselor and a physician, will be tasked to conduct regular supervision along with the program team of the implementing partners to the community groups at least once a month in the first six months. After the six months, supervisory visits will be extended to once every two months.
40942684|NCT04766710|OTHER|ART multi-month dispensing (MMD)|The control arm participants will receive routine services under the MMD model based on standard community-based prevention, care, and support practices in Cambodia. The NCHADS has introduced MDD in all ART sites across the country. However, so far, not all ART sites currently operate the MMD. The MMD is designed to help ART service providers implement MMD for eligible patients-that is, patients whose condition is determined to be stable-which will reduce the need for frequent visits and providers' workload. Stable people living with HIV receive care and support from counselors and ARVs at the clinics every four to six months.
40942685|NCT01104155|DRUG|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
40942686|NCT01104155|DRUG|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
41284004|NCT05937711|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG|"PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes~Duloxetine 30 mg p.o 1X1 (daily)"
41284005|NCT05937711|DRUG|Duloxetine 30 MG|Duloxetine 30 mg p.o 1X1 (daily)
41284006|NCT04813510|DEVICE|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi, electroacupuncture stimulation apparatus(HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
41284007|NCT04813510|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints).. Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
41284008|NCT02334709|RADIATION|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
41284009|NCT06417632|OTHER|Graded Zirconia Crown|monolithic implant supported crown
41284010|NCT06417632|OTHER|Conventional Zirconia Crown|monolithic implant supported crown
41284011|NCT03289689|DEVICE|Whole-body vibration (WBV)|Whole-body vibration (WBV) is a novel neuromuscular therapeutic intervention that has recently been developed since in the mid-1960s. Hagbart and Eklund showed in human experiments that a reflex muscle contraction can result as a consequence of applying vibrations to the muscular-tendon system. The subjects stand on a platform that generates stochastic vibrations at a frequency between 1-12.5 Hz.
41284012|NCT03738956|DRUG|Tofacitinib|"The study subjects fulfilling the inclusion criteria will receive tofacitinib 5mg BD.~All the patients in the study group will go through disease history, clinical examination and baseline investigations. Baseline charachteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. Primary endpoint of efficacy will be assessed using ASAS 20 response at the end of 12 th wk. At the end of 12 th week, those patients will achieve primary endpoint will continue with the same dose and those patients who will not achieve primary endpoint will be put on tofacitinib10 mg BD. Those patients who will not respond to treatment at the end of 24 th wk will discontinue the therapy and put on alternative treatment."
41284013|NCT02851654|DEVICE|Infrared oculography|The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
41284014|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
41284015|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
40942687|NCT02404467|DEVICE|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
41132253|NCT05467566|DEVICE|Transcranial direct current stimulation|Exercise protocol + application of active direct current stimulation for 30 minutes.
41132254|NCT05467566|DEVICE|Sham Transcranial direct current stimulation|Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
41132255|NCT01473485|DEVICE|ExAblate Transcranial System|MR Guided Focused Ultrasound
41284016|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
41284017|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
41284018|NCT03563534|DRUG|Silver Diamine Fluoride|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.
41284019|NCT03563534|DRUG|Glass Ionomer|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
41284020|NCT01175512|DRUG|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
41284021|NCT01175512|DRUG|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
41132256|NCT06033040|OTHER|MRI|Functional sequence imaging (MDME, IVIM) sequences were added to the routine MRI scan of patients with bladder tumor
41132257|NCT00703391|DRUG|AZD9668|30mg oral tablets twice daily (bid) for 14 days
40942694|NCT04485910|OTHER|Single step media|Usage of single step media in embryo culture
40942695|NCT04485910|OTHER|Sequential media|Usage of sequential media in embryo culture
41284022|NCT06388720|DRUG|Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml|Intravesical sequential treatment of Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml.
41284023|NCT00413751|DRUG|Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)|
41284024|NCT06463912|OTHER|Does not apply|A descriptive cross-sectional study will be carried out in the city of Armenia-Colombia. A total of 205 PWID, 18 years to 65 years old will be included. They will be selected through the implementation of the respondent-driven sampling (RDS).
41284025|NCT02302495|DRUG|Carfilzomib|"DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study."
40942696|NCT03469050|DRUG|Rifaximin delayed released 400mg Tablet|Rifaximin delayed released
40942697|NCT03469050|OTHER|Placebo|Placebo BID + Placebo BID
40942698|NCT00167557|DRUG|Pegylated Interferon|180mcg SC weekly starting 30 days post transplant
40942699|NCT00167557|DRUG|Ribavirin|goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
40942700|NCT00167557|PROCEDURE|Liver Biopsy|Liver biopsies performed at 9 points in time from time of liver transplant
40942701|NCT01284582|BIOLOGICAL|ATH03|4 vaccinations
40942702|NCT05126498|OTHER|no intervention|no intervention was applied
40942703|NCT01567735|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
40942704|NCT04399837|DRUG|Spesolimab|Solution for injection
40942705|NCT04399837|DRUG|Placebo|Solution for injection
40942706|NCT04171297|PROCEDURE|Ultrasound evaluation of DE|To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis.
40942707|NCT03506061|DRUG|Trikafta|Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (2 tablets taken in the morning), and 150 mg of ivacaftor taken in the evening.
40942708|NCT04196751|OTHER|Clinical Supervision|After baseline data collection, participants will be invited to attend training on clinical supervision (CS). Education will be delivered in 3 phases. 1-Orientation to the CS model 2-Integration of theory into practice and 3-Skill advancement for supervisors. After training, participants will be encouraged to choose a supervisor, identify objectives for skill development. They will be advised to meet their supervisor once a month for 60 minutes (Due to COVID 19 pandemic the participants can have either one-to-one session in-person or virtually (Microsoft Team), however, if the supervisor and the supervisee working in the same campus can have their one-to-one session as per their preferences. Supervisor-supervisee will be working together to achieve the stated goals. Only the recorded attendance and nature of the session will be used for research purpose. Data will be collected at baseline, 6\&12 month with pre-specified tools.
40942709|NCT05201742|OTHER|Inspiratory muscle training|Threshold inspiratory muscle training was performed for 6 weeks with device.
40942710|NCT05201742|OTHER|Incentive Spirometry|Incentive spirometry was performed for 6 weeks with device.
40942711|NCT04068610|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
40942712|NCT04068610|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
40942713|NCT04068610|DRUG|FOLFOX|Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
41132258|NCT00703391|DRUG|Placebo|Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
41132259|NCT03400579|DEVICE|autoRIC® device|The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
41132260|NCT03163563|DEVICE|Easywarm|Warming blanket
41132261|NCT03163563|DEVICE|BairHugger|Patient warming mattress with continuous warm air.
41132262|NCT04995588|OTHER|Blood test|Unique blood draw of 45mL for all the participants
41132263|NCT01645046|DRUG|Coenzyme A|Coenzyme A 200mg per day.
41132264|NCT01645046|DRUG|Coenzyme A|Coenzyme A 400mg per day.
41132265|NCT01645046|DRUG|Placebo|Capsule without coenzyme A.
41132266|NCT02923479|DEVICE|Specific ankle rehabilitation by ARBOT device|ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
41132267|NCT02923479|OTHER|General Rehabilitation|All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
41132268|NCT02923479|OTHER|Specific ankle rehabilitation performed by physiotherapist|Subjects in the control group underwent manually assisted range of motion exercises.
41132269|NCT02923479|DEVICE|Specific ankle rehabilitation by Biodex System 3 dynamometer|Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
41132270|NCT02923479|DEVICE|Specific ankle rehabilitation by ProKin PK254 platform|Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
41132271|NCT05909449|OTHER|exercises|participants will be given a structured home exercise program
41132272|NCT05671211|OTHER|Task-Oriented Training|Participants in this group will receive 30 minutes of task-oriented training and 1 hour of conventional therapy for 6 weeks 5 times a week.
41132273|NCT05671211|OTHER|Conventional Therapy|Conventional therapy will be consisted of balance,upper and lower extremity strengthening exercises.
40942714|NCT04068610|DRUG|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
40942715|NCT06551636|OTHER|respiratory physiotherapy (AAD)|The AAD technique involves placing the physiotherapist's hands on the chest where the secretions are identified and applying pressure to the chest. The maneuver will last according to the patient's tolerance, in an average of approximately 10 min.
40756854|NCT02767687|OTHER|Noninvasive ventilation|Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
40942716|NCT01563744|PROCEDURE|EGD-assisted administration of colonoscopy prep|Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
40942717|NCT01563744|PROCEDURE|Control Group received standard prep by oral administration|Control group receive standard oral colonoscopy prep.
40942718|NCT01134731|DRUG|paliperidone|1-5 mg daily (QD)
40942719|NCT01134731|DRUG|lithium|300-1500mg QD
40942720|NCT01134731|DRUG|Placebo|1-5 placebo capsules
40942721|NCT02385370|DRUG|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
40942722|NCT02385370|DRUG|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
40942723|NCT05599269|DEVICE|Examination of dentures with SR Phonares II teeth|The intraoral situation will be examined similar to a standard dental examination. The dentures are then removed, cleaned and examined extraoral. Pictures and an impression of the dentures are taken.
40942724|NCT06058078|DRUG|RY_SW01 cell injection|Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
40942725|NCT06058078|DRUG|Basic treatment|Drugs for LN treatment
40942726|NCT00891007|BIOLOGICAL|MVA-mBN85B|Low Dose arm, 1x 10E7 TCID50
40756855|NCT03538821|DIETARY_SUPPLEMENT|Intact cod protein from fillet|Intact cod protein from fillet 8 g protein daily for 8 weeks
40756856|NCT03538821|DIETARY_SUPPLEMENT|Intact cod protein from residual material|Intact cod protein from residual material, 8 g protein daily for 8 weeks
40756857|NCT03538821|DIETARY_SUPPLEMENT|Control|Control group receive tablet containing fillers
40942727|NCT00891007|BIOLOGICAL|MVA-mBN85B|Normal Dose arm, 1x 10E8 TCID50
40942728|NCT00891007|BIOLOGICAL|Rouvax|Standard measles vaccine, approved in South Africa
40942729|NCT03173027|DRUG|Fangji Huangqi pill or Fangji Huangqi pill placebo|For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
40942730|NCT00993161|DEVICE|Motriplate|Number of contact couples
40942731|NCT00993161|DEVICE|Motriplate|Number of contact couples
40942732|NCT00455767|DRUG|EPI-hNE4|I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
40942733|NCT00455767|DRUG|Placebo|Placebo
40942734|NCT02464371|OTHER|kinetic of microRNAs|blood samples will be drawn to measure microRNAs
40942735|NCT05533216|OTHER|Performance of different upper limb functional tests|The participants will have to perform 3 to 5 different upper libm functional tests, depends on the sport they practice.
40942736|NCT06061731|DRUG|low-frequency acupoint electrical stimulation|In order to determine the efficacy of low-frequency acupoint electrical stimulation and electroacupuncture to improve thumb to finger action after stroke
41267277|NCT01916278|DEVICE|Emervel Lips Lidocaine|
41267278|NCT01916278|DEVICE|Juvéderma Volbella with Lidocaine|
41267279|NCT05518604|BEHAVIORAL|Counseling with goal of modifying eating behaviors|Dietary counseling will occur virtually a minimum of 4x and as desired by participant in the first year postpartum according to a standard protocol
41267280|NCT04019366|OTHER|Balance Training|Experimental group received balance training on Biodex stability System along with traditional exercise program. During balance training on Biodex, patients were instructed to stand on the platform with bare feet with open eyes and both legs supported. Patients were looking forward to screen having hands hang by the sides. The patients were instructed not to change their feet position and balance the body. The handles were accessible for safety point. But touching the handles cancelled the trail. Total time of training was 10 minutes each set is of 3 minutes with 20 sec rest intervals.
41267281|NCT04019366|OTHER|Conventional Training|Control group has received traditional exercises i.e Quadriceps strength exercises, Hamstrings flexibility exercises and Balance exercises.
41267282|NCT00804687|OTHER|Placebo|Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.
41267283|NCT00804687|DRUG|JNJ-39220675|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
41267284|NCT00804687|DRUG|Pseudoephedrine|Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
41267285|NCT00191672|DRUG|Gemcitabine|
41267286|NCT00191672|DRUG|Paclitaxel|
41267287|NCT00191672|DRUG|Docetaxel|
41267288|NCT00450580|DRUG|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
41267289|NCT06094101|BIOLOGICAL|Peptide vaccine IPX|"Peptide vaccine is a combination of~1. class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~2. class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~3. control peptide derived from Survivin.~4. adjuvant: toll like receptor (TLR) 1/2 ligand XS15."
41267290|NCT01743573|OTHER|yoga|
40756858|NCT03492294|DIAGNOSTIC_TEST|functional magnetic resonance imaging|Patients with disorders of consciousness were assessed by functional magnetic resonance imaging while they were exposed under the condition of music.
40756859|NCT05457205|OTHER|Electrical neuromodulation|Electrical neuromodulation intervention using transcutaneous spinal stimulation: two self-adhesive semicircle electrodes (forming a 5cm round electrode) will be centered midline over the T11-12 spinal processes, and two 8×13 cm electrodes will be placed paraumbilical and interconnected to serve as a counter electrode. A current-controlled stimulator will deliver symmetric biphasic pulses (500-μs/phase). Electrical stimulation will be applied according to the description in each study arm.
40756860|NCT05952375|DRUG|Chimeric antigen receptor T cell preparation targeting Claudin18.2|Chimeric antigen receptor T cell preparation targeting Claudin18.2
40756861|NCT04843839|DRUG|Nepafenac 0.1% Oph Susp|Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months
40756862|NCT04843839|DRUG|Refresh Tears 0.5% Lubricant Eye Drops|Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months
41284026|NCT06487403|RADIATION|Standard of care external beam radiotherapy (single integrated boost)|70Gy in 35 fractions, 56 Gy in 35 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
41284027|NCT06487403|RADIATION|Standard of care external beam radiotherapy (two-phase treatment)|70Gy in 35 fractions, delayed 40 Gy in 20 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
41284028|NCT00930410|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
40756863|NCT00307580|DRUG|Cathflo Activase (Alteplase)|
40756864|NCT01379937|BIOLOGICAL|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
40756865|NCT01379937|BIOLOGICAL|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
41284029|NCT05069740|DRUG|Salsalate Pill|Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
40756866|NCT01379937|BIOLOGICAL|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
40756867|NCT01379937|BIOLOGICAL|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
40756868|NCT03731455|DEVICE|WISE Cortical Strip|The WISE Cortical Strip is a medical device composed by a strip and by a cable.
40756869|NCT06541080|DIAGNOSTIC_TEST|Shallow Whole Genome Sequencing (sWGS)-GIPXplore|GIPXplore will be used to mine shallow whole genome sequencing cell free DNA data for identification of signatures.
40756870|NCT06541080|DIAGNOSTIC_TEST|methylation-sensitive restriction enzymes (MSRE)-Single-molecule molecular inversion probes (smMIP)-seq assay|Aberrant methylation in ccfDNA will be analyzed using the novel, highly sensitive MSRE-smMIP-seq technology.
41284030|NCT05069740|DRUG|Placebo|Placebo for the salsalate intervention
41284031|NCT02381158|DRUG|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
40756871|NCT03564067|DEVICE|Soterix Medical tDCS mini-Clinical Trials system (mini-CT)|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). Home-based tDCS will involve 30-min tDCS (3 days per week) for the first 3 months and once weekly for the subsequent 3 months.
40756872|NCT03564067|BEHAVIORAL|Computerized CBT (cCBT)|Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
40756873|NCT03165695|DRUG|Ramelteon|Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
41284032|NCT00004046|DRUG|exatecan mesylate|
41284033|NCT04184648|OTHER|no interventions|no intervention
41284034|NCT05460208|DIETARY_SUPPLEMENT|Enriched spread|The experimental spread is made with a base made with 90% extra virgin olive oil to which plant sterols are added.
41284035|NCT05460208|DIETARY_SUPPLEMENT|Control spread|The control spread will be the same base spread made with extra virgin olive oil without the added plant sterols.
41284036|NCT01927458|DEVICE|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
41284037|NCT01812525|DRUG|NaCl 3%|NaCl 3%: 4ml QID
41284038|NCT01812525|OTHER|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
41284039|NCT02453841|DRUG|Oxymetazoline|
41284040|NCT03397186|PROCEDURE|Biopsy|Undergo biopsy
41284041|NCT03397186|OTHER|Laboratory Biomarker Analysis|Correlative studies
41284042|NCT03397186|DRUG|Trabectedin|Given as standard of care
41284043|NCT03947294|DEVICE|Q-NRG®|Energy expenditure measurements
40942737|NCT00756015|OTHER|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
40942738|NCT00756015|OTHER|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
40942739|NCT04064788|OTHER|Consecutive Modified Constraint-Induced Movement Therapy|Consecutive mCIMT group received 6 hours per day mCIMT sessions for consecutive 10 days. Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
40756874|NCT03165695|DRUG|Placebo|Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
40756875|NCT05196503|BIOLOGICAL|Treatment|"Experimental product: product derived from autologous blood, obtained after centrifugation.~Treatment modalities: intraoperative periradicular administration of autologous PRF."
40942740|NCT04064788|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
41267291|NCT05427578|OTHER|fNIRS measurement|measurement using functional near-infrared spectroscopy
41267292|NCT02613208|DRUG|Bevacizumab|Bevacizumab will be administered as per local clinical practice and local labeling.
41267293|NCT02613208|DRUG|Paclitaxel|Paclitaxel will be administered as per local clinical practice and local labeling.
41267294|NCT02804360|DEVICE|dexamethasone injection|intravitreal dexamethasone in retinitis pigmentosa cystoid macular edema
41267295|NCT03211182|BEHAVIORAL|lifestyle modification intervention|healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI\>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
41267296|NCT02935972|DRUG|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
41267297|NCT02935972|DRUG|Lidocaine 1%|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
41267298|NCT02935972|DRUG|Diazepam and Lidocaine 1%|received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
41267299|NCT00786045|OTHER|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
41267300|NCT01073579|DRUG|Sabril®|"Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily."
41267301|NCT05173584|DRUG|Levalbuterol|Levalbuterol nebulizer solution 1.25mg/3ml with a total dose of 5 mg (12ml) for each patient.
41267302|NCT05173584|DRUG|Albuterol|Albuterol nebulizer solution 2.5 mg/3ml with a total dose of 0 mg (12ml) for each patient.
41267303|NCT01815645|BEHAVIORAL|ST+CM|12 weeks of the standard treatment offered by a open treatment service for drug addiction of the city of Sao Paulo (AME) plus Contingency Management
41267304|NCT01815645|BEHAVIORAL|standard treatment|12 weeks of standard treatment offered by AME (a open treatment service for drug addiction of the city of Sao Paulo)
41267305|NCT04106388|BEHAVIORAL|Virtual Behavioral Health Integration|The virtual behavioral health integration program, implemented in primary care settings, is a structured mental illness treatment program that includes both behavioral treatment and counseling components aimed at reducing cost of care, developing and sustaining adaptive coping strategies, and improving short term acute care utilization.
41267306|NCT03377647|BEHAVIORAL|Asthma Care Provider Training|In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.
41267307|NCT03377647|BEHAVIORAL|School Staff Asthma Education|In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.
41267308|NCT01030692|DRUG|Placebo|The placebo groups will receive the same dosage throughout the study.
41267309|NCT01030692|DRUG|Rivastigmine 3 mg|The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
41267310|NCT01030692|DRUG|Huperzine A 0.4 mg|The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
41267311|NCT01030692|DRUG|Rivastigmine 6 mg|The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
41284044|NCT00196885|DRUG|N-acetylcysteine|
41284045|NCT05509244|DRUG|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
41284046|NCT05509244|DRUG|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
41284047|NCT02201823|DRUG|ABTL0812|ABTL0812. Five cohorts and one extension phase.
41284048|NCT04006769|DRUG|Entacapone|Entacapone tablet
41284049|NCT04006769|DRUG|Imatinib Mesylate|Imatinib Mesylate tablet
41284050|NCT02300129|DRUG|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
41451862|NCT02152618|OTHER|Parent Management Training - Oregon Model (PMTO)|Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
41451863|NCT01269658|DRUG|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
41451864|NCT01269658|DRUG|Vehicle|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
41451865|NCT05137093|DEVICE|Actigraphy Device|Patients will wear actigraphy device which detects scratching events.
40942741|NCT04064788|OTHER|Intermittent Modified Constraint-Induced Movement Therapy|Intermittent mCIMT group received mCIMT session 6 hours per day for 10 days, spread over 5 weeks (two days per week). Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
41284051|NCT02300129|DRUG|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
41284052|NCT02300129|DRUG|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
41284053|NCT02300129|DRUG|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
41284054|NCT03157544|BEHAVIORAL|multimodal non-pharmacological Pain Relief Kit|"Participants will be told: No two people have the same kind of pain and that pain management must be individualized to your pain. Thus, we want you to try the four modes of the non-pharmacological interventions included in the kit individually and in combination in order to determine what works best to relieve your pain~The Pain Relief kit will also include written instructions and materials for three behavioral techniques directed at maintaining compliance with the non-pharmacological interventions. During the review of the Pain Relief Kit with a member of the research staff participants will be informed about the recommended use of the three behavioral techniques including setting goals, working with a buddy and keeping a graph of your progress. This information will also be included in written form in the Pain Relief Kit."
41284055|NCT03352440|DEVICE|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
41284056|NCT03352440|DEVICE|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
41284057|NCT03352440|DEVICE|Control Group - Kinect|Group with typical development that will perform the task on Kinect
41284058|NCT03352440|DEVICE|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
41284059|NCT05518786|OTHER|Exposure of interest: critical illness|Patients admitted to an intensive care unit (ICU) will be followed-up to evaluate post-ICU long-term sequelae
41284060|NCT03499054|OTHER|Breathing exercises|During hemodialysis, the participants in the exercise group are asked to keep ttheir muscles relaxed, breathe normally through the nose at a rate of 3-8 times per minute with each breath held over 5 seconds in length. At the same time, the particpants are asked to also perform lower leg lifts for about 8 seconds per lift. The exercise is performed for 15-20 minutes, and after resting, blood pressure, oxygen saturation and HRV are measured.
41284061|NCT02621385|DRUG|tradipitant|test agent
41284062|NCT02621385|DRUG|Midazolam|substrate for drug-drug interaction assessment
41284063|NCT05575518|DRUG|Optimised rifamycin|optimised dose rifampicin with or without moxifloxacin
41451866|NCT00942721|BEHAVIORAL|Web-based CBT for PPD|A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
41451867|NCT04556045|BEHAVIORAL|Exercise therapy|The exercise therapy intervention will last 4 weeks. Each participant assigned to this intervention will receive a personalized ET regimen, including in-person, supervised exercise sessions; other activities to be followed at home. Participants will exercise between one and seven times per week depending on their tolerance to the treatment and exercise program.
41451868|NCT00268216|DRUG|Salmeterol 50mcg/ Fluticasone Propionate 500mcg|
41451869|NCT00913627|DRUG|ibuprofen|
41451870|NCT00913627|DRUG|ibuprofen|
41451871|NCT00913627|DRUG|naproxen|
41451872|NCT00913627|DRUG|Placebo|
40942742|NCT00221260|PROCEDURE|anesthesia|Intraoperative general anesthesia AND postoperative IV narcotic analgesia.
41284064|NCT01939262|OTHER|Limitation of Animal Fat and Protein in the Diet|Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
41284065|NCT01939262|OTHER|Control|Participants assigned to the control group will be instructed to follow their usual diets.
41284066|NCT00730743|PROCEDURE|Intermittent Pringle maneuver|Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
41284067|NCT05375292|OTHER|PREHABILITATION|"Customized program made by the physical therapist based on the first visit.~It includes 3 parts :~1. Nutrition advices that ensures adequate caloric and protein intake to support muscle anabolism~2. Muscle building over a few sessions with a physiotherapist to learn exercises and then independently redo them~3. Cardio-respiratory endurance exercises."
41284068|NCT01363505|DEVICE|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
41284069|NCT03484026|DIETARY_SUPPLEMENT|BioFe|BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
41284070|NCT04286308|OTHER|electrophysiological data collection|Electrophysiological data collection at the time of DBS surgery.
41284071|NCT02158533|DRUG|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
41284072|NCT02158533|DRUG|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
41284073|NCT02158533|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
41284074|NCT00001446|DRUG|thalidomide|
40942743|NCT03078907|DRUG|Selexipag|Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
41284075|NCT04599790|DRUG|TACE combined with lenvatinib and sintilimab|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
41284076|NCT04746521|DIAGNOSTIC_TEST|Multitest 6 color TBNK and BD Lyotubes|The Multitest 6 color TBNK allows us to count the population-specific B, T, NK cells
41284077|NCT04746521|BIOLOGICAL|genomicDNA extraction|Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood \& Tissue kit (QIAGEN), according to manufacturer protocols
41284078|NCT04248777|OTHER|standardised OCT-guided intervention|The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
41284079|NCT04181281|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|This is a regular ultrasound scanner used with an ultrasound contrast agent injected through veins to allow for kidney perfusion acquisition.
41284080|NCT04181281|DIAGNOSTIC_TEST|Arterial Spin Labelling -Magnetic Resonance Imaging|Arterial spin labelling is an MRI technique allow for measuring tissue perfusion. It uses magnetically labelled arterial blood water protons as a tracer.
41284081|NCT01623466|DRUG|levonorgestrel|transdermal contraceptive delivery system
41284082|NCT02200107|BEHAVIORAL|self management education|
41284083|NCT03384043|BEHAVIORAL|Smartphone Personal Assistant|Electronic memory aids (e.g., pagers) are known to support memory for goals and intentions (prospective memory) in individuals with cognitive impairment. Smartphone technology has the potential to enhance the benefits of previous electronic memory aids because they can provide reminders not only at the correct time, but also at the correct location.
41284084|NCT03384043|BEHAVIORAL|Implementation Intention|Verbally specifying when and where one intends to complete a goal or action (prospective memory) is known to improve the likelihood of later completing that prospective memory. The implementation intention is the best known memory strategy for prospective memory in patients with mild cognitive impairment.
41284085|NCT00080210|DRUG|Puricase|
41284086|NCT02699775|OTHER|Motion Analysis|Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
41284087|NCT03195101|PROCEDURE|transconjunctival orbitotomy approach|approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
40942744|NCT03078907|DRUG|Placebo|Matching film coated tablets
41132274|NCT02725138|DIETARY_SUPPLEMENT|Probiotic|Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
41284088|NCT05134623|DIAGNOSTIC_TEST|immunohistochemistry of tumors samples|routine resection of tumors, further analysis and immunohisochemical staining of the tissue slides.
41284089|NCT05191082|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
41284090|NCT05191082|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
40756876|NCT05114291|OTHER|Explorations are planned as part of the one-day hospitalization|"* Clinical parameters : Interrogation, physical examination, morphological data measurements (weight, height, waist circumference, hip circumference) and impedencemetry (body composition).~* Biological samples : Blood and urine exam, fasting urine sample (urinary osmolarity)~* Standardized blood pressure measurement :~  * After 5 to 10 minutes of rest, with automated measurements at 1 minute intervals : un-attended, then attended~* Hemodynamic parameters :~  * Sphygmocor® : measure of the central blood pressure and pulse wave velocity~ * MESI® tool : measure of the Systolic Pressure Index (PSI or IPS)~ * pOpmetre® : Calculation of the speed of the pulse wave by the pOpmetre® device~* Others : if indicated (echocardiography, ABPM)"
40756877|NCT05066139|OTHER|EPODIG-G program (coordination of supportive care)|EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)
41284091|NCT05191082|DEVICE|Palatal Wound treated with Neurotensin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with neurotensin and 4.0 silk sutures.
40756878|NCT01807741|DRUG|Asenapine|Available in 5 and 10 mg.
40756879|NCT01807741|DRUG|Placebo|
41284092|NCT05721885|BEHAVIORAL|nutrition management|Nutritional management was performed by clinical pharmacists and registered dietitians to develop nutritional intervention strategies based on patient clinical assessment and nutritional assessment. PG-SGA score was 0-3 points, and diet guidance was given. PG-SGA score \> 4 points, artificial nutrition intervention was carried out, and the way and amount of nutritional intervention were clarified to achieve the final daily energy and protein target requirements. Nutritional interventions and assessments were adjusted over time.
41284093|NCT04526587|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples
41284094|NCT04526587|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
41284095|NCT04526587|OTHER|Medical Chart Review|Patient's electronic health records are reviewed
41284096|NCT02722577|PROCEDURE|Radio-frequency Ablation|A procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats.
41284097|NCT03485612|DIAGNOSTIC_TEST|Change of Optic Nerve Sheath Diameter|In patients, the optic nerve sheath width (ONSD) examination will be performed twice: for the first time immediately after general anesthesia and again after surgery after placing the patient in a position on the back.
41284098|NCT04946110|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
41284099|NCT00293280|DRUG|lomustine|
41284100|NCT04086043|DEVICE|Endovascular Denervation|multi-electrode catheter-based endovascular denervation
41284101|NCT00021866|BEHAVIORAL|Differential Abilities Scale|IQ measurement at 3, 4.5 and 6 years of age
41284102|NCT00021866|BEHAVIORAL|Neuropsychological Testing|Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
41284103|NCT05171738|DEVICE|skeletally anchored distal jet|used from day one and activated every month
41284104|NCT04154982|DRUG|Acetyl cysteine|1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.
41284105|NCT02215629|DRUG|VS-4718|
41284106|NCT04048577|DRUG|Dosing Interruption of Natalizumab|Planned 12 week dosing interruption of natalizumab
41284107|NCT05426044|DRUG|Metformin|"To investigate whether metformin has a neuroprotective effect in patients with primary open-angle glaucoma by comparing the rates of change of average retinal nerve fiber layer ganglion cell inner plexiform layer (RNFL-GCIPL) thickness (primary outcome measure) between patients randomized to receive metformin versus those randomized to receive placebo.~To identify the risk factors associated with progressive RNFL-GCIPL thinning and progressive decline in visual field mean deviation in patients with glaucoma."
41284108|NCT05426044|DEVICE|Placebo|This study takes 24 months. Participants will have 12 visits within 24 months. All of the investigations will be carried out at Grantham Hospital and Hong Kong Eye Hospital. Patients will be randomly assigned in a 1:1 ratio to receive, twice daily, oral metformin 750mg (i.e. 1500mg/day) or identical-appearing oral placebo. The investigators and patients will be blinded to the treatment assignment. Participants will be followed up at 2-month intervals for 24 months.
41284109|NCT00043147|DRUG|beclomethasone dipropionate|
40756880|NCT03997591|OTHER|Ready2E.A.T. PROGRAM|"Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy."
41284110|NCT00043147|DRUG|methylprednisolone|
41284111|NCT00043147|DRUG|prednisone|
41284112|NCT05659121|DEVICE|robotic exoskeleton training|robotic exoskeleton training using EksoGT will be incorporated into subject's conventional physiotherapy training.
41284113|NCT03989063|BEHAVIORAL|Instructions to perform a motor task (external vs. internal focus instructions)|During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).
40756881|NCT00071994|DRUG|gefitinib|Given orally
41284114|NCT04332549|DRUG|PICS (Reconstitution Method 1 or 2)|dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
40942745|NCT05300633|BEHAVIORAL|Group-Based Community Reinforcement Approach and Family Training-Early Psychosis Intervention (CRAFT-EPI)|Behavioral therapy adapted for families of young people experiencing early psychosis delivered via telemedicine to groups following an individual orientation. Group session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, and problem solving. A happiness scale will be completed at each session. Will be provided in the context of an early psychosis intervention program that provides coordinated specialty care to 16- to 29-year-olds experiencing any diagnosis that can manifest as early psychosis.
41451873|NCT04468880|OTHER|Group (A1 → A2)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A1A2 milk for 2 weeks (period 1), then they will consume A2A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
41451874|NCT04468880|OTHER|Group (A2 → A1)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A2A2 milk for 2 weeks (period 1), then they will consume A1A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
40942746|NCT02121782|BIOLOGICAL|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
40942747|NCT02121782|BIOLOGICAL|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
41284115|NCT04430348|DRUG|PTX-35|Monoclonal antibody PTX-35
41284116|NCT05453253|BIOLOGICAL|Delayed second dose of oral cholera vaccine, Euvichol-Plus|The intervention arms (6 and 12 months) will modify the recommended interval for administration of the second vaccine dose, which will be extended to 6 and 12 months according to the intervention arm.
40756882|NCT00071994|OTHER|laboratory biomarker analysis|Correlative studies
40942748|NCT04852497|PROCEDURE|Ventricular tachycardia ablation|patients having undergone ventricular tachycardia radiofrequency ablation using of pace mapping strategy to identify the critical isthmus
41284117|NCT05453253|BIOLOGICAL|Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice|"Euvichol-Plus, a WHO prequalified oral cholera vaccine, contains modified killed whole cell vaccine of formalin killed Vibrio cholerae strains of O1 Inaba, O1 Ogawa and O139.~In the control arm, participants will receive the Euvichol-Plus following the manufacturer recommendations: two doses administered orally 14 days apart for individuals aged ≥1 year."
40756883|NCT00009542|DRUG|kava (Piper methysticum)|
40756884|NCT01026428|DRUG|Safinamide + Levodopa|Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
40756885|NCT01026428|OTHER|Placebo + Levodopa|Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
40756886|NCT03307590|DRUG|Dexmedetomidine|Caudal block by dexmedetomidine and bupivavaine
40756887|NCT03307590|DRUG|Bupivacaine|Caudal block by bupivavaine alone
40756888|NCT00562198|DRUG|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
40942749|NCT04877743|OTHER|None (Observational study)|The main data sources for the study will be participants and their medical records. Vaccination details will be verified by a vaccination card, batch/lot number, and/or using a regional vaccination register. Participants will report all study outcomes using the study app, web portal, or call centre. Participants can also select a proxy to communicate on their behalf: a caregiver, family member, or other trusted individual. Participants will be asked for an emergency contact in case of death or incapacity.
40942750|NCT01076231|RADIATION|proton beam radiation therapy|
40942751|NCT01076231|DRUG|cisplatin|Given IV
40942752|NCT01076231|DRUG|etoposide|Given IV
40942753|NCT01076231|PROCEDURE|therapeutic conventional surgery|
40942754|NCT03773211|DRUG|Renaparin|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
40942755|NCT03773211|DRUG|Placebo|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
40942756|NCT03590873|DRUG|Vasopressin|Vasopressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to arginine vasopressin. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). Arginine vasopressin has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, arginine vasopressin constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.
41284118|NCT04902248|DEVICE|The OTSC® System Set|The endoscope was extracted and equipped with the OTSC system. OTSC system is deployed on the lesion with suction to target lesion
41284119|NCT04902248|PROCEDURE|angiographic embolization|Transcatheter selective embolization to bleeding arteries
41451875|NCT00627796|DRUG|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were \> 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were \< 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels \<1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
40756889|NCT00562198|DRUG|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
40942757|NCT03300960|DRUG|Provera 10 mg.|One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
40942758|NCT03300960|DRUG|Ganirelix (GnRH antagonist)|One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
40942759|NCT01580358|DRUG|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
40942760|NCT01580358|DRUG|Starch|It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
40942761|NCT02644031|PROCEDURE|mtwo rotary system|post-treatment pain after using mtwo rotary system
40942762|NCT02644031|PROCEDURE|safe-sider rotary system|post-treatment pain after using safe-sider rotary system
40942763|NCT02644031|PROCEDURE|hand files|post-treatment pain after using hand files
40942764|NCT00336154|DRUG|tetracyclin|
40942765|NCT02883166|DRUG|abiraterone|integested with a continental breakfast
40942766|NCT04134052|DRUG|ketamine sedation versus midazolam sedation|Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
41132275|NCT02725138|OTHER|Placebo|Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
41451876|NCT01989884|DRUG|Ortataxel|75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
40756890|NCT00529815|DEVICE|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
40942767|NCT02715973|DIETARY_SUPPLEMENT|Nutritional Supplement|Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
40942768|NCT02715973|DIETARY_SUPPLEMENT|Standard Nutritional Treatment|Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
40942769|NCT01539642|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
40942770|NCT01539642|DRUG|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
40942771|NCT00723931|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
40942772|NCT03722199|DIETARY_SUPPLEMENT|flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)|single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
40942773|NCT03722199|OTHER|Placebo|single intake of capsules with a placebo
40942774|NCT02892032|BEHAVIORAL|Attention Modification Training|Subjects are taught to disengage attention from a certain stimuli
40942775|NCT02892032|BEHAVIORAL|No Attention Modification Training|Subjects are exposed to two stimuli, but attention is not manipulated in any way
41451877|NCT01203215|BEHAVIORAL|2 print based physical activity interventions|physical activity promotion
40756891|NCT00529815|DEVICE|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
40756892|NCT04130425|DEVICE|Hely & Weber MTC Fracture Brace|Prefabricated muenster orthosis
40756893|NCT04130425|DEVICE|Thermoplastic orthosis|Muenster orthosis fabricated out of thermoplastics and secured with Velcro
40756894|NCT04130425|DEVICE|Delta cast orthosis|Muenster orthosis fabricated out of Delta Cast and secured with Velcro
40942776|NCT02643329|DRUG|BF-Gliclazide Tablet 80mg|BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
40942777|NCT02643329|DRUG|Diamicron 80mg Tablet|Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
40942778|NCT00000862|DRUG|Zidovudine|
40942779|NCT00185991|DRUG|gentamicin|"Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours)."
40942780|NCT06515977|PROCEDURE|TXI (Group A)|Patients in Group A will undergo colonoscopy with TXI.
40942781|NCT06515977|PROCEDURE|TXI followed by WLI (Group B)|Patients in group B will first undergo colonoscopy with TXI and every polyp found should be removed. Then switch to WLI for a second withdrawal to detect lesions that were not observed the first time.
40942782|NCT06515977|PROCEDURE|WLI (Group C)|Patients in Group C will undergo colonoscopy with WLI.
40942783|NCT06515977|PROCEDURE|WLI followed by TXI (Group D)|Patients in group D will first undergo colonoscopy with WLI and every polyp found should be removed. Then switch to TXI for a second withdrawal to detect lesions that were not observed the first time.
41451878|NCT05129176|DRUG|Levofloxacin|levofloxacin-tetracycline-containing quadruple regimens
41451879|NCT05129176|DRUG|Metronidazole|Metronidazole-tetracycline-containing quadruple regimens
41451880|NCT05762458|DRUG|Ammoxetine|Ammoxetine hydrochloride enteric-coated tablets
41451881|NCT05762458|DRUG|Placebo|placebo to Ammoxetine.
40942784|NCT00540319|BEHAVIORAL|HIP|"The Health in Pregnancy (HIP) computer program provides tailored, interactive Video Doctor counseling about behavioral risks, educational worksheets for the patients, and a cueing sheet for providers."
40942785|NCT04223583|DRUG|Anlotinib Hydrochloride|The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
40942786|NCT00090051|DRUG|Rituximab|Intravenous repeating dose
40942787|NCT00090051|DRUG|Fludarabine Phosphate|Intravenous repeating dose
40942788|NCT00090051|DRUG|Cyclophosphamide|Intravenous repeating dose
40942789|NCT00140478|DRUG|Mifepristone|200mg orally once daily
40942790|NCT05495971|DEVICE|NaturalVue Multifocal|EDOF
41284120|NCT00855712|DEVICE|Organ Care System|The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
41284121|NCT00855712|DEVICE|Cold Cardioplegia Solution|This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
41284122|NCT01591590|OTHER|FDG PET-CT|All patients will undergo FDG PET-CT at inclusion and 2 weeks after
41284123|NCT01591590|OTHER|Diffusion MRI|All patients will undergo Diffusion MRI at inclusion and 2 weeks later
41284124|NCT01591590|OTHER|Blood samples (plasma preparation and CTC)|
41284125|NCT05300529|OTHER|Vestibular Rehabilitation Exercises|The Vestibular Rehabilitation program focuses on stabilizing the gaze and gaining the Vestibular Ocular Reflex (VOR). The general mechanisms of recovery from vestibular injuries are vestibular adaptation and replacement exercises, which are designed to improve gaze stability and the interaction between sight and the vestibular system during head movements. The exercises will be carried out progressively according to the tolerance of the patient, varying the stimulus in intensity and frequency.
40942791|NCT03706131|OTHER|cervical mobilisation|manual therapy
40942792|NCT02584699|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
40942793|NCT03711201|BEHAVIORAL|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
40942794|NCT02119169|DEVICE|Pigtail catheter|pigtail catheter for pleural drainage
40942795|NCT02647437|DRUG|Levetiracetam|
40942796|NCT02647437|DRUG|Placebo|
40942797|NCT02787005|BIOLOGICAL|Pembrolizumab|Intravenous infusion
40942798|NCT05272839|DIETARY_SUPPLEMENT|Hypoglycemic food group|A booklet with 4 common food products, clinically validated against diabetes, with instructions for use will be presented to the diabetic patient. The selected food products have been assessed as anti-diabetic for humans through at least one fair randomized comparative clinical trial, with a follow-up of several weeks or months. While continuing to take his/her standard medication if any, the patient will be encouraged to follow his/her preferences within the established list of foods and spices: he is expected to choose 2 plants from the list and to consume each of them every day during the whole duration of the trial (12weeks).
40942799|NCT05272839|DIETARY_SUPPLEMENT|Control group|The control group will receive only lifestyle and dietary recommendations.
41284126|NCT05300529|OTHER|Conventional Rehabilitation exercises|The conventional rehabilitation program in which exercises are performed to improve joint range, flexibility, and gait. It will always be done with the eyes open, on a firm surface and will not include training in sensory strategies
41132276|NCT03883828|DRUG|Chlorhexidine gluconate solution|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
41132277|NCT03883828|DRUG|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
41132278|NCT01849536|DEVICE|SENSIMED Triggerfish®|
41284127|NCT04146532|DRUG|Aspirin 500 MG|Single 500mg aspirin capsule.
41284128|NCT04146532|DRUG|Placebo|Single 500mg placebo capsule.
41284129|NCT04507750|DRUG|Camrelizumab|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
41284130|NCT01541605|DRUG|methylphenidate|tablets for oral use
41284131|NCT01541605|DRUG|Placebo|tablets for oral use
41284132|NCT00668967|DRUG|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
41284133|NCT00668967|DRUG|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
41132279|NCT00980213|DRUG|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
41132280|NCT02105259|BEHAVIORAL|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for patients social anxiety disorder
41284134|NCT03767569|DRUG|Myo-inositol|Myo-inositol and Folic acid daily
41284135|NCT03767569|DRUG|Folic Acid|Folic Acid daily
41284136|NCT02054650|OTHER|Osteopathic Manual Treatment (OMT)|Osteopathic Manual Treatment (OMT) is a system of hands-on techniques used by osteopathic physicians to increase function and reduce pain.
41284137|NCT02054650|OTHER|Sham OMT|Sham OMT involves hand contact, active and passive range of motion, and sham techniques that simulate OMT, but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force.
41284138|NCT01115712|DRUG|Placebo|Placebo (to match pioglitazone 30 mg) once daily
41284139|NCT01115712|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg once daily
40756895|NCT05284071|DEVICE|Device: Actiste 1.0 and the Companion app with TBL Backend|Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes and may improve the patients' adherence to treatment plans. Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes.
40756896|NCT06429085|DEVICE|Rex robotic assisted balance exercises|Individual is supported by a Rex robotic exoskeleton which enables assisted and supervised practise of balance exercises. This intervention took place as a supported and supervised series of 5 sessions over 5 weeks as an Out-patient.
41132281|NCT02105259|OTHER|Waiting list|Waiting list, where participants wait for delayed treatment
41132282|NCT02417285|DRUG|Obinutuzumab|1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.
41451882|NCT05470153|DEVICE|Continuous Positive Airway Pressure|For each patient with Obstructive Sleep Apnea, titration of Continuous Positive Airway Pressure (CPAP) pressure will be performed by conventional polysomnography or using auto-CPAP equipment using a validated protocol. The CPAP device should have an hour meter recording system, so that machine-on time hours could be checked at each clinical visit.
41132283|NCT02417285|DRUG|CC-122|CC-122 1mg, 2mg, 3mg, 4mg or 5mg administered orally once daily on a 5/7-day schedule in each 28-day cycle. In addition, subjects will be enrolled on the CC-122 formulated capsule (F6) and evaluated for safety and tolerability in combination with GA101 (Obinituzumab) in a separate cohort. The CC-122 dose will be escalated until the MTD is established on the CC-122 formulated capsule (F6) in combination with GA101 (Obinituzumab).
41132284|NCT03528603|OTHER|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal
41132285|NCT03528603|OTHER|Oleocanthal-low Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal
41132286|NCT02324387|PROCEDURE|Molecular Breast Imaging (MBI)|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
41132287|NCT02324387|DRUG|Tc99m sestamibi|8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
41132288|NCT04275960|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
41132289|NCT05750043|DRUG|bi-annual CDTI|"bi-annual community directed treatment with ivermectin (CDTI) and community-based slash and clear vector control intervention"
41132290|NCT06074744|OTHER|SSNB + IPACK|already included in arm/group description
41132291|NCT06074744|OTHER|FNB + IPACK|already included in arm/group description
41267312|NCT01030692|DRUG|Huperzine A 0.8 mg|The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
40756897|NCT05819866|DRUG|Leriglitazone|Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml
40756898|NCT05819866|DRUG|Placebo|Placebo will match the study drug visually and by taste
40756899|NCT02156505|PROCEDURE|placement of double bare stent|
40756900|NCT02156505|DEVICE|DoubleBare stent|
40756901|NCT01082458|DRUG|remifentanil / lidocaine|"Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.~Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery."
40756902|NCT02262221|OTHER|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
40756903|NCT05530915|OTHER|Gel capsule|Single capsule per dose
40756904|NCT03977298|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
40756905|NCT03977298|PROCEDURE|CTG|CTG will be positioned in the buccal aspect of the peri-implant tissue
40756906|NCT00048308|DRUG|pexelizumab|
40756907|NCT01548885|DEVICE|CONTOUR® NEXT EZ BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of CONTOUR® NEXT EZ BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
41267313|NCT06526780|PROCEDURE|Bronchscopy|Bronchscopy in critical ill children with airway diseases
41267314|NCT06361641|DIAGNOSTIC_TEST|Monocytes signatures in myeloproliferative neoplasms at diagnosis|The monocytes signatures will be perform from a peripheral blood sample. The signature will be derived from (i) surface marker expression, (ii) cytokines profiles, (iii) genes expression.
41267315|NCT03632395|DIAGNOSTIC_TEST|computed tomography|computed tomography
41267316|NCT04249882|DRUG|Placebo|Matched to active medication
41267317|NCT04249882|DRUG|Naltrexone|50 mg once a day
41267318|NCT04249882|DRUG|Varenicline|1 mg twice a day
41267319|NCT00065026|BEHAVIORAL|Physical activity opportunities for low-income women|
41267320|NCT02257047|DIETARY_SUPPLEMENT|Tea|
41267321|NCT02257047|DIETARY_SUPPLEMENT|RYR|red yeast rice
41267322|NCT04390087|OTHER|Exercise|Upper-body rowing performed while participants are sitting in their own wheelchair.
41267323|NCT00004054|DRUG|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
41267324|NCT00004054|DRUG|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
41267325|NCT00004054|DRUG|etoposide|50 mg/m\^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
41267326|NCT00004054|DRUG|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
41267327|NCT00004054|DRUG|paclitaxel|135 mg/m\^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
41267328|NCT00004054|DRUG|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
41267329|NCT00004054|RADIATION|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
41267330|NCT00004054|DRUG|warfarin|To keep international normalized ratio (INR) \> 1.5 and \< 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
41267331|NCT03906253|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
41267332|NCT04481022|OTHER|proximal control exercises|"study investigates the effectiveness of proximal control exercises for patients with PFPS in improving pain and function. The findings of this systematic review are consistent with previous evidence reporting effectiveness of exercise for PFPS. In particular, there is consistent moderate to high quality evidence (three RCT, one CCT, three cohort studies, and one case series) that proximal interventions provide relief of pain and improved function in the short term, whereas the knee programs have variable effectiveness. Physical therapists should consider using proximal interventions for early stage treatment for PFPS (Peters et al., 2013).~After 4 weeks of a combined knee and hip strengthening exercise program, sedentary females with PFPS had a greater reduction in pain during stair descent compared to the group who performed knee strengthening exercises only. Both groups also showed significant improvement in function and pain during stair ascent (Fakuda et al., 2010)."
41267333|NCT00501475|DRUG|NAC Bicarbonate|
41267334|NCT00755079|DRUG|extended release beta-2 adrenergic agonist|Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.
41267335|NCT00755079|DRUG|placebo|An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
41267336|NCT00036335|DRUG|Duloxetine Hydrochloride|
41284140|NCT01115712|DRUG|Comparator: Hyperinsulinemic Euglycemic Clamp|Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
41284141|NCT04685603|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
41284142|NCT03014869|DEVICE|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
41284143|NCT04803812|OTHER|"Remote SMS (short message service, also known as text message) delivery"|Assessing the comparative effects of SMS types (storytelling; resources/strategies; and a combination of both) on physician wellbeing.
41284144|NCT00463437|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose.
41284145|NCT00463437|BIOLOGICAL|Prevenar|Intramuscular injection, 1 dose.
41284146|NCT00463437|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 1 dose. In Germany and Poland.
41284147|NCT00463437|BIOLOGICAL|Infanrix IPV Hib|Intramuscular injection, 1 dose. In Spain.
41284148|NCT00463437|BIOLOGICAL|Infanrix penta|Intramuscular injection, 1 dose. In Germany and Poland.
40942800|NCT02434367|BEHAVIORAL|Walk With Ease Arm A|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
40942801|NCT04338984|DRUG|General anesthetic|Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.
40942802|NCT04338984|DRUG|Ropivacaine 0.5% Injectable Solution|"Bilateral single shot erector spinae plane block is performed before induction of general anaesthesia.~Ropivacaine 0.5% total dose 3mg/kg with Dexamethasone 8mg/20 ml Ropivacaine 0.5%."
40942803|NCT03956134|DRUG|Tapentadol Test Product 1|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2
40942804|NCT03956134|DRUG|Tapentadol Test Product 2|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1
41284149|NCT00463437|BIOLOGICAL|Infanrix IPV|Intramuscular injection, 1 dose. In Spain.
41284150|NCT00463437|BIOLOGICAL|Meningitec|Intramuscular injection, 1 dose.
41284151|NCT00463437|BIOLOGICAL|NeisVac-C|Intramuscular injection, 1 dose.
41284152|NCT00463437|BIOLOGICAL|Menitorix|Intramuscular injection, 1 dose.
41284153|NCT04632199|DRUG|111In-IPN01087 Low dose|Administered once via slow intravenous injection.
41284154|NCT04632199|DRUG|111In-IPN01087 High dose|Administered once via slow intravenous injection.
40942805|NCT03956134|DRUG|Tapentadol Prolonged-release Reference Product|Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
40942806|NCT06002243|DIAGNOSTIC_TEST|SPLASH echocardiography screening|Screening echocardiogram performed by a briefly trained health worker with images reviewed off site by an expert cardiologist or cardiac sonographer to determine screening outcome. Screening outcome may include: screen positive, screen negative or uninterpretable images.
41284155|NCT03650439|DIAGNOSTIC_TEST|culture on Sabouraud's Dextrose Agar (SDA)|• Clinical samples will be cultured onto Sabouraud's Dextrose Agar (SDA) plates supplemented with chloramphenicol. the culture was incubated at 25 C° and at 37° C (for yeasts and moulds isolation )
41284156|NCT00550628|GENETIC|DNA methylation analysis|
41284157|NCT00550628|GENETIC|fluorescence in situ hybridization|
41284158|NCT00550628|GENETIC|gene expression analysis|
41284159|NCT00550628|GENETIC|polymerase chain reaction|
41284160|NCT00550628|GENETIC|protein expression analysis|
41284161|NCT00550628|GENETIC|reverse transcriptase-polymerase chain reaction|
41284162|NCT00550628|OTHER|diagnostic laboratory biomarker analysis|
41284163|NCT00550628|OTHER|immunoenzyme technique|
41284164|NCT00550628|OTHER|immunohistochemistry staining method|
41284165|NCT00550628|PROCEDURE|biopsy|
41284166|NCT00550628|PROCEDURE|therapeutic conventional surgery|
41284167|NCT00550628|RADIATION|fludeoxyglucose F 18|
41284168|NCT04648462|OTHER|ProTRAIT|The participants are seen at the outpatient clinic by a physician, physician assistant or trial nurse at standard follow-up times at 2.5, 5, 7.5 and 10 years after radiotherapy.
41284169|NCT05033210|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a WHO developed support strategy that involves humane, supportive and practical help for individuals living in a serious humanitarian crisis. PFA does not necessarily involve a discussion of the event(s) that cause the distress but aims particularly at five basic elements that are crucial to promote in the aftermath of crises, i.e. a sense of safety, calm, self- and community efficacy, connectedness, and hope (Hobfoll et al., 2007). It consists of a conversation (approximately 30-45 minutes) that a helper has with a participant which can be provided remotely (e.g. videoconferencing or telephone). It has various themes; the helper provides non-intruding practical care and support, listen to needs and concerns, helps people to address basic needs (e.g. information), listens to people without pressuring them to talk, comforts people and helps them to feel calm, helps people to connect to information, services, and social support, and protects people from further harm (WHO, 2011).
41284170|NCT05033210|BEHAVIORAL|Care as Usual (CAU)|In addition to PFA, both arms will be allowed to receive any usual care (CAU). CAU ranges from community care to specialised psychological treatments.
41284171|NCT05033210|BEHAVIORAL|Doing What Matters in Times of Stress (DWM)|DWM is based on the acceptance and commitment therapy (ACT), a form of cognitive-behavioural therapy, with distinct features (Hayes, Levin, Plumb-Vilardaga, Villatte \& Pistorello, 2013). ACT is based on the concept that ongoing attempts to suppress unwanted thoughts and feelings can make these problems worse, so instead it emphasises on learning new ways to accommodate these thoughts and feelings without letting them dominate. ACT has been shown to be useful for a range of mental health issues (Tjak et al., 2015) and has been used successfully in a guided self-help format (Hayes et al., 2013). DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, will be adapted for use on a smartphone or other device with internet access.
41284172|NCT05033210|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011). The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. In these 90-minute sessions participants may talk to trained non-professional helpers (who are supervised by registered (clinical) psychologists). PM+ has four core features: it is brief (five sessions); delivered by non-specialist helpers; transdiagnostic thereby addressing depression, anxiety, PTSD, stress and problems as defined by people themselves; and originally designed for people in low-income country communities but easily adaptable to different (vulnerable) populations, cultures and languages.
40942807|NCT04378946|BEHAVIORAL|Intensive physical rehabilitation type training|Multiple reaching tasks aiming at increasing voluntary elbow range of motion
41284173|NCT04522752|OTHER|Size and pathological type of benign epithelial gastric polyp|All subjects will undergo gastroscopy and biopsy to determine the size and pathological type of benign epithelial gastric polyps.The correlation between polyp size and type and polyp development was observed at 6 months, 12 months and 18 months after inclusion.
40942808|NCT04378946|DEVICE|Robotic system for supporting and monitoring arm motion|"Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training."
41284174|NCT01631357|BIOLOGICAL|CIK cell|CIK cell injection
41284175|NCT01631357|DRUG|Gemcitabine Injection|Gemcitabine injection
41284176|NCT01631357|DRUG|Cisplatin injection|Cisplatin injection
41284177|NCT00548314|OTHER|dermal matrix|1mm thickness matrix composed of collagen-elastin hydrolosate
41284178|NCT00548314|PROCEDURE|Split skin graft|
41284179|NCT00548314|DEVICE|VAC therapy (KCI)|VAC therapy for 3-5 days 125mmHg
41284180|NCT05738616|COMBINATION_PRODUCT|Lenvatinib combined with TACE and Camrelizumab|Once subjects have signed the informed consent and passed screening, they will be randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib combined with TACE).
41284181|NCT05567328|DEVICE|Research FibroScan (FS)|"Exams will be performed with the M or XL probe as per FS recommendations. Same probe must be used for all exams Exploratory exam after patient 151 are performed with adapted view of Research FS~Patients 1 to 90 \& 151 to 190 Exam1 Exploratory exam with the Research FS Exam2 Reference exam with the CE-marked FS~Patients 91 to 130 \& 191 to 230 Exams1\&2 Two consecutive Exploratory exams with the Research FS Exams3\&4 Two consecutive Reference exams with the CE-marked FS~Patients 131 to 150 Exams1\&2 Two consecutive Exploratory exams with automatic function of the Research FS Exam3 Reference exam with the CE-marked FS~Patients 231 to 270 Exams1 (novice operator) Exploratory exam with the Research FS Exams2 (novice operator) Reference exam with the CE-marked FS Exams3 (experienced/expert operator) Exploratory exam with the Research FS Exams4 (experienced/expert operator) Reference exam with the CE-marked FS"
41284182|NCT04926155|DRUG|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
41284183|NCT04021472|BEHAVIORAL|Text message|Two months of daily text messages to support meeting a health goal
41284184|NCT00716521|DRUG|placebo|single oral dose placebo
41284185|NCT00716521|DRUG|zolpidem|single oral dose, 5 mg zolpidem
41284186|NCT00716521|DRUG|zolpidem|single oral dose, 10 mg zolpidem
41284187|NCT01538771|DRUG|Darbepoetin alfa|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
41284188|NCT01538771|DRUG|Control Saline|Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
40942809|NCT04378946|DEVICE|Actigraph Activity Monitor|Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate
40942810|NCT04378946|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Done once before treatment (PRE)
41284189|NCT00480961|PROCEDURE|intramiocardiac autograft of autologous stem cells|
41284190|NCT05612997|OTHER|Dietary Assessment|Food Frequency Questionnaire and 24h Recalls.
41284191|NCT02135640|DRUG|denosumab 60mg|solution
40942811|NCT04378946|DIAGNOSTIC_TEST|Montreal Spasticity Measure (MSM)|Used to identify the actual spatial threshold (ST) prior to every training session
41284192|NCT02135640|DRUG|denosumab 120 mg|solution
41284193|NCT02135640|DRUG|placebo|solution
41284194|NCT04118556|BIOLOGICAL|Decidua Stroma Cells (DSC)|"Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response."
41284195|NCT04118556|DRUG|Best available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
41284196|NCT05780281|BIOLOGICAL|VIR-7831|VIR-7831 is a fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibody (mAb) derived from antibody S309 from a survivor of SARS-CoV-1.
41284197|NCT05780281|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
41284198|NCT05780281|BIOLOGICAL|Remdesivir|Antiviral agent
41284199|NCT00500071|DRUG|Vyvanse (lisdexamfetamine dimesylate)|Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
40942812|NCT02542982|DEVICE|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
40942813|NCT00975637|DRUG|70 mg SC|70 mg SC
40942814|NCT00975637|DRUG|210 mg SC|210 mg SC
40942815|NCT00975637|DRUG|140 mg SC|140 mg SC
40942816|NCT00975637|DRUG|280 mg SC|280 mg SC
40942817|NCT00975637|DRUG|Placebo|Placebo SC
40942818|NCT00037960|PROCEDURE|Constrained Induced Therapy|
40942819|NCT00641303|PROCEDURE|acupuncture therapy|Given weekly for 8 sessions
40942820|NCT00641303|PROCEDURE|sham intervention|Given weekly for 8 sessions
40942821|NCT05176509|DRUG|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
40942822|NCT05176509|DRUG|YH001|YH001 will be administered intravenously over 60 minutes every 21-day cycle.
40942823|NCT05176509|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
40942824|NCT03418623|DRUG|GET73|GET73 300 mg oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
40942825|NCT03418623|OTHER|Placebo|Placebo oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
41284200|NCT01040832|DRUG|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter \[mg/m\^2\] over 120 minutes followed by 250 mg/m\^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
41284201|NCT01040832|DRUG|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram \[mg/kg\] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
41284202|NCT05763940|DIETARY_SUPPLEMENT|OmegaBoost|"An ultra-pure omega-3 fish oil supplement with no fishy aftertaste and no fish burps.~10x more omega-3 from fish oil than the leading omega-3 gummies. Gel bites have better absorption than ordinary, hard-to-swallow fish oil pills."
41284203|NCT05763940|DIETARY_SUPPLEMENT|Nature Made (soft gel)|A commercially-available omega-3 soft gel formula
41284204|NCT05763940|DIETARY_SUPPLEMENT|Nature Made (gummy)|A commercially-available omega-3 formula in gummy form
41284205|NCT01519115|OTHER|early physical therapy intervention|instruction in home care program to be followed for first six weeks after ACF surgery
41284206|NCT01519115|OTHER|usual care|one physical therapy visit in hospital following ACF surgery
41284207|NCT04537637|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
41284208|NCT02153515|OTHER|Your own ( autologous) finger prick of blood produced with a diabetic lancet|
41284209|NCT06273904|DEVICE|Active transcranial focused ultrasound (tFUS)|Active non-invasive low-intensity focused ultrasound will be delivered using a proprietary head-worn device and control software from Attune Neurosciences. On an active stimulation day, focused ultrasound will be delivered to the brain region of interest using parameters from published research that are demonstrated to safely cause temporary changes in the activity in that brain area.
40942826|NCT03865771|BEHAVIORAL|Neuropsychological testing|memory, executive testing, behaviour questionnaire, visual attention,
40942827|NCT03865771|BEHAVIORAL|Neuropsychological procedure|Rey auditory verbal learning test, Delayed recall : 1h, 5h, 24h (after one night sleep)
40942828|NCT03865771|OTHER|Video EEG and polysomnography|Video EEG : 10 electrodes + 3 electrodes for PSG 2h wake EEG Whole night EEG
40942829|NCT04836312|BEHAVIORAL|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
40942830|NCT00530101|DRUG|Doxorubicin|"This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:~Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2"
40942831|NCT05635071|DRUG|Nintedanib 100 MG [Ofev]|Nintedanib 100mg bid \*15 days orally after hysteroscopic surgery
40942832|NCT05635071|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150mg bid \*15 days orally after hysteroscopic surgery
40942833|NCT03880604|PROCEDURE|Triple tourniquets|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels
40942834|NCT03880604|DRUG|TA|1-gram tranexamic acid (10 ml) in 100 ml saline infusion
40942835|NCT03880604|OTHER|placebo to TA|placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
40942836|NCT04911413|DRUG|Tranexamic acid|The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.
40942837|NCT05691907|DEVICE|THE therapy|"THE therapy consisting of:~* Heating Pad~* Interferential Therapy"
40942838|NCT05691907|PROCEDURE|Directional Preference Exercises|Directional Preference Exercises consisting of Mckenzie's extension protocol
40942839|NCT05691907|PROCEDURE|Motor Control Exercises|Motor Control Exercises consisting of External limb loading extension protocol
41284210|NCT06273904|DEVICE|Sham transcranial focused ultrasound (tFUS)|Non-active low-intensity ultrasound will also be conducted using a proprietary head-worn device and control software from Attune Neurosciences. On the sham stimulation day, the device will be activated in a manner that produces similar sensory effects (i.e., low-volume beeping-type noise from the device) but also prevents delivery of a focused ultrasound beam to the brain area of interest or any other brain area.
41284211|NCT02164565|DRUG|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
41284212|NCT02164565|DRUG|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
41284213|NCT01979510|DRUG|MK-0663B|MK-0663B once daily for 8 days.
41451883|NCT01956318|BEHAVIORAL|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
40756908|NCT01548885|DEVICE|FreeStyle Freedom Lite® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of FreeStyle Freedom Lite® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
40942840|NCT00857415|DRUG|florbetapir F 18|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
40942841|NCT06065423|OTHER|Manuel Lymphatic Drainage(MLD), Exercises|"MLD:It is a unique massage technique that uses specific hand movements to provide a gentle pumping effect on the skin.~Massage movements follow the direction of lymph flow and produce rapid results. The aim of this method is to achieve maximum skin tightening effect with minimum pressure.~Exercise, on the other hand, increases physical performance, improves body composition, and provides an increase in quality of life by providing acute and chronic reductions in fatigue. Both aerobic exercises and strengthening exercises have been found effective on physical performance. It shows that a mixed program consisting of components such as aerobics, strengthening, coordination and stretching can positively affect flexibility, pain and energy expenditure in breast cancer patients."
40942842|NCT04843852|DRUG|Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]|one 0.5ml intramuscular injection on day 0 and week 4.
40942843|NCT05182099|DIAGNOSTIC_TEST|Liver MRI|Gd-EOB-DTPA enhanced MRI consists of T2-weighted image (T2WI), diffusion weighted image (DWI) and precontrast T1-weighted image (T1WI), dynamic T1WI (arterial, portal and transitional phases), and hepatobiliary phase.
40942844|NCT06345846|DEVICE|IFIOL|Implanted IFIOL
40942845|NCT06345846|DEVICE|SFIOL|Implanted SFIOL
40942846|NCT01860781|DRUG|paliperidone palmitate|paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
40942847|NCT06426719|PROCEDURE|Alveolar ridge wideninig via applying osseodensification protocol using densah burs|alveolar ridge expansion using densah burs in horizontally deficient maxillary alveolar ridges prior to dental implants insertion
40942848|NCT06426719|PROCEDURE|Alveolar ridge widening via hand osteotomes|Alveolar ridge expansion using hand driven osteotomes in horizontally deficient maxillary alveolar ridges prior to dental Implant insertion
40942849|NCT02666716|DRUG|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
41284214|NCT01979510|DRUG|DOLOCAM PLUS®|DOLOCAM PLUS® once daily for 8 days.
41284215|NCT01979510|DRUG|Acetaminophen 500 mg|Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
41284216|NCT01488981|OTHER|Upper Extremity Therapy without stimulation|Two 12 week phases of occupational therapy without electrical stimulation.
41284217|NCT01488981|DEVICE|Upper Extremity Therapy with stimulation from the Radiofrequency Microstimulator (RFM) System (Alfred Mann Foundation, Santa Clarita, CA)|Two 12 week phases of occupational therapy that incorporates electrical stimulation from the RFM System.
41284218|NCT02165540|OTHER|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
41284219|NCT03844438|DRUG|LPM3480226|The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
40756909|NCT01548885|DEVICE|ACCU-CHEK® Aviva BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of ACCU-CHEK® Aviva BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
40942850|NCT05633004|DEVICE|Vivio|Non-invasive estimation of Left-Ventricular End Diastolic Pressure (LVEDP)
41284220|NCT05738512|PROCEDURE|Medial Flap Coblation Turbinoplasty|Reduction of the inferior turbinate to manage inferior turbinate hypertrophy
41284221|NCT05738512|PROCEDURE|Submucous Resection|Submucous Resection
40942851|NCT00503438|DEVICE|Salto Talaris Ankle|Salto Talaris Anatomic Ankle total joint prosthesis
40942852|NCT05568537|DRUG|Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)|Piflufolastat F18 will first be given intravenously over about 5 seconds.
41284222|NCT00410891|DRUG|gatifloxacin|
41284223|NCT02721862|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
41284224|NCT02721862|DRUG|Placebo|The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
41284225|NCT02721862|RADIATION|Gallbladder Ultrasound|Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
41284226|NCT06338449|BEHAVIORAL|Aerobic training (AT)|An exercise program was developed by a full-time physical education teacher, with all group exercises conducted at the outdoor track and field facility of Xuzhou Medical University. Participants in the aerobic training group, after completing a warm-up, were required to perform moderate-intensity aerobic running for 60 minutes per session, 4-5 times a week. The exercise intensity was set to reach 50%-70% of the maximum heart rate (Maximum heart rate = 220 - age). The exercise sessions were scheduled in the evening after dinner, from 17:30 to 19:00.All participants were continuously intervened for 8 weeks.
41284227|NCT06338449|BEHAVIORAL|Resistance training (RT)|Participants in the resistance training group were required to complete moderate-intensity resistance exercises 4-5 times per week. Each session included a warm-up, followed by exercises such as knee lifts with torso twists, knee-to-hand taps under the hips, jumping jacks, burpees, sit-ups, planks, and squats. The routine was structured to perform 5-6 exercises per session, with 6-8 repetitions for each set. There was a 30-second rest interval between sets, and the total exercise time was 60 minutes. The timing for these exercise sessions was the same as for the AT group, conducted in the evening after dinner.All participants were continuously intervened for 8 weeks.
41284228|NCT06338449|BEHAVIORAL|Combined aerobic and resistance training (AT + RT)|Participants in the combined aerobic and resistance training (AT+RT) group started their sessions with a warm-up, followed by 30 minutes of aerobic running. After the aerobic training, they engaged in resistance training. The resistance training regimen was the same as that for the RT group, except that the duration of the resistance training was shorter. The total duration of the exercise session was 60 minutes.All participants were continuously intervened for 8 weeks.
40942853|NCT00591266|DRUG|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
40942854|NCT00591266|DRUG|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
40942855|NCT00591266|DRUG|Amlodipine|Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
40942856|NCT05068310|DEVICE|Cellular resolution full-field optical coherence tomography|Device: ApolloVue® S100 Image System
40942857|NCT05068310|DEVICE|Confocal microscopy|Device: Vivascope® will be used for skin imaging for a subset of skin lesions.
41451884|NCT05811793|DRUG|Tislelizumab and Bevacizumab|Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.
41451885|NCT01139762|DRUG|Tadalafil|5 milligrams (mg) administered orally, once daily for 26 weeks
41451886|NCT01139762|DRUG|Placebo|Administered orally, once daily for 26 weeks
41451887|NCT01139762|DRUG|Finasteride|5mg administered orally, once daily for 26 weeks
41451888|NCT01949805|DRUG|Peg-P-IFN-alpha-2b (AOP2014)|Pegylated interferon alpha 2b given Q2W as SC injection
41451889|NCT01949805|DRUG|Hydroxyurea|Hydroyurea capsules taken daily po
40942858|NCT05068310|DEVICE|Optical coherence tomography imaging|Device: Vivosight® will be used for skin imaging for a subset of skin lesions.
40942859|NCT05068310|DEVICE|Dermoscopy imaging|Device: Dermoscopy imaging will be conducted using but not limited to dermoscope DermLite FotoX®
40942860|NCT05391529|BEHAVIORAL|Interview|Semi structured patient interview via telephone
40942861|NCT00000656|DRUG|Zidovudine|
40942862|NCT00000656|DRUG|Didanosine|
40942863|NCT00001115|DRUG|Acyclovir|
40942864|NCT00098098|BIOLOGICAL|rBV A/B|
40942865|NCT05901792|OTHER|Virtual Reality Games|Six different Nintendo Wii Fit Plus games will be employed for six weeks, three days a week, for a total of 18 sessions ranging from 40 to 60 minutes. The games will be chosen from those that emphasize shifting the body's center of gravity. In addition, participants will be given basic correction exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the beginning of the study and instructed to practice them at home for six weeks.
41284229|NCT05843201|DEVICE|The AquaPass System|The system is a non-invasive, multiple use device intended for use at the hospital, at the outpatient clinic settings or at home. The system administers warm, dry air around the patients' body in order to create environmental conditions that increase the patients' sweat rate. Throughout the treatment, fluids from the interstitial compartment are removed from the body by the eccrine sweat glands.
40942866|NCT05901792|OTHER|Waiting List|As the control group, the cases on the waiting list will be evaluated. The control group will be given basic elements of corrective exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the start of the study and instructed to practice at home for six weeks.
40942867|NCT03781544|DRUG|Tramadol|A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm).
40942868|NCT03781544|DRUG|Paracetamol|A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm).
40942869|NCT03781544|DRUG|Diclofenac|A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
40942870|NCT05578703|PROCEDURE|Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
40942871|NCT05578703|DEVICE|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
40942872|NCT05578703|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label
40942873|NCT04609969|DIAGNOSTIC_TEST|RT-qPCR test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
40942874|NCT04609969|DIAGNOSTIC_TEST|COVID-VIRO® test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
40942875|NCT06243627|OTHER|Sunscreen C Color 2.0 SPF 70|Sunscreen C color 2.0 SPF 70 will be applied topically on half of the face.
40942876|NCT06243627|OTHER|Sunscreen C Color 3.0 SPF 70|Sunscreen C color 3.0 SPF 70 will be applied topically on half of the face.
40942877|NCT06243627|OTHER|Sunscreen M Very Light SPF 50|Sunscreen M very light SPF 50 will be applied topically on half of the face.
40942878|NCT06243627|OTHER|Sunscreen M Golden Color SPF 50|Sunscreen M golden color SPF 50 will be applied topically on half of the face.
40942879|NCT06039488|BEHAVIORAL|Exercise|"A combination of resistance exercise and cardiovascular exercise (performed 2 days per week for 8-weeks) is tailored to each individual in accordance with their medical/cancer-related history, baseline assessments of physical function, and overall goals.~Resistance exercise includes 6-8 exercises targeting major muscle groups. The first week of the program is used to familiarize participants to the exercises of the program, provide coaching on safe and appropriate technique, and identifying initial load for 2 sets of 12 repetitions (equivalent to \~65% 1 repetition maximum), with a goal of working towards 4 sets of 8 reps. Additionally, participants are asked to perform 20-30 minutes of moderate-to-vigorous aerobic activity (approximately 60-85% age-predicted heart rate maximum) via walking, jogging, or cycling each session."
40942880|NCT03965767|DRUG|Tranexamic Acid|comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
40942881|NCT01874743|DRUG|Rosuvastatin 20 mg/day|All patients must take 20mg/day of rosavastatin during 3 months
40942882|NCT01442038|DRUG|Ranolazine|"Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
40942883|NCT01442038|DRUG|Placebo|"Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
40942884|NCT03130491|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
40942885|NCT03130491|DEVICE|EMBLOK filter|Embolic Filter Protection System During TAVR
40942886|NCT00620464|DRUG|Radiopaque Implanon|Radiopaque rod for 3 years
40942887|NCT00620464|DRUG|Implanon (etonogestrel implant)|Implanon (etonogestrel implant) for 3 years
40942888|NCT06243224|OTHER|High intensity interval training|High intensity will be calculated based on load (watt) at % 75-85 of VO2 max analyzed during the CPET in HIIT group.Patients will perform 4 minutes of active high-intensity training with this load. Patients will perform for 1 minute each with a load (watt) of 50-60% of VO2 max in the interval phase.HIIT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
40942889|NCT06243224|OTHER|Moderate intensity continuous training|Moderate intensity will be calculated based on load (watt) at % 50-60 of VO2 max analyzed during the CPET in MICT group. Patients will complete their training sessions without changing this load determined during the treatment process.MICT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
40942890|NCT05993039|DRUG|Isoflurane Inhalant Product|1.5-2%
40942891|NCT05993039|DRUG|Sevoflurane inhalant product|1-2% adults 0.6-1.5% Children
40942892|NCT05993039|DRUG|Propofol injection|1mg/kg-mcg/kg/min adults 100-200mcg/kg/min children
40942893|NCT05993039|DRUG|Remifentanil Injection|0.05-2ug/kg/min adults and children
40942894|NCT02316912|DRUG|ATX2417|Randomised double blind parallel group ascending dose assessment
41451890|NCT04200833|DRUG|Golimumab|subcutaneous injection
41451891|NCT04168580|OTHER|Exercise Training Intervention|Older sedentary participants will undergo 8 weeks of exercise training. The exercise program will be supervised by a certified exercise physiologist and will take place at the AdventHealth Translational Research Institute (TRI) exercise training facility. Exercise compliance will be monitored for exercise training 4 days per week (32 total sessions). Aerobic training will be 30 minutes of brisk walking, jogging, cycle ergometry. Walking will be the primary mode of aerobic exercise given its widespread popularity and ease of administration across a broad segment of the older adult population. Walking will be at a moderate intensity and determined based on Heart Rate (50-70% of Maximal Heart Rate from most recent VO2max) and rating of perceived exertion using Borg's scale (ranges from 6 to 20).
40942895|NCT02316912|DRUG|Placebo|Randomised double blind parallel group ascending dose assessment
40942896|NCT04832087|DRUG|Teduglutide|Standard of care Teduglutide dosing
40942897|NCT01498601|OTHER|Enhanced oral care protocol|"* Changing mouth suction equipment every 24 hours~* Mouth assessment every 2-4 hours~* Cleansing mouth with toothbrush every 12 hours~* Cleansing oral mucosa with oral rinse solution every 2-4 hours~* Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours~* Suction mouth and throat as needed~* Head of the bed elevated to a minimum of 30° during oral care"
41132292|NCT00091988|BEHAVIORAL|Lifestyle & Behavioral Change Program|Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.
41132293|NCT00091988|BEHAVIORAL|Structured Education Program|Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
41132294|NCT05137600|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
41132295|NCT05137600|DRUG|Midazolam|Midazolam is a sensitive CYP3A index substrate
41132296|NCT05137600|DRUG|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)
41132297|NCT02733159|DRUG|pembrolizumab|anti PD-1
41132298|NCT05413200|DRUG|Isotretinoin|oral isotretinoin with a standard dose regime for 90 days
41132299|NCT03500523|DIAGNOSTIC_TEST|corneal biomechanical properties|We want to investigate changes of corneal biomechanical properties during pregnancy. The Ocular Response Analyzer (ORA) evaluate the in vivo corneal biomechanical properties in form of corneal hysteresis (CH) and corneal resistance factor (CRF)
41132300|NCT01256359|DRUG|Docetaxel and AZD6244|Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
41132301|NCT01256359|DRUG|Docetaxel and placebo|Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
41132302|NCT05230966|DEVICE|Remote Ischemic Conditioning (RIC)|RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.
41132303|NCT00856687|DRUG|PF-03893787|Oral, two doses 12 hours apart
41132304|NCT00856687|DRUG|Placebo|Oral, two doses 12 hours apart
41132305|NCT00856687|DRUG|Montelukast|Oral, two doses 12 hours apart
41132306|NCT03385291|DEVICE|music,name,and noise sound|A 5-minute baseline silence was followed by the presentation of three contrasting auditory stimuli(music,name,and noise), with a 2-minute washout silence separating each stimulus
41132307|NCT04144088|DRUG|Wu Ling San|assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
41132308|NCT04144088|DRUG|Yin-Chen Wu Ling San|assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
41132309|NCT04144088|DRUG|Placebo|1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
40942898|NCT05052658|PROCEDURE|Neuraxial block placement|The time and ease of administering neuraxial blocks in high BMI patients,for the management of labor and delivery pain, will be assessed.
40942899|NCT04082559|OTHER|Arm 1- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
40942900|NCT04082559|OTHER|Arm 2- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
40942901|NCT04082559|OTHER|Arm 1- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
40942902|NCT04082559|OTHER|Arm 2- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
40942903|NCT04082559|OTHER|Arm 1- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
40942904|NCT04082559|OTHER|Arm 2- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
40942905|NCT04082559|OTHER|Arm 3- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
40942906|NCT02193581|DEVICE|MDS|Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
40942907|NCT00315536|DRUG|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
40942908|NCT03451942|DRUG|FLOT regimen chemotherapy|FLOT regimen chemotherapy
40942909|NCT03451942|PROCEDURE|D2 gastric and imaging metastases resection|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
40942910|NCT00990938|DRUG|IMO-2125|IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
40942911|NCT00990938|DRUG|Saline|Subcutaneous injection once per week for four weeks
40942912|NCT06489353|BEHAVIORAL|Video-watching|Participants will watch age-appropriate and engaging videos.
40942913|NCT06489353|BEHAVIORAL|Blowing Pinwheels|Participants will blow pinwheels during the venipuncture procedure
40942914|NCT00309478|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2
40942915|NCT00309478|DRUG|Methotrexate|Methotrexate 40mg/m2
40942916|NCT00309478|DRUG|Fluorouracil implant|Fluorouracil 600mg/m2
40942917|NCT00309478|DRUG|Goserelin|Zoladex 3.6mg/28 days for 3 years
40942918|NCT00309478|DRUG|Tamoxifen|Nolvadex 20mg/day for 5 years
40942919|NCT02130024|DRUG|Ranibizumab 0.5 mg|Administered as an intravitreal injection
40942920|NCT02130024|DRUG|Aflibercept 2.0 mg|Administered as an intravitreal injection
41451892|NCT01273467|DRUG|CNTO 0007 or placebo (Stage A)|a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
41451893|NCT01273467|DRUG|CNTO 0007 or placebo (Stage B)|a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
40942921|NCT04561427|OTHER|Study of Sleep architecture in children with narcolepsy|Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children
40942922|NCT02860455|DEVICE|RAD57 measurement (SpCO)|"SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin."
40942923|NCT02860455|DEVICE|CO-oximeter|"COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin."
40942924|NCT04620655|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
40942925|NCT02906371|DRUG|Tocilizumab|Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
40942926|NCT02906371|DRUG|Tocilizumab|Patients with ˂ 40% blasts in the bone marrow at pre-infusion (\~ Day -5 to -1) will follow the standard CRS Rx algorithm
40942927|NCT02906371|BIOLOGICAL|CART 19|CART-19 cells transduced with a lentiviral vector to express either anti-CD19ζ scFv TCRζ:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of \~1.5 x107 - 5 x109 (\~3x105 - 1x108/kg) T cells.
40942928|NCT02853851|OTHER|interviews|Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).
40942929|NCT00590798|BEHAVIORAL|Walking|Patient will walk within 30 minutes of vascular closure system procedure
41132310|NCT00624637|OTHER|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
41132311|NCT06195306|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41132312|NCT06195306|PROCEDURE|Mammography|Undergo mammography
41132313|NCT06195306|DRUG|Omega-3-Acid Ethyl Esters|Given PO
41132314|NCT06195306|OTHER|Questionnaire Administration|Ancillary studies
41132315|NCT06195306|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
41132316|NCT06195306|DRUG|Tamoxifen|Given PO
41451894|NCT00275249|DRUG|levorphanol|
40942930|NCT01690637|DRUG|Oseltamivir phosphate suspension|
40942931|NCT01690637|DRUG|Placebo|
40942932|NCT01499069|DRUG|Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium|"Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .~Duration; 3 or 6 months"
40942933|NCT06523283|OTHER|Natural Landscape Pictures Accompanied by Music|after data collection tools filled by participants , they will watch the video one time in hospital bed while breastfeeding , second time in their home while researchers is there and they will also receive the video link so they will contunie to watch video 8 more time. in total 10 sessions will be completed.
40942934|NCT03622359|DIAGNOSTIC_TEST|SPECT/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
40942935|NCT03622359|DIAGNOSTIC_TEST|PET/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
40942936|NCT05044000|DEVICE|Deep propioceptive stimulation|Participants will start using the blanket (of the arm name), 30 days wash-out and 15d with the other blanket
40942937|NCT05131360|BEHAVIORAL|Introduction Only|This is the placebo condition in which participants engage in one day of introductory mindfulness activities.
40942938|NCT05131360|BEHAVIORAL|Purpose Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of purpose-based mindfulness techniques.
40942939|NCT05131360|BEHAVIORAL|Connection Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection-based mindfulness techniques.
40942940|NCT05131360|BEHAVIORAL|Connection and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection and purpose-based mindfulness techniques.
40942941|NCT05131360|BEHAVIORAL|Awareness Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness-based mindfulness techniques.
40942942|NCT05131360|BEHAVIORAL|Awareness and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and purpose-based mindfulness techniques.
40942943|NCT05131360|BEHAVIORAL|Awareness, Purpose, and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness, connection, and purpose-based mindfulness techniques
40942944|NCT05131360|BEHAVIORAL|Awareness and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and connection-based mindfulness techniques.
40942945|NCT00620347|DRUG|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
40942946|NCT02031211|DRUG|Etanercept|The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.
40942947|NCT02031211|DRUG|Placebo|The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
40942948|NCT03368703|DEVICE|Anodal transcranial direct-current-stimulation|2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.
40942949|NCT03368703|DEVICE|Sham transcranial direct-current-stimulation|"Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions."
41284230|NCT00071773|PROCEDURE|modified-ETDRS photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
40756910|NCT01548885|DEVICE|TRUEtrack® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of TRUEtrack® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
40942950|NCT03707054|DIAGNOSTIC_TEST|Study Arm|Measurements of optic nerve diameter, serum and urine osmolarity, serum vasopressin
41284231|NCT00071773|PROCEDURE|Mild Macular Grid photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
41284232|NCT00298571|DRUG|.5% bupivacaine with epinephrine|
41284233|NCT04721314|DEVICE|Adjustment of lower rate limit|Patients with preserved ejection fraction (EF \>50%) and implanted pacemakers will have the lower rate limit adjusted to a personalized heart rate based on a heart rate algorithm.
41284234|NCT04721314|DEVICE|Maintenance of lower rate limit|Lower rate limit will be maintained at 60 beats-per-minute
41284235|NCT03730896|PROCEDURE|Dry needling|Dryneedling of the sternocleidomastoid muscles within a standard treatment approach of physical therapy
41284236|NCT04624932|BEHAVIORAL|RR Digital Tool|This is the intervention condition. Participants in this condition will take the RR digital tool available at https://outsideplay.ca.
41284237|NCT04624932|BEHAVIORAL|Position Statement on Active Outdoor Play|This is the control condition. Participants in this condition will read the position statement that summarizes the issues and research regarding children's access to outdoor play.
40942951|NCT00766883|BEHAVIORAL|Problem Solving Education|
40942952|NCT06215612|OTHER|Blood draw, MRI|Blood draw, MRI
40942953|NCT05386823|DRUG|HF1K16|HF1K16 for Injection doses will be calculated based on subject weight measured at admission, and diluted in sterile saline (0.9% sodium chloride). Doses will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
40942954|NCT05386823|DRUG|Placebo|Placebo will be sterile saline (0.9% sodium chloride) which will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
40942955|NCT03964766|DEVICE|Rotary instrumentation|using pedo rotary files in cleaning and shaping the root canals of infected primary molars
40942956|NCT03964766|DEVICE|Hand instrumentation|using conventional hand files in cleaning and shaping the root canals of infected primary molars
41284238|NCT02346448|PROCEDURE|endoscopic sphincterotomy|sphincterotomy during ERCP
41284239|NCT02346448|PROCEDURE|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
40942957|NCT04776031|DEVICE|R:GEN Laser System|Laser Treatment
40942958|NCT04753476|BIOLOGICAL|Injection of Secretome-MSCs|"Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :~Day 1: 1 cc every 12 hours~Day 2: 1 cc every 12 hours~Day 3: 1 cc every 12 hours"
40942959|NCT04753476|DRUG|Standard treatment of Covid-19|Patients will be given Standard treatment of Covid-19 which accordance with National protocol
40942960|NCT03174249|BEHAVIORAL|Exposure therapy|Daily training at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.
40942961|NCT05692167|DRUG|Topical dexmedetomidine|Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic
41284240|NCT02346448|PROCEDURE|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
41284241|NCT01480180|DRUG|turoctocog alfa pegol|Administered i.v.
41284242|NCT03952286|DRUG|ED-Dispensing home and school supervision|"1. Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~2. 360 ug of budesonide inhalation powder once-daily for at-home use, and~3. albuterol sulfate as needed for relief of acute respiratory symptoms."
41284243|NCT01981187|DRUG|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
41284244|NCT03401606|DRUG|remifentanil|remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished
41284245|NCT03401606|DRUG|Dexmedetomidine|dexmedetomidine, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
41284246|NCT03932240|DRUG|Fibrinogen Concentrate (FC)|The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
41284247|NCT03932240|DRUG|Cryoprecipitate|The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
41284248|NCT00097266|DRUG|Placebo|Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
41284249|NCT00097266|DRUG|Aripiprazole|Tablets, oral, 15-30 mg, once daily, 12 weeks.
41284250|NCT00097266|DRUG|Haloperidol|Capsule, oral, 5-15 mg, once daily, 12 weeks.
41284251|NCT05932433|BEHAVIORAL|Exercise|Each session (45 minutes aprox) is made by: mobility, endurance and final exercise to rest. The sesion is going to perform twice a week during 6 weeks.
41284252|NCT06091501|BEHAVIORAL|Lev Livet|"The program consists of a total of 9 sessions with a duration of two and a half to three hours for each session. In the first four sessions coping skills are taught across different chronic diseases. In this part of the program citizens suffering from different chronic diseases can participate. Citizens living with T2D then move on to four diabetes-specific sessions, followed by a ninth follow up session. The sessions are held consecutively over eight weeks. The ninth session is held three weeks after the eighth session.~The 8 weeks supervised HIIT-protocol will be comprised of blocks of 5 x 1 min high-intensity intervals interrupted by 1 min active recovery. The HIIT intervention will progress continuously, from two weekly training sessions with two training blocks (22 minutes of training) in the first two weeks, to two weekly training sessions with four training blocks in the last four weeks of the intervention."
41284253|NCT00566306|OTHER|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
41284254|NCT05164328|OTHER|No intervention|No intervention
41284255|NCT02135536|BIOLOGICAL|NGM282|NGM282
41284256|NCT05308212|BIOLOGICAL|Flu-M Tetra [Inactivated split influenza vaccine] w/p|solution for intramuscular injection, 0.5 ml
41284257|NCT05308212|BIOLOGICAL|Flu-M Tetra [Inactivated split influenza vaccine] w/o/p|solution for intramuscular injection, 0.5 ml
41284258|NCT05308212|BIOLOGICAL|Ultrix [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
41451895|NCT02589067|DRUG|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
41284259|NCT00046566|DIETARY_SUPPLEMENT|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
41284260|NCT00046566|DIETARY_SUPPLEMENT|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
41451896|NCT02589067|DRUG|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
41284261|NCT00046566|BEHAVIORAL|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
41284262|NCT04754711|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|We will propose to the patients of group 1 several different oral nutritional supplements according to taste, and consistency of each child in order to optimize observance. Each of those different oral nutritional supplements will be adapted to the nutritional survey and the age of children without exceeding recommended intake of proteins, carbohydrates, lipids and micronutrients. Those patients will consume the Oral Nutritional Supplement during 12 months.
41284263|NCT00174941|DRUG|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
41284264|NCT00174941|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
41284265|NCT00174941|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
40942962|NCT05692167|DRUG|Reginal dexmedetomidine|Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
40942963|NCT04578678|OTHER|Steering|Fine tuning of the STN-DBS settings
41284266|NCT05097911|DRUG|MTL-CEBPA|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
41284267|NCT05097911|DRUG|Atezolizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
41284268|NCT05097911|DRUG|Bevacizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
41284269|NCT03390686|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks on Day 1
41284270|NCT03390686|DRUG|HD204|15 mg/kg IV every 3 weeks on Day 1
41284271|NCT03390686|DRUG|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
41284272|NCT03390686|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
41284273|NCT05621863|OTHER|Aim 1 Meal Challenge 1|A meal challenge will be provided that contains 1 serving of peaches and 2 servings of strawberries as a smoothie and 2 servings of tomatoes and 1 serving of carrot as a vegetable dish.
41284274|NCT05621863|OTHER|Aim 1 Meal Challenge 2|A meal challenge will be provided that contains 1 serving of banana and 2 servings of peaches as a smoothie and 1 serving of tomatoes and 2 servings of green beans as a vegetable dish.
41284275|NCT05621863|OTHER|Aim 1 Meal Challenge 3|A meal challenge will be provided that contains 2 serving of bananas and 1 serving of strawberries as a smoothie and 1 serving of green beans and 2 servings of carrots as a vegetable dish.
41284276|NCT05621863|OTHER|Aim 2 Typical American Diet|The diet will provide sufficient calories for weight maintenance and will contain refined grains and low amounts of fruits and vegetables, representative of the typical American diet. No bananas, strawberries, peaches, green beans, carrots, or tomatoes will be provided.
41284277|NCT05621863|OTHER|Aim 2 Typical American Diet Plus Test Foods|This diet will provide sufficient calories for weight maintenance and will contain refined grains and low amounts of fruits and vegetables, representative of the typical American diet. Bananas, strawberries, peaches, green beans, carrots, and tomatoes will be provided in amounts less than or equal to 1 serving per day each.
41284278|NCT05621863|OTHER|Aim 2 Dietary Guidelines for Americans Diet Plus Test Foods|This diet will provide sufficient calories for weight maintenance and will contain whole grains and high amounts of fruits and vegetables, representative of the Dietary Guidelines for Americans. Bananas, strawberries, peaches, green beans, carrots, and tomatoes will be provided in amounts greater than or equal to 1 serving per day each.
41284279|NCT01774916|GENETIC|blood samples|
41284280|NCT00184847|DRUG|acetylcholine|
41284281|NCT00184847|PROCEDURE|twenty minutes of forearm ischemia|
41284282|NCT00184847|PROCEDURE|three 5-minute periods of forearm ischemia|
41284283|NCT00184847|DRUG|adenosine|
41284284|NCT00184847|DRUG|caffeine|
41284285|NCT00491530|DRUG|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
41284286|NCT00491530|DRUG|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
41284287|NCT00491530|DRUG|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
41284288|NCT00491530|DRUG|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
41284289|NCT01861197|DRUG|Dovitinib|Dovitinib 500mg daily for 5 days on/ 2 day off until progression
41284290|NCT06196840|GENETIC|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
41284291|NCT06196840|BIOLOGICAL|Aflibercept intravitreal injection|Commercially available Active Comparator
41284292|NCT00133926|PROCEDURE|Treatment of periodontal disease|
41284293|NCT04782622|DRUG|Apatinib+Camrelizumab|Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d
41284294|NCT03361501|DRUG|CaPre|4 x 1 g capsules administered orally once daily for 26 weeks
41284295|NCT03361501|DRUG|Placebo|4 x 1 g capsules administered orally once daily for 26 weeks
41284296|NCT05078814|OTHER|Observational research|Observational research
41284297|NCT03916068|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy at 2.4 atmospheres for 90 minutes for 30 sessions.
41284298|NCT03916068|DRUG|Trental Pill|Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily
41284299|NCT03916068|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 400 IU twice daily, in combination with Trental 400 mg three times daily
41284300|NCT02201940|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
41284301|NCT02201940|DRUG|Placebo|Tablet administered orally once daily
41284302|NCT00221091|PROCEDURE|ventriculo-peritoneal shunt|
41284303|NCT00351715|DRUG|Sublingual Methadone|
41284304|NCT01273818|DRUG|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
41284305|NCT01273818|DRUG|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
41284306|NCT01273818|DRUG|Gentamicin|80 mg gentamicin application intraoperatively
41284307|NCT06104683|DRUG|Placebo|Administered orally
41284308|NCT06104683|DRUG|Pirtobrutinib|Administered orally
41284309|NCT02344940|DRUG|Toremifene|patients will take toremifene 60 mg qd.
41284310|NCT02344940|DRUG|Tamoxifen|patients will take tamoxifen 10 mg bid.
41284311|NCT00599651|DEVICE|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
41284312|NCT00599651|OTHER|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
41284313|NCT05008887|DRUG|Methotrexate|Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo
41284314|NCT05008887|DRUG|5-fluorouracil|Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
41284315|NCT05008887|DEVICE|Fractional CO2 laser|Fractional CO2 laser-assisted cutaneous delivery of methotrexate and 5-fluorouracil solution in stable, non-segmental vitiligo
41284316|NCT03554590|BEHAVIORAL|carbohydrate counting|patients will attend a 5 meetings-structured training to learn how to manage their insulin therapy depending on the amount of carbohydrates contained in foods
41284317|NCT03554590|BEHAVIORAL|insulin therapy according to standard care|patients will not manage their insulin therapy depending on the amount of carbohydrates contained in foods, but will follow a fix basal bolus scheme
41284318|NCT05969210|OTHER|Toe strengthening exercise|12 participants will be in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol.
41284319|NCT05969210|OTHER|Control Group|12 participants will be in control group they will do only there running training.
41284320|NCT02554643|OTHER|Diet|Nutrition intervention, once a week during 12 weeks
41284321|NCT02554643|OTHER|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
41284322|NCT02554643|OTHER|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
41284323|NCT04967430|DRUG|Peginterferon Lambda-1A|"Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose."
41284324|NCT04967430|OTHER|Placebo|The placebo will be 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
41284325|NCT03540017|DRUG|Cisplatin|Heated Intraperitoneal Chemotherapy will be administered after the completion of interval cytoreductive surgery after three cycles of neoadjuvant chemotherapy.
41284326|NCT03856450|DEVICE|DTS|Subjects undergo wrist imaging using DTS.
41284327|NCT03856450|DEVICE|X-ray|Subjects undergo wrist imaging using standard X-ray imaging.
41284328|NCT03856450|DEVICE|MRI or CT|Subjects may undergo wrist imaging using MRI or CT.
41284329|NCT00678496|OTHER|CBT Software|"Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one."
41284330|NCT00678496|OTHER|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
41284331|NCT05067634|DRUG|Xcopri|Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
41284332|NCT06508983|DRUG|SG301 Injection|Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
41284333|NCT06508983|DRUG|SG301 placebo|Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
41284334|NCT06508983|DRUG|pomalidomide|Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.
41284335|NCT06508983|DRUG|dexamethasone|Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.
41284336|NCT02393092|BEHAVIORAL|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
41284337|NCT02393092|BEHAVIORAL|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
41284338|NCT02393092|BEHAVIORAL|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
41284339|NCT05597566|PROCEDURE|modified electroconvulsive therapy|The patient underwent MECT therapy. The treatment instrument is Xingmaitong IV ECT multifunctional treatment instrument (USA, SOMATICS THYMATRON company), fasting for 6 hours before surgery, emptying urine. Routine preoperative preparations were made, followed by intravenous injection of atropine, propofol, and succinylcholine chloride injection, artificial respiration, placement of dental pads, and electroconvulsive therapy. The whole process is completed by an anesthesiologist and a therapist in cooperation with each other. The first 3 times are once a day, and the next 5 times are once every other day. A total of 8 courses of treatment.
41284340|NCT04416516|BIOLOGICAL|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
41284341|NCT02128581|DRUG|Exendin-9,39|use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
41284342|NCT02128581|OTHER|Saline|
41284343|NCT00488943|DEVICE|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
41284344|NCT04272606|DRUG|Tranexamic Acid|Antifibrinolytic Agent
41284345|NCT04272606|DRUG|Saline Solution|Placebo
41284346|NCT04272606|DIAGNOSTIC_TEST|Visual Acuity Exam|Supplemented into standard of care daily neurological exam on day of surgery and day after
41284347|NCT04272606|DIAGNOSTIC_TEST|3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)|3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
41284348|NCT03063073|DRUG|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection \[Precedex\]
41284349|NCT03063073|DRUG|Bupivacaine|
41284350|NCT04786288|OTHER|massage with lavender essential oil mixed in a carrier oil|22 elderly participants received a one session M technique hand massage that lasted 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the M technique hand massage
41284351|NCT04786288|OTHER|massage with odourless baby oil|odourless baby oil was used for the application of one session M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.
41451897|NCT02185144|BEHAVIORAL|PATH For Triples|In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
41284352|NCT02820259|DRUG|Tacrolimus|
41284353|NCT03900676|DRUG|VB-1953 - 2%|Topical Gel
41284354|NCT03900676|DRUG|VB-1953 - 0% (Vehicle)|Topical Gel
41451898|NCT02185144|BEHAVIORAL|Treatment as Usual|Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
40756911|NCT01548885|DEVICE|OneTouch® Ultra®2 BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® Ultra®2 BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
40942964|NCT05644444|DEVICE|Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
40942965|NCT05644444|DEVICE|Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
40942966|NCT04149873|PROCEDURE|MIE|MIE
40942967|NCT01121731|DRUG|Interferon α-5|3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
40942968|NCT01121731|DRUG|Interferon-α5 plus Interferon-α 2b|Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
40942969|NCT01121731|DRUG|Interferon α-2b (INTRON® A)|3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
40942970|NCT00398827|DRUG|Dexmedetomidine|
40942971|NCT00398827|DRUG|Placebo|
40942972|NCT01039974|DRUG|GSK962040|"GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1"
40942973|NCT01039974|DRUG|Ketoconazole|400 mg
41284355|NCT03540121|BEHAVIORAL|Video education + adherence contract|Participants will receive standard education along with the home-based video education plus an adherence contract. Following the baseline assessment, access to videos will be provided electronically so that the patient can watch them at home. The videos will be initially viewed in the following order: Video 1: Introduction, Video 2: Medications, Video 3: Your New Life. Approximately one month after transplant, after the video series has been viewed in its entirety, participants will receive an email link inviting participants to reflect on their goals about transplantation and pledging to taking their medications as directed. The contract will be non-enforceable, but it will provide patients with the opportunity to formally commit to a goal of taking the medications as prescribed. At 3 months, and 12 months, the participant will have the opportunity to reflect and modify adherence goals as desired.
41284356|NCT05614947|DIETARY_SUPPLEMENT|Powdered tart cherry|500 mg freeze-dried tart cherry per capsule
41284357|NCT05614947|DIETARY_SUPPLEMENT|Placebo|500 mg colored cornstarch per capsule
41284358|NCT03383367|BEHAVIORAL|Tempo Colo|Reminder letter for people at high risk of colorectal cancer.
41284359|NCT05965570|DRUG|Brensocatib|Oral tablets.
41284360|NCT05965570|DRUG|Clarithromycin|Oral tablets.
41284361|NCT05421754|DEVICE|ANNE Sleep|ANNE Sleep system for 1 night with HST followed by 3 nights of ANNE Sleep system alone.
41284362|NCT05727774|OTHER|Water Biking in hot water condition|Training protocol includes 10 water biking sessions in hot water temperature (35°C) for this group
40942974|NCT04178473|PROCEDURE|total abdominal hysterectomy|total abdominal hysterectomy at time of sacrocolpopexy
40942975|NCT04178473|PROCEDURE|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy at time of sacrocolpopexy
40942976|NCT01368432|DRUG|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
40942977|NCT01368432|DRUG|Placebo|Sugar pill placebo
40942978|NCT05277961|RADIATION|Ultraviolet radiation|UV6 tubes
40942979|NCT04553354|PROCEDURE|cortical resections|is the removal of the epileptic focus either temporal or extra temporal area
40942980|NCT04247776|COMBINATION_PRODUCT|Prehab|Exercise: functional exercises, walking, Fitbit goals Nutrition: handout, supplements (protein, vitamins, minerals) Stress reduction: deep breathing
40942981|NCT04247776|OTHER|ERAS|Enhanced Recovery After Surgery guidelines are applied.
40942982|NCT04247776|BEHAVIORAL|Fitbit|Fitbit is worn to monitor step counts.
40942983|NCT02285283|DRUG|Itraconazole|
40942984|NCT02285283|DRUG|Placebo|
40942985|NCT02259218|OTHER|laboratory biomarker analysis|Correlative studies
40942986|NCT05254223|OTHER|Antiinflammatory Diet|The intervention group is recommended to follow a diet, inspired in mediterranean diet, rich in anti-inflammatory foods. They are provided with a table with the recommended foods as well as the frequency of daily/weekly/biweekly consumption.
40942987|NCT05254223|OTHER|Control Diet|The control group is recommended to follow their usual diet. Only in the case of detecting a serious nutritional problem the participant is recommended to correct it with the appropriate advice of the nutritionist.
40942988|NCT02701842|DEVICE|ImPACT Online/Paper Pencil Tests|
40942989|NCT02701842|DEVICE|ImPACT Online|
40942990|NCT03566511|DRUG|Diazoxide|Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
40942991|NCT03566511|DRUG|Placebo|Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
40942992|NCT01532973|DRUG|Elbasvir|Elbasvir was administered orally by tablet(s)
40942993|NCT01532973|DRUG|Placebo|Dose-matched placebo tablets were administered orally.
40942994|NCT04152707|DEVICE|Splendor X|The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).
40942995|NCT02587039|PROCEDURE|Remote ischemic pre-conditioning|Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.
40942996|NCT02587039|BEHAVIORAL|Delirium Assessment|The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
40942997|NCT02236481|DRUG|Anakinra|
40942998|NCT02236481|DRUG|TNF alpha inhibitors|
41284363|NCT05727774|OTHER|Water Biking in neutral water condition|Training protocol includes 10 water biking sessions in neutral water temperature (25°C) for this group
40942999|NCT03671993|PROCEDURE|Electrical pudendal nerve stimulation|Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum). Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45\~55 mA). EPNS was given for 60 min a time, 3 sessions per week for 6 weeks.
40943000|NCT03671993|PROCEDURE|Intravesical instillation|The patient should lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine should be drained. A mixture of the Cystistat (sodium hyaluronate, 50ml 40mg, Bioniche Teoranta, Ireland) solution and Lidocaine hydrochloride (40mg :20ml, Fangming Pharmacy company, Shangdong, China) is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the mixture solution inside the bladder, retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at 6 weeks.
40943001|NCT01367431|DIETARY_SUPPLEMENT|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
40943002|NCT05102695|DIAGNOSTIC_TEST|Serum CRP , ferritine and d-dimer|Correlation between the results of the tests with outcome of the patient
40943003|NCT04573998|PROCEDURE|LSG|bariatric surgery
40943004|NCT01240876|DRUG|CEP-37247|0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
40943005|NCT01240876|DRUG|Placebo|Matching placebo vials will be filled with the buffered solution for CEP-37247.
40943006|NCT00326677|BEHAVIORAL|Problem Solving Therapy|6 to 8 Problem Solving Therapy sessions over the course of 6 to 16 weeks followed by 3 booster PST sessions over the course of 2 years
40943007|NCT00326677|BEHAVIORAL|Dietary Education|6 to 8 Diet Education sessions over the course of 6 to 16 weeks followed by 3 booster Diet Education sessions over the course of 2 years
40943008|NCT06229418|OTHER|DFR AED Pilot Program|Integrate AED drone delivery into an existing FAA-approved drone-as-first-responder programs
40943009|NCT02767505|OTHER|gastric bypass|Type of surgery: gastric bypass
40943010|NCT02767505|OTHER|Sleeve gastrectomy|Typ of surgery: sleeve gastrectomy
41284364|NCT00479466|DRUG|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
41284365|NCT00479466|DRUG|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
41284366|NCT00479466|DRUG|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
41284367|NCT00479466|DRUG|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
40943011|NCT00799110|DRUG|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
40943012|NCT00799110|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
40943013|NCT00799110|DRUG|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
40943014|NCT02808377|OTHER|Surgical Pelvic Organ Pessary|In participants randomized to intervention, the SPOP will be placed at the completion of surgery, following routine placement of IDC and prior to placement of vaginal pack. The SPOP is available in 4 sizes and the surgeon will select the appropriate size so that the SPOP rests snugly without undue tension inside the hymeneal remnant. The SPOP is sutured in place with 2/0 Vicryl to prevent dislodgement at the level of the hymen.
41284368|NCT00002187|DRUG|Fomivirsen sodium|
40943015|NCT04502979|BEHAVIORAL|Responsive Feeding Training|Families will receive 4 monthly 1-hour sessions: (1) Signing with infants; (2) infant communication and responsive feeding; (3) nutrition, portion sizes, and neophobia; and, (4) infant intentionality.
40943016|NCT01669096|BIOLOGICAL|GSK Biologicals' investigational TB vaccine GSK 692342|2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
40943017|NCT01279473|DRUG|Nilotinib|
40943018|NCT04868058|DRUG|Ropivacaine injection|Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine
40943019|NCT00143117|DRUG|UK-390,957|
40943020|NCT01316354|OTHER|Bread types|Bread with 50 g available carbohydrate
40943021|NCT03964116|OTHER|Questionnaires set all 3 months|"This longitudinal study based upon repeated and multicentric measurement will recruit AYA with cancer in care Units dedicated to them or not. Measures will be quantitative, and repeated every 3 months by questionnaires, as well as qualitative (social network questionnaire, psychological research interview) for teenagers declaring a negative event or a death event during treatments.~Those patients presenting a high depression score will be contacted by a research psychologist for semi-directed interview."
41284369|NCT01462292|DRUG|GSK2402968 3mg/kg/week|Comparison of 2 doses of GSK2402968
41284370|NCT01462292|DRUG|GSK2402968 6 mg/kg/week|Comparison of 2 doses of GSK2402968
41284371|NCT01462292|DRUG|Placebo to match GSK2402968 3 mg/kg/week|Matched placebo
41284372|NCT01462292|DRUG|Placebo to match GSK2402968 6 mg/kg/week|Matched Placebo
41284373|NCT03863938|DRUG|Tegoprazan 50mg|K-CAB
41284374|NCT00006812|DRUG|capecitabine|
41284375|NCT06345040|BEHAVIORAL|Virtual-reality intervention|For the experimental condition, participants will receive seven individual sessions of Virtual Reality Therapy conducted by a therapist trained in both eating disorder psychotherapy and virtual reality-based therapy, including avatar therapy. In the initial stage of therapy participants create a virtual avatar embodying their eating disorder voice. This enables the person to engage in real time face to face dialogue with the eating disorder voice. The main goal of the intervention is to encourage participants to stand up to the negative comments and commands made by the eating disorder voice and hereby increase their power and agency in the context of the eating disorder voice.
41284376|NCT06345040|BEHAVIORAL|TAU - specialized treatment|The control condition encompasses treatment as usual comprising seven sessions of specialized treatment, such as individual or group psychotherapy and dietary guidance, provided by interdisciplinary health professionals.
40756912|NCT05476848|DIAGNOSTIC_TEST|ELISA test for Cytokines|ELISA tests specific for cytokines (IL-1, IL-6, IL-10) and immunoglobulins (IgA, IgG, IgM) will be performed by a biochemistry lab, both for blood samples and oral swap samples.
40943022|NCT05515172|OTHER|Mindfulness-based Intervention|"The intervention was designed by a volunteer multidisciplinary team expert in different mind-body medicine techniques (for example, medicine, psychology, thanatology, meditation, health, and wellness coaches, certified Qi Gong, and yoga instructors) and is made up of 3 components main: micropractices, cohesion and support groups, which will be implemented for a period of 12 weeks."
40943023|NCT05417243|OTHER|Trauma life support training|Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.
40943024|NCT05561010|DRUG|Intra-articular injection of bupivacaine in the knee joint|25 participants will be allocated to the bupivacaine arm.
40943025|NCT05561010|DRUG|Intra-articular injection of placebo in the knee joint|25 participants will be allocated to the placebo arm.
40943026|NCT04538573|DEVICE|Virtual Reality Distraction|Patients in this group will be offered to use Oculus Rift goggles while undergoing the burn treatments, dressing changes and hydrotherapy to reduce pain and anxiety during treatment. The goggles will display Dreamland, a virtual reality videogame created by our team to maximize fun, diminish difficulty, and motion sickness. The system will be available 5 minutes before treatment to the patient in order to ease acclimatation to the goggles until the end of the treatment session.
41284377|NCT03206658|DRUG|Spironolactone 25 mg|A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
40756913|NCT01757496|DEVICE|Cough Assist|
40756914|NCT05756556|COMBINATION_PRODUCT|T3011 + Cobimetinib|1e8 plaque-forming units (PFU)/mL (up to 10 mL, every 2 weeks \[Q2W\], 28 days/cycle) T3011 will be administered in combination with 60 mg Cobimetinib (once daily \[QD\] for the first 21 days of each 28-day cycle)
40756915|NCT00980629|DRUG|M516102|Twice a day
40756916|NCT00980629|DRUG|placebo|Twice a day
41284378|NCT03206658|DRUG|Placebo oral capsule|The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
40756917|NCT04038008|DRUG|Fluconazole|Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.
41284379|NCT00002042|DRUG|Epoetin alfa|
40943027|NCT04538573|DRUG|Standard Treatment|"Standard pharmacological care as per the unit's protocol will serve as the control for half of the duration of every treatment session. It consists of different analgesic and sedative medication used in combination in order to help patients go through the procedure. The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.~Use of any co-interventions for pain or anxiety management (music, comforting, child life specialist or other) during this sequence will be documented."
41284380|NCT05641454|DIETARY_SUPPLEMENT|ElevATP supplement|ElevATP supplement containing apple and ancient peat extract
41284381|NCT05641454|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
41284382|NCT05508568|DIAGNOSTIC_TEST|ADXBLADDER|ADXBLADDER is a non-invasive, qualitative ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the monitoring of bladder cancer recurrence in non-muscle-invasive bladder cancer patients. Participants will be asked to provide a full void urine specimen, which will be centrifuged before the urine sediment is lysed. The lysed sample will then be tested with ADXBLADDER.
40943028|NCT02760576|DRUG|BAY 987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
40943029|NCT01624051|OTHER|Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Cisplatin dosing calculated at the rate of 75 mg/m2
41284383|NCT04008212|OTHER|Fusion imaging|Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
41284384|NCT00871858|DRUG|anastrozole|Given orally
40756918|NCT04038008|DRUG|Diflucan®|Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.
41284385|NCT00871858|DRUG|fulvestrant|Given intramuscularly
41284386|NCT04863807|PROCEDURE|Regional Anaesthesia|Thoracic epidural/Erector Spinae block/Serratus Anterior block
41284387|NCT02207192|OTHER|Postural change in lung volumes: sitting to Supine|"Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position."
40943030|NCT01624051|OTHER|Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass|Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
41284388|NCT00084786|DRUG|docetaxel|
41284389|NCT00084786|DRUG|gefitinib|
41284390|NCT04329936|BEHAVIORAL|Retention center Geispolsheim population|All recently held individuals in the retention center can be included in the study after signing the information and consent protocol.
41284391|NCT00216008|DRUG|docetaxel|
41284392|NCT00216008|DRUG|cisplatin|
41284393|NCT00216008|PROCEDURE|radiation|
41284394|NCT00216008|PROCEDURE|surgery|
41284395|NCT03644797|GENETIC|Exome sequencing|Detection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.
41284396|NCT01061008|OTHER|Post operative progressive handgrip exercise|As soon as possible post operation the patient will commence an eight week progressive handgrip training intervention
41284397|NCT01061008|OTHER|Treatment as usual|Continue routine care, with removal of exercise information given to patients(if anye.g. do not give out squeeze balls)
41284398|NCT04891601|PROCEDURE|polypropelene mesh|compare use mesh alone or combined mesh and darn repair
41284399|NCT05739708|OTHER|Questionnaires|The time to complete the different questionnaires is estimated to be 60 minutes.
41284400|NCT03985137|OTHER|mucocutaneous sampling by swab at the balano-preputial furrow.|the sample is made by the patient
41284401|NCT01810809|PROCEDURE|articular lavage with saline injection|Patients will receive articular lavage with saline injection
41284402|NCT01810809|DRUG|1 ampoule of Hylan GF-20|Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
41284403|NCT01810809|DRUG|2 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
41284404|NCT01810809|DRUG|3 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
41284405|NCT04887311|DRUG|MBM-01|Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
40756919|NCT00625105|BEHAVIORAL|Biofeedback|
40756920|NCT05594875|DRUG|SHR-1921|Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles
41284406|NCT03145129|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
41284407|NCT06041347|DIAGNOSTIC_TEST|Transvaginal ultrasound|Preoperative detection with TVUS of proximity or the involvement of the sacral nerve roots in women diagnosed with deep endometriosis or other benign or malignant pelvic tumors would also contribute to the safety of surgical interventions (e.g laparoscopy, tru-cut biopsy) It aslo provides correct counseling and select the appropriate surgical team and assess the likely operative complexity of the surgery. Until now the diagnosis was based on MRI.
41284408|NCT02453399|DEVICE|Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.|Transcutaneous electro stimulation
41284409|NCT04244825|DRUG|BLD-2660|BLD-2660 - 150 mg capsules '00' size (PO) BID
41284410|NCT04244825|DRUG|Control: Placebo|Placebo - 150 mg capsules '00' size (PO) BID
41284411|NCT03237403|OTHER|observational study|observational study between clinical criteria collected at SAMU regulation centre call and hospital orientation
41284412|NCT01855438|BEHAVIORAL|Living Donor Transplant Education|The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
41284413|NCT03811600|DIAGNOSTIC_TEST|PD1/PD-L1 exosomal expression|exosomal PD1/PD-L1 expression
41284414|NCT03545516|DRUG|Bupivacaine|Injection of bupivacaine into the surgical incision prior to its closure.
41284415|NCT03545516|DRUG|Dexmedetomidine|Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
41284416|NCT03545516|DRUG|Placebo|Injection of a placebo into the surgical wound
41284417|NCT02991612|DRUG|Rifaximin|Patients receive Rifaximin 400mg bid for 2 months
41284418|NCT00388089|DRUG|bortezomib|Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
41284419|NCT00388089|DRUG|topotecan hydrochloride|Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
41284420|NCT00388089|OTHER|flow cytometry|No description
41284421|NCT00388089|OTHER|immunoenzyme technique|No description
41284422|NCT00388089|OTHER|immunohistochemistry staining method|No description
41284423|NCT00388089|OTHER|laboratory biomarker analysis|No description
41284424|NCT05782855|OTHER|Active Robot assisted physical training during acute hospitalisation|"Active training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the exercise movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform extension of hip and knee. The patient must use their muscular power to stretch the leg while ROBERT® provides resistance.~Training is defined as a minimum of three sessions before discharge."
41284425|NCT05782855|OTHER|Passive Robot assisted physical training during acute hospitalisation|"Passive training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform passive extension of hip and knee. ROBERT® moves the leg independently without the patient using any muscle power.~Training is defined as a minimum of three sessions before discharge."
41284426|NCT04652024|DEVICE|Anorectal manometry|, patients are instructed to isolate the anal sphincter and puborectalis muscles and improve its strength by using modified Kegel exercises in lying position with a probe in situ. Visual and verbal feedback techniques are used to reinforce the maneuvers, as they are being performed. The anal and rectal pressure changes displayed on the monitor provides visual feedback to the patient.
41284427|NCT02486068|DEVICE|ABSORB scaffold|
41284428|NCT02486068|DEVICE|Xience|
41284429|NCT02417623|BEHAVIORAL|Smartphone Application group|Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
41284430|NCT02830373|DEVICE|LVIS stents|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
41284431|NCT02789696|OTHER|Diagnosis of acromegaly|Biological analysis of IGF-1
41284432|NCT03844971|PROCEDURE|Computer assisted arthrocentesis of|Under general anesthesia : patients specific preoperative prefabricated surgical guide will be used intraoperative for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction
41451899|NCT04358237|DRUG|Lurbinectedin|"Lurbinectedin will be presented as a lyophilized powder for concentrate for solution for infusion in 4-mg vials. Before use, the 4-mg vial will be reconstituted with 8 mL of sterile water for injection, to give a solution containing 0.5 mg/mL of PM01183. For administration to patients as IV infusion, reconstituted vials will be diluted with glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) solution for infusion.~PM01183 will be administered as a 1 hour IV infusion Q3W, in a minimum volume of 100 mL of solution for infusion (either 5% glucose or 0.9% sodium chloride), or a minimum volume of 250 mL if through a peripheral line, always at a fixed rate and through a pump device."
41451900|NCT04358237|DRUG|Pembrolizumab|Pembrolizumab will be supplied as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
41451901|NCT01506622|DRUG|Administration of propofol|Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
41451902|NCT01506622|DRUG|Administration of fentanyl|Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
41451903|NCT01506622|DRUG|Administration of saline|Saline will be administered to control group at the end of anesthesia.
40943031|NCT00057876|DRUG|Gemcitabine|"Induction: Patients receive the first cycle of gemcitabine 1000 mg/m\^2 intravenously once per week for 6 weeks followed by 1 week rest.~Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m\^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles."
41284433|NCT05852210|OTHER|Infrared Imaging|This study will use thermal forward looking infrared (FLIR) imaging to assess the severity of Complex Regional Pain Syndrome in newly diagnosed patients.
41284434|NCT04680923|PROCEDURE|CPPLAI|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
41284435|NCT04680923|OTHER|Placebo|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal 40 ml of sterile water.
41284436|NCT04680923|DRUG|Bupivacaine 0.25%|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
41284437|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
41284438|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
41284439|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)|Single dose administered intranasally on Day 1
41284440|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
41284441|NCT04909021|OTHER|Placebo (single-dose)|Single dose administered intranasally on Day 1
40943032|NCT00057876|RADIATION|radiation therapy|"Induction: Patients receive gemcitabine 600 mg/m\^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.~Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy."
41451904|NCT04516187|DIAGNOSTIC_TEST|signs and symptoms, blood tests|signs and symptoms as observed by the treating physician + blood tests (CRP, Procalcitonin, White blood cell count)
41451905|NCT01457092|DEVICE|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
41284442|NCT04909021|OTHER|Placebo (two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
41284443|NCT04248166|DEVICE|Photoacoustic imaging|"1. Photoacoustic image of thyroid nodule is obtained by using probe of photoacoustic imaging equipment and image data and data are stored in the device.~2. The patient's examination is the same as the general ultrasound, and the patient is asked to hold his breath for about 3-4 seconds to get the photoacoustic image."
41451906|NCT04624360|DRUG|Dexamethasone|Intravenous of Dexamethasone 8 mg post clamping of the umbilical cord
40943033|NCT00943124|DRUG|MK0524B (ER niacin (+) laropiprant (+) simvastatin)|Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
40943034|NCT00943124|DRUG|MK0524A (ER niacin + laropiprant)|Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
41284444|NCT05846633|DEVICE|C mell treadmill|C Mell treadmill provides Virtual Reality environment for rehabilitation with obstacles and motivational assistance
41284445|NCT00337948|DRUG|Epoetin alfa|
41284446|NCT01336101|DEVICE|EPIC™ Self-Expanding Nitinol Vascular Stent|SFA/Popliteal Artery stenting
41284447|NCT03851601|OTHER|blood samples|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
41284448|NCT06022770|DIETARY_SUPPLEMENT|Nutritional counseling，Enteral Nutrition|patients with esophageal cancer and gastric cancer undergoing chemotherapy were selected as the study objects for nutritional risk screening, malnutrition assessment and quality of life assessment. Randomly enter the nutrition consultation group (NC) and nutrition support treatment group (NST)
41284449|NCT03591822|BEHAVIORAL|A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot|Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
41284450|NCT03591822|BEHAVIORAL|B : Systemic evaluation of the pain|A systematic evaluation of the pain
41451907|NCT04624360|OTHER|Placebo|2cc 0.9% Saline
41284451|NCT02873546|DEVICE|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
41284452|NCT03227861|DRUG|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
41451908|NCT02831920|OTHER|CEUS and targeted biopsies|
40943035|NCT00943124|DRUG|Simvastatin|Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
40943036|NCT06484491|RADIATION|Standard-dose intensity-modulated proton therapy (IMPT-60)|The standard care group will receive 60.0 Gy (RBE) to the whole clinical target volume
40943037|NCT06484491|RADIATION|Dose-escalated intensity-modulated proton therapy (IMPT-74)|Heterogeneous simultaneous integrated boost of 74.0 Gy (RBE) to primary tumor \>15mm away form mediastinal envelope, and 64.0 Gy (RBE) to primary tumor =\< 15mm away from mediastinal envelope. The rest of the clinical target volume, including affected lymph nodes, receives 60.0 Gy (RBE).
41284453|NCT04901507|DEVICE|The Voutia System|Participants will wear the Voutia System oral irrigation device continuously through the day and night, removing for cleaning and if otherwise necessary, but not for time extending beyond six-eight hours.
41284454|NCT03129438|DIAGNOSTIC_TEST|continuous EEG (cEEG)|differential use of continuous versus routine EEG
41284455|NCT03129438|DIAGNOSTIC_TEST|routine EEG (rEEG)|differential use of continuous versus routine EEG
41284456|NCT05107414|PROCEDURE|Total Knee Arthroplasty|Participants have previously undergone a total knee replacement surgery.
41284457|NCT00540540|DEVICE|Diffuse Optical Spectroscopy|Breast properties scanning
41284458|NCT00004177|BIOLOGICAL|filgrastim|as prescribed by physician
41284459|NCT00004177|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks from treatment
41284460|NCT00004177|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
41284461|NCT00004177|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
41451909|NCT02831920|OTHER|MRI and targeted biopsies|
41451910|NCT01674387|DEVICE|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
41451911|NCT01674387|OTHER|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
41451912|NCT06356558|OTHER|Educational intervention (VISACT)|The intervention is an implementation strategy called VISACT: VISuAl aids, Coach providers in communication, and Train organizations in health literacy. This strategy will be delivered to patients, providers, and organizations through a novel interactive response platform.
41451913|NCT05084963|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
41451914|NCT05084963|DRUG|Placebo|Matching placebo for IRL201104
41284462|NCT02493751|DRUG|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
41284463|NCT02493751|DRUG|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
41451915|NCT05480423|BEHAVIORAL|Mindfulness-based intervention|1. Psychoeducation video on mindfulness and mindful parenting. 2. Audio files of mindfulness exercises including mindfulness of breath, body scan, mindful stretching, mindfulness of soles of the feet, befriending exercises. 3. Informal mindfulness exercises by applying mindfulness in daily lives
41284464|NCT02797561|OTHER|5 year Follow-up|
41284465|NCT00013884|DRUG|T-20|
41284466|NCT01568944|DRUG|Oral Antibiotic and Oral Rinse|PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
41284467|NCT01568944|PROCEDURE|Standard Treatment|Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
41284468|NCT00787735|BEHAVIORAL|Counseling compliance|Rates of attendance to call counseling session over specific time points
41284469|NCT00432133|BEHAVIORAL|Protection Motivation Theory-Based Intervention|Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
41284470|NCT00432133|BEHAVIORAL|Environmenta|Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
41451916|NCT03098485|DRUG|Levofloxacin|5 days of levofloxacin administration
41451917|NCT03098485|DRUG|Azithromycin|5 days of azithromycin administration
41284471|NCT01318902|DRUG|Ixazomib|Ixazomib capsules.
40943038|NCT06484491|DRUG|Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy|"Induction course:~-Cisplatin (75 mg/m2) or carboplatin (AUC 6) + pemetrexed (500mg/m2).~Concurrent chemoradiotherapy:~* Weekly cisplatin (20mg/m2) + docetaxel (20mg/m2) on Mondays.~* Radiotherapy will be given for 5x5 days."
41284472|NCT01318902|DRUG|Dexamethasone|Dexamethasone tablets.
41284473|NCT04002323|DRUG|Dolutegravir 50mg Tab|The subjects starts their ART with this drugs, once a day
41284474|NCT04002323|DRUG|Lamivudine 300 mg|The subjects starts their ART with this drugs, once a day
41284475|NCT02467881|BEHAVIORAL|Physical Activity Increase (GLB-MOD)|"The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.~The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
41284476|NCT02467881|BEHAVIORAL|Sedentary Time Decrease (GLB-SED)|"As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
41284477|NCT02467881|OTHER|6-month delayed (DELAYED)|Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
41284478|NCT04782739|OTHER|None - Descriptive study|Descriptive study
41284479|NCT06483893|PROCEDURE|US-guided thyroid cartilage plane block (group TCPB)|Participants in the (group TCPB) will receive US-guided thyroid cartilage plane block. Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 3ml of 2% lidocaine is injected on the surface of the thyroid cartilage plate. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
41451918|NCT03098485|DRUG|Cefpodoxime|5 days of cefpodoxime administration
41451919|NCT05538338|OTHER|Platelet Rich Plasma Intrauterine infusion|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group of participants
41451920|NCT05538338|OTHER|Normal saline Intrauterine infusion|an intrauterine infusion of normal saline will be administered to this group of participants
41451921|NCT05004649|BEHAVIORAL|Psychophysical task|A psychophysical task will be used to measure participants' ability to discriminate the horizontal position of the central object that is presented within the context of background objects in a natural visual scene. The task will be a two-interval forced choice task that presents one stimulus per interval. Between the two stimulus intervals, two masks will be shown in succession at the center of the monitor. The task of the participant will be to determine whether, compared to the central object presented in the first interval, the central object presented in the second interval is to the left or to the right. One of two feedback tones will be presented after the response is entered, indicating whether the participant was correct or incorrect. For trials in which there is no difference in the position of the central object between the two intervals, the response that will receive the correct feedback tone will be randomly selected per trial.
41451922|NCT01202435|DRUG|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for four days.
41284480|NCT06483893|PROCEDURE|US-guided traditional superior laryngeal nerve block (group traditional SLNB)|Participants in the (group traditional SLNB) will receive US-guided traditional superior laryngeal nerve block. Traditional Superior Laryngeal Nerve Block is performed using the thyrohyoid muscle and thyrohyoid membrane as an anatomical landmark. The thyroid cartilage and the greater horn of hyoid bone are hyperechoic signals on sonography. 3ml of 2% lidocaine is injected above the thyrohyoid membrane next to the superior laryngeal artery between two hyperechoic structures. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
41284481|NCT02108457|RADIATION|[18F]Fluorothymidine (FLT) PET/CT Imaging|
41284482|NCT05926206|DRUG|Devimistat|Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3
41284483|NCT05926206|DRUG|Modified FOLFIRINOX|Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1
41451923|NCT01202435|DRUG|Pregabalin immediate release, 25 mg|25 mg immediate release capsules administered three times daily for four days
41451924|NCT01198392|DRUG|s-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
41451925|NCT01198392|DRUG|5-Fu plus cisplatin|"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.~Number of Cycles: until progression or unacceptable toxicity develops."
41451926|NCT05886803|OTHER|Spontaneous ventilation test|The purpose is to mimic ventilation conditions after extubation and thus to help the clinician predict the outcome of an extubation decision.
41451927|NCT00891787|DIETARY_SUPPLEMENT|Probiotic Supplement|
41451928|NCT05389813|DRUG|Oxycodone 20 Mg Oral Tablet|Oxycodone is a semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.
41284484|NCT01912040|DRUG|Administration of 123Iodine MIBG|Patients will be administered the locally produced 123 Iodine MIBG
41284485|NCT02723630|DRUG|Lenvatinib 10 mg|"Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%"
41284486|NCT04945655|OTHER|Adolescents and parents' education and motivation at school (component 1)|"The component 1 includes first an information group session (duration: 1h30) on HPV infection and vaccination for parents. This session starts with a webconference delivered by two medical experts on HPV, using a standardized presentation. Then, a discussion is open for parents' questions and/or comments.~Second, adolescents participate during the school time to two educational group sessions on HPV infections and vaccination, using a pedagogy based on active learning. These sessions (duration: 2h each) are delivered by the school staff (e.g., nurse, teacher in life sciences) using an educational package comprising: a guide that describes activities that should be implemented during each session; one video and a fact sheet developed by health students; a serious video game that promotes HPV vaccination and accessible on an internet website. Before the sessions, the school staff is encouraged to attend an e-learning training course (duration: 1 hour)."
41284487|NCT04945655|OTHER|General practitioners' training (component 2)|The component 2 consists of an individual e-learning training session for general practitioners (GPs) that is accessible on computer and smartphone. Lasting 3 hours, GPs are able to access to the training whenever they want and then to progress at their own pace. The training includes three main parts: up-dated information on HPV infection and vaccination; an introduction to the use of motivational interviewing techniques in the field of vaccination; and a presentation of the decision aid tool developed as part of the intervention and explanation of how to use it during consultations. GPs may ask questions to the consortium team by using a dedicated chat.
41284488|NCT04945655|OTHER|Access to vaccination at school (component 3)|The component 3 aims at enhancing access to HPV vaccination for adolescents by offering them the first free-of-charge injection at school, without any medical prescription. For each concerned school, we organise a vaccination day inside the school premises where health professionals (one physician and one nurse) from the local vaccination centre initiate HPV vaccination with Gardasil-9® (in accordance with the French recommendations) for all eligible adolescents.
41284489|NCT05227573|PROCEDURE|Orthopedic surgery|Knee-, hip-, shoulder- and elbow surgery
41284490|NCT04427592|DIAGNOSTIC_TEST|ultrasound|trans-vaginal and trans-abdominal ultrasound using different modalities such as grey-scale, Doppler, multi-planer mode
41284491|NCT04427592|PROCEDURE|closure of uterine wall defect|uterine incision above placental bulge by at least 5 mm then complete separation of the placenta starting from areas of least resistance to areas of high resistance leaving a clear defect which will be closed by non locked running sutures from inside the uterus starting from one edge, hitch the bed to the other edge of the defect and controlling placental bed hemorrhage then closing the uterine incision via running sutures in 2 layers with compressing the bed from outwards in the first layer. hemostasis of the abnormal pelvic vasculature if excessive bleeding internal iliac artery may be ligated then insertion of intra-peritoneal drain followed by closing the abdomen.
41284492|NCT04373369|DRUG|Vorolanib|Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.
41284493|NCT04373369|DRUG|Atezolizumab|Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
41284494|NCT06067477|DIETARY_SUPPLEMENT|Vitamin D Supplement|Vitamin D Supplement
41284495|NCT00154505|DEVICE|Lateral trunk support of wheelchair seating|
41284496|NCT03676309|DRUG|Nutriceutical Oral Capsule,|nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks
40943039|NCT06484491|DRUG|Immunotherapy: adjuvant durvalumab|"Adjuvant treatment will be given starting 1-6 weeks after chemoradiotherapy if no progression, good performance (PS 0-1), no other contra-indication for immunotherapy.~Doses:~* Start durvalumab 10 mg/kg 1x/14 days.~* If possible after 2 courses switch to 1500 mg flat dose 1x/4 wk.~* Continue for 12 months in total."
40943040|NCT00138177|DRUG|oxaliplatin|Given IV
40943041|NCT00138177|DRUG|leucovorin calcium|Given IV
41284497|NCT03676309|DRUG|Placebo Oral Tablet|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
41284498|NCT04685148|DRUG|Transdermal patch estradiol|Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
41284499|NCT04685148|DRUG|Transdermal patch placebo|Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
41284500|NCT06512974|BEHAVIORAL|NeuroTrainer|Virtual reality based cognitive training
41284501|NCT04893850|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to improve parent well-being and promote supportive parenting practices. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target parental mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
41284502|NCT04893850|BEHAVIORAL|Community Services as Usual Clinical Referral list|The community services as usual clinical referral list provides information on accessing psychological and family support services in Winnipeg. This resource is used to locate: crisis, distress, and support phone lines, counselling and peer-support resources, and free apps relating to mindfulness and meditation.
41284503|NCT06207344|DRUG|Dexmedetomidine and propofol|Group 1: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Meantime, propofol was infused at 4-12mg/kg/h intravenously to maintain the depth of anesthesia.
41284504|NCT06207344|DRUG|Dexmedetomidine and desflurane|Group 2: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was inhaled to maintain the depth of anesthesia.
41284505|NCT03322800|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
41284506|NCT03322800|OTHER|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
41284507|NCT00188448|DEVICE|MRI|
41284508|NCT06231108|OTHER|Kinesio Taping|"Three different taping applications will be applied, namely ankle correction, quadriceps facilitation, and gluteus maximus facilitation.~1. Taping: Functional correction technique will be used to facilitate dorsal flexion movement.~2. Taping: Quadriceps Femoris (QF) Facilitation Technique - In taping to activate the QF muscle and regulate muscle tone, the patient will be placed in a supine position with hips and knees in neutral.~3. Taping: Gluteus Maximus (GM) Facilitation Technique - For taping to facilitate the GM muscle, a double-band application will be performed."
41284509|NCT04320095|DEVICE|Bizact tonsillectomy device|Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.
41284510|NCT04302181|DRUG|Ropivacaine injection|6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
41284511|NCT05910593|DIAGNOSTIC_TEST|Dexterity Assessment Tool|Measures finger dexterity using pressure sensor pads.
41284512|NCT04707248|DRUG|DS-6000a|Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
40943042|NCT00138177|DRUG|vorinostat|Given orally
40943043|NCT00138177|DRUG|fluorouracil|Given IV
40943044|NCT04258514|PROCEDURE|Virtual Reality during vasectomy|Virtual Reality
40943045|NCT04258514|PROCEDURE|Standard Vasectomy|No Virtual Reality
40943046|NCT02589379|PROCEDURE|Pancreatic Resection|Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
40943047|NCT02643030|BEHAVIORAL|hypercapnia|Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
40943048|NCT02643030|BEHAVIORAL|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
40943049|NCT00835159|DRUG|Rivastigmine Patch|Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
41451929|NCT05389813|DRUG|Pregabalin 150mg|Pregabalin is a gabapentinoid and acts by inhibiting certain calcium channels. Specifically it is a ligand of the auxiliary α2δ subunit site of certain voltage-dependent calcium channels (VDCCs), and thereby acts as an inhibitor of α2δ subunit-containing VDCCs. There are two drug-binding α2δ subunits, α2δ-1 and α2δ-2, and pregabalin shows similar affinity for (and hence lack of selectivity between) these two sites. Pregabalin is selective in its binding to the α2δ VDCC subunit. Despite the fact that pregabalin is a GABA analogue. r synthesizing GABA, and hence may have some indirect GABAergic effects by increasing GABA levels in the brain. In accordance, inhibition of α2δ-1-containing VDCCs by pregabalin appears to be responsible for its anticonvulsant, analgesic, and anxiolytic effects.
41284513|NCT04707248|DRUG|DS-6000a|Intravenous administration at RDE on Day 1 of Cycle 1
41284514|NCT05306678|BEHAVIORAL|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
40943050|NCT00835159|OTHER|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
41284515|NCT05306678|BEHAVIORAL|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
41284516|NCT00618956|DRUG|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily \[BID\]), oral administration.
41284517|NCT00618956|DRUG|Placebo|Placebo
41284518|NCT01532661|OTHER|observational study|data collected by investigators
41284519|NCT01104831|DEVICE|Cryotherapy|cooled sleeve placed over fracture site.
41284520|NCT01104831|DEVICE|Room temperature cuff|sleeve with room temperature water placed over fracture site.
41284521|NCT01887444|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938 probiotic|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.
41284522|NCT01887444|OTHER|Placebo|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
41284523|NCT03020693|PROCEDURE|Invasive electrostimulation combined with exercises|Procedure for producing analgesia by introducing the TENS current through a needle combined with a exercises program.
41284524|NCT03020693|PROCEDURE|Placebo electrostimulation and exercises|First: Sham dry needling. After: electrostimulation using surfaces electrodes. Finally a exercises program.
41284525|NCT03312946|DEVICE|Modellata|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
41284526|NCT06434168|BEHAVIORAL|Yoga intervention|Patients in the yoga group will receive a 60-minute session, twice per week over 12 weeks for a total of 24 sessions. Each yoga session consists of a warm-up, yoga postures standing or seated depending on the capability of the patient, and relaxation.
41284527|NCT06434168|BEHAVIORAL|Control condition|Patients in the control group will receive care-as-usual from their healthcare providers and will be asked to avoid engaging in yoga during their 3 months in the study.
41284528|NCT02202681|DEVICE|OFDI Capsule|Imaging of the duodenum with the OFDI capsule and system
41284529|NCT01634347|DRUG|Propranolol and memory reactivation|Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.
41284530|NCT01634347|DRUG|Placebo and memory reactivation|Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
41284531|NCT02054858|PROCEDURE|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
41451930|NCT05389813|DRUG|Multivitamin with Minerals|Vit A 3000 IU, Vit B1 2.5mg, Vit B2 2.0mg, Vit B12 10mcg, Vit C 150mg, Vit D3 400 IU, Vit E10 IU, Biotin 25mcg, Nicotimamide 30mg, Calcium Pantothenate 3mg, Folic acid 800mcg, Iron Fumarate 18mg, Calcium 125mg, Magnesium Oxide 10mg, Iodine Potassium 150mcg, Manganese sulfate 0.5mg, Phosphorus 23.8mg, Copper sulfate 1.0mg, Molybdinium Sodium 0.10mg, Zinc Sulfate 5.0mg.
41451931|NCT02718963|DEVICE|Synchronized Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
41451932|NCT01466894|BIOLOGICAL|IMM 124-E|Tablets orally twice a day for 24 weeks
41451933|NCT01466894|BIOLOGICAL|Placebo|Tablets orally twice daily for 24 weeks
40756921|NCT01217047|DEVICE|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
40943051|NCT04645888|PROCEDURE|Impacted tooth surgery|Surgical extraction of İmpacted tooth
41284532|NCT03623750|DRUG|EGFR-TK Inhibitor|Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.
41284533|NCT03623750|BIOLOGICAL|EGF-PTI|"The first day of dosing with EGF-PTI will be designated Day 1. Immunisation with EGF-PTI will commence 3 days after low dose cyclophosphamide and commencement of EGFR TKI, and will be repeated on Day 14, Day 28, Day 43, and Day 92. After the 5~th vaccination, patients will enter a maintenance phase during which reduced dose vaccinations will be performed every 2 or 3 months in conjunction with the interval between detailed check-up of the patient. As this interval can vary between patients, the interval for maintenance vaccination can also vary between 2 and 3 months."
41451934|NCT05022979|OTHER|Observational only|"The investigator collected the patient's data from the medical record and interviewed the patient to complete the nutritional questionnaire.~The required biological, blood and urine samples were collected during routine blood sampling upon entry and hospitalization."
41451935|NCT02588911|PROCEDURE|Conventional Surgery|Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein
41451936|NCT02588911|PROCEDURE|Radiofrequency Ablation|Catheter-based ablation of the great saphenous vein
41451937|NCT05746143|DRUG|Zolpidem Tartrate 10 mg|two days preoperatively and five days postoperatively
40943052|NCT05867173|OTHER|Montreal Cognitive Assessment (MoCA)|Subjects will be asked to complete this one-page cognitive test assesses short-term memory recall and attention. This test takes approximately 10 minutes.
40943053|NCT05867173|OTHER|Detection Threshold Testing|"Subjects will be asked to listen for the softest sound they can hear (threshold') with different electrode configurations"
41284534|NCT03623750|DRUG|Cyclophosphamide|Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
41284535|NCT03403244|PROCEDURE|US-MR image fusion-guided PTED|patients diagnosed with lumbar disc herniation undergoing US-MR image fusion-guided PTED
41284536|NCT03403244|PROCEDURE|fluoroscopy-guided PTED|patients diagnosed with lumbar disc herniation undergoing fluoroscopy-guided PTED
41284537|NCT00671151|DRUG|Theophylline|Theophylline 100 mg bid for 3 months
41284538|NCT00908297|DIETARY_SUPPLEMENT|Coenzyme Q10|"By mouth (wafer) once daily for duration of study (8 weeks).~Dose escalation:~* 300 mg for two weeks~* 600 mg for two weeks~* 1200 mg for two weeks~* 1800 mg for final two weeks"
41284539|NCT00749632|DRUG|oxybutynin|low dose oxybutynin administered daily
41284540|NCT00749632|DRUG|oxybutynin|middle dose oxybutynin administered daily
41284541|NCT00749632|DRUG|oxybutynin|high dose oxybutynin administered daily
41284542|NCT03465956|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy using the gastro-intestinal anastomosis stapler.
41284543|NCT04893668|OTHER|Depression|Any participants who develop depression symptoms according to DSM 5 criteria
41284544|NCT04893668|OTHER|Anxiety|Any participants who develop anxiety symptoms according to DSM 5 criteria
40943054|NCT05867173|OTHER|Psychophysical Testing|Subjects will be asked to determine the difference between different types of sounds, such as those that vary in pitch and/or volume. Sometimes they will be asked to judge the sound quality of sounds that have very small differences, or make loudness judgments and comparisons.
40943055|NCT05867173|OTHER|Speech Perception Testing|Subjects will be asked to listen to words and sentences in quiet and/or in the presence of background noise. For this task they will be asked to repeat the words or sentences following its presentation or use the computer mouse to respond.
41132317|NCT01850342|PROCEDURE|Periurethral injection of fat micrograft enriched with ADRC|Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
41284545|NCT00487812|PROCEDURE|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
41284546|NCT03672617|OTHER|No treatment given|"No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion."
41284547|NCT00244218|DRUG|tetrahydrobiopterin (BH4)|Either placebo or tetrahydrobiopterin (BH4) , 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
41284548|NCT05965713|DEVICE|Neurolutions IpsiHand System|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
41284549|NCT05965713|OTHER|Standard of Care - Home Exercise Program for Upper Extremity|Subjects will receive a customized home range of motion exercise program. Subjects will be recommended to complete their exercises daily, 5 out of 7 days per week for 12 weeks
41284550|NCT01703312|DRUG|QGE031|Drug administered by subcutaneous injection
41284551|NCT01703312|DRUG|omalizumab|Drug administered by subcutaneous injection
41284552|NCT01703312|DRUG|placebo|Drug administered by subcutaneous injection
41284553|NCT02459171|OTHER|Questionnaire|Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.
41284554|NCT02459171|OTHER|Blood sample|"Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.~For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs."
41284555|NCT02459171|OTHER|Nasal wash|Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
41132318|NCT01849107|BIOLOGICAL|Plasma citrulline|
41284556|NCT02459171|OTHER|Throat swab|Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
41132319|NCT01138969|DRUG|esomeprazole|esomeprazole 20 mg qd for 6 months
41132320|NCT01773993|DRUG|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
41284557|NCT02569489|DRUG|HBI-8000|
41284558|NCT02569489|DRUG|Trastuzumab|
41284559|NCT02569489|DRUG|Paclitaxel|
41284560|NCT00000249|DRUG|20% N2O|20% inhaled N2O
41284561|NCT00000249|DRUG|30% N2O|30% inhaled N2O
41284562|NCT00000249|DRUG|40% N2O|40% inhaled N2O
41284563|NCT02813538|DRUG|Indocyanine green clearance|To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
41284564|NCT02813538|OTHER|Thromboelastometry|To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
41284565|NCT02333708|OTHER|Blood sample|
41132321|NCT00759798|DRUG|Fludarabine|25 mg/m\^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
41284566|NCT01132014|BIOLOGICAL|OCDC|OCDC,an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with either intravenous Daclizumab, or with a combination of Daclizumab and intravenous Bevacizumab.
41284567|NCT02525172|DRUG|Rituximab|
41451938|NCT05746143|DRUG|Placebo|two days preoperatively and five days postoperatively
41451939|NCT04758208|DIAGNOSTIC_TEST|Hematology Parameters|Measurement of hematology parameters on BC-6800Plus
41451940|NCT03648931|BEHAVIORAL|Focus Group Discussion (FGD)|"No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding"
41451941|NCT03648931|BEHAVIORAL|In-depth Interview (IDI)|"No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women"
40756922|NCT01217047|DEVICE|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
40756923|NCT01217047|PROCEDURE|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
40756924|NCT01217047|BEHAVIORAL|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
40756925|NCT01796470|DRUG|Entospletinib|Entospletinib tablets administered orally twice daily
40756926|NCT01796470|DRUG|Idelalisib|Idelalisib tablets administered orally twice daily
40756927|NCT04287647|DEVICE|Transpyloric stent|See arm/group descriptions
40756928|NCT04287647|OTHER|Sham|Sham
40756929|NCT03220256|DRUG|Lamotrigine|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
40756930|NCT01125644|DRUG|SPK-843|SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
41132322|NCT00759798|DRUG|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
40756931|NCT01348490|DRUG|Ruxolitinib|Ruxolitinib (INCB018424), 5 mg bid
40756932|NCT03060707|DRUG|Rocuronium Bromide|Continuously infuse, or bolus administer rocuronium.
40756933|NCT04043247|DEVICE|TEAS|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
40756934|NCT04043247|DEVICE|TEAS without electrical stimulation|Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
40943056|NCT05867173|OTHER|Telemetry Recordings|Subjects who wear a cochlear implant, for each cochlear implant channel or pair of channels, measurements will be made from other available electrodes in their implant.
40943057|NCT01962831|DRUG|Dinoprostone|
41132323|NCT00759798|DRUG|Rituximab|"375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
41132324|NCT05335044|DRUG|CKD-331|QD, PO
41132325|NCT05335044|DRUG|EX5619|QD, PO
41132326|NCT00592891|DRUG|Hyperbaric oxygen therapy|Total body pressurized oxygen
41132327|NCT00002090|DRUG|Azithromycin|
41132328|NCT04030585|DEVICE|Robot|Patients with upper limb amputation using myoelectric prosthesis will done robot-assisted exercise program
41132329|NCT04030585|OTHER|Home exercise|Patients with upper limb amputation using myoelectric prosthesis will done home exercise program
41132330|NCT03658252|BEHAVIORAL|Targeted education|Educational video developed by the hospital, addressing common misconceptions of topical steroids. A patient information leaflet on topical steroids
41132331|NCT03658252|BEHAVIORAL|Online disease specific forum|An invitation to join an online moderated disease specific social forum
41132332|NCT00725972|OTHER|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
41132333|NCT00725972|PROCEDURE|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
41132334|NCT05635357|DRUG|Anastrozole|Anastrozole claim is used as the exposure group.
41132335|NCT05635357|DRUG|Exemestane/Letrozole|Exemestane/Letrozole claim is used as the reference group.
41132336|NCT02167451|DRUG|Maraviroc|
41132337|NCT00838994|OTHER|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
41284568|NCT02525172|DRUG|intravenous immune globulin|
41284569|NCT02525172|DRUG|Bortezomib|
41451942|NCT00851305|DEVICE|Endomicroscope (Pentax, Tokyo, Japan)|A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.
41451943|NCT00851305|DEVICE|Gastroscopes (Pentax, Tokyo, Japan)|Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
41284570|NCT02525172|DRUG|Methotrexate|
41284571|NCT02456623|BEHAVIORAL|Intervention|Home-based session targeting the parent
41284572|NCT02456623|BEHAVIORAL|Attention Control|Attention condition with newsletters and support phone calls
41284573|NCT00567931|DRUG|1-methyl-d-tryptophan|Given orally
41284574|NCT00567931|OTHER|pharmacological study|Correlative studies
41284575|NCT00567931|OTHER|laboratory biomarker analysis|Correlative studies
41284576|NCT06198257|DEVICE|spider cage|5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
41284577|NCT06198257|DEVICE|modified suits therapy|5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
41284578|NCT04744415|OTHER|Epidemiology of admissions|Cardiology Intensive Care Unit admission
40943058|NCT01962831|DEVICE|Single balloon foley catheter|
40756935|NCT03915756|PROCEDURE|Drainage of surgical wound|Introduction of a drain before full fascial closure
40756936|NCT06223880|DRUG|AXS-05|"Up to 10 weeks in open-label period;~Up to 26 weeks in double-blind period"
40756937|NCT06223880|DRUG|Bupropion|Up to 26 weeks in double-blind period
41284579|NCT04616586|DRUG|Siltuximab|11 mg/kg IV administered over 1 hour
41284580|NCT04616586|OTHER|Normal Saline|IV administered over 1 hour
41284581|NCT05952830|OTHER|ESWT group|subjects in ESWT-group receiving one session shock wave therapy given 6,000 impulses at 0.06-0.07 mJ/mm2 (1.2-1.4 bar) at 18 Hz on biceps brachii (17). Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
41284582|NCT05952830|OTHER|DN group|Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
41284583|NCT03426059|OTHER|No Intervention|No Intervention. This is an observational study.
41284584|NCT00674531|PROCEDURE|Artery resection|Artery resection
41284585|NCT04204681|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.
41284586|NCT01208181|DRUG|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
41284587|NCT01208181|DRUG|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
41284588|NCT01208181|DRUG|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
41284589|NCT01208181|DRUG|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
41284590|NCT03425383|DIAGNOSTIC_TEST|FMD and c-IMT|"The diameter of the target artery (right brachial artery) will be measured from two- dimensional ultrasound images, with a 70 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA).~c-IMT will be assessed by M-mode ultrasonography via a vivid 7 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA) with participants in the supine position."
41284591|NCT03572634|DRUG|TP-0903|"Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression."
41451944|NCT02280863|DEVICE|Medtronic Hybrid Closed-loop System - Android Platform|A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.
41451945|NCT02280863|DEVICE|Medtronic Hybrid Closed-loop Integrated System|A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
41132338|NCT06510608|DIAGNOSTIC_TEST|Biochemical analysis of saliva sample|It is the examination of saliva samples taken with biochemical methods. In this way, the substances in its content and the concentration of cytokines are analyzed.
41132339|NCT02032836|DRUG|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
41132340|NCT02032836|DRUG|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
41132341|NCT05313412|DEVICE|Lens A (comfilcon A lens)|6 hours
41132342|NCT05313412|DEVICE|Lens B (lehfilcon A lens)|6 hours
41132343|NCT03676569|BIOLOGICAL|ADRC transplantation in autoimmune refractory epilepsy|
41132344|NCT05338567|DIAGNOSTIC_TEST|Small intestine length measurement method|Accuracy of digital 3D reconstruction for predicting small bowel length
41132345|NCT06297057|OTHER|Neurophysiological Recordings|"Eyes-open resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes open and staring at a white cross in the center of a light grey screen to limit their eye movements.~Eyes-closed resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes closed.~ASSR: this block will last approximately 6 minutes. Stimuli will consist of a train of sounds presented repeatedly at high frequency.~MMN: this block will last approximately 3 minutes. Stimuli will consist of a train of equal sounds presented alternating with a 'deviant' (rarer frequency) sound."
41132346|NCT02113826|DRUG|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
41132347|NCT02676011|DRUG|IM atropine|Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
41132348|NCT02676011|DRUG|IV atropine|Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
41132349|NCT02676011|DRUG|Atropine mixed with second dose succinylcholine|Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
41132350|NCT02676011|DRUG|IM normal saline|1 ml normal saline IM 30 minutes before induction of anesthesia
41132351|NCT02676011|DRUG|IV normal saline|IV 10 ml normal saline 3 minutes before induction of anesthesia
41132352|NCT02676011|DRUG|Normal saline mixed with second dose succinylcholine|Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
41132353|NCT03090698|DRUG|Hylan G-F 20|intra-articular administration
41132354|NCT03090698|DRUG|Triamcinolone|Intra-articular administration
41132355|NCT01604824|DRUG|Alirocumab|SC injection in the abdomen
41132356|NCT01604824|DRUG|Placebo|SC injection in the abdomen
41132357|NCT05913791|DIETARY_SUPPLEMENT|Nutrients-fortified egg|Consumption of 2 cooked nutrients fortified eggs (half-boiled, hard-boiled, or steamed)
41132358|NCT05913791|OTHER|Regular egg|Consumption of 2 regular eggs, prepared in the same manner as nutrients-fortified egg, which serves as a placebo comparison.
41132359|NCT00399828|DEVICE|TRI-ACTIVE LASERDERMOLOGYTM (DEKA M.E.L.A., Itália)|
41132360|NCT01593020|DRUG|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
41132361|NCT01593020|DRUG|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
41132362|NCT01593020|DRUG|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
41132363|NCT01593020|DRUG|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
41132364|NCT01593020|DRUG|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
41284592|NCT03572634|COMBINATION_PRODUCT|TP-0903 and ibrutinib combination therapy|"Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period)."
41284593|NCT05314348|DEVICE|High-density surface EMG|High-density surface EMG for fasciculation detection
41284594|NCT05314348|DEVICE|Ultrasound|Ultrasound for fasciculation detection
41284595|NCT05126095|RADIATION|Radical radiotherapy|Intensity-modulated radiation therapy (IMRT)
41284596|NCT02967523|DEVICE|DEB-TACE with Surefire Precision Infusion System|Subjects have undergone/will undergo DEB-TACE using the Surefire Precision Infusion System.
41284597|NCT03071432|DIAGNOSTIC_TEST|Paced breathing at 6, 10 and 15 breaths per minute|
41284598|NCT03088605|DRUG|TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
41284599|NCT03088605|DRUG|Placebo to TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
41284600|NCT01011062|PROCEDURE|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
41284601|NCT01011062|DRUG|Losartan|Acute administration of losartan 200mg total prior to clamp
41284602|NCT01011062|DRUG|Saline|Infusion of Saline as a volume control intervention
41284603|NCT02750566|PROCEDURE|Osteopathic Manipulative Treatment|Manual treatment of musculoskeletal restrictions that may be prevent proper healing post-concussion.
41284604|NCT02750566|OTHER|Counseling|Patients will be counseled on concussion awareness, symptoms, and treatment for 30 minutes by a physician.
41284605|NCT04673994|BEHAVIORAL|Single, acute bout of high intensity interval exercise|Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
41284606|NCT04674163|BIOLOGICAL|Blood sample and Cerebrospinal fluid (CSF) collection.|An additional blood sample (25 ml) and a cerebrospinal fluid (CSF) sample (2 ml) will be taken.
41284607|NCT06408090|OTHER|IDECIDE-HOSPICE|12-pg educational booklet detailing information about hospice including what hospice is, why someone would use hospice, who pays for hospice, and where hospice services are delivered
41284608|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 2mg, Once daily, 6 weeks.
41284609|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 5mg, Once daily, 6 weeks.
41284610|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 10mg, Once daily, 6 weeks.
41284611|NCT00080327|DRUG|Placebo|Tablets, Oral, 0mg, Once daily, 6 weeks.
41284612|NCT02330029|DRUG|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
41284613|NCT02330029|DEVICE|Atractylodes|Atractylodes (\~10-15g)
41284614|NCT02330029|DEVICE|Paeonia Lactiflora|Paeonia Lactiflora (\~15-30g)
41284615|NCT02330029|DEVICE|Tangerine Peel|Tangerine Peel (\~10g)
41284616|NCT02330029|DRUG|Ledebouriella Root|Ledebouriella Root (\~10g)
40943059|NCT06038981|DRUG|Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced|"The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)"
41284617|NCT02330029|DRUG|Radix codonopsitis|Radix codonopsitis (\~10-15g)
41284618|NCT02330029|DRUG|Radix curcumae|Radix curcumae (\~10g)
41284619|NCT02330029|DRUG|Fingered citron|Fingered citron (\~10g)
41284620|NCT02330029|DRUG|Tuckahoe|Tuckahoe (15g)
41284621|NCT02330029|DRUG|Placebo|Placebo is blindly given to patients.
41284622|NCT00278824|DRUG|Matrix Transdermal Fentanyl/CHADD Drug Delivery System|Patch applied every 3 days for 15 days
40943060|NCT04343300|OTHER|Pilates|Intervention of12 weeks of Pilates
40943061|NCT04343300|OTHER|exercise without Pilates|exercise without Pilates
40943062|NCT04367129|DIAGNOSTIC_TEST|ECG|12 lead electrocardiogram
41284623|NCT00278824|DRUG|Placebo Patch|Placebo patch applied every 3 days for 15 days
41284624|NCT02128490|DRUG|Febuxostat IR|Febuxostat IR over-encapsulated tablets
41284625|NCT02128490|DRUG|Febuxostat XR|Febuxostat over-encapsulated capsules
41284626|NCT02128490|DRUG|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
41284627|NCT02128490|DRUG|Colchicine|Colchicine tablets
41284628|NCT02128490|DRUG|Naproxen|Naproxen tablets
41284629|NCT02128490|DRUG|Lansoprazole|Lansoprazole capsules
41284630|NCT00883753|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
41284631|NCT03469310|DRUG|Acetaminophen 500Mg Cap|non-narcotic medication first with narcotic as second choice
41284632|NCT03469310|DRUG|Tylenol #3 Oral Tablet|Narcotic medication first
41284633|NCT03469310|DRUG|Tramadol|non-narcotic medication first with narcotic as second choice
41284634|NCT00691574|DIETARY_SUPPLEMENT|Melatonin|up to 3 mg, daily, for up to 1 year
41284635|NCT00691574|DEVICE|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
41284636|NCT01392690|BEHAVIORAL|Dominique's Handy Tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
41284637|NCT00680732|DIETARY_SUPPLEMENT|Multiple micronutrients supplements (MMS)|Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
41284638|NCT00680732|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Iron 60 mg and folic acid 400 mcg
41284639|NCT00680732|DRUG|Chloroquine (CQ)|Tablets 100 mg of chloroquine base
41284640|NCT00680732|DRUG|Sulphadoxyne-pyrimethamine (SP)|Tablets
40943063|NCT04821544|BEHAVIORAL|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion
40943064|NCT05960942|DRUG|propofol combined with esketamine|In group PE, esketamine was firstly administered at a dose of 0.3 mg.kg-1, followed immediately by propofol with a single intravenous dose of 2.0 mg.kg-1.
41284641|NCT01999673|BIOLOGICAL|bavituximab|
41284642|NCT01999673|DRUG|Docetaxel|
41284643|NCT01999673|OTHER|Placebo (for bavituximab)|
41284644|NCT04341610|DRUG|Stem Cell Product|100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline
41284645|NCT05634564|DRUG|Tislelizumab|Tislelizumab 200mg administered intravenously on Days 1 of every 3 weeks.
41284646|NCT05634564|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
41284647|NCT05634564|DRUG|Nab paclitaxel|Gemcitabine 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
41284648|NCT05634564|RADIATION|Hypofractionated radiotherapy with simultaneous integrated boost|Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions.
41284649|NCT05069038|DRUG|Palbociclib 125mg|Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days on 7 days off schedule (meaning: on Days 1-21of each 28-day cycle). If a subject misses a day's dose entirely, she must be instructed not to make it up the next day but just take her regular dose at the next assigned time. If a subject vomits any time after taking a dose, she must be instructed not to retake the dose but resume subsequent dosing at the next assigned time. If a subject inadvertently takes an extra dose during a day, she must be instructed to not take the next day's dose.
41284650|NCT00997074|DRUG|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
41284651|NCT04651777|DRUG|FF/UMEC/VI|The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
41284652|NCT05747404|DIAGNOSTIC_TEST|Echocardiography|- Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and both the intra-beat and respiratory variation of the regurgitant volume
41284653|NCT04545307|BIOLOGICAL|Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis|The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
41284654|NCT04708990|DEVICE|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
41284655|NCT04402489|DRUG|Placebo|Placebo
41284656|NCT04402489|DRUG|MT-7117 Low Dose|MT-7117 Low Dose
41451946|NCT04162171|RADIATION|Stereotactic Body Radiotherapy (SBRT) ablation of VT|"Additional imaging for SBRT planning and implementation:~* Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~* SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems."
40756938|NCT03599297|PROCEDURE|Bilateral synchronous simultaneous stone surgery|Patients undergoing Bilateral synchronous simultaneous stone surgery (one kidney undergoing percutaneous nephrolithotomy, other kidney undergoing ureteroscopy at the same time in a single patient)
40756939|NCT02133677|DRUG|temozolomide 100mg|WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
40756940|NCT03497117|DEVICE|Lung Clearance Index|To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.
40756941|NCT03497117|DRUG|MRI with PFP|"* Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
41284657|NCT04402489|DRUG|MT-7117 High Dose|MT-7117 High Dose
41284658|NCT03660501|DEVICE|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor, Nonin WristOx 3150, Empatica E4, and Radiometer TCM5 FLEX monitor.
41284659|NCT03578705|DEVICE|"Electrical Impedance Myography unit or EIM"|
41284660|NCT04210973|DRUG|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
41284661|NCT04210973|DRUG|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
41284662|NCT03820115|DEVICE|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
41284663|NCT00467883|DRUG|Liposomal Amphotericin B|high dosage
41284664|NCT05585853|OTHER|virtual reality|Virtual reality glasses application is a method without any side effects. Patients will be treated for an average of 10 minutes. Data will be collected before, during, immediately after the application, at the 15th and 30th minutes.
41284665|NCT05246410|DEVICE|Spot stent system|Spot stent system designed and produced by Acotec
41451947|NCT02331511|DRUG|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
41284666|NCT05246410|DEVICE|Self-expanding peripheral stent system|Self-expanding peripheral stent system designed and produced by Ev3, Inc
41284667|NCT00920309|DRUG|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
41284668|NCT00920309|OTHER|Standard of Care-Placebo|
41284669|NCT04403867|PROCEDURE|Sentinel lymph node (SLN) biosy +/- lymphadenectomy|Evaluation of type and volume of lymph nodal disease
41284670|NCT03899740|OTHER|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
41284671|NCT03899740|OTHER|Ranking - Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
41284672|NCT03899740|OTHER|Ranking - Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
41284673|NCT03899740|OTHER|Ranking - Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
41284674|NCT01380093|DRUG|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
41284675|NCT01380093|DRUG|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
41451948|NCT02331511|DRUG|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
41451949|NCT02331511|DRUG|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
41451950|NCT01232660|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily orally
41284676|NCT01380093|DRUG|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
41284677|NCT00542815|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
41284678|NCT00542815|DRUG|Another Phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
41284679|NCT02715648|DRUG|Phenazopyridine|
41284680|NCT04038333|OTHER|No intervention|This is an observational study without any interventions.
41284681|NCT01416181|DRUG|natalizumab|Administered as specified in the treatment arm
41284682|NCT01416181|DRUG|Placebo|Matched placebo in part 1
41284683|NCT02655198|DRUG|Fenfluramine|study of efficacy and safety of add-on fenfluramine at different dosages in refractory Lennox Gastaut patients : 0.2 - 0.4 and 0.8 mg/kg/day (max 30 mg).
41284684|NCT03461926|BEHAVIORAL|(SB-related planning + daily text messages)|Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions/coping plans specifying when, where, how, and for how long they would reduce workplace sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will focus on increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing standing and light-intensity PA time, during work hours. Participants will receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions.
41284685|NCT02838550|BEHAVIORAL|Motivational Online Intervention|"The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention."
41284686|NCT02838550|BEHAVIORAL|Pedometer|Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
41284687|NCT00641147|DRUG|Curcumin|Given PO
40756942|NCT04591587|PROCEDURE|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery using VisuMax Femtosecond laser- Smile module surgery with primary objective to increase central corneal thickness and secondary objective to improve visual acuity and reduces K-values
41284688|NCT00641147|OTHER|Laboratory Biomarker Analysis|Correlative studies
41284689|NCT00641147|OTHER|Placebo|Given PO
41284690|NCT06007248|DIAGNOSTIC_TEST|Protocol-defined Examinations|Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, Birmingham Vasculitis Activity Score (BVAS-3), 6-minute walk test, 1-minute squat test, vascular ultrasound, fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT), coronary angiography, optical coherence tomography (OCT), tests for exploratory biomarkers.
40943065|NCT05960942|DRUG|propofol-sufentanil|In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.
41284691|NCT04889677|DRUG|Danicopan|
41284692|NCT04889677|DRUG|Placebo|
41284693|NCT00016315|DRUG|carboplatin|
40943066|NCT01288027|BIOLOGICAL|Alglucosidase Alfa|Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
41284694|NCT00016315|DRUG|gemcitabine hydrochloride|
41284695|NCT00016315|DRUG|paclitaxel|
41284696|NCT00016315|RADIATION|radiation therapy|
41284697|NCT04920448|DRUG|N-Acetyl cysteine|Administered as specified in the treatment arm
41284698|NCT03351673|DIAGNOSTIC_TEST|endometrial volume 2D TVS|calculation the endometrial volume using 2D ultrasound and correlation the results with the pathological findings of endometrial biopsy
41284699|NCT05394298|DRUG|Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity from a pre-stablished list of antibiotics included
41284700|NCT05394298|DRUG|Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity a pre-stablished list of antibiotics included
41284701|NCT03974919|OTHER|NO intervention required|NO intervention required
41284702|NCT01157169|DRUG|Buprenorphine|8 mg Sublingual Tablets
41284703|NCT01157169|DRUG|Buprenorphine|8 mg Sublingual Tablets
41284704|NCT05162235|DEVICE|Augmented Reality-assisted localization of solitary pulmonary nodule|In this study, AR was utilized to assist in the localization of SPNs during sublobectomy lung resection in patient to assess the safety and effectiveness of the technique.
41284705|NCT02975323|DRUG|Carvedilol|Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
41284706|NCT01936337|DRUG|DLX105 Hydrogel|topical administration on psoriatic plaque
41284707|NCT01936337|DRUG|Placebo|topical administration on psoriatic plaque
41284708|NCT04760548|OTHER|Observational study|
41284709|NCT01451333|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
41284710|NCT01451333|DRUG|Efavirenz|400mg qd; 2 x 200mg
41284711|NCT02109029|DRUG|Insulin Peglispro|Administered IV
41284712|NCT02109029|DRUG|Human Insulin|Administered IV
41284713|NCT00149214|DRUG|pemetrexed|500 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
41284714|NCT00149214|DRUG|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
41284715|NCT00149214|DRUG|doxorubicin|60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
41284716|NCT00149214|DRUG|docetaxel|100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)
41284717|NCT06283706|OTHER|Tryptophan|There are 7 different tryptophan test levels ranging from 0.5, 2, 4, 6, 8, 10, 12 mg.kg-1.day.1
41284718|NCT02927223|DRUG|Atropine|
41284719|NCT02927223|PROCEDURE|Exercise treadmill test|
41284720|NCT01444391|DEVICE|Tympanostomy tube placement (Acclarent iontophoresis device)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
41284721|NCT03999970|OTHER|Sand fly bite|Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)
41284722|NCT04590729|BEHAVIORAL|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
41284723|NCT04590729|BEHAVIORAL|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 15 minutes for 3 hours, totaling 36 minutes of cycling exercise.
41284724|NCT04978753|DRUG|Anlotinib|"1. Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA\<1.6 m2), once a day orally, taking two weeks and stopping for one week;~2. Almonertinib: 110mg, orally once a day;"
41284725|NCT02404506|DRUG|Eribulin mesilate|Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
41284726|NCT02708212|PROCEDURE|EGD and colonoscopy|Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
41284727|NCT04850950|DRUG|Tenofovir Alafenamide fumarate 25mg Oral Tablet|Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.
41284728|NCT02131701|BEHAVIORAL|Physical activity|
41284729|NCT00262405|DRUG|zileuton|
41284730|NCT00262405|DRUG|azathioprine/prednisone|
41284731|NCT04363216|DRUG|Ascorbic Acid|Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
41284732|NCT03394495|OTHER|BCE Combination group|The combination intervention programme consists of a weekly exercise training sessions and 6 sessions of Behavioral Change Enhancement (BCE) programme.
41284733|NCT06057571|DRUG|TT-00420 (tinengotinib)|TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.
40943067|NCT00658008|DRUG|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
41284734|NCT02723435|DRUG|Midostaurin|Given PO
41284735|NCT01370070|DRUG|MK-2206|200mg weekly repeated q 28 days
41284736|NCT02739139|DIETARY_SUPPLEMENT|AlphaBrain|Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
41284737|NCT02217735|BEHAVIORAL|Writing Intervention|Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
41284738|NCT02589977|DRUG|regadenoson|evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
41284739|NCT05460507|DRUG|Retreatment Rhenium Liposome|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
41284740|NCT05812508|DEVICE|corneal topography|corneal topography before and after pterygium surgery by two techniques bare scleral and conjunctival autograft
41284741|NCT02913625|OTHER|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
41284742|NCT02913625|OTHER|Ultrasound guided infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
41284743|NCT03267355|DEVICE|Endoscopic Ultrasound|Indication of EUS
41284744|NCT03610412|OTHER|Cinnamomum Cassia|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.
41284745|NCT03610412|OTHER|Placebo (calcined magnesia)|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.
41284746|NCT02396147|DRUG|TAK-385 T2 Formulation|TAK-385 T2 Formulation tablets
40943068|NCT00658008|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
40943069|NCT00658008|DRUG|PD 0332334|Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
40943070|NCT00658008|DRUG|Paroxetine|Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
40943071|NCT00658008|DRUG|Placebo|Capsules, oral, placebo bid, 8 weeks with 2 week taper
40943072|NCT04663373|OTHER|Step counting|Patients are given a physical activity tracker (wrist band) that they are asked to wear for two weeks after discharge from percutaneous coronary intervention.
40943073|NCT00796185|DRUG|Paliperidone ER|
40943074|NCT03392077|PROCEDURE|Caesarean section|Caesarean section will be done to deliver the baby
40943075|NCT03392077|OTHER|cervical dilatation|Cervical dilatation will be done by double gloves digital dilatation postpartum
40943076|NCT03392077|OTHER|No cervical dilatation|after delivery of the baby cervix will be remain closed
40943077|NCT05382533|DIETARY_SUPPLEMENT|Menu plans|The study participants in group A and C receive defined personal nutritional counselling every two weeks and they are provided with daily menu plans (isocaloric) with optimized nutrient profiles and chosen study products (plant oils, nuts mixture etc.) over the study period of 10 weeks.
40943078|NCT05997771|OTHER|Personal Nutrition Advisor|The study intervention will be the use of the PNA data analysis tool during remote nutritional counselling sessions delivered by certified dietitians, also referred to as PNA-assisted remote nutritional counselling.
40943079|NCT04288180|OTHER|No intervention|There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.
40943080|NCT05521724|PROCEDURE|exercise|resistance and strengthening exercises will be applied to a randomized patient group.
40943081|NCT03476668|OTHER|MIRT|4-week multidisciplinary intensive rehabilitation treatment
40943082|NCT06033612|DRUG|RV299|Oral Suspension
40943083|NCT06033612|DRUG|Placebo|matching placebo
40943084|NCT06033612|DRUG|Midazolam|pre-filled oral syringe
40943085|NCT05933070|BIOLOGICAL|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent. INKumne is a replication-incompetent tumor cell line that does not require donor matching.
40943086|NCT03847870|DIAGNOSTIC_TEST|MORU in-house ELISA test followed by IFA if positive|An in-house rickettsial IgG ELISA test will be used for this study to determine previous rickettsial infections by measuring IgG levels. All specimens will be tested for IgG antibodies using ELISA tests for scrub typhus (Orientia tsutsugamushi strains Karp, Kato, Gilliam and TA716), murine typhus (Rickettsia typhi strain type Wilmington), and spotted fever rickettsiosis (Rickettsia honei and Rickettsia conorii). If the sample tests positive, it will be retested for the same antigens using the IFA test. The sample will be considered positive if both the ELISA and the IFA are positive.
40943087|NCT06293131|DRUG|Ciprofol|Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
40943088|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 0.3 mg, Once daily, once
40943089|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 1.5 mg, Once daily, once
40943090|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 5.0 mg, Once daily, once
40943091|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 15.0 mg, Once daily, once
41284747|NCT02396147|DRUG|TAK-385 T4 Formulation B|TAK-385 T4 Formulation B tablets
41284748|NCT02396147|DRUG|TAK-385 T4 Formulation C|TAK-385 T4 Formulation C tablets
40943092|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 50 mg, Once daily, once
40943093|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 100 mg, Once daily, once
40943094|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 200 mg, Once daily, once
40943095|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 400 mg, Once daily, once
40943096|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Capsule, Oral, 50 mg, Once daily, once
40943097|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 800 mg, Once daily, once
40943098|NCT01454115|DRUG|Placebo matching BMS-708163|Oral Solution, Oral, 0 mg, Once daily, once
40943099|NCT01454115|DRUG|Placebo matching BMS-708163|Capsule, Oral, 0 mg, Once daily, once
40943100|NCT02320318|DRUG|Ibodutant 10 mg|Oral tablet, once daily.
40943101|NCT02320318|DRUG|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
40943102|NCT04537039|DIAGNOSTIC_TEST|Frailty screening for people over 65 living at home.|The home care services will carry out the SEGA-A test.
40943103|NCT01814618|DRUG|Budesonide Respules|Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
40943104|NCT06310915|DRUG|Navelbine oral,Pembrolizumab|Oral vinorelbine was administered three times weekly, and pembrolizumab was administered every 3 weeks
41132365|NCT01593020|DRUG|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
41284749|NCT05136391|DRUG|XTR003|Single dose of 8.0-10 mCi of XTR003 will be injected on the first day of the study (Day 1). Serial whole-body PET imaging will be acquired after dose injection.
41451951|NCT05435638|DIAGNOSTIC_TEST|Serum chemistry|"Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126).~Serum chemistries will include assessment of total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), alkaline phosphatase, glucose, sodium, potassium, blood urea nitrogen (BUN), and creatinine."
40756943|NCT02957903|DRUG|Ropivacaine|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
40756944|NCT02957903|DRUG|Isotonic Saline|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
40756945|NCT02057666|DRUG|Tasquinimod|A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.
40756946|NCT02057666|DRUG|Placebo|Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
41284750|NCT01401244|DRUG|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
41284751|NCT01401244|DRUG|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
41284752|NCT03682796|DRUG|TRPH-222|administered by IV, 21-day Cycle
41284753|NCT01863862|RADIATION|Radiochemotherapy or radiotherapy|"50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.~Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.~Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision."
41284754|NCT03312855|DRUG|Revacept 80 mg|single dose, intravenous application of 80 mg Revacept
41284755|NCT03312855|DRUG|Revacept 160 mg|single dose, intravenous application of 180 mg Revacept
41284756|NCT03312855|DRUG|Placebo|single dose, intravenous application of Placebo solution
41284757|NCT05368675|DRUG|medication for opioid use disorder|This is an open-label study. The project proposes to enroll up to 500 opiate dependent individuals entering Medication Assisted Treatment (Methadone or buprenorphine/naloxone) at Go Vap Clinic, HCMC, Vietnam. All participants who appear to meet inclusion criteria and who express interest in drug treatment will be invited to be screened for participation in the research. All participants will receive BDRC sessions (weekly for 12 weeks, monthly thereafter until week 52).
41284758|NCT02817438|BEHAVIORAL|Good Days Ahead|Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
41284759|NCT02527304|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo adaptive staged SBRT
41284760|NCT02527304|OTHER|Quality-of-Life Assessment|Ancillary studies
41284761|NCT02527304|OTHER|Questionnaire Administration|Ancillary studies
41284762|NCT02527304|RADIATION|Stereotactic Body Radiation Therapy|Undergo adaptive staged SBRT
41284763|NCT05881850|OTHER|Education Program on Increasing Osteoporosis Awareness Given to Women Aged 18-49. The research is carry out as a randomized controlled experimental in a pretest-posttest design.|The education program consisting of three sessions was held once a week and each session lasted approximately 40-50 minutes. In the realization of the education program, a power point presentation consisting of the contents of the education booklet prepared for Osteoporosis awareness, a three-dimensional bone model with Osteoporosis and normal bone tissue, some food samples containing calcium during nutrition education, and measuring cups to show portions and amounts were used. During the training, a question and answer activity was also held. The education booklet was also given to the intervention group at the end of the first session.
41284764|NCT00493389|DRUG|Adrenocorticotrophic hormone|
41284765|NCT05249192|DEVICE|Immediate urinary catheter removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
41284766|NCT05249192|DEVICE|Early urinary catheter removal|urinary catheter removal on the first postoperative day (6 a.m)
40756947|NCT02040012|DRUG|AZP-531|
41284767|NCT00117767|DRUG|Terbinafine hydrochloride (HCl)|Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
41284768|NCT00117767|DRUG|Griseofulvin|Griseofulvin pediatric suspension o.d. administration
41284769|NCT02285010|DRUG|placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
40756948|NCT02040012|DRUG|Placebo|
40756949|NCT00063362|DRUG|Lithium|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
41132366|NCT02343094|DRUG|PBA 7,5g/d|Treatment for 14 days with PBA
40943105|NCT03075046|DEVICE|Blue LED 405 nm|It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
40943106|NCT03075046|OTHER|Questionnaire of anamnesis|The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist
40943107|NCT01783054|PROCEDURE|Surgery|Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
41284770|NCT02285010|DRUG|Pregabalin|"Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed."
41451952|NCT05435638|DIAGNOSTIC_TEST|Hematology|Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126). The CBC assessment will include a red blood cells (RBC), hemoglobin, hematocrit, platelet count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MCV), white blood cells (WBC), neutrophils (% and abs.), lymphocytes (% and abs.), monocytes (% and abs.), eosinophils (% and abs.), basophils (% and abs.), large unstained cells (% and abs.).
40943108|NCT01783054|GENETIC|Genetic Expression|Subjects will have genetic expression testing done on their tissue samples.
40943109|NCT01783054|DRUG|Chemotherapy|Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
40943110|NCT02866994|BEHAVIORAL|Project Connect Online|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family
40943111|NCT02866994|BEHAVIORAL|PCO PLUS|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family, as well as other women diagnosed with breast cancer
41284771|NCT00659672|DIETARY_SUPPLEMENT|Whey Protein|40 grams per day Whey Protein
41284772|NCT00659672|DIETARY_SUPPLEMENT|Soy Protein|40 grams per day soy protein
41284773|NCT00659672|DIETARY_SUPPLEMENT|Control (carbohydrate)|40 grams per day maltodextrin
40943112|NCT04407052|DRUG|Double trigger|Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
40943113|NCT04407052|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
40943114|NCT00006363|DRUG|cytarabine|Given IV
40943115|NCT00006363|DRUG|daunorubicin hydrochloride|Given IV
40943116|NCT00006363|DRUG|etoposide|Given IV
40943117|NCT00006363|DRUG|valspodar|Given IV
40943118|NCT00006363|BIOLOGICAL|filgrastim|Given SC
40943119|NCT00006363|DRUG|busulfan|Given orally
40943120|NCT00006363|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
41284774|NCT03636828|DIAGNOSTIC_TEST|ultrasonographic measurement of gastric antral cross-sectional area|Each participant fasted for 10 hours and subjected to a baseline gastric ultrasound and serial sonographic gastric evaluations was performed every hour after 2 hours of the ingestion of a 420 g, 536 Kcal rice-based meal (bibimbap) until the stomach was completely empty.
41284775|NCT06065046|DRUG|Baricitinib 4 MG|Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days
41284776|NCT06065046|OTHER|Standard treatment|Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.
41284777|NCT00981435|DRUG|Prednisolone 1%|Prednisolone 1% to lasered eye 4 times/day for 4.5 days
40943121|NCT00006363|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous PBSCT
40943122|NCT00006363|BIOLOGICAL|aldesleukin|Given SC
40943123|NCT00006363|OTHER|clinical observation|Undergo clinical observation
40943124|NCT00006363|OTHER|pharmacological study|Correlative studies
40943125|NCT00354471|PROCEDURE|Uterine Artery Embolization|
40943126|NCT05530031|PROCEDURE|trabeculotomy ( angle glaucoma surgery )|a scleral flap is raised at the selected site with UBM and a cutdown in shlemm's canal is performed, a metal trabeculotome is used to cannulate and tear through a section of the inner wall of SC and trabeculum into the AC. Closure of the scleral flap and conjunctiva with 10/0 nylon. Viscoelastic is used to dilate the schlemm's canal, form the anterior chamber and decrease the risk of hyphema.
40943127|NCT00118690|DRUG|Fluticasone propionate/salmeterol|
40943128|NCT03779360|DRUG|Erythromycin 4% topical gel formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
40943129|NCT03779360|DRUG|Clindamycin 1% lotion formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.
41132367|NCT02343094|DRUG|PBA 15g/d|Treatment for 14 days with PBA
41284778|NCT00981435|DRUG|Ketorolac|Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
41284779|NCT00981435|DRUG|Artificial Tears|Artificial saline tears to lasered eye 4 times/day for 4.5 days
41284780|NCT02386423|DEVICE|RESTIFFIC™ Brand Pressure Application System|The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
41284781|NCT05288465|DRUG|Cerebrolysin|Patients prescribed for Cerebrolysin treatment due neurological disease are invited to donate a scalp punch biopsy prior to and after completing the prescribed treatment.
41284782|NCT05159765|DEVICE|Single vision contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
41284783|NCT05159765|DEVICE|Multifocal contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
41132368|NCT02377700|DEVICE|Xeltis Vascular Patch, Model COR-VP-001|The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
41284784|NCT00654927|DRUG|Fampridine-SR b.i.d. (Twice Daily)|Dosage form - tablets.
41284785|NCT01554215|BEHAVIORAL|Mom Power Intervention Group|attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
41284786|NCT01554215|BEHAVIORAL|Mom Power Attentional Control Group|at home control, weekly mailings
41284787|NCT00649961|DRUG|Melatonin injection|"A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr."
41284788|NCT00813839|OTHER|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
41284789|NCT01525394|DRUG|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
41284790|NCT01525394|DRUG|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
41284791|NCT01525394|DRUG|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
41284792|NCT04391140|OTHER|Prone position|HFNC set to a SpO2 of 90-95% combined with prone position. At least 2 sessions of 30 minutes or more will be performed daily.
41284793|NCT03385356|DRUG|Vitamin D|Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
41284794|NCT05063370|DRUG|Levosimendan|Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
41284795|NCT05063370|DRUG|Standard Care|Patients will not receive Levosimendan and will receive standard care according to the institution protocol
41284796|NCT01813487|DRUG|HBsAg vaccine with Entecavir|
41284797|NCT02678806|RADIATION|Postoperative radiotherapy|The radiotherapy group received prophylactic radiotherapy 1 month after operation. All the patients in the experimental group were treated with 6 to 8 MV X-ray, intensity-modulated irradiation (IMRT) technique, which was divided into 4-5 fields, 2Gy/25 times. 5f/W, total dose 50Gy
41284798|NCT02678806|DRUG|Postoperative TACE|In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 \~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
41284799|NCT04844502|OTHER|Physical rehabilitation|Rehabilitation can be applied to the intervention group in two ways: in person or by home orientation. The face-to-face form will correspond to 5 weeks of intervention, 3 sessions per week, which should include: a) aerobic resistance training of 30 minutes in total, five minutes of cooling down); b) strengthening of peripheral muscles using 20-minute sessions of calisthenic exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups. The home-based intervention will correspond to three months of daily activities, monitored twice a week in the first month and once a week in the second and third months, by telephone or video conference, and will follow an exercise protocol that includes: a) aerobic resistance training for 15 uninterrupted minutes; b) anaerobic training to strengthen the peripheral muscles for 15 minutes at intervals with breathing exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups.
41284800|NCT04057963|OTHER|Conventional plus Functional Inspiratory Muscle Training Group|functional inspiratory muscle training is an exercise program that practises gradual training of the diaphragm muscle.
40943130|NCT03779360|DRUG|Prednisolone tablet (0.5mg/kg; parallel comparison):|2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.
40943131|NCT03779360|DRUG|Clobetasol propionate 0.05% topical formulation (crossover comparison):|"2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.~Clobetasol propionate 0.05% topical formulation (crossover comparison):~Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2."
41132369|NCT04069455|OTHER|Electronic Patients Reported Outcomes|ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice
41284801|NCT04057963|OTHER|Conventional Physiotherapy Program|conventional physiotherapy is a treatment program consisting of evidence based modalities as mobilization and specific exercises.
41284802|NCT00648310|DRUG|Tolterodine 4 mg|
41284803|NCT00648310|DRUG|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
41284804|NCT01390168|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
41284805|NCT01390168|BEHAVIORAL|Waitlist|active waitlist
41284806|NCT04169477|DEVICE|CEFAR Primo Pro (TENS device)|"During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS.~\[Cross-over\] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day.~In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer."
41284807|NCT04507074|DEVICE|lumbar traction therapy|The application of traction forces on the traction table (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with a maximum strength of 30% of the patient's body weight).
41284808|NCT02220374|OTHER|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
41284809|NCT05533125|DRUG|Rituximab|Rituximab 1000mg in 250ml NaCl 0.9% intravenously with usual premedication
41284810|NCT05533125|DRUG|Placebo|Placebo in 250ml NaCl 0.9% intravenously with usual premedication
41284811|NCT00002700|DRUG|asparaginase|
41284812|NCT00002700|DRUG|cyclophosphamide|
41284813|NCT00002700|DRUG|cytarabine|
41284814|NCT00002700|DRUG|daunorubicin hydrochloride|
41132370|NCT03127605|DRUG|Inotuzumab Ozogamicin|
41284815|NCT00002700|DRUG|dexamethasone|
41284816|NCT00002700|DRUG|doxorubicin hydrochloride|
41284817|NCT00002700|DRUG|leucovorin calcium|
41284818|NCT00002700|DRUG|mercaptopurine|
41284819|NCT00002700|DRUG|methotrexate|
41284820|NCT00002700|DRUG|mitoxantrone hydrochloride|
41284821|NCT00002700|DRUG|prednisolone|
41284822|NCT00002700|DRUG|prednisone|
41284823|NCT00002700|DRUG|therapeutic hydrocortisone|
41284824|NCT00002700|DRUG|vincristine sulfate|
41284825|NCT00002700|PROCEDURE|allogeneic bone marrow transplantation|
41284826|NCT00002700|PROCEDURE|autologous bone marrow transplantation|
41284827|NCT00002700|RADIATION|radiation therapy|
41284828|NCT01174784|DEVICE|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
41284829|NCT05079035|BIOLOGICAL|TTAX03|Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
41284830|NCT05079035|BIOLOGICAL|Saline|2 mL Sterile, preservative free 0.9% NaCl
41284831|NCT02517515|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
41284832|NCT02517515|DRUG|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
41284833|NCT02065778|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
41284834|NCT03933501|DRUG|amoxicillin and metronidazole|375 mg amoxicillin and 250 mg metronidazole prescribed on the day of treatment, every 8 hours for 7 days.
41284835|NCT03933501|DRUG|Placebos|Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
41284836|NCT02032953|DIETARY_SUPPLEMENT|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
41451953|NCT05435638|DIAGNOSTIC_TEST|Urinalysis|"General urinalysis will be performed, by dipstick, during Screening, on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Cohort 2: Day 112) and follow-up EoS visits (arm 1: Day 91; Arm 2: Day 126).~Approximately 7-10 mL urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin urobilinogen and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated."
41451954|NCT05435638|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed at Screening, at all in-clinic study visits, and at the End of Study visit.~The physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, GI, urogenital, musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~• Symptom-directed physical examinations will be performed at all other study visits."
41451955|NCT05435638|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (body temperature, pulse and resting systolic and diastolic blood pressure) will be measured at Screening, at all in-clinic study visits, and at the End of Study visit. Vital signs will be measured in supine position after at least five minutes of rest.
41451956|NCT05435638|DIAGNOSTIC_TEST|ECG Test|A 12-lead, resting, digital ECG will be taken for each participant during Screening, on Days 42 and 84 (for both arms), and on day 112 (Arm 2 only), after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT and QRS intervals and QTC. The report will be signed by the Investigator, who will record in the CRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the participants will be reviewed.
41451957|NCT05435638|DIAGNOSTIC_TEST|PK|"Blood PK analyses will be performed on ≥5ml blood collected in 5-mL K-EDTA CRO coded pre-labeled tubes, refrigerated immediately after collection. Plasma will be separated by centrifugation within 2h, and then frozen at -20C.~Blood samples will be collected pre-dose on Days 0, 7, and 84, as well as pre-dose at EoT (Arm 2: Day 112), and at any point during the in-clinic visit at EoS (Arm 1: Day 91; Arm 2: Day 126)."
41451958|NCT05435638|DIAGNOSTIC_TEST|IGA scoring|"Lesions severity will be assessed using the Investigator's Global Assessment (IGA) scale,which is a 5-point scale (from 0 =no disease to 4=severe disease) based on Simpson et al. 2020, IGA for atopic dermatitis (see Table 4; Simpson et al. 2020).~The IGA score is selected using the descriptors below that best describe the overall appearance of the lesions at a given timepoint. It is not necessary that all characteristics under morphological description are present. Excoriations should not be considered when assessing disease severity."
41284837|NCT02032953|DRUG|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg\*min. Ten minuts after starting the insulin, and when the the blood glucose is\<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
41451959|NCT05435638|DRUG|KM-001 1% cream 12 weeks treatment|"KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
40943132|NCT03779360|OTHER|Lipopolysaccharide|As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
40943133|NCT00202176|DRUG|Ipratropium Bromide|Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
40943134|NCT06391385|PROCEDURE|protective ileostomy|Preparation of the bowel was performed before surgery with the administration of intravenous perioperative antibiotic prophylaxis. The surgical procedure was performed by laparotomy, with resection of the rectum and mesorectum (TME) up to the level of the pelvic diaphragm, sparing the autonomic nerves. End-to-end anastomosis was performed either with a stapler or by hand-sewn.
40943135|NCT05626582|PROCEDURE|pain delivery - learning only|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin just during the Day 1 learning period.
41132371|NCT04886349|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma injection for first CMC OA
41284838|NCT01495819|DRUG|Saline|5cc's of saline give at least once.
41284839|NCT01495819|DRUG|Nicotine|(0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
41284840|NCT03338556|DRUG|PrEP-001|
41284841|NCT03338556|OTHER|Placebo|
41284842|NCT03261869|OTHER|Cold application|
41284843|NCT04970680|PROCEDURE|glossopharyngeal nerve block|glossopharyngeal nerve block either blindly or using the ultrasonic technique
40943136|NCT05626582|PROCEDURE|pain delivery - learning and retention|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin during the Day 1 learning period and again during the Day 2 retention period.
41284844|NCT05552638|OTHER|Telecare|The University of Kentucky (UK) will embed telehealth stations at community-based senior centers. Individuals who utilize these telehealth stations will be invited to complete a demographic survey prior to their telehealth appointment. Following their appointment, they will be invited to complete a semi-structured interview with the research team. Participants who elect to use telehealth station will be doing so as telehealth visits already scheduled with patients as Standard of Care (SOC). The telehealth station in the senior center will be used to increase ease and access to telehealth should the patient/provider choose to use such an approach (for example, in instances when the patient does not have sufficient technology, internet access, or capability to operate telehealth at home).
41284845|NCT02715271|PROCEDURE|therapeutical surgery for TB|Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine
41284846|NCT04506424|OTHER|CT Guided Cochlear Implant Programming|Flat Panel (high resolution) CT scans of the temporal bones, including the inner ears, will be obtained. The research team will use the scans to generate custom cochlear implant (CI) programs for use by the participants.
41451960|NCT05435638|DIAGNOSTIC_TEST|Clinician global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator at screening and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
41284847|NCT02708823|OTHER|CogCheck application|The application is administered once to all study participants.
41284848|NCT03832231|DEVICE|Shear Wave Elastography|Ultrasound technology to assess tissue stiffness
41284849|NCT00165737|DRUG|Donepezil Hydrochloride|
41284850|NCT03120338|DIAGNOSTIC_TEST|The Development and Wellbeing Assessment|The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
41284851|NCT01999829|DRUG|citrate of caffeine|
41284852|NCT01999829|DRUG|placebo|
41284853|NCT00004415|DEVICE|Medlink spinal cord electrode|
41284854|NCT04233346|DRUG|Ponatinib|CP-CML patients will be randomized into 30 mg and 45 mg dose groups at the ratio of 1:1,each group taken orally once daily. Other patients taken 45mg orally once daily.
41451961|NCT05435638|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS)|"The VAS score will be collected on every in-clinic visit during the treatment period (Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.).~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
41451962|NCT05435638|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI-C scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) answering the question Since the start of the trial, my overall status has."
41284855|NCT06172543|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants were assigned to ingest a single serving daily of either A) a 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb); or B) a 25-gram dose of Whey Protein Isolate + 25-gram dose of carbohydrate powder + 5-gram dose of creatine monohydrate (Creatine) for a 17-21-day period.
41284856|NCT06172543|DIETARY_SUPPLEMENT|Control|A 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb)
41284857|NCT02333838|DRUG|IV Thiotepa|IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
41284858|NCT02333838|DRUG|IV Fludarabine|IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
41284859|NCT02333838|DRUG|IV Busulfan|(Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
41284860|NCT02333838|DRUG|IV Anti-thymocyte globuline|(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
41284861|NCT00878228|DRUG|Ondansetron|The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
41284862|NCT00878228|DRUG|Placebo|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
41284863|NCT04837391|DEVICE|Near Infrared Spectroscopy (NIRS)|Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.
41284864|NCT04837391|DIAGNOSTIC_TEST|Blood sample|Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.
41284865|NCT04837391|DIAGNOSTIC_TEST|Addenbrooke Cognitive Examination III (ACE-III)|ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.
41284866|NCT04837391|DIAGNOSTIC_TEST|Confusion Assessment Method|Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.
41284867|NCT02173600|BEHAVIORAL|Group-level Intensive dietary Counselling|
41284868|NCT02173600|BEHAVIORAL|Individual-level Intensive Dietary Counselling|
41284869|NCT00608465|DRUG|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
41284870|NCT00608465|DRUG|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
41284871|NCT00984230|OTHER|BSF|feeding amount according to individual baby need
41284872|NCT00984230|OTHER|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
41284873|NCT00984230|OTHER|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
41284874|NCT00189358|DRUG|ZD1839|
41284875|NCT00189358|DRUG|tamoxifen|
41284876|NCT04673838|OTHER|neurodevelopmental therapy|Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.
41284877|NCT04673838|OTHER|Lower extremity sensory training|Lower extremity sensory training will only be applied to the Intervention Group for 4 weeks, 3 days a week and 12 sessions in total. In the lower extremity, 3 sets of soft tissue needing, stroking and fascia stretching will be applied on 5 areas as Quadriceps, Hamstring, Gastrosoleus Group, Peroneal muscles, ankle and foot. In addition, sensory stimulation will be applied in the same five regions of the lower extremity with 3 repetitions and 3 sets with a knurled ball, brush and sponge. Lower extremity mobilizations of PANat Therapy approach will be used with traction and gliding applications in all joints in the ankle and foot. Finally, intrinsic muscle stimulation will be performed for 3 minutes with a bottle and towel under the sole of the foot.
41284878|NCT00363415|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
41284879|NCT00363415|DRUG|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
41284880|NCT00363415|DRUG|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
41284881|NCT02873221|DRUG|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
41284882|NCT02873221|DRUG|Placebo-matching Ubrogepant|Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
41284883|NCT02873221|DRUG|Usual Care|Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
41284884|NCT05873530|OTHER|Grape|Reconstituted whole grape powder
41284885|NCT06507020|BEHAVIORAL|Fall prevention knowledge education|"Frequency of Intervention: 4 sessions, 60 mins each, weeks 1, 3, 5, 8.~Intervention format：group intervention, 12-15 participants in one group.~Intervention content: Elderly fall risks, home safety improvements, community hazard identification, behavior modification.~Intervention tools: digital teaching PPTs.~Intervention deliverers: 2 members per community, one as leader for organizing health ed. activities (lectures, discussions, exercises, Q\&A), the other as assistant for support and participant safety during exercises."
41284886|NCT06507020|BEHAVIORAL|Exercise education|"Frequency of intervention: 4 sessions Duration of intervention: 30 minutes/session, once in each of the 1st, 3rd, 5th and 8th weeks of the intervention period.~Intervention format: group intervention, 12 people in a group (in principle, no more than 15 people).~Intervention content: The content of health education included (1) basic knowledge of exercise safety, 4 methods of balance function exercise (2) review 4 methods of balance function exercise(3) methods of exercising muscle strength (4) 2 methods of endurance exercise.~Intervention tools: accompanying teaching materials Intervention deliverers: same as before."
41284887|NCT06507020|BEHAVIORAL|Home hazard reduction education|"Intervention Time:~One home fall risk assessment and modification instruction at week 6 of health education.~Frequency of Intervention:~Single session.~Intervention Format:~Project staff conduct in-home fall risk assessments by appointment.~Intervention Content:~1. Evaluate fall risks in elderly living areas.~2. Provide personal guidance, complete two written forms-one for records, one for the participants.~3. Supply night lights, anti-slip mats, warning signs, and carpet mats; more services encouraged where possible.~Intervention Tools:~Utilize Elderly Home Fall Risk and Retrofitting Guide for detailed assessments and suggestions. Include tools like night lights, mats, and signs.~Intervention Deliverers:~Skilled community social workers or community health center staff."
41284888|NCT02587403|DEVICE|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
41284889|NCT02587403|DEVICE|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
41451963|NCT05435638|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI-S scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) answering the question Please rate the severity of your disease right now."
41284890|NCT02862210|DRUG|Lithium Carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
41284891|NCT02862210|DRUG|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
41284892|NCT03762980|OTHER|Bilateral training (BAT)|Each group received bilateral training) for upper extremities for 3 days per week for 01 hour/day for up to 6 weeks. Tasks included functional tasks such as stacking cones and cups, positioning the cup upright, throw a ball into basket, carrying a wooden block and buttoning and unbuttoning of shirt with counting. Each task was performed for 10 minutes and had a rest break of 1 minute.
41284893|NCT01309126|BIOLOGICAL|Imprime PGG + cetuximab|Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
41284894|NCT01309126|DRUG|Cetuximab|Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
41284895|NCT01573468|DRUG|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
41284896|NCT01573468|DRUG|Placebo|Placebo orally once on Day 1 of each cycle
41284897|NCT01573468|DRUG|Capecitabine|Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
41284898|NCT02277132|DRUG|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
41284899|NCT02277132|DRUG|Placebo|Placebo tablets three times daily orally from randomization until delivery
41284900|NCT04757337|DRUG|Doxorubicin|6 x 3-week cycles corresponding to a maximal duration of 18 weeks
41284901|NCT04757337|DRUG|Cyclophosphamide|Until progression up to 24 months
41284902|NCT04880174|DIAGNOSTIC_TEST|serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
41284903|NCT02489370|DEVICE|Home telemonitoring|The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
41284904|NCT00418288|DRUG|glucagon-like-peptide-1|intravenous infusion of 1.2pmol/kg/min for 7 hours
41284905|NCT00418288|DRUG|placebo|intravenous infusion of 1.2pmol/kg/min
41284906|NCT02366819|DRUG|Oxaliplatin|Given IV
41284907|NCT02366819|DRUG|Leucovorin Calcium|Given IV
41284908|NCT02366819|DRUG|Irinotecan Hydrochloride|Given IV
41284909|NCT02366819|DRUG|Fluorouracil|Given IV
41284910|NCT02366819|PROCEDURE|Conventional Surgery|Undergo surgery
41284911|NCT04049825|DRUG|OPB-111077|OPB-111077+bendamustine
41284912|NCT04049825|DRUG|OPB-111077|OPB-111077+rituximab+bendamustine
41284913|NCT03825042|DIETARY_SUPPLEMENT|A mix of bioactive natural compounds|A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets
41284914|NCT03825042|DIETARY_SUPPLEMENT|Placebo|Inactive compound in oral tablets
41284915|NCT02764840|OTHER|isokinetic dynamometer|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
41284916|NCT02764840|OTHER|elastic tube|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
41284917|NCT05824208|BEHAVIORAL|PRENAYOGA - prenatal yoga|The intervention is a prenatal yoga module developed for prenatal women. Intervention details: bi-weekly yoga classes (60 minutes of duration) will be delivered in person in a yoga studio in London for 8 consecutive weeks. Participants will be provided with yoga mats, blocks, bolsters and yoga straps at the studio. The class will be adapted to pregnancy and for all levels of ability, focusing on slow movements and body awareness. The content of the class will include loosening exercises (warm up exercises), simple postures (standing, balancing, sitting, kneeling, supine and restorative poses), breathing exercises and meditation. Classes will be delivered by an internationally certified and trained yoga teacher and will be accompanied by soft instrumental music.
41284918|NCT02066662|DRUG|Rivaroxaban or Marcumar|"Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR \> 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0."
41284919|NCT02730247|DRUG|ramucirumab|it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
41284920|NCT02730247|DRUG|nab-paclitaxel|it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
41284921|NCT03665155|DRUG|89Zr-daratumumab|2 mCi of 89Zr-daratumumab will be administered on day 0.
41284922|NCT03665155|DEVICE|PET/CT scans|PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
41284923|NCT03665155|OTHER|Blood draws|Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
41284924|NCT02672956|PROCEDURE|Ten mm trocar|
41284925|NCT05498298|DEVICE|Biopotentials measurement with gtec device|A measurement of 40 minutes is performed with the gtec g.Hlamp to collect biopotential signals. 32 electrodes are attached to the body (abdomen, thorax and back).
41284926|NCT05619848|DRUG|Rocuronium Bromide|0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation
41284927|NCT00156728|DEVICE|Vitatron biventricular pacemaker|
41451964|NCT05435638|DIAGNOSTIC_TEST|Lesion photography|High-quality photographic documentation of the treated lesions will be performed on screening, and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, pre-dose, if applicable.
41451965|NCT05435638|DRUG|KM-001 1% cream 16 weeks treatment|"KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
41451966|NCT00307996|DRUG|Coenzyme Q10 (drug)|
41284928|NCT05325112|DIAGNOSTIC_TEST|FFRCT|FFRCT is a diagnostic test following a CCTA to help diagnose and treat coronary artery disease.
41284929|NCT00284115|DEVICE|Gait trainer|Mechanical gait repetitive training
41284930|NCT00284115|DEVICE|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
41284931|NCT02495363|PROCEDURE|PECS Block|"As standard departmental protocol ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
41284932|NCT02495363|DRUG|Bupivacaine 0.25-0.5%|"Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
41284933|NCT01351662|BEHAVIORAL|Arthritis Self Management Program|Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
41284934|NCT04802746|DRUG|Alprazolam|Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.
41284935|NCT04802746|OTHER|Placebo|Study participants will receive Staccato placebo at pre-specified time points in Part A and Part B matching the pre-specified Staccato alprazolam dosing.
41284936|NCT04287530|DIETARY_SUPPLEMENT|Poly-unsaturated fatty acids supplementation|Daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
41284937|NCT04287530|BEHAVIORAL|Neuropsychological intervention|"Rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session."
41284938|NCT04287530|DIETARY_SUPPLEMENT|Placebo|Daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
41284939|NCT02591615|DRUG|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
41284940|NCT02591615|DRUG|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
41284941|NCT02591615|DRUG|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
41284942|NCT02591615|DRUG|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
41284943|NCT05702944|DRUG|Phenoxybenzamine|Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
41284944|NCT01259466|DRUG|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
41284945|NCT05626491|DEVICE|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
41284946|NCT05626491|DEVICE|Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive sham treatment (no active stimulation) every other day via a headband.
41284947|NCT05681728|DRUG|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion
41284948|NCT05681728|DRUG|Paclitaxel|On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
41284949|NCT05681728|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection
41284950|NCT05681728|DRUG|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion
41284951|NCT00161317|BEHAVIORAL|Living with Hope Program|
41284952|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
41284953|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
41284954|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
41284955|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
41132372|NCT05825404|DEVICE|Smart Ambient Bright Light (SABL)|The Proposed Smart Ambient Bright Light (SABL) includes tunable LED lights, photosensors, and controllers. The SABL will provide bright light targeted at 400 lux and CS=0.3 in participant bedrooms and designated areas such as the dining room and activity room during the day and provide dim light ≤40 lux and CS≤0.1 in participant bedrooms at night
41132373|NCT05825404|OTHER|Control|Usual light.
41132374|NCT01437410|PROCEDURE|EUS-FNA|tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
41451967|NCT00816413|DRUG|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
41284956|NCT05057351|OTHER|Isopentenyltheophylline 0.44% + Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
41284957|NCT05057351|OTHER|Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
41284958|NCT04582240|OTHER|no intervention|no intervention
41284959|NCT03196713|BEHAVIORAL|Early Intensive Behavioral Intervention|
41284960|NCT06114082|PROCEDURE|IDA-TACE|Stable chemoemulsion will be produced by dissolving 10 mg of idarubicin powder (Zavedos; Pfizer, New York, NY, USA) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
41284961|NCT06114082|PROCEDURE|DOX-TACE|Stable chemoemulsion will be produced by dissolving 50 mg of doxorubicin powder (Adriamycin RDF; Ildong Pharmaceutical, Seoul, Republic of Korea) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
41284962|NCT01843556|DRUG|E2022 Tape Formulation|E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
41451968|NCT00816413|DRUG|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
41451969|NCT00816413|DRUG|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
41284963|NCT02798523|DRUG|Methylprednisolone sodium succinate(Solu-Medrol)|"Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried."
41284964|NCT02798523|DRUG|Topical methylprednisolone (Advantan emulsion 0 /1%)|1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
41284965|NCT00987766|DRUG|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
41284966|NCT00987766|DRUG|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
41284967|NCT00987766|DRUG|oxaliplatin|Given through a vein in the arm 1 time every other week.
41284968|NCT00987766|OTHER|laboratory biomarker analysis|Blood and tissue collection.
41284969|NCT03978650|OTHER|Observational|Participants from the Canadian Longitudinal Study on Aging will be evaluated for cognitive status, occurrence of falls, and fall-related injuries.
41284970|NCT01583036|DRUG|Digoxin Alone|Single administration of digoxin 0.25mg
41284971|NCT01583036|DRUG|Digoxin + Retigabine|Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
41284972|NCT05446844|OTHER|A nurse caring behavior protocol|"Nursing interventions based on caring behaviors protocol was provided as follows:~* Caring behaviors during ICU admission and orientation processes included orienting patients to time, place, and person.~* Caring behaviors during physical care informing patients regarding the purpose and expected duration of mechanical ventilator use.~* Caring behaviors during psychological care included offering religious sound meditation.~* Caring behaviors during social interaction included maintaining eye contact during nurse-patient interaction.~* Caring behaviors during health teaching included providing health teaching for patients.~* Caring behaviors during maintaining a safe healing environment included providing patients with an explanation regarding nursing activities."
41284973|NCT05446844|OTHER|Routine nursing care|Routine nursing care was concentrated mainly on hard skills of physically demanding care such as monitoring vital signs.
41284974|NCT05223101|DRUG|Telminone 80 mg|Single administration of telmisartan 80 mg
41284975|NCT05223101|DRUG|Drug: Micardis 80 mg|Single administration of telmisartan 80 mg
41284976|NCT02283944|DEVICE|TMS|Pulsed non-invasive brain stimulation using electromagnets
41284977|NCT06099054|DEVICE|Pigtail catheter|Pigtail catheter will be inserted using Seldinger technique under US guidance to drainage exudative pleural effusion by a trained radiologist
41284978|NCT06099054|DEVICE|Intercostal tube|Chest tube will be inserted according to BTS guideline for insertion of ICT by a trained thoracic surgeon
41451970|NCT00816413|GENETIC|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
41284979|NCT04885049|DRUG|Racecadotril|Anti secretary
41284980|NCT04885049|DRUG|DiaResQ Children's Powder for Suspension|oral immunoglobulins
41284981|NCT00003323|DRUG|finasteride|5 mg/d PO
41284982|NCT00003323|DRUG|flutamide|250 mg PO tid
41284983|NCT00003323|OTHER|quality-of-life assessment|Assessment survey administered at baseline, and 3 \& 6 months post initiation of treatment
41284984|NCT04913805|DRUG|Potassium Nitrate|Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
41284985|NCT04913805|DRUG|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
41284986|NCT04913805|OTHER|Potassium Chloride|Active control
41284987|NCT03645291|DIAGNOSTIC_TEST|Local insect allergen extracts skin test|Every patient received both local and commercial insect allergen extracts but in blinded methods
41284988|NCT05733481|DEVICE|CapBuster System Medical Device for the Crossing of Chronic Total Occlusions in Coronary Arteries|The CapBuster System is a medical device intended to facilitate the intraluminal placement of conventional guidewires beyond chronic total occlusions prior to the utilization of interventional devices. The device system, manufactured by Praxis Medical, comprises the CapBuster support catheter and CapBuster penetrating wire which are mated together with a screw thread.
41284989|NCT04598438|BEHAVIORAL|Music behavioral early intervention program|The program consists of carefully designed play-based enhancement strategies implemented in the form of hybrid online/in-person playgroups. Following a teach-model-coach-review approach, parents will learn to implement various skills that are expected to enhance infant's language and communication skills through singing and engaging in musical play with their child at home.
41284990|NCT04598438|BEHAVIORAL|Arts and crafts early enhancement program|The program follows the same general structure with the music intervention program. Parents will learn how to implement a series of arts and crafts activities at home, with an aim to enhance infant's visual-perceptual, motor, and sensory integration development.
41284991|NCT01020331|DRUG|Memantine|
41284992|NCT01609933|DRUG|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
41284993|NCT01609933|DRUG|ABT-267|ABT-267 (tablets)
41284994|NCT01609933|DRUG|pegylated interferon alpha-2a (pegIFN)|pegIFN alpha-2a (syringe)
41284995|NCT01609933|DRUG|Ribavirin (RBV)|Ribavirin (tablets)
41284996|NCT05842798|DRUG|TNM002|TNM002, intramuscular injection
41284997|NCT05842798|DRUG|Placebo|Placebo, intramuscular injection
41451971|NCT00816413|GENETIC|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
41132375|NCT04598594|DRUG|Patch, Nicotine|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
41132376|NCT04598594|DRUG|Patch, Placebo|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
41132377|NCT01961609|BIOLOGICAL|Secukinumab (AIN457)|Secukinumab was supplied in 150mg pre-filled syringes.
41132378|NCT01420497|DRUG|intra-articular infiltration|intra articular infiltration
41132379|NCT01420497|DRUG|epidural infiltration|epidural infiltration
41132380|NCT06387810|DRUG|irinotecan liposome II combined with 5-FU/LV and oxaliplatin|"irinotecan liposome II: 60mg/m2, intravenously for at least 90min, D1, administered every 2 weeks; oxaliplatin: 85 mg/m2, intravenous infusion, D1, every 2 weeks; calcium leucovorin: 400 mg/m2, 30±10min intravenously, D1, every 2 weeks; 5-fluorouracil: 2400 mg/m2 intravenously for 46-48 hours or according to study Center clinical practice, D1, administered every 2 weeks.~Irinotecan liposome II, oxaliplatin, LV and 5-FU were given successively, and corresponding prophylactic administration could be selected according to clinical needs."
41132381|NCT03408028|OTHER|Medical File consultation|Medical File consultation
41132382|NCT01969916|DRUG|Regadenoson|Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
41132383|NCT02753998|COMBINATION_PRODUCT|Additional angioplasty with paclitaxel-coated balloon|Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
41132384|NCT02753998|COMBINATION_PRODUCT|Additional angioplasty with placebo balloon|Additional angioplasty with placebo balloon after conventional angioplasty
41132385|NCT02753998|PROCEDURE|Conventional angioplasty|
41132386|NCT02331485|DEVICE|PICO + Acticoat group|Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
41132387|NCT03582566|BEHAVIORAL|Phonological Awareness|Earobics training
41132388|NCT03582566|BEHAVIORAL|Working Memory|Cogmed training
41132389|NCT03582566|BEHAVIORAL|Phonological Awareness + Working Memory|Earobics + Cogmed training
41132390|NCT03582566|BEHAVIORAL|Active Control|Spashmath
41132391|NCT01282957|BEHAVIORAL|Financial Incentive Group I|Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
41132392|NCT01282957|BEHAVIORAL|Financial Incentive Group II|Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
41132393|NCT04873206|OTHER|routine stain by H&E.|formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.
41132394|NCT03543631|OTHER|Survey|Online survey
41132395|NCT03411382|OTHER|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
41132396|NCT03411382|OTHER|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
41132397|NCT03411382|OTHER|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
41132398|NCT03411382|OTHER|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
41132399|NCT04630509|PROCEDURE|traumatic cataract extraction|Irrigation/aspiration of traumatic cataract in children with posterior chamber intraocular lens implantation
41132400|NCT06271850|OTHER|Ergonomics breastfeeding training|The ergonomics training includes the most ergonomically appropriate methods to breastfeed and ergonomic guidelines, including how to cuddle and breastfeed the baby correctly.
41284998|NCT03792711|DIETARY_SUPPLEMENT|Ensure® Plus Advance|"Previous studies suggest that protein supplementation is an effective dietary strategy to decrease frailty by positively influence the weight loss or sarcopenia in elderly.~Lean body mass includes all body tissue except fat and is well recognized to be associated with an increased risk of morbidity and mortality. Oral nutrition supplements have been shown to increase food intake and body weight, but not lean body mass. In previous studies, β-hydroxy-β-methylbutyrate, which is leucine metabolite, has been shown to enhance protein synthesis and decrease protein degradation leading to increase lean body mass. It showed that β-hydroxy-β-methylbutyrate supplement with exercise increased lean body mass in health elderly population and improved the physical performance in elderly women."
41284999|NCT01094483|DRUG|PN400|naproxen 500 mg/esomeprazole 20 mg oral tablet
41285000|NCT01094483|DRUG|ASA|Asprin 81 mg enteric coated tablet
41285001|NCT01094483|DRUG|Placebo|
41285002|NCT03393351|OTHER|Shared decision-making program|"The intervention is shared decision-making. The implementation strategy to foster shared decision-making in routine cancer care is a multicomponent implementation program. The implementation program consists of the following components:~1. shared decision-making trainings for health care professionals,~2. individual coaching for physicians,~3. patient activation strategy,~4. provision of patient information material and decision aids,~5. revision of the clinics quality management documents, and~6. critical reflection of current organization of multidisciplinary team meetings.~Implementation: after baseline assessment (t0) for clinic 1, after assessment at t1 for clinic 2, after assessment at t2 for clinic 3."
41285003|NCT03393351|OTHER|Usual Care|No specific study related intervention. Treatment decisions are made according to current routine practice at the comprehensive cancer center in Germany.
41451972|NCT00816413|GENETIC|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
41451973|NCT00816413|OTHER|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
41451974|NCT00816413|OTHER|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
41451975|NCT00816413|OTHER|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
41285004|NCT00802477|PROCEDURE|Application of autologous blood products.|Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
41451976|NCT00816413|OTHER|reduced-intensity transplant conditioning procedure|"Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .~Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .~Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.~Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.~Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4)."
41451977|NCT00816413|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
41285005|NCT00802477|PROCEDURE|Standard Modified Radical Mastectomy|Mastectomy per standard procedure without the application of autologous blood products.
41285006|NCT00820040|DEVICE|acellular porcine dermal collagen mesh|porcine mesh for hernia repair/ abdominal wall reconstruction
41451978|NCT00816413|PROCEDURE|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
41451979|NCT00816413|RADIATION|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
41285007|NCT01415440|DRUG|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
41285008|NCT01415440|DRUG|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
40943137|NCT05255029|DEVICE|POD T 49P implantation experimental|The investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye.
40943138|NCT02568137|BEHAVIORAL|Smart-phone based technology|
41285009|NCT04918693|DEVICE|Ultrasound scanning|All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.
41285010|NCT05146622|BEHAVIORAL|Workplaces in the World|Formative research activities to better understand attitudes and behaviors of outdoor workers with respect to UV safety.
41285011|NCT04124367|DRUG|Cerebrolysin|30 ml once daily (+70 ml 0.9% saline)
41285012|NCT04124367|DEVICE|non-invasive brain stimulation|2 mA/35 cm² for 2x20 minutes, once daily
40943139|NCT01479504|DRUG|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
40943140|NCT01479504|DRUG|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
40943141|NCT01479504|DRUG|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
40943142|NCT01479504|DRUG|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
40943143|NCT04845373|OTHER|Mediterranean diet|Diet intervention:Mediterranean diet
40943144|NCT04845373|OTHER|Control diet: Low fat diet|Low fat diet
41285013|NCT04124367|DRUG|Placebo|100 ml once daily 0.9% saline
41132401|NCT06271850|OTHER|Pilates exercises|Pilates exercises, 3 times per week, for 8 weeks, in the form of neck extensor stretching, neck extensor and rotation stretching, pectoral muscle stretching, strengthening of deep neck flexors and scapular retractor, and core strengthening exercises ( pelvic bridging, plank, cat and camel, curl up, single leg abdominal press and double leg abdominal press).
41285014|NCT04124367|DEVICE|sham intervention|0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
41285015|NCT03994640|COMBINATION_PRODUCT|Cannabis Cream|Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles
40943145|NCT05041517|BEHAVIORAL|BOLT + PTC|BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).
40943146|NCT01819376|OTHER|Facebook Status Update|
40943147|NCT00950911|DRUG|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
41285016|NCT03994640|COMBINATION_PRODUCT|Placebo Cream|Topical, bilteral skin application of placebo cream with self-massage of masseter muscles
41285017|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with high levels of vitamin D3 and K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
41285018|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with low levels of vitamin D3 and high K1|The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
41285019|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with high levels of vitamin D3 and low K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
41285020|NCT02615301|DIETARY_SUPPLEMENT|Supplement with vitamin D and Calcium|The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
41132402|NCT01030237|OTHER|FID 114657|1 drop both eyes four times a day for 6 weeks
40943148|NCT02057393|DRUG|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
40943149|NCT02057393|DRUG|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
40943150|NCT02057393|DRUG|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
41132403|NCT01030237|OTHER|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
41132404|NCT03272412|DIAGNOSTIC_TEST|Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.
41132405|NCT03301870|DRUG|ATx201 Gel 2%|2% active gel
41132406|NCT03301870|DRUG|ATx201 Gel 4%|4% active gel
41285021|NCT02125994|PROCEDURE|Interscalene nerve block|
41285022|NCT02851446|OTHER|measure dyspnoea> Borg 7|
41285023|NCT02185469|PROCEDURE|Pneumatic retinopexy|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
41451980|NCT04501848|PROCEDURE|adenotonsillectomy|adenotonsillectomy surgery
40943152|NCT04048551|BEHAVIORAL|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
40943153|NCT04048551|BEHAVIORAL|Young Women's Health CoOp (YWHC)|In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
40943154|NCT03118973|PROCEDURE|Goff trans-pancreatic septotomy vs. Double wire technique|Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
40943155|NCT04112524|DEVICE|App|"* Alleye® Test Alleye® Test is a mobile medical software application indicated for the detection and characterization of metamorphopsia. For the mean Alleye score (±standard deviation (SD) deviations of dots from an ideal line are calculated for each eye.~* AMD-A Metamorphopsia Detector® Is based on the Amsler grid. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Degree and dimension of distorted lines or scotoma are transformed into indices."
40943156|NCT03722771|BEHAVIORAL|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to surgery
40943157|NCT03722771|OTHER|Anxiety Questionnaires 1|Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
40943158|NCT03722771|OTHER|Anxiety Questionnaires 2|State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
40943159|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 1|Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
40943160|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 2|Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
40943161|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 3|Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
40943162|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 4|Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
40943163|NCT06174259|OTHER|intermittent fasting|16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day)
40943164|NCT03375827|OTHER|IGCDG|The IGCDG reviews topics of concern for patients with metastatic breast cancer.
40943165|NCT02648269|DRUG|SEL-110|
40943166|NCT02648269|BIOLOGICAL|SEL-212|
40943167|NCT02648269|BIOLOGICAL|SEL-037|
40943168|NCT05250752|DRUG|Dapagliflozin 10 MG [Farxiga]|Primary end-points are measure before (day 0), on treatment (day 1 and day 3) and after treatment (day 21)
40943169|NCT03115073|DRUG|Candiplus|Administration of Candiplus
40943170|NCT03115073|DRUG|Clotrimazole|Administration of Clotrimazole
40943171|NCT01316471|BEHAVIORAL|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
40943172|NCT01316471|OTHER|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
40943173|NCT00904306|DIETARY_SUPPLEMENT|Sugar Pill|placebo oral tablet taken once per day
40943174|NCT00904306|DIETARY_SUPPLEMENT|chromium picolinate|1000 ug/day chromium picolinate for 6 months
40943175|NCT00904306|DIETARY_SUPPLEMENT|chromium picolinate|600 ug/day chromium picolinate
41285024|NCT02185469|PROCEDURE|vitrectomy|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
40943176|NCT00225446|DEVICE|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
40943177|NCT02005432|DRUG|Intravitreal Ranibizumabe|Intravitreal injection 0,05ml Ranibizumabe
40943178|NCT02005432|DRUG|panfotocoagulation (PASCAL)|
40943179|NCT02005432|DRUG|panfotocoagulation (PRP) single shoot (ETDRS)|
40943180|NCT02907580|BEHAVIORAL|Local educational information|Participants in this arm receive educational information regarding influenza vaccination based on local educational information.
40943181|NCT02907580|BEHAVIORAL|National educational information|Participants in this arm receive educational information regarding influenza vaccination based on national educational information.
40943182|NCT00234234|DRUG|Adalimumab|
40943183|NCT02312271|OTHER|enteral formula|standard tube feeding formulas
40943184|NCT00642720|DRUG|Pegvisomant|if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
41285025|NCT02185469|DRUG|sulfur hexafluoride (SF6)|
41285026|NCT02185469|DEVICE|5/8-in 25-gauge needle|
41285027|NCT02185469|DEVICE|laser|intraoperative laser retinopexy
41285028|NCT03914547|BEHAVIORAL|REDCHiP|REDCHiP includes 10 telehealth sessions. REDCHiP uses a three-pronged approach to reduce parents' FH. It uses T1D education and problem-solving to enhance parents' knowledge and skills. It uses child age-appropriate behavioral parent training to promote parents' skills and confidence in managing disruptive child behaviors and reducing their reliance on hypoglycemia avoidance behaviors. It uses cognitive-behavioral therapy strategies to help parents reduce maladaptive thinking/coping related to hypoglycemia fear.
41285029|NCT03914547|BEHAVIORAL|ATTN|Provides a similar attention control. ATTN includes 10 telehealth sessions.
40943185|NCT04199936|DEVICE|Electrical Muscle stimulation|Electrical muscle stimulation
40943186|NCT05550649|PROCEDURE|embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
40943187|NCT04056351|DIAGNOSTIC_TEST|Post-Operative (OP) Computer Tomography (CT)|Post-OP CT of the treated shoulder
40943188|NCT04056351|OTHER|Questionnaires on patient activity and comorbidities|"* Shoulder activity scale (Marx)~* Parker Mobility Scale~* Barthel index~* Charlson Comorbidity Score"
40943189|NCT04056351|OTHER|Grip strength measurement|Grip strength will be measured using a CE marked hydraulic hand dynamometer device.
40943190|NCT04056351|OTHER|Non-invasive shoulder activity tracking usinig wearable sensors|Post-OP activity will be assessed via wearable CE-marked accelerometer sensors.
40943191|NCT06405620|OTHER|Assistance robot|the child controls the robot at his parent's home from his room
41285030|NCT06509698|OTHER|virtual reality|STEP I: For the warm-up, the examiner will perform passive stretching exercises to maintain the range of motion. STEP II: The patient will receive the game instructions by the examiner. STEP III: The patient will play the Adventure games and Sport games including tennis, boxing and kicking. virtual reality (20 minutes) using Nintendo Wii®, Wii Fit game will be used to stimulate and reinforce the improvement of balance and gait and enhance the quality of life.(30) Balance game: Soccer Heading, Penguin Slides, Balance Bubble, Torso Twists, and Single Leg Stance. Motor function: Boxing, Kicking, Tennis and Bowling Aerobic Games: 2-P run, advanced step, Title city and Basic Run. Step IV: (cool-down): Same as step one.
41285031|NCT06509698|OTHER|Frenkel's exercise|Frenkel's activities, which included learning how to turn around, sit down, and get up using a variety of commonplace objects like chairs, beds, or traces drawn on the floor, as well as learning how to walk with upper limb coordination. This is a typical workout regimen used in testing and rehabilitation centers. Patients engaged in the following activities, each activity time is 1.5 minutes
41285032|NCT05358834|DIETARY_SUPPLEMENT|Melatonin|Oral melatonin administered as a single pill.
41285033|NCT05358834|DIETARY_SUPPLEMENT|Placebo|Oral placebo administered as a single pill.
40943192|NCT00532155|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
40943193|NCT00532155|DRUG|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
40943194|NCT00532155|DRUG|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
40943195|NCT00532155|DRUG|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
41285034|NCT00388466|DEVICE|GALILEO|
41285035|NCT02273973|DRUG|Letrozole|Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
41285036|NCT02273973|OTHER|Placebo|Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
41285037|NCT02273973|DRUG|Taselisib|Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
41285038|NCT03167697|DIETARY_SUPPLEMENT|Synergy|Small serving (x1 33 g serving daily) of the new phenylalanine-free protein substitute made up with 100mL of water daily (28 days).
41451981|NCT02873182|DEVICE|Autonomic nervous system monitoring|Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
40943196|NCT05770869|DEVICE|ALIBIRD mHealth platform|Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.
40943197|NCT05895071|DRUG|5%potassium hydroxide|. In group-A 30 patients were given topical 5% potassium hydroxide solution on affected area once at night for upto 4 weeks
40943198|NCT05895071|DRUG|Liquid nitrogen|in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks. The treatment carried out upto 12 weeks or until complete recovery from warts.
40943199|NCT05080907|OTHER|Observational|Subjects for observational study Various conditions \& healthy subjects
40943200|NCT01465061|BEHAVIORAL|Online support group|Joining online support group
41285039|NCT03167697|OTHER|Routine|Patients will continue their usual dietary and/or protein substitute regimen (28 days).
41285040|NCT02599012|DRUG|Ferinject®|intravenous Ferinject 1000mg injection
41285041|NCT00792766|DRUG|everolimus (RAD001)|Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
41451982|NCT00375284|DRUG|Pramipexole|
41451983|NCT02046863|DEVICE|Automated Programming|Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
40943201|NCT06228885|BEHAVIORAL|handwriting experiment and motor ability test|Participants will be instructed to participate in a handwriting experiment, which involves utilizing a Force Acquisition Pen (FAP) system and Near Infrared Spectroscopy (NIRS) to collect force data and cortical activation, respectively, during handwriting tasks. Children will be tasked with completing various assignments, such as tracing lines, writing numbers, and characters, among others. Additionally, assessments of motor ability and handwriting proficiency will be conducted using the Movement Assessment Battery for Children (MABC) and the Chinese Handwriting Evaluation Form (CHEF). The Pinch Holding Up Activity (PHUA) Test will also be administered to assess their sensorimotor ability.
40943202|NCT05183893|DIETARY_SUPPLEMENT|L-citrulline|5 g of L-citruline + 5 g of additives
40943203|NCT05183893|DIETARY_SUPPLEMENT|Citrulline-malate|8g of citrulline-malate + 2 g of additives
40943204|NCT05183893|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrine
40943205|NCT02616419|DEVICE|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
40943206|NCT02616419|DRUG|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
40943207|NCT00801918|DRUG|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
40943208|NCT00801918|DRUG|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
40943209|NCT01920009|BEHAVIORAL|Pharmacist counselling session with a motivational interview|"The intervention:~The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.~The intervention group consultation:~Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.~The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication"
40943210|NCT01436916|DRUG|oral cholecalciferol + life style counselling|oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
40943211|NCT01436916|DRUG|placebo + life style counselling|Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
40943212|NCT00471016|BEHAVIORAL|Guided intervention|
41285042|NCT05907915|DEVICE|low level laser therapy|They recieved LLLT 1 session daily, 3 session per week for 3 weeks,with the following parameters( 650 nm wavelength, 150 mw power output, 0.25 cm2 radiation area, 0.6 W/cm2 power density, continuous mode, 2 j/ cm2, 90 seconds / cm2) in addition to the conventional medical treatment and traditional wound care (dressing)
41285043|NCT05907915|BEHAVIORAL|placebo|They received placebo laser 1 session daily, 3 session per week for 3 weeks in addition to the conventional medical treatment and traditional wound care (dressing)
41285044|NCT02317731|OTHER|Straw|Bowel preparation ingestion with a straw
41285045|NCT00986336|DRUG|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
41285046|NCT00986336|DRUG|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
41285047|NCT00986336|DRUG|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
40943213|NCT00591344|BEHAVIORAL|Progressive resistance training|Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
40943214|NCT00591344|BEHAVIORAL|Modified Fitness Counts|The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
40943215|NCT04741607|DEVICE|Implant placement (BLX implant system, Straumann, Basel, Switzerland)|Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
40943216|NCT04741607|PROCEDURE|Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)|Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
40943217|NCT04741607|PROCEDURE|Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)|The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.
40943218|NCT01904058|DRUG|LUM001|
40943219|NCT01904058|DRUG|Placebo|
40943220|NCT01904058|DRUG|Ursodeoxycholic Acid|
40943221|NCT05755737|DRUG|Ondansetron|Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)
40943222|NCT05755737|DRUG|Placebo|Matching placebo identical in appearance.
40943223|NCT03727425|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
40943224|NCT02521766|DEVICE|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
40943225|NCT02521766|DEVICE|Commercially Available Intraocular Lens|IOL per investigator's standard of care
40943226|NCT02521766|PROCEDURE|Optic exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
41285048|NCT00986336|DRUG|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
41285049|NCT05357183|DRUG|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
41285050|NCT05382481|DIAGNOSTIC_TEST|Peak value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the peak level of anti-Xa after 4 to 6 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the peak value of anti Xa.
41285051|NCT05382481|DIAGNOSTIC_TEST|Trough value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the trough level of anti-Xa after 12 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the trough value of anti Xa.
41285052|NCT05382481|DIAGNOSTIC_TEST|Control Group|This group will receive fixed dose of low molecular weight heparins (LMWH) 40mg, once a day. And will not detect the level of anti-Xa
41285053|NCT05164523|DIAGNOSTIC_TEST|24-hour rhythm Holter|Before starting their newly prescribed medication, the investigators will apply 24-hour rhythm Holter and repeat it at the end of the trial.
41451984|NCT01731457|DRUG|etanercept|adding appropriate dose of etanercept to the perfusion fluid
40943227|NCT05554523|DEVICE|Photoacoustic imaging|Photoacoustic imaging
40943228|NCT03139097|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
40943229|NCT01795638|DRUG|Sodium chloride|
40943230|NCT01795638|DRUG|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
40943231|NCT05996874|DRUG|Semaglutide|Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.
40943232|NCT05432141|BIOLOGICAL|sIPV vaccine /DTaP vaccine|All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
40943233|NCT05432141|BIOLOGICAL|sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine|All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
40943234|NCT01284530|DRUG|TPM XR|Equivalent TDD in XR form, QD, Day 1-14
40943235|NCT03052907|BEHAVIORAL|BSPAN|"1. Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~2. Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach \& Health Promotion and Delivery \& Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach \& Health Promotion component (Medium Capacity).~3. Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up."
40943236|NCT05321927|DEVICE|Trancutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes. continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 9 pulses per burst for the last 5 minutes, with a stimulation/rest ratio of 1:2.
40943237|NCT05321927|OTHER|Strength training|Three training sessions for 10 minutes per muscle, per week, for four weeks in total.
40943238|NCT05321927|DEVICE|Sham stimulation|Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds. This will alternate for 10 minutes. The intensity equals the intensity that is just felt by the individual.
40943239|NCT01977937|DRUG|Gabapentin 250mg/5mL NDC:59762-5025-01|
40943240|NCT01977937|DRUG|Simple Syrup|
40943241|NCT00428129|DRUG|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
40943242|NCT05241483|DIAGNOSTIC_TEST|mesure valition|Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems
40943243|NCT04119310|OTHER|Lumbar-thrust mobilization|The intervention group will receive passive spinal rotational grade V thrust-mobilization, based on Maitland's approach. The intervention will be performed with the subject in right sidelying and left sidelying. The operator's palpating hand is placed over the L2-3 intervertebral space, and the other hand bends both legs of the participant up to the range at which the L2-3 midposition is found. The participant is then asked to straighten the lower leg and hook the upper leg over it with the upper leg's knee positioned over the side of the plinth. While the lower component is kept still, the participant's trunk is rotated until the hip starts to lift off from the plinth. The bottom hand and uppermost hand rest under a pillow and the chest wall, respectively. With the starting position settled, the operator stands behind the participant, takes up the slack within the spine and then provides a grade V thrust- mobilization while stabilizing the uppermost shoulder.
40943244|NCT04119310|OTHER|Sham thrust-mobilization|Subjects are positioned in right sidelying. The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension passive range of motion without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
40943245|NCT02193698|DRUG|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
40943246|NCT00902733|OTHER|medical chart review|
40943247|NCT00902733|OTHER|questionnaire administration|
40943248|NCT00902733|PROCEDURE|fatigue assessment and management|
40943249|NCT00902733|PROCEDURE|psychosocial assessment and care|
40943250|NCT00902733|PROCEDURE|quality-of-life assessment|
40943251|NCT00850161|DRUG|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
40943252|NCT00850161|DRUG|Nasulin™|100 IU(2 puffs in each nostril)
40943253|NCT06348680|OTHER|Video assisted episiotomy repair training|Midwifery Intervention The 'video recording' prepared by researchers specialized in the field of midwifery to increase the episiotomy repair skills of midwifery students will be used as training material. The content of the video recording is as follows: control before episiotomy repair, episiotomy repair, subcutaneous suturing, skin suturing, suturing techniques (Continuous, Simple Intermittent, Mattress). After the video recording is completed, it will be restarted and shown to the students in the experimental group continuously throughout the application period. At the end of the application period, students will be re-evaluated.
40943254|NCT02210273|DEVICE|Solace Bladder Control (Vesair) Balloon|Subjects may undergo treatment every 12 months until study completion.
40943255|NCT02210273|DEVICE|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon
40943256|NCT04095832|PROCEDURE|Epidural anesthesia|Epidural anesthesia using standardized technique
40943257|NCT03543618|DEVICE|Sloped|Placement of implant with sloped design
41285054|NCT05164523|DIAGNOSTIC_TEST|36 item Short Form Survey (SF-36)|Before starting their newly prescribed medication, the investigators will apply SF-36 survey and repeat it at the end of the trial.
41285055|NCT00298532|PROCEDURE|Advanced Life Support|
41285056|NCT01189773|DRUG|ibuprofen and codeine|ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
41285057|NCT04260269|DRUG|Fluoropyrimidine|"This is the assessment of a specific evaluation of cardiac safety for patients with solid tumors who have experienced cardiotoxicity grade 1-4 during treatment with a fluoropyrimidine based treatment and are re-challenged with a different fluoropyrimidine.~This multicentre, retrospective database is built to assess the impact on the cardiac and global safety of two different fluoropyrimidine based treatment regimens, of which the first has caused cardiotoxicity grade 1-4.~Cardiac data will be collected by medical record review from initiation of first fluoropyrimidine-based treatment and switch to second fluoropyrimidine-based treatment until death or last follow-up. Basic demographics, cancer and treatment information from the whole course of cancer until death or last follow-up."
41285058|NCT00582231|OTHER|Questionnaires.|Questionnaires.
40943258|NCT03543618|DEVICE|Control|Placement of implant with conventional design
40943259|NCT05075382|PROCEDURE|Elbow surgery for fracture|This group will undergo a surgery in order to fix a broken elbow.
40943260|NCT05997758|OTHER|SEEG stimulation|Electrodes already implanted in patient's anterior insula will be stimulated below the patient-specific threshold at which a seizure was induced. This stimulations will coincide with certain trials in the adaptation task.
40943261|NCT05997758|BEHAVIORAL|Adaptation task|Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.
40943262|NCT03187756|DRUG|Cyclophosphamide|Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.
40943263|NCT02188342|BEHAVIORAL|HIT|12 HIT exercise sessions in 31 days on a stationary cycle ergometer
40943264|NCT01953861|DRUG|EC905|Oral
40943265|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
41285059|NCT03446924|DIETARY_SUPPLEMENT|Phosphatidic Acid|To be administered a single dose of 1.5 g phosphatidic acid in capsule form (250 mg / capsule).
41285060|NCT03446924|DIETARY_SUPPLEMENT|Rice flour|Rice flour placebo to be administered a single dose of 1.5 g in capsule form (250 mg / capsule).
41451985|NCT06056115|DRUG|Tislelizumab,Platinum|"1. Induction therapy stage:~   Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment.~2. Maintenance treatment phase:~After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy ."
41451986|NCT02729090|OTHER|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks. Device: treadmill.
40943266|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
40943267|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
40943268|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
40943269|NCT00529984|BIOLOGICAL|AVX701|4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
40943270|NCT03411915|BIOLOGICAL|XmAb18087|monoclonal bispecific antibody
41451987|NCT02729090|OTHER|Device: treadmill Train_Comb_aerobic|Device: treadmill Train_Comb_aerobic. strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series. Device: treadmill Train_Comb_aerobic
40943271|NCT04753307|DIAGNOSTIC_TEST|Laboratory measurements|Inflammatory and cardiac biomarkers will be measured before surgery, and on the first, second, third and fifth postoperative day
40943272|NCT06271486|DRUG|Pregabalin 75mg|Group A (pregabalin group) received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.
40943273|NCT06271486|BIOLOGICAL|An epidural blood patch (EBP)|Group B (EBP group) received active therapy in the form of an EBP
40943274|NCT06271486|COMBINATION_PRODUCT|conservative treatment.|Group C (control group) received conservative treatment providing recommendations to the patients, including 24 hours of bed rest, stool softener, and consuming a minimum of 2.0 liters of fluid daily. Analgesics were permitted for pain relief depending on the patient's disease status.
40943275|NCT00365651|PROCEDURE|Youth Soccer|
40943276|NCT00013234|PROCEDURE|Teledermatology|
41132407|NCT03301870|DRUG|Positive Control|Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
40943277|NCT05494320|DRUG|Folfox Protocol|Folfox: It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
40943278|NCT04014309|OTHER|Supportive and survivorship care program|Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.
41132408|NCT03301870|DRUG|Negative Control|Water for Injection, USP
41132409|NCT03301870|DRUG|ATx201 Placebo|matching placebo gel
41132410|NCT03998098|DIAGNOSTIC_TEST|Oxygen Saturation (Oximetry)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
41132411|NCT03998098|DIAGNOSTIC_TEST|Heart Rate (Pulse)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
41132412|NCT03998098|DIAGNOSTIC_TEST|Respiratory Rate|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
41132413|NCT03998098|DIAGNOSTIC_TEST|Blood Pressure|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings."
41132414|NCT04880018|DEVICE|Capsular Tension Ring|Experimental group uses Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd;control group uses Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd
41132415|NCT01728324|DRUG|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
41451988|NCT01573819|DRUG|GSK356278|Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
40943279|NCT04014309|OTHER|Usual care|Usual care
40943280|NCT06045650|OTHER|baseline serum oxytocin levels|Both cases and controls will be assessed for their baseline serum oxytocin levels
40943281|NCT06045650|OTHER|Emotional Sensitivity test|To assess the level of emotional sensitivity in the participant
40943282|NCT06045650|OTHER|Neuro-economical game|A game played to assess the trust-index of participants
40943283|NCT06045650|OTHER|Childhood Trauma Questionnaire|to assess childhood trauma score
40943284|NCT06045650|OTHER|Relationships Questionnaire|to assess attachment type
40943285|NCT06045650|OTHER|demographic questionnaire|To obtain basic data on demographics
40943286|NCT01981759|DRUG|D-Cycloserine|Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
40943287|NCT01981759|OTHER|Placebo|Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
40943288|NCT01981759|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
40943289|NCT01133561|DRUG|actozone A|pioglitazone 30 mg tablet , once daily dose for 10 weeks
40943290|NCT01133561|DRUG|actozone B|one tablet of vehicle without active ingredient pioglitazone
40943291|NCT05126953|DEVICE|samfilcon A Lenses with EPG01 Packaging Solution|samfilcon A Lenses with EPG01 Packaging Solution
40943292|NCT05126953|DEVICE|B+L Ultra Lenses|Commercially available Biotrue ONEday lenses
40943293|NCT02824965|DRUG|Pembrolizumab|Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
40943294|NCT02824965|BIOLOGICAL|CVA21|CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
40943295|NCT00000188|DRUG|Selegiline|
40943296|NCT00558727|DRUG|RH-1|1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
40943297|NCT05154201|DRUG|ORIN1001|Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
40943298|NCT01304160|RADIATION|stereotactic body radiotherapy|30Gray in 5 fractions
40943299|NCT02129829|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 245 mg once daily
40943300|NCT02188225|PROCEDURE|acupuncture|12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes
40943301|NCT02188225|DRUG|fluoxetine|10 mg/ daily
40943302|NCT03236831|OTHER|Clinical Recommendations|"The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following:~1. Avoidance of potentially nephrotoxic medications.~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Minimizing IV contrast exposure when appropriate~5. Treating severe anemia~6. Optimization of hemodynamics (Mean arterial BP\>65mmHg)"
41451989|NCT01573819|DRUG|Placebo|Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
40943303|NCT04008238|DRUG|Trabectedin|- Trabectedin will be prescribed as per market authorization and will be administered by intraveinous infusion (1,5 mg/m²) every 3 weeks. A treatment cycle is defined as a 3-weeks period
40943304|NCT02752204|DRUG|AZD 2014|AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
40943305|NCT02752204|DRUG|Rituximab|Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
40943306|NCT04738409|OTHER|Lifestyle intervention|The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA\&T), in terms of improvement in androgens level and immune-metabolic risk parameters
40943307|NCT04738409|OTHER|Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls|The purpose of the intervention is to evaluate the effectiveness of the anti-inflammatory diet (AIDiet) among normal weight (N) and overweight/obese (Ov/Ob) women with PCOS.
41132416|NCT01728324|DRUG|Ribavirin: 24-week treatment|24 weeks of active treatment
41132417|NCT01728324|DRUG|BI 207127: 24-week treatment|24 weeks of active treatment
41132418|NCT01728324|DRUG|Faldaprevir: 24-week treatment|24 weeks of active treatment
41132419|NCT01728324|DRUG|Faldaprevir: 24-week treatment|24 weeks of active treatment
41132420|NCT01728324|DRUG|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
41451990|NCT05854563|OTHER|Observational only, all subjects; measure DNA mutation and proteomic survey.|Observational only, all subjects; measure DNA mutation and proteomic survey.
41451991|NCT05915351|DRUG|Enfortumab vedotin|Enfortumab vedotin 1.25 mg/kg on D1, D8, D15 every 28 days
40943308|NCT01033188|PROCEDURE|Single bundle|"Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon."
40943309|NCT01033188|PROCEDURE|Double bundle|"Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith \& Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon."
40943310|NCT04701788|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.
40943311|NCT03181815|DRUG|Cladribine|5mg/㎡ d1-5
40943312|NCT03181815|DRUG|G-CSF|300ug d0-9
40943313|NCT03181815|DRUG|Aclarubicin|10mg d3-6
40943314|NCT03181815|DRUG|Cytarabine|10mg/㎡ q12h SC d3-9
40943315|NCT00441454|DEVICE|Transobturator Tension-free vaginal tape (TVT-O)|tension-free vaginal tape (TVT)
40943316|NCT00441454|DEVICE|Retropubic Tension-free vaginal tape (TVT)|Retropubic Tension-free vaginal tape (TVT)
40943317|NCT02378727|DEVICE|Active: Comparator Loss Of Resistance Syringe|Lumbar epidural procedure utilizing Loss of Resistance Syringe
40943318|NCT02378727|DEVICE|Experimental: CompuFlo® Epidural System|CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space
40943319|NCT04535765|OTHER|early warm water sitz bath|The experimental group started the warm water sitz bath 6 hours after the end of the hemorrhoid surgery.
41285061|NCT03078491|OTHER|eCGM (enhanced CGM)|Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
41285062|NCT02414295|DRUG|Mesenchymal stem cell injection|Aspirated bone marrow then separation for Mesenchymal stem cell
41285063|NCT00125203|DRUG|Botulinum toxin type B (Myobloc)|
41285064|NCT00125203|PROCEDURE|Injection of salivary glands|
41285065|NCT00944944|BEHAVIORAL|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
41451992|NCT00924638|DEVICE|Reveal® XT Insertable Cardiac Monitor|The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
40943320|NCT04535765|OTHER|Regular time warm water sitz bath|According to the routine, the control group started the warm water sitz bath on the first day after the hemorrhoid surgery.
40943321|NCT00686179|DRUG|AZD3480|Capsule, oral, single dose, 6 days
40943322|NCT00686179|DRUG|Moxifloxacin|Capsule(encapsulated), oral, single dose
40943323|NCT00686179|DRUG|PLACEBO|Capsule, oral, single dose
40943324|NCT05274685|PROCEDURE|haemodialysis|continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
40943325|NCT00598702|DRUG|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
40943326|NCT05035641|DRUG|AND017|Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
40943327|NCT05035641|DRUG|Placebo|Orally, 3 times per week
40943328|NCT02634749|OTHER|Systematic introduction of taste portions|A systematic introduction of plant foods from the Nordic diet
40943329|NCT02634749|OTHER|Protein reduced complementary foods|Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars
40943330|NCT02634749|OTHER|Nordic diet|Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
40943331|NCT00666874|BEHAVIORAL|lifestyle changes|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
40943332|NCT00666874|BEHAVIORAL|Control - general information|General information about healthy food choices and exercise
40943333|NCT02725853|DEVICE|tDCS|Application of 1.5 mA tDCS for 30 minutes
40943334|NCT02725853|DEVICE|sham tDCS|Application of sham tDCS for 30 minutes
40943335|NCT02725853|BEHAVIORAL|personalized practice|arm exercise consisting of whole arm movement within a restricted elbow range of motion
40943336|NCT02725853|BEHAVIORAL|non-personalized practice|arm exercise consisting of unrestricted whole arm movement
40943337|NCT03839082|OTHER|Usual Care then FitBit|Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
40943338|NCT03839082|OTHER|FitBit then Usual Care|Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
40943339|NCT02310932|BEHAVIORAL|Healthy Living Intervention|"Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support."
40943340|NCT05067673|OTHER|Dry needling|The dry needling will be performed using disposable stainless steel needles (AGU-PUNT needles of size 0.30x50mm or 0.30x60mm depending on the patient) that will be inserted perpendicularly at the point of major hyperalgesia using the Hong technique. The patient will be in the prone position with a pillow placed in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. After this time, the needle will be inserted at the point indicated by the evaluator before reaching the lumbar multifidus by means of echolocation. Once it is assured that it is in the right place, a total of 10 repetitions are performed. The needle will be removed by depositing it in a needle container and a compression will be removed in the treated area until hemostasis is achieved.
40943341|NCT05067673|OTHER|Placebo dry needling|Placebo dry needling will be performed with DongBang DB100 Acupuncture Needles which, upon contact with the patient, retract, hiding in the needle handle. The patient will be in the prone position with a pillow in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. At the point indicated by the evaluator, the placebo needle will be placed initially and the introduction of the needle and its location will be simulated with the ultrasound system. 10 repetitions will be performed. The needle will be removed by depositing it in a needle container and a compression will be made in the treated area.
40943342|NCT05947578|DRUG|CLZ-2002|Low dose group (6×10\^6 cells), Mid dose group (12×10\^6 cells), High dose group (24×10\^6 cells)
40943343|NCT04252365|DRUG|Sintilimab|Given i.v.
40943344|NCT04252365|DRUG|Pembrolizumab|Given i.v.
40943345|NCT06557174|DRUG|IMC-002|intravenous injection: Weekly administered for a period of first 4 weeks, then rest for 20 weeks. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
40943346|NCT06557174|DRUG|mycophenolate mofetil， MMF|daily oral 0.2g
40943347|NCT02658058|OTHER|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
41285066|NCT00944944|BEHAVIORAL|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
41451993|NCT03572335|DIAGNOSTIC_TEST|PFT's (pulmonary function testing)|The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.
41451994|NCT06122805|DEVICE|Toothbrush|We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.
41451995|NCT01896479|DRUG|Cabozantinib (XL184) 140 mg|
41451996|NCT01896479|DRUG|Cabozantinib (XL184) 60 mg|
41451997|NCT01896479|DRUG|Placebo tablet|
41132421|NCT01728324|DRUG|BI 207127: 24-week treatment|24 weeks of active treatment
41132422|NCT01728324|DRUG|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
41132423|NCT01728324|DRUG|Faldaprevir: 16-week treatment|16 weeks of active treatment
41132424|NCT01728324|DRUG|Ribavirin: 16-week treatment|16 weeks of active treatment
41451998|NCT01896479|DRUG|Placebo capsule|
40943348|NCT02658058|OTHER|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
40943349|NCT02658058|OTHER|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
40943350|NCT01373307|BEHAVIORAL|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
40943351|NCT02218983|DEVICE|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
40943352|NCT02218983|OTHER|Usual care|
40943353|NCT03850665|PROCEDURE|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
40943354|NCT03850665|PROCEDURE|Anterolateral approach|Anterolateral approach surgery to replace the hip.
40943355|NCT04735575|BIOLOGICAL|EMB-06|EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.
40943356|NCT03200158|OTHER|Endoscopy biopsy and blood|Medical operation
40943357|NCT01813110|DRUG|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
40943358|NCT01813110|DRUG|Placebo|olive oil
41285067|NCT01065480|BEHAVIORAL|Live teleconference supervision|Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
41285068|NCT01065480|BEHAVIORAL|Taped Review Supervision|Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
41285069|NCT03802721|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
41285070|NCT03802721|DRUG|Brussels sprouts before 50 ng dose|Brussels sprouts for 7 days before 50 ng (5.4 nCi) dose of BaP
41285071|NCT03802721|DRUG|DIM supplement before 50 ng dose|DIM supplement for 7 days before 50 ng (5.4 nCi) dose of BaP and coadministration with DIM supplement
41285072|NCT06073314|DIAGNOSTIC_TEST|Quantitative MRI|Patients will be asked to remain in the scanner for an additional 10 minutes while we acquire additional quantitative MR images
41285073|NCT06073314|DIAGNOSTIC_TEST|Reproducibility study|A subset of patients will be invited back for a repeat MRI scan (prior to any treatment for their condition) to help measure reproducibility of our Artificial Intelligence model
41285074|NCT02242279|DRUG|BEA 2180 BR|
41285075|NCT02242279|DRUG|Tiotropium|
40756950|NCT00063362|DRUG|Lamotrigine|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
40756951|NCT00063362|DRUG|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
40943359|NCT02435147|DRUG|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
40943360|NCT03190369|DEVICE|Hylan G-F 20 (GZ402662/SAR402662)|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
40943361|NCT03190369|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
40943362|NCT03263585|DEVICE|Spinal orthosis Spinomed|
40943363|NCT03263585|OTHER|Equipment training|
40943364|NCT05026723|BEHAVIORAL|MTM + ILI|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program
40943365|NCT05026723|BEHAVIORAL|Standard MTM|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian
40943366|NCT03810391|DRUG|Butorphanol|intravenous loading dose of 15ug/kg butorphanol,and followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
40943367|NCT03810391|OTHER|physiological saline|intravenous infusion of the same volume of physiological saline
40943368|NCT05780697|PROCEDURE|Surgery of Drainage of septic hip arthritis|Surgery for septic hip arthritis by anterior or lateral approach and inspection of femoral head
40943369|NCT01270061|BEHAVIORAL|HIV testing|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
40943370|NCT01270061|BEHAVIORAL|General Health Screen|A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
41132425|NCT01728324|DRUG|RBV: 24-week treatment|24 weeks of active treatment
41132426|NCT01728324|DRUG|BI 207127: 16-week treatment|16 weeks of active treatment
41285076|NCT02242279|DRUG|Placebo|
41285077|NCT04605679|PROCEDURE|Kidney Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive kidney graft
41285078|NCT06232915|PROCEDURE|Mechanical ventilation|Mechanical ventilation during surgery
41285079|NCT03460418|OTHER|Phone contact|Assessment of the different outcomes by means of a phone contact
41285080|NCT00467649|DRUG|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
41285081|NCT00467649|DRUG|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
41451999|NCT03888235|PROCEDURE|Immediate corrective exercises|The sacroiliac forward flexion test (SIFFT) finds the position of each innominate bone. Subjects learn 1 of 3 exercises. To correct anterior rotation, flex the thigh hard against the ilium, pushing it backwards. To correct posterior rotation, hyperextend the thigh to pull the ilium forward. 1.Genuflect, anterior foot and posterior knee on the floor hands on the floor on either side of the foot, sliding the knee backwards to hyperextend the thigh. 2. Supine, anterior foot on an assistant's sternum, posterior thigh hyperextended. Assistant leans forward, forcing the anterior thigh against the ilium and pushing down on the posterior thigh. 3. For anterior rotation alone: anterior foot on a chair seat, pulling up hard with both hands, leaning back, forcing the thigh against the ilium. Hold position for 2 minutes. Use as needed for pain control. They are reassessed one month later when they receive the pelvic support belt. Both treatments used together will be assessed one month after.
41285082|NCT00467649|DRUG|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
41285083|NCT01275248|DRUG|Ondansetron|Oral tablets in 0.5mg or 0.75mg strength
41285084|NCT01275248|DRUG|Placebo|Oral tablet to match the experimental interventions
41285085|NCT03095105|DRUG|200 mg BIA 6-512|capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
41285086|NCT00302640|DRUG|Alinia (nitazoxanide)|
41285087|NCT05978869|OTHER|physical fitness training|Through a three-step process, gamified physical fitness training was developed by a multidisciplinary team.
41285088|NCT00652821|DRUG|Tramadol/ APAP|Tablets 37.5mg /325mg
41285089|NCT00652821|DRUG|Ultracet|Tablets, 37.5mg/325mg
41285090|NCT02846675|BIOLOGICAL|autologous SVF|SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.
41285091|NCT02846675|BIOLOGICAL|Placebo|a Placebo treatment without SVF cells
41285092|NCT02007837|DRUG|Combined aspirin and multinutrient supplement|Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
41285093|NCT02007837|OTHER|Daily text reminder text messages|
41285094|NCT05987670|DEVICE|AI-stethoscope|"Clinicians at practices in the intervention arm will be provided with one session of in-person training in use of the AI-stethoscope within 2 weeks of randomisation, including~1. Delivery and setup~2. Smartphone app installation and login~3. Pairing of all clinician smartphones with all AI-stethoscopes in the same practice~4. Demo of patient examination The AI-stethoscope will be used within its CE/UKCA-marked intended purpose. The clinical guidelines for use have been agreed by the NHS North West London Integrated Care System and Betsi Cadwaladr University Health Board Cardiovascular Executive Groups. Patients will be examined with the AI-stethoscope in accordance with these guidelines, and/or where stethoscope examination is deemed clinically appropriate. Patients will provide verbal consent for examination with the AI-stethoscope as per any physical examination performed by healthcare professionals for direct care, in accordance with UK law and General Medical Council guidelines."
41285095|NCT02951923|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum vs. soy during rugby training
41285096|NCT02951923|DIETARY_SUPPLEMENT|Soy|
41285097|NCT04421651|BEHAVIORAL|Dance Movement Therapy group|DMT-intervention was facilitated by a dance movement therapist and included 20 x 75 mins sessions within 10 weeks.
41285098|NCT03737864|BEHAVIORAL|Patient navigation|The patient navigator will provide support to patients upon discharge and will maintain regular contact either in person or by phone at a minimum of once per week for 30 days, or until the patient successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
41285099|NCT03737864|BEHAVIORAL|Motivational interviewing (MI)|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
41285100|NCT01790061|PROCEDURE|Standardized FMT|Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut or whole colon
41285101|NCT01790061|DRUG|Traditional treatments|Medications
41285102|NCT01649492|DIETARY_SUPPLEMENT|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
41285103|NCT03289715|DEVICE|On Demand Humidification system Mark 2|The on demand humidification humidifier is set up to alternate between periods of humidification and no humidification totaling 6 periods of 30 minutes duration each. Thus, the test will consist of 3 cycles of disabled humidification and enabled humidification. Each cycle will be with a different humidification setting to assess which setting is most comfortable. In the second phase, the patient will be treated with the dose they had the best experience with in the first test.
41285104|NCT02243176|DRUG|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd.
41285105|NCT02243176|DRUG|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
41285106|NCT02334267|DEVICE|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
41285107|NCT02334267|DEVICE|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
40943371|NCT02413177|BEHAVIORAL|EEG-no RTNF|All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
40943372|NCT02413177|BEHAVIORAL|EEG-RTNF|All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
40943373|NCT04112888|COMBINATION_PRODUCT|Collagen|Patients will receive 3 to 5 collagen infiltrations in the scar once per week. Patients with episiotomy will receive 3 collagen infiltrations while patients who underwent a cesarean section will receive 5 collagen infiltrations. The infiltration will be done by tunneling technique, that is, it will be applied along the scar, placing the needle almost tangential to the entire length of the area, then it will be injected and at the same time the needle will be removed. Infiltrations will be carried out intradermally, previously performing asepsis in the area to be infiltrated. 2 ml syringes will be used to infiltrate the episiotomy scars (we will use 1 vial of 2 ml ) and 5 ml for cesarean scars (2 vials of 2 ml ) and sterile needles of 30G, 13mm.
40943374|NCT04112888|PROCEDURE|Rehabilitation sessions|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
40943375|NCT05357547|DRUG|Buspirone 20mg|Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism
40943376|NCT05357547|DRUG|Placebo comparator|Lactose-sucrose tablets in opaque capsule
40943377|NCT00246896|BEHAVIORAL|care management|
40943378|NCT03378375|OTHER|nutritional assessement|
40943379|NCT00857402|DIETARY_SUPPLEMENT|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
40943380|NCT00857402|DIETARY_SUPPLEMENT|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
40943381|NCT03824171|DRUG|Raloxifene 60mg/Cholecalciferol 800IU|Raloxifene 60mg/Cholecalciferol 800IU tablet
40943382|NCT03824171|DRUG|AD-102|AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet
40943383|NCT06003569|BEHAVIORAL|BACK-S|"BACK = Better Asthma Control for Kids:~The BACK -Standard package includes a tailor-and-adapt to context strategy of approaches necessary to implement BACK in schools based on our past work, operationalized as an implementation blueprint to coordinate with partner roles of child/family, schools, healthcare teams and community resource agencies. This includes a facilitation strategy to support problem-solving through regular learning collaborative meetings for asthma navigators (bi-weekly), school nurses (monthly to bi-monthly) and health care champions (quarterly)."
40943384|NCT06003569|BEHAVIORAL|BACK-E|The BACK-Enhanced package includes the BACK-Standard package plus an Enhanced strategy to develop interrelationships with students/family, schools, and community agencies providing resources to address social determinants of health.
40943385|NCT05235477|PROCEDURE|Tube technique|"An excavator (smaller than the width of the defect; evaluated pre-surgically on a study model) is used to carefully reflect the papilla away from the alveolar bone and root surfaces on the buccal aspect to access the interproximal region to prepare the bed for the graft. The excavator is used to do the same on the palatal aspect. The amount of reflection should yield a very relaxed papilla flap that permits placement of the papilla at the new coronal position without tension. The recipient site at this time should resemble a tube with two openings; one on the buccal aspect at the mucogingival junction and one on the palatal aspect."
40943386|NCT01241084|DIETARY_SUPPLEMENT|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
41132427|NCT01141257|DRUG|Angiocal® (PRS-050-PEG40)|Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.
41132428|NCT04497545|DEVICE|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
41132429|NCT04497545|DEVICE|lower limb rotor|The duration of the overall therapeutic intervention in both groups will be the same.
41285108|NCT01923610|BIOLOGICAL|Experimental|"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-\~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"
41285109|NCT04304677|DEVICE|Percutaneous coronary intervention|"1. Pre-PCI FFR pullback recording was done with conventional system~2. Automated algorithm to calculate delta FFR per unit time was developed~3. PCI was performed using 2nd generation DES"
40943387|NCT01241084|DIETARY_SUPPLEMENT|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
40943388|NCT01180647|DRUG|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
40943389|NCT01180647|BEHAVIORAL|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
40943390|NCT03327454|BIOLOGICAL|Benepali|Administered as specified in the treatment arm.
40943391|NCT02632643|BEHAVIORAL|Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.|
40943392|NCT04407481|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
40943393|NCT04407481|DRUG|Iohexol Inj 300 milligrams per milliliter (MG/ML)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
41285110|NCT03467022|DRUG|Vitamin C|Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three months
41285111|NCT01916369|BIOLOGICAL|CTX DP|Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
41285112|NCT02832492|BEHAVIORAL|pupil near response|
41285113|NCT05778318|DRUG|The group of patients who received Lianhua Qingwen orally|Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
41285114|NCT05778318|OTHER|The group of patients who did not receive Lianhua Qingwen orally|The group of patients who did not receive Lianhua Qingwen orally.
41285115|NCT04387474|DEVICE|Brain-computer interface|brain-computer interface rehabilitation training.
41285116|NCT04387474|OTHER|Traditional rehabilitation|traditional rehabilitation training.
41285117|NCT05347056|DIAGNOSTIC_TEST|Lumbar Spine Magnetic Resonance|Metal artifact reduction sequence (mars), axial t2 sequence
41285118|NCT05347056|DIAGNOSTIC_TEST|Isokinetic trunk flexion-extension trunk muscle strength and endurance test|To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s
41285119|NCT05347056|DIAGNOSTIC_TEST|Lomber Region Range of motion assessment|To evaluate for lomber region ROM with digital inclinometer
41285120|NCT05347056|DIAGNOSTIC_TEST|Radiograph|spinal radiograph AP/Lateral
41285121|NCT05347056|BEHAVIORAL|SRS 22|SRS-22 Patient Questionnaire
41285122|NCT04937270|DEVICE|High frequency therapy (5 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 5 minutes using a 500 kHz resistive electric transfer (RET).
41285123|NCT04937270|DEVICE|High frequency therapy (7 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 7 minutes using a 500 kHz resistive electric transfer (RET).
41285124|NCT04937270|DEVICE|High frequency therapy (9 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 9 minutes using a 500 kHz resistive electric transfer (RET).
41285125|NCT04937270|DEVICE|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
41285126|NCT01030042|DRUG|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
41285127|NCT01030042|DRUG|Irinotecan/Cetuximab|"CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression."
41285128|NCT00437905|PROCEDURE|angioplasty|
41285129|NCT02391610|OTHER|No intervention|
40943394|NCT04407481|RADIATION|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
41452000|NCT03888235|DEVICE|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their sacroiliac joints. The belt is fitted tightly around the pelvis, over the sacrum and below the anterior superior iliac spines (ASISs) to prevent opening the joint. (The upper part of the innominate bones flares out so pushing them inwards will move the lower part outwards, away from the sacrum, opening the sacroiliac joints, increasing their instability). They will use this belt for activities which have in the past precipitated back pain. They will be reassessed one month later.~At that time they will be given the exercises to correct their sacroiliac malrotation and the concurrent use of both treatments will be assessed at their last visit one month later."
40943395|NCT01528215|DEVICE|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
40943396|NCT01528215|DEVICE|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
40943397|NCT05883371|OTHER|Root-cause autoimmune treatment program|The AndHealth autoimmune treatment program combines validated and guideline-driven approaches along with emerging evidence-based modalities. The program includes a comprehensive assessment of disease severity, analysis of root causes and comorbidities, and an evaluation of the patient's readiness for implementing important lifestyle changes. This is followed by the development of an optimized and personalized plan to achieve and sustain clinical remission while monitoring their progress. Each patient participating in the AndHealth program receives a personalized care plan developed by the patient's medical provider in collaboration with a team of healthcare specialists. Helping a patient manage everyday lifestyle decisions can have a profound effect on their ability to achieve and maintain remission. The AndHealth Program has organized these into four basic groups of lifestyle behaviors: 1.) Dietary/Nutrition, 2.) Sleep/Circadian, 3.) Stress/HPA axis, and 4.) Physical Activity.
40943398|NCT04228393|DRUG|6-mercaptopurine|6-mercaptopurine was administered orally to patients once daily.
41285130|NCT01600781|DIETARY_SUPPLEMENT|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
41285131|NCT02403206|DEVICE|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
41285132|NCT02403206|PROCEDURE|Continuous Curvilinear Capsulorhexis (CCC)|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
41285133|NCT04191668|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
41285134|NCT02632825|DEVICE|Nasal High Flow|Nasal High Flow Therapy
41285135|NCT05353569|DIAGNOSTIC_TEST|OCT Device(s)|Results from standard-of-care examinations will be compared to research-only examination(s) (OCT device(s)).
41285136|NCT05412329|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
41285137|NCT02923271|DEVICE|CellControl|Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.
41285138|NCT05335122|DRUG|OTX-TIC low dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
41285139|NCT05335122|DRUG|OTX-TIC high dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
41285140|NCT05335122|DRUG|Durysta, Bimatoprost Intracameral Implant 10 µg|Durysta is injected into the anterior chamber of the eye.
41285141|NCT03203629|DEVICE|Wearable Cardioverter Defibrillator (WCD)|Observe and compare the heart sound measurements recorded by the WCD
41285142|NCT04831944|DRUG|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
41285143|NCT03604666|OTHER|Health care process with Nurse Navigator|"A Nurse Navigator will:~* Be present at the announcement consultation~* Give information on the outpatient circuit~* Offer assistance for patients over 75 years~* Complete onco-geriatric orientation questionnaires~* Take care of patients on the ambulatory circuit"
41285144|NCT02739477|DRUG|Favipiravir|"Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results."
41285145|NCT05771922|DIAGNOSTIC_TEST|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
41285146|NCT03545243|DRUG|Pantoprazole 40mg|Peroral Pantoprazole 40mg once daily during 28 days
41285147|NCT03545243|OTHER|PPI withdrawal|PPI withdrawal for 8 weeks
40756952|NCT00063362|DRUG|Placebo|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
41285148|NCT04234438|DEVICE|SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)|Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.
41285149|NCT01956981|DRUG|Magnesium Sulfate|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
41285150|NCT01956981|DRUG|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
41285151|NCT00609271|BEHAVIORAL|low carbohydrate diet|\<40 grams carbohydrate/day
41285152|NCT00609271|BEHAVIORAL|low fat diet|\<30% fat, \<7% saturated fat
41285153|NCT02793375|DRUG|Montelukast|Age appropriate dose of Montelukast given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
41285154|NCT02793375|DRUG|Placebo|Age appropriate dose of placebo given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
40943399|NCT04228393|PROCEDURE|Standard treatment|The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.
40943400|NCT04228393|PROCEDURE|Individualized treatment|The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.
40756953|NCT02369939|RADIATION|Irradiation|Radiotherapy 55,8 Gy - 59,4 Gy
40756954|NCT02369939|DRUG|Mitomycin C|MMC w1, w5
40756955|NCT02369939|DRUG|5-Fluorouracil|5-FU w1, w5
40756956|NCT02369939|PROCEDURE|Hyperthermia|6x deep regional hyperthermia
40943401|NCT04918576|DRUG|Tranexamic acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
41285155|NCT01383122|DEVICE|Pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
41285156|NCT01383122|DEVICE|Inactive pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
40943402|NCT04918576|DRUG|Normal Saline|40 mL topical of 0.9% normal saline
40943403|NCT02753933|OTHER|MRI scan|MRI head scan to be performed as the first Secondary Care contact.
40943404|NCT02753933|OTHER|Neurology Appointment|Outpatient appointment with Neurologist as the first Secondary Care contact
40943405|NCT00745173|DRUG|Premarin|
40943406|NCT04302818|BEHAVIORAL|SKOLKONTAKT|N=21 participants are offered manualized and structured group training SKOLKONTAKT. The intervention includes 12 weeks, 3 sessions (50 minutes) per week.
40943407|NCT04302818|BEHAVIORAL|Social activity group|N=21 participants. The active comparison group includes 12 weeks, 3 sessions (50 minutes) per week. Sessions will include socially oriented activities such as board games, sports or baking as well as a recommended, general agenda.
40943408|NCT06450080|OTHER|MRI and MRS acquisitions|All MRI and MRS acquisitions for this study will be carried out on the GIE Faire Faces ACHIEVA 3T TX DStream Philips® Research MRI using a 32-channel head antenna located at the Amiens-Picardie University Hospital .
41285157|NCT02533115|DRUG|CPX-351|"CPX-351 (cytarabine:daunorubicin) Liposome for Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.~CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials. Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL). Each unit (u) contains 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5˚ ± 3PoPC."
41285158|NCT05780866|OTHER|Video and Activity Tracker|"At enrollment, the participants will complete a baseline survey, PDQ-39 (Parkinson's disease questionnaire), and the Unified Parkinson's Disease Rating Scale (UPDRS) assessment. The researchers will provide the participant with a camera, small tripod, and a set of written directions about how to record the UPDRS motor self-assessment video.~After completing the baseline assessments, the research team will provide the participant with a Fitbit Inspire 3 activity tracker watch. The participant will wear the activity tracker for 24 hours a day for the next 14 days except for if the device needs charging and when bathing.~At 14 days, the research team will send participants a link to complete a web-based exit survey about their experience with the activity tracker during the study."
41285159|NCT02035423|DIETARY_SUPPLEMENT|120 IU milk|Daily consumption of milk fortified with 120 IU vitamin D
41285160|NCT02035423|DIETARY_SUPPLEMENT|200 IU Milk|Daily Consumption of milk fortified with 200 IU vitamin D
41285161|NCT02035423|DIETARY_SUPPLEMENT|Non-Fortified Milk|Daily consumption of non-fortified milk
41285162|NCT00432198|DRUG|Zolpidem (Myslee®)|Oral
41285163|NCT00432198|DRUG|placebo|Oral
41285164|NCT01712360|DRUG|NAFT500 (pediatric)|Applied to both feet and groin area
41285165|NCT01712360|DRUG|NAFT600 (pediatric)|Applied to both feet only
41285166|NCT01712360|DRUG|NAFT500 (adult)|Applied to both feet and groin area
40943409|NCT00719095|DRUG|buprenorphine taper followed by naltrexone maintenance|direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial
40943410|NCT00719095|BEHAVIORAL|Behavioral therapy|
40943411|NCT05355311|DRUG|Acetyl-l-carnitine|Acetyl-L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
40943412|NCT05355311|DRUG|Placebo|Matching placebo (sugar pill)
40943413|NCT05464173|DRUG|Chidamide|10-30mg biw
40943414|NCT05464173|DRUG|Abemaciclib|150mg or 100mg bid
40943415|NCT05464173|DRUG|endocrinotherapy（doctor's choice）|According to the drug insert
40943416|NCT00234390|DRUG|Pulmicort (budesonide) pMDI|
40943417|NCT03652883|OTHER|ItFits-toolkit|The ItFits-toolkit provides evidence-informed methods, materials, knowledge on determinants and implementation strategies, and concrete guidance on tailoring implementation strategies to local determinants of practices, apply them and evaluate their impact. It applies a standardised four-step approach to iteratively develop evidence-informed implementation strategies. The ItFits-toolkit is based on the Normalisation Process Theory (NPT), which suggests that lasting changes in practice only happen through people working together. The ItFits toolkit functions as an online self-help toolkit with minimal support. The toolkit will provide instructions for the IL to establish a core team and to create a sounding board consisting to enable co-creation.
40943418|NCT03652883|OTHER|Implementation as Usual|IAU refers to any existing efforts to embed and integrate iCBT within an organisation.
40943419|NCT02853344|BIOLOGICAL|Pembrolizumab|IV infusion
41285167|NCT01712360|DRUG|NAFT600 (adult)|Applied to both feet
41285168|NCT03906695|DRUG|ASTX727|oral decitabine 5mg + cedazuridine
41285169|NCT03906695|DRUG|ASTX727|oral decitabine 5mg + cedazuridine
40943420|NCT04598789|OTHER|no intervention|no intervention, observational study
41132430|NCT06509321|PROCEDURE|subinguinal loupe-assisted varicocelectomy (LV)|to assess the efficacy and safety of sub inguinal loupe-assisted varicocelectomy with nitroglycerin instillation as a vasodilator and compare its results versus subinguinal microscopic varicocelectomy
41132431|NCT06509321|PROCEDURE|subinguinal microscopic varicocelectomy (MV)|we are using surgical microscope to perform varicocelectomy as control group
41132432|NCT06509334|DRUG|JYB1904|Participants will receive JYB1904 at week0 and receive placebo at week4,8,12
41285170|NCT03906695|DRUG|ASTX727|oral decitabine 10mg + cedazuridine
41285171|NCT03906695|DRUG|ASTX727|oral decitabine 20mg + cedazuridine
41285172|NCT03906695|DRUG|ASTX727|oral decitabine 10mg + cedazuridine
40756957|NCT02976844|PROCEDURE|Positive end-expiratory Pressure|Positive end-expiratory pressure will be used during mechanical ventilation.
41285173|NCT03920605|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
41285174|NCT03920605|DRUG|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
41285175|NCT03920605|DRUG|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
41285176|NCT05519943|BEHAVIORAL|The Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
41285177|NCT05519943|BEHAVIORAL|TAU condition|A TAU waitlist condition during which participants received routine care services tailored to each child individually.
41285178|NCT04336150|OTHER|Hypopressive exercises|See information included in arm/group descriptions.
41285179|NCT04336150|OTHER|Hypopressive maneuver|See information included in arm/group descriptions.
41285180|NCT04336150|OTHER|Hypopressive exercises plus pelvic floor muscle contraction|See information included in arm/group descriptions.
41285181|NCT04336150|OTHER|Hypopressive maneuver plus pelvic floor muscle contraction|See information included in arm/group descriptions.
41285182|NCT05157425|DIETARY_SUPPLEMENT|Food Supplement|Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
41285183|NCT05157425|DIETARY_SUPPLEMENT|Placebo|One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
41285184|NCT03858582|DRUG|pembrolizumab|pembrolizumab 200mg
41285185|NCT03858582|RADIATION|Radiation|52.8Gy/24Fx or 59.4Gy/27Fx
41285186|NCT01057121|DRUG|Lenalidomide|Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
41285187|NCT01615510|DRUG|Tapentadol immediate release|100 mg, single administration
41285188|NCT01615510|DRUG|placebo|placebo, single administration
41285189|NCT05955742|DEVICE|Control|The operator prepared the glide path using a #15K-type stainless-steel hand file.
41285190|NCT05955742|DEVICE|ProGlider|The operator prepared the glide path using the ProGlider file.
41285191|NCT05955742|DEVICE|WaveOne Gold Glider|The operator prepared the glide path using the WaveOne Gold Glider file.
40756958|NCT01963832|DRUG|Fluoxetine|
40756959|NCT01963832|DRUG|Placebo|
40756960|NCT01963832|PROCEDURE|eCMIT|
40756961|NCT01963832|PROCEDURE|Usual Care|
40756962|NCT00875407|OTHER|Scintigraphy in 123I-IBZM|
40756963|NCT05213351|OTHER|Graded Motor Imagery|"Graded Motor Imagery program will be performed two times a week for six consecutive weeks and will include the following three steps: laterality training, imagined movements, and mirror therapy.~1. Right-left discrimination training (lateralization training)~2. Imagination of hand movements (motor imagery):~3. Mirror therapy Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc."
41285192|NCT01887912|BIOLOGICAL|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
41285193|NCT01887912|BIOLOGICAL|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
41132433|NCT06509334|DRUG|JYB1904|Participants will receive JYB1904 at week0,8 and receive placebo at week4,12
41285194|NCT02488278|DEVICE|GlucoMe Glucose Monitoring Device|Perform a blood glucose test using the application and device
41285195|NCT00542698|BEHAVIORAL|Effect of Physical Activity on Type II Diabetes Mellitus|Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
41285196|NCT00393822|DRUG|palifermin|dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
41285197|NCT00393822|DRUG|placebo|one bolus IV injection at 120 μg/kg/day of matched placebo
41285198|NCT02137668|DRUG|Oral Vancomycin|Oral Vancomycin is given to PSC or BA participants
40756964|NCT05213351|OTHER|Exercise|Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc.
40756965|NCT03608007|DRUG|X-396 Capsule|225 mg once daily
40756966|NCT03146793|DRUG|Sodium Thiosulfate|25g intravenously 3 times per week
41132434|NCT06509334|DRUG|Omalizumab|Participants will receive Omalizumab every 4 weeks for 12 weeks
41132435|NCT02132039|OTHER|12-step sitting Tai Chi Chuan|The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.
41285199|NCT04432441|OTHER|Therapeutic physical exercise program for scapulo-humeral stabilitation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation during a month
41285200|NCT04432441|OTHER|Therapeutic physical exercise program for scapulo-humeral stabilitation + electrostimulation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation added electrostimulation during a month
41285201|NCT05922683|DRUG|Vivomixx|"Vivomixx (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center or vice-versa on a bi-weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm."
41285202|NCT05922683|DEVICE|CapScan®|"The only non-standard sample collection instrument is the CapScan device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
41285203|NCT05259475|OTHER|Lifestyle Advice|Maintain a weekly healthy diet and regular exercise.
41285204|NCT05259475|OTHER|Diet Intervention|Calorie-restricted meals (lunch and dinner)
41285205|NCT05259475|OTHER|OCFA Meal-Based Diet-Intervention|OCFA-containing food product
40943421|NCT03736694|BEHAVIORAL|Cognitive behavioural therapy for insomnia|CBTI involves habitual, belief and attitude alterations so as to eliminate factors preventing sleep (Morin, Savard, Ouellet, \& Daley, 2003). It is recommended by the American College of Physicians as the first-line therapy for insomnia (Qaseem, Kansagara, Forciea, Cooke, \& Denberg, 2016). CBTI workshops are a relatively novel and emerging way of delivery which involves a greater number of patients than group CBTI, increases availability and accessibility by concentrating the content into half or whole day and taking place in the community settings, and reduces diagnostic labeling and cost (Bonin, Beecham, Swift, Raikundalia, \& Brown, 2014; Swift, Stewart, Andiappan, Smith, Espie, \& Brown, 2012). Self-help CBTI involves independent learning of the provided materials via the Internet, video or audio recording, books and pamphlets (Bruin, Bogels, Oort, \& Meijer, 2015).
40943422|NCT03736694|BEHAVIORAL|Sleep hygiene education|SHE, is commonly provided verbally or through leaflets during consultations (Espie, 2009), and is also included as a part of CBTI (Morin, Savard, Ouellet, \& Daley, 2003).
40943423|NCT06459765|DEVICE|Mi2000 TICI|Cochlear Implantation
40943424|NCT05685836|DRUG|Bevacizumab Zirconium Zr-89|See Arm description.
40756967|NCT02465814|DRUG|Vilaprisan (BAY1002670)|Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
40756968|NCT02465814|DRUG|Vilaprisan (BAY1002670|Placebo (12 weeks),Vilaprisan (12 weeks)
41285206|NCT00224016|DRUG|Oxybutynin|1.3, 2.6, 3.9 mg/day transdermal
40943425|NCT01334892|DRUG|Cyclosporine Inhalation Solution|Cyclosporin for inhalation twice daily
40943426|NCT02106910|DEVICE|Cytosponge|The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
40943427|NCT02507973|OTHER|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
40943428|NCT02507973|OTHER|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
40943429|NCT00000519|BEHAVIORAL|diet, reducing|
40943430|NCT00000519|BEHAVIORAL|exercise|
40943431|NCT00000519|BEHAVIORAL|diet, fat-restricted|
40943432|NCT02534818|DRUG|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
40943433|NCT02534818|DRUG|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
40943434|NCT02088242|DRUG|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
40943435|NCT02088242|DRUG|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
41285207|NCT00224016|DRUG|Oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
40756969|NCT02465814|DRUG|Vilaprisan (BAY1002670|Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
41285208|NCT05073081|OTHER|Prehab for LSS|The 8-week prehabilitation program will be delivered online by physiotherapists, chiropractors, and kinesiologists through synchronous and asynchronous exercise sessions, along with online educational sessions.
41285209|NCT05073081|OTHER|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice.
41452001|NCT03888235|OTHER|Delayed treatment|Participants will continue the treatments they are currently using to relieve their low back pain for one month. At their one-month visit, they will be taught how to assess the direction of sacroiliac malrotation and how to do the corrective exercise. They will also be fitted for a pelvic stabilization belt.
40756970|NCT02465814|DRUG|Vilaprisan (BAY1002670)|Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
40756971|NCT02465814|DRUG|Ulipristal|Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
41452002|NCT00694044|DRUG|varenicline|0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
40756972|NCT02465814|DRUG|Ulipristal|Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
40756973|NCT02465814|DRUG|Ulipristal|Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
40756974|NCT04719312|PROCEDURE|Y modification of transconjunctival approach|"Section of the orbital septum is done at the Arcus Marginalis and subperiosteal dissection done to expose the infraorbital rim and orbital floor.~Subsequently, canthotomy of the superficial limb of the lateral canthal ligament is performed and subperiosteal dissection is carried out to expose the fracture at the frontozygomatic region.~The cutaneous Y will transform into a box when retracting its corners, increasing the working area and allowing access of the frontozygomatic (FZ) suture, lateral orbital wall, body of the zygoma, infraorbital rim, and floor of the orbit with a single approach.~A small upper vestibular incision is placed to expose the fracture at the zygomatic buttress. Reduction and fixation of fractures in a regular fashion are accomplished."
40756975|NCT01893814|DIETARY_SUPPLEMENT|Probiotics|
40756976|NCT01893814|DIETARY_SUPPLEMENT|Control|
40756977|NCT01965483|RADIATION|once-weekly breast irradiation|
40756978|NCT03990337|DEVICE|Ultrasound|Ultrasonography of cricoid cartilage.
40756979|NCT06475495|DRUG|KYV101|an autologous fully-human anti-CD19 CAR T-cell immunotherapy
40943436|NCT02143700|OTHER|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
40943437|NCT05648760|BEHAVIORAL|Simulation training|Participants randomized to the simulation condition received simulation training based on a standard training of how to communicate bad news to patients
40943438|NCT01483807|BEHAVIORAL|Sound Production Treatment - Blocked|Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.
40943439|NCT01483807|BEHAVIORAL|Sound Production Treatment - Random|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.
40943440|NCT01689168|BEHAVIORAL|Counseling|Tobacco cessation counseling
40943441|NCT01689168|PROCEDURE|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
40943442|NCT00497276|PROCEDURE|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
40943443|NCT00612183|DRUG|bendamustine hydrochloride|bendamustine hydrochloride is administered by 60-min drip infusion at 120 mg/m2/day for 2 consecutive days, and the course is then observed for 19 days. This is one cycle and administration is repeated for 3 - 6 cycles. From the second cycle, the dose is reduced or administration is discontinued as required based on adverse events observed in the previous cycle or observation of the course.
40943444|NCT04766073|PROCEDURE|Niche prevention suture|This group will have the uterus sutured in two layers using a new technique.
40943445|NCT05833334|BEHAVIORAL|Public health infographic (AIM 3)|Standard public health infographic about home air radon testing, plus information about requesting a free home air radon test kit
40943446|NCT05833334|BEHAVIORAL|Online health promotion intervention tailored by smoking status (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit
40943447|NCT05833334|BEHAVIORAL|Online health promotion intervention tailored by smoking status, plus reminder messages (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit, plus reminder messages about home air radon testing sent over two months
40943448|NCT05833334|BEHAVIORAL|Focus group with educational overview (AIM 1)|90-minute online focus group discussion about home air radon testing, plus an educational overview about home air radon testing using a standard public health infographic
40943449|NCT04019587|DIAGNOSTIC_TEST|Fear of Falling Avoidance Behavior Questionnaire administration|The Questionnaire includes 14 items dealing with avoidance behavior. All items will be asked by face to face technique.
40943450|NCT04937855|OTHER|no intervention|no intervention
40943451|NCT02271373|BEHAVIORAL|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
40943452|NCT01848704|BEHAVIORAL|interpretation of the abstract|
40943453|NCT04685031|DRUG|Nitroglycerin ointment|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
40943454|NCT04685031|DRUG|Clobetasol Topical|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
40943455|NCT04951440|DRUG|Nitrate ketone oxazine|Intervention group: 30min intravenous point. Drop qiu was given 1400 mg of injected sichuan nitrone I bed, and the drug was given 100 mL at day F Set 12 h, and at odds with another 7 days, that is, about 14 times in total.
40943456|NCT02126371|DRUG|LEO32731|
40943457|NCT02204007|DEVICE|3D imaging & surrogate bone model|3D imaging \& surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
40943458|NCT05113290|DRUG|Recombinant Human Adenovirus Type 5 injection|Intratumoral injection of lesions with dose of 3 vials (1.5 × 10\^12 vp) if the sum of the maximum lesion diameters was \> 10 cm, 2 vials (1.0 × 10\^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
40943459|NCT05113290|DRUG|Sorafenib|Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
40943460|NCT01865084|DRUG|Tadalafil|Administered orally
40943461|NCT01865084|DRUG|Placebo|
40943462|NCT00729924|DRUG|Raltegravir|400mg orally every 12 hours for 7 days
40943463|NCT00857428|DRUG|oxymorphone|Tablets
40943464|NCT00857428|DRUG|Oxymorphone|40 mg tablets
40943465|NCT02586051|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV infusion.
40943466|NCT02586051|DRUG|Intravenous Immunoglobulin|High dose (2 grams per kilogram \[g/kg\]) IVIG (maximum 140 grams).
40943467|NCT03503136|DRUG|docetaxel, nedaplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
40943468|NCT03503136|DRUG|nedaplatin|Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
40943469|NCT03503136|DRUG|docetaxel, cisplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
40943470|NCT03503136|DRUG|cisplatin|Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
40943471|NCT03503136|DRUG|docetaxel, cisplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
41452003|NCT00694044|DRUG|varenicline|0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
41285210|NCT02298244|PROCEDURE|PV isolation + GP Ablation|In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
40756980|NCT06475495|DRUG|Rituximab (active comparator)|anti CD20 monoclonal antibody
40943472|NCT03503136|DRUG|docetaxel, nedaplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
40943473|NCT06207838|DEVICE|MiniMed 780G system|The MiniMed™ 780G system automatically adjust insulin delivery to patient needs for an easier way to stabilise glucose levels. It features an advance level of automation for diabetes management, known as SmartGuard™ technology. If patient glucose levels are trending high, it gives patient more insulin. Technology is CE marked.
40943474|NCT04453228|OTHER|Classification statistics|We classified skiers in the two snow seasons by injury site, type of injury, cause of injury, etc
40943475|NCT05660681|DRUG|glycerin 0.7%/PEG 400 0.3%|Eye drop with active agents from the OTC Monograph.
40943476|NCT05660681|DRUG|polyethylene glycol 400 0.4%/propylene glycol 0.3%|Eye drop with active agents from the OTC Monograph.
40943477|NCT04483323|PROCEDURE|Erector Spinae Plane Block|"The patient will be placed in the lateral position. Following skin disinfection, counting down from the C7 spinous process and using ultrasound guidance, the level of T2 transverse process will be identified. A 2-5 MH2 curved array transducer (sono site Edge, Bothell, Will behington) will be positioned transversely to visualize the lateral tip of T2 transverse Process. A longitudinal parasagittal orientation will be obtained over the transverse process using a 22 - gauge 8 cm block needle (visioplex, Vygon , France) will be inserted in plane to US beam in a caudal to cranial direction to place the needle tip between the posterior fascia of the erector spinae muscle and the T2 transverse process.~Position of the needle tip in the ESP deep to the erector spinae muscle will be confirmed using hydrodissection with 0.5 - 1 ml of normal saline and visualization of the linear fluid spread deep to the erector spinae muscle following which 20 ml of 0.25% bupivacaine will be injected."
40943478|NCT04483323|PROCEDURE|Intraarticular Injection|Intraarticular injection of local anesthetic through the surgical port
40943479|NCT01406925|DRUG|Placebo control|Placebo cream
40943480|NCT01406925|DRUG|NRL001 cream|Cream for single-dose intra-anal application
40943481|NCT00974766|DRUG|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
40943482|NCT00974766|DRUG|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
41132436|NCT02132039|OTHER|Control|The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
41452004|NCT00694044|DRUG|varenicline|0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
41452005|NCT00694044|DRUG|Placebo|Placebo for 21 days
40943483|NCT00723216|DRUG|enoxaparin|20 mg twice a day
41132437|NCT03530631|DRUG|Adderall|Participants will be administered Adderall
40943484|NCT00723216|OTHER|Physical prophylaxis|
40943485|NCT06087146|OTHER|Sauerkraut (Brassica oleracea v. capitata)|The research material is a donation from the company Eko Bio Zrnje, Vrbovec, Croatia. It's grated pickle cabbage produced by fermentation in a saline solution (NaCl) in which the fermentation was stopped by pasteurization and was packed in glass 500g jars. The nutritional and microbiological composition was tested by the laboratories of the Faculty of Food and Biotechnology, as well as by the cultural laboratory approach confirmed the presence of bacteria that produce lactic acid (4.82·103 (±2.31) CFU/mL)
40943486|NCT04447755|DRUG|Lenvatinib|Lenvatinib capsules administered orally at 14 mg/m\^2 QD
40943487|NCT00814788|DRUG|Bicalutamide|50 mg oral tablet daily
40943488|NCT00814788|DRUG|Everolimus|10 mg oral capsule daily
40943489|NCT05806723|DRUG|Atorvastatin 40 Mg Oral Tablet|daily drug intake during six months
40943490|NCT04314310|DRUG|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
40943491|NCT04314310|DRUG|Placebo|equal volume of normal saline
40943492|NCT04923815|DEVICE|THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter|THERMOCOOL SMARTTOUCH® catheter is a pressure catheter irrigated with cold saline, contact force sensing catheter. When used with Carto ®3 system, this catheter can provide a real time measurement for contact force. The magnitude and direction of the contact force can be displayed visually in the form of vector arrow on the top of catheter in Carto®3 system. It can be used for electrophysiological mapping and ablation of the heart.
40943493|NCT05690646|DRUG|Nirmatrelvir/ritonavir|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days
41132438|NCT03530631|DRUG|Placebo|Participants will be administered placebo
41132439|NCT01596231|DIETARY_SUPPLEMENT|Kudzu|Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
41132440|NCT01596231|DIETARY_SUPPLEMENT|Placebo|Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
41452006|NCT03453840|DRUG|Artemether-lumefantrine|Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.
40756981|NCT01933152|DRUG|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
40756982|NCT01232582|DEVICE|Exablate treatment|MR guided Focused Ultrasound treatment
40756983|NCT00638391|DRUG|Anastrozole|
40943494|NCT05690646|DRUG|Ursodeoxycholic acid|ursodeoxycholic acid 15mg/kg/day bid for5 days
40943495|NCT06289062|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
40943496|NCT06289062|DRUG|Cisplatin|75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
40943497|NCT06289062|DRUG|Nab paclitaxel|260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
40943498|NCT06289062|PROCEDURE|biopsy|cone biopsy + pelvic lymphadenectomy or Cervical biopsy + pelvic lymphadenectomy
40943499|NCT06412575|PROCEDURE|JNT Guided OGT-overlap Oesophagojejunostomy|In the JNT group, the Joint Nasogastric Tube (JNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
40943500|NCT06412575|PROCEDURE|TNT Guided OGT-overlap Oesophagojejunostomy|In the TNT group, the Traditional Decompression Nasogastric Tube (TNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
40943501|NCT00462540|DRUG|Formoterol Fumurate inhalation solution 20 mcg|
40943502|NCT00462540|DRUG|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
40943503|NCT05093348|DEVICE|Click2Print artificial eye|Digitally designed and manufactured ocular prosthesis
40943504|NCT05093348|DEVICE|Hand-made artificial eye|Hand-made artificial eye
40943505|NCT02688712|DRUG|LY2157299|Small molecule inhibitor of transforming growth factor-beta signaling pathway
40943506|NCT02688712|DRUG|Capecitabine|Antimetabolite chemotherapy
40943507|NCT02688712|DRUG|Fluorouracil|Antimetabolite chemotherapy
40943508|NCT02688712|PROCEDURE|Tumor specific mesorectal excision|Tumor specific mesorectal excision
40943509|NCT02374515|DEVICE|EndoCuff-assisted colonoscopy|Adenoma detection rate
40943510|NCT02374515|DEVICE|Standard Colonoscopy|
40943511|NCT05323110|DRUG|CBS001|Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.
40943512|NCT05323110|DRUG|Placebo|CBS001 matched placebo
40943513|NCT03239158|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
40943514|NCT03239158|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
40943515|NCT05384275|DEVICE|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
40943516|NCT00910988|DRUG|Olanzapine|olanzapine/Zyprexa
40943517|NCT00910988|DRUG|Ziprasidone|ziprasidone/Geodon
40943518|NCT00420667|DRUG|Enoxaparin|
40943519|NCT04121988|DIAGNOSTIC_TEST|MRI|"1 mm slice thickness with deep learning based reconstruction algorithm applied to the following sequences:~* Coronal T2 weighted imaging~* Dynamic contrast enhanced T1 weighted imaging~* Coronal contrast enhanced T1 weighted imaging"
40943520|NCT00642473|DRUG|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
40943521|NCT00642473|DRUG|Metronidazole Actavis|Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
40943522|NCT00642473|OTHER|Non-active Moisturizing Cream|Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
40943523|NCT03352765|DRUG|rituximab|rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
41452007|NCT06254014|DRUG|Exendin-4 Fc fusion protein injection|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
40943524|NCT03352765|DRUG|bendamustine|bendamustine 160 mg/m2 intravenously on days -3 and -2
40943525|NCT03352765|DRUG|melphalan|melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
40943526|NCT03352765|PROCEDURE|Autologous Stem Cell Transplantation (ASCT)|reinfusion of autologous stem cells on day 0.
40943527|NCT05068024|DRUG|FWD1509 MsOH|FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.
40943528|NCT02779712|PROCEDURE|Remote ischaemic conditioning|1 dose (=4 cycles) of intermittent upper limb ischaemia (1 cycle = 5minutes inflation to 20mmHg above systolic BP, 5 minutes deflation). Dose escalation: (i) Recruits 1-20 receive this cycle once (ii) Recruits 21-40 receive a second dose of 4-cycles one hour after the first. (iii) Recruits 41-60 receive further dosing, twice daily until day 4.
40943529|NCT02779712|PROCEDURE|Sham|4 cycles of intermittent sham procedure (1 cycle = 5 minutes inflation to 30 mmHg, 5 minutes deflation), matching the dose escalation described in the intervention
40943530|NCT02360111|DRUG|Cyclophosphamide|
40943531|NCT01690026|BEHAVIORAL|Motivation interviewing based brief intervention|
40943532|NCT01690026|BEHAVIORAL|Standard Intervention|
40943533|NCT03169309|DEVICE|Brain Entrainment Technology|Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
40943534|NCT02549053|PROCEDURE|esophagus biopsies (pathologic and healthy zones)|Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
40943535|NCT02549053|PROCEDURE|esophagus biopsies (healthy zones)|Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
40943536|NCT01158703|DRUG|clopidogrel|clopidogrel 75mg daily by mouth daily for 12 months
40943537|NCT01158703|DRUG|sugar pill|sugar pill by mouth daily for 12 months
40943538|NCT01158703|DRUG|Aspirin|aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
41452008|NCT06254014|DRUG|Exendin-4 Fc fusion protein injection|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
40943539|NCT02748473|OTHER|Pilates Exercises program|"The volunteers were divided in two groups:~Group I: Pilates exercise program involving only the Pilates exercises protocol Group II: Pilates exercises program with voluntary pelvic floor muscle contraction.~The protocol of both groups consisted of 24 bi-weekly 1-h individual sessions of Pilates exercises program.~Both groups performed the same protocol . For the group PEP + PFMC the instructor asked for the maximum contraction muscle of the pelvic floor muscle, during expirations with 5 repetitions performed alternately, thus avoiding pelvic floor muscle exhaustion.~After the 24 sessions, both groups were retested with the same measured methods of the baseline."
40943540|NCT02748473|OTHER|Pelvic floor muscle strength|evaluated the pelvic floor strength by oxford scale and vaginal pressure before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
41452009|NCT06254014|DRUG|Placebo|0.6 ml, placebo injection, biweekly subcutaneous abdominal injections for 26 weeks (core treatment period), after which placebo was randomized 1:1 to JY09 (1.2 mg) and JY09 (2.4 mg) continued subcutaneous abdominal injections biweekly for 28 weeks (extended treatment period).
41452010|NCT03340623|DEVICE|Venous coupler|A coupler can be used to perform a venous anastomosis. It is a double ring with pins on only one of its 2 faces. The technique consists in clamping the two veins, estimating the intima-to-intimal diameter of the vessels, choosing the coupler of the appropriate size, sliding the vein in the ring and evers the edges of the vessel to fix them on the pins, redo the same thing for the other vein and finally bring the two vessels together in order to clip them together.
40943541|NCT02748473|OTHER|3D perineal ultrasound|evaluated the pubovisceral muscle thickness and levator hiatus area by 3D perineal ultrasound before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
40943542|NCT01015053|PROCEDURE|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
40943543|NCT01015053|PROCEDURE|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
40943544|NCT02496962|DRUG|Atorvastatin|atorvastatin were taken daily for 5 days
40943545|NCT02496962|DRUG|placebo|placebo were taken daily for 5 days
40943546|NCT02685046|DRUG|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
40756984|NCT00338611|BEHAVIORAL|Home-based Pencil Push-Up Therapy|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose
40943547|NCT02588937|DRUG|EntecaBell ODT. 0.5mg|
40943548|NCT02588937|DRUG|Baraclude Tab. 0.5mg|
40943549|NCT06010706|OTHER|Supervised physical therapy manual exercise program.|"1. Mobilization Techniques :~   The joint mobilization technique will be the anterior-posterior glide of the talus. The participant will be positioned in supine or long sitting.~2. Stretching Exercise:~   Passive stretching with therapist assistance was used for ankle dorsiflexion with the knee both flexed and extended. Force during passive stretching was modified to patient tolerance. Each participant flexed the knee slightly while standing on a 10° incline board. The participant was asked to slightly flex both knees until a stretch was felt in the calf muscle.~3. Strengthening Exercise:~The resistance training protocol will be based on the progressive resistance training principle and was a modification of the protocol used by Frontera et al \[10\] in older men. Plantar-flexion resistance training will be performed on a customized hydraulic apparatus, which provide a constant resistance over the entire ROM and allow for concentric as well as eccentric."
40943550|NCT06010706|OTHER|Stretching exercise, ROM, Strengthening exercises.|Patients at the control group will receive instruction for home based exercise program of physical therapy exercise. The home program primarily consisted of exercises targeting deficits in joint ROM, muscle flexibility and strength, and balance.
40943551|NCT04515927|DRUG|JS002|Biological: JS002 Administered by subcutaneous injection
41452011|NCT04218435|DRUG|Sacubitril / Valsartan Oral Tablet|"Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.~Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB."
40756985|NCT00338611|BEHAVIORAL|Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose combined with additional computer vision therapy
40756986|NCT00338611|BEHAVIORAL|Office-based Vision Therapy/Orthoptics|Weekly hour-long sessions of office-based vision therapy with a trained therapist and performed at-home reinforcement exercises
40756987|NCT00338611|BEHAVIORAL|Placebo Office-based Vision Therapy/Orthoptics|Vision activities designed to simulate office-based therapy
40756988|NCT01918020|BEHAVIORAL|Go Wild with Fruits and Veggies!|Fruits and Vegetables
40756989|NCT01918020|BEHAVIORAL|Go Wild with Fruits and Veggies! delayed|Go Wild with Fruits and Veggies! delayed
40943552|NCT02836275|OTHER|Diffusion/Perfusion-weighted Magnetic Resonance Imaging|
40943553|NCT03619343|PROCEDURE|ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
40943554|NCT02563990|PROCEDURE|High Pressure Injection|Adductor canal block performed at greater than 20 psi injection pressure
40943555|NCT02563990|PROCEDURE|Low Pressure Injection|Adductor canal block performed at less than 15 psi injection pressure
40943556|NCT01244945|DIETARY_SUPPLEMENT|L. reuteri DSM 17938|L. reuteri will be administered at 1x10\^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10\^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10\^8 CFU/die) for 90 days.
40943557|NCT01244945|OTHER|Placebo Group|Placebo tabs identical in form, taste and consistency to active tabs
41452012|NCT05726825|DEVICE|Therapeutic Plasma Exchange (TPE)|"The TPE treatment will be initiated within 6 hrs after randomization. Duration of TPE treatment is approximately 120-180 minutes. An additional second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min after 24 hours following the first TPE procedure.~Both unfractionated heparin (UFH) and citrate may be used as anticoagulant medication.~To ensure treatment comparability between different patients, we will replace plasma in a fixed ratio of 1.2 x the individual patient's total plasma fluid."
41452013|NCT05031260|DEVICE|applying COMORAL®|The individuals in the experimental group will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
40943558|NCT03084510|DEVICE|Lotus Edge™ Valve System|"• The Lotus Edge™ Valve System consisting of two main components:~* a bioprosthetic bovine pericardial aortic valve, and~* a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter."
41132441|NCT02718196|BEHAVIORAL|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
40756990|NCT01539525|BEHAVIORAL|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
40756991|NCT01539525|OTHER|Treatment as Usual|Subjects given a brochure listing relevant recovery resources in the local area.
40756992|NCT00498407|DRUG|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
40756993|NCT05947422|DIAGNOSTIC_TEST|High resolution CT Chest|"CT chest in our institution will be done with standard high resolution protocol . No I.V contrast will be given. Scans will be obtained during full inspiration in supine position from the thoracic inlet to the level of the diaphragm.~Patients with CT chest performed outside our institution will be reviewed in DICOM format and assessed for its compatibility to be integrated into the computer-based analysis software."
40756994|NCT05947422|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed using standard techniques according to ATS-ERS criteria 2019 . Spirometry device (Zan 300, NSPIRE HEALTH GMBH Co.) will be used. Percentage predicted values (%pred) will be calculated based on reference values for healthy adults. All patients will be required to undergo spirometry in a reproducible way, and the best values will be reported. Spirometry should meet international acceptability and repeatability standards
40756995|NCT00130559|PROCEDURE|BNP guided diagnostics and initial therapy|BNP guided diagnostics and initial therapy
40756996|NCT05293262|PROCEDURE|Endourological surgery|Includes ureteral stent insertion, ureteroscopies and retrograde intrarenal surgeies
41132442|NCT03412266|DRUG|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
41452014|NCT04892147|BEHAVIORAL|Mobility-Oriented Behavioral Activation|12-weeks of mobility-oriented behavioral activation group
40756997|NCT05023174|PROCEDURE|Hiatal Hernia Repair with Platelet Rich Plasma|Platelet rich plasma will be injected into the crura of the diaphragm and coating the mesh placed during surgery.
40756998|NCT05023174|PROCEDURE|Hiatal Hernia Repair without Platelet Rich Plasma|Surgery will be performed without the addition of platelet rich plasma injection
40756999|NCT01433861|PROCEDURE|Laparoscopy-assisted gastrectomy|Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
41132443|NCT00297349|DRUG|Topiramate|Individualization of the treatment should begin from 25 mg for 1 week.
40757000|NCT00968630|OTHER|Laboratory Biomarker Analysis|Correlative studies
40757001|NCT00968630|PROCEDURE|Leukapheresis|Undergo leukapheresis
40943559|NCT06045104|DIETARY_SUPPLEMENT|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
40943560|NCT06045104|DIETARY_SUPPLEMENT|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
41132444|NCT01925144|DRUG|Baricitinib|Administered orally
41132445|NCT01925144|DRUG|Omeprazole|Administered orally
41132446|NCT00252005|DRUG|Apixaban|
40757002|NCT01084759|DRUG|Testosterone injection|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. \> 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
40757003|NCT01084759|DRUG|Etoposide|On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
41132447|NCT01427400|DRUG|Botulinum Toxin-A|100 Units diluted in 25cc saline
41132448|NCT01427400|DRUG|Saline|Dispensed in a 25cc syringe
40943561|NCT01066000|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
40943562|NCT04425824|DRUG|Toripalimab combine with Rituximab|"Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).~Drug: Rituximab Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC)."
40943563|NCT05231681|DIETARY_SUPPLEMENT|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer|Eye Concealer
40943564|NCT01206868|PROCEDURE|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
40943565|NCT01206868|PROCEDURE|Control|Standard kidney transplantation
40943566|NCT01069627|DRUG|bevacizumab [Avastin]|15 mg/kg intravenously on day 1 of every 3 week cycle
40943567|NCT01069627|DRUG|fotemustine|100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
40943568|NCT01359007|DRUG|Irinotecan, Oxaliplatin, Leucovorin, 5-FU|5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
41132449|NCT06430424|BIOLOGICAL|Relapsed glioblastoma|Paired tumor samples diagnosis/relapse
41132450|NCT00705406|DRUG|Peramivir|600 mg peramivir administered as bilateral 2-mL intramuscular injection
41132451|NCT00705406|DRUG|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
41132452|NCT05106842|OTHER|Hydrotherapy|Aquatic therapy was performed in a swimming pool (depth 125-140 cm, temperature 28-31°C) supervised by a physiotherapist. Patients were asked to kneel or sit to submerge both shoulders to perform exercises consisting of progressive passive and active motion of the shoulder for 4-6 weeks, then strengthening exercises in a swimming pool for 2-4 months.
41132453|NCT05106842|OTHER|Land-based Therapy|Land-based therapy was performed at a rehabilitation center supervised by a physiotherapist. Patients performed progressive passive and active-assisted motion of the shoulder for 4-6 weeks, then strengthening exercises for 2-4 months.
41132454|NCT05106049|DIAGNOSTIC_TEST|serum Adiponectin|serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
41132455|NCT05997563|DRUG|Micronized progesterone|Vaginal micronized progesterone effervescent once daily until delivery
41132456|NCT06509828|BIOLOGICAL|AVB-114|AVB-114 is a mesenchymal cell substrate system comprised of autologous mesenchymal cells incubated with a 3-dimensional bioabsorbable substrate. The drug substance is expanded, pure mesenchymal stem cells (MSC) which are known to modulate local inflammation and orchestrate tissue healing. By incubating cells with a 3-dimensional bioabsorbable substrate designed for anal fistula geometry, cells are locally delivered into the fistula tract to promote healing.
41132457|NCT05900466|DRUG|Metformin|500 mg Metformin ER tablets once daily in the morning for 8 weeks
41132458|NCT05900466|DRUG|Placebo|Matching tablets once daily in the morning for 8 weeks
41132459|NCT01263132|DRUG|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
41132460|NCT01263132|DRUG|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
41132461|NCT04147637|COMBINATION_PRODUCT|FreeStyle Libre with MiaoMiao|Use of FreeStyle Libre with MiaoMiao Bluetooth adjunct and mobile device application to enable calibration and alarms
41132462|NCT04147637|DEVICE|FreeStyle Libre alone|Use of standard FreeStyle Libre with Libre Link app and mobile phone scanning
41132463|NCT05823818|DEVICE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
41452015|NCT02937935|BIOLOGICAL|Protocol Guided Renal Replacement Therapy|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph\<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
41452016|NCT02937935|BIOLOGICAL|On Demand Renal Replacement Therapy|Patients to be randomized to the intervention as per standard of care
40943569|NCT02634281|DRUG|Varenicline|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
40943570|NCT02634281|DRUG|placebo|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
40943571|NCT03868306|OTHER|CBC , Iron study and Haemoglobin electrophoresis .|The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.
40943572|NCT04020328|DRUG|Leflunomide 20 mg+prednisone 0.5mg/kg/d|Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR\<50ml/min
40943573|NCT02810340|BIOLOGICAL|Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM), and 125 μg Al3+adjuvant.
40943574|NCT02810340|BIOLOGICAL|Non-Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, and 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM).
40943575|NCT02810340|BIOLOGICAL|Menactra®|Menactra® vaccine was a clear to slightly turbid solution supplied in a 0.5 mL single dose vial. Each 0.5 mL dose of vaccine was formulated in sodium phosphate buffered isotonic sodium chloride solution to contain four mcg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 μg of diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 μg (0.000532%), by calculation.
40943576|NCT01527318|DRUG|Fibrate treatment|Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
40943577|NCT06343389|DIAGNOSTIC_TEST|serum creatinine|to detect patients with Acute kidney injury
40943578|NCT04151329|BIOLOGICAL|BAT1306 and BAT8001 2.4mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result
40943579|NCT04151329|BIOLOGICAL|BAT1306 and BAT8001 3.6mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
40943580|NCT02452697|BIOLOGICAL|NK Cell enriched-DLI only|"The first NK cell-enriched DLI will be administered one to six months post transplant. The second NK cell-enriched DLI will be administered one to three months post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.~If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started."
40943581|NCT02452697|BIOLOGICAL|NK-DLI + DUK-CPG-001|"DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.~On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI."
40943582|NCT03327597|OTHER|Clinical follow-up 1|Participants receive routine care outside the bounds of the trial. No further work-up.
40943583|NCT03327597|OTHER|Mental Health and Quality of Life questionnaire|Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
40943584|NCT03327597|OTHER|Standard follow-up or treatment.|Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
41452017|NCT01558635|DEVICE|Cardioblate CryoFlex Surgical Ablation|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure During mitral valve surgery a surgical ablation was performed, using the Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.
41452018|NCT01558635|PROCEDURE|Mitral Valve surgery|Classic mitral valve surgery was performed
40757004|NCT01657331|DRUG|Brentuximab Vedotin|Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
40757005|NCT01657331|DRUG|Bendamustine|Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
40757006|NCT01657331|DRUG|Neulasta|(Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
40943585|NCT03327597|OTHER|Clinical follow-up 2|Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
40943586|NCT03327597|OTHER|Clinical follow-up 3|Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
40943587|NCT03327597|OTHER|Clinical follow-up control|Control clinical visit
40943588|NCT04706910|DRUG|18F-DOPA|All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study
40943589|NCT04706910|DRUG|Furosemide Injection|Some participants will receive an intravenous injection of furosemide (40mg, single dose)
40943590|NCT02857361|DRUG|Sublingual ketamine wafers|Two sublingual ketamine 25 mg wafers
40943591|NCT03366779|DEVICE|6mm annular closure device|6MM Barricaid annular closure device implantation following standard lumbar discectomy
40943592|NCT00589290|DRUG|Belinostat (PDX101)|1000 mg/m\^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
41452019|NCT01558635|DEVICE|Medtronic Reveal XT Insertable Cardiac Monitor|During the procedure, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor episodes of AF during follow-up period
40943593|NCT06433401|BEHAVIORAL|Transitional care training with brochures, posters and slide training materials|Education at 3 and 6 months after the first interview
40943594|NCT05229978|OTHER|Showing an existing Dynamic Consent (computer interface) as prompt|An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.
40943595|NCT03060733|OTHER|Post-Therapy|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
40943596|NCT00892242|DRUG|Zoledronic acid|
40757007|NCT03355092|DEVICE|vBloc Therapy|The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
40943597|NCT05914922|OTHER|Educational Tool|20 MSK short case simulations were developed based on authentic patient experiences. Strategies to optimize learning of MSK conditions to prepare learners for real-world clinical encounters would be important for family medicine resident learners. To address this need, 20 case simulations of 15 minute duration were developed. This study will determine if an online educational tool may be impactful for determining competency of family medicine resident learners in developing skills and knowledge of 20 MSK conditions while also determining if the tool impacts patient care and satisfaction.
40943598|NCT05025254|OTHER|Neurocognitive testing|"We are assessing several cognitive domains and have made minor adaptations (reducing the total number of trials or lengthening response windows) to several standard neuropsychology tests including measures of executive function, working memory, visuospatial function, declarative memory, reward processing, response inhibition.~Overall, the tests we use follow a standard set-up: participants are shown stimuli on the screen and are asked to provide a response using either a keyboard or a mouse, based on a specific set of instructions. We always provide a detailed set of on-screen instructions and a practice phase. In some cases, information about performance is provided in the form of points, in other cases, none is provided."
40943599|NCT04865640|DIAGNOSTIC_TEST|Noninterventional and noninvasive|The ADI At-Home CPM (Cardiopulmonary Management) System is intended for adults undergoing monitoring for cardiopulmonary conditions under the direction of a licensed medical professional to measure, record, and periodically transmit physiological data.
40943600|NCT06488547|OTHER|Diaphragmatic breathing (DF)|Diaphragmatic breathing (DF), also known as belly or abdominal breathing, is a technique that can teach people how to use their diaphragm correctly while breathing, in order to activate the parasympathetic branch of the autonomic nervous system and to control stress.
40943601|NCT06488547|OTHER|Progressive Muscle Relaxation (PMR)|"Progressive Muscle Relaxation (PMR) is a technique that is helpful in the reduction of stress.~PMR by alternately tensing and relaxing different muscle groups in the body helps participants to become more aware of physical sensations and can be particularly helpful to muscle tension and relaxation."
40943602|NCT06081400|PROCEDURE|Cryoablation|Percutaneous imaging-guided cryoablation
40943603|NCT06081400|DRUG|Chemotherapy drug|"Either :~methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months."
40943604|NCT04899427|DRUG|orelabrutinib|Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
40943605|NCT04899427|DRUG|Sintilimab|Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
40943606|NCT04899427|DRUG|Tislelizumab|Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
40943607|NCT03694912|PROCEDURE|Partial or radical nephrectomy|The investigators perform partial or radical nephrectomy those diagnosed as RCC.
41132464|NCT06017700|BEHAVIORAL|Interpersonal Psychotherapy Group|IPT is a psychological intervention that focuses on four common problems that trigger depression: grief, disputes, role transitions and social isolation. Using techniques and strategies such as linking mood to event and event to mood, role play and skill-building, IPT encourages the individual to analyse and improve their interpersonal relationships context. IPT was developed in the USA to treat depressed adults but it has also been used to treat other mental disorders and among different age groups.
41132465|NCT06017700|BEHAVIORAL|Enhanced Usual Care|Participants attending schools in the control arm will receive enhanced usual care. In intervention and control arms, we will train health workers in health posts and primary care centres using the WHO mental health GAP Action training package (mhGAP). Participants in the control clusters will receive a handout with information about the location of these trained health workers and how they can access treatment. Adolescents in the control cluster reporting a current suicide plan (i.e. in the past 2 weeks) or suicide attempt in the past three months will be assessed by a psychosocial counsellor employed through the project and offered counselling or referral to other services as per need.
41132466|NCT04495426|OTHER|Non-interventional study|There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.
41132467|NCT01536366|DRUG|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
41132468|NCT01536366|DRUG|Repaglinide|0.5 mg repaglinide (single-dose)
41132469|NCT01486459|DRUG|Lithium|250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
41452020|NCT01558635|PROCEDURE|MAZE III|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure
41452021|NCT05804786|DEVICE|Guided bronchoscopy|It is performed when a pulmonary lesion with a possibility of malignancy is found on chest CT and histological diagnosis and differentiation are required.
40943608|NCT04550910|RADIATION|Hypofractionation Schedules for Breast Cancer patients after mastecomy|Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.
40943609|NCT00985816|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
40943610|NCT00985816|DIETARY_SUPPLEMENT|Placebo|Placebo
40943611|NCT00458068|DRUG|Oral administration of ferrous sulphate|
40943612|NCT02121990|DRUG|Paclitaxel,|
40943613|NCT02121990|DRUG|Bevacizumab|
40943614|NCT02121990|DRUG|Cisplatin|
40943615|NCT02121990|DRUG|Olaparib|
40943616|NCT02147028|RADIATION|Hippocampal sparing whole brain radiotherapy|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
40943617|NCT02147028|RADIATION|Conventional whole brain radiotherapy|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
40943618|NCT04722549|DIETARY_SUPPLEMENT|Placebo|Cellulose
40943619|NCT04722549|DIETARY_SUPPLEMENT|Butyrate|Sodium butyrate
40943620|NCT01927341|DRUG|MEK162|Tablet for oral use, 45 mg (three 15 mg tablets), BID
40943621|NCT01927341|DRUG|Panitumumab|Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
40943622|NCT01977651|DRUG|Enzalutamide|Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.
40943623|NCT04152031|OTHER|Prompting|Participants receive medication reminders on a smartphone. The reminders are generated through machine learning algorithms that automate the process of medication prompting according to successful medication contexts that occurred in the past.
40943624|NCT00054717|DRUG|Tipranavir|
41452022|NCT02600247|DRUG|Duloxetine|"Experimental: Duloxetine group~1. Phase I (preemptive): 1day before operation (30mg for 1 day)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon~Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
40757008|NCT04081012|DRUG|N-acetyl cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.
40943625|NCT00054717|DRUG|Ritonavir(r)|
40943626|NCT00054717|DRUG|Comparator Protease Inhibitor (CPI)|
40943627|NCT00562029|PROCEDURE|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
40943628|NCT00753428|OTHER|Community-based Survey|"Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults."
40943629|NCT04933903|DRUG|Ipilimumab|1mg/kg IV on day 1 (1 dose total)
40943630|NCT04933903|DRUG|Nivolumab|3mg/kg (to a maximum of 240mg) IV on days 1, 15, 29 (+/- 3 days) (3 doses total)
40943631|NCT04933903|RADIATION|SBRT|1 fraction or 2 fractions delivered to the gross primary tumor and nodal disease, following the first treatment with ipilimumab + nivolumab on days 1-3.
40943632|NCT06175975|OTHER|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
40943633|NCT03754673|DEVICE|MRI|MRI pulmonary with no contrast administration
40943634|NCT05702866|DIAGNOSTIC_TEST|Transcutaneous oximetry|Comparison of the TcpO2 values recorded during dynamic maneuver with the estimated rate of compression of the subclavian and axillary vessels determined on dynamic angiography.
40943635|NCT03552458|DRUG|Lactobacillus Reuteri Oral Solution [BioGaia]|BioGaia Lactobacillus Reuteri drops
40943636|NCT03552458|DRUG|Placebos|Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
40943637|NCT00752024|DEVICE|YL-1 type of intracranial hematoma puncture needle|"YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
40943638|NCT00752024|DRUG|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
40943639|NCT03935412|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block
40943640|NCT02407418|OTHER|Spinal Manipulation|Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
40943641|NCT02407418|OTHER|Sham Manipulation|A simulated lumbar spine manipulation in which no vertebral contact was made
40943642|NCT02745210|DIAGNOSTIC_TEST|13C magnetic resonance spectroscopy|acquisition of 13C MR spectroscopy in the brain
40943643|NCT05468385|DEVICE|Vagus nerve stimulation via tragus|The device will send stimulus intensity of around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
40943644|NCT05468385|DEVICE|Sham stimulation via earlobe|The device will send stimulus intensity of around 0.5mA via the earlobe in the left ear (based on participants' subjective reports), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
40943645|NCT01845883|PROCEDURE|Deep Brain Stimulation (DBS)|Patients with DBS will participate to the study both when the stimulation is off and on.
40943646|NCT05005754|DIETARY_SUPPLEMENT|Probiotics|During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
40943647|NCT05005754|DIETARY_SUPPLEMENT|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
40943648|NCT00760214|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
40943649|NCT00760214|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
40943650|NCT00760214|DRUG|Ramipril|Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
40943651|NCT02981810|DEVICE|Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55*|The treatment was conducted using an Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55\* for tonsillar tissue ablation at low temperatures with only one treatment. All the patients underwent tonsil channeling treatment with coblation, and 4-6 channels were done in each tonsil under local anesthesia, in the operating room. The patients were observed overnight.
40943652|NCT02981810|PROCEDURE|tonsillectomy|
40943653|NCT00890266|PROCEDURE|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
40943654|NCT05832021|PROCEDURE|Open reduction and internal fixation (under WALANT)|Open reduction and internal fixation with volar Henry approach under WALANT.
40943655|NCT05832021|PROCEDURE|Open reduction and internal fixation (under peripheral nerve block)|Open reduction and internal fixation with volar Henry approach under peripheral nerve block.
40943656|NCT05804474|OTHER|Observational study|Observational study
41132470|NCT04226456|DRUG|N-acetyl cysteine|Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears
41132471|NCT02911961|DRUG|Acetaminophen|1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
41132472|NCT04929600|DRUG|sacubitril/valsartan|Sacubitril/valsartan oral tablets (200mg) one pill a day + matching placebo of amlodipine one pill a day.
41132473|NCT04929600|DRUG|Amlodipine|Amlodipine oral tablets (5mg) one pill a day + matching placebo of sacubitril/valsartan one pill a day.
40757009|NCT04081012|DRUG|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
41132474|NCT02161354|DRUG|NTC-510 capsules|Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
41132475|NCT02161354|DRUG|Placebo Capsules|Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
41132476|NCT02161354|DRUG|NTC-510A Capsules|Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
40757010|NCT04130971|OTHER|No intervention, just observation|No intervention, just observation of the differences between groups and within patients.
40757011|NCT03607786|PROCEDURE|Retrograde Inferior Vena Caval Perfusion|Retrograde Inferior Vena Caval Perfusion is achieved by tethering the inferior vena cava with a band around the cannula and by clamping the distal end of the inferior vena cava drainage tube, which allowed a pump to drive oxygenated blood into the inferior vena cava. Pump pressure is maintained at 20-30 mmHg, and blood flow is maintained at 8-12 mL/min/kg. The aim of RIVP is to maintain the lower body perfusion during circulation arrest, and reduce the ischemia-associated vital organ injury.
40757012|NCT03607786|PROCEDURE|Select antegrade cerebral perfusion|Antegrade cerebral perfusion is achieved using a 12 F cannula inserted into the brachiocephalic artery or right axillary artery. The antegrade perfusion flow rate is maintained at 6-12 mL/min/kg
40943657|NCT05443360|DIETARY_SUPPLEMENT|DENSITY™ (Amorphous calcium carbonate, ACC)|"1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg amorphous calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 ACC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
40943658|NCT05443360|DIETARY_SUPPLEMENT|Crystalized calcium carbonate (CCC)|"1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg crystalized calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 CCC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
40943659|NCT00053365|DRUG|irofulven|Given IV
40943660|NCT05220917|DRUG|SGLT2 inhibitor|Any SGLT2i dispensing claim
40943661|NCT05220917|DRUG|DPP-4 inhibitor|Any DPP-4 inhibitor claim
40943662|NCT05220917|DRUG|GLP-1RA|Any SGLT2i dispensing claim
40943663|NCT05220917|DRUG|2nd generation SU|Any 2nd generation SU claim
41132477|NCT05566444|DEVICE|Heat stimulus|Contact heat pain stimulus with a termode set at 46 degrees and contact warm stimulus with a termode set at 40 degrees
40943664|NCT05346393|PROCEDURE|TIPS|A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver
40943665|NCT05346393|DRUG|Standard of Care|Terlipressin/Albumin treatment is the preferred standard of care treatment. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.
40943666|NCT01796756|OTHER|Handover program|
40943667|NCT05917769|OTHER|Rocabdo exercises|"The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day.~It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction. This group will only perform Rocabdo exercises."
40943668|NCT05917769|OTHER|Postural correction exercises|"* Posture correction exercises will be performed six times a day for six days.~* Patient will be assessed on the first day and then on the last day of the treatment, i.e., on 6th day the patient will be re-assessed after they have performed posture correction exercises.~* Posture correction exercises consist of chin tuck in, chest stretch, wall stretch, on your Back chest stretch and face down arm lifts."
40943669|NCT06136247|DIAGNOSTIC_TEST|Neurocognitive battery|The Penn Computerized Neurobehavioral Battery (CNB) consists of a series of cognitive tasks, measuring accuracy and speed of performance in major cognitive domains, including executive functions (i.e., abstraction, sustained attention, working memory), episodic memory (i.e., verbal, facial, and spatial memory), complex cognitive processing (i.e., language reasoning, nonverbal reasoning, spatial processing), social cognition (i.e., emotion identification, emotion intensity differentiation, age differentiation) and processing speed (i.e., sensorimotor and motor).
40943670|NCT06136247|DIAGNOSTIC_TEST|fNIRS|Functional near-infrared spectroscopy (fNIRS) is a noninvasive optical imaging technique that measures changes in oxygenated and deoxygenated hemoglobin (Hb) concentrations within the brain by means of their characteristic absorption spectra of the wavelengths range of 700-1000 nm \[35,36\].
40943671|NCT01933711|DRUG|rituximab|
40943672|NCT04482712|DRUG|Rapamycin|Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized
40943673|NCT04482712|DRUG|Placebo|Administration of investigational drug placebo for up to 4 weeks while hospitalized
40943674|NCT02789878|DRUG|Goserelin|Androgen Deprivation Therapy
40943675|NCT02789878|DRUG|Prednisone|Corticosteroid
40943676|NCT02789878|DRUG|Abiraterone|CYP17 inhibitor
40943677|NCT02789878|DRUG|Apalutamide|Androgen-receptor antagonist
40943678|NCT04081233|PROCEDURE|surgical stabilization|Surgical procedure utilizing any commercially available internal rib fixation system
40943679|NCT04081233|PROCEDURE|Usual care|Usual care typically consists of breathing exercises and pain control,often including opioids
40943680|NCT01776047|DRUG|Exforge®|
40943681|NCT01776047|DRUG|G-0081|
40943682|NCT06413212|DIAGNOSTIC_TEST|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.|Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.
40943683|NCT02372240|DRUG|VLX1570 and dexamethasone|
40943684|NCT02694523|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
40943685|NCT02694523|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
40757013|NCT02430714|DRUG|Lenvatinib|24mg once daily oral dosing to Unresectable thyroid cancer patients
40943686|NCT02694523|DRUG|placebo for risankizumab|Placebo risankizumab administered by subcutaneous (SC) injection
40943687|NCT02694523|BIOLOGICAL|placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
40943688|NCT01413477|DRUG|Calcipotriol, Betamethasone, Calcipotriol & Betamethasone|All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
40943689|NCT02156531|BEHAVIORAL|Self-Administered, Active Cognitive Bias Modification (CBM)|Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
40943690|NCT02156531|BEHAVIORAL|Self-Administered, minimally effective attention-control version of the CBM program|Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
40943691|NCT04926623|DEVICE|FreeStyle Libre 24 weeks|FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)
40943692|NCT04926623|OTHER|SMBG (22 weeks) and blind CGM (2 weeks)|Self-Monitoring of Blood Glucose and Continuous Glucose Monitoring
41285211|NCT02298244|PROCEDURE|PV isolation + GP ablation + Pulmonary GP ablation|"The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.~8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min."
40943693|NCT03141073|DRUG|HMS5552|BID oral administration
40943694|NCT03141073|DRUG|Placebo|BID oral administration
40943695|NCT00815399|DRUG|Pioglitazone|15-45 mg/die
40943696|NCT00815399|DRUG|Metformin|500-2000 mg/die
40943697|NCT00406094|DRUG|montelukast|10mg
40943698|NCT00406094|DRUG|placebo|placebo
40943699|NCT02547948|BIOLOGICAL|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
40943700|NCT02027376|DRUG|LDE225|
40943701|NCT02027376|DRUG|Docetaxel|
40943702|NCT06281288|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive behavioral therapy
40943703|NCT06281288|OTHER|Exercise Training|Moderate intensity (\~63% maximum heart rate; HRmax) aerobic (\~25 min) and resistance (\~25 min) activities
40943704|NCT04537455|DIAGNOSTIC_TEST|Ultra-high frequency electrocardiography|Patients will have an ultra-high frequency electrocardiography performed.
40757014|NCT00771147|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
40757015|NCT04540900|BIOLOGICAL|KB301|non-integrating HSV-1 vector expressing human type III collagen
40757016|NCT04540900|OTHER|Placebo|sterile isotonic saline
40757017|NCT06425731|OTHER|Fasting|Participants (Dance for PD, in-person only) will engage in one of their routine weekly dance sessions while a portable indirect calorimeter is used for energy expenditure analysis. Before this session, participants will be asked to fast for at least 4-hours. In this way, participants in this study arm will engage in a self-controlled study design wherein they complete a 4-hour fast before engaging in an oxygen uptake assessment during their routine dance classes. During the 4-hour fasting period, participants will be asked to refrain from eating any food and drinking any beverages except for water.
40757018|NCT06425731|OTHER|No Intervention|No Intervention
40757019|NCT04331951|DIAGNOSTIC_TEST|Targeted biopsy within Sydney protocol|Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.
40757020|NCT05389371|BEHAVIORAL|Alberta Healthy Living Program|Weight management services
40757021|NCT05389371|BEHAVIORAL|Alberta Obesity Centre Program|Multi-disciplinary obesity management
40943705|NCT03049618|OTHER|Laboratory Biomarker Analysis|Correlative studies
40943706|NCT03049618|BIOLOGICAL|Pembrolizumab|Given IV
40943707|NCT03049618|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
40943708|NCT02910869|GENETIC|Pathway Genomics FIT test|
40943709|NCT02604056|BEHAVIORAL|Audit + Feedback|Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
40943710|NCT02604056|BEHAVIORAL|Audit + Feedback + Educational Outreach|"The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia. The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home."
40943711|NCT01289457|DRUG|Clofarabine|"Phase I: 15 mg/m2 by vein (IV) daily for 5 days of a 28 day cycle.~Phase II: Clofarabine (dose selected based on Phase I portion) by vein over approximately 1 hour daily for 5 days (days 1-5) for a 28 day cycle."
40943712|NCT01289457|DRUG|Idarubicin|10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.
40943713|NCT01289457|DRUG|Cytarabine|1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
40943714|NCT01289457|DRUG|Fludarabine|30 mg/m2 by vein over approximately 30 minutes daily for 5 days (days 1-5).
40943715|NCT05049369|DEVICE|Polysomnography|Polysomnography is performed one time overnight
40943716|NCT01798680|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
40943717|NCT01798680|OTHER|Placebo|Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
40943718|NCT00136071|DEVICE|Transobturator tape-ARIS|
40943719|NCT00136071|DEVICE|TVT-O|
40943720|NCT06198127|OTHER|combination of core stability exercises and kinesio-taping|the patient in the experimental group will receive the core stability exercises with kinesiology taping on trunk stabilizer muscles. the time of intervention was 30 minutes per day. The exercises such as Abdominal draw-in with a double knee to chest, Trunk twist while sitting on a medicine ball, Lying in a supine position on bed and rotating the trunk from side-to-side, Bridging exercises, the I-shaped elastic KT will apply to the four trunk muscles from their insertion to their origin: Kinesio-taping is used on global muscles such as Rectus abdominis, External obliques, Erector spinae, Quadratus lumborum. Kinesio-taping will 1 inch wide and apply on muscles for 1 to 2 days then remove for 24 hours then again apply a new one. The tension will be 10 to 15% and tape will apply on muscles which will be stretched by maintaining a posture.
40943721|NCT06198127|OTHER|Core stability exercises|After the baseline assessment, the patient in the control group will receive the core stability exercises with kinesio-taping on trunk stabilizer muscles. Time of rehabilitation will be 30 minutes per subject and four days per week. In first few minutes, the subject will be explained her/his task Subject will execute the exercises such as Abdominal draw-in with a double knee to chest 10- 15 times. Trunk twist while sitting on a medicine ball 10- 15 times. Lying in a supine position on bed and rotating the trunk from side-to-side 10- 15 times. Lying in a supine position on a mat and pulling upper and lower limbs upward 10- 15 times. Bridging exercises 10- 15 times, Deep Breathing and Wheelbarrow.
40943722|NCT04543409|BIOLOGICAL|Benralizumab|Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
40943723|NCT04543409|BIOLOGICAL|Matching placebo|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
40943724|NCT06551688|DIAGNOSTIC_TEST|Serum 25(OH)D level|The characteristics of 25 (OH) D3 are relatively longer half-life than 1.25 (OH)2 D3, stability, strong detection repeatability, and no biological activity. Generally, systemic levels of the more stable 25 (OH) D3 are considered to be the best index to reflect status of vitamin D in the individual patient
40943725|NCT03377114|PROCEDURE|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
40943726|NCT03377114|PROCEDURE|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
40943727|NCT05342402|OTHER|Somatosensory Rehabilitation Program|Somatosensory rehabilitation program includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
40943728|NCT05342402|OTHER|Educational Pain Management Program|Educational Pain Management Program includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
40943729|NCT04754243|DRUG|Gonadotropin|Giving patients gonadotropins and antagonist cetrotide
40943730|NCT04754243|DRUG|Standard protocol in IUI|Giving patients gonadotropins without antagonist cetrotide
40943731|NCT00009061|DRUG|Ritonavir|
40943732|NCT00009061|DRUG|Abacavir sulfate|
40943733|NCT00009061|DRUG|Nelfinavir mesylate|
40943734|NCT00009061|DRUG|Lamivudine|
40943735|NCT00009061|DRUG|GW433908|
40943736|NCT05199740|OTHER|in vitro analysis|in vitro analysis of mesoangioblasts from mtDNA mutation carriers
40943737|NCT03960931|OTHER|Aquatic rehabilitation|Rehabilitation sessions using hydrophysiotherapy will occur in a pool of Grand Nancy Thermal, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
41285212|NCT05087186|BEHAVIORAL|Guided imagery and FLASH technique|"Five virtual group sessions delivered by psychological therapists;~* Sessions 1 and 2: Guided imagery~* Sessions 3 and 4: FLASH technique~* Session 5: Refresher on guided imagery and FLASH technique"
40757022|NCT05389371|BEHAVIORAL|Osteoarthritis advice|Living Your Best Life with Osteoarthritis Handbook
40943738|NCT03960931|OTHER|Land based physical activities|Rehabilitation sessions on treadmill will occur at Physical Medicine and Rehabilitation Regional Institute (IRR), on the University Hospital's site, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking, where intensity of effort can be modulated by speed and inclination of treadmill. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
40757023|NCT05389371|BEHAVIORAL|Physiotherapy|GLA:D physiotherapy programs.
41285213|NCT03758937|PROCEDURE|volume-controlled ventilation|
40943739|NCT03960931|OTHER|Conventional rehabilitation|Conventional rehabilitation sessions will occur in private practices in which patients receive their habitual care (same physiotherapist). This care will be guided by prescription delivered by the neurologist. This prescription suggests to work on active and passive upper and lower limb stretching, on hip and shoulder dissociation, and balance control management on unstable ground.
40943740|NCT03239964|DRUG|Dexamethasone|the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
40943741|NCT03239964|OTHER|surgical excision|total extralesional surgical excision of the keloid is performed and minimal undermining
40943742|NCT00597974|PROCEDURE|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
40943743|NCT00597974|DEVICE|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson \& Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson \& Johnson), Wallstent® (Boston Scientific Medi-Tech)
40943744|NCT00597974|OTHER|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
40943745|NCT00597974|PROCEDURE|Angiography|(non-experimental) Coronary angiography
40943746|NCT00543491|DRUG|MK0767|
40757024|NCT02489045|DRUG|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
40757025|NCT00005898|DRUG|anti-thymocyte globulin|
40757026|NCT00005898|DRUG|cyclophosphamide|
41285214|NCT03758937|PROCEDURE|pressure-controlled ventilation|
40757027|NCT00005898|DRUG|cyclosporine|
40757028|NCT00005898|DRUG|filgrastim|
40757029|NCT00005898|DRUG|fludarabine|
40757030|NCT00005898|DRUG|methylprednisolone|
40757031|NCT01821846|DRUG|liraglutide|Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
40757032|NCT05420337|PROCEDURE|Group ıntramuscular|Group I will be applied 20 ml of % 0.25 bupivacain internal oblique and transversus abdominis muscle and 0.1 mg/kg morphine ıntramuscular. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
40757033|NCT05420337|PROCEDURE|Group TAP|Group T will be applied 20 ml of % 0.25 bupivacain and 0.1 mg/kg morphine internal oblique and transversus abdominis muscle. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
40757034|NCT03743142|PROCEDURE|endovascular repair of the AAA|The Investigator will ensure that investigational devices are used only in subjects properly enrolled in the clinical study in accordance with the protocol. Subjects will undergo endovascular repair of their AAA. Procedural details may vary between sites, but will follow standard hospital protocol for EVAR and patient care management.
40757035|NCT03859856|OTHER|hormone panel and ultrasonography|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH, LH, E2 and AMH hormone levels and ultrasonography for antral follicle count and ovarian volume measurement will be done.
40757036|NCT03788044|OTHER|Education|Education + Medication adherence monitoring + Feedback when low adherence
40943747|NCT03432156|BIOLOGICAL|Autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells in peripheral blood and then given back to the patient after amplified in vitro.
40943748|NCT02449720|DRUG|Ropivacaine|Intraperitoneal instillation and infusion
40943749|NCT02449720|DRUG|0.9% Saline|Intraperitoneal instillation and infusion
40943750|NCT04792515|DRUG|Camrelizumab combined with SOX/ or apatinib|"Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing."
40943751|NCT05873673|DRUG|Coenzyme Q10|cystic jaw defect filled with coenzyme Q10 gel
40943752|NCT05873673|DRUG|control group|cystic jaw defect filled with placebo gel
40943753|NCT00815243|PROCEDURE|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
40943754|NCT00815243|PROCEDURE|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
40943755|NCT02594332|DRUG|Mepolizumab|100 mg SC every 4 weeks for 13 injections
40943756|NCT02594332|DRUG|Placebo|
40943757|NCT00725504|DRUG|Intravenous lidocaine|Intravenous lidocaine administered up to 5 µg/ml.
40943758|NCT02653534|BEHAVIORAL|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
41285215|NCT02646436|OTHER|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
41132478|NCT05503368|PROCEDURE|surgical treatment of vitiligo using NCES|NCES is the standard technique for surgical treatment of vitiligo, herein we compare the standard technique, to added autologous cellular micro-grafts and to follicle cell suspension
40943760|NCT01485393|DRUG|Dexmedetomidine|A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).
41452023|NCT02600247|DRUG|celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
40757037|NCT03702595|OTHER|Hip flexors stretching protocol|Stretching protocol of rectus femoris, vastus lateralis and iliopsoas according to Kaltenborn- Evjenth Orthopaedic Manual Therapy Concept (OMT)
40943761|NCT01485393|DRUG|Zolpidem|12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
40943762|NCT00715923|OTHER|Modified consent form|modified consent form used
40943763|NCT00715923|OTHER|Standard consent form|standard consent form used
40943764|NCT05573828|PROCEDURE|ICG angiography to show vascular map of parathyroid glands|Using ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then perform the thyroidectomy. After it, ICG angiography is done to predict immediate parathyroid functio
40943765|NCT02897765|BIOLOGICAL|NEO-PV-01|Personal cancer vaccine
40943766|NCT02897765|BIOLOGICAL|Nivolumab|monoclonal antibody against PD1
40943767|NCT02897765|OTHER|Adjuvant|immune adjuvant
40943768|NCT05554575|BIOLOGICAL|BT-007 CD7 CAR-T cells|T cells purified from the peripheral blood mononuclear cell (PBMC) of subjects or subjects' relatives which depend on their conditions, transduced with 4-1BB/CD3ζ lentiviral vector, expanded in vitro for future administration.
40943769|NCT00199069|DRUG|Asparaginase|
40943770|NCT00199069|DRUG|Vincristine|
40943771|NCT00199069|DRUG|Daunorubicin, Adriamycin|
40943772|NCT00199069|DRUG|Cyclophosphamide|
40943773|NCT00199069|DRUG|Ifosfamide|
40943774|NCT00199069|DRUG|Cytarabine|
40943775|NCT00199069|DRUG|Mitoxantrone|
40943776|NCT00199069|DRUG|Methotrexate|
40943777|NCT00199069|DRUG|6-Mercaptopurine|
40943778|NCT00199069|DRUG|6-Thioguanine|
40943779|NCT00199069|DRUG|VM26|
40943780|NCT00199069|DRUG|Dexamethasone / Prednisolone|
40943781|NCT00199069|PROCEDURE|CNS Irradiation|
40943782|NCT00199069|PROCEDURE|Mediastinal Irradiation|
40943783|NCT00199069|PROCEDURE|Stem Cell Transplantation|
40943784|NCT02199860|DRUG|SD I|
40943785|NCT02199860|DRUG|SD II|
40943786|NCT02199860|DRUG|Placebo|
40943787|NCT00562627|DRUG|ropivacaine|intraoperative and 1. postoperative day
40943788|NCT00562627|DRUG|adrenaline|intraoperative LIA (IV and IA) and continuous EDA
40943789|NCT00562627|DRUG|ketorolac|intraoperative and 1. postoperative day
40943790|NCT00562627|DRUG|morphine|intraoperative
41132479|NCT02089295|DRUG|Oxycodone|One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
40943791|NCT00562627|DRUG|fentanyl|continuous postoperatively
40943792|NCT00562627|DRUG|bupivacaine|continuous postoperatively
40943793|NCT01837732|OTHER|Relational Touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
40943794|NCT01837732|OTHER|Relational:|Relational: 10 mn verbal patient's centered exchanges
40943795|NCT00543738|DRUG|MK0767|
41132480|NCT02089295|DRUG|Oxycodone|One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
41285216|NCT02646436|OTHER|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
40943796|NCT01889524|OTHER|Mesh nebulizer|VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
40943797|NCT01889524|OTHER|Jet nebulizer|"The JN (Misty Max, Air Life, Yorba Linda, USA) with a particle MMAD of 5 µm (according to the manufacturer information) was positioned in the circuit using a T piece placed between the circuit leak and the mask, and operated with oxygen flow at 8 L/min. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL."
40943798|NCT01889524|OTHER|Noninvasive ventilation-NIV|Bilevel positive airway pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted to12 cmH2O peak inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure. Patients were adapted to use NIV before starting measurements, pressures were titrated before reaching the established levels and just after this period masks were fitted using the straps. They were oriented to use a breathing pattern inspiring deeply and exhaling slowing to avoid ventilator-patient asynchrony.
40943799|NCT05019794|DRUG|Infigratinib|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
40943800|NCT03387150|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in
40943801|NCT03387150|BIOLOGICAL|Placebo|Sodium Chloride for Injection USP, 0.9%; administered by IM injection
40943802|NCT01251744|PROCEDURE|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
40943803|NCT01251744|PROCEDURE|Cord blood sample|Cord blood sample taken at the time of delivery.
40943804|NCT01251744|PROCEDURE|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
40943805|NCT01251744|PROCEDURE|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
40943806|NCT01251744|PROCEDURE|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
40943807|NCT01035580|DRUG|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
40943808|NCT01035580|DRUG|curcumin|all patients received the drug
40943809|NCT00348179|PROCEDURE|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
40943810|NCT02484690|DRUG|Faricimab|Faricimab will be administered as per the regimen specified in the individual arm.
40943811|NCT02484690|DRUG|Ranibizumab|Ranibizumab will be administered as per the regimen specified in the individual arm.
41132481|NCT02089295|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
41132482|NCT00083590|DRUG|Huperzine A|
40757038|NCT01778621|DEVICE|Acupuncture(Hwato®)|acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
40757039|NCT03408808|PROCEDURE|Platelet rich plasma|Aspiration of ganglion and injection with platelet rich plasma.
40757040|NCT03408808|PROCEDURE|Aspiration alone|Aspiration of the ganglion
40943812|NCT02484690|DRUG|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
40943813|NCT02649114|BEHAVIORAL|Cognitive-Behavioural Therapy|
40943814|NCT02649114|BEHAVIORAL|Compassion-Focused Therapy|
40943815|NCT05843162|DRUG|Telmisartan|Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Telmisartan 80 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
40943816|NCT05843162|DRUG|Losartan|Subjects assigned to the control group are oral administered Losartan 50 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Losartan 100 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
41132483|NCT03438409|OTHER|Robotic gait training|Robotic gait training
41132484|NCT01782105|BEHAVIORAL|Healthy lifestyle counseling|Nutritionnal and physical activity counseling and physical activity session group
41132485|NCT01782105|BEHAVIORAL|Control group|Evaluation of nutritional and physcial activity habits
41132486|NCT03524131|OTHER|risk-framed leaflet|2-sided leaflet, emphasizing health risks of not going to the NHS Health Check
41132487|NCT03524131|OTHER|benefits-framed leaflet|2-sided leaflet, emphasizing benefits of attending an NHS Health Check
41132488|NCT03524131|OTHER|current national leaflet|4-sided leaflet
40943817|NCT03005938|PROCEDURE|Spinal manipulation|"Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.~SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position."
40943818|NCT03005938|PROCEDURE|Imitation of the spinal manipulation|Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
40943819|NCT03654066|DRUG|Botulinum toxin type A|Botox injection in the LES
40943820|NCT03654066|DEVICE|Endoscope balloon dilator|Distal esophageal dilation
40943821|NCT03654066|OTHER|Patient reported outcomes|Subjects will complete two patient reported outcome measures (Eckardt and MADS).
40943822|NCT03654066|DIAGNOSTIC_TEST|Barium esophagram|Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium
40943823|NCT03420417|DEVICE|Esophageal pressure measurement|Use of a nasogastric tube equipped with esophageal balloon to assess respiratory mechanics
40943824|NCT00145704|DRUG|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
40943825|NCT00145704|DIETARY_SUPPLEMENT|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
40943826|NCT00145704|DIETARY_SUPPLEMENT|Calcium|calcium supplement given to patients with growth hormone deficiency
40943827|NCT05105022|DRUG|Propofol|Intravenous induction of general anesthesia in infants 3 months or less.
40943828|NCT04450836|DRUG|Regorafenib then Trifluridine/Tipiracil|"REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.~Then TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle."
40943829|NCT04450836|DRUG|Trifluridine/Tipiracil then Regorafenib|"TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.~Then REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off."
40943830|NCT02413021|DRUG|Cytarabine|20 mg/m\^2 , SC, two times a day for 10 days every 30 days for 1 cycle
40943831|NCT02413021|DRUG|Deferasirox|20 mg/kg ,oral, per day
40943832|NCT05718804|OTHER|Whether renal injury occurred and differences in intestinal flora|Whether renal injury occurred and differences in intestinal flora
41452024|NCT02448862|DEVICE|Fentanyl based IV-PCA|We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
40757041|NCT01045239|DEVICE|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
40943833|NCT02291744|PROCEDURE|resection of primary lesion|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
41132489|NCT04390516|DEVICE|COViage|The COViage machine learning algorithm is designed to predict mechanical ventilation and mortality within 24 hours after hospital admission.
40943834|NCT02291744|DRUG|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
40943835|NCT03143881|BEHAVIORAL|Education|Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
40757042|NCT01045239|DEVICE|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
40943836|NCT05044091|DRUG|PARP inhibitor|Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions
40943837|NCT02239224|BIOLOGICAL|Placebo|Concentrate for solution for infusion
41285217|NCT00772967|DRUG|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
40943838|NCT02239224|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
40943839|NCT00861536|DRUG|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
40943840|NCT00861536|DRUG|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
40943841|NCT04372797|DEVICE|Diagnostic test|A battery of oculomotor tests
40943842|NCT02857582|BIOLOGICAL|Cultured human intestinal microbiota|Secondary treatment for C diff in replacement for regular vancomycin.
40943843|NCT02857582|DRUG|Vancomycin|Active comparator to treatment with ACHIM
40943844|NCT02857582|DRUG|Metronidazole|Primary treatment for C diff in all treatment arms
40943845|NCT02606890|OTHER|MRI|Stroke patients routinely undergo MRI at Charite Campus Benjamin Franklin. Type of MRI stroke pattern is evaluated with regard to presence or detection of (new) atrial fibrillation.
40943846|NCT03161821|OTHER|Observational|
40943847|NCT01573351|DRUG|Asunaprevir|
40943848|NCT01573351|DRUG|Daclatasvir|
40943849|NCT01573351|DRUG|Peg-interferon Alfa-2a|
40943850|NCT01573351|DRUG|Ribavirin|
40943851|NCT05203289|DRUG|BI 695501 - higher concentration|BI 695501 - higher concentration
40943852|NCT05203289|DRUG|BI 695501 - lower concentration|BI 695501 - lower concentration
41452025|NCT05874596|BEHAVIORAL|AI-aided clinical feedback system coupled with multi-aspect intervention basd on Behaviour Change Wheel model|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
41452026|NCT02919462|DRUG|Oral vinorelbine|Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
41452027|NCT02919462|DRUG|Cisplatin|Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
41452028|NCT02919462|DRUG|Maintenance with Metronomic Oral Vinorelbine|Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
41452029|NCT02919462|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
40943853|NCT02690883|DRUG|Exenatide|Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid
40943854|NCT02690883|DRUG|Lispro|Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG \<10.0mmol/L.
40943855|NCT04708600|BEHAVIORAL|Pitch Elevation Therapy|"Goal: mean fundamental frequency of 180Hz (range 140 and 300Hz); Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory discrimination of lower and higher tones~* pitch glides~* pitch glides using straw phonation and resonance tube phonation~* practice of higher pitch voice (target: 180Hz) in isolated vowels - syllables - mono and bisyllabic words -phrases - sentences and texts - conversation (generalization to spontaneous speech)"
40943856|NCT04708600|BEHAVIORAL|Articulation Resonance Therapy|"Goal: increase in lipspreading, forward tongue carriage, larynx elevation, forward resonance, precise articulation; 5 sessions Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory and visual discrimination of forward vs backed tongue carriage and lip spreading vs lip rounding)~* practice of technique on isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* practising larynx elevation through the twang technique, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* forward resonance, focusing on oral forward resonance rather than chest resonance, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* clear, precise articulation and cork exercise"
40943857|NCT04708600|BEHAVIORAL|Sham therapy|"Goal: active sham treatment, 4 sessions Doses and duration: 4 one hour and 15 minutes sessions (5h), 4 weeks~Content:~* providing information about vocal function, vocal surgery, vocal hygiene, transgender health care~* discussing communication aspects and patterns, possible exercise contexts, communication partners, expectations of voice modification, conversational subjects~* active intervention on nonverbal communication (Kinesics, gestures and sign language, facial expression, haptics, proxemics, occulsics, and physical appearance)~* practising costo abdominal breathing patterns"
40943858|NCT00533923|DRUG|Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF|intravenous
40943859|NCT00191646|DRUG|Gemcitabine|"1000 mg/m\^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m\^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity"
40943860|NCT00191646|DRUG|Paclitaxel|"175 mg/m\^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m\^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m\^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity"
40943861|NCT00191646|DRUG|Carboplatin|"Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles"
40943862|NCT02180269|DRUG|JNJ-54861911 (25 mg)|Single oral dose of JNJ-54861911, 25 mg on Day 1.
40943863|NCT02180269|DRUG|JNJ-54861911 (50 mg)|Single oral dose of JNJ-54861911, 50 mg on Day 1.
40943864|NCT02180269|DRUG|JNJ-54861911 (100 mg)|Single oral dose of JNJ-54861911, 100 mg on Day 1.
41452030|NCT02919462|DRUG|Cisplatin|Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
41452031|NCT02919462|DRUG|Maintenance with Pemetrexed|Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
40943865|NCT02180269|DRUG|Placebo|Single oral dose of placebo matched to JNJ-54861911 on Day 1.
40943866|NCT02159612|OTHER|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
40943867|NCT04176575|OTHER|Acupuncture|Acupuncture involves inserting thin needles into precise points on the body, known as acupuncture points, for therapeutic effect. Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method.
40943868|NCT04033198|PROCEDURE|Appendectomy|patients diagnosed as acute appendicitis , appendectomy done
40943869|NCT05080309|DIETARY_SUPPLEMENT|carbohydrate oral intake|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
40943870|NCT05080309|OTHER|free water only|Women will have free access to water only
41132490|NCT03306498|DRUG|Aminoleban (8% amino acids infusion)|Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
41285218|NCT00772967|DRUG|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
41452032|NCT02476045|DRUG|5-fluorouracil,leucovorin,panitumumab|Maintenance treatment (ARM A)
41452033|NCT02476045|DRUG|panitumumab|Maintenance treatment (ARM B)
40757043|NCT02532907|PROCEDURE|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
40943871|NCT05746962|DEVICE|ScopeGuide Navigated Colonoscope|colonoscopes equipped with ScopeGuide
40943872|NCT05746962|DEVICE|Navigation screen|ScopeGuide's 3D visualisation screen
40757044|NCT05099211|PROCEDURE|Muscle biopsies|"Optional~In pre-training:~Biopsy performed during the digestive surgery procedure~Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department."
40757045|NCT05099211|OTHER|Muscle Strengthening|3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.
40757046|NCT05099211|BIOLOGICAL|Blood and urine samples|fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls
40757047|NCT05099211|OTHER|Aerobic Training|"3 sessions per week for 18 weeks. Duration: 1 hour Training on a classic pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities."
40757048|NCT05099211|OTHER|Evaluation 1 pre-surgery|"Carried out at least 15 days before surgery~1. st visit:~   * Nutritional assessment~  * Body composition~  * Psychometric tests of quality of life + IPAQ Test~  * VO2pic~2. nd visit:~   * Neuromuscular tests~  * Functional tests"
41285219|NCT00772967|DRUG|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
41452034|NCT02476045|DRUG|Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab|Induction treatment
41452035|NCT01513239|BIOLOGICAL|MK-6072|Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
40757049|NCT05099211|OTHER|Evaluation 2 post-surgery|"1. st visit:~   * Body composition~  * Nutritional assessment~  * Psychometric tests of quality of life~2. nd visit:~   * neuromuscular tests~  * Functional tests~  * Familiarization with training equipment if patient participates in re-training"
40943873|NCT03029130|DEVICE|Catheter extension|Foley transurethral catheter placed to allow continuous drainage of urine.
40943874|NCT04409600|BEHAVIORAL|Supervised Gait Retraining|The participants allocated to this group will attend 8 sessions during the course of 6 weeks in the clinic with a trained medical professional to complete a supervised gait retraining program.
40943875|NCT04409600|BEHAVIORAL|Home Based Gait Retraining|The participants allocated to this group will have 1 session in the clinic with a trained medical professional and be given a gait retraining program to complete at home.
40943876|NCT04409600|DRUG|Saline Injection|The participant will receive a saline injection to their painful lower leg compartment(s).
41132491|NCT02233556|DRUG|Memantine|"Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~1. Mismatch negativity(MMN)~2. P50"
41132492|NCT04773431|DRUG|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
41132493|NCT00794300|DEVICE|second magnetic resonance imaging scan|
41452036|NCT01513239|BIOLOGICAL|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
41452037|NCT01513239|BIOLOGICAL|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
41452038|NCT01513239|DRUG|SOC|SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
40943877|NCT04409600|DRUG|Botulinum Toxin Injection|The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).
40943878|NCT05120661|OTHER|food product|a food product containing 50 gram carbohydrates
40943879|NCT01012167|DRUG|Oxytocin|Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
41452039|NCT03024801|DRUG|autologous platelet-rich plasma|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
40943880|NCT01012167|DRUG|Galantamine|Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
40943881|NCT01012167|OTHER|Placebo-Oxytocin|Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
40943882|NCT01012167|OTHER|Placebo-Galantamine|Placebo tablets twice a day for 6 weeks
40943883|NCT04043728|BEHAVIORAL|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.
40943884|NCT00055224|DEVICE|Threat of shock|During threat, a participant could receive a shock. During safe, a participant could not receive as shock. Participants selected their highest tolerable level of shock.
40943885|NCT00014404|DRUG|celecoxib|
40943886|NCT06340061|OTHER|Observational study|The ocular biomechanical differences between the normal control group and primary glaucoma patients, including those treated with conventional medication, laser therapy, and surgery, were compared. Additionally, an investigation was conducted to explore the relationship between anterior chamber parameters, corneal biomechanics, and the severity of glaucoma
40943887|NCT00438451|DRUG|Levetiracetam|LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.
40943888|NCT00438451|DRUG|Carbamazepine|CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.
40943889|NCT00438451|DRUG|Lamotrigine|LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.
40943890|NCT01702571|DRUG|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
40943891|NCT04407260|DEVICE|Oxygen Hood|High-Flow Oxygen Hood with neck dam and intake and exhaust tubing incorporating a Bacterial/Viral HEPA filter and optional PEEP attachment.
40943892|NCT05575128|BEHAVIORAL|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
40943893|NCT05575128|OTHER|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
40943894|NCT05575128|OTHER|Care as usual|Care as usual, with written resources provided
40943895|NCT06356090|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions (SPACE)|SPACE is a parent-based treatment (parent-stand-alone treatment) for parents of youth with anxiety symptoms or OCD. The manualized treatment protocol contains 12 sessions, in which parents are taught to reduce family accommodation (FA) and to increase supportive responses to their child.
40943896|NCT02269046|OTHER|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
40943897|NCT02269046|DRUG|Simvastatin|10mg/d,p.o,12 weeks.
40943898|NCT02269046|OTHER|Therapeutic Lifestyle Change|"* Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity"
40943899|NCT05695196|BIOLOGICAL|nasal microbiota transplant (NMT)|nasal microbiota transplant
40943900|NCT05695196|BIOLOGICAL|Placebo|Placebo sterile saline
40943901|NCT04432337|PROCEDURE|The role of the activation of the NLRP3 inflammasome after cardiac surgery|Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery
40943902|NCT06019429|BEHAVIORAL|HiRO|"HiRO consists of weekly lessons. The lessons are aimed to promote social-emotional development. More specifically, lessons are designed to develop and enhance 1) trust, 2) collaboration, 3) respect, 4) self control, 5) resilience, 6) discipline, 7) joy. The annual program consists of four phases:~Phase 1 \& 3: Fundamental phase (6 weeks) Engaging with the values through movement. In these phases, group formation and establishing behavioral expectations are central. In the Fundamental phase, one value is addressed school-wide each week. The entire school starts with trust and ends with discipline.~Phase 2 \& 4: Theme weeks (12 lessons) A customized series of Experiential lessons for each class. Experiential learning is the guiding principle of the program, with a strong foundation based on the values upheld in judo. The learning cycle forms the basis for each experiential lesson within HiRO, and focusses on concrete experience, reflective observation, conceptualization, and practice."
40943903|NCT06019429|BEHAVIORAL|HiRO +judo|In the condition HiRO with judo, students receive the same treatment as offered in the HiRO condition. In addition, they receive physical judo classes that are designed to translate the above-mentioned values to the behavioral level.
40943904|NCT06019429|BEHAVIORAL|School as usual|Any amount of classes offered to promote social-emotional development
40943905|NCT00093548|BIOLOGICAL|alpha fetoprotein adenoviral vector vaccine|
40943906|NCT00093548|BIOLOGICAL|alpha fetoprotein plasmid DNA vaccine|
40943907|NCT00093548|BIOLOGICAL|sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant|
40943908|NCT01298973|DRUG|Viscoat|One group will receive Viscoat for incision closure
40943909|NCT01298973|DRUG|Saline|One group will receive Saline to irrigate the wound
41132494|NCT00403494|OTHER|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
41132495|NCT00403494|DRUG|Sapropterin Dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
41132496|NCT01351259|DEVICE|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
40943910|NCT02680509|PROCEDURE|Sympathicotomy R3|sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
40943911|NCT04831957|DIAGNOSTIC_TEST|Assesment of thyroïd function|Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample
40943912|NCT01360281|OTHER|Neuromuscular Electrical Stimulation|
40943913|NCT01360281|OTHER|ECR|Resisted exercises
40943914|NCT05760105|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
40943915|NCT03298373|DRUG|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
40943916|NCT03298373|DRUG|11β-methyl-nortestosterone-dodecylcarbonate|11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
40943917|NCT02466373|DRUG|Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml|clonidine intravenous
40943918|NCT03948607|OTHER|Electroencephalography during sustained attention task.|"The Continuous Temporal Expectancy Task (CTET) (O'Connell et al., 2009) is a very demanding discrimination task with sustained attention. It consists of the presentation on a computer screen of a visual pattern resembling a checkerboard that changes orientation at regular intervals of time. In this task the subject must respond (pressing a response button) to the appearance of rare target stimuli that have a longer duration (1120 ms) than non-target stimuli (800 ms).~SART (Sustained Attention to Response Task) (Robertson et al., 1997) is a task of inhibition (Go / No-Go task) to evaluate the capacities of sustained attention. It consists in the successive and random presentation on a computer screen of the numbers from 1 to 9. In this task the subject must respond, by pressing a response button, to the appearance of all the numbers (very non-target stimuli frequent), with the exception of the number 3."
40943919|NCT04737447|DEVICE|Whole Body Vibration Training|Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.
40943920|NCT04504279|BIOLOGICAL|FB-401|Topical application
40943921|NCT04504279|BIOLOGICAL|Placebo|Vehicle
40943922|NCT01589328|OTHER|Early Palliative care integrated with usual oncologic care|"Drug: The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
40943923|NCT04104334|DRUG|Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively|NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume
40943924|NCT04104334|DRUG|Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices|Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
40943925|NCT00956956|DRUG|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
41452040|NCT03024801|DRUG|normal saline|The patients with knee cartilage injury were randomized to the normal saline group.
40757050|NCT05099211|OTHER|Intermediate Evaluation 3|performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6
40757051|NCT05099211|OTHER|Final post-training evaluation 4|Tests identical to evaluation 1 + TM6
40943926|NCT00956956|DRUG|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
41132497|NCT03956628|BEHAVIORAL|stay safe program|Prevention consist of 5-6 lessons having topics about learning safety skills which includes identifying touch, safe and unsafe environment/events, bullying, the good or bad secrets and strangers.
41132498|NCT01281436|OTHER|HeartSmartKids & Web-based Provider Training|The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
41452041|NCT03366948|OTHER|IGDT-10 self-administered questionnaire|"Patients and their parents will answer the French version of the IGDT-10 self-administered questionnaire (IGDT-10-P in the parents 'questionnaire).~The IGDT-10 is a self-administered questionnaire based on DSM-5 internet gaming disorder criteria and the IGDT-10-P is a parental version specially adapted from the IGDT-10 for this study."
41452042|NCT00348517|OTHER|Systane Free Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
41452043|NCT00348517|OTHER|Refresh Liquigel Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
40757052|NCT00661154|DRUG|Bevacizumab|2-12microCi IV injection
40757053|NCT03841474|DRUG|Psychiatric treatment with sertraline|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI
40757054|NCT03841474|DRUG|Psychiatric treatment with escitalopram|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
40757055|NCT00736736|OTHER|Additional Hip Muscle Strengthening to Leg Press Exercise|
40757056|NCT00736736|OTHER|Leg Press Exercise|
40757057|NCT02766478|DRUG|Genistein|Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.
40757058|NCT02766478|DRUG|Placebo|A placebo pill will be taken orally for 12 weeks.
40943927|NCT04575454|OTHER|Multimodal evaluation of brain function : PET-MRI, electrophysiology, eye-tracking|"After 2 days of sedation withdrawal, each data should be collected within 3 days for organisation purposes :~1. After installation and movement management with standardized routine care protocol: 18Fluoro-Desoxy-Glucose's infusion for PET~2. Starting PET continuous acquisition~3. Morphological MRI sequences~4. MRI in Resting state N°1~5. MRI DTI acquisition~6. IRM in 2D-Arterial Spin Labelling~7. IRM in Resting state 2~8. End of PET continuous acquisition The day before or the day after PET-MR: standard 20 min EEG, somaesthetic evoked potentials, auditory evoked potentials, mismatch negativity, P300 oddball paradigm, local-global paradigm, P300 after music stimulation, EEG resting state for 10 min, CRS-R repeated before each examination (and at least 5 times for chronic patients), eye-tracking study of the environmental exploration."
40943928|NCT04879277|BIOLOGICAL|Blood samples|Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.
40943929|NCT02499978|DRUG|Darunavir/Cobicistat|Fixed dose combination medication
40943930|NCT02499978|DRUG|Dolutegravir|single tablet medication
40943931|NCT03666624|BEHAVIORAL|Personalized care network|The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
40943932|NCT06146881|DRUG|Diquafosol sodium 3%|Diquafosol sodium 3% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
40943933|NCT06146881|DRUG|Sodium hyaluronate 0.1%|Sodium hyaluronate 0.1% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
40943934|NCT03988413|DRUG|25mg|SYHA1402 25mg or Placebo 25mg
40943935|NCT03988413|DRUG|50mg|SYHA1402 50mg or Placebo 50mg
40943936|NCT03988413|DRUG|100mg|SYHA1402 100mg or Placebo 100mg
40943937|NCT03988413|DRUG|200mg|SYHA1402 200mg or Placebo 200mg
40943938|NCT03988413|DRUG|400mg|SYHA1402 400mg or Placebo 400mg
40943939|NCT03988413|DRUG|800mg|SYHA1402 800mg or Placebo 800mg
40943940|NCT02209831|DEVICE|BIBR 796 BS|single dose
40943941|NCT02209831|DRUG|Pantoprazole|5 days
40943942|NCT04483778|BIOLOGICAL|second generation 4-1BBζ B7H3-EGFRt-DHFR|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR
40943943|NCT04483778|BIOLOGICAL|second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
40943944|NCT04483778|DRUG|Pembrolizumab|SCRI-CARB7H3(s)x19 plus pembrolizumab
40943945|NCT02637336|DEVICE|Acupuncture|Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
40757059|NCT05760612|DRUG|Trastuzumab and nelatinib|Postoperative adjuvant treatment, for about 1 year
40943946|NCT02637336|DEVICE|Aerobic exercise|aerobic exercise of moderate intensity
40943947|NCT02637336|DEVICE|Aromatherapy|inhalation of eucalyptus essential oil
40943948|NCT01199731|DRUG|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
40943949|NCT01199731|DRUG|GSK2248761 200 mg once daily|2 100mg capsules OAD
40943950|NCT01199731|DRUG|Etravirine|2 100mg tablets twice daily
40943951|NCT03298776|DEVICE|I-Scan|I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
40943952|NCT03298776|DIAGNOSTIC_TEST|Standard endoscopy|Patients referred for standard endoscopy to receive standard of care only
40943953|NCT04163497|DEVICE|ICU Diaries|To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
40943954|NCT00453518|DEVICE|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
40943955|NCT02043314|DRUG|Isoniazida|
41285220|NCT03626051|DEVICE|Rigid tape|This taping method used an anchor, two stirrups, three figure-six's (two preventing inversion and one preventing eversion), heel lock and a lock off. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
41452044|NCT04005638|BIOLOGICAL|blood sample|45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
41452045|NCT04005638|BIOLOGICAL|urine sample|12 ml
40943956|NCT04625790|DEVICE|Repetitive transcranial magnetic stimulation|"Transcranial Magnetic Stimulation(TMS) has been used for diagnostic and therapeutic purposes in the treatment of many neurological and psychiatric diseases such as stroke, multiple sclerosis, myelopathy, amyotrophic lateral sclerosis, movement disorders, epilepsy, and depression. It is a way to stimulate the targeted areas in the cerebral cortex without invasive methods. The application of TMS in the aphasia usually consists of repetitive stimulations, in order to activate or deactivate the target area.~In this study, 10 sessions of 1-Hz low frequency rTMS for 20 minutes will be applied to the inferior frontal gyrus of the right frontal lobe."
40943957|NCT04625790|OTHER|Speech therapy|Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
40943958|NCT01056731|DRUG|Aliskiren and HCTZ|Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
40943959|NCT05426798|DRUG|TQB2618 injection azacitidine, AZA decitabine, DAC|"Drug1: TQB2618 injection is a novel tim-3 inhibitor.~Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter hypomethylation.~Drug3: Decitabine is a cytidine deoxy nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation."
40943960|NCT06119035|OTHER|Single dose of 75 grams glucose in 200ml water|Consume single dose of 75 grams glucose in 200ml water
41452046|NCT04699084|OTHER|Mozart music|A 20-minute piece composed by W.A Mozart ( Sonata K. 448 in D Major for 2 pianos) was applied in music group, directly after the arrival of patients in the Post Anesthesia Care Unit (PACU), while they were receiving usual postoperative care.
40943961|NCT02831244|DEVICE|Agili-CTM|Consenting individuals will be selected from the population of patients with osteoarthritis of the great toe examined by a participating investigator. Following signing an informed consent, candidates will be evaluated by an adjudication committee for possible inclusion in the trial based on medical history and Standing Foot X-ray. Candidates that are approved or conditionally approved by the adjudication committee will undergo Agili-CTM implantation procedure
41452047|NCT05766670|DRUG|Vancomycin Hydrochloride|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
40757060|NCT05760612|DRUG|Trastuzumab and Parstuzumab|Postoperative adjuvant treatment, for about 1 year
40757061|NCT02224079|DRUG|BIIB 722 CL|
40757062|NCT02224079|DRUG|Placebo|Hydroxypropyl-beta-cyclodextrin (HPβCD)
40757063|NCT01514838|DRUG|ASP1941|oral
41285221|NCT03626051|DEVICE|Fibular tape|This taping method used a rigid strapping tape to reinforce a posterior-superior mobilisation of the distal fibula. Tension was applied on the tape in a posterior and superior direction. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
40757064|NCT01514838|DRUG|acarbose|oral
40757065|NCT01514838|DRUG|Placebo|oral, used only during placebo run-in period
40943962|NCT01672229|DRUG|Bortezomib|If improvements are seen at any dose level and patients have no DLTs, they will stay at their dose level until the end of the study. This is to avoid any possible toxicity while the patient is benefiting from their current dosing of bortezomib. If the continuous improvement in GVHD stalls at any point, or the GVHD progresses after the original improvement, while the dose level is maintained, then the dose will be increased to the next dose level. Patients will remain enrolled until exacerbation of the GVHD on increasing dose schedule or closure of the study. Clinical activity will be monitored every other week after the initiation of bortezomib until the study closes.
41452048|NCT05766670|DRUG|Gentamicin|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
40757066|NCT05860868|DRUG|2 cycles induction chemotherapy|"Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
40757067|NCT05860868|DRUG|3 cycles induction chemotherapy|"Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
41452049|NCT05766670|OTHER|Standard Intramedullary Nail|Standard Intramedullary Nail
41452050|NCT03866460|DIAGNOSTIC_TEST|Distortion product otoacoustic emission measurement (DPOAE)|Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
40757068|NCT03137407|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
40757069|NCT03137407|BIOLOGICAL|Placebo|Intramuscular injection
40757070|NCT05151380|DEVICE|CO2 laser MonaLisa Touch ®|"3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed.~The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice"
40757071|NCT04487821|OTHER|Cawthorne Cooksey Exercises|"Activity sitting on the Exercise Ball swing (eye movements, first slow and then fast)~Swing sitting activity (head movements, first slow then fast - eyes open and eyes closed)~Trunk activities focusing on balance~Dynamic balance activity focusing on standing"
40943963|NCT01826071|OTHER|Static Stretch|
40943964|NCT01826071|OTHER|Active Elongation|
41452051|NCT02077907|DIETARY_SUPPLEMENT|Super Cereal Plus (SC+)|
41452052|NCT02077907|DIETARY_SUPPLEMENT|Super Cereal (SC), fortified oil, sugar|
40757072|NCT00183612|DRUG|Olanzapine|
40757073|NCT04304287|PROCEDURE|Preoperative autologous blood donation, 14 days before surgery|
40943965|NCT04862377|DRUG|Poractant Alfa Intratracheal Suspension [Curosurf]|"Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg."
41132499|NCT01281436|OTHER|Web-based Provider Training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
41132500|NCT03807596|PROCEDURE|Periodontal treatment with Hyaluronic acid associated with SRP|In addition to SRP, patients in the test group received adjunct subgingival application of hyaluronic acid in all selected periodontal pockets.
41132501|NCT03807596|PROCEDURE|Scaling & root planning alone|Patients received full-mouth supra- \& sub-gingival SRP with the use of ultrasonic device \& periodontal universal \& Gracey curettes under local anesthesia.
41452053|NCT02077907|DIETARY_SUPPLEMENT|Plumpy Sup|
40943966|NCT04862377|DRUG|Budesonide 0.5 MG/ML|"Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide."
40757074|NCT04304287|PROCEDURE|Preoperative autologous blood donation, 72 hours before surgery|
41132502|NCT02134171|OTHER|Biological and imaging investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide \[BNP\]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
41132503|NCT04812249|OTHER|Clinical assessment|Clinical assessment and follow up of oral feeding ability
41132504|NCT06143007|DRUG|BB3008 tablet|BB3008 tablets will be administered orally once daily (QD).
41452054|NCT02077907|DIETARY_SUPPLEMENT|Corn Soy Blend 14 (CSB14) and fortified oil|
41285222|NCT03826914|DIETARY_SUPPLEMENT|CardioFlex Q10|CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.
41285223|NCT03826914|DIETARY_SUPPLEMENT|Placebo|Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
41285224|NCT03135093|OTHER|No intervention|No Intervention
41452055|NCT04768114|BEHAVIORAL|Genetically-Informed RiskProfile|"* Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~* This is a fully remote trial, with intervention delivered via video conferencing."
41452056|NCT04768114|OTHER|Brief Cessation Advice|"* Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~* This is a fully remote trial, with brief cessation advice delivered via video conferencing."
40757075|NCT04304287|PROCEDURE|Without preoperative blood donation|
40757076|NCT05839821|BEHAVIORAL|noF-noRAS|resting state, that is, without finger-tapping and without listening to RAS
40757077|NCT05839821|BEHAVIORAL|F-noRAS|finger-tapping without listening to RAS
40757078|NCT05839821|BEHAVIORAL|noF-100RAS|listening to RAS with the 100% of the baseline tempo and without finger-tapping
40757079|NCT05839821|BEHAVIORAL|F-100RAS|finger-tapping and listening to RAS with 100 % of baseline tempo
40757080|NCT05839821|BEHAVIORAL|F-105RAS|finger-tapping and listening to RAS with 105 % of baseline tempo
40757081|NCT05839821|BEHAVIORAL|F-110RAS|finger-tapping and listening to RAS with 110 % of baseline tempo
40757082|NCT03588429|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
40757083|NCT03588429|DRUG|Isoflurane|Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
41132505|NCT02797132|DRUG|LUM/IVA|
40757084|NCT03763266|OTHER|1 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
41285225|NCT00815308|DRUG|cetuximab (Erbitux)|Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8)
41285226|NCT00815308|DRUG|Paclitaxel|Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8)
40757085|NCT03763266|OTHER|3 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
40757086|NCT04505280|DRUG|Lidocaine 1% Injectable Solution|Greater occipital nerve and cervical region injections once a week for 4 weeks
40757087|NCT04508413|OTHER|KB295|KB295 is a novel glycan
41285227|NCT00815308|DRUG|Cisplatin|Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-8)
41285228|NCT00815308|RADIATION|Radiation|Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
41285229|NCT05068804|PROCEDURE|Cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
41285230|NCT05068804|OTHER|control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
40943967|NCT00521612|DRUG|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
40943968|NCT00521612|DRUG|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
40943969|NCT02470416|DEVICE|Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD|Cases and controls will have a standard VCE procedure at our institution.
40943970|NCT05107427|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
40943971|NCT05107427|BIOLOGICAL|Avelumab 20 mg/mL Intravenous Solution (IV)|"Avelumab is an IV administered monoclonal antibody that blocks the interaction of programmed death ligand-1 (PD-L1) with its receptors PD-1 and B7.1 on T cells and antigen-presenting cells, and has been shown to activate adaptive and innate immune functions.~The study dosing regimen is 800 mg (four 20mL vials of 20mg/mL solution) for IV infusion once every two weeks"
40943972|NCT04971707|OTHER|Standardized exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the standard cardiovascular rehabilitation program combining both continuous moderate exercise sessions (MICT) and high intensity interval exercise sessions (HIIT). MICT sessions will be performed 2 times per week and HIIT sessions will be performed once a week.
40943973|NCT04971707|OTHER|HRV-guided exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the individualized cardiovascular rehabilitation program. Daily exercise (MICT, HIIT, or active recovery) will be prescribed according to the HRV-index measured on the morning of the session.
40943974|NCT00424801|DRUG|Lercanidipine|Individual titration, max. dose 20 mg OD for 8 months
40943975|NCT00424801|DRUG|Valsartan|Individual titration, max. dose 160 mg OD for 8 months
40943976|NCT00424801|DRUG|Nicorandil|Individual titration, max. dose 20 mg BD for 8 months
40943977|NCT00424801|DRUG|Doxazosin|Individual titration, max. dose 4 mg OD for 8 months
40943978|NCT00424801|DRUG|Moxonidin|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
40943979|NCT00424801|DRUG|Pindolol|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
40943980|NCT00424801|DRUG|Amiloride, hydrochlorothiazide|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
40943981|NCT01810211|OTHER|Horizontal Adduction Stretch and Pendulums|
40943982|NCT01810211|OTHER|Modified Sleeper Stretch and Pendulum|
40943983|NCT03971071|DRUG|Erenumab 70 mg|Erenumab once every 4 weeks. Subcutaneous injection.
40943984|NCT03971071|DRUG|Erenumab 140 mg|Erenumab once every 4 weeks. Subcutaneous injection.
40943985|NCT03971071|DRUG|Placebo|Placebo once every 4 weeks. Subcutaneous injection.
40943986|NCT04574323|RADIATION|Curative radiotherapy|Standard curative radiotherapy
40943987|NCT04574323|OTHER|Paleolithic lifestyle intervention|This intervention consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed.
40943988|NCT03624231|DRUG|Durvalumab|Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
40943989|NCT03624231|DRUG|Tremelimumab|Tremelimumab (75 mg) for up to 4 doses/cycles
40943990|NCT03624231|RADIATION|Radiotherapy|Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
40943991|NCT00747812|DEVICE|Precision|Implantable Neurostimulator
40943992|NCT00750880|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv (60 minute infusion)
41132506|NCT02813525|OTHER|ISI index on Doppler systolic flow in the aortic isthmus|Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus
41132507|NCT00958321|PROCEDURE|computed tomography|
41132508|NCT00958321|RADIATION|3-dimensional conformal radiation therapy|
40757088|NCT02034266|DIETARY_SUPPLEMENT|Omega-3 supplementation|5 mL twice daily, administered under the tongue
41132509|NCT00958321|RADIATION|fludeoxyglucose F 18|
41285231|NCT03972371|DEVICE|The ProVee Urethral Expander System|The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.
40757089|NCT06439784|OTHER|whole body SPECT/CT|Patient will unergo a whole body SPECT/CT in treatment position
40757090|NCT01992081|DEVICE|Automated telehealth system|The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.
40757091|NCT01992081|OTHER|Usual care|Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
40757092|NCT03824054|PROCEDURE|colorectal resection|Surgery includes laparoscopic resection of all visible endometriosis, including resection of the affected bowel with primary anastomosis
40757093|NCT02393469|OTHER|pulmonary rehabilitation|Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
40943993|NCT04940208|OTHER|Pain and neuropsychological questionnaires|Patient-reported outcomes, listed in the Secondary Outcome Measure Section
40943994|NCT04940208|DIAGNOSTIC_TEST|Quantitative Sensory testing|Summation pain threshold test and Heat pain threshold skin test
40943995|NCT03701399|DRUG|troriluzole|200 mg by mouth
40943996|NCT03701399|DRUG|Placebos|200 mg by mouth
41132510|NCT00958321|RADIATION|radiation therapy treatment planning/simulation|
41132511|NCT02525822|DRUG|IDP-123 Lotion|Investigational Product: IDP-123 Lotion
41132512|NCT02525822|DRUG|Tazorac Cream, 0.1%,|Comparator Product: Tazorac Cream, 0.1%
41285232|NCT04238845|DRUG|AQSP Administration|Three days treatment of all children with AQSP for SMC
41285233|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Plumpy'Doz|Daily supplementation of children with Plumpy'Doz
40757094|NCT02393469|OTHER|Education and self-management for COPD|Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
40757095|NCT00912509|DRUG|riboflavin|riboflavin 0.1% is applied every 2 minutes for 30 minutes
41452057|NCT01261767|DRUG|anti-IL-20|Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
40943997|NCT03953417|DEVICE|Accelerated intermittent theta-burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Treatment will be targeted by utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to left DLPFC using the MagPRo stimulator."
40943998|NCT04578808|OTHER|Unruptured intracranial aneurysms|UIA of bifurcation between 3 and 7 mm for whom a clinical and imaging follow-up without occlusion treatment was scheduled by local multidisciplinary staff will be included. Extensive clinical, biological and imaging data will be recorded during a 3 years follow-up (visits at 1 and 3 years after inclusion).
40943999|NCT04670055|DRUG|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
41132513|NCT02525822|DRUG|Vehicle Cream|Comparator Product: Vehicle Cream
41132514|NCT02525822|DRUG|Vehicle Lotion|Comparator Product: Vehicle Lotion
41452058|NCT01261767|DRUG|placebo|Placebo for subcutaneous (under the skin) injection
41452059|NCT01264523|OTHER|Chronologically scheduled snacking with 40-30-30 products|Short-term analysis of the effects of the substitution of the habitual breakfast, mid-morning and afternoon snack of type-2 diabetes patients by 40-30-30 products. Longitudinal 2-period study
40757096|NCT00912509|DEVICE|UVX Light|UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
40757097|NCT02575183|DRUG|Varinecline (Chantix)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
40944000|NCT04209348|BEHAVIORAL|Physical Activity Intervention|Motivational interviewing techniques helped participants set reasonable, specific, and achievable individual goals at each session: a duration (i.e., minutes) and frequency (i.e., days of the week) of walking or stepping, and potentially, a step count (i.e., a proxy for intensity). Individual goals often differed from the program goal in an effort to meet the participants 'where they are'.
40944001|NCT04209348|OTHER|Wellness Education|The following topics were addressed: postpartum contraception, maternal immunizations, infant immunizations, car seat safety and planning for your hospital stay, and safe sleep and skin to skin. No information on PA was provided to the control group (i.e., neither encouragement for PA nor instructions to limit PA).
41132515|NCT02794363|BIOLOGICAL|Autologous platelet rich plasma|5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
40757098|NCT02575183|DRUG|Placebo (for Varenicline)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
41132516|NCT01355172|BIOLOGICAL|AdimFlu-S|0.25mL per injection 2 injections at 4 weeks apart
41132517|NCT01747707|DRUG|Docetaxel|
41132518|NCT01747707|DRUG|Cisplatin|
41132519|NCT01747707|DRUG|S-1|
41132520|NCT03259568|DEVICE|Repetitive TMS|1-10 Hertz rTMS will be administered
41132521|NCT04072328|DRUG|Propofol|Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.
41132522|NCT04072328|DRUG|Midazolam|midazolam with propofol
41132523|NCT05657210|GENETIC|Mutation|
41132524|NCT06397196|OTHER|Laser guided proprioceptive exercises|Participants will receive Laser guided Proprioceptive exercises on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
41285234|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Vitamin A|Single dose supplementation with Vitamin A to all children
41452060|NCT01102660|DRUG|PH-797804|Tablet, 6 mg once daily for 2 weeks
41452061|NCT01102660|DRUG|Placebo|Tablet, 0 mg once daily for 2 weeks
41452062|NCT01102660|DRUG|Placebo|Tablet, 0 mg once daily for 2 weeks
41452063|NCT01102660|DRUG|PH-797804|Tablet, 6 mg once daily for 2 weeks
41452064|NCT01102660|DRUG|Naproxen|Tablet, 500 mg twice daily for 2 weeks
41452065|NCT01102660|DRUG|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
40757099|NCT02575183|BEHAVIORAL|Behavioral Therapy|This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
40757100|NCT04968600|PROCEDURE|total knee arthroplasty|Posterior-cruciate-ligament is retained in one arm and sacrificed in another arm during total knee arthroplasty
41285235|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Zinc|Daily supplementation with Zinc
40757101|NCT02365064|DEVICE|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
40757102|NCT01210599|DRUG|Pamidronate|The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
40757103|NCT05122143|DEVICE|Treatment A|"Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril"
40757104|NCT05122143|DEVICE|Treatment B|"Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~Two Sprays of AM-301 per nostril (with different spray angles)"
40757105|NCT05122143|OTHER|Treatment C|No treatment
40757106|NCT05931965|DIETARY_SUPPLEMENT|L-methylfolate|Participants receive L-methylfolate 400µg orally twice daily for 4 weeks
40757107|NCT05931965|DIETARY_SUPPLEMENT|Vitamin B12|Participants receive mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
40757108|NCT05931965|DIETARY_SUPPLEMENT|magnesium|Participants receive magnesium glycinate 400mg twice daily orally for 4 weeks (elemental 120mg approx.)
40757109|NCT06498531|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
40757110|NCT06498531|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
40757111|NCT05498220|DRUG|Polatuzumab vedotin (PV)|1.8 mg/kg, intravenous, at day 1, in every 21 days
40757112|NCT05498220|DRUG|Rituximab|375 mg/m2 intravenous, at day 1 or day 2, in every 21 days
40757113|NCT05498220|DRUG|Hyaluronidase|1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days
40757114|NCT05498220|DRUG|Gemcitabine|1,000 mg/m2 intravenous at day 1 and 8, in every 21 days
40757115|NCT05498220|DRUG|Cisplatin|75 mg/m2, intravenous, at day 1, in every 21 days
41132525|NCT06397196|OTHER|Routine Physical therapy|Participants will receive routine physical therapy on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
40757116|NCT05498220|DRUG|Dexamethasone|40 mg intravenous at day 1, Per oral days at days 2-4
40757117|NCT05498220|DRUG|GCSF|granulocyte-colony stimulating factor (GCSF )
40757118|NCT02893436|PROCEDURE|Surgery with tracheal intubation curarisation|
40757119|NCT05856461|PROCEDURE|Pulmonary vein isolation|Circumferential pulmonary vein isolation procedure using 3D navigation systems with entrance and exit block verification
40757120|NCT05856461|PROCEDURE|Sham pulmonary artery denervation|Sham pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries with creation of the false ablation points. No true ablation lesions will be performed in the pulmonary artery
41285236|NCT04192604|OTHER|WMSDsQ|Work-related MusculoSkeletal Disorders Questionnaire
41285237|NCT01580475|OTHER|Training - detraining - retraining|Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
41285238|NCT00513344|DIETARY_SUPPLEMENT|Dark Chocolate|1 portion
41452066|NCT01102660|DRUG|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
41452067|NCT01102660|DRUG|Naproxen|Tablet, 500 mg twice daily for 2 weeks
41285239|NCT00513344|DIETARY_SUPPLEMENT|Milk Chocolate|1 portion
41285240|NCT00513344|DIETARY_SUPPLEMENT|"Control (polyphenol-free) Chocolate"|one portion
41285241|NCT00812110|DRUG|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
41285242|NCT03527043|DRUG|Escitalopram|10mg by mouth daily for 6 weeks
41285243|NCT03527043|OTHER|Placebo|matched placebo control by mouth for 6 weeks
41285244|NCT05921448|BIOLOGICAL|Vaxigripetra|Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.
41285245|NCT05921448|BIOLOGICAL|Flumist|Tetravalent live attenuated influenza vaccine administered as a nasal spray. Mechanism of action: Not fully understood according to the prescribing information, but may involve influenza-specific T-cells and antibodies (serum and mucosal).
40757121|NCT05856461|PROCEDURE|Pulmonary artery denervation|Pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries and 3 circles of ablation lesions (bifurcation of the main pulmonary artery, left and right pulmonary arteries)
41285246|NCT04886765|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
40757122|NCT02397369|OTHER|Tobacco users: Self Help|This group will be given pictorial material and minimal written materials/ pamphlets describing health hazards of smokeless forms of tobacco and tips on tobacco cessation in general. The material will be interactively tailored to individual tobacco consumption characteristics and they will be followed up after 12 months.
40757123|NCT02397369|BEHAVIORAL|Tobacco users:Telephonic counseling|This group will be given proactive as well as reactive counseling. Medical social workers will proactively call all participants regularly and offer tobacco cessation counseling. In addition, they will call those participants who have planned their quit dates. Dedicated independent mobile numbers with 12 hours help lines will be made available to the participants to maximise the level of support. It will be scheduled in response to the needs to answer any type of help pertaining to quitting tobacco.
40944002|NCT05139082|DRUG|TQB3616 capsules＋ TQB2450 injection|"TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
40944003|NCT00915356|DRUG|AZD1305|Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
41285247|NCT05619926|DRUG|STSP-0601 for Injection|Intravenous Injection
41285248|NCT03560440|OTHER|Plasma exposure vancomycin|Investigation of plasma exposure of vancomycin.
41285249|NCT05704530|OTHER|Blood sample|Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.
41285250|NCT03525977|PROCEDURE|Fascia iliaca block arm|The fascia iliaca block will be performed by the anesthesiologist on call
41285251|NCT01882725|DEVICE|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
41285252|NCT05069363|DEVICE|Whole-Body Photobiomodulation Therapy|"* All participants entering the trial will receive a course of whole-body PBM therapy~* The NovoTHOR Whole-Body PBM therapy device consists of a hinged, clamshell design with light-emitting diodes (LEDs) arranged to emit near-infrared and visible red light therapy is delivered to the entire body at once.~* Participants will be expected to lie horizontal in the device with the lid as closed as they are comfortable with.~* 18 sessions is the currently recommended and widely instituted and accepted practice with the NovoTHOR device.~* The LED equipment delivers red and near infrared light therapy to the participant~* Session 1 = 6 minutes~* Session 2 = 12 minutes~* Sessions 3-18 = 20 minutes~* Timescale: 3 treatments/week for 6 weeks~* The dosage of LED light (also known as 'fluence') will be equivalent to 25J/cm2. The device will supply a dual wavelength of red and near-infrared light with a 50:50 ratio; 660nm and 850nm respectively"
41285253|NCT04788563|OTHER|Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
41285254|NCT04788563|DRUG|Original antihypertensive treatment (compulsively randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
40944004|NCT00915356|DRUG|Placebo|iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
41285255|NCT04788563|OTHER|Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
41285256|NCT04788563|DRUG|Original antihypertensive treatment (voluntarily randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
41452068|NCT03601585|DEVICE|Comparison of dental biofilm removal.|Comparison of the use of 4 methods for dental biofilm removal
40757124|NCT02397369|BEHAVIORAL|Tobacco users:Behavioural therapy Only|"1. Focus Group discussion:~   This tobacco cessation intervention session will involve thirty minutes of focus group discussion with group behavioral therapy in groups of 5-10 individuals for reinforcement of tobacco use prevention and cessation advice. Group discussion is intended to improve understanding by exploring, sharing and reflecting psychosocial, familial, environmental issues which attribute to the problem.~2. Individual tobacco cessation counseling sessions:~Individual counseling is commonly used to help people who are trying to quit tobacco. The counseling adopting an interactive problem-solving approach will be done by trained Medical Social Workers providing face-to-face sessions for 10-15 minutes per participant."
40757125|NCT02397369|OTHER|Tobacco users:Pharmacologic|"Pharmaco Therapy will consist of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months Side effects: Bad taste, Throat irritation, burning in mouth, nausea, vomiting, hiccups, increased heart beat etc~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks Side effects: Skin irritation, dizziness, sleep problems, increased heart beat etc"
40757126|NCT02363127|DRUG|subcutaneous progesterone|subcutaneous progesterone 25 mg/day
40757127|NCT02363127|DRUG|vaginal progesterone|vaginal progesterone in capsules 200 mg/3 times a day
41132526|NCT05481346|PROCEDURE|Multidomain training|"The training program has a duration of 18 weeks with 2 training sessions per week. The training will have a gradual progression of intensity. One day they train two blocks of strength and one block of cognitive exercises and on the second day, they train one block of power, one block of strength+cognitive and one block of aerobic training.~All sessions are 60 minutes long (10 minutes of warm-up, 40 minutes of training and 10 minutes of cool-down). Classes are in small groups of no more than 8 members."
40757128|NCT02867423|DEVICE|CK Boost radiation|single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation
40757129|NCT06032598|DIETARY_SUPPLEMENT|Berry extract 1|The study foresees the intake of 1 capsule per day during 84 days
40757130|NCT06032598|DIETARY_SUPPLEMENT|Berry extract 2|The study foresees the intake of 1 capsule per day during 84 days
40757131|NCT06032598|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 84 days
40757132|NCT02914483|BEHAVIORAL|Enhanced Usual Care|"Participants randomized into the EUC group will complete 8 weekly individual sessions by phone. Each weekly session consists of: brief check-in and review of AHA brochure- Women, Heart Disease and Stroke."
41285257|NCT04788563|OTHER|Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
40757133|NCT02914483|BEHAVIORAL|Stress Management|Participants randomized into the stress management group will complete 8 weekly group sessions by phone. The intervention is a telephone adaptation of mindfulness-based cognitive therapy (MBCT) and focuses on building cognitive-behavioral and mindfulness skills to help manage and cope with stress. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and home-based practice assignment.
41132527|NCT03951259|DRUG|SM934|In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
41285258|NCT04788563|DRUG|Original antihypertensive treatment (preference selection arm)|In this group, patients will maintain their original antihypertensive treatment.
41285259|NCT02510599|DRUG|solithromycin|
41285260|NCT03701503|BEHAVIORAL|Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women|
41285261|NCT04442529|BEHAVIORAL|Mothers and Babies (MB)|Mothers and Babies is an evidence-based postpartum depression prevention intervention. It consists of 12 sessions which each last between 15-20 minutes. Intervention sessions are to be delivered either in person or by phone. The intervention is based on principles of cognitive-behavioral therapy (CBT).
41452069|NCT05323149|OTHER|Saline|Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).
40757134|NCT02914483|DIAGNOSTIC_TEST|Actigraph|The Actigraph (wGT3X-BT) will monitor sleep activity and will be worn by participants for 7 days, pre- and post stress based intervention.
41452070|NCT05323149|DRUG|Tranexamic acid|Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
41452071|NCT00496860|BIOLOGICAL|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
40757135|NCT01348906|PROCEDURE|intermittent normoxia|3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
40757136|NCT03719300|DRUG|inodiftagene vixteplasmid|"BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks"
40757137|NCT02451007|DRUG|lurbinectedin (PM01183)|
41132528|NCT03951259|DRUG|Placebos|The placebo pills are made identical to the investigating SM934 in appearance.
41452072|NCT04432753|BEHAVIORAL|Lung Cancer Screening Decision Aid with Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid with the addition of information on incidental findings for lung cancer screening.
41452073|NCT04432753|BEHAVIORAL|Lung Cancer Screening Decision Aid without Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid that does not include information on incidental findings.
41452074|NCT03586219|BEHAVIORAL|Opioid-specific educational patient pamphlets|See prior description
41452075|NCT06559956|OTHER|Daytime titration polysomnography|A titration polysomnography assesses the device settings and, if necessary, the stimulation strength will be adjusted based on observed respiratory events and/or snoring. Patients in the daytime titration PSG cohort were instructed to refrain from sleeping during the night, and in the morning, they were permitted to sleep in a soundproof room without daylight at the sleep lab.
40757138|NCT03076164|DRUG|Trametinib|Trametinib 1.5mg once daily by mouth
40757139|NCT03076164|DRUG|Erlotinib|Erlotinib 75mg once daily by mouth
40757143|NCT04032262|DIAGNOSTIC_TEST|Gastrointestinal and Parkinson's Disease|Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.
41132529|NCT03589768|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|Used for active immunization of adults and children 7 years of age and older against diphtheria and tetanus.
41132530|NCT03589768|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide|A sterile isotonic suspension of tetanus and diphtheria toxoids and pertussis antigens adsorbed on Aluminum hydroxide.
41285262|NCT05131971|DRUG|GSK3888130B|GSK3888130B will be administered.
41285263|NCT05131971|DRUG|Placebo|Placebo will be administered.
41452076|NCT04212845|DRUG|Bupivacaine;Dexamethasone Solution for Injection|8 mg Dexamethasone and %0.25 bupivacaine
41452077|NCT04212845|DEVICE|Fluoroscopy|Fluoroscopy-guided transforaminal injection
40757144|NCT01044043|PROCEDURE|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
40757145|NCT01506336|DRUG|masitinib|masitinib 12 mg/kg/day
41452078|NCT04212845|DEVICE|Ultrasound|Ultrasound-guided erector spinae plane block
41452079|NCT02786953|BEHAVIORAL|Sleep Promotion|Behavioral intervention to improve sleep quality and duration.
41285264|NCT03035812|DRUG|Alkali|Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
40757146|NCT01506336|DRUG|sunitinib|sunitinib 50 mg/day
40757147|NCT04588558|DEVICE|Flywheel exercise|Flywheel training is a strength training modality that offers the possibility of performing exercises with eccentric overload and variable resistance as compared to conventional gravity-based resistance training. Flywheel exercise applied three days a week for 8 weeks
40757148|NCT04588558|OTHER|Home exercise|The active ROM exercise was performed via knee in extension to full-flexion, then knee in flexion to full-extension exercises, repeated 10 times. The strengthening exercises consisted of quadriceps strengthening by holding maximal isometric contractions for 10 s and performing 10 repetitions. Stretching targeted the gastrocnemius- soleus and hamstring muscle and was performed by asking the patient to stretch the muscle for 30 s and to complete three repetitions for each muscle group.
41132531|NCT04584866|PROCEDURE|Endonasal endoscopic pituitary surgery in semi-sitting position|Patients will be placed in semi-sitting position. To achieve the semi-sitting position, the patient is placed in supine position. The operating table is then separated and flexed to elevate the torso (angle of 30°). The head, which is fixed in a head clamp, is slightly flexed to bring the floor of the sella right in front of the surgeon and gently rotated toward the operating team.
40944005|NCT06181591|DRUG|Mirabegron 50 MG|Mirabegron (IP: Hibero) is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). It is used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. Through a 8 weeks clinical trial, it aims to evaluate the efficacy and safety of Hibero (Mirabegron), especially in maximum voided volume.
40944006|NCT06181591|DRUG|Oxybutynin Chloride 5 MG|Oxybutynin has been used to treat overactive bladder (OAB). The subject will take 5 mg of Ditropan (Oxybutynin Chloride) twice a day, in total of 10 mg for 8 weeks.
41285265|NCT00872066|DEVICE|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
41452080|NCT03439085|BIOLOGICAL|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|Given IM and via electroporation
41452081|NCT03439085|BIOLOGICAL|Durvalumab|Given IV
40757149|NCT04588558|DEVICE|Electrotherapy group|"The participants in the electrotherapy group received TENS (Intellect; Chattanooga Group, Hixson, TN), therapeutic ultrasound (Intellect 340 Combo) and exercise. TENS was applied via four electrodes around the knee joint: two on the medial and two on the lateral aspect on either side of the joint line for approximately 20 min. For pain relief, the devices were set to a continuous mode (110 Hz, 50 μ). Electrical pulses were asymmetric and biphasic.~Therapeutic pulsed ultrasound therapy was administered using a 1-MHz frequency, 0.8 W/cm power ultrasound device with a sound-head area of 5 cm2 and effective radiating area of 3.5-5 cm2 . Ultrasound was applied to the medial and lateral parts of the knee in circular movements for a duration of 5 min with the patient in a supine position.~All participants received the same standardized exercise program. The exercises included aerobic, active ROM, strength, and stretching exercises"
41132532|NCT04584866|PROCEDURE|Endonasal endoscopic pituitary surgery in supine position|Patients will be operated in the standard supine neutral position
41132533|NCT03142490|OTHER|Acupuncture|Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.
41132534|NCT03142490|OTHER|Questionnaires|Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
41132535|NCT04852471|BEHAVIORAL|Standard Post-Operative Counseling + FACT-G|Counseling at discharge + FACT-G at enrollment, at 15-18 and at 30-32 days post-operative.
41132536|NCT04852471|BEHAVIORAL|PROM symptom tracker|A 12-item symptom tracker adopted from the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE), delivered via text, on days 4, 6, 8, 12, 18, 24, and 30 post surgery.
41132537|NCT02501694|OTHER|Auscultation|Electronic stethoscope
41132538|NCT04034966|DEVICE|Claria telemedicine device|Use of Claria telemedicine module, which stores patient information in the cloud.
41452082|NCT00326872|DRUG|Cediranib Maleate|
41452083|NCT05797480|OTHER|Real Dry needling|Real dry needling will be applied to the pelvic floor, hip and lower back muscles.
41452084|NCT05797480|OTHER|Non penetrating dry needling|Sham non penetrating dry needling (fixed needle in an introducer tube) will be applied to the pelvic floor, hip and lower back muscles.
41452085|NCT00246662|DRUG|Vosaroxin|All patients receive vosaroxin Injection
40944007|NCT06058559|DIETARY_SUPPLEMENT|Sunflower lecithin|Lecithins are a group of essential phospholipids that are involved in a number of biological functions such as lipid-cholesterol transport, transmembrane signaling, and neurological function
40757150|NCT05199935|BEHAVIORAL|Video|Information on violence and safety behaviors. Women are encouraged to share their experience of domestic violence with others.
40757151|NCT05199935|OTHER|Control|Control video on healthy pregnancy
40944008|NCT06058559|DIETARY_SUPPLEMENT|Olive oil|Extra virgin olive oil
40944009|NCT01460589|PROCEDURE|timing to initiate the adjuvant chemotherapy|Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
40944010|NCT04126551|OTHER|Methylation status|Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function
40944011|NCT05005078|DRUG|WST-057|WST-057 topical solution
40757152|NCT05378100|DRUG|Ketamine|Infusion of ketamine 0.5 mg/kg over 40 minutes
40757153|NCT05378100|DRUG|Midazolam|Infusion of midazolam 0.05 mg/kg over 40 minutes
40757154|NCT00394225|DRUG|Oxygen|
40757155|NCT00394225|DRUG|Helium|
40757156|NCT06410131|DRUG|FTL008.16|IV infusion every 2 weeks
40944012|NCT05005078|DRUG|Placebo|WST-057 Matching placebo
40944013|NCT06481839|OTHER|Starting dose of NE|Patients will be randomized to either low-dose (5mcg/min) or high-dose (15mcg/min) norepinephrine (NE) for their first vasopressor in shock.
40944014|NCT00411437|DRUG|Tolterodine ER|
40944015|NCT00411437|DRUG|Oxybutynin ER|
41285266|NCT00872066|DEVICE|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
41452086|NCT00702507|DRUG|0.25 % Miconazole Nitrate Ointment|Topical Application
41452087|NCT03611387|DEVICE|CASIA 2 OCT|Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods
41452088|NCT05168722|OTHER|No interventions|No interventions
41452089|NCT03766360|BEHAVIORAL|Functional Analytical Psychotherapy (FAP)|The intervention itself is based on the procedures of Functional Analytic Psychotherapy, a behavioral intervention focusing on improving social functioning.
41452090|NCT03307551|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient (CLADS group)
41452091|NCT03307551|DRUG|Propofol|Propofol delivery will be controlled using infusion pumps which will be manually controlled to deliver propofol to maintain consistent anaesthetic depth (BIS-50). (Manual group)
41452092|NCT06516172|OTHER|Comprehensive disease-specific rehabilitation|"Participation in (a) inpatient rehabilitation, (b) outpatient centre-based, (c) outpatient digitally-enhanced centre- and home-based, or (d) outpatient home-based digital/tele rehabilitation.~Duration is 3 weeks for inpatient and 12 weeks for outpatient programmes."
41452093|NCT05177107|BIOLOGICAL|Phage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
41452094|NCT05177107|OTHER|Placebo|Placebo (normal saline)
41452095|NCT03526484|BEHAVIORAL|Standard of Care|The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.
41452096|NCT03526484|BEHAVIORAL|Experimental|The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
41452097|NCT03643731|DEVICE|HeatTens (HV-F311-E)|Patients need to apply the device during 30 minutes.
41452098|NCT04327401|DRUG|Dexamethasone|Dexamethasone administration for 10 consecutive days after randomization.
41452099|NCT03155867|OTHER|Meal replacement|The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.
41452100|NCT05492162|OTHER|well-being promotion intervention|"The intervention will be organized on both conferences and workshops.~Four themes will be covered :~* Well-being (Workshops)~* Smoking prevention (Conference)~* Balanced diet (Workshop)~* Optimal organization for daily healthy living (Conference)"
41452101|NCT00999687|DRUG|Indigo Naturalis Extract in Oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
41452102|NCT00999687|OTHER|Olive Oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
41452103|NCT03396939|DEVICE|Orthosis|All participants in the experimental group will be given an orthotic device for a 12-week period to use alongside their functional goal- and task-oriented training program.
41452104|NCT06406088|DEVICE|EarGenie MVP test|The EarGenie MVP test consists of placing the EarGenie headgear containing light emitting diodes (LEDs) and light detectors on the infant and running the fNIRS tests of sound detection or sound discrimination via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation in temporal and prefrontal regions of the cortex. Automatic analyses are run to determine whether the infant heard the sounds (at levels 35, 50, and 65 dBSPL) or discriminated between two sounds (Ba/Tea, Ba/Bee, or Ba/Ga). The infant will be in a natural sleep or quiet awake state when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
41452105|NCT06563219|OTHER|Glasgow coma scale|The levels of response in the components of the Glasgow Coma Scale are 'scored' from 1, for no response, up to normal values of 4 (Eye-opening response) 5 ( Verbal response) and 6 (Motor response) The total Coma Score thus has values between three and 15, three being the worst and 15 being the highest.
41452106|NCT06563219|OTHER|Hunt-Hess scale|"The Hunt-Hess scale was used to assess SAH severity according to the clinical presentation and the visible neurological deficits. The Grades run from 1 to 5:~* Grade 1: Asymptomatic or minimal headache, slight neck stiffness.~* Grade 2: Moderate to severe headache, and neck stiffness, but no neurological deficit except cranial nerve palsy.~* Grade 3: Drowsiness, confusion, or a mild focal deficit.~* Grade 4: Stupor, moderate to severe hemiparesis, early decerebrate rigidity, and vegetative disturbance.~* Grade 5: Deep coma, decerebrate rigidity, and a moribund appearance."
41452107|NCT06563219|OTHER|World Federation of Neurological Surgeons (WFNS) scale|"The World Federation of Neurological Surgeons (WFNS) scale, introduced in 1988, is used to evaluate the clinical severity of patients with SAH. This scale is derived from the GCS score and considers the presence of motor deficits:~* Grade 1: GCS score of 15, no motor deficit~* Grade 2: GCS score of 13 to 14, no motor deficit~* Grade 3: GCS score of 13 to 14, with motor deficit~* Grade 4: GCS score of 7 to 12, with or without motor deficit~* Grade 5: GCS score of 3 to 6, with or without motor deficit"
40757157|NCT02714543|DRUG|aloevera juice|aloevera juice to drink twice daily for 3 months.
40944016|NCT02602899|PROCEDURE|PINS'Deep Brain Stimulator device|deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
40944017|NCT04478123|DRUG|Romiplostim|Romiplostim 3.0 mcg/kg SC on Day +1 and Romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated weekly until platelet count is \>50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second Romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. Patients will receive a maximum of six weekly doses of romiplostim.
40944018|NCT03041987|OTHER|Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc|
40944019|NCT01209923|DEVICE|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
40944020|NCT00390598|DRUG|PEG (solution given 4 L)|
40944021|NCT00390598|DRUG|senna glycoside 36 mg and PEG (solution given 2 L)|
40944022|NCT04282278|DRUG|Camrelizumab/sintilimab+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
40944023|NCT04282278|DRUG|Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po
40944024|NCT04282278|DRUG|Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
40944025|NCT05472324|DRUG|TQC2731 injection|TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.
40944026|NCT05472324|DRUG|Placebo|The drug is a placebo Comparator.
40944027|NCT06130917|OTHER|Multisystem Exercise|"Proprioception: Seated ankle ball. Single leg stance with support and with extension of knees. Single leg stance (hip extension) with support and with extension' of knees.~Muscle strengthening: Seated alternate double knee lifts with weights, chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Training Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support.. Crossover with support Reaction time Seated alternate touches to front. Seated alternate touches to back. Seated alternate touches to side. Seated alternate touches to 3 steps (forward, side, backward)."
41132539|NCT02554006|BEHAVIORAL|good clinical practice|education from physician regarding dual antiplatelet therapy as part of the routine discharge process
41132540|NCT02554006|BEHAVIORAL|bundle group|visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
41132541|NCT04784390|DEVICE|Binocular video games|Patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
41285267|NCT05418946|DRUG|Dapagliflozin 10mg|Treatment of T2D and cardio-renal prevention
41285268|NCT04655625|BIOLOGICAL|Group A (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 2-week intervals
41285269|NCT04655625|BIOLOGICAL|Group A (Placebo)|Placebo twice at 2-week intervals
41285270|NCT04655625|BIOLOGICAL|Group B (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 4-week intervals
41285271|NCT04655625|BIOLOGICAL|Group B (Placebo)|Placebo twice at 4-week intervals
41285272|NCT01631162|OTHER|Breath sample in all patients|Breath sample will be collected by a special nylon bag
41285273|NCT01364415|DRUG|Pasireotide LAR|
41285274|NCT03497299|DEVICE|Active rTMS (20Hz)|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
40757158|NCT02714543|DRUG|Hydrocortisone|intralesional injection of hydrocortisone 100mg once a week for 6 weeks
40757159|NCT02714543|DRUG|Hyaluronic Acid|injection hyaluronic acid 1500IU once a week for 6 weeks
40757160|NCT02714543|DRUG|antioxidant|Capsules SM Fibro (antioxidants) once daily for 3 months.
40944028|NCT06130917|OTHER|Conventional Treatment|"ROM exercises Passive ROM exercise of hip. Passive ROM exercise of knee. Passive ROM exercise of ankle Muscle strengthening Seated alternate double knee lifts with weights. chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support. Crossover with support Stretching exercises Stretching exercise of hamstring. Stretching exercise of quadriceps. Stretching exercise of calf muscle"
40944029|NCT06085794|PROCEDURE|Endoscopic combined intrarenal surgery|Combined complex stone clearance with mini-nephroscope and flexible URS
40944030|NCT06085794|PROCEDURE|Percutaneous nephrolithotomy|Clearance of renal stone with nephroscope in prone position
40944031|NCT02128906|DRUG|Cisplatin|Cisplatin 40 mg/m2 weekly x 7
40944032|NCT02128906|RADIATION|IMRT|IMRT: once daily, M-F, 7 weeks (70 Gy)
40944033|NCT02128906|DRUG|Docetaxel|Docetaxel 15 mg/m2 weekly x 7
40944034|NCT02128906|DRUG|Cetuximab|Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
40944035|NCT00294476|DRUG|IVIG|
40944036|NCT00294476|PROCEDURE|Biological Therapy|
40944037|NCT06091579|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a Plastiape capsule-based dry powder inhaler.
40944038|NCT06091579|DRUG|Placebo|Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
40944039|NCT00004920|DRUG|cisplatin|
41285275|NCT03497299|DEVICE|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
40757161|NCT02714543|DRUG|aloevera gel|aloevera gel one scoop to be applied 3-4 times daily for 3 months
40944040|NCT00004920|DRUG|raltitrexed|
41285276|NCT01052285|PROCEDURE|Transversus abdominis plane block|UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
41285277|NCT01052285|PROCEDURE|Saline|UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
41285278|NCT01052285|PROCEDURE|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
41285279|NCT04905329|DRUG|Empegfilgrastim|Extimia®
41285280|NCT00939263|OTHER|assessment of disease activity using the EEsAI|disease activity index
40944041|NCT02672228|DEVICE|MalariaSense device|All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology
40944042|NCT05281952|PROCEDURE|endoscopic ligation|the surgical ligation of one or both sphenopalatine arteries by endoscopic way.
40944043|NCT05281952|PROCEDURE|Supra-selective embolization|occlusion of the terminal branches of the nasal external carotid artery.
40944044|NCT00697073|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
40944045|NCT02302534|DEVICE|MRI|MRI
40944046|NCT02674776|DRUG|HuZhen Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
40944047|NCT02674776|DRUG|Placebo Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
41285281|NCT05394844|DEVICE|Dexcom G6|Dexcom G6 CGM device
41285282|NCT06382753|OTHER|Gingival inflammation|Patients were scored for their status of gingival inflammation using Gingival Index and Bleeding on Probing Scores
40757162|NCT01517776|DRUG|Cilengitide|Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
40944048|NCT05577403|BEHAVIORAL|Mulligan's mobilization with movement MWM added isometric strength training|"Mulligan's mobilization with movement added isometric exercise:~the participants in the experimental group will receive a Mulligan's mobilization with movement added isometric exercise.~Treatment will be given for the period of three weeks, for five days a week in both groups.~Data will be collected before intervention and after 2nd \& 4th week of intervention."
41285283|NCT02112110|DRUG|BMS-791325|
41285284|NCT02112110|DRUG|[13C]-BMS-791325|
40757163|NCT01517776|DRUG|Temozolomide|Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
40944049|NCT03785938|DIETARY_SUPPLEMENT|Probiotic|Liquid probiotic supplied by the company Symprove
40944050|NCT03785938|OTHER|Placebo|Placebo made of maltdextrin. Will be similar in taste and consistency
40944051|NCT00914485|BEHAVIORAL|Provider Communication Skills Training|"Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity."
40944052|NCT03010150|PROCEDURE|Biospecimen Collection|Provide blood samples
40944053|NCT03010150|OTHER|Questionnaire Administration|Ancillary studies
41285285|NCT02657239|BEHAVIORAL|MOVE UP|Weight management behavioral program
41285286|NCT00784069|DRUG|Lactic Acid|Lactic Acid (Dermacyd Breeze)
41285287|NCT02464631|DRUG|Sofosbuvir + Ribavirin 1|
41285288|NCT02464631|DRUG|Sofosbuvir + Ribavirin 2|
41285289|NCT02464631|DRUG|Sofosbuvir + Ribavirin 3|
41452108|NCT06563219|OTHER|modified Fisher scale|"The modified Fisher scale was used to evaluate SAH severity by reference to the extent of hemorrhage as revealed by CT of the brain. Four grades are depending on the degree of bleeding observed:~* Grade 0: No hemorrhage apparent in CT.~* Grade 1: Minimal hemorrhage without intraventricular hemorrhage (IVH).~* Grade 2: Thin or diffusely thin (\<1mm) hemorrhage with bilateral IVH.~* Grade 3: Thick (\> 1 mm) hemorrhage without bilateral IVH.~* Grade 4: Thick (\> 1 mm) hemorrhage with bilateral IVH."
40944054|NCT01934881|DEVICE|voltage adjustment only|Only voltage will be adjusted in all programming sections.
41285290|NCT03476239|DRUG|Blinatumomab|"Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator."
40944055|NCT01934881|DEVICE|Multiple parameters adjustment|More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
40944056|NCT05405933|DIAGNOSTIC_TEST|Propioceptive Neuromuscular Facilitation|Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait
40944057|NCT05405933|DIAGNOSTIC_TEST|Balance Exercise|Balance Exercise Along With Conventional Therapy for Balance and Gait
40944058|NCT05074043|COMBINATION_PRODUCT|antiviral, surgical|surgical debridment
40944059|NCT00810381|DRUG|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
40944060|NCT00810381|DRUG|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
40944061|NCT00810381|DRUG|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
40944062|NCT00810381|DRUG|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
40944063|NCT05913648|OTHER|Tool Translation|The Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with the help of two professional translators and then it will be back-translated into English to cross-check the clarity of the text. The translation will focus more on the context and understanding of the text rather than literal word-to-word meanings. The translation will be done according to the WHO guidelines. The Urdu version of MENQOL will be used to assess content validity on menopausal women.
40944064|NCT02557659|DEVICE|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
41132542|NCT04784390|DEVICE|Patching of the sound eye|Patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
41132543|NCT01488656|DIETARY_SUPPLEMENT|Placebo|7-pill placebo dietary packed visually identical to active dietary supplement
41132544|NCT01488656|DIETARY_SUPPLEMENT|Antioxidant, anti-inflammatory dietary supplement|A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
41132545|NCT03455985|OTHER|Discharge Order Set (DOS)|In addition to the elements in ESC, for the DOS group the primary team will be contacted to complete the Diabetes Discharge order set, which will be pre-populated into the electronic discharge navigator. Follow-up phone calls in the DOS group will also assess and reinforce insulin dose self-titration.
41132546|NCT03455985|OTHER|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
41452109|NCT06563219|OTHER|VASOGRADE scale|"The VASOGRADE scale was established to estimate the risk of delayed cerebral ischemia following SAH. This scale is based on the WFNS and the modified Fisher scales at admission. There are three categories:~* Green: WFNS score of 1 or 2 and modified Fisher scale of 1 or 2.~* Yellow: WFNS score of 1 or 3 and modified Fisher scale of 3 or 4.~* Red: WFNS score of 4 or 5 and any modified Fisher scale score."
41452110|NCT06563219|OTHER|Ogilvy and Carter scale|"The Ogilvy and Carter scale is a grading system used to predict the outcomes of surgical treatment in patients with SAH due to a ruptured aneurysm. The scale considers multiple factors, including age, Hunt and Hess grade, Fisher grade, and aneurysm size, with a score assigned to each of these variables:~* Age greater than 50~* Hunt and Hess grade of 4 to 5~* Fisher grade scores of 3 to 4~* Aneurysm size \>10 mm~* An additional point is added for a giant posterior circulation aneurysm (≥25 mm)"
41132547|NCT02163148|BEHAVIORAL|Massed speech exposure session|One session consisting of 4 speech exposures, each 5 minutes long.
41132548|NCT06028308|DEVICE|Smartphone playing a sound|A sound will be played from a portable device (smartphone mounted with earphones) during movement
41132549|NCT02879136|DRUG|Methylphenidate|Patient will be randomized to Methylphenidate
41132550|NCT02879136|OTHER|Physical Therapy|All Patients will have standard of care PT used for PD patients
41132551|NCT02879136|DRUG|Atomoxetine|Patient will be randomized to Atomoxetine
41132552|NCT05108259|DRUG|PBP1502|40 mg/0.4 mL single SC injection via PFS
41132553|NCT05108259|DRUG|EU-licensed Humira|40 mg/0.4 mL single SC injection via PFS
41132554|NCT05108259|DRUG|US-licensed Humira|40 mg/0.4 mL single SC injection via PFS
41132555|NCT04129099|BIOLOGICAL|GC022F|GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.
41132556|NCT00874588|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
41285291|NCT03476239|DRUG|Dexamthasone|Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
41285292|NCT03929042|DEVICE|Posture correction girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
41285293|NCT05502588|BEHAVIORAL|Self-Guided Forest Bathing|Participants will participate in two, 60-90 minute self-guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails and be given prompts to consciously use their five senses in the forest.
41285294|NCT05502588|BEHAVIORAL|Guided Forest Bathing|Participants will participate in two, 60-90 minute guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails. They will be invited by a certified forest therapy guide to consciously use their five senses in the forest.
41285295|NCT05233995|PROCEDURE|Damage Control Surgery|Delayed anastomosis
41285296|NCT03563248|DRUG|FOLFIRINOX|"FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~* Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle"
41285297|NCT03563248|DRUG|Losartan|Losartan is a drug that is used to lower blood pressure
41285298|NCT03563248|DRUG|Nivolumab|Nivolumab is an antibody that may cause programmed cell death of cancer cells
41285299|NCT03563248|RADIATION|SBRT|Radiation therapy is believed to increase the likelihood of response of immunotherapy
41285300|NCT03563248|PROCEDURE|Surgery|definitive surgical resection
41285301|NCT01963637|DEVICE|gastric tomodensitometry with gas at 3 months and 12 months|
41285302|NCT01707875|OTHER|fetal brain neurosonography|fetal brain neurosonography according to the ISUG guidelines
41285303|NCT06208176|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Patients will receive 20 sessions of active HD-tDCS for a duration of 20min. Sessions will be delivered twice-daily over 2 weeks on the 5 consecutive working days. The number of electrodes used, electrode placement on the scalp (based on EEG 10/10), and the individual currents that need to be injected from each electrode will be determined based on the brain networks identified as involved in their hallucinations during a fMRI acquisition performed at baseline, and computed using a neurotargeting software that allows determining optimal electrode montages for achieving maximal brain current flow in the targeted brain region.
41285304|NCT06208176|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|Participants will receive 20 sessions of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS. However, stimulation will only be administered in the initial 30 seconds of the 20-minute period, with no further stimulation during the remaining duration. This approach aims to replicate the tingling sensation commonly associated with active stimulation.
41285305|NCT01121406|DRUG|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
41285306|NCT01121406|DRUG|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
41285307|NCT01121406|DRUG|Topotecan|Patients receive topotecan in 3 or 4 week schedule
41285308|NCT01121406|DRUG|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
41285309|NCT01121406|DRUG|BI 6727|Patients receive BI 6727 infusion every 3 weeks
41285310|NCT02651610|BIOLOGICAL|Bavituximab|Biological: bavituximab
41285311|NCT02651610|DRUG|Taxane|Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
41285312|NCT05859815|BEHAVIORAL|Physical Therapy|As part of their normal care, participants will receive any combination of the following interventions to address their specific needs identified during the initial evaluation: cervical spine repeated movements (active range of motion), cervical spine stabilization exercise, aerobic exercise, motor control training, oculomotor/vestibular rehabilitation, stretching, soft-tissue mobilization, joint mobilization, and postural re-education activities.
41452111|NCT05683561|BIOLOGICAL|CoronaVac|D0; intramuscular injection
41452112|NCT05683561|BIOLOGICAL|SCTV01E|D0; intramuscular injection
41452113|NCT04956289|DRUG|Viltolarsen|Received during weekly intravenous infusions
41285313|NCT03396081|BEHAVIORAL|PRADO-IC|"1. Help of administrative employees to schedule the first medical visits after an hospitalization for heart failure.~2. Home nurse's visiting program, during 2 to 6 months after the hospitalization for heart failure."
40944065|NCT05527405|DEVICE|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
40944066|NCT05674175|BIOLOGICAL|Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)|CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
41285314|NCT03396081|BEHAVIORAL|No intervervention Usual Care|Advices about the care pathway, provided by care givers. Prescription of home nurse's visits if needed.
41285315|NCT00760175|BIOLOGICAL|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
41285316|NCT06316661|DIAGNOSTIC_TEST|stress perfusion cardiac magnetic resonance|stress perfusion cardiac magnetic resonance according to guidelines, with quantitative evaluation for microvascular dysfunction assessment
41285317|NCT06316661|DIAGNOSTIC_TEST|cardiopulmonary exercise test|bike exercise with ECG and non invasive respiratory gas exchange monitoring
41285318|NCT05089565|DIAGNOSTIC_TEST|Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation|Measurement of humeral and cell-mediated immune responses to SARS-CoV-2 vaccination
41285319|NCT05041543|DRUG|NTX-101|Eye drops, topical administration
41285320|NCT05041543|DRUG|Placebo|Placebo as eye drops
41452114|NCT04635007|DRUG|Tranexamic acid|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
41452115|NCT04635007|DRUG|Misoprostol 200mcg Tab|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
41452116|NCT00864396|DRUG|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
41452117|NCT04306601|DEVICE|Low-Intensity Focused Ultrasound|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
41452118|NCT05919199|OTHER|No intervention|No intervention
41285321|NCT01960010|DRUG|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
41285322|NCT01960010|DRUG|Vehicle|Vehicle dosed BID
41285323|NCT02429648|PROCEDURE|DCC first then PVI|DCC performed prior to PVI
41285324|NCT02429648|PROCEDURE|PVI then DCC after|DCC performed after PVI, if patient remains in Atrial Fibrillation
41285325|NCT03489291|GENETIC|AAV5-hFIXco-Padua (AMT-061)|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
41285326|NCT01025336|OTHER|Blood draw|Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1
41285327|NCT01025336|OTHER|Blood draw|Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
41452119|NCT02518139|DRUG|TD-4208|Subjects receiving TD-4208 are blinded to one of two doses of 4208.
41452120|NCT02518139|DRUG|Tiotropium|There is not a placebo, there is an active comparator (Tiotropium) arm.
41452121|NCT05863221|DRUG|ZYNRELEF 200Mg-6Mg Extended-Release Solution|ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
41452122|NCT05263635|OTHER|Music therapy|Music therapy will include music intervention based on recommendations from literature such as slow, flowing rhythm, approximately 60-80 beats/minute and played by string instruments, played with a volume of approximately 45 decibel and will be reviewed by qualified music therapists.
41285328|NCT02490540|DRUG|Sufentanil SPI analgesia|Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
40944067|NCT05674175|BIOLOGICAL|Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)|HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
40757164|NCT03615768|COMBINATION_PRODUCT|Adapalene-Clindamycin Combination Gel|5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
40757165|NCT03615768|DRUG|Adapalene Gel|Differin 0.1% Gel, applied nightly for 12 weeks
41285329|NCT02490540|DRUG|Sufentanil ANI analgesia|Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
41285330|NCT02490540|DRUG|Sufentanil anesthesiologist analgesia|Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
41285331|NCT01723306|GENETIC|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
41285332|NCT06364748|DEVICE|Cellular enabled blood pressure cuff|Smart cuff
40757166|NCT03615768|DRUG|Clindamycin Gel|Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
40757167|NCT00803049|DRUG|Teriflunomide (HMR1726)|Tablet, oral administration QD.
41285333|NCT06364748|DEVICE|Standard of Care Cuff|Standard blood pressure cuff
40757168|NCT00004163|DRUG|Trastuzumab|
41132557|NCT03444415|OTHER|Motivational interviewing in groups|Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children.
41132558|NCT03444415|OTHER|Usual care|Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits
41132559|NCT05996900|DEVICE|Intracranial electrodes|Intracranial electrodes will be used for the delivery of invasive brain stimulation.
40757169|NCT01093534|DRUG|Placebo|Matching solifenacin placebo tablet
41285334|NCT01744899|OTHER|Sitting posture|The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
40944068|NCT06333093|PROCEDURE|Cold snare|Two (2) cold snare resections of the duodenal mucosa during an already scheduled upper gastrointestinal interventional endoscopy under deep sedation (propofol).
40944069|NCT03181893|DRUG|PF-06823859 low|A humanized immunoglobulin neutralizing antibody
40944070|NCT03181893|DRUG|Placebo Arm|Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
40944071|NCT03181893|DRUG|PF-06823859 high|A humanized immunoglobulin neutralizing antibody
40944072|NCT05191654|DIAGNOSTIC_TEST|evaluation of cardiopulmonary parameters, gross motor development and hand grip strength|Gross motor development was evaluated with Gross Motor Function Measure (GMFM-88). Hand grip strength was measured with the Baseline Pneumatic Bulb Dynamometer. Cardiopulmonary parameters values was evaluated with echocardiography.
40944073|NCT03409068|PROCEDURE|C2-C4 compartment anesthetic block|C2-C4 compartment anesthetic block is performed by injecting levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenus muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
40944074|NCT03409068|PROCEDURE|Costagliola block|Costagliola block is performed by injected by injecting levobupivacaine 0.375% 20 mL along the anterior and the posterior border of sternocleidomastoid muscle
40944075|NCT00904319|OTHER|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
40757170|NCT01093534|DRUG|solifenacin|Tablet for oral administration
40757171|NCT01345942|DRUG|RO5428029|Single oral dose
41285335|NCT02267928|OTHER|Check Symptoms|"Symptoms are Checked"
41132560|NCT05996900|DEVICE|TMS|TMS will be used for the delivery of noninvasive brain stimulation both before and after implantation electrode surgery.
40757173|NCT05875610|DRUG|Venlafaxine 75 MG|Venlafaxine 75 mg extended release capsules for a 7-days duration
40757174|NCT05875610|DRUG|Gabapentin 400 mg|Gabapentin 400 mg capsules
40757175|NCT06549920|RADIATION|Internal mammary node irradiation|Irradiation of the internal mammary nodes in intercostal space 1-4.
40757176|NCT03752073|DEVICE|Trans-cervical cervical balloon|Insertion of Foley Catheter
40944076|NCT00772083|BEHAVIORAL|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
40944077|NCT00772083|BEHAVIORAL|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
40944078|NCT06282393|DEVICE|FibriCheck recordings|PPG and single-lead ECG measurements
40944079|NCT03842085|DRUG|Recombinant Humanized Bispecific Monoclonal Antibody MBS301|The patients confirming to the eligibility criteria will be assigned to the 8 dose groups based on the sequence of inclusion. MBS301 will be administered intravenousely on day 1 of each 21-day cycle for each patient.The first intravenous infusion for each patient will be last for 90 minutes.It could be changed to 60 minutes for the subsequent infusions if the drug is well tolerated.
40944080|NCT03509831|DRUG|INT-2150|"1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg"
40944081|NCT03509831|DRUG|Irsogladine maleate 2 mg+Nizatidine 150 mg|"1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~2. Period: INT-2150"
40944082|NCT04877873|BEHAVIORAL|Gait analysis pre- and post- surgery|None (observational)
40944083|NCT04330183|DRUG|Ketamine|0.3mg/kg of ketamine
40944084|NCT04330183|DRUG|Normal Saline|3cc of normal saline
41132561|NCT02186106|DRUG|Cholecalciferol|
41285336|NCT02267928|OTHER|Uncheck Symptoms|"Symptoms are Un-checked"
40944085|NCT00674973|DRUG|Erlotinib|Participants received erlotinib 150 mg tablet orally once daily.
40944086|NCT00674973|DRUG|Placebo|Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
40944087|NCT01279031|DEVICE|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound|Comparison of vision after cataract surgery based on two different types of equipment.
40944088|NCT01279031|DEVICE|Alcon Infiniti wiht the OZIL Torsional Handpiece|Comparision of vision after cataract surgery based on two different types of equipment.
40944089|NCT03300323|DIAGNOSTIC_TEST|IV fluid challenge administration|Administration of an intravenous fluid challenge to assess for fluid responsiveness
40944090|NCT01938872|PROCEDURE|paclitaxel eluting balloon angioplasty in below-the-knee lesions|
40944091|NCT02290327|DRUG|Pantoprazole|Proton pump inhibitor
40944092|NCT02290327|DRUG|Placebo|50 ml of 0.9% normal saline
40944093|NCT04587544|BEHAVIORAL|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
40944094|NCT02155569|PROCEDURE|Extraperitoneal Cesarean|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
40944095|NCT02155569|PROCEDURE|Transperitoneal Cesarean|Pfannenstiel-Kerr technique for laparatomy and uterine entry
41285337|NCT02267928|OTHER|Experienced|Focus of instructions is on symptoms the participant has experienced
41452123|NCT05263635|OTHER|Standard of Care Enhanced Recovery After Surgery (ERAS)|Patients will receive the standard of care treatment for surgery and post-operative pain management, following the Enhanced Recovery After Surgery (ERAS) protocol
40944096|NCT05919329|DRUG|Piflufolastat|Given IV
40944097|NCT05919329|PROCEDURE|PSMA PET/CT Scan|Undergo PSMA PET/CT
40944098|NCT05919329|PROCEDURE|PSMA PET/MRI scan|Undergo PET/MRI
40944099|NCT05919329|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40944100|NCT05919329|OTHER|Electronic Health Record Review|Ancillary studies
40944101|NCT01241773|DRUG|raltegravir|One 400 mg tablet twice daily for 7 days
40944102|NCT01241773|DRUG|TMC435 + raltegravir|Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
40944103|NCT01241773|DRUG|TMC435|Two 75 mg capsules once daily for 7 days
40944104|NCT01241773|DRUG|TMC435 + efavirenz|Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
40944105|NCT01241773|DRUG|TMC435|Two 75 mg capsules once daily for 14 days
40944106|NCT01241773|DRUG|efavirenz|One 600 mg tablet once daily for 14 days
41285338|NCT02267928|OTHER|Not Experienced|Focus of instructions is on symptoms the participant has NOT experienced
41285339|NCT03580447|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
41285340|NCT03580447|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
40944107|NCT05486754|BEHAVIORAL|Cognitive behavioral stress management|Participants will receive in-person weekly stress management group sessions (3-8 participants) for two hours per week for ten weeks total. Each session will consist of a half hour of relaxation training and one and a half hours of stress management skill training, including coping effectiveness training, anger management, assertiveness training, and stress awareness.
40944108|NCT05486754|BEHAVIORAL|Psychoeducational Control|Participants will receive one four-hour seminar in-person groups (3-8 participants) of educational information related to prostate cancer and abbreviated psychological information provided in cognitive behavioral stress management.
40944109|NCT00520832|DEVICE|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
40944110|NCT00520832|DEVICE|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
40944111|NCT00920933|BIOLOGICAL|AIN457|
40944112|NCT00920933|OTHER|Placebo|
41285341|NCT01283620|BEHAVIORAL|modified constraint induced movement therapy (mCIMT)|The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
41285342|NCT01283620|OTHER|Usual and Customary Care|Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
41285343|NCT01505062|DRUG|SAR421869|"Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
41285344|NCT01839994|RADIATION|CF-CRT combined with BT or SBRT boost.|CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
41285345|NCT01839994|RADIATION|CF-CRT alone|Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
41285346|NCT01839994|DRUG|Hormonal treatment (neoadjuvant androgen deprivation)|Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
40757177|NCT03752073|DEVICE|Hygroscopic cervical dilator|Insertion of Dilapan-s
40757178|NCT04481438|OTHER|Acupunch Exercises|The acupunch exercise program was developed based on Jing-Luo theory of tranditional Chinese Medicine. The experiment group will receive Acupunch exercise for 40 minute sessions, 3 times a week, for 24 weeks
40757179|NCT03279068|OTHER|Teaching and EFM Paper|Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
40944113|NCT00920933|DRUG|prednisolone|
40944114|NCT04924959|OTHER|Logistic Regression Analysis|Using logistic regression analysis to analyze the independent risk factors of PICC catheter displacement
41132562|NCT06052722|OTHER|Correlation assessment|The relationship between the Premenstrual Syndrome Impact Scale and the Fonseca Anamnestic Index will be examined for individuals with premenstrual syndrome. The relationship between Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea Score and Fonseca Anamnestic Index will be examined for individuals with primary dysmenorrhea.
41132563|NCT05125224|DRUG|Dihydropyridine calcium channel blocker|Dihydropyridine calcium channel blocker claim is used as the exposure group.
41132564|NCT05125224|DRUG|Hydrochlorothiazide|Hydrochlorothiazide claim is used as the reference group.
41132565|NCT02399241|DEVICE|Bluetooth enabled nebuliser device (I-neb)|
40944115|NCT04124653|DRUG|PF-06842874|Single dose administration of PF-06842874
41132566|NCT05964426|OTHER|Turkey Health Literacy Scale (TSOY-32)|A survey will be conducted.
41132567|NCT03082313|BEHAVIORAL|Movement Intervention|At each visit, the caregiver will be reminded of the infant's movement rate from the last visit. The research team will help the caregiver to determine possible ways to achieve the goal of 1200 movements per hour of awake time. Strategies to increase leg movements will be encouraged based on the infant's developmental level and what they demonstrate a response to, including: shake a toy when infant moves legs, sing a line of a song when infant moves legs, change the position of the infant to encourage more leg movement, or lightly tickle the legs and feet of the infant. The intervention will be based upon the GAME (Goals - Activity - Motor Enrichment) protocol, a motor learning, environmental enrichment intervention that has recently been shown to be effective for improving motor skills in infants at high risk of cerebral palsy compared to standard care.
41132568|NCT02923349|DRUG|INCAGN01949|Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
41132569|NCT04806841|BEHAVIORAL|Motivational intervention|Three group meeting of 60 minutes to help create effective goals and methods on maintaining motivation to exercise regularly. These meetings will help participants create effective goals and methods on maintaining their motivation to exercise regularly. They will then receive a monthly phone call follow-up at months 4-6.
40944116|NCT04124653|DRUG|Placebo|Single dose administration of placebo
41285347|NCT04789785|DIAGNOSTIC_TEST|ultrasound|observation with usg
40944117|NCT04124653|DRUG|Relative Bioavailability|Relative bioavailability assessment of modified-release formulation
40944118|NCT03946488|DEVICE|Functional electrical stimulation|Functional electrical stimulation of finger's muscles in order to open the hand
40944119|NCT02699359|DEVICE|HS-1000 recording|
40944120|NCT03793868|DRUG|Perampanel|Oral tablet
40944121|NCT03793868|OTHER|Placebo|Placebo (not drug)
40944122|NCT02913612|DRUG|0.25% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
40944123|NCT02913612|DRUG|0.5% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution
40944124|NCT04143087|DRUG|withdrawal TKIs or halve TKIs|Stop TKIs or treated by half TKIs
40944125|NCT02215031|DRUG|BI 44370|
40944126|NCT02215031|DRUG|Placebo|
41132570|NCT04806841|OTHER|Control intervention|Participants in the control group will be simply encouraged to exercise at the EPIC center and complete the online surveys. Participants in the control group will receive the skills/tactics at the end of the study.
41452124|NCT05411653|OTHER|Virtual reality training with motor imagery|comprised of 30 minutes, VRT (15 minutes) and MI (15 minutes) daily for 3 days respectively. Five Xbox Kinect gaming will be selected and explained to the patients for the virtual training session and additional 15 minutes will be given to them for practice. The games consists of 20,000 water leaks, river rush, reflex ridge, soccer and football for the patients.
40944127|NCT06166082|DEVICE|Active iTBS-DLPFC|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.
40944128|NCT06166082|DEVICE|Sham iTBS-DLPFC|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
40944129|NCT05435209|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|Gardasil
41452125|NCT05411653|OTHER|Conventional physical therapy|range of motion exercises, muscle strengthening, functional training, balance training, and gait training. The specific tasks will be selected by the therapist based on the requirement of each patient. It will be performed for 30 minutes for 3 days a week for 6 weeks
41452126|NCT04198090|BEHAVIORAL|SGM Competency Training Program|A validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for oncology
41452127|NCT02719665|DIETARY_SUPPLEMENT|SPM Emulsion, Dose-modality|"Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml"
40944130|NCT05133076|BIOLOGICAL|Lactobacillus gasseri BGP345A|Active and placebo capsules for oral use
40944131|NCT05133076|BIOLOGICAL|Placebo|Placebo
40944132|NCT02933112|DEVICE|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
40944133|NCT05476536|BEHAVIORAL|self-management skills and healthy technology APP|self-management skills and healthy technology APP
40944134|NCT00506610|DRUG|T-62|
40944135|NCT01722773|DEVICE|Bipap (Respironics, Inc)|Bipap every night pressure at 15/5 with heated humidifier
40944136|NCT03851471|DRUG|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
40944137|NCT00740077|OTHER|Low calorie, sugar-free cranberry juice cocktail (54% juice)|Single-dose, 24 hour pharmacokinetic trial of 8 oz dose administered orally.
41132571|NCT00738400|DRUG|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
41132572|NCT00738400|DRUG|Placebo|Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
41132573|NCT01320800|BEHAVIORAL|Skills for Academic and Social Success|12-week cognitive-behavioral, school-based group intervention
40944138|NCT05115578|DRUG|Remifentanil 1 MG Injection [Ultiva]|Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.
40944139|NCT05115578|DRUG|Midazolam 1 MG/ML Prefilled Syringe|Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv
40944140|NCT05115578|DRUG|Saline solution|Group III Control
40944141|NCT05115578|DEVICE|Algometry|The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.
41132574|NCT01320800|BEHAVIORAL|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors.
40944142|NCT03854188|PROCEDURE|Acupuncture|Use acupuncture therapy in the treatment of chronic pelvic pain.
41132575|NCT00569166|BEHAVIORAL|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
41132576|NCT00569166|BEHAVIORAL|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
40944143|NCT01624337|DRUG|DHA-piperaquine|"Drug: Dihydroartemisinin piperaquine~40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)"
40944144|NCT01624337|DRUG|placebo|
40944145|NCT02192073|PROCEDURE|Suprapectoral Biceps tenodesis|
40944146|NCT02192073|PROCEDURE|Subpectoral biceps tenodesis|
40944147|NCT06337422|DRUG|Celecoxib 200 mg capsule|Celecoxib 200 mg capsule
41132577|NCT00569166|BEHAVIORAL|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
41132578|NCT05419466|DIETARY_SUPPLEMENT|dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm|dietary supplement is dosed at 1.9 mg of melatonin, 10 mg of zinc and 200 mg of lemon balm for one tablet
41132579|NCT01719172|DEVICE|Veriset™ Hemostatic Patch|Topical Hemostat
41132580|NCT05853952|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA
41285348|NCT05126615|DRUG|Auriculotherapy|Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.
41285349|NCT05126615|BEHAVIORAL|Chronic Post-Surgical Pain evaluation|"Different questionnaires :~BPI : Brief Pain Inventory DN4"
41285350|NCT04096937|OTHER|Focus groups|Focus groups will be conducted with adult stakeholders and with youth in Appalachia. Feedback from the focus groups will guide cultural tailoring of the Journey of Hope in Appalachia intervention for use in a later phase.
41285351|NCT02213718|DRUG|Desflurane|desflurane (7%-8% end-tidal concentration)
41285352|NCT02213718|DRUG|propofol|propofol (TCI:3.5-4.0μg/min)
41285353|NCT02213718|DRUG|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
41285354|NCT05738980|BIOLOGICAL|Autologous RAK cells|Autologous RAK cells were treated by intravenous reinfusion
41285355|NCT02778997|PROCEDURE|CSF Shunt treatment for hydrocephalus|State after CSF shunt implantation
40944148|NCT01498835|DRUG|Sunitinib|"Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual."
40944149|NCT04229979|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
40944150|NCT04229979|DRUG|Azacitidine|injection
40944151|NCT04229979|DRUG|Venetoclax|tablet
41285356|NCT00365781|DRUG|ISIS 113715|
41285357|NCT01901328|DRUG|CB-5945|
41285358|NCT01901328|DRUG|Placebo|
41285359|NCT05150860|BEHAVIORAL|At-home COVID-19 testing|At-home over-the-counter (OTC) COVID-19 testing kits provided to middle school students and staff
41285360|NCT05150860|BEHAVIORAL|Family-based model|Making the COVID-19 testing program available to household/family members to increase participation of students and staff in the school COVID-19 testing program
41285361|NCT05150860|BEHAVIORAL|Onsite COVID-19 testing|Onsite COVID-19 testing for middle school students and staff
41285362|NCT04684030|DEVICE|Continuous glucose monitoring system(CGMS)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in CGMS group will given education on how to use the device and check the result using the smart phone. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total numbers of scans conducted during the study period.
41285363|NCT04684030|DEVICE|Self-monitoring of blood glucose (conventional fingerpricking method)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in SMBG group will check their blood glucose by finger pricking method and record the data in a notebook to share the data in their outpatient clinic visit.
40944152|NCT04229979|DRUG|Decitabine|injection
40944153|NCT04229979|DRUG|Cytarabine|injection
41285364|NCT04462042|RADIATION|Proton radiotherapy|Proton radiotherapy
41285365|NCT04462042|RADIATION|Photon radiotherapy|Conventional photon radiotherapy
41285366|NCT00256555|DRUG|Nutropin AQ|
41285367|NCT04668378|OTHER|Time restricted eating|TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.
41285368|NCT04668378|OTHER|Normal Diet|ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.
40757181|NCT04009135|BEHAVIORAL|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
40757182|NCT04009135|BEHAVIORAL|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind \& acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
41132581|NCT05853952|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
40757183|NCT04009135|OTHER|Attention Control (AC)|1-module of psychoeducation about chronic pain and major depression. Weekly contact to complete measures of symptomatology and well-being.
40757184|NCT02969226|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
40757185|NCT02969226|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
40757186|NCT02969226|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS \>0 and =\< 8 cm H2O with PEEP\>0 and =\< 5 cm H2O
40757187|NCT02969226|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
40757188|NCT03387579|DRUG|Smoflipid 20% Lipid Emulsion for Injection|Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
40757189|NCT03387579|DRUG|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day
40757190|NCT03387579|DRUG|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day
40757191|NCT03216291|BEHAVIORAL|biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems. Complete training sessions once a week for 6 weeks in the office.
40757192|NCT03216291|DEVICE|Home Biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems, but instead of an office therapy, the subject will use a biofeedback device to gain strength in their anorectal muscles. This device will be taught how to use in the first session and then the subject will take it home to complete at least 1 session a day for 6 weeks.
40757193|NCT04718441|DRUG|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
40757194|NCT02845180|PROCEDURE|Adipose Allograft Extracellular Matrix (AAM) Injection|Injection followed by surgery
40757195|NCT02620865|BIOLOGICAL|Aldesleukin|Given SC
40757196|NCT02620865|BIOLOGICAL|Antibody Therapy|Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
41285369|NCT01228773|BEHAVIORAL|Tailored web-based care program (Health Navigation®)|When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
41285370|NCT02646904|DRUG|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
40757197|NCT02620865|DRUG|Fluorouracil|Given IV
40757198|NCT02620865|DRUG|Gemcitabine Hydrochloride|Given IV
40757199|NCT02620865|DRUG|Irinotecan Hydrochloride|Given IV
41285371|NCT02646904|DRUG|CERCHIO 10 mg/ml OS|For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days.
40757200|NCT02620865|OTHER|Laboratory Biomarker Analysis|Correlative studies
41285372|NCT05897424|DRUG|INBRX-101|A1PI, Recombinant, Bivalent Fc Fusion Protein
40757201|NCT02620865|DRUG|Leucovorin Calcium|Given IV
40757202|NCT02620865|DRUG|Oxaliplatin|Given IV
40757203|NCT02620865|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
40757204|NCT02620865|BIOLOGICAL|Sargramostim|Given SC
40757205|NCT00423865|DRUG|cisplatin|cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
40757206|NCT00423865|DRUG|everolimus|escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
40944154|NCT04229979|OTHER|Observation|palliative management
40944155|NCT04229979|BIOLOGICAL|GM-CSF|subcutaneous injection
40944156|NCT04229979|OTHER|Montanide|adjuvant
40944157|NCT02469207|OTHER|Removal of tissue post-mortem|
40944158|NCT05563844|DRUG|PM 8.4 mg/m2|1 case, Take the medicine once on D1,D 1-21.
40944159|NCT05563844|DRUG|PM 11.2 mg/m2|1 case, Take the medicine once on D1,D 1-21.
40944160|NCT00596297|DRUG|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
40944161|NCT00596297|PROCEDURE|pars plana vitrectomy|4 weeks after baseline
40944162|NCT04945031|OTHER|cannabis|This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.
40944163|NCT02715245|PROCEDURE|Home-based rehabilitation|Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
40944164|NCT03079180|OTHER|Strength training at 80% 1RM|Detailed in Arms section's
40944165|NCT03079180|OTHER|Strength training at 55% 1RM|Detailed in Arms section's
40944166|NCT02575131|OTHER|whole wheat bread yeast basis|
40944167|NCT02575131|OTHER|Oatmeal|
40944168|NCT02575131|OTHER|Cheerios|
40944169|NCT02575131|OTHER|whole wheat sourdough bread|
40944170|NCT02575131|OTHER|standard breakfast|
41132582|NCT01413659|BIOLOGICAL|Symbiotic|Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
41132583|NCT01583166|DRUG|Bupivacaine|10ml 0.5% bupivacaine
40944171|NCT04565184|DRUG|Artesunate-amodiaquine combination|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
40944172|NCT04565184|DRUG|Artemether, Lumefantrine Drug Combination|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
40944173|NCT06008028|DRUG|BR1015|One tablet administered alone
40944174|NCT06008028|DRUG|BR1015-1|One tablet administered alone
40944175|NCT06008028|DRUG|BR1015-2|One tablet administered alone
40944176|NCT03250429|PROCEDURE|Sinus surgery|Standard Clinical Sinus Surgery
40944177|NCT04280146|BEHAVIORAL|daily energy intake|Investigate daily energy intake according to eating rate and food processing
40944178|NCT04075110|DRUG|Montelukast 10mg|Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
40944179|NCT04075110|DRUG|Placebo|Placebo tablet once daily
40944180|NCT03857035|OTHER|Piezosurgery group|Piezosurgery technique will be examined about impacted third molar surgery.
41132584|NCT01583166|DRUG|Saline|10ml 0.9% sodium chloride
40944182|NCT03024814|DRUG|Acetaminophen|"The first group will receive acetaminophen as the following~1. Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~2. Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
41132585|NCT01583166|DRUG|Epinephrine|1:200,000 epinephrine
41132586|NCT01084941|BEHAVIORAL|Lifestyle Intervention group|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
41132587|NCT01084941|BEHAVIORAL|Standard of Care|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
41132588|NCT01523392|DRUG|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
41132589|NCT01523392|DRUG|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
41132590|NCT00523419|DRUG|Pemetrexed|500 mg/m\^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
40944183|NCT03024814|DRUG|Dextrose 5|"The second group will receive placebo (D5W) as the following~1. Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~2. Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
40944184|NCT01267656|DEVICE|Lubricating and Rewetting Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
40944185|NCT01267656|DEVICE|AMO Blink Contacts Lubricant Eye Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
41132591|NCT01335867|DRUG|Vigabatrin|Vigabatrin escalated to 3 grams daily for 8 weeks
40944186|NCT06253546|DRUG|TV-44749|"Pharmaceutical form:~extended-release injectable suspension~Route of administration: subcutaneous injection"
40944187|NCT06253546|DRUG|Oral Olanzapine|"Pharmaceutical form:~tablet~Route of administration:~oral"
41285373|NCT00376688|OTHER|Laboratory Biomarker Analysis|Correlative studies
41285374|NCT00376688|DRUG|Temsirolimus|Given IV
41285375|NCT06374641|DIETARY_SUPPLEMENT|Mitochondrial Substrate Supplement|Mitochondrial Substrate supplement, 2xdaily 65 mL drink
40944188|NCT02600351|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
40944189|NCT02600351|DRUG|RBV|Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
40944190|NCT02276365|DRUG|BI 10773|
41285376|NCT06374641|DIETARY_SUPPLEMENT|Placebo Supplement|Placebo supplement, 2xdaily 65 mL drink
41285377|NCT02950129|OTHER|SIJ pain diagnostic tests|The subjects will undergo a specific physical exam of tests reported to be diagnostic of sacroiliac joint (SIJ) pain prior to receiving the routine injection in the SIJ; all tests will be repeated after the SIJ injection
41285378|NCT03958201|COMBINATION_PRODUCT|Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
40944191|NCT02276365|DRUG|Pioglitazone|
41285379|NCT06209697|DIETARY_SUPPLEMENT|red clover|Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
41285380|NCT02463591|DRUG|Beriplex|Beriplex 50 IU/Kg i.v. , single dose.
41285381|NCT04415138|DEVICE|Robotic-assisted mitral valve repair|Mitral valve repair using robotic technology (DaVinci X platform)
41285382|NCT04099342|DEVICE|FEAST|FEAST with standard electrode configuration and current flow
41285383|NCT04099342|DEVICE|FEAST RP|FEAST with standard electrode configuration and reversed current flow
41285384|NCT04392986|OTHER|Sunlight exposure|The weather was sunny and found suitable for outside activity and sunlight exposure program, with a mean temperature of 27.0-28.5 °C, the humidity of 64-80%, and global solar exposure of 1.28 to 2.99 MJ/m2 during treatment.\[15\] Participants were asked to lie on the beach for 45 minutes per day between 2 to 3 pm to avoid extreme skin irritation and sunburn from direct sunlight exposure.
41285385|NCT00215618|DEVICE|Uterine Balloon Therapy|UBT with post procedure curettage
41285386|NCT00215618|DEVICE|Uterine Balloon Therapy|UBT without post procedure curettage
41285387|NCT01606722|DRUG|Darunavir/ritonavir|Darunavir/ritonavir (800/100 mg once daily) monotherapy
40944192|NCT00690222|PROCEDURE|Intracameral injection of mydriatic agent|A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
40944193|NCT00773929|DRUG|TAK-593|"Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety"
40944194|NCT01336192|DRUG|Gemcitabine|Gemcitabine 1250mg/m\^2 Day 1 and 8, 28 days per cycle until PD
40944195|NCT01336192|DRUG|Best supportive care|Best supportive care
40944196|NCT03929627|OTHER|Cortisol awakening response|Cortisol awakening response
40944197|NCT03689673|OTHER|Data collection|
40944198|NCT00063193|DRUG|minocycline|
40944199|NCT00063193|DRUG|creatine|
40944200|NCT01632046|DRUG|lactate and bicarbonate buffered dialysis solutions|Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
41285388|NCT02215681|DEVICE|acupuncture|
41285389|NCT00735332|DRUG|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
41285390|NCT04663620|BEHAVIORAL|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
41285391|NCT04663620|BEHAVIORAL|No Saving Babies Lives Programme|No comprehensive neonatal healthcare package
40944201|NCT03626168|DIETARY_SUPPLEMENT|100% watermelon juice|Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.
40944202|NCT03626168|OTHER|Placebo beverage|Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.
40944203|NCT00544999|DRUG|cytarabine|
40944204|NCT00544999|DRUG|daunorubicin hydrochloride|
40944205|NCT00544999|DRUG|everolimus|
40944206|NCT00544999|OTHER|laboratory biomarker analysis|
40944207|NCT00544999|OTHER|pharmacological study|
40944208|NCT01703273|BEHAVIORAL|manual based low key group intervention (innovation)|6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.
41285392|NCT01355432|OTHER|Observation|There is no intervention, this is an observational study.
41285393|NCT00002676|DRUG|carmustine|
41285394|NCT00002676|DRUG|cyclophosphamide|
41285395|NCT00002676|DRUG|cytarabine|
41285396|NCT00002676|DRUG|dexamethasone|
41285397|NCT00002676|DRUG|doxorubicin hydrochloride|
41285398|NCT00002676|DRUG|methotrexate|
41285399|NCT00002676|DRUG|vincristine sulfate|
41285400|NCT00002676|RADIATION|low-LET cobalt-60 gamma ray therapy|
41285401|NCT00002676|RADIATION|low-LET photon therapy|
41285402|NCT02977091|OTHER|change in fitness level|fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness
41285403|NCT03942614|BEHAVIORAL|Nordic pole walking|
40757207|NCT00423865|GENETIC|gene expression analysis|Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.
40757208|NCT00423865|OTHER|immunohistochemistry staining method|After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study
40757209|NCT00423865|OTHER|laboratory biomarker analysis|Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)
40757210|NCT00423865|OTHER|pharmacological study|For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.
40757211|NCT00423865|PROCEDURE|biopsy|"Pre-treatment Research Biopsy: Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy: Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day."
40757212|NCT06483217|BEHAVIORAL|Patient-directed follow up|Patients will be instructed to follow up for repeat injection based on bladder symptomatology at their own self-determined time interval.
41285404|NCT03370146|BEHAVIORAL|Mental training based on Motor Imagery|Patients of the experimental group will be instructed to imagine walking, from a first person perspective, focusing on the kinaesthetic sensations typically associated with the movement. The motor imagery training will be performed using the support of a laptop, on which there will be presented complex static scenes, representing different kind of paths with different landmarks to reach during the mental walking.
41452128|NCT02719665|DIETARY_SUPPLEMENT|SPM Softgel, Dose-Modality|Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration
41452129|NCT02719665|DIETARY_SUPPLEMENT|Placebo Softgel|Days 43-47: 4 Placebo softgel; Day 48-64 Washout
40757213|NCT01977976|PROCEDURE|Endometrial aspiration by pipelle|Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
40757214|NCT01955265|BEHAVIORAL|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
40757215|NCT01955265|BEHAVIORAL|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
40757216|NCT01433081|DRUG|Placebo infusion of .9 normal saline|administration of .9 normal saline
40757217|NCT01433081|DRUG|administration of magnesium sulfate|administration of magnesium sulfate
40944209|NCT01703273|BEHAVIORAL|standardized, manual based routine care|6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
40944210|NCT01229371|BIOLOGICAL|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
40944211|NCT01229371|BIOLOGICAL|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
40944212|NCT03885440|OTHER|Age|Age\<40 years old is chosen as the cutoff value.
40944213|NCT03885440|OTHER|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
40944214|NCT05380310|DEVICE|"Active SMART ANGEL solution"|Nurse intervention according to the alert level + traditional monitoring
40757218|NCT02438397|DRUG|premix insulin|Premix-insulin(human insulin or analog) treatment will continue
40757219|NCT02438397|DRUG|metformin|500 mg tid by Merck
40757220|NCT02438397|DRUG|Acarbose|100mg tid by Bayer
40944215|NCT05380310|DEVICE|"Inactive SMART ANGEL solution"|No alert + traditional monitoring + alert in case of imminent life threat
41132592|NCT01335867|DRUG|Placebo|Placebo pills
41285405|NCT03370146|BEHAVIORAL|Cognitive training|Patients of the control group 1 will undergo a general cognitive training, not based on motor imagery.
41285406|NCT03370146|BEHAVIORAL|Evaluation of gait abilities|All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
41285407|NCT04154540|OTHER|Motion analysis|Gait and posture recording
41285408|NCT03898570|BEHAVIORAL|Patient reported outcomes|"Patients will download the research app onto their phone and enter pertinent medical history and surgical history data similar to standard registries for specific procedures. Over the next 12 months the investigators will obtain patient-reported outcomes (PROs) using the patient's phone.~Specifically, the investigators will obtain daily activity data, weekly 6-minute-walk tests, and quarterly quality of life surveys"
41285409|NCT01574781|PROCEDURE|Blood draw|Blood is drawn at the appropriate time given their cohort inclusion.
41285410|NCT01574781|PROCEDURE|Cheek swab/Saliva Sampling|In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
41285411|NCT04653415|DRUG|Gabapentin 300mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
41285412|NCT04653415|DRUG|Methylprednisolone 125 mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
41285413|NCT04653415|DRUG|Tablet|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
41285414|NCT04653415|DRUG|Normal Saline 10 mL Injection|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
41285415|NCT00934063|DRUG|somatropin|For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
41285416|NCT00934063|OTHER|No treatment given|Control group not receiving treatment
40944216|NCT03207204|PROCEDURE|35% Hydrogen peroxide bleaching|Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
40944217|NCT03207204|PROCEDURE|30% Carbamide peroxide bleaching|Protocol: Application of 35% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
40944218|NCT03207204|PROCEDURE|Violet LED bleaching 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
40944219|NCT03207204|PROCEDURE|Violet LED bleaching 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
41285417|NCT02146846|DRUG|Imatinib|Patients with chronic myeloid leukemia who receive Imatinib as treatment
41285418|NCT05990530|BIOLOGICAL|YD02-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
41285419|NCT00110643|DEVICE|CoolTouch II laser|
41285420|NCT03398408|BEHAVIORAL|Training|The intervention group will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
41285421|NCT00233571|BIOLOGICAL|Adalimumab 40 mg subcutaneous (SC) every other week (EOW)|
41285422|NCT00707577|BEHAVIORAL|Internet-based maintenance program|The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
41285423|NCT06443112|PROCEDURE|transvaginal cervical cerclage by Mc Donald technique|In the McDonald operation, a suture is is inserted around the exo-cervix as high as possible to approximate to the level of the internal os and thereby prevent second-trimester abortion.
41285424|NCT04282928|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Definitive Human umbilical cord mesenchymal stem cells selected by immunomodulatory assay through coculture with BV2 cell
41285425|NCT04282928|PROCEDURE|Routine treatment|"According toInfluenza diagnosis and treatment plan (2019 version)"
41285426|NCT04977505|DEVICE|pushlock|The surgery procedure was performed with pushlock for fixation
41285427|NCT04977505|DEVICE|gryphon|The surgery procedure was performed with Gryphon for fixation
40757221|NCT02824549|DEVICE|FreeStyle Libre Flash Glucose Monitoring|
40757222|NCT00273663|DEVICE|TCES|
40757223|NCT01314248|DEVICE|each child will receive both the LMA and ILA|each child will receive both the size 2 LMA and size 1.5 ILA
40757224|NCT03021005|BEHAVIORAL|HIV Self-testing|
40757225|NCT01830101|DRUG|TMZ plus concurrent re-irradiation|
41132593|NCT04573218|DRUG|Placebo|The placebo contains glucose
41132594|NCT04573218|DIETARY_SUPPLEMENT|250 mg OPP|250 mg Oil Palm Phenolics
41132595|NCT05917236|PROCEDURE|hepato-portoentostomy|the retro-colic Roux-en-Y limb of the jejunum, and finally hepato-portoentostomy (Kasai operation)
40944220|NCT03207204|PROCEDURE|Photochemical protocol 1|Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
40944221|NCT03207204|PROCEDURE|Photochemical protocol 2|Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
40944222|NCT03207204|PROCEDURE|Hybrid technique 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.
41132596|NCT04979598|OTHER|Home exercise program|A home exercise program is provided but this is an observational study. The effect of the exercise program is not under investigation.
41285428|NCT00009867|DRUG|arsenic trioxide|Given IV
41285429|NCT05465681|DRUG|HR20013 for injection；dexamethason|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
40757226|NCT01830101|DRUG|Temozolomide|low-dose temozolomide daily for one year
41285430|NCT00117338|DRUG|montelukast sodium|Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
40757227|NCT02904265|DRUG|Diazepam|
40757228|NCT02904265|DRUG|Acetazolamide|
41285431|NCT00117338|DRUG|Comparator: placebo (unspecified)|Pbo for a study approximately 120 minutes in duration
41285432|NCT01570010|OTHER|Norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
41285433|NCT02818010|OTHER|Global Physical Activity Questionnaire|The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.
41285434|NCT04146545|BEHAVIORAL|"Community Rx-Dementia CRxD Caregiver Resources"|A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
40757229|NCT05381597|DRUG|Combination cream of 5-fluorouracil and calcipotriene|Apply the cream to the size of the lesion extending to the 0.5 cm area of skin surrounding the lesion.twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
40757230|NCT05381597|DRUG|5-fluorouracil cream|Apply the cream to the size of their lesion extending to the 0.5 cm area of skin surrounding the lesion twice daily for 28 days.
40757231|NCT02500342|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
40757232|NCT02500342|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
40757233|NCT02439463|PROCEDURE|Below-knee amputation|Patients with traumatic below-knee amputation.
40757234|NCT02241031|BIOLOGICAL|MPs|MPs are generated from cord blood using a combination of cytokines.
40757235|NCT02241031|DRUG|thrombopoietin (TPO) and interleukin-11|Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
41285435|NCT01089777|DEVICE|ultrasound Doppler monitoring|Ultrasound Doppler monitoring throughout the stress test
41285436|NCT05531240|PROCEDURE|Prostate Artery Embolization|Prostate Artery Embolization (PAE) is performed by experienced interventional radiologists. The method involves catheterization of the prostate vessels superselectively with two to three French microcatheters. PAE is performed with microspheres of 250 to 400 µm in size.
41285437|NCT05531240|PROCEDURE|Transurethral Prostate Resection (TURP)|Under general/regional anesthesia, a resectoscope is inserted into the urethra that carries an electric metal loop (monopolar or bipolar diathermy) that is used to cut and extract the prostate tissue.
41285438|NCT02534337|DRUG|GEMOX|gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
41285439|NCT02534337|DRUG|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
41285440|NCT00326820|DRUG|ibandronate sodium|
41285441|NCT00326820|DRUG|zoledronic acid|
40944223|NCT03207204|PROCEDURE|Hybrid technique 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
40944224|NCT02976792|PROCEDURE|Renal Resistive Index/NephroCheck™test|Renal Resistive Index and NephroCheck™ test before TAVI and after TAVI
40944225|NCT06324708|DIAGNOSTIC_TEST|DXA|Patients will undergo a femoral and lumbar DXA
41132597|NCT02245529|DRUG|Tamsulosin|
41285442|NCT00326820|DRUG|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
41285443|NCT01565525|BEHAVIORAL|Maternal focused intervention|This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
41132598|NCT02926118|DIETARY_SUPPLEMENT|Low glycemic load|Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
41132599|NCT02926118|DIETARY_SUPPLEMENT|High glycemic load|High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
41132600|NCT02095678|PROCEDURE|liver biopsy|patients with HCC or metastatic lesions will have a liver biopsy performed after the experimental MRI. This biopsy will be examined to confirm the imaging results
41285444|NCT01565525|BEHAVIORAL|Ounce of Prevention|This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
41285445|NCT03329872|OTHER|Data collection|data collection about symptoms without any specific clinical or biological intervention
41285446|NCT02124798|DEVICE|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
41285447|NCT06058611|OTHER|Cognitive stimulation|Cognitive stimulation through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
40944226|NCT05805930|DRUG|Anakinra|: Patients will continue daily treatment with anakinra up to week 12. Treatment will be then progressively tapered through the reduction of an administration of the drug per week. Reductions will be performed every 2 weeks up to discontinuation. Therefore, if a relapse does not occur, the treatment will be withdrawn at week 24.
40944227|NCT05805930|DRUG|Prednisone|Steroids will be progressively tapered with a reduction of 0,1-0,15 mg/kg/day of prednisone (or 5 mg in patients in treatment with the maximum dosage of 50 mg/day) from the ongoing treatment every week up to discontinuation. If a relapse does not occur, the treatment will be withdrawn in a period of time of 10 weeks.
41452130|NCT01608984|PROCEDURE|Remote ischemic preconditioning (RIPC)|"3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations."
41452131|NCT01608984|PROCEDURE|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
40757236|NCT03944005|PROCEDURE|Spinal Anesthesia + ACB continious catheter + iPACK + Sham LIA|"ACB - On identification of adductor canal,10ml ropivacaine 0.5% with 1:400,000 epinephrine will be injected to surround the femoral artery.Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr 0.2% ropivacaine will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of femoral condyle and popliteal artery, 20ml ropivacaine 0.5% with 1:400,000 epinephrine will be infiltrated in muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients in Group 1 will receive local infiltration 100ml of normal saline around the knee capsule of 100ml of normal saline by the surgeons as a Sham injection."
40757237|NCT03944005|PROCEDURE|Spinal Anesthesia + LIA + Sham Blocks|"ACB - On identification of adductor canal, 10ml of saline as a sham solution will be injected to surround the femoral artery. Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr of saline will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of the femoral condyle and popliteal artery, 20ml of saline will be infiltrated in the muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following the nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine injected at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients will receive local infiltration by the attending surgeon intraoperatively with 300mg of ropivacaine (100ml of 0.3% ropivacaine),30 mg of ketorolac, and 10mg of morphine around the knee capsule."
40944228|NCT04889222|DEVICE|INVSENSOR00050|Noninvasive pulse oximeter sensor
40944229|NCT04889222|DEVICE|RD SET SpO2|Noninvasive pulse oximeter sensor
40944230|NCT01782833|OTHER|This is Non-interventional study|
40944231|NCT06359431|DEVICE|Novel Smart Speculum|"The examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately."
41132601|NCT02095678|DEVICE|free-breathing MRI|All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to \<8 seconds and validate quantifiable techniques which improve liver image quality
41452132|NCT01608984|PROCEDURE|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
41452133|NCT00220844|DRUG|Desipramine|
41452134|NCT00220844|DRUG|Amitriptyline|
41452135|NCT03032536|DRUG|AL-3778|AL-3778 tablets or capsules
40944232|NCT06359431|DEVICE|Standard speculum|"he examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately."
41452136|NCT03032536|DRUG|Entecavir|Entecavir once daily for 14 days
41452137|NCT03032536|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate once daily for 14 days
41452138|NCT02933658|DRUG|Telmisartan|
41452139|NCT02933658|DRUG|Amlodipine|
40944233|NCT02517866|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil tablets
41452140|NCT02933658|DRUG|Rosuvastatin|
41452141|NCT04595591|DRUG|2mg/kg/min|titration dosing speeds of propofol at 2mg/kg/min
41452142|NCT04595591|DRUG|1mg/kg/min|titration dosing speeds of propofol at 1mg/kg/min
41452143|NCT04595591|DRUG|0.5mg/kg/min|titration dosing speeds of propofol at 0.5mg/kg/min
41452144|NCT06066671|OTHER|GCO (Experimental copaiba oil resin gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the GCO will receive the application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
41452145|NCT00018460|DRUG|Vitamin B|
41452146|NCT03704103|OTHER|iSage|The provider will choose a treatment algorithm within the iSage app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The patient is instructed to perform daily fasting glucose measurements and follow the app's recommendations for insulin adjustment.
41452147|NCT03404921|PROCEDURE|ESTD|During the ESTD procedure,after marking and submucosal injection, incisions were made at both the anal and oral sides of the lesion, and the submucosa under the lesion was then dissected to create a tunnel between the distal and proximal incisions. When the endscope reached the lower incision, the distal end of the esophageal lumen could be visualized , then two lateral mucosal incisions were made, thus completing the ESD procedure.
41452148|NCT03404921|PROCEDURE|ESD|The ESD procedure involved marking,injection,circumferential cutting, submucosal dissection.
41452149|NCT04759989|PROCEDURE|Actual Body Weight Dosing|30cc/kg initial bolus calculated using Actual Body Weight
41452150|NCT04759989|PROCEDURE|Adjusted Body Weight Dosing|30cc/kg initial bolus calculated using Adjusted Body Weight
41452151|NCT04759989|PROCEDURE|Ideal Body Weight Dosing|30cc/kg initial bolus calculated using Ideal Body Weight
41452152|NCT05636254|DIAGNOSTIC_TEST|MRI Brain and spine|"* MRI Brain~* Ax T2 TSE~* 3D Sag T1~* Ax DWI~* 3D Sag Flair~* Ax SWI~* Post-gad 3D Sag T1~* 3D TOF Circle-of-Willis~* MRI Spine~* Sag T2 whole spine (2 stations)~* Post-gad Sag T1 whole spine (2 stations)"
40944234|NCT00685555|BEHAVIORAL|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
40944235|NCT00685555|BEHAVIORAL|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
40944236|NCT04716088|DIAGNOSTIC_TEST|Rapid antigen test for SARS CoV2|Defining diagnostic performance of repeated testing regimen in hospital setting
40944237|NCT05233293|PROCEDURE|Spyglass + RFA|SpyGlass direct Vision guided RFA
40944238|NCT05233293|PROCEDURE|Cytobrush + RFA|After Cytobrush ,taking RFA through ERCP
40944239|NCT03139279|DRUG|Dexmedetomidine|Dexmedetomidine 0.3 ug/kg intravenous bolus
40944240|NCT03139279|OTHER|Saline placebo|Intravenous saline/placebo
40944241|NCT03139279|DRUG|Propofol|Propofol titrated intravenous boluses
40944242|NCT05883683|OTHER|Molecular Profiling & drug testing in tumor organoids and PDXs|Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.
40944243|NCT04130984|DEVICE|EZ-IO|The insertion site locates at 1 cm medial tibial tuberosity. EZ-IO (U.S. Teleflex® Corporation) will be used with an adult 15G needle. Pull out the needle when having a sense of frustration, withdraw the bone marrow with the syringe, bolus 20 mL of normal saline to open intramedullary path and begin drug resuscitation at the same time. The retention time of IO route should be less than 24 h, and venous access should be established after winning rescue time as soon as possible to continue treatment.
40944244|NCT00913575|OTHER|preoperative neuromuscular training|The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.
40944245|NCT00913575|BEHAVIORAL|knee OA School|The education group will only receive 4 sessions of the Knee OA School.
40944246|NCT04433533|DRUG|Rosuvastatin 20|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
40944247|NCT04433533|DRUG|Rosuvamibe 10/10|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
40944248|NCT06160076|DEVICE|Radiofrequency|Patient with atrial fibrillation ablated per catheter using radiofrequency energy
40944249|NCT06160076|DEVICE|Pulsed electric field|Patient with atrial fibrillation ablated per catheter using pulsed electric field
40944250|NCT00678080|DRUG|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
40944251|NCT00678080|DRUG|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
40944252|NCT01886716|BEHAVIORAL|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
40944253|NCT01886716|BEHAVIORAL|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
40944254|NCT01886716|BEHAVIORAL|Control Training|Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
40944255|NCT03422627|DRUG|Efavaleukin Alfa|"Phase 1: This study will be conducted as a multiple ascending dose (MAD) study. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen for up to an additional 208 weeks through an extended dosing period. All subjects who continue to receive efavaleukin alfa during the extended dosing period will be reevaluated every 6 months for their response to treatment.~Phase 2: All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for 52 weeks."
40944256|NCT02795793|DRUG|Non-operative management group (NOM)|With intravenous Piperacillin with Tazobactam (Tazocin)
40944257|NCT02795793|PROCEDURE|Appendectomy group (Operative management, OM)|
41285448|NCT06058611|OTHER|Stimulating leisure activities|"Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (\< 30 min, 30min-1 hour, 1-2 hours, \> 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life."
41285449|NCT01513018|OTHER|high tidal volumes|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
41285450|NCT01513018|OTHER|low tidal volume|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
41285451|NCT03836521|DEVICE|Transcatheter aortic valve replacement|
41285452|NCT05495295|DRUG|PhOx430|"A standard 3 + 3 design will be followed. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.~A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval."
41452153|NCT05636254|DIAGNOSTIC_TEST|Reference standard diagnostic criteria|"Diagnostic criteria-TBM~* Microbiologic evidence of TB in CSF~* Microbiologic evidence of TB from pulmonary or extrapulmonary sites~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication suggestive of tuberculosis~* Other relevant investigations like CSF analysis not suggestive of alternative diagnosis such as neurocysticercosis/cryptococcal/other fungal infections/other causes of chronic meningitis such as brucella/ nocardia/ syphilis/recurrent viral meningitis/ carcinomatous/ lymphomatous meningitis or non infective causes such as sarcoidoisis/sub-arachnoid hemorrhage etc.~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication ruling out competing diagnoses~* Patients who develop features or test results suggestive of alternative diagnosis with will be considered to be not due to tubercular meningitis"
40944258|NCT02027038|DEVICE|Pelvic belt application|
40944259|NCT02639156|DIETARY_SUPPLEMENT|AYMES LONDON|AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
40944260|NCT06191523|OTHER|Control Group|The control group will receive standard therapy and placebo.
40944261|NCT06191523|DRUG|Treatment Group|The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
40944262|NCT05027672|DRUG|Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and all other interventions as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
40944263|NCT06392971|DRUG|Deep-sea fish oil|Starting from radiotherapy, the whole course of prophylactic oral deep-sea fish oil should be taken at the recommended dosage of 1g po bid according to the instructions (the administration method is to take it with the drug, remove the film on the drug surface, slowly swallow it in a supine position, and make the liquid fully contact with the esophageal mucosa). If no acute radioactive esophagus was assessed during the course of treatment, the patient was administered orally until the end of radiotherapy. If the patient developed radioactive esophagitis during the course of treatment, the relevant outcome measures were recorded and used as the endpoint event of the phase I study. The end point for patients without acute radiation esophagitis was at the completion of radiation therapy.
40944264|NCT06392971|OTHER|Placebo|Take a capsule made of food oil that looks like deep-sea fish oil at a dose of 1g po bid. Treatment is discontinued when patients develop acute radiation esophagitis.
40944265|NCT03090841|BIOLOGICAL|Bio-specimen collected|
41285453|NCT05495295|DRUG|PhOx430|The implementation of this cohort (Step 3) was decided by the Protocol Steering Committee (PSC) based on clinical and pharmacokinetic data obtained in Steps 1 and 2. Six patients will be enrolled, who will receive PhOx430 orally thrice a day (tid) at a -6-hour interval over 12 hours for 21 days, and then, starting from day 22, four times a day (qid) at a 4-hour interval over 12 hours, continuously in cycles of 21 days. PhOx430 will be taken in single doses of 1,200 mg to patients weighing ≥ 50 kg and of 600 mg to patients weighing \< 50 kg, with no requirement for a full or empty stomach. The first patient will be observed after treatment start for at least 21 days before enrolling the following two. After the third patient is observed for 21 days after treatment start, 3 additional patients will be enrolled without waiting time between them. If the daily dose tested with the tid schedule is not deemed safe, the flat dose will be tested twice a day (bid) at a 12-hour interval.
41285454|NCT03518840|DEVICE|SIJ Belt|Support Belts
41285455|NCT02212418|OTHER|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
41285456|NCT00163540|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
41285457|NCT05144165|OTHER|Experts consensus|Consensus opinion using Delphi Methodology
40757238|NCT01019174|DRUG|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
40757239|NCT01019174|DRUG|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
40757240|NCT01899378|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|10\^8 CFU
40757241|NCT01899378|DIETARY_SUPPLEMENT|Bifidobacterium longum infantis|10\^9 CFU
40944266|NCT04152044|OTHER|Observation of different types of obesity and liver pathology in patients undergoing and oesophagectomy|Patinets undergoing surgery
40944267|NCT05880654|PROCEDURE|Scaling & root planning|Non Surgical periodontal therapy
40944268|NCT03853343|DIETARY_SUPPLEMENT|Seaweed extract|1 capsule 3 times per day
40944269|NCT03853343|DIETARY_SUPPLEMENT|Placebo|1 capsule 3 times per day
40944270|NCT01933958|DRUG|Regorafenib (Stivarga, BAY73-4506)|The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
40944271|NCT04386031|DIAGNOSTIC_TEST|Throat culture for fungal pathogens|Throat culture for fungal pathogens will be taken before surgery, at post-operative day (POD) 3 and 2 weeks after the operation
40944272|NCT06380829|OTHER|Questionnaire|Self-Care Assessment Scale for Children with CP aged 3-6 years - Parent Form (SPÇÖS-EF): A draft scale named SPÇÖS-EF was prepared by the researchers, using the literature, to determine the self-care status of children with cerebral palsy aged 3-6.
41285458|NCT05815953|DEVICE|Polarstem|Stem used in total hip replacement. Manufacturer: Smith \& Nephew Orthopaedics AG, Baar, Switzerland.
41285459|NCT05815953|DEVICE|Corail|Stem used in total hip replacement. Manufacturer: De Puy Int Ltd, Leeds, UK.
41285460|NCT06085391|OTHER|REThink Game|REThink Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of seven levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change, positive bias, distinction between useful and useless thoughts, problem solving and compassion.
41285461|NCT06085391|OTHER|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
41285462|NCT06085391|OTHER|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress."
41452154|NCT06170762|OTHER|Pulp capping|Pulp capping material for immature permanent teeth in case of carious or traumatic pulp expures
40944273|NCT02808650|OTHER|Laboratory Biomarker Analysis|Correlative studies
40944274|NCT02808650|OTHER|Pharmacokinetic (PK) study|Correlative studies
41452155|NCT06170762|DRUG|Sodiumhexametaphosphate|Sodiumhexametaphosphate
41452156|NCT06170762|OTHER|MTA|MTA
41452157|NCT03330990|DRUG|Entrectinib|600 mg oral capsule (fasted and fed)
41452158|NCT03330990|DRUG|Midazolam Hydrochloride|2 mg oral syrup (fasted)
40944275|NCT02808650|DRUG|Prexasertib|Given IV
40944276|NCT02239627|DRUG|Epidural steroid|
40944277|NCT02239627|DRUG|Clonidine|
40944278|NCT00093782|DRUG|temsirolimus|Given IV
40944279|NCT00093782|OTHER|laboratory biomarker analysis|Correlative studies
40944280|NCT05861310|DRUG|Metronidazole 1% Cream,Top|Cream that has an active ingredient in the form of metronidazole with a content of 1%. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the participants were given metronidazole 1% cream which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
40944281|NCT05861310|DRUG|Placebo|Cream that has not medicine. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the research subjects were given Placebo cream (without the drug substance) which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
40944282|NCT01135212|DRUG|Fimasartan 60mg|Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
40944283|NCT01135212|DRUG|Fimasartan 120mg|Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
40944284|NCT01135212|DRUG|Candesartan cilexetil|Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
40944285|NCT00094029|DRUG|Sutent|Sutent, 25, 37.5, or 50 mg daily
40944286|NCT05306431|DRUG|Polyhexamethylene biguanide|Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant
40944287|NCT05306431|DRUG|Sodium Hypochlorite|A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter
40944288|NCT01982578|DIETARY_SUPPLEMENT|Genistein|Subjects will be randomized 1:1 to receive 360 days of double blind treatment of genistein.
40944289|NCT01982578|OTHER|Placebo|360 days of double blind treatment of placebo.
40944290|NCT05923528|DEVICE|IPL|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter
40944291|NCT05923528|DEVICE|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
40944292|NCT05923528|DEVICE|LipiFlow®|LipiFlow® can control the variables of temperature, pressure, and MG expression technique
40944293|NCT05923528|DEVICE|EyePeace®|The silicone-made flexible hand-held gadget applies regulated, vertical pressure to the closed eyelids.
40944294|NCT05109845|DIAGNOSTIC_TEST|Spheres & Shield Maze Task|"A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards."
40944295|NCT02977130|BEHAVIORAL|Map group|diabetes shared care plus conversation map intervention
40944296|NCT02977130|BEHAVIORAL|Control group|diabetes shared care
40944297|NCT03383471|BIOLOGICAL|Invossa K Inj.|Invossa K Inj.
40944298|NCT03383471|DRUG|Placebo|Placebo control
40944299|NCT05392257|DRUG|Rituximab + zanubrutinib + lenalidomide|Rituximab at 375mg / m2, Day 0; Zanubrutinib 160mg bid continuously oral; Lenalidomide 25mg qd oral on days 1-21; 28 days as a course of treatment
40944300|NCT02319837|DRUG|Enzalutamide|
40944301|NCT02319837|DRUG|Placebo (No longer applicable in Open Label study period)|Sugar pill to mimic enzalutamide
40944302|NCT02319837|DRUG|Leuprolide Open Label|
41452159|NCT05237635|OTHER|descriptive case-scenarios|Each case-scenario will include: (1) a GRADE Summary of Finding (SoF) table providing information about the Population, Intervention, Comparator, Outcome (PICO), the relative and absolute anticipated effects of the intervention, and the certainty in the evidence; (2) a Health Outcome Descriptor describing key attributes of the outcome under consideration including symptoms, time horizon, testing and treatment, and consequences; a measure of the impact on health of the outcome (also known as 'value' of the outcome or 'health utility' in health economics).
41452160|NCT05235022|OTHER|Questionnaires|"The participants included in the study will have to answer:~1. a questionnaire created specifically for the study concerning the possible difficulties encountered during their return to work,~2. the Multidimensional Fatigue Inventory (MFI), a questionnaire assessing fatigue through 5 dimensions (general fatigue, physical fatigue, mental fatigue, reduced activity and reduced motivation).~These 2 questionnaires will be filled during a 30-minute face-to-face or phone interview."
41452161|NCT03641001|BEHAVIORAL|Child feeding counselling, food voucher, micronutrient powder, WASH|Child feeding counselling will be assisted by food voucher, micronutrient powder and WASH messages
41452162|NCT05493163|DRUG|Thrombolytic|Local, catheter-directed thrombolysis with a total dose of 10mg per affected lung administered over 9 hours.
41452163|NCT05493163|DRUG|Standard anticoagulation|Standard anticoagulation therapy of acute pulmonary embolism.
41452164|NCT05828290|BEHAVIORAL|Child Yoga|The children's yoga consists of compositions such as playing, stories, postures, breathing exercises, imitations things in nature, memory games, music, dance and daydreaming.
41452165|NCT05832957|BEHAVIORAL|Drive fun|"The Drive Fun intervention program aims to promote the development of adaptive self-awareness and facilitate the acquisition of management strategies that foster safe and confident driving among participants. The program utilizes a driving simulator to provide a guided learning experience, which incorporates various sources of information, as well as games and thinking tasks. Additionally, participants will engage in reflective exercises that draw upon their occupational experiences and their driving performance within the simulator. Parental involvement is also incorporated to ensure ongoing support for the continued practice of learned skills."
40944303|NCT03660345|PROCEDURE|PPV/MP|23 gauge Pars Plana Vitrectomy with Internal Limiting Membrane Peeling
40944304|NCT03660345|DRUG|Intravitreal injection|Intravitreal ziv-Aflibercept
40944305|NCT04650776|OTHER|Heat strain|The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.
40944306|NCT00227773|DRUG|octreotide acetate|
40944307|NCT00227773|DRUG|vatalanib|
41452166|NCT05832957|BEHAVIORAL|educational intervention|7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games
40944308|NCT00227773|PROCEDURE|anti-cytokine therapy|
40944309|NCT00227773|PROCEDURE|antiangiogenesis therapy|
40944310|NCT00227773|PROCEDURE|biological therapy|
40944311|NCT00227773|PROCEDURE|endocrine therapy|
40944312|NCT00227773|PROCEDURE|enzyme inhibitor therapy|
40944313|NCT00227773|PROCEDURE|growth factor antagonist therapy|
40944314|NCT00227773|PROCEDURE|hormone therapy|
41452167|NCT05832957|OTHER|No intervention|one-time short guidance on safe driving at the end of the study.
41452168|NCT00044876|DRUG|CDB-2914|
41452169|NCT04682951|PROCEDURE|Decompressive Craniectomy|
41452170|NCT01690780|DRUG|Oral morphine|oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
40944315|NCT00227773|PROCEDURE|protein tyrosine kinase inhibitor therapy|
40944316|NCT00227773|PROCEDURE|somatostatin analogue therapy|
40944317|NCT05441761|DRUG|liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle."
40944318|NCT06039410|DEVICE|ISO-101|ISO-101 is an experimental wearable class 1 medical device which when used is able to raise the blood pressure upon standing via controlled isometric muscular contractions
41452171|NCT01690780|DRUG|Ibuprofen|Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
40944319|NCT02623478|DRUG|Insulin Lispro|Administered subcutaneously (SC)
40944320|NCT01310881|DRUG|NSI-189 Phosphate|Once daily oral administration
41452172|NCT05685316|DEVICE|COPLA® cartilage implant|In the investigation, the subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery of the knee with bone marrow stimulation.
41452173|NCT02957942|DEVICE|1Hz repetitive transcranial magnetic stimulation (rTMS)|1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
41452174|NCT00950300|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
41452175|NCT00950300|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
41452176|NCT00950300|DRUG|Docetaxel|Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
41452177|NCT00950300|DRUG|Epirubicin|Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
41452178|NCT00950300|DRUG|Herceptin IV [trastuzumab]|Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
40944321|NCT04093414|DEVICE|Select Secure pacing lead|A Select Secure pacing lead is placed in the bundle of His or Left bundle branch area based upon randomization
40944322|NCT06115668|OTHER|Positive end-expiratory pressure 5 (PEEP 5)|Fixed positive end-expiratory pressure of 5 cmH2O will be maintained throughout the duration of surgery
41452179|NCT00950300|DRUG|Herceptin SC [trastuzumab]|Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
41452180|NCT05663255|DRUG|Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)|Discontinuation or reduction of at least one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
41452181|NCT00659828|DRUG|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
41452182|NCT01121601|PROCEDURE|hepatic surgery of resection|after metastasis liver resection , Coseal will be administered at 4 mL by dose, administration of 1 to 3 dose in fontion of liver adherence Coseal will be administered by spray at 5 to 10 cm of liver.
41452183|NCT01121601|PROCEDURE|hepatic surgery of resection|this is a liver metastasis resection according to liver chirurgical guidelines study drug not administered in this group
41452184|NCT04658225|PROCEDURE|0.12% chlorhexidine|the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
41452185|NCT04599751|DEVICE|Hair removal treatment|Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).
41452186|NCT05529238|BEHAVIORAL|biofeedback training|participants received biofeedback training for kegel exercises in the supervised group. the unsupervised group practised their Kegel exercises at home
41452187|NCT03333551|DRUG|F18 Florbetapir (amyvid) cardiac PET/CT imaging|Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
41452188|NCT06560632|DRUG|RP-3467 at assigned dose and schedule|Eligible participants will be treated with escalating doses of RP-3467 monotherapy
41452189|NCT06560632|DRUG|Olaparib 200-300 mg BID, daily|Eligible participants will be treated with escalating doses of RP-3467 in combination with Olaparib
41452190|NCT03895879|DRUG|Tocilizumab|Tocilizumab sc (162 mg) once every 2 weeks
41452191|NCT03895879|DRUG|Tocilizumab|Tocilizumab sc (162 mg) once every week
41452192|NCT05204368|DRUG|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection
41452193|NCT05204368|DRUG|Meropenem|Meropenem 1g for injection
41452194|NCT05693623|OTHER|cold application|cold application
41452195|NCT01103843|DRUG|Loading Dose Arm|Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
41452196|NCT01103843|DRUG|Maintenance Dose Arm|Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
41452197|NCT00269386|DRUG|Clarithromycin|Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
41452198|NCT00269386|DRUG|Placebo|
40757242|NCT02943499|BEHAVIORAL|App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
41452199|NCT01687335|OTHER|answering questionnare in differents time of the treatment|
41452200|NCT05650307|DIAGNOSTIC_TEST|MRI|The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.
41452201|NCT03584308|DIETARY_SUPPLEMENT|Viusid®|The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.
41132602|NCT04948736|COMBINATION_PRODUCT|Combined exercise and nutrition intervention|"Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks).~Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol.~Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink."
41132603|NCT04948736|OTHER|Conventional medial care|"Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein-rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
41285463|NCT04934735|PROCEDURE|Rehabilitation program group|"The case-management rehabilitation program was conducted by a clinical social worker within the occupational medicine clinic and included several components:~1. Intake by a case manager~2. Referral to an occupational physician was within one week of the intake.~3. Charting an occupational rehabilitation program and timing the RTW date~4. Coordinating between the patients and their family, treating physicians, the employer, community services, and meeting with the patient's family - all on a needful basis.~5. Provision of a guidance booklet for employers on the RTW of cardiac patients.~6. The psychosocial intervention was tailored to the patient's emotional state, occupational needs, and specific requests.~7. Intensive follow-up sessions aimed to ensure that the rehabilitation program was carried out as planned."
41285464|NCT00315601|DRUG|Telithromycin|800 mg once a day for 5 days
41285465|NCT00315601|DRUG|azithromycin|500 mg on day 1, and then 250 mg once-daily on days 2 through 5
41452202|NCT03584308|DIETARY_SUPPLEMENT|Glizigen®|The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
41452203|NCT03584308|DIETARY_SUPPLEMENT|Viusid Placebo|The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
41452204|NCT03584308|DIETARY_SUPPLEMENT|Glizigen Placebo|The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
41132604|NCT03608293|DIAGNOSTIC_TEST|Broncho Alveolar Lavages (BAL)|BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
41132605|NCT05585632|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
41132606|NCT05585632|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
41132607|NCT05585632|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
41132608|NCT05585632|BIOLOGICAL|mRNA-1045|Formulation for injection
41132609|NCT05585632|BIOLOGICAL|mRNA-1230|Formulation for injection
41285466|NCT00315601|PROCEDURE|bronchoalveolar lavage|One bronchoscopy with bronchoalveolar lavage with each drug administration
41452205|NCT05913245|DIETARY_SUPPLEMENT|Maltodextrin 12.5%|Preoperative Maltodextrin 12.5%
41452206|NCT05913245|OTHER|Water|Preoperative water
41452207|NCT02271035|DRUG|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
40944323|NCT06115668|OTHER|Individualized positive end-expiratory pressure (PEEPIND)|Patients will receive the individualized positive end-expiratory pressure. Titration process will be started after establishment of pneumoperitoneum: setting the initial PEEP to 5 cmH2O, then increasing positive end-expiratory pressure (PEEP)according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing positive end-expiratory pressure , until the calculated Cstat shows a downward trend, set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEPIND for this patient. The highest PEEP is limited to 20 cmH2O
40944324|NCT00195572|DRUG|Isovorin|
40944325|NCT00195572|DRUG|TS-1|
40944326|NCT01704521|DRUG|PegInterferon|
40944327|NCT01704521|DRUG|Ribavirin|
40944328|NCT01704521|DRUG|Telaprevir|
40944329|NCT00997061|DRUG|HYCAMTIN|Observing patients on HYCAMTIN and other drugs for SCLC.
40944330|NCT06131723|BEHAVIORAL|Behaviorally informed tickler email|The email notification from patients' PCP office will inform patients that a new review of their records shows they are due for an important medical exam. This intervention harnesses behavioral principles related to importance (medical exam described as important), personalization (records described as belonging to participants), urgency (participants are asked to sign in and make the recommended appointment as soon as possible), timeliness (participants are told that there has been a new review of their records), source effects and accountability (participants are told that a message from their PCP's office is waiting for their response). To make it easier for patients to find and review the MAP letter, the email also contains a link that directs patients to the MAP letter on their patient portal.
40944331|NCT02239354|COMBINATION_PRODUCT|VC-01™ Combination Product|Biologic and Device
40944332|NCT05732220|BEHAVIORAL|EMA assessment|Subjects will be asked to complete 3 waves of ecological momentary assessment (EMA) about smoking cues and smoking consumption via mobile phone at the first, second and third month after baseline (total 6 weeks)
41285467|NCT00315601|DRUG|Telithromycin|Telithromycin 800 mg once a day
40944333|NCT05732220|BEHAVIORAL|EMA-based cessation counselling|Subjects will receive tailored peer counselling based on the participants' EMA responses at 1-month and 3-month telephone follow-ups.
40944334|NCT05732220|BEHAVIORAL|Usual peer counselling|Subjects will receive peer counselling through telephone during follow-ups (usual care), in which the counsellor will apply the 5As model and motivational interviewing techniques.
40944335|NCT03962855|DRUG|Ifetroban Sodium|Ifetroban sodium 250 mg capsule once daily for 4 weeks
40944336|NCT03962855|OTHER|Placebo|Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
40944337|NCT01742936|DEVICE|CoaguChek|Hand held coagulation monitor.
40944338|NCT01742936|OTHER|Hospital Laboratory|Coagulation testing done by hospital laboratory.
40944339|NCT03221907|DRUG|GLA5PR GLARS-NF1|Pregabalin tablet
41285468|NCT02293343|OTHER|blood profile|
40944340|NCT03221907|DRUG|GLA5PR GLARS-NF1 placebo|tablet manufactured to mimic GLA5PR GLARS-NF1
40944341|NCT03221907|DRUG|Pregabalin|Pregabalin capsule
40944342|NCT03221907|DRUG|Pregabalin placebo|tablet manufactured to mimic pregabalin capsule
40944343|NCT01649609|DRUG|Tacrolimus|Reduction of standard immunosuppression - The standard of care immunosuppression treatment commonly used for renal transplant patients
40944344|NCT01649609|DRUG|Mycophenolate acid|Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients
41285469|NCT05128617|DRUG|Epirubicin-cyclophosphamide|1 cycle of Epirubicin-cyclophosphamide
41285470|NCT05128617|DRUG|Paclitaxel|1 cycle of Paclitaxel
41285471|NCT05449392|DRUG|Neosporin|Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units. The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
41285472|NCT05449392|OTHER|Vaseline|The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
40944345|NCT01649609|DRUG|Sirolimus|mTOR Substitution - Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
41285473|NCT03456765|DIAGNOSTIC_TEST|Ultrasound|US will be made to assess kidneys
40944346|NCT04585152|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
41285474|NCT00000110|PROCEDURE|magnetic resonance spectroscopy|
41285475|NCT00000110|DRUG|dietary fat|
41285476|NCT01069848|DEVICE|Vedera KXS|One treatment session with Vedera KXS
40944347|NCT02999399|OTHER|Brussel Sprouts|Subjects are given \~150 g of Brussels sprouts once daily for 7 consecutive days.
40944348|NCT02999399|DRUG|Deuterated Phenanthrene|Subjects are given 1 microgram of deuterated phenanthrene \[D10\]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
40944349|NCT05191563|DRUG|HCP1904-1|Take it once per period.
40944350|NCT05191563|DRUG|RLD2006|Take it once per period.
40944351|NCT05191563|DRUG|RLD2001-2|Take it once per period.
40944352|NCT01354327|DIETARY_SUPPLEMENT|Limicol|3 tablets / day during 4 months
40944353|NCT01354327|DIETARY_SUPPLEMENT|Placebo|3 tablets / day during 4 months
40944354|NCT04208464|DRUG|Baricitinib|4mg daily for 24 weeks from baseline
41285477|NCT00969722|BIOLOGICAL|MAb-3F8|
41285478|NCT00969722|BIOLOGICAL|Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|
41285479|NCT00969722|BIOLOGICAL|13-cis-Retinoic Acid|
41285480|NCT01719575|DRUG|Motilitone|
41285481|NCT01719575|DRUG|Placebo|
41285482|NCT06209957|DRUG|Local corticosteroid injection|Local corticosteroid injection;1 ml of triamcinolone acetonide 40 milligram/1.0 mL
41285483|NCT06209957|DRUG|Platelet-rich Plasma Local injection|Platelet-rich Plasma (From 2-step centrifugation of patient blood) Local injection.
41285484|NCT00201851|DRUG|Tamoxifen|20 mg po daily x 5 years
41285485|NCT00201851|PROCEDURE|Surgery: Oophorectomy|Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
41285486|NCT01367743|DRUG|epinephrine perfusion|perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
41285487|NCT01367743|DRUG|norepinephrine perfusion|perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
41285488|NCT05761327|OTHER|Mediterranean Diet|In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.
41285489|NCT05761327|DIETARY_SUPPLEMENT|Curcumin Supplementation|Participants will take a daily supplement of 1600 mg of curcumin. It is planned that the participants will use 120 capsules of curcumin supplement during the research.
41285490|NCT05761327|DIETARY_SUPPLEMENT|Resveratrol Supplementation|Participants will take a 500mg resveratrol supplement daily. Participants are planned to use 120 capsules of resveratrol supplement during the study.
40944355|NCT04208464|DRUG|Baricitinib|4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
40944356|NCT04940767|DRUG|Isotretinoin|Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
40944357|NCT04940767|DRUG|Amzeeq 4% Topical Foam|AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
40944358|NCT01658852|DRUG|metronidazole|
41285491|NCT00500097|DEVICE|Digital retina image|
41285492|NCT00500097|DEVICE|direct ophthalmoscopy|
41285493|NCT00500097|PROCEDURE|comprehensive eye exam|
41285494|NCT02650310|DEVICE|Thermostable device|Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
41285495|NCT05816681|DRUG|DWJ1230|Daewoong Pharmaceutical
41285496|NCT05816681|DRUG|DWB2001|Daewoong Bio
41285497|NCT06439043|OTHER|EMDR Psychotherapy|EMDR psychotherapy will be delivered in person by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
41285498|NCT06439043|OTHER|Online EMDR Psychotherapy|Online EMDR Psychotherapy will be delivered online by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
41285499|NCT02067312|OTHER|Thai massage|
40944359|NCT01658852|DRUG|Placebo|
40944360|NCT00244517|DRUG|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
40944361|NCT00244517|DRUG|Sevoflurane, Isoflurane, Desflurane|1 MAC
40944362|NCT05413031|DEVICE|relative motion splint|splint with ability to move the fingers
40944363|NCT05413031|DEVICE|static splint|splint with immobility of wrist, and fingers
40944364|NCT05318937|DRUG|SAGE-718|Softgel capsules
40944365|NCT05318937|DRUG|SAGE-718-matching placebo|Softgel capsules
41452208|NCT02271035|DRUG|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
41452209|NCT03210038|DRUG|Lidocaine|Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes
41452210|NCT03210038|DRUG|Water|Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
40757243|NCT02943499|BEHAVIORAL|App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
40757244|NCT02943499|DEVICE|Smartphone|
40944366|NCT04780581|DRUG|Dexamethasone|6 mg/24h - 10 days
40944367|NCT04780581|DRUG|Methylprednisolone|250 mg/ 24h - 3 days
41452211|NCT05862805|PROCEDURE|Sample Collection and Endometrial Biopsy|Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
41452212|NCT06069037|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|SALT for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
41452213|NCT01368380|BEHAVIORAL|Psychological intervention|Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
41452214|NCT03882762|DRUG|Cebranopadol 200 μg tablet|200 μg cebranopadol film-coated tablet was taken with 240 mL of water under fed conditions.
40944368|NCT00853034|DIETARY_SUPPLEMENT|FOS-IN|"prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
41452215|NCT01448096|DRUG|Rituximab|R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
41452216|NCT01448096|PROCEDURE|Prophylactic intrathecal chemotherapy|Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
40944369|NCT00853034|DIETARY_SUPPLEMENT|AXOS|"arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
40944370|NCT00311662|DRUG|Tonabersat|Tablet 40mg daily for 12 weeks
40944371|NCT00311662|DRUG|Placebo|Tablet once daily for 12 weeks
40757245|NCT01704573|DRUG|2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine|"The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA."
40757246|NCT02006836|DIETARY_SUPPLEMENT|Pomelo|The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
40757247|NCT02006836|DIETARY_SUPPLEMENT|Glucose|We dissolved 50 g of glucose in 200 ml water.
40757248|NCT02006836|OTHER|Blank|For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
40757249|NCT02006836|DRUG|Insulin|Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
40757250|NCT02006836|DRUG|met or diet|In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
40944372|NCT01296438|DRUG|Faster-acting insulin aspart|Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)
41285500|NCT05975307|DRUG|Toripalimab|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the induction and concurrent phases, respectively."
40757251|NCT05484557|DRUG|Apixaban|treatment for 6 to 12 weeks
40757252|NCT05484557|DRUG|Enoxaparin Sodium|treatment for 6 to 12 weeks
40757253|NCT01647256|DRUG|Nikkomycin Z|Capsule, 500 mg, single-dose
40757254|NCT06237764|OTHER|No intervention|No intervention.
40757255|NCT02527265|BIOLOGICAL|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
40757256|NCT02062255|DRUG|Aspirin|
40757257|NCT02062255|DIETARY_SUPPLEMENT|Omega 3 FFA|
40757258|NCT03682146|PROCEDURE|Prostatectomy|Comparison of robotic-assisted and conventional laparoscopic radical prostatectomy
41452217|NCT05438433|DEVICE|St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets|St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
40757259|NCT02898675|DEVICE|Platelet rich fibrine|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
40757260|NCT02898675|DEVICE|Open Flap Debridement|Only open flap debridement treatment the bone loss limitedly
40757261|NCT02565186|DRUG|Lasmiditan|oral tablet
40757262|NCT06375863|DIAGNOSTIC_TEST|QT and QTc interval|measuring of QT and QTc on ECG
40757263|NCT05618847|DEVICE|Acapella,ACBTS|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
40757264|NCT05618847|OTHER|ACBTs|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
40757265|NCT01853085|DRUG|Bimatoprost Ophthalmic Solution|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
40757266|NCT00233961|BIOLOGICAL|filgrastim|
41285501|NCT05975307|DRUG|Gemcitabine|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles."
40757267|NCT04883554|OTHER|Olfactory therapeutic|The sessions of the olfactory sensory therapy group take place according to the care framework at a frequency of one session of 45 minutes per week
41285502|NCT05975307|DRUG|Cisplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
41452218|NCT02419339|PROCEDURE|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
40757268|NCT04883554|OTHER|Body therapy|very specific stages at a weekly frequency and lasts 1 hour. Kinesic time or time to set the body in motion (20 min) Kinesthetic time: time of slow movements (20 min) Talk time (20 min)
40757269|NCT04628052|PROCEDURE|Colonoscopy|Music vs. No-Music
40757270|NCT05508165|DEVICE|Stream Dx|home uroflowmetry device
40757271|NCT05508165|DEVICE|DFree|at home wearable bladder scanner
40757272|NCT05508165|DEVICE|TestCard|mobile urinalysis reader
41452219|NCT01662050|DRUG|Rituximab, Bendamustine, Cytarabine.|6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
41285503|NCT05975307|DRUG|Carboplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate \< 40 ml/min, area under curve = 2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
41285504|NCT05975307|RADIATION|Intensity-modulated radiation therapy|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Radiotherapy: performed by using the technique of intensity-modulated radiation therapy, with a total dose of 65 and 45 Gy for the gross tumor and lymphatic drainage regions."
41285505|NCT06511154|OTHER|Cognitive Rehabilitation|"Cognitive rehabilitation is a treatment method used to regain or improve cognitive abilities.For the cognitive rehabilitation program, the Daily Exercise Package of the Norosoft Program, which mainly includes exercises to improve attention, information processing speed, verbal and visual memory functions, will be applied.~Core-based Upper Extremity Exercises~Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises"
41285506|NCT06511154|OTHER|Core-based Upper Extremity Exercises|Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
41285507|NCT05115318|DRUG|Medical Cannabis|Patients with GTS were assessed before, 4 and 12 weeks after Medical cannabis initiation for consumption habits, efficacy and side effect profile
41285508|NCT01507246|DRUG|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
41285509|NCT01507246|DRUG|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
41285510|NCT05779852|OTHER|self-hypnosis and dressing|self-hypnosis during dressing
41285511|NCT05779852|OTHER|dressing|dressing without self-hypnosis
41285512|NCT06407362|DIAGNOSTIC_TEST|Cerebral Oxygen Saturation|We have designed this study to evaluate the accuracy of PVI, PI and rSO2 in both ventilation modes in patients undergoing septorhinoplasty operation under general anaesthesia
41285513|NCT04467112|DEVICE|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
41285514|NCT03180762|DRUG|JNJ-64140284 0.1 mg|0.1 mg of JNJ-64140284 will be administered as an oral solution.
41285515|NCT03180762|DRUG|JNJ-64140284 0.5 mg|0.5 mg of JNJ-64140284 will be administered as an oral solution.
41285516|NCT03180762|DRUG|JNJ-64140284 2.5 mg|2.5 mg of JNJ-64140284 will be administered as an oral solution.
41285517|NCT03180762|DRUG|JNJ-64140284 10 mg|10 mg of JNJ-64140284 will be administered as an oral solution.
41285518|NCT03180762|DRUG|JNJ-64140284 50 mg|50 mg of JNJ-64140284 will be administered as an oral solution.
41285519|NCT03180762|DRUG|JNJ-64140284 150 mg|150 mg of JNJ-64140284 will be administered as an oral solution.
41285520|NCT03180762|DRUG|JNJ-64140284 (dose to be determined [TBD])|JNJ-64140284 (dose to be determined) will be administered as an oral solution.
41285521|NCT03180762|DRUG|Placebo|Matching placebo will be administered.
41285522|NCT00735358|PROCEDURE|Cyanoacrylate|Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
41285523|NCT00735358|PROCEDURE|Cyanoacrylate|Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
41285524|NCT03991962|DRUG|mFOLFIRINOX|Patients will receive 6-12 cycles of mFOLFIRINOX every 2 weeks
41285525|NCT03991962|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved lymph nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
41285526|NCT02053246|DRUG|Nebivolol|Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
41285527|NCT02580734|DIETARY_SUPPLEMENT|melatonin|Cross-over randomized clinical trials
41285528|NCT02124850|DRUG|Motolimod|
41285529|NCT02124850|DRUG|Cetuximab|
41285530|NCT02124850|DRUG|Nivolumab|
41285531|NCT03414359|DRUG|2% Lidocaine|2% Lidocaine using a combined spinal-epidural (CSE)
41285532|NCT03414359|DRUG|3% Chloroprocaine|3% Chloroprocaine using a combined spinal-epidural (CSE)
41285533|NCT00814710|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
41285534|NCT00814710|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 3 doses
41285535|NCT00814710|BIOLOGICAL|Hiberix|Intramuscular injection, 3 doses
40757273|NCT04321031|DRUG|Placebo|Tablet
40757274|NCT04321031|DRUG|PF-06865571|Tablet
41285536|NCT00814710|BIOLOGICAL|Tritanrix-HepB|Intramuscular injection, 3 doses
41285537|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 75 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
41285538|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 100 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
41285539|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 150 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
41285540|NCT02355340|OTHER|Dual energy x-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
41285541|NCT02355340|OTHER|Peripheral quantitative computed tomography (pQCT)|Subjects will undergo pQCT assessment of radius and tibia.
41285542|NCT04761185|DRUG|Raltitrexed|Raltitrexed in HIPEC
41285543|NCT01784471|DEVICE|Magic Foot™|Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
41285544|NCT01571986|PROCEDURE|Non-invasive ventilation|Non-invasive ventilation
41285545|NCT00863668|DRUG|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
41285546|NCT00863668|DRUG|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
41285547|NCT00863668|PROCEDURE|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
41285548|NCT00863668|PROCEDURE|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
41285549|NCT04611477|OTHER|Rice Hulk|Placebo
41285550|NCT04611477|OTHER|Synbiotic365 Ver 5|Active Comparator
41285551|NCT04611477|OTHER|Synbiotic365 Ver 7|Active Comparator
41285552|NCT00395785|DEVICE|Carotid Stent Implantation|
41285553|NCT00395785|DEVICE|Embolic Protection|
41285554|NCT03077295|OTHER|High Fibre|High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).
41285555|NCT03077295|OTHER|High Protein|• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
41285556|NCT03050463|PROCEDURE|Biospecimen Collection|Undergo blood and saliva sample collection
41285557|NCT03050463|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI related tasks
41285558|NCT03050463|OTHER|Questionnaire Administration|Ancillary studies
41285559|NCT03047005|DRUG|NB medication (Naltrexone Bupropion combination)|NB medication
41285560|NCT03047005|OTHER|Placebo|Placebo
41285561|NCT02772380|DEVICE|Defibrillation following induction of VT/VF|Up to 10 attempts to induce two VF/VT episodes for defibrillation testing
40757275|NCT04321031|DRUG|PF-05221304|Tablet
41285562|NCT05954039|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex|The study foresees the intake of 2 capsules per day during 84 days
41285563|NCT05954039|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
41285564|NCT04558008|BEHAVIORAL|Online MBSR|Described previously
41285565|NCT01845077|DRUG|2x500 mg Metformin (Glumetza)|2 tablets
41285566|NCT01845077|DRUG|5 mg Linagliptin/1000 mg Metformin FDC|FDC tablet
40944373|NCT01296438|DRUG|insulin aspart|Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
41285567|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
41285568|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
41285569|NCT01845077|DRUG|3x500 mg Metformin (Glumetza)|3 tablets
41285570|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
41285571|NCT01845077|DRUG|2 x 500 mg Metformin (Glumetza)|2 tablets
41285572|NCT01845077|DRUG|5 mg Linagliptin/1000mg Metformin FDC|FDC Tablet
41285573|NCT01845077|DRUG|2 x 2.5 mg Linagliptin/750 mg Metformin FDC|2 FDC tablets
41285574|NCT00474227|BEHAVIORAL|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
41285575|NCT05095389|DEVICE|ADRCs|Administration of Autologous Adipose Derived Regenerative Cells into the Diabetic Foot Ulcer
41285576|NCT05095389|OTHER|standard care|standard care
41285577|NCT05095389|OTHER|Placebo|placebo
41452220|NCT01859637|BIOLOGICAL|Filgrastim|Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.
41285578|NCT03518957|BEHAVIORAL|Exercise|"Week 1: Patients will undergo an introductory session where the occupational therapist will assess the general condition and physical fitness of the subjects.~Week 1 to Week 12: Group exercise sessions supervised by a physiotherapist, twice per week, each session lasting 1 hour, with no more than 8 participants in each group exercise session. The exercise regimen for each session will be personally tailored for the subjects, and will include stretching, cardiovascular and strength training, and cooling down exercises.~Week 12 onwards: Patients will receive phone calls- monthly for the first 6 months and then 3 monthly up to the 2-year mark, to encourage them to continue with their exercise regimen at home."
41285579|NCT02857712|DRUG|Axitinib|Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
41285580|NCT04321863|OTHER|Faecal calprotectin (FC)|FC is a surrogate marker of neutrophil influx into the gut lumen. It accurately predicts mucosal healing (MH) at colonoscopy, and thus is already widely used in clinical practice in disease monitoring in CD patients (standard of care).
41452221|NCT03613038|BEHAVIORAL|Phonetic complexity effects on speech motor performance|Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.
41452222|NCT02684786|DRUG|reserpine|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status
40757276|NCT03084900|OTHER|Arm 1|Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
41452223|NCT02684786|PROCEDURE|stellate ganglion block|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
40757277|NCT00410436|BEHAVIORAL|Resistance Exercise|Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
41452224|NCT02684786|DRUG|lidocaine|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
40757278|NCT00948935|DRUG|Gemcitabine, Irinotecan, Panitumumab|Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
41452225|NCT00580541|BEHAVIORAL|variety|variety and nonvariety
41452226|NCT01395628|DRUG|in vitro sensitivity-directed chemotherapy|
40757279|NCT00675233|DRUG|HPPH|Given IV
40757280|NCT00675233|PROCEDURE|laser therapy|Escalating light doses with 665 nm light
40757281|NCT04310774|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug)|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
40757282|NCT00253955|DRUG|Levofloxacin|
41285581|NCT04321863|OTHER|quantitative Faecal Immunochemical Testing (qFIT)|Stool test for haemoglobin. It has been shown to predict mucosal healing in Crohn's disease and ulcerative colitis. This study will compare the ability of qFIT and FC to predict flare in CD (qFIT is a cheaper, more stable test with a quicker turn-around time than FC, and is also less labour intensive for the lab).
40757283|NCT00253955|DRUG|Piperacillin/Tazobactam|
40757284|NCT04987450|DRUG|Methylprednisolone, prednisone|The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.
41285582|NCT04321863|OTHER|Serum and faecal zinc|Blood sample for serum zinc will be taken at same time as routine (standard of care) monitoring bloods which include CRP - no additional venipuncture will be required. A single stool sample will be sufficient to measure FC (as outlines above) and faecal zinc. This study will compare the ability of serum/faecal zinc and CRP at predicting relapse in patients with quiescent (inactive) luminal (affecting the small and/or large bowel) CD.
41285583|NCT03160144|PROCEDURE|open lung approach|
40757285|NCT03616093|OTHER|Test Beet Shot|Active supplement containing 6.2 mmol nitrate
41285584|NCT03037294|DIETARY_SUPPLEMENT|Preoperative protein supplementation|Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
41285585|NCT00584350|OTHER|Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
41285586|NCT00584350|OTHER|normal saline|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
40757286|NCT03616093|OTHER|Placebo Beverage|Placebo supplement containing negligible nitrate
41285587|NCT00584350|OTHER|Sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
40757287|NCT00421408|DIETARY_SUPPLEMENT|Whey protein supplement|40-g whey protein supplement daily for 18 months
40757288|NCT00421408|DIETARY_SUPPLEMENT|Placebo|Placebo supplement daily for 18 months
40757289|NCT05396612|OTHER|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
40757290|NCT05212935|BIOLOGICAL|Rotavirus Vaccine|administration of the 3 doses of Rotavirus human bovine pentavalent reassortant vaccine
41285588|NCT05233046|BEHAVIORAL|Nutrition and Mental health counseling|Nutrition and Mental health counseling with a standardized format included in each session
41285589|NCT05233046|BEHAVIORAL|Nutrition and Mental health counseling with Nourish Carolina|Nutrition and Mental health counseling with a standardized format included in each session combined with the intervention of a 12 week immersion of mindfulness based program ,Nourish Carolina, on CMS , school district employees. Nourish Carolina inlcudes, detailed lessons and descriptions with a caledar that includes mindful eating tips, activities, meditations recipes and videos. The program has monthly themes of mindfulness,gratitude and giving
41452227|NCT01395628|OTHER|cell proliferation assay|
41452228|NCT01395628|OTHER|fluorescence activated cell sorting|
40757291|NCT02411851|DRUG|ingenol mebutate 0.015%|one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
40757292|NCT02411851|OTHER|dermasil lotion|Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
40757293|NCT01002729|OTHER|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI \< 30 given Oseltamivir
40757294|NCT01002729|OTHER|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI \> 40 given Oseltamivir
40757295|NCT06230055|DEVICE|Ommaya reservoir|Intrathecal chemotherapy through Ommaya reservoir
40944374|NCT03225729|DEVICE|CRYOBEAUTY MAINS ET DECOLLETE|The intervention lasts up to 6.5 s. The device will be applied on spots \<6 mm which are previously selected by the investigator team.
40944375|NCT03225729|DEVICE|Liquid nitrogen|The intervention lasts up to 3 s. The liquid is stored in well-isolated recipients. Each patient has his recipient to avoid contamination. The investigator applies on spots \<6 mm a small amount of nitrogen liquid.
40944376|NCT03109054|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory Test|All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
40944377|NCT05002283|OTHER|patient specific guide|harvesting palatal free gingival graft using the patient specific guide
40944378|NCT00200161|DRUG|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
40944379|NCT00200161|DRUG|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
40944380|NCT01502280|DRUG|5-Aminolevulinic acid (ALA)|Following informed consent, within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
40944381|NCT01502280|DRUG|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
40944382|NCT01646073|BIOLOGICAL|Adalimumab|adalimumab eow
40944383|NCT01646073|BIOLOGICAL|placebo|placebo
40944384|NCT00261079|DRUG|Fexofenadine|
40944385|NCT02080637|DRUG|Ambrisentan|Once daily oral dosing
40944386|NCT02080637|OTHER|Placebo|
40944387|NCT01164683|BEHAVIORAL|Peer-driven intervention|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
40944388|NCT01164683|OTHER|Usual Care|All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
40944389|NCT06030310|OTHER|The developmental Exercise Programme of INPP|"The INPP school motor program consists of a series of developmental movements based on the normal movements of a child in their first year of life. Exercises must be performed as slow as possible and must be repeated for at least six weeks.~Once the children have performed a set of movements, a new set will be presented for practice in a more complex position.~The exercises are done on the floor and aid in developing:~Proper alignment of the head with the body, trunk stability. Balance and coordination. The ability to use both sides of the body and upper and lower parts independently.~Muscle tone in prone and supine position. Hand-eye coordination and visual skills"
40944390|NCT04357366|DRUG|Anakinra|Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days
40944391|NCT04904679|DEVICE|Pars plana Vitrectomy with internal limiting membrane peeling|The vitrectomy technique using pars plana 23-gauge will be performed with removal of the ILM (when present adhered to the macula) and placement of an amniotic membrane plug or a internal limiting membrane flap in the macular hole, with a fluid-air exchange and a buffering gas infusion (C3F8 12, 5%). The amniotic membrane plug will be made with a dermatological punch with a diameter of 1.0 to 2mm depending on the size of the macular hole measured by the OCT, and will be positioned inside de macular hole with the chorionic side facing the RPE ( retinal pigmented epithelium) with a 23 gauge forceps. The chorionic side of the membrane is the sticky one. The internal limiting membrane flap will be created at the same time of peeling and will bem positioned in as inverted flap over and inside the macular hole with a 23 gauge ILM forceps. These technics will be helped with de use of a extra lighting sclerotomy.
40944392|NCT02337738|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
40944393|NCT02337738|DRUG|TVP-1012 0.5mg|TVP-1012 0.5mg Tablets
40944394|NCT02337738|DRUG|Placebo|Placebo Tablets
40944395|NCT01681017|BEHAVIORAL|HBB/ENC Training and Equipment|See the detailed description section
40944396|NCT01681017|OTHER|HBB/ENC supplies|Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
40944397|NCT03110731|BEHAVIORAL|Physical training|Physical training (2x / week) was performed for 12 weeks
40944398|NCT04193358|DIETARY_SUPPLEMENT|FERTILIS HOMME®|L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg
40944399|NCT04193358|OTHER|PLACEBO|Sugar pills
40944400|NCT03111966|OTHER|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
40944401|NCT02004392|DRUG|EVP-6124|
41452229|NCT01395628|OTHER|laboratory biomarker analysis|
41452230|NCT01395628|OTHER|microscopy|
40944402|NCT03057379|OTHER|Vaccine Reminder Recall|The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
40944403|NCT01676727|DEVICE|CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
40944404|NCT06411028|DIAGNOSTIC_TEST|Polymyography|We will measure muscle activity using surface electromyography and tremor using inertial measurement units while subjects perform rest, posturing and kinetic tasks.
40944405|NCT06411028|DIAGNOSTIC_TEST|Muscle ultrasound|We will obtain B-mode images and videos of upper extremity muscles of the most affected upper extremity.
40944406|NCT06411028|DIAGNOSTIC_TEST|(Functional) magnetic resonance imaging|Subjects will undergo (f)MRI scanning involving concurrent electromyography, accelerometry and functional magnetic resonance imaging.
40944407|NCT06411028|DIAGNOSTIC_TEST|Clinical assessment|We will assess tremor and dystonia severity using clinical scales.
40944408|NCT06411028|DIAGNOSTIC_TEST|Questionnaires|We will collect patient-reported outcomes.
40944409|NCT00817544|DRUG|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
40944410|NCT02089854|DRUG|Toremifene; Anastrozole|Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
40944411|NCT00969904|DRUG|N-acetylcysteine|600 mg TID for 12 weeks
40944412|NCT00969904|DRUG|placebo|placebo tablet TID for 12 weeks
40944413|NCT01088737|DRUG|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
40944414|NCT00234273|PROCEDURE|Rehabilitation programme in Adapted Physical Activity (APA)|
41452231|NCT02484807|OTHER|no intervention, only observation of different groups|
40944415|NCT00234273|BEHAVIORAL|Therapeutic education primarily focused on dietary|
40944416|NCT03183011|OTHER|MRI|Cardiac MRI
40944417|NCT01050491|DRUG|sitaxentan|100 mg once a day during one year. Bronchial fibroscopy
40944418|NCT01050491|DRUG|placebo|placebo, one per day, during one year. Bronchial fibroscopy
40944419|NCT05030246|DRUG|Surufatinib/Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
40944420|NCT04070144|DEVICE|IQ-Tip(tm) system|Physician performs therapeutic or diagnostic lumbar puncture using Injeq IQ-Tip(tm) system
40944421|NCT04622982|OTHER|Multidisciplinary treatment of obesity (diet + vitamin D + exercise + psychotherapy)|"Body weight reduction was induced by a low-energy mixed diet (55 % carbohydrates, 30 % lipids and 15 % proteins) providing 600 kcal less than individually estimated energy requirements based on the measured REE. The energy content and macronutrient composition of the diets adhered to the nutritional recommendations of the American Diabetes Association.~Patients were administered vitamin D supplement only if they presented a value of 25-hydroxyvitamin D (25OHD) \<30 ng/ml in blood tests at the beginning.~Patients were following an individualized physical activity plan within the hospital and were aided by a psychodynamic approach therapist."
41452232|NCT03911037|DRUG|G-CSF|G-CSF will be administered as prefilled syringes at a dosage of 5 μg/Kg subcutaneously every 12 hr for five consecutive days. Four such cycles will be administered at three monthly intervals.
41452233|NCT03911037|DRUG|Placebo|Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
41452234|NCT02448160|DEVICE|alfapump|Implantation of alfapump
40944422|NCT01905410|DRUG|VVZ-149 Injection|VVZ-149 in water for injection
41285590|NCT02604719|DRUG|Tranexamic Acid and Ethamsylate|The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
41285591|NCT02414477|DRUG|Deuterated NNN|Smokeless tobacco study product
41285592|NCT00831051|DRUG|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
41285593|NCT00831051|DRUG|Morphine sulfate|One morphine sulfate 12mg IR capsule q6h
40757296|NCT06230055|DRUG|Systematic chemotherapy|Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), or iribrin(1.4mg/m2, d1,8, q3w, iv).
40757297|NCT05995561|OTHER|no intervention is planned.|no intervention is planned.
40944423|NCT01905410|DRUG|placebo|water for injection
40944424|NCT01410539|DEVICE|OCT guided PCI|OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
40944425|NCT01410539|DRUG|OCT guided medical therapy|OCT guided medical therapy. Tailored antiplatelet therapy.
40944426|NCT03959072|DEVICE|Robotic CTO PCI|Randomized to robotic CTO PCI.
40944427|NCT03959072|PROCEDURE|Conventional (Manual) CTO PCI|Randomized to manual CTO PCI.
40944428|NCT03802227|DRUG|NKTR-181|A combination of NKTR-181 and oxycodone IR placebo
40944429|NCT03802227|DRUG|Oxycodone IR|A combination of oxycodone IR and NKTR-181 placebo
41285594|NCT00831051|DRUG|Oxycodone HCl|One oxycodone HCl 8mg IR Capsule q6h
40757298|NCT05547854|BEHAVIORAL|Behavior Therapy Training Institute|In-person therapist training will follow the Tourette Association of America's established Behavior Therapy Training Institute procedures and will consist of 12 hours of in-person training conducted over the course of 2 days. Day 1 will involve standardized didactic lectures on tic disorders and video demonstrations of therapeutic techniques. Day 2 will involve break-out groups and role-play practice of CBIT techniques. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a training instructor while providing CBIT to a study-enrolled patient.
40757299|NCT05547854|BEHAVIORAL|CBIT-Trainer|In the online therapist training condition participants will be provided with access to the CBIT-Trainer program and asked to complete the training over the course of 4 weeks. CBIT-Trainer is designed for the average user to complete in approximately 12 hours. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a CBIT expert while providing CBIT to a study-enrolled patient.
40757300|NCT01367756|DRUG|RO4995819|multiple oral doses, Days 10-16
40757301|NCT01367756|DRUG|citalopram|multiple oral doses, Days 1-16
40944430|NCT04216121|RADIATION|Local ablative therapy|Stereotactic body radiotherapy
40944431|NCT04216121|PROCEDURE|Local ablative therapy|Surgery
40944432|NCT01806558|PROCEDURE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
40944433|NCT04348461|DRUG|Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells|Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg
41285595|NCT00831051|DRUG|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
40944434|NCT05850312|DEVICE|Gamified Digital Intervention - Feasibility Analysis on MoM|In first round we aim to clinically analyze the game Militant of the Maze (MoM) as a vehicle for Exposure Theory, including, play, observation, and feedback from five clinicians.
40944435|NCT05850312|DEVICE|Gamified Digital Intervention|In the first phase of round 2 of the study, 5 clinicians will play the game to evaluate the revised game MoMG. In the next phase, 5 carefully-selected non-clinician participants will play the game. under real-time observation of clinicians, to ensure that subjects experience no harm, and that the gameplay is interesting and enjoyable.
41285596|NCT00831051|DRUG|Morphine sulfate|Two morphine sulfate 3mg IR capsules q6h
41285597|NCT00831051|DRUG|Oxycodone HCl 4mg|Two oxycodone HCl 2mg IR Capsules q6h
41285598|NCT03645187|DRUG|FOLFERI|FOLFERI regimen
41285599|NCT03645187|DRUG|Folferi and celecoxib|Folferi regimen and celecoxib
41285600|NCT03429647|DIAGNOSTIC_TEST|visible light spectroscopy|Sigmoid perfusion was assessed using visible light spectroscopy
41285601|NCT03021837|OTHER|antenatal corticosteroid|Will look at maternal glucose level after corticosteroids
41285602|NCT01418755|BIOLOGICAL|platelet rich plasma injection|The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
41285603|NCT02755636|BEHAVIORAL|PCPHC|Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard
41285604|NCT02755636|OTHER|Usual care|Primary care as usual
41285605|NCT04163783|DRUG|[14C]-BGB-3111|20-mg capsule containing \~200 μCi of \[14C\]-BGB-3111,
41285606|NCT04163783|DRUG|BGB-3111|Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111
41285607|NCT02788539|BEHAVIORAL|Our Whole Lives Website|OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
41285608|NCT00889356|DRUG|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
41285609|NCT00889356|DRUG|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
41285610|NCT04033679|OTHER|Active TDCS|Participants will receive active TDCS stimulation.
41285611|NCT04033679|OTHER|Sham TDCS|Participants will receive sham TDCS stimulation.
41285612|NCT04063761|DEVICE|esophageal cooling device (Attune Medical, Chicago, IL)|Prospective, single center pilot study
40757302|NCT01367756|DRUG|placebo|multiple oral doses, Days 10-16
40757303|NCT02504775|DRUG|Mejoral® 500 Tablets|500 mg tablet of paracetamol
40757304|NCT02504775|DRUG|Tylenol® Caplets|500 mg tablet of paracetamol
41285613|NCT03319654|DIAGNOSTIC_TEST|DNA fragmentation by TUNEL assay|Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
41285614|NCT01412242|OTHER|Extensive search for isolated calf DVT|Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
41285615|NCT04047030|OTHER|None- Observational Study|No Intervention
41285616|NCT05713955|DEVICE|Obsidian|To create OBSiDiAN BioMatrix, 120 ml of the the patient's blood is added to the processing unit. The Vivostat® processor unit heats, separates, centrifugates to get the plasma. Batroxobin is added. After again processing, the result is an OBSiDian syringe filled with BioMatrix Obsidian®ASG. This will be applied on the anastomosis
41285617|NCT01039168|BEHAVIORAL|Workplace dialogue|
40944436|NCT00753766|OTHER|Multifactorial Intervention|
40944437|NCT03508375|BIOLOGICAL|blood samples|blood samples
41285618|NCT01039168|OTHER|Care as usual|
41285619|NCT04553887|DRUG|Almonertinib|single agent, 110mg p.o once daily until disease progressed
41285620|NCT06512480|PROCEDURE|colonic resection|colonic resection with the Hugo RAS robotic platform.
41285621|NCT05036538|DEVICE|Intervention with natural sounds administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
41285622|NCT05036538|DEVICE|Intervention with natural sounds and binaural beats administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
41285623|NCT05036538|DEVICE|Intervention with natural sounds and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
41285624|NCT05036538|DEVICE|Intervention with natural sounds, binaural beats and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
41285625|NCT05301244|OTHER|laughter yoga for nurses|The experimental group was divided into three groups as 17-17-16 people. For four weeks, laughter yoga sessions were held between 20.00 and 21.00, 2 days a week for each group. Laughter yoga sessions were held for the 1st group between 20.00-21.00 on Mondays and Thursdays, for the 2nd group between 20.00-21.00 on Tuesdays and Fridays, and for the 3rd group between 20.00-21.00 on Wednesdays and Sundays. The first sessions lasted 45 minutes, every other session 40 minutes.
41285626|NCT05301244|OTHER|laughter yoga for nurses-Deep breathing exercises|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
41285627|NCT05301244|OTHER|laughter yoga for nurses-Warm-up exercises|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
41285628|NCT05301244|OTHER|laughter yoga for nurses-Childish games|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
41285629|NCT05301244|OTHER|laughter yoga for nurses-Laughter exercises|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
41285630|NCT03771872|DEVICE|Virtual Prism Adaptation Therapy|Hand trajectory will deviate to the right side in the virtual reality.
41285631|NCT03771872|DEVICE|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
40944438|NCT02828969|OTHER|Phone call or physical consultation|
40944439|NCT00950287|DEVICE|No intervention|The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
41285632|NCT00929292|OTHER|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
41285633|NCT00929292|OTHER|Modilac 1|Infant formula used for non breastfed children
41285634|NCT00824421|DRUG|UK-453, 061|UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
41285635|NCT00824421|DRUG|UK-453, 061|UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
41285636|NCT00824421|DRUG|EFV +TVA|Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
41285637|NCT03155451|DIAGNOSTIC_TEST|methylation markers screening|ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis
41285638|NCT02767570|OTHER|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback to encourage them to adopt a new foot progression angle. Participants will walk for an additional ten minutes per day to internalize their new foot progression angle over 52 weeks.
41285639|NCT02767570|OTHER|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback to encourage them to maintain a consistent foot progression angle. Participants will walk an additional ten minutes per day to internalize the consistency of their foot progression angle over 52 weeks.
41285640|NCT02677779|PROCEDURE|CO2 laser|Single session of CO2 laser debridement
41285641|NCT02677779|PROCEDURE|traditional surgery|Single session of traditional debridement
41285642|NCT02700581|PROCEDURE|low PEEP conventional ventilation|
41285643|NCT02700581|PROCEDURE|moderate PEEP conventional ventilation|
41285644|NCT02700581|PROCEDURE|low PEEP protective ventilation|
41285645|NCT02700581|PROCEDURE|moderate PEEP protective ventilation|
41285646|NCT06342167|RADIATION|Radiotherapy|Interventions consist of 50-60 Gy in 25-30 fractions of radiotherapy.
41285647|NCT06342167|DRUG|Programmed Cell Death Protein 1 Inhibitor|200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.
41285648|NCT06342167|DIETARY_SUPPLEMENT|Immunonutrition support|600-1600 ml of TPF-T per day according to the nutrition status evaluation
41285649|NCT01554202|BEHAVIORAL|assessment of memory|
41285650|NCT01554202|BIOLOGICAL|circulating tPA dosage|
40944440|NCT03848442|OTHER|'Uptime' participation|The intervention are designed for each individual and are consistent with the model for participation-based interventions. The interventions are goal-oriented (meaningful and family/client-selected goals), family/client-centered (promoted self-determination and decision making), collaborative (partnership between caregivers), strength-based (built on participant and caregiver strengths) and ecological (natural environment and real-life experiences). Design of the intervention comprised three steps: 1) Preparation period (6 weeks); 2) Intervention period (12 weeks); 3) Follow-up period (12 weeks)
40944441|NCT01925274|DRUG|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
40944442|NCT01925274|DRUG|irinotecan|90 minutes IV infusion of irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
40944443|NCT01925274|DRUG|Cetuximab|120 minute IV infusion of cetuximab 400mg/m\^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
40944444|NCT01925274|DRUG|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
40944445|NCT00528827|DRUG|Cardene® I.V.|"* 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V."
40944446|NCT04398251|DRUG|Febuxostat 40mg Tab|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week.
40944447|NCT04398251|BEHAVIORAL|Non-drug control group|All patients in the group are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly
40944448|NCT01385007|BEHAVIORAL|Preventing Aggression in Veterans with Dementia (PAVeD)|PAVeD-Telephone consists of three components: pain-management strategies, improvement of patient-collateral communication skills, and behavioral activation through increased pleasant activity planning. The intervention will be primarily geared toward the caregiver; but patients may be involved in some modules, depending on their dementia severity and willingness. The goal of the sessions is to prevent aggression in veterans with dementia. The sessions will include didactics, skill-building, and discussion. Participants will also be provided a copy of the book, Pain Management for Older Adults: A Self-help Guide, as an additional resource for optional reading on the topics covered in the intervention. The intervention is proposed to include six to eight sessions of weekly treatments, lasting 30 minutes to 45 minutes, specifically developed to address the recognition and management of pain in persons with dementia.
40944449|NCT03445520|BEHAVIORAL|Intervention Coaching Group|Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
40944450|NCT06090591|OTHER|SGLT-2 inh therapy, CIED implantation, thromboaspiration,|long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
40944451|NCT01443273|OTHER|Medical Records study|No interventions will be done related to the study besides summary of the Medical Files.
40944452|NCT03120312|PROCEDURE|total hip replacement|primary hip replacement patients during past 5 years．
40944453|NCT04545554|DRUG|Romosozumab|Participants will receive multiple doses of romosozumab via a SC injection.
40944454|NCT04545554|DIETARY_SUPPLEMENT|Calcium|All participants will receive daily supplements of elemental calcium.
40944455|NCT04545554|DIETARY_SUPPLEMENT|Vitamin D|All participants will receive daily supplementation with vitamin D.
40944456|NCT03270644|DRUG|Lasmiditan|Administered orally
41285651|NCT01554202|GENETIC|ApoE4|
40944457|NCT03270644|DRUG|Propranolol|Administered orally
41285652|NCT01554202|OTHER|Brain imaging examination MRI and PET examinations|
41285653|NCT05858411|PROCEDURE|SRP+rhPDGF|The infrabony defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in rhPDGF.
41285654|NCT05858411|PROCEDURE|SRP+collagen sponge|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in saline solution.
41285655|NCT05858411|PROCEDURE|SRP alone|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
41285656|NCT00949650|DRUG|Pemetrexed|Pemetrexed IV given once every 3 weeks for up to 6 cycles
41285657|NCT00949650|DRUG|BIBW 2992|BIBW 2992 once daily until progression
41285658|NCT00949650|DRUG|Cisplatin|Cisplatin IV given once every 3 weeks for up to 6 cycles
41285659|NCT05417828|DEVICE|Emulation of Active Daily Living tasks with a robotic device (SPINDLE)|SPINDLE will provide an assistive and resistive force to aid in rehabilitating the subject's upper limb
41285660|NCT01259739|OTHER|Cocoa|dissolved in water twice-daily intervention
41285661|NCT03656887|DEVICE|Continuous interstitial glucose sensor|Installing and removing the sensor
41285662|NCT03656887|OTHER|Sensor Scan|Scan of the sensor, using the Freestyle Pro free version reader, at installation then before removal after 14 days.
41285663|NCT02559505|BIOLOGICAL|Seasonal IIV 0.25 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
41285664|NCT02559505|OTHER|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
41285665|NCT02559505|BIOLOGICAL|Seasonal IIV 0.5 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
41285666|NCT00939172|DRUG|TTP607|3.3 mg/m\^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
41285667|NCT02234011|DRUG|Ketamine|
41285668|NCT02234011|DRUG|Placebo|
40944458|NCT02478372|DRUG|Patient Controlled Epidural (PCEA)|Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
40944459|NCT02478372|DRUG|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
40944460|NCT03387683|DRUG|dapagliflozin|dapagliflozin 10mg
40944461|NCT03387683|DRUG|placebo|placebo to match dapagliflozin
40944462|NCT04886739|DRUG|CGB-400|Topical gel
40944463|NCT04886739|DRUG|Vehicle Gel|Topical gel
40944464|NCT00644657|DRUG|Clopidogrel|All subjects will receive a 300 mg loading dose
40944465|NCT02396251|DEVICE|HA experimental|
40944466|NCT02396251|DEVICE|HA comparator|
40944467|NCT01241240|DRUG|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
41285669|NCT02997514|BEHAVIORAL|Solution Focused Coaching|SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
41285670|NCT02997514|BEHAVIORAL|Intensive Solution Focused Coaching|Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
41285671|NCT00095303|BEHAVIORAL|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
41285672|NCT00095303|BEHAVIORAL|Treatment as Usual|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
41285673|NCT01331395|OTHER|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
40944468|NCT01241240|DRUG|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
40944469|NCT01743456|OTHER|Targeted intra-operative depth of anaesthesia|The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
40944470|NCT00141388|DRUG|Pregabalin|
40944471|NCT03987776|BEHAVIORAL|Anti-inflammatory energy-restricted diet|During 6 months the participants will we asked to use recommended energy-reduced diet with anti-inflammatory properties, based on colorful vegetables and fruits, legumes, nuts, seeds, marine fish, whole-grain products, and daily use of olive oil, green/black tea, multiple spices and herbs.
40944472|NCT03987776|BEHAVIORAL|Control energy-restricted diet|During 6 months the participants of control group will be asked to use recommended energy-reduced diet based on standard obesity management (55-60% carbohydrates, 25% fat, 15-20% protein)
40944473|NCT02996734|PROCEDURE|curettage and resection|the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration
40944474|NCT03267303|DRUG|TS-091 5mg|Orally taken once daily for 3 weeks
40944475|NCT03267303|DRUG|TS-091 10mg|Orally taken once daily for 3 weeks
40944476|NCT03267303|DRUG|Placebo|Orally taken once daily for 3 weeks
40944477|NCT01031706|DRUG|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
40944478|NCT01031706|DRUG|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
40944479|NCT00973271|DRUG|290 mg DCCR|290 mg diazoxide choline
40944480|NCT00973271|DRUG|435 mg DCCR|435 mg diazoxide choline
41452235|NCT02448160|DRUG|salt-poor Human Albumin solution|Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
40944481|NCT00973271|DRUG|135 mg fenofibric acid|135 mg fenofibric acid
40944482|NCT00973271|DRUG|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
40944483|NCT00973271|DRUG|atorvastatin|20 mg atorvastatin
40944484|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS|JUUL 5%, ENDS for 6-days in confinement
40944485|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS|JUUL 3%, ENDS for 6-days in confinement
40944486|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS|JUUL 5%, ENDS for 6-days in confinement
40944487|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS|JUUL 3%, ENDS for 6-days in confinement
40944488|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS|JUUL 5%, ENDS for 6-days in confinement
40944489|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS|JUUL 3%, ENDS for 6-days in confinement
40944490|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS|JUUL 5%, ENDS for 6-days in confinement
40944491|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS|JUUL 3%, ENDS for 6-days in confinement
40944492|NCT04107779|OTHER|Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette|Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
40944493|NCT04107779|OTHER|Tobacco/Nicotine Abstention|No smoking for 6-days in confinement.
41285674|NCT04844879|DEVICE|NextAR TKA system|The NextAR TKA system is a surgical guidance system which measures intra-operatively the effect of prosthesis alignment and positioning on soft tissue balance.
41285675|NCT03157128|DRUG|LOXO-292|Oral LOXO-292
41285676|NCT00337636|PROCEDURE|Surgery to implant human CNS stem cells (HuCNS-SC)|single dose
40757305|NCT03075436|BEHAVIORAL|Enhanced demand-side sanitation, hygiene|The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
40757306|NCT03075436|BEHAVIORAL|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
40757307|NCT01625078|DEVICE|Placement and use of Baska mask|Use of Baska mask as a supraglottic airway during general anesthesia
41285677|NCT00337636|DRUG|Medication to suppress the immune system|Immunosuppression for 12 months post transplant
41285678|NCT03115255|DRUG|intravitreal ranibizumab|0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
41285679|NCT03471910|DRUG|Diosmin|Diosmin 600mg tablet, once daily
41285680|NCT03471910|DRUG|Diosmin / Hesperidin|Diosmin 900 mg / Hesperidin 100mg tablet, once daily
41285681|NCT00877838|DRUG|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
41285682|NCT00877838|DRUG|Placebo|Gelatin capsules resembling the ones containing the active substance
41285683|NCT02985346|BIOLOGICAL|Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis|
41285684|NCT01343615|PROCEDURE|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
41285685|NCT01343615|PROCEDURE|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
41285686|NCT01499576|PROCEDURE|Acetic acid chromoendoscopy|Acetic acid chromoendoscopy Spraying 1.5% acetic acid(or vinegar), during screening gastroduodenoscopy
41285687|NCT01668069|DRUG|Ondansetron|Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
40944494|NCT04107779|OTHER|Usual Brand of cigarettes|Continue smoking UB for 6-days in confinement.
40944495|NCT00619138|BEHAVIORAL|individual cognitive-behavioural therapy|1 session per week for 12 weeks
40944496|NCT00619138|BEHAVIORAL|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
40944497|NCT02091908|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
41285688|NCT06266637|OTHER|Conventional Physical Therapy Program|"Conventional Physical Therapy program:~trunk muscles strengthening exercises, trunk muscles endurance exercises, trunk proprioception exercises . postural correction exercises. Core exercise Spinal mobility exercises"
41285689|NCT06266637|OTHER|Physiotherapeutic Scoliosis-Specific Exercise (Schroth)|It uses exercises customized for each patient to return the curved spine to a more natural position. The spine is addressed in all three anatomical planes - sagittal, frontal and transverse. The purpose of the method is to create spinal balance and stability by improving body mechanics and spinal stabilization to prevent further curve progression
40944498|NCT02091908|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
40944499|NCT02091908|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
41285690|NCT05774470|DEVICE|Owlet OSS 3.0|The Owlet OSS 3.0 is a non-invasive monitoring device. The Sock secures the Sensor to the baby's foot. The Sensor measures the baby's SpO2, heart rate, and movement, and transmits the baby's readings to the Base Station. The Base Station records and monitors the baby's readings and can indicate prompts as needed based on the data sent from the Sensor.
41285691|NCT01760434|OTHER|Long-term outcomes|Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
41285692|NCT01835444|OTHER|PA/MD model|Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
41452236|NCT06464549|DIAGNOSTIC_TEST|EEG-EOG recording at rest and during an auditory oddball paradigm|Participants will attend an electroencephalogram-electrooculogram (EEG-EOG) recording session. Eye blinking will be examined during a rest condition (duration: 8 min) and during an active auditory oddball task (duration: 8 min), consisting of randomly intermixed tones (non-target: 500 Hz, overall probability: 80%, n=312; target: 1000 Hz, overall probability: 20%, n=78) presented with a 1-s inter-stimulus interval through headphones.
41452237|NCT05997797|OTHER|FAAM|The FAAM is made out of two subscales including ADL and Sports subscales that have a complete score of 84 and 32, individually
40944500|NCT02091908|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
40944501|NCT02296281|DRUG|Pirfenidone|
40944502|NCT00550849|DRUG|RTA 402|5 mg oral capsules
40944503|NCT00550849|DRUG|RTA 402|25 mg oral capsules
40944504|NCT00550849|DRUG|RTA 402|50 mg oral capsules
40944505|NCT00912678|DRUG|MMF (Cellcept) and Steroids|Prograf was withdrawn completely after randomization, MMF and steroids were given.
40944506|NCT00912678|DRUG|Tacrolimus (Prograf)|After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
40944507|NCT01193660|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells \> 3x10\^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
40944508|NCT01193660|DRUG|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
40944509|NCT01193660|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
40944510|NCT01193660|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
40944511|NCT01193660|OTHER|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
40944512|NCT02387931|DIETARY_SUPPLEMENT|Vitamin D3|Nature Made Vitamin D 2000IU, 1 softgel taken daily
40944513|NCT02387931|DIETARY_SUPPLEMENT|Fish Oil|Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
40944514|NCT02387931|OTHER|Placebo|Placebo capsule, 2 taken daily
40944515|NCT02413372|DRUG|BMS-986036|
40944516|NCT02413372|DRUG|BMS-986036|
40944517|NCT02413372|DRUG|Placebo|
40944518|NCT00003821|DRUG|aminopterin|
40944519|NCT00586066|DRUG|Memantine|Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.
40944520|NCT00586066|DRUG|Placebo|Inactive comparator. Placebo-matching memantine tablet.
40944521|NCT05165407|DRUG|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
40944522|NCT05165407|DRUG|IBI310|IBI310 1mg/kg be intravenously administered on Day 1 of every 2 cycle
41285693|NCT00001923|PROCEDURE|Transcranial magnetic stimulation|
40757308|NCT00919360|PROCEDURE|collection of maternal blood specimen prior to delivery|approximately 5 cc. of maternal blood will be drawn prior to delivery
40757309|NCT00919360|PROCEDURE|collection of placental cord blood after delivery|approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
40757310|NCT00919360|PROCEDURE|collection of placental tissue|within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
40757311|NCT00919360|PROCEDURE|collection of strip of decidua from uterine lining from cesarean section deliveries|A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
41452238|NCT02256943|DRUG|Amitriptyline|100 mg single dose
41452239|NCT02256943|DRUG|Tolterodine|Placebo 1 mg single dose
40757312|NCT01555424|DIETARY_SUPPLEMENT|High dose|This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
40944523|NCT05165407|DRUG|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously
41285694|NCT03671044|DRUG|Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
41285695|NCT03671044|DRUG|Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
41285696|NCT03671044|DRUG|Taxotere® (100 mg/m2)|Docetaxel Injection Concentrate; 20 mg/0.5 mL
41452240|NCT02754219|DRUG|Evogliptin|DPP4-inhibitor, Evogliptin
41452241|NCT05542056|OTHER|Data and biosample collection|Collection of spot urine, blood sampling, vital parameters, body weight, medical history, patient questionnaires, drinking protocol, drug diary at at Visit 1 (before thiazide initiation), at Optional 2 hours-challenge, at Visit 2 (4 weeks after thiazide initiation), at Visit 2.1 (4 weeks after dose change), at Visit 3 (3-months after thiazide initiation)
41452242|NCT02651987|DRUG|Lanreotide autogel 120 mg|
41132610|NCT06002867|PROCEDURE|SAPB (Serratus Anterior Plan) Block|The patient will be in the supine position. The area where the procedure will be performed will be cleaned with povidone iodine. Using a 22-gauge, 80 mm insulated Quincke needle with a high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath, the latissimus dorsi muscle and the serratus muscle will be visualized at the level of the 4th and 5th ribs. After determining the fascia between the two muscles, the block needle will be advanced from caudal to cranial and 40 ml of 0.25% bupivacaine (local anesthetic) will be injected on the serratus muscle between the two muscles.
41132611|NCT00677209|BIOLOGICAL|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
41132612|NCT00233610|DRUG|Bicalutamide|
41132613|NCT00233610|DRUG|Tamoxifen|
41132614|NCT02961634|DEVICE|Nailner 2 in 1|Nailner 2 in 1 is a combination of assets that alter the pH of the nail and is used as an adjunct in the treatment of onychomycosis.
41452243|NCT04790643|OTHER|Exercise-based cardiac rehabilitation program (Stage 1)|In Stage 1 the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest (where the vital signs are evaluated); II. Warming-up (composed of 15 minutes of stretching and global exercises); III. Aerobic exercise (composed of 30 minutes of treadmill or cycle ergometer exercise, the intensity established varies from 40 to 70% of the heart rate reserve for those diagnosed with cardiovascular diseases and from 60 to 80% of the heart rate reserve for those with only cardiac risk factors); IV. Cooldown (composed of 5 minutes of slow walking).
41452244|NCT04790643|OTHER|Exercise-based cardiac rehabilitation program (Stage 2)|In Stage 2, the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest; II. Warming-up; III. Aerobic exercise (these three activities are the same as stage 1); IV. Resistance training (composed of 15 minutes of individualized resistance exercises); V. Cooldown.
41452245|NCT02704091|DRUG|Smecta|
40944524|NCT03769298|DRUG|Envarsus XR|The Envarsus XR® drug will be administered to study participants once daily, orally. The dosage can be 0.75 mg, 1 mg or 4 mg. The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.
41452246|NCT02704091|DRUG|Smecta placebo|
40944525|NCT02988154|OTHER|Simulation training|Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).
41132615|NCT02961634|DRUG|Ciclopirox 8%|Ciclopirox 8% is a glaze used in the treatment of onychomycosis
41132616|NCT02188836|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
41132617|NCT02188836|DEVICE|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
41132618|NCT00004784|DRUG|methotrexate|
41132619|NCT00004784|DRUG|ursodiol|
41132620|NCT04609735|OTHER|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound
41132621|NCT04609735|OTHER|Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound vs. Manual Therapy, Exercise and Ultrasound
41285697|NCT01302275|DRUG|Oxcarbazepine|Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
41285698|NCT01980446|PROCEDURE|Auditory-evoked potentials|cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
41285699|NCT04299269|OTHER|Questionnaire|Questionnaire including questions about Quality of life, symptoms and general informations
41285700|NCT06394063|BIOLOGICAL|Telitacicept|Telitacicept 160 mg SC every other week
41285701|NCT06394063|DRUG|Placebo|Placebo to Telitacicept
41285702|NCT00581607|DRUG|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
41285703|NCT00581607|DRUG|Placebo|Placebo twice a day
41452247|NCT06159647|BEHAVIORAL|Mouth cancer warning|Participants will view messages about the risk of mouth cancer from alcohol consumption.
40757313|NCT01555424|DIETARY_SUPPLEMENT|Reference dose|This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
41285704|NCT00581607|DRUG|Bosentan|drug given for 16 weeks
41285705|NCT00581607|DRUG|Placebo|placebo
41285706|NCT02856737|OTHER|eye masks and earplugs|Materials similar to those offered on long commercial flights
40757314|NCT06026696|OTHER|follow-up|Long term follow-up
40757315|NCT00083447|DRUG|TransMID™|
40757316|NCT01034657|DRUG|LBH589|LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
40944526|NCT02988154|OTHER|''See one, do one'' approach|The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
41285707|NCT04936425|DEVICE|OTSC Stentfix|The OTSC stentfix will be placed during upper endoscopy after a self-expanding metal stent has been deployed.
41285708|NCT02450253|DRUG|Tadalafil|single dose, 20 mg capsule p.o.
41285709|NCT02450253|DRUG|Placebo|single dose, matching capsule p.o.
41285710|NCT02450253|BEHAVIORAL|Cognitive functioning tests|Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control
40757317|NCT01034657|DRUG|Epoetin Alfa|Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
40944527|NCT04795622|DEVICE|Ultherapy treatment|Focused ultrasound energy delivered below the surface of the skin
41285711|NCT02450253|BEHAVIORAL|Neuropsychological tests|"Neuropsychological tests will be performed prior to pre IMP dose MRI scan \& then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart"
41285712|NCT02450253|OTHER|MRI Scan - Arterial Spin Labelling|Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
41285713|NCT00628810|BIOLOGICAL|bevacizumab|
40757322|NCT05148663|DIAGNOSTIC_TEST|CCM Hemorrhagic Panel|Biomarker
41285714|NCT00628810|DRUG|fluorouracil|
41285715|NCT00628810|DRUG|irinotecan hydrochloride|
41285716|NCT00628810|DRUG|leucovorin calcium|
41285717|NCT03551886|BEHAVIORAL|Advanced Emotion App|The app is designed to help TAY better recognize their emotions using enhanced features
41285718|NCT03551886|BEHAVIORAL|Basic Emotion App|The app is designed to help TAY better recognize their emotions using basic features
41452248|NCT06159647|BEHAVIORAL|Throat cancer warning|Participants will view messages about the risk of throat cancer from alcohol consumption.
41452249|NCT06159647|BEHAVIORAL|Voice box (larynx) warning|Participants will view messages about the risk of voice box (larynx) cancer from alcohol consumption.
41452250|NCT06159647|BEHAVIORAL|Esophagus cancer warning|Participants will view messages about the risk of esophagus cancer from alcohol consumption.
40944528|NCT04795622|DEVICE|Untreated-control / delayed-treatment|Untreated-control, followed by Ultherapy treatment (focused ultrasound energy delivered below the surface of the skin)
40944529|NCT00706810|DRUG|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
40757323|NCT05205720|PROCEDURE|Celiac plexus block|The surgeon is instructed to perform a single celiac plexus block under direct vision. 10ml 0.5% ropivacaine is injected into the nerve in both sides.
40757324|NCT05205720|DRUG|Ropivacaine|Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.
40944530|NCT00706810|DRUG|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
40944531|NCT00815607|DRUG|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
40944532|NCT00815607|BIOLOGICAL|INXN-3001|Intratumoral injection
40944533|NCT00402272|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
40944534|NCT01231347|DRUG|AMG 479|AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
40944535|NCT01231347|DRUG|Placebo|Placebo administered intravenously on days 1 and 15 of a 28 day cycle
40944536|NCT01231347|DRUG|AMG 479|AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
41452251|NCT06159647|BEHAVIORAL|Liver cancer warning|Participants will view messages about the risk of liver cancer from alcohol consumption.
40944537|NCT01231347|DRUG|gemcitabine|gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
41452252|NCT06159647|BEHAVIORAL|Colon and rectum cancer warning|Participants will view messages about the risk of colon and rectum cancer from alcohol consumption.
40944538|NCT00667602|BIOLOGICAL|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
40944539|NCT00667602|BIOLOGICAL|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
40944540|NCT00667602|BIOLOGICAL|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
40944541|NCT00667602|BIOLOGICAL|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
40944542|NCT00667602|BIOLOGICAL|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
40944543|NCT05218239|BEHAVIORAL|Active Comparator: Routine education group|Behavior guidance on pelvic floor muscle function training , including Knack method education , and Kegel exercise and other pelvic floor muscle training methods were taught to postpartum women.
40944544|NCT05218239|BEHAVIORAL|Experimental: Global training group|Global training was added on the basis of control group. The 30min-training plan is divided into 9 sections, of which, groups 1 to 8, each group takes about 3 minutes, the ninth group is cool down section, including stretching for 5 minutes and foam axis stretching for 1 minute.
40944545|NCT01395667|OTHER|CCRT|Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
40944546|NCT00729287|DIETARY_SUPPLEMENT|selenium|Given orally
40944547|NCT00729287|OTHER|placebo|Given orally
40944548|NCT00808561|OTHER|Group 1: Alternative Fistula|Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
41452253|NCT06159647|BEHAVIORAL|Breast cancer|Participants will view messages about the risk of breast cancer from alcohol consumption.
41452254|NCT06159647|BEHAVIORAL|Cancer (generic, not site-specific)|Participants will view messages about the risk of cancer (not site-specific) from alcohol consumption.
40757325|NCT06289283|OTHER|Urine samples and tissue samples: Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigera|"Samples for microbiome analysis:~Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigerator until be analyzed at the microbiology laboratory of TBRI.~Urine samples (50 ml) for microbiome analysis will be collected during cystoscopy examination. Samples will be stored at -80 °C until processing.~Tissue and urine samples from patients with bladder cancer: Under standard procedure of diagnostic cystoscopy urine sample will be collected under complete aseptic conditions, patients who has bladder tumor will undergo transurethral resection of bladder tumor, a tissue sample 0.5x0.5 cm will be investigated for microbiome analysis. Samples will be stored at -80 °C until processing. Histopathological diagnosis with Hematoxylin and eosin stain will be done by an expert pathologist for tumor grade and stage according to WHO 22, and EAU guidelines 2023. This procedure will be applied for"
40944549|NCT00808561|OTHER|Group 2: Forearm AV Graft|a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
40944550|NCT06407271|DEVICE|CAD/CAM custom ZrO2 healing abutment|Application of custom, zirconium-dioxide healing abutment, fabricated with computer aided design and manufacturing, following immediate implantation.
40944551|NCT06407271|DEVICE|Cylindrical ZrO2 healing abutment|Application of cylindrical, zirconium-dioxide healing abutment following immediate implantation.
40944552|NCT02503410|BEHAVIORAL|Usual care|Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.
40944553|NCT02503410|BEHAVIORAL|Interactive gaming|Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
40944554|NCT00259454|BEHAVIORAL|In-home intervention|occupational therapy techniques to reduce caregiver stress
40944555|NCT02196207|DRUG|Eloctate Prophylaxis|Prevention Trial, Arm A: Eloctate (65 IU/kg) will be administered weekly by intravenous infusion for up to 48 weeks in previously untreated children with severe hemophilia A beginning before the first bleed.
40944556|NCT02196207|DRUG|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab (1.5 mg/kg) will be administered weekly by subcutaneous injection for up to 48 weeks in previously untreated children with severe hemophilia A.
41285719|NCT05012566|DEVICE|Juvederm|"* Juvederm Volbella: 15mg/ml, it is injected 1.5ml per patient per treatment (a total of 3ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Volifit: 17.5mg/ml, it is injected 3ml per patient per treatment (a total of 6ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Voluma: 20mg/ml, it is injected 5ml per patient per treatment (a total of 10ml per patient split in 2 treatment sessions at a 4 months interval)"
41285720|NCT05012566|DRUG|Vistabex|Vistabex: 50U/vial, it is injected up to 80U per patient per treatment (2 treatment sessions at a 4 months interval)
41285721|NCT02522377|DRUG|Ketamine|inter venous injections
41285722|NCT02522377|DRUG|Midazolam|inter venous injections
41452255|NCT06159647|BEHAVIORAL|Addiction and neurological changes|Participants will view messages about the risk of addiction and neurological changes from alcohol consumption.
41285723|NCT02865369|DRUG|Daclatasvir and Asunaprevir|Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
40757326|NCT00832026|DEVICE|Trans Nasal Insufflation (TNI) [nasal canula]|"Trans Nasal Insufflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.~By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing."
40944557|NCT02196207|DRUG|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion plus Emicizumab (1.5 mg/kg) weekly by subcutaneous injection will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
40944558|NCT02196207|DRUG|Eloctate ITI|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
40757327|NCT05127785|PROCEDURE|LVAD or Heart Transplant|Patients undergoing advanced heart failure intervention including LVAD implantation or heart transplantation
40757328|NCT02594943|DEVICE|Boston Scientific Large Capacity with needle Biopsy|The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
41285724|NCT01199341|DRUG|AZD1981|100 mg per oral, twice daily for 14 days
41285725|NCT01199341|DRUG|Warfarin|10 x 2.5 mg per oral, once daily at day 1 and day 15
41452256|NCT06159647|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
41452257|NCT06159647|BEHAVIORAL|Liver damage|Participants will view messages about the risk of liver damage from alcohol consumption.
40757329|NCT02594943|DEVICE|Endodrill 1A (BIBBInstruments, Lund, Sweden)|The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
40757330|NCT03063164|DEVICE|Intralase IFS150|Intralase flap creation
40757331|NCT03063164|DEVICE|Visumax|Visumax flap creation
40757332|NCT03318393|DRUG|Bivalirudin|Continuous infusion
40757333|NCT03318393|DRUG|Unfractionated heparin|Continuous infusion
40757334|NCT04606849|OTHER|Physician Survey|Our questionnaire includes questions on respondent demographics and Likert-style questions about respondent experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components.
40944559|NCT04965909|OTHER|Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.|Online group therapeutic program (small groups), applied for 3 months.
41285726|NCT01199341|DRUG|AZD1981|4 x 100 mg per oral, twice daily for 14 days
40757335|NCT04606849|DEVICE|ePNa-CheXED|ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in \<1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion).
41285727|NCT06402253|BEHAVIORAL|Music composition / edition|"Participants in this group will complete two 1-hour music composition training intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these music composition lessons has been developed specifically for this project, in collaboration and based on the educational music composition programs from the American Composers Orchestra (ACO).~Lessons review basic structural musical concepts, practicing active listening and music appreciation skills, teaching about the use of music-composition specific software (i.e., Soundtrap), and helping the students in expressing themselves / their identity through music, learning about musical story-telling through the creation of their own musical pieces from scratch."
41452258|NCT06159647|BEHAVIORAL|Harm to fetus|Participants will view messages about the risk of harm to a fetus from alcohol consumption during pregnancy.
40757336|NCT05197374|DRUG|Estradiol Valerate 4mg|Estradiol valerate 2 mg (two tablet once daily) started 5 days before expected menses (or 7 days after ovulation of previous cycle). After start of menses, estradiol pretreatment was stopped and controlled ovarian stimulation started.
40757337|NCT05586685|OTHER|effect of diaphragmatic release on upper crossed syndrome|"The patients will be positioned in the supine position. The therapist stood at the head of the patient.therapist make manual contact of ribs and ask patient to inspire the move ribs laterally and then expire~conventional exercise Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position"
41452259|NCT06159647|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
41452260|NCT06159647|BEHAVIORAL|Impaired sleep|Participants will view messages about the risk of impaired sleep from alcohol consumption.
40757338|NCT06569784|DRUG|[14C]HSK31858|A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.
40757339|NCT00432991|DRUG|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
40757340|NCT00432991|DRUG|Saline Placebo|0.5 mL, IM (in the muscle), one time
41452261|NCT06159647|BEHAVIORAL|Drinking guidelines|Participants will view messages about guidelines for alcohol consumption.
41452262|NCT06159647|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
41452263|NCT06159647|BEHAVIORAL|Road injuries|Participants will view messages about the risk of road injuries from alcohol consumption.
41452264|NCT04989244|BEHAVIORAL|Weight loss program|Women with obesity were included to the weight loss program which included physical exercise and dietary guidelines
40757341|NCT03923998|DRUG|Neoadjuvant chemotherapy|Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
40944560|NCT06159608|DRUG|Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)|Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
40944561|NCT06159608|OTHER|Chronic estrogen exposure|differences in urine estrogen levels across the menstrual cycle between women groups only
40944562|NCT06333301|OTHER|Surveys|Group will complete several surveys
40944563|NCT01670604|DRUG|6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)|
40944564|NCT01670604|DRUG|Tetraspan, B. Braun, Melsungen, Germany|
40757342|NCT03923998|RADIATION|Neoadjuvant radiotherapy|Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
41452265|NCT05744492|OTHER|Vivifrail multicomponent exercise program|"Resistance: 3 sets of 2 repetitions of 3-4 exercises with a 1 to 3-minute break between sets. Intensity from 30-repetition maximum (RM) at weeks 1-6 to 20-RM at weeks 7-12.~Balance training: both static and dynamic. Subjects will increase the number of repetitions, the difficulty of the exercises or will add external perturbations to the tasks (unstable surfaces, obstacles, or visual deprivation) along the duration of the interventions to guaranteeing progression. In the case of high risk of falling the number, frequency and volume of balance exercises will be increased.~Flexibility: a set of stretching exercises at the end of each session. Subjects will be instructed to stretch until they feel tension in their muscles without reaching discomfort. Stretching will be maintained for 10 sec. and repeated 2-3 times.~Cardiovascular: walking-based activities oriented to increase cardiorespiratory fitness. They will range from 5-10 sec. to 45 min/session."
41452266|NCT00981838|DRUG|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients \> 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
41452267|NCT00940433|PROCEDURE|open properitoneal hernia repair|suprapubic retro-inguinal approach
40757343|NCT03923998|PROCEDURE|Resection and reconstruction|Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
40944565|NCT05126680|OTHER|Supervised exercise therapy: intermittent treadmill walking exercise and moderate intensity functional training|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (15-30 min.) and moderate intensity functional training (MIFT) (15 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min. In MIFT, subjects must complete in 15 min. the highest number of repetitions / rounds possible (AMRAP) to a circuit composed of 6 global functional exercises from which they performed 10 repetitions with a rating of perceived exertion (RPE) of 5-7 on a 1 to 10 scale in each exercise.
40944566|NCT05126680|OTHER|Supervised exercise therapy: intermittent treadmill walking exercise|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (30-45 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min.
40944567|NCT05224765|OTHER|Fall prevention class|Participants attend fall prevention discharge class per hospital protocols
40944568|NCT03502096|BEHAVIORAL|To-Go container|Subjects were provided a to-go container in which leftover foods would be packaged
40944569|NCT03502096|OTHER|Control|Subjects were not provided a to-go container with the meal
40944570|NCT02927782|PROCEDURE|Early Mobilization|early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.
40757344|NCT06147869|DEVICE|phonophoresis|Phonophoresis is a method of driving topically applied substances across tissues using ultrasound (US) to enhance percutaneous absorption of selected drugs such as corticosteroids, local anaesthetics, and salicylates
40757345|NCT06147869|DEVICE|Low level laser therapy|Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
40757346|NCT02207101|DIETARY_SUPPLEMENT|E-OJ-01 (OXYJUN)|
40757347|NCT02207101|DIETARY_SUPPLEMENT|Placebo|
40757348|NCT04392570|DIAGNOSTIC_TEST|Fasting|blood samplings will be taken 08:00 am and again 2 hours before breaking the fast
40944571|NCT02927782|PROCEDURE|Bed Rest|48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
40944572|NCT01225796|DRUG|Sodium bicarbonate|Sodium bicarbonate 650mg by mouth three times daily for 6 months.
40944573|NCT04704973|BEHAVIORAL|Transdiagnostic short-term psychotherapy|Focused clinical functional analysis, formulation of a valued life direction includings strategies to handle obstacles, and a summarizing exercise including relapse prevention.
41285728|NCT06402253|BEHAVIORAL|Photography composition / edition|"Participants in this group will complete two 1-hour photography/visual-arts composition/edition intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these photography composition lessons has been developed specifically for this project, in collaboration and based on educational photography/film programs from Downtown Community TV Center (DCTV).~Lessons review basic structural photography/visual-arts concepts, practicing visual-arts appreciation skills, teaching about the use of photography edition specific software (i.e., Photoshop), and helping the students in expressing themselves/their identity through photography, learning about visual story-telling through the creation of their own photographical projects from scratch."
41285729|NCT01435512|BEHAVIORAL|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
40944574|NCT03848104|OTHER|bone and joint infection treated with cefoxitin|the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
41285730|NCT06024252|DRUG|TACE|TACE in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks.
41285731|NCT01089855|DRUG|Carbamazepine|
41285732|NCT01172314|DIETARY_SUPPLEMENT|EAA+LEU vs total AA|15 g as a bolus
41285733|NCT01172314|DIETARY_SUPPLEMENT|Total AA vs EAA+LEU|15 g as a bolus
41285734|NCT06170255|BEHAVIORAL|Behavioral Activation (BA)|Behavioral activation involves an exploration of the patient's individualized values and follows with goal setting to improve depression symptoms.
40757349|NCT06510075|BEHAVIORAL|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
40757350|NCT06510075|BEHAVIORAL|Community Health Worker|Health care information delivered via CHW.
40944575|NCT04352946|DRUG|Hydroxychloroquine Pre-Exposure Prophylaxis|HCQ PreP 400mg daily
40944576|NCT04352946|DRUG|Placebo oral tablet|Placebo tablets 400mg daily
41132622|NCT05127902|DIAGNOSTIC_TEST|Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy)|"Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy) Balance performance of subjects will be tested on the proprioceptive-stabilometric assessment machine.~Noraxon wireless TELEmyo Direct Transmission System (TELEmyo DTS) with product code of 580 (Noraxon, USA Inc., USA)~The sampling frequency will be of 1000Hz and bandwidth of 10-500Hz. Bipolar silver chloride electrodes of 15mm diameter will be used for EMG signals collection, the interelectrode distance will be fixed at 20mm. Normalization procedure will be done by asking subjects to perform isometric maximum voluntary contractions (MVC). The MVC will be measured by Lafayette hand-held dynamometer connected to flat stirrup. MVC will be tested as listed below.~The sEMG signals during each experiment will be normalized to the sEMG at isometric MVC and expressed as percentages of the maximum sEMG activity (%EMG_max) for comparison with normalization signal processing program in Noraxon System."
41132623|NCT00780494|DRUG|bevacizumab|Intravenous 15 mg/kg
41285735|NCT05015361|DRUG|Remimazolam Tosilate|Treatment group A: Remimazolam Tosilate; high dose Treatment group B: Remimazolam Tosilate; low dose
41285736|NCT05015361|DRUG|Propofol Injection.|Treatment group C: Propofol Injection.
40757351|NCT06510075|BEHAVIORAL|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
40757352|NCT04381377|DRUG|azoximer bromide|Investigational medicinal product
40757353|NCT04381377|OTHER|Placebo|Placebo
40757354|NCT00059280|BIOLOGICAL|Myozyme|20 mg/kg qow or 40mg/kg qow
40757355|NCT00276003|DRUG|Gemcitabine, Irinotecan, Allopurinol.|Gemcitabine - 1000mg/m2; IV; d1, 8; q 21 days Irinotecan - 100mg/m2; IV; d1, 8; q 21 days Allopurinol - 300 mg; PO; day 1-5; 1st cycle
40944577|NCT06376331|DRUG|washed microbiota transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
40944578|NCT00833820|PROCEDURE|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
41132624|NCT00780494|DRUG|carboplatin|AUC 6, Intravenously Day 1 every 21 days
41285737|NCT00479362|DRUG|Warfarin|Warfarin is either interrupted or uninterrupted prior to device implantation
41285738|NCT00479362|DRUG|Aspirin|Aspirin is continued without interruption prior to device implantation
41285739|NCT00479362|DEVICE|Permanent pacemaker|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
41285740|NCT00479362|DEVICE|Implantable Cardioverter-defibrillator|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
41285741|NCT06430255|OTHER|Global Postural Re-education|Program for treatment
41285742|NCT06430255|OTHER|Laser-guided Supervised Exercise|Program for treatment
41452268|NCT00940433|PROCEDURE|Lechtestien hernia repair|onlay mesh repair
40944579|NCT00833820|PROCEDURE|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
41285743|NCT02308280|DRUG|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
41285744|NCT04331899|DRUG|Peginterferon Lambda-1a|Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care
41285745|NCT04331899|OTHER|Placebo|Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection
41285746|NCT04230538|DEVICE|DJO Walker|
41285747|NCT04230538|DEVICE|Traditional plaster cast|
41285748|NCT02011022|DRUG|3g MTX|The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL
41285749|NCT02011022|DRUG|5g MTX|The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
41285750|NCT06498271|DEVICE|Personalized and automated digital coaching using a mobile application|Participants allocated to the experimental group will be invited to download a smartphone application which will appraise their motivation and automatically propose: 1) exercises to be performed at home and adapted to their pain levels; 2) audio recordings for pain management; and 3) educational and coaching content adapted to their motivation. In addition, the smartphone application enables users to plan their home exercises
40944580|NCT03929510|DRUG|14C-PF-06651600|Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
41285751|NCT05144022|BEHAVIORAL|Bungee jump|Bungee jump from a cran
41452269|NCT00940433|PROCEDURE|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
40944581|NCT03929510|DRUG|14C-PF-06651600 IV|IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
40944582|NCT03929510|DRUG|PF-06651600|Oral solution 200mg
40944583|NCT01561378|DRUG|Aspart insulin|40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
41285752|NCT03052153|OTHER|No investigational intervention performed for this study|No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
41285753|NCT00564928|DRUG|IPI-504|IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle
41285754|NCT03419702|DIETARY_SUPPLEMENT|Almonds|During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.
41285755|NCT00203346|PROCEDURE|Greater Occipital Nerve Block|
41285756|NCT05598086|DRUG|Tranexamic acid|local infiltration of TXA or normal saline in the post-operation would
41452270|NCT00940433|PROCEDURE|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
41452271|NCT03580915|BEHAVIORAL|Functional Literacy Program|The intervention will be provided twice weekly in 2-hour sessions, over 8 weeks. The 16 intervention sessions will provide the opportunity for participants to learn functional literacy skills to (1) manage an apartment, (2) access community resources, (3) manage finances, (4) access free recreational activities. All sessions will address literacy skills needed to complete basic daily life activities in the home and community environments. Literacy skills will first be learned and practiced within the supported shelter, and then extended to the community.
41452272|NCT03580915|BEHAVIORAL|Usual Care Management Services|The control group will receive the usual housing services without additional intervention.
41452273|NCT00197873|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus supplementation|Lactophilus supplementation is administered during chemotherapy.
41285757|NCT05797766|BEHAVIORAL|Fluid Distribution Timetable|a scheduled distribution of predetermined amounts of fluid intake daily depicted in a 5x6 table. The timetable has three major columns. The first column has six-time points of a day with a four-hour interval. The second column, which was divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intake per day, usual level of activity, time of medication intake, and common time they encounter thirst for a day. The third column indicates the converted percentage of fluid allotment into milliliters.
41285758|NCT02469246|DRUG|F/TAF|200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily
41285759|NCT02469246|DRUG|ABC/3TC|600/300 mg FDC tablets administered orally once daily
41285760|NCT02469246|DRUG|ABC/3TC Placebo|Tablets administered orally once daily
41285761|NCT02469246|DRUG|F/TAF Placebo|Tablets administered orally once daily
41285762|NCT02469246|DRUG|3rd ARV agent|An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
41285763|NCT06447792|OTHER|Loading protocol|The prosthetic restoration and functional loading of the dental implant.
41285764|NCT01373554|DRUG|Placebo|30mig/bid or 60mg/bid P.O
41452274|NCT00197873|OTHER|Placebo administration.|Placebo is administered during chemotherapy.
40944584|NCT01561378|DRUG|Normal saline|200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
41285765|NCT01373554|DRUG|Oltipraz|30mig/bid or 60mg/bid P.O
41285766|NCT00960817|DRUG|Statin, aspirin|
41285767|NCT00960817|DRUG|Dipyridamole|
41285768|NCT04511299|OTHER|SMOFlipid 20%|Fish oil-enriched intravenous lipid emulsion
41285769|NCT04511299|OTHER|Lipofundin 20%|MCT/LCT standard intravenous lipid emulsion
41285770|NCT01401569|BEHAVIORAL|Exercise and counseling (for smoking cessation and physical activity)|Exercise and counseling (for smoking cessation and physical activity)
41285771|NCT03852212|OTHER|Manipulation|Thrust technique application
41285772|NCT00044447|DRUG|Glimepiride|
41285773|NCT04050748|PROCEDURE|Achilles tendon repair|Patients will be undergoing achilles tendon repair
41285774|NCT01965925|DRUG|Modafinil|Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
41285775|NCT01965925|DRUG|Placebo|For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
40944585|NCT01561378|DEVICE|Intranasal mucosal atomizer device|Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
41132625|NCT00780494|DRUG|capecitabine|850mg/m2, Orally twice daily days 1-14 every 21 days.
41132626|NCT01214759|DRUG|Truvada|Tenofovir 200mg/emtricitabine 300mg once a day
41132627|NCT01214759|DRUG|Raltegravir|Raltegravir 400mg twice a day
41285776|NCT04902885|DRUG|Trilaciclib, carboplatin, etoposide，or Topotecan|Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients
41285777|NCT04902885|DRUG|placebo, carboplatin, etoposide，or Topotecan|placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients
41285778|NCT02363647|OTHER|Tumor Genomic Analysis|"Tumor mutations identified by deep DNA and RNA sequencing of individual tumors are screened for tumor drivers, which are then incorporated into the personal Drosophila model and tested against a library of FDA approved drugs. Fly mortality is used as a surrogate for toxicity and increased survival to adulthood; improvements in tumor mutation-linked eye and/or wing abnormalities serve to quantify efficacy. This allows rapid and parallel screening of FDA approved drugs and subsequent drug combinations. The most efficacious and least toxic combinations are tested in xenograft models and a multidisciplinary tumor board of experts select the best therapeutic option. The objective is to demonstrate that the personalized drosophila model approach is superior to the current standard. Patient will be offered an unique personalized single drug or combination of drugs, all FDA approved, based on the Drosophila drug screening process."
41285779|NCT03604328|DRUG|PA5108|single ocular implant, administered on day 1
41452275|NCT02396888|DRUG|Insulin|Half of the wound surface was treated daily with 10 units of intermediate insulin.
41452276|NCT02396888|DRUG|Placebo|Half of the wound surface was treated daily with 0.1 cc of normal saline.
41132628|NCT04440800|DEVICE|Wearable activity tracker - FitBit|Participants will be given a wearable activity tracker and their daily step count recorded. If there is a reduction from baseline of over 1000 steps, the participant will be contacted and an ambulatory review organised if the reduction is not due to a device compliance issue
41132629|NCT00336791|DRUG|5-Fluorouracil|"FEC Chemotherapy: 500 mg/m\^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m\^2 IV on day 1 and day 4 of 21 day cycle."
41452277|NCT05316636|DEVICE|Vibrational forces|
41132630|NCT00336791|DRUG|Cyclophosphamide|"FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle."
41132631|NCT00336791|DRUG|Doxorubicin|FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
41132632|NCT00336791|DRUG|Paclitaxel|80 mg/m\^2 by vein (IVPB) over 1 hour every week for 12 weeks
41132633|NCT00336791|DRUG|Epirubicin|FEC: 100 mg/m\^2 IV on day 1 of 21 day cycle.
41452278|NCT05316636|PROCEDURE|Orthodontic treatment with clear aligners|
41452279|NCT01706757|DEVICE|go-cart|conducts exercises with the help of a go-cart
41452280|NCT02951247|DEVICE|Hearing Aid|Successor of Phonak Virto V90-10 NW O
41452281|NCT03302832|OTHER|Physical Therapy|Physical therapy includes both the in-person and home-based interventions prescribed for each individual participant in order to maximize overall patient outcomes including: ambulation, range of motion, strength, functional activities, pain, swelling, balance, patient safety, and other items within the scope of physical therapy practice.
41132634|NCT03477214|DIAGNOSTIC_TEST|Biomechanical and electromyography mapping|The vaginal tactile imaging probe will acquire biomechanical and electromyography high definition measurements for anterior and posterior compartments along entire vagina.
41132635|NCT05109598|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).
40944586|NCT03796533|DRUG|Posaconazole|"* PCZ will be used as recommended in tablet formulation at an initial dosage of 300 mg twice a day on the first day and then once a day at a dose of 300 mg the following days.~* PCZ prophylaxis will be started on the same day as the start of chemotherapy and will be continued until the end of aplasia.~* The dosage of the PCZ can be adjusted according to the results of the PCZ assay. It may be interrupted if the transaminase level is greater than 3 times higher than normal (3N) or on medical decision."
40944587|NCT00300105|DRUG|Tesaglitazar|
41132636|NCT00746759|DEVICE|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
40944588|NCT05526391|DRUG|TAK-341|TAK-341 IV infusion
40944589|NCT05526391|DRUG|Placebo|TAK-341 placebo-matching IV infusion
41132637|NCT01809457|OTHER|educational poster|educational poster for dental trauma
41132638|NCT05818852|DRUG|VX-548|Tablets for oral administration.
41132639|NCT05818852|DRUG|Moxifloxacin|Capsules for oral administration.
41132640|NCT05818852|DRUG|Moxifloxacin Placebo|Capsules for oral administration.
41132641|NCT05818852|DRUG|VX-548 Placebo|Tablets for oral administration.
41132642|NCT00635700|DRUG|ziprasidone|20-160 mg/d
41132643|NCT00635700|DRUG|placebo|placebo
41132644|NCT05485116|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
41132645|NCT01553266|BEHAVIORAL|Mobile Diabetes Education Teams intervention|A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
41132646|NCT01313663|DRUG|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
41132647|NCT01313663|DRUG|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
41132648|NCT05726526|DEVICE|VIEWER virtual care platform|VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
41132649|NCT03629366|BEHAVIORAL|Supported Employment (SE)|Supported Employment
41132650|NCT03629366|BEHAVIORAL|Treatment as usual (TAU)|Treatment as usual
41132651|NCT05808205|DEVICE|• ALIAXIN EV: Essential Volume • ALIAXIN FL: Lips • ALIAXIN SR: Shape & Restore • ALIAXIN GP: Global Performance • ALIAXIN LV: Lips Volume|"According the investigator judgment and IP' Instruction For Use (IFU), each subject can be treated in one or more of following face area:~* Temporal / frontal area~* Orbital / Malar area~* Perioral area~* Lips."
41132652|NCT01354574|OTHER|High Glycemic Index meals|Dietary intervention with meals containing high glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only high glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
41132653|NCT01354574|OTHER|Low Glycemic Index meals|Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
41132654|NCT00872248|PROCEDURE|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
41132655|NCT00872248|PROCEDURE|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
41132656|NCT02555306|DRUG|0.5 mg of DE-122|DE-122 Injectable Solution
41132657|NCT02555306|DRUG|1.0 mg of DE-122|DE-122 Injectable Solution
41132658|NCT02555306|DRUG|2.0 mg of DE-122|DE-122 Injectable Solution
41132659|NCT02555306|DRUG|4.0 mg of DE-122|DE-122 Injectable Solution
41132660|NCT00794807|DRUG|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
41132661|NCT05292118|DEVICE|Navitian|Patients in whom treatment with (Navitian) has been attempted
41452282|NCT03302832|OTHER|In-home Exercise Equipment|The in-home exercise component of the study will supplement physical therapy services. This exercise equipment will be utilized daily for up to 90 minutes as guided by the healthcare team
40944590|NCT05199493|DRUG|Angiotensin II|Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.
40944591|NCT05199493|DRUG|Control|Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo
40944592|NCT00312182|DRUG|Nelfinavir|
40944593|NCT03246620|DRUG|Olanzapine oro-dispersible 5Mg Tab|Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
40944594|NCT03246620|DRUG|Haloperidol 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
40944595|NCT03246620|DRUG|Diazepam 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
41285780|NCT00310505|DRUG|Amphotericin B deoxycholate given as daily administration|
41452283|NCT01237444|DRUG|lopinavir/ritonavir plus one nucleoside|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
40944596|NCT00000612|DRUG|estrogens, conjugated|
40944597|NCT00000612|BEHAVIORAL|diet, soy proteins|
40944598|NCT00000612|BEHAVIORAL|dietary supplements|
40944599|NCT04794634|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects
40944600|NCT04794634|DIAGNOSTIC_TEST|Optical coherence tomograpohy angiography (OCTA)|to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects
40944601|NCT01291654|DRUG|Paracetamol|po Paracetamol 15 mg/kg every 6 hours x 3 days
40944602|NCT01291654|DRUG|NSAID|IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
40944603|NCT01291654|DRUG|D5W|Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
40944604|NCT02197273|DRUG|Liposomal bupivacaine|
40944605|NCT02197273|DRUG|Standard of care analgesia|
40944606|NCT05484778|PROCEDURE|Dual tasking paradigm|The dual task methodology is a testing model that requires one person to perform two tasks at the same time. The dual task is divided into two as motor-motor or motor-cognitive. Dual tasks provide an opportunity to examine the attention demands of both tasks and allow possible interference to be observed. The idea behind this design is that central processing capacity has a limit and must be distributed among concurrent tasks.
40944607|NCT05388396|OTHER|PIMS-TS diagnostic a treatment|PIMS-TS diagnostic a treatment
41452284|NCT01237444|DRUG|lopinavir /ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype."
40944608|NCT02497300|DRUG|Spironolactone|
40944609|NCT02497300|DRUG|Amiloride|
40944610|NCT02368704|OTHER|No intervention|
41452285|NCT02571686|DEVICE|Surveyor S4|
40944611|NCT04594148|BEHAVIORAL|Weight-shift training|Weight-shift training will consist of a single session of 10x 2.5min of mediolateral weight-shifting in the VR Wasp Game. Including breaks, the session will approximately take 45min.
40944612|NCT06058403|DIETARY_SUPPLEMENT|20g whey protein drink ingestion|Ingestion of a 300 mL drink containing 20g whey protein
40944613|NCT06058403|DIETARY_SUPPLEMENT|20g native canola protein drink ingestion|Ingestion of a 300 mL drink containing 20g native canola protein
40944614|NCT06058403|DIETARY_SUPPLEMENT|20g processed canola protein #1 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #1
40944615|NCT06058403|DIETARY_SUPPLEMENT|20g processed canola protein #2 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #2
40944616|NCT01180634|DRUG|Aeroquin|Inhalation Solution
40944617|NCT01180634|DRUG|Placebo|Inhalation Solution
40944618|NCT06185127|DRUG|Dexmedetomidine|Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).
40944619|NCT06185127|DRUG|Ketamine|A bolus dose of 50 mg ketamine dissolved in 10 ml saline was given 15 minutes after Dexmedetomidine initiation.
40944620|NCT06185127|DRUG|Midazolam|Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam were administered.
40757356|NCT01284738|OTHER|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.~In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units."
40944621|NCT06185127|DRUG|Fentanyl|Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 150 μg of fentanyl were administered.
40757357|NCT01284738|OTHER|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat."
40757358|NCT03239054|BEHAVIORAL|Physical activity|pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy
40757359|NCT03239054|BEHAVIORAL|Control group|Information will be given as part of standard care
40757360|NCT04401631|DEVICE|Blood Collection|"Between-Run Reproducibility K3-EDTA venous whole blood 3 mL 1 venous draw~Operator-to-operator imprecision (abioSCOPE) K3-EDTA capillary whole blood 0.05 mL/draw; 0.15 mL total 3 finger sticks (3 different fingers)~Sample type comparison (abioSCOPE) K3-EDTA capillary whole blood, venous serum, venous K3-EDTA plasma 0.35 mL (finger stick), 9 mL of whole blood to get a minimum of 3 mL of serum and 9 mL of whole blood K3-EDTA to get a minimum of 3 mL of plasma 1 finger stick; 1 venous draw into serum tube (9 mL) and 1 venous draw into K3-EDTA plasma tube (9 mL), in total 18 mL~Method comparison (abioSCOPE and ImmunoCAP/Phadia) K3-EDTA capillary whole blood, venous K3-EDTA plasma 0.05 mL (finger stick), 9 mL of whole blood to get a minimum of 3 ml of plasma 1 finger stick; 1 venous draw into K3-EDTA plasma tube (9 mL tube)"
41132662|NCT03684993|DRUG|Arabic, Gum|natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
41132663|NCT03684993|DRUG|Licorice Root|natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
40757361|NCT04491110|OTHER|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be done by using mobile telephones.
40757362|NCT04491110|OTHER|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through mobile phones.
40757363|NCT05844319|OTHER|tele-education|The treatment of the patients will be carried out by tele-education method.
40757364|NCT00283985|DRUG|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
40757365|NCT00283985|DRUG|Methotrexate|3 gr/m2 at J1
40944622|NCT05942859|DIAGNOSTIC_TEST|Artificial Intelligence and Machine Learning technology|Artificial Intelligence describes computer software designed to mimic human cognitive function. Machine learning is a type of artificial intelligence in which the model created is exposed to data, identifies patterns, and recognises relationships between features seen in the data and the 'ground truth'. This technology will be applied to participants ECGs.
40944623|NCT03347188|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
40757366|NCT00283985|DRUG|Dexamethasone|40 mg/ per os at J1, J2 and J4.
40757367|NCT00283985|DRUG|Erwinase|"In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles"
40944624|NCT03347188|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
40944625|NCT04251273|OTHER|This is Quitting|Text message-based intervention for quit vaping support.
40944626|NCT04251273|OTHER|Assessment only Control|Assessment only
41452286|NCT05411276|DRUG|Pyrotinib maleate|Pyrotinib maleate tablets 400 mg/day, oral within 30 minutes after breakfast, every 4 weeks is a cycle
40944627|NCT02024282|DEVICE|Use of C-reactive protein (CRP) point of care test|
40944628|NCT02024282|OTHER|Brief intervention and parent leaflet|"Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely Are you concerned?, What exactly concerns you? and Why does this concern you?. This intervention is easy to implement in daily practice and no additional training is required.~We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced."
40944629|NCT02024282|DEVICE|Finger Pulse Oximeter|All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
40944630|NCT05597670|OTHER|traditional knee rehabilitation program|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
40944631|NCT05597670|OTHER|proximal stabilization|the principles of proximal stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
40944632|NCT03352310|BIOLOGICAL|autologous umbilical cord blood (UCB)|autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth
40944633|NCT03352310|PROCEDURE|standard care|standard care procedure to the newborn infants presence of HIE and/or anemia
40944634|NCT04870281|DEVICE|CRT-DX|Evaluation of overall health, including heart failure and atrial fibrillation improvement, changes in physical fitness, and general quality of life.
40944635|NCT04964843|DRUG|N-acetylcysteine|N-acetylcysteine is an FDA approved medication that is used to treat acetaminophen overdose.
40944636|NCT04964843|DRUG|Placebo|Placebo
40944637|NCT00268866|BEHAVIORAL|Education|
40944638|NCT02103049|DRUG|Ezetimibe|Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
41285781|NCT05813821|BEHAVIORAL|Antimicrobial stewardship in surgery|"Hospitals were invited to form a surgical antibiotic stewardship program (ASP) with surgeons, pharmacists and infectious disease specialists. The interventional ASP relied on an audit and feedback strategy to issue recommendations aimed at reducing the duration of antibiotic treatment and the use of drugs with a particular impact on microbial ecology.~All patients hospitalized in surgical departments were prospectively analyzed weekly. A computerized alert allowed the ASP team to identify patients with antibiotic treatment \>7 days. The team meet to discuss the appropriateness of each antibiotic treatment, issuing a written recommendation for each patient. The intervention was performed only once for each patient, except if they had a new focus of infection. The recommendations available for prolonged treatments were: withdraw, maintain, de-escalate, broaden, change route, optimize dose, no recommendation. Adherence to the recommendations was recorded 48 hours later by the ASP team."
41285782|NCT03364998|DRUG|Damoctocog (Jivi, BAY94-9027)|60 international units (IU)/kg, given as a 10 minute injection, 1 dose
41285783|NCT03364998|DRUG|Elocta|60 IU/kg, given as a 10 minute injection, 1 dose
41132664|NCT03684993|DRUG|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
41132665|NCT00002095|DRUG|Ganciclovir|
40944639|NCT04430829|DIAGNOSTIC_TEST|Weight-Bearing CT arthrography|A 20ml mixture of 5ml 0.5% ropivacaine, 5ml preservative-free sterile saline, and 10ml of non-ionic iodinated contrast media (e.g. iohexol 240) will be instilled into the knee joint of each patient prior to WBCTa imaging of the knee (LineUp, CurveBeam, LLC).
40944640|NCT04430829|DIAGNOSTIC_TEST|Knee MRI|MRI will be acquired (in-plane 0.25mm x 0.25mm, and 1.00mm slab thickness/separation and In-plane 0.25mm x 0.25mm, and 2.00mm slab thickness/separation)
40944641|NCT01013298|DEVICE|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
40944642|NCT05842876|DEVICE|Continuous Renal NIRS Monitoring|Renal oxygenation data collected every 6 seconds
40944643|NCT05842876|DIAGNOSTIC_TEST|Standard Clinical Care|q6 h BP, q6 h Pulse ox, Echo at 24-72h
40944644|NCT05842876|DIAGNOSTIC_TEST|Standard Clinical Care|Renal oxygenation data collected every 6 seconds, q6 h BP, continuous Pulse ox, Echo at 12-72h
40944645|NCT05842876|OTHER|Satisfaction Survey|Survey to assess which method of monitoring is preferred
40944646|NCT02414451|DRUG|Propranolol|Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning \& night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, \& 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning \& 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules
40944647|NCT02414451|DRUG|Placebo|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning \& night Weeks 3 - 8: 3 capsules, morning, afternoon, \& night Week 9: 2 capsules, morning \& night Week 10: 1 capsule, nightly Week 11: no capsules"
40944648|NCT02808793|DRUG|AK002|
40944649|NCT02597868|DRUG|Capecitabine|Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
40944650|NCT02597868|PROCEDURE|endocrine therapy|endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
40944651|NCT04375969|OTHER|whole body cryostimulation treatment|The WBC is apporved by National Ministry of Health. It uses cryochamber with low temperature -110 oC. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
40944652|NCT04375969|OTHER|Connection WBC treatment and HIIT training|WBC combination with Exercise HIIT according to Litlle protocol from 2011. This exercise protocol will be applied together with cryo-sessions
40944653|NCT04375969|OTHER|Control Group|This group willnot to change their daily habits . The measurements will be taken at baseline and at the end of the study
40944654|NCT04375969|OTHER|HIIT training group|This group will do the training program without cold exposure
40944655|NCT05794971|DRUG|Regorafenib and DIBIRI|"Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)~Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.~Procedure: TACE Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to decrease the tumor's blood supply.~Device: drug eluting-bead The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer."
40944656|NCT05794971|DRUG|Regorafenib|Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)
41452287|NCT04479527|DRUG|Camrelizumab|Camrelizumab for injection is used to treat patients with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy. Approved by the Drug Administration (NMPA) on March 4, 2020, for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib therapy and/or oxaliplatin-containing chemotherapy.Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR to play an anti-angiogenic effect. It has been approved by the China Food and Drug Administration (CFDA) in November 2014. It is used as a monotherapy for advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma that has progressed or relapsed after receiving two kinds of systemic chemotherapy. Apatinib Mesylas can effectively inhibit VEGFR2 at very low concentrations, and higher concentrations can also inhibit PDGFR, c-Kit and c-Src and other kinases.
40944657|NCT05568407|DRUG|Avelumab|As used in real world practice
40944658|NCT04733144|DRUG|Prednisolone|7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
40944659|NCT04733144|DRUG|Dexamethasone|1,125 mg dexamethasone 4,5 mg dexamethasone
40944660|NCT04447417|DRUG|Dupilumab SAR231893|Pharmaceutical form:solution for injection Route of administration: subcutaneous
40944661|NCT00356733|DRUG|Erythropoietin administration|50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
40944662|NCT02857179|PROCEDURE|bariatric surgery|gastric bypass Or gastric banding Or Biliopancreatic diversion with duodenal switch Or sleeve gastrectomy Or endoscopic procedure (Endobarrier,...)
40944663|NCT01986140|DEVICE|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
40944664|NCT01986140|OTHER|Control No treatment|No treatment to prevent hair loss
40944665|NCT01008397|DRUG|AHIST NDC#58407-012-01|Oral tablet containing chlorpheniramine tannate 12mg.
40944666|NCT05665023|DRUG|Bevacizumab + modified FOLFIRINOX|Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
40944667|NCT00960739|DRUG|Topotecan hydrochloride|The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)
40944668|NCT00960739|PROCEDURE|Autologous hematopoietic stem cell transplantation|Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG
40944669|NCT00960739|RADIATION|iobenguane I 131|444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity
40944670|NCT00960739|RADIATION|total-body irradiation|the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)
40944671|NCT00309738|DRUG|pitavastatin|
40944672|NCT00309738|DRUG|simvastatin|
40944673|NCT01649388|BIOLOGICAL|FCR001|Enriched hematopoietic stem cell infusion
40944674|NCT00750386|DRUG|Paclitaxel|175 mg/m2, I.V, every 2 weeks
40944675|NCT00750386|DRUG|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
40944676|NCT02563977|DEVICE|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
40944677|NCT04504773|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants will receive a single session of virtual reality exposure therapy that targets the participant's specific phobia stimuli.
40944678|NCT05064735|DRUG|semaglutide 2.4 mg|semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
40944679|NCT05064735|DRUG|semaglutide 2.4 mg (placebo)|semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
40944680|NCT04449510|OTHER|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
40944681|NCT02647840|BEHAVIORAL|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
41132666|NCT05537012|DIAGNOSTIC_TEST|clinical and radiological staging, pathological types, grading and lymphovascular space invasion|70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion.
41132667|NCT01989793|DRUG|Losartan|Losartan will be given in increasing doses to those in the losartan arm.
40944682|NCT03182062|PROCEDURE|Alveolar recruitment maneuver|To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
40944683|NCT03182062|PROCEDURE|PEEP Titration Trial|The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
40944684|NCT03182062|PROCEDURE|Lung protective ventilation|Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
40944685|NCT03436836|DRUG|Nalbuphine|"Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe.~If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study.~After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery"
40944686|NCT03436836|DRUG|lidocaine, bupivacaine, hyaluronidase , saline|lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).
40944687|NCT03436836|DRUG|lidocaine, bupivacaine , hyaluronidase|2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)
40944688|NCT04903665|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
40944689|NCT00857883|DRUG|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
40944690|NCT05784597|DRUG|[68Ga]Ga-OncoFAP administration|All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
40944691|NCT01225770|DIETARY_SUPPLEMENT|green tea|Gargling three times daily for 90 days
40944692|NCT03496571|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
40944693|NCT03496571|OTHER|Placebo|Placebo
40944694|NCT05695300|DIETARY_SUPPLEMENT|BLM ORGANIC GOLD+|Participants in this arm need to be fed the assigned infant formula daily for three months, no other formula or breast milk
40944695|NCT05695300|DIETARY_SUPPLEMENT|BLM ORGANIC|Participants in this arm need to be fed the assigned infant formula daily for three months,no other formula or breast milk
40944696|NCT05695300|DIETARY_SUPPLEMENT|Breast milk|Participants in this arm need to be fed with breast milk daily for three months, no infant formula
40944697|NCT03975062|DRUG|dabigatran etexilate|150 mg twice daily (BID)
40944698|NCT03271229|BIOLOGICAL|Concentrated Bone Marrow Aspirate (BMAC)|Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
40944699|NCT03271229|BIOLOGICAL|Platelet-Rich Plasma (PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
40944700|NCT01455831|DRUG|Tinzaparin|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
40757368|NCT01150370|DEVICE|The PrePex a novel device for adult male circumcision|The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
40944701|NCT01455831|DRUG|Tinzaparin|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
40944702|NCT01090973|DRUG|LBH589|"The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses."
41132668|NCT01989793|DRUG|Placebo|Placebo will be given to those in placebo arm
41132669|NCT02142725|DRUG|LT-02|four times per day
41132670|NCT02142725|DRUG|LT-02|two times per day
41132671|NCT02142725|DRUG|Placebo|four times per day
41285784|NCT01686503|DRUG|IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose|Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
41452288|NCT04463108|OTHER|No Intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
40944703|NCT05536479|PROCEDURE|Autogenous stored mineralized dentin graft (ASMDG)|"Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.~The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction"
41285785|NCT06016543|PROCEDURE|osteopathic manipulative treatment (OMT)|Osteopathic manipulative treatment provided at the discretion of the treating physician and based on the patient's response to previous treatments.
40757369|NCT06054061|BEHAVIORAL|Experimental: experimental wellbeing promotion group (Think and Cope Positively)|"Session 1: Welcome. 2: Identifying and amplifying positive emotions. 3: Experiencing positive emotions. 4: Identifying my negative trap thoughts. 5: Transforming my automatic thoughts into positive ones. Session 6: Experiencing my positive thoughts I. 7: Experiencing my positive thoughts II. 8: Learning to be kinder to myself. 9: Identifying a life project (Individual appointment).10: Identifying coping strategies I. 11: Identifying coping strategies II. 12: Identifying adaptive coping strategies linked to well-being. 13: Building my life purpose with my environment. 14: Helping me to build my life purpose? 15: Multi-family session, farewell and closing."
40944704|NCT05536479|PROCEDURE|Autogenous fresh mineralized dentin graft (AFMDG)|Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.
40944705|NCT06270329|OTHER|Neuromuscular training program|"Hotpack application TENS (transcutaneous electrical stimulation) Warm-up phase: bicycle ergometer (ten minutes)~Exercise phase:~core stabilization and postural control exercises postural orientation exercises lower extremity strengthening exercises functional exercises (balance and proprioception exercises using a balance board) Cool-down Phase"
40944706|NCT06270329|OTHER|conventional physical therapy program|Hotpack application TENS (transcutaneous electrical stimulation) Conventional physical therapy exercises (straight leg raises, knee flexor and extensor strengthening, hip muscle strengthening)
40944707|NCT02367131|DRUG|JARDIANCE®|JARDIANCE®
40944708|NCT00386607|DRUG|Aliskiren|Aliskiren 300 mg
40944709|NCT00386607|DRUG|Valsartan|Valsartan 320 mg
40944710|NCT00386607|DRUG|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
40944711|NCT04920422|OTHER|No intervention|Retrospective analysis using database without any intervention assigned in the study.
41285786|NCT00565630|DEVICE|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
41285787|NCT00811629|OTHER|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
41285788|NCT00651040|DRUG|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
41285789|NCT00651040|DRUG|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
41285790|NCT00221676|BIOLOGICAL|Alfarix|
41285791|NCT06408792|DEVICE|Deepithelized graft and protection technique|To obtain the graft in all cases, on the day of surgery, 4% articaine with epinephrine 1:100,000 will be administered to block the greater palatine nerve. Gingival grafts from all groups will be deepithelialized intraorally using a sterile 834 turbine diamond bur. This drill will go deeper into the palatal mucosa 0.5mm (half of the outermost active part of the drill). The gingival grafts will be obtained with the surgical technique described by Zucchelli et al. 2010.
41285792|NCT03304951|DEVICE|Sinopsys® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid access.
41285793|NCT00308815|DEVICE|Automatic CPR machine|
41285794|NCT00003018|DRUG|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
40944712|NCT05216003|BEHAVIORAL|PATH4YOU|PATH4YOU offers patient-center, comprehensive, contraceptive counseling; pregnancy planning; and same to next day access to birth control. This clinical care program will reduce obstacles to contraception in Indiana and enables access to healthy pregnancy planning conversations.
40944713|NCT01483768|PROCEDURE|Sleeve gastrectomy for morbid obesity|Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
40944714|NCT06382831|DRUG|Dexmedetomidine|Opioid free anesthesia
40944715|NCT06382831|DRUG|Fentanyl|Control given Opioid balanced anesthesia
40944716|NCT05285644|DRUG|AR 15512 Ophthalmic Solution|Topical ocular administration of one drop in both eyes BID for 90 days.
40944717|NCT05285644|DRUG|Vehicle|Topical ocular administration of one drop in both eyes BID for 90 days.
40944718|NCT05205954|BEHAVIORAL|Hepatology Home Hospital|The Hepatology Home Hospital intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with hepatology clinicians regarding care delivered at home to ensure continuity of care.
40944719|NCT00937391|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
40944720|NCT06070311|COMBINATION_PRODUCT|Thymoquinone (0.5%) and Olive oil ointment|"Preparation of the Thymoquinone and Olive oil ointment:~Thymoquinone Oleaginous base ointment containing olive oil will be prepared for intranasal administration. The ointment will be prepared using the fusion method as follows:~Anhydrous lanolin and white soft paraffin will be melted at 70°C and then olive oil will be added with continuous stirring, Thymoquinone will be added to the congealing mixture as it is being cooled and stirred finally, the congealing mixture is left to cool at room temperature tell solidification and sterilized using UV radiation. The final product will be characterized for spreadability, drug content, drug release and stability."
40944721|NCT02164773|DRUG|Magnesium Sulfate|use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
40944722|NCT02164773|DRUG|0.9%normal saline|use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
40944723|NCT05440188|DIAGNOSTIC_TEST|Breath Detect Platform|Use of the Breath Detect platform for respiratory health monitoring.
40944724|NCT04064177|DEVICE|NICAS cardiac output monitor|Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
40944725|NCT03588871|OTHER|Dental bleaching with PaintOn Plus VivaStyle|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent)
40944726|NCT03588871|OTHER|Dental Bleaching impact in quality of life with PaintOn Plus Vivastyle|Evaluation of oral quality of life after dental bleaching treatment with PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
40944727|NCT03588871|OTHER|Dental bleaching with Opalescence GO|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence GO 6% HP (Ultradent)
40944728|NCT03588871|OTHER|Dental Bleaching impact in quality of life with Opalescence GO|Evaluation of oral quality of life after dental bleaching treatment with Opalescence GO 6% HP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
40944729|NCT03588871|OTHER|Dental bleaching with Opalescence PF|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence PF 16% CP (Ultradent)
41452289|NCT05088551|OTHER|Patient Education|The education was divided into three parts. The information in the first part of the booklet (general information, preoperative preparation, and operation day) is given in the preoperative period. In the postoperative period, the patients were visited and the information in the second part (postoperative hospital stay, first, second, and third-day goals after surgery) was given. Before the patients were discharged, the information in the third section (things to be considered in the recovery process at home) was presented. According to the physical conditions of the clinic, patient education was carried out in an area suitable for teaching as much as possible.
41452290|NCT05971394|DEVICE|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
40944730|NCT03588871|OTHER|Dental Bleaching impact in quality of life with Opalescence PF|Evaluation of oral quality of life after dental bleaching treatment with Opalescence PF 16% CP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
40944731|NCT02373722|PROCEDURE|Mohs Surgery|Undergo Mohs surgery
40944732|NCT02373722|OTHER|Internet-Based Intervention|Watch website application based educational video
40944733|NCT02373722|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
40944734|NCT02373722|OTHER|Educational Intervention|Watch website application based educational video
40944735|NCT02373722|BEHAVIORAL|Exercise Intervention|Use Fitbit
40944736|NCT02373722|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied to the wound area
40944737|NCT02373722|OTHER|Questionnaire Administration|Ancillary studies
40944738|NCT02373722|OTHER|Survey Administration|Ancillary studies
40944739|NCT03448055|DIETARY_SUPPLEMENT|Immunocal|cysteine-rich whey protein isolate
40944740|NCT05721222|DRUG|PRO1160|Intravenous infusion of PRO1160
40944741|NCT04637490|DEVICE|patellar component|patellar resurfacing
40944742|NCT03337607|DEVICE|rESWT|"rESWT will be performed as follows:~* Four rESWT sessions~* One rESWT session per week~* 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.~* rESWs applied at 15 Hz~* Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.~* No application of local anaesthetics"
40944743|NCT03337607|DRUG|Celecoxib|1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks
40944744|NCT03337607|DRUG|Eperisone|3 x 50 mg per day for four weeks
40944745|NCT04467931|DRUG|ACEI/ARB|Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
40944746|NCT04467931|DRUG|Non-ACEI/ARB|Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.
40944747|NCT04467931|DRUG|ACEI|Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.
40944748|NCT04467931|DRUG|ARB|Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
40944749|NCT00443105|DRUG|Tacrolimus 0.03% ointment (Protopic)|
40944750|NCT00643773|DIETARY_SUPPLEMENT|Leucine|capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day
40944751|NCT00643773|DIETARY_SUPPLEMENT|Wheat flour|Wheat flour
40944752|NCT04727931|BEHAVIORAL|Neuropsychological assessement and questionnaires|Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
40944753|NCT05816031|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet administrated to obese patients planned for right laparoscopic adrenalectomy
41452291|NCT06338891|OTHER|Main questionnaire|Main questionnaire will evaluate the demographic and genetic characteristics, clinical manifestations, and self-perception of sensitivity to wheat or other food and the possible relationship between the intake of wheat or other foods and the flare-ups of the disease in FMF patients
40757370|NCT06054061|BEHAVIORAL|TAU|The usual treatment in the intervention of people affected by severe mental disorder in the network of public and subsidized centers in Spain consists of improving psychosocial functioning. To this end, and depending on the characteristics of the user, work is done in groups and individually on social skills, psychoeducation about the disease, adherence to pharmacological treatment, improvement of daily living activities, promotion of independent leisure, support to families in the process of relapse prevention, and training for labor market insertion.
40757371|NCT05257213|DRUG|Heparin solution|3 ml saline solution containing 5000 IU heparin.
40757372|NCT05257213|DRUG|Anti-adhesion barrier gel|2 ml biodegradable barrier gel containing sodium hyaluronate (10 mg/ml), sodium chloride (8.5 mg/ml), disodium hydrogen phosphate (0.34mg/ml), sodium dihydrogen phosphate (0.14 mg/ml) and water for injection (QS to weight).
40944754|NCT04008823|OTHER|Retrospective and observational epidemiological study, by review of clinical histories,|Retrospective and observational epidemiological study, by review of clinical histories,
40944755|NCT02629484|OTHER|Focused cardiac ultrasound|focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
40944756|NCT02101203|DRUG|Placebo|
40944757|NCT02101203|DRUG|0.5 mgTestosterone + 10 mg Buspirone|"A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days)."
40944758|NCT06556719|BEHAVIORAL|Hoosier Sport Re-Social|Hoosier Sport Re-Social is a 6-week school-based intervention designed to reduce cardiovascular disease risk in rural children. It includes twice-weekly physical activity sessions during PE classes and weekly social media literacy training in health classes, promoting healthier physical and digital behaviors.
40757373|NCT03039985|DEVICE|Zirconia crowns (Prettau®)|Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism
41132672|NCT00747006|DRUG|TI Inhalation Powder and Humalog (Amendment 1)|Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
41132673|NCT00747006|DRUG|TI Inhalation Powder (original protocol)|Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
41132674|NCT00317395|DRUG|Otamixaban (XRP0673)|intravenous administration
41285795|NCT00003018|DRUG|fluorouracil|200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle
41285796|NCT00003018|DRUG|leucovorin calcium|30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle
41285797|NCT00003018|DRUG|mitomycin C|10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
41132675|NCT00317395|DRUG|unfractionated heparin|intravenous administration
40757374|NCT03039985|DEVICE|lithium disilicate crowns (IPSe.max®)|lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
41132676|NCT00317395|DRUG|eptifibatide|intravenous administration
41132677|NCT06212661|DRUG|Ubrogepant|Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
41285798|NCT02728934|BIOLOGICAL|Golimumab Intravenous (IV)|This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.
41285799|NCT02728934|BIOLOGICAL|Infliximab|This is an observational study. Patients who will receive infliximab will be observed for 3 years.
41132678|NCT06212661|DRUG|Rimegepant|Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
41132679|NCT06212661|DRUG|Atogepant|Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
41285800|NCT02728934|BIOLOGICAL|Biosimilar Infliximab|This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
41285801|NCT02343328|BIOLOGICAL|Fecal Microbiota Transplant|
41132680|NCT06212661|DRUG|Eptinezumab|Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
41132681|NCT06212661|DRUG|Fremanezumab|Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
41132682|NCT06212661|DRUG|Galcanezumab|Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
41132683|NCT06212661|DRUG|Erenumab|Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
41132684|NCT06212661|DRUG|Botulinum toxin A|Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
41132685|NCT01812759|DRUG|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
41285802|NCT02343328|BIOLOGICAL|Placebo|
40944759|NCT05955053|OTHER|Midwifery care applied in line with Midwife-Pregnant cooperation|Pregnant women who apply to the obstetrics clinic will be informed about the research by the doctor and the pregnant woman whose labor has started will be sent to the delivery room. The researcher will be welcomed by the midwife from the first time the pregnant woman arrives in labor (delivery room), and firstly she will be informed about the purpose of the research and an informative consent form and a pregnant identification form will be filled in that she agrees to participate in the research. During labor and labor, the research midwife (HYY) will be with a pregnant woman until she gives birth and care will be given according to the items in the midwifery care checklist prepared based on the partnership model. After giving birth to a pregnant woman and applying the scales, another pregnant woman will be transferred and care will be given in the same way according to the midwifery care model checklist.
40944760|NCT00538564|DRUG|tadalafil|10mg oral tablets taken 3 times a week for 2 months
40944761|NCT00538564|DRUG|placebo|Placebo tablets taken orally 3 times a week for 2 months
40944762|NCT03153956|DEVICE|Calibrated AposTherapy®|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
40944763|NCT03153956|DEVICE|Non-Calibrated Sham Apos Therapy Device|The comparator group will receive a non-calibrated sham device.
40944764|NCT05099393|DIETARY_SUPPLEMENT|Non Nutritive Sweeteners|"The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo.~The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period."
40944765|NCT01822496|RADIATION|Radiation Therapy|30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
40944766|NCT01822496|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22."
40944767|NCT01822496|DRUG|Cisplatin|50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
40944768|NCT01822496|DRUG|Crizotinib|250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
40944769|NCT01822496|DRUG|Erlotinib|150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
40944770|NCT01822496|DRUG|Etoposide|50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
40944771|NCT01822496|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
40944772|NCT01407744|OTHER|laboratory biomarker analysis|Correlative studies
40944773|NCT00659360|DRUG|saracatinib|Given orally
40944774|NCT04542044|OTHER|management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia|Data collected with a cohorte of SARS-CoV-2 pneumonia in an outpatient basis
41285803|NCT03654547|DRUG|TT-00420|"TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg."
41285804|NCT05052203|OTHER|Exposure of interest: study DNA methylation (epigenetics) and gene expression (transcriptomics) of blood leukocytes|The primary objective is to study DNA methylation (epigenetics) and gene expression (transcriptomics) of blood leukocytes between sepsis survivors at ED admission and three months after hospital discharge
41285805|NCT03381040|DEVICE|Restylane Lyft|Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.
40944775|NCT04804540|DRUG|Vedolizumab IV|Vedolizumab IV infusion
40944776|NCT03564028|OTHER|energy conservation technique|During the session of stair climbing, patients will perform a break at least of 5 seconds every 3 steps.
40944777|NCT03564028|OTHER|control session|Patients will realize one session of stair climbing at their own pace
40944778|NCT01710046|DRUG|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
40944779|NCT01710046|DRUG|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
40944780|NCT01710046|DRUG|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
40944781|NCT01710046|DRUG|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
40944782|NCT06516484|DRUG|Romiplostim|Enrolled patients were given roprostin (20 µg/kg subcutaneously once weekly) for at least 3 months, with discontinuation of roprostin for platelet counts ≥50 x 10\^9/L and continuation of roprostin for platelet counts \<50 x 10\^9/L. Responders were continued to 6 months. Responders continue to use the drug until 6 months.
40944783|NCT06556693|DEVICE|Dual Channel Stimulation|implant of dual channel stimulation device
40944784|NCT02450188|DRUG|Vardenafil|"In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
41132686|NCT01812759|DRUG|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
41285806|NCT03381040|DEVICE|Restylane Volyme|"Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.~Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope."
41285807|NCT05527925|DEVICE|MRI|Brain testing of patients using MRI
41285808|NCT04076566|DEVICE|alfapump system|active implantable device for treatment of malignant ascites
41285809|NCT03050684|PROCEDURE|vaginal lavage group|vaginal washing will be applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
41285810|NCT03050684|PROCEDURE|Control Group|vaginal washing will be not applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
41452292|NCT06338891|OTHER|Secondary questionnaire|Secondary questionnaire will investigate the possible appearance of gastrointestinal and extraintestinal symptoms linked to the ingestion of gluten/wheat, which are not identifiable, by the patient, as FMF flare-ups, but might be compatible with a NCGS/NCWS diagnosis
41452293|NCT02167594|DRUG|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
40944785|NCT02450188|BEHAVIORAL|CBST|"The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
40944786|NCT04234451|PROCEDURE|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations . The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4)."
41132687|NCT01812759|OTHER|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
41132688|NCT05962749|OTHER|Assessment|3 meter backward walk test (3MBWT), 10 meter walk test (10MWT), Selective Control Assessment of the Lower Extremities (SCALE), Trunk Control Measurement Scale (TCMS), Pediatric Balance Scale (PBS), Functional Independence Measure for Children (WeeFIM), Modified Ashworth Scale (MAS)
41132689|NCT01092416|DEVICE|Diamondback 360 Orbital Atherectomy System|Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
41285811|NCT04265989|DEVICE|Single BMS|Single bare metal stent covered the coronary artery aneurysm
41285812|NCT04265989|DEVICE|Single or Double BMS|Single or double layer bare metal stents covered the coronary artery aneurysm
41285813|NCT04265989|DEVICE|Single or Double BMS|Treated with single or double layer bare metal stents
41452294|NCT02167594|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post-injection
41452295|NCT00408616|BIOLOGICAL|Grazax-R|Grass tablet, 75.000 SQ per day for one year
40944787|NCT04234451|PROCEDURE|sham acupuncture|For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle. The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4).
40944788|NCT05782231|BEHAVIORAL|GetActive+|This is a 10-week group mind body program focused on improving self- report, performance based and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increased in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
40944789|NCT04533685|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination that include a direct scheduling link, enabling the patient to directly schedule a flu vaccination only visit
40944790|NCT04533685|BEHAVIORAL|Portal Reminders for Influenza Vaccination: No direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination (no direct scheduling link included)
40944791|NCT04533685|BEHAVIORAL|Pre-Commitment Prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
40944792|NCT04533685|BEHAVIORAL|Pre-Appointment flu vaccine reminders|Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine
40944793|NCT02504996|DRUG|Paracetamol|1 g paracetamol via intravenous route in 100 ml normal saline
40944794|NCT02504996|DRUG|morphine|0.1 mg/kg morphine via intravenous route in 100 ml normal saline
40944795|NCT02504996|DRUG|Placebo|Intravenous 100 ml normal saline
40944796|NCT02380001|DRUG|Dexketoprofen trometamol|White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
40944797|NCT02380001|DRUG|Preoperative control|white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
40944798|NCT03242538|BEHAVIORAL|Pelvic Exercise|Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
40944799|NCT04794088|DRUG|Imatinib Mesylate intravenous solution|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 200mg imatinib (100mg/h).
40944800|NCT04794088|DRUG|Placebo|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).
40944801|NCT04045795|DRUG|isatuximab SAR650984 IV|"Pharmaceutical form: solution~Route of administration: intravenous"
41285814|NCT04265989|DEVICE|BMS+DES|Treated with bare metal stent combined with drug eluting stent
41285815|NCT05840705|PROCEDURE|Small curved incision with apex lateral|Small curved incision with apex lateral
41285816|NCT03963544|DRUG|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR
40944802|NCT04045795|DRUG|pomalidomide|"Pharmaceutical form: tablet~Route of administration: oral"
40944803|NCT04045795|DRUG|dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
40944804|NCT04045795|DRUG|isatuximab SAR650984 SC|"Pharmaceutical form: solution~Route of administration: subcutaneous"
40944805|NCT04045795|DEVICE|Investigational injector device|Subcutaneous administration
41132690|NCT04701372|BEHAVIORAL|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by licensed therapists remotely via video. The treatment was augmented by between-session text messaging and online community support.
41132691|NCT05054270|OTHER|Chest examination with Ultrasound device|Chest examination with Ultrasound device
41132692|NCT05964023|DEVICE|pBFS rTMS|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
41132693|NCT05964023|DEVICE|5-cm rTMS|"Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be localized by 5-cm rule."
41132694|NCT05864196|RADIATION|Two-Fraction Stereotactic Body Radiation Therapy (SBRT)|Two-fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer.
40944808|NCT05936125|OTHER|Annuloplasty Using Flexible Band|Tricuspid valve annuloplasty using a flexible band; (Polyethylene terephthalate band): (Dacron band)
40944809|NCT01877018|BEHAVIORAL|electronic reminder|Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
40944810|NCT01262209|DEVICE|portable CCTV|This is a small handheld mini screen intended to improve reading.
40944811|NCT01262209|DEVICE|Telescopes, telemicroscopes and microscopes|These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
40757375|NCT05835596|DEVICE|Access to MumCare app|Education, push warning to book cardiovascular health follow-up at own general practitioner , registration of BP and lipids, HbAc
40944812|NCT01262209|DEVICE|Absorptive filters|These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
40944813|NCT01768767|DRUG|Placebo|
40944814|NCT01768767|DRUG|Ketamine|
40944815|NCT01768767|DRUG|Ketamine/Lithium|
40944816|NCT03497078|OTHER|Bone scintigraphy|Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.
40944817|NCT00277797|DEVICE|Biowave Targeted Non-Invasive Electronic Pain Control Device|"This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (Feed Signals) between two electrodes."
40944818|NCT00277797|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
40944819|NCT00945997|DRUG|misoprostol|mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
40944820|NCT00945997|DRUG|misoprostol|mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
40944821|NCT00452855|PROCEDURE|Sevoflurane-remifentanil anaesthesia|
40944822|NCT01209728|OTHER|Placebo/ethanol (blinded)|Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
40944823|NCT03906136|BIOLOGICAL|Secukinumab/Adalimumab-Biosimilar|Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab-Biosimilar, s.c.
40944824|NCT03906136|OTHER|Standard-of-care|Patients will receive treatment according to local practice standards by their treating physician following the current treatment recommendations.
40944825|NCT03432312|DRUG|Nicotine lozenge|Nicotine mint lozenge, 4 mg
40944826|NCT03432312|DRUG|Nicotine lozenge|NiQuitin mint lozenge, 4 mg
40944827|NCT00880373|DRUG|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
40944828|NCT00880373|DRUG|Placebo|Matching placebo three times daily for 4 days
40944829|NCT00880373|DRUG|Diamorphine or Morphine|Diamorphine or Morphine by PCA
40944830|NCT00060515|DRUG|RG2133 (2',3',5'-tri-O-acetyluridine)|
40944831|NCT05401240|BEHAVIORAL|information reveal|the experimental group will be informed that there will be an important examination about his/her cardiopulmonary fitness condition at the outpatient department (OPD)
40944832|NCT02850354|OTHER|anti-g maneuvers|investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
41132695|NCT06239519|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
41132696|NCT02597699|DRUG|Remifentanil + Lidocaïne|
41452296|NCT00408616|BIOLOGICAL|Grazax Placebo|Grazax Placebo, 0 SQ tablet per day for one year
40757376|NCT03635879|OTHER|MCTprocal medical food|32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
40757377|NCT03635879|OTHER|Milk/tricaprilin oil blend|154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
40757378|NCT03635879|OTHER|AC-1207|AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
41132697|NCT02597699|DRUG|Sufentanil + Lidocaïne|
41132698|NCT05120674|BEHAVIORAL|NAP|During the ERRT session, the tone will be played softly so as not to interfere with the session and will be played throughout the entire session. Before sleep, the veteran will play the 40-60hz tone via their smartphone while they read their rescripted nightmare. During sleep, the 40-60hz tone will be delivered during slow-wave-sleep (SWS) by the DREEM device. The pairing of the tone with the intervention is expected to trigger benefits of the exercise in reducing nightmare disturbance during sleep.
41132699|NCT05120674|BEHAVIORAL|CPT|Cognitive Therapy for PTSD
41132700|NCT05120674|BEHAVIORAL|ERRT|ERRT asks individuals to rewrite the traumatic event that triggered their nightmares and then review the rescription before bed. This technique has been proven to drastically reduce the frequency of chronic nightmares.
41132701|NCT05120674|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia that includes behavioral and cognitive interventions related to sleep hygiene, increasing sleep drive, and modifying behaviors that result in association between laying in bed and wakeful states.
41132702|NCT01862159|PROCEDURE|laparoscopic gastric bypass surgery|laparoscopic gastric bypass surgery
41452297|NCT03694197|DRUG|Praluent|Subcutaneous (SC) administration
41452298|NCT00028925|BIOLOGICAL|filgrastim|
41452299|NCT00028925|DRUG|carboplatin|
41452300|NCT00028925|DRUG|topotecan hydrochloride|
41452301|NCT00028925|RADIATION|WBRT|
41285817|NCT03175523|DEVICE|quantitative coronary angiography guided Bioresorbable scaffold implantation|In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.
41285818|NCT03175523|DEVICE|imaging guided Bioresorbable scaffold implantation|In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
40944833|NCT03732690|OTHER|Diet HP|"2000kcal for men 1800 kcal for women. Food boxes (HP pre-cooked meals and meat/chicken/fish portions, HP breads and snacks) will be provided to the participants throughout the study reaching 40-50% of their prescribed daily energy intake for 6 days per week. In total 932 kcal are provided through this food boxes (54g of carbohydrate, 101g of protein, 34,6g of fat). The rest of the daily food intake will be guided by a dietician with a list of recommended high protein foods.~Subjects are required to keep food diaries three days a week and will also have weekly contact with a dietician."
40944834|NCT03732690|OTHER|Diet LP|2000kcal for men 1800 kcal for women. Food boxes (LP pre-cooked meals, LP breads and snacks) will be provided to the participants throughout the study
40944835|NCT04664959|DRUG|SB16 (Proposed Denosumab Biosimilar)|"Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously."
40944836|NCT04664959|DRUG|Prolia® (Denosumab)|Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
40944837|NCT01994928|DEVICE|Nose-mouth mask|Preoxygenation using a nose-mouth mask.
40944838|NCT01994928|DEVICE|High flow nasal cannula oxygen|Preoxygenation using high flow nasal cannula oxygen.
40944839|NCT01994928|PROCEDURE|Intubation|Intubation
40944840|NCT01527175|OTHER|Approach for ultrasound-guided subclavian venous catheterization|Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
40944841|NCT01327456|BEHAVIORAL|Self-Management Intervention|patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
40944842|NCT00464269|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg, 10 mg and 25 mg~* Route of Administration: Oral use"
40944843|NCT00464269|DRUG|Brivaracetam 2.5 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"
40944844|NCT00464269|DRUG|Brivaracetam 10 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg~* Route of Administration: Oral use"
40944845|NCT00464269|DRUG|Brivaracetam 25 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
40944846|NCT03400644|DEVICE|Cervical collar|Cervical neck collar which is routinely made for post-laminoplasty patients
40944847|NCT01331733|DRUG|hMG-HP|
40944848|NCT01331733|DRUG|hMG + GnRH antagonist|
41285819|NCT05056714|OTHER|Questionaries|The patient will answer several questionaries
41285820|NCT01930071|DEVICE|PQ Bypass Guide Wire Delivery System|The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
41452302|NCT01214590|DEVICE|VascuActive device|self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
41452303|NCT03257956|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
41452304|NCT03257956|DEVICE|reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
41452305|NCT00343681|BIOLOGICAL|Inactivated influenza vaccine (split virion)|0.5 mL, Intramuscular
40944849|NCT00050271|DRUG|Acetyl-L-carnitine|
40944850|NCT04648254|DRUG|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
40944851|NCT02708901|DIETARY_SUPPLEMENT|Vivomixx®|Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
40944852|NCT02708901|DIETARY_SUPPLEMENT|Placebo|Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
40944853|NCT00771316|DRUG|MK0826 (ertapenem)|A single dose of 1.0g IV infused over a 30 minute interval at hour 0
40944854|NCT00771316|DRUG|Comparator: meropenem|500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
40944855|NCT03225742|DIAGNOSTIC_TEST|to measure the residual volume after catheterization|after first micturition to measure the residual volume in bladder
41452306|NCT01226953|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
41452307|NCT01934816|OTHER|Intradermal injections of GLP-1 and its analogues|native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
41452308|NCT04866979|DEVICE|Experimental: Continuous TBS (cTBS)|Application of cTBS. cTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), with a stimulation intensity equal to 80% of the motor threshold value at rest.
40944856|NCT01550471|DRUG|Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
40944857|NCT01550471|DRUG|Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
40944858|NCT01550471|DRUG|QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
40944859|NCT01550471|DRUG|QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
40944860|NCT01550471|DRUG|Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
40944861|NCT01550471|DRUG|Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
40944862|NCT04710134|BIOLOGICAL|Reslizumab|Reslizumab 3,4, or 5 mg/kg IV q4 weeks
40944863|NCT05907980|DRUG|ROSE12|ROSE12 as a IV infusion
40944864|NCT05907980|DRUG|Atezolizumab|Atezolizumab as a IV infusion
40944865|NCT03572751|DIAGNOSTIC_TEST|Bed-, wrist- and ECG-sensor monitoring|Bed-, wrist- and ECG-sensor monitoring
40944866|NCT00168701|DRUG|BG00012|
40944867|NCT03191240|DRUG|Vasopressins|Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation
40944868|NCT03191240|DRUG|Normal saline|Placebo
40944869|NCT04945876|BEHAVIORAL|Digital follow-up|"Participants will receive:~One session of individual exercise and diet guidance focusing on goals and motivation.~An activity tracker and instructions on how to use it both for motivation, daily activity tracking, logging of specific exercise and using the wristbands heart rate monitor to control intensity level during exercise.~Monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise.~Opportunity to send sms with questions regarding nutrition and exercise. Participants who are malnourished, or at risk of malnutrition will be offered a total of two hours of additional individualized, digital guidance on nutrition as needed."
40944870|NCT02197793|BEHAVIORAL|Community Mobilization Program|
40944871|NCT02883192|DRUG|Ondansetron|Zofran 4 mg.
40944872|NCT02883192|DRUG|Placebo|Placebo
40944873|NCT04160962|PROCEDURE|lappg|Laparoscopic gastrectomy for pylorus preservation
40944874|NCT03036306|DRUG|SCX-001|Nefopam cream formulation
40944875|NCT03036306|OTHER|Placebo|Cream formulation without Nefopam
40944876|NCT04996381|DIAGNOSTIC_TEST|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
40944877|NCT00005928|DRUG|Ramipril|
40944878|NCT01826721|OTHER|Transplant Medication Information Teaching Tool|Online e-learning tool for post-transplant medication education.
40944879|NCT00660751|DRUG|Duloxetine|SNRIs
40944880|NCT01517685|DIETARY_SUPPLEMENT|Organic flax seed oil|2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
40944881|NCT01517685|DIETARY_SUPPLEMENT|fish oil|5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
40944882|NCT06218368|BEHAVIORAL|Educational toolkit on MMR and polio vaccination|The educational video about vaccines was adapted from a health educational toolkit that aims to promote community confidence in vaccines in the ultra-poor Philippine households. This toolkit contains persuasive messaging on vaccination guidelines, vaccines safety and efficacy, and myths and misconceptions of MMR and polio vaccines. Participants in the intervention arm will receive our educational video about MMR and polio vaccines. Additionally, health educators from ICM will teach the participants to understand their vaccination cards and orally remind them to have their children vaccinated at each week's Transform Program session from week 12 until week 15. After the end of the Transform Program, about 40-50% of the participants in the intervention arm will attend another community-based program run by ICM called the Savings Groups, where the participants will receive weekly reminding messages about MMR and polio vaccination in their group meetings for three months.
40944883|NCT03316339|DRUG|Dexmedetomidine|Opioid-free anesthesia
40944884|NCT03316339|DRUG|Remifentanil|Opioid anesthesia
40944885|NCT05837624|DRUG|Estetrol/Drospirenone|6-month course of oral estetrol/drospirenone (15 mg estetrol monohydrate / 3 mg drospirenone) once daily for the study duration
40757379|NCT03635879|OTHER|AC-1205|AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
40944886|NCT05600738|DEVICE|RNS/DBS activation|This will be performed to study the EEG responses to DBS/RNS stimulation electrical pulses. The stimulation frequencies will be sequentially increased and each stimulation will last for 2 minutes.There will be a 1-2 minute wash out period after each trial.
40944887|NCT05616273|OTHER|Mixed Meal Tolerance Test (MMTT)|At either Visit 1 or Visit 2, participants will be given Ensure HP or Fortisip (a drink containing the same amounts of carbohydrates, protein and fats as there would be in a meal; 6ml/kg to a max of 360mls), and have blood samples collected, to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 30, 60, 90, 120 minutes post meal. This test is used to measure how a participant's beta cells are working to produce insulin after a meal and to check for reactive hypoglycaemia.
40944888|NCT05616273|OTHER|Arginine Stimulation Test (AST)|At either Visit 1 or Visit 2, and Visit 3, participants will be given a dose of Arginine Hydrochloride (5 g Arginine during 1 min) by intravenous injection, and have blood samples collected to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 2, 5, 10, 15 and 30 minutes following the Arginine bolus injection. This test is designed primarily to test the maximum insulin secretion capacity of a participant's beta cells.
40944889|NCT05616273|OTHER|Home Finger Prick Sample|Participants will be provided with a kit to collect an optional home finger prick sample the day after each visit, and return the sample using the prepaid addressed padded envelope provided.
40944890|NCT02607007|OTHER|2% M.F. Milk|
40944891|NCT02607007|OTHER|White Bread|
40944892|NCT02607007|OTHER|Strawberry Jam|
40944893|NCT02607007|OTHER|31% M.F. Cheddar Cheese|
40944894|NCT02607007|OTHER|2% M.F. Plain Greek yogurt|
40944895|NCT02607007|OTHER|Soy Beverage|
40944896|NCT02607007|OTHER|Water|
40944897|NCT02717273|DRUG|standard|peri-operative antibiotic regimen only
40944898|NCT02717273|DRUG|extended|extended three-day course of antibiotics
40944899|NCT02717273|OTHER|liver transplant|orthotopic liver transplantation
40944900|NCT04255030|BEHAVIORAL|Coping Together Booklets and Workbook|Dyads in this group will complete Coping-Together, a 6-week, booklet-based, self-directed coping and self-management skills training intervention. This intervention addresses key psychosocial challenges by offering evidence-based practical skills to: (a) manage symptoms, (b) cope with anxiety, (c) collaborate with the health care team, (d) engage in shared decision-making, (e) communicate with partner and family, and/or (f) obtain the community resources needed. A relaxation CD is also included, in addition to a workbook that accompanies the Coping-Together booklet-based intervention. The workbook aims at helping dyads choose a booklet relevant to their cancer-related challenges faced, find coping skills that best meet these challenges, and make a plan to use one of the coping skills successfully.
40944901|NCT04255030|BEHAVIORAL|Lay telephone coaching|Dyads will receive Coping-Together support via weekly telephone calls from a lay coach. Sessions will range between 10-15 minutes. The goal of coaching will be to provide information on how to use the workbook and booklets. Although no formal therapy will be provided, the coach will maintain a positive and encouraging attitude when interacting with participants regardless of their adherence to the intervention recommendations. The sessions will start with the coach setting a predetermined agenda based on the section of the workbook to review that week that week. Then, coaches will ask about the use of the booklets over the previous week, and ask participants about any required support or clarification in using the booklets. Sessions conclude with setting a goal related to the workbook, booklets and/or coping technique to focus on over the coming week.
40944902|NCT04255030|BEHAVIORAL|Motivational Interviewing|Six, 45-60 minute weekly telephone-based sessions with a trained Motivational Interviewing Specialist to progress toward goals. Here, dyads are given one-on-one guidance from a HCP Motivational Interviewing Specialist to practice the skills they need. Calls will focus on problem-solving principles and core components of self-management (70), including: (a) identifying dyads' concerns, (b) reviewing management efforts, (c) identifying goals, (d) identifying skills needed to achieve goals, and (e) addressing barriers to applying skills to current situations, including level of self-efficacy. At each meeting, progress, subsequent goals, and corresponding plans will be discussed.
40944903|NCT04515979|DRUG|Vactosertib 300 mg BID and pembrolizumab 200 mg IV|Vactosertib 300 mg orally (PO) BID(5 days on/2days off) and pembrolizumab 200 mg IV (Q3W).
40944904|NCT03911713|DRUG|VX-561|VX-561 tablets for oral administration.
40944905|NCT03911713|DRUG|IVA|150-mg film-coated tablet for oral administration.
40944906|NCT03911713|DRUG|Placebo|Placebo matched to IVA.
40944907|NCT03911713|DRUG|Placebo|Placebos matched to VX-561.
40944908|NCT04120948|DEVICE|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
40944909|NCT04120948|DEVICE|Tongue scraper|mechanical scraping of the dorso-posterior surface of the tongue
40944910|NCT01461980|BIOLOGICAL|rLP2086 + MCV4 + Tdap|At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.
40944911|NCT01461980|BIOLOGICAL|MCV4 + Tdap + saline|At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.
40944912|NCT01461980|BIOLOGICAL|rLP2086 + saline|At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).
40944913|NCT02356315|OTHER|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
40944914|NCT01134315|DRUG|Paricalcitol|
40944915|NCT01134315|DRUG|Calcitriol|
40757380|NCT03635879|OTHER|AC-1206|AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
40944916|NCT00629772|DRUG|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
40944917|NCT00629772|DRUG|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
40944918|NCT03152032|BEHAVIORAL|In-House Vocational Training Programs|At the beginning of the IHVT programs, the job placement for each participant was determined jointly by the participant's interest, the demands of local job markets and the team evaluation. The programs covered 6 to 10 months in length, 5 days a week and 4 to 6 hours a day. The programs contained three sessions: (a) the work-related behavior training session, such as proper appearance, communication and self assertion, and workplace social skills, (b) the on-the-job skill training session where participants gained job-specific training and interventions from job coaches and occupational therapists, and (c) the life balance counseling session including individual and group counseling that aimed to enhance the participants' ability to tackle potential hardships and barriers to work.
40944919|NCT02225509|PROCEDURE|FNA biopsy for thyroid nodule(s)|"The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.~The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit."
40944920|NCT02884531|OTHER|Patient Education and Basic Body Awareness Therapy|Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
40944921|NCT02884531|BEHAVIORAL|Patient Education|Patient education (1/2 day)
40944922|NCT00068783|DRUG|imatinib mesylate|Given orally
40944923|NCT00068783|OTHER|laboratory biomarker analysis|Correlative studies
41285821|NCT06077981|PROCEDURE|Submucous Endoscopic Dissection with hydroxyethylamide|The resection will be performed in three stages using hydroxyethylamide : delimitation, incision and dissection. Initially we will inject the hydroxyethylamide and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
40944924|NCT00210132|DRUG|Ropivacaine|
40944925|NCT02173873|DRUG|ziv-aflibercept drug|intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
41285822|NCT06077981|PROCEDURE|Submucous Endoscopic Dissection with Hyaluronic acid (TS-905 Blue Eye)|The resection will be performed in three stages using Hyaluronic acid (TS-905 Blue Eye) : delimitation, incision and dissection. Initially we will inject the Blue-Eyed and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
40944926|NCT03784417|DEVICE|EUS-guided laser ablation|EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.
40944927|NCT00958789|DEVICE|Triathlon TS Knee System|Total knee replacement for revision cases
40944928|NCT04253912|DRUG|VBP-245|2% Povidone-Iodine Gel
40944929|NCT04253912|DRUG|Placebo Gel (no Povidone-Iodine)|Placebo Gel (no Povidone-Iodine)
40944930|NCT04542304|DRUG|Metolazone|Participants will be given a metolazone for the 1-week study period.
40944931|NCT04542304|DRUG|Placebo|Participants will be given a placebo for the 1-week study period.
40944932|NCT02344615|PROCEDURE|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
41132703|NCT01082900|OTHER|Prophylactic CPAP Administration|"EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)~CONTROL GROUP: Provision of standard care in the Delivery Room"
41132704|NCT02046304|DRUG|Gemcitabine|Starting dose: 400 mg/m2 by vein on days 1, 8, 22, 29, 43, and 50.
40757381|NCT03635879|DRUG|AC-1202|AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
40944933|NCT02344615|PROCEDURE|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
41132705|NCT02046304|RADIATION|Radiation Therapy|Radiation therapy dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks.
40757382|NCT02618187|DRUG|SER-287|
40757383|NCT02618187|DRUG|Placebo|
40757384|NCT02618187|DRUG|Placebo Pre-Treat|
40757385|NCT02618187|DRUG|Vancomycin Pre-Treat|
40757386|NCT01117662|DRUG|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
40757387|NCT01117662|DRUG|Placebo|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
40757388|NCT02928822|BEHAVIORAL|VR-based sensorimotor aphasia therapy|VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
40944934|NCT05492110|DEVICE|Coronary sinus reducer|The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.
41132706|NCT04082507|DIAGNOSTIC_TEST|Serum alpha-fetoproteine|Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
41132707|NCT03877354|OTHER|Data from anaesthesia records for ventilation setting screening|Data from anaesthesia records will be retrospectively screened for the ventilation settings
41132708|NCT03877354|OTHER|Data from intensive care records for ventilation setting screening|Data from paediatric intensive care charts will be retrospectively screened for the ventilation settings
41132709|NCT01054859|DRUG|avanafil|200 mg avanafil tablet QD plus 0.5 g/kg alcohol
41132710|NCT01054859|OTHER|alcohol|0.5 g/kg alcohol
41132711|NCT01054859|DRUG|avanafil|200 mg avanafil tablet QD
40944935|NCT05492110|OTHER|Sham-procedure|Implantation procedure with no device implanted
40944936|NCT05492110|DIAGNOSTIC_TEST|Invasive coronary physiology|Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
40944937|NCT01021579|DRUG|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
40944938|NCT01021579|DRUG|Metfomin plus Simvastatin|
40944939|NCT03561363|BEHAVIORAL|High-fat diet|The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.
40944940|NCT02703220|OTHER|Hyperoxia/oxygen|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure
40944941|NCT02703220|DRUG|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
40944942|NCT02703220|DRUG|Finasteride|Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
40944943|NCT00198926|BEHAVIORAL|covert v overt nutrition labeling|
40944944|NCT00198926|BEHAVIORAL|varying meal nutrition manipulation|
40944945|NCT05263596|DIAGNOSTIC_TEST|dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound|"Results from the routine geriatric assessment:~* Mini Mental State Exam (MMSE)~* Clock-drawing test (CDT)~* Geriatric depression scale (GDS)~* Functional independence measure (FIM) at admission~* Timed up and go Test (TUG)~* Gait speed~* Hand grip strength (HGS)~* Nutritional risk screening (NRS)~Additional measurements:~* Chair-stand-test~* Clinical frailty scale (CFS)~* Calf circumference and mid-arm circumference~* Body impedance analysis (BIA)~* US~* DXA"
40944946|NCT02037958|DEVICE|Laryngeal Mask Airway-Supreme|Patients who receive the LMA-S
40944947|NCT02037958|DEVICE|Endotracheal Tube|Patients who receive endotracheal intubation
40944948|NCT05657431|OTHER|essential oils (Ylang ylang oil)|inhaler aromatherapy
40944949|NCT05657431|OTHER|placebo (saline solutions)|placebo saline solutions
40944950|NCT05657431|OTHER|essential oils (lemon oil)|inhaler aromatherapy
40944951|NCT02219347|DRUG|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
40944952|NCT03855956|OTHER|KB174|KB174 is a novel mixture of oligosaccharides.
40944953|NCT03855956|OTHER|Maltodextrin|Maltodextrin is a commercially available easily digestible polysaccharide.
40944954|NCT03920410|OTHER|serotonergic stimulation|Increase of serotonergic activity by a single oral administration of 10 mg Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), packed in a coloured hydroxypropylmethylcellulose capsule.
40944955|NCT03920410|OTHER|no serotonergic stimulation|Oral administration of a placebo. The placebo will consist of a coloured hydroxypropylmethylcellulose capsule filled with microcrystalline cellulose.
40944956|NCT05137990|BEHAVIORAL|HIIT Exercise Intervention|Exercise trainers will provide encouragement and supervision for exercise prescription adherence and youth will select an age-appropriate music playlist from Spotify to enhance enjoyment throughout each session. Each exercise session consists of a 5-minute warm-up (10% HRmax), followed by a 20-minute HIIT protocol. The 20-minute HIIT protocol consists of seven bouts of 1-min high intensity exercise (90% HRmax) followed by 2-min of active recovery (10% HRmax). Participants will be encouraged to complete each exercise session with at least 24 hours of rest between each session.
40944957|NCT05137990|BEHAVIORAL|Stretching Intervention|This group will perform a home-based program of the same stretches utilized in the exercise group. The stretching protocol consists of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. As flexibility exercises are low-intensity, low-impact and low-volume, minimal caloric expenditure is expected to be incurred. To increase compliance and aid in the standardization of the home-based stretching, participants will be provided a booklet of the flexibility exercises. Participants will be shown how to use the booklet and instructed in the stretching exercises by an exercise trainer prior to the intervention.
40944958|NCT01176331|PROCEDURE|20 and 23 gauge pars plana vitrectomy|
40944959|NCT05700318|DEVICE|neurostimulator|The ShiraTronics Migraine Therapy System
40757389|NCT02928822|BEHAVIORAL|Control Group (conventional aphasia rehabilitation)|8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
40944960|NCT06104657|OTHER|Non-Interventional Study|Non-interventional study
40944961|NCT04234802|OTHER|Heat Education and Awareness Tools|HEAT training will be delivered to agricultural workers by research staff in this study in the spring. HEAT training uses interactive approaches to engage participants and posters with visuals. Training covers types of heat-related illness and treatments, risk factors, appropriate clothing and hydration, and keeping cool in the home and community. The HEAT awareness application was developed in collaboration with Washington State University's AgWeatherNet Program to notify supervisors signed up for the service about hot weather conditions that might increase the risk for adverse health effects for workers. The HEAT awareness application is designed to allow subscribers to select weather stations of interest and view current heat indices as well as maximum daily heat indices forecasted over the following week. This information is coupled with information about health effects and prevention of adverse heat health effects. Materials are provided in English and Spanish.
40944962|NCT06202690|PROCEDURE|Single-port robotic-assisted thoracic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the SP robotic system.~A 4-cm single incision will be made below the subcostal margin. A chest tube will be inserted in same incision."
40944963|NCT06202690|PROCEDURE|Single-port video-assisted thoracoscopic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the VATS.~A 4-cm single incision will be made at 5th intercostal space. A chest tube will be inserted in same incision."
40944964|NCT01147640|DRUG|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
40944965|NCT01147640|DRUG|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
40944966|NCT00493623|DRUG|Placebo|Placebo i.v. single dose
40944967|NCT00493623|DRUG|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
40944968|NCT03920748|OTHER|Group D|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 3-4 is defined as Group D
40944969|NCT03920748|OTHER|Group E|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 1-2 is defined as Group E
40944970|NCT00486551|BEHAVIORAL|Anger control training|
40944971|NCT00341445|BEHAVIORAL|Effect of Cockroach Allergen|
40944972|NCT03838965|DEVICE|biobeat sensor|biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth and after 24 hours.
40944973|NCT01330706|DRUG|Polihexanide|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
40944974|NCT05109052|DRUG|PXS-5505 and Atezolizumab and Bevacizumab|Open label safety and tolerability assessment of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab
40944975|NCT04763174|BEHAVIORAL|mHealth Coping Skills Training for Symptom Management (mCOPE)|mCOPE participants will complete 5 videoconferencing sessions (within 5-9 weeks) with a psychologist, each lasting 45-60 minutes, from a location convenient to the patient (e.g., home, work). Sessions will include cognitive behavioral coping skills designed to target pain, fatigue and psychological distress symptoms unique to colorectal cancer patients. mCOPE will include a mobile app for: 1) coping skills content (e.g., audio, video), 2) daily symptoms assessment and coping skills use tracking transmitting in real-time to study staff, and 4) push notifications for reminders, encouragement, and personalized feedback.
40944976|NCT06110572|DRUG|Carboplatin|Given by IV
40944977|NCT06110572|BIOLOGICAL|Atezolizumab|Given by IV
40944978|NCT06110572|DRUG|Etoposide|Given by IV
40944979|NCT06110572|RADIATION|Total Body Irradiation|Undergo Total Body Irradiation
40944980|NCT06110572|RADIATION|Hypofractionated Radiation Therapy|Undergo Hypofractionated Radiation Therapy
40944981|NCT06110572|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
40944982|NCT05553067|GENETIC|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.
40944983|NCT00160173|DRUG|Estrogel|
40944984|NCT00160173|OTHER|Placebo|
40944985|NCT06392607|DEVICE|Euclid orthokeratology (standard coating)|Lens with the current coating
40944986|NCT06392607|DEVICE|Euclid orthokeratology (enhanced coating)|Lens with the enhanced coating
40944987|NCT06195683|DRUG|Serplulimab|Serplulimab for 4.5mg/kg IV Q3W day 1,22,43,64
40944988|NCT02872168|OTHER|Not intervention|None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
40944989|NCT03956381|DEVICE|Primary Total Hip Replacement with Trinity cup and TriFit TS stem via posterolateral surgical approach.|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
40944990|NCT03956381|DEVICE|Primary Total Hip Replacement with Trinity cup and MetaFix stem via direct anterior surgical approach|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
40944991|NCT03563287|DRUG|cocktail of nine CYP probe drugs|"Two equally loaded capsules containing:~Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone (62.5 mg) Midazolam (1.85 mg) Dextromethorphan (30 mg) as an oral solution was administered separately after the capsules."
40944992|NCT04040270|BEHAVIORAL|Live drama+DVD+Worksheets|"Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
40944993|NCT04040270|BEHAVIORAL|DVD+Worksheets|"The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
40944994|NCT00132639|DRUG|Preoperative docetaxel-cisplatin combination chemotherapy|Preoperative docetaxel-cisplatin combination chemotherapy
40944995|NCT00132639|DRUG|Preoperative docetaxel monotherapy|Preoperative docetaxel monotherapy
40944996|NCT06015971|DIETARY_SUPPLEMENT|omega-3|Take 2 omega-3 enriched oral supplements per day plus physical activity and Mediterranean Diet
40944997|NCT06015971|DIETARY_SUPPLEMENT|Standard|Take 2 hypercaloric hyperproteic oral supplements per day plus physical activity and Mediterranean Diet
40944998|NCT05707936|DRUG|Normal Saline Flush 20 ml|Normal Saline Flush 20 ml
40944999|NCT05707936|DRUG|Normal Saline Flush 10 ml|Normal Saline Flush 10 ml
40945000|NCT05707936|DRUG|Heparin Flush (1000 USP, 10ml)|Heparin Flush (1000 USP, 10ml)
40945001|NCT03986151|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
40945002|NCT01670318|DEVICE|platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)|
40945003|NCT05839483|DIAGNOSTIC_TEST|CXCR4|Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET imaging.
40945004|NCT01008150|DRUG|Paclitaxel|
40945005|NCT01008150|DRUG|Trastuzumab|
40945006|NCT01008150|DRUG|Neratinib|
40945007|NCT01008150|DRUG|Doxorubicin|
40945008|NCT01008150|DRUG|Cyclophosphamide|
40945009|NCT03634644|DRUG|Omega 3 fatty acid|Omega 3 fatty acid,mainly composed of EPA and DHA.
40945010|NCT03634644|DRUG|Placebo oral capsule|mainly composed of corn oil
40945011|NCT00772473|OTHER|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
40945012|NCT00767949|BIOLOGICAL|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
40945013|NCT05725577|OTHER|care via the telemedicine system|Care via the telemedicine system
40757390|NCT04691115|DRUG|AM1476|AM1476 Capsules
40945014|NCT05725577|OTHER|Routine care|Routine care
40945015|NCT03821207|BEHAVIORAL|The exercise group|The students will make exercise during the first three days of the menstrual period
40945016|NCT03821207|BEHAVIORAL|The abdominal massage group|The students will make abdominal massage during the first three days of the menstrual period
40945017|NCT03821207|BEHAVIORAL|Control Group|The students will nor massage or exercise
40945018|NCT03985384|DRUG|Semaglutide 2 MG/1.5 ML Subcutaneous Solution|Semaglutide 2 MG/1.5 ML Subcutaneous Solution
40945019|NCT03985384|DRUG|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
40945020|NCT05454501|OTHER|Exercise Training|For eight weeks, they will receive real-time online exercise training for 30 minutes, three days a week, with a peer group of 5-6 people. Before starting the exercise, physical activity will be monitored for seven days.
40945021|NCT05454501|OTHER|Patient Education|After the first face-to-face evaluation session, these patients and their families will receive a 1-hour patient education program specific to the disease and exercise. Information brochures containing physical activity and exercise recommendations will be given. They will be followed up with weekly phone calls throughout the study period. At the end of 8 weeks, the second evaluation interview will be held. Afterward, the patients in the control group will be able to participate in the online exercise training program if they request it.
40945022|NCT04672720|DRUG|L-carnitine 1000 Mg|Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
40945023|NCT05264688|DIAGNOSTIC_TEST|68Ga-FAPI-04 imaging agent|1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg) intravenously
40945024|NCT01907100|DRUG|Nintedanib|triple kinase inhibitor; 200mg starting dose
40945025|NCT01907100|DRUG|Pemetrexed|backbone chemo
40945026|NCT01907100|DRUG|Cisplatin|backbone chemo
40945027|NCT01907100|DRUG|Cisplatin|backbone chemo
40757391|NCT04691115|DRUG|Placebo|Placebo Capsules
40757392|NCT01866735|OTHER|Standardized Rehabilitation Therapy|
40945028|NCT01907100|DRUG|Pemetrexed|backbone chemo
40945029|NCT01907100|DRUG|Placebo|Nintedanib matching placebo
40945030|NCT00497315|DRUG|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
40945031|NCT00497315|RADIATION|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
40945032|NCT03883399|OTHER|Survey|Survey among colorectal surgeons
40945033|NCT01205815|OTHER|Tissue and blood collection|Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.
40945034|NCT05768971|OTHER|Mild diet|
40945035|NCT05768971|OTHER|Provocative diet|
41285823|NCT05167786|DEVICE|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform lower limb locomotor activities.
41285824|NCT05167786|DEVICE|Noninvasive spinal stimulation|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation to subjects.
40945036|NCT02505178|OTHER|Problem Solving Therapy|PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
40945037|NCT00580970|DRUG|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
40945038|NCT00860288|DRUG|Vildagliptin|
40945039|NCT00860288|DRUG|Metformin|
40945040|NCT00860288|DRUG|Placebo|
40945041|NCT00860288|DRUG|Sitagliptin|
40945042|NCT03768973|PROCEDURE|Elective cardiac surgery|Both groups will undergo elective cardiac surgery as an intervention.
40945043|NCT00646919|PROCEDURE|Nose swab|
40945044|NCT05020197|DIAGNOSTIC_TEST|self-questionnaires on attachment and PTSD|The questionnaires (attachement type, PTSD symptoms) are administered face to face at the inclusion visit (at D0-D3). Validated self-questionnaires in French will be sent to the patients, either electronically or by post, according to their choice at D30 and D90. To describe the characteristics of the subjects, socio-demographic data, lifestyle, and medical history will be collected. The questionnaires will be administered three times to study the evolution of the parameters over time.
40945045|NCT04378127|OTHER|Educational program|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
40945046|NCT00551044|DRUG|Bicalutamide|Bicalutamide 150mg once daily, oral administration, for 12 months
40945047|NCT02883842|BEHAVIORAL|Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
40945048|NCT02243969|DIETARY_SUPPLEMENT|Flaxseed oil|The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
40945049|NCT02243969|DIETARY_SUPPLEMENT|high oleic sunflower oil (HOSF)|The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
40945050|NCT01887340|DRUG|Carboplatin|"- carboplatine: Dose (mg) = AUC x (GFR + 25)~* GFR : glomérulaire filtration (ml/min)~* AUC : area under curve (mg/ml x min)"
40945051|NCT01887340|DRUG|Etoposide|100 mg/m2 D1 to D5
40945052|NCT01887340|DRUG|Cisplatin|20 mg/m2 de D1 to D5
40945053|NCT02245178|PROCEDURE|Lung spirometry|measurement of pulmonary function pre- and post-bronchodilator
40945054|NCT02245178|OTHER|CT scan analysis|Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
40945055|NCT00994318|DRUG|FCM (Ferric carboxymaltose) high ferritin target|
40945056|NCT00994318|DRUG|FCM (Ferric carboxymaltose) low ferritin target|
40945057|NCT00994318|DRUG|Oral Iron (Ferrous sulphate)|
40945058|NCT01270542|DRUG|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
40945059|NCT01270542|OTHER|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
40945060|NCT04770337|DEVICE|STARSTIM device|Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
41132712|NCT04230434|BEHAVIORAL|Safety Plan Intervention|The SPI has 6 key steps: (1) identify personalized warning signs for an impending suicide crisis; (2) determine internal coping strategies that distract from suicidal thoughts and urges; (3) identify family and friends who are able to distract from suicidal thoughts and urges and social places that provide the opportunity for interaction; (4) identify individuals who can help provide support during a suicidal crisis; (5) list mental health professionals and urgent care services to contact during a suicidal crisis; and (6) lethal means counseling for making the environment safer (Stanley \& Brown, 2012)
41132713|NCT01844401|DRUG|Albuterol Spiromax®|Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
41132714|NCT01844401|DRUG|ProAir® HFA|ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
41132715|NCT04867382|BEHAVIORAL|Online training|This intervention consisted of two different interactive online trainings delivered through an online learning platform at HealthPartners.
40945061|NCT04770337|DEVICE|Sham Device|Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp
40945062|NCT06206265|DRUG|TRYP-0082|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
40757393|NCT02412436|DRUG|Depot medroxyprogesterone acetate|Depot medroxyprogesterone acetate intramuscular injection
40945063|NCT06206265|BEHAVIORAL|Psychotherapy|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
40945064|NCT00501579|DRUG|Difluprednate|
40945065|NCT00501579|DRUG|Prednisolone Acetate|
40945066|NCT05264727|DRUG|Dextrose|Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes
40945067|NCT05264727|DRUG|Clinisol 15%|Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
40945068|NCT05049681|DRUG|Camrelizumab|SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
40945069|NCT05049681|DRUG|Apatinib|Apatinib 250mg, q.d.po
40945070|NCT03964805|OTHER|20% oxygen|culture excusively at 20% O2 (Day 0 to Day 6)
40945071|NCT03964805|OTHER|5% oxygen|culture excusively at 5% O2 (Day 0 to Day 6)
40945072|NCT03964805|OTHER|20 % and 5 % oxygen|culture at 5% from Day 0 to Day 3, then at 20% from Day 3 to Day 6)
40945073|NCT02163980|DRUG|Caudal ropivacaine + normal saline|
41285825|NCT05167786|DEVICE|Conventional gait training|Subjects will receive lower limb locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
41285826|NCT05167786|OTHER|Sham|Subject will not receive either transcutaneous electrical spinal cord stimulation or perform lower limb locomotor activities.
41285827|NCT05167786|OTHER|Exploratory Phase - Optimization of Gait Training and Spinal Stimulation|Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
41285828|NCT04024410|OTHER|Evaluation of PEEP in prone position|Assessment of optimal Positive End-Expiratory Pressure (PEEP) in patients undergoing scheduled spine surgery in prone position.
40757394|NCT05128929|DRUG|Hymecromone (H01)|800 mg oral H01 two times a day (total dose: 1600 mg/day).
40945074|NCT02163980|DRUG|Caudal ropivacaine + dexmedetomidine|
41285829|NCT05003245|DRUG|HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL solution at a 4-week interval for intravitreal injection
41285830|NCT05003245|DRUG|Lucentis|0.05mL solution at a 4-week interval for intravitreal injection
41285831|NCT03368859|DRUG|Leucovorin|Intravenous
40945075|NCT05612698|BEHAVIORAL|Aerobic training|Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax. Due to any form of aerobic exercise involving large muscle groups and causes sustained increases in HR is likely to be beneficial, the type of aerobic exercise will be agreed with each group of patients, varying from 4 to 8 people. There will be a choice of ex-ercises and participants will be able to choose a combination of up to 2 different exercises. The participants' choice of the type of activity to be performed is expected to encourage greater adherence. The range of exercises will be brisk walking or running, swimming, and/or aerobic dancing.
40945076|NCT05612698|BEHAVIORAL|Aerobic training plus resistance training|Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action. In each session, between 5 and 10 exercises will be worked on, per-forming 10-15 repetitions, and progressing to 8-10 lifting as the weight increases, involving the major muscle groups from the core, lower body and upper body. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session.
41285832|NCT03368859|DRUG|Fluorouracil - bolus|Intravenous
41285833|NCT03368859|DRUG|Bevacizumab|Intravenous
41285834|NCT03368859|DRUG|Fluorouracil - infusion|Intravenous
41285835|NCT03368859|DRUG|ABT-165|Intravenous
40757395|NCT05128929|DRUG|Placebo|Oral tablet placebo (inactive ingredients) two times a day.
40757396|NCT04989517|DRUG|AT193|Topical
40757397|NCT05388968|BIOLOGICAL|Metatranscriptomic|Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling
41132716|NCT00845520|DEVICE|Lens implantation +1.00 D postop target|Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
41132717|NCT00845520|DEVICE|Lens implantation -1.00 D postop target|Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
41132718|NCT00845520|DEVICE|Lens implantation 0.00 D postop target|Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
41285836|NCT03368859|DRUG|Irinotecan|Intravenous
41285837|NCT00158977|DEVICE|CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT
41285838|NCT05957562|PROCEDURE|EA/TOF primary repair with Azygos vein preservation|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
41285839|NCT05957562|PROCEDURE|EA/TOF primary repair with Azygos vein sacrifice (disconnection)|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
40757398|NCT05388968|DIAGNOSTIC_TEST|Specific microbiologic diagnosis|If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)
41452309|NCT04866979|DEVICE|Intermittent TBS (iTBS)|Application of iTBS. iTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), alternating 2 seconds of stimulation with a pause of 8 seconds, with a stimulation intensity equal to 80% of the motor threshold value at rest.
40945077|NCT05612698|BEHAVIORAL|High intensive interval training|Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO. Starting with 4 intervals lasting 1 minute keeping in a range of 85-90% HRMax, separated by 1 minute of low intensity activity (no static) (4 × 1 min intervals.) A progression will be followed by increasing the number of circuits, up to 10 (10 × 1 min intervals) \[25, 78, 79\]. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session. Although the target popula-tion is a sedentary population, we expect the HIIT approach, despite being high intensity, to be well received, due to its growing popularity, as demonstrated by a study in which 62% of inactive participants preferred HIIT to other types of exercise.
40945078|NCT04332380|DRUG|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
40945079|NCT00428662|DEVICE|drug eluting nonpolymeric nanoporous stent|
40945080|NCT04814862|BEHAVIORAL|3 validated questionnaires (ADHD-RS, SRS, BRIEF) for the diagnosis of neurodevelopmental disorders|Completion of three validated questionnaires for the diagnosis of neurodevelopmental disorders
40945081|NCT04280289|DRUG|cannabidiol extract|"The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials"
40945082|NCT01131156|BEHAVIORAL|Smoking Relapse Prevention|Mothers were given information about normal newborn behaviors using books, DVDs, and handouts that were appropriate for their baby's gestational age and were also encouraged to participate in frequent skin-to-skin holding of their babies.
40945083|NCT06327659|DEVICE|30 mL syringe manual thrombectomy catheter|30 mL syringe manual thrombectomy catheter
40945084|NCT06327659|DEVICE|50 mL syringe manual thrombectomy catheter|50 mL syringe manual thrombectomy catheter
40945085|NCT00940030|OTHER|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
40945086|NCT00940030|OTHER|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
40945087|NCT01854203|DRUG|Inductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
40945088|NCT01854203|DRUG|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
40945089|NCT02770170|DRUG|BI 655064 dose 1|
40945090|NCT02770170|DRUG|BI 655064 dose 2|
40945091|NCT02770170|DRUG|BI 655064 dose 3|
40945092|NCT02770170|DRUG|Placebo|
40945093|NCT04139473|PROCEDURE|Hepaticojejunostomy / Duct-to-duct anastomosis|
40945094|NCT05708586|BEHAVIORAL|Control|This is the control condition and anxiety is addressed in a standard way of having the care taker calm the child during the intervention.
40945095|NCT05708586|DEVICE|Virtual Reality (VR)|The child who is undergoing a procedure uses VR as a distraction during the intervention
41452310|NCT04866979|BEHAVIORAL|Cognitive training (CT).|Cognitive training (memory rehabilitation via RehaCom computer software) of 25 min. The training will be focused on memory rehabilitation, implementing a face-name association paradigm. The software uses an individualized adaptive methodology based on the participant's performance.
40945096|NCT01365065|DRUG|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
40945097|NCT03583723|RADIATION|Radiotherapy Group|Patients will be immobilized with customized devices. Either four-dimensional CT or slow CT images using a multislice CT scanner will be acquired to evaluate internal target motion. Initially, gross tumor volume (GTV) will be determined in the maximum intensity projection on the initial size of the tumor and involved lymph nodal sites defined as PET-positive nodes and/or a node diameter greater than 1 cm, clinical target volume (CTV) will be defined as equal to the GTV plus node-positive stations and hilar stations, and planning target volume (PTV) will be created equal to the CTV plus a 0.5-cm safety margin. Treatment will be performed with a linear accelerator in a photon regimen, with a 6-to 15-megavolt (MV) nominal energy and three-dimensional (3D) conformal technique.
41285840|NCT01121016|DRUG|Montelukast|10mg, qn, 4 weeks
41285841|NCT01121016|OTHER|placebo to montelukast|same appearance, flavor, weight, and size to montelukast pills, 1 pill daily, for 4 weeks
41452311|NCT04866979|DEVICE|Sham Stimulation (shamTBS)|"Sham rTMS (TBS) will be administered by applying a 30mm thick piece of wood or plastic to a real TMS coil during stimulation, and this additional element will be constructed in such a way that it appears to be an integral part of the apparatus such that the patient remains unaware that they are not receiving stimulation (Rossi et al., 2007 ).This 30mm distance is adequate to ensure that the magnetic pulse does not reach the cortex."
40757399|NCT04722679|DRUG|Non-VKA Oral Anticoagulants (NOAC)|Follow clinical practice.
41132719|NCT03631966|DRUG|Dysport|BTX-A (Dysport-Ipsen Inc.) will be injected into the proximal third of the medial and lateral gastrocnemius muscles of the symptomatic leg(s). Total dose per leg will be 400 units, 200 per injection site. Injections will be performed with the aid of real-time ultrasound (Sonosite, Bothwell, WA) guidance.
40757400|NCT06075537|DRUG|tividenofusp alfa|Intravenous repeating dose
40757401|NCT04298658|DIAGNOSTIC_TEST|Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised|Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
41132720|NCT04913532|RADIATION|Hypofractionation with simultaneous integrated boost|Hypofractionation with simultaneous integrated boost
41132721|NCT01697683|DRUG|Probiotic Lactobacilli|Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
41132722|NCT01697683|DRUG|Placebo|
41132723|NCT03293238|PROCEDURE|Joint line ultrasound|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
41132724|NCT03293238|PROCEDURE|Joint line landmark|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
41132725|NCT03293238|PROCEDURE|Suprapatellar ultrasound guided|Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
41132726|NCT03293238|PROCEDURE|Suprapatellar Landmark|Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
41132727|NCT03124472|PROCEDURE|uterine artery ligation|Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged
41285842|NCT02062931|BIOLOGICAL|Stem Cell Preparation and Injection|"Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.~Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
41285843|NCT02371629|DRUG|NVA237|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
41285844|NCT02371629|DRUG|Placebo|Placebo to NVA237
41285845|NCT02371629|DRUG|Salbutamol|All patients received salbutamol (100 μg) as only rescue medication
41285846|NCT04910750|DEVICE|Pulse oximetry|Pulse oximeters are a non-invasive, accurate and easy to use method of evaluating blood oxygen saturation
41285847|NCT04910750|DEVICE|Clinical Decision Support Algorithm|Tablet-based clinical decision support algorithms, based on guidelines for the assessment and management of sick children under 5 years of age at primary care
41285848|NCT05782088|PROCEDURE|Single Piezocision|Piezocision will be performed only once before the onset of canine retraction (T0) on one side of the maxillary arch that will be randomly chosen.
41285849|NCT05782088|PROCEDURE|Repeated Piezocision|Piezocision will be repeated three times, on a monthly basis (T0, T1, and T2), over the 12-week study period.
41285850|NCT06153381|OTHER|Chatbot|Rehabilitation program based on standard care, but assisted via an instant messaging application using a personal smartphone
41285851|NCT06153381|OTHER|Standard car|Rehabilitation program based on standard care, assisted with one education session plus informative brochure
41285852|NCT03827876|DRUG|Enstilar 0.005%-0.064% Topical Foam|Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
41285853|NCT03411603|OTHER|Diet and socio-demographic questionnaires|24-hr recall or food diary questionnaires; socio-demographic questionnaires
41285854|NCT00850499|DRUG|fludarabine|fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
41285855|NCT00850499|DRUG|rituximab|rituximab 375mg/m2 on Day 1 of every 35-day cycle
40757402|NCT04298658|DIAGNOSTIC_TEST|Resmed ApneaLink Air device (Resmed, San Diego, CA).|Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
40945098|NCT06422195|OTHER|Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA)|Ultrasound guided radial artery cannulation by Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. The ultrasound transducer is oriented transversely to the radial artery at the wrist, and the vessel appears as a circular anechoic structure in the ultrasound screen with gradual advancing of the needle till reaching the radial artery. Meanwhile, the ultrasound probe is being moved proximally in advance of the needle tip until it disappears from the ultrasound image. The cannula then advanced in the direction of the artery.
41285856|NCT00850499|DRUG|VELCADE|1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
41285857|NCT01277575|DEVICE|rtACS stimulation (Verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation
41452312|NCT04125394|DEVICE|hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose|Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container
41452313|NCT02278809|BEHAVIORAL|Movie Models|"The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring..."
41452314|NCT04261374|DIAGNOSTIC_TEST|Measurement of sublingual microcirculation|Measurement of sublingual microcirculation
40757403|NCT04298658|OTHER|Quantitative Sensory testing (QST)|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
41285858|NCT01277575|DEVICE|placebo condition|A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
41285859|NCT02552407|DEVICE|Manual Aspiration Thrombectomy|Thrombus aspiration
41285860|NCT06198920|PROCEDURE|Stenting of the superficial femoral artery|Submitted to stenting of the superficial femoral artery for stenosis or occlusion causing intermittent claudication or critical limb ischemia
41285861|NCT05523492|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|All clients will receive the Culturally Enhanced Wellbeing Course. The Course was originally developed at Macquarie University in Australia and was then culturally enhanced by the Online Therapy Unit in Saskatchewan Canada. The course is a trans-diagnostic Internet-delivered cognitive behaviour therapy intervention targeting symptoms of depression and anxiety. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in order over 8 weeks. Therapists will spend \~15 mins. per week/per client offering support via emails and or phone calls.
41285862|NCT02277886|DRUG|sodium alginate|oral suspension, 50mg/ml, 20ml once at bed time
41285863|NCT02277886|DRUG|esomeprazole|40mg/tablet, one tablet once before breakfast
41285864|NCT06511752|BEHAVIORAL|Psychosocial educational, support group and implementation of strategies|Psychosocial educational, support group and implementation of strategies
41285865|NCT00172380|DRUG|Docetaxel Plus CDDP|docetaxel 36mg/m2 and cisplatin 75mg/m2
41285866|NCT03045380|OTHER|Game based physical activity training|Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with motion sensor (Microsoft) and a 50'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades of the games and types of the games will be changed. A game based physical activity training session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
41285867|NCT03045380|OTHER|Conventional physiotherapy|A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented. A conventional physiotherapy session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
41285868|NCT02513446|DRUG|BI 1026706|Single dose of BI 1026706 on Day 1
41285869|NCT02513446|DRUG|Itraconazole|7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
41285870|NCT04802837|DRUG|Ridinilazole|Ridinilazole 200mg dosed BID for 10 days.
41285871|NCT04802837|DRUG|Vancomycin|Vancomycin 125mg dosed QID for 10 days.
41285872|NCT01158898|DRUG|TPI ASM8|ASM8 4mg/mL (low dose) daily for 14 days by inhalation
41285873|NCT01158898|DRUG|TPI ASM8|ASM8 4mg/mL (high dose) daily for 14 days by inhalation
41285874|NCT01158898|DRUG|TPI ASM8|Placebo PBS solution daily for 14 days by inhalation
41285875|NCT02907944|BEHAVIORAL|Implementation Facilitation|"Implementation Facilitation is an evidence-based strategy tailored to the specific needs of the clinic, designed to increase uptake of evidence based treatments for tobacco, alcohol and opioid use disorders. Will include provider education and academic detailing.~* External Facilitator: Outside content expert who assists site~* Local Champion: Site stakeholder who promotes change~* Provider Education and Academic Detailing: Provision of unbiased peer education~* Stakeholder Engagement: Aligning goals of implementation and those impacted~* Tailor Program to Site: Addressing site specific needs based on Aim 1~* Performance Monitoring and Feedback: Assess implementation of screening and treatment efforts and inform site of results~* Formative Evaluation: Quant. and qual. determination of impact~* Establish a Learning Collaborative: Shared learning opportunities tailored to stakeholders~* Program Marketing: Increase attention to availability of on-site addiction treatment services"
41285876|NCT00288340|DEVICE|functional magnetic resonance imaging|
41285877|NCT06334835|DIAGNOSTIC_TEST|lncRNA signature analyses|Evaluation of a signature of identified lncRNA in a cohort of childhood T-ALL patients in comparison with healthy subjects.
41285878|NCT01755481|OTHER|Probiotic|
41285879|NCT01755481|OTHER|Whey protein concentrate|
41285880|NCT02513381|OTHER|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
41285881|NCT02513381|OTHER|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
41285882|NCT05934760|OTHER|High intensity interval training (HIIT)|"Each HIIT session last 15 minutes. Participants will be asked to measure their own heart rate during their rest periods and provided with an estimated max heart rate which they should be aiming to achieve within the final 2 exercises. Participants will be provided with a logbook to record the heart rate achieved in each exercise. The regimen will include:~* 2 min warm-up: jogging on the spot~* Each of the following exercises performed for 60seconds, interspaced by 90 seconds rest~  * Star jumps~ * Standing squats~ * On-the-spot sprints~ * Standing squats~ * Star jumps~* 2 min cool-down: jogging on the spot"
41285883|NCT05934760|OTHER|Resistance based training (RET)|"Each RET session lasts an estimated 20minutes. Participants will be provided with a set of resistance bands to provide resistance to their workout, and a logbook to record the number of repetitions and band used.~Each session will include:~* 2 min warm-up jogging on the spot~* 2 sets of 12-15 repetitions of:~* Squats~* Hip flexion~* Hip extension~* Hip abduction~* Seated row~* Bench press~* Lateral raises~* 2 min jogging on the spot cooldown.~Each exercise will be separated by 1-minute rest, with participants encouraged to workout to mild fatigue on their final repetition in each set. If able to perform more than the allocated maximum of 15 repetitions prior to fatigue, then participants will be informed to increase the resistance by using a tougher resistance band."
40757404|NCT04298658|DIAGNOSTIC_TEST|OraQuick Advance Rapid HIV 1/2 Swab test|Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.
41285884|NCT03592862|DRUG|HTL0018318|Oral capsule
41285885|NCT03592862|DRUG|Placebo|Oral capsule
41285886|NCT03037905|DEVICE|SignatureSuite OR Integration System by STERIS Corporation|SignatureSuite OR Integration System by STERIS Corporation is a device that controls audio and visual components of the operating room environment in order to provide a more relaxing and calming operating room environment for patients prior to surgery and on emergence from anesthesia after surgery.
41285887|NCT04630015|OTHER|Survey Administration|Participants will complete study specific survey
40945099|NCT06422195|OTHER|Long Axis Approach (LA)|Ultrasound guided radial artery cannulation in Long Axis Approach (LA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. In the LA-IP approach, an ultrasound probe is placed parallel to the radial artery and the artery appears as a tubular anechoic structure in ultrasound.
40945100|NCT04932759|BEHAVIORAL|music listening|music listening during dental treatment
40945101|NCT00152529|BEHAVIORAL|Screening (Behavior)|
40945102|NCT03158987|OTHER|Medical record review|Review of medical records of patients diagnosed for the first time as HIV seropositivity
40945103|NCT03602729|OTHER|Breastfeeding education|Breastfeeding education in three different forms: written/verbal/video
40945104|NCT01823354|OTHER|Polysomnography|Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
40945105|NCT01823354|OTHER|Clinical Scales|Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
40945106|NCT01823354|OTHER|Assessment of executive functions|"Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing)."
41285888|NCT00761111|BEHAVIORAL|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
40757405|NCT04298658|DIAGNOSTIC_TEST|Cluster of Differentiation 4 (CD4) and Viral load|Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.
40757406|NCT01381887|DRUG|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
40757407|NCT01381887|DRUG|Canagliflozin 300mg/Placebo|"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
40757408|NCT01381887|DRUG|Canagliflozin 300mg/Canagliflozin 150mg|"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
41285889|NCT01733563|PROCEDURE|Soft drink consumption|
41285890|NCT02913807|PROCEDURE|Customized Jigs and Plates|The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
40757409|NCT01381887|DRUG|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
40757410|NCT01265147|DRUG|Cisplatin|40mg/m2/w
40757411|NCT01265147|DRUG|Nedaplatin|40mg/m2/w
40757412|NCT05827237|DIAGNOSTIC_TEST|Clinical decision rule|Clinical decision rule for acute chest pain, consisting of the Marburg Heart Score (5 questions) combined with a high-sensitive troponin I point of care test
40757413|NCT02369679|DEVICE|Precast Adjustable Compression Wrap (Circaid)|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
40757414|NCT02369679|DEVICE|Multilayer Compression Bandages|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
40757415|NCT02105480|DEVICE|Computer aided auscultation (CAA)|
40757416|NCT02056951|PROCEDURE|Multidisciplinary rehabilitation|"Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:~* health education~* exercise therapy~* back school~* physical treatments~* psychological interventions in groups and individual counselling~* rehabilitation/social counselling."
40945107|NCT01823354|OTHER|Medical consultation|open questions
40945108|NCT00351988|BEHAVIORAL|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
40945109|NCT00351988|BEHAVIORAL|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
41285891|NCT02913807|PROCEDURE|Hand Contoured Osteotomies and Reconstruction Bars|This will be the traditional method of hand-conjuring the bar and bony sites.
41285892|NCT06100562|BEHAVIORAL|Adapted Dance Program|"* Participants will attend a 2x/weekly adaptive dance session for 10 weeks. If participants miss a class due to illness or an unexpected event (loss of transportation, family emergency/need) they will receive a video of the content missed and can complete the session at home.~* Each class will start with a 10 min warm-up that will include stretching and motor games.~* Learn a section of choreography every session using action-based intervention for 30 minutes.~* Break for 5 min.~* Improvisation part of class for 10 min.~* Cool-down for 5 min."
41285893|NCT01430195|DRUG|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
40945110|NCT01841307|DRUG|Cromolyn Sodium|
40945111|NCT02550041|OTHER|T specific response for diagnostic of aspergillus bronchitis|
40945112|NCT05095831|DIAGNOSTIC_TEST|Pancreas EUS shear wave|"EUS Shear wave elastography (SWE) is a form of ultrasound elastography used in transabdominal ultrasonography. It measures tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI). The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals \[kPa\] or meters per second. Also, the dispersion slope or ultrasound shear wave dispersion (SWD) will be recorded. It is the measure of viscosity \[(m/sec)/kHz\] using SWE.~A first endoscopist will perform EUS over pancreas tissue. Without any elastography assessment (strain ratio/histogram) , the endoscopist will take ten shear wave measurements of pancreas tissue elasticity by generating shear waves inside the pancreas using the ARFI."
40945113|NCT05095831|DIAGNOSTIC_TEST|Pancreas EUS-elastography and EUS-guided biopsy|"Pancreas EUS-elastography measures the pancreatic tissue stiffness through strain ratio (SR) and strain histogram (SH).~A second endoscopist blind to pancreas tissue shear wave findings will perform EUS-elastography with corresponding SR and SH measurements. The SR/SH will be measured and documented. Finally, a pancreas tissue biopsy will be performed. The impossibility of biopsy is an exclusion criterion (except in control patients). Due to ethical purposes, a biopsy will not be performed on patients from the control group."
40945114|NCT03767101|BEHAVIORAL|Cognitive behavioral therapy|In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
40945115|NCT05594810|BEHAVIORAL|TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)|A total of six 45-90 min. sessions of AF-EMDR therapy with an average frequency of twice per week added to a SCP embedded in CRA. AF-EMD therapy consists of a rationale, installating a treatment goal, desensitasing mental video's, installation of positive cognition, future template and positive ending.
40945116|NCT05594810|BEHAVIORAL|TAU only: Community Reinforcement Approach (CRA) + SCP|"CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.~Within CRA a regular smoking cessation program is embedded."
40945117|NCT00952042|OTHER|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
40945118|NCT00952042|OTHER|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
40945119|NCT00877201|DRUG|CDR2|
40945120|NCT05391542|OTHER|aligning archwires|At the day of bonding, 0.016-inch archwire will be placed for the TuNT group. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. While, for the CuNT group, 0.014-inch archwire will be placed at the day of bonding and eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. Archwires will be tied to the bracket by elastomeric modules which will be changed every 4 weeks. A good-quality alginate impression for the lower arch should be taken pre-treatment and after 4, 8, 12 and 16 weeks and a stone study model is obtained. Periapical X-ray for the mandibular central incisors will be taken pre-treatment and after 16 weeks. The participants will be provided by a visual analog scale (0-10) to record their pain perception during the first week after each wire placement.
40945121|NCT03029429|DRUG|Theophylline|oral theophylline
40945122|NCT03029429|DRUG|Placebos|oral placebo
40945123|NCT00535366|DRUG|Tiotropium|Oral inhalation by HandiHaler® device
40945124|NCT00535366|DRUG|Salmeterol|Oral inhalation from Diskus®
40945125|NCT00535366|DRUG|Fluticasone|Oral inhalation from metered dose inhaler (MDI)
40945126|NCT00535366|DRUG|Ciclesonide low|Oral inhalation from MDI
40757417|NCT02056951|PROCEDURE|Interprofessional rehabilitation|"Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:~* education about low back pain~* behavioural exercise therapy~* coping with pain~* relaxation~* work related informations"
40757418|NCT03484195|DRUG|FOLFOXIRI|Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
40945127|NCT00535366|DRUG|Ciclesonide high|Oral inhalation from MDI
41132728|NCT03124472|PROCEDURE|Lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~* Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~* Closure of the anterior abdominal wall in layers"
40945128|NCT00535366|DRUG|Placebo|Oral inhalation from MDI
40945129|NCT05582031|COMBINATION_PRODUCT|Regorafenib in combination with Tislelizumab|Regorafenib 30 mg/tablet + Tislelizumab 100 mg/10 ml vial
40945130|NCT00975325|DRUG|Yohimbine|yohimbine 5 mg, one tablet, single dose only
41132729|NCT04025255|DIETARY_SUPPLEMENT|Braini|A novel, neuro-protective and neuro-restorative dietary supplement composed of a combination of active ingredients which have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) status in 2018
41132730|NCT04025255|DIETARY_SUPPLEMENT|Placebo|Matched placebo
41285894|NCT01430195|PROCEDURE|Narrow-Band UVB Light Treatment|To be administered 3 times/week for 6 months. 72 treatments in total.
41285895|NCT00002445|DRUG|IM862|
41285896|NCT00907738|DRUG|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
41285897|NCT06513780|OTHER|Observation|No intervention were made.
40945131|NCT00975325|DRUG|Yohimbine|yohimbine 5 mg, one tablet, single dose only
40945132|NCT04539873|DRUG|Colchicine 0.5 MG|Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
40945133|NCT04539873|COMBINATION_PRODUCT|CONTROL GROUP|In this case, the centers where the patients are enrolled will adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases)
41132731|NCT02762201|PROCEDURE|PASI|"Implant-secured removable partial denture will be delivered in 2 large steps: implant delivery followed by denture delivery.~* Implant delivery will take 4 dental consultations : a pre-implant study at Day14 after inclusion, the surgical implant insertion at D28 after inclusion, stitches removal at D35 after inclusion, and finally functional implant delivery between 3 or 6 month after surgery (to allow implant osteointegration).~* Denture delivery will take 6 weekly dental consultations between Week 3 and Week 8 after the functional implant delivery."
41132732|NCT02762201|PROCEDURE|PAC|Metalic standard removable partial denture, the standard treatment, will be delivered in 4 steps at Day 7, D14, D21, D28 after inclusion, as classically.
41285898|NCT04207073|DEVICE|Mobilization of median nerve|Neural mobilization
41285899|NCT04964726|BEHAVIORAL|Real-time fMRI dyadic neurofeedback|Participants will attempt to regulate their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
41285900|NCT05121337|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
41285901|NCT05121337|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
41285902|NCT04325815|DEVICE|CADDIE- Computer Aided (AI) Device used in Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
41452315|NCT02280707|OTHER|Grab a Cup, Fill it Up|The intervention involved installing promotional posters encouraging students to drink water as well as cup dispensers stocked with disposable 5 ounce cups near water fountains in school lunchrooms.
41452316|NCT04990648|DEVICE|Buzzy|Buzzy ® device (Buzzy ® Mini Healthcare) has been used to reduce pain by using local cold application and vibration effect. Buzzy ® was developed by Dr. Amy Baxter in 2009. The size of the Buzzy ® device measures 2⅞ꞌꞌ x 1⅞ꞌꞌ x ⅞ꞌꞌ (7,2 cm x 4,8 cm x 2,2 cm). It is a bee-shaped device made of hard plastic with a vibrating motor (2 settings - fixed and pulsed), powered by a 2AAA battery. There are 4 ice packages and elastic fastening strap. On the part where the device touches the skin, there is an ice package in the shape of a wing. When the button on the device is pressed, it vibrates.
41452317|NCT05325268|PROCEDURE|Osteosynthesis|Treatment of fracture with open reduction and osteosynthesis
40945134|NCT01303354|PROCEDURE|Lumbar Transforaminal Epidural Steroid Injection|
40945135|NCT02761928|OTHER|Beighton score for hypermobility|The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.
40945136|NCT05985005|OTHER|online simulation of high alert medication safety training|online simulation of high alert medication safety training
40945137|NCT00698984|DIETARY_SUPPLEMENT|BONISTEIN(R) bone blend|2 Capsules per day over a period of 6 months
40945138|NCT00698984|DIETARY_SUPPLEMENT|Placebo|2 capsules per day over a period of 6 months
40945139|NCT01354067|BEHAVIORAL|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
40945140|NCT01354067|BEHAVIORAL|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
40945141|NCT04867057|DRUG|Trichomylin for SAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
40945142|NCT04867057|DRUG|Placebo for SAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
40945143|NCT04867057|DRUG|Trichomylin for MAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
40945144|NCT04867057|DRUG|Placebo for MAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
40945145|NCT01342276|BEHAVIORAL|vHFC|Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
40945146|NCT00032032|DRUG|carboplatin|
40945147|NCT00032032|DRUG|paclitaxel|
40945148|NCT00032032|RADIATION|radiation therapy|
40945149|NCT02578771|DRUG|ZuraPrep with 70% IPA|Apply topically
40945150|NCT02578771|DRUG|ZuraPrep without 70% IPA|Apply topically. 0% IPA
40945151|NCT02578771|DRUG|ChloraPrep CHG/IPA Teal Tint|Apply topically
40945152|NCT02578771|OTHER|Normal Saline|Apply topically
40945153|NCT04222231|OTHER|Blood-flow restriction resistance training|Training program: After 10 minutes of warm-up the participant performs three exercises with BFRT for the lower extremities. The intensity is about 15-30% of 1-RM.
40945154|NCT04222231|OTHER|Classical resistance training|Training program: After warm-up the participant performs three exercises for lower body. The intensity is about 60-80% of 1-RM.
40945155|NCT00943696|DIETARY_SUPPLEMENT|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
41452318|NCT01120028|DRUG|Alemtuzumab|Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
41452319|NCT01120028|DRUG|Basiliximab|20 mg intravenously, two doses 96 hours apart
41452320|NCT01120028|DRUG|Sirolimus|Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
41452321|NCT01120028|DRUG|Tacrolimus|Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
40945156|NCT04436211|PROCEDURE|Total Knee Arthroplasty|The common procedure of Total Knee Arthroplasty is investigated in order to compare the techniques of implantation (kinematic vs mechanical alignment)
40945157|NCT00794781|DRUG|E6201|E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m\^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
40945158|NCT00361582|DRUG|CG5503 IR; tapentadol|
40945159|NCT01343927|BEHAVIORAL|Weekly yoga classes|Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
40757419|NCT04297774|BEHAVIORAL|virtual reality treatment|18 virtual reality training through Pablo system (30 minutes a time, 2-3 times a week). Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. The controller was attached to lower extremity or trunk to control the game, such as elevator, hot air balloon, shooting cans, etc.
40945160|NCT01343927|BEHAVIORAL|Individual physical therapy treatment|12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
41285903|NCT01461525|PROCEDURE|Abdominoperineal resection|After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
41285904|NCT01461525|PROCEDURE|Sphincter preservation surgery|After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
41452322|NCT04688333|OTHER|Internet-Based Intervention - Complete iConquerFear program|Online adaptation of a highly effective face-to-face treatment for fear of recurrence.
41452323|NCT04688333|OTHER|Quality-of-Life Assessment|Ancillary studies
41452324|NCT04688333|OTHER|Questionnaire Administration|Complete questionnaires
41452325|NCT03563833|OTHER|Minimal Flow Anesthesia|Minimal Flow Anesthesia with 0,4 L min-1
41452326|NCT03563833|OTHER|High Flow Anesthesia|High Flow Anesthesia with 2 L min-1
41452327|NCT03351296|DRUG|LV5FU2|LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
41452328|NCT03351296|DRUG|Streptozocin|streptozotocin 800 mg/m² day 1 every 14 days
40945161|NCT01343927|BEHAVIORAL|Education|"Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care."
40945162|NCT05378373|BEHAVIORAL|Garmin, Pattern Health App|Wearable sensors will deliver individualized feedback to participants according to their assigned intervention
40945163|NCT05912660|DEVICE|Aortic Valve Replacement|Aortic Valve Replacement (surgically or TAVI)
40945164|NCT04290312|OTHER|Mastiha oil|After overnight fasting, the authorized study staff inserted a plastic cannula in an arm vein of the volunteers in order to minimize discomfort during consecutive blood sampling. A blood sample was collected on time point 0h and then the volunteers consumed 1mL of MO. The dose selection was based on the study of Papada et al. (2017) who administered healthy volunteers with 10g of Mastiha (containing \~10% MO). Afterwards blood samples were collected on time points 0.5h, 1h, 2h, 4h, 6h and 24h after MO intake, and were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum isolation. All samples were stored at -80◦C until further analysis.
40945165|NCT00886184|PROCEDURE|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
40945166|NCT00886184|PROCEDURE|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
40945167|NCT02724150|DRUG|Omeprazole High dose|High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days
40945168|NCT02724150|DRUG|Omeprazole Low dose|low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days
40945169|NCT01200524|DRUG|AZD2423|20 mg tablet
40945170|NCT01200524|DRUG|AZD2423|50 mg tablet
40945171|NCT01200524|DRUG|Placebo|Placebo
41285905|NCT02795156|DRUG|Afatinib|40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
41285906|NCT02795156|DRUG|Regorafenib|160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
41285907|NCT02795156|DRUG|Cabozantinib|60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
41452329|NCT03351296|DRUG|Capecitabine|Capecitabine 750 mg/m² twice daily, days 1-14
41285908|NCT05683132|BEHAVIORAL|Trauma-Informed CBT-I|5 individual sessions incorporating behavioral and cognitive therapy components and trauma-informed adaptations with a trained instructor.
41285909|NCT05683132|BEHAVIORAL|PTSD Psychoeducation|5 individual sessions incorporating psychoeducation about PTSD symptoms with a trained instructor.
41285910|NCT02660697|PROCEDURE|Extraction site development|In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
41452330|NCT03351296|DRUG|Temozolomide|temozolomide 200 mg/m² once daily, days 10-14, every 28 days
41452331|NCT03351296|DRUG|Bevacizumab|bevacizumab 5 mg/kg every 14 days
41452332|NCT05333471|DRUG|MTP 101-LF|Each unit of MTP-101-LF contains approximately 35 mL of fecal transplant product. Participants will receive approximately 32 mL via colonoscopy.
40945172|NCT05726734|DRUG|Vonoprazan|potassium-competitive acid blocker
40945173|NCT05726734|DRUG|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
40945174|NCT05726734|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
40945175|NCT05726734|DRUG|Esomeprazole|Proton pump inhibitor
40945176|NCT04037046|BEHAVIORAL|Screening HCV attached onto CCR screening|Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
40945177|NCT04037046|BEHAVIORAL|Screening HCV attached onto CCR screening by self-testing|Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT
40945178|NCT04037046|BEHAVIORAL|Screening HCV at primary care center|DBS for HCV screening at primary care center
40945179|NCT03873610|BEHAVIORAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
40945180|NCT03873610|BEHAVIORAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
40945181|NCT00643396|RADIATION|thoracic radiotherapy|
40945182|NCT02443116|BIOLOGICAL|NGM282|
40945183|NCT02443116|OTHER|Placebo|
40945184|NCT04515173|DIAGNOSTIC_TEST|Artificial intelligence diagnosis and treatment assistance system|An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
40945185|NCT03583528|DIAGNOSTIC_TEST|68Ga-DOTATOC PET/CT|"Blood pressure, heart rate, and oxygen saturation levels will be recorded prior to the injection and at 5 - 15 minutes after injection.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. After this uptake phase, the blood pressure, heart rate, and oxygen saturation levels will be recorded again. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
40945186|NCT03583528|DIAGNOSTIC_TEST|18F-FDG PET/CT|"18F-FDG PET/CT For 18F-FDG as fasting period of 6 hours is required before the scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
40945187|NCT02076633|DRUG|L19IL2+L19TNF|Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
40945188|NCT03404427|BEHAVIORAL|Normal sleep night|Usual hours of sleep
40945189|NCT03404427|BEHAVIORAL|Sleepless night|Total sleep deprivation the first night
40945190|NCT02938039|DEVICE|Ambu LMA|Ambu Laryngeal Mask Airways
40945191|NCT02938039|DEVICE|I-Gel LMA|I-Gel Laryngeal Mask Airways
40945192|NCT01231854|DRUG|Ciclosporin|In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).
41285911|NCT01812304|OTHER|hands-on training|the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
40945193|NCT01231854|DRUG|Alitretinoin|In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
40945194|NCT03727399|OTHER|blood withdrawal|Blood withdrawal
40945195|NCT03828409|PROCEDURE|Short stitch|The rectus sheath are cleaned off the subcutaneous fats. Short stitch technique uses smaller needle and suture material. The suture is placed nearer to each other as compared to our conventional long stitch technique. It has inter-suture distance of 5mm and 5mm distance from rectus edge. The suture will be started at one end and sutured continuous until the other end. Hence, this technique is applied without tension.
40945196|NCT03828409|PROCEDURE|Long stitch|Long stitch uses a larger needle and suture material. The suture is placed 1cm from the linea alba and 1 cm from previous suture. This technique include mass closure sutures at the midline laparotomy
40945197|NCT03180697|DIAGNOSTIC_TEST|APT MR Imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
41285912|NCT01812304|OTHER|frontal teaching|one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
41285913|NCT00264277|DRUG|Vitamin K antagonist (Coumarin anticoagulants)|
40945198|NCT02715401|DRUG|HCP1303|
40945199|NCT02715401|DRUG|HGP1201|
40945200|NCT02715401|DRUG|HIP1402|
41285914|NCT04627545|OTHER|2h exposure to sperm for IVF|Oocytes will only be briefly (2h) exposed to progressive motile sperm for insemination
41285915|NCT04627545|OTHER|overnight exposure to sperm for IVF|Oocytes will be exposed for a longer duration (overnight, 16-20h) to progressive motile sperm for insemination
40945201|NCT01936077|DRUG|Recombinant LH (Luveris)|150 IU recombinant LH daily.
40945202|NCT06074861|PROCEDURE|Fasting-mimicking diet + non-surgical periodontal therapy|Test group will receive a full-mouth non-surgical periodontal therapy (also named professional mechanical plaque removal-PMPR) and, in the same day (starting at morning), a fasting-mimicking diet (FMD) will be started (for a cycle of 5 days). Other two cycles of FMD will be followed at 45- and 85- days after treatment, respectively.
40945203|NCT00427271|DRUG|aspirin|
40945204|NCT04532502|DRUG|Anesthetics, Inhalation|Work environmental exposure
40945205|NCT03563976|OTHER|Retrospective Study|The medical charts are the subjects. The institutional charts will be identified by the use of definitive radiation therapy correlating with an early stage lung cancer diagnosis during the above time frame. The data from these charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number. These are all patients treated by all hospitals and clinics affiliated with UTSW and Parkland. At the time of study, some of the patients will have expired but some will be alive and in the regional North Texas area. Thus, given the minimal risk nature of this retrospective chart review, we could not reasonably conduct this research with a full waiver of consent. The NLST external dataset is proved by the NCI, with no identifying characteristics.
40945206|NCT02836353|DRUG|Somatostatin|Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
40945207|NCT02836353|DRUG|Rifaximin|1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
40945208|NCT03550885|OTHER|High taurine and saturated fat diet|This is a 3-week (21 day) isocaloric Western-type diet with all meals, snacks, beverages and condiments provided.
40945209|NCT03550885|OTHER|Low in taurine and saturated fat diet|This is a 3-week (21 day) isocaloric largely plant-based diet with all meals, snacks, beverages and condiments provided.
40945210|NCT06132308|PROCEDURE|PENG Block with 0.25% bupivacaine|Peng block was performed.
41285916|NCT00036790|DRUG|doxorubicin hydrochloride|
40945211|NCT02963935|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
40945212|NCT02963935|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
40945213|NCT02963935|BEHAVIORAL|CMS Intensive Behavior Therapy|Intensive Behaviour Therapy for obesity
40945214|NCT03111173|DEVICE|Holter Device|MyECG E3.80 Holter Recorder
41285917|NCT00036790|DRUG|motexafin gadolinium|
41285918|NCT03338946|DEVICE|CIED interrogation|CareLink Express interrogation
41285919|NCT00932087|PROCEDURE|Blood sample|Blood sample for lipidomic study
40945215|NCT03507062|OTHER|0.9% saline administration|Each patient will receive 0.9%saline based on attending physician decision
40945216|NCT03507062|OTHER|Ringer's lactate administration|Each patient will receive Ringer's lactate based on attending physician decision
40945217|NCT03507062|OTHER|Plasmalyte-like solution administration|Each patient will receive Plasmalyte-like solution based on attending physician decision
40945218|NCT02835131|DRUG|Pasireotide|
40945219|NCT05975359|DEVICE|Interi Manifold Drain System|The Interi manifold surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the interi drain will be monitored daily and the Interi drain will remain in the surgical site until criteria for drain removal are met. Removal of the Interi drain will be performed in clinic by surgical staff.
41285920|NCT04101110|OTHER|Renal biopsy|Kidney biopsy will be done to understand the nature and degree of structural kidney damage
41285921|NCT04353947|DIAGNOSTIC_TEST|Mini Cognitive Examination (MCE)|This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.
41285922|NCT04353947|DIAGNOSTIC_TEST|Beck Depression Inventory-II (BDI-II)|This test evaluates the absence or presence of depressive symptoms.
41285923|NCT04353947|DIAGNOSTIC_TEST|Global Deterioration Scale (GDS)|This scale measures the level of deterioration of the subject.
41285924|NCT04353947|DIAGNOSTIC_TEST|Memory alteration test (M@T)|In this test different memory subtypes are evaluated.
41285925|NCT04353947|DIAGNOSTIC_TEST|Spanish-Complutense Verbal Learning Test (TAVEC)|This test is used to assess immediate memory, deferred memory and learning ability.
41285926|NCT04353947|DIAGNOSTIC_TEST|Barcelona test (BT)|"This test evaluates categorical evocation and verbal fluency. The categorical recall subtest consists of recalling the maximum number of words linked to a specific category animals in 1 minute. In the case of verbal fluency, the subject is asked to evoke the maximum number of words that begin with the letter p in 3 minutes."
40945220|NCT05975359|DEVICE|Jackson Pratt Drain System|The Jackson Pratt surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the Jackson Pratt drain will be monitored daily and the drain will remain in the surgical site until criteria for drain removal are met. Removal of the Jackson Pratt drain will be performed in clinic by surgical staff.
40945221|NCT03393312|DEVICE|Transcranial direct current stimulation (tDCS)|Electric current
40757420|NCT04297774|BEHAVIORAL|standard treatment|18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
41285927|NCT04353947|DIAGNOSTIC_TEST|Rey-Osterrieth Complex Figure Test (ROCFT)|In this test, the person must carefully copy a complex geometric drawing, which must be memorized later. The first part evaluates multiple cognitive processes such as planning, motor skills, working memory, and visual-constructive and spatial skills. In the second part, memory is evaluated.
41285928|NCT04353947|DIAGNOSTIC_TEST|Frontal assessment battery (FAB)|This test is a composite tool for assessing executive functions related to the frontal lobe.
40945222|NCT02207023|BEHAVIORAL|Healthy Lifestyle Training Program|Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.
40945223|NCT00389727|DRUG|Radiotherapy|Radiotherapy
40945224|NCT02395783|DRUG|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
40945225|NCT02395783|DRUG|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
40945226|NCT02395783|OTHER|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
41285929|NCT04353947|DIAGNOSTIC_TEST|Positive and Negative Affect Scale (PANAS)|It is a self-report questionnaire made up of 20 items (10 of positive affect and another 10 of negative affect) that the subject must answer, obtaining in this way a score in positive affectivity (AP subscale) and another in negative affectivity (AN subscale).
41285930|NCT04353947|DIAGNOSTIC_TEST|Auto-Assessment Manikins (SAM)|It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes.
41285931|NCT01954290|DRUG|Conivaptan|Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
41285932|NCT01954290|DRUG|Hypertonic saline|Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
41285933|NCT01954290|DRUG|Mannitol|Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
41285934|NCT05060042|OTHER|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week
41285935|NCT05060042|OTHER|Bilateral proprioceptive training|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
41285936|NCT04352660|DRUG|Mitomycin-C injection|MMC delivered by preoperative subconjunctival injection
41285937|NCT04352660|DRUG|Mitomycin-C sponge|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
41452333|NCT04935905|DEVICE|Mechanical Insufflator-Exsufflator|This device augments a cough by applying a positive pressure via the upper airway or tracheostomy to increase lung volume to maximal inspiratory capacity, followed by a rapid and quick change to negative pressure to increase expiratory flow and simulate normal cough mechanism
40757421|NCT04297774|BEHAVIORAL|balance training|18 balance training sessions (30 minutes a time, 2-3 times a week) (1) Facilitated the balance reaction through weight shifting exercise with standing on even surface to uneven surface, such as tilting board.(2) Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. (3) Changed the standing requirement, such as single legged stance or lunge stance. (4) Increased perception complications through cognition or upper extremity task to improve dual task attention.
40757422|NCT01885338|DRUG|N-acetylcysteine (NAC)|
40945227|NCT02993718|DRUG|Dexmedetomidine|As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
41285938|NCT04098380|PROCEDURE|Small Bite|the bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
41285939|NCT04098380|PROCEDURE|Larger bite|the bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
41285940|NCT06399549|DIAGNOSTIC_TEST|Dead bug exercise|the participant in supine, lying on a mat with shoulders, hip joints and knees flexed to 90°. With the lumbopelvic region being maintained in the neutral position, the participant will be instructed to draw in the abdomen, lower two contra lateral limbs (opposite arm and leg) toward the floor, hold for the stipulated time, then return to starting position. The same movement will be repeated with the opposite limbs. In the DBG, both pairs of limbs will be moved an equal number of times withinthe stipulated time. The patients in both groups will perform the corresponding exercises 3 days a week for a period of 3 weeks and a rest interval of 2 minutes between exercises along with conventional physiotherapy exercises.
41452334|NCT06420076|BIOLOGICAL|CD5/CD7 CAR-T|"The intervention in this clinical trial involves a novel approach using CD5/CD7 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD5/CD7 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD5/CD7 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD5/CD7 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
41452335|NCT04941638|PROCEDURE|Distal radial access|Vascular access for primary PCI in patients with STEMI
40757423|NCT01885338|DRUG|Inactive placebo capsule|
40757424|NCT04019704|DRUG|AXS-05|Oral AXS-05 tablets, taken daily for 6 weeks.
40757425|NCT04019704|DRUG|Placebo|Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
40757426|NCT05301699|OTHER|data analysis; validating the nomogram|Not Applicable. Our study did not involve intervention
40757427|NCT03199651|OTHER|Best Practice|Receive usual care
41452336|NCT01988636|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
41452337|NCT01988636|DRUG|Placebo|Placebo
41452338|NCT02426450|PROCEDURE|RFA|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics)."
40757428|NCT03199651|PROCEDURE|Biospecimen Collection|Undergo collection of tumor tissue and blood sample for repository
41452339|NCT02426450|DRUG|Oxaliplatin|4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
41452340|NCT02426450|DRUG|5-Fluorouracil/Leucovorin|"4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
40945228|NCT02993718|DRUG|Propofol|Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
40945229|NCT01941693|BEHAVIORAL|Integrated care|Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.
40945230|NCT01941693|BEHAVIORAL|Usual care|Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
40945231|NCT05428293|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)|Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
40945232|NCT05428293|DRUG|A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
40945233|NCT05428293|DRUG|A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
40945234|NCT03509610|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
40945235|NCT03714308|DRUG|Ivt. Aflibercept (Eylea, BAY86-5321)|Treatment is applied according to routine clinical practice and independent of the study setting.
40945236|NCT03401736|DEVICE|Mechanical Ventilation|Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.
41452341|NCT06561984|BEHAVIORAL|antenatal education|Giving educational sessions to the intervention group regarding modes of delivery
41452342|NCT00464763|DRUG|Dexmedetomidine|
41452343|NCT00464763|DRUG|Placebo|
41452344|NCT04820322|OTHER|Fibersym|RS4-type resistant modified wheat starch
41452345|NCT04820322|OTHER|Control cookie|control cookie
40757429|NCT03199651|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample for AGIT/DS
40757430|NCT03199651|OTHER|Laboratory Biomarker Analysis|Correlative studies
40757431|NCT03199651|OTHER|Medical Chart Review|Undergo medical record abstraction
40757432|NCT03199651|OTHER|Quality-of-Life Assessment|Ancillary studies
40945237|NCT03401736|DRUG|Midazolam|The impact of Midazolam on the diversity of intestinal microbiota.
40945238|NCT03401736|DRUG|Dexmedetomidine|The impact of dexmedetomidine on the diversity of intestinal microbiota.
40945239|NCT01565642|BEHAVIORAL|Goals of care decision support|Decision aid and care plan meeting
40945240|NCT04625816|DEVICE|whole body tilt device (Spine Balance 3D)|The symmetry of the deep muscle was evaluated using a whole body tilt device (Spine Balance 3D, Cyber Medic Co., Ltd., Korea). Spine Balance 3D can evaluate the maintenance strength and maximum strength of the core muscles, and perform a personalized core muscle training program based on the evaluated results.
40945241|NCT00355654|BIOLOGICAL|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
40945242|NCT00355654|BIOLOGICAL|DT3aP-HBs-IPV|0.5 mL, IM
40945243|NCT03796832|DEVICE|Flat Flexible Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \<15 mm, (ii) shoe pitch \<10 mm, (iii) absent arch support/motion control, (iv) minimal sole rigidity, (v) weight \<=200g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
40945244|NCT03796832|DEVICE|Stable Supportive Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \>30 mm, (ii) shoe pitch \>10 mm, (iii) present arch support/motion control, (iv) sole rigidity, (v) weight \>300g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
41132733|NCT02491489|OTHER|Glenohumeral mobilization|Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (\~50 degrees abduction, slight horizontal adduction, external rotation).
41132734|NCT06455306|PROCEDURE|Air-polishing with erythritol at different time points|The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline, 1 month and 2 months
41132735|NCT06455306|PROCEDURE|Single Air-polishing with erythritol|The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline only.
41132736|NCT01502813|DRUG|Citicoline, Omega-3 Fatty Acids and Creatine|Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
41452346|NCT05591729|OTHER|Pilates exercises|Each Pilates session will last for one hour. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centering which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the craniocervical junction). A pilates exercise program will consist of 11 levels of treatment program.
41452347|NCT05591729|OTHER|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push-up-plus, head-neck-retraction, and Kibler squeeze
41452348|NCT04403035|DIAGNOSTIC_TEST|ID NOW vs. Accula|Comparison of the ID Now assay vs. the Accula assay in detecting Covid-19.
41452349|NCT00101439|DRUG|ezetimibe|
40757433|NCT03199651|OTHER|Questionnaire Administration|Ancillary studies
40757434|NCT03199651|BEHAVIORAL|Smoking Cessation Intervention|Undergo usual care or NCCN-driven CTC/DS
40757435|NCT05814614|OTHER|pelvic physical therapy|Pelvic floor muscle exercises, biofeedback, bladder training
41452350|NCT00101439|DRUG|Comparator: placebo|
41452351|NCT05612958|DEVICE|DKM-410|Injection up to 2.0ml
41452352|NCT05612958|DEVICE|Juvederm ULTRA PLUS XC 1.0ml|Injection up to 2.0ml
41452353|NCT01949922|PROCEDURE|Injection of autologous muscle fibers into the anal sphincter.|
40757436|NCT04795453|OTHER|score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
40757437|NCT04795453|OTHER|usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
40757438|NCT04002557|OTHER|Interview-Questionnaire|Questionnaire
40757439|NCT01783236|DRUG|IV Acetaminophen|1000mg IV Ofirmev given every six hours for a total of four doses.
41452354|NCT01949922|PROCEDURE|Pelvic floor muscle training|Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
41452355|NCT01949922|BEHAVIORAL|Dietary intervention|Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
41452356|NCT01949922|DRUG|Analgesia|Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
41452357|NCT03256396|PROCEDURE|PEEP setting based on esophageal pressure measured|PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
40945245|NCT03796832|OTHER|Exercise Therapy|The 3-month supervised exercise program will consist of one group session per week of approximately 30 minutes complemented with home-based exercises 3 times per week. Group sessions will consist of a 10-min warm-up followed by a circuit training of strengthening and/or neuromuscular exercises. Subsequently, during a 6-month unsupervised home exercise program, participants will perform strengthening exercises of the lower limb muscles 3 times weekly. Throughout the 9-month intervention, participants will be encouraged to maintain a daily routine of aerobic exercises, consisting of structured activity bouts of at least 10 minutes at a moderate intensity (grade 5-6 (out of 10, maximum exertion) on a Rate of Perceived Exertion scale), achieving at least 70 minutes of weekly physical activity at 3 months and 150 minutes at 9 months.
40945246|NCT02714907|DEVICE|Cortrium C3 device|Data is read from Cortrium C3 monitor
40945247|NCT02714907|DEVICE|Holter device|Date is read from Holter device
41285941|NCT06399549|DIAGNOSTIC_TEST|The McGill Curl Up|"Lie down on your back. Extend one leg and bend the knee of the other leg. The Side Bridge. Lie on your side, with your forearm on the floor and elbow underneath your shoulder.~The Bird Dog. Assume a hands-and-knees position on the floor. The patients in both groups will perform the corresponding exercises 3 days a week for a period of 3 weeks and a rest interval of 2 minutes between exercises along with conventional physiotherapy exercises. The exercise program includes a warm-up session of five exercises (awareness of the back, pelvic tilt, lumbar rotation, arm movements, whole-body movement in standing), well-known exercises targeting the muscles of the back extensors, abdominals, lateral buttocks, trunk rotators, posterior buttocks, leg muscles, oblique abdominals (e.g. the plank, diagonal arm and leg lift), as well as exercises for flexibility. The exercises will be taught to the patients at the end of the first session in both groups."
41285942|NCT05466110|DEVICE|Spinal Cord Stimulation|Epidural application of electrical current to the spinal cord
41285943|NCT05466110|PROCEDURE|Spinal Fusion Surgery|screw-rod system based spinal instrumentation
41285944|NCT05355012|OTHER|5A organizational innovation|"This project is based on three strategic axes:~* A gradation of the care offer allowing to adapt the means and resources mobilized on the territory~* Personalized care by developing specific treatment paths based on the risk factors and/or vulnerabilities of the pregnant woman~* Coordination of territorial resources to support pregnant women in quitting smoking These three key elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population."
41285945|NCT04862637|PROCEDURE|pull through group|pull through method
41285946|NCT04862637|PROCEDURE|mandibular-lip split group|traditional mandibular-lip split method
41285947|NCT04889703|DRUG|15% Trichloroacetic acid peel|Trichloroacetic acid peel (15%) will be applied topically to the face for 2 treatments at 4 week intervals.
40757440|NCT01783236|DRUG|Saline Placebo|Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
41285948|NCT04889703|DRUG|30% Salicylic acid peel|Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4 week intervals.
41285949|NCT04691661|DRUG|Radotinib HCl 50 mg|Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
41285950|NCT04691661|DRUG|Placebo|Placebo
41285951|NCT00064701|DRUG|Tacrolimus Modified Release (MR)|The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
41285952|NCT00064701|DRUG|Tacrolimus|The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
41285953|NCT00064701|DRUG|cyclosporine microemulsion|The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
41285954|NCT00064701|DRUG|mycophenolate mofetil|Oral
41452358|NCT06411873|DIETARY_SUPPLEMENT|Control Group|Composition of formula per 100 mL : energy (100 kcal), protein (3 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 12%, osmolarity (310 mOsm/L), renal solute load/RSL (27.5 mOsm/100 kcal)
41452359|NCT06411873|DIETARY_SUPPLEMENT|Intervention Group|Composition of formula per 100 mL : energy (105.5 kcal), protein (4.35 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 16.5%, osmolarity (333.5 mOsm/L), renal solute load/RSL (27.7 mOsm/100 kcal)
40757441|NCT02852005|BIOLOGICAL|MVA/HIV62B vaccine|1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
40945248|NCT05320185|DEVICE|RuiXin-CoronaryAI software|RuiXin-CoronaryAI, based on Computed Tomography Angiography (CTA) and was independently designed by RaysightMed Inc., which has been already authorized by National Medical Products Administration (NMPA).
41452360|NCT04133311|DRUG|DE-130A|Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.
41452361|NCT04133311|DRUG|Xalatan®|Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.
40757442|NCT02852005|BIOLOGICAL|AIDSVAX B/E vaccine|600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid
40757443|NCT02852005|BIOLOGICAL|Placebo|Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid
40945249|NCT02063711|BEHAVIORAL|Yoga intervention|
41452362|NCT04133311|DRUG|DE-130A/DE-130A|After Week 12, received DE-130A continuously.
40757444|NCT06386874|DEVICE|BQ 3.0 system|frequency and intensity parameters will be set to zero so that no stimulation is delivered
40757445|NCT06386874|DEVICE|BQ 3.0|The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
41285955|NCT06067113|PROCEDURE|Supraaortic and transcranial duplex|Ecographic evaluation of supraaortic and transcranial arteries, including presence of plaques, flow velocities and pulsatility index
41285956|NCT02669563|DRUG|[18F]4F-MHPG|IV injection of \[18F\]4F-MHPG
41132737|NCT02170259|OTHER|The suboccipital technique|"The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region. Patients lied on the stretcher, in supine position, with their occiput resting against the physiotherapist's hands. Fingertips slide until contacting the posterior arch of atlas so that it hangs from the fingers. A deep and progressive pressure is applied, perpendicularly to muscle fibers, until the therapist perceives that muscle tone decreases. Approximate duration of ST is 10 minutes and it is performed with patients' eyes closed because of the connection between craniocervical muscle tone and eye movements"
40945250|NCT06558006|DRUG|Predimenol tablet|2 tablets of Predimenol (400 mg Predimenol) will be taken with 220 mL of water (one glass of water).
40945251|NCT06558006|DRUG|Predimenol tablet + Placebo tablet of Predimenol|1 tablet of Predimenol (200 mg Predimenol) + 1 tablet of placebo will be taken with 220 mL of water (one glass of water).
41132738|NCT02170259|OTHER|The articulatory technique|The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
41132739|NCT02170259|OTHER|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
41132740|NCT00853528|OTHER|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
41132741|NCT00853528|PROCEDURE|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
41132742|NCT00853528|PROCEDURE|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
41132743|NCT00853528|RADIATION|hypo-fractionated SRS|two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
41285957|NCT02669563|DRUG|[18F]3F-PHPG|IV injection of \[18F\]3F-PHPG
41452363|NCT04133311|DRUG|Xalatan®/DE-130A|From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.
41452364|NCT04309773|DRUG|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy Treatment duration : 24 months Bezafibrate/AUDC : daily oral dose
40757446|NCT00694928|DRUG|clindamycin phosphate/butoconazole nitrate|semi-solid, single dose
40757447|NCT00694928|DRUG|butoconazole nitrate|semi-solid, single dose
40757448|NCT00933166|DEVICE|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
41285958|NCT02669563|DRUG|[13N]ammonia|IV injection of \[13N\]ammonia
41285959|NCT02669563|DRUG|[11C]HED|IV injection of \[11C\]HED
41285960|NCT06427889|DRUG|Canoderm|humectant
41452365|NCT04309773|DRUG|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate (400mg) in addition to standard 15-20 mg/kg/Day UDCA therapy Treatment duration : 24 months Placebo/AUDC : daily oral dose
40945252|NCT06558006|DRUG|Placebo tablet of Predimenol|2 tablets of placebo tablet of Predimenol will be taken with 220 mL of water (one glass of water).
41132744|NCT00853528|RADIATION|single-fraction SRS|two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
41132745|NCT02168309|DRUG|Labetalol|Titrate up for blood pressure control
41132746|NCT02168309|DRUG|Nifedipine|Titrate up to achieve blood pressure control
41132747|NCT01450007|DRUG|Ropivacaine|25 ml ropivacaine 0.5%
41132748|NCT01450007|DRUG|Dexamethasone|8 mg dexamethasone (perineural)
41132749|NCT01450007|DRUG|Dexamethasone|8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)
41132750|NCT01450007|DRUG|Normal saline|5 ml normal saline (intravenous)
41285961|NCT06427889|DRUG|Oviderm|humectant + antimicrobial
41285962|NCT06427889|DRUG|Decubal|Non-humectant
41285963|NCT02029430|DRUG|50 mg/m2 aldoxorubicin|
41285964|NCT02029430|DRUG|100 mg/m2 aldoxorubicin|
41285965|NCT02029430|DRUG|150 mg/m2 aldoxorubicin|
41285966|NCT01520792|DRUG|Paracetamol (drug)|Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
41285967|NCT05295329|DRUG|Compound Danshen Dropping Pills|use Compound Danshen Dropping Pills
41285968|NCT05295329|DRUG|Placebo|use placebo
41285969|NCT05265351|DIAGNOSTIC_TEST|Transdiaphragmatic pressure measurement|Ultrafast ultrasound imaging of the diaphragm during artificially evoked responses
41452366|NCT01322633|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
41452367|NCT01322633|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
41285970|NCT05265351|DIAGNOSTIC_TEST|EMG|Surface electromyography of the diaphragm for phrenic nerve conduction study
41285971|NCT00248950|BEHAVIORAL|Positive affect induction and /or self affirmation induction|
41285972|NCT01165008|DRUG|Anakinra|
41285973|NCT00405041|DIETARY_SUPPLEMENT|Dietary supplement GVG 2|2.670 g/day for 14 days
41452368|NCT02315963|OTHER|Performance Feedback|Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
41132751|NCT01450007|DRUG|Normal saline|0.8 ml normal saline (perineural)
40945253|NCT04756869|OTHER|COVID-19 Monitoring Using Wearable Sensors and Smartphone Technology|Health care workers are on-study for 30 days, in which they wear a smart watch and temperature patches up to daily. Subjects also may provide nasal and saliva samples up to daily during the study period, and they may opt-in to blood samples lasting up to 1 year after study completion. Through a smartphone app, participants complete surveys at baseline and at study completion, as well as daily mood surveys and symptom-reporting surveys. Finally, exit interviews occur at the end of the study period, and follow-up interviews may occur at specified timepoints up to 1 year after study completion.
41132752|NCT02311062|OTHER|Eccentric hamstring exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
40945254|NCT06352658|DEVICE|Conventional mandibular advancement device|With a vacuum mahine (Biostar, NY) a 2-mm-thick hard, clear resin sheet was adapted to the cast. The excess material was cut, borders were trimmed and smoothed. Maxillary mandibular casts were mounted by a protrusive the interocclusal record. The appliances were re-placed on the mounted casts to be splinted to form a Monoblock MAD by autopolymerizing acrylic resin at the premolar -molar area.
40945255|NCT06352658|DEVICE|CAD CAM mandibular advancement device|"3D models for the stone casts were constructed with laser scanning machine (accuracy \<20 µm; D500, 3shape).~Maxillary and mandibular casts were rescanned in the achieved 75% advancement position and monoblock device was designed by CAD (computer-aided design) with 3D software (3-matic; Materialise) and printed by"
41285974|NCT01491945|DEVICE|Ventana Fenestrated Stent Graft System|"The Ventana Fenestrated Stent Graft System consists of the following:~bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts"
41285975|NCT01815684|DRUG|ASP3652|Oral
41452369|NCT00862212|BEHAVIORAL|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
41452370|NCT05644392|DRUG|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
41452371|NCT05644392|DRUG|Regorafenib|Regorafenib 80mg, po, orally once daily
41452372|NCT05689541|OTHER|Mobile app intervention|"A mobile-based application will be developed to provide parents with a supplemental curriculum that will include games and activities focusing on motor outcomes. The focus of these games and activities will correspond with the adapted horseback riding program's weekly lesson plan. The mobile app will be created with Glide, which allows us to create a mobile application with basic spreadsheet skills.~The mobile app will aim to incorporate 10-12 games and activities designed to improve specific motor outcomes. Parents will be instructed to partake in the app-delivered activities with their children daily for at least 30-45 minutes."
40945256|NCT02746068|DRUG|AXS-02|
40945257|NCT02746068|DRUG|Placebo|
40945258|NCT03725215|BEHAVIORAL|Split-Belt Treadmill Training|One session of 6 x 5 min with 1 min intervals.
40945259|NCT05560776|PROCEDURE|Endobronchial ultrasound|Two or three passes per lymph node
40945260|NCT01601431|DEVICE|Cap Assisted Colonoscopy|Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate
40945261|NCT01601431|DEVICE|Conventional colonoscopy|Regular colonoscopy as per standard clinical guidelines
41132753|NCT02311062|OTHER|Unistable exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
41132754|NCT02311062|OTHER|Control|Only soccer training
41132755|NCT01436175|DRUG|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
41285976|NCT01815684|DRUG|Placebo|Oral
41285977|NCT04701411|BIOLOGICAL|Darvadstrocel|Darvadstrocel perilesional injection.
41285978|NCT02265211|BEHAVIORAL|Self-Help App|
41285979|NCT00465738|DRUG|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)"|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride \[NaCl\] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
41285980|NCT05315440|OTHER|graston tecnique|Graston technique involves the use of steel tools that are used non-invasively on the skin to identify and treat areas that have stiffness or inflammation. These areas can be located with greater precision than the manual technique precisely because the instruments do not compress in contact with the patient's skin, as is the case with the physiotherapist's fingertips. Thanks to the instruments it is therefore possible to detect the areas of altered consistency and to treat them by pressing a minimum pressure.
41285981|NCT05315440|OTHER|Conventional rehabilitation|30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
41285982|NCT02542345|PROCEDURE|magnetic resonance imaging|
41285983|NCT03020511|OTHER|Ancient wheat flours|Ancient wheat flours will be administered in open label for 30 days
41285984|NCT02589587|PROCEDURE|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
41285985|NCT02589587|OTHER|no intervention|lean control group
41285986|NCT00003176|DRUG|carmustine|
41285987|NCT00003176|DRUG|temozolomide|
41285988|NCT01718717|OTHER|Thoracic Epidural Analgesia (TEA)|
41285989|NCT01718717|OTHER|TEA followed by Intravenous morphine|
41452373|NCT02068651|BEHAVIORAL|Advance care planning programme|It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
41132756|NCT01968824|PROCEDURE|Brachial Plexus Nerve Block|The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
41285990|NCT04012411|PROCEDURE|Brain MRI|Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
41285991|NCT04012411|PROCEDURE|Lumbar Punction|Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
41285992|NCT04012411|GENETIC|Blood sample|Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
41452374|NCT04003441|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
41452375|NCT04003441|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
41132757|NCT02950883|DRUG|Active Treatment Group 7% Hypertonic Saline|"Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline"
41132758|NCT02950883|DRUG|Control Group 0.9% Isotonic Saline|"Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline"
41132759|NCT03857321|DRUG|Insulin|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly \& Company)
41132760|NCT03857321|OTHER|Placebo|Matching placebo (sterile saline) to 20 IU Humulin® R U-100
41132761|NCT03857321|DEVICE|intranasal nebulizer-like device|Participants will be assigned to receive placebo or regular insulin (U100, 20 IU) administered through an intranasal nebulizer-like device.
41132762|NCT03664882|DRUG|Fexofenadine M016455|Pharmaceutical form: tablet Route of administration: oral
41132763|NCT03664882|DRUG|Placebo|Pharmaceutical form: tablet Route of administration: oral
41132764|NCT05842265|OTHER|Self acupressure|patients will do self acupressure
41285993|NCT04012411|OTHER|Cognitive evaluation|Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
41285994|NCT00744367|DRUG|metformin|\>1500 mg/day or maximum tolerated dose (MTD)
41285995|NCT00744367|DRUG|pioglitazone|\>= 30 mg/day
41285996|NCT00744367|DRUG|placebo|sc once weekly
41285997|NCT00744367|DRUG|taspoglutide|10 mg sc once weekly;
41285998|NCT00744367|DRUG|taspoglutide|20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
41285999|NCT05941052|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|The investigators will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
41452376|NCT00115063|BEHAVIORAL|group sessions|group sessions lead by a trained primary care clinic employee
41286000|NCT01850810|OTHER|Experimental Study Product|
40945262|NCT02284360|DRUG|APOSEC™ for cutaneous use|"On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure."
41452377|NCT00115063|DRUG|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
41452378|NCT00115063|BEHAVIORAL|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
41452379|NCT00115063|OTHER|Intensive Medical Combination Therapy for Obesity|"Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox."
41286001|NCT01850810|OTHER|Control Study Product|
41286002|NCT00690872|BIOLOGICAL|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
40945263|NCT05716399|DEVICE|Transcutaneous electric stimulation pretreatment|Within 30 minutes before spinal anesthesia or 30 minutes after hypotension, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points, and the current intensity was only as high as the patient could comfortably tolerate (the electrical stimulation intensity was 2-3 times of the sensory threshold, for example, if the electrical stimulation intensity was 5 mA, 10-15 mA was used for stimulation), Record the specific value of current. FTEAS group pastes electrode piece, turns on the power, but there is no current output.
41286003|NCT00690872|DRUG|carboplatin|
41286004|NCT00690872|DRUG|gemcitabine hydrochloride|
41286005|NCT00690872|GENETIC|polymerase chain reaction|
41286006|NCT00690872|OTHER|fluorescence activated cell sorting|
41286007|NCT00690872|OTHER|immunoenzyme technique|
41286008|NCT00662155|DRUG|Zolpidem|sedative-hypnotic
41452380|NCT00115063|OTHER|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
41452381|NCT00414726|DRUG|NBO (Normobaric Oxygen)|High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
41452382|NCT00414726|DRUG|Room Air|Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
41132765|NCT05686499|OTHER|Didactic Lectures and demonstrations|"1. Trainees will receive 4-6 hours of didactic colonscopy lecture sessions based on the American Board of Surgery Flexible Endoscopy curriculum for general surgery residents, general surgery resident curriculum (SCORE) endoscopy module, and the Joint Advisory group on GI Endoscopy program adapted to Nigeria context.~2. Trainees will have the opportunity to practice colonoscopy on HF or LF simulators (depending on the arm) with immediate feedback from instructors."
40945264|NCT05716399|DEVICE|Transcutaneous acupoint electrical stimulation treatment|Transcutaneous acupoint electrical stimulation treatment
41132766|NCT03464955|BEHAVIORAL|Technology Based Distractions|Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
41286009|NCT00662155|DRUG|Placebos|Placebo
41286010|NCT02696746|OTHER|Observation|No intervention
41286011|NCT04923373|OTHER|telerehabilitation|"Procedure for both groups:~I pre surgery evaluation~1. initial training in hospital~2. physiotherapeutic programme telerehabilitation versus standard 7 times a week~Therapy duration: 6 weeks post-surgery II 6weeks post-surgery evaluation"
41132767|NCT00199056|DRUG|Dexamethasone / Prednisolone|
41132768|NCT00199056|DRUG|Cyclophosphamide|
40945265|NCT05716399|DEVICE|Transcutaneous acupoint pseudo electric stimulation|Transcutaneous acupoint pseudo electric stimulation
40945266|NCT02301130|BIOLOGICAL|mogamulizumab|Mogamulizumab will be administered intravenously (IV).
40945267|NCT02301130|BIOLOGICAL|MEDI4736 (Durvalumab)|MEDI4736 will be administered intravenously (IV).
41132769|NCT00199056|DRUG|Methotrexate|
40945268|NCT02301130|BIOLOGICAL|tremelimumab|Tremelimumab will be administered intravenously (IV).
41132770|NCT00199056|DRUG|Vincristine / Vindesine|
41132771|NCT00199056|DRUG|Daunorubicin|
41132772|NCT00199056|DRUG|Asparaginase|
41132773|NCT00199056|DRUG|G-CSF|
41132774|NCT00199056|DRUG|Cytarabine|
41132775|NCT00199056|DRUG|6-Mercaptopurine|
41132776|NCT00199056|DRUG|VP16|
41132777|NCT00199056|DRUG|Adriamycin|
41132778|NCT00199056|DRUG|Thioguanine|
41132779|NCT00199056|DRUG|VM26|
41132780|NCT00199056|DRUG|Idarubicin|
41132781|NCT00199056|DRUG|Fludarabine|
41132782|NCT00199056|DRUG|Ifosfamide|
41132783|NCT00199056|PROCEDURE|CNS irradiation|
41286012|NCT04923373|PROCEDURE|standard physiotherapy|standard physiotherapy
41132784|NCT00199056|PROCEDURE|Mediastinal irradiation (if residual tumor)|
41132785|NCT00199056|PROCEDURE|stem cell transplantation|
41286013|NCT03708692|BEHAVIORAL|Group F|After general anesthesia, the time of return of the behaviors such as opening the eyes, fulfilling the orders or saying the age will be recorded and evaluated as the recovery criteria. In the postop recovery period, the patient will be subjected to mini mental state testing (MMST) and cognitive functions will be evaluated.
41286014|NCT02739412|BIOLOGICAL|Interleukin-2|Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
41286015|NCT00364910|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
40945269|NCT05272462|DRUG|Minoxidil|Minoxidil is an antihypertensive vasodilator medication commonly used for the treatment of high blood pressure and pattern hair loss.
41132786|NCT04757194|DIAGNOSTIC_TEST|openTriage - Alitis algorithm|A machine learning algorithm (Gradient boosting) applied to structured data collected in the Alitis Clinical Decision Support system, patient demographics, and free-text notes.
41132787|NCT03058757|DRUG|intravesical mitomycin-C 40mg/20ml instillation|"neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation~* one day before surgery~* four hours before surgery"
41132788|NCT06452069|OTHER|IMMUNO19|"280 participants will be divided into 2 groups. There will be 140 participants in the groups.~The 1st group will receive IMMUNO19 10 mL one time, The 2nd group will receive Placebo 10 mL for one time."
41132789|NCT05162560|OTHER|patients with acute diverticulitis|registry and hospital charts of patients with acute diverticulitis
41452383|NCT02878148|DEVICE|Diagnostic imaging modalities for suspected renal colic|"All patients with suspected acute uncomplicated renal colic included will undergo ultrasonography in addition to unenhanced CT of pelvis and abdomen and plain X-ray of the abdomen.~Imaging examination will be performed according to current guidelines.~Ultrasonography study and colour doppler will include the kidney, ureterovesical joint and ureters. Unenhanced CT will be performed using a dedicated low-dose protocol."
40945270|NCT05168449|OTHER|Mobile Application|mobile phone applications directed to chronic kidney disease patients to improve their medication.
41132790|NCT03789357|DIAGNOSTIC_TEST|Aldosterone renin ratio|Aldosterone Renin Ratio to screen for Primary Aldosteronism
41452384|NCT06123195|OTHER|Constipation treatment|Lactulose 15 mL (10 g) will be taken orally once daily (in the evening), which can be titrated at 1-week intervals in 15 mL (10 g) increments or decrements up to 60 mL (40 g) as a total daily dose.
41286016|NCT00364910|BEHAVIORAL|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
41286017|NCT02799381|DRUG|Optimized antiparkinsonian treatment|Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
41286018|NCT02799381|DRUG|Levodopa-Carbidopa Intestinal Gel (LCIG)|Dose levels were individually optimized.
41286019|NCT02799381|DEVICE|CADD-Legacy ambulatory infusion pump|(manufactured by Smiths Medical)
41286020|NCT02799381|DEVICE|Percutaneous endoscopic gastrostomy tube|(PEG tube)
41452385|NCT03448094|DIETARY_SUPPLEMENT|Resveratrol|Participants will consume one of the treatment types daily for a period of three months.
41452386|NCT03448094|DIETARY_SUPPLEMENT|Placebo|Participants will consume one of the treatment types daily for a period of three months.
41452387|NCT03222921|PROCEDURE|High tibial osteotomy|Patients undergoing high tibial osteotomy are investigated by a pressure insole for post-operative weight bearing behavior
41132791|NCT05585710|OTHER|Pulsed Lavage Washout|Use of pressurized, pulsed triple antibiotic solution to irrigate mastectomy pocket
41452388|NCT02941159|BIOLOGICAL|SF2000SD|This is an intergrase inhibitor
41452389|NCT02941159|BIOLOGICAL|Placebo|
41452390|NCT04268797|DEVICE|HR rTMS|high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days
41452391|NCT04268797|DEVICE|sham|SHAM HF rTMS coil once daily x 20 days
41132792|NCT05585710|PROCEDURE|Implant-based breast reconstruction|Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket
41132793|NCT05585710|PROCEDURE|Bilateral or unilateral mastectomy|Standard of care
41132794|NCT05585710|DEVICE|Tissue expander|Standard of care
41132795|NCT05585710|OTHER|Acellular dermal matrix|Standard of care
41132796|NCT01240707|OTHER|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
41132797|NCT04132154|PROCEDURE|Convective Forced-Air Active Warming|Underbody Blanket Model 585 of the 3M BairHugger Series
41286021|NCT02799381|DEVICE|Jejunal extension tube|(J-tube)
41286022|NCT01166269|BIOLOGICAL|phleum pratense (grass-allergen)|6 injections of grass-allergen. Every dose will be 1000 SQ-U.
41286023|NCT01166269|BIOLOGICAL|phleum pratense (grass allergen)|3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)
41286024|NCT01166269|OTHER|physiological saline|6 injections of placebo (physiological saline)in a lymph node.
41286025|NCT04064710|PROCEDURE|Vertebral Body Augmentation|Use allograft tissue in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.
41286026|NCT04064710|DEVICE|Manual Surgical Instruments|Lenoss Medical manual surgical access and cavity creation instruments will be used when implanting the allograft tissue.
41286027|NCT02128568|BEHAVIORAL|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
41287293|NCT01620996|BEHAVIORAL|Motivational Enhancement|"Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.~The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance~These stages are specific to different behaviours."
41452392|NCT01977456|DRUG|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
41452393|NCT01798628|DRUG|Treatment A: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
41452394|NCT01798628|DRUG|Treatment B: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
41132798|NCT04274790|PROCEDURE|Scheduled and planned surgery|Collection of tumour samples from samples collected as part of standard patient management. Diagnostic pathological analysis will be a priority. These samples will be taken by experienced staff during the hospital visit scheduled as part of standard care.
40757449|NCT06395766|DIAGNOSTIC_TEST|BREF,MSPSS|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL )~2. the Zimet Multidimensional Scale of Perceived Social Support -. The original version on the MSPSS"
41132799|NCT01959776|PROCEDURE|Vitrectomy|
40945271|NCT05038046|OTHER|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
40945272|NCT00839852|DRUG|Cariprazine|Cariprazine was supplied in capsules.
40945273|NCT03810339|DRUG|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
40945274|NCT00734370|BEHAVIORAL|Virtual Reality Exposure Therapy for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Virtual reality Exposure to agoraphobic situations and interoceptive exposure~* Relapse prevention"
41132800|NCT05183126|DRUG|Paclitaxel|Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. All other doses administered as a 1-hour infusion for a total of 12 weekly doses.
41132801|NCT05183126|DRUG|Paclitaxel|"Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion.~During doses 2-12, patients with low SMA will receive one 2-hour infusion and patients with sarcopenic SMA will receive one 3-hour infusion. All other doses during weeks 2-12 are standard infusion time."
41132802|NCT02508441|DRUG|Andes-1537 for Injection|"Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle~Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle"
41132803|NCT00186446|DRUG|bupropion and smoking cessation behavioral intervention|
41132804|NCT02078518|OTHER|Questionnaires|
40945275|NCT00734370|BEHAVIORAL|Standard exposure in vivo for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Standard exposure in vivo to agoraphobic situations and interoceptive exposure~* Relapse prevention (according to the protocol of Craske \& Barlow)"
40945276|NCT04515446|DIAGNOSTIC_TEST|Rapid test for diagnosis orientation|Rapid tests screen for influenza viruses in less than 30 minutes. They detect internal viral nucleoproteins by immunochromatography using specific antibodies attached to one or more strips.
40945277|NCT04515446|DIAGNOSTIC_TEST|quantitative PCR|Molecular biology method of gene amplification in vitro. It allows a large number of known DNA or RNA sequences to be duplicated
40945278|NCT05145192|DEVICE|COSMED K5 CPET (Cardiopulmonary Exercise Test)|In this randomized crossover trial of eligible adults, we will compare peak measurements of oxygen consumption (VO2) and carbon dioxide production (VCO2) during three maximal cardiopulmonary stress exercise tests (CPET), each seven to ten days apart. Subjects will be randomized into either the K5 or ParvoMedics (PM) group for their first CPET using a 1:1 randomization scheme and will serve as their own control in the subsequent test seven to ten days after the previous one. After both a K5 and a PM CPETs have been completed, the participants will complete an additional K5 CPET for test-retest reliability. A within-subjects analysis will be performed.
40945279|NCT05145192|DEVICE|ParvoMedics CPET|ParvoMedics CPET
40945280|NCT00876746|PROCEDURE|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
40945281|NCT03587948|DIAGNOSTIC_TEST|Diabetes mellitus|Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.
40945282|NCT02010827|BIOLOGICAL|isoglycemic intravenous glucose infusion and Glucagon infusion, day C|Infusion of 0.8ng/kg/min glucagon from time 0-25min
40945283|NCT02010827|BIOLOGICAL|Oral glucose tolerance test, day A|
40945284|NCT02010827|BIOLOGICAL|intravenous iv glucose infusion, day B|
40945285|NCT05226273|OTHER|no intervention|no intervention
40945286|NCT03547986|DIAGNOSTIC_TEST|Duplex Ultrasound (DUS)|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
40945287|NCT03547986|DIAGNOSTIC_TEST|IVUS with Intraarterial pressure measurement (IAP) if needed|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed
40945288|NCT06377306|BEHAVIORAL|Effect of training loads and sport performance level on health and sport performance|Effect of training loads and sport performance level on health and sport performance
40945289|NCT02549833|BIOLOGICAL|GBM6-AD and poly-ICLC before and after surgery|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
40945290|NCT02549833|BIOLOGICAL|GBM6-AD and poly-ICLC after surgery only|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
40945291|NCT00289367|DRUG|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
40945292|NCT00289367|DRUG|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
40945293|NCT02572609|DRUG|Ambroxol hydrochloride soft pastille|
41132805|NCT04039646|COMBINATION_PRODUCT|ERAS treatment|The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
40945294|NCT02572609|DRUG|Mucosolvan ® adult syrup|
40945295|NCT05334485|DRUG|Pyridostigmine Bromide|Oral 60mg pyridostigmine bromide
40945296|NCT05334485|OTHER|Placebo|Oral starch placebo
40945297|NCT02612038|DEVICE|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
40945298|NCT02612038|DEVICE|Sham expiratory resistance|Sham expiratory resistance will be added to the patient's respiratory circuit
40945299|NCT03893175|DRUG|Ibuprofen|400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
40945300|NCT03893175|DRUG|Acetaminophen|500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
40945301|NCT03893175|DRUG|Placebo|By mouth
40945302|NCT03893175|DRUG|Oxycodone|5 mg by mouth every 6 hours as needed for pain
40945303|NCT02643290|DEVICE|Peak Scoliosis Bracing System|Brace is fit to adult scoliosis patients for 2-4 hours a day and tracked for six months.
41132806|NCT01201772|DRUG|Prasugrel|Prasugrel 10mg, 30mg, or 60mg
41132807|NCT03987074|DRUG|Semaglutide|Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
41132808|NCT03987074|DRUG|Firsocostat|Tablets administered orally once daily
40945304|NCT03038568|DIAGNOSTIC_TEST|CT scan|Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
41132809|NCT03987074|DRUG|Cilofexor|Tablets administered orally once daily
41132810|NCT02076594|DRUG|Docetaxel|Powder for solution for infusion
41132811|NCT02076594|DRUG|Epirubicin|Solution for infusion
41132812|NCT02076594|DRUG|Oxaliplatin|Powder for solution for infusion
41132813|NCT02076594|DRUG|Capecitabine|Film coated tablets
41132814|NCT02399605|OTHER|Stimulation|Subcutaneous abdominal electrical stimulation
41132815|NCT03810170|BEHAVIORAL|safe sex and HIV/STD prevention education via a website|website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.
41132816|NCT03810170|OTHER|written materials on safe sex|2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
41452395|NCT01798628|DRUG|Treatment C: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
41132817|NCT06031818|OTHER|The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will fill in a questionnaire to evaluate the usability of the interpretable framework.
41287294|NCT00072189|DRUG|7-hydroxystaurosporine|Given IV
41452396|NCT02035163|PROCEDURE|Two sites cryoablation|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
41452397|NCT05424757|DRUG|PEG 3350|"Data and biospecimens will be collected from two groups of children:~* Children who have taken PEG 3350 daily for at least 30 days.~* Children who have NOT taken PEG 3350 for at least 30 days.~No changes to medicines are recommended as part of this study."
41452398|NCT00553124|DRUG|selenium|
41452399|NCT00553124|DRUG|vitamin E|
41452400|NCT00553124|PROCEDURE|biopsy|
40945305|NCT01555983|DRUG|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
41132818|NCT06031818|OTHER|The model prediction|The radiologist and clinicians will be provided the model prediction results without the explanation of the model and they will be asked to give their own prediction.
40945306|NCT05816096|COMBINATION_PRODUCT|Hall technique|The child will be placed to them SSC on one of their HSPM affected teeth. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
41132819|NCT06031818|OTHER|The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will be asked to give their own prediction.
41132820|NCT00881296|DRUG|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
41132821|NCT00881296|DRUG|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
41132822|NCT04198441|DEVICE|Wound dressing|Clean wound, fill wound, dress wound
41132823|NCT05706246|DIAGNOSTIC_TEST|diagnostics|Serum tryptase levels were evaluated in all suspected children with perioperative hypersensitivity
41132824|NCT02888821|BEHAVIORAL|CLS-FUERTE|The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
41132825|NCT01687920|DRUG|BAY94-8862 (1.25mg)|
41287295|NCT00072189|OTHER|laboratory biomarker analysis|Correlative studies
41287296|NCT00072189|OTHER|pharmacological study|Correlative studies
41452401|NCT00553124|PROCEDURE|chemoprevention|
40945307|NCT05816096|COMBINATION_PRODUCT|ART|The child will be restored to them one of their HSPM affected teeth by GIC. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
40945308|NCT05355610|DRUG|Gentamicin|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
41452402|NCT00553124|PROCEDURE|cryopreservation|
41452403|NCT00553124|PROCEDURE|cytology specimen collection procedure|
41452404|NCT00553124|PROCEDURE|diagnostic procedure|
41452405|NCT00553124|PROCEDURE|gene expression analysis|
41452406|NCT00553124|PROCEDURE|immunohistochemistry staining method|
41452407|NCT00553124|PROCEDURE|laboratory biomarker analysis|
41452408|NCT00553124|PROCEDURE|medical chart review|
41132826|NCT01687920|DRUG|BAY94-8862 (2.5mg)|
41452409|NCT00553124|PROCEDURE|mutation analysis|
40945309|NCT05355610|DRUG|Dexamethasone|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
41132827|NCT01687920|DRUG|BAY94-8862 (5mg)|
41132828|NCT01687920|DRUG|BAY94-8862 (7.5mg)|
41132829|NCT01687920|DRUG|BAY94-8862 (10mg)|
41132830|NCT01028287|DRUG|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
41132831|NCT01028287|DRUG|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
41132832|NCT01128595|DRUG|FF/GW642444M|
41132833|NCT01128595|DRUG|GW642444M|
41132834|NCT01128595|DRUG|Fluticasone Furoate|
41132835|NCT01128595|DRUG|Placebo|
41132836|NCT06511089|PROCEDURE|carotid artery stenting during EVT|"Patients with an ipsilateral high grade carotid artery stenosis or occlusion of presumed atherosclerotic origin and an proximal intracranial large vessel occlusion in the anterior circulation will be randomized using a web-based randomization tool to immediate carotid artery stenting or deferred treatment strategy of carotid artery stenosis.~In the intervention group, the cervical carotid artery lesion will be treated with a stent during the EVT (just before or directly after intracranial thrombus removal), the control group will be treated according to the national guidelines with carotid endarterectomy of carotid artery stenting (for patients with non-disabling stroke) or medical management alone (for patients with severe disabling stroke)."
41132837|NCT06511089|OTHER|no carotid artery stenting during EVT|A deferred treatment approach: carotid revascularization within two weeks after stroke onset or best medical management only, depending on the functional recovery of the patient.
41132838|NCT01934036|DIETARY_SUPPLEMENT|Obex|After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.
41132839|NCT01934036|DRUG|Placebo|After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
41132840|NCT00000215|DRUG|Pergolide|
41132841|NCT04642898|BEHAVIORAL|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
41452410|NCT00553124|PROCEDURE|polymerase chain reaction|
41452411|NCT00553124|PROCEDURE|quality-of-life assessment|
41452412|NCT00553124|PROCEDURE|questionnaire administration|
41452413|NCT00553124|PROCEDURE|study of socioeconomic and demographic variables|
41286028|NCT04323501|OTHER|Experimental treatment|"Exercises may include UPPER LIMB Passive exercises (stretching), each one greater or equal to 10 minutes; greater or equal once a day: pectoralis; back muscles and triceps; subscapular muscle; elbow flexor; both pronator muscles; flexor of the wrist and fingers; flexor, adductor and opponent muscles of the thumb.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: shoulder abduction, flexion, external rotation; elbow extension and supination; wrist extension; finger extension; thumb extension and abduction.~LOWER LIMB Passive exercises, each one greater or equal to 10 minutes; greater or equal once a day: hamstring; adductor of the hip; gluteus muscles.~Greater or equal to 5 minutes; greater or equal to twice a day: soleus and gastrocnemius.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: hip abduction and flexion; knee flexion; dorsiflexion of ankle; seat-standing"
41286029|NCT04323501|OTHER|Control group|Usual care
41286030|NCT03255278|BIOLOGICAL|Single GamTBvac vaccination (0.25 dose)|Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
41286031|NCT03255278|BIOLOGICAL|Placebo administration|Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
41286032|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (0.25 dose)|Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
41452414|NCT03979664|DEVICE|Activapatch intellidose 2.5 using active Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
41452415|NCT03979664|DEVICE|Activapatch intellidose 2.5 using inactive Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Inactive medication will be used in the study. Using a syringe, 2 cc of inactive medication will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
41452416|NCT03979664|DRUG|Dexamethasone|Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
41452417|NCT03191305|DRUG|Coumadin|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
41452418|NCT03191305|DRUG|Rivoroxaban|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
41452419|NCT03756233|DRUG|Remifentanil|Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.
41452420|NCT03174158|DRUG|Mailed nicotine replacement therapy|Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
41452421|NCT03174158|BEHAVIORAL|Text messaging|12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
41286033|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (0.5 dose)|Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
41286034|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (1.0 dose)|Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
41286035|NCT05863936|DRUG|Methylprednisolone Injectable Suspension|Methylprednisolone pulse therapy, total dose from 1500mg to 3000mg.
41286036|NCT05863936|DRUG|Belimumab Injection|Belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks for 24 weeks.
41286037|NCT05863936|DRUG|Immunosuppressive Agents|"1. Mycophenolate Mofetil, oral, 1.0-1.5g per day;~2. Tacrolimus, oral, 2-4mg per day."
41286038|NCT01914133|DRUG|Acarbose|Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
41286039|NCT01914133|DRUG|Placebo|Placebo given prior to meal the standardized meal
40945310|NCT05991349|DRUG|IBI129|Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
41286040|NCT02218203|DRUG|Dextromethorphan|Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)
41286041|NCT02218203|DRUG|Lidocaine|0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)
41286042|NCT02218203|DRUG|Placebo (Dextromethorphan)|0mg Dextromethorphan
41286043|NCT02218203|DRUG|Placebo (Lidocaine)|0mg/kg LBM Lidocaine
41286044|NCT03988712|DIAGNOSTIC_TEST|Colonoscopy, gastroscopy, virtual colonoscopy, CT scan|Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.
41286045|NCT01979744|PROCEDURE|IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
41286046|NCT01979744|DEVICE|Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
41286047|NCT01979744|DEVICE|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
41452422|NCT03174158|BEHAVIORAL|Brief advice|Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
40945311|NCT03039192|DRUG|Esketamine|Intranasal esketamine solution 84 milligram (mg)
40945312|NCT03039192|OTHER|Placebo|Intranasal Placebo solution
40945313|NCT03039192|OTHER|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
40945314|NCT04953429|BEHAVIORAL|workload|Mental needs, physical needs, time needs, self performance, effort, frustration, technical autonomy, decision-making autonomy and work needs of nursing work
40945315|NCT00335478|DRUG|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is \>500 cells/mm\^3.
40945316|NCT02969551|DEVICE|Manometry and possibly DISE|A Manometry is performed on all patients. After it in some Patient DISE is followed
40945317|NCT02428608|BIOLOGICAL|DWP-450 (Botulinum purified neurotoxin, Type A)|Botulinum toxin, Type A
40945318|NCT06174064|DEVICE|Broadband Light treatment|While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.
41452423|NCT01200186|DRUG|EV/DNG (Qlaira, BAY86-5027)|At the discretion of the attending physician
41452424|NCT01200186|DRUG|Progestin Only Pills|At the discretion of the attending physician
40945319|NCT06174064|DEVICE|Sham broadband light treatment|The light will be occluded on the usual BBL device so that no treatment is delivered but the preparation and procedure will otherwise be the same.
40945320|NCT05806983|OTHER|Technology Based Psychosocial Program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
40945321|NCT00484809|DRUG|Enbrel (Etanercept)|
40945322|NCT04137224|BIOLOGICAL|IgPro20|Human normal immunoglobulin for subcutaneous administration
40945323|NCT04137224|BIOLOGICAL|IgPro10|Human normal immunoglobulin for intravenous administration
40945324|NCT05410015|OTHER|Normal clinical treatment without intervention|Normal clinical treatment without intervention
40945325|NCT05794412|OTHER|No intervention|No intervention
41132842|NCT04642898|BEHAVIORAL|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
40945326|NCT06106607|BEHAVIORAL|Intervention group|"A 20-week intervention with a basic part, including~1. A group session with education about IBD,physical activity and exercise in relation to IBD (definitions, evidence and recommendations). Furthermore, access to a video with general information about IBD, physical activity and exercise~2. Four individual motivational counselling sessions (two physical, two by telephone) with a project nurse. These will involve identifying individual motivation and opportunities for increasing physical activity and behavioral goal setting.~An optional intervention part will follow, including choises between (or all of)~1. A one-hour individual session with a physiotherapist, involving guidance in physical activity and exercise tailored to the individual.~2. Being teamed up with 1-2 'exercise buddies' (other participants from the overall intervention group).~3. Access to 4 short 2-3 minutes videos/'reels' of a physiotherapist explaining and demonstrating beneficial physical exercises."
40945327|NCT05341934|OTHER|Evaluative Conditionning Task|A word will appear in one of the four quadrants on the computer screen. They will have to answer the word as quickly as possible by pressing the space bar. They will also be told that an image will be displayed briefly (400 ms) in the same quadrant by pressing the answer key. This procedure will be repeated for 120 trials: 30 trials with alcohol-related Conditional Stimulus (CS), 30 trials with CS related to non-alcoholic beverages and 60 trials with the CS of filling. The CS referring to alcohol will be the words Beer, Wine ...; The CS referring to soft drinks will be the words Coca-Cola, Fanta... and Filling CS referring to vegetables and fruits will be: Apple, Banana...In experimental conditions, alcohol-related CS will be followed by negative Unconditional Stimuli (US) (images from the International Affective Picture System (Lang, Bradley, \& Cuthbert, 1997)), CS referring to soft drinks linked to positive images and CS referring to fruits and vegetables will be linked to neutral US.
40945328|NCT01275456|PROCEDURE|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
40945329|NCT00206310|DRUG|CRESTOR|
41132843|NCT04642898|BEHAVIORAL|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
41132844|NCT01052974|DRUG|ropivacaine|"A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo."
41132845|NCT00391170|DRUG|Topical Dexamethasone|dexamethasone 0.01%
41132846|NCT00391170|DRUG|Placebo|Placebo
41132847|NCT04949113|DRUG|Neoadjuvant ipilimumab + nivolumab|2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
41132848|NCT04949113|DRUG|Adjuvant nivolumab|Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
40945330|NCT00978107|BIOLOGICAL|MVA-FCU1, flucytosine|"1. TG4023: single IT injection; possibility to re-administer once,~   * Percutaneous IT injections, under radiological or ultrasound imaging guidance~  * Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),~  * MTD injected to up to 3 different lesions (Cohort #4)~2. 5-FC (5-fluorocytosine)/flucytosine~   * Dose and dosing schedule:~     * Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L~    * Duration: 2 weeks.~  * Possible routes of administration:~     * PO: 500 mg tablets, qid~    * IV: 1% 250 mL vials, 45-minute infusions."
40945331|NCT05785351|PROCEDURE|Laparoscopic Bariatric Surgery|Laparoscopic Bariatric Surgery: Gastric Sleeve and Roux-en-Y Gastric Bypass
40945332|NCT05227378|BIOLOGICAL|neoantigen tumor vaccine with or without PD-1/L1|personalized neoantigen tumor vaccine with or without PD-1/L1
40945333|NCT00718302|DEVICE|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
40945334|NCT00718302|DEVICE|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
40945335|NCT00002895|DRUG|chemotherapy|
40945336|NCT01003444|PROCEDURE|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
40945337|NCT04350606|BIOLOGICAL|PF-06462700|PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.
40945338|NCT02783677|PROCEDURE|Percutaneous balloon angioplasty|
40945339|NCT04441671|DRUG|Disodium Pyrophosphate|Absorption trial
40945340|NCT04326959|BIOLOGICAL|Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium|Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
40945341|NCT04326959|BIOLOGICAL|Conditioned Medium|Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
40945342|NCT04326959|BIOLOGICAL|Triamcinolone Acetonide|Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
40945343|NCT00632073|DRUG|Vicriviroc|One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
41132849|NCT06232421|DRUG|Foscelantan|"Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus"
41286048|NCT01979744|PROCEDURE|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
41286049|NCT00090285|BIOLOGICAL|(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
41286050|NCT00090285|BIOLOGICAL|Comparator: placebo (unspecified)|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
41286051|NCT03335124|DRUG|Vitamin C|Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.
40945344|NCT01043146|DRUG|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
40945345|NCT01043146|DRUG|placebo|intravenous 0.9 % NaCl
41132850|NCT06232421|DRUG|Povidon-iodine|Povidone-iodine solution 100 mg/ml produced by BelAseptika CJSC, Republic of Belarus
41132851|NCT02697968|DEVICE|Electroacupuncture|
40945346|NCT00972088|DEVICE|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
41132852|NCT01683188|DRUG|vemurafenib + HD IL-2|
41286052|NCT03335124|DRUG|Hydrocortisone|Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.
41286053|NCT03335124|DRUG|Thiamine|Intravenous thiamine will be applied as per instructions described in arm/group descriptions.
41286054|NCT03335124|DRUG|0.9% Sodium Chloride Injection|0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.
40945347|NCT00730444|DRUG|Iobenguane I 123 Injection|1-10 mCi administered intravenously
41286055|NCT05747014|DEVICE|Novapak Nasal Sinus Packing and Stent|Potential subjects will have the need to undergo nasal/sinus surgery using a space-occupying stent and will perform daily self-saline nasal irrigations.
40945348|NCT03057509|DRUG|Ga-68-DOTA-TOC|Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
40945349|NCT03057509|DEVICE|Siemens PET/MR scanner|Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
40945350|NCT03057509|OTHER|Standard Siemens Software|The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
40945351|NCT03057509|DRUG|LAR Octreotide|LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
40945352|NCT01667692|DRUG|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.\[1\] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
40945353|NCT01667692|DRUG|clarithmycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
40757450|NCT05500131|BEHAVIORAL|Observation|"Ankle joint dorsiflexion was evaluated with the Weight-bearing lunge test through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). Subjects were instructed to try to bring the knee to touch the metal rod (initially placed at a distance of 10 cm) without lifting the heel off the ground. The distance achieved was recorded in centimeters.~Single-leg squat test was analyzed through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). It consists of performing a monopodial squat to test dynamic knee valgus. They were to perform a single-leg squat to 30° knee flexion. The knee was considered to be aligned if the patella was over the second toe."
40757451|NCT00055887|DRUG|carboplatin|
40757452|NCT00055887|DRUG|cisplatin|
40757453|NCT00055887|DRUG|efaproxiral|
40757454|NCT00055887|DRUG|gemcitabine hydrochloride|
40757455|NCT00055887|DRUG|paclitaxel|
40757456|NCT00055887|DRUG|vinorelbine ditartrate|
40757457|NCT00055887|PROCEDURE|radiation therapy|
40757458|NCT00005839|DRUG|capecitabine|
40757459|NCT00005839|DRUG|oxaliplatin|
41452425|NCT06339424|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
41452426|NCT06339424|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
41452427|NCT06339424|RADIATION|Photon radiotherapy|"* 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
41452428|NCT02928744|OTHER|COPD|Plethysmography
41452429|NCT02928744|OTHER|COPD|Forced oscillations
41452430|NCT04748991|DRUG|Vernakalant|Post operative AF after cardiac surgery. Vernakalant 3mg/kg over 10 minutes followed by 2mg/kg over 10 minutes if still in AF.
41452431|NCT04748991|DRUG|Amiodarone|Post operative AF after cardiac surgery. Amiodarone 150mg IV followed by 1 mg/min x 6 hours then 0.5 mg/min x 12 hours
41452432|NCT05314257|DRUG|Granisetron Hydrochloride|IV granisetron 1mg
41452433|NCT05314257|OTHER|0.9% normal saline|IV 5ml of 0.9% normal saline
41452434|NCT04672538|PROCEDURE|Low Vt protocol|Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2
41452435|NCT04672538|PROCEDURE|High Vt protocol|High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.
41452436|NCT06561555|DRUG|RC48|RC48 at a dosage of 2mg/kg administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
41452437|NCT06188663|DIETARY_SUPPLEMENT|Salt supplementation (encapsulated sodium chloride)|A high salt intake range will be achieved through unchanged dietary intake and supplementary salt in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
41452438|NCT01447511|DRUG|Control - Warfarin only|A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
41132853|NCT04221711|DEVICE|Repetitive pulsed magnetic stimulation|"OMNITRON ProMed is a rPMS (repetitive peripheral magnetic stimulation) device used for deep stimulation of muscles and/or neurones (outside the brain). The energy is delivered by way of a special round treatment coil, whose cover material is tested for biocompatibility.~The OMNITRON ProMed device produces a high-energy impulse field and stimulates tissue, in particular soft tissue, muscles and neurons, by means of repetitive peripheral magnetic stimulation (rPMS). Short, extremely strong magnetic fields in the microsecond range are emitted non-invasively. OMNITRON ProMed works with short-term energy emission at a peak power of up to 60 million watts and a magnetic field strength of up to 100 milliTesla.~The intensity of treatment can be set between 20 and 100 %. The device automatically adjusts the magnetic field strength and the frequency of the pulses emitted depending on the intensity selected.~For comfortable transport and application the product is compact and portable."
41286056|NCT05212246|DRUG|5% Imiquimod cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
41286057|NCT05212246|DRUG|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
41452439|NCT01447511|DRUG|Fluconazole - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
40945354|NCT00749515|DRUG|Deferoxamine|After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.
41286058|NCT05879939|PROCEDURE|Transcutaneous, repetitive phrenic nerve electrical stimulation|Phrenic nerve electrical stimulation with different stimulation intensity and frequency
41452440|NCT01447511|DRUG|Rifampin - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
41452441|NCT02873832|BIOLOGICAL|Blood sample|
41452442|NCT02873832|OTHER|Flow cytometry|
41452443|NCT02873832|OTHER|western blot|
41452444|NCT04432558|DIAGNOSTIC_TEST|Spielberger's State-Trait Anxiety Inventory|Patients will be wanted to fill the Spielberger's State-Trait Anxiety Inventory the night before the surgery.
40945355|NCT00749515|DRUG|Deferasirox|After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
40945356|NCT00749515|RADIATION|HIDA|All patients had a HIDA scan to assess physiologic liver clearance capacity.
40945357|NCT02024529|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
40945358|NCT02024529|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
40945359|NCT05280210|OTHER|PTC drug screening|PTC is an in vitro tumor model, which serves as a structural and functional unit recapitulating the original tumors in genotype, phenotype, and drug response. PTC will be used in drug screening.
40945360|NCT03652376|DRUG|Benralizumab|Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
40945361|NCT05593471|OTHER|high intensity exercises|resistance training progressively increasing according to specific criteria (10 repetitions maximum). for the major muscles of the body
40945362|NCT05593471|OTHER|low intensity aerobic exercises|low-intensity exercises performed using arm or leg ergometer machines
40945363|NCT01315912|DRUG|Letrozole|2.5 mg /day for 5 days
40945364|NCT01998815|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass surgery|
40945365|NCT02562768|DRUG|LY3154207|Administered orally
40945366|NCT02562768|DRUG|Placebo|Administered orally
40945367|NCT02248415|OTHER|No pump|In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.
40945368|NCT02248415|OTHER|Pump|In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.
40945369|NCT02248415|OTHER|Blood sample collection: after induction of anaesthesia (T0)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
40945370|NCT02248415|OTHER|Blood sample collection: after arrival at the ICU (T1)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
40945371|NCT02248415|OTHER|Blood sample collection: 4 hours in ICU (T2)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
40945372|NCT02248415|OTHER|Blood sample collection: the first postoperative day (T3)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
40945373|NCT03805906|PROCEDURE|L5 Dorsal ramus block|Ultrasound-guided L5 dorsal ramus block
40945374|NCT03164577|BEHAVIORAL|Drum-Assisted Recovery Therapy for Native Americans (DARTNA)|An intervention that utilizes AI/AN drumming as its core component of treatment.
40945375|NCT03164577|OTHER|Usual Care Plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
40945376|NCT01218282|BEHAVIORAL|Home exercise training|20-30 min/day for at least 4 days/week
40945377|NCT01218282|BEHAVIORAL|NO Exercise Training|No intervention
40945378|NCT00810472|OTHER|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial \[8\]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method \[6\]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
40945379|NCT00810472|PROCEDURE|Penetrating keratoplasty|Corneal transplantation.
40945380|NCT00885053|DIETARY_SUPPLEMENT|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
40945381|NCT00885053|DIETARY_SUPPLEMENT|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
40945382|NCT02035475|DEVICE|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
40945383|NCT02493387|OTHER|Exercise|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale
40945384|NCT02493387|OTHER|Physical activity|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
41286059|NCT02354001|DRUG|Raloxifene hydrochloride|120mg daily- 1 capsule for 12 week trial
40945385|NCT03753269|DRUG|Fasudil Hydrochloride|2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
40945386|NCT03753269|DRUG|Placebo saline|15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
41286060|NCT02354001|DRUG|Placebo|1 capsule daily for 12 week trial - lactose
40945387|NCT01570920|BEHAVIORAL|physical training|walking many times a week
40945388|NCT02810977|DEVICE|Ultrasound|Ultrasound assessment of gastric content and volume
40945389|NCT00986479|DRUG|AZD6765|Single IV infusion of 150 mg AZD6765.
40945390|NCT00986479|DRUG|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
41132854|NCT04221711|PROCEDURE|Eccentric Calf Muscle Training for Achilles Tendinopathy|"Patients will be asked to stand with their full body weight on the injured leg. From an upright body position and standing with all body weight on the forefoot and the ankle joint in plantar flexion, the calf muscle is then loaded by having the patient slowly lower the heel beneath the forefoot. The calf muscle will only be loaded eccentrically, not concentric. Instead, the non-injured leg is used to get back to the start position. The first set of this exercise is performed in an upright position, followed by a second set with the knee bent to 45°. This regimen is performed 2x per day.~The patients are told to go ahead with the exercise even if they experienced pain. However, they are told to stop if the pain becomes disabling."
41286061|NCT03317587|BEHAVIORAL|INSPIRE|Eight week program of weekly group sessions with homework assignments addressing beauty ideals, establishing a healthy relationship with food and exercise, and tolerating and managing uncomfortable emotions. Participants will complete questionnaires are separate time points (one week before the program, one week after the program, and 1 month after the program) to evaluate the impact of the program on various behavioral and psychological outcomes.
40757460|NCT04195672|DEVICE|NIPE (MDoloris®) and CBS values|"During different procedures of care with the bed-side nurse, NIPE ware recorded. Monitoring started 15 minutes before care and continuously recorded until 10 minutes after the procedure. Pain assessment was evaluated by the CBS under 3 periods for each patient: 1- before any procedure (T1) representing the baseline, 2- during the procedure of care (T2), and 3- after the procedure (T3). Investigator who performed the CBS was blind to NIPE during the procedure recording.~This study did not change the procedure of care before or after and had no impact on care"
40757461|NCT01716637|BIOLOGICAL|Etanercept|
41286062|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
40757462|NCT01716637|DIETARY_SUPPLEMENT|Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.|
40945391|NCT04462185|DIAGNOSTIC_TEST|A genomic and transcriptomic landscape analysis|A genomic and transcriptomic landscape analysis will be developed to identify and characterize the transcriptome of benign versus malignant by using RNA sequencing, and to profile cfDNA in blood samples collected from patients with pulmonary nodules.
41286063|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
40945392|NCT01645137|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
40945393|NCT01645137|OTHER|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
40945394|NCT05689697|DIETARY_SUPPLEMENT|PanTrek|administration of exogenouse keton body
40945395|NCT00335920|DRUG|Dexamethasone-dihydrogenphosphate (4mg/ml)|
40945396|NCT06393543|OTHER|No intervention, only registration|No intervention, only registration
40945397|NCT02545075|DRUG|Ipilimumab|
40945398|NCT02545075|DRUG|Dacarbazine|
41286064|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
41286065|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
40757463|NCT06571409|DIETARY_SUPPLEMENT|Coriander Seed Oil - Dose 1|The study foresees the intake of 1 capsule per day during 56 days
40757464|NCT06571409|DIETARY_SUPPLEMENT|Coriander Seed Oil - Dose 2|The study foresees the intake of 1 capsule per day during 56 days
40945399|NCT03712631|PROCEDURE|tunneling technique bone augmentation|horizontal ridge augmentation using mixture of xenograft,autogenous bone
40945400|NCT06069648|BEHAVIORAL|printed screening decision aid|a booklet form of screening decision aid containing information of cervical cancer screening options
40945401|NCT06069648|BEHAVIORAL|a leaftlet|a leaflet containing information about healthy lifestyles
40945402|NCT06069648|BEHAVIORAL|mobile screening decision aid|a mobile app format of screening decision aid containing information of cervical cancer screening options
40945403|NCT04595240|DIAGNOSTIC_TEST|semen analysis|semen analysis
40945404|NCT00400231|DRUG|Study drugs: Metformin and fenofibrate|145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.
40945405|NCT00400231|DRUG|Study Drug: Metformin|2000mg/day
40945406|NCT00400231|DRUG|Study Drug: fenofibrate|145mg/day of fenofibrate
40945407|NCT00400231|DRUG|Metformin and Fenofibrate placebo|placebo metformin and fenofibrate
40945408|NCT04190173|DRUG|Prucalopride|1-2 mg once daily enteral feeding for 5 consecutive days
41452445|NCT04432558|OTHER|Visual analog scale, Ramsay's sedation scale|The analgesic consumption of the patients will be recorded by evaluating the pain with VAS (Visual analog scale) and sedation status with Ramsay's sedation scale in the 1st, 4th, 12th and 24th hour of postoperative period.
40945409|NCT04190173|DRUG|Placebo|1/2-1 tablet once daily enteral feeding for 5 consecutive days
40757465|NCT06571409|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 56 days
40757466|NCT02907957|DEVICE|FLIR ONE|Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
40757467|NCT02907957|PROCEDURE|Regional Anesthesia - Caudal Nerve Block|Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
40757468|NCT02118831|BIOLOGICAL|Blood Sample Collection|Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.
40757469|NCT02118831|DRUG|Aflibercept|an intravitreal injection of Aflibercept administered three times on a monthly basis.
40945410|NCT04102670|DEVICE|Ultherapy|Subjects will be treated with Ultherapy, which is a microfocused ultrasound, on the lower face, neck, and chest.
41452446|NCT04432558|DRUG|Tramadol, paracetamol, diclofenac sodium|The analgesic consumption of the patients will be recorded
40757470|NCT02118831|DRUG|Bevacizumab|an intravitreal injection of Bevacizumab administered three times on a monthly basis.
40757471|NCT02118831|DRUG|Ranibizumab|an intravitreal injection of Ranibizumab administered three times on a monthly basis.
40945411|NCT04102670|DEVICE|Xeomin|Vertical neckbands, also known as platysma bands, will be injected with Xeomin to relax the bands.
41452447|NCT03503435|BEHAVIORAL|Group art therapy|Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
40945412|NCT04102670|DEVICE|Belotero Balance|Horizontal necklace lines will be filled using Beletero Balance.
40945413|NCT04102670|DEVICE|Dilute Radiesse|The chest area will be injected with dilute Radiesse to stimulate collagen.
40945414|NCT04102670|OTHER|Neocutis Micro Firm Face and Neck Cream|Neocutis Micro Firm Face and Neck Cream will be provided to subjects for topical use at home.
40945415|NCT02477969|DRUG|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
40945416|NCT02477969|DRUG|PEX168(200µg)|PEX168,Subcutaneous injection,once a week. continued for 52 weeks
40945417|NCT02477969|DRUG|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
40945418|NCT02477969|DRUG|Metformin|0.5mg,oral,tid.
40945419|NCT01046370|BEHAVIORAL|Amygdala Retraining Program|Mind-body intervention.
40945420|NCT04620395|DIAGNOSTIC_TEST|Punch biopsy|A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)
40945421|NCT04944628|DIETARY_SUPPLEMENT|Probiotic|Probiotic in liquid format (oil suspension) administered 10 drops once daily for 2 weeks (2x10\^9 cfu/day)
40945422|NCT06235333|BEHAVIORAL|Gambling Disorder Screening Day screener|See descriptions
40945423|NCT06235333|BEHAVIORAL|Gambling Disorder Screening Day information sheet|See descriptions
40945424|NCT04047576|DRUG|Sirolimus|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
40945425|NCT04047576|DRUG|Corticosteroid|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
40945426|NCT00185835|DRUG|ZD-1839|
40945427|NCT00185835|DRUG|Cisplatin|
40945428|NCT02034032|PROCEDURE|Regenexx SD|stem cell treatment
40945429|NCT02034032|BEHAVIORAL|Exercise Therapy|exercise therapy control
40945430|NCT05843760|OTHER|personal information form|undergraduate student(participants) will be asked; age, weight, height, smoking and alcohol use, and headache.
40945431|NCT05843760|OTHER|headache-specific questionnaires|ıd migraine test, numeric rate scale, hit-6 headache impact test, headache information form
40945432|NCT05843760|OTHER|Questionnaires for assessing biopsychosocial status|hospital anxiety depression, Discomfort Intolerance Test, pittsburgh sleep quality index, fatigue severity scale, self compassion scale, Body Awareness Questionarre, cervical range of motion, İnternational Physical Activity Questionnaire, 12-Item Short-Form Health Survey
40945433|NCT06391346|DIAGNOSTIC_TEST|MSOT|Non-invasive transcutaneous imaging of muscle components via infrared and near-infrared laser pulses
40945434|NCT06310044|OTHER|Root canal irrigant Commiphora Myrrh 50%|Root canal irrigant
40945435|NCT05771792|OTHER|ECCENTRIC EXERCISE|Eccentric Exercise training group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, Eccentric Exercise training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. Eccentric exercise training protocol is as follow: Prone Hamstring Curl, Seated TheraBand Hamstring Curl, Exercise Ball (or glider) Bridge with Curl, Stiff-Legged Deadlift, Single Leg Deadlift, Nordic Hamstring Curl.
40757472|NCT01095965|BEHAVIORAL|Nutrition education|Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
40757473|NCT05418920|PROCEDURE|left-opening single-flap technique|left-opening single-flap technique
40757474|NCT05418920|PROCEDURE|double-flap group technique|double-flap group technique
40945436|NCT05771792|OTHER|CONVENTIONAL EXERCISES PROGRAM|The participant of the Control Group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, conventional training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. The exercise will be as follow: Side Lunges, Split Squats, Calf Raises.
40945437|NCT02890667|OTHER|Incident cancer|The number of incident cancer cases
40945438|NCT02301611|DRUG|TLPLDC|Autologous tumor lysate, particle-loaded dendritic cell vaccine
40945439|NCT02301611|DRUG|Placebo|
40945440|NCT02685514|DEVICE|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
41132855|NCT04171674|DRUG|Treatment with high-dose ceftobiprole (500mg loading dose followed by 2.5g under continuos infusion).|High-dose ceftobiprole (500mg loading dose) will be administered to patients for 30 minutes followed by 2.5g under continuous infusion for 24 hours.
41132856|NCT03678792|DRUG|Buprenorphine/naloxone|Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day
41452448|NCT04640298|DEVICE|Cingal|Single injection into the hip joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
40945441|NCT00892658|DRUG|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
40945442|NCT02864719|OTHER|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
41452449|NCT03018990|OTHER|Ethanol|1 milliliter per kilogram body weight adjusted for elevated body mass index
41452450|NCT01895764|DRUG|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
41452451|NCT01895764|DRUG|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
41452452|NCT01032590|BEHAVIORAL|Internet weight loss intervention|Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
41452453|NCT00503867|DEVICE|SIR-Spheres microspheres|SIR-Spheres Yttrium-90 microspheres
41452454|NCT05475964|DEVICE|Endoscopic ultrasound|Endoscopic ultrasound and biopsy intake of suspected lesions
40757475|NCT02714842|DRUG|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
40757476|NCT02714842|DRUG|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
41452455|NCT02169752|DRUG|Ambrisentan|"Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner."
41452456|NCT01730846|DRUG|Doxazosin 4mg/day|4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
41452457|NCT01730846|DRUG|Placebo|Placebo
40757477|NCT02714842|DRUG|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
40757478|NCT02714842|DRUG|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
40757479|NCT06184763|OTHER|6-minute walk test|"6-minute walk test in a 40-metre corridor. Included patients are used to performing this test, which is part of the standard care performed during patient follow-up, at least once a year.~Parameters collected during the test: distance walked, minimum SpO2, average SpO2, maximum heart rate, average heart rate, average heart rate over the last 2 minutes, dyspnea scale."
40757480|NCT05101161|BEHAVIORAL|Neurofeedback|Modulating brain oscillations based on visual neurofeedback
41452458|NCT01730846|DRUG|Doxazosin 8mg/day|8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
40757481|NCT06571903|OTHER|Teaching from videos|Teaching from videos for independent study
41452459|NCT05291195|DEVICE|Laser-device group|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the laser-device groups, the adjuvant treatment approaches were performed either by means of photodynamic therapy (HELBO, Photodynamic Systems GmbH) or high power diode laser (940nm, Biolase ® Technology, CA, USA). Performing photodynamic therapy the root canals were filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Germany) for 2 min following irradiation of diode laser (HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW)) for 60 s. Performing only diode laser the root canals were be irrigated with a diode laser (λ = 940 maximal power 10W) for 60 s."
40757482|NCT00705965|BEHAVIORAL|Psychotherapy|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
40757483|NCT00705965|BEHAVIORAL|Information session|One information session about living with heart disease.
40757484|NCT00705965|OTHER|Usual cardiological care|Usual cardiological care
40757485|NCT05281458|PROCEDURE|Early drainage of peripancreatic fluid collections|Participants will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
40757486|NCT05249855|BEHAVIORAL|Psychological measurement|Psychological assessment
40757487|NCT02124980|BEHAVIORAL|Recovery Line|
40757488|NCT01848457|DRUG|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)
40945443|NCT05930769|PROCEDURE|Gynecological laparoscopic surgery without augmented reality|Minimally invasive gynecological surgery assisted by laparoscope.
41452460|NCT05291195|DRUG|Essential Oil|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the EO group, the adjuvant treatment approaches were performed either by means of essential oil (Cymbopogon martinii and Thymus vulgaris, Herba oils, Herba d.o.o, Belgrade, Serbia)"
41452461|NCT05291195|DRUG|Sodium hypochlorite group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
40945444|NCT05930769|PROCEDURE|Gynecological laparoscopic surgery with augmented reality|Minimally invasive gynecological surgery assisted by laparoscope with the display of additional information through augmented reality.
40757489|NCT01848457|DRUG|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
41286066|NCT00839163|DRUG|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
41452462|NCT06033417|OTHER|Increased lifestyle walking (intervention)|Participants will increase their baseline steps by a minimum of 3,000 extra steps/day, 5-days/week, for 8-weeks. Baseline steps will be assessed using a pedometer over a 7-day period before the intervention, after which a new (higher) daily step target will be assigned. The intervention will take place in the free-living setting, with participants reaching their step goals by engaging in more activities of daily living or via purposeful physical activity. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants will be supported in their efforts to meet their daily step targets by engaging in once-weekly walking groups (30-mins/session) led by research staff. They will also receive 20-minute phone calls once every two weeks to set goals and create action plans for reaching their step targets.
41452463|NCT06033417|OTHER|Health education only (control)|Those randomized to the delayed participation group will be instructed to maintain their 'normal' lifestyle activities, thereby avoiding any significant increase in daily step counts beyond their 'baseline' values. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants in this group will attend once-weekly group health education sessions (30-minutes/session), in addition to 5-minute, 'touch base' phone calls once every 2-weeks, but these phone calls will not involve goal-setting or action planning. After completing the initial 8-week period, these individuals can then opt to undertake the 'increased lifestyle walking' intervention of 3,000 extra steps/day over 5-days for 8-weeks if desired.
41286067|NCT00501852|DRUG|NVA237|single-dose dry-powder inhaler (SDDPI)
41286068|NCT00501852|DRUG|Placebo|single-dose dry-powder inhaler (SDDPI)
41286069|NCT00501852|DRUG|Tiotropium|Handihaler inhaler
40757490|NCT06162468|PROCEDURE|Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel|EUS-PCA using gemcitabine and paclitaxel
40757491|NCT05525715|DRUG|2mg QY201 tablets or 2mg QY201 placebo,BID|2mg QY201 tablets or 2mg QY201 placebo,BID
40757492|NCT05525715|DRUG|5mg QY201 tablets or 5mg QY201 placebo,BID|5mg QY201 tablets or 5mg QY201 placebo,BID
40757493|NCT05525715|DRUG|10mg QY201 tablets or 10mg QY201 placebo,QD|10mg QY201 tablets or 10mg QY201 placebo,QD
40757494|NCT05525715|DRUG|10mg QY201 tablets or 10mg QY201 placebo,BID|10mg QY201 tablets or 10mg QY201 placebo,BID
40757495|NCT05525715|DRUG|15mg QY201 tablets or 15mg QY201 placebo,BID|15mg QY201 tablets or 15mg QY201 placebo,BID
41286070|NCT06398392|DRUG|[18F]PBR111|\[18F\]PBR111 is a radiotracer produced at University Hospital of Geneva in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 10 mL (max) of formulated product, the maximal applicable dose being 200 MBq.
40757496|NCT05525715|DRUG|20mg QY201 tablets or 20mg QY201 placebo,BID|20mg QY201 tablets or 20mg QY201 placebo,BID
41286071|NCT06398392|PROCEDURE|PBR111 injection|\[18F\]PBR111 will be administered once, intravenously in the antecubital fossa at a dose of 200 MBq
40757497|NCT05525715|DRUG|5mg QY201 tablets，BID|5mg QY201 tablets，BID
40757498|NCT05525715|DRUG|10mg QY201 tablets，BID|10mg QY201 tablets，BID
40757499|NCT05525715|DRUG|20mg QY201 tablets，BID|20mg QY201 tablets，BID
40757500|NCT05525715|DRUG|QY201 placebo，BID|QY201placebo，BID
40945445|NCT03995836|DEVICE|CPAP|Decision of CPAP treatment is according to clinical guidelines
41286072|NCT06398392|DEVICE|PET scan|Upon administration of the radiotracer, a 120-minute PET/CT scan will be initiated.
41286073|NCT06398392|RADIATION|PBR111 dosimetry|to establish the exposure of the organs/tissues to a standard radioactive dose (200 MBq) of \[18F\]PBR111
40757501|NCT06199830|DIAGNOSTIC_TEST|positive bronchial provocation test|Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation. This test was stopped until a reducing in baseline FEV1 of 20%.
40757502|NCT06014723|PROCEDURE|Submaximal balloon angioplasty|The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
40757503|NCT01655446|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
40757504|NCT01655446|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
41286074|NCT03366714|DEVICE|nasal CPAP support with RAM cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support RAM cannula.
41286075|NCT03366714|DEVICE|nasal CPAP support with Hudson cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support Hudson cannula.
41286076|NCT02603640|DEVICE|MRI scanning|
41286077|NCT05578521|DRUG|Cerebralcare pills|a dose of 2 packages, twice a day of Cerebralcare pills
41286078|NCT05578521|DRUG|Cerebralcare pills placebo|Cerebralcare pills placebo will be administrated at the same rate with experimental group
41286079|NCT02750410|DRUG|Dulaglutide|Administered subcutaneously (SC)
41286080|NCT02750410|DRUG|Placebo|Administered SC
41286081|NCT04706598|DRUG|Camrelizumab|Solution for Infusion (Intravesical)
40757505|NCT01655446|BEHAVIORAL|Robotic Rehabilitation|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
40757506|NCT01655446|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
40757507|NCT01655446|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.
40757508|NCT01682603|DRUG|Botulinum toxin A|BoNT-A (BOTOX 300U)
40757509|NCT03154567|DRUG|Yohimbine|Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
41286082|NCT02107144|DRUG|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
40757510|NCT04460261|OTHER|Functional Inspiratory Muscle Training|Both groups were trained 3 days a week under the supervision of a physiotherapist and other days of the week without a supervisor. The treatment program consisted of 4 weeks of foundation IMT followed by 4 weeks of functional IMT. Foundation IMT was applied during the first 4 weeks of training. The participants were asked to sit in a comfortable upright position. Following the foundation IMT, all participants underwent four weeks of functional IMT. Initially, all participants were taught diaphragmatic breathing and activating abdominal wall musculature. Each training session started with warm-up exercises and ended with cool-down exercises. During the loading phase, core stability, dynamic trunk activation and postural control exercises were applied together with IMT.
40757511|NCT06570928|OTHER|Cannabis|0,2 ml of CBD:THC (50 mg:5 mg)
40757512|NCT06570928|OTHER|Placebo|Product vehicle, medium chain triglycerides (MCT)
40757513|NCT03196089|PROCEDURE|Oxygen application|Supplemental oxygen via mask
40945446|NCT03995836|PROCEDURE|Bariatric Surgery|All patients.
41132857|NCT03678792|DRUG|Morphine|Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day
41286083|NCT04610307|PROCEDURE|buffered anesthesia|patients will undergo surgery under buffered local anesthesia
41286084|NCT03396549|DEVICE|new sham tDCS|1 ch TCT transcranial stimulator
41286085|NCT03396549|DEVICE|real tDCS|1 ch TCT transcranial stimulator
41286086|NCT04282577|DIAGNOSTIC_TEST|urinary nephrin and alpha one microglobulin|urinary nephrin and alpha one microglobulin are biomarkers of glomerular filtration barrier injury and tubular injury respectively measured by ELISA
41286087|NCT03537729|BEHAVIORAL|Salient Cues|Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.
41286088|NCT03537729|BEHAVIORAL|Spaced Retrieval Education|Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
41286089|NCT01186653|DRUG|budesonide / formoterol|budesonide / formoterol, 400 micrograms/9 micrograms one IH bd
41286090|NCT01186653|DRUG|fluticasone/salmeterol|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
41286091|NCT04076761|DRUG|Trifluridine/Tipiracil|FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
41286092|NCT05895851|RADIATION|head and neck radiation|RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.
41286093|NCT01088412|DRUG|Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)|Dose, frequency and duration at discretion of attending physician.
41286094|NCT01232725|DIETARY_SUPPLEMENT|Donor Human Milk|Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
41286095|NCT03237780|DRUG|Atezolizumab|Given IV
41286096|NCT03237780|PROCEDURE|Biopsy|Undergo biopsy
41286097|NCT03237780|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41286098|NCT03237780|PROCEDURE|Computed Tomography with Contrast|Undergo CT scan
41286099|NCT03237780|DRUG|Eribulin Mesylate|Given IV
41286100|NCT05879263|OTHER|INTERMITTENT ENTERAL NUTRITITION (IEN)|Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.
41286101|NCT05879263|OTHER|CONTINUOS ENTERAL NUTRITITION (CEN)|Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
41452464|NCT04053816|DRUG|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
41452465|NCT04303221|OTHER|Exercise|The exercises will be performed three times a week (Mondays, Wednesdays and Fridays), lasting 60 min, 10 minutes of warm-up, 40 min of multisensory exercises, and 10 min of final relaxation, for 12 weeks.
41286102|NCT03661385|DRUG|Nitric Oxide|Addition of nitric oxide 20ppm into bypass circuit
41286103|NCT03399890|DIAGNOSTIC_TEST|Neurological physical exam|Neurological physical exam is performed in all patients at the OR table, immediately after the operation.
41286104|NCT00565955|DRUG|montelukast|"Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; \> 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid."
41286105|NCT00565955|DRUG|Placebo|The patients will receive placebo tablets.
41286106|NCT03503123|DEVICE|Monitoring physiology with Electrical Impedance Tomography, Electromyography and transcutaneous carbon dioxide measurements.|Both groups get the same exposures: with measure physiology in both groups by using non-invasive measurement techniques. The techniques we use are Electrical Impedance Tomography to determine degree of hyperinflation. We use Electromyography to analyse respiratory drive. We measure transcutaneous carbon dioxide to assess the effects of non-invasive ventilation. Thereby, we will perform lung function tests.
41286107|NCT04654325|DIAGNOSTIC_TEST|conjunctival swab|Patients will have conjunctival swab for SARS-CV-2 genome detection
41452466|NCT02666807|DIETARY_SUPPLEMENT|Ginger|Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
41286108|NCT04720352|DEVICE|Active treatment|Active treatment delivers radiofrequency and cryogen
41286109|NCT04720352|DEVICE|Sham|Sham delivers non therapeutic levels of radiofrequency and cryogen
41286110|NCT03992300|DEVICE|Clinical adjustment|Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
41286111|NCT05542615|DRUG|Prolonged-Release Pirfenidone|1200 mg / day of Pirfenidone (KitosCell® LP)
40757514|NCT05747937|DIAGNOSTIC_TEST|Skin biopsy|A punch skin biopsy of 3mm will be used to analyze cutaneous innervation
41286112|NCT03652454|DEVICE|micro-osteoperforation|Propel device (ABD) using for regional acceleratory phenomenon
41452467|NCT02666807|DIETARY_SUPPLEMENT|placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
41132858|NCT03678792|DRUG|Tramadol|Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
41286113|NCT03652454|OTHER|conventional fixed appliance treatment|conventional fixed appliance treatment
41286114|NCT04024228|BIOLOGICAL|Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
41286115|NCT04024228|BIOLOGICAL|High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
41286116|NCT01789879|DRUG|Levonorgestrel|Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
41286117|NCT01789879|DRUG|Nevirapine|Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
41286118|NCT01789879|DRUG|Efavirenz|Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
40757515|NCT05747937|DIAGNOSTIC_TEST|Cardiovascular Reflexes testing|Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
40757516|NCT05747937|DIAGNOSTIC_TEST|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms|We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire
41286119|NCT03896425|DEVICE|Transcranial direct current stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
41286120|NCT03671369|OTHER|Safety data collection (following routine vaccination) by a continuous surveillance method.|"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) were collected as part of safety data in this PMS."
41286121|NCT05372315|DRUG|Dextenza 0.4Mg Ophthalmic Insert|(dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.
41286122|NCT02263365|DRUG|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
41286123|NCT00291629|DRUG|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
41286124|NCT00291629|PROCEDURE|collection of mobilized peripheral blood stem cells|
41286125|NCT00291629|PROCEDURE|Intracoronary infusion of mobilized cells|
41286126|NCT03504033|DRUG|Xenon|inhalation to maintain anesthesia
41286127|NCT03504033|DRUG|Desflurane|inhalation to maintain anesthesia
41286128|NCT02261740|BEHAVIORAL|Yoga Therapy|"A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).~Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice."
41286129|NCT03388970|DRUG|Vitamin K 1|Research group use Vitamin K1
41286130|NCT03388970|DRUG|normal saline|Placebo group use normal saline
41286131|NCT04400500|DIAGNOSTIC_TEST|Approaches to differential diagnosis and risk stratification|Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.
41286132|NCT01817010|BEHAVIORAL|Multi-Component Rehabilitation (CMC)|
41286133|NCT01817010|BEHAVIORAL|Control (CON)|
41286134|NCT02805699|DRUG|Baofeikang Granule|To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
41286135|NCT02805699|DRUG|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
40757517|NCT05747937|DIAGNOSTIC_TEST|Dinamic Sweat Test|Test for the functional assessment of postganglionic sudomotor pathway
40757518|NCT00104403|DRUG|GW679769|
40757519|NCT00104403|DRUG|Dexamethasone|
40757520|NCT00104403|DRUG|Ondansetron Hydrochloride|
41286136|NCT01955486|OTHER|flight simulation|
41286137|NCT00395122|DEVICE|Retinal nerve fiber layer and macular thickness measurements|
41286138|NCT02188446|BEHAVIORAL|Educational programme for smoking and alcohol cessation|5 meetings within 6 weeks containing education and pharmacologic support
41286139|NCT00943878|BIOLOGICAL|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
41286140|NCT00943878|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
40757521|NCT01391299|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
40757522|NCT01391299|DRUG|Normal Saline|Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
40757523|NCT01189721|DRUG|propofol, sevoflurane|"Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively."
40757524|NCT01103115|DIETARY_SUPPLEMENT|Calcium 600mg plus Vit D 400 IU|Daily supplementation with 600mg Calcium plus 400IU Vitamin D3
40757525|NCT01103115|DIETARY_SUPPLEMENT|Calcium 600mg plus Vit D 800 IU|Daily supplementation with 600mg Calcium plus 800IU Vitamin D3
40757526|NCT01103115|DIETARY_SUPPLEMENT|Placebo|placebo tablets
40757527|NCT02579551|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical excision
40757528|NCT02250573|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
40757529|NCT02965456|DRUG|IDP 121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
40757530|NCT02965456|DRUG|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
40757531|NCT02416544|OTHER|Lunch which is calorie-restricted and low-salt|Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
40945447|NCT05377008|BEHAVIORAL|OPTIMAL-SSI|The purpose of the intervention feedback session will be twofold: 1) to provide the results of the previous assessment, and 2) to provide general psychoeducation on psychological and neurocognitive functioning and tailored cognitive and behavioral interventions based on the results in order to reduce the impact of psychological and neurocognitive deficits.
40757532|NCT00631241|PROCEDURE|Single Photon Emission Computed Tomography|First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
40945448|NCT05437211|DEVICE|Virtual-reality (VR) Based Solution|VR-based solution comprises a mobile phone application including explanation on the different steps to be followed to perform infusions in satisfactory conditions, notably as regards safety, as well as VAS for pain and anxiety to be completed at each Factor VIII or Factor IX infusion between inclusion and the Week 4 visit. It also comprises a 3D mask (to be used before or during infusions) including simulation of the infusions themselves (before infusion) and a relaxing and distracting content (during and after infusions).
40945449|NCT01033721|DRUG|Palomid 529|comparison of different dosages of drug
40757533|NCT00631241|PROCEDURE|Intraoperative Lymphatic Mapping|Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
40757534|NCT01690325|DRUG|Docetaxel|
40757535|NCT01690325|DRUG|Trastuzumab|
40757536|NCT01690325|DRUG|Bevacizumab|
40757537|NCT01690325|DRUG|Epirubicin|
40757538|NCT01690325|DRUG|Cyclophosphamid|
40757539|NCT01512251|DRUG|BKM120 Combined with Vemurafenib (PLX4032)|"Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)~Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid~Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid~Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid~Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid~Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid~Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D"
40757540|NCT04000711|OTHER|Outpatient oral treatment.|Participants allocated in oral outpatient group were discharged home with oral antibiotic to continue management. Participants were given Cefixime oral suspension (100 mg/5 mL). Antibiotic was given to the caretakers with written instructions about dosage and time of administration. Dosage indicated was 8 mg/kg/day to be given orally as a single dose (max dose 400 mg/day). Oral antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
40945450|NCT04953299|BEHAVIORAL|Functional Imagery training|Behavioural intervention focused upon motivation and reaching achievable goals.
40945451|NCT04953299|BEHAVIORAL|NHS 12 week weight loss programme|The plan is designed to help individuals lose weight at a safe rate of 0.5kg to 1kg (1lb to 2lb) each week by sticking to a daily calorie allowance and introducing exercise.
41132859|NCT01709006|RADIATION|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
41286141|NCT00943878|DRUG|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
41286142|NCT00379730|DRUG|Prednisolone|
40945452|NCT02779465|DRUG|Vitamin D3|Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
41132860|NCT05497882|BEHAVIORAL|E-Learning Prototype for Dementia Care|Usability testing System Usability Scale
40757541|NCT04000711|OTHER|Inpatient intravenous treatment.|Participants allocated in the intravenous inpatient group continued receiving Cefepime 150 mg/kg/day every 8 hours (max dose 2 grams per dose or 6 grams per day) according to local standard of care guidelines. Intravenous antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
40757542|NCT00527748|DEVICE|Non-Measuring Ankle Exerciser|Stretching exercise performed 10 times per day, for six (6) weeks.
40757543|NCT02591407|PROCEDURE|TAP Block|This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
40757544|NCT02591407|PROCEDURE|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion
40757545|NCT00049283|DRUG|erlotinib hydrochloride|Given orally
41286143|NCT06210126|OTHER|local anesthetic injection|Ultrasound-guided pectointercostal fascial plane block group using 20 mL of 0.25% bupivacaine
41286144|NCT06210126|OTHER|Standard perioperative and postoperative analgesia protocol|postoperative IV morphine PCA and paracetamol will be given. If VAS is 3 or above, 75 mg dexketoprofen trometamol will be administered.
41286145|NCT03194425|DIAGNOSTIC_TEST|Pelvic floor EMG|Define pelvic floor EMG template measured by probe
40757546|NCT00049283|DRUG|docetaxel|Given IV
40757547|NCT00049283|RADIATION|radiation therapy|Undergo radiotherapy
40757548|NCT00049283|PROCEDURE|therapeutic conventional surgery|Undergo neck dissection
40757549|NCT00049283|OTHER|laboratory biomarker analysis|Correlative studies
40757550|NCT00049283|OTHER|pharmacological study|Correlative studies
40757551|NCT03382860|DIAGNOSTIC_TEST|Fundus videos|Recordings of fundus videos
40945453|NCT01759511|DRUG|Simtuzumab|200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)
40945454|NCT03211338|BIOLOGICAL|Culture with progesterone|Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells
40945455|NCT03211338|BIOLOGICAL|Culture without progesterone|Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone
40945456|NCT03211338|BIOLOGICAL|Culture with growth factors|Culture of placental IMC cells with growth hormones only and analysis
41132861|NCT03268499|DRUG|Cisplatin|The procedure of TACE is the same irrespective of which regimen is used.
41132862|NCT01837368|OTHER|observational research|It is a observational research, no intervention are performed
41286146|NCT03477916|BIOLOGICAL|FMT|fecal microbial transplantation (FMT)
40945457|NCT00258284|DRUG|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
40945458|NCT00258284|DRUG|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
40945459|NCT02387710|DRUG|Tiagabine|GABA reuptake inhibitor
41132863|NCT04370561|PROCEDURE|ORIF non-locking|Open reduction and internal fixation using 1/3 tubular plate
41132864|NCT04370561|PROCEDURE|ORIF locking|Open reduction and internal fixation using active ankle polyaxial locking plate
41132865|NCT04707170|DEVICE|MRI with gadolinium injection|"Patients presenting for imaging for whom an MRI examination with gadolinium injection has been prescribed and who meet the inclusion and non-inclusion criteria will be offered to participate in the study.~The patients included, hospitalized at the A. de Rothschild Foundation Hospital for at least 24 hours, may be included in the ancillary study to meet secondary objective number 5."
41132866|NCT02103556|OTHER|Mineral oil|4 ml daily (adjusted as needed), for 4 weeks
41132867|NCT02103556|DIETARY_SUPPLEMENT|Olive oil|4 ml daily (adjusted as needed), for 4 weeks
40945460|NCT02387710|DRUG|Placebo|Placebo comparator
40945461|NCT00886912|OTHER|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
40945462|NCT00886912|OTHER|normoxia|training under normoxic conditions
40945463|NCT06154538|DRUG|Cadonilimab|PD-1/CTLA-4 bi-specific antibody
41286147|NCT03477916|BIOLOGICAL|Placebo FMT|Placebo fecal microbial transplantation (FMT)
41286148|NCT03477916|DIETARY_SUPPLEMENT|Prebiotic Fiber|combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber
40945464|NCT06154538|DRUG|FOLFOX regimen|FOLFOX chemotherapy
41286149|NCT03477916|DIETARY_SUPPLEMENT|Cellulose|Cellulose
41286150|NCT03319628|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
41286151|NCT03291002|BIOLOGICAL|CV8102|CV8102 alone
41286152|NCT03291002|BIOLOGICAL|CV8102 + anti-PD-1 therapy|CV8102 in combination with standard of care anti-PD-1 therapy
41286153|NCT02395315|DEVICE|Well-controlled diabetic (WC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
41286154|NCT02395315|DEVICE|Poorly controlled diabetics (PC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
41286155|NCT03158584|DRUG|Intrathecal Morphine|Intrathecal administration of Morphine in children undergoing major abdominal surgeries
41286156|NCT01476930|PROCEDURE|cupping and serkangabin syrup|wet cupping serkangabin syrup
41286157|NCT01476930|DRUG|conventional migraine drug treatment|nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
41286158|NCT05249595|DEVICE|Surface electromypgraphy-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the sEMG signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
40945465|NCT00302198|BEHAVIORAL|ALS Registry|
40945466|NCT06434298|BEHAVIORAL|Choose to Move|As described under study arm description
41132868|NCT02103556|DIETARY_SUPPLEMENT|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
41132869|NCT04881409|DEVICE|Respiratory support with nasal high-flow (NHF)|Patient with AECOPD is treated with NHF.
40945467|NCT00294801|DRUG|flex-a-new (food supplement)|
40945468|NCT03388385|DRUG|Sodium Chloride 0.9% Intravenous Solution|Physiologic saline infusion will be infused in day 1.
40945469|NCT03388385|DRUG|Ferinject|Ferric carboxymaltose will be infused in day 2.
40945470|NCT04671524|OTHER|Exercise protocol|a combination of stretching, range of motion, and strengthening exercise.
40945471|NCT02869438|DRUG|Benralizumab|Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
40945472|NCT02869438|OTHER|Placebo|Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
40945473|NCT04708379|BEHAVIORAL|Lifestyle intervention|Nutrition and physical activity education.
40945474|NCT02943460|DRUG|Cilofexor|Tablet(s) administered orally once daily with food
40945475|NCT02943460|DRUG|Placebo to match cilofexor|Tablet(s) administered orally once daily with food
40945476|NCT00739999|DRUG|Atorvastatin|6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
40945477|NCT00739999|DRUG|Atorvastatin|10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
40945478|NCT00853073|DRUG|bevacizumab|1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
40945479|NCT00853073|OTHER|balanced salt solution|0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
40945480|NCT06236620|DIETARY_SUPPLEMENT|Processing of wheat|Investigating if the consumption of sprouted or hydrothermally processed wheat affects the iron and zinc absorption in humans
40945481|NCT02549729|BEHAVIORAL|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
40945482|NCT04885946|OTHER|Fecal microbiota transplantion (FMT)|Single donor, fecal microbiota transplantion (FMT) from healthy human donors.
40945483|NCT04885946|OTHER|Placebo|Food coloring, water, glycerol
40945484|NCT04759144|DEVICE|CamAPS FX using faster insulin aspart|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
40945485|NCT04759144|DEVICE|CamAPS FX using standard insulin aspart|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
40945486|NCT03424668|BEHAVIORAL|diet|lifestyle factors
40945487|NCT05800860|DRUG|GH001|GH001 administered via inhalation
40945488|NCT05800860|DRUG|Placebo|Placebo administered via inhalation
40945489|NCT00463203|DRUG|Bevacizumab|10 mg/kg every 2 weeks
40945490|NCT00463203|DRUG|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
40945491|NCT02671773|DRUG|Inhaled corticosteroid dose/type|
40945492|NCT04034082|DEVICE|Intermittent hypoxia therapy|Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
40945493|NCT04034082|OTHER|Conventional phase 2 cardiac rehabilitation programme|The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
40945494|NCT03757338|DRUG|Fingolimod Reference Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the reference product produced by Novartis Pharmaceutical with the proposed test product manufactured by Asofarma S.A.I. y C. in healthy volunteers, under fasted conditions.
40945495|NCT03757338|DRUG|Fingolimod Test Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the proposed test product manufactured by Asofarma S.A.I. y C. with the reference product produced by Novartis Pharmaceutical in healthy volunteers, under fasted conditions.
40945496|NCT05840718|DRUG|Thiamin|Patients in thiamine group received two daily dosis of 200 mg of thiamin diluted in 50 ml of 5% dextrose during 7 days
40945497|NCT02328911|DEVICE|Laser treatment|Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
41132870|NCT04881409|DEVICE|Respiratory support with non-invasive ventilation (NIV)|Patient with AECOPD is treated with NIV.
41132871|NCT05252468|DEVICE|TaffiX™|Personal nasal powder spray.
41132872|NCT01034488|BIOLOGICAL|Suine|5000UI /mL
41132873|NCT01034488|BIOLOGICAL|Suine|5000UI/mL
41132874|NCT05123079|DRUG|Darigabat|Tablets
41132875|NCT00485693|DRUG|Bupivacaine HCl|150 mg Bupivacaine HCl
41132876|NCT00485693|DRUG|SKY0402|600 mg SKY0402 (study drug)
40945498|NCT02328911|DEVICE|Sham treatment|A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
40945499|NCT03239600|DRUG|GSK2618960 2 mg/kg|GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
40945500|NCT03239600|DRUG|Placebo|Placebo solution will be administered by IV infusion.
41286159|NCT05249595|DEVICE|Ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
41286160|NCT05249595|DEVICE|Surface electromypgraphy and ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by combining sEMG and ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
41286161|NCT01606488|DRUG|Florbetapir F 18 (18F-AV-45)|Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
41286162|NCT01606488|OTHER|no intervention|
41286163|NCT05124769|BEHAVIORAL|Pain Allowing Program (PAllow)|Performing exercises considered to have a considerable supraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \> 40% MVC).
41286164|NCT05124769|BEHAVIORAL|Pain Avoiding Program (PAvoid)|"Performing exercises selected to have a minimal insupraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \<20% MVC).~These unloading exercises are performed for 6 weeks. In the second part of the exercise protocol, the loading exercises are applied, however without pain.~In case the patient still feels pain during the exercises in that period, the unloading exercises are continued."
40945501|NCT03239600|DRUG|Methotrexate|MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
40945502|NCT01542073|DRUG|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
40945503|NCT04307914|RADIATION|External beam radiotherapy|The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.
40945504|NCT04307914|PROCEDURE|MR-HIFU|MR-HIFU is a non-invasive treatment modality that delivers acoustic energy to heat tissue to ablative temperatures of more than 60°C. The combination of focused ultrasound with magnetic resonance imaging (MRI) enables physicians to perform localized tumor tissue ablation, with real-time temperature monitoring using magnetic resonance (MR) thermometry.
40945505|NCT04209062|DEVICE|Medical device validation|The medical devices will both record electrical signals for comparison
41452468|NCT03849846|OTHER|Focus groups|Participants will also complete a sociodemographic questionnaire. The moderator will conduct the discussion using a semi-structured interview guide, based on the construct of the Theory of Planned Behaviour. The interview guide has been developed to identify the beliefs that determine the participants' attitudes (advantages/disadvantages), subjective norms (approval/disapproval of important others) and perceived behavioural control (facilitators/barriers) related to a hypothetical participation in the NutriQuébec study. The participants will also be questioned about their preferences regarding the recruitment as well as their concerns about the security, use and share of data.
41452469|NCT05633186|BEHAVIORAL|Moodbuster Life|All participants get access to the Moodbuster Life intervention. Moodbuster Life is an online self-help intervention that contains 5 web-based modules focusing on lifestyle and coping: psycho-education, behavioral activation, physical activity, problem-solving, and worrying. All participants start with module 1, psycho-education. Next, participants can choose what module they wish to continue with. All modules take about 45 minutes to complete and contain text, exercises, video clips and preparing the home-work assignments. Executing the home-work assignments may take 20 minutes each week.
41452470|NCT05633186|BEHAVIORAL|Mobile application|The participants randomized to receive this component will receive access to a mobile application. The aim of this app is two-folded, (1) used for diary ratings, (2) sending out personalized automated messages. First, the participants will rate their mood, sleep and related factors on a daily basis. The participants are prompted to rate the diary ratings three times a day (morning, afternoon, evening). Moreover, the application graphically pictures progression over time. Second, the application will send personalized automated messages. The content of the messages is informative, affirmative or encouraging. The investigators will use reinforcement learning (RL) to find so-called policies that show best long-term engagement and most sustained improvement of participants' mood. To drive choices, the investigators will use the data mentioned in the advising for the modules as well as behavioral data (mood ratings), data across all users is exploited.
40945506|NCT04317976|OTHER|paralaryngeal pressure|cricoid pressure with paralaryngeal pressure by fingertips applied under ultrasound guidance
40945507|NCT04317976|OTHER|cricoid pressure|cricoid pressure by fingertips applied under ultrasound guidance
40945508|NCT00473473|DRUG|Potassium Dichromate (Homeopathy)|twice daily with an interval of 12 hours, for a period of up to 14 days
40945509|NCT00473473|DRUG|Placebo homeopathic remedy|identical to treatment without active component
40945510|NCT05400824|DIAGNOSTIC_TEST|Blood, DNA, feces, urine, hair and skin microbiota collection|See above
40945511|NCT04214873|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of POH
40945512|NCT04860427|DEVICE|trapezoidal condylar plate|trapezoidal condylar plate open reduction and fixation
40945513|NCT04860427|DEVICE|two miniplates|two miniplates open reduction and fixation
40945514|NCT00359918|DRUG|fibrinolysis|Primary PCI
40945515|NCT00359918|PROCEDURE|Primary PCI|Primary PCI
40945516|NCT02514603|DRUG|Prexasertib|Administered IV
40945517|NCT06203236|DRUG|Furosemide 20 MG|"1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation."
40945518|NCT06203236|OTHER|diuretic therapy|diuretic therapy
40945519|NCT03360747|DRUG|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.
40945520|NCT06056674|BEHAVIORAL|U-PEACE Intervention|"This program will involve about 13 group sessions, with each group session lasting approximately 40-50 minutes. The program session will be held about 2 times a week during the school day (e.g., lunch time) if the group meets in person, or at a pre-scheduled time every week if the group meets online via Zoom.~Participants will learn how to better understand emotional experiences and use this understanding to embrace agency in challenging situations. Participants will develop skills to better deal with emotions by increasing awareness of what is happening in different settings and choose how to respond. Skill-building exercises may include mindfulness practices, flexible thinking, behavioral activation, problem-solving, and exposure activities."
40945521|NCT06056674|BEHAVIORAL|SAU|Participants in this group will continue to receive standard of care within their school clinic.
40945522|NCT05508997|DEVICE|respiratory parameters on mechanical ventilator (PEEP)|"The 3rd \& 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~1. Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~2. Secondary outcome.~   * Ventilation by PaCO2 value from ABGs.~  * Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~  * Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups."
40945523|NCT02590926|PROCEDURE|Fractional Flow Reserve, Myocardial|The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
40945524|NCT01617525|OTHER|Controlled Feeding Dietary Intervention|All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
40945525|NCT00002240|DRUG|Atazanavir|
40945526|NCT00002240|DRUG|Nelfinavir mesylate|
40945527|NCT00002240|DRUG|Stavudine|
40945528|NCT00002240|DRUG|Didanosine|
41452471|NCT05633186|BEHAVIORAL|Guidance by a coach|A coach will provide support once per week at a scheduled time to participants who are allocated to receive support. The coaches are psychologists who are not part of the research team. The support will be provided via the Moodbuster Life messaging system and is focused on helping the participant work through the modules, showing empathy and motivating the participants to continue with the modules. The coaching is not aimed at developing a patient-therapist relationship.
40945529|NCT00563355|DRUG|erythropoietin|
40945530|NCT02447562|DEVICE|Platform NOMHADchronic|Intervention group with a health Platform NOMHADchronic
40945531|NCT02447562|OTHER|Phone-based care group|
40945532|NCT02447562|OTHER|Usual care group|
40945533|NCT02187705|DRUG|Telmisartan tablets|All patients were treated with different doses of telmisartan for 14 days
41132877|NCT03754660|DRUG|BAY1237592|Oral inhalation with dry powder inhaler, single dose.
41132878|NCT01989689|DRUG|Etanercept|Etanercept 50mg twice weekly
41132879|NCT01989689|DRUG|Placebo|
41132880|NCT00481572|DRUG|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
41132881|NCT00481572|DRUG|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
41132882|NCT00481572|DRUG|Norepinephrine|titrated norepinephrine over a period of 48 hrs
41132883|NCT03847545|DRUG|Fampridine|sustained-release tablet 10 mg morning and evening.
40945534|NCT05522231|DRUG|fruquintinib+sintilimab|fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
40945535|NCT05522231|DRUG|axitinib / everolimus|axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle.
40945536|NCT05522231|DRUG|fruquintinib|fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
40945537|NCT05061966|BEHAVIORAL|immi|The intervention has four main content areas: 1) gender identity (the gender guide), 2) sexual orientation (the queerness guide), 3)stress and coping (the stress guide), and 4) internalized stigma (the internalized stigma guide).
40945538|NCT05061966|BEHAVIORAL|Control|The control will have access to resources on the website, but will not receive any engagement reminders, matching the conditions present in real world contexts in which web-based resource lists are available.
40945539|NCT01104701|DRUG|exenatide once weekly|subcutaneous injection, 2 mg, once a week
40945540|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
40945541|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
40945542|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
40945543|NCT05895864|DRUG|utidelone injection|utidelone monotherapy in patients with recurrent or metastatic urothelial carcinoma by utidelone
40945544|NCT02127723|DEVICE|Hyaluronic acid injection (Macrolane VRF30)|Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
40945545|NCT05921747|OTHER|Standard core stability exercise program|The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.
40945546|NCT05921747|DEVICE|Off-the-shelf virtual reality system|HTC Vive (HTC Corporation, Bellevue, WA) VR Head-Mounted Display (110º field of view, 1080 × 1200 pixels/eye, 90 Hz refresh) along with the Vive hand controllers and trackers to provide an immersive VR experience. The Vive Tracker can be used to track limb and trunk position and motion while in a VR experience. This setup will be paired with a gaming computer with the power to run a VR experience at a high frame rate to mitigate the risk of motion sickness. KVET™( Karuna Virtual Embodiment Training) consists of 10-30 minute sessions of exercises in an embodied VR experience.
40945547|NCT04894292|OTHER|Non intervention|During the study there is no extra intervention planned for the participants.
40945548|NCT02047227|DRUG|Pergoveris®|Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
41132884|NCT00312208|DRUG|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
41132885|NCT00312208|DRUG|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
41132886|NCT00360269|DRUG|Atomoxetine|25 to 100 mg daily
41132887|NCT00360269|PROCEDURE|Motivational enhancement therapy|Three sessions
41132888|NCT00360269|DRUG|Placebo|25 to 100 mg daily
40945549|NCT02047227|DRUG|GONAL-f®|GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
40945550|NCT02047227|DRUG|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
40945551|NCT06556472|DRUG|Terlipressin|1. Patients in this group will receive continuous terlipressin infusion (1 mg/24 hr on day 1, increasing to 1 mg in 24 hours if target MAP not achieved ,reaching maximum terlipressin dose of 4 mg/24 hr on day 4).If target MAP not achieved by terlipressin dose ,increase noradrenaline dose keeping terlipressin maximum 1 mg ,2 mg ,3mg ,4mg at Day 1,2,3,4 respectively.
40945552|NCT06556472|DRUG|Norephrine|1. Patients in this group will receive norepinephrine only, with a dose range of 0.05 mcg/kg/min to 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.
40945553|NCT04090073|PROCEDURE|Electroacupuncture|As above
40945554|NCT04090073|OTHER|Fast-track Perioperative program|As above
40945555|NCT00781508|DRUG|sildenafil|Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
41286165|NCT04243369|DEVICE|Non-diagnostic software solution|Collaboration Live is a non-diagnostic software solution intended for use with Philips (Philips Ultrasound, 22100 Bothell Everett Highway, Bothell, Washington 98021) EPIQ and Affiniti Series Ultrasound Systems (software version 5.0.2) that allows users to communicate (by text, voice, screen share, webcam video and remote takeover) from an ultrasound system or workstation to a remote destination.
41286166|NCT02822365|PROCEDURE|Computed Tomography|Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
41286167|NCT02822365|DEVICE|Imaging Phantoms|Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
40945556|NCT00781508|OTHER|Placebo|Changes in left ventricular filling pressure 1 hour after oral administration of placebo
40945557|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
40945558|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
40945559|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
40945560|NCT04495933|OTHER|Placebo|sterile saline
40945561|NCT01051466|DRUG|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
40945562|NCT04668807|DEVICE|Connected Medical Device|Monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) with a Connected Medical Device (DMC) in the operating room
40945563|NCT04668807|DEVICE|Traditional transmission system|Monitoring of physiological parameters with a traditional wired transmission system between the sensor and the data processing device in the operating room
40945564|NCT05361785|BIOLOGICAL|FMT|FMT from healthy donor or placebo
40945565|NCT04210583|DEVICE|Vulvovaginal Treatment|"Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).~Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).~Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).~Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment)."
40945566|NCT01641874|PROCEDURE|Exercise|Directional specific exercise
40945567|NCT01641874|PROCEDURE|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
40945568|NCT02058173|DRUG|150 mg/daily chloroquine compare to placebo for 12 week|
40945569|NCT02058173|DRUG|Chloroquine|
40945570|NCT02058173|DRUG|placebo|
40945571|NCT00358423|DRUG|Pegaptanib Sodium|0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
40945572|NCT00358423|DRUG|Control|Sham injections, every 6 weeks, up to a total of 3 sham injections
40945573|NCT04979520|DRUG|Brodalumab|Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
40945574|NCT03614507|DEVICE|FreeO2 (modèle FO2-220-00) automatic oxygen flow titration|Automatic adjustment of oxygen flow titration through the FreeO2 device. The monitor allows continuous monitoring and recording of SpO2 and Heart rate
40945575|NCT03614507|DEVICE|FreeO2 (modèle FO2-220-00) manual oxygen flow titration|Manual oxygen flow titration performed by the healthcare provider in charge of the patient (nurse, physician). For this group, the FreeO2 device will only monitor and record SpO2 and heart rate.
40945576|NCT04710420|DEVICE|Endovascular therapy|Endovascular treatment for critical limb threatening Ischemia
40945577|NCT00392080|DRUG|CJ-023,423|75 mg BID
40945578|NCT00392080|DRUG|placebo|placebo
40945579|NCT00392080|DRUG|naproxen|naproxen
40945580|NCT00470847|DRUG|Lapatinib|Orally twice daily
40945581|NCT00470847|PROCEDURE|Whole Brain Radiation|15 treatments over a period of 3 weeks
40945582|NCT00470847|DRUG|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
40945583|NCT03728530|OTHER|Deep Breathing exercises|"In pursed lip exercise subject was guided to inhale through nose with mouth closed and exhale through pressed lips (pursed lips).~In Diaphragmatic breathing subject was instructed to place his one hand below the rib cage and the other hand on chest. The patient inhaled slowly so that stomach moves out against the hand. Tighten the stomach muscle while exhaling through pursed lip.~In powered breathing subject was to inhale and exhale forcefully with some movements like subject was instructed to inhale forcefully while moving his hands upward and exhale forcefully while moving hands downward.~These three exercise techniques were advised to each subject of experimental group. They have to practice these exercises 3-4 times a day with 10 repetitions each. These exercises can be performed in sitting position or in supine lying position. Subject can adopt any position in which he feels comfortable."
40945584|NCT03473951|DIAGNOSTIC_TEST|Hyperuricemia|Hyperuricemia vs. normouricemia
40945585|NCT04824976|DIETARY_SUPPLEMENT|Blueberry|freeze-dried Northern highbush blueberry powder twice daily 15g = 60kcal
40945586|NCT04824976|DIETARY_SUPPLEMENT|Placebo|matched powder maltodextrin twice daily = 60kcal
40945587|NCT02054377|OTHER|Tai chi|"Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD."
40945588|NCT00836030|OTHER|No treatment given|No treatment given
40945589|NCT01434407|OTHER|Dietary meal intervention|Test meals with different AGE content made by different cooking methods
40945590|NCT05352373|DIETARY_SUPPLEMENT|calcium|calcium carbonate
40945591|NCT05352373|DIETARY_SUPPLEMENT|placebo|sodium bicarbonate
41132889|NCT05866575|OTHER|escitalopram|Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
40945592|NCT00004198|BIOLOGICAL|keyhole limpet hemocyanin|
40945593|NCT00004198|BIOLOGICAL|sargramostim|
40945594|NCT00004198|BIOLOGICAL|tumor cell-based vaccine therapy|
40945595|NCT05820061|DIAGNOSTIC_TEST|upper endoscopy|data will be collected from the enoscopy archive files in Department of Tropical Medicine and Gastroenterology,Sohag University Hospital
41286168|NCT02822365|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan as clinically indicated.
40945596|NCT06119399|OTHER|Diaphragmatic Breathing Exercise|Diaphragmatic breathing exercise will be taught by placing the subject comfortably positioned with either therapist or the patient's hand directed over the abdominal area and instructing the subjects to focus on an outward movement of the abdominal area throughout inspiration and an inward movement of the abdominal area during expiration. (4 sets, and as each set had 4 complete breathing breaks, these exercises will be conducted for 3 days a week for 6 weeks)
40945597|NCT06119399|OTHER|Pursed Lip Breathing Exercise|Pursed lip breathing exercises will be performed by necessitating the subjects to inhale through their nose and then exhaling slowly for a period of 4-6 s by pursing the lips
41286169|NCT03730389|DEVICE|External Physical Vibration Lithecbole (EPVL)|Using the the way of external physical vibration to promote separation of stones from ureteral mucosa and promoting the excretion of ureteral stones
41286170|NCT02179398|BIOLOGICAL|Allocation to the Lab-score group|
41132890|NCT05866575|OTHER|vortioxetine|Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
41132891|NCT03936192|DRUG|glucosamine sulphate 1500mg and meloxicam 15mg|glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
41132892|NCT03936192|DRUG|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
41132893|NCT03936192|DRUG|Placebos|Placebo administered once daily for 12 weeks.
41286171|NCT02179398|BIOLOGICAL|Allocation to the control group|
41286172|NCT04354025|BIOLOGICAL|Cytokine induced memory-like NK cells|-The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.
41286173|NCT04354025|DRUG|Fludarabine|-Fludarabine (dose: 30 mg/m\^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
41286174|NCT04354025|DRUG|Ara-C|-Ara-C (dose: 2000mg/m\^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.
41452472|NCT05633186|BEHAVIORAL|Motivational Content|Participants who are randomized to this component, receive access to extra content that is based on the principles of motivational interviewing. This includes an extended first module that contains psychoeducation on the importance of motivations and on how persons can motivate themselves to engage with the interventions. Participants are asked about their life goals (long term) and intervention goals (short time) and are guided in how they should formulate these goals to increase the chance of success. Moreover, in each of the 4 modules a short exercise aimed at increasing motivation is included.
41286175|NCT04354025|DRUG|G-CSF|-Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.
41286176|NCT04354025|DRUG|Interleukin-2|-IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).
41286177|NCT04354025|PROCEDURE|Leukapheresis|-Donor only
41286178|NCT04082572|BIOLOGICAL|Pembrolizumab|Given IV
41286179|NCT01742923|BEHAVIORAL|Complex tailored intervention|
41286180|NCT01742923|BEHAVIORAL|Usual care|
41286181|NCT05835258|DIETARY_SUPPLEMENT|Melatonin with phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement with phenyl capsaicin
41286182|NCT05835258|DIETARY_SUPPLEMENT|Melatonin without phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement without phenyl capsaicin
41286183|NCT05121246|DRUG|MB05 (Proposed palivizumab biosimilar)|Single IM dose of 3 mg/kg
41286184|NCT05121246|DRUG|EU-Synagis®|Single IM dose of 3 mg/kg
41286185|NCT05121246|DRUG|US-Synagis®|Single IM dose of 3 mg/kg
41286186|NCT01089725|BIOLOGICAL|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
41286187|NCT01089725|BIOLOGICAL|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
41452473|NCT03997799|PROCEDURE|uniportal lobectomy with complete lymphadenectomy|uniportal lobectomy with complete lymphadenectomy
41452474|NCT02910687|OTHER|This is an observational study|
41452475|NCT03793803|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
40945598|NCT06119399|OTHER|Doming of the diaphragm|"* The physiotherapist places the thumbs just inferior to the patient's lower costal margin and xiphoid process with the thumbs pointing cephalad.~* The patient is instructed to take a deep breath and exhale. On exhalation, the physiotherapist's thumbs follow the diaphragm, which permits the thumbs to move posteriorly.~* The patient is instructed to inhale, and the physiotherapist gently resists this motion.~* The patient is instructed to exhale, and the physiotherapist gently follows this motion posteriorly and cephalad, as the thumbs are now beneath the costal margin and xiphoid process.~* The patient inhales as the physiotherapist maintains pressure on the upper abdomen and then, on repeated exhalation, encourages further cephalad excursion.~* This procedure is repeated for three to five respiratory cycles until the diaphragm domes easily at the end of exhalation."
40945599|NCT06119399|OTHER|Conventional exercise program for chronic neck pain|"Patients will perform three repetitions of stretching exercises for neck flexor, extensor, lateral flexor, and rotator for 30 seconds as warm-up and cool-down exercises, to relieve tension on each side of the neck.~Then cranio-cervical flexion exercise will be started using feedback from an air-filled pressure sensor placed behind the neck. Subjects will lay in the crook lying position. The pressure biofeedback unit will be placed below the occiput and inflated up to a baseline pressure of 20 mmHg. The subjects will be instructed to perform head-nodding action to progressively target 5 pressure levels (hold 10 seconds with brief rest periods between each contraction 3-5 seconds). This includes 3 sets in a session for 10 repetitions each with 2 minutes of rest between sets and 3days a week for 6 weeks."
40945600|NCT06021665|OTHER|Fortetropin supplement|Test Formulation: 10g serving Calories: 64.8g Carbohydrates: 0.45g Fats: 5.5g Protein: 3.38g
40945601|NCT06021665|OTHER|Cheese protein|"The cheese powder will act as the control product. Cheese powder has been chosen as it matches the macronutrient content of the test product, but without the active ingredient.~Control Formulation: 20g serving Calories: 93g Carbohydrates: 8g Fats: 5g Protein: 3g"
40945602|NCT01609231|DRUG|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
40945603|NCT01609231|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
40945604|NCT01609231|DRUG|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m\^2 followed by weekly infusions of 250 mg/m\^2. Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
40945605|NCT00211484|DRUG|Anecortave Acetate|
40945606|NCT01899664|PROCEDURE|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
40945607|NCT03405896|OTHER|Turning|start to walk with normal speed, and then turn to approach the terminal under different angle.
40945608|NCT02069132|DRUG|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
40945609|NCT05438888|DRUG|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
40945610|NCT05438888|DRUG|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
40945611|NCT01545258|OTHER|Exercise|Physiotherapy supervised exercise training. 60 minutes 3 times per week
40945612|NCT05934942|DRUG|Yasmin®|Ethinylestradiol (EE) and Drospirenone (DRSP)
41286188|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
41452476|NCT03398486|DIAGNOSTIC_TEST|Kinesiotaping|Dynamic adhesive taping is a method that involves the application of specific tapes to the surface of the patient's skin in order to use the natural self-healing processes of the body. It is often used as an element that sustains the therapeutic effect. Its action is based mainly on the action normalizing muscle tone, supporting the work of joints, improving the function of weakened muscles, increasing microcirculation at the site of application.
41452477|NCT03398486|DIAGNOSTIC_TEST|inactivation of trigger points (TrP)|A procedure for releasing trigger points using physiotherapy using the ischemic compression method, which involves applying pressure to the active trigger point, until it is switched off, i.e. pain ceases.The location of the trigger point is done palpatively, with a pliers grip, covering the strained tissue on the inside and outside of the cheek with the thumb and index finger.
41452478|NCT04738864|DIAGNOSTIC_TEST|ultrasound|extracranial and intracranial ultrasound assessment
40945613|NCT05934942|DRUG|BI 1358894|BI 1358894
40945614|NCT01858376|DIETARY_SUPPLEMENT|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
40945615|NCT00417508|DIETARY_SUPPLEMENT|Sip feeding|Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)
41286189|NCT01089725|BIOLOGICAL|Placebo IV|1 ml placebo administered IV every 8 weeks
40945616|NCT00417508|DIETARY_SUPPLEMENT|Dietary Advice|The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
40945617|NCT04709471|DRUG|Nicotine|Participants will reduce their nicotine intake
40945618|NCT04709471|DEVICE|Juul e-cigarette|Participants will switch to Juul pods containing less nicotine
41132894|NCT03956407|DEVICE|Repetitive peripheral nerve stimulation|Active repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For active stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.
41286190|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
41286191|NCT01089725|BIOLOGICAL|Placebo IV|1ml placebo administered IV every 8 weeks
41286192|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
41286193|NCT01089725|BIOLOGICAL|Placebo IV|1ml placebo administered IV every 8 weeks
40945619|NCT04709471|BEHAVIORAL|Reduction|Participants will reduce the number of Juul pods that they use
40945620|NCT05234658|BIOLOGICAL|PHITAH|Tissue Engineered Human Artificial Skin: Fibrin-Hyaluronic Acid
40945621|NCT05234658|BIOLOGICAL|PHIT|Human artificial skin created by tissue engineering: fibrin-agarose
40945622|NCT05234658|BIOLOGICAL|Skin Autograft|Skin Autograft
40945623|NCT03297814|BIOLOGICAL|Platelet lysate|Intramuscular injection of platelet lysate
40945624|NCT03297814|BIOLOGICAL|Placebo|intramuscular injection of normal saline
40945625|NCT05271071|DIAGNOSTIC_TEST|Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection
40945626|NCT00978471|DRUG|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
40945627|NCT01481181|DIETARY_SUPPLEMENT|Zinc enriched water|3mg zinc/L of purified water from a filter installed in the households
40945628|NCT03949985|OTHER|Tests of biological hemostatic profile associated with contraceptives|Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)
40945629|NCT05995119|DRUG|Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)|The subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods.
40945630|NCT04569253|DEVICE|TempSure|Non-invasive radiofrequency treatments
41452479|NCT03968328|OTHER|Interview|Take part in interview
40945631|NCT03886662|DRUG|LB-100|"Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.~Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes."
40945632|NCT05734833|DIETARY_SUPPLEMENT|Culturelle Probiotic + Fiber|The experimental group will receive the study product which is Culturelle Probiotic + Fiber
40945633|NCT05734833|OTHER|Placebo|The Placebo comparator arm will receive placebo sachets
41286194|NCT01089725|BIOLOGICAL|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
41286195|NCT01089725|BIOLOGICAL|Placebo SC|1ml placebo administered SC every 8 weeks
41286196|NCT01123304|DRUG|MORAb028|1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
40945634|NCT01417936|DRUG|Sym004|Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
40945635|NCT01068652|DRUG|insulin detemir|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
40945636|NCT01068652|DRUG|insulin aspart|Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
40945637|NCT01068652|DRUG|biphasic insulin aspart 30|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
41286197|NCT04856085|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
41452480|NCT03968328|OTHER|Survey Administration|Respond to survey
41452481|NCT06348329|OTHER|Birth Preparation Training|Birth Preparation Training is planned to include a 4-week program by an internationally certified instructor.
40945638|NCT01068652|DRUG|metformin|1000-2000 mg/day in combination with insulin treatment
40945639|NCT01638767|DRUG|Contraceptives, Oral|0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
40945640|NCT01638767|DRUG|Contraceptive, Vaginal ring|etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
40945641|NCT02758171|DRUG|Empagliflozin|
40945642|NCT02758171|DRUG|Linagliptin|
41286198|NCT04856085|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
41286199|NCT04856085|DRUG|PEG-IFNα|PEG-IFNα given by subcutaneous injection
40945643|NCT01225627|OTHER|Coordinated discharge|In intervention group, a discharge coordinator contacts hospitalized patients the day after randomization. During hospitalization, discharge coordinator visits are scheduled according to patients' problems and home-care needs. At 48 hours after hospital discharge, a discharge coordinator calls patients by phone to check the process of adjustment to home environment and to inquire about additional needs patients might have. Thereafter, phone contacts are scheduled according to the patients' needs and 7-10 days after the hospital discharge a home visit is performed by discharge coordinator, respectively.
40945644|NCT01225627|OTHER|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
40945645|NCT05544370|BEHAVIORAL|Intensive high intensity intervallic training group|The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
40945646|NCT05544370|BEHAVIORAL|Extensive high-intensity intervallic training|The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
40945647|NCT05449522|DIETARY_SUPPLEMENT|Vitamin D|High dose of vitamin D with 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) is given orally or enterally via a feeding tube
40945648|NCT05449522|DIETARY_SUPPLEMENT|Placebo|Medium-chain triglyceride (MCT)
40945649|NCT01891110|PROCEDURE|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
40945650|NCT01891110|PROCEDURE|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
40945651|NCT01891110|PROCEDURE|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
40945652|NCT03439657|BIOLOGICAL|HZ/su vaccine GSK1437173A|2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
40945653|NCT03439657|BIOLOGICAL|Prevenar13|1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
40945654|NCT05399303|PROCEDURE|obturation|obturation using different types of sealers
40945655|NCT02654847|DRUG|Norepinephrine|
40945656|NCT02654847|DRUG|Normal Saline|0.9% sodium chloride solution, used as a diluent.
40945657|NCT00715000|PROCEDURE|Oral rehydration therapy|oral rehydration solution
40945658|NCT00715000|PROCEDURE|classical hydration via intravenous infusion|intravenous infusion
40945659|NCT05092854|OTHER|PR Lotion - AMP Human Performance|"Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.~Other Names:~NDC Code: 72358-101-01 NDC Code: 72358-101-02 NDC Code: 72358-101-03"
41132895|NCT03956407|DEVICE|Sham Repetitive peripheral nerve stimulation|Sham repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For sham stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.
41132896|NCT05181735|DRUG|Luspatercept Injection [Reblozyl]|All patients will receive Luspatercept subcutaneously on day 1 of each 21 day cycle (every 3 weeks) at the selected dose according to part A : 1.75mg/kg or 1.33 mg/kg or 0.8 mg/kg
40945660|NCT05092854|OTHER|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
41286200|NCT00849212|DRUG|E2007|The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
41286201|NCT01849848|DRUG|SyB L-0501|The administration of SyB L-0501 at 90 mg/m\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
41286202|NCT03002493|DRUG|Eribulin mesylate|"Treatment phase: During Cycle 1, eribulin mesylate was administered as a 2 to 5 minute (min) intravenous (IV) infusion at 1.4 mg/m2 on Day 1 and Day 15 of 21-day cycle. During subsequent cycles, eribulin mesylate administration as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of a 21-day cycle.~Extension phase: Eribulin mesylate was administered continuously as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of 21-day cycles, as long as the Investigator considered eribulin mesylate therapy to be clinically appropriate."
40945661|NCT05092854|OTHER|AminoVital - Rapid Recovery|AminoVITAL Rapid Recovery is a commercially available supplement that is not currently regulated by the FDA but does complete both internal quality control and third-party testing for all of their products. AminoVITAL Rapid Recovery has been certified by the Banned Substance Control Group (BSCG; https://www.bscg.org/certified-drug- free-supplements/?AminoVITAL) and has been certified to be free of 496+ drugs including WADA Prohibited Substances as well as prescription, over the counter, and illicit drugs not banned in sport. AminoVITAL Rapid Recovery is safe to consume multiple times within a single day and has been found most effective when taken within 30 minutes of cessation of exercise. No known side effects are associated with the ingestion of aminoVITAL Rapid Recovery; however, side effects of amino acid toxicity include gastrointestinal distress, nausea and headache.
40945662|NCT05092854|OTHER|Placebo Supplement|Supplement will be created by the aminoVITAL company and will include all ingredients similar to the commercially available Rapid Recovery product except for the exclusion of the amino acid blend.
40945663|NCT04370431|DRUG|TTYP01 single ascending doses|TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)
40945664|NCT04370431|DRUG|Placebo|Placebo control for Part A of the study
40945665|NCT04370431|DRUG|TTYP01, 60 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
40945666|NCT04370431|DRUG|TTYP01, 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
41452482|NCT06563063|DRUG|Flumazenil|The dose determination for flumazenil followed a biased-coin up-and-down design. Starting with an initial dose of 5 mcg, if there was an improvement in respiratory distress, the biased-coin method was used to give the same dose in the next patient with a probability of 8/9, and a decreased dose of 5 mcg in the next patient with a probability of 1/9.
40945667|NCT04370431|DRUG|Radicut® (ampoule), 30 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes
40945668|NCT04370431|DRUG|Radicut® (bag) , 60 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes
40945669|NCT04370431|DRUG|TTYP01, up to 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)
41286203|NCT03002493|DRUG|Eribulin mesylate|
40945670|NCT00537875|DIETARY_SUPPLEMENT|Ginger|Capsule, 1000 mg, BID, 3 days
40945671|NCT00537875|DIETARY_SUPPLEMENT|Placebo|Capsule, 1000 mg, BID, 3 days
41132897|NCT05181735|DRUG|Eprex|Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
41132898|NCT02558205|RADIATION|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
41286204|NCT03002493|DRUG|Rifampicin|Treatment phase: Rifampicin 600 mg was administered orally once a day, from Day 9 to Day 20 of 28-day cycle of Cycle 1.
41452483|NCT04511208|DEVICE|Cooling Vest|Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.
41452484|NCT04511208|DEVICE|Without cooling vest|Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.
41132899|NCT02558205|RADIATION|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
41132900|NCT03314324|DRUG|ODM-201|ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.
41132901|NCT03314324|DRUG|Enzalutamide|Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
41286205|NCT04649853|OTHER|Standardized nursing care|All patients will receive standardized evidence based nursing care
41286206|NCT02226016|DEVICE|FG-5000A|a measuring device for the assessment of levator muscle strength
41286207|NCT00018863|DRUG|Methylphenidate|
41132902|NCT00130182|DRUG|denufosol tetrasodium (INS37217)|
41286208|NCT01479725|PROCEDURE|HBOT|HBOT
41286209|NCT04151004|OTHER|Incremental cycling test (ICT)|Incremental cycling test to volitional exhaustion
41286210|NCT04151004|OTHER|Constant load cycling test (CET)|Constant load cycling test to volitional exhaustion.
41286211|NCT04151004|OTHER|Incremental respiratory muscle test (IncRMET)|Incremental respiratory muscle test to volitional exhaustion.
41286212|NCT04151004|OTHER|Incremental quadriceps muscle test (IncQMT)|Incremental quadriceps muscle test to volitional exhaustion.
41286213|NCT04151004|OTHER|Respiratory muscle training like interventions|Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
41286214|NCT03020186|OTHER|Physical activity|
41286215|NCT03020186|OTHER|Physical activity+ MED diet|
41452485|NCT00654186|DRUG|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
41452486|NCT06475651|GENETIC|Methylation analysis|Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.
40757552|NCT05235828|BEHAVIORAL|Sudarshan Kriya Yoga (SKY)|This is the experimental arm of the study, where participants will be trained in a form of breathing based meditation that incorporates different breathing techniques centred around controlling arousal and attention. Participants will be encouraged to learn all of the techniques that are covered during these sessions and also utilize the techniques that are most appropriate for their personal needs. After some initial training sessions, participants will be encouraged to practice their new SKY techniques in environments and situations that they have been avoiding. They would begin with situations that are less triggering, and progress to more difficult situations. At each group session, participants will describe their experiences and discuss ways to continue to incorporate the SKY techniques into their daily lives, until it reaches a point of being natural to use these skills throughout the day, both in practice, and in application.
40945672|NCT03401593|DRUG|midazolam with fentanyl|Radio-frequency catheter ablation is performed in the post-absorptive state after sedation with midazolam and fentanyl. Multipolar catheters were positioned in the coronary sinus, His, and the right atrium. The three-dimensional LA geometry was reconstructed using a CARTO or NavX electroanatomical mapping system. Circumferential pulmonary vein isolation was performed in all patients using a irrigated-tip catheter. A circular mapping catheter was used to confirm the isolation of the pulmonary veins. Successful ablation was defined by the elimination of all the pulmonary vein potentials along the antrum or inside the veins. If the AF was not terminated after elimination of all the pulmonary vein potentials, linear ablation and complex fragmented atrial electrogram ablation were performed.
40945673|NCT00508222|DRUG|Kaletra Tablets|Kaletra 800/200 OD
40945674|NCT05067907|PROCEDURE|Early physiotherapy|"Respiratory physiotherapy included:~1. early and functional mobilization: passive and active mobilization, muscle strengthening, improving independence in activities of daily living (ADL), sitting out of bed, standing, walking;~2. patient positioning to achieve better ventilation/perfusion ratio and gas exchange;~3. airway clearance;~4. aerosol administration;~5. invasive mechanical ventilation weaning;~6. use of non-invasive mechanical ventilation (NIMV) and continuous positive airway pressure (CPAP);~7. tracheostomy management and weaning;~8. swallowing assessment;~9. management of oxygen delivery;~10. lung expansion;~11. patient assessment and functional scale administration."
40945675|NCT02503007|DIETARY_SUPPLEMENT|Placebo|
40945676|NCT02503007|DIETARY_SUPPLEMENT|HMB-FA|
40945677|NCT02907268|DRUG|onabotulinumtoxinA|OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
41132903|NCT04263740|PROCEDURE|Kinesio Taping|Taping for 3 days every week and two sessions of PT twice a week. The PI also instructed the patient to inform him if the tape gets off or become loose. KT was removed after 72 hours, and then reapplied after a few days rest to allow the skin to recover and to avoid skin irritation. The patient was instructed to refrain from getting the tape wet for 30 to 45 minutes after application to allow for better adherence. Patients were also instructed to be careful during dressing and undressing so the tape does not get caught with their clothes if the edges of the tape get slightly loose. No physical therapy treatment or taping was provided during the rest period except for the prescribed home exercise program. Patients in both groups received the same traditional physical therapy treatment two times a week.
40757553|NCT00718731|DRUG|GSI-136|
40757554|NCT00718731|OTHER|Placebo|
40945678|NCT02907268|DRUG|abobotulinumtoxinA|AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
40945679|NCT04357340|OTHER|Pulmonary Physiotherapy Techniques|Participants will receive pulmonary physiotherapy techniques in six session during three days (twice daily). Four distinguished interventions will be provided for the patients: 1) Chest expansion exercises (for prevention and treatment of potential atelectasis); 2) Techniques to Mobilize or loosen the pulmonary secretions (Active cycle breathing, Coughing techniques, Vibration and Postural drainage); 3) Hold breathing exercise (3 sets, 10 repetition) and; 4) Walking training (based on patient's tolerance until 6 minute).
40945680|NCT00569270|DRUG|Placebo|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
40945681|NCT01135823|PROCEDURE|Patient survey|
40945682|NCT04082143|DEVICE|Allograft mucosal enhancement with dental implant|implant placement with allograft mucosal enhancement
40945683|NCT04082143|DEVICE|No allograft mucosal enhancement at time of dental implant placement|implant placement without allograft mucosal enhancement
40945684|NCT04049643|DEVICE|Audiologist-based fitting|Hearing aids will be fitted by audiologists using established procedures.
40945685|NCT04049643|DEVICE|Service-only Fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. In this intervention group, audiological services plus hearing aids that provide minimum amplification will be provided. Specifically, patient participants in this group will receive audiological services (e.g., counselling and education), except that the hearing aids will be set to provide no amplification other than what is needed to overcome any sounds that are dampened by the earpieces.
40945686|NCT04049643|DEVICE|Device-only fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. The patient participants in this intervention group will have minimum services regarding the pre-fitting, selection, and orientation of the hearing aids. The participants will have a hearing evaluation, including pure-tone audiometry. The audiologist will select the amplification characteristics and non-custom ear piece based on the audiogram. The audiologist will then briefly orient the participant on how to use the hearing aids and counsel on how to optimize their performance.
40945687|NCT05181033|DRUG|Lenvatinib + Letrozole|"Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity.~Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities.~Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled.~Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing.~For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake.~There is no dose modifications for letrozole."
40945688|NCT05181033|DRUG|Fulvestrant|Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.
40945689|NCT00394446|DRUG|MPC-6827|2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
40945690|NCT01856907|DRUG|Sitagliptin-Metformin|Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
40945691|NCT01856907|DRUG|Metformin|Biguanide- insulin sensitizer
40945692|NCT01856907|DRUG|Placebo pill|Will evaluate effect of lifestyle and diet only
40945693|NCT01810432|DRUG|Evacetrapib|Administered orally
40945694|NCT01810432|OTHER|High-fat Meal|Administered orally, at breakfast.
40945695|NCT02908243|OTHER|collection of baseline data|collection of baseline data including ages, types, severity, inhibitors and comorbidities
40945696|NCT03308955|DRUG|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
40945697|NCT03308955|PROCEDURE|Ultrasound guided Quadratus Lumborum block|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
40945698|NCT03308955|PROCEDURE|Ultrasound guided placebo Quadratus Lumborum block|Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
40945699|NCT00752037|DRUG|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
40945700|NCT00224705|DEVICE|Molecular Adsorbent Recirculating System (MARS®)|
40945701|NCT00570414|DEVICE|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
40945702|NCT00570414|DEVICE|Endotracheal tube|Airway management by the use of endotracheal tube
41286216|NCT03020186|OTHER|Physical activity+green MED diet|\*\*\*\*Sub-study from all 3 main arms: Autologous fecal microbiota supplement intervention derived from the time of maximal weight loss: At the 6-month time period, the time of anticipated greatest weight reduction, participants's feces samples will be processed to capsulized inocula. Samples will be frozen within 2 hours and will be kept at -80c pending analysis. Participants will be randomized to receive either research capsules or identical placebo capsules between 8 and 14 months time period. Placebo capsules will consist of a combination of powdered cocoa and vegetable gelatin in normal saline/glycerol and will be identical in appearance to research capsules.
40945703|NCT00052780|DRUG|O6-benzylguanine|Given IV
40945704|NCT00052780|DRUG|temozolomide|Given PO
40945705|NCT00052780|BIOLOGICAL|filgrastim|Given SC or IV
40945706|NCT00052780|OTHER|pharmacological study|Correlative studies
40945707|NCT00052780|OTHER|laboratory biomarker analysis|Correlative studies
40945708|NCT04805762|OTHER|Your COACH Next Door|Children in the study are attending the lifestyle intervention Your COACH Next Door. A coach is supporting the child and it's family to reach their goals regarding lifestyle.
40945709|NCT06220279|DRUG|Diclofenac|Each were monitored for pain within 24 hours
40945710|NCT03658057|DRUG|Rocuronium|whether neuromuscular blockade by administering rocuronium is performed or not.
40945711|NCT04017000|DIAGNOSTIC_TEST|Bladder Shape Test|Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
40945712|NCT04017000|OTHER|Calibration images|Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
40945713|NCT00747461|DEVICE|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
40945714|NCT04206007|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06
40945715|NCT01349179|DEVICE|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
40945716|NCT05034718|OTHER|PIBIS clinical decision support|The intervention is the presence of the PIBIS physician alert and powerform, which is clinical decision support for the treating provider if a patient meets inclusion criteria for Pittsburgh Infant Brain Injury Score (PIBIS) calculation.
40945717|NCT05034718|OTHER|Standard of care|Standard of care, absent the PIBIS powerform and alert for providers.
40945718|NCT01580514|DRUG|exenatide BYETTA® (Amylin-Lilly)|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
40945719|NCT01580514|DRUG|Saline|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
40945720|NCT02415257|DRUG|Gentamicin|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
40945721|NCT02463968|PROCEDURE|Venipuncture for blood draw|Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
40945722|NCT02463968|PROCEDURE|Arthrocentesis for synovial fluid draw|Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
40945723|NCT04432272|BIOLOGICAL|COVID-19 convalescent plasma|Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit
40945724|NCT03250169|DRUG|Alemtuzumab|Licensed dose
40945725|NCT05621915|DRUG|Nadroparin|Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.
40945726|NCT03824184|PROCEDURE|manipulation of endometrium|Manipulation of endometrium with saline
40945727|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fasting condition
40945728|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fed condition
40945729|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
40945730|NCT01298310|DRUG|Xylocaine|1 mg/mL solution for injection
40945731|NCT01298310|DRUG|Xylocaine|10 mg/mL solution for injection
40945732|NCT01298310|DRUG|Placebo|solution for injection
40945733|NCT01512342|BEHAVIORAL|Pacing|3 one-on-one sessions weekly for 3 consecutive weeks
40945734|NCT01512342|BEHAVIORAL|relaxation therapy|3 one-on-one sessions weekly for 3 consecutive weeks
40945735|NCT03589469|DRUG|Loncastuximab tesirine|intravenous infusion
40945736|NCT04642612|DEVICE|TCD Measurement|"CBFV measurements will be acquired continuously with the patient supine and the head neutral. Analysis of CBFV measurements will be undertaken at 3 timepoints:~1. Patient awake and supine in the holding area~2. After sedation~3. After interscalene nerve block"
40945737|NCT03642665|DRUG|Natural cycle|no medication
40945738|NCT03642665|DRUG|Estradiol Valerate|Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
40945739|NCT03642665|DRUG|Micronized progesterone|Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
40945740|NCT00214643|DRUG|Fosmidomycin|30 mg/kg
40945741|NCT00214643|DRUG|clindamycin|10 mg/kg
40945742|NCT03048474|DRUG|nivolumab and ipilimumab|
40945743|NCT03805607|DRUG|Ketorolac Tromethamine 30 MG/ML|Ketorolac 30 mg
40945744|NCT03805607|DRUG|Placebos|Normal Saline
40945745|NCT02947412|OTHER|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
40945746|NCT04025983|DIETARY_SUPPLEMENT|GastimunHp Plus|Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.
41132904|NCT04263740|PROCEDURE|Traditional Physical therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.
40945747|NCT04025983|OTHER|Placebo|The placebo contains neither IgY nor L. johnsonii.
40945748|NCT04708106|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS Tobacco Flavor product
40945749|NCT04708106|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS Menthol product
40945750|NCT04708106|OTHER|RELX ENDS Tobacco and Menthol Flavors|Ad libitum use of the RELX ENDS Tobacco and Menthol Flavor products
40945751|NCT02849665|OTHER|Kangaroo Position|
40945752|NCT03135626|DRUG|Biodentine|
40945753|NCT03135626|DRUG|ProRoot (Aggregate)|
40945754|NCT03135626|DRUG|MTA Plus|
40945755|NCT03135626|DRUG|Ferric Sulfate 20 % Dental Gel|
40945756|NCT05686954|OTHER|CSO LOW|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as cottonseed oil for 28 days.
40945757|NCT05686954|OTHER|CSO MID|Participants are provided a breakfast shake and a snack daily that delivers 20% of the participant's estimated energy needs as cottonseed oil for 28 days.
40945758|NCT05686954|OTHER|CSO HIGH|Participants are provided a breakfast shake and a snack daily that delivers 30% of the participant's estimated energy needs as cottonseed oil for 28 days.
41286217|NCT00060086|DIETARY_SUPPLEMENT|pomegranate juice|Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
41286218|NCT02896725|DEVICE|Keratin dressings|Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
41286219|NCT02896725|DEVICE|Usual care dressings|Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
41286220|NCT06126445|DEVICE|Battery operated toothbrush|Device on plaque removal efficacy
41286221|NCT06126445|DEVICE|Manual toothbrush|Device on plaque removal efficacy
41286222|NCT05066893|OTHER|telehealth visits|intensive visits with doctor
41286223|NCT06510426|DRUG|Rebif 44 MCG Per 0.5 ML Prefilled Syringe|Rebif 44mcg per 0.5ml administered subcutaneously
41286224|NCT06510426|DRUG|Saline|0.5mL of saline administered subcutaneously
41286225|NCT00252863|DRUG|Symbicort, used twice daily (b.i.d) and as needed (prn)|
41452487|NCT04955990|OTHER|PAH Therapies|No Drug will be administered as part of this study. Real world data will be collected in participants who newly initiate PAH therapies in routine clinical setting or have already been receiving macitentan 10 mg for at least 3 months prior to the index date.
40945759|NCT05686954|OTHER|CONTROL|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
40945760|NCT04986644|DEVICE|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
40945761|NCT05593133|OTHER|Pnf exercises|"PNF techniques will comprise of Warm up, Rhythmic stabilization, Hold Relax, Contract Relax and light exercises and performed on three muscle groups ( Hamstring, Quad and Calf).~20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks."
40945762|NCT05593133|OTHER|Gait training exercises|gait Training exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking. 20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.
40945763|NCT00638807|DRUG|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
40945764|NCT00638807|OTHER|Placebo|Matched oral placebo for 6 weeks
40945765|NCT02788929|DEVICE|Fitbit Charge HR|Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
40945766|NCT00454701|DRUG|Alefacept exposure|Observational
41286226|NCT00252863|DRUG|Budesonide Turbuhaler 200 µg|
41286227|NCT00252863|DRUG|Fluticasone Discus 250 µg|
41286228|NCT00252863|DRUG|Formoterol Turbuhaler 4.5 µg|
41286229|NCT00252863|DRUG|Terbutaline Turbuhaler 0.5 mg|
41286230|NCT00252863|DRUG|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
41286231|NCT00252863|DRUG|Salmeterol Discus 50 µg|
41286232|NCT00252863|DRUG|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
41286233|NCT00252863|DRUG|Fluticasone/Salmeterol Discus 250/50 µg|
41286234|NCT00252863|DRUG|Fluticasone/Salmeterol Discus 500/50 µg|
41286235|NCT00252863|DRUG|Theophylline 200 mg|
41286236|NCT00252863|DRUG|Theophylline 300 mg|
41286237|NCT00252863|DRUG|Singulair 10 mg|
41286238|NCT05687760|BIOLOGICAL|bromelain|is a proteolytic enzyme derived from the stem part and fruit of pineapples (Ananas comosus).used as intracanal medication
41286239|NCT05687760|DRUG|Calcium hydroxide|calcium hydroxide
41286240|NCT01708564|BIOLOGICAL|rhFVIIa|Patients will be administered low, intermediate and high doses of rhFVIIa
41286241|NCT01221545|DRUG|AZD1656|3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
41286242|NCT01221545|DRUG|Placebo|Placebo
41286243|NCT03959618|OTHER|dietary supplements questionary|Patient Questionary Patient to be carried out at the last cure
41286244|NCT02156700|PROCEDURE|Shear wave elastography|Measurement of tumor stiffness by Shear wave elastography - SWE™
41452488|NCT00803816|DRUG|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
41452489|NCT02488239|DEVICE|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
40945767|NCT06072248|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
40945768|NCT06072248|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
40945769|NCT06072248|DEVICE|ventilator|ventilator
40945770|NCT04996823|DRUG|Ipilimumab|Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.
40945771|NCT04996823|DRUG|Axitinib|Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)
40945772|NCT02084212|OTHER|Microperimetry|
40945773|NCT04342273|DRUG|KW-6356|KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7
40945774|NCT04342273|DRUG|KW-6356|KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7
40945775|NCT04342273|DRUG|Placebo|Placebo will be administered once daily at Day 1 through Day 7
40945776|NCT04342273|DRUG|Moxifloxacin|Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.
40945777|NCT06217380|DEVICE|Masimo SafetyNet Alert (MSNA)|This study will explore the feasibility of implementing the Masimo SafetyNet Alert (MSNA) oxygen saturation monitoring system and the acceptance of MSNA by individuals living in a supportive housing program, who inject opioids.
40945778|NCT02231918|DRUG|MIRAPEX® - low|
40945779|NCT02231918|DRUG|MIRAPEX® - medium|
40945780|NCT02231918|DRUG|MIRAPEX® - high|
40945781|NCT04454164|BIOLOGICAL|PRP|platelet rich plasma
40945782|NCT04454164|DRUG|Saline|serum physiologic
40945783|NCT03452228|DRUG|evinacumab|Administered by Intravenous (IV)
40945784|NCT03452228|DRUG|Placebo|Administered by Intravenous (IV)
40945785|NCT02427828|DEVICE|Visensia Respiration Rate Estimation Service (VRES)|Medical device product to provide respiration rate from PPG signal
40945786|NCT02047383|OTHER|Respiratory infection|An assessment of the patients included in the study will be conducted
40945787|NCT02258425|BEHAVIORAL|FEM-CARE|
41132905|NCT05886972|BEHAVIORAL|Awareness about propofol injection induced pain|The aim of the study is to observe the effect of patient awareness about the possibility of occurrence of pain during propofol injection on the rate of incidence and severity of pain during injection as a primary goal as the pain score of propofol injection pain is the main end point of the study .
40945788|NCT02258425|BEHAVIORAL|Health Promotion|
40945789|NCT00547573|DRUG|tadalafil|10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
40945790|NCT00547573|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
40945791|NCT00547573|DRUG|placebo|placebo tablet taken by mouth as needed for 12 weeks not more than once a day
40945792|NCT04612582|DRUG|Thalidomide|Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection); thalidomide (d 1-28 50-100mg, oral); dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, the patients will complete six courses of treatment after entering the group, and the total observation time is one year after the end of treatment.
40945793|NCT04612582|DRUG|Cyclophosphamide|Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
40945794|NCT00333801|BEHAVIORAL|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
40945795|NCT00333801|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
41132906|NCT04254549|DRUG|Rifaximin|550 mg by mouth three times daily for 14 days
41132907|NCT04254549|DRUG|Placebo|By mouth three times daily for 14 days
40945796|NCT03029442|DRUG|Denosumab (Prolia)|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
40945797|NCT03029442|OTHER|Placebo (normal saline)|Identical Denosumab volume of normal saline
40945798|NCT05533723|PROCEDURE|Endoscopic epidural neuroplasty|"EEN catheter, iDolphine S2 (Meta Biomed Co., Ltd, Osong, Korea) was placed in the epidural space through sacral hiatus. EEN was done on the target segments.~During EEN, normal saline was infused into epidural space under epiduroscopic vision. Dexamethasone (5 mg), 0.3% mepivacaine 10 mL, and hyaluronidase (3000 IU) were injected through catheter at the target segments. Holmium-Yag laser was used to cut epidural fibrous bands and for coagulation of epidural bleeding."
40945799|NCT05533723|PROCEDURE|Percutaneous epidural neuroplasty (PEN)|PEN catheter, EDEN-CC (JMT, Yangju, Korea) was placed in the epidural space and neural foramen . PEN was done on the target segments. Dexamethasone (5 mg), 0.3% mepivacaine 10 ml, and hyaluronidase (3000 IU) were injected through the PEN catheter.
40945800|NCT02942927|OTHER|Medication reduction|Systematic approach to reduction in polypharmacy.
40945801|NCT00058487|DRUG|epirubicin hydrochloride|
40945802|NCT00058487|DRUG|thalidomide|
40945803|NCT02330484|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|Give incentives to patients based on their own HbA1c improvement
40945804|NCT02330484|BEHAVIORAL|Give incentives to physician based on their patient's HbA1c improvement|Give incentives to physician based on their patient's HbA1c improvement
40945805|NCT00807131|BEHAVIORAL|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
40945806|NCT00807131|BEHAVIORAL|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
40945807|NCT00807131|BEHAVIORAL|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
40945808|NCT00807131|BEHAVIORAL|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
41132908|NCT03067974|DRUG|Ketamine Hcl 100Mg/Ml Inj|10mg/kg of Ketamine Hcl 100Mg/Ml Inj to be administered intranasally for pediatric procedural sedation
40945810|NCT03917459|DRUG|LCZ696|sacubitril/valsartan 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
41132909|NCT03388736|BEHAVIORAL|Supplementary Medicine|A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.
41132910|NCT05088200|PROCEDURE|surgery|Our study is observational and we use secondary data
41132911|NCT03502369|PROCEDURE|Anterior Quadratus lamborum block|Local anaesthetic will be injected in the fascial plane between psoas major muscle and quadratus lumborum muscle.
41132912|NCT05734690|DRUG|SGLT2i, beta blocker, ARNI, MRA, MTD|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
41286245|NCT05141526|OTHER|Non-restrictive satiating intervention|Diet group containing satiating foods
41286246|NCT05141526|OTHER|Conventional restrictive intervention + non-restrictive satiating intervention|Diet group with a calorie deficit during the first phase followed by a diet containing satiating foods in the second phase
40945811|NCT03917459|DRUG|Enalapril matching placebo|Placebo to Enalapril 10 mg film-coated tablets
40945812|NCT03917459|DRUG|Enalapril|Enalapril 10 mg film-coated tablets
40945813|NCT03917459|DRUG|LCZ696 matching placebo|Placebo to LCZ696 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
40945814|NCT05996627|DRUG|Belumosudil|Given PO
40945815|NCT05996627|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40945816|NCT05996627|OTHER|Electronic Health Record Review|Ancillary study
40945817|NCT05996627|DRUG|Placebo Administration|Given PO
40945818|NCT03906461|DEVICE|Radiofrequency Ablation|The Tacticath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) is designed to facilitate electrophysiological mapping of the heart chambers and to transmit radiofrequency (RF) current to the catheter tip electrode for intracardiac ablation purposes.
40945819|NCT02200783|DEVICE|TripTable|Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.
40945820|NCT02200783|DEVICE|Radial|Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.
40945821|NCT02200783|DEVICE|Femoral|Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
40945822|NCT00971880|OTHER|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
40945823|NCT01833988|DEVICE|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
40945824|NCT01833988|OTHER|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
40945825|NCT04558593|PROCEDURE|Active surveillance|Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)
40945826|NCT04558593|PROCEDURE|Surgery|Per standard of care: partial or full resection of the kidney, imaging annually
40945827|NCT02671409|OTHER|Neural Mobilization (exercise)|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
40945828|NCT01433731|DRUG|placebo for SHAPE (SHP-141)|topical gelled solution
40945829|NCT01433731|DRUG|SHAPE (SHP-141) 0.1% BID|topical gelled solution
40945830|NCT01433731|DRUG|SHAPE (SHP-141) 0.5% BID|topical gelled solution
40945831|NCT01433731|DRUG|SHAPE (SHP-141) 1.0% BID|topical gelled solution
40945832|NCT05770583|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"* FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~* FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98~* FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
40945833|NCT05770583|PROCEDURE|SpO2 (oxygen saturation)|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation≤%98
40945834|NCT01222884|DRUG|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
40945835|NCT01222884|DRUG|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
40945836|NCT02765685|DEVICE|brace ODRA (PROTEOR company)|Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.
40945837|NCT02765685|OTHER|Usual care|"The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, ...), non-medicinal (physiotherapy, port of an orthosis, ...), even surgical, according to the influencers."
40945838|NCT06161272|DRUG|Fluzoparib|single
40945839|NCT06161272|DRUG|Fluzoparib+Apatinib|combination
40945840|NCT05949385|DRUG|ZX-7101A|Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules
40945841|NCT00702689|DRUG|Gleevec, STI571(Imatinib Mesylate)|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m\^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m\^2 oral dose daily (increase to 130 mg/m\^2 daily after 28 days if well tolerated)"
40945842|NCT04603612|PROCEDURE|Primary TURBT|"As shown in (Fig. 1), all patients will be thoroughly evaluated by medical history and physical exam, laboratory investigations, abdominal pelvic ultrasound (US). Then, all patients will be managed by cystoscopy and initial complete TURBT. Patients with benign pathology, non-urothelial carcinoma or muscle invasive disease, will be excluded from the study.~After 4-6 weeks, eligible patients will be appointed for repeat resection TURBT."
40945843|NCT02860377|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
40945844|NCT02860377|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
40945845|NCT01015599|BEHAVIORAL|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
40945846|NCT01572259|DRUG|Growth Hormone|
40945847|NCT01572259|OTHER|interruption of the traitment with growth hormone|
40945848|NCT03457688|DIETARY_SUPPLEMENT|prebiotic inulin-type fructans|
40945849|NCT03457688|DIETARY_SUPPLEMENT|placebo maltodextrin|
40945850|NCT00410202|DRUG|Entecavir|Tablets, Oral, 1mg, once daily, 100 weeks
41286247|NCT05141526|OTHER|Control group|This group will receive minimal healthy guidelines
40945851|NCT00410202|DRUG|Tenofovir|Tablets, Oral, 300 mg, once daily
40945852|NCT00410202|DRUG|Adefovir|Tablets, Oral, 10mg, once daily, 100 weeks
40945853|NCT00410202|DRUG|Lamivudine|Tablets, Oral, 100mg, once daily, 100 weeks
40945854|NCT01638364|DRUG|alcoholic beverage|An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
40945855|NCT01638364|DRUG|non-alcoholic beverage|This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
40945856|NCT04960800|OTHER|Specific exercises|Specific exercises which aims to contract the recti abdominis combined with functional exercises with the aim to contract all the layers of the anterior abdominal wall. Strengthening dosage will be applied with 3 sets, containing between 8 and 12 repetitions of maximal load.
40945857|NCT04750603|DRUG|Fluticasone furoate (FF)/Vilanterol (VI)|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints
40945858|NCT04750603|DRUG|Salbutamol|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints.
40945859|NCT02095067|DEVICE|Video consultation|
40945860|NCT00177996|DRUG|sertraline hydrochloride|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
40945861|NCT03708185|DIETARY_SUPPLEMENT|Beta-alanine|N/A: see arm description
40945862|NCT03708185|DIETARY_SUPPLEMENT|Placebo|N/A: see arm description
41132913|NCT05734690|BEHAVIORAL|Education-First|For the first 3-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 3 months, be invited to participate in the remote heart failure clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for heart failure therapy. Provider education will also consist of the program's medical algorithm and a summary sheet on indications, outcomes, prescribing, and monitoring information
41132914|NCT03176056|DIETARY_SUPPLEMENT|Low carbohydrate diet|For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.
41132915|NCT03176056|DIETARY_SUPPLEMENT|Calori restricted diet|For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI \> 24 and 30 kcal/day for underweight subjects with a BMI \<18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
41132916|NCT01719874|BIOLOGICAL|TCN-032|
41132917|NCT01719874|BIOLOGICAL|Placebo (saline)|
41132918|NCT02736422|OTHER|Hyperpolarised Xenon|Hyperpolarised gas Magnetic resonance imaging (MRI) (3He and 129Xe) has enabled novel methods of in-vivo functional lung imaging that do not rely on the use of ionising radiation.
41132919|NCT04231279|DRUG|synthetic human secretin|Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
41132920|NCT01878305|DEVICE|Molecular Adsorbent Recirculating System (MARS)|MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
41267337|NCT00809380|BEHAVIORAL|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
41286248|NCT06136338|BEHAVIORAL|Mindfulness training|Women in the experimental group underwent four sessions of mindfulness training. The mindfulness training started at the 28th week of pregnancy for the women, the second training was at the 30th week of pregnancy, the third was at the 32nd week of pregnancy, and the last was at the 34th week of pregnancy, with each session lasting 45 minutes.
41286249|NCT02955186|DRUG|Saracatinib|Saracatinib 125 mg once per day for 8 days
41286250|NCT02955186|DRUG|Placebos|Placebo once per day for 8 days
41286251|NCT05777525|COMBINATION_PRODUCT|"application of cream La Chinata"|application of cream enriched with essential oil
41286252|NCT05248958|OTHER|Turkish Validity and Reliability of The CRAVE Scale|The aim of this study is to adapt the Cravings for Rest and Volitional Energy Expenditure (CRAVE) scale to Turkish society and to make its validity and reliability in Turkish.
41286253|NCT02138110|DEVICE|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
40945863|NCT06402643|PROCEDURE|Pterygium Excision|Pterygium will be surgically removed utilizing conventional resection techniques, entailing a blunt resection of the head, neck, and body of the pterygium. Subsequent to the resection, the surgical site will be polished using a surgical diamond burr if deemed necessary, and hemostasis will be achieved using bipolar cautery.
40945864|NCT02140112|BIOLOGICAL|Trichuris suis ova|
40945865|NCT02140112|OTHER|Placebo|
41286254|NCT02378753|BIOLOGICAL|rVSVΔG-ZEBOV|The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
41286255|NCT00728416|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
40945866|NCT02777333|BEHAVIORAL|Simulation training|Simulation training in a skills lab for 1 hour per week over 13 weeks on dry, bench-top box trainers and anatomical simulators
40945867|NCT03098355|BIOLOGICAL|4SCAR19/22 T cells|CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)
40945868|NCT03098355|DRUG|Interleukin-2|Interleukin-2 of 250,000iu/m\^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
40945869|NCT00200642|DEVICE|Stretta® System|
41286256|NCT00728416|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
41286257|NCT02948595|OTHER|Video feedback followed by structured verbal feedback|Video feedback followed by structured verbal feedback
40945870|NCT05627648|DRUG|KP-100LI|Intracordal injection, 20 mcg once per week, 3 weeks
40945871|NCT05627648|DRUG|Placebo|Intracordal injection, once per week, 3 weeks
41286258|NCT02948595|OTHER|Structured verbal feedback followed by video feedback|Structured verbal feedback followed by video feedback
41286259|NCT05910463|OTHER|AXOMOVE Therapy Medical Device|Personalized exercise programs for the self-rehabilitation of low back pain patients
41286260|NCT03388125|DRUG|Injection Sclerotherapy|5% ethanolamine oleate group
41286261|NCT03388125|DRUG|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
41286262|NCT01534832|DEVICE|Innervision Surgical Smoke Removal System|Smoke removal by electrostatic precipitation
41286263|NCT02935881|DEVICE|Radio Frequency Ablation (RFA) (Stretta Procedure)|Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
41286264|NCT02935881|PROCEDURE|Sham Procedure|Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
40757555|NCT05160285|DRUG|Nivolumab 100 MG in 10 ML Injection|If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.
40945872|NCT05991700|DRUG|Freeze-Dried California Table Grape|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
40945873|NCT05991700|DRUG|Placebo|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
40945874|NCT05803473|DEVICE|Dexcom G6 Continuous Glucose Monitoring System (Dexcom Inc., San Diego, USA)|"For CGM-arm subjects, glucose data are obtained by the CGM Dexcom G6 which via an iPhone SE 3 transmits data to the in-hospital diabetes team stations to be displayed on an iPad 9 10.2."
40945875|NCT05803473|DEVICE|FreeStyle Precision Pro Glucometer for glucose POC testing|For the POC-arm subjects, glucose assessment is done by standard ward glucometer.
40945876|NCT00027937|BIOLOGICAL|aldesleukin|
40945877|NCT00027937|BIOLOGICAL|filgrastim|
40945878|NCT00027937|BIOLOGICAL|sargramostim|
40945879|NCT00027937|DRUG|busulfan|
40945880|NCT00027937|DRUG|cyclophosphamide|
40945881|NCT00027937|DRUG|melphalan|
40945882|NCT00027937|DRUG|paclitaxel|
40945883|NCT00027937|DRUG|thiotepa|
40945884|NCT00027937|PROCEDURE|bone marrow ablation with stem cell support|
41286265|NCT02190591|DEVICE|Peanut Labor Ball|Peanut Labor Ball
40945885|NCT00027937|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
40945886|NCT03170856|OTHER|Sub-maximal exercise|Subjects will participate in aerobic exercise 5 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 20 minutes 5times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
40945887|NCT04342234|OTHER|data collection of palatal casts and palatal images of cleft patients routinely treated at the institution|data collection of palatal casts and palatal images of cleft patients, using routinely taken intraoral/palatal photographs and palatal casts of infants with cleft lip and palate deformity
40945888|NCT05231044|DRUG|KX01 ointment 1%|The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.
40945889|NCT05231044|DRUG|Placebo|Vehicle Ointment is used in participants with Clinically typical AK on the face or scalp.
41286266|NCT00058370|DRUG|cisplatin|
41286267|NCT00058370|DRUG|lomustine|
41286268|NCT00058370|DRUG|vincristine sulfate|
41286269|NCT00058370|PROCEDURE|adjuvant therapy|
41286270|NCT00058370|RADIATION|iodine I 131 monoclonal antibody 3F8|
41286271|NCT00058370|RADIATION|radiation therapy|
41286272|NCT03241173|DRUG|INCAGN01949|In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
41286273|NCT03241173|DRUG|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
41286274|NCT03241173|DRUG|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
41286275|NCT06080750|GENETIC|Quantitative Real Time Polymerase chain reaction (qRT-PCR)|to study gene expression of NLRP3 inflammasome and IL-1B in blood
41286276|NCT06080750|DIAGNOSTIC_TEST|ELISA and colorimeter|IL-6 and total LDH
41286277|NCT03250520|DRUG|Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania|Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
41286278|NCT03199365|BEHAVIORAL|Behavioral Dietary Intervention|Undergo TSSC intervention sessions
41286279|NCT03199365|BEHAVIORAL|Behavioral Intervention|Undergo TSSC intervention sessions
41286280|NCT02024581|DRUG|10% East Indian sandalwood oil cream|A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
40757556|NCT02375256|BIOLOGICAL|AERAS-402|Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).
40945890|NCT03220984|BIOLOGICAL|Immuncell-LC intravenous infusion using a CIK cell agent|Patients with metastatic colorectal cancer, which is refractory to the 3rd-line chemotherapy are enrolled in this study. Enrolled patients receive a total of 12 times of Immuncell-LC therapy: 8 times in every 1 week and the next 4 times in every 2 weeks. The treatment responses of immuncell-LC are evaluated by radiologic findings (Abdomin-pelvic CT and Chest CT), immune-markers and a selorogic tumor marker (Carcinoembryologic antigen (CEA)) at the 8th week and 17th week. The safety of Immuncell-LC is evaluated by the results of serologic tests, vital signs, ECOG-PS and adverse events. The follow-up period is the 1 year after the enrolled date.
40945891|NCT00828854|DRUG|Entinostat|Entinostat 5 mg PO every week
40945892|NCT00828854|DRUG|Aromatase Inhibitor (AI) Therapy|AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.
40945893|NCT00729755|DIETARY_SUPPLEMENT|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
40945894|NCT00729755|DIETARY_SUPPLEMENT|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
40945895|NCT03166878|BIOLOGICAL|UCART019|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
40945896|NCT03405610|BEHAVIORAL|The Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
40945897|NCT02761434|OTHER|Hypertonic Saline (3% NaCl)|0.1 ml of 3% NaCl per kg of body weight per minute
40945898|NCT02761434|OTHER|Isotonic Saline (0.9% NaCl)|0.1 ml of 0.9% NaCl per kg of body weight per minute
40757557|NCT02375256|BIOLOGICAL|Placebo|Identical buffer solution in which AERAS-402 is formulated.
40945899|NCT02801305|DRUG|Diltiazem Gel 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
40945900|NCT02801305|DRUG|Nitroglycerin Ointment 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
41286281|NCT02024581|DRUG|Placebo Cream|A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
40945901|NCT02801305|DRUG|Vaseline|This is used as the topical placebo agent.
40945902|NCT02563951|DRUG|GNS Spray 0.5mg|
41286282|NCT05573685|DEVICE|DiNaMo Study App|Study App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
40945903|NCT02563951|DRUG|GNS Spray 1.0mg|
40945904|NCT02563951|DRUG|GNS Spray 2.0mg|
40945905|NCT02563951|DRUG|Kytril 1mg (IV injection)|
41286283|NCT05573685|DEVICE|Placebo App|Placebo App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
41286284|NCT02652429|DRUG|Inhaled Nitric Oxide|
41286285|NCT05081622|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|"Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~A one-day ICC-T refresher workshop aiming to refresh and re-emphasize the key aspects of the intervention is implemented about 6 to 12 months after the initial intervention."
41286286|NCT04652687|OTHER|VIA Disc NP (HCT/P)|VIA Disc NP - Allograft tissue injection
41286287|NCT05431465|OTHER|Vita Ambria|onlay restoration will be fabricated from Zirconia reinforced lithium disilicate glass ceramic(vita ambria)
41286288|NCT05431465|OTHER|IPs emax onaly|onlay restoration will be fabricated from lithium disilicate glass ceramic(IPS emax)
40757558|NCT02375256|BIOLOGICAL|BCG (1-8 x105 cfu ID)|BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
40757559|NCT02660346|DRUG|Daptomycin|Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
40757560|NCT02660346|DRUG|Vancomycin|Control Arm Treatment
40945906|NCT02563951|DRUG|Kytril 1mg (Tablet)|
40945907|NCT04072562|DRUG|AZD7594|"Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation."
40945908|NCT00570167|PROCEDURE|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
41286289|NCT01836601|BEHAVIORAL|Family-centered nighttime communication bundle|
41286290|NCT02798081|BEHAVIORAL|Single arm study|In Step 1 the elderly will participate of eight conventional computer classes which they were spontaneously enrolled. In Step 2, 10 minutes of the next eight classes will be used to practice serious games using virtual reality, using physical interface (keyboard or mouse).
41286291|NCT05594992|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
41286292|NCT03830138|GENETIC|Oxidized-LDL gene polymorphism|Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA
40945909|NCT00570167|PROCEDURE|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
40945910|NCT06076707|DRUG|bupivacain-tramadol|Comparing effectiveness of tramadol and bupivacaine for postoperative pain treatment and prevention for cesarian section
40945911|NCT05501223|OTHER|Medication review|30-60 minutes extra consultation regarding the patients drugs
41286293|NCT00863733|DRUG|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
41286294|NCT03461289|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
40945912|NCT05501223|OTHER|Standard care|Standard care i.e. visit at the Dept. of Endocrinology.
40945913|NCT05310656|BEHAVIORAL|Mindfulness Based Empowerment Programme|Mindfulness Based Strengthening Program consists of 8 sessions, once a week. Each session has specific goals and objectives, and each session also has a separate theme along with its subject. The subject of the program sessions is as follows: 1st session; Getting to know, explaining the operation plan of the program, defining violence against women and its causes, 2nd session; Emotions and Perceptions, session 3; Being in the Body and Developing Self-Esteem; Session 4, Stress and Meeting Stress with Conscious Awareness; Session 5, The Case of Violence and the Meanings We Ascribe; Session 6, Aware Communication and Conflict Resolution; Session 7, Self-Care and Self-Compassion; Session 8 is Ending the Empowerment Program, Farewell, and a New Beginning. Each session is planned to last an average of 90-120 minutes. Mindfulness teachings and practices will be applied in the content of the program.
41286295|NCT05133427|DEVICE|TOOsonix system ONE-M|All selected BCC areas will be treated by high intensity focused ultrasound
41286296|NCT00798512|DEVICE|Carotid artery stenting|"The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.~For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal)."
41286297|NCT02163369|DRUG|Peppermint and Lavender Essential Oils|
41286298|NCT06058234|DRUG|Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease|FDA approved monoclonal antibodies directed against amyloid for the treatment of AD
41286299|NCT03881163|DRUG|N-acetylcysteine (NAC)|Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.
41286300|NCT05819346|BEHAVIORAL|Lifestyle|Participants assigned to the intervention group receive access to a lifestyle mobile application for three months after inpatient rehabilitation has finished. The digital program is target group-specific and includes personalization and interactive elements without face-to-face appointments during the intervention. One virtual appointment at the beginning of the intervention (about one week post-rehabilitation) with the study staff ensures that participants familiarize themselves with the mobile application and that they are assigned to a suitable program level. The intervention is mainly based on the following behavior change technique (BCT) clusters: goals and planning, feedback and monitoring, shaping knowledge, and comparison of behavior.
41286301|NCT04573777|DRUG|Repatha|140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
41286302|NCT00891657|DEVICE|SprayShield™|Anti-adhesion barrier
41286303|NCT02246270|DRUG|Intravesical Heparin|Heparin bladder instillation
41286304|NCT02246270|OTHER|Placebo|Intravesical saline
40757561|NCT02660346|DRUG|Ceftaroline|Study Arm Treatment
41286305|NCT00466752|DRUG|sorafenib tosylate|Given PO
41286306|NCT00466752|GENETIC|microarray analysis|Correlative studies
41286307|NCT00466752|OTHER|immunohistochemistry staining method|Correlative studies
40757562|NCT05639803|DRUG|PEGIFNα1b|100μg/vial
40757563|NCT05639803|DRUG|Placebo|0.5ml/vial
40757564|NCT01627106|DRUG|Vernakalant|Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
40757565|NCT01627106|DRUG|Amiodarone|Administered IV as per product label
40757566|NCT00028288|DRUG|Daclizumab|
40757567|NCT01091883|DEVICE|Exablate treatment|MR Guided Focused Ultrasound
41286308|NCT00466752|GENETIC|gene expression analysis|Correlative studies
41286309|NCT00466752|PROCEDURE|needle biopsy|Correlative studies
41286310|NCT00466752|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy
41286311|NCT00466752|OTHER|laboratory biomarker analysis|Correlative studies
41286312|NCT00466752|GENETIC|western blotting|Correlative studies
40757568|NCT01091883|RADIATION|Radiation|External Beam Radiation
40945914|NCT05792423|DEVICE|GE ultrasound system with increased acoustic output settings|We will perform liver stiffness measurements with standard settings and an increased acoustic output enhanced ultrasound system. Pre and post ultrasound LFTs will be collected to monitor unexpected liver tissue damage.
40945915|NCT06187337|DEVICE|Maxillary expansion device|The maxillary expansion device is a orthodontic appliance that is used to expand the maxilla in children.
40945916|NCT02151695|PROCEDURE|panretinal photocoagulation|
40945917|NCT02151695|DRUG|Aflibercept intravitreal injections|
40945918|NCT02366988|DEVICE|Endoscopic Biliary Stenting|Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months
40945919|NCT02366988|PROCEDURE|Surgical treatment Bilio-enteric anastomosis|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
40945920|NCT02497612|DRUG|Ferroquine SSR97193|Pharmaceutical form:Capsules Route of administration: oral
40945921|NCT02497612|DRUG|Artefenomel|Pharmaceutical form:Granules for suspension Route of administration: oral
40945922|NCT02497612|OTHER|Placebo|Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.
40945923|NCT03583164|DRUG|Olorofim|30mg oral tablets
40945924|NCT03265665|BEHAVIORAL|ACTION Intervention|The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive lifestyle physical activity intervention for African American (AA) women. There are 2 phases to the intervention: Adoptive (24 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. 1 Group session (maintenance): watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking, reinforce barriers and facilitators to walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.
40945925|NCT03265665|OTHER|Enhanced usual care|"Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.~Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks."
40945926|NCT02848404|DEVICE|Categorical Language Fluency Smartphone Application|4 weeks' training
40945927|NCT05657925|DRUG|ondansetron 8 mg|Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
40945928|NCT05657925|DRUG|Matching placebo|Matching placebo will be identical in appearance to the active treatment pill
40945929|NCT01237938|BEHAVIORAL|Low Glycemic Diet|Changing to low glycemic diet
40945930|NCT06196346|BEHAVIORAL|Psychotherapy|see group description
40945931|NCT03031158|BEHAVIORAL|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
40945932|NCT03031158|BEHAVIORAL|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
40945933|NCT03274271|BEHAVIORAL|Action planning|Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
40945934|NCT03274271|BEHAVIORAL|Coping planning|Coping planning is the behaviour change technique used to make users think about possible hindrances and according solutions when trying to reach their goal.
40945935|NCT03274271|BEHAVIORAL|Self-monitoring|Self-monitoring is the behaviour change technique used to make users keep track of their goal.
40945936|NCT03274271|BEHAVIORAL|Feedback and tips|In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
40945937|NCT00261300|DRUG|Pantoprazole|Long term Pantoprozole trial
40945938|NCT01933217|DRUG|Methylphenidate|
40945939|NCT01933217|DRUG|Placebo|
40945940|NCT06152731|GENETIC|tests to determine HRD status|"Test Giscar AND test myChoice will be performed.~If one or two tests identifies a HRD status :~a PARP inhibitor treatment may be initiated according to current recommendations"
40945941|NCT01691898|DRUG|Obinutuzumab|Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
40757569|NCT01832194|DRUG|Botox|
40945942|NCT01691898|DRUG|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
40757570|NCT06011824|OTHER|Blood draw|10-12mL of blood will be drawn one time, unless a redraw is needed, in which case up to 24 mL will be drawn (10-12 mL each draw)
40757571|NCT04279769|DRUG|CB-280|CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
40757572|NCT04279769|DRUG|Placebos|Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
40945943|NCT01691898|DRUG|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
40945944|NCT01691898|DRUG|Rituximab|RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.
41267338|NCT00809380|BEHAVIORAL|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
41267339|NCT00065143|DRUG|clofarabine|
40945945|NCT03029273|DRUG|Cyclophosphamide and Fludarabine|Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.
40945946|NCT03029273|BIOLOGICAL|Anti-NY-ESO-1 TCR transduced T cells|A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject.
40945947|NCT00791310|DRUG|Flucis|FDG injected i.v
40945948|NCT02876627|BEHAVIORAL|Exercise training|twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve
40945949|NCT02613949|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
40945950|NCT01200862|DRUG|Investigational new drug company code: BGS649|
40945951|NCT01200862|DRUG|Placebo|
40945952|NCT03682887|PROCEDURE|Cryoballoon PV isolation group|"1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
40945953|NCT03682887|PROCEDURE|Cryoballoon PV isolation with Additional RA linear ablation group|"1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
40945954|NCT04281641|DIAGNOSTIC_TEST|TCHP|"Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin~Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta~Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6~Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~All study drugs were administered intravenously.~Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery~Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery."
40945955|NCT00101712|DRUG|vildagliptin|
40945956|NCT00101712|DRUG|Vildagliptin Placebo|
40945957|NCT03677908|OTHER|ElectroEncephaloGraphy|Density ElectroEncephaloGraphy analysis
40945958|NCT04081324|DRUG|Lasmiditan|Administered orally
40945959|NCT04081324|DRUG|Placebo|Administered orally
40945960|NCT06169228|DEVICE|mandibular advancement|The multidisciplinary sleep unit assessment and follow-up protocol will be followed for this group of patients based on the Spanish Clinical Practice Guideline of the Spanish Sleep Society (SES) on the use of mandibular advancement devices in the treatment of patients with obstructive sleep apnea
40945961|NCT03032133|PROCEDURE|Regional pain control|Regional pain catheter
40945962|NCT03032133|PROCEDURE|Local pain control|Local intraarticular pain catheter
40945963|NCT00884377|DRUG|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
40945964|NCT00884377|DEVICE|ThermoMed|ThermoMed heat treatment device, one treatment
40945965|NCT00496509|DRUG|ZD6474 (Zactima) 100mg|
40945966|NCT00496509|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
40945967|NCT00496509|PROCEDURE|Biomarker Draws|
40945968|NCT00496509|DRUG|ZD6474 (Zactima) 300mg|
40945969|NCT04400942|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasonographic scan aims to evaluate number, size (diameter and volume), location and appearance of submucous uterine myomas, concomitant presence of adenomyosis
40945970|NCT04400942|BEHAVIORAL|Anamnesis|Anamnesis aims to collect data about age, BMI, previous hormonal therapies (such as ulipristal acetate or gonadotropin-releasing hormone agonists) with submucous uterine myomas
40945971|NCT04400942|PROCEDURE|Operative hysteroscopy|Operative hysteroscopy allows a direct evaluation of number, size (diameter and volume), location and appearance of submucous uterine myomas. This exam allows the resection of the myomas.
40945972|NCT00136331|BIOLOGICAL|Pandemic influenza vaccine|
40945973|NCT00004307|BEHAVIORAL|Protein and calorie controlled diet|
40945974|NCT00004307|GENETIC|Ornithine transcarbamylase vector|
40945975|NCT06115785|BEHAVIORAL|Cognitive Stimulation Therapy|Cognitive Stimulation Therapy CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and in progress10 min. 45 minutes in total, including the ending.
40945976|NCT03266523|OTHER|Natural images in imaging waiting rooms|Standard environment for hospital imaging waiting rooms
40945977|NCT01843088|DRUG|Mannitol cream|25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
40945978|NCT01843088|DRUG|Placebo Cream|This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
40945979|NCT01199328|DRUG|Aspirin|81mg Tablet oral, once daily
41267340|NCT00065143|DRUG|Ara-C|
40945980|NCT01199328|DRUG|Esomeprazole|20 mg Tablet oral, once daily
40945981|NCT00130676|DRUG|Mifepristone|daily for 7 days
40945982|NCT00130676|DRUG|matching placebo|daily for 7 days
40945983|NCT06307873|DIAGNOSTIC_TEST|pre and post operative POP-Q results|Comparison of pre and postoperative POP-Q values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
40945984|NCT06307873|BEHAVIORAL|pre and post operative PİSQ-12 results|Comparison of pre and postoperative PİSQ-12 values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
40945985|NCT00689078|DRUG|Prednisolone Acetate 1%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
40945986|NCT00689078|DRUG|Prednisolone Acetate 0.12%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
40757573|NCT06569264|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft and i-PRF|Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. Followed by inspection of extraction socket integrity, using a William's graduated periodontal probe. Extracted teeth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries or restorations using a high-speed fine finishing stone and saline irrigation. The pulp chamber will be cleaned with sterile endodontic files. Teeth will be ground, using hand bone mill.The (ADDG) particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralized then washed twice in saline and dried with sterile gauze. For i-PRF blood will be withdrawn in plastic tubes. The tube will be centrifuged at around 700 RPM for 3 minutes, and extraction socket will be filled with the graft material.
40757574|NCT06569264|PROCEDURE|Alveolar ridge preservation using vitamin C with dentin graft and i-PRF|Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. 25mM of pure vitamin C in Fresh blood, and the tube will be centrifuged at around 700 RPM for 3 minutes. Extraction socket will be filled with the corresponding graft material and the dentin graft.
40757575|NCT03600441|DRUG|Abexinostat|Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.
40757576|NCT05591768|PROCEDURE|Monopolar radiofrequency|In monopolar group : . Inferomedial, superomedial, and superolateral GN branches of the patients were identified with ultrasonography, and a 22 Gauge, 10 cm radiofrequency (RF) cannula with a 10 mm active tip was advanced to the targeted nerves under fluoroscopy guidance. The location of the RF cannula was visualized by anteriorposterior and lateral images. Sensory stimulation was applied at 50 Hz to determine the nerve position. Since the sensory stimulation threshold must be \< 0.6 V, nerve position was tested with the absence of fasciculation in the relevant area of the lower extremity upon 2.0 V stimulation at 2 Hz.
40757577|NCT05591768|PROCEDURE|Bipolar radiofrequency|a similar technique will be used to insert the canula, except that, instead of one cannula two cannulae (approximately 10 mm apart) apart) will be inserted and no manipulation of cannulae was done to stimulate the target nerve as done in MRFA Target areas were similar to monopolar technique Each nerve will be ablated for 90 s in both the groups. All procedures were done by one pain physician who had more then 10 years' experience of radiofrequency procedures.
40945987|NCT00689078|DRUG|Loteprednol Etabonate 0.2%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
40945988|NCT00689078|DRUG|Placebo|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
40945989|NCT05273307|DIETARY_SUPPLEMENT|Miraculin|Given orally
40945990|NCT05273307|DIETARY_SUPPLEMENT|Miracle Fruit Placebo Cube|Given orally
40945991|NCT03283917|BIOLOGICAL|Daratumumab|Given IV
40945992|NCT03283917|DRUG|Dexamethasone|Given IV or PO
40945993|NCT03283917|DRUG|Ixazomib|Given PO
40945994|NCT02617888|RADIATION|CCTA ~ BREAST SHIELDS|Breast shield placement (randomized) among women.
40945995|NCT02611960|BIOLOGICAL|Pembrolizumab|IV infusion
40945996|NCT02611960|DRUG|Capecitabine|oral tablet
40945997|NCT02611960|DRUG|Gemcitabine|IV infusion
40945998|NCT02611960|DRUG|Docetaxel|IV infusion
40945999|NCT01225887|DRUG|Nintedanib|Given PO
40946000|NCT04239092|DRUG|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
40946001|NCT04239092|DRUG|Irinotecan|Irinotecan 50 mg/m2/day administered over 90 minutes IV on days 1-5 every 21 days.
40946002|NCT04239092|DRUG|Temozolomide|Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 of a 21 day cycle.
40946003|NCT04239092|DRUG|Cyclophosphamide|Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5 of a 21 day cycle.
41286313|NCT00466752|GENETIC|RNA analysis|Correlative studies
40946004|NCT04239092|DRUG|Topotecan|Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5 of a 21 day cycle.
40946005|NCT04549961|OTHER|Nutrition|type and amount of food eaten or type and amount of oral nutritional supplements as well as enteral or parenteral nutrition
40946006|NCT05083754|DRUG|Retifanlimab|Anti-PD-1 Therapy
40946007|NCT05083754|DRUG|Temozolomide|Anti-PD-1 Therapy
40946008|NCT05083754|RADIATION|Radiation Therapy|Standard of Care
40946009|NCT04493580|BEHAVIORAL|iDBT|Electronic DBT sessions designed to mirror in-person DBT.
40946010|NCT04493580|BEHAVIORAL|In-Person DBT|In-person DBT
40946011|NCT03355781|DEVICE|magnetic resonance imaging (MRI)|brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity
40946012|NCT03355781|PROCEDURE|Blood sample|27,5 ml of blood sample : genetic analysis and biobank
41286314|NCT06382688|DIETARY_SUPPLEMENT|NAD+ (nicotinamide adenine dinucleotide) IV|NAD+ enables cells to generate cellular energy from the food that one eats
40946013|NCT03355781|OTHER|Clinical psychiatric evaluation|Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)
40946014|NCT00657449|DRUG|valdecoxib|valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
40946015|NCT00657449|DRUG|rofecoxib|rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
40946016|NCT01842815|DEVICE|755 nm alexandrite laser|755 nm alexandrite laser for the treatment of unwanted, non cosmetic, tattoos.
40946017|NCT01524757|DRUG|Pantoprazole|pantoprazole 40mg 1dd1; 12 months
40946018|NCT02725034|DEVICE|Standard endoscopy|
40946019|NCT02725034|DEVICE|High definition endoscopy with Optic Enhancement|
41286315|NCT06382688|DIETARY_SUPPLEMENT|Niagen® (nicotinamide riboside) IV|NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an IV administration.
41286316|NCT06382688|DIETARY_SUPPLEMENT|Niagen® (nicotinamide riboside) oral|NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an oral administration.
41286317|NCT06382688|OTHER|Placebo|These individuals received a saline IV
41286318|NCT02837172|OTHER|Diffusion Weighted Imaging (DWI)|"MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, DTI imaging (MRI), and neurological examination.~Expert evaluation: Record review, PD Medical History and PD Family History Form, the Montreal Cognitive Assessment, PDQ-39. standard, full, neurological examination, and MDS-UPDRS"
40757578|NCT02269774|PROCEDURE|Standard pulmonary vein isolation|The MM will be carried out during a elective standard pulmonary vein isolation procedure. The MM will be performed using an occluded mouthpiece with a small air leak to prevent complete closure of the glottis during inspiration and thus assure negative pressure throughout the entire airway. After expiration, inspiration with a target negative intrathoracic pressure of -40mmHg will be carried out against the mouthpiece.
40946020|NCT00096083|DRUG|isolated perfusion|
40946021|NCT00096083|DRUG|melphalan|
40757579|NCT03902483|DEVICE|renal doppler ultrasound|renal doppler ultrasound measuring renal resistive index
40757580|NCT04356027|PROCEDURE|ICA (Invasive Coronary Angiography)|Patients will undergo a Pre-PCI Angiography
40757581|NCT04356027|PROCEDURE|OCT|OCT pullback images will be collected pre-PCI and (optional) post-PCI procedure
40757582|NCT04356027|PROCEDURE|FFR|FFR will be measured
41286319|NCT01215318|DEVICE|modified vaginal tampon|modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
40757583|NCT04356027|OTHER|VFR Analysis|VFR will be calculated offline using the OCT pullback images
40757584|NCT06571318|OTHER|Destress and Perform Capsule-U001|Two Capsules in sequence daily after meal for 60 days.
40757585|NCT06571318|OTHER|Destress and Perform Capsule-I001|Two Capsules in sequence daily after meal for 60 days.
40757586|NCT06571318|OTHER|Placebo capsules 002|Two Capsules in sequence daily after meal for 60 days
40757587|NCT05522829|BIOLOGICAL|SCTV01E-1 on D0|Day 0; intramuscular injection
40757588|NCT05522829|BIOLOGICAL|SCTV01E-1 on D28|Day 28; intramuscular injection
40757589|NCT05522829|BIOLOGICAL|SCTV01E-1 on D150|Day 150; intramuscular injection
40946022|NCT02071927|DRUG|CB-839|Single-agent CB-839
41286320|NCT05734287|DIAGNOSTIC_TEST|clinical, biophysical and biochemical assessment of young females with clinical hyperandrogenism|To assess clinical, biophysical and biochemical criteria of young females with clinical hyperandrogenism as a search for PCOS
41286321|NCT04075604|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
41286322|NCT04075604|DRUG|Anastrozole|Specified Dose on Specified Days
40757590|NCT05522829|BIOLOGICAL|SCTV01E on D0|Day 0; intramuscular injection
40757591|NCT05522829|BIOLOGICAL|SCTV01E on D28|Day 28; intramuscular injection
40757592|NCT05522829|BIOLOGICAL|SCTV01E on D150|Day 150; intramuscular injection
40757593|NCT05522829|BIOLOGICAL|SCTV01E-1 on D120|Day 120; intramuscular injection
40757594|NCT05522829|BIOLOGICAL|SCTV01E on D120|Day 120; intramuscular injection
41286323|NCT04075604|DRUG|Palbociclib|Specified Dose on Specified Days
40757595|NCT06421454|DRUG|Melatonin|Pressure Ulcer will be treated with a melatonin cream daily
40757596|NCT06421454|DRUG|Hydrogel|Pressure ulcer will be treated with hydrogel daily as a comparator
40757597|NCT02571881|PROCEDURE|Caesarean section|After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication
40757598|NCT02571881|DRUG|Oxycodone|
40946023|NCT02071927|DRUG|CB-Aza|CB-839 in combination with standard dose azacitidine
40946024|NCT03134833|BEHAVIORAL|Automated Messaging & Monitoring|"Youth will receive messages 1-5 messages per day for 24 months. Message banks of about 750 text messages (70-120/domain) will focus on the HIV Prevention Continuum, with messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for MSM and non-MSM. Youth will be able to choose the time that they receive daily texts. Text timing and the frequency of texts (e.g., if the youth comes out) will be updated at 4-month intervals.~Youth will complete weekly monitoring surveys by text message. The survey will cover seven domains related to the HIV Prevention Continuum. In case of non-response, reminder messages will be sent to the youth. After three days of non-response, a follow-telephone call will occur."
40946025|NCT03134833|BEHAVIORAL|Peer Support|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
40946026|NCT03134833|BEHAVIORAL|Coaching|Youth will have access to a dedicated Coach to assist with crisis support and problem-solving, linkage to HIV and related services (e.g., for substance use, mental health), and care coordination. Coaches will be accessible electronically (using social media, e-mail, text messaging) and by phone. In cases where virtual support has failed, Coaches will be available in-person (e.g., to accompany a participant to a doctor's appointment). We anticipate that Coaches will provide each youth with 10 hours of support, on average, per year.
40946027|NCT02796742|OTHER|Collecting samples from all patients presenting with SSTIs requiring drainage|The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
40757599|NCT02571881|DRUG|oxycodone-naloxone|
40946028|NCT04102956|DRUG|Kallikrein|HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
40946029|NCT05137262|OTHER|Abiraterone acetate|Given by IV
40946030|NCT05137262|DRUG|Durvalumab|Given by IV
40946031|NCT05137262|DRUG|Methotrexate|Given by IV
40946032|NCT05137262|DRUG|Vinblastine|Given by IV
40946033|NCT05137262|DRUG|Doxorubicin Hydrochloride|Given by IV
40946034|NCT05137262|DRUG|Cisplatin|Given by IV
40946035|NCT00617851|BIOLOGICAL|Lot A of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
40946036|NCT00617851|BIOLOGICAL|Lot B of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
40946037|NCT00617851|BIOLOGICAL|Lot C of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
40946038|NCT00617851|BIOLOGICAL|Comparator influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
40946039|NCT00617851|BIOLOGICAL|All 3 consecutive lots of influenza virus vaccine pooled|1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
40946040|NCT00795925|DRUG|propiverine hydrochloride|"coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d."
40946041|NCT01052844|DRUG|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
40946042|NCT01052844|DRUG|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
41286324|NCT06288386|DEVICE|GrandioSO Heavy Flow|Attachment will be performed with GrandioSO Heavy Flow.
41286325|NCT06288386|DEVICE|Filtek Z350XT Flowable|Attachment will be performed with Filtek Z350XT Flowable.
41286326|NCT01207544|BEHAVIORAL|Fitball exercise|Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
40946043|NCT02022631|OTHER|Alternative summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
41286327|NCT01207544|BEHAVIORAL|task-oriented motor training program|Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
41286328|NCT01165229|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
41286329|NCT01165229|BIOLOGICAL|Placebo|Intramuscular injection.
41286330|NCT04132726|OTHER|Massage therapy|Massage therapy performed by a physiotherapist
41286331|NCT04132726|OTHER|non-effective treatment|non-effective treatment
41286332|NCT03604614|DRUG|Hyperthermic Intraperitoneal Chemotherapy|The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
40757600|NCT01862965|DRUG|PredEver|Firstline treatment with prednisone and Everolimus
40757601|NCT04969107|PROCEDURE|taTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in a rendezvous procedure of an abdominal and a transanal approach.
41286333|NCT03604614|DRUG|Without Hyperthermic Intraperitoneal Chemotherapy|The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
40757602|NCT04969107|PROCEDURE|abdTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in an abdominal Approach.
40757603|NCT03787212|DEVICE|MiBo ThermoFlo|Test Device
40757604|NCT03787212|DEVICE|Bruder Mask|Control Device
40757605|NCT01825863|DRUG|Ropivacaine|
40757606|NCT01825863|DRUG|Saline 9%|
40757607|NCT03193437|DRUG|Open Label Selinexor|Selinexor 40 mg oral tablets will be administered twice weekly, either on Monday/Wednesday, Tuesday/Thursday, Wednesday/Friday, Thursday/Saturday, or Friday/Sunday in a 3-weeks-on and 1-week-off schedule.
40757608|NCT01522274|BEHAVIORAL|Moderate intensity exercise|Brisk walking on a treadmill for 56 minutes 3x per week.
40757609|NCT01522274|BEHAVIORAL|Health education|Videos
40757610|NCT05139862|DEVICE|Repetitive Transcranial Magnetic Stimulation|This study utilizes intermittent theta burst stimulation (iTBS) to the left DLPFC.
40757611|NCT05158166|DRUG|DaxibotulinumtoxinA|This is a long-acting alternative to traditional Botox A treatment.
40757612|NCT01046994|PROCEDURE|biliopancreatic diversion|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve
40757613|NCT01046994|DRUG|antidiabetics|patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
40757614|NCT04465305|PROCEDURE|entraped treatment|patients with tarlov cysts treated by entraped and plasty nerve root
40946044|NCT02022631|OTHER|Current summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
40946045|NCT04645420|PROCEDURE|Global gene expression profiles obtained from synovial biopsies.|Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.
40946046|NCT02395016|DRUG|nimotuzumab|nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
41286334|NCT01688648|DRUG|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
41286335|NCT01688648|DRUG|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 \~ 0.7 mcg/kg/hr during the surgery
41286336|NCT05924477|PROCEDURE|Sulcus tube placement|GDD implantation surgery with tube placement in the ciliary sulcus
41286337|NCT05924477|PROCEDURE|Anterior chamber (AC) tube placement|GDD implantation surgery with tube placement in the anterior chamber
40757615|NCT04465305|PROCEDURE|plasty treatment|patients with tarlov cysts treated by plasty nerve root
40757616|NCT03233971|OTHER|rPATD Questionnaire|A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.
40946047|NCT02395016|DRUG|Gemcitabine|Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
40946048|NCT02395016|OTHER|Placebo|Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
40946049|NCT04521777|BEHAVIORAL|Exercise Intervention|Participate in an 8-week home-based strengthening and walking program
40946050|NCT04521777|OTHER|Physical Performance Testing|Complete a physical function test
40946051|NCT04521777|OTHER|Questionnaire Administration|Ancillary studies
41286338|NCT03966586|BEHAVIORAL|Active outreach|Participants will get bidirectional weekly SMS messaging / automated voice messaging (depending on literacy), with messages to be programmed by the participant in the enhanced counseling sessions.
40946052|NCT01094756|DIETARY_SUPPLEMENT|meal replacements, psychotherapy, dietary education|After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
40946053|NCT00082589|DRUG|Eplerenone|
40946054|NCT03487523|BEHAVIORAL|Text Message|As already stated
41286339|NCT03966586|BEHAVIORAL|Appointments|Participants in the enhanced-care intervention will be given specific appointment times/dates.
41286340|NCT03966586|BEHAVIORAL|Financial support|Participants in the enhanced-care intervention will receive free clinic visits, labs, and medications. They will also receive transportation incentives on a sliding scale based on distance to clinic, to range between 200-700 INR to be given each clinic/study visit. All participants, in both the usual care and enhanced care arms, will be offered VL testing free of charge, although this will not be known to the participants prior to the visit.
40757617|NCT03718403|DRUG|Theophylline|Theophylline will be given to maintain a peak level between 10-15 mcg/mL
40757618|NCT03057301|DEVICE|iCare home tonometer|All subjects will be taught to use the home care tonometer.
40946055|NCT04926077|DEVICE|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
40946056|NCT03875820|DRUG|VS-6766|"VS-6766 will be supplied as 0.8mg hypromellose (HPMC) capsules for oral administration. The capsule fill consists of VS-6766 and the inactive ingredients mannitol and magnesium stearate.~VS-6766 will be administered on a twice weekly (Monday and Thursday or Tuesday and Friday) schedule for 3 weeks followed by 1 week off in every 4 week cycle, under fasting conditions (approximately 1 hour prior or 2 hours after a meal). The starting dose, based on the previous Phase I trial will be 3.2 mg given orally as a single daily dose. This can be escalated to a maximum of 4mg (as per dose escalation rules in the protocol)."
40946057|NCT03875820|DRUG|Defactinib|"Defactinib is formulated as a white to off-white oval tablet for oral administration and supplied in single unit dose strength of 200 mg in 120 cc (HDPE) bottles. In addition to Defactinib, formulation components include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, and magnesium stearate.~Patients will receive Defactinib orally immediately after a meal twice daily (approximately every 12 hours) for 3 weeks followed by 1 week off in every 4 week cycle. The starting dose will be 200mg. This can be escalated to a maximum of 400mg (as per dose escalation rules in the protocol)."
40946058|NCT06410404|PROCEDURE|transversus thoracis plane block|with the patient lying in the supine position. After skin disinfection, a high frequency linear ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, different drugs according to the different groups will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
40946059|NCT06410404|DRUG|Dexmedetomidine|the dexmeditomedine group shall undergo bilateral transversus thoracis plane block with 15 ml of 25% levobupivacaine, and 0.05 ug/kg dexmeditomedine on each side of the sternum
40946060|NCT06410404|DRUG|Levobupivacaine|A local anesthetic that will be instilled in the transversus thoracic plane in a dose of 15 ml of a 25% concentration on both sides of the sternum in both groups
40946061|NCT03188627|BIOLOGICAL|Bronchial basal cells|Transplantation of autologous bronchial basal cells
40946062|NCT00362037|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.
40946063|NCT01851915|BEHAVIORAL|Cognitive Behavioral Therapy|14 sessions psychological treatment for depression
40946064|NCT01851915|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|14 sessions psychological treatment for depression
41132921|NCT05036837|DRUG|OZOPROMAF_SEQ1|"OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ."
41286341|NCT03966586|BEHAVIORAL|Microenterprise|YRG CARE is affiliated with two microenterprise programs in bag-making and food-vending which can be leveraged as part of an intervention, particularly for women. There is an established training and mentoring program for individuals who wish to join the bag-making or food-making ventures. Participants who opt for this will be linked to the bag-making and food-vending programs, with all up-front costs (e.g. vending kiosk, training, serving materials, etc.) covered.
40946065|NCT05419986|GENETIC|Blood collection|Molecular monitoring by measure of DNA methylation levels in blood samples collected by fingerstick blood drops, as opposed to veinous phlebotomy
40946066|NCT02687373|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
40946067|NCT02687373|OTHER|Normal Saline|0.9% Sodium chloride
40946068|NCT03293797|BEHAVIORAL|Abbreviated-Mindfulness-based Therapy|A-MBT will be delivered in group format, 120 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
40946069|NCT00187031|DRUG|Topotecan, Filgrastim (G-CSF), Pegfilgrastim|See detailed description section for additional details.
40946070|NCT05040399|OTHER|Locking Compression Plates|Plates and screws for sternal fixation
40946071|NCT05040399|OTHER|Sternal Wires|sternal wires used for fixation of sternum
40946072|NCT01226043|DRUG|Insulin Glargine|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous"
40946073|NCT05938062|PROCEDURE|the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)|the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
40946074|NCT01346969|DRUG|EXC 001|Single-dose administered by injection four different times
40946075|NCT01346969|DRUG|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
40946076|NCT01346969|DRUG|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
40946077|NCT01346969|DRUG|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
40946078|NCT05826808|DIAGNOSTIC_TEST|Polysomnography|The polysomnographic recordings include electroencephalogram (EEG), electrooculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), pulse oximetry, transcutaneous capnography, nasal airflow and thoracic and abdominal respiratory effort.
40946079|NCT04327973|BIOLOGICAL|ATB200|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
40946080|NCT04327973|DRUG|AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
40946081|NCT01193842|DRUG|Cyclophosphamide|Given IV
40946082|NCT01193842|DRUG|Doxorubicin Hydrochloride|Given IV
40946083|NCT01193842|DRUG|Etoposide|Given IV
40946084|NCT01193842|OTHER|Laboratory Biomarker Analysis|Correlative studies
40946085|NCT01193842|OTHER|Pharmacological Study|Correlative studies
40946086|NCT01193842|DRUG|Prednisone|Given PO
40946087|NCT01193842|BIOLOGICAL|Rituximab|Given IV
40946088|NCT01193842|DRUG|Vincristine Sulfate|Given IV
40946089|NCT01193842|DRUG|Vorinostat|Given PO
40946090|NCT03285672|DRUG|FP-101|Dose 1
40946091|NCT03285672|DRUG|Placebo Comparator|Dose 1
40946092|NCT06052072|DEVICE|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
40946093|NCT01725607|DRUG|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
40946094|NCT01725607|PROCEDURE|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
40757619|NCT00251966|DRUG|Esomeprazole|
40946095|NCT00273910|DRUG|gp100:209-217 (210M)|
40946096|NCT00273910|DRUG|Montanide ISA-51|
40946097|NCT00273910|DRUG|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
40946098|NCT00013468|PROCEDURE|Tinnitus|
40946099|NCT03120559|DEVICE|New Floss Holder - Gum Chucks|Dental inter-proximal control with GumChucks floss holder
40946100|NCT03120559|DEVICE|New Floss Holder - Gum Chucks/SMS|Dental inter-proximal control with GumChucks floss holder and receiving 16 SMS during first 4 months.
40946101|NCT02256072|OTHER|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
40946102|NCT02256072|OTHER|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
40946103|NCT02556203|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10mg OD (once-daily)
40946104|NCT02556203|DRUG|Acetylsalicylic Acid (ASA)|75-100mg OD
40946105|NCT02556203|DRUG|Clopidogrel|75mg OD
40946106|NCT02556203|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|In case of NOAF, 20/15 mg OD (once-daily)
40946107|NCT02556203|DRUG|Vitamin K antagonist (VKA)|In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
40946108|NCT00526604|BEHAVIORAL|work related rehabilitation|"The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks."
40946109|NCT01061216|DEVICE|Intradermal insulin delivery: BD Research Catheter Set|1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
40946110|NCT01061216|DEVICE|Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set|1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
40946111|NCT02350569|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
40946112|NCT04977557|DIETARY_SUPPLEMENT|Thiamine|Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
41286342|NCT03966586|BEHAVIORAL|Enhanced counseling|Participants in the enhanced-care intervention will participant in an individual enhanced counseling program called Steps to Success, based upon a Life Steps and Problem Solving curriculum. Steps to Success will consist of five one-on-one sessions of approximately 1 to 1.5 hours each. The first session will take place at the time of the participant's second clinical visit to YRG CARE, which will be between 1-3 weeks after the participant is recruited.
41286343|NCT03966586|BEHAVIORAL|Usual clinical care and counseling|Usual clinical care and counseling
41452490|NCT05435534|OTHER|ActiveFLS intervention|"* A comprehensive geriatric assessment with a multicomponent physical exercise program guideline based on ActiveHip+ for 3 months. In the subsequent revisions, exercise guidelines from the Vivifrail program will be given~* A protocolized nutritional intervention will be carried out. In case of oral nutritional supplementation, supplements enriched in β-hydroxy-β-methylbutyrate (HMB) will be selected~* Osteoporosis treatments according to national guideline~* A review and adaptation of the treatment will be carried out according to the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria~* An approach will be made to the patient's mood and fear of falling. In case of depression, both pharmacological and non-pharmacological approaches will be assessed~* Screening for cognitive impairment will be performed. In the event of evidence of memory problems, a recommendations for cognitive stimulation will be delivered"
41452491|NCT05435534|OTHER|Usual care group|Participants randomly assigned to the usual care group will receive normal outpatient care, including physical rehabilitation when needed.
41452492|NCT01750827|DRUG|SB659032|single dose
41452493|NCT05475392|OTHER|Traditional Physical Therapy|A 2-week physical therapy program will be arranged. Each patient will be given 60 min session , 10 min for neck ROMS (10 reps for each ROM) , 10 min neck Isometrics (5 reps on each side) , 30 sec static gentle stretch of levator scapulae (3reps) , 30 sec static gentle stretch of trapezius (3reps), 5 min Soft tissue manipulation , 5 min Shoulder shrugging (10reps) , 10 min for PIR
41286344|NCT01210937|PROCEDURE|CEA and TCD monitoring|All patients will receive carotid endarterectomy. During the surgery, all of them will be monitored by TCD. Record the blood flow velocity and blood pressure on specified time.
41286345|NCT00506389|DRUG|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.
41286346|NCT00506389|DRUG|Placebo|The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
41452494|NCT05475392|OTHER|Post Isometric Relaxation|The exercise will be combined with the baseline treatment 3 sets PIR will be applied per session.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction, the patient is asked to relax and exhale while doing so. Following this, a gentle stretch is applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times.
41452495|NCT04814160|PROCEDURE|mixture of bioactive glass and autogenous bone graft|bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
41452496|NCT04814160|PROCEDURE|autogenous bone graft|bone expansion was performed and autogenous bone alone was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
41452497|NCT06000163|DEVICE|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the skin, which is non-invasive, and skin thickness and blood flow parameters will be measured.
41452498|NCT04254315|BEHAVIORAL|Group based cognitive therapy|"Patients are informed about the Optima program in the inclusion interview, and patients are participating in groups of maximum 4 persons. Each of the 5 session has a duration of 1,5 - 2 hours.~The psychologist have developed the content of each session, with attention to thoughts and feelings regarding the current situation after a heart-condition, and the effects on life conditions. Patients get the tools to overcoming the difficulties, they experience, f.x. anxiety and stress.~When other hospitals are joining the Optima project, the project nurse and psychologist are training the hospital staff as well as supervising."
41452499|NCT03590119|DRUG|Lutetium Lu 177-DOTATATE|Intra-arterial infusion of Lu-177-DOTATATE
41452500|NCT06212076|DRUG|IPG1094|IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg
41452501|NCT02336074|DRUG|Combination Antiretroviral Therapy (cART)|Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.
41452502|NCT02336074|DRUG|Raltegravir|All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.
40757620|NCT02056145|PROCEDURE|LFCNB|LFCNB - Normal Saline solution 10 cc
40946113|NCT01945827|DEVICE|DeltaMaxx Microcoil System|
41286347|NCT00765479|DIETARY_SUPPLEMENT|soy protein isolate|Given orally
41286348|NCT00765479|OTHER|placebo|Given orally
41286349|NCT03318367|OTHER|Educational Intervention|Complete virtual reality education module
41286350|NCT03505983|DEVICE|ESR Prosthetic Foot First|Subjects will start with an ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
41286351|NCT03505983|DEVICE|Articulating ESR Prosthetic Foot First|Subjects will start with an articulating ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
41286352|NCT03505983|DEVICE|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR foot and an ESR foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
41286353|NCT02612597|OTHER|Bedrest|
41286354|NCT02612597|OTHER|Exercise Training|
41286355|NCT04701281|COMBINATION_PRODUCT|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
41452503|NCT02336074|DRUG|Vorinostat|"Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).~Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
40757621|NCT02056145|PROCEDURE|FNB|FNB - Normal saline solution 10 cc
41452504|NCT02336074|BIOLOGICAL|ChAdV63.HIVconsv (ChAd)|Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 00.
41452505|NCT02336074|BIOLOGICAL|MVA.HIVconsv (MVA)|Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 08 Day 1 (2 prior to start of vorinostat)
41452506|NCT04815239|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based treatment for BP adults that prevents or delays mood episodes by stabilizing sleep and daily routines.
41452507|NCT04815239|BEHAVIORAL|The Healthy Lifestyle Behavior Intervention (HL)|HL includes structured psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health.
41452508|NCT05456594|OTHER|Conventional bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a conventional bra (bra condition #1).
41452509|NCT05456594|OTHER|Bounceless bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Bounceless bra (bra condition #2a).
41452510|NCT05456594|OTHER|Shefit bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Shefit bra (bra condition #2b).
41452511|NCT01466374|DRUG|Placebo|Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
41452512|NCT01466374|DRUG|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
40757622|NCT02056145|PROCEDURE|LFCNB|LFCNB - Chirocaine 0.25%, 20 cc
40757623|NCT02056145|PROCEDURE|FNB|FNB - Chirocaine 0.25%, 20 cc
40757624|NCT06148285|DEVICE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
41452513|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
41286356|NCT00941980|BIOLOGICAL|Osteocel Plus|biologic
41286357|NCT01984814|BIOLOGICAL|Stem cell|Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
41286358|NCT00005912|DRUG|Voriconazole|
41286359|NCT05344833|DRUG|Isatuximab|Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39.
41286360|NCT05344833|DRUG|Lenalidomide|Lenalidomide 15mg PO Days 1-21 Cycle 4 and can continue until disease progression.
41286361|NCT03168061|DRUG|NC 6300|Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
41286362|NCT06511388|OTHER|Non-Interventional Study|Non-interventional study
40757625|NCT06569537|DRUG|Lidocaine topical|4%
40757626|NCT06569537|DRUG|BLT|Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
40757627|NCT06121635|COMBINATION_PRODUCT|Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation|At the robot-assisted gait training, 20-minute gait training for the patient at an appropriate speed with the Locohelp Woodway device. The aim is to re-teach proper walking, gait cycle timing, and create a near-normal gait pattern through multiple repetitions. Robot-assisted gait training will be performed immediately following the stimulation applied to the patients.
40757628|NCT06121635|COMBINATION_PRODUCT|Sham ts-DCS and sham t-DCS|Sham ts-DCS and sham t-DCS
40757629|NCT06476821|DRUG|BMS-986435|Specified dose on specified days
40757630|NCT05758142|DIETARY_SUPPLEMENT|Potassium Chloride|Oral administration of potassium chloride tablets
40757631|NCT05758142|OTHER|Placebo|Oral administration of inert placebo tablets
40757632|NCT02688166|OTHER|Complete Cardiac Magnetic Resonance Imaging (MRI)|Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy
41286363|NCT00219180|DRUG|aliskiren|
41286364|NCT02596776|PROCEDURE|Fat biopsy|up to 16 biopsy samples will be taken from each subject
41286365|NCT02596776|DRUG|Propranolol and fat biopsy|subset of subjects will receive propranolol and have fat biopsy performed
41286366|NCT02596776|OTHER|heavy water and fat biopsy|subset of subjects will be given heavy water and have fat biopsy performed
41452514|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
41452515|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days
40946114|NCT05928260|DEVICE|Medtronic Guardian Connect Sensor 3|This is a real-time CGMS which transmits all the blood glucose readings into the application downloaded in a device continuously and also gives alarms and alerts to the person.
40946115|NCT05928260|DEVICE|Abott Freestyle Libre Sensor|This system is an is-CGMS in which the participant gets his blood glucose only when the device is scanned.
40946116|NCT05928260|OTHER|Self blood Glucose monitoring by a glucometer|In this all patients will check their blood glucose using a needle prick and glucometer at pre-specified intervals.
41452516|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days
41452517|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
40946117|NCT04855370|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds every 15 minutes for 12 to 24 hours. If two finger probes are available, measurements will alternate between fingers.
40946118|NCT05839587|PROCEDURE|Robotic TAPP|Robotic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of docking of the robot and port placement and part 4 consists of de-docking and skin closure
40946119|NCT05839587|PROCEDURE|Laparoscopic TAPP|Laparoscopic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of port placement only and part 4 consists of skin closure only.
40946120|NCT04058418|OTHER|Survey Administration|Completion of a short survey.
40946121|NCT02645097|PROCEDURE|Saphenous Nerve Block|A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
40946122|NCT01460316|BIOLOGICAL|Bood sampling for biochemicals and genetic analysis|There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
40946123|NCT01223638|OTHER|Audiometry|Audiometry
40946124|NCT04840732|BEHAVIORAL|VR training program|Use VR software to make a training education program.
40946125|NCT04840732|BEHAVIORAL|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
40946126|NCT05787288|BIOLOGICAL|Extracellular Vesicles from Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cell-derived extracellular vesicle preparation; Specification: 5ml, with extracellular vesicle concentration of 1 × 109 particles/ml in the preparation;
40946127|NCT03420859|DIAGNOSTIC_TEST|qPCR for abnormal vaginal microbiota|qPCR for A.vaginae and/or G.vaginalis as developed in the pilot study (Hum Reprod. 2016 Apr;31(4):795-803. doi: 10.1093/humrep/dew026. Epub 2016 Feb 23.)
40946128|NCT00622973|OTHER|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
40946129|NCT00622973|OTHER|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
40946130|NCT05844397|DEVICE|WaveLight EX500 Excimer Laser System|LASIK Refractive Surgery Using Contura with Phorcides
40946131|NCT05844397|DEVICE|VisuMax Surgical Laser|SMILE Refractive Surgery
40946132|NCT04516369|GENETIC|voretigene neparvovec|Voretigene neparvovec is an adeno-associated viral type 2 (AAV2) gene therapy vector driving expression of normal human retinal pigment epithelium 65 kDa protein (hRPE65) gene.
40946133|NCT02161029|DEVICE|Flexible drill biopsy instrument|Biopsies taken with the new drill biopsy instrument for flexible endoscopy
40946134|NCT02161029|DEVICE|conventional biopsy instrument|Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
40946135|NCT01995630|DEVICE|AMO Tecnis ZA9003|
40946136|NCT01995630|DEVICE|AMO Sensar AR40e|
40946137|NCT00876876|DRUG|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
40946138|NCT00175695|DRUG|Recombinant human activated protein C or drotrecogin alpha|We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.
40946139|NCT04042181|DIETARY_SUPPLEMENT|Placebo|standard food grade excipients
40946140|NCT04042181|DIETARY_SUPPLEMENT|Bifidobacterium longum|Target dose of 1x10\^10 CFU/day, plus standard food grade excipients
40946141|NCT05058352|DRUG|HS269|Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.
40946142|NCT00494273|BEHAVIORAL|Cognitive Behavioral and Standard Care with Healthy Living|
40946143|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
41132922|NCT03087318|BEHAVIORAL|Physical activity|"Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~* during 3 months."
41286367|NCT03466710|PROCEDURE|Colposcopy|"Women will undergo colposcopy at 6 and 12 months after randomization. Those with CIN II will be managed according to standard of care. Those with CIN 1 6 months post randomization will have a second exam 6 months later and if still CIN I will have an exit colposcopy 6 months later.~All women in the Pap and HPV testing policies as well as all women in the colposcopy policy with CIN 1 after 2 exams will have an exit colposcopy 18 months after randomization. The exit colposcopy is a safeguard against the possibility of any false negatives in the follow up policies. The exit colposcopy will also establish the true numbers of CIN lesions in the 3 policies in order to determine their sensitivities and specificities. At the exit colposcopy,all will have an endocervical curettage,and either a minimum of 2 directed biopsies of any mucosal abnormality or in the event no abnormality is identified,2 random biopsies from the cervix."
41452518|NCT01978925|OTHER|Pharmaceutical care|"The clinical pharmacist will provide a structured 30-minute intervention for enhancing their medication adherence.~The recommendations include: discussion on hypertension and/or diabetes, risk of complications, prescribed drug therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, schedule of administration and correct storage. The pharmacist will also emphasize the importance of lifestyle modifications. Printed educational material, with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions was prepared to assist in the intervention and will be handed to patients in the end of the session."
41132923|NCT04526639|BEHAVIORAL|Virtual Reality-based Interactive Cognitive Training Program|Three virtual reality-based games designed to train inhibitory control, working memory, and cognitive flexibility among children with TBI
41452519|NCT03218813|BEHAVIORAL|Intervention cohort ('after' group)|"The intervention will take place during hospitalisation. Patients will complete the BMQ-S and their responses will form the basis of what will be discussed in Session 1. Pharmacists will elicit patients' thoughts and opinions about their medicines and highlight the need to take them. Any erroneous treatment beliefs will be discussed and any concerns will be addressed.~After Session 1, patients will be given a planning sheet and will be asked to think about their usual daily routine and how taking medicines may fit into it. Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose')."
41452520|NCT00258687|BIOLOGICAL|GVAX|4 vaccines every two weeks
41452521|NCT05392959|DRUG|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg per day
41452522|NCT05392959|DRUG|Placebo|Placebo for dapagliflozin film-coated tablets 10 mg
41452523|NCT04173611|DRUG|EXPAREL|Injection into the Intrathecal space.
41452524|NCT04173611|DRUG|Bupivacaine Hydrochloride|Injection into the Intrathecal space.
41452525|NCT04173611|OTHER|Placebo|Injection into the Intrathecal space.
41452526|NCT06557603|DRUG|Ivermectin cream|\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
41452527|NCT06557603|DRUG|Soolantra ® (Ivermectin) cream|\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
41452528|NCT02344550|DRUG|Everolimus(afinitor)|Everolimus 10mg p.o. daily
40946144|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
41452529|NCT02344550|DRUG|Letrozole|Letrozole 2.5 mg p.o. daily
41452530|NCT02344550|DRUG|Leuprolide(Lorelin Depot)|Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
40946145|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
40946146|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
40946147|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
40946148|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
40946149|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
40946150|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
40946151|NCT03161132|DRUG|Olaparib|Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.
41132924|NCT04526639|BEHAVIORAL|Placebo Virtual Reality Game|A virtual playground for control group to interact without training executive functions
41452531|NCT04833205|DRUG|Nimotuzumab|Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks
41452532|NCT02601963|DRUG|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
41452533|NCT02601963|DRUG|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
41452534|NCT02601963|DRUG|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
40946152|NCT03161132|DRUG|Pegylated Liposomal Doxorubicin|PLD 40mg/m2 every 28 days intravenous
40946153|NCT01385631|DRUG|Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
41132925|NCT03072303|OTHER|Web-based Survey|Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.
41132926|NCT02562274|DIETARY_SUPPLEMENT|Placebo|Subjects are received placebo treatments once daily for 8 weeks
41132927|NCT02562274|DIETARY_SUPPLEMENT|MP 50 mg/day|Subjects are received MP 50 mg/day treatments once daily for 8 weeks
41132928|NCT02562274|DIETARY_SUPPLEMENT|MP 1500 mg/day|Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
41132929|NCT01706666|DRUG|bortezomib|Given SC
41132930|NCT01706666|DRUG|cyclophosphamide|Given PO
41132931|NCT01706666|DRUG|lenalidomide|Given PO
41132932|NCT01706666|OTHER|laboratory biomarker analysis|Correlative studies
41132933|NCT01706666|DRUG|dexamethasone|Given PO
41132934|NCT01706666|PROCEDURE|quality-of-life assessment|Ancillary studies
41132935|NCT04455204|DIAGNOSTIC_TEST|Serum asymmetteric dimethyl arginine|Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay
41132936|NCT04455204|DIAGNOSTIC_TEST|serum lipid profiles|serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits
41132937|NCT04455204|DIAGNOSTIC_TEST|Serum vaspin|vaspin concentrations will be assayed using commercially available ELISA kits
41132938|NCT04455204|DIAGNOSTIC_TEST|Serum resistin|resistin concentrations will be assayed using commercially available ELISA kits
41132939|NCT05995795|DEVICE|ARTHROSCOY|arthroscopy
41132940|NCT06510829|DEVICE|Diode laser|Application of laser waves on the lesion
41132941|NCT05072002|OTHER|no intervention / observational study|no intervention / observational study
41132942|NCT01264172|PROCEDURE|PCCP|PCCP: an minimal-invasive surgery technique, in wich a special plate is pushed in position and fixed through 2 small approaches only (about 2 cm long)
41132943|NCT01264172|PROCEDURE|DHS|Conventional surgical treatment of proximal femur fracture including one longer approach from lateral
41132944|NCT01264172|PROCEDURE|Osteosynthesis with nails|Osteosynthesis with nails is a minimal-invasive surgery technique for proximal femur fractures.
41132945|NCT06387966|DRUG|flunotinib|Day one will be used for drug administration, and Day two\~Day seven will be used for experimental data collection.
41132946|NCT06387966|DRUG|flunotinib placebo|Day one will be used for drug administration, and Day two\~Day seven will be used for experimental data collection.
41132947|NCT00776009|DRUG|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
41132948|NCT00776009|DRUG|Placebo|Placebo Comparator
41132949|NCT02628626|DRUG|Colesevelam|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
41132950|NCT02628626|DRUG|Clonidine|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
41132951|NCT02628626|OTHER|Placebo|Placebo will be identical in appearance to the active drug.
41286368|NCT03466710|OTHER|Pap test|"Women will receive Pap tests at 6 and 12 months after randomization. The Pap test will be prepared using the Thinprep® system which is the standard at Calgary Laboratory Services. Women with a Pap test result of malignant, HSIL, AIS, AGC, ASC-H, or LSIL-H (\>LSIL) at 6 or 12 months post randomization will be referred for colposcopic examination. Women with an ASC-US or LSIL result (\</=LSIL) will have a second follow up Pap test 6 months later (12 months post randomization). Those with a persistent result of ASC-US or LSIL or \>LSIL at 6 or 12 months will be referred for colposcopic examination. Outcome in the Pap policy is positive when the histopathology is \>/=CIN II. Results of \</=CIN I equal a negative outcome.~All other Pap test results will have an exit colposcopy 6 months later (18 months post randomization)."
41286369|NCT03466710|DIAGNOSTIC_TEST|HPV test|Women will have an HPV test performed on a cervical scrape sample 12 months after randomization. Women with a positive result will be referred for colposcopy. Outcome in the HPV testing policy is positive when histopathology obtained at the colposcopic exam shows CIN II. All other results equal a negative outcome. HPV negative women will have an exit colposcopy 18 months post randomization. HPV testing will be performed using Cervista™HPV HR(Third Wave Technologies Inc./Hologic Inc, Madison, WI, USA).This HPV DNA test identifies 14 high risk types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). Testing will be performed on the residual cervical scrape sample which is fixed in the PreservCyt® solution of the Thinprep® liquid based system(Hologic Inc, Marlborough, Ma, USA). Cervical samples may be held for up to 24 wks at room temperature before DNA extraction.This allows time for transportation without refrigeration.The samples will be sent by overnight express delivery to the laboratory.
41286370|NCT01864135|DEVICE|3T MRI (Magnetom Verio 3T, Erlangen, Germany)|
41286371|NCT01864135|DEVICE|Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)|
41286372|NCT00345072|DEVICE|Web-based decision aid system|
41286373|NCT01756157|BIOLOGICAL|CINRYZE with rHuPH20|
41286374|NCT05066815|OTHER|Vita Enamic (Hybrid dental ceramic)|Vita Enamic (Hybrid dental ceramic) is provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology.
41452535|NCT02206893|BEHAVIORAL|Self-monitoring via Smartphone|
41452536|NCT02206893|BEHAVIORAL|Peer support via Smartphone|
41452537|NCT02206893|BEHAVIORAL|Professional support via Smartphone|
41452538|NCT02206893|BEHAVIORAL|Self-monitoring via Web (Static)|
41452539|NCT03867760|BEHAVIORAL|Recorded Hypnosis Intervention|The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days). The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.
41452540|NCT03867760|BEHAVIORAL|Recorded Relaxation Intervention|The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
41452541|NCT01174186|DRUG|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
41452542|NCT02010918|DRUG|glucosamine sulfate /chondroitin sulfate - capsules|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
40946154|NCT01385631|DRUG|Placebo|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
40946155|NCT05720507|BEHAVIORAL|Cafe Move|Participants will be offered the opportunity to choose from a number of physical function assessments and subsequently provided personalized reports of performance results.
40946156|NCT04069078|DRUG|Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule|Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia
40946157|NCT04069078|OTHER|Normal saline|Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia
40946158|NCT01087242|DRUG|Tang-min Lin pill|Tang-min Lin pill 6g,tid,treat 12 weeks.
40946159|NCT02979197|DRUG|OE 10 mg amlodipine besylate tablet|
41452543|NCT02010918|DRUG|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
40946160|NCT02979197|DRUG|OE 200 mg celecoxib capsule|
40946161|NCT02979197|DRUG|Matched placebo for OE amlodipine besylate tablet|
40946162|NCT02979197|DRUG|Matched placebo for OE celecoxib capsule|
40946163|NCT05008614|PROCEDURE|Erector spinae plane block group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under ultrasound guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 18G 85 mm perineural catheter (Silverstim, Vygon, Ecouen, France) (basal infusion: 10ml/hr, bolus 5ml, lockout time: 20min)"
40946164|NCT05008614|PROCEDURE|Thoracic epidural analgesia group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under fluoroscopy guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 17-gauge catheter (FlexTip Plus®, Teleflex Medical, USA) (Silverstim, Vygon, Ecouen, France) (basal infusion: 3ml/hr, bolus 1ml, lockout time: 20min)"
40946165|NCT03210623|DEVICE|stent retriever(TonbridgeMT)|mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)
40946166|NCT03210623|DEVICE|Solitaire™|mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
40946167|NCT06525012|OTHER|Usual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin|During hospitalization (2013-2021), patients were managed after multidisciplinary consultation in accordance with national recommendations between resuscitators, neurosurgeons and neuroradiologists, depending on the severity of the initial management and the patient's comorbidities, either by interventional radiology, neurosurgery or medical treatment.
40946168|NCT04844619|DRUG|4mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
40946169|NCT04844619|DRUG|16mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
40946170|NCT01645904|BEHAVIORAL|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
40946171|NCT01645904|BEHAVIORAL|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
40946172|NCT01645904|BEHAVIORAL|Audiotaped Interview|"Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website."
40946173|NCT01645904|BEHAVIORAL|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
40946174|NCT00195273|DRUG|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
40946175|NCT00195273|DRUG|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
40946176|NCT00195273|DRUG|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
40946177|NCT00195273|DRUG|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
40946178|NCT00195273|DRUG|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
41452544|NCT02010918|DRUG|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
41452545|NCT02440997|OTHER|aromatherapy|
41452546|NCT02440997|OTHER|foot bath|
41286375|NCT03016234|DRUG|Desflurane|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4\~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
41132952|NCT04630899|OTHER|Active joint mobilization|The participants bend his knees in a prone position. The physical therapist holds the medial malleolus with one hand and the lateral malleolus with the other. At the same time, the physical therapist touches the participant's soles to the sternum area and presses them in the dorsal direction. At this time, medial malleolus glides anterior and lateral malleolus glides posterior. The first procedure is to passively recognize movement. The second procedure is accompanied by active movement of the participant.
41132953|NCT04630899|OTHER|Passive joint mobilization|PJM uses Maitland's Mobilization method, grade III (high amplitude in the end range of the joint and 1 second vibration in the middle range through linear motion in which tissue resistance is felt). The participant is in a supine position, and the physical therapist holds the talus with one hand and the tibia with the other hand, and performs joint mobilization in the posterior direction with the hand holding the talus.
40946179|NCT06257485|DIAGNOSTIC_TEST|99mTc-pyrophosphate Single Photon Emission Computed Tomography|All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram
41132954|NCT04634851|BEHAVIORAL|Virtual home visits|These participants will have a tailored evaluation of dietary choices based on their home dietary environment (refrigerator, pantry, etc). This will be conducted over video exchange.
41132955|NCT01961466|OTHER|psychological and social self-administered questionnaires|
41132956|NCT02118311|BIOLOGICAL|T Regulatory cells|Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
41132957|NCT02118311|DRUG|Fludarabine|Fludarabine 30mg/m\^2 IV over 1 hour on days -6 through -2 from transplant
41132958|NCT02118311|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
41132959|NCT02118311|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
41132960|NCT02230046|DRUG|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
41132961|NCT02230046|DRUG|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
41286376|NCT03016234|DRUG|Propofol|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
41286377|NCT06070610|DRUG|BI 1015550|BI 1015550
41286378|NCT06070610|DRUG|Nintedanib|Soft capsules
41286379|NCT06070610|DRUG|Pirfenidone|Film-coated tablets
41286380|NCT00542984|DRUG|teriparatide 20 micrograms/day subcutaneous|
41286381|NCT00542984|DRUG|salmon calcitonin 100 IU/day subcutaneous|
41286382|NCT00942708|DRUG|Fluoxetine|"Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID"
41286383|NCT00502710|DRUG|Placebo|Placebo po daily.
41286384|NCT00502710|DRUG|RO4876904|Escalating doses, at a starting dose of 12.5mg po daily.
41286385|NCT00501319|BEHAVIORAL|Interactive Voice Response (IVR)|Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.
41132962|NCT02230046|DRUG|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
41132963|NCT01953679|DRUG|Ulipristal Acetate|
41132964|NCT01246804|DRUG|raltegravir single dose|single dose 400mg raltegravir
41132965|NCT01246804|DRUG|ginkgo biloba multiple dose|15 days ginkgo biloba 120mg BID
41132966|NCT01935375|BEHAVIORAL|CNM Interpersonal Psychotherapy|Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
41132967|NCT01935375|BEHAVIORAL|Treatment as Usual|Treatment as Usual is psychotherapy provided by a mental health provider
41132968|NCT03020498|BIOLOGICAL|Fluzone|Influenza Virus Vaccine Suspension for Intramuscular Injection
41132969|NCT03020498|BIOLOGICAL|FluMist|Influenza Virus Vaccine Live, Intranasal Intranasal Spray
41132970|NCT01543893|BEHAVIORAL|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
41132971|NCT01543893|BEHAVIORAL|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
41132972|NCT05001126|BEHAVIORAL|HIFT 1x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 1x/week represents a dose of one HIFT workout per week.
41132973|NCT05001126|BEHAVIORAL|HIFT 2x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 2x/week represents a dose of two HIFT workouts per week.
41132974|NCT05001126|BEHAVIORAL|HIFT 3x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 3x/week represents a dose of three HIFT workouts per week.
41132975|NCT05500352|OTHER|Hyperglycemia with slow decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
41132976|NCT05500352|OTHER|Hyperglycemia with rapid decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
41132977|NCT05500352|OTHER|Rebound hyperglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L)
41132978|NCT05500352|OTHER|Rebound euglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in euglycemia (PG: 5-8 mmol/L).
41132979|NCT05500352|OTHER|Hypoglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L) or euglycemia (PG: 5-8 mmol/L)
41132980|NCT05500352|OTHER|Hypoglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
41132981|NCT05500352|OTHER|Hypoglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
41286386|NCT00501319|BEHAVIORAL|Questionnaire|Questionnaires taking 20 minutes to complete.
41286387|NCT02859701|DRUG|AK002|IV AK002
41286388|NCT02859701|OTHER|Placebo|
41286389|NCT02438930|BEHAVIORAL|Motivational interviewing intervention during HIV testing|
41286390|NCT02438930|BEHAVIORAL|Standard-of-care counseling during HIV testing|
41286391|NCT06092398|OTHER|PRP and PRFG in treatment of anal fistula|The tract fistula was cleaned with betadine 10% before PRP and PRFP were applied. Then, 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. The operation time was about 20-30 minutes, the clot formation usually takes about 8 minutes, but the anesthesia was extended to 20 minutes to make sure a complete clot in the place of fistula
41286392|NCT04394169|BEHAVIORAL|Intervention program|"Medical visits:~There will be three medical visits stipulated as follows:~* Visit 1 Intervention Group, four weeks after hospital discharge.~* Visit 2 Intervention Group, eight weeks after hospital discharge.~* Visit 3 Intervention Group, 18 weeks after hospital discharge.~Components of visits:~* Interview and physical examination.~* Therapeutic education about the intensive care syndrome orally and with a specific document that will be delivered at the end of the visit.~* Therapeutic education around pain. If the patient reports pain, a specific document will be prepared that will be delivered at the end of the visit.~Psychological intervention:~Inclusion criteria for psychological intervention: Patients with a score higher than 8 on the HAD (hospital anxiety and depression) test depression subscale.~Description :~The intervention protocol consists of 7 weekly sessions lasting one hour and a half. The intervention in depression is based on Rehm's model of self-control."
41286393|NCT04107220|DRUG|Sacubitril/Valsartan|Effect of Sacubitril/Valsartan on BNP and NT-proBNP
41286394|NCT01506791|DRUG|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
41286395|NCT01771302|DEVICE|Bio-Oss|It is a bone substitute of bovine origin
41286396|NCT01771302|DEVICE|calcium phosphate ceramic|It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
41286397|NCT01466114|DRUG|estriol|4 capsules of 2 mg (total of 8 mg) PO QD
41286398|NCT01466114|OTHER|Placebo|4 capsules PO QD
40946180|NCT02020187|OTHER|Exercise on a cycle-ergometer|Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
40946181|NCT00376376|DRUG|levofloxacin at 250, 500, 750, and 1000 mg doses|
41132982|NCT05500352|OTHER|Hyperglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
40946182|NCT01948037|OTHER|hydrotherapy|30-minutes/per day,for 4weeks
40946183|NCT01948037|OTHER|hydrotherapy|30-minutes/per day;4weeks
40946184|NCT03412708|OTHER|Vestibular Rehabilitation supported with Virtual Reality|Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
41132983|NCT05500352|OTHER|Hyperglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
41132984|NCT04383067|PROCEDURE|Tumor Infiltrating Lymphocytes (TIL)|Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation. Patient will undergo surgery to remove either the primary tumor or a tumor metastasis. The cells collected in this surgey will be cultured and reintroduced to the patient. Following the cell infusion, patient will receive a high-dose bolus of IL-2.
41132985|NCT04383067|DRUG|Proleukin|high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered
41132986|NCT04130932|OTHER|Ergonomic flooring|Specially designed flooring system to optimize ergonomics of participants
41132987|NCT05558683|OTHER|Randomized clinical trial.|Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.
41132988|NCT01585623|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
41132989|NCT01585623|DRUG|omeprazol|"Pharmaceutical form:capsule~Route of administration: oral"
41132990|NCT01585623|DRUG|metoprolol|"Pharmaceutical form:tablet~Route of administration: oral"
41132991|NCT01585623|DRUG|midazolam|"Pharmaceutical form:solution~Route of administration: oral"
41132992|NCT00964236|DRUG|Sapropterin|Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
41132993|NCT06510166|BEHAVIORAL|Children's Fear and Anxiety normal nebulizer and mask+ distraction|Children in group 2 will receive their inhaler treatment with a normal nebulizer and mask, while at the same time one of the distraction techniques of their choice (drawing a picture, reading a story or watching an age-appropriate cartoon) will be applied.
41132994|NCT06510166|BEHAVIORAL|Children's Fear and Anxiety a toy nebulizer and a toy mask|Children in Group 3 will receive their inhaler treatment using a toy nebulizer and a toy mask.
41132995|NCT02596061|BEHAVIORAL|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
41132996|NCT02596061|OTHER|Incentives|Patients receive incentives for completing smoking cessation activities.
40946185|NCT01753141|BEHAVIORAL|Cognitive Behavioral Therapy for smoking cessation|
40946186|NCT01753141|BEHAVIORAL|Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.|Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
40946187|NCT00107783|DRUG|Nitisinone (NTBC)|Treatment
40946188|NCT05095454|DEVICE|Percutaneous epidural electrical spinal stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Ripple Neuromed Nomad Neurostimulation System"
40946189|NCT05095454|DEVICE|Transcutaneous electrical spinal stimulation|Digitimer DS8R Bipolar Constant Current Stimulator
40946190|NCT04522531|OTHER|Open cinetic chain shoulder exercise on unstabil ground|Open cinetic chain shoulder exercise will be performed on BOSU which provides an unstabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
40946191|NCT02378623|DRUG|Apixaban|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
40946192|NCT02378623|DRUG|Placebo|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
40946193|NCT05140850|BIOLOGICAL|neuroimaging examination,neuro-cognitive test,blood pressure,blood sample|neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested
40946194|NCT02538328|DEVICE|Harmonic scapel|different surgical devices used in the obesity surgery
40946195|NCT02538328|DEVICE|Ligasure|Bipolar vessel sealing system used in obesity surgery
40946196|NCT03654859|OTHER|cardiopulmonary resuscitation|no pre-specified
40946197|NCT03277157|DIETARY_SUPPLEMENT|B. lactis B94|A probiotic dose of 15 billion per capsule.
40946198|NCT03277157|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
41286399|NCT01466114|DRUG|Norethindrone|Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
41286400|NCT01466114|OTHER|Progestin Placebo|Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
40946199|NCT01884623|DRUG|Cetuximab|
40946200|NCT01884623|DRUG|Methotrexate|
40946201|NCT03764085|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
40946202|NCT03764085|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
41132997|NCT03069391|BEHAVIORAL|physical exercise alone (PES) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
41132998|NCT03069391|DEVICE|cognitive exercise alone (iCE) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
41286401|NCT05539430|BIOLOGICAL|LB1908|Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells
41286402|NCT02255838|DEVICE|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
41286403|NCT02255838|DEVICE|Bronchoscope disposable (aScope 4)|Bronchoscopy and alveolar lavage
40946203|NCT01368978|DEVICE|InsuPatch|device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
40946204|NCT03949439|PROCEDURE|Elective Cardiac Surgery|Surgical interventions (coronary artery bypass \[CAB\], valve replacement or valve repair).
41286404|NCT05928741|BEHAVIORAL|Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload|Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast consisting of 2 slices of white bread and honey (350 kcal in total) after a 12-hour fast. Two hours later they were offered 347 mL of the enriched orange juice (containing 50 g available carbohydrates), and 3 hours after the preload they were offered an ad libitum lunch (chicken breast with white rice). Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. Fingertip capillary blood glucose samples and visual analog scales (VAS) of 100 mm were collected at baseline and at 60, 120, 135, 150, 180, 210, 240, 270, 300, 330, 360, 390, and 420 minutes after breakfast consumption. Blood pressure was measured at baseline, 120, 300, and 420 minutes.
40946205|NCT02919098|BEHAVIORAL|Bystander, a game-based bystander intervention program|A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
40946206|NCT02919098|BEHAVIORAL|Infection City, a game-based program about meningitis|A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
40946207|NCT01761175|PROCEDURE|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
40946208|NCT01761175|PROCEDURE|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
40946209|NCT01957332|PROCEDURE|Molecular imaging|On the day of FES-injection\&scan or the day after FES-injection, 89Zr-trastuzumab (\~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
40946210|NCT01957332|PROCEDURE|Molecular imaging|All patients receive 18F-FES (\~200MBq) injection followed by a FES-PET.
40946211|NCT01281137|GENETIC|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
40757633|NCT01326637|OTHER|Patient Overview Document|"The Intervention has two components:~1. Pre-visit care coordination:~   * 5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~  * The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~2. Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD."
40757634|NCT04197505|BEHAVIORAL|FLIR E95 camera|Video will be recorded during the thermal reading for later computer analysis. The following variables will be analyzed: (1) the difference between the mean temperature between the injured and healthy extremities, (2) the difference between the maximum temperatures of both the injured and healthy extremities (ΔTmax), and (3) the difference between the area covered by each isotherm in both the injured and uninjured extremities (Δpix). FLIR software tools and MATLAB software will be used for the analysis.
40757635|NCT06144658|DEVICE|Augmented Reality Headset / Hololens 2 or Varjo XR3|Augmented Reality Headset
40757636|NCT01791179|BEHAVIORAL|Comprehensive substance abuse services|
40946212|NCT01281137|OTHER|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
40946213|NCT01281137|PROCEDURE|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
41132999|NCT03069391|DEVICE|interactive Physical and Cognitive Exercise (iPACES™)|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
41133000|NCT00724126|DRUG|Rifaximin|
41133001|NCT00724126|DRUG|Placebo|
41133002|NCT05965700|DRUG|NVG-291|A once daily injection
41133003|NCT00775866|PROCEDURE|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
40757637|NCT00216931|DRUG|iloprost|
40757638|NCT04126174|DEVICE|femtosecond laser system arcuate corneal incision|Corneal arcuate incision made either with a blade (manual) or femtosecond laser system.
40757639|NCT04126174|OTHER|Manual LRI|Manual LRI
40946214|NCT03292575|DRUG|Anticoagulants|
40946215|NCT00276146|DRUG|oral dipyridamole, oral magnesium, or a combination of both|
40946216|NCT04676412|BIOLOGICAL|Pembrolizumab|IV infusion
40946217|NCT04676412|DRUG|Lenvatinib|oral capsule
40946218|NCT04676412|DRUG|Placebo for lenvatinib|oral capsule
40946219|NCT04568421|DRUG|Immunosuppressive Agents|Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician
40946220|NCT04627701|DEVICE|Omega|Omega Implantation
40946221|NCT04032392|BIOLOGICAL|autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
40946222|NCT00602173|DRUG|Cilostazol|
40946223|NCT02003365|DRUG|FX006 10 mg|Extended-release formulation
40946224|NCT02003365|DRUG|FX006 40 mg|Extended-release formulation
40946225|NCT02003365|DRUG|TCA IR 40 mg|Immediate-release formulation
40946226|NCT03719443|BIOLOGICAL|VIS649|Single IV dose of study product on Day 1 of study
40946227|NCT03719443|BIOLOGICAL|Placebo|Singe IV dose of placebo administered via IV on Day 1 of study
40946228|NCT02519465|OTHER|10l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 10l/min
40946229|NCT02519465|OTHER|30l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 30l/min.
40946230|NCT02519465|OTHER|50l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 50l/min.
40946231|NCT00131508|DRUG|Glutamine|0.6 gm/kg of oral glutamine per day, in two doses for one year.
40946232|NCT00131508|DRUG|Placebo|Placebo
40946233|NCT05288478|COMBINATION_PRODUCT|Dentoxol mouthrinse dosages|Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
40946234|NCT01140373|BIOLOGICAL|engineered autologous T cells|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
40946235|NCT01140373|DRUG|cyclophosphamide|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 10\^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
40946236|NCT00935298|DRUG|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5\*1/\*1 type and CYP3A5\*1/\*3 type administer 0.15mg/kg/d，CYP3A5\*3/\*3 type administer 0.08mg/kg/d).
41133004|NCT01824225|DRUG|Aflibercept|
40946238|NCT02863276|PROCEDURE|Intensified insulin therapy|
40946239|NCT02232334|OTHER|Global Osteopathic Manual Treatment|subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
41286405|NCT05528276|PROCEDURE|Repair surgery|"1. a circumscribing skin incision was made 2 mm below the hypospadias meatus,~2. penile degloving,~3. the para-urethral plate incision was made,~4. A vertical midline incision of the urethral plate was made from within the hypospadiac meatus and extended up to the mid-glans.~5. The urethral plate was tubularised, beginning proximally, and closed in two layers using 6/0 polyglactin 910 suture.~6. The neomeatus was formed on a catheter 2 F larger than the urethral stent.~7. A flap was harvested from the prepuce to cover the neourethra and finally glanuloplasty.~8. A suitable urethral stent was left in situ for 7-10 days, with a compressive dressing applied.~   * Grafted tubularised incised-plate .~1.Same steps but adding a graft (dorsal inlay) , 2. The graft will be taken from the inner preputial skin . 3. The graft will be sutured to overlying plate incision line from the old meatus to the tip of the glans."
41452547|NCT04436198|DEVICE|MORCHER® EYEJET® CTR Types 14, 14A, and 14C|"Intervention. Toric IOL + CTR. Whether the subject receives 14, 14A, or 14C is an either or scenario depending on the eye's axial length and is a single intervention:~Axial length \> 28.0 mm: CTR model 14A Axial length 24.0-28.0 mm: CTR model 14C Axial length \< 24.0 mm: CTR model 14~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
41133005|NCT03259269|OTHER|This is a non-intervention observational study|No applicable intervention; this is a secondary data analysis observational study.
41133006|NCT03736980|DRUG|Placebo|100% lactose
41286406|NCT06485544|DRUG|Adebrelimab + Etoposide + Platinum-based Therapy|"Intervention Description for Treatment Group:~This intervention includes Adebrelimab in combination with Etoposide and Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Adebrelimab is administered intravenously at a fixed dose of 1200 mg over 30 minutes on Day 1 of each 3-week cycle, followed by Etoposide at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment."
41286407|NCT06485544|DRUG|Etoposide + Platinum-based Therapy|"Intervention Description for Control Group:~This intervention includes Etoposide in combination with Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Etoposide is administered at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each 3-week cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment."
41452548|NCT04436198|DEVICE|Toric IOL Only|"Control. Toric IOL only. Standard of care cataract surgery without placement of a capsular tension ring.~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
41452549|NCT00625560|DRUG|Entecavir|entecavir 1.0 mg QD
41286408|NCT01333618|DEVICE|curving introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
41286409|NCT01333618|DEVICE|straight introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
40946240|NCT02208531|BEHAVIORAL|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
41286410|NCT00072969|DRUG|Daclizumab|
41286411|NCT05324943|GENETIC|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
41286412|NCT05396118|DRUG|18F-FDG|Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
41286413|NCT05396118|DRUG|Injection of hyperpolarized [1-13C]Pyruvate|Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by MRS / MRSI.
41286414|NCT05396118|PROCEDURE|PET/MR/MRS/MRSI scanning|Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized \[1-13C\]Pyruvate.
41286415|NCT04229147|RADIATION|Radiotherapy|Patients who received a total dose of 30 Gy
41286416|NCT03110822|DRUG|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
41286417|NCT03110822|DRUG|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
41286418|NCT03110822|DRUG|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
41286419|NCT00360516|BEHAVIORAL|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
41452550|NCT00625560|DRUG|Lamivudine|lamivudine 100 mg QD
41452551|NCT01756807|DEVICE|The COMBO Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
40946241|NCT02973490|DEVICE|Transanal Tube Drainage|Using transanal tube drainage after colorectal ESD
41286420|NCT03163030|DEVICE|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
41452552|NCT01968369|DIETARY_SUPPLEMENT|tomato sauce|We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
40946242|NCT03023787|DRUG|Hepalatide|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
40946243|NCT03023787|DRUG|Placebo|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
40946244|NCT03004196|DRUG|Probiotic Toothpaste|G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
40946245|NCT03004196|DRUG|Dr. Reddy's Clohex|0.20% Chlorhexidine Mouthwash
40946246|NCT03004196|OTHER|Control Group|No Probiotic toothpaste \& Chlorhexidine Mouthwash
40946247|NCT03508739|DRUG|Sacubitril/Valsartan 200mg (blinded)|study day 2 for AB and study day 3 for BA
40946248|NCT03508739|DRUG|Valsartan 160mg (blinded)|study day 3 for AB and study day 2 for BA
40946249|NCT04173234|OTHER|Aerobic Training|Aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
40946250|NCT04173234|OTHER|Home exercise program|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
40946251|NCT04268589|OTHER|virtual reality game|routine
40946252|NCT03455582|OTHER|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
40946253|NCT03455582|OTHER|Ecological evaluation|Virtual reality task and Actual reality
41286421|NCT04275752|OTHER|Exercise Program|Perform endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training twice a week for a period of one hour per session, for a total of 16 sessions.
41286422|NCT02328716|PROCEDURE|Cytoreduction|Cytoreduction
41452553|NCT00421304|BIOLOGICAL|Motavizumab|A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.
41452554|NCT00421304|OTHER|Placebo|A single IV dose of placebo matched to motavizumab will be administered on Day 0 of the study.
41452555|NCT04756739|DEVICE|Clearblue Connected Ovulation Test System|Clearblue Connected Ovulation Test System which is a CE marked device used for tracking the menstrual cycle
41452556|NCT01206803|DRUG|Ovarian stimulation in a GnRH-antagonist protocol|Long-acting FSH 150µg \& daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
41452557|NCT00503919|PROCEDURE|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
41452558|NCT03675763|OTHER|Manual treatment|Craniosacral therapy protocol.
41452559|NCT06182449|DEVICE|Virtual Reality Distraction|In a private NICU room, mothers will wear a head-mounted VR device when they will initiate the expression of their maternal milk. The video within the VR system will provide a calm forest environment with waterfalls, animals, and birdsong (INSPIRE® Program). The baby may or may not be present in the room during the intervention. This will be documented.
41452560|NCT06182449|OTHER|Standard Protocol|Mothers will express their maternal milk in a private room in the NICU with their baby or a photo of the baby. Use of any co-interventions for anxiety management (e.g. music) durign this sequence will be documented.
41452561|NCT03791541|BEHAVIORAL|Pharmacist services|Additional pharmacist/pharmacy student follow-ups, counseling, and other services
41452562|NCT04341883|DRUG|anti-PD-1+Albumin-Bound Paclitaxel|"anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years.~Other Name: Programmed cell death 1 antibody"
41452563|NCT00000595|DRUG|deferoxamine|
40757640|NCT02239042|PROCEDURE|LLLT|The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
40757641|NCT06467656|OTHER|Individualized, periodized endurance training for ultra-endurance triathlon.|Endurance exercise consisting of swimming, cycling and running training for a minimum of 3 hours /week up to a maximum of 20 hours/week with regular rest days and intensities being fluctuated throughout the program to optimize training stimulus and adaptation. Strengthening exercises to complement the aerobic training, enhance conditioning and prevent injury will also be performed 1-2 hours/week for the first 9-months of the program.
40757642|NCT06467656|OTHER|Time-Aligned Control|Participants will receive no specific intervention and will continue to live their lives as if they were not in a study.
40757643|NCT03903341|OTHER|fMRI|bold signal in visual pathway
40757644|NCT06570083|BEHAVIORAL|Mobile Exercise Support|Participants receive three months of personalized support via WeChat, including tailored exercise recommendations, motivational messages, and educational content.
40757645|NCT06570083|BEHAVIORAL|Self-help physical activity booklet|Participants receive a self-help booklet to promote physical activity among the elderly. The booklet will include guidelines for safe and effective exercises, tips for staying motivated, and information on the health benefits of regular physical activity.
40757646|NCT02098603|BEHAVIORAL|Testing & Intervention|Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
40946254|NCT03455582|OTHER|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
40946255|NCT03455582|OTHER|Psychological evaluation|questionnaires for depression, anxiety and fatigue
40946256|NCT03455582|DEVICE|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
41133007|NCT03736980|DRUG|Psilocybine|Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight
41286423|NCT02328716|DRUG|Hipec with Cisplatin|Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
41286424|NCT04340869|OTHER|Theobromine|Natural extract from Cocoa
41286425|NCT04340869|OTHER|Remin Pro|Remin Pro
41286426|NCT05301348|DEVICE|Photoacoustic Flow Cytometry|Detection of circulating blood clots
41286427|NCT05237882|OTHER|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
41286428|NCT02227212|DRUG|Insulin glargine U300 (new formulation of insulin glargine) HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
41286429|NCT02785757|OTHER|Thrombin Generation Assay|
41286430|NCT03156153|DRUG|Bumetanide|bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
41286431|NCT03156153|DRUG|Placebo|placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
41286432|NCT04366271|BIOLOGICAL|Mesenchymal cells|1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
41286433|NCT04366271|DRUG|Standard of care|Best treatment option for COVID-19 according to investigator criteria
41286434|NCT05823506|COMBINATION_PRODUCT|PDE5 inhibitor (tadalafil) and BTL-6000 fSWT|The mechanism of low-intensity shockwave therapy in patients with ED based on the effect on the endothelium of the cavernous arteries, the release of NO and the enhancement of vascularization due to release of angiogenic factors.
41286435|NCT05823506|DRUG|PDE5 inhibitor (tadalafil)|Tadalafil improves erectile function by inhibiting PDE5 isoenzyme, thereby blocking cGMP degradation. As a result, the PDE5 inhibitors act synergistically with NO to markedly increase the levels of cGMP, which in the presence of sexual stimulation, lead to an erection. In the absence of sexual stimulation, NO is not released locally and the PDE5 inhibitors do not affect the penis. Thus, sexual stimulation is needed to initiate the erectile mechanism for the PDE5 inhibitors to take effect.
41133008|NCT05098405|DRUG|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
41286436|NCT02388230|DEVICE|Ultrasound imaging|
41133009|NCT05098405|DRUG|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
41133010|NCT04349319|DEVICE|Digital preoperative planning|Before the osteosynthesis of distal humerus fracture, we perform digital preoperative planning.
41286437|NCT01161836|DRUG|Iniparib|"Solution for infusion~60-minute intravenous infusion"
41452564|NCT04917991|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil-enriched chocolate spread|the intervention consists in the administration of 100g Extra Virgin Olive Oil-enriched chocolate spread each day for 14 days.
40946257|NCT00737438|DRUG|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|"Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. \> 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery."
40946258|NCT03950011|PROCEDURE|Enhanced recovery after surgery program|Enhanced Recovery After Surgery Programs (ERP) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (LOS).
40946259|NCT01913223|DEVICE|Nestis® jet injector system with a bi-functional catheter|
40946260|NCT03320226|DIETARY_SUPPLEMENT|Probiotic 10 (Nature's Bounty)|The Probiotic 10 (Nature's Bounty) that contains 20 billion live cultures of Lactobacillus plantarum 299v (Lp299v®), Lactobacillus bulgaricus Lb-87, Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus salivarius Ls-33, Lactobacillus brevis Lbr-35, Lactobacillus acidophilus La-14, Bifidobacterium lactis Bl-04, Lactobacillus paracasei Lpc-37, Lactobacillus casei Lc-11, which are under Lactobacillus and Bifidobacterium.
40946261|NCT04603053|BEHAVIORAL|mHealth app|Participants will receive access to CBot-A app for 12 weeks.
40946262|NCT01133041|OTHER|Observation using NBI system|NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
40946263|NCT01133041|OTHER|Observation using i-Scan system|I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
40946264|NCT01826773|DRUG|CardioPET™|CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
41452565|NCT04917991|DIETARY_SUPPLEMENT|Palm Oil-enriched chocolate spread|the intervention consists in the administration of 100g Palm Oil-enriched chocolate spread each day for 14 days.
40946265|NCT01438073|DRUG|kisspeptin 112-121|24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
40946266|NCT01438073|DRUG|GnRH|Single intravenous dose of GnRH (2.5-250 ng/kg)
40946267|NCT05504473|DEVICE|NEURO-BLINK Device|The NEURO-BLINK is a class IIa medical device that intends to restore the blink function in patients with facial palsy through the application of transcutaneous electrical stimulation.
41286438|NCT02556086|DRUG|Daclatasvir|
41286439|NCT02556086|DRUG|Sofosbuvir|
41286440|NCT01220778|BEHAVIORAL|Exercise|
41452566|NCT05623592|DRUG|Methotrexate|17,5/15/10 mg Methotrexate subcutaneously
41452567|NCT05623592|DRUG|Sodium chloride|Sodium chloride subcutaneously
41452568|NCT06152848|OTHER|Data and samples collection|Collection of clinical, anamnestic and lifestyle data; collection of faecal, blood and saliva samples
41452569|NCT03914196|DIAGNOSTIC_TEST|Liver Stiffness Ultrasound|Research imaging will include liver assessments of stiffness (ultrasound shear wave elastography), tissue attenuation (if available), and blood flow (gray-scale and Doppler imaging).
41452570|NCT02235558|DRUG|Verapamil|Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
41452571|NCT04816396|BEHAVIORAL|reminiscence Therapy|Application Stages of Reminiscence Therapy Based on Roy Adaptation Model Week 1 (Session 1):Introduction-Meeting-Infancyand Family Life Week 2 (Session 2):Childhood and School Years Week 3 (Session 3):Unforgettable Historical Periods,Old movies, Old Songs Week 4 (Session 4):Loved, meals,Desserts and Recipes,Nutrition Style Week 5 (Session 5):Work and Marriage Week 6 (Session 6):Home and Garden Works,Animals, Plants Week 7 (Session 7): Travels, Vacation Memories Week 8 (Session 8): Celebration Memories, Evaluation Posttest Closing.
41452572|NCT02387034|BEHAVIORAL|Physical activity on prescription|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
41286441|NCT06197607|OTHER|theraputty hand exercises|Theraputty hand exercises will be done in following manners: Finger flexion, Metacarpophalangeal joint flexion, Interphalangeal joint flexion, Finger grip strengthening, Finger abduction and Rolling putty into ball and pinching it between, thumbs and finger with both the hands. There will be 20 repetitions with one set of each
41286442|NCT06197607|OTHER|sensory stimulation|Sensory Stimulations (30 min) will be given following forms; All and single joint shaking, Multivariate sensory stimulations, Skin stretch in the muscular region, Fast stretch of the upper limb joints in different directions of motor action, brushing on the large muscles of arm and forearm, brushing on the fingers, Circular massage of the thenar and hypothenar area and pressing the tip of fingers.
41452573|NCT02387034|OTHER|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
41452574|NCT03797196|DRUG|low dose tacrolimus in combination with everolimus|a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
41452575|NCT03797196|DRUG|standard dose tacrolimus with mycophenolate mofetil|A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
41452576|NCT03717896|DRUG|200mg IV thiamine in 50mL 0.9% saline|Thiamine 200mg IV every 12 hours for 2 days
41452577|NCT03717896|DRUG|Placebo|50mL 0.9% saline
41452578|NCT00835796|DRUG|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
40946268|NCT00513656|DRUG|Oxycodone|
40946269|NCT00513656|DRUG|Oxycodone/Naloxone|
40946270|NCT03865134|DIAGNOSTIC_TEST|Snellen Test|Visual acuity measurement
41452579|NCT00835796|DRUG|PROSCAR® 5mg tablets|1 x 5 mg, single dose fasting
40946271|NCT03865134|DIAGNOSTIC_TEST|Autorefractometer|Refraction measurement
40946272|NCT03865134|DIAGNOSTIC_TEST|Titmus Stereo Fly Test|Stereopsis measurement
40946273|NCT03865134|DIAGNOSTIC_TEST|Optical Kohlerans Tomography|Retinal development measurement
40946274|NCT03865134|BEHAVIORAL|Investigation of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
40946275|NCT03865134|BEHAVIORAL|Peabody Developmental Motor Scales - II|Evaluation of motor development
40946276|NCT03865134|BEHAVIORAL|World Health Organization Quality of Life - BREF|Assesment of quality of life
40946277|NCT03865134|BEHAVIORAL|State - Trait Anxiety Inventory|Assesment of anxiety
40946278|NCT00514566|DEVICE|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
40946279|NCT02910362|DEVICE|Alcon phacoemulsification equipment|cataract surgery with Alcon phacoemulsification equipment.
40946280|NCT02910362|DEVICE|AMO phacoemulsification equipment|cataract surgery with AMO phacoemulsification equipment.
40946281|NCT03275792|DRUG|D5-0.9%NS|Admission for intravascular volume expansion
40946282|NCT03275792|DRUG|Routine home oral rehydration|Routine oral fluids as is given at home to all children with acute diarrheal disease
41452580|NCT03852745|BEHAVIORAL|Cognitive Behavioral Therapy|cognitive behavioral therapy; focus on learning skills including acceptance and commitment
40757647|NCT04442750|PROCEDURE|Erector spinae plane block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will be then rotated into a longitudinal orientation 2-3 cm lateral to vertebral column. The lumbar skin region will be sterilized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex A'; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a cranial-to-caudal direction until contact will made with the L4 transverse process. Local anesthetic solution will be injected and its type will be selected according to the studied group and patients were placed in a supine position and general anesthesia will be started.
40946283|NCT03537612|DRUG|Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
40946284|NCT03537612|OTHER|Morphine|Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
40946285|NCT02097043|DRUG|DA-7218|
40946286|NCT02097043|DRUG|Placebo|
41286443|NCT01266096|DRUG|PET scan with 124I-cRGDY-PEG-dots|Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
41452581|NCT05461157|DEVICE|Preoperative silicone ointment|The silicone ointment in this study is the Biodermis Scar Aid Silicone Stick, an FDA-approved silicone ointment that is available for purchase over the counter.
41452582|NCT05461157|OTHER|Preoperative placebo ointment|The placebo ointment in this study is a generic, non-flavored lip balm that is identical in packaging and texture to the Biodermis Scar Aid Silicone Stick used in the treatment arm.
40946287|NCT04697056|DRUG|Imsidolimab|Humanized Monoclonal Antibody
41133011|NCT04727294|BEHAVIORAL|Questionnaire|Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
41452583|NCT01530048|DRUG|insulin aspart|A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
40946288|NCT04697056|BIOLOGICAL|placebo|placebo
41133012|NCT03075683|BEHAVIORAL|Cognitive behavioural therapy|Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
41286444|NCT06345781|BEHAVIORAL|Abdominal Functional Electrical Stimulation|Functional electrical stimulation electrodes will be applied to the abdomen during a bowel program to assess effects of stimulation on bowel management time.
41286445|NCT04219306|OTHER|Alert on dispatchers screen 'Suspect cardiac arrest'|Alert on dispatchers screen 'Suspect cardiac arrest'
41452584|NCT04299087|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy using a magnet to target and stimulate certain areas of the brain.
41452585|NCT04299087|OTHER|Control group|No application of rTMS
41452586|NCT05014438|DRUG|BMS-986166|Specified dose on specified days
41452587|NCT05014438|DRUG|Branebrutinib|Specified dose on specified days
41452588|NCT05014438|OTHER|Placebo|Specified dose on specified days
41452589|NCT04934007|DEVICE|rTMS Treatment|1 Hz rTMS
41452590|NCT01002287|DEVICE|SprayShield Adhesion Barrier System|Adhesion Barrier Device
41452591|NCT01002287|PROCEDURE|Good Surgical Technique Alone|Good Surgical Technique Alone
41452592|NCT03539926|DEVICE|Lit-control®pH Meter|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.
41452593|NCT03539926|DIAGNOSTIC_TEST|Reactive strips|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.
41452594|NCT02623257|OTHER|mutation detection|
41452595|NCT02623257|OTHER|ARMS|
40946289|NCT04529915|DIAGNOSTIC_TEST|Exosome sampling|"* Centrifugation of blood plasma~* Size exclusion chromatography~* ELISA assay, Western blotting~* Deep-learning analysis"
41133013|NCT03075683|BEHAVIORAL|Applied relaxation|Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
40757648|NCT04442750|PROCEDURE|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 1-1.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium o.1 m\\kg will be provided every 30 minutes.~Rescue analgesia of fentanyl 1 μg/kg will be given if the mean arterial blood pressure or heart rate rises above 20% of baseline levels.~At the end of surgery, residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and will extubation be performed after complete recovery of the airway reflexes."
40757649|NCT04442750|DRUG|Bupivacaine 0.5%|The patient will receive 30ml bupivacain 0.5% in erector spinae block
40946290|NCT02188771|DEVICE|intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)|Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
41452596|NCT02623257|GENETIC|ctDNA analysis|
41452597|NCT00284791|DRUG|Lamotrigine (drug)|
41452598|NCT00284791|DRUG|Fluoxetine (drug)|
40757650|NCT04442750|DRUG|Bupivacaine 0.375%|The patient will receive 30ml bupivacain 0.375% in erector spinae block
40946291|NCT06393868|DRUG|Omeprazole 20 mg Oral Tablet|Omeprazole once daily for 90 days
40946292|NCT06393868|OTHER|Placebo|Placebo once daily for 90 days
40946293|NCT00117195|DEVICE|Automated Neuropsychological Assessment Matrix|"This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions.~In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome."
40946294|NCT00052273|DRUG|capecitabine|
41286446|NCT02526849|DRUG|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
40757651|NCT04442750|DRUG|Bupivacaine 0.25%|The patient will receive 30ml bupivacain 0.25% in erector spinae block
41452599|NCT00284791|DRUG|sertraline (drug)|
40946295|NCT00052273|DRUG|enzastaurin hydrochloride|
40946296|NCT04537390|DIAGNOSTIC_TEST|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
41286447|NCT02526849|BEHAVIORAL|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
41286448|NCT05129839|DEVICE|lightened and musical baby mobile|Before going to sleep in the infant's room in the intervention group, a lightened and musical baby mobile was used.
41440962|NCT04030091|DRUG|3 hours humulin R 100 IU/mL PIT|PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.
40757652|NCT05751811|DEVICE|Virtual reality|"The immersive video simulated a magical journey through a calming starry sky on a flying carpet. The headset will play the immersive video content throughout the hysteroscopic procedure; and will stop playing the content as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
40757653|NCT05751811|PROCEDURE|Music therapy|"Relaxing and light music will play throughout the hysteroscopic procedure; and will stop playing as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
40757654|NCT06570642|BEHAVIORAL|Physical Activity Goals mHealth Intervention|On days participants plan to exercise, they engage in two daily goal sessions (morning and evening). Morning sessions provide an activity goal for the day and ask the participant to create a plan, anticipate barriers, and brainstorm solutions for achieving this goal. The affect-based goal condition asks participants to engage in either (1) a type (50% of daily goals) or (2) a context (50% of daily goals) of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity (1) in a place; (2) in a social situation; or (3) while listening to something that makes them feel good. The intensity-based goal condition asks participants to maintain a certain target heart rate range during physical activity. Starting heart rate reflects the approximate age-adjusted heart rate max, with goals progressively increasing from 55% to 70% heart rate max.
40946297|NCT02107404|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
40946298|NCT02664610|BEHAVIORAL|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
40946299|NCT05824091|DRUG|MK-7762 (TBD09)|Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
40946300|NCT05824091|OTHER|Placebo|A subset of participants from each of the 6 dosing cohorts will receive placebo.
40946301|NCT05043675|DRUG|[18F]APN-1607|Subjects will receive one injection of \[18F\]APN-1607 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
40946302|NCT02520661|BEHAVIORAL|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
40946303|NCT05116007|DRUG|AK112|IV infusion
40946304|NCT05116007|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
40946305|NCT05116007|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
40946306|NCT04205708|DIAGNOSTIC_TEST|Tuberculosis test|Tuberculosis (TB) test: A blood sample is collected for lab testing to determine if you have tuberculosis (QuantiFeron test). Alternatively, the test is done by injecting a small amount of fluid (called tuberculin) into the skin on the lower part of the arm. A person given the tuberculin skin test must return within 48 to 72 hours to have a trained health care worker look for a reaction on the arm.
40946307|NCT04205708|DIAGNOSTIC_TEST|Chest X-ray|Chest X ray: non-invasive medical test that helps physicians diagnose and treat medical conditions of the lungs and chest. The Chest X-ray will be done to check for abnormalities on the lungs. The test is non-invasive.
40946308|NCT04205708|DIAGNOSTIC_TEST|Pulmonary Function Test|A pulmonary function test (PFT, spirometry) is a breathing test that measures how much air your lungs can hold as well as how hard and fast you can blow air out of your lungs. The test is not invasive and involves blowing into a machine.
40946309|NCT04096742|DRUG|tretinoin 0.05% lotion (Altreno)|Altreno topical lotion
40946310|NCT04096742|OTHER|Vehicle|Lotion not containing active ingredient (tretinoin)
40946311|NCT02703233|DRUG|Nitrous Oxide|
41440963|NCT04030091|DRUG|2 hours humulin R 100 IU/mL PIT|"As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less."
41440964|NCT06563206|PROCEDURE|Exergame|Hand Training assisted with Virtual-Reality
41440965|NCT06563206|PROCEDURE|Robotic|Hand Training assisted with Robotic Syrebo
41286449|NCT01418872|OTHER|Didactic Concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
41286450|NCT02046135|DRUG|Sodium Bicarbonate|
40946312|NCT02703233|OTHER|Oxygen|
40946313|NCT03980977|OTHER|skin biopsy|"skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or punch, 12 G)."
40946314|NCT03980977|OTHER|tumor biopsy|an additional tumor sample will be taken during programmed diagnostic procedure.
40946315|NCT03980977|OTHER|blood sample|blood sample will be taken for biological collection
41286451|NCT02046135|DRUG|Sodium Chloride|
41286452|NCT01373905|PROCEDURE|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
41286453|NCT01373905|PROCEDURE|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
41286454|NCT02259231|DRUG|Omaveloxolone Capsules (2.5 mg/capsule)|Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
40946316|NCT05538871|DIAGNOSTIC_TEST|Survey + Physical exam|"Survey:~Demographic data Pain Oswestry disability index International Physical Activity Questionnaire Scoliosis Research Society (SRS-22r) Spinal appearance questionnaire Fear Avoidance and Beliefs Questionnaire Short Orebro musculoskeletal pain questionnaire Work Ability Index~Physical exam:~Repeated movements (MDT) Posture ROM Neuro Updated treatment based classification tests Pathoanatomical classification tests"
41286455|NCT02259231|DRUG|Ipilimumab (3 mg/kg)|Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
41286456|NCT02259231|DRUG|Nivolumab (240 mg)|Sterile solution containing nivolumab to be delivered intravenously at 240 mg
40946317|NCT01286727|DRUG|BB3|intravenous drug
40946318|NCT04623307|DIAGNOSTIC_TEST|Non-contact DCS-Speckle multi-parameter imaging|The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
41440966|NCT06563206|PROCEDURE|Conventional|Hand Training with Physical Therapist
41286457|NCT02259231|DRUG|Omaveloxolone Capsules (10 mg/capsule)|Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
41286458|NCT02259231|DRUG|Omaveloxolone Capsules (50 mg/capsule)|Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
41286459|NCT03497962|PROCEDURE|Venepuncture|Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.
40757655|NCT06570642|BEHAVIORAL|TYPE/CONTEXT enhancement|TYPE/CONTEXT augments intervention effects by providing tailored recommendations for activity types and contexts that satisfy personally-important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk will be used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm will then recommend the corresponding activity type or context while accounting for reported constraints (e.g., ability, access). These details will be incorporated into a tailored recommendation provided to participants each Sunday as they make activity plans for the upcoming week. Specifically, the program will randomly select either type or context (i.e., location, audio, social) recommendations and will rotate every two weeks. For TYPE, participants' top 3 activity types are recommended; for CONTEXT, participants' top 3 activity contexts are recommended.
40757656|NCT06570642|BEHAVIORAL|SAVOR enhancement|SAVOR implements a brief savoring exercise on the smartphone that takes place either after the planned physical activity session or during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer three open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty. Savoring prompts will rotate daily and have a day lag built in every week (i.e., Week 1 Monday Savoring Prompts are Week 2 Tuesday Savoring Prompts).
40757657|NCT00345280|PROCEDURE|impression cytology, obtain the tear fluid|Vitamin A
40946319|NCT02608203|DRUG|[68Ga]-DOTANOC PET/CT|
40946320|NCT03898960|DEVICE|NIMBUS Device|NIMBUS Geometric Clot Extractor
40946321|NCT04833673|BEHAVIORAL|PMR: Progressive Muscle Relaxation|tensing and relaxing the body muscles accompanied with deep breathing
41286460|NCT03497962|PROCEDURE|Bronchoscopy|Broncho-alveolar lavage to obtain alveolar macrophages
41286461|NCT01601015|OTHER|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
41440967|NCT01630083|DRUG|epirubicin|Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.
41440968|NCT01630083|DRUG|oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.
40757658|NCT05882565|BEHAVIORAL|A brief (14-day) online mindfulness intervention|The content of the online mindfulness intervention is based on studies by Cavanagh et al. (2013, 2018). There is an approximately 10-minute audio tutorial that participants will listen to daily for 14 days. In the first week, participants will be instructed to apply their learned mindfulness skills to their daily activities. In the second week, they will continue practicing by learning to walk in a mindful manner.
40757659|NCT05882565|BEHAVIORAL|Psychoeducation online|"The online psychoeducation was modified from the study by Harrer et al (2019, 2021).~This intervention consists of 14 audio tutorials about stress for 14 days, each lasting approximately 10 minutes. Additionally, there is a text version of each audio tutorial, which can be accessed by participants after listening to the audio."
40757660|NCT01517178|DEVICE|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
41286462|NCT01601015|OTHER|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
41452600|NCT03229057|DRUG|OCP + Metformin|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
40946322|NCT04833673|BEHAVIORAL|BRT:Benson Relaxation Technique|relaxation using mental imagery and mediation
40946323|NCT04170842|OTHER|Music intervention|Participants will work with the music therapist to make their selections. Music therapists will provide input on how best to synchronise type, tempo and genre of music to the wound dressing procedure. As musical preference is very personal, the choice of music provided will try to strike a balance of providing what is acceptable to patients while not exposing them to music with known stimulatory effects.
40946324|NCT06319638|BEHAVIORAL|Rehabilitation therapy|During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
40946325|NCT06319638|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40946326|NCT06319638|PROCEDURE|Placebo block|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40946327|NCT06319638|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
40946328|NCT05059171|DEVICE|OneSahpe single file|The rotary motion of OneShape single file
40946329|NCT05059171|DEVICE|WaveOne Gold single file|reciprocation motions of WaveOne Gold single file
40946330|NCT03204461|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
40946331|NCT03204461|OTHER|1H-magnetic resonance spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
40946332|NCT02448810|BIOLOGICAL|BAX69 + infusional 5-FU/LV|"Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection"
40946333|NCT02448810|BIOLOGICAL|BAX69 + panitumumab|"Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection"
41286463|NCT01601015|OTHER|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
40946334|NCT02448810|BIOLOGICAL|BAX69 + 5-FU/LV|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
40946335|NCT02448810|BIOLOGICAL|BAX69 + panitumumab|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
40946336|NCT02448810|DRUG|Standard of Care|"* Investigator's choice~* Dose according to drug label"
40946337|NCT02448810|BIOLOGICAL|Standard of Care|"* Investigator's choice~* Dose according to drug label~* Choice includes panitumumab in KRAS \&NRAS wt group only"
41286464|NCT01601015|OTHER|placebo treatment|"The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
41452601|NCT03229057|DRUG|OCP + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
40946338|NCT02055807|OTHER|PEEP and recruitment maneuvers|
40946339|NCT02055807|OTHER|ZEEP (no PEEP nor recruitment maneuver)|
40946340|NCT05919004|DIAGNOSTIC_TEST|App-based spirometer|App-based spirometer to perform serial spirometry to assess lung function variatione
40946341|NCT03368612|OTHER|Electronic evaluation system|spirometry, plethysmography, cardiopulmonary exercise test
40946342|NCT03368612|OTHER|Electronic evaluation system|AirGo recording
40946343|NCT01979965|DRUG|Ranolazine (Active drug)|Ranolazine therapy for three months
40946344|NCT01979965|DRUG|Placebo|Placebo therapy for three months
40946345|NCT02583373|DRUG|CAL02 Low-dose|Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
40946346|NCT02583373|DRUG|CAL02 High-dose|Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
40946347|NCT02583373|DRUG|Placebo|Placebo administered administered 2 times (24 hours apart) as i.v. infusion
40946348|NCT02288598|DEVICE|Anodal TDCS|20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
40946349|NCT02288598|BEHAVIORAL|Fluency Training|Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
40946350|NCT04200560|OTHER|Rhythmic Handgrip Exercise|60 minute rhythmic handgrip exercise
40946351|NCT04200560|OTHER|Chronic Exercise Training|Handgrip exercise training consisting of three 60-minute training sessions per week for eight weeks.
40946352|NCT06022601|DEVICE|DNA Nudge|DNA Nudge wearable, DNA-based dietary advice
40946353|NCT01636531|DRUG|gantenerumab|High concentration liquid formulation (HCLF), single dose sc
40946354|NCT01636531|DRUG|gantenerumab|Lyophilized formulation (LyoF), single dose sc
40946355|NCT01593410|DRUG|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
40946356|NCT01593410|DRUG|Dexamethasone|Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
40946357|NCT06298890|DEVICE|Artificial tears (sodium hyaluronate 0.2%)|Patients randomised into Ist study group will use artificial tears 7 days before the cataract surgery 4 times a day and they will continue to use them after surgery for 3 months.
40946358|NCT03532958|DRUG|BNZ-1|PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
40946359|NCT03532958|DRUG|Normal saline|Dose volume consistent with weight-based dosing of BNZ-1
40946360|NCT04354961|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
40946361|NCT05906173|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
41286465|NCT04865081|DEVICE|VACCIN box|The VACCIN box is a translucid box that can be placed over the patient's head. It has entry holes on the front and the side of the box in which nitrile gloves can be attached. The anesthesiologist can intubate with arms and hands inside the box. Its also has the capacity to create a negative pressure environment inside the box by connecting an air suction cable from the box to the OR medical aspiration line.
41286466|NCT00674934|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
40946362|NCT05530785|COMBINATION_PRODUCT|radiotherapy combined with sintilimab and bevacizumab biosimilar|After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
40946363|NCT00449527|DRUG|Budesonide/formoterol pMDI|
40946364|NCT00449527|DRUG|Budesonide HFA pMDI|
40946365|NCT02524405|OTHER|Pittsburgh Compound B [11C]-PIB|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
40946366|NCT02566668|OTHER|1 year Observational Follow-up|Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
40946367|NCT03989765|OTHER|Programme to reduce involuntary treatment episodes|See description of trial arms
40946368|NCT05088720|DRUG|misoprostol 800 µg|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
40946369|NCT05088720|DRUG|misoprostol 400 µg|received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
40946370|NCT06281938|OTHER|Weight estimation using 3D camera|Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
40946371|NCT06281938|OTHER|Standard care weight estimation|Standard care (unspecified) will be used to determine weight-based dosing and other management.
40946372|NCT03203070|DRUG|Metamizol iv|Postoperative analgesia iv with Metamizol 2g/8h will be administered.
40946373|NCT03203070|PROCEDURE|TAP block|Intraoperative laparoscopic-guided TAP block will be performed with 30ml Bupivacaine 0.5%
40946374|NCT04669327|OTHER|gait analysis|Vicon nexus with MTI force plate form
41452602|NCT03229057|DRUG|Metformin + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
40946375|NCT04248751|DEVICE|Regeneten|A new scaffold material made of highly purified, type I collagen from bovine tendons has shown great promise as a bioinductive implant that helps induce the formation of new tendon-like tissue over the surface of partial- or full-thickness rotator cuff tears. This new graft material has the benefit of decreasing surgery time, as it takes a few minutes to put in place, while increasing healing and tendon thickness.
40946376|NCT04248751|PROCEDURE|Debridement|The bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin
40946377|NCT03688009|BEHAVIORAL|Mindfulness-Based Family Psycho-Education (MBFBE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
41133014|NCT03725020|OTHER|Fluoride varnish|The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.
41286467|NCT05074784|DEVICE|IOPI Therapy|Obtain IOPI reading at start of session, record the best of 3 readings as baseline strength. Calculate exercise resistance for session at 60% of baseline strength. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets.
40946378|NCT03688009|BEHAVIORAL|Family Psycho-Education (FPE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
40946379|NCT04148820|DRUG|Aspirin, Atorvastatin, Perindopril|Cardiovascular drugs will be administered all together every day at the same time
40946380|NCT05982548|OTHER|VR intervention|"VR intervention of no more than 7 minutes~Participants viewed the home as a first person character and experience psychotic phenomena including auditory hallucinations."
41452603|NCT03413202|DRUG|butylphthalide(NBP)|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.
40946381|NCT05982548|OTHER|VR control intervention|"VR intervention of no more than 7 minutes~Participants viewed the same home as a first person character without psychotic phenomena"
40946382|NCT02633501|DRUG|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
40946383|NCT02633501|DRUG|Gadobenate dimeglumine|Single IV bolus injection at a rate of 2 mL/second
40946384|NCT02633501|DEVICE|MRI|
40946385|NCT04128371|BIOLOGICAL|mepolizumab|Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials were reconstituted according to the manufacturer, for a total dose of 700mg administered as intravenous infusion.
40946386|NCT00223171|DRUG|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
41133015|NCT00406887|DRUG|Difluprednate Ophthalmic Emulsion|
41286468|NCT05074784|DEVICE|Tongue Depressor Traditional Intervention|Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set
41286469|NCT00003641|BIOLOGICAL|interferon alfa-2b|Given IV
41286470|NCT00003641|OTHER|observation|Patients undergo observation for 4 weeks.
41286471|NCT02280811|DRUG|Fludarabine|Patients will receive Fludarabine 25 mg/m\^2/day for 5 days.
41286472|NCT02280811|DRUG|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
41286473|NCT02280811|BIOLOGICAL|E6 TCR|On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
41286474|NCT02280811|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
41286475|NCT03425656|DRUG|Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide|Trastuzumab (8 mg/kg IV loading dose at cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for four 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)
41286476|NCT04146558|DRUG|Individualized internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
41286477|NCT04146558|OTHER|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
41452604|NCT03413202|DRUG|placebo|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
41452605|NCT04981704|DRUG|Poziotinib|Poziotinib Tablets
41452606|NCT04981704|DRUG|Itraconazole|Itraconazole Oral solution
41452607|NCT04981704|DRUG|Phenytoin|Phenytoin Capsules
41452608|NCT04981704|DRUG|Paroxetine|Paroxetine Tablets
41452609|NCT05266287|DIETARY_SUPPLEMENT|a supplement containing 2'-fucosyllactose (2'-FL)|Participants will be asked to take a commercially available dietary supplement containing 833 mg of 2'-FL, 220 mg of a blend of organic beet root and okra fruit, 100 mg of Collinsonia root, 37.5 mg organic rice hull concentrate, and 14 mg calcium stearate.
41452610|NCT05266287|DIETARY_SUPPLEMENT|Placebo Supplement|Participants will be asked to take a placebo supplement containing 510.9 mg organic sucanat, 385.4 mg calcium phosphate, 304.7 mg cellulose, 143.4 mg date powder, 39.4 mg rice bran powder, 9.0 mg gum arabic, and 7.2 mg calcium stearate.
41452611|NCT00918684|DRUG|Escitalopram|10mg tab daily
40946387|NCT01413412|PROCEDURE|Ventral hernia repair using full thickness skin graft|25 patients
40946388|NCT01413412|PROCEDURE|Ventral hernia repair using mesh|25 patients
40946389|NCT01123850|DEVICE|Copios|Bone Void Filler
40946390|NCT05610514|OTHER|E-Cigarette|Altering the availability of e-cigarettes
40946391|NCT05610514|BEHAVIORAL|Financial Incentives|Altering the availability of financial incentives for abstaining from combustible cigarettes
40946392|NCT03648827|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
40946393|NCT04156477|DIETARY_SUPPLEMENT|Ketone ester|Intake of weight adjusted drink of a ketone ester
40946394|NCT04156477|DIETARY_SUPPLEMENT|Glucose|Isocaloric and - volumetric taste adjusted drink
40946395|NCT04156477|DIETARY_SUPPLEMENT|Tap water|Isovolumetric taste adjusted tap water (placebo)
40946396|NCT02421029|DRUG|edetate calcium disodium|All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
41133016|NCT03955926|DIETARY_SUPPLEMENT|preoperative oral carbohydrate loading|Carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg) 800 mL is given to the NO-NPO group until 2 hours before surgery
41286478|NCT02048514|DEVICE|The Nellix® EndoVascular Aneurysm Sealing System|
41286479|NCT02226068|DRUG|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
41286480|NCT02226068|OTHER|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
41286481|NCT03271489|OTHER|Elagolix Placebo|Tablets
41286482|NCT03271489|DRUG|E2/NETA|Capsules
41286483|NCT03271489|OTHER|E2/NETA Placebo|Capsules
41286484|NCT03271489|DRUG|Elagolix|Tablets
41286485|NCT05399693|PROCEDURE|platelet transfusion|platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
41286486|NCT04396457|DRUG|Pembrolizumab|Human PD-1 Monoclonal antibody
41452612|NCT04129060|DRUG|Cholinergic antagonist|The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo
40757661|NCT01517178|DEVICE|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
40757662|NCT05451329|DRUG|VVN539 Ophthalmic Solution 0.02%|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
41133017|NCT06098105|PROCEDURE|Ultrasound-guided transversus abdominis plane block|This group will receive ultrasound-guided transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL as a control group.
40757663|NCT05451329|DRUG|VVN539 Ophthalmic Solution 0.04%|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
40757664|NCT05451329|DRUG|VVN539 Ophthalmic Solution Vehicle|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
41286487|NCT04396457|DRUG|Pemetrexed|Antineoplastic antimetabolite
41286488|NCT03894540|DRUG|IPN60090|Oral capsules given daily
41286489|NCT03894540|DRUG|pembrolizumab|An intravenous solution in single-use vial to be diluted for infusion.
41286490|NCT03894540|DRUG|paclitaxel|An intravenous solution in single-use vial to be diluted for infusion.
41286491|NCT03894540|DRUG|IPN60090 single administration|Oral capsules given once
41286492|NCT04541823|DRUG|Desﬂurane|Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
41286493|NCT04541823|DRUG|Propofol|Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
41286494|NCT00685178|DRUG|topiramate|"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial"
41286495|NCT00685178|BEHAVIORAL|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
41286496|NCT00685178|DRUG|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
41286497|NCT02302911|BEHAVIORAL|Early intensive behavioral intervention|at least 10 hours a week of early intensive behavioral intervention
41286498|NCT02302911|BEHAVIORAL|Early intensive eclectic intervention|at least 10 hours a week of early intensive eclectic intervention
41286499|NCT02302911|OTHER|Treatment as usual|receipt of any Intervention that is less intensive than 10 hours a week
41286500|NCT05615714|OTHER|Paresthesia-free Peripheral Nerve Field Stimulation|High frequency and sub-paresthesia threshold intensity parameters will be used for paresthesia-free stimulation of trigeminal nerve branches.
41286501|NCT05615714|OTHER|Sham stimulation|Stimulation will be turned off.
41286502|NCT04804644|DRUG|Memantine Hydrochloride|Given PO
41286503|NCT04804644|OTHER|Neurocognitive Assessment|Ancillary studies
41286504|NCT04804644|RADIATION|Stereotactic Radiosurgery|Undergo SRS
40757665|NCT03599726|DRUG|Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
40757666|NCT03599726|DRUG|Placebo|Placebo 5 mg per day for week 1-2 or 5-6
40757667|NCT05950997|DRUG|Acalabrutinib|100 mg capsules administered by mouth once daily (28-day cycles)
41286505|NCT04804644|RADIATION|Whole-Brain Radiotherapy|Undergo HA-WBRT
41286506|NCT01596829|DIETARY_SUPPLEMENT|Probiotic|Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
41286507|NCT01596829|DIETARY_SUPPLEMENT|Placebo|A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
41286508|NCT04536324|PROCEDURE|Subcutaneous parenteral hydration|Patients will twice receive a subcutaneous infusion of 250 ml isotonic sodium chloride (NaCl) with 30 MBq Tc-99m pertechnetate mixed in. The patients will receive the first infusion during admission to our geriatric ward (when they are acutely ill) and the second infusion approximately 8 weeks after discharge when they are no longer acutely ill. The subcutaneous access will be placed on the abdomen in the lower left or right quadrant.
41452613|NCT01679158|DEVICE|Using The IOP system from USGI to place suture anchors|"Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control"
41452614|NCT04488380|OTHER|dental restoration|Restoration of carious mandibular 2nd molar teeth either with high viscosity glass ionomer or nanohybrid composite resin
41286509|NCT01661647|DEVICE|3D knee kinematic assessment under local anesthesia|3D knee kinematic assessment under local anesthesia
41286510|NCT03442127|BEHAVIORAL|CaringGuidance™ After Breast Cancer Diagnosis|Web-based, psychoeducational, self-management tool
41286511|NCT04460027|OTHER|Woebot Substance Use Disorder|Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
41286512|NCT00810160|DIETARY_SUPPLEMENT|ProlactPlus|Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
40946397|NCT03816982|PROCEDURE|Single-injection bupivacaine HCl plus liposomal bupivacaine|Patients in the liposomal bupivacaine with added bupivacaine HCl ISB group will be given a single injection LB ISB in the preoperative area only by faculty who are part of the regional anesthesia division. The injectate will include liposomal bupivacaine 10ml (133mg) mixed with bupivacaine HCl 0.5% 10 ml.
40946398|NCT03816982|PROCEDURE|Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB|Patients in the bupivacaine CISB group will undergo catheter placement with ultrasound guidance only by faculty who are part of the regional anesthesia division. A 20 mL single bolus ISB with 0.25% bupivacaine will be administered followed by catheter infusion of 0.125% bupivacaine at a rate of 5mL/hour postoperatively by the ON-Q pump
40946399|NCT06135480|OTHER|subcision ,PRP or saline and microneedling|minimally invasive procedures
40946400|NCT06363357|DEVICE|Shoulder orthosis|muscle-mimicking, fabric-type shoulder orthosis
40946401|NCT00924079|DRUG|nalbuphine|oral dosage form, 66 mg, single dose
40946402|NCT01262573|PROCEDURE|Closure of vaginal cuff|Closure of the vaginal cuff
41286513|NCT00810160|DIETARY_SUPPLEMENT|GOS galacto-oligosaccharides|Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
41452615|NCT04735172|OTHER|specific MRI Acquisition (NMR spectroscopy) at 7T|"The MRI protocol will be performed at 7T on a Siemens NMR imaging system (Magnetom Terra, Siemens Healthcare, Erlangen, Germany), the radio frequency emission and signal reception will be done through a head quadrature resonator (64-channel phase-array coil). To avoid motion-related artifacts, the patient will be seated in a supine position, with the arms along the body and the head immobilized using a suitable head restraint. The MR protocol will take place in two phases:~* Acquisition of 3D multi-slice T1 and T2-weighted morphological images to identify areas of interest;~* Acquisition of 1D RMN spectra in the right and left putamen and STN. Spectra will be acquired in volumes of interest of 15mmx15mmx15mm using a localized spectroscopy sequence with and without suppression of the water signal. Main parameters are: TR (repetition time)=3000ms; TE (echo time)=20 ms; number of repetitions=128; scan time 6min)."
41286514|NCT00810160|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
40946403|NCT01967433|DRUG|Diphenhydramine|
40946404|NCT01967433|DRUG|Placebo|
40946405|NCT01347229|DEVICE|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
40946406|NCT03003156|PROCEDURE|25 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
41286515|NCT00810160|DIETARY_SUPPLEMENT|Bifidobacterium animalis|Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
41286516|NCT05545397|DRUG|Propofol|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
41452616|NCT02028039|DRUG|IPI-145|75 mg orally twice daily for 4 weeks.
41452617|NCT02028039|BEHAVIORAL|Follow-up Visit/Call|Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
41452618|NCT02188628|DEVICE|H-Man|H-man is a portable end-effector planar upper limb robot.
41452619|NCT02188628|OTHER|Additional Conventional Therapy|Repetitive goals based arm therapy
40946407|NCT03003156|PROCEDURE|50 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
40946408|NCT04751942|DEVICE|Non-compressive Bioactive Garment|patients will be assigned to wear the non-compressive bioactive garment following total knee arthroplasty
41452620|NCT00177580|DRUG|Pravastatin|
41452621|NCT00804011|OTHER|ATC|Automatic tube compensation
41452622|NCT00804011|OTHER|PSV|Pressure support ventilation
41452623|NCT01624233|DRUG|80 mg ixekizumab|Administered SC
40946409|NCT04751942|DEVICE|thrombo-embolic deterrent|patients will be randomized to wear the gold standard TED hose following total knee arthroplasty
41286517|NCT05545397|DEVICE|EEG montior|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
41286518|NCT04010422|DIAGNOSTIC_TEST|no intervention|no intervention
41286519|NCT06319911|DEVICE|AETOS|The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration
41286520|NCT06282172|DEVICE|Treatment with BTL-785-7|Treatment with BTL-785-7 delivering simultaneously radiofrequency (RF) and HIFES energy on the submental area
41286521|NCT06070129|PROCEDURE|surgical pulmonary embolectomy|open heart surgery with cardiopulmonary bypass with opening of the pulmonary artery and its major branches and extraction of the embolus
40946410|NCT05241431|DRUG|SGLT2 inhibitor|10 mg orally once daily in addition to standard medical treatment.
40946411|NCT05241431|DRUG|Placebo|Placebo tablets similar to active treatment.
40946412|NCT00902668|DRUG|lovastatin|
40946413|NCT00902668|OTHER|questionnaire administration|
41133018|NCT06098105|PROCEDURE|Laparoscopic-assisted transversus abdominis plane block|Patients will receive laparoscopic-assisted transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL.
40757668|NCT05950997|DRUG|Obinutuzumab|100 mg administered intravenously on Day 1 and 900 mg administered intravenously on Day 2, 1000 mg administered intravenously on Day 8 and 15 of cycle 2 and 1000 mg on Day 1 of subsequent cycles for a total of 6 cycles (28-day cycles)
41286522|NCT05174637|DRUG|FDA018-ADC|FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
41286523|NCT01928030|BIOLOGICAL|recombinant human hyaluronidase|Given SC
41286524|NCT06005506|DIETARY_SUPPLEMENT|Prebiotic fiber|Moradyn active prebiotic fiber product
41286525|NCT06005506|DIETARY_SUPPLEMENT|Dietary fiber|Fibregum non-active fiber product
41286526|NCT06005506|DIETARY_SUPPLEMENT|Probiotic|Defense Plus probiotic complex
41286527|NCT05387590|BEHAVIORAL|Preventiometer device with wellness coaching|Four wellness coaching sessions with a certified wellness coach to develop and implement your own personalized wellness plan will be included in this study.
41286528|NCT01635933|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
40757669|NCT06570265|DEVICE|GBR membrane|GBR procedure is a technique often used in conjunction with dental implants to enhance the success and stability of the implant. This technique involves using barrier membranes to protect the bone graft or defect site from the rapid proliferation of surrounding soft tissues. In this clinical investigation resorbable, collagen membrane will be used.
40757670|NCT01118637|BEHAVIORAL|StopPulling.com|subsidized access to an interactive self-help website for TTM
40757671|NCT00057512|DRUG|M4N|Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
40757672|NCT01961180|DRUG|Cipralex|the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
40757673|NCT01961180|DRUG|Placebo|Placebo
40757674|NCT03830398|DRUG|Paracetamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
40757675|NCT03830398|DRUG|Deksketoprofen trometamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
40757676|NCT03830398|DRUG|Placebo|The investigators apply placebo during a week in preoperative room 45 min before ECT
40757677|NCT04524429|PROCEDURE|Bariatric Surgery|Bariatric surgery includes sleeve gastrectomy and gastric bypass.
40946414|NCT00902668|PROCEDURE|adjuvant therapy|
40946415|NCT00902668|RADIATION|accelerated partial breast irradiation|
40946416|NCT00902668|RADIATION|external beam radiation therapy|
40946417|NCT04968795|OTHER|Heartfulness Meditation|A four-week Heartfulness Wellness seminar, where people are exposed to Heartfulness Meditation and its meditation tools. Participants experience: Heartfulness Guided Relaxation, Heartfulness Meditation and Heartfulness Unwinding/Rejuvenation Technique.
41133019|NCT06098105|PROCEDURE|Laparoscopic-assisted intraperitoneal instillation|This group will receive laparoscopic-assisted intraperitoneal instillation by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL will be instilled into the peritoneal cavity immediately after gas insufflation.
40946418|NCT00743899|PROCEDURE|The aggressive group|Stents were implanted in lesions with diameter stenosis \>50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis \>50% and RD ≥2.0 mm and \<2.25 mm.
40946419|NCT00743899|PROCEDURE|The conservative group|Stenting was performed only in lesions with diameter stenosis \>70% and reference diameter (RD) ≥2.25 mm
41133020|NCT06098105|DRUG|Bupivacaine|bupivacaine
41286529|NCT01635933|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
41286530|NCT03042949|DEVICE|Blood pressure measurement|Blood pressure measurement with a standard plethysmograph
41286531|NCT03042949|DEVICE|Blood pressure measurement with the new device|Blood pressure measurement with the optical sensor, Elfor -1 device.
41286532|NCT06454968|DRUG|Orelabrutinib, obinutuzumab, lenalidomide|Orelabrutinib: 150mg qd d1-d21/C1-C6 obinutuzumab: 1000mg iv d1,d8,d15/c1, 1000mg iv d1/C2-C6 lenalidomide：25mg po qd d1-14/C1-C6 Orelabrutinib: 150mg qd d1-d28/C7-C12
41286533|NCT05343910|OTHER|Aroma massage|The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
41286534|NCT04468750|DEVICE|kinesiotape|During the rehabilitation program, all patients with GHS had kinesiotaping three times a week.
41286535|NCT04083222|DRUG|Placebo|ISIS 757456-matching placebo solution administered as SC injection.
41286536|NCT04083222|DRUG|ISIS 757456|ISIS 757456 administered as SC injection.
41286537|NCT05673603|DRUG|Brensocatib|Oral tablet
41440969|NCT01630083|DRUG|capecitabine|The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
41452624|NCT02672267|BIOLOGICAL|Stem cells|human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
41452625|NCT02672267|OTHER|Placebo|Lactated Ringer's Solution
41286538|NCT02214758|OTHER|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
41286539|NCT01912118|DRUG|Propofol|Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
41286540|NCT01912118|DRUG|Remifentanil|Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
41286541|NCT03811951|DRUG|Novolin R|Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
41286542|NCT03154138|DEVICE|The prismatic adaptation (PA)|Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
41286543|NCT03154138|DEVICE|The sham prismatic adaptation (S-PA)|"The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)"
41286544|NCT00380159|DRUG|Elvucitabine|Elvucitabine 10 mg in combination with background ART
41286545|NCT00380159|DRUG|Lamivudine|
41286546|NCT00380159|DRUG|Emtricitabine|
41452626|NCT00406393|DRUG|Tacrolimus|"Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL."
41452627|NCT00406393|DRUG|Methotrexate|Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
41452628|NCT00406393|DRUG|Sirolimus|"Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.~Children: Children aged \< 12.0 years OR weighing \< 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.~The target serum level for sirolimus is 3-12 ng/mL."
41452629|NCT03993535|DRUG|selective serotonin reuptake inhibitor|open treatment based on patient preference and treatment availability
40757678|NCT02376855|OTHER|eConsult|"An electronic consultation or eConsult is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit."
41452630|NCT06205264|OTHER|Strength training at high and low speeds.|"The training program will last for 8 weeks with a frequency of 3 sessions per week. Session duration will be 40-60 minutes, depending on the week within the developed schedule. To form the groups, participants will be randomly divided into two groups. On one hand, the explosive group will perform exercises in less time with faster movements, while the conventional group will execute the training with slower movements. The entire session will be designed and supervised by three exercise specialists. Each child must have a written informed consent completed by their parent/guardian.~Three days of strength training will be conducted following WHO recommendations, emphasizing multi-joint exercises."
40757679|NCT01313325|OTHER|Hippotherapy|Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
40757680|NCT01414790|PROCEDURE|ADM|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
41133021|NCT01241526|OTHER|Disease Management|"* Individual, group and phone education sessions~* Telephone supporter follow-up~* LTOT monitoring"
41133022|NCT01241526|OTHER|Usual site management|"* Usual education as per site protocol~* Usual follow-up as per site protocol~* LTOT monitoring"
41133023|NCT02170337|DRUG|AMG 282|AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
41133024|NCT02170337|DRUG|Placebo|Contains no active drug
41286547|NCT05864040|DEVICE|Bitrack System-assisted laparoscopic radical/simple nephrectomy|Robot-Assisted Laparoscopic Transperitoneal Radical/Simple Nephrectomy is performed under general anesthesia. Using blunt dissection, the inferior pole of the kidney is lifted, and ureter and gonadal veins released from fat and connective tissue. The ureter is dissected caudally and sectioned after being sealed with a distal endoscopic clip. Dissection proceeds along the psoas muscle with anterior elevation of the ureter and lower renal pole towards the hilium. Main hilar are circumferentially dissected and sectioned and the kidney is entirely mobilized and released. Gerota´s capsule and suprarenal gland may be preserved if oncologically safe. Once the specimen is completely released, a laparoscopic bag is introduced by the assistant and the specimen entrapped. The robot is undocked, gas evacuated from the abdomen and specimen retrieved. Abdominal wall incisions over 10mm are closed using a continuous suture. Skin incisions are closed using skin staplers.
41286548|NCT06278636|DIAGNOSTIC_TEST|Laparoscopi ultrasound examination|Analysis of feasibility and fellow surgeons learning curve in minimally invasive gynecological procedures
41286549|NCT00117962|BIOLOGICAL|cetuximab|400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
41286550|NCT00117962|DRUG|carboplatin|AUC = 5 q 21 days for 4 cycles
41286551|NCT00117962|DRUG|pemetrexed disodium|500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
41452631|NCT01582464|BEHAVIORAL|Social Marketing for protective headgear|"Social marketing was done using a CQI manner after each focus group with experts and with seniors using a structured interview approach with an iterative process to develop a progressive method of presenting information about head injuries and their input on a new prevention.~To measure changes in attitudes, the participants were given an attitudes questionnaire (PHAQ), \& a demographic \& functional status questionnaire. Input into the social marketing content was sought in a structured interview manner, and by using an audience response system with questions projected by power point. At the conclusion of the social marketing, the PHAQ was repeated and sent to participants 2 weeks after the focus group to gage stability of changes in attitudes."
41452632|NCT02571530|DRUG|Intra-arterial Cerebral Infusion of Trastuzumab|
41452633|NCT01822119|DEVICE|Baha Attract System|
41452634|NCT06071338|DIAGNOSTIC_TEST|Clinical Periodontal Examination|No details will be published from the clinical assessment.
41133025|NCT01960738|OTHER|A pre-dive checklist|The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
40757681|NCT05417256|DEVICE|Tappa Endobronchial Blocker|After intubation, the Tappa bronchial blocker will be advanced either through the intubation tube or outside the tube using a fiberoptic broncoscope. Once the position of the blocker is confirmed, the cuff of the blocker will be inflated with 1-3 mL of air. Since Tappa blocker has an autoinflation system, the anaesthetist can both inflate the cuff with one hand and operate the fiberoptic broncoscope at the same time.
40757682|NCT05417256|DEVICE|Arndt Endobronchial Blocker|After intubation, the endobronchial blocker will be passed through a multiport airway adapter that is placed at the proximal end of the tracheal tube.The fiberoptic broncoscope will be passed through the port and then through the guidewire loop at the end of the blocker. The bronchial blocker and the broncoscope will be advanced as a single unit into the target part of a right or left lung. The broncoscope will be withdrawn into the trachea and the blocker cuff will be inflated and the position of the blocker will be confirmed using the fiberoptic broncoscope. The wire loop will be removed after correct placement of the blocker. Once the guide wire is removed, the blocker can't be replaced.
40757683|NCT02901561|DRUG|misoprostol 200|
40757684|NCT02901561|DRUG|misoprostol 400|
40757685|NCT01560559|PROCEDURE|Peroral endoscopic myotomy|"An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.~This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips."
40757687|NCT05691569|OTHER|doll therapy|empathy dolls
40757688|NCT04021368|DRUG|RVU120(SEL120)|RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
41133026|NCT01428206|OTHER|Liverpool care pathway|Liverpool care pathway is started tha last day in life for elderly at nursing homes
41286552|NCT00117962|RADIATION|radiation therapy|Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
41452635|NCT00886522|PROCEDURE|Intrabone cord blood infusion|"Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27"
40757689|NCT05736887|DRUG|N-Acetylcysteine|N-Acetylcysteine in 600mg tablets
40757690|NCT05736887|DRUG|Placebo|Placebo in 600mg tablets
40757691|NCT05633056|BEHAVIORAL|Adherence support intevention|Compare the effects of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform.
40757692|NCT01994005|BEHAVIORAL|Facebook|Facebook page with contraception information used for counseling
41133027|NCT02052687|DRUG|LFX453 H1|LFX453 high dose cream 1
41133028|NCT02052687|DRUG|LFX453 L1|LFX453 low dose cream 1
41133029|NCT02052687|DRUG|LFX453 H2|LFX453 high dose cream 2
41133030|NCT02052687|DRUG|LFX453 L2|LFX453 low dose cream 2
41133031|NCT02052687|DRUG|Imiquimod|Imiquimod cream
41133032|NCT02052687|DRUG|Placebo 1|Placebo cream 1
40757693|NCT01994005|BEHAVIORAL|Pamphlet|Contraceptive knowledge pamphlets
40757694|NCT04921306|DRUG|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.
40946420|NCT03070444|DEVICE|CTC retainer|The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.
40946421|NCT03070444|DEVICE|Essix retainer maxilla|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
40946422|NCT03070444|DEVICE|Essix retainer mandible|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
41452636|NCT06390813|BEHAVIORAL|Otago Exercise Training|A total of 18 sessions of Otago Training were conducted 3 days a week for 6 weeks, each session lasting 60 minutes in total, including 5 minutes of warm-up and cool-down periods.
40757695|NCT04921306|DRUG|Placebo|Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
40946423|NCT03070444|PROCEDURE|Alginate impression|Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.
40946424|NCT03070444|OTHER|Questionnaire|A questionnaire is completed at the follow-up visits.
40946425|NCT05509166|BEHAVIORAL|LGBTQ-affirmative Cognitive Behavioral Therapy|10-session LGBTQ-affirmative psychotherapy using CBT techniques
40946426|NCT05509166|BEHAVIORAL|LGBTQ-affirmative Treatment-As-Usual|10-session LGBTQ-affirmative psychotherapy
40946427|NCT00976677|DRUG|erlotinib hydrochloride|Given PO
40946428|NCT00976677|DRUG|paclitaxel|Given IV
41133033|NCT02052687|DRUG|Placebo 2|Placebo cream 2
41133034|NCT04975087|OTHER|Patients group|Patients will complete the mentioned questionnaires.
41133035|NCT04495140|DRUG|[14C]PF-06882961, 50 mg|A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.
40946429|NCT00976677|DRUG|carboplatin|Given IV
40946430|NCT00976677|BIOLOGICAL|bevacizumab|Given IV
40946431|NCT04168697|BEHAVIORAL|Wim Hof method|8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation
41133036|NCT04495140|DRUG|PF-06882961, 50 mg and [14C]PF-06882961, 100 ug|A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.
41286553|NCT02453412|DEVICE|AVF-simulation|A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
41286554|NCT02195648|OTHER|Suboccipital inhibition|"Experimental: Suboccipital inhibition~The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles."
41286555|NCT00770861|DRUG|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
41286556|NCT00770861|DRUG|Placebo|Matching placebo tablets, oral administration
40757696|NCT01670149|DRUG|Rifaximin|Tablets
40757697|NCT01670149|DRUG|Placebo|Tablets
40757698|NCT04824287|OTHER|pelvic floor muscle exercise|pelvic floor muscle exercises training from the researcher using the Roy Adaptation Model in addition to routine discharge training Face-to-face training was given to the individuals in the experimental group on the day before the operation, on the second and third postoperative days, and on the day of discharge. The training continued with phone calls at the first, second and third weeks and the first, second, third, and sixth months after the surgery Patients practiced exercises 6 month after surgery
40946432|NCT00415376|DRUG|levetiracetam|
40946433|NCT00415376|PROCEDURE|quality-of-life assessment|
40946434|NCT06477133|DRUG|Magnesium sulfate|Pre-mixed solution of 2 grams of magnesium sulfate dissolved in 20 mL sterile water
40946435|NCT00949273|PROCEDURE|cylindrical abdominoperineal resection|Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer
40946436|NCT00176527|BIOLOGICAL|recombinant interferon alfa-2b|
40946437|NCT00176527|DRUG|docetaxel|
40946438|NCT00176527|DRUG|estramustine phosphate sodium|
40946439|NCT00176527|DRUG|isotretinoin|
40946440|NCT00176527|GENETIC|polyacrylamide gel electrophoresis|
40946441|NCT00176527|GENETIC|protein expression analysis|
40946442|NCT00176527|OTHER|immunohistochemistry staining method|
40946443|NCT01416844|BIOLOGICAL|anti-OX40|Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.
41133037|NCT01981746|PROCEDURE|Adductor canal block with ropivacaine 0.1%|US-guided adductor canal block
41133038|NCT00640588|DRUG|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
41452637|NCT06390813|BEHAVIORAL|Square Stepping Exercise Training|A total of 18 sessions of SSE were performed 3 days a week for 6 weeks, each session lasting 40 minutes.
41452638|NCT04602754|DRUG|BERLIM 25/20 ASSOCIATION|Berlim 25/20 association coated tablet.
40946444|NCT03012724|DEVICE|H7-Coil|Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
40946445|NCT03012724|DEVICE|H1-Coil|Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
40946446|NCT06312956|DEVICE|Continuous Positive Airway Pressure Ventilotherapy|Breathing support device during sleeping
40946447|NCT00140634|BIOLOGICAL|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap.
40946448|NCT05635669|DEVICE|Sacral acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached transversely to the needle handles at bilateral Huiyang(BL35) and Zhongliao(BL33) .
40946449|NCT05635669|DEVICE|Abdominal acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached to the needle handles respectively at Zhongji(RN3) and one side of Dahe(KI12), as well as Guanyuan(RN4) and another side of Dahe(KI12).
40946450|NCT05635669|DEVICE|Alternating acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. The application of electroacupuncture is the same as Sacral group and Abdominal group.
40946451|NCT00302107|DRUG|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
40946452|NCT00302107|DRUG|Placebo|Look-a-like placebo tablets under double-blind conditions
40946453|NCT02899845|OTHER|postural task|
40946454|NCT02899845|OTHER|walk task|
40946455|NCT02595138|DRUG|Zoledronic acid|
40946456|NCT01695148|DIETARY_SUPPLEMENT|β-Carotene Biofortified Maize Flour|
40946457|NCT01695148|DIETARY_SUPPLEMENT|White Maize Flour|
40946458|NCT00833716|DRUG|semaglutide|10 mg/mL of semaglutide solution for s.c. injection, single dose
40946459|NCT00001122|DRUG|Nelfinavir mesylate|
40946460|NCT00001122|DRUG|Efavirenz|
40946461|NCT00001122|DRUG|Stavudine|
40946462|NCT00001122|DRUG|Didanosine|
40946463|NCT06223919|BIOLOGICAL|LC16m8|"LC16m8 should be stored at temperatures between -35°C and -20°C. The product should not be stored at temperatures below -35°C, because deterioration or damage of the rubber stopper could occur.~The virus in this product is sensitive to sunlight and is quickly inactivated, so care should be taken to avoid exposure to light, both before or after reconstitution.~Carefully examine the content at the time of reconstitution. Do not use if precipitation, contamination of foreign substances, or other abnormalities are observed.~This product should be dissolving the drug immediately before inoculation. Once dissolved, it should be used immediately. Since this product does not contain thimerosal, once the stopper is removed, any solution remained in the vial must be disposed of.~Do not restore or reuse the remaining solution. Shelf Life: 10 years from the date of passing the national test for lot-release Bottle containing about 250 doses"
40946464|NCT06557031|DIAGNOSTIC_TEST|ABTest Card®REF and ABTest Card®NEW|Pre transfusional control with the ABTest Card®REF device (predicate device) and the ABTest Card®NEW device (investigational device).
41452639|NCT04602754|OTHER|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
41452640|NCT04602754|OTHER|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin calcium placebo coated tablet.
41286557|NCT06070038|BEHAVIORAL|Integrated Behaviour Change Based Intervention Materials|The intervention will be delivered over a three-month period as a series of four zoom hosted workshops, online content, and a moderated social support group. Zoom workshops will last 45 minutes and will target key constructs from the integrated behavior change model. Main topics of the workshops are autonomy Supportive parenting (Week 1), goal setting and outcome beliefs (Week 3), physical activity norms (Week 5), and encouraging self-efficacy and maintenance (Week 8). Following each workshop, participants will receive links to online content that builds on workshop themes, such as messages, worksheets, and reflection tasks. Throughout the trial, participants will be able to participate in social support chat groups to discuss their progress with other members of the intervention group and intervention facilitators.
41286558|NCT02823912|DRUG|Capsaicin|
41286559|NCT02823912|DRUG|Magnesia calcinada|
41286560|NCT05335083|DEVICE|CPAP|A positive CPAP intervention
41286561|NCT06079502|DEVICE|Neuromuscular Electrical Stimulation|A supervised program of intradialytic NMES of the quadriceps and calf muscles of both lower limbs with different phases, types and current intensity. The electrical stimulation program will included (total time, intensity, contraction-relaxation phase time): a toning program in the first two weeks.
41286562|NCT06079502|OTHER|resistive training program|"Part one: Warming up for 5 minutes in the form of lower limbs range of motion (active free) exercise from supine position.~Part two: The main part is the resistive training for quadriceps and calf muscles from supine position using weights in the form of sand bags for 20 min.~Part three: Cooling down for 5 minutes in the form of lower limbs range of motion (active free) exercise from supine position.~The training parameters:~The exercise training will be done during the first 2 hours of HD session using free leg weights. The patient will assume a supine lying position on the treatment plinth and perform the exercises for every lower limb separately while the other limb will be supported on the plinth by therapist or the patient himself. Resistance will be placed at the malleoli level in the distal third of the leg."
41286563|NCT01019408|DRUG|Chloroquine|Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
41286564|NCT00302237|DEVICE|RX ACCULINK, RX ACCUNET Embolic Protection System|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
41452641|NCT04602754|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
41452642|NCT04602754|DRUG|ROSUVASTATIN CALCIUM|Rosuvastatin 20 mg coated tablet.
41452643|NCT04602754|OTHER|BERLIM 25/20 ASSOCIATION PLACEBO|Berlim 25/20 association placebo coated tablet.
41286565|NCT03941548|DRUG|CTP-543|Administered as 12 mg tablets.
41452644|NCT05405023|OTHER|Concentric exercises with wrist mobilization|Participants will receive concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements.
41452645|NCT05405023|OTHER|Concentric exercises without wrist mobilization|Participants will receive concentric exercises only.
41452646|NCT03149900|DRUG|Secukinumab|See Arm Description
41452647|NCT03283748|DEVICE|Wearable sensors|Wearable sensors will be given to the participants to be worn and movement data will be collected
41452648|NCT03252990|DIAGNOSTIC_TEST|PET-MRI|Additional 18F-choline PET-MRI examination
41452649|NCT03252990|PROCEDURE|Optical Coherence Tomography|Additional optical coherence tomography (OCT) examination (during the already planned routine PCI procedure)
41452650|NCT04561115|BIOLOGICAL|Gamunex-C|Intravenous infusion.
41452651|NCT04561115|BIOLOGICAL|IVIG-PEG|Intravenous infusion.
41452652|NCT04269122|OTHER|No Intervention|No intervention
41452653|NCT01298050|PROCEDURE|ECMO|Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
41452654|NCT05521360|BEHAVIORAL|Autonomic Modulation Training|AMT is a six week online behavioral intervention comprised of two components. The first component is an adapted (to online format) version of an established and publicly available HRVBF protocol (Lehrer et al, 2013, Biofeedback).The second is the integration of meta-cognitive coping skills and autonomic modulation breathing techniques into the HRVBF protocol (Arpaia \& Andersen, 2019 Frontiers in Psychiatry; Andersen, Arpaia \& Gustafsberg, 2021 Int J Emerg Ment Health and Human Resilience).
40757699|NCT06538987|PROCEDURE|percutaneous epicardial ablation|Epicardial catheter ablation is often necessary for the successful treatment of scar-induced ventricular tachycardia (VT), especially in patients with nonischemic cardiomyopathy (NICMP) where scarring is more extensive on the mid-myocardial or epicardial surface. Because epicardial mapping can be painful and patient movement can limit mapping and safe epicardial access, a common strategy for these patients is general anesthesia.
40757700|NCT03019263|DIETARY_SUPPLEMENT|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
40757701|NCT03019263|OTHER|Control|Nutritional counseling
40757702|NCT00154245|DRUG|Enteric-Coated Mycophenolate sodium (EC-MPS)|
40757703|NCT02989025|DRUG|17 OHPC|The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
40757704|NCT05642390|DEVICE|Breast implant|Patients operated for breast augmentation or reconstruction.
40757705|NCT05533372|DRUG|IA-14069|IA-14069 for oral administration.
41286566|NCT03941548|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
40946465|NCT01543971|DRUG|TXA127|TXA127 : 300mcg/kg per day for 5 days, injection
40757706|NCT05533372|DRUG|Placebo|Placebo for oral administration.
40757707|NCT05533372|DRUG|Methotrexate|Methotrexate for oral administration.
40757708|NCT00854737|DIETARY_SUPPLEMENT|cytidine|cytidine (2g po daily for 4 months)
40757709|NCT00854737|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 fatty acids (4g po daily for 4 months)
40757710|NCT00854737|DRUG|placebo|sugar pill
40757711|NCT04839926|DRUG|0.5mg CY150112|single oral CY150112 while fasting on day 1.
40757712|NCT04839926|DRUG|1.5mg CY150112|single oral CY150112 while fasting on day 1.
40757713|NCT04839926|DRUG|4.5mg CY150112|single oral CY150112 while fasting on day 1.
40757714|NCT04839926|DRUG|10mg CY150112|single oral CY150112 while fasting on day 1.
40757715|NCT04839926|DRUG|18mg CY150112|single oral CY150112 while fasting on day 1.
40757716|NCT04839926|DRUG|24mg CY150112|single oral CY150112 while fasting on day 1.
40757717|NCT02755883|BEHAVIORAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
40946466|NCT01543971|DRUG|Neupogen (filgrastim)|Neupogen : 10mcg/kg per day for 5 days, injection
40946467|NCT00543543|BIOLOGICAL|Comparator: GARDASIL|GARDASIL (quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
40946468|NCT00543543|BIOLOGICAL|Experimental: V503|V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
40946469|NCT03215979|PROCEDURE|Platelet enriched plasma administration|It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft
40946470|NCT03215979|PROCEDURE|Placebo Arm|5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.
40946471|NCT03425513|DIAGNOSTIC_TEST|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).
40946472|NCT03425513|OTHER|Questionnaire|Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.
40946473|NCT03697057|PROCEDURE|General anaesthesia|Standard general anaesthesia for gynecologic surgery in patient group
41286567|NCT01226667|DRUG|Pregabalin|"Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.~Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly."
41286568|NCT01566838|DRUG|Subpleural pain catheter with infusion of 0.125% bupivacaine|Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
41440970|NCT01630083|DRUG|zolbetuximab|Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.
40946474|NCT04634799|DRUG|TM5614|TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
40946475|NCT04634799|OTHER|Placebo|Matching placebo will be provided and participants will take 6 tablets in the evening for up to 7 days.
40946476|NCT02575742|DEVICE|3D-Transit system|
40757718|NCT02755883|BEHAVIORAL|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
40946477|NCT02100579|DRUG|Bupivacaine|10 ml of 0.25% bupivacaine
40946478|NCT02100579|DRUG|Preservative free normal saline|10 ml of preservative free normal saline
40946479|NCT05777343|OTHER|Experimental|Cognitive training combined with the recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
40946480|NCT05777343|OTHER|Exercise and PNE|Recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
40946481|NCT05777343|OTHER|Cognitive training|Online sessions of cognitive training.
40946482|NCT04483167|DRUG|99mTccAbVCAM1-5 injection|intravenous injection of 99mTccAbVCAM1-5 with dose increase
40946483|NCT05830773|OTHER|Resonance Breathing Exercises|This intervention uses the Camera Heart Rate Variability (CHRV) smartphone application, a resonance breathing app that is available for download to iPhones and Android devices. The CHRV app uses Photoplethysmography (PPG) technology to measure heart rate. PPG is a noninvasive technology that uses a light source (the phone's flashlight) and a photodetector (the phone's camera lens) at the surface of one's skin to measure the volumetric variations of blood circulation. The app also has a timer (to allow the participant to see how long they use the app in each session). The iPhone version of the app also has a breathing pacer (a bar that moves up and down to show the participant when to inhale and exhale). Participants are instructed to initiate a resonance breathing session for at least 5 minutes every day and whenever they experience cravings, feel like they are going to relapse, feel anxious or stressed, or just want to feel calm.
40946484|NCT00351000|DRUG|Ziprasidone|
40946485|NCT03603054|OTHER|Active neck mobilization|The subjects, receive an active neck mobilization intervention.
41133039|NCT00640588|DRUG|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
41133040|NCT05372224|DRUG|Cholecalciferol|4000 IU were administrated once a day for 3 months.
41133041|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
41133042|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
41133043|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
40946486|NCT03603054|OTHER|Active Mobilization of the sciatic nerve|The subjects, receive an active sciatic nerve mobilization intervention.
40757719|NCT03258229|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
40946487|NCT05548673|BEHAVIORAL|Psychoeducation|The implementation phase is planned for Ankara Yıldırım Beyazıt University (AYBU) Nursing Faculty students. The stress management training program, which consists of eight sessions, is completed in 8 weeks, once a week.
40946488|NCT04673968|OTHER|prehabilitation|inhospital exercise training 5 times/week, 5\~6 weeks during nCRT; home exercise 5 times/week, 5\~6 weeks, between completion of nCRT and before surgery
40946489|NCT00571610|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
40946490|NCT05759611|OTHER|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises lasting about 20 minutes per session
40757720|NCT03258229|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 weeks
40946491|NCT05759611|OTHER|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + a specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects.
40946492|NCT00209768|DEVICE|Filter: NOE96E, ELD96E, NLF1E, TNA1E|
40946493|NCT02932423|OTHER|Control product E|Plain water
40757721|NCT04824677|OTHER|Hospital treatment of COVID disease|Hospital treatment of COVID disease
40946494|NCT02932423|OTHER|Test product A|Beverage with no sugar but sweetener
40946495|NCT02932423|OTHER|Test product B|Beverage with 22 g/L sugar and sweetener
40946496|NCT02932423|OTHER|Test product C|Beverage with 33 g/L sugar and sweetener
40946497|NCT02932423|OTHER|Test product D|Beverage with 47 g/L sugar and sweetener
40946498|NCT02932423|OTHER|Comparative product F|Beverage with 98 g/L sugar
40946499|NCT03021304|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.
40946500|NCT04185376|OTHER|Questionnaire|a self-administered questionnaire for the assessment of pelvic floor disorders, their risk factors and their impact of quality of life during pregnancy and postpartum period which integrates bladder, bowel and sexual function, pelvic organ prolapse, severity, bothersomeness and conditions specific quality of life in women with urinary incontinence (UI) and/or POP. The questionnaire is divided into four main domains (bladder, bowel, pelvic organ prolapse, sexual function) and each question is scored from zero to three. The additive scores are divided by the maximum reachable score and multiplied by ten, giving a value between zero (0 = no symptoms) and ten (10 = maximum symptoms) for each of the domains.
40946501|NCT02475031|DEVICE|TAP-C|TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
41440971|NCT03565133|DIETARY_SUPPLEMENT|Quinine sham feeding quinine|Oral sham feeding with quinine
40946502|NCT02475031|DRUG|TAP-S|Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
40946503|NCT04943718|BIOLOGICAL|personalized vaccine|Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; patients would be vaccinated on day 1, 4, 8 ,15, 22 and then on week 12, 20.
41440972|NCT03565133|DIETARY_SUPPLEMENT|Gastric quinine|A gastric capsule containing quinine
40946504|NCT00559754|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
40946505|NCT00559754|DRUG|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
40946506|NCT00559754|DRUG|Standard chemotherapy|As prescribed
41133044|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
41133045|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
41133046|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
41440973|NCT03565133|DIETARY_SUPPLEMENT|Oral sham feeding placebo|Oral sham feeding with placebo (tap water)
41133047|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
40757722|NCT06548295|BEHAVIORAL|modified constraint induced movement therapy (mCIMT)|"Restraint the involved extremity by using a mitten. Repetitive task practice i.e filling a glass, drinking a glass of water, and eating with a spoon , stacking cones and stacking blocks, grasping and releasing of an object, reaching forward and sideways, lifting and dropping of an object from the one end of table to the other end.~The shaping exercises included cube stacking, card turning, throwing balls into a box, grasping/holding and placing objects of different sizes, and drawing and painting exercises. Intervention: 5 sessions per week for 50 minutes for 6 weeks"
40757723|NCT06548295|COMBINATION_PRODUCT|conservative treatment|"The conservative rehabilitation program consisted of upper-limb range of motion exercises, positioning, stretching, and strengthening exercises, Passive mobilization of the shoulder ,elbow , wrist and small joints of hand Stretching of the affected arm including biceps, triceps and muscles of forearm and hand.~Strengthening exercises of upper arm and forearm muscles involved. Intervention: 5 sessions per week for six weeks and 50 mintues"
40757724|NCT05103111|OTHER|No intervention|no intervention
40757725|NCT00866775|DRUG|Eslicarbazepine acetate|1600 mg QD
40757726|NCT00866775|DRUG|Eslicarbazepine acetate|1200 mg QD
40757727|NCT01918358|DRUG|Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|
40757728|NCT01918358|DRUG|Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|
40757729|NCT01918358|DRUG|Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|
40757730|NCT01918358|DRUG|Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|
40757731|NCT01918358|DRUG|Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|
40757732|NCT01918358|DRUG|Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)|
40757733|NCT03890107|DEVICE|OtoSight Middle Ear Scope|OtoSight imaging using a near-infrared laser
41440974|NCT03565133|DIETARY_SUPPLEMENT|Gastric placebo|A gastric capsule containing placebo (cellulose)
41452655|NCT00538109|DRUG|Glivec®/Gleevec®|Chemotherapy
41452656|NCT05576831|PROCEDURE|Re-excision|Re-excise (one take back only) Excise scar aiming for 1-2cm margin
40757734|NCT04841798|OTHER|[11C]SL25.1188 PET radiotracer|Monoamine oxidase B (MAO-B) occupancy before and after medication treatment using \[11C\]SL25.1188 PET
40946507|NCT01309165|BEHAVIORAL|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
41133048|NCT03074032|DRUG|ONC1-0013B|ONC1-0013B per os daily
41452657|NCT01751854|DRUG|SSRI|SSRI alone or with training
41452658|NCT01751854|DRUG|Placebo|Placebo alone or with training
41452659|NCT01125072|OTHER|Echocardiography with strain analysis|Clinical routine echocardiogram with additional off line strain analysis
41452660|NCT00339157|DRUG|Anakinra|
41452661|NCT00339157|BIOLOGICAL|Pneumo23|
41452662|NCT06251895|OTHER|DKA protocol|IV fluids and IV insulin as per guidelines. reference 1-2
41452663|NCT04693611|BEHAVIORAL|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 24 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants without any neurocognitive disorder.
40946508|NCT01309165|BEHAVIORAL|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
40946509|NCT03763864|OTHER|Skin Biopsy|Skin Biopsy
40946510|NCT06276231|DRUG|Salbutamol|Salbutamol 10mg nebulization over 5 minutes ( flow rate 5-7 liters).
40946511|NCT06276231|OTHER|0.9% Normal Saline|Normal saline nebulization over 5 minutes ( flow rate 5-7 liters).
40946512|NCT06276231|DRUG|Diclofenac Injection|75 mg of Diclofenac intramuscular Injection
40946513|NCT03845751|DRUG|HIFU hemi-ablation combined with ADT.|Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session
40946514|NCT01340547|DRUG|palifosfamide-tris|palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
40946515|NCT01340547|DRUG|Normal Saline|0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
40946516|NCT02437513|DEVICE|NewBreez|Intralaryngeal prosthesis to protect the airways
40946517|NCT04579029|PROCEDURE|Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging|Lymphoedema is well recognized as a chronic debilitating disease resulting from an abnormal collection of protein-rich fluid within the subcutaneous tissues of the body. Given the need to identify more effective treatments, more recent advances in super microsurgical techniques have seen the introduction of new procedures, perhaps the most successful of which have involved re-routing the lymphatic fluid by using microsurgery to divert small lymphatic channels into venules in the sub-dermal plane (LVA surgery). This procedure is performed under regional or general anaesthetic as a day-case operation, leaving only a few very short scars in the skin of the arm or leg.
40946518|NCT03276793|OTHER|MRI scan|Patients will undergo an MRI scan
40946519|NCT03276793|BEHAVIORAL|Behavioral testing|Patients will complete a series of cognitive tasks
40946520|NCT05403034|PROCEDURE|Muscle biopsy|Peroperative muscle biopsy will be performed during a planned shoulder surgery (arthrolysis and/or muscle transfer)
40946521|NCT03344354|DEVICE|Biogel|Sterile surgical gloves used during surgical procedures.
41286569|NCT01566838|DRUG|Standard acute pain management|"A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.~Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
40946522|NCT03344354|DEVICE|Ansell|Sterile surgical gloves used during surgical procedures.
40946523|NCT03344354|DEVICE|Cardinal|Sterile surgical gloves used during surgical procedures.
40946524|NCT03344354|DEVICE|Medline|Sterile surgical gloves used during surgical procedures.
40946525|NCT00805701|DRUG|avodart|0.5 avodart once daily for 13 weeks
40946526|NCT00805701|DRUG|Placebo|placebo
40946527|NCT01310504|PROCEDURE|SonoSite Ultrasound|Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
40946528|NCT01310504|PROCEDURE|SonoSite Ultrasound|Paramedics will scan the abdomen and determine it there's fluid within.
40946529|NCT04979104|PROCEDURE|Hip arthroplasty with SL Cementless|Total or partial hip arthroplasty with implant of SL cementless femoral stem.
40946530|NCT03038451|DRUG|S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet|
40946531|NCT01022749|DRUG|Vaccine|MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
40946532|NCT01022749|BIOLOGICAL|Vaccine anti-H1N1|patients who received the vaccine anti-H1N1
40946533|NCT05353309|PROCEDURE|Standard Angioplasty|Angioplasty Iliac done following standard practice
40946534|NCT05353309|PROCEDURE|Angioplasty with D images|Angioplasty Iliac under additional 3D Images merged as surgery support
40946535|NCT04709354|DIAGNOSTIC_TEST|Dermoscopic examination|The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.
40946536|NCT01904227|BEHAVIORAL|standard outpatient DBT|Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
40946537|NCT01904227|BEHAVIORAL|Inpatient Adaptation of DBT|"The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly."
40946538|NCT00935051|OTHER|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
40946539|NCT00920634|DRUG|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
40946540|NCT01516073|DRUG|Fluticasone Propionate|FP BID for 12 weeks
40946541|NCT04484948|OTHER|scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT|"1. Participants will perform the SHAQ.~2. BHT and 6MWT will be performed in the randomized way for each participant.~3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.~4. 6MWT will be performed according to the ATS guidelines.~5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.~6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.~7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT."
40946542|NCT02973828|PROCEDURE|Imaging|This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
40946543|NCT05078242|DEVICE|EaseVRx|Participants will experience 7 sessions of the EaseVRx device for chronic pain.
40946544|NCT01388595|DRUG|FLUTICASONE PROPRIONATE|1. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.
40946545|NCT01388595|DRUG|Salmeterol|Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor
40946546|NCT01388595|DRUG|PLACEBO|4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported \& QP release tested in UK : DHP Clinical supplies, Powys, UK
40946547|NCT05454306|DEVICE|Anser Clavicle Pin|The Anser Clavicle Pin is an intramedullary device that has been studied in 20 patients in an EU-based prospective case series.28 A 100% union rate was found. The Constant-Murley score at 1-year was 96.7 (SD 5). The Disabilities of Arm, Shoulder and Hand score was 5.1 (SD 10). There were no infections, neuropathy of the supraclavicular nerve or hardware irritation requiring removal of hardware. Three device-related complications (15%) occurred including plastic deformation, protrusion and hardware failure. VAS satisfaction was 8.9 (SD 1) at the 1-year follow up.
40946548|NCT00467857|PROCEDURE|InteguSeal* skin sealant and standard surgical preparation|Surgical skin preparation prior to incision using InteguSeal\* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
40946549|NCT00467857|OTHER|Standard preoperative skin preparation|Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
40946550|NCT04560790|DRUG|BD111 Adult single group Dose|3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
40946551|NCT05029700|OTHER|Combined exercise training|Combined exercise group (CEG) performed 30 minutes of aerobic training and also received trunk stabilization training in about 30 minutes after a 10-minute resting period. CEG received treatment 2 times a week for 8 weeks. During trunk stabilization training, the participants were taught how to contract the transversus abdominis and multifidus muscles. Due to the progression protocol, endurance levels of trunk muscles were increased by holding each posture for longer periods. The training was started with theraband resistance, which could be repeated between 10-12 repetitions, and the repetition time was increased up to 20. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
41133049|NCT01827982|DRUG|JNJ-54861911 1mg|JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
41286570|NCT03705923|PROCEDURE|Bariatric surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
41286571|NCT01498510|BEHAVIORAL|Web-based CBT for chronic pain|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
41286572|NCT03537690|OTHER|Laboratory Biomarker Analysis|Correlative studies
41286573|NCT03537690|DRUG|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
41286574|NCT03537690|OTHER|Pharmacokinetic Study|Correlative studies
41286575|NCT04606121|COMBINATION_PRODUCT|enhanced day care of TCM include acupuncture, massage, tai ji quan, TCM herbal medicine|acupuncture twice in enhanced day care of TCM massage twice in enhanced day care of TCM tai ji quan one time in enhanced day care of TCM TCM herbal powder three times a day
41286576|NCT05959499|DRUG|BR6002A|One tablet administered alone
41286577|NCT05959499|DRUG|BR6002B|One tablet administered alone
41286578|NCT05959499|DRUG|BR6002|One capsule administered alone
41286579|NCT01098968|BEHAVIORAL|Physical activity program|School intervention program specifically designed to increase health-related physical fitness
41286580|NCT02879500|OTHER|Diet beverages|
41286581|NCT00887081|DRUG|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
41286582|NCT04359953|DRUG|Hydroxychloroquine|Hydroxychloroquine 2 x per day during 14 days
41286583|NCT04359953|DRUG|Azithromycin|Azithromycin 2 x per day during 14 days
41286584|NCT04359953|DRUG|Telmisartan|Telmisartan 2 x per day during 14 days
41452664|NCT04693611|PROCEDURE|Functional near-infrared spectroscopy (fNIRS)|The acquisition by fNIRS will be performed in each CS session in four regions of interest (ROIs) in the prefrontal cortex: left dorsolateral prefrontal cortex (LDLPFC); left medial prefrontal cortex (LMPFC); right medial prefrontal cortex (RMPFC); right dorsolateral prefrontal cortex (RDLPFC).
41452665|NCT04884022|PROCEDURE|Miniplates in mandibular symphysis & infrazygomatic|Fixed functional appliance (pushing orthopedic force) in conjunction with direct skeletal anchorage
41452666|NCT04884022|PROCEDURE|Miniplates in external oblique ridge & anterior maxillary region|Coil spring (pulling orthopedic force) in conjunction with direct skeletal anchorage
41452667|NCT00273013|DRUG|GW274150|GW274150 will be available as 30 mg white oval tablets.
40946552|NCT05029700|OTHER|Aerobic training|Control group (CG) performed 30 minutes of aerobic training.CG received treatment 2 times a week for 8 weeks. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow their heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
40946553|NCT00549380|DEVICE|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
41286585|NCT04555213|DRUG|NOX66|NOX66 Suppository
41452668|NCT00273013|DRUG|Singulair|Singulair will be available as over encapsulated 10 mg orange tablets.
41452669|NCT00273013|DRUG|Placebo|Matching placebo for Singulair and GW274150 will be available.
40946554|NCT03274232|DEVICE|SUNEKOS ® 200|micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
40946555|NCT03585842|OTHER|No intervention|No intervention
41133050|NCT01827982|DRUG|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as a single oral dose.
41452670|NCT03486496|DRUG|gefitinib|Patients will be treated with gefitinib, 250 mg p.o., daily
41133051|NCT01827982|DRUG|JNJ-54861911 9 mg|JNJ-54861911 9 mg will be administered as a single oral dose.
41133052|NCT01827982|DRUG|JNJ-54861911 27 mg|JNJ-54861911 27 mg will be administered as a single oral dose.
41133053|NCT01827982|DRUG|JNJ-54861911 81 mg|JNJ-54861911 81 mg will be administered as a single oral dose.
41286586|NCT04054310|DIAGNOSTIC_TEST|Liver Multi Scan|MRI to create cT1, T2\* and PDFF images of patients liver.
41286587|NCT04087096|DRUG|Denosumab|Denosumab will be administered at postoperative months 1, 7, and 13
41286588|NCT04087096|DRUG|Placebo|Placebo will be administered at postoperative months 1, 7, and 13
41286589|NCT04087096|DRUG|Zoledronic Acid|Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
41286590|NCT02524080|PROCEDURE|Triage to optimal healthcare level|Triage to optimal healthcare level
41452671|NCT03486496|DRUG|Berberine|Patients will be treated with Berberine, 50 mg p.o., tid
41452672|NCT00002253|DRUG|Octreotide|
41452673|NCT04206267|DEVICE|Acceledent|Device for accelerating tooth movement
41452674|NCT03805633|DIAGNOSTIC_TEST|Venous blood sample|Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.
41452675|NCT03805633|DIAGNOSTIC_TEST|Ultrasound of pancreas|Ultrasound of pancreas will be obtained on all study participants.
41286591|NCT03431948|DRUG|Nivolumab|Nivolumab 240 mg given by intravenous infusion every 2 weeks
41286592|NCT03431948|DRUG|Cabiralizumab|Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
40757735|NCT05447858|OTHER|SWEA|Managers with one or several l staff experiencing WRNP will be educated in the Prehab guide. The manager should read and listen to all modules and a 1-h lecture recorded by the research team before participating in two workshops (4 h each), together with other managers and an experienced expert in work environmental health and rehabilitation. In the workshops, different themes will be discussed, such as physical, psychological, and organisational work-related health, prevention, and rehabilitation, how to lead problem-solving dialogue, how work-related adaptations can be performed related to WRNP, and questions about the Prehab guide. The Prehab guide will be used to deliver managerial support in the work with the Swedish Work Environment Authority's regulations regarding SWEA and the prevention of ill health, sick leave, and accidents, work adaptations, and workplace-oriented rehabilitation.
40757736|NCT05447858|OTHER|Neck-specific exercise|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control .
40757737|NCT01880775|DRUG|Prilocaine|experimental
40757738|NCT01880775|DRUG|Bupivacaine|marcaine heavy 0.5% 7.5 mg intrathecal
40757739|NCT01893099|DRUG|Sorafenib|Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
41286593|NCT03431948|DRUG|Urelumab|Urelumab 8 mg given by intravenous infusion every 4 weeks
41286594|NCT03431948|RADIATION|Stereotactic Body Radiation Therapy|Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
41286595|NCT00793104|PROCEDURE|Placement of allograft CR Plug in primary injury site|Core defect and implant allograft CR plug
41286596|NCT02424539|DRUG|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
41286597|NCT02424539|OTHER|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
41286598|NCT01483404|PROCEDURE|Measurement with O2c|Intra-surgery measurement of the microcirculation with the O2c device
41286599|NCT00492921|DRUG|Cyclophosphamide|
40757740|NCT01893099|DEVICE|Radioembolization with SIR-Spheres® (Yttrium Microspheres)|
40757741|NCT04768478|DRUG|CBD|25mg CBD ODTs (orally disintegrating tablet), with instructions to take CBD tablets t.i.d. (total of 50mg per dose t.i.d.) to be administered with routine post-operative pain management
41452676|NCT01654484|DRUG|DE-117|Ophthalmic Solution, QD, 28 Days
41133054|NCT01827982|DRUG|JNJ-54861911 160 mg|JNJ-54861911 160 mg will be administered as a single oral dose.
40946556|NCT00775216|BEHAVIORAL|"Behavioral counseling plus telephone helpline"|A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
40946557|NCT00020774|DRUG|gemcitabine hydrochloride|
40946558|NCT00020774|DRUG|lonafarnib|
40946559|NCT00020774|PROCEDURE|conventional surgery|
40946560|NCT02116231|DRUG|Concurrent chemotherapy with cisplatin|Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT
40946561|NCT02116231|RADIATION|Intensity modulated radiotherapy|Intensity modulated radiotherapy is a technique of radiotherapy.
40946562|NCT06397573|RADIATION|Reirradiation|Ablative reirradiation of 50 Gy in 5 fractions (5 sessions) that will occur once per day, either for 5 days in a row, or every other day.
40946563|NCT04462510|PROCEDURE|Block/Local infiltration|One group received ILI/IHG Block and the other group received local anesthetic infiltration for pain relief
40946564|NCT04052282|DEVICE|Mobile Health App|There is no intervention
40946565|NCT05956873|DEVICE|REVAR|Endovascular repair of ruptured TAAAs with available technique and devices: endovascular treatments were performed in urgent or emergent setting, compulsory within the first 24 hours, using an off-the-shelf stent grafts, or an available custom-made fenestrated/branched device or a physician-modified endografts with fenestrations/branches or parallel endografting for renal and visceral arteries
40946566|NCT02479269|OTHER|Aerobic exercise|Aerobic exercise for 8 weeks
40946567|NCT01115361|BEHAVIORAL|Family planning for postpartum women|"A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.~B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.~C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.~D.Convenient offer of FP services to women attending vaccination services for their infants."
40946568|NCT03132012|BEHAVIORAL|Indoor tanning intervention|6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
40946569|NCT03132012|BEHAVIORAL|Standard of care control|One website with content similar to those available in dermatology offices on skin cancer prevention
40946570|NCT01154829|DRUG|amisulpride|Individually dosed, according to symptoms, for a period of 6 weeks
40946571|NCT01154829|DRUG|aripiprazole|Individually dosed, according to symptoms, for a period of 6 weeks
40946572|NCT01090284|DEVICE|Inguinal hernioplasty|A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.
40946573|NCT02326675|OTHER|Ice|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
40757742|NCT04768478|DRUG|Placebo|Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
40757743|NCT06230393|DEVICE|STREAMLINE® SURGICAL SYSTEM|STREAMLINE® SURGICAL SYSTEM
40757744|NCT05757349|BEHAVIORAL|Face-down position time 1-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
40946574|NCT02326675|OTHER|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
40946575|NCT01024231|DRUG|BMS-936558 (MDX1106-04)|
40946576|NCT01024231|DRUG|Ipilimumab|
40946577|NCT00611533|DRUG|atomoxetine|Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
40946578|NCT00611533|DRUG|placebo|Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
40946579|NCT00785018|DRUG|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
40946580|NCT00785018|DRUG|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
40946581|NCT02499276|DEVICE|PSV, NAVA, PAV, Variable-PSV|Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
40946582|NCT01110304|OTHER|Conservative treatment - brace|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
40946583|NCT01110304|DEVICE|Hook plate by Synthes|The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
40946584|NCT06558084|DRUG|CDK4/6 Inhibitor|CDK4/6 inhibitor in first and second lines
40946585|NCT00694707|DRUG|Placebo|Placebo was supplied in capsules.
40946586|NCT00694707|DRUG|Cariprazine|Cariprazine was supplied in capsules
40946587|NCT00694707|DRUG|Risperidone|Risperidone was supplied in capsules
41133055|NCT01827982|DRUG|JNJ-54861911 tbd|The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
41133056|NCT01827982|DRUG|JNJ-54861911 9 mg|Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
41133057|NCT01827982|DRUG|Placebo|Matching placebo will be given as a single oral dose.
41133058|NCT01567605|DRUG|Lidocaine lubricant|Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
41133059|NCT01567605|OTHER|Placebo lubricant|Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
41133060|NCT02381132|DRUG|Norco 7.5mg/325|
40757745|NCT05757349|BEHAVIORAL|Face-down position time 3-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
41286600|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) with intact MFGM. One sandwich for breakfast and one sandwich for lunch.|1) Sandwich with butter-like dairy product (40g milk fat) with intact MFGM.
41286601|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM. One sandwich for breakfast and one sandwich for lunch.|2) Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM.
41286602|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) without MFGM. One sandwich for breakfast and one sandwich for lunch.|3) Sandwich with butter-like dairy product (40g milk fat) without MFGM.
41286603|NCT01243931|DRUG|OCT-guided laser phototherapeutic keratectomy|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
41286604|NCT01977144|OTHER|Comprehensive Chromosomal Screening|
41286605|NCT02734550|OTHER|Standard of care|Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
41286606|NCT02734550|OTHER|(1,3)-β-D-glucan guided therapy|Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
40946588|NCT02806245|OTHER|Biventricular pacing|"Randomization into one of 3 study arms for acute phase and for extended phase.~Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):~1. Atrial sensing- right ventricular pacing 10 min.~2. 5 min no pacing (washout).~3. Atrial sensing - biventricular pacing 10 min.~4. 5 min no pacing (washout).~5. Intrinsic rhythm~6. 5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.~Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.~Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped."
41286607|NCT00073944|DRUG|forodesine hydrochloride|
41286608|NCT02169076|DEVICE|Cardiac Resynchronization Therapy|The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
41286609|NCT02584985|PROCEDURE|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
40757746|NCT04770545|DRUG|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
41286610|NCT02584985|PROCEDURE|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
41286611|NCT04792996|OTHER|No intervention|No intervention. case - control design.
41286612|NCT03312010|DEVICE|Spinal Cord Stimulator HF|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
41286613|NCT03312010|DEVICE|Spinal Cord Stimulator Sham|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
41286614|NCT00004346|DRUG|chenodeoxycholic acid|
41286615|NCT00004346|DRUG|lovastatin|
41286616|NCT05045053|DRUG|Xiidra 5% Ophthalmic Solution|lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
41286617|NCT03429556|BIOLOGICAL|Botulinum Neurotoxin Serotype E|Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.
41452677|NCT01654484|DRUG|0.0015% tafluprost|Ophthalmic Solution, QD, 28 days
41286618|NCT03429556|DRUG|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
40946589|NCT05438784|PROCEDURE|orbital bone reconstruction with patient specific titanium implant|orbital defects reconstruction will be virtually planned by software and a patient specific titanium implant will be manufactured using milling technique depending on CAD-CAM technology
41286619|NCT06513598|PROCEDURE|Major visceral surgery for gastrointestinal cancer|This is a longitudinal observational study of the patients undergoing major visceral surgery for gastrointestinal cancer. Biological samples will be collected to compare gastrointestinal and infection site metastases and develop biomarkers for postoperative infections.
41286620|NCT03348683|DRUG|Propranolol|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.
41286621|NCT03348683|DRUG|Placebo|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
41286622|NCT03935646|DRUG|Adderall IR 10mg|At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.
41286623|NCT03935646|DRUG|Placebo|Placebo
41286624|NCT05042245|DRUG|Ornithine aspartate granule|Ornithine aspartate granules in the experimental arm.
41133061|NCT02381132|DRUG|MNK155|
40757747|NCT00027300|DRUG|Natalizumab|Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
40757748|NCT00027300|DRUG|Placebo|Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
40757749|NCT05042466|DRUG|Trauma|0.15g. thru 0.33g., M/W/F and monthly 1 time a dose of 1g. to 1.5g monthly. 8 week trial.
41286625|NCT05042245|DRUG|Silymarin capsule|Silymarin capsules in the active comparator arm.
41286626|NCT05042245|DRUG|Silymarin capsule simulant|Silymarin capsule simulant in the experimental arm.
41286627|NCT05042245|DRUG|Ornithine aspartate granule simulant|Ornithine aspartate granule simulant in the active comparator arm.
41286628|NCT06367270|DRUG|Pressured Intraperitoneal Aerosol Chemotherapy|PIPAC cycles will be scheduled every 6-8 weeks and 2 weeks after the last systemic chemotherapy administration. The bidirectional program for the combination of intraperitoneal and systemic chemotherapy is designed as follows: systemic chemotherapy followed by PIPAC two weeks later, followed by a one-week interval, and then systemic chemotherapy once again until three PIPAC cycles have been completed. Up to a one-week delay in returning to systemic chemotherapy after PIPAC and vice versa were considered acceptable. Systemic drug choice was based on previous chemotherapy exposure and the medical oncologists' decision. The study ends after the 3rd cycle of PIPAC.
41452678|NCT01654484|DRUG|DE-117 and 0.0015% tafluprost|Ophthalmic Solutions, QD, 28 days
40946590|NCT05438784|PROCEDURE|orbital bone reconstruction with preformed titanium plate preoperatively bended on stereolithographic model|orbital defects reconstruction will be virtually planned by software and a reconstructed stereolithographic model will be 3D printed and used for preoperatively bending of preformed titanium implant.
41286629|NCT05429515|PROCEDURE|HFR-SUPRA|HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.
41286630|NCT05429515|PROCEDURE|hemodialysis|hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.
41286631|NCT05429515|DRUG|Chemotherapy|chemotherapy protocol will be made by hematologists.
41286632|NCT02458976|DEVICE|PDL|
40946591|NCT04351854|OTHER|Retrospective data collection|Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
41286633|NCT04677842|DRUG|ART Therapy|
40946592|NCT03368534|DEVICE|Autologous Regenerative Technology (ART)|ART device with single-needle, fluid-assisted skin tissue harvesting technology.
40946593|NCT02519218|DEVICE|Ellipse Technologies Intramedullary High Tibial Osteotomy Nail System|
40946594|NCT01187433|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|0.5 mL, Subcutaneous (SC)
40946595|NCT01187433|BIOLOGICAL|NaCl 0.9%|0.5 mL, Subcutaneous
41286634|NCT01367132|PROCEDURE|Doppler ultrasound|Ultrasound using Doppler mode to detect blood flow in umbilical cord vasculature and determine the number of vessels present
41286635|NCT03866551|DEVICE|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
41286636|NCT00334750|OTHER|There is no intervention in this study.|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
41286637|NCT03703531|PROCEDURE|Cardiopulmonary resuscitation|CPR performed because of out-of-hospital cardiac arrest
41286638|NCT05981521|DIAGNOSTIC_TEST|Optimo prenatal screening test|Prenatal screening test done between weeks 11 and 13 of pregnancy to detect conditions such as trisomy 13, 18 and 21
41286639|NCT05191329|DIAGNOSTIC_TEST|TPQue Greek version, NEI-VFQ-25 Greek version|Study participants with non surgical presbyopic correction will be evaluated with TPQue regarding their personality traits. Visual acuity will also be assessed. Study participants with pseudophakic presbyopic correction will be evaluated with the TPQue before surgery. They will also be visual acuity evaluation and NEI-VFQ-25 assessment six months after surgery.
41286640|NCT01522495|DEVICE|SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)|Intravenous(1X) in conjunction with SPY Imaging (1 arm)
41286641|NCT01522495|DEVICE|SPY Imaging|SPY Imaging to assess tissue perfusion
41286642|NCT00129714|OTHER|cervical collar|
40757750|NCT04867629|DIETARY_SUPPLEMENT|Rapeseed oil|20mL of rapeseed oil to be consumed daily in replacement to habitual oil
40757751|NCT04867629|DIETARY_SUPPLEMENT|Sunflower oil|20mL of sunflower oil to be consumed daily in replacement to habitual oil
40757752|NCT05179005|DEVICE|RibFix Advantage|Intrathoracic rib fracture stabilization
40757753|NCT02475863|DEVICE|Warfarin Dosing Aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
40757754|NCT02475863|OTHER|Standard Practice|Warfarin dose adjustments according to standard unit protocol
40946596|NCT01187433|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|0.5 mL, Intramuscular
40757755|NCT02946411|PROCEDURE|Cardiac surgery|Glucose level will be measured after cardiac surgery.
40757756|NCT01442571|DEVICE|Hyaluronic Acid Injection|
40757757|NCT01442571|DRUG|Saline Injection|
41286643|NCT00129714|OTHER|physiotherapy|
41286644|NCT03543865|BEHAVIORAL|New Hope (NH)|New Hope will be implemented over 1 visit (2-4 hours) in a youth-preferred setting after Emergency Department (ED) discharge for a suicide attempt, and in the past few years has been updated to also target suicide ideation and binge behavior. NH emphasizes the seriousness of a suicide attempt; teaches coping skills to reduce risk, including emotion regulation, cognitive restructuring, social support, and safety planning; and helps participants overcome barriers to treatment motivation, initiation, and adherence. A center-piece of the intervention is a 20-minute video produced by with Native actors, vignettes specific to this community, and Elders speaking in Apache (with sub-titles) about the seriousness of suicide, its impact on the community, their concern for the adolescent, and beliefs about the communal importance of each individual's life.Youth will be encouraged to choose a support person from his/her family to take part in the intervention.
41440975|NCT04118192|PROCEDURE|Tumour bed core biopsy|Collection of up to 8 core biopsies across 4 zones of the whole tumour bed to detect residual cancer post neo-adjuvant treatment
41452679|NCT01654484|DRUG|Placebo|Ophthalmic Solution, QD, 28 days
40946597|NCT01187433|BIOLOGICAL|Meningococcal A+C vaccine|0.5 mL, Intramuscular
40946598|NCT04137432|DRUG|Oxytocin nasal spray|Intranasal administration of 24 international units oxytocin.
40946599|NCT04137432|DRUG|Placebo|The placebo nasal sprays contains identical ingredients except for the peptide itself.
40946600|NCT04890431|DRUG|Oxygen|oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)
40946601|NCT04890431|DRUG|Placebo|ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
40946602|NCT01385371|BIOLOGICAL|Grass (Phleum pratense) pollen allergen extract|One dissolving tablet sublingually once daily
40946603|NCT01385371|BIOLOGICAL|Placebo for SCH 697243|One dissolving tablet sublingually once daily
40946604|NCT04721951|PROCEDURE|Endovascular Aortic Repair using Carbon Dioxide Angiography|Endovascular Aortic Repair using Carbon Dioxide Angiography
40946605|NCT05655052|DEVICE|Virtual Reality (VR) Group|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care."
40946606|NCT05655052|DEVICE|Group using distraction cards|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care."
40946607|NCT02805972|DRUG|Naloxone|4 mg / 0.1 ml
40946608|NCT02805972|DRUG|Placebo|0.1 ml
40946609|NCT00849537|DRUG|Triamcinolone|Injection of intravitreal Triamcinolone
40946610|NCT00378339|DEVICE|gold berlocks|
40946611|NCT00240695|DRUG|galantamine hydrobromide|
40946612|NCT05722457|OTHER|external focus task focus in addition to physiotherapy and rehabilitation exercises|"The first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
40946613|NCT05722457|OTHER|internal focus task focus in addition to physiotherapy and rehabilitation exercises|"he first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
40946614|NCT04953351|PROCEDURE|Cognitive registration targeted biopsy and TRUS-system biopsy|Cognitive registration is a visual guidance technique in which the surgeon samples a visually estimated location on ultrasound that corresponds to the MRI suspicious regions location. TRUS-system biopsy includes 12 biopsy cores.
40946615|NCT04953351|PROCEDURE|MRI-ultrasound fusion targeted biopsy and TRUS-system biopsy|MRI-ultrasound fusion targeted biopsy is conducted with an mpMRI-TRUS biopsy system that provides realtime fusion of TRUS images and MRI images to guide the biopsy needles. TRUS-system biopsy includes 12 biopsy cores.
40946616|NCT00248131|DRUG|Octreotide acetate in microspheres|
40946617|NCT00673946|OTHER|True saturation values displayed|Physicians will be presented with real saturations.
40946618|NCT00673946|OTHER|Altered saturation values displayed.|Physicians will be presented with saturation measurements three percentage points above the true values.
40946619|NCT04908657|DRUG|Sildenafil 20 MG|oral sildenafil 20 mg three times per day for 3 years
40946620|NCT03063203|DRUG|Decitabine|"* After 2 cycles, patients with progressive disease or relapse (a clear progression with at least \>20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant~* Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles~* Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses~* Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference."
40946621|NCT03063203|PROCEDURE|Bone marrow biopsy/aspirate|"* Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse~* Biopsy/aspirate on Cycle 1 Day 10 is for participants enrolled at Washington University only~* Biopsy/aspirate on Cycle 2 Day 28 is at the discretion of the treating physician"
40946622|NCT03063203|PROCEDURE|Peripheral blood draw|-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse
41286645|NCT03543865|BEHAVIORAL|Elders Resilience (ER)|Elders' Resiliency is a monthly manualized curriculum taught by Elders in the community intended to bolster Apache youths' resilience to suicide ideation, attempts and substance abuse by promoting Apache cultural identity and values, youth's self-worth and role in the community, and fostering connectedness to society and community, with an emphasis on extended family as a nexus of strength. Each lesson introduces youth to cultural knowledge, stories, and songs with an emphasis on respect and the sacredness of each life. Our community-based Apache staff will select Elders who both express an interest in the current project and have demonstrated affinity and skill for teaching the current curriculum in the schools. After this group of Elders is recruited and agree to participate, they will be paired with our paraprofessional Apache study staff.
40946623|NCT03063203|PROCEDURE|Skin biopsy|"* Optional but if refuse skin biopsy then participant can provided buccal swab~* There is no required time frame for this sample - it may have been collected months or even years prior to the first dose of decitabine~* If WBC at time of enrollment is \>30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy or thereafter"
41286646|NCT03543865|OTHER|Case Management (CM)|Research Program Assistants, who are trained Surveillance System Staff, will conduct the monitoring and case management visits in participants' homes or other private settings at baseline, 1, 2, 3 and 6 months post-enrollment. The CM visit includes rapport-building, use of the Suicide Ideation Questionnaire (SIQ) to assess imminent risk, and if youth report not yet having connected to services, referral to Apache Behavioral Health Services (ABHS), the local community mental health center. At CM visits, the Research Program Assistants will also monitor participants' completion of the study battery, which will be self-administered using tablets. In addition, Research Program Assistants will score the SIQ before leaving the youth. If the SIQ reveals the participant is at imminent risk, Research Program Assistants will employ a protocol for rescue services, which involves triaging youth immediately to the ED for further assessment and care.
41286647|NCT04642664|DRUG|Apatinib plus Camrelizumab|Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. During the treatment, apatinib can reduced to half of piece or once every other day considering the grade of treatment related adverse events. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. The intermittent period of camrelizumab was no longer than 6 weeks. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
41286648|NCT04371510|OTHER|blood sample|a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms
41286649|NCT06319430|OTHER|robots|LEGO robots with adaptation according to child's age and developmental skills.
41286650|NCT06319430|OTHER|conventional|A pack of conventional play tools consists of dolls, teddy bears, miniature wild animals, and small cars. All are available, and the child can choose to play with them.
41286651|NCT04243044|DEVICE|Transcutaneous spinal stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic stimulation with a single round electrode as the cathode placed directly over the spine at the T11/T12 (and the lumbar spine for dual-site stimulation) spinous interspace, and two interconnected dispersive (reference) electrodes placed on the abdomen, lateral to the umbilicus. Stimulation intensity will be set to the specified level determined through a pre-stimulation assessment (0.8x reflex threshold). Treatments will be a minimum of 48 hours apart.
41286652|NCT00643045|DRUG|Safinamide|
41286653|NCT00643045|DRUG|Safinamide|
41286654|NCT00643045|DRUG|Placebo|
41286655|NCT04649710|BIOLOGICAL|BMS-986036|Specified dose on specified days
40946624|NCT03063203|PROCEDURE|Buccal swab|-Baseline (if skin biopsy declined) and Cycle 2 Day 28
40946625|NCT02908867|OTHER|Therapeutic Strategies|Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
40946626|NCT02730689|DRUG|DP-R207|
41286656|NCT04649710|OTHER|Placebo|Specified dose on specified days
41286657|NCT00124540|DRUG|misoprostol|
40946627|NCT02730689|DRUG|Rosuvastatin|
40946628|NCT02730689|DRUG|Ezetimibe|
40946629|NCT04122534|BEHAVIORAL|Somatic Mindfulness Training|Educational and experiential training to reduce occupational-based secondary trauma.
41286658|NCT00124540|DRUG|placebo|placebo resembling misoprosotl
40946630|NCT04928443|OTHER|Scar dressing group|Patients treated with scar dressing for surgical scar care are invited to participate this study and allocated in scar dressing group despite the length of caring period.
40946631|NCT04928443|OTHER|Regular care group|Patients receiving regular scar care are retrospectively identified with matching factors, such as gender, age, length of surgical wound and surgical procedure.
40946632|NCT01945112|DEVICE|Paper Tape|Applied to blister prone areas of the foot
40946633|NCT00265551|DRUG|SCA-136 (200 mg)|
41286659|NCT01319955|BIOLOGICAL|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
40946634|NCT00265551|DRUG|SCA-136 (400 mg)|
40946635|NCT00265551|DRUG|olanzapine (15 mg)|
40946636|NCT00265551|DRUG|placebo|
41286660|NCT02937610|PROCEDURE|percutaneous endoscopic gastrostomy|PEG tube inserted with pull technique
41286661|NCT01398254|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Participants will be randomly assigned an access site, radial or femoral, for PPCI.
41286662|NCT05032508|DRUG|Lidocaïne Aguettant 20 mg/ml|Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
41286663|NCT05032508|DRUG|NaCl 0,9%|Placebo (NaCl 0,9%), applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
41286664|NCT03541577|DEVICE|TruePhysioTM Microcatheter|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
41286665|NCT03541577|DEVICE|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
40946637|NCT00051454|BIOLOGICAL|HIV DNA plasmid vaccine plus recombinant fowlpox vector|
40946638|NCT01986907|DRUG|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
40946639|NCT03470948|OTHER|Observe postoperative complications|The aim of this study is to confirm the utility of a 10-point Surgical Apgar Score to rate surgical outcomes in Whipples procedure in patients with pancreatic cancer.
40946640|NCT06235632|BEHAVIORAL|Policy and Training Intervention|The intervention is a combination of a policy training and access to an in-depth training program to teach marijuana vendors the skills needed to refuse intoxicated customers
41286666|NCT00002423|DRUG|Indinavir sulfate|
41286667|NCT00002423|DRUG|Abacavir sulfate|
41286668|NCT00002423|DRUG|Amprenavir|
41286669|NCT00002423|DRUG|Nelfinavir mesylate|
41286670|NCT00002423|DRUG|Lamivudine|
41286671|NCT05134974|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
41286672|NCT05134974|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
41286673|NCT01274377|BIOLOGICAL|CMV Specific T Cell donor lymphocyte infusion|Donor Lymphocyte Infusion (DLI)
41452680|NCT05149209|PROCEDURE|cervical restoration|A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.
40946641|NCT06235632|BEHAVIORAL|Usual and Customary Policy and Training (UC-PT) (Control) Condition|The active control training that is already provided to marijuana vendors by the Oregon Liquor and Cannabis Commission
40946642|NCT04666675|DRUG|Upadacitinib|Oral; Tablet
41452681|NCT02232945|DRUG|placebo of oseltamivir phosphate|
40946643|NCT04666675|DRUG|Placebo for Upadacitinib|Oral; Tablet
40946644|NCT05266716|BEHAVIORAL|Affect Methamphetamine Treatment Program|"Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.~Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change."
41452682|NCT02232945|DRUG|oseltamivir phosphate|
41452683|NCT02232945|DRUG|Banlangen (Radix Isatidis) granules|
40946645|NCT02058472|DRUG|G3041|
40946646|NCT02058472|DRUG|SEVIKAR®|
40946647|NCT04264689|PROCEDURE|serratus anterior block|ultrasound guided block
40946648|NCT04264689|PROCEDURE|thoracic epidural|thoracic epidural
40946649|NCT04264689|PROCEDURE|erector spinae block|ultrasound guided block
40946650|NCT00447005|DRUG|Axitinib (AG-013736)|AG-013736 5mg twice daily \[BID\]
41452684|NCT02232945|DRUG|placebo of Banlangen(Radix Isatidis) granules|
41452685|NCT00664196|BIOLOGICAL|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
41452686|NCT00940563|DRUG|Imatinib|
41452687|NCT02721563|DRUG|Sodium Glycididazole|Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
41452688|NCT02721563|DRUG|Placebo|Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
41452689|NCT02440607|OTHER|Electronic Cognitive Aid|
41452690|NCT02440607|OTHER|Static Cognitive Aid|
41452691|NCT04672603|PROCEDURE|Complete Preservation of Denonvilliers' Fascia|Patients accept L-PANP surgery with complete preservation of Denonvilliers Fascia
41452692|NCT00223093|DRUG|TAIZ|
40946651|NCT02943031|OTHER|Individualized Precision Therapy Programs|After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
40946652|NCT02595996|DRUG|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
40946653|NCT04863092|BEHAVIORAL|Educational Intervention|The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group.
40946654|NCT02263209|DEVICE|Bioguard Group|Patients randomised to receive the study investigative device will receive a Bioguard implant
40946655|NCT02263209|DEVICE|Control Group|Patients randomised to receive the control device will receive a Exceed Taperlock implant
40946656|NCT00044720|DRUG|Rapamune|
40946657|NCT06365541|DRUG|Dapagliflozin|oral Dapagliflozin tablets 10mg/day for 6 months
40946658|NCT05131919|DRUG|Pembrolizumab|Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.
40946659|NCT02972853|BEHAVIORAL|Mindfulness Training for Primary Care (MTPC)|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study"
40946660|NCT02857985|DEVICE|3D RA|3D RA is realised just after angioplasty.
40946661|NCT02857985|DEVICE|MRI|MRI is realised between 24h and 96h post angioplasty.
40946662|NCT05089162|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, ASCEND and Ambrosy scores) will be performed during day hospitalization or consultation
40946663|NCT05089162|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds are optional
41286674|NCT02690896|BEHAVIORAL|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
41286675|NCT02690896|BEHAVIORAL|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
41286676|NCT02621333|BIOLOGICAL|CIK|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
41452693|NCT03708536|DRUG|S-1|S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).
40946664|NCT05089162|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
40946665|NCT05089162|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after day hospitalization or consultation
40946666|NCT05089162|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
40946667|NCT01470859|DRUG|pramipexole|tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
40946668|NCT01470859|DRUG|Sinemet CR|tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
40946669|NCT03144531|BEHAVIORAL|Sleep Intervention for Kids and Parents (SKIP)|Dyadic approach using self-efficacy theory to set goals, anticipate barriers, problem solve
41286677|NCT02621333|DRUG|chemotherapy|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
41286678|NCT02759822|PROCEDURE|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).
41286679|NCT06064318|PROCEDURE|Revision|Any type of knee revision, excluding knee arthrodesis and femur amputation
41286680|NCT05783258|PROCEDURE|Periodontal surgery with CAF+tSCTG|Coronally advanced flap and subepithelial connective tissue graft harvested from the maxillary tuberosity area.
41286681|NCT05783258|PROCEDURE|Periodontal surgery with CAF+L-PRF|Coronally advanced flap and L-PRF membranes
41286682|NCT02952716|BIOLOGICAL|Human cord blood mononuclear cell|The patients were treated by human cord blood mononuclear cell through subarachnoid space
41286683|NCT02952716|OTHER|hyperbaric oxygen|The patients were treated by hyperbaric oxygen
41286684|NCT01898312|DRUG|Mifepristone|Randomised controlled trial of Mifepristone and placebo comparator Triobe
41440976|NCT05915091|DIAGNOSTIC_TEST|Dry Needling|Dry needling is a treatment that healthcare providers use for pain and movement issues associated with myofascial trigger points. With this technique, a provider inserts thin needles into or near your trigger points. The needles stimulate your muscles, which causes them to contract or twitch
41452694|NCT03708536|DRUG|Bevacizumab|Bevacizumab (7.5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 3-week cycle.
41452695|NCT03708536|DRUG|Capecitabine|Capecitabine 2000mg/m2/d is administered orally on days 1 to 14 of a 21-day cycle.
40946670|NCT03346044|DEVICE|Carpentier-Edwards SAV bioprostheses|Performance of these bioprostheses
40946671|NCT03346044|DEVICE|Medtronic Mosaic bioprostheses|
40946672|NCT03319173|BEHAVIORAL|Dietary intervention|"Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD)."
40946673|NCT05883423|OTHER|FPCMP-Old Age|"1. Exercise program：The main purpose of the exercise program is to improve cardiorespiratory endurance, upper and lower limb muscle strength and endurance, body flexibility, sense of balance and coordination. The exercise program is carried out with a suspension training system, which can improve core muscle strength, improve physical fitness, activate more core and stabilizing muscle groups, increase joint stability, and strengthen ligaments.~2. Health integrated nursing management courses (nutrition, psychosocial, drug and other health management activities involved)"
40946674|NCT04977921|OTHER|lab session|assign students to clinical modules for study the clinical lab scope of practice
40946675|NCT02073110|DEVICE|Percutaneous Optical Biopsy (OCT and DRS)|
40946676|NCT01606644|PROCEDURE|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
40946677|NCT01502007|OTHER|Accelerometer feedback and lifestyle counseling|Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
40946678|NCT01502007|OTHER|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
40946679|NCT03042325|DRUG|Alogliptin|Alogliptin tablets
40946680|NCT00482027|BIOLOGICAL|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
40946681|NCT00437320|DRUG|Metvix Cream 160 mg/g|Participants were treated with topical administration of Metvix cream.
40946682|NCT00437320|DRUG|Metvix Vehicle Group|Participants were treated with topical administration of Metvix Vehicle cream.
40946683|NCT05059587|DRUG|MBA-P01|MBA-P01 will be injected into the Glabellar line.
40946684|NCT05059587|DRUG|BOTOX|Botox will be injected into the Glabellar line.
40946685|NCT06330454|DEVICE|I-ONE|Pulsed Electromagnetic fields joint therapy
40946686|NCT03090412|DRUG|HPPH|Given IV
40946687|NCT03090412|OTHER|Laboratory Biomarker Analysis|Correlative studies
40946688|NCT03090412|DRUG|Photodynamic Therapy|Undergo PDT
40946689|NCT03090412|OTHER|Quality-of-Life Assessment|Ancillary studies
40946690|NCT03090412|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
40946691|NCT04554173|PROCEDURE|surgical resection neurogenic tumors|Patient who was treated for a thoracic neurogenic tumor by minimally invasive surgery
40946692|NCT01264016|DEVICE|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
40946693|NCT02698878|DIETARY_SUPPLEMENT|lupin protein|19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)
40946694|NCT02698878|OTHER|Neuromuscular electrical stimulation|Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
40946695|NCT02698878|DEVICE|HEPHAISTOS unloading orthotic device|Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
40946696|NCT03617354|PROCEDURE|Total Laparoscopic Hysterectomy|The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
40946697|NCT06077448|DEVICE|MRI|imaging modality
40946698|NCT05333328|DRUG|Ovarian function suppression with endocrine treatments|"* Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~* Either goserelin acetate or leuprorelin Acetate is allowed.~* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~* Chemotherapy is omitted in these patients."
41286685|NCT06390618|OTHER|Aerobic Exercise (AE) Group|"A total of 24 sessions of aerobic exercise will be performed in 8 weeks, 3 days a week.~For aerobic exercise, a moderate intensity (50-60%) aerobic exercise program will be applied using the karvonen method. According to the aerobic exercise intensity karvonen method, the formula (Maximal Heart Rate (220-years) - Resting Heart Rate) x 50-60% + Resting Heart Rate) will be used. 1-4. week 50%, 5-8. Exercise intensity will be increased by 60% per week."
41286686|NCT06390618|OTHER|Combined Exercise (CE) Group|"In the combined exercise group, biopsychosocial exercise will be performed in addition to aerobic exercise.~In the combined exercise group, in addition to aerobic exercise (3, 8 weeks, 24 sessions of aerobic exercise per week), 16 sessions of biopsychosocial-based group exercise treatment will be performed 2 days a week for a total of 8 weeks.~BETY approach will be used in group exercise treatment."
41286687|NCT02434887|DEVICE|KL029 Intimate Lubricant Gel|
41286688|NCT00385333|PROCEDURE|Feasibility Study - Imaging System|
41452696|NCT01312064|DRUG|rituximab and everolimus|rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus initial dose: 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
41452697|NCT01312064|DRUG|thymoglobulin and tacrolimus|thymoglobulin induction and tacrolimus-based immunosuppressive therapy. thymoglobulin dose: 1.0mg/kg/d for 3 days daily dose of tacrolimus: 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation
41452698|NCT06405243|DRUG|Myoinositol|Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile
41452699|NCT06405243|DRUG|Chromium|chromium picolinate may potentiates the therapeutic effect of letrozol on pituitary hormones (FSH and LH), improvement of ovulation, normalization of Estrogen level, improvement of endometrial thickness related to ovulation
40946699|NCT00251173|BEHAVIORAL|Strengths Based Case Management (SBCM)|
40946700|NCT00251173|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
40946701|NCT00251173|BEHAVIORAL|Brief Informational Feedback (BIF) session|
41286689|NCT00881829|DEVICE|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
41440977|NCT05915091|OTHER|Cross Friction Massage|Cross friction massage breaks down scar tissue and remodels the tissue into more flexible, pliable, and functional, healthy soft tissue. Also known as transverse friction massage, this technique is a deep tissue massage technique performed at the site of injury
41440978|NCT02004535|PROCEDURE|Cochlear Implantation|The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
41286690|NCT05065424|DRUG|IV Atropine and Fentanyl Premedication Arm|"Prior to the LISA procedure, the blinded bedside nurse will infuse IV Atropine, labelled as Atropine/Placebo, over 1 minute, followed by IV fentanyl, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After medication infusion, a primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record."
41452700|NCT06405243|DRUG|l-arginine|new antioxidant that minimizes the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO
41440979|NCT02557347|BEHAVIORAL|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
41452701|NCT06405243|DRUG|Letrozole 2.5mg|selective aromatase inhibitor
41440980|NCT01079585|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
41440981|NCT04620057|DIETARY_SUPPLEMENT|butyrate|sodium butyrate (20 mg/kg body weight/day)
41440982|NCT04620057|OTHER|placebo|cornstarch
41440983|NCT00003291|GENETIC|cytogenetic analysis|
41440984|NCT00003291|GENETIC|mutation analysis|
40946702|NCT02777710|DRUG|Pexidartinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
41286691|NCT05065424|DRUG|IV Normal Saline Placebo Arm|"Prior to the Less Invasive Surfactant Administration procedure, the blinded bedside nurse will infuse IV Normal Saline, labelled as Atropine/Placebo, over 1 minute, followed by a second infusion of IV Normal Saline, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After Normal Saline infusion, primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record."
41286692|NCT01855555|DRUG|sedation with propofol|"When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported."
41286693|NCT03067311|BEHAVIORAL|I-CAT|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
40757758|NCT06480461|DRUG|VGN-R09b|This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.
41286694|NCT03067311|BEHAVIORAL|Treatment as Usual|Treatment as usual defined by participant clinician at OASIS clinic.
41286695|NCT04789824|BEHAVIORAL|eyelid hygiene|EH
41286696|NCT03094247|DRUG|Amoxicillin|All patients with severe acute malnutrition will receive a course of amoxicillin.
41286697|NCT03094247|DIETARY_SUPPLEMENT|HO-RUTF|HO-RUTF: Milk, perilla oil, palm oil, white sugar, high oleic peanuts
41286698|NCT03094247|DIETARY_SUPPLEMENT|D-HO-RUTF|D-HO-RUTF: DHA, milk, perilla oil, palm oil, white sugar, high oleic peanuts
41286699|NCT03094247|DIETARY_SUPPLEMENT|S-RUTF|S-RUTF: Milk, canola oil, palm oil, white sugar, standard peanuts
41286700|NCT00302601|PROCEDURE|Scintigraphic interpretation|Not relevant
41286701|NCT00211523|DRUG|MBI 226 Acne Solutions|
41286702|NCT06106698|OTHER|WMT|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive one dose of WMT for CDI. During follow-up, those who have non-response or CDI recurrence within 4-week post-WMT will receive rescue WMT.
41286703|NCT04936880|DEVICE|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
41452702|NCT02945618|DEVICE|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
41452703|NCT02945618|OTHER|Ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
41452704|NCT03483818|PROCEDURE|Assessment & Treatment of HCV infection with oral antivirals|This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.
40757759|NCT02029612|DRUG|Nicotine Patch|10 week supply of nicotine patches given to participants at baseline.
41286704|NCT04936880|DRUG|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
41286705|NCT06287047|PROCEDURE|Epidural analgesia|Epidural analgesia alone or with dural puncture with different sizes of spinal needles
41286706|NCT01296386|BIOLOGICAL|IC84|IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
41286707|NCT05179395|OTHER|Brasthesis|Brasthesis is a harness that is integrated with an off the shelf sports bra
41286708|NCT00476931|BIOLOGICAL|SB-509|60 mg dose
41286709|NCT00476931|OTHER|Placebo|Saline
41286710|NCT05807828|PROCEDURE|VR simulation on basic THA skills|The medical students' VR group will perform three VR simulation sessions on basic THA skills on the cup and stem implantation before actual implantation.
41286711|NCT04331730|DRUG|AKST4290|Oral AKST4290
41286712|NCT04331730|DRUG|Placebo|Oral placebo
41286713|NCT04331730|DRUG|Aflibercept|Aflibercept intravitreal injection
41286714|NCT03618225|DRUG|Oral Duloxetine 60mg|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
41286715|NCT03618225|DRUG|placebo pill|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
41440985|NCT00003291|OTHER|laboratory biomarker analysis|
41452705|NCT01567553|OTHER|USPIO MRI - Gadolinium MRI|"USPIO MRI scanning will be performed at :~* baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~* baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~* baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~* baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~* baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36."
41286716|NCT00488527|DRUG|Insulin glargine|Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (\<6.0 mmol/L), and the active treatment is to be continued for three more months.
41286717|NCT04757363|DRUG|regorafenib|regorafenib (80 mg on days 1-21 of the 28-day cycle)
40946703|NCT02777710|DRUG|Durvalumab|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
41286718|NCT04757363|DRUG|nivolumab|nivolumab (240 mg on days 1 and 15 of the 28-day cycle).
41286719|NCT04757363|DRUG|FOLFOX chemotherapy with oxaliplatin|FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h).
41286720|NCT06510842|OTHER|External drainage of intraventricular hemorrhage|An EVD is required to be eligible for the DRAIN IVH study. Weaning from the EVD is at the discretion of the local investigators. Imaging is at discretion of local investigators. Use, timing and frequency of fibrinolysis via EVD is at local discretion, too.
41286721|NCT05692349|DEVICE|MRI|MRI will be employed to assess muscle composition, evidence of degeneration or replacement by fat
41286722|NCT06334133|DRUG|Cadisegliatin 800 mg QD|Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
41286723|NCT06334133|DRUG|Cadisegliatin 800 mg BID|Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
41286724|NCT06334133|DRUG|Placebo|Placebo
41286725|NCT03826953|OTHER|Nurse Led Allergy Clinic|Project to investigate if it is feasible to establish a nurse-led primary care-based allergy clinic intervention in NHS Lothian, and to understand the acceptability and estimate the impact of this service on improving access and outcomes in patients with allergic conditions.WE will undertake a mixed-methods longitudinal evaluation of the community-based nurse-led allergy clinic.
41452706|NCT01057368|BEHAVIORAL|Day of intensive meditation practice|Long-term meditators practice for \~6 hours of meditation at each time point
41452707|NCT01057368|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8-week class designed to enhance well-being through training in mindfulness meditation
40757760|NCT02029612|BEHAVIORAL|Phone Counseling|Each participant counseled on quitting smoking at baseline.
40757761|NCT02029612|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 3 months, and at 6 months.
40946704|NCT04377516|OTHER|pelvic floor muscle training|pelvic floor muscle training
40946705|NCT04377516|OTHER|pelvic floor muscle combined global muscle exercise training|pelvic floor muscle combined global muscle exercise training
40946706|NCT04377516|OTHER|education of pelvic girdle|education of pelvic girdle
40946707|NCT00284596|PROCEDURE|High tibial osteotomy|HTO
40946708|NCT05390931|BEHAVIORAL|6-session motivational interviews|A total of 6 motivational interviews will be held once a month. Motivational interviews will be conducted individually.
41286726|NCT03202121|OTHER|insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
41286727|NCT03202121|OTHER|non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
41286728|NCT03202121|OTHER|normal control|Persons without stroke or insomnia served as normal controls that contained 25 cases.
41286729|NCT00121732|DRUG|E7974|Maximum tolerated dose = 0.15 mg/m\^2 administered on Days 1, 8, 15 of 28-day cycle.
41286730|NCT00121732|DRUG|E7974|Maximum tolerated dose = 0.37 mg/m\^2 administered on Days 1 and 8 of 21-day cycle.
40946709|NCT05390931|OTHER|Health education structured according to the health belief model|After the participants enrolled in the study, the patients in the study group will be given a health education structured according to the health belief model at the first interview.
41286731|NCT05027269|DRUG|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
41286732|NCT05027269|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
40946710|NCT05390931|OTHER|Training booklet prepared by the researchers on healthy lifestyle behavior changes|After the participants enrolled in the study and take health education, a training booklet prepared by the researchers on healthy lifestyle behavior changes will be given to the participants.
40946711|NCT05390931|OTHER|6 month follow-up|Follow-ups will be made 3 times in total, on the basis of pre-test, intermediate follow-up test (3 months), and post-test (6 months).
40946712|NCT05416151|OTHER|Freeze-dried biotic|2 sticks of 3g consumed daily for 28 days
40946713|NCT05416151|OTHER|Maltodextrin|2 sticks of 3g consumed daily for 28 days
40946714|NCT03579576|DRUG|sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.|Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
41286733|NCT03634046|PROCEDURE|Percutaneous transforaminal endoscopic discectomy|The same as the descriptions in experimental group.
41286734|NCT03634046|PROCEDURE|Radiofrequency ablation|The same as the descriptions in active comparator group.
41286735|NCT02203552|DRUG|minocycline hydrochloride|100 mg bid given by mouth for 9 weeks
41286736|NCT02203552|OTHER|placebo|Placebo given by mouth for 9 weeks
41286737|NCT02203552|OTHER|laboratory biomarker analysis|Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
41452708|NCT01057368|BEHAVIORAL|Health Enhancement Program (HEP)|8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
41452709|NCT00624351|BIOLOGICAL|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
41452710|NCT00624351|OTHER|Placebo|Phosphate-buffered Saline (PBS) infusion.
41452711|NCT03983837|OTHER|Neocate Splash|Neocate Splash is a hypoallergenic, amino acid based elemental liquid diet that is taken orally.
40946715|NCT00072631|DRUG|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
40946716|NCT03356054|COMBINATION_PRODUCT|R-DHAP|3 cycles q 3 weeks
40946717|NCT03356054|DRUG|Brentuximab Vedotin|3 cycles q 3 weeks added to R-DHAP
40946718|NCT01460368|DRUG|LY2409021|Administered orally
41286738|NCT02203552|OTHER|Questionnaire administration|The CES-D and STAI will be administrated weekly.
40946719|NCT01460368|DRUG|Placebo|Administered orally
41286739|NCT00014742|DRUG|collagenase|
41286740|NCT01251523|BEHAVIORAL|PACE|The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.
41452712|NCT04007835|DRUG|Anlotinib Hydrochloride|anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
41452713|NCT05909397|DRUG|ARV-471 (PF-07850327)|Pharmaceutical form: Tablets. Route of Administration: Oral
40946720|NCT01460368|DRUG|Moxifloxacin|Administered orally
40946721|NCT04773119|PROCEDURE|PVI only|Patients in this group receive PVI only
40946722|NCT04773119|PROCEDURE|PVI with substrate ablation|Patients in this group receive PVI as well as substrate ablation
41440986|NCT02756663|DRUG|panobinostat (capsules)|Panobinostat capsules, oral: 10mg, 15mg, 20mg dosing 3x a week, 1 week on / 1 week off, in a 4 week cycle (28 days). Treatment arm A: only capsules of 10mg will be used Treatment arm B: capsules of 10mg and 15mg are foreseen for dose reduction only.
41452714|NCT05909397|COMBINATION_PRODUCT|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
41452715|NCT05909397|DRUG|Letrozole|Pharmaceutical form: Capsules. Route of Administration: Orally
41452716|NCT05909397|COMBINATION_PRODUCT|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
41452717|NCT04132063|DRUG|Generic levetiracetam|Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
41452718|NCT01888276|OTHER|evaluation of word generation and of motivation|"Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The test of Stroop that assesses selective attention~During the session 2:~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The task of the casino (Iowa Gambling Test)~* The task of landing~* The test of Stroop"
41452719|NCT04462276|DRUG|Atezolizumab|fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
41452720|NCT04462276|RADIATION|thoracic radiotherapy (TRT)|30 Gy in 10 fractions
41452721|NCT01496495|DRUG|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
41452722|NCT04391270|BEHAVIORAL|blended intervention|A blended intervention group combining the web-based components with face-to-face workshops and posters
41452723|NCT04391270|BEHAVIORAL|web-based intervention|A web-based intervention only referred to the use of internet without traditional face-to-face workshops and posters
41452724|NCT04440358|DEVICE|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system to deliver carboplatin
41452725|NCT04440358|DRUG|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
41452726|NCT00383058|DRUG|the extract of green tea|
41452727|NCT06447753|PROCEDURE|Direct pulp capping|after caries excavation, the pulp will be inspected visually. If bleeding present, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Cases in which bleeding will not stop within 6 minutes will be excluded from the study and further managed by RCT. The exposed pulp will be capped with MTA which will be freshly mixed according to manufacturer's instructions and placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier following which the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. Then tooth will be restored using composite resin following etch and rinse technique.
41452728|NCT06447753|PROCEDURE|Complete Pulpotomy|exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant 28to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 6 minutes. After hemostasis, ProRoot MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier. After placement, the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. The tooth then will be restored using composite resin following etch and rinse technique.
40946723|NCT02951338|BEHAVIORAL|PROPEL program|The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
41286741|NCT01251523|BEHAVIORAL|PACE Plus|In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
41286742|NCT02620540|DEVICE|Accuracy of an algorithm and the Broselow Tape|Computer based comparison of the two devices based on collected patient data
41286743|NCT00332657|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
41286744|NCT00332657|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
41286745|NCT00332657|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
41286746|NCT01872351|DRUG|Nutraceuticals|
41286747|NCT03096028|OTHER|maternal vitamin B12 folate level during pregnancy|Maternal Vitamin B12 and folate level at 18\&28 weeks of pregnancy is the primary exposure of interest
41286748|NCT05090345|OTHER|Biorepository Trial|participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
41286749|NCT02976831|DRUG|AZD0284|Oral solution, concentration: 2 mg/mL and 15 mg/mL
41286750|NCT02976831|DRUG|Placebo|Placebo matching AZD0284 in the form of an oral solution with water.
41286751|NCT06510478|BEHAVIORAL|Group Life Skill Intervention|This 13-session life skills program covers essential topics in one-hour sessions. It starts with introductions and team building, then progresses through leadership, self-esteem, communication, stress management, positive thinking, confidence building, volunteering, decision-making, problem-solving, conflict resolution, and negotiation. Each session includes ice-breakers, discussions, and targeted exercises. Each session incorporates ice-breakers, open discussions, and targeted exercises to ensure active learning and skill internalization. Duration of each session was 1 hour.
41286752|NCT06510478|BEHAVIORAL|Treatment as Usual for Control Group|Standard psychological interventions i.e. Debreathing, Meditation, supportive counseling, or psychoeducation.
41286753|NCT02765893|OTHER|No Foley|Patients will have Foley catheter removed 6 hours post-op.
41286754|NCT06244927|PROCEDURE|Replantation surgery|Surgery
41286755|NCT02054832|DIETARY_SUPPLEMENT|Glycosade|
41286756|NCT04888221|DRUG|Tocilizumab|"Tocilizumab will be administered subcutaneously at a dose of 162mg/0.9mL weekly (each week, on the same day) from week 0 to week 24.~At the first injection (Baseline D0), a therapeutic education is provided for patients/caregivers who can carry out the injections themselves as part of their usual care."
41286757|NCT04888221|DRUG|Placebo|Placebo administered subcutaneously (SC) weekly during 24 weeks
41286758|NCT06103552|BEHAVIORAL|Building Lifestyle Options for Orthopedic Mobility (BLOOM)|This intervention is a lifestyle program with includes dietary coaching from a dietitian and regular doctor appointments with a bariatric medicine specialist over the course of 24 weeks.
41286759|NCT03968510|PROCEDURE|parathyroidectomy|routine parathyroidectomy will be done for the treatment of adenoma
41286760|NCT00983775|DEVICE|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
41286761|NCT00983775|DEVICE|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
41286762|NCT00294346|DRUG|AV608|
41286763|NCT06034223|OTHER|Proprioceptive training using head mounted laser|Exercises include head relocation practice, i.e., relocating the head back to the natural head posture and to pre-determined positions in range with eyes open using feedback from a laser attached to their head. And then tracing the figure of eight with the help of laser.
41286764|NCT06034223|OTHER|Conventional Physical therpay|Conventional physical therapy for mechanical neck pain which includes cervical range of motion (flexion, extension, lateral rotation, and rotation), neck isometric exercises, stretching's (scalene, trapezius, SCM) and TENS with heating pad.
41286765|NCT01374282|DRUG|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
41286766|NCT01809236|BIOLOGICAL|Conbercept|intravitreal injection of 0.5 mg Conbercept
41286767|NCT03060577|DRUG|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
41286768|NCT03060577|DRUG|Evolocumab|Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
41440987|NCT02756663|DRUG|carfilzomib (infusion)|Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)
40757762|NCT02029612|BEHAVIORAL|Breath Test|Breath test performed at 3 month and 6 month visit.
40757763|NCT02029612|BEHAVIORAL|Proactive Cell Phone Smoking Cessation Counseling|Participant receives 11 phone calls from study staff over a 6-month period.
41440988|NCT02756663|DRUG|dexamethasone (tablets)|Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)
41286769|NCT03607734|DRUG|Amoxicillin|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~* 50mg amoxicillin (10% total dose)~* 250mg amoxicillin (50% total dose)~* 200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
41286770|NCT00609440|OTHER|physiotherapeutic treatment|At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
41286771|NCT03953638|DIAGNOSTIC_TEST|Next Generation Sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
41286772|NCT04701086|DEVICE|Cationorm Pro|Eye Drops
41286773|NCT04701086|DEVICE|Vismed|Eye Drops
41286774|NCT02606773|DRUG|Ascorbic Acid|Ascorbic acid in different ways and doses
41286775|NCT06034730|DEVICE|Portable GC device for brath analysis|Patients were asked to orally exhale 1-2 L breath into a 5 L Tedlar bag via a one-way mouthpiece and Nafion filter for moisture removal, as shown in Figure 1B. The process usually takes about a few minutes. The breath analysis took place either in-situ immediately after the breath sample collection or within 24 h of breath collection. The Tedlar bags were stored under ambient condition until analyzed. During the breath analysis, the Tedlar bag was connected to the sampling port of the portable GC (Figure 1C). Approximately 350 mL of breath was pulled from the Tedlar bag into the GC for analysis. The GC operation was controlled using LabView via a laptop. The total assay time was 30 min, including 5 min of breath sampling time from the Tedlar bag at a flow rate of 70 mL/min (see the blue path in Figure 1A), 5 min of desorption/transfer time, 10 min of chromatographic separation time (see the orange path in Figure 1A), and 10 min of GC system cleaning time.
41286776|NCT05283707|BEHAVIORAL|Paula Method Exercises|The Paula Method Exercises were administered by the researcher for 6 to 8 hours, for 10 to 15 minutes on the post-op first day and post-op second day, to women who had a cesarean section.
41286777|NCT02946229|DEVICE|Ultrasound scan|Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
41286778|NCT00677950|PROCEDURE|Spinal fusion|Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
41286779|NCT04827537|DRUG|20-hydroxyecdysone Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
41286780|NCT04827537|DRUG|Metronidazole Oral|500 mg (one pill) x two times a day orally, 10 consecutive days
41286781|NCT04827537|DRUG|Placebo Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
41286782|NCT05170191|BEHAVIORAL|Sleep Deprivation|The participants will stay awake for 24 hours.
41286783|NCT04975048|DIETARY_SUPPLEMENT|Egg yolks|Two egg yolks/day was designed for the study. However, uneven egg sizes during period 1 made the intervention unable to achieve the protocol's recommended cholesterol intake level, and the intervention was modified in period 2 to be 0.8 g egg yolk/day/kg body weight. This dosage was calculated by dividing the 35 g egg yolk with the lightest weight among the volunteers, which was 45 kg. This provides a more consistent cholesterol intake between persons as the egg yolk dosage is standardized for persons with different weights.
41286784|NCT04975048|DIETARY_SUPPLEMENT|Macronutrients equivalent control|The macronutrients equivalent control group was served 42 g egg white cooked with 10 g olive oil, designed to best imitate the energy and macronutrients of 35 g egg yolk (energy 119 kcal, protein 5 g, fat 10 g, carbohydrate 1 g) since the average weight of two large egg yolk was presumed to be 35 g. As an egg yolk dose of 0.8 g egg yolk per kg body weight per day was served during the intervention period 2, the macronutrients equivalent control was likewise adjusted as follow: subjects who weighed less than 55 kg were served 51 g egg white cooked with 12 g olive oil, which is equivalent to 40 g egg yolk; those who weighed from 55 kg to 65 kg were served 61 g egg white cooked with 14 g olive oil, which is equivalent to 48 g egg yolk; and those who weighed more than 65 kg were served 71 g egg white cooked with 17 g olive oil, which is equivalent to 56 g egg yolk.
41286785|NCT04819425|DEVICE|Elastic Adhesive Strips|Securement of Endotracheal tube with Elastic Adhesive Strips
41286786|NCT04819425|DEVICE|Lace in A Protective Sheath|Securement of Endotracheal tube with Lace in A Protective Sheath
41286787|NCT04128098|OTHER|Evaluation|"* Functional tests: 400-meter walking test, 200-meter brisk walking test, Sorensen test, Shirado test, measurement of maximum isometric force of extensors/back flexors.~* 3D analysis of locomotion and posture~* Test of the flexion-relaxation phenomenon of the lumbar erector muscles"
40757764|NCT02029612|BEHAVIORAL|Text Message Smoking Cessation Support|Participants receive text messages for support about quitting smoking over a 6 month period.
41286788|NCT04128098|OTHER|Questionnaires|Self-questionnaires: Oswestry, Québec, SF-12, VAS pain, HAD, pain dramatization questionnaire, physical activity questionnaires, VAS and GPE satisfaction, FABQ, GPE functional status and EPICES score.
41286789|NCT04128098|OTHER|Rehabilitation care program|"* Personalized global exercises (aerobics) on ergometers~* Muscle strengthening with resistance~* Balneotherapy~* Learning health skills related to their condition (therapeutic education)~* Personal and group motivational interviews~* Nutritional advice~* Relaxation session"
41286790|NCT05751525|DRUG|Sulfonylurea|Glibenlclamide / glyburide
41286791|NCT01666522|DRUG|Vitamin D|vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
40946724|NCT02951338|OTHER|Group aerobic exercise|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
41286792|NCT01666522|OTHER|Physical activity|Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
41286793|NCT04332419|DEVICE|PET/CT|Standard Imaging
41452729|NCT06179953|OTHER|NAO intervention|"The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The robot provides instructions and if the child requests it, it elects prompts."
40946725|NCT02474381|BIOLOGICAL|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
40946726|NCT02474381|DEVICE|Single PTA|Angioplasty of arteries below tibial plateau level only
40946727|NCT05446636|DEVICE|Huawei bracelet|Huawei bracelet was used to continuously record maternal respiration, heart rate, temperature and sleep data, and then calculate maternal circadian rhythm state
40946728|NCT03509467|BEHAVIORAL|Personalized Information|Personalized information about ways that participants can protect themselves and their child from developing melanoma.
40946729|NCT03509467|BEHAVIORAL|Standard Information|Standard information about ways that participants can protect themselves and their child from developing melanoma.
40946730|NCT03509467|OTHER|DNA Extraction Determination of MC1R Genotypes|After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
40946731|NCT01863420|RADIATION|Bone Marrow-sparing Intensity-Modulated Radiotherapy|Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
40946732|NCT05938530|DEVICE|Sirolimus drug-coated balloon|The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.
40946733|NCT05938530|DEVICE|Stent graft|Stent graft has been shown to be superior than plain balloon angioplasty in the treatment of AVG dysfunction.
40946734|NCT03998878|BEHAVIORAL|Low-Carbohydrate Diet|Participants will be instructed to follow a low-carbohydrate diet.
40946735|NCT03998878|BEHAVIORAL|Intermittent Energy Restriction|Participants will be instructed to follow intermittent energy restriction.
40946736|NCT03998878|BEHAVIORAL|Hunger Training|Participants will be instructed to follow Hunger Training.
40946737|NCT00071396|DRUG|Campath-1H|15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
41286794|NCT04332419|DEVICE|PET/MR|Additional Imaging
41286795|NCT04332419|RADIATION|SIRT with Y-90|SIRT with Y-90 for palliative treatment of the liver malignancy.
41286796|NCT04522102|DRUG|Start antiplatelet monotherapy|Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation
41286797|NCT04509089|DEVICE|Suremedix Device|Performing measurements using the Suremedix Device by applying gradually ascending air pressure to the subject lungs through a mouse piece while measuring respiratory chest motion, PPG and ECG.
41286798|NCT04756895|OTHER|Vancomycin dose adjustment using the Bayesian method|This intervention is the experimental method. The AUC/MIC target is 400-600 mg\*hour/L.
41286799|NCT04756895|OTHER|Vancomycin dose adjustment using the trough level method|This intervention is the standard method. Previous clinical guidelines recommended this method. The trough target is 10-15 mg/L for non-severe infections and 15-20 mg/L for severe infections.
41286800|NCT01782599|OTHER|Dual nicotine patch and electronic cigarette|
40946738|NCT00071396|DRUG|Rituximab|375 mg/m\^2 IV infusion on day 1, then 500 mg/m\^2 on days 8, 15, and 22.
40946739|NCT04036734|DIAGNOSTIC_TEST|Longitudinal|Longitudinal orientation of ultrasound to long axis of vein to guide access needle
40946740|NCT04036734|DIAGNOSTIC_TEST|Transverse|Transverse orientation of ultrasound to long axis of vein to guide access needle
40946741|NCT06255184|BEHAVIORAL|Sernity intervention|Serenity Therapy is a holistic intervention that boosts psychological well-being and emotional balance through relaxation techniques, mindfulness, and guided imagery
40946742|NCT05731323|DRUG|D-cycloserine|Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).
41286801|NCT00298662|DRUG|Interferon beta-1b and Tacrolimus|
41286802|NCT05629962|DRUG|Bemnifosbuvir (BEM)|BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
41286803|NCT05629962|DRUG|Placebo|Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
41286804|NCT04804852|OTHER|sarcopenia assessment|evaluation of sarcopenia by CT san at the C3 vertebrae
40946743|NCT05731323|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
40946744|NCT02144129|OTHER|active Whole Body Electromyostimulation|
41286805|NCT03831503|BIOLOGICAL|INO-A002|Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
41286806|NCT03831503|DEVICE|CELLECTRA® 2000|Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
40946745|NCT02144129|OTHER|Passive WB-EMS|
41286807|NCT03831503|DEVICE|Dengue Fever Antibodies (IgG)|To determine if the subject is Dengue seronegative at baseline
41286808|NCT04048239|PROCEDURE|cochlear implantation|cochlear implantation is a system developed to restore hearing in people with profound sensorineural hearing loss, whose classical hearing aids are ineffective. Surgery is necessary to insert the internal part into the cochlea and requires milling the mastoid to access the round window. This approach is technically difficult, and is performed under a microscope by an experienced surgeon.
41286809|NCT04048239|OTHER|computerized tomography (CT) scan|computerized tomography (CT) scan of the facial nerve
41286810|NCT04048239|OTHER|electromyograph|electromyographic verification of the facial nerve
41286811|NCT06330753|OTHER|Trauma-informed Care Plan-|Per our IRB protocol patient participates will be consented for this study. A member of the healthcare team ( licensed nurse, social worker or doctor) will conduct the TICP with the patient. The TICP will be placed in the electronic medical record right below the patients name. The workflow is such is that if any plan of care placed on the Storyboard (under the patient's name) should be read first before engaging with a patient.
40946746|NCT02144129|DEVICE|WB-EMS application|
40946747|NCT06025305|DIAGNOSTIC_TEST|Intravascular imaging test|Coronary artery disease patients first underwent CCTA and then intravascular imaging test within 3 months
40946748|NCT06247800|DEVICE|Virtual Reality Device|A virtual reality headset is a heads-up display that allows users to interact with simulated environment.
40946749|NCT06247800|OTHER|Without virtual reality|Patients undergoing intercostal chest drain without the use VR device
40946750|NCT04510376|DEVICE|Test Article|Omeza Collagen Matrix
40946751|NCT04510376|OTHER|Positive Control|1.0 mg/mL Histamine Base
40946752|NCT04510376|OTHER|Negative Control|Aqueous Negative Control
40946753|NCT04680156|DRUG|Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies|No treatment to be administered - Observational only
41286812|NCT00379483|DRUG|Deferasirox|
40757765|NCT03684785|DRUG|Cavrotolimod|Intratumorally dosed cavrotolimod.
40946754|NCT05338359|BIOLOGICAL|Blood sample|Blood sample of 34 mL
40946755|NCT05338359|OTHER|Phone-call|Phone-call to the participant 15 days after recruitment to fix the final diagnosis
40946756|NCT04292769|DRUG|Decitabine|Decitabine 10mg / d, intravenous administration d-5 ～ d-1
40946757|NCT04292769|BIOLOGICAL|DC-CIK|Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
40946758|NCT03414281|PROCEDURE|TMQLB group 1|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
41286813|NCT00729430|DRUG|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
41286814|NCT00729430|DRUG|Placebo|Placebo tablets taken orally once per day for 6 months
41440989|NCT05631587|BEHAVIORAL|WExercise|A 10-weekly technology-based intervention delivered in a mobile application using the M-PAC framework to promote PA in post-treatment cancer survivors. Participants will be given individualised access to the app. Participants will be sent reminders (3 days apart) by WhatsApp/WeChat each time they have a class due.
41440990|NCT05631587|BEHAVIORAL|Control|A control group receiving an information sheet for self-directed exercise.
41440991|NCT01532635|RADIATION|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
40946759|NCT03414281|PROCEDURE|TMQLB group 2|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
40946760|NCT03414281|PROCEDURE|TPVB|"The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe of Philips CX50 is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the paravertebral space of T10.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
40946761|NCT02372370|PROCEDURE|Microneedle pretreatment + MAL-PDT|Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
40946762|NCT02372370|PROCEDURE|Sandpaper pretreatment + MAL-PDT|Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
40946763|NCT02372370|PROCEDURE|Curettage pretreatment + MAL-PDT|Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
40946764|NCT02372370|PROCEDURE|Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT|Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
40946765|NCT02372370|PROCEDURE|Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT|Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
40946766|NCT02372370|DRUG|MAL Control.|Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
40946767|NCT02372370|OTHER|Untreated Control|Untreated control. No interventions.
40946768|NCT04558684|DRUG|Chemotherapy|CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
40946769|NCT04558684|DRUG|Immunotherapy|Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
40946770|NCT04558684|RADIATION|IMRT|Radiotherapy (5 Gy x 5 fractions)
40946771|NCT06392802|DEVICE|Rehabilitation treatment using Muvity|The users have the support of the telerehabilitation system Muvity
40946772|NCT04634838|DEVICE|MedCu Antibacterial Wound Dressings with Copper Oxide|Comparison between the efficacy of antibacterial wound dressings containing copper oxide microparticles to improve the wound healing of pressure sores and post-op wounds as compared to silver wound dressings
40946773|NCT03829774|DEVICE|Primary Relief v 2.0|The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
40946774|NCT03829774|DRUG|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
40946775|NCT01303861|DRUG|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
40946776|NCT01303861|DRUG|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
40946777|NCT01303861|DRUG|Nicotine patches|"Nicotine Replacement Therapy Groups:~1. For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~2. For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~1. For smokers with high baseline CO: 42 mg/24 h for 1 week~2. For smokers with low baseline CO: 21 mg/24 h for 1 week"
40946778|NCT01303861|DRUG|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
40946779|NCT05666622|OTHER|Only routine non-surgical periodontal treatment was applied to the patients.|The study included 70 systemically healthy individuals, as a test group of 35 patients with Stage 3, Grade A periodontitis and a control group of 35 individuals with no periodontal disease. Blood samples were taken for the examination of DNI, white blood cells (WBC), immature granulocytes (IG), procalcitonin, C-reactive protein (CRP), lymphocyte count and neutrophil count. For the patients with periodontitis, blood sample assays were repeated 3 months after non-surgical periodontal treatment
41440992|NCT01532635|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
40946780|NCT04197752|OTHER|Regional anesthesia/analgesia techniques|Neuroaxial or peripheral block anesthesia/analgesia technique that is appropriate for the patient's surgery
40946781|NCT02747654|GENETIC|genotype|Patients were randomly assigned to a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight) or model-based treatment group; INH dose determined based on developed model,
40946782|NCT02279238|PROCEDURE|cardiac rehabilitation|"It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest \[Washout time\] in between the two test.~6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.~3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.~The data of \[HR, SPO2, PSG RPE scale, Distance walked, BP\] the participants are collected before, during and after the completion of each lap \[according to American Thoracic Society \[ATS\] protocol\]."
40946783|NCT00997880|DRUG|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
40946784|NCT00997880|DRUG|Rosuvastatin calcium10mg|Rosuvastatin 10mg
40946785|NCT01865188|DRUG|LCZ696|Experimental monotherapy doses
40946786|NCT01865188|DRUG|Amlodipine|Active comparator monotherapy doses
40946787|NCT01865188|DRUG|LCZ696 and amlodipine combination|Experimental combination doses
40946788|NCT01865188|DRUG|Placebo|Placebo comparator dose
40946789|NCT02460107|BIOLOGICAL|Botulinum toxin type A|
40946790|NCT02460107|OTHER|Normal saline|Placebo
40946791|NCT06313827|BEHAVIORAL|Exercise plus Monitoring Group (TG-2)|Participants will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus a dossier on the use of monitoring equipment such as: pulse oximeter, thermometer, digital spirometer, Medical Research Council dyspnoea scale. If the patient detects an exacerbation (due to symptoms or monitoring of the equipment), they can contact a physiotherapist who can adjust the treatment.
40946792|NCT06313827|BEHAVIORAL|Exercise plus monitoring and follow-up group (TGF-3)|"Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus dossiers on the use of monitoring equipment ; plus telematic control of exacerbations (questionnaires and monitoring of the parameters of the aforementioned equipment). Depending on the follow-up, physiotherapy treatment will be adjusted.~The questionnaire includes tracking of the following parameters: cough, secretions (quantity, colour, viscosity), chest tightness, dyspnoea, exercise tolerance, tiredness and appetite).~The follow-up will consist of weekly filling the spreadsheet to which the physiotherapist will have access and who, by reviewing the parameters, will be able to adjust the treatment. The physiotherapist will systematically make videocalls to the participants and if the follow-up values require it, he/she will call every week."
40946793|NCT06313827|BEHAVIORAL|Exercise Group (CG-1)|Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene
40946794|NCT05965778|DEVICE|T2769|T2769: sodium hyaluronate, Trehalose, Naaga in a 12.5 mL ABAK® multi-dose bottle.
40946795|NCT05965778|DEVICE|Vismed® Multi|Hyaluronic acid
40946796|NCT05089955|BEHAVIORAL|Ambient Experience|MRI examination with Ambient Experience
40946797|NCT06357312|DEVICE|hip trochanteric nail|hip trochanteric nail with and without distal interlocking screw
40946798|NCT02906904|OTHER|Case Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
40946799|NCT02906904|OTHER|Control Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
40946800|NCT04835480|DRUG|OrsHSA|OsrHSA a recombinant HSA, which was expressed and purified from the plant Oryza sativa
40946801|NCT04835480|DRUG|HSA|Albutein® 20% (ALBUMIN HUMAN INFUSION 20% 50ML)
40946802|NCT04473846|DRUG|PK general anesthesia|Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).
40946803|NCT04473846|DRUG|PFK combination|Each patient received an initial dose of 0.05 ml/kg from the solution, then after waiting for 60 seconds, another 0.05 ml/kg were given. Maintenance was given as boluses of 0.025 ml/kg every three to five minutes.
40946804|NCT03438383|DEVICE|Bi-PAP|The Bi-PAP system combines inspiratory support-IPAP (inspiratory positive airway pressure) with expiratory support-EPAP (expiratory positive airway pressure) and has been used, with good results, in a number of different clinical conditions such as COPD, respiratory failure due to neuromuscular disease, cardiogenic pulmonary edema and immediately post-operatively with pro-phylactic purpose.
40946805|NCT03438383|DEVICE|Sham Bi-PAP|"Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of the conventional Bi-PAP system. By doing so, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O."
40946806|NCT00005602|DRUG|carboplatin|
40946807|NCT00005602|DRUG|cereport|
41440993|NCT01532635|DRUG|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
41440994|NCT01532635|DRUG|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
40946808|NCT00005602|RADIATION|radiation therapy|
40946809|NCT05296733|DRUG|BI 456906|BI 456906
40946810|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 40% of prior stable drip rate.
40946811|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 60% of prior stable drip rate.
40946812|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 80% of prior stable drip rate.
40946813|NCT00299351|DRUG|Depsipeptide|
40946814|NCT02496065|DRUG|BLZ-100|
40946815|NCT05591131|OTHER|genetic testing|Undergo genetic testing
40946816|NCT05591131|OTHER|Survey Administration|Complete survey
41440995|NCT01532635|DRUG|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
40946817|NCT05258643|OTHER|Blood analysis|Venipuncture and collection of serum and whole blood
40946818|NCT04045275|BEHAVIORAL|Calm|"Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice."
40946819|NCT03276988|DRUG|Period 1 GX-30, Period 2 THYROGEN®|Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
40946820|NCT03276988|DRUG|Period 1 THYROGEN®, Period 2 GX-30|Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
40946821|NCT04016233|DRUG|Tenofovir douche|660 mg TFV in 125 mL hypo-osmolar solution
40946822|NCT06503055|OTHER|Questionnaire|"A questionnaire targeting a convenience sample of medical field professionals including physicians with different specialties, pharmacists, medical students, nursing staff, and the general population in Gharbia governorate (about 1000 subjects).~The questionnaire will be written and digital in both Arabic and English versions. Moreover, an awareness campaign will be designed to educate the participants on appropriate antibiotic use principles."
40946823|NCT05885854|DRUG|XTR003|"Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~1. Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~2. In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes."
40946824|NCT01336296|DRUG|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
40946825|NCT02516254|DIETARY_SUPPLEMENT|fortified bread|50 g of fortified bread + placebo daily
40946826|NCT02516254|DIETARY_SUPPLEMENT|supplement|vitamin D supplement+ plain bread
40946827|NCT02516254|DIETARY_SUPPLEMENT|placebo|plain bread+placebo
40946828|NCT05046184|DRUG|Ketamine Hydrochloride|Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of ketamine (0.5 mg/kg). Ketamine will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
40946829|NCT05046184|DRUG|Midazolam injection|Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of midazolam (0.02 mg/kg). Midazolam will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
40946830|NCT02149719|OTHER|Desensitisation using boiled peanut|
40946831|NCT02149719|OTHER|Desensitisation using boiled peanut (deferred start)|
40946832|NCT02958501|DRUG|Colecalciferol|Drug
40946833|NCT04295473|PROCEDURE|Reduced port laparoscopic gastrectomy|The ports were reduced in the surgery of intervention arm.
40946834|NCT04569656|DRUG|hydrolyzed guar gum|treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
40946835|NCT03107663|DRUG|⁸⁹Zr-Df-IAB22M2C Infusion|A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
40946836|NCT04363177|BEHAVIORAL|Web-based psychosocial peer-to-peer support|"The evidence-based eHealth peer-to-peer psychosocial intervention Thinking Healthy, will be tested in this RCT. In line with the World Health Organization's mhGAP Intervention Guide (mhGAP-IG), Thinking Healthy is used to identify and manage perinatal mental health conditions (distress, symptoms of depression, and anxiety) in non-specialized psychosocial support setting."
40946837|NCT04864301|PROCEDURE|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
40946838|NCT01745965|DRUG|T-DM1|
40946839|NCT01745965|DRUG|Trastuzumab|
40946840|NCT05589272|OTHER|Active tDCS|cognitive training + active-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
40946841|NCT05589272|OTHER|Sham tDCS|cognitive training + sham-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
40946842|NCT05232981|PROCEDURE|Ligation of the bilateral internal iliac arteries|"opening the posterior peritoneum overlying the bifurcation of the common iliac arteries. Then careful dissection of the internal iliac artery is carried out on each side and the anterior division of the internal iliac artery is ligated 4 cm below the bifurcation of the common iliac on both sides by single ligation procedure using Vicryl 1.0 .~Re-checking of the femoral pulsation of both sides is performed. Then, the placenta is removed manually in a piecemeal manner, any remaining bleeding points from the placental site are then controlled by hemostatic sutures ."
41267341|NCT06166628|PROCEDURE|Geniculate artery embolization|Femoral arterial access will be obtained under ultrasound guidance. An angiographic catheter will then be advanced to the distal superficial femoral artery. Angiography will be performed to identify the appropriate genicular branches supplying the regions of hyperemia. A microcatheter (1.7-2.4-French) will then be advanced super-selectively into the genicular arteries and 100-300 um EmboSpheres (Merit Medical) will be injected under fluoroscopic guidance. Multiple geniculate arteries may be embolized until neovascularity is no longer seen and pathologic hyperemia is resolved. A repeat lower extremity angiogram will be performed to evaluate for success of embolization and to exclude complication. The catheter and sheath will then be removed, and hemostasis will be achieved using an AngioSeal (Terumo Vascular Interventions) vascular closure device.
40946843|NCT05232981|PROCEDURE|Shehat's technique|"The three-step technique (Shehata's technique) entailed 3 steps, the first step is double bilateral ligation of uterine arteries before placental separation. Uterine artery ligation is made at 2 levels. First will be done at the isthmus and second will be done 1 cm above the cesarean incision. Regarding timing of ligation , we will apply the uterine artery ligation before placental separation to minimize blood loss at the attempt of placental separation.~Placenta is separated manually either totally or in piecemeal. If manual separation failed, placenta is removed by scissors.~Application of quadruple sutures is done at the lower uterine segment to compress and secure the neovascularization in the bed of placenta.~Insertion of triple way catheter is commenced from inside the uterine incision downwards using long artery forceps or uterine sound and the pulled by the assistant from below. The catheter balloon is inflated by 50 cc saline and left for 48 hours"
40946844|NCT02528175|DEVICE|Magnetic resonance-guided focused ultrasound|Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.
40946845|NCT02528175|RADIATION|Standard Radiation|30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).
40946846|NCT02528175|DRUG|Chemotherapy|3.5 weeks concurrent with radiation therapy (institutional standard).
40946847|NCT03428607|DRUG|AZD6738|AZD6738 160mg QD
40946848|NCT03428607|DRUG|Olaparib|Olaparib 300mg BID
40946849|NCT04761822|BIOLOGICAL|Moderna COVID-19 Vaccine|Intramuscular injection
40946850|NCT04761822|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine|Intramuscular injection
40946851|NCT04761822|BIOLOGICAL|Placebo|Intramuscular injection
40946852|NCT05076071|GENETIC|NGS|Next Generation Sequencing
40946853|NCT03802812|DEVICE|Thin bronchoscope and VBN|targeted washing at more adjacent TB lesion using thin bronchoscope and virtual bronchoscopic navigation system
40946854|NCT03920787|DIETARY_SUPPLEMENT|Inofolic Combi|Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg. 2 capsules every day for 1 month.
40946855|NCT03920787|OTHER|Placebo|2 capsules every day for 1 month
40946856|NCT05986760|BEHAVIORAL|SPARK|Functional Motor training
40946857|NCT02373878|BEHAVIORAL|Telecoaching plus Plate|A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
40946858|NCT02373878|BEHAVIORAL|Usual Care|Subjects were provided with institutional pamphlets on healthy eating and exercise habits
40946859|NCT02642302|BEHAVIORAL|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
40946860|NCT02642302|BEHAVIORAL|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
40946861|NCT02642302|BEHAVIORAL|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
40946862|NCT05032248|DRUG|Tacrolimus ointment|oral gel
40946863|NCT01428362|DRUG|VI-1121|
40946864|NCT01428362|DRUG|Placebo|
40946865|NCT03310710|DEVICE|Viabahn BX stent|Viabahn BX stent graft used as the branch device with a fenestrated EVAR graft
40946866|NCT01074372|DRUG|REGN727|4 cohorts (dose 1, 2, 3, 4)
40946867|NCT01074372|DRUG|Placebo|4 cohorts (dose 1, 2, 3, 4)
40946868|NCT05261282|BEHAVIORAL|Mindful Hand Hygiene|Physicians and nurses randomized to the intervention arm will receive mindfulness education and tools to prompt mindfulness during hand hygiene.
40946869|NCT06418750|OTHER|dermo-cosmetic product|For patients in the preventive group, treatment with hand serum, gloves/slippers and fortifying solution/dissolving oil will be started on the day of the first administration of Ac bispecific. In the curative group, treatment will begin on inclusion in the study and will be adapted to the lesions present on D0. Treatment will be readjusted on a weekly basis according to the lesions present at the time of the follow-up visit.
40946870|NCT03102112|OTHER|MRI examination|A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
40757766|NCT03684785|BIOLOGICAL|Pembrolizumab|Pembrolizumab dosing as per the US prescribing information.
40946871|NCT03605212|DRUG|Febuxostat|Intervention is orally administered to patients in this arm.
40946872|NCT01914731|DRUG|Fecal Microbiota Transplant|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule"
40946873|NCT02103218|BEHAVIORAL|Education, activities, empowerment, racial pride building|Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
40946874|NCT02103218|BEHAVIORAL|General Health education, activities|Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
40946875|NCT00006223|BIOLOGICAL|recombinant flt3 ligand|
41267342|NCT06166628|PROCEDURE|Genicular nerve phenol nerve ablation|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 2 cc of 6% phenol will be injected at each location with an end target of fascial expansion under the relevant fascial plane.
41267343|NCT06166628|PROCEDURE|Skin infiltration of 2cc of 0.25% bupivacaine at the knee|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis will be identified. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 1.5 cc of sterile saline will then be injected at each location.
41267344|NCT04120155|PROCEDURE|Dissection of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the dissection group, we will dissect the inferior pulmonary ligament during the surgery.
40946876|NCT04798495|OTHER|Multimodal interdisciplinary rehabilitation programme (HAPPY)|A 6-month multimodal interdisciplinary rehabilitation programme abbreviated HAPPY was tested. The programme consisted of motivating interviewing technique, individual dialogues with fixed subjects, individual supervised physical exercise training, relaxation exercises, nutritional counselling, and group sessions (a combination of topics and exchange of experiences) with patients and relatives. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and a digital physical exercise programme.
40946877|NCT02322021|DRUG|E2609|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
40946878|NCT02322021|DRUG|Placebo|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
40946879|NCT01464944|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
40946880|NCT01464944|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
40946881|NCT01464944|DRUG|Paracetamol|Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
40946882|NCT01464944|DRUG|Paracetamol|Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
40946883|NCT01464944|DRUG|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
40946884|NCT01596387|DRUG|Propofol|General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
40946885|NCT02148107|DRUG|BI 691751|BI 691751 Dose 1
40946886|NCT02148107|DRUG|BI 691751|BI 691751 Dose 2
41286815|NCT03968146|PROCEDURE|Erector Spinae Plane Block|The linear multi-frequency 6-13 megahertz transducer will be used. In the prone position,under aseptic conditions, the probe will be placed in a longitudinal position 2-3 cm lateral to the vertebral column. The transverse processes of the vertebrae at (mid) level of surgery, the Erector Spinae muscle and the psoas muscle are identified. A 22 gauge echogenic needle will be inserted in an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, A test dose of 5% dextrose in water can expand the fascial plane and confirm needle-tip location prior to injection of local anaesthetic. Then, 0.5 ml/kg of bupivacaine 0.25% with 0.1 mg/kg dexamethasone and adrenaline 1 : 200000 will be injected between erector spinea muscle and transverse process, taking in consideration not exceeding the toxic dose of bupivacaine; 4 mg/kg . the same procedure will be repeated on the contralateral side.
41286816|NCT03968146|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
40757767|NCT03684785|BIOLOGICAL|Cemiplimab|Cemiplimab dosing as per the US prescribing information.
40946887|NCT02148107|DRUG|BI 691751|BI 691751 Dose 3
40946888|NCT02148107|DRUG|BI 691751|BI 691751 Dose 4
40946889|NCT02148107|DRUG|BI 691751|BI 691751 Dose 5
40946890|NCT02148107|DRUG|BI 691751|BI 691751 Dose 6
40946891|NCT02148107|DRUG|Placebo|Placebo
41286817|NCT03968146|DRUG|additional Fentanyl|patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
41286818|NCT03968146|DRUG|Morphine|After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
40946892|NCT03516812|OTHER|Laboratory Biomarker Analysis|Correlative studies
40946893|NCT03516812|DRUG|Olaparib|Given PO
40946894|NCT03516812|OTHER|Quality-of-Life Assessment|Ancillary studies
40946895|NCT03516812|OTHER|Survey Administration|Ancillary studies
40946896|NCT03516812|DRUG|Testosterone Enanthate|Given IM
40946897|NCT03516812|DRUG|Testosterone Cypionate|Given IM
40946898|NCT04821856|DRUG|Cannabidiol Oil|Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma
40946899|NCT04821856|DRUG|Placebo|MCT oil and flavoring solution, also manufactured by THC Pharma
40946900|NCT04263831|DRUG|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
40946901|NCT00147251|DRUG|FDA approved drugs to treat blood pressure and cholesterol|
40946902|NCT01501370|DRUG|Vorinostat|Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
40946903|NCT01501370|DRUG|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
40946904|NCT01501370|DRUG|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
40946905|NCT01501370|DRUG|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
40946906|NCT01501370|DRUG|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
40946907|NCT03894046|DRUG|Sulbactam|1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).
40946908|NCT03894046|DRUG|Durlobactam|"1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h).~Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated."
40946909|NCT03894046|DRUG|Colistin|Treatment for 7 days up to 14 days if clinically indicated.
40946910|NCT03894046|DRUG|Imipenem/Cilastatin 500 mg/500 mg|1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
40946911|NCT03724786|DIAGNOSTIC_TEST|Six-hour urine protein collection|This intervention includes the analysis of a 6-hour urine collection for protein, to serve for a calculated 24-hour result, according to which pregnancy will be managed.
40946912|NCT00573248|DRUG|Nicotine|"21 mg nicotine patches for smokers for 2 days~7 mg nicotine patches for nonsmokers for 2 days"
40946913|NCT00573248|OTHER|Placebo|Placebo Patch
40946914|NCT03699683|OTHER|Combined aerobic and resistance training program|
40946915|NCT04226560|DEVICE|41% Silicone Hydrogel Soft Contact Lenses(SHSCL)|Silicone Hydrogel
40946916|NCT04226560|DEVICE|ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens|Senofilcon C (USFDA Device License #K160212)
40946917|NCT04226560|OTHER|Contact Lens Care Product|Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
40946918|NCT04226560|OTHER|Contact Lens Case|"Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)"
40946919|NCT00004756|PROCEDURE|Tailored educational program|
40946920|NCT00004756|PROCEDURE|Educational materials|
40946921|NCT05423054|OTHER|Abdominal massage|"* Patients will be positioned on their back while their knees will be flexed.~* Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~* The PR will be standed on the right side of the patient during the massage practice.~* The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
40946922|NCT02540616|DEVICE|Transcranial Electrical Stimulation|A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.
41286819|NCT03968146|DRUG|rescue Morphine|Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
40946923|NCT03252119|DEVICE|High flow humidified oxygen therapy|application of high flow humidified oxygen therapy at 2l/kg/min
40946924|NCT03659955|OTHER|Autologous blood applied to dry eye|See previous description for the study arm.
40946925|NCT02155881|DRUG|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
40946926|NCT02155881|DRUG|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
40946927|NCT01601132|DRUG|theophylline|300mg (80mg/15ml elixir)
40946928|NCT01601132|DRUG|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
40946929|NCT00982124|DRUG|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
40946930|NCT03852004|OTHER|ostheopathy|standardized osteopathic treatment
40946931|NCT03852004|OTHER|simulated osteopathic treatment|standardized simulated osteopathic treatment
41286820|NCT03968146|DRUG|pethidine|After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
41286821|NCT03968146|DRUG|Ketorolac|patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
41286822|NCT03968146|DRUG|Acetaminophen|patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
40946932|NCT02919371|DRUG|Sunitinib|Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
40946933|NCT02919371|DRUG|Bevacizumab|Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
40946934|NCT01397201|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
40946935|NCT01397201|DRUG|BI 54903|BI 54903
40946936|NCT01397201|DRUG|Fluticasone propionate|Fluticasone propionate
40946937|NCT04875962|DRUG|UCB0599|Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
40946938|NCT04875962|DRUG|Placebo|Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
40946939|NCT05906979|OTHER|PAHOLA (digital health assistant)|Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.
40946940|NCT05906979|OTHER|Standard information on alcohol use and health|A brochure on alcohol use and health as produced by the Pan American Health Organization will be provided to participants.
40946941|NCT04747639|OTHER|500 ml glucose-depleted apple juice|
40946942|NCT04747639|OTHER|500 ml conventional apple juice|
40946943|NCT04747639|OTHER|250 ml glucose-depleted apple juice|
40946944|NCT04747639|OTHER|250 ml conventional apple juice|
40946945|NCT02706054|OTHER|saline|The patients received an IM injection of saline near the nerve root (periradicular)
40946946|NCT02706054|DRUG|Meloxicam|The patients received an IM injection of meloxicam near the nerve root (periradicular)
40946947|NCT03180593|DRUG|Valsartan 80 mg|Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
41286823|NCT05117801|DEVICE|Petale|The child sits on the companion's lap between the two enclosures, and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.
41286824|NCT02708511|DIAGNOSTIC_TEST|Computed Tomography|Undergo PET/CT
41286825|NCT02708511|DRUG|Copper Cu 64-DOTA B-Fab|Given IV
41286826|NCT02708511|OTHER|Laboratory Biomarker Analysis|Correlative studies
40946948|NCT01440452|DEVICE|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
40946949|NCT01440452|DEVICE|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
40946950|NCT01440452|PROCEDURE|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
40946951|NCT01440452|BEHAVIORAL|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
40946952|NCT03461263|OTHER|phonophoresis treatment using pumpkin seeds oil|phonophoresis treatment using pumpkin seeds oil
40946953|NCT00484627|PROCEDURE|Use of creatine monohydrate (a dietary supplement)|
40946954|NCT00484627|BEHAVIORAL|Progressive resistance exercise training|
40946955|NCT06557109|OTHER|Popular Music|A funky D mix version of a popular Turkish song
40946956|NCT04108442|BEHAVIORAL|Traditional|Surgeons (rather than individual subjects) will be randomized to traditional Postoperative follow-up modality groups. They will adhere to this form of postoperative follow-up for all of their surgical patients (subjects) for one month.
40946957|NCT04108442|BEHAVIORAL|Virtual|Surgeons (rather than individual subjects) will be randomized to virtual postoperative follow-up modality group. They will adhere to that form of postoperative follow-up for all of their surgical patients (subjects) for one month.
40946958|NCT00884533|DRUG|Rosi XR|Rosi XR
40946959|NCT00884533|OTHER|Placebo|Placebo
40946960|NCT00884533|DRUG|Moxifloxacin|400mg single dose
40946961|NCT04533633|PROCEDURE|Retrograde Percutaneous Coronary Intervention of Chronic Total Occlusion|Retrograde CTO-PCI using epicardial collateral connections
40946962|NCT04336358|OTHER|Telemedicine|Telemedicine consultation online
40946963|NCT04466176|DRUG|Test Product|2 inhalations of Test and Reference product in each study period
40946964|NCT04466176|DRUG|Reference Product|2 inhalations of Test and Reference product in each study period
40946965|NCT03959254|PROCEDURE|Physiotherapy post-surgical protocol for femoroacetabular impingement|"The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise."
40946966|NCT05623839|DRUG|LY3305677|Administered SC
40946967|NCT05623839|DRUG|Placebo|Administered SC
40946968|NCT05860335|DRUG|Cisplatin/Nedaplatin, albumin paclitaxel|During induction chemotherapy, triplelimab JS001 was administered before cisplatin/Nedaplatin and albumin paclitaxel. JS001 Intravenous infusion of cisplatin/Nedaplatin was administered 60 minutes after the end of infusion and beginning on day 1 of each cycle 40mg/m 2, D1, D2 albumin paclitaxel 230 mg/m 2; Chemotherapeutic drugs are administered in accordance with the drug label and local prodrome and other standard protocols for prophylactic use, every 3 Once a week (Q3W) for 2 cycles
40946969|NCT02060188|DRUG|Ipilimumab|Specified dose on specified days
41286827|NCT02708511|OTHER|Pharmacological Study|Correlative studies
40946970|NCT02060188|DRUG|Nivolumab|Specified dose on specified days
40946971|NCT02060188|DRUG|Cobimetinib|Specified dose on specified days
40946972|NCT02060188|DRUG|Daratumumab|Specified dose on specified days
40946973|NCT02060188|DRUG|BMS-986016|Specified dose on specified days
40946974|NCT01323946|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
40946975|NCT01303328|DRUG|C1|Local application of the experimental gel or placebo gel.
41286828|NCT02708511|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo PET/CT
40757768|NCT03684785|DRUG|Cavrotolimod|Subcutaneously dosed cavrotolimod
41286829|NCT04735029|DEVICE|Thermal gun|"Thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
41286830|NCT04735029|OTHER|Heat pack|A hydrocollator heat pack used to simulate traditional thermal therapy
41286831|NCT04562324|DRUG|SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics|Medications to relieve anxiety
40757769|NCT06004583|DIAGNOSTIC_TEST|Biochemical blood analysis|Serum CRP and albumin levels
40946976|NCT01724879|DRUG|Dasatinib|Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
40946977|NCT05586243|OTHER|No intervention|This is an observational study looking at brain chemicals related to oxidative stress and inflammation using magnetic resonance spectroscopy (MRS).
40946978|NCT03600298|OTHER|Simulation|Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.
40946979|NCT04190667|DIAGNOSTIC_TEST|Genomic testing|A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status.
40946980|NCT05096728|DRUG|Nifedipine XL|"Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~* Once daily Nifedipine XL 60mg Vs.~* Twice daily Nifedipine XL 30mg"
40946981|NCT00537238|DRUG|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
40946982|NCT00537238|DRUG|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
40946983|NCT02128932|DRUG|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
40946984|NCT02128932|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
40946985|NCT05679518|BEHAVIORAL|ConquerFear intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
40946986|NCT05679518|BEHAVIORAL|CALM intervention|CALM is a semi-structured, manualized, individual psychotherapy intervention designed for patients with advanced cancer. It includes 3-6 individual therapy sessions, with each approximately lasts 45-60 minutes, delivered over 3-6 months. The sessions cover 4 domains: 1) symptom management and communication with health care providers; 2) changes in self and relations with close others; 3) sense of meaning and purpose; and 4) the future and mortality. All modules will be addressed with each patient, but the sequencing and time devoted to each domain can be varied, based on the concerns that are most relevant to each patient.
40946987|NCT05679518|BEHAVIORAL|Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
40946988|NCT04446572|BIOLOGICAL|Lactobacillus salivarius CECT5713|Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
40946989|NCT01649050|DRUG|BGG492|
40946990|NCT01649050|DRUG|Placebo|
40946991|NCT01904539|DRUG|obeticholic acid 10 mg|Single dose OCA 10mg in each arm
40946992|NCT01841177|DRUG|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
40946993|NCT03150160|DRUG|brinzolamide 1%/brimonidine 0.2% fixed combination|One drop applied topically to the affected eye(s) in the morning and evening
40946994|NCT03150160|DRUG|Placebo|One drop applied topically to the affected eye(s) in the morning and evening
40946995|NCT03150160|DRUG|travoprost 0.004% ophthalmic solution|One drop applied topically to the affected eye(s) in the evening
40946996|NCT03985111|DEVICE|Central Venous Catheter|Insertion of a central venous catheter insertion pre-operatively (electively)
41286832|NCT04562324|DEVICE|Neurofeedback system|EEG-neurofeedback is an operant conditioning procedure in which people learn to improve the brain's functional activity and used as a way to effect long-term change in abnormal brain activity thus alter corresponding cognitive function. In addition, its potential to be used to elucidate the mechanisms underlying psychopathology by evaluating the subjective effect of the modulation of specific brain areas has become apparent. Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
40946997|NCT06263595|DEVICE|gastric antral sonography|Participant will undergo gastric antrum ultrasound and be scanned in the supine position followed by the right lateral decubitus position. Qualitative and quantitative assessments will be completed.
41440996|NCT01532635|BIOLOGICAL|Hematopoietic Stem Cell Transplant (HSCT)|"CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells."
41440997|NCT02832063|BIOLOGICAL|B244|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
40946998|NCT02395666|DRUG|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
40946999|NCT01347307|RADIATION|SBRT for Benign Extradural Spine Tumors|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
41440998|NCT02832063|BIOLOGICAL|Placebo|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
41440999|NCT03872596|DRUG|Seroquel IR 300mg|Administered during Part A, administered orally BID with water, over 5 days.
40947000|NCT01347307|RADIATION|SBRT for Vertebral/Paraspinal Metastases|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
40947001|NCT03511664|DRUG|177Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.
40947002|NCT03511664|OTHER|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator
40947003|NCT04242173|DRUG|Cemiplimab-Rwlc|Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
40947004|NCT02043275|OTHER|Leg training|Lower body resistance training twice per week for one hour each time.
40947005|NCT02043275|OTHER|Arm training|Upper body resistance training twice per week for one hour each time.
40947006|NCT03625934|BIOLOGICAL|VVX001|5 s.c. injections of 20 micrograms of VVX001 four weeks apart
40947007|NCT03625934|BIOLOGICAL|Placebo|5 s.c. injections of matching Placebo four weeks apart
40947008|NCT05427006|DEVICE|Z5-BL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
40947009|NCT05427006|DEVICE|Z5-TL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
40947010|NCT03416907|BEHAVIORAL|Original consent form|Participants will review the full-length, original consent form for the clinical trial.
40947011|NCT03416907|BEHAVIORAL|Shortened consent form|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
40947012|NCT03416907|BEHAVIORAL|Reordered, shortened consent form|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
40947013|NCT03416907|BEHAVIORAL|Shortened consent form with a highlights box|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
40947014|NCT03416907|BEHAVIORAL|Interactive, shortened consent form|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
41267345|NCT04120155|PROCEDURE|Preservation of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the preservation group, we will preserve the inferior pulmonay ligament during the surgery.
40947015|NCT03072732|DEVICE|u-Cor System|Monitoring System
40947016|NCT03072732|DEVICE|ZOE Fluid Status Monitor|Monitoring System
40947017|NCT03171051|DEVICE|950 nm LED Device|Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.
40947018|NCT03171051|DEVICE|1050nm Diode Laser Device|FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
40947019|NCT01562158|PROCEDURE|standard therapy|Standard treatment of bleeding
40947020|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
40947021|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
40947022|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
40947023|NCT01562158|DRUG|placebo|Placebo
40947024|NCT00046748|DRUG|Omalizumab|
40947025|NCT02755298|DRUG|Acetazolamide|
40947026|NCT02755298|DRUG|Placebo|
40947027|NCT01464996|PROCEDURE|Adhesive: OptiBond XTR; Composite: Herculite Ultra|The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.
40947028|NCT01464996|PROCEDURE|Adhesive: OptiBond FL; Composite: Herculite Ultra|Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
40947029|NCT03126903|DEVICE|KeraKlear Non-Penetrating Keratoprosthesis|The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
40947030|NCT04205253|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.
40947031|NCT05781373|PROCEDURE|Peep individualization|Intraoperative Peep individualization in order to achieve the lowest driving pressure
40947032|NCT06449898|OTHER|hemodialysis group|Data were collected from patients undergoing treatment at a hemodialysis center in Kırşehir. Participants were informed about the study objectives and provided written consent. Data collection took approximately 20-30 minutes per participant and included a face-to-face interview where socio-demographic and clinical information was recorded.
41267346|NCT03258892|OTHER|Educational Intervention|Receive STG
41267347|NCT03258892|OTHER|Quality-of-Life Assessment|Ancillary studies
41267348|NCT03258892|OTHER|Survey Administration|Ancillary studies
41267349|NCT01054079|OTHER|laboratory biomarker analysis|Correlative study
41267350|NCT01054079|PROCEDURE|quality-of-life assessment|Ancillary study
41267351|NCT01054079|OTHER|questionnaire administration|Ancillary study
41267352|NCT01054079|DRUG|cinacalcet hydrochloride|Given PO
41267353|NCT00110942|DRUG|Systemic AMG 108|300 mg SC AMG 108 Q4W for 3 doses
41267354|NCT00110942|OTHER|Placebo|SC placebo injection Q4W for 3 doses
41267355|NCT03926676|OTHER|grandio blocks|nano hybrid composite blocks
41267356|NCT03926676|OTHER|emax|ceramic blocks
41267357|NCT03595540|OTHER|Prolon|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
40947033|NCT01595633|DRUG|Switching from adefovir (10mg/day) to tenofovir (300mg/day)|active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
40947034|NCT05424523|DRUG|Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
40947035|NCT06379087|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.
40947036|NCT06379087|DRUG|Tislelizumab Injection|Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody.
40947037|NCT06379087|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy Extent of radiotherapy: Primary lesion in the lung. Radiotherapy technique: IGRT. Radiotherapy delivery equipment: linear accelerator or TOMO accelerator or CyberKnife.
40947038|NCT03234673|DRUG|Tacrolimus ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.
40947039|NCT03234673|DRUG|calcipotriol ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.
40947040|NCT03234673|DRUG|NB-UVB|3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
41452730|NCT06179953|OTHER|Traditional intervention|"The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The therapist provides instructions, and if the child has difficulty responding, he or she may ask the operator for prompts."
40947041|NCT00449410|DRUG|Atorvastatin|
40947042|NCT00449410|DRUG|ezetimibe|
40947043|NCT04595331|DEVICE|Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection|Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles
40947044|NCT04857970|OTHER|Electronic HRQoL questionnaires with feedback to physicians|Use of the CHES software for HRQoL collection and graphical display of the patients' HRQoL scores to physicians
40947045|NCT04857970|OTHER|Paper-pencil HRQoL questionnaires w.o. feedback to physicians|Use of paper-pencil HRQoL questionnaires, the results of which are not presented to physicians
41267358|NCT03860948|DRUG|Savolitinib Test Preparation|Test preparation (T): dry granulation savolitinib tablets.
41267359|NCT03860948|DRUG|Savolitinib Reference Preparation|Reference preparation (R): wet granulation savolitinib tablets.
41452731|NCT04471116|DIETARY_SUPPLEMENT|OMNi-BiOTiC® FLORA plus+|OMNi-BiOTiC® FLORA plus + is a dietary supplement for the treatment of a disturbed vaginal flora (dysbiosis). The product combines probiotic bacterial strains with a special fiber mixture. The product contains the following strains: Lactobacillus crispatus LBV88, Lactobacillus rhamnosus LBV96, Lactobacillus gasseri LBV150N and Lactobacillus jensenii LBV116
41441000|NCT03872596|DRUG|Seroquel IR 25mg|Administered during Part B, as a single, 25mg dose taken with water.
41441001|NCT03872596|DRUG|Quetiapine Formulation A 300mg|Administered during Part A, administered orally BID with water, over 5 days.
41441002|NCT03872596|DRUG|Quetiapine Formulation B 300mg|Administered during Part A, administered orally BID with water, over 5 days.
41441003|NCT03872596|DRUG|Quetiapine Formulation 25mg|Administered during Part B, as a single, 25mg dose taken with water.
41441004|NCT01815320|PROCEDURE|Contrast-enhanced ultrasound (CE-US)|
41441005|NCT01815320|DEVICE|SonoVue|
41441006|NCT05865769|OTHER|Balance|measuring pulmonary and vestibular functions in all subjects
41452732|NCT00174421|DRUG|Treatment with Genotropin in different dosages|
41452733|NCT04968925|DEVICE|ACUVUE Oasys 1-Day|TEST
40947046|NCT02641132|DRUG|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
40947047|NCT02641132|PROCEDURE|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
41267360|NCT03089307|DEVICE|Dornier Aries- ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
41267361|NCT01795547|DRUG|Aripiprazole and aripiprazole once-monthly|Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
41267362|NCT01795547|DRUG|Paliperidone and paliperidone palmitate|Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
41267363|NCT03665363|OTHER|SCOPE|SCOPE is a internet-delivered, coach-guided, psychoeducational intervention, intended to serve as a first-line intervention for intellectually able adolescents and young adults with ASD. The SCOPE program is based on information comprising neuropsychology, pedagogy, and also interdisciplinary clinical experience regarding ASD. The content is aimed at providing information about typical and specific impairments of ASD, as well as the associated strengths.
41267364|NCT03665363|OTHER|Self-study|Active control consisting of directed self-studies on internet.
41267365|NCT00189644|PROCEDURE|6 FEC 100|
41267366|NCT00189644|PROCEDURE|4 FEC 100 followed by 4 Taxol|
41267367|NCT04258579|BEHAVIORAL|PROTECT with Technology Augmentation|PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.
41267368|NCT01505894|DRUG|BI 409306|Film-coated tablet
41267369|NCT01505894|DRUG|Placebo|Film-coated tablet
41267370|NCT06549751|BIOLOGICAL|MT-601|Cellular Therapy
41267371|NCT03135405|BEHAVIORAL|Automated messages|Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.
41267372|NCT03135405|BEHAVIORAL|Home BP monitors|Participants will have the option of receiving home blood pressure monitors.
41267373|NCT03135405|BEHAVIORAL|Care partner reminders|Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
41267374|NCT00004029|BIOLOGICAL|recombinant viral vaccine therapy|
41267375|NCT00004029|BIOLOGICAL|sargramostim|
41267376|NCT02867007|DRUG|KHK2455|oral dosing
41267377|NCT02867007|DRUG|Mogamulizumab|i.v. administration
41267378|NCT01075347|OTHER|autologous serum|with postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
41267379|NCT01075347|OTHER|Non-autologous serum|without postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
41267380|NCT05055232|DRUG|XZP-3621|tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.
41267381|NCT00206921|DEVICE|Pulsed dye laser|
41267382|NCT00206921|DEVICE|Intense pulsed light|
40947048|NCT00928395|DEVICE|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
40947049|NCT02642029|DEVICE|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
40947050|NCT02642029|DEVICE|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
40947051|NCT02642029|DEVICE|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
40947052|NCT00506337|DRUG|Qingyi granules|"Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD."
40947053|NCT03575897|DIAGNOSTIC_TEST|Assessment of infant body composition|Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
40947054|NCT03835104|DEVICE|CRP point-of-care testing|CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
40947055|NCT05137704|OTHER|No intervention|This is a non-interventional study.
40947056|NCT03645928|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with Lifileucel followed by IL-2 administration. Lifileucel will be administered to patients once (on Day 0) during the study.
40947057|NCT03645928|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.
40947058|NCT03645928|DRUG|Pembrolizumab|"Humanized antibody.~Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years."
40947059|NCT03645928|BIOLOGICAL|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145-S1) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.
40947060|NCT03645928|DRUG|Ipilimumab|"Monoclonal antibody~Ipilimumab will be administered as a single dose prior to tumor resection."
40947061|NCT03645928|DRUG|Nivolumab|"Monoclonal antibody~Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks for up to 2 years."
40947062|NCT03272516|BEHAVIORAL|Mindfulness based cognitive therapy (MBCT)|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.
40947063|NCT03272516|OTHER|Treatment as usual (TAU)|Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
41286833|NCT05098288|BEHAVIORAL|Multicentre Pain Monitor + Unified Protocol|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMA. In terms of monitoring, the Multicentre Pain Monitor is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
40947064|NCT05191173|PROCEDURE|Cardiac Surgery|No intervention, just observation is performed.
40947065|NCT03939156|OTHER|Completion of questionnaires|Completion of questionnaires at the time of study entry
40947066|NCT02081131|PROCEDURE|Open surgery|pancreatic head resection by open method
40947067|NCT02081131|PROCEDURE|Laparoscopic surgery|laparoscopic pancreatoduodenectomy
41286834|NCT05065138|BEHAVIORAL|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
40947068|NCT02797015|DRUG|RPC1063|Oral capsule daily
40947069|NCT04820166|OTHER|monitoring portal pressure gradient or hepatic venous pressure gradient|measuring portal pressure gradient or hepatic venous pressure gradient regularly
41267383|NCT05977413|OTHER|Notification of CAC|Provider and patient are notified of coronary artery calcium present on patient's CT scan. Notification includes a personalized image of CAC from the patient's CT scan performed for lung cancer screening.
41452734|NCT04968925|DEVICE|Precision 1|CONTROL
41267384|NCT05977413|OTHER|Usual Care|Patients randomized to Usual Care will receive usual medical care provided by their clinician informed by widely publicized clinical practice guidelines.
41267385|NCT06545357|PROCEDURE|Acupuncture|To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture at biceps brachii muscle, supraspinatus muscle and deltoid muscles or acupoints on The Yang Ming Channel for 20 minutes, frequency ≤ 20 Hz, intensity from 2- 10mA
41441007|NCT00836758|DEVICE|Analysis with AED and manual PSG scoring|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
41452735|NCT05064917|DIAGNOSTIC_TEST|Blood draw|The burden for child/parents in this study is low as it is limited to a single blood draw, which is already necessary for usual diagnostic care in about 70% of the children
41452736|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 1)|Three doses will be administered intramuscularly, at Month 0, 2 and 6.
41452737|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 2)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
41267386|NCT04141176|DEVICE|Spiri+|CPAP Spiri+ will be weared during one night for each included patient.The validation of the CPAP Spiri+ algorithm will be in the first 10 patients and appreciation of overall clinical efficacy on the 10 last OSAS.
41267387|NCT04788082|DIAGNOSTIC_TEST|3D Printed Heart Model|Prior to surgical intervention, the surgeon will be exposed to clinically-indicated images and a patient-specific 3D printed model of the subject's heart anatomy.
41267388|NCT05086042|DIAGNOSTIC_TEST|Ultrasonography, Magnetic resonance imaging|The cross-sectional area of the median nerve was measured with US and MRI.
41267389|NCT06028633|DRUG|pembrolizumab|pembrolizumab 200mg IV on day 1 for every 3 weeks
41267390|NCT06028633|DRUG|lenvatinib|lenvatinib 8mg taken orally every day
41267391|NCT06028633|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks
41267392|NCT04991831|DEVICE|Unilateral thalamotomy|Unilateral thalamotomy using focused ultrasound for the treatment of medication-refractory tremor dominant idiopathic Parkinson's Disease.
41267393|NCT03841552|DEVICE|Augmented Feedback|An inertial measurement unit (IMU) system is the basis of the augmented feedback (AF) system, where the IMU-system communicates with a laptop using a bluetooth dongle. The corresponding software includes therapeutic games. Movements of the lower back and pelvis by the patient are used to control an avatars movement or the graphical interface in computer exercises. The AF-system provides real-time feedback regarding the patient's performance and helps to rectify incorrect execution of the exercises. The intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
41267394|NCT03841552|OTHER|Control Group|Conventional impairment-specific physiotherapy exercises for low back pain patients.The control intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
41267395|NCT04828863|BEHAVIORAL|Neurocognitive testing|Participants will undergo a battery of neurocognitive tests that examine intellectual, executive, and adaptive function. The tests will be given remotely via internet-based surveys.
41267396|NCT00746499|DRUG|Raltegravir|400mg raltegravir BID x 7 days
41267397|NCT03270215|PROCEDURE|Computed tomography|The diagnostic power to discriminate malignant from nonmalignant causes of e pleural effusion
41267398|NCT02769598|DEVICE|ANI Index for Hospitalized children|Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
41267399|NCT01098890|DRUG|Tissue Plasminogen Activator|2mg tPA will be given every twelve hours for a maximum of 5 doses
41267400|NCT01098890|DRUG|Placebo|Placebo will be administered every 12 hours for a maximum of 5 doses.
41267401|NCT02700178|OTHER|Biofeedback|The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
41267402|NCT01365156|PROCEDURE|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
41267403|NCT01365156|RADIATION|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
41267404|NCT06032221|DEVICE|Thermidas Vista Telehealth App|Thermal camera with telemedicine app
41267405|NCT05087615|DRUG|Metoclopramide|This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.
41267406|NCT05087615|DRUG|Ondansetron|This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.
41267407|NCT05087615|DRUG|Metoclopramide and Ondanteron|This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.
41286835|NCT00922545|OTHER|Implementation of Clinical Practice Guidelines (GPC) and Health Education Program|Intervention: The program includes giving clinical results to the health care workers(doctor and nurse), from the medical records and interview. A training course (20h)that deals with aspects related to GPC, motivational interview and health education (tobacco, inhalers, alimentation, exercise and physiotherapy).
40947070|NCT06339632|OTHER|Transcutaneous electrical phrenic nerve stimulation (TEPNS)|"The characteristics of the electrical current: biphasic waves, set at a stimulation frequency of 10 Hz, pulse width of 200 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. The application of TEPNS will initially be performed by defining the trajectory of the phrenic nerve in the cervical region. The negative pole (active point), a stick with a spherical tip for micro-current of 2 mm will be positioned with slight pressure in the region of the phrenic nerve pathway between the two heads of the sternocleidomastoid muscle. Additionally, at the positive pole (passive point), a self-adhesive electrode sized (2.0 x 2.0 cm) will be positioned on the skin in the shoulder region. The intensity, measured in milliamperes (mA), will be adjusted to the maximum tolerated by the patient. The total stimulation time will be 10 minutes, applied continuously in a single session."
40947071|NCT06339632|OTHER|Transcutaneous electrical diaphragm stimulation (TEDS)|The characteristics of the electrical current are: biphasic waves, set at a stimulation frequency of 30 Hz, pulse width of 400 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. Two self-adhesive electrodes sized (5.0 x 5.0 cm) will be used, positioned in the bilateral parasternal region next to the xiphoid process and the other electrode in the intercostal space between the 6th and 7th ribs bilaterally, at the mid-axillary line. The intensity, measured in milliamperes (mA), will be adjusted to the maximum intensity tolerated by the patient until diaphragmatic contraction is observed with the naked eye, without contraction of other muscles in the abdominal region. The total stimulation time will be 10 minutes, applied continuously in a single session.
40947072|NCT06253104|DIAGNOSTIC_TEST|BodyMetrix Body Composition Ultrasound|We will use a BodyMetrix Pro A-mode ultrasound device (BodyMetrix Pro, Intelametrix Inc., Livermore, CA) which is a lay imaging tool designed specifically to assess body composition. Images will be taken at two sites; the lateral thigh and bicep on the dominant side if able to identify, or else on the right side. On each visit, five images will be taken at each site (the lateral thigh and bicep). Participants will be measured 2-3 days from initiation in study, then 7 days after, and then weekly from the first measurement until time of advanced therapy, discharge, or death. This measurement sequence will then be repeated following advanced therapy up until discharge or death. Each measurement session will last about 20-30 minutes. This will be performed by the PI or members of the study team who have been trained by the research coordinator.
40947073|NCT05735353|BEHAVIORAL|High-Speed Circuit Resistance Training|three times per week; 45 minutes per session; 12-weeks
40947074|NCT05735353|BEHAVIORAL|High-Speed Multidirectional Yoga|two times per week; 60 minutes per session; 12-weeks
40947075|NCT04098848|OTHER|Cycling exercise|Intradialytic cycling exercise for 30 minutes a time
40947076|NCT06173934|DRUG|insulin injection 15 minutes before meals|Adjust insulin injection time to observe blood glucose spectrum
40947077|NCT06173934|DRUG|Insulin injection 15 minutes after eating|Adjust insulin injection time to observe blood glucose spectrum
40947078|NCT00546650|DRUG|Sumatriptan succinate|NP101 iontophoretic transdermal system
40947079|NCT00546650|DRUG|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
40947080|NCT01782911|DIETARY_SUPPLEMENT|Resveratrol|The patients will take 2 g of resveratrol per day for 40 days.
40947081|NCT01782911|DIETARY_SUPPLEMENT|Placebo pills|The patients will take placebo for 40 days.
40947082|NCT03866525|BIOLOGICAL|OH2 injection, with or without irinotecan or HX008|OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody
41267408|NCT05087615|DRUG|Granisetron|This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
41267409|NCT03038646|DRUG|MIN-101|
41286836|NCT01520922|BIOLOGICAL|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
41452738|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
41267410|NCT01463813|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
41286837|NCT01520922|DRUG|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
41286838|NCT03611140|DIETARY_SUPPLEMENT|DP|a package containing a mix of functional foods
41267411|NCT01463813|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 80 micrograms (3200 IU) per day
41267412|NCT01463813|DIETARY_SUPPLEMENT|Placebo|Inactive placebo
41286839|NCT03611140|DIETARY_SUPPLEMENT|Placebo|a package containing maltodextrins and caseinate calcium to mimic the DP
41286840|NCT02167477|DEVICE|Macintosh laryngoscopy|Tracheal intubation
41286841|NCT02167477|DEVICE|Storz C-MAC, standard blade|Tracheal intubation
41286842|NCT02167477|DEVICE|Storz C-MAC, D-BLADE|Tracheal intubation
40947083|NCT03213600|DEVICE|transcranial Direct Current Stimulation tDCS|75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
40947084|NCT05169268|DRUG|ARIPiprazole Injection [Abilify]|subject already receiving the combination of Abilify Maintena and Rexulti
40947085|NCT05169268|DRUG|Brexpiprazole|subject already receiving the combination of Abilify Maintena and Rexulti
40947086|NCT00987545|DRUG|QAX576|QAX576 injection
41286843|NCT02123329|BEHAVIORAL|Pharmacist delivered smoking cessation program|"The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.~To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.~• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems"
40947087|NCT00987545|DRUG|QAX576 placebo|Placebo to QAX576 injection
40947088|NCT05427162|DRUG|Prostacyclin Receptor Agonist|Prostacyclin receptor agonist will be administered.
41286844|NCT02123329|OTHER|Control arm (i.e: regular care)|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
41452739|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
41452740|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Three doses will be administered intramuscularly, at Month 0, 2 and 6
41452741|NCT01807026|DRUG|LY2886721|
40947089|NCT00136123|PROCEDURE|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
40947090|NCT02398656|DRUG|Tenecteplase|TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
40947091|NCT02398656|DRUG|Antiplatelet treatment|Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
40947092|NCT03848338|PROCEDURE|Electrocochleography|Electrocochleography measurement Intra-operatively and Post-operatively at follow-up appointments along with correlative measurements (Impedance, eCAP, PTA, Speech)
40947093|NCT00173888|DRUG|Docetaxel, Cisplatin|docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
40947094|NCT00173888|DRUG|Gemcitabine, Cisplatin|gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
41286845|NCT04150757|DRUG|Intranasal ketamine|Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
41286846|NCT01570491|OTHER|ultrasound-guided spinal anesthesia|ultrasound-guided technique for block placement
41286847|NCT01570491|OTHER|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
41452742|NCT01807026|DRUG|Placebo|
41452743|NCT03221049|DIAGNOSTIC_TEST|radiomics|
40947095|NCT02862899|DEVICE|Thermowire|
40947096|NCT04234997|DRUG|Suvorexant 20 mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
40947097|NCT04234997|DRUG|Suvorexant 0mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
40947098|NCT02228434|BEHAVIORAL|Monitoring and Tailored prescription|
40947099|NCT02228434|BEHAVIORAL|Happy 10 program|
40947100|NCT02228434|BEHAVIORAL|Specified nutrition education|
40947101|NCT02228434|BEHAVIORAL|General Health Education|
40947102|NCT04318327|BIOLOGICAL|PHE885|Infusion
41133062|NCT06270732|BEHAVIORAL|iMentalize Program (iMentalize)|"This is a 30-hour group training involving 30 sessions lasting 45 minutes and 7.5 hours of inter-sessions work.~Session 1: Program presentation; Session 2: Reflective Parenting; Session 3: Cartoon's session I (baseline); Session 3: What is Mentalization; Session 4: Fundamentals of Human Interaction; Session 5: Cartoon's session II (the beginnings); Session 6: Mentalization and Mental Health; Session 7: MISC context and cultural components; Session 8: Cartoon's session III (practice with MISC context comp.); Session 9: The importance of emotions in human interaction; Session 10: MISC emotional components; Session 11: Cartoon's session IV (practice with emotional comp.); Session 11: How mentalization is developed; Session 12: MISC cognitive components; Session 13: Cartoon's session V (practice with cognitive comp.); Session 14: How to foster children mentalization skills. Sessions 15 to 30: Cartoon's sessions using MISC components to foster children mentalization."
41267413|NCT05762926|OTHER|Transcranial pulse stimulation (TPS)|Clinical treatment consists in ten sessions of neuronavigation system guided halocranial application of 6000 focused sound wave pulses, with energy flux density of 0.25 mJ/mm2, depth of focus of 5 cm and useful energy between 4 to 6 cm, frequency of 4 Hz, total energy applied will be 50 Joules, for it will be used the Storz Neurolith™ equipment.
41267414|NCT00389025|DRUG|Olopatadine (generic name)|
41267415|NCT01555229|DEVICE|Intermittent subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
41267416|NCT01555229|DEVICE|Continuous subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
41267417|NCT02549716|DRUG|IV acetaminophen|Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
41267418|NCT02549716|DRUG|Oral acetaminophen|Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
41267419|NCT02549716|DRUG|Oral placebo|Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
41267420|NCT02549716|DRUG|IV placebo|Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
41267421|NCT00556426|DEVICE|Bard Recovery G2 Filter System|Retrieval of previously placed RECOVERY G2 IVC filter
41267422|NCT02435602|PROCEDURE|NBI endoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
41267423|NCT02435602|PROCEDURE|Lugol chromoendoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions \>= 5 mm diameter Pathologic examination of all biopsy tissue specimens
41452744|NCT05467163|DEVICE|Biventricular pacemaker implantation|Implantation of permanent pacemaker with biventricular stimulation with or without defibrillator lead placement using standard techniques. The right ventricle lead will be positioned in the RV apex or septum, while the left ventricle lead will be delivered to the most appropriate coronary sinus tributary, preferably posterolateral or lateral vein.
41133063|NCT06270732|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 30-hour individual training involving 30-weekly online, individual, self-administered 45' sessions (22.5h) + 7.5h of between sessions work (readings, supervision, video- recordings for later video-feedback, reﬂection exercises). BLOCK I: Session 1: Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC; Sessions 9-18 (MISC practice and video-feedback); Summer break: Recording daily life interactions; BLOCK II: Session 19: Recap; Sessions 20-30: guided reﬂection and video-feedback.
41267424|NCT00599417|DRUG|Bacterial Lysates|Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
41267425|NCT00599417|DRUG|placebo|placebo controlled
41267426|NCT05585749|OTHER|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
41267427|NCT00018954|DRUG|asparaginase|
41267428|NCT00018954|DRUG|cyclophosphamide|
41267429|NCT00018954|DRUG|cytarabine|
41267430|NCT00018954|DRUG|daunorubicin hydrochloride|
41267431|NCT00018954|DRUG|doxorubicin hydrochloride|
41267432|NCT00018954|DRUG|etoposide|
41267433|NCT00018954|DRUG|ifosfamide|
41267434|NCT00018954|DRUG|mercaptopurine|
41267435|NCT00018954|DRUG|methotrexate|
41267436|NCT00018954|DRUG|prednisone|
41267437|NCT00018954|DRUG|vincristine sulfate|
41267438|NCT00018954|PROCEDURE|conventional surgery|
41267439|NCT00018954|RADIATION|radiation therapy|
41267440|NCT02008825|DEVICE|Utilization of ViSiGi calibration tube|Utilization of ViSiGi calibration tube
41267441|NCT02008825|DEVICE|Usual non suction Bougie|Usual non suction Bougie
41267442|NCT04111614|DRUG|Tofacitinib tablet|Single dose of tofacitinib 5 mg tablet
41267443|NCT04111614|DRUG|Tofacitinib Oral Solution|Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
41267444|NCT01871792|DRUG|Pitavastatin|
41267445|NCT01871792|DRUG|Placebo|Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
41267446|NCT06158503|DEVICE|AID|Initiation of an automated insulin delivery system
41267447|NCT01256177|DRUG|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
41267448|NCT01256177|DRUG|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
41267449|NCT04922866|OTHER|no intervention|no intervention
41267450|NCT05480319|OTHER|EDICARS|The investigators propose to (1) Embed the EDICAS into our hospital information system (HIS) in real-time at ED triage to identify high-risk patients (EDICAS 6+); and (2) Distribute wearable smart wristbands to high-risk patients to augment vital signs monitoring and send alerts based on GBTM results. The detection and intervention components together form the rapid response system, the Emergency Department In-hospital Cardiac Arrest Response System (EDICARS).
41267451|NCT05480319|OTHER|Usual care|Usual care will be assigned to this arm. No additional interventions.
41267452|NCT02718859|BIOLOGICAL|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
41267453|NCT02718859|PROCEDURE|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
41267454|NCT06261411|DIAGNOSTIC_TEST|Lung Ultrasound|Diagnostic ultrasound of pulmonary tissues such as pleura, plural spaces, and parenchyma.
41267455|NCT04130802|DRUG|OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL|OCS-01 eye drops
41267456|NCT04130802|DRUG|Placebo|Vehicle eye drops
41267457|NCT03804671|DRUG|BI 730357|Oral dose
41267458|NCT03804671|DRUG|BI 730357 mixed with [C-14] BI 730357 BS|Intravenous dose
41267459|NCT02168595|DRUG|GMI-1271|GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
41267460|NCT02168595|DRUG|Placebo|
41267461|NCT01509625|DRUG|Fulvestrant|It is an observacional retrospective study to asses the results of the administration of fulvestrant in the routine clinical practice.
41267462|NCT01705015|BEHAVIORAL|direct feedback about exercise|
41267463|NCT01705015|BEHAVIORAL|PLacebo|UCFit plus encouraged exercise
41267464|NCT01262625|DEVICE|CCTA|Complete diagnostic CCTA per protocol specifications.
41267465|NCT01262625|DEVICE|SPECT MPI/ICA|Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
40947103|NCT01322659|DEVICE|Helmet|Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet
40947104|NCT01322659|DEVICE|Endotracheal tube|Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
41286848|NCT04730323|DRUG|Tocilizumab|"Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded.~Any side effects noted after administration of TCZ/ Corticosteroid were recorded."
40947105|NCT04297059|OTHER|Ajyal Salima|It comprises in class-activities, meetings with parents and improvement of school foodservice
40947106|NCT06400511|DRUG|Pimecrolimus 0.3% Ophthalmic Ointment|Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.
40947107|NCT06400511|DRUG|Placebo Ophthalmic Ointment|Placebo will be applied twice a day to both eyelid margins.
40947108|NCT05420675|OTHER|Single Leg Squat|After initial data collection (Demographic data, Inclusion criteria), surface electromyography EMG assessments will be obtained from 1 muscle ( Vastus Medialis). EMG evaluation will be done in different arm positions during the single leg squat. These records will be taken in 4 different situations: 1) Arms free, 2) Arms flexed to 90 degrees, 3) Hands on hips, 4) Arms across the chest.
40947109|NCT02952729|DRUG|XMT-1522|one intravenous dose administered in-clinic every 21 days
40947110|NCT06254378|PROCEDURE|Sinus lifting with allograft|Participants will receive sinus lifting and allograft with immediate implant in premolar-molar area.
40947111|NCT06254378|OTHER|Sinus lifting without graft|Participants will receive sinus lifting with immediate implant in premolar-molar area without graft
40947112|NCT04299542|PROCEDURE|Percutaneous lung biopsy using conventional MDCT|Conventional CT biopsy will be performed using a 64 slice CT scanner. A preliminary plain CT is acquired covering the entire target lesion with a skin marker, and the interventional radiologist would decide on the skin puncture site and the needle pathway. A post-procedural CT scan will be made to detect pneumothorax or pulmonary haemorrhage. All images will be archived in the picture achieving and communication system (PACS).
40947113|NCT04299542|PROCEDURE|Percutaneous lung biopsy CBCT|CBCT guided biopsy will be performed in the angiography suite. A preliminary CBCT (DynaCT) is acquired covering the entire target lesion is first performed. Image data will be displayed and processed using Syngo iGuide system. A potential needle trajectory will be drawn from skin to lesion. Integration of the cross-sectional images and real time fluoroscopy will result in three system positions: one bull's eye view and two progression views. During fluoroscopy, the planned needle trajectory and target will be overlaid on the real time fluoroscopy image. After the needle reaches the target, another CBCT will be performed to confirm needle position. Biopsy using coaxial system and post-procedural CT scans will be performed in similar fashion as the conventional CT group.
41286849|NCT06091423|DRUG|XELOX combined with Fruquintinib and Sintilimab|XELOX:Capecitabine：800mg/m2, po, bid, d1-14。Oxaliplatin：130mg/m2，ivgtt 2-6h，d1，q3w; Fruquintinib: 5 mg/d，qd po，d1-14，q3w; Sintilimab: 200mg d1, q3w
41286850|NCT00404040|DRUG|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
41286851|NCT00404040|DRUG|Lactulose|
41286852|NCT02714205|DRUG|transdermal nitroglycerin|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
41286853|NCT02714205|DRUG|Placebo|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
41286854|NCT01564654|DEVICE|iTotal KRS|Total Knee Replacement System
41452745|NCT05467163|DEVICE|Conduction system pacing device implantation|Left bundle branch pacing (LBBP) will be the preferred pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory. If LBBP will be unobtainable, His bundle pacing (HBP) implantation will be attempted. His bundle potential mapping will be performed with the use of the electrophysiological system and under fluoroscopic guidance. Distal HB potential with a large ventricular signal and a small atrial signal will be targeted before the pacing lead will be screwed into position. Backup RV lead will be mandatory for all patients receiving HBP devices.
40947114|NCT02193477|DEVICE|TEAS|Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
41286855|NCT00947154|DRUG|aripiprazole|aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
40947115|NCT02193477|DEVICE|Sham TEAS|Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
40947116|NCT00140946|DRUG|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
40947117|NCT00140946|DRUG|Comparator: placebo / Duration of Treatment: 16 weeks|
40947118|NCT06345131|OTHER|Non invasive blood pressure monitoring|Non invasive blood pressure monitoring
40947119|NCT02633813|DRUG|Naftifine hydrochloride 2%|Topical application for two weeks
40947120|NCT02633813|DRUG|Placebo|Topical application for two weeks
40947121|NCT02633813|DRUG|Naftin® 2% (Naftifine hydrochloride 2%)|Topical application for two weeks
40947122|NCT06557434|DEVICE|MIRIA|The MIRIA Skin Treatment System is a 1550nm-based laser system indicated for use in dermatologic procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures.
40947123|NCT05098899|GENETIC|MyGeneMyDiet® Recommendations for Weight Management|This group will receive Nutrition and Lifestyle recommendation based on SNPs known to have an impact to body weight and body composition, and responses to physical activity and dietary fat intake
40947124|NCT05098899|OTHER|Usual Standard of Care for Weight Management|This group will receive the conventional and standard nutrition lifestyle recommendation for weight management
40947125|NCT04040244|OTHER|Exhaled Breath Collection|Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.
40947126|NCT04040244|OTHER|Blood sample|Blood samples collected simultaneously with routine standard of care blood draws.
40947127|NCT05594654|OTHER|Smart Phone Application|"Breathe is an app that can be used by people with asthma to promote collaborative self-management. It is a platform that empowers patients to self-manage their condition. Breathe helps patients detect when they might be exacerbating or adequately controlled based on symptoms entered by the user into the application. The application then feeds these symptoms through a rules-based algorithm that identifies the early onset of an exacerbation, based on the user's zone of control or action plan. It also stores the patient's self-management action plan and gives them relevant instructions when it sees that their symptoms are getting better or worse. These instructions are delivered through a chatbot that provides information, support, and education to the patient through a friendly, human-like text message conversation."
40947128|NCT06403215|OTHER|Chewing gum group|Women in this group chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation.
40947129|NCT06403215|OTHER|Fennel tea group|Women in this group started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
41286856|NCT04273243|GENETIC|AT-GTX-501|No study drug is administered in this study. Subjects who received AT-GTX-501 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
41452746|NCT05467163|PROCEDURE|AV node ablation|Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
41452747|NCT00397735|PROCEDURE|amniocentesis|Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
41452748|NCT00397735|DRUG|N-acetylcysteine or placebo|Only women with amniocentesis results consistent with infection/inflammation will be randomized
41452749|NCT06185244|BEHAVIORAL|Therapist-supported internet-delivered trauma-focused CBT|12 weeks of therapist-supported internet-delivered trauma-focused CBT for both the youth and the care giver.
40947130|NCT06403215|OTHER|Chewing gum+Fennel tea group|Women in this group both chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation and started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
40947131|NCT06403215|OTHER|Control group|No intervention
40947132|NCT02068027|DRUG|Clonidine Gel 0.1%|
40947133|NCT02068027|DRUG|Placebo|
40947134|NCT03530800|DRUG|Dronabinol|Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)
40947135|NCT03530800|DRUG|Placebo|Placebo for 10 weeks
40947136|NCT02635776|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
40947137|NCT02635776|BIOLOGICAL|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
40947138|NCT05177133|DRUG|Capecitabine|PO Capecitabine
40947139|NCT05177133|DRUG|Oxaliplatin|IV Oxaliplatin
40947140|NCT05177133|DRUG|Retifanlimab|IV retifanlimab
41286857|NCT02608164|DIETARY_SUPPLEMENT|3000IU(75μg) vitamin D3|
41286858|NCT00156078|DRUG|pregabalin|
41286859|NCT04573959|DEVICE|SV-3 Capsule Endoscopy|The purpose of this study is to validate an updated version of the CapsoCam SV-3 Endoscopy System with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam SV-3 capsule endoscopy.
41286860|NCT00000681|DRUG|Bleomycin sulfate|
41286861|NCT00000681|DRUG|Vincristine sulfate|
41286862|NCT00000681|DRUG|Doxorubicin hydrochloride|
40947141|NCT05517993|DRUG|Gui-Lu-Er-Xian-Jiao-Wan|Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) is an ancient CHM formula, mainly originating from processed tortoise shells, antlers, Ginseng, and wolfberry.
40947142|NCT01212107|DRUG|FGF Receptor|LY2874455 administered orally.
40947143|NCT01212107|DRUG|Phosphate Binders|
40947144|NCT02436681|DEVICE|MIROMESH|
41286863|NCT00000681|DRUG|Zidovudine|
41286864|NCT00000681|DRUG|Sargramostim|
41286865|NCT01597869|DEVICE|Endobronchial ultrasound|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions.
41452750|NCT06185244|BEHAVIORAL|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.
40947145|NCT04120441|BEHAVIORAL|Group Mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions.
40947146|NCT03169686|BEHAVIORAL|Cognitive and Behavioral Intervention|Participants who allocate to the intervention group will receive regular smoking cessation related information by professional team.
40947147|NCT04850313|DEVICE|ProProKera Plus®|ProKera® is a sutureless form of CryoTek amniotic membrane that is clipped into a dual polycarbonate ring system with the epithelial side up when in contact with the ocular surface.
40947148|NCT05013034|DRUG|Basiliximab Injection|Subjects will be given IV dosing with basiliximab up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
40947149|NCT05013034|DRUG|Placebo|Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
40947150|NCT04790396|DEVICE|Carotid ultrasound under pulsed-wave doppler mode|Carotid ultrasound under pulsed-wave doppler mode to check whether carotid pulse is present
40947151|NCT05574998|DRUG|Recombinant human endostatin (Endostar)|"The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed."
40947152|NCT04142593|OTHER||
40947153|NCT03211871|DRUG|Dexmedetomidine|Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
40947154|NCT03211871|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Intraoperative intravenous normal saline infusion
40947155|NCT02639546|DRUG|Cobimetinib|Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
40947156|NCT01021306|DEVICE|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
40947157|NCT01021306|DEVICE|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
40947158|NCT01021306|OTHER|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
40947159|NCT01021306|OTHER|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
40947160|NCT01785407|DIETARY_SUPPLEMENT|Iron Supplement (Ferrous Sulfate Dried)|Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
40947161|NCT05021081|DEVICE|TRP-200|JJVC Investigational Contact Lens
40947162|NCT05021081|DEVICE|ACUVUE Oasys 1-Day|JJVC Marketed Contact Lens
41452751|NCT04659668|DEVICE|MMG-23-04-2019|"The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, G spot."
40947163|NCT02537028|DRUG|MSC2364447C|Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
40947164|NCT02537028|DRUG|MSC2364447C|Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
41452752|NCT00006153|BIOLOGICAL|HIV-1 Immunogen|
40947165|NCT02537028|DRUG|Placebo|Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
40947166|NCT04779996|DIAGNOSTIC_TEST|Laboratory Samples|"1. After full vaccination with a Covid 19 vaccine, the following laboratory samples will be taken one time only, two weeks after full dose vaccination: i. Serologic rapid test (IgG, IgM) ii. Serum quantitative immunoglobulin levels iii. CD4 level iv. CD8 level~2. Laboratory samples will be taken at Hospital Auxilio Mutuo Laboratorio Clínico. Likewise, the Immuno Reference Lab might be used as an alternative.~3. Since monoclonal antibody therapy can induce hypogammaglobulinemia, we will measure gammaglobulin levels to correlate with antibody response to vaccine. Similarly, we will evaluate the CD4 and CD8 counts."
41452753|NCT00973219|DRUG|Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate|Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
40947167|NCT01358773|OTHER|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
40947168|NCT00891462|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
41452754|NCT05318859|OTHER|Pharmacopuncture|Registry (observational study)
41452755|NCT00200785|DIETARY_SUPPLEMENT|garlic powder added to ambient water|consumed 2.7 grams of garlic powder added to ambient water (equivalent to 8 grams fresh or raw garlic) in a sandwich, once a day for four weeks
41452756|NCT00200785|DIETARY_SUPPLEMENT|garlic powder added to boiling water|consumed 2.7 grams of garlic powder added to boiling water (equivalent to 8 grams of cooked garlic) in a sandwich, once a day for four weeks
40947169|NCT00891462|DRUG|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
41452757|NCT04070898|PROCEDURE|Remove urinary catheter after surgery|Remove bladder catheter after surgery
41452758|NCT00774189|DRUG|clarithromycin 250 mg tablets|
40947170|NCT00891462|DRUG|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
40947171|NCT00629720|DRUG|alfuzosin (SL770499)|
40947172|NCT04757246|OTHER|MouthLab Device|Use of MouthLab system
40947173|NCT03437512|DEVICE|Anodal tDCS|20 minutes of 2mA anodal stimulation.
40947174|NCT03437512|BEHAVIORAL|Fluency training|Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
40947175|NCT03437512|DEVICE|Sham tDCS|For sham stimulation, current is ramped up and back down over 30 seconds.
40947176|NCT03012971|DRUG|Dexmedetomidine supplemented morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
40947177|NCT03012971|DRUG|Morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
40947178|NCT03582878|DRUG|Sirolimus Oral Product|Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation
40947179|NCT03582878|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
40947180|NCT04141046|DEVICE|XCSITE100 Stimulator - Individualized theta-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
40947181|NCT04141046|DEVICE|XCSITE100 Stimulator - Individualized alpha-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
40947182|NCT04141046|DEVICE|XCSITE100 Stimulator - Active Sham|20 seconds of ramp-in to 40 seconds of 10 Hz tACS with a ramp out of 20 seconds for a total of 80 seconds of stimulation
40947183|NCT03610438|DRUG|Inotuzumab Ozogamicin (IO)|"After course 1 MRD will be evaluated:~- patients MRD negative will enter into short maintenance or long maintenance according to investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance."
40947184|NCT03610438|DRUG|Inotuzumab Ozogamicin (IO)|After course 2 MRD will be evaluated; patients MRD negative will enter into short maintenance or long maintenance by investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
40947185|NCT01568515|PROCEDURE|Electronic Message|Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention \& control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
40947186|NCT05124405|OTHER|Fitbit|wearable activity tracker
40947187|NCT05124405|OTHER|Continuous Glucose Monitor|wearable activity tracker
40947188|NCT01365247|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
40947189|NCT01365247|BEHAVIORAL|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
41452759|NCT01554410|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|45 Gy in 25 daily fractions (1.8 Gy per fraction)
40947190|NCT01365247|BEHAVIORAL|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
40947191|NCT02061618|BEHAVIORAL|Bollywood Dance Exercise|
40947192|NCT04004962|DEVICE|Infrared spectroscopy|Infrared spectroscopy
40947193|NCT03070886|DRUG|Bicalutamide|Given orally (PO)
41452760|NCT01554410|DRUG|Cisplatin|Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
41452761|NCT01554410|DRUG|Gemcitabine|Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
41452762|NCT05604651|OTHER|no intervention|no intervention
41452763|NCT00498264|BEHAVIORAL|walking program, resistance muscular exercise|
40947194|NCT03070886|DRUG|Degarelix|Given IM
41286866|NCT02777463|OTHER|diffusion-weighted MRI|Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
41452764|NCT03129685|PROCEDURE|HALED|This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.
40947195|NCT03070886|DRUG|Docetaxel|Given IV
40947196|NCT03070886|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
40947197|NCT03070886|DRUG|Flutamide|Given PO
40947198|NCT03070886|DRUG|Goserelin|Given IM
40947199|NCT03070886|DRUG|Goserelin Acetate|Given IM
41452765|NCT00484679|DRUG|Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
41452766|NCT03820063|DRUG|PTC-Pz|"* Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~* Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~* Carboplatin AUC 6mg•ml/min administered intravenously on day 1~* Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~* Treatment cycles are repeated on day 22~In case of non pCR; Adjuvant T-DM1, 3.6mg/kg Q 22 days, for 14 cycles."
41452767|NCT04199494|OTHER|Antibiotic Stewardship Program|The patient do the routinely preoperative lab tests, including the rectal swab (RS). The Antibiotic Stewardship Program (ASP) has been shown to effectively reduce unnecessary antibiotic use and optimize the treatment of infectious diseases. To be successful, multiple aspects should be considered in the ASP. Initially, the infection control specialists will follow the routine activity of each department in order to define what could immediately be improved. Internal antibiotic prophylaxis and therapy guidelines will be defined and shared between groups. The RS, collected at the preoperative testing, is evaluated by the infection control specialist. In case of identification of MDR bacteria, each patient will receive a tailored AP based on the antibiograms of the RS. In any case, the infection control specialist will choose the best solution for the patient avoiding the key antibiotics
40947200|NCT03070886|OTHER|Laboratory Biomarker Analysis|Correlative studies
40947201|NCT03070886|DRUG|Leuprolide|Given intramuscularly (IM)
41452768|NCT03064620|BIOLOGICAL|PCV|PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011
41452769|NCT02717260|DEVICE|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
41452770|NCT04221347|OTHER|blood sampling|blood samples will be taken in specified time points
41452771|NCT04143880|DRUG|Progesterone|intramuscular injection intranasal administration
41452772|NCT04143880|OTHER|saline|intramuscular injection intranasal administration
40947202|NCT03070886|DRUG|Leuprolide Acetate|Given IM
40947203|NCT03070886|DRUG|Nilutamide|Given PO
41133390|NCT03999788|PROCEDURE|Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity|iTBS will be delivered over the scalp site corresponding to the leg area of primary motor cortex contralateral to the affected limb. The active motor threshold (AMT) will be defined as the minimum stimulation intensity required to evoke a liminal motor potential from the Soleus muscle during voluntary contraction. The stimulation intensity will be about 80% of AMT. The iTBS stimulation protocol consists of 10 bursts, each burst composed of three stimuli at 50 Hz, repeated at a theta frequency of 5 Hz every 10 s for a total of 600 stimuli (200 s). If no MEP will be detectable from the contralateral leg, the site of stimulation will be determined as symmetrical to the motor hot spot. If no MEP will be detectable even from the contralateral leg the coil will be held tangentially to the scalp with its centre placed 1 cm ahead and 1 cm lateral from CZ (10-20 EEG system). In these cases, stimulation intensity will be set to 50% of the maximum stimulator output.
41452773|NCT04010045|DEVICE|Endovascular Treatment of PAD|PAD endovascular treatment using the DABRA Laser System + other FDA cleared/ approved devices for the treatment of PAD.
41452774|NCT06165419|RADIATION|SBRT to the spine|Stereotactic body radiation therapy (SBRT) administered to spine metastases
41452775|NCT03921918|DEVICE|Breast Pump|Hydraulic Breast pump
41452776|NCT01360086|BIOLOGICAL|cetuximab|6 cycles of intravenous Cetuximab (500mg/m²),
41452777|NCT01360086|DRUG|cisplatin|Cisplatine (50mg/m²)
40947204|NCT03031132|BEHAVIORAL|HP-Beverage Breakfast|Participants will consume high protein beverage (shake) breakfast meals each morning.
40947205|NCT03031132|BEHAVIORAL|HP-Solid Breakfast|Participants will consume high protein solid (traditional food items) breakfast meals each morning.
40947206|NCT03031132|BEHAVIORAL|Breakfast Skipping|Participants will skip breakfast each morning.
40947207|NCT03484637|OTHER|Lifestyle-medicine intervention|
41452778|NCT01360086|DRUG|fluorouracil|LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
41452779|NCT01360086|DRUG|leucovorin calcium|
40757770|NCT06391489|BEHAVIORAL|HOBSCOTCH-PACS|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PD is an adaptation of the HOBSCOTCH program for people with PD and incorporates education about Parkinson Disease and cognition into the education module.
40947208|NCT05246397|DRUG|Sugammadex administration|Sugammadex will be given in 50 mg increments every five minutes for reversal of neuromuscular blockade until reaching a train-of-four ratio of 0.9
41286867|NCT00167908|DRUG|Ethyol (drug)|
41452780|NCT01360086|PROCEDURE|adjuvant therapy|
41452781|NCT01360086|PROCEDURE|neoadjuvant therapy|
41452782|NCT01360086|PROCEDURE|quality-of-life assessment|
41452783|NCT01360086|PROCEDURE|therapeutic conventional surgery|Surgery was planned 3-4 weeks after the end of neaodjuvant CT
40947209|NCT01943773|PROCEDURE|Functional Assessment|"Both arms of the study will undergo functional assessments at three points during the study progress.~BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.~ASSESSMENT OF INTERVENTION EFFECTIVENESS:~Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.~POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation."
40947210|NCT01943773|PROCEDURE|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions.
40947211|NCT00493532|DRUG|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
40947212|NCT04087213|DEVICE|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
40947213|NCT00494299|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
40947214|NCT00494299|DRUG|Placebo|Placebo: matching placebo
40947215|NCT01254097|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsule, 2 capsules twice daily
41452784|NCT04257838|DRUG|Piperacillin/tazobactam or Meropenem|"The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:~1. Just before the antibiotic infusion (T0)~2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.~A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels."
41452785|NCT06065839|OTHER|non-nutritive sucking 5 minutes|Give pacifier non-nutritive sucking for 5 minutes before feeding
41452786|NCT06065839|OTHER|non-nutritive sucking 15 minutes|Give pacifier non-nutritive sucking for 15 minutes before feeding
41452787|NCT05756218|OTHER|nursing diagnoses - taboo game|Playing 7 weeks nursing diagnoses taboo cards
40757771|NCT02749461|PROCEDURE|heel stick|Consecutive routine blood sampling heel sticks
40947216|NCT05788900|BIOLOGICAL|Heparin|intravenous Heparin
40947217|NCT01934244|DEVICE|NovaSure Endometrial Ablation|The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
40947218|NCT05994365|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation.
40947219|NCT02761733|BEHAVIORAL|Moving Patient Outcomes toward Wellness and Recovery (mPOWR)|An mPOWR intervention and toolkit that consists of strategies, prompts, and decision aids designed to foster patient involvement in treatment. The mPOWR intervention includes a questionnaire that assesses quality of life and consumer functioning for use in the development of consumer-centered goals and outcomes within the mPOWR intervention.
40947220|NCT00747331|DRUG|Fenoldopam mesilate|Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation
40947221|NCT00747331|DRUG|Placebo|"Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug"
40947222|NCT03559673|DRUG|Lacosamide|Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses.
40947223|NCT01554020|DIETARY_SUPPLEMENT|Blood Sugar Take Care|One 1200 mg soft gel capsule administered 3X/day for duration of study
40947224|NCT01554020|DIETARY_SUPPLEMENT|Placebo|One 1200 mg soft-gel capsule administered 3X/day for duration of study
40947225|NCT04806503|DRUG|UNR844|Ophthalmic solution for topical ocular administration
40947226|NCT04806503|DRUG|Placebo|Placebo
40947227|NCT05557474|OTHER|Early-stage lung cancer prognostic kit -- ELISA|blood sample with ELISA
40757772|NCT01366014|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
40947228|NCT05557474|OTHER|Early-stage lung cancer prognostic kit -- IHC|surgical tumor part with IHC
40947229|NCT06235307|OTHER|motivational interviewing|Upon entry into the program, all patients will be seen for an assessment of their physical condition at the premises of Amiens Métropole by a teacher in adapted physical activity (APA) in order to be assessed and directed to a club or a approved associations. The EM group will also benefit from a motivational interview at 0 and 3 months by a doctor trained in the technique. The entire cohort will complete the SF12 (perception of quality of life) and IPAQ (current level of physical activity) questionnaires at 0 and 6 months during the usual appointments with the APA teacher.
40947230|NCT03993470|BEHAVIORAL|Short foot excercise for intrinsec muscles of the foot|to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
41452788|NCT00785135|DEVICE|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
41452789|NCT00785135|DEVICE|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
41452790|NCT06203080|DRUG|ancetate gel|An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
40757773|NCT01366014|DRUG|Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral|multiple dose, single schedule
40757774|NCT01366014|DRUG|Placebo; oral|matching placebo
41452791|NCT06203080|DRUG|nonoxinol gel|The nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be utilized for the intervention. Each product weighs 5 g and contains 50 mg of N-9. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
41286868|NCT04764032|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be undertaken by a range of appropriately competent practitioners including; intensive care clinicians, cardiologists and specialist echocardiographers. Imaging obtained will be in keeping with the protocol required for a Focused Intensive Care Echo (FICE) scan and should include ECG monitoring at all times. A focused dataset will be used to answer the primary outcome. If available and the echocardiographers competency and experience permit, further measures of RV function will be obtained at this time.
41452792|NCT02699762|OTHER|self rehabilitation of upper limb in experimental group|The patients in the self-rehabilitation group will be taught the self-rehabilitation program by a physiotherapist who is not involved in the patient follow-up. They will receive a log book which will be used to evaluate compliance and tolerance to the program. They will be instructed to carry out the exercises 7 days per week for the whole duration of the study and to record which exercises they carried out and for how long, after each exercise session.
41286869|NCT01645163|BEHAVIORAL|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
41452793|NCT01018862|DRUG|Azelastine hydrochloride nasal spray 0.15%|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
41452794|NCT01018862|DRUG|Azelastine hydrochloride nasal spray 0.10%|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
41452795|NCT01018862|DRUG|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
41452796|NCT00627744|DRUG|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
41452797|NCT00235027|OTHER|Adverse Drug Event Monitoring|The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
41452798|NCT04366635|PROCEDURE|Impacted third molar surgery|Under local anesthesia, flap will be raised and mesioangular or horizontal impacted third molar tooth will be removed with routine technique. And then extraction socket will be irrigated with salin and will be primarily closed.
41452799|NCT04366635|PROCEDURE|Application of mineralised plasmatic matrix|After extraction of impacted third molar tooth, Mineralized Plasmatic Matrix will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
41286870|NCT03910699|DEVICE|Three-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a three-row circular stapler, defunctioning colostomy is performed.
41286871|NCT03910699|DEVICE|Two-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a two-row circular stapler, defunctioning colostomy is performed.
41452800|NCT04366635|PROCEDURE|Application of β-tricalcium phosphate|After extraction of impacted third molar tooth, β-tricalcium phosphate will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
41452801|NCT05783089|BIOLOGICAL|Anti-mesothelin CAR-T cells|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
41452802|NCT04941313|DRUG|3D229|3D229 is an investigational drug.
41452803|NCT04941313|OTHER|Placebo|Matching placebo
40947231|NCT03352973|OTHER|active tDCS on the dlPFC|During active tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the active tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
40947232|NCT03352973|OTHER|sham tDCS on the dlPFC|During the sham tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the sham tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
40947233|NCT03334110|PROCEDURE|A method of operation: LIMA-GSV-SCVBG|On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
40947234|NCT03334110|PROCEDURE|BIMA-SCVBG|On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
40947235|NCT02589405|DRUG|Benzoyl Peroxide|
40947236|NCT02589405|OTHER|Dermotivin® Soft Liquid cleanser|
41452804|NCT00936351|BEHAVIORAL|Mindfulness Meditation|Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses. This intervention has been adapted from mindfulness based stress reduction treatment.
41452805|NCT00936351|BEHAVIORAL|Support Group (control)|A support group during which participants can discuss with each other any issues, problems, or successes at work will be conducted as the control portion.
41452806|NCT04043702|DRUG|The intervention being studied|Intervention Other Names have not been specified
41286872|NCT05219643|DEVICE|NAVA|Nava level is set to maintain the target tidal volume: 6-10ml / kg (pbw). The trigger sensitivity is 0.5uv. The expiratory trigger sensitivity: the built-in software of the ventilator is set to 70% of the peak value of diaphragm electrical activity.
41286873|NCT05219643|DEVICE|PSV|According to the doctor's experience, maintain the target tidal volume: 6-10ml / kg (pbw); trigger sensitivity: 1.5-2l/min, expiratory trigger sensitivity: 30% inspiratory peak flow rate.
40947237|NCT02589405|OTHER|Cetaphil® Dermacontrol Moisturizer SPF30|
41286874|NCT04079777|DRUG|Clinical treatment|Liquid Resuscitation, Anti-infection
40947238|NCT00227929|PROCEDURE|Care Management|
40947239|NCT05128318|PROCEDURE|Nissen Fundoplication, cholecystectomy|Collection of adipose tissue pieces in the context of programmed abdominal surgery to treat to treat hiatal hernia, gastroesophageal reflux or vesicular lithiasis. During the surgery treatment, adipose tissue of 1-2 cm3 will be collected for the protocol by laparoscopy by the surgeon in charge of the procedures.
40947240|NCT01310153|PROCEDURE|prone positioning|newborn babies in prone positioning
40947241|NCT01310153|PROCEDURE|Supine|newborn babies in supine positioning
40947242|NCT00003742|DRUG|cisplatin|
40947243|NCT00003742|DRUG|irinotecan hydrochloride|
40947244|NCT00003742|DRUG|paclitaxel|
40947245|NCT05722093|DRUG|Manzi Guben granules|Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
40947246|NCT03647332|PROCEDURE|Cooled RFA treatment|cooled radiofrequency ablation
40947247|NCT03647332|DRUG|Steroid Drug|steroid injection
41133064|NCT06270732|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|"This is an equivalent 30-hour online self-administered training involving 30 x 45' individual online sessions (22.5h), mostly based on reﬂection exercises around brief readings, pills, and animated shorts, but not video- feedback and guided practice. This is complemented with 7.5h of between-sessions work based on looking for new information, adult-child (non-guided) activities (and not for later video- feedback) or out-of-line guided reﬂective exercises.~Session 1: Program presentation; Session 2-8: Theoretical bases of MISC and mentalization; Session 9-16: MISC and mentalization applied to mental health; 17-18: Benefits of MISC to improve children learning; 19-20: Benefits of MISC for self-esteem; 21-22: The importance of MISC to foster mentalization; 23-24: Mentalization and pro-social behavior; 25-26: The importance of MISC to promote secure attachment; 27: MISC impact in epistemic trust; 28-29: MISC and well-being; 30: MISC, mentalization and environmental enrichment."
41133065|NCT06324344|DEVICE|High-Dose TENS|high-dose TENS device delivers 1 hour of TENS therapy per session.
41286875|NCT01819961|DRUG|MCT/LCT and fish oil|
41286876|NCT01819961|DRUG|MCT/LCT|
41286877|NCT04613011|DEVICE|Ultrasound|Checking vein width snd copression using US
41286878|NCT04507217|DRUG|Tislelizumab, Carboplatin, Pemetrexed|"Tislelizumab: 200mg administered intravenously (IV) on Day 1 of each 21-day cycle~Carboplatin: AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles~Pemetrexed: 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle"
41452807|NCT05782439|OTHER|Manual evaluation of ITB tension|There will be a double evaluation for each sampling session: 1) if there is a uniformity of the tension between the two sides, or if there is a prevalence on one side; 2) quantification of the difference, if present, with a graduation in 3 levels.
40947248|NCT02231697|OTHER|Non-interventional, retrospective medical chart review|Non-interventional, retrospective medical chart review
40947249|NCT03775031|DEVICE|Fractional Laser and Chemical Peel|Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
40947250|NCT00734123|DRUG|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
40947251|NCT00734123|DRUG|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
40947252|NCT00734123|DRUG|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
40947253|NCT00734123|DRUG|Rimonabant|"In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care"
40947254|NCT06462885|BEHAVIORAL|home support, hiving alone|Home support: living alone
40947255|NCT06462885|BEHAVIORAL|home support, living with others|Home support: living with others
40947256|NCT00400738|DRUG|Saquinavir, lopinavir, ritonavir|arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
40947257|NCT04521374|BEHAVIORAL|Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein|Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
40947258|NCT04955132|BEHAVIORAL|E-learning|The participants in the experimental arm will be able to use a food allergy e-learning tool, that provides comprehensive knowledge of the most common food allergies (milk, egg and wheat), their management and dietary guidelines.
41133066|NCT06324344|DEVICE|Low-Dose TENS|low-dose TENS device delivers 6 minutes of TENS therapy per session.
41133067|NCT02663804|DEVICE|Total Knee Arthroplasty|
41133068|NCT05040152|BEHAVIORAL|Dietary Counseling and Surveillance|Receive dietary recommendations
41133069|NCT05040152|OTHER|Exercise Intervention|Complete home exercises
41133070|NCT05040152|OTHER|Informational Intervention|Receive education brochures
41133071|NCT05040152|OTHER|Questionnaire Administration|Ancillary studies
41286879|NCT04819672|OTHER|Low Intensity Training associated with Partial Blood Flow|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
41452808|NCT04844411|DRUG|JNJ-67835989|JNJ-67835989 will be administered orally.
41452809|NCT04844411|DRUG|Placebo|Matching placebo will be administered orally.
41452810|NCT00057226|DRUG|Radafaxine|
41452811|NCT01534845|DRUG|Temozolomide (Temodal)|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
40947259|NCT01415895|DRUG|Naltrexone and Clonidine Combination|subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
41452812|NCT06195865|PROCEDURE|DIEP-flap|Breast reconstruction with a deep inferior epigastric perforator flap
41452813|NCT06195865|PROCEDURE|Implant|Breast reconstruction with an implant-based technique
41452814|NCT03025087|DRUG|Hydroxychloroquine|Participants will be getting hydroxychloroquine
40947260|NCT01415895|DRUG|placebo|subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
40947261|NCT00994929|BIOLOGICAL|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.
40947262|NCT04378907|OTHER|ECIG Lab Session, 30 watts|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
40947263|NCT05920278|DEVICE|Pulse oximeter|Devices (2) were placed on the finger and the fingertip. Blood samples were taken at each stable level of oxygenation.
40947264|NCT04265053|DRUG|Indomethacin 25 MG/50 MG|Indomethacin is a nonsteroidal anti-inflammatory drug commonly used to reduce fever, pain, stiffness, and swelling from inflammation. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation. We will use Indomethacin to test COX as a potential mechanism explaining sex differences in CBF control. Indomethacin usage is IND exempt.
40947265|NCT04265053|DRUG|Placebo - Lactose|Subjects will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit. Placebo usage is IND exempt.
40947266|NCT04265053|DRUG|Ganirelix Acetate|"Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3."
41133072|NCT05040152|BEHAVIORAL|Telephone-Based Intervention|Receive telephone-based weight loss intervention
41133073|NCT02291406|PROCEDURE|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
41452815|NCT03066544|DRUG|Bupivacaine|Nerve blocks with bupivacaine will be performed at initial visit
41452816|NCT03066544|DRUG|Naratriptan Pill|one pill will be administered twice each day for 5 days
41452817|NCT03066544|DRUG|Dexamethasone|one tablet will be administered twice each day for 3 days
41452818|NCT03066544|DRUG|Ketorolac|ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
41452819|NCT02287480|BIOLOGICAL|VSV-ZEBOV|See arm/group descriptions.
41452820|NCT00351039|DRUG|Bevacizumab|Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.
41452821|NCT00351039|DRUG|Erlotinib|Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.
41133074|NCT02291406|PROCEDURE|Robot assisted laparoscopic hysterectomy|Robotic assisted total laparoscopic hysterectomy.
41133075|NCT01227421|DRUG|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
41133076|NCT01227421|DRUG|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
41452822|NCT00351039|DRUG|Pemetrexed|Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
41452823|NCT06140082|GENETIC|GSTP1 A313G （AA）|Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups.
40947267|NCT04265053|DRUG|Testosterone Transdermal Product|In Aim 3, males receive this for 7-9 days of the ganirelix treatment.
40947268|NCT04265053|DRUG|Estradiol Topical|In Aim 3, females receive this for 7-9 days of the ganirelix treatment.
40947269|NCT04265053|DRUG|Antacid|Subjects will also be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Subjects will also be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.
40947270|NCT06432231|OTHER|Low glycemic index diet treatment|This study was a non-randomized, single centre, pre/post-intervention study. A low glycemic index diet was prescribed by a dietician for 3 months. LGID treatment consisted of 10% (40-60 g) low glycaemic index (glycaemic index \<50) carbohydrate, 20-30% protein and 60-70% lipid
40947271|NCT03061097|BIOLOGICAL|Autologous fecal microbiota transplant (Auto-FMP Enema)|FMT is the process by which processed donor microbiota material is transplanted into recipients. The aim is to reconstitute the normal intestinal microbial flora in recipients. In this study, the fecal microbiota preparation will be made from the participant's own stool and processed into an auto-FMP enema formulation.
40947272|NCT03061097|OTHER|Placebo Enema Preparation|The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
40947273|NCT04810481|DEVICE|BIS Complete Monitoring System|The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BIS™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.
40947274|NCT04925908|DIAGNOSTIC_TEST|RT-PCR for SARS-Cov-2|Nasopharyngeal swab for detecting Novel Coronavirus-2 by reverse transcriptase polymerase chain reaction
40947275|NCT05693116|PROCEDURE|Rhinectomy|Surgery will be performed according to extension of the tumour, i.e. local resection limited to the vestibule, partial rhinectomy, total rhinectomy, extended total rhinectomy
40947276|NCT01404975|OTHER|Thoracic paravertebral block (PVB)|"We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines."
40947277|NCT04198116|DRUG|Varenicline|Varenicline 2mg/day
40947278|NCT04198116|DRUG|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
40947279|NCT06019949|DEVICE|Transcutaneous spinal cord stimulator|Stimulation to the spinal cord will be administered using Neostim/Biostim (Cosyma Inc., Denver CO) device by applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes.
40947280|NCT06019949|DEVICE|Respiratory Training|Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the respiratory training intervention.
40947281|NCT00547196|BIOLOGICAL|filgrastim|
40947282|NCT00547196|DRUG|Busulfan|
40947283|NCT00547196|DRUG|Cyclophosphamide|
41133077|NCT01227421|DRUG|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
41133078|NCT04197791|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to core stabilization muscles will be applied using 8 electrodes. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
40947284|NCT00547196|DRUG|Cyclosporine|
40947285|NCT00547196|DRUG|Fludarabine phosphate|
40947286|NCT00547196|DRUG|Melphalan|
40947287|NCT00547196|DRUG|Mycophenolate Mofetil|
40947288|NCT00547196|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40947289|NCT00547196|PROCEDURE|umbilical cord blood transplantation|
41452824|NCT00171145|DRUG|Darifenacin|Darifenacin 15 mg tablets once daily
41452825|NCT00171145|DRUG|Placebo|Placebo tablets once daily
40947290|NCT00547196|RADIATION|total-body irradiation|
41286880|NCT04819672|OTHER|Low Intensity Training associated with Partial Blood Flow-Sham|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
40947291|NCT00547196|RADIATION|Fractionated total body irradiation|
41286881|NCT04135625|BEHAVIORAL|Integrated nutrition and agricultural (INA) trainings|Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.
41452826|NCT01194908|DRUG|Decitabine, LBH589, Tamoxifen|"Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2"
41452827|NCT00657254|DRUG|Nexavar (Sorafenib, BAY43-9006)|Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
41286882|NCT04135625|BEHAVIORAL|Ceremonial Gifting of Livestock|Egg laying chickens will be presented as a gift to the child by a community champion (their religious leader or village chief)) during a gifting ceremony
40947292|NCT00364754|DRUG|Tesmilifene (YMB 1002)|
40947293|NCT05920694|DEVICE|Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after initiation of CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
40947294|NCT05920694|OTHER|Delayed Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after the study period of 12 weeks. After 12 weeks, participants will immediate receive CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
40947295|NCT02266914|DEVICE|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
40947296|NCT01690429|DEVICE|Somnocheck micro|Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
41286883|NCT06304441|DRUG|Osimertinib|Double-dose of TKI (e.g. 'osimertinib' 160 mg) was administered orally once daily until disease progression or unmanageable drug-related toxicity.
41286884|NCT06304441|DRUG|Pemetrexed|Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
40947297|NCT02890927|OTHER|Cardio-geriatric co-management|"A comprehensive geriatric assessment on admission will stratify patients in groups:~1. Low risk patients are expected to do well and will not receive co-management.~2. Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~3. High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning."
40947298|NCT03010670|DRUG|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
40947299|NCT03010670|OTHER|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
40947300|NCT00235469|DRUG|SPM 927|
40947301|NCT02120612|OTHER|Naloxone Education Intervention|"The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders."
40947302|NCT00973674|DRUG|Premarin IV|One time dose of Premarin IV
40947303|NCT00973674|DRUG|Placebo|One time dose of Placebo
40947304|NCT00744276|DRUG|danazol|danazol applied topically once per day for 4 treatment cycles
40947305|NCT00744276|DRUG|Placebo|placebo topically applied once daily for 4 treatment cycles
40947306|NCT05859256|OTHER|Experimental|The intervention consists of the application of a treatment protocol based on an initial active warm-up consisting of 3 active exercises, walking for 1 minute performing slow and controlled movement of the ankle, raising the heels, 15 repetitions, dorsiflexion of the ankle in the standing position. gentleman, 15 reps. Subsequently, the floss band will be placed, performing again the 3 active warm-up exercises with the band on. After this, the passive manual techniques will be carried out for the remaining time, removing the flossing at the end of the latter, and actively mobilizing again.
40947307|NCT05859256|OTHER|Control|The same procedures will be carried out, but placing the flossing without tension and performing the Kaltenborn manual techniques without sliding and without joint mobilization.
40947308|NCT00003678|DRUG|tamoxifen citrate|
40947309|NCT00003678|PROCEDURE|adjuvant therapy|
40947310|NCT00095992|DRUG|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
40947311|NCT03897023|BIOLOGICAL|Gut Microbiota|Status of microbiota
40947312|NCT01436396|BIOLOGICAL|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 12, 18, and 24 months
40947313|NCT01436396|BIOLOGICAL|Yellow fever vaccine|0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
40947314|NCT01436396|BIOLOGICAL|Measles, mumps, and rubella (MMR) vaccine|0.5 mL, subcutaneous at age 12 to 13 months.
40947315|NCT01436396|BIOLOGICAL|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
40947316|NCT01436396|BIOLOGICAL|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
40947317|NCT01436396|BIOLOGICAL|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
40947318|NCT01436396|BIOLOGICAL|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
40947319|NCT01436396|BIOLOGICAL|Yellow Fever Vaccine|0.5 mL, subcutaneous at age 12 to 13 months
40947320|NCT01436396|BIOLOGICAL|Placebo (NaCl)|0.5 mL, subcutaneous at age 12 to 13 months
40947321|NCT01436396|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 13 to 14 months
40947322|NCT01436396|BIOLOGICAL|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
41133079|NCT04197791|OTHER|Core Stabilization Exercises|Warm-up and cool-down exercises will be performed before and after core stabilization exercises. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
40947323|NCT01436396|BIOLOGICAL|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
40947324|NCT01436396|BIOLOGICAL|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
40947325|NCT03183531|DIAGNOSTIC_TEST|C reactive protein|Addition of C-reactive protein test for management strategies to follow-up febrile neonates in outpatient.
40947326|NCT04659239|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
40947327|NCT04659239|BIOLOGICAL|Placebo|The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
40947328|NCT02403856|DRUG|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
40947329|NCT02403856|DRUG|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
40947330|NCT02403856|PROCEDURE|Ultrasound-guided Needling and Lavage|
40947331|NCT03226678|DRUG|APL-2|Complement (C3) Inhibitor
40757775|NCT06570239|PROCEDURE|intervention group|"Protocol A combines dry physiotherapy and psychological support. It will be organised on an outpatient basis. Weeks 1, 2 and 3: 8 sessions of dry physiotherapy and 3 sessions of psychotherapy. 5 psychotherapy sessions will be given over the following five weeks.~Protocol B combines hydro-physiotherapy and hydro-thermal treatments with psychological support. Protocol B begins with 3 weeks in a spa establishment - Care provided during weeks 1, 2 and 3: 8 hydrokinesitherapy sessions, 32 hydrothermal treatments, 3 psychotherapy sessions. 5 psychology sessions will be given over the following five weeks."
40757776|NCT02708368|OTHER|blood withdrawal|3 times
40947332|NCT04997915|OTHER|Observational study exploring the epidemiology and outcomes of AKI in critical COVID-19 patients admitted to the ICU|Critical COVID-19 patients admitted to the ICU
40947333|NCT02530463|DRUG|Azacitidine|Given IV
40947334|NCT02530463|BIOLOGICAL|Ipilimumab|Given IV
40947335|NCT02530463|OTHER|Laboratory Biomarker Analysis|Correlative studies
40757777|NCT03324958|DEVICE|Virtual reality Helmet|The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.
40757778|NCT03324958|OTHER|No Virtual Reality Helmet|The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
40757779|NCT02812537|OTHER|patients with conduct disorders|interview with a specialist
40947336|NCT02530463|BIOLOGICAL|Nivolumab|Given IV
40757780|NCT01550965|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
40757781|NCT00538278|OTHER|Database|database
40757782|NCT01901757|DRUG|HCP1201, Fasted followed by fed|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
40757783|NCT01901757|DRUG|HCP1201, Fed followed by fasted|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
40757784|NCT05356429|OTHER|Small molecule LCDM|The cocktail of small molecules includes four chemical components of LCDM were added to GV oocyte culture medium.
40757785|NCT02567032|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
40757786|NCT02567032|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
40947337|NCT01136031|DRUG|Paclitaxel and irinotecan|"In phase I part, Level Paclitaxel (mg/m²) Irinotecan (mg/m²)~1. 100 100~2. 100 120~3. 135 120~4. 135 160~every 3 week"
40947338|NCT01960673|DEVICE|LMA proseal|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
40947339|NCT01960673|DEVICE|igel LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.
40947340|NCT01960673|DEVICE|air Q LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
40947341|NCT01960673|DEVICE|ambu LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
40947342|NCT04683562|OTHER|Pregnant women at 28-32 weeks|Pregnant women at gestational age 28-32 weeks
40947343|NCT04683562|OTHER|at delivery|women delivered at term
40947344|NCT06137560|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
40947345|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Kit 1|Standard single vision spectacle lens + S.T.O.P.® Kit 1
40947346|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Kit 2|Standard single vision spectacle lens + S.T.O.P.® Kit 2
40947347|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Film|Standard single vision spectacle lens + S.T.O.P.® Film
40947348|NCT06137560|DEVICE|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
40947349|NCT06319261|PROCEDURE|guided biofilm therapy|Removing plaque and calculus by initially detecting it with a disclosing agent followed by the use of air abrasive powder for the removal of supra and subgingival plaque.
40947350|NCT06319261|PROCEDURE|root surface debridement|Removing plaque and calculus by conventional root surface debridement
40947351|NCT02056639|DEVICE|Bioteque cup pessary|
40947352|NCT01173939|DRUG|Pravastatin|5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
40947353|NCT01173939|DRUG|Rosuvastatin|5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
40947354|NCT00251212|BEHAVIORAL|Adapted Motivational Interviewing & Skills Training|Single session, 45 minute brief intervention during Emergency Department Visit
40947355|NCT05179655|BEHAVIORAL|Emotion Regulation Individual Therapy for Adolescents (ERITA)|The ERITA intervention as add-on to TAU consists of 11 weeks, manualized online therapy based on the methods of Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Acceptance and Commitment Therapy (ACT) adapted for youth. The ERITA content consists of psychoeducation, emotion recognition, awareness training and theory of emotion regulation, including acceptance and validation skills.
40947356|NCT05179655|OTHER|Treatment as usual|Within Mental Health Services in Denmark child and adolescent psychiatrists provide specialized treatment for young psychiatric patients as outpatient services. In this trial the control intervention is treatment as usual (TAU) and consists of clinical assessment and treatment for patient's current primary psychiatric condition. TAU encounters a variety of clinical treatment and assessment offers, however, all within the field of expertise in child and adolescent psychiatry; out-patient care may consist of treatment for OCD, eating disorders, psychoses or affective disorders. TAU may consist of pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy (CBT), supportive counselling and/or psychoeducation.
40947357|NCT06391125|DRUG|normal Saline|0.5ml normal saline solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
40947358|NCT06391125|DRUG|Lidocaine|0.5ml 1% lidocaine solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
40947359|NCT00468468|BEHAVIORAL|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
40947360|NCT03751644|OTHER|Electrical stimulation|Patients with systemic autoimmune myopathies will receive peripheral electrical stimulation in thigh muscles
40947361|NCT03878238|DIETARY_SUPPLEMENT|Probiotic Bths-003|Probiotic with maltodextrin as a carrier.
40947362|NCT03878238|OTHER|Placebo|Placebo with maltodextrin base.
40947363|NCT04909931|DRUG|Vitamin D 2|Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks
40947364|NCT04909931|DRUG|Placebo|Second arm : add on placebo for 12 weeks
40947365|NCT01501331|DEVICE|CRTD or ICD (Energen)|RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
40947366|NCT03358797|BEHAVIORAL|Attention-control|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics
41133080|NCT01828671|OTHER|Oral Glucose Solution 296 mls|Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
40947367|NCT03358797|BEHAVIORAL|Community based intervention with resilience training|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
41286885|NCT03455946|BEHAVIORAL|DASH cloud with Alexa|"Participants will download and install the Alexa and Nutritionix application (app) onto their smartphone and study staff will setup the study-specific account to send data to Duke's software system called Prompt. Participants will be instructed to invoke through voice their dietary intake daily for three months using the Nutritionix app through the Amazon Alexa personal assistant. DASH Cloud will access participant's dietary intake data through the Nutritionix application programing interface (API) for three months. Participants' data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send a daily or weekly feedback text message with a score reflecting DASH adherence for the prior days or week's food consumption using a previously validated scoring system."
40757787|NCT03269266|DIAGNOSTIC_TEST|Scrub Typhus RDT Test|"A transfer pipette or loop will be used to transfer 10 µL of whole blood from a finger prick to the sample pad area on the scrub typhus test strip and the test will be performed on site according to the manufacturer's instructions. Tests will be read by two independent readers and results recorded as positive, negative or invalid.~In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi."
40757788|NCT00963885|DRUG|Copegus|1000 or 1200mg po daily for 24 or 48 weeks
40757789|NCT00963885|DRUG|Pegasys|180micrograms sc weekly for 24 or 48 weeks
40757790|NCT00963885|DRUG|Placebo|po for 12 weeks
40757791|NCT00963885|DRUG|Placebo|po for 24 weeks
41286886|NCT04403438|OTHER|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
40757792|NCT00963885|DRUG|RO5190591 (Danoprevir)|300mg po q8h for 12 weeks
40757793|NCT00963885|DRUG|RO5190591 (Danoprevir)|600mg po q12h for 12 weeks
40757794|NCT00963885|DRUG|RO5190591 (Danoprevir)|900mg po q12h for 12 weeks
40757795|NCT00963885|DRUG|RO5190591 (Danoprevir)|300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
40757796|NCT05646173|DEVICE|vagus stimülation device|Vagustim is a wearable medical technology device that focuses on non-invasive bilateral auricular vagus nerve stimulation (VNS). VNS is a clinically approved, safe and effective neuromodulation method.
40757797|NCT05646173|DEVICE|Electrophysical agents|Electrophysical agents (EPAs) are those modalities that administer thermal, mechanical, electrical or light energy to the patient to provide physiological effects and therapeutic benefits.
40757798|NCT05646173|OTHER|home exercise program|The home exercise program will be explained to the patients by the physiotherapist and will also be given to the patient in the form of a brochure. Patients will be instructed to do the exercises regularly, three times a day for ten repetitions each day. The content of the exercises is updated weekly.
40757799|NCT03633058|DRUG|Ketamine|oral ketamine dosed twice daily for 5 days
40757800|NCT00289978|DRUG|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
40757801|NCT00289978|DRUG|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
41286887|NCT02821286|OTHER|Observational study|Blood sampling
40757802|NCT00289978|DRUG|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
40757803|NCT01337505|DRUG|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
40757804|NCT00912873|DRUG|0.1% Ropivacaine|Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
40757805|NCT00912873|DRUG|0.4% Ropivacaine|Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
41133081|NCT01828671|OTHER|Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
41133082|NCT01828671|OTHER|Low Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
40757808|NCT05405257|DRUG|Oxytocin|IV 1IU Oxytocin in 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
40757809|NCT05405257|OTHER|Placebo|IV, 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
40757810|NCT05996445|BIOLOGICAL|XmAb662|Intravenous (IV) administration
40757811|NCT05996445|BIOLOGICAL|Keytruda® (pembrolizumab)|Intravenous (IV) administration
41133083|NCT01828671|OTHER|Moderate Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
41286888|NCT03845283|BEHAVIORAL|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.
41286889|NCT03845283|BEHAVIORAL|Physical Activity Intervention|An program designed to help participants gradually increase their physical activity and maintain an active lifestyle. The program encourages bouts of moderate-to-vigorous physical activity. Participants in this group will receive a Fitbit Versa to help them monitor their physical activity that they will be advised to wear daily. Participants will receive brief (5-10 minute) lessons weekly for the first 3 months and monthly for the last 3 months.
41286890|NCT03845283|BEHAVIORAL|Bite Counter|Participants will receive a Bite Counter device to help them monitor and reduce their within-meal consumption. Participants will be asked to wear the device daily.
40757812|NCT00423462|BEHAVIORAL|Brief dynamic psychotherapy|
40757813|NCT02618733|DRUG|Ticagrelor|90mg, twice a day
40757814|NCT02618733|DRUG|Clopidogrel|75mg, once a day
40757815|NCT03795870|DIETARY_SUPPLEMENT|Polymeric Tube Feeds|Polymeric tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with blenderized tube feeds
40757816|NCT03795870|DIETARY_SUPPLEMENT|Blenderized Tube Feeds|Blenderized tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with polymeric tube feeds
40757817|NCT01740518|DRUG|polyethylene glycol, ascorbic acid|comparison of different solutions for bowel preparation
40757818|NCT00266032|DRUG|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
40757819|NCT00266032|DRUG|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
40757820|NCT00266032|DRUG|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
40757821|NCT05708690|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
40757822|NCT05708690|DRUG|normal saline|Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
41133084|NCT01828671|OTHER|High Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
41133085|NCT00686465|OTHER|PET/CT scan|Patients will undergo whole body FDG-PET/CT imaging
41133086|NCT06148441|DIAGNOSTIC_TEST|bone morphogenetic protein-2 (BMP-2)|novel biomarkers associated with in-stent restenosis after percutaneous coronary intervention
41133087|NCT00006350|BIOLOGICAL|daclizumab|
41133088|NCT00006350|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41133089|NCT00006350|DRUG|mycophenolate mofetil|
41133090|NCT00006350|DRUG|tacrolimus|
41133091|NCT00006350|PROCEDURE|peripheral blood stem cell transplantation|
41133092|NCT03004625|DRUG|daclatasvir|to evaluate the treatment efficacy and safety of the drug in HCV patients
41452828|NCT00113919|DRUG|Busulfan|Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin\* 10 mg/m, Continuous infusion 1-4 Adriamycin\*\* 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
41452829|NCT01166464|BEHAVIORAL|text messaging for smoking cessation|A 7-week program of daily text messages
41452830|NCT01166464|BEHAVIORAL|Generic text messages|non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
41452831|NCT02349763|DRUG|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
41452832|NCT02349763|DRUG|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
41133093|NCT03004625|DRUG|asunaprevir|to evaluate the treatment efficacy and safety of the drug in HCV patients
40757823|NCT00545948|DRUG|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
40757824|NCT00545948|DRUG|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
40947368|NCT03358797|BEHAVIORAL|intervention-HPP|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics. In addition, there will be training in leadership skills, community interventions, community needs assessment, intervention planning and outcomes assessment.
41133094|NCT03004625|DRUG|Ribavirin|to evaluate the treatment efficacy and safety of the drug in HCV patients
41452833|NCT05526703|DRUG|D064, D701, placebo of D012|Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
41452834|NCT05526703|DRUG|D012, placebo of D064, placebo of D701|Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
41133095|NCT01487460|DRUG|TAP311|
41133096|NCT03194659|DIETARY_SUPPLEMENT|Choline|Choline chloride is a water soluble choline salt that will be provided in a juice solution to participants to be consumed daily. The intervention will increase dietary choline intake by 500mg/day.
41133097|NCT00405990|BEHAVIORAL|Voluntary counselling and HIV testing in ANC for PMTCT|VCT for 30 minutes in ANC
41286891|NCT03845283|BEHAVIORAL|Virtual Reality|This program allows participants to practice behavioral weight loss skills using a virtual reality system compatible with their home device. This program helps patients practice these skills in the following artificial settings: at home, at work, at the gym, and at a party. Each participant will be asked to play through each scene at least once during their participation, though they are encouraged to use the program regularly.
41286892|NCT03845283|BEHAVIORAL|Virtual Meetings|Participants will attend virtual meetings using their own device. Each virtual meeting focuses on a specific topic that will help patients lose weight. Participants are asked to virtually attend at least 6 meetings during their participation. There is no limit to how many they can attend. The meeting topics will rotate and repeat on a schedule.
41286893|NCT02614846|DRUG|Hetrombopag Olamine|
41286894|NCT05785754|DRUG|DCSZ11|A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
41286895|NCT05785754|DRUG|Pembrolizumab|Pembrolizumab injection
41286896|NCT01993355|OTHER|Physiotherapy|Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
41133098|NCT00405990|BEHAVIORAL|VCT|HIV VCT for PMTCT
41133099|NCT01128959|DRUG|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
41286897|NCT01993355|OTHER|Intervention 1|Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.
41286898|NCT01993355|BEHAVIORAL|Intervention 2|Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
41286899|NCT02808715|OTHER|Blood Sample Collection|Blood draw #1 Site of blood draw: IMU Volume of blood: 20mL Purpose of blood draw: Isolation of genomic DNA Site of storage: NHRIS biobank Coding: Specimens will be identified using a research ID that will be affixed to samples using bar-coding. After the blood is collected, stored the blood at 4 degree Celsius and contact the NHCS biobank coordinator to collect the blood samples. The blood samples must be collected within 1 hour of collection.
41286900|NCT02850250|DRUG|Cefuroxime|Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
40947369|NCT03358797|BEHAVIORAL|Pilot|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
40947370|NCT00946478|DRUG|Pimecrolimus|"20 AD patients will be given pimecrolimus 1% to apply twice daily for up to three weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
40947371|NCT00946478|OTHER|Vehicle cream|"20 AD patients will be treated with vehicle cream twice daily for up to 3 weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
41133100|NCT00476736|DRUG|Effect on small airways (N-Acetylcystein)|
41286901|NCT02319772|DRUG|BCX4430|
41286902|NCT02319772|DRUG|Placebo|
41286903|NCT01224899|PROCEDURE|Left cervico-thoracic sympathetic blockade|Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
41286904|NCT04550507|BEHAVIORAL|Mindful sensory awareness intervention|The mindfulness sensory awareness exercise will be a brief (3-5 minutes), guided meditation focusing on sensory and interoceptive awareness developed by Co-I Price, modified slightly to meet the needs of this age group and targeted for attention to indicators of fatigue or a sense of overstimulation. Youth will be asked to use the exercise after ending media use but before trying to sleep. The meditation component will be delivered via an audio-guided MP3, along with illustrated instructions in both handout and video, and a guided workbook that coaches youth over the 8-week intervention period to practice their skills, reflect on their experiences, and maintain adherence.
41452835|NCT04046380|DIAGNOSTIC_TEST|work of breath measurement and calculation|The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.
41452836|NCT02795858|DRUG|Ramucirumab|
41452837|NCT02795858|DRUG|Somatostatin Analog|
41452838|NCT01167335|DRUG|BGG492|
41452839|NCT01167335|DRUG|Placebo|
40757825|NCT04098913|BEHAVIORAL|Reduced screen-based media use|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use screen-based media for necessary contact/errands. If one of the adult participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
40947372|NCT02570360|BEHAVIORAL|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
40947373|NCT02570360|BEHAVIORAL|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
40947374|NCT06112548|PROCEDURE|primary unilateral TKA|Primary unilateral total knee arthroplasty with cruciate scarifying cemented DePuy Synthes PFC Sigma prosthesis.
40947375|NCT06112548|DRUG|Bupivacain|low body weight (0.50%, 20cc) intraoperative periarticular injection
40947376|NCT06112548|DRUG|ketorolac|1ml of 30mg/ml ketorolac intraoperative periarticular injection
40947377|NCT06112548|DRUG|epinephrine|0.5ml Adrenaline 1mg/ml intraoperative periarticular injection
40947378|NCT06112548|DRUG|Paracetamol|IV Paracetamol \[Ofirmev\] introduced every 6 hours after surgery
40947379|NCT06112548|DRUG|Ketorolac|IV Ketorolac {Toradol} introduced every 12 hours after surgery.
40947380|NCT06112548|DRUG|Tramadol|IV Tramadol \[Ultram\] introduced when needed after surgery
40947381|NCT03643159|COMBINATION_PRODUCT|Abilify MyCite - Digital Medicine System|The Abilify MyCite system is a drug-device combination product comprised of aripiprazole (an atypical antipsychotic) tablets embedded with a sensor that communicates with a patch (wearable sensor) and a medical software application with collected information (ingestion, mood, activity, rest) tracked and summarized for participants, healthcare providers, and potential caregivers. Abilify MyCite is intended to track drug ingestion and is indicated for the treatment of adults with schizophrenia (SCH), bipolar 1 disorder (BP1) (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with major depressive disorder (MDD).
41133101|NCT04843449|DRUG|ASC40|Oral tablets
41452840|NCT00854126|DRUG|GDC-0980|Escalating repeating dose
41452841|NCT02918058|OTHER|MedSafer|MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
40757826|NCT01507103|BIOLOGICAL|Tecemotide (L-BLP25)|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
40947382|NCT03643159|DRUG|Aripiprazole or other oral antipsychotics|For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
40947383|NCT03222011|PROCEDURE|Standard (single) endoscopic stricture dilatation|single endoscopic stricture dilatation
40947384|NCT03222011|PROCEDURE|Intensive endoscopic stricture dilatation|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
40947385|NCT05567315|DRUG|local anaesthetic injection|Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
40947386|NCT05567315|DEVICE|hypnosis with Virtual reality mask|A 20-minute virtual reality hypnosis session is performed from the time the patient is placed on the surgical table until the end of the oocyte poncture
40947387|NCT01863953|DRUG|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
40947388|NCT01863953|DRUG|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
40947389|NCT01863953|DRUG|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
40947390|NCT01863953|DRUG|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
40947391|NCT03424473|DRUG|Tucatinib|
40757827|NCT01507103|DRUG|cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
40947392|NCT02423837|DRUG|Rituximab, bendamustine|
40947393|NCT04215250|OTHER|andropulous method|Counts the CVC depth using specific equation
40947394|NCT04215250|DEVICE|ECG|Using ECG to monitor the insertion of the CVC
40757828|NCT01507103|OTHER|Chemoradiotherapy|Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m\^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
40757829|NCT03073070|DRUG|biotin labeled RBCs|Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
40757830|NCT05805150|DEVICE|Control Lens (stenfilcon A)|One week wear
40757831|NCT05805150|DEVICE|Test Lens (senofilcon A)|One week wear
40757832|NCT04680208|PROCEDURE|Surgical procedure under anesthesia|Different varieties of surgical procedures done under anesthesia
40757833|NCT02446288|DEVICE|TMJ Next Generation|
40757834|NCT02446288|DEVICE|DSG Relaxer|
40757835|NCT01269320|DRUG|Femarelle|Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
40757836|NCT03906955|BEHAVIORAL|Efficacy for Lifestyle PA|The intervention group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for engaging in lifestyle physical activity.
40757837|NCT03906955|BEHAVIORAL|Efficacy for Work-life Balance|The time-matched control group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for work-life balance.
40947395|NCT05053711|DEVICE|rTMS+rPMS_iTBS_M|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
40947396|NCT05053711|DEVICE|rTMS+rPMS_cTBS_M|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
41133102|NCT04843449|DRUG|Itraconazole|Oral capsules
41133103|NCT04843449|DRUG|rifampicin|Oral capsules
41133104|NCT01822756|DRUG|ruxolitinib|
41133105|NCT01822756|DRUG|gemcitabine|Other names: Gemzar®
41133106|NCT01822756|DRUG|nab-paclitaxel|Other names: Abraxane®
41133107|NCT01822756|DRUG|filgrastim|Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
41133108|NCT06487702|DRUG|fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium|"Fruquintinib administration for 2 weeks followed by 1-week break~Candonilimab：10 mg/kg，D1，Q3W；~Tegafur，Gimeracil and Oteracil Potassium：30mg BID for body surface area \< 1.25 m2; 40mg BID for body surface area of 1.25-1.5 m2; and 50mg BID for body surface area \>1.5 m2; D1-14, q3w"
41286905|NCT04550507|BEHAVIORAL|Mindful sensory awareness + mindful body awareness check-ins intervention|During the intervention period for Group B: Mindful Sensory \& Body Awareness(the second 8 weeks), they will receive the same mindful sensory awareness intervention, and also learn the mindful body awareness check-ins to guide media use choices strategy (referred to here as the check-ins component). We will coach youth to pause briefly every 30 minutes during media use to discern if they detect physical, cognitive, or emotional signs of escalated state arousal, and to make an intentional and real-time choice about possible changes in media use content or duration to help decrease state arousal levels before bed.
41286906|NCT03235908|OTHER|Observation only|Observation only
40757838|NCT06088277|BEHAVIORAL|TM HIV|Participants will receive 5 intervention text messages (TM) about HIV risk and testing per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
41286907|NCT02734732|DRUG|Trimethoprim/Sulfamethoxazole|
41286908|NCT02734732|DRUG|Ciprofloxacin|
40757839|NCT06088277|BEHAVIORAL|TM HL|Participants will receive 5 intervention text messages (TM) about promoting healthy living (HL) per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
41286909|NCT04119908|DEVICE|Sublingual videomicroscopy|Measurement of sublingual capillary density by video microscopy
41286910|NCT04119908|BIOLOGICAL|blood sample|Collection of citrate tubes of 5 mL at baseline and at 36 months
40757840|NCT00168285|BEHAVIORAL|Pulmonary Rehabilitation|
41133109|NCT02070809|PROCEDURE|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
41286911|NCT00598130|BIOLOGICAL|Fleece|Fibrin Patch
41286912|NCT02367612|DIETARY_SUPPLEMENT|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
41286913|NCT02367612|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
41286914|NCT01457339|DRUG|SPD489 (Lisdexamfetamine dimesylate)|SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
40947397|NCT05053711|DEVICE|rTMS+sham rPMS_M|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
40947398|NCT05053711|DEVICE|rTMS+rPMS_iTBS_U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at ulnaris nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
40947399|NCT05053711|DEVICE|rTMS+rPMS_cTBS_U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at ulnar nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
40947400|NCT05053711|DEVICE|rTMS+sham rPMS_U|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at ulnar nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
40947401|NCT03860597|DRUG|Memantine|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
40947402|NCT03860597|DRUG|Placebos|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
40947403|NCT00145782|BEHAVIORAL|Life style|
41286915|NCT01457339|DRUG|Placebo|Placebo Capsule(s) for oral use taken once daily for 30 days
41286916|NCT00865501|DRUG|spironolactone|25mg per oral once daily
41286917|NCT00865501|DRUG|placebo|placebo
41286918|NCT02886312|DEVICE|Supplemental Oxygen Delivery System|
41452842|NCT02099318|OTHER|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
41452843|NCT02099318|OTHER|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
40757841|NCT05406531|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
40757842|NCT05406531|BEHAVIORAL|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
40757843|NCT05406531|BEHAVIORAL|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
40947404|NCT00263731|OTHER|13-C-glucose|"10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer."
41133110|NCT02070809|PROCEDURE|split-thickness skin graft method|This method is traditional split-thickness skin graft
41133111|NCT04165018|PROCEDURE|Fine-Needle Biopsy (FNB)|Fine-needle biopsy may be used to take samples of a pancreatic neoplasm.
40947405|NCT00299182|DRUG|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
41133112|NCT03150758|DEVICE|10Hz + 100 micro-seconds|10Hz Electrical Stimulation with a pulse width of 100 micro-seconds
41133113|NCT03150758|DEVICE|10Hz + 200 micro-seconds|10Hz Electrical Stimulation with a pulse width of 200 micro-seconds
41133114|NCT03150758|DEVICE|7Hz + 100 micro-seconds|7Hz Electrical Stimulation with a pulse width of 100 micro-seconds
41133115|NCT03150758|DEVICE|7Hz + 200 micro-seconds|7Hz Electrical Stimulation with a pulse width of 200 micro-seconds
41452844|NCT02179190|DEVICE|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
41452845|NCT06217432|OTHER|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
41452846|NCT01239303|DIETARY_SUPPLEMENT|Citrulline|single dose
41452847|NCT01239303|DIETARY_SUPPLEMENT|alanine|single dose
41452848|NCT05686993|DRUG|Cinnarizine|Cinnarizine oral 30mg TDS
40947406|NCT00299182|DRUG|Rituximab|375 mg/m\^2 by vein over 4-6 hour infusion day 1, each cycle.
41452849|NCT05686993|DRUG|NIFEdipine ER|Nifedipine oral 60mg daily extended release
41452850|NCT05756829|OTHER|High frequency, low touch virtual health care|Virtual visits between certified diabetes educators and patients occurring every 2 +/- 1 weeks for a total of 6 months
41452851|NCT02483507|OTHER|Ultrasound-guided approach to peripheral vascular access|the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
41286919|NCT04844827|GENETIC|Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily|Interventions will consist of a diagnostic and symptomatic videothoracoscopy in patients with pleural metastasis under general anesthesia, as part of a standard of care procedure. Fragments of these pleural biopsies (one for routine diagnosis and two for scientific purposes) will enrich the biocollection. Five blood samples will be taken at the time of surgery (3 to 5 ml / tube). These biological samples will be stored in the HCL CRB tumor bank. At the same time, patient demographic data will be collected and anonymized. In the long term, the biological material will be used by IARC for carrying out multi-omics and bioinformatics analyzes
41286920|NCT00863187|BIOLOGICAL|rituximab|b cell depletion
41286921|NCT01581411|DRUG|Tissue Plasminogen Activator|Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
41286922|NCT00215501|DRUG|Capecitabine|Orally twice a day for 14 days (dosage will vary)
41452852|NCT03541252|DRUG|AFL-assisted cisplatin+5-FU|Patients will receive AFL-assisted cisplatin+5-FU as a treatment for their BCC. In brief, treatment areas consisting of tumors and a 5 mm margin will undergo CO2 laser exposure followed by 60 min topical application of a marketed and commercially available IV cisplatin solution (0.1%) After removal of cisplatin, a commercially distributed 5-FU cream (5%) will be applied to the treatment area at a dose of 0.125 ml per cm2 and left under occlusion. After skin evaluations on Day 1 and 5 after treatment, the same 5-FU dose will be applied, again left under occlusion. In total, 5-FU will remain on the skin for 7 days after AFL treatment whereafter it will be washed off. An additional repeat AFL-cisplatin+5-FU treatment on Day 30 will be offered if tumors persist, based on clinical evaluation and imaging on Day 30.
41452853|NCT03006757|OTHER|titanium dioxide denture base|
40757844|NCT05952310|OTHER|Natural Killer (NK) cells (a new immunotherapy)|"It is proposed to infuse allogeneic NK cells from a haploidentical donor, after administration of lymphoablative chemotherapy and/or radiotherapy, as a treatment in patients with sarcomas, who have completed conventional treatment but maintain detectable residual disease.~The administration of low doses of radiotherapy is aimed at stressing residual tumor cells by increasing the expression of NK cell activating receptor ligands.~The administration of prior chemotherapy aims at immunosuppressing the patient, allowing immunotherapy with allogeneic NK cells from haploidentical donor as well as autologous NK cell recovery to lead the immune reconstitution after chemotherapy, prolonging the antitumor effect.~In conjunction with NK cell infusion, low doses (1x106/UI/m2) of interleukin 2 (IL-2) will be administered subcutaneously every 48h for a maximum of 6 doses, to favor the expansion and antitumor effect of NK cells."
40757845|NCT02189967|RADIATION|conventional fractionation|In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
40757846|NCT02189967|RADIATION|accelerated fraction|In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
40757847|NCT03338920|DRUG|sumatriptan nasal powder|nasal powder administered via nosepiece
40757848|NCT03338920|DRUG|Placebo|lactose monohydrate powder administered via nosepiece
40757849|NCT05855278|DIAGNOSTIC_TEST|PET/MRI|The participants receive 18F-FDG PET/MRI before and during definitive chemoradiotherapy.
40757850|NCT01941342|PROCEDURE|Pancreatoduodenectomy|
40757851|NCT01941342|PROCEDURE|ENBD and Pancreatoduodenectomy|
40757852|NCT01941342|PROCEDURE|EBD and Pancreatoduodenectomy|
40757853|NCT01941342|PROCEDURE|PTCD and Pancreatoduodenectomy|
40757854|NCT02039206|DEVICE|Deep TMS|1Hz Stimulation
40947407|NCT00299182|DRUG|Cyclophosphamide|300 mg/m\^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, \& 5.
41286923|NCT00215501|DRUG|5-Fluorouracil (5-FU)|Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
40947408|NCT00299182|DRUG|Vincristine|1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.
40947409|NCT00299182|DRUG|Doxorubicin|50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.
40947410|NCT00299182|DRUG|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,\& 5.
41452854|NCT04879537|OTHER|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
41452855|NCT04946708|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions. All participants (and immediate caregiver if necessary) will receive training in: 1) basic device management (join a zoom meeting, watch a YouTube video), 2) use of the portable spirometer and its associated app, 3) use of finger pulse oximeter and 4) recording of the values in a dairy.
40757855|NCT03090542|DIETARY_SUPPLEMENT|clinoptilolite|randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases
40757856|NCT02478749|PROCEDURE|arm retraction|gently pulling through the ipsilateral arm to the knee
40757857|NCT04125758|BEHAVIORAL|Mindfulness training|Brief audio recordings discussing mindfulness or guided mindfulness practices.
40757858|NCT04125758|BEHAVIORAL|Tracking time spent on mobile device|Participants will record each day how much time they estimate they spent on their smart phone in the past 24 hours.
40947411|NCT00299182|DRUG|Methotrexate|200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours Day 2, Cycles 2, 4 \& 6.
40947412|NCT00299182|DRUG|Cytarabine|3 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4; OR,1 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4 for patients \> 60 years and for patients with serum creatinine \> 1.5 mg/dL; Cycles 2,4,\& 6.
40947413|NCT00299182|DRUG|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
40947414|NCT00037622|DRUG|ACH-126, 443 (beta-L-Fd4C)|
40947415|NCT05688449|DRUG|Bupivacaine-fentanyl|A 20 ml bolus of 2 mcg/ml fentanyl + 0.125% bupivacaine solution will be administered to the bupivacaine group via the epidural catheter, and 5ml/hour infusion will be started.
40947416|NCT05688449|DRUG|Saline|A 20 ml bolus of saline will be administered to the saline group via the epidural catheter, and 5ml/hour infusion will be started.
40947417|NCT05353361|DRUG|SHR-A1811：Pyrotinib|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral
41286924|NCT00215501|DRUG|Irinotecan|Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
41286925|NCT00215501|DRUG|Cisplatin|Intravenously weekly for 2 weeks followed by a one week rest period
41286926|NCT06479005|DEVICE|Oura Ring|The Oura ring will remotely monitor the patients vitals at home continuously
40947418|NCT05353361|DRUG|SHR-A1811；Pertuzumab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip
40947419|NCT05353361|DRUG|SHR-A1811；Adebrelimab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip
40947420|NCT05353361|DRUG|SHR-A1811；Albumin paclitaxel|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip
40947421|NCT06366100|BEHAVIORAL|Dialectical Behavior Therapy for Substance Use Disorder (DBT-SUD)|"In phase 1, DBT online training will consist of the following contents:~Block 1~1.1. Introduction to the key concepts 1.2. DBT-SUD program 1.3. Why DBT for alcohol addiction? 1.4. Proposed content for the group intervention.~Block 2~2.1. DBT skills training modules~In phase 2, DBT-SUD intervention will consist of about the following sessions:~GOALS OF SKILLS TRAINING AND MINDFULNESS:~S1: Goals of skills training; Observing, Describing and Participating~S2: Non-judgmentally, One-mindfulness, Effectively~DISTRESS TOLERANCE:~S3: Crisis Survival skills~S4: Crisis Survival and Radical Acceptance~ADDICTION SKILLS:~S5: Dialectical Abstinence.~S6: Clear Mind~S7: Burning Bridges-Building New Bridges~S8: Community Reinforcement~EMOTIONAL REGULATION:~S9: Identifying emotions and model of emotion~S10: Check the facts. Opposing Action~S11: Problem Solving. Reducing vulnerability~S12: Self-management and rehabilitation"
40947422|NCT06366100|BEHAVIORAL|Unified Protocol (UP)|"In phase 1, the UP training will have following contents:~Block 1~1.1. Introduction to key concepts 1.2. Why UP for alcohol addiction? 1.3. Dimensional assessment and case formulation. 1.4. Main characteristics of UP~Block 2~2.1. Modules of UP~In phase 2, UP intervention will consist of:~MOTIVATION:~S1: Motivation enhancement for treatment~UNDERSTANDING EMOTIONS:~S2: Understanding and model of emotions S3: Tracking emotional responses~MINDFULNESS:~S4: Emotion awareness~COGNITIVE FLEXIBILITY:~S5: Cognitive reappraisal to increase thinking flexibility~EMOTION DRIVEN BEHAVIORS:~S6: Emotional avoidance S7: Emotion-driven behaviors and alternative action~AWARENESS AND TOLERANCE:~S8: Tolerance of physical sensations~EMOTIONAL EXPOSURE:~S9: Interoceptive and situational emotion exposure S10: Exposure practice~RELAPSE PREVENTION:~S11: Relapse prevention S12: Review of progress"
40947423|NCT02770833|OTHER|Fish and carbohydrats with low or high GI|
40947424|NCT02770833|OTHER|Veal and carbohydrats with low or high GI|
40947425|NCT00076973|DRUG|montelukast sodium|Duration of Treatment: 6 months
40947426|NCT00076973|DRUG|Comparator: placebo|Duration of Treatment: 6 months
41286927|NCT00527852|DEVICE|Flocked swab|
41286928|NCT03294304|DRUG|Nivolumab|Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
41286929|NCT03294304|DRUG|Cisplatin|Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
41286930|NCT03294304|DRUG|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
41286931|NCT00998101|DRUG|cetuximab|400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes
41286932|NCT00998101|DRUG|carboplatin|AUC=6 Day 1 of treatment over 30 minutes every 21 days
41286933|NCT00998101|DRUG|ixabepilone|30 mg/m2 , Day 1 over 3 hours every 21 days
41286934|NCT01507194|DRUG|Ondansetron|Single IV dose
41286935|NCT01507194|DRUG|Vestipitant|Single IV dose
41286936|NCT05203965|DRUG|Mavoglurant (AFQ056)|Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.
40757859|NCT06570135|DIAGNOSTIC_TEST|Detecting Brain Activity with Functional Near Infrared Spectroscopy|Use a functional near-infrared spectroscopy to detect brain activity in the two groups of subjects during resting state and task state.
41286937|NCT05203965|DRUG|Placebo|Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.
40757860|NCT04883775|DRUG|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent.
40757861|NCT04883775|DRUG|MVT-5873|MVT-5873 will be administered intravenously over at least 60 minutes.
40757862|NCT05579288|DRUG|Nitrous oxide (N2O/O2)|Nitrous oxide (N2O/O2) for pain alleviation
40947427|NCT05900895|DRUG|Olaparib|Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
40947428|NCT05900895|DRUG|17b-estradiol|17b-estradiol will be taken orally three times per day.
41286938|NCT03147027|PROCEDURE|VT ablation|Substrate mapping for VT will be performed with the CARTO electroanatomical system.
41286939|NCT03147027|OTHER|medication|medication to prevent sustained VT and ICD therapies
41286940|NCT01430247|OTHER|Amblyopia screening|Monocular vision testing at near (40cm) and distance (3m)
41286941|NCT00971321|BIOLOGICAL|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections
41286942|NCT00852930|PROCEDURE|laser and MLD combined|The intervention is therapist administered laser and mld treatment combined
41286943|NCT00852930|PROCEDURE|laser alone|The intervention is therapist administered laser
41286944|NCT00852930|PROCEDURE|manual lymphatic drainage|The intervention is therapist administered manual lymphatic drainage
41286945|NCT00676039|DRUG|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
41286946|NCT00676039|DRUG|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
40757863|NCT05579288|DRUG|Oxygen (O2)|Oxygen (O2) as placebo for control group
41286947|NCT00676039|DRUG|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
41286948|NCT00676039|DRUG|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
41286949|NCT04697147|BEHAVIORAL|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
41286950|NCT01642537|DEVICE|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
41286951|NCT01043640|DRUG|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
41286952|NCT01043640|DRUG|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
40947429|NCT05873062|DRUG|AUT00201|Single oral dose
41286953|NCT01043640|DRUG|Busulfan|Administered every 6 hours: If \< or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If \> 12 kg then 0.8 mg/kg/dose IV
41286954|NCT01043640|PROCEDURE|Allogeneic stem cell transplantation|Administered \> 24 hours after last dose of busulfan.
41286955|NCT01043640|DRUG|Cyclosporine A|"2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~* If body weight is ≤ 40 kg dosing will be 3 times daily~* If body weight is \> 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose)."
41286956|NCT01043640|DRUG|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC\>500 x 10\^6 neutrophils/L x 3 days and chimerism \>90%), whichever is later.
40947430|NCT05873062|DRUG|Placebo|Single oral dose
41286957|NCT01893177|BIOLOGICAL|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
41286958|NCT01986205|COMBINATION_PRODUCT|Hyperbaric Oxygen|Hyperbaric oxygen (USP oxygen \>99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.
40947431|NCT00169546|DRUG|Salmeterol/fluticasone propionate|
40947432|NCT00169546|DRUG|Fluticasone propionate|
40947433|NCT03530527|PROCEDURE|ERCP with biliary stenting|ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.
40947434|NCT03530527|PROCEDURE|EUS guided biliary drainage|EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.
40947435|NCT05543889|OTHER|Educational package|Online learning package that will discuss the van Herick technique, grading, accuracy and information and discusses the current guidelines for primary angle closure suspect referral.
40947436|NCT04763785|DEVICE|Corneal tomography with Eyestar 900|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
40947437|NCT04763785|DEVICE|Corneal tomography with Pentacam|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
40947438|NCT04763785|DEVICE|Biometry with IOL-Master|Non-invasive biometry for presurgical intraocular lens calculation
40947439|NCT04763785|OTHER|retrospective analysis, no intervention|retrospective analysis of 4500 existing, fully anonymised picture data
40947440|NCT01293773|DEVICE|Taxus Element stent|paclitaxel-eluting stent
40947441|NCT01293773|DEVICE|Integrity Resolute stent|ABT 578-eluting stent
40947442|NCT01293773|DEVICE|Xience Prime stent|Everolimus-eluting stent
40947443|NCT06534034|PROCEDURE|Dental implant placement|Dental implant placement on edentulous jaw.
40947444|NCT00776282|DRUG|loratadine 10 mg orally disintegrating|
40947445|NCT01497431|DIETARY_SUPPLEMENT|Selenium|Given PO
40947446|NCT01497431|OTHER|Placebo|Given PO
41286959|NCT01986205|COMBINATION_PRODUCT|Minimal pressure air|Room air delivered in a hyperbaric chamber with minimal pressurization.
41286960|NCT00002828|DRUG|fluorouracil|
41286961|NCT00002828|DRUG|raltitrexed|
41286962|NCT02119130|DEVICE|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
41286963|NCT04349930|DRUG|Cannabidiol vaginal suppository|Cannabidiol vaginal suppository
41286964|NCT04349930|DRUG|Placebo vaginal suppository|Placebo vaginal suppository
41286965|NCT03229577|BEHAVIORAL|Sudarshan Kriya Yoga|Yoga-based breathing program.
41286966|NCT03229577|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness program.
41286967|NCT03229577|BEHAVIORAL|Emotional Intelligence|Emotional Intelligence program.
41286968|NCT01850381|DRUG|GM608|For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
41286969|NCT01850381|DRUG|Placebo Comparator|For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
41286970|NCT03728673|DRUG|Escitalopram Oral Capsules|Active capsules will contain 10 mg escitalopram oxalate.
41286971|NCT02203370|DEVICE|NIRS - Near-infrared spectroscopy|
41286972|NCT04760652|BEHAVIORAL|Cognitive Behavioral Therapy CBT|CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT
41286973|NCT04758793|OTHER|blood samples|3 citrated tubes and 3 EDTA tubes
41286974|NCT04758793|OTHER|biopsy of abdominal paroie|a muscle biopsy will be performed on the incision area
41286975|NCT00361530|DRUG|Statin|
41286976|NCT00834548|PROCEDURE|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
40757864|NCT03391791|GENETIC|Genetically engineered T Cell Receptors|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
41286977|NCT03556696|DEVICE|ANI-REMI-loop|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
40757865|NCT02808611|DRUG|propranolol|Reduction of the ANS response
40757866|NCT02808611|DRUG|Placebo|
40757867|NCT05722353|OTHER|Biocollection|Collection of blood samples and feces specimen at inclusion visit; clinical and biological assessment at each visit.
40947447|NCT01497431|OTHER|Laboratory Biomarker Analysis|Correlative studies
40947448|NCT01497431|OTHER|Pharmacological Study|Correlative studies
40947449|NCT01497431|DRUG|Methylselenocysteine|Given PO
41286978|NCT03556696|DEVICE|remifentanil pK/pD target administration device|standard practice, remifentanil administration using Minto's pK/pD model
40757868|NCT05528445|DEVICE|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
40757869|NCT00001789|DRUG|BG9588|
40757870|NCT03491085|DRUG|Amoxicillin/clavulanate|after tonsillectomy half of our patients will receive Amoxicillin /clavulanate for one week and the other half will not receive it.
40757871|NCT04198337|PROCEDURE|Endoscopic Full Thickness Resection|Endoscopic full thickness resection achieved by resecting the submucosal tumor using retraction techniques and submucosal dissection, followed by closure
41286979|NCT03556696|DRUG|Remifentanil|Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.
41286980|NCT03556696|DRUG|Propofol|propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range
40947450|NCT03455127|OTHER|FSI ECD|Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
40757872|NCT06569433|PROCEDURE|THERAPEUTIC EXERCISE AND MOBILISATION OF THE FEMORAL NERVE|"the control group that will perform only therapeutic exercise will perform a specific exercise programme for knee tendinitis under the supervision of a physiotherapist, while the intervention group that will perform therapeutic exercise plus femoral nerve mobilisation will receive therapeutic exercise sessions and femoral nerve mobilisations performed by a trained physiotherapist.~The intervention will last for 6 weeks, during which 60-minute sessions will be held at the centre, measurements will be taken during the six weeks, using standardised questionnaires to evaluate the variables (set out below) and always measuring the range of movement and femoral nerve mobility with the Slump Test on the same day of the week and at the same time of treatment."
40947451|NCT06496464|BEHAVIORAL|Intervention|"Phase 1 MASTER Coach Development Workshop (weeks 1) PE teachers participated in a 6-hour theory and practical teacher education workshop to a research team (JY) member, including 4h of reading relevant papers and books regarding the game-based approach (GBA) .~Phase 2 Eight weeks of teaching mentoring (weeks 2-7) This 8-week phase involved coaches implementing MASTER elements (e.g. 10-minute stretching before a sports game, teachers will give 1-2 sentences of praise during the game for individual students who make a reasonable effort) in their regular training sessions.~Phase 3 3 weeks peer assessed teaching/discussions (weeks 8-10) The mentor prepared and implement a 2-h training session designed to highlight important aspects of the MASTER framework and games-based coaching practices."
40947452|NCT03624244|DRUG|Aromatase Inhibitors|Maintenance of AI versus interruption of AI
40947453|NCT03945695|PROCEDURE|"Pneumatic Vitreolysis in combination with Drinking-Bird-Technique"|"1. Appropriate anesthesia and antiseptic preparation of the surgical field~2. Prophylactic paracentesis of the anterior chamber~3. One intravitreal injection of 0.2 to 0.3 ml of filtered sulfur hexafluoride gas (SF6) into the test eye Remark: Intraocular pressure of the examined eye is to be controlled before the intervention and kept at an appropriate level after paracentesis by manual application of pressure.~4. Patients are instructed to avoid supine position and to lie on one side or the abdomen during sleep until complete resorption of intraocular gas occured. In this period they should bend over several times during the day up to an angle of 90º or as much as possible, resembling the movement of a bird drinking water. (Hence the name drinking-bird-technique.)"
40947454|NCT03036904|DRUG|Venetoclax|Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
40947455|NCT03036904|DRUG|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
40947456|NCT03036904|DRUG|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
40947457|NCT03036904|DRUG|Vincristine Sulfate|Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
40947458|NCT03036904|DRUG|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
40947459|NCT03036904|DRUG|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
41286981|NCT03556696|DEVICE|ANI monitor|"ANI (Analgesia Nociception Index) value is used in the std_practice arm for guidance of the remifentanil Ce target"
41286982|NCT01358383|DRUG|naproxen|250mg, oral dose
41286983|NCT01358383|DRUG|esomeprazole|20mg, oral dose
41286984|NCT04272307|BIOLOGICAL|Blood samples|"At inclusion, at day 5, day 42 and at 3 months, one 2 ml EDTA blood tube will be collected for metabolomics.~Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method.~At inclusion, one 2 ml EDTA tube will be stored as a DNA collection."
41286985|NCT04272307|PROCEDURE|Stool samples|"One stool sample will be taken at baseline, day 5, day 42 and at 3 months and frozen at -80°C and divided in 2 aliquots.~One stool aliquot will be used for metabolomics. Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method. The other one will be used for microbiota analysis. Samples will be sent to the McGill University (Prof. SALEH's lab) for extraction and then, Génome Québec Innovation Centre (McGill University, Montréal, Canada) for sequencing of the V4 region of the 16S rRNA gene on Illumina MiSeq in paired-end mode."
41286986|NCT04272307|PROCEDURE|Colorectal biopsies|During routine flexible sigmoidoscopy, 6 biopsies will be collected with a 5 mm biopsy forceps at baseline and at 3 months. Biopsies will be placed into a sterile vial containing RNAlater (Qiagen, Hilden, Germany) and stored at -80°C. Two biopsies will be used for mucosal microbiome analysis in the same way as the stool sample. Four biopsies will be used for RNAseq. Samples will be shipped to Prof. SALEH's lab in Montréal for nucleic acid extraction. The McGill University and Génome Québec Innovation Centre (McGill University, Montréal, Canada) will provide library preparation and next generation sequencing. The average number of uniquely mapped reads per sequencing run will be 30 million reads per sample.
40757873|NCT04833907|DRUG|rAAV-Olig001-ASPA|Intracerebroventricular administration of a single dose
40757874|NCT04833907|DRUG|Levetiracetam|Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.
40947460|NCT03036904|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
41286987|NCT03133715|PROCEDURE|laparoscopic repair|surgical repair of ventral hernia using laparoscopic repair
41286988|NCT03133715|PROCEDURE|robot-assisted repair|surgical repair of ventral hernia using robot-assisted repair
40757875|NCT04833907|DRUG|Prednisone|Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.
40757876|NCT02003157|PROCEDURE|hypnosis during embryo transfer or usual transfer procedure|
40947461|NCT03606044|DEVICE|3D-models|"The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly"
41452856|NCT05053360|BEHAVIORAL|Healing Touch|"Healing Touch (HT), with a foundation in holistic nursing, is a gentle therapy that uses touch to promote health and well-being by balancing the human energy system. Healing Touch (HT) is a biofield therapy in which practitioners use their hands in a heart-centered and intentional way to provide energetic balance to support physical, emotional, mental and spiritual health. It is safe for all ages and works in harmony with, is complementary to, and may be integrated with standard medical care. Healing Touch is a collection of standardized, noninvasive techniques that clear, energize, and balance the human and~environmental energy fields."
41452857|NCT05053360|OTHER|Control|Quiet Time (QT) session is when a subject is provided with quiet for 15 minutes
40947462|NCT01384942|BEHAVIORAL|Meaning-Based Bereavement Group|A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
40947463|NCT01384942|BEHAVIORAL|Conventional Bereavement Group|An 8 week traditional bereavement group that follows a more conventional approach to grief support.
40947464|NCT00694915|BIOLOGICAL|Mycobacterium w|Immunomodulator
40947465|NCT00694915|BIOLOGICAL|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
40947466|NCT04111809|BIOLOGICAL|Blood and urine collection|collected 10 mL of blood and 15 mL of urine every 2 months until 12 months
40947467|NCT06136195|DRUG|Mavoglurant|The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.
40947468|NCT03561116|DIETARY_SUPPLEMENT|XAN|Daily intake of a sachet containing 12 mg of XAN
41286989|NCT05813470|BIOLOGICAL|Omalizumab (CinnaGen)|Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection
41452858|NCT03840577|DEVICE|Monitorization of sedation by Bispectral Index|The sedative dose administered through a continuous infusion pump will be adjusted based on the BIS value to maintain a target range of 40 to 60. If the BIS value is below the target range, the dose will be increased, and if it exceeds the range, the dose will be decreased, aiming to keep the BIS within the desired range.
41452859|NCT02516189|OTHER|Strength training program|"Strength Training program applied twice a week for sixteen weeks. Each training exercises has a total time of 50 minutes. Warm-up: 5 minutes of stretching. Training: Leg press; Leg Curl; Vertical traction; Chest press; Abdominal crunch; Lower back. Gametherapy.~Relaxation: 5 minutes of stretching."
41452860|NCT01519947|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants received 50-250 mcg SC according to local label
40947469|NCT03561116|DIETARY_SUPPLEMENT|Placebo|Daily intake of a sachet containing excipient
41286990|NCT05813470|BIOLOGICAL|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection
41452861|NCT01438060|DRUG|Aripiprazole (BMS-337039)|"Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks"
40947470|NCT00111488|DEVICE|Flex 4 and Generator|
40947471|NCT05907590|OTHER|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
40947472|NCT05907590|OTHER|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
40947473|NCT05907590|OTHER|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
40947474|NCT05907590|OTHER|Proprioceptive accuracy measurement during postural control|"The effect of muscle vibration on center of gravity displacement (center of pressure or COP) will be examined. Muscle vibration of the m. triceps surae (ankle muscles) and the lumbar multifidus (back muscles) (Johanson et al., 2011; Brumagne et al., 2008; Claeys et al., 2011; Cleays et al., 2015) will be used to examine the role of proprioception during postural control."
40947475|NCT05907590|OTHER|Proprioceptive accuracy measurement of the neck|The head reposition accuracy task will be carried out to assess proprioceptive accuracy of the neck. The most commonly used procedure is the head repositioning accuracy to neutral head position (HRA-to-NHP), first described by Revel and colleagues (1991).
40947476|NCT02614651|PROCEDURE|Find visual comfort threshold related to light intensity|"In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally."
40947477|NCT02614651|PROCEDURE|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
40947478|NCT02614651|PROCEDURE|Effectiveness of brightness control|"During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object."
41286991|NCT03376828|DEVICE|Macintosh laryngoscopy|Endotracheal intubation time using the Macintosh laryngoscope
41286992|NCT03376828|DEVICE|C-Mac Videolaryngoscope|Endotracheal intubation time using the C-Mac Videolaryngoscope
40947479|NCT02614651|PROCEDURE|Performance of color correction|"During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions."
40947480|NCT02614651|DEVICE|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
40947481|NCT00418249|DRUG|AS101|
40947482|NCT01940562|DRUG|eltrombopag|"Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children \< 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets."
40947483|NCT05336227|BEHAVIORAL|Virtual Reality Exergaming|The VR intervention will include home-based exercise using the Oculus Quest, a heart rate monitor (Polar OH1), BP cuff, and mobile application. The games will include rhythmic movements to music and sport/recreation activities that elicit high energy expenditure. Participants will be instructed to reach 150 minutes per week of moderate-exercise in week 1 and maintain this volume across the 12-week intervention. The intervention will include behavioral, physical education coaching through videoconference, which we refer to as Tele-PE. Tele-PE will aim to enhance adherence, provide basic exercise knowledge, and increase mastery playing the games. Calls will last 15 minutes, and be provided weekly in month 1, bi-weekly in month 2, and one call at the end of month 3.
40947484|NCT04293731|DIETARY_SUPPLEMENT|Symbiter-Smectite|Symbiter-Smectite contains biomass of alive probiotic microorganism symbiosis, colony forming units - CFU/g: Lactobacillus - 1.0х109, Bifidobacterium - 1.0х109, Lactococcus - 1.0х108, Propionibacterium - 1.0х108 and Acetobacter - 1.0х105; and smectite gel (250 mg)
40947485|NCT04293731|DIETARY_SUPPLEMENT|Placebo|Placebo
40947486|NCT00415350|DRUG|Azithromycin|Azithromycin Tablet 250 mg daily
40947487|NCT00415350|OTHER|Placebo|Placebo tablet 1 daily
41286993|NCT02525224|DIETARY_SUPPLEMENT|Nutritional Supplement|2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
41286994|NCT04668846|OTHER|non-invasive sample collection of skin tissue|Both lesional and non-lesional skin will be sampled with up to 24 adhesive patches.
41286995|NCT04512079|DRUG|Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min) Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)
41286996|NCT04512079|DRUG|Apixaban|(5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
41286997|NCT03823638|DIETARY_SUPPLEMENT|Oral D-Mannitol of Placebo|Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
41286998|NCT04686890|PROCEDURE|erector spinea plane block administered preoperative open nephrectomy|erector spinae plane block applied in this group before open nephrectomy
40947488|NCT02026960|DEVICE|RNA extraction and amplification from biopsy specimens|
40947489|NCT02987842|DEVICE|TruScan Neurofeedback|Neurofeedback and quantitative EEG system
40947490|NCT05640804|DRUG|CTTQ Dasatinib tablet|Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Chia Tai Tianqing Pharmaceutical Group.
40947491|NCT05640804|DRUG|Sprycel Dasatinib tablet|Sprycel Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Bristol Myers Squibb.
40947492|NCT03877731|PROCEDURE|isolated septal myectomy|
40947493|NCT03877731|PROCEDURE|septal myectomy + edge-to-edge mitral valve repair|
40947494|NCT03877731|PROCEDURE|septal myectomy + posterior leaflet sliding plasty|
40947495|NCT03877731|PROCEDURE|septal myectomy + secondary chordae transection|
40947496|NCT00253760|DRUG|dietary amino acids; cysteine and methionine|
40947497|NCT00272428|BEHAVIORAL|ascorbic acid, vitamin E, beta carotene, selenium, zinc|
40947498|NCT00190970|DRUG|Ruboxistaurin|
40947499|NCT04651985|OTHER|Eccentric strengthening exercises of the Achilles tendon|This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.
40947500|NCT00879099|DRUG|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
40947501|NCT00879099|DRUG|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
40947502|NCT00879099|DRUG|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
40947503|NCT00879099|DRUG|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
41286999|NCT04686890|PROCEDURE|intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg|intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
40947504|NCT02380027|DEVICE|MRI|This will be a multi-parametric MRI of the prostate
40947505|NCT02380027|PROCEDURE|MRI-targeted biopsy|This will be a biopsy targeted to suspicious areas on the MRI
40947506|NCT02380027|PROCEDURE|TRUS-biopsy|This will be a standard 12 core trans-rectal prostate biopsy
40947507|NCT01297920|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
40947508|NCT01297920|DRUG|Brinzolamide ophthalmic suspension, 1%|
40947509|NCT01297920|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
40947510|NCT02048969|DRUG|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
40947511|NCT02048969|DRUG|Placebo|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
40947512|NCT04633356|DEVICE|EUS-portal pressure gradient measurement (PPGM)|EUS-guided PPGM is performed under conscious sedation. An OGD would be performed to evaluate for findings consistent with portal hypertension such as varices and portal hypertensive gastropathy. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein. A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle. Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The process is repeated for the hepatic vein. The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
41287000|NCT00299377|DRUG|Abciximab i.v.|
41287001|NCT00299377|DRUG|Abciximab i.c.|
41287002|NCT04706546|OTHER|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
41452862|NCT01438060|DRUG|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
40947513|NCT04087174|DRUG|Capivasertib|Patients will receive multiple oral dose of capivasertib.
40947514|NCT04087174|DRUG|Enzalutamide|Patients will receive 160 mg oral dose of enzalutamide.
40947515|NCT04087174|DRUG|Abiraterone|Patients will receive 1000 mg oral dose of abiraterone.
40947516|NCT02103712|OTHER|Qualitative|
40947517|NCT01238185|DRUG|acetylsalicylic acid|
40947518|NCT01238185|GENETIC|gene expression analysis|
40947519|NCT01238185|GENETIC|protein expression analysis|
40947520|NCT01238185|OTHER|laboratory biomarker analysis|
40947521|NCT01238185|OTHER|questionnaire administration|
40947522|NCT01238185|PROCEDURE|biopsy|
40947523|NCT01642407|DRUG|Sildenafil|Body weight \> 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
40947524|NCT04110678|DRUG|NeuroEPO|NeuroEPO \[CIMAB S.A, Havana, Cuba\]
40947525|NCT05088395|OTHER|Blood sample|Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples taken per patient for up to 24 months.
40947526|NCT05088395|OTHER|Biopsy|If a specific tumor sample is required, it will be collected only once during the study
40947527|NCT00411112|PROCEDURE|blue and isotopic detection of sentinel lymph nodes|
41287003|NCT04706546|OTHER|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
41287004|NCT00410371|DRUG|Lamotrigine|Lamotrigine
41452863|NCT04125407|OTHER|Sensorimotor foot orthoses|The interventional group will receive one customized pair of sensorimotor insoles and will be instructed for their using on a daily bases for the period of 3 months. The duration of using the insoles was established as 1 hour at the day after receiving the insoles. After that, the insoles' tolerance will be assessed based on the email correspondence and further adjustments of insole will be consulted with manufacturer if necessary. Recommended progression in time of using the insoles was established as +1 hour per each day (if possible) with no maximal limit. After 3 weeks, control examination will take place for the control of subjective effect of insoles. Consulting will be offered to the participants through the duration of research. Participants will not undergo any other supplementary treatment (physiotherapy, ...) focusing on the flatfoot deformity.
41452864|NCT01172912|BIOLOGICAL|filgrastim|
41452865|NCT01172912|BIOLOGICAL|pegfilgrastim|
41452866|NCT01172912|DRUG|carboplatin|
41287005|NCT00410371|DRUG|GI267119|25 mg ODT
40757877|NCT06418269|OTHER|Therapeutic Play|"Children will be asked to fill in the Child Patient Identification Form, State Anxiety Scale in Children and Child Fear Scale 30 minutes before insulin treatment. Before the insulin treatment, the children in the experimental group will have their blood glucose measured and insulin administered on a doll using the therapeutic play method. The child will be told that the doll is hospitalized with a diagnosis of Type 1 diabetes and will be expected to assume the role of a nurse to administer insulin to the doll. Then, the steps of blood glucose measurement and insulin treatment (subcutaneous) will be explained to the child and the child will be asked to administer insulin to the baby. Within 10 minutes after subcutaneous insulin treatment, the child will be asked to fill out the State Anxiety Scale in Children and Child Fear Scale."
41287006|NCT01821963|DRUG|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
41287007|NCT01821963|DRUG|Ribavirin|Starting dose: 1,000 mg by mouth daily.
41287008|NCT01821963|DRUG|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
41287009|NCT02187640|BEHAVIORAL|Self-administered acupressure|Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
40947528|NCT02602392|BEHAVIORAL|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
40947529|NCT02602392|BEHAVIORAL|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
41287010|NCT02187640|BEHAVIORAL|Sham control group|Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
41287011|NCT00609128|DRUG|olopatadine|olopatadine one drop in one eye for one week
41452867|NCT01172912|DRUG|cisplatin|
41452868|NCT01172912|DRUG|dexamethasone|
41452869|NCT01172912|DRUG|etoposide|
41452870|NCT01172912|DRUG|ifosfamide|
41452871|NCT01172912|OTHER|high-dose chemotherapy with autologous stem cell rescue|
41452872|NCT01172912|OTHER|laboratory biomarker analysis|
41452873|NCT01172912|PROCEDURE|autologous hematopoietic stem cell transplantation|
41452874|NCT01172912|PROCEDURE|peripheral blood stem cell transplantation|
41452875|NCT03004508|DIETARY_SUPPLEMENT|Gingko Biloba Extract|120mg/day, twice a day, 6 month
40947530|NCT05634915|DRUG|Individual ATG|Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on population pharmacokinetic modeling). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
40947531|NCT05634915|DRUG|ATG|ATG 10mg/kg: The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2. Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
40947532|NCT02256371|BEHAVIORAL|Hypnosis sessions|1 session per week during 8 weeks
40947533|NCT02256371|BEHAVIORAL|Relaxation group|1 relaxation session per week during 8 weeks
40947534|NCT01422252|DEVICE|Vigi'Fall®|Precocious fall detection device
41133116|NCT06441305|BEHAVIORAL|SWITCH intervention package|"* Addition of digital monitoring \& supervision by CHA~* Digitized registration of households by CHPs every 6 months~* Digital reminders to CHP to conduct home visit if a child has never been visited in 3 mo.~* Digital reminder for timely training to family MUAC of all family members through home visit by CHP when child turns 6 months of age.~* Platform for 2-ways messaging: biweekly SMS reminders to caregivers through the CHP's app; feedback by caregiver~* Community level screening based on weight and weight-for-age (WAZ) led by CHP every other month (aligned with Community Action Days),~* Digital calculation of WAZ.~* CHP and Growth Monitoring and Promotion refer to health facility if WAZ\<-3 to check on WHZ eligibility~* At the end of every wasting treatment consultation, compilation of the list of defaulters and non-respondents, for immediate transmission by CHA to relevant CHP through digital task of an instruction for immediate follow-up."
41452876|NCT03004508|DIETARY_SUPPLEMENT|Placebo|120mg/day, twice a day, 6 month
41452877|NCT01987128|PROCEDURE|Intraneural injection|BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.
41452878|NCT01987128|PROCEDURE|Extraneural injection|BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.
41452879|NCT01987128|DRUG|Ropivacaine|
41452880|NCT01987128|DEVICE|PAJUNK SonoPlex 22G needle.|
41452881|NCT04386577|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
40757878|NCT03638180|DRUG|BLU-5937|BLU-5937 oral tablet
40947535|NCT00239395|DRUG|Meloxicam ampoule|
40947536|NCT00239395|DRUG|Meloxicam tablet|
40947537|NCT04574973|DEVICE|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
40947538|NCT04574973|BEHAVIORAL|intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills to help the individual function better in daily life.
40947539|NCT01474148|DEVICE|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
40947540|NCT01757262|DRUG|90 mg Ticagrelor|Morning and Evening dose for 5 days
40947541|NCT01757262|DRUG|75mg Clopidogrel|Morning dose for 5 days
40947542|NCT05887232|PROCEDURE|Fractional CO2 laser|Patient in group A received FCL treatments four sessions with four weeks apart
40947543|NCT05887232|PROCEDURE|Fractional CO2 with Platelet Rich Plasma|Group B received four PRP and FCL sessions 4 weeks apart
40947544|NCT03686761|PROCEDURE|A Involvement with the osteotomy site of the surgery|A Involvement with the osteotomy site of the surgery
40947545|NCT04659720|DEVICE|Hydrolic lifter device|evaluation of implant stability after closed sinus lifting by hydraulic lift technique using hydraulic lifter device
40947546|NCT04659720|BEHAVIORAL|Patient satisfaction evalution using hydraulic lifter device|patients satisfaction will be evaluated numerically after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
40947547|NCT05942300|DRUG|CPI-0209|A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.
40947548|NCT05942300|DRUG|carboplatin|Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
40947549|NCT02322073|PROCEDURE|Laparoscopic surgery|Roux-en-Y gastric bypass or other benign laparoscopic surgery
41133117|NCT00385866|BEHAVIORAL|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
41133118|NCT00385866|BEHAVIORAL|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
41133119|NCT01409837|DRUG|Lisinopril|"The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug DY1 while group B was started on the coded drug DZ2. Both DY1 and DZ2 were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug DZ2 while group B changed to drug DY1. There was no intervening washout period. The codes were concealed until after the data analysis."
41133120|NCT03854734|BEHAVIORAL|Community Event|Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.
41133121|NCT03854734|BEHAVIORAL|Educational Material|Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
41287012|NCT06377995|OTHER|Placebo technique|The patient is in a supine position with a 90° knees flexion. The osteopath lies cephalad to the patient and places their hands on their shoulders.
40757879|NCT03638180|DRUG|Placebo|Matching placebo to BLU-5937
40757880|NCT03044899|PROCEDURE|All surgeries in adult patients|All surgeries in adult patients
41287013|NCT06377995|OTHER|Diaphragm protocol|The patient is in a supine position with a 90° knees flexion.To stretch the diaphragm, the osteopath stands at the head of the bed and places his hands on the lower edge of the ribcage and accompanies the lifting of the ribs during inhalation and maintains it during deep exhalation for up to 2 sets of 10 deep breaths separated by 1 minute. For the neuromuscular technique, the osteopath is positioned contralateral to the side to be treated and slides with the thumb under the lower part of the thorax, applying a force in the opposite direction.To inhibit the phrenic centre, the osteopath places one hand on the sternum in a caudal direction and the other in the projection of the phrenic centre in a cephalic direction.The participant inhales deeply and the osteopath presses in both directions during the expiratory phase for 10 respiratory cycles.
40757881|NCT03139266|BEHAVIORAL|UPLIFT|Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.
40757882|NCT03139266|BEHAVIORAL|Treatment as usual|The control group will receive the recommendation to consider maintaining mental health services
40757883|NCT02261610|PROCEDURE|Procalcitonin algorithm|Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
40947550|NCT02556827|OTHER|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
40947551|NCT02556827|DEVICE|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
40947552|NCT02556827|DEVICE|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
40947553|NCT02556827|DEVICE|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
40947554|NCT02727842|DEVICE|CP950 Sound Processor|An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor
40947555|NCT02727842|DEVICE|Wireless programming pod|The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
40947556|NCT00282074|PROCEDURE|laparoscopic bilateral hernia repair|
40947557|NCT05289427|PROCEDURE|ultrasound guided triple injection peri-sartorius block|Patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision
40947558|NCT05289427|PROCEDURE|Femoral Nerve Block|Patients will receive femoral nerve block (FNB) before surgical incision
41133122|NCT01792401|DRUG|Probiotics|
40947559|NCT04027829|DRUG|Dexmedetomidine Hydrochloride|Intravenous infusion of dexmedetomidine at the rate of 0.5mcg/kg for 10 min, then 0.5mcg/kg/hr for 50 min.
41133123|NCT01792401|DRUG|Placebo|
40757884|NCT05019807|OTHER|WhatsApp group|Patients under intervention group will attend an education sessions by structured videos and images with the help of digital tool-WhatsApp group chat administered by the researcher. The group will have the objective interaction with patients and researchers to convey about their view of opinion on sight threatening diabetic retinopathy and management. The structured programme included definition of diabetes mellitus, symptoms, risk factors, awareness of DM and DR, importance of self-care about the disease (eye care and blood glucose monitoring), dietary management and importance of physical activity (Life style modification). The groups will be tracked frequently by WhatsApp/telephonic call and will be documented. Confidentiality of all participants will be maintained.
40757885|NCT05019807|OTHER|Control group|Patient under non-intervention group will not attend or take part in the education sessions or interaction with other patients. Will receive only the general instructions or advises from ophthalmologists about management and follow-up visit.
40947560|NCT03312998|RADIATION|Xrays|Plain x-rays anteroposterior and lateral views to determine system failure
40947561|NCT04592107|DIAGNOSTIC_TEST|eGFR|estimated glomerular filtration rate
40947562|NCT06193525|DRUG|Talazoparib|Talazoparib is administered daily as single agent, 1 mg orally until unacceptable toxicity or progression of disease.
40947563|NCT02932683|DEVICE|MedNav|MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
40947564|NCT00632840|DRUG|Atorvastatin and fenofibrate|atorvastatin (40mg/day) fenofibrate (200mg/day)
40947565|NCT06557538|DEVICE|Automatic Ankle Brachial Pressure Index device assessment|The automatic device assesses 3 limbs, providing automatic simultaneous ABPI measurement of systolic, diastolic and mean arterial blood pressure on to calculate the patient\&#39;s ABPI (Medi UK 2022).
41133124|NCT05636397|DIETARY_SUPPLEMENT|L-Citrulline|Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
41133125|NCT04934033|OTHER|Neurological assessments|The participants will have a MRI, and language and cognitive assessments.
41133126|NCT04473703|DRUG|renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor|Patients with odd random number will treat with RASI（renin-angiotensin system inhibitors）, and those with even random number will treat with ARNI（angiotensin-receptor-neprilysin inhibitor）
41133127|NCT00877019|DEVICE|Sonicare elite medium brush head|
40757886|NCT03940157|BEHAVIORAL|Oh Happy Day Class - Still I Rise|one-time, 4-hour class focused on awareness of depression and healthy self-management strategies
40757887|NCT04938843|DIETARY_SUPPLEMENT|F. prausnitzii and D. piger|Dietary supplementation with capsules containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
40757888|NCT04938843|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo capsules identical to those containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
40757889|NCT00220792|BEHAVIORAL|Brief supportive-expressive group therapy|
40757890|NCT00004856|BIOLOGICAL|trastuzumab|Given IV
40757891|NCT03301415|DRUG|Valganciclovir|Valganciclovir, 16 mg/kg/dose given orally twice daily for four months
40757892|NCT06501248|DRUG|Triticum Aestivum|The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
40757893|NCT06501248|DRUG|Placebo (calcined magnesia)|The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
40757894|NCT05791630|OTHER|the labour care guide (LCG)|The labour care guide is a tool to be used for assessing labour progression and monitoring care in labour
40757895|NCT04356378|OTHER|Data record|Data record
40757896|NCT06550089|DRUG|Oxytocin|Oxytocin is a synthetic molecule used to reduce the likelihood of postpartum hemorrhage.
40757897|NCT06019728|DRUG|AGALSIDASE BETA (GZ419828)|Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion
40757898|NCT06019728|DRUG|Acetaminophen|Tablet or solution; Oral
40757899|NCT06019728|DRUG|Diphenhydramine|Tablet or solution; Oral
40757900|NCT06019728|DRUG|Dexamethasone|Tablet or solution; Oral
40757901|NCT06019728|DRUG|Montelukast|Tablet or chewable tablet or oral granules; Oral
40757902|NCT04594603|OTHER|Phacoemulsification for cataract|Phacoemulsification for removal of cataract
40757903|NCT05106062|DEVICE|on remote monitoring|This group will turn on the RM function 0 to 45 days after defibrillator implantation. Patient should be seen at clinic once a year, or if there is any adverse event notification
40757904|NCT00285714|PROCEDURE|3D stereophotogrammetric imaging|
40757905|NCT00285714|PROCEDURE|3D CT-imaging with cone-beam CT|
41287014|NCT00411515|DRUG|Mycophenolate Mofetil 2x 1g|
41287015|NCT01334112|DRUG|Axitinib (AG-013736)|5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
40757906|NCT00285714|PROCEDURE|Case report form|
40757907|NCT05363215|DRUG|S-217622|Tablet for oral administration
40757908|NCT04078516|DIAGNOSTIC_TEST|Perception Threshold Tracking (PTT)|low-current electrical stimulation of both large- and small nerve fibers.
41287016|NCT01268397|PROCEDURE|open reduction and internal fixation with a volar plate|flexor carpi radialis approach, open reduction, fixed-angle volar plate, plaster cast 2 weeks at the surgeon's discretion
41287017|NCT01268397|PROCEDURE|closed reduction and plaster treatment|closed reduction, below elbow plaster cast, semicircular for 5 week
40757909|NCT04078516|DIAGNOSTIC_TEST|Axon-flair mediated respons|Laser-doppler examination of small blood vessels in the peripheral skin.
40757910|NCT04078516|DIAGNOSTIC_TEST|Heart rate variability|4 measurements of heart rate.
40757911|NCT04078516|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Seven tests measuring 13 parameters including heat- and cold-detection and pain thresholds, mechanical pain treshold, mechanical detection threshold, pressure pain treshold and vibration threshold.
40757912|NCT04078516|DIAGNOSTIC_TEST|Peripheral blood pressure and transcutaneous oxygen tension|Ankle/brachial index, toe/brachial index, TcpO2.
40757913|NCT04078516|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI-scans of peripheral nerves and the central nervous system. Blood oxygen level dependent (BOLD) MRI.
40757914|NCT04078516|DIAGNOSTIC_TEST|Questionnaires|Questionnaires for detecting painful neuropathy
41133128|NCT00877019|DEVICE|Sonicare elite mini brushhead|
40757915|NCT04078516|DIAGNOSTIC_TEST|Corneal Confocal Microscopy /CCM)|Confocal microscopy of the cornea measuring NBD, NFD, NFL
40757916|NCT02487329|OTHER|Calcium Hydroxide|Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
40757917|NCT02487329|OTHER|Er,Cr:YSGG laser + calcium hydroxide|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
40757918|NCT02487329|OTHER|TheraCal LC|TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
40757919|NCT02487329|OTHER|Er,Cr:YSGG laser + TheraCal LC|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
40757920|NCT06498180|OTHER|Periodontal initial treatment under local anesthesia|Removal of plaque retention factors, supragingival scaling and subgingival scraping under local anesthesia with articaine (combined with manual and ultrasound methods), and polishing
40757921|NCT06498180|DRUG|Glucocorticoid Therapy|Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
40757922|NCT06498180|BEHAVIORAL|oral hygiene instruction|Instructions and demonstrations for using manual toothbrushes Instructions and demonstrations for using dental floss or interdental brushes
40757923|NCT02540902|DEVICE|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
40757924|NCT06548113|DEVICE|TMS|transcranial magnetic brain stimulation
40757925|NCT02257021|DRUG|BILR 355 BS|
40757926|NCT02257021|DRUG|Tipranavir|
40757927|NCT02257021|DRUG|Low dose of ritonavir|
41133129|NCT00877019|DEVICE|GABA Elmex sensitive extra soft toothbrush|
41287018|NCT00283712|DRUG|Infliximab|Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
40757928|NCT02257021|DRUG|High dose of ritonavir|
40757929|NCT06549322|OTHER|The exercise in morning|"Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: AM 11:00-11:30"
40757930|NCT06549322|OTHER|The exercise in evening|"Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: PM 05:00-05:30"
41287019|NCT00283712|OTHER|Placebo Comparator|Placebo administered in place of infliximab for control group
41452882|NCT04386577|DRUG|fish oil|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
41452883|NCT06009796|DEVICE|Tooth Tissue Borne Rapid Palatal Expansion|In all rapid palatal expansion groups, the appliances were cis bonded after being made by the same technician. The expansion screw was turned twice a day until the desired width was achieved.
41452884|NCT06009796|DEVICE|Tooth Bone Borne Rapid Palatal Expansion|After the Marpe appliance was attached, 4 miniscrews were applied to the midline of the palate with a miniscrew driver. The expansion screw was turned twice a day until the desired width was achieved.
40757931|NCT05676008|BEHAVIORAL|Microdosing of mindfulness|The intervention consists of two parts: 1) four structured training sessions offered as online synchronous classes, and 2) self-microdosing of mindfulness activities in everyday life.
41452885|NCT01675596|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable subjects
40757932|NCT04392362|DRUG|Adenosine|A vial of adenosine with 6mg
40757933|NCT04604366|DRUG|misoprostol|it stimulates uterine contractions
40757934|NCT01855503|PROCEDURE|Core Biopsy|
41133130|NCT00877019|DEVICE|ADA reference toothbrush|
41133131|NCT00960206|DEVICE|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
41452886|NCT02003391|DRUG|Beta-blocker monotherapy|Per participant's current prescribed therapy
41452887|NCT02003391|DRUG|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
41452888|NCT06557421|DRUG|Venetoclax|complete discontinuation of Venetoclax
40757935|NCT03136094|BEHAVIORAL|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
40757936|NCT03136094|BEHAVIORAL|SBIRT+Usual Care|Patients receive usual SBIRT care
40757937|NCT06216262|OTHER|Control group|Brushing teeth twice a day for 8 weeks
40757938|NCT06216262|OTHER|Arginine|Brushing teeth twice a day for 8 weeks
40757939|NCT06216262|OTHER|Novamin|Brushing teeth twice a day for 8 weeks
40757940|NCT06216262|OTHER|Propolis|Brushing teeth twice a day for 8 weeks
40757941|NCT06216262|OTHER|Casein Phosphopeptide Amorphous Calcium Phosphate|Following the procedure in the control group, it is applied to the tooth surface once a day for 3 minutes before going to bed at night for 8 weeks
40757942|NCT06216262|OTHER|Potassium Nitrate|Following the procedure in the control group, mouthwash twice a day in the morning and evening for 8 weeks
40757943|NCT04569825|DRUG|Ophtamesone|local application intranasally as drops
41287020|NCT04696744|BIOLOGICAL|CTC detection|"The collection and analysis of CTCs will be carried out in the following 6 steps: A blood sample will be taken: a maximum volume of 30 ml on 3 x 10 ml BD Vacutainer® EDTA tubes is required for the study.~CTCs will be enumerated and characterized by immunofluorescence after immunostaining with the following antibodies: anticytokeratin, anti-CD44, anti-N-cadherin and anti-PD-L1.~• - Secondary criterion(s) : Different tumor and clinical parameters will be analysed to find a correlation with CTC detection Gene expression profiles will be analyzed using the RNAseq single-cell at different times: before treatment, at interim times, and in case of relapse in order to establish correlations between patients at high risk of relapse and their molecular profiles"
41287021|NCT04479761|BEHAVIORAL|Visual and Auditory Cues|Within each scene there will be 2 levels of visual input (static or dynamic) combined with 3 levels of sounds (static, none or dynamic). Postural responses to each combination will be evaluated in order to assess the role of generated and natural sounds in postural control and whether static sounds can improve balance within dynamic virtual environments.
41287022|NCT03918993|DRUG|Tadalafil 5mg tablet|Once-a-day 5 mg dose of tadalafil for 8 weeks
40757944|NCT04650256|OTHER|Complementary and alternative medicine (CAM)|CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
40757945|NCT04236947|BEHAVIORAL|SCPP-YA|SCPP-YA includes two modules. In the first module of ten sessions, students will learn to employ a 6-step social information processing framework for solving a wide range of real-life problems. The six-step process consists of 1) stop, clam down, and think before you act; 2) say the problem and how you feel; 3) set a positive goal; 4) think of many solutions; 5) think ahead to the consequences and 6) go ahead and try the best plan. The second module offers 1) current and accurate information about the health, social, and legal consequences of substance use, 2) correct mistaken beliefs that students have about substance use, 3) enhances awareness of social and media influences; and 4) teachers assertiveness and critical thinking skills to resist peer pressure.
40947566|NCT06557538|DEVICE|Manual Ankle Brachial Pressure Index assessment|The manual device assesses 4 limbs, providing brachial, ankle and pedal systolic pressures. A simple calculation is then made by the clinician to determine the ratio of ankle and brachial systolic pressure (ABPI) (Day 2015).
41133132|NCT00960206|DEVICE|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
41133133|NCT00960206|DEVICE|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
41133134|NCT05716425|DRUG|STI-1558|STI-1558 will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 600 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
40947567|NCT00784641|DEVICE|Novel Bausch & Lomb daily disposable contact lenses|Lenses to be worn and replaced daily for 2 weeks.
40947568|NCT00784641|DEVICE|Bausch & Lomb SofLens daily disposable contact lenses.|Lenses to be worn and replaced daily for 2 weeks.
40947569|NCT00784641|DEVICE|Johnson and Johnson 1-Day Acuvue Moist contact lenses|Lenses to be worn and replaced daily for 2 weeks.
40947570|NCT05862597|DIAGNOSTIC_TEST|HRV and Pulse diagnosis|Palpation of the 6 pulse positions (right cun, right guan, right chi, left cun, left guan, left chi) measured by the pulse diagnostic instrument.
40947571|NCT05348473|DEVICE|Alpha type|Tips of the seton will be tied as alpha-shaped.
40947572|NCT05348473|DEVICE|Beta type|Tips of the seton in this group will be overlapped and tied
40947573|NCT05348473|DEVICE|Comfort type|Knotless seton will be applied
40947574|NCT02764697|DRUG|H.P. ACTHAR SUBCUTANEOUS GEL INJECTION|Subcutaneous injection twice weekly
40947575|NCT00057954|PROCEDURE|Extracorporeal Photopheresis|Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
40947576|NCT00057954|DRUG|Pentostatin|Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
40757946|NCT06570954|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching patients to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. The PNES is explained as behaviors learned through classical and operant conditioning.
40757947|NCT06048497|DEVICE|Corrected carotid flow time measurement guided fluid preload|Preoperative FTcs of pregnant women who underwent C/S operation were measured, and those below the cut-off value (327 ms) determined in previous studies were preloaded with Ringer Lactate until FTc was \> 327 ms.
40757948|NCT01487785|DRUG|LDE225+gemcitabine|Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
40757949|NCT03102528|OTHER|No intervention|No intervention
40757950|NCT03357497|OTHER|Very early mobilization|The patient will be mobilized by a physiotherapist in our postoperative care unit. The intervention uses the SOMS protocol.
40757951|NCT05384548|BEHAVIORAL|Problematic smart phone use course|A 6 session, online, group-based, psychological course targetting problematic smart phone use.
40947577|NCT00057954|RADIATION|Total body irradiation (TBI)|Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
40947578|NCT00057954|PROCEDURE|Allogeneic bone marrow transplantation|Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10\^6 CD34/kg
40947579|NCT00057954|DRUG|Cyclosporin (CSA)|Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
40947580|NCT00057954|DRUG|Mycophenolate mofetil (MMF)|At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
40947581|NCT00057954|DRUG|Methotrexate (MTX)|"The dose of Methotrexate is based on the corrected ideal body weight for patients with \> 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)"
40947582|NCT06253884|DEVICE|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
41133135|NCT05716425|DRUG|STI-1558 placebo|STI-1558 placebo will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 0 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
41133136|NCT03247595|DIETARY_SUPPLEMENT|Magnesium Citrate Capsules|36 magnesium citrate gelatin capsules
40947583|NCT00142610|DIETARY_SUPPLEMENT|Vitamin|This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
40947584|NCT00528177|DRUG|Morphine and oxycodone|"At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.~The patients will use the PCA until the next morning."
41133137|NCT03247595|OTHER|Polyethylene Glycol 3350|4 liters of Polyethylene Glycol for colonoscopy preparation
41133138|NCT03247595|OTHER|Dulcolax Tablets|4 Dulcolox Tablets
41452889|NCT06557421|DRUG|Azacitidine|complete discontinuation of Azacitidine
40947585|NCT05816226|DRUG|Hydrocortisone 2.5%|Applied four times daily to TMJ with arthralgia
40947586|NCT05816226|DRUG|Diclofenac 1% topical|Applied four times daily to TMJ with arthralgia
41452890|NCT06356636|BEHAVIORAL|Financial Inclusion Improves Sanitation and Health|This innovative model engages transformative partnerships which include four key stakeholders (communities, communities, governments, entrepreneurs, and financiers) to improve sanitation services and supply value chains. The work is two-sided: to create demand for improved sanitation facilities in communities while facilitating microcredit access for people and sanitation businesses on the supply side.
41452891|NCT03482180|DRUG|KI1106 4g, QD|KI1106 4 Capsules
41452892|NCT03482180|DRUG|Atorvastatin Calcium 20mg, QD|Atorvastatin Calcium 20mg
41452893|NCT00831103|DRUG|EPB-348|Treated over seven days
41452894|NCT00831103|DRUG|Valacyclovir|Treated over seven days
41287023|NCT04252378|PROCEDURE|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
41287024|NCT04252378|PROCEDURE|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
41287025|NCT02864303|OTHER|Saliva samples|saliva specimens were collected using a neutral or citric acid impregnated Salivette cotton swabs on Alzheimer patients to quantify the level of amyloid peptides
41287026|NCT06217406|DRUG|Intravenous acyclovir (ACYCLOVIR )|Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge).
41287027|NCT06217406|DRUG|Saline bags|Patients randomized in the control arm will receive placebo, eg. saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge).
41287028|NCT00252850|GENETIC|CERE-120: AAV2-NTN|
40757952|NCT03721458|OTHER|Sequence|Potentially identifying genetic defects that could have clinical significance
40757953|NCT05428007|DRUG|Sarilumab|Injectable solutions of sarilumab are formulated in 2 mL of aqueous solution in a 5 mL vial containing 175 mg/ml of sarilumab arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection USP.Patients will be administered sarilumab at a dose of 150 mg subcutaneously in combination with ipilimumab, nivolumab and relatlimab given intravenously, with nivolumab/relatlimab given intravenously, or sarilumab at a dose of 150 mg subcutaneously given alone.
40757954|NCT05428007|DRUG|Ipilimumab Injection|Ipilimumab injection is a sterile, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution, single-use, preservative-free, isotonic aqueous solution that may contain particles. It is formulated at a concentration of 5 mg/mL ipilimumab in TRIS hydrochloride (also known as 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride), sodium chloride, mannitol, pentetic acid (also known as diethylenetriaminepentaacetic acid or DTPA), polysorbate 80, and water at pH 7.0. Sodium hydroxide and/or hydrochloric acid may be used to adjust the pH of the solution. Ipilimumab Injection 200 mg/40 mL (5 mg/mL) is packaged in a 50-cc Type I flint molded glass vials.
40757955|NCT05428007|DRUG|Nivolumab/Relatlimab|The FDC drug product, referred to as nivolumab/relatlimab, contains relatlimab and nivolumab in a single vial in a kit of 2 vials. The product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution for IV infusion. It is formulated at a total protein concentration of 16 mg/mL (4 mg/mL relatlimab and 12 mg/mL nivolumab) and is packaged in a 20-cc glass vial in a kit of two vials. Each vial contains 80 mg of relatlimab and 240 mg of nivolumab.
40757956|NCT00909688|DRUG|BLI-489|
40757957|NCT00909688|DRUG|placebo|
40757958|NCT03308773|OTHER|Lifestyle modification in routine care of patients|Diabetes Prevention Program Lifestyle recommendations and non-investigational pharmacotherapy in routine care of patients
40757959|NCT05531201|PROCEDURE|collaboration general practitioner and physiotherapist|training general practitioner and physiotherapist
40757960|NCT02505672|RADIATION|Chemoradiotherapy for nasopharyngeal carcinoma|Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
40757961|NCT01421459|DRUG|LY2963016|Administered subcutaneously
40757962|NCT01421459|DRUG|Lantus|Administered subcutaneously
40757963|NCT01421459|DRUG|OAMs|Administered orally
40757964|NCT01407887|DRUG|artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)|The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
40757965|NCT00392288|DRUG|Ciclesonide|Ciclesonide MDI 40 µg BID over twelve weeks
40757966|NCT00392288|DRUG|Ciclesonide|Ciclesonide MDI 80 µg BID over twelve weeks
40757967|NCT00392288|DRUG|Placebo|Placebo MDI over twelve weeks
41287029|NCT03410147|DIAGNOSTIC_TEST|13C-octanoate breath test for gastric emptying|"The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations."
40757968|NCT02912611|PROCEDURE|Education and Protocol based management|
40757969|NCT00470808|DRUG|POMx|
40757970|NCT05830097|DRUG|CBP-1019|Light yellow to yellow loose lumps or powder；50mg/vial; Infusion for 90 minutes (± 10 minutes), once every 2 weeks.
40757971|NCT05944393|DRUG|Ropivacaine 0.2% Injectable Solution|Ultrasound-guided Erector Spine Plane block with 10 mL 0.5% ropivacaine
40757972|NCT05944393|DRUG|Normal saline 0.9% Injectable Solution|Ultrasound-guided Erector Spine Plane block with 10 mL 0.9% normal saline
40757973|NCT05262673|BIOLOGICAL|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL
40757974|NCT00003907|DRUG|cisplatin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
40757975|NCT00003907|DRUG|doxorubicin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
41287030|NCT02928419|DRUG|Eltrombopag/Revolade|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
41452895|NCT05440968|OTHER|Point of Care - Glycated Hemoglobin (A1c)|Test for diagnosis of Diabetes through a Point of care device
41287031|NCT02928419|OTHER|Placebo|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
41452896|NCT05440968|OTHER|Oral Glucose Tolerance Test|Routinary diagnosis diabetes test by venous blood sample
41452897|NCT03519139|OTHER|individual dietary counselling|individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
40757976|NCT00003907|DRUG|mitomycin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
41452898|NCT01923740|DEVICE|XIENCE V EECSS|Subjects receiving XIENCE V
41452899|NCT01923740|DEVICE|Absorb BVS System|Subjects receiving Absorb BVS System
41452900|NCT06627413|DRUG|Lumateperone Capsule|Lumateperone 42 mg capsule, oral administration
41452901|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-E2 IM injection
40757977|NCT00003907|PROCEDURE|embolization|Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
40757978|NCT01141868|BEHAVIORAL|Internet Intervention|online treatment for insomnia
40757979|NCT06238856|DRUG|SLIT™ Amikacin|Amikacin administered via the Pari LC STAR™ nebulizer.
40757980|NCT06238856|DRUG|Placebo|Nebulized saline.
40757981|NCT00928720|DEVICE|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
40757982|NCT00928720|DEVICE|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
40757983|NCT05513573|DRUG|HLX07|1500 mg, D1，Q3W
40757984|NCT05513573|DRUG|HLX10|300 mg, D1, up to 2 years,Q3W
40757985|NCT05513573|DRUG|placebo|1500 mg, D1，Q3W
40757986|NCT05513573|DRUG|chemotherapy|gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles
40757987|NCT04486677|BEHAVIORAL|Caring Cards Group|Group of Veteran card-makers.
40757988|NCT04486677|BEHAVIORAL|Caring Cards Recipients|Group of Veteran card-recipients.
40757989|NCT00072995|BEHAVIORAL|Four Diets Differing in Macronutrient Composition|
40757990|NCT00072995|BEHAVIORAL|Diets Low in Saturated Fat|
40757991|NCT00900042|GENETIC|DNA ploidy analysis|
41452902|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-E3 IM injection
41452903|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-X2 IM injection
41452904|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-X5 IM injection
40757992|NCT00900042|GENETIC|DNA stability analysis|
40757993|NCT00900042|GENETIC|chromosomal translocation analysis|
40757994|NCT00900042|GENETIC|cytogenetic analysis|
40757995|NCT00900042|OTHER|flow cytometry|
40757996|NCT00900042|OTHER|laboratory biomarker analysis|
40757997|NCT04840771|PROCEDURE|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
40757998|NCT01773889|DRUG|Denileukin Diftitox/SC Pegylated IFNα-2a|
40757999|NCT05812300|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
40758000|NCT04787016|OTHER|Pilate training|Pilates is an exercise training program used to build core strength and flexibility.
40758001|NCT01647880|DRUG|Verum arm receiving Gilenya®|
40758002|NCT01647880|DRUG|Active Comparator receiving Extavia®|
40758003|NCT04942327|BEHAVIORAL|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
40947587|NCT02842307|PROCEDURE|Manual acupuncture implemented by senior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.
41133141|NCT04003558|OTHER|No interventions|As this is a patient registry, there are no interventions.
41133142|NCT04718259|DRUG|intrathecal bupivacaine|The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
41133143|NCT04718259|DRUG|midazolam|midazolam
41133144|NCT05037305|OTHER|Educational video|The brief educational video provides information about pharmacogenetic testing, the results of pharmacogenetic testing, and how to find these results in the patient portal.
41133145|NCT00491400|DRUG|Fenofibrate|140 mg/day for 8 weeks
41133146|NCT00491400|DRUG|Atorvastatin|20 mg/day for 8 weeks
41133147|NCT05443945|DEVICE|Nasal Spray|3 sprays in each nostril 3 times per day
41133148|NCT00336349|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
41133149|NCT00327730|DRUG|Eperisone|
41452905|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
41452906|NCT03883126|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
41452907|NCT03883126|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
41287032|NCT02928419|DRUG|Lenalidomide|All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
41287033|NCT00204386|DRUG|Topiramate|
41287034|NCT05434910|OTHER|Changes in mean arterial pressure|MAP set at 65 mmHg for 25 min by infusion of noradrenaline. MAP set at 80 mmHg for 25 min by infusion of noradrenaline. MAP set at 95 mmHg for 25 min by infusion of noradrenaline.
41287035|NCT06270992|DIAGNOSTIC_TEST|NCCN (National Comprehensive Cancer Network) diagnosis|For diagnostic evaluation, the necessary procedures from the standard protocols consisting of anamnesis, physical examination, laboratory tests, radiological imaging methods, and tissue biopsy will be followed. Computerized Tomography (CT) and Positron Emission Tomography-Computed Tomography (PET-CT) will be used as imaging methods, while fiberoptic bronchoscopy and video-assisted mediastinoscopy will be applied for tissue diagnosis and staging.
41287036|NCT06498908|DRUG|Nitrous oxide|Nitrous oxide, commonly known as laughing gas, is a colorless, non-flammable gas with a slightly sweet odor, used for its analgesic and anesthetic properties in medical and dental procedures to provide pain relief and sedation.
41452908|NCT03946787|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|The reprocessing and desensitization of each traumatic memory occurs in eight phases. In the first two phases, the therapist identifies targets and develops a treatment plan, enhances and develops personal resources, before working on traumatic memories. In stages 3 to 6, reprocessing and desensitization of memory is done. The patient focuses on the image of the event, negative beliefs and associated bodily sensations, while moving the eyes from side to side, following the therapist's fingers or other dual attention stimuli (eg, manual touch, auditory stimulation). Phases 7 and 8 are closing and reassessing, where the therapist determines if the memory has been processed properly.
41452909|NCT03946787|OTHER|Treatment as Usual|TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
41452910|NCT03558295|DRUG|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, edoxaban
40758004|NCT05887466|BIOLOGICAL|Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) Low Dose|"Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)_Low Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -Low Dose :~   7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
41287037|NCT06498908|DRUG|Oxygen|Oxygen is a colorless, odorless gas essential for human respiration and used medically to treat conditions resulting from low oxygen levels in the blood. In this trial Oxygen is being used as a placebo.
41452911|NCT05999916|DEVICE|Personalized Miamind Neurostimulator|60 min. 40 Hz max. 1mA / electrode \& total of max. 2 mA across all electrodes. 30- s ramp-up personalised intervention based on individual modelling of electric field distribution to maximise therapeutic effect in the target region. Three target regions, consecutively stimulated (20min each).
41287038|NCT00673673|DRUG|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
41287039|NCT00673673|DRUG|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
41287040|NCT00550238|DRUG|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
41287041|NCT01970150|DEVICE|rTMS real|
41287042|NCT00964795|DRUG|Intravitreal Aflibercept Injection 2mg|
41287043|NCT05822869|PROCEDURE|EIT-guided mechanical ventilation strategy|During prone ventilation, the PEEP level is adjusted based on EIT monitoring. The optimal PEEP is the lowest sum of collapse and overdistension percentages
41287044|NCT05822869|PROCEDURE|Lung protective ventilation group|Lung-protective ventilation strategy during prone positioning that continues the supine position.
41287045|NCT05207462|BEHAVIORAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
41441008|NCT05802485|OTHER|collection of blood and tumor samples|"The study consists of the collection of a 25 ml blood sample:~* Before the start of treatment~* Approximately 2 months after the start of induction chemotherapy~* At the end of induction chemotherapy~* Prior to local treatment (radiotherapy, surgery)~* At the time of tumor progression~At the time of collection of tumor material:~* During the initial diagnostic biopsy~* On the operating room in case of surgery~* During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities."
41452912|NCT00440063|DRUG|epoetin beta [NeoRecormon]|
41452913|NCT03103594|DRUG|DMSO|DMSO will be instilled intravesically.
41452914|NCT03103594|DRUG|Botox|Botox will be instilled intravesically with DMSO.
41452915|NCT03261843|BIOLOGICAL|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
41452916|NCT03261843|PROCEDURE|posterior lumbar interbody fusion without autologous platelet rich plasma|performing posterior lumbar interbody fusion without using platelet rich plasma
41452917|NCT05861973|BEHAVIORAL|Adaptive SMARTer intervention (SMARTer)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be loaned a Fitbit tracking device and a wireless bluetooth scale for 6 months.
41452918|NCT05861973|BEHAVIORAL|Diabetes Prevention Program Participants (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist.
40947588|NCT02842307|PROCEDURE|Manual acupuncture implemented by junior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
41133150|NCT05359796|BIOLOGICAL|Chronic hyperglycemia|For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.
41452919|NCT02325180|DRUG|Dihydroartemisinin-Piperaquine|
41452920|NCT02325180|DRUG|Artemether-lumefantrine|
40758005|NCT05887466|BIOLOGICAL|Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) High Dose|"Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)_High Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -High Dose :~   1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
40758006|NCT02762890|DRUG|Deep neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
40758007|NCT02762890|DRUG|Moderate neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
40758008|NCT04409769|OTHER|Description of use of ceftaroline and ceftobiprole|Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
40758009|NCT06309433|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|Patient will undergo periodic (6-12-24m) dexa scans on the periprosthetic bone
40758010|NCT01260311|DRUG|Fesoterodine|Any dose of Fesoterodine
40758011|NCT05516407|DRUG|FEN164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
40758012|NCT01942460|DRUG|Ferumoxytol|
40758013|NCT05128448|OTHER|Cross-body stretch (CBS)|CBS is a self administered stretch that aims to stretch posterior shoulder structures
40758014|NCT05128448|OTHER|Mobilisation with movement (MWM)|WMW is a musculoskeletal procedure that aims to improve restricted and/or painful range of movement
40758015|NCT00921544|OTHER|Sucrose|0.2 ml sucrose 24% given by mouth using a syringe and pacifier
40758016|NCT00921544|OTHER|Sterile water|Sterile water administered 2 mins prior to eye exam
40758017|NCT04891861|DRUG|Apixaban|Direct Oral Anticoagulation all at label dose and frequency
40758018|NCT03829514|DRUG|Fenofibrate|40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides \>150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.
40758019|NCT05634070|DEVICE|PCL Pectus scaffold implantation and autologous fat grafting|A suitable incision will be made using a scalpel and diathermy following standard surgical procedures.The implant pocket shall be rinsed with saline. The PCL Pectus Scaffold shall be inserted into the pocket following the Instruction for Use and fixed to the thoracic wall using 2 to 4 sutures. The device shall not be modified for any patient in any manner. The incision shall be closed using 2-0 Vicryl or Monocryl and 3-0 Monocryl sutures, if applicable. Number of layers to be sutured will be decided by the PI for each patient. Sterile bandaging as well as Steri-Strips shall be applied on the sutures. A prophylactic antibiotic such as Cefazolin 1g (3 shots per day x 2 days) shall be administered to the patient. In case the patient has Cefazolin allergy, Clindamycin 600 mg shall be prescribed. Autologous Fat Grafting procedure shall be performed immediately after implantation. The patients shall be hospitalized for the necessary number of days under clinical observation.
40758020|NCT01758471|DRUG|Glipizide|glipizide 5mg per pill 5mg tid p.o. for 3 month
40758021|NCT01758471|DRUG|Acarbose|Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
40758022|NCT06003400|DEVICE|Study treatment administration (TriO FITT)|Patients will be treated with the study device 2-3 times per week (determined by their wagner score) for an hour at each visit. treatment will include a combination of methods (the exact details is patented by the company and can not be elaborated).
40758023|NCT06003400|DIAGNOSTIC_TEST|Physical Examination|physical examination will include an overall examination of the patient's body for any iregular findings and or physical changes from baseline.
40758024|NCT06003400|DIAGNOSTIC_TEST|Vital Signs|vital signs measurement will include blood pressure, pulse and oral temperature as well as hight and weight.
40758025|NCT06003400|DIAGNOSTIC_TEST|Hematology Blood Tests|complete CBC, coagulogram (PT, aPTT); D-dimer; C-reactive protein;; Ferritin; fibrinogen,
40947589|NCT02842307|PROCEDURE|Manual acupuncture on P6 point|Manual acupuncture implemented by junior acupuncturists once per day. P6 point, bilaterally, should achieve deqi sensation by even manipulations. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
41452921|NCT00171015|DRUG|valsartan plus hydrochlorothiazide|
41452922|NCT03053856|DRUG|Pembrolizumab|Adjuvant pembrolizumab 200 mg every 3 weeks for up to 24 months. (treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection)
40947590|NCT02640573|DRUG|Hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
40947591|NCT03268837|DEVICE|Programmed Intermittent Bolus|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide programmed intermittent bolus for the interscalene block.
40947592|NCT03268837|DEVICE|Continuous Infusion|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide continuous infusion for the interscalene block.
40947593|NCT05239260|DIAGNOSTIC_TEST|CMR|CMR
40947594|NCT06412224|DRUG|RRG001|Administered by subretinal injection. Dosage form: injection.
40947595|NCT02387177|BEHAVIORAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
40947596|NCT02387177|BEHAVIORAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
40947597|NCT02777736|DRUG|Methotrexate|i.v. or intrathecal CNS prophylaxis
40947598|NCT05751044|DRUG|Dasatinib|Oral
40947599|NCT05751044|DRUG|Venetoclax|oral
40947600|NCT05751044|DRUG|Dexamethasone|oral/intervenous
40947601|NCT05751044|DRUG|Cyclophosphamide|intravenous
40947602|NCT05751044|DRUG|Cytarabine|intravenous
40947603|NCT05751044|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
40947604|NCT03299270|OTHER|Questionnaires|Quality of Life and Functional recovery questionnaires
40947605|NCT00572897|DRUG|Fludarabine, Melphalan +/- ATG|"Conditioning regimen for Allogenic Stem Cell Transplant:~Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)~Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 \[given over 6 hours\], and 2 mg/kg on days -2 and -1 \[given over 4 hours\])"
40947606|NCT00736957|DRUG|Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)|Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
40947607|NCT05055128|DRUG|X842|Patients will receive X842 tablets.
40947608|NCT05055128|DRUG|X842 Dummy|Patients will receive matching placebo tablets for X842.
40947609|NCT05055128|DRUG|Lansoprazole|Patients will receive Lansoprazole capsule.
40947610|NCT05055128|DRUG|Lansoprazole Dummy|Patients will receive matching placebo capsules for Lansoprazole.
40947611|NCT03422042|OTHER|Short duration of antibiotic|Patient will received intravenous antibiotic until the body temperature is less than 37.8 c fir 72, then antibiotic is discontinued.
40947612|NCT03422042|OTHER|Standard treatment of antibiotic|Patient will received intravenous antibiotic for 7 days, followed by oral antibiotic for 7 days, regardless of the body temperature.
40947613|NCT06078410|PROCEDURE|Cardiac surgery|The TA-BSM group will undergo transapical beating-heart septal myectomy and the group of cardiac surgery involving left heart operation will udergo patients received cardiac surgery involving left heart operation, such as valvuloplasty, valve replacement, repair of auricular septal defect, repair of auricular/ventricular septal defect.
40947614|NCT01557049|OTHER|Control Group|No physical intervention was given, patients were treated only with medication if necessary.
40947615|NCT01557049|OTHER|Global Reeducation Group|They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
40947616|NCT02572388|BIOLOGICAL|R21|
40758026|NCT06003400|DIAGNOSTIC_TEST|Biochemistry Blood Test|urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides).
40758027|NCT06003400|DIAGNOSTIC_TEST|Wound Digital Photography|3 photographs of the wound taken before wash, after wash and after treatment.
40947617|NCT02572388|BIOLOGICAL|Matrix-M1|
40947618|NCT01588639|DRUG|Insulin (Scilin N, BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.
40947619|NCT01588639|DRUG|Insulin (Scilin R _BAY81-9924|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
40947620|NCT01588639|DRUG|Insulin(Scilin M30_BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
40947621|NCT04108702|DEVICE|Virtual reality heart|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off SYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
41133151|NCT05359796|BIOLOGICAL|Residual islet function|For each follow-up, fasting and stimulated C-peptide levels will be measured.
41133152|NCT05359796|GENETIC|Genetic variation|Genetic variations of interest will be detected with the blood sample collected at baseline.
41133153|NCT05359796|DIETARY_SUPPLEMENT|Dietary constitutes|For each follow-up, the dietary constitutes for the past 3 days will be recorded.
41452923|NCT03053856|PROCEDURE|Curative resection|Neoadjuvant concurrent chemoradiotherapy followed by curative resection
40947622|NCT04108702|DEVICE|Virtual reality control|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off ASYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
40758028|NCT06003400|DIAGNOSTIC_TEST|Urine pregnancy test|for women with childbearing potential
40758029|NCT06003400|OTHER|Numeric Pain Rating Scale|Numeric Pain Rating Scale - numeral scale from 1 to 10 measuring pain, 10 being worst pain.
40947623|NCT04108702|OTHER|Standard therapy|Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
40758030|NCT06003400|OTHER|Visual Analogue Scale|Visual Analogue Scale - visual scale scoring 1-10 measuring pain, 10 being worst pain.
40758031|NCT06003400|OTHER|SF-36|SF-36 - quality of life questionnaire scaling from 0-100, 100 being best quality of life.
40758032|NCT06003400|DIAGNOSTIC_TEST|Wounds evaluation|including size measurements and visual description.
40758033|NCT01558505|DEVICE|PEB|paclitaxel-eluting balloon angioplasty
40758034|NCT01558505|DEVICE|POBA|conventional balloon angioplasty
40758035|NCT02529956|DRUG|UCB4940|"* Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use"
40758036|NCT02529956|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9 % sodium chloride aqueous solution~* Route of Administration: Intravenous use"
40758037|NCT04305652|OTHER|The Progressively Lowered Stress Threshold Model|PLST is a conceptual model for reducing behavioral symptoms in individuals with dementia. The PLST model provides the foundation for a psychoeducational intervention that assists formal and informal caregivers in understanding behaviors and planning care for individuals with dementia. If the model is to be applied at home, at least three home visits are made in line with the listed principles. While making a diagnosis during the first home visit, a maintenance plan for the problems is created in other home visits and the caregiver is trained to implement the care plan. After the home visits, the process is carried out by providing counseling through telephone calls or face-to-face interviews when necessary.
40758038|NCT02719860|DIETARY_SUPPLEMENT|Green tea|4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
40758039|NCT02719860|DIETARY_SUPPLEMENT|Black tea|4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
40758040|NCT02719860|DIETARY_SUPPLEMENT|Placebo tea|4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
40758041|NCT03825666|OTHER|ProvideXtra® Fresenius Kabi|Improving wellbeeing
40758042|NCT04802005|OTHER|Aerobic Interval Training|The aerobic interval training group
40758043|NCT06097988|DEVICE|ABIO3419|Intra-articular injection
40758044|NCT01818648|DRUG|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
40947624|NCT02400177|BEHAVIORAL|emotion regulation training|This is a workshop for parents that help them to understand how to deal with emotions generally and specifically with their ASD children's emotion
40947625|NCT00269594|DRUG|Lamictal (lamotrigine)|
40758045|NCT01818648|DRUG|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
40758046|NCT01357746|PROCEDURE|Transthoracic pulmonary doppler recording|A 30 min recording of doppler signals from the right chest wall including measurements while the patient performs Valsalva maneuvers
40947626|NCT01892267|DEVICE|PEG-J placement|PEG-J placement
41133154|NCT05359796|GENETIC|Microbiome composition and function|For each follow-up, the fecal and oral samples will be collected for measurement.
41133155|NCT05359796|BIOLOGICAL|Metabolome composition|For each follow-up, the serum and urine samples will be collected for measurement.
41133156|NCT05359796|BIOLOGICAL|Composition of peripheral blood immune cells|For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.
41133157|NCT00701259|DRUG|Lansoprazole|Lansoprazole 15 mg once per day for 14 days
41452924|NCT03053856|PROCEDURE|Neoadjuvant concurrent chemoradiotherapy|RT 44 Gy/22 Fractions for 5 weeks With Chemotherapy (Cisplatin 25mg/m2 once weekly, Paclitaxel 50mg/m2 once weekly)
41452925|NCT03053856|DRUG|Cisplatin|25mg/m2 once weekly
41133158|NCT00701259|DRUG|Lansoprazole|Lansoprazole 30 mg once per day for 14 days
41133159|NCT00701259|DRUG|placebo|
41452926|NCT03053856|DRUG|Paclitaxel|50mg/m2 once weekly
41452927|NCT00337493|DRUG|mycophenolate mofetil [CellCept]|Concentration-controlled
41452928|NCT00337493|DRUG|mycophenolate mofetil [CellCept]|1g po bid
41452929|NCT00337493|DRUG|Cyclosporine or tacrolimus|Reduced
41452930|NCT00337493|DRUG|Cyclosporine or tacrolimus|Standard, as prescribed
40947627|NCT05420792|BEHAVIORAL|Peplau Interpersonal Relations based IPSRT will be applied to the intervention group|IPSRT based on peplau Interpersonal Relations theory will be applied to the intervention group. First of all, information about the study will be given. An informed consent form will be filled and a history will be taken from the patient. With the Life Events Chart, past attacks and life events, interpersonal relations will be compared. Interpersonal Circle will be made to better understand the individual and relationships. A Joint Study Plan, which summarizes the disease history, life events, and interpersonal circle, will be created and presented to the patient in summary form. The patient will be given psychoeducation about his illness, drugs and social rhythms. A Social Rhythm Metric (SRM) will be created and monitored throughout therapy to assess their daily routine. Early warning signs of impending attacks will be discussed, managing symptoms, situations that may disrupt social rhythm will be determined (travel, vacation, moving, changing job)
40947628|NCT06558461|DRUG|3% Sodium Chloride|4ml nebulized three times daily
40947629|NCT06558461|OTHER|Standard care|Standard care
40947630|NCT06151431|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
40947631|NCT06151431|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
41441009|NCT03876639|OTHER|Application of emulsion|Daily application of the assigned formulation on the non-dominant volar forearm for 4 weeks
40758047|NCT05366660|OTHER|Interrogation/programming|As the study investigates remote programming, we will describe two locations: local (patient side) and remote (expert side). Local support is defined by a physician or a technician under the direct responsibility of a nearby physician who connect the patient to the remote programming system. Similar to a conventional check-up, an external defibrillator will be located in the near vicinity of the patient. The patient will first be connected to the programmer as during a conventional follow-up. The programmer will then be connected to a local PC which captures the programmer VGA video output and controls the programmer through a mouse emulator. This local PC will be remotely controlled by the remote PC using Cisco Webex, a communication software used worldwide to support telemedicine.
40758048|NCT00292903|BEHAVIORAL|Brief interpersonal psychotherapy|IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.
40758049|NCT00292903|BEHAVIORAL|Facilitated referral for treatment as usual|F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
40758050|NCT05335967|BEHAVIORAL|Self-management program|The self-management group will receive the self-management program for 12 weeks, including a self-management application, a self-management manual, and Professional support.
40758051|NCT05335967|OTHER|Information package|The patients in this group will receive an information package on a healthy diet.
40758052|NCT04712227|OTHER|intubation|intubation
40758053|NCT04712227|OTHER|mask ventilation|mask ventilation
40758054|NCT02091830|DRUG|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
40758055|NCT02091830|OTHER|Physiotherapy|
40758056|NCT02091830|DRUG|Cortisone Injection|
40758057|NCT02091830|OTHER|Others|
40758058|NCT00461812|DRUG|Mometasone|
41133160|NCT06294249|DEVICE|Laser-induced Incision|On the treatment side, an incision was made on the crest of the alveolar soft tissue using the laser.
41441010|NCT03876639|PROCEDURE|Measurement of physiological skin parameters|Weekly measurement of physiological skin parameters using confocal Raman spectroscopy, Corneometer® CM 825, Sebumeter®, Skin-pH-Meter®, AquaFlux® and Epsilon®
40758059|NCT00461812|DRUG|Advair|
40758060|NCT06494436|DEVICE|All Microvention Class III implantable device CE marked|Endovascular treatment of ruptured or unruptured intracranial aneurysms with commercially available MicroVention implant devices.
40758061|NCT01432431|PROCEDURE|spiritual therapy|Undergo palliative spiritual care
40947632|NCT05739630|DRUG|mitoxantrone liposome|Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
40947633|NCT05739630|DRUG|ATG|Control group:the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
40947634|NCT03912064|DRUG|Ipilimumab|Ipilimumab is an antibody that acts against CTLA-4
40947635|NCT03912064|BIOLOGICAL|CD25hi Treg depleted DLI|Donor lymphocyte product
40947636|NCT00989157|DRUG|Duloxetine|Single dose of 60 mg of duloxetine
40947637|NCT01928069|DRUG|Torrent's Montelukast Sodium Tablets 10 mg|
40947638|NCT02160990|DRUG|Exenatide|5 mcg exenatide subcutaneously twice daily for 30 days
40947639|NCT02160990|DRUG|Placebo|placebo subcutaneously twice daily for 30 days
41287046|NCT02426606|OTHER|Various lentil varieties (varying in slow digested starch content)|"Randomized, cross-over block design.~Comparison of glycemic and insulinemic responses following meals composed of:~* white rice or white rice combined with 1 of 3 different lentil varieties or~* white potato or white potato combined with 1 of 3 different lentil varieties~Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.~Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit)."
41287047|NCT06513468|OTHER|Group education session by DESMOND Program|is a validated structured education program for people with type 2 diabetes and their family members or carers (as appropriate)' This management approach was advised by the National Institute for Health and Care Excellence (NICE) in the UK since 2008. The program consists of a 6-hour face-to-face education session delivered by two trained educators over one day or two half-days to a group of 8-12 people with newly-diagnosed or ongoing type 2 diabetes. Annual reinforcement and review are part of the program , it is delivered as a business and usual in the secondary healthcare system of Qatar. The program is culturally adapted for Qatar considering beliefs and other health festivities.
40947640|NCT04839146|BIOLOGICAL|ABNCoV2 Vaccine|SARS-CoV-2 vaccine
41287048|NCT05643300|OTHER|Survey|Data collection from participants via questionnaire
41287049|NCT02097199|OTHER|Increased sports workload|"At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The Recommendations for Adults From the American College of Sports Medicine and the American Heart Association clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study."
41287050|NCT00861042|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
41452931|NCT06251206|BEHAVIORAL|ADL/Postoperative Instruction|This is an education video which includes demonstration of simple ADL tasks that the participant can do at home after surgery. Handout includes the same information and a QR code to watch the video.
40758062|NCT01432431|OTHER|questionnaire administration|Ancillary studies
40947641|NCT04314154|OTHER|Monitoring PROM @ PREM data on participating patients|"125 patients (ages 18-55) admitted to SHALVATA mental health center and their clinicians will be recruited to participate in a prospective longitudinal assessment. Each will include PREMs, PROMs clinician rated outcomes and assessment of the degree to which clinical indicators (reflected processes of clinical guidelines) were carried out. The assessments will take place at admission, discharge and every 3 months for up for 9 months. The design is a repeated measures design with evaluating the interaction effect between assessed levels of indicators (between subject effect) and level of change in the PREMs, PROMs clinician along the research trajectory (within subject effect)."
40947642|NCT04379544|OTHER|Observation only|There is no intervention. This study is purely observational. This study simply follows COVID-19 patients who get CPUS based on their clinician deeming it necessary.
40947643|NCT05397873|DEVICE|Biofeedback training|The training of oculomotor functions is done on the biofeedback module of a microperimeter MAIA.
41133161|NCT06294249|PROCEDURE|Punch Incision|On the control side, a punch incision was made on the crest of the alveolar soft tissue using using a punch.
41452932|NCT06251206|BEHAVIORAL|Postoperative Instruction|This is an education video that only includes the postoperative instructions. Handout includes the same information and a QR code to watch the video.
40947644|NCT05076396|DRUG|PM14|PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety. Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
40947645|NCT05835531|DEVICE|Catheters comparation|Assessment of incidence of complications associated with midline catheters
41452933|NCT01174849|DRUG|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
41452934|NCT01174849|DRUG|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium."
41452935|NCT01174849|DRUG|COMBO|COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
40758063|NCT01432431|OTHER|survey administration|Ancillary studies
40758064|NCT01432431|OTHER|counseling intervention|Undergo palliative spiritual care
40947646|NCT05485454|DEVICE|Aria Health Aria Free|An in-clinic therapy session with the Aria Free for a duration of 30 minutes under the direct supervision of the Principal Investigator.
41452936|NCT03478007|DEVICE|Intervention Technology|Subjects will perform their exercises using the provided monitoring device. They will be able to contact the investigators with questions regarding the use of the monitoring device, however, no encouragement or coaching will be provided
40758065|NCT01432431|OTHER|psychosocial support for caregiver|Undergo palliative spiritual care
40947647|NCT05485454|DEVICE|A Traditional PCD|An in-clinic therapy session with the traditional PCD for a duration of 30 minutes under the direct supervision of the Principal Investigator.
40947648|NCT01030068|BEHAVIORAL|Yoga|Yoga twice weekly
40947649|NCT01030068|BEHAVIORAL|Wellness|Health and wellness classes twice weekly
40947650|NCT01030068|OTHER|Smoking cessation therapy|Smoking cessation therapy
40947651|NCT05693883|OTHER|Pilates training|Subject participating in 60-min sessions for 10 weeks and Each session consisted of a 10-min warm up (Breathing, Imprint \& release, Hip release, Spine rotation, Hip rolls, Scapula isolation, Arm circle, Elevation \& depression scapulae, Head nod, Cat stretch), Pilates program 40-min (Toe tap, Ad prep, Breast stroke preps, Heel squeeze prone, Side leg lift, Single leg extension, One leg circle, Shoulder bridge prep, Four point, kneeling, Spine twist, Hundred prep, Roll up prep, shoulder bridge prep2, Breast stroke, Swimming, Half roll back) and 10-min cool down (Spine stretch forward, Shell stretch, Side bending, Cat stretch, Roll down)
40947652|NCT01975051|DRUG|Mitefosine|Tablet Miltefosine 100 mg in two devided doses for 12 weeks
40947653|NCT05183815|OTHER|slow stroke massage and murrotal quran|murrotal quran and slow stroke massage
40947654|NCT03020173|OTHER|Laboratory study|Laboratory analysis to determine composition of granulosa and oocytes
40947655|NCT00333177|BEHAVIORAL|Cognitive remediation training (CT)|Cognitive remediation training includes computerized cognitive training plus learning skills group.
40947656|NCT00333177|BEHAVIORAL|Healthy behavior training (HBT)|Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.
40947657|NCT00333177|DRUG|Risperidone, administered orally (Oral Ris)|Oral risperidone at dosage judged optimal by treating psychiatrist
40947658|NCT00333177|DRUG|Risperidone, administered via injection (RLAI)|Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
40947659|NCT01423578|BEHAVIORAL|Hatha Yoga (HY)|3 Sessions of yoga instruction
40947660|NCT01423578|BEHAVIORAL|Cardiovascular Exercise (CE)|3 sessions of cardiovascular exercise
41287051|NCT03864354|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment (OMT) is a cost-effective, noninvasive treatment that is used to optimize the body's structure and function. By improving the biomechanical, autonomic, and circulatory mechanisms involved in the disease process of asthma, OMT can help maximize respiratory function. The specific OMT protocol used in this study included the following: supine OA joint myofascial release (MFR), supine cervical spine Still technique, supine thoracic inlet MFR, supine rib raising soft tissue, supine rib MFR, supine abdominal diaphragm MFR, seated thoracic spine Still technique, and seated posterior rib Still technique. Treatments were performed by Predoctoral Osteopathic Manipulative Medicine (OMM) Fellows at Des Moines University (DMU) and supervised and checked by one of two board-certified OMM/NMM physicians from the OMM Department at DMU. The treatment lasted an average of 21 minutes and repeated three times, spaced one week apart.
41452937|NCT03478007|DEVICE|Intervention Technology Plus Coaching|Subjects will perform their exercises using the provided monitoring device. They will also be coached by a trained health coach through a weekly call.
40758066|NCT01432431|PROCEDURE|psychosocial assessment and care|Undergo palliative spiritual care
40758067|NCT02715856|OTHER|Monitoring Device|Undergo surgical wound and physical activity monitoring
40947661|NCT01423578|BEHAVIORAL|Smoking Cessation Counseling|4 smoking cessation counseling visits.
40947662|NCT03570697|DRUG|Evolocumab|Participants will receive evolocumab (AMG 145) subcutaneous monthly.
40947663|NCT03570697|DRUG|Placebo|Participants will receive matching placebo subcutaneous monthly.
40947664|NCT03570697|DRUG|Statin therapy|"high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization."
40947665|NCT00754988|DRUG|Metformin|As prescribed
40947666|NCT00754988|DRUG|Placebo (matching sitagliptin)|Once daily oral administration of placebo (matching sitagliptin).
40947667|NCT00754988|DRUG|Placebo (matching taspoglutide)|Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
40947668|NCT00754988|DRUG|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin.
40947669|NCT00754988|DRUG|Taspoglutide|Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
40947670|NCT03454685|OTHER|without intervention type|Without intervention,this study is just an observational study.
40947671|NCT01739114|PROCEDURE|"IPPV group"|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
40947672|NCT01739114|PROCEDURE|SI group|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided"
41452938|NCT06272617|DEVICE|verum acupuncture|a type of acupuncture which is useful
41452939|NCT06272617|DEVICE|sham acupuncture|a type of acupuncture which is useless
41452940|NCT05039541|DEVICE|Alio Device|Subjects will wear the Alio device over their vasculature.
40758068|NCT02715856|OTHER|Physical Activity Measurement|Undergo physical activity measurement
40758069|NCT02715856|OTHER|Quality-of-Life Assessment|Ancillary studies
40758070|NCT02715856|OTHER|Questionnaire Administration|Ancillary studies
40758071|NCT02715856|PROCEDURE|Standard Follow-Up Care|Undergo standard follow-up care
40758072|NCT02715856|OTHER|Survey Administration|Ancillary studies
40758073|NCT02685852|DRUG|Exenatide|Exenatide at a dose of 5 mcg
40758074|NCT02685852|DRUG|Acarbose|Acarbose at a dose of 25 mg
40758075|NCT02685852|DRUG|Exenatide Placebo|Placebo for Exenatide
40758076|NCT02685852|DRUG|Acarbose Placebo|Placebo for Acarbose
40947673|NCT05517551|PROCEDURE|robotic assisted radical prostatectomy|Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery
40947674|NCT03207893|BEHAVIORAL|GEM lifestyle modification & continuous glucose monitoring|Four treatment sessions of GEM lifestyle modification in 3 months and continuous glucose monitoring during the first 14 days of each of the 3 months.
40947675|NCT03207893|OTHER|Routine Care|Subject's current t2d treatment
41287052|NCT00800761|DRUG|Deferoxamine and Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
41287053|NCT00800761|DRUG|Deferoxamine|deferoxamine vials,40 mg/kg,12 hours/die
41287054|NCT02446782|DRUG|Cefazolin|Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
41452941|NCT05685550|DRUG|Toposide capsules combined with anrotinib and Emvolizumab group|Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd\*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd\*14d,every 21 days until disease progression or adverse reactions that were tolerated.
41452942|NCT02553863|PROCEDURE|Acupuncture|Acupuncture for 30min \[twice weekly for 8 weeks\]
41452943|NCT02553863|PROCEDURE|Standard care|Standard care
41452944|NCT06406010|DRUG|Ropivacaine 5mg/ml 20ml|administered in a pericapsular nerve group (PENG) block
41287055|NCT02446782|OTHER|saline|100 mL normal saline 15-30 minutes before the start of the procedure
41287056|NCT04503980|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
41452945|NCT06406010|DRUG|Saline 0.9%|administered in a pericapsular nerve group (PENG) block
40947676|NCT06324383|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
40947677|NCT01132274|PROCEDURE|Radiofrequency catheter ablation|Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
40947678|NCT01132274|PROCEDURE|Radiofrequency catheter ablation|Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.
40947679|NCT05829031|BEHAVIORAL|Targeted music listening|Participants listen to self-selected relaxing music. They can choose between a duration of either 10 minutes or 20 minutes.
41441011|NCT03876639|PROCEDURE|Tape stripping|Removal of 40 adhesive strips after application of a model drug-loaded emulsion and determination of the transepidermal water loss
41452946|NCT00348296|DRUG|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
41452947|NCT04386122|DRUG|FABALOFEN 60|Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
40947680|NCT01509508|DRUG|Immediate ARV treatment initiation with TDF/FTC/EFV|"All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD."
40947681|NCT01509508|OTHER|South African recommendation guided ARV (TDF/FTC/EFV) initiation|"HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~* CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~* WHO clinical stage 3 or 4 irrespective of CD4 count~* MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD."
40947682|NCT02577497|DRUG|beclomethasone|
40947683|NCT02577497|DRUG|fluticasone|
40947684|NCT02740439|OTHER|Avocado|The intervention meals will contain 1 large avocado.
40947685|NCT02740439|OTHER|Control|The control meals will be isocaloric to the intervention meals but will not contain avocado.
40947686|NCT04992910|DEVICE|Functional electrical stimulation through medical device|"The patient will receive a therapy with functional electrical stimulation. For this, a device called Fesia Grasp will be used.~Duration: 80 min twice a week, for 6 weeks."
40947687|NCT04992910|OTHER|Standard therapy|Physical therapy applied to the subject. Duration: 80 min twice a week, for 6 weeks.
41287057|NCT04422587|OTHER|RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
41287058|NCT04071665|PROCEDURE|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion
41287059|NCT01535937|DRUG|Ketamine|0.5 mg/kg IV over 40 minutes
41287060|NCT01535937|DRUG|Midazolam|0.025 mg/kg IV over 40 minutes
41133162|NCT06294249|PROCEDURE|Implant Placement|Implant placement was done in both laser and punch arms. The drilling was performed based on the company (Straumman) protocol. On each side, a dental implant (Straumman SP, Basel, Switzerland) and healing abutment were placed. Patients were visited at 24, 48, 72 hours, and 7 days after insertion.
41287061|NCT00534846|DRUG|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
40758077|NCT03382873|BEHAVIORAL|Group Lifestyle Balance (GLB)|The intervention included the following key features: group-based sessions led by a lifestyle coach; a structured, state-of-the-art, 16-session core-curriculum that emphasized behavioral self-management strategies for weight loss and physical activity; 8-months of extended care with bimonthly or monthly sessions; self-monitoring of diet and physical activity.
41287062|NCT00534846|DRUG|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
41133163|NCT03960359|OTHER|Clinical, microbiological and inflammatory phenotype|Clinical phenotype: temporal pattern of wheeze (EVW, SIW, MTW), history and clinical data, allergy diagnosis work-up Microbiological phenotype: viral status (PCR in nasal swab sample), bacteriological status (culture of induced sputum) Inflammatory phenotype: profile of cytokines, phenotype of immune cells in the blood and the sputum, cytokine response to TLR ligands by peripheral blood mononuclear cells.
41287063|NCT00969618|DRUG|Atomoxetine|40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
41287064|NCT05870475|DRUG|Ruxolitinib|Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed.
41287065|NCT05870475|DRUG|Pegylated interferon α-2b|Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.
41441012|NCT05180422|DRUG|AMG 510|Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.
41441013|NCT05180422|DRUG|MVASI|Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).
40758078|NCT03382873|BEHAVIORAL|Group Lifestyle Balance Plus (GLB+)|The GLB+ intervention arm included participants who did not achieve the targeted percent weight loss by week 5 and incorporated enhanced training in values clarification, mindful decision making, planning, and problem solving. GLB+ included the same number of group-based sessions as GLB.
40758079|NCT00188032|PROCEDURE|Computer-Assisted diagnostic Decision Support|
40758080|NCT00188032|PROCEDURE|written diagnostic guidelines|
40758081|NCT00188032|PROCEDURE|electronic therapeutic reminders|
40758082|NCT04733482|BEHAVIORAL|Cosmetic care|
40758083|NCT03037008|DEVICE|Perineal Sonography|In a modified lithotomy position (supine position with elevated legs), probands will get an examination of their pelvic floor by using a common ultrasound probe head on the perineum. During the examination, the bladder should be filled with around 300ml. If patient appear with empty bladder, the examination can be repeated on an other date. During the examination, the pelvic floor will be observed during rest, coughing and valsalva-maneuver. One examination takes around 30minutes. During ultrasound, we want to illustrate the urethral mobility, the bladder neck opening and the urethral angle as well as the distance from the urethra to the symphysis.
40758084|NCT03247673|DRUG|CT-P16|CT-P16 is a biosimilar product for Avastin
41441014|NCT04482465|DIAGNOSTIC_TEST|blood sample|blood sample to determine omega6/omega 3 ratio, EPA, DHA, zinc, cupric oxide, vitamine D
41452948|NCT04386122|DRUG|JAPROLOX TABLET|Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
40758085|NCT03247673|DRUG|EU-approved Avastin|EU-approved Avastin
40758086|NCT03247673|DRUG|US-licensed Avastin|US-licensed Avastin
41133164|NCT00718120|BIOLOGICAL|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
41133165|NCT01399099|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
41133166|NCT04559633|OTHER|cognitive and behavioral therapy (CBT)|"The CBT program is delivered by a multidisciplinary team with 4 half day hospitalization that includes individual, group CBT and education time (2 hours per day delivered by the teacher). Participants have homework to do in their own time at home.~CBT is a manualized program with anxiety psychoeducation, stress management, cognitive restructuration, problem solving techniques, progressive exposure, assertiveness exercises and self-esteem work."
41133167|NCT05192382|DRUG|Paltusotine|Paltusotine, tablets, once daily by mouth
41133168|NCT05192382|DRUG|Placebo|Placebo, tablets, once daily by mouth
40758087|NCT06542380|DEVICE|TAVI, pacemaker|Retrospective analysis of need for pacemaker implantation after TAVI
40758088|NCT02544763|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
41133169|NCT03977194|DRUG|Carboplatin|AUC 6 every 4 weeks
41133170|NCT03977194|DRUG|Paclitaxel|90 mg/m² D1, 8, 15, every 4 weeks
41133171|NCT03977194|DRUG|Atezolizumab|1200 mg every 3 weeks
41133172|NCT03183050|BEHAVIORAL|Question Prompt List|Patients receive a booklet that contains questions regarding their diagnosis, testing and treatment.
41287066|NCT06201299|OTHER|Standard Exercise Program|The program content consists of breathing exercises, upper and lower extremity strengthening with theraband and self-walking. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Resistance exercises will be performed as strengthening exercises for the major muscle groups of the upper and lower extremities using medium-hard theraband. Patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
41287067|NCT06201299|OTHER|Chair-based Exercise Program|The program content consists of breathing exercises and chair-supported exercises. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Chair exercises are given in the exercise brochure. Exercises are performed with a chair support or sitting on a chair. In addition, patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
41287068|NCT01950884|DRUG|Ezetimibe|Ezetimibe tablets
41287069|NCT01950884|BEHAVIORAL|Lifestyle|lifestyle
41287070|NCT00199186|DRUG|imatinib|
41287071|NCT00199186|DRUG|vincristine|
41287072|NCT00199186|DRUG|cyclophosphamide|
41287073|NCT00199186|DRUG|cytosine arabinoside|
41287074|NCT00199186|DRUG|dexamethasone|
41287075|NCT00199186|DRUG|idarubicin|
41287076|NCT00199186|DRUG|methotrexate (intrathecal)|
41452949|NCT06089057|BEHAVIORAL|Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This is a 16-week power-training and physical activity-focused intervention that contains group in-center and individual at-home components and motivational coaching. Participants will meet 2-3 times per week for the in-center power training. Participants will also be asked to wear accelerometers at home in order for their physical activity frequency to be measured.
41452950|NCT06089057|BEHAVIORAL|Attention Control for Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This will be the attention control arm that will involve receipt of a physical activity education booklet, use of an accelerometer, and weekly check-in calls. No power training or motivational coaching will be delivered.
40758089|NCT02544763|DRUG|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
40758090|NCT03962816|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
40758091|NCT03962816|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
41133173|NCT06067776|BIOLOGICAL|Cetuximab|Given IV
41133174|NCT06067776|DRUG|Osimertinib|Given PO
41133175|NCT06067776|DRUG|Tucatinib|Given PO
41133176|NCT00337610|DRUG|sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
41452951|NCT04865471|PROCEDURE|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
40758092|NCT03962816|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
40758093|NCT06538350|OTHER|Telemedicine Consultation|Telemedicine intervention will be delivered via Zoom and Video WhatsApp platforms via a secure internet connection.
40758094|NCT06538350|OTHER|Face-to-Face Consultation|Face-to-Face consultation according to the standard of care.
40758095|NCT02716246|BIOLOGICAL|ABO-102|Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
40758096|NCT02716246|DRUG|Adjuvant Immunosuppression (IS) Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IS therapy. Not all participants may receive IS therapy.
40947688|NCT04203810|DEVICE|Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
41133177|NCT00337610|DRUG|comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
41133178|NCT02972424|DRUG|Teriparatide Prefilled Syringe|TPTD 20 mcg
41133179|NCT02972424|DRUG|Placebo|Matching placebo as a prefilled syringe with all inactive ingredients
41133180|NCT02091752|DRUG|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to \<200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
41287077|NCT00199186|DRUG|AraC (intrathecal)|
41287078|NCT00199186|DRUG|dexamethasone (intrathecal)|
41287079|NCT00316901|PROCEDURE|computed tomography|
41287080|NCT00316901|PROCEDURE|positron emission tomography|
41287081|NCT00316901|RADIATION|fludeoxyglucose F 18|
41287082|NCT03445286|DEVICE|Silver Diamine Fluoride|Silver Diamine Fluoride (Advantage Arrest) for the experimental group
41287083|NCT03445286|OTHER|Normal Saline|Normal Saline for the control group
41287084|NCT06008379|DRUG|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
41287085|NCT06008379|DRUG|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
41287086|NCT00292123|DRUG|Methadone|
41287087|NCT00292123|BEHAVIORAL|Contingency Management|
40947689|NCT04203810|DEVICE|EMSER® Hals-und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
40947690|NCT04069169|DRUG|Lidocaine|Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).
40947691|NCT04069169|DRUG|Saline Solution|Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.
40947692|NCT02940080|OTHER|Dietary|
40947693|NCT00026962|PROCEDURE|measuring estradiol and progesterone levels in saliva|
40947694|NCT03384888|DEVICE|Active tDCS|Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.
40947695|NCT03384888|DEVICE|Sham tDCS|Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.
40947696|NCT02494362|OTHER|Computer gaming hand exercise regimen.|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
40947697|NCT03783975|GENETIC|Simplified Cascade Screening|Screening of the KCNQ1 Thr224Met variant for family members of probands
40947698|NCT05185323|OTHER|Breastfeeding usual known aids and osteopathic treatment|Breastfeeding usual known aids and osteopathic treatment
40947699|NCT05185323|OTHER|Breastfeeding usual known aids|Breastfeeding usual known aids
40947700|NCT01039844|DRUG|LOC-paclitaxel|"Phase I Starting Dose: 100 mg/m\^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
40947701|NCT00032942|DRUG|Lofexidine|
40947702|NCT02362178|PROCEDURE|Thromboelastography to guide blood products infusion|A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time\>40 mm and/or platelets (PLTs 10 units/Kg) for MA\<30 mm
40947703|NCT02362178|PROCEDURE|Standard of care coagulation tests to guide blood products infusion|Patients received FFP (10 ml/kg) if INR\>1.8 and/or PLTS (10 units/Kg) If PLTs count \< 50000/μl
41287088|NCT02604966|DRUG|Artesunate (AS) group|Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
41287089|NCT02604966|DRUG|DHA - PPQ group|Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
40758097|NCT06189846|DEVICE|International Cohort|"Assessing tumour response following neoadjuvant treatment in rectal cancer include :~* Digital rectal examination~* Rectal MRI~* Rectoscopy ( Lumeneye device)~The monitoring of tumour response intervals up to 6 months following completion of the neoadjuvant treatment at 8 weeks, at 16 weeks, at 24 weeks after the end of neoadjuvant treatment."
40758098|NCT04546243|PROCEDURE|resection group|patients received VATS
40758099|NCT04546243|RADIATION|radiotherapy group|patients received radiotherapy
40758100|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland
40947704|NCT00487682|DRUG|ASP2151|oral
40947705|NCT00487682|DRUG|Valacyclovir hydrochloride|oral
40947706|NCT00014261|BIOLOGICAL|PEG-interferon alfa-2b|
40947707|NCT00014261|DRUG|temozolomide|
40947708|NCT02004600|PROCEDURE|Photodynamic therapy (PDT)|1 session of Photodynamic therapy (PDT) on epidermis dysplasia
40947709|NCT02727413|PROCEDURE|Blood sample collection|Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery
40947710|NCT02727413|OTHER|Assessment of signs of organ dysfunction|Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge
40947711|NCT00002746|BIOLOGICAL|aldesleukin|
40947712|NCT05537896|DRUG|Eravacycline|"Eravacycline will be continued until one of the following criteria is met:~* neutrophil recovery (ANC \>500, post-nadir)~* febrile neutropenia~* breakthrough infection~* any grade 3-4 toxicity related to eravacycline use~* 21 days of therapy (maximum duration allowed per study protocol)"
40947713|NCT00244283|DRUG|Sevoflurane|
40947714|NCT00244283|PROCEDURE|High thoracic epidural analgesia|
40947715|NCT01008176|BEHAVIORAL|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
40947716|NCT02138773|DRUG|Tamsulosin formulation-A|oral
40947717|NCT02138773|DRUG|Tamsulosin formulation-B|oral
40947718|NCT02526901|OTHER|No intervention|
41287090|NCT05652660|DRUG|ARV-471|Experimental
41287091|NCT05652660|DRUG|Rosuvastatin|Probe substrate
41287092|NCT02011503|PROCEDURE|Multi-layer compression therapy|Application of multi-layer compression therapy.
41287093|NCT02011503|OTHER|Application of dHACM|Application of dHACM to ulcer.
40947719|NCT01454960|BEHAVIORAL|Clinical Decision Support: Accountable Justification|Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).
41287094|NCT01652833|OTHER|Physician Survey|Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
41287095|NCT01079923|DIETARY_SUPPLEMENT|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
40947720|NCT01454960|BEHAVIORAL|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
41287096|NCT01079923|DIETARY_SUPPLEMENT|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
41287097|NCT04937257|OTHER|Virtual Reality|The training included the following in the specified order: (1) A tutorial with an introduction to the program and a overview of the correct donning and doffing sequence, based on Center for Disease Control (CDC) guidelines, (2) a training mode to practice the correct sequences with step-wise feedback, and (3) a testing mode that repeated until the sequence was completed perfectly without any mistakes. A study member was present to assist with the device and record the duration of training.
41133181|NCT05640505|BEHAVIORAL|School based Gratitude Interventions|Three gratitude interventions including Count your blessings, Gratitude Letter and Loving Kindness Meditation were applied with modification focusing on school related experiences. For example, writing a gratitude letter to a teacher, mentor or coach who played a significant role in one's life then imagining on the same person during LKM exercise of imagery. There were 9 sessions with 3-4 exercises in each session.
41133182|NCT01203943|DRUG|CC-930|CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
41133183|NCT01203943|OTHER|Placebo|Placebo
41133184|NCT01203943|DRUG|CC-930|CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
41133185|NCT01203943|DRUG|CC-930|C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
41287098|NCT04937257|OTHER|E-module|The instructional video included step-by-step instruction and demonstration of adequate donning and doffing procedures. The 14-slide presentation contained the same content as used by the home institution for competency training, based on Center for Disease Control (CDC) guidelines. Participants were instructed to review the material however they liked and their duration of training was recorded.
40758101|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^10 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland
40758102|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland
40758103|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^11 vg/gland (both glands)|intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland
40758104|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland
41287099|NCT06411184|DRUG|Regulator T Cells|Autologous Regulatory T-Lymphocytes 1\*10\^6/kg, 2\*10\^6/kg, 4\*10\^6/kg and 8\*10\^6/kg, respectively until restrictive toxic reaction occurs
41287100|NCT04847830|DEVICE|Er:YAG laser (Waterlase)|The WaterLase iPlus tissue cutting system is a unique device with diverse, hard- and soft-tissue dental applications. It utilizes advanced laser and water atomization technologies to safely and effectively cut, shave, contour, roughen, etch, and resect oral hard-tissue, and direct laser energy to perform oral soft-tissue removal, incision, excision, ablation and coagulation.
40758105|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^11 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland
41287101|NCT04847830|PROCEDURE|root surface dbridement|root surface debridement under local anaesthesia
41287102|NCT03427840|PROCEDURE|Procedure/Surgery: superior hypogastric block|superior hypogastric blockade during surgery
41287103|NCT01327430|DIETARY_SUPPLEMENT|Milk phospholipid|During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.
41133186|NCT01263496|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
41133187|NCT01263496|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
41133188|NCT01263496|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
41133189|NCT01263496|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
41133190|NCT01263496|DRUG|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
41452952|NCT06386523|DIAGNOSTIC_TEST|Passage of olfactory tests|test TODA2 and Sniffin Stick Test
40758106|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland
40758107|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^12 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland
40758108|NCT04413708|BEHAVIORAL|P3-T PrEP Adherence App|"P3-T provides daily PrEP reminders, a medication tracker and calendar, personalized medication adherence strategies, refill reminders, and tailored adherence support messages; social support via a social wall that includes daily discussion prompts; daily quests to build knowledge and skills; a multimedia knowledge center; interactive narrative collections; personalized adherence counseling provided by an adherence counselor via in-app messaging; in-app rewards; a bank account that rewards daily app use by adding or subtracting a small financial reward based on daily app use; and, a user profile that includes a user-selected avatar."
40758109|NCT06106295|DRUG|Metyrapone|250 to 1000 milligram (mg) orally in one or two doses in the evening (administered 4 and 2 hours prior to bed)
40758110|NCT00660959|DRUG|lixivaptan|oral capsule
40758111|NCT00660959|DRUG|placebo|oral capsule
40758112|NCT02769416|OTHER|Data and sample repository|Subjects with spinal cord and/or traumatic brain injury, family members and healthy volunteers will provide data and samples.
40758113|NCT06207617|PROCEDURE|Immediate implant placement + customized healing abutment|Immediate implant placement in fresh extraction molar sites + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant. no grafting material included in this arm
40758114|NCT06207617|PROCEDURE|Immediate implant placement + xenogeneic bone graft material + customized healing abutment|Immediate implant placement in fresh extraction molar sites + xenogenic bone graft + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant.
40758115|NCT00109668|DRUG|beclomethasone dipropionate (QVAR)|
40758116|NCT03767387|OTHER|Trimodal Prehabilitation|Prehabilitation before major surgery consisting of: i) motivational interview to assess patient's adherence profile and to co-design the characteristics of the physical activity program with the patient; ii) personalised program to promote daily physical activity; and iii) supervised high-intensity endurance exercise training program.
40758117|NCT00698412|DEVICE|Cane|This group use the cane every day since the baseline
40758118|NCT05806528|OTHER|Ultrasound|Use ultrasound to make placental invasion index
40758119|NCT00165308|DRUG|Tamoxifen|Given orally, daily for one year.
40758120|NCT03269721|BEHAVIORAL|Neuropsychological Assessment|Assessments include: Paper and pencil computerized measures of Memory, Language, Visuospatial Function, Executive Functioning-Processing Speed, and Attention
40758121|NCT03269721|PROCEDURE|Spirometry|Pre and post bronchodilator spirometry will be administered according to the American Thoracic Society (ATS) guidelines.
40758122|NCT03269721|PROCEDURE|Arterial Blood Gas|Radial artery blood sample will be collected to measure gas exchange hemoglobin; arterial oxygen and carbon dioxide will be examined as potential covariates.
40758123|NCT03269721|PROCEDURE|Diffusion Capacity of the Lung for Carbon Monoxide|For measurement of gas exchange in the lung. DLCO adjusted for hemoglobin will be the primary variable of interest and will be examined as a potential covariate.
40758124|NCT03269721|DIAGNOSTIC_TEST|6 Minute Walk Test|Distance walked in 6 minutes will be the primary outcome.
40758125|NCT03269721|PROCEDURE|Systemic Vascular Measures|Carotid artery ultrasound, pulse wave velocity, brachial artery endothelium-dependent flow mediated dilation and endothelium-independent dilation will be measured.
40758126|NCT03269721|BIOLOGICAL|Blood Biomarkers|High sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.
40758127|NCT03269721|BEHAVIORAL|Symptom Questionnaire Measures|M.I.N.I Screen 7.0.0, Beck Depression Inventory-II (DBI-II), State Trait Anxiety Inventory (STAI), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), MMRC Dyspnea Scale (MMRC), Berlin Questionnaire
40758128|NCT03269721|PROCEDURE|Brain MRI|Primary neuroimaging outcomes of interest are white matter structural integrity
40758129|NCT05677360|BEHAVIORAL|HPV MISTICS -Provider Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.
40758130|NCT05677360|BEHAVIORAL|HPV MISTICS - Parent Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.
40758131|NCT05677360|BEHAVIORAL|HPV MISTICS- HPV Vaccine Champion Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses
40758132|NCT06492148|OTHER|Myofascial Release|The myofascial release technique is a widely used manual therapy method characterized by low-load, prolonged mechanical forces applied to manipulate the myofascial complex, aiming to restore optimal length, alleviate pain, and improve function.
40758133|NCT06492148|OTHER|Sham-Myofascial Release|The hands of the researcher applying the technique will be placed in the same areas as the myofascial release technique, with only the palms in light contact for the same duration. However, no intervention will be made to create any pressure or open the tissue barrier.
40758134|NCT00979615|DRUG|Olopatadine HCL (Patanase) Nasal Spray, 0.6%|2 sprays/ nostril BID
40758135|NCT00979615|DRUG|Azelastine HCl (Astelin) Nasal Spray, 137 mcg|2 sprays/ nostril BID
40758136|NCT05428670|DRUG|Zanubrutinib+Rituximab+Lenalidomide|Zanubrutinib is a bruton' s tyrosine kinase inhibitor independently developed in China.
40758137|NCT05428670|DRUG|RCHOP/RCDOP|RCHOP/RCDOP is the classic treatment of diffuse large B cell lymphoma.
40758138|NCT04917939|OTHER|RNA sequencing|Samples in both groups will be sequenced by single-cell sequencing and spatial transcription sequencing.
41287104|NCT01828827|DRUG|PA-824 1000 mg|Two single administrations of 1000mg each administered by 5 tablets of 200mg, one administered in the fed state and one administered in the fasted state.
40947721|NCT01454960|BEHAVIORAL|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
40758139|NCT06103799|BEHAVIORAL|IMB model-based continuity of care|The information-motivation-behavioral skills (IMB) model, first proposed by Fisher, is composed of three elements-information, motivation, and behavioral skills-and is aimed at transferring patients' behavior into a positive direction, including self-behavior management ability, medication compliance and so on. For diabetic patients with poor adherence, the IMB model of care can be considered.
40758140|NCT00562107|DEVICE|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
40758141|NCT00562107|DEVICE|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
40758142|NCT00181246|DRUG|Transdermal Fentanyl|
40758143|NCT04799717|BEHAVIORAL|Gaming session|Participants will be provided the option to play an online game with the clinician for the first half of the session through an online platform.
40758144|NCT01079390|DEVICE|acupuncture|patient will receive high dose, low dose or sham acupuncture treatment.
40758145|NCT03818880|DEVICE|Novel spectacle lens design|Spectacle lens to control progression of myopia
40758146|NCT02368873|PROCEDURE|Application of IPOM mesh|
40758147|NCT01171937|DRUG|Risperidone|children get randomized to either placebo or active risperidone
40758148|NCT01171937|DRUG|Placebo|Children get randomized to either placebo or risperidone
40758149|NCT04080531|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
40758150|NCT04080531|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
40947722|NCT03326726|DRUG|2% CHG|Chlorhexidine Gluconate
40758151|NCT06566703|BEHAVIORAL|All Nations Snuff Out Smokeless|All Nations Snuff Out Smokeless is a culturally tailored smokeless tobacco cessation program that incorporates group-based and individual counseling.
40758152|NCT06566703|BEHAVIORAL|Healthy Living|Healthy Living is an educational program that provides information about diet, exercise, stress, and general health. It uses group-based and individual discussion, along with educational materials.
40758153|NCT05609058|DEVICE|dedicated treatment board with no degree|the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
40947723|NCT01093638|BIOLOGICAL|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with infant formula
40947724|NCT01093638|BIOLOGICAL|Placebo|Oral formulation of placebo fed concomitantly with infant formula
40947725|NCT04008173|OTHER|Non-interventional patient registry|Non-interventional patient registry
40947726|NCT02635763|PROCEDURE|Femoral nerve and the lateral cutaneous nerve block|Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
40947727|NCT02635763|PROCEDURE|Lumbar plexus and sacral plexus nerve block|Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
40947728|NCT06530225|OTHER|Education and Mentoring for Prescribing Pharmacists|Pharmacists enrolled in the PrEP prescribing cohort will receive implicit bias, health disparity and health equity training for HIV prevention. In addition, the pharmacists will receive mentorship and receive an implementation toolkit on best practices for PrEP prescribing.
40947729|NCT06229639|DEVICE|Passy Muir Valve|
40947730|NCT06229639|DEVICE|Tracheostomy Plug|
40758154|NCT00690352|BEHAVIORAL|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
41452953|NCT06627270|DRUG|Metronidazole|Participants will receive metronidazole (500 mg t.i.d. x 10 days)
40758155|NCT06199752|DIETARY_SUPPLEMENT|probiotic agent 25 Billion CFU (Nowfoods, USA) , ). Inulin capsules 1000mg Herbamama USA|probiotic agent 25 Billion CFU (Nowfoods, USA), composed of ten strains of bacteria (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantaLactobacillus paracasei, Bifidobacterium breve, Streotococcus thermophiles, Lactobacillus salivarius, and Bifidobacterium longum),
40758156|NCT03791424|DRUG|Midazolam|Administering premedication with sedative drug to relieve anxiety
40758157|NCT03418363|DIETARY_SUPPLEMENT|DHEA Oral Capsule|Daily 100mg DHEA supplement
40758158|NCT03418363|OTHER|Placebo Oral Capsule|Daily oral capsule
40758159|NCT03737890|OTHER|Inspiratory Muscle Training|"Participants in the experimental group were given Inspiratory Muscle Training by using an IMT device. For this training, the inspiratory load for each participant was set at 30 cmH2O.~In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
40758160|NCT03737890|OTHER|Hold Relax Pectoral Stretch|"In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
40758161|NCT03958097|COMBINATION_PRODUCT|NK cell and PD-1 antibody|Each patient enrolled the study will received both NK cell and PD-1 antibody.
40758162|NCT03194932|DRUG|Venetoclax|Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.
41452954|NCT06627270|OTHER|Chlorhexidine|Mouth rinse chlorhexidine (10 ml t.i.d. x 10 days)
40758163|NCT03194932|DRUG|Cytarabine|Given intravenously (IV) or intrathecally (IT).
40758164|NCT03194932|DRUG|Idarubicin|Given IV.
40758165|NCT03194932|DRUG|Intrathecal Triple Therapy|Given IT.
40758166|NCT03194932|DRUG|Azacitidine|Given IV.
40947731|NCT01307982|PROCEDURE|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
40947732|NCT01307982|PROCEDURE|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
41452955|NCT03347058|OTHER|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
41452956|NCT00691782|OTHER|Survey of exercise practices|detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
41452957|NCT05813847|DRUG|local anaesthetic injection|Local infiltration of study drug
41452958|NCT00012818|BEHAVIORAL|relaxation technique|
40758322|NCT06368674|OTHER|Intervention group Case Manager (CM)|The CM will be informed about the discharge plan from the nurse at the geriatric ward, as will the municipality for those with need of home help care. An outline of the intervention has been created with managers from primary care and rehabilitation within primary care and municipality care. Core components in the intervention will be active follow-up of the discharge, rehabilitation and care plans. If there are plans that have not been executed or unmet needs, the CM will take adequate contacts to ensure that actions are made to meet the needs. These contacts can be, e.g. the GP for medical needs, the rehabilitation unit in primary or municipality care for unmet rehabilitation needs, and the home help service for unmet care needs. The CM will have a network of contact persons in hospital, primary and community care, as well as in rehabilitation in primary and community care, in order to facilitate for prompt actions to meet the needs.
41453642|NCT01924247|BEHAVIORAL|Outpatient secondary prevention program|The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.
40758323|NCT06368674|OTHER|Control Group|The participants in the control group with a planned follow-up by a primary health care centre within the catchment area of the Sahlgrenska University Hospital that does not have CMs designated for active follow up of discharged frail older people. Thus, the participants in the control group will not actively be followed-up after discharge.
40758324|NCT05077111|PROCEDURE|Thoracic Epidural Anesthesia|Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.
40758325|NCT05077111|PROCEDURE|General Anesthesia with One Lung Ventilation|Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).
40758326|NCT02569008|DRUG|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
40758327|NCT04980963|BEHAVIORAL|Cognitive Support Technology (CST)|Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment. CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012).
40758328|NCT01340534|DEVICE|Supplemental oxygen 80% FIO2|Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)
40758329|NCT01340534|PROCEDURE|Use of air (no oxygen during surgery)|No use of oxygen during surgery or in the 2 hours after the procedure.
40758330|NCT05855096|OTHER|Google Form Questionnaire|Google form questionnaire is performed by responders.
40758331|NCT00306280|DEVICE|Phototherapy|
40758332|NCT05524948|OTHER|Experimental Dentifrice|Dentifrice containing 0.454% stannous fluoride with 0.3% zinc chloride.
40758333|NCT05524948|OTHER|Reference Dentifrice|Standard fluoride dentifrice containing 0.243% sodium fluoride.
40758334|NCT00842803|DRUG|Albumin infusion (25% albumin)|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
40758335|NCT01130428|DEVICE|Juvent 1000 Vibration Platform|"As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.~The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (\~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading \[38\]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes."
40786366|NCT04812431|BIOLOGICAL|Neural precursor cells derived from human embryonic stem cell line|When the Dose Limiting Toxicity (DLT) is not presented in the first three subjects administered with PSA-NCAM(+) NPC, two additional patients are added to the clinical study.
40786367|NCT01486303|PROCEDURE|Facial Cosmetic Acupuncture|Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
40786368|NCT01336244|DRUG|GLPG0778|capsules containing 50 or 100 mg of GLPG0778
41453643|NCT01924247|BEHAVIORAL|Standard treatment by family physician|Standard treatment by family physician.
41453644|NCT02665962|OTHER|Perioperative Caloric Restriction Program|
41466382|NCT05193409|DRUG|225 mg BNC210|225 mg BNC210
41466383|NCT05193409|DRUG|675 mg BNC210|675 mg BNC210
41466384|NCT05193409|DRUG|Placebo|Placebo
40758336|NCT05281575|BEHAVIORAL|Baby Friendly Spaces (BFS)|Designed to meet the unique needs of populations living in humanitarian contexts, BFS focus on two domains: psychosocial support that targets maternal wellbeing and childcare practices that target caregiver functioning to also address child wellbeing and development. In so doing, BFS strengthens mothers' internal resources and skills in caring for their children both in quantity (time spent caring for the child) and quality (responsiveness), to positively impact the health status and wellbeing of their children. In BFS, the following activities are delivered by trained psychosocial workers: counselling for infant and young child feeding practices; hygiene education and promotion; mother-child bonding activities that provide psychosocial stimulation essential for children at risk of, or experiencing, malnutrition; and provision of maternal psychosocial support (i.e. psychoeducation, stress management).
40947891|NCT05014217|BEHAVIORAL|Dialectical Behavior Therapy-inspired Treatment|A psychotherapy developed by M. Linehan for patients with borderline personality disorder that combines cognitive behavioral therapy techniques (emotional regulation, practical exercises) with Buddhist meditation principles (stress tolerance, acceptance, open-mindedness) (Linehan, M. M. \& Dimeff, L., 2001). As opposed to Linehan's model, individual meetings are bi-weekly, no emergency phone service is offered, the mindful meditation module is reorganized into life habits modules, and every module includes mindfulness exercises. Patients assist psychoeducative group meetings beforehand, along with a pre-treatment of 4-6 individual meetings (over 4-8 weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts one year, but can be extended to two years for eligible patients who are interested. Psychiatric follow-up appointments are on an as-needed basis. Every every patient has a treatment contract with specific and measurable treatment objectives.
40947892|NCT01274650|PROCEDURE|Indirect Calorimetry|Indirect Calorimetry
40947893|NCT04948788|DRUG|SHR1459 ；YY-20394|SHR1459 plus YY-20394
40947894|NCT04948788|DRUG|SHR1459 ；YY-20394|SHR1459 plus YY-20394
40947895|NCT04948788|DRUG|Gemcitabine-Oxaliplatin|Gemcitabine-Oxaliplatin
40947896|NCT02280070|OTHER|Laboratory test|Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
41287297|NCT00863629|DRUG|Insulin|In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
40758337|NCT02241772|DRUG|TA-8995|
40758338|NCT02241772|DRUG|Placebo|
40758339|NCT04991597|OTHER|Cold Compress Pack|Palmar aspect of forearm will have a cold compress pack placed on it.
40758340|NCT04991597|OTHER|Room Temperature Compress Pack|Palmar aspect of forearm will have a room temperature compress pack placed on it.
40758341|NCT04991597|DRUG|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
40758342|NCT04991597|DRUG|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
40947897|NCT02280070|OTHER|Medical history and physical examination|medical history and physical examination
40947898|NCT02280070|OTHER|BW and height|Body weight (kg) and height (cm)
41287298|NCT03990948|OTHER|Blood sampling|Blood sample collection
40758343|NCT04052126|OTHER|Individualized physical activity program|"Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment."
40758344|NCT01582555|DRUG|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
40758345|NCT01582555|DRUG|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
40758346|NCT01812746|DRUG|BIND-014|
40758347|NCT00005931|DRUG|SU5416|
40786369|NCT01336244|DRUG|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
40786370|NCT02523287|BIOLOGICAL|Fluad|Randomized assignment
40947899|NCT02280070|OTHER|Performance status|ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead
40947900|NCT02280070|OTHER|Creatinine clearance|Creatinine clearance (CCr, mL/min) was estimated by Cockcroft \& Gault method using serum creatinine (mg/dL), age and body weight (kg).
40947901|NCT02280070|OTHER|Biomarker|Carcinoembryonic antigen and carbohydrate antigen 19-9
40947902|NCT02280070|RADIATION|Contrasting CT|Computed tomography
41287299|NCT05505422|DEVICE|Routine ECMO|Routine ECMO during lung tansplant
41466385|NCT04086758|DRUG|zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion
40947903|NCT02280070|OTHER|Adverse event|AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
40947904|NCT02280070|OTHER|HBs antigen and HCV antibody|check for exclusion criteria
40947905|NCT02280070|OTHER|Endoscopy|Endoscopy for lower digestive tract
41287300|NCT05505422|DEVICE|On demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery~2. Prolonged high dose pressor required to maintain adequate perfusion~3. A sustained drop in cerebral saturation \> 25% of baseline despite initial attempts at optimization~4. Inability to tolerate pulmonary artery clamping~5. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~6. Inadequate exposure to the surgical field"
40758348|NCT05196061|OTHER|Questionnaire|"Subjects will be asked to complete a questionnaire. The questionnaire will garner demographic data, medical history, medication and supplement history, gut-specific, skin-specific questions; etc. The complete questionnaire is provided with this submission for review. Demographic data includes:~1. Age~2. Sex~3. Race~4. Ethnicity"
40947906|NCT02280070|OTHER|HBs antibody and HBc antibody|Check according to hepatitis B guideline
40947907|NCT02280070|DRUG|S-1|S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
40947908|NCT02280070|DRUG|L-OHP (130mg/m2)|L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
40947909|NCT02280070|DRUG|L-OHP (85 mg/m2)|L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
40947910|NCT02280070|DRUG|l-LV|l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
40947911|NCT02280070|DRUG|5-FU|5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
40947912|NCT02623920|DRUG|Brentuximab|Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
40947913|NCT02623920|DRUG|Bendamustine|Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
40947914|NCT02623920|DRUG|Rituximab|Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
40947915|NCT06102915|DRUG|Rocuronium Bromide 10 MG/ML|Comparative
40947916|NCT06102915|DRUG|Nimbex 10 MG in 5 ML Injection|Comparative
40947917|NCT05542199|OTHER|Multicomponent nutrition supplement (MCNS)|Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
40947918|NCT05542199|BEHAVIORAL|Behavioral weight loss program|Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
40947919|NCT05734573|BEHAVIORAL|Family-based treatment|FBT is carried out by a family therapist who has received FBT training. The duration of FBT is commonly 6-12 months, in most cases comprising 10-20 sessions. At the beginning of treatment, there are weekly sessions; later in treatment, the sessions are less frequent. The patient and their family meet their psychiatrist every four to six weeks, and the family therapist also takes part in these meetings. The treatment is implemented in accordance with the FBT treatment manual.
40947920|NCT05516589|DRUG|Nab-paclitaxel|260mg/m\^2 IV Q3W
40947921|NCT05516589|DRUG|Cisplatin|75mg/m\^2 IV Q3W
40947922|NCT05516589|BIOLOGICAL|Tislelizumab|200mg IV Q3W
40947923|NCT05516589|DRUG|Afatinib|30mg PO QD
40947924|NCT02976922|DIETARY_SUPPLEMENT|Probiotic lozenge|10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
40947925|NCT06556641|DRUG|GZR33 Injection|Administered as once daily subcutaneous dose
41466386|NCT02306837|DRUG|Bu-CY-E|mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
40786371|NCT02523287|BIOLOGICAL|Saline|Randomized assignment
40947926|NCT06556641|DRUG|GZR101 Injection|Administered as once daily subcutaneous dose
40947927|NCT06556641|DRUG|Placebo|Administered as once daily subcutaneous dose
40947928|NCT06556641|DRUG|Insulin Degludec|Administered as once daily subcutaneous dose
40947929|NCT03459482|OTHER|Food Elimination Diet|Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
40947930|NCT03228420|DEVICE|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
40947931|NCT03228420|OTHER|CMM|Conventional Medical Management
40947932|NCT05843955|OTHER|Questionnaire|Nutritional status, physical activity levels, anthropometric measurements, and biochemical parameters of individuals were examined. A food consumption frequency questionnaire was administered.
40947933|NCT06203379|OTHER|Neuromuscular Exercise Training|Neuromuscular Exercise Training
40947934|NCT06203379|OTHER|control exercise|Exercise Training
40947935|NCT02235519|DRUG|Azilsartan 40 mg.|Patients will take 40 mg of azilsartan during 12 weeks
40947936|NCT02235519|DRUG|Azilsartan 80 mg|Patients will take 80 mg of azilsartan during 12 weeks
40947937|NCT01663168|DRUG|Rifabutin|
40947938|NCT02905149|PROCEDURE|Serrato|Serratus plane block.
40947939|NCT02905149|PROCEDURE|Control|Standard anesthesia
40990438|NCT00895258|BEHAVIORAL|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
40990439|NCT00895258|BEHAVIORAL|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
40990440|NCT05147909|DIETARY_SUPPLEMENT|Sodium Phosphate|Sodium Phosphate 2 capsules daily (containing a total of 500 mg of Pi, 372mg of sodium)
40947940|NCT04768725|BEHAVIORAL|Dietary intervention combined with physical-cognitive exergaming|Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\] combined with physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
40947941|NCT04768725|BEHAVIORAL|Dietary intervention|Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\].
41287301|NCT04786210|COMBINATION_PRODUCT|Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil|Split-scar fractional ablative erbium laser-assisted delivery of 50mg/mL of 5-fluorouracil solution to one half of the scar (4 treatments)
40947942|NCT04768725|BEHAVIORAL|Physical-cognitive intervention|Physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
41287302|NCT04786210|COMBINATION_PRODUCT|Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide|Split-scar fractional ablative erbium laser-assisted delivery of 10 mg/mL of triamcinolone acetonide solution to the other half of the scar (4 treatments)
41287303|NCT04952727|BIOLOGICAL|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
40786372|NCT05970926|DEVICE|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the extremity arteries, which is non-invasive, and the parameters of arterial structure and blood flow will be measured.
40990441|NCT05147909|DIETARY_SUPPLEMENT|Sodium Chloride|Sodium Chloride 2 capsules daily (NaCl, containing a total of 372mg of sodium)
40990442|NCT05337592|DRUG|BI 1815368 formulation 1|BI 1815368 formulation 1
40990443|NCT05337592|DRUG|Placebo|Placebo
40990444|NCT05337592|DRUG|BI 1815368 formulation 2|BI 1815368 formulation 2
41287304|NCT04952727|BIOLOGICAL|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
41287305|NCT01611077|DRUG|Candesartan cilexetil|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
41287306|NCT01611077|DRUG|Olmesartan medoxomil|Switch to olmesartan 40 mg tablets once daily for 42 days,
41287307|NCT01611077|DRUG|Olmesartan/amlodipine|then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
41287308|NCT04438512|DRUG|Midomafetamine|Administration of 80 or 120 mg MDMA in combination with psychotherapy and a supplemental dose offered 1.5/2 hrs later of 40 or 60 mg MDMA respectively
41287309|NCT04438512|BEHAVIORAL|Psychotherapy|Standardized non-directive psychotherapy performed by therapist team
41287310|NCT03444025|DRUG|Goserelin|Goserelin is Luteinizing hormone releasing hormone (LHRH) analogue.
40758349|NCT05196061|OTHER|Stool sample|Stool samples will be collected using a specific kit consisting of a ready-to-use package, including a user guide. When stool samples are collected, they will be immediately placed in previously prepared Fast prep tubes (MP, Cat# 5076-200-34340) containing 500 μL glass beads (Sigma-Aldrich G8772-100g) and 1 mL ASL™ lysis buffer (Qiagen DNA Extraction Kit) and transported to the laboratory where assays will be conducted. Samples will be kept in a - 20 degree Celsius freezer until they are analyzed.
41287311|NCT02242396|DRUG|Telmisartan|
40947943|NCT03002363|BEHAVIORAL|Video Modeling Intervention|Prior to arrival of the audiological evaluation, the child and caregiver will be required to watch one of two videos created by the research personnel. One video, the intervention video, is a behavior modeling video walking through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment. The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
40947944|NCT03002363|BEHAVIORAL|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
40947945|NCT01634763|DRUG|LDK378|
40947946|NCT03004443|DRUG|Infliximab|Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
40947947|NCT03004443|DRUG|Placebo|Saline solution will be administered intravenously over a 2 to 2.5 hour period.
40947948|NCT02869503|OTHER|Data collection|
40947949|NCT00751218|DRUG|desloratadine|desloratadine, 5mg oral tablets, once daily for 28 days
40947950|NCT00751218|DRUG|placebo|placebo, once daily for 28 days
40947951|NCT00751218|DRUG|cetirizine|cetirizine, 10 mg capsules once daily for 28 days
40947952|NCT00183820|DRUG|paclitaxel, gemcitabine, and oxaliplatin|"1. Paclitaxel 170 mg/m2 IV d 1 14 days~2. Gemcitabine 800 mg/m2 IV d 1 14 days~3. Oxaliplatin 100 mg/m2 IV d 1 14 days"
40947953|NCT04562467|DRUG|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]|2 x 1g capsules BID as per REDUCE-IT
40990445|NCT01296256|DRUG|Bendamustine-EAM|Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
40990446|NCT06297447|OTHER|PNE4Adults - pain science education|Is formerly described under arm descriptions
41287312|NCT02242396|DRUG|Telmisartan hydrochlorothiazide|
41307776|NCT05366972|DEVICE|Ultrasonographic measurements|"Posterior layers of the thoracolumbar fascia ,middle layers of the thoracolumbar fascia thickness and Lumbar interfacial triangle thickness~CSA (cross-sectional area) measurements of erector spinae muscles, quadratus lumborum muscles and the latissimus dorsi muscles"
40758350|NCT05196061|OTHER|Skin swab|Skin swabbing is a safe, non-invasive method to sample microbiota on human skin. Areas to be swabbed: Right upper back, Non-dominant ventral forearm or Most representative lesion
40758351|NCT05196061|OTHER|Oral rinse|Briefly, 20-25 ml saline will be provided in separately labelled blue capped 50-mL Falcon™ centrifuge tubes (Fisher Scientifics Co.). Each subject will be asked to swish and gargled the saline from the tube into their mouth for 2 minutes and expectorate the rinse into the tube. The tubes will be closed tightly and stored in -80 C until sequencing can be completed. Prior to use, all the tubes with oral wash samples will be completely thawed on ice, then centrifuged at 4000 rpm for 15 minutes and 20-25 ml supernatant transferred into fresh 50-mL centrifuge tubes. The pellet left in each tube will be used to extract DNA for microbiome studies
40758352|NCT04367389|BEHAVIORAL|Physical activity promotion|Physical activity promotion activities consist of two phone or video calls with a therapists, two group video calls with a therapist, a complementary e-learning course and a fitness tracker that was provided.
40758353|NCT04367389|BEHAVIORAL|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for persons with MS. However, they can be adjusted according to participants prior physical activity level and their time for exercise during the week.
40758354|NCT05513170|PROCEDURE|Use of Densah Burs in closed sinus lift|Closed sinus will be performed using Densah Burs. Densah Burs enhance bone quality through osseodensification; a process through which bone is compacted and auto-graphted in the marrow spaces and apically to elevate the sinus floor and enhance bone density.
40758355|NCT05513170|PROCEDURE|Closed sinus lift using osteotomes|Closed sinus lift will be performed using osteotomes. Osteotomes elevate the sinus floor and enhance the bone quality.
41307777|NCT02149056|BEHAVIORAL|observation|
41307778|NCT02149056|OTHER|Impaired Glucose Tolerance|Impaired Glucose Tolerance
40947954|NCT06449521|BEHAVIORAL|BECOME intervention|The intervention, BECOME, includes: a) Evidence-based stress reduction (EBSR): as recommended in the WHO mhGAP guidelines, diaphragmatic breathing and body scan will be used to manage stress and anxiety. b) Behavioral activation (BA): as recommended in the mhGAP guidelines, this evidence-based strategy will increase the time that patients spend engaging in pleasurable activities to both treat depression and increase physical activity, depending on their cognitive and physical capabilities (e.g., going to a neighbor's house for tea or walking to the local market). c) Motivational interviewing (MI): an evidence-based patient-interaction strategy that increases the patient's internal motivation to engage in healthy behaviors (e.g., quit tobacco) both to prompt change (if they are not engaging in healthy behaviors) and maintain them (if they are already engaged in healthy behaviors), as recommended by Package of Essential Noncommunicable disease interventions) PEN protocols.
40947955|NCT03216642|DIAGNOSTIC_TEST|bacterial culture and analysis|Specimens were collected with soft-tipped applicators of sterile cotton swabs after syphilis of lacrimal passages.
40947956|NCT01038193|OTHER|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
40947957|NCT06534749|DEVICE|ultrasound|Ultrasound screening: by (SonoScape A6, Yizhe Building, Yuquan, Road Shenzhen, 518051, China). General-purpose diagnostic abdominal ultrasound equipment was used, with a 7.5-MHz linear-type probe. Screenings will be performed by radiologist with appropriate practice. The ultrasound examination will take 10 min for each patient. The recordings will consist of two bilateral renal images will be obtained and one transverse and longitudinal images. The urinary bladder will be observed with the patient in a supine position, and images will be recorded when abnormalities will be identified. The following will be investigated by ultrasound: number, size (including differences between sides), and location of the kidneys; pelvic dilatation; echogenicity, and other findings indicating cysts or tumours. Shape and wall thickening of the urinary bladder, as well as ureter dilatation, will be also examined
40947958|NCT01070758|DRUG|Lanreotide autogel|The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
40947959|NCT01298531|DRUG|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
40947960|NCT01298531|DRUG|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
40947961|NCT01298531|DRUG|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
40947962|NCT01162928|DRUG|Nutriflex Omega special + Oxepa|3-chamber-bag combined with enteral nutrition
40947963|NCT01162928|DRUG|Nutriflex Lipid special + Pulmocare|3-chamber-bag combined with enteral nutrition
40947964|NCT01836965|BEHAVIORAL|Social Skills Intervention|Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
41287313|NCT05088317|DIAGNOSTIC_TEST|Exercise capacity|The incremental shuttle walking test at increasing speed (ISWT) is one of the field tests used to evaluate exercise capacity. It has been shown that ISWT is a valid and reliable assessment tool that can be used to evaluate exercise capacity in obese individuals. This test is an exercise test in which walking between two cones 10 m apart at increasing speed for 12 minutes is counted as one sit-up for each 10-meter walk between the two cones. It is continued until the patient is unable to continue the test due to shortness of breath, the heart rate reaches 85% of the maximum expected heart rate, or completes the 12-minute test. In this test, the primary measure is the distance walked, and the result is calculated based on the number of shuttles completed.
41287314|NCT00200681|DRUG|Velcade|
41287315|NCT02662439|DEVICE|Body Composition Monitor (BCM)|In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
41287316|NCT00820638|DEVICE|myomo e100|use of the myomo e100 in home
41287317|NCT05352217|DEVICE|Mobile app ovarian cancer followup (ePRO)|The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.
41287318|NCT05282706|DRUG|Lavender Oil|A hydrogel lavender oil infused aromatherapy patch
41287319|NCT05282706|DRUG|Mandarin Oil|A hydrogel mandarin oil infused aromatherapy patch
41287320|NCT05282706|DRUG|Peppermint oil|A hydrogel peppermint oil infused aromatherapy patch
41287321|NCT05282706|OTHER|Placebo|A placebo patch containing no aromatherapy oil
41287322|NCT01163422|DEVICE|Implantation of 3-chamber pacemaker|Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
41287323|NCT05946252|OTHER|Motor imagery|"Motor imagery will be performed according to the PETTLEP (Physical,Environment,Task,Time,Learn,Emotion,Perspective) model for 15 minutes.~1. To imagine walking activity in different environments (seaside, beach, walking path).~2. The rest activity will be imagined by sitting on a bench.~3. Upper extremity strengthening exercises with dumbbells, lower extremity strengthening exercises with elastic band and trunk-oriented bridging, posterior pelvic tilt and table top stabilization exercises will be visualized.~4. The rest activity will be imagined by sitting on a bench.~5. Imagination will end with homecoming and domestic activities."
41287324|NCT05946252|OTHER|Diaphragmatic breathing|Diaphragmatic breathing will be shown to pregnant women in the supine position, eyes closed, with one hand on the chest and the other hand on the abdomen. This practice will last for five minutes.
40947965|NCT05596942|DIETARY_SUPPLEMENT|Albumin Channa Striata Extract|This study is a randomized controlled trial of 42 patients at the ICU of Dr. Moewardi General Hospital. The control group received 20 grams of human albumin on the first day and the study group received 15 grams of Channa striata extract daily for two days. Subsequently, eNOS, NLR and PLR are measured before and three days after treatment, and the examiners compare the three markers statistically.
40947966|NCT06529757|OTHER|Whole body cooling|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to whole body skin wetting. Skin wetting will be performed by spraying water onto the whole body throughout the exercise bout.
40990447|NCT06297447|OTHER|Usual care|Is formerly described under arm descriptions
40947967|NCT06529757|OTHER|Non-cooling|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modalities.
40758356|NCT00773461|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
40947968|NCT02670434|DRUG|NK-104-CR|NK-104-CR 8 mg daily for 52 weeks
40947969|NCT02670434|DRUG|Placebo|Placebo daily for 12 weeks
40758357|NCT00773461|DRUG|Placebo|iv every 4 weeks for 24 weeks
40758358|NCT05620719|BEHAVIORAL|Cognitive Behavioral Therapy for Posttraumatic Headache|CBT for Posttraumatic Headaches consists of 8 sessions of cognitive behavioral therapy that focus on (1) discussions and exercises that increase awareness of what may be related to headaches, (2) relaxation techniques to manage physiological stress, and (3) problem-solving techniques to manage common stressors. Sessions are delivered weekly and can last between 45 to 75 minutes based on clinical content and patient response to the material.
40947970|NCT02670434|DRUG|Livalo|Livalo® IR daily from week 12 to week 52
40947971|NCT01927627|DRUG|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
41287325|NCT05803564|DEVICE|Thoracoabdominal aortic stent system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system.
41287326|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
41453645|NCT01944722|DEVICE|BD Onclarity™ HPV assay on BD Viper™ LT|The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
40758359|NCT05620719|OTHER|Treatment as Usual|Participants will continue to engage in medical care as usual for 8 weeks.
40758360|NCT05620719|OTHER|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|Participants assigned to TCBT will receive 8 sessions of cognitive behavioral therapy using telemedicine rather than face-to face office visits.
40758361|NCT01608308|DRUG|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
40758362|NCT01608308|DRUG|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
40758363|NCT00376558|BEHAVIORAL|Community Reinforcement Approach|Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
40758364|NCT04300790|DRUG|Alpelisib|Alpelisib (BYL719): starting dose at 300 mg/QD.; 2 tablets once a day, oral administration, continuously during 28-day cycles until disease progression or unacceptable toxicity.
40758365|NCT04300790|DRUG|Metformin|500 mg BID with breakfast and dinner. After 3 days, if no (GI) intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days
40758366|NCT04300790|DRUG|Fulvestrant|"fulvestrant (500 mg IM injections; loading dose 500mg every two weeks for the first month; then every 4 weeks as per standard of care \[SoC\].~Patients should be started on metformin and fulvestrant within 7 to 14 days prior to start on alpelisib (D1C1)"
40758367|NCT04300790|DRUG|Letrozole|Letrozole 2.5 mg tablets, once daily, orally
40758368|NCT04300790|DRUG|Exemestane|Exemestane 25 mg tablets, once daily, orally
40758369|NCT04300790|DRUG|Vildagliptin|Vildagliptin 50 mg tablets, twice daily, orally with breakfast and dinner
40758370|NCT04300790|DRUG|Tamoxifen|Tamoxifen 20 mg tablets, once daily, orally
40758371|NCT04881097|BEHAVIORAL|no intervention|no intervention
40786373|NCT00000413|BEHAVIORAL|Psychoeducational program|
40786374|NCT03338985|GENETIC|Genetic analysis|Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.
40947972|NCT00895856|OTHER|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
40947973|NCT01604187|DRUG|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
40947974|NCT01604187|DRUG|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
40947975|NCT06322069|OTHER|Self-compassion intervention group|Participants would be provided a 14-days online course, and they need to finish the courses within 21 days.
40947976|NCT00810524|DRUG|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
40947977|NCT00810524|DRUG|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
40947978|NCT00810524|DRUG|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
40947979|NCT00810524|DRUG|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
40947980|NCT05825781|DRUG|Pertuzumab|i.v.
40947981|NCT05825781|DRUG|Perjeta®|i.v.
40947982|NCT03633617|DRUG|Dupilumab|Solution for injection administered subcutaneously
40947983|NCT03633617|DRUG|Placebo|Matching placebo
40990448|NCT02345811|DEVICE|Sapphire|silicone-hydrogel contact lens
40990449|NCT02345811|DEVICE|senofilcon A|contact lens
40990450|NCT01170182|DRUG|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
40990451|NCT01170182|DEVICE|Prilosec® 40 mg|Prilosec® 40 mg
41287327|NCT02100553|DRUG|Itraconazole|Two 100 mg capsules, once daily for 7 days
41287328|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
41287329|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
41287330|NCT02100553|DRUG|Itraconazole|Two 100 mg capsules, once daily for 7 days
41287331|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
41287332|NCT02741531|OTHER|Bladder filled with saline solution|Patients in this arm will have their bladders filled with 150 cc of saline solution.
41453646|NCT01944722|PROCEDURE|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
41287333|NCT02741531|OTHER|saline solution|Saline solution will be used to partially fill patients' bladders
41287334|NCT00066781|DRUG|gemcitabine hydrochloride|Given IV
41453647|NCT03417076|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg, and bexagliflozin by IV
41453648|NCT06026267|BIOLOGICAL|20% High Dose Albumin|"A\]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy.~Duration of albumin over 24 hours."
41453649|NCT06026267|OTHER|Standard Medical Treatment|Standard Medical Treatment
41287335|NCT00066781|DRUG|irinotecan hydrochloride|Given IV
41287336|NCT04663035|DRUG|Tislelizumab|200mg, iv. drip, Q3W. Tislelizumab will start within 3-7 days after ablation treatment. The longest course of treatment is 12 months.
40786375|NCT03493958|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|The SHUTi program is an automated, interactive, internet-based intervention based on well-established face-to-face cognitive behavioral therapy for insomnia (CBT-I) components including sleep restriction, stimulus control, sleep hygiene, cognition
41287337|NCT04663035|PROCEDURE|Ablation|After local anesthesia and intravenous sedative injection, the unipolar needle would be gradually inserted into the lesion and placed on the deepest edge of the lesion. The ablation electrode is a unipolar needle with a bare end of 2 or 3 cm (adjusted to tumor size). The ablation power is 150 watts (range from 100 to 200 watts). In general, the average ablation time for each lesion is about 12 minutes (ranging from 10 to 15 minutes).
41287338|NCT00231140|DRUG|Thalidomide (drug)|
41287339|NCT04143971|OTHER|intermittent fasting diet|intermittent fasting diet
41453650|NCT06026267|BIOLOGICAL|20% Reduced Dose Albumin|"B\]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.~Duration of albumin over 24 hours."
41453651|NCT05565690|DEVICE|MRS|It is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain
41453652|NCT03401281|OTHER|Coconut oil|50g extra virgin coconut oil daily for four weeks
41453653|NCT03401281|OTHER|Butter|50g butter daily for four weeks
40947984|NCT05534685|OTHER|intratracheal administration of surfactant/budesonide|328 patients will be included from Group A: 164 patients, from Group B: 164 patients who meet the selection criteria within the first 4 hours of hospital stay, after the authorization of the parents or guardian signing the informed consent. According to the assigned group, the preparation of surfactant or surfactant/budesonide in the syringe will be carried out, prior to performing the tracheal cannulation procedure. Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg. Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.
40947985|NCT05534685|OTHER|incidence of bronchopulmonary dysplasia|. Subsequently, follow-up will be carried out at 12 hours to assess the administration of the second dose of surfactant, type of mechanical ventilation, inspired fraction of oxygen (Fi02), arterial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2 ), mean airway pressure (PMVA), oxygen index (IO), oxygen saturation by pulse oximetry, weekly follow-up of the patient will continue for 28 days, evaluating the same parameters to make a diagnosis of bronchopulmonary dysplasia and finally at 36 postmenstrual weeks of gestation in those under 32 SDG or at discharge and at 56 postmenstrual days of life in those over 32 SDG or at discharge, allowing the severity of the disease to be determined
40947986|NCT03875768|BEHAVIORAL|Tracking plus coaching|Participants will track their nutrition intake every day for six months using a study app and receive tailored feedback via text message based on their nutritional intake and adherence to the DASH dietary pattern. If necessary, they will receive responsive coaching from a Nourish registered dietitian in order to increase adherence to the DASH dietary pattern and their engagement with the intervention.
40947987|NCT03212690|DRUG|Local standard of care|Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
40947988|NCT03212690|PROCEDURE|Mechanical ventilation|Mechanical ventilation will be based on volume-assist control mode, with a target tidal volume of 6-8 milliliter per kg (mL/kg) and a target plateau pressure of 30 centimeter of water (cmH2O).
40947989|NCT04872153|BEHAVIORAL|Dividat Senso Exergames|"The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 15 to 20 training sessions in total.~Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min)."
40947990|NCT02955797|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
40947991|NCT02955797|BIOLOGICAL|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
40947992|NCT02955797|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
40947993|NCT02955797|BIOLOGICAL|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
40947994|NCT03685695|OTHER|Laboratory Biomarker Analysis|Correlative studies
40947995|NCT03685695|DEVICE|Monitoring Device|Wear Fitbit Charge 2
41287340|NCT04143971|OTHER|low calorie diet|continuous low calorie diet
41287341|NCT00208468|DEVICE|European Hip|A cementless femoral component for use in total hip replacement
41287342|NCT00208468|DEVICE|Zweymüller|A cementless femoral component for use in total hip replacement
41287343|NCT00208468|DEVICE|CLS Spotorno|A cementless femoral component for use in total hip replacement
41453654|NCT03401281|OTHER|Olive oil|50g extra virgin olive oil daily for four weeks
41287344|NCT01968876|OTHER|Medication Adherence Smartphone App|MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
41287345|NCT06104904|BEHAVIORAL|MAPP|Behavioral intervention based on exposure therapy strategies.
41287346|NCT05730608|OTHER|18F-FDG PET/CT|Included breast cancer patients will undergo a 18F-FDG PET/CT scan in addition to conventional imaging with CT and bone scintigraphy.
41287347|NCT05488054|PROCEDURE|Physical Therapy|Patients will undergo physical therapy following surgical intervention
41287348|NCT05488054|PROCEDURE|Monitored Work-out|Healthy volunteers will undergo a monitored workout for comparison of data
41453655|NCT00496990|BEHAVIORAL|Enhanced care|this group received counseling, contingency management and methadone or detoxification
40947996|NCT03685695|OTHER|Physical Activity|Complete aimed walking steps
40947997|NCT03685695|OTHER|Quality-of-Life Assessment|Ancillary studies
40947998|NCT03685695|OTHER|Questionnaire Administration|Ancillary studies
40947999|NCT04398316|DRUG|Lidocaine Iv|2 mg/kg over 5 minutes
40948000|NCT04398316|DRUG|HYDROmorphone Injection|1 mg over 5 minutes
40948001|NCT03282370|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
41287349|NCT05488054|DEVICE|Moxy Oxygen Sensor Device|Individuals will wear a Moxy sensor device during workouts to monitor oxygen and hemoglobin levels in their muscles
41453656|NCT00496990|BEHAVIORAL|control|this group receives the opportunity to participate in a support group
41453657|NCT03392051|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
41453658|NCT03392051|DRUG|Clopidogrel|75mg tablet administered orally
41453659|NCT03548480|DIETARY_SUPPLEMENT|Placebo|Intervention with a daily dose of placebo
41453660|NCT03548480|DIETARY_SUPPLEMENT|Probiotic|Intervention with a daily dose of probiotic
41453661|NCT06498986|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
41453662|NCT06498986|DRUG|Osimertinib Mesylate Tablets|Oral administration, 80mg daily for a cycle of 3 weeks.
40758372|NCT02084186|OTHER|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
41287350|NCT04436913|OTHER|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
41287351|NCT04436913|OTHER|Signal toothpaste|fluoride based toothpaste as a part of a caries preventive regimen
41287352|NCT04436913|OTHER|Signal toothpaste and fluoride varnish|application of fluoride varnish and using fluoride based toothpaste
41287353|NCT05452746|DEVICE|Acupuncture|"Unilateral and bilateral acupuncture points:~Du 20 and GV 29,39 MS1, MS2, MS3 and MS4,40~Location of points:~Number of needles: 9~Depth of insertion:~MS1, MS2, MS3: insert the needle obliquely in the frontal direction for 1 cm Du 20: insert the needle obliquely in the frontal direction for 0.5 cm GV 29: insert the needle obliquely and downward for 0.5 cm Needles retained for 20 min Needle type: Han Yi 0.25x25 mm Treatment regimen: once per day for 2 weeks"
41287354|NCT05452746|OTHER|Treatment as usual|Inpatient psychiatric care for depression
41453663|NCT04872777|BEHAVIORAL|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~1. Noom application set-up and troubleshooting on smartphone (license provided)~2. Digital scale provision (subjects may keep the scale)~3. Capture of available clinical information over preceding 28-days."
41453664|NCT00015925|DRUG|entinostat|
40758373|NCT02084186|OTHER|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
40758374|NCT01272258|DRUG|PRO 140|SC injection
40758375|NCT01272258|DRUG|Placebo|SC injection
40758376|NCT00389480|DRUG|AR-67 (formerly DB-67)|infusion daily x 5 days, every 21 days
40758377|NCT01832038|DRUG|Lacosamide|"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 \[NCT01710657\], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
40758378|NCT05562856|COMBINATION_PRODUCT|surface pre-reacted glass filler coating material|the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
40758379|NCT04925089|OTHER|Blood and Tissue collection|Blood and tissue will be collected and analyzed for detection of ctDNA and genetic change
40758380|NCT01629563|DRUG|PGL4001 5 mg|PGL4001 5 mg daily administration
40758381|NCT01629563|DRUG|PGL4001 10 mg|PGL4001 10mg daily administration
40758382|NCT06010563|DEVICE|Transcatheter pulmonary valve implantation (TPVI)|A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.
41453665|NCT05188404|BEHAVIORAL|Choice of cannabis product|Participants choose and purchase their own cannabis product
41287355|NCT04526522|OTHER|No intervention|No intervention
41287356|NCT00003565|DRUG|docetaxel|
41287357|NCT03724708|DEVICE|IUD|IUD insertion
41453666|NCT02924025|BEHAVIORAL|Motivational interview|Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
41453667|NCT05024682|DEVICE|conventional pulsed radiofrequency|After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 120 seconds pulse mode which consisted of four cycles (8 minutes)
41287358|NCT00643539|DRUG|Zithromax|azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
41287359|NCT00643539|DRUG|Clamoxyl|Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
40758383|NCT06010563|DEVICE|VenusP-ValveTM System|"VenusP-ValveTM System consists of two components:~1. Transcatheter Pulmonary Valve (TPV)~2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue.~For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV.~The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper."
40758384|NCT06305234|DRUG|Pegvaliase|Must be enrolled in the 165-501 PALace study. Subjects currently receiving or who plan to receive pegvaliase treatment within 30 days after the date of enrollment in the 165-501 study, including subjects who previously received pegvaliase as part of the clinical development program and have completed study participation
40758385|NCT02090894|DEVICE|UV Light (Laser Genesis)|
40758386|NCT01730573|PROCEDURE|interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
40758387|NCT01730573|PROCEDURE|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
40758388|NCT02062346|DRUG|BQ123|Intravenous infusion of BQ123 ( selective ETA antagonist )
40758389|NCT02062346|DRUG|BQ123/788|or BQ123/788 (mixed ETA/B antagonists)
40758390|NCT02062346|DRUG|Placebo|Intravenous infusion of saline
40758391|NCT00188435|PROCEDURE|Minimum Dose CT|
40758392|NCT03493893|DEVICE|Intermedullary nail|investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.
40758393|NCT00903344|DRUG|Vitamin D3|4000IU vitamin D3 tablet taken daily
40758394|NCT00903344|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin containing 400IU vitamin D in tablet taken daily
40758395|NCT01248468|DRUG|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
40758396|NCT01248468|DRUG|Sumatriptan|100 mg Sumatriptan
40758397|NCT01248468|DRUG|Placebo|placebo
40758398|NCT00265005|DRUG|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
40758399|NCT03614832|DRUG|Ticagrelor 90 mg|half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
40758400|NCT03614832|DRUG|Clopidogrel 150 mg|double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
40758401|NCT02093520|PROCEDURE|MILD Procedure|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
40758402|NCT02093520|DRUG|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
40758403|NCT05845892|OTHER|stress ball|The use of the stress ball by the experimental group patients will be reminded by a hemodialysis nurse who was not involved in the study.
40758404|NCT06497946|BEHAVIORAL|SlimTrack Plataform|SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available
40758405|NCT06497946|BEHAVIORAL|Diet prescription|Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
40758406|NCT05547867|PROCEDURE|Radial head prosthesis|Radial head arthroplasty in comminuted radial head fractures.
40758407|NCT04314973|DEVICE|Active Pelvis Orthosis|Walking with the robotic device providing the assistive protocol.
40758408|NCT04314973|OTHER|Walking exercises|Walking exercises without wearing the robotic device.
40758409|NCT06569654|DEVICE|Saebo splint|"The SaeboFlex orthosis was fitted individually for each participant in the intervention group. The orthosis was adjusted to ensure proper alignment and comfort.~Participants were instructed on how to don and doff the orthosis correctly and safely.~The orthosis positions the wrist and fingers in extension in preparation for grasp and release activities, enabling participants to perform functional tasks despite limited voluntary movement.~Task-Oriented Repetitive Training:~The intervention consisted of 45-minute sessions, conducted twice a week, over a period of 12 weeks.~Each session focused on repetitive, task-oriented exercises designed to improve motor function and enhance neuroplasticity.~Training Activities:~* Moving the Ball~* Bringing the Ball to the Mouth~* Reaching Towards a Target~* Manipulating the Ball Around a Target~* Placing the Ball into Tubes~* Throwing the Ball~* Catching a Rolling Ball"
40758410|NCT05802836|OTHER|no interventions|no intervention, only 3 different patients groups
40758411|NCT06214325|BEHAVIORAL|Music Therapy|Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, a minimum of 24 hours apart, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
40758412|NCT01272219|DRUG|liraglutide|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).
41287360|NCT00005963|DRUG|carboplatin|
40758413|NCT01272219|DRUG|placebo|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
40758414|NCT01272219|DRUG|liraglutide|Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
40758415|NCT01272219|DRUG|placebo|Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
40758416|NCT01713244|PROCEDURE|RFA assisted Hepatectomy|Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.
41287361|NCT00005963|DRUG|docetaxel|
40948002|NCT03282370|BIOLOGICAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
40948003|NCT05649566|DEVICE|Virtual Reality game|"The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
41287362|NCT05337722|BEHAVIORAL|SFT 2.0|The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person
41287363|NCT05337722|BEHAVIORAL|Active control|Low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session
40758417|NCT01713244|PROCEDURE|Hepatectomy|Treat the advanced HCC with the hepatectomy only.
40758418|NCT00742742|BEHAVIORAL|healthy life style education|healthy life style education
40758419|NCT06219174|DRUG|Pembrolizumab|200 mg IV Q3 weeks
40758420|NCT06219174|DRUG|Difluoromethylornithine|Dose Level -1: 4500 mg/m2 by mouth (PO) daily Dose Level 1: 6750 mg/m2 by mouth (PO) daily Dose Level 2: 9000 mg/m2 by mouth (PO) daily
40758421|NCT01905085|DEVICE|No intervention|
40758422|NCT00725231|BIOLOGICAL|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
40758423|NCT00725231|DRUG|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
40758424|NCT06147401|PROCEDURE|PENG plus LFCN block|"The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN~The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus.~The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine."
40758425|NCT06147401|PROCEDURE|FIC Block|"The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block.~The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment."
40758426|NCT01829763|DRUG|injection botox|
40758427|NCT02665650|BIOLOGICAL|AFM13|
40758428|NCT02665650|BIOLOGICAL|Pembrolizumab|
40758429|NCT03907579|BEHAVIORAL|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
40758430|NCT05541666|BEHAVIORAL|The Emotional Freedom Technique|The Emotional Freedom Technique (EFT) is a method that uses cognitive functions and physical components (tapping acupuncture points) to bring about psychological changes. The Emotional Freedom Technique is a non-invasive procedure that uses acupuncture meridians. We stimulate these energy points by touching the 14 basic meridian points ın this technique. We make suggestions to our subconscious by repeating the setup sentence for the problem we want to solve. Thus, we try to solve the blockages in the meridians that prevent the flow of energy. Energy blockages disrupt the balance of the mind/body/energy system. This situation causes negative emotions such as stress, panic, fear, and sadness in the person. And with the effect of emotions, disturbances may occur in our physical body. When the energy blockage is removed, the person can feel positive emotions such as happiness, personal power, feeling good, understanding, and loving behavior.
40758431|NCT04131894|BIOLOGICAL|autogenous dentin graft|
40758432|NCT04131894|BIOLOGICAL|platelet rich fibrin (PRF)|
40758433|NCT01789502|DEVICE|Fully covered metal stents|Fully covered metal stents were inserted by ERCP
40758434|NCT01789502|DEVICE|Plastic stents|Plastic stents were inserted by ERCP
40758435|NCT05904379|DRUG|AK112|Subjects receive AK112 intravenously.
40758436|NCT05904379|DRUG|AK104|Subjects receive AK104 intravenously.
41287364|NCT01240018|DIETARY_SUPPLEMENT|Probiotic|Parallel, randomized, controlled 2 arms study.
41287365|NCT06513702|PROCEDURE|Transesophageal lung ultrasound (TELUS) guided recruitment maneuver|"1. Lung reinflation guided by transesophageal lung ultrasound (TELUS) after cardiopulmonary bypass weaning~2. TELUS guided recruitment maneuver with continuous positive pressure of 30cmh20 for 20 seconds and 40cmh20 for 20 seconds during sternal wiring"
40758437|NCT05904379|DRUG|Carboplatin|Subjects receive carboplatin intravenously.
40758438|NCT05904379|DRUG|paclitaxel|Subjects receive paclitaxel intravenously.
40758439|NCT05904379|DRUG|pemetrexed|Subjects receive pemetrexed intravenously.
40758440|NCT05904379|DRUG|Docetaxel|Subjects receive docetaxel intravenously.
40758441|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection low dose administered by subcutaneous injection
40758442|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection medium dose administered by subcutaneous injection
40948004|NCT00844584|PROCEDURE|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
40948005|NCT01669928|DRUG|Anti-hypertensive Medication -|"Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00)."
40948006|NCT04795986|PROCEDURE|HEARO Procedure|robotic access to the middle and inner ear in cochlear implantation
40948007|NCT04718961|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.
40758443|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection high dose administered by subcutaneous injection
40758444|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection lowest dose administered by subcutaneous injection
40758445|NCT02579759|DRUG|PXT3003 dose 1|Liquid oral solution, 5 ml twice a day, morning and evening with food
40758446|NCT02579759|DRUG|PXT3003 dose 2|Liquid oral solution, 5 ml twice a day, morning and evening with food
40758447|NCT02579759|DRUG|placebo|Liquid oral solution, 5 ml twice a day, morning and evening with food
40758448|NCT05308719|DEVICE|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
40948008|NCT04718961|DRUG|Placebo|Capsules matched to study drug minus active substance.
40948009|NCT06013475|DRUG|Apalutamide|Decision by the treating physician
40948010|NCT06013475|DRUG|Darolutamide (BAY 1841788)|Decision by the treating physician
40948011|NCT06013475|DRUG|Enzalutamide|Decision by treating physician
41453668|NCT05024682|DEVICE|pulse dosed pulsed radiofrequency|After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 240 seconds pulse dose mode which consisted of two cycles (8 minutes).
40758449|NCT06231472|PROCEDURE|peroperative inferior vena cava measurement|peroperative inferior vena cava measurement
40758450|NCT05143515|BEHAVIORAL|PACE label|There were 34 food and drinks choices available for consumption in the pop up café. The labels were displayed next to the food/drink item in the pop up café. The food items were kept in the same position for each participant kitchen to simulate the café environment. Then researchers changed the labels on the display according to the randomisation allocation of each participant. After randomsation participants were informed that they have £10 to spend in the pop-up café and that they could eat the food they selected in a private social eating room.
40758451|NCT03088111|OTHER|Collection of samples|To the extent possible, blood samples will be collected from all subjects prior to infusion and at specified time points post-infusion to determine serum obiltoxaximab concentrations and ATA titers. Scavenged blood samples can be utilized, if acceptable, to maximize sample analyses for pharmacokinetic and other investigational parameters. Data on other relevant laboratory testing will only be collected and evaluated if available in the subject's record (eg, protective antigen (PA), anti-PA, anti-lethal factor (LF), anti-edema factor, IgG antibodies, anthrax lethal toxin neutralizing activity, presence of anthrax LF, incidence and duration of B. anthracis bacteremia, and demonstration of B. anthracis antigens in tissues).
40758452|NCT03088111|BIOLOGICAL|Obiltoxaximab|Obiltoxaximab standard of care
40758453|NCT00382473|BEHAVIORAL|Aerobic exercise program - 8 weeks|No drugs. Regular aerobic exercise in structured prescription format
40948012|NCT05828134|OTHER|protein-enriched soup|The participants in experimental group have a protein-enriched soup a day and do exercise a week
40948013|NCT02725931|BEHAVIORAL|Pulmonary rehabilitation (PR) plus PA-focused intervention|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychosocial support and education sessions (once a week). Patients will also have their PA levels monitored on weeks (W) 1, 7 and 12 and receive feedback in the following weeks.
40948014|NCT00764296|OTHER|no treatment|collection of samples of wound biofilm in Acute and Chronic Wounds
41287366|NCT06513702|OTHER|Manual bag lung reinflation|"After weaning of CPB, Lung will be reinflated by 5 deep manual bag infaltion until full inflation observed by the anesthetist.~During sternal wiring, Lung ultrasound will be examine - LUNG ultrasound score will be taken- no recruitment maneuver will be done in this contro group (Basically this group of patient is a routine practice in cardiac surgery"
41453669|NCT02947945|DRUG|Reslizumab|All subjects will receive Reslizumab
41453670|NCT01812993|DEVICE|Non-invasive ventilatory treatment with auto-BPAP|
41466387|NCT06123468|DRUG|Sacituzumab govitecan|10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)
40948015|NCT00764296|OTHER|no treatment|collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
40948016|NCT06203093|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
40948017|NCT04879225|BEHAVIORAL|Tobacco e-liquids|Marketplace includes tobacco flavored e-liquids
40948018|NCT04879225|BEHAVIORAL|Menthol and Tobacco e-liquids|Marketplace includes menthol and tobacco flavored e-liquids
40948019|NCT04879225|BEHAVIORAL|Mint, Menthol and Tobacco e-liquids|Marketplace includes mint, menthol and tobacco flavored e-liquids
40948020|NCT04879225|BEHAVIORAL|All e-liquid flavors|Marketplace includes fruit, dessert, mint, menthol and tobacco flavored e-liquids
40948021|NCT06266312|BEHAVIORAL|A multimodal prehabilitation programme|"1. During the weekly chemotherapy infusion (week 10-20), a supervised moderate-intensity endurance training (MIET) on a cycle ergometer is performed (11x):~   * 5 min. warm-up~  * 35 min. cycling at 40-60% of (HR reserve + resting HR)~  * 5-10 min. cool-down~2. + strength training~During week 17-22 a supervised high-intensity interval training + strength training programme is performed (8x):~HITT:~* 3 min warm-up (20W)~* 14 intervals (30sec. work intervals at 60% of WRpeak alternates with 60-sec. rest intervals at 20W) --1 min. cool-down~Muscle strength:~4 exercises (leg press, chest press, abdominal crunch, lateral pulldown), 3 sets, 8-12 repetitions at 60% of 1-RM.~3) During 4 consultations with a dietician (week 9, 15, 20, 22) nutritional intake is evaluated and advice is given on energy and protein requirements. Patients are advised to use a digital food diary to record their intake for ≥3 days a week."
40948022|NCT02098252|PROCEDURE|Neurosurgery|Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.
40948023|NCT02098252|RADIATION|Radiation therapy|when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.
40948024|NCT02098252|PROCEDURE|Embolization|Curative embolization, when the lesion is considered curable by embolization.
40948025|NCT02140242|DRUG|study part 1 - dose daunorubicin|standard induction dose of daunorubicin 60 mg/m2 on days 3-5
40948026|NCT02140242|PROCEDURE|induction cycles|single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
40948027|NCT05744908|OTHER|Pentosan Polysulphate|300mg 3 times a day
40948028|NCT01976676|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate|
40948029|NCT01976676|DIETARY_SUPPLEMENT|folic Acid|
40948030|NCT06550687|OTHER|Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis|Phase 1: Observation of doctor-patient consultations Phase 2: Adaptation of information tools Phase 3: Assessment of understanding of information tools
40948031|NCT01484041|DRUG|Dovitinib|Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
40948032|NCT01484041|DRUG|Aromatase Inhibitors|Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
40948033|NCT04768075|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
40948034|NCT04768075|DRUG|Placebo|IV infusion Simulator of Camrelizumab
40948035|NCT04768075|DRUG|Cisplatin|IV infusion
40948036|NCT04768075|DRUG|Carboplatin|IV infusion
40948037|NCT04768075|DRUG|Pemetrexed|IV infusion
40948038|NCT04768075|DRUG|Paclitaxel|IV infusion
40948039|NCT04768075|DRUG|Albumin paclitaxel|IV infusion
40948040|NCT06558474|BEHAVIORAL|Liberal post-dilatation strategy during PCI|"A liberal post-dilatation strategy for stent optimization during PCI will be implemented in multiple centers in the Netherlands.~This include an increase of post-dilatation use of at least 20% per operator, or a percentage of post-dilatation of at least 85%.~Operators will be asked to enforce a very low threshold for post-dilatation in general, with a mandatory HPNC post-dilatation for the following indications:~* In case of any calcification~* Delta of ≥ 0.5mm between the distal and proximal reference diameter of the treated coronary segment~* Stent length \>24 mm~* Signs of incomplete stentframe-deployment on angiography or StentBoost~* In case of CTO~* In case of bifurcation PCI (Left main and non-left main)~  * Proximal Optimisation Technique (POT) with NC balloon~ * Final Kissing Balloon dilatation (FKB) with preferentially first sequential high-pressure inflations and final low pressure kiss both with NC balloons"
40948041|NCT04044495|OTHER|Multimodal brain imaging (MRI)|Multimodal brain imaging (MRI)
40948042|NCT04044495|OTHER|Actimetry|7 days actimetry
40948043|NCT04044495|OTHER|Sleep Diary|7 days Record of sleep and wake cycle
40948044|NCT03250871|OTHER|Hypnosis|Hypnosis will be supervised by a nurse trained by the French Institute of Hypnosis.
40948045|NCT03250871|OTHER|Placebo|Placebo consists in non-hypnotic relaxation suggestions and in hearing white noise through headphones
40758454|NCT03047044|OTHER|Optimizing basal infusion (B.I)|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 8 hr: 2 - 4 ml, 8-24 hr: 1 - 3 ml, 24 hours \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 0.5 ml).
40758455|NCT03047044|OTHER|Conventional PCA mode|Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes
40948046|NCT04915027|OTHER|a usual follow-up with Rehabkompassen®|Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.
40948047|NCT04915027|OTHER|a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®|Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.
40948048|NCT03375008|DIAGNOSTIC_TEST|Imaging diagnostic and biopsy|Liver biopsy and MRI scan
40786376|NCT04118725|DIAGNOSTIC_TEST|Pulmonary function test|Diaphragmatic electromyography with measurement of transdiaphragmatic pressure in cases of dyspnea and/or abnormal pulmonary function test (maximum inspiratory pressure and/or lying/seating low vital capacity ratio)
40948049|NCT02201849|DRUG|Study Drug|
40948050|NCT02201849|DRUG|Active Control|
40948051|NCT02201849|DRUG|Placebo|
40948052|NCT04970641|BEHAVIORAL|Three Good Things (3GT) Positive Psychology journaling activity|Evening journaling activity each day to reflect on three good things that the subject has noticed about their day's events.
40948053|NCT05272878|DRUG|IRBESARTAN, tablet, 150 mg|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
40948054|NCT05272878|DRUG|Placebo, tablet, 150 mg|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
40948055|NCT00586651|DRUG|lestaurtinib|60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration
40948056|NCT01230723|DEVICE|Everolimus-Eluting-Stent|due randomization everolimus-eluting-stent will be implanted
40786377|NCT03461471|BEHAVIORAL|Exercise Intervention|Exercise intervention
40786378|NCT00353080|DRUG|risedronate (HMR4003)|
40786379|NCT00093366|BIOLOGICAL|etanercept|
41453671|NCT04872231|DRUG|Voriconazole Inhalation Powder|"PART A (SAD): Voriconazole Inhalation Powder (VIP) will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 10 mg, Cohort 2: 20 mg, Cohort 3: 40 mg, Cohort 4: 80 mg.~PART B (MAD): Voriconazole Inhalation Powder (VIP) and will be administered with a will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~MAD subjects will receive VIP BID for a total of 13 doses. Subjects in Cohort 1 will receive 10 mg BID, Cohort 2: 20 mg BID, Cohort 3: 40 mg BID, Cohort 4: 80 mg BID."
40758456|NCT06467058|DEVICE|DABQ questionnaire versus Actigraph as reference method|"In this study, participants will have one contact session with the researcher, which will be held either at Ghent University Hospital or at the participants' home. During this session, participants will be provided with an accelerometer device and two questionnaires (to be filled in after wearing the Actigraph), namely the Daily Activity Behavior Questionnaire (DABQ) and general information questionnaire.~The participants will receive an Actigraph wGT3X+BT accelerometer which will be worn for seven consecutive days. Instructions will be given on how to wear the accelerometer (e.g. during the day at the hip and during the night at the wrist). At the end of this week, the participants will fill in both questionnaires. After wearing the accelerometer for seven consecutive days and filling in both questionnaires, the researcher will visit the participants to collect the devices, or the participants will send them back by postal package."
40758457|NCT05118438|OTHER|Health Promotion Nursing Intervention|A one-on-one program was conducted over six sessions, with each session ranging from 60 to 120 minutes. The caring program for health promotion included the following concepts: understanding the self; sharing traumatic events and negative emotions; re-framing the meaning of traumatic events; identifying thoughts and physical and emotional responses; developing health-promoting activities; and maintaining a positive attitude during the process of change .
40786380|NCT00093366|DRUG|arsenic trioxide|
40786381|NCT02945124|OTHER|K tape|Applying K tape to children to the lower limb muscles during motor activities.
40786382|NCT01674504|DRUG|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
40786383|NCT01446874|DRUG|0.12% chlorhexidine solution|Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
40758458|NCT02322931|PROCEDURE|Intra-operative C-arm CT imaging|"1. Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.~2. Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.~3. One Cine loop C-arm scan in the sagittal plane while retracting the probe.~4. One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down)."
40758459|NCT00935207|OTHER|Pediatric Pain Diary|Pain diary designed for pediatric patients
40758460|NCT01974479|BIOLOGICAL|anti-CD19 redirected NK cells|Haploidentical donor NK cells will be expanded and electroporated over 10 days and infused. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day - 7 , and Fludarabine 25 mg/m2/day will be given on day -6 to day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
40758461|NCT02672605|OTHER|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
40758462|NCT04241432|DEVICE|vibrating platform|Use of two different types of vibrating platform
40758463|NCT05277935|DEVICE|Use of the WeCancer app combined with the smartwatch.|To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy
40758464|NCT01204385|PROCEDURE|Sample collection|Middle ear fluid and urine
40758465|NCT04377776|OTHER|Practice details|Questionnaire
40758466|NCT04338620|DRUG|camrelizumab、albumin-bound paclitaxel and platinum|Experimental Group：camrelizumab、albumin-bound paclitaxel and platinum. Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg on day1 of each cycle. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin
40758467|NCT04338620|DRUG|albumin-bound paclitaxel and platinum|"Control group：albumin-bound paclitaxel and platinum. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle.~Platinum included Cisplatin/carboplatin/Nedaplatin"
40758468|NCT03997500|DRUG|normal saline|a bolus of normal saline was given followed by normal saline infusion
40758469|NCT03997500|DRUG|Norepinephrine|a bolus of norepinephrine was given followed by norepinephrine infusion
40758470|NCT03612414|DIETARY_SUPPLEMENT|Aqualief|Three tablets/day
40758471|NCT03612414|DIETARY_SUPPLEMENT|Placebo|Three tablets/day
40758472|NCT04794478|DEVICE|Dexcom Continuous Glucose Monitoring System|Dexcom Continuous Glucose Monitoring System
40758473|NCT03248661|BEHAVIORAL|Now I'm Telling You|Messages will be sent trough Facebook, Twitter, Instagram, e-mail, texting or other electronic/social media specified by study volunteers.
40758474|NCT00449787|DRUG|Sumatriptan 100 mg|Sumatriptan 100mg tablet
40758475|NCT00449787|DRUG|Naproxen|Naproxen 500mg tablet
40758476|NCT03150641|PROCEDURE|Umbilical cord clamping|The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
40990452|NCT03698474|DRUG|Natrium picosulfate / Magnesium citrate|bowel preparation formula
41453672|NCT04872231|DRUG|Placebo|"PART A (SAD): Placebo capsules will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART A will receive a single dose of placebo.~PART B (MAD): Placebo will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART B will receive Placebo BID for a total of 13 doses."
41453673|NCT02426918|DRUG|Debio 1450 IV|Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
40758477|NCT04775758|BEHAVIORAL|Self-evaluating questionnaires|Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
40758478|NCT04775758|BEHAVIORAL|iMotions analysis platform|While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
40758479|NCT03364257|DIAGNOSTIC_TEST|iDTECT Blood|Next generation sequencing-based shot-gun metagenomic test for the diagnosis of viral or bacterial infections using blood samples
40758480|NCT05227014|PROCEDURE|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
40758481|NCT02137278|DRUG|Vasoactive drug therapies|Continue current vasoactive therapy
40758482|NCT02137278|OTHER|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
40758483|NCT06230146|DRUG|Insulin group|"Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\\ml solution).~Dose: injection of 0.1 ml\\cm3 of the lesion avoiding subcutaneous injection as much as possible especially in fatty areas."
40758484|NCT06230146|DRUG|Botulinum toxin group|Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible. The dose will be adjusted to 2.5 U/cm3 of the lesion, not exceeding 100 units per session.
40758485|NCT06230146|DRUG|Triamcinolone acetonide group|Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml .Maximum drug injected during each session will be 40 mg triamcinolone.
40758486|NCT00290628|DRUG|anti-thymocyte globulin|
40758487|NCT00290628|DRUG|busulfan|
40758488|NCT00290628|DRUG|cyclophosphamide|
40758489|NCT00290628|DRUG|cyclosporine|
40758490|NCT00290628|DRUG|filgrastim|
40758491|NCT00290628|DRUG|melphalan|
40758492|NCT00290628|DRUG|methylprednisolone|
40758493|NCT00290628|DRUG|mycophenolate mofetil|
40758494|NCT00290628|PROCEDURE|radiation therapy|
40758495|NCT00290628|PROCEDURE|umbilical cord blood transplantation|
40758496|NCT04637620|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of MDD
40758497|NCT04637620|DRUG|Sertraline|Use of SSRI as an active comparator
40758498|NCT04637620|DRUG|Placebo Cap|Use of placebo as a comparator
40758499|NCT00272805|DRUG|carvedilol|
40758500|NCT01546987|DRUG|GnRH agonist|LHRH agonists are administered with a variety of techniques. The manufacturer's instructions should be followed. Begins within 6 weeks after registration (if not started prior) at same time as anti-androgen and TAK-700 (if applicable).
40758501|NCT01546987|DRUG|Anti-androgen|Starts at same time as GnRH agonist, ends at end of radiation therapy. Either flutamide (orally 250 mg three times a day) or bicalutamide (orally 50 mg once a day).
40758502|NCT01546987|DRUG|TAK-700|300 mg twice daily (BID) (600 mg per day) orally, continuously for 2 years starting with ADT.
40758503|NCT01546987|RADIATION|Radiation therapy|Starts 8-10 weeks after initiation of ADT. Initially 45 Gy (1.8 Gy / fraction) to prostate and pelvic lymph nodes delivered with 3DCRT/IMRT, then a boost using intensity-modulated radiation therapy (IMRT), low dose rate (LDR) brachytherapy, or high dose rate (HDR) brachytherapy.
40948057|NCT01230723|DEVICE|Zotarolimus-Eluting-Stent|due randomization zotarolimus-eluting-stent will be implanted
40758504|NCT00226044|DRUG|Omeprazole rectally 1mg/kg|A single dose of 1 mg/kg rectally administered omeprazole.
40758505|NCT02395328|BEHAVIORAL|Care Worker Home Visitation|Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
40758506|NCT02580006|DRUG|EPORON|single dose administration subcutaneously
41453674|NCT02426918|DRUG|Debio 1450 Oral|Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
40758507|NCT02580006|DRUG|EPREX|single dose administration subcutaneously
40758508|NCT03785847|DIAGNOSTIC_TEST|Ventica|Impedance pneumography measurement
40758509|NCT00124033|PROCEDURE|Transcystic Stenting (Facilitated ERCP)|
40758510|NCT00747201|BEHAVIORAL|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
40758511|NCT00747201|BEHAVIORAL|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
40990453|NCT03698474|DRUG|Polyethylene glycol / Ascorbic acid|bowel preparation formula
40990454|NCT03698474|DRUG|Natrium/ Kalium/ Magnesium sulfate|bowel preparation formula
40990455|NCT03849859|DEVICE|Single plastic stent|Deployment of single plastic stent
40948058|NCT05736510|OTHER|Binaural sound|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the experimental group, the allocated file is binaural sound with 40Hz beat. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
40758512|NCT05055427|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|"Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. In additional, patients also receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.~Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.~Daily dose: 1 bag per time, 2 times per day"
40758513|NCT06137092|DRUG|Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)|rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over
40758514|NCT01764932|PROCEDURE|Fluoroscopic imaging|Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
41287367|NCT04133753|BEHAVIORAL|Facilitator-Based Intervention|Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
40990456|NCT03849859|DEVICE|Multiple plastic stents|Deployment of multiple plastic stents
40990457|NCT03030573|PROCEDURE|Reconstruction of the bile duct with the round ligament|In patients who had bile duct defect by injury or resection, the Round ligament will be used to reconstruct the defect. Surgical technique, the early and long term postoperative measures are detailed in the investigators protocol.
40758515|NCT05314075|PROCEDURE|Upper Body Forced Air Warming device|Patients will have the Bair Hugger placed over the body
40758516|NCT05314075|PROCEDURE|Under Body Forced Air Warming device|Patients will have the Bair Hugger placed under the body
40990458|NCT00957073|DEVICE|Rheos® system|Implant procedure
41287368|NCT03607682|PROCEDURE|Tumor Treating Fields (TTF) Therapy|Undergo TTF therapy
41287369|NCT03607682|DEVICE|NovoTTF-200A Device|Undergo TTF therapy
41287370|NCT03607682|OTHER|Quality-of-Life Assessment|Ancillary studies
40758517|NCT03268278|DRUG|Buprenorphine|Buprenorphine plus local anesthetic
41287371|NCT03644576|DRUG|ozanimod|ozanimod
41287372|NCT03644576|DRUG|Pseudoephedrine|Pseudoephedrine
40758518|NCT03268278|DRUG|Sterile saline|Placebo 1,8 ml
41287373|NCT03644576|DRUG|ozanimod placebo|ozanimod placebo
41287374|NCT00077233|DRUG|cetuximab|IV
40948059|NCT05736510|OTHER|Control|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the control group, the allocated file is silent. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
40948060|NCT03898843|OTHER|Animal assisted therapy|Patients of AAT group will leave their hospital bedroom to go in the session room, where they will meet a dog, who has come with his veterinary student master. Animal assisted therapy session will last at most 20 minutes, in which the patient is going to interact with the dog, pet him, play with him, etc.
40948061|NCT03898843|BIOLOGICAL|Nasal swab sampling|All patients will have nasal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
40948062|NCT03898843|BEHAVIORAL|STAI-Y and POMS Questionnaires|Before and after AAT or sham session, patients will answer State-Trait Anxiety Inventory Y (STAI-Y), Profile of Mood States (POMS) questionnaires.
40948063|NCT03898843|PROCEDURE|physiological parameters measure|Before and after AAT or sham session, blood pressure, heart rate dans respiratory rate will be measured.
40948064|NCT03898843|OTHER|Visual Analog Scale (VAS)|Before and after AAT or sham session, pain will be evaluated thanks to VAS
40948065|NCT03898843|BEHAVIORAL|Impact of Event Scale - Revised (IES-R)|Patients will answer IES-R questionnaire 3 months after AAT or sham session
40948066|NCT03898843|BEHAVIORAL|satisfaction questionnaire|Patients of the AAT group will answer satisfaction questionnaire at the end of the AAT session and 3 months after AAT
40948067|NCT03898843|BIOLOGICAL|Rectal swab sampling|All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
40948068|NCT06104176|BEHAVIORAL|CBT in group|"All subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
40948069|NCT06104176|OTHER|Virtual reality exposure|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
40948070|NCT06104176|BEHAVIORAL|individual CBT|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
40948071|NCT02357979|DEVICE|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
40948072|NCT02357979|OTHER|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
40948073|NCT04464057|DIETARY_SUPPLEMENT|early oral feeding or early enteral nurtrion|The patients in the experimental group were fed orally within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
41287375|NCT00077233|DRUG|5-FU|IV
41287376|NCT00077233|DRUG|irinotecan|IV
41287377|NCT00077233|DRUG|leucovorin|IV
40758519|NCT03268278|DRUG|lidocaine, epinephrine (Local anesthetic)|2% lidocaine 1:100,000 epinephrine
40990459|NCT03822676|DEVICE|Prophylactic pancreatic stent|Prophylactic pancreatic stent before segmental pancreatic surgery
41287378|NCT00077233|DRUG|oxaliplatin|IV
41287379|NCT04092036|DEVICE|Optic Nerve Sheath Diameter (ONSD) measurement by ultrasound|"ONSD measurements will be performed in the supine patient. Ultrasound gel will be applied over the closed upper eyelid. The ultrasound probe will be placed on the temporal area of the eyelid. Then the probe will be angled in order to display the entry of the optic nerve into the globe.~ONSD will be measured 3 mm behind the globe in the transverse plane perpendicular to the optic nerve. For each optic nerve three measurements will be made. The ONSD corresponds to the mean of the six values which will be obtained from each patient (three measurements for each eye)."
41287380|NCT01938222|PROCEDURE|Short Stitch|MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
41287381|NCT04526977|DIAGNOSTIC_TEST|Immune response study|"* ACE2 and CD26 receptor study~* Cytokine profile: Quantification of plasma cytokine levels~* SARS-CoV-2 CD4/CD8 T cell response~* TLR7/8 activation~* KIR characterization"
41287382|NCT01197573|DRUG|rTPA Treatment|Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
41287383|NCT01197573|OTHER|No TPA Treatment|Standard of Care
40948074|NCT01561729|DEVICE|RightSpot pH Indicator|The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).
40948075|NCT01561729|RADIATION|Chest radiograph|Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
40758520|NCT06074406|DEVICE|Hyperfine|Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO
40758521|NCT04087876|DRUG|derazantinib|derazantinib will be administered orally
40758522|NCT01309100|DEVICE|Investigational Lens|Bausch \& Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
40758523|NCT01309100|DEVICE|Acuvue Oasys Lens|Johnson \& Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
40758524|NCT01309100|DEVICE|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
40758525|NCT06570837|DIETARY_SUPPLEMENT|Iron|observation effect of iron dificincy
40758526|NCT02082782|PROCEDURE|Irreversible electroporation (IRE)|Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
40758527|NCT06256432|DRUG|Ambrisentan|Endothelin receptor antagonist
40758528|NCT06256432|DRUG|Terlipressin|Terlipressin
40758529|NCT05918146|DRUG|Dextrose|Dextrose injection plus physical therapy
40758530|NCT05918146|DRUG|Normal saline|Normal saline injection plus physical therapy
40758531|NCT03344887|OTHER|RBC Transfusion from male donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.
40758532|NCT03344887|OTHER|RBC Transfusion from female donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.
40758533|NCT06569693|BEHAVIORAL|My Sleep Our Sleep (MSOS) Program|"MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week."
40758534|NCT06569693|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|"BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time they spend in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week."
40758535|NCT00983801|DRUG|Ixabepilone|Vial, Injection, Intravenous (IV), 40 mg/m\^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
40758536|NCT01681875|OTHER|very low nicotine content cigarettes|
40758537|NCT01830465|DRUG|Bortezomib (VELCADE)|1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.
40948076|NCT03414320|OTHER|Gathering data|Gathering data about sleep, heart rate, carbohydrate intake, insulin pump, continuous glucose sensor, meals.
40948077|NCT03793556|DEVICE|GERDOFF® + Omeprazole|GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg + Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
40948078|NCT03793556|DRUG|Omeprazole|Omeprazole, 2 capsules 20 mg, once a day before breakfast
40758538|NCT01830465|DRUG|Rituximab|375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
40758539|NCT03965117|DRUG|Norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is \> 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
40758540|NCT06381960|DRUG|Fuzheng Quxie Recipe|Treatment group: Fuzheng Quxie Recipe (Yifei Sanjie Recipe) ingredients: Sheng Huang Qi 15g, Jiao Bai Zhu 15g, Bai Fu Ling 15g, Bei Sha Shen 15g, Zhe Mai Dong 15g, Dang Shen 15g, Shu Yang Quan 15g, Xia Ku Cao 15g, Sheng Mu Li 15g, Shi Jian Chuan 15g, Shi Shang Bai 15g, and Hai Zao 15g. Combined with basic chemotherapy after lung cancer.
40758541|NCT06381960|DRUG|Fuzhengquye Fang Recipe simulant|Control group: Fuzhengquye Fang Recipe simulant, which was prepared into control group placebo drug according to 5% of the drug content in the treatment group. Combined with basic chemotherapy after lung cancer.
40758542|NCT06184087|OTHER|Educational/Instructional|ICAP constructive-interactive engagement mode
40948079|NCT00169754|OTHER|mapping kidney anatomy|videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
41453675|NCT02426918|DRUG|Linezolid|Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
41453676|NCT02426918|DRUG|Debio 1450 Oral Placebo|Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
40758543|NCT01443312|GENETIC|Laboratory analysis.|The blood transfusions given to the patients are in accord to physician decision and not related to the study
40758544|NCT05459779|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 with activated assistance.
40758545|NCT05459779|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 without activating assistance.
40758546|NCT01482403|DRUG|Copegus|total daily dose of 1000 mg or 1200 mg for 24 weeks
40758547|NCT01482403|DRUG|Copegus|total daily dose of 1000 mg or 1200 mg for 48 weeks
40758548|NCT01482403|DRUG|Pegasys|180 microgram subcutaneous once a week for 24 weeks
40758549|NCT01482403|DRUG|Pegasys|180 microgram subcutaneous once a week for 48 weeks
40758550|NCT01482403|DRUG|boceprevir|800 mg three times a day for 24 weeks
40758551|NCT01482403|DRUG|boceprevir|800 mg three times a day for 48 weeks
40758552|NCT01482403|DRUG|mericitabine|1000 mg twice daily for 24 weeks
40758553|NCT01482403|DRUG|mericitabine placebo|mericitabine placebo
40758554|NCT01482403|DRUG|boceprevir placebo|boceprevir placebo
40758555|NCT01482403|DRUG|boceprevir|800 mg three times a day for 44 weeks
40758556|NCT03694730|OTHER|Exercise Treatment|Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
40758557|NCT03694730|OTHER|Pain- Guided Activity Modification|Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
40758558|NCT03403127|DIAGNOSTIC_TEST|PET/CT Scans|PET Imaging requires the use of an investigational drug, a radioactively-labelled sugar called 18F-Fluorodeoxyglucose (FDG). FDG is glucose labelled with a radioactive fluorine atom. It is given by intravenous injection and is particularly absorbed by cancer cells. The radioactive signal given off by the FDG can then be detected by the PET scanner providing an image of the cancer (or tumour).
40758559|NCT05846919|PROCEDURE|face-mask preoxygenation|face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
40758560|NCT05846919|PROCEDURE|HFNOC preoxygenation|HFNOC preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
40758561|NCT05846919|PROCEDURE|HFNOC + face-mask preoxygenation|HFNOC (flow 2 L/kg/minute) + face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) - with 100 % oxygen for three minutes.
40758562|NCT02038647|DRUG|Alisertib|Alisertib tablets
40758563|NCT02038647|DRUG|Placebo|Placebo matching tablets
40758564|NCT02038647|DRUG|Paclitaxel|Paclitaxel intravenous injection
40758565|NCT05327543|BEHAVIORAL|Iyengar Yoga|Iyengar Yoga focuses on the correct alignment of the body while practicing the physical exercises of yoga. Props are used to support the body in finding the right alignment. Relaxation is also part of this intervention. Participiants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
40758566|NCT05327543|BEHAVIORAL|Meditative Yoga|Meditative Yoga in the context of this study means practicing the physical exercises of yoga as well as meditation. Additionally, each week one of the yamas/niyamas, which are ethical principles to live by in the Yoga philosophy, will be presented at the beginning of each class and will form the theme of the class. Participants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
40758567|NCT04171869|OTHER|no intervention|observational study, no intervention
40758568|NCT05077605|OTHER|Functional residual capacity measure by electrical impedance tomography|Patient functional residual capacity will be measured by electrical impedance tomography before extubation and then at 0, 10, 15 and 20 min after extubation.
40758569|NCT05626686|DEVICE|CLINY catheter|Subjects using a single use catheter for bladder management at inclusion. During the study period, subjects will use the reusable CLINY catheter for 28 test-days
40758570|NCT00189878|DRUG|Methotrexate (drug)|Methotrexate 10 to 15 mg weekly for 8 weeks
40758571|NCT00189878|DRUG|placebo capsules|4-6 placebo capsules - identical to capsules containing methotrexate
40758572|NCT04802109|DEVICE|wearing level D personal protective equipment|rubber gloves + surgical face mask + general isolation clothing
40758573|NCT04802109|DEVICE|wearing Level C personal protective equipment with N-95|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing"
40758574|NCT04802109|DEVICE|wearing Level C personal protective equipment with Powered Air-Purifying Respiratory|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory"
41453677|NCT02426918|DRUG|Linezolid Placebo|Linezolid placebo will be supplied as film-coated compressed tablets.
41453678|NCT02426918|DRUG|Vancomycin IV|Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
40758575|NCT00594997|BEHAVIORAL|Education|Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
40758576|NCT00594997|BEHAVIORAL|Control (pre and post surveys)|Students fill out a pre and post survey and then receive the same intervention given to the controls.
40758577|NCT06430411|PROCEDURE|Radical prostatectomy|Removal of the prostate and seminal vesicles.
40948080|NCT01904565|RADIATION|Hyperthermia and Proton Beam|"1. Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade~2. Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose."
40948081|NCT02325310|BIOLOGICAL|Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®|One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
40948082|NCT02810522|DEVICE|OneTouch Select® Plus Glucose Test Strips|
40948083|NCT03009500|DRUG|Bupivacaine|
40948084|NCT03009500|DRUG|Depo-Medrol Injectable Product|
40948085|NCT03009500|OTHER|Saline (Sodium Chloride) solution|
40948086|NCT03009500|DRUG|Lidocaine|Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
40948087|NCT02840240|DRUG|Gabapentin enacarbil|600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative
40948088|NCT02840240|DRUG|Placebo|600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
40948089|NCT00439023|PROCEDURE|dialysis with glucose in dialysis water|
40948090|NCT01995643|DIETARY_SUPPLEMENT|Active Capsule|GSE Capsule
40948091|NCT01995643|DIETARY_SUPPLEMENT|Placebo Capsule|Placebo Capsule
40948092|NCT00388830|PROCEDURE|Ultrasound|
40948093|NCT06079658|BEHAVIORAL|Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss|This intervention seeks to investigate two different caloric restriction protocol on fat mass.
40948094|NCT06303921|DRUG|11C-M503 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-M503
40948095|NCT06303921|DIAGNOSTIC_TEST|Brain MRI|MRI scan of brain.
40758578|NCT06430411|RADIATION|Prostate irradiation|Radiation therapy of the prostate.
40948096|NCT06303921|DIAGNOSTIC_TEST|Amyloid PET|PET scan with Florbetaben F18 or 11C-PiB
40758579|NCT06430411|PROCEDURE|Surgical metastasectomy|Surgical removal of metastases.
40758580|NCT06430411|RADIATION|Irradiation of metastases|Radiation therapy of metastases.
40758581|NCT06430411|DRUG|Abiraterone acetate|Administered as part of multimodal treatment for oligometastatic prostate cancer
40758582|NCT06430411|DRUG|Enzalutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
40758583|NCT06430411|DRUG|Darolutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
40948097|NCT06303921|BEHAVIORAL|Neurological assessments|Neurological assessments, including a video interview.
40948098|NCT03901547|BEHAVIORAL|Communication Skills Training|Education training in the serious illness communication guide (SICG) by Ariadne labs.
40948099|NCT03901547|BEHAVIORAL|Profile feedback|Providing participants their personal documentation rate of SICG in the electronic medical record
40948100|NCT03901547|OTHER|Maslach burnout inventory|Maslach burnout inventory
40948101|NCT03901547|OTHER|Emotion Regulation Skills Question (ERSQ)|This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL). This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL).
40758584|NCT06430411|DRUG|Apalutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
40758585|NCT06430411|DRUG|Docetaxel|Administered as part of multimodal treatment for oligometastatic prostate cancer
40758586|NCT06430411|DRUG|Lutetium-PSMA|Administered as part of multimodal treatment for oligometastatic prostate cancer
40758587|NCT06430411|DRUG|Androgen deprivation treatment|Administered as part of multimodal treatment for oligometastatic prostate cancer
40758588|NCT04957082|BEHAVIORAL|Culturally Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a one minute video based messaging adjunct meant to enact a culturally targeted framing of health information presented to African Americans.
40758589|NCT04957082|BEHAVIORAL|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information
40948102|NCT03901547|OTHER|Semi-structured interview|Interviewer asked subjects are a series of questions based on interview guide. Current guide designed to assess subject perception of implementation of training in clinical encounters, most recent encounter with patient with serious illness, barriers to documentation and coaching by faculty on communication. Interviews will be recorded and expected duration is 20-40 minutes.
40948103|NCT03901547|BEHAVIORAL|Priming|"Participants will be provided a list of 30 patients they have encountered before that 1) have at least one documented note and 2) have a high probability for having serious illness as determined by electronic medical record screening. Participants will be asked 4 yes or no questions on each patient. Questions: 1) do you believe this patient has serious illness?; 2) would you be surprised if this patient died in the next year?; 3) would the patient benefit from the serious illness conversation guide? and 4) If you saw this patient again, would you use the serious illness conversation guide with him/ her?"
40948104|NCT00214760|DEVICE|PGET|resolbable liner
40948105|NCT00214760|DEVICE|PMMA|cement liner
40948106|NCT02713373|BIOLOGICAL|Cetuximab|Given IV
40948107|NCT02713373|OTHER|Laboratory Biomarker Analysis|Correlative studies
40948108|NCT02713373|BIOLOGICAL|Pembrolizumab|Given IV
40948109|NCT03110926|DRUG|mFOLFOX6|Induction Chemotherapy
40948110|NCT03110926|COMBINATION_PRODUCT|Chemoradiation|Chemoradiation
40948111|NCT02028312|DRUG|Loteprednol etabonate|
40948112|NCT02028312|DRUG|Artificial Tears|
40948113|NCT02028312|DRUG|Restasis|
40948114|NCT04961294|DEVICE|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
40948115|NCT04266223|DEVICE|Mask-free surface monitoring|Mask-free headrest and couch for patient positioning for radiation therapy combined with a surface monitoring system
40948116|NCT05927584|PROCEDURE|Transanal local excision|Transanal full thickness local excision
40948117|NCT00005878|DRUG|celecoxib|
40948118|NCT05753618|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.
40948119|NCT05753618|DRUG|Omission of Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy
40948120|NCT03157167|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
40948121|NCT00003927|BIOLOGICAL|filgrastim|
40948122|NCT00003927|DRUG|amifostine trihydrate|
40948123|NCT00003927|DRUG|cyclophosphamide|
40948124|NCT00003927|DRUG|doxorubicin hydrochloride|
40948125|NCT00003927|DRUG|paclitaxel|
40758590|NCT04544605|OTHER|Individualized-Chinese herbal medicine|"I. Lung and spleen qi deficiency syndrome Clinical manifestations: shortness of breath, fatigue, fatigue, anorexia, nausea, fullness, weak stool, and uneasiness. The tongue is pale and greasy. Recommended prescription: French Pinellia 9g, Chenpi 10g, Codonopsis 15g, Sunburn Astragalus 30g, Stir-fried Atractylodes 10g, Poria 15g, Huoxiang 10g, Amomum villosum 6g (later), and Licorice 6g~II. Qi and Yin deficiency syndrome Clinical manifestations: fatigue, shortness of breath, dry mouth, thirst, palpitations, sweating, poor appetite, low or no lever, dry cough and little sputum; dry tongue, fine or weak pulses. Recommended prescription: North and south radix salviae 10g, 15g ophiopogonis, 6g American ginseng, 6g schisandra, 6g gypsum l5g, 10g light bamboo leaves, 10g mulberry leaves, 15g reed root, 15g salviae miltiorrhiza, 6g raw liquorice."
40758591|NCT06539104|PROCEDURE|arteficial inteligence evaluation of oocyte and embryo development|apply AI to find out the complex oocyte quality, embryo development, embryo ploidy and pregnancy success probability from the sequence of the data starting from the recording of the meiotic spindle in polarized light, through paternal factors up to the time lapse record of early embryo development.
40758592|NCT04970589|OTHER|Mango|400g of mango/day
40758593|NCT04970589|DIETARY_SUPPLEMENT|Probiotics|1 probiotics capsule/day
40758594|NCT04970589|OTHER|Placebo|1 Placebo capsule/day
40758595|NCT00128492|DRUG|AZLI 75 mg two times a day (BID)/ three times a day (TID)|
40758596|NCT02549300|OTHER|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
40758597|NCT06055699|OTHER|Fecal sampling|"Stool samples are a collection of products derived from the human body that is not invasive in any way and samples not taken as part of usual care.~Stool samples will be collected at home within 7 days of the visit M0, M3 and M6 and within 14 days of the visit M12 in an ethanol tube and in DNA/RNA shield, and transported at room temperature to Saint-Antoine Hospital (CRB SAT, AP-HP, Pr. SIMON ), samples will be aliquoted (3 aliquots per tubes) and stored at -80°C for a period of 5 years (renewable) At the end of the research, stool samples will be analysed using metagenomics sequencing.~DNA extraction will be performed following the standards of the The International Human Microbiome Standards . DNA will be stored at -80°C."
40786384|NCT04935255|OTHER|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessments will be performed (on day 2 and day 4). Each pharmacokinetic assessment consists of 10 samples (5 ml blood).
40948126|NCT00003927|PROCEDURE|peripheral blood stem cell transplantation|
40948127|NCT02337270|BIOLOGICAL|Ad5Ag85A|Aerosol administration of Ad5Ag85A
40948128|NCT00671333|PROCEDURE|LRTI|"Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture."
40948129|NCT00671333|PROCEDURE|Ascension PyroDisk|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
40948130|NCT00254761|DRUG|Cannabis|
40948131|NCT05363410|DIETARY_SUPPLEMENT|MagnéVie B6®|micronutrient supplement
40948132|NCT05363410|OTHER|Placebo|placebo supplement
40948133|NCT02927886|PROCEDURE|Per-oral endoscopy pyloromyotomy|
40948134|NCT02927886|PROCEDURE|Intrapyloric injection of Botulinum toxin|
40948135|NCT04666480|DEVICE|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
40948136|NCT00290277|BIOLOGICAL|HPV-16/18 L1/AS04|
40948137|NCT02484183|DEVICE|bubble continuous positive airway pressure (CPAP)|This study will use an Airsep® oxygen concentrator and a Fisher \& Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer \& Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer \& Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
40948138|NCT03835910|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
41453679|NCT02155153|OTHER|Sugar Free Chewing Gum|'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
41453680|NCT06466421|DRUG|Fexofenadine|Fexofenadine 60 mg orally once daily for 3 months
40758598|NCT06055699|OTHER|Blood sampling|"Blood samples (serum, 15 ml) are an additional and minimal collection performed following a sample taken as part of usual care.~Blood samples (serum) will be collected during the visit at M0, M3 (± 7 days), M6 (± 7 days) and M12 (± 7 days).~In the hours following collection, the samples must be aliquoted and stored at -80°C in a secure place in the participating centre."
40758599|NCT00885898|PROCEDURE|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
40758600|NCT00885898|PROCEDURE|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
40758601|NCT03111108|DRUG|EBR/GZR (50 mg/100 mg) FDC|One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
40758602|NCT05087446|BEHAVIORAL|Early assessment team|Early assessment team (EAT):The patients receive their first assessment by an early clarification team within a few weeks after the team receiving the referral. The team then decides whether further assessment and/or treatment should be given in the general outpatient clinic, and/or whether any other follow-up may be appropriate. In the first meeting the patient preferably meets two therapists, who conduct a semi-structured interview with focus on health and level of functioning. If considered appropriate, the team may offer a short-term intervention.
40758603|NCT05087446|BEHAVIORAL|Admission to General psychiatric outpatient clinic|Ordinary procedures for admission to an outpatient clinic are followed in accordance with the Norwegian Directorate of Health's national prioritization guide. Referrals are assessed on the basis of severity and placed on a regular waiting list (usually a waiting period of 1-3 months). The patients receive their first personal assessment from a therapist in a general outpatient clinic who takes a position on what is to be initiated and, if necessary, offers further assessment / treatment in accordance with procedures in the outpatient clinics. This is not standardized beyond current practice.
40758604|NCT05982379|OTHER|Technology Based Motivation Program|"A 10-week Technology Based Motivation Program was given to the intervention group. The website and four training modules were used with the children in the intervention group. Nine coaching interviews with each child (once a week) were conducted over WhatsApp. The children were encouraged to do progressive relaxation and breathing exercises at least twice a week, and eight therapeutic stories (once a week) were sent to the child's phone in the form of animation.~Three training modules were used with the primary caregivers, and coaching interviews were conducted on WhatsApp twice during the program. Primary caregivers practiced progressive relaxation and breathing exercises at least twice a week. In addition, eight motivation messages were sent to the child and primary caregiver, and 24/7 consultancy was provided."
40758605|NCT05313958|DRUG|Cladribine|5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
40758606|NCT05313958|DRUG|G-CSF|5ug/kg/day d0-5,if Peripheral blood leukocytes\<20,000/ul
40758607|NCT05313958|DRUG|Cytarabine|2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
40758608|NCT05313958|DRUG|Idarubicin|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
40758609|NCT05313958|DRUG|Mitoxantrone|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
40758610|NCT05313958|DRUG|Sorafenib|200mg/m2/day was taken orally until molecular biology remission for 2 years
40758611|NCT05600257|DEVICE|DBT|Image with digital breast tomosynthesis
40758612|NCT05600257|DEVICE|DM|Image with digital mammography
40758613|NCT03224377|DIAGNOSTIC_TEST|anti mutated citrullinated vimentin antibodies|Blood sampling using ELisa technique
40758614|NCT01523431|DRUG|Irinotecan Injection [Camptosar]|CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
40758615|NCT01523431|DRUG|5-fluorouracil|The 5-FU dosage will remain the standard.
40758616|NCT01523431|DRUG|Leucovorin|The LV dosage will remain the standard.
40758617|NCT03194529|BIOLOGICAL|FMT|Fecal Microbiota Transplantation, single dose, 50g of stool, delivered via standard of care upper endoscopy into jejunum.
40758618|NCT03261375|DEVICE|Renal Artery Radiofrequency Ablation System (Generator and Catheter )|A renal denervation system with a mesh 6-electrode radiofrequency ablation catheter and multi-channel radiofrequency generator
40758619|NCT03261375|DRUG|Antihypertensive Agents|Calcium channel blocker, Diuretic
40758620|NCT03261375|DEVICE|Sham Procedure|Catheterization without renal denervation
40786385|NCT03848416|BIOLOGICAL|Ixekizumab|Administered SC
40786386|NCT03846661|DEVICE|Physiomesh|difference in risk for recurrence and postoperative complication
41453681|NCT06466421|DRUG|Gabapentin|100 mg after each dialysis session (thrice weekly). Dose may be titrated after 2 weeks, according to response and tolerability, to 100 mg orally once daily for 3 months.
40948139|NCT03835910|PROCEDURE|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
40948140|NCT03835910|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
40948141|NCT03835910|PROCEDURE|Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
40948142|NCT06054893|DRUG|Omaveloxolone|Administered as specified in the treatment arm
40948143|NCT04113720|DRUG|Levobupivacaine hydrochloride|levobupivacaine 0.25%
40948144|NCT04113720|DRUG|Levobupivacaine Hydrochloride + Dexmedetomidine|Levobupivacaine plus Dexmedetomidine
40948145|NCT02837146|BIOLOGICAL|Tocilizumab (TCZ)|Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
40948146|NCT02837146|DRUG|Methotrexate (MTX)|Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
40948147|NCT06015464|DRUG|Orelabrutinib|Addition of novel BTK inhibitor, Orelabrutinib，150 mg qd, to standard treatment regimens, which include R-CHOP and Pola-R-CHP
40948148|NCT00085904|DRUG|SB-485232|
40948149|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 4 mg|4 mg of candesartan as capsule
40948150|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 8 mg|8 mg candesartan as capsule
40948151|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 20 mg|20 mg nifedipine as tablet
40948152|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 30 mg|30 mg nifedipine as tablet
40948153|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 60 mg|60 mg nifedipine as tablet
40948154|NCT01303783|DRUG|Placebo|3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
40948155|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 16 mg|16 mg of candesartan as capsule
40948156|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 32 mg|32 mg of candesartan as capsule
40948157|NCT02280538|DEVICE|Intra-Articular Hyaluronic Acid|
40948158|NCT02280538|DEVICE|Placebo|
40948159|NCT04799574|OTHER|music therapy activities|"Music therapy activity course design (Protocol):~The researchers in this study are the leaders of the activities and the nurses who had completed training in music therapy courses and obtained a senior music activity leadership certificate and qualification, such as books and internship certificates. The course design uses the percussion music theory and Dalcroze and Orpff music pedagogy to plan activities, as follows:~Each class in the music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle. The content of the weekly main activities uses different music, musical instruments, props, or rhythms to lead the rhythm music activities."
40948160|NCT04238585|BEHAVIORAL|Mobile messaging|Mobile health messages
40948161|NCT02556658|DEVICE|General anesthesia managed by the Smartpilot® View|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
40948162|NCT02556658|DEVICE|General anesthesia managed without the Smartpilot® View|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
40948163|NCT03054454|PROCEDURE|Podiatry|Podiatry treatments and care from the multidisciplinary team.
40948164|NCT04388384|DRUG|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
40948165|NCT01149837|DEVICE|InnoLIA HTLV I/II Score line immunoassay|This intervention consists of testing a residual serum or plasma sample from a blood donation or donor follow-up sample using the InnoLIA HTLV I/II Score line immunoassay
40948166|NCT03633136|BEHAVIORAL|electronic video education|Solid Organ Transplantation: An Educational Mini-Series for Patients consists of 6 videos ranging in length between 3 and 23 minutes, and has been developed according to best practice for designing education for patients with end-stage renal disease pursuing transplant. Each video outlines a subsequent stage of the transplant process, featuring an animated character embarking on a transplant journey. Animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives keep the content relevant and culturally inclusive. The educational intervention was developed with experts in medication adherence, video education, motivational psychology, cultural education (First Nations perspective), healthcare providers, and most importantly patients.
40948167|NCT00080275|DRUG|Niacin Extended-Release and simvastatin Tablets|
40948168|NCT03102333|DEVICE|Variable-rate Feedback Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
41453682|NCT03999008|DRUG|Budesonide Oral|"The subjects will be included at time of the first dilation for an anastomotic stricture.~Basal physical exam and clinical evaluation (weight and height, dysphagia score, gastroesophageal reflux, feeding problems, respiratory symptoms, other symptoms).~Randomization will be conducted by centre. Because long gap esophageal atresia, high tension anastomosis and history of anastomotic leak are reported as risk factors for occurrence of anastomotic strictures, a stratification at randomization will be performed according to these criteria in each centre.~OVB or placebo will be given by the parents and started the day of the dilation at the first meal after recovering of the dilation and anesthesia.~Parents will be asked to bring the empty caps which will be counted for assessment of compliance."
41453683|NCT03999008|DRUG|Placebos|Apple Sauce 5 mL+ 1 mL saline
41453684|NCT01165060|DRUG|Bezafibrate|Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
41287384|NCT03921892|BEHAVIORAL|Parenting Education|Parenting education such as positive parenting interactions with their child, knowledge of developmental milestones and interactions with the child to support that development, as well as co-parenting skills will be provided either in-person or on-line to adolescent fathers
41287385|NCT01900548|DIETARY_SUPPLEMENT|Whey protein (HPHL)|The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
41453685|NCT03467360|DRUG|acetazolamide in combination with platinum and etoposide-based radiochemotherapy|Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
40948169|NCT03102333|DEVICE|Constant-rate Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
41287386|NCT01900548|DIETARY_SUPPLEMENT|Soy protein (HPLL)|The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
41287387|NCT01900548|DIETARY_SUPPLEMENT|Placebo (P)|Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
41287388|NCT01900548|OTHER|Resistance training|For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
41287389|NCT03619122|PROCEDURE|Second Examination|The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
41287390|NCT00330629|BEHAVIORAL|Standard Behavioral Treatment|Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
41287391|NCT00330629|BEHAVIORAL|SBT+LOV|The focus will be on the elimination of meat products as a means to reduce fat intake.
41287392|NCT03115385|DIETARY_SUPPLEMENT|VSL#3|VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).
41287393|NCT03115385|DIETARY_SUPPLEMENT|Placebo|A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
41287394|NCT03257046|DRUG|ITI-214|Oral
41287395|NCT03257046|OTHER|Placebo|Oral
41287396|NCT01767233|PROCEDURE|ERCP and pancreatic stenting|
40948170|NCT02268955|DRUG|IV Ibuprofen|Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
41287397|NCT04169607|PROCEDURE|Dynamic compliance guided individualized positive end-expiratory pressure titration strategy|"Basic ventilation: Volume-controlled ventilation (VCV) mode with positive end-expiratory pressure (PEEP) of 8cm H2O after induction of anesthesia，~Recruitment maneuver (RM): Pressure-controlled ventilation (PCV) mode increasing PEEP from 10 to 25cmH2O in step of 5cmH2O per 30s.~PEEP-titration maneuver: ventilation parameters reset as basic ventilation with PEEP still 25cmH2O.Decrease PEEP to 5cmH2O in step of 2cmH2O per 10 respiratory cycles to confirm the highest dynamic lung compliance (Cdy).~After titration: A new RM will be performed and the final PEEP will be the one related to highest Cdy plus 2cm H2O.~Randomized after the second RM. Individualized PEEP arm: maintain individualized PEEP; PEEP8 arm: maintain a fixed PEEP of 8cm H2O.~VCV with other ventilation parameters the same as basic ventilation until extubation .~After discharged from postoperative anesthesia care unit (60 to 90 minutes after extubation): chest CT ."
41287398|NCT02765412|OTHER|Webinar, Promotion, and Tool Access|All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.
41287399|NCT02765412|OTHER|LEAP|Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).
41287400|NCT02765412|OTHER|Audit and Feedback|Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).
41287401|NCT02765412|OTHER|Academic Detailing|All sites will be offered an academic detailing approach to implementation of Lung Decision Precsion. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations.
40786389|NCT00734552|DIETARY_SUPPLEMENT|α-Keto Acid with low protein diet|"Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.~Low Protein Diet: Diet contain protein 0.8g/kg/d."
40948171|NCT02268955|DRUG|Saline|Saline will be administered to the placebo group
41287402|NCT01902160|DRUG|Brentuximab Vedotin|Given IV
41287403|NCT01902160|OTHER|Laboratory Biomarker Analysis|Correlative studies
41287404|NCT01902160|DRUG|Temsirolimus|Given IV
41287405|NCT03397485|DIETARY_SUPPLEMENT|Growing milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
41307779|NCT04476355|OTHER|Select and Tailor implementation interventions|Based on previously adapted guidelines and the assessment of innovation, adopters and practice environment for barriers and supports, the interventions mainly include patients education, practioners education and system changes.
40948172|NCT03584061|PROCEDURE|Fat grafting|The area of dermal pain is identified and marked prior to surgery. The surgery starts with liposuction, either on the abdomen or the thigh. The harvested fat is prepared for fat grafting by sedimenting it for 10 minutes. The fat is then injected into the painful area, marked pre-surgery.
40948173|NCT04801173|COMBINATION_PRODUCT|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
40948174|NCT04801173|BEHAVIORAL|Low calorie standard diet|Low calorie standard diet with no specified dietary supplement addition
40948175|NCT02833350|DRUG|GDC-0853|Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
40948176|NCT02833350|DRUG|Adalimumab|Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
41453686|NCT03862547|DIAGNOSTIC_TEST|A peripheral blood sample from the cubital vein|"Evaluation of NGF and Cytokine levels A portion of each blood sample and medium conditioned by PBMC will be used for the enzyme immunoassay of NGF and pro and anti-inflammatory cytokine levels (TNF alfa and IL-10).~Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs The remaining part of each blood sample and PBMC of the in vitro experiment will be used for the cytofluorimetric evaluation of the expression of TrKA, p75NTR and the pro and anti-inflammatory cytokines and reactive oxygen species."
41453687|NCT04694963|PROCEDURE|Blood sample|2 ml venous blood was collected and separated into serum.
41453688|NCT04694963|PROCEDURE|Data collection|"1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;"
41453689|NCT04694963|PROCEDURE|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
40758621|NCT04339374|DEVICE|Photoacoustic imaging, photoacoustic microscopy|"* Emerging technique in which a short-pulsed laser beam penetrates diffusely into a tissue sample, causing the release of acoustic waves due to a transient temperature rise~* The transient acoustic waves, or photoacoustic waves, are then measured around the sample by US transducers~* The resolution of the devices can be altered by changing the wavelengths of laser light and spectrum analysis of the receiver. In this manner, human colorectal pathology will be examined under multiple types of photoacoustic ranges (broadly termed photoacoustic microscopy and photoacoustic imaging)~* The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants"
40758622|NCT04339374|DEVICE|Endorectal photoacoustic imaging probe|"* Based on data gathered in the ex vivo cohort of patients, an endorectal imaging device using coregistered photoacoustic and ultrasound imaging will be constructed. This probe will then be used to perform in vivo imaging among patients with rectal pathology intraoperatively.~* The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants"
40758623|NCT06548022|BEHAVIORAL|Rare Group Problem Management Plus|The World Health Organization's Group Problem Management Plus (Group PM+) intervention has been demonstrated to effectively provide psychological help for adults impaired by distress in communities exposed to adversity. We will test an adapted model for use on-line and with family caregivers of children with rare diseases. Managing Stress. Teaching participants a brief stress management strategy will help them better manage problems related to anxiety and stress. Managing Problems. This is a strategy to apply in situations where a participant is experiencing practical problems (e.g. conflict in the family). Get Going, Keep Doing. This strategy targets depression and inactivity. Strengthening Social Support. Individuals with emotional problems can be isolated from supportive people and organizations. Strengthening social support promotes well-being. Staying Well and Looking Forward. This is a review, ends with a closing ceremony, and suggestion that the group members keep in touch.
40758624|NCT02795962|OTHER|Direct transfer to an Endovascular Center|Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
40758625|NCT00883311|DEVICE|BRT-FC-83C|BRT-FC-83C is a topical cream to treat atopic dermatitis. It is applied topically, twice a day, to the atopic dermatitis skin lesion for six weeks.
40758626|NCT05985174|DIAGNOSTIC_TEST|CD64 , HLA-DR|"CD64 is atype of integral membrane glycoprotein , when activated , it increases the neutrophils' potential for phagocytosis and bacterial killing .~HLA-DR is on the surface of monocyte\\macrophages , dendritic cells and plays a crucial role in adaptive immune response"
40758627|NCT06549907|OTHER|Multi-omics testing|Samples include tissue, blood, urine and stool, and multi-omics approaches include single-cell sequencing, spatial transcriptome sequencing, macro transcriptome sequencing, whole exome sequencing, microproteomics, immunohistochemistry, and multiplex fluorescence immunohistochemistry.
40758628|NCT06549907|OTHER|MRI|MRI will be conducted to investigate image characteristics during treatment
40758629|NCT02473302|OTHER|ham|160g per day during 4 days
40758630|NCT02473302|OTHER|ham + pomegranate extract|160g per day during 4 days
40758631|NCT02473302|OTHER|ham + tocopherol|160g per day during 4 days
40758632|NCT02473302|OTHER|rare sirloin steak|110g per day during 4 days
40758633|NCT02473302|OTHER|marinated rare sirloin steak|110g per day during 4 days
40758634|NCT02473302|OTHER|marinated cooked sirloin steak|110g per day during 4 days
40758635|NCT05317247|DIAGNOSTIC_TEST|Cough sounds|The investigators will discover a cough audio signature and then validate it.
40758636|NCT05615350|OTHER|Meals served during breakfast with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during breakfast at the eating behaviour lab
40758637|NCT05615350|OTHER|Meals served during lunch with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during lunch at the eating behaviour lab
40758638|NCT00203242|DRUG|Depacon IV and Depakote ER|
40786390|NCT00734552|DIETARY_SUPPLEMENT|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
41453690|NCT05608239|DEVICE|Sculptra aesthetic|The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples with total volume of the diluted product as 9 ml (8 ml of sterile water and 1 ml of Lidocaine).
40948177|NCT02833350|DRUG|Folic Acid|Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
40948178|NCT02833350|DRUG|MTX|Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
40948179|NCT02833350|DRUG|Placebo|Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
40948180|NCT00627549|PROCEDURE|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
40948181|NCT00627549|PROCEDURE|Conventional surgery (anterior repair)|Anterior repair surgery
40948182|NCT05742958|DRUG|Intrathecal morphine|The study will be conducted in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery under spinal anesthesia. In this arm, 0.1 mg intrathecal morphine in addition to spinal anesthesia will be used for perioperative pain management. A placebo addctor canal block will also be performed for masking in these patients. The quality of recovery will be evaluated with a postoperative quality of recovery scale (QoR-40 questionnaire) at postoperative 24-hour and 14-day.
40948183|NCT05742958|DRUG|Adductor canal block|After providing complete sensory block in the lower extremities with spinal anesthesia, the thigh where the surgery will be performed will be brought into slight abduction and external rotation while the patient is in the supine position. The blockage of the saphenous nerve in the adductor canal will be performed with 30 mL of local anesthetic (0.25% bupivacaine) solution with a 22 gauge 5-8 cm long block needle from the mid-medial part of the thigh under ultrasound guidance. The quality of recovery will be evaluated with QoR-40 questionnaire at postoperative 24-hour and 14-day.
40948184|NCT00801320|PROCEDURE|Tumor collection|Tumor collected at the time of planned surgery
40948185|NCT00376883|DRUG|pamidronate|
40948186|NCT03049722|DEVICE|Pacemaker|
40948187|NCT04138069|OTHER|PLB+Aerobic Bicycling|"Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes"
40948188|NCT04138069|OTHER|Aerobic Bicycling|"Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes"
40948189|NCT05218720|DIAGNOSTIC_TEST|EuroSCORE II|"* Euro score II: Predicts risk of in-hospital mortality after major cardiac surgery. Risk category will be defined as very low risk \<1, low risk 1-2.99, moderate risk 3-4.99, high risk \>5.~* CAM- ICU: The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) is a tool used to assess delirium among patients in the intensive care unit. It is an adaptation of the CAM which was originally developed to allow non-psychiatrists to assess delirium at the bedside. It ranges from 0 to 7, score greater to or equal to 3 will be considered positive for delirium, further categorized as 0-2 no delirium, 3-5 mild delirium 6-7 severe delirium with 7 being most severe."
40948190|NCT00004635|DRUG|Thalidomide|Thalidomide 200 mg given orally every evening at 9pm. Treatment may continue indefinitely provided that there are no dose-limiting toxicity.
40948191|NCT00004635|DRUG|leuprolide acetate|Injections of leuprolide once a month for six months.
40948192|NCT00004635|DRUG|goserelin|Injections of Goserelin once a month for six months.
40948193|NCT00004635|OTHER|Placebo|Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
40948194|NCT03974360|DRUG|AMG 334|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
40948195|NCT05248620|DRUG|Amoxicillin Clavulanic 500/125mg or placebo|Prophylactic antibiotic treatment
40948196|NCT05073211|PROCEDURE|PDT|A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
40948197|NCT05183763|BEHAVIORAL|STAR-MAP health coaching|Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior
40948198|NCT05183763|BEHAVIORAL|Medication reminder tools|Medication-taking reminder app and pillbox
40948199|NCT00611208|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
40948200|NCT02649088|DEVICE|Microscan|It allows to look at sublingual microcirculation
41453691|NCT05722080|OTHER|Eyesi simulator|Eyesi simulator learning curve for new ophthalmology residents
41453692|NCT05722080|OTHER|Sleep deprivation|See how experienced residents perform after sleep deprivation using the Eyesi simulator
41453693|NCT01957280|DRUG|patritumab|
41453694|NCT02770690|DRUG|ethyl chloride spray|apply the spray for 5 seconds on the dorsal hand before propofol iv injection
41453695|NCT02770690|DRUG|lidocaine|apply lidocaine under the tourniquet state before propofol iv injection
40948201|NCT02649088|DEVICE|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
40948202|NCT00968890|BIOLOGICAL|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
40948203|NCT00968890|BIOLOGICAL|Fluarix™|Intramuscular injection, 1 dose
40948204|NCT00968890|BIOLOGICAL|Placebo|Intramuscular injection, 1 dose
41453696|NCT02770690|DRUG|placebo|apply normal saline before propofol iv injection
41453697|NCT06012006|OTHER|constant work-rate cycling exercise test|Description: at the end of pulmonary rehabilitation, a constant work-rate second cycling exercise test will be performed with the same duration as the cycling exercise test at inclusion
41453698|NCT03667963|OTHER|Glucose|50g glucose dissolved in 250ml water
41453699|NCT03667963|OTHER|Glucose plus lactulose|50g glucose plus 10g lactulose dissolved in 250ml water
40948205|NCT04911166|COMBINATION_PRODUCT|Atezolizumab and Interleukin-12 Gene Therapy|To determine the safety and tolerability of the atezolizumab and ADV/IL-12 gene therapy combination in patients with metastatic NSCLC who have disease progression after a prior line of either single agent immunotherapy or a regimen of chemoimmunotherapy.
40948206|NCT02295410|BEHAVIORAL|CPT|
40948207|NCT05050929|RADIATION|Targeting All Brain Metastases|Volumetric Modulated Arc Therapy
40948208|NCT06327009|BEHAVIORAL|fasting month of ramadan|100 patients with glomerulonephritis who decided to fast month of ramadan
40948209|NCT04032548|DRUG|Placebo mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
40948210|NCT04032548|DRUG|Propolis mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
41453700|NCT03667963|OTHER|Hot Rice|Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.
41453701|NCT03667963|OTHER|Cold Rice|Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.
40758639|NCT03656614|DRUG|Sugammadex|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)"
40758640|NCT03656614|DRUG|Neostigmine|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow."
40758641|NCT03656614|DRUG|Saline 0.9%|At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.
40758642|NCT00742157|DRUG|Growth Hormone|dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
40758643|NCT01959919|DEVICE|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
40758644|NCT01201044|DRUG|Gemcitabine, Nedaplatin, iV|Gemcitabine, Injection, 1000mg/m2, D1 \& D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.
40758645|NCT01201044|RADIATION|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
40758646|NCT01201044|RADIATION|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
40758647|NCT01201044|DRUG|Gemcitabine，Nedaplatin, BAI|"Drug: Gemcitabine, Nedaplatin, iV~Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI"
40758648|NCT03931811|DEVICE|Short wave diathermy|SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device).
40758649|NCT03931811|OTHER|Prolotherapy|Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
40758650|NCT04512625|BIOLOGICAL|Desensitizers|The main aims and objectives of the present study were to evaluate and compare the effectiveness of three commercially available desensitizing agents: Gluma (Hareus Kulzer), Sheildforce Plus (Tokuyama), and Telio CS (Ivoclar Vivadent) desensitizer in reducing the pre- and post-cementation sensitivity for full coverage restorations.
40758651|NCT00178139|BEHAVIORAL|Music Therapy|Music Therapy
40758652|NCT02741193|DEVICE|The Magstim Rapid2,|"Transcranial Magnetic Stimulation, which is a microprocessor-controlled machine which delivers both single and repetitive transcranial magnetic stimulation (TMS).~single and repetitive transcranial magnetic stimulation (TMS). TMS will be applied as single pulses to determine motor evoked potentials (MEPs), there will be no modulation of cortical excitability."
40758653|NCT01156467|DEVICE|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with Edi-catheter
40758654|NCT01156467|DEVICE|Control group, ventilation with i-Servo or Stephanie|Ventilatory support is given as routinely is done in the neonatal intensive care unit, with the ventilators available. Normal nasogastric tube is used.
40758655|NCT02423954|DRUG|Temsirolimus|
40758656|NCT02423954|DRUG|Irinotecan|
40758657|NCT02423954|DRUG|Irinotecan + capecitabine|
40758658|NCT02423954|DRUG|nivolumab|
40786391|NCT04831671|OTHER|Surgical Approach - Infra-patella nailing|The intra-medullary nail will be introduced via an infra-patella incision.
40786392|NCT04831671|OTHER|Surgical Approach - Supra-patella nailing|The intra-medullary nail will be introduced via a supra-patella incision.
40786393|NCT00287781|DRUG|Lidocaine|
40786394|NCT02143349|DIETARY_SUPPLEMENT|Coleus forskohlii extract|Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks
40948211|NCT04032548|DRUG|Chlorhexidine mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
40948212|NCT01120535|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
40948213|NCT06467942|DRUG|Chinese medicine and Lactobacillus|combined drug group
40948214|NCT06467942|DRUG|Chinese medicine|Single Chinese medicine group
40948215|NCT06467942|DRUG|Lactobacillus|Single Lactobacillus group
40948216|NCT01817244|OTHER|care management|6-month care management
40948217|NCT01408797|PROCEDURE|donor specific transfusion|before transplantation,200mL of donor whole blood will be transfused to the recipient
40948218|NCT01408797|DRUG|MMF, Bortezomib|MMF and Bortezomib will be administered after donor specific transfusion
41453702|NCT05545436|DRUG|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ) Drug: Camrelizumab 200mg Drug: oxaliplatin 130 mg/m2 Drug: Teggio 40 mg/m2 Drug: oxaliplatin 130 mg/m2 Drug: capecitabine 1000 mg/m2 Q3W for 3 cycles. Radical surgery was performed 3 weeks after the last neoadjuvant treatment.
41453703|NCT04436718|DIAGNOSTIC_TEST|Daily pocus exam|Daily evaluation of lung ultrasound for B line artifacts plus IVC assessments
40948219|NCT01408797|PROCEDURE|drugs added according to the immuno condition of the recipients|drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
40948220|NCT01238354|BEHAVIORAL|With friend|
40948221|NCT01238354|BEHAVIORAL|Without friend|
40948222|NCT03414229|DRUG|Epacadostat|100mg bid days 1-21
40948223|NCT03414229|DRUG|Pembrolizumab|200mg/dose Day 1, Q 3 weeks
40948224|NCT00005017|DRUG|Ritonavir|
40948225|NCT00005017|DRUG|Abacavir sulfate|
40948226|NCT00005017|DRUG|Amprenavir|
40948227|NCT00005017|DRUG|Efavirenz|
40948228|NCT00005017|DRUG|Lamivudine|
40758659|NCT01554358|BEHAVIORAL|Lifestyle intervention|"The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake \<30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.~--------------------------------------------------------------------------------"
40758660|NCT05701631|DIAGNOSTIC_TEST|Radiomic model|Radiomic model for PCP diagnosis
40758661|NCT01664715|BEHAVIORAL|150 Min/Week|Performs 150 min/wk of planned moderate intensity aerobic exercise.
40758662|NCT01664715|BEHAVIORAL|225 Min/Week|Performs 225 min/wk of planned moderate intensity aerobic exercise.
40758663|NCT01664715|BEHAVIORAL|300 Min/Week|Performs 300 min/wk of planned moderate intensity aerobic exercise.
40758664|NCT04632342|DRUG|HL301 tablet 300mg|"* Experimental group 1 : 2 tablets at once, twice a day~* Experimental group 2 : 2 tablets at once, three times a day"
40758665|NCT04632342|DRUG|Placebo of HL301 tablet|2 tablets at once, three times a day
40758666|NCT02796482|DIETARY_SUPPLEMENT|EnergieShake 1.5kcal Complete|Participants will be given EnergieShake 1.5 kcal Complete drink twice daily. i.e. 2 bottles of ONS per day during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days, followed by 8 day intervention on EnergieShake 1.5 kcal Complete drink.
40758667|NCT05230654|DRUG|Fosaprepitant|Fosaprepitant: 4 mg/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.
40758668|NCT05230654|DRUG|Placebo(normal saline)|Placebo(normal saline): 4 ml/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
40948229|NCT00005017|DRUG|Stavudine|
40948230|NCT03401762|BEHAVIORAL|MCI|EMG-controlled game
40948231|NCT03401762|BEHAVIORAL|Sham MCI|Sham control game
40948232|NCT04937361|OTHER|rectal swab|collection of rectal swabs
40948233|NCT03292484|BIOLOGICAL|AR101|AR101
40948234|NCT03126370|DRUG|TDF with a boosted protease inhibitor|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment"
40948235|NCT03126370|DRUG|TAF with a boosted protease inhibitor|"Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment"
40948236|NCT03126370|DRUG|TAF with a boosted protease inhibitor and LDV/SOF|"After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment"
40786395|NCT02143349|OTHER|Placebo|Ingestion of 250 mg placebo capsule twice a day for 12 weeks
40948237|NCT04473092|DEVICE|TMVR|Patients who undergo TMVR for MR at the PI´s site
40948238|NCT02601599|BEHAVIORAL|Motivational interviewing|"The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support."
40948239|NCT04752384|DRUG|Buprenorphine|Transdermal buprenorphine will be started at 5 mcg/hr once a week. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 20 mcg/hr once a week.
40948240|NCT04752384|DRUG|Tramadol|Oral tramadol will be started at 50 mg/day. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 400 mg/day.
40948241|NCT04752384|DEVICE|Oral Mucositis (OM) Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
40948242|NCT01122433|DEVICE|Endotracheal intubation using the C-MAC video laryngoscope|Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
40948243|NCT06413927|BEHAVIORAL|Online Vehicle and Driver Safety Training|This online video education program provides education in vehicle and driver safety (e.g. vehicle maintenance, adjusting car seats and seatbelts). This online training will take up to 2 hours to complete and will have a short quiz at the end to determine compliance with this online training.
40948244|NCT06413927|BEHAVIORAL|Online Driver Skills Training|The online driver training is the Accelerated Curriculum to Create Effective Learning (ACCEL) is designed to enhance the ability to anticipate, recognize and respond to hazards and to maintain attention to the road. The training is delivered online via a computer and can be done from home or at a school or other site that has a computer with internet access. It requires up to two hours to complete, and will be hosted on a platform that will track progress and completion through the training (such as accuracy, duration in modules, time to complete) and a short quiz will be provided at the end to assess learning.
40948245|NCT06413927|BEHAVIORAL|Behind-the-Wheel Driver Training|The professional behind-the-wheel training course will be conducted in-person, delivered by local driving school partner Driver Training Services. The curriculum consists of 6 hours of training with assigned practice between lessons, and meets Pennsylvania and national standards. Post-lesson forms completed by the instructors will record adherence and consistency (intervention fidelity).
40948246|NCT04326829|DRUG|QL1604|QL1604, IV infusion
40948247|NCT03071159|DEVICE|FreeStyle Flash Libre glucose monitoring system|glucose monitoring system with sensors
40948248|NCT00140933|DRUG|MK0966; rofecoxib|
40948249|NCT00140933|DRUG|Comparator: diclofenac, placebo|
40948250|NCT03926871|OTHER|Ergonomic Training|The ergonomic training consisted of an educational program in Ergonomics with a duration of 60 (sixty) minutes divided into a theoretical exposition and videos of the occupational tasks performed by the workers themselves. Theoretical lecture covered topics such as ergonomics, human anatomy, worker health, prevention measures to minimize the risks of musculoskeletal diseases. A better way of performing the work to protect the musculoskeletal system was demonstrated.
40990460|NCT01357265|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
40758669|NCT02576197|DIETARY_SUPPLEMENT|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
40758670|NCT02576197|DIETARY_SUPPLEMENT|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
40758671|NCT00326014|DEVICE|iStent|Glaucoma Surgery
40758672|NCT02093273|BIOLOGICAL|tOPV pilot batch|the tOPV vaccine is given orally
40758673|NCT02093273|BIOLOGICAL|tOPV commercial batch|tOPV vaccine is given orally
40758674|NCT05818007|DRUG|Hyaluronic acid|The main function of HA appears to be in tissue healing, by activating and modulating inflammatory responses, stimulating cellular proliferation, migration, and angiogenesis, inducing basal keratinocyte proliferation and re-epithelization by reducing collagen deposition and scarring
40758675|NCT05818007|DRUG|Sodium bicarbonate|sodium bicarbonate solution
40758676|NCT04884074|PROCEDURE|Standard Sleeve Gastrectomy plus Anterior Crural Repair|The procedure is performed in a similar fashion as standard sleeve gastrectomy. After gastric mobilization is completed as standard sleeve gastrectomy, the anterior phrenoesophageal ligament is divided and distal 3cm esophagus is mobilized. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist and the hiatus opening is closed with 2/0 non-absorbable suture over the bougie anterior to the esophagus. The hiatus repair was sized by comfortably placement a dissection forceps adjacent to the esophagus without tension. Sleeve gastrectomy is then performed as the standard technique.
40758677|NCT04884074|PROCEDURE|Standard sleeve gastrectomy (SSG, the control group)|"The procedure is performed in French position with a standard 5-port approach and a pneumoperitoneum not exceeding 15mmHg.~The greater omentum is then completely detached from the greater curvature of stomach using either ultrasonic or bipolar shear device. All adhesion between posterior gastric wall and pancreatic capsule is freed and the cardia is completely free with left crura completely exposed. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist with its balloon tip reaching the gastric antrum and insufflated with 50cc of air. Sleeve gastrectomy is then performed using laparoscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up cardia at about 1cm lateral to the angle of His, along the Mid-sleeve tube which is lying against the lesser curve of stomach. The staple line is reinforced with absorbable sutures. Distal stomach is anchored at retroperitoneum with non-absorbable stitch."
40758678|NCT02431520|PROCEDURE|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
40758679|NCT02431520|PROCEDURE|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
40758680|NCT02925143|OTHER|E-learning course in neuromuscular monitoring|An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
40758681|NCT04964752|DEVICE|continuous glucose-monitoring|Continuous glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients with diabetes.
40758682|NCT02658188|DRUG|ASP8825|Oral
40758683|NCT02011542|DRUG|VSL#3|This is a probiotic mixture
40758684|NCT02011542|DRUG|Placebo|This is a pill with inactive ingredients.
40758685|NCT01259531|DRUG|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
40758686|NCT04519138|DEVICE|Endodrill Model X|The investigational device Endodrill Model X is used for biopsy sampling in the upper gastrointestinal tract
40758687|NCT04519138|DEVICE|Fine-needle aspiration/biopsy|The standard method is used for biopsy sampling in the upper gastrointestinal tract
40758688|NCT04868071|BEHAVIORAL|Physical Exercise|Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).
40758689|NCT06083571|DRUG|Ketorolac|Non-inferiority
40758690|NCT06083571|DRUG|Prochlorperazine|Adjunct
40758691|NCT06083571|DRUG|Diphenhydramine|Adjunct
40758692|NCT02452593|OTHER|"Tibial stimulation and pelvic floor exercises"|A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
40758693|NCT04309500|BEHAVIORAL|Personalized DAT Risk Disclosure Protocol|Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.
40758694|NCT06500936|OTHER|SMS|The intervention included two series of SMS messages. First, women of IG received one weekly SMS messages for 2 weeks. Those women that did not register a mammography in SITAM 45 days after the 2nd message, received the second series, consisting of one weekly SMS message over two weeks.
40758695|NCT05570162|OTHER|Diabetes educational program|30-minute long diabetes educational program
40758696|NCT05795712|OTHER|Therapy Change from Baseline|The patient will be followed up from the point of view of therapy according to symptoms and flare-ups irrespective of systemic or peripheral eosinophil assessment
40758697|NCT01830387|DEVICE|Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump.
40758698|NCT01830387|OTHER|Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
41453704|NCT01669980|DRUG|Ceftaroline fosamil|"* Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)~* Subjects \< 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
40758699|NCT02759809|OTHER|Pasteurized donor human breastmilk|
40758700|NCT02759809|OTHER|Preterm formula|
40758701|NCT05113342|DRUG|Descartes-25|allogeneic Mesenchymal Stem Cell product.
40758702|NCT05081271|BIOLOGICAL|Homologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
40758703|NCT05081271|BIOLOGICAL|Heterologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
40758704|NCT02798003|OTHER|Functional magnetic resonance imaging (fMRI)|The food-cue elicited response in the reward-circuitry of the brain will be assessed by using fMRI. This technique is based on different magnetic properties of oxygenated and deoxygenated blood. Increased neuronal activity causes an increase in blood flow. Thereby, neuronal activity is indirectly reflected by changes in blood oxygenation level-dependent (BOLD) contrast.
40758705|NCT02940223|DRUG|Ethyl Icosapentate|Given by mouth 2 gm orally daily plus physical activity
40758706|NCT02940223|BEHAVIORAL|Exercise Intervention|Complete resistance exercises and undergo walking program
40758707|NCT02940223|BEHAVIORAL|Exercise Intervention|Meet with exercise specialist and complete stretching exercises
40758708|NCT02940223|OTHER|Laboratory Biomarker Analysis|Correlative studies
40758709|NCT02940223|OTHER|Placebo|Given PO
40758710|NCT02940223|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
40758711|NCT02940223|OTHER|Questionnaire Administration|Ancillary studies
40758712|NCT00004228|DRUG|asparaginase|Given IV
40758713|NCT00004228|DRUG|cyclophosphamide|Given IV
40758714|NCT00004228|DRUG|cytarabine|Given IV
40758715|NCT00004228|DRUG|daunorubicin hydrochloride|Given IV
40758716|NCT00004228|DRUG|dexamethasone|Given IV
40758717|NCT00004228|DRUG|doxorubicin hydrochloride|Given IV
40758718|NCT00004228|DRUG|leucovorin calcium|Given IV
40990461|NCT04731376|OTHER|Best Practice|Receive standard peri-operative care
40758719|NCT00004228|DRUG|mercaptopurine|Given IV
40990462|NCT04731376|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
41287406|NCT03397485|DIETARY_SUPPLEMENT|Fortified milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
41287407|NCT03157557|BEHAVIORAL|Lifestyle treatment|Lifestyle treatment
41287408|NCT04946344|BEHAVIORAL|Diet & Exercise|Participants will attend exercise and diet classes.
41287409|NCT04946344|BEHAVIORAL|Attention Control|Participants will attend healthy living classes and receive phone calls/emails/texts.
41287410|NCT03406195|DEVICE|Transcranial magnetic stimulation (TMS)|TMS paradigm called theta burst stimulation
40948251|NCT04976062|DIAGNOSTIC_TEST|Combined near-infrared spectroscopy and intravascular ultrasound imaging (NIRS-IVUS)|The NIRS-IVUS technique is an intravascular imaging technique, combining morphological information derived from intravascular ultrasound (IVUS) and molecular information on plaque composition, namely its respective lipid-core burden, using spectral differences between cholesterol and collagen, detected by near-infrared spectroscopy (NIRS). A combined NIRS-IVUS pullback results in a color-coded map indicating the probability of lipid-rich plaque presence in yellow, co-registered to the corresponding IVUS cross-sections.
40948252|NCT05647057|COMBINATION_PRODUCT|A: gelofusine + ringers|750 milliliter (mL) modified fluid gelatin (Braun Melsungen, Germany), 650 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
40948253|NCT05647057|COMBINATION_PRODUCT|B: albumine + ringers|200 mL human albumin (20%, Sanquin, Amsterdam, Netherlands), 1200 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
40948254|NCT05647057|COMBINATION_PRODUCT|C: ringers + retrograde autologous priming|"1400 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands) with retrograde autologous priming.~Retrograde autologous priming (RAP) is applied using clinical parameters such as Central Venous Pressure, Mean Arterial Pressure (MAP), and intra cardiac filling pressure based on Trans Esophageal Echo as guidance to the amount of fluid displaced. RAP is applied to a maximum volume of 475 mL provided that systolic blood pressure will remain \>90 millimeter of mercury (mmHg). Phenylephrine can be administered up to 200 mcg to keep the system hemodynamics stable during RAP. In case of a body surface area \<1.7m2, a maximum volume of 375 mL is desired. Once the desired amount of prime is displaced, the transfusion bag is clamped and CPB is started. If additional fluids are needed during CPB to maintain optimal perfusion, the displaced prime is used prior to the vasoplegia protocol."
40948255|NCT00990873|GENETIC|gene expression analysis|
40948256|NCT00990873|GENETIC|microarray analysis|
40948257|NCT00990873|GENETIC|reverse transcriptase-polymerase chain reaction|
40948258|NCT00990873|OTHER|laboratory biomarker analysis|
40948259|NCT06283524|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
40948260|NCT01677546|DEVICE|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
40948261|NCT01677546|DEVICE|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
40948262|NCT00003052|DRUG|doxorubicin hydrochloride|
41287411|NCT04271163|DEVICE|MemorEM|The MemorEM device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range to the entire forebrain, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. Everyday for the 12M treatment period, the subject's caregiver will administer one or two 1-hour treatments (two daily treatments during the first 2M period).
41287412|NCT04382651|DRUG|MAS825|MAS825 liquid solution for intravenous infusion
41287413|NCT04382651|OTHER|Placebo|Placebo liquid solution for intravenous infusion
40948263|NCT00003052|DRUG|etoposide|
40948264|NCT00003052|DRUG|ifosfamide|
40948265|NCT00003052|PROCEDURE|conventional surgery|
40948266|NCT00003052|PROCEDURE|hyperthermia treatment|
40948267|NCT00003052|RADIATION|radiation therapy|
40948268|NCT02637154|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing method
40948269|NCT02637154|BEHAVIORAL|Standard Education|Standard Education material will be used
40948270|NCT05285657|DIAGNOSTIC_TEST|Two-step malaria RDT detecting PfHRP2/pLDH (SD Ag Bioline Malaria Ag P.f/Pan: Standard Diagnostics, Hagal-Dong, Korea)|"The interpretation of the two-step malaria RDT will be done as follow:~* PfHRP2(+)/pLDH(+): falciparum malaria or co-infection with non-falciparum malaria;~* PfHRP2(-)/pLDH(+): non-falciparum malaria or falciparum malaria with deletion of hrp2;~* PfHRP2(-)/pLDH(-): negative results~* PfHRP2(+)/pLDH(-): inconclusive results and information on previous antimalarial treatment is needed to differentiate:~Within the past 28 days:~* If previous antimalarial treatment is reported, the malaria diagnosis is reported as negative result. Nonetheless, the antimalarial treatment decision will be based on malaria microscopy;~* If previous antimalarial treatment is not reported, the malaria diagnosis is reported as positive result.~Other PoC tests for bacterial infections The two-step malaria RDT will be supported by PoC test listed above to diagnose bacterial or viral infection in all patients."
40990463|NCT04731376|OTHER|Questionnaire Administration|Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively
40990464|NCT04731376|DRUG|Testosterone Cypionate|Given IM
40990465|NCT01758185|BIOLOGICAL|recombinant hepatitis b vaccine|0.5ml intramuscular
41287414|NCT04382651|DRUG|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
41287415|NCT04500288|DEVICE|LEFT Device|LEFT device is a novel electronic wearable device that was developed as a sleep position therapy for patients who suffer from nighttime gastroesophageal reflux symptoms. It is simple, noninvasive and low-cost technology which has been developed by Side Sleep Technologies B.V. Singel, Amesterdam, The Netherland.
40948271|NCT01245920|BIOLOGICAL|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
40948272|NCT01245920|OTHER|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
40948273|NCT06009029|RADIATION|Stereotactic body radiation(SBRT)|"SBRT: 7-10 Gy/F, 5 doses~Zimberelimab: 240mg d1 iv Q21D, within 7 days after SBRT completion. Receiving a minimum of six cycles of treatment, or disease progression or intolerable toxic side effects."
40948274|NCT06009029|DRUG|Zimberelimab (GLS-010)|Zimberelimab (GLS-010),240mg d1 iv Q21D
40948275|NCT00485433|DRUG|Bupivacaine HCl|Bupivacaine HCl given during hernia repair
40948276|NCT00485433|DRUG|SKY0402|SKY0402 given during hernia repair
40948277|NCT06417125|DRUG|Dexmedetomidine Hydrochloride|Patients were premedicated with intranasal dexmedetomidine 2 μg/kg in the holding area.
40948278|NCT06417125|DRUG|Midazolam|Patients were premedicated with oral midazolam 0.5 mg/kg in the holding area.
40948279|NCT06417125|DRUG|normal Saline|Patients were premedicated with normal saline 0.02 mL/kg in the holding area.
40948280|NCT06417125|DRUG|Glucose solution|Patients were premedicated with oral sweet solution 0.25 mL/kg in the holding area.
40948281|NCT05119673|OTHER|bi-plane sonographic view to difficult peripheral vascular access using Butterfly iQ+®|Bi-plane Butterfly iQ+® sonographic visualization will be used to help Emergency Department operators to get a venous peripheral access in a population of patients considered difficult for this task based on their history or the present clinical situation.
40948282|NCT06248567|DRUG|ZSP1273|Oral
40948283|NCT04863547|OTHER|Data collection|Data collection
40948284|NCT03285984|OTHER|67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride|Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
40948285|NCT03285984|OTHER|67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride|Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
40948286|NCT03285984|OTHER|62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium|Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
40948287|NCT03285984|OTHER|0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride|Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
40948288|NCT00721123|DRUG|Tocilizumab|Tocilizumab (myeloma receptor antibody \[MRA\]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
40948289|NCT05005910|DRUG|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours)
40948290|NCT05005910|DRUG|PPIs IV infusion|Pantoprazole 80 mg IV loading then 8 mg/hr
40948291|NCT05916820|OTHER|Tanzberger Exercises|It consists of patients who will receive Tanzberger exercise 3 sessions per week for 4 weeks. e.g. Rolling on the ball forward, Back to back sitting.
40948292|NCT05916820|OTHER|Pelvic floor muscle training|It consists of patients who will pelvic floor muscles exercise 3 sessions per week for 4 weeks. e.g. Assisted heel drop, Bridge, Dead Bug, Bird DOG
40948293|NCT03527030|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of the Greater London area.
40948294|NCT03527030|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in users of IQOS residing in the Greater London area.
40948295|NCT05361421|DRUG|Intensive targeting group|Intensive lipid lowering therapy with LDL-cholesterol goal of \<55mg/dL. Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use and ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by the discretion of the investigator.
40948296|NCT05361421|DRUG|Conventional therapy group|Only moderate intensity statin therapy (atorvastatin 5, 10, and 20mg ) are allowed. Ezetimibe or PCSK-9 inhibitor is not allowed to use.
40948297|NCT04834674|COMBINATION_PRODUCT|DEB-TACE combined with apatinib and PD-1 antibody|combination of local therapy (DEB-TACE), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)
40948298|NCT01047735|PROCEDURE|Roux-en-Y Gastric Bypass Surgery|Participants assigned to the Roux-en-Y Gastric Bypass treatment group will undergo a surgical procedure that limit foods intake and causes nutrients malabsorption. The procedure is performed with small incisions or laparoscopically. A small stomach pouch is created, the size of an egg, and the small intestine is connected to the pouch. Some of the stomach and small intestine are consequently bypassed by this anatomic change. Those in this treatment group will begin a gradual diet post surgery and will take life long vitamin supplements.
40948299|NCT01047735|PROCEDURE|Laparoscopic Adjustable Gastric Banding|Those assigned to the Laparoscopic Adjustable Gastric Banding study group will undergo a surgical procedure where an adjustable silicone band is placed around the upper stomach to decrease its capacity so that you will feel full sooner. It will assist in weight loss by helping you to limit intake of calories. The band will be placed by using several small incisions and telescopic instruments. A thin tube connects the band to an access port just under the skin that you may be able to feel but you will not be able to see it. This allows the band to be tightened or loosened to decrease or increase your stomach capacity as needed. The surgery will take on average 30-45 minutes.
40990466|NCT01758185|BIOLOGICAL|Aleph influenza vaccine|0.5ml intramuscular
40990467|NCT00930995|DRUG|Candesartan|16mg po daily
40990468|NCT00930995|DRUG|Placebo|once daily
40990469|NCT06490328|DRUG|DKF-MA102|Administered twice at 12-week intervals
40948300|NCT01047735|BEHAVIORAL|Lifestyle Weight Loss Intervention|Participants will receive a standard behavior weight control program in an in-person format over a period of 12 months conducted by an experienced team of weight loss counselors. During the initial 6 months of study treatment, will attend weekly in-person individual sessions with a weight loss counselor. During months 7-12, will attend in-person sessions on the 1st and 3rd week of the month and will receive a brief (less than 10 minutes in duration) telephone call on the 2nd and 4th week of the month. Each session will focus on a specific behavioral topic related to weight loss, eating behaviors, or exercise behaviors.
40948301|NCT04171765|DRUG|Placebo|Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
40948302|NCT04171765|DRUG|BFKB8488A|Participants will receive subcutaneous (SC) BFKB8488A.
40948303|NCT00751166|DRUG|Desloratadine|Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
40948304|NCT00751166|DRUG|Cetirizine|Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
40948305|NCT00751166|DRUG|placebo|placebo once daily for 28 days
40948306|NCT04165473|BEHAVIORAL|Training Program for Developing Social- and Personal Resources|"The training-method shows how one's own resonance can be exposed in order to live the balance between one's own needs and those of others.~Living one's own resonance means: more quality of life, work-life balance, holistic health through living feelings and talents, live equal, respectful and loving relationships, more personal responsibility, authentic decision making find new role models in private and professional areas.~The teaching and learning methods of the trainings and seminars are implemented according to the latest state of brain research and enable new perspectives with regard to new learning strategies, goals, enthusiasm and motivation.~With the Kutschera-Resonanz® method we teach and learn to consciously use this unconscious reservoir so that completely new dimensions in thinking and acting open up.~In this training program the basic tools of communication and interaction according to the Kutschera-Resonanz® method are taught and experienced by the participants."
40948307|NCT01100346|DRUG|Gonal-f (Follitropin alpha)|A starting dose of 75 IU/day subcutaneously is maintained for a period of 7 to 14 days. The follitropin alpha dose would be subsequently increased by 37.5 IU/day at weekly intervals based on the ovarian response.
40948308|NCT05995808|PROCEDURE|Bone marow biopsy and aspiration|Bone marrow biopsy and biopsy aspiration
40948309|NCT05995808|DIAGNOSTIC_TEST|biochemical and heamatological tests|complete blood count ,serum urea and creatinine
40948310|NCT04355507|DIAGNOSTIC_TEST|Chest computed tomography (CT)|Chest computed tomography (CT) examination
40948311|NCT04355507|DIAGNOSTIC_TEST|Reverse-transcription polymerase chain reaction (RT-PCR)|Identification of viral RNA by reverse-transcription polymerase chain reaction
40948312|NCT00932126|DRUG|PF-03758309|Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
40948313|NCT00810693|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
40948314|NCT00810693|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
41287416|NCT01109706|OTHER|biological parameters dosage|"200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).~After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).~Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up."
41287417|NCT03767010|OTHER|Control (no PLM)|Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
40948315|NCT00810693|DRUG|Placebo|Matching Placebo tid orally for 12 weeks
40948316|NCT00002651|DRUG|bicalutamide|Given orally
40948317|NCT00002651|DRUG|goserelin acetate|Given subcutaneously
40948318|NCT00002651|OTHER|clinical observation|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
40948319|NCT05173597|DRUG|Follitropin delta|REKOVELLE® (follitropin delta), solution for injection - delivered with an injection pen, ATC code G03GA10, is a recombinant human FSH approved for the controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.
40948320|NCT05224414|BEHAVIORAL|Cognitive bias modification for interpretation bias|Sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
40948321|NCT05224414|BEHAVIORAL|Psychoeducation|Sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
40948322|NCT04232774|DEVICE|The Neurotronic arterial ablation catheter|a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.
40948323|NCT02787460|BEHAVIORAL|Behavioral Text Messages|
40948324|NCT03157960|OTHER|Blueberry drink|Participant receive blueberry drink
40948325|NCT03157960|OTHER|Blueberry and pizza|Participant receive blueberry drink and a slice of pizza
41287418|NCT03767010|OTHER|PLM|PLM Participants will take the PLM on the location of the brachial plexus at the level of the interscalene groove on surface ultrasound images. They will also take a pretest, a post-test and a delayed test at 6 months. Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
41287419|NCT03692273|PROCEDURE|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
40948326|NCT03157960|OTHER|Soft beverage|Participant receive a soft beverage drink
41287420|NCT03692273|PROCEDURE|0.5mm punch biopsy|punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
41287421|NCT01824602|DRUG|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
40758720|NCT00004228|DRUG|methotrexate|Given IV
40758721|NCT00004228|DRUG|prednisone|Given IV
40758722|NCT00004228|DRUG|thioguanine|Given PO
40948327|NCT03157960|OTHER|Soft beverage and pizza|Participant receive a soft beverage drink and a slice of pizza
40948328|NCT03157960|OTHER|Fructose|Participant receive a drink containing fructose
40948329|NCT03157960|OTHER|Fructose and pizza|Participant receive a fructose drink and a slice of pizza
40948330|NCT01291953|PROCEDURE|Screening|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
40948331|NCT01291953|PROCEDURE|Control|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
41287422|NCT01824602|DRUG|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
41287423|NCT01824602|DRUG|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
41287424|NCT01824602|DRUG|Placebo|Placebo sugar pills
41287425|NCT03440112|DRUG|Clarithromycin (Not used as of 4/2020)|Clarithromycin (generic) capsule 250mg each
41287426|NCT03440112|DRUG|Placebo (Not used as of 4/2020)|Lactose in a gel capsule
41287427|NCT03440112|DRUG|Transdermal flumazenil (Added 4/2020)|Transdermal flumazenil 24mg/mL
41287428|NCT03440112|DRUG|Placebo (Added 4/2020)|Transdermal placebo
40948332|NCT04690348|PROCEDURE|Craniotomy|Craniotomy
40948333|NCT04690348|RADIATION|Cesium-131 brachytherapy|Intracavitary Cesium-131 brachytherapy
40948334|NCT04853030|DRUG|Fiasp|Advanced closed-loop insulin therapy with Faster acting insulin Aspart (Fiasp)
40948335|NCT04853030|DRUG|Novorapid|Advanced closed-loop insulin therapy with Standard acting insulin Aspart (Novorapid
40948336|NCT01558193|DIETARY_SUPPLEMENT|Placebo|"Placebo for DHA of identical appearance - based on olive oil~Placebo for vitamins/minerals of identical appearance"
40948337|NCT01558193|DIETARY_SUPPLEMENT|Multi-vitamin/mineral|Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
40948338|NCT01558193|DIETARY_SUPPLEMENT|Docosahexaenoic acid|22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
40948339|NCT01558193|DIETARY_SUPPLEMENT|DHA plus vitamins/minerals|The DHA and vitamin/mineral supplements are as above
40948340|NCT06324331|PROCEDURE|Decidual sparing|Endometrial free uterine closure technique
41287429|NCT02862912|DRUG|Chloroprocaine|Administered as a single injection or continuously through an indwelling catheter - 50 mg
41287430|NCT02862912|DRUG|Bupivacaine|A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
41287431|NCT02862912|DRUG|Fentanyl|15 mcg Fentanyl will be included int he spinal anesthetic in both groups
41287432|NCT02862912|DRUG|Saline|Preservative free normal saline (0.3 ml) to bring the volume to \~ 2 ml
41287433|NCT01409889|BEHAVIORAL|Diabetes Prevention Program|
40948341|NCT06324331|PROCEDURE|Non decidual sparing|Routine uterine closure technique including endometrium
40948342|NCT05726916|DRUG|Soliris®|Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
40948343|NCT05726916|DRUG|Renin angiotensin system blockers|Blood pressure control with renin angiotensin system blockers
40948344|NCT04172896|PROCEDURE|Intraperitoneal Uterosacral Ligament Suspension|Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
40948345|NCT04172896|PROCEDURE|Extraperitoneal Uterosacral Ligament Suspension|Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
40948346|NCT01252381|OTHER|12 weeks Strength exercise training|Training 3 times a week, leg extensions and leg press
41287434|NCT01409889|BEHAVIORAL|Healthy Living Program|
41287435|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
41287436|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
40948347|NCT04294667|DRUG|DZP|Subjects will receive dapirolizumab pegol at prespecified time-points.
40948348|NCT04294667|OTHER|Placebo|Subjects will receive placebo at prespecified time-points.
41287437|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
40948349|NCT00147212|DRUG|ET 743|ET-743 administered IV by 24-hr infusion every 3 weeks
40948350|NCT05792787|DIAGNOSTIC_TEST|Echo-color-doppler|"To perform the initial screening patients will undergo panoramic radiography and clinical examination followed by periapical radiographs of the teeth suspected of AP using the long cone paralleling technique with a film holder. The following parameters will be recorded:~1. The number of decayed, missing and filled teeth (DMFT index)~2. The number of teeth with AP~3. Periapical Index Score All individuals will undergo a cardiovascular examination in the Unit of Vascular Surgery, University of Siena (Siena, Italy). The cardiovascular assessment included physical examination, blood pressure measurement, past medical history and echo-color-doppler for the assessment of carotid intima-media thickness (cIMT), presence of abdominal aortic aneurysm and presence of peripheral pulses."
40948351|NCT00903318|BEHAVIORAL|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
40948352|NCT01341197|OTHER|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
40948353|NCT01931618|BEHAVIORAL|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
40948354|NCT01931618|BEHAVIORAL|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
40948355|NCT01931618|BEHAVIORAL|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
40948356|NCT04336410|DRUG|INO-4800|INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.
40948357|NCT04336410|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.
40948358|NCT03731845|GENETIC|Blood sample for genetic test|Patients will be genotyped for single nucleotide polymorphism previously found to be associated with age at natural menopause
40948359|NCT03731845|BIOLOGICAL|Blood sample for hormonal measurement|at each visit : 2x7ml. At the end of the study hormonal measurements (AMH, P4, LH, FSH, E25)
40948360|NCT03731845|OTHER|Ovarian ultrasound scan|Ovarian ultrasound scan at follow up visits (Y1,Y1.5, Y2.5 Y3.5 Y4.5 Y5.5)
40948361|NCT03306810|OTHER|AG service|The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
40948362|NCT00444652|DRUG|Enoxaparin|injection of enoxaparin a few time
40948363|NCT01052376|DEVICE|Confocal endomicroscopy|
40948364|NCT00524654|PROCEDURE|HVLA chiropractic manipulation|
40948365|NCT06557252|BEHAVIORAL|PDCA training|Improve diagnostic rate
40948366|NCT02476422|DRUG|Diclofenac potassium|Single dose of diclofenac 50 mg soft gelatin capsule
40948367|NCT02476422|DRUG|Ibuprofen|Single dose of ibuprofen 400 mg tablet
40948368|NCT02476422|DRUG|Placebo to ibuprofen|Single dose of placebo to ibuprofen 400 mg tablet
40948369|NCT02476422|DRUG|Placebo to diclofenac potassium|Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
40948370|NCT06427473|BEHAVIORAL|Dietary program|Participants will attend 8-week online dietary course. In addition to weekly classes, participants are required to photograph each meal.
40948371|NCT06427473|BEHAVIORAL|Exercise program|Everyday walking steps more than 4000 steps. To accurately track participants' daily step counts, the research team provided quailfied pedometers.
40948372|NCT06427473|BEHAVIORAL|Mindfulness program|Participants will attend 8-week online mindfulness course. In addition to weekly classes, participants practiced mindfulness individually for 5 minutes each day and maintained a mindfulness diary.
40948373|NCT05745623|DRUG|ICP-723|ICP-723 tablet administered orally，once a day，for every 28 days as one cycle
40948374|NCT02328417|OTHER|Consecutive radical cystectomies|Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
40948375|NCT00384254|BEHAVIORAL|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
40948376|NCT00384254|BEHAVIORAL|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
40948377|NCT04567823|DIETARY_SUPPLEMENT|Smoothie with microalgae|Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
40948378|NCT06097182|DIETARY_SUPPLEMENT|Post-biotic (Colonic-Delivery capsule)|250mg post-biotic once daily in a polymer coated vegan gelatine capsule (colonic delivery)
40948379|NCT06097182|DIETARY_SUPPLEMENT|Post-biotic (Regular Administration capsule)|250mg post-biotic once daily in a regular uncoated vegan gelatine capsule
40948380|NCT06097182|OTHER|Placebo|250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
41287438|NCT00772460|DEVICE|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
40758723|NCT00004228|DRUG|vincristine sulfate|Given IV
40758724|NCT00004228|RADIATION|radiation therapy|
40948381|NCT01923987|RADIATION|Short Course Radiotherapy|Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
40990470|NCT04682626|DIETARY_SUPPLEMENT|Soft gelatin capsules each contains 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.|Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
40990471|NCT01056809|PROCEDURE|Chemotherapy and surgery|Treatment not specified but in accordance with national guidelines
40990472|NCT06454409|DRUG|Azacitidine|Given IV
40990473|NCT06454409|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40948382|NCT01923987|DRUG|Chemotherapy|"* Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~* Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~* Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~* 5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~* Bevacizumab 5 mg/kg IV over 90 mins on Day 1~* Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~* FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~* Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)"
40948383|NCT01923987|PROCEDURE|Delayed Surgery|If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
40948384|NCT03009409|DRUG|Ketamine Injectable Solution|"Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.25 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (5 mcg/kg/min to a maximum of 60 mg/hour) will be initiated by the anesthetist through the pump interface.~The study drug will be infused at a constant rate of 5 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 100 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 2.5 mcg/kg/min), or stop the infusion entirely."
40948385|NCT03009409|OTHER|Placebo|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
40948386|NCT00907712|OTHER|cardiac echo examination|cardiac echo examination - before and after the surgery
40948387|NCT00610623|DRUG|azithromycin|300 mg/day, IV from day 1 to 20
40948388|NCT00610623|DRUG|placebo|once per day, IV from day 1 to 20
40948389|NCT00161473|DRUG|prazosin|"Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.~Duration was 8 weeks."
40948390|NCT00161473|DRUG|placebo (inert substance)|Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
40948391|NCT00369122|BIOLOGICAL|Bevacizumab|Given IV
40948392|NCT00369122|DRUG|Cisplatin|Given IV
40948393|NCT00369122|RADIATION|External Beam Radiation Therapy|Undergo EBRT
40948394|NCT00369122|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
40948395|NCT00854542|BEHAVIORAL|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
40948396|NCT06556784|BEHAVIORAL|12-week at-home immersive virtual reality exergame|12-week training of at least 150 minutes per week at-home immersive virtual reality exergame playing with a set device of Meta Quest 2 and maintaining regular eating and working habits without making significant changes.
40948397|NCT06430320|OTHER|NA- no intervention|NA- no intervention
40948398|NCT04269590|BEHAVIORAL|Dual Task (DT) training|Participants will practice the Swipe Slide Pattern (SSP) task in combination with a secondary task, i.e. counting red or green lights. On day 1, participants perform 2 runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, 9 trials of 30s are performed, alternated with rest periods of 14s. Instructions are provided before each trial (i.e. view of the pattern in combination with instruction to count red or green lights, 4s), as well as an answer option (i.e. participants have to indicate how many red or green lights they counted by circling a number from zero to nine, 6s). For the following 4 days, participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. During at home practice, the same pattern as during scans is included, in combination with 2 new patterns.
40948399|NCT04269590|BEHAVIORAL|Single Task (ST) training|Participants will practice the Swipe Slide Pattern (SSP) task without the presence of a secondary task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
40948400|NCT01931930|DIETARY_SUPPLEMENT|Perilla extract|
40948401|NCT01931930|DIETARY_SUPPLEMENT|Maltodextrin|
40948402|NCT04161027|DRUG|Pregabalin 75mg|Pregabalin 75 mg capsule
40948403|NCT04161027|DRUG|Placebos|Placebo capsule
40948404|NCT01727843|DRUG|Tranexamic Acid|drug and placebo applied topically at end of surgery at hip site.
40948405|NCT01727843|OTHER|placebo|applied topically to surgical site in OR.
40948406|NCT04764487|DEVICE|KidneyPRO|Web-application for symptoms assessment
40948407|NCT04764487|OTHER|standard follow-up|usual follow-up
40948408|NCT00040339|PROCEDURE|hypothermia (body temperature lowered to 33°C or 91.4°F)|
40948409|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
40948410|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
40948411|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
40948412|NCT00809848|DRUG|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
40948413|NCT00809848|DRUG|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
40948414|NCT02215096|DRUG|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
40948415|NCT02215096|DRUG|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
40948416|NCT05132634|OTHER|Hand Massage|Like a massage, the superficial kneading technique which is included in the Swedish massage technique will be applied in a way to create a slight pressure on the patient, and it will be terminated again with the effleurage technique. The procedure was concluded in a way that each massage technique was applied and the massage was for a total of 15-20 minutes.
40948417|NCT01270854|OTHER|Plasmalyte A|Intravenous fluid
40948418|NCT01270854|OTHER|Normal Saline|Intravenous fluid
40948419|NCT01356927|DRUG|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
40948420|NCT01356927|DRUG|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
40948421|NCT02286583|DEVICE|Microwave Thermography RTM-01-RES|Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
40948422|NCT00871325|DRUG|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
40948423|NCT00871325|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
40948424|NCT00871325|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
40948425|NCT04864418|DRUG|AST-021p|3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization
40948426|NCT05421871|BEHAVIORAL|Spinal Stabilization Exercises|Spinal Stabilization Exercises technique
40948427|NCT05421871|BEHAVIORAL|Maitland Mobilization Along With Laser Therapy|Maitland Mobilization Along With Laser Therapy technique
41287439|NCT04561388|PROCEDURE|Electrocochleography|"Electrocochleographic responses will be evoked using different pure tone sounds delivered through an insert placed in the external auditory duct. The responses will be recorded with the electrodes of the cochlear implant connected to a dedicated interface.~Electrocochleographic responses will be collected continuously during the electrode-array insertion at the implantation surgery using 500Hz pure tone and after suturing with 250, 500, 750 and 1000Hz pure tones. Then, electrocochleographic responses to pure tones from 125 to 8000HZ (according to the subject residual hearing) will be recorded 2 weeks, 1 month, 2 months and 4 months after implantation."
41287440|NCT04561388|OTHER|Pure Tone Audiometry|"The perception thresholds to 125, 250, 500, 750, 1000, 2000, 4000 and 8000 Hz pure tones will be measured within the month preceding the implantation using the same insert t.~Pure tone audiometry with the same frequencies will be done 2 weeks, 1, 2 and 4 months after the implantation."
40948428|NCT06134960|BIOLOGICAL|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
40948429|NCT01333579|OTHER|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
40948430|NCT04668573|OTHER|Trunk exercise|Trunk exercise includes trunk muscles stretching, trunk muscles strengthening, and task-related trunk control training for 30 minutes per session, twice a week for 12 weeks.
40948431|NCT04956952|DEVICE|EECP|1 hour of treatment with EECP
40948432|NCT04200573|DRUG|Ampreloxetine|The study drug will be administered orally as a single Dose A tablet
40948433|NCT03819426|BEHAVIORAL|Low Intensity Exercise Intervention|Those in the walking intervention will be instructed to take walks below a brisk pace (low intensity) to improve mood
41287441|NCT04561388|OTHER|Speech audiometry|The speech perception will be assessed in silence and in noise in free field 1 and 4 months after implantation. The speech perception in silence will be assessed using monosyllabic words 60 dB SPL. Speech in noise will be assessed using an adaptative test with fixed noise level (60 dB SPL).
40948434|NCT03819426|BEHAVIORAL|High Intensity Intervention|Instructed in high intensity interval training techniques and will be provided videos to follow for implementation of intervention at home that will include short bursts of high energy
40948435|NCT03824418|PROCEDURE|Surveillance colonoscopy with chromoendoscopy|Surveillance colonoscopy with chromoendoscopy
40948436|NCT01822678|DRUG|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
40948437|NCT01822678|DRUG|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
40948438|NCT01822678|DRUG|Placebo|Placebo
40948439|NCT02030938|DEVICE|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
40948440|NCT03053583|DEVICE|Laryngoscope blade|The POGO score assesses the percent of the glottic opening that can be seen with each blade
40948441|NCT02854150|GENETIC|characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.|
40948442|NCT03081975|DEVICE|HD white light or NBI|Use of NBI or HD white light
41287442|NCT02446366|OTHER|Laboratory Biomarker Analysis|Correlative studies
41287443|NCT02446366|OTHER|Quality-of-Life Assessment|Ancillary studies
41287444|NCT02446366|RADIATION|Stereotactic Body Radiation Therapy|Undergo hypofractionated SBRT
41287445|NCT05102981|PROCEDURE|emergency procedure|The difference between groups is the timing or type ie emergency as opposed to planned
41287446|NCT00581503|DEVICE|diagnostic|oct imaging
40758725|NCT01414647|DIETARY_SUPPLEMENT|300 g of strawberry, raspberry and cloudberry|100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
41287447|NCT05857956|OTHER|Proper Wild energy shot|100% plant-based energy shot containing natural caffeine, L-Theanine, purified water, pineapple juice concentrate, natural flavors, kiwi juice concentrate, organic lemon juice concentrate, organic strawberry juice concentrate, monk fruit juice concentrate, pink himalayan sea salt.
41287448|NCT03389334|OTHER|massage|The techniques include myofascial release and manual active and passive stretching with the intention to lengthen overly contracted or shortened tissue, increase range of motion, and restore any malpositioning of structural landmarks as defined by its contralateral counterpart. By addressing the symptoms of the somatic dysfunction, you will in turn reduce the overall perceived pain in the body caused in these related tissues. The duration of each massage treatment session will be 45 minutes long and therapists will use a timer to ensure all subjects receive the same length of treatment. Patients will continue to receive treatment from the same therapist to maintain consistency of results.
40758726|NCT01414647|DIETARY_SUPPLEMENT|400 g of bilberry|Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
40758727|NCT01414647|OTHER|Control diet|Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
40758728|NCT06446323|DRUG|0.2 ml dose of sucrose|Both interventions aim to provide pain relief to neonates following minor procedures by administering sucrose solution orally. The study evaluates the efficacy of each dose (0.2 ml vs. 0.5 ml) in reducing post-procedural pain intensity, as measured by the Premature Infant Pain Profile (PIPP). Additionally, any adverse events associated with the administration of sucrose solution are documented and analyzed as part of the study.
40758729|NCT03818971|OTHER|electroretinogram (flash, pattern and multifocal)|we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
40758730|NCT03211845|OTHER|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self-measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
40758731|NCT06501105|DEVICE|WOUNDCHEK Bacterial Status|Lateral flow point of care test for the qualitative detection of bacterial protease activity in wound fluid.
40758732|NCT06269666|DEVICE|P200TxE|SLO and OCT imaging
40758733|NCT01258985|BEHAVIORAL|Tai Chi|12 weeks of Tai Chi
41287449|NCT03321812|PROCEDURE|decalcification bone scaffold|Decalcification bone scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.
41287450|NCT03321812|PROCEDURE|microfracture|Microfracture is the surgical option for conventional treatment of cartilage defects.
41453705|NCT01669980|DRUG|IV Ceftriaxone and Vancomycin|"* IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND~* IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
40758734|NCT01258985|BEHAVIORAL|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
40948443|NCT00120523|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
40948444|NCT00120523|DRUG|Topical corticosteroids|TCS
41287451|NCT01441544|BEHAVIORAL|Variety of Active Videogames|Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
41453706|NCT04878211|DRUG|Ofatumumab|3 loading doses followed by monthly administrations
41453707|NCT04878211|BIOLOGICAL|mRNA COVID-19 vaccine|Pfizer or Moderna mRNA Vaccine
41453708|NCT04878211|DRUG|interferon or glatiramer acetate|iDMT
41287452|NCT02682329|OTHER|Hydrogen Peroxide and Carbamide Peroxide|Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
41287453|NCT02682329|OTHER|Hydrogen Peroxide and Hydrogen Peroxide|Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
41287454|NCT01405079|DRUG|Gefitinib|Gefitinib 250 mg/day oral daily
40758735|NCT03810365|BEHAVIORAL|Brief behavioral treatment for insomnia|Brief Behavioral Treatment for Insomnia includes content on sleep restriction, stimulus control, and sleep hygiene content with 1 month for primary outcome followed by 3 month 12 month follow-up visits.
40948445|NCT02502175|DRUG|opium|Opium tincture (10mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
40948446|NCT02502175|DRUG|methadone|Methadone (5mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
41287455|NCT01405079|DRUG|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
40948447|NCT00970073|BIOLOGICAL|Thymoglobulin 3mg total|1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
41287456|NCT00153166|DRUG|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
41287457|NCT00153166|DRUG|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
41287458|NCT00153166|DRUG|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
41287459|NCT00153166|DRUG|placebo/placebo|placebo orally three times daily
41287460|NCT01825434|DIETARY_SUPPLEMENT|yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019|NCFM Group
41287461|NCT04666883|OTHER|Review of records and follow up|Follow up to identify patients who developed splenic hilar nodal metastases
41287462|NCT03685656|OTHER|Slimming gel|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
41287463|NCT03685656|OTHER|Slimming gel placebo|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
41287464|NCT06128941|OTHER|Repeated sprint|"* Duration of the study: 8 weeks of participation.~* Each repeated sprint training protocol: 2 training sessions per week for 4 weeks.~* Collection sessions: 3 collection sessions will be carried out: before the start of the training protocol - T0; at the end of the protocol, in week 4 - T1; and late, 4 weeks after the end of the protocol, in week 8 - T2.~* Training sessions: will be carried out on an ergometer and will consist of 3 sets of 5 sprints of 10s all-out with 20s of rest between sprints, and 5 minutes of rest between sets."
40758736|NCT03810365|BEHAVIORAL|Healthy Eating Control|Healthy eating control involves healthy eating content with 1 month for primary outcome followed by 3 month and 12 month follow-up visits.
40758737|NCT03098706|PROCEDURE|Procedure control: normothermia|Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
41287465|NCT00191529|DRUG|somatropin|
40758738|NCT03098706|PROCEDURE|Procedure active|Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
40758739|NCT02163356|DRUG|Fenretinide/LXS Oral Powder|Oral Powder
40758740|NCT02163356|DRUG|Ketoconazole|Oral Tablet
40758741|NCT02163356|DRUG|Vincristine|IV
40758742|NCT00930800|OTHER|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
40758743|NCT01044459|DRUG|Aclidinium Bromide 200 µg|aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
40948448|NCT00970073|BIOLOGICAL|Thymoglobulin 4.5mg total|1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
40948449|NCT00970073|DRUG|Mycophenolate mofetil|1000 mg PO/IV BID for up to 6 months
40948450|NCT00970073|DRUG|tacrolimus 3-8|Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
40948451|NCT00970073|DRUG|tacrolimus 8-12|Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
40948452|NCT00011973|DRUG|fenretinide|
40948453|NCT02937428|BEHAVIORAL|Look away from the needle|Participant looks away from the needle during vaccination
40948454|NCT02937428|BEHAVIORAL|Look at the needle|Participant looks at the needle during vaccination
40948455|NCT04786392|DIETARY_SUPPLEMENT|Lutein supplement|5 mg lutein supplement.
40948456|NCT04786392|OTHER|Food, blended|5 mg lutein from baby spinach, blended.
40948457|NCT04786392|OTHER|Food, unprocessed|5 mg lutein from baby spinach, in whole food form.
40948458|NCT05073640|DRUG|Oxopurin|Subjects will receive two capsules per day.
40948459|NCT04962048|DEVICE|pulse-synchronized negative pressure (PSNP) device|The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.
40948460|NCT04962048|OTHER|Control - no intervention|The other leg serves as non-treated control
41287466|NCT03004846|DRUG|GSK2981278 ointment|"GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.~GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas ."
41287467|NCT03004846|DRUG|Vehicle ointment|It will be supplied as white to off-white vehicle ointment for topical application.
40948461|NCT03024879|DRUG|Erythromycin|
40948462|NCT03024879|DRUG|Saline|
41287468|NCT01618656|DRUG|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
41453709|NCT00288704|DRUG|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
41453710|NCT00288704|DRUG|Placebo|Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
41453711|NCT00288704|DRUG|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
41453712|NCT04892420|DRUG|Dexamethasone|The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia.
41453713|NCT04892420|DRUG|Dexmedetomidine|The patients receive 20 ml plain bupivacaine(0.5)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
41453714|NCT04892420|DRUG|Magnesium sulfate|The patients receive 20 ml plain bupivacaine(0.5)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
41453715|NCT04892420|DRUG|Bupivacain|The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
41453716|NCT01711801|DRUG|Placebo|Single ascending dose
41453717|NCT01711801|DRUG|RO5545965|Single ascending dose
41453718|NCT01711801|DRUG|RO5545965|Single dose, in fed and fasted state
41453719|NCT00473954|GENETIC|EGEN-001 (phIL-12-005/PPC)|"In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals."
41453720|NCT05284539|DRUG|Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab|Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.
40948463|NCT06009978|DEVICE|Neuromuscular electrical stimulation (NMES)|Neuromuscular electrical stimulation (NMES) 2 times a day á 15 minutes from the third to the eight week after injury. The additional treatment will be perform in the patients home by themselves
41287469|NCT01618656|DRUG|Placebo|Sugar pill
41287470|NCT04673903|OTHER|Copenhagen adduction exercise|The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.
41453721|NCT03040895|OTHER|Group-based ICDP-intervention|Group-based ICDP-intervention for caregivers through a sequence of eight meetings
41287471|NCT04673903|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
41287472|NCT00002669|BIOLOGICAL|aldesleukin|
41287473|NCT00002669|BIOLOGICAL|recombinant interferon alfa|
41453722|NCT03040895|OTHER|Treatment as usual|Treatment as usual through the data collection period (6 months)
41453723|NCT05453487|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine
41453724|NCT05453487|BIOLOGICAL|COVID-19 vaccine|received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)
41453725|NCT05453487|BIOLOGICAL|rabies vaccine|received three dose of rabies vaccine
41453726|NCT01415596|DRUG|salbutamol|
41453727|NCT01415596|DRUG|Placebo|
40948464|NCT04642807|PROCEDURE|Long arm soft cast|Participants in group 2 will have a long arm soft cast applied without clinical or radiological follow up.
40948465|NCT04642807|PROCEDURE|Long arm full cast|Participants in group 1 will have a long arm full cast applied.
40948466|NCT00328549|DRUG|Pegylated Interferon and Ribavirin|
40948467|NCT02846545|BIOLOGICAL|Golimumab|Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
40948468|NCT02846545|BIOLOGICAL|Placebo|Matching Placebo to golimumab.
40948469|NCT03081468|DEVICE|Binocular OCT prototype|Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
40990474|NCT06454409|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40990475|NCT06454409|DRUG|Regorafenib|Given PO
41287474|NCT00002669|DRUG|cisplatin|
41287475|NCT00002669|DRUG|dacarbazine|
41287476|NCT03937986|DRUG|Suvorexant|The pharmacodynamic effects of suvorexant maintenance will be determined.
41287477|NCT03937986|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
41453728|NCT05280080|OTHER|Resistance exercise|Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.
41453729|NCT02439515|DEVICE|Cycling|Voluntary cycling augmented by electrical stimulation and biofeedback
41453730|NCT02439515|DEVICE|Balance|Balance control exercises with visual biofeedback
41287478|NCT03937986|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
41287479|NCT03260023|BIOLOGICAL|TG4001|PhIb: Dose escalation PhII: Established RP2D for TG4001
41287480|NCT03260023|DRUG|Avelumab|Anti PD-L1
41287481|NCT05057624|OTHER|Placebo GC-MRT|Participants will hear music continuously throughout the trials, without regard to the faces they look at.
41287482|NCT05057624|OTHER|GC-MRT|Participants will hear music as a reward for looking at neutral faces and the music will stop when they focus on angry faces.
41287483|NCT05057624|OTHER|Exposure|Participants will hear music of their choice when they focus on angry faces, and when they look at neutral faces the music will stop.
41453731|NCT02439515|OTHER|Standard physical therapy|It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
41453732|NCT05649358|DEVICE|Lactate sensor (Lactisense)|Non-invasive monitoring of interstitial lactate levels during and after exercise.
41453733|NCT02263703|BIOLOGICAL|Quadrivalent HPV vaccine|Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
41453734|NCT05488158|OTHER|Osteopathic manipulation|Pain and somatic disfunction were treated with osteopathic manipulations as deemed appropriate by a trained DO.
41453735|NCT03813290|DEVICE|Neuro-technological Intervention|During the intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. Each session will begin with a brief audio-guided mindfulness practice, follow by a 15 minutes VR game. Game performances will be influenced by individual's level of anxiety arousal and ability to regulate it.
41453736|NCT01059058|PROCEDURE|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
40758744|NCT01044459|DRUG|Aclidinium Bromide 400 µg|aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
40758745|NCT02025218|DRUG|Gefitinib standard dose|
40758746|NCT04491708|OTHER|Pilates exercises|The participants attended two half-hour Pilates exercise classes twice a week, for one month, to familiarize themselves with the exercises and to learn the 5 Pilates' principles. After the learning period, two experimental sessions were performed: a Mat Pilates session and a Reformer apparatus Pilates session. The order of each session was randomized and drawn beforehand. Each experimental session lasted about one and a half hours and the interval between the sessions was 48 hours. Participants were asked to not perform any exercise and to refrain from food or fluids except water eight hours prior to each experimental session. Prior to the start of the experimental sessions, participants received a standard breakfast of 321 kcal that was 76% (61 g) carbohydrate, 8% (6,7 g) protein, 16% (5,9) fat, provided by the study researchers. All sessions were conducted at the same time in the morning, and the room temperature (22°C) and humidity (40-50%) were controlled during the whole session.
40758747|NCT03882372|DEVICE|Nasal high flow|See arm description.
41453737|NCT01059058|PROCEDURE|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
41453738|NCT01059058|PROCEDURE|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
40758748|NCT06536855|BIOLOGICAL|Gardasil 9|"GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.~GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11."
40758749|NCT06375564|DRUG|177Lu-AB-3PRGD2 radioligand therapy|Radioligand therapy using 177Lu-AB-3PRGD2 80 mCi (2.96 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
40758750|NCT00101738|DRUG|Myfortic|
41287484|NCT01969656|DRUG|2MD|
41287485|NCT01969656|DRUG|Calcitriol|
41287486|NCT01969656|DRUG|Placebo|
41287487|NCT05076968|PROCEDURE|Complete denture fabrication|Patient satisfaction was assessed regarding dentures fabricated by students and specialists after 8 weeks of delivery
41287488|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using water at room temperature|The use of water at room temperature to solve the 75g glucose.
41287489|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using hot water|The use of hot water to solve the 75g glucose.
41287490|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using cold water|The use of cold water to solve the 75g glucose.
41287491|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using hot water with tea bag|The use of hot water with tea bag to solve the 75g glucose.
41287492|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using room temperature water with tea bag|The use of room temperature water with tea bag to solve the 75g glucose.
41287493|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using cold water with tea bag|The use of cold water with tea bag to solve the 75g glucose.
41287494|NCT05508425|DIAGNOSTIC_TEST|Oral glucose tolerance test using bubble water at room temperature|The use of bubble water at room temperature to solve the 75g glucose.
40758751|NCT02688335|DEVICE|Cloud9|Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
41287495|NCT05508425|DIAGNOSTIC_TEST|Oral glucose tolerance test using bubble water|The use of cold bubble water to solve the 75g glucose.
40758752|NCT01872182|DRUG|ALS-L1023|daily twice for 12 weeks
40758753|NCT01872182|DRUG|placebo|daily twice for 12 weeks
40758754|NCT06572033|BEHAVIORAL|Simulation|Observational study with simulations.
40948470|NCT03081468|DEVICE|Konan RAPDx|Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
40948471|NCT01491971|DRUG|Degarelix|
40948472|NCT00320931|DEVICE|Hybrid PET/CT|Rest and vasodilation stress rubidium PET and coronary angiography with CT were performed using standard doses for clinically indicated studies.
40948473|NCT05135247|OTHER|Exercise|3 different types of training or control
41287496|NCT04210570|DEVICE|Memsorb|Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit
40948474|NCT01031602|BEHAVIORAL|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
40990476|NCT06454409|DRUG|Venetoclax|Given PO
41287497|NCT04210570|DRUG|Chemical granulate absorber|Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
41287498|NCT01736683|DRUG|Sotatercept|Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
41287499|NCT03624998|OTHER|Cognitive and physiatric testing|Neuropsychological test battery and physiatric tests
40758755|NCT05928208|DIAGNOSTIC_TEST|no intervention|no intervention
40758756|NCT00787800|DEVICE|Dual Chamber ICD|Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
40758757|NCT00787800|DEVICE|Single Chamber ICD|"Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.~VT/VF detection and therapies with discrimination criteria for single chamber device."
40758758|NCT06276075|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery|66 stroke patients were randomly assigned to three groups (22 people each) with different therapy (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, Berg Balance Scale to assess balance, as well as the Riablo device to measure static balance. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
40758759|NCT03160573|DRUG|ClōSYS® Unflavored Rinse|
40758760|NCT03160573|DRUG|ClōSYS® Flavored Rinse|
40758761|NCT03160573|OTHER|Placebo-Flavored Oral Rinse|Flavor-matched placebo rinse
40990477|NCT00067366|BEHAVIORAL|Cognitive-Behavioral treatment|Cognitive-Behavioral skills training for chronic pain
40990478|NCT00067366|BEHAVIORAL|Attention and lifestyle counseling|Attention and lifestyle counseling added to Standard Care
40948475|NCT02033187|OTHER|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
40948476|NCT02033187|OTHER|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
40948477|NCT01422018|DRUG|Avastin (bevacizumab)|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
40948478|NCT05129670|DEVICE|Calcite chewing gum|The calcite chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
40948479|NCT05129670|DEVICE|Unmatched Placebo chewing gum|The placebo chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
40948480|NCT02954627|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
40948481|NCT00900107|PROCEDURE|Exercise|
40948482|NCT02124486|PROCEDURE|Bariatric surgery|Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
40948483|NCT02124486|BEHAVIORAL|Dietetic intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
40948484|NCT03561961|RADIATION|Moderate Hypo-fractionation|66-68Gy in 25#
40948485|NCT03561961|RADIATION|Extreme Hypo-fractionation|35-36.25 Gy in 5#
40948486|NCT04050072|OTHER|Childhood Cancer Survivors (CCSS)|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
40948487|NCT04050072|OTHER|SJLIFE|To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.
40948488|NCT04050072|OTHER|Community non-cancer control|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
40948489|NCT03115047|DRUG|Dexmedetomidine Injection|0.35 mcg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
40948490|NCT03115047|DRUG|Meperidine Injection|0.35 mg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
40948491|NCT03028103|DRUG|Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2
40948492|NCT03028103|DRUG|Fluconazole|200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
40948493|NCT03028103|DRUG|Omeprazole|Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
40948494|NCT03028103|DRUG|Repaglinide|Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
41287500|NCT03530540|DEVICE|low-intensity extracorporeal shockwave therapy|Active shockwaves
40758762|NCT03160573|OTHER|Placebo-Unflavored Oral Rinse|Unflavored-matched placebo rinse
40758763|NCT06343142|OTHER|Nuts|Isocaloric meal with nuts
40758764|NCT06343142|OTHER|Nut-free meal|Isocaloric meal without nuts
40758765|NCT00007943|DRUG|gemcitabine hydrochloride|
40758766|NCT05992740|DEVICE|bronchoscope|bronchoscpe with broncial brush and biopsy or bronchial wash and biopsy
40758767|NCT02534623|PROCEDURE|Spinal anesthesia|
40758768|NCT02534623|PROCEDURE|General anesthesia|
40758769|NCT02534623|DRUG|bupivacaine|
40758770|NCT02534623|DRUG|fentanyl|
40758771|NCT02534623|DRUG|propofol|
40758772|NCT02534623|DRUG|sevoflurane|
40758773|NCT04960943|DRUG|Pyrotinib with or without trastuzumab|After enrollment, patients of all the three cohorts were given 400 mg/d oral pyrotinib continuously, every 21 days as a cycle; Cohort 1 and 2 : Patients with gastric cancer or esophageal adenocarcinoma were combined with paclitaxel 80 mg/m2, intravenously, once on the first and eighth day. Cohort 3: Patients with colorectal cancer were given trastuzumab at an initial load dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
40948495|NCT00723580|DRUG|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
40758774|NCT02977871|PROCEDURE|Bladder flap|Performing uterine incision and cesarean section with a bladder flap.
40948496|NCT06279520|DEVICE|VR Driving Simulator|Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
40758775|NCT00526851|OTHER|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
40758776|NCT03933631|DRUG|Pilocarpine|pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)
40948497|NCT06279520|OTHER|Computerized Neurocognitive Function Test|Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
40948498|NCT06279520|OTHER|Driver Test Station|Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
40948499|NCT06279520|OTHER|On-road field driving Test|Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
40948500|NCT01413061|PROCEDURE|Subtalar Arthrodesis|
40948501|NCT04488939|DEVICE|Restylane® Skinboosters™ Vital (SBV)|Hyaluronic acid
40948502|NCT05748197|BIOLOGICAL|ADCLEC.syn1 CAR T cells|There are 4 planned flat-dose levels: 25 × 10\^6, 75 × 10\^6 , 225 × 10\^6 , and 450 × 10\^6 CAR T cells and 1 de-escalation dose: 10 × 10\^6 CAR T cells.
40948503|NCT05748197|DRUG|Conditioning chemotherapy|Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
40948504|NCT06098274|BEHAVIORAL|Motivational interviewing program based on transtheoretical model|It will be determined at which stage of change of the transtheoretic model the participants in the intervention group are. A varying number of motivational interviews will be held depending on the stage of change and a maximum of 6 motivational interviews. Those in the preparatory phase will be trained on smartphone addiction. Following completion of the motivational interviewing and training content, the study scales will be re-administered and the effectiveness of the motivational interviewing and training content will be evaluated by comparison with the baseline data.
40758777|NCT03933631|DRUG|Prednisolone|Prednisolone acetate ophthalmic suspension 1%
40758778|NCT03933631|DRUG|Ofloxacin|Ofloxacin Drops
40758779|NCT02533128|DRUG|Liberal blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 60 mmHg
40948505|NCT01046162|DRUG|Alprazolam|Single tablet
40948506|NCT01046162|DRUG|Alprazolam|Single tablet
40948507|NCT06427759|PROCEDURE|arm aesthetic surgery|liposuction of arms brachioplasty of arms
40948508|NCT01837407|PROCEDURE|Composite Flap|nerve transfer with the dorsal branch of the digital nerve
40948509|NCT02025166|DRUG|Paracetamol|"Pain treatment with aniline analgesics (paracetamol) at the time of the procedure"
40758780|NCT02533128|DRUG|Tight blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 75 mmHg
40758781|NCT04523519|BEHAVIORAL|Video directly observed therapy with contingency management|PrEP adherence will be assessed by visual recognition software during video capture and reviewed for confirmation by study staff, ensuring that videos demonstrate study medication dosing by participant. Participants will receive small financial incentives upon confirmation of dosing.
40948510|NCT02025166|DRUG|lornoxicam|"Pain treatment with NSAID (lornoxicam) at the time of the procedure"
40948511|NCT05877573|DRUG|Toripalimab|Toripalimab 240mg,d1,q3w
40948512|NCT05877573|RADIATION|short-term radiotherapy|25Gy/5Fx
40948513|NCT05877573|DRUG|Oxaliplatin|135mg/m2 d1 q3w
40948514|NCT05877573|DRUG|Capecitabine|1200mg/m2 d1-14 q3w
40948515|NCT01054326|OTHER|Exercises|
40948516|NCT00387803|DEVICE|Cardiac Resynchronization Therapy with Defibrillation|
40948517|NCT04088643|DEVICE|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with 4Hz frequency and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
41287501|NCT03530540|DEVICE|Placebo LI-ESWT|Placebo shockwaves
41287502|NCT03530540|DEVICE|Penile pump|both groups will be treated with a penile pump
41287503|NCT04674137|DRUG|XC8 100 mg|1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
41287504|NCT04674137|DRUG|Placebo|1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
41287505|NCT01472237|OTHER|Nutritional intervention|Modification of diet
41287506|NCT05585372|OTHER|CT guided opening mobilization of cervical intervertebral foreman|"1. the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~2. cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~3. Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~4. Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved."
41453739|NCT02893735|OTHER|Charisma-Diamond|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
40758782|NCT04523519|BEHAVIORAL|Integrated Next-Step Counseling|Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.
41287507|NCT02355093|PROCEDURE|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
41287508|NCT02355093|PROCEDURE|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
41287509|NCT02355093|DRUG|ropivacaine|
41287510|NCT03689231|OTHER|Volumetric measurements of liver metastases|"Depending on the available data and to be reproducible, patients will be divided into 2 sub-groups of follow-up imaging: CT only or MRI only, combined evaluation being not reliable for tumor detection~Patient follow-up at CT or MRI will be analyzed at baseline (date of discovery of hepatic metastatic disease), then 3-6 months after the start of the study, then annually.~At each assessment, a radiologist will analyze: the total volume of liver metastases (mm3), the estimated volume of the two target lesions chosen for RECIST follow-up (mm3), the number of liver lesions, and the evolution according to the RECIST criteria based on uni-dimensional measurements.~We will then correlate the following clinical data collected for patients: age, sex, presence of a carcinoid syndrome, Ki67 (%) and chromogranin A blood level (%) at diagnosis, number and location of other metastases, Octreoscan or Stereotactic Radio Surgery data if available."
40758783|NCT00124657|DRUG|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
40948518|NCT04088643|DEVICE|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
40948519|NCT02824237|DEVICE|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
40948520|NCT03882190|DRUG|GnRHa|patients in the experimental group are supposed to receive GnRHa preoperatively and postoperatively according to their individual situation
40948521|NCT00399620|PROCEDURE|Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).|
40948522|NCT00839722|PROCEDURE|embolization|fertility after embolization
40948523|NCT00763048|DRUG|Fluoride|Brush twice daily for 6 weeks
40948524|NCT00763048|DRUG|Fluoride, triclosan|Brush twice daily
40948525|NCT04634890|BEHAVIORAL|Exercise intervention|Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.
40948526|NCT04603716|OTHER|Eccentric Muscle Energy Technique|"Conventional Treatment given to both groups (Hot pack for 15 minutes, Mobilization, AROM Exercises 10 sets x 3days in a week)~Reciprocal inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) causing relaxation, patient force is minimal towards maximal therapist force, 5-7 repetition for 2-4seconds 3 days in a week up to 6 weeks.~Muscle is taken from shortened to lengthened position."
40948527|NCT04603716|OTHER|Concentric muscle energy technique|"Group B: Concentric Muscle Energy Technique: (Autogenic inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) patient force is greater than therapist force, 5-7repitition for 3-4seconds)Muscle is taken from lengthened to shortened position.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 1st 3rd and 6th week"
40948528|NCT01016353|DEVICE|NPWT|ABThera Open Abdomen Negative Pressure Therapy System
40948529|NCT01016353|DEVICE|BVPT|Barker's Vacuum Packing Technique
41287511|NCT02989948|DEVICE|Physician-modified aortic endograft|Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
40948530|NCT00036296|DRUG|talampanel|75mg per day divided into 3 doses for 22 days
40948531|NCT01513096|DRUG|itopride|itopride, 10mg, twice per day, for 1 day
40948532|NCT06274307|PROCEDURE|Transversus abdominis plane block|A transversus abdominis plane block (TAP) block using a long-acting local anesthetic is used to manage pain during the intermediate (12-24hr) post-operative period following laparoscopic abdominal surgeries. Drug: The local anesthetic to be used in this specific intervention will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% and divided equally bilaterally.
41133476|NCT00504205|DRUG|multitargeted receptor tyrosine kinase inhibitor MP470|
41133477|NCT00504205|OTHER|laboratory biomarker analysis|
41133478|NCT00504205|OTHER|pharmacological study|
41133479|NCT00504205|PROCEDURE|positron emission tomography|
41133480|NCT05729386|DRUG|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
41133481|NCT05729386|DRUG|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
41133482|NCT05729386|DRUG|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
41133483|NCT05729386|DRUG|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
41133484|NCT03418610|DRUG|Azelaic Acid foam 15%|mild to moderate rosacea
41133485|NCT01396629|PROCEDURE|cartridge|IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
41133486|NCT01344980|PROCEDURE|Stainless steel suture|Stainless steel suture material will be used (size 3-0) in an MGH repair technique
41133487|NCT01344980|PROCEDURE|Polypropylene suture|Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique
41133488|NCT01344980|BEHAVIORAL|Aggressive early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.
40948533|NCT04761510|BEHAVIORAL|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile-health adaptation of MBTR-R - a mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs. During participation in the Mindfulness-SOS for Refugees intervention program, participants will be encouraged to complete 2 sessions per week and practice each day for 4 weeks but can choose to extend this up to 8 weeks. Delivery of Mindfulness-SOS for Refugees entails administrative guidance as well as adherence-focused guidance.
40948534|NCT05804396|DEVICE|Relivion®|Active stimulation device
40948535|NCT03931824|OTHER|PRP|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used(18, 19). To provide blindness, all injections were done using injectors coated with non transparent tape."
40948536|NCT03931824|OTHER|Exercise|All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.
40948537|NCT00224848|BEHAVIORAL|Palm-Pilot Intervention|"Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as lunch and learn sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed."
40948538|NCT01462487|DRUG|Treatment with zanamivir|Subjects treated with zanamivir
40948539|NCT05253846|DRUG|Irinotecan|chemotherapy treatment
40948540|NCT05253846|DRUG|Oxaliplatin|chemotherapy treatment
40948541|NCT05253846|DRUG|Lederfolin|treatment
40948542|NCT05253846|DRUG|5-Fluorouracil|chemotherapy treatment
40948543|NCT05253846|RADIATION|Short-course radiotherapy|RT
40948544|NCT05253846|PROCEDURE|TME|surgery
40948545|NCT06243484|DIETARY_SUPPLEMENT|TOTUM-070|12 weeks of TOTUM-070 supplementation with Placebo (blinded arms)
40948546|NCT06243484|DIETARY_SUPPLEMENT|PLACEBO|8 capsules per day to consume orally in two intakes
40948547|NCT01050855|DRUG|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
40948548|NCT01050855|DRUG|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
40948549|NCT01050855|DRUG|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
40948550|NCT04898387|COMBINATION_PRODUCT|Bimatoprost Timolol (T4030)|Eye drop
40948551|NCT04898387|COMBINATION_PRODUCT|Bimatoprost Timolol (Ganfort)|Eye drop
40948552|NCT02663908|DRUG|Degarelix|
40948553|NCT02663908|DRUG|Leuprolide|
40948554|NCT00547547|DIETARY_SUPPLEMENT|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
40948555|NCT00547547|DRUG|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
40948556|NCT00547547|DRUG|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
40948557|NCT03378765|BEHAVIORAL|Diet and physical activity monitoring|Lifestyle monitoring
40948558|NCT04340297|DRUG|Tongjiang series prescription(Tongjiang granules, Jianpi Qinghua granules and Wenpi Qingwei granules)|According to the syndrome differentiation of TCM, Tongjiang granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal.
40990479|NCT04147455|BEHAVIORAL|Adapted RealConsent|The program is a novel, theory-driven, evidence-based serial drama and educational program tailored to young men and delivered in six episodes via the web. Participants will view six 30-minute modules designed to prevent sexual violence in young men
41453740|NCT02893735|OTHER|Filtek-Z550|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
41453741|NCT02089282|DEVICE|Ultrasound|
41453742|NCT05758753|DEVICE|Quantitative Sensory Test|Quantitative Sensory Test (Medoc Ltd, Israel), QST is a non-invasive neurophysiological method that refers to a group of procedures that assess the perceptual responses to systematically applied and quantifiable sensory stimuli (modalities including heat, cold and vibration) for the purpose of characterizing somatosensory function or dysfunction. For this test, subjects will be seated comfortably on a chair in a quiet room, or laying supine in a horizontal examination chair, with ambient temperature of 24-25◦ C. Medial upper eyelid; just below the supraorbital notch, nasolacrimal sac area; 4-5 mm medial to nasal cantus, and non-dominant forearm will be used as test sites. Patients will be instructed in detail of the nature of the test and the need to react attentively and promptly to change in temperatures.
41453743|NCT05193734|DRUG|Pertagen®|"Schedule:~Group Pertagen will receive two doses of Pertagen®. (one vaccination on Day 0 and 6 months later for each volunteer.)~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
40758784|NCT06225037|DEVICE|Sedline EEG monitoring|Propofol titrated according to the raw EEG and spectrogram, aiming to maintain sedation (alpha oscillations +/- slow oscillations) and preventing burst suppression, keeping the PSI greater than 25 where possible.
40758785|NCT06225037|DEVICE|Sedline EEG with output concealed|Clinician will be blinded to the sedline output but data will be collected for analysis (Sedline output will only be analysed at data analysis)
40758786|NCT06501183|BIOLOGICAL|Anti-CDH17 CAR-T cells|Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.
41453744|NCT05193734|DRUG|Revaxis®|"Schedule:~Group Control will receive one dose of Revaxis® on Day 0 followed by 1 dose of Pertagen® 6 months later for each volunteer.~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
41453745|NCT02671630|OTHER|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
41453746|NCT05827263|DIAGNOSTIC_TEST|T-Scan occlusal recording No. I|Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.
40948559|NCT04340297|DRUG|Acid inhibitors|In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
40990480|NCT04147455|BEHAVIORAL|Health Education Control Condition|Participants will view six 30-minute web-based serial drama modules designed to promote health.
40758787|NCT00498966|DRUG|Perifosine|"Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.~Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food."
40758788|NCT06196320|DRUG|Tenecteplase|Intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus within 5-10 seconds) within 24 hours ± thrombectomy at treating clinician's discretion
40758789|NCT06196320|DRUG|Best Practice (which may include intravenous Alteplase)|Intravenous alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion
40758790|NCT04204902|DRUG|Tepotinib 100 mg|Participants received a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in either treatment period 1 or 2.
40948560|NCT04340297|DRUG|Placebo|Tongjiang granules placebo , Jianpi Qinghua granules placebo and Wenpi Qingwei granules placebo. The above three kinds of granulated placebo are respectively made of the simulation containing the low dose original prescription. Taking method is the same as Tongjiang series prescription.
41287512|NCT03435900|DRUG|Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed. Hereafter, the intervention group will receive three days of orally administered antibiotics: 500 mg amoxicillin combined with 125 mg clavulanic acid and 500 mg metronidazole. These doses will be administered three times daily.
41453747|NCT05827263|DEVICE|Usage of the hydrostatic appliance|The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.
41453748|NCT05827263|DIAGNOSTIC_TEST|T-Scan occlusal recording No. II|The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
40758791|NCT04204902|DRUG|Tepotinib 250 mg|Participants received a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in either treatment period 1 or 2.
40948561|NCT00579098|DRUG|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
40758792|NCT05007925|DEVICE|Intravascular Lithotripsy|Localized peripheral intravascular lithotripsy
40948562|NCT00579098|DRUG|Placebo|Placebo tablet taken by mouth once daily for 90 days
40948563|NCT06117358|OTHER||Descriptive cross section study
40948564|NCT03047707|DIAGNOSTIC_TEST|S-Shearwave and TE|S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
40990481|NCT05039008|OTHER|Blood flow restriction|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, at the same time. The intervention will last 4 weeks, with a periodicity of 3 weekly sessions. In total there will be 12 sessions that will last between 15 and 30 minutes depending on the number of joints affected.
41453749|NCT00503477|DRUG|AZD2171|oral tablet
41453750|NCT02373462|DRUG|Olmesartan|
40758793|NCT06286475|DRUG|VRG50635|Specified dose on specified days
40758794|NCT06286475|DRUG|Placebo|Specified dose on specified days
40758795|NCT04016428|BEHAVIORAL|OPTIMISM|Six-week online program that emphasizes mindfulness and skills for improving sleep during pregnancy.
41453751|NCT02373462|DRUG|other anti-hypertensive drug|CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
41453752|NCT05871463|BIOLOGICAL|MSC-derived exosomes|Patients will receive standard medication plus MSC-derived exosomes at a final dose of 40mg in three weeks. Standard medication includes: a) treatment of the underlying cause of cirrhosis such as drug treatment of hepatitis B and C. b) symptomatic treatment of port complications such as ascites, prevention of variceal bleeding, treatment and prevention of hepatic encephalopathy.
41453753|NCT04084639|DIETARY_SUPPLEMENT|Mycoprotein Ingestion|Ingestion of various doses of mycoprotein compared to placebo control
41453754|NCT00084097|DRUG|Omalizumab|
41453755|NCT03850457|OTHER|No intervention|The treatments will be determined by their neonatologists and no additional investigational drugs will be applied to the infants included in this study.
41453756|NCT05060458|OTHER|No intervention|No intervention
41287513|NCT03435900|DRUG|Standard antibiotics intravenously|4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery followed by 4 g piperacillin/500 mg tazobactam and 500 mg metronidazole administered intravenously three times daily for three days.
41287514|NCT03502135|DRUG|Tetracaine HCl and oxymetazoline HCl nasal spray|Two intranasal sprays of anesthetic. Each spray delivers 0.2 mL of solution containing 6 mg tetracaine hydrochloride and 0.1 mg of oxymetazoline hydrochloride
41287515|NCT00495846|DRUG|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
40758796|NCT04016428|BEHAVIORAL|Sleep Education|Six-week online program that provides education on sleep during pregnancy.
40758797|NCT05861401|GENETIC|Janus Kinase 1 and 2|Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
40948565|NCT02211222|DRUG|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
40948566|NCT01951222|DRUG|V0162|
40948567|NCT01951222|OTHER|Placebo|
40758798|NCT03706066|DEVICE|Acrysof IQ PanOptix IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery
40948568|NCT06474143|DEVICE|Apneal device|Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
40948569|NCT05150145|RADIATION|Radiotherpy will be performed to thoracic and liver metastasis after chemotherapy.|Intensity modulated radiotherapy will be performed to liver metastasis and thoracic SCLC patients who achieved CR or PR after chemotherapy .
40948570|NCT03242889|DRUG|DARA SC|Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
40948571|NCT05879601|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding.
40948572|NCT05879601|OTHER|delayed orthodontic retainer delivery.|post orthodontic treatment patients will be given orthodontic retainer after 24 hours of debonding.
40948573|NCT00591994|DRUG|piribedil|50 mg once a day, after lunch 3 month therapy
40948574|NCT01824342|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
40948575|NCT02437383|DRUG|Propranolol ER|Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.
40948576|NCT02437383|DRUG|Placebo|Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
40948577|NCT01313312|BIOLOGICAL|Botulinum toxin type A|"Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U."
40948578|NCT05750160|OTHER|music therapy|Music therapy that have been made by Music Therapist after Focus Group discussion, given three times a week for 4 weeks
41287516|NCT00495846|OTHER|Locoregional treatments|
41287517|NCT03341104|DRUG|Bupivacaine liposome|Replace bupivacaine with bupivacaine liposome
41287518|NCT02962635|DEVICE|bioelectrical impedance measurement and biomarker measurement|Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
41287519|NCT00033735|DRUG|fluorouracil|5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
41287520|NCT00033735|DRUG|Irofulven|Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
41287521|NCT01874704|BEHAVIORAL|Comparison of biomarkers of stress|
40948579|NCT00067574|BEHAVIORAL|Structured treatment interruption|
40948580|NCT00068328|PROCEDURE|psychosocial assessment and care|
40758799|NCT03706066|PROCEDURE|Cataract surgery|Per investigator's standard of care
41133489|NCT01344980|BEHAVIORAL|Early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
41287522|NCT00858832|DRUG|Methergine|Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
40758800|NCT01543230|DEVICE|Total hip replacement|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
40758801|NCT02594579|DRUG|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
40758802|NCT02594579|DRUG|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
40758803|NCT03027050|PROCEDURE|T-PRF|Applied for treatment of periodontal bone loss.
40758804|NCT03027050|PROCEDURE|Open Flap Debridement alone|
40948581|NCT00068328|PROCEDURE|quality-of-life assessment|
41453757|NCT03759704|DRUG|Hyperpolarized 13CPyruvate|Bolus injection of study drug during MRSI.
41453758|NCT01323062|DRUG|Bavituximab|Administered 3 mg/kg weekly
41453759|NCT03587129|DRUG|Apatinib|An anti-tumor Targeted drug
41287523|NCT03477188|BEHAVIORAL|Somatosensorial and Vestibular Exercises|In the experimental group, the subjects who were taken to the somatosensorial and vestibular exercises program after pre- treatment evaluations. The subjects in this group were given classical physiotherapy and somatosensorial combined with vestibular exercise performed 5-7 days a week, 1 set of 10 times with physiotherapist control. In the content of the training, in addition to the general physiotherapy program applied for Brunnstrom and Bobath exercises and spasticity inhibition according to in-bed mobility, Flask and spasticity conditions in the experimental group, a mutual study program was prepared with Cawthorne-Cooksey and Frenkel exercises in the bed, then balance and walking will be performed with the exercises
40948582|NCT04203498|DRUG|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
41287524|NCT03477188|BEHAVIORAL|Conventional Group|In the control group, The subjects who were taken into the study were taken to the classical physiotherapy based on Bobath and Brunnstrom will be applied to increase the mobilization and spasticity up to the discharge stage known as 5-7 days a week
41287525|NCT02606786|OTHER|Lumbopelvic stabilization exercises|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
41287526|NCT03065673|PROCEDURE|Potassium oxalate 5% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
41287527|NCT03065673|PROCEDURE|Placebo gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
41287528|NCT03551899|OTHER|Different ventilation parameters|mode of ventilation, tidal volume per body weight and PEEP settings
41287529|NCT03780517|DRUG|BOS172738|Oral capsules
41287530|NCT05337943|BEHAVIORAL|CBT-I|Weekly sessions with a therapist to improve sleep for 8 weeks.
41287531|NCT05337943|DEVICE|Bright Light Therapy|Daily light therapy for 30 minutes for 8 weeks.
41287532|NCT05669885|DRUG|Sildenafil|Study participants will be allocated to receive oral administration of 100 mg sildenafil.
41287533|NCT05669885|DRUG|Placebo|Study participants will be allocated to receive oral administration of placebo.
41287534|NCT00035815|DRUG|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
41287535|NCT00035815|DRUG|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
40758805|NCT05208957|OTHER|No intervention|No intervention
41287536|NCT00295893|DRUG|cyclophosphamide|Given IV
40758806|NCT06105645|DEVICE|DIXI Medical Microdeep® Micro- Macro Depth electrodes|It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.
41287537|NCT00295893|DRUG|docetaxel|Given IV
40758807|NCT06105645|DEVICE|Standard electrodes|Standard electrodes used usually during the SEEG
41287538|NCT00295893|DRUG|doxorubicin hydrochloride|Given IV
40758808|NCT01827306|DRUG|Biofreeze|
41133490|NCT06250868|DEVICE|Kerato-Refracto Tonometer|measures pressure inside the eye and thickness of the cornea.
41287539|NCT00295893|BIOLOGICAL|Trastuzumab|Given IV
40758809|NCT01498380|DRUG|Dexmedetomidine|The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease \< 20% or blood pressure decrease/increase \< 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease \>/= 20% or SBP/DBP/MAP decrease or increase \>/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
40758810|NCT03720275|GENETIC|Systematic screening of TTR mutations|The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
41287540|NCT00295893|DRUG|Carboplatin|Given IV
40990482|NCT04690504|OTHER|dim light melatonin onset (DLMO)|A series of saliva samples will be collected and assayed for melatonin so that the timing of melatonin secretion onset can be determined.
41287541|NCT00295893|DRUG|Paclitaxel|Given IV
41287542|NCT06391034|DRUG|hyperpolarized pyruvate +/-urea (13C/15N)|Given IV
40948583|NCT04203498|DRUG|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
40948584|NCT05790083|OTHER|Body Lotion and Intensive Care|Body Lotion, applied twice daily on whole body, for 3 months. Intensive Care, applied as needed on affected body areas.
40948585|NCT03376048|PROCEDURE|Wound infiltration plus TAP|"1. TAP block: At the beginning of the main surgical procedure the surgeon will perform a TAP with ropivacaine infiltration, bilaterally in the anterior axillary line, between the costal margin and iliac crest in the intermuscular plane between the internal oblique and transversus abdominis muscles, the anesthesiologist under ultrasound guidance, the surgeon under laparoscopic guidance (two pops technique).~2. Wound infiltration : Wound infiltration of ropivacaine will be performed by the surgeon before skin incision."
41287543|NCT06391034|RADIATION|Non-investigational Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy given outside of this study
41287544|NCT06391034|PROCEDURE|Radiotherapy (RT)|Radiation therapy given outside of this study
41287545|NCT06391034|PROCEDURE|Multi-parametric magnetic resonance imaging (mpMRI)|Imaging scan
41287546|NCT06391034|BIOLOGICAL|Non-interventional hormone therapy|Therapy given outside of this study as part of standard of care
41287547|NCT06391034|PROCEDURE|Prostate Biopsy|Biopsies may be taken from Trans-rectal ultrasound (TRUS) -visible lesion at the urologist's discretion
41287548|NCT03701789|DRUG|Baricitinib|Effect of Baricitinib on vBMD measured by HR-pQCT
41287549|NCT00539721|DRUG|Rolapitant Dose 1|Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
41287550|NCT00539721|DRUG|Rolapitant Dose 2|Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
41287551|NCT00539721|DRUG|Rolapitant Dose 3|Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
41287552|NCT00539721|DRUG|Rolapitant Dose 4|200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
41287553|NCT00539721|DRUG|Ondansetron|Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
41287554|NCT00539721|DRUG|Placebo|Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
41287555|NCT03575468|BEHAVIORAL|Enhanced E-cigarette Coaching|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
41287556|NCT03575468|BEHAVIORAL|Quitline treatment as usual|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
41287557|NCT00288210|PROCEDURE|Primary angioplasty in acute myocardial infarction|
41287558|NCT04073615|DRUG|Rivoceranib|Film-coated tablets
41287559|NCT04073615|DRUG|Trifluridine/Tipiracil|Film-coated tablets
41287560|NCT05337449|OTHER|silver diamine fluoride|silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries
41287561|NCT05337449|OTHER|conventional composite resin restoration|Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.
41287562|NCT00304473|DRUG|Quetiapine fumarate|
41453760|NCT03183622|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
41453761|NCT04828538|DIETARY_SUPPLEMENT|Vitamin D|Daily 4000 IU Vitamin D for 60 days
40758811|NCT06470867|BEHAVIORAL|VA S.A.V.E.|The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
40948586|NCT03376048|PROCEDURE|Wound infiltration|Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
41453762|NCT04828538|DIETARY_SUPPLEMENT|Omega DHA / EPA|Daily 1000mg Omega DHA/EPA for 60 days
40758812|NCT06470867|BEHAVIORAL|Control training|"An attention control informational video containing information relevant to veterans' mental health but not including elements thought to be active ingredients in the intervention."
40758813|NCT00706537|DRUG|Active treatment|20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
40758814|NCT00706537|DRUG|Placebo|Placebo as two tablets once daily for three weeks
40758815|NCT06265818|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
40758816|NCT06265818|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
40758817|NCT04642079|BIOLOGICAL|20vPnC|20-valent pneumococcal conjugate vaccine
40758818|NCT00127478|DRUG|Atrasentan|
40758819|NCT00001476|DRUG|Gene Therapy Method for CGD|
40758820|NCT00001476|DEVICE|Isolex 300i Magnetic Cell Selector|
40948587|NCT00331422|DRUG|carboplatin|Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
40948588|NCT00331422|DRUG|paclitaxel|Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
41287563|NCT02424669|OTHER|ALS Functional rating Scale-revised (ALS FRS-R)|
41287564|NCT02424669|OTHER|slow vital capacity|
41287565|NCT02424669|OTHER|Blood sample|
41287566|NCT02424669|OTHER|Cerebrospinal Fluid (CSF) sample|
41287567|NCT01667744|DRUG|Citalopram|10 mg/day
41287568|NCT00933946|DRUG|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
41287569|NCT00736281|OTHER|Food Drops: Food Allergens (peptides)|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
40758821|NCT00945542|OTHER|Massive transfusion protocol|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
40758822|NCT00945542|OTHER|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR\>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
40758823|NCT04665895|DRUG|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals|twice daily inhalation throughout the study
40758824|NCT04665895|DRUG|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK|twice daily inhalation throughout the study
41133491|NCT02792907|DEVICE|Compressive stocking|"After hindfoot and middlefoot surgery the patients from the Intervention Group will be treated with compressive stockings the removal of the suture. That means from the end of week 2 until the end of week 6 after surgery.~Additionally the patients wearing behaviour is monitored by a electronic sensor, which is implanted in the patient´s stocking."
41133492|NCT04751981|PROCEDURE|Patient Specific Guide|For lumbar fusion pedicle screws will be placed with the aid of patient specific guides.
40758825|NCT04665895|DRUG|Placebo|twice daily inhalation throughout the study
40758826|NCT01687595|DRUG|HerpV and QS-21|HerpV (recombinant human heat shock protein 70 \[rh-Hsc70\] polyvalent peptide complex) in combination with adjuvant QS-21
40758827|NCT01687595|DRUG|Placebo|phosphate buffered saline
40758828|NCT03203265|OTHER|Group A: Offline HTC|Offline or online referral to HIV treatment facility HIV-positive participants can choose to receive either an offline or online referral to HIV treatment facilities. An offline referral method usually includes a referral letter and/or a telephone call, followed by a series of calls to participants to ensure successful referral. Those who choose an online referral will be able to register online with an HIV treatment facility which provides ART without cost under the national programs. Participants will receive a registration code which will allow them to access HIV treatment clinics directly without the need to go through the regular registration and appointment system at that facility.
40948589|NCT00331422|PROCEDURE|cytoreductive surgery|Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
40948590|NCT03687112|OTHER|non ontervention / observational study|non intervention
41133493|NCT04751981|PROCEDURE|Navigation|Conventional navigation will be used to place pedicle screws.
41133494|NCT04353050|PROCEDURE|Non-invasive adhesive system (patch)|The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice
41287570|NCT02515669|DRUG|RO7239361|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
41287571|NCT02515669|DRUG|Placebo|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
41287572|NCT05564130|DRUG|Sodium bicarbonate|Sodium bicarbonate 1 mmol/ml
41287573|NCT05564130|DRUG|Sodium chloride|Sodium chloride 9 mg/mL
41287574|NCT03729180|PROCEDURE|Routine Elective Surgery- In patient or out patient elective surgery|Participants will be undergoing routine planned surgeries.
40758829|NCT03203265|OTHER|Group B1: Offline HIV testing and post-test counseling|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only referred from the Adam's Love Online Clinic.
40758830|NCT03203265|OTHER|Group B2: Online HIV testing and post-test counseling|A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit,obtaining blood through finger prick,performing the testing steps,reading the test result. A positive result from the first test will trigger the need for referral to confirmatory tests. The provisional nature of the positive result from the single rapid HIV test will be emphasized but the urgency to get immediate confirmatory tests and linkage to HIV treatment facilities will encouraged and supported. HIV positive test result will be confirmed only with three positive tests. Any online testing session with uncertain qualities at any step will be repeated at a later time or the participant will be offered offline HIV testing.
40758831|NCT05378425|DRUG|NTX-1088|IgG4 mAb targeting the poliovirus receptor (PVR, CD155).
41287575|NCT03729180|DIAGNOSTIC_TEST|Blood test for genetic testing|Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.
40758832|NCT05378425|DRUG|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
41287576|NCT03729180|OTHER|Drug-genetic Profile|Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.
41453763|NCT04828538|DIETARY_SUPPLEMENT|Vitamin C, Vitamin B complex and Zinc Acetate|"Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)"
41453764|NCT04828538|OTHER|Placebo|Placebo
41287577|NCT06457438|DIAGNOSTIC_TEST|Elecsys Anti-HEV IgG, IgM|Diagnostic test used to determine antibodies in blood and serum.
41287578|NCT02544984|DRUG|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
40758833|NCT02096926|DRUG|Placebo|
40758834|NCT02096926|DRUG|Ibuprofen|400 mg PO
41287579|NCT02544984|DRUG|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
41287580|NCT06477341|DIETARY_SUPPLEMENT|various available nutrition as those contain high protein content as ensure milk|note effect with usually prescribed suitable oral and parenteral nutrition for head and neck cancers receiving radiotherapy
41287581|NCT02896140|OTHER|Type 2 diabetes in WhyWAIT Program|The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
41287582|NCT05114889|BIOLOGICAL|BSI-045B|BSI-045B will be administered weekly, subcutaneously
41453765|NCT06246591|OTHER|Extracorporeal Shockwave Therapy (Group A)|Each patient was evaluated before treatment for trigger points; patients underwent focal ESWT (PulseWave 2 - Mectronic Medicale s.r.l.) with a specific program for muscle contractures and myofascial pain (80-100 mJ with 2250 pulses of 5-10 Hz).
40758835|NCT03615274|DEVICE|Executive function training|Home-based executive function training with adaptive difficulty, through Cogmed and Cognifit systems over 6 weeks (30-45 minuts/day, 5 days per week). Cognitive training will consist on working memory training (Cogmed, www.cogmed.com) and executive/inhibitory function training (Cognifit, www.cognifit.com).
40758836|NCT03615274|OTHER|Psychoeducation|Learning basic healthy habits through daily Prezi presentations that include healthy food recommendations, funny receipts to families, ideas for exercising, emotion and behavioral management strategies, etc.
40758837|NCT03615274|DEVICE|Placebo non-adaptive training|Executive function training with non-adaptive difficulty through Cognifit system over 6 weeks (30-45 minuts/day, 5 days per week). Exercices will be the same as the ones in the experimental group but minimizing the executive/working memory component and without incresing difficulty.
41287583|NCT03228186|DRUG|Pevonedistat|25mg/m2 days 1, 3, 5
41287584|NCT03228186|DRUG|Docetaxel|75mg/m2 day 1
40758838|NCT00339365|BEHAVIORAL|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
41453766|NCT06246591|OTHER|Mesotherapy (Group B)|Each patient was evaluated before treatment for trigger points; after disinfection with Chlorhexidine 2% and sterile gauze, Thiocolchicoside fl 4mg/2ml, and a local anesthetic, Mepivacaine fl 10mg/1ml, diluted in 0.9% NaCl saline, for a final volume of 10 ml, were inoculated mesodermally; 6 to 12 microinjections with needle 26G 0.40x4mm, were performed.
41453767|NCT04852627|BEHAVIORAL|Brisk walking|Walking
41287585|NCT04278742|OTHER|Patient education|Using a collaborative approach to engage patients in their own care, allowing patients to continue to have full control of their treatment. The clinician and patient co-creates the treatment plan.
40948591|NCT05321108|OTHER|Group A (GA)(Aerobic exercise group)|Aerobic Exercise has been demonstrated to be a safe strategy to improve several health outcomes in Systemic lupus erythematosus (SLE)SLE, including depressive symptoms or, even more importantly, fatigue and quality of life.
40948592|NCT05321108|OTHER|Group B (GB) (Whole-body vibration (WBV) group)|(WBV) has been growing over the years. WBVE occurs when the subject is in contact with the vibrating platform in operation and is exposed to the generated mechanical vibrations. WBV has a positive action on muscle strength, bone formation, balance, flexibility, functional capacity and fatigue.
41453768|NCT04162899|DRUG|Drug: SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
40948593|NCT01974154|OTHER|Cohort I|We will evaluate serum and lung ELF obtained by bronchoalveolar lavage, under previous protocols, from 159 individuals at baseline and at 0, 3, 6 and 12 months.
40948594|NCT01974154|OTHER|Cohort II|Quantify the cilia length on prepared slides from 67 cohort II samples of airway epithelium from biological samples were already obtained from subjects who were consented to participate in prior WCMC IRB approved protocols.
40948595|NCT00881673|DRUG|AL38583 Ophthalmic Solution|Topical ophthalmic
40948596|NCT00881673|DRUG|Maxidex|Topical ophthalmic
40948597|NCT00881673|DRUG|Vehicle|AL38583 Vehicle
40948598|NCT03130608|OTHER|Inspiratory Muscle Training|Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
40948599|NCT04599829|DEVICE|AnkleSTRONG100/500/900|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.
40948600|NCT01419626|DEVICE|Interdental cleaning device with water|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
40948601|NCT01419626|DEVICE|Interdental cleaning device with essential-oil mouthrinse|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
40948602|NCT01706796|DRUG|PF-06273340|Oral solution, single dose, fasted
40948603|NCT01706796|DRUG|PF-06273340|Immediate Release Tablet, single dose, fasted
40948604|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fasted
40948605|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fasted
40948606|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fed
40948607|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fed
41453769|NCT04552405|DIETARY_SUPPLEMENT|Anti-inflammatory Diet|FAP individuals followed for 3 months a low-inflammatory diet
41453770|NCT06380387|DIETARY_SUPPLEMENT|Meal|Liquid meal
41453771|NCT02725580|GENETIC|AT-GTX-501|CLN6 Gene delivered by Self-Complementary AAV9
40948608|NCT03521427|OTHER|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
40948609|NCT03521427|OTHER|Intensive neurodevelopmental therapy|Ninety hours of intensive neurodevelopmental therapy
41453772|NCT06339658|PROCEDURE|Targeted axillary dissection (TAD) by ICG|Use of ICG during the targeted axillary dissection (TAD)
41453773|NCT06339658|PROCEDURE|Targeted axillary dissection (TAD) by Blue patent|Use of Blue patent during the targeted axillary dissection (TAD)
41453774|NCT00061464|DRUG|pemetrexed|
41453775|NCT00061464|DRUG|gemcitabine|
41453776|NCT00681486|DRUG|Ghrelin|High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
40948610|NCT02127710|DRUG|AZD6094|AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
40948611|NCT00905827|BEHAVIORAL|CAMS|Collaborative assessment management in suicidality
40948612|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-SD-03 50g of AC-SD-03 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
40948613|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-LMP-01 50g of AC-LMP-01 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
41133495|NCT02638506|DRUG|Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
41133496|NCT02638506|OTHER|Salinex|All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
40948614|NCT03971123|DRUG|Placebo|Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
40948615|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-1202 60g of AC-1202 (20g caprlic triglyceride) mixed in 240mL dosing liquid at Hour 0 Day 1
40948616|NCT01526772|PROCEDURE|Endoscopy|Transoral endoscopy versus transoral endoscopy
41287586|NCT00947102|OTHER|Observation|
41287587|NCT03378206|DEVICE|hinged 8-figure plate|Hinged 8-figure plate has two arms and a built-in hinge. The rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. That automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking.
40948617|NCT04972929|OTHER|Spinal Manipulation|Diversified (i.e. crossed bilateral hypothenar contact) chiropractic technique will be administered at levels of identified spinal joint restriction/dysfunction (derived from thoracic spine x-rays, static and motion palpation, and confirmed or provoked localized tenderness in paraspinal soft tissues).
40948618|NCT04972929|OTHER|Sham Spinal Manipulation|Sham-SM will be delivered by setting the expansion control knob on an Activator II (Activator Methods®, Phoenix AZ) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician (no actual instrument contact with study participant). At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted to the participant.
40948619|NCT05077878|BIOLOGICAL|DSPP level in GCF|quantification of DSPP
41287588|NCT03378206|DEVICE|conventional 8-figure plate|Conventional 8-figure plate is a widespread device to treat angular deformity of lower limbs with moderate successful rate. The device was designed based on the principle of tension band model. It consists of a plate and two screws (epiphyseal screw and metaphyseal screw).
40948620|NCT01737502|DRUG|Auranofin|Given PO
40948621|NCT01737502|DRUG|Sirolimus|Given PO
40948622|NCT01737502|OTHER|Laboratory Biomarker Analysis|Correlative studies
40948623|NCT01737502|OTHER|Pharmacological Study|Correlative studies
40948624|NCT04102943|DRUG|tacrolimus tablet|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
40948625|NCT04102943|DRUG|tacrolimus capsules|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
41287589|NCT00645242|DRUG|fluconazole|Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
41287590|NCT02660658|DRUG|Intrathecal dexmedetomidine|The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
40948626|NCT04781504|BEHAVIORAL|Exercise|intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session
40948627|NCT03468985|DRUG|Cabozantinib|Given PO
40948628|NCT03468985|BIOLOGICAL|Ipilimumab|Given IV
40948629|NCT03468985|BIOLOGICAL|Nivolumab|Given IV
40948630|NCT01118871|DRUG|Darunavir, Ritonavir, Truvada|Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily
40948631|NCT01118871|DRUG|Darunavir, Ritonavir and Etravirine|Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily
41287591|NCT06481358|DIAGNOSTIC_TEST|Artificial intelligence|AI extract intestinal region and reconstruct into 3D image.
40948632|NCT04348279|DEVICE|propylene mesh|propylene mesh as a palatal stent for palatal wound
40948633|NCT00135733|DRUG|Amevive (Alefacept)|
41287592|NCT01666132|OTHER|intramyocardial injection of BM cells|only intramyocardial, NOGA guided injection on BM cells.
41287593|NCT01666132|OTHER|intramyocardial / intracoronary injection of BM cells|combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
41287594|NCT01666132|OTHER|Best medical therapy|initially no intervention; crossover to therapy 6 months after enrollment
40758839|NCT00339365|BEHAVIORAL|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
40948634|NCT00135733|DRUG|Placebo|
40948635|NCT04091009|DRUG|Buprenorphine|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
40948636|NCT04091009|DRUG|Buprenorphine/naloxone|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
41287595|NCT03320629|COMBINATION_PRODUCT|apatinib S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
41287596|NCT03320629|COMBINATION_PRODUCT|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
40948637|NCT00032097|DRUG|motexafin gadolinium|
40948638|NCT00032097|RADIATION|radiation therapy|
40948639|NCT06540027|PROCEDURE|rectal cacer surgery|minimally invasive surgery
40948640|NCT02402829|PROCEDURE|Peripheral Vein Blood draw|Drawing blood through a peripheral vein in the arm.
40948641|NCT00092157|DRUG|MK0733, simvastatin|
40948642|NCT00092157|DRUG|Comparator: simvastatin|
40948643|NCT01067066|DRUG|TPI 287|Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
40948644|NCT01067066|DRUG|Temodar (Temozolomide)|Starting dose cycle 1, 85 mg/m\^2 by mouth (PO) daily, Day 1 to 5.
40948645|NCT05816720|DRUG|Lutetium-177 DOTATATE|Intravenous administration
40948646|NCT01044706|DRUG|Bicalutamide|50 mg Oral Tablet
41287597|NCT03949777|DEVICE|Aer-O-Scope Colonoscopy|resection or biopsy of colonic abnormalities for histopathalogical evaluation
41287598|NCT03513380|BEHAVIORAL|Exergaming|free access to the exergame PedalTanks during 6 months
41453777|NCT00681486|DRUG|Ghrelin|Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
41453778|NCT05455658|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given IV
41453779|NCT05455658|BIOLOGICAL|Sargramostim|Given ID
41453780|NCT05595980|DIETARY_SUPPLEMENT|Probiotic|Participants will consume 1 capsule containing 2 billion CFU of a Bacillus strain spore preparation once daily for 56 days
40948647|NCT03610451|BEHAVIORAL|Floatation-REST plus usual care|Individuals will receive Floatation-REST plus usual care. Floating creates an environment with minimal visual, auditory, tactile, proprioceptive, and thermal input to the brain. The float rooms are lightproof and soundproof. A high concentration Epsom salt water solution allows individuals to effortlessly float on their back while remaining completely still, reducing both proprioceptive and tactile input to the brain. The temperature of the water is calibrated to the temperature of the skin (\~94° F) and the temperature of the air is calibrated to the temperature of the water, making it difficult to discern the boundary between air and water, thus reducing thermal input to the brain while minimizing the need for thermoregulation of the skin.
40948648|NCT03610451|BEHAVIORAL|Usual care|Individuals will receive usual care on the inpatient unit of the Laureate Eating Disorders Program.
40990483|NCT05533931|OTHER|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
40990484|NCT05533931|OTHER|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
40990485|NCT02617823|PROCEDURE|lateral position|patients placed on their left side after epidural catheter insertion
40990486|NCT00950547|DEVICE|CARDIOPAT|Cell Saver System at bedside for ICU stay
40990487|NCT00950547|DEVICE|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
41453781|NCT05595980|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1 capsule containing maltodextrin once daily for 56 days
41453782|NCT02827045|DEVICE|Vestibular test|
41453783|NCT04702191|BEHAVIORAL|Triple P|Triple P - level 4 group is a group-based parenting intervention for families with children who exhibit behavioural or emotional difficulties. Group sessions typically focus on topics such as positive parenting, helping children develop, managing misbehaviour, and planning ahead. Practitioners then provide individual feedback on progress using positive parenting strategies and goal setting. Trained practitioners will deliver the program according to the manualized protocol (Turner, Markie-Dadds, \& Sanders, 2010). This will include eight weekly sessions with maximum of 12 parents. The first four sessions will be as group sessions. These four group sessions will be followed by three one-to-one practical and personalised telephone consultations. Finally, there will be one group session, which will complete the programme and parents' contact with the Triple P practitioners. The main aim of this session is to review progress and plan for the future.
41287599|NCT05630144|BEHAVIORAL|HomeMed|The HomeMed intervention is a multidisciplinary deprescribing intervention including home visits and team-based telehealth communication (optional). The components included in the HomeMed intervention include home medication review, medication education and provision of tools to assist the patients with medication administration, assessment of deprescribing targets by a trained geriatric clinical pharmacist, communication with the patient's treating primary care provider about deprescribing recommendation, deprescribing implementation (optional), and deprescribing monitoring (optional). Depending on the patient's treating primary care provider's decision on deprescribing and monitoring, the number of home visits ranges from a minimum of three to more with the entire duration of the intervention ranging from approximately 1 to 3 months.
41287600|NCT05716451|DEVICE|Device-assisted mobilisation with the sit/stand stabilizer Liana|Non-invasive device-assisted mobilisation with LIANA
41287601|NCT02162875|DRUG|Praziquantel|Six different treatment strategies with praziquantel
41287602|NCT00686205|DEVICE|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
41287603|NCT02522481|DRUG|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
41287604|NCT05000801|BIOLOGICAL|DC vaccine|Autologous/or HLA-matched donors' DCs loaded with WT1/TERT/survivin
41287605|NCT02914626|DRUG|Intravitreal ranibizumab|Intravitreal ranibizumab injection
41287606|NCT00442312|DRUG|Combigan Ophthalmic Solutiom|
41287607|NCT04751279|OTHER|Blood sample|Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml
41287608|NCT05784792|OTHER|Lugol -|Patients that undergo total thyroidectomy without Lugol solution pretreatment
41453784|NCT04702191|BEHAVIORAL|Circle of Security Parenting|Circle of Security - Parenting (COS-P) will be delivered according to the protocol outlined by Cooper, Hoffman and Powell (Cooper et al., 2009). COS-P is a manualized eight-session parent-education group program which has the same broad aims and core components of the COS-Intensive model from which it was developed (i.e., to increase caregiver sensitivity and responsiveness to child cues, empathy for the child by supporting parental reflective functioning, recognition and understanding of child attachment cues, and awareness of the impact of the caregiver's own attachment history on caregiving patterns). The program is led by one or two facilitators and includes 10-12 caregivers. The program uses clinical DVD clips of problematic parent-child interaction and healthy alternatives to illustrate attachment patterns and parenting styles, and to promote group discussion.
40758840|NCT05756413|BEHAVIORAL|Self-determination theory|"SDT is relatively unique among theories of motivation due to its focus on the quality, rather than the quantity, of motivation. Central to SDT is the distinction between selfdetermined or autonomous and non-self-determined or controlled forms of motivation. These types of motivation differ from one another based on the degree to which actions are (or are not) fully self-endorsed by the individual. Autonomous motivation reflects freely chosen and fully or whole-heartedly self-endorsed reasons for engaging in a behavior, such as because it is important and because it is enjoyable. In contrast, controlled motivation reflects reasons for acting that are not self-endorsed because one is pressured into doing them because of internal pressure, such as this is something I should do, even though I don't really want to, or because of environmental contingencies because I have to; it is required that I do this."
40758841|NCT01348581|DEVICE|Marigen Wound Dressing|The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
40758842|NCT00002256|DRUG|Zalcitabine|
40758843|NCT01235117|DRUG|azacitidine|
40758844|NCT01235117|OTHER|laboratory biomarker analysis|
40758845|NCT00001311|DEVICE|heparin-surface modified intraocular lens|
40758846|NCT04983238|DRUG|BYON5667 & SYD985|Ocular administration: BYON5667, Intravenous administration: SYD985
40758847|NCT04983238|DRUG|Placebo & SYD985|Ocular administration: Placebo, Intravenous administration: SYD985
40758848|NCT01883375|BEHAVIORAL|Dignity Talk|Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
40758849|NCT01883375|BEHAVIORAL|The Dignity Talk Communication Topics|There have not been any non-completers - this arm not being used currently
40758850|NCT06221046|OTHER|Cream D|"Prevention~1. Daily cleansing /moisturizing protection using 3-in-1 perineal wipes after each incontinence episode~2. Avoid rubbing/scrubbing~3. Reduce exposure to moisture as much as possible~4. Reassess frequently~Management - no clinical signs of infection~MILD/MODERATE~1. Continue with prevention methods, apply CREAM ARM 2 as a barrier product after every fecal incontinence event~2. Discontinue CREAM ARM 2 use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~Management - with clinical signs of infection~FUNGAL: Continue with prevention methods, adding Clotrimazole 1% cream twice daily.~1. Prescribe order required for Clotrimazole 1% and must be reordered every 7 days unless prescribed for a longer duration~2. Discontinue use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~BACTERIAL: requires physician assessment"
41307780|NCT05522712|DEVICE|Acapella user|"The exercise session will include three sets of deep breaths. Each set will include 10 repetitions which were fol¬lowed by 30 to 60 seconds pause in between. Patients will be instructed to perform slow maximal inspiration, while expiration was done through acapella in a prolonged manner to minimize airway closure and alveolar collapse. In the Acapella device, resistance was increased continuously on each successive day. The technique will be applied for 15 minutes.~Components of Acapella® treatment will include :~* Breathing control~* 10 breaths through the Acapella® device~* Inhaling up to approximately three - quarter maximum breathing capacity~* 2-3 second breath hold~* Active exhalation to Functional residual capacity but not too forcefully (3-4 second)~* The patient did 2-3 huffs at the end of the session, Cough or forced expiration in a set cycle."
41453785|NCT01274143|BEHAVIORAL|TeleCARE|Personalized telephone-delivered cancer risk assessment.
41453786|NCT01274143|BEHAVIORAL|Pamphlet intervention|Mailed pamphlet about familial colorectal cancer risk and screening.
41453787|NCT04027023|DRUG|Diabetes mellitus Type 2 De-escalation treatment (DET)|"All employed drugs are approved in the US for treatment of type 2 diabetes and are used within their label. There will be defined individual treatment drug combinations at an earlier stage of diabetes as in standard treatment. The DET combination will be composed out of one each or more of the drugs and interventions listed below.~A. Relieve for the insulin-producing ß-cells insulin glargine (6 to 20 U at bedtime) insulin degludec (5 to 15 U at bedtime) B. Reduction of hormonal visceral lipid tissue activity/chronic inflammation Weight loss liraglutide (0.6 mg/day) exenatide (15 µg/day) C. Treatment of metabolic and vascular insulin resistance Pioglitazone (30 mg) D. Treatment of glucose toxicity Empagliflozin (SGLT-II inhibitor; 10 mg) Dapagliflozin (SGLTII-Inhibitor, 10 mg) Canagliflozin (SGLT-II inhibitor, 100 mg) Metformin (inhibition of hepatic glucose production, 500 mg)~To avoid hypos, all drugs are initially given in the lowest possible dose."
41453788|NCT05580744|OTHER|Traditional occupational therapy|Motor training targeted to goals that are relevant to the functional needs of the patient
41453789|NCT05580744|OTHER|Mirror therapy using a mirror box|Mirror therapy using a mirror box
41453790|NCT05580744|OTHER|Augmented reality-based mirror therapy|Augmented reality-based mirror therapy
41453791|NCT03807037|DIETARY_SUPPLEMENT|Tocotrienols|Mixed tocotrienols (derived from palm oil) to be orally administered at 200mg (1 capsule) twice daily, to achieve dosage of 400mg/day
40948649|NCT03577288|BEHAVIORAL|manipulation of the level of realism|"The realism of the virtual experience will be manipulated. In one condition the realism will be high and in another condition the realism will be low. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., high realism with negative stimuli, low realism with negative stimuli, high realism with positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement (only in part A) and Late Positive Potential (EEG - only in part B) will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
40990488|NCT04322357|DRUG|Prednisone|A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
40990489|NCT04322357|BEHAVIORAL|In-home Exercise Training|For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.
41133497|NCT05760950|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for intracerebral hemorrhage.
41133498|NCT01958346|OTHER|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
41133499|NCT01958346|OTHER|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
41133500|NCT01958346|DEVICE|Fiberoptic Intubation|
41133501|NCT00002866|BIOLOGICAL|filgrastim|
41133502|NCT00002866|DRUG|docetaxel|
41133503|NCT00002866|DRUG|epirubicin hydrochloride|
41133504|NCT01697228|DIETARY_SUPPLEMENT|Vitamin D|
41133505|NCT05804825|BEHAVIORAL|Argument inoculation messages|Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
41133506|NCT05804825|BEHAVIORAL|Simple forewarning message|Participants will be presented with a simple forewarning message.
41133507|NCT04154007|DIAGNOSTIC_TEST|kidney function tests - urine output|"AKI was classified based on the worst of either creatinine or urine output criterion as follows:~Stage I 1.5-1.9 times baseline OR ≥0.3 mg/dl increase in the serum creatinine, OR urine output \<0.5 ml/kg per hour for 6 to 12 hours.~Stage II 2.0-2.9 times baseline increase in the serum creatinine OR urine output \<0.5 ml/kg per hour for ≥12 hours.~Stage III 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to ≥4.0 mg OR urine output of \<0.3 ml/kg per hour for ≥24 hours, OR anuria for ≥12 hours OR the initiation of renal replacement therapy."
41133508|NCT04477707|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
41133509|NCT00783146|DRUG|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
40990490|NCT04322357|DRUG|Prednisone plus exercise|Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
40990491|NCT02067299|DRUG|JNJ-42847922|Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.
40990492|NCT02067299|OTHER|Placebo|Participants will receive placebo orally on Day 1 of the appropriate treatment periods.
40990493|NCT03198533|DEVICE|Triathlon PA|Implantation of Knee Prosthesis
40990494|NCT03198533|DEVICE|Triathlon Pressfit|Implantation of Knee Prosthesis
40990495|NCT05049070|DIAGNOSTIC_TEST|Mobile medical application to self administer a subjective refraction test|GoEyes is a software as a medical device and mobile medical application, which is downloaded to a smartphone and is a self-administered subjective refraction test that measures the refractive error of the user's eyes in the home environment without any contact or help from health care professionals
40990496|NCT05049070|DIAGNOSTIC_TEST|Standard of care refraction test|Standard of care subjective manifest refraction test performed by a healthcare professional
40990497|NCT00581568|OTHER|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
41287609|NCT00753922|DEVICE|Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface|Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
41287610|NCT02427581|BIOLOGICAL|Personalized synthetic long peptide vaccine (Poly ICLC)|
41287611|NCT02427581|DRUG|Poly ICLC|
41287612|NCT01344122|OTHER|KPI training only|See comparison arm description.
41287613|NCT01344122|OTHER|KPI plus OLI|See experimental arm description.
41287614|NCT01905735|DRUG|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
40758851|NCT06221046|OTHER|Control|"Prevention~1. Daily cleansing /moisturizing protection using 3-in-1 perineal wipes after each incontinence episode~2. Avoid rubbing/scrubbing~3. Reduce exposure to moisture as much as possible~4. Reassess frequently~Management - no clinical signs of infection~MILD/MODERATE~1. Continue with prevention methods, apply CREAM ARM 1 as a barrier product after every fecal incontinence event~2. Discontinue CREAM ARM 1 use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~Management - with clinical signs of infection~FUNGAL: Continue with prevention methods, adding Clotrimazole 1% cream twice daily.~1. Prescribe order required for Clotrimazole 1% and must be reordered every 7 days unless prescribed for a longer duration~2. Discontinue use after the skin has healed~3. If no improvement after 3 days, consult a physician / NP~BACTERIAL: requires physician assessment"
40758852|NCT05407766|BIOLOGICAL|OSSM-001|Single injection of OSSM-001 at dose of 100M or 300M cells
40758853|NCT05407766|OTHER|Placebo|Single injection of placebo (saline)
40758854|NCT01456403|OTHER|Histological validation|3D ultrasound, PET/CT, MRI, contrast ultrasound
40758855|NCT02115243|DRUG|Ipilimumab|
40758856|NCT01084135|DRUG|Rivastigmine|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
40758857|NCT01084135|OTHER|Liquid Placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
40758858|NCT04941573|COMBINATION_PRODUCT|Hyperpolarized 129-Xenon (MagniXene) MRI of the lung|Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.
40758859|NCT00364195|DRUG|Tesmilifene (YMB1002)|
40758860|NCT00003067|BIOLOGICAL|aldesleukin|
40758861|NCT00003067|BIOLOGICAL|lymphokine-activated killer cells|
40758862|NCT02595437|DRUG|Triferic|
40758863|NCT04787341|DRUG|Regorafenib|"regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening."
41453792|NCT03807037|DRUG|Placebo oral capsule|Matching placebo to be administered orally at 1 capsule, twice daily
40990498|NCT02419742|DRUG|Carboplatin|TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams\*milliliter/minute \[mg\*mL/min\]) multiplied by (Glomerular Filtration Rate \[GFR\] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
40990499|NCT02419742|DRUG|Cyclophosphamide|AC-TH regimen: Cyclophosphamide 600 mg/m\^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
41453793|NCT02115776|DRUG|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
41453794|NCT02115776|DRUG|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
41453795|NCT02115776|DRUG|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
41453796|NCT05592808|DEVICE|Extracorporeal Shockwave Therapy (ESWT)|Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar
41453797|NCT05592808|OTHER|Low-Dye Taping|After ESWT application, Low-Dye Taping will be applied 3 times, once a week.
40948650|NCT03577288|BEHAVIORAL|manipulation of the presence and size of avatar|"The presence of avatar in the virtual experience will be manipulated. In one condition the avatar will be present and in another condition the avatar will not be present. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., with avatar and negative stimuli, without avatar and negative stimuli, with avatar and positive stimuli, etc.).~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar.~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
40990500|NCT02419742|DRUG|Docetaxel|AC-TH regimen: Docetaxel 100 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m\^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
41287615|NCT01905735|DRUG|placebo|1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
41453798|NCT05592808|OTHER|Kinesio Taping|After ESWT application, Kinesio Taping will be applied 3 times, once a week.
41453799|NCT04692558|BIOLOGICAL|HYALURONIC ACID|Hyaluronic acid will be applied on denuded root surface after reflection of isolated gingival recession.
41453800|NCT04692558|PROCEDURE|coronally advanved flap with connective tissue harvesting|Coronally advanced flap surgery with connective tissue harvesting from palate
41453801|NCT00597454|OTHER|Patient Navigation|"we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose."
41453802|NCT05801822|DIAGNOSTIC_TEST|serum T.S.H level test|, the blood samples will be collected and to be assessed for the routine antenatal screening CBC, random blood sugar, HBV and HIV, the same blood sample will be used to asses TSH level.
41287616|NCT02601781|PROCEDURE|Primary percutaneous coronary intervention (PPCI)|Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
41287617|NCT02601781|DEVICE|Bioresorbable Vascular Scaffold (BVS ABSORB)|BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
40786396|NCT01035502|DRUG|Elacytarabine plus idarubicin|"Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.~Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.~It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy."
41287618|NCT01614457|DRUG|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
41287619|NCT01614457|DRUG|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
41287620|NCT03738124|DEVICE|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA device is a modular two-component system consisting of a main stent graft (MSG) and a branch stent graft (BSG), delivered separately, designed to maintain LSA perfusion. Briefly, under general anesthesia and after heparin injection, a MSG access is achieved via a femoral artery. A Through-and-through wire access for delivery of the BSG is achieved via a brachial artery. After the placement of the main aortic stent graft in the arch with the cuff at the level of the ostium of the LSA, the BSG is placed through a femoral access.
41287621|NCT03887572|OTHER|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
41287622|NCT02975648|BEHAVIORAL|educational model + follow up|Orientation from health professionals at discharge, educational program with explanation of booklets and telephone follow-up (three calls)
41287623|NCT02975648|BEHAVIORAL|usual care|Hospital health professionals offered orientation on care after discharge
41287624|NCT05858008|BEHAVIORAL|Time-restricted eating|Subjects will be educated about the health benefits of time-restricted eating. Each subject will self-select a 10-hour (10hr +/- 1 hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily calories for the duration of the study.
41287625|NCT00408278|DRUG|ATRA|45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
41287626|NCT00408278|DRUG|Idarubicina|Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
41287627|NCT00408278|DRUG|Mitoxantrone|Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
41287628|NCT00408278|DRUG|ARA-C|In high risk patients, consolidation with ara-C in cycles 1 and 3.
41287629|NCT05253131|DRUG|Selumetinib|"* Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low grade gliomas, and NF1-associated plexiform neurofibromas.~* BI is a potent and selective inhibitor of BRD4/BET bromodomain currently in development for adult malignancies.~* Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is currently indicated for patients with advanced urothelial carcinoma and unresectable non-small cell lung cancer."
41287630|NCT04230850|OTHER|Static Cupping|Two cups will be applied unilaterally to the lumbar paraspinals. The skin will be elevated to 1.5 cm ensuring standardized pressure. Cups will remain on the treatment area statically for 4 minutes prior to removal. Another 4 minute bout of identical treatment to the contralateral side will follow. (Participants will be equally dispersed into three treatment groups via stratified randomization).
41287631|NCT04230850|OTHER|Dynamic Cupping|One cup will be applied ipsilaterally, raising skin to 1.2 cm of standard pressure. The cup will be continuously moved in a sweeping motion between L1 and L5 within a defined width. This process will be repeated on the other side. Each side will be treated for 4 minutes dynamically for a total treatment duration of 8 minutes. (Participants will be equally dispersed into three treatment groups via stratified randomization).
41287632|NCT04230850|OTHER|Stretching|The stretching program performed will involve a double knee to chest stretch, cat stretch, camel stretch, and pelvic tilts. Participants will receive a 30 second rest break between each of the four stretches. (Participants will be equally dispersed into three treatment groups via stratified randomization).
41287633|NCT02207387|DRUG|Azilect|Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
41287634|NCT02207387|BEHAVIORAL|Exercise|Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
41287635|NCT02207387|OTHER|Music|
41287636|NCT02981212|DRUG|Mycophenolate Mofetil|less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally
41287637|NCT02981212|DRUG|ACE inhibitor|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
41287638|NCT02981212|DRUG|Corticosteroid|combination with Mycophenolate Mofetil
41287639|NCT02981212|DRUG|ARB|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
41287640|NCT03466554|DEVICE|Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes|60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
40948651|NCT03577288|BEHAVIORAL|manipulation of interaction|"Virtual experience condition will be manipulated. In one condition the participants will be exposed to the virtual experience in which they will be able to interact with some of the stimuli, in another condition they will not be able to interact with the stimuli (passive watching). In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., interaction possible - negative stimuli, interaction impossible - negative stimuli, interaction possible - positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
40948652|NCT03577288|BEHAVIORAL|manipulation of the nature of stimulus|The nature of the stimuli with which the participants will interact will be manipulated. During virtual experience the participants will have a choice to interact or not with the virtual environment, in one condition with animate stimuli and in another condition with inanimate stimuli. In addition, emotional category of animate and inanimate stimuli will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., condition with animate negative stimuli, condition with inanimate negative stimuli, condition with animate positive stimuli). The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
41287641|NCT00236561|DRUG|topiramate, propranolol|
41287642|NCT06340594|PROCEDURE|Laproscopic cholecystectomy (LC)|Removal of gallbladder via laparoscopy
41287643|NCT06340594|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Removal of bile duct stones via endoscopy
41287644|NCT03083912|DIETARY_SUPPLEMENT|Fortimel Complete|The residents included receive 2 bottle por day.
41287645|NCT05734872|DEVICE|Virtual Reality Technology|Make a pair of glasses through virtual reality technology, through which participants can observe and participate in the treatment process.
41287646|NCT05734872|OTHER|Routine mental health course training|Conduct mental health education for patients by making a speech.
40786397|NCT04554303|DRUG|S-amlodipine 2.5mg|Oral administration, 1 tablet per day
40948653|NCT06285461|BEHAVIORAL|Non-palatable meal|Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with low hedonic reward.
40948654|NCT06285461|BEHAVIORAL|Palatable meal|Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with high-hedonic reward.
40948655|NCT05290792|BIOLOGICAL|Administration of FluMist (Live Attenuated Influenza Vaccine)|Participants will received the intranasal FluMist vaccine that will serve as a proxy for a viral respiratory tract infection and trigger a mild immune response.
40948656|NCT04080960|BEHAVIORAL|Lifestyle modification education|Lifestyle modification education and goal setting
40948657|NCT01898208|DEVICE|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
40948658|NCT01898208|BEHAVIORAL|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
40948659|NCT01898208|OTHER|Bacterial culture|This test identifies the pathogen responsible for an infection.
40948660|NCT01898208|OTHER|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
40948661|NCT01192373|OTHER|Metabolic substrate modulation|for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
40948662|NCT01192373|OTHER|metabolic substrate modulation|low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
41287647|NCT00787007|DRUG|S-equol|capsule, oral, single dose
41287648|NCT00787007|DRUG|Placebo|capsule, oral, single dose
40786398|NCT04554303|DRUG|Amlodipine 5mg|Oral administration, 1 tablet per day
41287649|NCT04416776|DRUG|Strabismus diagnostic system.|An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
41287650|NCT05616234|PROCEDURE|Resistance Exercise|Participants will perform a bout of lower body resistance exercise consisting of leg press, leg extension and leg curls.
41287651|NCT03721328|COMBINATION_PRODUCT|vancomycin hydrochloride and tobramycin sulfate|vancomycin hydrochloride and tobramycin sulfate via local irrigation
41287652|NCT00463970|BEHAVIORAL|Brief Intervention|Physical examination, education and follow up by a physiotherapist
41287653|NCT00463970|BEHAVIORAL|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
41287654|NCT00463970|DIETARY_SUPPLEMENT|Seal oil|20 capsules per day for 3 months
41287655|NCT00463970|DIETARY_SUPPLEMENT|Soy oil|20 capsules per day for 3 months
40948663|NCT01381484|DRUG|10% Argireline|10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
40948664|NCT05660226|OTHER|Home blood pressure monitoring (telemonitoring)|Using a digital mobile phone based telemonitoring platform to A: monitor patients and adjust their treatment accordingly based on the remote monitoring outcomes and B: provide E-Coaching/self learning modules (lifestyle)
40948665|NCT05660226|OTHER|Standard care|Standard outpatient blood pressure management
40758864|NCT04787341|DRUG|Panitumumab|"panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening."
40758865|NCT02219100|DRUG|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
40758866|NCT04823052|DRUG|Sulindac (HLX-0201), dose strength 1|Sulindac (HLX-0201) Capsule
40758867|NCT04823052|DRUG|Sulindac (HLX-0201), dose strength 2|Sulindac (HLX-0201) Capsule
40758868|NCT04823052|DRUG|Placebo|Placebo Capsule
40758869|NCT04823052|DRUG|Gaboxadol (HLX-0206)|Gaboxadol (HLX-0206) Capsule
40758870|NCT02094885|BIOLOGICAL|Bioseal Fibrin Sealant|
40758871|NCT02094885|OTHER|Manual Compression|
40758872|NCT05073731|OTHER|Telerehabilitation-based Upper Extremity Training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.~Synchronized telerehabilitation provides the participant with advantages such as customized treatment, instant feedback, and a social environment such as face-to-face training."
40758873|NCT00318136|DRUG|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
40758874|NCT00318136|DRUG|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
40758875|NCT00318136|DRUG|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
40758876|NCT06500689|DRUG|Allisartan Isoproxil/Sustained-Release Indapamide|"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil/Sustained-Release Indapamide.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."
40758877|NCT06500689|DRUG|Allisartan Isoproxil|"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."
40758878|NCT04601831|RADIATION|Focal radiation therapy (RT)|"Radiation therapy for phase II:~Definitive 40-50 Gy EQD2 (i.e. 30 Gy in 5 fractions)~Hypofractionated regimen (i.e. 5 fractions in 1-2 weeks) recommended, but other fractionation schemes (10-20 fractions in 2-4 weeks) allowed."
40758879|NCT00667043|DRUG|remifentanil and propofol|Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
40758880|NCT00667043|DRUG|fentanyl and midazolam|Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
40948666|NCT03918161|DEVICE|MRE exam|Magnetic Resonance Elastography
40948667|NCT04269707|DRUG|Ferric carboxymaltose|IV iron
40948668|NCT05490875|PROCEDURE|Carotid ultrasound|Carotid ultrasound will be done to both sides of the neck to look at the carotid arteries.
40758881|NCT01594814|PROCEDURE|RFA|radiofrequency ablation of slow pathway or accesory pathway
40758882|NCT01489826|DRUG|Dexanabinol|Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.
40758883|NCT01489826|OTHER|Cremophor|Drug vehicle.
40758884|NCT06415383|DRUG|Vitamin B6 100 MG|Vitamin B6 in for the form of pyridoxal phosphate (PLP)
40758885|NCT06415383|OTHER|Placebo|Placebo tablet containing microcrystalline cellulose
40758886|NCT03303066|DRUG|FG-4592|Oral
40758887|NCT03303066|DRUG|Placebo|Oral
40758888|NCT03578263|DRUG|Carbetocin|Group (A): included 100 patients who received carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby.
40758889|NCT03578263|DRUG|oxytocin|Group (B): included 100 patients who received a combination of intraoperative oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist and
40758890|NCT03578263|DRUG|ergometrine|intramuscular ergometrine 0.2 mg.
40786399|NCT02735018|DRUG|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
40786400|NCT02735018|DRUG|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
40786401|NCT04524988|PROCEDURE|Laparoscopic Simulation Training|All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).
40786402|NCT03824392|BIOLOGICAL|Efzofitimod 1.0 mg/kg or Placebo|Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
40948669|NCT05490875|OTHER|Blood draw|This optional blood draw could occur anytime from the time of enrollment on the study until 90 days after the research ultrasound.
40948670|NCT05490875|OTHER|Survey|Participants will complete a 15-minute survey about how acceptable participants find the ultrasound procedure, whether participants would be open to it in the future if a doctor thought it was necessary, whether participants would be open to getting treatment for artery problems, and how participants feel about their own risk of stroke.
41287656|NCT00718133|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
40948671|NCT05868759|RADIATION|Roentgen Stereophotogrammetric Analysis (RSA)|"Roentgenstereophotogrammetric analysis (RSA) is a radiographic technique, highly accurate both to evaluate the primary stability of the implant, then the micromovements between bone and implant prosthetic, both for the evaluation of the kinematics of the prosthetic components. The RSA technique in dynamics is able to obtain, with patient in motion, a series of radiographic frames in sequence in two projections, which are captured simultaneously. Each pair of orthogonal projections corresponds to a specific moment of the movement carried out by the patient and will be used to obtain, through dedicated software, a reconstruction three-dimensional instant defined RSA scenes."
40948672|NCT05868759|DEVICE|Delos Postural Proprioceptive System (computerized oscillating platform)|The Delos Postural Proprioceptive System uses electronic tilting tables (on a single axis or three axes) with high frequency that allows very short stop and reversal times that allow both to study the proprioception and the patient's response to the modification of movement of the inclined plane
40948673|NCT05868759|DIAGNOSTIC_TEST|Modified Star Excursional Balance Tests|The Star Excursional Balance Test (SEBT) is a clinical test designed for the evaluation of dynamic physical performance of the tibiotarsica. The first literary references date back to 1998 and the test, remaining in balance with the ankle in the studio, the achievement of the maximum possible distance with the contralateral foot along well-defined axes.
40948674|NCT05868759|DEVICE|Inertial sensors Xsens MVN|"The inertial motion acquisition system Xsens MVN is easy to use and economic to detect the movement of different anatomical districts. MVN is based on inertial sensors in miniature through communication solutions combined with advanced fusion algorithms sensors, using hypotheses of biomechanical models.~This MVN system is a system of inertial kinematic measurement of the whole body, which incorporates synchronized data. Instant graphic output is provided, including angles of motion articular."
40948675|NCT05868759|OTHER|American Orthopaedic Foot and Ankle Score (AOFAs)|American Orthopaedic Foot and Ankle Score (AOFAs) is a clinical trial commonly used in scientific literature which serves to assess, in terms of value from 0 to 100, the autonomy, pain, stability, ankle alignment and back foot of the patient.
40948676|NCT05868759|OTHER|Visual Analogue Scale (VAS)|The Visual Analogue Scale (VAS) is a visual representation of the extent of pain that the patient subjectively warns. The VAS is represented by a 10 cm long line in the original version validated, with or without notches at each centimeter. One end indicates the absence of pain and corresponds to 0, the other end indicates the worst pain imaginable and corresponds to 10.
40948677|NCT05868759|OTHER|12-Item Short Form Survey (SF-12)|The 12-Item Short Form Survey (SF-12) is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
40948678|NCT01161732|PROCEDURE|Early surgery|Early surgery is performed within 2 months of randomization.
40948679|NCT02104752|DRUG|Curcumin|360 mg/day (divided into twice daily oral doses)
40948680|NCT02104752|DRUG|Placebo|"Inactive, matched placebo (Sugar Pill)"
40948681|NCT05130918|DEVICE|Phenolmicin P3 and Bosexil suppository|The suppository we herein investigated includes different active principles, namely: Bosexil®, that is a vegetal extract derived from the resin of the Boswellia serrata, a plant native to India. It has already been published that the Boswellic acids contained show anti-inflammatory and antioxidant properties in a variety of inflammatory diseases whose physio-pathological pathways are shared with those of prostatitis; phenolmicin P3 is a polyphenolic extract derived from beehive propolis, that also demonstrated anti-inflammatory and antioxidant properties in preclinical reports. It has also been reported to have the ability to create a microenvironment hostile to the reproduction of pathogenic bacteria.
40948682|NCT03303014|DEVICE|5-0 Prolene, 5-0 Fast Absorbing Gut|The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
40948683|NCT06019585|DEVICE|Splint inmmobilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with a plaster splint of París for 3 weeks
40948684|NCT06019585|DEVICE|Bandage immovilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with compressive bandage for 3 weeks
40948685|NCT05317624|COMBINATION_PRODUCT|Platelet rich plasma|platelet rich plasma will be obtained from the particepants own blood mixed with activator and bupivacaine
40948686|NCT05317624|COMBINATION_PRODUCT|Methylprednisolone|1ml methyl prednisolone 40mg\\ml mixed with normal saline and bupivacaine
40948687|NCT05931874|BEHAVIORAL|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the study self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the study. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the study app and provide Fitbit data to the study team in real-time.~The core study app will support BCS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
40990501|NCT02419742|DRUG|Doxorubicin|Participants will receive Doxorubicin 60 mg/m\^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
40990502|NCT02419742|DRUG|Paclitaxel|AC-TH regimen: Paclitaxel 175 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
41287657|NCT04876664|DEVICE|measuring blood pressure with noninvasive blood pressure device|To measure blood pressure in different circumstances with noninvasive blood pressure device
41287658|NCT06295926|DRUG|Serplulimab|Undergo 4 cycles of synchronous radiotherapy and chemotherapy combined with Sintilimab immunotherapy, followed by Sintilimab monotherapy for maintenance treatment until disease progression or up to 1 year.
41287659|NCT03507400|BEHAVIORAL|Introvision: mental and emotional self-regulation|Participants learn Introvision
41287660|NCT02005523|DRUG|RNS60|
41287661|NCT02005523|DRUG|Saline|
41287662|NCT01351519|DRUG|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
41287663|NCT06480045|PROCEDURE|Performed PECS II block with AI integrated USG|A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with AI-integrated USG.
41133510|NCT00783146|DRUG|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
41287664|NCT06480045|PROCEDURE|Performed PECS II block with conventional USG|A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with conventional USG.
41287665|NCT02545374|OTHER|Telemedicine|
41287666|NCT02545374|OTHER|Control|
41287667|NCT03490344|DRUG|Daratumumab|"* Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)~* Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)"
41287668|NCT03490344|DRUG|Lenalidomide|Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.
41287669|NCT04740749|DEVICE|Compress Compliant Pre-Stress System|Treatment of malignant femor tumors with the Compress Compliant Pre-Stress System
41287670|NCT06108479|DRUG|DF6215|Immunotherapy (cytokine) targeting effector cells.
41287671|NCT00231920|BIOLOGICAL|Fluzone|
41287672|NCT05837260|OTHER|Sample collection only|Sample collection only
41453803|NCT03769428|PROCEDURE|erector spinae plane block|The ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Local anesthetic (LA) is injected between the erector spinae muscle and transverse process. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid. Then 40cc of Ropivacaine (3.75mg/cc) will be injected .The distribution will be observed in both cranial and caudal directions.
41453804|NCT03769428|PROCEDURE|sham erector spinae plane block|The sham ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid a total of 40 mL of fluid will be injected next between the erector spinae muscle and transverse process. Then 40cc of normal saline will be injected.The distribution will be observed in both cranial and caudal directions.
41453805|NCT02637141|BIOLOGICAL|AMG 714|AMG 714 administered by subcutaneous injection
41453806|NCT02637141|BIOLOGICAL|Placebo|Matching placebo to AMG 714 administered by subcutaneous injection
41453807|NCT02637141|OTHER|Placebo Gluten Challenge|Gluten-free cookies (Finnish rusks)
41133511|NCT00783146|DRUG|placebo|placebo, once daily for 15 days
40786403|NCT03824392|BIOLOGICAL|Efzofitimod 3.0 mg/kg or Placebo|Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
40786404|NCT03824392|BIOLOGICAL|Efzofitimod 5.0 mg/kg or Placebo|Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
41133512|NCT02751710|OTHER|Whole-body FDG PET-CT alone|FDG PET-CT imaging
41133513|NCT01961076|OTHER|overnight nutrition regime|Patients receive the specified overnight nutrition regimen
41287673|NCT01145391|OTHER|Active Outreach to Patients and Providers|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
41287674|NCT05679726|BEHAVIORAL|massage|reflexology foot massage
41287675|NCT04293250|PROCEDURE|Compare the severity of postoperative pain of the physical activity group Vs non-physical activity group|Compare postoperative pain scores for the physical activity Vs non-physical activity group
41287676|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
41287677|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
41287678|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
41287679|NCT01341873|OTHER|educational intervention|Undergo APN FCI
41287680|NCT01341873|OTHER|psychosocial support for caregiver|Undergo APN FCI
41287681|NCT01341873|PROCEDURE|quality-of-life assessment|Ancillary studies
41287682|NCT01341873|OTHER|questionnaire administration|Ancillary studies
41287683|NCT01623687|DEVICE|Component for acetabulum (Regenerex RingLoc cup)|A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
41287684|NCT01623687|DEVICE|Components for the acetabulum (Lubinus cross linked cup)|cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
41287685|NCT01623687|DEVICE|Arthroplasty components are for the femur (Cemented Lubinus SP II stem)|Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
41287686|NCT01623687|DEVICE|Arthroplasty components are for the femur (Corail stem)|Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson \& Johnsson, USA).
41287687|NCT04073212|OTHER|Dry Needling|Dry needling directly to the long head of the biceps tendon. The DN will be performed with disposable stainless-steel needles (.3 X 40mm; Seirin; Weymouth, MA) inserted into the skin over the most painful and/or thickened areas of the tendon, confirmed with palpation. Prior to insertion of the needle the overlying skin will be cleaned with alcohol. The needle will be inserted into the tendon. The technique will be a fast-in and fast-out technique described by Chiavaras et al.26 for 20-30 repetitions per session in up to 3 areas. An eccentric-concentric exercise program of the biceps muscle/tendon will follow each DN session and will be performed daily for the course of treatment and will be performed as described by McDevitt et al.
41287688|NCT04073212|OTHER|Heavy Slow Load Exercise|Eccentric exercise protocols have been found to be an effective treatment for tendinopathies of the upper and lower extremities and recent evidence supports heavy slow resistance training (including the addition of a concentric phase) as having better outcomes over eccentric exercise alone. Patients will use 1-5 pound weights to perform slow and controlled concentric and eccentric exercise to biceps muscle.
41287689|NCT04073212|OTHER|Rotator cuff and scapular stabilization exercise program|Both groups will be treated with a stretching and strengthening program. The rotator cuff and scapular stabilization strengthening and flexibility program used in this study has 3 phases and patients progress in phases based on their ability to perform a number of exercises using theraband or body weight resistance.
41287690|NCT04073212|OTHER|Soft tissue mobilization|Both groups will receive soft tissue mobilization to the anterior shoulder.
40758891|NCT03223805|OTHER|Respiratory Distress Symptom Intervention|"The RDSI comprises of four components~1. Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~2. Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~3. Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~4. Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required"
40758892|NCT06402474|PROCEDURE|sunbed position|30° reverse trendelenburg legs together 30° hip flexion (sunbed position)
41287691|NCT03679494|OTHER|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions
41287692|NCT03797443|DRUG|Ascorbic Acid|"Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid."
41133514|NCT06128915|OTHER|vaccine|Vaccination against 20 serotypes of S. pneumoniae
41287693|NCT03797443|DRUG|nab paclitaxel|30 minute IV infusions on days 1 and 8 repeated every 21 days, followed by Cisplatin
41287694|NCT03797443|DRUG|Cisplatin|60minute IV infusion on days 1 and 8 repeated every 21 days followed by Gemcitabine
41287695|NCT03797443|DRUG|Gemcitabine|30 minute IV infusion on days 1 and 8 repeated every 21 days
41287696|NCT04019496|DRUG|antibodies against calcitonin-gene related peptide or its receptor|the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient
41287697|NCT03974178|DRUG|Fexinidazole|Adults and Children patients will receive fexinidazole tablets every day for 10 days
41453808|NCT02637141|OTHER|Gluten Challenge|Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving
41453809|NCT01693809|DRUG|Caffeine|
41287698|NCT03946306|DRUG|5,25% NaOCl with syringe needle irrigation alone|In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
41287699|NCT03946306|DEVICE|EDDY|In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.
41287700|NCT01326962|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
41287701|NCT04883073|DEVICE|Use of Endo App|Use of Endo App
41287702|NCT02509338|DEVICE|Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)|Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
41287703|NCT01037712|DRUG|Valacyclovir (ZELITREX)|2g, 8g/day, 4 a day 23 weeks maximum.
41133515|NCT02449785|DEVICE|MR measurements of lung morphological changes in cystic fibrosis (Avanto dot, Siemens)|
41287704|NCT01037712|DRUG|Placebo|placebo
41287705|NCT00053820|BIOLOGICAL|aldesleukin|
40758893|NCT00730600|PROCEDURE|Thai Traditional massage|Thai traditional massage for 2 hours by a single masseuse.
40758894|NCT01029873|DRUG|Cisplatin|Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
41133516|NCT02449785|DEVICE|CT measurements of lung morphological changes in cystic fibrosis|
41133517|NCT00830856|DRUG|Fluconazole|Fluconazole 800mg po qday
41133518|NCT00830856|DRUG|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
41287706|NCT00053820|BIOLOGICAL|recombinant interferon alfa|
41287707|NCT00053820|DRUG|fluorouracil|
41287708|NCT01269034|DRUG|Exenatide|1.25 mcg before the boost sub-cutaneously.
41287709|NCT01269034|DRUG|Rapid and long acting insulin|Depends on their Carbohydrate ratio and body needs
41287710|NCT01269034|DRUG|long acting insulin + rapid acting + 1.25 mcg Exenatide|Depends on their body needs.
41287711|NCT05182515|DRUG|Therapeutic plasma exchange|"Plasma exchange techniques reported in COVID-19 vary from study to study. No consensus exists on the use of a specific technique.~The use of a central venous catheter will be left to the discretion of investigators. If so, central venous catheter will be inserted through the internal jugular or femoral route under ultrasound control by a trained operator. After radiographic control of the position of the catheter and the absence of complications in the placement of the catheter, plasma exchanges will be carried out.~Three plasma exchanges of 1.5 plasma volume will be carried out every 48 hours on D1, D3 and D5. Plasma volume will be assessed by this equation VP = (1-Hct)x70xweight Body(measured). The substitution volume will be 5% albumin as first intervention. The use of a hemofiltration or centrifugation technique will be left to the discretion of each center."
41133519|NCT00830856|DRUG|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
41287712|NCT02596880|DRUG|Sofosbuvir|400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
41287713|NCT02596880|DRUG|Daclatasvir|60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
41287714|NCT02596880|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
41287715|NCT01533155|DRUG|Nektar 118|Oral 25 mg tablet
41287716|NCT01533155|DRUG|Quinidine|Oral 200 mg tablet
41453810|NCT05092035|DIAGNOSTIC_TEST|single high-fidelity expiratory CO2 analysis|in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed
40758895|NCT01029873|BIOLOGICAL|ALT-801|"Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)"
40758896|NCT05333588|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|The autologous TILs will be intravenous infused into patients.
40758897|NCT03123562|COMBINATION_PRODUCT|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
40758898|NCT03370835|DRUG|Metoprolol succinate ER|Cardioselective beta-blocker
40758899|NCT03370835|DRUG|Carvedilol|Non-cardioselective beta-blocker
40758900|NCT04717479|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
40758901|NCT03699995|OTHER|Confocal Microscopy|Undergo confocal microscopy
40758902|NCT03699995|OTHER|Dermoscopy|Undergo digital dermoscopy
40758903|NCT03699995|PROCEDURE|Imaging Technique|Undergo MoleMapper/Sklip app/native smartphone camera app imaging with smartphone
40758904|NCT03699995|DRUG|Lidocaine|Given SC
40758905|NCT03699995|PROCEDURE|Punch Biopsy|Undergo punch biopsy
40758906|NCT03699995|PROCEDURE|Shave Biopsy|Undergo shave biopsy
40758907|NCT04495998|DIAGNOSTIC_TEST|Brief Motor Scale_portuguese version (BMS_pt)|translate, adapt and validate Brief Motor Scale for portuguese population with schizophrenia
40758908|NCT06500455|PROCEDURE|Computed Tomography|Undergo CT
41287717|NCT01533155|DRUG|Quinidine placebo|Oral Tablet
41287718|NCT01533155|DRUG|Morphine|10 mg/ml, intravenously
41287719|NCT04696835|DIAGNOSTIC_TEST|speech audiometry|65dB, 55dB or 75dB SPL speech audiometry
41287720|NCT02973672|DRUG|SGM-101|4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
41287721|NCT01347684|BEHAVIORAL|Behavioral therapy, splint therapy and physical therapy|Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
41287722|NCT01347684|DRUG|Standard care using current drugs|Standard Drug therapy
41287723|NCT01220219|DRUG|Pregabalin controlled release, 82.5 mg|Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
41453811|NCT01875562|DRUG|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
41287724|NCT01220219|DRUG|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for four days.
41287725|NCT01220219|DRUG|Pregabalin immediate release, 75mg|75 mg immediate release capsule administered every 12 hours for four days
41287726|NCT00749086|DEVICE|balloon kyphoplasty|Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
41287727|NCT00749086|PROCEDURE|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
41287728|NCT03882840|BIOLOGICAL|ITNK cell therapy|Infusion of ITNK/CAR-ITNK cells
41287729|NCT01042301|OTHER|Blood samplings|
41287730|NCT02887846|DEVICE|Heated Humidified High-Flow Nasal Cannula|Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 \< 0,40, Pa CO2 \< 65 mmHg, pH\> 7.20, MAP (mean airway pressure) \<7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is\<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 \< 0.30 at 24 hours and above, free oxygen will be introduced.
41287731|NCT03714841|OTHER|CRP|Knowledge of CRP value
41287732|NCT06251388|DRUG|AK104|AK104（10.0 mg/kg，intravenous (IV) infusion，Q3W）maintained with no more than 1 year.
41287733|NCT06296810|DEVICE|aDBS|adaptive deep brain stimulation
41287734|NCT05197244|BEHAVIORAL|Culinary Medicine Intervention|A 2-hour practical culinary medicine program facilitated by a culinary dietitian at a hospital-based teaching kitchen, followed by 3 virtual group follow-up sessions occurring monthly, each lasting approximately 30 minutes. The follow-up sessions will be facilitated by a culinary dietitian and will be conducted using a secure telephone/video conference platform.
41287735|NCT04298346|OTHER|no intervention|no intervention
41453812|NCT05714293|RADIATION|CT scan with contrast medium|Multi-detector CT scan (if possible with prospective-ECG gated sequential scan) with contrast medium injection of nonionic contrast agent. All CT datasets will be analysed for the qualitative and quantitative assessment of the aortic root. The coronary height will be assessed at baseline in relation to the aortic annulus and in relation to the stent of the bioprostheses after aortic valve replacement.
41453813|NCT01790685|DRUG|dexamethasone implant|
41287736|NCT02652819|DRUG|FG-4592|
41287737|NCT02652819|DRUG|Placebo|
41287738|NCT00116311|BEHAVIORAL|allergen inhalation|
41287739|NCT00116311|BEHAVIORAL|withdrawal of medication|
41287740|NCT00116311|PROCEDURE|sputum induction|
41287741|NCT01415960|DRUG|Leuprolide acetate 22.5 mg depot, GP-Pharm SA|Administered by im injection, twice during the study, three months apart
41287742|NCT03048448|DRUG|Fevipiprant|Single 450mg dose
41287743|NCT03173521|BIOLOGICAL|AAV2/8.TBG.hARSB|"Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Four dose levels are available:~* Starting dose is 6x1011 gc of vector per kg of body weight;~* High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT;~* Very high dose is 6x1012 vector per kg of body weight and will be administered after three subjects at the high dose have experienced no DLT;~* Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
41453814|NCT06320860|DEVICE|Kidney Stone Retrieval|Using FlexStone Basket aimability to retrieve kidney stones
41453815|NCT05215587|DEVICE|TEVAR|A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.
41453816|NCT00292227|DRUG|Rotigotine|"Rotigotine patch applied once daily for a 24-hour period.~Rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
41453817|NCT00292227|OTHER|Placebo|"Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
41453818|NCT00292227|DRUG|Moxifloxacin infusion|Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
40758909|NCT06500455|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FSRS
40758910|NCT06500455|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40948688|NCT05931874|BEHAVIORAL|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
40948689|NCT05931874|BEHAVIORAL|Buddy|"Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the study app modules the participant has access to for their assigned condition.~The study app include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcast (one every 3 weeks) during the first 24 weeks of the intervention. Each webinar will provide social support training and peer discussion of challenges and successes in providing BCS with MVPA support."
41453819|NCT00292227|OTHER|Placebo infusion|Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
41453820|NCT00292227|OTHER|Placebo infusion|Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
41453821|NCT02164435|PROCEDURE|Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.|
40758911|NCT06500455|RADIATION|Stereotactic Radiosurgery|Undergo SRS
40758912|NCT02448173|BIOLOGICAL|OncoVAX and Surgery|OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
40758913|NCT02448173|PROCEDURE|Surgery|Surgical resection of Stage II colon cancer
40758914|NCT03722628|DIAGNOSTIC_TEST|MMP1 genotypes polymorphism|Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis
40758915|NCT02206438|DEVICE|Insertion of C-LMA|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
40758916|NCT02206438|DEVICE|Insertion of air-Q according|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
40758917|NCT04957927|DRUG|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
40758918|NCT05683275|OTHER|IASTM|IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute.
40758919|NCT05683275|OTHER|ESWT|ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application.
40758920|NCT05683275|OTHER|Home Exercise|Special static stretching and eccentric strengthening exercises for the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks.
40758921|NCT02100033|DEVICE|acupuncture|
40758922|NCT01832298|DRUG|Simmitecan Hydrochloride for Injection|Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
40758923|NCT05231252|PROCEDURE|Cyclophotocoagulation|Transcleral cyclophotocoagulation is used to treat glaucoma secondary to silicone oil.
40758924|NCT04332185|PROCEDURE|vestibular socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
40758925|NCT06434779|DEVICE|JETi 6F and 8F Thrombectomy system|To demonstrate the efficacy and safety of the mechanical thrombectomy device (JETi 6F and 8F) for treatment of patients with symptomatic peripheral artery disease (PAD) due to acute or acute on chronic occlusions of the femoral and/or popliteal arteries and the first 10 cm of the below-the -knee arteries.
40758926|NCT01888198|BEHAVIORAL|(EORTC QLQ-C30) questionnaire|
40758927|NCT01888198|BEHAVIORAL|EuroQol EQ-5D 7-item questionnaire|
40758928|NCT03733782|DIETARY_SUPPLEMENT|Modular enteral protein - Prosource|Supplemental protein (2 gm/kg/day of Prosource; Medtrition, Lancaster, PA) was administered via the nasal/oral feeding tube in 60 - 180 ml bolus infusions 2 - 4 times per day, independently of the enteral formula received. That is, the daily target amount of protein was initially administered as the supplement boluses and only after the enteral formula infusion approached the target rate was the amount of supplement decreased. Supplemental protein was reduced by 50% once the patient received 75% of targeted caloric intake over the previous day (0700 - 0700). Once the patient reached the target caloric intake for 48 hours, the amount of supplemental protein was decreased in order that the total protein prescribed equaled 2 gm/kg/day.
40758929|NCT04502186|BEHAVIORAL|Raising Our Spirits Together|Raising Our Spirits Together (ROST) is an 8-session computer-assisted cognitive behavioral therapy for depression. Core CBT content, including behavioral activation, cognitive restructuring, and problem solving, are delivered via the computer-assisted platform using video and text-based elements. The computer-assisted intervention is complemented by a workbook that includes in-session exercises as well as homework/action plans. ROST is delivered weekly, either virtually or in-person at a local church, and facilitated by a local pastor.
40758930|NCT04502186|OTHER|Enhanced Control Condition|The Enhanced Control Condition intervention consists of providing participants randomized to this condition with a self-help book for depression (The Depression Helpbook; Katon et al, 2008) that is widely used and found to be beneficial, a local resource guide, and referrals.
40758931|NCT03009461|PROCEDURE|HAIC|Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
40758932|NCT03009461|DRUG|Sorafenib|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
40758933|NCT05333965|DEVICE|Lens A (lehfilcon A lens)|Daily wear for 1 month.
40758934|NCT05333965|DEVICE|Lens B (comfilcon A lens)|Daily wear for 1 month.
40758935|NCT03717454|OTHER|Surgery|The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .
40758936|NCT03717454|DRUG|Drug treatment|The medication will continue if DA causes tumors to shrink.
40758937|NCT02980185|PROCEDURE|Laparoscopic primary cytoreduction|Primary cytoreduction for ovarian cancer performed through a completely minimally-invasive approach
40758938|NCT03015779|OTHER|cultured autologous oral mucosal epithelial cell sheet|a prospective study,Before and after self control
40758939|NCT02346812|OTHER|Controlled diet without brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
40758940|NCT02346812|OTHER|Controlled diet with brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
41287744|NCT02498223|OTHER|experiment protocol|"the subjects will undergo the following experiment protocol:~1. recruitment and medical examination day.~2. physiological evaluation day- the subjects will perform twice\* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.~3. biomechanical valuation day- the subjects will perform twice\* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.~   * once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances."
41287745|NCT05313230|OTHER|CITRASATE SLED|Applying of CITRASATE SLED
41287746|NCT04932590|OTHER|End-expiratory occlusion test|The test consists in interrupting the ventilator at end-expiration for 15 seconds and assessing the resulting changes in cardiac output. Delays necessary to allow sufficient pulmonary transit time to allow good pulmonary venous return and therefore an increase in cardiac preload.
40758941|NCT03199534|DRUG|Botulinum toxin A 50u|Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
40758942|NCT03199534|DRUG|Botulinum toxin A 100u|Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.
40758943|NCT03199534|DRUG|Botulinum toxin A 150u|Subject will receive injection of 150u Botulinum toxin A while anesthetized.
40758944|NCT06143423|DRUG|AP026 (TQA2226) for injection|AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.
40758945|NCT06143423|DRUG|AP026 (TQA2226) for injection matching placebo|AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.
40758946|NCT05175378|OTHER|Lifestyle intervention|We investigated the potential cardiovascular health effects of the Mediterranean dietary pattern on adult women with relapsing-remitting multiple sclerosis, in regards to body weight, body composition, cardiovascular blood biomarkers (fasting glucose, lipids, C-reactive protein), as well as depression and anxiety levels.
40758947|NCT06081959|DRUG|SKB264|IV infusion on day 1 and Day 15 of each 28 day cycle
40758948|NCT06081959|DRUG|Eribulin|1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
40758949|NCT06081959|DRUG|Capecitabine|1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
40758950|NCT06081959|DRUG|Gemcitabine|1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
40758951|NCT06081959|DRUG|Vinorelbine|25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
40758952|NCT04010838|PROCEDURE|spinal cord stimulation|The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
40758953|NCT05678127|PROCEDURE|Skin biopsy|"Two 3mm skin biopsies from the abdominal wall will be taken. One at the triggerpoint of the pain, the second one at the contralateral, non-affected side of the abdominal wall.~Lidocaine will be used for local anaesthesia of the skin, before the biopsies will be taken."
40758954|NCT03640988|DEVICE|dermaPACE|Shockwave application
40758955|NCT03345082|BIOLOGICAL|OPT-302|Intravitreal injection
40758956|NCT03345082|BIOLOGICAL|ranibizumab|Intravitreal injection
40758957|NCT03345082|OTHER|sham intravitreal injection|Sham (mock) intravitreal injection
40758958|NCT02557919|OTHER|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
40758959|NCT02557919|OTHER|Usual Best Practice|.5 day training on tobacco control and emerging products.
40758960|NCT06569277|OTHER|A mobile application|Those who agreed to download a mobile app for colonoscopic bowel preparation on their smartphones.
40758961|NCT04990310|DRUG|[14C]-CORT113176|\[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
40758962|NCT00674063|DRUG|alefacept|IV
40758963|NCT04205916|DRUG|Dexamethasone|Drugs to be administer during cataract surgery to experimental group
40758964|NCT04205916|OTHER|Standard of care surgery|Standard method used for surgery and the use of post operative drops
40758965|NCT04462419|RADIATION|Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography|Undergo PET-MRI imaging
40758966|NCT04462419|OTHER|Fluciclovine F18|Given IV
40758967|NCT02771145|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution that uses a platinum catalyst for neutralization and is intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
40758968|NCT02771145|DEVICE|Soft contact lenses (SCL)|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (180 days). A fresh pair will be dispensed on Day 0, Day 30, Day 60, and Day 135.
40758969|NCT02771145|DEVICE|SCL preservative solution|Commercially available solution for rinsing soft contact lenses
40758970|NCT03075943|DIETARY_SUPPLEMENT|InSea2|Daily supplement: 2 capsules of InSea2
40758971|NCT03075943|DIETARY_SUPPLEMENT|Placebo|Daily supplement: 2 capsules of Placebo
40758972|NCT05809154|DIAGNOSTIC_TEST|Video-Urodynamics|Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.
40758973|NCT02772120|DRUG|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
40758974|NCT02772120|DRUG|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
41287747|NCT03809546|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
41287748|NCT03809546|DRUG|dextrose|We are administering dextrose to health volunteers for our placebo group
41287749|NCT02756455|OTHER|gastric cancer pts undergoing surgery|Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
41287750|NCT00827203|DRUG|Elesclomol Sodium|Chemotherapy agent
40758975|NCT04297761|OTHER|Filtered Air|Ambient air will be filtered and used for control exposure.
41287751|NCT05295277|OTHER|Standard of care genetic testing group|N/A - no intervention as this is an observational study.
41287752|NCT03761953|DRUG|Oritavancin Injection|single 1200mg infusion of IV oritavancin.
41287753|NCT05994625|DEVICE|Stream™ Platform|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~Stream™ Platform utilizes the continuous measurements of drain effluent characteristics to generate a Risk Score that is provided to the surgeon. The Risk Score is intended to provide an additional tool for the early diagnosis of anastomotic leakage."
41287754|NCT05994625|DEVICE|Stream™ Platform with Risk Score Omitted|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~This version of Stream™ Platform is utilized purely for observational purposes. Therefore, no Risk Score is generated. This allows postoperative monitoring of patients without any influence from the Stream™ Platform."
41287755|NCT00642616|DRUG|Technosphere® Insulin|Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
41287756|NCT00642616|DRUG|Usual Care|Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
41287757|NCT06445335|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement.
41287758|NCT03176212|DIETARY_SUPPLEMENT|Milk fat globule membrane|
40758976|NCT04297761|OTHER|Wood Smoke|Wood smoke is generated by smoldering dry white oak logs and the exposure level will be maintained at an average of 500 µg/m\^3 for 2 hours.
41287759|NCT03048097|DRUG|Fluorodeoxyglucose|a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
41287760|NCT03048097|DRUG|Rubidium|used in PET scans
41287761|NCT03048097|DIAGNOSTIC_TEST|FDG-PET/CT with Rb82 Myocardial Perfusion Imaging|A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
41287762|NCT05441046|DRUG|Genakumab|genakumab plus tislelizumab 200 mg
41287763|NCT01347164|BEHAVIORAL|RISE life coaching intervention|6 2-hour sessions
41287764|NCT01347164|BEHAVIORAL|HIV Counseling|Standard one-hour HIV counseling session
41287765|NCT01407562|DRUG|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
40758977|NCT01951729|DRUG|Control|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Starting at 0 minutes, an intravenous infusion of saline containing 1% human albumin will continue for 240 minutes."
40758978|NCT01951729|DRUG|Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a constant dose of 4 pmoles/kg/min until 240 minutes."
40758979|NCT01951729|DRUG|GIP without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes."
41287766|NCT01407562|DRUG|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
41287767|NCT01407562|DRUG|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
41287768|NCT01385696|DEVICE|Genuair® (Almirall S.A.)|Inhaler with only placebo, once daily, 14 days
41287769|NCT01385696|DEVICE|HandiHaler® (Boehringer Ingelheim's)|Inhaler with only placebo, once daily, 14 days
41287770|NCT00683553|DRUG|I5NP|Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
41287771|NCT00683553|DRUG|Placebo|Single IV injection of saline
41287772|NCT04777955|OTHER|core stabilization exercises|"Core is at the center of almost all kinetic chains in the body. Core force, balance, and motion control maximize all kinetic chains of upper and lower limb function. A stable and strong core can contribute to more efficient use of the lower extremities. Core stability is defined as the ability of the lumbo-pelvic hip complex to prevent bending of the vertebral column and return to balance after perturbation.~Neuromuscular electrical stimulation (NMES) is a technique in which muscle contraction is electrically stimulated in the area where the surface electrodes are connected. It improves secondary muscle atrophy and weakness in immobilization by preventing a decrease in muscle protein synthesis.~Kinesiological banding (CT) is a treatment method used in the treatment of various musculoskeletal and neuromuscular deficits. The mechanism of action of CT is to facilitate muscle activation, increase blood and lymph circulation and reduce pain due to neurological suppression."
41287773|NCT02906046|DEVICE|Weight in Lower Limbs|
41287774|NCT04740866|RADIATION|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy (IMRT) technique. (\[50Gy in 25 fractions conventional fractionation including tumor bed \& pelvic lymph nodes\]
41287775|NCT00385086|DRUG|TNF blocker|Treatment with TNF-alpha blocker
41287776|NCT00385086|DRUG|Placebo|Treatment with placebo
41287777|NCT05594524|BEHAVIORAL|Body Confident Athletes|The Body Confident Athletes program is a three-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10-20 girls. The sports organizations will work with the community partner and researchers on how to schedule the intervention over a three-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sports organization. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Knowledge (20 mins), The Skills (20 mins), and The Final Score (15 mins). A variety of activity modalities will be utilized to convey learning outcomes, including group and individual activities and discussion-, writing-, and movement-based activities.
41287778|NCT02894983|OTHER|Flexion-ulnar cast|The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
40758980|NCT01951729|DRUG|Placebo with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
40758981|NCT01951729|DRUG|Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
40758982|NCT01951729|DRUG|GIP with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (iin saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
40758983|NCT01951729|DRUG|GIP plus Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes."
41287779|NCT02894983|OTHER|Functional cast|The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
41287780|NCT05943639|OTHER|The Cultural Marginality Theory-Based Education|The Cultural Marginality Theory-Based Education program will be held in a face-to-face classroom environment for the students in the experimental group. This training program has been developed based on the concepts of Cultural Marginality Theory. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the theory. The training program was created in a certain flow, based on the concepts of recognizing intercultural conflict (2 sessions), marginal living (2 sessions) and alleviating cultural tension (2 sessions). There are 6 sessions in the program and the frequency of sessions is 2 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 foreign nursing students in the experimental group.
41287781|NCT01235533|DIETARY_SUPPLEMENT|N-3 polyunsaturated fatty acids|Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.
40758984|NCT01951729|DRUG|GIP plus Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
40758985|NCT06144853|OTHER|scan|Fluorodeoxyglucose (FDG)-positron emission tomography/Computed tomography scan
41146707|NCT04929444|OTHER|Training on vertigo|"Online training on vertigo management in primary care with a face-to-face session.~On the one hand, the course will contain theoretical content and clinical cases will be used as the methodology of the course, with feedback paths for each correct or incorrect answer from the students and videos recorded expressly for the course. In addition, there will be a face-to-face session where all participants must perform the diagnostic and therapeutic maneuvers proposed in the course, to evaluate the use of the training and also to standardize the way of doing them for the study"
41287782|NCT02429505|DRUG|Miltefosine|miltefosine: target 2.5 mg/kg/day for 28 days
41287783|NCT06356662|DRUG|Tenofovir Disoproxil Fumarate|take tenofovir disoproxil fumarate 300mg/d
41287784|NCT01686984|OTHER|Altered breath|
41287785|NCT03224533|DIAGNOSTIC_TEST|Diabetes Outcome|based on self report definition, fasting plasma glucose, and hemoglobin A1c
41146708|NCT05778253|DIAGNOSTIC_TEST|WES and ctDNA detection|WES and ctDNA detection
40758986|NCT00569075|OTHER|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
41287786|NCT05624372|DIAGNOSTIC_TEST|hearing and cognitive assessment|psychiatric assessment, hearing assessment and brief cognitive assessment
41287787|NCT06244966|DIAGNOSTIC_TEST|HIV diagnostic testing|Finger-prick capillary blood will be tested alongside venous blood
41287788|NCT01425866|BEHAVIORAL|Structured self-management group education during 2 years|After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.
41287789|NCT05509608|DEVICE|RM Electrode|The RM Electrode is a corneal ERG electrode. The distinguishing features of the RM electrode are that it is a soft contact lens with a recessed electrode (i.e. no metal electrode makes direct contact with the eye). The RM Electrode also has an integral speculum to hold the wearer's eye lids open. The electrode is designed for superior positional stability on the eye during testing. These features work together to improve ERG signal quality.
41287790|NCT05509608|DEVICE|ERG Jet Electrode|The ERG Jet electrode is an FDA approved, commercially available corneal ERG electrode.
41287791|NCT05484063|OTHER|Multicomponent, mobility-focused intervention|The intervention group will receive early therapist review (within one working day of admission to HOME unit), to be mobilised at least three times a day. They will also receive additional group exercise therapy sessions, as well as nurse screening for geriatric syndromes. Besides that, they will be screened for 4Ms (Mobility, Mentation, Medication, What Matters) by doctor on admission.
41287792|NCT01426386|DRUG|FE 999049|
41453822|NCT03694106|BEHAVIORAL|TEAM PSYCHOTHERAPY|Patients data will be collected from the first to the final psychotherapy session as performed normally by TEAM trained clinicians. The treatment-as-usual includes therapy sessions of 50 to 110minutes long, typically once or twice per week for an average of 8-12 sessions. Treatment as usual by these clinicians includes the use of psychological symptoms survey immediately before and after each psychotherapy session. Typically patients will fill out these surveys in the clinic's waiting area before and after each session.
41453823|NCT04146090|OTHER|Low-pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 10 mmHg
41453824|NCT04146090|OTHER|Standard pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 14 mmHg
41453825|NCT03212820|PROCEDURE|Drilling at low speed|
41453826|NCT03212820|PROCEDURE|Drilling at conventional or high speed|
40758987|NCT00000437|DRUG|Naltrexone Tablet and Nicotine Patch|
41287793|NCT01426386|DRUG|Gonal - F|
41453827|NCT00847535|BIOLOGICAL|autologous muscle cell injection|Injection of autologous muscle cells
40758988|NCT00000437|DRUG|Naltrexone Tablet and Placebo Patch|
41453828|NCT04883164|OTHER|Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples|Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.
40758989|NCT00000437|DRUG|Placebo Tablet and Nicotine Patch|
40758990|NCT00000437|DRUG|Placebo Tablet and Placebo Patch|
40758991|NCT02616952|DIETARY_SUPPLEMENT|Chinese herbal therapy|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
40786405|NCT06082804|OTHER|APN and medical management|Patients are followed by the advanced practice nurse and the hematologist.
40786406|NCT06082804|OTHER|Medical management|Patients are followed by the hematologist only (standard of care).
40786407|NCT06082804|BEHAVIORAL|Quality of life assessment|EORTC-QLQ-C30 questionnaire
40786408|NCT06082804|BEHAVIORAL|Treatment compliance assessment|GIRERD questionnaire
40786409|NCT00560508|DRUG|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
40786410|NCT00560508|DRUG|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
40758992|NCT02616952|BEHAVIORAL|Pelvic floor muscle training|In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
40758993|NCT05062200|DRUG|JNJ-77242113|JNJ-77242113 will be administered as an oral tablet.
40758994|NCT05062200|DRUG|Placebo|Matching placebo will be administered as an oral tablet.
40758995|NCT03574714|OTHER|Extracellular pH|Extracellular pH gradient
40758996|NCT02120261|DRUG|Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
40758997|NCT02120261|DRUG|Lidocaine Hydrochloride|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
40758998|NCT02120261|DRUG|Triamcinolone acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
40758999|NCT05633771|OTHER|Hyrimoz|There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.
40759000|NCT06553157|DRUG|Statin|Statins are drugs known to help lower total cholesterol and reduce the risk of a heart attack or stroke. Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.
40759001|NCT06553157|OTHER|placebo|placebo
40759002|NCT06384703|DIAGNOSTIC_TEST|Taking blood for kit study|Taking blood for kit study (Elisa kit)
40759003|NCT04157738|DRUG|Rapid-Acting Insulin|Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)
40759004|NCT04157738|DRUG|Long acting insulin|Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)
40759005|NCT04820452|BIOLOGICAL|Low dose IBI302|Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection
40759006|NCT04820452|BIOLOGICAL|High dose IBI302|High dose IBI302 intravitreal injection given as every other month after three loading monthly injection
40759007|NCT04820452|DRUG|Aflibercept|Intraocular injection
40759008|NCT03949114|BEHAVIORAL|Evaluation|Evaluate a weak debilitating phenotype screening on the patients before surgery;
40759009|NCT03949114|BEHAVIORAL|nursing care|Traditional post-operative nursing care
40759010|NCT03949114|BEHAVIORAL|rehabilitation|"1. Postoperative vital signs were stabilized for 2 hours and then assisted to turn over; 2 to 3 hours to change position, awake without swallowing dysfunction, to fluid diet; 6 hours later, raise the bed 15 to 30 °, eat a half-flow diet.~2. On the first day after surgery, raise the bed 45 °, row and position training; catheter clamping training; assessment of pain, preventive analgesia. Early rehabilitation training was performed for 60 minutes each time for 5 consecutive days."
40759011|NCT00870324|DEVICE|OptiSense Lead|"The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead."
40759012|NCT00870324|DEVICE|Tendril Lead|"The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead."
40759013|NCT05601063|BEHAVIORAL|Winterlight Speech Assessment|Digital assessment of speech and language abilities
40759014|NCT05373680|DRUG|Metformin|Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
41133520|NCT03868878|OTHER|Capoeira training|The Capoeira training protocol, based in the modern styles was applied by an instructor with 16 years of experience. The protocol followed the directions of the ABADÁ Capoeira system, being adapted to the sample of older adults of the present study. The experimental protocol for Capoeira progressive training program lasted 12 weeks and was performed twice a week with duration of 60 minutes each. Each session was divided in three parts, being: 1) initial part: consisting of 10 minutes warm-up with recreational activities at low intensity; 2) main part: consisting of 30 minutes of basic movements in the modality and; 3) final part: consisting of 20 minutes with theoretical instructions related to Capoeira and musicality (singing and touch of typical instruments). In order to perform the Capoeira progressive training program, the technical improvement naturally occurred every week, resulting in a higher speed in movements execution and thus to a gradual increase in training intensity.
40759015|NCT05373680|DRUG|Empagliflozin|Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
40759016|NCT05373680|OTHER|Control|Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
41133521|NCT00005869|DRUG|gemcitabine hydrochloride|
41133522|NCT00005869|DRUG|rubitecan|
40759019|NCT00551993|PROCEDURE|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
40759020|NCT00551993|PROCEDURE|Laparoscopic Sacral Colpopexy|Standard laparoscopy
40759021|NCT04300998|BEHAVIORAL|Activities of Daily Living/ADLs|7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14
40786411|NCT05845112|DIAGNOSTIC_TEST|Molecular Diagnostics|pooled sputum samples will be used at the site of sample collection on the EDGE platform using Xpert ULTRA cartridges
40948690|NCT05931874|BEHAVIORAL|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the study app.
40948691|NCT05931874|BEHAVIORAL|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the study app.
40948692|NCT04872400|DRUG|Vancomycin|1 vial of Vancomycin 1g powder applied topically to the open fracture wound injury.
40948693|NCT04872400|DRUG|Tobramycin|1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
40948694|NCT00437892|DRUG|atorvastatin|tablets, 40 mg day, 3 months
40948695|NCT00437892|DRUG|atorvastatin|tablets, 40 mg once daily
40948696|NCT00437892|BEHAVIORAL|diet|daily
41287794|NCT03306771|DIAGNOSTIC_TEST|Ultrasound Duplex|The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery
41453829|NCT00218335|BEHAVIORAL|Intervention Condition|In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
41453830|NCT00218335|BEHAVIORAL|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
40948697|NCT00437892|BEHAVIORAL|diet|daily diet
40948698|NCT00792077|DRUG|Lenalidomide|5 mg daily for 56 days.
40948699|NCT02772887|DIETARY_SUPPLEMENT|L-Citrulline|amino acid supplement
40948700|NCT02772887|OTHER|Placebo|placebo
40948701|NCT03436004|DEVICE|Colonoscopy|Patients undergoing screening colonoscopy
40948702|NCT03436004|DEVICE|Colonoscopy with specific device (Endocuff Vision)|Patients undergoing screening colonoscopy using the Endocuff Vision device
40948703|NCT04726670|OTHER|Evaluation of postoperative pain|"A participant voluntary consent form was obtained from each patient. Ninety patients were numerically coded in computer environment by someone who was not included in the study for randomization (www.random.org).~A single clinician performed retreatment on each of the 90 teeth during a single visit."
41287795|NCT02896335|DRUG|Palbociclib|125 mg by mouth daily
41287796|NCT05450861|OTHER|SF DNA extraction composition|the composition of small fragments of DNA from fish
41287797|NCT05450861|OTHER|Placebo|the scalp conditioning solution without SF DNA extraction composition
40948704|NCT00878670|DRUG|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
40948705|NCT05149599|DRUG|Saccharomyces cerevisiae|Saccharomyces cerevisiae, which is a pro-biotic, was given in capsule form, 500mg twice daily for 1 month
40948706|NCT05376943|DRUG|Direct Acting Antivirals|Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
40948707|NCT02389062|OTHER|Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.|After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.
40948708|NCT00100061|DRUG|Cranberry juice|liquid juice taken daily
40948709|NCT00100061|DIETARY_SUPPLEMENT|Cranberry Juice|Taken orally
40948710|NCT00100061|DIETARY_SUPPLEMENT|Placebo cranberry juice|Placebo comparitor
40948711|NCT00804622|DRUG|telbivudine|daily oral administration,600mg,over 12 weeks
41453831|NCT01046097|BIOLOGICAL|Synflorix™|Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
41453832|NCT00642993|DRUG|SCH 497079|100 mg capsule administered orally
40759022|NCT04300998|BEHAVIORAL|Instrumental Activity of Daily Living|8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.
40948712|NCT00804622|DRUG|tenofovir disproxil fumarate|daily oral administration,300mg,over 12 weeks
40948713|NCT00804622|DRUG|telbivudine plus tenofovir disproxil fumarate|daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
40948714|NCT03342014|DEVICE|Ultrasound|3DPD and UAD acquisitions (10 min)
40948715|NCT03342014|BIOLOGICAL|Blood sample collection|A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
40948716|NCT02662634|BIOLOGICAL|AGS-003-LNG|autologous dendritic cell immunotherapy
40759023|NCT04300998|BEHAVIORAL|Timed Up and Go|Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (\<10 seconds, 10-20 seconds, \>20 seconds)
40759024|NCT04300998|BEHAVIORAL|Cognition|Mini-Cognition test: CDT and 3-word recall
40759025|NCT04300998|BEHAVIORAL|Geriatric Depression Scale|Four yes/no questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of \>/=1 is usually indicative of depression.
40759026|NCT04300998|BEHAVIORAL|Social Support|Four 5-point Likert scale questions addressing 4 domains of social support: emotional/ informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.
40759027|NCT04300998|BEHAVIORAL|Brief Test of Attention|assess selective auditory attention.
40759028|NCT04300998|BEHAVIORAL|Trail Making Test|Assesses visual scanning, graphomotor speed, and set shifting.
40759029|NCT04300998|BEHAVIORAL|Controlled Oral Word Association Test|A timed test of verbal fluency
40759030|NCT04300998|BEHAVIORAL|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.
40759031|NCT04300998|OTHER|Blood draw|collection of blood tests
40759032|NCT04745832|DRUG|Zandelisib|Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3
40759033|NCT04745832|DRUG|Rituximab|Rituximab IV 375 mg/m2 for 6 cycles
40759034|NCT04745832|DRUG|Bendamustine|Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles
40759035|NCT04745832|DRUG|CHOP|Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
40759036|NCT03485885|DIETARY_SUPPLEMENT|Standardized maqui berry extract enriched in anthocyanins|Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules - 250mg each) with 200ml still water
40759037|NCT03622515|COMBINATION_PRODUCT|Anesthesia level and cerebral perfusion pressure|Anesthetic dose and blood pressure
40759038|NCT06570408|BEHAVIORAL|Western Ontario and McMaster University Osteoarthritis Index (WOMAC)|1. WOMAC is widely used in the evaluation of Hip and Knee Osteoarthritis. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales
40759039|NCT06570408|BEHAVIORAL|Visual Analogue Scale (VAS)|2. VAS is one of the pain rating scales used in epidemiologic and clinical research to measure the intensity or frequency of various symptoms.
40759040|NCT06570408|DIAGNOSTIC_TEST|Kellgren Lawrence Grading Scale (KL score)|3. KL score is the most widely used clinical tool for the radiographic diagnosis of OA.Each radiograph was assigned a grade from 0 to 4,
40759041|NCT06570408|BEHAVIORAL|Quality of Life Questionnaires and Assessments:|4. Quality of Life Questionnaires and Assessments: include quality of life, intestinal tract, conscious assessment of pain relief.etc.
40759042|NCT06220266|DRUG|Phytoestrogen|consume 1 capsule twice a day for 2 months which one capsule composed of dry weight 50 mg of Pueraria Mirifica 1or Pueraria Mirifica 2 or Pueraria Mirifica 3
40759043|NCT06220266|DRUG|Diet control & life style modification|Diet control \& life style modification
40759044|NCT01016041|DEVICE|everolimus stent|stenting
40759045|NCT01016041|DEVICE|paclitaxel stent|stenting
40759046|NCT01578746|PROCEDURE|Direct lateral approach in total hip arthroplasty|The use of direct lateral approach in total hip arthroplasty
40759047|NCT01578746|PROCEDURE|Anterior approach|The use of anterior approach in total hip arthroplasty
40948717|NCT02662634|DRUG|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
40948718|NCT02662634|DRUG|Abraxane|Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
41133523|NCT00597376|OTHER|Cerefolin NAC (a medical food)|Cerefolin NAC one tablet each day
40759048|NCT02302326|DRUG|Metformin|Dose: metformin (1700 mg / day) for 12 weeks
40759049|NCT02302326|DIETARY_SUPPLEMENT|Myo-inositol + folic acid|Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
40759050|NCT00544726|BEHAVIORAL|Physical training|
40759051|NCT00544726|BEHAVIORAL|No training|
40759052|NCT01917032|DIETARY_SUPPLEMENT|Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food|1 g orally on weekdays during 11 weeks
40759053|NCT01917032|DIETARY_SUPPLEMENT|placebo|
40948719|NCT02662634|DRUG|Alimta|By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
40948720|NCT02662634|DRUG|Cisplatin|Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
40948721|NCT02662634|DRUG|Taxol|Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
40948722|NCT02662634|RADIATION|Radiation Therapy|Causes DNA strand breaks.
41133524|NCT00597376|OTHER|Cerefolin NAC placebo|Placebo tablet once a day
41133525|NCT02321956|DIAGNOSTIC_TEST|Ultrasound|Using ultrasound to determine the size of endotracheal tube
41453833|NCT00642993|DRUG|Placebo|Placebo capsules matching SCH 497079 administered orally
41453834|NCT01257984|DRUG|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
41453835|NCT01257984|DRUG|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
41453836|NCT03505996|BIOLOGICAL|CS1001|Monoclonal antibody
41453837|NCT00276536|BIOLOGICAL|recombinant interferon alpha-1b|interferon
41453838|NCT00276536|DRUG|IFN|IFN daily
41453839|NCT05128058|DRUG|Ritlecitinib 50 mg|50 mg single dose
41453840|NCT05128058|DRUG|Ritlecitinib 200 mg|200 mg single dose
41453841|NCT05767905|DRUG|PF-06821497 Treatment A|A single dose of PF-06821497 administered under fasting conditions.
40948723|NCT00887653|DRUG|raltegravir|This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
41453842|NCT05767905|DRUG|PF-06821497 Treatment B|A single dose of PF-06821497 administered under fasting conditions.
41453843|NCT05767905|DRUG|PF-06821497 Treatment C|A single dose of PF-06821497 administered under fasting conditions.
41453844|NCT05767905|DRUG|PF-06821497 Treatment D|A single dose of PF-06821497 administered under fasting conditions.
41453845|NCT05767905|DRUG|PF-06821497 Treatment E|A single dose of PF-06821497 administered after low fat meal
41453846|NCT05767905|DRUG|PF-06821497 Treatment F|A single dose of PF-06821497 administered after high fat meal.
41453847|NCT05264207|BEHAVIORAL|Nursing students' home-visit programme|"12-week home-visit program conducted by nursing students. Participants will receive weekly 45-minute visits. The visits will aim to promote self-care behaviours and will focus on:~1. Self-care of chronic conditions and medication management~2. Healthy habits: physical activity and healthy eating~3. Access to social support resources~4. Patients' rights and autonomous decision-making~The visits program will follow the WHO recommendations for the implementation of health promotion activities. All topics will be assigned 3 visits. In the first visit, the students will assess the participants' information needs and preferences in relation to the topic addressed and will provide generic information about it. In the second visit, the students will present individually-tailored information and will use individually-adapted strategies to convey such information. In the third visit, the student will explore the impact of the two previous visits and reinforce self-care behaviours."
41453848|NCT05264207|BEHAVIORAL|Standard care from Public Andalusian Health Service|Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
41453849|NCT02042599|DRUG|Sedation with sevoflurane during 48-hr in ICU|
41453850|NCT00582205|DRUG|Paclitaxel, Cisplatin IP|Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
41453851|NCT00002033|DRUG|Zidovudine|
41453852|NCT00002033|DRUG|AS-101|
40948724|NCT01479023|DRUG|64Cu-DOTA-U3-1287|
40948725|NCT01479023|DRUG|U3-1287 (unlabeled)|
40948726|NCT02572362|OTHER|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
40759054|NCT02674828|BEHAVIORAL|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
40759055|NCT02674828|OTHER|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it \>2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
40759056|NCT06462573|DRUG|locally infilterating anaethesia like lidocaine|which patients will undergo ESWL under locally infiltrated anaesthetic. Using ultrasound guidance, the quadratus lumborum muscle will be identified. Then a mixture of 0.5 % bupivacaine (10 ml) and 2 % lidocaine (10 ml) will be injected into the muscle as a single shot 20 minutes before the procedure.
40948727|NCT00484094|DRUG|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
40948728|NCT01006460|DRUG|Rhodiola rosea, L|3 Capsules twice a day
40759057|NCT06462573|DRUG|general anaethesia|"which patients will undergo ESWL under systemic analgesia. The latter will be achieved using one gram of paracetamol IV infusion at the beginning of the procedure.~In case of unsatisfactory pain control in either group, systemic analgesia using IV Ketorolac injection will be used on demand or the required dose will be recorded at the end of the session."
40759058|NCT00564070|BEHAVIORAL|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
40759059|NCT00564070|BEHAVIORAL|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
40759060|NCT06268730|OTHER|SinuSonic|The SinuSonic is a commercially available, over-the-counter, self-applied nasal device designed to enhance physical well-being by reducing nasal congestion via simultaneous administration of acoustic vibration and gentle oscillating expiratory pressure.
40759061|NCT01018056|DRUG|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
40759062|NCT01018056|DRUG|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
40759063|NCT01018056|DRUG|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
40759064|NCT02225795|OTHER|Hematopoietic stem cell transplantation|"Immuno-ablative regimen for HSCT:~Day Treatment~* 6 r-ATG 2 mg/kg~* 5 r-ATG3 2 mg/kg~* 4 r-ATG3 2 mg/kg~* 3 Cyclophosphamide with Mesna~* 2 Cyclophosphamide with Mesna~* 1 REST 0 PBSC infusion~  * 3 Cyclophosphamide with Mesna~ * 4 Cyclophosphamide with Mesna~ * 6 Start GCSF"
40948729|NCT01006460|DRUG|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
40948730|NCT01006460|DRUG|Panax ginseng|3 capsules twice a day
40948731|NCT01006460|DRUG|Placebo - dark brown sugar|3 capsules twice a day
40948732|NCT00486473|DRUG|Multihance|0.5 Molar at a single dose injection
40948733|NCT00486473|DRUG|Magnevist|0.5M at a single dose injection
40948734|NCT03801083|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
40948735|NCT05820373|BEHAVIORAL|Yoga therapy|Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course. In each yoga class, participants will be taught to perform a standardized yoga sequence including postures and breathing exercise. Each class lasts 60 minutes. A DVD demonstrating the yoga sequence will be given to each participant to prompt daily home practice.
40948736|NCT05820373|BEHAVIORAL|Active control group|Women being allocated to the active control group will attend a 12-week, weekly, relaxation course. In each relaxation class, participants will be taught to learn mediation and guided relaxation, called Shavasana. Participants will be asked to lie on their back, with legs apart and their eyes closed. During the practice, participants learn how to relax the body and breath normally. Each session lasts 60 minutes.
41133526|NCT03365232|DEVICE|non custom base attachment|non custom base attachment
41287798|NCT00928980|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
40759065|NCT06057025|BIOLOGICAL|"Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition"|"Single intramuscular injection of Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition."
40759066|NCT01546779|DEVICE|Tri-Gym|40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
40759067|NCT00890656|DRUG|Cyclophosphamide (CTX)|300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
40948737|NCT05820373|BEHAVIORAL|Passive control group|The passtive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group. A DVD demonstrating the post-operative exercise will be given to participants to practice at home daily.
40759068|NCT00890656|DRUG|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
40759069|NCT00890656|DRUG|Doxorubicin|50 mg/m\^2 by vein (IV) over 24 hours
40759070|NCT00890656|DRUG|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
40759071|NCT00890656|DRUG|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
40759072|NCT00890656|DRUG|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
40759073|NCT00890656|DRUG|Ara-C|3 gm/m\^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
40759074|NCT00890656|DRUG|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
40759075|NCT03584386|DEVICE|V-CAMS (aka Jaspr)|V-CAMS is an integrated software system for use on any device by suicidal patients.
40759076|NCT00323986|DRUG|azithromycin (drug)|
40759077|NCT04682691|DRUG|Erythromycin (400mg)|oral Erythromycin (400mg)
40759078|NCT04682691|DRUG|metoclopramide (10mg)|oral metoclopramide (10mg)
40759079|NCT04682691|DIETARY_SUPPLEMENT|naturally flavored water|naturally flavored water
41133527|NCT03365232|DEVICE|custom base attachment|custom base attachment
41287799|NCT00928980|DRUG|Optimal Medical Care|Therapeutic dose of antidepressant medication
41287800|NCT00758615|BEHAVIORAL|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
40759080|NCT05889741|DRUG|Ropivacaine injection|6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
40759081|NCT05889741|DRUG|Normal saline|6.5cc of Normal Saline one time into the stellate ganglion.
40759082|NCT02145520|DRUG|Magnesium Sulfate|The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay
40759083|NCT02145520|OTHER|placebo|use of placebo with standard therapy
40759084|NCT01724307|PROCEDURE|Neurostimulation of stellate ganglion|An electrical nuerostimulation of the stellate ganglion up to 60 minutes
40759085|NCT02080130|DIETARY_SUPPLEMENT|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
40759086|NCT02080130|DIETARY_SUPPLEMENT|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
40759087|NCT02080130|OTHER|Placebo|Placebo
40759088|NCT00252148|BIOLOGICAL|ADMVA|experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat
40948738|NCT00002008|DRUG|Sargramostim|
40948739|NCT02627625|DRUG|Tiotropium|4 inhalations
40948740|NCT04306029|OTHER|Postpartum Family Planning Package|"Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
41133528|NCT04002349|DRUG|Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
40759089|NCT05862441|DRUG|AV2-SA2|AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.
41453853|NCT04143607|DRUG|ASK120067|ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
40759090|NCT05862441|DRUG|SA|Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
40759091|NCT03992482|DRUG|Intravenous Immune Globulin (IVIG)|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
40759092|NCT03992482|DRUG|Placebo|Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
40759093|NCT02430610|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
40759094|NCT02430610|DEVICE|NanoKnife|
40759095|NCT06166641|PROCEDURE|Surgical procedure at operating room|A surgical procedure in an operating room is a medical intervention that involves making incisions or using minimally invasive techniques to treat a specific condition or perform a diagnostic procedure. The operating room, also known as the operating theater or surgical suite, is a sterile environment specifically designed to minimize the risk of infection and ensure the safety of both the patient and the surgical team.
40759096|NCT02858778|OTHER|Early order of palliative care consultation|
40759097|NCT04165902|DRUG|compare the effects of steroid plus hyaluronic acid and destrose plus hyaluronic acid on knee osteroarthritis|compare the immediate effect (one week after 3 times of injections), short-term effects (one month and three months after 3 times of injections), and midterm effect (6 months after 3 times of injections).
40786412|NCT05845112|DIAGNOSTIC_TEST|Qualitative C-Reactive Protein (CRP)|CRP qualitative (POC) rapid tests are immunochromatographic based assays for qualitative or semiquantitative determination of CRP circulating in blood, serum or plasma at the Point of Care with a time to result in 5 minutes.
40948741|NCT00651391|DRUG|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
41133529|NCT04002349|DRUG|Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
41133530|NCT04002349|DRUG|0.9% natural saline|Detailed in arm descriptions
41146709|NCT03117218|DIAGNOSTIC_TEST|Coronary MR angiography|Quantitative analysis of coronary MR angiogram
41146710|NCT05082545|DRUG|SHR-2002 and SHR-1316|Cohort study
41146711|NCT04584736|DRUG|Livalo, Ezetrol|Pitavastatin+Ezetimibe Pitavastatin
41453854|NCT04143607|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
40948742|NCT00651391|DRUG|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
40759098|NCT05534490|OTHER|therapatic Foot massaje (sweden technic)|Everything is explained to the individuals on the day of surgery. After the surgery, when the individuals regains consciousness in the service, the Swedish massage technique is applied bilaterally for 10 minutes. In addition to the demographic data of the patient before the application and in the preoperative period; pain, mental level, delirium status, mobility, kinesiophobia, balance, and functional independence level measurement evaluations are made. Massage is continued for a total of 20 minutes, 10 minutes for each foot, once a day until the patient is discharged. The measurements are repeated on the day the individual will be discharged.
40948743|NCT00651391|DRUG|Placebo|oral placebo once daily in the evening for 12 weeks
40948744|NCT02162316|DRUG|Motilitone®|
40948745|NCT02162316|DRUG|A-Cilin®, Clari® and Pantoline®|
40759099|NCT04203771|DIETARY_SUPPLEMENT|Probiotic AB-DENTALAC|Orodispersible tablets containing Lactobacillus plantarum \[now Lactoplantibacillus plantarum\] KABP051 (CECT7481) and Lactobacillus brevis \[now Levilactobacillus brevis\] KABP052 (CECT7480) as active ingredients, at a minimum dose of 5x10\^8 cfu each, and sorbitol (E420) and guar gum (E412) as excipients, taken b.i.d. for 7 days.
40759100|NCT04203771|OTHER|Placebo|Orodispersible tablets made of sorbitol (E420) and guar gum (E412), taken b.i.d for 7 days.
40759101|NCT04203771|PROCEDURE|Surgical removal of mandibular third molars at baseline|Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.
40759102|NCT04203771|DRUG|Ibuprofen|Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
40759103|NCT00756444|DRUG|Panitumumab|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
40759104|NCT00756444|DRUG|Cisplatin|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
40948746|NCT03872323|PROCEDURE|Endovascular treatment|The arteries injuries are repaired by endovascular treatment.
40948747|NCT03872323|PROCEDURE|Open surgery|The arteries injuries are repaired by open surgical operation.
40948748|NCT02059252|DEVICE|SmartMatrix dermal replacement scaffold|SmartMatrix dermal replacement scaffold
40948749|NCT00494455|DEVICE|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
40948750|NCT00494455|DEVICE|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
40759105|NCT00756444|DRUG|5FU|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
40759106|NCT03133780|DRUG|Ketamine|Patient will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
40759107|NCT03133780|DRUG|Midazolam|Patient will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
40759108|NCT06497686|DIAGNOSTIC_TEST|mesoscale nonlinear optical gigascope|An nonlinear optical microscope with ultra-large field of view and ultra-high resolution.
40759109|NCT06497686|DIAGNOSTIC_TEST|Fluorescence microscope|An optical microscope used to examine the fluorescence signal from stained tissues.
40759110|NCT02273427|DRUG|BIIL 284 BS|
40759111|NCT02273427|OTHER|high fat meal|
40759112|NCT02273427|OTHER|low fat meal|
40759113|NCT05390320|PROCEDURE|PAOO|Periodontally accelerated osteogenic orthodontics will be applied to treat patients with moderate crowding.
40759114|NCT05390320|OTHER|Fixed appliance|Fixed appliances will be applied to treat patients with moderate crowding without any acceleration methods.
40759115|NCT02991859|DRUG|Fluticasone furoate (FF) Dry Powder Inhaler|Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
40948751|NCT01931332|PROCEDURE|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
40948752|NCT01931332|PROCEDURE|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
40948753|NCT01626495|BIOLOGICAL|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
40948754|NCT01844557|OTHER|Swallowing Exercises|Participants perform 3 swallowing exercises.
40948755|NCT01844557|BEHAVIORAL|Symptom Inventory|Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
40948756|NCT01844557|BEHAVIORAL|Questionnaires|Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
40948757|NCT00946361|OTHER|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
40948758|NCT01066403|DRUG|Pergolide|"0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group."
40948759|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
40948760|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
41287801|NCT05387161|OTHER|Nutritional intervention|The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative ungrammatical daily diet plan, which must be followed for the entire period of intervention (6 months).
41287802|NCT00591383|DRUG|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
41287803|NCT00591383|DRUG|erlotinib|erlotinib taken at 150 mg every morning with food.
41287804|NCT03534271|DEVICE|iPhone with Kenek Edge and Samsung S8|Smartphones with pulse oximetry and heart rate monitoring capabilities
41453855|NCT04143607|DRUG|Gefitinib|Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
40759116|NCT02991859|DRUG|Fluticasone propionate (FP) Dry Powder Inhaler|Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods
40759117|NCT02991859|DRUG|Budesonide (BUD) Turbuhaler|Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
40759118|NCT02991859|DRUG|Placebo (ELLIPTA or DISKUS)|Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.
40759119|NCT03434886|OTHER|CFView|Registry patient portal
40759120|NCT03434886|OTHER|CF educational videos|CF educational videos
40759121|NCT01829503|DRUG|decitabine and cytarabine|
40759122|NCT01829503|OTHER|Supportive Care|blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
40759123|NCT02555358|DRUG|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
40948761|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
40948762|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
40759124|NCT02555358|DRUG|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
40948763|NCT01620554|DRUG|Placebo|1 capsule per week during 2 weeks
40948764|NCT05352178|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions
40948765|NCT05352178|DRUG|Androgen deprivation therapy|Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
40759125|NCT04880590|OTHER|Sex intercourse|A heterosexual sexual relationship
40759126|NCT04602598|DRUG|Zanubrutinib 80 MG|Zanubrutinib 80 MG for 24 weeks
40759127|NCT03373669|BIOLOGICAL|Oral Cholera Vaccine|Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi. Shanchol requires no oral buffer for administration, is approved for persons greater than 1 year of age, and requires 2 doses at two-week intervals. It became World Health Organization (WHO) prequalified in 2011.
40759128|NCT03373669|BIOLOGICAL|Adjusted Dose Oral Cholera Vaccine|The Adjusted Dose Oral Cholera Vaccine is given in two doses, with the second dose given at six months, rather than the manufacturer described 2 week interval between first and second dose.
40759129|NCT02554474|BEHAVIORAL|Education, Fitbit/FitViz, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
40759130|NCT02554474|BEHAVIORAL|Same intervention with a 9-week delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 9-week delay.
40759131|NCT01574495|OTHER|Error Augmentation|error augmentation for arm motor recovery in individuals with stroke
40759132|NCT06412055|DEVICE|NEURO SWING AFO (Fior& Gentz, Lüneburg In Duderstadt, Germany)|stiffness-optimized custom-made spring-hinged AFO with the NEURO SWING® system ankle joint build in
40759133|NCT06412055|DEVICE|WalkOn Reaction® (Ottobock, Duderstadt)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (2.8 Nm/degree).
40948766|NCT05352178|DRUG|Androgen receptor targeted therapy|Enzalutamide
40948767|NCT01155505|DRUG|Lenalidomide (CC-5013)|CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
40948768|NCT02749331|DRUG|AdVince|Virus solution for infusion in intrahepatic artery
41146712|NCT06119256|BIOLOGICAL|EBV-TCR-T cells|The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.
41146713|NCT01381185|DRUG|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
41146714|NCT00907933|DRUG|SB-705498|0.5mg intranasal SB-705498
41146715|NCT00907933|DRUG|SB-705498|1.5mg intranasal SB-705498
41146716|NCT00907933|DRUG|SB-705498|3mg intranasal SB-705498
41146717|NCT00907933|DRUG|SB-705498|6mg intranasal SB-705498
41146718|NCT00907933|DRUG|SB-705498|12mg intranasal SB-705498
41146719|NCT00907933|DRUG|Placebo|Placebo '498
41146720|NCT00907933|DRUG|SB-705498|6mg intranasal SB-705498 for 14 days bid
41146721|NCT00907933|DRUG|SB-705498|12mg intranasal SB-705498 14 days bid
41146722|NCT00907933|DRUG|Placebo|Placebo
41146723|NCT01190995|DRUG|24% Sucrose|The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
40948769|NCT02664545|DEVICE|BEAR Scaffold|A sponge, or scaffold, which is surgically placed between the torn ligament ends and sutures are used to repair the torn anterior cruciate ligament.
40948770|NCT02664545|PROCEDURE|Tendon Graft|A graft of tendon (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee)
40948771|NCT02660931|OTHER|AKI Risk Notification|When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
40948772|NCT01896336|DRUG|Zolpidem Hemitartrate|"Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD"
40948773|NCT03253575|DIAGNOSTIC_TEST|CANscript|CANscript is a predictive test that supports informed selection of cancer therapeutics for each individual patient. CANscript has the potential to predict the response of the patient under evaluation to either single-agent cancer therapeutics or combination therapeutic regimens. This is accomplished by using fresh tumor tissue from the patient in plates coated with a specific set of tumor matrix proteins (TMP). Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature along with autologous immune cells. In essence, CANscript recapitulates the tumor microenvironment.
40948774|NCT05514301|DIAGNOSTIC_TEST|Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection|"Both diagnostic interventions will be performed in all patients~1. High definition colonoscopy performed by high experienced endoscopists blinded to Polydeep.~2. Polydeep: a CADe and CADx system. The gold standard will be the histological diagnosis of the lesion."
40948775|NCT03144973|DIAGNOSTIC_TEST|periosafe|mouth rinsing quick-test
40948776|NCT06188533|OTHER|Urinary activin A in AKI|Urinary activin A in AKI patient
40948777|NCT05841836|DEVICE|the Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
40948778|NCT05841836|DEVICE|Perclose ProGlide Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
40948779|NCT01358851|PROCEDURE|Cryotherapy|1-2 times during the treatment time
41453856|NCT04143607|DRUG|Placebo ASK120067|Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
41287805|NCT03380949|PROCEDURE|Opioid administration (remifentanil) in intervention group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
40948780|NCT01358851|DRUG|LAS41005|once daily
40948781|NCT03866954|COMBINATION_PRODUCT|EE-TP|Ecoli thymidine phoshorylase encapsulated within autologous erythrocytes
40948782|NCT02758132|BIOLOGICAL|Denosumab|One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
40948783|NCT02758132|DRUG|Enzalutamide|160 mg enzalutamide by mouth daily
40948784|NCT02758132|DRUG|Abiraterone|1000 mg abiraterone by mouth daily
41287806|NCT03380949|PROCEDURE|Opioid administration (remifentanil) in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by clinical signs in the control group.
41287807|NCT05916638|OTHER|blood sample|blood sample collection
41287808|NCT05788068|BEHAVIORAL|Cognitive behavior therapy|"Participants will receive CBT intervention for smoking cessation via wechat-based mini-program developed by a professional team."
41287809|NCT03876340|OTHER|Treatment algorithm|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures. The thermograms will be used to dictate the initial treatment.
41287810|NCT03876340|OTHER|Current treatment|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures, but the results will be kept sealed until the study is finished. The patients will receive the usual standard of care as dictated by the surgical team.
41453857|NCT00980941|DIETARY_SUPPLEMENT|soup with or without starch|
41453858|NCT03857828|OTHER|semen sample|• seminal sample for measuring clusterin level.
41453859|NCT00587730|DEVICE|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
40759134|NCT06412055|DEVICE|Matrix Max2® (TruLife, Dublin, Ireland)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (1.4 Nm/degree)
40948785|NCT02758132|DRUG|Prednisone|5 mg prednisone by mouth twice daily
41453860|NCT00893919|DRUG|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
40759135|NCT06412055|DEVICE|Matrix® (TruLife, Dublin, Ireland)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (0.6 Nm/degree)
40948786|NCT04151173|PROCEDURE|laparoscopic aspiration/electrocoagulation|laparoscopic aspiration/electrocoagulation of ovarian endometrioma
40948787|NCT04151173|PROCEDURE|laparoscopic cystectomy|laparoscopic cystectomy of ovarian endometrioma
40948788|NCT00110903|DRUG|Etanercept Liquid|
40948789|NCT01663025|BEHAVIORAL|Hand Reflexology|The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
41453861|NCT05169931|BIOLOGICAL|RegenerEyes|Biologic eye drop
40759136|NCT04636580|BEHAVIORAL|parent accompanying the child during treatment|After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment
40759137|NCT02727699|DRUG|Xanamem™|Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
40759138|NCT02727699|DRUG|Placebo (for Xanamem™)|Excipient blend capsules manufactured to mimic Xanamem™ capsules
40759139|NCT02174445|DRUG|Imatinib|Imatinib, 400 to 800 mg p.o., daily
40759140|NCT02174445|DRUG|Nilotinib|300mg p.o., twice-daily
40759141|NCT06568796|OTHER|randomize controlled study|eswt treatment
40759142|NCT03320083|BEHAVIORAL|Educational care derived from POSSUMS|Intervention group were offered a sleep education session on healthy practices for parent-baby sleep which included information on sleep needs, sleep hygiene, training in strategies to remove obstacles that get in the way of healthy sleep. Information were provided to guide the parent in forming an action plan based on cued care which included aligning the circadian clock with real time, removing the obstacles that get in the way of healthy sleep, physical activity, mindfulness, and relaxation techniques for mothers derived from the POSSUMS approach. However, we could not use Acceptance and Commitment Therapy, because none of the investigators had sufficient training on ACT at the time the study was conducted.
40759143|NCT02773823|BEHAVIORAL|Intervention group|Diet instruction for 3-4 times/semester,exercise 60min/day for 5d/week for 8 months.
40759144|NCT01755156|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)
40759145|NCT01755156|DRUG|Matching placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)
40759146|NCT01755156|DRUG|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
40759147|NCT01755156|DRUG|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
40759148|NCT01755156|DRUG|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
40759149|NCT01755156|DRUG|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (\>= 1500 mg daily) throughout the study.
40759150|NCT00236795|DRUG|norelgestromin + ethinyl estradiol; triphasil.|
40759151|NCT02370147|BEHAVIORAL|Smoking reduction intervention|Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
40759152|NCT02370147|BEHAVIORAL|Exercise and diet advice control|Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
40759153|NCT02534155|DEVICE|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
40759154|NCT02534155|PROCEDURE|Mitral valve Surgery|Repair or replace mitral valve
40759155|NCT06366165|PROCEDURE|seemingly irrelevant funny videos and memes in teaching|linking funny videos and memes to special care dentistry curriculum lectures
40759156|NCT06472024|PROCEDURE|Verum Acupuncture|Acupuncture therapy uses filiform needles at a perpendicular angle at acupuncture points to produce a therapeutic effect.
40759157|NCT06472024|PROCEDURE|Sham Acupuncture|Sham Acupuncture therapy uses filiform needles but is only attached with tape to acupuncture points
40759158|NCT01837953|BEHAVIORAL|Group Psychodynamic Interpersonal Psychotherapy|For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy (GPIP) condition, this intervention will consist of 16 weekly 90 minute sessions of GPIP. GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment. Examples of the patient's cyclical relational patterns (CRPs) that may underlie their symptoms are discussed and the patient will be encouraged to work on these in the groups. Therapists will be given a written summary of each patient's CRP.
40759159|NCT01837953|BEHAVIORAL|Unguided Self-Help|All participants will first receive 10 weeks of Unguided Self-help. The USH will be based on Dr. Christopher Fairburn's CBT-oriented and evidence based self-help treatment plan for binge eating explained in his book, Overcoming Binge Eating. The USH program follows six steps: (1) Getting Started: Self-monitoring, weekly weighing; (2) Regular Eating: Establishing a pattern of regular eating; (3) Alternatives to Binge Eating: Substituting alternative activities; (4) Problem Solving and Taking Stock: Practicing problem solving and reviewing progress; (5) Dieting and Related Forms of Avoidance: Tackling the three forms of dieting and other forms of avoidance eating; and (6) What Next? Preventing relapse and dealing with other problems.
40759160|NCT00181545|PROCEDURE|escalation of dose (radiotherapy treatment)|
40759161|NCT02931227|PROCEDURE|temperature obtained by the non-invasive method of zero-heat flux|
40759162|NCT02931227|PROCEDURE|esophageal temperature|
40759163|NCT02931227|PROCEDURE|intracerebral temperature|
40759164|NCT02931227|PROCEDURE|arterial temperature|
40948790|NCT01422460|BIOLOGICAL|Platelet Rich Plasma|"Platelet Rich Plasma (Preparation Rich in Growth Factors)~intra articular injection 2ml~Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)"
41453862|NCT00694408|DRUG|methyl prednisolone, hydrocortisone, prednisolone|Will be specific dependant on weight of patients
40948791|NCT05592951|DIETARY_SUPPLEMENT|Crystal Light (once serving)|Citric Acid, Potassium Citrate, Sodium Citrate, Aspartame (Phenylketonurics: Contains Phenylalanine), Magnesium Oxide, Maltodextrin, Contains Less than 2% of Natural Flavor, Acesulfame Potassium, Soy Lecithin, Yellow 5, Artificial Color.
41453863|NCT00694408|OTHER|No steroids|Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
40759165|NCT01586897|DEVICE|Medication Metronome|Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
40759166|NCT01586897|OTHER|Usual Care|
41133531|NCT00679406|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting \>1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
41133532|NCT03435367|DEVICE|Virtual Reality Program|VR with head mounted display (HMD) and headphones.
40759167|NCT00594308|DRUG|Cyclophosphamide|60mg/kg/day for two consecutive days (-7,-6).
40759168|NCT00594308|DRUG|Fludarabine|25mg/m2/day for 5 consecutive days
40759169|NCT00594308|DRUG|Cyclosporine|3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
40759170|NCT00594308|DRUG|Mycophenolate mofetil|1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
40759171|NCT00594308|DRUG|Basiliximab|20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
40759172|NCT02343250|DRUG|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
40759173|NCT02343250|DRUG|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
40759174|NCT02343250|DRUG|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
40759175|NCT02343250|DRUG|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
40759176|NCT02333474|BIOLOGICAL|MV mix vaccine|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
40759177|NCT02333474|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
40759178|NCT02542280|PROCEDURE|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
40759179|NCT02542280|PROCEDURE|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
40759180|NCT02542280|DRUG|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
41453864|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
41453865|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days
40759181|NCT00964522|OTHER|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
40759182|NCT05438771|COMBINATION_PRODUCT|Ankaferd Blood Stopper|mouth wash
40759183|NCT05438771|OTHER|Bicarbonate|mouth wash
40759184|NCT04376008|PROCEDURE|Standard prostate biopsy|Transperineal TRUS guided standard prostate biopsy (SB).
40759185|NCT04376008|PROCEDURE|Targeted and standard prostate biopsy|Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).
40759186|NCT06554899|OTHER|Clinician-led intervention to address fear of cancer recurrence (CIFeR)|The intervention includes five components informed by theoretical models and existing interventions for FCR: 1) FCR normalization: reassurance that FCR is a common and normal phenomenon after treatment for cancer, 2) Providing prognostic information: asking patients whether they would like information about their risk of recurrence and, if yes,providing this information, 3) Providing education and take-home information on red-flag recurrence symptoms, 4) Brief advice on managing worry: distraction, meditation, mindfulness, reassurance, and links to online resources to manage FCR, and 5) referral to a psychologist if FCR is high (FCRI-SF \>= 22), or if deemed helpful by the patient or clinician. Access will be provided to ConquerFear-Group delivered online by trained psychologists.
41133533|NCT03435367|DEVICE|iPad Tablet|iPad with headphones
41133534|NCT05499767|BEHAVIORAL|HEPPI|Homebound Elderly People Psychotherapeutic Intervention
41453866|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days
41453867|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days
41287811|NCT01717612|DRUG|Thrombin|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
40759187|NCT06045286|RADIATION|Radiation: High- and Low-dose radiotherapy|High-dose radiotherapy (6-8Gy×3-7F) followed by low-dose radiotherapy (0.5-1.4Gy×3-7F) starting within 7 days after completion.
40759188|NCT06045286|DRUG|PD-1 Inhibitors|Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.
40948792|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (one serving)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
40948793|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (two servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
40948794|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (three servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
40948795|NCT05870774|PROCEDURE|Soft tissue augmentation with CTG|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Harvesting of free connective tissue graft from the maxilla tuberosity area~4. Fixation of the graft to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly"
40948796|NCT05870774|PROCEDURE|Soft tissue augmentation with CM|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly"
40948797|NCT05780073|DRUG|Dasatinib 70 mg|Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind
40948798|NCT05780073|OTHER|Placebo|Maltodextrin capsules with identical size and appearance (shape, size, colour and flavour) as the dasatinib-containing capsules.
40948799|NCT02020577|DRUG|Cetuximab( erbitux®)|once per week
40948800|NCT02020577|DRUG|Afatinib|once per day
40948801|NCT02562833|DEVICE|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
40948802|NCT02562833|DEVICE|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
40948803|NCT04406974|PROCEDURE|Surgery or treatment for local recurrence|Surgery or treatment for local recurrence
40948804|NCT04406974|PROCEDURE|Surgery for advanced colorectal cancer|Surgery for advanced colorectal cancer
40948805|NCT02439294|OTHER|Without Obstructive Sleep Apnea (syndrome)|
40948806|NCT02439294|OTHER|Mild or moderate Obstructive Sleep Apnea (syndrome)|
40948807|NCT02439294|OTHER|Severe Obstructive Sleep Apnea (syndrome)|
40948808|NCT02439294|DEVICE|CPAP|
40759189|NCT03416387|DEVICE|3D PRINTING|A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.
40759190|NCT04755231|DEVICE|AcrySof IQ PanOptix Presbyopia Correcting IOL|UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
40759191|NCT04755231|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL
40948809|NCT00658580|DRUG|Cisplatin + etoposide|"Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
40948810|NCT00658580|DRUG|Epirubicin + ifosfamide + etoposide|"Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
41287812|NCT01717612|DRUG|Histoacryl|The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
41287813|NCT04425850|COMBINATION_PRODUCT|Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)|Topical application in the nose and oral cavity
41287814|NCT02471417|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be on a single occasion by the study subjects.
41287815|NCT02471417|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be on a single occasion by the study subjects.
41287816|NCT02628730|DEVICE|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
41287817|NCT02628730|DEVICE|RFA ablation data comparison|Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
40759192|NCT01897896|DRUG|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
40759193|NCT05768347|BIOLOGICAL|Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)|Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies.
40759194|NCT01601561|DRUG|Regular human insulin injection|"Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose."
40948811|NCT04842734|OTHER|Physical exercise|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour
40948812|NCT04842734|OTHER|Physical exercise and computerized cognitive training|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour. The CCSP is planned for 12 weeks, minimum 3 to maximum 5 days a week, approximately 10 minutes, for a total of 36-60 sessions
40948813|NCT03696173|OTHER|Non-Interventional|Non-Interventional
40948814|NCT03696173|OTHER|Non-Interventional|Non-Interventional
40948815|NCT03678025|DRUG|Abiraterone|Given PO
40948816|NCT03678025|DRUG|Bicalutamide|Given PO
40948817|NCT03678025|DRUG|Degarelix|Given via injection
40948818|NCT03678025|DRUG|Docetaxel|intravenous
40948819|NCT03678025|DRUG|Flutamide|Given PO
40948820|NCT03678025|DRUG|Goserelin Acetate|Given SC
40948821|NCT03678025|DRUG|Histrelin Acetate|Receive SC
40948822|NCT03678025|DRUG|Leuprolide Acetate|Receive SC or IM
40948823|NCT03678025|DRUG|Nilutamide|Given PO
40948824|NCT03678025|PROCEDURE|Orchiectomy|Undergo bilateral orchiectomy
40948825|NCT03678025|DRUG|Prednisone|Given PO
40948826|NCT03678025|OTHER|Quality-of-Life Assessment|Ancillary studies
40948827|NCT03678025|RADIATION|Radiation Therapy|Standard radiation
40948828|NCT03678025|PROCEDURE|Radical Prostatectomy|Standard surgery
40948829|NCT03678025|DRUG|Triptorelin|injection
40948830|NCT04906460|DRUG|WVE-N531|WVE-N531 is an antisense oligonucleotide (ASO)
40948831|NCT02081183|DRUG|Mycophenolate mofetil (MMF)|1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
40948832|NCT02081183|DRUG|Cyclophosphamide, Maintenance Phase|0.5-1 g/m\^2 IV pulse once every 3 months
40948833|NCT02081183|DRUG|Cyclophosphamide, Induction Phase|0.5 - 1 g/m\^2 IV pulse once per month
40948834|NCT02081183|DRUG|Prednisone|1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
41453868|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
40948835|NCT02402101|DEVICE|Procedure: active tDCS|Intensity 2 mA during 20 minutes
40948836|NCT02402101|DEVICE|Procedure: sham tDCS|sham condition as delivered by the stimulator
40948837|NCT00215683|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
40948838|NCT04422743|DIETARY_SUPPLEMENT|Citicoline 500 mg plus Homotaurine 50 mg|Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy
40948839|NCT02134197|DRUG|Lupartumab Amadotin (BAY1129980)|Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
40948840|NCT01092507|BIOLOGICAL|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
40948841|NCT01092507|BIOLOGICAL|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
40948842|NCT05063890|PROCEDURE|Muscle Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at muscles of the neck prone to get short
41453869|NCT02911909|DEVICE|Delfi|Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
41453870|NCT02911909|OTHER|Standard rehabilitation|Patients will receive standard of care post-operative ACL reconstruction rehabilitation
40948843|NCT05063890|PROCEDURE|Movement Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at specific movements of the cervical spine
40948844|NCT05063890|PROCEDURE|unilateral postero-anterior glide|3 sets of unilateral posteroanterior glide (10-15 oscillations) at the involved segment
40948845|NCT05063890|PROCEDURE|Heating and TENS|Heating and TENS for 10 minutes
40948846|NCT02781779|DEVICE|Silverlon®|Silverlon wound dressings
40948847|NCT02781779|DEVICE|AQUACEL® AG|AQUACEL® AG wound dressings
40948848|NCT03595774|DIETARY_SUPPLEMENT|Beet root juice|Beet root juice
40948849|NCT04629885|DRUG|Oxytocin 400 IU vaginal gel|
40948850|NCT04629885|DRUG|Placebo|Matching placebo gel with identical appearance to the test product, used as reference treatment.
40948851|NCT06335134|DRUG|XW003 injection|Administered subcutaneously
40948852|NCT06335134|DRUG|Metformin|Administered orally
40948853|NCT06335134|DRUG|Warfarin|Administered orally
40948854|NCT06335134|DRUG|Rosuvastatin|Administered orally
40948855|NCT06335134|DRUG|Digoxin|Administered orally
40948856|NCT00113087|DRUG|Enalapril|Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)
40948857|NCT00113087|DRUG|Placebo|Participants will receive placebo
40948858|NCT05551208|DRUG|fluzopanib and bevacizumab|fluzopanib and bevacizumab were used for maintenance treatment
40948859|NCT03996759|DIAGNOSTIC_TEST|Laboratory diagnostic medicine|Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
40948860|NCT00315146|DRUG|Pioglitazone|
40948861|NCT00315146|BEHAVIORAL|Resistance exercise training to maximize muscle power|
40948862|NCT00315146|BEHAVIORAL|Hypocaloric diet|
40948863|NCT00315146|DRUG|Placebo|
40948864|NCT01680965|DRUG|Ofatumumab|"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"
40948865|NCT05997550|OTHER|Pursed Lip Breathing Exercise|Pursed Lip Breathing Exercise for The COPD
40948866|NCT05997550|OTHER|Laughter Therapy|Laughter Therapy for the COPD
40948867|NCT05997550|OTHER|the control group.|Attention-match training is given to the patients in the control group.
40759195|NCT04402073|DRUG|Sonidegib|Sonidegib is a selective smoothened inhibitor that inhibits the sonic hedgehog-signaling pathway. It is used in patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
40759196|NCT04402073|DRUG|Cisplatin|Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours. The application route is through the veins.
40759197|NCT04402073|DRUG|Lomustine|Lomustine is a nitrosourea used in the treatment of brain tumours and Hodgkin's disease. The application route is oral.
40759198|NCT04402073|DRUG|Vincristine|Vincristine sulfate (VCR) is an inhibitor of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vincristine sulfate is indicated in acute leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. The application route is through the vein.
40759199|NCT04402073|RADIATION|radiotherapy|Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
40948868|NCT02409212|BEHAVIORAL|Aerobic exercise training|Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
40948869|NCT02409212|BEHAVIORAL|Placebo surveillance and written exercise guidelines|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
40948870|NCT00645723|DRUG|Colistin|intravenous colistin and nebulized colistin
40759200|NCT00978185|OTHER|medical chart review|
40759201|NCT00978185|OTHER|questionnaire administration|
40759202|NCT00978185|PROCEDURE|acupressure therapy|
40759203|NCT00978185|PROCEDURE|quality-of-life assessment|
40759204|NCT00978185|PROCEDURE|sham intervention|
40759205|NCT00978185|PROCEDURE|standard follow-up care|
40759206|NCT06214741|DRUG|survodutide|once weekly subcutaneous injection
40759207|NCT06214741|DRUG|Placebo matching BI 456906|Once weekly subcutaneous injection
40759208|NCT00626665|DRUG|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
40948871|NCT00645723|DRUG|Colistin and saline solution|intravenous colistin and nebulized saline solution
40948872|NCT00814866|DRUG|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
40759209|NCT02290574|RADIATION|Hyperthermia with concurrent chemo-radiation therapy|
40759210|NCT02667561|DRUG|Testosterone gel 1% 2.2 mg|Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
40759211|NCT02667561|DRUG|Testosterone gel 1% 4.4 mg|Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
40759212|NCT02667561|DRUG|Testosterone gel 1% 8.8 mg|Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
40759213|NCT02667561|DRUG|Placebo of Testosterone Gel 1%|Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
40948873|NCT01787422|OTHER|Traditional versus Telemedicine office visit|
41453871|NCT02538211|BIOLOGICAL|Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine|All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
40759214|NCT00484328|DRUG|Ribavirin|different dosing regimes of Ribavirin
40759215|NCT06183593|OTHER|Radiofrequency application|Radiofrequency stimuli will be applied at pain threshold intensity. Arm and leg will be stimulated.
40759216|NCT06183593|OTHER|Pinprick stimuli|Pinprick stimuli will be administered at varying speeds and forces using an automated device
40759217|NCT01293955|DRUG|JOINS 200mg|1 tablet at each time, 3 times a day
40759218|NCT01293955|DRUG|Placebo|placebo of Joins 200mg
40759219|NCT06080204|DRUG|Octreotide LAR|Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。
40759220|NCT01798823|PROCEDURE|History, physical, LF, SPT, blood sample, FeNO, EBC.|Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
40759221|NCT03351959|RADIATION|neo-adjuvant treatment|long-course radio-chemoradiation; short-course radiation with immediate/delayed surgery
40759222|NCT05101148|DRUG|Selumetinib|The dosing regimen for selumetinib (25 mg/m2 bid) will be based on BSA, during T1 and T2 the dose will be 25mg/m2, consistent with the approved prescribing information in the US. If T3 is required, appropriate dose of selumetinib will be defined by Data Review Committee for T3.
40759223|NCT04050436|DRUG|Cemiplimab|Cemiplimab administered intravenously
40759224|NCT04050436|BIOLOGICAL|RP1|RP1 administered intratumorally
40759225|NCT03487458|PROCEDURE|Rib Fixation Surgery|Rib Fixation Surgery
40759226|NCT01066299|DRUG|Syntocinon®|single dose of OXT (24 IU)
40759227|NCT01066299|DRUG|inactive nasal spray|single dose (24 IU)
40759228|NCT03241160|OTHER|Chewing evaluation|Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
40948874|NCT01556880|BEHAVIORAL|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
40948875|NCT03390673|DRUG|HD204|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
41287818|NCT04483362|BEHAVIORAL|Complex physical activity intervention|"Structured weekly sessions with a Physiotherapist over an 8 week period, including:~* Evaluation of current levels of physical activity and physical function - including discussion of results~* Education regarding the importance of physical activity~* Supervised physical activity session with a physiotherapist~* Structured weekly sessions applying behavioural change techniques which aim to increase participation in physical activity. Sessions include: provision of activity monitor (Fitbit Inspire), goal setting, monitoring, collaborative problem solving and action plan implementation. Intervention includes additional time allowance of 1 hour per week to assist in implementing action plan items"
41453872|NCT05659680|DEVICE|WiSE-CRT|Participants undergo pre-procedural CT, implantation of the WiSE-CRT system targeting the left bundle branch area, and post procedural non-invasive electro-anatomical mapping using electrocardiographic imaging and haemodynamic assessment.
41453873|NCT01768260|DEVICE|Enhanced external counterpulsation|EECP is performed for 1 hours every day, for a total of 36 hours.
41453874|NCT01768260|DRUG|Aspirin|Standard drug therapy
41453875|NCT05429944|OTHER|Motor Relearning Program|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
40759229|NCT03477591|OTHER|Evidence-based information|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
40759230|NCT03477591|OTHER|Patient Decision Aid|Patient Decision Aid for prostate cancer screening decision
40759231|NCT03477591|OTHER|Sham information|Educational information not specific to PSA testing or cancer screening
40759232|NCT06121297|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
40759233|NCT03039751|DRUG|AdvVEGF-D|AdvVEGF-D will be injected into 10 sites of the myocardium
40948876|NCT03390673|DRUG|Avastin|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
40948877|NCT06135402|DEVICE|Treatment with Monalisa Glide Laser|3 fractional laser treatment-sessions with Monalisa Glide
40948878|NCT06135402|DRUG|Treatment with Clobetasol|Application of Clobetasol twice per week
40948879|NCT02359344|DRUG|CNV1014802|
40948880|NCT02359344|DRUG|Placebo|
40948881|NCT04256226|PROCEDURE|Tumor excision|Excision of GIST
40948882|NCT06381531|DIAGNOSTIC_TEST|Imaging with CT and MRI|Quantitative and anthropometric analysis of brain and skull strutcure of imaging (CT/ MRI) undertaken as part of diagnosis or treatment for patients with brain tumor
40948883|NCT05413070|BEHAVIORAL|Multimodal approach to QI for Low-Value Care|Up to 4 brief educational components in existing quality meetings Informational email/newsletter Individualized performance feedback reports Educational resources for patients
40948884|NCT01114152|DRUG|AZD9742|IV Formulation
40948885|NCT01114152|DRUG|Placebo|IV Formulation
40948886|NCT01680887|DRUG|Varenicline|
40948887|NCT01680887|DRUG|Placebo|
40759234|NCT03039751|DRUG|Control Rx|Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
40759235|NCT01333787|DIETARY_SUPPLEMENT|Dietary Fiber Mixture|"During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg."
40759236|NCT03159676|RADIATION|Proton beam|Proton beam
40759237|NCT05522400|BEHAVIORAL|Virtual Reality (VR) and human computer interaction system|The experimental group used VR technology and human-computer interaction system for exercise, while the control group used traditional exercise program
40948888|NCT06306989|DRUG|Letermovir|Participants will be categorized into high-risk and intermediate-risk groups based on risk factors for CMV infection.Initiate letemovir prophylaxis on day +1 in high-risk patients and on days +7 to +14 in non-high-risk patients.(240 mg, qd in patients with concomitant cyclosporine; 480 mg, qd in patients with concomitant tacrolimus) to +100 days. For patients with comorbid GVHD who require intensive immunosuppression, consider extending the regimen to +200 days.
40948889|NCT03657446|DRUG|Clazosentan|Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
40948890|NCT03657446|DRUG|Placebo|Matching placebo infusion
41453876|NCT05429944|OTHER|Proprioceptive Neuromuscular Facilitation|"The techniques administered included Rhythmic Initiation, Slow Reversal and Agonistic Reversal.~The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks."
40759238|NCT00993473|DRUG|Insulin glargine (HOE901)|"100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve the following glycemic targets without hypoglycemia:~* Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,~* Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,~* Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and~* HbA1c \<7.5%."
40759239|NCT00993473|DRUG|Neutral Protamine Hagedorn (NPH) insulin|"NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve glycemic targets as described above for insulin glargine"
40759240|NCT00993473|DRUG|Insulin lispro|Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
40759241|NCT06549868|BEHAVIORAL|Yoga-based bedtime routine|"Dyads in the yoga intervention group receive a picture book outlining a bedtime-themed yoga routine and are instructed to incorporate it into their bedtime routine at least four nights per week for four weeks. The routine guides children through a sequence of yoga poses, starting with the mountain pose and ending in child's pose, designed to calm them as the story progresses. Parents are given a bedtime diary to record the date, whether the child completed the yoga routine each evening, and any comments about their experience with the book.~At week 6, families return to the lab, complete anthropometric assessments and questionnaires, and are fitted with accelerometers to wear for the next week. The accelerometers are returned and data is downloaded a week later. Families are then encouraged to continue using the yoga routine as often as they wish for an additional four weeks, although the frequency of use is not tracked during this maintenance period."
40759242|NCT03615430|PROCEDURE|serratus plane block with local anesthetic|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml 0.25% ropivacaine was administered.
40759243|NCT03615430|PROCEDURE|serratus plane block with saline|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml saline was administered.
40759244|NCT05179915|OTHER|Therapeutic Touch focused on sacral region|In the latent phase of labor, the field energy of the sacral region will be cleared for an average of 15 minutes.
40759245|NCT00617903|DRUG|Azelaic acid|15% foam to be applied topically twice daily
40759246|NCT00617903|DRUG|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
40759247|NCT00121966|DRUG|Insulin Aspart|
40759248|NCT00121966|DRUG|Insulin NPH|
40948891|NCT03657446|DRUG|Moxifloxacin|Film-coated tablet containing 400 mg moxifloxacin
40948892|NCT00537992|PROCEDURE|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
40948893|NCT05840731|DIETARY_SUPPLEMENT|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
40948894|NCT05840731|OTHER|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
40948895|NCT03533101|DRUG|Tocilizumab|IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome
40948896|NCT01919671|DRUG|Tongxinluo capsule|for 90 days
40759249|NCT00121966|DRUG|Metformin|
40759250|NCT00121966|DRUG|Rosiglitazone|
40948897|NCT01919671|DRUG|placebo capsule|for 90 days
40948898|NCT05467371|BEHAVIORAL|Parenting Action Plan|The parenting action plan a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby.
40948899|NCT05467371|BEHAVIORAL|Safe Kids Home Safety Checklist|Safe Kids created a home safety checklist to help keep kids safe, room by room.
41453877|NCT05429944|OTHER|Conventional Physical Therapy|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
40948900|NCT05522452|OTHER|Telerehabilitation|Telerehabilitation program: Intervention will be applied by video interview for 12 weeks, 2 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
40948901|NCT05522452|OTHER|Face to face rehabilitation|Face to face program: Intervention will be applied by physiotherapist for 12 weeks, 2 days a week, 45 minutes a day in clinic. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
40948902|NCT03936660|OTHER|Intense Education Intervention|Intervention will involve guideline-based care education.
40948903|NCT03278756|BEHAVIORAL|Cognitive control training|10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
40948904|NCT03278756|BEHAVIORAL|Active control training|10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
40948905|NCT03547960|DIETARY_SUPPLEMENT|Guar gum|Fibre supplement to be taken with each meal
40948906|NCT03547960|DIETARY_SUPPLEMENT|Cellulose|Placebo. Fibre supplement to be taken with each meal
40948907|NCT00555685|DRUG|NaCl 7,5% (Hypertonic Saline Solution)|Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
40948908|NCT00555685|DRUG|NaCl 0,9%|Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
40948909|NCT01801826|DEVICE|Treatment with CryoTouch IV|Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
40948910|NCT06099717|DEVICE|Dual-cantilevered implant bridge|A 3-unit supported by one implant in the middle
40948911|NCT06099717|DEVICE|3-unit iFDP|3-unit fixed dental prosthesis supported by two implants
40759251|NCT01235637|DRUG|Alfentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: 10μg/Kg, dilution: 1 ml = volume equivalent to 66μg or 10μg/kg = 1.43μg/kg fentanyl.~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
40759252|NCT01235637|DRUG|Sufentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
40948912|NCT02175628|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient."
40759253|NCT06135012|DEVICE|Cavitron ultrasonic surgical aspirator (CUSA)|Transection of pancreatic tissue with cavitron ultrasonic surgical aspirator (CUSA).
40759254|NCT06135012|OTHER|Scalpel|Transection of pancreatic tissue with scalpel.
40759255|NCT05187910|BEHAVIORAL|Speech Therapy|Training with a Speech Language Pathologists for voice disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
40948913|NCT04799327|DRUG|SHR20004|SHR20004：low dose
40948914|NCT04799327|DRUG|SHR20004|SHR20004: medium dose
40948915|NCT04799327|DRUG|SHR20004|SHR20004: high dose
40948916|NCT04799327|DRUG|placebo|Placebo
40759256|NCT05187910|BEHAVIORAL|Swallowing Therapy|Training with a Speech Language Pathologists for swallowing disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
40948917|NCT05645354|BEHAVIORAL|SmokefreeSGM|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of LGBTQ+ smokers.
40948918|NCT05645354|BEHAVIORAL|SmokefreeTXT|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of the general population
40948919|NCT01781364|BEHAVIORAL|Brain Fitness Training, Posit Science SF|Computer aided cognitive training based on principles of neuroplasticity
40948920|NCT04094623|OTHER|Dialectical behavior therapy|15 patients in a group are treated by 2 psychotherapist by DBT including mindfulness skills, distress tolerance skills, emotional regulation skills and interpersonal effectiveness skills.
40948921|NCT04094623|OTHER|Social support group therapy|15 patients in a group are treated by 2 psychotherapist by SSGT.(Giving support to each other.)
40948922|NCT00760500|OTHER|Nasopharyngeal Swab|Nasopharyngeal Swab
41453878|NCT02379533|OTHER|Aerobic exercise|
40948923|NCT03373071|BIOLOGICAL|CD19-CAR T cell|"Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment"
40948924|NCT01407822|DRUG|Erlotinib|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
40948925|NCT01407822|DRUG|Gemcitabine/cisplatin|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
40948926|NCT04993560|BIOLOGICAL|BBIBP-CorV|Inactivated virus COVID-19 vaccine
40759257|NCT05187910|BEHAVIORAL|Upper Airway Therapy|Training with a Speech Language Pathologists for upper airway disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
40948927|NCT04993560|BIOLOGICAL|BNT162b2|mRNA-based COVID-19 vaccine
40759258|NCT02327143|DRUG|LY2835219|Administered orally
40948928|NCT03949842|DRUG|Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists|A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
40948929|NCT03949842|DRUG|Fluticasone furoate/umeclidinium/vilanterol|The first strip will contain FF at a dose strength of 100 mcg will be blended with lactose. The second strip will be contain UMEC and VI at a dose strength of 25 mcg and 62.5 mcg blended with lactose and magnesium stearate with respectively.
40759259|NCT02327143|DRUG|¹³C₈-LY2835219|Administered IV
40759260|NCT01633112|DRUG|fingolimod|capsule
40759261|NCT01633112|DRUG|glatiramer acetate|subcutaneous injection
40759262|NCT05204329|BIOLOGICAL|MSC Secretome Eye Drops|MSC Secretome eye drop will be dispensed.
40759263|NCT02192086|OTHER|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
40759264|NCT02192086|OTHER|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg \* wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
40759265|NCT03822715|OTHER|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
40759266|NCT03822715|DRUG|standard of care aromatase inhibitors|standard of care aromatase inhibitors
40759267|NCT03807648|OTHER|Data Inclusion|Patients in this group will be included in the project
40759268|NCT02134808|DRUG|Creatine|Creatine is a nutritional supplement.
40759269|NCT02134808|DRUG|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
40759270|NCT02605967|DRUG|Spartalizumab|Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
40948930|NCT00914680|PROCEDURE|magnetic seizure therapy|antidepressant treatment with MST
40948931|NCT04587271|DIETARY_SUPPLEMENT|Moringa oleifera (high dose)|Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.
40948932|NCT04587271|DIETARY_SUPPLEMENT|Moringa oleifera (low dose)|Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.
40948933|NCT04587271|DIETARY_SUPPLEMENT|Placebo|Mothers and children will receive porridge with placebo.
40948934|NCT01499758|DRUG|Atorvastatin|80 Mg tablets
40948935|NCT01032174|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
40948936|NCT01032174|DRUG|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
40948937|NCT06556758|OTHER|stripping massage + conventional therapy|Stripping massage on rhomboid major and minor active trigger point in the direction of muscle fiber from origin to insertion of muscle. Frequency: 3 minutes for 3 times/week for 4 consecutive weeks. Conventional PT including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set) Frequency: 3 times/ week for 4 weeks
40948938|NCT06556758|OTHER|Conventional therapy|conventional therapy including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set ) Frequency : 3 times/ week for 4 weeks
40948939|NCT06301217|OTHER|There is no intervention|There is no intervention
40948940|NCT00933829|PROCEDURE|Absorbable Suture Arm|use of irradiated polyglactin 910
40948941|NCT00933829|DEVICE|Non-absorbable suture (Prolene)|suture
40948942|NCT00933829|PROCEDURE|suture|non-absorable sutures and absorable sutures
40948943|NCT03257696|DIAGNOSTIC_TEST|Close-ended questionnaire|"Yes/no questionnaire used in order to identify reliable respondent and unreliable respondent"
40948944|NCT00425347|DRUG|HuLuc63|Not applicable for HuLuc63.
40948945|NCT05776472|DRUG|Pegcetacoplan|Pegcetacoplan will be prescribed according to the label in patients with PNH.
40948946|NCT02059902|DRUG|Lidocaine|Lidocaine infusion runs for a total of 24 hours
40948947|NCT02059902|OTHER|Placebo|Normal saline runs for a total of 24 hours
40948948|NCT03386474|DRUG|Brolucizumab 6 mg|Administered as opthalmic solution for an intravitreal injection to the study eye
40948949|NCT03386474|DRUG|Aflibercept 2 mg|Administered as an opthalmic solution for intravitreal injection to the study eye
40948950|NCT00910273|DRUG|etanercept|etanercept 50 mg/week
40948951|NCT03661710|OTHER|Investigating Adherence to Standard of Care Medication and Cardiac Rehabilitation|Information from health care insurance providers on how many patients adhered to prescribed medication and how many underwent cardiac rehabilitation and how adherence influenced cardiovascular outcome will be retrieved
40948952|NCT04288752|DEVICE|VR101 Lubricating Intravaginal Ring|VR101 Lubricating Intravaginal Ring is a personal lubrication device, for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication.
40948953|NCT04288752|DEVICE|Sham Ring|Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added.
40948954|NCT04686604|OTHER|Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
41453879|NCT04145635|DEVICE|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
40759271|NCT02605967|DRUG|Investigator choice of chemotherapy|Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
40759272|NCT06163807|DRUG|Antiasthmatic|real-life
40759273|NCT01871922|DRUG|Placebo|Saline
40948955|NCT00936611|DRUG|LBH589|
40948956|NCT01488500|OTHER|Bronchoscopy|24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
40759274|NCT01871922|DRUG|Atropine|Atropine
40786413|NCT05845112|DIAGNOSTIC_TEST|Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP|CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.
40948957|NCT05047068|DEVICE|OCS Heart System|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
40948958|NCT01222624|DRUG|PankoMab-GEX™|
40948959|NCT02276326|DIETARY_SUPPLEMENT|VSL#3 sachets|4 sachets a day for 4 months
40948960|NCT05859685|OTHER|Experimental|"Manual therapy techniques:~* Talar dorsal sliding technique. Dorsal mobilization of the talus, with the patient in the supine position and ankle dorsiflexion, without pain or discomfort. The physiotherapist will exercise an anteroposterior mobilization of the talus, with a dorsal glide~* Mulligan movement mobilization technique: The patient will be in a standing position, with the ankle to be treated forward. You will be given an aid or support in the upper extremity to maintain stability."
40948961|NCT05859685|OTHER|Control|The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and times of administration will be the same
40948962|NCT05797662|DRUG|Propranolol|Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks
40948963|NCT06041490|DRUG|multi-kinase inhibitors in combination with bevacizumab|The eligible participants will start taking multi-kinase inhibitors between 4-8 weeks after liver transplantation. The choice of the specific multi-kinase inhibitor, including sorafenib, lenvatinib, or regorafenib, will be determined by the researchers based on factors such as the participant's tumor characteristics, liver function, physical condition, risk of side effects, economic status, and personal preference. The specific dosage and administration details can be found in the table provided. The maximum duration of multi-kinase inhibitor treatment will be 12 months or until any of the following conditions occur, whichever comes first: 1) The participant experiences intolerable toxic reactions that do not alleviate with dose adjustments, or 2) The participant has documented disease recurrence confirmed through imaging or withdraws from the study for other reasons.
40948964|NCT02651350|DRUG|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
40948965|NCT02651350|DRUG|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
40948966|NCT03192956|OTHER|No active intervention|No active intervention is performed
40948967|NCT02371304|RADIATION|Adjuvant chemoradiotherapy|Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
40948968|NCT02371304|PROCEDURE|Additional TME surgery|
40948969|NCT02371304|DRUG|capecitabine|
40948970|NCT00237887|DRUG|adalimumab|
40948971|NCT06321562|DRUG|TimoD implant|Consists of 1 TimoD implant administration in the study eye
40948972|NCT06321562|DEVICE|Injector system|"This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use."
40948973|NCT03388931|RADIATION|Radiation Therapy|Increased radiation therapy dose
40948974|NCT03388931|COMBINATION_PRODUCT|Chemotherapy|Standard-of-care chemotherapy with treatment regimen to be determined by the treating physician
40948975|NCT00562250|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
40759275|NCT02011529|OTHER|TEAMcare treatment of diabetes|TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
40759276|NCT03976141|DIAGNOSTIC_TEST|mri|knee mri
41287819|NCT05332899|BIOLOGICAL|Influenza Virus Type A H3N2 Challenge|The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device or by natural exposure to infected participants. Participants will be admitted to the hospital and quarantined for 8 to 12 days for monitoring, and will receive care and supportive treatment as necessary. Participants will be followed for a total of 12 weeks.
41453880|NCT02528019|DRUG|DPP-4 inhibiotors|
40759277|NCT02548819|OTHER|MRI|MR imaging of patients with implanted cardiac devices
40948976|NCT00562250|DRUG|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
40948977|NCT00562250|DRUG|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
40948978|NCT05160090|DRUG|Bupropion HCl MR tablets 300mg|In each study period, a single 300 mg dose of Bupropion will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
40948979|NCT05931640|DEVICE|Virtual Reality|Virtual Reality Therapy that includes use of VR goggle, VR headset and play station if available. Virtual games like move-pro will be used for upper limb movements. A session of 12-45 minutes, twice weekly will be done. And scoring will be done with the help of additional tools.
41453881|NCT02528019|DRUG|SGLT2 inhibitors|
41453882|NCT02528019|DRUG|Glimepiride|
40759278|NCT01050218|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
40759279|NCT04945369|OTHER|clinical and biological measurements and questionnaires|"Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.~Assessment of body composition by BOP-POD and by impedancemetry. Assessment of pulse wave by popmetre. Assessment of physical activity by accelerometer and by questionnaire Questionnaires for analysis of eating behaviour"
40948980|NCT05931640|DEVICE|Plyometric Training|Plyometric therapy that includes 10 minutes of ball throwing, push-ups, jumping and hopping/skipping. At start intensity and speed is low, but will be increased gradually. Every score will be noted with the help of additional tools.
40948981|NCT06097338|PROCEDURE|bariatric surgery (BS)|bariatric surgery (BS) is a very attractive choice for severely obese patients. After bariatric surgery, long-term weight loss (15%-25%) and diabetes remission can occur \[16\], as well as long-term mortality, cardiovascular events and tumor occurrence \[17\]. Regardless of the surgical procedure used for weight loss surgery, studies have shown that weight loss surgery can significantly reduce the liver NAFLD activity score (from 5 to 1), and 33.8% of patients have reduced liver fibrosis \[18\]. The follow-up results for a longer period of time (10 years) also indicate that weight loss surgery significantly reduces the occurrence of major adverse outcomes related to liver cirrhosis, liver cancer, liver transplantation, and liver related deaths
41453883|NCT02799992|PROCEDURE|689 nm Laser Treatment of the Macula|
41453884|NCT02799992|PROCEDURE|Half Dose Photodynamic Therapy|
41453885|NCT03289260|DRUG|Imiquimod 5% cream|Patients receive topical Imiquimod therapy for 12 weeks.
41287820|NCT05078034|DEVICE|Helmet Non-Invasive Ventilation (HNIV)|HNIV will be connected to a ventilator by a conventional closed respiratory circuit. Sessions of HNIV will be delivered with PEEP targeting a minimum 12 hours/day. PEEP will be titrated according to patient comfort, work of breathing, and O2 saturation. Pressure support will be titrated to lowest level tolerated. Between HNIV sessions, patients will be supported with HFNO at the same required FiO2. Starting on study day 3, patients will be screened for discontinuation of HNIV. Once HNIV is stopped, patients will be transitioned to HFNO and then weaned from HFNO as tolerated.
41287821|NCT05078034|DEVICE|High Flow Nasal Oxygen|HFNO will be provided. FiO2 will be titrated to achieve a target O2 saturation of 92-97%, and flows will be initiated at 50 litres/minute and titrated as per usual practice for comfort and oxygenation. Once the target O2 saturation is achieved, the FiO2 will be titrated to the minimal value to maintain this target saturation. HFNO will be provided continuously over a minimum of 2 calendar days. Starting on study day 3, patients will be weaned from HFNO as tolerated.
41287822|NCT02202603|DRUG|Teriparatide|single oral tablet
40759280|NCT03339765|BEHAVIORAL|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants will receive weekly game sessions to play at home for three months.
40759281|NCT01627912|OTHER|Robola, Cabernet Sauvignon wines|4 treatments on separate days: the subjects randomly consumed 4ml of drink \[white wine or red wine or 12.5% ethanol or water\]/kg of individual, parallel with a standardized meal.
41287823|NCT02202603|DRUG|Teriparatide|subcutaneous standard injection
40759282|NCT04369612|PROCEDURE|Standard follow-up|Standard post-transplant follow-up
40759283|NCT04369612|PROCEDURE|Home-based monitoring|Patients take capillary blood sample by finger-prick and send to lab for analyses. Telecom follow-up that day by treating physician
40759284|NCT03049397|OTHER|Communication Intervention|Complete Enhancing Connections program
40759285|NCT03049397|OTHER|Questionnaire Administration|Ancillary studies
40759286|NCT05530538|BEHAVIORAL|BrainWeighve App|46 total adolescents (14-18 years old) with %BMIp95 will be recruited via various sources (e.g., clinic referrals, flyers, social media advertising) to participate in one of two stages of the study: the beta testing stage or the trial stage. Beta testing will enroll two successive groups of eight teens to test the app for three weeks; participants will be assessed in-person pre- and post-intervention. After each group, the app will be modified to incorporate their feedback in order to promote youth engagement. The trial stage will enroll 30 adolescents to participate in a four-month intervention; participants will complete three assessments, baseline, post-intervention (both in-person) and one-month post-intervention (either in-person or virtually).
40759287|NCT03402581|DEVICE|c-mac laryngoscope|type of laryngoscopes
40759288|NCT06318416|DIAGNOSTIC_TEST|urine spectrophotometry for rifampin absorbance|All participants will received conventional weight-based TB therapy, standard of care for active TB disease. After enrollment, participants will be randomized to early Day 14 or delayed Day 21 dose modification of rifampin informed by urine spectrophotometry where absorbance is determined above or below a threshold. Below a threshold, single tablets of rifampin are added to conventional fixed drug combination standard of care, above a threshold, no additional rifampin is added. Dose adjustment of rifampin may be up to \~30mg/kg and will be continued through day-56.
40759289|NCT02532946|BEHAVIORAL|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
40759290|NCT06509074|DRUG|Beta blocker|Pragmatic design. Any beta-blocker with alpha or NO activity may be used
40759291|NCT02767973|OTHER|Wood Smoke Particles (WSP)|After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
40948982|NCT03645590|BEHAVIORAL|Stroke Ready|Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
41287824|NCT02202603|DRUG|placebo|Oral placebo
40759292|NCT04125719|BIOLOGICAL|PVSRIPO|Intralesional injection of PVSRIPO
40759293|NCT04125719|DRUG|Nivolumab|Nivolumab infusion
40759294|NCT03939494|BEHAVIORAL|Telehealth Encounter|Contact will be made with participants via Face Time or Skype.
40759295|NCT01983670|OTHER|Temporal electrical stimulation|
41287825|NCT02908802|DIETARY_SUPPLEMENT|Probiotic|Probiotic
41287826|NCT02908802|DIETARY_SUPPLEMENT|Placebo|Probiotics capsules without the active ingredient
41287827|NCT04187001|OTHER|Content Validity|Use Delphi technique for achieve consensus
41287828|NCT04187001|OTHER|Cultural adaptation|Adapt the content to the target population
41453886|NCT03289260|DRUG|Placebo cream|Patients receive topical Doritin therapy for 12 weeks
40948983|NCT02919696|DRUG|Abemaciclib|Administered orally
40948984|NCT05111808|DEVICE|Methylene blue fluorescence|IV administration of methylene blue, detection with deep infrared camera and light source
40948985|NCT06096935|OTHER|bood sample|Exome measurements
40948986|NCT05366517|DEVICE|Dornier Aries 2 device|For 6 weeks, patients will receive 6 sessions with active LiST probe, 2 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7) frequency = 5Hz
40948987|NCT01672008|DRUG|NOX-100|
40948988|NCT06557928|OTHER|measurement|Measurement of multiple physiological indicators and psychological status and multi-omics study
40948989|NCT00921128|DRUG|Muscimol|
40948990|NCT06435728|DIAGNOSTIC_TEST|AccuIMR and AccuFFR|AccuFFR and AccuIMR were obtained by reviewing coronary angiography at the time of primary PCI
40948991|NCT06383065|OTHER|IMT Group|Inspiratory muscle training involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in.
40948992|NCT01482273|PROCEDURE|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
40948993|NCT01482273|PROCEDURE|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
40948994|NCT03120234|DRUG|Dexmedetomidine|
40948995|NCT03120234|DRUG|Ketamine|
40948996|NCT03120234|DRUG|Fentanyl|
40948997|NCT03120234|DRUG|Placebos|o.9% normal saline will be used instead of ketamine
40948998|NCT02511990|BIOLOGICAL|3 mg/kg, single dose IV administration of 10-1074|3 mg/kg, single dose IV administration of 10-1074
40948999|NCT02511990|BIOLOGICAL|10 mg/kg, single dose IV administration of 10-1074|10 mg/kg, single dose IV administration of 10-1074
40949000|NCT02511990|BIOLOGICAL|30 mg/kg, single dose IV administration of 10-1074|30 mg/kg, single dose IV administration of 10-1074
40949001|NCT04715425|PROCEDURE|Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation|Bilateral pulmonary vein isolation using radiofrequency energy
41287829|NCT05202977|DEVICE|SinocrownTM Transcatheter Aortic Valve Replacement System|Subjects receiving SinocrownTM Transcatheter Aortic Valve Replacement System of Lepu Medical
41287830|NCT01522651|DRUG|Ranolazine|Tablets administered orally twice daily.
40949002|NCT04715425|PROCEDURE|Catheter pulmonary vein isolation without additional lesions|Bilateral pulmonary vein isolation using radiofrequency energy
41287831|NCT01522651|DRUG|Dronedarone|Capsule administered orally twice daily
41287832|NCT01522651|DRUG|Ranolazine placebo|Tablets administered orally twice daily.
41287833|NCT01522651|DRUG|Dronedarone placebo|Capsules administered orally twice daily
41287834|NCT01243476|DRUG|Lenalidomide|Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).
41287835|NCT01243476|OTHER|Placebo|Placebo, oral use, daily during study treatment (104 weeks)
41287836|NCT06511661|PROCEDURE|Complete lymphadenectomy|At least 3 N1 stations and 3 N2 stations are examined during surgery, including station 7.
41287837|NCT06511661|PROCEDURE|Incomplete lymphadenectomy|Less than 3 N1 stations or 3 N2 stations are examined during surgery, or those without station 7 lymph node dissection.
40949003|NCT02247531|DRUG|Lampalizumab|10 mg dose of lampalizumab administered intravitreally.
41287838|NCT02443844|PROCEDURE|Transurethral Resection|Endoscopic treatment of bladder cancer
40949004|NCT02247531|OTHER|Sham Comparator|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
40949005|NCT00685542|DRUG|diacerein|Diacerein 50mg bid
40949006|NCT00685542|DRUG|placebo|placebo
40949007|NCT01934972|OTHER|CR + DCS (D-cycloserine)|CR + DCS
40949008|NCT01934972|OTHER|CR + placebo|CR + placebo
40949009|NCT02436304|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
40949010|NCT02436304|PROCEDURE|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
40949011|NCT05363631|DRUG|Selenomethionine (SLM)|Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)
40949012|NCT05363631|DRUG|Axitinib|Axitinib is a small molecule tyrosine kinase inhibitor.
40949013|NCT05363631|DRUG|Pembrolizumab|Pembrolizumab is a type of immunotherapy
40949014|NCT02216760|DEVICE|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
40949015|NCT02216760|DEVICE|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
40949016|NCT03959631|BEHAVIORAL|Virtual Communities of practice|based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
40949017|NCT02326662|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
40949018|NCT02030418|DEVICE|Leadless Pacemaker|Patients will undergo an attempted leadless pacemaker implant
40949019|NCT05736471|DIAGNOSTIC_TEST|Computational dissociation of the causes of cognitive rigidity in depression|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
41287839|NCT02443844|DRUG|Tamsulosin|Medical treatment for benign prostate hyperplasia
41453887|NCT03289260|PROCEDURE|Fulguration|Surgical Excision and Fulguration of condyloma
40949020|NCT04112420|DIAGNOSTIC_TEST|Trans-esophageal echocardiography|"The department registers an unplanned admission of a patient to the intensive care unit. The indication is verified again by the intensive care physician.~In this case, the patient is then admitted to the intensive care unit, supervised by an intensive care physician, orientated and initiated therapeutic and diagnostic measures.~As part of the planned transthoracic cardiac ultrasound examination, it is then selected whether the patient is suitable according to the patient's will and the inclusion or exclusion criteria.~After clarification, time to think and consent, the examination is then carried out according to the protocol by approved doctors of the Clinic for Anesthesia, intensive care and pain therapy. Followed by digital storage for the finding.~After the subsequent operation, the investigator determines whether knowledge of detected pathologies would have an effective influence on the anesthesiological procedure or not."
40949021|NCT05626062|DEVICE|Toilet alarm|A Malem toilet alarm (wristworn, discretely in underwear, or bed mat) will be used to promote prompred voiding in a toilet
40949022|NCT04956926|DRUG|JS201|JS201 is administered intravenously Q3W at the corresponding dose.
40949023|NCT05058716|DIAGNOSTIC_TEST|blood sample|weekly blood sample - coenzym q10 levels
40949024|NCT04280835|BEHAVIORAL|Group Psychoeducation that Focused on Social Skill Development|Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.
40949025|NCT06556550|RADIATION|stereotactic ablative radiation therapy|stereotactic ablative radiation therapy in effective doses to each metastatic site
40949026|NCT06556550|RADIATION|palliative radiation therapy|palliative radiation therapy (8 Gy/1 Fx, 3 Gy x 10-15 Fx, 4,5 Gy x 5 Fx)
40949027|NCT06556550|DRUG|Chemotherapy|prescribed drug line
40949028|NCT02007616|OTHER|Non-action video game training|Based on cognitive training Lumosity
40949029|NCT02846324|DRUG|GBT440|Capsules which contain GBT440 drug substance in Swedish orange
40949030|NCT02846324|DRUG|Placebo|Placebo capsules
40949031|NCT03592654|BEHAVIORAL|infant telehelp|Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
41287840|NCT05896176|DIAGNOSTIC_TEST|a clinical examination and anamnesis|The investigators compare the results of the PSQ alone with the elements provided by the clinical examination regarding the referral of patients to the Otolaryngologist (ENT) consultation.
41287841|NCT05113524|OTHER|Dance|The dance program consists of 3 months of dance classes. Classes are specifically designed for people with Parkisnon's and lead by a qualified dance instructor experienced in teaching this population. The in-person dance classes are conducted in an appropriate room with chairs and ballet barres once a week. In addition, the participants received a CD containing a video of the recorded dance routine to be performed at home once a week. The class typically included a warm-up (10-15 min.), barre ballet exercises (10-15 min.), general dance-related activities (15-20 min), and a cool-down (10-15 min).
40949032|NCT04652427|DRUG|Dexmedetomidine Hydrochloride 0.1 MG/ML|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
40949033|NCT04652427|DRUG|0.9% Sodium Chloride Injection|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
40949034|NCT00794703|DRUG|micafungin (Mycamine)|Intravenous
40949035|NCT00794703|DRUG|itraconazole|oral
41287842|NCT05113524|OTHER|No intervention|Controls, not alter their personal lifestyle, but will undergo the same testing as the exercise intervention group.
41287843|NCT06508567|RADIATION|High Dose Rate Brachytherapy|2 fractions of MRI-guided HDR Brachytherapy (13Gy each) delivered over 14 days (± 7 days).
40786414|NCT05845112|DIAGNOSTIC_TEST|Urine lateral flow tests|The assay combines a pair of high affinity monoclonal antibodies directed towards largely Mycobacterium tuberculosis-specific lipoarabinomannan epitopes and a silver-amplification step that increases the visibility of test and control lines. This enables the detection of urinary lipoarabinomannan concentrations that are approximately 30 times lower than that detected by a previous test called AlereLAM and improved analytical specificity compared with AlereLAM.
40949036|NCT00109200|DRUG|Xolair (omalizumab)|
40949037|NCT02858011|OTHER|Cash distribution during first 36 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
41287844|NCT05147350|DRUG|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 (Oral) in combination with FOLFIRI (IV)
41287845|NCT00669773|DRUG|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
41287846|NCT00669773|DRUG|Docetaxel|Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
40759296|NCT06537401|BEHAVIORAL|Hypercaloric, High Fat Diet|Participants will select meals from a list of sample breakfast, lunch, and dinner options from grocery stores. Typical intake will be estimated as 160-170% of resting metabolic rate, which will then be multiplied by 1.65 as the target calorie intake for the HFD. Target fat intake will be 65% of the HFD calorie target. To ensure participants will achieve the desired calorie and fat intake, they will also be provided with pre-made nutrient shakes and half-and-half. Participants will supplement their food intake with one to three shakes per day for each of the three days, depending on the fat and calorie content of the foods they select. They will be asked to add half-and-half equally between across the shakes.
41287847|NCT05652192|RADIATION|SBRT|SBRT was added to systematic treatment (chemo+ PD-1 antibody)
40759297|NCT00896844|BEHAVIORAL|emotional disclosure|writing about emotional events from the past
40759298|NCT00896844|BEHAVIORAL|placebo writing|writing about how they spent their time the previous day
40759299|NCT02829918|DRUG|Nivolumab|Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.
40759300|NCT00251654|PROCEDURE|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
40759301|NCT04928287|BIOLOGICAL|HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
40759302|NCT04928287|OTHER|Placebo|Placebo will be administered intravenously to study participants who qualify.
40759303|NCT02162173|PROCEDURE|Endoscopy|Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
40759304|NCT05874804|DEVICE|Carry Life UF|A 5-hour treatment with the Carry Life UF used with a 1.36% glucose PD fill.
40759305|NCT05874804|DRUG|2.27% glucose peritoneal dialysis dwell|A 5-hour CAPD dwell with a 2.27% glucose PD fluid.
40759306|NCT06570317|DRUG|Nintedanib|For patients with unresectable NSCLC, nidanib is administered during sequential radiotherapy
40759307|NCT04967001|DIAGNOSTIC_TEST|PSMA PET|68Ga-PSMA PET
40759308|NCT06160778|DRUG|Ketorolac Tromethamine|Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
40759309|NCT06160778|DRUG|Morphine Sulfate|Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
40759310|NCT06160778|DRUG|normal saline|Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
40759311|NCT06160778|DRUG|Normal saline|Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
40949038|NCT02858011|BEHAVIORAL|Accompanying information sessions on health, child nutrition, household economics and education during first 36 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
40949039|NCT02858011|DIETARY_SUPPLEMENT|Preventive Nutrition Packages during last 12 months|Fortified flour supplements for children (Supercereal Plus)and pregnant/lactating mothers (super Cereal)
41287848|NCT05689060|OTHER|mulling Straight leg raising technique|Subject was in supine lying, therapist stood at the side of limited, therapist placed subjects flexed knee over therapists shoulder and subject was asked to push therapist away with his leg and then relax. At this point therapist pushed subjects bent knee up as far as in the direction of shoulder.
40949040|NCT02858011|OTHER|Cash distribution during the last 12 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
40949041|NCT02858011|BEHAVIORAL|Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
40949042|NCT06337838|DRUG|Desmopressin Injectable Solution|Intravenous desmopressin, 20 mcg, single dose administration.
40949043|NCT06337838|DRUG|Tranexamic Acid Injectable Product|Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.
40949044|NCT06337838|OTHER|Placebo|Intravenous 0.9% saline solution
40949045|NCT05143450|OTHER|Manual Pressure|In the experimental group manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher before the procedure. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated.
40949046|NCT05553314|DRUG|Carvedilol|patients randomized to carvedilol group will receive carvedilol-SR.
40949047|NCT05553314|DRUG|Placebo|patients randomized to placebo group will receive placebo.
40949048|NCT01879514|DRUG|Chinese Herb Prescription Granule plus prednisone|Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
40949049|NCT01879514|DRUG|Placebo|Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
40949050|NCT01771042|OTHER|Dietary weight loss at 25% energy deficit|Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
40949051|NCT06047808|BEHAVIORAL|Storytelling Through Music|"Storytelling Through Music is a six-week expressive arts intervention."
40949052|NCT04470778|DRUG|BMS-986256|Specified dose on specified days
40949053|NCT04470778|DRUG|Famotidine|Specified dose on specified days
40759312|NCT02203279|OTHER|Rebase II Fast|It is going to be used a direct relining material
40949054|NCT02932215|DRUG|lorcaserin|Open label
40949055|NCT02932215|OTHER|Fitbit Charge HR|This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
40949056|NCT02540226|DRUG|Intravenous tranexamic acid|
40949057|NCT02540226|DRUG|Topical tranexamic acid|
40949058|NCT02540226|DRUG|Intravenous saline|
40949059|NCT02540226|DRUG|Topical saline|
40759313|NCT02203279|OTHER|Flexacryl|This is going to be used as a second direct relining material
40759314|NCT02203279|OTHER|Vertex|This is going to be used as an indirect relining material
40759315|NCT03107299|OTHER|Communication methods to encourage adherence|Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
40949060|NCT02219438|DRUG|Bolus|An adductor canal catheter was inserted and ropivacaine 0.2% administered as hourly bolus doses of 8 mL each: one at time point zero and then on the hour for 7 additional doses.
40949061|NCT02219438|DRUG|Basal|An adductor canal catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for a total of 8 hours.
40949062|NCT03333304|DIAGNOSTIC_TEST|Procalcitonin measurement|Discontinuation of antimicrobials according to Procalcitonin Kinetics
40949063|NCT04231890|OTHER|IPI monitoring|Patients in this arm will have IPI monitoring
40949064|NCT06556511|DRUG|Zinc Sulfate|Zinc is administered at a dose of 10 mg per day for children under the age of 6 months, and 20 mg per day for children above the age of 6 months accompanied with standard therapy in the zinc group for a period of 10 days.
40949065|NCT06556511|DRUG|Placebo|Placebo is administered with standard therapy in the placebo group for a period of 10 days.
40949066|NCT00783965|DRUG|tazarotene|Applied to the skin
40949067|NCT00783965|OTHER|placebo|Applied to the skin
40949068|NCT02254941|DRUG|Chemotherapy|Metastatic colon cancer, first line treatment with conventional chemotherapy
40949069|NCT02254941|BIOLOGICAL|Chemotherapy plus monoclonal antibody|Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
40949070|NCT05890144|OTHER|Big Canoe|The Big Canoe will involve an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. It is 10 modules long and takes 10 weeks to complete (1 hour of learning per week).
40949071|NCT05890144|OTHER|Little Canoe|The Little Canoe involves a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session
40949072|NCT05890144|OTHER|Control|The control is a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
40949073|NCT02819869|DRUG|Statin and Metformin use|
40949074|NCT01081288|OTHER|Invitation for breast screening|Invitation for breast screening to women in different age groups
40949075|NCT02666885|RADIATION|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
40949076|NCT04123652|DRUG|Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992|"An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours."
40949077|NCT06557317|BEHAVIORAL|Black Girls for Wellness In-Person|Weekly for 12 weeks, adolescent/caregiver dyads will attend 1) an in-person Wellness Session (mindfulness, nutrition lesson, dance class, program reflection) (90 min/wk) and 2) a home cooking experience using ingredients provided at the Wellness Session (60 min/wk).
40949078|NCT02544074|BEHAVIORAL|neuropsychological testing|standard neuropsychological testing including brief standardized assessments
40949079|NCT02544074|BEHAVIORAL|eSAGE testing|Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
40949080|NCT01297075|BEHAVIORAL|Outreach visits|The 16 facilitators in the project attend an educational programme designed to provide them with the necessary skills and tools for the task. The facilitators visit general practice clinics from March 2011 until the end of 2012. Each clinic is offered three visits. The facilitator is to act as a change agent who motivates and helps the clinic team in the process of defining common goals, and choosing the appropriate means for achieving them.
40949081|NCT02601027|PROCEDURE|Transversus Abdominis Plane (TAP) block|
40949082|NCT02601027|DEVICE|Nimbus Infusion Pump IV Administration|
40759316|NCT00215657|DRUG|Degarelix|Degarelix 120 mg (20 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
40759317|NCT00215657|DRUG|Degarelix|Degarelix 120 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
40949083|NCT02601027|DRUG|Bupivacaine infusion|
40949084|NCT02601027|DRUG|Acetominophen|
40949085|NCT02601027|DRUG|Hydromorphone|
40949086|NCT02601027|DRUG|Oxycodone|
40949087|NCT02601027|DRUG|Ondansetron|
40949088|NCT01423019|DIETARY_SUPPLEMENT|Advantra Z|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
40949089|NCT01423019|DIETARY_SUPPLEMENT|Advantra Z + Naringin + Hesperiden|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
40949090|NCT01423019|OTHER|Sugar pill|Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
40949091|NCT00589901|DRUG|capecitabine and cyclophosphamide|"capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14"
40949092|NCT06029712|DRUG|Heart failure polypill|Copackaging of heart failure medications (beta blocker, SGLT2i, MRA, and ACE/ARB/ARNI) in an overencapsulated polypill. Individual tablets will be hand-packed into a single capsule at the level of the pharmacy. Specific medications and doses will be individualized to the participant.
40759318|NCT00215657|DRUG|Degarelix|Degarelix 160 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
40949093|NCT06029712|DRUG|Control Rx|GDMT delivered as individual tablets
40949094|NCT00357357|DRUG|HF0220|comparison of different dosages of drug
40949095|NCT04010032|DEVICE|Programmed intermittent epidural bolus|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device
40949096|NCT04010032|DEVICE|Continuous epidural infusion|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device
40949097|NCT01683019|DEVICE|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
40949098|NCT01683019|DEVICE|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
40949099|NCT03267251|OTHER|Vacteens Web app for mobile devices|The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
40949100|NCT03267251|OTHER|Standard Usual and Customary HPV Information - CDC pamphlet|The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
40949101|NCT00334607|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
40949102|NCT02830061|OTHER|Interviews|Individual semi-structured interviews for 30-60 minutes using an interview schedule developed from an interpretative phenomenological analysis framework.
40949103|NCT05780190|DEVICE|New artificial liver CABA system (BS330+CA280) +PE|The new artificial liver CABA system (BS330+CA280) combioned plasma exchange in the treatment of end-stage liver disease with inflammatory status
40949104|NCT00277446|DRUG|Soy isoflavones|
40949105|NCT04594811|DRUG|NT-I7|Administered by intramuscular (IM) injection.
40949106|NCT04594811|DRUG|Nivolumab|Administered by intravenous (IV) injection.
41287849|NCT05689060|OTHER|post facilitation stretch|Muscle energy technique was applied using post facilitation stretch While the participant lying in supine position, the pelvis was strapped down to the table for stabilization and control on accessory movement and the contralateral limb was securely strapped down to the table to prevent excessive hip and pelvic rotations during procedures.The participant's hip was passively flexed and the leg extended until tension was sensed and the participant reported a moderate stretching sensation.
41453888|NCT02929472|BEHAVIORAL|Physical exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
41453889|NCT02929472|BEHAVIORAL|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
41453890|NCT06428539|DIAGNOSTIC_TEST|T-reg cells|laboratory test
40759319|NCT00215657|DRUG|Degarelix|Degarelix 200 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
40759320|NCT00215657|DRUG|Degarelix|Degarelix 200 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
40759321|NCT00215657|DRUG|Degarelix|Degarelix 240 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
40759322|NCT00215657|DRUG|Degarelix|Degarelix 240 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
40949107|NCT01480648|DRUG|BI 144807 Placebo|Placebo that represents BI drug
40949108|NCT01480648|DRUG|BI 144807|single dose (low to high dose)
40949109|NCT02297048|DIETARY_SUPPLEMENT|Potassium depletion|Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
40949110|NCT02806570|DEVICE|Mitral valve repair|
40949111|NCT06310200|DRUG|Lidocaine Topical 4% Topical Solution|Intranasal administration
40949112|NCT06310200|DRUG|Bitrex|Bittering agent
40949113|NCT06310200|DRUG|normal saline|Placebo
40949114|NCT00000663|DRUG|CD4-IgG|
40949115|NCT00343590|DEVICE|Whole Body Vibration machine|
40949116|NCT01034150|DEVICE|Relief band (Somatosensory stimulation)|Electrical median nerve stimulation
40949117|NCT01034150|DEVICE|Placebo stimulation|Placebo stimulation
40949118|NCT00423514|BIOLOGICAL|filgrastim|
40949119|NCT00423514|DRUG|clofarabine|
40949120|NCT00423514|DRUG|melphalan|
40949121|NCT00423514|DRUG|mycophenolate mofetil|
40949122|NCT00423514|DRUG|tacrolimus|
40949123|NCT00423514|DRUG|thiotepa|
40949124|NCT00423514|PROCEDURE|allogeneic bone marrow transplantation|
40949125|NCT00423514|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40949126|NCT00423514|PROCEDURE|peripheral blood stem cell transplantation|
40949127|NCT05516277|BEHAVIORAL|Behavioral Sleep Education Intervention|Manual-based education program focusing on behavioral sleep provided in individual 60-minute sessions for 5 weekly sessions.
40949128|NCT05516277|BEHAVIORAL|General Sleep Education Intervention|Manual-based education program focusing on general sleep provided in individual 60-minute sessions for 5 weekly sessions.
40949129|NCT02325648|DRUG|HIPEC cytoreductive surgery|At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
41133535|NCT03676504|BIOLOGICAL|CD19.CAR T Cells|Dose Level 1: 1×10\^6 transduced cells/m\^2; Dose Level 2: 5×10\^6 transduced cells/m\^2; Dose Level 3: 20×10\^6 transduced cells/m\^2; Dose Level 4: 5x10\^7 transduced cells/m\^2; Dose Level 5: 10x10\^7 transduced cells/m\^2; Dose Level 6: 20x10\^7 transduced cells/m\^2
41133536|NCT03676504|DRUG|Fludarabine|3 days of fludarabine 30 mg/m\^2/day
41133537|NCT03676504|DRUG|Cyclophosphamide|3 days of cyclophosphamide 500 mg/m\^2/day
40949130|NCT05823532|DRUG|Infliximab|"Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specific symptom domains.~Double-blinded infusions of infliximab will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist."
40949131|NCT05823532|DRUG|Placebo|Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
40949132|NCT04401826|PROCEDURE|Tunneling micro-surgical crown lengthening approach using piezo-surgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery via tunneling
41287850|NCT04361110|RADIATION|Computerized tomography scan of the abdomen|Non-specific abdominal ct´s with different phases and contrast +/-.
40759323|NCT00215657|DRUG|Degarelix|Degarelix 320 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
40759324|NCT05064618|DRUG|Am80|medicine taken internally
41453891|NCT00874276|DRUG|Dichloroacetate (DCA)|Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
40759325|NCT05064618|DRUG|Gemcitabine|Administered intravenously at a dose of 1000mg/m2
40759326|NCT05064618|DRUG|nab-Paclitaxel|Administered intravenously at a dose of 125mg/m2
40759327|NCT02608086|BEHAVIORAL|Psychoeducation|"Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma."
40949133|NCT04401826|PROCEDURE|Micro-surgical crown lengthening approach using Piezosurgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery with conventional flap elevation.
41133538|NCT00147667|DRUG|Erythromycin|
40759328|NCT02608086|BEHAVIORAL|Psychological First Aid|"Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?."
41453892|NCT00874276|GENETIC|Genetic Marker on Chromosome 14q24.3|Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
41453893|NCT00556673|DRUG|indacaterol maleate/mometasone furoate|Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
40759329|NCT06094738|DRUG|Relacorilant under fasted conditions|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions
40759330|NCT06094738|DRUG|Relacorilant after a high-fat meal|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal
40759331|NCT06094738|DRUG|Relacorilant after a low-fat meal|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal
41453894|NCT00556673|DRUG|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
41453895|NCT00556673|DRUG|fluticasone proprionate / salmeterol xinafoate|Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
40759332|NCT04031950|DEVICE|Novel wearable paediatric device|The patient will wear the novel wearable paediatric device at the same time as polysmnography
40759333|NCT00004083|DRUG|cisplatin liposomal|
40759334|NCT04365881|OTHER|Cross-sectional observational study|Survey
40759335|NCT06499909|OTHER|Hypnosis|The patient will receive a course of hypnosis
40759336|NCT06124313|DIETARY_SUPPLEMENT|Vaginal Probiotic|"This product contains:~Probiotic Blend - 5 Strains Lactobacillus acidophilus Lactobacillus rhamnosus Lactobacillus gasseri Lactobacillus acidophilus (NCFM) Lactobacillus casei"
40759337|NCT03207087|DEVICE|WEB Aneurysm Embolization|Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.
40759338|NCT04913116|DIAGNOSTIC_TEST|Comparison of antigen tests with RT-PCR as reference method|Antigen tests are performed locally including sampling from multiple anatomical testing sites. A reference oropharyngeal swab is always send for RT-PCR for SARS-CoV-2 at DTU to verify the status of the patient. RT-PCR samples from other anatomical test locations may be included.
40759339|NCT02262325|RADIATION|hypofractionated radiation therapy|Radiation boost in week 1 (days 1-5)
40759340|NCT02262325|DRUG|cisplatin|Given IV
40759341|NCT02262325|DRUG|etoposide|Given IV
40759342|NCT02262325|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
40759343|NCT02262325|OTHER|laboratory biomarker analysis|Correlative studies
40759346|NCT04801901|PROCEDURE|dTRA|Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)
40759347|NCT04801901|PROCEDURE|fTRA|Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.
40759348|NCT03288259|PROCEDURE|transnasal endoscopy|Transnasal endoscopy without sedation with ultra-thin endoscopes in patients who are candidates for bariatric surgery
40759349|NCT03288259|DRUG|Local Anesthetics,Topical|Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
40759350|NCT01635530|DRUG|Doxycycline|Doxycycline: 100mg tablet two times per day, four weeks
40759351|NCT01635530|DRUG|Ceftriaxone|2 g intravenous once a day, three weeks
40759352|NCT01509404|DRUG|Valganciclovir|Valcyte per package insert guidelines for 200 days post transplant
40759353|NCT01509404|BIOLOGICAL|CMV hyperimmune globulin|100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
40759354|NCT01509404|DRUG|Valganciclovir|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
40786415|NCT05845112|DIAGNOSTIC_TEST|Portable Chest X Ray Image Acquisition|Qure.ai (Qure.ai, New York, USA) is a computer aided detection (CAD) software for the automated screening of tuberculosis. Qure.ai is a mobile based interpretation software that screens chest X-Ray to detect TB in less than a minute. Qure.ai can distinguish abnormal scans from normal and detect abnormalities in the lungs, pleura, mediastinum, bones, diaphragm, and heart.
41453896|NCT03106545|DRUG|Liposome bupivacaine|
40949134|NCT02583282|OTHER|Doxycycline|500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
40949135|NCT02583282|OTHER|Iodopovidine|20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
40949136|NCT00194909|DRUG|sildenafil (Viagra)|
40949137|NCT05782712|BIOLOGICAL|adenosine dosage|Whole blood is collected using finger puncture followed by deposit a drop of blood (20 μL) using finnpipette, on a blotting paper (Whatman 903 protein saver cards™) and dried over night at room temperature to obtain dried blood spot (DBS).
40949138|NCT04736082|OTHER|Intervention Group: Infant Formula with hydrolyzed protein|Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (intervention formula manufactured from extensively hydrolysed whey protein).
40949139|NCT04736082|OTHER|Control Group: Infant Formula with intact protein|Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (control formula manufactured from intact cow's milk protein).
40949140|NCT06150625|OTHER|Orthopedic Manaual Therapy|Can include either spinal mobilizations or spinal manipulation therapy targeting the stiff or symptomatic level of the lumbar spine. Various types of mobilization or manipulation may be used based on the therapists clinical reasoning. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data. Common mobilizations techniques involve gently and repeatedly applying pressure over different parts of the patient's spine that is associated with their symptoms. For a manipulation, the patient will be positioned in side-lying position. The therapist will then position the patient further to target the symptomatic level. The patient is asked to take a deep breathe in and out. The therapist will slowly add pressure through the trunk and apply a fast but small thrust motion toward the table.
40949141|NCT06150625|OTHER|Dry Needling|dry needling both sides of the symptomatic level(s) of the lumbar spine as well as needling other areas in the lower extremity and pelvis based on the results of their clinical evaluation and/or the subjects presenting symptoms. Dry needling involves the insertion of a monofilament needle (nothing is injected) into symptomatic soft tissue. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data.
41287851|NCT06431386|BEHAVIORAL|Behavioural Activation (BA) Therapy|Participants will receive weekly one-hour BA sessions on a day they are not receiving esketamine, delivered virtually or in person as per participant preference. The aim is for participants to learn to observe the relationship between what they did, felt, and thought and what was happening around them, and to identify conditions which maintained, increased, or weakened maladaptive behaviours. Functional behaviour analysis will be used in problem and behaviour evaluation and in planning and reviewing changes introduced by participants between sessions. Other techniques include self-observation and self-report, elaboration of activity hierarchies, behaviour programming, rehearsal and behavioural modelling, and contingency management. Between-session homework will develop relevant and rewarding routines to offer reinforcement in each participant's environment. Participants will be offered 12 BA sessions in total.
40759355|NCT05299957|DIAGNOSTIC_TEST|PETMRI|PET/MRI data will be acquired on the integrated PET/MRI scanner. After fast-view T1-weighted MR localizer sequence for scout imaging and Dixon VIBE sequence for attenuation correction, a whole-body PET scan will be performed to cover from the head to the proximal thigh, with an acquisition time of 4 min per bed position. Simultaneously, whole body MR image acquisition will be performed with the axial HASTE sequence and coronal STIR sequence as well as the sagittal T1-weighted Turbo spine echo and STIR sequence. Afterwards, regional PET and MRI images will be simultaneously performed. DWI will be performed using a single shot spin-echo echo-planar technique. A total of 10 b values will be used for the reconstruction of IVIM and kurtosis imaging. DCE-PWI will be acquired by using a 3D T1-weighted spoiled gradient-echo sequence. Thereafter, dedicated regional MRI will be obtained. Finally, whole body axial VIBE with fat saturation will be performed.
40759356|NCT01919476|OTHER|Bagel|
40759357|NCT01919476|OTHER|Cream Cheese|
40949142|NCT06150625|OTHER|Home exercise program|5 exercises will be selected from 10 options intended to reinforce the improvements made from treatment.
40949143|NCT06150625|OTHER|Patient education|Patient education on the low back condition, advice to stay active, and home exercise performance.
40949144|NCT04597229|DIETARY_SUPPLEMENT|Instant multigrain supplement|A twice daily instant multigrain supplementation for 12 weeks
40949145|NCT02416219|PROCEDURE|Cricoid pressure|participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
40949146|NCT02416219|DEVICE|Ultrasound|
40949147|NCT02019277|DRUG|Docetaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
40949148|NCT02019277|DRUG|Nab-paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
40949149|NCT02019277|DRUG|Paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
40949150|NCT02019277|DRUG|Pertuzumab|Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
40759358|NCT01919476|OTHER|Almond Butter|
40949151|NCT02019277|DRUG|Trastuzumab|Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
40949152|NCT05085574|DRUG|Famotidine|80 mg tablet, QID for 14 days
40759359|NCT00002985|DRUG|daunorubicin hydrochloride|
40759360|NCT00002985|DRUG|pegylated liposomal doxorubicin hydrochloride|
40759361|NCT04667962|OTHER|Online questionnaire|Participants will have to complete 3 online self-questionnaires: the first one at enrollment, the second one 1 month after enrollment (M1) and the third one 3 months after enrollment (M3). Each questionnaire will take an estimated 20 minutes to complete.
40759362|NCT01418105|PROCEDURE|Videofluroscopic swallow study (VFSS)|Barium, radiation
40759363|NCT01418105|PROCEDURE|cervical spine isometric exercises|patients with cervical scoliosis will execute isometric exercises of the cervical spine
40759364|NCT01418105|PROCEDURE|Fiberoptic endoscopic esophageal study (FEES)|food for swallowing
40759365|NCT02003898|DEVICE|Medtronic MiniMed 530G Insulin Pump|
40759366|NCT02811614|PROCEDURE|Endoscopic Evacuation|Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.
40759367|NCT02811614|PROCEDURE|Stereotactic Aspiration|Using image guidance to aspirate hematoma.
40759368|NCT02811614|PROCEDURE|Craniotomy|Craniotomy with a big bone flap to evacuate intracerebral hematoma.
40759369|NCT05424705|DIAGNOSTIC_TEST|OCT, NIRS|
40759370|NCT02144246|OTHER|Non-hormonal period|
40759371|NCT02144246|DRUG|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
40949153|NCT05085574|DRUG|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
40949154|NCT05085574|DRUG|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
40949155|NCT03308786|DRUG|Recombinant Interleukin-2|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles
40949156|NCT05406648|OTHER|Morus nigra concentrate|The experimental group was given 20 grams of black mulberry (morus nigra) concentrate per day for 12 weeks.
40949157|NCT02682771|DEVICE|Bilevel positive airway pressure|The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume
40949158|NCT02682771|DEVICE|PowerBreathe|Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.
40949159|NCT02682771|PROCEDURE|Conventional Respiratory Physiotherapy (CRP)|CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
40949160|NCT01736462|DRUG|Mapracorat|One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
41287852|NCT06431386|DRUG|Esketamine|Participants will receive intranasal esketamine twice weekly during the induction phase (first 4 weeks of treatment). Maintenance treatments are administered once per week or once every two weeks at the discretion of the treating physician for 8 additional weeks, totaling 12 weeks of esketamine treatment. Dosing for esketamine usually starts at 56mg on Day 1, followed by 56 or 84mg doses for subsequent treatments.
41287853|NCT02506777|DRUG|metformin|
40759372|NCT06286072|OTHER|Education and message|COPD general education content and fatigue-specific coping strategies. Messages sent to phones
40759373|NCT01171079|DEVICE|application of oxidized regenerated cellulose|
40759374|NCT01110512|DRUG|Flavonid|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day."
40759375|NCT01110512|DRUG|Daflon|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day"
40759376|NCT02691494|DRUG|Elagolix|Film-coated tablets
40759377|NCT02691494|DRUG|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
40759378|NCT02691494|DRUG|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
40759379|NCT02691494|DRUG|Placebo for Elagolix|Film-coated placebo tablets
40759380|NCT04310657|DIAGNOSTIC_TEST|mNGS|Metagenomics second generation sequencing technology
40759381|NCT05490472|DRUG|JAB-2485 (Aurora A inhibitor)|Administered orally
40759382|NCT05490472|DRUG|JAB-2485 (Aurora A inhibitor)|Administered orally
40759383|NCT04507269|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
41287854|NCT02506777|DRUG|Fluoruracil|
41453897|NCT06419920|OTHER|Flat terrain locomotor training|The training will be comprised of up to 12 sets of 2-min continuous walking on a level treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
40759384|NCT04507269|DRUG|Placebo|Saline given by subcutaneous injection
40759385|NCT05856942|OTHER|Health service - home-based PrEP monitoring|Home-based PrEP care
40759386|NCT06349837|DRUG|Tislelizumab|Patients will receive treatment with Tislelizumab (200 mg, iv, d1), every 3 weeks for a maximum of 48 months.
40759387|NCT06349837|RADIATION|Low Dose Radiotherapy|LDRT (d1-d3): 6Gy/3f with conventional external beam radiation.
40759388|NCT06349837|RADIATION|Stereotactic Ablative Radiotherapy|Partial SBRT at dose escalation levels: 24Gy/3f, 30Gy/3f, 45Gy/3f.
40759389|NCT03829683|DRUG|Vitamin C|200mg/kg/24hours
40759390|NCT03829683|DRUG|Dextrose 5% in water|50mL intravenously every 6 hours
40759391|NCT01569763|DEVICE|Aurora Endometrial Ablation|Endometrial Ablation using the Aurora Endometrial Ablation system
40759392|NCT01569763|DEVICE|Rollerball Ablation/Resection|Hysteroscopic rollerball resection/ablation
40759393|NCT04859231|OTHER|Control|Cow's milk-based formula
40759394|NCT04859231|OTHER|Investigational|Cow's milk-based formula with added source of enriched whey protein
40759395|NCT03376282|OTHER|Hyperbaric Oxygen oxygen therapy (HBOT)|60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
40759396|NCT04539405|DEVICE|To evaluate sevoflurane consumption when using Memsorb|Sevoflurane administration at 0.2L.min-1 (minimal gas flow)
40759397|NCT04539405|DEVICE|To evaluate sevoflurane consumption when using classical Dräegersorb|Sevoflurane administration at 2L.min-1 (classical gas flow)
40786416|NCT04582006|PROCEDURE|Bariatric surgery|Surgical treatment of morbid obesity.
40786417|NCT02255929|RADIATION|Gamma Knife Radiosurgery|
40786418|NCT04658927|DRUG|Dexamethasone, 0.4mg|iLUX + dextenza
40786419|NCT04658927|DRUG|Prednisone acetate|Prednisolone acetate 1% and iLux
40786420|NCT04658927|OTHER|Control|iLUX alone.
40949161|NCT02400229|PROCEDURE|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
41287855|NCT02506777|DRUG|Doxorubicin|
41287856|NCT02506777|DRUG|Cyclophosphamide|
41287857|NCT02506777|DRUG|melatonin|
40949162|NCT02400229|PROCEDURE|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
41287858|NCT04635644|PROCEDURE|Erector Spinae Plane Block|Patients will be turned into the prone position. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T8 spinous process. The erector spinae muscles will be identified superficial to the tip of the T8 transverse process. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine, a 21G 10 cm needle will be inserted using an in-plane approach in a cranial to caudal direction to contact the T8 transverse process. The location of the needle tip will be confirmed by hydrodissection with 2 mL of lidocaine 2% and visualizing linear fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of 0.25% Bupivacaine is injected will be injected at this point. The same procedure will be repeated for the opposite side.
41287859|NCT04635644|PROCEDURE|Intrathecal morphine|Patients will be placed on their right side. An intrathecal injection of morphine 200 μg (0.2 mL of morphine sulfate 1 mg/mL) diluted in 1.8 mL normal saline will be administered at the L3-L4 or L4-L5 level with a 25 G Whitacre spinal needle.
41287860|NCT03402763|BEHAVIORAL|Educational Video|The intervention is an educational video presented to patients in the ED with the intent to promote ACP among older adults.
40949163|NCT05933824|DRUG|LP-98 injection|Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
41453898|NCT06419920|OTHER|Uneven terrain locomotor training|The training will be comprised of up to 12 sets of 2-min continuous walking on an uneven terrain treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
40949164|NCT01924988|DEVICE|Prostatic Embolization with Embosphere Micropsheres|"Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudendal or obturator branches as well.~The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries."
40949165|NCT02759874|DEVICE|specialized breathalyzer w face recognition technology|
41453899|NCT05710458|DEVICE|25 gauge 20,000 cpm Hypervit Dual Blade|Vitrectomy blade with increased cutting rate to 20,000 cut/min
40949166|NCT00424450|PROCEDURE|lower limb artery bypass surgery|bypass of severe atherosclerotic vascular lesion
40949167|NCT00424450|PROCEDURE|percutaneous angioplasty (PTA)|PTA of severe atherosclerotic lesion
40949168|NCT04274387|BEHAVIORAL|Mindfulness-based Stress Reduction(MBSR)|A structural program focusing on the practice about attending to the current moment with non-judgmental attitude
40949169|NCT01457820|DRUG|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
40949170|NCT01457820|DRUG|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
40949171|NCT01457820|DRUG|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
40949172|NCT04188470|BEHAVIORAL|person-centered care model|A multidisciplinary team (clinical pharmaceutical, expert physician on chronic management disease, and basic healthcare team) will review the frailty, complexity, the therapeutic goals of the patients to propose changes on the therapeutic plan to improve the appropriateness, these changes will we agreed with the patient or caregiver.
40949173|NCT03997604|DEVICE|Full Dentures created by additive manufacturing|Full dentures created by Additive manufacturing (Carbon Printers)
40949174|NCT00635375|DEVICE|LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)|35-50 mW/cm2/nm
40949175|NCT00635375|DEVICE|Metal halide phototherapy (Spot PT metal halide phototherapy)|29.3-57.6 mW/cm2/nm
40949176|NCT00635375|DEVICE|LED bank phototherapy (Natus neoBlue LED bank phototherapy)|12-35 mW/cm2/nm
40949177|NCT00635375|DEVICE|Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)|29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm
40949178|NCT03594526|BEHAVIORAL|Maternal support to become mother|"AMACOM-PRI: Apoyo Materno para Convertirse en Madre - Primerizas. Maternal support to become first-time mothers is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of.~1. Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~2. Four Educational sessions and support sessions for maternal empowerment in each home visit.~3. Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
40949179|NCT03594526|BEHAVIORAL|Control Group: usual care|"This intervention is usual care, which consists of:~1. care of the mother and her newborn during the puerperium~2. Teaching about breastfeeding."
40949180|NCT03007407|DRUG|durvalumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive durvalumab (1500 mg IV infusion) on Day 1 for 4 cycles (in combination with tremelimumab). Beginning with Cycle 5 through Cycle 12, patients will receive durvalumab alone (1500 mg/IV infusion) on Day 1 of each 28 day cycle.
40949181|NCT03007407|DRUG|Tremelimumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive tremelimumab (75 mg IV infusion) on Day 1 for 4 cycles (in combination with durvalumab).
40949182|NCT05583565|OTHER|sensory integration approach|Sensory integration refers to how the nervous system receives messages from multimodal sensory information systems to maintain balance, posture, and balance by monitoring head movement and stabilizing the eyes about the environment
40949183|NCT05583565|OTHER|traditional physical therapy program|"conventional physiotherapy training programs such as the following: 1)Hand function training by locating the Grading of the hand and training this level until it is well developed to transfer to the next level according to 8 parameters (partner's height-shape-weight-texture -reaction time-speed-accuracy-number of trials).~2) equilibrium training by promoting posture reaction. 3)ADL activity training (nutrition training-dressing training-toilet training). 4) Functional skill training through walking (walking on sand, weight on legs, and Climbing stairs )."
40949184|NCT01172262|PROCEDURE|MRI|This is an observational study, no intervention will occur.
40759398|NCT04564014|BEHAVIORAL|ISSS|The ISSS aims to help participants acquire problem-solving (e.g., interpersonal problems) and time management based on the treatment manual of the therapy. Video introductions for each session and example teacher characters who depict the targeted problems and demonstrate implementation of coping/management techniques in a variety of situations. ISSS will use metaphors, daily examples, and lively narrative stories to enhance motivation for participation and understanding of the intervention contents. Session 2-5 will assign exercise and homework. Within 48 hours, participants will receive personalized written feedback (e.g., suggestions) from an e-Coach on the exercises they have completed. Participants can contact e-Coaches via the online system if they have any questions regarding the contents. Questions that beyond the contents will be referred to the health psychologist (PI) by e-Coaches.
40949185|NCT04607980|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
40759399|NCT04564014|OTHER|Education Materials|Participants will recieve education materials addressing the following issues: (1) introduction to mental health and mental illness; (2) signs and symptoms of depression; (3) treatment of depression and available community resources; (4) signs and symptoms of anxiety; (3) treatment of anxiety and available community resources. The education materials will be carefully developed by the health psychologists and clinical psychologist of the research team who are very experienced in education intervention for mental and emotional health.
40759400|NCT02363283|DRUG|Glembatumumab Vedotin|Given IV
40759401|NCT02363283|OTHER|Laboratory Biomarker Analysis|Correlative studies
40949186|NCT04607980|DRUG|Ustekinumab|Participants will receive SC injection of ustekinumab.
40949187|NCT04365920|COMBINATION_PRODUCT|Recovery Management Checkups (RMC)|"The RMC model was designed to improve treatment linkage, engagement, and long-term treatment retention. The conceptual framework was based on the public health theory of chronic disease management, which utilizes ongoing assessment and monitoring through regular face-to-face checkups and early (re)intervention to facilitate detection of relapse, reduce the time to treatment re-entry, and consequently, improve long-term outcomes. The original RMC model includes: 1) a fixed schedule of face-to-face quarterly checkups to assess need for SUD treatment, 2) personalized feedback based on an assessment and motivational interviewing to increase treatment motivation, 3) problem solving around barriers to treatment access and retention, and 4) assistance with scheduling and linkage to treatment. Individuals were deemed to be in need of treatment if they reported weekly, or more frequent, substance use since the last checkup, any past-month SUD symptoms, or self-perceived need for treatment."
41453900|NCT05710458|DEVICE|25 gauge 10,000 cpm Ultravit Vitrectomy Cutter|Existing Vitrectomy blade with cutting rate 10,000 cut/min
40759402|NCT02363283|OTHER|Pharmacological Study|Correlative studies
40949188|NCT04365920|COMBINATION_PRODUCT|RMC-Adaptive|"Participants in the RMC-Adaptive group will receive face-to-face monthly checkups during the first 2 months post-release with additional face-to-face checkups dependent upon the participant's progress. Based on the data presented in the prior section, as long as participants need treatment, they will receive monthly checkups.~In addition, for every checkup that a participant does NOT need treatment, the number of months before the next checkup will be increased by 1 month (e.g., after 2 checkups without need, they will receive the next checkup 2 months later, after 3 it will be 3 months, after 4 it will be 4 months, and so on). Based on these decision rules, individuals who have NO treatment need over 24 months will still receive 5 checkups."
40949189|NCT03095833|OTHER|Odors|"Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.~In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed."
41287861|NCT03402763|BEHAVIORAL|Primary Care Provider Email|For intervention patients, an email will be sent to primary care providers explaining that the patient has seen a video about advance care planning, providing a synopsis of the video, and giving instructions about how to document end-of-life care preferences in the electronic health record.
41287862|NCT05976737|DRUG|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
41287863|NCT05976737|DRUG|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
41287864|NCT01498991|DEVICE|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
41287865|NCT03021525|PROCEDURE|Individualized Goal Directed Therapy|The trial intervention period will commence from the induction of anesthesia until 8 hours after surgery, or until discharging from the postoperative intensive or intermediate care unit. All patients in the intervention group receive basic vital sign monitoring. For inotropic support dobutamine, and as vasopressor norepinephrine are drugs of choice. Hemodynamic management is performed according to standard treatment until an arterial line is placed. The signal of the arterial line is then processed either by calibrated or non-calibrated pulse contour analysis for pulse pressure variation (PPV) and cardiac index (CI) measurement. Fluid challenge will be performed by infusion of 500 ml in \<15 minute. Choice of fluid in case of indicated fluid loading is determined on basis of the recent guideline for intravasal volume therapy. Patients receive fluids and vasoactive agents following a protocol of individualized parameters regularly achieved by extended hemodynamic monitoring.
41453901|NCT04244760|BEHAVIORAL|Pain assessment for verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical and thermal), and psychological state via the completion of questionnaires by the patient.
40759403|NCT03636230|DEVICE|Remote Monitoring|Remote Monitoring only
41287866|NCT03021525|PROCEDURE|Control Group|Patients in the control group will be treated according to established basic treatment goals (heart rate \<100 bpm, mean arterial pressure \>65 mmHg, SpO2\>94%, and core temperature \>36° C). Basic anesthesiological monitoring by five-lead-electrocardiogram, pulse oximetry, non-invasive blood pressure monitoring and capnography is performed in every patient of the control group. Placement of an arterial and central venous line, as well as fluid and catecholamines administration, are at the discretion of the treating clinician.
41287867|NCT02348047|DEVICE|Hamilton T1|
41453902|NCT04244760|BEHAVIORAL|Pain assessment for non-verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical), and psychological state via the completion of questionnaires by the parent of the patient.
41453903|NCT05674188|BEHAVIORAL|Augmented Reality Headset|Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors
41453904|NCT01336088|DRUG|ADX48621|oral administration
41453905|NCT01336088|DRUG|Placebo|oral administration
41453906|NCT00795158|DRUG|desloratadine|desloratadine 5 mg tablets; one tablet orally once a day for 28 days
41453907|NCT03835780|OTHER|No intervention|A observation of outcomes in usual practice
41453908|NCT06348277|BEHAVIORAL|Mindfulness plus mood monitoring|mobile app that provides guided mindfulness exercises in addition to prompting for mood monitoring three times per day
41453909|NCT06348277|BEHAVIORAL|Mood monitoring|mobile app that prompts for mood monitoring three times per day
40759404|NCT03636230|OTHER|Standard of care|In-Clinic visits only
40759405|NCT00938080|BIOLOGICAL|AG013|Mouth rinse once a day for 14 days
40759406|NCT00938080|BIOLOGICAL|AG013|Mouth rinse three times a day for 14 days
40759407|NCT00938080|BIOLOGICAL|AG013|Mouth rinse six times a day for 14 days
40759408|NCT00938080|OTHER|Placebo|Mouth rinse once a day for 14 days
40759409|NCT00938080|OTHER|Placebo|Mouth rinse three times a day for 14 days
40759410|NCT00938080|OTHER|Placebo|Mouth rinse six times a day for 14 days
40759411|NCT04026958|DRUG|Clarithromycin|Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
40759412|NCT04026958|DRUG|Placebo|A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
40759413|NCT02236897|OTHER|PET Scanning|
40759414|NCT00003158|DRUG|carboplatin|
40759415|NCT00003158|DRUG|etoposide|
40759416|NCT00003158|DRUG|paclitaxel|
40759417|NCT00003158|RADIATION|radiation therapy|
40759418|NCT03062436|OTHER|Stopping the standard drug therpy|Stopping the standard drug therapy of CML patients and monitoring their treatment free remission status
40759419|NCT03062436|DIAGNOSTIC_TEST|Quantitative bcrabl recording every month for first 6 months|Monthly recording of quantitative bcrabl by RQPCR on patients peripheral blood derived RNA. RQPCR will have minimum sensitivity of log4.5
40949190|NCT03095833|OTHER|Visual stimulation|Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
40949191|NCT03095833|OTHER|Experimental Task|"The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds."
40949192|NCT03095833|OTHER|Blood tests|Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
40949193|NCT03095833|OTHER|Questionnaires and test administered|The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
40949194|NCT03095833|OTHER|fMRI|The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
40759420|NCT06569615|OTHER|shock wave therapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Radial shockwave therapy, (Storz Medical Shock Master MP200 device) for 10 minutes/session, one session/week, for 8 weeks."
40759421|NCT06569615|OTHER|LASER Therapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given LASER, (LEVELASER EZ1 EASYONE) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks."
40949195|NCT03095833|OTHER|Odors 2|To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
41287868|NCT04628871|BIOLOGICAL|SB-318|No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.
41287869|NCT04628871|BIOLOGICAL|SB-913|No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
41287870|NCT04628871|BIOLOGICAL|SB-FIX|No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.
41287871|NCT01009112|BEHAVIORAL|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
41287872|NCT01009112|BEHAVIORAL|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
41287873|NCT02340104|DRUG|Baricitinib|4 milligrams (mg) administered orally
41287874|NCT02340104|DRUG|[^13C4D3^15N]-baricitinib|4 micrograms (μg) administered intravenously (IV)
41287875|NCT03668548|DIETARY_SUPPLEMENT|Leucine|192 mg/kg body mass/day
41287876|NCT03668548|DIETARY_SUPPLEMENT|Placebo|A taste and calorie-matched placebo
41287877|NCT03977389|PROCEDURE|Total wrist denervation|Study of the files
41287878|NCT06511011|DRUG|Modified Suan ZaoRen Tang-TianWang BuXin Dan|Chinese medicine granules for 6 weeks
41287879|NCT06511011|DRUG|Placebo|Placebo granules for 6 weeks
41287880|NCT01050777|DRUG|Liposomal meglumine antimoniate (Glucantime)|Liposomes containing meglumine antimoniate
41287881|NCT01050777|DRUG|Liposomal meglumine antimoniate|Liposomal form of meglumine antimoniate
41287882|NCT01050777|DRUG|Liposomal Paromomycin|Liposomal form of 10% Paromomycin
41287883|NCT01050777|DRUG|Placebo|Placebo
41287884|NCT04230577|DEVICE|Real LED Intervention|A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).
41287885|NCT04230577|DEVICE|Sham LED Intervention|A series of Sham at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, Vielight Neuro Alpha Head Frame Device (with intranasal) with Sham LEDs that emit no photons. Sham and Real Devices look and feel identical.
41287886|NCT03515798|DRUG|Pembrolizumab Injection|Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks
41287887|NCT03515798|DRUG|neoadjuvant EC-paclitaxel chemotherapy|The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
40949196|NCT03095833|OTHER|Images|The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
40949197|NCT03095833|OTHER|Experimental Task fMRI|For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
40949198|NCT03095833|OTHER|Genotyping for susceptibility to β-ionone|Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
40949199|NCT03095833|OTHER|Experimental Task 2|The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
41133539|NCT01170845|DRUG|sivelestat sodium hydrate|saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
41287888|NCT05717322|BEHAVIORAL|TENS|apply TENS after orthognathic surgery
41287889|NCT05717322|BEHAVIORAL|sham TENS|apply non active TENS after orthognathic surgery
41287890|NCT05861947|DRUG|AUR106|Once or twice daily
41453910|NCT03680001|BEHAVIORAL|Training in Rating Emotional Connection|Didactic education (video-supported educational module) on emotional connectivity will be offered to the subjects. Subjects will conference with PI to review ratings on modules.
41453911|NCT01547728|DRUG|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
41453912|NCT04837456|DIETARY_SUPPLEMENT|Calorie restricted diet and exercise intervention|the calorie restricted diet were prescribed a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement.Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%\[36\]. Participants were guided by a dietitian for adjustments of their caloric intake weekly for six months.Participants performed 1 or 2 sets at a resistance of approximately 65% of their one-repetition maximum, with 8 to 12 repetitions of each exercise; they gradually increased the intensity to 2 to 3 sets at a resistance of approximately 80% of their one-repetition maximum, with 6 to 8 repetitions of each exercise.
40759422|NCT06569615|OTHER|Cryotherapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Cryotherapy, (Gymna UniphyCryoflow 1000 IR Shock Master ICE-CT device) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks."
40759423|NCT06569615|OTHER|Exercises|The assigned exercises for all participants will include 1. Bilateral bridging, 2. Knee to chest, 3. Back extension within a pain-free range, 4. Plank, 5. Baby pose stretch, 6. Cat and camel, 7. Bilateral adductor ball squeezes and 8. Stretching exercise (Gluteal /Piriformis stretch, Quads /Hams stretch. The treatment plan involved performing three sets of exercises, with each set comprising 8 to 10 repetitions. 20-30 minutes of exercise session will be conducted three times per week over a span of 8 weeks.
40759424|NCT00191698|DRUG|atomoxetine hydrochloride|
40759425|NCT00191698|DRUG|placebo|
40759426|NCT00002431|DRUG|Chlorhexidine gluconate|
40759427|NCT04582487|OTHER|bone marrow and/or peripheral blood samples withdrawal|bone marrow and/or peripheral blood samples evaluation
41133540|NCT00144235|DRUG|Pharmaton PHL 00749|
41133541|NCT00144235|DRUG|Placebo|
41133542|NCT04895670|BEHAVIORAL|Empowering Youth Aging out of Foster Care|App that allows storage of health information, and access to reputable health information and community resources.
41133543|NCT05519852|BEHAVIORAL|Pilates training|the pilates group (20 patients) will be trained 30 minutes of pilates exercise (before it there will be warm up period and after it there will be cooldown period , each will be 5 minutes). the pilates will be repeated five sessions per the week for 3 months
41287891|NCT02864875|DRUG|Fibrinogen concentrate|Receive fibrinogen concentrate 50mg/kg of body weight after randomization
41287892|NCT03630068|PROCEDURE|Stereotactic percutaneous image-guided microwave ablation|Stereotactic percutaneous image-guided microwave ablation implies the use of computer-assisted navigation technology for 3D trajectory planning and stereotactic placement of ablation probes, before applying local microwave ablation therapy
41287893|NCT01607723|OTHER|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
41287894|NCT01607723|OTHER|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
41287895|NCT03707093|DRUG|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg,10 mg/kg or 300mg flat dose depending on cohort at enrollment.
41287896|NCT04373122|DEVICE|REBOA|Resuscitative Endovascular Balloon Occlusion of the Aorta
41287897|NCT01508676|DRUG|Pennsaid|
41287898|NCT01508676|DRUG|Placebo (2.3% DMSO solution)|
41287899|NCT05750667|BEHAVIORAL|Cascade screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
41287900|NCT03914352|DRUG|PD-1 antibody|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
41287901|NCT03914352|PROCEDURE|TACE|In this group enrolled patients were treated with TACE at the30 days after hepatic resection.
41287902|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 25 mg, Once daily, 3 days
41287903|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 100 mg, Once daily, 3 days
41287904|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 400 mg, Once daily, 3 days
41287905|NCT01525212|DRUG|BMS-929075|Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
41287906|NCT01525212|DRUG|Placebo matching BMS-929075|Oral Suspension, 0 mg, Once daily, 3 days
41287907|NCT01525212|DRUG|Placebo matching BMS-929075|Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
41287908|NCT05491642|DRUG|BAY3283142|Oral administration
40949200|NCT00752102|DRUG|Calcitriol (Rocaltrol®)|Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.
40949201|NCT00752102|DRUG|Paricalcitol|Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
41133544|NCT05995730|OTHER|Lavender oil inhalation|Lavender inhalation will be administered to this group. Participants will be asked to drop three drops of lavender oil solution on a small piece of cotton on the 1st, 2nd, and 3rd days of their first menstrual bleeding after enrollment in the study, hold it 7-10 cm from their noses, and sniff for 5 minutes. Participants will be asked to apply this application immediately after the onset of dysmenorrhea pain on the first day of their menstruation and to continue regularly every 8 hours for the first three days of menstrual bleeding. Participants will be asked to apply this application in the same way in two consecutive menstrual cycles and the participants will be followed in this process.
41287909|NCT05491642|DRUG|Placebo to BAY3283142|Oral administration
41287910|NCT06375798|PROCEDURE|radiotherapy|If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area.If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously. Clinical standard treatment plan (chemotherapy, endocrine therapy, etc.) was developed based on postoperative pathological and immunohistochemical reports.
41287911|NCT01142648|DRUG|Sugammadex|Sugammadex 200 mg iv, single dose, bolus.
41287912|NCT01142648|DRUG|Neostigmine and glycopyrrolate|Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
41287913|NCT02718846|DRUG|Meniace|6 mg of Meniace tablets were administered 3 times per day after meals
41287914|NCT02718846|DRUG|Isobide|an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
41287915|NCT01483573|OTHER|neural mobilization|stretch the nerve
41287916|NCT01483573|OTHER|straight leg raise|stretch the hamstring
41287917|NCT01434225|DRUG|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
41287918|NCT05431686|BEHAVIORAL|SMA visits|SMA visit once every 3 months over a 12 month period
41287919|NCT06027983|DRUG|Chimeric receptor T-cells + Trastuzumab|Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.
41287920|NCT06027983|DRUG|Fludarabine and Cyclophosphosphamide|3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion
41287921|NCT00907725|OTHER|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
41287922|NCT00907725|OTHER|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
41287923|NCT00148629|DRUG|multivitamin, mebendazole|
41287924|NCT06082778|BEHAVIORAL|Fermented food intake above habitual level|Participants increase their habitual intake of fermented foods by three portions per day, compared to their habitual intake level at baseline.
41453913|NCT04837456|PROCEDURE|libitum diet and waiting list control group|libitum diet and waiting list control group, participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
41453914|NCT04837456|PROCEDURE|Early arthroscopic partial menisectomy group|Early APM group participants received APM with syndrome within 3 to 6 months
40759428|NCT04872946|DIETARY_SUPPLEMENT|Tea|Ashwagandha(Withania somnifera) root and leaf extract (32% Withania Oligosaccharides, 10% Withanolide Glycosides, 0.5% Withaferin A) 125 mg Saffron(Crocus Sativus) stigmas extract (3.48% Crocin and 0.03% Safranal) 28mg
40759429|NCT04872946|OTHER|Serum|Aqua/Water/Eau, Glycerin, Propanediol, Diheptyl Succinate, Caprylic/Capric Triglyceride, Lactococcus Ferment Lysate, Sorbitol, Dimethicone, Steareth-21, Octyldodecyl Neopentanoate, Sodium Polyacrylate, Steareth-2, Caprylyl Glycol, Hydrogenated Polydecene, Trideceth-6, Octyldodecanol, Panthenol, Sodium PCA, Azelaic Acid, Bisabolol, Capryloyl Glycerin/Sebacic Acid Copolymer, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Caprylhydroxamic Acid, Phytic Acid, Aminomethyl Propanol, Lactic Acid, Sodium Chloride, Phenoxyethanol, Sodium Benzoate.
40759430|NCT04872946|OTHER|Moisturizer|Aqua/Water/Eau, Glycerin, Diisopropyl Dimer Dilinoleate, Coco-Caprylate, Lactococcus Ferment Lysate, Myristyl Myristate, Dimethicone, Propanediol, Behenyl Alcohol, Glyceryl Stearate SE, Potassium Cetyl Phosphate, Palmitic Acid, Ammonium Acryloyldimethyltaurate/Beheneth-25 Methacrylate Crosspolymer, Myristyl Laurate, Caprylyl Glycol, Hydroxyethylcellulose, Myristic Acid, Tocopherol, Ethylhexylglycerin, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Helianthus Annuus (Sunflower) Seed Oil, Trisodium Ethylenediamine Disuccinate, Lactic Acid, Sodium Hydroxide, Sodium Phosphate, Disodium Phosphate, Sodium Chloride, t-Butyl Alcohol, Phenoxyethanol, Sodium Benzoate.
40759431|NCT05746273|DRUG|Transdermal Nicotine Patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
40759432|NCT05746273|DRUG|Transdermal Placebo Patch|Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
40759433|NCT04450212|GENETIC|Phase I, Buccal Swab Collection for DNA Isolation|Buccal swab will be taken from study participants for DNA isolation.
40759434|NCT04450212|DIETARY_SUPPLEMENT|Phase II, Vitamin K (Vitacost) Supplementation|1-mg/day phylloquinone (Vitacost; Natures Life K-1 Phylloquinone) for 10 consecutive days. Each dose will be taken in the morning (\~ 8 am), with one half pint of 2% milk to facilitate absorption. Blood and urine samples collection before and during the vitamin K supplementation period.
40759435|NCT02853214|GENETIC|Genetic analysis of peripheral blood samples|M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
40759436|NCT06019494|PROCEDURE|Oocyte retrieval with low aspiration flow rate|All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.42 ml/sec.
40759437|NCT06019494|PROCEDURE|Oocyte retrieval with high aspiration flow rate|High aspiration flow rate All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.62 ml/sec.
41287925|NCT04984135|PROCEDURE|Percutaneous coronary intervention|All patients were treated with a loading dose of clopidogrel 300 or 600 mg before the procedure followed by maintenance clopidogrel 75 mg daily for 6 months. 100 U/ kg of unfractionated heparin was injected intravenously to maintain an activated clotting time ≥ 250 s during the procedure. For DCB treatment, the patient underwent predilation with an optimal-sized balloon (non-compliant balloon or cutting balloon) based on angiography (balloon-to-vessel ratio of 1.0), with the standard balloon shorter than the intended DCB size. The DCB was sized at 1:1 balloon-to-vessel ratio, delivered rapidly (median of 15 s) and inflated at nominal pressure for 60 s.
41287926|NCT05065021|DRUG|Niraparib|Niraparib works by blocking poly(ADP-ribose) polymerases (PARP) 1 and PARP 2 from working. PARP 1 and PARP 2 are proteins that are involved in cell growth, cell survival, and cell death, including cancer cells. It is believed that blocking PARP1 and PARP 2 from working will slow or stop the growth of cancer cells.
41287927|NCT05065021|DRUG|Dostarlimab|Dostarlimab is a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumor growth. Dostarlimab attaches to PD-1 and inhibits the interaction of PD-L1 and PD-L2 with PD-1.
41287928|NCT05065021|DRUG|Bevacizumab|Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.
41287929|NCT05065021|DRUG|Paclitaxel|Paclitaxel is a chemotherapy drug commonly used for the treatment of various cancers.
41287930|NCT06156098|OTHER|No Intervention|No Intervention
41287931|NCT01341912|BIOLOGICAL|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
41287932|NCT05361512|DEVICE|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
41287933|NCT05361512|DEVICE|epidural waveform analysis|A pressurized 500ml normal saline bag will be connected to a pressure transducer kit and the transducer will be connected to a portable monitor with the scale set at 0-40 mmHg or to optimum scale. The transducer will be levelled with the heart approximated at the patient's manubrio-sternal angle, with the patient in the sitting position. Sterile tubing will be connected to the epidural needle and attached to transducer. The tubing connection will be filled with saline to ensure proper reflection of the pressure transducer tracing. Test will be considered positive in case of pulsatile waveform is observed in synchrony with heart rate.
40949202|NCT03924635|COMBINATION_PRODUCT|SYMBICORT and salbutamol|Salbutamol is a short-acting β-agonist and SYMBICORT (fixed dose combination of inhaled corticosteroid plus long-acting β2-agonist) is an anti-inflammatory reliever for asthma. SYMBICORT will be given in a TURBOHALER. Salbutamol will be given in a pressurised metered dose inhaler.
41287934|NCT00583739|BEHAVIORAL|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
41287935|NCT04227977|DEVICE|JuxtaFlow System|The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.
41133545|NCT05995730|OTHER|Placebo|Olive oil will be administered to the placebo group. The application will be similar to the experimental group.
41133546|NCT06194695|PROCEDURE|drug eluting beads-transcatheter arterial chemoembolization|transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
41133547|NCT06194695|DRUG|envatinib plus anti-PD(L)1|oral use of lenvatinib plus intravenous injection of anti-PD(L)1 antibodies. Anti-PD-L1 antibodies includes duravalumab, atezolizumab, or envolizumab, and anti-PD1 antibodies include pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab, or toripalimab.
41287936|NCT03210077|DEVICE|Monitoring|Monitoring
41287937|NCT03424551|DEVICE|vibrator|Local or whole body vibration was applied at six different frequencies
41287938|NCT04180410|DEVICE|EIT|Electrical Impedance Tomography is performed before extubation, during follow-up visits of extubation and 48H after extubation. Follow-up visits are shortened in case of extubation failure.
41287939|NCT05205707|DIAGNOSTIC_TEST|ACE serum levels|Circulating ACE2 level will be measured
41453915|NCT04837456|PROCEDURE|delayed APM group recruit participants with symptoms lasting for more than 6 months|delayed APM group recruit participants with symptoms lasting for more than 6 months
40949203|NCT06462638|OTHER|Neurobehavioral states and physiological parameters evaluation|"Each individual infant included in the study will be assessed 3 times a week for at least two weeks: specifically, two detections of neurobehavioral states in response to interaction with the mother, two detections with the father, and two detections with the nurse(s) will be made.~For each infant involved in the study, an audio/video recording of cradle movements and vocalizations will be made at 3 different consecutive times (5 minutes each): baseline; recording during interaction with either parent or nurse; post-interaction assessment.~The parent or nurse is asked to interact freely with the baby, choosing whether to use voice and touch or only one of the sensory stimulation channels. During the interactions, parents and nurse will in turn be assessed relative to some basic physiological parameters through the use of a band applied to the chest; the infant's physiological parameters during the 3 times will also be recorded."
40949204|NCT06462638|OTHER|Maternal vocal pitch evaluation to assess depressive/anxious state|"Regarding the assessment of any depressive/anxious states of the mother, as an additional support to the self-report questionnaires the maternal vocal pitch will be specifically assessed through the Talking about software (AI algorithm applied to maternal postpartum depression research)."
41287940|NCT05180669|OTHER|OARSCM Software Application|Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
40949205|NCT04834232|DEVICE|compression therapy|compression bandaging or graduated compression hosiery consists of applying a type of elastic device, mainly on the limbs, to exert a controlled pressure on the lower limbs. The controlled pressure exerted by medical compression stockings reduces the diameter of major veins, thereby increasing the velocity and volume of blood flow, along with conditions beneficial for the healing of chronic inflammatory disorders (e.g. cellulitis, erysipelas, venous leg ulcers, etc.), through reduced pro-inflammatory cytokine levels and higher levels of the anti-inflammatory cytokines.
40949206|NCT04834232|PROCEDURE|iliac vein stenting|using x-ray guidance (fluoroscopy) to place a an expandable metal mesh tube against the vein walls, acting as a scaffold to keep the veins open and improve blood flow
40949207|NCT03529331|DRUG|Morphine Sulfate Immediate Release|15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
40949208|NCT03529331|DRUG|Oxycodone/Acetaminophen|5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
40949209|NCT03529331|DRUG|Hydrocodone/Acetaminophen|5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
40949210|NCT04382391|DEVICE|gammaCore® Sapphire (non-invasive vagus nerve stimulator)|"Administer gammaCore® Sapphire daily, prophylactically, for three treatments (morning, mid-day and night, one hour before bed), each treatment consisting of two 2-minute doses/stimulations, one on each side of the neck. This would be a total of 6 treatments (2 doses x 3 times per day) of stimulation.~For acute respiratory distress or shortness of breath (SOB), administer one treatment consisting of two 2-minute stimulations, on the neck. If respiratory distress or shortness of breath persists 20 minutes after the start of the first treatment, administer a second treatment."
40949211|NCT04382391|OTHER|Standard of care therapies|Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms
40949212|NCT04359667|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]|1 - 8 mg per kg of body weight once, maximal 800 mg per dose (can be repeated once more after 12 hours, per clinician's assessment)
40949213|NCT00549874|DRUG|Rosiglitazone|oral 8 mg/once daily for 6 months
40949214|NCT00549874|DRUG|Glyburide|20 mg/ once daily for 6 months
40949215|NCT04189575|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
40949216|NCT00413400|DRUG|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
40949217|NCT00413400|DRUG|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
40949218|NCT04483973|DRUG|Ebselen|Glutathione peroxidase mimetic
40949219|NCT04483973|DRUG|Placebo|Matching placebo containing excipients
40949220|NCT05347277|DIAGNOSTIC_TEST|Kappa Free Light Chain (K-FLC)|A biochemical test measured on CSF sample via nephelometry on Beckman Immage-800 analyzer using kits from Freelite, The Binding Site, according to the manufacturer's instructions.
40949221|NCT04958772|BIOLOGICAL|Filgrastim Megalabs|Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose
40949222|NCT04958772|BIOLOGICAL|Granulokine|Granulokine 5 μg/Kg/day, subcutaneous single dose
41133548|NCT06006962|OTHER|Aging Well through Interactions and Scientific Education - Action Plan|20-week program designed to provide education and individualized planning with a goal of improving brain health.
41133549|NCT05664672|OTHER|OTDN Product 1|Mint on!® 2 mg nicotine pouches
41133550|NCT05664672|OTHER|OTDN Product 2|Mint on!® 4 mg nicotine pouches
41287941|NCT05180669|OTHER|MyMAT Software Application|Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
41287942|NCT00917410|BEHAVIORAL|SMS support|"The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.~1. Remember to take your preventive asthma medication (sent at 8.00 am).~2. Were you awakened during the night due to your asthma? Answer YES or NO.~3. How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.~4. What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study)."
41287943|NCT01868269|DRUG|Dexamethasone acetate|"First step:~immunosuppressive treatment with dexamethasone"
41287944|NCT01868269|DRUG|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
41287945|NCT01868269|DRUG|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
40759438|NCT06522386|DRUG|Pirtobrutinib|Given by mouth
41287946|NCT02197962|DEVICE|Extracorporeal Radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
41287947|NCT02197962|DEVICE|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
40949223|NCT05198583|OTHER|E-Fit|The intervention lasts a total of 8 weeks and is structured in 3 modules. The first module consists of a weekly strategy training in which problems resulting from executive dysfunction are addressed. Online games form the second module. These are games implemented online to promote EF through play. The third module is also based on games: The families receive several board games to play together at home. This third module is voluntary.
40949224|NCT01571310|OTHER|Omitted Breakfast|Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
41287948|NCT06512987|OTHER|technology-driven, interactive ICU diary|Through the diary platform, patients can share their feelings and needs, while family members can send supportive messages, pictures, and videos. Healthcare providers will use the platform to connect with families and monitor patient conditions.
41287949|NCT01731015|DRUG|Medical Grade Oxygen|At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience \~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
41287950|NCT03991637|DEVICE|Non-Invasive Comprehensive Metabolic Panel|The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.
41287951|NCT00350064|BEHAVIORAL|Exercise Training|16 weeks of aerobic exercise training at two different intensities
41287952|NCT04107012|DEVICE|Orthodontic treatment with clear aligner|Included orthodontic treatment with clear aligner (eon Aligners)
41287953|NCT00483951|DEVICE|Toshiba Aquilion ONE CT|The Toshiba Aquilion ONE CT system has the ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy.
41287954|NCT00483951|DEVICE|SWiemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
41287955|NCT05325164|DRUG|Methadone|Methadone
41287956|NCT05325164|DRUG|Morphine|Morphine
41453916|NCT03955276|OTHER|Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)|Biologically targeted matched treatment (chosen by treating physician)
41453917|NCT00901719|DRUG|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
41453918|NCT00901719|DRUG|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
40759439|NCT06522386|DRUG|Rituximab|Given by vein (IV)
40949225|NCT01571310|OTHER|Breakfast|"In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:"
40759440|NCT06522386|DRUG|Venetoclax|Given by mouth
40759441|NCT03016702|OTHER|Cognitive stress tests during functional MRI|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
40949226|NCT01828879|DRUG|Tacrolimus|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
41133551|NCT05664672|OTHER|OTDN Product 3|Mint on!® 8 mg nicotine pouches
41133552|NCT05664672|OTHER|No Tobacco|subjects completely stop all tobacco product usage for 7 days
41287957|NCT03401489|DEVICE|PACESETTER|Patients will be given a Viaca electronic pill tray \& blue-toothed UA-767 Plus BT BP device and the PACESETTER app installed on their smart phone for automatic relay of BP data. The Vaica tray emits a blinking light for 30 minutes when it is time to take the meds. If the compartment is not opened and emptied, an intermittent chime ensues for 30 minutes. If the compartment is not opened and emptied, the subject /caregiver receives an automated SMS. PACESETTERs will be given a questionnaire. Responses will be used to generate personalized motivational \& reinforcement messages guided by self-determination theory constructs of competence \& autonomous regulation. In addition to personalized messages, PACESETTERs will receive text messages 2 times per week on HTN/stroke facts, importance of med adherence, and tips on expressing questions/concerns with a physician. We will calculate medication possession ratios, on all subjects' HTN medications at each evaluation.
41287958|NCT04201912|DIAGNOSTIC_TEST|saliva analysis for Toll like receptor activity|Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
41453919|NCT00901719|DRUG|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
40949227|NCT03610360|DRUG|MesoPher|Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
40949228|NCT06287190|OTHER|Dental interns|Assessing self-assessment
40949229|NCT06059573|PROCEDURE|dental implant robot|Implant placement will be navigated by a dental implant robot based on a digital plan.
40949230|NCT06059573|PROCEDURE|Freehand surgery|Implant will be placed under freehand surgery.
40949231|NCT06205615|DRUG|BXP154B|BXP154B will be self-administered topically following wound induction
40949232|NCT06205615|DRUG|Placebo|Placebo will be self-administered topically following wound induction
40949233|NCT00775073|DRUG|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
40949234|NCT05723601|DRUG|Estradiol vaginal cream|Participants will use vaginal estradiol cream for 3 months
40949235|NCT05723601|DRUG|Estradiol Vaginal Tablet|Participants will use vaginal estradiol tablet for 3 months
40949236|NCT04402060|DRUG|APL-9|Complement (C3) Inhibitor
40949237|NCT04402060|OTHER|Vehicle Control|Normal saline of equal volume to active arm
40949238|NCT05427734|DEVICE|Jaspr2.0|Participants assigned to this condition will receive access to Jaspr2.0 and its companion mobile app, Jaspr-at-Home, for 12 weeks.
40949239|NCT05427734|DEVICE|Active-Control app + electronic wellness resources brochure|Participants assigned to this condition will receive access to Virtual Hope Box, a well-regarded suicide prevention self-help app, for 12 weeks plus an electronic wellness resources brochure.
40949240|NCT06556459|PROCEDURE|Bariatric Surgery|"The patient performs:~* psychological clinical interview~* psychodiagnostic examination~* internal medical examination~* blood tests~* electrocardiogram~* bariatric surgery~* surgical visit"
40949241|NCT03260920|DRUG|Syntocinon|Intranasal Oxytocin
40949242|NCT02298023|BIOLOGICAL|allogenic adipose stem cell injection|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
40949243|NCT02298023|BIOLOGICAL|fibrin glue/normal saline injection|Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise
40949244|NCT02298023|BIOLOGICAL|normal saline injection|Total 1cc of normal saline injection and range of motion exercise
40949245|NCT01180101|BEHAVIORAL|Diet and exercise|This group will follow a hypocaloric diet and supervised exercise training for 12 weeks.
40949246|NCT01180101|PROCEDURE|Bariatric Surgery|Patients will undergo bariatric surgery
40949247|NCT01025154|DRUG|Clofarabine|Induction Cycle: 20 mg/m\^2 IV over approximately 1 hour daily for 5 days (days 1-5)
41287959|NCT06114654|BEHAVIORAL|Physical Therapy|Specific physical tests to assess muscle strength, ankle stability and activation of the lower extremity musculature: Single Leg Stance Test, Hurdle Step test and Single leg vertical jump.
41453920|NCT00901719|DRUG|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
41453921|NCT00163345|DRUG|Ciclesonide|
40949248|NCT01025154|DRUG|Idarubicin|Induction Cycle: 10 mg/m\^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
40949249|NCT01025154|DRUG|Cytarabine|Induction Cycle: 1 g/m\^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
40949250|NCT01498328|DRUG|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
40949251|NCT01498328|DRUG|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
40949252|NCT01498328|DRUG|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
40949253|NCT02617043|RADIATION|hypofractionated whole breast irradiation with simultaneously integrated boost|deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
40949254|NCT03515252|BIOLOGICAL|Immune Killer Cells (IKC)|
41287960|NCT06313203|DRUG|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution. The patients in this arm will also be given GemOX as systemic chemotherapy
41287961|NCT06313203|PROCEDURE|Selective Internal Radiation Therapy (SIRT)|Radioactive Yttrium 90 (Y-90) labeled particles are injected selectively into the feeding arteries of the tumour(s). This allows a high radiation dose in the lesions while limiting systemic side effects.
41287962|NCT04259710|BEHAVIORAL|Goal-setting intervention|The participant will meet weekly with the investigator, report steps and set goals for the following week.
41453922|NCT02772822|DRUG|SCT400 plus CHOP|
41453923|NCT02772822|DRUG|Rituximab plus CHOP|
41287963|NCT04259710|BEHAVIORAL|Goal setting with implementation intentions|In addition to the standard goal-setting intervention, the participant will fill out a form that directs them to perform implementation intentions at weeks 1, 5 and 9.
40759442|NCT03016702|OTHER|Cognitive stress tests during gait task|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
40949255|NCT06556355|OTHER|neoadjuvant chemoradiation and McKeown esophagectomy|"Treatment protocol:~1. All patients were irradiated a total prescribed dose of 40-50.4 Gy in 20-28 fractions by a 6-8 MV photons linear accelerator with the intensity-modulated radiotherapy or volumetric modulated arc therapy technique.~2. Concurrent chemotherapy was cisplatin-based.~3. McKeown esophagectomy (three incision) consisted of thoracic esophageal mobilization with lymphadenectomy, abdominal exploration and stomach mobilization with lymphadenectomy, and subsequently left cervical incision for anastomosis. The lymphadenectomy was total two-field (thoracic + abdomen)."
40949256|NCT03550664|DEVICE|Monitoring of neuromuscular transmission|Monitoring of neuromuscular transmission will be done by TOFScan (IdMed, Marseille, France). This device is CE marked, and is used routinely in daily clinical practice. Prior to induction of anesthesia, the TOFScan is placed on a patient's hand and the two stimulation electrodes (ECG electrodes) are placed at the level of the ulnar nerve at the wrist. After induction of anesthesia and before administration of a curare, the TOFScan is calibrated according to the manufacturer's instructions. The TOFScan is placed in automatic mode, it will then automatically adapt its mode of stimulation to the depth of the curarization. The TOFScan measurements will be recorded on a PC connected to the TOFScan.
40949257|NCT03523234|DRUG|neoadjuvant chemotherapy|etoposide with cisplatin/carboplatin, undergoing in prior to the surgery
40949258|NCT03523234|PROCEDURE|radical surgery for stage II and IIIA small cell lung cancer (SCLC)|Lobectomy/total lung resection plus mediastinal lymph node dissection.
40949259|NCT03523234|PROCEDURE|prophylactic cranial irradiation|prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously
40949260|NCT03523234|DRUG|Chemotherapy|etoposide with cisplatin/carboplatin
40949261|NCT02173938|OTHER|Tobacco Dependence Treatment|face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
40949262|NCT00178750|DEVICE|18G Tuohy epidural needle|
40949263|NCT00178750|DEVICE|CompuFlo® computerized syringe pump|
40949264|NCT05369676|DRUG|SSD8432 dose 1/Ritonavir|Cohort 1:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
40949265|NCT05369676|DRUG|SSD8432 dose 2/Ritonavir|Cohort 2:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
40949266|NCT06359990|BEHAVIORAL|BrotherlyACT|BrotherlyACT is a digital intervention to prevent youth violence and substance use among trauma-exposed young Black males, ages 125-24. This intervention combines life skills coaching, safety planning tools, and an AI-driven chatbot to reduce the risk and effects of violence and early substance use.
40949267|NCT06359990|OTHER|BrotherlyACT Waitlist Control Group (WCG)|During the waiting period, participants in the control group do not receive the BrotherlyACT intervention but may continue with their usual activities or interventions.
41453924|NCT04106063|OTHER|KID SSQ12 questionnaire|During a face to face interview (maximum 15 minutes), the child will complete a short questionnaire (KID SSQ12 questionnaire) to assess his auditory difficulties
41287964|NCT04259710|BEHAVIORAL|Pedometer only|the participant will be given a pedometer and instructed how to use it.
40786421|NCT04872569|BEHAVIORAL|Decision-making tool|"Participants will be directed to use the decision tool for 3 months using it at their own pace.~The tool covers topics relevant to women with disabilities in considering or planning a pregnancy and reflects core elements of decision making tools based on the Ottawa Framework for Decision Support."
40786422|NCT06113003|DIETARY_SUPPLEMENT|Prebiotic|Wheat dextrin fiber
40786423|NCT06113003|DIETARY_SUPPLEMENT|Probiotic|Probiotic packet
40949268|NCT04779918|DEVICE|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
40949269|NCT05929976|OTHER|No intervention|No intervention
40949270|NCT00257465|BIOLOGICAL|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
40949271|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
40949272|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|2.5 million cells
41287965|NCT06076330|BIOLOGICAL|20% Albumin|S. albumin \> 3 g/dl: 20g of 20% iv albumin @10-15 ml/hr S. albumin \< 3 g/dl: 40g of 20% iv albumin @10-15 ml/hr
41287966|NCT06076330|BIOLOGICAL|5% Albumin|5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose In case of failure to attain a sustained MAP \>65 mmHg, Fluid boluses will be administered guided by lung ultrasound and IVC.
41453925|NCT00174980|DRUG|perfluorocarbon emulsion (Oxycyte) infusion|one time dose of 3mL/kg over 15 minutes
40949273|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|0.5 million cells
40949274|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|0 cells
40949275|NCT04562792|DRUG|Daunorubicin|Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
40949276|NCT01044251|DRUG|Frovatriptan|2.5 mg po bid for 10 days
41453926|NCT06018116|DRUG|Bicalutamide 150 mg|nonsteroidal antiandrogen
41453927|NCT06018116|DRUG|Placebo|placebo
40759443|NCT03784729|OTHER|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted. For the bilateral BL25, sterile disposable steel needles (Huatuo, Suzhou, China; 0.3 mm×75 mm) will be inserted to a depth of 50-70mm until until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Huatuo, Suzhou, China; 0.3 mm×40 mm) will be inserted to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi. It should be noted that the needle at KI3 will be inserted at an angle of 45°obliquely downward. There will be 18 treatment sessions with 3 times a week for continuous 6 weeks and a 30 min treatment per session."
40949277|NCT01044251|DRUG|Placebo|1 tab po bid for 10 days
40759444|NCT03784729|OTHER|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm .No manipulation of needles without deqi will be conducted. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
40759445|NCT01778231|DIETARY_SUPPLEMENT|Nutrof Total|Antioxidant and trace element supplement
40759446|NCT01778231|DIETARY_SUPPLEMENT|Placebo|
40759447|NCT05075473|OTHER|Segmental stabilization|Physiotherapist will perform activation of multifidus in prone position. It also includes activation of transverse abdominas in crook lying position, in sitting as well as in point kneeling position to re-establish simultaneous contraction of deep muscles synergy.
40759448|NCT05075473|OTHER|Generalized Lumber stabilization exercsies|It can by performed by patient him or her self under physiotherapist's assistance. Lumber neutral position is maintained. Bridging in prone as well as supine position will be maintained.
40759449|NCT03422887|DRUG|Nalbuphine|Nalbuphine administration during surgery
40759450|NCT03422887|DRUG|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
40759451|NCT03422887|DRUG|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
40759452|NCT06029166|DEVICE|Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)|Implantation of a subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®) before beginning the Bruton's tyrosine kinase inhibitor treatment.
40759453|NCT02169258|PROCEDURE|Systemic Strategy|Significant CAD needing further revascularization is defined as patients who have luminal stenosis \> 70% of the major epicardial vessels and bypass graft vessel or their major branches (\> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (\<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
40759454|NCT02527083|DRUG|Propofol|
40949278|NCT04197531|OTHER|Irrigation Method|Irrigation Method
40949279|NCT06231732|DEVICE|high-frequency transcranial alternating current stimulation|The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA
40949280|NCT06231732|DEVICE|sham high-frequency transcranial alternating current stimulation|The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
41133553|NCT00324948|DRUG|Topical alprostadil (PGE-1)|
40759455|NCT02527083|DRUG|Sevoflurane|
40759456|NCT02527083|DRUG|Remifentanil|
41453928|NCT04823091|DRUG|Fludarabine + Cyclophosphamide + CAR7-T Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0.
41453929|NCT00002158|DRUG|Nitazoxanide|
41453930|NCT01025141|DEVICE|Skeletal anchorage (MINISCREW)|Skeletal anchorage
41453931|NCT01025141|DEVICE|dental anchorage|dental anchorage (reference)
40759457|NCT02527083|DRUG|Ketamine|
40759458|NCT02392728|BEHAVIORAL|Immersive Virtual Reality (VR)|Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
41453932|NCT01037231|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU oxalobacter formigenes twice daily for 24 weeks
40759459|NCT02392728|BEHAVIORAL|Guided Imagery|Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
41453933|NCT01037231|DRUG|Placebo|placebo
41453934|NCT03498235|DRUG|Sevoflurane|In Team Sevoflurane,patients undergo sevoflurane.
41453935|NCT03498235|DRUG|Propofol|In Team Propofol ,anesthesia is maintained with propofol
41453936|NCT00889486|DRUG|TZP-102|
41453937|NCT00889486|DRUG|Placebo|
40759460|NCT01592747|DRUG|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3-15mg/day; administered orally
40759461|NCT01592747|DRUG|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3mg every other day to 6mg/day; administered orally.
40759462|NCT01592747|DRUG|Placebo capsules|Once daily, oral administration.
40759463|NCT06310694|COMBINATION_PRODUCT|intervention group (Elastane circular dressing on sterile transparent dressing)|A circular dressing made of elastane material was placed on the patients in the intervention group on a sterile transparent dressing to provide additional fixation on the peripheral intravenous catheter.
40759464|NCT00827307|DRUG|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
40759465|NCT00827307|DRUG|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
40759466|NCT00223379|PROCEDURE|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
40759467|NCT01378273|DRUG|Epo|Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.
40759468|NCT01378273|OTHER|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
40949281|NCT05515315|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
40949282|NCT05515315|DRUG|Albumin paclitaxel|Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks
41287967|NCT06076330|DRUG|Plasmalyte|Plamalyte will be given at an initial bolus of 15-20 ml/kg over 15-30 mins followed by 100ml/hr maintenance
40759469|NCT06307366|OTHER|No intervention will be used|This is a qualitative study, no intervention will be used
40759470|NCT03768050|OTHER|Advanced care for frail elderly|"Home-based case management group receives advanced nursing care meeting the health and social needs of patient and/or carer. It is carried out through a process of evaluation, planning\&coordination, facilitating the provision, monitoring and evaluation of the options and resources necessary for the resolution of the case. It is person-centred. The service also provides palliative care.~Home hospitalisation/early discharge dispenses medical and nursing care at home on a transient basis after hospitalisation when patients still need surveillance and assistance. It is done in the acute, subacute or post-acute phase. In the last phase the focus is on functional recovery.~The geriatric residences group is assisted by health care teams with expertise in geriatrics. They coordinate with primary care and health professionals of the residences to improve the attention. They are highly accessible, have high-resolutive capacity and can activate the resources of the healthcare network."
40759471|NCT06569849|OTHER|De-Stress and Focus capsule- U001|Two capsules in sequence daily after meal for 60 days.
40949283|NCT05515315|DRUG|Nedaplatin|Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks
40949284|NCT05515315|RADIATION|radiotherapy|50-60Gy/25-30f
40949285|NCT01973569|DRUG|denosumab|denosumab administered subcutaneously
40949286|NCT01973569|DRUG|placebo|placebo administered subcutaneously to match denosumab
40949287|NCT02486666|DRUG|Enoxaparin|WEIGHT ADJUSTED FiXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES AND CHILDREN WITH THROMBOSIS (FiXET)
40949288|NCT01146912|OTHER|Text Message|Text message vaccine reminders
40949289|NCT01146912|OTHER|automated call|Automated call
40949290|NCT03849807|OTHER|Experimental group|the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).
41287968|NCT04134845|DRUG|Dantrolene/Ryanodex|muscle relaxant
40949291|NCT03849807|OTHER|Control group|Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
40949292|NCT06083077|OTHER|Chest wall strapping|An elastic band (6 cm wide) is placed around the lower part of the chest wall (at the junction of the chest and abdomen) to tighten the chest wall for 10 min at PEEP 7 cmH2O and 10 min without PEEP
40949293|NCT01593189|BEHAVIORAL|KITS Program|This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
40949294|NCT01017471|PROCEDURE|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
40949295|NCT02528604|PROCEDURE|Catheter ablation|Left atrial ablation of persistent atrial fibrillation and implantable loop recorder insertion.
40949296|NCT02528604|PROCEDURE|Pacemaker and AV node ablation|Permanent pacemaker implant followed by AV node ablation
40949297|NCT02528604|PROCEDURE|DC Cardioversion|Electrical cardioversion for Persistent Atrial Fibrillation and implantable loop recorder insertion.
40949298|NCT02528604|DEVICE|Implantable loop recorder|
40949299|NCT04020588|DRUG|Celecoxib 200mg|Will be administered for 6 weeks
40759472|NCT06569849|OTHER|De-Stress and Focus capsule - I001|Two capsules in sequence daily after meal for 60 days.
40949300|NCT04020588|DRUG|Placebo oral capsule|Will be administered for 6 weeks
40949301|NCT04020588|DRUG|Minocycline 100mg|Will be administered for 6 weeks
40949302|NCT04043273|BEHAVIORAL|Noninterventional characterization of patients expectations and preferences regarding their treatment|Patients will be clustered before and after a principal components analysis (PCA) on Patients Needs Questionnaire (PNQ). Observations will be clustered by the Ward method. The number of clusters will be chosen using the Kolinski criteria. Characteristics of patients will be described by cluster.
40949303|NCT04509869|PROCEDURE|varicocelectomy|operation for varix ligation
40949304|NCT04317404|DRUG|40 mg Triamcinolone acetonide|Unilateral knee steroid injection
40949305|NCT05780684|OTHER|FOX dose-escalation algorithm|Chemotherapy dose-escalation algorithm based on the FOLFOX and FOLFOXIRI regimens
41287969|NCT04134845|DRUG|Placebo|Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
41287970|NCT04215692|DIAGNOSTIC_TEST|Pulmonary ultrasound|Pulmonary ultrasound is a basic application of critical ultrasound, defined as a loop associating urgent diagnoses with immediate therapeutic decisions.
41287971|NCT02958137|PROCEDURE|Arthroscopic Resection Arthroplasty|Surgical removal of the arthritic joint(s) using a minimally invasive technique.
41287972|NCT04453150|OTHER|Standard hypocaloric die|Standard hypocaloric diet
41287973|NCT04453150|OTHER|Intermittent fasting 16/8 (early fasting)|Intermittent fasting 16/8 (early fasting)
40759473|NCT06569849|OTHER|Placebo capsules 001|Two capsules in sequence daily after meal for 60 days.
40759474|NCT04161482|DRUG|Furosemide 80 mg (8 mg/mL)|Furoscix will be administered as a subcutaneous infusion.
40759475|NCT04911751|DRUG|KBL697|1 capsule BID of KBL697 or Placebo
40759476|NCT04911751|DRUG|KBL697|5 capsules BID of KBL697 or Placebo
40759477|NCT05520866|BEHAVIORAL|PrehabPal|Web based application
40759478|NCT03092193|DRUG|Naproxen|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
40759479|NCT03092193|DRUG|Naproxen-esomeprazole|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
40759480|NCT01176500|DRUG|(18)Fluciclatide|
40759481|NCT02157727|DEVICE|Infants hospitalized in health facilities performing Tele-expertise|
40759482|NCT04547387|DEVICE|Trans-carotid access revascularization with MicroNET covered stent implantation|Implantation of the micronet covered self-expanding carotid stent during temporary cerebral flow reversal achieved with direct common carotid artery puncture
40759483|NCT03618069|DIAGNOSTIC_TEST|CCI scanning (CTA, cardiac CT), and MRI scanning|Scanning
40759484|NCT02144337|BEHAVIORAL|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
40759485|NCT03801109|OTHER|Hyperbaric group|Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.
40759486|NCT03801109|OTHER|Magnetic group|There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.
40759487|NCT03801109|OTHER|Physical group|A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.
40759488|NCT03801109|OTHER|Baseline group|This group will be the control group that did not take any action, perform the activities of daily life
40759489|NCT04217057|DRUG|64Cu-DOTA-ECL1i|Will be produced by the Cyclotron Facility at Washington University School of Medicine
40759490|NCT04488887|DIAGNOSTIC_TEST|Optical coherence tomography angiography|patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test
40759491|NCT05626335|DIAGNOSTIC_TEST|Intraoral scan|On the day of debonding, directly following retainer bonding, intraoral scans were performed (T0), using 3Shape Trios 4 (3Shape, Copenhagen, Denmark). The scans were repeated after a month. The patients were invited for repeating the scans after 1 (T1), 3 (T2) and 6 months (T3).
40759492|NCT02323620|PROCEDURE|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
40759493|NCT02189629|DRUG|CD5789 (trifarotene)|
40759494|NCT00019838|DRUG|7-hydroxystaurosporine|
40759495|NCT00019838|DRUG|fludarabine phosphate|
40759496|NCT05961631|OTHER|Bio-electrical Impedance Analysis|Variable measured: Fluid accumulation (FA), volume excess (VE), total body weight (TBW), extracellular water (ECW), intracellular water (ICW)
40759497|NCT03689088|DEVICE|Goldfish|Goldfish will be placed in the eye for 24h monitoring
40759498|NCT03689088|DEVICE|Tonometry|Fellow eye will be measured by tonometry
40759499|NCT06419907|BEHAVIORAL|Type 2 Live Well (structured diabetes self management education programme)|Structured diabetes self management education programme designed to support those with type 2 diabetes self care and prevent long term associated complications.
40759500|NCT02915601|DRUG|Sodium bicarbonate|
41287974|NCT04453150|OTHER|Intermittent fasting 16/8 (late fasting)|Intermittent fasting 16/8 (late fasting)
41287975|NCT04453150|OTHER|Alternate-day fasting|Alternate-day fasting
41287976|NCT04453150|OTHER|Ketogenic diet|Ketogenic diet
40949306|NCT05741307|BEHAVIORAL|Self-hypnosis application|"The Hypnotidoo application offers screenless self-hypnosis sessions for 5-12 year olds. Each session lasts 6 to 8 minutes and focuses on one of the following themes: stress and anxiety, sleep, daily troubles and discomforts, hypersensitivity, hyperactivity and difficulty concentrating, self-confidence, difficult life events, anger. Each session begins with breathing and refocusing work, followed by self-hypnosis through stories and metaphors suitable for children.~The application will be used by patients in the context of research for 6 weeks, 5 days out of 7 in parallel with the usual treatment."
40759501|NCT02915601|DRUG|Placebo|
40759502|NCT02585180|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
40759503|NCT02585180|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
40759504|NCT06570629|DEVICE|Oronasal CPAP|In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
40759505|NCT06570629|DEVICE|Nasal CPAP plus Chinstrap|In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
40759506|NCT06379620|DEVICE|Hi-OxSR Sequential Rebreathing mask (oxygen concentrator)|Subjects will self-administer oxygen gas at 1to 3LPM via a Hi-OxSR Sequential Rebreathing mask (oxygen concentrator), twice a day for 30 minutes with ventilation supplemented by the subject's rebreathed exhaled air. Total treatment is for 14 days
40759507|NCT00383565|DRUG|romidepsin|Given IV
40759508|NCT01532219|BEHAVIORAL|Internet-delivered Psychodynamic Treatment|Ten weeks of guided self-help + therapist contact, via the Internet.
40949307|NCT05741307|OTHER|Questionnaires|"Before and after (at T0, T1, T2 and T3) the 6-week period of use of the application and a wash-out period of 2 weeks (= usual treatment only), self- and hetero-questionnaires which constitute the gold standard for evaluating the symptoms of inattention and anxiety are proposed: Conners III, Child Behavior Checklist (CBCL) and Revised-Children's Manifest Anxiety Scale (R-CMAS).~* T0: inclusion~* T1: 6 weeks after T0 (inclusion)~* T2: 2 weeks after T1~* T3: 6 weeks after T2"
40759509|NCT01532219|BEHAVIORAL|Internet-delivered structured support|Ten weeks of therapist contact, via the Internet.
40759510|NCT03576651|BIOLOGICAL|JHL1149|Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion
40759511|NCT03576651|BIOLOGICAL|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
40759512|NCT03576651|BIOLOGICAL|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
40759513|NCT05134519|DRUG|Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)|Regimen: RC48-ADC: 2.0 mg/kg, intravenous drip, once every 2 weeks,4-6 cycles
40949308|NCT02773290|BIOLOGICAL|Romiplostim|Weekly SC administration
40949309|NCT02269748|PROCEDURE|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
40949310|NCT02269748|PROCEDURE|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
40949311|NCT02269748|DRUG|Analgesic Therapy|Ibuprofen 600 mg TID
40949312|NCT05613400|DRUG|Simvastatin 10mg|One simvastatin 10mg-tablet
40949313|NCT05613400|DRUG|Ezetimibe 10mg|One ezetimibe 10mg-tablet
40949318|NCT01570088|DIETARY_SUPPLEMENT|Folic acid|One roll/bun per day fortified with 400 µg of folic acid
40949319|NCT01570088|DIETARY_SUPPLEMENT|L-5-MTHF|One roll/bun per day fortified with 452 µg of L-5-MTHF
40759514|NCT03186183|BEHAVIORAL|GPS program|GPS is a sexual health promotion and HIV prevention program. It has 4 components: provision of information on HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care in the local community (e.g., referrals to medical, social service, social, mental health, and substance use programs). Among HIV-positive men who have sex with men (MSM) GPS is associated with positive health outcomes including decreased likelihood of condomless anal sex (CAS), particularly CAS with serodiscordant partners. GPS is also associated with decreased fear of being rejected for insisting on condom use and increased condom use self-efficacy.
40759515|NCT00370955|PROCEDURE|phacoemulsification using either high vacuum or low vacuum techniques|All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
40759516|NCT06189612|OTHER|Clinical reasoning based physiotherapy + cervical movement control training|An individualized cervical motor control training based on the positive tests of the test battery introduced by Patroncini et al. (2014).
40759517|NCT06189612|OTHER|Clinical reasoning based physiotherapy + orofacial movement control training|An individualized orofacial motor control training based on the positive tests of the test battery introduced by von Piekartz et al. (2017).
40759518|NCT06189612|OTHER|Clinical reasoning based physiotherapy + standard exercises|A generalized training regimen based on exercises which are taught in physiotherapy training for the neck and scapula region preventing the overlap with exercises of the test batteries.
40759519|NCT06304012|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
40786424|NCT00297869|PROCEDURE|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
40949320|NCT01570088|OTHER|Placebo|Placebo contains no folic acids
40949321|NCT06069531|DIETARY_SUPPLEMENT|Lactobacillus johnsonii, Placebo Comparator: White pomegranate extract|Group A: Placebo; Group B: heat-killed Lactobacillus johnsonii TCI250; Group C: White pomegranate extract, dosage of 500mg for 8 weeks.
40949322|NCT03638622|COMBINATION_PRODUCT|Photodynamic Therapy|Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
40949323|NCT01578070|BIOLOGICAL|0.2μg Act-HIB®|0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
40949324|NCT01578070|BIOLOGICAL|ViscoGel® and 0.2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
40949325|NCT01578070|BIOLOGICAL|ViscoGel® and 2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
40949326|NCT01578070|BIOLOGICAL|2μg Act-HIB®|2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
40949327|NCT01578070|BIOLOGICAL|10μg Act-HIB®|Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
40949328|NCT05882357|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
40949329|NCT05882357|DRUG|IVA|Granules for oral administration
40990503|NCT02419742|DRUG|Trastuzumab|AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
40759520|NCT06304012|DEVICE|Intermittent Oro-esophageal Tube Feeding|The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
41287977|NCT05286151|BEHAVIORAL|Rhythm discrimination|Participants will complete a rhythm discrimination task once per year for 3 years.
41287978|NCT03758677|DRUG|Apatinib|30 patients who progressed after EGFR-TKI treatment without T790M mutation will receive apatinib 250mg qd orally combine with chemotherapy , if the patient has a grade 3/4 adverse reaction during such treatment, apatinib should be reduced to 250mg orally once per two days. Chemotherapeutic agents are limited to platinum-based double drugs(Pemetrexed,Gemcitabine,Docetaxel).
40759521|NCT06304012|BEHAVIORAL|Rehabilitation therapy|"Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers."
40759522|NCT00044733|DRUG|Mylotarg (gemtuzumab ozogamicin) Injection|
40949330|NCT03897504|PROCEDURE|feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap|the prepuce of the females with congenital adrenal hyperplasia will be tubularized and used as pedicled flap in creating the new vagina, the urethra will be completed with the urogenital sinus, no mobilization either partial or complete urogenital mobilization will be needed in cases with low and intermediate confluence level (less than 30 mm), in case with high confluence (more than 30 mm) laparoscopic vaginal pullthrough will be attempted first then the same previously described technique will be applied, the depth of the confluence will be determined before starting surgery by doing genitograph under general anaesthesia, stent will be kept in the new vagina for 5 days and further scheduled calibrations and dilatations will be applied regularly with paying attention to urinary complications like incontinence and urethrovaginal fistula by doing urodynamics and micturating cystourethrogram if there is a complain.
40949331|NCT04206800|DIAGNOSTIC_TEST|Ejaculatory abstinence less than 24 hours|Males will have ejaculatory abstinence less than 24 hours before providing a semen sample the day of egg retrieval
40949332|NCT00474760|DRUG|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
40949333|NCT06141018|DEVICE|Cross-linked intra-articular hyaluronic acid|Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
40949334|NCT06141018|OTHER|Placebo|Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
41287979|NCT00003789|DRUG|isolated limb perfusion|Undergo isolated limb perfusion
40949335|NCT02291354|DRUG|Pectin|Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
40949336|NCT02291354|OTHER|Placebo|Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
41287980|NCT00003789|DRUG|melphalan|Given via limb perfusion
41287981|NCT00003789|BIOLOGICAL|recombinant tumor necrosis factor family protein|Given via slow injection into the arterial line
41287982|NCT00003789|OTHER|pharmacological study|Correlative studies
40759523|NCT06142305|PROCEDURE|DDH surgery and casting|DDH surgery and casting
41287983|NCT00003789|OTHER|laboratory biomarker analysis|Correlative studies
41287984|NCT02472483|BEHAVIORAL|Cognitive and Behavior Therapy (CBT)|20-weeks CBT
41287985|NCT02472483|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|8-weeks MBCT
41287986|NCT04103918|DEVICE|Jalucomplex|Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
41287987|NCT06040177|DRUG|Cadonilimab|Cadonilimab will be administered within 2 weeks after the completion of the radiotherapy treatment once every 3 weeks (Q3W), for up to 2 years
41287988|NCT06040177|RADIATION|Stereotactic radiotherapy|Radiation therapy: Stereotactic radiotherapy (5-8Gy\*5F) for portal vein thrombus within 21 days after entry
41287989|NCT06040177|DRUG|Renvatinib|Renvatinib: 8mg (weight \<60kg) or 12mg (weight 60kg) once a day until disease progression, intolerable toxicity
41287990|NCT02362438|GENETIC|scAAv9/JeT-GAN|scAAV9/JeT-GAN is a biological gene transfer reagent
41287991|NCT06274567|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study uses intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
41287992|NCT06274567|DEVICE|Sham (placebo) TMS|Sham stimulation works by blocking the magnetic field with an internal spacer on the sham side of the TMS coil, allowing the operator to place the coil surface against the scalp. A brief electric pulse calibrated to the stimulator output is delivered to the scalp simultaneous to the TMS pulse to mimic the scalp sensation during the sham condition. 75 Importantly, the electric pulse is calibrated to the stimulator output to ensure a realistic sham condition.
40759524|NCT02459600|OTHER|instulling cyclopentolate drops in the eye|measuring refraction with and wirthout cyclopentolate drops under general anesthesia
40759525|NCT02826681|DRUG|Injectafer® (Ferric Carboxymaltose - FCM)|Intravenous Iron
41287993|NCT02095730|DRUG|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
40759526|NCT02826681|DRUG|Placebo (Normal Saline)|Normal Saline Solution
40759527|NCT04701710|DRUG|Ivermectin / Iota-Carrageenan|The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
41287994|NCT02095730|DRUG|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
41287995|NCT02095730|DEVICE|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
41287996|NCT02095730|DEVICE|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
40759528|NCT04985682|BIOLOGICAL|ADVATE|Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.
40759529|NCT03116178|OTHER|Group G -PVI( Masimo co oximeter) guided fluid therapy|"goal directed fluid therapy maintaining pvi 4-11. when pvi\<4 fluid rate is 50-60ml/hr and pvi\>11 200ml colloid bolus transfusion till pvi value achieves normal range.~In the control group crystalloid was administered @ 6-8 ml/kg and blood loss was replaced by colloids. Hourly urine output was measured and if less than 0.5ml/hr bolus crystalloid 100-200ml was administered"
40759530|NCT03116178|OTHER|Group B- Body weight guided intravenous fluid @6-8ml/kg|Intravenous fluid @6-8ml.kg and blood loss replacement with colloids maintaining urine output of 0.5ml/kg
40949337|NCT02291354|PROCEDURE|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
40759531|NCT04493203|DRUG|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of Immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
40759532|NCT04493203|DRUG|Axitinib|Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor.Its primary mechanism of action is thought to be vascular endothelial growth factor receptor 1-3, c-KIT and PDGFR inhibition, this, in turn, enables it to inhibit angiogenesis (the formation of new blood vessels by tumours)
40759533|NCT03792737|DEVICE|Spiral PDS Plus|The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
40759534|NCT03792737|DEVICE|Spiral MONOCRYL Plus|The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
40759535|NCT03792737|DEVICE|PDS Plus|PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
40759536|NCT03792737|DEVICE|MONOCRYL Plus|MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
40759537|NCT03792737|DEVICE|VICRYL Plus|VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
40759538|NCT06154850|OTHER|Immersive virtual reality|Oculus Quest 2 will be used with NatureTrek application for 10 minutes.
40759539|NCT06154850|OTHER|Non-immersive virtual reality|Patients will watch a video including scenes from NatureTrek application on a screen.
40759540|NCT05597124|BEHAVIORAL|Cardio-Dance Fitness|This is an aerobic cardio-dance fitness exercise class in a social context with aerobic intensity assessed by heart rate monitoring throughout the class. Participants will meet three times a week for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
40759541|NCT05597124|BEHAVIORAL|Strength, Flexibility & Balance|This intervention will serve as a stringent, structurally equivalent, active comparator to the CDF intervention, identical in duration, frequency, and social contact except for the content of this non-aerobic intervention. SFB will involve non-aerobic activity with strength, flexibility, and balance training.
40759542|NCT05584631|DRUG|Intravenous immune globulin G|Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.
40759543|NCT05584631|DRUG|Subcutaneous immune globulin G|Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
40786425|NCT04189835|DIAGNOSTIC_TEST|EBV DNA in whole blood and plasma|Consecutive measurements of EBV DNA in whole blood and plasma
40786426|NCT02176629|OTHER|Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|
40786427|NCT02176629|OTHER|Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)|
40949338|NCT01161784|DIETARY_SUPPLEMENT|Probiotics fermented milk|80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
40949339|NCT01161784|DIETARY_SUPPLEMENT|Nutrient drink|80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
40949340|NCT06315023|DEVICE|DETOUR System|Percutaneous Transmural Arterial Bypass Therapy using the DETOUR™ System
40949341|NCT04335032|DRUG|Eicosapentaenoic acid gastro-resistant capsules|same as in arm/group description
40949342|NCT04335032|DRUG|Placebo|same as in arm/group description
41287997|NCT00650585|BEHAVIORAL|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
40949343|NCT03530358|DEVICE|Technology-aided rehabilitation|"VRRS involves performing different kinds of motor tasks with the patient holding a real manipulable object in their hands while interacting with a virtual scenario.~Braccio di Ferro task consists in center-out reaching movements and return. The subject is required to start from a central target, reach one of five peripheral targets arranged on a semi-circle with a 20 cm radius and then return to the central target."
40990504|NCT05663307|DRUG|Ginkgo diterpene lactone meglumine injection|Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
41133554|NCT01123174|BEHAVIORAL|ALGOS algorithm of case management|"If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.~If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt."
41287998|NCT06085157|OTHER|electronic diary|a smartphone application for self-documentation of drinking pattern
41287999|NCT04965714|BIOLOGICAL|Nivolumab|Given IV
41288000|NCT04965714|BIOLOGICAL|Pegargiminase|Given IM
41288001|NCT04965714|PROCEDURE|Resection|Undergo surgical resection
41288002|NCT02558023|DRUG|Urapidil|"Urapidil (Eupressyl\*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
41288003|NCT02558023|DRUG|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
41288004|NCT01328873|OTHER|Microbiological analysis|Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
41288005|NCT01388400|OTHER|conventional occupational therapy|upper limb exercises
41288006|NCT01388400|DEVICE|video capture virtual reality|virtual reality delivered uppe limb exercises
41288007|NCT05292677|DRUG|Steroid/Anesthesia Mixture|Steroid will be Triamcinolone Acetonide (40mg/mL). Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine. These will be pre-mixed by a qualified personnel within the ENT department.
41288008|NCT05292677|DRUG|Placebo|2 mL of Normal Saline
41288009|NCT03191175|OTHER|blood sample|47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).
41288010|NCT05776459|DRUG|AC102 gel|Drug: AC102 Single intratympanic injection
41288011|NCT05776459|DRUG|Prednisolone|Active comparator: Prednisolone Tablets taken daily by mouth
41288012|NCT05776459|OTHER|Placebo Tablets|Placebo Tablets taken daily by mouth
41453938|NCT05302128|OTHER|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of nausea and vomiting before and 15 minutes after the cold vapor application in the recovery room and at the 2nd, 6th,12th, and 24th hours after the cold vapor application in the postoperative service.
41133555|NCT06153745|DEVICE|Tecnis Eyhance ICB00 intraocular lens (Johnson&Johnson Vision, Santa Ana, California USA)|pediatric cataract surgery
41288013|NCT05776459|OTHER|Placebo gel|Placebo Single intratympanic injection
40786428|NCT06074588|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg of MK-sacituzumab tirumotecan by IV infusion
40786429|NCT06074588|DRUG|Docetaxel|75 mg/m\^2 of docetaxel by IV Infusion
40759544|NCT00645138|PROCEDURE|Paravertebral Block|"Sedation will be provided with midazolam and fentanyl. The transverse processes of T1-T6 will be located using ultrasound guidance. The area will be prepped with betadine. At each level, a 21 Gauge, 4-inch Stimuplex needle will be inserted in order to make contact with the transverse process. Once the transverse process has been located, the needle will be walked off the process and inserted 1 cm deep to its inferior border. After negative aspiration, 3 mL of 1.5% mepivacaine with epinephrine 1:200,000 and bicarbonate and 3 mL of 0.5% bupivacaine with epinephrine 1:200,000 will be injected. Sedation will be provided with 50-100 mcg/kg/min of propofol during the surgical procedure. Approximately 20 minutes before the end of the procedure, 4 mg of zofran will be administered."
40759545|NCT00645138|PROCEDURE|General Anesthesia|Patients in the general anesthesia group will receive midazolam preoperatively for anxiolysis. Anesthesia will be induced with propofol and fentanyl. An LMA will be inserted and anesthesia maintained with sevoflurane in air and oxygen. 4 mg of zofran will be administered approximately 20 minutes before the end of the surgical procedure. The LMA will be removed and the patient will be transported to the PACU at the conclusion of the surgery.
40759546|NCT04872647|BEHAVIORAL|Phone-Based Health Coaching Utilizing Lifestyle Action Plans|Culturally sensitive health coaches trained in motivational interviewing provide 10-20 minutes of weekly phone-based health coaching. They not only guide the patient in creating a SMART goal, but assess and build off of the previous weeks' goal and problem-solve with the patient. During the week, the coach and patient text regarding daily blood glucose monitoring with real-time feedback and coaching about the implementation of the patients' goal.
40759547|NCT06571838|DEVICE|DAISY system|DAISY is a The humanoid robot with an ipad and attached peripheral devices capable of taking blood pressure and temperature
40759548|NCT04210102|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)|"Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs."
40759549|NCT04210102|DIAGNOSTIC_TEST|Chest radiography (CR)|The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.
40949344|NCT03530358|BEHAVIORAL|Conventional rehabilitation|The patients will be asked to perform a wide range of exercises, including: shoulder flexion-extension, abduction-adduction, internal-external rotation, circumduction, elbow flexion-extension, forearm pronation-supination, hand-digit motion. Standardized instructions and modalities will be followed when providing exercises to the patients in order to control for any variability in leading the therapy session due to the therapist.
40949345|NCT02954250|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
40949346|NCT04172623|BEHAVIORAL|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
41133556|NCT02461979|OTHER|The VDR genotype|The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
41453939|NCT00509990|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
40759550|NCT05346640|DEVICE|Cionic Neural Sleeve|Adaptive, functional electrical stimulation
40949347|NCT04172623|BEHAVIORAL|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
40949348|NCT04600570|OTHER|ultrasound|ultrasound measurement for optic nerve outer diameter
40949349|NCT03025841|DRUG|Ceftaroline|
40949350|NCT04308096|DRUG|KRN23|The starting dose of KRN23 will be the dose used for the last administration in the preceding studies. The dose may be modified subsequently in accordance with the criteria for dose and dose adjustment.
41133557|NCT06152718|OTHER|Karisma|Use of regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen
41453940|NCT02888964|DRUG|Add-on therapy|Pioglitazone therapy
41453941|NCT05501158|DRUG|Tamoxifen|Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
41453942|NCT00370539|DRUG|verteporfin, bevacizumab, triamcinolone acetonide|
41453943|NCT04470739|DIAGNOSTIC_TEST|chest x-ray|First Chest X-ray in the first 6 hours of infants
41453944|NCT02959619|DRUG|Ensartinib|Oral ensartinib was given daily at escalating doses in a 28-day cycle
41453945|NCT04637139|DRUG|Vebicorvir (VBR)|300mg Vebicovir containing 2 µCi \[14C\]VBR.
40949351|NCT00354614|DEVICE|ApneaLink Sleep Screener|Device used to evaluate for the presence of OSA
40949352|NCT05510531|BEHAVIORAL|Diabetes Survival Skills Training|During the course of the DSS sessions, participants receive blood glucose logs, glucose meters; lancets, testing strips and demonstration insulin pens with injecting pillow will only be used in class. In summary, the DSS is focused on increasing knowledge, motivation, and self-efficacy and decreasing diabetes related distress, IMB components relevant to incarcerated persons and proximal to behavior change, through engagement, return demonstrations, skill practice, and positive reinforcement.
41288014|NCT02289755|DRUG|ALLN-177|ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
41288015|NCT04440241|PROCEDURE|regenerative treatment periimplantitis|"Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps."
41288016|NCT01737164|BEHAVIORAL|Aerobic Exercise|
41288017|NCT02307526|DRUG|Pyridostigmine Bromide|After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
41288018|NCT02307526|DEVICE|Tilt table test|After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
41288019|NCT01933984|DRUG|Bronchodilators inhalation|Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
41288020|NCT00330824|DRUG|antibiotic/steroid combination|1gtt, 4x/d, 15 days
41288021|NCT00330824|DRUG|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
40949353|NCT05772429|DRUG|Epidiolex|Administered as an oral solution
40949354|NCT02548533|DEVICE|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
40949355|NCT02548533|DRUG|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
41288022|NCT03749642|DRUG|trazodone/gabapentin 2.5/25 mg|The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
41288023|NCT03749642|DRUG|trazodone/gabapentin 5/50 mg|The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.
41288024|NCT03749642|DRUG|trazodone/gabapentin 10/100|The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.
41288025|NCT03749642|DRUG|Gabapentin|"The total daily doses administered will be:~* 600 mg from day 0 to day 6 (±1)~* 900 mg from day 7 (±1) to day 13 (±1)~* 1200 mg from day 14 (±1) to day 20 (±1)~* 1800 mg from day 21 (±1) to day 56 (±2)"
40759551|NCT04422834|OTHER|Questionnaire|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
40949356|NCT02548533|DRUG|EMLA cream|Topical application 2 hours prior to the treatment.
40949357|NCT04962620|DRUG|Bovhyaluronidase azoximer|Rectally or vaginally 1 suppository of Longidaze every 2 days. The main course of treatment - 10 suppositories (for 30 days). Then (according to the doctor's decision) supportive therapy is prescribed for 1 suppository 1 time in 7 days. Course of supportive treatment - 17 suppositories for another 120 days. The patients took dienogest according to the instructions for use.
41288026|NCT03749642|DRUG|Placebo oral capsule|Two capsules, three times a day, for 8 weeks.
41288027|NCT05599217|OTHER|Dietary and nutritional questionnaire|Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.
41288028|NCT05599217|OTHER|Neurological function, cognitive function, and life quality assessment|Neurological function, cognitive function, and life quality will be examined using Glasgow Coma Scale, Modified Rankin Scale, Markwalder Grade Scale, Mini-mental state examination, and EuroQol five dimensions questionnaire.
40949358|NCT00004868|DRUG|semaxanib|
41288029|NCT05599217|OTHER|Peripheral blood test|Collect peripheral blood samples from patients.
40949359|NCT04048187|DEVICE|Phone Application|Phone application is developed to adjust hearing aids. It incorporates functionalities like volume control and program change.
40949360|NCT03343067|DRUG|elagolix|Tablets
40949361|NCT03343067|DRUG|estradiol/norethindrone acetate (E2/NETA)|Capsules
40949362|NCT04997278|DEVICE|Coordinated Reset spinal cord stimulation|"Abnormal neuronal synchrony in terms of enhanced 4-9 Hz theta oscillations in EEG/MEG recordings appears to be an important pathophysiological finding in patients with neurogenic pain. To specifically counteract abnormal neuronal synchrony, we here set out to perform Coordinated Reset (CR)-Spinal Cord Stimulation (SCS). CR stimulation (Tass, 2003) aims at an anti-kindling, i.e. an unlearning or resetting of abnormal neuronal synchrony and abnormal synaptic connectivity, and, hence, long-lasting, sustained therapeutic effects that persist following cessation of stimulation (Tass \& Majtanik, 2006)."
40990505|NCT05663307|DRUG|Ginkgo diterpene lactone meglumine injection simulation|Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
40990506|NCT05663307|DRUG|Aspirin|plus aspirin at a dose of 100 mg per day for 90 days.
40990507|NCT01288911|DRUG|enzalutamide|capsules
41288030|NCT05599217|OTHER|Metabonomic test|Collect urine and stool samples from patients.
41288031|NCT05599217|OTHER|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
40990508|NCT01288911|DRUG|bicalutamide|tablets
41453946|NCT06141460|DRUG|RRG001|Administered via Subretinal injection. Dosage form: injection solution.
40949363|NCT05158634|OTHER|Evaluations|"Within the scope of the study, the participants will be evaluated for 30 minutes in a single session. The participants' trunk stabilization and endurance, balance, functional mobility, upper extremity endurance, functional health and quality of life will be questioned by questionnaires, scales and tests. Evaluation will begin with a literature-supported demographic data form prepared for the participants.~Assessments to be made are listed below. Trunk Control Measurement Scale (TCMS) Pediatric Balance Scale (PBS) Time Up and Go test (TUG) Trunk Flexor Test (TFT) The Pediatric Outcomes Data Collection Instrument (PODCI)"
40759552|NCT03908294|DIAGNOSTIC_TEST|Lab tests, non-invasive fibrosis (Fibroscan/ARFI)|Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.
40759553|NCT01946269|OTHER|Goal-directed Resuscitation Therapy (GDT)|"* A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.~* The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.~* When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%.~* If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg."
40759554|NCT01946269|OTHER|Standard protocol|The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
40759555|NCT04499001|OTHER|Pharmacist's consultation|Information about bDMARDs management.
40759556|NCT02936323|DRUG|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose of 1 mg with each subsequent cohort increased starting dose level until MTD is reached.
41453947|NCT00961376|BIOLOGICAL|PBMC re-infusion|Autologous PBMC re-infusion
41453948|NCT00961376|BIOLOGICAL|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
41453949|NCT03153462|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
41453950|NCT02625298|DEVICE|ProRoot MTA|Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
41453951|NCT02625298|DEVICE|MTA+ Cerkamed|Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
41453952|NCT04046705|PROCEDURE|Allogeneic matched related haematopoietic stem cell transplantation|Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen
40786430|NCT06074588|DRUG|Pemetrexed|500 mg/m\^2 of pemetrexed by IV infusion
40949364|NCT03773367|DRUG|Fluorouracil|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
40990509|NCT01548612|DRUG|Sodium nitroprusside|Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
41288032|NCT04696406|DEVICE|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
41288033|NCT05914779|OTHER|No use of antibiotics|Subjects will be randomized into antibiotics and no antibiotics groups based on inclusion and exclusion criteria
41288034|NCT05914779|OTHER|with antibiotics treatment|with antibiotics treatment
41453953|NCT04046705|OTHER|Standard arm|In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
41453954|NCT00818298|DRUG|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
40949365|NCT03773367|DRUG|Oxaliplatin|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
41288035|NCT04063943|DEVICE|Sidus Stem-Free Shoulder|Device: Sidus Stem-Free Total Shoulder Arthroplasty System
41453955|NCT00690495|DRUG|Propofol|Propofol (drug), intravenous, induction of anesthesia
40759557|NCT02936323|DRUG|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.
40759558|NCT00944840|DRUG|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
40990510|NCT01548612|DRUG|Glucose solution|Intravenous infusion of glucose solution 5% for 240 minutes
41288036|NCT04222621|OTHER|Pregnant women without intervention|Pregnant women with those exposures of interest determined in specific research based on the registry
41453956|NCT00690495|DRUG|Propofol 1%|Propofol (drug), intravenous, induction of anesthesia
41453957|NCT06212869|DEVICE|Transcranial direct current stimulation|tDCS group will give active tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
40949366|NCT03773367|DRUG|Irinotecan|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
40949367|NCT02080910|BEHAVIORAL|Psychoeducation|
40949368|NCT02869074|GENETIC|VWF gene analysis|52 exons adjacent intronic regions and promotor of VWF will be analyzed
41453958|NCT06212869|DEVICE|Sham transcranial direct current stimulation|Sham tDCS group will give sham tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
40949369|NCT02851940|PROCEDURE|Rubber Band Ligation|Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)
40949370|NCT02851940|PROCEDURE|Hypertonic Saline Infusion|Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
40949371|NCT04425356|BEHAVIORAL|LifeXT Program|The intervention involves participation in and completion of the 4-month LIFEXT program, including: A baseline 15-20 minute health assessment administered online, a 50 minute introductory, one-on-one telephonic coaching session, four 50 minute one-on-one telephonic coaching sessions, optional coaching session follow-up activities (such as videos, practice exercises, and reading materials), and a post-intervention 15-20 minute health assessment administered online.
40759559|NCT00944840|DRUG|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
40759560|NCT00557739|DRUG|mometasone furoate|Topical 0.1% mometasone furoate
40949372|NCT05661409|DRUG|Sugammadex|"Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated."
40949373|NCT05661409|DRUG|Placebo|Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
40949374|NCT01148888|DRUG|Magnesium|Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
40949375|NCT04823182|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|The Cardiac MRI protocol consists of static T2 weighted in all three planes and T2 weighted imaging with fat saturation in the short axis plane.
40949376|NCT04135365|BEHAVIORAL|neurocognitive assessment|Observational study therefore there are no interventions
41453959|NCT06212869|DEVICE|Green light|Green light group will give green light exposure with the prescribed medications for 1-2 hour. The intervention will conduct 5 days in a week.
40759561|NCT00557739|DRUG|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
40759562|NCT00557739|DRUG|Vehicle (placebo)|Topical placebo
40759563|NCT03366259|DRUG|Misoprostol 200Mcg Tab|administration of 200 Mcg of misoprotol rectal
40759564|NCT03366259|PROCEDURE|elective cesarean section|elective cesarean section for full term patients
40759565|NCT00803855|DRUG|AZD1446|oral, single dose
40759566|NCT03999073|OTHER|Ultrasound measurement|Ultrasound measurement
40949377|NCT04135365|BEHAVIORAL|neuroimaging assessment|Observational study therefore there are no interventions
40949378|NCT00702104|OTHER|survey administration|
40949379|NCT04512950|DRUG|Ringer's lactate|Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
40949380|NCT04512950|DRUG|0.9% saline|Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
40949381|NCT04965246|BEHAVIORAL|Physical Activity|The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.
40759567|NCT01335685|DRUG|Ixazomib|Ixazomib capsules
40759568|NCT01335685|DRUG|Melphalan|Melphalan tablets
41288037|NCT02179632|BEHAVIORAL|Exposure to disclosure website|Participants are exposed to a physician payment disclosure website.
41288038|NCT03501212|DRUG|Topical Anesthetic|EMLA Cream 2.5 gr applied to both wrists
41288039|NCT03501212|DRUG|Placebo|Placebo Cream 2.5gr applied to both wrist
41288040|NCT02551172|DRUG|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
40759569|NCT01335685|DRUG|Prednisone|Prednisone tablets
41288041|NCT02551172|DRUG|HGP0816|Rosuvastatin
40759570|NCT02998320|DRUG|Genvoya|Oral use (one tablet each day); 150/150/200/10 mg; 28 days
40759571|NCT06003647|OTHER|Educational Intervention|Educational module and video
40759572|NCT04951544|OTHER|LetSync v1.0|Study B will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. Participants will then continue to use LetSync v1.0 while the Waitlist-Control group begins to use LetSync v2.0.
40759573|NCT04951544|OTHER|LetSync v2.0|LetSync v2.0 will be developed by taking feedback from participants regarding LetSync v1.0. Participants in the waitlist-control group will be given LetSync v2.0 to use during the last 6 months of the trial.
41288042|NCT02551172|DRUG|Placebo of HCP1105|Soybean Oil
41288043|NCT02551172|DRUG|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
41288044|NCT03680677|PROCEDURE|Bone Marrow or Peripheral Blood Graft (BMT)|Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
41288045|NCT03680677|OTHER|Cancer-directed Therapy or Best Supportive Care|"Cancer-directed therapy with intensive regimens (7+3, Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care."
41288046|NCT03680677|DIAGNOSTIC_TEST|Frailty Assessment|Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
41288047|NCT03785080|OTHER|restart NOAC very early|withhold NOAC less than 24 hours Post OGD
41453960|NCT00673660|BEHAVIORAL|Patient Compliance|Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
41453961|NCT03567551|OTHER|Women w/ Preeclampsia w/o Visual Disturbances or Headache|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
41453962|NCT03567551|OTHER|Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
40759574|NCT03401879|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
40949382|NCT04965246|OTHER|Usual Care|Participants in the usual care group will receive no intervention
41288048|NCT03785080|OTHER|restart NOAC early|withhold NOAC for 72 to 84 hours Post OGD
41288049|NCT00632593|PROCEDURE|Laparoscopic Gastric Bypass|
41288050|NCT00632593|PROCEDURE|Laparoscopic Gastric Bypass|
41288051|NCT02238613|DEVICE|radioactive stent|radioactive stent carrying seed iodine 125
41288052|NCT02238613|DEVICE|plastic stent|common plastic stent without carrying seed iodine 125
41453963|NCT03567551|OTHER|Women w/o Preeclampsia|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
41453964|NCT01404351|DEVICE|PEAK PlasmaBlade|
41453965|NCT01404351|PROCEDURE|Scalpel and Traditional Electrosurgery|
40759575|NCT03401879|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
40759576|NCT03401879|DEVICE|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
40759577|NCT03401879|DEVICE|Optical coherence tomography angiography (OCTA)|Retinal microvasculature will be assessed using OCTA.
40759578|NCT04037644|PROCEDURE|Fluid loading with Albumin|Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure
40759579|NCT04037644|PROCEDURE|Fluid loading with Ringer Lactate|Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
40759580|NCT05653011|OTHER|Endoscopic biopsy|"When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions."
40759581|NCT00987935|DRUG|Sorafenib|400 mg twice daily
40759582|NCT00987935|DRUG|BIBF 1120|Twice daily
40759583|NCT00090675|DRUG|ZD1839|
41288053|NCT02436239|DRUG|Vilazodone|Vilazodone tablets, once daily, oral administration
41288054|NCT03275870|DRUG|Hydroxychloroquine|Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
41288055|NCT05631925|DRUG|propofol bolus|Propofol will be added in bolus doses of 0.5mg/kg.
41288056|NCT05631925|DRUG|propofol infusion|Propofol will be administered as 10mg/kg/hour infusion.
41288057|NCT03750838|BEHAVIORAL|Text Messaging Intervention|The content for the text messaging Intervention will be designed to be non-confrontational in tone, seek to increase motivation to drink lightly or not at all, and based both on general information about light and non-drinking as well as information provided during the baseline assessment.
41288058|NCT02333045|DRUG|Truvada qd|Truvada 1 tablet PO daily for 7 days
40759584|NCT05579522|PROCEDURE|Fat graft injection|Fat graft injection in the interdental papilla.
40759585|NCT05579522|PROCEDURE|Hyaluronic acid injection|Hyaluronic acid injection in the interdental papilla
41288059|NCT02333045|DRUG|Maraviroc 300 qd|Maraviroc 300 mg PO daily for 7 days
41288060|NCT00539344|DRUG|ANG1005|IV infusion once every 21 days
41288061|NCT02273115|DRUG|Oxytocin|
40759586|NCT00006377|DRUG|carboplatin|
40949383|NCT03814083|DEVICE|Active-tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
40949384|NCT03814083|DEVICE|Sham-tDCS|Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
40949385|NCT03814083|OTHER|Wait-list|No intervention
41288062|NCT02273115|DEVICE|Transcervical Foley catheter|
41288063|NCT01538173|DRUG|250ml HES 6%|Application twice a day 250ml HES 6% for three days postoperatively.
41288064|NCT01538173|DRUG|9% NaCl 500ml|Application twice a day 500ml 9% NaCl for three days postoperatively.
41288065|NCT05252312|BEHAVIORAL|Psycho-acoustic tests|"Listeners' cognitive and biological responses to vocal stimuli will be tested using psycho-acoustic tests. After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?).~These stimuli might be human voices, animal voices or synthetic voices Physiological measures will be simultaneously taken using an array of complimentary, non-invasive techniques such as the Nociception Level (NOL) Index or video pupillometry"
41288066|NCT03634072|PROCEDURE|PVR|Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve
41453966|NCT03265860|DEVICE|IntraVoxel Incoherent Motion sequence|The IVIM diffusion sequence with a duration of 2 minutes is added to the imaging protocol.
41453967|NCT00087529|DRUG|placebo|Intravenous repeating dose
40949386|NCT02439190|DRUG|BMS-986120|
40949387|NCT02439190|DRUG|Aspirin|
40949388|NCT02439190|DRUG|Clopidogrel|
40949389|NCT03813043|DRUG|Midazolam injection|Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)
41288067|NCT00708877|PROCEDURE|Liver Transplantation|Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
41288068|NCT05600010|OTHER|Microplastics|Detection of microplastics as a yes/no value
41288069|NCT00404729|DRUG|Citicoline|Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
41288070|NCT01720251|DRUG|placebo|SC injections of placebo on days 1, 7, 14, 28 and 56
41453968|NCT00087529|DRUG|rituximab|Intravenous repeating dose
41453969|NCT02858037|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
41453970|NCT01449188|DRUG|ondansetron|FDA approved drug used to treat nausea and vomiting
41453971|NCT01449188|DRUG|moxifloxacin|FDA approved antibiotic commonly used as a positive control in thorough QT studies
41453972|NCT01449188|OTHER|saline|USP saline IV solution used as placebo for ondansetron IV.
41453973|NCT06245928|DEVICE|Individualized Respiratory Exercise Device|The Individualized Respiratory Exercise device will include both inspiratory muscle training, expiratory muscle training, and intensive spirometer features.
40759587|NCT00006377|DRUG|doxorubicin hydrochloride|
40759588|NCT00006377|DRUG|paclitaxel|
40759589|NCT04147169|BEHAVIORAL|Focused end-of-life conversations to promote connections among patients, family members and clinicians.|All eligible patients and families who were invited to participate in wish elicitation and implementation. For family interviews, criterion sampling was used. For the clinician focus groups, criterion sampling was used, based on involvement in the care of a 3WP patient. For the manager/hospital administrator interviews, purposive sampling was used, based on relevant leadership positions. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data include characteristics of patients, families and clinicians, questionnaire responses from families who agree to interviews, and clinicians who agree to focus groups, respectively, types of wishes elicited and implemented, and their cost. Qualitative data was obtained through individual family interviews, inter-professional clinician focus groups, project team field notes, additional ideas about the costs and benefits of the project from manager interviews, and analysis of project documents.
40759590|NCT06252987|OTHER|routine treatment|Routine medical treatment, basic rehabilitation training and individualized cognitive training
40759591|NCT06252987|OTHER|Non-invasive brain stimulation|tDCS\&rTMS
40759592|NCT03241615|OTHER|Dysphagia evaluation|Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
41453974|NCT06245928|DEVICE|Threshold® IMT + Threshold™ PEP|The Threshold® IMT device allows inspiratory muscle training and the Threshold™ PEP device allows expiratory muscle training.
41453975|NCT04435782|DRUG|JNJ-67896049|Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
41453976|NCT01320722|DRUG|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
41453977|NCT01320722|DRUG|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
41453978|NCT01320722|DRUG|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
40759593|NCT05307094|BEHAVIORAL|Improving Parents as Communication Teachers|A parent-mediated naturalistic developmental behavioral intervention delivered 2-times per week with a primary caregiver and the child.
40759594|NCT05226195|OTHER|Sterile Kinesio Taping|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group in the operating room at the end of the surgery in a sterile manner according to the epidermis-dermis-fascia (EDF) technique previously described in the literature (without tension). Original KinesioTex® Tape will be used in the study. The day of taping will be considered as Day 0 and the tapes will be changed on the 4th day, the 7th day.
40759595|NCT02272985|OTHER|[15O]H2O PET-CT scan|All participants will undergo 3 \[15O\]H2O PET-CT scans during the hemodialysis study session
40759596|NCT02272985|OTHER|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
40759597|NCT00926900|DRUG|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
40759598|NCT00926900|DRUG|Placebo|Placebo
40759599|NCT02884479|DRUG|PT-112|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
40759600|NCT02884479|DRUG|Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
41453979|NCT01320722|DRUG|Placebo|Placebo soft gel once per week for 8 weeks
40759601|NCT01724814|DRUG|HM12460A|Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
40759602|NCT01724814|DRUG|Placebo|Singe dose SC administration of Placebo
40759603|NCT03124602|DEVICE|Red Diamond Disposable Pulse Oximeter Sensor|Noninvasive Pulse Oximeter Sensor
40759604|NCT06466837|BEHAVIORAL|Just-in-time intervention|The intervention group participants will receive just-in-time intervention from a developed app for healthy behavior reminder
40759605|NCT06466837|BEHAVIORAL|Active control|The control group participants will receive six nursing consultations during the 3-month program period.
40759606|NCT03105765|DRUG|Placebo|Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
40759607|NCT03105765|DRUG|Ketamine|Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
40759608|NCT00474357|BEHAVIORAL|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
40759609|NCT04952519|DRUG|Amantadine|Patients are treated with high doses of amantadine.
40759610|NCT05339425|OTHER|No additional intervention will be administered.|No additional intervention will be administered.
40759611|NCT04774562|BEHAVIORAL|Video-Assisted Discharge Education (VADE)|Video-Assisted Discharge Education (VADE): Information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities.
40759612|NCT04774562|BEHAVIORAL|Physiotherapy (PT) Program|Physiotherapy (PT): Breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation.
40759613|NCT02584647|DRUG|PLX3397|PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)-internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.
40759614|NCT02584647|DRUG|Sirolimus|"Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.~Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day."
40759615|NCT01861275|DEVICE|Nasal CPAP|Nasal CPAP treatment for obstructive sleep apnoea
40759616|NCT03017911|PROCEDURE|Piccline|
40759617|NCT02372357|DRUG|Posaconazole prophylaxis 120 mg/m² tid|Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
40759618|NCT02372357|PROCEDURE|Blood sampling|During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
40759619|NCT05398692|OTHER|Virtual vs On Site Pulmonary Rehabilitation|As part of the on site or virtual visits, the subject will receive standard pulmonary rehabilitation educational instruction on balance and strength training, stretching, nutrition, hydration, pacing, proper breathing, small or mini-lectures, and information on relaxation techniques. If post exertional malaise is present, the patient will only receive the educational sessions, no aerobic training.
40759620|NCT00151073|DRUG|Zoledronic acid|
40759621|NCT00151073|DRUG|Estramustine|
40759622|NCT00151073|DRUG|Docetaxel|
40759623|NCT05045417|DIAGNOSTIC_TEST|Serum level of IL-17|"Measurement of serum level of IL-17 :~1. To explore the role of IL-17 in systemic lupus erythematosus~2. To determine the relation between IL-17 and lupus disease activity~3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)"
40759624|NCT00913835|BIOLOGICAL|Olaratumab|20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity
40759625|NCT00913835|DRUG|liposomal doxorubicin|40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
40759626|NCT04245605|PROCEDURE|Coronary angiography|Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure
40949390|NCT03545100|OTHER|motor control therapy|scapular muscle progressive resistive exercise(PRE)
40759627|NCT03539640|OTHER|PEEP: 5 cmH2O|During second part of the study (MRI)
40759628|NCT03539640|OTHER|PEEP: 10 cmH2O|During second part of the study (MRI)
40759629|NCT03539640|OTHER|PEEP: 15 cmH2O|During second part of the study (MRI)
40759630|NCT02759510|DRUG|Norepinephrine|Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
40759631|NCT02759510|DRUG|Phenylephrine|Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of phenylephrine 40 μg.
40759632|NCT05062707|PROCEDURE|Blood sampling|Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).
40759633|NCT03975179|PROCEDURE|Omission of intraoperative frozen section biopsy for margin status|Omitting intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
40949391|NCT03545100|OTHER|regular physical therapy|transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
41288071|NCT01720251|DRUG|AllerT low dose|SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56
41288072|NCT01720251|DRUG|AllerT full dose|SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
40759634|NCT03975179|PROCEDURE|Frozen section biopsy for margin status|Performing intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
41133558|NCT03044652|DEVICE|WO2085 Moisturising Cream|2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. After improvement of the symptoms the frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
41288073|NCT05346562|DIETARY_SUPPLEMENT|Cannabidiol|Cannabidiol tablets
41288074|NCT05346562|DIETARY_SUPPLEMENT|Placebo|Cannabidiol-matched placebo tablets
41288075|NCT00368368|DRUG|GK Activator (2)|100mg po
41288076|NCT04763265|BIOLOGICAL|"Botulinum toxin A BoNT/A-DP"|To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
41453980|NCT01320722|DRUG|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
40759635|NCT02362763|PROCEDURE|Acupuncture|Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
40759636|NCT00468546|DRUG|MabThera/Rituxan|1
40759637|NCT00468546|DRUG|Methotrexate|2
40759638|NCT00468546|OTHER|Placebo|3
40759639|NCT00607477|DRUG|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
41133559|NCT03044652|DRUG|Estriol Cream 0.1%|0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks. Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.
41133560|NCT05659394|OTHER|Standard Wound Care Alone|gold standard compression therapy
41133561|NCT05659394|DEVICE|Stand Wound Care plus IPC|gold standard compression therapy plus IPC (WoundExpress)
41288077|NCT04763265|BIOLOGICAL|"Botulinum toxin A Botox Cosmetics"|To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.
41453981|NCT00512811|DRUG|furosemide|
41453982|NCT04257695|BEHAVIORAL|TapPro|Manualized intervention administered by a clinician to facilitate opioid tapering during clinical visits.
41453983|NCT05226390|BIOLOGICAL|MVA-SARS-2-ST|In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
41453984|NCT02036086|DRUG|Vemurafenib|Drug
41453985|NCT02036086|DRUG|Cobimetinib|Drug
41453986|NCT04762251|OTHER|Time-restricted eating|Time restricted eating for a self-selected 9 hour window per day
41453987|NCT04762251|OTHER|Current Best Practice|Best practice guidelines to improve diet quality
41453988|NCT04276064|DEVICE|Auditory closed-loop stimulation: slow oscillation boosting|Auditory-closed loop stimulation: slow oscillation boosting
41453989|NCT04276064|DEVICE|Auditory closed-loop stimulation: slow oscillation disruption|Auditory closed-loop stimulation: slow oscillation disruption
41453990|NCT04276064|DEVICE|Sham stimulation|Sham stimulation
41288078|NCT00881920|BIOLOGICAL|Kappa CD28 T cells|"T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10\^7 cells/m\^2 CAR-Kappa~Group 2: 1x10\^8 cells/m\^2 CAR-Kappa~Group 3: 2x10\^8 cells/m\^2 CAR-Kappa"
41288079|NCT03505242|DEVICE|bronchial blocker for BB group|Using bronchial blocker to block right middle lower lobe during surgery.
41288080|NCT03505242|DEVICE|double lumen tube for DLT group|Using double lumen tube to achieve single lung ventilation during surgery.
41288081|NCT00489983|DRUG|pemetrexed|
41288082|NCT00489983|DRUG|gemcitabine|
41288083|NCT04097288|DRUG|Citalopram 40mg|Single dose
41288084|NCT04097288|DRUG|Reboxetine 8 mg|Single dose
41288085|NCT04097288|DRUG|Placebo oral tablet|Single dose
41288086|NCT04097288|DRUG|Placebo oral tablet|Single dose
41133562|NCT00326183|BIOLOGICAL|VAQTA®|0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
41288087|NCT04512729|DIAGNOSTIC_TEST|Colonoscopy|"For all patients, either moderate sedation with intravenous midazolam or conscious sedation with intravenous propofol will be administered in a standard fashion prior to undergoing colonoscopy.~The colonoscope will be inserted and cecum will be intubated. Photo documentation of the cecum will be performed. The colonic mucosa will be carefully visualized upon withdrawal of the colonoscope.~The time spent in inspecting the mucosa during withdrawal of the colonoscope will be documented as the withdrawal time. Meticulous technique will be employed during the withdrawal phase with special efforts to visualize portions of colonic mucosa on the proximal aspects of haustral folds, flexures and valves.All polyps detected will be documented: size, location, and morphology. Photo documentation of the polyps will be performed."
41288088|NCT03542552|DRUG|Magnesium Sulfate|Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
41288089|NCT03542552|DRUG|Nifedipine|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
41288090|NCT06329453|PROCEDURE|Colon Tissue Biopsy|Colonoscopy and colon tissue biopsy.
41288091|NCT00953121|DRUG|bevacizumab and CPT-11 and Carboplatin|Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
41288092|NCT02857465|DRUG|Dexamethasone|single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
41288093|NCT02857465|DRUG|Placebo|single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
41288094|NCT02857465|DRUG|Ropivacaine|NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
41288095|NCT02857465|DRUG|Sufentanil|Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
40949392|NCT01039870|PROCEDURE|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
40949393|NCT01039870|PROCEDURE|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
40949394|NCT04389216|DEVICE|Cool-tip electrode for Radiofrequency Ablation|Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable
40949395|NCT01570556|OTHER|Antibiotic treatment|In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
40949396|NCT04685967|DEVICE|Glass ionomer|Equia Forte HT, GC, Tokyo, Japan
41288096|NCT05413694|OTHER|telephone interview 24 months after hospitalization for Covid-19|telephone interview 24 months after hospitalization for Covid-19
41288097|NCT00600002|BIOLOGICAL|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
41288098|NCT02729961|DRUG|Brentuximab Vedotin|Given IV
41288099|NCT02729961|DRUG|Ceritinib|Given PO
41288100|NCT02729961|OTHER|Laboratory Biomarker Analysis|Correlative studies
41288101|NCT02729961|OTHER|Pharmacological Study|Correlative studies
41288102|NCT01432639|OTHER|Exercise-based cardiac rehabilitation program|The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
41288103|NCT00813228|DRUG|Sitagliptin (Januvia)|
41288104|NCT00145340|DRUG|pioglitazone|30 Mg/day
41288105|NCT00239460|DRUG|Tiotropium|
41288106|NCT00997685|DRUG|Capecitabine plus oxaliplatin|"Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles"
41288107|NCT04330625|BIOLOGICAL|REMD-477|REMD-477 will be administered as a subcutaneous injection for four weekly doses
40759640|NCT00607477|DRUG|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
40949397|NCT04685967|DEVICE|Bulk-fill composite|SonicFill2, Orange, CA, USA
40949398|NCT03629210|DRUG|OZURDEX|OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.
40949399|NCT03629210|BIOLOGICAL|Eylea|EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment. AFL (2.0 mg) has received approval from Health Canada for the treatment of DME. Health Canada has also granted approval for AFL (2.0 mg) in the treatment of age-related macular degeneration, and ME secondary to retinal vein occlusion.
40949400|NCT04414748|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger
40949401|NCT04414748|DRUG|oral Duphaston|oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.
41288108|NCT04538352|DRUG|Semaglutide|Medication for type 2 diabetes management
41288109|NCT04538352|DRUG|Insulin Degludec|Medication for type 2 diabetes management
41288110|NCT04538352|DRUG|Insulin aspart|Medication for type 2 diabetes management (rapid-acting)
41288111|NCT05796089|RADIATION|Thoracic Radiotherapy|"Participants will receive thoracic radiotherapy to a dose of 30 Gray (Gy) in 10 fractions (3 Gy per day) concurrently with cycle 3 or 4 of chemo-immunotherapy (Group 1).~Participants who are unsuitable for concurrent radiotherapy may receive consolidation radiotherapy. Consolidation thoracic radiotherapy will be administered to a dose of 30 Gy in 10 fractions, following 4 cycles of chemo-immunotherapy (Group 2).~Treatment fractions will be delivered daily, where treatment should be completed within 15 days (9-10 fractions a fortnight)."
40759641|NCT02971137|BEHAVIORAL|Smoking Cessation plus CBI|proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
40949402|NCT01462643|DRUG|LAS41004|once daily, topical ointment, 100 microgram per day
40949403|NCT04604314|DEVICE|CEREC Tessera|Full ceramic endocrown restorations will be made from the high strength ceramic, CEREC Tessera
40949404|NCT03814473|OTHER|Diet|"Participants provided with a brochure providing a thorough description of the diet, \~8 example recipes for each meal (i.e. breakfast, lunch, dinner, and snacks) included as a sample menu, and guidance to assist in shopping and self-preparation of food for the prescribed diet and to improve adherence. Diet consisted of following the popular paleolithic diet"
41288112|NCT05796089|DRUG|Etoposide with Carboplatin or Cisplatin|"The chemotherapy in this study is a standard treatment for extensive-stage small-cell lung cancer (EC-SCLC). The combination of chemotherapy (etoposide + carboplatin or etoposide + cisplatin) which the participant will receive is dependent on what is standard at the treatment centre.~Chemotherapy will be administered via an intravenous infusion every 3 weeks (21 days) for 4 cycles."
40949405|NCT00398294|DRUG|MK0733, simvastatin / Duration of Treatment: 12 Weeks|
40759642|NCT02971137|BEHAVIORAL|Smoking Cessation Standard|standard telephone-based smoking cessation intervention
41133563|NCT00326183|BIOLOGICAL|ProQuad|0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
40949406|NCT03901651|DIAGNOSTIC_TEST|Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique|"Colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the standard colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location."
40949407|NCT03901651|DIAGNOSTIC_TEST|Colonoscopy with standard colonoscope and forward withdrawal technique|"A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location."
40949408|NCT01385761|DEVICE|Laryngeal Mask Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
40949409|NCT01385761|DEVICE|air-QTM Intubating Laryngeal Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
41133564|NCT02611869|PROCEDURE|Cryoballoon|Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
41133565|NCT02611869|PROCEDURE|RF ablation|Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
41133566|NCT03392194|BEHAVIORAL|Sleep hygiene intervention|The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.
41133567|NCT03392194|BEHAVIORAL|Yoga intervention|Following the SH intervention, participants randomized to the SH+Y arm will participate in 8 weekly beginner level yoga classes. Classes will increase participants' skill and comfort with yoga postures and relaxing breathing exercises so that participants can adopt an evening yoga practice (10 weeks).
41133568|NCT04565652|DEVICE|Device Wearers|The intervention arm will wear the LOIS ICD Smartband during routine ICD defibrillation following elective ICD implant.
41133569|NCT00905294|OTHER|Blood draws|Observational: blood draws only
40759643|NCT01620047|DRUG|Fentanyl|Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
41133570|NCT02892019|DRUG|Indacaterol acetate 75 μg|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
41133571|NCT02892019|DRUG|Indacaterol acetate 150 μg|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
41133572|NCT01946100|GENETIC|Multifocal Lung Adenocarcinoma|Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
41133573|NCT00366470|DRUG|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
41133574|NCT00366470|OTHER|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
41288113|NCT05796089|DRUG|Durvalumab|"The immunotherapy in this study is a standard treatment for ES-SCLC.~Participants will receive a dose of 1500 mg of Durvalumab via an intravenous infusion every 3 weeks (21 days) for 4 cycles, concurrently with chemotherapy.~A 1500 mg maintenance dose of Durvalumab will administered every 4 weeks after completion of chemotherapy (monotherapy)."
41288114|NCT03283839|DIAGNOSTIC_TEST|Posturography|Evaluation of postural control and of orientation function
41288115|NCT01009775|DRUG|YM155|intravenous infusion
41288116|NCT01009775|DRUG|Docetaxel|intravenous infusion
41288117|NCT03350711|OTHER|Microbiota Enrichment Program (MEP)|"Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study.~Once determined to be eligible for study entry, study-specific screening procedures may include:~* Health history and physical examination~* Urinalysis~* Urine or serum pregnancy test~* Blood tests for Hepatitis B, Hepatitis C, HIV, chemistry panel (which includes liver function, kidney function), complete blood count with differential, platelet count, partial thromboplastin time (PTT), international normalized ratio (INR)~* Electrocardiogram (EKG or ECG)~* Stool studies~Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database."
40759644|NCT01620047|DRUG|Ropivacaine|Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
41133575|NCT04196309|DRUG|low molecular weight heparin|LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)
40759645|NCT01620047|DRUG|Fentanyl|0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
40759646|NCT04806945|DRUG|HLX10|IV infusion.
40759647|NCT04806945|DRUG|Paclitaxel|IV infusion
40759648|NCT04806945|DRUG|Cisplatin|IV infusion
40759649|NCT04806945|DRUG|Carboplatin|IV infusion
40759650|NCT04806945|DRUG|Placebo to HLX10|IV infusion
40759651|NCT01555580|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
40759652|NCT05800626|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|ERCP performed for clinical practice
40759653|NCT04192838|PROCEDURE|Laparoscopic incisional ventral hernia repair|Laparoscopic repair of incisional ventral hernias (5-15 cm) with adouble-layer polypropylene- expanded polytetrafluoroethylene (ePTFE) mesh.
41133576|NCT04205799|DRUG|Cabozantinib|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
41133577|NCT04235205|DRUG|Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
40949410|NCT06058026|OTHER|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
40949411|NCT03714620|DRUG|Ketamine|Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes
41288118|NCT01137630|DRUG|K40a|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
40759654|NCT04192838|PROCEDURE|Open incisional ventral hernia repair|Standard polypropylene mesh was positioned as an inlay, or as an onlay over the external oblique fascia (i.e., subcutaneously), as preferred by the operating team. The mesh was fixed with absorbable stitches. Drains were usually placed.
40759655|NCT00057798|DRUG|gemcitabine hydrochloride|
40949412|NCT05122871|OTHER|Scape Room|Practical training through scape-room with simulator
40949413|NCT05122871|OTHER|Simulation|Practical training through simulator
40949414|NCT04845477|DEVICE|Magnetic tape|magnetic tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
40949415|NCT04845477|DEVICE|Kinesiology tape|kinesiology tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
40949416|NCT03469362|PROCEDURE|Extracorporeal Urinary Diversion|Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
40949417|NCT03469362|PROCEDURE|Intracorporal Urinary Diversion|Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
40949418|NCT03469362|DEVICE|Da Vinci Robot|Da Vinci Robotic Surgical System
41288119|NCT01137630|DRUG|K40b|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
40759656|NCT00057798|DRUG|vinorelbine ditartrate|
40759657|NCT00057798|GENETIC|cytogenetic analysis|
40759658|NCT00057798|GENETIC|loss of heterozygosity analysis|
40759659|NCT00057798|GENETIC|microarray analysis|
40759660|NCT00057798|PROCEDURE|conventional surgery|
40759661|NCT00057798|PROCEDURE|neoadjuvant therapy|
40759662|NCT03906708|OTHER|Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)|Infant lung function testing
40759663|NCT02402907|DEVICE|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
40759664|NCT02402907|DEVICE|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
41453991|NCT04614857|OTHER|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
41453992|NCT01855880|BIOLOGICAL|AbGn-168H|
41453993|NCT01855880|BIOLOGICAL|placebo|
41453994|NCT05038800|BIOLOGICAL|MK-0482|IV infusion
40759665|NCT02232932|PROCEDURE|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
40759666|NCT02232932|PROCEDURE|RESECTION|Intent-to-treat R0 liver resection
40759667|NCT04597411|RADIATION|225^Ac-PSMA-617|administered intravenously under the dose escalation schedule
40759668|NCT04597411|RADIATION|68^Ga-PSMA-11|administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)
40759669|NCT06570499|OTHER|Implant impression|definitive impressions on implants
40759670|NCT06542341|DEVICE|decoLITE (TN2037)|Red/Near infra red light therapy
40759671|NCT01111552|DRUG|Escitalopram|Escitalopram oral capsules.
40759672|NCT01111552|DRUG|Aripiprazole|Aripiprazole oral capsules.
40759673|NCT01111552|DRUG|Placebo|Study drug matching placebo capsule.
40759674|NCT01485198|PROCEDURE|Bone Marrow Autologous Stem Cells Infusion|Extraction and knee infusion of Bone Marrow Autologous Stem Cells
40759675|NCT01485198|DRUG|Acetaminophen|Acetaminophen (750mg orally TID) administration
40759676|NCT03733535|DRUG|Benralizumab|Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
40759677|NCT03733535|DRUG|129 Xenon|1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
40759678|NCT01269437|DRUG|Budesonide dry powder inhaler|200mcg per inhalation, twice daily, for 12 weeks
40759679|NCT00879619|DRUG|sunitinib malate|Given PO
40759680|NCT00879619|DRUG|docetaxel|Given IV
40759681|NCT00879619|DRUG|prednisone|Given PO
40759682|NCT04951843|DIETARY_SUPPLEMENT|Black soybean koji product|Black soybean koji product
40759683|NCT05639725|PROCEDURE|maxillary Ist premolar extraction|Procedure/Surgery: Patients will undergo bilateral maxillary 1st premolars extraction before bonding followed by leveling \& alignment.
40759684|NCT05639725|PROCEDURE|SURGICAL|Surgery:After leveling and alignment,placement of zygomatic miniplates in bilaterally
40759685|NCT01813227|DRUG|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
40786431|NCT01585402|DRUG|Etidronate|Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
40949419|NCT06201663|DRUG|Romiplostim|Weekly subcutaneous injections
40949420|NCT00922233|DRUG|levonorgestrel|oral contraceptive pills
40949421|NCT00661973|DRUG|budesonide|inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
40949422|NCT01611610|OTHER|Functional tests|"The ambulant patients will perform~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Timed tests (time to rise from the floor,...)~* 6 minute walk test~* PedsQL - neuromuscular module"
41133578|NCT04235205|DRUG|Elobixibat 10mg + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks
40949423|NCT01611610|OTHER|Functional tests|"The non-ambulant patients will perform:~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Upper Limb Functional Items~* Egen Klassifikation 2 questionnaire - EK2~* PedsQL questionnaire - neuromuscular module"
41288120|NCT01137630|DRUG|Placebo|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
41288121|NCT03836638|DRUG|30 Units of botulinum toxin|30 Units of botulinum toxin to upper face
41288122|NCT03836638|DRUG|50 Units of botulinum toxin|50 Units of botulinum toxin to upper face
41288123|NCT03356132|DEVICE|Silimed® Textured Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® Textured Silicone Gel-Filled Breast Implant.
41288124|NCT03356132|DEVICE|Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® silicone gel-filled breast implants with polyurethane foam covered surface.
41453995|NCT01085981|DRUG|arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%|On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
41453996|NCT01085981|DRUG|Topical study cream|One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
40759686|NCT01813227|DRUG|Rituximab|"If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s)."
40759687|NCT01813227|DRUG|Dexamethasone|"If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter."
40759688|NCT00658073|PROCEDURE|Kidney transplantation with MSCs infusion|Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
40759689|NCT00658073|PROCEDURE|kidney transplantation without MSC infusion|kidney transplantation with standard immunosuppressive treatment regime
40759690|NCT03611361|DEVICE|SpectralMD DeepView Wound Imaging System 2.0|The DeepView is an imaging device which simultaneously performs multispectral imaging (MSI) measurements across the visible and infrared spectrum to obtain a quantitative tissue viability assessment. These optical measurements are integrated using a machine learning (ML) algorithm to categorize microvascular blood flow and provide a quantitative assessment for selection of tissue healing.
40759691|NCT06292507|OTHER|MYOFASCIAL STRETCH|Group A 10 participants will receive Myofascial Stretching
40759692|NCT06292507|OTHER|CONTRACT-RELAX TECHNIQUE|group B 10 participants will receive Control-Relax Stretching Technique.
40759693|NCT00833729|DRUG|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
40949424|NCT02165371|BEHAVIORAL|Sinovuyo Caring Families Programme|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
41288125|NCT05347654|OTHER|Local treatment with silver sulphadiazine only|Local treatment with silver sulphadiazine and tulle from day 0 to day 8 (included). From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
40759694|NCT00648713|DRUG|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fed
40759695|NCT00648713|DRUG|Lamisil® Tablets 250 mg|250mg, single dose fed
40759696|NCT01505803|DIETARY_SUPPLEMENT|Zinc supplements|Participants will receive 40 mg of zinc each day for 12 weeks.
40759697|NCT01505803|DIETARY_SUPPLEMENT|Omega 3 supplements|Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
40759698|NCT01505803|DIETARY_SUPPLEMENT|Placebo supplements|Participants will receive placebo supplements each day for 12 weeks.
40949425|NCT03316365|OTHER|Rhythmic Auditory Stimulation (RAS)|The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
40949426|NCT04903522|BEHAVIORAL|Baroque music listening|"Patients will listen to a 30-minute musical path of baroque pieces. Before and after this, anxiety, depression and consciousness fluidity will be evaluated thanks to different questionnaires"
40949427|NCT00590889|DEVICE|Artificial Mechanical Heart Valve|Both arms used market released mechanical heart valves in accordance with approved labeling
40990511|NCT03809442|DRUG|Ropivacaine + Ketamine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).
41133579|NCT04235205|DRUG|Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
40759699|NCT06159582|BEHAVIORAL|eSTEP|eSTEP (Electronic Support to Engage with PrEP) is an mHealth intervention to promote engagement on the full PrEP care continuum and is tailored to the unique needs of GBMSM and TW. eSTEP is a mobile app (eSTEP) intervention with interactive components delivered before in-person HIV testing and PrEP initiation visit and interactive components delivered after PrEP is initiated.
40759700|NCT06159582|BEHAVIORAL|Usual Care|Usual HIV testing and PrEP clinical care
40759701|NCT04248153|DRUG|BR55|BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg
40990512|NCT03809442|DRUG|Ropivacaine + Tramadol|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).
41133580|NCT04235205|DRUG|Elobixibat placebo + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks
41288126|NCT05347654|OTHER|Local treatment with silver sulphadiazine followed by URGOCLEAN® dressing|Local treatment of silver sulphadiazine with tulle from day 0 to day 4, then with URGOCLEAN® dressing every 48h from day 5 to day 8. From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
41288127|NCT06512090|DIETARY_SUPPLEMENT|LGI steam bread|"LGI Steam bread called Mangusteam bread"
41288128|NCT06512090|DIETARY_SUPPLEMENT|Diabetic diet|the calorie intake of Diabetic diet will by recommended by nutritionist
41288129|NCT02473653|BIOLOGICAL|HER-2/neu Pulsed DC1 vaccine|There will be no exceptions to eligibility, contraindicated treatment/therapies/interventions or safety tests.
41288130|NCT06193083|OTHER|Semi-directed individual interviews|Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)
40759702|NCT01254539|PROCEDURE|Laminectomy and bone marrow stem cells transplantation|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation"
40759703|NCT01254539|PROCEDURE|Intrathecal infusion of autologous bone marrow stem cells|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells."
41133581|NCT04301999|PROCEDURE|Photodynamic therapy|The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visualradiography. The dilation catheter was then withdrawn to leavethe PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s.
41133582|NCT04301999|PROCEDURE|radiofrequency ablation|an RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
41133583|NCT05483088|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected for analysis with the NEPHROCLEAR CCL14 Test
41133584|NCT01229384|DEVICE|Positive Airway Pressure nebulization|Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure
41133585|NCT01229384|DEVICE|Standard passive nebulization of respiratory medications|Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
41133586|NCT04224415|DRUG|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
41133587|NCT03393559|PROCEDURE|leg elevation|Patients' leg will be raised by a pillow under both legs and the hip and knee joints will be flexed 45 degrees to position both knees at the heart level.
40759704|NCT01254539|PROCEDURE|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
40759705|NCT05118529|OTHER|Routine care|Mobilization to chair
40759706|NCT00873886|DRUG|Oseltamivir (Tamiflu)|"The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected."
41133588|NCT03978728|DEVICE|Extra-corporeal membrane oxygenation|Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.
41133589|NCT04790331|DRUG|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
41453997|NCT01085981|DRUG|GRAS cream|1 gram of active cream will be applied by nurse then 10 minutes later clitoral blood flow will be assessed by doppler studies see protocol
41453998|NCT00629057|BIOLOGICAL|MVA-BN-PRO|1x10e8 TCID50 q 4 wks x 6
40759707|NCT00873886|PROCEDURE|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
40759708|NCT05109195|OTHER|Standard of Care (SOC)|Participants will not receive any intervention as a part of this study. Participants will receive SOC treatment.
40759709|NCT03989479|BEHAVIORAL|Brushing demonstration using T shaped toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
40949428|NCT04079010|PROCEDURE|BFR|Blood flow restriction (BFR) training is a non-invasive technique that uses wraps, bands, or inflated blood pressure cuffs to change blood flow within targeted muscles. Occlusion pressure of the femoral artery will be determine before each training session using the Delfi Personalize Tourniquet System for Blood Flow Restriction (2.0) which has embedded ultrasound technology to continually measure the blood flow and with auto-adjust the pressure. The target percent of occlusion is 50% of total blood flow while completed a prescribed resistance training regimen 4 times per week.
40949429|NCT04079010|DIETARY_SUPPLEMENT|Arginine|"The BFR+Arg group will consume Arginine supplement daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg L-Arginine (ARG; Kyowa). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
40949430|NCT04079010|DIETARY_SUPPLEMENT|Placebo Pill|"The CON and BFR groups will consume placebo pill daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg Maltodextrin placebo (PLA; MALTRIN-M100; Grain Processing Corporation; Muscantine, IA). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
40949431|NCT04769661|DIAGNOSTIC_TEST|Cytokines|Doing cord blood cytokines level in preterm infants
40949432|NCT05108844|PROCEDURE|Videocapsule endoscopy|Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
40949433|NCT02837068|DEVICE|Wheelchair handrail compensator|Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
40949434|NCT02837068|DEVICE|Ordinary wheelchair|Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
40949435|NCT00769522|BIOLOGICAL|Rituximab|"cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d"
40949436|NCT00769522|DRUG|Bendamustine|cycle 1-6: 90mg/m² i.v., day 1-2, q28d
40949437|NCT00769522|DRUG|Cyclophosphamide|cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
40949438|NCT00769522|DRUG|Fludarabine|cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
40949439|NCT05350306|DEVICE|Chincup|Patients will receive an individual fabricated bonded bite block and occipital chincup. A 400-500g/side retroactive force will be applied in the direction of the condyles. Patients or panthers will be instructed to wear the appliance /14-16/ hours a day.
40949440|NCT05350306|OTHER|Control group|The changes in condyle-mandibular volumes and superficial areas and relative positions of the condyles and glenoid fossa will be calculated after 16 months of observation.
40949441|NCT04110587|BIOLOGICAL|Hyaluronic Acid|1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .
40949442|NCT04110587|PROCEDURE|Temporomandibular Joint Arthroscopy|Lysis and Lavage
40949443|NCT04110587|DRUG|Antibiotic therapy|Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
40949444|NCT04110587|DRUG|corticosteroid|Dexamethasone, 4 mg I.V. (Intraoperative)
40949445|NCT04110587|DRUG|Antiinflammatories|Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
40949446|NCT04110587|DRUG|Analgesics|Metamizol 575 mg / 8h by mouth (Post-operatively)
40949447|NCT04110587|OTHER|Exercise program|Home exercise program
40949448|NCT04223973|DEVICE|Medtrum A7+ insulin Pump|Use of the Medtrum pump during 3 months in combination with a CGM (Continuous Glucose Measurement)
40759710|NCT03989479|BEHAVIORAL|Brushing demonstration using conventional toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
40949449|NCT04223973|BIOLOGICAL|Lab A1C|Measure of Lab A1C at baseline and end of study
40949450|NCT04498312|OTHER|Extracorporeal shock wave|The participant was placed into supine lying position then the head of the shock wave was applied on the anterior or posterior aspect of the thigh which was scanned with 2000 shots for both horizontal direction and vertical direction. The period of each session was 15 minutes, 2 times/week for 4 weeks
40949451|NCT04127942|PROCEDURE|platelet-rich plasma injection therapy of TMD|The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
40949452|NCT05734989|DIAGNOSTIC_TEST|BP|Blood pressure measurements and HbA1c tests will be conducted to identify participants with or at risk for high blood pressure and/or Type 2 Diabetes. Those identified will be referred to PCP for follow up/treatment.
40949453|NCT05734989|DIAGNOSTIC_TEST|HbA1c|HbA1c will screen to identify patients with Type 2 diabetes
40949454|NCT05734989|BEHAVIORAL|PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD|Guidelines will be developed and provided to PCPs to use with their Hispanic/Latinx patients with or at risk for CKD.
41453999|NCT00629057|BIOLOGICAL|MVA-BN-PRO|2 x 10e8 TCID50 q 4 wks x 6
41454000|NCT00629057|BIOLOGICAL|MVA-BN-PRO|4 x 10e8 TCID50 q 4 wks x 6
40759711|NCT00626951|DEVICE|LMA Supreme|Extraglottic airway devices
40759712|NCT00626951|DEVICE|LMA ProSeal|
40759713|NCT01080547|PROCEDURE|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
40759714|NCT01080547|DRUG|XELOX Chemotherapy|XELOX chemotherapy
40949455|NCT03844607|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
40949456|NCT03844607|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
41454001|NCT03148054|DEVICE|Computer Tomography and Endoscopy|"Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).~Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system."
41454002|NCT05215873|DRUG|Misoprostol|a synthetic prostaglandin E1 analogue
40759715|NCT01080547|DRUG|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
40759716|NCT01080547|OTHER|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
40759717|NCT01080547|OTHER|Conventional Perioperative Treatment|Conventional treatment during perioperation period
40759718|NCT01080547|PROCEDURE|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
40759719|NCT04698447|DIETARY_SUPPLEMENT|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS|20 eligible subjects with the metabolic syndrome (MetS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months and as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
40759720|NCT04698447|DIETARY_SUPPLEMENT|Placebo (without any active ingredients)|20 eligible subjects with the metabolic syndrome will take placebo in a spray-dried formulation (without any active ingredients) directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
40759721|NCT04698447|DIETARY_SUPPLEMENT|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS|20 eligible healthy subjects (HS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months, maintained at fixed doses for the entire study.
40759722|NCT04560530|RADIATION|Non-enhanced CT scan of the chest|Non-enhanced CT scan of the chest with multi-slice CT scan machine.
40759723|NCT01992939|OTHER|Specialized pulse oximetry probe with external heat pack|Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.
40759724|NCT01992939|OTHER|Standard of Care Pulse Oximetry Probe|Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
40759725|NCT02324907|DEVICE|Procedure/Surgery|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
40759726|NCT02096887|BEHAVIORAL|Patient Education|"Patient Education using the following two instruments:~1. Framingham Risk Score calculator:~2. Know your numbers patient booklet"
40759727|NCT05855993|OTHER|Nerve Glide Exercise with Ultra Sound|A brief demonstration will be given to perform the nerve glides exercises to both group. The duration of exercise programmed is 15 minutes every 3 to 5 times per day for 4 weeks. Group A will perform exercise with ultrasound
40759728|NCT05855993|OTHER|Nerve Glide Exercise without Ultra Sound|Group B will perform exercise for 10 minutes every 3 to 5 times per day without ultrasound.
40759729|NCT05504746|DRUG|SHEN26 capsule|"Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used."
40759730|NCT05504746|DRUG|SHEN26 capsule|Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
40759731|NCT05504746|DRUG|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose."
40949457|NCT00834678|DRUG|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
40949458|NCT00834678|DRUG|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
40949459|NCT00834678|DRUG|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
41288131|NCT06193083|OTHER|The self-administered questionnaires, rPATD and BMQ|"rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.~This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal)~BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .~The Beliefs about Medicine Questionnaire (BMQ) is an 18-item self-administered questionnaire designed to explore patient perceptions of medicine. It has been validated in French and is free to use.~It comprises 10 items relating to specific beliefs about prescribed treatments:~A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief."
41288132|NCT06193083|OTHER|The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)|"FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf )~Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy :~Functional literacy: basic reading and writing skills sufficient to function effectively in everyday situations Communicative or interactive literacy: more advanced cognitive and literacy skills that, combined with social skills, can be used to actively participate in everyday activities, extract information and meanings from different forms of communication, and apply new information to changing circumstances Critical literacy: more advanced cognitive skills which, combined with social skills, can be applied to the critical analysis of information and the use of that information to exercise greater control over life events and situations"
41288133|NCT00118170|DRUG|sorafenib tosylate|Given orally
41288134|NCT00118170|OTHER|pharmacological study|Correlative studies
41288135|NCT06510335|OTHER|Lavender essential oil-based product system|"Participants used the study products in a sequential, additive manner approximately 30-60 minutes before bedtime each night for 6 weeks. Usage consists of the following:~* 20 drops of essential oil blend in approximately 250 mL of water in a diffuser, which operated for 8 hours at nighttime.~* 3 x 6 swipes of the topical stick on the upper chest area, and 2 x 3 swipes on the inside of each wrist for topical application.~* 2 capsules of the dietary supplement.~Participants used the essential oil blend alone for 1 week, then added the topical stick for another 1 week. Finally, participants used the essential oil blend, the topical stick, and the dietary supplement for four weeks."
41288136|NCT05285852|OTHER|Dry Needling|Dry needling technique is maneuvered by different skilled health practitioners aiming to reduce central sensitization, i.e., the hypersensitivity to pain of the central nervous system. It is also apprehended to reduce the local and referred pain, and improve the muscle activation patterns leading to improved range of motion.
41288137|NCT05285852|OTHER|Placebo Dry Needling|Placebo Dry Needling only causes a pricking sensation
41288138|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 0: 2.5 x10\^5 CAR-20/19-T cells/kg (starting dose level)"
41288139|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 1: 7.5 x10\^5 CAR-20/19-T cells/kg"
41288140|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 2: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b Expansion Dose Level: 2.5 x 10\^6 cells/kg (single infusion)"
41288141|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.
41454003|NCT05215873|DRUG|Syntocinon|synthetic oxytocin
41454004|NCT04235660|RADIATION|Yttrium-90 Radiation Segmentectomy|This therapy arm involves two separate steps, a planning/mapping arteriogram and a therapy delivery. The planning arteriogram will be performed to confirm arterial anatomy is acceptable for RS (≤2 segment delivery) and that lung shunting is not too high to preclude treatment with RS. Once confirmed, patients will return for RS (within 45 days of mapping). Dose will be calculated based off the desired treatment volume using pre-treatment cross-sectional imaging. The desired segmental dose will be calculated to be ≥ 200Gy. RS will be performed by one of three separate interventional radiologists with experience in radioembolization. Actual administered activity and location of dose administration will be recorded.
41454005|NCT04235660|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be delivered with linear accelerator-based photon beams with either fixed angle non- coplanar fields or dynamic arcs. An internal target volume (ITV) will be generated to account for tumor movement during breathing cycle. Finally, a planning target volume (PTV) will be an expansion of 3- 5mm from the ITV. For Child Pugh A patients, prescription dose will either be 5000cGy in 5 fractions delivered every other day or 4800cGy in 3 fractions delivered twice weekly. For Child Pugh B patients, prescription dose of 4000cGy in 5 fractions delivered every other day. Inverse planning will be used. 95% of the PTV or more will receive at least 100% of the prescription dose. Normal tissue dose constraints for each dose level will be respected with acceptable deviations permitted as outlined in appendix VII. Patients will be seen at least once per week by a clinician to grade toxicities, with on- treatment labs (CBC, CMP, INR) each week.
40949460|NCT03761667|OTHER|Endoscopy using Narrow band imaging|Inspection of resection margin of SSA/P for the evaluation of complete resection or the presence of remnant lesion using NBI method
40949461|NCT05972473|DRUG|Aflibercept Ophthalmic|2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W).
40949462|NCT05972473|BIOLOGICAL|IBI302|8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol.
40949463|NCT02329821|OTHER|hartmann solution|hartmann solution infusion in patients for hepatic resection
40949464|NCT01033461|DIETARY_SUPPLEMENT|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
40759732|NCT05504746|DRUG|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days."
40759733|NCT06571292|DEVICE|Intensive training with robotic exoskeleton for upper limbs|Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
40759734|NCT06571292|DEVICE|Task specific training|Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
40949465|NCT01033461|DIETARY_SUPPLEMENT|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
40759735|NCT04008069|DRUG|Sarilumab|Sarilumab 200 mg administered subcutaneously
40759736|NCT04008069|DRUG|Placebo|Placebo administered subcutaneously
40759737|NCT05900349|OTHER|Carbohydrate mouth rinsing|the carbohydrate solution was prepared by dissolving 6.4 g of colorless and odorless maltodextrin in 93.6 mL of water; the mixtures were then adjusted to a 6.4% maltodextrin solution for the participants to rinse their mouths for 20 seconds
40759738|NCT05900349|OTHER|200 mg caffeine gum|Chewing caffeinated gum for 20 minutes
40949466|NCT01033461|OTHER|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
40949467|NCT02796703|DIETARY_SUPPLEMENT|Heat Inactivated probiotics|Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
41288142|NCT05645666|BEHAVIORAL|Well-being therapy|Well-being therapy is a short-term, organized and problem-oriented treatment program that is based on Riff's psychological well-being model. Its purpose is to help patient in order to improve His/her functions in six dimensions; personal growth, environmental mastery, purposefulness of life, and autonomy, self-acceptance and positive relationships with others Therapists help patients find well-being experiences in their present and past lives and pay attention to these experiences, no matter how small or short they are.
40949468|NCT02796703|DIETARY_SUPPLEMENT|Placebo|2 cc of milk will be given to control group
40949469|NCT06157255|DRUG|AZD4604 Inhalation Powder, 1 mg|3 mg dose, inhaled, fasted
40949470|NCT06157255|DRUG|[14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)|30 μg, intravenous, fasted
41288143|NCT03213639|DRUG|Esomeprazole 40 mg Oral Tablet|once daily oral tablets
41288144|NCT03213639|DRUG|Placebo Oral Tablet|once daily oral tablets
41288145|NCT05293938|DRUG|Obeticholic Acid 5 MG|once daily, oral administration
40759739|NCT06571968|DEVICE|fully guided stent|The guides were designed with metal sleeves for guided drilling and guided implant placement and additional guide sleeves for the stabilization of the template by fixation screws. All surgical procedures with drills were done thiough the stent.
40759740|NCT00050011|DRUG|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
40759741|NCT00050011|DRUG|Letrozole|Participants received Letrozole 2.5 mg daily.
40759742|NCT02172651|DRUG|Vitamin D3|Take five 10,000 IU capsules (total 50,000 IU) once daily for 7 days, followed by one 10,000 IU capsule once daily until surgery.
40759743|NCT02172651|DRUG|Placebo|Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
40759744|NCT05957094|DRUG|Pharmacological agent: Citalopram|Participants will be given 40 mg in capsule form, which is a normal clinical dose.
40759745|NCT05957094|OTHER|Placebo|Participants will ingest a placebo (sugar pill) that is identical in appearance to the drug condition.
40759746|NCT01628770|DRUG|Iron isomaltoside 1000|Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
40759747|NCT01628770|DRUG|Ferrous sulphate|200mg twice daily
40759748|NCT00812539|OTHER|"Subject/Provider Portal Diabetes Connected Health tool - Deluxe"|"Subjects enrolled into the Deluxeintervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal (Diabetes Connected Health tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system). Subjects with new high or low readings will be flagged. Providers can initiate messages to subjects regarding symptoms or medications. A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading."
40759749|NCT00812539|OTHER|"Subject only Portal Diabetes Connected Health Tool Basic"|"Patients enrolled in the Diabetes Connect Basic intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the Diabetes Connected Health tool) where they can view their readings in a less detailed/journal fashion. No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management. Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system."
40759750|NCT04619628|BIOLOGICAL|COVI-VAC|intranasal, live attenuated vaccine against SARS-CoV-2
40759751|NCT04619628|OTHER|Placebo|normal saline
40759752|NCT05089084|DRUG|Plozasiran|ARO-APOC3 injection
40759753|NCT05089084|DRUG|Placebo|sterile normal saline (0.9% NaCl)
40759754|NCT02993666|DEVICE|Bair Hugger|forced air warming with Bair Hugger air warmer
40759755|NCT05848089|BEHAVIORAL|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
41288146|NCT05293938|DRUG|Obeticholic Acid 10 MG|once daily, oral administration
41288147|NCT05293938|DRUG|Standard of Care: UDCA|No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record.
41288148|NCT03865342|BEHAVIORAL|Noom Coach DPP|Subjects receiving the smartphone app will receive the DPP core curriculum for 16 weeks and then the post-core curriculum for 36 weeks through the app. The Noom mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve DPP goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the DPP group interaction through the application.
41288149|NCT00069121|DRUG|Capecitabine|1000 milligrams per square metre of body surface area (mg/m\^2) orally twice daily on days 1-15 of each 3-week cycle.
41288150|NCT00069121|DRUG|Oxaliplatin|130 mg/m\^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
40949471|NCT06157255|DRUG|[14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)|4 mg, oral, fasted
40949472|NCT01892865|OTHER|Scheduling using historical means|Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time
40949473|NCT01892865|OTHER|Scheduling using regression modeling system|A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
40949474|NCT04628741|BEHAVIORAL|Dynamic Coaching Model|This is a behavioral intervention which includes metacognitive strategy training and personalized strategy and external aid use training.
40949475|NCT04628741|BEHAVIORAL|Apprenticeship Approach|This is a behavioral intervention which includes explicit education about traumatic brain injury, its symptoms, and individuals who may provide assistance post-injury, metacognitive strategy training and personalized strategy and external aid use training.
40949476|NCT01444131|DRUG|Varenicline, Nicotine Patch|active nicotine patches added to varenicline.
40949477|NCT01444131|DRUG|Varenicline and Placebo Patch|placebo nicotine patches added to varenicline.
40949478|NCT00736814|DRUG|carboplatin|Given intravenously
40949479|NCT00736814|DRUG|docetaxel|Given intravenously
40949480|NCT00736814|DRUG|gemcitabine hydrochloride|Given intravenously
40949481|NCT00736814|DRUG|vinorelbine tartrate|Given intravenously
40949482|NCT04040946|DIAGNOSTIC_TEST|MIBI scintigraphy|Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET
40949483|NCT04040946|DIAGNOSTIC_TEST|F18-choline PET|Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy
40949484|NCT03628794|DEVICE|D-SCAN|"Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks"
40949485|NCT02242188|DRUG|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
40949486|NCT02242188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (packed in identical sachets as active products)
40949487|NCT03498066|DRUG|Beta-blockers withdrawal|withdrawal of all type of betablockers
40949488|NCT03498066|DRUG|Continuation of the Betablockers (βB) treatment|Use Betablockers treatment
40949489|NCT01473043|DRUG|Axitinib|5mg twice daily \[BD\] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
40949490|NCT04055961|DEVICE|Atrial Fibrillation Ablation|A procedure used to treat an irregular heart rhythm (arrhythmia)
40949491|NCT05875571|DRUG|Ketorolac|Patients will get IV ketorolac during IUD placement under sedation
40949492|NCT05875571|DRUG|Placebo|Patients will get IV placebo during IUD placement under sedation
40949493|NCT03861650|OTHER|Bone Marrow Aspirate Concentrate|A rich MSCs prepration made by centrifugation and concentration of aspirated bone marrow
40949494|NCT03861650|OTHER|Saline|Physiological saline is added in control group to act as placebo
40949495|NCT06375512|BIOLOGICAL|HZ Vaccine (IN001)|Formulation for injection
40759756|NCT05848089|BEHAVIORAL|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
40759757|NCT05848089|BEHAVIORAL|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
40759758|NCT05187988|PROCEDURE|supraclavicular brachial plexus block|group will receive brachial plexus block above clavicle,Injection of anaesthetic will be done in brachial plexus around subclavian artery
40949496|NCT06375512|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) for injection
40949497|NCT06375512|BIOLOGICAL|Shingrix|Sterile suspension for injection
40949498|NCT00646074|BEHAVIORAL|Self-Care Talk|6 conversational sessions
40949499|NCT03898258|OTHER|Qualiveen full version|Qualiveen full version questionnaire with 40 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
40949500|NCT03898258|OTHER|Qualiveen short-form|Qualiveen short-form questionnaire with 8 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
40949501|NCT03400995|DRUG|AK0529|A solution containing 300 mg radiolabelled AK0529.
40759759|NCT05187988|PROCEDURE|Retroclavicular brachial plexus block|group will receive brachial plexus block inferior to the clavicle,injection of anaesthetic will be done around axillary artery
40949502|NCT01199172|BEHAVIORAL|voice hygiene|subjects will receive voice hygiene training
40949503|NCT01199172|BEHAVIORAL|VH + VP|subjects will be trained in voice hygiene and voice production training
40949504|NCT03882112|DRUG|HIP1601 40mg|Single dosing of HIP1601 40mg, orally
40949505|NCT05016219|DEVICE|Circadian-Effective Light|Narrowband blue light
40949506|NCT05016219|DEVICE|Rhythmic Light|40 hertz (Hz) flicker
41288151|NCT00069121|DRUG|Leucovorin (LV)|Administered by one of two regimens, as specified in the arm description.
41288152|NCT00069121|DRUG|5-Fluorouracil (5-FU)|Administered by one of two regimens, as specified in the arm description.
40759760|NCT02214212|DEVICE|Bright White Light (BWL)|The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
40759761|NCT02214212|DEVICE|Red Light (RL)|The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
40949507|NCT05016219|DEVICE|Placebo Light|Narrowband red light
40949508|NCT05016219|DEVICE|Placebo Rhythmic Light|Random flicker for placebo rhythmic effect
40949509|NCT04622293|DRUG|Solriamfetol Oral Tablet [Sunosi]|Solriamfetol will be given to those participants placed in the experimental group, and given at three possible dosages ( 37.5 mg, 75 mg, and 150 mg). Solriamfetol is already FDA approved for treatment of excessive daytime sleepiness, and has been found safe to use. In this study, we are determining if solriamfetol can also be used to treat chronic fatigue syndrome.
40949510|NCT04622293|DRUG|Placebo|A placebo encapsulated to look the same as the experimental drug will be given to the control group.
40949511|NCT00532324|OTHER|CA-MRSA Decolonization|In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
41133590|NCT04790331|DRUG|Diltiazem|"Diltiazem is a calcium channel blocker. It works by relaxing the muscles of your heart and blood vessels.~Diltiazem is used to treat hypertension and angina."
41133591|NCT04790331|DRUG|Placebo|Placebo oral tablet
41133592|NCT05305391|OTHER|Dietary intervention|The arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.
41133593|NCT04802681|DEVICE|FFR-measurement with different pressure guidewires|Measuring FFR with different pressure guidewires
41288153|NCT03591952|PROCEDURE|Suction-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
41288154|NCT03591952|PROCEDURE|Gravity-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
41288155|NCT03694522|BIOLOGICAL|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
41288156|NCT03694522|DRUG|Placebo|Administered by intravenous infusion over approximately 30 minutes
41288157|NCT03694522|DRUG|Modified FOLFOX6|"mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours"
41288158|NCT02648230|DEVICE|St. Jude Medical Pressure Wire|FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time
41288159|NCT02648230|DEVICE|ACIST Navvus Microcatheter|FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
40759762|NCT00592280|DRUG|Two-Layer Method pancreas preservation system drug|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
40949512|NCT04300231|DRUG|epidural bupivacaine 0.05%|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
41133594|NCT04703907|OTHER|Auricular stimulation|"Auricular acupuncture-like stimulation (percutaneous sensory stimulation of cranial nerves)"
41288160|NCT04336176|DEVICE|PulseFlow DF boot|Offloading boot
41288161|NCT04336176|DEVICE|Usual standard of care|Usual standard of care (offloading device)
41288162|NCT04336176|DEVICE|Sham|Sham shoe (closest to barefoot or baseline pressures)
40949513|NCT04300231|DRUG|Liposomal bupivacaine|20 ml
40949514|NCT04300231|DRUG|bupivacaine 0.125%|40 mL
40949515|NCT04300231|DRUG|bupivacaine 0.5%|60 mL
40949516|NCT04300231|DRUG|/hydromorphone 0.05mg/ml|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
40949517|NCT04300231|DRUG|injectable saline|40 mL
40949518|NCT05255211|DRUG|Remimazolam tosilate|IV before procedure
40949519|NCT05255211|DRUG|Propofol|IV before procedure
41133595|NCT04198467|BIOLOGICAL|Platelet rich plasma|Platelet rich plasma : 100 billion platelets in 10 ml of plasma(PRP) administered intra-articular
41133596|NCT04198467|DRUG|Hyaluronic Acid|Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
41133597|NCT02268708|PROCEDURE|Oncological pulmonary resection|Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care
41133598|NCT01752959|DRUG|Remifentanil|0.1-0.3 micg/kg/min Remifentanil iv infusion
41133599|NCT01752959|DRUG|Esmolol|500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
41133600|NCT02599025|DEVICE|Innowalk cycling system|Innowalk is a unique, motorized medical device
41288163|NCT04316481|DEVICE|AngelMed Guardian System|The AngelMed Guardian System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events. The Guardian System is indicated as an adjunct to patient recognized symptoms.
41288164|NCT05082870|BEHAVIORAL|Supportive-expressive group therapy (SEGT)|The SEGT approach fosters mutual support, promotes openness and emotional expression. SEGT will be delivered and co-facilitated by a psychiatrist and an allied healthcare professional. It is a 6-module program held over a 3-week period (approximately 2 hour sessions X 2 week) that is framed within social cognitive theory, whereby resilience to adversity (limb loss in this instance) relies on personal enablement.
40786432|NCT01585402|DEVICE|MRI Scan|Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the high degree of calcification is precluding that evaluation by CT.
41133601|NCT02599025|DEVICE|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
40949520|NCT05255211|OTHER|saline solution|IV before procedure
41133602|NCT04926519|OTHER|Type of periodontal treatment|Identify factors that contribute to disease recurrence due to periodontal classification and periodontal treatment. One group have got the diagnosis aggressive periodontitis at baseline and the other group chronic periodontitis. Since 2018 we have the classification system with stage and grade.
41133603|NCT04639999|OTHER|Echocardiography|LV vortex flow in Echocardiography
41133604|NCT04203966|DIAGNOSTIC_TEST|12-item General Health Questionnaire (GHQ-12)|Structured validated screening tools to assess for the presence of CMDs, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
41133605|NCT04203966|DIAGNOSTIC_TEST|WHO AUDIT (World Health Organization- Alcohol Use Disorders Inventory Tool)|Structured validated screening tools to assess for the presence of alcohol use disorders, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
41288165|NCT02557503|DRUG|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
41288166|NCT02597595|OTHER|spirulina|oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
41133606|NCT02131922|PROCEDURE|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
40759763|NCT00592280|DEVICE|Two-Layer Method pancreas preservation system device|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
40759764|NCT01950039|DRUG|Betaine|Betaine or placebo administered orally in divided doses over 12 weeks
40759765|NCT01950039|DRUG|Placebo|Placebo administered orally in divided doses over 3 months
40759766|NCT05715723|DRUG|Reamberin|Reamberin® in the average daily dose of 10 ml/kg daily
41288167|NCT01804855|BEHAVIORAL|W82GO|MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
41288168|NCT01804855|DEVICE|smartphone application|Behavior change smartphone application for adolescents aiming to reduce obesity
41288169|NCT04125745|DRUG|CXA-10|Each subject will receive oral CXA-10 at the dose of 300 mg once daily for 12 weeks
41288170|NCT01916577|DRUG|Plerixafor mobilization of autologous CD117 stem cells|Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
41288171|NCT04372355|DRUG|WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.
41288172|NCT02405312|BEHAVIORAL|advance care planning|patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
41288173|NCT04723537|DRUG|Part A: Upamostat 200 mg|1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
41288174|NCT04723537|DRUG|Part A: Upamostat 400 mg|2 capsules, each capsule comprising 200 mg of upamostat
41288175|NCT04723537|DRUG|Part A and B: Placebo|1 or 2 capsules, each capsule a matching placebo
41288176|NCT04723537|DRUG|Part B: Upamostat 200 or 400 mg|"Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days."
41288177|NCT00936949|PROCEDURE|surgical approach|Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
41288178|NCT00936949|PROCEDURE|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
41288179|NCT00414440|DRUG|Placebo|placebo comparator
41288180|NCT00414440|DRUG|Everolimus|experimental
40759767|NCT00801255|DRUG|RO5024048|500mg po bid/100mg po q8h for 7 days
41288181|NCT06217159|DIETARY_SUPPLEMENT|Poikilocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will wear a specialized face mask and breathe room air for 60 min. The face mask will be attached to an automated gas-blender system; however, only room air will be delivered.
41288182|NCT06217159|DIETARY_SUPPLEMENT|Normocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will be outfitted with a specialized face mask and breathe air with a slightly higher concentration of CO2 to maintain PetCO2 to resting baseline values for 60 min. Gas will be continuously delivered by an automated gas-blender system.
41288183|NCT04068389|PROCEDURE|Pulmonary Tissue Collection|Pulmonary Tissue Collection
40759768|NCT00801255|DRUG|danoprevir|500mg po bid/100mg po q8h for 14 days
40759769|NCT00801255|DRUG|danoprevir|1000mg po bid/100mg po q8h for 14 days\\n500mg po bid/200mg po q8h for 14 days
40759770|NCT00801255|DRUG|danoprevir|1000mg po bid/200mg po q8h for 14 days
40759771|NCT00801255|DRUG|danoprevir|1000mg/600mg po twice daily for 14 days
40759772|NCT00801255|DRUG|danoprevir|1000mg/900mg po twice daily for 14 days
41133607|NCT02131922|PROCEDURE|Dental Hygienization Treatment|
41288184|NCT01924715|BEHAVIORAL|ISTDP|An emotion focused brief psychotherapy format.
41288185|NCT03952130|DRUG|LY900014|Administered SC
41288186|NCT03952130|DRUG|Insulin Lispro|Administered SC
41288187|NCT03952130|DRUG|Insulin Glargine|Administered SC
41288188|NCT03952130|DRUG|Insulin Degludec|Administered SC
41288189|NCT03901378|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab in combination with cisplatin or carboplatin and etoposide in first line metastatic or unresectable high grade neuroendocrine carcinoma:
40949521|NCT00901407|DRUG|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
41133608|NCT02131922|DRUG|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
41288190|NCT00950417|DRUG|Nimotuzumab|
41288191|NCT05561621|OTHER|Voice analysis|Voice analysis
41288192|NCT04950738|OTHER|pess tack acupuncture|Patients enrolled will receive intervention in a form of either press tack acupuncture needles or press tack placebos. Three total intervention sessions will be taken place on day 1,3,5 from patient's enrolment. Needles/placebos skin withdrawal will be done 48 hours after treatment by an acupuncture doctor or by a trained ICU nurne. In cases when a patient will be transferred from the ICU, the 3 study interventions will be continued in the new ward.
41288193|NCT04950738|OTHER|pess tack placebo|pess tack stickers without a needle
41288194|NCT01634243|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
41288195|NCT05863429|BIOLOGICAL|Taking biological samples (blood) and keeping records with phone calls|Within the scope of the study, no intervention will be made to the participants. According to the vaccination program implemented in Turkey, subjects who apply to the study centers for TURKOVAC vaccine will be invited to the study.
41288196|NCT01429649|PROCEDURE|cryotherapy or radiofrequency ablation|Cryoablation or Radiofrequency ablation is performed under CT image guidance.
41288197|NCT01213810|BIOLOGICAL|Zostavax|Biological/Vaccine
40759773|NCT06291727|DRUG|Mepivacaine|Patients will be administered a standard dose of mepivacaine 1.5% (4.5ml, 67.5mg) for total knee arthroplasty prior to surgery
40759774|NCT06291727|DRUG|Bupivacaine|Patients will be administered a standard dose of 0.75% hyperbaric bupivacaine (1.4ml, 10.5mg) for total knee arthroplasty prior to surgery
40759775|NCT00458705|DRUG|bortezomib|
40759776|NCT00458705|DRUG|dexamethasone|
41288198|NCT02511080|DEVICE|Spot-On|use of active hot measures
41288199|NCT02968030|OTHER|Muscle strength|"Strength training The strength training for lower limbs muscles occurred twice a week, 40 minutes per session for eight consecutive weeks.~n the first two weeks of training, each elderly performed the exercises with 50% of its load defined in 8RM test, increasing to 60 and 70% of the load in the third and fourth subsequent weeks, respectively. After this period, a new evaluation by 8RM strength test was conducted, adopting the fifth and sixth weeks of training 50% of value of the new load defined in 8RM test and to finalize the program in seventh and eighth weeks applied, respectively, 60% and 70% of the new charge. The exercises were performed for the quadriceps, hamstrings, muscles adductor and abductor hip."
41288200|NCT00027131|BIOLOGICAL|Heat Shock Protein 70-peptide complexes (HSP70)|
41288201|NCT01269125|DRUG|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
41288202|NCT01269125|PROCEDURE|IVF|Assisted Reproduction Technique.
40759777|NCT00458705|DRUG|pegylated liposomal doxorubicin hydrochloride|
40759778|NCT00458705|DRUG|thalidomide|
41133609|NCT01861015|DRUG|Epinephrine|
41133610|NCT01861015|DRUG|Vasopressin|
40759779|NCT01986023|BEHAVIORAL|SMS- Short Messaging Service|
40759780|NCT01283945|DRUG|Lucitanib|"Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)"
40759781|NCT03842280|DEVICE|Diaphragm ultrasound assessment & Esophageal pressure measurement|Diaphragm ultrasound assessment and/or Esophageal pressure measurement before, during and after spontaneous breathing trial
40759782|NCT04044820|DRUG|Standardized Prescription|"Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~* 0-5 pills for simple surgeries such as a trigger finger release~* 10 pills for carpal tunnel or Dupuytren's contracture releases~* 15 pills for a ganglion cyst excision or simple tendon transfer~* 20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion."
40949522|NCT00901407|DRUG|placebo|placebo: 1-2 tablets bid; 10 weeks
40949523|NCT00901407|DRUG|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
40949524|NCT04605042|PROCEDURE|wet suction|Before pucturing the lesion, the stylet was removed and the needle was pre-flushed with 1-2 mL of saline using a 10-mL syringe, the endoscopist then punctured the lesion and replaced the 10-mL syringe with a 10-mL pre-vacuum syringe
40949525|NCT04605042|PROCEDURE|standard negative pressure suction|after puncturing the lesion, the endoscopist removed the stylet and attached a 10-mL pre-vacuum syringe for aspiration.
40949526|NCT01655797|BEHAVIORAL|Cognitive behavior therapy for insomnia|Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
40949527|NCT00489060|PROCEDURE|Cryoablation and External Beam Radiation|
41133611|NCT04105751|DEVICE|Novel Communication System|Small hand held device that aids in answering questions. Used in conjunction with a tablet computer.
41133612|NCT04163042|BEHAVIORAL|12-week videoconferencing behavioural support intervention to promote physical activity behaviour|Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
41133613|NCT02804256|OTHER|Blood Sample Collection|10 patients with ICCs to provide a second blood sample (20mls - 2 tablespoons) on top of the samples that will be collected for the biorepository.
40949528|NCT05188196|PROCEDURE|alveolar ridge preservation|Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
41133614|NCT05871385|DEVICE|rTMS group|Twenty five randomly assigned patients with peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises
40759783|NCT02096380|DRUG|One cycle TPF induction chemotherapy for NPC|"One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
40949529|NCT06051422|DEVICE|three dimensional formetric system|A three-dimensional computer program that automatically detects pelvic torsion, surface rotation, and anatomical landmarks. Aesculap-Meditec GMBH, based in the Netherlands, creates the Formetric Instrument System. Different subject heights could be accommodated by adjusting the scanner.
40990513|NCT03809442|DRUG|Ropivacaine + Midazolam|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).
40990514|NCT03809442|DRUG|Ropivacaine + Dexmedetomidine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).
40990515|NCT03809442|DRUG|Ropivacaine + Dexamethasone|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).
41288203|NCT05417529|OTHER|music therapy intervention|"Participants did not receive premedication with midazolam 0,02 mg/kg intravenous and received music therapy intervention by a certified music therapist FAMI . Music Treatment consisted of 3 steps:~(1)30 minutes before surgery, music therapist (MTp) engaged the patient in an individual brief conversation (10 min.) to identify preferred musical genre/songs and prepared a customized playlists to listen to during induction; (2)After being monitored in the operating room, patients were prepared to listening to music ; (3)Music listening during anesthesia induction. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation"
41288204|NCT05417529|DRUG|Standard Preparation|Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
40759784|NCT02096380|DRUG|Three cycles TPF induction chemotherapy for NPC|"Three cycles TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
40759785|NCT02839928|DRUG|Intranasal ketamine|The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
40759786|NCT02839928|DEVICE|Intranasal atomizer|Ketamine will be applied to each nare via intranasal atomizer
40759787|NCT02839928|DRUG|EMLA|
40759788|NCT00324545|BEHAVIORAL|Medium-intensity Minimally-directive Counseling|
40759789|NCT00313521|DRUG|thiotepa|
40759790|NCT00313521|PROCEDURE|adjuvant therapy|
41133615|NCT05871385|DEVICE|placebo rTMS group|Twenty five randomly assigned patients with peripheral vestibular disorders will undergo placebo rTMS plus designed vestibular rehabilitation exercises.
40759791|NCT00313521|RADIATION|radiation therapy|
40759792|NCT02981160|OTHER|Dietary|The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
40759793|NCT04407247|BIOLOGICAL|Infliximab|Given IV
40759794|NCT04407247|BIOLOGICAL|Vedolizumab|Given IV
41288205|NCT02024464|DEVICE|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
40759795|NCT00764426|DRUG|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
40759796|NCT00764426|DRUG|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
40759797|NCT04544631|OTHER|Virtual reality game as adjunctive pain management tool|A smart phone virtual reality-based pain alleviation tool (VR-PAT).
41133616|NCT06032689|COMBINATION_PRODUCT|Xtra-fill|the material was placed in bulk.
41133617|NCT06032689|COMBINATION_PRODUCT|x-base|The x-base liner was placed and then veneered with Xtra-fill.
41288206|NCT02024464|DEVICE|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
41288207|NCT02024464|PROCEDURE|Cataract removal and intraocular lens (IOL) implantation|Cataract removal with phacoemulsification using standard techniques, followed by implantation with a posterior-chamber IOL suitable for glaucoma subjects
41288208|NCT05340400|OTHER|ROME IV Criteria|Collaborators will use Rome IV criteria for diagnosing IBS by the presence of the abdominal pain at least once a week in the last 3 months, in addition to at least two of the following: abdominal pain related to defecation, change in stool frequency, or shape.
40990516|NCT03809442|DRUG|Ropivacaine|Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
40990517|NCT01801644|DRUG|gemcitabine plus cisplatin|gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
40759798|NCT00092742|DRUG|MK0663, etoricoxib|
40759799|NCT00092742|DRUG|Comparator: Diclofenac sodium|
40990518|NCT04878523|DIETARY_SUPPLEMENT|multi berries juice|Testing product
40990519|NCT04878523|DIETARY_SUPPLEMENT|Placebo drink|Blank
41133618|NCT06032689|COMBINATION_PRODUCT|Admira fusion x-tra|bulk placement of the restoration Admira fusion -xtra.
41288209|NCT05554900|PROCEDURE|preventive regenerative peripheral nerve interface reconstruction|Each RPNI unit consists of nerve stump and free autologous muscle graft that is cut off from healthy muscle of the amputated limb. The muscle graft is approximately 30×15×5 mm.The ends of the transected nerve are placed within the muscle belly of the free muscle grafts in an orientation that is parallel to the muscle fibers. Next, the nerve is secured distally with 6-0 non-absorbable monofilament sutures in an epimysial-to-epineurial fashion. The nerve is then wrapped around completely via muscle graft and epimysial securing sutures. All RPNI units are placed in areas remote from the surgical incision and from the weight-bearing surface of the limb.
40949530|NCT03576495|OTHER|PACTS curriculum|"The cultural dexterity curriculum, known as PACTS (Provider Awareness Cultural Dexterity Toolkit for Surgeons) focuses on developing cognitive skills to adapt to individual patients' needs to ensure personal, patient-centered surgical care.~The curriculum is comprised of four educational modules on establishing trust in the physician-patient relationship, communicating effectively with patients with limited English proficiency, discussing informed consent, and issues surrounding pain management. Each module consists of an independent learning activity, an interactive role-play, and a post-lesson assessment."
40949531|NCT03576495|OTHER|Standard Residency Curriculum|The standard residency curriculum consists of previously scheduled resident didactic sessions at all academic medical centers that may or may not include topics on cultural competency or cross-cultural care.
40949532|NCT05247593|DRUG|Dayingpian|The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.
40949533|NCT05247593|DRUG|conventional mood stabilizers|Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.
40949534|NCT01219673|OTHER|Placebo|1 by mouth twice a day.
40949535|NCT01219673|DRUG|Armodafinil|150 mg by mouth once a day.
40949536|NCT01219673|DRUG|Minocycline|100 mg by mouth twice a day.
40949537|NCT01219673|DRUG|Bupropion|100 mg by mouth twice a day.
41288210|NCT03976856|DRUG|GB226|Geptanolimab, 210mg，q2w，ivgtt.
40759800|NCT01558258|BEHAVIORAL|Mindful Awareness practices (MAPs)|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
40949538|NCT03637023|BEHAVIORAL|Virtual Reality|Virtual Reality Based Rehabilitation including static balance, dynamic balance and walking
40949539|NCT03637023|BEHAVIORAL|Exercise Therapy|The conventional physical Therapy program includes parameters for improving strength, flexibility, transfers, posture, balance and coordination, and sensory stimulation. These activities consist of various types of exercises that focus on lower extremity movements.
40949540|NCT02821637|OTHER|Eurofit Tests of Physical Fitness (Eurofit)|Eurofit tests are a physical skills assessment. For the study, tests performed on the 1st and the 13th session of the program, then 3 more times : 2 months, 6 months and 12 months after the 13th weekly session.
40949541|NCT02821637|BEHAVIORAL|Child Health Questionnaire (CHQ)|The CHQ is a questionnaire about quality of life. The CHQ children form (CHQ-CF87) and the CHQ parent form (CHQ-PF50) are completed each time the Eurofit tests are performed : at the 1st and 13th weekly session then 2 months, 6 months and 12 months later.
40949542|NCT02821637|OTHER|Effort rehabilitation program|Part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse, the program consists in 13 sessions of 1hour30 of adapted physical activity. The physical activity in this program use cycles of games where rules are adapted to the overweight or obese children. The activities are performed in a playful atmosphere, for example using creative games like tchoukball or peteca, with each session aiming a specific objective each time.
40949543|NCT03594734|BEHAVIORAL|Group Lifestyle Balance™|The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.
40990520|NCT00638313|BIOLOGICAL|Placebo|Subjects will be given either Placebo or PF-04603629.
40990521|NCT00638313|BIOLOGICAL|PF-04603629|Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
40990522|NCT03024723|DEVICE|nasal mask CPAP|CPAP and ventilation administered via nasal mask
40990523|NCT03424174|DEVICE|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
40990524|NCT03424174|DEVICE|Standard Total Knee Arthroplasty|Implantation StandardTotal Knee Arthroplasty
40990525|NCT02174068|DRUG|paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os|
40990526|NCT02784821|DRUG|Antibiotic|Babies that are assigned to antibiotics receive therapy based on the clinical team's discretion.
40990527|NCT02784821|OTHER|Gastric fluid|Microbiome evaluated using gastric aspirate.
40990528|NCT02784821|OTHER|Breast milk|Microbiome will be evaluated using mother's breast milk.
40990529|NCT02784821|OTHER|Stool samples|Microbiome will be evaluated using infant's stool.
40990530|NCT02784821|DRUG|Antibiotics|Babies that are randomized to antibiotics receive therapy based on the clinical team's discretion.
40990531|NCT04430777|DRUG|Tranexamic acid|Administration of tranexamic acid 1 gr either intravenously or subcutaneously
40990532|NCT03889769|DIAGNOSTIC_TEST|OSNA test|Analysis of lymph node with OSNA
40990533|NCT05126147|DRUG|Hydroxychloroquine|Compare the effects of hydroxychloroquine 200mg twice daily for 6 months with those without treatment.
41133619|NCT06032689|COMBINATION_PRODUCT|Admira fusion x-base|Admira fusion x-base liner was used and then veneered by Admira fusion x-tra.
40759801|NCT01881932|DEVICE|Acupuncture using Seirin® needles|"Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion."
40759802|NCT01881932|DEVICE|Sham Acupuncture using Park Sham placebo acupuncture device|"Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion."
40759803|NCT02042144|DRUG|Stivarga (Regorafenib, BAY73-4506)|Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
41133620|NCT01318850|BEHAVIORAL|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
41133621|NCT01318850|BEHAVIORAL|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
41133622|NCT01318850|OTHER|Healthy controls|No intervention
41133623|NCT00236509|DRUG|topiramate|
41146724|NCT01190995|DRUG|Placebo|The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
41288211|NCT03976856|DRUG|Fruquintinib|Fruquintinib, 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off
41288212|NCT01466751|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
41288213|NCT05447962|BEHAVIORAL|Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)|Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.
40759804|NCT06290037|DEVICE|VR Driving Simulator|Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
40759805|NCT06290037|OTHER|Computerized Neurocognitive Function Test|Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
41288214|NCT05447962|BEHAVIORAL|Barbershop-Based Facilitation (BF)|Trained and qualified facilitators assist community health workers (CHWs) to: 1) increase their confidence in delivering CLIP; 2) understand participants' concerns and beliefs about hypertension (HTN); and 3) develop skills in lifestyle counseling to help the men initiate lifestyle modification.
41288215|NCT01746602|DRUG|Timoptic® 0.5%|Timoptic® 0.5% Eye Drops, Merck, single instillation
41288216|NCT01746602|DRUG|Timophtal sine® 0.5%|Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
41454006|NCT03516058|OTHER|Simulation-Based Education|"Participating residents receive lectures on TAP block and the use of ultrasound devices from an expert before training, and then receive simulation-based training for an hour from the anesthesiologist's staff. The residents performed three ultrasound guided TAP blocks using an anesthetized porcine model during the training session.~The residents filled out a questionnaire before and after the training session. Ten multiple-choice questions tested general knowledge in abdomen ultrasound and TAP block. Subjective comfort levels with ultrasound machine and block device functionality, patient positioning, proper block technique, image documentation, needle safety and overall procedural confidence and anxiety levels were reported on a 5-point Likert scale before and after training."
40759806|NCT06290037|OTHER|Driver Test Station|Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
40759807|NCT06290037|OTHER|Short Physical Performance Battery|Evaluation of functional capability and provide a measure of the biological age of an older individual by measuring lower extremity physical performance status(standing balance, walking speed, and chair stand tests).
41146725|NCT02060071|OTHER|Blood test|Blood test
41288217|NCT01746602|DEVICE|Genteal HA®|Genteal HA® Eye Drops, Novartis, single instillation
41288218|NCT01746602|DEVICE|Hylo-Comod®|Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
41288219|NCT01746602|DEVICE|Thealoz®|Thealoz® Eye Drops, Thea, France, single instillation
41454007|NCT03458741|OTHER|Glycogen Supercompensation|The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. Upon arrival in the morning the subjects were given a meal corresponding to 5% of their daily energy intake (\~600-800 kJ). During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
41454008|NCT02431949|OTHER|Admission to BCPP|There is no intervention associated with this study.
41288220|NCT04215549|OTHER|No intervention|cross sectional study，no intervention
41288221|NCT00393458|DRUG|Indacaterol|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
41288222|NCT00393458|DRUG|Formoterol|Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
41288223|NCT00393458|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
41288224|NCT00393458|DRUG|Placebo to formoterol|Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
40990534|NCT03817242|PROCEDURE|Tympanoplasty using tragal cartilage graft|tympanoplasty type I is performed using tragal cartilage in arm 1
41146726|NCT02297854|DRUG|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
41288225|NCT01237548|OTHER|Smoking Narghile for 30 min|No Other intervention will be used
41288226|NCT03731715|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
41288227|NCT01221298|DRUG|ABT-450|tablets
41288228|NCT01221298|DRUG|ABT-072|tablets
41288229|NCT01221298|DRUG|Ribavirin|tablets
41288230|NCT01221298|DRUG|Ritonavir|capsules
41288231|NCT05971329|DEVICE|Cervical Fusion (ZetaFuse™ Bone Graft)|Fusion of the C3-C7 cervical vertebral bodies
41288232|NCT05076708|OTHER|IQOS|All participants switch from cigarette smoking to IQOS use for a 14-day phase.
41454009|NCT00960596|BEHAVIORAL|Health promotion and health education for smoking habits|We provide the education to intervention group.
41454010|NCT06236880|DRUG|GM-2505|IV
41454011|NCT05372419|DRUG|Lebrikizumab|Administered SC
40759808|NCT06290037|OTHER|On-road field driving Test|Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
40759809|NCT03773562|DRUG|Erenumab|Erenumab will be used per label instructions.
40759810|NCT00908141|BIOLOGICAL|sargramostim|Given subcutaneously on varying schedule
40990535|NCT03817242|PROCEDURE|Tympanoplasty using temporalis fascia graft|tympanoplasty type I is performed using temporalis fascia in arm 2
40990536|NCT02013648|DRUG|Dasatinib|
40990537|NCT02013648|DRUG|Cytarabine|
41146727|NCT05466422|BIOLOGICAL|MK-2214|MK-2214 in escalating doses as an IV infusion on Days 1, 29, and 57
41146728|NCT05466422|DRUG|Placebo|Placebo as an IV infusion on Days 1, 29, and 57
41146729|NCT00136851|DRUG|amlodipine besylate/benazepril hydrochloride|
41146730|NCT01846078|DEVICE|optical biometric measurement (IOLMaster)|IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
41288233|NCT05124938|DIAGNOSTIC_TEST|Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.|a-Complete blood count. b-Liver function test. c-kidney function test d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
40759811|NCT02155972|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotic supplement
40759812|NCT02155972|OTHER|Placebo|Placebo capsules
41288234|NCT05861583|OTHER|fat tissue|fat tissue sample collected while cosmetical liposuction
40759813|NCT06563713|DRUG|STSP-0902 injection|Subjects will receive the administration dose on Day 0 following protocol requirements
40759814|NCT06563713|DRUG|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements
40759815|NCT01663363|DEVICE|LASIK correction of myopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
40759816|NCT01729429|BEHAVIORAL|HPV brochure, recall, reminders|"* HPV-vaccine specific brochure mailed before clinic visit~* Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~* Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
40759817|NCT01729429|BEHAVIORAL|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
40990538|NCT02013648|DRUG|Daunorubicin|
40990539|NCT02013648|DRUG|Idarubicin|
40990540|NCT00001758|DRUG|Abacavir|
40990541|NCT00001758|DRUG|Amprenavir|
40990542|NCT00001758|DRUG|Efavirenz|
40990543|NCT04214756|PROCEDURE|Acute Pancreatitis|All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
40990544|NCT01951339|DRUG|Sitagliptin|100 mg sitagliptin
40990545|NCT01951339|DRUG|Glimepiride|"Active Comparator~2mg glimepiride"
40990546|NCT01951339|DRUG|Placebo|2 mg placebo once daily
40990547|NCT01951339|DRUG|Placebo|100 mg placebo once daily for three months
41288235|NCT05861583|OTHER|lipoedema tissue (stage 1)|lipoedema tissue sample (stage 1) collected while medical liposuction
41288236|NCT05861583|OTHER|lipoedema tissue (stage 2)|lipoedema tissue sample (stage 2) collected while medical liposuction
41454012|NCT06451653|BEHAVIORAL|Men in Maternity Health (MiM) Intervention|The six-month MiM education program focused on maternal health education for male partners of pregnant women in the intervention area. Assigned midwives offered two-hour-long, face-to-face health education and discussion sessions at five selected health centres every second and fourth Sunday, respectively, to accommodate participants' work schedules. Attendance consistently remained high at 80% of participants every month, with home visits for absentees to provide health education.
41454013|NCT00558402|BEHAVIORAL|Meditation|meditation class 1/week for 8 weeks
41454014|NCT00558402|BEHAVIORAL|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
40949544|NCT03594734|OTHER|Attention Control Group|"The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication."
40949545|NCT01315964|DIETARY_SUPPLEMENT|plant stanol ester|3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
40949546|NCT03636165|DRUG|Methylprednisolone|The local infiltration solution containing 1.25mg Methylprednisolone per milliliter.
40949547|NCT03636165|DRUG|Ropivacaine|The local infiltration solution containing 2mg Ropivacaine per milliliter.
40949548|NCT05927701|OTHER|Group comparaison|Questionnaires
40949549|NCT04987268|GENETIC|clonal hematopoiesis of indeterminate potential|Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)
41288237|NCT05861583|OTHER|lipoedema tissue (stage 3)|lipoedema tissue sample (stage 3) collected while medical liposuction
41288238|NCT02694029|DEVICE|Active Breathing Coordinator (ABC)|The ABC system has a digital spirometer that records real time breathing. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
41288239|NCT02694029|DEVICE|VisionRT|A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH.
40949550|NCT05698056|OTHER|No intervention.|No intervention.
40949551|NCT04313842|DEVICE|AVATAMED|tumor specimen will be sent for in vitro drug screening experiment and the result will be analyzed by 'AVATAMED' to predict the clinical response
40949552|NCT04094051|DRUG|Ibrutinib|In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.
40949553|NCT01772160|OTHER|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
40949554|NCT06302478|BEHAVIORAL|5E program|"Participants in the 5E program group will receive 7-day nursing interventions including~* Education: health education regarding venous thromboembolism prevention~* Elevation: leg elevation of 10-20 degrees~* Exercise: ankle exercises~* Enough fluid: adequate fluid uptake~* Early application of intermittent pneumatic compression (IPC): IPC use within 48 hours after admission"
41133624|NCT00783952|DEVICE|Cerebral/Somatic Tissue Oximeter device|"Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.~Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy."
41454015|NCT00558402|BEHAVIORAL|Respite only|Respite care 90 mins per week for 8 weeks
40759818|NCT05269082|OTHER|No intervention|This is a non-interventional study.
41454016|NCT05341180|DRUG|Polyethylene Glycol|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Polyethylene glycol syrup at a dose of 15-30 ml will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
41133625|NCT00783952|DEVICE|Pulmonary artery catheter|Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
40759819|NCT02577575|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
40759820|NCT02577575|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
40759821|NCT03109067|OTHER|Standardized meal|Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal
40759822|NCT03229863|OTHER|Sweet Potatos|Plum Organics, Just Sweet Potato
41133626|NCT05388045|OTHER|Patient Reported Outcome Measure|A Recovery Patient-Reported Outcome Measure (PROM, 19 items and 2 questions for each item, collected via online survey) will be completed by eligible patients at baseline and again at months 3 and 6. The initial Recovery PROM will be shared with the clinician, at the visit most closely scheduled following the baseline visit, for review and discussion with the patient. At the 3- and 6-month visits, the clinician will be asked to re-review and compare the earlier Recovery PROM(s) as well as the current Recovery PROM. The clinician is encouraged to use the PROM results during interim clinical visits with the patient. Efforts will be made to contemporaneously track how often the PROM is discussed in clinical sessions conducted during the 6 months.
41146731|NCT03699761|PROCEDURE|Closure of the pelvic peritoneum|Closure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
41146732|NCT03699761|PROCEDURE|Nonclosure of the pelvic peritoneum|Nonclosure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
41146733|NCT00202228|DRUG|cofactor supplementation (thiamine, riboflavin, L-carnitine)|Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
40949555|NCT02841189|DEVICE|King Vision video Laryngoscope|The King Vision video laryngoscope (Ambu) will be used for tracheal intubation.
40949556|NCT05303363|DEVICE|VV-ECMO|VV-ECMO is indicated in case of severe respiratory failure refractory to other therapies. Indications for VV-ECMO include severe pneumonia, acute respiratory distress syndrome (ARDS) (a.o. due to COVID-19) or near-drowning. ECMO is considered a 'last resort' therapy, in which other maneuvers - such as prone positioning and neuromuscular blockage - have shown to be insufficient. Patients are generally receiving invasive mechanical ventilation and are almost always unconscious, since due to the severe respiratory failure, high doses of sedatives and neuromuscular blockage are often applied to prevent further ventilator-induced damage. After the decision for VV-ECMO is made, the patient is directly cannulated in the ICU or OR following standard protocols.
40949557|NCT06557486|BEHAVIORAL|Mindfulness-Based Stress reduction|Participants assigned to the 8-week mindfulness program attended weekly 120-150 minute in-person group sessions for the entire duration. In these sessions, the instructor progressively will introduce and guide formal mindfulness practices while facilitating the sharing of experiences.
40949558|NCT03848065|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
40949559|NCT03848065|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
40949560|NCT03848065|BIOLOGICAL|Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)|Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
40949561|NCT03659539|DRUG|PROPOFOL|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
40949562|NCT03659539|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
40949563|NCT00003023|BIOLOGICAL|BCG vaccine|
40949564|NCT00003023|BIOLOGICAL|monoclonal antibody A1G4 anti-idiotype vaccine|
40949565|NCT04635189|DRUG|Daratumumab|Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
40949566|NCT04635189|DRUG|Lenalidomide|Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle
40949567|NCT04635189|DRUG|Dexamethasone|Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab
40949568|NCT02122458|DEVICE|mild-gain hearing aids with high-frequency emphasis over 6-months|open-fit hearing aids with mild amplification in the high frequencies.
40949569|NCT00304239|COMBINATION_PRODUCT|Metvix-PDT|Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 Joule/square centimeter (J/cm²). All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
40949570|NCT00304239|COMBINATION_PRODUCT|Vehicle-PDT|Vehicle Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 J/cm². All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
40949571|NCT01356979|PROCEDURE|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
40949572|NCT01699490|DRUG|Fluoxetine + Valsartan|The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
40949573|NCT01699490|DRUG|Fluoxetine + Placebo|The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
41146734|NCT02964234|BEHAVIORAL|Empowerment|Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
41146735|NCT02964234|BEHAVIORAL|Education|Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
41146736|NCT01026441|DEVICE|Vela100 (Aesthetic)|6 treatments once a week
40990548|NCT06067945|OTHER|microleakage|prevention of microleakage and secondary carries
40990549|NCT05804175|DEVICE|Linshom Continuous Predictive Respiratory Monitoring|Observational study. Monitoring of Linshom, pulse oximetry and capnography data with comparison to current standard of care.
40759823|NCT03229863|OTHER|Pears|Earth's Best, First Pears
41146737|NCT03529006|PROCEDURE|Sequent Please inflation|PCI procedure for treatment of ISR with DEB - Sequent Please - inflation
41288240|NCT06293092|DEVICE|leg pedaling cycling device|Intradialytic aerobic cycling exercise program ,each patient will receive the treatment program three times per week for three months.
41288241|NCT06293092|DEVICE|sand bags|Intradialytic resistive exercise program , each patient will receive the treatment program three times per week for three months.
41288242|NCT06293092|DEVICE|hemodialysis sessions|hemodialysis sessions ,each patient will receive the treatment program three times per week for three months.
41288243|NCT01214512|OTHER|blood-sample based diagnostic assay|A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
41288244|NCT05558345|BEHAVIORAL|Contingency Management|A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.
40759824|NCT05546372|DEVICE|Endobiliary radiofrequency ablation (eRFA)|Intraductal radiofrequency ablation of tumor prior to stent placement
40759825|NCT05546372|DEVICE|uncovered self-expanding metal stent (uSEMS)|Intraductal placement of uncovered metal stent
40759826|NCT00005995|DRUG|shark cartilage extract AE-941|
40759827|NCT01345903|PROCEDURE|therapeutic conventional surgery|Undergo robotic-assisted surgery
40759828|NCT06001008|OTHER|PQA|PQA is a questionnaire consisting of 16 questions developed to measure the quality of anesthesia service received by patients based on their experiences. Patients will be asked to answer questions by the researcher 24 hours after surgery.
41288245|NCT03741881|OTHER|No treatment given|Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
41288246|NCT05930249|BEHAVIORAL|Personalized multidomain intervention|"1. Patients will complete personalized cognitive training based on baseline fNIRS on APP (20-30 mins/day, 3-4 days/week, 6 months).~2. Shared decision-making on risk factor of stroke between doctors and patients~3. Social support by grouping patients online to ensure close interaction with other patients in the same arm"
41288247|NCT03940170|DEVICE|vistacam proof|Light fluorescence device
41288248|NCT03940170|OTHER|ICDASII|visual examination
40949574|NCT05626816|DEVICE|Genital Nerve Stimulation|Electrical stimulation applied to the genital nerve with surface electrodes using an off the shelf TENS unit (Ultima Plus). First, an amplitude threshold for the pudendo-anal reflex responses will be determined. Then, sham (1-2 Hz) and effective stimulation (20 Hz) will be briefly applied to record responses. Then, stimulation will be applied in random presentation order to record any changes in anorectal manometry outcomes due to both sham and effective stimulation.
40949575|NCT05626816|DIAGNOSTIC_TEST|Clinical exam|Examination by physician determines the presence of pelvic reflexes (pudendo-anal and bulbocavernosus) which are essential for GNS to have an effect.
40949576|NCT05626816|DIAGNOSTIC_TEST|Collection of SCI common data elements|Data regarding participant demographics, history of injury, and medical history will be collected.
40949577|NCT05626816|DIAGNOSTIC_TEST|Bowel function survey completion|Two surveys will be conducted to assess the bowel function of the participant. The International SCI Bowel Function Basic Data Set (ISCI BF BDS v2.1) and the SCI Qulaity of Life Bowel Management Difficulties (SCI-QoL BMD) survey scales collect data on overall bowel function and how any difficulties impact the participants quality of life.
41288249|NCT03940170|PROCEDURE|fissurotomy|histological validation
41288250|NCT06414122|OTHER|mid-frequency whole-body electromyostimulation (WB-EMS)|supervised group training sessions at least once and optionally twice a week, lasting 11-20 minutes, over 12 weeks, 12-24 training sessions in total
41288251|NCT06414122|OTHER|conventional exercise training|supervised group training at least once a week, optional additional home-based training once a week, lasting 40 minutes, over 12 weeks, 12-24 training sessions in total
41288252|NCT06414122|OTHER|nutritional therapy|conventional nutritional counselling with guidelines and digital nutritional coaching
41288253|NCT06016621|BEHAVIORAL|Improvisational Music Therapy|The therapist engages with the child by playing and sharing musical instruments, and/or sings while being attuned to the child's behaviour and expression. Various improvisational techniques are employed to engage the child. There are opportunities for pulse, rhythmic, dynamic or melodic patterns, and timbre to be mirrored, reinforced, or complemented, which allows for moments of synchronization between the therapist and the child, giving the child's musical expressions a pragmatic meaning within this context. The therapist may also gently provoke the child by violating expectations or patterns that have been jointly developed in order to elicit specific social communication behaviours. Further, there are opportunities for the child to develop and enhance social communication skills such as joint attention, sharing affect, reciprocity, shared history, scaffolding, imitation and turn-taking. These have been shown to develop social competency and also resilience.
41146738|NCT03529006|PROCEDURE|Absorb BVS implantation|PCI procedure for treatment of ISR with Absorb BVS implantation
41146739|NCT04449445|DIETARY_SUPPLEMENT|Isocaloric and iso-nitrogenous standard enteral tube feeds|Dietary supplement
41146740|NCT04449445|DIETARY_SUPPLEMENT|Nestle IMPACT AR|Dietary supplement
40759829|NCT02704000|BEHAVIORAL|Home visiting program (Jamaica curriculum)|Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
40759830|NCT05438160|DEVICE|Digital therapeutics app CT-155|Patients to be treated with digital therapeutics app CT-155 downloadable into personal smartphones
41288254|NCT05477771|PROCEDURE|Arthroscopic rotator cuff repair|The rotator cuff tears were repaired under arthroscopy. A subacromial decompression was performed in all patients. Then the long head of the biceps with severe lesions were treated by tenotomy while the others were reserved according to the surgeon's judgment during the surgery.
41288255|NCT03976401|DRUG|EFX|Administered by subcutaneous injection
41288256|NCT03976401|DRUG|Placebo|Administered by subcutaneous injection
40759831|NCT02682251|OTHER|PHR Messaging|PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
40759832|NCT00363363|BEHAVIORAL|Physical Activity|Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.
40759833|NCT00363363|BEHAVIORAL|Education|Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.
40759834|NCT05757726|DEVICE|Velocity pAVF system|A second generation percutaneous AVF device that creates an AVF between the proximal radial artery and cubital perforating vein.
40759835|NCT01103518|DRUG|Ethinyl Estradiol + Cyproterone acetate|Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
40759836|NCT04162158|BIOLOGICAL|allogeneic NK cells therapy|PBMC was isolated from the peripheral blood of the donors and infused to the patient after 14 days incubation. In each cycle, patients will be infused 4.0-5.0×10'9 allogeneic NK cells. All patients in the experimental group received a total of three cycles of treatment with one month interval between each treatment.
40759837|NCT05708508|DRUG|ROVALCYTE|"Immuno-guided strategy arm"
40759838|NCT03070067|OTHER|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
40759839|NCT03169374|DEVICE|Virtual Reality Technology|Patients in this arm will participate in virtual reality sessions planned for 5 minutes at a time, during which they are shown relaxing virtual environments.
40759840|NCT02842242|DRUG|MYK-461|
40759841|NCT02644057|DRUG|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
40759842|NCT02644057|DRUG|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
41133627|NCT02106078|BEHAVIORAL|Moderated Discussion Board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).~The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
41288257|NCT06046508|OTHER|blood samples collection|patients, who meet all the inclusion criteria and none of the exclusion criteria, will be enrolled and they will perform a blood withdrawal before PFO correction and 180 days after the intervention
40949578|NCT05626816|DIAGNOSTIC_TEST|International Standard for Neurological Classification of SCI (ISNCSCI)|The physician will conduct the ISNCSCI to determine the level and severity of injury to the spinal cord. This is done by determining the ability to detect light touch and pinprick stimulation. Outcomes will be a Spinal Injury Association Impairment Scale (AIS) grade of A-D.
40949579|NCT05626816|DIAGNOSTIC_TEST|Response to genital nerve stimulation (GNS)|GNS will be applied to determine if there is a response in the participant. If the participant has no response to the stimulation they will be excluded from the second visit as it is dependent on the ability to respond to GNS.
40949580|NCT05626816|DIAGNOSTIC_TEST|Anorectal Manometry testing (ARM)|"The participant will be instrumented for ARM testing. This requires a special balloon catheter to be inserted into the anus and secured, surface electrode pads being applied to the anal sphincter, and electrode pads being applied to the genital nerve stimulation sites.~Once instrumented, the participant will be tested with the London Classification procedure. This procedure asks the participant to perform several actions (squeeze to withhold a bowel movement, push to have a bowel movement, and cough) as well as inflating the balloon on the catheter to determine reflex thresholds (RAIR, retroanal inhibitory reflex which relaxes the anal sphincter in response to rectal distension) and sensory thresholds (first senstation,"
40949581|NCT01978418|DRUG|salbutamol|Medication given once as a dose of 4 puffs at 30-60 minutes of age
41133628|NCT02106078|BEHAVIORAL|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~1. What is bipolar disorder? - Content about symptoms and diagnosis~2. Stress and triggers of illness~3. Medication and the biological basis of bipolar disorder~4. Depression - Symptoms, early detection and helpful strategies~5. Mania and hypomania - Symptoms, early detection and helpful strategies"
41288258|NCT02104310|DRUG|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
41288259|NCT04318574|OTHER|Balance, Agility, Strengthening Exercise (BASE) Class|The BASE class will be conducted twice weekly for 1.5 hours each session over a 6-week period and will include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly falls prevention and mobility enhancement education provided during the class.
41133629|NCT02106078|BEHAVIORAL|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviors, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
41288260|NCT05816356|DRUG|Decitabine|Oral administration of decitabine as a single dose to healthy male subjects
41288261|NCT05816356|DRUG|Tetrahydrouridine|Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
40759843|NCT01257243|DRUG|Syrup of oxomemazine, guaifenesin and potassium iodate|5ml each 4 hours
40949582|NCT01978418|DRUG|Placebo|Placebo given once as a dose of four puffs at 30-60 minutes of age
41133630|NCT00005799|DRUG|fludarabine phosphate|Given IV
41133631|NCT00005799|RADIATION|total-body irradiation|Undergo low-dose TBI
41133632|NCT00005799|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative HSCT
41133633|NCT00005799|PROCEDURE|allogeneic bone marrow transplantation|Undergo nonmyeloablative allogeneic bone marrow transplantation
41288262|NCT00986193|PROCEDURE|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
41288263|NCT00986193|PROCEDURE|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
41288264|NCT04676243|DRUG|Quizartinib|20 mg coated tablets, orally administered
41288265|NCT04676243|DRUG|Treatment according to Physician's Choice|Usually daunorubicin/ cytarabine or idarubicin/Cytarabine plus FLT3 inhibitor (usually midostaurin)
41288266|NCT04676243|DRUG|Standard of Care Chemotherapy|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine
41288267|NCT01342640|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
40949583|NCT04356742|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg, orally, once daily, up to 24weeks
40949584|NCT04356742|DRUG|Placebo|Dapagliflozin Placebo, orally, once daily, up to 24weeks
40759844|NCT01257243|DRUG|Syrup of guaifenesin|5ml each 4 hours
40759845|NCT02365688|PROCEDURE|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
40759846|NCT05704634|DRUG|Cemiplimab|Given by Injection under the skin every 2 weeks
40759847|NCT05704634|DRUG|Kevzara (Sarilumab)|Given by IV (vein) over about 30 minutes every 3 weeks.
40759848|NCT06190990|OTHER|Otago Exercise + Exer gaming|In this group the participant will receive otago exercises and exer-gaming based exercises. The duration of each session this group will receive is of 60 minutes A total of 12 sessions will be held, 3 times a week for 4 weeks. Reading will be taken on baseline, after 2 week
40759849|NCT06190990|OTHER|exer gaming based programme|In this group the participant will receive exer-gaming based exercises. The duration of each session this group will receive is of 60 minutes A total of 12 sessions will be held, 3 times a week for 4 weeks. Reading will be taken on baseline, after 2 weeks and then after 4 weeks.
40759850|NCT02486770|BIOLOGICAL|Aerucin 2.0mg/kg|IV Aerucin 2.0 mg/kg over 1 hour
41133634|NCT00005799|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
40759851|NCT02486770|BIOLOGICAL|Aerucin 8.0mg/kg|IV Aerucin 8.0 mg/kg over 1 hour
40759852|NCT02486770|BIOLOGICAL|Aerucin 20.0 mg/kg|IV Aerucin 20 mg/kg over 1 hour
40949585|NCT04356742|DRUG|Evogliptin 5mg|Evogliptin 5mg, orally, once daily for background therapy
40949586|NCT04356742|DRUG|Metformin≥1000mg|Metformin≥1000mg, orally, daily for background therapy
40949587|NCT03106350|OTHER|Questionnaire|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.
40949588|NCT00326066|DEVICE|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
40949589|NCT00326066|PROCEDURE|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
41288268|NCT06282380|DEVICE|FibriCheck Mobile Application|PPG measurement with reference diagnosis
41288269|NCT00758862|DRUG|2% TD1414 Cream|Application 3 times daily for 7 days
41288270|NCT03045146|OTHER|Multimodal brain imaging|Comparison of the Rate of Good Neurological Functional Outcome defined by Modified Rankin Scale 0-2, 3 Months after an acute ischemic stroke treated by thrombectomy according to the presence or not of a Target Mismatch on Baseline imaging (MRI or CTP).
41288271|NCT03032887|BEHAVIORAL|voice prompts|voice prompts on disinfectant dispenser
40949590|NCT01691274|DRUG|PF-04895162|Tablets, 300 mg, single, 1 day
40949591|NCT01691274|DRUG|PF-04895162|Tablets, 300 mg, twice a day, 14 days
40949592|NCT01691274|DRUG|PF-04895162|Tablets, to be decided, twice a day, 14 days
40949593|NCT01691274|DRUG|Placebo|Tablets, twice a day, 14 days
40949594|NCT02154737|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
40949595|NCT02154737|DRUG|Erlotinib|Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
41288272|NCT03032887|BEHAVIORAL|agitation|Education, reminders and optimising materials
40949596|NCT00191906|DRUG|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
41133635|NCT00005799|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
41288273|NCT05460780|DEVICE|MATTISSE TEC|Tissue engineering chamber MATTISSE
41288274|NCT01887210|BEHAVIORAL|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
41288275|NCT01887210|BEHAVIORAL|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
41288276|NCT00013052|BEHAVIORAL|Peer led classes. Led by trained veterans with a chronic disease.|
40949597|NCT00191906|DRUG|placebo|Placebo, every day (QD), by mouth (PO)
40949598|NCT02547675|DRUG|Rociletinib|Rociletinib will be administered to patients orally
40949599|NCT03419520|BEHAVIORAL|Nutritional counseling|Schoolchildren, parents and teachers from intervention schools, will regularly receive nutrition and healthy lifestyle guidelines performed by nutritionists. Moreover, workshops aimed to reinforce the healthy habits will also be held along the study.
40949600|NCT05504395|DRUG|CSTI-500|Single 10 mg capsule
40949601|NCT01464892|BEHAVIORAL|Imagery Rescripting and Reprocessing Therapy|This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting
40949602|NCT01464892|BEHAVIORAL|STAIR + Imagery Rescripting|A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.
40949603|NCT01419522|OTHER|Gait Training Method|Treadmill training at constant velocity
40949604|NCT00810108|DRUG|lopinavir/ritonavir (Kaletra®) tablets|The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
40949605|NCT01612104|BEHAVIORAL|Psychological First Aid|A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
40949606|NCT03830632|OTHER|Plyometric Training|
40949607|NCT03830632|OTHER|Traditional Training|
40949608|NCT04080440|PROCEDURE|Extubation readiness clinical score|"After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the intervention group, after a successful spontaneous breathing trial in unconscious patients, the score will be evaluated.~If the score is \>9, extubation has to be completed"
41133636|NCT00005799|DRUG|cyclosporine|Given PO
41133637|NCT00005799|DRUG|mycophenolate mofetil|Given PO
41133638|NCT00005799|OTHER|pharmacological study|Correlative studies
41133639|NCT00005799|OTHER|laboratory biomarker analysis|Correlative studies
41133640|NCT00942344|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
41288277|NCT02333331|DRUG|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
41288278|NCT02333331|OTHER|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
41288279|NCT02021422|DRUG|anakinra|Dosage Route Administration 100 mg SC Every Other Day
41288280|NCT02021422|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 2-4 hours
41288281|NCT02021422|DRUG|Irinotecan|Irinotecan 180 mg/m2 90 minutes
41288282|NCT02021422|DRUG|fluorouracil|fluorouracil 2400 mg/m2 48 hours
41288283|NCT06512883|DRUG|Benralizumab|Benralizumab will be administered as SC injection on Q4W.
41288284|NCT04129723|OTHER|Stopping biological therapy|Stopping biological therapy The primary endpoint is clinical relapse at 12 months
40949609|NCT04080440|PROCEDURE|Standard of care|"After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the control group, after a successful spontaneous breathing trial in unconscious patients, the extubation will be achieved according to the standard of care"
40949610|NCT03124446|BEHAVIORAL|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
41454017|NCT05341180|DRUG|Isabgol + Lactulose|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Isabgol husk at a dose of 2 teaspoons in 200 ml of warm water before bedtime and 30 ml of syrup lactulose at bedtime will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
40759853|NCT05500846|DEVICE|The Visual Ice Cryoablation System|Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.
40759854|NCT05476731|DIAGNOSTIC_TEST|culture and antifungal sensitivity and molecular detection|"Samples will be cultured on Modified Dixon media for 10 days at temperature between 32-34°C.Molecular detection of malassezia species by Restriction Fragment Length Polymorphism (RFLP) .~Antifungal susceptibility testing of the isolates will be performed using the following antifungals Fluconazole, AmphotericinB and Fluocytosine"
40759855|NCT02193347|BIOLOGICAL|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
40786433|NCT03457714|BEHAVIORAL|Guided ICBT for persons with Spinal Cord Injury|An 8-week guided internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a guide with experience delivering ICBT will provide support by email or telephone once a week. The guide will spend approximately 15 minutes per week/per client.
40990550|NCT00992082|DRUG|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
41133641|NCT00942344|DRUG|Amlodipine|amlodipine 5mg, 10mg
41133642|NCT00942344|DRUG|Losartan|Losartan 50mg, 100mg
41454018|NCT03095781|DRUG|XL888|Given PO
41454019|NCT03095781|BIOLOGICAL|Pembrolizumab|Given IV
40759856|NCT02193347|BIOLOGICAL|Tetanus-Diphtheria Toxoid (Td)|After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
40759857|NCT02193347|DRUG|Temozolomide|Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
40759858|NCT03052608|DRUG|Lorlatinib|ALK-positive NSCL treatment
40759859|NCT03052608|DRUG|Crizotinib|ALK-positive NSCL treatment
40759860|NCT06521593|PROCEDURE|Applying a tourniquet for either a short or long time during total knee replacement|All patients underwent spinal anesthesia and the tourniquet was applied to the middle of the thigh; in group one who underwent long-duration application of a tourniquet, it was applied only before the skin incision by inflating it to 150 mmHg above the systolic blood pressure of the patients and deflation finishing of bone cementation while in group two who underwent short duration application of a tourniquet, the tourniquet was only applied just before cementation, was inflated also to 150 mmHg above the systolic blood pressure of the patients, and was deflated after bone cementation.
40759861|NCT03308331|OTHER|Tobacco smoking and nicotine patch|Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use
40759862|NCT03003065|DRUG|Temoporfin|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
41288285|NCT01399827|DRUG|ADHD Medication|For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
40759863|NCT03605550|DRUG|PTC596|Oral tablets
40759864|NCT03605550|RADIATION|Radiotherapy|Cycle1
40759865|NCT02251470|OTHER|HBE Wii (EG)|Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
40759866|NCT02251470|OTHER|HBE Control (CG)|Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
40759867|NCT05795660|BIOLOGICAL|platelet rich plasma|platelet rich plasma injection
40759868|NCT05283629|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"Behavioral: Neuroplasticity-based Computerized Cognitive Remediation The nCCR has two major components: Bottom up and Top down training.~* Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~* Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
41133643|NCT01354782|DRUG|Roflumilast|"Period I: single dose of roflumilast 500 μg orally in the morning.~Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days."
41133644|NCT02568306|DRUG|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose \[SD\] or multiple dose \[MD\] with daily dosing.
41133645|NCT02568306|DRUG|placebo|Administered subcutaneously (s.c., under the skin) single dose \[SD\]) or multiple dose \[MD\] with daily dosing.
41288286|NCT01399827|DRUG|Omega-3 Fatty Acids|Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
41288287|NCT03863496|PROCEDURE|Scoliosis surgery|All patients will be implanted Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control and standard anesthetic support.
40759869|NCT05283629|BEHAVIORAL|Education Control Condition|The education control condition is a learning-based approach that utilizes DVDs on history, art, science, etc. This active condition is comparable to nCCR in length of exposure, audio-visual presentation, computer use and contact with research staff.
40759870|NCT02976688|OTHER|Sodium Propionate|Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
40759871|NCT04551053|DRUG|parsaclisib|parsaclisib will be administered QD orally
40759872|NCT04551053|DRUG|ruxolitinib|ruxolitinib will be administered BID orally
40759873|NCT04551053|DRUG|placebo|placebo will be administered QD orally
40759874|NCT02349477|DRUG|Gabapentin|gaba potentiating medication
40759875|NCT02349477|DRUG|Placebo|a pill that looks exactly like the active medication but does not contain medication
40759876|NCT02862262|DEVICE|ARIES Bordetella Assay|
40759877|NCT04902482|DEVICE|iCycle Mark 3|The iCycle Mark 3 is a cycle ergometer, designed to be used by people with SCI while they are seated in their own wheelchairs. The purpose of iCycle is to stimulate the leg muscles in the correct phase for cycling while motivating the person with a Virtual Reality cycling event, perhaps a race, to try to use their muscles.
40949611|NCT03124446|BEHAVIORAL|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
41133646|NCT06061900|OTHER|Group exercise program|Group fitness program
40759878|NCT06377592|OTHER|Sample collection without intervention|No Intervention
40949612|NCT05749211|DRUG|Huaier granule|Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity
40949613|NCT00776724|DRUG|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
40759879|NCT01916226|DRUG|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
40759880|NCT01916226|DRUG|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
40759881|NCT01916226|DRUG|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
40759882|NCT01916226|DRUG|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
40786434|NCT03457714|OTHER|Survey|Caregiver burden and mental health will be assessed through online questionnaires.
40990551|NCT00992082|DRUG|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
40990552|NCT02616042|OTHER|Centella asiatica and bamboo salt|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.
40990553|NCT02616042|OTHER|Centella asiatica|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.
40990554|NCT02621411|DRUG|Substance use|Patients are found use of substances by preoperative screen
40990555|NCT00000296|DRUG|Cotinine fumarate|
40990556|NCT04834635|PROCEDURE|FundoRingOAGB|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia
40990557|NCT04834635|PROCEDURE|OAGB|laparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia
40759883|NCT01931826|PROCEDURE|Endoscopic treatment|The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
41288288|NCT01615003|DRUG|Xuesaitong soft capsule|Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
41288289|NCT01615003|DRUG|Xuesaitong soft capsule Placebo|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
41288290|NCT00827619|DEVICE|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
41288291|NCT03886077|DRUG|glecaprevir/pibrentasivir|12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
41288292|NCT00446212|DRUG|Propofol|target controlled infusion of propofol
41288293|NCT00446212|DRUG|desflurane|Anaesthetic maintenance with desflurane
41288294|NCT03498872|DEVICE|AMPfoot 4.0|The novel prosthetic device, i.e. AMPfoot 4.0, was tested during walking in amputees. A dual-task was conducted and non-invasive electro-encephalography was used to investigate neural dynamics.
41288295|NCT03498872|OTHER|No intervention|The control group included healthy subjects. Comparisons were made between amputees and able-bodied individuals.
41288296|NCT04404400|DRUG|Investigational products administration|"Investigational products include:~* Hydrocortisone hemisuccinate 50 mg: one intravenous injection every 6 hours, and~* 9 alpha fludrocortisone 50 μg: one tablet per day via a nasogastric tube.~All treatments will be stopped after 7 days or until the patient has left the intensive care unit (whichever occurs first) without tapering off."
41133647|NCT04982588|DEVICE|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~2. EnVeo™ PRO Delivery Catheter System (DCS)~3. EnVeo™ PRO Loading System (LS)"
41133648|NCT04153851|PROCEDURE|neurectomy of nasopalatine nerve|Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal. Dental implant will be inserted in the central incisor location
41288297|NCT04404400|DRUG|Placebo administration|Placebos for hydrocortisone and for fludrocortisone, administered in same manner as the active drugs in the interventional arm, for 7 days.
41288298|NCT00866294|DRUG|paroxetine IR 10mg tablet|1 or 2 tablets once a day
41288299|NCT00866294|DRUG|paroxetine IR 20mg tablet|1 tablet once a day
41288300|NCT00866294|DRUG|matched placebo to paroxetine IR 10mg or 20mg|1 or 2 tablets once a day
41288301|NCT00866294|DRUG|Paroxetine CR 12.5mg tablet|1 or 2 tablets once a day
41288302|NCT00866294|DRUG|Paroxetine CR 25mg tablet|1 or 2 tablets once a day
41288303|NCT00866294|DRUG|matched placebo to paroxetine CR 12.5mg or 25mg|1 or 2 tablets once a day
41288304|NCT03891277|DRUG|Ferrous succinate|"Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks."
41288305|NCT02035072|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2
40759884|NCT01931826|PROCEDURE|Total EGDS+ endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
41288306|NCT02035072|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2
40759887|NCT02007044|DRUG|Ibrutinib|Given PO
40759888|NCT02007044|OTHER|Quality-of-Life Assessment|Ancillary studies
40759889|NCT02007044|OTHER|Questionnaire Administration|Ancillary studies
40759890|NCT02007044|BIOLOGICAL|Rituximab|Given IV
40759891|NCT05355298|DRUG|AMP945 ascending doses|Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.
40759892|NCT05355298|DRUG|AMP945 RP2D|Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
40759893|NCT06498791|OTHER|Venipuncture|Blood drawing
40759894|NCT06498791|OTHER|Questionnaire|Completion of the questionnaire
40759895|NCT05206045|OTHER|Standard of care|Standard of care for patients with Sezary Syndrome
40786435|NCT01220492|DRUG|conventional plus MSC treatment|received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 8 weeks.
41146741|NCT02342275|DRUG|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
40786436|NCT01220492|DRUG|conventional plus placebo treatment|received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
40786437|NCT05851443|DRUG|povorcitinib|povorcitinib
41288307|NCT02035072|RADIATION|Hypofractionated RT|Hypofractionated radiotherapy (35 Gy in 7 fractions)
40786438|NCT05851443|OTHER|placebo|placebo
40786439|NCT05851443|DRUG|ICS-LABA|Background Therapy
41288308|NCT01348178|PROCEDURE|Follow-up|Follow-up
41288309|NCT05942274|DIAGNOSTIC_TEST|We propose to validate these smartwatch ECG functions to support FDA submissions|1) Obtain a simultaneous recording of a Lead I (RA-LA) ECG from the Smartwatch and a clinical standard device (GE Cardiosoft ECG). Subsequent recordings will be acquired from the other models of the Smartwatch as well as a recording utilizing the FDA-cleared KardiaMobile.
41288310|NCT03867253|DRUG|ORY-2001 Low dose|0.6mg ORY-2001 capsule
40759896|NCT05460286|OTHER|Chiropractic Manipulation|20 participants with low back pain existing more than 3 months was included in the CSMT group. Lumbar region chiropractic HVLA (High Velocity, Low Amplitude) spinal manipulation and/or sacroiliac joint chiropractic HVLA manipulation were applied to participants. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
41133649|NCT04220983|RADIATION|MR-Guided Prostate SBRT|Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.
41146742|NCT02342275|DRUG|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
41146743|NCT01958047|DRUG|ASP3652|Oral
40786440|NCT06170567|OTHER|The effect of puzzles on students' course success|The effect of puzzles on students' course success
40786441|NCT01382771|DRUG|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
40786442|NCT01382771|DRUG|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
40786443|NCT03395496|DRUG|Biodentine|Biodentine pulpotomy agent
40786444|NCT03395496|DRUG|ProRoot (Aggregate)|ProRoot MTA pulpotomy agent
40949614|NCT00776724|DRUG|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|"Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8."
40949615|NCT02728622|DRUG|Tamoxifen|endocrine treatment
40949616|NCT02728622|DRUG|Chemotherapy|Paclitaxel or pegylated liposomal doxorubicin
40949617|NCT03839498|DRUG|Axitinib|"Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.~Starting dose level 1: 5 mg every morning; 5 mg every evening. Dose level 2: 7 mg every morning; 7 mg every evening. Dose level 3: 10 mg every morning; 10 mg every evening. Dose level -1: 3 mg every morning; 3 every evening. Dose level -2: 2 mg every morning; 2 mg every evening.~Axitinib is supplied as 1 and 5-mg tablets and is administered orally twice a day with or without food, each morning and evening (i.e., every 12 hours). Axitinib will be given as self-administered."
40949618|NCT01160211|DRUG|lapatinib|1000 mg by mouth once a day
40949619|NCT01160211|DRUG|trastuzumab|Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks
40949620|NCT01160211|DRUG|Aromatase inhibitor|Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
40949621|NCT01160211|DRUG|lapatinib|1500 mg by mouth once daily
40949622|NCT01944033|DRUG|Bricanyl/Iprovent|5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
40949623|NCT01944033|DRUG|Bricanyl|5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
40759897|NCT05460286|OTHER|Spinal Decompression Device Treatment|20 participants with low back pain existing more than 3 months was included in the SD group. Lumbar region spinal decompression (traction) device therapy was applied to participants, and as a standard of treatment was given a hot pack for 15 minutes before applying and a cold pack for 10 minutes after applying. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
40949624|NCT01372228|BIOLOGICAL|hematopoietic stem cell infusion|Enriched hematopoetic stem cell infusion
40949625|NCT02359422|BEHAVIORAL|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.
40949626|NCT01297556|BEHAVIORAL|Cognitive Behavior Therapy(CBT)|Cognitive Behavior Therapy(CBT) for 6 weeks.
40949627|NCT00805948|DEVICE|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
40949628|NCT03808831|DEVICE|Fall detection and prevention system|The fall detection and prevention system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
40949629|NCT03808831|DEVICE|Sham fall detection and prevention system|The sham system with record but no alert function
40759898|NCT06572150|PROCEDURE|Deep Brain Stimulation - Minimal Electrophysiology|Participants will undergo standard work-up and follow-up for DBS, but with minimal intraoperative electrophysiological testing.
40949630|NCT02103907|OTHER|Targeted dynamic balance training|Participants in this study group will complete dynamic balance training exercises four times per week, for ten weeks. Exercise sessions at the university will last approximately one hour, and home exercise sessions will take approximately 30 minutes to complete. Exercises will emphasize dynamic balance control, muscle strength and proprioception and will be progressed over three phases during the ten weeks (with more difficult exercises phased in, and exercises that have been mastered phased out).
41146744|NCT00828139|BIOLOGICAL|ziv-aflibercept|Given IV
41146745|NCT00828139|DRUG|topotecan hydrochloride|Given IV
41288311|NCT03867253|DRUG|ORY-2001 High dose|1.2mg ORY-2001 capsule
41288312|NCT03867253|DRUG|Placebo|Placebo capsule
41288313|NCT01460836|DRUG|Tobramycin solution for inhalation|
41288314|NCT01460836|DRUG|Aztreonam lysine for inhalation|
41288315|NCT00122499|DRUG|tadalafil|
40759899|NCT06572150|PROCEDURE|Deep Brain Stimulation - Standard|Participants underwent DBS surgery with standard intraoperative electrophysiological testing.
40786445|NCT04979806|DRUG|Cefepime-zidebactam (FEP-ZID)|3 g (2 g FEP + 1 g ZID) IV q8h
40786446|NCT04979806|DRUG|Meropenem|1 g IV q8h
40949631|NCT01514071|BEHAVIORAL|Pop-up picture|"An animated picture depicting the key elements of the PECARN CT scan head injury rules will be explained. The picture will pop-up when a provider selects the order set for a CT scan due to head injury. Providers will need to select a box stating the patient either meets criteria or does not meet criteria in order to close the animated picture window."
40949632|NCT01715935|DRUG|Everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
40949633|NCT04601402|DRUG|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 1x10\^11 colony-forming units (CFU)
40949634|NCT04601402|DRUG|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
41146746|NCT02687841|DRUG|AST-120and pentoxyphylline (PTX)|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
41288316|NCT03533790|DRUG|DEP-Ru|"* Drug: ruxolitinib~* Drug: doxorubicin~* Drug: etoposide~* Drug: methylprednisolone"
41454020|NCT02189811|BIOLOGICAL|IPV|IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
40949635|NCT04021108|DRUG|Nivolumab 240 MG|Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
40949636|NCT06146205|PROCEDURE|Direct lateral approach|The hip joint is approached from laterally, and parts of the gluteus medius tendon is released from the greater trochanter before the hip joint is entered from the anterior side.
40949637|NCT06146205|PROCEDURE|SPAIRE|The hip joint is entered from posterior, and the approach preserves the external rotators of the hip joint.
40949638|NCT04633733|DRUG|HL237 tablet|HL237 400mg will be administered orally twice a day.
40949639|NCT04633733|DRUG|tacrolimus capsule|tacrolimus 5mg will be administered orally once a day.
40949640|NCT06352983|PROCEDURE|Fixed dental prosthesis|Fixed dentals prosthesis made out of high translucent zirconium dioxide with or without a porcelain veneer.
40949641|NCT05763095|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
40949642|NCT05420597|DRUG|Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w. Then a total dose of 70Gy in 35 fractions was administered, with concurrently weekly cisplatin (30mg/m2 qw).~At 3-6 weeks post-radiotherapy, maintenance Toripalimab was administered for 8 cycles (240mg d1 q3w, in total 8 cycles)."
40949643|NCT01595672|DEVICE|AN69 hemofilter|An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
41146747|NCT02687841|DRUG|pentoxyphylline (PTX)|pentoxyphylline 400mg QD PO x 10 days.
40759900|NCT01121029|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
40759901|NCT03789370|DRUG|Propofol|Maintanance of general anaesthesia with propofol
40759902|NCT03789370|DRUG|Sevoflurane|Maintainance of general anaesthesia with sevoflurane.
40759903|NCT06164600|DIETARY_SUPPLEMENT|Bovine colostrum|A powdered form of the first 6 hours bovine colostrum \[65 mg lactoferrin, lactoperoxidase: 2.8 unit and immunoglobulins in the form of 350 mg IgG, 35.3 mg of Ig A and 25.3 mg Ig M\]
40759904|NCT06164600|DRUG|Placebo|Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
40759905|NCT04919473|BIOLOGICAL|Gene Therapy product:vMCO-I|The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
40786447|NCT03819257|DIAGNOSTIC_TEST|Endoanal ultrasound|For the assessment of the internal and external anal sphincter integrity. To evaluate fistulas/perianal abscess and seton placement.
40949644|NCT01595672|OTHER|conventional treatments|Patients receive conventional treatments recommended by guidelines only.
40949645|NCT01298635|PROCEDURE|combined phacotrabeculectomy|trabeculectomy plus phacoemulsification with intraocular lens implantation
40949646|NCT01298635|PROCEDURE|trabeculectomy|
40949647|NCT06204978|DIETARY_SUPPLEMENT|short-chain fructo-oligosaccharides (dose 1)|10 g / day at breakfast during 7 days (Day 8 - Day 14)
40949648|NCT06204978|DIETARY_SUPPLEMENT|short-chain fructo-oligosaccharides (dose 2)|20 g / day at breakfast during 7 days (Day 8 - Day 14)
40949649|NCT06204978|OTHER|Baseline|0 g / day of short-chain fructo-oligosaccharides during 7 days (Day 1 - Day 7)
40949650|NCT02225197|RADIATION|CyberKnife Radiosurgery|25 Gy delivered in 5 fractions of 5 Gy per fraction
40949651|NCT01781754|PROCEDURE|Blood withdrawal|This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
40949652|NCT02841436|DEVICE|Irreversible Electroporation (IRE) System|
40949653|NCT04935281|OTHER|percutaneous repair with an intraoperative assisted ultrasound|Under general or regional anesthesia, the patient laid in prone position In group A, an intraoperative ultrasound was done by a radiologist before the repair .
41454021|NCT02189811|BIOLOGICAL|bOPV|bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age
40759906|NCT00635050|DRUG|Doxil, Paclitaxel, Cyclophosphamide, Avastin|"Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation."
40759907|NCT02853084|DRUG|HL2351|The dose will be adjusted based on disease activities
40759908|NCT03813121|DRUG|midazolam intravenous infusion|Participants will receive a single drug infusion
40759909|NCT03813121|DRUG|placebo intravenous infusion|Participants will receive a single placebo infusion
41288317|NCT00538733|DRUG|thalomid|"Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)"
41454022|NCT02189811|BIOLOGICAL|bOPV and IPV|bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age
41454023|NCT02189811|BIOLOGICAL|bOPV and IPV and IPV2|bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age
41454024|NCT02189811|BIOLOGICAL|tOPV|tOPV till 22 weeks of age
40759910|NCT03813121|DRUG|ketamine intravenous infusion|Participants will receive a single drug infusion
40759911|NCT00619242|DRUG|sorafenib|2 tablets with water by mouth twice a day for two weeks.
40759912|NCT00998959|BEHAVIORAL|Mindfulness Based Stress Reduction and Psychoeducation|Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.
40759913|NCT00998959|BEHAVIORAL|Psychoeducation|Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
40759914|NCT04769778|DRUG|Valsartan 80Mg Oral Tablet|treatment with 80mg /day of valsartan
40759915|NCT00720083|DRUG|cisplatin|Given IV
41288318|NCT00538733|DRUG|lenalidomide|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle"
41454025|NCT00048334|DRUG|Depsipeptide, FR901228, FK228|
41454026|NCT02093728|DRUG|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
41454027|NCT02093728|DRUG|itraconazole|Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
41454028|NCT02093728|DRUG|itraconazole|Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.
41454029|NCT02093728|DRUG|selumetinib|Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.
41454030|NCT02093728|DRUG|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
41454031|NCT02093728|DRUG|fluconazole|Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.
41454032|NCT02093728|DRUG|fluconazole|Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E
41454033|NCT02093728|DRUG|selumetinib|Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
41454034|NCT05197062|DRUG|14C-aticaprant|14C-aticaprant will be administered orally as capsule on Day 1.
41454035|NCT05913843|DEVICE|Take photo|We will use the camera to take 2 front and side images of the participant, and select one of the better images to upload to the facial analysis system (GestaltMatcher Database) for analysis.
41454036|NCT00284518|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
41454037|NCT00284518|DRUG|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
40949654|NCT04935281|OTHER|percutaneous repair without an intraoperative assisted ultrasound|For patients in group B, the course of the sural nerve was determined according to the technique described by Blackmon et al.The medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. We used the technique described byMaffulli et al with six stab incisions, one cm each. Four incisions were on medial and lateral edge of the proximal stump and the other two were around distal stump.
40949655|NCT01179893|BIOLOGICAL|IVIG|Intravenous immunoglobulin
40949656|NCT01179893|PROCEDURE|PLEX|Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
40949657|NCT05852184|OTHER|Hb Scope APP|"The study intervention is the Hb Scope APP, a camera-based real-time Hb estimation tool using a data collection function and a machine learning-based algorithm to analyze the image of HD tubing and output the estimated Hb value.~Our proposed Hb Scope APP can provide a non-invasive and real-time estimation of Hb level for detecting the alarming Hb status (i.e., \<=10 g/dL) during every HD session. The software is for information management purposes only and is not intended for diagnostic use."
40949658|NCT03314142|OTHER|Glucose as reference food|Ten subjects (male: 7, female: 3) consumed 50g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
40949659|NCT03314142|OTHER|White bread as reference food|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from white bread along with 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
40949660|NCT03314142|OTHER|Bread enriched with coarse wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with coarse wheat bran along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40949661|NCT03314142|OTHER|Bread enriched with fine wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40949662|NCT03314142|OTHER|Bread enriched with fine wheat bran and carob seed flour|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40949663|NCT00033605|DRUG|octreotide acetate|
40949664|NCT00033605|OTHER|placebo|
40949665|NCT00033605|RADIATION|radiation|
40949666|NCT03540030|DRUG|Gabapentin|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
40949667|NCT03540030|DRUG|Celecoxib|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
40949668|NCT03540030|DRUG|toradol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
40949669|NCT03540030|DRUG|acetaminophen|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
40949670|NCT03540030|DRUG|regional block|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
41146748|NCT05609864|OTHER|Quantification of injectable drugs wastage|Drugs are prescribed at discretion of physicians. For each patient who have anesthesia in the operating room, all labelled syringes having contained drugs (name + dilution) are collected and analyzed.
40759916|NCT00720083|DRUG|vandetanib|Given orally
40759917|NCT00720083|RADIATION|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
40759918|NCT05518981|DEVICE|Respiratory Remote Patient Monitor (Spire Health Tag)|"The RPM service, tailored to chronic respiratory disease patients, utilizes a system that includes three components: undergarment-adhered cardiorespiratory sensors, in-home data transmission hub, and web-based clinical dashboard. The sensors are a set of six proprietary, skin-safe devices that include sensors for intermittent photoplethysmography, continuous respiratory force, and tri-axis accelerometers for activity. Clinical liaisons monitor deviations from patient-specific baselines and contact subjects for a risk assessment call, including questions about symptoms. If a subject fails the risk assessment, they are escalated to the site to be seen, and potentially treated, by their pulmonologist."
40949671|NCT03540030|DRUG|propofol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
40949672|NCT03540030|DRUG|IV lidocaine|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
40759919|NCT06571669|DEVICE|Neuromodulation|Neuromodulation
40949673|NCT03540030|DRUG|rocuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
41288319|NCT00538733|DRUG|clarithromycin|"During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)"
41288320|NCT00538733|DRUG|dexamethasone|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)"
41288321|NCT01172288|DRUG|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
40949674|NCT03540030|DRUG|vecuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
41288322|NCT01172288|DRUG|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
40949675|NCT03540030|DRUG|sevoflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
40949676|NCT03540030|DRUG|desflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
40949677|NCT06452589|DEVICE|FieldForce Ablation System|The FieldForce Ablation System is indicated for cardiac electrophysiologic mapping, delivery of diagnostic pacing stimuli, and pulse field ablation of cardiac tissue. When used with the FieldForce Ablation Catheter, the FieldForce System is intended to be used in the right/left atria and/or left/right ventricle to deliver PFA ablation lesions in the selected areas of the chamber.
40949678|NCT00864721|DRUG|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
40949679|NCT00001438|DRUG|all-trans-retinoic acid with IFN-alpha2a|
40949680|NCT01954160|DEVICE|Symplicity Renal Denervation|Renal denervation
40949681|NCT03419611|BEHAVIORAL|Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.
40949682|NCT03419611|OTHER|Treatment as Usual|Teacher provided with word list and teacher intervening as usual.
40949683|NCT03419611|BEHAVIORAL|High Intensity Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 5 times per week.
40949684|NCT06022250|DRUG|JS207|Patients will receive specific dose of JS207 via intravenous infusion.
41288323|NCT01619618|GENETIC|mutation analysis|
41288324|NCT01619618|GENETIC|polymerase chain reaction|
41288325|NCT01619618|GENETIC|polymorphism analysis|
41288326|NCT01619618|OTHER|laboratory biomarker analysis|
41288327|NCT06021743|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
40949685|NCT01578421|DEVICE|4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)|4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
40949686|NCT02744703|DRUG|total-etch adhesive|comparator use of total-etch adhesive
40949687|NCT02744703|DRUG|CAPE-T|experimental group
41288328|NCT06021743|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
40949688|NCT02744703|DRUG|self-etch adhesive|comparator use of total-etch adhesive
40949689|NCT02744703|DRUG|CAPE-S|experimental group
40949690|NCT01999751|DEVICE|MRI Scan|Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
40949691|NCT00114387|DRUG|DL-alpha-tocopherol|
40990558|NCT04345575|DEVICE|PainCare VR|Didactic content delivered in virtual reality to support participants in learning cognitive and behavioral self-management skills based on cognitive-based therapy, biofeedback, and mindfulness strategies for pain management.
40990559|NCT04345575|OTHER|Audio content|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the VR program could not be included in the audio. Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
41288329|NCT06021743|DIAGNOSTIC_TEST|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
41288330|NCT06021743|DIAGNOSTIC_TEST|Measurement of inflammatory cytokines|A panel of pro- and anti-inflammatory markers will be determined by flow cytometer microsphere-based assay.
40949692|NCT05868954|BEHAVIORAL|MedDiet Program|Subjects allocated to the MedDiet Program group will receive counseling based on the principles of the traditional MedDiet with a focus on a general change in diet instead of micronutrients or macronutrients. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional MedDiet meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive olive oil and nuts during their enrollment visit and during their routine 26-30 week prenatal visit.
41288331|NCT04535570|OTHER|Indirect Calorimetry|In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.
41288332|NCT05093166|DRUG|"Ex vivo expanded autologous human oral epithelium containing stem cells"|The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.
41288333|NCT00379938|BIOLOGICAL|VAI-VP705 (parvovirus B-19 vaccine)|Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.
41288334|NCT00379938|DRUG|Placebo|Saline control
41288335|NCT00379938|BIOLOGICAL|MF-59|Adjuvant
40949693|NCT05868954|BEHAVIORAL|ACOG-based Dietary Program|Following ACOG recommendation, subjects allocated to the ACOG-based Dietary Program group, will receive routine counseling on healthy eating. This will include advice on the consumption of grains, fruits, vegetables, protein, and dairy foods recommended during pregnancy. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional healthy meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive canola oil and healthy snacks during their enrollment visit and during their routine 26-30 week prenatal visit.
40949694|NCT02256592|DRUG|Fecal Microbiota|300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
41288336|NCT00796783|DRUG|Cushing's syndrome confirmation|
41288337|NCT05839548|DRUG|Mepivacaine 2% with epinephrine 1:100,000|Local Anesthesia
40949695|NCT01034189|DRUG|Cetuximab|Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3\~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
40949696|NCT01034189|DRUG|Paclitaxel|T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
40949697|NCT01034189|DRUG|Cisplatin|P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
40949698|NCT01034189|RADIATION|Radiotherapy|Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
40949699|NCT02439983|DIETARY_SUPPLEMENT|Proprietary Nutritional Supplement|2 capsules taken by mouth with morning and evening meals.
41288338|NCT05839548|DRUG|Articaine (4%) with epinephrine 1:100,000|Local Anesthesia
41288339|NCT04252807|BEHAVIORAL|Intervention arm|In addition to the routine care delivered by Lady Health Workers (LHWs), the participants in the intervention arm will receive common elements based integrated intervention. The providers of the intervention are lay health workers who will be trained in the intervention using an online course. The lay health worker will complete the online training course in a group, with interactive group activities and role plays. Lay health workers will be supported online and in-person by the trainers in monthly supervision meetings. The lay health workers will deliver intervention to distressed mothers in 15 monthly sessions. The intervention consists of three modules including 1) mothers' well-being, 2) infant nutrition,early stimulation and breastfeeding and 3) mother-infant interaction.
41288340|NCT04252807|OTHER|Treatment as Usual|The participants in the control arm will receive the routine visits by LHWs of their respective areas. The LHWs are trained to provide antenatal care and referral, immunization services and support to community mobilization, provision of family planning and basic curative care via door to door visits to the households of their allocated areas.
41288341|NCT00072722|DRUG|CC-4047|
40949700|NCT02439983|DIETARY_SUPPLEMENT|Placebo|2 capsules taken by mouth with morning and evening meals.
40949701|NCT03468829|BIOLOGICAL|ALX-0171 Dose 1|Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days
41288342|NCT05890391|OTHER|Time-Restricted Eating|They were fed ad libitum between 10.00 a.m-06.00 p.m and fasted between 06.00 p.m-10.00 a.m.
40949702|NCT03468829|BIOLOGICAL|ALX-0171 Dose 2|Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days
40949703|NCT03468829|BIOLOGICAL|Placebo|Oral inhalation of Placebo once daily for a maximum of 14 days
40949704|NCT05460260|DEVICE|Cascade CGM|21-days of CGM wear
40949705|NCT04332133|PROCEDURE|laser interference,INTRAVITREAL INJECTION|sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2
40949706|NCT05329532|BIOLOGICAL|Modi-1/Modi-1v|Modi-1/Modi-1v administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).
40949707|NCT05329532|BIOLOGICAL|Pembrolizumab|Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.
40949708|NCT05329532|DEVICE|MicronJet600™ microneedle device (NanoPass)|Intradermal injection device
40949709|NCT01967173|DRUG|Flovent Diskus® 100 mcg|Flovent is an ICS
40949710|NCT01967173|DRUG|Flovent Diskus® 250 mcg|Flovent is an ICS
40949711|NCT01967173|DRUG|Flovent Diskus® 500 mcg|Flovent is an ICS
40949712|NCT01967173|DRUG|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
40949713|NCT01967173|DRUG|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
40949714|NCT02443519|BEHAVIORAL|MBCT for Migraine|8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
40949715|NCT05095038|DIETARY_SUPPLEMENT|Appethyl®|Spinach extract, capsules, 5g/day, 26 weeks.
40949716|NCT05095038|DIETARY_SUPPLEMENT|Placebo|Pea protein, capsules, 5g/day, 26 weeks.
40949717|NCT01792271|OTHER|Inhaled 7% HS (NaCl) home treatment|Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
40949718|NCT01232231|DRUG|pharmacological decolonization treatment|Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
40949719|NCT01232231|BEHAVIORAL|Education|No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
41133650|NCT04347941|PROCEDURE|Prone Positioning|Patient will be asked to remain for at least one hour and to a maximum total of 16 hours in prone position with 45 minutes breaks for meals. Immediately prior to proning, if spO2 \<94% on FiO2 0.4, start on 100% O2 to ensure stability during proning. A nurse or assistant will assist patient to turn on side and then face down with the support of pillows as required for comfort, ensure that they are predominantly on their chest rather than on their side. Arms can be at side, in swimmer position and can be moved to patients' comfort, pillows under knees and chest for comfort and call bell to be at patient's arm's length. Vitals and work of breathing score will be measured before and at 1 hour into each proning session and at the end of each session. Total length of time in prone position will be recorded. Intervention to continue daily until oxygen requirement to maintain spO2 \>94% is below FiO2 0.4 via venturi facemask or high flow nasal cannula
40949720|NCT04157543|OTHER|electroacupuncture|acupuncture with electricity
40759920|NCT03494842|DEVICE|Transcutaneous nerve stimulation (TENS)|The active TENS unit (delivers electrical stimulation) with indicator light
40759921|NCT03494842|DEVICE|Placebo Transcutaneous nerve stimulation (TENS)|the placebo TENS unit (delivers no electrical stimulation) with indicator light
40786448|NCT03819257|DIAGNOSTIC_TEST|High-resolution anorectal manometry|"1. rest - basal anal pressures at rest over 60 s~2. squeeze - anal pressure during voluntary effort; long squeeze - anal pressure during sustained voluntary effort~3. cough - anorectal pressure changes during cough~4. push - anorectal pressure changes during simulated defecation~5. rectoanal inhibitory reflex - reflex anal response to rectal distension~6. rectal sensation - assessment of rectal sensitivity to distension."
40949721|NCT06059248|OTHER|"the head in the sniffing position "|"Intubation was performed with the head in the  elevation  position"
40949722|NCT04046237|OTHER|Periodontal treatment|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9.~Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
40949723|NCT00965809|DRUG|Tetrahydrocannabinol|Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
41133651|NCT04347941|PROCEDURE|Standard of care.|Standard of care. Prone positioning may be administered as a rescue therapy
40949724|NCT00965809|OTHER|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
41288343|NCT05890391|OTHER|Energy-Restricted Diet|The total energy expenditure (TEE) of individuals was determined using the 'Resting Energy Expenditure (REE) x Physical Activity Level (PAL) ' formulation. 'TEE-500 kcal' formulation was used for the diet to be given to individuals.
40949725|NCT05631600|BIOLOGICAL|Manuka honey|The honey was applied with special designed cannula. The dosage is not exactly define so we inject the amount of honey until until the excess of the material was observed in the sulcus.
40949726|NCT04021420|DEVICE|SONOCLOUD|"The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.~The SonoCloud System consists of :~1. an implantable ultrasound transducer,~2. a needle connection device,~3. an external radiofrequency generator, and~4. an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa)."
40949727|NCT04021420|DRUG|Nivolumab Injection|Nivolumab (flat dose: 240mg, 30 minutes infusion)
40949728|NCT02309593|DEVICE|PROFEMUR® Xm Femoral Stems|THA using PROFEMUR® Xm Femoral Stems
40949729|NCT06284096|BEHAVIORAL|Psychoeducation|The study is planned to consist of 7 sessions, occurring once a week, with approximately 70-80 minutes allocated for each session. Considering the attention span of the participants, the sessions will be divided into two parts, with a session lasting 30-40 minutes followed by a 15-minute break.
40949730|NCT00091416|BIOLOGICAL|VRC-HIVADV014-00-VP|
40949731|NCT04195282|OTHER|Plasma exchange|Patients will receive treatment of plasma exchange for three times in two weeks. The volume of fresh frozen plasma used in plasma exchange is about 2000 millilitre per time.
40949732|NCT04195282|OTHER|RL-1 Novel Human-derived Bio-artificial Liver Treatment|Patients will receive RL-1 Novel Human-derived Bio-artificial Liver treatment for three times in two weeks. The volume of plasma exchanged in the system is about 4000 millilitre per time.
40949733|NCT03325049|BEHAVIORAL|The health-promoting conversations|The health-promoting conversations
40949734|NCT03325049|OTHER|Usual Care|Usual Care
40949735|NCT00735254|DEVICE|pulsed dye laser|patient will have scar treated with pulsed dye laser
40949736|NCT00735254|DEVICE|Affirm Laser|patient will have scar treated with Affirm laser
40949737|NCT00735254|DEVICE|combined PDL and Affirm Lasers|patient will have scar treated with Affirm and pulsed dye lasers
40949738|NCT00735254|OTHER|Placebo|patient will receive no treatment
40949739|NCT05384938|BIOLOGICAL|Benralizumab|Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India
40949740|NCT02788760|DEVICE|Cervical collar (Miami J collar - Össur)|The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment
41133652|NCT05724966|DEVICE|mHealth app|We wish to examine the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. Usual procedure to assess side effect prior to cancer treatment with Bortezomib is a telephone call the day before.
41133653|NCT00637104|DEVICE|Mar-Tyn TiN coated Co-Cr Numen stent implant|Implant of the Mar-tyn TiN coated stent
41133654|NCT00637104|DEVICE|Vision Co-Cr stent implant|Implant of the Vision stent
41288344|NCT02185170|PROCEDURE|Trans-urethral resection|All subjects of the study are going to have a trans-urethral resection of prostate.
41288345|NCT02185170|DEVICE|Use of the FEMTO-ST institute medical device|The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
41288346|NCT02185170|DEVICE|Use of the Light-CT scanner|The Light-CT Scanner is use in the tissue structural observation
40786449|NCT03819257|DIAGNOSTIC_TEST|Balloon expulsion test|A non-latex balloon will be inserted in the rectum after applying lubricating gel. This balloon is then filled with 50ml of warm water. The patient is ask to sit on a commode and to try to expel the device in privacy, while the time is being recorded. The test ends when the patient expelled the balloon or when 3 minutes are reach.
40786450|NCT02185534|DRUG|Clopidogrel|European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
40786451|NCT01341743|DRUG|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
40786452|NCT01341743|DRUG|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
40786453|NCT01341743|DRUG|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
40786454|NCT05165095|DEVICE|Pacemaker implantation|De novo implantation, device upgrade to dual chamber or device replacement
40786455|NCT05718817|DRUG|XEN1101|XEN1101 capsules
40786456|NCT01169480|BEHAVIORAL|Give a massage|Participants in this arm will give a 50-minute Swedish massage to a volunteer.
40786457|NCT02947633|DRUG|Single-injection sciatic PNB|Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
40786458|NCT02947633|DRUG|Continuous sciatic PNB|"Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief."
40786459|NCT01153204|BEHAVIORAL|Group Psychotherapy|
40786460|NCT01153204|OTHER|Group Psychotherapy plus Sildenafil citrate|
40786461|NCT01153204|DRUG|Sildenafil citrate|
40949741|NCT00132210|DRUG|pegylated interferon|Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.
40949742|NCT03925064|OTHER|myocardial performance index|fetal right ventricular myocardial performance index measured with tissue doppler
40949743|NCT00991120|DEVICE|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
40949744|NCT04357782|DRUG|L-ascorbic acid|50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)
40949745|NCT03113916|BEHAVIORAL|Behavioural Lifestyle Intervention|A culturally tailored behavioral intervention.
40949746|NCT04324931|OTHER|Biomechanical corrections|Biomechanical corrections is to be done to correct the varus deformity of knee joint and for pain management.
40949747|NCT04324931|OTHER|Conventional Physiotherapy|Conventional therapy includes Hydrocollatoral pack for 20 minutes, Interferential therapy for 15 minutes beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program of 3 sessions for 20 minutes on alternative days for 3 weeks for management of knee osteoarthritis.
40949748|NCT00065988|DEVICE|Dispersed phase amalgam restoration /composite restoration|
40949749|NCT02876094|DRUG|celecoxib|dose-response
40949750|NCT03510754|PROCEDURE|Eus guided biliary drainage|"After reaching the cardia or the lesser curvature of the stomach, for the transgastric approach, or the duodenal bulb, for the transduodenal one, intrahepatic left and extrahepatic bile ducts were punctured with a 19-gouge needle and the access was confirmed the injection of contrast under fluoroscopy to obtain an anterograde cholangiogram.~A 0.035-inch guide was advanced into the selected bile duct and under EUS and fluoroscopic view a stent was placed through the hepatogastrostomy between a left bile duct and the gastric lumen or through the choledochoduodenostomy between the common bile duct and the duodenal lumen."
40949751|NCT01852305|OTHER|Lab Sleep Study Group|Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI\>30) or moderate sleep apnea (AHI\>15 to \<30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI\>5 to \<15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
40949752|NCT01852305|DEVICE|Oximetry|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI\>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
40949753|NCT02122432|OTHER|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.~Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)~Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?"
40949754|NCT02292342|DIETARY_SUPPLEMENT|Water|Control
40949755|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 0.1 mg/kg|EC 0.1 mg/kg
40949756|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 0.5 mg/kg|EC 0.5
40949757|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 1.0 mg/kg|EC 1.0
40949758|NCT02956070|DRUG|Dexamethasone acetate|The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
40949759|NCT02956070|DRUG|Potassium Nitrate|The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch \[50%\], lactose monohydrate \[35%\], dibasic calcium phosphate \[14%\], and magnesium stearate \[1%\]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
40949760|NCT04138004|DRUG|polyethylene glycol in combination with lubiprostone|2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
40949761|NCT04138004|DRUG|polyethylene glycol alone|4-litre polyethylene glycol split-dose
40949762|NCT03272230|BEHAVIORAL|ECOCAPTURE|45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system
40949763|NCT03272230|BEHAVIORAL|Cognitive and Behavioral experimental tasks|Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions
40949764|NCT03272230|DIAGNOSTIC_TEST|Neuropsychological assessment|MMS / MADRS / EBI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING / STROOP / STARKSTEIN / DAS
40949765|NCT03272230|BEHAVIORAL|ICM_APATHY_TASKS|Apathy experimental task
40949766|NCT03272230|OTHER|MRI|T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI
40949767|NCT03272230|BIOLOGICAL|Neurohormonal mechanisms|Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage
40949768|NCT03272230|DIAGNOSTIC_TEST|Supplementary Neuropsychological Assessment - Parkinson's Disease|ACDD / QUIP / BIS-11 / ECMP / QUIP-RS
40949769|NCT04525352|BIOLOGICAL|RP-L401|CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene
40949770|NCT01578330|DRUG|Fingolimod|Fingolimod 0.5mg orally once a day without food.
40949771|NCT01785420|DRUG|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
40949772|NCT01785420|DRUG|Placebo|A 90 minute intravenous infusion of saline as placebo
40759922|NCT01704989|PROCEDURE|SLT Laser|At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
40759923|NCT01704989|DRUG|Prostagladin|Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (\>35 mmHg) or advanced damage at presentation.
40759924|NCT02928900|BEHAVIORAL|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
40949773|NCT05890742|DRUG|Sintilimab|In ARM Phase Ib Control group, Sintilimab will be used twice, q3w.
40949774|NCT05890742|DRUG|IBI310&Sintilimab|In ARM Phase Ib\&III Experimental group，IBI310\&Sintilimab will be used in first cycle, Sintilimab will be used in second cycle(q3w). Radical surgery after neoadjuvant therapy.
40949775|NCT05890742|PROCEDURE|Radical surgery|In ARM Phase Ib\&III Experimental group, Phase Ib Control group, subjects will receive radical surgery after neoadjuvant therapy. In ARM Phase III Control group,subjects will receive radical surgery without neoadjuvant therapy
40949776|NCT02121522|DRUG|BI 144807|twice daily
40949777|NCT05189379|OTHER|Non-Alcoholic Odour|A chemical used in fragrances and flavouring with a smell close to a nutty, buttery structure. Used as a 1:100 deionised water dilution.
40949778|NCT05189379|OTHER|Alcoholic Odour|Alcoholic beverage beer / Alcoholic beverage red wine / Alcoholic beverage brandy / The type of the Alcoholic Odour intervention will be presented in a participant-preference basis.
40949779|NCT05189379|OTHER|Non-Alcoholic Images|Images of non-alcoholic items, namely; broom, duster, clothing iron, lightbulb, mat, mulch, penlight, rack, rock, kitchen scissors, trough, vent are presented in parallel with the non-alcoholic odour
40949780|NCT05189379|OTHER|Alcoholic Images|Images of alcoholic items, namely, beer, wine, schnapps are presented in parallel with the alcoholic odour
40949781|NCT00881257|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
40949782|NCT04888078|PROCEDURE|Bassini hernia repair|Non-mesh tissue inguinal hernia repairs
40949783|NCT01825525|DEVICE|Exposure to ScopeGuide|The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
40949784|NCT04619927|GENETIC|Direct CYP2C19 genotyping|CYP2C19 genotype will be determined by the Spartan RX CYP2C19 point-of-care system.
40949785|NCT04619927|GENETIC|CYP2C19 genotyping at the end of the study|Blood-based CYP2C19 genotyping will be performed at the end of the study
40949786|NCT04619927|DRUG|Poor metabolisers|Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily
40949787|NCT04619927|DRUG|Intermediate metabolisers|Clopidogrel 75mg twice daily
40949788|NCT04619927|DRUG|Normal metabolisers and unknown metaboliser state|Clopidogrel 75mg once daily
40949789|NCT01964131|DRUG|D961H sachet 20 mg|"Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2).~Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
40949790|NCT01964131|DRUG|D961H HPMC capsule 20 mg|"Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
40949791|NCT05688007|DIAGNOSTIC_TEST|parathyroid hormone level|Serum level of parathyroid hormone
40949792|NCT05688007|DIAGNOSTIC_TEST|serum electrolytes|Serum levels of: magnesium, phosphorus, calcium, and albumin
40949793|NCT05590494|PROCEDURE|Ultrasonic tenotomy|Ultrasonic procedure as part of standard of care, as clinically indicated, to stimulate healing of the partial tear. The procedure uses ultrasound guidance that allows a needlelike device to gradually break up and remove tendinopathic tendon tissue.
40949794|NCT06189690|DEVICE|rTMS|Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.
40949795|NCT04365868|DRUG|belapectin|intravenous
40949796|NCT04365868|DRUG|Placebo|intravenous
40949797|NCT01612858|DRUG|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
40949798|NCT01612858|DRUG|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
40949799|NCT01209507|OTHER|Chemotherapy|This study is designed only to look at the prevalence of adrenal suppression during chemotherapy. If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
40949800|NCT02017418|DIETARY_SUPPLEMENT|zeaxanthin|softgel
40949801|NCT02017418|DIETARY_SUPPLEMENT|combinatory supplement|softgel
40949802|NCT03434769|DRUG|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
40949803|NCT03434769|DRUG|Fludarabine|Fludarabine 25mg/m\^2 IV on days -5 to -3
40949804|NCT03434769|BIOLOGICAL|CAR-T Cells|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0~Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
40949805|NCT03468101|OTHER|Pulmonary Function Testing|Pulmonary Function Testing, Cardiopulmonary exercise testing, 6 Minute walk test, Thoracic CT
40949806|NCT00867685|DRUG|AZD2624|Single dose of 40 mg AZD2624 liquid suspension, PO
40949807|NCT00867685|DRUG|AZD2624|Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
40949808|NCT01988220|OTHER|sensory retraining|
40949809|NCT01988220|OTHER|repeated sensory input|sensory stimulation without attentive learning focus
40949810|NCT03991858|OTHER|Phone call follow-up|A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic
40949811|NCT03991858|OTHER|Telerehabilitation follow-up|A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
40949812|NCT04524806|OTHER|stabilization splint|Stabilization splint is an appliance which applied to upper or lower jaw and regulating the occlusal forces in the temporomandibular joint that can cause disorders, also preventing excessive contraction of the masticatory muscles
40949813|NCT05769998|BEHAVIORAL|Acceptance and Commitment-based treatment|The ACT-based group intervention includes four 1-hour group sessions over two weeks. The treatment manual was developed by the authors of this study following the ACT framework and adapting materials and resources from ACT-based treatments developed for other settings. The focus of the intervention is to provide patients with pain education specific for patients who underwent TKA and to promote psychological flexibility. Each session employs experiential exercises, including mindfulness meditation, and metaphors addressing the core components of ACT.
41146749|NCT01705444|DEVICE|Foley Catheter and The Spanner Insertion|A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
40949814|NCT05769998|OTHER|Treatment as usual|Standard pharmacotherapy and physical exercise plan provided to all the patients in the rehabilitation unit.
40949815|NCT05192733|OTHER|Survey|This is a cross-sectional practice survey. There is no intervention.
40949816|NCT05093140|DRUG|Camrelizumab|"Induction therapy:~Camrelizumab 200mg, ivd, D1, Rituximab 375mg/m2, ivd, D1 every 3 weeks up to 2 cycles~Immunochemotherapy:~Rituximab: 375mg/m2, ivd, D1; Cyclophosphamide: 750mg/m2, iv or ivd, D1; Hydroxyldaunorubicin: 50mg/m2, iv or ivd, D1; Vincristine: 1.4 mg/m2 , iv(max：2mg), D1; Prednisone: 60mg/m2, po, d1-5 every 3 weeks up to 6 cycles Maintenance therapy: Camrelizumab 200mg, ivd, D1 every 4 weeks up to 6 cycles"
40949817|NCT02127593|DRUG|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
40949818|NCT02127593|DRUG|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
40949819|NCT01807039|PROCEDURE|hip fracture surgery|we evaluate the relationship between the monitored parameters and 30 day survival
40949820|NCT04348110|DIETARY_SUPPLEMENT|Placebo tablets|consume 2 tablets per day for 8 weeks
40949821|NCT04348110|DIETARY_SUPPLEMENT|Blueberry Chewable Tablets|consume 2 tablets per day for 8 weeks
40949822|NCT01042678|BIOLOGICAL|MP0112|Single intravitreal injection of MP0112 in the study eye
40949823|NCT03094988|BEHAVIORAL|Cognitive and physical prehabilitation|Participants engage in cognitive and physical training daily for approximately 2-4 weeks prior to surgery.
40949824|NCT03094988|OTHER|Active attention control|Participants will be provided with personal health educational materials and access to the control version of cognitive training program.
40949825|NCT02974478|DIETARY_SUPPLEMENT|Orange juice with meals|orange juice (20% of energy requirement/day)
40949826|NCT02974478|DIETARY_SUPPLEMENT|Orange juice between meals|orange juice (20% of energy requirement/day)
40949827|NCT02974478|DIETARY_SUPPLEMENT|Sugar sweetened beverage between meals|Sugar sweetened beverage (20% of energy requirement/day)
40949828|NCT06453902|DRUG|TGRX-678|All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally
40949829|NCT05322733|DRUG|Orelabrutinib|150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
40949830|NCT05322733|DRUG|Obinutuzumab|1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
40949831|NCT05322733|DRUG|Fludarabine|25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
40949832|NCT05322733|DRUG|Cyclophosphamide|250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
40949833|NCT02787265|DEVICE|spinal cord stimulation|
40949834|NCT04208997|DRUG|Antiarrhythmic drug|Continuation of amiodarone or sotalol.
41288347|NCT06060080|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|Lymphoma/multiple myeloma patients who meet the inclusion criteria will be administered PEG-rhG-CSF injection at a fixed dose of 6 mg on the second day after hematopoietic stem cell infusion, and the effectiveness and safety of the treatment will be observed.
40759925|NCT04426513|OTHER|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
40949835|NCT03283111|BIOLOGICAL|autologous stem cell transplantation|autologous stem cell transplantation
40759926|NCT06517511|DRUG|Selinexor Oral Tablet [Xpovio]|Selinexor (60mg po D1, 8) is added from the second cycle of R-CHOP regimen.
40759927|NCT06517511|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
40759928|NCT04361331|DRUG|Lenvatinib combined with gemox|Arm2: Lenvatinib + gemox
40759929|NCT04361331|DRUG|Toripalimab combined with lenvatinib|Toripalimab combined with lenvatinib
40949836|NCT00560768|DEVICE|Ovatio VR 6250 or DR6550|"The study requires the implantation of locally approved material:~* A right ventricular defibrillation lead~* In case of use of a dual chamber ICD a right atrial pacing lead~* A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar."
40949837|NCT02869607|OTHER|Data collection|
40949838|NCT04308304|DRUG|MK-1942|MK-1942 1 mg, 5 mg, and/or 10 mg capsules taken twice daily (BID) by mouth.
40949839|NCT04308304|DRUG|Donepezil|Donepezil 5 mg and/or 10 mg tablets taken once daily (QD) by mouth.
41146750|NCT01305837|DRUG|methylprednisolone|500 mg of methylprednisolone taken in 3 days every month
41146751|NCT00091676|BIOLOGICAL|FNHLId1|5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
41146752|NCT00091676|BIOLOGICAL|KLH + GM-CSF|5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
41146753|NCT00164021|PROCEDURE|Physiotherapy, exercise, percutaneous gastrostomy feeds|
40949840|NCT04308304|DRUG|Placebo|Placebo capsule matched to MK-1942 taken BID by mouth.
40949841|NCT03719820|DRUG|aggressive medical management|Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management
40949842|NCT00595465|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
41146754|NCT00164021|DRUG|Anti-reflux pharmacotherapy|
41288348|NCT03070132|DRUG|BIIB074|Administered as specified in the treatment arm
41288349|NCT03070132|DRUG|Placebo|Matched placebo
41288350|NCT03835338|DEVICE|Pulmonary Vein Isolation|Pulmonary Vein Isolation by RF Ablation
40949843|NCT02096237|DEVICE|IgE adsorber|Two plasma volumes of each patient in the apheresis group will be treated per session
40949844|NCT03472651|DRUG|test treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose
40949845|NCT03472651|DRUG|reference treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose
40949846|NCT00640861|BIOLOGICAL|CpG oligodeoxynucleotide|
40949847|NCT00640861|BIOLOGICAL|HER-2/neu peptide vaccine|
41288351|NCT03835338|DEVICE|LAA Isolation|LAA Isolation by RF Ablation
40759930|NCT06570811|DRUG|Placebo|Placebo tablets is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
40759931|NCT06570811|DRUG|Coenzyme Q10 200mg twice daily|400 mg daily (200mg twice daily) of Coenzyme Q10 (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
40949848|NCT00640861|BIOLOGICAL|MUC-1 peptide vaccine|
40949849|NCT00640861|BIOLOGICAL|incomplete Freund's adjuvant|
40949850|NCT00640861|BIOLOGICAL|sargramostim|
40949851|NCT00640861|OTHER|immunoenzyme technique|
40949852|NCT00640861|OTHER|immunologic technique|
41288352|NCT03835338|DEVICE|LAA Occlusion|LAA Occlusion by implantation of the WATCHMAN LAAC Device
40759932|NCT00091897|DRUG|Rituximab|
40759933|NCT00091897|DRUG|rituximab or placebo|A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
40759934|NCT03699163|DIAGNOSTIC_TEST|Breath sample|Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
40759935|NCT04873193|DEVICE|Leo device|Children's respiratory flow and volume measurements will be continuously recorded using the Leo device during oscillometry and pneumotach procedures.
40949853|NCT02960152|OTHER|diagnostic|full-mouth periodontal examination
40949854|NCT00820352|DRUG|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
40949855|NCT00820352|DRUG|placebo|placebo twice a day for 12 weeks
40949856|NCT03881670|DEVICE|Lotrafilcon B|commercially available contact lens
40949857|NCT03881670|DEVICE|lotrafilcon B with Hydraluxe|commercially available contact lens
40949858|NCT02544178|RADIATION|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
40949859|NCT06295107|DIAGNOSTIC_TEST|Ankle Passive Range of Movement (pROM)|Ankel and knee pROM measurements.
40949860|NCT06295107|DIAGNOSTIC_TEST|Knee Passive Range of Movement (pROM)|Ankel and knee pROM measurements.
40949861|NCT00406718|BEHAVIORAL|Med-eMonitor|Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
40949862|NCT00406718|BEHAVIORAL|PharmCAT|Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
40949863|NCT00406718|BEHAVIORAL|Treatment as Usual|Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
40949864|NCT01868503|DRUG|lapatinib ditosylate|Given PO
40949865|NCT01868503|RADIATION|radiation therapy|Undergo radiation therapy
40949866|NCT01868503|OTHER|laboratory biomarker analysis|Correlative studies
40949867|NCT00185562|DRUG|Adalimumab|
40949868|NCT04406220|OTHER|Small clog size|Participants will be randomized to run in small clogs
40949869|NCT04406220|OTHER|Large clog size|Participants will be randomized to run in large clogs
41146755|NCT06286319|DEVICE|Angel Cooler|Device that provides cooled oxygen (between 4-8°C) directly to the lung airways along with external cooling to lung surfaces using cold preservation solutions.
41288353|NCT02903511|DRUG|Metformin|Monitoring of safety and tolerability
41288354|NCT02903511|DRUG|Placebo|Monitoring of safety and tolerability
40949870|NCT06452238|OTHER|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal plane block .
40949871|NCT06452238|OTHER|Transversus Abdominis Plane Block|Patients will receive ultrasound-guided transversus abdominis plane block.
41288355|NCT00530712|DEVICE|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
41288356|NCT01757457|DRUG|Intracoronary administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
41288357|NCT01757457|DRUG|Intravenous administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
40949872|NCT00014482|PROCEDURE|pain therapy|
40949873|NCT00014482|PROCEDURE|psychosocial assessment and care|
40949874|NCT04206059|RADIATION|MRI|A non-contrast brain MRI will be acquired for localizing EEG slow waves
40949875|NCT04206059|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
40949876|NCT04206059|DIAGNOSTIC_TEST|Home sleep study|Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
40949877|NCT04206059|OTHER|Acoustic stimulation (65db) up-slope of EEG with QST|Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
40949878|NCT04206059|OTHER|Acoustic stimulation (65db) down-slope of EEG with QST|65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
40949879|NCT04206059|OTHER|0 db with QST|sham stimulation (0 dB volume)
40949880|NCT04206059|DRUG|Dexmedetomidine|All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
40949881|NCT04206059|OTHER|Breathe-Squeeze Task|All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
40949882|NCT04300439|DEVICE|knee total arthroplasty with two types of ancillaries|"-For the Arm A, the surgical procedure of knee total arthroplasty will be done with metallic reusable ancillary.~For the Arm B, the surgical procedure of knee total arthroplasty will be done with Efficiency single use ancillary."
40949883|NCT06251752|DIAGNOSTIC_TEST|X-rays: load bearing inferior limbs, lateral knee, axial patella|X-rays at 5 years follow-up minimum
40949884|NCT00002078|DRUG|Interferon alfa-n3|
40949885|NCT01769989|PROCEDURE|Electrodermabrasion|
40949886|NCT01769989|PROCEDURE|Dermabrasion|
40949887|NCT05538533|RADIATION|46 Gy Radiation Therapy|Dose per fraction of 4.6.
40949888|NCT05538533|RADIATION|40 Gy Radiation Therapy|Dose per fraction 5.7.
40949889|NCT05538533|RADIATION|35 Gy Radiation Therapy|Dose per fraction 7.0.
40949890|NCT05379777|DRUG|Remimazolam|Remimazolam The starting dose of remimazolam is 1 mg/kg/hr. If sedation does not proceed successfully, increase the infusion rate by 0.2 mg/kg/hr in the next patient. (However, if the infusion rate is less than 0.6mg/kg/hr, the dose is increased by 0.1mg/kg/hr.) If sedation has progressed successfully until the end of surgery, the next patient will use the same dose with a probability of 0.89 or 0.11 It is reduced by 0.2 mg/kg/hr with a probability of (However, if the infusion rate is 0.6mg/kg/hr or less, reduce it by 0.1mg/kg/hr.)
40949891|NCT04896879|BEHAVIORAL|interviews|semi-structured interviews will be conducted in patients with major LARS and their informal caregiver to explore their experiences and needs. Focus groups will be perfomed with healthcare professionals of several professions.
40949892|NCT03277690|DRUG|Levoketoconazole|"During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.~During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo."
41288358|NCT04908137|DRUG|2-octyl cyanoacrylate|Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet No. 2. It is provided as a single use applicator in a blister package
41288359|NCT01359540|DEVICE|OMNI Apex Modular™ Hip Device|
40949893|NCT03277690|DRUG|Placebo|"During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole."
40949894|NCT01613365|DRUG|Chlorhexidine Gluconate|Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
41133655|NCT03836651|OTHER|Dietary Antioxidant (V8® Low Sodium 100% vegetable juice)|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants randomized to the intervention group will receive a month's supply of the V8® 100% Low-Sodium Vegetable juice as the dietary antioxidant intervention. Participants will be asked to drink one V8® juice each day for 30 days. Each V8® juice can is 11.5 ounces and can be consumed in divided amounts or all at once. The average daily intake of lycopene is estimated to be 5mg, one can of V8 juice provides 24 mg of lycopene. Thirty days duration for the intervention of V8® juice is based on previous data that indicates plasma antioxidant concentrations rise significantly within a two-week period and a plateau effect is reached within 4 weeks.
40949895|NCT01613365|DRUG|Placebo|Oropharyngeal and nasopharyngeal decontamination with placebo
40949896|NCT02817074|BEHAVIORAL|MIND Diet|3-year dietary counseling to adhere to the MIND diet and for mild weight loss
40949897|NCT02817074|BEHAVIORAL|Mild Weight Loss|3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
40949898|NCT00805454|DRUG|OPC-34712|Single oral dose, 0.5 to 25 mg
40759936|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
40949899|NCT02213354|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
40949900|NCT02213354|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
40949901|NCT02605304|DRUG|Ledipasvir/sofosbuvir|Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
40949902|NCT02605304|DRUG|Ribavirin|"Based on weight at entry:~For weight \<75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally."
40949903|NCT04260711|DRUG|DMT|Discontinuation of patients' own disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
40949904|NCT01816529|DRUG|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
40949905|NCT01816529|DRUG|Vehicle Cream|Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
40949906|NCT01816529|DRUG|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
40949907|NCT01816529|DRUG|Saline (0.9%)|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
40949908|NCT05490407|DRUG|Carboplatin|Patients will receive neoadjuvant chemotherapy according to ESGO guidelines
40949909|NCT02626767|OTHER|Novel high-intensity interval exercise training|Please see information already included in the 'intervention' arm description.
40949910|NCT05847361|DIAGNOSTIC_TEST|BH4 blood level|from admission to END OF PREGNANCY, a blood sample is taken.
40949911|NCT00002665|DRUG|asparaginase|10,000 units/d IV or IM 15 - 24
40949912|NCT00002665|DRUG|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
40949913|NCT00002665|DRUG|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
40949914|NCT00002665|DRUG|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
40949915|NCT00002665|DRUG|dexamethasone|main: 10 mg/m2/day PO 1 - 28
41288360|NCT01359540|DEVICE|OMNI Apex ARC™ Hip Device|
41288361|NCT01899144|DRUG|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
41288362|NCT01899144|DRUG|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
41288363|NCT01899144|DRUG|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
40949916|NCT00002665|DRUG|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
40949917|NCT00002665|DRUG|etoposide|60 mg/kg based on ideal body weight day -3
40949918|NCT00002665|DRUG|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC \< 3,000 /μl
40949919|NCT00002665|DRUG|mercaptopurine|con: 60 mg/m2 PO 1 - 28
40949920|NCT00002665|DRUG|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
40949921|NCT00002665|DRUG|prednisone|"ind: 60 mg/m2/d PO 1 - 21\*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.~ind2: 60 mg/m2/d PO through day 42"
40949922|NCT00002665|DRUG|thioguanine|main: 60 mg/m2/day PO 1 - 14
40949923|NCT00002665|DRUG|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
40949924|NCT00002665|PROCEDURE|allogeneic bone marrow transplantation|day 0
40949925|NCT00002665|RADIATION|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
40949926|NCT03555734|OTHER|Dietary pulses or legumes|Dietary pulses (dried beans, dried peas, chickpeas, lentils). If no data available specifically for dietary pulses than legumes will be assessed as the exposure (includes pulses, soybeans, peanuts, fresh peas, fresh beans).
40949927|NCT05788653|PROCEDURE|Thiele Massage|Transvaginal Massage
41133656|NCT03836651|OTHER|Control group|The control group will continue to be medically managed by their health care provider as usual. The control group will have the same visit and call schedule as the intervention group.
41133657|NCT05302115|DEVICE|S-ICD|Implantation of an S-ICD
41133658|NCT01987518|OTHER|Procedure surgery behavioral and genetic diagnosis|Observational Study
40759937|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
40759938|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|"Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~* Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~* Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~* Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~* Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~* Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~* Methotrexate 15 mg, IT, Days 36, 56"
40759939|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
40759940|NCT03627468|DRUG|Sofpironium Bromide Gel, 5%|Sofpironium Bromide Gel, 5%
40759941|NCT03627468|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
40759942|NCT04989166|DIETARY_SUPPLEMENT|Nano-curcumin|Nano-curcumin soft gels
40759943|NCT04989166|DRUG|Placebo|Placebo
40949928|NCT05788653|PROCEDURE|Transverse Friction Massage|Transvaginal Massage
40949929|NCT05269433|BEHAVIORAL|OCAT-sham|Placebo version of the online contingent attention training preceded by a psycho-education movieclip.
40949930|NCT05269433|BEHAVIORAL|OCAT|Online contingent attention training preceded by a psycho-education movieclip.
40949931|NCT05269433|OTHER|Psycho-education video|All groups watch a psycho-education video before the start of the 10-day attention training.
40949932|NCT05269433|OTHER|Motivational video|Participants in the OCAT+ condition watch a short motivational video before each training session.
40949933|NCT00003870|DRUG|cyclophosphamide|
40949934|NCT00003870|DRUG|methotrexate|
40949935|NCT00003870|PROCEDURE|allogeneic bone marrow transplantation|
40949936|NCT00003870|RADIATION|iodine I 131 monoclonal antibody BC8|
40949937|NCT00003870|RADIATION|radiation therapy|
40949938|NCT04210778|BEHAVIORAL|Cognitive orientation to daily occupational performance (CO-OP)|The CO-OP is a client-centered, goal directed approach aimed at enabling individuals to identify strategies that will improve daily function. A Weekly (1hr) session is delivered remotely via video conferencing.
40949939|NCT04210778|BEHAVIORAL|Computerized Cognitive Training (BrainHQ, posit science)|The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)
40949940|NCT02422173|DEVICE|Anodal transcranial direct current stimulation|The active electrode is placed on the affected hemisphere
40949941|NCT02422173|DEVICE|Cathodal transcranial direct current stimulation|The active electrode is placed on the unaffected hemisphere
41133659|NCT01987518|PROCEDURE|quality of life after different type of surgery|
41133660|NCT01005914|DRUG|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
41133661|NCT01005914|DRUG|cytarabine|Day 2 \& 3: 3g/m2 IV over 2 hours q12 X 4
41133662|NCT01005914|DRUG|dexamethasone|Day 1-4; 11-14: 40 mg daily
41133663|NCT01005914|DRUG|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
41133664|NCT01005914|DRUG|imatinib mesylate|600 mg/day
41133665|NCT01005914|DRUG|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
41133666|NCT01005914|DRUG|methylprednisolone|Day 1-3: 50mg IV BID
41133667|NCT01005914|DRUG|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
41133668|NCT01005914|DRUG|vincristine sulfate|Day 4 \& 11: 2 mg IV
41133669|NCT04009772|DRUG|Cefepime|Antibiotic prophylaxis
40949942|NCT02422173|DEVICE|Bilateral transcranial direct current stimulation|The cathode and anode is positioned as active electrodes on the unaffected and affected hemisphere,respectively.
40949943|NCT02422173|DEVICE|Sham transcranial direct current stimulation|Placebo stimulation, with emission current by only 30 seconds
41133670|NCT04009772|DRUG|Cefuroxime plus Metronidazole|Antibiotic prophylaxis
41133671|NCT04668729|OTHER|Chiropractic Manipulation|"Lumbar vertebrae and sacroiliac joints of the participants that have lost their normal joint motion will be detected by static and dynamic palpation techniques.~Lumbal Chiropractic HVLA Spinal Manipulation: HVLA manipulation will be applied in the left transverse process of the lumbar vertebra (mammillary process) of the participants whose problem is to the left of the lumbar vertebra.~Sacroiliac Chiropractic HVLA Manipulation: Participants who lost normal joint motion in the anterior and superior directions in the left sacroiliac joint will be treated with HVLA manipulation in the left PSIS (Posterior Superior Iliac Spine: PSIS). Participants who have lost normal joint motion in the left sacroiliac joint in the posterior and inferior directions will be applied HVLA manipulation in the left ischial tuberosity.~For both applications, it will be positioned in the opposite position for the problems on the right and the application will be made in the opposite position."
41288364|NCT00827268|BEHAVIORAL|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
41288365|NCT05357040|DRUG|Nitrous oxide gas for inhalation|"60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
41288366|NCT05357040|DRUG|Placebo|"60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
41288367|NCT01720667|DRUG|Intravenous levetiracetam|Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
41288368|NCT01720667|DRUG|Intravenous phenobarbital|Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
40949944|NCT01173757|DRUG|PF-04995274|Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
40949945|NCT03526575|DRUG|Zolpidem|
40949946|NCT03714802|PROCEDURE|Szabo T-Stenting Technique|2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
40949947|NCT03714802|PROCEDURE|T-Stenting Technique|2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
40949948|NCT03396705|PROCEDURE|Liver Biopsy|liver tissue will be collected via core biopsy during liver resection surgery and post-operatively by fine needle aspiration biosy
41146756|NCT02081976|BEHAVIORAL|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
41288369|NCT03911570|DRUG|Glucosamine Sulfate|Therapy with the prescription formulation of crystalline glucosamine sulfate
41288370|NCT03023410|PROCEDURE|VERASENSE|Sensor-Assisted Revision TKA
41288371|NCT02679066|DEVICE|Sugar-tong splint|Plaster immobilization including the elbow
41288372|NCT02679066|DEVICE|Short forearm cast|Fiberglass immobilization with elbow free
41288373|NCT02106208|OTHER|Cheese diet|
41288374|NCT02106208|OTHER|Butter diet|
41288375|NCT02106208|OTHER|CHO diet|
41288376|NCT02106208|OTHER|MUFA diet|
41288377|NCT02106208|OTHER|PUFA diet|
41288378|NCT02133014|PROCEDURE|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
41288379|NCT02133014|DRUG|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
41288380|NCT05221125|BEHAVIORAL|Psychologically-Informed Physical Therapy (PIPT)|The PIPT group will receive evaluation and treatment based on the PT's assessment of the individual patient's clinical presentation and condition.
41288381|NCT06220344|BIOLOGICAL|Honey Dressing|Honey Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
40949949|NCT03577873|OTHER|gallbladder preserved|Gallbladders will be remained after clearance of bile duct stones with ERCP and conventional therapy, such as fluid replacement and prophylactic anti infection, will be accepted.
40949950|NCT03577873|PROCEDURE|cholecystectomy|Cholecystectomy will be done right now after clearance of bile duct stones with ERCP, and then conventional therapy will be accepted.
40949951|NCT00851344|DRUG|GSK835726 (10mg)|GSK835726 (10mg) tablet
40949952|NCT00851344|DRUG|GSK835726 (50mg)|GSK835726 (50mg) tablet
40949953|NCT00851344|DRUG|GSK835726 (100mg)|GSK835726 (100mg) tablet
40949954|NCT00851344|DRUG|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
40949955|NCT00851344|OTHER|Placebo|Placebo to match active
41288382|NCT06220344|DRUG|Iodine Dressing|Iodine Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
41288383|NCT05590299|OTHER|Fish oral immunotherapy (codfish)|Codfish in mixture of potato prepared under food manufacturing regulations provided in varying doses
40759944|NCT06569966|BEHAVIORAL|preoperative prehabilitation treatment of ileostomy contents filtrate reinfusion through distal ileocolon or retention of enema colon|The contents of the ileostomy were collected and placed in a wide mouth container, mixed with 500mL normal temperature saline, and placed in a funnel with double layer medical gauze. The filtrate of the ileal contents was collected and placed into an enema for use. The catheter was placed into the ileal output end of the ostomy through anterograde enema or transanal retention enema, and slowly infused for 15-20 minutes, 2-3 times a day for 4 weeks. The adverse reactions such as abdominal pain, abdominal distension and fever were observed. The number, time, antegrade/retrograde prehabilitation operation, adverse reactions during the operation and other special conditions were recorded every day, and the weight of the patient was recorded
40759945|NCT05211960|BEHAVIORAL|Mindfulness-based meditation|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness.
40759946|NCT02712216|PROCEDURE|Laparoscopy|Determine best port sites to insert bariatric trocars
40759947|NCT03464552|DRUG|Celecoxib 200mg|oral capsule 3 hours before procedure
40949956|NCT02436252|DRUG|DSP-7888|3.5-10.5 mg/body,Id every 2-4 weeks
40949957|NCT03427671|DEVICE|Occlusin 500 Microspheres|Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.
40949958|NCT02397031|BEHAVIORAL|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
41133672|NCT02298842|DEVICE|Platelets stored in InterSol|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
41133673|NCT02298842|DEVICE|Platelets stored in Plasma|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
41133674|NCT04643574|BIOLOGICAL|NeoTIL|Adoptive transfer of ex vivo expanded Autologous Tumor-Infiltrating Lymphocytes enriched for tumor antigen specificity (NeoTIL)
41133675|NCT04643574|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
41133676|NCT04643574|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
41133677|NCT04643574|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.
41288384|NCT05590299|OTHER|Placebo oral immunotherapy|Placebo in potato mixture prepared under food manufacturing regulations provided in varying doses
41288385|NCT05024760|DRUG|Chlorhexidine|Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.
41288386|NCT05024760|DRUG|Hydrogen Peroxide|Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
41288387|NCT02636790|PROCEDURE|Surgery wait time|VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
40949959|NCT02397031|BEHAVIORAL|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
40949960|NCT00619593|OTHER|Intensified diagnostic and treatment measures following 1st appropriate ICD therapy|"* Assessment of general health status (weight, BP, NYHA)~* Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)~* Echocardiography (LVEF, LVEDD, mitral regurgitation)~* Non-invasive ischemia evaluation~* Coronary angiography (if indicated by ischemia evaluation)~* Upgrade to CRT, if indicated~* Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)~* 24 hrs ECG Holter (Heart rate variability)~* Further treatment (if applicable)~* Changes in ICD settings, or medication"
40949961|NCT00619593|OTHER|Standard follow-up|Standard follow-up in patients without appropriate ICD therapy
40949962|NCT02353520|OTHER|motricity index strength assessment|
40949963|NCT05663229|DEVICE|Ankle foot orthosis|We evaluate the difference of with or without ankle foot orthosis
40949964|NCT01542333|GENETIC|gene expression analysis|
40949965|NCT01542333|GENETIC|proteomic profiling|
40949966|NCT01542333|GENETIC|reverse transcriptase-polymerase chain reaction|
40949967|NCT01542333|GENETIC|western blotting|
40949968|NCT01542333|OTHER|immunohistochemistry staining method|
40949969|NCT01542333|OTHER|laboratory biomarker analysis|
40949970|NCT01542333|PROCEDURE|spectroscopy|
40949971|NCT05200559|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.
40949972|NCT05200559|DRUG|E7777|E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
40949973|NCT00152620|DRUG|Dexamethasone|
40949974|NCT00152620|DRUG|Methylprednisolone|
40949975|NCT03048916|OTHER|general swallowing therapy|including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
40949976|NCT03048916|OTHER|NMES therapy|he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
40949977|NCT03458975|RADIATION|MRI|Magnetic Resonance Imaging
40949978|NCT03458975|RADIATION|Perfusion CT scan|Perfusion Computerized tomography scan
40949979|NCT03458975|OTHER|Contrast enhanced ultrasound|Contrast enhanced ultrasound
40949980|NCT03458975|DRUG|Sonoporation|Gaseous microbubbles (Sonovue) combinated with Ultrasounds
40949981|NCT00286507|PROCEDURE|Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
40949982|NCT06291246|BEHAVIORAL|Virtual Family Navigation|4 sessions of 1:1 virtual family navigation delivered via phone or video call.
40949983|NCT06291246|BEHAVIORAL|Educational Materials|Participants will receive individualized recommendations for early intervention for their child at the time of the diagnosis of autism spectrum disorder.
40949984|NCT06044389|DEVICE|Fructosin|"Fructosin® is a CE marked medical device. The capsules with 30.23 mg xylose isomerase are taken as recommended. This means that, depending on the total intake, 1-2 capsules are to be taken with water 15 minutes before meals containing fructose, a maximum of 3 times a day.~Use as needed during the 4-week intake phase."
40949985|NCT01870284|DRUG|Ixekizumab|Administered SC
40949986|NCT01870284|DRUG|Placebo|Administered SC
40949987|NCT01870284|DRUG|Adalimumab|Administered SC
40949988|NCT03727607|DRUG|Desflurane|Desflurane vs TIVA, bariatric surgery. Postoperative nausea and pain
41133678|NCT04643574|RADIATION|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to tumor lesions once before NeoTIL infusion.
40949989|NCT04652440|DRUG|PD-1 monoclonal antibody|The enrolled patients received intravenous injections of PD-1 monoclonal antibody (Tislelizumab 200mg) on the 1 day before radiofrequency or microwave ablation treatment, and 21(±7) days, 42(+7) and 63(+7) after ablation.
40949990|NCT04652440|PROCEDURE|Radiofequencey or microwave ablation|The enrolled patients received primary radiofrequency or microwave ablation on the day after the first dose of PD-1 antibody treatment.
40949991|NCT04540276|DRUG|Inspiratory oxygen fraction|Median inspiratory oxygen fraction during general anesthesia
40949992|NCT03502460|OTHER|Operating Room Fluid Administration Lung Ultrasound|Use of lung ultrasound to limited fluid administration
40949993|NCT04404062|DIAGNOSTIC_TEST|Membrane-based immunoassay kit|The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.
40949994|NCT04404062|DIAGNOSTIC_TEST|Quantitative antibody Tests|Antibody titres will be measured from whole blood samples taken from volunteers.
40949995|NCT04404062|DIAGNOSTIC_TEST|PCR Test|PCR tests will be conducted on throat swabs taken from volunteers.
40949996|NCT00416546|DRUG|AEB071|
41133679|NCT03340961|DRUG|DFD-29 Extended Release Capsules (40 mg)|Oral Treatment
41133680|NCT03340961|DRUG|DFD-29 Extended Release Capsules (20 mg)|Oral Treatment
41133681|NCT03340961|DRUG|Oraycea® (doxycycline) Capsules|Oral Treatment
41133682|NCT03340961|DRUG|Placebo Capsules|Oral Treatment
41133683|NCT01540500|DRUG|Tasimelteon|5.66 mg dose on Day 1 and Day 8
41133684|NCT01540500|DRUG|Fluvoxamine|50 mg Dose on Days 2-8
41133685|NCT04377191|OTHER|exergame|Microsoft Xbox 360 Kinect The exercises were advanced from simple to complex. The program started with exercises in a sitting position. In the next stage, the games requiring weight transfer and use of upper limbs in standing position were continued. The program ended with games that require more complex movements such as lunge and mini squats.
40949997|NCT05180617|BEHAVIORAL|Music Therapy|Music therapy participants will interact both musically and verbally with the therapist and will be given a range of both electronic and acoustic instruments to choose from. Music therapy sessions will be based upon music improvisation, and as such participants are not required to have any previous instrument or other music experience and be invited to improvise freely using the instruments. The music therapist will accompany participants in the improvisation. This provides participants with an opportunity to connect with emotions and feelings connected to hidden psychic material. Following improvisations, the therapist and client will identify these moments of interest which can be further explored either verbally or through further improvisation. The music created within sessions will be recorded and participants can take a copy of the recordings home and it will be used in the therapeutic monitoring and analysis of sessions.
41288388|NCT03686202|BIOLOGICAL|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
40759948|NCT03464552|PROCEDURE|Colposcopic guided biopsy|Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
40949998|NCT02772055|OTHER|Moxibustion|Moxibustion at three acupuncture point(EX-LE04,ST35,ST36).12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
40949999|NCT02772055|OTHER|Moxa smoke purification device|Investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke.
40950000|NCT03613480|OTHER|Motivational Interviewing|Regular sessions of Motivational Interviewing at 2 weeks and then at monthly intervals for a period of 6 months
40759949|NCT03464552|DRUG|Placebo oral capsule|oral capsule 3 hours before procedure
40950001|NCT06308419|DRUG|Gemcitabine|Given by IV
40950002|NCT06308419|DRUG|Nab-Sirolimus|Given by IV
40950003|NCT05653037|DRUG|RBD4059|Subcutaneously Administered RBD4059 in Healthy Subjects.
40950004|NCT05653037|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
40950005|NCT04875663|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
40950006|NCT01276600|DRUG|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
40950007|NCT03509883|DRUG|Drug: Apixaban sprinkle capsules|Single dose (25 x 0.1 mg capsules), oral administration
40950008|NCT03509883|DRUG|Experimental: Apixaban tablets followed by apixaban sprinkle capsules|Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration
40950009|NCT05578248|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Non-invasive imaging technology that produces three-dimensional detailed anatomical images
40950010|NCT05578248|PROCEDURE|ACL reconstruction|Surgical procedure to repair damaged or severed anterior cruciate ligament in the knee
40950011|NCT04971421|DIAGNOSTIC_TEST|ctDNA - circulating tumor DNA|lcWGS and WGS of circulating tumor DNA
40759950|NCT04231851|DRUG|Glasdegib|Given PO
40759951|NCT04231851|DRUG|CPX-351|Given IV
40759952|NCT04543253|OTHER|MUSE biofeedback|biofeedback through a headband
40759953|NCT01266200|PROCEDURE|Mantis|percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms
40950012|NCT04971421|DIAGNOSTIC_TEST|TEP - Tumor Educated Platelets|sequencing miRNA from TEPs
41133686|NCT04377191|OTHER|exergame|ALDA In the training, games that could be controlled by balance swing, trunk movements and weight transfer in sitting or standing position were used.
40950013|NCT03930758|COMBINATION_PRODUCT|Behavior intervention of uphill exercise|40 minutes of uphill exercise
40950014|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise before the meal|40 minutes of uphill exercise completed 1 h before the meal
40950015|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of uphill exercise|40 minutes of uphill exercise
40950016|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise after the meal|40 minutes of uphill exercise started 1 hour after gthe meal
40950017|NCT03930758|COMBINATION_PRODUCT|Behavior intervention of downhill exercise|40 minutes of downhill exercise
40950018|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise before the meal|40 minutes of downhill exercise completed 1 hour before the meal
40950019|NCT03930758|COMBINATION_PRODUCT|Behavioral intervention of downhill exercise|40 minutes of downhill exercise
40950020|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise after the meal|40 minutes of downhill exercise started 1 hour after the meal
40950021|NCT03930758|COMBINATION_PRODUCT|Behavioral intervention of sedentary no-exercise trial|Sedentary no-exercise trial
40950022|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of eating two meals|Meals eaten at 10 and 17 h during a sedentary trial
40950023|NCT02826278|OTHER|External genitalia measurements in female newborns|
40950024|NCT03273543|DEVICE|Restylane® Defyne|hyaluronic acid filler injection
40950025|NCT00821106|PROCEDURE|Right radial|diagnostic or interventional procedures performed through right transradial approach
40950026|NCT00821106|PROCEDURE|left radial|diagnostic or interventional procedures performed through left transradial approach
40950027|NCT04295759|DRUG|INCB7839|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
40950028|NCT06556966|DRUG|LY03020|LY03020 for one single dose
40950029|NCT06556966|DRUG|Placebo|Placebo for one single dose
40950030|NCT06238271|DEVICE|Acriva BB UDM 611|Acriva BB UDM 611 intraocular lens will be implanted into the capsular bag in patients who undergo cataract extraction with phacoemulsification.
40950031|NCT03088371|DRUG|Bupivacaine 0.25%|For psoas sciatic block.
40950032|NCT03088371|OTHER|Pajunk Needle|For local anaesthesia application in psoas sciatic block
40950033|NCT03088371|OTHER|Portex combined spinal epidural kit|For combined spinal epidural anaesthesia
40950034|NCT03088371|DRUG|Lidocaine 1%|For psoas sciatic block.
40950035|NCT03088371|DRUG|Bupivacaine 0.5%|For spinal anaesthesia in combined spinal epidural anaesthesia.
40950036|NCT03088371|DRUG|Lidocaine 2 %|For psoas sciatic block in the post-operative period
40950037|NCT03088371|DRUG|Bupivacaine 0.125 %|For combined spinal epidural in the post-operative period.
40950038|NCT01869881|DRUG|Anplag(Sarpogrelate)|Sarpogrelate 100mg 2 tablets, bid, 400mg/day
40950039|NCT01869881|DRUG|Placebo|Placebo 100mg 2 tablets, bid, 400mg/day
40950040|NCT00005118|DRUG|Indinavir sulfate|
40950041|NCT00005118|DRUG|Ritonavir|
40759954|NCT01266200|PROCEDURE|XIA|Treatment of the fracture with Xia and conventional operation technique
40950042|NCT02090075|DRUG|apixaban|5 po or 2.5 po bid.
40950043|NCT02090075|DRUG|warfarin|
40950044|NCT00002449|DRUG|Aldesleukin|
40950045|NCT03141593|DRUG|Vitamin D: liquid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
40950046|NCT03141593|DRUG|Vitamin D: liquid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
40950047|NCT03141593|DRUG|Vitamin D: solid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
41288389|NCT02628223|PROCEDURE|Selective Laser Trabeculoplasty|The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
41288390|NCT02628223|DEVICE|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
41288391|NCT04916197|DRUG|Dexmedetomidine prolonged sedation|Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.
40950048|NCT03141593|DRUG|Vitamin D: solid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
40950049|NCT02038881|BIOLOGICAL|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
40950050|NCT00000304|DRUG|Dextroamphetamine|15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
40950051|NCT00000304|DRUG|D-Amphetamine|30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
40950052|NCT00000304|DRUG|Placebo|Placebo
40950053|NCT01887223|PROCEDURE|Transconjunctival needling revision|Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
40950054|NCT01887223|DRUG|Medical treatment|Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
40950055|NCT04680052|DRUG|tafasitamab|tafasitamab will be administered IV for 12 cycles
40950056|NCT04680052|DRUG|rituximab|Rituximab will be administered IV on cycles 1 - 5
40950057|NCT04680052|DRUG|lenalidomide|Lenalidomide will be administered PO for 12 cycles
40950058|NCT04680052|DRUG|placebo|placebo will be administered IV for 12 cycles
40950059|NCT04608487|DRUG|Fludarabine|Intravenous infusion
40950060|NCT04608487|DRUG|Cyclophosphamide|Intravenous infusion
40950061|NCT04608487|BIOLOGICAL|Axicabtagene Ciloleucel|Intravenous infusion
40950062|NCT01805128|OTHER|Facial recognition of emotions|The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
40950063|NCT01805128|OTHER|understanding metaphors|Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
40950064|NCT01805128|OTHER|Attribution of intentionality to others in social situations depending on the type of situation|Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
40950065|NCT03836703|DRUG|Feroglobin single daily use|Feroglobin single daily use ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
41288392|NCT04916197|DRUG|0.9% saline|An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.
41288393|NCT05906446|OTHER|Multicomponent (Exercise + Protein Supplementation)|"* Exercises selected from a pre-specified list, reassessed weekly~* Participants will receive individualized exercise sessions, (e.g. 15-30 minutes per session, one session per day, offered five times a week)~* Participants will also be offered a protein supplement within 30 min of exercise.~* Sessions will be supervised"
41288394|NCT02673112|BEHAVIORAL|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
41288395|NCT02673112|BEHAVIORAL|Light stretching (LS)|Brief daily stretching routine.
41288396|NCT04575662|RADIATION|STAR Treatment|Radiation therapy that delivers non-invasive, image-guided, precise high-dose of radiation to targets reducing dose exposure to adjacent normal tissue and minimizing the treatment toxicity.
41288397|NCT02277210|OTHER|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
41288398|NCT03494725|DIETARY_SUPPLEMENT|Lpc-37|Lacticaseibacillus paracasei Lpc-37 at 1.75 x 10\^10 colony forming units (CFU) per day, microcrystalline cellulose, magnesium stearate, silicon dioxide
41288399|NCT03494725|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, magnesium stearate, silicon dioxide
41288400|NCT00009594|PROCEDURE|Naturopathic Medicine|
41288401|NCT00009594|PROCEDURE|Traditional Chinese Medicine|
40950066|NCT03836703|DRUG|Feroglobin twice daily dose|Feroglobin twice daily dose ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
40950067|NCT00087165|BIOLOGICAL|GTI-2040|
40950068|NCT00087165|DRUG|docetaxel|
40950069|NCT00087165|DRUG|prednisone|
40950070|NCT02424448|PROCEDURE|Biopsies, blood and urine samples|"Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken."
40950071|NCT02334631|DRUG|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
41288402|NCT02873715|BEHAVIORAL|Family-based treatment|Family based treatment as the invention to randomized participants. Family Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two year study
41288403|NCT02873715|BEHAVIORAL|Usual Care|Usual care is a treatment that is normally provided to patients in pediatric offices by a pediatrician, physician assistant, or other primary care staff.
41288404|NCT00053612|DRUG|Vitamin A|
41288405|NCT06331585|RADIATION|low dose radiotherapy|LDRT (5Gy/5f) of oligometastasis, oligoprogression, and oligopersistence of NSCLC after immunotherapy
41288406|NCT00345371|DRUG|Topiramate|
41288407|NCT00345371|DRUG|Placebo Oral Tablet|
41288408|NCT02234401|DEVICE|Bi level pressure support|
41288409|NCT02234401|OTHER|Standard Care|
41288410|NCT03727711|OTHER|TPTNS|We will be comparing hospital treatment to TPTNS at home
41288411|NCT06353646|BIOLOGICAL|XH001|mRNA neoantigen cancer vaccine
41288412|NCT06353646|DRUG|Ipilimumab Injection|a type of immunotherapy that targets CTLA-4 protein on T cells
41288413|NCT06353646|DRUG|Chemotherapy|gemcitabine + capecitabine
41288414|NCT00249262|DRUG|Taxoprexin|
41288415|NCT01936246|DIETARY_SUPPLEMENT|Increased protein|
41288416|NCT03991624|DIAGNOSTIC_TEST|cognitive assessment|"* MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease"
40950072|NCT02334631|DRUG|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
40950073|NCT03091933|BIOLOGICAL|GLIDE|Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
40950074|NCT06393036|DEVICE|Continuous Positive Airway Pressure|The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. Although the study is designed as an observational cohort study, where patients self-selected whether to receive treatment rather than being assigned, there is still an intervention project, CPAP, present in the observational cohort. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
41288417|NCT03991624|OTHER|Inhibition evaluation|"* Stroop Victoria : This test consists of 3 sheets of 24 items, organized in 6 lines of 4 (points, neutral words or names of colours), from which the subject must identify the ink of the stimuli as quickly and precisely as possible.~* Stop Signal task on the computer to give a response to the presentation of a target stimulus (Go signal) (e.g. pressing a button when a red circle appears on the screen, but doing nothing when a blue triangle appears), and prevent this response when the stimulus is followed or preceded by a beep (stop signal) (e.g. the appearance of a red circle is immediately preceded or followed by a beep, the subject should not press the button)."
41288418|NCT03991624|OTHER|Assessment of mental flexibility|"* a letter-number pair task. The subject sees 4 blocks of 48 letter-number pairs appear successively on a screen. When the pair appears at the top, the subject must make a parity judgment but when the pair appears at the bottom, the subject must make a consonant / vowel judgment.~* a category change task, which consists in classifying a word according to one category or another according to a visual clue that appears. The task consists of 4 blocks of 48 stimuli."
41288419|NCT03991624|OTHER|Evaluation of the update|"* an update span task for which letters appear on a screen sequentially, and subjects must memorize the last three, without knowing the length of the list. The task will consist of 3 tests of training and then 20 tests. After three errors consecutive, the task ends.~* an n-back task that consists of a sequential presentation of letters, during which the subject must indicate when the stimulus. The task consists of 3 levels, with n = 1, n= 2 or n = 3. For level 1 (with n = 1), the subject must press a button when the same letter appears twice in a row on the screen. This task consists of 75 letters."
41454038|NCT04367519|DIAGNOSTIC_TEST|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography was performed with the patients placed in supine position with closed eyes. A layer of ultrasound gel was applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine was placed on the temporal area of the eyelid with the hand holding it resting on the forehead of the patient. The probe is then adjusted to a suitable angle in order to display the entry of the optic nerve into the globe. ONSD is then measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. it was performed for all enrolled parturients within 24 hour before delivery and at 24 hour post-delivery.
41454039|NCT01916239|DIETARY_SUPPLEMENT|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
41454040|NCT01916239|DIETARY_SUPPLEMENT|Pomegranate extract formulation-1|New pomegranate extract formulation-1
40950079|NCT01254331|DRUG|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
40759955|NCT02868931|BEHAVIORAL|INPUT|"Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators."
40950080|NCT04743466|OTHER|Electronic Health Record Review|Biobank records are reviewed
40950081|NCT03477123|DEVICE|Walking therapy with Exo-H2 exoskeleton|
40950082|NCT01330784|DRUG|hMG-HP|
40950083|NCT05186285|DRUG|CM338|CM338 : a humanized monoclonal antibody.
40950084|NCT05186285|DRUG|Placebo|Placebo.
41133687|NCT04377191|OTHER|exercise|Standard Exercise Program The program included warm-up, main exercise and cooling. Warm-up and cooling included neck, trunk, upper-lower extremity range of movement (ROM) exercises and stretching exercises. Main exercise included postural alignment, strengthening for trunk and lower extremity, balance and walking exercises.
41133688|NCT00690404|DRUG|AZD2066|single oral dose
41133689|NCT04074252|DEVICE|Lofstrand Crutches|Device: Set of Lofstrand Crutches
41133690|NCT04074252|DEVICE|Axillary Crutches|Device: Set of Axillary Crutches
41133691|NCT02470806|DEVICE|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
41133692|NCT02470806|DEVICE|tNPWT System|NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
40950085|NCT04410029|OTHER|Healthwise Decision Aid|Healthwise, a non-profit company that develops health content and patient information for hospitals, has created a decision aid for EPL management that is available through the EPIC Systems, an electronic medical record. Participants will be given this decision aid after EPL diagnosis and prior to options consultation with a provider.
40950086|NCT04410029|OTHER|Control informational handout|Participants randomized to the control arm will be given an informational handout of treatment options after EPL diagnosis and prior to options consultation with a provider.
40950087|NCT01971242|DRUG|Exenatide|2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide
40950088|NCT01971242|OTHER|Placebo|Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
40950089|NCT05153772|DRUG|AlphaMedix|212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors
40950090|NCT05175027|DRUG|hypochlorous acid|Randomize
41133693|NCT03605732|BEHAVIORAL|self help sleep hygiene intervention application|This intervention lasts for six weeks. The intervention is App-based and mainly consists of the most potent CBT techniques as well Health action process approach. Weekly feedback is provided by health psychologists.
41133694|NCT03605732|OTHER|patients education|Participants in the PE group will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
41133695|NCT04649645|OTHER|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
41146757|NCT02081976|OTHER|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
41146758|NCT04655833|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
41146759|NCT00472368|DRUG|LBH589|
41146760|NCT06233422|OTHER|No intervention involved|No intervention involved
40950091|NCT00808483|OTHER|Walking skill training program|12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
40950092|NCT03731039|OTHER|Observational study|Pain assessment, Anxiety assessment, Depression assessment
40950093|NCT06476327|BEHAVIORAL|experimental 1 group|"A camera is installed on the walker used in the training, and the recorded video is mirrored in real-time to a tablet computer. Participants can view this video through smart glasses connected to the tablet computer. A glasses strap will be used to secure the glasses, ensuring there is no interference with walking.~Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation."
40950094|NCT06476327|BEHAVIORAL|experimental 2 group|"Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation."
40950095|NCT03265301|PROCEDURE|Hysteroscopy|Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)
40950096|NCT03265301|PROCEDURE|Office hysteroscopy|will be done in out patient clinic without anesthesia
40950097|NCT03265301|PROCEDURE|Conventional hysteroscopy|will be done in operative room under general anesthesia
40950098|NCT02410551|DRUG|Pacritinib|200 mg by mouth twice a day for 60 days.
40950099|NCT02410551|DRUG|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
41288420|NCT03991624|OTHER|working memory|"* the empan baba task, which mainly involves maintaining information, and which consists in retaining a series of letters, appearing sequentially on a screen, and whose latency time between two word presentations is required for a secondary task: the repetition of baba syllables.~* the task of reading operations which consists in recalling operations series of letters whose presentation is interspersed with the reading aloud of simple operations and of their results.~* the ongoing operational task of recalling a list of letters, the presentation of which is interspersed with operations that are simple to read aloud and to to solve head-on."
40950100|NCT02410551|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
40950101|NCT02410551|BEHAVIORAL|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
40950102|NCT02410551|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
40950103|NCT02410551|DRUG|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
41146761|NCT02572986|DRUG|Permethrin|
41288421|NCT03991624|OTHER|episodic memory|- A recognition task with a Remember/Know paradigm
41454041|NCT01916239|DIETARY_SUPPLEMENT|Pomegranate extract formulation-2|New pomegranate extract formulation-2
40950104|NCT01565720|DRUG|Isavuconazole|oral
40950105|NCT01565720|DRUG|Placebo|oral
40950106|NCT01565720|DRUG|Moxifloxacin|oral
40950107|NCT02212470|DEVICE|Drug Eluting Balloon Angioplasty|Angioplasty with Drug eluting balloon after pre dilatation
41454042|NCT03259841|OTHER|Ultrasound assessment of gastric contet|Ultrasound assessment of gastric content is performed in fasted patient undergoing cholecystectomy.
40950108|NCT02212470|DEVICE|Nitinol stenting|Nitinol stent deployment
40950109|NCT05314738|COMBINATION_PRODUCT|NXL Energy 1|Riboflavin drops + NXL System to Total Energy Level 1
40950110|NCT05314738|COMBINATION_PRODUCT|NXL Energy 2|Riboflavin drops + NXL System to Total Energy Level 2
40950111|NCT05314738|COMBINATION_PRODUCT|NXL Energy 3|Riboflavin drops + NXL System to Total Energy Level 3
40950112|NCT05314738|COMBINATION_PRODUCT|Sham Treatment|Sham Drops and No exposure to NXL system
40950113|NCT05038670|DEVICE|Total Knee Replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either PERSONA PS or JOURNEY II BCS
40950114|NCT02386631|DEVICE|Custom Made Orthotic|Provides longitudinal arch support
40950115|NCT04696523|DRUG|Xenon|Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care
40950116|NCT04696523|DRUG|air/oxygen|Control group will be treated with air/oxygen
40950117|NCT02526446|BEHAVIORAL|Self-administered acupressure|"The intervention consists of a total of 28 hours over a period of 8 weeks:~i) Individual learning and practice: The training session will be one-on-one provided twice a week for two consecutive weeks (5 hours) in the participant's home.~ii) Self-practice at home: From 3rd to 8th week, participant will engage in self-administered acupressure at home for 15 minutes twice a day for 6 weeks (21 hours).~iii) Home follow-up: During the 3rd and 4th week (i.e. after the 2-week training session), a 1-hour home visit will be conducted for reinforcement of learning and self-practice by the same team of trainers once a week for 2 weeks (2 hours)."
40950118|NCT02526446|OTHER|wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
40950119|NCT03096483|DEVICE|OEC Elite system|Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
40950120|NCT05179850|DIAGNOSTIC_TEST|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
40950121|NCT06240130|PROCEDURE|Partial pulpotomy|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 3% NaOCl in partial pulpotomy
40950122|NCT06240130|PROCEDURE|Partial pulpotomy|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 2% Chlorhexidine in partial pulpotomy
40950123|NCT00000702|DRUG|Zidovudine|
40950124|NCT03608371|DRUG|BTRX-246040|oral capsule 40 mg
40950125|NCT03608371|DRUG|Placebo|oral capsule matching BTRX-246040 40 mg capsule
40950126|NCT01355926|OTHER|Flexible Fiber-based CO2 Laser, Quality of Life forms|. Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
40950127|NCT01355926|OTHER|electrocautery resection and quality of life forms|Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
40950128|NCT01108120|DRUG|continuous intra-femoral thrombolysis group|Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
40950129|NCT01108120|DRUG|Conventional therapy group|All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
40950130|NCT04533763|BEHAVIORAL|Technology-based Mindful Living program|The program is delivered using web-based group conferencing. During each session, participants are taught new stress management and coping techniques. Each week there is opportunity to apply techniques to real world situations for practice. Participants have a group orientation session, and then meet for 10 weeks. Group sessions last 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post- randomization. Program includes training in mindfulness, cognitive behavioral stress management, relaxation, imagery, prioritizing meaningful activities, communication, and coping strategies. Content is geared toward concerns of cancer survivors.
41133696|NCT04649645|OTHER|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).
41133697|NCT04649645|OTHER|NOT SMOKING|Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
41133698|NCT00491296|DEVICE|SYNERGO|
41133699|NCT00491296|DEVICE|SYNERGO-intravesical chemotherapy instillation combined with hyperthermia|
41133700|NCT00528216|DRUG|Capsaicin Dermal Liquid|
41454043|NCT02687958|DRUG|Everolimus|Maintenance therapy
41133701|NCT01052935|BIOLOGICAL|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."
41288422|NCT01883310|DEVICE|sham tDCS + TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
41288423|NCT01883310|DEVICE|real tDCS +TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
41288424|NCT04271709|BEHAVIORAL|Enhanced Intervention Using Patient Navigators|Enhanced support includes patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
41288425|NCT04271709|OTHER|Usual Care|Usual Care subjects who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
41133702|NCT02434276|BIOLOGICAL|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
41133703|NCT02434276|BIOLOGICAL|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
41288426|NCT00824694|OTHER|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
41288427|NCT00824694|OTHER|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
41288428|NCT00824694|OTHER|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
41133704|NCT03351400|BIOLOGICAL|Stem cells administered to participants|Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.
41133705|NCT01667198|PROCEDURE|Train the leaders course|Screening centre leaders randomized to the training intervention group will be invited to take part in a train-the-leaders course. The Train-the-leaders course will consist of three phases: (i) pre-training assessment, (ii) hands-on-training and (iii) post-training evaluation and feedback. The Train-the-leaders course will be run in polish by the team from the Maria Sklodowska-Curie Memorial Cancer Center and Institute on Oncology, Warsaw, which was trained in delivering such intervention by experts from the United Kingdom.
41288429|NCT03484533|BEHAVIORAL|HIV self-test kit|We will conduct a randomized trial to evaluate whether provision of oral HIV self-test kits to HIV-positive pregnant women overcomes their male partners' reluctance to be tested in PMTCT clinics. Pregnant women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.
41288430|NCT03484533|BEHAVIORAL|Standard of Care|In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.
41288431|NCT04023422|BEHAVIORAL|Clinical intervention|The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
41288432|NCT04023422|BEHAVIORAL|Feedback|The community health navigator will give the clinician real-time feedback on guideline-related health.
41288433|NCT02743637|DRUG|SDX-7320|SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
41288434|NCT05112185|BEHAVIORAL|Healthy Drinks, Healthy Futures|The Healthy Drinks, Healthy Futures intervention consists of increased access to healthy beverages in childcare centers and education directed to children and their families to increase the intake of healthy beverages, including motivational beverage counseling for families and lessons for children in childcare centers.
41288435|NCT06375850|OTHER|Sesame oil|"A peripheral venous catheter will be channeled to the patient admitted to the unit and who requires it. The indications included in the guide for channeling venous access of the Marqués de Valdecilla hospital will be followed.~Once the venous access has been channeled, it will be fixed with, leaving the puncture point visible for future monitoring.~The sesame oil chosen for the project is Sesame bio - 100% pure vegetable oil from the Naissance brand.~To perform the procedure, two drops of sesame oil will be applied daily by the nurse in charge of the patient during the morning shift in the area about 2 cm above the insertion point and coinciding with the course of the vein channeled for intravenous therapy. A small massage of the area of application will be performed, with an approximate extension of 3x3cm, until its absorption. It will be left to dry in the air."
41288436|NCT06375850|OTHER|Saline solution|After cannulation of the vein following the same procedure as explained in the intervention arm, patients belonging to the control arm will be administered two drops of saline solution.
41288437|NCT00291304|PROCEDURE|MRI|pre-surgery
41288438|NCT02024256|OTHER|Cold pads soaked in Magnesium sulfate solution|
41288439|NCT02024256|OTHER|Cold pads soaked in water|
41288440|NCT02333539|BEHAVIORAL|Adherence behaviors and recommendations for improvement.|
41288441|NCT02333539|BEHAVIORAL|Adherence behavior that needs improvement is targeted|
41288442|NCT01801397|DRUG|osteoanabolic therapy|
41288443|NCT03928873|DEVICE|Low energy ESWT|1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks
41133706|NCT01667198|BEHAVIORAL|Audit and feedback|Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
41133707|NCT02650505|DRUG|LEO 43204|
41133708|NCT02650505|DRUG|LEO 43204 Vehicle|
40759956|NCT04231019|OTHER|self-administered questionnaire|"Self-administered questionnaires with plain language statements and brief description of the clinical features and photographs of MIH were used to determine the knowledge, awareness and perception regarding the prevalence, severity, etiology and treatment modalities of molar-incisor hypomineralization (MIH) among Egyptian fifth year dental students, general dental practitioners and dental specialists.~There were two routes for delivering the questionnaire either as online questionnaire sent to the participants by email or as a hard copy that is hand delivered."
40759957|NCT05885750|BEHAVIORAL|Unprocessed|Participants will consume unprocessed or minimally processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
41133709|NCT03111706|PROCEDURE|Cesarean section|During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
41133710|NCT04871555|OTHER|MRI|structural imaging
41133711|NCT01342497|DRUG|isoniazide|Tablets, dosing 3 times daily, 12 weeks
41133712|NCT01342497|DRUG|placebo|tablets, dosing 3 times daily, 12 weeks
41133713|NCT00752414|DRUG|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
41133714|NCT00752414|DRUG|Placebo|same frequency as MP-376
41133715|NCT05136066|OTHER|massage with peppermint oil|Peppermint oil diluted with 1/10 pure olive oil will be applied to the pregnant to reduce labor pain.
41133716|NCT01939249|DEVICE|Abbott Laboratories Xience|
41133717|NCT01939249|DEVICE|Biotronik Orsiro|
41133718|NCT03942575|DEVICE|Negative pressure wound therapy|Wound dressing with negative pressure on closed incisions
41288444|NCT03928873|DEVICE|High energy ESWT|1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks
41288445|NCT03928873|DEVICE|Sham ESWT|sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks
41288446|NCT05437094|DRUG|CRD-740|CRD-740
41288447|NCT05437094|DRUG|Itraconazole|Itraconazole
41288448|NCT00990015|DRUG|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
41288449|NCT00990015|DRUG|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
41454044|NCT02549638|GENETIC|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
40759958|NCT05885750|BEHAVIORAL|Mildly processed|Participants will consume mildly processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
41133719|NCT02144597|DIETARY_SUPPLEMENT|Liquid formula low-calorie diet (LCD)|The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
41133720|NCT02144597|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Participant went through Roux-en-Y gastric bypass (RYGB) surgery
41133721|NCT02144597|OTHER|Control diet|
41133722|NCT02765126|BIOLOGICAL|Seasonal influenza vaccine|Intramuscular standard seasonal influenza vaccine
41133723|NCT02765126|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine|Intramuscular DTaP vaccine
41133724|NCT01262456|DRUG|Desmopressin|
41133725|NCT01262456|DRUG|Placebo|
41133726|NCT00036140|DRUG|Investigational drug|
41133727|NCT03154775|BIOLOGICAL|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
41133728|NCT03398980|RADIATION|survivors treated with CRT|Radiotherapy technology included conventional radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).
41133729|NCT02945059|PROCEDURE|Selective reversible portal vein embolization|Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.
41133730|NCT00355888|DRUG|MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
40759959|NCT05885750|BEHAVIORAL|Heavily refined|Participants will consume heavily refined processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
40759960|NCT00133432|DRUG|Zinc|
40759961|NCT03221335|DEVICE|EUS-guided RFA|All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
40759962|NCT02197065|DRUG|Atorvastatin|Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45
40759963|NCT02197065|DRUG|Placebo|
41133731|NCT02158806|DRUG|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
41133732|NCT02158806|DRUG|Placebo|Matching placebo capsule containing inert bulking agent
41133733|NCT03462485|OTHER|Golf|Eight weeks of twice-daily golf training
41133734|NCT03704519|DRUG|Darolutamide (BAY1841788)|300 mg tablet darolutamide, once orally
41133735|NCT03704519|DRUG|Enzalutamide|4 x 40 mg capsules, once orally
41133736|NCT03704519|OTHER|Placebo|4 placebo tablets, once orally
41133737|NCT05473806|DRUG|Pioglitazone 15 Mg Oral Tablet|24weeks dose
41133738|NCT05473806|DRUG|Evogliptin 5mg|24weeks dose
41133739|NCT01833598|PROCEDURE|PNT + PRP|The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
41288450|NCT05760625|DIAGNOSTIC_TEST|analysis BDNF|We analysed consentration of BDNF in venous blood of patient with primary headache
41288451|NCT05074095|OTHER|retrospective analysis|
40950131|NCT04533763|BEHAVIORAL|Technology-based Healthy Lifestyles program|The program is delivered using web-based group conferencing. Sessions include content from the National Cancer Institute, American Cancer Society, and health care providers with expertise in oncology. All content is geared to promoting healthy living among ovarian cancer survivors. Participants have a group orientation session, and then meet for 10 weeks, with group sessions lasting 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post-randomization. Healthy Lifestyle sessions include topics such as nutrition, exercise, sleep, quality of life, survivorship, and cognitive function with content geared toward concerns of cancer survivors.
40950132|NCT04314934|DRUG|ANAVEX2-73|Oral capsules
40950133|NCT04730687|DEVICE|Traditional non surgical mechanical therapy|Mechanical instrumentation in all groups was made with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH \& Co, Ltd, Stockach, Germany).
40950134|NCT04730687|DEVICE|Diode laser assisted non-surgical mechancal therapy|One week after mechanical treatment, a 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) with a 300 µm diameter optical fiber tip applied approximately 1 mm above the most apical part of the peri-implant pocket, parallel to the implant surface (E3-9 mm).
40950135|NCT04730687|DEVICE|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical treatment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), short pulse '' H '' with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) mode has been applied.
40950136|NCT02653183|DEVICE|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.
40950137|NCT02653183|DEVICE|Experimental: Mepilex Border Post-Op|"Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
40950138|NCT06556901|OTHER|retrospective study about reasons for consultations|retrospective study about reasons for consultations
40950139|NCT04383158|OTHER|PRGF ENDORET® obtained from ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16)|ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16) is a system for obtaining plasma rich in growth factors (PRGF), which can be applied in the regeneration of bone and other connective tissues in oral surgery. PRGF is a completely autologous blood platelet concentrate that stimulates tissue regeneration due to enrichment with autologous growth factors, acting as a biological system.
40950140|NCT05312073|OTHER|Biological samples|Blood samples Superficial skin Biopsy Collection of fallen squames Tapes - stripping
40950141|NCT05312073|OTHER|Skin biopsy|healthy skin from surgery interventions
40950142|NCT00004364|DRUG|desmopressin|
40950143|NCT00354744|BIOLOGICAL|dactinomycin|"Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), \< 1 year 0.025 mg/kg.~Day 1 of Weeks 35, 38, 41 and 44.~Given IV"
40950144|NCT00354744|DRUG|cyclophosphamide|"Age based dosage: ≥ 3 years 1200 mg/m2, \<3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV"
40950145|NCT00354744|DRUG|doxorubicin hydrochloride|"Age based dosage: ≥ 1 year: 37.5mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV"
40950146|NCT00354744|DRUG|etoposide|"Age based dosage: ≥ 1 year: 100 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
40950147|NCT00354744|DRUG|ifosfamide|"Age based dosage: ≥ 1 year: 1800 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
40950148|NCT00354744|DRUG|irinotecan hydrochloride|"Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV"
40950149|NCT00354744|DRUG|vincristine sulfate|"Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and \< 3 years 0.05 mg/kg (max dose 2 mg), \< 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV"
40950150|NCT00354744|PROCEDURE|conventional surgery|"Resection of the primary tumor with a surrounding envelope of normal tissue"
40950151|NCT00354744|RADIATION|radiation therapy|Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
40950152|NCT00354744|BIOLOGICAL|filgrastim|"5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.~Given subcutaneously."
40950153|NCT02785484|OTHER|Label with constituent disclosure message|Labels with constituent disclosure messages that include text about chemicals in cigarette smoke and health effects of the chemicals will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 disclosures selected at random; at the week 3 visit, they will get one of the 2 remaining disclosures selected at random, and at the week 4 visit they will get the remaining disclosure. Study investigators developed the text and design of these labels.
40950154|NCT02785484|OTHER|Label with litter message|Labels with litter messages that include text about littering cigarette butts will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 litter messages selected at random; at the week 3 visit, they will get one of the 2 remaining litter message selected at random, and at the week 4 visit they will get the remaining litter message. Study investigators developed the text and design of these labels.
41133740|NCT01833598|PROCEDURE|PNT alone|The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
41133741|NCT04535999|DRUG|Secukinumab Auto-Injector|300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)
41133742|NCT01473069|DRUG|JTK-853, ketoconazole|JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
40759964|NCT01943084|DRUG|Norditropin® FlexPro® pen|Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
40950155|NCT05328674|PROCEDURE|Arthroscopic reconstruction of cartilage defects in the knee joint with the use of autogenous cartilage transplant with PRP GF (platelet plasma with growth factor)|Arthroscopic reconstruction of cartilage defects in the knee joint using an autogenous PRP GF cartilage transplant.
40950156|NCT05328674|PROCEDURE|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method.
40950157|NCT03064750|BEHAVIORAL|pelvic floor exercises|In preparation for surgery, patients receive individual information by a physiotherapist on pelvic floor anatomy and correct pelvic floor contraction. Patients are told to do the following pelvic floor exercises 3 times a day: 8-12 maximal contractions, hold contractions during 10 seconds, and 3 fast contractions after each long contraction. In addition exercise in groups with skilled physical therapists once a week during 12 weeks.
40950158|NCT03064750|OTHER|Waiting list|patients wait as usual until surgery without special treatment.
40950159|NCT02891109|BIOLOGICAL|Biological tests|From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
40950160|NCT03652168|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
40950161|NCT04820517|OTHER|Roy Adaptation Model Based Strengthening Program|"Applications included in the strengthening program sessions:~* Awareness study on social media addiction and its effects~* Awareness work on the correct and effective use of leisure time~* As a result of social media addiction, within the scope of Roy Adaptation Model, scenario sharing and problem solving process related to the problems arising in the fields of physical, group identity - self, role and interdependence~* Awareness work on recognizing and managing emotions~* Relaxation and Breathing Exercise in Emotion Management"
40950162|NCT03123367|DEVICE|Group 1: Nella VuSleeve|Sleeve
40950163|NCT03123367|DEVICE|Group 2: Nella NuSpec|Speculum
40950164|NCT03123367|DEVICE|Group 3: NellaSpec|Speculum
40950165|NCT03123367|DEVICE|Group 4: Nella Insert|Sleeve
40950166|NCT01028885|PROCEDURE|radiation therapy treatment planning/simulation|
40950167|NCT01028885|PROCEDURE|intensity-modulated radiation therapy|
40950168|NCT01028885|PROCEDURE|image-guided radiation therapy|
40950169|NCT01028885|PROCEDURE|magnetic resonance imaging|
40950170|NCT01028885|PROCEDURE|computed tomography|
40950171|NCT01469624|DRUG|Pentoxifylline|pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
40950172|NCT01250431|BEHAVIORAL|EFT (Emotional Freedom Techniques)|10 EFT sessions
40759965|NCT01943084|DRUG|Genotropin Pen®|Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
40786462|NCT04245709|DRUG|Clenbuterol|The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).
40950173|NCT01469234|DRUG|loratadine|loratadine, one 10 mg tablet, orally
40950174|NCT01469234|DRUG|fexofenadine|fexofenadine, one 180 mg tablet, orally
40950175|NCT01469234|DRUG|placebo to loratadine|one tablet, orally
40950176|NCT01469234|DRUG|placebo to fexofenadine|one tablet, orally
40950177|NCT02406183|RADIATION|Stereotactic body radiotherapy (SBRT)|The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43
40950178|NCT02406183|DRUG|Ipilimumab|Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
40950179|NCT04674202|OTHER|Phone interview|The participant will have 2 phone interview in which they will be asked about their knowledge of direct oral anticoagulants.
40950180|NCT02789631|OTHER|assessment|
40950181|NCT05702918|DEVICE|BTL-6000 FSWT|The energy will be set to 0.14 mJ/mm2, frequency 6 Hz, total number of shocks 1800. The application will be semi-static at the location of the largest USG finding. 600 shocks are applied from all three sides (medial, lateral, dorsal).
40950182|NCT05702918|OTHER|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
40950183|NCT03243942|DRUG|Definity|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
40950184|NCT00646789|DRUG|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
40950185|NCT01722396|DIETARY_SUPPLEMENT|Vitamin D|
41133743|NCT01473069|DRUG|JTK-853 or Placebo|JTK-853 Tablets or Placebo, twice a day for 14 days
41288452|NCT03805880|DIAGNOSTIC_TEST|cerebral desaturation monitoring and cognitive examination|Before general anesthesia, continuous monitoring of cerebral oxygenation(rSO2) was started using an INVOS 5100 (Somaneic, Tro, MI) .Patient cognitive function was assessed using Mini-Mental State Examination (MMSE) on the day before surgery (baseline) and then after 1 day after surgery.
40950186|NCT00445978|DRUG|Sapropterin Dihydrochloride|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
40950187|NCT03020030|DRUG|Pegaspargase|Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
40950188|NCT03020030|DRUG|Erwinia asparaginase|Only for patients with Pegaspargase allergy or silent inactivation.
40950189|NCT03020030|DRUG|Cyclophosphamide|Standard of Care
40950190|NCT03020030|DRUG|CYTARABINE|Standard of Care
40950191|NCT03020030|DRUG|DASATINIB|Standard of Care
40950192|NCT03020030|DRUG|DEXAMETHASONE|Standard of Care
40950193|NCT03020030|DRUG|Dexrazoxane|Standard of Care
40950194|NCT03020030|DRUG|Doxorubicin|Standard of Care
40950195|NCT03020030|DRUG|ETOPOSIDE|Standard of Care
40950196|NCT03020030|DRUG|HYDROCORTISONE|Standard of Care
40950197|NCT03020030|DRUG|LEUCOVORIN CALCIUM|Standard of Care
40950198|NCT03020030|DRUG|MERCAPTOPURINE|Standard of Care
40950199|NCT03020030|DRUG|METHOTREXATE|Standard of Care
40950200|NCT03020030|DRUG|NELARABINE|Standard of Care
40950201|NCT03020030|DRUG|Vincristine|Standard of Care
40950202|NCT00322101|RADIATION|total-body irradiation|Radiation
40950203|NCT00322101|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
40950204|NCT00322101|DRUG|cyclophosphamide|Given IV
40950205|NCT00322101|DRUG|mycophenolate mofetil|Given orally
40950206|NCT00322101|DRUG|busulfan|Given IV or orally
40950207|NCT00322101|DRUG|cyclosporine|Given IV or orally
40950208|NCT00322101|DRUG|fludarabine phosphate|Given IV
40950209|NCT00322101|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
40950210|NCT00322101|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
40950211|NCT00322101|OTHER|laboratory biomarker analysis|Correlative studies
40950212|NCT00322101|GENETIC|cytogenetic analysis|Correlative studies
40950213|NCT00322101|OTHER|flow cytometry|Correlative studies
40950214|NCT00322101|GENETIC|fluorescence in situ hybridization|Correlative studies
40950215|NCT00322101|OTHER|pharmacological study|Correlative studies
40950216|NCT00322101|GENETIC|polymorphism analysis|Correlative studies
40950217|NCT00322101|DRUG|tacrolimus|Given IV or orally
40950218|NCT00322101|DRUG|methotrexate|Given IV
40950219|NCT03250221|DEVICE|barbed sutures|Use of the barbed sutures for robotic or laparoscopic myomectomy
40950220|NCT03250221|DEVICE|Vicryl@ suture|Use of Vicryl@ suture for robotic or laparoscopic myomectomy
40950221|NCT04767620|DRUG|Rugdenzengsheng No. 1 prescription|The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
40950222|NCT02908451|BIOLOGICAL|AbGn-107|Antibody Drug Conjugate
40950223|NCT01884532|DEVICE|ASR-XL Metal-on-Metal|All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
40950224|NCT02661685|BIOLOGICAL|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
40950225|NCT01014000|DEVICE|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
40950226|NCT01014000|DEVICE|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
40950227|NCT06557824|OTHER|speleotherapeutic intervention|In the study, medical records of 415 Czech children diagnosed with bronchial asthma who took part in speleotherapeutic intervention between January 2022 and October 2023 were analysed.
40786463|NCT02273102|DRUG|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
40786464|NCT02273102|DRUG|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
40950228|NCT05346497|PROCEDURE|Bentall|Bentall procedure: include replacement of both aortic valve and root
40950229|NCT05346497|PROCEDURE|David|David procedure: include replacement of aortic root and aortic valvuloplasty
40950230|NCT05346497|PROCEDURE|ARR|Aortic root reconstruction: reconstruction instead of replacement of aortic root, without surgery of the valve. include sandwich procedure, adventitia invertion procedure, etc.
40950231|NCT02448186|BEHAVIORAL|ESTEEM|10-session cognitive behavioral treatment
40950232|NCT06436261|PROCEDURE|Hybrid Fractional Laser|A hybrid fractional HALO™ laser treatment was performed after a 7-day washout period. Subjects were numbed for 30 minutes to 1 hour prior to the procedure with a topical numbing cream containing benzocaine, lidocaine, and/or tetracaine. After numbing was completed, patients received one full-face HALO™ laser treatment with settings 350/20/20.
40950233|NCT06436261|OTHER|Facial Cleanser|Subjects were to use the provided cleanser twice daily (morning and evening) during the 7-day washout period and 7-day post-procedure timeline.
40950234|NCT06436261|OTHER|Facial Moisturizer|"Subjects were to use the provided bland facial moisturizer as follows:~WASHOUT PERIOD (7 days): After cleansing, 1-2 pumps were to be applied twice daily (morning and evening) to the full face avoiding the eye area~POST-PROCEDURE (7 days): After applying the Post-Procedure Cream and Active Comparator based on split-face randomization, the facial moisturizer was to be applied twice daily (morning and afternoon)."
40950235|NCT06436261|OTHER|Sunscreen|During the 7-day washout period and 7-day post-procedure timeline, subjects were to apply the provided basic sunscreen in the morning and afternoon after applying facial moisturizer. Sunscreen was to be reapplied as needed throughout the day per FDA recommendations.
40950236|NCT00874107|BIOLOGICAL|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
40950237|NCT00874107|BIOLOGICAL|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
40950238|NCT00874107|DRUG|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
41288453|NCT05582837|DRUG|nortriptyline + topiramate|nortriptyline (7.5mg) + topiramate (10mg) taken 1x per day and escalate weekly as needed for 8 weeks
40950239|NCT00874107|DRUG|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
40950240|NCT00579592|DRUG|Campath-1H, rituximab, myfortic|Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
40950241|NCT03325088|PROCEDURE|Bronchial endoscopy|Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
40950242|NCT03325088|PROCEDURE|Bronchial biopsies|5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
40950243|NCT03325088|PROCEDURE|Bronchial alveolar enema|For participants who had signed ancillary research consent
41288454|NCT01676376|DEVICE|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
40950244|NCT00920101|DRUG|Atorvastatin|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.
40950245|NCT00920101|BEHAVIORAL|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
40950246|NCT05592262|DRUG|SHR2554|On an empty stomach - after meals
40950247|NCT05592262|DRUG|SHR2554|After meals - on an empty stomach
40950248|NCT03815539|DEVICE|0.1% sodium hyaluronate|In dry eye group, part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
40950249|NCT04951804|PROCEDURE|EUS-CPN without bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to inject a neurolytic agent such as absolute alcohol around the base of the celiac artery.
40950250|NCT04951804|PROCEDURE|EUS-CPN with bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to firstly inject bupivacaine and secondly a neurolytic agent such as absolute alcohol around the base of the celiac artery.
40950251|NCT00806338|DRUG|Trodusquemine (MSI-1436)|A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.
40950252|NCT00806338|DRUG|Placebo|
40950253|NCT03954132|DRUG|Spiolto® Respimat®|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
40950254|NCT03954132|DRUG|Triple-Therapy (LAMA/LABA/ICS)|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
40950255|NCT06009692|OTHER|Upper limb Neuro-dynamics (Slider/ Tensioner Technique)|The experimental group will receive neuro-dynamic mobilization techniques along with task oriented training. Slider versus tensioner technique will be applied according to each patient's need. Session time will be 25-30 minutes. Four series of 10 tensioning movements at a rhythm of ∼6s per cycle and 1 min rest between each series will be performed. After each cycle of 10 repetitions, the position will hold for 10s.
40950256|NCT06009692|OTHER|Conventional Therapy for Upper limb|Conventional treatment will include therapeutic ultrasound for 4 min, TENS for 10 min. Task oriented training will be designed according to patient's functional outcomes. Sessions will be given for 6 days a week, 25-30 minutes per day.
40950257|NCT02624674|DEVICE|Multi-spectral Imaging Device (MSID)|
40950258|NCT02277730|DEVICE|vasopressor delivery automated system|vasopressor delivery using phenylephrine and ephedrine
40950259|NCT02277730|DRUG|phenylephrine|
40950260|NCT02277730|DRUG|ephedrine|
40950261|NCT02277730|DEVICE|manual vasopressor delivery|
40950262|NCT05768074|OTHER|Qualitative Interview|Therapists and agency leaders receiving intervention from the main study will participate in qualitative interviews
40950263|NCT02016573|DEVICE|Renal Denervation|Renal Denervation Catheter
40950264|NCT01834118|PROCEDURE|Renal Denervation|Sympathetic nerve ablation via transcatheter renal denervation
40950265|NCT02169479|DRUG|BIA 9-1067|OPC, Opicapone
40950266|NCT02169479|DRUG|Placebo|PLC, Placebo
40950267|NCT02169479|DRUG|Sinemet® 100/25|Immediate-release levodopa/carbidopa 100/25 mg
40950268|NCT04746196|OTHER|Serum galectin-3 concentration was measured.|Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
40950269|NCT00331864|DRUG|Ranibizumab|
40950270|NCT03368248|OTHER|Survey|A survey was conducted among all professionals in neonatal resuscitation services : doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical. All questions were closed, and a free comment area was proposed at the end. The questionnaire was preceded by a comment recalling the objectives of the study, the voluntary and individual nature of participation, and insisted on respect for anonymity. It consisted of 49 questions, allowing 197 possible answers. For most questions, several answers could be chosen.
40950271|NCT02360995|DRUG|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
40950272|NCT02360995|DRUG|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
40950273|NCT02360995|DRUG|fluoride toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
41146762|NCT06157294|PROCEDURE|Intra-articular pulsed radiofrequency|Intra-articular pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the intra-articular joint, which is the target tissue, is reached with the help of fluoroscopy images, pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
41288455|NCT01676376|OTHER|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
41288456|NCT00955240|BIOLOGICAL|cetuximab|
41288457|NCT00955240|DRUG|cisplatin|
40950274|NCT02360995|DRUG|Fluoride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
40950275|NCT02360995|DRUG|cetylpyridinium chloride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
40950276|NCT05117333|OTHER|Reminder (information letter)|Reminders
40950277|NCT00479323|BIOLOGICAL|Pneumovax 23|Licensed pneumococcal vaccine (Pneumovax 23).
40950278|NCT01756053|DRUG|ABT-089|Selective neuronal nicotinic receptor agonist.
40950279|NCT01756053|DRUG|Placebo|Matched placebo capsules supplied by study drug supplier.
40950280|NCT00406965|DRUG|HAE1 (PRO98498)|
40950281|NCT03675620|DEVICE|BFR|Delfi's Personalized Tourniquet System for Blood Flow Restriction will be used with leg extension and leg press exercises. Bilateral thigh cuffs will be applied to the participants and occlusion pressure will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each participant will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between exercises. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
40950282|NCT03675620|OTHER|Standard Rehabilitation|The control group will perform perform 4 sets of leg extensions and leg press (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
40950283|NCT02651467|OTHER|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
40950284|NCT02651467|OTHER|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
40950285|NCT02651467|OTHER|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
40950286|NCT03179527|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc
40950287|NCT03179527|DRUG|Lipid Regulating Drugs|Mainly including statins
40950288|NCT03179527|DRUG|Coronary Vasodilator|Mainly including nitrates
41288458|NCT00955240|DRUG|fluorouracil|
41288459|NCT00955240|OTHER|laboratory biomarker analysis|
41288460|NCT00955240|RADIATION|radiation therapy|
41288461|NCT02026271|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection or 1.0 x 10\^12 viral particles (vp) per injection~* one intratumoral injection of Ad-RTS-hIL-12"
41288462|NCT02026271|DRUG|veledimex|"* 4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)~* 14 oral daily doses of veledimex~* 1 Expansion cohort at a single dose level at or below MTD"
41288463|NCT01300286|DRUG|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
41288464|NCT06289725|DRUG|antiviral treatment|The patient was treated with antiviral drugs according to the protocol of the Ministry of Health of Vietnam 2019
40950289|NCT03179527|DRUG|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
40950290|NCT00302263|DRUG|Metobes-compound|
40950291|NCT03501303|PROCEDURE|No touch technique|Veins for CABG is harvested with the no touch technique
40950292|NCT03501303|PROCEDURE|Control technique|Veins for CABG is harvested with the Control technique.
40759966|NCT03912753|BEHAVIORAL|Comunică|Comunică is based on the Information-Motivation-Behavioral Skills (IMB) model of health behavior change, which postulates that individuals must possess the requisite information for enacting sexual health, motivation to change their HIV risk and alcohol use, and behavioral skills necessary for reducing their risk. Therefore, Comunică includes MI to provide accurate information about HIV transmission, alcohol abuse, and local GBM-affirmative health resources and build motivation to improve behavioral skills (via CBST). CBST is a therapeutic approach used in the treatment of various behavioral problems, such as alcohol abuse and depression and more recently HIV risk. CBST can help modify cognitions driving unhealthy behaviors, promote awareness of contextual triggers and unhealthy behavioral patterns, and teach coping skills to improve health. Comunică also draws upon minority stress theory recognizing that stigmatizing societal contexts compromise health behavior.
40950293|NCT02764333|BIOLOGICAL|TPIV200|
40950294|NCT02764333|BIOLOGICAL|Durvalumab|
41146763|NCT06157294|PROCEDURE|Median branch pulsed radiofrequency|Median branch pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the median branch region, which is the target area, is reached with the help of fluoroscopy images, location confirmation will be provided by giving sensory and motor stimulation. Pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
41288465|NCT03927976|BEHAVIORAL|Path2Quit - culturally specific text message intervention|SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
41288466|NCT02893254|DRUG|IBI303|12 cycles. IBI303: 40 mg, iH
40950295|NCT04811378|OTHER|HaemoCer|Randomized application of 3g haemostatic powder (HaemoCer) in the wound site during breast-conserving surgery.
40950296|NCT01997853|DRUG|Omega 3 fatty acid|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
41288467|NCT02893254|DRUG|Adalimumab|12 cycles. Adalimumab: 40mg, iH
41288468|NCT04824872|DRUG|Dasiglucagon|dasiglucagon SC, low dose
40950297|NCT01997853|DRUG|Placebo|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
40950298|NCT00316771|DRUG|P38 Inhibitor (4) 150mg|150mg po qd
40950299|NCT00316771|DRUG|P38 Inhibitor (4) 25mg|25mg po bid
40950300|NCT00316771|DRUG|P38 Inhibitor (4) 300mg|300mg po qd
40950301|NCT00316771|DRUG|P38 Inhibitor (4) 50mg|50mg po qd
40950302|NCT00316771|DRUG|P38 Inhibitor (4) 75mg|75mg po bid
40950303|NCT00316771|DRUG|Placebo|po bid
40950304|NCT02281773|DRUG|BI 409306 100 mg QD|
40950305|NCT02281773|DRUG|BI 498306 50 mg QD|
40950306|NCT02281773|DRUG|Placebo|
40950307|NCT02281773|DRUG|BI 498306 25 mg QD|
41288469|NCT04824872|DRUG|Dasiglucagon|dasiglucagon SC, high dose
41288470|NCT04824872|DRUG|Placebo|placebo for dasiglucagon
41288471|NCT03982225|DRUG|Polyene phosphatidylcholine injection|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
40950308|NCT02281773|DRUG|BI 409306 10 mg QD|
40950309|NCT05745012|PROCEDURE|endoscopic mucosal resection|The procedure consists of performing endoscopic mucosal resection of the 3/4 of the circumference of the esogastric junction using the Duette system (Cook Endoscopy, USA). The procedure will be performed under general anesthesia in an intubated patient, and realized in ambulatory setting.
40950310|NCT05745012|PROCEDURE|sham|The procedure consists of performing endoscopic exploration, no mucosal resection
40950311|NCT04741230|DEVICE|Gebauer Lenticule|The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.
40950312|NCT05303077|DIETARY_SUPPLEMENT|Nutribén Innova® 1|Infants are fed solely with infant formula supplemented with an inactive probiotic and omega 3 fatty acids over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's
40950313|NCT05303077|DIETARY_SUPPLEMENT|Nutribén®|Infants are fed solely with infant formula over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's age.
40950314|NCT05303077|DIETARY_SUPPLEMENT|Breastfeed|Infants are breastfeeding solely over the first 6 months of their life, from then on the infants are fed as recommended by their caregiver, as if they are not participating in a research study.
40950315|NCT05955625|OTHER|TIMELY|The TIMELY app works with several devices, including a wearable activity tracker that collects activity levels, heart rate and sleep characteristics. Based on patient's activity levels, self-reported momentary mental states, health-related behaviours and environmental and clinical background factors, the app will enable patient-tailored recommendations relevant to improving lifestyle behaviours during daily life. In addition, patients will receive a blood pressure monitor that measures hemodynamic parameters through pulse wave analysis (PWA) and an easy-to-use ECG device which will be used to assess changes in heart rate and other cardiovascular measures at rest and with exercise.
40950316|NCT01743417|BEHAVIORAL|Computerised cognitive rehabilitation training|24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
40950317|NCT01332084|OTHER|HA wheat cereals|HA wheat cereals used in SOTI test and as part of desensitization plan
41454045|NCT04985149|OTHER|Electromyographic measurement:|"Nerve conduction studies; assesses nerve function and includes motor, sensory, and mixed nerve tests.~Micromed (Italy 2020) EMG device will be used in the electrophysiological examination. Sensory and motor conduction studies will be performed in the lower and upper extremities by paying attention to the extremity temperatures of the cases.~Nerve conduction studies will be performed by another physician who is unaware of the diagnosis of the patients. Bilateral lower extremity sural sensory responses of the patients will be taken.~In the antidromic method in sural nerve conduction examination, the bipolar superficial electrode is placed behind the lateral malleolus; stimulation will be made with bipolar surface electrodes 12-15 cm proximal to the recording site. Initial latency should be \< 3.8 ms, amplitude \> 10 Mv, and conduction velocity \> 36 m/sec in sensory response of the sural nerve."
41454046|NCT04985149|OTHER|Ultrasonographic measurement:|Sural nerve ultrasonography (US) will be performed by another clinician (Merve Akdeniz leblebicier) who is experienced in musculoskeletal ultrasonography and unaware of clinical evaluation, using a 6-18 Mhz linear probe. (Mindray -UMT 200, United States) Both sural nerve joints of the patients will be evaluated. The patient will lie on the stretcher in the prone position, the ankle will be out of the bed. The 14 cm above the malleolus will be marked as the main line, the nerve will be detected in the lateral of the tendon of the gastrocnemius muscle and the proximal of the saphenous vein. Nerve diameter measurement will be measured 3 times in mm2 and the average will be taken. Then, possible inflammatory pathologies will be ruled out by providing clinical confirmation using the Doppler mode (11).
40950318|NCT00283231|BEHAVIORAL|Paced Respiration|
40950319|NCT05634031|RADIATION|PET imaging|PET imaging visit, which will take approximately 1-2 hours.
40950320|NCT05634031|RADIATION|Coronary CT angiogram|A coronary CT angiogram if the participant has not had one recently.
41133744|NCT05038215|BEHAVIORAL|adherence promotion techniques|The experimental group will receive adherence promotion techniques in addition to routine care, including 1-additional information tailored for the spouse/partner, persons living with the patient. 2- Educational material delivered at follow up appointments and by mail at intervals agreed upon by the patient and the clinician. 3- Electronic reminder/communication system established by patient and provider. 4-Follow up communication from the dental provider of the oral appliance to the primary care physician and with patient's approval, their general dentist. 5- After the 3 month follow up visits the patient will be provided with reports about their appliance wear per week. 6-Gift card delivery, $25, at 6 month follow up if a follow up with sleep physician is scheduled.
41133745|NCT05038215|PROCEDURE|Routine Care|The control group will receive routine care
41454047|NCT05368753|OTHER|Blood sample|Lidocaine blood sample 30 min before the end of the surgery Lidocaine blood sample at the end of the infusion lidocaine and ropivacaine blood sample 2 h after the ropivacaine infusion of the TEA Ropivacaine blood sample 24h after the infusion of the TEA
41133746|NCT03403036|DRUG|Brodalumab|Weeks 0, 1, 2, and every 2 weeks thereafter through and including Week 16.
41133747|NCT01989416|DRUG|2% chlorhexidine wipe|The ICU patients will be bathing with 2% chlorhexidine wipe
41133748|NCT01989416|DRUG|Soap|The ICU patients will be bathing with Soap
41133749|NCT00005974|DRUG|alvocidib|Flavopiridol 50 mg/m2 IV over 1 hour daily x 3 days every 3 weeks
40759967|NCT03912753|OTHER|Education Attention Control|The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.
41133750|NCT05710757|OTHER|myofascial release|Myofascial release (MFR) is a technique that involves applying gentle sustained pressure into the myofascial connective tissue restrictions to eliminate pain and restore motion.
41146764|NCT05670678|DIETARY_SUPPLEMENT|a2 growing up stage 3 formula puls lactoferrin supplement|The participants in this group will consume 4-5 scoops (8.5g/scoop) of the assigned formula each time, and 4 times per day
40950321|NCT05634031|PROCEDURE|Functional Angiography|"A subset of patients with abnormal results on cardiac PET myocardial perfusion imaging study (estimated number of patients = 12) will be invited to participate in an invasive sub-study wherein they would undergo detailed invasive coronary physiology evaluation.~Functional Angiography (coronary reactivity test- CRT): is an angiography procedure done in the catheterization laboratory. It evaluates the coronary artery microcirculation and how the blood vessels respond to different medications."
40950322|NCT05634031|PROCEDURE|Treadmill exercise stress study|A treadmill exercise stress study
40950323|NCT01743183|DEVICE|Threshold|The load adjustment was done weekly by a single examiner.
40950324|NCT05155150|BEHAVIORAL|Providing patient-reported outcome|Patients receive personalized information on expected quality of life one year after ICU during ICU admission (during a family meeting)
40950325|NCT06142630|OTHER|Alteration of patients' position after erector spinae plane block|After the erector spinae plane block was completed, the patients kept supine, lateral or prone position according to the group allocated for 30 minute to ensure the spread of local anesthetic
40950326|NCT05342610|OTHER|Distant reiki|Reiki; It is the transfer of energy to other people by the hands of the person who receives the theoretical training and attunement (initiation) from the reiki master, close or distant. When the hands are brought closer to the body in suitable positions or when the reiki practitioner visualizes the person in his/her thoughts, the energy flow starts spontaneously and the transferred energy is shaped according to the needs of the reiki recipient. The biggest advantage of Reiki; It is an easy and cost-effective method to ensure that the individual restores the balance between body, mind and spirit, has no side effects, has no negative effects on behavior and attitudes.
40950327|NCT00697359|DEVICE|Implantable loop recorder (ILR)|The ILR will be implanted subcutaneous following standard surgical procedure.
40950328|NCT05769309|PROCEDURE|Erector spinae block|After induction, the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
40950329|NCT05769309|DRUG|Fentanyl|fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
40950330|NCT04045548|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
40950331|NCT04045548|DRUG|Placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
40950332|NCT02385682|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
40950333|NCT02385682|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
40950334|NCT05488171|DRUG|Methylone|Single oral dose of 200 mg of methylone.
40950335|NCT05488171|DRUG|3,4-methylenedioxymethamphetamine|Single oral dose of 100 mg of MDMA.
40950336|NCT05488171|DRUG|Placebo|Single oral dose of placebo.
40950337|NCT01716390|DIETARY_SUPPLEMENT|Drink that contains plant stanols|
40950338|NCT01716390|DIETARY_SUPPLEMENT|Placebo drink|
40950339|NCT05763212|OTHER|Reverse Walking+Baseline treatment|Reverse Walking+Baseline treatment
40950340|NCT05763212|OTHER|Whole Body Vibration + Reverse Walking+Baseline treatment|Whole Body Vibration + Reverse Walking+Baseline treatment
40950341|NCT02213042|DRUG|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
41146765|NCT05670678|DIETARY_SUPPLEMENT|Enfinitas growing up stage 3 formula|The participants in this group will consume 4 scoops (10g/scoop) of the assigned formula each time, and 3 times per day
40950342|NCT02213042|BIOLOGICAL|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
41454048|NCT05368753|DRUG|Lidocain|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end) The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
40759968|NCT02704377|OTHER|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
41288472|NCT03982225|DRUG|Placebo|Phosphate buffered saline placebo for injection
41288473|NCT05700240|DEVICE|orthokeratology|rigid contact lenses
41288474|NCT05700240|DEVICE|single-vision spectacle correction|simple wear of spectacle
41288475|NCT00552799|DRUG|Penicillin VK|Biconcave tablet 250mg oral, b.d.
41288476|NCT00552799|OTHER|placebo|biconcave tablet matching active comparator as much as possible in size and shape
41454049|NCT05368753|DRUG|ropivacaine|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end), then ropivacaine will be injected in the TEA at the same time and infused during 24h. The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
41454050|NCT03222531|DRUG|sofosbuvir/velpatasvir|Drug: sofobuvir/velpatasvir
40950343|NCT02213042|DRUG|Aromatase Inhibitors (AIs)|Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
40950344|NCT01739361|DRUG|Acetaminophen|
40759969|NCT02704377|PROCEDURE|Dual X-ray Absorptiometry|Undergo iDXA
40759970|NCT02704377|OTHER|Laboratory Biomarker Analysis|Correlative studies
40759971|NCT02704377|OTHER|Quality-of-Life Assessment|Ancillary studies
40950345|NCT01739361|DRUG|placebo|
40950346|NCT02281565|BEHAVIORAL|survey|Survey about Knowledge, Attitude and Practice About Blood Donation
41288477|NCT03237208|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.
41288478|NCT03237208|DEVICE|placebo group|Transcutaneous electrical nerve stimulation treatment will not be activated.
41288479|NCT03320512|BEHAVIORAL|P3|P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
41454051|NCT03673267|BEHAVIORAL|Nutricity|Participants will use their smartphone or web-accessing device to access the Nutricity website to potentially increase nutrition literacy and set nutrition goals. Participants will have their own user name and password to access the site. Access to Nutricity will last approximately 3 months.
41454052|NCT06102148|OTHER|PNF Group|Exercise training and PNF training
41454053|NCT06102148|OTHER|Control Group|Exercise training
40759972|NCT02704377|OTHER|Questionnaire Administration|Ancillary studies
41454054|NCT02786433|OTHER|conventional physiotherapy|
41454055|NCT02786433|OTHER|Virtual Reality with X- Box Kinect®|
40950347|NCT02486354|DRUG|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
40950348|NCT06438939|OTHER|Biopsy for diagnostical purposes|Incisional biopsy is the current golden standard for OPMD/OSCC diagnosis. Yet, the site it shall be performed is choosen by clinician at naked eyes. We will compare and study the results of performing the common golden standard biopsy site when guided by NBI.
40950349|NCT04736342|OTHER|PALI questionaire|Survey comprised of a series of multiple choice questions
40950350|NCT05882188|PROCEDURE|Oil-based contrast|oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.
40950351|NCT05882188|PROCEDURE|ExEm Foam|ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
40950352|NCT01146275|RADIATION|Radiologial breast examination|MRI of breast, mammography and ultrasound of breast
40950353|NCT03295500|RADIATION|Dose fraction forms|The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.
40950354|NCT02409810|DRUG|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
40950355|NCT04796545|DEVICE|SING IMT(TM) System, model NG SI IMT 3X|The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.
40950356|NCT00384410|DRUG|Nabilone|
40950357|NCT03307642|OTHER|Text message notification|Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication
40950358|NCT02108782|DRUG|dovitinib lactate|Given PO
40950359|NCT02108782|OTHER|pharmacological study|Correlative studies
40950360|NCT02108782|OTHER|laboratory biomarker analysis|Correlative studies
40950361|NCT01175460|DRUG|S-1, Nedaplatin|nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
40950362|NCT00004195|DRUG|eniluracil|Will be given to either subject pre-operative and metastatic disease
40950363|NCT00004195|PROCEDURE|conventional colon surgery|Only if the subject is amenable to surgical resections
40950364|NCT03434574|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
40950365|NCT03434574|DIETARY_SUPPLEMENT|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa).
40950366|NCT03326739|PROCEDURE|Arterial Line Placement|arterial line placement
40950367|NCT00703196|DIETARY_SUPPLEMENT|folic acid|Given orally once daily
40950368|NCT00703196|OTHER|placebo|Given orally once daily
40950369|NCT01228864|PROCEDURE|quality of life|survey
40950370|NCT01228864|PROCEDURE|Quality of life|
40950371|NCT00154557|BEHAVIORAL|elite judo athletes program|
40950372|NCT00004006|BIOLOGICAL|filgrastim|
40950373|NCT00004006|DRUG|carboplatin|
40950374|NCT00004006|DRUG|cyclophosphamide|
40950375|NCT00004006|DRUG|doxorubicin hydrochloride|
40759973|NCT04739215|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg / day oral
40950376|NCT00004006|DRUG|etoposide|
40950377|NCT00004006|DRUG|topotecan hydrochloride|
40950378|NCT00004006|PROCEDURE|autologous bone marrow transplantation|
40950379|NCT00004006|RADIATION|radiation therapy|
40950380|NCT02260440|DRUG|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
40950381|NCT02260440|DRUG|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
40950382|NCT00002451|DRUG|Indinavir sulfate|
40950383|NCT00002451|DRUG|Ritonavir|
40950384|NCT00002451|DRUG|Lamivudine|
40950385|NCT00002451|DRUG|Stavudine|
40950386|NCT05531383|DRUG|Memantine Hydrochloride|study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in patients with moderate to severe TBI as well as their outcome.
40950387|NCT00137215|DEVICE|Silverlon|dressing for donor site mamagement
40950388|NCT01498978|BIOLOGICAL|ipilimumab|Given IV
40950389|NCT01498978|OTHER|laboratory biomarker analysis|Correlative studies
40950390|NCT04140838|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.
41133751|NCT05710757|DEVICE|blood flow restriction|Blood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response.
41133752|NCT05710757|OTHER|myofascial release|Sham MFR.
40950391|NCT04140838|BEHAVIORAL|Behavioral Activation Therapy for Depression (BATD)|"Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.~Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.~Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.~Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.~Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.~Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about."
40950392|NCT04140838|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.
40950393|NCT01354457|DRUG|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
40950394|NCT00675259|DRUG|bevacizumab|bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days \[1 cycle\] for 5 cycles
40950395|NCT00675259|DRUG|carboplatin|AUC 2 IV on days 1, 8, and 15
40950396|NCT00675259|DRUG|nab-paclitaxel|100 mg/M2 IV
40950397|NCT00675259|PROCEDURE|Surgery|lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
40950398|NCT00675259|DRUG|Adjuvant chemotherapy|All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
40950399|NCT04423510|PROCEDURE|Crystallized phenol treatment|
40950400|NCT00978770|DRUG|systemic chemotherapy|
40950401|NCT00978770|PROCEDURE|diffusion-weighted magnetic resonance imaging|
40950402|NCT00978770|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
40950403|NCT00978770|PROCEDURE|magnetic resonance spectroscopic imaging|
40950404|NCT00978770|PROCEDURE|neoadjuvant therapy|
40950405|NCT00193531|DRUG|Paclitaxel|
40950406|NCT00193531|DRUG|Carboplatin|
40950407|NCT00193531|DRUG|Etoposide|
40950408|NCT05968339|OTHER|Survey|"The survey will be distributed via scientific anesthesiology societies and will be open for a total of 12 consecutive months.~Participation in the survey will be voluntary and anonymous - individual consent will be implied by willingness to complete the survey.~The survey will be conducted via SurveyMonkey. SurveyMonkey allows Health Insurance Portability and Accountability Act (HIPAA)(12) compliant surveys to be created. These follow strict rules around the protection of health information. Of note, SurveyMonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored. Access to the database will be password protected and only the authors will have access for the purpose of data analysis at the end of the survey period. Analysis using chi squared tests and logistic regressions will be performed by trained statisticians."
40950409|NCT05661357|DRUG|Disitamab Vedotin Combined With Fruquintinib|Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)
40950410|NCT00370071|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
40950411|NCT04198597|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
40950412|NCT04198597|BEHAVIORAL|Process-based Cognitive Behavioral Therapy|Please see arm/group descriptions
40950413|NCT05169190|PROCEDURE|Stellate Ganglion Block|After procedure informed consent, the procedure will be done using an ultrasound guided technique with a high frequency (6 to 13 MHz) linear transducer and confirmation of placement by fluoroscopy at sites who do this in clinical practice. The subject will be prepped and draped and placed in supine position in a suite with continuous vital sign monitoring and advanced cardiac life support equipment and IV placement. Local anesthesia with 1% buffered lidocaine will be achieved. After visualization of Chassaignac's tubercle of C6 is identified along with the carotid artery, internal jugular vein and longus colli and capitus muscles, a 25-gauge echo-enhanced needle will be inserted to inject anesthetic over 2 minutes anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle. The needle will be withdrawn and the subject will be monitored for a minimum of 30 minutes.
40950414|NCT05169190|PROCEDURE|Sham Stellate Ganglion Block|"The Sham protocol is identical to the SGB protocol except After needle tip confirmation and negative aspiration, normal saline (0.9%) + contrast (unlabeled to keep treater blinded) will be slowly injected over 2 minutes while closely monitoring the subject."
40950415|NCT02677064|OTHER|assessments|All laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.
40950416|NCT06125548|OTHER|Lactation Management Model|The mother provides skin-to-skin contact to her baby 12 times a day, 8 times on the 2nd day, 4 times on the 3rd day, hot application to the breast (5 minutes), relaxation technique (3 minutes) and breast massage (5 minutes by hand milking, 2 minutes by breast massage). Head stimulation, stroking for 3 minutes) were asked.
41133753|NCT04055818|DRUG|Nicotinamide|Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
41133754|NCT04746404|BEHAVIORAL|Emotional Skills Development Program|Emotional Skills Development Program (positive psychology)
41454056|NCT05010135|DEVICE|Zebris Gait System assessment for gait weight distribution + EMG evaluation of Quadriceps, Hamstrings, Tib Anterior and Calves + Positional Sense assessment|To measure the above parameters and to compare between the healthy subjects and the vertebral fracture subjects
41133755|NCT00949117|DIETARY_SUPPLEMENT|Ensure|Given orally
41133756|NCT00949117|DIETARY_SUPPLEMENT|PediaSure|Given orally
41133757|NCT00949117|DRUG|cyproheptadine hydrochloride|Given orally
41133758|NCT01894737|OTHER|Placebo supplementation|Seven days of one-legged knee immobilisation with placebo supplementation
41454057|NCT00068042|DRUG|Pegvisomant|
41454058|NCT00068042|DRUG|Sandostatin LAR|
41133759|NCT01894737|OTHER|Creatine supplementation|Seven days of one-legged knee immobilisation with creatine supplementation.
40950417|NCT06343233|OTHER|usual care|The aim is to set up a collection of clinical and instrumental data of usual care from patients hospitalized for acute heart failure aged ≥ 65; at the time of admission and after 6-12 and 18 months from the event (admission).
40950418|NCT05934643|DEVICE|ActivPAL accelerometer|All patient will have an accelerometer (activPAL) applied to characterise the type and quantity of movement during the inpatient postoperative period after undergoing major surgery for colorectal cancer surgery.
40950419|NCT05934643|OTHER|Hospital Anxiety and Depression Scale (HADS) Questionnaire|The use of the HADS questionnaire to ascertain if any correlation between level of activity and and inpatient mood.
40950420|NCT05133908|BEHAVIORAL|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
40950421|NCT05133908|BEHAVIORAL|dCBTi-ADHD|The dCBTi adopts a multi-module approach, consisting of 7 weekly modules including psychoeducation on sleep and ADHD, insomnia, organization strategies and distractibility reduction skills, sleep hygiene, sleep restriction and prescription, circadian-related activity scheduling, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep. A virtual coach is also included in the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
40950422|NCT04752683|OTHER|MyBuddy Employee Wellbeing App|"The intervention is not being evaluated in this research study.~The MyBuddy app contains five core components to help employees track their wellbeing (assisting employers in managing their employees' wellbeing). The six core components are: (1) a 'Budometer' stress measure (measure to be validated); (2) working from home information and assessment designed to inform employees about the legal requirements and risks they and their employers are subject to when home working; (3) messaging service for employees to contact their HR department or their line manager; (4) a 'Think Room' forum for staff to discuss ideas; (5) an 'Appreciation Page' for staff to show appreciation for their colleagues; and (6) 'my hours this week' log to track the hours they have worked. A seventh element is available for HR departments demonstrating data for the employees (employees are aware that HR will be able to see their data)."
40950423|NCT04202471|DEVICE|Chlorhexidine Cloth|2% chlorhexidine gluconate cloth
40950424|NCT06319131|PROCEDURE|TIPS|Using the transjugular approach, TIPS was created under local anesthesia. The first branch of the left or right portal vein (PV) was punctured by RUPS-100 set guided by digital subtraction angiography. After successful access into PV, direct portography was performed and all visible varices and/or concurrent spontaneous portosystemic shunts (SPSS) were embolized with coils and n-butyl cyanoacrylate. A polytetrafluoroethylene-covered stent (Viatorr Endoprosthesis, GORE and Associates, Flagstaff, Arizona, USA) with a diameter of 8 mm was implanted and fully dilated.
40950425|NCT06319131|DRUG|Nadroparin|Nadroparin calcium will be subcutaneously injected with the dose of 85IU/kg q12h
40950426|NCT04537195|BEHAVIORAL|ADSMP-C|A transdiagnostic, lay-led, group-based self-management program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom management of anxiety and depression in cancer (ADSMP-C)
40950427|NCT03643575|DRUG|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
40950428|NCT03643575|DRUG|Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
40950429|NCT03643575|DRUG|Organ-I- NR tablet|Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
40950430|NCT02405780|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
40950431|NCT02405780|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
40950432|NCT03838146|BEHAVIORAL|Types of Exercise|moderate intensity exercise
40950433|NCT01411618|OTHER|free alcohol essential oil mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
40950434|NCT05678582|DIAGNOSTIC_TEST|Liver biopsy|liver biopsy were taken then evaluated by histopathological examination
40950435|NCT01501396|DRUG|Megestrol Acetate|
40950436|NCT01501396|DRUG|Mirtazapine|
40950437|NCT01055522|DRUG|Arm 1: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
40950438|NCT01055522|DRUG|Arm 3: Dacarbazine|Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
40950439|NCT01055522|DRUG|ARM 2: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
41133760|NCT03568409|DEVICE|ABO-GLYC|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
41133761|NCT03568409|OTHER|ABO-GLYC Placebo|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
41133762|NCT01688765|OTHER|Observational|
41133763|NCT00595959|DEVICE|CLiRpath Photoablation System|Use of CLiRpath Laser Catheter to improve vessel lumen diameter.
41454059|NCT01604941|DRUG|SPD602|50 mg/kg/day orally twice daily for 24 weeks
41288480|NCT03320512|BEHAVIORAL|P3+|In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.
41288481|NCT03320512|BEHAVIORAL|Control|Control participants will receive the standard of care for receiving a prescription for PrEP.
41288482|NCT03903055|DIAGNOSTIC_TEST|MDS group|patients diagnosed as MDS with high risk，aged 18-80，men/wemen
41288483|NCT04065763|OTHER|Ultrasound assessment of dural sac dimension|Dural sac dimension is assessed using ultrasonography in the lateral decubitus position for spinal anesthesia.
41288484|NCT01481246|BEHAVIORAL|Categorization training|Behavioral intervention consisting of cognitive training exercises to improve categorization performance
41288485|NCT01481246|BEHAVIORAL|Psychosocial and Psychoeducational Group training|Group treatment with a focus on psychosocial and psychoeducational intervention in healthy adults and in adults with cognitive decline. Ten week cycle, 2 hours per week group intervention study.
41288486|NCT04570891|PROCEDURE|Ultrasound-guided fascia iliaca compartment block|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
41288487|NCT04570891|PROCEDURE|Control|No regional block is provided at the end of surgery.
41288488|NCT04986527|PROCEDURE|Chest tube suction|The chest tubes will be inserted using our institutional standard chest tube insertion tray. The chest tubes used will be our institutional standard and will range from 14 to 32Fr in size. After chest tube placement, an Atrium Oasis Dry Suction Water Seal Chest Drain (Getinge USA Sales, LLC) will be used.
41288489|NCT01073189|DRUG|Intra-Renal Fenoldopam|Placement of an intra-renal catheter for infusion of fenoldopam mesylate
41288490|NCT01073189|DRUG|Furosemide|Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
41288491|NCT05508152|DRUG|Wound irrigation with amoxicillin-clavulanate in saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio.~For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~In the experimental arm of the study, the circulating nurse will prepare a solution of amoxicillin-clavulanate acid (1000 mg of antibiotic in 500 mL of saline) outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with the antibiotic solution, and the soaked gauze placed on the wound for 3 minutes."
41288492|NCT05508152|DRUG|Wound irrigation with a saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio. For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~If the case belongs to the sham group, at the end of the intervention, the circulating nurse will prepare a sham solution contaning only normal saline outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with saline, and the soaked gauze placed on the wound for 3 minutes."
41288493|NCT00510692|DRUG|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
41146766|NCT06467240|PROCEDURE|hybrid rapid maxillary expander assisted with Micro-osteo perforation (MOPs)|patients with constricted maxillary will applied for hybrid expansion and group of them will assisted by Micro-osteo perforation (MOPs)
41288494|NCT00510692|PROCEDURE|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
41454060|NCT05446519|BEHAVIORAL|Survey|Survey is proposed to all pilots who are members of the National Union of Airline Pilots
41454061|NCT01881763|DRUG|Ketamine|Ketamine 1-2 mgr/ kg IV
41454062|NCT01881763|DRUG|Methohexital|Methohexital 0.5-1mg/kg IV
41454063|NCT02173964|DRUG|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
41454064|NCT02173964|DRUG|water|same amount of water for pinverin administration
41454065|NCT02986555|DEVICE|Existing Biofeedback|Using relaxing assisted biofeedback approach
41454066|NCT02986555|DEVICE|Biofeedback accompanied with virtual reality|Using relaxation approach with existing biofeedback accompanied by virtual reality relaxation
41454067|NCT00989716|DRUG|Transdermal glyceryl trinitrate patch|5mg per day
41454068|NCT00989716|DRUG|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
41454069|NCT02238587|OTHER|Control group|In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.
41454070|NCT02238587|DIETARY_SUPPLEMENT|Ganoderma Spores Powder Capsules|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.
41454071|NCT02730533|DRUG|Esomeprazole|Proton pump inhibitor
41146767|NCT00005635|BIOLOGICAL|trastuzumab|
41146768|NCT00005635|DRUG|paclitaxel|
40950440|NCT02330965|PROCEDURE|Blood Draw|Blood draws (65 mLs \[\~4 tablespoons\] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
40950441|NCT02330965|PROCEDURE|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (\<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
40950442|NCT02214407|DRUG|Decitabine|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts \> 30 G/L, and mandatory if WBC \> 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
40950443|NCT02214407|DRUG|HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
40950444|NCT02282358|DRUG|Mocetinostat|
41288495|NCT00510692|PROCEDURE|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
41288496|NCT00510692|DRUG|Placebo|2 x 500mg placebo capsules twice daily for 6 months
41288497|NCT04215094|DIAGNOSTIC_TEST|postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun|All patients in Intracranial Infection group were cured with antibiotic treatment
41288498|NCT00051844|DRUG|Capravirine|
41288499|NCT01687231|OTHER|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
41288500|NCT04346225|DRUG|Hyperpolarized C13|Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
40759974|NCT04739215|DRUG|Placebo|One Placebo capsule daily oral
40950445|NCT00238888|PROCEDURE|asthma control awareness|Repeated assessments of the child's asthma control using the Asthma Quiz for Kidz, with recommendation for asthma education and medical visit
40950446|NCT00238888|PROCEDURE|Usual care|Recommendation for asthma education and/or follow-up at the physician's discretion
41288501|NCT04346225|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
41288502|NCT04396912|PROCEDURE|Total thyroidectomy|Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.
41288503|NCT01418768|OTHER|inpatient rehabiliation|inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
41288504|NCT05982873|DRUG|ABBV-400|Intravenous (IV) Infusion
41288505|NCT01332032|BEHAVIORAL|Reminder Letter|A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
40759975|NCT03987685|DRUG|Oratopo|Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
40759976|NCT04007731|DIETARY_SUPPLEMENT|DrRip - high protein, high fibre and creatine load|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
40950447|NCT05414877|DRUG|Ephedrine|vasopressor
40950448|NCT05414877|DRUG|Phenylephrine|vasopressor
40950449|NCT05414877|DRUG|Norepinephrine|vasopressor
40950450|NCT02552589|OTHER|Amine fluoride|toothpaste
40759977|NCT04007731|DIETARY_SUPPLEMENT|Voltage energy bar|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
40950451|NCT02552589|OTHER|Placebo|toothpaste
40950452|NCT02967432|DRUG|Mupirocin Topical Ointment|Mupirocin ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
40950453|NCT02967432|DRUG|Petroleum Jelly|Petroleum jelly ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
40950454|NCT02095418|DRUG|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
40950455|NCT02095418|DRUG|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
41288506|NCT01332032|BEHAVIORAL|Reminder Call|A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
41454072|NCT02730533|DRUG|No PPI treatment|No PPI treatment before ESD procedure
40759978|NCT01137565|DRUG|AMG 853|Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
40950456|NCT01268020|DRUG|[18F]-FMH3|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) or 2 ug of \[18F\]-FMH3, whichever is greatest.
40950457|NCT06292234|DEVICE|PSI|Fabrication of PSI implants using virtual surgical planning
41454073|NCT05372250|OTHER|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
40950458|NCT06292234|DEVICE|Conventional miniplates|Ready made miniplates
40950459|NCT01728350|BEHAVIORAL|HOPE - Helping Others through Purpose and Engagement|
40950460|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous fumarate|labeled iron as Ferrous Fumarate
40950461|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous fumarate + prebiotics|labeled iron as Ferrous Fumarate + galacto-oligosaccharides
40950462|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous sulfate + prebiotics|labeled iron as Ferrous Sulfate + galacto-oligosaccharides
40950463|NCT00496223|DRUG|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
40950464|NCT00496223|DRUG|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
40950465|NCT00072657|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.
41133764|NCT03750682|OTHER|Physical Activity (PA) Intervention|The PA intervention will consist of a twice per week group- based moderate-intensity multimodal program that includes aerobic, strength, flexibility, and balance training, as previously described. The Community Health Promoter will be trained and certified by Dr. Reid to deliver the PA intervention. PA will be conducted at the Holland Street Senior Center in Somerville, MA. The center is equipped with a large dining hall and corridors which will be utilized to perform the various components of the PA intervention for ENGAGE-B. This real-world approach was shown to be safe, feasible and effective in the initial ENGAGE study among older adults with severe mobility-limitations. Throughout PA, walking will be the primary mode of exercise, given its widespread applicabilityThe study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all PA subjects.
41133765|NCT03750682|OTHER|Healthy Aging Education (HE) Intervention|"The HE intervention will also be conducted at the Holland Street Senior Center in Somerville, MA. Participants will receive bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics of relevance to older adults (e.g., nutrition for brain health, effective negotiation of the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services and screenings, resources for reliable health information, etc.). All intervention materials will be submitted for IRB approval prior to the presentation. In addition to educational offerings, an instructor led program (5-10 minutes) of gentle upper extremity stretching exercises and relaxation techniques are to be performed during each class.~The study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all HE subjects."
41133766|NCT01353274|DRUG|Micamlo|Telmisartan plus Amlodipine T40/A5
41133767|NCT03100370|DEVICE|tsDCS-Anodal Stimulation|2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
41133768|NCT03100370|DEVICE|tsDCS-Cathodal Stimulation|2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
41133769|NCT03100370|DEVICE|tsDCS-Sham Stimulation|2.5mA sham tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
41133770|NCT03100370|DEVICE|Robotic-assisted training of arm and hand functions|70 minutes of robotic-assisted training (RAT) of arm and hand functions will follow each of the tsDCS sessions, five days a week, for two weeks. Robotic-assisted training will be provided by using the MAHI Exo-II device.
41133771|NCT06510088|PROCEDURE|3-week multimodal prehabilitation program|"This program included four components:~Aerobic and Resistance Exercises A designated physical therapist supervises the resistance exercises and offers corrective guidance. Training intensity was continuously monitored and fine-tuned based on Borg scale assessments.~Respiratory Training Respiratory training was conducted using a respiratory trainer. Patients were instructed to engage in respiratory training at least three times daily, with each session lasting 10 minutes.~Nutrition Intervention Those in the multimodal prehabilitation group received daily whey protein powder to ensure a recommended protein intake of 1.5 g/kg/d. Protein supplements were to be consumed within one hour of exercise to promote muscle synthesis.~Psychological Intervention Anxiety-coping interventions included relaxation techniques and deep breathing exercises, administered in a one-to-one format by a nurse trained in psychological care."
41133772|NCT01034306|DRUG|CF101|orally q12h
41133773|NCT01034306|DRUG|Placebo control|orally q12 hours
41133774|NCT00963092|GENETIC|DNA analysis|
41133775|NCT00963092|GENETIC|RNA analysis|
41133776|NCT00963092|GENETIC|microarray analysis|
41133777|NCT00963092|GENETIC|protein analysis|
41133778|NCT00963092|OTHER|cytology specimen collection procedure|
41133779|NCT00963092|OTHER|laboratory biomarker analysis|
41133780|NCT00963092|OTHER|questionnaire administration|
41133781|NCT00606216|PROCEDURE|MRI and cognitive evaluation|Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
41133782|NCT00606216|PROCEDURE|MRI and cognitive evaluation|Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
41133783|NCT00606216|PROCEDURE|brain MRI study and a brief neuropsychological evaluation|A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
40759979|NCT01137565|DRUG|Placebo|Placebo to AMG 853
40759980|NCT06209450|PROCEDURE|Ventral hernia repair with mesh fixation|Sutured versus suturless mesh fixation
40759981|NCT03602495|DRUG|Donafenib|Donafenib 0.3g Bid orally, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
40759982|NCT03602495|DRUG|Placebo|Matching placebo Bid orally, continuously.
40759983|NCT02709707|DEVICE|Blood glucose monitor|
40759984|NCT00242892|PROCEDURE|Intra coronary measures of pressure|Intra coronary measures of pressure
41133784|NCT04552015|DIAGNOSTIC_TEST|TST vs PPD microneedle test|TST vs First patch: 800 um in length, PPD1 formulation; Second patch: 1,500 um in length, PPD1 formulation; Third patch: 800 um in length, PPD2 formulation; and Fourth patch: 1,500 um in length, PPD2 formulation
41133785|NCT05827185|BIOLOGICAL|Ergonomic modifications|A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains (7 items related to office chair, 9 items related to office desk, 8 items related to keyboard and mouse, 5 items related to computer screen, 3 items related to telephone and 5 items related to the office environment -) and it has a good reliability and validity. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
40759985|NCT03324412|DRUG|Treatment of MTX|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
40759986|NCT03324412|DRUG|Treatment of MTX and TwHF|Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
40759987|NCT05452005|DRUG|[18F]-αvβ6-BP|Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
40759988|NCT05972785|DRUG|Calcium channel blocker|Drugs with ATC code C08 will be categorised as calcium channel blockers.
40759989|NCT05972785|DRUG|Beta blocker|Drugs with ATC code C07 will be categorised as beta-blockers.
40759990|NCT05972785|DRUG|Diuretic|Drugs with ATC code C03 will be categorised as diuretics.
40759991|NCT05972785|DRUG|RAS|Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
40759992|NCT05972785|DRUG|Other AHT|Drugs with ATC code C02 will be categorised as other antihypertensives.
40759993|NCT05972785|DRUG|None AHT|None AHT
40759994|NCT04565353|BEHAVIORAL|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
40759995|NCT01347086|DRUG|Matching placebo (low dose)|single dose of matching placebo
40759996|NCT01347086|DRUG|BI 207127 NA (medium dose)|Single does of BI 207127 NA
41146769|NCT03213379|DEVICE|Actimetry measures|The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
41146770|NCT01156194|DRUG|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
40759997|NCT01347086|DRUG|BI 207127 NA (low dose)|single dose of BI 207127 NA
40759998|NCT01347086|DRUG|Matching placebo (medium dose)|Single dose of matching placebo
40759999|NCT01347086|DRUG|BI 207127 NA (high dose)|Single dose of BI 207127 NA
40760000|NCT01347086|DRUG|Matching placebo (high dose)|Single dose of matching placebo
41288507|NCT01332032|BEHAVIORAL|Counselor Call|Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
41288508|NCT01919411|DRUG|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
41288509|NCT01919411|DRUG|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
41288510|NCT05464277|OTHER|Oxygen|Oxygen to achieve assigned SpO2 (or FiO2) targets will be administered to study subjects. The treating clinician can alter oxygenation targets at any time if deemed necessary. The oxygenation goal will be based on SpO2 rather than arterial oxygen saturation (SaO2) or arterial pressure oxygen (PaO2) from arterial blood gases. However, PaO2 can be used instead in situations where the treating clinician considers that peripheral perfusion is poor or SpO2 readings are unreliable. Assigned SpO2 targets will apply to the study subjects for a total duration of 6 hours from intubation or until death or until transfer to the operating theater (whatever comes first).
41288511|NCT02984475|DRUG|Metformin|
41288512|NCT02243566|DRUG|MicardisPlus®|
40760001|NCT02956863|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment delivered on pragmatic way.
40760002|NCT02956863|PROCEDURE|Exercises|Exercise for stretching and strength for neck muscles
41146771|NCT01156194|DRUG|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
41146772|NCT01156194|DRUG|Placebo|globule identical to true homeopathy comparators
41454074|NCT02183727|DEVICE|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
41288513|NCT04936139|BEHAVIORAL|Art Therapy|"During the 12 planned sessions, different artistic disciplines will be used: visual arts, music, play, narrative, dramatization, movement and body expression.~Each session is structured in 3 phases:~i. A first part of encounter and contextualization, to make contact with oneself, with the art therapist and with the group through a relaxation or meditation activity (35 minutes).~ii. A second part, where the session continues with the work of artistic elaboration and production with the different materials and the different artistic languages (50 minutes).~iii. A third part where the participants will be invited to make a closing, a moment to welcome and share whoever wishes, the experiences that have been experienced. A dialogue is created between Work-Patient-Art Therapist (35 minutes)."
41288514|NCT02617121|DRUG|Gabapentin|oral gabapentin 300 mg 1 hour before induction of anesthesia
41288515|NCT02617121|DRUG|Ramosetron|ramosetron 0.3 mg iv at end of surgery
41288516|NCT02617121|DRUG|Gabapentin and Ramosetron|oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
41288517|NCT00920543|DRUG|Placebo|Twice daily dosing
41288518|NCT00920543|DRUG|FP 100mcg|Twice daily dosing
41288519|NCT00920543|DRUG|FP 500mcg|Twice daily dosing
41288520|NCT00920543|DRUG|FP 250mcg|Twice daily dosing
41288521|NCT00920543|DRUG|FSC 100/50mcg|Twice daily dosing
41288522|NCT00920543|DRUG|FSC 250/50mcg|Twice daily dosing
41288523|NCT00920543|DRUG|FSC 500/50mcg|Twice daily dosing
40786467|NCT04631809|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
41133786|NCT05827185|BIOLOGICAL|Physiotherapy|First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. To perform the C1-C2 cervical spine manipulation (CSM) the participant was instructed to lie in a face-up position with upper and lower extremities kept aside relaxed. The head was kept in a neutral position and the treating therapist stands at the patient's head side and holds the chin of the patient with the right side hand. The therapist left hand holds the posterior aspect of the head and does two to three free rotatory movements. Afterwards, the therapist did HVLAT technique in either the right or left direction based upon the symptoms informed by the patient.
41133787|NCT05827185|BIOLOGICAL|Ergonomic modifications and Physiotherapy|"A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given."
41133788|NCT05827185|BIOLOGICAL|Patient education|Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
41133789|NCT03884842|BIOLOGICAL|Dupilumab/Dupixent|a monoclonal antibody designed for the treatment asthma and atopic dermatitis.
41133790|NCT03884842|BIOLOGICAL|Placebo|Matched placebo
41133791|NCT00082836|BIOLOGICAL|rituximab|
41133792|NCT00082836|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
41146773|NCT03204175|OTHER|FIT Plus|"* Group handwashing facilities~* Daily group handwashing and toothbrushing activities~* Sanitation operation and maintenance manuals for school officials~* Toilet cleaning consumable~* Toilet and handwashing station maintenance kits~* Soap, toothbrushes, and toothpaste"
41146774|NCT03204175|OTHER|Comparator arm|This is the same intervention as FIT Plus, but will be delivered to schools following endline data collection
41288524|NCT03183635|PROCEDURE|Balance training|Improvement of balance ability in stroke patients
41288525|NCT03502746|DRUG|Nivolumab|Nivolumab 240mg, IV over 30 minutes.
41288526|NCT03502746|DRUG|Ramucirumab|8mg/kg, IV over 60 minutes.
41288527|NCT03366311|PROCEDURE|holding position|two types of holding positions plus two types of shapes of stylet, with or without epiglottis lift
41288528|NCT00744055|DRUG|Prazosin|prazosin (16mg/day) 2 times a day
41288529|NCT00744055|DRUG|Placebo|Placebo
40950466|NCT00072657|BEHAVIORAL|Tai Chi Chih|Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.
40950467|NCT00072657|BEHAVIORAL|Health Education Seminar|Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
40950468|NCT06210464|OTHER||Trial have no Intervention measures.
40950469|NCT01976195|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
40950470|NCT01976195|DRUG|Thalidomide|Thalidomide 150mg per day, 15 consecutive days
40950471|NCT06556654|DEVICE|TRBR Device|The GORE® Tissue Reinforcement for Breast Reconstruction device is intended to reinforce the soft tissue surrounding the tissue expander in preparation for the breast implant in post-mastectomy breast reconstruction
40950472|NCT00381550|DRUG|fludarabine phosphate|Given IV
40950473|NCT00381550|DRUG|triapine|Given IV
40950474|NCT00381550|PROCEDURE|laboratory biomarker analysis|Correlative study
40950475|NCT05720260|DRUG|Goserelin|Hormone therapy
40950476|NCT05720260|DRUG|Fulvestrant|Hormone therapy
41133793|NCT06403410|OTHER|Delirium Prevention Guideline|Each intervention group patient randomized will receive the Delirium Prevention Guideline. The guideline is designed to be followed by nurses. However, collaboration with the physician is required for some aspects of the guideline (pain control, ordering/follow-up of laboratory tests, etc.). Support will be obtained from the intensive care physician, who is a member of the research team, for these steps. The guideline includes standard practices used by intensive care nurses in patient monitoring. In addition to routine follow-ups, eye masks and earplugs will be applied to patients in the intervention group between 24:00 and 06:00.
41133794|NCT01519557|DRUG|DAR-100A|15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
41133795|NCT01519557|DRUG|Placebo|Placebo
40950477|NCT05720260|DRUG|Capivasertib|AKT inhibitor
40950478|NCT05720260|DRUG|Durvalumab|immunotherapy
41288530|NCT00735423|DEVICE|No intervention|IDE used for outcome measurement not intervention
41288531|NCT03208192|PROCEDURE|liver transection during laparoscopic liver resection|liver transection during laparoscopic liver resection
41288532|NCT03490786|DRUG|GT-001|PK, PD Study to Determine Safety of Escalating Doses of GT-001
40950479|NCT06167564|DIAGNOSTIC_TEST|Routine allergy tests|Prick test, specific IgE detection
40950480|NCT06167564|DIAGNOSTIC_TEST|Newly developed microarray-based diagnostic test system|Newly developed microarray-based diagnostic test system for the detection of the specific IgE
40950481|NCT05111704|OTHER|Balance Body Tape|The intervention group received a three-week treatment with Balance Body Tape (BBT) (product by Babota AB), the control group received no treatment. A questionnaire regarding pain, including a Numeric Rating Scale (NRS) measuring pain intensity, and a Photographic posture analysis measurement (PPAM) of habitual sitting posture were accomplished before and after the intervention for both groups.
40950482|NCT03402113|DRUG|Dexmedetomidine|consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.
40950483|NCT03402113|DRUG|Midazolam|consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.
40950484|NCT06556771|OTHER|Gongs mobilization + conventional physical therapy|3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks
40950485|NCT06556771|OTHER|Kaltenborn mobilization along with traction + conventional therapy|3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks.
40950486|NCT04118842|DRUG|Savolitinib|Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.
40950487|NCT04118842|DRUG|Rifampicin|Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
40950488|NCT02586064|BEHAVIORAL|Interpersonal Therapy for PTSD|Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
40950489|NCT02586064|BEHAVIORAL|Prolonged Exposure|Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
40950490|NCT05646095|BEHAVIORAL|Bolstering Sleep and Adjustment in Foster Environments (B-SAFE)|We will adapt CBT for insomnia for children in foster care using a trauma-informed approach that considers the child's individual history, unique family environment, and child welfare policies regarding safe sleep practices.
41146775|NCT00456235|DRUG|Mycophénolate Mofétil|
41288533|NCT00142103|DRUG|CPG10101|CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
41288534|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
41288535|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks
41288536|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
41288537|NCT00142103|DRUG|Control|Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
41288538|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
41288539|NCT02770287|DEVICE|Venus Freeze Diamond Polar|The Venus Freeze Diamond Polar is a non-invasive dermatological treatment system that combines Multi Polar Radiofrequency and Pulsed Magnetic Fields. The radiofrequency energy penetrates the skin and results in tissue heating that has known effect on skin laxity, the magnetic field that is simultaneously induces increases fibroblast collagen production through non thermal mechanism and contributes to the clinical effect of skin laxity improvement. Only the Diamond Polar applicator will be used in this study for the treatment of the Mons pubis, vaginal introitus and Labia. Minor modification to the hand-piece for operator and/or patient comfort may occur mid-study, however no change in range of energy modality or amount of energy delivered will occur at any point during the study.
40760003|NCT01013870|DRUG|Atorvastatin|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
40760004|NCT01013870|DRUG|Placebo|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
40760005|NCT01772251|DRUG|Oshadi Icp|
40950491|NCT05667987|DRUG|Intravenous lidocaine administration|General anesthesia with intravenous lidocaine administration
40950492|NCT00573937|DRUG|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
40950493|NCT00573937|DRUG|Morphine|Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
40950494|NCT04763759|DRUG|TRL1068, a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
41133796|NCT01792557|DRUG|Crystallized phenol|Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
41133797|NCT01792557|PROCEDURE|Limberg Flap|Limberg Flap surgery for pilonidal disease treatment
41288540|NCT04595955|OTHER|CMyLife|CMyLife is a digital patient platform for Patients With Chronic Myeloid Leukemia.
41133798|NCT01792557|PROCEDURE|Modified Limberg Flap|Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.
41288541|NCT01381523|DRUG|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
41288542|NCT01381523|DRUG|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
41288543|NCT02477098|DRUG|preoperative 0.5% ropivacaine hydrochloride preoperative|Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
41288544|NCT02477098|DRUG|postoperative 0.5% Ropivacaine hydrochloride|Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
41288545|NCT05719064|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
40950495|NCT03671980|OTHER|My Medical record website|Website comprising patient records, blood and other test results, useful information on IBD, and messaging service to communicate with IBD team, plus home smartphone faecal calprotectin monitoring.
41133799|NCT01792557|PROCEDURE|Karydakis Flap|Karydakis Flap surgery for pilonidal disease treatment
41288546|NCT05719064|BEHAVIORAL|Computer-Delivered Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
41288547|NCT05719064|BEHAVIORAL|Automated Text Reminders|Scheduled text reminder to take medication
40760006|NCT02338557|DEVICE|motor relearning programme|MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects
40786468|NCT04631809|PROCEDURE|CT-Coronary Angiography + Coronary angiography +/- percutaneous coronary intervention|Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
41146776|NCT00456235|DRUG|Ciclosporine A|
41146777|NCT00456235|DRUG|Tacrolimus|
40950496|NCT05099081|PROCEDURE|diode laser application|Local anesthesia will be applied Lesion will be excised with diode laser (Medency, Italy) continuous wave mode 980 nm wave length with an output power 3 W in contact mode
41288548|NCT00750347|DRUG|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
40760007|NCT02338557|DEVICE|MIRROR THERAPY|Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
40760008|NCT01793454|OTHER|Fraction of inspired oxygen 40%|
40760009|NCT01793454|OTHER|Fraction of inspired oxygen 80%|
40950497|NCT05099081|PROCEDURE|intra-lesional injection of ethanolamine oleate|"Local anesthesia will be applied Injection of ethanolamine oleate (sclerosing gent) with concentration 5% diluted in distilled water to form 2.5% ethanolamine oleate According to lesion size range from 1.5 to 3 ml of solution will be injected slowly into lesion using gauge needle until leaked from lesion.~Lesion will be compressed for 5 minutes. Lesion will be observed once a week after injection until it becomes necrotic and falls off spontaneously.~Repeated injection may be needed."
41146778|NCT03427177|BEHAVIORAL|mychoice|The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
41288549|NCT01070355|DRUG|Eicosapentaenoic acid free fatty acid|An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
41288550|NCT01070355|DRUG|Placebo|2 capsules taken twice daily for 2-6 weeks before liver resection.
40760010|NCT04103931|BEHAVIORAL|"Treatment Choices for Aortic Stenosis Decision Aid"|"A decision aid, titled Treatment Choices for Aortic Stenosis, produced by the American College of Cardiology that contains information for patients deciding between TAVR and surgery to treat their aortic stenosis."
41288551|NCT01959204|DRUG|Oxycodone|Pain
41288552|NCT06184581|DRUG|Lithium Carbonate|The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
41288553|NCT06184581|DRUG|Lamotrigine|The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
41288554|NCT00075517|DRUG|docetaxel|
41288555|NCT00075517|DRUG|gemcitabine hydrochloride|
41288556|NCT04257461|DRUG|Fluoropyrimidine|Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.
41288557|NCT04257461|DRUG|Oxaliplatin|Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.
40760011|NCT00298701|BIOLOGICAL|ALK Grass tablet|
40950498|NCT04835519|BIOLOGICAL|chimeric antigen receptor T cell|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 5 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m\^2( body surface area) and cyclophosphamide 250 mg/m\^2( body surface area) for 3 days. Then this study will be using the Bayesian optimal interval phase I/II (Boin12) trial design. The protocol preset 2 dose levels: Dose 1 (DL-1) was 5×10\^5 (±20%) CAR T cells/kg, and dose 2 (DL-2) was 1×10\^6 (±20%) CAR T cells/kg. If the above dose cannot be met, subjects can still enter the study upon investigator consideration but require documentation of dosing. The lowest dose is 1×10\^5 CAR T cells/kg (±20%), and the highest dose is 1×10\^6 CAR T cells/kg (±20%). If the dose is out of the range mentioned above, entry into the trial will not be considered.
41288558|NCT03662464|OTHER|No intervention|develop and validate a specific tool to score the risk of escaping in Nursing Homes residents
41288559|NCT00002365|DRUG|LXR015-1|
41288560|NCT03047538|DRUG|Atorvastatin, Amlodipine, Perindopril|To compare free and fixed combination of atorvastatin, perindopril, amlodipine
41288561|NCT00377650|DEVICE|Percutaneous thrombectomy|
41288562|NCT02348567|OTHER|Unannounced hospital surveys|This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
40950499|NCT03127046|DRUG|Aceclofenac|Oral single dose administration of aceclofenac 200mg
41288563|NCT02348567|OTHER|announced hospital surveys|
40950500|NCT03127046|DRUG|Esomeprazole|Oral single dose administration of aceclofenac 200mg
40950501|NCT03127046|DRUG|Aceclofenac and Esomeprazole|Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
40950502|NCT06292104|DIAGNOSTIC_TEST|multimodal diagnostic testing|Serological testing, cardiac MRI, skin biopsy, cardiovascular testing, blood volume measurements
40950503|NCT00555451|DRUG|HE3286|"Dose escalating cohort driven study. 6 planned cohorts.~1. HE3286 5 mg or placebo QD for 28 days;~2. HE3286 10 mg (5 mg BID) or placebo BID for 28 days~3. HE3286 20 mg (10 mg BID) or placebo BID for 28 days~4. HE3286 40 mg (20 mg BID) or placebo BID for 28 days~5. HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days~6. HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)"
41288564|NCT06394999|DRUG|Mifepristone 50 mg|Once-weekly oral mifepristone 50 mg
41288565|NCT01532453|DEVICE|MD-3511356|Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.
41133800|NCT04943640|OTHER|kinesio taping|Kinesio tape was developed by Kenzo Kase in the 1970s. It is an elastic tape, and its adhesive face is sinusoidal wavy. This feature has been shown to increase daily living activities and functions, as it supports the tissue while also allowing movement \[12\]. Kinesio tape lifts the skin and subcutaneous soft tissues of the fascia, which are painful and inflamed regions upon contractions seen in the tissue after tense adhesion to the skin. Therefore, it has been reported to reduce oedema and inflammation by creating more space and providing blood and lymphatic fluid flow.
40760012|NCT01674062|DRUG|Pertuzumab|Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.
41133801|NCT04943640|OTHER|rigid taping|The tape material used in rigid (athletic) tape application is hard. It is used to position and unite the soft tissue, to protect the tissue from impact and to prevent local swelling.There are studies in the literature supporting the sensorimotor and proprioceptive sensation-enhancing effect of the athletic band, which provides a very good sensory input through the skin.
41133802|NCT04943640|OTHER|placebo taping|Placebo taping was applied to the patients in this group, using betafix, an elastic fixation band, as the material. The patient was told that taping would be applied. A straight line betafix was applied to the non-painful scapular inferior level of the spine on the right and left sides of the standing patient.
41133803|NCT01481974|DRUG|Treprostinil|"The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.~Treatment phase activities include:~• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design."
41288566|NCT01532453|OTHER|Standard Sun Protection Measures|Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
41288567|NCT02786537|DRUG|SOF/LDV (sofosbuvir/ledipasvir)|Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
40760013|NCT01674062|DRUG|Trastuzumab|2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
40950504|NCT03397615|BEHAVIORAL|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
41133804|NCT06405906|OTHER|Fat-free diet|The low-fat diet will consist of instructions to avoid fatty foods.
41133805|NCT06405906|OTHER|Balanced WHO diet|The balanced WHO diet will adhere to the recommendations of the World Health Organization (WHO) and the Dietary Guidelines for Americans 2020-2025
41288568|NCT02786537|DRUG|PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)|Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
41288569|NCT02786537|DRUG|EBR/GZR (elbasvir/grazoprevir)|Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
41288570|NCT02786537|DRUG|Ribavirin|200 mg pills (1-3 pills, 1-2 times per day)
41288571|NCT03267329|DRUG|Duowell®|telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
41454075|NCT02183727|PROCEDURE|Hamstring Autograft|The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
40760014|NCT00002461|BIOLOGICAL|filgrastim|
40760015|NCT00002461|BIOLOGICAL|sargramostim|
40760016|NCT00002461|DRUG|carmustine|
41133806|NCT03153176|BEHAVIORAL|Training|Training program 30 hours accumulated before, during and after intervention
41133807|NCT03153176|BEHAVIORAL|Individual level|7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break
41133808|NCT03153176|BEHAVIORAL|Organizational level|Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
41133809|NCT00090415|BEHAVIORAL|Intensive behavioral therapy|Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
41133810|NCT04012242|DIAGNOSTIC_TEST|Ultrasound application|Shear wave elastography, shear wave dispersion, attenuation imaging, and intensity analysis
41133811|NCT01235520|DRUG|Placebo|Oral doses, once a day for 52 weeks
41133812|NCT01235520|DRUG|RO4917838|Oral dose level 1, once a day for 52 weeks
41133813|NCT01235520|DRUG|RO4917838|Oral dose level 2, once a day for 52 weeks
41133814|NCT03138499|BIOLOGICAL|Nivolumab|Specified dose on specified days
41133815|NCT03138499|BIOLOGICAL|Brentuximab vedotin|Specified dose on specified days
41133816|NCT03973021|BIOLOGICAL|Very small embryonic-like stem cell(VSEL)|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
41133817|NCT01115140|DRUG|metformin plus placebo|metformin 850 mg cp, 2 cps daily
41133818|NCT01115140|DRUG|Metformin plus folic acid|metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
41133819|NCT01115140|DRUG|placebo plus folic acid|Placebo 1 cp daily plus folic acid 0.4 mg daily
41133820|NCT01115140|DRUG|placebo alone|placebo cp, 2 cps daily
41133821|NCT04914702|DEVICE|Everion®|The Everion® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
41133822|NCT04914702|DEVICE|CORE®|The CORE® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
41133823|NCT05949866|BEHAVIORAL|Movement and Cognition Intervention Group|"Preschool centers assigned to the Movement and Cognition (MAC) group will receive the 6-month intervention, which will be implemented 4 days per week. To ensure consistency of intervention delivery, centers will be provided with the MAC modules on a bi-weekly basis. The MAC intervention will be implemented using a train-the-trainer (gradual release) model. This will be a gradual release model, in which interventionist will first serve as a co-provider and will eventually serve in a support role, as providers become primary implementers.~The MAC intervention will consist of gross motor skill curriculum consists of 30 individual lesson plans. The number of days needed to instruct each lesson plan activities ranges between 3 to 5 days. In each lesson, specific instruction and activities are designed to teach fundamental movements (e.g., running, leaping, kicking, jumping, throwing, catching)."
40760017|NCT00002461|DRUG|cisplatin|
40760018|NCT00002461|DRUG|cyclophosphamide|
40760019|NCT00002461|DRUG|etoposide|
40760020|NCT00002461|PROCEDURE|autologous bone marrow transplantation|
40760021|NCT00002461|PROCEDURE|in vitro-treated bone marrow transplantation|
40760022|NCT00002461|PROCEDURE|peripheral blood stem cell transplantation|
40760023|NCT00002461|RADIATION|radiation therapy|
40760024|NCT01985282|BEHAVIORAL|Nutrition Status Questionnaires and Physicial Function Test|Nutrition status questionnaires will be administered, Physical functional status will be tested
40786469|NCT05758324|DIETARY_SUPPLEMENT|Nutri PNEA|4 sequences of 10 tablets (one intake)
40786470|NCT05758324|DIETARY_SUPPLEMENT|Placebo|4 sequences of 10 tablets (one intake)
40786471|NCT01117194|DEVICE|Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)|Use an intelligent robot to assist upper limb rehabilitation.
40786472|NCT00286377|DRUG|prosaptide|
41133824|NCT05949866|BEHAVIORAL|Health Tracker Group (Control Group)|Preschool centers assigned to the health tracker g group will be asked to maintain their usual daily schedule and to not participate in other physical activity programs during the 6-month intervention.
41288572|NCT03267329|DRUG|Telmisartan|telmisartan 80mg
40950505|NCT00174330|DRUG|atorvastatin|
40760025|NCT06125301|DEVICE|MS Sherpa|MS sherpa® is a medical device, intended to support monitoring of persons with MS in order to give patients and their professional healthcare team(s) insight into the presence and progress of symptoms related to MS. MS sherpa® is a system consisting of a smartphone app for data collection and data presentation, a cloud service for data storage, analysis algorithms, and a clinician or research dashboard for user management and data visualization. The device measures the course of symptoms related to MS with respect to walking speed (average walking speed derived from the distance walked during a 2-minute walk), cognitive processing speed, number of correct answers on a smartphone variant of the symbol digit modalities test (SDMT) and patient reported outcomes, through predefined questionnaires regarding fatigue, amongst others. MS sherpa® measures changes in these parameters over time and shows these on an insights screen in the app and on the clinician dashboard.
40760026|NCT04611009|BEHAVIORAL|motor training|In the sensorimotor training program task-specific and non-task specific aspects will be combined. It will start with assignments to improve general finger and wrist movements. After four weeks more specific writing exercises will be added.
41288573|NCT00757523|DRUG|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
41288574|NCT00757523|DRUG|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
41288575|NCT03450889|PROCEDURE|Colonoscopy|"Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'."
41288576|NCT00887042|DRUG|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, \& -6)
41288577|NCT01717846|DRUG|Group 1 or Orencia treated group|Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
41288578|NCT01717846|OTHER|Group 2 (DMARDS treated group)|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
41288579|NCT02227407|DEVICE|RGOs(reciprocating gait orthoses)|using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
41288580|NCT03767738|DRUG|Intravitreal Aflibercept Injection (IAI)|IAI prepared and administered with a pre-filled syringe (PFS)
40950506|NCT00174330|DRUG|amlodipine|
40950507|NCT00395733|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
41133825|NCT03650166|OTHER|MyBP|This program includes online video high BP education and longitudinal, personalized assistance of home BP self-monitoring.
41133826|NCT03650166|OTHER|Personal BP monitor|Battery-powered BP monitor for personal use
40950508|NCT00395733|DRUG|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
40950509|NCT00418639|DRUG|Nitazoxanide|
40950510|NCT00376064|DRUG|Octreotide acetate and cabergoline/Octrotide and Somavert|
41133827|NCT03011047|PROCEDURE|endoscopic trans-antral approach|new surgical approach to repair the orbital floor fractures through the maxillary sinus
41133828|NCT03011047|PROCEDURE|trans-orbital surgical approach|through the lower eyelid below the eyelashes ,then down to bone the herniated orbital content will be reduced through this incision traditional surgical approach to repair orbital floor fractures
41133829|NCT03315299|DRUG|ASP2215|Subject will take ASP2215 by mouth daily for 28 day cycles
41133830|NCT05364606|DEVICE|Patient Specific Talus Spacer|Patient Specific Talus Spacer is a solid polished replica of the patient's bone.
41133831|NCT01056159|DRUG|Albuterol dry powder inhaler|Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
41288581|NCT05394545|DEVICE|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
41288582|NCT00249886|DRUG|Citalopram|
41288583|NCT01015443|BIOLOGICAL|Tecemotide|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 918 microgram (mcg) of tecemotide (L-BLP25) at Week 1, 2, 3, 4, 5, 6, 7, and 8 (primary treatment phase) and then at 6-Week intervals, beginning at Week 14 (maintenance phase) until disease progression (PD) is documented or the subject discontinues for any other reason.
41288584|NCT01015443|DRUG|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.
41288585|NCT01015443|DRUG|Placebo|Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
41288586|NCT01015443|OTHER|Saline|A single IV infusion of 0.9 percent (%) sodium chloride (saline) will be given 3 days before first placebo vaccination.
41288587|NCT01015443|OTHER|Best Supportive Care (BSC)|The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.
40950511|NCT02678273|OTHER|Intervention group|"The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents~."
41133832|NCT01056159|DRUG|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
41288588|NCT01812720|DRUG|carfilzomib|Given IV
41288589|NCT01812720|DRUG|dexamethasone|Given PO
41288590|NCT01812720|OTHER|laboratory biomarker analysis|Correlative studies
41288591|NCT03940573|DEVICE|Eclipse Insert|Rectal Control System.
41288592|NCT00163137|DRUG|lasofoxifene|lasofoxifene 0.25mg
41133833|NCT02282254|OTHER|Overnight intervention|Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
41133834|NCT01171638|DEVICE|Near infrared spectroscopy (NIRS)|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
41288593|NCT00163137|DRUG|raloxifene|raloxifene 60 mg/day
41288594|NCT00163137|DRUG|Placebo|0 mg/day
41288595|NCT00641940|BEHAVIORAL|Girls in Transition (GT) program|In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
41288596|NCT00641940|BEHAVIORAL|Waitlist Control|Participants in the waitlist control group will complete the GT program during the third year of the study.
41288597|NCT02396862|DRUG|Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
41288598|NCT00230490|DRUG|pradefovir mesylate|
41288599|NCT00230490|DRUG|adefovir dipivoxyl|
41288600|NCT00545818|DEVICE|OsseoSpeed™ length 6 mm|OsseoSpeed™ dental implant, length: 6 mm
41288601|NCT00545818|DEVICE|OsseoSpeed™ length 11 mm|OsseoSpeed™ dental implant, length: 11 mm
41288602|NCT01024244|DRUG|Placebo|Administered po BID, prior to morning and evening meals for 12 weeks.
41288603|NCT01024244|DRUG|LY2599506|Administered po for 12 weeks
41288604|NCT05914753|DRUG|Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
41288605|NCT05914753|DRUG|Epirubicin, Cyclophosphamide, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
41288606|NCT05056480|OTHER|Surveys|Parent/caregivers participants will complete multiple repeating surveys to gather family-reported perspectives on the impact of the PCCI care management program. Clinical staff participants will complete multiple repeating surveys that gather clinician perspectives on the impact of the PCCI care management program. Parent/caregiver and clinical staff participants will also be invited to participated in one-on-one semi-structured interviews with the study team.
41288607|NCT03580057|BEHAVIORAL|Breastfeeding promotion intervention|Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.
41288608|NCT03580057|BEHAVIORAL|Diet and weight loss intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
41288609|NCT02887144|DEVICE|SenSura|SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
41288610|NCT02887144|DEVICE|SenSura test product|SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
41454076|NCT02920476|DRUG|TAS-102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.~Days 6 through 7: Rest~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Rest"
41133835|NCT01253798|OTHER|Group training|Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
41146779|NCT01763502|OTHER|FOOD|The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
41146780|NCT01763502|OTHER|CASH|Cash transfers equal the estimated value of the food basket if purchased in the market.
41288611|NCT01674426|BEHAVIORAL|Cognitive behavior therapy|16 sessions of 45 minutes each to review stress management
41288612|NCT04372589|DRUG|Heparin|"Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement."
41454077|NCT03619330|DRUG|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
40950512|NCT03465358|OTHER|Items completion|"Patients will complete his Motor Function Measure in the usual way, except items 18, 19 and 22 which will be completed twice: once using conventional material and once on a digital tablet.~The order of completion between conventional material or digital tablet will be allocate randomly."
41146781|NCT00958971|DRUG|TKI258|All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
41288613|NCT05869344|DIETARY_SUPPLEMENT|Black bean protein hydrolysates (BPH)|Participants were blinded to treatment and received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of BPH.
41288614|NCT05869344|OTHER|Commercial non-caloric beverage|Participants were blinded to treatment and received 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of placebo.
41288615|NCT00703807|DRUG|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
41288616|NCT00703807|DRUG|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
41288617|NCT02428140|DEVICE|Medtronic Reveal LINQ|
41288618|NCT02428140|DEVICE|Sorin Spiderflash-t|
41288619|NCT05073289|BEHAVIORAL|Sandplay activity|The sandplay in psychiatric care, with a creative and fun approach, makes it easier for patients to verbally express their personal life stories and feelings in a safe environment, individually or as a group.
41146782|NCT03344458|DRUG|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
41288620|NCT05073289|OTHER|Routine Care|Routine care is the care given to the control group by the nurse to the patients in the psychiatry clinic.
41288621|NCT04036266|PROCEDURE|medial open wedge high tibial osteotomy|opening of medial aspects of the proximal tibial metaphysis and change the coronal alignment of the tibia in order to shift the center of force passing axially through the knee from the arthritic region of the knee towards the unaffected side then fixation with a plate (the standard plate is the T-locked plate )
41288622|NCT01718314|DRUG|Sublingual Misoprostol|
41288623|NCT01718314|DRUG|Lidocaine pump spray|
41288624|NCT01718314|DRUG|Placebo (for Misoprostol)|Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
41288625|NCT01718314|DRUG|Placebo (for Lidocaine)|The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
41288626|NCT00455546|DRUG|A-002|
41288627|NCT03040583|OTHER|No intervention|Patients data will be collected during their disease follow-up
41288628|NCT05966701|DRUG|SSGJ-613|SSGJ-613 subcutaneous injection.
41288629|NCT05966701|DRUG|Placebo|Placebo subcutaneous injection.
40760027|NCT04611009|BEHAVIORAL|mindfulness exercises|The awareness training will contain mindfulness exercises. The goal is to consciously experience the here and now in sensual perception of oneself and the environment.
41146783|NCT00692757|DRUG|Hypochlorous acid|Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray
41146784|NCT00692757|DRUG|Iodopovidone|Iodopovidone
41288630|NCT00881205|DRUG|Rivastigmine transdermal patch|Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
41288631|NCT00881205|DRUG|Placebo|Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
41288632|NCT00783289|OTHER|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
41288633|NCT00783289|BIOLOGICAL|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
41288634|NCT00783289|BIOLOGICAL|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
41288635|NCT00783289|BIOLOGICAL|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
40950513|NCT02015585|PROCEDURE|interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
40950514|NCT02015585|PROCEDURE|Relining of the complete dentures|Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.
40950515|NCT02015585|PROCEDURE|Complete denture rehabilitation|All patients will be rehabilitated with new complete dentures in the study
40950516|NCT02433457|DRUG|CC-292|
40950517|NCT02433457|DRUG|Oral Omeprazole (OMP)|
40950518|NCT01074905|DRUG|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
40950519|NCT01074905|DRUG|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
40950520|NCT01074905|DRUG|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
40950521|NCT02051842|DRUG|Metadoxine|
40950522|NCT01126086|DRUG|otamixaban XRP0673|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
40950523|NCT03993132|DRUG|Empagliflozin|new users (initiators) of Empagliflozin
40950524|NCT03993132|DRUG|Liraglutide|initiators of Liraglutide
40950525|NCT02202837|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
40950526|NCT02202837|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
40950527|NCT04905966|BEHAVIORAL|Nutrition education and Physical activity intervention|Schools randomized to the experimental group received nutrition education sessions and physical activity classes.
40950528|NCT03208127|DRUG|Treatment with Direct Acting Antiviral tablet|HCV Treatment for 12 Weeks
40950529|NCT04641858|BIOLOGICAL|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
40950530|NCT04641858|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.
40950531|NCT06556628|DEVICE|Increased Body Temperatures|Collecting data on patients whose body temperatures increase due to fighting an illness.
40950532|NCT00412997|DRUG|LBH589|
40950533|NCT00053573|BIOLOGICAL|Myozyme|20 mg/kg to 40 mg/kg qow
40950534|NCT01216670|BEHAVIORAL|remote patient's management|scheduled remote CareLink data transmission
40950535|NCT01572350|OTHER|Grid laser|Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
40950536|NCT01572350|DRUG|Triamcinolone Acetonide|Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
40950537|NCT01572350|DRUG|Bevacizumab|Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
40950538|NCT05933616|DEVICE|Device: Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
40950539|NCT04753528|DEVICE|AuriMod CT01_A|AuriMod CT01 is a wearable medical device for personalised pain treatment through auricular vagus nerve stimulation. AuriMod CT01 is a battery-operated electrical stimulation device, to be placed behind the ear on the neck. AuriMod CT01 connects to three needle electrodes, which are placed in vagally innervated regions of the auricle. It emits electrical signals with a personalized set of stimulation parameters and adjustable amplitude.
40950540|NCT04753528|DEVICE|AuriMod CT01_B|AuriMod CT01 with a fixed set of stimulation parameters and adjustable stimulation amplitude.
41288636|NCT05932810|BEHAVIORAL|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
41454078|NCT03619330|DRUG|Testosterone|In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
40950541|NCT04753528|DEVICE|AuriMod CT01_C|AuriMod CT01 with a fixed set of stimulation parameters and amplitude.
40950542|NCT01461083|DRUG|[18F]MPPF|Subjects will be dosed by intravenous bolus injection of \[18F\]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not \>10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
40950543|NCT00115635|DRUG|docetaxel|
40950544|NCT00115635|DRUG|gemcitabine|
40950545|NCT03528707|DIETARY_SUPPLEMENT|Symbiter-Omega|"Symbiter Omega which contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×101"
40950546|NCT03528707|DIETARY_SUPPLEMENT|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
40950547|NCT03398200|BIOLOGICAL|Hyperbaric Oxygen Therapy|The intervention consists of exposure to hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours, in a single see-through hyperbaric chamber, breathing 100% oxygen for 90 minutes while subjects are resting in supine position. During the 2 hours, there will be compression and decompression phases for 15 minutes each in which subjects will be breathing compressed environmental air (21% oxygen).
40950548|NCT03398200|OTHER|No Hyperbaric Oxygen Therapy|The reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell transplant.
40950549|NCT03499548|OTHER|INSPiRe Programme|Intensive CBT for suicide
40950550|NCT05283278|DRUG|Lactoferrin Bovine|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day starting from birth to the 30th day of life for neonates in group A
40950551|NCT05283278|COMBINATION_PRODUCT|Lactoferrin Bovine and probiotics|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day in combination with the probiotic Lactobacillus Delbrueckii and Lactobacillus Fermentum (Lacteol fort®) given in a dose of 5 billions starting from birth to the 30th day of life for neonates in group B
40950552|NCT05283278|OTHER|Placebo|Placebo will be given starting from birth to the 30th day of life for neonates in group C.
41146785|NCT03468348|DRUG|Duloxetine|patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
41146786|NCT05867992|OTHER|Type of trauma|Patients in case group have the severe traumatic brain injury, while patients in control group have the traumatic bone fracture without brain injury.
41288637|NCT05932810|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
41288638|NCT04596813|DEVICE|CytoSorb 300 mL device|Intra-and postoperative CytoSorb hemoadsorption
41288639|NCT06251687|PROCEDURE|Transbronchial Cryobiopsy，TBLC|Transbronchial lung cryobiopsy (TBLC) is a novel technique that has proved its diagnostic value in various diffuse parenchymal lung diseases
41288640|NCT06251687|PROCEDURE|Transbronchial Lung Biopsy，TBLB|Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
41288641|NCT05534334|DRUG|Solu-Cortef|A vial sol. used for intra-mascular injection
41288642|NCT02641704|BEHAVIORAL|Multidisciplinary program|Coordinated multidisciplinary program
41288643|NCT05208112|DRUG|M6229|Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).
41288644|NCT05744986|DEVICE|SYMPICITY Spyral RENAL DENERVATION (RDN) SYSTEMTM|The second generation SYMPLICITY RDN catheterTM has 4 times electrodes that are arranged in spirally in 90-degree intervals. Theoretically, the newer generation catheter can provide more efficient and extensive denervation in a shorter period of time16. Its efficacy was confirmed in SYMPLICITY HTN ON-MED and OFF-MED trial, which confirmed a consistent and durable BP reduction that lasted into 36 months with or without adjuvant anti-hypertensive drugs
41288645|NCT03421223|OTHER|No intervention|No intervention
41288646|NCT02433249|BEHAVIORAL|1 Physical Activity|Fall reducing strength (5), balance (12) and flexibility (4) exercises as well as walking. Participants were also given a Fitbit One with instructions on how to use
41288647|NCT02433249|BEHAVIORAL|Interpersonal Motivation|Strategies used to support Interpersonal motivational targets include: a) discuss and model ways to provide and receive more support for physical activity, b) identify environmental barriers to being physically active, c) problem-solve environmental and social barriers to being physically active, d) use and create new resources that support physical activity behavior
41288648|NCT02433249|BEHAVIORAL|Intrapersonal Motivation|Strategies used to support intrapersonal motivation included a) use of the goal attainment scale, b) facilitating the formation of action plans, c) identify and problem solve personal barriers to being active, d) identify satisfying aspects of being active, e) self-evaluate physical activity patterns and progress.
41146787|NCT05885334|OTHER|control|Caregivers will not receive any educational solution different than what is done by routine in centers. After six months, performance in caregivers tasks will be video recorded.
41288649|NCT04600999|DRUG|Favipiravir|Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]
41288650|NCT02365857|DRUG|Dexmedetomidine & Bupivacaine.|Intrathecal injection of Dexmedetomidine \& Bupivacaine.
41288651|NCT02365857|DRUG|Bupivacaine Only.|Intrathecal injection of Bupivacaine only.
41146788|NCT05885334|OTHER|Virtual Reality|Caregivers will receive a educational solution of virtual reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
41288652|NCT03854955|OTHER|iScribes|Device-based scribing service.
41288653|NCT00447421|DRUG|pemetrexed|"Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)~Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles"
41288654|NCT00447421|DRUG|cisplatin|Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
41288655|NCT00447421|RADIATION|radiation|Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
41288656|NCT03115645|OTHER|Dynamic Work|The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
41288657|NCT04835272|PROCEDURE|the Decannulation Protocol With Suctioning|In the intervention group, the decision to decannulate was based on suctioning frequency. Patients underwent decannulation when they had had no more than two aspirations every 8 hours during during a 24-hour period. Patients in this group did not undergo capping trials.
41288658|NCT01984112|DEVICE|Locked plate|Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture
41288659|NCT01984112|DEVICE|Intramedullary locked nail|Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
41288660|NCT04640246|BIOLOGICAL|TBX-3400|Autologous transfusion
41288661|NCT05294848|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
41288662|NCT05294848|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
41288663|NCT05294848|BEHAVIORAL|Neutral Control|Dot-probe task using only neutral stimuli with no training toward threat
41288664|NCT03863392|DRUG|Misoprostol|induction of labor
41288665|NCT03040050|OTHER|rPCR results|Interventional group: rPCR results will be shared with the clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care prostate biopsy.
41288666|NCT03040050|OTHER|Control group|Control group: rPCR results will not be shared with the clinical provider at time of standard of care prostate biopsy. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
41288667|NCT02167061|DRUG|DA-1229_01|complex single administration
41288668|NCT02167061|DRUG|E+M|co-administration of 2 drugs
41288669|NCT02167061|DRUG|DA-1229_01 fast|
41288670|NCT02167061|DRUG|DA-1229_01 fed|
41288671|NCT00652093|DRUG|opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
41288672|NCT00652093|DRUG|opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
41146789|NCT05885334|OTHER|Augmented reality|Caregivers will receive a educational solution of augmented reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
41288673|NCT00652093|DRUG|placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
41288674|NCT00652093|DRUG|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
41288675|NCT00652093|DRUG|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
41288676|NCT00652093|DRUG|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
41288677|NCT04265534|DRUG|Telaglenastat|Oral Glutaminase Inhibitor
41288678|NCT04265534|DRUG|Carboplatin Chemotherapy|IV infusion
41288679|NCT04265534|DRUG|Pemetrexed Chemotherapy|IV infusion
41288680|NCT04265534|BIOLOGICAL|Pembrolizumab Immunotherapy|IV infusion
41288681|NCT04265534|DRUG|Placebo|Oral placebo
41288682|NCT04265534|DIETARY_SUPPLEMENT|Folic acid 400 -1000 μg|Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.
41288683|NCT04265534|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
40950553|NCT02778087|BEHAVIORAL|Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.
41288684|NCT04265534|DRUG|Dexamethasone 4 mg|For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
41288685|NCT04927650|DIAGNOSTIC_TEST|HPV testing|Undergo collection of cervical samples for HPV testing
41288686|NCT04927650|OTHER|Questionnaire Administration|Complete questionnaires
40950554|NCT02778087|BEHAVIORAL|Sham Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on an opaque mirror throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: AROM, functional tasks with objects, and object manipulation.
40950555|NCT03146377|DRUG|Capecitabine|1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
41288687|NCT03566966|BIOLOGICAL|Non-organ-specific Ab positive|Antiviral administration and evaluation of SVR24 and side effects
41288688|NCT03566966|BIOLOGICAL|Non-organ-specific Ab negative|direct-acting antiviral agents
41288689|NCT03697239|DRUG|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
40950556|NCT03146377|DRUG|Oxaliplatin|85 mg/m2 IV on day 1 of a 2-week cycle
40950557|NCT03146377|DRUG|Irinotecan|165 mg/m2 IV on day 1 of a 2-week cycle
41288690|NCT03697239|DRUG|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
41288691|NCT03697239|DRUG|Cisplatin|25mg/m2 in 500\*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
41288692|NCT03697239|DRUG|Gemcitabine|1000mg/m2 in 500\*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
41288693|NCT03796741|OTHER|Data collection on Stable Ischemic heart disease|No intervention only description of management and treatment
41288694|NCT04423939|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The ACT sessions will be tailored to the clinical challenges of HCT. Sessions are with a mental health professional and are 45-60 minutes in duration and include both the participant and caregiver.
41288695|NCT00318838|DRUG|Azimilide dihydrochloride|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
41288696|NCT00318838|DRUG|Placebo|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
41288697|NCT06152601|PROCEDURE|anticipated bipedal standing position in the immediate post-operative phase|"Realization of a first stand-up within 6 hours after entry into PACU or extubation for admitted patients intubated, in PACU or on admission to ICU by a state-certified physiotherapist.~Immediately postoperatively, during his stay in a Intensive Care Unit, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position."
41288698|NCT04442581|DRUG|Cabozantinib S-malate|Given PO
41288699|NCT04442581|BIOLOGICAL|Pembrolizumab|Given IV
41288700|NCT06212440|DIAGNOSTIC_TEST|Identification rate of sentinel lymph node for each dual method|Direct comparison of identification rate between A arm and B arm, A arm and C arm.
41288701|NCT01217281|PROCEDURE|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
41288702|NCT05186532|RADIATION|Dry Heat Application|50 postnatal women they were encouraged to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for ten minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researchers were demonstrated for each woman how to use infrared lamp, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study.
41288703|NCT05186532|OTHER|Moist Heat Application|included 50 postnatal women they were encouraged to sit in a basin (tub) of warm water (45 o C -59 o C) without pressure on the perineum and with the feet flat on the floor for 10 minutes. The researchers were demonstrated for each woman how to do warm sitz bath, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days.
41288704|NCT04760132|BIOLOGICAL|COMIRNATY - BioNTech Manufacturing GmbH|Vaccination as part of the the Danish national government programme
41288705|NCT04760132|BIOLOGICAL|COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH|Vaccination as part of the the Danish national government programme
41288706|NCT04760132|BIOLOGICAL|COVID-19 Vaccine AstraZeneca suspension for injection|Vaccination as part of the the Danish national government programme
41454079|NCT01953185|OTHER|Sham manual diaphragm release technique|For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone \& Russo, 2006).
41288707|NCT03120910|DEVICE|Pulse CO-Oximeter Sensor|Investigational Pulse Oximeter Sensor will measure hemoglobin (SpHb), pulse rate (PR), perfusion index (PI), pleth variability index (PVI), oxygen reserve index (ORI), etc.
41288708|NCT04331704|DRUG|PrEP acronym (pre-exposure prophylaxis)|A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.
41288709|NCT04331704|BEHAVIORAL|Initial Web Survey|Web-based assessment questions regarding alcohol and other substance use and sexual health behaviors
41288710|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) monitoring|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking
40950558|NCT06557135|PROCEDURE|Carotid Artery Stenting (CAS)|CAS involves inserting a catheter or tube into an artery in the brachial or the femoral, and then threading the catheter through the arteries of the body to the location of the stenosis within the carotid artery in the neck. A stent is then placed in the stenosis and holds the artery open.
41288711|NCT04331704|BEHAVIORAL|Educational material on alcohol and sexual health behavior|Educational material to provide information, resources and techniques to enhance awareness regarding alcohol and other substance use, along with sexual health behavior.
41288712|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) assessment with personalized information|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking with personalized and information based on daily IVR responses
41454080|NCT01953185|OTHER|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
41454081|NCT00870116|RADIATION|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
41454082|NCT00870116|RADIATION|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
40950559|NCT00763529|DRUG|Mometasone|Mometasone furoate cream 0.1% applied once daily
41288713|NCT04331704|BEHAVIORAL|Personalized information based on web-based survey responses & standardized information|Personalized and information on alcohol use and sexual health behavior based on responses to the web-based survey along with standardized information.
41288714|NCT02395679|BIOLOGICAL|MesoCancerVac|A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
41288715|NCT00677144|DRUG|OS (oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
41454083|NCT00870116|RADIATION|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
40950560|NCT00763529|DRUG|Fluticasone|Fluticasone propionate cream 0.05% applied twice daily
40950561|NCT01604915|PROCEDURE|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
41288716|NCT00677144|DRUG|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
41288717|NCT01858883|DRUG|itacitinib|
41288718|NCT01858883|DRUG|Gemcitabine|
41288719|NCT01858883|DRUG|nab-paclitaxel|
40950562|NCT01604915|PROCEDURE|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
40950563|NCT02106975|DRUG|Ascorbic Acid|Intervention
40950564|NCT02106975|DRUG|Placebo: 5% Dextrose in water|Placebo
40950565|NCT03608254|OTHER|100% watermelon juice|Participants consumed a one-time dose of 100% watermelon juice. Blood was sampled before and 2 hours after ingestion. Blood pressure and brachial artery flow-mediated dilation were measured before and 2 hours after ingestion.
40950566|NCT00562835|DRUG|Methylprednisolone|"Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14\*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21\*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25\*‡ 0.25 mg/kg/day; Days 26 to 28\*‡ 0.125 mg/kg/day~\*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion"
40950567|NCT00562835|OTHER|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc \[prednisolone + diluting fluid\], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
40950568|NCT04996771|DRUG|Surufatinib,Etoposide,Cisplatin,Toripalimab|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed."
40950569|NCT04996771|DRUG|Surufatinib,Etoposide,Cisplatin|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed."
40950570|NCT06546657|OTHER|Breakfast|Breakfast meal
40950571|NCT05514418|PROCEDURE|Intensive Adherence Counselling (IAC)|Intensive adherence counselling is offered to people living with HIV (PLHIV) having a non-suppressed viral load (VL) result ( a VL of 1,000 copies/ml or more) and this is given once every month for three months. In our study, we are going to give IAC to PLHIV with low-level viraemia (having a VL of 50 copies/ml but less than 1,000 copies/ml) and determine its effectiveness in causing a non-detectable VL (less than 50 copies/ml), which is desirable for PLHIV on ART.
40950572|NCT05939570|OTHER|Interview|Prospective, semi-structured, qualitative interview.
40950573|NCT03269604|PROCEDURE|Prophylactic antibiotic during five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
40950574|NCT03269604|PROCEDURE|Prophylactic antibiotic during three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
40950575|NCT03269604|PROCEDURE|Only a single dose of Prophylactic antibiotic|This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
41133836|NCT06372340|PROCEDURE|Personalized pelvic floor rehabilitation program generated by the intelligent diagnosis and treatment system.|Utilizing machine learning to process and analyze vast amounts of previously collected data, the investigators will establish an intelligent system that can generate personalized pelvic floor exercise prescription by matching factors such as general clinical information and pelvic floor muscle strength data. The experimental group will receive tailored program, including pelvic floor muscle training with diverse intensity and frequency, electrical stimulation, magnetic stimulation, biofeedback and other treatments. The results will ultimately be compared with those taking standardized pelvic floor muscle training only.
41288720|NCT01858883|DRUG|filgrastim|
41288721|NCT04881877|DEVICE|Synthetic nitrite Condom|The condoms is composed of a synthetic nitrile rubber latex and 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and clear and colourless. It is manufactured by Karex Industries. It is currently experimental.
41288722|NCT04881877|DEVICE|Latex and graphene Condom|The condom is composed of a natural rubber latex with graphene. It is 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is greyish in colour. It is manufactured by Karex Industries. It is currently experimental.
41454084|NCT00362687|DRUG|Truvada (TDF+FTC) alone|tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
41454085|NCT00362687|DRUG|FTC alone|emtricitabine 200 mg
41454086|NCT00362687|PROCEDURE|No HAART|No HAART
41454087|NCT03534076|OTHER|Cohort Observational study|Cohort Observational study - there is no intervention
40950576|NCT01758523|DRUG|Dutasteride|
40950577|NCT01758523|DRUG|sugar pill|
40950578|NCT02514525|DEVICE|CryoBalloon Ablation System|CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
40950579|NCT00478946|DRUG|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
40950580|NCT00478946|DRUG|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
40950581|NCT00478946|DRUG|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
40950582|NCT05073978|OTHER|No intervention|This is an observational study without any intervention
41133837|NCT06372340|PROCEDURE|Standard pelvic floor muscle training(PFMT) program|Participants will be given handbooks with detailed training program: the basic regimen consists of 3 sets of 8 to 12 contractions sustained for 8 to 10 sec each, performed 3 times a day. Patients should try to do this every day and continue for at least 15 to 20 weeks.
41133838|NCT03732807|DRUG|PF-06651600 Induction Dose|Oral tablets taken once daily (QD)
41454088|NCT03987295|DRUG|AL001|60 mg/kg of AL001 every 4 weeks
40950583|NCT06145373|DRUG|Fitusiran (SAR439774)|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous (SC) injection
40950584|NCT06145373|BIOLOGICAL|Clotting factor concentrates (CFC) or bypassing agents (BPA)|Pharmaceutical form: Solution for injection-Route of administration: Intravenous (IV) injection
40950585|NCT06145373|BIOLOGICAL|Antithrombin concentrate (ATIIIC)|Pharmaceutical form:Solution for injection-Route of administration:Intravenous (IV) injection
40950586|NCT06145373|BIOLOGICAL|Emicizumab|Pharmaceutical form:Solution for injection-Route of administration:SC injection
40950587|NCT03505554|DRUG|Lorlatinib|100 mg QD
40950588|NCT02515448|DRUG|gentamicin|
40760030|NCT00967252|DRUG|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
40760031|NCT00967252|DRUG|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
40760032|NCT00967252|DRUG|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
41288723|NCT04881877|DEVICE|Standard latex condom|The condoms is composed of a natural rubber latex. It is 180 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is natural in colour. It is manufactured by Karex Industries. It has World Health Organisation (WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union, South African Bureau of Standards and US FDA approval
41454089|NCT03456063|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase~Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase"
41454090|NCT03456063|DRUG|Placebo Comparator|Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
41454091|NCT03456063|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
41288724|NCT06510465|DRUG|utidelone|utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；
41288725|NCT06510465|DRUG|Cisplatin|cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.
41454092|NCT03456063|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
41454093|NCT03456063|DRUG|Carboplatin|Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
41454094|NCT03456063|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
41454095|NCT03456063|DRUG|Gemcitabine|Gemcitabine 1250 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
40950589|NCT05147935|BEHAVIORAL|Palliative Care Consultation|In person or telehealth clinic visit with palliative care physician or nurse practitioner
41288726|NCT06510465|DRUG|Trastuzumab|Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d
41454096|NCT04893408|OTHER|observational study|
41454097|NCT01662960|BEHAVIORAL|Mirror therapy|A home-based therapy involving mirrored visual feedback
41454098|NCT01662960|BEHAVIORAL|Divider therapy|A home-based therapy involving removed visual feedback.
41454099|NCT03306277|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
41454100|NCT00934323|DRUG|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
41454101|NCT00934323|DRUG|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
41454102|NCT05461716|DEVICE|periodic use of Continuous Glucose Monitoring (CGM)|Identification of hypoglycaemia events, based on use of Continuous Glucose Monitoring (CGM) for at least 14days, in subgroups of T2DM patients with high risk of hypoglycaemia
40760033|NCT00967252|DRUG|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
40760034|NCT00967252|OTHER|Control|No statin being taken
40950590|NCT06558331|OTHER|Preoperative Quality of Recovery-15 (QoR-15T)|The quality of recovery score (QoR)-15 questionnaire, preoperative
40950591|NCT06558331|OTHER|Postoperative 24th hour Quality of Recovery-15 (QoR-15T)|The quality of recovery score (QoR)-15 questionnaire, postoperative 24th hour
40950592|NCT04689269|OTHER|"The simulated easy airway"|A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create an easy airway situation by adjusting the manikin until it becomes in a neutral position
40950593|NCT04689269|OTHER|"The simulated difficult airway"|"A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create a difficult airway scenario will be established by placing the occiput on an Oasis Elite™ Prone Head Rest, Adult (140 mm in height) (Covidien, Mansfield, MA, USA), and inhibiting head and neck movement by securing the head with an adhesive tape, simulating the effect produced by a cervical-collar."
40950594|NCT04689269|DEVICE|King Vision Laryngoscope|Using a King Vision Laryngoscope for placement of the DLT
40950595|NCT04689269|DEVICE|MacGrath Laryngoscope|Using a MacGrath Laryngoscope for placement of the DLT
40950596|NCT06000397|OTHER|Enhanced reminders|"The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically:~* Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine,~* Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and~* Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit"
40950597|NCT06000397|OTHER|Standard CANImmunize notifications|"Push notifications at two time points:~* two weeks prior to the immunization due date~* one week after the immunization due date"
40950598|NCT05776368|OTHER|Syntactic comprehension battery (BCS)|"The BCS is a battery for assessing syntactic skills. In this study, only one part of the BCS will be performed, namely task C2.~It consists in assessing the ability to assign thematic roles. To do this, the participant selects the image corresponding to the sentence he/she hears on a board of 2 images.~Task C2 consists of 50 tests of 2 images. A total score is given out of 50 points. The higher the score, the more successful the test."
40950599|NCT05776368|OTHER|Montreal Cognitive Assessment (MOCA)|"The MOCA is a short 30-question test that assesses several cognitive domains and allows for early detection of cognitive disorders. The MOCA test takes about 10-15 minutes to administer and consists of several sections, the first of which is an assessment of orientation in time and space. Then there are tasks that assess memory, concentration and reasoning ability, as well as language and visuospatial ability tasks.~The MOCA score can range from 0 to 30 points, with a score of 26 points or more considered normal."
40950600|NCT05776368|OTHER|Purdue Pegboard Test|"The Purdue Pegboard Test is a test of fine motor skills and hand-eye coordination. The test consists of a perforated board with holes into which participants must insert pegs or counters.~The assessment consists of four subtests, each repeated 3 times:~* Right hand (30 seconds): The total number of pins placed in the right column with the right hand in 30 seconds.~* Left hand (30 seconds): The total number of rods placed in the left column with the left hand in 30 seconds.~* Two hands (30 seconds): The total number of pairs of rods placed in both columns using both hands simultaneously, in 30 seconds.~* Assembly (60 seconds): The total number of rods, washers and clamps assembled in the allotted time, using both hands."
40950601|NCT05776368|OTHER|The Box and Block Test (BBT)|"The Box and Block Test (BBT) is a standardised test of manual dexterity used to assess motor function and hand-eye coordination in people of all ages.~The subject must move, one by one, a maximum number of cubes from one compartment of the box to another of equal size for 60 seconds. He starts with the healthy upper limb or, if not, with the dominant side. A 15 second trial period is allowed at the beginning of each side."
40950602|NCT05776368|OTHER|Motor training with a tool|"The patient will do around 30 minutes of motor training with a tool (pliers). They have to put most pieces as possible in the board with the pliers. Patients hold the pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder).~For E1 Arm1 and E1 Arm 4: the participant will do the motor training with a tool one time in this study.~For E3 Arm 1: the participant will do the motor training with a tool During 4 weeks (3 to 5 training sessions of 30 minutes)"
40950603|NCT05776368|OTHER|Motor training with a hand|The patient will do around 30 minutes of motor training with the hand. They have to put most pieces as possible in the board with the right hand (dominant hand) or with the left one if not possible (motor disorder).
40950604|NCT05776368|OTHER|on/off effect of tool motor training|"During 4 weeks, patients switch between tool training weeks (on) and control weeks (off) during which they don't practice motor training.~During on weeks they do 3 to 5 tool motor training sessions of 30 minutes. They use pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder) and have to put most pieces as possible in the board.~During off weeks they do 3 to 5 control sessions where they only do the two linguistic tasks separated between a 30-minutes break."
40950605|NCT05776368|OTHER|linguistic tasks|"The linguistic tasks consists in the presentation of correct sentences at the center of a computer screen. The sentence can be a coordinated one ( The policeman stopped the woman and asked the question ), or a subject relative (i.e.,  The policeman who stopped the woman asked the question ), or an object relative ( The policeman who the woman stopped asked the question ). After the sentence an affirmation test is proposed of the kind  the policeman stopped the woman , and the participant has to respond ads quick as possible whether it is true or false."
40950606|NCT03980431|DIAGNOSTIC_TEST|FBY PET Examination|A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
41133839|NCT03732807|DRUG|PF-06651600 Maintenance Dose #1|Oral tablets taken QD
41133840|NCT03732807|DRUG|PF-06651600 Maintenance Dose #2|Oral tablets taken QD
41133841|NCT03732807|DRUG|PF-06651600 Maintenance Dose #3|Oral tablets taken QD
40950607|NCT01067937|PROCEDURE|appendectomy|Randomisation will apply to the 8 participating centers as follow: During a first survey period of 6 month, the algorithm is not applied; The six following months, 4 randomised centers applied the algorithm, the others being still survey; The six last month, all centers will apply the algorithm
40950608|NCT03516825|OTHER|Musical Neglect Training|MNT uses musical exercises which are structured in pitch, time and tempo, and musical equipment (tone bars, keyboards, drums) configures to focus attention to the neglect visual field.
40950609|NCT02609828|DRUG|Tanezumab|Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
40950610|NCT04171154|BEHAVIORAL|Expectation|writing task
41288727|NCT06510465|DRUG|Pertuzumab|Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase
41288728|NCT03469193|PROCEDURE|internal PUC implanted with mechanical ancillary|The control group consists of patients operated with a mechanical ancillary (reference surgery in our department). In this technique, bone sections are made with a standardized ancillary (manually adjusted bone cutting guides), according to preoperative radiological planning. The positioning of the implants is done manually and controlled by the placement of test implants.
41288729|NCT03469193|PROCEDURE|Internal PUC implanted with robotic assistance|Patients are operated by robotics (surgery that we want to develop systematically in our service). 3D modeling of the knee allows the operator to perform a dynamic planning taking into account the reducibility of the deformation and the model of the implant. The operator can position the implants in three dimensions of the space without difficulty. This makes it possible to visualize, before the bone resections, the angular correction obtained between 0 and 130° flexion and alignment of the prosthesis by visualizing the contact points between the two implants. Bone resections will be performed using a guided retro bone drill. The system retracts more or less the cutter according to the bone thickness to be removed. This technique requires the insertion of two threaded plugs in the tibia and two in the femur to position the sensors that will allow the acquisition of anatomical landmarks of the lower limb and then 3D modeling
41288730|NCT01594099|RADIATION|irradiation|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10)."
41288731|NCT01594099|DRUG|Cisplatin|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy."
40950611|NCT04171154|BEHAVIORAL|Acceptance|listening
40950612|NCT03420625|DEVICE|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
40950613|NCT03420625|DEVICE|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
40950614|NCT03420625|DEVICE|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
40950615|NCT03420625|DEVICE|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
40950616|NCT02477839|DRUG|Lacosamide|Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
41454103|NCT05479760|OTHER|KP-Led HCV test and treat service|"After completing informed consent procedures, screening procedures will take place to assess eligibility. Clients who are anti-HCV and HCV-RNA positive, but meet one/more ineligible characteristics for simplified treatment will be referred to a hepatologist for treatment initiation.~Participants who are HCV-RNA positive and otherwise eligible will be offered to initiate DAAs at the CBO, followed by telehealth visits at week 4 and 8 and CBO visits at week 12, and week 24. If a visit is requested by the client, it can be conducted through telehealth or in-person at the clinic depending on client preferences. Substance use will be assessed using ASSIST, Retention in care, occurrence of adverse events during treatment, completion of treatment, and SVR achievement will be assessed. Clients who achieve SVR will be retested with HCV-RNA every 3 months to assess HCV re-infection. Clients who do not achieve SVR will be referred for further analysis and treatment."
40760035|NCT00117442|DRUG|carboplatin|Chemotherapy
40950617|NCT02477839|OTHER|Placebo|Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
40950618|NCT00252824|DRUG|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
40950619|NCT03944031|DRUG|LY3372689|Administered orally.
40950620|NCT03944031|DIAGNOSTIC_TEST|[18F]LSN3316612|Administered IV.
40950621|NCT02319512|OTHER|Chewing gum|ChiczaTM organic chewing gum 6 pieces a day
40950622|NCT02319512|OTHER|Glucose|12ml glucose solution (13,6g) per day
40950623|NCT02676115|OTHER|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
40950624|NCT02676115|OTHER|Medipore Tape|"* One layer of Medipore tape will be placed across the incision.~* Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken."
40950625|NCT02308189|BEHAVIORAL|Exercise with blood flow restriction|Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
41133842|NCT03732807|DRUG|Placebo|Oral tablets taken QD
41133843|NCT02667366|BEHAVIORAL|Tel-PT|
41133844|NCT02667366|BEHAVIORAL|TAU and text messages|
41133845|NCT00667732|DRUG|exenatide|5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
41133846|NCT00667732|DRUG|placebo|5mcg twice a day, increased to 10mcg twice a day for 24 weeks
41133847|NCT03726593|DRUG|Artesunate and Pyronaridine|Standard weight based dosing
41133848|NCT03726593|DRUG|Atovaquone Proguanil and Artesunate Pyronaridine|Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
41133849|NCT03726593|DRUG|Atovaquone Proguanil and Artesunate Mefloquine|Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
41133850|NCT02746107|OTHER|decision aid|decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself
41133851|NCT00635609|DRUG|Doxycycline hyclate (Doryx)|150mg/day, oral, delayed release tablets
41133852|NCT00635609|DRUG|Doxycycline hyclate|100 mg/day, oral, tablets, immediate release
41133853|NCT04913506|OTHER|Group Mirror|For 30 minutes, ROM exercises will be applied to the solid upper extremity in all directions in front of a real mirror by the practitioner. (3 weeks, 5 days a week, 15 sessions in total)
41133854|NCT04913506|DEVICE|Group NMES|NMES will be applied to the hemiplegic arm(deltoid, elbow extensors and forearm) for 30 minutes by the practitioner (3 weeks, 5 days a week, 15 sessions in total)
41133855|NCT04913506|OTHER|Group Mirror+NMES|The practitioner will be synchronized with visual or auditory stimuli, and ROM exercises in all directions in front of the real mirror for 30 minutes, and NMES therapy for 30 minutes on the paretic upper extremity will be applied together. (3 weeks, 5 days a week, 15 sessions in total)
41133856|NCT05611385|OTHER|Difference in development of Acute Lung Injury in Amphetamine positive and negative patients|No Intervention
41133857|NCT04129372|BEHAVIORAL|New Foods Take Time|New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
41133858|NCT03536845|DRUG|Vitamin D 3|oral drops
41133859|NCT02601859|DRUG|Lithium Carbonate|
41454104|NCT05006560|OTHER|Pulmonary Rehabilitation (usual care)|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days.
41133860|NCT01513733|DRUG|tasquinimod|tasquinimod 0.25 mg continuously
41133861|NCT01513733|DRUG|tasquinimod 0.25 mg; 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
41133862|NCT01513733|DRUG|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
41133863|NCT01349270|DRUG|Immunoglobulin perfusion|patient who received monthly 2g/kg intravenous cure of immunoglobulin
41133864|NCT01349270|DRUG|Prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
41133865|NCT03152435|BIOLOGICAL|EGFR CART|EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).
41133866|NCT02038049|DRUG|VAY736|Single intravenous infusion of VAY736 (10 mg/kg)
41133867|NCT02038049|DRUG|Placebo|Placebo to VAY736
41133868|NCT03141918|DIETARY_SUPPLEMENT|Curcumin|The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
41133869|NCT03141918|OTHER|Placebo of Curcumin|"The intervention will consist of the placebo administration curcumin for 30 days.~The Curcumin placebo will be given in 2 doses of 500mg per day."
41133870|NCT00725959|BEHAVIORAL|Online social networking HIV prevention|messages about HIV posted in online social networking sites
41133871|NCT02285218|OTHER|serum blood sampling|
41133872|NCT06181656|BIOLOGICAL|Pneumonia vaccine|Given by SC
41133873|NCT05936385|BEHAVIORAL|Healthy Lifestyle|Healthy lifestyle counseling and goal setting every month with a team of experts, mobile app with healthy lifestyle resources and goal tracking tool, access to social services and lifestyle programs in the community, and community health worker outreach every month.
41133874|NCT05936385|BEHAVIORAL|Standard of Care|Weight checks and lifestyle counseling with primary care provider every other month.
41133875|NCT06509204|DIETARY_SUPPLEMENT|Glucotrojan|"Day 1: Start wearing the CGM sensor and let it self-calibrate for 24 h Day 2: Consume 1 serving of Test Meal for breakfast. Log the meal in the app. Day 3: Consume 1 serving of Test Meal with GlucoTrojan for breakfast. Log the meal in the app.~Days 4-8: Participants will be instructed to take GlucoTrojan twice per day. Once during their typical breakfast meal and once during their typical dinner meal. Each breakfast and dinner will be logged in the app.~Days 9-13: Participants will continue with their typical lives but continue to log meals - breakfast and dinner - in the app.~Day 14: end"
41133876|NCT05252832|PROCEDURE|Superficial Cervical Plexus Block|Location of injection for block.
41133877|NCT05252832|PROCEDURE|Local Infiltrate|Local infiltration location.
41133878|NCT02043041|OTHER|Number of DBS Spots|The number of DBS spots on the card constitutes the experimental condition.
41133879|NCT04514562|DEVICE|NeVa Stent Retrievers|mechanical neurothrombectomy
41133880|NCT03096470|PROCEDURE|anesthesia|no anesthesia
41133881|NCT05545800|DRUG|metformin+empagliflozin+insulin glargine|Randomization was performed with the use of a computer-generated system provided by the sponsor. The dose of metformin will be initiated at 0.5 grams three times a day (the maximum dose is 2g/day); the dose of empagliflozin will be 10 milligrams once a day; insulin glargine will be received once daily at bedtime and the dose will be initiated at the 50% of 0.4-0.5 units/kg/day. All groups received counseling on lifestyle modification.
41146790|NCT05885334|OTHER|360 videos|Caregivers will receive a educational solution of 360 degrees videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
40950626|NCT02308189|BEHAVIORAL|Exercise|Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
40950627|NCT04112407|DEVICE|Blue Light Phototherapy|Phototherapy in the blue light spectrum
40950628|NCT04112407|DRUG|Benzyl Peroxide|Benzyl peroxide wash to be used preoperatively during showering to the operative shoulder site.
40950629|NCT04112407|OTHER|Control|Standard surgical site preparation with no P. acnes pretreatment
40950630|NCT00944671|DRUG|famotidine (+) calcium carbonate (+) magnesium hydroxide tablet|A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
40950631|NCT00944671|DRUG|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water|A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
40950632|NCT00944671|DRUG|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water|A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
40950633|NCT01881373|OTHER|CHL program|Multiple component environmentally focused program designed with community engagement.
40950634|NCT01881373|OTHER|Delayed Optimized CHL program|CHL programs with fewer component and shorter duration.
40950635|NCT03830385|DRUG|PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin|All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy
40950636|NCT03542123|DEVICE|NeuroTronik CANS Therapy® System|The NeuroTronik CANS Therapy® System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
40950637|NCT04882046|OTHER|Blood collection|Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment
40950638|NCT04882046|OTHER|Data collection|collection of socio-demographic, clinical and biological data.
40950639|NCT03296098|DRUG|Ulipristal acetate|Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
40950640|NCT02420158|DEVICE|Trans-cutaneous vagal nerve electrical stimulation|
40950641|NCT03622814|BEHAVIORAL|Partners at Meals|The focus of the intervention is to facilitate meals using knowledge of the person with dementia's past history and lifelong preferences as well as their stage of disease, altering the behavior of the caregiver at meals to ameliorate dysfunctional behaviors, and altering the environment to make it more focused on the process of meals.
40950642|NCT03622814|BEHAVIORAL|Enhanced Usual Condition|Enhanced Usual Condition (EUC) Staff and volunteers at the EUC sites will receive training in communication between family and friends of the person with dementia. Following the general model of the Savvy Caregiver (Hepburn), communication training will occur every six months in these two sites. Families will be trained by project staff to record three meals including behavior at home each month. The Project Manager will attend the monthly support group for family members about communication. The administrator of the EUC RCC will be interviewed every 6 months the project is in place.
40950643|NCT06180291|OTHER|PRECOP program|"PRECOP program is the first program combining early detection of cerebral palsy with implementation of early interventions following the latest international recommendations (multidisciplinary program at home, with the possibility of intensive courses, coaching parental, in the first 2 years of life).~This comprehensive monitoring is implemented as soon as the infant arrives at home, by a multidisciplinary team and continues during the child's first 2 years. It includes:~* Follow-up organized primarily at home~* Monitoring of psychomotor development~* Screening for possible cerebral palsy~* Comprehensive support for the child's development: weight, diet, sleep...~* Reeducation, implementation of SMART type objectives (Specific, Measurable, Achievable, Achievable, Timely defined) determined with parents~* Creation of equipment if necessary: early seating installation in particular~* Parental support and guidance for optimizing early care~* Parental psychological support."
40950644|NCT06558175|RADIATION|stereotactic body radiation therapy (SBRT)|Patients will be assigned to treatment doses using the TITE-CRM model.
41133882|NCT05545800|DRUG|IDegLira|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will be initiated on 16 units (16 units degludec/0.58 mg liraglutide) and titrated twice weekly. The maximum dose of IDegLira was 50 units (50 units degludec/1.8 mg liraglutide). All groups received counseling on lifestyle modification.
40950645|NCT06281574|PROCEDURE|Questionnaires|"To assess the shoulder function, the following questionnaires will be used:~The validated Dutch translation of the Oxford Shoulder Score (OSS) The validated Dutch translation of the Simple Shoulder Test (SST) The Subjective Shoulder Value (SVV) To assess the work ability patients will use the validated Dutch work-related questionnaire for upper extremity disorders (WORQ-UP)"
41133883|NCT05545800|DRUG|premixed insulin analogues|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will received twice a day. The total daily insulin dose will be initiated at 0.4-0.5 units/kg/day and adjusted according to the plasma glucose. All groups received counseling on lifestyle modification.
41133884|NCT03418545|DEVICE|JUVÉDERM VOLBELLA® XC injectable gel|JUVÉDERM® VOLBELLA™ XC dermal filler injected into the infraorbital and adjacent area.
41133885|NCT04723615|OTHER|Orebro Musculoskeletal Screening Questionnaire-12|It is a 12-item self-report questionnaire that aims to estimate the severity of the problem, functional impairment, reporting status, cost and recovery time in musculoskeletal problems.
41133886|NCT04723615|OTHER|Visual Analog Scale|A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.
41133887|NCT04723615|OTHER|The Tampa Scale of Kinesiophobia|The Tampa Scale of Kinesiophobia that was developed in 1990 is a 17 item scale originally developed to measure the fear of movement related to chronic lower back pain.
41133888|NCT04723615|OTHER|Short Form-12 (SF-12)|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
41146791|NCT02212275|DRUG|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
41288732|NCT01594099|DRUG|liposome paclitaxel|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy."
41133889|NCT01279707|BIOLOGICAL|humanised monoclonal antibody, veltuzumab|Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
41133890|NCT01279707|BIOLOGICAL|humanised monoclonal antibody epratuzumab|Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
41288733|NCT02884466|BEHAVIORAL|Multidisciplinary rehabilitation intervention|Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
41288734|NCT04419415|DIETARY_SUPPLEMENT|Breakfast with high protein dairy|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) for breakfast.
41288735|NCT04419415|OTHER|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
41133891|NCT01279707|BIOLOGICAL|humanised monoclonal antibodies veltuzumab and epratuzumab|Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
41288736|NCT04419415|OTHER|Skipping breakfast|Participants will be asked to skip breakfast.
41288737|NCT04494009|DRUG|INCMGA00012|INCMGA00012 (also known as MGA012) is a humanized, hinge-stabilized IgG4 monoclonal antibody against human PD-1, which blocks the interaction of PD-1 with PD-L1 and PD-L2, interrupting PD-1 signaling, enhances antigen-induced interferon-γ release, and has a favorable preclinical profile.
41288738|NCT05013528|OTHER|Bal-A-Vis-X training|"Bal-A-Vis-X training Performed thrice a week for 10 minutes after baseline assessment Standard Physical therapy treatment along with following exercises.~1. ball Rectangle~2. ball rectangle and 2 ball drop/pass/catch two-foot jumping forward, tandem walking on ground and tandem walking on the balance beam. ."
41288739|NCT05013528|OTHER|Aerobic Training Group|"Aerobic training group performed exercises thrice a week for 10 minutes after baseline assessment.~Standard Physical therapy treatment along with aerobic training as Running is performed"
41466388|NCT06137807|DEVICE|TricValve® Transcatheter Bicaval Valve System|The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The system is a single use, sterile device compatible with all the valve sizes. The valves are premounted in the TricValve® Delivery System. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system available in sizes 25 and 29 for superior vena cava and 31 and 35 for inferior vena cava. The valve is implanted percutaneously by the transfemoral approach. The valves are supplied already premounted into the TricValve® Delivery System.
40950646|NCT06419335|DRUG|CoQ10|The core component of this pilot study will be a single center open label randomized trial comparing low dose and high dose CoQ10 among 30 patients with Crohn's disease and fatigue (Cohort 1) and 15 healthy volunteers (Cohort 3).
41288740|NCT05780840|OTHER|Dihydroxyacetone|Application of 10% dihydroxyacetone (2 mg per square cm skin)
41288741|NCT05780840|OTHER|Placebo|Application of lotion to the skin (2 mg per square cm skin)
40760036|NCT00117442|DRUG|paclitaxel|chemotherapy
40760037|NCT00117442|DRUG|pegfilgrastim|Growth factor for mobilization
40760038|NCT05181085|DRUG|NST 6179|orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
41133892|NCT03585400|OTHER|Observational Study|Observational Study: Not Applicable for Observational Studies
41133893|NCT04154085|OTHER|Psychotherapy|Group psychotherapy
41133894|NCT02356055|BEHAVIORAL|STOMP (Skill-building through Task-Oriented Motor Practice)|The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
41146792|NCT00401050|PROCEDURE|chiropractic manipulative therapy|
41288742|NCT01678846|BEHAVIORAL|Good School Toolkit|The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good_school_toolkit.php).
41288743|NCT00102037|DRUG|eptacog alfa (activated)|
40950647|NCT02451111|DRUG|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
41146793|NCT00401050|PROCEDURE|knee exercises|
41146794|NCT00401050|PROCEDURE|Graston Instrument Soft Tissue Mobilization (GISTM)|
41146795|NCT01817894|DRUG|Eflornithine cream 11.5 w/w %|Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
41466389|NCT04980456|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
41466390|NCT04980456|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
41466391|NCT04980456|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
41466392|NCT02092337|OTHER|computer-assisted speech training|
41288744|NCT02214589|OTHER|Oral glucose, facilitated tucking, NNS|
41288745|NCT02214589|OTHER|Oral glucose and NNS|
41466393|NCT05743634|BIOLOGICAL|YY001|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
41466394|NCT05743634|BIOLOGICAL|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
40760039|NCT05181085|DRUG|Placebo|inactive analogue
40786473|NCT05835310|BIOLOGICAL|Anifrolumab|Participants will receive a single dose of Anifrolumab via IV infusion.
41288746|NCT02214589|OTHER|Facilitated tucking and NNS|
41307781|NCT05522712|DEVICE|Incentive spirometer user|"1. Sit upright in a chair or in bed. Hold the incentive spirometer at eye level, hold a pillow to help splint or brace the incision to decrease pain at incision.~2. Put the mouthpiece in mouth and close lips tightly around it. Slowly breathe out (exhale) completely.~3. Breathe in (inhale) slowly through mouth as deeply as possible. As taking the breath, the ball will rise.~4. Try to get the ball as high as possible.~5. When getting it, hold breath for 10 seconds, or as long as possible.~6. Then, breathe out slowly through mouth. Then, Rest for a 30-60 seconds.~7. Repeat 10 times. Try to get the ball to the same level or higher with each breath.~8. repeat 10 times for 3 sets."
41288747|NCT05770414|BEHAVIORAL|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by caregivers and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching caregivers to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
41133895|NCT05068050|PROCEDURE|Horse-assisted therapy|"12 horse-assisted therapy sessions (45 mins each) for 6 weeks.~Each session will comprise the next stages:~Groundwork, Approachment and preparation of the horse, Warm up exercises~Development of the main part (riding):~Introduction - beginning: Breathing control and body awareness, maintain sitting (riding position) while walking on the horse, perceiving the movement Exercises for the postural and balance control: Variations in the walking of the horse, realize different figures in the arena (circles, serpentines, change direction...), Stopping and Walking, Arms situation combined with the movement of the horse All exercises are determined in the track design protocol Exercises for the acquisition of motion skills: Finished the riding with relaxation activities. Final part: Dismount the horse, Unsaddled and unbridle, feedback and goodbye procedure."
41288748|NCT05495399|PROCEDURE|Spondylectomy|Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.
41466395|NCT05743634|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
40950648|NCT02451111|DRUG|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
41466396|NCT00622687|DRUG|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
41466397|NCT00622687|DRUG|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
41146796|NCT00406276|DRUG|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
40950649|NCT02495831|DRUG|Diclofenac sodium|Diclofenac sodium 50 mg single dose
41133896|NCT05068050|PROCEDURE|Physical exercise|"12 physical exercise sessions (45 mins each) for 6 weeks. Each session Each session Lessons will be held by physical activity professionals. The proposed exercises are focussed on improving the articular movements, aerobic resistance and the proprioception, always on the premises of No Pain.~Lessons will be divided in three parts :~1. Warmup - 2. Main part - 3. Return to calm~Lessons will be hold online"
40760040|NCT03514693|PROCEDURE|PVI|Ipsilateral circumferential PVI is the recommended PVI strategy. The success of PVI is defined as the achievement of the dissociation of PV potentials in all PVs. Disappearance of PV potentials is reconfirmed at the end of the procedure, a minimum of 20 minutes after the initial success of PVI.
40760041|NCT03514693|PROCEDURE|PVI plus additional ablation|In addition to PVI, CFAE ablation, linear ablation, or both; the choice of which is decided by the physician
40760042|NCT05535855|DRUG|CD19 Directed CAR T Cell|The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
40760043|NCT03008213|DRUG|Netupitant and Palonosetron|300 mg of netupitant and 0.5 mg of palonosetron
40760044|NCT02262663|DRUG|Vilaprisan (BAY1002670)|
40760045|NCT06571006|OTHER|music|"The musical intervention will start 10 minutes before the lumbar puncture procedure begins and continue for another 20 minutes after the intervention. Babies will be kept away from noise during this study. W.A. It was decided to use the piece Adagio from the Violin Concerto No. 3 in G major, KV 216, composed by Mozart. The track will be played through two speakers on opposite sides, 30 cm away from the baby's ears, to optimize sound perception. High quality digital audio will be used to make babies listen. Music will be played at a level that can be heard in high noise pollution (i.e. the noise of incubator operation and the white noise of the recorder), but taking into account the permissible sound level recommended by the American Academy of Pediatrics, i.e. 65-70 dB"
40760046|NCT06455800|DIAGNOSTIC_TEST|lung function measurements|Patients will once a year be monitored with different lung function methods
40760047|NCT02502383|BEHAVIORAL|ACTION PAC|School-based health center providers will use motivational interviewing to assist students with adopting strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI and other health results discussion with clinical providers. Adolescents with overweight/obesity will meet with providers for 16 sessions over 2 years.
40760048|NCT02502383|BEHAVIORAL|Communication with parents|A letter containing BMI and other health results and obesity prevention recommendations will be sent to parent/guardians.
40760049|NCT02410200|DRUG|dimethyl fumarate|
40760050|NCT00000603|PROCEDURE|stem cell transplantation|
41133897|NCT04728191|OTHER|Physiotherapy|physiotherapeutical instructions and training as described.
41133898|NCT04728191|OTHER|standard care|Standard care as described.
41466398|NCT00622687|DRUG|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
40760051|NCT03361631|DRUG|Autologous Bone Marrow derived Mesenchymal Stem Cells|Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination \& Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores \& Pharmaco-Doppler
40760052|NCT06496100|DRUG|Triticum Aestivum|The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
40760053|NCT06496100|DRUG|Placebo (calcined magnesia)|The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
40786474|NCT05835310|DRUG|Placebo|Participants will receive matching placebo via IV infusion
40950650|NCT02495831|DRUG|Diclofenac sodium and safinamide|Diclofenac 50 mg single dose and safinamide 200 mg single dose
40950651|NCT02829255|OTHER|altitude exposure|altitude exposure
41133899|NCT06009666|DIAGNOSTIC_TEST|Shear Wave Elastography and B Mode Ultrasonography|We evaluated the both upper extremities of the patient and control group with elastography and B mode ultrasonography. Shear wave elastography evaluates tissue deformation caused by acoustic radiation force. A highly focused ultrasound radiation is produced; The propagation speed of the shear wave depends on the stiffness of the tissue. It is a simple, inexpensive, bedside, widely available, non-invasive technique. B mode USG can be used to assess skin and subcutaneous tissue thickness and echogenicity. Skin and subcutaneous thickness were measured with b mode ultrasound. Skin and subcutaneous tissue stiffness was measured by shear wave ultrasonography
41146797|NCT00406276|DRUG|Docetaxel|In combination with RAD001
41288749|NCT05495399|RADIATION|SBRT|Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
41466399|NCT05244317|DEVICE|cast|the cast of the upper limb from just below elbow joint to the knuckle of fingers
41288750|NCT02814214|DEVICE|ECG+IEGM|Cardiac Resynchronization Therapy programming adjustments
41288751|NCT02409498|DRUG|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
41288752|NCT02409498|DRUG|no pudendal block|preemptive pudendal nerve blockade with 10 ml of normal saline to each side
41288753|NCT03004014|OTHER|Sleep endoscopy during propofol induced sleep|It will be performed a sleep endoscopy during drug induced sleep endoscopy
41288754|NCT02516930|BEHAVIORAL|crowdsourced video|video promoting condom use
41288755|NCT02516930|BEHAVIORAL|social marketing video|
41288756|NCT06302634|OTHER|Exercise-based cardio-oncology rehabilitation|Within the multidisciplinary approach of cardio-oncology rehabilitation, the exercise program will include recommendation and supervision of strength, aerobic and mobility exercises.
41466400|NCT05244317|DEVICE|splint|Removable splint
41288757|NCT06292312|OTHER|Craniosacral therapy|Craniosacral therapy is defined as an alternative, massage-like treatment approach using gentle manual force to address somatic dysfunctions of the head and the rest of the body.
41466401|NCT06353750|OTHER|Magnesium supplement|Intravenous magnesium supplement (10mmol).
40760054|NCT01903863|BIOLOGICAL|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
40950652|NCT02096679|DRUG|AZD9291|Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1
41288758|NCT06292312|OTHER|Conventional physiotherapy|Range of motion, stretching, resistance exercises. Spasticity inhibition Balance and coordination exercises Walking training Stabilization exercises Breathing exercises
41288759|NCT06143579|DRUG|FOLFOX-HAIC+Lenvatinib+Envolizumab|"FOLFOX-HAIC: Oxaliplatin 130 or 85 mg/m2; leucovorin 200 mg/m2; fluorouracil 400 mg/m2 intravenous bolus followed by fluorouracil 2400 mg/m2 continuous infusion over 23 hours, Q3W, 2 to 4 cycles;~Lenvatinib: 8 mg/day (BW \< 60 kg) or 12 mg/day (BW ≥ 60 kg), PO, 3-4 cycles;~Envolizumab: 300 mg, SC, Q3W, 3-4 cycles."
41288760|NCT02351037|DRUG|Ibrutinib|Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
41288761|NCT02351037|DRUG|Ibrutinib + LD-AraC|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
41288762|NCT02351037|DRUG|Ibrutinib+Azacitidine|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
41288763|NCT03418246|DEVICE|GIC|tooth colored filling
41288764|NCT03418246|DEVICE|Biodentine|White filling -Biodentine
40760055|NCT06372041|DEVICE|transcranial Alternating Current Stimulation|tACS will be performed by using a Conformite Europeenne (CE) marked stimulator device (Starstim ®, Neuroelectrics, Barcelona, Spain). By applying alternating current at the gamma frequency band (range 30-80), known to be associated to motor performance, tACS can entrain or synchronize neural oscillations in the targeted brain regions. By modulating cortical excitability of the cerebellum, a region strongly involved in motor learning and coordination, tACS is expected to influence the strength and coordination of motor responses elicited during the training. tACS will be delivered through two saline-soaked surface sponge electrodes (dimension: 25cm2 each), one placed over F3 (left frontal region) and the other over the right cerebellar hemisphere. The intensity will be set to 1mA, and this value will be gradually reached with a ramping-up phase of 30 secs. The frequency of the stimulation will match the IGF identified during the EEG recording performed at rest.
41288765|NCT06481189|BIOLOGICAL|GNR-086|The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.
41288766|NCT06481189|BIOLOGICAL|Ilaris®|The reference drug Ilaris® was administered as a subcutaneous injection at a single dose of 150 mg.
41288767|NCT01709877|PROCEDURE|Cholecystectomy|Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
40760056|NCT00245154|DRUG|carboplatin|Given IV
41454105|NCT05006560|OTHER|Pulmonary Rehabilitation (usual care) + familiarization with components of the aftercare program|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days. Additionally, participants use several functions of the aftercare program's mobile application. This includes using the application during endurance and strength training (as part of usual care) and using a consumer activity monitor to count daily steps.
41288768|NCT05979012|BEHAVIORAL|MIndfulness Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.It is up to them if they want to listen to the daily recordings."
41454106|NCT05006560|OTHER|After care: Exercise and physical activity promotion|"Participants will agree with their therapist on an exercise plan (endurance and resistance training) that are made available for participants through the study's mobile app. Frequency and duration of endurance and strength training are prescribed in accordance with exercise guidelines for persons with COPD. However, they can be adjusted according to participants needs.~Next to the exercise, participants receive physical activity counseling. This consists of phone or video calls with a therapist, group video calls with a therapist, a complementary e-learning course as well as complementary functions of the study's mobile app."
41454107|NCT05269563|OTHER|Surgical intervention|Pars Plana Vitrectomy for Macular Hole Closure
41454108|NCT01719770|DRUG|rocuronium|continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
41454109|NCT01719770|OTHER|placebo|continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
41454110|NCT04627857|DEVICE|Manual toothbrush|Patients in group 1 (''reference procedure'') receive a manual toothbrush with a small compact head to facilitate access to the posterior teeth and soft bristles.
41454111|NCT04627857|DEVICE|Manual toothbrush and water flosser (Philips Sonicare AirFloss)|- Group 2 patients receive a manual toothbrush with a small, compact head for easy access to the posterior teeth and soft bristles. They also receive a Philips brand interdental microjet (Philips Sonicare AirFloss Ultra) which must be filled with water.
41454112|NCT04627857|DEVICE|Sonic toothbrush|- Group 3 patients receive a rechargeable sonic electric toothbrush from Philipps with an integrated excess pressure sensor and a compact toothbrush head for easy access to the posterior teeth.
41288769|NCT05979012|BEHAVIORAL|Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.They will have access to electronic audio recordings, with the order of listening labeled for each day. The recordings will increase gradually throughout the study, starting with about 10 minutes each day in the first week and reaching 30 minutes each day in the final week. The schedule is as follows: Week 1= 10 minutes, Week 2= 15 minutes, Week 3= 20 minutes Week 4= 30 minutes. It is up to them if they want to listen to the daily recordings."
41288770|NCT00795626|BEHAVIORAL|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
41288771|NCT01150110|DEVICE|resilient occlusal splints|"A resilient occlusal splints (silicone 2mm) was fabricated on the maxillary arch, using a vacuum pressing machine. The occlusal splints were adjusted to eliminate the gross interferences and to obtain occlusal stability with maximum posterior bilateral contacts.~Patients were instructed to use the occlusal splints for 24 hours during 30 days. The use was interrupted only during meals."
41288772|NCT03411733|OTHER|Blood and stool samples collection|Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection
41307782|NCT05522712|PROCEDURE|Control|This group is a control group will not receive new intervention just traditional chest physiotherapy and mobilization
41307783|NCT05277870|DEVICE|Nanodropper adaptor|Patients will use their standard prescription for open-angle glaucoma or ocular hypertension with a Nanodropper attachment on the medication bottle.
41307784|NCT05277870|DEVICE|control|Patients will use their prescribed IOP-lowering medication using standard eyedropper on the medication bottle.
41454113|NCT04627857|DEVICE|Sonic toothbrush (Philips Sonicare) and water flosser (Philips Sonicare AirFloss)|- Group 4 patients receive a Philips Sonicare ProtectiveClean rechargeable sonic electric toothbrush with an integrated excess pressure sensor and 2 compact toothbrush heads for easy access to the posterior teeth. They also receive an interdental microjet from Philips (Philips Sonicare AirFloss Ultra) which must be filled with water.
40950653|NCT06340516|DIAGNOSTIC_TEST|Plasma NT-proBNP|Replacement of measurement of plasma NT-proBNP instead of ECHO/MUGA at 6 months and 12 months of trastuzumab treatment to assess cardiotoxicity
40950654|NCT00896935|OTHER|biologic sample preservation procedure|biologic sample preservation procedure
41288773|NCT04612088|BEHAVIORAL|Cognitive Dissonance|"A blood sample will be taken before the first take of the multivitamins and at the end of the intervention to measure: Hemoglobin, Calcium, Phosphorous, Iron, Copper, Zinc, Vitamin D, and Folate.~During the three months of the intervention, the intervention group will receive one psycho-educative session and five Cognitive Dissonance sessions.~Several tests will be applied to the patients at the beginning of the program and after the sessions to measure: patient knowledge and adherence to the multivitamin, self-efficacy, self-care, and Psycho-pathological symptoms.~The No intervention group on the wait list will receive the five Cognitive Dissonance sessions after the three months of the study."
41133900|NCT06009666|DIAGNOSTIC_TEST|Quick Dash Questionnare|Quick-DASH is an assessment questionnaire that measures activity and participation limitations in all upper extremity disorders. In the questionnaire, the difficulties of the patients during their daily living activities are questioned with 11 questions. Each answer is scored from 1 to 5 on a Likert scale, from best to worst.
41133901|NCT06009666|DIAGNOSTIC_TEST|The Lymphedema Life Impact Scale|The Lymphedema Life Impact Scale is a questionnaire developed to evaluate the physical, functional and psychosocial effects of lymphedema. It consists of 18 questions; It includes 8 physical, 4 psychosocial and 6 functional subgroups. Each question is scored from 1 to 5, with higher scores indicating increased seriousness.
41288774|NCT02082184|DEVICE|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
41288775|NCT02082184|DEVICE|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
41288776|NCT04403737|DEVICE|Rothman Index|The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.
41288777|NCT03823768|DRUG|Envarsus|Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
41288778|NCT03823768|DRUG|Tacrolimus Immediate release|Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
41288779|NCT03078985|PROCEDURE|ablation for typical atrial flutter|Typical atrial flutter is treated by catheter ablation.
41288780|NCT03078985|DEVICE|catheter ablation with study device|The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
41288781|NCT03665597|BIOLOGICAL|Pembrolizumab Dose C|SC injection
41288782|NCT03665597|BIOLOGICAL|Pembrolizumab Dose A|SC injection
41454114|NCT03701451|DRUG|Demethylated drug decitabine|Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
41454115|NCT01663896|DEVICE|OCT stent guidance|Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT
41454116|NCT04553406|DRUG|SPR720|Capsules for oral administration
40760057|NCT00245154|DRUG|cediranib maleate|Given orally
40760058|NCT00245154|DRUG|paclitaxel|Given IV
40760059|NCT00245154|OTHER|placebo|Given orally
40950655|NCT03376269|BIOLOGICAL|HBOT|•HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments
40950656|NCT03376269|BEHAVIORAL|Psychotherapy|creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions
40950657|NCT04945512|PROCEDURE|Epidural Analgesia|In the anesthesia preparation room, an epidutal catheter will be placed with a toue needle through the L4-5 spinal space. After induction of general anesthesia, 10 ml of 0.25% bupivacaine will be injected through the epidural catheter.Afterwards, peroperative and postoperative analgesia will be provided with epidural PCA.
40760060|NCT06036264|OTHER|Collected of Datas|age, sex, mode of dialysis, emergency context, approach, date of creation of the arteriovenous fistula (if concerned), date of start of dialysis, transplant status, date of registration on the renal transplant waiting list (if concerned), nephrologist, date of first consultation with the pre-nurse in advanced practice (APN) (if concerned)
41288783|NCT03665597|BIOLOGICAL|Pembrolizumab Dose B|IV infusion
41288784|NCT03665597|BIOLOGICAL|Pembrolizumab Dose D|IV infusion once every 6 weeks
41288787|NCT04534894|DIAGNOSTIC_TEST|fluorescence lifetime imaging microscopy|collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it
41288788|NCT01105351|DIETARY_SUPPLEMENT|folic acid plus B6 and B12|folic acid 400 µg plus vitamin B12 plus B6
41288789|NCT01105351|DIETARY_SUPPLEMENT|folic acid|folic acid 400 µg
41288790|NCT06450028|DRUG|10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine|Injection of 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine.
40760061|NCT06036264|OTHER|semi-structured interview|Semi-structured interviews will be realized. The goal is to establish a qualitative analysis of the relevance and organization of pre-transplant assessments, of the reactivity in the adjustment of requests and assessments, and to identify the strong points or areas for improvement.
41133902|NCT06009666|DIAGNOSTIC_TEST|Questioning lymphedema-related symptoms|Arm pain and feeling of tension, heaviness and stiffness in the arm were evaluated separately by numerical scale. This scale is a 10 cm ruler that writes no pain, no tension, no heaviness, no stiffness on one side, and unbearable pain, tension and heaviness on the other side. Patients were asked to rate their associated symptoms on this scale between 0 and 10.
41133903|NCT06009666|OTHER|Extremity circumference and volume measurement|For the diagnosis of lymphedema, a detailed physical examination and extremity circumference were measured. This measurement was taken from both wrists to arm height with 4 cm intervals. Those with a circumference difference greater than 2 cm and/or no 10% volume difference were considered preclinical (latent) and those with clinical lymphedema.
41133904|NCT06498609|BIOLOGICAL|iprf|i-PRF with leveling and alignment
41133905|NCT06498609|PROCEDURE|MOPs with leveling and alignment|mop
41133906|NCT02516709|RADIATION|Linear LDR Source|The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.
41133907|NCT00486304|OTHER|ADD|The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day
41133908|NCT00486304|OTHER|Placebo|Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
41133909|NCT02430454|BEHAVIORAL|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
41288791|NCT06450028|DRUG|6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine|Injection of 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine.
41288792|NCT04671680|DEVICE|LiDCO CNAP Monitoring Equipment|A continuous non-invasive arterial blood pressure monitor for rapidly changing hemodynamics.
41288793|NCT00564707|BEHAVIORAL|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
41288794|NCT00564707|PROCEDURE|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
40760062|NCT03208179|DRUG|dihydroartemisinin-piperaquine|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
41288795|NCT02383394|OTHER|follow up antenatal care|ultrasound follow up of pregnancy
41288796|NCT03323307|DEVICE|OCT imaging|imaging of retina using OCT device
41288797|NCT01716169|DEVICE|Helicoll|Helicoll Collagen I Wound Dressing
41288798|NCT01716169|DEVICE|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
41288799|NCT05153005|OTHER|examination methods|Some advanced methods: mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen (CrAg) serological detection, qPCR, dd- PCR and mass spectrometry identification, QFC.
41288800|NCT01100021|DRUG|Tamsulosin and avanafil|tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
41288801|NCT01100021|DRUG|Doxazosin and avanafil|doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
41288802|NCT01180725|DIETARY_SUPPLEMENT|Dried Plum|
41288803|NCT01180725|DIETARY_SUPPLEMENT|Metamucil|
41307785|NCT02436577|DRUG|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
41454117|NCT04553406|DRUG|Placebo|Capsules for oral administration
40760063|NCT03208179|DRUG|sulphadoxine-pyrimethamine|Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
40950658|NCT03784703|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg per day atorvastatin (ATROVA group, n= 80) for 6 months
41288804|NCT00469235|DRUG|Avotermin|"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."
40760064|NCT03208179|DRUG|dihydroartemisinin-piperaquine plus azithromycin|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
41133910|NCT02434991|DEVICE|Barostat|"* During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.~* A urine pregnancy test for females of childbearing years.~* Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.~* At this point healthy controls have completed the study.~* Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.~* Patients will be contacted to complete a phone survey 3 \& 6 months and 2 \& 4 years after treatment."
41133911|NCT03897699|DEVICE|Transcranial Direct Current Stimulation|A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively.
41133912|NCT03897699|BEHAVIORAL|Mindful Breathing|MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
41133913|NCT03897699|OTHER|Sham|Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.
41133914|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
41288805|NCT04996576|PROCEDURE|infrazygomatic approach sphinopalatine ganglion block|"A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
41288806|NCT04996576|PROCEDURE|intranasal injection approach of sphinopalatine ganglion block|method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia
41288807|NCT03660904|BIOLOGICAL|home made vitrification & thawing kit|home made vitrification was made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
41288808|NCT03660904|BIOLOGICAL|commercially made vitrification & thawing kit|commercially available vitrification \& thawing kit were made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
41288809|NCT00006452|DRUG|motexafin gadolinium|
41288810|NCT00006452|RADIATION|radiation therapy|
41288811|NCT05328843|DRUG|PB119|"Each subject received only one dose of study drug during the study period. After completing the pre-dose procedure on the morning of the first day of the study, the subjects were given a subcutaneous injection of PB-119 0.3 mL (150 μg) once in the abdomen by the study nurse. The actual time of administration will be recorded in the subject's eCRF.~Subjects should remain on an empty stomach for at least 10 hours prior to administration."
41288812|NCT01330381|DRUG|prucalopride|"prucalopride~* subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml~* subjects with weight \>50 kg: prucalopride 2 mg tablet once daily"
41288813|NCT01330381|DRUG|Placebo|Matching oral solution or oral tablets given once daily
41288814|NCT01330381|DRUG|PEG 4000|
41288815|NCT05347732|DIAGNOSTIC_TEST|Successfull thrombolysis|Biomarker levels will be compared between patients with successful and failed thrombolysis.
41288816|NCT01772979|DRUG|Trabectedin|
41288817|NCT02631187|DEVICE|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
41288818|NCT04095208|DRUG|Association of Nivolumab + Relatlimab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\].~Relatlimab will be administered as a 60-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[80 mg\]."
41288819|NCT04095208|DRUG|Nivolumab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\]."
41307786|NCT02436577|DRUG|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
40760065|NCT01013259|DRUG|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
40760066|NCT01013259|DRUG|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
40950659|NCT03784703|DRUG|Rosuvastatin 10 Mg Oral Tablet|10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months
41288820|NCT01264315|DRUG|Lenalidomide|"Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~* absolute neutrophil count \>1x109/L without growth factors~* platelet count \>75x109/L without transfusion support~* calculated/measured creatinine clearance: ≥20mL/minute~* total bilirubin \<2 x the upper limit of normal~* AST (SGOT) and ALT (SGPT) \<2.5 x upper limit of normal~* \<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart."
41288821|NCT01713348|DEVICE|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
40760067|NCT05336357|DEVICE|Goal-Directed Therapy|"Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 65 mmHg.~If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell."
40760068|NCT04391608|DRUG|Switching to Tenofovir Alafenamide|Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
41454118|NCT04553406|DRUG|Open-label Standard of Care|"Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~* Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~* Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days."
40760069|NCT02695771|DRUG|Mitomycin C|Cancer chemotherapeutic agent
40760070|NCT02695771|DRUG|Gemcitabine|Cancer chemotherapeutic agent
40760071|NCT01188993|COMBINATION_PRODUCT|early septic shock|Each patient will be assessed by both the transpulmonary thermodilution and Transesophageal Echocardiography.
41133915|NCT03915678|DRUG|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
41133916|NCT03915678|DRUG|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
41133917|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
41288822|NCT01713348|DEVICE|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
41288823|NCT04735900|PROCEDURE|Liquid biopsy sampling|Biweekly liquid biopsy sampling to measure circulating tumor DNA (ctDNA) level up to and including 9 months after start first-line therapy.
41288824|NCT02357277|DRUG|Budesonide|inhaled glucocorticoid budesonide as dry powder inhaler
41288825|NCT02357277|OTHER|Placebo Inhaler|inhaled placebo
41307787|NCT02436577|DRUG|Ticagrelor IR tablet (90 mg) administered with 150 mL of water|Ticagrelor 90 mg IR tablet, single dose
41307788|NCT02874404|DRUG|Ibrutinib|Given PO
41307789|NCT02874404|OTHER|Laboratory Biomarker Analysis|Correlative markers
40760072|NCT02980458|DRUG|Deferiprone 500Mg Tablet|
40760073|NCT02980458|DRUG|Deferiprone 500 MG Oral Tablet [Ferriprox]|
40760074|NCT01564030|OTHER|Empty|overnight fast
40950660|NCT03947996|OTHER|Stretching exercise|Stretching (30 minutes, 5 days per week, 8 weeks)
41288826|NCT00503971|DRUG|Vorinostat plus Erlotinib|"Phase I:~Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily~Phase II:~Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily"
40950661|NCT03947996|OTHER|Walking exercise|Walking (30 minutes, 5 days per week, 8 weeks)
40760075|NCT01564030|OTHER|Fluid|250mL apple juice
40950662|NCT03985306|PROCEDURE|Inforatio technique|"We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment."
40950663|NCT01594671|DRUG|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
40950664|NCT01594671|DRUG|Tranexamic Acid|One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
40950665|NCT01594671|OTHER|haemostasia|The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
40950666|NCT03904173|DIAGNOSTIC_TEST|Multi-parameter tests|Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).
40950667|NCT03014557|DEVICE|left atrial appendage closure device implantation|to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
40950668|NCT02031796|OTHER|CAVAREC Image Processing algorithm|After deployment of the TAVI prosthesis, other trans catheter valve, or stent, but before the patient care episode is completed, a set of rotational x-ray angiography images will be acquired and reconstructed using the clinical DyanCT and research CAVAREC algorithms.
40950669|NCT00222560|BEHAVIORAL|Intensive physical activity counselling by an integrated physical activity counsellor|
40950670|NCT01457573|DRUG|Tamsulosin|Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).
40950671|NCT01457573|DRUG|Solifenacin|Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
40950672|NCT05193552|DRUG|Hizentra|subjects level of immunoglobulin replacement therapy will be adjusted for bioavailability as per manufacturer's instructions
40950673|NCT06101550|PROCEDURE|partial pulpotomy|Partial removal of pulp tissue in young permanent teeth
40950674|NCT06101550|PROCEDURE|Complete pulpotomy|Complete removal of pulp tissue in young permanent teeth
41133918|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
41133919|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
41133920|NCT06509282|BEHAVIORAL|Concurrent training|"Protocol:~Duration: 6 weeks. Frequency: 3 times a week. Type: Concurrent. This consists of a combination of aerobic exercise and muscular resistance exercise.~Details of the type of exercise:~Aerobic exercise:~Participants will perform 5-10 intervals per session of walking or jogging at a moderate to high intensity, with a rating of 5 to 10 points on the modified Borg scale of 1-10 points. Each interval will consist of 1 minute of walking or jogging, followed by 2 minutes of inactive pause.~Muscular resistance exercise:~Participants will perform concentric and eccentric and/or isometric contractions for 1 minute at an intensity of 5-10 according to the OMNI-RES scale. The rest period will last 2 minutes, and each exercise will be repeated 3 times. Three exercises per session will be performed: squats, push-ups, and plank.~Pharmacological treatment:~Participants will be asked to maintain their lifestyle, including taking prescribed medication as usual."
41133921|NCT03862898|OTHER|Lumbar stabilization exercises|Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
41307790|NCT02874404|DRUG|PI3K-delta Inhibitor TGR-1202|Given PO
40760076|NCT01564030|OTHER|Solid|breakfast
40950675|NCT02867150|DEVICE|Ward Photonics Photonica Professional|"Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy."
40950676|NCT05595096|PROCEDURE|General anesthesia with preservation of spontaneous breathing|non-intubation group, thoracic paravertebral nerve block was performed before anesthesia induction,when the BIS value drops to between 40 and 60, laryngeal mask airway(LMA) is placed,and observation of breathing
40950677|NCT06246760|OTHER|Exercise|Incremental exercise test until volitional exhaustion
40950678|NCT02364921|DEVICE|Two multilayer compression bandage|"Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.~Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days"
40950679|NCT02364921|DEVICE|Crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
40950680|NCT03798847|DEVICE|Journey II XR TKA|Journey II XR Total Knee System
40950681|NCT00236587|DRUG|risperidone|
40950682|NCT01161108|DRUG|Fast Release Melatonin (FR MLT)|3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
40950683|NCT01161108|DRUG|Fast Release Placebo|"A matching FR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
40950684|NCT01161108|DRUG|Timed Release Melatonin (TR MLT)|"3 mg capsules will be used.~The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
40950685|NCT01161108|DRUG|Timed Release Placebo|"A matching TR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
40950686|NCT01696071|DRUG|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
40950687|NCT01696071|DRUG|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
40950688|NCT03285854|DIAGNOSTIC_TEST|Collection of blood, urine and stool samples|Collection of blood, urine and stool samples, diet diary and bone scans
40950689|NCT04877483|PROCEDURE|Acupuncture|Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
40950690|NCT04877483|DIAGNOSTIC_TEST|Oral microbiota|Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
40950691|NCT04877483|DIAGNOSTIC_TEST|Schirmer's test|Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
41288827|NCT04685330|PROCEDURE|Ultrasound guided procedure|Single-arm, open-label device efficacy study to enroll 200 patients who have been ordered to have an ultrasound-guided procedure by the MGH Interventional Radiology department, including paracentesis, thoracentesis, biopsy, or ultrasound-guided drain placement. Patients will be restricted to adults who can consent.
41288828|NCT04685330|DEVICE|Portable ultrasound|The FDA approved Healcerion SONON portable ultrasound (linear and curved) will be used during clinically indicated standard ultrasound-guided procedures following clinical standard of care. A standard clinical ultrasound will subsequently be used for image guidance as the gold standard. Images will be compared and improved. The efficacy of the portable ultrasound will be monitored by the clinical user and any complications within 30 days will be determined by chart review.
40950692|NCT04877483|DIAGNOSTIC_TEST|Tear breakup time|Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
40950693|NCT04877483|DIAGNOSTIC_TEST|OSDI(Ocular Surface Disease Index)|Group GB20 and Group GB20 plus BL2 will take the OSDI test.
40950694|NCT04877483|DIAGNOSTIC_TEST|TCM pattern|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
40950695|NCT04877483|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) tongue diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
40950696|NCT04877483|DIAGNOSTIC_TEST|TCM pulse diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
40950697|NCT04877483|DIAGNOSTIC_TEST|TCM heart rate variability|Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
40950698|NCT04877483|DIAGNOSTIC_TEST|ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)|Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
40950699|NCT04877483|DIAGNOSTIC_TEST|Whole-genome genotyping(TWBv2.0)|Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
40950700|NCT04877483|DIAGNOSTIC_TEST|Cytokine markers|Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.
40950701|NCT04877483|DIAGNOSTIC_TEST|Blood biochemical analysis|Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
40950702|NCT04877483|DIAGNOSTIC_TEST|complete blood count (CBC)|Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.
40950703|NCT04877483|DIAGNOSTIC_TEST|SF-36(36-Item Short Form Survey )|Group GB20 and Group GB20 plus BL2 will take the SF-36 test.
40950704|NCT02414659|PROCEDURE|Umbilical cord blood collection, in-utero|Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
40950705|NCT04945577|DIAGNOSTIC_TEST|Inflammatory Parameters|Laboratory measurement of patient's inflammatory status in unit of % and mg/dl
41454119|NCT03031951|BEHAVIORAL|Lifestyle Intervention Group|The intervention group will start the lifestyle intervention with a 60-minute nutrition appointment given by a certified dietitian. This meeting is intended to provide a well-balanced personalized diet plan, calculated to create a moderate reduction from \~300 to 500kcal/day according to each participant's energy requirements and preferences. Two additional follow-up appointments are also planned to adjust the individual energy requirements throughout the intervention. Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Weight will be monitored weekly.
41454120|NCT01328782|DRUG|Oxycodone with Acetaminophen|0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
41454121|NCT01328782|DRUG|Bupivacaine 0.25%|"* Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)~* Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
41454122|NCT01328782|DRUG|Ropivacaine 0.20%|"* Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)~* Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
41454123|NCT01694563|DEVICE|Synergy Ablation System|"Patient will undergo an elective open cardiac surgical procedure to be performed on cardiopulmonary bypass for one or more of the following:~* Coronary Artery Bypass Grafting (CABG)~* Mitral valve repair or replacement~* Aortic valve repair or replacement~* Tricuspid valve repair or replacement The aim of the treatment is a complete bi-atrial Maze IV procedure which includes pulmonary vein isolation coupled with lesions made on both the left and right atria."
40760077|NCT01177358|DRUG|Botulinum Toxin Type A|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy."
40760078|NCT01177358|DRUG|Normal Saline|0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
40760079|NCT02389738|DRUG|Regadenoson|Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
40760080|NCT02389738|DRUG|Temozolomide|Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
40760081|NCT02389738|DEVICE|Microdialysis catheter|Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
40760082|NCT05851365|DRUG|Hyperpolarized Bicarbonate (13C)|Given IV
40950706|NCT04945577|OTHER|25 OH Vitamin D Level|Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
41133922|NCT03477968|DIAGNOSTIC_TEST|DDimer test|Measuring the level of DDimer in blood sample
41133923|NCT01549951|DRUG|Orteronel+Prednisone|Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
41133924|NCT02110381|DEVICE|Device guided breathing RESPeRATE|"Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.~Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit."
41133925|NCT02110381|DEVICE|Isometric hand grip Zona Plus|"Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.~Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit."
41133926|NCT01670526|DRUG|Rivastigmine Transdermal Patch|Cholinesterase Inhibitor
41133927|NCT04603300|DRUG|INT301|INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste
41133928|NCT04603300|DRUG|Placebo|Fully functional toothpaste containing no immunotherapy agents
41133929|NCT01707303|OTHER|Early ICU rehabilitation strategies|Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
40760083|NCT05851365|PROCEDURE|Magnetic Resonance imaging|Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
41133930|NCT01707303|OTHER|Usual Care|All typically applied hospital rehabilitative services applied in the usual fashion
41288829|NCT01596205|BEHAVIORAL|Robot assisted cognitive training|We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
40950707|NCT04876144|DEVICE|Kogito|"Users of the Kogito app progress throught the deep self-help intervention in a sequence of 5 modules. The base of the Kogito app is in the cognitive-behavioral therapy (CBT), relaxation techniques and peer support.~Module~1. Introduction to the CBT (psychoeducation) and deep breathing relaxation plus perinatal peer support videos. Emotional tracking.~2. Behavioral activization, relaxation techniques, CBT diary, psychoeducation on anxiety and depression, peer support.~3. CBT - vicious circle, progressive muscle relaxation, peer support content~4. Cognitive distortions, relaxation in imagination, peer support content~5. Cognitive restructuring, mindfulness relaxation, peer support content.~Progress in the Kogito app is conditional on the completion of various CBT tasks"
40950708|NCT00002532|BIOLOGICAL|filgrastim|
40950709|NCT00002532|DRUG|asparaginase|
40950710|NCT00002532|DRUG|cytarabine|
40950711|NCT00002532|DRUG|daunorubicin hydrochloride|
40950712|NCT00002532|DRUG|dexamethasone|
40950713|NCT00002532|DRUG|etoposide|
40950714|NCT00002532|DRUG|idarubicin|
40950715|NCT00002532|DRUG|ifosfamide|
40950716|NCT00002532|DRUG|leucovorin calcium|
40950717|NCT00002532|DRUG|methotrexate|
40950718|NCT00002532|DRUG|prednisolone|
40950719|NCT00002532|DRUG|vindesine|
40950720|NCT06086275|DRUG|Buprenorphine|At each visit, the participant will receive a single dose of buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.
40950721|NCT00535457|OTHER|Preoperative Magic Tricks|"Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction."
40950722|NCT00436774|PROCEDURE|assessment of therapy complications|
40950723|NCT00436774|PROCEDURE|quality-of-life assessment|
40950724|NCT01369160|BEHAVIORAL|Quality of Life measures|measuring QOL with different therapies
40950725|NCT00816920|OTHER|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
40950726|NCT03870100|DRUG|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous
40950727|NCT03870100|DRUG|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous
40950728|NCT04242550|BEHAVIORAL|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT (see description below) with executive function training. EF-BED will focus on teaching compensatory strategies to enhance adherence to the strategies recommended in CBT.
40950729|NCT04242550|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
40950730|NCT04204122|DRUG|Vigamox|-FDA approved medication
40950731|NCT04204122|DRUG|Placebo|-The placebo is artificial tear drops
40950732|NCT00187200|DEVICE|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
40950733|NCT00187200|DEVICE|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
40950734|NCT01080742|DRUG|Lodoz (Combination of bisoprolol and hydrochlorothiazide)|The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
40950735|NCT03553771|DEVICE|LVIS and LVIS JR|Braided coil assist stents used for aneurysm embolization
40950736|NCT02736838|DEVICE|tcpO2|Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.
40950737|NCT02736838|DEVICE|Laser Doppler|
40950738|NCT04948489|DRUG|norethindrone acetate (NETA)|5mg of the NETA capsule by mouth daily for 12 months
40950739|NCT04948489|DRUG|Placebo|Placebo capsule everyday for 12 months
40950740|NCT00810355|BEHAVIORAL|Support Group|General support and problem solving for work activity
40950741|NCT00810355|BEHAVIORAL|Cognitive Behavior Therapy|Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
40950742|NCT00810355|BEHAVIORAL|Cognitive Remediation|Computerized training to enhance cognitive functioning.
41307791|NCT02328989|DEVICE|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
40950743|NCT05202028|OTHER|Reflexology|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
40950744|NCT05202028|OTHER|Connective Tissue Massage|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
40950745|NCT05202028|OTHER|Classic abdominal massage|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
40950746|NCT04746222|BIOLOGICAL|Oral capsule faecal microbiota transplantation|Single dose of 30 oral capsules containing healthy donor stool from a stool bank
40950747|NCT04746222|OTHER|Placebo|Single dose of 30 oral placebo capsules
40950748|NCT04051281|BEHAVIORAL|Letter|Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
40950749|NCT06315374|OTHER|Use soft mist inhaler|Only use soft mist inhaler
40950750|NCT06315374|DEVICE|Use soft mist inhaler with a 3D assistive device|Use soft mist inhaler with a 3D-printed assist device
40950751|NCT00406354|DRUG|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
40950752|NCT00406354|DRUG|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
40950753|NCT00546559|DRUG|statins (simvastatin, pravastatin)|
40950754|NCT05677022|OTHER|Adapted motor activity|15-month adapted motor activity program based on a postural and functional analysis
40950755|NCT00203073|DRUG|glatiramer acetate 20 mg|glatiramer acetate 20 mg
40950756|NCT00203073|DRUG|glatiramer acetate 20 mg, with mitoxantrone|glatiramer acetate 20 mg, with mitoxantrone
40950757|NCT05602350|BEHAVIORAL|Self-administered survey|Subjects will self-administer questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
40950758|NCT05602350|BEHAVIORAL|Enumerator-administered survey|Subjects will have enumerator-administered questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
40950759|NCT00621959|DRUG|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
40950760|NCT00621959|DRUG|placebo|0mg (matching oral tablet)for 14 days
40950761|NCT02194855|DRUG|rocuronium|Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus
40950762|NCT02194855|DRUG|cisatracurium|cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus
40950763|NCT01519154|DRUG|Propofol|Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
40950764|NCT01519154|DRUG|Ketamine-Propofol|Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
40786475|NCT03782064|DRUG|Nivolumab|Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
40950765|NCT02545257|OTHER|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
40950766|NCT04213482|RADIATION|Panoramic Radiography|Diagnostic Panoramic Dental Radiographs were taken.
40950767|NCT03153527|DRUG|Prednisone|The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
41133931|NCT01836159|OTHER|iPad Intervention|"Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total dose received. Patients may receive outpatient rehabilitation as required as part of usual care.~The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:~1. Popping a stationary balloon~2. Popping a moving balloon~3. Popping a pair of stationary balloons~4. Popping a pair of moving balloons~5. Stretching a balloon to pop~6. Balloon/Text distraction test"
41133932|NCT01836159|OTHER|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
41133933|NCT05771857|DEVICE|Obesity|the objective of identifying the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19
41133934|NCT02392507|DRUG|Necitumumab|Administered IV
41133935|NCT02392507|DRUG|Nab-Paclitaxel|Administered IV
41133936|NCT02392507|DRUG|Carboplatin|Administered IV
41133937|NCT05357677|DRUG|SR419|SR419 capsule
40786476|NCT03782064|BIOLOGICAL|DC/myeloma fusions/GM-CSF|The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
40950768|NCT03153527|OTHER|Placebo Arm|The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
40950769|NCT01897714|DRUG|Melflufen|
40950770|NCT01897714|DRUG|Dexamethasone|
40950771|NCT05375708|RADIATION|Stereotactic body radiation therapy (SBRT)|Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.
40950772|NCT05375708|DRUG|Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)|"CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.~5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~When S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks."
40950773|NCT02746172|DEVICE|Cochlear implant with in-situ audiometry|
40950774|NCT05221710|BEHAVIORAL|electroacupuncture|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling).The needle will be kept in place for approximately 30 minutes. The point of acupuncture is determined by a traditional Chinese medicine doctor.~Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points.~On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation in electroacupuncture group."
40950775|NCT03804008|DRUG|Ultrasound-guided corticosteroid injection|A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
40950776|NCT03804008|OTHER|Heavy-slow resistance training|Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. Participants are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.
40950777|NCT03804008|OTHER|Fundamental advice and a silicone heel cup|Participants receive brief information about pathology, risk factors and advice on how to decrease activities that lead to symptom flares and slowly increase their activity level based on their symptoms. They also receive a leaflet that includes the same information as the research assistants will deliver orally after inclusion and a silicone heel cup.
40950778|NCT01825070|DIETARY_SUPPLEMENT|Montmorency cherry concentrate|Tart Montmorency cherry juice concentrate
40950779|NCT06166680|OTHER|Sleep quality assessment|"The following item will be assessed in all subjects (n=420):~1. Sleep, through the Pediatric Sleep Questionnaire."
40786477|NCT05402254|OTHER|Pharmacovigilance Program|Knowledge of the risks in the use of the drug, identification and notification of ADE
40786478|NCT03457077|BEHAVIORAL|Brief intervention|A brief motivational intervention with feedback about drinking levels compared to norms
40786479|NCT06416228|DIETARY_SUPPLEMENT|Beetroot juice|Participants will take on dose in the morning and one in the afternoon, for 7 days during their final academic examinations
40786480|NCT00332618|DEVICE|OXYGENATED GLYCEROL TRIESTERS|
40786481|NCT00276432|DEVICE|iSTAT point of care analyzer|
40786482|NCT03815747|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
40786483|NCT04892030|BEHAVIORAL|Whole Food Plant-Based Behavioral Weight Loss Treatment|Over the course of 12-weeks, participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies through an e-learning platform. Each week, participants will also complete a 15-minute coaching call to provide positive reinforcement and problem-solving support.
40786484|NCT03816787|PROCEDURE|Negative pressure therapy|Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks
40786485|NCT05180513|BEHAVIORAL|Teleconference Mindfulness Intervention|The teleconference intervention is administered by a trained interventionist via Zoom and is based on a manual adapted from a traditional MBSR version. Practices and activities include meditations, mindful breathing exercises and movements, discussions, and reflections, which participants learn at weekly sessions and practice on their own throughout the week. To adapt the traditional MBSR program for the target community population, intervention materials were reviewed for feedback from community stakeholders, and modified according to their feedback.
41288830|NCT01596205|BEHAVIORAL|Conventional cognitive training group|"Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.~In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil."
41288831|NCT04301453|OTHER|Maternal Scent|Mothers will wear a breast pad during their visit. The breast pad will be placed in the hats of infants for 24 hours.
41288832|NCT04837040|DRUG|Paltusotine|Paltusotine, tablets, once daily by mouth
41288833|NCT04837040|DRUG|Placebo|Placebo, tablets, once daily by mouth
41288834|NCT05347446|PROCEDURE|Hybrid ESD|Method of removing colon lesion
41288835|NCT05347446|PROCEDURE|Non-hybrid ESD|Method of removing colon lesion
41288836|NCT06498375|DIAGNOSTIC_TEST|Bioelectrical impedance|Fluid distribution measured by bioelectrical impedance Bodystat Multiscan 5000 Bodystat Ltd, Isle of Man, British Isles
41288837|NCT05581719|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
41288838|NCT05581719|DRUG|Nivolumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
41288839|NCT05581719|DRUG|Tislelizumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
41288840|NCT02247830|OTHER|Chamomilla recutita gel|Such intervention will be characterized by topical application of C. recutita gel, concomitantly to the initiation of radiotherapy, should be applied on the irradiated region three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
41288841|NCT02247830|DRUG|Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
41288842|NCT03576872|OTHER|Psychoeducational|Providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients for chemotherapy
41288843|NCT00251069|DRUG|Glucosamine sulphate|
41288844|NCT02928640|DEVICE|ClariCore System|Data collection to build the prostrate tissue classification algorithm.
41288845|NCT02413515|DRUG|Nifedipine (Adalat GITS, BAY1040)|Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
40760084|NCT06515106|BEHAVIORAL|Remote cognitive rehabilitation program|Behavioral: Remote cognitive rehabilitation program Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
40760085|NCT06571929|OTHER|INTERACT|INTERACT is an individualized, task-specific training program that includes environmental enrichment, natural and augmented realities, and active training.
40760086|NCT01472185|DRUG|Ranolazine|Ranolazine tablets administered orally twice daily.
40760087|NCT01472185|DRUG|Placebo|Placebo to match ranolazine administered orally twice daily.
41288846|NCT02133937|DRUG|gantenerumab|Single subcutaneous injection of a high concentration liquid formulation
41288847|NCT02133937|DRUG|gantenerumab|Single subcutaneous injection of a lyophilized formulation
41288848|NCT00634673|OTHER|sandwich|standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
41288849|NCT02307968|OTHER|insulin injection site|insulin injected site between inner thigh and out thigh
40760088|NCT01472185|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
40760089|NCT01472185|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
40760090|NCT04074837|DRUG|NNI-362|NNI-362 small molecule in liquid suspension.
40760091|NCT04074837|DRUG|Placebo|Placebo liquid suspension
41288850|NCT05376202|DRUG|Cetuximab-IRDye800CW|Patients will receive 75mg Cetuximab followed by 15mg Cetuximab-IRDye800CW two days prior to surgery
41288851|NCT05450055|PROCEDURE|intraperitoneal lidocaine analgesic or normal saline as control|Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
41288852|NCT02420652|DRUG|Aspirin|Given PO
41288853|NCT02420652|OTHER|Laboratory Biomarker Analysis|Correlative studies
41288854|NCT02420652|DRUG|Metformin Hydrochloride|Given PO
41288855|NCT02420652|OTHER|Placebo|Given metformin hydrochloride placebo PO
40950780|NCT06166680|OTHER|Anthropometry|"The following items will be assessed in all subjects (n=420):~2. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate (with the Quick Tongue-Tie assessment tool)"
40950781|NCT06166680|OTHER|Tongue strength assessment|"The following items will be assessed in all subjects (n=420):~3. Tongue pressure (in kPa) exerted against the IOPI (Iowa Oral Performance Instrument) bulb while swallowing.~4. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb) during 3 sec. of tongue elevation.~5. Tongue peak pressure during 3 sec. of tongue protrusion."
40950782|NCT06166680|OTHER|Tongue endurance assessment|"The following items will be assessed in all subjects (n=420):~6. The tongue endurance (i.e., the time to task failure in maintaining a pressure equal to 50%Pmax against the IOPI bulb) during tongue elevation.~7. The tongue endurance during tongue protrusion."
40950783|NCT06166680|OTHER|Orofacial praxis assessment|- The following item will be assessed in a subset of subjects (n=31): 8. Orofacial praxis through the Motricité Bucco-Linguo-Faciale (MBLF) test.
40950784|NCT04948515|DIAGNOSTIC_TEST|laboratory test|genotyping of IL 17 and IL23
40950785|NCT04948515|DIAGNOSTIC_TEST|laboratory test|estimation of serum level of IL 17
40950786|NCT02112344|RADIATION|IMRT|
40950787|NCT02008630|OTHER|Animal-assisted activity|
40950788|NCT02008630|OTHER|Animal-assisted therapy|
40950789|NCT04416659|DEVICE|Neuro-vascular access|Adjunctive device providing a conduit for retrieval device during thrombectomy
40950790|NCT04442412|DRUG|Vitamin D3 (Cholecalciferol)|patients in the Experimental arm (Arm B) will receive also a prephase therapy with VitD and a supplementation of VitD during the intere period of immunochemotherapy according to a prefixed schedule. Choice of type of immunochemotherapy will not rely on Comprehensive Geriatric Assessment (CGA) result, but treatment at reduced doses with R-miniCHOP is highly recommended option for UNFIT and FRAIL patients.
40950791|NCT04442412|DRUG|RCHOP o R-miniCHOP at standard doses|"Patients on both arms receive pre-treatment with prednisone oral before 6 cycles of 21 days each of immunochemotherapy with RCHOP~o R-miniCHOP at standard doses"
40950792|NCT00660673|DRUG|Levodopa-Carbidopa Intestinal Gel (LCIG)|LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
40950793|NCT00660673|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
40950794|NCT00660673|DEVICE|Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)|All participants previously had a PEG-J placed in one of the prior LCIG studies.
40950795|NCT01627483|OTHER|Medication review|Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
40950796|NCT01903031|DEVICE|Nuvaring|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
40760092|NCT00295503|DRUG|bevacizumab|15 mg/kg IV every 3 weeks
40950797|NCT01903031|DRUG|EFV|Participants received EFV 600 mg daily with two or more NRTIs
40950798|NCT01903031|DRUG|ATV/r|Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
40950799|NCT01903031|DRUG|TDF|Participants received 300 mg of tenofovir in Arm C
40950800|NCT01903031|DRUG|NRTIs|Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
40950801|NCT02318875|DIETARY_SUPPLEMENT|Kritech administration|300mg/day (1 capsule) during 12 weeks; oral ingestion
40950802|NCT02318875|OTHER|Placebo adminstration|1 placebo capsule per day during 12 weeks; oral ingestion
40950803|NCT03925311|PROCEDURE|endometrial biopsy and blood sampling|patient will be performed endometrial biopsy and collected blood samples at particular time points
40950804|NCT03403088|DEVICE|Experimental: • Group LA|to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
41454124|NCT04506619|OTHER|No Intervention|This is a non-interventional study.
40760093|NCT00295503|DRUG|cisplatin|75 mg/m2 IV every 3 weeks
40760094|NCT00295503|DRUG|pemetrexed|500 mg/m2 every 3 weeks
40760095|NCT01514279|BEHAVIORAL|HealthyCHANGE|"Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
40760096|NCT01514279|BEHAVIORAL|SystemCHANGE|"Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
40950805|NCT03403088|DEVICE|Placebo Comparator: • Group LA-P|to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
40950806|NCT03403088|OTHER|Experimental: • Group DE|to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
40950807|NCT03403088|OTHER|Placebo Comparator: • Group DE-P|to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
40950808|NCT03403088|OTHER|Experimental: • Group RGI|to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
40950809|NCT03403088|OTHER|Experimental: Group RX|to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity product for 20 seconds.
40950810|NCT01428271|OTHER|Ultrasonography|The confirmation of the real site of the sacral hiatus by ultrasonography
41133938|NCT01708278|DRUG|Quercetin|"COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~1. Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~2. Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~3. Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin"
40760097|NCT00931541|DRUG|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
40760098|NCT00931541|DRUG|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
40760099|NCT00808756|DIETARY_SUPPLEMENT|Fermentable carbohydrates.|Infant formula enriched with fermentable carbohydrates.
40760100|NCT00808756|OTHER|Standard infant formula.|Standard infant formula.
40760101|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks
40760102|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg) and Syrup Orofer (5 ml = 50 mg)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral iron 25 mg from Emcure Pharmaceuticals Ltd. to be administered once daily for 24 weeks
40760103|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg) and Tablet Tayo (60000 IU)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral vitamin D3 (60000 IU) from Eris Lifesciences Ltd to be administered once in 3 months for 24 weeks
40760104|NCT04228731|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total knee arthroplasty
40760105|NCT04228731|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total knee arthroplasty
40760106|NCT00088881|BIOLOGICAL|rituximab|Given IV
40760107|NCT00088881|DRUG|prednisone|Given orally
40760108|NCT00088881|DRUG|cyclophosphamide|Given IV
40760109|NCT00088881|DRUG|doxorubicin|Given IV
40760110|NCT00088881|DRUG|vincristine|Given IV
40760111|NCT00088881|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
40760112|NCT00088881|RADIATION|radiation therapy|Undergo radiotherapy
40760113|NCT00088881|PROCEDURE|positron emission tomography|Undergo PET scans
40760114|NCT02005926|PROCEDURE|Wire-localized abnormal node|Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
40760115|NCT02017834|PROCEDURE|surgical resection|neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
40760116|NCT04216550|DRUG|Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
40760117|NCT00842465|BIOLOGICAL|blood collection for hormonal status analysis|for hormonal status analysis
40760118|NCT00842465|PROCEDURE|breast Biopsy or surgery|breast Biopsy or surgery
40760119|NCT00842465|GENETIC|blood collection|blood collection for prlR gene sequencing
40760120|NCT00842465|OTHER|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
40760121|NCT03141970|DRUG|Prednisolone|Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
40760122|NCT06541587|BEHAVIORAL|mindfulness based virtual reality|mindfulness based virtual reality
40760123|NCT06541587|BEHAVIORAL|mindfulness based audio practice|mindfulness based audio practice
40760124|NCT00814736|DRUG|UK369,003|oral tablet, once a day
40760125|NCT00814736|DRUG|sildenafil|single oral dose on day 14 or day 17
40760126|NCT00814736|DRUG|sildenafil matching placebo|single oral dose on day 14 or day 17
40760127|NCT06413875|OTHER|education|Education Specific to Menopause Symptoms
40760128|NCT00160368|BEHAVIORAL|Potassium supplementation|
40760129|NCT05434702|BEHAVIORAL|Digital Diet Diary|Participants will be asked to complete the Fitbit 3-day food record, which consists of inputting each food and beverage consumed for two weekdays and 1 weekend day into the Fitbit application. This digital diary includes taking photos of each food and beverage consumed during the 3 day food record period on the participant's iphone or ipad.
40760130|NCT05434702|BEHAVIORAL|NHANES Food Frequency Questionnaire (FFQ)|Participants will complete the the Food Frequency questionnaire which indicates usual food intake over the past year.
40760131|NCT05434702|BEHAVIORAL|Fitbit data collection|Participants will be asked to wear a Fitbit continuously (24/7) for one week to track steps and activity intensity. The Fitbit is worn on the wrist and uses accelerometer and heart rate technology to quantify steps taken and integrated barometric altimeter to measure activity intensity. The resulting Fitbit data will be automatically pulled from the participant's smartphone or study device.
40760132|NCT05434702|BEHAVIORAL|Quality of Life questionnaire|The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) includes questions about participant's quality of life during the past week, self-reported general health, self reported chronic conditions and psychological distress using a scale from 1-5, 1=excellent, 5= poor. A lower total score indicates better qualify of life.
40950811|NCT01923831|DRUG|Magnesium Sulfate|Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
41133939|NCT01708278|OTHER|Placebo - sugar chew|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
41133940|NCT00647075|DIETARY_SUPPLEMENT|Yunzhi extract|3.5 g/day
41133941|NCT00647075|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
41133942|NCT04039776|DIAGNOSTIC_TEST|"Cone Beam Computed Tomography (CBCT)"|"Cone Beam Computed Tomography (CBCT), a machine that use a low dose of radiation compared to traditional CT systems, and allows the examination in supine and standing position knee . In this way, for the same patient it will be possible to calculate the bone indexes both in weight-bearing condition and in non-weight-bearing, comparing the values between them, to identify possible differences due to the influence of orthostatism."
40950812|NCT01923831|DRUG|dexamethasone|Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
40950813|NCT02947555|OTHER|Non interventional|
40950814|NCT01871142|DRUG|Placebo|100 mL
40950815|NCT01871142|DRUG|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
40950816|NCT01871142|DRUG|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
40950817|NCT02806531|BIOLOGICAL|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
40950818|NCT05249348|DRUG|PC14586|An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
40950819|NCT00886561|BEHAVIORAL|HIV risk reduction intervention|Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
40950820|NCT03002220|DRUG|radium-223|Radium-223 at a dose of 55 kBq
40950821|NCT01628172|DEVICE|Biosense Webster Celcius Thermacool catheter|catheter-based sympathetic renal denervation
40950822|NCT01050543|DRUG|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
40950823|NCT01050543|DRUG|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
40950824|NCT00762216|DEVICE|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
40950825|NCT03905408|DRUG|50 mL of 50% Glucose|1st dose
40950826|NCT03905408|DRUG|100 mL of 50% Glucose|2nd dose
40950827|NCT03905408|DRUG|150 mL of 50% Glucose|3rd dose
40950828|NCT03905408|DRUG|200 mL of 50% Glucose|4th dose
40950829|NCT04328766|DRUG|DWC202005, alone|DWC202005, as a single dose
40950830|NCT04328766|DRUG|DWP14012 + DWC202005|DWP14012 and DWC202005, as a single dose
40950831|NCT04328766|DRUG|DWP14012 + DWC202005, after multiple doses of DWP14012|DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
40950832|NCT06221462|DRUG|Sintilimab|200mg, every 3 weeks, 3 cycles, in the neoadjuvant setting, and adjuvant 200mg,every 3 weeks no more than one year
40950833|NCT06221462|DRUG|Anlotinib|8mg, orally, D1-14, every 3 weeks, 2 cycles in only neoadjuvant setting
40950834|NCT02606084|DRUG|Esketamine|Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
41133943|NCT05103891|DRUG|Binimetinib Oral Tablet|two-period, crossover study
41133944|NCT05866354|DRUG|Tisotumab Vedotin|Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.
41133945|NCT03339466|DEVICE|Inspiratory muscle therapy|6 weeks of inspiratory muscle therapy
41133946|NCT04921540|PROCEDURE|Ingrown toenails with surgery with chemical cauterisation|Removal of the ingrown lateral part of the toenail and chemical cauterisation
41133947|NCT04921540|PROCEDURE|Ingrown toenails with only surgery|Removal of the ingrown lateral part of the toenail with directed Healing pad
41133948|NCT00797550|BIOLOGICAL|Bone Repair Cells (BRCs)|BRCs will be administered during spine fusion surgery
40950835|NCT06205823|DRUG|Immunotherapy|Immunotherapy
40950836|NCT05072782|DRUG|Infliximab CT-P13|"Stratification 1: Infliximab-CT-P13~Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors"
40950837|NCT05072782|DRUG|Immunosuppressors (Thiopurines or Methotrexate)|"Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose"
40950838|NCT02145585|DEVICE|Test of pharmacologic anesthesia robot (labVIEW® software)|
40950839|NCT02847975|DIETARY_SUPPLEMENT|Sodium nitrate|Sodium nitrate will be ingested orally
40950840|NCT05544812|DRUG|Sintilimab ，bevcizumab/cetuximab，XELOX|"Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W"
40950841|NCT06556810|DRUG|Atibuclimab (IC14)|Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system
40950842|NCT06050369|DEVICE|EEG|Recording, from the scalp, the electrophysiological activity of the brain.
40950843|NCT06050369|DEVICE|MRI|Get the anatomical shape of the brain.
40950844|NCT04849923|OTHER|Strength training session|Conduct of an 8-week strength training intervention of key muscle-tendon groups associated with knee joint stability in the training-specific setting of each participant. Participants are randomly allocated into three study groups with increasing levels of loading (Group#1: no training, Group#2: 1 training per week, Group#3: 3 trainings per week) with the same number of subjects and gender distribution in each group (n=12 per group, 6F and 6M). The same guidelines for the warm-up and the type of exercises will be given prior to the intervention study to each participant. Participants are asked to record exercise load and volume as well as monitor training-related variables and 1RM using the iOS Strength Control app. Participants perform the strength training self-directedly in their chosen fitness/training facilities as it fits into their weekly routine. Contact to the study investigator is ensured at all times in case of questions.
40950845|NCT01206166|DRUG|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
40950846|NCT01373489|BEHAVIORAL|Technology-Assisted Case Management|The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time. Medications are titrated under supervision of a primary care and endocrinology physicians
40950847|NCT05650060|DRUG|Secukinumab|all patients with psoriasis who received secukinumab
40950848|NCT03349931|DIAGNOSTIC_TEST|DNA extraction and detection of Aspergillus fumigatus in serum samples|Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
40950849|NCT01757327|DRUG|Erismodegib|
40950850|NCT01757327|DRUG|Placebo|
40950851|NCT06199778|BEHAVIORAL|Rehabilitation therapy|"1. Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~2. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~3. Others: Regular turning, back patting, and position changes performed by caregivers."
40950852|NCT06199778|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
40950853|NCT06199778|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
40950854|NCT06199778|DRUG|Reserpine|Reserpine was administered to patients to nourish their nerves, with frequency based on their condition.
40950855|NCT06199778|DRUG|Levofloxacin|The levofloxacin was administered to patients as antibiotic treatment, with frequency based on their condition.
40950856|NCT01744184|DRUG|Entonox|Entonox arm
40950857|NCT01744184|DRUG|Midazolam|up to 5mg midazolam as appropriate
41454125|NCT05852873|DRUG|Nirmatrelvir/ritonavir|Participants in the intervention arm will receive a standard 5-day treatment course Paxlovid (nirmatrelvir plus ritonavir) in addition to standard of care.
41454126|NCT05852873|DRUG|Placebo|Participants in the control arm will receive a 5-day course of placebo tablets, with the same appearance and quantity, in addition to standard of care.
40950858|NCT04241250|DEVICE|EAW+SCES (exoskelton and spinal cord epidural stimulation)|Three months of exoskeleton training followed by 6 months of epidural stimulation.
40950859|NCT04241250|DEVICE|EAW+TS (exoskelton and transspinal stimulation)|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
40950860|NCT03540212|DRUG|Daclatasvir and sofosbuvir|"Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2."
40950861|NCT05521620|BEHAVIORAL|The father-friendly NICU|"* Fathers have skin-to-skin contact with their infants~* Fathers participate in important situations~* Fathers receive information and guidance directly~* Both parents participate in meaningful conversations~* The department organize mother and father groups~* The families have the opportunity to have a close family member to support them~* Older siblings have the opportunity to stay overnight.~* The department offer counseling by a social worker"
40950862|NCT01628705|OTHER|Nutritional intervention|"The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.~The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat \<7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber)."
41133949|NCT00797550|PROCEDURE|Autologous bone graft|
41133950|NCT03683615|PROCEDURE|repair of orbital floor fractures using resorbable plates|
40760133|NCT05434702|BEHAVIORAL|Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire|The Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
40950863|NCT01628705|DIETARY_SUPPLEMENT|Green tea|The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
41133951|NCT00824408|DRUG|pemetrexed|500 mg/m\^2 i.v. on day 1 of 21 day cycle
41133952|NCT00824408|DRUG|pemetrexed|500 mg/m\^2 i.v. on day 1 of 21 day cycle
41133953|NCT00824408|DRUG|BI 6727|BI 6727 i.v. on day 1 of a 21 day cycle
41288856|NCT02420652|OTHER|Placebo|Given aspirin placebo PO
41288857|NCT05927909|DIAGNOSTIC_TEST|Low Back Activity Confidence Scale (Lobacs)|Confidence Scale (LOBACS) is a self-report questionnaire designed to assess an individual's level of confidence in performing various physical activities involving the lower back region, to evaluate their perceived functional ability, and to assess the impact of low back pain on their daily life and functional performance.
41288858|NCT06319898|BEHAVIORAL|Lavender aromatherapy sticker|Lavender aromatherapy during procedure, music and dim lighting
41454127|NCT00533156|DEVICE|Vascular access site closure (7F Ensure)|
40950864|NCT01422174|PROCEDURE|Implantable Cardio Defibrillator (ICD),|Standard ICD implantation (as per clinical decision)
40950865|NCT02681783|DRUG|aflibercept|Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).
40950866|NCT00216710|BEHAVIORAL|Home Visiting|
40950867|NCT00156897|DRUG|ATL-962|
40950868|NCT00156897|DRUG|Orlistat|
40950869|NCT03650556|DEVICE|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™|Ablation procedure for Persistent AF
40950870|NCT03025009|DRUG|LY3192767|Administered SC.
40950871|NCT03025009|DRUG|Basal Insulin Peglispro|Administered SC.
40950872|NCT03025009|DRUG|Insulin Glargine|Administered SC.
40950873|NCT03025009|DRUG|Placebo|Administered SC.
40950874|NCT00000432|BEHAVIORAL|Education about disease prevention|
40950875|NCT05613881|OTHER|Education and Telephone Follow-up|The individuals in this group will be given an education and training booklet by the researcher after the pre-tests are applied in the first face-to-face interview. After the first meeting, the individual will be called every 15 days, 5 times in total for 3 months, and the training will be repeated in line with the individual's needs. After 3 months, the final tests will be applied.
40950876|NCT00917501|DRUG|OMega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day
40950877|NCT00917501|DRUG|Placebo|Placebo given twice a day which will be compared to Omega 3
40950878|NCT01549600|DIETARY_SUPPLEMENT|psyllium|1 level tablespoon (\~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
40950879|NCT01549600|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|1 level tablespoon (\~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
40950880|NCT00715455|DRUG|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.
40950881|NCT00715455|DRUG|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.
40950882|NCT00715455|DRUG|Unfractionated Heparin|Heparin will be administered per standard of care at sites
40950883|NCT00100178|DRUG|Mycophenolate mofeteil (MMF)|
41133954|NCT06272526|OTHER|Internet Based Intervention - GUIDED|The experimental group participants will be in treatment through web-based intervention consisting of five to seven weeks. The intervention program will be offered to participants through the website https://kendikendineyardim.org, the online self-help platform in Turkey. Participants will be able to use the system with their e-mail addresses and passwords.The intervention consists of five modules consisting of behavioral, emotional and cognitive content. The modules include text, interactive forms, animated videos, audio recordings, and images. Participants in this arm will receive weekly feedback from guides via the platform's message sending feature.
40950884|NCT00100178|DRUG|Daclizumab (DZB)|
40950885|NCT00100178|DRUG|Placebo control for Mycophenolate mofeteil (MMF)|Placebo pills taken orally
40950886|NCT00100178|DRUG|Placebo control for Daclizumab (DZB)|saline intravenous infusions
40950887|NCT00704678|DRUG|SBR759|1g tid
40950888|NCT00704678|DRUG|Sevelamer HCl|1.6 g tid
40950889|NCT00704678|DRUG|Sevelamer HCl|1.5 g tid
40950890|NCT00704678|DRUG|Sevelamer HCl|0.8 g tid
40950891|NCT05406362|DRUG|VAD044|capsules to be taken once daily for 12 weeks
40950892|NCT00585962|RADIATION|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
40950893|NCT04879628|DRUG|SAR441344 IV|Pharmaceutical form: Solution Route of administration: IV infusion
40950894|NCT04879628|DRUG|placebo IV|Pharmaceutical form: Solution Route of administration: IV infusion
40950895|NCT04879628|DRUG|SAR441344 SC|Pharmaceutical form: Solution Route of administration: SC injection
40950896|NCT04879628|DRUG|placebo SC|Pharmaceutical form: Solution Route of administration: SC injection
41133955|NCT04264884|DRUG|Daratumumab|Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.
40950897|NCT04879628|DRUG|MRI contrast-enhancing preparations|gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem
40950898|NCT02297191|PROCEDURE|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.~1. Ultrasound images will be saved using the nomenclature TLIP Anatomy~2. Photos will only include surface anatomy of the low-to-mid back.~3. Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped."
40950899|NCT02297191|DRUG|Ropivicaine|
40950900|NCT01669499|DRUG|Dexamethasone acetate|
40950901|NCT01669499|DRUG|Placebo|
40950902|NCT02041767|DRUG|Ertapenem|One single injection of 1g of ertapenem before surgery
40950903|NCT00117455|DRUG|pegfilgrastim|
40950904|NCT00117455|DRUG|filgrastim|
40950905|NCT05473208|DEVICE|Exoskeleton|Lumbar assistive exoskeleton evaluation
40950906|NCT02670720|DRUG|avoralstat|
40950907|NCT05235087|DEVICE|Bovine atelocollagen intradermal injection|Intradermal skin test injection
40950908|NCT05648578|OTHER|Reiki attempt|Four reiki sessions were applied twice a week, on the same days of the week, lasting 25-35 minutes each.
41133956|NCT00192959|DRUG|Xenon vs propofol|
41133957|NCT03794232|DIETARY_SUPPLEMENT|NIUCHANG|
41133958|NCT03794232|DIETARY_SUPPLEMENT|Placebo|
40950909|NCT02785315|BEHAVIORAL|rehabilitation & remediation approach|The rehabilitation \& remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
40950910|NCT02785315|BEHAVIORAL|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
40950911|NCT01761864|BEHAVIORAL|academic detailing intervention|
40950912|NCT04450173|DRUG|Ibrutinib|Given PO
40950913|NCT04450173|BIOLOGICAL|Obinutuzumab|Given IV
40950914|NCT04450173|DRUG|Venetoclax|Given PO
40950915|NCT00413244|DRUG|AndroGel 5 Grams|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
40950916|NCT00413244|DRUG|Placebo|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
40950917|NCT01015144|DRUG|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
40950918|NCT05146310|DEVICE|I.SPACE®|"I.SPACE® is a viscoelastic sodium hyaluronate gel use as a surgical aid in ophthalmic anterior segment surgery by maintaining the intraocular space and protecting the corneal endothelium.~The baseline injection is performed at V1. The volume of product to use will be at the Investigator discretion, and will be completely removed after surgery."
40950919|NCT04487106|DRUG|Azacitidine|Given IV or SC
40950920|NCT04487106|DRUG|Trametinib|Given PO
40950921|NCT04487106|DRUG|Venetoclax|Given PO
40950922|NCT05254808|DRUG|Fosfomycin|Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
40950923|NCT05254808|DRUG|Nitrofurantoin|Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
40950924|NCT02249442|DRUG|Tipranavir (TPV)|
41288859|NCT02066090|DEVICE|Real acupuncture|"manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today"
41307792|NCT01422278|OTHER|Rehabilitation|Three weeks of rehabilitation in Hospital.
41307793|NCT03317275|DEVICE|18F-Fluoride-PET/MRI|facet joint injection guided by the anatomical localization of causative structures by PET/MRI compared to standard assessment techniques.
41454128|NCT01170741|BEHAVIORAL|Tailored Cue Cards|The proposed intervention uses education to increase knowledge and skill building to influence behavior-specific self-efficacy and outcome expectations. In addition to providing general information regarding drug use and diseases, the cue-cards include information that is designed to raise awareness regarding perceived threats (perceived susceptibility and perceived severity) related to HIV and other STIs and blood-borne infections, which increases motivation to reduce risk behaviors. The cue-cards also provide information regarding risk reduction strategies. The cue-cards also contain instructions on how to anticipate and avoid risky situations (e.g., using alcohol or drugs prior to sex). This information is augmented with an exercise that involves modeling and guided practice. This combination of information and exercises modifies outcome expectations by increasing confidence (i.e., perceived self-efficacy) that a protective action can be performed
40950925|NCT02249442|DRUG|Ritonavir (r)|
40950926|NCT04489459|DRUG|Colistin|Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h
40950927|NCT04489459|DRUG|Meropenem|Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
40950928|NCT04489459|DRUG|Tigecycline|Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12
41133959|NCT01995214|DRUG|Propofol|Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
41133960|NCT01995214|DRUG|Sevoflurane|Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
41133961|NCT02622698|DIETARY_SUPPLEMENT|Prostat AWC|Prostat AWC- patients received protein supplementation after surgery
41133962|NCT02622698|OTHER|Placebo|Placebo- Patients did not take any protein supplementation after surgery
41133963|NCT01580436|PROCEDURE|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
41133964|NCT05704192|PROCEDURE|TACE ± Systemic therapy|TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
41133965|NCT05364385|DRUG|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
41133966|NCT05364385|DRUG|Infants in the control group (S/P group) receive placebo (Normal saline 1mL)|Infants in the control group (S/P group) will receive surfactant 2.5 mls/kg and placebo (Normal saline 1mL)
41133967|NCT02160600|OTHER|Standard multiphase CT|
41133968|NCT02160600|OTHER|split bolus Dual energy CT|
41133969|NCT04886674|DIETARY_SUPPLEMENT|bovine colostrum|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for \< 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
41133970|NCT01452867|DEVICE|Bag-Valve-Mask-Ventilation (Ambu Facemask)|Bag-Valve Mask-Ventilation
41133971|NCT01452867|DEVICE|Laryngeal Mask (Laryngeal Mask Airway Supreme)|Ventilation
41133972|NCT01452867|DEVICE|Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))|Ventilation
41133973|NCT02085512|PROCEDURE|Neurocognitive retraining Web Based Intervention|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
41133974|NCT02085512|OTHER|Control, web-based tasks|No training modules
41133975|NCT00831506|DRUG|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
41133976|NCT00831506|DRUG|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
41288860|NCT02066090|DEVICE|Sham acupuncture|"sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)"
41288861|NCT04323189|DRUG|Sitagliptin 100mg|Sitagliptin will be administered daily for 7 days, with a study day on day 7.
41288862|NCT04323189|DRUG|Placebo Oral Tablet|Placebo will be administered daily for 7 days, with a study day on day 7.
40950929|NCT05476458|RADIATION|White Light Imaging|white light imaging is often the preferred option for poem surgery due to its effective results. However, it also comes with some drawbacks that make it difficult to identify areas of bleeding, unlike RDI, WLI cannot enhance the visibility of deep vessels This can lead to longer haemostasis time as the physician must wait for a longer period before stopping the bleeding. This can make it challenging as it may lead to excessive bleeding. This makes RDI a potential solution for those seeking a more accurate approach to treatment.
40950930|NCT05476458|RADIATION|Red Light Imaging|Red dichromatic imaging (RDI) is a next-generation image enhancement technique which works by employing green, amber and red wavelengths. Greenlight(520-550nm) can visualize small blood vessels in superficial tissue without extending deep into the mucosa. Amber(595-610nm) and red light (620-640nm) can penetrate deep into the tissue owing to low scattering property. The blood vessels in the deeper tissues absorb the amber light because of strong affinity with hemoglobin. Even though red light can penetrate deep into the tissue, it is weakly absorbed by hemoglobin. Hence the reflected light contains red light and amber light without attenuation.
41288863|NCT02247206|BEHAVIORAL|Behavior Therapy for Tics (CBIT)|CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
41288864|NCT05980000|DRUG|Ramucirumab|Ramucirumab is administered at a dose of 10 mg/kg over 60 minutes.
41454129|NCT00870935|PROCEDURE|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
41454130|NCT00870935|PROCEDURE|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
41454131|NCT03255733|DEVICE|Intense Therapeutic Ultrasound Treatment|
40786486|NCT05180513|BEHAVIORAL|Smartphone App Mindfulness Intervention|The smartphone app intervention is administered through the app. The smartphone app aligns with the traditional MBSR format, but training and practice is done individually and independently by members of this group. To adapt the traditional MBSR program for the target community population, the app was tested by community stakeholders and modified according to their feedback.
40786487|NCT06547034|DEVICE|Ultrasound|Breast Ultrasound
40950931|NCT04099628|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT); Serological and molecular tests on DBS|"The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.~Other Names:~rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)"
40950932|NCT03584100|DEVICE|Tourniquet 8000|Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure
40950933|NCT05737849|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
41133977|NCT00831506|DRUG|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
41133978|NCT00606333|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
41133979|NCT00606333|DEVICE|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
40786488|NCT02438033|DEVICE|Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator|Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
40786489|NCT02700438|DRUG|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
40950934|NCT04852770|BEHAVIORAL|Trial-Based Cognitive Therapy|TBCT is an approach that includes psychoeducation and cognitive restructuring techniques concerning automatic thoughts, underlying assumptions and core beliefs related to the traumatic events. It is conducted in a therapeutic setting that makes use of experiential techniques, allowing the patient to refer to him/herself in the third person and thus taking distance from him or herself. One of TBCT techniques for dealing with guilt and shame, emotions that provoke great limitation to patients with PTSD, is the participation grid (PG). Another important technique is the consensual role-play (CRP), designed to help patients resolve ambivalence and make decisions. In addition, the most important TBCT technique, the Trial, was developed to help patients change dysfunctional negative core beliefs. Therapists who will conduct this approach have a specialization level in CBT. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
40950935|NCT04852770|BEHAVIORAL|Mindfulness-Based Health Promotion|"The MBHP protocol is a structured program developed over 8 sessions, in group, where participants (8-15 people) meet every week for 2 hours (standard duration of one session), to experience the concepts and techniques of mindfulness. Participants are also given suggestions of daily activities to be implemented at home or in the workplace, that last in average 15-20 minutes, but may last up to 45 minutes in the case of more motivated and compliant participants. They are also encouraged to incorporate the idea of Mindfulness in their daily lives (the so-called informal practice), so that all daily activities somehow become opportunities to practice Mindfulness. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line."
40950936|NCT04852770|BEHAVIORAL|Positive psychotherapy|PPT is the clinical and therapeutic work derived from PP. PPT consists of 15 specific practices that have been empirically validated, either separately, or in conjunction with two or three practices. After empirical validation, these practices were organized in a cohesive protocol of 15 sessions called PPT. Many of these practices have been studied through online interventions. In the present study, the protocol will be reduced to 14 sessions, with sessions called positive relationships, positive communication, and practical wisdom removed. It was understood that the other 12 would be more easily adapted to the moment of the study. (DUCKWORTH; STEEN; SELIGMAN, 2005; MONGRAIN; ANSELMO-MATTHEWS, 2012; RASHID; SELIGMAN, 2019). In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
40950937|NCT05744011|OTHER|Tango intervention|"The interventions will be implemented by ABB Reportages and will be carried out by nursing staff who had previously received training in therapeutic tango at the University of Burgundy.~A dance movement therapist and a musician will accompany the interventions twice a month.~Participants will attend a 1-hour tango session, twice a week for twelve weeks."
40950938|NCT05744011|OTHER|Adapted Physical Activity|"The intervention will be carried out by an Adapted Physical Activity professor and by nursing staff.~Music is prohibited during the sessions. Participants will attend a 1-hour APA, twice a week for twelve weeks."
40950939|NCT06232694|DRUG|Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;|Induction Phase Regimen
40950940|NCT06232694|DRUG|Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;|Consolidation therapy after remission
40950941|NCT06232694|OTHER|utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).|Four cycles in total.Patients who meet the criteria for autologous stem cell transplantation (ASCT) during the treatment process can undergo ASCT.Patients who meet the transplantation criteria and have a suitable donor can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
40950942|NCT03451266|DRUG|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
40950943|NCT03451266|DRUG|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
40950944|NCT03281707|PROCEDURE|NIRS|NIRS devices patch will be applied on patients' head in order to measure the cerebral saturation of each cerebral emisphere
40950945|NCT03281707|OTHER|DO2i|Oxygen delivery standardized to the body surface area will be calculate in order to optimize tissue perfusion
40950946|NCT02739165|DRUG|ART-123|380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
40950947|NCT02739165|DRUG|Placebo|Placebo by intravenous drip infusion in addition to standard of care steroid therapy
41133980|NCT03863405|DRUG|Metformin|metformin 850 mg bid for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
41133981|NCT03863405|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
41133982|NCT03863405|DRUG|Placebo Oral Tablet|oral tablet
40760134|NCT05434702|BEHAVIORAL|Godin Exercise Leisure-Time questionnaire|The Godin Exercise Leisure-Time questionnaire measures the frequency of strenuous, moderate, and mild exercise for periods of 15 minutes or more during the participant's free time throughout a typical week. The scoring using the formula leisure score index (LSI) which is obtained using the following formula: (frequency of mild × 3) + (frequency of moderate × 5) + (frequency of strenuous × 9).
40760135|NCT05434702|BEHAVIORAL|Zoom interviews|A subset of 30 participants (10 African American, 10 Hispanic, 10 non-Hispanic white) will participate in semi-structured interviews to explore (a) sociocultural, environmental, and individual factors associated with lifestyle behaviors; (b) awareness of American Cancer Society (ACS) guidelines, current practices, and essential intervention modules (ex. integrating cultural foods and preferences) to provide study team with information needed to develop healthy behavior interventions for young adult cancer survivors.
41133983|NCT04819698|OTHER|Troponin I (cTnI ) monitoring|cTnI will be measured at baseline prior to surgery, as well as on 1h,12h, 24h and 72h after surgery for each patient in study B.
41288865|NCT05980000|DRUG|Pembrolizumab|Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.
40950948|NCT04354142|DEVICE|iSpy|iSpy is a novel healthcare application that hopes to address an important clinical need by facilitating carbohydrate counting using pictures or voice recognition. Proprietary algorithms adjust for portion size and identify hidden carbohydrates (such as in ketchup or other condiments) and quantify the amount of carbohydrates in a meal.
40950949|NCT00397215|BIOLOGICAL|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
40950950|NCT00397215|BIOLOGICAL|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
40950951|NCT05192473|DEVICE|Pulse Intravascular Lithotripsy System|Treatment with Pulse Intravascular Lithotripsy System
40950952|NCT04500730|DRUG|Shaoyao Gancao Decoction Jiawei|"Study herb will be prescribed for 28 consecutive days. Study follow up will be offered every 7 days till 56th day after enrolment.~Daily leg cramps log will be filled in by each individual everyday from day 0 to day 56."
40950953|NCT00122096|DRUG|valdecoxib|
40950954|NCT03403374|DRUG|evolocumab|Administered by SC injection via autoinjector (AI)/pen
40950955|NCT06419621|DRUG|PM8002|PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle
40950956|NCT06419621|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
40950957|NCT06419621|DRUG|Placebo|Placebo 20 mg/kg via IV infusion on Days 1 and 15 of each 28-day cycle
40950958|NCT01431131|PROCEDURE|Intrasocket graft|Intrasocket mineralized cancellous allograft
41288866|NCT00597558|DRUG|Egg white protein|Egg white protein powder
41288867|NCT03033108|DRUG|Emixustat|Once daily, tablet for oral administration
41288868|NCT00683189|DRUG|Warfarin|Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
40950959|NCT01431131|PROCEDURE|Intrasocket plus facial overlay graft|Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
40950960|NCT01582568|DRUG|Certolizumab|Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
40950961|NCT00611507|DRUG|Oxaliplatin, 5-Fluorouracil|5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
40950962|NCT03529812|BEHAVIORAL|CBCT-informed training|Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
40950963|NCT00332878|BEHAVIORAL|Stepping Stones|a comprehensive sexual and reproductive health promotion programme lasting about 50 hours comprising 13 content sessions of about 3 hours duration and 4 meetings of peer groups
41288869|NCT04971811|OTHER|Snack with energy density less than 1.5 kcal/g|Snack meal with snack food having energy density less than 1.5 kcal/g
41288870|NCT04971811|OTHER|Snack with energy density greater than 1.5 kcal/g|Snack meal with snack food having energy density greater than 1.5 kcal/g
41288871|NCT01370954|OTHER|CerefolinNAC®|CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
41288872|NCT02189330|DRUG|Tafamidis|20 mg of current commercial formulation.
41288873|NCT02189330|DRUG|Tafamidis|12.2 mgA free acid tablet.
40950964|NCT00332878|BEHAVIORAL|stepping Stones short|3 hour intervention on HIV and safer sex
40950965|NCT00245661|DRUG|Temazepam|
40950966|NCT02328183|DRUG|Polymyxin B|administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
40950967|NCT05540444|DEVICE|RadConnect|"The study will be performed in a clinical setting at the department of radiology of LUMC, meaning that we aim to test the hypothesis that (RadConnect) can reduce the number of phone calls from a select set of extension used by technologists (the Sending Extensions) to another select set of extensions manned by radiologists (Receiving Extensions)."
40950968|NCT02248831|DEVICE|Recording Doppler ultrasound signals noninvasively|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
40950969|NCT01157923|DEVICE|MD Logic Pump Advisor|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
40950970|NCT02536651|PROCEDURE|Ankle surgery|Plastic or orthopedic surgery of the ankle
41288874|NCT02189330|DRUG|Tafamidis|20 mg new soft gelatin capsule.
41288875|NCT02189330|DRUG|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
41288876|NCT02189330|DRUG|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
41288877|NCT06213701|DEVICE|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
41288878|NCT06213701|OTHER|Psychoeducation app|Psychoeducation app
41307794|NCT03317275|PROCEDURE|facet injection|facet joint local anesthetic and corticosteroid injection according to the 18F-Fluoride-PET/MRI result or based on current standard clinical practise (MRI and clinical correlation) respectively
40950971|NCT03429660|OTHER|Medical information|"The information collected are about :~* Introduction or non-introduction of treatment~* Cumulative dose of treatment~* Drug dispensation and withdrawal~* Hospitalization reason~* Safety information~* Demographic data (date of death)"
40950972|NCT02520830|DIETARY_SUPPLEMENT|Blueberry Group|22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
40950973|NCT02520830|DIETARY_SUPPLEMENT|Placebo Group|Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
40950974|NCT04523948|BEHAVIORAL|Behavioral and pharmacological support to reduce combustible tobacco use.|Behavioral and pharmacological support to reduce combustible tobacco use.
40950975|NCT05807230|BEHAVIORAL|Three-level network rehabilitation services within the medical alliance|Data of all levels of medical and health institutions in Huzhou region are shared, and advanced rehabilitation technologies are passed down from senior hospitals to grassroots medical institutions. Grassroots medical institutions to patients home for 3 months of rehabilitation training.
40950976|NCT02856698|DRUG|Midazolam|Dose use according to the product technical sheet
40950977|NCT02856698|DRUG|Morphine|Dose use according to the product technical sheet
40950978|NCT00281307|DRUG|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
40950979|NCT01554085|DRUG|ALS-002158|ALS-002158
40950980|NCT01554085|DRUG|Placebo|placebo
40950981|NCT00003962|BIOLOGICAL|aldesleukin|
40950982|NCT06354062|BEHAVIORAL|Talent management intervention program|Talent management intervention program
40950983|NCT02423109|DEVICE|fanfilcon A|contact lens
40950984|NCT02423109|DEVICE|enfilcon A|contact lens
40950985|NCT00551447|DRUG|MK0653, ezetimibe / Duration of Treatment: 27 Weeks|
40950986|NCT00551447|DRUG|MK0733, simvastatin / Duration of Treatment: 27 Weeks|
40950987|NCT00551447|DRUG|Comparator: simvastatin / Duration of Treatment: 27 Weeks|
40950988|NCT01191411|OTHER|Mailed invitations for FIT test kits|Mailed invitations for the non-invasive immunochemical stool blood test will be the intervention compared to the standard care at John Peter Smith Hospital. Patients will be invited to complete a free home-based, non-invasive immunochemical stool blood test.
40950989|NCT01191411|OTHER|Mailed invitations for a colonoscopy|These patients will be mailed invitations to directly book a free colonoscopy, or to see a physician for free pre-operative screening at John Peter Smith Hospital.
40950990|NCT01191411|OTHER|Visit Based Care|Visit based standard care at John Peter Smith Hospital. Patients will continue to see their regular physician and follow the physician's recommendations as they normally would.
40950991|NCT04131725|DEVICE|Cardiac Performance System (NSR)|Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
40950992|NCT03939754|BEHAVIORAL|Dedalo project|Physical activity, healthy food, socialization and mental activity promotion
40950993|NCT03439059|BEHAVIORAL|Reducing Sedentary Behaviour Group|Participants will be prompted to perform 10min of light physical activity (\>1.5 METS) 3x/day for 6 weeks
40950994|NCT01181908|DRUG|single dose|Subjects will receive a single dose of GSK1144814 or placebo.
40950995|NCT00000503|DRUG|nitroglycerin|
40950996|NCT00000503|DRUG|streptokinase|
40950997|NCT00000503|PROCEDURE|heart catheterization|
40950998|NCT01982565|DEVICE|NOx dressing|The NOx dressing should be changed at least every 2 days.
40950999|NCT01982565|OTHER|Standard of Care|The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
40951000|NCT00446056|DRUG|MK0476, montelukast sodium / Duration of Treatment: 4 Weeks|
41133984|NCT05281081|DRUG|intraperitoneal levobupivacaine and morphine|istillation of the peritoneum with levobupivacaine mixture with morphine
41133985|NCT06510764|OTHER|intradermal needles|Disposable intradermal needles will be used for acupoint stimulation and Tai Chong, Taixi, Sanyinjiao, Hegu as well as Yanglingquan are chosed for acupuncture point. Acupuncture point pressure will last for 10 minutes each time, three times per day, and the intradermal needles will be changed every 2 days.
41133986|NCT06510764|DRUG|Ziyinxiehuo Granules of tradional Chinese Medicine|Ziyinxiehuo Granules of tradional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.
40951001|NCT00446056|DRUG|Comparator: ketotifen / Duration of Treatment: 4 Weeks|
40951002|NCT03646825|DIETARY_SUPPLEMENT|Natural Antioxidant supplement|1 capsule orally three times a day for 12 weeks
40951003|NCT02505295|DIETARY_SUPPLEMENT|Selenium|4 vials selenase stat and 2 vials daily for 5 days
40951004|NCT02505295|DRUG|normal saline|Normal saline infusion like intervention group
41133987|NCT05193526|OTHER|No intervention|No intervention
41133988|NCT06509022|DIAGNOSTIC_TEST|PEPTEST test|Quantitative determination of gastric salivary amylase。
41133989|NCT00057499|BIOLOGICAL|IBC-VS01|IBC-VS01
41133990|NCT00057499|BIOLOGICAL|IBC-VS01 placebo|IBC-VS01 placebo
41133991|NCT01077700|DRUG|ABT-288 Low Dose|
41133992|NCT01077700|DRUG|Placebo|inactive substance
41133993|NCT01077700|DRUG|ABT-288 High Dose|
41133994|NCT02384382|DRUG|Enzalutamide|
41133995|NCT00655824|DRUG|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
41133996|NCT04422392|DRUG|Carboplatin|(IV, Q3W)
41133997|NCT04422392|DRUG|Pemetrexed or Nab-paclitaxel|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
41133998|NCT04422392|DRUG|PD-1 antibody|(IV, Q3W)
40951005|NCT05455268|OTHER|eHOPE|"e-Haematological Oncology Parents Education (eHOPE) consists of caregiving information for parents of children with leukaemia and lymphoma, presented in multimedia format through an online learning platform. The contents are developed in Malay language, encompassing basic information on disease and treatment, medical caregiving, emotional caregiving, appraising information, communication and self-care. Parents will be able to access multimedia information designed to support them in the care of their sick child. There are 4 self-paced activities in eHOPE with the following objectives:~1. Parents should be able to outline key tasks related to care for their child at home.~2. Parents should be able to outline strategies to initiate discussions with their child's healthcare providers.~3. Parents should be able to appraise reliability of information sources.~4. Parents should be able to identify coping strategies that they can use when faced with stressful situations."
40951006|NCT05455268|OTHER|Usual care|Face-to-face verbal discussions and caregiver training will be provided as deemed necessary by the clinicians.
41454132|NCT04544800|DEVICE|Use of Splint for UADT Visualization|The use of a splint to assist the patient and the surgeon with UADT procedures.
41454133|NCT01635582|OTHER|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
41454134|NCT01635582|OTHER|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
40951007|NCT06330545|RADIATION|Radiation therapy|Patients with Dupuytren's Contacture will undergo Collagenase Clostridium Histolyticum injection and release followed by two 5-day courses of radiation therapy separated by 6-8 weeks. They will then be followed for 3 years for recurrence.
40951008|NCT01581710|DRUG|Montelukast to placebo|Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
40951009|NCT01581710|DRUG|Placebo to montelukast|Subjects will receive matching placebo. Each treatment period consists of 2 weeks
41133999|NCT03080805|DRUG|Pyrotinib Plus Capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/ m\^2 BID)
41134000|NCT03080805|DRUG|Lapatinib Plus Capecitabine|Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
41134001|NCT05421572|DIAGNOSTIC_TEST|Fibrotouch|Fibrotouch will be performed showing the stiffness and fat content of liver
41134002|NCT03170050|DEVICE|YYD701-2|HA Filler
41134003|NCT03170050|DEVICE|Restylane Perlane Lidocaine|HA Filler
41134004|NCT02000752|DEVICE|Acupuncture|
41134005|NCT02000752|DEVICE|Sham acupuncture|Sham point acupuncture
41134006|NCT01271244|DRUG|Escitalopram|10-20mg daily for 12 weeks
41134007|NCT00229970|DRUG|montelukast sodium|7 mg or 14 mg single injection
41134008|NCT00229970|DRUG|Comparator: Placebo|Placebo single injection
41134009|NCT02342652|DRUG|ASLAN003|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
41134010|NCT02342652|DRUG|Matched Placebo|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
41134011|NCT01049516|BEHAVIORAL|Prolonged Exposure Therapy - Massed|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
41134012|NCT01049516|BEHAVIORAL|Prolonged Exposure Therapy - Spaced|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
41134013|NCT01049516|BEHAVIORAL|Minimal Contact Control|Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
41134014|NCT01049516|BEHAVIORAL|Present-Centered Therapy|10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
41134015|NCT05059106|BIOLOGICAL|Half dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.
41454135|NCT03578822|DRUG|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
41454136|NCT03578822|DRUG|Aspirin|Aspirin 300mg is taken orally at the beginning of thrombolysis.
41454137|NCT03578822|DRUG|rhPro-UK simulation agent|Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
40951010|NCT03023449|DRUG|Nitric Oxide|Inhaled Nitric Oxide gas
40951011|NCT04396665|BEHAVIORAL|Precam|6 months Web-App intervention related with: diet, physical activity, self-care and breast cacner risk prevention
40951012|NCT00375037|BEHAVIORAL|feedback|
40951013|NCT00375037|BEHAVIORAL|Education|
41134016|NCT05059106|BIOLOGICAL|Standard dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.
41134017|NCT04007705|BEHAVIORAL|Anti-inflammatory and low FODMAPs diet|Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
41134018|NCT04007705|BEHAVIORAL|General healthy eating|Healthy eating counseling according to the World Health Organization
41134019|NCT04760678|OTHER|Observational study|No intervention (observational study in human participants)
41134020|NCT03041155|BEHAVIORAL|Muscle respiratory training|Muscle respiratory training during hemodialysis sessions
41134021|NCT00219466|OTHER|Zinc Oxide Diaper Rash Ointment|Desitin Original at diaper change
41134022|NCT00219466|OTHER|Aloe Vera/Tocopherol/Zinc Oxide Cream|Desitin Creamy at diaper change
41134023|NCT06124170|PROCEDURE|Preoperative pain managment|propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery
41134024|NCT06124170|PROCEDURE|Intraoperative pain managment|Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;
41134025|NCT06124170|PROCEDURE|Postoperative pain managment|The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡
40951014|NCT00375037|OTHER|usual care|
40951015|NCT00325702|BEHAVIORAL|community-level intervention for young MSM|The community-level intervention includes small media in the form of role model stories, peer outreach and web-based intervention
40951016|NCT05656508|BIOLOGICAL|ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)|2 doses of vaccine with an interval between doses of 28 days. Administration route: Intramuscular (IM) injection
40951017|NCT05466929|BEHAVIORAL|TeACH System Resources|Patients who screen positive for anxiety will receive psychoeducation and mental health recommendations (e.g., evidence-based apps) selected for use with the TeACH System through a collaborative, stakeholder-engaged approach completed in phases 1 and 2 of this project.
40951018|NCT01488305|DIETARY_SUPPLEMENT|MNP (micro-nutrient powders)|MNP is added to explore the additional value of MNP in existing AAMA program
40951019|NCT01488305|OTHER|AAMA project activities (HFP and IYCF BCC)|This is the existing AAMA program
40951020|NCT01800396|DIETARY_SUPPLEMENT|Milk protein|
40951021|NCT01800396|DIETARY_SUPPLEMENT|Milk protein rich in phospholipids|
41307795|NCT03317275|OTHER|pain assessment by VAS|VAS questionnaire immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
40951022|NCT03382275|DRUG|Iron Supplement|any oral or intravenous prescription iron supplement
40951023|NCT03395392|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
40951024|NCT03395392|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
40951025|NCT02759497|OTHER|serum amyloid A level|serum amyloid A level (SAA)
40951026|NCT02027519|OTHER|HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation|"Partners of the index participants and other household members will be offered HIV self-testing by the mobile testing team. Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:~* Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results~  * Self-administer HIV rapid test and read test results~ * Provide study staff with self-testing result~ * Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance"
40951027|NCT04783038|OTHER|Distance Reiki|Reiki therapy session performed remotely over a Zoom® video conferencing platform led by Reiki Practitioners who are also Health Care Providers at the Mayo Clinic, and have at least 6 months of experience in Reiki.
40951028|NCT04783038|OTHER|Sham distance Reiki|Session performed remotely over a Zoom® video conferencing platform led by a Health Care Provider employed at the Mayo Clinic, but will have no experience in Reiki and will not be a certified Reiki Practitioner.
40951029|NCT03369470|BEHAVIORAL|App Dexterity|App based dexterity training by means of Finger Zirkus (see for more details: www.fingers-in-motion.de)
40951030|NCT03369470|BEHAVIORAL|Theraband|Active control being five traditional hand strengthening (Thera-band) exercises, which we published in our previous RCT, being feasible and effective in improving dexterity (for more details see for Kamm et al. 2015).
40951031|NCT02340507|OTHER|Rice and bread (high GI)|Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
40951032|NCT02340507|OTHER|Rice and bread (low GI)|Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
40951033|NCT00645749|BIOLOGICAL|Helminth ova|2500 ova per dose (liquid form)
40951034|NCT04687384|PROCEDURE|Robotic-assisted colectomy|Robotic-assisted colectomy performed by usage of da Vinci Xi robotic technology
40951035|NCT04687384|PROCEDURE|Conventional laparoscopic colectomy|Conventional laparoscopic colectomy
40951036|NCT02656914|DRUG|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
40951037|NCT02656914|DRUG|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
40951038|NCT06285331|DEVICE|Automatic Bed|The automatic bed is controlled by a screen and allows clinicians to perform passive leg raising on patients without touching them physically.
40951039|NCT06285331|DEVICE|Manual|The clinicians will perform passive leg raising on patients by touching their legs physically.
40951040|NCT01349231|DRUG|ketamine|Ketamine (a single 0.5mg intravenously over 40 minutes).
40951041|NCT02848170|DRUG|CS-3150|CS-3150 2.5mg, oral
40951042|NCT02848170|DRUG|olmesartan medoxomil|olmesartan medoxomil 10 mg, oral
40951043|NCT05381844|OTHER|Blood sampling|30 ml blood sampling for virological research
40951044|NCT00005673|DRUG|Capravirine|
40951045|NCT01229826|RADIATION|MR Elastography|MRE is performed at the end of the examination after the standard MRI protocol. A test vibration is first applied on the patient to familiarize the patient with the vibration. The MRE sequence is performed with either a body coil or a pelvic-array coil. The total acquisition time is split into four periods of suspended respiration of 16 seconds for acquisition of wave images at four phase offsets. To obtain a consistent position of the fibroid for each phase offset, patients are asked to quietly breath and remain still.
40951046|NCT00112008|DRUG|De Novo Administration of Darbepoetin Alfa|Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
40951047|NCT04639531|BEHAVIORAL|Orientation and Mobility Training with VR-IOMSs|Learning Orientation and Mobility skills from virtual-reality-based, automated, intelligent computer training programs - VR-IOMSs
40951048|NCT04639531|BEHAVIORAL|Orientation and Mobility Training with COMS|Learning Orientation and Mobility skills from human Certified Orientation and Mobility Specialists (COMS)
40951049|NCT04639531|BEHAVIORAL|No Orientation and Mobility Training|No Orientation and Mobility training. Watch low vision education videos and discuss low vision issues not related to O\&M with COMS
40951050|NCT05464550|BEHAVIORAL|Eye tracker|Eye movements on a screen are captured with an eye tracker during a repeated measures before/after a directed autobiographical recall.
41307796|NCT05342584|DRUG|Venetoclax Oral Tablet|Given PO
41307797|NCT05342584|DRUG|Daunorubicin|Given IV
41307798|NCT05342584|DRUG|Cytarabine|Given IV
40786490|NCT02700438|PROCEDURE|Urgent PC Neuromodulation System®|Subjects underwent one 30-min session of percutaneous posterior tibial nerve stimulation 2 days per week for 8 consecutive weeks in an outpatient clinic, with a Urgent PC Neuromodulation System®. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion.
40786491|NCT00041340|DRUG|imatinib mesylate|Given orally
40786492|NCT00041340|OTHER|laboratory biomarker analysis|Correlative studies
40760136|NCT01808170|PROCEDURE|Laparoscopic ovarian cystectomy|will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.
40786493|NCT04478903|OTHER|Questionnaire|Zarit Burden Inventory French version and SF12
40951051|NCT00745940|BEHAVIORAL|MBCT for TBI|Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
41454138|NCT03578822|DRUG|Aspirin simulation agent|Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
40951052|NCT06266689|BEHAVIORAL|Personalized Diet Information|These participants will receive a report detailing their genomic food data based on the investigators' DNA metabarcoding technique in addition to standard dietary guidance to see if receiving the report modifies what they choose to feed their infant.
40951053|NCT06397833|DEVICE|Acorai ICPM system|Patient will have the handheld Acorai ICPM system placed on their chest, for a period of 5 minutes for sensor recording time
41454139|NCT00003357|BIOLOGICAL|GM2-KLH vaccine|
41454140|NCT00003357|BIOLOGICAL|QS21|
41288879|NCT02396407|BEHAVIORAL|Combined water, sanitation, and hygiene|"Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.~Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.~Handwashing: Handwashing stations including soapy water bottles and detergent soap.~Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children \< 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces."
41288880|NCT00180115|DRUG|Cytarabine Dosage|
41288881|NCT03114969|DEVICE|Relvar ELLIPTA|ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.
41288882|NCT03114969|DEVICE|Symbicort TURBUHALER|TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.
41288883|NCT03114969|DEVICE|Seretide DISKUS|DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.
41288884|NCT03114969|DEVICE|Spiriva HANDIHALER|HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.
41288885|NCT03114969|DEVICE|BREEZHALER|BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.
40951054|NCT02600065|OTHER|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
40951055|NCT04859673|DEVICE|radial extracorpeal shock wave|Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
40951056|NCT01706978|PROCEDURE|Bone Trephination|
40951057|NCT01706978|PROCEDURE|Soft Tissue Trephination|
41134026|NCT02647333|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
41134027|NCT02647333|DIETARY_SUPPLEMENT|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
41134028|NCT00974805|DRUG|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
41134029|NCT00853606|DRUG|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
41134030|NCT04365959|PROCEDURE|Prone position|The objective of the study is to value the ability of the prone position to increase the oxygenation of the patient with SARS-cov-2 pneumonia as a lung recruitment index; the PP also prevents the need for intubation and the consequent risk deriving from the procedure itself and from the predisposition to develop superinfections (VAP).
41134031|NCT02542943|DEVICE|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
41134032|NCT02542943|DEVICE|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
41134033|NCT02542943|OTHER|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
41134034|NCT02542943|DRUG|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
41134035|NCT04602949|DIAGNOSTIC_TEST|Breath Biopsy Analysis|Analysis of a single breath Biopsy
41134036|NCT01632956|BEHAVIORAL|in-person support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
41134037|NCT01632956|BEHAVIORAL|virtual support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
41288886|NCT03114969|DEVICE|Incruse ELLIPTA|ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.
41288887|NCT03114969|DEVICE|Anoro ELLIPTA|ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
41288888|NCT01787591|OTHER|Fat-Free Milk|Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
41288889|NCT01787591|OTHER|Low-Fat Milk|Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
41288890|NCT01787591|OTHER|Full-Fat Milk|Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
41134038|NCT04114019|DIAGNOSTIC_TEST|Vaginal tactile imager|Vaginal elasticity evaluation using a vaginal tactile imager
41134039|NCT01278914|BIOLOGICAL|Dendritic Cells (DC) prostate|
41134040|NCT00047385|DEVICE|low-dose helical computed tomography|A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.
41134041|NCT00047385|DEVICE|chest radiography|The chest x-ray in this study was a single posterior-anterior film done with the participant upright.
41288891|NCT01787591|OTHER|Soy Milk|Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
41288892|NCT02796989|DIETARY_SUPPLEMENT|Wheat bran|20 g each day
41288893|NCT02796989|DIETARY_SUPPLEMENT|Placebo|20 g each day
41288894|NCT00856752|DRUG|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
41288895|NCT00856752|DRUG|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
41288896|NCT00856752|DRUG|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
41288897|NCT01944215|DIETARY_SUPPLEMENT|Meal|effect of meal
41288898|NCT01944215|OTHER|Exercise|effect of exercise
41288899|NCT01944215|RADIATION|Sestamibi|reduce radiation dose
40760137|NCT01808170|PROCEDURE|laparoscopic cyst deroofing|will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
40760138|NCT05973045|PROCEDURE|Operative Hysteroscopy 24 Centigrade Degree|Operative hysteroscopy will be performed at room temperature distention medium.
41288900|NCT01944215|DRUG|Caffeine Tablet|effect of caffeine
41288901|NCT01944215|OTHER|External Heating|Heating Pad and warm blanket robe
41288902|NCT01964365|DRUG|Cresto 20mg|tablet, rosuvastatin 20mg
40760139|NCT05973045|PROCEDURE|Operative Hysteroscopy 37 Centigrade Degree|Operative hysteroscopy will be performed using a heated distention medium.
40760140|NCT02621853|DEVICE|Raman spectroscopy of the liver|Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
41288903|NCT01964365|DRUG|Fenofibric acid 135mg|capsule, fenofibric acid 135mg
41288904|NCT01964365|DRUG|Cresto 20mg, Fenofibric acid 135mg|rosuvastatin 20mg, Fenofibric acid 135mg
41288905|NCT02803372|OTHER|Goal-directed circulatory management|In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP \> 95 mmHg, SVV \< 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.
41288906|NCT02803372|OTHER|Routine circulatory management|Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output \> 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
41288907|NCT00232570|DRUG|quetiapine|
41288908|NCT02234622|BEHAVIORAL|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
40951058|NCT00806975|DEVICE|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
40951059|NCT01595035|BEHAVIORAL|psychoeducational|Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
40951060|NCT00422097|DRUG|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
40951061|NCT00422097|DRUG|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
40951062|NCT00422097|DRUG|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
40951063|NCT00422097|DRUG|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
40951064|NCT00422097|DRUG|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
41134042|NCT04033250|DRUG|Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure|Bowel preparation
41134043|NCT00000170|DRUG|Atropine|Atropine
41134044|NCT00000170|DEVICE|Eye Patch|Patching
41134045|NCT04577326|DRUG|cyclophosphamide|A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m\^2 will be administered 2-7 days before the infusion.
41134046|NCT04577326|BIOLOGICAL|CAR T cells|A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. Cohorts of 3 patients will be treated at each dose level, up to a maximum of 3 x 10\^7 T cells/kg or until the MTD has been reached.
41134047|NCT06415994|DRUG|Buprenorphine or Methadone Treatment|Pregnant mothers must be taking Buprenorphine or Methadone
41134048|NCT06415994|DIAGNOSTIC_TEST|Fetal and Placental MRI|"Two MRIs :~* Second Trimester~* Third Trimester"
40760141|NCT02113280|PROCEDURE|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
40760142|NCT02113280|PROCEDURE|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
41134049|NCT06415994|BEHAVIORAL|Child Developmental Assessment|At 1 year of life child will receive a developmental assessment
41454141|NCT06051942|DEVICE|Robotic Waterjet Treatment|The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System. During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan.
40760143|NCT04386239|DRUG|Sarilumab Prefilled Syringe|Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
40760144|NCT04256018|DRUG|Mogamulizumab|Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
40760145|NCT04256018|RADIATION|LD TSEBT|Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
40760146|NCT00135876|DRUG|dalteparin|
40760147|NCT05787782|DEVICE|Masimo INVSENSOR00063|Masimo INVSENSOR00063 will be used to measure temperature
40760148|NCT05007860|BIOLOGICAL|PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.|Vaccines administered per standard of care
40760149|NCT03578172|DRUG|human menopausal gonadotrophin|experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)\<100pg/ml，progesterone (P)\<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.
40760150|NCT03578172|DRUG|hormone replacement therapy|Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration \>60 days.
41454142|NCT04852133|OTHER|Burn subjects|see eligibility criteria
41454143|NCT05549687|OTHER|Questionnaire Administration|Ancillary studies
41454144|NCT05549687|PROCEDURE|Supportive Care|Participate in Pack Health, an electronic support program
41454145|NCT05549687|PROCEDURE|Supportive Care|Access to telephone triage line for support care services
41454146|NCT05579548|DRUG|Pegvaliase|Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.
40951065|NCT00422097|DRUG|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
41134050|NCT06415994|BEHAVIORAL|Questionnaires|Participants will answer questionnaires on their medical history, pregnancy, substance use, and after birth: their child's development
40951066|NCT00422097|DRUG|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
41134051|NCT06415994|OTHER|Blood and Placental Samples|"At each MRI visit a blood sample will be collected for substances, DNA, RNA, epigenetics, and placental biomarkers.~At delivery: A sample of placenta will be collected for RNA, DNA, and epigenetic analysis."
41134052|NCT02183272|DRUG|Intranasal Ketamine|Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.
41134053|NCT02183272|DRUG|Intranasal Saline Placebo|Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
41134054|NCT05478096|BEHAVIORAL|GetStarted|Guided internet-based intervention for procrastination.
41134055|NCT04460066|DRUG|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
40951067|NCT00422097|DRUG|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
41134056|NCT04460066|DRUG|albumin bound paclitaxel|Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
41288909|NCT02234622|BEHAVIORAL|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
41288910|NCT05768906|OTHER|observational|Observation of disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians
40760151|NCT01965951|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
40760152|NCT01965951|OTHER|Commercially available computerized training|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
40760153|NCT00089583|DRUG|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
40760154|NCT00089583|DRUG|Ritonavir|Ritonavir solution bid
40951068|NCT01492569|PROCEDURE|electroacupuncture therapy|Undergo TAPS at sham point
40951069|NCT01492569|OTHER|questionnaire administration|Ancillary studies
40951070|NCT01492569|PROCEDURE|electroacupuncture therapy|Undergo TAPS
41288911|NCT04810546|DIETARY_SUPPLEMENT|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Lactoferrin (Apolactoferrin) 250mg contains \~17.6 mg/100g of iron
41288912|NCT05197101|PROCEDURE|balloon catheter combined with oxytocin induction|Balloon catheter for 12 hours and oxytocin for up to 3days.If failed , they will be treated ceacrean.
40760155|NCT03007693|DRUG|JNJ-61393215|Participants will receive JNJ-61393215 for 7 days.
40951071|NCT05847855|DIAGNOSTIC_TEST|Blood collection|Blood collection for fragmentomic profiles of plasma cell-free DNA
40951072|NCT02250859|DRUG|FMX101, Minocycline 4% foam|FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
40951073|NCT06277596|OTHER|Exercise|Clinical Pilates exercises (basic and advanced stabilization exercises)
40951074|NCT05171543|PROCEDURE|Periapical surgery with placement of an allograft and a membrane|Periapical surgery will be done followed by placement of an allograft into the defect and a membrane over the defect before closure of the flap.
40951075|NCT01664065|DRUG|200 mg Ceftaroline fosamil|1 h infusion
40760156|NCT03007693|DRUG|Placebo|Participants will receive JNJ- 61393215 matching placebo for 7 days.
41134057|NCT04460066|DRUG|cisplatin|Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
41134058|NCT04460066|DRUG|placebo|Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
41134059|NCT04460066|PROCEDURE|radical resection of esophageal carcinoma|Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
41134060|NCT05870085|BEHAVIORAL|Neuro-linguistic program|"Intervention: Neuro-linguistic program developed by three specialists (a clinical psychologist, a social worker, and one education specialist).~4 (45 minutes) sessions for teachers, and 2 for children (total of 6 sessions)"
41134061|NCT03939897|DRUG|Abemaciclib|Given PO
41288913|NCT00002516|BIOLOGICAL|dactinomycin|
41288914|NCT00002516|DRUG|cyclophosphamide|
41288915|NCT00002516|DRUG|doxorubicin hydrochloride|
41288916|NCT00002516|DRUG|etoposide|
41288917|NCT00002516|DRUG|ifosfamide|
41288918|NCT00002516|DRUG|mesna|
41288919|NCT00002516|DRUG|vincristine sulfate|
41288920|NCT00002516|PROCEDURE|conventional surgery|
41288921|NCT00002516|RADIATION|low-LET cobalt-60 gamma ray therapy|
41288922|NCT00002516|RADIATION|low-LET photon therapy|
41288923|NCT00144300|DRUG|Mirapex|Standard marketed product dispensed according to manufacturer's guidelines
41288924|NCT00144300|DRUG|Requip|Standard marketed product dispensed according to manufacturer's guidelines
41288925|NCT05459805|DRUG|traditional chinese medicine Xuanfei-Zhike formula|200ml, bid, for 8 weeks
41288926|NCT05459805|DRUG|inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)|one suction, q12h, for 8 weeks
41288927|NCT01804595|OTHER|Sunscreen|
40951076|NCT01664065|DRUG|600 mg Ceftaroline fosamil|1 h infusion
40951077|NCT02168127|DRUG|Drug: PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
40951078|NCT02168127|DRUG|PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
40951079|NCT02800343|PROCEDURE|routine administration of 0.9% sodium chloride|0.9% sodium chloride is used as the wash and suspension solution for red blood cells during the Intraoperative red blood cell salvage (ICS) procedure.
41134062|NCT03939897|PROCEDURE|Biopsy|Undergo tissue biopsy
41288928|NCT01804595|BEHAVIORAL|Text-Message Reminders|
41288929|NCT01804595|OTHER|Sunscreen and Text Message Reminders|
41288930|NCT01804595|BEHAVIORAL|Education|
41288931|NCT01187212|DRUG|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
41288932|NCT01187212|DRUG|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
41288933|NCT00934531|DRUG|Donepezil|"Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline."
41288934|NCT06244186|DIETARY_SUPPLEMENT|Probiotics|Probiotics contains a probiotic known as Lactobacillus delbrueckii subsp. Bulgaricus, a key bacterium utilized in the production of yogurt, cheeses, and various naturally fermented products. Studies suggest that the metabolites of Lactobacillus bulgaricus can enhance immunity and digestion, reduce the risk of infection, and lower blood cholesterol levels. The composition of probiotics has been developed by TCI CO., Ltd.
41288935|NCT06244186|DIETARY_SUPPLEMENT|Placebo|Placebo is provided by TCI CO., Ltd.
41288936|NCT04407507|DRUG|Ivermectin|ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
41288937|NCT04407507|DRUG|Placebo|Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
41288938|NCT01009463|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
41288939|NCT01009463|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
41307799|NCT04935125|PROCEDURE|Standard Program + Endurance and Strength training|Sessions of strength training added to a standard inpatient multidisciplinary programme
41454147|NCT02339038|DRUG|Ledipasvir 90 mg and Sofosbuvir 400 mg|Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
40951080|NCT04875169|DRUG|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
41134063|NCT03939897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41134064|NCT03939897|DRUG|Copanlisib Hydrochloride|Given IV
41134065|NCT03939897|PROCEDURE|Diagnostic Imaging|Undergo imaging
40951081|NCT04875169|DRUG|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
40951082|NCT04875169|DRUG|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
40951083|NCT04875169|DRUG|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
41134066|NCT03939897|PROCEDURE|Echocardiography|Undergo ECHO
41134067|NCT03939897|DRUG|Fulvestrant|Given IM
41134068|NCT03939897|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41134069|NCT01582321|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
41134070|NCT01582321|DRUG|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
40951084|NCT04875169|DRUG|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
41134071|NCT03765658|DRUG|GRT0151Y dose escalation|Single doses of 150, 200, 250, 300, 350 and 400 mg (3, 4, 5, 6, 7 or 8 capsules of 50 mg)
41134072|NCT03765658|DRUG|Matching placebo|Matching placebo capsules (3, 4, 5, 6, 7 or 8 capsules)
41134073|NCT03014037|PROCEDURE|Unilateral Bone Marrow Procurement|A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes.
41134074|NCT03014037|PROCEDURE|Bilateral Bone Marrow Procurement|30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.
41134075|NCT06511310|OTHER|Exercise|High Intensity Exercise
41134076|NCT03719352|PROCEDURE|Experimental: Deep dry needling|Deep dry needling until achieving twitch response of the muscle
41134077|NCT03719352|PROCEDURE|Experimental: Superficial dry needling|Superficial dry needling to achieve sensitive pain with needle rotation
40760157|NCT06571071|OTHER|De-Stress and Chill Gummies-U001|Two gummies in sequence daily after meal for 60 days
40951085|NCT01786148|BEHAVIORAL|mobile phone application|
40951086|NCT01705730|DRUG|tocilizumab|Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
40951087|NCT05992181|OTHER|NEORTHO|early orofacial stimulation
40951088|NCT06281678|DRUG|IBI363|IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks. Subjects will receive study medication until disease progression, toxicity intolerance, withdrawal of consent, the duration of treatment reaches 24 months, or any other reason that requires discontinuation of the study treatment, whichever occurs first.
40951089|NCT02838446|PROCEDURE|Cognitive Therapy|"Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)"
40951090|NCT00001688|DRUG|Ritonavir|
40951091|NCT00001688|DRUG|Nevirapine|
40951092|NCT00001688|DRUG|Stavudine|
40951093|NCT06558396|BEHAVIORAL|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (20 minutes), nutrition education lesson/cooking lab (65 minutes, odd weeks) OR professional development session (65 minutes, even weeks). On any day during the 2-week cooking period, the students will make a dish using groceries they received with their parent/guardian (1 hour).
41134078|NCT03719352|PROCEDURE|Placebo Comparator: Placebo Gastrocnemius dry needling|Simulate pain with de plastic needle guard in the gastrocnemius muscle
41307800|NCT04935125|PROCEDURE|Standard Program|Standard inpatient multidisciplinary programme (including endurance training)
41454148|NCT04509154|OTHER|Multimodal pain therapy|For the elaboration of the contents of the multi-component treatment of the mobile device application (APP), a set of guidelines has been developed for the care of one's own health, based on scientific evidence and adapted to the language of citizens, applying participatory methodology (Loewenson et al. 2014) and consensus, both by professionals (physicians,, nurses, psychologists, pharmacists, social educators and health professionals), and expert patients, who guarantee their validity, allowing the analysis and selection of the interventions that respond to the health problem. This intervention consists in the implementation of a protocol of standard activities of the interactive psychosocial therapy type.
41454149|NCT04509154|OTHER|Standardized treatment.|Face-to-face health education sessions led by nurses and physicians, with the possibility to have access to a non-interactive website with pain management materials from a self-help approach.
41288940|NCT01828125|PROCEDURE|Hypoglycaemic hyperinsulinemic clamp|A first catheter will be inserted for infusion of D-\[6,6-2H2\] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-\[6,6-2H2\] glucose. A third catheter will be inserted for sampling. D-\[6,6-2H2\] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
40760158|NCT06571071|OTHER|De-Stress and Chill Gummies-I001|Two gummies in sequence daily after meal for 60 days
40760159|NCT06571071|OTHER|Placebo Gummies-001|Two gummies in sequence daily after meal for 60 days
41134079|NCT03472352|BIOLOGICAL|An anticancer medication (A01) and immune cells (IC01)|The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
41134080|NCT02372318|DRUG|Nalmefene|18mg of Nalmefen will be administered orally
41134081|NCT02372318|DRUG|Placebo|Placebo tablet
41134082|NCT00163501|DRUG|Ciclesonide|
41134083|NCT05445349|DEVICE|Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy|The DPI inhaler devices are empty, without any active ingredient or/and carrier substances. Patients are not inhaling drug doses because of the study. They are inhaling only the type and quantity of aerosol drugs that they would inhale because of their treatment. The study does not influences the undergoing treatment by medication in any way.
41134084|NCT01286311|BEHAVIORAL|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
41134085|NCT02139241|DRUG|Ramosetron|0.3 mg IV as bolus before induction of general anesthesia
41134086|NCT02139241|DRUG|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
41134087|NCT05892445|BEHAVIORAL|Graphic Warning Labels|Based on a thorough review of the literature on e-cigarette risks and adverse effects, a graphic designer will be contracted to create ten experimental aversive health warnings related to e-cigarettes. These warnings will be exported as high-quality images and shown to participants in the intervention group prior to questions that obtain data on the primary endpoint.
41134088|NCT04726657|DRUG|Premixed Human Isophane Insulin Suspension + Human Insulin Injection|premixed human insulin
41134089|NCT04726657|DRUG|Premixed Insulin|Premixed Insulin Analog Biphasic Aspart 30
41134090|NCT04788810|OTHER|Administration of d12-Cl2BPA|Administration of d12-Cl2BPA
41134091|NCT01116206|DRUG|Prucalopride|2 mg tablet, orally once daily, for 12 weeks
41134092|NCT01116206|DRUG|Placebo|1 tablet, orally once dailyfor 12 weeks
41134093|NCT05589337|BEHAVIORAL|Baduanjin|The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
41134094|NCT05589337|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
41134095|NCT00003088|DRUG|cyclophosphamide|given IV
41134096|NCT00003088|DRUG|doxorubicin hydrochloride|given IV
41134097|NCT00003088|DRUG|paclitaxel|given IV
41134098|NCT06510244|DEVICE|EEG EMOTIV|The teeth will be dried with 2x2 gauze; then, Endo Ice will be applied. The patient response will be written on a sheet numbering to choose from 0 to 10, and at the same time, the brain waves will be recorded through EEG.
41134099|NCT05584748|DEVICE|transcranial direct current stimulation|tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).
41134100|NCT01084525|DRUG|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
41134101|NCT01084525|DRUG|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
41134102|NCT01084525|DRUG|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
41134103|NCT02459860|BEHAVIORAL|Problem Solving Treatment|Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
41134104|NCT02459860|BEHAVIORAL|Enhanced Usual Care|EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
41134105|NCT00360191|DRUG|Buspirone|
41134106|NCT00360191|PROCEDURE|Motivational enhancement therapy|
41134107|NCT05435105|BEHAVIORAL|Virtual reality|Distraction method
41134108|NCT05435105|BEHAVIORAL|Local cold-vibration|Distraction method
41134109|NCT00134186|DRUG|motexafin gadolinium|
41134110|NCT02894554|DRUG|Telbivudine|
41134111|NCT02894554|DRUG|Lamivudine|
41134112|NCT00806767|BIOLOGICAL|therapeutic immune globulin|
40760160|NCT02498795|OTHER|Group of Dry Needling|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
40760161|NCT02498795|OTHER|Group of Electrolysis|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
41134113|NCT00806767|DRUG|busulfan|
41134114|NCT00806767|DRUG|fludarabine phosphate|
41134115|NCT00806767|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41134116|NCT03774849|DEVICE|PicoWay™ 532nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
41134117|NCT03774849|DEVICE|PicoWay™ 730nm wavelength|PicoWay™ Laser System is picosecond 532/1064/785 laser
41134118|NCT03774849|DEVICE|PicoWay™ 1064nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
41288941|NCT01828125|DRUG|Glucagon|
41288942|NCT06326151|BEHAVIORAL|Interdisciplinary Psychoeducational Programme|This intervention is based on the principle of complementing and integrating both disciplines in order to meet the psychological needs of family carers and to train them in knowledge and strategies aimed at the correct performance of activities of daily living in order to promote the maximum autonomy and functionality of dependent people with cognitive impairment, and that this favours discharge, self-care, improvement of the affective state and quality of life of family carers.
41288943|NCT06326151|BEHAVIORAL|Health Education Programme|Upon discharge from the hospital, at the end of the baseline assessment, caregivers will receive instructions and recommendations for maintaining an active and healthy lifestyle. This will be done by encouraging self-care and good practices in caring for their dependent family member, as part of a health education programme. The benefits of an active lifestyle and general guidelines are emphasized.
41288944|NCT01709799|BEHAVIORAL|Exercise|"Participants will do physical activity that raises heart rate to a target heart rate (THR)zone which is pre-calculated using the Karvonen Formula:~(THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Participants begin exercise regimen starting at 50% THR for intensity and gradually increase by 5% up to a maximum of 75% THR.~Activity duration begins at 10 mins./day and increases 5 mins. every week following to a maximum of 40 mins. Polar Heart Rate monitors are used to measure THR and save resulting data."
41288945|NCT01709799|BEHAVIORAL|Exergames|"Participants experience Wii Video Games in a standardized format, beginning with 15 mins of seated play per day on week one, and then increasing 5 mins./week on each week following up to a maximum of 40mins. of play.~Participants are made aware of the Target Heart Rate Zone for the week, but are not required to reach that zone during play. The THR is calculated by the Karvonen Formula:~THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Polar Heart Rate monitors are used to measure THR and save resulting data."
40951094|NCT03844100|DRUG|efficacy and safety of CNU® Capsule|All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.
40951095|NCT06049082|DRUG|KB408 (Nebulization)|Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
41288946|NCT01709799|BEHAVIORAL|Cognitive Training|"Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.~INSIGHT Assessments are done at baseline, the start of each training week and at week 28."
41288947|NCT01754896|OTHER|mailing of FIT kit directly to patient|Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
41307801|NCT05181319|OTHER|occurrence of bronchopulmonary dysplasia|We observe the incidence of bronchopulmonary dysplasia
40760162|NCT02498795|OTHER|Control Group|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
40760163|NCT05875831|BEHAVIORAL|Active Cycle of Breathing|Active Cycle of Breathing Technique to Improve Pulmonary Functions in Post-Surgical Patients
40951096|NCT03749473|BEHAVIORAL|Choice + Immediate|Participants in the choice + immediate goal arm will choose a step goal and must attempt to achieve this new step goal immediately at the start of the study.
40760164|NCT05875831|DIAGNOSTIC_TEST|Coughing|Coughing to Improve Pulmonary Functions in Post-Surgical Patients
41288948|NCT01754896|OTHER|mailed invitation to pick up lab requisition and then kit|Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
40951097|NCT03749473|BEHAVIORAL|Choice + Gradual|Participants in the choice + gradual goal arm will choose a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
40951098|NCT03749473|BEHAVIORAL|Assigned + Immediate|Participants in the assigned + immediate goal arm will be assigned a step goal and must attempt to achieve this new step goal immediately at the start of the study.
41134119|NCT05085704|DEVICE|Magnetic resonance imaging|Medical imaging technique used in radiology to form pictures of the anatomy.
41134120|NCT00664599|DRUG|Rituximab|Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
41134121|NCT00664599|DRUG|Cytotoxic Combination|Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
41134122|NCT03196869|DEVICE|Chrono-chemotherapy|Chrono-chemotherapy+concurrent radiochemotherapy
41134123|NCT03196869|DEVICE|Routine intravenous drip|Routine intravenous drip-chemotherap
41134124|NCT03196869|DRUG|induction Chrono-chemotherapy|Experimental group:docetaxel,cisplatin,5-FU
41134125|NCT03196869|DRUG|induction Routine-chemotherapy|control group:docetaxel,cisplatin,5-FU
41288949|NCT01754896|OTHER|mailing completed kits in for processing|Patients mails completed kit in for processing using postage-paid reply envelope provided.
41307802|NCT04721015|DRUG|ABBV-637|Intravenous (IV) Infusion
40760165|NCT04650893|DRUG|Intravenous Ketorolac|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
41134126|NCT03196869|DRUG|cisplatin chrono-chemotherapy|Experimental group: cisplatin chrono-chemotherapy
41134127|NCT03196869|DRUG|cisplatin routine-chemotherapy|control group:cisplatin routine-chemotherapy
41134128|NCT03196869|RADIATION|intensity-modulated radiation therapy|control group is similar to Experimental group
41134129|NCT00875706|BEHAVIORAL|Educational Intervention|The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.
40760166|NCT04650893|DRUG|Intravenous Dexamethasone|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
40760167|NCT04650893|DRUG|Placebo|Control
40760168|NCT03816579|OTHER|PRO-A|30 g of beef protein will be consumed at each meal
40760169|NCT03816579|OTHER|PRO-B|30 g of complementary proteins will be consumed at each meal
40760170|NCT03816579|OTHER|PRO-C|30 g of complementary proteins will be consumed over 24 hours
40760171|NCT03147885|DRUG|Selinexor|Given PO
41134130|NCT00390884|BIOLOGICAL|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
41134131|NCT00390884|BIOLOGICAL|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
41134132|NCT05884515|DIAGNOSTIC_TEST|SARS CoV-2 antigen tests|The intervention is to compare antigen tests
41134133|NCT00071500|DEVICE|MedSignals™|An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
41288950|NCT01754896|OTHER|dropping completed kits at lab for processing|Patient takes completed FIT in to lab patient service centre for processing.
41288951|NCT00147771|DRUG|Imiquimod 5% cream|Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.
41288952|NCT02061137|DRUG|fingolimod (FTY720)|0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
41288953|NCT05813093|DEVICE|rTMS|Accelerated iTBS treatment
41288954|NCT03475394|OTHER|Chlorhexidine gel|0.1 ml of Chlorhexidine gel was administered into the periodontal pocket
41288955|NCT03475394|OTHER|Morus alba gel|0.1 ml of Morus alba gel was administered into the periodontal pocket
40760172|NCT04753567|DEVICE|nCap pain relief patch|Each participant will be randomly assigned to sham or actual patch. Patches will be worn for 3 weeks. Pain and quality of life will be assessed and compared between groups
41288956|NCT03475394|OTHER|Placebo|0.1 ml of Placebo gel was administered into the periodontal pocket
41288957|NCT03633643|DRUG|oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)|"five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day~1 and 2 after surgery while the patient is in hospital."
41288958|NCT03633643|DRUG|oral applications of Placebo|five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
41288959|NCT03450772|DRUG|Creon® 25000|Experimental drug
41288960|NCT03450772|DRUG|Creon® 10000|Active comparator
41288961|NCT00446394|BEHAVIORAL|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
41307803|NCT04721015|DRUG|Docetaxel|Intravenous (IV) Infusion
41288962|NCT00446394|BEHAVIORAL|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
41288963|NCT05174715|OTHER|BIA|nutritional status was evaluated using BIA
41288964|NCT00211822|PROCEDURE|fMRI|fMRI
41134134|NCT05237999|BEHAVIORAL|KopOpOuders-PTSD|See arm description
41288965|NCT03426969|DRUG|Cyclophosphamide|Given IV
41288966|NCT03426969|BIOLOGICAL|Filgrastim|Given SC
41288967|NCT03426969|DRUG|Fludarabine Phosphate|Given IV
41288968|NCT03426969|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
40760173|NCT04753567|DEVICE|Sham Patch|Sham patch will be worn for 3 weeks exactly like actual pain patch
40951099|NCT03749473|BEHAVIORAL|Assigned + Gradual|Participants in the assigned + gradual goal arm will be assigned a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
40951100|NCT03749473|BEHAVIORAL|Daily performance feedback|Participants will receive daily performance feedback on their daily step count.
40951101|NCT03749473|BEHAVIORAL|Gamification|All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.
40951102|NCT06383936|PROCEDURE|intensive rehabilitation after uncemented TKA|patients undergoing an intensive rehabilitation protocol after uncemented tka
40951103|NCT00000488|DRUG|cholestyramine|
41134135|NCT03805672|DRUG|Low Dose Enoxaparin|
41134136|NCT03805672|DRUG|High Dose Enoxaparin|
41134137|NCT05232110|DRUG|Pozelimab|
41134138|NCT01465152|DRUG|metformin|Adminstered orally during the three main meals for 24 weeks
41288969|NCT03426969|DRUG|Melphalan|Given IV
41288970|NCT03426969|DRUG|Mycophenolate Mofetil|Given PO
41288971|NCT03426969|DRUG|Tacrolimus|IV or PO
41134139|NCT01465152|DRUG|repaglinide|Administered orally before the three main meals for 24 weeks
41134140|NCT01252420|DRUG|Enoxaparin|1.5mg/kg daily for 2 weeks
41288972|NCT03426969|RADIATION|Total-Body Irradiation|Undergo TBI
41288973|NCT03199911|DRUG|Topical Antibiotic Product|Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
41288974|NCT03199911|DRUG|Topical Non-Antibiotic Ointment|Mineral oil/petrolatum-based artificial tear ointment.
41288975|NCT00085969|DRUG|Placebo 0.04 mL twice daily|Subcutaneously injected, 0.04 mL, twice daily
41288976|NCT00085969|DRUG|Placebo 0.04 mL once daily|Subcutaneously injected, 0.04 mL, once daily
41288977|NCT00085969|DRUG|Placebo 0.08 mL once daily|Subcutaneously injected, 0.08 mL, once daily
41288978|NCT00085969|DRUG|B - Exenatide 10 mcg twice daily|Subcutaneously injected, 10 mcg (0.04 mL), twice daily
41288979|NCT00085969|DRUG|C - Exenatide 10 mcg once daily|Subcutaneously injected, 10 mcg (0.04 mL), once daily
41288980|NCT00085969|DRUG|Exenatide 20 mcg once daily|Subcutaneously injected, 20 mcg (0.08 mL), once daily
40951104|NCT00000488|BEHAVIORAL|diet, fat-restricted|
41288981|NCT01144546|PROCEDURE|passive leg raising (45 degree leg elevation for 1-2 min)|the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
41288982|NCT03848520|PROCEDURE|TKA|TKA performed in the past
41288983|NCT01938170|BIOLOGICAL|FluMist|Subjects receiving Flumist vaccine
41288984|NCT03987399|OTHER|Tailored educational intervention|Educational day (lecture and workshop), clinical supervision and reminders
40760174|NCT04390009|DIAGNOSTIC_TEST|Entire-body PET-CT scans|Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.
41307804|NCT04721015|DRUG|Osimertinib|Oral Tablets
40951105|NCT00111982|BIOLOGICAL|Liatermin|Liatermin
40951106|NCT04767763|DIAGNOSTIC_TEST|Assessment of TSH, fT3, fT4,TRH, TT3, TT4, rT3 in patients with CVVHDF|blood samples were collected before initiation of CRRT and at 1,2,3,6,9-day following. Last samples were collected 3 days after the end of CRRT.
40951107|NCT04710264|OTHER|AURORA-Rec|Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.
40951108|NCT03488355|OTHER|Modified laboratory report|"Report from microbiology laboratory: This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results."
41134141|NCT02798016|PROCEDURE|Platelet-Rich Plasma|This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
41134142|NCT02798016|PROCEDURE|Micro-needling|Micro-needling will be applied on the acne scars in one side of the face.
41134143|NCT00005921|DRUG|L-743,872|
41307805|NCT00240630|DRUG|sumatriptan succinate/naproxen sodium|Combination Tablet of Treximet
40951109|NCT06090396|DIAGNOSTIC_TEST|cardiac output monitoring with electrical cardiometry|comparison of limits of agreement between the two monitoring modalities
40951110|NCT06284902|DRUG|Fexofenadine HCl Coated tablet|Film-coated tablet.
40951111|NCT06284902|DRUG|Fexofenadine HCl New Formulation Tablet|New formulation tablet.
41134144|NCT00524797|DIETARY_SUPPLEMENT|Profonycia|
41134145|NCT01307254|PROCEDURE|blood analysis|A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
41134146|NCT00042926|OTHER|immunohistochemistry staining method|
41134147|NCT00042926|PROCEDURE|conventional surgery|
41134148|NCT00042926|PROCEDURE|lymphangiography|
41134149|NCT00042926|PROCEDURE|radionuclide imaging|
41134150|NCT00042926|PROCEDURE|sentinel lymph node biopsy|
41134151|NCT00042926|RADIATION|technetium Tc 99m sulfur colloid|
41134152|NCT01332266|DRUG|E7050|E7050 given orally at 200, 300, or 400 mg once daily.
41134153|NCT01332266|DRUG|Cetuximab|Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
41134154|NCT03158506|DRUG|HMS5552|\[14C\]-labelled HMS5552
41288985|NCT06513767|DEVICE|Zirconia Dental Ceramics|This investigation was conducted by enrolling subjects who met the enrolment criteria, using the investigational device (Zirconia Dental Ceramics) to perform dental prosthesess.
41288986|NCT03358862|DEVICE|NaturalVue Multifocal Contact Lens|NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
41288987|NCT04509856|BEHAVIORAL|Teach-back educational method|In the teach-back method, after teaching new information to the patient, the patients were asked to explain that new information in their own words. Then the patients' knowledge and the adequateness of their explanations were determined. The patient should repeat the instructions in their own words. In this way, the healthcare professional can evaluate how the patient understands the information. If the patient repeated the information correctly, the teach-back phase for that information was completed, and progression for new information was resumed. However, if there was a deficiency or error in the information, it was corrected and repeated by the healthcare professional.
41307806|NCT00240630|DRUG|placebo|placebo to match
41307807|NCT03445897|DRUG|miltefosine plus intralesional pentamidine|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
40951112|NCT03716193|OTHER|Oxygen|Patients will be given oxygen via a facemask during the measurement session
40951113|NCT03172819|BIOLOGICAL|OBP-301|"Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.~Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.~The patients in Phase 1a, Pembrolizumab administration has continued, are included.~The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles."
41134155|NCT06356285|BEHAVIORAL|Presentation of Antimicrobial Resistance|Participants will be presented with a poster containing information about antibiotics, each intervention poster will have a different name at the top, representing a new way to frame antimicrobial resistance.
41134156|NCT03491566|OTHER|Clinic Pilates Group|"Clinical Pilates exercises include Hundreds, One Leg Stretch, Shoulder Bridge, One Leg Kick, Swimming , Double Leg Stretch, Swan Dive Circle , Arm Opening , Spine Twist , Roll Down exercises."
41134157|NCT03491566|OTHER|Aerobic Exercise Group|Aerobic exercise with using an elliptical bike, or bike or treadmill under supervision of a physiotherapist.
41134158|NCT00464893|DRUG|Catumaxomab|10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
41134159|NCT00464893|DRUG|catumaxomab|10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
41288988|NCT00850772|DIETARY_SUPPLEMENT|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
41288989|NCT02514070|DRUG|EPA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
41288990|NCT02514070|DRUG|DHA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
41134160|NCT06207006|BEHAVIORAL|eConquerFear-HK|The key goals of the intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
41288991|NCT01364610|DEVICE|Bravo|Bravo pH Monitoring System sited manometrically.
41288992|NCT01364610|DEVICE|Standard Care|Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
41288993|NCT05483972|BEHAVIORAL|Whole Prediabetes Diet Intervention|Participants will be instructed by RDN on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled adults in the study, the goal is to maintain complete diet adherence during the two-week intervention. The focus for children/adolescents will be on encouragement and exposure of the diet by the index parent and any additional household parent/guardian/caregiver. Participants will receive groceries that are tailored specifically to the prescribed diet menus/recipes for each week. Foods will be distributed using either a grocery delivery service or via participant pick-up. Each household will receive enough groceries to feed a household of four-persons for each week of the intervention.
41288994|NCT01539629|DEVICE|Cardiac pacing|Cadiac pacing via a pulse generator and implaned intracardiac leads.
40760175|NCT04390009|DRUG|Amyvid radiopharmaceutical|Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants
40760176|NCT05917964|DRUG|LP-168 tablet|LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
40760177|NCT00593619|DRUG|Iron dextran|300mg in 250cc normal saline given over 2 hours
40760178|NCT00593619|DRUG|Iron sucrose|300mg in 250cc normal saline given over 2 hours
40760179|NCT00892450|DRUG|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
41134161|NCT06207006|BEHAVIORAL|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
40760180|NCT00295412|DRUG|quetiapine (drug)|
40760181|NCT00855166|DRUG|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 102 weeks
40760182|NCT00855166|DRUG|Metformin|Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
40951114|NCT03172819|DRUG|Pembrolizumab|200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.
40951115|NCT04742075|DRUG|Olaparib + durvalumab + UV1|The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
40951116|NCT03750617|DIAGNOSTIC_TEST|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
40951117|NCT01058655|DRUG|Everolimus|
40951118|NCT01058655|DRUG|Tivozanib|
41134162|NCT02108171|DRUG|Dexmedetomidine|intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
40951119|NCT05652881|PROCEDURE|Joint Lavage|An arthrotomy will be made at the time of temporary external fixation and 1L normal saline will be used to irrigate the ankle joint.
40951120|NCT05545007|RADIATION|Hypofractionated Radiosurgery (HSRS)|HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.
40951121|NCT05545007|PROCEDURE|Brain metastases surgical resection|Complete surgical resection of brain lesions with adeguate margins.
40951122|NCT05736614|BEHAVIORAL|Stage 1 Strength Based Case Management (SBCM) Condition|Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.
40951123|NCT05736614|BEHAVIORAL|Stage 2 PrEPare for Work Intervention Condition|Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
40951124|NCT01570296|DRUG|Gefitinib and BKM120|Dose escalation study of gefitinib and BKM120 with expansion cohort
40951125|NCT05627297|OTHER|CEUS and CEMRI|contrast-enhanced ultrasound and contrast-enhanced MRI examination
40951126|NCT01752985|DRUG|BMS-813160|
40951127|NCT01752985|DRUG|Placebo matching with BMS-813160|
40951128|NCT03491267|DRUG|Retinoic acid|The study team will treat skin with topical retinoic acid
40951129|NCT03491267|DEVICE|Laser|The study team treat skin with a surface laser.
40951130|NCT03491267|DRUG|Sham treatment|No drug will be given
40951131|NCT03491267|DEVICE|Sham treatment|No laser treatment will be given
40951132|NCT05888077|OTHER|ESWL_LL|Extracorporeal shock wave lithotripsy using latest lithotripter and laser lithotripsy for difficult Bile duct stones
40951133|NCT03599388|BEHAVIORAL|Self- management for adequate sleep intervention (SASI)|Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains \>90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
40951134|NCT02846714|BEHAVIORAL|FLARE|
40951135|NCT00709657|DRUG|ranibizumab, bevacizumab or pegaptanib|measurements are performed one week before and after anti-VEGF intravitreal injection
40951136|NCT06357858|DRUG|INQOVI (decitabine and cedazuridine)|Oral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1).
40951137|NCT06357858|DRUG|Nivolumab|Nivolumab will be administered on D8 with every 4 week cycle.
40951138|NCT06450158|DEVICE|Robot (Amadeo)-assisted Training|"Amadeo® is an FDA Class I Exempt hand/finger robot that has the capacity to precisely measure hand/finger functions.~To use Amadeo, a participant will be seated in a chair. The height of the robot arm support will be adjusted to achieve a comfortable position for the participant. One of the participant's arms will be will be placed on the robot arm support. Magnetic finger tips will then be attached to fingers and thumb. After this, fingers and thumb will be connected to the robot finger sliders. To use Amadeo, the movement range and maximal force of each finger will be configured according to the finger's capability. The following four types of function assessments will be performed with Amadeo: Force, range of motion, tone, and spasticity. Each session will last approximately one hour."
40951139|NCT02985437|DRUG|Surfactants|
40951140|NCT02985437|DRUG|Saline Solution|
40951141|NCT04639700|BEHAVIORAL|Psycho-educational intervention|"Participant will be sent a baseline survey, and will then be contacted by the interventionist to complete 4 sessions, which feature the following areas:~Session 1: Identifying CG Needs for Information \& Support, Communication with Healthcare Team~Session 2: Communication with Patient and Family~Session 3: Self-care: Emotional \& Spiritual Needs, Self-care: Physical Needs~Session 4: Re-Assessing Needs, Planning for the future"
40951142|NCT05890339|PROCEDURE|Laparoscopic Proximal Gastrectomy With Double-flap Technique|Patients in this group receive laparoscopic proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p and 11d). The double-flap technique is used for the esophagogastric reconstruction.
40951143|NCT05890339|PROCEDURE|Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction|Patients in this group receive laparoscopic total gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p and 11d, 12a). The Roux-en-Y esophagojejunostomy method is used for the esophagojejunal reconstruction.
40951144|NCT01272973|DRUG|semaglutide|Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
40951145|NCT01272973|DRUG|placebo|Placebo (oral) administered once daily for 10 weeks.
40951146|NCT01272973|DRUG|semaglutide|Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
40951147|NCT03954691|OTHER|brain tumor-immune cells communication|tumoral and immune cell isolation from biopsis
40951148|NCT04137627|DRUG|Melatonin 20 MG Oral Capsule|The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.
40951149|NCT04137627|DRUG|Placebo oral capsule|The administration of placebo capsule in addition to neoadjuvant chemotherapy
40951150|NCT01130675|OTHER|caffeinated coffee|8 oz. of caffeinated cofee/breakfast\&noon meal. No intervention for 2nd arm.
40951151|NCT01435070|PROCEDURE|Kirschner wire fixation|"The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.~A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment."
40951152|NCT01435070|PROCEDURE|Volar Locking Plate fixation|The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
40951153|NCT02388919|DRUG|Anlotinib|Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
40951154|NCT02388919|DRUG|Placebo|Basic dosage, take once when limosis in the morning.
40951155|NCT01788488|OTHER|Use of procalcitonin as biomarker to guide therapy|
40951156|NCT00000471|BEHAVIORAL|diet, vegetarianism|
40951157|NCT00000471|BEHAVIORAL|diet, fat-restricted|
40951158|NCT00000471|BEHAVIORAL|exercise|
40951159|NCT00000471|BEHAVIORAL|smoking cessation|
40951160|NCT01400165|DRUG|Trazodone|each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
40951161|NCT01400165|DRUG|Quetiapine|each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
41134163|NCT02108171|DRUG|placebo|0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
41134164|NCT04869449|DRUG|Ketoconazole|400 mg (two 200 mg tablets) orally
41134165|NCT01616537|OTHER|QUALITY OF LIFE QUESTIONNAIRE|QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION
41134166|NCT04248868|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
41134167|NCT04248868|DRUG|r-tPA|Pulse spray and infusion
41134168|NCT00237224|DRUG|Letrozole|
41134169|NCT00028548|DRUG|R(+)XK469|
41134170|NCT04027985|OTHER|Kinesiotaping|inesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
41134171|NCT04027985|OTHER|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period.
40951162|NCT01400165|DRUG|Pindolol|each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
40951163|NCT01400165|PROCEDURE|Blood Collection|Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
40951164|NCT03412760|DIAGNOSTIC_TEST|Exome sequencing|Expansive genetic test performed for affected fetus or neonate.
40951165|NCT01536743|DRUG|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
40951166|NCT00436384|PROCEDURE|Monitoring-blood samples drawn for CMV testing|
40951167|NCT01328431|OTHER|Brief Intervention with NRT Initiation|Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
41134172|NCT04027985|OTHER|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
41134173|NCT03735849|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion
41134174|NCT00000418|PROCEDURE|Psychosocial intervention|
40760183|NCT00855166|DRUG|Sitagliptin|Tablet oral 100 mg total daily dose once daily rescue medication
40951168|NCT06205966|DIETARY_SUPPLEMENT|BioGaia Pharax (L. reuteri PTA 5289 and DSM 17938)|BioGaia Pharax drops (with PTA5289 and DSM 17938) with vitamin D3 will be manufactured and delivered by BioGaia AB as oil suspension.
40951169|NCT06205966|OTHER|Placebo|Placebo product contains vitamin D3 and is identical to the active product but lacks L. reuteri.
40951170|NCT05946395|DEVICE|Hearing aid|Fitting a hearing aid
40951171|NCT05946395|OTHER|Speech therapy session|As speech therapy is part of standard care, the objective of the study will be to compare the impact of synchronous or delayed audioprosthetic and speech therapy care on the impact of deafness in elderly patients.
40951172|NCT00165659|DRUG|DONEPEZIL HYDROCHLORIDE|
41288995|NCT03682588|OTHER|Physical activity|The Functional exercise group performed functional exercise training for 45 minutes twice a week for 14 weeks. The Stretching exercise group performed stretching exercises with the same duration and frequency.
41288996|NCT02376439|OTHER|Kool-aid|Participant drank two different types of kool-aid (sugar free and regular)
41288997|NCT00893789|DRUG|Armodafinil|Armodafinil 50 mg/day
41288998|NCT00893789|DRUG|Armodafinil|Armodafinil 150 mg/day
41288999|NCT00893789|DRUG|Armodafinil|Armodafinil 250 mg/day
41289000|NCT00893789|OTHER|Placebo|Placebo
41289001|NCT05296057|DEVICE|Participants Receiving VR-Exposure Therapy Treatment|In the baseline interview with an exposure therapy specialist and a member of the research team, participants will be presented with approximately three sets of possible exposure scenarios, each associated with approximately three different scenes that increase in severity level. Through discussion with the exposure therapy specialist, the participant will choose the exposure scenario (out of the three options) that most closely resembles their own epilepsy- or seizure-related fears. As the treatment, the participant will be exposed to the scenes that are associated with their chosen exposure set in a hierarchical manner using an immersive head-mounted display. The participant will work through the three levels of the chosen exposure scenario for approximately two weeks, ideally on each level for four days.
41289002|NCT00003270|BIOLOGICAL|anti-thymocyte globulin|IV
41289003|NCT00003270|BIOLOGICAL|filgrastim|IV
41289004|NCT00003270|DRUG|busulfan|IV
41289005|NCT00003270|DRUG|cyclophosphamide|IV
41289006|NCT00003270|DRUG|cyclosporine|IV
41134175|NCT05658094|DEVICE|Exosome|Each patients will receive 4 injection with an interval of 14 days during two months
41134176|NCT05991804|OTHER|Transcutaneous spinal cord stimulation added to inpatient rehabilitation|Non-invasive electrical stimulation delivered over the spine, targetting movement of the upper limbs
41289007|NCT00003270|DRUG|methylprednisolone|IV
41289008|NCT00003270|PROCEDURE|bone marrow ablation with stem cell support|IV
41289009|NCT00003270|PROCEDURE|umbilical cord blood transplantation|IV
41289010|NCT00003270|RADIATION|radiation therapy|High energy X-rays
41289011|NCT05217862|DIAGNOSTIC_TEST|PCR for COVID-19 testing|PCR for asymptomatic adult undergoing elective cataract surgery
41289012|NCT01583647|DRUG|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
41289013|NCT01583647|DRUG|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
41454150|NCT04565587|OTHER|Xanthan-gum based thickener|Participants will undergo a screening procedure (V-VST) with two of the viscosities levels determined and prepared with mineral water and Tsururinko Quickly (200 and 800mPa·s). After the V-VST, a Videofluoroscopy (VFS) will be performed with thin liquid and 5 viscosity levels prepared with X-Ray contrast (Omnipaque), mineral water and Tsururinko Quickly (100, 200, 400, 800, 1600mPa·s). Participants swallow will be studied with VFS in a lateral projection and images will include the oral cavity, pharynx, larynx and cervical oesophagus. Swallows will be analysed by equipment developed to capture and digitize the swallowing sequences to assess VFS signs of safety and efficacy according to accepted definitions and to measure the timing and spatial events of the swallow response.
41454151|NCT04830540|DEVICE|OOFOS Recovery Footwear|The OOFOS shoes/ sandals are a commercially available footwear with a compliant, energy absorbing midsole material.
40760184|NCT00855166|DRUG|Placebo|Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
40760185|NCT05772130|OTHER|Best Practice|Receive family letter and genomic test report
41289014|NCT04952012|DRUG|LT4|LT4 is used to improve the thyroid function of pregnant women.
41289015|NCT06513104|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
41289016|NCT06513104|DRUG|Levonorgestrel + Ethinylestradiol|Levonorgestrel + Ethinylestradiol will be administered orally.
41289017|NCT06513104|DRUG|Paracetamol|Paracetamol will be administered orally.
41454152|NCT00000245|DRUG|Desipramine|
41454153|NCT05330533|RADIATION|scrotal duplex|Scrotal colour doppler ultrasonography
41454154|NCT04784169|DEVICE|free middle turbinate flap|Repairing low flow leak using free middle turbinate flap
41454155|NCT04784169|DEVICE|vascularized nasoseptal flap|Repairing low flow leak using fascia lata
40951173|NCT04325178|OTHER|Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.|Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.
40951174|NCT00414271|DRUG|Docetaxel|Docetaxel 60 mg/m2 IV on day 1
40951175|NCT00414271|DRUG|Capecitabine|Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
40951176|NCT05351021|DRUG|Metformin|cidophage 850 gm twice daily
41289018|NCT04807946|PROCEDURE|lower third molar extraction|"All surgeries were performed by the same expert surgeon (RP), with the buccal approach using local anesthesia, and included the following maneuvers:~* luxation of the coronal portion of the tooth/root in an ipsilateral or parallel direction with respect to the IAN position and running, in order to minimize nerve compression;~* post-extraction residual bone cavity inspection using a Zeiss 4x300 magnification optical system to better identify intra-operative nerve exposure.~No material was inserted into the residual cavity, neither by regeneration nor by haemostasis.~After one week, sensitivity was tested on both sides with the tactile test using a 27-gauge needle tip and, if a difference was found, the patient was followed up once a week for the first month and every two weeks thereafter, until he/she reported to perceive the pin-prick test in the affected side the same way as the healthy side."
41289019|NCT04956484|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg
41289020|NCT04956484|DRUG|Standard of care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
41289021|NCT05821504|BEHAVIORAL|High-Intensity Interval Training|The training intervention is a popular exercise format that consist of alternating brief bouts of high-intensity efforts with bouts of light effort or complete rest.
41289022|NCT02007239|DRUG|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
41454156|NCT01528293|DEVICE|ActiVAC System|The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.
41454157|NCT01528293|OTHER|Compression therapy|Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
41454158|NCT00252564|DRUG|Bevacizumab|5 mg/kg over 30 minutes on Days 1 and 15
41454159|NCT00252564|DRUG|Oxaliplatin|85 mg/m2 on Days 1 and 15
41289023|NCT03488992|DIETARY_SUPPLEMENT|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 8 weeks
41289024|NCT03488992|DIETARY_SUPPLEMENT|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
40951177|NCT05351021|DRUG|Placebo|placebo twice daily for treatment period
40951178|NCT03155971|DEVICE|Paclitaxel-Coated Balloon|SeQuent ® Please; B.Braun, Melsungen, Germany
40951179|NCT01748266|OTHER|microcirculatory reactivity|Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
40951180|NCT00011661|BEHAVIORAL|Education on behaviors to reduce lead exposure|
40951181|NCT01446107|OTHER|placement of fissure sealant|placement of resin-based fissure sealant at baseline without replacement
40951182|NCT01446107|OTHER|fluoride varnish|topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
40951183|NCT01446107|OTHER|silver fluoride|topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
40951184|NCT01446107|OTHER|placebo control|application of water onto tooth surface every year
40951185|NCT00003831|PROCEDURE|conventional surgery|
40951186|NCT05856188|DIETARY_SUPPLEMENT|Glutamine|Biologic
40951187|NCT04419675|OTHER|Observational Cohort, usual care = physical therapy|usual care = physical therapy
40951188|NCT03084770|DIAGNOSTIC_TEST|Radiological imaging studies|Patients will be submitted to radiological imaging studies (CT scan and/or MRI and/ or 68Gallium PET/CT and/or Octreoscan and/or EUS+FNAand/or Octreoscan and/or EUS+FNA) at diagnosis, and then every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. Every 12 months (or 6 months for patients with Ki67\> 2%) a high quality imaging (CT scan or MRI) is required.
41289025|NCT01821677|DRUG|Danazol Capsules|
41289026|NCT01821677|DRUG|Placebo|
41289027|NCT05203627|OTHER|Best Practice|Receive standard nutritional support
41289028|NCT05203627|OTHER|Questionnaire Administration|Ancillary studies
41454160|NCT00252564|DRUG|Leucovorin|400 mg/m2 on Days 1 and 15
41454161|NCT00252564|DRUG|Fluorouracil|400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
41454162|NCT00252564|DRUG|Cetuximab|400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
40951189|NCT03084770|OTHER|Quality of Life Assessment|quality of life and the perceived burden of surveillance or follow-up after surgery for participants, will be investigated by administrating HADS questionnaire and EORTC QLQ-C30 (version 3) and EORTC QLQ-GI.NET21 Module.
40951190|NCT06558071|DRUG|Galatonol 300 mg/Striatin 30 mg|1 film-coated caplet of Herba Asimor, twice daily
40951191|NCT06558071|DRUG|Placebo|1 film-coated caplet of placebo Herba Asimor, twice daily
41134177|NCT05991804|OTHER|Inpatient rehabilitation alone|Standard inpatient rehabilitation given at the Royal National Orthopaedic Hospital NHS Trust
41289029|NCT05203627|OTHER|Telemedicine Visit|Receive telehealth sessions
41289030|NCT05734937|OTHER|gastric assessment of gastric volume|ultrasound assessment of gastric volume is going to bel evaluted in the Preoperative and postoperative period while the patients lay in right lateral decubitus position.
41289031|NCT01738399|DIETARY_SUPPLEMENT|Coffee|
41134178|NCT02631655|OTHER|impact of device 18F-FDOPA PET on treatment decisions|Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
41289032|NCT01738399|DIETARY_SUPPLEMENT|Placebo|
41289033|NCT00873444|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
41289034|NCT00873444|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
41289035|NCT04132544|OTHER|standardized gerontological evaluation (EGS)|Evaluation (EGS): initially, the patient benefits from a complete EGS and a complete fall balance realized by a Gerontological Assessment Nurse (initial visit V0) in the 7 working days following the intervention of the SAMU for fall. This assessment is based on the EGS and the assessment of risk factors for falls (HAS, INPES).
41454163|NCT00680498|DRUG|Ranibizumab|Ranibizumab 0.5 mg
41454164|NCT00680498|DRUG|Ranibizumab plus Photodynamic therapy|Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
41454165|NCT00623077|BIOLOGICAL|filgrastim|"Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) \> 1,000/mm\^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses."
41454166|NCT00623077|DRUG|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (\>4 yrs of age) or 13.2 mg/kg IV (\< 4 years of age),every 6 hours on Days -8 through -6.
41134179|NCT02819999|DRUG|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
41134180|NCT02819999|DRUG|Cisplatin|
41134181|NCT02819999|DRUG|Etoposide|
41134182|NCT04266496|OTHER|Questionnaires|ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI
41134183|NCT04266496|DIAGNOSTIC_TEST|Frequency Volume Chart|Collect a frequency volume chart for 3 days: measure the amount of voids and volume urinated.
41134184|NCT04266496|DIAGNOSTIC_TEST|Collect urine during 1 day|Volunteers are asked to collected their urine during the last day of the frequency volume chart. Volunteers get 2 jars: One for collection during the day, and 1 for overnight collection of urine. Osmolality and sodium of urine is tested
41134185|NCT04266496|DIAGNOSTIC_TEST|Blood sample|Blood collection to measure plasma sodium and osmolality.
41289036|NCT04132544|OTHER|Proposal for a personalized intervention plan (PIP)|"A PIP containing personalized recommendations to improve the patient's state of health, treatment and environment as well as risk factors for falls is proposed during the multi-professional consultation and discussed by telephone with the attending physician (pre-arranged telephone appointment). with the latter).~The PIP validated by the attending physician is delivered and explained to the patient by the Gerontological Assessment Nurse in the week following the Multidisciplinary Team Meeting (MDTM) during the V1 visit to the patient's home."
41289037|NCT04132544|OTHER|Follow-up|"Four follow-up visits at 6, 12, 18 and 24 months (V2, V3, V4, V5) are performed at the patient's home. During these visits, the Gerontological Assessment Nurse reassesses the person from the gerontological point of view and from the point of view of risk factors for falls.~A mail containing the elements of interest is sent to the attending physician after each visit. The patient is also contacted by telephone by the Gerontological Assessment Nurse at 2, 4, 9, 15 and 21 months of follow-up to maintain a link, identify possible difficulties and encourage him / her to apply the PIP recommendations."
41289038|NCT04132544|OTHER|Usual care|"The patients included in the control group will benefit from the usual care as well as documentation on general recommendations to be put in place to prevent falls and to age in good health \[series of brochures published by INPES for the elderly. They are informed by telephone of their home group by the Gerontological Assessment Nurse. The documents are sent by mail to the patient's home address."
41289039|NCT04943900|DRUG|BMS-986416|Specified dose on specified days
41289040|NCT04943900|DRUG|Nivolumab|Specified dose on specified days
41454167|NCT00623077|DRUG|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m\^2/day intravenous (IV) over 1 hour for 5 days.
41454168|NCT00623077|DRUG|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day intravenous (IV) over 1 hour on for 5 days.
41134186|NCT04266496|DIAGNOSTIC_TEST|Measurement of the circumference of the lower legs|"Circumference of the lower legs wil be measured twice:~* After awakening, when still laying dowing in bed~* Before goin to sleep~Circumference should be measured 2 cm above the medial malleolus"
41134187|NCT03009344|DRUG|Tazemetostat|Tazemetostat tablets.
41134188|NCT01480375|DEVICE|Smartbx™ system.|The SmartBx™ system semi-automated downloads the biopsy cores from the biopsy needle onto a designated cassette which integrates into the routine pathology lab processing. The core is downloaded in an oriented and straightened fashion while preserving core fragments in its original locations relative to the needle notch.
41134189|NCT04366193|DIAGNOSTIC_TEST|Oximetry|Validation of a high-resolution wireless oximeter for OSA diagnosis comparing with a well established and validated method (home sleep test).
41134190|NCT02656199|PROCEDURE|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
41134191|NCT01558908|BIOLOGICAL|Administration of ERC|Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
41289041|NCT02467764|OTHER|Retrospective study|
41454169|NCT00623077|DRUG|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m\^2 intravenous (IV) over 30 min on Days -5 through -4.
41454170|NCT00623077|DRUG|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m\^2 intravenously (IV) over 2 hrs on Days -3 through -2.
41454171|NCT00623077|PROCEDURE|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
41454172|NCT00623077|RADIATION|tomotherapy|"We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate)."
41134192|NCT01379885|BEHAVIORAL|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
41134193|NCT01379885|BEHAVIORAL|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
41134194|NCT05146635|DRUG|Intravesical Bcg|Patients will receive induction and maintenance BCG after complete TURBT.
41134195|NCT05146635|DRUG|Intravesical chemotherapy (epirubicin)|Patients will receive induction and maintenance epirubicin after complete TURBT.
41134196|NCT03367299|DRUG|Chemotherapy + Blinatumomab|Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
41134197|NCT05376982|DIAGNOSTIC_TEST|Neurodevelopmental Treatment|Using Neurodevelopmental Treatment Method
41134198|NCT05376982|DIAGNOSTIC_TEST|Body weight supported treadmill training along with conventional therapy|Using Body weight supported treadmill training along with conventional therapy Method
41134199|NCT03185793|DRUG|Placebo|Placebo once daily for 5 weeks
41134200|NCT03185793|DRUG|SHR4640|1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
40760186|NCT05772130|OTHER|Electronic Health Record Review|Ancillary studies
40760187|NCT05772130|BEHAVIORAL|Personal Contact|Receive family letter and genomic test report with provider-mediated contact
41134201|NCT03185793|DRUG|benzbromarone|25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
41134202|NCT03260998|DIAGNOSTIC_TEST|electrocardiogram|measurment of QT dispersion and corrected QT and other electrocardiogram changes
41134203|NCT06269029|OTHER|Chest mobility exercises|exercises were repeated 6 times on each side with rest of period for 30 seconds in between. The intervention will be carried out for one week with total of 7 sessions. Each Exercise will be accompanied by breathing pattern. In neutral position of exercises, subjects will be asked to exhale during flexion, turning or extension subject will be asked to do inhale.
41134204|NCT06269029|OTHER|proprioceptive neuromuscular facilitation|The technique used in this study Proprioceptive neuromuscular facilitation technique of hold and relax stretching for isolated clavicular head of the pectoralis major muscle. The subjects sitting on a chair with back support to keep spine in a neutral position and both their arms are extended and hands are placed behind the occipital region. His both arms will be positioned in glenohumeral horizontal extension, and glenohumeral abduction and external rotation with elbow bent to perform stretch position of pectoral muscle. Then ask him to contract the pectoral muscles .This isometric contraction is held for 6 seconds. The patient then relaxed and passive stretch in the opposite direction . and it was repeated 6 times with rest period 30 seconds. The session will be given every day for one week
41134205|NCT02633085|DEVICE|Fixed Bearing or Mobile Bearing UKA|Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
41134206|NCT02729246|PROCEDURE|Laparoscopic Gastric Bypass|
40951192|NCT02549534|PROCEDURE|Axon Reflexes|"\*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~* Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33\*C.~* Heat Ramp: Increasing the heat in the heat probe to 42\*C at approx. 0.1\*C/10 sec.~* Skin Heating: Heating the skin of the toe for 30 minutes 42\*C.~* Heat Ramp: Increasing the heat in the heat probe to 44\*C at 0.1\*C/10 sec..~* Skin Heating: Heating the skin for an additional 5 minutes at 44\*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted."
40951193|NCT02549534|PROCEDURE|Axon Flares|Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
41454173|NCT00623077|RADIATION|total marrow irradiation|"TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9."
40951194|NCT02549534|PROCEDURE|Self-Reported Signs & Symptoms of CIPN|Self-reported signs \& symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
40951195|NCT02167425|OTHER|IMAT|The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
40951196|NCT06274320|OTHER|Group A: holistic approach|2-week Lipikar Urea 30% application (once daily in the evening) + 4-week Tolak® treatment (once daily in the evening)
40951197|NCT06274320|OTHER|Group B: Tolak® Standard of use|4-week Tolak® alone treatment (once daily in the evening)
40951198|NCT05909683|DIAGNOSTIC_TEST|Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.|After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.
40951199|NCT05909683|OTHER|Standard of Care|Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.
41454174|NCT00623077|DRUG|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day divided in every 6 hrs dosing for 5 days.
41454175|NCT00623077|RADIATION|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
40951200|NCT03439917|DIETARY_SUPPLEMENT|L-Carnitine tartrate|2g L-Carnitine tartrate as a powder consumed twice a day
40951201|NCT03439917|DIETARY_SUPPLEMENT|Meal Replacement Drink|325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
40951202|NCT03439917|DIETARY_SUPPLEMENT|Maltodextrin|2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day
40951203|NCT01234831|DEVICE|nucleic acid amplification of nasal swab; nasal swab culture|Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.
40951204|NCT01234831|OTHER|Nasal swab culture|Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
40951205|NCT00115648|DRUG|Nevirapine|Oral NVP daily dosage
40951206|NCT00115648|DRUG|AZT|Oral AZT daily
40951207|NCT00115648|DRUG|NVP and AZT|Oral single dose NVP plus oral daily AZT during the first weeks
40951208|NCT00115648|DRUG|NVP|Oral NVP daily to age 14 weeks
40951209|NCT00115648|DRUG|NVP+AZT|Oral NVP daily plus oral AZT daly to age 14 weeks
40951210|NCT00386386|OTHER|hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion|Above
40951211|NCT00291889|BIOLOGICAL|Mtb72F/AS02.|
40951212|NCT02737280|DEVICE|Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy|High flow nasal cannula therapy with Airvo (TM, Fisher \& Paykel Healthcare) device
40951213|NCT02737280|DEVICE|MedKit Finland - Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
40951214|NCT05983588|DRUG|RAVICTI 1.1 g/ml|"Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
40951215|NCT05983588|DRUG|Placebo|"Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
40951216|NCT06261918|PROCEDURE|Influence of metabolic syndrome on the achievement of pathological complete response|The proposed activity aims to assess the transcriptional and epimetabolic profile of locally advanced luminal or HER2+ or triple negative breast cancer in patients with/without metabolic syndrome to predict the therapeutic response to neoadjuvant chemotherapy.
40951217|NCT02515396|DRUG|MMI-0100|
40951218|NCT02515396|DRUG|Placebo|
40951219|NCT01858571|DRUG|Low dose chemotherapy|"Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Etoposide (50 mg/m2/d)~Cycle B~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
40951220|NCT04798755|DRUG|Methotrexate|Inicial dose 15mg/week increasing up to 25 mg/week
40951221|NCT04798755|DRUG|Adalimumab|At the Baselin visit adalimumab 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.
40951222|NCT04798755|DRUG|Adalimumab+Methotrexate|"Adalimumab: at the Baseline visit 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.~Methotrexate:Inicial dose 15mg/week increasing up to 25 mg/week"
40951223|NCT05235451|OTHER|Human-Animal Interactions|Human-animal interactions (HAI) is a powerful and cost-effective strategy to improve reading fluencies and comprehension of children with learning differences. Emerging data suggest that HAI help promote classroom behaviors and learning, including effects on cognition, emotional functioning, and motor skills for children with and without learning differences. The HAI reading group will receive reading instruction as usual plus visits from a registered therapy dog team (dog + animal handler) twice a week over 12 weeks.
40951224|NCT02180165|DRUG|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
40951225|NCT02180165|DRUG|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
40951226|NCT03617510|DRUG|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
40951227|NCT03617510|DRUG|Placebos|Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
40951228|NCT04915898|OTHER|Oral Hygiene - teeth brushing|Oral hygiene using a special kit with recommended materials and instructions: Use of an ADA approved toothbrush, toothpaste with dentifrice, antiseptic mouthwash and non-drying lip moisturizer encouraged after meals and at bedtime
40951229|NCT00354887|DRUG|Capecitabine|Oral capecitabine 750 mg/m\^2 twice daily (total daily dose 1500 mg/m\^2) on Days 1-14 in 21 Day Cycle.
40951230|NCT00354887|DRUG|Oxaliplatin|130 mg/m\^2 by vein Day 1 over 2 hours in 21 Day Cycle
40951231|NCT03475680|DRUG|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
40760188|NCT05772130|OTHER|Survey Administration|Ancillary studies
41289042|NCT04945993|DEVICE|Endomethasone N|Endomethasone N is a powder intended to be mixed extemporaneously with a eugenol-based liquid (i.e, Endomethasone Liquid) to obtain a permanent root canal sealer. After selection of dentists, they will screen consecutively and systematically eligible patients, will send them the Patient Information Letter and will enroll them in the clinical investigation if non opposition from the patient. Patient clinical data will be recorded in an electronic Case Report Form. Pseudonymized retro-alveolar radiographies at baseline consultation and at 5 and 10 years post-obturation consultations will be recorded in the e-CRF. These radiographies will be examined by 2 independent endodontists and the results of these examinations will be recorded in the e-CRF. Site data will be collected on a Site Questionnaire with Visual Analog Scales.
41289043|NCT02519764|OTHER|Hydration when thirsty.|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
40760189|NCT00103701|DRUG|Dasatinib|Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
40760190|NCT00555373|DRUG|Sirolimus|"1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
41289044|NCT02519764|OTHER|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
40951232|NCT03475680|DRUG|Oral Gentamycin|Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
40760191|NCT00532415|DRUG|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
40760192|NCT03686189|DEVICE|Iliac Bifurcation Stent Graft System|Device placement after preoperative preparation. For patients with the aortoiliac aneurysm, the placement of short-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft, or the placement of long-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft are recommended.
41289045|NCT02598713|DRUG|Aspiration Marker|Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.
40760193|NCT05660291|BEHAVIORAL|Early time-restricted eating|Subjects can eat whatever they want between the hours of 8:00 AM and 4:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 4:00 PM to 8:00 AM).
40760194|NCT05660291|BEHAVIORAL|Late time-restricted eating|Subjects can eat whatever they want between the hours of 12:00 PM and 8:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 8:00 PM to noon).
40760195|NCT02292355|OTHER|Pilates|The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
41454176|NCT03923322|DRUG|Botanical Tincture|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
40951233|NCT03475680|DRUG|Oral Ornidazole|"Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
40951234|NCT03475680|DRUG|Oral placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
41289046|NCT03332953|OTHER|E-cigarettes with varying concentrations of nicotine & flavor|Subjects will be asked to vape various e-cigarettes containing e-liquids at three concentrations of nicotine and sweet flavor (9 stimuli per subject).
41289047|NCT00355589|DRUG|Ramipril and hydrochlorothiazide|
41289048|NCT00169468|DRUG|Rituximab -CHOP plus Velcade|
41289049|NCT03989687|DEVICE|Fuji Triage|glass ionomer sealant
41289050|NCT03989687|OTHER|isolation|rubber dam or cotton roll isolation
41454177|NCT03923322|OTHER|Placebo|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
41454178|NCT01769222|BIOLOGICAL|Ipilimumab|Given intratumorally
41454179|NCT01769222|RADIATION|Radiation therapy|Undergo local radiation therapy, 10 Gy x 3 fractions
40951235|NCT03475680|DRUG|Oral placebo Ornidazole|"Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
41289051|NCT00231062|DEVICE|Sinuplasty|
41289052|NCT01112215|DRUG|Azathioprine|Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
41289053|NCT01112215|DRUG|Enteric-Coated Mycophenolate Sodium|Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
40951236|NCT03815474|DRUG|anlotinib|Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
40951237|NCT00427947|DRUG|ropivacaine/placebo|Continuous sciatic nerve bloc
40951238|NCT03967301|DIETARY_SUPPLEMENT|Probiotic|Intervention: defined as probiotic consumption
40951239|NCT03967301|DIETARY_SUPPLEMENT|Placebo|Placebo consumption. The placebo will be provided by the company that produces the probiotic.
41289054|NCT02602431|DEVICE|Extra-oral laser irradiation|Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
40951240|NCT02888301|PROCEDURE|Computed Tomography|Undergo 18F-clofarabine PET/CT
40951241|NCT02888301|RADIATION|Fluorine F 18 Clofarabine|Given IV
41289055|NCT02602431|DEVICE|Intra-oral laser irradiation|Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
41289056|NCT02602431|DEVICE|Extra-oral placebo|Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
41289057|NCT02602431|DEVICE|Intra-oral Placebo|Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
41289058|NCT00055198|DRUG|daptomycin|
41454180|NCT03259113|DEVICE|Insertable cardiac monitor|Insertable cardiac monitor (SJM Confirm Rx) subcutaneously.
41454181|NCT01665508|DRUG|Nebivolol|Patient to start nebivolol and have repeat testing in 3 months
41454182|NCT04778358|DRUG|Follitropin Delta, Recombinant|15 µg of follitropin delta will be administered subcutaneously daily
40760196|NCT05377814|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
40760197|NCT03796286|OTHER|Medium-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
40951242|NCT02888301|PROCEDURE|Positron Emission Tomography|Undergo 18F-clofarabine PET/CT
40951243|NCT00531401|DRUG|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
40951244|NCT06257628|DEVICE|Index Event|Patients with at least one Beckman High Sensitivity Troponin test at the Emergency Department visit
40951245|NCT04925726|OTHER|Land based exercise|The patients who had land based exercise
41454183|NCT02227550|DRUG|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
40951246|NCT04925726|OTHER|Water based exercise|The patients who had water based exercise
40951247|NCT02697487|OTHER|No treatment|This is an observational study with no intervention.
41454184|NCT02227550|DRUG|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine \>= 1.5 mg/dl (133mM), \<= 60 kg body weight or age \>= 80 years.
40760198|NCT03796286|OTHER|High-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
40760199|NCT03796286|OTHER|Control bar (0 g fiber)|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
40951248|NCT02239588|OTHER|Oral consumption|"Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
40951249|NCT04901676|DRUG|Leronlimab|Leronlimab 700 mg (first dose) followed by weekly 350 mg
40951250|NCT04901676|DRUG|Placebo|Placebo
40760200|NCT03686982|OTHER|Active Nitrate Bar|Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione
41289059|NCT04102891|OTHER|Microbiota modulation diet|The Collect\&Go shopping carts of the 400 participants will be adapted by replacing food products by healthier alternative ones based on the Flemish food-based dietary guidelines and the microbiota modulation diet guidelines for the control and study arm respectively. Based on these guidelines, and the habitual dietary pattern and level of food literacy of the participant, personalized dietary advice will be provided. A dietitian helpline will be available for further nutritional issues as well.
41454185|NCT03443492|DRUG|S-1|Intervention is administered to patients in this Arm.
40760201|NCT03686982|OTHER|Placebo Bar|No active ingredients
40951251|NCT03570944|PROCEDURE|HRS, KRS|Elective HRS or KNR in adult patients, with any ERAS compliance
41289060|NCT05115201|PROCEDURE|Scaling and root planing with antibiotics|Patients will be given amoxicillin and metronidazole, 500mg and 400mg respectively (AMX+MTZ) to be taken thrice daily for 7 days, as an adjuvant to scaling and root planing.
41289061|NCT05115201|PROCEDURE|Scaling and root planing only|Patients will be treated with scaling and root planing
41289062|NCT04429932|OTHER|Myblu flavor A_2.4|Use of Myblu e-cigarette with flavor 1 at 2.4% nicotine
41289063|NCT04429932|OTHER|Myblu flavor B_2.4|Use of Myblu e-cigarette with flavor 2 at 2.4% nicotine
41289064|NCT04429932|OTHER|Myblu flavor C_2.4|Use of Myblu e-cigarette with flavor C at 2.4% nicotine
41289065|NCT04429932|OTHER|Myblu flavor D_2.4|Use of Myblu e-cigarette with flavor D at 2.4% nicotine
41289066|NCT04429932|OTHER|Myblu flavor E_1.2|Use of Myblu e-cigarette with flavor 1 at 1.2% nicotine
41454186|NCT03443492|DRUG|Leucovorin(oral )|Intervention is administered to patients in this Arm.
41454187|NCT03443492|DRUG|Gemcitabine|Intervention is administered to patients in this Arm.
40760202|NCT03115463|OTHER|Titration of oxygen during neonatal resuscitation|Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
40760203|NCT02866331|DRUG|G-CSF (Leucostim)|
40760204|NCT02866331|BIOLOGICAL|CB (autologous cord blood)|
40760205|NCT02866331|DRUG|Placebo (Normal saline)|
40760206|NCT04172688|DIETARY_SUPPLEMENT|Prebiotic oligofructose-enriched inulin|Synergy1
41134207|NCT01507506|RADIATION|Radiotherapy|"Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
41134208|NCT01507506|RADIATION|Experimental arm|"Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA\> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
41134209|NCT04378036|OTHER|Neurodevelopmental Therapy|The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.
41134210|NCT04378036|DEVICE|Hippotherapy Simulator|Horse Riding Simulator (HRS) device was used as a hippotherapy simulator device. HRS is a device that moves forward, backward, backward-to-back, right-to-left swing and up-and-down swing in 3 dimensions, similar to the movements of a real horse, forming an 8-shaped movement on five axes. After the children sat in the saddle section, they were first taken to the warm-up speed program for 5 minutes, then to another one of the other speed levels (gradually moved to other speed levels as appropriate for the development and tolerance of children) and finally to the warm-up speed program for 5 minutes.
41134211|NCT01728298|BIOLOGICAL|SLITone ULTRA HDM immunotherapy|
41134212|NCT02067663|DEVICE|Paragard|The IUD will be placed as part of standard clinical care.
41134213|NCT02067663|DRUG|Mirena|The IUD will be placed as part of standard clinical care.
41134214|NCT00365885|OTHER|Computer-based clinical decision support.|computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
41134215|NCT00650169|DRUG|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fed
41134216|NCT00650169|DRUG|Plavix® Tablets 75 mg|75mg, single dose fed
41146798|NCT04301102|DEVICE|Hemosphere platform® together with the FloTrac Acumen IQ® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management. It incorporates predictive parameters such as the hypotension prediction index and decision support parameters such as dynamic arterial elastance and maximum dP / dT.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
40760207|NCT04172688|DIETARY_SUPPLEMENT|Placebo maltodextrin|Equicaloric dose of maltodextrin
40760208|NCT04582812|OTHER|Bilateral and simultaneous diaphragm ultrasonography reeducation plus inspiratory training|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
40760209|NCT04582812|OTHER|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
40760210|NCT06285357|DIETARY_SUPPLEMENT|EGCG + folic acid + B12|EGCG + folic acid + B12
40760211|NCT00332566|BIOLOGICAL|DTPw-HBV/Hib Kft vaccine GSK323527A|Intramuscular injection, 1 dose
40760212|NCT00332566|BIOLOGICAL|Tritanrix™-HepB/Hiberix™|Intramuscular injection, 1 dose
40760213|NCT03115515|DRUG|levothyroxine|To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
40951252|NCT05328063|OTHER|Control group|"All subjects will carry out a gluteus maximus strengthening work out. The exercises should be performed at a frequency of 3 times/week and with a dosage of 3 sets of 8 repetitions.~1-4 Weeks: 1. Bilateral gluteal bridge: Supine decubitus with knees and hips bent and feet supported. To raise the pelvis until the knees are flexed to 90° and then returns to the starting position. 2.Clam shell: Lateral decubitus with knees and hips bent to 45º, working leg placed on top of the other. Separate this knee while feet remain in contact using a medium density Theraband on the distal thighs. Bilateral work. 3. Side-Step: Bipedestation with Knees and hips bent. The exercise then consists of two steps taken in one direction followed by two steps in the opposite direction to return to the starting position. The elastic band shall be placed above the knees.~4-8 Weeks: 1.Unilateral gluteal bridge. 2 Clam shell: hips bents to 60º. 3. Side-Step: placing the elastic band over the ankles"
41134217|NCT04933474|BEHAVIORAL|painTRAINER®|PainTRAINER is among the most widely-validated mHealth interventions for pain management.18-25 Originally developed by members of our team at Duke and Northwestern University under NIH funding, the app teaches evidence-based pain coping skills using a self-administered, home-based software program. The system delivers eight sessions via any web-connected platform, including Android or iOS smartphones, tablets, or personal computers. The digital curriculum covers progressive muscle relaxation, activity/rest cycling, pleasant activity scheduling, recognizing negative automatic thoughts, pleasant imagery/distraction, problem solving, and monitoring for maintenance. Patients complete one session per week in a pre-determined order. The program can be completed in a flexible manner to accommodate life and medical events.
41134218|NCT04933474|DEVICE|PICO G2 4k|Patients allocated this arm will use a multi-modal, skills-based, selfmanagement VR program, called EaseVRx. Developed by AppliedVR (Los Angeles, CA) in partnership with Stanford pain psychologist Dr. Beth Darnall, the program teaches and trains users based on evidenced-based strategies and biofeedback exercises. EaseVRx combines psychoeducation, pain education, breathing training, relaxation exercises, and executive functioning games to provide a mind-body approach toward living better with pain. The standardized, reproducible, 56-day program delivers a combination of skills training and CBT-related treatments through scheduled daily virtual experiences. Each VR experience lasts between 2-16 minutes.
41134219|NCT03839550|COMBINATION_PRODUCT|Apatinib Mesylate +SHR-1210|"Apatinib mesylate tablets: 250 mg, orally once a day. Take about half an hour after a meal with warm water (the daily dose should be as much as possible.~SHR-1210: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks. A total of 6 months of treatment,starting 4-8 weeks after radical hepatic resection."
41134220|NCT03839550|PROCEDURE|Hepatic Arterial Infusion(HAI)|Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment (the specific time interval depends on the recovery of liver function of the patient). The specific dosage regimen is 80-100 mg of epirubicin or 50 mg of epirubicin + oxaliplatin 50 mg per HAI treatment.
41134221|NCT00357916|DRUG|PEP005 Topical Gel (0.01% concentration)|
41134222|NCT02162082|DEVICE|stent or scaffold|implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
41289067|NCT04429932|OTHER|Myblu flavor F_1.2|Fse of Myblu e-cigarette with flavor F at 1.2% nicotine
41289068|NCT04429932|OTHER|Myblu flavor G_2.4|Use of Myblu e-cigarette with flavor G at 2.4% nicotine
41454188|NCT03443492|DRUG|Oxaliplatin|Intervention is administered to patients in this Arm.
41454189|NCT03443492|DRUG|Irinotecan|Intervention is administered to patients in this Arm.
41454190|NCT03443492|DRUG|5-FU|Intervention is administered to patients in this Arm.
40760214|NCT02529488|DEVICE|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
40760215|NCT06034431|OTHER|Ride Share|"The Investigators' proposed study addresses the Prostate Cancer Research Program overarching challenge of Advancing Health Equity and Reducing Disparities in PCa by examining and addressing travel burden to PCa treatment centers. Investigators will focus on Black men (including those of Caribbean descent), a high-risk population experiencing poorer health outcomes for unjust and preventable reasons.~This research will inform efforts to reduce travel burden in the healthcare acquisition process and improve the timeliness of treatment in Black men with PCa in Massachusetts and other states. This project will improve the quality of life and enhance outcomes and overall health and wellness for this group. Investigators will use findings from this pilot study to obtain future funding for a multicenter randomized clinical trial that will estimate the effect of equity - oriented programs that remove transportation barriers to treatment and reduce Black-White disparities in PCa outcomes"
40760216|NCT06399484|OTHER|Manual mobilizations of the median nerve|"Slippage of the median nerve in the wrist: the subject's starting position (P0) will be recumbent supine with the cervical spine in a neutral position, the shoulder girdle in neutral position, 30º of glenohumeral abduction in neutral rotation, 90º of elbow flexion, prone-supination of the neutral forearm, wrist and fingers in neutral position. From this position the movements will be 1) Glenohumeral abduction up to 90º; 2) Glenohumeral external rotation to the frontal plane; 3) Supination of the forearm; 4) Extension of the wrist and fingers; 5) Elbow extension. This position is will combine with an ipsilateral cervical inclination (distal sliding). The proximal slide is carried out bringing the fingers of the hand towards the flexion while performing a contralateral cervical tilt.~Median nerve tension: the starting position and movements are the same described above but this time it will be done with contralateral cervical tilt."
40760217|NCT06399484|OTHER|Wrist movements|Movements of the wrist joint will be performed as a placebo treatment
40951253|NCT05328063|OTHER|Intervention group|"All subjects will receive a specific program of manual therapy on the hip joint. 10 sessions of manual therapy will be applied during 8 weeks, 1 session per week, except the first week when two sessions will be applied.~The protocol consists of passive manual joint therapy at low speed on the hip, applying each mobilization in 3 series of 10 repetitions. It also includes muscle stretching, performing 3 series and holding the stretch for 25 seconds.~Manual therapy includes: 1. Anteroposterior (AP) and posteroanterior (PA) displacement of the hip. 2. Lateromedial and mediolateral displacement of the hip. 3. Distraction of the long axis/traction of the hip. 4. Lower slip in internal rotation (IR) and external rotation (ER) of the hip. 5. Iliopsoas stretch. 6. Piriformis stretch.To perform the protocol, the patient shall be placed in the supine decubitus position.~In addition to the same gluteus maximus strengthening programme used for the control group."
40951254|NCT00137631|BEHAVIORAL|Many Men, Many Voices (3MV)|Small-group, 6-session HIV prevention intervention for Black MSM.
40951255|NCT02701699|BIOLOGICAL|18-F-FAZA|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
40951256|NCT03082261|DEVICE|Prodigy, Prodigy MRI or Proclaim Elite IPG|Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
40951257|NCT00968864|DEVICE|CliniMACS® (T cell depletion)|Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
40951258|NCT04737928|DRUG|Latanoprost|latanoprost 0.05%(one drop, once daily)
40951259|NCT04737928|DRUG|tafluprost|tafluprost 0.015% (one drop, once daily)
40951260|NCT05767125|DEVICE|APRV|Patients with moderate-to-severe ARDS were supported with APRV.
40951261|NCT05767125|DEVICE|LTV|Patients with moderate-to-severe ARDS were supported with LTV.
40951262|NCT02051231|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
41289069|NCT04429932|OTHER|Myblu flavor H_2.4|Use of Myblu e-cigarette with flavor H at 2.4% nicotine
40951263|NCT00631696|DRUG|Pregabalin|pregabalin 600 mg given twice a day
40951264|NCT00631696|DRUG|Placebo|Placebo
40951265|NCT02272478|DRUG|Arm A Mylotarg plus DA Versus CPX-351|Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
40951266|NCT02272478|DRUG|Arm B Vosaroxin and Decitabine|If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
40951267|NCT02272478|DRUG|Arm D Small molecule or Not|The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
40951268|NCT02272478|DRUG|Arm C DA V FLAG-Ida V DAC|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
41134223|NCT00495066|DRUG|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
41289070|NCT04855877|DRUG|Oral tablet|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
40760218|NCT02973152|PROCEDURE|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
40951269|NCT02272478|DRUG|Arm E CPX-351 (200 V 300)|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
40951270|NCT02272478|DRUG|Arm F DA V IDAC|Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
41289071|NCT04855877|DRUG|Placebo|Oral administration of lactose tablet (placebo)
41289072|NCT00922935|DEVICE|Cresco|Cresco components loading 10 days post surgery
40951271|NCT03890406|DRUG|Rocuronium: PTC(Post-tetanic count) 1~2|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
40951272|NCT03890406|DRUG|Rocuronium: TOF(Train-of-four) 1~2|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
41134224|NCT00912171|DRUG|budesonide (Aircort 50 nasal spray)|50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
41134225|NCT00912171|DRUG|montelukast (Singulair)|Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
41134226|NCT03030365|DEVICE|"Siemens Biograph mMR PET-MR (3T)"|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.
41289073|NCT00922935|DEVICE|Cresco|Cresco loading at 6-8 weeks post surgery
41289074|NCT00922935|DEVICE|Straumann components|Straumann components loading 6-8 weeks post surgery
41289075|NCT02725385|OTHER|Laboratory Biomarker Analysis|Correlative studies
41289076|NCT02725385|OTHER|Physiologic Testing|Undergo Trier Social Stress Test
41289077|NCT02725385|OTHER|Questionnaire Administration|Complete questionnaire
41454191|NCT03443492|DRUG|Leucovorin(IV)|Intervention is administered to patients in this Arm.
41454192|NCT03574545|BIOLOGICAL|ianalumab|Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
40951273|NCT05158608|DRUG|Post-transplantation Cyclophosphamide at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
40951274|NCT05158608|DRUG|Post-transplantation Cyclophosphamide at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
40951275|NCT01162070|OTHER|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
41289078|NCT04634123|OTHER|Pulpotomy therapy by White Portland Cement|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined using a sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White Portland Cement
40951276|NCT01162070|OTHER|Standardized strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
40951277|NCT04650022|DEVICE|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
40951278|NCT04466956|DEVICE|Virtual reality|Virtual reality headset worn with short relaxing video played during MVA procedure
40951279|NCT03565601|OTHER|Follow-up|Clinical data, radiological data and laboratory tests follow-up
40951280|NCT03364569|PROCEDURE|Tranexamic acid|Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.
40951281|NCT00163111|DRUG|VFENDÂ® I.V., Oral|
40951282|NCT00163111|DRUG|Conventional amphotericin B|
40951283|NCT00163111|DRUG|Diflucan IV, oral|
41134227|NCT03190148|OTHER|OGTT|A standardized 75g oral Glucose tolerance test was accomplished.
41134228|NCT03190148|OTHER|IVGTT|For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished
41134229|NCT03190148|OTHER|1H-magnetic resonance spectroscopy|For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
41454193|NCT06322485|BEHAVIORAL|Internet-based self-management intervention|An internet-based cognitive-behavioral therapy with six modules.
41454194|NCT04065607|PROCEDURE|Reopen the abdomen to check missed pathology or abdominal washouts|Re opening of the abdomen once the patient is stabilized after 24-48 hours to check the missed injury after damaged control surgery in trauma and to control the sepsis in fecal peritonitis due to abdominal tuberculosis or typhoid perforation
41454195|NCT04112199|DRUG|BIV201 continuous infusion|BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
40760219|NCT02973152|PROCEDURE|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
40760220|NCT05310357|DIAGNOSTIC_TEST|Testing for chromosomal instability (CIN)|The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment.
40760221|NCT06239753|BEHAVIORAL|Dynamic Neuromuscular Stabilization|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes. Application of Dynamic Neuromuscular Stabilization (DNS).
40951284|NCT06076954|BEHAVIORAL|CoolMinds|CoolMinds consists of 11 adolescent sessions and 9 parent sessions to be completed simultaneously during a 14-week treatment period. The main components comprise psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The parent program also comprises information on how to handle school absenteeism for parents and teachers or pedagogues. The intervention is mainly transdiagnostic within the anxiety disorders but also includes diagnosis specific modules and content allowing for more personalized treatment. The treatment is delivered via a telephone app but can also be accessed via computer.
40951285|NCT02060123|BEHAVIORAL|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~* Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~* Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~* Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
40951286|NCT02060123|OTHER|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
40951287|NCT06404671|PROCEDURE|Delayed interval cytoreductive surgery (DICS)|"patients will receive six courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by delayed interval cytoreductive surgery (DICS) within 6 weeks of the last cycle of chemotherapy. After DICS, patients will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks."
40951288|NCT06404671|PROCEDURE|Early interval cytoreductive surgery (EICS)|"patients will receive three courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by early interval cytoreductive surgery (EICS) within 6 weeks of the last cycle of chemotherapy. After EICS, patients will receive adjuvant three courses of intravenous carboplatin and paclitaxel every 3 weeks, then will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks."
40951289|NCT04205981|OTHER|Aerobic exercise|8-week aerobic exercise (moderate intensity), 5 times per week, 60 min per session. Exercise training under supervision of trained staff.
40951290|NCT06319378|DRUG|psilocybin 25 mg sod|psilocybin 25 mg sod
40951291|NCT06319378|DRUG|psilocybin 1 mg sod|active placebo
41289079|NCT04634123|OTHER|Pulpotomy therapy by White MTA|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined usinga sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White MTA
41289080|NCT05753111|DIETARY_SUPPLEMENT|PEA|PEA supplementation
41289081|NCT05753111|DIETARY_SUPPLEMENT|PLACEBO|Maltodextrin supplementation
41454196|NCT02638922|DRUG|Estradiol|Estradiol containing compounds administered orally in a non-randomized manner.
40760222|NCT06239753|BEHAVIORAL|Standard Prenatal Education Program Implementation|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes.
40760223|NCT06267014|BEHAVIORAL|Virtual Reality sessions|One session during 10-15 minutes per week for 6 weeks.
40760224|NCT03778697|PROCEDURE|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness suture system to plicate the greater curvature of the stomach
40760225|NCT01907646|DEVICE|bladder training|vescical catheter
40760226|NCT01907646|PROCEDURE|No bladder training|
40951292|NCT04610385|PROCEDURE|radical cystectomy with urinary diversion|surgical removal of the urinary bladder and other organs and perform a urinary shunt
40951293|NCT00687895|PROCEDURE|Clinical algorithm and microscopy diagnosis of malaria|"Clinical alogarithm~The content of the package included~1. description of signs and symptoms of malaria disease~2. history taking relevant to malaria and physical examination~3. identification of danger signs and severe illness for referral~4. appropriate treatment~5. counseling patients on the use of drugs.~Malaria microscopy. contents~1. make thick blood smears from patients with fever and stain with Giemsa~2. identify and count malaria parasites~3. maintain the microscope and store blood slides."
40951294|NCT04488796|BEHAVIORAL|Assigned Strategies: Opt-in|Participants will be assigned two behavioural strategies with the opt-in choice structure
40951295|NCT04488796|BEHAVIORAL|Assigned Strategies: Active Choice|Participants will be assigned two behavioural strategies with the Active choice structure
41454197|NCT05920395|OTHER|Electro-acupuncture|Patients lie supine on the treatment bed, and after routine disinfection, a 0.30×60mm or 0.30×40mm disposable sterile acupuncture needle is inserted directly into the acupoint. Once obtaining qi, the needle is manipulated with even reinforcing and reducing techniques to maintain needle sensation. Acupoints selected include Zhongwan, Zusanli, Neiguan, and Tianshu, connected to the 6805-All electro-acupuncture therapy device. Zhongtuo and Tianshu acupoints are connected to a set of electrodes, with the positive pole connected to Zhongtuo and the negative pole connected to one side of Tianshu. The stimulation uses sparse and dense wave pulses with a frequency of 2Hz/100Hz, with the stimulation intensity determined based on individual patient tolerance. Each session lasts for 30 minutes, with a treatment frequency of once every other day, for a total of 4 weeks.
41454198|NCT05920395|OTHER|Sham electro-acupuncture group|Shallow acupuncture needles are used and then disconnected from the electrode. They are tied with black tape and connected to the sham electrode. The device is not powered on, and the rest of the treatment is the same as the electro-acupuncture group.
40951296|NCT04488796|BEHAVIORAL|Assigned Strategies: Enhanced Active Choice|Participants will be assigned two behavioural strategies with the Enhanced Active choice structure
40951297|NCT04488796|BEHAVIORAL|Choice of Assignment: Opt-in|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Opt-in choice structure
41134230|NCT00764166|DRUG|Docetaxel + hormonal treatment (LH-RH agonist)|"Docetaxel will be administered:~* To D1 of every cycle in the dose of 70 mg/m²,~* Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally"
40760227|NCT04494737|BEHAVIORAL|Active Comparator: Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
40760228|NCT04494737|BEHAVIORAL|Active Comparator: Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
41134231|NCT00764166|DRUG|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
40760229|NCT00968045|DRUG|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
40951298|NCT04488796|BEHAVIORAL|Choice of Assignment: Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Active choice structure
40951299|NCT04488796|BEHAVIORAL|Choice of Assignment: Enhanced Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Enhanced Active choice structure
40951300|NCT02044445|PROCEDURE|Oocyte retrieval will be performed 36 h or 38 h after hCG administration|Oocyte retrieval will be performed 36 h or 38 h after hCG administration
41289082|NCT01252329|PROCEDURE|elective lymph node dissection|This entails selective lymph node dissection in patients with negative lymph node exams. The nodes dissected are those that drain from the high risk cutaneous squamous cell cancer. Subsequent radiation and/or chemotherapy may be administered in a small percentage of subjects, depending on the result of the neck dissection.
41289083|NCT04205422|PROCEDURE|BIPAP|Biphasic Intermittent Positive Airway Pressure
41289084|NCT04205422|PROCEDURE|APRV|Airway Pressure Release Ventilation
41289085|NCT04101422|BEHAVIORAL|Augmented Reality 1|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) and non-smoking related stimuli (pens, notebook, eraser).
41289086|NCT04101422|BEHAVIORAL|Augmented Reality 2|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of smoking related AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.). They will also be presented with real smoking (e.g., ashtray) and non-smoking (e.g., pencil) items. Their urge to smoke rating following each presentation will be compared for AR images vs. vivo items, and smoking-related vs. non-smoking related.
41289087|NCT04101422|BEHAVIORAL|Augmented Reality 3|Participants will use an Augmented Reality )AR) application on smart phones in locations and situations where they typically smoke. the application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays). Participants will have a goal of using application at least 5 times per day for 7 days. Usage and rating data will be collected in real-time.
41289088|NCT04101422|BEHAVIORAL|Augmented Reality 4|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.) Their urge to smoke rating following each presentation will be compared from baseline urge to smoke. The post-test urge to smoke will be compared between control group and extinction group.
41289089|NCT02252978|DRUG|ciprofloxacin|Given PO
41289090|NCT02252978|OTHER|placebo|Given PO
41289091|NCT02252978|OTHER|quality-of-life assessment|Ancillary studies
41289092|NCT02252978|OTHER|laboratory biomarker analysis|Correlative studies
41289093|NCT03560895|DEVICE|cuffed endotracheal tube|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube
41289094|NCT03560895|DEVICE|Uncuffed endotracheal tube|Patients will be anesthetized using uncuffed endotracheal tube
41289095|NCT03177577|DEVICE|Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.
41289096|NCT03177577|DEVICE|Splint with strengthening exercises|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
40760230|NCT06418763|DIETARY_SUPPLEMENT|Baobab spread mixed with fermented brown seaweed|5-day intake period
40951301|NCT04763668|OTHER|Pregnant HIV positive women on ARTs|Cardiovascular disease risk in pregnant HIV positive women on ARTs
40951302|NCT04763668|OTHER|Babies born to HIV positive mothers on ARTs|cardiovascular disease risk in the offspring of HIV positive mothers on ARTs
40951303|NCT02829073|DEVICE|Neuromonics Tinnitus Treatment Program|The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
41289097|NCT03939910|DEVICE|Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.|Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
41289098|NCT06239311|DRUG|Methotrexate|Solution for injection in prefilled pen
41289099|NCT06239311|DRUG|Placebo|Solution for injection in prefilled pen
41289100|NCT02250040|OTHER|Conventional physiotherapy|Physiotherapy techniques that included muscle training, stretching and endurance.
41454199|NCT02148744|BIOLOGICAL|XmAb7195|Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8
41454200|NCT02148744|BIOLOGICAL|Placebo|
40760231|NCT06418763|DIETARY_SUPPLEMENT|Baobab spread|5-day intake period
40760232|NCT05898334|DEVICE|Active Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the strong biophoton field so her/his entire body will be energized to promote self-healing.
40760233|NCT05898334|DEVICE|Inactive Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the normal hotel bed and the participant will not receive any biophotons.
40760234|NCT06536881|BEHAVIORAL|Fasting|The dietician will review the patient's chemotherapy schedule, and confirm the fasting window (as windows may be 24, 26 or 48 hours; and chemotherapy start times can vary from patient to patient).
41289101|NCT02250040|OTHER|Techniques based on patients' functional level were added.|The added techniques aimed to improve balance and movement dissociation.
41289102|NCT03598777|BIOLOGICAL|Botulinum toxin type A|Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.
41289103|NCT03598777|DRUG|Placebo|The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
41289104|NCT04980183|DEVICE|Arthroscopic surgical robot|The surgeon performs cruciate ligament bone canal positioning and ligament reconstruction with the assistance of an arthroscopic surgical robot
41289105|NCT04980183|DEVICE|Conventional arthroscopic cruciate ligament reconstruction|The surgeon performs conventional arthroscopic cruciate ligament reconstruction surgery without other auxiliary equipment
40760235|NCT06002594|OTHER|group low-volume irrigation|Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 4 ml of 0.9% sodium chloride(NaCl) solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
40951304|NCT02829073|DEVICE|Placebo Device|A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
40951305|NCT05541042|OTHER|Observational only|This is an observational study
40951306|NCT04803539|DRUG|capecitabine|capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
41289106|NCT05977543|OTHER|Functional crackers enriched with grape seed flour|The crackers was enriched with 10% grape seed flour
41289107|NCT05977543|OTHER|Functional crackers with 40% barley flour and enriched with β-glucans|The crackers consisted of 60% wheat flour, 40% barley flour and was enriched with β-glucans.
41289108|NCT05275829|OTHER|Tele simulation|Interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform).
41289109|NCT00377299|DRUG|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
40951307|NCT04803539|DRUG|capecitabine + camrelizumab + apatinib|Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
41289110|NCT00377299|DRUG|Placebo|Placebo matching active medication in all other physical aspects
41289111|NCT01419171|DEVICE|OMEGA™ Monorail Coronary Stent System|All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.
41289112|NCT00233636|DRUG|Iressa (Gefitinib)|
41289113|NCT00233636|PROCEDURE|Radiotherapy|
41289114|NCT01362322|BIOLOGICAL|Boostrix TM (new syringe presentation)|Single dose, intramuscular administration in a new syringe presentation
41289115|NCT01362322|BIOLOGICAL|Boostrix TM (previous syringe presentation)|Single dose, intramuscular administration in previous syringe presentation
41289116|NCT03088241|OTHER|switch|switch to second-line ART
41289117|NCT02616653|PROCEDURE|L3-L4 location: Palpation method confirmed by US|An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
41289118|NCT00046826|DRUG|docetaxel|
41289119|NCT00046826|DRUG|estramustine phosphate sodium|
40951308|NCT02524093|BEHAVIORAL|Positive Mental Training|Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
41289120|NCT00046826|DRUG|thalidomide|
41289121|NCT05395169|OTHER|dietary supplement ,electronic treadmill ,DASH diet.|Control group Will be receive medical treatment for 12 weeks. Study group Will be receive the same medication as in control group in addition to DASH diet and aerobic exercise for 12 weeks.
40951309|NCT02524093|OTHER|treatment as usual|
40951310|NCT01560403|DRUG|Teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 12 months
40951311|NCT05933447|DRUG|Rodatristat Ethyl|Oral, Tablet, 300 mg QD, 300 mg BID, 600 mg BID, 900 mg BID, 900 mg QD
41289122|NCT01811030|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
40951312|NCT05933447|DRUG|Moxifloxacin|Oral, Tablet, 400 mg QD
40951313|NCT05933447|DRUG|Placebo for Rodatristat|Oral, Tablet, O mg QD, 0 mg BID
40951314|NCT05933447|DRUG|Placebo for Moxifloxacin|Oral, Tablet, 0 mg QD
41289123|NCT00722176|DRUG|BL-1020|10 mg
41289124|NCT00722176|DRUG|BL-1020 10-30 mg|BL-1020 10-30 mg
41289125|NCT00722176|DRUG|risperidone|risperidone
41289126|NCT03675399|OTHER|Supra-threshold isometric exercise|The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).
41289127|NCT03675399|OTHER|Infra-threshold isometric exercise|The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
41289128|NCT06512402|DRUG|Norepinephrine|patients will receive norepinephrine infusion at rate of 0.05 mcg/Kg/min
41289129|NCT06512402|DRUG|Epinephrine|patients will receive epinephrine infusion dose of 0.03 mcg/Kg/min
41289130|NCT03787069|DRUG|iv Lignocaine vs placebo|Lignocaine is available in an ampule of 10 ml containing 20 mg/ml of lignocaine or 2%, Lignocaine will be given in dose of 1.5 mg/kg I/V
40951315|NCT06558058|DRUG|Rivaroxaban 10 mg film-coated tablet|One tablet of the test drug was given orally after an overnight fast.
40951316|NCT06558058|DRUG|Xarelto 10 mg film-coated tablet|One tablet of the reference drug was given orally after an overnight fast.
40951317|NCT04622306|DEVICE|Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B|Condom functionality study to determine failure rates
40951318|NCT04245072|PROCEDURE|Intravitreal injection|Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.
40951319|NCT04245072|DIAGNOSTIC_TEST|Fluorescent angiography|Ophthalmic examination
40951320|NCT04245072|DIAGNOSTIC_TEST|Visometry|Ophthalmic examination
40951321|NCT04245072|DIAGNOSTIC_TEST|Refractometry|Ophthalmic examination
40951322|NCT04245072|DIAGNOSTIC_TEST|Slit lamp examination|Ophthalmic examination
40951323|NCT04245072|DIAGNOSTIC_TEST|Ophthalmoscopy|Ophthalmic examination
40951324|NCT04245072|DIAGNOSTIC_TEST|OKT|Ophthalmic examination
41289131|NCT01515072|OTHER|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
41289132|NCT05960955|DRUG|Cadonilimab|IV infusion,Specified dose on specified days
41289133|NCT05960955|DRUG|AK117|IV infusion,Specified dose on specified days
40951325|NCT03463512|DRUG|Racecadotril plus ORS|Racecadotril plus ORS
40951326|NCT03463512|DRUG|ORS|ORS
40951327|NCT00000337|DRUG|Selegiline|
40951328|NCT03015857|DRUG|phenylephrine|- phenylephrine; a vasopressor drug given to prevent post spinal hypotension
40951329|NCT03015857|DRUG|Norepinephrine|- norepinephrine; a vasopressor drug given to prevent post spinal hypotension
41134232|NCT04568213|DRUG|Hypochlorous Acid Gel 0.02%|0.02% Hypochlorous Acid Gel (OCusoft Hypochlor GEL) will be sprayed onto the closed eyelid of the surgical eye while covering the fellow eye with palm of the hand, left for 60 seconds, then wiped off with a clean gauze, tissue, or cotton ball.
41289134|NCT05960955|DRUG|Oxaliplatin|IV infusion,Specified dose on specified days
41289135|NCT05960955|DRUG|Tegafur-gimeracil-oteracil potassium|Oral,Specified dose on specified days
41134233|NCT05772338|DRUG|BNP105 (25 + 25 + 15)|BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.
41289136|NCT05960955|DRUG|Docetaxel|IV infusion,Specified dose on specified days
41454201|NCT01586039|DEVICE|Visible light|We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
40951330|NCT03015857|DRUG|Bupivacaine|intrathecal bupivacaine 10 mg will be given in both groups
40951331|NCT03015857|DRUG|Fentanyl|intrathecal fentanyl 20 mcg will be given in both groups
40951332|NCT03015857|DRUG|Placebo (normal saline)|
40951333|NCT06398808|DRUG|Arm1|ZYIL1 capsules 25 mg for oral administration + 50 mg placebo
40951334|NCT06398808|DRUG|Arm 2|ZYIL1 capsules 50 mg for oral administration + 25 mg placebo
40951335|NCT02002832|DRUG|Lurasidone tablets|Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
40951336|NCT02002832|DRUG|Risperidone tablets|Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
40951337|NCT04045964|DRUG|nicotine replacement therapy (NRT)|Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home
40951338|NCT04045964|BEHAVIORAL|motivational advice|Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol
40951339|NCT04045964|BEHAVIORAL|Quitline referral|Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
40951340|NCT00166465|DRUG|ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)|
40951341|NCT00156520|DRUG|aprotonin; epsilon aminocaproic acid|
40951342|NCT03177057|BEHAVIORAL|Compliance Monitoring|Record behavior
40951343|NCT03177057|OTHER|Health Telemonitoring|Receive health monitoring text messages
40951344|NCT03177057|OTHER|Questionnaire Administration|Ancillary studies
40951345|NCT02182739|DRUG|Meloxicam|tablets or injectable solution
41134234|NCT05772338|OTHER|Placebo|Placebo. Up to six applications per day.
41289137|NCT05960955|DRUG|5-Fluorouracil|IV infusion,Specified dose on specified days
40760236|NCT06002594|OTHER|group high-volume irrigation|Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 20 ml of 0.9% NaCl solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
40760237|NCT01908699|DRUG|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
41289138|NCT02627950|DRUG|Morphinhydrochloricum|5 mg morphine intravenously
40760238|NCT01908699|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
41289139|NCT02627950|DRUG|Metoclopramide|10 mg MCP intravenously
41289140|NCT02627950|DRUG|Ticagrelor|180 mg ticagrelor orally
41289141|NCT02627950|DRUG|Isotonic sodium chloride|10 ml NaCl 0.9% intravenously
40760239|NCT00190528|DRUG|neoadjuvant chemotherapy + radical hysterectomy|
41289142|NCT04478422|OTHER|Muscle strengthening with vascular occlusion|The muscle strengthening group with partial vascular occlusion will perform the strengthening exercises: single leg squat on 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat. The equipment for vascular occlusion will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017). If necessary, the pressure can be adjusted at intervals and after the end of the exercise, an interval of 5 minutes is suggested for blood reperfusion.
41289143|NCT04478422|OTHER|Conventional muscle strengthening|The conventional muscle strengthening group perform the same exercises as the intervention group: One-legged squat on a 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat, however, without restriction on blood flow.
41289144|NCT06513520|BIOLOGICAL|Blood sampling|Additional blood tube collection during routine blood sampling.
40760240|NCT00190528|PROCEDURE|radical hysterectomy|
41289145|NCT02556762|RADIATION|Radiotherapy with simultaneous modulated accelerated boost|Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases
41289146|NCT02556762|RADIATION|Standard dose radiotherapy|Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease
41289147|NCT02556762|DRUG|PF|Chemotherapy: Cisplatin and 5fluorouracil
41289148|NCT02467114|DEVICE|Transcranial magnetic stimulation (TMS)|This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
41289149|NCT02467114|DEVICE|Sham coil stimulation|Stimulation with a sham coil as a comparison
41289150|NCT02467114|OTHER|Control without stimulation|
41289151|NCT03615027|BEHAVIORAL|Dementia-specific advance care planning|see detailed description
41289152|NCT06074172|DRUG|Cannabidiol in Oral Dose Form|Cannabidiol press pills provided by Steve Goods CBD (Longmont, Colorado). CBD pills were tested by the chemistry lab at CSU Pueblo and by Botanacor in Denver, CO. Both laboratories determined CBD pills to be 99.98% pure with no THC, heavy metals, bacteria, and pesticides detected.
40951346|NCT02284542|PROCEDURE|Awake|Upon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
40951347|NCT02284542|PROCEDURE|Non-Awake|"The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.~(Falowski et al., 2011)."
40951348|NCT02296073|DRUG|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
41454202|NCT04205539|DRUG|Dexmedetomidine|This medication will be administered sublingually using an LMA Intranasal Mucosal Atomization Device, which allows the medication to be administered in the form of a spray. Patients will be instructed to keep the medication in their mouth for about 2 minutes, or until fully absorbed. Pulse oximetry and blood pressure will be monitored throughout the duration of treatment. After the subject is asleep, the second DTI scan will be done.
40760241|NCT06456684|DIAGNOSTIC_TEST|Fluoro[18F]promethazine|It is the first F-18-labeled VMAT2 imaging agent for PET imaging that is currently being used in the clinic internationally. In the brains of Parkinson's disease (PD) patients, the target binding of fluoro\[18F\]promethazine was significantly reduced compared with that of normal controls, with an 81% reduction in the posterior region of the nucleus accumbens, a 70% reduction in the anterior region of the nucleus accumbens, and a 48% reduction in the caudate nucleus; the radioactivity uptake in the caudate nucleus of PD patients was correlated with the extent of their disease
40760242|NCT06571331|OTHER|De-Stress & Snooze Gummies-U001|Two gummies daily in sequence 30-45 minutes before bed for 60 days
40760243|NCT06571331|OTHER|De-Stress & Snooze Gummies-I001|Two gummies daily in sequence 30-45 minutes before bed for 60 days
40760244|NCT06571331|OTHER|Placebo Gummies 002|Two gummies daily in sequence 30-45 minutes before bed for 60 days
40760245|NCT05169944|DRUG|Magrolimab|Anti-cancer therapeutic agent targeting the CD47-signal receptor protein-alpha (SIRP-alpha) axis
40760246|NCT05137626|DRUG|AT-527 + digoxin|"* Day 1: A single dose of digoxin will be administered.~* Day 15: A single dose of AT-527 and digoxin will be co-administered."
40760247|NCT05137626|DRUG|AT-527 + digoxin|"* Day 1: A single dose of digoxin will be administered.~* Day 15: A single staggered dose of AT-527 and digoxin will be administered (2 hours later)."
40760248|NCT00323245|BEHAVIORAL|Physiotherapy for urinary incontinence|See Detailed Description.
40760249|NCT06501339|PROCEDURE|maintenance ECT|Frequency of weekly sessions for 1 month, then fortnightly for 5 months
40951349|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
41454203|NCT00516295|DRUG|topotecan hydrochloride|Given IV
40760250|NCT06501339|DRUG|Aripiprazole tablet|Aripiprazole 10 mg in the morning throughout the study period
40760251|NCT00000501|BEHAVIORAL|diet, sodium-restricted|
40760252|NCT00000501|BEHAVIORAL|diet, reducing|
40760253|NCT00000501|DRUG|potassium|
41454204|NCT00516295|DRUG|vincristine sulfate|Given IV
40760254|NCT06570681|DIAGNOSTIC_TEST|Video call assisted assessment of acute stroke|If the patient is eligible for study inclusion, eight symptoms from the study protocol are evaluated and registered in the Prehospital Patient Journal (PPJ) on the amPHITM Prehospital Health Care Record (Amphi Systems, Hasserisvej 125, 9000 Aalborg, Denmark), on a tablet mounted in each EMT vehicle. Afterwards, the EMS personnel will contact the on-call neurologist and if the vehicle is in the intervention arm a live video stream is initiated. The on-call neurologist then examines the patient via via the video-call and triages the patient.
40760255|NCT00945880|DRUG|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
40760256|NCT03066518|DRUG|Melatonin 5 mg|
40760257|NCT03066518|OTHER|Placebo|
40951350|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
40951351|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
40951352|NCT02296073|DRUG|Fentanyl|Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
41454205|NCT00516295|DRUG|cyclophosphamide|Given IV
41454206|NCT00516295|BIOLOGICAL|bevacizumab|Given IV
41454207|NCT04535986|DRUG|Ensifentrine|Dosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks or 48 weeks
41454208|NCT04535986|DRUG|Placebo|Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks
41454209|NCT04797936|DRUG|BNO 1030|Imupret 25 drops х 6 times per day for 14 days
40951353|NCT02296073|OTHER|assessment|Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
40951354|NCT04711434|DRUG|PD-1 Antibody|Toripalimab: 240mg IV every 3 months for a year
40951355|NCT05661110|OTHER|Observational|All patients will be treated with standard of conversion treatment with HIPEC combined PD1/PDL1 inhibitor. After obtaining written informed consent, participants will have serial blood, tumor tissue collection. The blood collection (10 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. Participants will remain on the study for as long as they are being followed or treated at Affiliated Cancer Hospital \& Institute of Guangzhou Medical University. Participants can withdraw from the study at any time.
40760258|NCT02570425|DEVICE|Training on BF Spiromax followed by SYMBICORT Turbohaler|Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
41289153|NCT06074172|DRUG|Placebo in Oral Dose Form|Placebo press pills provided by Steve Goods CBD (Longmont, Colorado). Placebo pills were tested by the chemistry lab at CSU Pueblo and by Botanacar in Denver, CO. Both laboratories determined placebo pills to be pure with no heavy metals, bacteria, and pesticides detected.
41289154|NCT01312155|OTHER|Intubation|Intubation, endotracheal
41289155|NCT02642861|DRUG|Cyclobenzaprine|cyclobenzaprine administration for 2 weeks
41289156|NCT02642861|DRUG|Calcium Carbonate|Calcium carbonate for 2 weeks
41289157|NCT01998646|DRUG|ASP4058|Oral tablet
40951356|NCT05092646|BIOLOGICAL|Axolotl Ambient|Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.
40951357|NCT05092646|DRUG|"Drug/Placebo: 0.9% Normal Saline"|"Drug/Placebo: 0.9% Normal Saline"
40951358|NCT00519454|OTHER|Peripheral lab draws|100ml blood for analysis, taken no more than 4 times in one year.
41289158|NCT01998646|DRUG|Placebo|Oral tablet
41289159|NCT04791969|DRUG|Naltrexone Hydrochloride|Intermittent Oral Naltrexone, 50 mg
40760259|NCT02570425|DEVICE|Training on SYMBICORT Turbohaler followed by BF Spiromax|Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
41289160|NCT04791969|DRUG|Placebo|Intermittent Oral Placebo
41289161|NCT04791969|BEHAVIORAL|Ecological Momentary Intervention|"Receive ecological momentary intervention if ecological momentary assessment reports meth craving, stress, not taking study drug, or antecedents detected for high risk meth use."
41289162|NCT02990338|DRUG|Isatuximab|Pharmaceutical form: solution for infusion Route of administration: intravenous
41289163|NCT02990338|DRUG|Pomalidomide|Pharmaceutical form: capsule Route of administration: oral
41289164|NCT02990338|DRUG|Dexamethasone|Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
40760260|NCT00192478|BIOLOGICAL|Medi-524|IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
40951359|NCT06352996|OTHER|Three-Dimensional Assessment of Maxillary Canine Retraction with Power Arm|A nickel titanium closed coil spring will be stretched from the mini-implant to the power arm will be used for canine retraction.
41454210|NCT04797936|OTHER|Standard care|isolation mode symptomatic therapy as needed: antipyretic (paracetamol) saline solutions in the nose x 4 times a day -14 days
40760261|NCT05692557|DEVICE|Virtual reality|"The Oculus Rift's (Lenovo, Beijing, China) Fujii - Mystical Journey was the game played by the VRD group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations.~The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there."
40760262|NCT05692557|PROCEDURE|Progressive muscle relaxation|The patients of the control group performed Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds.
40760263|NCT06417788|DEVICE|Dental implant placement|Dental implant placement guided by Navident® (ClaroNav Inc., Toronto, Canada)
40951360|NCT06352996|OTHER|Three-Dimensional Assessment of Maxillary Canine Retraction without Power Arm|A nickel titanium closed coil spring will be stretched from the mini-implant to the canine bracket will be used for canine retraction.
40951361|NCT00722800|DRUG|drospirenone and ethinyl estradiol (YAZ)|1 tablet daily for 24 weeks
40951362|NCT00722800|DRUG|Placebo|1 tablet daily for 24 weeks
40760264|NCT06417788|PROCEDURE|Static guided implant placement|Dental implant placement guided by a stereolithographic pilot drill guide.
40760265|NCT02787174|OTHER|Asthma Medication Adherence Education|
40951363|NCT02677961|OTHER|Observation|
40951364|NCT00788073|DRUG|STX209|Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
40951365|NCT00788073|DRUG|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
41134235|NCT01375790|DEVICE|Exercise with Whole-body vibration platform|The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).
41454211|NCT06466499|BEHAVIORAL|The intervention group|Is described in arm
41454212|NCT06256224|DRUG|Toripalimab|Toripalimab combined with CCRT
41454213|NCT06256224|RADIATION|CCRT|CCRT includes cisplatin (40 mg/m2, once a week for 5 weeks), radiotherapy (45-50.4Gy/25-28Fx, 5 fractions a week, followed by brachytherapy 24-30Gy/3-5Fx)
41454214|NCT05778760|OTHER|Retinol|Topical retinol (0.5%) applied to the face
40951366|NCT05904912|DRUG|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
41134236|NCT01375790|OTHER|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
41134237|NCT00176319|BEHAVIORAL|Aerobic endurance exercise training (ergometer)|
41134238|NCT06122025|DEVICE|Patient Access|A 6-month pilot prospective interventional study with an independent groups design.
41134239|NCT06499142|DEVICE|Parakeet:The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample.|"The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample. The Parakeet is a point of care test completely controlled by the surgeon and operating team. It uses the scientific principle of Lateral Flow of antibody-antigen-conjugate complexes being arrested in a Test Line."
40760266|NCT05713838|DRUG|Durvalumab|1500 mg Durvalumab, IV, day 1 Q4W (max. 15 cycles)
41134240|NCT04798066|BIOLOGICAL|HB-adMSCs|Autologous adipose derived mesenchymal stem cells
41289165|NCT00959244|OTHER|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
41289166|NCT00959244|OTHER|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
41289167|NCT00959244|OTHER|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
41289168|NCT00959244|OTHER|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
40760267|NCT05713838|DRUG|FLOT|50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles
40760268|NCT05713838|DRUG|mFOLFOX-6|85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles
40760269|NCT05713838|RADIATION|Radiotherapy|5 weeks with 5 days a week radiotherapy (25 daily fractions with 2.0 Gy = ∑50Gy)
40760270|NCT02439411|DRUG|Trametinib|
41134241|NCT01855165|BEHAVIORAL|Advice on DDIs|
41134242|NCT01868230|BEHAVIORAL|Lifestyle Intervention|
40760271|NCT05032222|OTHER|Uroflowmetry|Diagnostic test
40760272|NCT05816161|DIAGNOSTIC_TEST|Integrated Neuromuscular Inhibition Technique|Exercises
40760273|NCT05816161|DIAGNOSTIC_TEST|Myofascial Release|Exercises
40760274|NCT02811419|DEVICE|i-scan|examination will be performed with i-scan digital enhancement
40760275|NCT02811419|DEVICE|standard high-definition white light|examination will be performed with high-definition white light
41454215|NCT05778760|OTHER|Adapinoid|Topical Adapinoid (0.5%) applied to the face
41454216|NCT02340780|DRUG|Buparlisib|
41454217|NCT06102057|RADIATION|standard Radiotherapy|standard FDG-PET-based radiotherapy
41454218|NCT06102057|DRUG|Chemotherapy|concurrent standard of care chemotherapy
41454219|NCT06102057|DRUG|Immunotherapy|standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.
41289169|NCT00746538|DEVICE|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
40786494|NCT04726891|BEHAVIORAL|Movement-2-Music + Social Networking Support|The primary goal of the proposed research is to conduct a 12-week pilot study of the SMART-HEALTH intervention in 30 individuals with SCI. There are several unique features of this study design, including a novel adapted exercise program (M2M), instructor-led, individualized training (M2M Live; described in D.2.1), individualized behavioral coaching, and social networking support.
40951367|NCT05904912|DRUG|PENG-Bupivacaine|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block area is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
41289170|NCT00739128|BIOLOGICAL|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
41289171|NCT00739128|BIOLOGICAL|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
41289172|NCT05767541|OTHER|Pilates exercises|The Pilates technique consist of hundred, swimming, prone leg lift, single leg stretch, spine stretch forward, arm circles, imprint and release, one leg circles and mini squat.
41289173|NCT05767541|OTHER|Resistance exercises|Resistance training include leg press, shoulder press, bench press, back arm press, seated row, knee extension, leg curl and seated calf raise
41289174|NCT00152412|DRUG|Levocetirizine oral solution|
41289175|NCT01300377|DRUG|Bupivacaine / Lidocaine|5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
41289176|NCT01300377|DRUG|Lidocaine|10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
41289177|NCT01982201|DRUG|Lesinurad 400 mg|
41289178|NCT01982201|DRUG|Tums 500 mg and 750 mg|
41289179|NCT01982201|DRUG|MINTOX 10 mL|
41454220|NCT06102057|RADIATION|Experimental Radiotherapy|FDG-PET-based small volume accelerated radiotherapy
41454221|NCT03141151|BEHAVIORAL|COACH: Healthy Bodies|Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
41289180|NCT02758795|DIETARY_SUPPLEMENT|CONTROL|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
41454222|NCT03141151|BEHAVIORAL|COACH: Strong Minds|School Readiness Intervention focusing on literacy and parent skills
40951368|NCT05904912|DRUG|Local infiltration-Bupivacaine|Local infiltration will be applied with 30 ml of a local anesthetic solution containing 0.25% bupivacaine by the surgical team
41134243|NCT01269307|PROCEDURE|1:1 ketamine-propofol mixture sedation|"Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine"
41134244|NCT01269307|PROCEDURE|Propofol Sedation|"Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol"
41134245|NCT00055991|DRUG|bexarotene|This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
41134246|NCT05670457|DRUG|Diosmin|diosmin 500 mg twice daily
41134247|NCT02707198|DRUG|kefir|4 ounces of kefir 3 times a day, with or without food.
41134248|NCT04884191|DRUG|Pacritinib|Pacritinib
41134249|NCT05511545|OTHER|Patient Education Booklet|Excretory system organs, signs and symptoms to be seen in kidney and ureteral stones, treatment methods, ureteroscopy procedure, what to do before and on the morning of surgery, and surgery, using the training booklet prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. An average of 25-30 minutes of training was given in the patient's room in an encouraging language, allowing the patient to ask questions about the situations he would encounter in the clinic after the surgery. She started asking questions she didn't understand. Afterwards, the questions of the patients were answered and the patient was given a training booklet.
41134250|NCT03021616|OTHER|energy drink|32oz of commercially available energy drink
41134251|NCT03021616|OTHER|Moxifloxacin 400mg|400mg moxifloxacin active control drink
41134252|NCT03021616|OTHER|Placebo|Placebo drink
41134253|NCT00019604|PROCEDURE|computed tomography|Scan to assess the effects of ablation.
41134254|NCT00019604|PROCEDURE|magnetic resonance imaging|Imaging used to assess the effects of this ablative therapy on tumor vascular density.
41134255|NCT00019604|PROCEDURE|positron emission tomography|Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.
41134256|NCT00019604|PROCEDURE|radiofrequency ablation|Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.
41134257|NCT00019604|PROCEDURE|radionuclide imaging|Imaging following injection of a radioactive material.
41134258|NCT00019604|PROCEDURE|ultrasound imaging|An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.
41454223|NCT02013050|DRUG|SGX942|
41134259|NCT00019604|RADIATION|fludeoxyglucose F 18 (FDG-PET)|FDG PET scans rely on metabolic changes to evaluate response to therapy.
41134260|NCT00019604|RADIATION|gadopentetate dimeglumine|Food and Drug Administration approved contrast agent.
41134262|NCT01680432|DIETARY_SUPPLEMENT|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
41134263|NCT01680432|DIETARY_SUPPLEMENT|Regular Cheese|
41134264|NCT03932214|DEVICE|ACCUVEIN|The nurse uses the Accuvein® device to identify the veins before puncture and then proceeds as usual, under illumination of the device.
41134265|NCT00726505|DRUG|Dapagliflozin|Tablets, Oral, Once Daily, up to 29 days:
41134266|NCT03427996|PROCEDURE|Rotational atherectomy|Percutaneous coronary intervention with rotational atherectomy
41134267|NCT05819294|PROCEDURE|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
41134268|NCT05318963|BIOLOGICAL|LCAR-AIO cells product|before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
41134269|NCT02337114|BEHAVIORAL|Acceptance and Commitment Therapy|A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
41134270|NCT02337114|BEHAVIORAL|Treatment as Usual|A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.
41134271|NCT04090476|OTHER|Exercise|During each of the exercise sessions the LSVT Big daily exercises will be performed along with functional tasks and gait/balance tasks. The functional tasks and gait/balance tasks will change weekly to monthly and all activities will be modified to the participant's mobility level.
41134272|NCT00774059|DEVICE|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
41134273|NCT05476900|DRUG|HR19042 Capsules|HR19042 Capsules
41289181|NCT02758795|DIETARY_SUPPLEMENT|NUTRIENT|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
41454224|NCT02013050|DRUG|Placebo|
40951369|NCT05929131|OTHER|discharge instructions with pamphlet|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
40951370|NCT05929131|OTHER|discharge instructions with video|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
40951371|NCT05929131|OTHER|verbal discharge instructions only|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
40951372|NCT03883360|DRUG|Cannabidiol (CBD)|Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
40951373|NCT03883360|DRUG|Placebo|Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
40951374|NCT00285818|DRUG|Mifepristone|Mifepristone is a glucocorticoid receptor antagonist.
40951375|NCT00285818|DRUG|Placebo Oral Capsule|Placebo is a capsule without a pharmacological active ingredient
41134274|NCT02893800|DEVICE|Locating system watch with GPS-technology|Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
41134275|NCT01673256|DEVICE|SJM Confirm ICM|
41134276|NCT02454959|DEVICE|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
41134277|NCT02454959|DEVICE|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
41134278|NCT05536869|PROCEDURE|Caesarean|Two different caesarean section techniques : intra or extraperitoneal
41134279|NCT02368041|DEVICE|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
41454225|NCT05055713|PROCEDURE|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
41454226|NCT05055713|PROCEDURE|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
41454227|NCT05055713|PROCEDURE|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
41289182|NCT00686751|DRUG|paricalcitol|Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
41289183|NCT03307447|DRUG|Secukinumab|Secukinumab 300 mg subcutaneous injection
41289184|NCT03186469|BEHAVIORAL|Safety Baby shower|"A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged."
41289185|NCT03186469|BEHAVIORAL|Standard of Care|Participants will received standard of care in regards to infant injury prevention. Written material on car seat safety, prevention of abusive head trauma, and safe sleep environments will be provide to participants.
41289186|NCT05101707|DEVICE|transcutaneous auricular vagus nerve stimulation|Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
41289187|NCT05101707|OTHER|Constraint induced movement therapy|Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
41289188|NCT03784430|PROCEDURE|Immediate dental implant placement|Tooth will be extracted and a dental implant will be positioned at the same time.
41289189|NCT03784430|PROCEDURE|Immediate dental implant placement with CTG|Tooth will be extracted and a dental implant will be positioned at the same time with a connective tissue graft.
41289190|NCT01258829|OTHER|Non-invasive haemodynamic optimisation|Comparing the method of non-invasive haemodynamic
41289191|NCT01258829|OTHER|ECHO optimisation|Standard ECHO optimisation method
41289192|NCT00213018|DRUG|Carraguard (PC-515)|
41289193|NCT06351410|DEVICE|Eye Wearing Contact Lens|Each participant will be given 2 types of a different group of contact lenses for each eye and need to wear for 8 hours only. Measurements will be done pre and post wearing of lenses
41289194|NCT03127020|DRUG|PQR309|taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
40786495|NCT05171153|OTHER|Densitometry with Trabecular Bone Score|"Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine."
41134280|NCT04082598|DRUG|Amoxicillin Clavulanate|tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
41289195|NCT06513637|DIAGNOSTIC_TEST|12-Lead ECG and home sleep study (HST) diagnostics|"* 12-lead ECG hookup will be performed following standard placement procedures.~* The Home Sleep Study diagnostic device placement will be performed by study personnel following the manufacturer's instructions."
41289196|NCT02973815|BEHAVIORAL|NU-HOME Intervention|The NU-HOME family intervention program consists of seven monthly group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
41289197|NCT01821248|DRUG|Gemcitabine, Cisplatin, S-1|"Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7"
41134281|NCT04082598|DIETARY_SUPPLEMENT|Bifidobacterium longum and Lactoferrin|
41134282|NCT02431767|BIOLOGICAL|PENNVAX®-GP HIV-1 DNA vaccine|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
41134283|NCT02431767|BIOLOGICAL|Interleukin-12 (IL-12) DNA adjuvant|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
41134284|NCT02431767|BIOLOGICAL|Placebo|Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
41289198|NCT05333562|OTHER|Motor control exercise|Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
41289199|NCT05333562|OTHER|Motor control exercise with mobilization|this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
41289200|NCT03005535|OTHER|Vitaminized corn oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
41289201|NCT03005535|OTHER|Olive oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
41134285|NCT00729794|DRUG|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|"Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR"
41134286|NCT00729794|DRUG|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
41134287|NCT03179046|DIAGNOSTIC_TEST|Laboratory tests and cardiac imaging|Laboratory tests (blood count, liver and kidney functions, antibodies, acute phase reactants), Echocardiography and gadolinium enhanced cardiac MRI
41134288|NCT03395600|DRUG|B1S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
41289202|NCT00984789|DRUG|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
40760276|NCT06478615|PROCEDURE|Coring out Fistulectomy with Closure of Internal Sphincter Opening|The patient was laid in the lithotomy position. Skin preparation and draping were done. Normal saline irrigation was performed. The anal canal was sufficiently dilated to permit the introduction of a self-retaining retractor. With H2O2 injection into the fistula tract, the internal opening and tract of the fistula will be identified. The incision was made around the external opening, and the tract was all cored out along the tract from the external opening to the internal sphincter. Meticulous hemostasis will be performed, stay suture by PDS 4/0 around fistiolous opening at the internal sphincter, excision of fistulous tract above stay suture, then closure of internal sphincter defect by PDS 3/0. Anal packing with 4 × 4 epinephrine gauze and sterile protective dressing was performed. After the operation, a stool softener and pain controller were prescribed, and patients were discharged.
41289203|NCT00984789|DRUG|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
41289204|NCT00419250|DRUG|lenalidomide|
41289205|NCT00419250|DRUG|lenalidomide|
41289206|NCT00419250|DRUG|lenalidomide|
41289207|NCT00419250|DRUG|lenalidomide|
40760277|NCT06478615|PROCEDURE|Lay Open Fistulotomy and Primary Sphincter Repair|Patients were put in a lithotomy position and the skin was then draped. After identification of the external fistula orifice probing of the fistula tract with identification of the fistulous tract and internal orifice with H2O2 injection into the fistula tract. The fistula was laid open and fistulectomy was then conducted and dissected with diathermy cautery help. Then Primary repair of the sphincter with PDS 3/0 with proper hemostasis using coagulation diathermy.
40760278|NCT00549211|DRUG|GSK557296|
40760279|NCT02513251|OTHER|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
41289208|NCT00419250|DRUG|lenalidomide|
41289209|NCT00623155|DRUG|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
41289210|NCT00000637|DRUG|Zidovudine|
41289211|NCT00000637|DRUG|Didanosine|
41289212|NCT00002993|DRUG|cisplatin|
41289213|NCT00002993|DRUG|doxorubicin hydrochloride|
41289214|NCT00002993|DRUG|mitomycin C|
41289215|NCT05901181|BEHAVIORAL|Laughter Yoga|"Laughter yoga is a childlike practice where group members make eye contact with each other.~It is a breath yoga practiced by imitating games and fake laughing. Brain the effects of real laughter on the body, as it cannot distinguish between fake and real laughter.~showing positive effects. It consists of sessions lasting at least 20 minutes and an average of 45 minutes."
41289216|NCT06511505|OTHER|TEMPUS AI-enabled ECG-based Screening Tool|The AI-enabled ECG-based screening tool, Tempus Next software, analyzes 12-lead ECG recordings to identify patients at increased risk for undiagnosed cardiovascular diseases, specifically atrial fibrillation (AF) and structural heart disease (SHD). Clinicians in the intervention group will receive a risk assessment for AF and SHD each time they order an ECG for their patients.
41289217|NCT00502060|DRUG|AZD2171|
40760280|NCT03292029|DIAGNOSTIC_TEST|T50 Calcification Inhibition Test (CIT)|Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
40760281|NCT05019963|BEHAVIORAL|NexJ Connected Wellness|NexJ Connected Wellness is an electronic case management platform with a patient-facing smart phone application and a clinician-facing web dashboard.
40760282|NCT05019963|OTHER|Usual Care|Participants will receive a treatment plan as decided on with their clinician(s).
40760283|NCT00521352|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
40951376|NCT02259101|BEHAVIORAL|CBT-I Treatment Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
41134289|NCT03395600|DRUG|B125S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
41134290|NCT03395600|DRUG|B1S10|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
41134291|NCT05608772|PROCEDURE|revision surgery|revision procedure after failed sleeve gastrectomy
40760284|NCT00521352|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
40760285|NCT02799043|PROCEDURE|Standard PVI|Standard PVI procedure without FIRMap.
40760286|NCT02799043|PROCEDURE|FIRM-Guided Procedure and PVI|
40760287|NCT05786547|DRUG|Varenicline|Per package dosing, tablet taken orally
40760288|NCT05786547|BEHAVIORAL|Positively Smoke Free Mobile (PSF-M)|Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone
41134292|NCT01860300|DRUG|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
41134293|NCT01860300|DRUG|placebo|
41134294|NCT00998517|DIETARY_SUPPLEMENT|Soy/peanut fortified spread|75kcal/kg/day
41289218|NCT00502060|DRUG|ZD1839|
41289219|NCT04634643|OTHER|Usual diet and physical activity|Patients will be followed up to assess the effect of the usual diet and physical activity on development of NAFLD
41289220|NCT01135433|DRUG|ipragliflozin|oral
41289221|NCT01135433|DRUG|Placebo|oral
41289222|NCT01135433|DRUG|metformin|oral
41454228|NCT05055713|PROCEDURE|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
40760289|NCT05786547|BEHAVIORAL|Standard Care|Brief cessation advice plus referral to local tobacco quitline
40760290|NCT06557811|DRUG|Semaglutide|After randomization, each patient will receive four blisters of 3 mg tablets (semaglutide or placebo) and four blisters of 7 mg tablets (semaglutide or placebo), to be taken before breakfast. After 60 days, the patient will receive a 14 mg dose (a total of 16 blisters with 7 tablets each). The possibility of maintaining the 14 mg dose of the study drug or reducing it to 7 mg will be evaluated depending on side effects and tolerability.
40760291|NCT05295953|DEVICE|TBS|Four sessions of TBS at 120 % resting motor threshold, delivered using MagVenture B65 A/P coil, each lasting 10 minutes and separated by 50 minutes intervals. Targeting will be done using neuronavigation and processed resting state brain scan.
40760292|NCT05295953|DEVICE|Sham TMS|Four sessions of sham TMS delivered using MagVenture B65 A/P coil.
40760293|NCT01813357|DRUG|Rosuvastatin|encapsulated tablet 20mg daily
40760294|NCT01813357|OTHER|Placebo|Placebo arm included to maintain blinding
40760295|NCT05554731|DEVICE|a New Balloon Catheter for Intraairway Hemostasis|In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.
40951377|NCT02259101|BEHAVIORAL|SH Comparison Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
40951378|NCT02998983|DRUG|Racotumomab|
40951379|NCT05136287|DRUG|GLP-1 receptor agonist|Patients are included after GLP1 agonists prescription , at the first dispensation
40951380|NCT06206642|DIAGNOSTIC_TEST|PET/CT|Low-dose CT images were first collected during scanning. The tube voltage was 120kilovolt, the tube current was 50-220Milliampere and the layer thickness was 3.75mm.
40951381|NCT05100901|DIETARY_SUPPLEMENT|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil, hydrolyzed whey protein, simple carbohydrates, vitamins and minerals.
40951382|NCT01404273|BEHAVIORAL|Meditation/Relaxation Response Training|1 hour weekly sessions with 20 min daily home practice for 6 weeks
40760296|NCT05554731|DEVICE|Traditional Therapy|A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.
40760297|NCT06570031|DRUG|ONO-4578|Specified dose on specified days
40760298|NCT06570031|DRUG|letrozole|Specified dose on specified days
40760299|NCT06570031|DRUG|Palbociclib|Specified dose on specified days
40760300|NCT06570031|DRUG|abemaciclib|Specified dose on specified days
40760301|NCT01321580|DEVICE|Masimo Pronto 7|non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
40951383|NCT05352711|DEVICE|active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand con|VR is mainly created by generating visual effects through head-mounted display (HMD) systems. An HMD is a device worn on the head or as part of a helmet with a built-in display and lenses, allowing the user to experience the virtual world with the help of a wide viewing angle, head and hand movements tracking as well as objects interacting by controllers.
40951384|NCT05352711|OTHER|active assisted range of motion exercise|Patients were treated active assisted ROM physical therapy 2 sessions per week for 4 weeks.
41134295|NCT00998517|DIETARY_SUPPLEMENT|Milk fortified corn/soy blend|75 kcal/kg/day
41134296|NCT00998517|DIETARY_SUPPLEMENT|Supplementary Plumpy®|75 kcal/kg/day
41134297|NCT01788371|DRUG|Telbivudine|About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
40760302|NCT01323543|DEVICE|Elaspine™|Implantation of device
40760303|NCT03008473|DEVICE|video laryngoscope and chest CT iminge|
40760304|NCT03008473|DEVICE|Conventional intubation of uniblocker|
40760305|NCT03709030|DIAGNOSTIC_TEST|magnetic resonance cholangiopancreatography (MRCP)|magnetic resonance imaging of liver, gall bladder, pancreas
40760306|NCT04858347|DEVICE|Total knee replacement|Implantation of the GEMINI SL Fixed Bearing PS knee prosthesis. The operation technique of the GEMINI SL Fixed Bearing PS knee prosthesis will be followed.
40760307|NCT06569758|DRUG|GenSci098|subcutaneous , 5 dose levels(15mg, 45mg, 90mg, 180mg and 270mg) will be assigned.
40951385|NCT06024460|PROCEDURE|non-pharmacological treatment strategy|Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment
41134298|NCT01788371|DRUG|Lamivudine|About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
41134299|NCT00479375|PROCEDURE|Adding Human Papillomavirus testing to organised cervical screening|
40951386|NCT06024460|PROCEDURE|pharmacological treatment strategy|"Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.~This group is treated using the above treatment strategies, and no drug is specified."
40951387|NCT04980781|BEHAVIORAL|Physical exercise and dietary therapy (PED-t)|Behavioral therapy: Physical exercise and dietary therapy (PED-t) is a treatment of bulimia nervosa and binge eating disorder, relying on guided, progressive resistance exercise therapy and dietary therapy (dietary education and group discussions) following a designed therapy manual.
41289223|NCT03054727|OTHER|Villalta phone score > or = to 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \> or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.~All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination."
41289224|NCT03054727|OTHER|Villalta phone score < 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \< 5, will don't have a clinical follow up.~All patients will have self administered-questionnaires."
41289225|NCT04560101|DRUG|botulinum toxin A|Intramuscolar injection of botulinum toxin in affected muscles
41289226|NCT02282332|DRUG|Ticagrelor|
41289227|NCT04125823|BEHAVIORAL|Video game-based physical activity training|"Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with a motion sensor (Microsoft) and a 52'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades and types of games will be changed.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
41289228|NCT04125823|BEHAVIORAL|Conventional physiotherapy program|"A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
41289229|NCT02067221|DEVICE|RIRS|"* RIRS arm~* Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract"
41289230|NCT02067221|DEVICE|MPCNL|"* MPCNL arm~* A new technique that reduced the size of percutaneous tract to make renal stone into small pieces."
41289231|NCT06068725|BEHAVIORAL|Training videos|After determining the application and control groups in the research, the purpose of the research was explained to both groups. The mobile phone usage skills of the individuals who will be included in the application group were evaluated with the Digital Literacy Scale. Training videos for 15 people each (30 minutes in total) regarding symptom management were shared on the phones of the patients/relatives in the application groups, and the patients and their relatives were informed and watched the training video. Data collection forms would be filled out before the application (Z0), on the 30th day of the application (Z1), and on the 90th day of the application (Z2).
41289232|NCT04430530|BIOLOGICAL|Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
40760308|NCT06569758|DRUG|GenSci098 Placebo|In SAD part only one dose of GenSci098 and GenSci098 Placebo to be given, in MAD part, GenSci098 and GenSci098 will be given on Day 1 and Day 85
41289233|NCT01031095|OTHER|coronary intervention|elective coronary intervention
41289234|NCT02126488|BEHAVIORAL|treadmill slip perturbation|Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.
41289235|NCT02126488|BEHAVIORAL|treadmill training placebo|An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.
40760309|NCT03133377|BEHAVIORAL|Early activity and mobilisation|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
40760310|NCT05848843|DRUG|Durvalumab|Given by vein (IV)
40951388|NCT04980781|PROCEDURE|Implementation program for PED-t in ERC|Participating in a training program for therapists in PED-t; to increase knowledge of eating disorders and to be able to implement and run the PED-t. Training program consists of a therapy manual, digital lectures, and 3 work shops.
40951389|NCT02624960|DEVICE|Accucinch Implant|Percutaneous implantation of the Accucinch Implant in the mitral subannular space
40951390|NCT06273436|OTHER|H.E.A.R. for Mamas|H.E.A.R. for Mamas is a patient and provider informed, multicomponent intervention that uses simple text/phone-based screenings to systematically and frequently monitor women for postpartum complications, chronic conditions and SDoH (Social Determinants of Health) and provides patients with immediate feedback and recommendations based on their screenings.
40951391|NCT03200184|DRUG|sofosbuvir and daclatasvir|A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.
40951392|NCT00723398|DIETARY_SUPPLEMENT|Lovaza 4gm oral|Dietary supplement; Take 4 mg oral capsules daily
40951393|NCT00723398|DRUG|Raloxifene 60 Mg Oral Tablet|60 mg orally every day for two years
40951394|NCT00723398|DRUG|Raloxifene 30 Mg Oral Tablet|30 mg orally daily for two years
40760311|NCT05848843|DRUG|Adagrasib|Given by PO
40760312|NCT04781842|OTHER|Boxing exercise program|Participants attended an hour long class once a week for 12 weeks. Included in class was a warm up, boxing activities including weight shifting, kicking, and punching bags, strengthening activities and a cool down.
40760313|NCT02281864|BEHAVIORAL|Smoking Cessation Intervention Bundle|Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.
40760314|NCT02281864|OTHER|Control Group: Quitline|Referral to the Quitline
40760315|NCT03188380|DIAGNOSTIC_TEST|Plain abdominal radiography|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
40951395|NCT00723398|DRUG|Lovaza 4gm & Raloxifene 30mg|Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
41289236|NCT02126488|BEHAVIORAL|observation training|An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
41289237|NCT00816972|DRUG|Desloratadine 2.5 mg|Desloratadine 2.5 mg BID
40760316|NCT03188380|DIAGNOSTIC_TEST|Abdominal ultrasound|If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
40760317|NCT01610401|DRUG|Metformin|metformin 500 mg three times a day, for 3 days
40951396|NCT05967000|OTHER|Preventive heart health and menopause programme|"This is a one-stop women's heart and menopausal service in a public hospital led by cardiologists and gynaecologists with a multidisciplinary team. Pre-existing speciality care and services are repackaged, and clinic workflows are reworked to provide more streamlined, convenient, and integrated care. Services encompass:~* Individualised risk assessment, screening, diagnosis, and treatment of CVD.~* Lifestyle education, adjustment, stress management, and counselling.~* Smoking cessation programs.~* Bone health screening, mammogram with access to our co-located gynaecologists and hormone replacement therapy.~* Virtual consults and health coaching."
40951397|NCT01529242|DRUG|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
40951398|NCT01529242|DRUG|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
40951399|NCT04339686|DIAGNOSTIC_TEST|Thoracic CT Scan|Retrospective analysis of the thoracic CT scan results compared to final discharge summary
41289238|NCT00816972|DRUG|Oxybutynin 2.5 mg|Oxybutynin 2.5 mg BID
41454229|NCT05055713|PROCEDURE|Endoscopic therapy+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
40951400|NCT04677790|BEHAVIORAL|assigned period of specific dietary restrictions|Step by step gradual introduction of egg containing food products
40951401|NCT02827227|BIOLOGICAL|lymphocytes immunophenotyping|"The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.~HIV patients with a known history of PHI and a minimum of 2 years of effective cART (\< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).~Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.~Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded."
40951402|NCT00691301|DRUG|cisplatin|Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of
40951403|NCT00691301|DRUG|pemetrexed disodium|
40951404|NCT04636151|BEHAVIORAL|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
40951405|NCT06557525|BEHAVIORAL|Neurofeedback|Subjects will receive neurofeedback training by visual stimulation using a software program on a PC or tablet (monitor) with reference to EEG data acquired with a portable electroencephalograph (EEG) to provide feedback on the state of the DLPFC in the brain. The DLPFC status of the subject's brain is then fed back to the subject to continue stimulating the subject's reward system. Before and after these neurofeedback training sessions, fMRI imaging will be performed to confirm changes in brain activity.
40951406|NCT00981240|DRUG|SAR103168|"Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion"
40951407|NCT00770939|DEVICE|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
40951408|NCT00599950|DRUG|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
40951409|NCT01613534|DRUG|Sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
41289239|NCT00816972|DRUG|Placebo for Desloratadine 2.5 mg|Placebo BID
41289240|NCT00816972|DRUG|Placebo for Oxybutynin 2.5 mg|Placebo BID
40951410|NCT01613534|DRUG|Placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks
40951411|NCT01892215|PROCEDURE|Cephalad-caudad expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
40951412|NCT01892215|PROCEDURE|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
40951413|NCT02380144|OTHER|Fresh orange fruit and pasteurized fruit juice|
41289241|NCT01164501|DRUG|BI 10773|BI 10773 tablets once daily
41454230|NCT05055713|PROCEDURE|Endoscopic therapy+PSE+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
40760318|NCT01610401|DRUG|Pretreatment with metformin in combination of infusion of caffeine.|Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
41289242|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 low dose
41289243|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 high dose
41289244|NCT01164501|DRUG|BI 10773|BI 10773 tablets once daily
41289245|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 low dose
41289246|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 high dose
41454231|NCT01240850|DRUG|Methotrexate+Prednisone|Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
41454232|NCT01240850|DRUG|Prednisone|
40951414|NCT04390061|DRUG|Tofacitinib|Jak-1/3 inhibitor
40951415|NCT04390061|DRUG|Hydroxychloroquine|Standard Therapy
40951416|NCT02000934|DRUG|TAK-659|TAK-659 tablet
40951417|NCT01232777|DRUG|Bevacizumab|A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
40951418|NCT04049864|BIOLOGICAL|DNA vaccine|conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.
40951419|NCT04049864|BIOLOGICAL|Salmonella oral vaccine|suspension 10\^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.
41289247|NCT03719573|OTHER|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
41289248|NCT01750021|DIETARY_SUPPLEMENT|High fat low carbohydrate diet|70E% fat, 20E% protein, 10E% carbohydrates
41289249|NCT01750021|DIETARY_SUPPLEMENT|Low fat high carbohydrate diet|20E% fat, 20E% protein, 60E% carbohydrates
41289250|NCT01722006|BEHAVIORAL|Pairing condition|
41289251|NCT01722006|BEHAVIORAL|Pairing condition|20 mg methamphetamine or placebo on four 4-hour laboratory sessions
41289252|NCT04567836|OTHER|Investigation of the prevalence of test positivity|"The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses ."
41289253|NCT02848885|OTHER|Active TDCS|Participants will receive active tDCS stimulation.
41289254|NCT02848885|OTHER|Sham TDCS|Participants will receive sham tDCS stimulation
41289255|NCT04569539|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
41289256|NCT04419506|DRUG|BI 1015550|18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
41289257|NCT04419506|DRUG|Placebo|placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
41289258|NCT01912885|DEVICE|TENS 1-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
40951420|NCT04049864|DRUG|Lenalidomide|Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
40951421|NCT00821483|DRUG|Frovatriptan|2.5mg, qd
40951422|NCT06557915|PROCEDURE|screening|screening and detection of nasal problems in Neonates and Infants Subjected to CPAP
40951423|NCT02554942|DRUG|Epoetin beta|Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
41289259|NCT01912885|DEVICE|TENS 1-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
41289260|NCT01912885|DEVICE|TENS 2-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
41289261|NCT01912885|DEVICE|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
41289262|NCT01912885|DEVICE|TENS 0-1|Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
41289263|NCT06027580|DEVICE|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis use 2 hours per day for 6 months
40951424|NCT00787761|BIOLOGICAL|anti-thymocyte globulin|"Anti-Thymocyte Globulin (ATG) is commercially available. The 1st vial contains 25 mg ATG, and the 2nd vial contains \> 5 mL SWFI diluent. Ampuls must be refrigerated (2º C - 8º C). Do not freeze.~Reconstitute 25 mg vial with diluent provided by manufacturer. Roll vial gently to dissolve powder. Use contents of vial within 4 hours. Dilute dosage to a final concentration of 0.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Gently invert admixture 1-2 times to mix. Use admixture solution immediately.~Infuse the 1st dose over at least 6 hours, and subsequent doses over at least 4 hours. Infuse through a 0.22 micron in-line filter. Premeds include acetaminophen 650 mg PO, diphenhydramine 25-50 mg PO/IV, and methyprednisolone 1mg/kg at the initiation and half-way through ATG administration."
40951425|NCT00787761|DRUG|busulfan|"Commercially available in 60 mg/10 mL ampuls.~Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL.~Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame.~IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses."
40951426|NCT00787761|DRUG|cyclophosphamide|"Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.~The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.~Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.~Each dose will be infused over 1-2 hr (depending on the total volume)."
40951427|NCT00787761|DRUG|fludarabine phosphate|"Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH.~Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration.~Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP.~Fludarabine will be administered as an IV infusion over 30 minutes."
40951428|NCT00787761|DRUG|methotrexate|"Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.~Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.~Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.~Administer via slow IV push."
40951429|NCT00787761|DRUG|tacrolimus|"Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg).~Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.~Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day.~Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F)."
41289264|NCT01335646|PROCEDURE|Lumbar Microdiscectomy|lumbar discectomy within 1 month of randomization
41454233|NCT00412464|DRUG|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
40786496|NCT05171153|OTHER|Quantitative Ultrasound of Calcaneus|Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).
40951430|NCT00787761|PROCEDURE|nonmyeloablative allogeneic HSCT|As demonstrated by groups in Houston, Jerusalem \& Seattle, RICT has been used to treat hematologic \& solid malignancies with related \& unrelated donors. Although adequate comparisons of RICT versus ablative alloHCT remain to be reported, the studies of RICT so far suggest that TRM is generally less than would be expected for similar patients undergoing ablative alloHCT; incidence of acute \& chronic GVHD is similar or less than ablative alloHCT; autologous hematopoietic recovery is more common than seen following ablative alloHCT if graft failure occurs; powerful GVT effects can be seen but are dependent on high levels of donor T-cell chimerism and RICT are less effective than ablative alloHCT in controlling aggressive malignancies
40951431|NCT02818361|DRUG|Topical tripterygium gel|
41289265|NCT01335646|OTHER|Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories|Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
41289266|NCT06513221|DRUG|Chemotherapy, Bevacizumab, Adebrelimab|Adebrelimab: 1200mg，q3w Bevacizumab: 7.5mg/kg，q3w Fruquintinib: 4mg po d1\~d14, q3w Chemotherapy: XELOX/mXELIRI: conventional dose
40951432|NCT02818361|DRUG|Placebo gel|
41289267|NCT02875288|DRUG|liposomal bupivicaine|"1. The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~2. The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~3. Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~4. Route of drug administration; Surgical site infiltration"
40951433|NCT02902068|DEVICE|NICaS Bio Impedance|"Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections."
40951434|NCT05243355|DRUG|"Envafolimab and Chemotherapy and Recombinant Human Endostatin"|"Envafolimab: 300 mg，D1，Q3W,until PD or intolerable toxicity Chemotherapy: Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w; Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles in total.~Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total."
40951435|NCT02970916|DRUG|FOLFIRI+aflibercept|"Aflibercept: 4 mg/kg administered intravenous infusion on day 1~FOLFIRI regimen immediately after aflibercept:~Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.~\* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)"
40951436|NCT06450262|DRUG|Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets|1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
40951437|NCT06450262|DRUG|Synjardy® 12.5mg/1000mg film-coated tablets|1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
40951438|NCT02518204|OTHER|BPT|Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
41289268|NCT04828876|BEHAVIORAL|Yoga practice|"Yoga basically consists of breathing techniques, asanas (postures) and relaxation phases.~Practiced Yoga Stages; 10 min. standing breathing exercise, 10 min. breathing exercise with seated asana, 10 min. lying down breathing exercise with asana, 20 min. sitting breathing exercise, 10 min. The session will be completed in 60 minutes, including deep relaxation stages by lying down. At the end of each session, patients' feedback about yoga practice will be received."
41289269|NCT04397679|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
41289270|NCT04397679|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
41289271|NCT04397679|DRUG|Temozolomide|Given PO
41289272|NCT04397679|DRUG|Chloroquine|Given PO
41289273|NCT04397679|PROCEDURE|Tumor Treating Fields Therapy (TTF)|Undergo TTF
41289274|NCT00108810|DRUG|Transdermal Ketoprofen Patch with CHADD|12 hours patch application for 28 days
41289275|NCT00108810|DRUG|Placebo transdermal patch|12 hours application for 28 days
41289276|NCT06417684|DRUG|Amitriptyline|25 mg prescribed to be taken once daily for 90 days each evening.
40760319|NCT01610401|DRUG|No pretreatment with metformin in combination with infusion of caffeine|No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
40760320|NCT00846482|DRUG|Oxaliplatin|Oxaliplatin will be administered once every 2 or 3 weeks
41134300|NCT00761267|DRUG|Anidulafungin|"Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days."
41134301|NCT00761267|DRUG|Fluconazole|Subjects may be switched to oral fluconazole \[6-12 mg/kg/day (not to exceed 800mg/day\] provided they meet specified criteria. Maximum total treatment duration is 49 days.
41454234|NCT04033484|PROCEDURE|Negative Pressure Wound Therapy|The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg
41134302|NCT01014559|DRUG|Oxycodone Naloxone|Oxycodone Naloxone PR Tablet taken twice daily
40760321|NCT00434941|DRUG|Capecitabine|
40760322|NCT00434941|RADIATION|Radiotherapy|
40951439|NCT02518204|OTHER|NP|"Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~* HRB: Halstead-Reitan Battery~* MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~* WAIS-IV: Weschler Adult Intelligence Scale - IV"
40951440|NCT06072196|DRUG|Novel hormonal therapy|As provided in real-world setting
40951441|NCT03591185|OTHER|FallSensing Clinical Tool|"FallSensing clinical tool will be applied to a group of community-dwelling adults aged 50 years or over, including a initial evaluation, 24 intervention sessions (2 or 3 sessions per week) and a final evaluation.~Inicial and final evaluation consists in six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for exercise."
41454235|NCT01896713|OTHER|MS3TMRI|Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
40951442|NCT04234607|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
40951443|NCT04234607|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
40951444|NCT04234607|DRUG|Etoposide|Etoposide is a cell cycle-specific antitumor drug
40951445|NCT04234607|DRUG|Carboplatin|Carboplatin is cell cycle nonspecific antitumor drug
40951446|NCT04234607|DRUG|TQB2450（blank）|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
41134303|NCT01014559|DRUG|Oxycodone PR Tablets|Oxycodone PR Tablets taken twice daily
41134304|NCT01209195|DRUG|MM-121|increasing doses of MM-121 IV QW
41134305|NCT01209195|DRUG|Paclitaxel|Paclitaxel - 80 mg/m2 IV QW
41289277|NCT01525511|DRUG|A|"Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"
41289278|NCT01525511|DRUG|B|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"
41289279|NCT02017249|DRUG|arginine in powder form|
41289280|NCT02017249|DRUG|Silica and cellulose placebo powder|
41134306|NCT02219659|DRUG|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
41134307|NCT02219659|DRUG|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
41289281|NCT00789204|OTHER|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
41289282|NCT00789204|OTHER|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
40951447|NCT04234607|DRUG|Anlotinib（blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
40951448|NCT04185311|BIOLOGICAL|Ipilimumab|Given IV
40951449|NCT04185311|BIOLOGICAL|Nivolumab|Given IV
40951450|NCT04185311|BIOLOGICAL|Talimogene Laherparepvec|Given intratumorally
41134308|NCT02219659|DRUG|Fentanyl Push First|Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
41289283|NCT04568174|DRUG|PPSGG|an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies
40951451|NCT00257608|DRUG|bevacizumab|Intravenous repeating dose
40951452|NCT00257608|DRUG|placebo|Oral repeating dose
40951453|NCT00257608|DRUG|erlotinib HCl|Oral repeating dose
40951454|NCT05316285|OTHER|Yoga exercise|Yoga lesson practices will be designed and implemented by instructors physiotherapists who have completed 200 hours of yoga instructor training (RYT-200). The yoga program, which will consist of one-hour sessions once a week, is planned to last 14 weeks. 4 weeks of classes will be theoretical lessons related to yoga philosophy, 10 weeks of yoga sessions will be applied every week on different concepts such as upper extremity and / or lower extremity focused strengthening and / or flexibility and breathing exercises. In addition to this training, students will be advised to repeat the practices once a week. Sessions will begin with breathing practices called pranayama, followed by yoga postures called asanas, and the sequence will be finished with savasana pose. In this pose, guided meditations will be performed on subjects such as body awareness and self-compassion.
40951455|NCT04462770|DRUG|EPX-100 (clemizole HCl)|Daily dose of EPX-100
40951456|NCT04462770|DRUG|Placebo|Daily dose of placebo
41134309|NCT03477266|DRUG|Mosapride|Intake mouthly dissolving mosapride tablets in immediate post cesarean section
41134310|NCT03477266|DRUG|Placebo Oral Tablet|Dummy identical tablets to mouthly dissolving mosapride tablets
41289284|NCT04568174|DRUG|Placebo|A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
40760352|NCT02500966|DEVICE|DUDA device|Insertion DUDA device
40760353|NCT02500966|PROCEDURE|LEEP|Loop Electrosurgical Excision Procedure
40760354|NCT03127163|DEVICE|Intraestromal corneal ring|The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.
41289285|NCT03077048|DRUG|Ketosteril®|Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.
41289286|NCT00940927|DRUG|albuterol|Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)
40760355|NCT04351672|BEHAVIORAL|Early Time-Restricted Feeding|Eat between 8 am and 4 pm for two weeks
40760356|NCT04351672|BEHAVIORAL|Late Time-Restricted Feeding|Eat between 1 pm and 9 pm for two weeks
40760357|NCT03032809|OTHER|Vessel Wall MR imaging|Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
40760358|NCT06020937|DIAGNOSTIC_TEST|TDI|Sniffin' Sticks Threshold and Identification Test
40760359|NCT06020937|DIAGNOSTIC_TEST|Trigeminal Test|Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response
40760360|NCT06020937|DIAGNOSTIC_TEST|Cognitive Evaluation by Montreal Cognitive Assessment|Montreal Cognitive assessment
40760361|NCT06020937|DIAGNOSTIC_TEST|Anxiety and Depression questionnaire|Specific test to evaluate patient's mood
40760362|NCT06020937|DIAGNOSTIC_TEST|Visual Analogue Scale Ratings|"* Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~* Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)"
41289287|NCT03606746|BIOLOGICAL|MDR-103|MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
41289288|NCT04208373|DRUG|JNJ-64417184|JNJ 64417184 tablets will be administered orally.
40760363|NCT06020937|DIAGNOSTIC_TEST|Quality of smell Questionnaire|Patients will answer to a validated questionnaire
41134311|NCT04863365|DRUG|Placebo ophthalmic solution|A matching placebo ophthalmic solution, 3 drops daily, 28 days
41134312|NCT04863365|DRUG|PHP-201 ophthalmic solution|PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
41134313|NCT02915211|DIETARY_SUPPLEMENT|Keyo|Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
41289289|NCT04208373|DRUG|Itraconazole|Itraconazole capsules will be administered orally
41289290|NCT04208373|DRUG|Etravirine|etravirine tables will be administered orally.
40760364|NCT04248673|OTHER|carbohydrate reduced bread|Consumption of carbohydrate reduced bread for three months.
40760365|NCT04248673|OTHER|carbohydrate rich bread|Consumption of carbohydrate rich bread for three months.
41134314|NCT04924166|DRUG|Placebo|Inactive dose of capsules that appear identical to active dose
41134315|NCT04924166|DRUG|Hydrocortisone|Hydrocortisone 180 mg in capsule form
40786497|NCT05171153|OTHER|Laboratory test|Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).
40786498|NCT02785328|OTHER|memory evaluation at V1 and V2 (with treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.
41134316|NCT00046475|DRUG|Midodrine Hydrochloride|
41289291|NCT02672839|DRUG|LGD-6972 Solution|15 mg of LGD-6972
41289292|NCT02672839|DRUG|LGD-6972 Capsules|15 mg LGD-6972
41289293|NCT03478124|BEHAVIORAL|Cognitive evaluation|An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
41289294|NCT05418361|DRUG|ACE inhibitor ,angiotensin receptor blockers|patients taking ACEI or ARBs with cardiovascular disease
41289295|NCT00450463|DRUG|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant deoxyribonucleic acid (DNA) technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
41289296|NCT00450463|DRUG|Flutamide (Eulexin)|Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
41289297|NCT00450463|BIOLOGICAL|PROSTVAC-F/ TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.
41289298|NCT00450463|BIOLOGICAL|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
41289299|NCT03495505|DEVICE|WiSE-CRT|Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
41289300|NCT01893788|DRUG|Aliskiren|Aliskiren: 150 to 300 mg daily for 48 weeks
41289301|NCT01893788|DRUG|Eplerenone|50 to 100 mg daily for 48 weeks
41289302|NCT05467735|OTHER|Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
41289303|NCT04244045|OTHER|Suboccipital muscle inhibition|"The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot"
41289304|NCT01200511|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
41289305|NCT01395485|DRUG|AMG 827 or Placebo|A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
41289306|NCT00105729|BEHAVIORAL|Intensive referral to 12-step self-help groups|
41289307|NCT02612090|DIETARY_SUPPLEMENT|Active Treatment Beverage|Strawberry
41289308|NCT02612090|DIETARY_SUPPLEMENT|Placebo Treatment Beverage|Placebo
41289309|NCT01903434|DRUG|Evacetrapib|Administered orally
41289310|NCT00637728|DRUG|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
40760366|NCT04525469|BEHAVIORAL|Narrative Exposure Therapy|"NET involves: 1) diagnostic interview and psychoeducation, 2) laying out the Lifeline, 3) NET therapy sessions (constructing the trauma narrative in context of the life course), 4) final session rituals. Laying out the Lifeline (using rope or string) allows participants to take a bird's eye view of the events of their life using simple items such as flowers to represent positive events and stones to represent traumatic events. The focus of NET sessions is to encourage participants to describe the details of traumas and integrating the cold memories (i.e., facts) with the hot memories (e.g., cognitions, emotions, physiological feelings, and sensory information). The therapist makes notes after each session narrating the details of the traumas (stones) and reads this at the beginning of each subsequent session. Final session rituals involve re-reading the trauma narrative, hopes for the future, and laying out the final Lifeline placing flowers for hopes and wishes for the future."
40760367|NCT01444924|DRUG|Bupivicaine|The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
40760368|NCT01444924|DRUG|Placebo|The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
40760369|NCT06475820|DRUG|Baricitinib|"GVHD prevention using a combination of post-transplantation cyclophosphamide~Prevention of GVHD:~Cyclophosphamide 80 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +60, +90 Vedolizumab 10 mg/kg/day, max. 300 mg on the days 0, +14, +28, +60 Baricitinib 4 mg/day per os (patient age \> 9 years), 2 mg/day (patient age \< 9 years), from day -3 to day +90 (after HSCT), orally, once a day."
40760370|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Zidovudine|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
41134317|NCT01328496|DRUG|Preparative Regimen|"Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1."
41134318|NCT00856362|DRUG|Moxidectin|
41134319|NCT00856362|DRUG|Midazolam|
41134320|NCT03100188|OTHER|modified PD prescription|For patients on CAPD, fewer daily exchanges or fewer total weekly exchanges are prescribed. Patients on CCPD are prescribed shorter cycler time or fewer total cycles during the week.
41289311|NCT00637728|DRUG|Placebo|Placebo oral suspension, 5 mL once daily
41289312|NCT02721004|DRUG|Tocilizumab|Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
41454236|NCT06366555|PROCEDURE|Manual Acupuncture Twirling,|Manual Acupuncture twirling : using 0.14x 25 mm needle, punctured and penetrated the skin and then a twirling manipulation is carried out, 180 degrees, 3 rad/second, for 30 second each at LU5 and PC2. The needles retained for 20 minutes and manipulated at 0 minutes and 10 minutes.
41454237|NCT06366555|PROCEDURE|Manual Acupuncture Sham|Manual Acupuncture Sham : Using 0.14x25mm needles on plesterin without being penetrated into skin and no manipulation given, retained for 20 minutes
41454238|NCT02988258|GENETIC|CMV-TCR transduced donor-derived T cells|Dose escalation
40951457|NCT05276596|DRUG|Ephedrine|The control group will be taken care of according to the protocols in force. The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.
40951458|NCT05276596|DRUG|Norepinephrine|Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
40951459|NCT04448938|OTHER|MRI|"The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional sequence of f-mRI, called resting state, and performed before injection of gadolinium contrast agent.~A consultation with an ophthalmologist will also be carried out the same day, at the Adolphe de Rothschild Foundation.~The subjects of the control group who agreed to participate will benefit from an MRI examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected NO."
40951460|NCT04448938|OTHER|visual acuity|Patients with NO will be seen in consultation by an ophthalmologist during a follow-up visit approximately 6 months after diagnosis. During this consultation, an OCT, a visual field and the measurement of visual acuity will be performed. This visit and the examinations carried out correspond to the usual care of patients suffering from NO and followed at the Adolphe de Rothschild Foundation Hospital
40760371|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
40951463|NCT05747287|DEVICE|microcatheter|supports the insertion of the guide wire，exchange of the guide wire and the delivery of contrast media
40951464|NCT03417219|BEHAVIORAL|Education and Skill Building Rehabilitation-mobile (ESBR-m)|Participants randomized to the ESBR-m group will participate in four, 90-minute group ( 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
40951465|NCT03417219|BEHAVIORAL|Usual Care (UC)|"Participants randomized to the UC group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
40951466|NCT04121923|DEVICE|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Total sleep time (Ring-TST) and respiratory event index (Ring-REI) are estimated
40951467|NCT05903495|DEVICE|Deep Brain Stimulation|randomized, sham-controlled, partial crossover study investigating DBS, targeting the nucleus accumbens (NAc) and ventral internal capsule (VC), for participants with severe, treatment refractory OUD.
41289313|NCT01501149|DRUG|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
40951468|NCT03499925|BEHAVIORAL|cognitive behaviors|Telephone consultation effectiveness and cognitive behaviors
40951469|NCT03499925|BEHAVIORAL|Telephone consultation|Telephone consultation effectiveness and cognitive behaviors
40951470|NCT06249984|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40951471|NCT06249984|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
41289314|NCT01501149|DRUG|Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）|MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
41289315|NCT06512428|DRUG|simmitinib plus irinotecan liposome|simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks
40951472|NCT06249984|BEHAVIORAL|Smokeless Tobacco Use|Use moist snuff
40951473|NCT06249984|OTHER|Survey Administration|Ancillary studies
40760372|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Raltegravir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
40951474|NCT03704987|DIAGNOSTIC_TEST|dual-energy X-ray absorptiometry|dual-energy X-ray absorptiometry
41289316|NCT06512428|DRUG|irinotecan liposome|irinotecan liposome 70 mg/m\^2 every 2 weeks
41289317|NCT06512428|DRUG|irinotecan|irinotecan 180mg/m\^2 every 2 weeks
41289318|NCT00114907|BEHAVIORAL|Consumption of black tea|
41454239|NCT03633214|OTHER|Online training module|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later; as well as to the control group.
40760373|NCT06569888|DEVICE|LIPUS stimulation|Low Intensity Pulsed Ultrasound stimulation of the gut at the pre-clinically optimized conditions and energy dosage
40760374|NCT06517758|DRUG|Iptacopan|Hard gelatin capsule
40760375|NCT06517758|OTHER|Matching Placebo|Hard gelatin capsule
40760376|NCT04226105|DRUG|GP40081|1 ml of the GP40081 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
41289319|NCT05429814|OTHER|Menthol Application|During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
41289320|NCT02831491|DRUG|Ramucirumab|Administered IV
41289321|NCT02831491|DRUG|Docetaxel|Administered IV
41289322|NCT04231981|DRUG|INCMGA0012|INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
40951475|NCT01633073|DEVICE|LMA Supreme: control device|LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
40760377|NCT04226105|DRUG|NovoMix 30|1 ml of the NovoMix 30 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
40760378|NCT04245579|OTHER|Multifactorial Memory Training Program (UMAM method)|
40760379|NCT06501352|DRUG|Dexmedetomidine|Additive to Local anesthetic mixture
40760380|NCT06501352|DRUG|Neostigmine|Additive to Local anesthetic mixture
40760381|NCT06501352|DRUG|Saline|Control
40760382|NCT02274675|DEVICE|Robot-assisted therapy for wrist and forearm|Robot therapy by using a single degree reconfigurable robot to train for wrist and forearm rehabilitation training.
40760383|NCT02274675|OTHER|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities
41146799|NCT04301102|DEVICE|Hemosphere platform® together with the FloTrac® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
40760384|NCT06395220|OTHER|Detection of donor-specific anti-HLA antibody (DSA)|"Detection methods~1. . Morphology: using microscope to observe the morphology of bone marrow.~2. . Immunophenotyping: using multi-color flow cytometry (MFC) to detect immunophenotype of leukemia cells and leukemia-associated immunophenotype of bone marrow samples.~3. . Cytogenetics analysis: G-band and/or fluorescence in situ hybridization (FISH) analysis are used in this study~4. . Molecular detection: Real-time quantitative RT-PCR (RQ-PCR) and/or next generation sequencing techniques are used to detect the molecular marker, such as: PML/RARA, AML-ETO, BCR/ABL, and WT1.~5. . HLA-Typing: HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 alleles were determined according to the literatures published by our group \[Huo MR, et al. Bone Marrow Transplant. 2018;53(5):600-608\]..~6. . Other analyses: Detection of minimal residual diseases were performed using MFC and RQ-PCR according to the methods reported by our group \[Li SQ, et al. Blood,2022;140(5):516-520\]."
40760385|NCT04171323|BEHAVIORAL|Cognitive Training|Participants will be completing a total of 40 computerized sessions.
40760386|NCT04171323|BEHAVIORAL|Computerized Cognitive Stimulation|Participants will be completing a total of 40 computerized cognitive stimulation sessions.
40760387|NCT06548516|PROCEDURE|Control group (conventional scalpel surgery)|The patients in the control group will undergo frenectomy using conventional scalpel surgery.
40760388|NCT06548516|PROCEDURE|Diode laser group|The patients in the laser group will undergo frenectomy using a diode laser.
40760389|NCT02496156|BEHAVIORAL|Usual Clinical Practice|Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
41146800|NCT05025553|DIETARY_SUPPLEMENT|Gut mobilization|Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Month. Children were observed and tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.
41146801|NCT00889863|DRUG|canakinumab|Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
41146802|NCT00889863|DRUG|placebo|Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
40760390|NCT02496156|BEHAVIORAL|Shared Medical Decision Making|Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
40760391|NCT01629888|OTHER|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (3 test products/day)
40760392|NCT01629888|OTHER|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (3 control products/day)
40786499|NCT02785328|OTHER|memory evaluation at V1 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
41146803|NCT04037592|DEVICE|Active standardized iTBS-DMPFC|Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
41146804|NCT04037592|DEVICE|Active high-dosage iTBS-DMPFC|Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
40951476|NCT01633073|DEVICE|i-gel: comparison device|i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
40951477|NCT02489578|OTHER|other|retrospective cohort study
40951478|NCT04143893|DEVICE|Mechanical circulatory support|Patients with cardiogenic shock who underwent MCS
41454240|NCT00842062|DEVICE|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
41454241|NCT06016582|DEVICE|Use of virtual reality hypnosis headset during frozen embryo transfer|"The virtual reality hypnosis headset will be used before, during, and after the FET procedure:~* The headset will be put on 5 minutes prior to the procedure, allowing time for immersion in the virtual world.~* The headset will be kept on throughout the entire procedure (procedure duration less than 5 minutes).~* The headset will be worn for up to 5 minutes after the procedure. The patient will be free to choose her own auditory and visual scenario for the session.~Prior to the procedure and the device setup, the patient will be asked to complete a self-assessment anxiety questionnaire, the State-Trait Anxiety Inventory. This self-assessment questionnaire is a validated and standardized tool designed to measure temporary state anxiety related to a specific situation (in this case, the embryo transfer). After the procedure, the patient will need to complete the questionnaire again, along with another set of questions specifically designed for our study."
41454242|NCT06288217|DEVICE|NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation)|Pulsed electrical stimulation of the trigeminal and vagus nerves paired with upper limb rehabilitation movements
40760393|NCT05250180|OTHER|Animal Assisted Therapy|Patients enrolled in the study will be randomly scheduled to have a dog be a part of their PT and OT sessions on two days (one in the first week and one in the second week) during their stay. On these days, the therapist will lead the therapy session and integrate the dog at whatever level is appropriate based on the patient's level of functioning and therapy goals.
40951479|NCT04143893|DRUG|Optimal medical treatment|Patients with cardiogenic shock who received optimal medical treatment including vasopressor
40951480|NCT02643173|OTHER|Volatile anesthetics|
40951481|NCT02643173|OTHER|Intravenous anesthetics|
40951482|NCT05143541|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
40951483|NCT00462631|DEVICE|Paclitaxel Eluting Balloon|Paclitaxel eluting balloon
40951484|NCT00462631|DEVICE|paclitaxel eluting stent|paclitaxel eluting stent
40951485|NCT00462631|DEVICE|bare metal stent|bare metal stent
40951486|NCT00722332|BIOLOGICAL|HepaGam B|Hepatitis B Immunoglobulin
40951487|NCT05204251|BEHAVIORAL|Questionnaire|Quality of Life assessed with the SF-36 questionnaire
40951488|NCT06324760|DIETARY_SUPPLEMENT|Alpha-lipoic acid combined with B vitamins|The investigational product utilized in this research, Tiobec® 400 is a dietary supplement enriched with ALA, B vitamins, and vitamins E and C. T400 is designed to mitigate oxidative stress and support the optimal functioning of the nervous system
40951489|NCT05024201|BEHAVIORAL|THERAPEUTİC TOUCH FOR HEMODİALYSİS PATİENTS|Therapeutic touch was applied to hemodialysis patients for 3 days every other day.
40951490|NCT02261454|OTHER|Gum chewing|1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
40951491|NCT00601198|DRUG|Amifostine|Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
40951492|NCT02212795|DRUG|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
40951493|NCT02212795|DRUG|Levofloxacin 250mg|Levofloxacin 250mg single dose
40760394|NCT05250180|OTHER|Control|treatment as usual as dictated by their treatment team
40760395|NCT05030389|BEHAVIORAL|Adapted Physical Activity (APA)|The APA program lasts 12 weeks and consists in three one-hour at-home sessions a week (total of 36 sessions), including two aerobic dominant web-based sessions and one muscle strengthening self-guided session.
40760396|NCT05030389|BEHAVIORAL|Bright Light Exposure (BLE)|Bright light exposure (BLE) consists in using lamps for light therapy during 12 weeks, at the rate of five one-hour at-home sessions a week.
40760397|NCT05030389|BEHAVIORAL|Galvanic Vestibular Stimulation (GVS)|The GVS program lasts 2 weeks and consists in five 20-minutes at-home sessions a week (total of 10 sessions), using a portable galvanic stimulator.
40951494|NCT02212795|DRUG|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
40951495|NCT03018600|BEHAVIORAL|diet and exercise intervention|consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
40951496|NCT06544122|DEVICE|Transcranial direct current stimulation|Anodal tDCS will be applied at an intensity of 2mA and duration of 20 minutes. The assembly of the electrodes during the tDCS sessions will be carried out as follows: primary motor cortex, the stimulation electrode (anode) will be positioned on C5 (international EEG 10-20 system), in S1 (2cm posterior to C5), at the PFCDL (Fp3), all with the cathode positioned on the region contralateral supraorbital. For cerebellar tDCS the anode will be positioned on the inion area and the cathode on the deltoide muscle.
40951497|NCT02152800|DRUG|valacyclovir hydrocholoride|
41134321|NCT02764905|BEHAVIORAL|intensive cognitive physical rehabilitation program|include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
41134322|NCT04463004|DRUG|Mavrilimumab|Treatment infusion
41134323|NCT04463004|DRUG|Placebos|Placebo infusion
41134324|NCT05410106|DEVICE|PneuX Endotracheal Tube|The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.
40760398|NCT05030389|BEHAVIORAL|Health Education program (HE)|The HE program lasts 14 weeks and consists in one one-hour at-home session a week (total of 14 sessions). This web-based intervention includes courses on general health (sleep habits, diet, physical activity, cardiovascular diseases, etc.).
41454243|NCT06288217|OTHER|Upper Limb Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
40951498|NCT05166564|BEHAVIORAL|A Protein Enriched Mediterranean Diet (PROMED) Intervention|Researchers will provide individually tailored dietary advice and written materials to encourage 'a little and often' meal plan to support adoption of the PROMED intervention. The daily energy and protein requirements of each participant will be calculated based on National Institute of Health \& Care Excellence guidance for Nutrition Support in Adults at Risk of Malnutrition. Several resources have been developed to facilitate behaviour change: a) A PROMED Diet Information Booklet to include an overview of the PROMED Diet, tips for incorporating more PROMED foods into the diet and information on the health benefits of a PROMED diet, b) A PROMED Recipe Book offering ideas for breakfast, lunch and dinner as well as suitable snack ideas and c) key PROMED foods ordered through a local supermarket's online delivery service and delivered to participants' homes on a weekly or fortnightly basis for the 3-month active intervention phase.
40951499|NCT05166564|BEHAVIORAL|A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention|Participants will receive a dietary intervention identical to PROMED participants, plus an exercise intervention. The home-based exercises are based on a modified version of the 'ExWell@home' programme developed by health professionals with significant expertise in community-based exercise rehabilitation for chronic disease. Cardiorespiratory fitness will be determined using a 3-minute step test and pulse rate. Participants will receive access to pre-recorded exercise classes and a written resource designed for older adults (ExWell@home) and adapted for the current study. Participants will be encouraged to complete two sessions per week (30-60 minutes per session). To cater for differing abilities, four levels of classes will be available for participants: Chair based, basic, standard and advanced.
40951500|NCT04612439|DEVICE|VABB Elite 10G|If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle
40951501|NCT04612439|DEVICE|BARD 14G CNB|If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
40951502|NCT00812851|DRUG|Dronabinol|
40951503|NCT01854996|DRUG|PF-05089771|450mg
40951504|NCT01854996|DRUG|PF-05089771|450mg
40951505|NCT01854996|DRUG|PF-05089771|450mg
40951506|NCT01784848|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass (LRYGB)|Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
40951507|NCT01784848|OTHER|Clinical treatment|Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
40951508|NCT01171040|OTHER|Echocardiography, including the measurements of left atrial (LA) distensibility|The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
40951509|NCT03225599|OTHER|Cranial Osteopathic Manipulative Medicine|"The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position"
40951510|NCT03746171|DIAGNOSTIC_TEST|Colonic polyp characterization by BLI|"All rectosigmoid \<5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment.~The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated."
40951511|NCT05969808|OTHER|baseline therapy and conventional therapy|These activities included were warm-up activities, general playtime, basic gross motor activities, and free play with toys three times a week for 45 minutes for a period of 12 weeks.
40951512|NCT05969808|OTHER|baseline treatment and adaptive physical activity|The experimental group's intervention plan had the following 12 elements . Each of which was completed for 10 minutes with two-minute breaks. Warm-up activities, puzzles and manipulatives, e.g., interlocking blocks or shape sorting toys, Balloon Badminton, Obstacle course (crawl in Tunnel ), Peg board play, Tactile sensory bin exploration filled with sand, Ball roll and catch, Tracing shapes, Play dough and clay activities, Cutting and pasting.
41134325|NCT05410106|DEVICE|Standard care (Taperguard, Covidien)|Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.
41134326|NCT00639418|BIOLOGICAL|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
41134327|NCT05582824|OTHER|Blood and urine test|Daily blood and urine samples
41289323|NCT01857986|DEVICE|AnapnoGuard 100 control unit|
40760399|NCT04071535|DEVICE|sudoscan、nerve conduction tests|To evaluate sudomotor nerve and macrofibropathy.
41454244|NCT06288217|OTHER|Sham Stimulation|Control sham stimulation of the trigeminal and vagus nerves is delivered at the start of each session. Performed alongside standard-of-care rehabilitation.
41454245|NCT05215197|DRUG|intracochlear platelet rich fibrin administration|intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
41454246|NCT00633022|DRUG|LOSMAPIMOD 7.5 MG|GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
40760400|NCT01755754|COMBINATION_PRODUCT|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
40760401|NCT01755754|DEVICE|Female Condom|Female condom
41454247|NCT00633022|DRUG|Placebo|Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
41454248|NCT00018616|BEHAVIORAL|MEMS caps|
40951513|NCT03813667|BEHAVIORAL|Intervention FamPALcare|"The FamPALcare intervention includes all standard care information on R-ALD home care plus 2 weeks of EOLPC coaching by community nurses experienced in EOLPC. The nurse uses the Conversation Ready pamphlet to guide discussion of EOL preferences. The nurse will: (1) support the patient and family in making decisions about EOL care options based on their preferences; (2) discuss options for EOL care when the patient's R-ALD symptoms become severe; (3) encourage completion of the advance directive forms at next physician appointment. The nurse will use teach-back processes to ensure that FamPALcare discussions are clear."
41454249|NCT02610881|DIETARY_SUPPLEMENT|Iron and Folic Acid (IFA)|1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
41454250|NCT02610881|DIETARY_SUPPLEMENT|Micronutrient Powders (MNP)|"One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base"
41454251|NCT02610881|BEHAVIORAL|Iron Plus Strategy Counseling|Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
41454252|NCT00715676|DRUG|Placebo|oral, once daily
41134328|NCT00573105|PROCEDURE|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
41454253|NCT00715676|DRUG|DP001|oral, once daily
41454254|NCT05762705|BEHAVIORAL|Multilevel Gaming Adherence Intervention|Information-Motivation-Behavior based mobile gaming application tailored for those taking PrEP and adherence-based text messages
40951514|NCT06318234|DIAGNOSTIC_TEST|18F-FAPI，18F-FDG|FAPI and FDG combined with PET/MR imaging in patients with rectal cancer after neoadjuvant therapy
41134329|NCT00573105|PROCEDURE|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
41134330|NCT01293292|DRUG|Teriparatide|Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
41134331|NCT00309439|PROCEDURE|ALA-rich diet|
41134332|NCT00715182|DRUG|TKI258|
41134333|NCT06353620|DIAGNOSTIC_TEST|High Density EEG recording|Recording of resting state high density EEG (128 channels)
41134334|NCT06353620|DIAGNOSTIC_TEST|Rey Complex Figure Test|Memeory functioning evaluation
41134335|NCT00706888|DIETARY_SUPPLEMENT|Vitamins B6, B9 and B12 and polyphenols|
41134336|NCT00706888|DIETARY_SUPPLEMENT|placebo|
41134337|NCT00645411|BIOLOGICAL|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
41134338|NCT00645411|BIOLOGICAL|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
41134339|NCT00645411|BIOLOGICAL|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
41134340|NCT00645411|BIOLOGICAL|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
41454255|NCT05762705|BEHAVIORAL|Treatment as Usual +|non-PrEP related mobile gaming application
41289324|NCT04270851|DIAGNOSTIC_TEST|LiMAx test|The LiMAx test is a fully licenced liver function test, testing liver maximum capacity via a breath test.
41289325|NCT04270851|DIAGNOSTIC_TEST|HepaT1ca magnetic resonance scan|The HepaT1ca scan is a pre-operative magnetic resonance scan providing a detailed report permitting interactive virtual pre-operative planning prior to liver surgery.
40951515|NCT03133130|DRUG|BMT101|BMT101 is administered to 6 subjects in each of 4 groups.
40951516|NCT03133130|DRUG|Placebo|Placebo is administered to 2 subjects in each of 4 groups.
40951517|NCT00302185|PROCEDURE|Acupuncture|Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.
40951518|NCT00302185|BEHAVIORAL|Nurse-led supportive care|20-30 minutes of supportive attention from an experienced palliative nurse.
40951519|NCT02349542|DRUG|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (\~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
40951520|NCT05342935|DEVICE|Inteligent Dialysis Assistant (IDA)|The IDA is a small dialysis system that allows a higher level of freedom to the patients, permitting them to perform the PD exchange while continuing to do their everyday activities
40951521|NCT01888757|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
41134341|NCT03102632|OTHER|High Water Intake|After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
41134342|NCT05621902|OTHER|Weekly symptom monitoring|Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire
41134343|NCT04817059|DEVICE|Caseforge headcase|We used a custom-fitted styrofoam head mold designed to reduce head motion during MRI scanning.
41134344|NCT05456932|DRUG|Intravenous iron|Included participants will receive intravenous iron therapy, the dosage will be based on national pharmaceutical formulary.
41134345|NCT05456932|DRUG|Ferric maltol|Included participants will receive oral iron therapy with ferric maltol (twice a day 30mg for 12 weeks)
41134346|NCT05456932|DRUG|Ferrous fumarate|Included participants will receive oral iron therapy with ferrous fumarate (twice a day 100mg for 12 weeks)
41134347|NCT00689351|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
41134348|NCT00689351|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
41134349|NCT01858324|OTHER|Educational tools|Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
41134350|NCT01232101|DEVICE|covered or uncovered stents|Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
41134351|NCT03132636|DRUG|cemiplimab|Regimen as per protocol
41134352|NCT00386685|DRUG|larotaxel (XRP9881)|intravenous administration
41134353|NCT00386685|DRUG|trastuzumab|intravenous administration
41289326|NCT01319760|DEVICE|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
41289327|NCT01319760|OTHER|Standard of care (Control)|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
41134354|NCT03349944|BEHAVIORAL|Training|The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
41134355|NCT01746576|OTHER|Use of impedance threshold device during spontaneous ventilation|
40760402|NCT00945087|OTHER|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
40760403|NCT02496754|DRUG|GnRH-a|In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
40760404|NCT02496754|DRUG|GnRH-a|In control group, patients use short term GnRH-a. Patients' serum or follicle fluid will be collected if needed.
40760405|NCT02344472|DRUG|pertuzumab|HER2 targeted Therapy
40760406|NCT02344472|DRUG|Trastuzumab|HER2 targeted Therapy
40760407|NCT02344472|DRUG|Capecitabine|Chemotherapy
40760408|NCT02344472|DRUG|Paclitaxel|Chemotherapy
40760409|NCT02344472|DRUG|Vinorelbine|Chemotherapy
40760410|NCT02344472|DRUG|Docetaxel|Chemotherapy
40760411|NCT02344472|DRUG|Exemestane|endocrine therapy
40760412|NCT02344472|DRUG|Letrozole|endocrine therapy
40760413|NCT02344472|DRUG|Anastrozole|endocrine therapy
40760414|NCT02344472|DRUG|Fulvestrant|endocrine therapy
40760415|NCT02344472|DRUG|Ribociclib|CDK 4/6 inhibitor
40760416|NCT02344472|DRUG|nab-Paclitaxel|chemotherapy
40760417|NCT02344472|DRUG|eribulin|chemotherapy
40760418|NCT02344472|DRUG|leuprorelin|endocrine therapy
40760419|NCT02344472|DRUG|goserelin|endocrine therapy
40760420|NCT05809830|DRUG|LB-100 plus Doxorrubicin|In Phase one the intervention will be LB-100 plus Doxorrubicin. The experimental arm in Phase II will also be LB-100 plus Doxorrubicin
40760421|NCT05809830|DRUG|Doxorubicin|The control arm in Phase II will be Doxorrubicin alone
41134356|NCT01270282|DRUG|AM-101 0.81 mg/mL|
41134357|NCT01270282|DRUG|Placebo|
40760422|NCT04917510|PROCEDURE|Erector spinae block|See experimental arm group description
40760423|NCT04917510|PROCEDURE|Local block|See control and study arm group descriptions for the local block
40760424|NCT02255656|DRUG|alemtuzumab GZ402673|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
40760425|NCT04961515|DRUG|Orelabrutinib|Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined regimen, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) and dose level 3 (250mg) with rules for escalation and de-escalation. If the DLT is not found, the dose of 250mg qd will be used for phase II trial.
40760426|NCT04961515|DRUG|Orelabrutinib|Orelabrutinib: orally maximum tolerated dose from phase 1b daily (150 mg or 200 mg or 250mg)
40760427|NCT04961515|DRUG|Sintilimab|The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks
40760428|NCT00963638|DIETARY_SUPPLEMENT|MagTabSR|MagTabSR/placebo 168 mgs BID for 6 six weeks
40760429|NCT00963638|DIETARY_SUPPLEMENT|Placebo|MagTabSR/placebo 168 mgs BID for 6 six weeks
40760430|NCT04634877|BIOLOGICAL|Pembrolizumab|IV infusion
40760431|NCT04634877|DRUG|Carboplatin|IV infusion
40760432|NCT04634877|DRUG|Paclitaxel|IV infusion
40760433|NCT04634877|DRUG|Placebo for pembrolizumab|IV infusion
40760434|NCT04634877|DRUG|Docetaxel|IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.
40760435|NCT04634877|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
40760436|NCT04634877|RADIATION|External Beam Radiotherapy (EBRT)|≥4500 cGY given according to local practice, at the discretion of the investigator
41134360|NCT04255225|BEHAVIORAL|Walking for 10 minutes|Participants will walk on a treadmill for 10 minutes at a moderate intensity.
41134361|NCT04255225|BEHAVIORAL|Walking for 20 minutes|Participants will walk on a treadmill for 20 minutes at a moderate intensity.
41134362|NCT04255225|BEHAVIORAL|Walking for 30 minutes|Participants will walk on a treadmill for 30 minutes at a moderate intensity.
41134363|NCT05569343|OTHER|No intervention|This is an observational study without any intervention
41134364|NCT01469585|DRUG|Doxycycline|40 mg orally at the start of cycle 3 (study day 57) for 28 days.
41134365|NCT01204996|DRUG|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection|10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
41134366|NCT01204996|DRUG|CNTO888 + gemcitabine|15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
41134367|NCT01204996|DRUG|CNTO888 + Paclitaxel and carboplatin|15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
41134368|NCT01204996|DRUG|CNTO888 + docetaxel|15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
41134369|NCT02745990|DRUG|Recombinant human erythropoietin|rhEPO is administered 500IU/kg, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
41134370|NCT02745990|DRUG|Normal saline|Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
41134371|NCT02499601|DEVICE|CORolla™ TAA device|
41134372|NCT01329406|DRUG|Milnacipran|1 tablet (100mg) by mouth twice daily for 28 days
41134373|NCT01329406|DRUG|Placebo|1 tablet by mouth twice daily for 28 days
41134374|NCT03556410|BEHAVIORAL|sleep|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.
40760437|NCT04634877|DRUG|Cisplatin (as radiosensitizer)|If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
40760438|NCT04634877|RADIATION|Brachytherapy|Given according to local practice, at the discretion of the investigator
41289328|NCT00848991|DRUG|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
41289329|NCT00848991|DRUG|Propofol|evaulation of propofol for emergence from anesthesia
41289330|NCT01645280|DRUG|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
41289331|NCT01645280|DRUG|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
41289332|NCT01645280|DRUG|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
41289333|NCT01645280|DRUG|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
41289334|NCT01645280|DRUG|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
40760439|NCT03983239|DRUG|Fedratinib|Fedratinib
40760440|NCT03983239|DRUG|Rifampin|Rifampin
40760441|NCT03983239|DRUG|Efavirenz|Efavirenz
40760442|NCT06570876|PROCEDURE|Surgery|The decision between RS and CS depended on the patient's performance status; on the cyst's main characteristics and contact with liver structures; and on intraoperative findings.
41289335|NCT02385123|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
41289336|NCT00679562|DRUG|Lactic Acid|Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
41289337|NCT00679562|OTHER|Distilled water|Application of patches containing distilled water for 24 hours
41289338|NCT02232438|BEHAVIORAL|Behavioral activation therapy|Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
41289339|NCT05947799|OTHER|Baseline questionnaires|Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.
41454256|NCT03616379|BEHAVIORAL|Psychoeducational Control|The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
40760443|NCT04148755|PROCEDURE|Endoscopic ultrasound guided fine needle aspirate|All patients are going to have an EUS guided elastography with FNA of solid pancreatic lesions
40760444|NCT05552365|BEHAVIORAL|Adapted Cognitive Behavioural|8-session cognitive behavioural intervention adapted for children indicated to have developmental language disorder. Intervention includes psychoeducative, bodily relaxation, graded exposure, cognitive restructuring and brainstorming. Adaptations include increasing the number of visual supports, use of physical objects to illustrate concepts in addition to language.
40760445|NCT05552365|OTHER|Treatment as Usual|Participants given a mental health brochure with contact information, where they can access services provided by mental health support service providers.
40760446|NCT03725527|PROCEDURE|Rectus Sheath Block|Sonar guided RSB will be performed using a 16-G, 8-cm TuohyUpon reaching this potential space, after careful aspiration.
40760447|NCT00748605|DRUG|S-2367 Placebo|Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks
40760448|NCT00748605|DRUG|S-2367 1600 mg q.d. 54 Weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD for a total of 54 weeks
40951522|NCT04857957|DRUG|Oral dose CNTX-6016 or oral dose Placebo|CNTX-6016 or Placebo
40760449|NCT00748605|DRUG|S-2367 1600 mg q.d. 60 weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD for a total of 60 weeks
40760450|NCT00748605|OTHER|LCD (low calorie diet)|A low calorie diet was utilized during the first 6 weeks of the study
40760451|NCT00748605|OTHER|RCD (reduced calorie diet)|A reduced calorie diet was used during the last 54 weeks for the study
40760452|NCT04025320|OTHER|Intraneural Facilitation|Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.
40951523|NCT02863744|PROCEDURE|coronally advanced flap with subepithelial connective tissue graft|"* Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~* The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures."
40951524|NCT02645201|DIETARY_SUPPLEMENT|Gastrus|to compare Gastrus 4x108 tbl twice a day to placebo tbl
40951525|NCT02645201|OTHER|Placebo|to compare Gastrus 4x108 tbl twice a day to placebo tbl
40951526|NCT04154930|DEVICE|Restylane-L®|Intradermal injection.
40951527|NCT01193270|DRUG|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
40951528|NCT01193270|DRUG|Placebo|Sterile water in volume equal to that of the comparator drug
40951529|NCT04195906|DRUG|Experimental: SNF472|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
40951530|NCT04195906|DRUG|Placebo Comparator: Placebo|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks
40951531|NCT04195906|DRUG|Experimatenl SNF472 (Open-label)|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
40951532|NCT06558097|DRUG|XXB750|Single SC dose of XXB750 (administered by single or multiple injections)
40951533|NCT06558097|OTHER|Placebo|Single SC dose of matching placebo (administered by single or multiple injections)
40951534|NCT02476201|DEVICE|MPP ON|Patients implanted with a Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead and with the MultiPoint Pacing (MPP) feature activated
40951535|NCT01056029|DRUG|G-202|Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
40951536|NCT05078398|BEHAVIORAL|POINT Protocol|Patients will receive counseling on risks and benefits of opioids for pain control, asked to choose whether they need opioid prescription when ready for discharge.
40951537|NCT05078398|BEHAVIORAL|Usual care|Will prescribe standardized amount of opioid for postoperative pain without patient input
40951538|NCT01391754|BEHAVIORAL|SafeCare|Behavioral home based family preservation. Weekly visits X six months.
40951539|NCT01391754|OTHER|In vivo coached quality control|Live observation of practice with expert coaching, feedback and fidelity monitoring
40951540|NCT01391754|BEHAVIORAL|Services As Usual|Home based services not using the SafeCare model
40951541|NCT01391754|OTHER|Uncoached|No in vivo coached quality control or fidelity monitoring
40951542|NCT06228274|DEVICE|ARTHRUM 2.5%|ARTHRUM 2.5%
40951543|NCT02650635|DRUG|Cyclophosphamide|Given IV
40951544|NCT02650635|OTHER|Laboratory Biomarker Analysis|Correlative studies
40951545|NCT02650635|BIOLOGICAL|Pegfilgrastim|Given SC
40951546|NCT02650635|OTHER|Pharmacological Study|Correlative studies
40951547|NCT02650635|DRUG|TLR8 Agonist VTX-2337|Given SC
40951548|NCT01068834|GENETIC|KIF6 genetic test|KIF6 carrier status with interpretation sheet provided to subject
40951549|NCT02486302|DRUG|Etanercept|Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
40951550|NCT03330288|DRUG|Theraflex, BAY 874017|The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
40951551|NCT06170892|OTHER|Kangaroo method|The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.
40951552|NCT04862455|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally/intranodally
41289340|NCT05947799|OTHER|Post-questionnaire|Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.
41289341|NCT05632250|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. Patient's wounds will be assessed and a dressing from the above will be applied as part of their normal standard of care. The wounds will be assessed on a weekly basis for up to 12 weeks.
41289342|NCT02858388|DEVICE|Sinuclean Nebules 45|Nebulization of solution
41289343|NCT02858388|OTHER|Saline solution|Nebulization of solution
40951553|NCT04862455|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
41134375|NCT03556410|BEHAVIORAL|exercise|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored and 45 min of exercise will be required during the shortened sleep days .
41134376|NCT06233552|PROCEDURE|conventional denture conversion|conventional workflow usually done to do immediate loading for full arch implant cases
41289344|NCT04472429|DRUG|carboplatin|carboplatin will be administered intravenous on Day 1 of each 28 day cycle
40760453|NCT04025320|OTHER|Sham|A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
40760454|NCT04849273|DRUG|TPX-0131|Oral TPX-0131 tablets
40760455|NCT01872000|PROCEDURE|Cataract surgery|
40786500|NCT02785328|OTHER|memory evaluation at V1 and V2 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
40951554|NCT04862455|BIOLOGICAL|Pembrolizumab|Given IV
41454257|NCT03616379|BEHAVIORAL|Affect Regulation|In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
40951555|NCT04862455|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41454258|NCT03616379|BEHAVIORAL|Affect Labelling|In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
41454259|NCT00052221|BIOLOGICAL|Epoetin alfa|
41454260|NCT00052221|OTHER|Placebo|
41454261|NCT06267339|DEVICE|transcranial random noise stimulation|This intervention will give children tRNS during reaching or grasping repetitive movements.
40951556|NCT05952817|DEVICE|virtual reality|Virtual reality (VR) technology is a new medical intervention technique founded on the principle of distraction, providing real perceptual stimuli such as visual images, spatial sounds, tactile, and sensory feedback stimuli.(Zhang et al., 2022)
41289345|NCT04472429|DRUG|paclitaxel|paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle
40760456|NCT05272280|OTHER|External oblique intercostal (EOI) block|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
40760457|NCT05272280|OTHER|Erector spinae plane block (ESPB)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of Local Anesthetic mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
40951557|NCT05952817|PROCEDURE|Physical Exercise|Rehabilitation program of exercise
40951558|NCT03808129|DRUG|Bupivacaine and Lidocaine|ESP block was administered under general anesthesia before the surgery. Patients with ESP block, 1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine
40951559|NCT03953820|DRUG|Diazepam Buccal Film|Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.
40951560|NCT03953820|DRUG|Diastat® Rectal Gel (Valeant Pharmaceuticals USA)|Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
40951561|NCT04789499|DRUG|Theophylline Powder|Twice daily nasal irrigation with 400 mg theophylline capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
40951562|NCT04789499|DRUG|Placebo Comparator|Twice daily nasal irrigation with 500 mg lactose powder capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
40951563|NCT03064230|OTHER|QoL questionnaire SF-12 and and a screening questionnaire|patient were asked to fill questionnaires
40951564|NCT01524731|DRUG|Saline|Normal Saline
40951565|NCT01524731|DRUG|Dexamethasone|4 mg
40951566|NCT01524731|DRUG|Dexamethasone|8 mg
40951567|NCT02891694|OTHER|in vitro immuno-histo-chemical analysis of corneal epithelium|
40951568|NCT04798456|BEHAVIORAL|Coma scales|CRS-R and GOSE
41134377|NCT06233552|PROCEDURE|digital denture conversion|An alternative workflow for construction of the fixed interim requires impressions, model production, and jaw relation records then digitizing all these data then designing and milling the restoration.
41289346|NCT04472429|DRUG|retifanlimab|retifanlimab will be administered intravenous on Day 1 of each 28 day cycle
41289347|NCT04706390|BIOLOGICAL|covid-19 vaccine|vaccination
41289348|NCT05574972|DEVICE|Timing Carotid Stent|all the participants in this group will be performed with Timing Carotid Stent
40951569|NCT04798456|DIAGNOSTIC_TEST|Imaging, electrophysiology, body signals, and brain stimulation|MRI, fMRI, EEG, TMS-EEG, Olfaction, Respiration, EKG
40951570|NCT04798456|BEHAVIORAL|Questionnaires|several questionnaires and an interview with the caregiver
40951571|NCT00199485|DRUG|Angelica Sinensis|Angelica Sinensis / placebo
40951572|NCT05143021|OTHER|Multidisciplinary Sickle Cell Disease- Obstetric Team|Modified multidisciplinary teams for pregnant women with sickle cell disease including members from an obstetrics team and sickle cell disease team.
40951573|NCT06181578|PROCEDURE|ganglionated plexus ablation|This intervention involves the targeted ablation of ganglionated plexus sites, specifically focusing on the left superior ganglionated plexus (LSGP), left inferior ganglionated plexus (LIGP), right anterior ganglionated plexus (RAGP), and right inferior ganglionated plexus (RIGP).
41289349|NCT05574972|DEVICE|Carotid Wallstent|all the participants in this group will be performed with Carotid Wallstent
40951574|NCT02083614|PROCEDURE|to clamp or release the catheter for 2 days before removal|
40951575|NCT00789490|DIETARY_SUPPLEMENT|Daminaide 995 - SuppleFem Sprinkles|The study agent SuppleFem will be a preblend manufactured by Acatris in Oakville Ontario and will be repackaged into 1 gram aliquots in white plastic Tamper Seal Vials.1 ram to be taken with test meal
41289350|NCT02094846|BEHAVIORAL|Voice messages|Voice messages reinforced with self-efficacy
41289351|NCT05167292|OTHER|Observational study|Routine clinical care was provided to all AKI cases presenting to the TTM Hospital in Samoa. This prospective observational study reviewed incidence, aetiology and outcomes for these cases.
41289352|NCT00875420|DRUG|RAD1901|10 mg Oral once a day for 28 days.
41289353|NCT00875420|DRUG|RAD1901|25 mg Oral once a day for 28 days
41289354|NCT00875420|DRUG|RAD1901|50 mg Oral once a day for 28 days.
41289355|NCT00875420|DRUG|RAD1901|100 mg Oral once a day for 28 days
40951576|NCT00789490|DIETARY_SUPPLEMENT|Materna|Materna is a pregnancy supplement available on the Canadian market and is manufactured by Wyeth. Dose is 1 tablet per day
40951577|NCT03896165|OTHER|Reiki|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the parent how to perform a simple 15-minute Reiki session. Parents will complete a return demonstration using light touch with their adolescent. Parents will be asked to complete a minimum of 15 minutes of Reiki with their adolescent at least five days per week for the four-week intervention period.
40951578|NCT01690585|DRUG|Ferinject 1000 mg|
40951579|NCT01690585|DRUG|Sodium chlorure 0,9 %|
40951580|NCT04177121|OTHER|qualitative analysis|Qualitative analysis of physiotherapy prescriptions
40951581|NCT04053322|DRUG|Durvalumab|Durvalumab will start 4 weeks after the first dose of olaparib (Cycle 2, Day 1) at 1500 mg intravenous (IV) every 4 weeks.
40951582|NCT04053322|DRUG|Olaparib|2 x 150 mg tablets taken in the morning and in the evening orally (2 X 300 mg daily)
40951583|NCT04053322|DRUG|Fulvestrant|Two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15, and then Day 1 of each subsequent 28-day cycle.
40951584|NCT02026284|OTHER|Questionnaire|A questionnaire was performed to gravid women who are to deliver, regarding theri anesthesia preferences.
40951585|NCT03071471|DEVICE|MID-C|"The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.~The MID-C System inherent benefits are:~* Only two screws are used~* Incision size is much smaller~* Simpler operation with shorter operative time~* Less complication thanks to the three points above.~* Minimal spinal mobility loss"
40951586|NCT04213417|OTHER|Bobath therapy and Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the BC was applied to the affected side of the body and lower extremity for 60 minutes in each session.The treatment was started from the thoracic region and a treatment direction was toward the lower extremity in the affected side.During the MRT procedure, the patient's active participation was ensured and the treatment was combined with the exercises.The patients were informed about MRT verbally and in writing before the application. Participants were treated 3 days a week for 4 weeks for a total of 12 sessions.
40951587|NCT04213417|OTHER|Bobath therapy|Both groups were treated with the BC as a neurodevelopmental therapy. Considering individual requirements and wishes of the patient, an exercise program that supports active participation of the person was established.Each treatment session was performed for 60 minutes.The treatment program that was established appropriately according to the patient contained weight transfer to the affected side in different positions,approximation to increase proprioceptive input, providing sensorial input to the sole of the foot using materials such as sensory ball,foot-ankle mobilization,functional reach activities, forward-side step, gait, and balance activities. Participants in both groups were treated 3 days a week for 4 weeks for a total of 12 sessions.
40951588|NCT05758571|DRUG|EGCG|EGCG (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day.
40951589|NCT02651818|PROCEDURE|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
40951590|NCT02173808|BIOLOGICAL|levonorgestrel butanoate|
40951591|NCT04469530|DRUG|Sirolimus|Sirolimus is given at a dose of 2 mg/m2 once daily. The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. The solution can be drunk or administered at once to assure delivery of all of the medication. It is safe for administration through a nasogastric or G-tube. For tablets, the tablet should not be crushed, split, or otherwise altered. As with the liquid dosing form, the tablets should be given within two hours each day and should be at consistent intervals with regard to meals.
40951592|NCT04469530|DRUG|Cyclophosphamide|"A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube."
40951593|NCT04469530|DRUG|Etoposide|A semisynthetic derivative of podophyllotoxin which functions as mitotic inhibitor but does not interfere with microtubular assembly. The drug is administered orally daily, in the formulation appropriate for age.
40951594|NCT04469530|DRUG|Celecoxib|The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
40951595|NCT00066729|BIOLOGICAL|NY-ESO-1 peptide vaccine|NY-ESO-1b peptide 100 μg mixed with 0.5 mL of Montanide® ISA-51
40760458|NCT01013337|PROCEDURE|acupuncture therapy|
40951596|NCT04442139|OTHER|Mini-Gastric Bypass|Mini-Gastric Bypass bariatric surgery
40951597|NCT06295536|DEVICE|Comparator device, Closed-field autorefractometer|"* Objective refraction without cycloplegia~* Distance visual acuity with objective refraction without cycloplegia~* Objective refraction with cycloplegia~* Distance visual acuity with objective refraction with cycloplegia"
41289356|NCT00875420|DRUG|Placebo|Placebo Oral once a day for 28 days
40760459|NCT01013337|PROCEDURE|sham intervention|Placebo acupuncture
40760460|NCT00011635|DRUG|Silymarin (milk thistle)|
40760461|NCT04060238|DIAGNOSTIC_TEST|Anomaloscope (colour vision test)|"The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)"
40760462|NCT04070846|DRUG|[14C] LC350189|Carbon-14 labelded LC350189
41289357|NCT02806427|OTHER|Enteral Formula|
41454262|NCT06267339|DEVICE|Sham stimulation|This intervention will give children sham stimulation during reaching or grasping repetitive movements.
40760463|NCT04816903|DIAGNOSTIC_TEST|Gyni|Vaginal discharge collection
40951598|NCT03343379|OTHER|Core stability tests|A test battery comprised of field tests to evaluate core stability
41289358|NCT02322307|OTHER|HealthPROMISE users|"Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.~Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings."
40951599|NCT00097318|DRUG|Interferon beta-1a|
40951600|NCT02326051|DRUG|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
41454263|NCT05951205|BIOLOGICAL|Exa-cel|Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
40951601|NCT02326051|DRUG|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
40951602|NCT00232648|DRUG|Pulmicort (budesonide) Respules|
40951603|NCT01191918|DRUG|Donepezil and Lithium|Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
40951604|NCT01191918|DRUG|Placebo plus Lithium|
40951605|NCT01938573|DRUG|Cisplatin|Given IV
40951606|NCT01938573|DRUG|Gemcitabine Hydrochloride|Given IV
40951607|NCT01938573|DRUG|Sirolimus|Given PO
40951608|NCT01938573|PROCEDURE|Cystectomy|Undergo cystectomy when appropriate
40951609|NCT00111501|BEHAVIORAL|Tobacco Use Disorder|Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component
40951610|NCT00111501|BEHAVIORAL|Standard Web-based intervention|General psychoeducational Web-based smoking cessation intervention
41289359|NCT02322307|OTHER|Control Group|In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.
40951611|NCT01842100|DRUG|Universal antibiotic prophylaxis|100 mg twice daily for 7 days starting on the day of induced abortion
41289360|NCT02989727|DRUG|Lamotrigine|Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.
41289361|NCT02989727|DRUG|Placebos|Placebo tablets
40951612|NCT01842100|OTHER|Screen-and-treat|Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
40951613|NCT00826761|DIETARY_SUPPLEMENT|probiotic|One capsule per meal test (high dose or low dose)
40951614|NCT00826761|DIETARY_SUPPLEMENT|placebo|1 capsuel every morning
40951615|NCT05369767|DRUG|SAD, SHR-2004|Ascending dose
40951616|NCT05369767|DRUG|SAD, SHR-2004 placebo|Ascending dose
41454264|NCT01924286|DRUG|Prednisone|
41454265|NCT01924286|DRUG|Placebo|
40951617|NCT05458934|OTHER|No intervention|no intervention
40951618|NCT04034836|DRUG|Scalp blocks with ropivacaine plus parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
41146805|NCT04037592|DEVICE|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
41146806|NCT00391794|BEHAVIORAL|Early Stage Memory Loss Support Group|8 week support group led by trained facilitators
41146807|NCT00391794|BEHAVIORAL|Educational Seminar|4 hour education session led by trained facilitators
41146808|NCT00267774|DEVICE|Fractional flow reserve|
41146809|NCT00267774|PROCEDURE|Angio-guided PCI|
41454266|NCT01393951|BIOLOGICAL|ASP7374|subcutaneous and intramuscular
41454267|NCT04808388|OTHER|MRI|Using MRI for fat fraction and Biodex for isometric strength
41289362|NCT05810779|OTHER|dynamic surface exercise|Optimal arousal Physio ball Make the child bounce, active/passive on the Swiss ball, slow/fast 5 times 5 sets Combined frontal and transverse plane movements Physio ball/ bolster High sitting: one hand weight bearing followed by trunk rotation to reach the toy on opposite side 5-7 each side 1 set Combined frontal and transverse plane movements Platform swing Reaching the toy with both the hands kept overhead and 45°-60° diagonal to the mid line 5-7 times each side 1 set
40951619|NCT04034836|DRUG|Scalp blocks with ropivacaine and intravenous parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
40951620|NCT04034836|DRUG|Scalp blocks with ropivacaine and intravenous saline|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
40951621|NCT00135564|BIOLOGICAL|MenC-TT|
40951622|NCT00135564|BIOLOGICAL|Hib-MenC-TT|
40951623|NCT00181155|DRUG|Allopurinol|intravenous infusion of allopurinol (300mg)
40951624|NCT00181155|DRUG|Placebo|intravenous infusion of 50 ml dose of 5% dextrose
40951625|NCT03155282|PROCEDURE|EUS-E to measure liver and spleen stiffness.|The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
40951626|NCT01476956|OTHER|Observational study|RA patients on standard DMARD therapy
41146810|NCT00447109|DEVICE|Closed system suction|
40760464|NCT02431026|DEVICE|Cooling pack activated Excel Cryo Cooling Collar|Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
40760465|NCT04145622|DRUG|Ifinatamab deruxtecan (I-DXd)|A total anti-B7H3 antibody and MAAA-1181a
41289363|NCT05810779|OTHER|trunk targeted training|"trunk training group (TTG) consist of exercises and activities focusing on the activation of the trunk muscles, pelvic control and proximal stabilization and these were combined with the trunk and gluteal muscle strengthening exercises.~The trunk elongation activities, the facilitation of spinal extension, weight shifting and weight-bearing activities The children in the TTG received 45-75-minute of physiotherapy twice a week for 8 weeks"
40760466|NCT04054882|BIOLOGICAL|Sabin-IPV and DTaP|simultaneously administration of Sabin-IPV and DTaP
40760467|NCT04054882|BIOLOGICAL|Sabin-IPV|administration of Sabin-IPV only
40760468|NCT04054882|BIOLOGICAL|DTaP|administration of DTaP only
40760470|NCT01873508|DRUG|RO4917523|Fast release MR capsule, single dose
40760471|NCT01873508|DRUG|RO4917523|Target release MR capsule, single dose
40951627|NCT03299465|BEHAVIORAL|Yoga|This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
40951628|NCT00431678|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
40951629|NCT00431678|DRUG|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
40951630|NCT02358681|DRUG|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
40951631|NCT02358681|DRUG|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
40951632|NCT02358681|DRUG|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
40951633|NCT02358681|DRUG|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
40951634|NCT05136352|PROCEDURE|adductor canal block|loco-regional anesthesia using adductor canal block
40951635|NCT05136352|PROCEDURE|iPACK block|loco-regional anesthesia using infiltration between the popliteal artery and the capsule of the posterior knee
40951636|NCT04224038|OTHER|The Inspire Bio-resource Research Platform for Healthy Aging|Several follow-up visits will be undertaken during the 10-year time frame of this project. Some of these visits are not regularly scheduled and will be conditioned by the remote monitoring of intrinsic capacity (IC) and the onset of other major clinical conditions. Other visits correspond to the regularly scheduled (yearly or every two years (biannual visits), depending on the outcome measures) waves of data collection.
40951637|NCT00239590|DRUG|Testosterone undecanoate|Licensed for androgen deficiency
41289364|NCT04067531|DRUG|treatment of BV with first Deqularum and then direkt after with vaginal clindamycin|All patients will get the same treatment
41289365|NCT00247325|DRUG|Iodixanol(Drug)|
41289366|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
41289367|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
41289368|NCT00336492|BIOLOGICAL|infliximab|infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
40760472|NCT01873508|DRUG|RO4917523|Slow release MR capsule, single dose
40760473|NCT01873508|DRUG|RO4917523|\[13C\]-labeled tracer dose i.v.
40760474|NCT03607500|BEHAVIORAL|caloric intake reduction|The caloric intake reduction arm will been seen by the kidney disease dietitian at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3).
40760475|NCT05560880|BEHAVIORAL|High Intensity Interval Gait training|Subjects will walk as fast as they can for 30 seconds, followed by a 60 second seated recovery. They will be guarded by a physical therapist at all times.
40760476|NCT05560880|BEHAVIORAL|Moderate Intensity Interval gait training|subjects will walk for 20 minutes at theri best comfortable pace
40760477|NCT00045331|GENETIC|proteomic profiling|
40951638|NCT02754154|DRUG|Warfarin|
40951639|NCT02754154|DRUG|Apixaban|
40951640|NCT02754154|DRUG|Dabigatran|
40951641|NCT02754154|DRUG|Rivaroxaban|
40951642|NCT05197621|BIOLOGICAL|mRNA COVID-19 vaccine (Pfizer or Moderna)|mRNA vaccine received at any time during pregnancy course
40951643|NCT00472719|BIOLOGICAL|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
40951644|NCT00472719|BIOLOGICAL|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
40951645|NCT00472719|BIOLOGICAL|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
40951646|NCT03240354|DEVICE|Saline cuff|Cuff of endotracheal tube inflated with saline rather than air (control)
40951647|NCT03240354|DEVICE|Control|Cuff of endotracheal tube inflated with air
40951648|NCT02502318|PROCEDURE|Video-thoracoscopy|
40951649|NCT02502318|PROCEDURE|thoracotomy|
40951650|NCT00469651|BIOLOGICAL|MSP 3 Long Synthetic Peptide|Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide
40951651|NCT00469651|BIOLOGICAL|MSP3 vaccine|Lyophilized vaccine adjuvanted in Aluminium hydroxide
40951652|NCT00469651|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
40951653|NCT00469651|BIOLOGICAL|MSP3 candidate vaccine|Lyophilized MSP3 adjuvanted in Aluminium hydroxide
40951654|NCT00469651|BIOLOGICAL|Hepatitis B control vaccine|Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
40951655|NCT00108173|DRUG|Zyban|
40951656|NCT02949531|DRUG|oxygen|
40951657|NCT04035109|DRUG|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.
40951658|NCT04035109|DRUG|Preservative-free 0.9% sodium chloride (Placebo)|A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.
41146811|NCT02958826|OTHER|Questionnaire|Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
41146812|NCT05473130|DEVICE|Breethe Oxy-1 System|To pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass with Breethe Oxy-1 System
40951659|NCT04035109|BIOLOGICAL|House dust mite allergen|Standardized house dust mite (Dermatophagoides farinae) allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to house dust mite (determined by skin prick testing) will undergo intranasal challenge with house dust mite allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
40951660|NCT04035109|BIOLOGICAL|Cat hair allergen|Standardized cat hair allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to cat hair (determined by skin prick testing) will undergo intranasal challenge with cat hair allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
41454268|NCT01821157|PROCEDURE|Open-flap|Open-flap(control group; n=28 sides/105 teeth): An internal beveled incision was performed at the buccal aspect of the involved teeth. Afterwards, a sulcular incision was completed to allow gingival tissue removal. A full-thickness mucoperiosteal flap was reflected to remove and remodel bone tissue by means of surgical chisels, as necessary, until a 3mm distance was achieved between the bone crest and the cement-enamel junction (CEJ). The exposed root surfaces were carefully planed with curettes. Interrupted sutures were performed at the papilla to allow GM stabilization in the CEJ position.
40951661|NCT03439787|DRUG|Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution|10 ml
40951662|NCT03439787|OTHER|Sodium Chloride 0.9 %|10 ml
40951663|NCT04112459|OTHER|prolonged mechanical ventilation|No intervention will be applied in this study
40951664|NCT02906332|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks x 2 cycles. This is followed by followed by pembrolizumab 200 mg IV every 3 weeks for 2 additional cycles.
40951665|NCT02906332|DRUG|Lenalidomide|Lenalidomide 25 mg po daily x 14 days once weekly for a 21-day cycle x 2 cycles. This is followed by lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for 2 additional cycles.
40760478|NCT00772200|PROCEDURE|Cognitive Assessment|Complete COG Standard Neuropsychological and Behavioral Battery
41289369|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
40760479|NCT00772200|OTHER|Quality-of-Life Assessment|Ancillary studies
40760480|NCT01840163|OTHER|Static version of CanSORT tool|
40760481|NCT01840163|OTHER|CanSORT Online Tool|
40951666|NCT02906332|DRUG|Dexamethasone|Dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles only.
40951667|NCT06128473|DEVICE|Soft Contact Lens|Vision Correction
40951668|NCT03531359|DEVICE|TIBD|Table-based Interactive Distraction using video-games will be used to prove efficacy in preventing preoperative anxiety.
40951669|NCT03531359|DRUG|Midazolam|Administration of midazolam oral or rectal 30 minutes to one hour prior to transfer to the theater.
40951670|NCT04978597|DRUG|Opicapone 50 mg|Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
40951671|NCT04978597|DRUG|Placebo|Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
40951672|NCT03888586|DEVICE|Trigger Point Dry Needling Technique|The type of needle and the depth of the entrance varied depending on the estimated muscle thickness (0.25 - 25 mm, 0.25 - 30 mm and 0.25-40 mm). The disposable stainless-steel sterile needles were inserted through the skin over the trigger point in the taut band of muscle using the fast-in/out technique. Forward and backward needling was repeated until the local twitch responses were obtained. The depth of the needle was changed depending on the muscle thickness. After the first local twitch response, the needle was moved up and down 3 to 5 mm in only vertical directions until no more local twitch responses were elicited. After removing the needle, the insertion area was compressed with a piece of cotton
40951673|NCT03888586|OTHER|Deep Friction Massage Technique|For supporting the normal healing conditions, the deep and transverse friction causes hyperaemia in the involved soft tissue, which results in increased blood ﬂow to the area.
40951674|NCT03979612|GENETIC|inclusion of subjects in the GENEPY network|The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index): relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients (Claes 2003), the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring.
41289370|NCT06449261|OTHER|Spinal Manual therapy used in Physiotherapy Practice|C5-C6 and thoracic spine mobilization with postural correction
40951675|NCT04584970|DEVICE|Applied VR|The Applied VR device is a lightweight mobile virtual reality headset with embedded software, creating an immersive experience. The Applied VR is specifically designed for medical use.
41289371|NCT03992235|OTHER|Chest physiotherapy|"All patients will receive chest physiotherapy including Breathing exercise, intensive spirometry use, coughing, ambulation."
40760482|NCT02483910|BEHAVIORAL|Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx)|"DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts (show me or point to or say the whole thing), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons."
40760483|NCT02483910|BEHAVIORAL|Standard of care delivered via telehealth (e.g., Zoom or WebEx)|Usual care including speech therapy in school, community or both
40760484|NCT04505787|DRUG|Esflurbiprofen hydrogel patch 165 mg (EFHP)|patch application with PK blood sampling
40760485|NCT04505787|DRUG|Froben 100 mg comprimidos revestidos|tablet administration with PK blood sampling
40760486|NCT03209765|OTHER|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
40760487|NCT05823441|DRUG|Oxytocin nasal spray|Volunteers inhale 24 units of oxytocin spray
40760488|NCT05823441|DRUG|Placebo|Volunteers inhale 24 units of placebo spray
40760489|NCT05823441|BEHAVIORAL|Stranger|Volunteers watch a video of a pain test and attach a photo of a stranger
41289372|NCT03992235|OTHER|Educational material|Exercise brochure with photos and explanations
41289373|NCT03518515|OTHER|White potato (french fries)|If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) each day for 30 days as a part of their usual dietary intake. French fries will be portioned and provided to participants.
40951676|NCT04584970|DEVICE|Apple iPad|The Apple iPad is a tablet device controlled by touch screen with a variety of games and applications.
41289374|NCT03518515|OTHER|White potato (French fries), +seasoning|If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) with added potential glycemia modifying seasoning mix each day for 30 days as a part of their usual dietary intake. French fries and seasoning will be portioned and provided to participants.
40951677|NCT06427824|OTHER|Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery)|An educational program designed by geriatricians, surgeons, anesthesiologists and palliative care physicians to help people with bladder cancer who plan to receive a cystectomy learn strategies to improve their mobility, medication management, mental clarity/delirium and how they document important side effects or health issues after surgery.
41289375|NCT03518515|OTHER|Almond|If randomized to this group, participants will be asked to consume 1 serving of almonds that is calorically-matched to the French fries (\~300 kcal) serving in the other arms each day for 30 days as a part of their usual dietary intake. Almonds will be portioned and provided to participants.
41289376|NCT00427661|OTHER|Busulfan; Fludarabine; cyclosporine A and MMF|Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
40760490|NCT05823441|BEHAVIORAL|Acquaintance|Volunteers watch a video of a pain test and attach a photo of an acquaintance
40760491|NCT01767857|DRUG|Xilonix|Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
40760492|NCT01767857|DRUG|Placebo|Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
41289377|NCT02413983|PROCEDURE|hepatectomy conventional incision|This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision
41289378|NCT02413983|PROCEDURE|hepatectomy midline incision|
41289379|NCT02413983|PROCEDURE|hepatectomy transverse incision|
41289380|NCT01050660|OTHER|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
41289381|NCT01050660|OTHER|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
41289382|NCT05334589|DEVICE|Prewarming|When patients in the study group come to the Preoperative Care Unit (PCU), their body temperature will be measured. Patients in the study group will be placed in such a way that the 3M™ Bair Hugger™ Whole Body Blanket covers the patient's body and prewarmed with the 3M™ Bair Hugger™ Warming Unit for 30 minutes before anesthesia is given in the PCU. Heating unit temperature will be adjusted to 43°C in line with company recommendations. After the patients in the study group are warmed up for 30 minutes, the preheating process will be completed and the whole body blanket will be taken and the blankets that the clinic routinely use for each patient will be covered to cover the patients' body.
41289383|NCT00552305|DRUG|lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
41289384|NCT02293681|DRUG|Infliximab|This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
41289385|NCT02293681|DRUG|NSAIDs|This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
41289386|NCT02293681|DRUG|DMARDs|This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
41289387|NCT04442620|OTHER|Physical activity and Mediterranean Diet (PA-MD)|Physical Activity plus caloric restricted Mediterranean diet
41289388|NCT04442620|OTHER|High meal frequency of Mediterranean Diet (HMF-MD)|High meal frequency of unaltered Mediterranean diet
41289389|NCT04442620|OTHER|Control diet (CD)|Control Diet
41454269|NCT01821157|PROCEDURE|Flapless|FL (test group; n=28 sides/105 teeth): Internal beveled and sulcular incisions and gingival tissue removal were performed as above described for the control group, replacing the GM in the CEJ position. However, the alveolar bone was removed and remodeled, as necessary, using micro chisels, via incisions, without flap elevation. The root surfaces were also carefully planed via incisions. The required distance of 3mm between the bone crest and the CEJ was checked by inserting a periodontal probe into the incision. Sutures were not performed.
41454270|NCT06010823|DEVICE|PlaXtreme|"A robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the patients hand movement.~The device consists of a controller and specifically designed games projected on a screen requiring 3D active reaching movements. During the treatment sessions, the device will be operated by a trained occupational therapist."
40760493|NCT04359329|DRUG|Estradiol patch|Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
40760494|NCT00760305|BEHAVIORAL|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
41134378|NCT05950607|BEHAVIORAL|TRAIN AD 2.0|"The study intervention is a multi-component training program targeting direct care providers and healthcare proxies for NH residents with moderate to advanced dementia intended to improve the management of urinary tract infections (UTIs) and lower respiratory tract infections (LRIs). The components include: A. Provider Orientation: At NH start-up and q2 months providers will be offered orientations sessions involving two 15-minute presentations, one focused on the background and rationale for the program and one focused on describing the program components. B. A case-based on-line course, Infection Management in Moderate to Advanced Dementia, C. Posters and pocket cards for providers displaying algorithms guiding appropriate antimicrobial initiation for suspected UTIs and LRIs that integrate patient preferences, and D. Proxies of ALL residents in the facility will be sent a booklet related to infection management for persons with moderate to advanced dementia. ."
41134379|NCT03877783|DIETARY_SUPPLEMENT|mediterranean diet|The recommended Mediterranean diet is based on lean meat, fish, eggs, vegetables, fruits, berries, and nuts. Extra-virgin olive oil is the recommended additional fat source for use in food preparation and dressings. Recommended exclusions or restrictions include dairy products, cereals, added salt, refined fats, and sugar. Participants in the intervention group will receive weekly deliveries of olive oil and mixed nuts, free of cost, and they will receive recipes for Mediterranean meals on a regular basis. During the study, the intervention group will receive written, personalized advice from a project dietician on how to improve their Mediterranean diets. This written personalized advice will be based on the reported food intake, its coherence with a Mediterranean diet, and its adherence to the recommended intakes of energy and nutrients for each participant.
41134380|NCT03877783|BEHAVIORAL|individualized fitness program|The exercise intervention will consist of individualized training programs designed to improve cardiovascular fitness (VO2). A personal trainer will distribute the training program instructions and monitor the training during the entire intervention. Support will be provided via text messages. The training intensity will be based on results from an extensive pre-test of individual physical fitness performance, and we will adjust the intensity over the study period, as fitness improves. The goal is to engage participants in training three times per week, for up to one hour per training session. The individualized training programs will consist of brisk walks, jogging, and cycling, tailored to each participant. To ensure that the training intensity is sufficient to improve cardiovascular fitness, heart rate will be monitored during each session.
41289390|NCT04714762|DEVICE|eMOM GDM application|"Participants in the intervention group will use the eMOM GDM -application one week/month.~eMOM GDM application includes:~* continuous glucose monitor (CGM, Medtronic)~* diet (digital food tracker) (min 3 days during one application week)~* heartrate, stress and physical activity with the wrist-worn activity tracker (Vivosmart 3)~* weight measured once a week~The sensors can be worn and the application used during the whole pregnancy (if a mother is interested in)"
41289391|NCT03852225|DIAGNOSTIC_TEST|Intra-arrest echocardiography|Intra-arrest echocardiography performed by portable ultrasound device during ongoing chest compressions.
41289392|NCT03942328|BIOLOGICAL|Atezolizumab|Given IV
41289393|NCT03942328|BIOLOGICAL|Bevacizumab|Given IV
41289394|NCT03942328|RADIATION|External Beam Radiation Therapy|Undergo high-dose EBRT
41289395|NCT03942328|PROCEDURE|Pheresis|Undergo apheresis
40951678|NCT06427824|OTHER|Geriatric Service/ Discharge Planning|A geriatric team will meet with participants after surgery to help them reinforce the strategies they learned in the education video sessions. As part of a geriatric service, this team will also help participants plan/coordinate their discharge from the hospital after surgery.
40951679|NCT06427824|OTHER|Questionnaires|These questionnaires will ask about the participants' mobility, frailty, quality of life and additional health/risk factors before and after surgery.
40951680|NCT02298231|OTHER|Standard of Care Balance Intervention|Standard balance therapy as performed by a physical therapist
40951681|NCT02298231|OTHER|Mystic Isle Balance Intervention|Balance therapy using virtual reality
40951682|NCT02298231|OTHER|Mystic Isle Balance Intervention with Dual Task|Balance therapy using virtual reality and performing cognitive tasks
40951683|NCT02000180|BEHAVIORAL|Progressive Group|
40760495|NCT02601365|DRUG|Sargramostim 0.04 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
40760496|NCT02601365|DRUG|Sargramostim 0.2mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
40951684|NCT00082342|DEVICE|Phoressor II (IOMED)|sham stimulation
41134381|NCT03877783|OTHER|recommended modified pharmacological treatment|"Hyperglycemia: first metformin till target level of HbA1c 1) 53-58 mmol/mol for patients with ≤2 coexisting chronic illnesses or 2) 59-64 mmol/mol for those with established cardiovascular disease (CVD). We will recommend a second glucose-lowering drug when HbA1c is not achieved and which reduce CVD even when the participant does not have a manifest CVD.~Hypertension: will be treated to achieve a target level according to European guidelines. Start with a combination of a renin-angiotensin system (RAS)-blocker and a thiazide in low dose or a combination of a RAS-blocker a calcium channel blocker in low dose. If the target is not reached within 12 weeks additional drugs should be added.~Dyslipidemia: Patients with a CVD risk of 2-8% within 5 years should receive treatment with atorvastatin 10mg +ezetimib 10mg; CVD risk 8-20%, atorvastatin 20mg + ezetimib 10mg and CVD risk \> 20% atorvastatin 40-80mg +ezetimib 10mg."
41134382|NCT00290537|DRUG|ZD6474|ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
41289396|NCT03942328|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
41289397|NCT03942328|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Given IT
41289398|NCT02747628|DRUG|Placebo|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
41289399|NCT02747628|DRUG|transdermal therapeutic system- nicotine.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
41289400|NCT02747628|DRUG|transdermal therapeutic system- melatonin.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
41289401|NCT05657977|OTHER|nonpharmacologic intervention (swaddling)|Swaddling method;The newborn will be placed on a square fabric blanket in the flexion and abduction position and will be loosely swaddled with a blanket.
41289402|NCT01914718|DRUG|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
41289403|NCT04977544|DEVICE|vert|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
41289404|NCT04977544|DRUG|Sertraline|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
41454271|NCT04272437|DRUG|Concentrated herbal extract granules TRA|Concentrated herbal extract granules Subjects in the TRA group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
40760497|NCT02601365|DRUG|Sargramostim 1 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
40951685|NCT00082342|DEVICE|Phoressor II (IOMED)|real tDCS stimulation
40951686|NCT05748470|OTHER|SkinCeuticals A.G.E|Ultrasound therapy combined with SkinCeuticals A.G.E + conventional moisturizing and sunscreen.
40951687|NCT05748470|OTHER|standard cream|Ultrasound therapy combined with standard cream + conventional moisturizing and sunscreen
40951688|NCT02949700|DRUG|Metformin|Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
40951689|NCT05249699|DRUG|Isoniazid|prevent the development of tuberculosis
40951690|NCT05249699|OTHER|without any additional anti-tuberculosis treatment|reduce the number of Participants With Treatment-Related Adverse Events
41134383|NCT00290537|DRUG|Carboplatin|6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel
41134384|NCT00290537|DRUG|Paclitaxel|200 mg/m\^2 IV Over 3 Hours On Day 1
41134385|NCT04988542|DIETARY_SUPPLEMENT|Circadian Wellness sleep SL strip|Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.
40760498|NCT05051059|OTHER|Functional outcome|3D-motion analysis and strength assessment
40951691|NCT06015646|BEHAVIORAL|Personalized lifestyle coaching and educational handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study. Participants will also receive a 30-minute focused, personalized lifestyle coaching within a week of the initial overnight shift. The lifestyle coach will be in close contact during the night shifts.
40951692|NCT06015646|BEHAVIORAL|Handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study
40951693|NCT00366977|BEHAVIORAL|Multi-session telephone counseling|
40951694|NCT00366977|DRUG|NRT patches|
40951695|NCT04784039|DIAGNOSTIC_TEST|Transesophageal echocardiography|Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE
40951696|NCT04784039|DIAGNOSTIC_TEST|D-Dimer analysis|Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion
40951697|NCT02754557|OTHER|Breath-Focused Meditation|"Participants will attend two breath-focused meditation sessions per week for three weeks. During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body."
40760499|NCT05051059|OTHER|Health related quality of life (HRQoL) assessment|Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
40951698|NCT02754557|DEVICE|Physiological Feedback|Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
40951699|NCT04354103|DRUG|Atomoxetine|Atomoxetine
40951700|NCT04764773|OTHER|No intervention|No intervention
40951701|NCT06149026|OTHER|Physical and nutritional therapy|The patients will be evaluated and followed by a nutritionist and a physical therapist for 12 weeks. In that time, the patients will receive workouts according to their evaluations and a specific nutritional guide according to the nutritionist's evaluations.
40951702|NCT00003591|DRUG|paclitaxel|
40951703|NCT00003591|RADIATION|radiation therapy|
40951704|NCT04153604|DRUG|doxycycline|a tetracycline antibiotic that fights bacteria in the body.
40951705|NCT01024335|DRUG|injectable naltrexone and dronabinol|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.
40951706|NCT01024335|DRUG|Naltrexone and placebo|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.
40951707|NCT05602870|DIAGNOSTIC_TEST|non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)|A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
40951708|NCT05668429|DRUG|Ibrexafungerp|carbon-14 (\[14\^C\])-Ibrexafungerp
40951709|NCT03385512|BEHAVIORAL|OPEN High Touch|This arm will contain three components: (a) a pre-visit questionnaire delivered through the patient portal of the EHR, asking patients what they most want to discuss with their physician in the upcoming visit; (b) an animated video for patients providing coaching on how to best prepare for their upcoming visits and get the most from the visits; and (c) Standardized Patient Instructor (SPI) providing communication coaching for physicians on how to incorporate what matter most to patients in the visit, with empathy, and clarity.
40951710|NCT03385512|BEHAVIORAL|OPEN High Tech|The patient components of the intervention will be identical to the patient components of the High Touch arm (i.e., the pre-visit survey and patient coaching video). The difference will be in the PCP training: we will replace the in-person SPI with a mobile app program.
40951711|NCT03385512|BEHAVIORAL|ASK Poster in Exam Rooms|This arm is intended to activate patients by encouraging them to ask three questions during their primary care visit: (1) What are my options? (2) What are the possible benefits and risks of each option? (3) How likely are the benefits and risks of each option to occur to me? This will involve placing posters with these questions in all exam rooms used by providers in clinics randomized to the ASK arm of the trial.
40951712|NCT03383458|BIOLOGICAL|Nivolumab|Specified dose on specified days
40951713|NCT03383458|OTHER|Placebo|specified dose on specified days
40951714|NCT02935231|DRUG|Nicotine Replacement Therapy (NRT)|1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
41289405|NCT04374903|DRUG|HCQ & AZ vs HCQ+SIR|Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus
40760500|NCT03948620|DRUG|Macrolides|Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
40951715|NCT02935231|BEHAVIORAL|Minimal Cessation Advice (MCA)|Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.
40951716|NCT02935231|OTHER|Health warning leaflet|An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
40760501|NCT03948620|DRUG|Penicillins|The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
40760502|NCT01140932|DRUG|Prednisolone|12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
40951717|NCT00144131|DRUG|Aranesp®|
40951718|NCT04624854|DRUG|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
40951719|NCT04624854|DRUG|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
40951720|NCT04311775|DEVICE|larengeal mask insertion with video laryngoscopy|it is a method of inserting a laryngeal mask into the airway with videolaryngoscopy
40951721|NCT04311775|OTHER|laryngeal mask insertion|laryngeal mask is a method of inserting atube into the upper airway
41134386|NCT03001206|DEVICE|Master Caution System|"The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG)."
41134387|NCT00000127|PROCEDURE|Optic Nerve Sheath Decompression Surgery|
41289406|NCT05616390|DRUG|Sintilimab|200mg IV d1,Q3W
41289407|NCT05616390|DRUG|Bevacizumab|7.5mg/kg IV d1,Q3W
40760503|NCT01140932|BEHAVIORAL|Lifestyle change|High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
40951722|NCT02508831|PROCEDURE|Double upper limb allograft|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
40951723|NCT00575991|DIETARY_SUPPLEMENT|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
40951724|NCT05310448|DEVICE|Optune device|Wear Optune device
40951725|NCT02716805|DRUG|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 ± 5 minutes at a fixed dose of 75 mg, regardless of weight.
40760504|NCT04837222|OTHER|No Intervention|This is a non-interventional study.
40760505|NCT06370663|RADIATION|Radiotherapy|Radiotherapy + Hepatic Arterial Infusion Chemotherapy (Gesitabine) + Chemotherapy (GEMOX)
40760506|NCT06370663|DRUG|HAIC (GEMOX)|Hepatic Arterial Infusion Chemotherapy (GEMOX)
40760507|NCT06370663|DRUG|Chemotherapy|Chemotherapy (Gesitabine)
40760508|NCT04975165|PROCEDURE|Total knee arthroplasty|Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty
40951726|NCT02716805|DRUG|Durvalumab|"Durvalumab was administered as an IV infusion over 60 ± 5 minutes at a fixed dose of 1500 mg for subjects weighing \> 30 kg. If a subject's body weight dropped to ≤ 30 kg on study, the subject was dosed at 600 mg for as long as the body weight remained ≤ 30 kg.~When applicable, the durvalumab infusion was to start at least 60 minutes after the end of the tremelimumab infusion."
40951727|NCT02716805|BIOLOGICAL|Prevnar-13|Prevnar-13 was administered as an intramuscular injection. The Prevnar-13 dose and the tremelimumab dose were to be separated by a minimum of 48 hours.
40951728|NCT02716805|DRUG|Melphalan|Melphalan was administered as an IV infusion according to institutional standard of care and local prescribing information.
40951729|NCT00644189|DRUG|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
40951730|NCT00066352|DRUG|bortezomib|
41134388|NCT02708394|DRUG|olanzapine|atypical antipsychotic
41134389|NCT02708394|DRUG|placebo|placebo control
41289408|NCT05616390|COMBINATION_PRODUCT|Liver Protective Support Therapy|Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy
40951731|NCT03868761|BEHAVIORAL|Sonoma Rises|All participants will receive the intervention, Sonoma Rises, a mobile app designed by psychologists at the National Center for PTSD for wildfire survivors to facilitate recovery from disaster. Users can access evidence-informed tools to help cope with stress, heal from loss, prioritize self-care, connect with others, manage anger, and track their mood using validated assessments. There are also tools designed just for teens and users are linked to psychoeducation on disaster and health and other mental health resources and services.
40951732|NCT05653193|DRUG|Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care|Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
40951733|NCT05653193|DRUG|Antifungals as standard of care|Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
40951734|NCT00041288|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40951735|NCT00041288|DRUG|cyclophosphamide|
40951736|NCT00041288|DRUG|cyclosporine|
41289409|NCT01773395|BIOLOGICAL|GVAX|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the GVAX arm will receive GVAX vaccine.
40760509|NCT05402072|PROCEDURE|Autologous matrix-induced chondrogenesis (AMIC)|AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.
40760510|NCT04279093|OTHER|No intervention, but participants will use a smartphone app daily to complete the EPDS|No intervention, but participants will use a smartphone app daily (ClinTouch DAWN-P) to complete the Edinburgh Postnatal Depression Scale
40760511|NCT02167126|DEVICE|Kinesio Taping|"using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity."
40760512|NCT02167126|DEVICE|Placebo Tape|"Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella."
40760513|NCT03919019|OTHER|Macuprev Group|oral supplementation (Macuprev) 2 capsules per day for 6 months
40951737|NCT00041288|DRUG|fludarabine phosphate|
40951738|NCT00041288|DRUG|methotrexate|
40951739|NCT00041288|DRUG|mycophenolate mofetil|
40951740|NCT00041288|DRUG|tacrolimus|
40951741|NCT00041288|PROCEDURE|peripheral blood stem cell transplantation|
40951742|NCT00041288|RADIATION|radiation therapy|
40951743|NCT00160589|DRUG|Levocetirizine|
40951744|NCT04937946|DRUG|Fentanyl|Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .
40951745|NCT05209269|OTHER|Work of breathing observation|We will place soft elastic bands around the infant's chest and abdomen to assess their work of breathing.
40951746|NCT00749060|OTHER|conventional treatment|with our without brace
40951747|NCT00749060|PROCEDURE|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
40951748|NCT00749060|PROCEDURE|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
40951749|NCT04596800|OTHER|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
40951750|NCT04596800|OTHER|Enhanced Recovery After Surgery|ERAS
40951751|NCT00526942|BEHAVIORAL|SAAGE-designed, visual memory-based cognitive training|Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
40951752|NCT04225962|OTHER|Intimate quality of life questionnaire|Preparation of an intimate quality of life questionnaire
40951753|NCT01986946|OTHER|Epidural Catheter - Dilaudid|Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
40951754|NCT01986946|DRUG|Dilaudid|Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
40951755|NCT03907228|DIETARY_SUPPLEMENT|RHT-3201|PROBIOTIC
40951756|NCT03653338|BIOLOGICAL|CD3/CD19 depleted leukocytes|Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.
40951757|NCT03653338|BIOLOGICAL|CD45RA depleted leukocytes|Negative selection for CD45RA will be performed on the CliniMACS® depletion device.
40951758|NCT03653338|DRUG|Hydroxyurea|Sickle Cell Disease Conditioning
40951759|NCT03653338|DRUG|Rituximab|Sickle Cell Disease Conditioning
40951760|NCT03653338|DRUG|Alemtuzumab|Sickle Cell Disease Conditioning
40951761|NCT03653338|DRUG|Fludarabine|Sickle Cell Disease Conditioning
40951762|NCT03653338|DRUG|Thiotepa|Sickle Cell Disease Conditioning
40951763|NCT01479127|DRUG|ABT-SLV187|
40760514|NCT03919019|OTHER|Placebo Group|oral placebo 2 capsules per day for 6 months
41454272|NCT04272437|DRUG|Placebo|Subjects in the placebo group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
40760515|NCT03026777|DRUG|intravenous crystalloid fluid, 500 mL|
40951764|NCT01479127|DRUG|Oral Levodopa/Carbidopa|Tablet; contains 100 mg levodopa and 10 mg carbidopa
40951765|NCT01479127|DEVICE|Infusion Pump: CADD-Legacy® 1400 Pump|General infusion pump, manufactured by Smiths Medical (US)
40951766|NCT01479127|DEVICE|NJ-Tube: Silicon ED Tube|Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
40951767|NCT01479127|DEVICE|Adaptor: Hakko Adaptor|Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
40951768|NCT01932359|OTHER|rapidly absorbable suture (Vicryl Rapide)|
40951769|NCT01932359|OTHER|non-absorbable suture (Ethilon)|
40760516|NCT04343768|DRUG|Hydroxychloroquine|This Drug will be used in all arms.
40760517|NCT04343768|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms.
40760518|NCT04343768|DRUG|Interferon Beta-1A|This drug will be only used in Arm 1.
40760519|NCT04343768|DRUG|Interferon Beta-1B|This drug will be only used in Arm 2.
40760520|NCT02312128|OTHER|Questionnaire|DASH Score, PRWE Score, Mayo Wrist Score
40951770|NCT05742711|DEVICE|Primary Relief|Continuous neurostimulation with a set of pre-assigned stimulation parameters.
40951771|NCT05742711|DEVICE|Primary Relief - Sham Device|Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.
40951772|NCT01254071|DRUG|Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)|In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
41134390|NCT02697552|DRUG|HBI-8000|Oral doses of 30mg, 40mg, 50mg twice weekly \[BIW\].
41134391|NCT02747537|DRUG|Sorafenib|
40951773|NCT02027207|BIOLOGICAL|Shanchol|"We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.~Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume."
40951774|NCT02027207|BIOLOGICAL|Placebo|Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
40951775|NCT04064957|BIOLOGICAL|HB-adMSCs|
40951776|NCT05746494|DEVICE|tDCS|active anodal tDCS and sham tDCS
40951777|NCT03632200|OTHER|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions"
40951778|NCT03998566|DEVICE|TraceIT Tissue Spacer implantation|The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.
40951779|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 500mg tablet, orally once on Day 1
40951780|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 750mg tablet, orally once on Day 1
40951781|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
40951782|NCT06473948|DRUG|Placebo|Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1
40951783|NCT04729621|COMBINATION_PRODUCT|TVB-009|TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
41289410|NCT01773395|BIOLOGICAL|Placebo Vaccine|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the placebo arm will receive placebo vaccine.
41289411|NCT01773395|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant|Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor. This is given as a transfusion through a central intravenous line (IV usually placed in the chest or arm).
41454273|NCT01685255|DRUG|Epacadostat|
40951784|NCT04729621|COMBINATION_PRODUCT|Prolia®|Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
40951785|NCT00938236|DRUG|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
40951786|NCT01248208|BIOLOGICAL|FluMist intranasal influenza vaccine|FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.
40951787|NCT01248208|BIOLOGICAL|"Intramuscular influenza injection (flu shot)"|"Subjects \< 2 years or \> 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.~Age 6-36 months: 0.25 mL IM x 1; Age \>36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose."
41134392|NCT02747537|DRUG|Irinotecan|
41134393|NCT04415307|OTHER|Acupuncture|Acupuncture over acupoints.
41134394|NCT04415307|OTHER|Far-Infrared heat-patch attachment|Far-Infrared heat-patch attachment over acupoints.
41134395|NCT04415307|OTHER|Acupuncture and Fir-Infrared heat-patch attachment|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
41289412|NCT01773395|DRUG|Busulfan|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
41454274|NCT01685255|DRUG|tamoxifen|
41454275|NCT06224088|OTHER|VV ECMO|treatment with VV ECMO in the ICU
41454276|NCT04755335|DIAGNOSTIC_TEST|Ultrasound|In this project, The investigators will use Alpinion ECUBE-12R (Alpinion, Bothell, WA) US platform. This state-of-the-art research US machine provides beam formed as well as Plane-Wave imaging options that allow high frame rate imaging. The investigators have characterized the acoustic output of this system for safe human studies and obtained the IRB approval for human studies. It should be noted that our technique is not limited to the Alpinion system; the investigators can also use other US systems, such as Verasonics, Vantage, (Redmond, WA). This technique can be adapted to other modern US machines in the future.
41454277|NCT04065646|OTHER|Mobile|
41289413|NCT01773395|DRUG|Fludarabine|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
41289414|NCT01773395|DRUG|Tacrolimus|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
41289415|NCT01773395|DRUG|Methotrexate|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
41289416|NCT01579201|DRUG|Carbetocin|First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
40951788|NCT04797078|PROCEDURE|Transperineal biopsy|Transperineal free hand MRI-US fusion prostate biopsy
40951789|NCT04797078|PROCEDURE|Transrectal biopsy|Transrectal MRI-US fusion prostate biopsy
40951790|NCT01845142|DRUG|single administration of 100.000 I.U. vitamin D|
40951791|NCT01845142|DRUG|Placebo|
40951792|NCT00978978|DRUG|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|"1. Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~2. Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists"
40951793|NCT05842733|DRUG|Naldebain|Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
40951794|NCT05842733|DRUG|SafeTynadol|Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
41454278|NCT05348928|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device
40951795|NCT05842733|DRUG|Naldebain + SafeTynadol|Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
40951796|NCT02884882|OTHER|Emotional induction|Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
40951797|NCT06362070|DEVICE|DaVinci® Surgical System|Assisted-robotic radical Gastrectomy
40951798|NCT06362070|DEVICE|Hugo™ RAS System|Assisted-robotic radical Gastrectomy
40951799|NCT06362070|DEVICE|Versius® Robotic Surgery System|Assisted-robotic radical Gastrectomy
41134396|NCT04415307|OTHER|Far-Infrared heat-patch attachment over acupoints without electric current passing.|Far-Infrared heat-patch attachment over acupoints without electric current passing.
41134397|NCT00729209|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
41134398|NCT00729209|DRUG|Placebo; oral|matching placebo
41289417|NCT00816218|DRUG|Pioglitazone|pioglitazone, 45 mg daily
41454279|NCT05348928|OTHER|Laboratory plasma glucose concentration determination|Laboratory plasma glucose concentration determination
41454280|NCT06042231|BEHAVIORAL|Exercise Intervention|Exercise and education intervention. Participants will be prescribed a tailored exercise program to complete before ('pre-habilitation') and after their AF ablation procedure (rehabilitation).
41454281|NCT06042231|BEHAVIORAL|Education Intervention|Education intervention. Participants will be given a 1-1 education session (up to 3 sessions) before and after their AF ablation procedure. Participants will be given behavioural strategies to improve adherence and compliancec to risk-factor modification.
41454282|NCT02739724|PROCEDURE|Adnexal surgery|
40760521|NCT02312128|RADIATION|X- Ray|X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
40951800|NCT03748108|DRUG|lidocaine|a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
40951801|NCT03748108|DRUG|Placebo|a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
40951802|NCT05023629|OTHER|Intracoronary balloon inflation|Patients with a significant coronary artery lesion in a proximal coronary segment will undergo intracoronary balloon inflation for 90s prior to PCI.
41134399|NCT03975400|BEHAVIORAL|search engine advertisement campaign|This proposal aims to explore whether targeted and proactive online outreach through search engine advertisements, coupled with engaging, informative, and interactive online resources, can effectively reduce the duration of untreated psychosis and facilitate earlier treatment initiation in New York State.
40760522|NCT02312128|OTHER|Grip Strength|Grip strength measurement
41134400|NCT01562184|DEVICE|Sham tDCS device|Sham tDCS
41134401|NCT01562184|DEVICE|Soterix tDCS device|Active tDCS
40951803|NCT03166007|BEHAVIORAL|Abdominal massage|The participant should be supine and in a relaxed atmosphere, though this may depend on level of disability. The massage comprises 4 basic strokes (10minutes); Stroking from the small of the back over the iliac crest and down both sides of the pelvis towards the groin; Effleurage follows the direction of the ascending colon across the transverse colon and down the descending colon. This is repeated several times with increasing pressure; Palmar kneading tracks down the descending colon up the ascending colon and down the descending colon once again. Effleurage is repeated and continued with a relaxing transverse stroke over the abdomen; Vibration over the abdominal wall to relieve flatus concludes the massage session. The participants in this group will receive one telephone call per week for 6 weeks and again at 24 weeks to further discuss their bowel management.
40951804|NCT03166007|BEHAVIORAL|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
40951805|NCT05297201|DRUG|CPL500036 - low dose|CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
40951806|NCT05297201|DRUG|CPL500036 - high dose|CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.
40951807|NCT05297201|DRUG|Placebo|Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
40951808|NCT01597531|DRUG|Liraglutide|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
40951809|NCT01597531|DRUG|Orlistat|Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
40951810|NCT01597531|DRUG|Liraglutide + Orlistat|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
40951811|NCT05280639|DEVICE|Wooden block|Individuals randomized to this group will be given a wooden block at no cost to them and a simplified version of home, self-guided exercises with instructions on how to do the exercises and how often to do so.
40951812|NCT05280639|OTHER|Formal physical therapy or Home Exercise Program|Individuals randomized to this group will receive the standard formal physical therapy which are sessions run by a physical therapist, usually 2-3 times a week to rehabilitate their ankle OR follow a standardized home exercise program which will be done by yourself with exercise outlined with how they should be performed and how often
40951813|NCT02320617|PROCEDURE|Diffusion Magnetic Resonance Imaging|Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
40951814|NCT03862560|OTHER|Strength training program|Strength training program in female soccer players
40951815|NCT02364622|DEVICE|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
40951816|NCT02364622|DEVICE|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
40760523|NCT02312128|OTHER|VAS Score|Measurement pain according to the visual analogue scale (VAS)
40951817|NCT02364622|DEVICE|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
40951818|NCT00734474|DRUG|LY2189265|
40951819|NCT00734474|DRUG|Sitagliptin|
41134402|NCT01296230|PROCEDURE|Hormone and semen measurements before varicocelectomy|Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
41454283|NCT05326880|DEVICE|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
40760524|NCT02312128|OTHER|Range of Motion measurement|Angle measurement of the active range of motion in the wrist
40760525|NCT02044146|DRUG|Ticagrelor, Prasugrel, Clopidogrel|
40760526|NCT04290676|DRUG|DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
40760527|NCT01122680|DRUG|Tiotropium bromide|inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
40760528|NCT01122680|DRUG|tiotropium bromide|inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
40951820|NCT00734474|DRUG|Placebo solution|
40951821|NCT00734474|DRUG|Placebo tablet|
40951822|NCT00734474|DRUG|Metformin|
40951823|NCT01127035|BIOLOGICAL|sublingual immunotherapy|
40951824|NCT01127035|BIOLOGICAL|placebo|
41134403|NCT01750424|PROCEDURE|Autologous Fat Grafting|
41289418|NCT00003139|DRUG|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
41289419|NCT00003139|OTHER|Placebo|
41289420|NCT04248257|BEHAVIORAL|PeACE|3 session peer coaching intervention
40760529|NCT01122680|DRUG|tiotropium bromide|inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
41289421|NCT04248257|BEHAVIORAL|Community peer coaching|Peer coaching provided by community organizations that support the HBOC community
40760530|NCT01122680|DRUG|Placebo|placebo inhalation solution
40760531|NCT01930708|DRUG|dimethyl fumarate|Administered as per the approved dosage in all countries where DMF has received marketing authorization.
40760532|NCT05134883|OTHER|PNF|A PNF stretching protocol will be performed with each participant assuming a long sitting position on a plinth with the knee maintained as extended as possible. At this moment, the participant will be asked to perform a maximum isometric hamstring muscle contraction for 5 seconds followed by 5 seconds of relaxation and 20 seconds of stretching. The therapist will show the participant how to maintain this isometric contraction with the flexion of the hip and ankle. Each participant will undergo 4 repetitions of PNF stretching (30 seconds/rep).
41134404|NCT01750424|OTHER|No intervention|Subjects in this arm will only be followed up and have no procedure performed.
41289422|NCT00816946|BEHAVIORAL|Enhanced education|"Enhanced Nutritional education/counseling to mothers on the following topics:~During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI \& protection against ARI"
41289423|NCT04820478|DIETARY_SUPPLEMENT|Beta Hydroxybutyrate Ester (KetoneAid KE4)|see arm/group description
41289424|NCT04820478|DIETARY_SUPPLEMENT|Placebo|see arm/group description
41289425|NCT02359123|OTHER|Cannabics capsules|Cannabis extract in an oil formulation
41289426|NCT02089737|DRUG|Panitumumab|Panitumumab for intravenous infusion
41289427|NCT04805931|BEHAVIORAL|Behavioral economics|Tailored behavioral economic text messaging vs. standard text messaging
41289428|NCT02720068|BIOLOGICAL|Favezelimab|IV infusion
40951825|NCT03841448|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
40951826|NCT03841448|DRUG|Cemdisiran|Cemdisiran was administered by SC injection.
40951827|NCT02655978|OTHER|Magnetic Resonance Imaging|
40951828|NCT04394611|OTHER|Obstetric ultrasound- doppler examination|Obstetric ultrasound- doppler examination and fetal- maternal assessment Tin (Sn), manganese (Mn), Vanadium (V), Magnesium (Mg), cobalt (Co), nickel (Ni), arsenic (As), chromium (Cr), cadmium (Cd), lead (Pb), mercury (Hg), antimony (Sb), aluminum (Al), zinc (Zn), copper (Cu), selenyum (Se), iron (Fe), vitamin D, vitamin A, vitamin B12 and folate concentrations measurements
40951829|NCT04192370|DRUG|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol for 3 days in an open-label fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL, and the drug will be procured by the Brigham and Women's Hospital (BWH) Investigational Drug Services (IDS) pharmacy. The first dose will be administered at the BWH Center for Clinical Investigation, while doses 2 and 3 will be self-administrated at home. The CBD will be repacked in pre-drawn syringes for the subjects to self-administer at home.
40951830|NCT00053443|DEVICE|Medication Reminder System/Adherence Tracker|
40951831|NCT02798146|OTHER|blood collection|Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
40951832|NCT06126926|BEHAVIORAL|group therapy|32 weeks of group therapy
40951833|NCT06126926|OTHER|Treatment as usual|Control participants remain in their current placement and may be eligible for a number of services offered to inmates to facilitate rehabilitation and planning for release to the community, including sexual offender treatment. MnDOC's sexual offender treatment is a two to three year program, thus most of our control subjects will not have enough time remaining on their sentences to complete such treatment. However, a number of them may participate in MnDOC's current program.
40951834|NCT06295757|OTHER|Cigarettes|Participants will smoke their own usual brand cigarettes. Cigarette butts will be collected.
40951835|NCT05472753|DIETARY_SUPPLEMENT|Experimental Treatment, DCOOP Product, Hydroxytyrosol extract|Intervention group will receive a nutritional formula from DCOOP (Spain).
40951836|NCT05472753|DIETARY_SUPPLEMENT|Experimental Treatment,Indukern product, Curcumin and selenium extract|Intervention group will receive a nutritional formula from Indukern (Spain).
41134405|NCT03611088|OTHER|Kangaroo Position.|The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
41134406|NCT00532350|DRUG|QAT370|
40760533|NCT05134883|OTHER|SMR|For the application of self-myofascial release, the subjects will assume a long sitting position on a firm and even surface by placing the arms backward and transferring their body weight to their palms. The roller foam, applied bilaterally, will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa by applying pressure for 2 minutes.
40760534|NCT06465641|DRUG|Methylphenidate Hydrochloride|Methylphenidate hydrochloride in capsules
40760535|NCT06465641|DRUG|Placebo|Microcrystalline cellulose in capsules
40760536|NCT06506513|OTHER|High-intensity interval training|High-intensity interval training
40951837|NCT05472753|OTHER|Control Treatment|Control group will receive a placebo (product loading substance)
40951838|NCT01744873|DRUG|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
40951839|NCT01744873|DRUG|Bisoprolol|10 mg tablet once a day
40951840|NCT02264639|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
40951841|NCT04216966|DEVICE|Control group|No intervention was given
40951842|NCT04216966|DEVICE|Gracey Curette|Lingual surface of tooth was debrided by Gracey Rigid curette
40951843|NCT04216966|DEVICE|After Five|Lingual surface of tooth was debrided by After Five Rigid curette
40951844|NCT04216966|DEVICE|Mini Five|Lingual surface of tooth was debrided by Mini Five Rigid curette
40951845|NCT06069323|DEVICE|repetitive Transcranial Magnetic Stimulation|Pediatric patients with ASD and ADHD will be randomized both in active and sham groups.
40951846|NCT01001013|DRUG|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
40951847|NCT01984983|BIOLOGICAL|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate|
40951848|NCT01984983|OTHER|0.9% saline placebo|
40951849|NCT02299882|DRUG|Vancomycin|Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
40951850|NCT05047770|BIOLOGICAL|HZ/su|2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.
40951851|NCT05047770|COMBINATION_PRODUCT|Flu D-QIV|1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.
40951852|NCT05047770|BIOLOGICAL|mRNA-1273|1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
40951853|NCT01128556|DRUG|Bepreve|Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
40951854|NCT01128556|DRUG|Refresh Tears|Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
40951855|NCT03948243|DIETARY_SUPPLEMENT|Licorice|Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days
40951856|NCT03948243|DRUG|Alprazolam 2 MG|probe substrate
40951857|NCT03948243|DRUG|Caffeine 100 MG|probe substrate
40951858|NCT03948243|DRUG|Tolbutamide 250 mg|probe substrate
40951859|NCT03948243|DRUG|Dextromethorphan 30mg|probe substrate
40951860|NCT01922557|DEVICE|NICOM|NICOM monitoring thoracic fluid content at baseline(T1), anhepatic phase(T2), 30 mins after reperfusion(T3) and 2 hrs after reperfusion(T4).
41134407|NCT00532350|DRUG|Placebo|
41134408|NCT00532350|DRUG|Tiotropium|
41134409|NCT04164446|DRUG|Placebos|The placebo that will be used contains starch and glucose.
41134410|NCT04164446|DIETARY_SUPPLEMENT|Oil Palm Phenolics|One capsule contains 250 mg OPP or 1 g OPP
41289429|NCT02720068|BIOLOGICAL|Pembrolizumab|IV infusion
40951861|NCT05031273|BEHAVIORAL|Residents moving into a congregate-living development with more features that support healthy living|Our team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the physical activity, healthy eating, and social connections of residents moving into the new building(s). We hope for the developer to integrate into the new building(s) as many as possible of our team's built environment design and amenity recommendations into their site and/or building plans. Additionally, discussions with the municipality are also occuring on built environment design and amenity recommendations to improve the neighbourhood surrounding the site. Although our team has provided these recommendations, it is ulimatily up to the discretion of the developer and the municipality as to whether and what design and amenity changes are made.
40951862|NCT04151433|PROCEDURE|Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).|cf. different arms
40951863|NCT00524381|DRUG|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
40951864|NCT00524381|DRUG|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
40951865|NCT02758704|OTHER|High stress|Generation of a stressful environment during a neonatal intubation procedure.
40951866|NCT02758704|OTHER|Low stress|Absence of stressful stimuli during neonatal intubation procedure
40951867|NCT02758704|OTHER|Endotracheal intubation on mannequin|Endotracheal intubation will take place at the simulation centre on a mannequin.
40951868|NCT02345226|DRUG|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
40951869|NCT02345226|DRUG|EFV/FTC/TDF Placebo|Tablets administered orally once daily
40951870|NCT02345226|DRUG|EFV/FTC/TDF|600/200/300 mg FDC tablets administered orally once daily
40951871|NCT02345226|DRUG|FTC/RPV/TAF Placebo|Tablets administered orally once daily
40951872|NCT03386318|DRUG|Oxycodone|Serum concentration per hour from 1 to 5 h
40951873|NCT01552993|DRUG|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and glucose
40951874|NCT01552993|DRUG|sucrose|pacifier and sucrose
41134411|NCT03985566|DIETARY_SUPPLEMENT|Fibre Grain|Healthy subjects will be provided with 30% Fibre Grain in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
41134412|NCT03985566|DIETARY_SUPPLEMENT|Jasmine white rice|Healthy subjects will be provided with Jasmine white rice in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
41134413|NCT00776139|DRUG|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
41289430|NCT02720068|DRUG|Oxaliplatin|IV infusion
41134414|NCT04661306|BEHAVIORAL|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
41289431|NCT02720068|DRUG|Irinotecan|IV infusion
41454284|NCT05326880|DEVICE|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
41454285|NCT04408924|DRUG|Abemaciclib|Administered orally
41454286|NCT00755235|OTHER|Depression care management by secure messaging|Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
41454287|NCT04710823|PROCEDURE|Thoracic paravertebral block|A bolus dose of 0.25% bupivacaine (0.3 ml/kg) will be injected slowly over 3-5 minutes. At 30 minutes after injection of the loading dose, the dermatomal loss of sensation to pinprick was tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion will be continued for 4 days.
40951875|NCT05244993|DRUG|AK105|AK105: 100mg per bottle, 200mg IV Day 1, cycled every 21 days
40951876|NCT05244993|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride: 12mg per capsule, 12 mg PO once daily on Days 1-14, cycled every 21 days
40951877|NCT05244993|DRUG|Albumin Paclitaxel|Albumin paclitaxel: 100mg per bottle, 125mg/m2 IV Days 1, 8, cycled every 21 days
40951878|NCT06201442|OTHER|Imaging - magnetic resonance imaging (MRI)|MRI knee - not standard of care
40951879|NCT06201442|OTHER|Blood sampling|blood sample taken and analysis - not standard of care
40951880|NCT06201442|OTHER|Assessment of functionality and strength|Movements and posture Analysis Laboratory Leuven measurement (3D motion analysis) and Biodex measurement - not standard of care
40951881|NCT06201442|OTHER|Activity monitoring|Actigraph measurement- not standard of care
40951882|NCT06201442|OTHER|Imaging - x-ray scan (RX)|RX Knee and EOS radiography full leg - not standard of care
40951883|NCT06201442|BEHAVIORAL|Questionnaires|Patient reported outcomes (PROMS)
40951884|NCT03676998|DEVICE|Measurement of diaphragm function|A bilateral magnetic stimulation induces a non voluntary diaphragm contraction and a drop in airway pressure that is measured.
41134415|NCT03710252|DRUG|paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin|OMB/PTV/r + DSV +/- RBV
41134416|NCT03890653|BEHAVIORAL|Performance-Based Financing|Incentive-based payments
41134417|NCT03890653|BEHAVIORAL|Decentralized Facility Financing|Financing not linked to service delivery.
41134418|NCT02123953|DRUG|TAK-438|TAK-438 tablets
41134419|NCT02123953|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
41289432|NCT02720068|DRUG|Leucovorin (Calcium Folinate)|IV infusion
41289433|NCT02720068|DRUG|Fluorouracil [5-FU]|IV infusion
41289434|NCT02720068|BIOLOGICAL|Favezelimab/Pembrolizumab|IV infusion
41289435|NCT02720068|DRUG|Lenvatinib|Oral
41289436|NCT03626415|DRUG|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
40951885|NCT04228874|DEVICE|coronary artery stents|"Coronary angiography was done for all the patients according to the Judkins technique. All images were evaluated by an experienced operator, significant coronary artery disease was defined as \> 70 % luminar diameter stenos. The following data was obtained:~* Site of stent implantation within LAD. The first Diagonal branch serves as the boundary between the proximal and mid portion of the LAD. Thus, the portion of the artery prior to the origin of the 1st diagonal is known as the proximal LAD, while the segment just below the1st diagonal branch is the mid LAD. The distal segment of the LAD is the terminal third of the artery (Cao et al., 2017).~* Length, diameter and number of stents.~* TIMI flow after stent deployment."
40951886|NCT01518348|BIOLOGICAL|Patch Test|Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
40951887|NCT01089673|OTHER|data collection|retrospective data collection
41134420|NCT04301752|DIAGNOSTIC_TEST|MoCA|Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.
41134421|NCT01218594|DRUG|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
41134422|NCT01722409|DRUG|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
41134423|NCT01722409|DRUG|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
40951888|NCT02850107|DEVICE|Medtronic HawkOne® or TurboHawk™|Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.
41134424|NCT00914771|BIOLOGICAL|H5N1 pandemic Influenza vaccine 3.75µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
41134425|NCT00914771|BIOLOGICAL|H5N1 pandemic Influenza vaccine 7.5µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
40760537|NCT06506513|OTHER|Moderate intensity exercise training|Moderate intensity exercise training
40760538|NCT06506513|OTHER|Low intensity exercise training|Low intensity exercise training
40951889|NCT02850107|DEVICE|Medtronic IN.PACT® Admiral® DCB|FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.
41454288|NCT04710823|PROCEDURE|Serratus anterior plane block|A bolus of 30 ml of 0.25% bupivacaine will be injected slowly over 3-5 minutes between latissmus dorsi muscle and serratus anterior muscle (Figure 15). Then a catheter was inserted through the Tuohy needle and advanced 3cm into the space and secured in place. At 30 minutes after injection of a loading dose, the dermatomal loss of sensation to pinprick will be tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion was continued for 4 days.
40951890|NCT02850107|DEVICE|Medtronic Spider™ Distal Protection Device (DPD)|It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
40951891|NCT02850107|DEVICE|"Volcano Visions® PV .014 IVUS catheter"|"Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases."
40951892|NCT02850107|DEVICE|Nitinol Stent Placement|Only FDA approved nitinol stents can be used if provisional stenting is required.
40951893|NCT03286738|DRUG|FOLFIRI, target agent|"* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab~* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab"
40951894|NCT02418429|OTHER|waxy maize starch|pancake test meal with waxy maize starch only
40951895|NCT02418429|OTHER|waxy maize starch and Whey Protein|pancake test meal with waxy maize starch and whey protein
40951896|NCT02418429|OTHER|Resistant Starch|pancake test meal with resistant starch only
40951897|NCT02418429|OTHER|resistant starch and whey protein|pancake test meal with resistant starch and whey protein
40951898|NCT02777619|DRUG|0.0ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0ng/ml
41454289|NCT04474145|PROCEDURE|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
40951899|NCT02777619|DRUG|0.4ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4ng/ml
40951900|NCT02777619|DRUG|0.6ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6ng/ml
40951901|NCT02777619|DRUG|0.8ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8ng/ml
40951902|NCT02777619|DRUG|Propofol|
40951903|NCT06030050|BEHAVIORAL|Animal-assisted intervention|The AAI is designed to promote patient comfort, uplift mood, and provide an opportunity for socialization. The nature of the dog interaction involves several different components, including but not limited to: petting the dog, talking to the dog, watching the dog do tricks, conversing with the dog handler, and being prompted to discuss any fond memories/stories of their own personal experiences with human-animal interactions. Therapy dogs are trained and certified animals who are leashed at all times and under direct care of their dog handler, NOT companion animals, personal pets, nor emotional support animals.
41134426|NCT06509555|OTHER|non-intervention|non-intervention
41134427|NCT00003984|BIOLOGICAL|lintuzumab|
41134428|NCT04775537|DEVICE|OssiMend™ Bioactive Moldable|Lumbar Spine fusion with OssiMend™ Bioactive Moldable
41134429|NCT03451461|OTHER|No intervention|Observational study. Clinical data recorded
41134430|NCT02748200|RADIATION|external beam radiotherapy (EBRT)|EBRT: 3 dose escalation levels
40951904|NCT06463405|OTHER|Splinted|The investigators will compare splinted versus non-splinted crowns in a randomized design. Whether the crowns will be splinted or not are decided by distant randomization separate from clinicians conducting the trial. Twenty sealed envelopes will be opened where its stands whether the crowns has to be splinted crowns or non-splinted crowns. The implants in the splinted side will have an intermediate titanium abutment and impression will be taken at abutment level, whereas impressions in the non-splinted side will be taken directly at the fixture level. The splinted as well as the non-splinted crowns will be screw-retained and produced in monolithic zirconia. An open-tray technique / (scanning) will be used for both reconstructions.
40760539|NCT03277872|DEVICE|Laryngoscopy with GlideScope (GVL) Blade|"1. st Laryngoscopy with GVL Blade~2. nd Laryngoscopy with MAC Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
40760540|NCT03277872|DEVICE|Laryngoscopy with MacIntosh (MAC) Blade|"1. st Laryngoscopy with MAC Blade~2. nd Laryngoscopy with GVL Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
40760541|NCT04901715|DRUG|Albuterol|Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.
40760542|NCT04901715|DIAGNOSTIC_TEST|Technetium99m - Sulfur Colloid (Tc99m-SC)|Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 uCi deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive ¾ of the adult dose to account for the smaller lung volume.
40760543|NCT03186378|COMBINATION_PRODUCT|VP-102 with applicator|Subjects will receive treatment to their molluscum contagiosum with VP-102.
40760544|NCT03059888|DRUG|Abatacept Injection|Subcutaneous administration of abatacept
40760545|NCT00349986|DRUG|Insuline glargine|
40760546|NCT00460915|DRUG|Lacidipine & Amlodipine|
40760547|NCT03399747|DRUG|Abb-R-CHOP|"Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy"
40760548|NCT00195611|DRUG|Prevenar|
40951905|NCT06183177|OTHER|Whole-Body Vibration|10 minutes of whole-body vibration when performing semi-squatting or forward lunges (12-16 Hz, varying intensity from low to high depending on patients' tolerance
40760549|NCT04097665|DEVICE|indocyanine green angiography|All patients treated with expanded flaps will be assessed by surgeons, and the possible area of necrosis will be marked based on clinical experience. This area will be further divided into perfusion units (1\*1 square centimeter for each), and the center of each perfusion unit will be marked. Then all patients will receive ICGA after the complete transfer of flap to the recipient site. For ICGA, a 2ml bolus of indocyanine green (2.5mg/ml) was injected through the patient's intravenous line. The detector/camera of the SPY imaging system should place over the flap at approximately 30cm for fluorescence image acquisition. The fluorescence value will be recorded afterwards.
40760550|NCT06220318|DRUG|C019199|The C019199 will be taken orally, once a day
40951906|NCT06183177|OTHER|Exercise|Four to five sessions of a physiotherapist-led exercise program with education talk (20 minutes), group exercises (30 minutes) and individual exercises (30 minutes) per week supplemented with home exercises
40951907|NCT04340531|OTHER|Best Practice|Receive usual care
40951908|NCT04340531|OTHER|Survey Administration|Ancillary studies
40951909|NCT04340531|OTHER|Tobacco Cessation Counseling|Receive referred to counseling session
40951910|NCT04340531|OTHER|Tobacco Cessation Counseling|Receive phone counseling
40951911|NCT04340531|OTHER|Training|Undergo training
40760551|NCT06220318|DRUG|Sintilimab|Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.
40760552|NCT04634136|DIAGNOSTIC_TEST|Lab tests|CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea \& creatinine, liver enzymes (AST, ALT, gGT)
40951912|NCT02231632|BIOLOGICAL|Live attenuated Poliomyelitis vaccine (Human Diploid Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
40951913|NCT02231632|BIOLOGICAL|Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
40760553|NCT04634136|DIAGNOSTIC_TEST|ECG|Electrocardiogram
40760554|NCT04634136|DIAGNOSTIC_TEST|Cannabinoid Levels|Determination of levels of cannabidiol (CBD) and delta-9-tetrahydrocannbinol (THC) for determination of levels at following time(s) after ingestion: 0, 1, 2, 4, 8 and 24 hours.
40760555|NCT04634136|DRUG|Full-spectrum Medical Canabis Product (HemPhar)|Active substance
40760556|NCT04634136|DRUG|Placebo|Placebo
40951914|NCT03524742|OTHER|Avocado-Mediterranean Diet|Mediterranean diet including 1/2 portion of Hass avocado per day, considering a minimum 35% of calories as fat (22% MUFA fat, 6% PUFA fat, and ±10% saturated fat), 15% proteins, and a maximum of 50% carbohydrates.
40951915|NCT03524742|OTHER|Control-Group Diet|A low fat-high complex carbohydrate diet, during 3 months.
40951916|NCT06128226|GENETIC|Blood Sampling|For Tripeptidyl Peptidase 1 enzyme level measurement, blood will be taken from the patient into a 5 mL EDTA tube at Gazi University Faculty of Medicine, Metabolism Laboratory, and for patients with low enzyme activity, the genetic evaluation test will be performed with whole blood at the Gene2Info Laboratory.
40951917|NCT02431338|PROCEDURE|Remote ischemic conditioning|Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
40951918|NCT03059433|OTHER|AVID Intervention|Advancement via Individual Determination (AVID) is a college preparatory program that participating high schools have available to students.
40951919|NCT03395665|OTHER|Estradiol level|Estradiol level measured at previous day of embryo transfer procedure
40951920|NCT03395665|OTHER|Progesterone level|Progesterone level measured at previous day of embryo transfer procedure
40951921|NCT03395665|OTHER|Endometrial thickness|Endometrial thickness measured at previous day of embryo transfer procedure
40951922|NCT02995031|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-177)
40951923|NCT02995031|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
40951924|NCT02225769|OTHER|Management of febrile children using e-POCT|Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
40951925|NCT02225769|OTHER|Management of febrile children using ALMANACH|Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
40951926|NCT04295772|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
40951927|NCT00446615|BEHAVIORAL|computer decision support tool|
40951928|NCT00446615|BEHAVIORAL|audit and feedback|
40951929|NCT00446615|BEHAVIORAL|group learning session|
40951930|NCT03867188|DRUG|Liposomal Bupivacaine|A 25 gauge or larger bore needle will be used to inject the liposomal bupivacaine at the site of operation following the prescription guidelines provided by Exparel®. The maximum dose allowable for this study is 266mg or 20 mL as indicated in the FDA package insert.
40951931|NCT03515083|DEVICE|Alive Cor Kardia mobile electrocardiogram monitor|Mobile ECG monitor paired with smart phone application
40951932|NCT04307784|DIETARY_SUPPLEMENT|VD3|VD3 (50.000 IU/week) for 8 weeks
40951933|NCT04307784|DIETARY_SUPPLEMENT|Omega-3FA|Omaga-3FA (300 mg/day) for 8 weeks
40760557|NCT04634136|DIAGNOSTIC_TEST|Spasticity level according to modified Ashworth scale (Bohannon)|"A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity.~Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):~0 No increase in muscle tone~1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )~2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved~3. Considerable increase in muscle tone, passive movement difficult~4. Affected part(s) rigid in flexion or extension~Best score is 0 (no spasticity), worst score is 4 (severe spasticity)."
40951934|NCT04307784|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks
40951935|NCT04307784|OTHER|Control|No intervention is given
40951936|NCT05091632|PROCEDURE|Electroencephalography|Undergo EEG
40951937|NCT05091632|OTHER|Questionnaire Administration|Complete questionnaires
40951938|NCT00241358|DRUG|AMD3100|
40951939|NCT00241358|PROCEDURE|Stem Cell Transplant|
40951940|NCT04324619|OTHER|Online interactive learning activities|"1. 3-hour video-storyline-based interactive learning program~2. Micro-learning activities that can be completed on mobile devices (eg, smartphones)"
40951941|NCT03970642|OTHER|Video directly observed therapy|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit. The app will automatically upload the video to a HIPAA compliant server. Research staff will regularly monitor videos using a password protected website and document each medication dose.
40951942|NCT00456157|DRUG|Intra-articular Injection of OP-1 to affected knee|
40951943|NCT05738629|DRUG|Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drops 0.125 ml/single eye/one time, four times a day for 12 weeks. The follow-up visit will be 12 weeks since the administration of PSC-MSC-Exo eye drops.
40951944|NCT02368197|DRUG|paclitaxel (Cardionovum Legflow drug eluting balloon)|Elution of paclitaxel from inflated balloon catheter into vessel wall
40951945|NCT02368197|DEVICE|Balloon angioplasty (Bard Dorado)|Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
40951946|NCT06061341|DIAGNOSTIC_TEST|TruGraf®|TruGraf® is a non-invasive blood-based test to assist the clinician in lowering immunosuppression in liver transplant patients. It is the first and only blood-based test that offers biomarker guidance to aid physicians in minimizing immunosuppression in transplant recipients.
41134431|NCT00953355|DRUG|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
41134432|NCT00953355|DRUG|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
41134433|NCT02733484|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
40951947|NCT02681601|DIETARY_SUPPLEMENT|Nutrawell Powder|"The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
40951948|NCT02681601|OTHER|Diet Only|Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
40951949|NCT02681601|DIETARY_SUPPLEMENT|OmegaRich fish oil supplement|"OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
40951950|NCT02583126|BEHAVIORAL|Guided Imagery and Music|Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
40951951|NCT00607815|BEHAVIORAL|Cognitive Processing Therapy|CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.
40951952|NCT00607815|BEHAVIORAL|Present Centered Therapy|"Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called present centered therapy to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors"
40951953|NCT03774758|DIAGNOSTIC_TEST|Guardant Health ct-DNA LUNAR assay|Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
41454290|NCT04474145|PROCEDURE|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
40951954|NCT04526938|DEVICE|Physician-Modified Cook Zenith Alpha Thoracic Endovascular Graft|Cook Zenith® Alpha Thoracic Endovascular Graft will be modified to allow for the maintenance of blood flow into the visceral and renal branch vessels.
40951955|NCT05824572|OTHER|Clinic visit audio recordings for self-management in older adults|The intervention is audio-recordings of primary care clinic visits that are shared with participating patients. All scheduled visits with study clinicians will be recorded and shared with patients randomized to the intervention group (AUDIO) for 12 months.
40951956|NCT05824572|OTHER|Usual Care|The Usual Care arm participants will receive After Visit Summaries (AVS) per the standard delivery at each institution
40951957|NCT00451451|DRUG|BG00012|
40951958|NCT00451451|DRUG|Placebo|
40951959|NCT00451451|DRUG|Glatiramer Acetate|
41454291|NCT01374451|DRUG|Everolimus|Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
41454292|NCT01374451|DRUG|Pasireotide LAR|Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
41134434|NCT02733484|DIETARY_SUPPLEMENT|Placebo|the patients in this arm will receive placebo intervention
41454293|NCT02658435|DRUG|Tafenoquine 150 mg|Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
41454294|NCT02658435|DRUG|Matched placebo 150mg|It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
41454295|NCT00945438|BIOLOGICAL|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
41454296|NCT00945438|BIOLOGICAL|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
40951960|NCT04932460|PROCEDURE|CEUS|CEUS is performed before neoadjuvant treatment and surgery to evaluate the status of axillary lymph node and locate the sentinel lymph node.
40951961|NCT04932460|PROCEDURE|blue dye|Before operation, blue dye is injected for sentinel lymph node mapping.
40951962|NCT01512212|PROCEDURE|biopsy|fnab
40951963|NCT05270122|DEVICE|Mechanical thrombectomy with ThrombX Retriever|Revascularization
40951964|NCT04703387|DIAGNOSTIC_TEST|transthoracic echocardiography|Trans-mitral flow velocities (peak early diastolic E and peak late diastolic A) will be recorded with pulsed-wave Doppler, placing the sample volume at the mitral valve tips from the apical 4-chamber view; deceleration time of the E wave (DTE) will be measured. Peak early diastolic velocity will be obtained with tissue Doppler imaging (TDI), in the apical 4-chamber view, positioning the pulsed-wave Doppler sample volume at or 1 cm within the septal insertion sites of the mitral leaflets, so as to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Then, the E/A ratio and the trans-mitral inflow E wave to mitral annular e' (E/e) will be calculated.Diaphragmatic thickness will be assessed in the zone of apposition of the diaphragm to the rib cage between the 8th and 10th intercostal spaces using a 3-12 MHz linear array probe , we will record changes in diaphragm vertical excursion using M-mode ultrasound.
41134435|NCT03040856|DIETARY_SUPPLEMENT|Alpha Linolenic Acid|Alpha Linolenic Acid enriched diet
41134436|NCT03040856|DIETARY_SUPPLEMENT|Omega 3 enriched diet ( DHA+EPA)|Omega 3 (DHA+EPA) supplementation enriched diet
40951965|NCT01216748|OTHER|quiet breathing|Subjects were instructed to breath normally at room air.
40951966|NCT01216748|OTHER|Hypocapnic Hyperventilation|hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.
41134437|NCT03040856|OTHER|Placebo|Placebo capsules containing olive oil
41134438|NCT04185818|OTHER|Reading a book|"Participants requested to specify usual genre of book they read.~1. Fiction~2. Non-Fiction~3. Other~4. Don't usually read a book in bed"
41134439|NCT02504411|DEVICE|Device Assisted Colonoscopy|This will be similar to the standard colonoscopy except the endocuff device will be used.
41134440|NCT02504411|DEVICE|Standard Colonoscopy|No endocuff device will be used on the study participants undergoing standard colonoscopy.
41454297|NCT06491927|GENETIC|No Intervention|Observational study
40951967|NCT01216748|OTHER|Hypercapnic Hyperventilation|For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg
40760558|NCT04634136|DIAGNOSTIC_TEST|Gross Motor Function Measure|"A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy~The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.~Reference curves exist for GMFM-88 for each age group.~Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75."
40760559|NCT04634136|DIAGNOSTIC_TEST|Borg rating of perceived exertion scale|Borg rating of perceived exertion scale
40760560|NCT04634136|DIAGNOSTIC_TEST|Edmonton symptom assessment system|Edmonton symptom assessment system and general impression scale (1 - very much improved; 7 - very much worse).
40760561|NCT04527744|PROCEDURE|the injection of onabotulinumtoxinA at different point|For experimental group, Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point. For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
40760562|NCT03652428|DRUG|Gemcitabine|see arm description
40760563|NCT03652428|RADIATION|Hypofractionated Ablative Proton Therapy|see arm description
40951968|NCT01216748|OTHER|eucapnic hyperventilation|For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.
40951969|NCT02619669|DRUG|TAK-228|Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.
41454298|NCT02416180|DEVICE|SERETIDE MDI|Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.
40951970|NCT02619669|DRUG|Letrozole|An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
40760564|NCT05723380|PROCEDURE|Erector spinae plane block|T2 ESPB group where ESPB is performed at T2 with local anesthetics 20ml
40760565|NCT03875443|OTHER|Instructional video|Video (produced by AO Trauma and Prof. Daniel Rikli) includes a stepwise and structured explanation of the different fluoroscopic views necessary to evaluate intraoperatively with the fluoroscope different aspects of the proximal femur. The video is publically available under: (https://www.aointeract.org/#/watch/video/L3YxL3ZpZGVvcy8xOTc=/intraoperative-imaging-of-femur).
40760566|NCT03875443|OTHER|Reduction algorithm|Intraoperative reduction algorithm (developed by PD Henrik Eckardt); each step in the algorithm will be checked and documented with the fluoroscope and archived using the store function of the fluoroscope.
40760567|NCT00663260|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
40951971|NCT01102270|DRUG|Eszopiclone|3mg tablet once prior to sleep
40760568|NCT00663260|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
40760569|NCT00663260|DRUG|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
40760570|NCT00023972|DRUG|exatecan mesylate|
40760571|NCT00023972|DRUG|gemcitabine hydrochloride|
40760572|NCT00237627|DRUG|PS-341|PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
40951972|NCT01102270|DRUG|Placebo|1 placebo capsule prior to sleep
40951973|NCT05875701|BIOLOGICAL|NVX-CoV2373|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
40951974|NCT05875701|BIOLOGICAL|SARS-CoV-2 rS antigen/Matrix-M Adjuvant|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
40951975|NCT03504254|DIAGNOSTIC_TEST|MRI examination|Three kinds of MRI techniques will be used in this study. These are (1) axial T1-weighted (T1WI) and T2-weighted imaging (T2WI), UTE MRI, (2) BOLD-based fMRI, and (3) diffusion tensor imaging (DTI).
40760573|NCT00237627|DRUG|Doxil|Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
40951976|NCT00819299|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
40951977|NCT05427708|BEHAVIORAL|Interoceptive Exposure|See: Arm/group descriptions
40951978|NCT05427708|DEVICE|Capnometry-Guided Respiratory Intervention|See: Arm/group descriptions
41134441|NCT04968509|DRUG|PCSK9 inhibitors and statins with or without ezetimibe|Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks) and conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
40951979|NCT05427708|BEHAVIORAL|Psycho-Education|See: Arm/group descriptions
41454299|NCT02416180|DEVICE|Placebo DISKUS Inhaler|Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1
40951980|NCT03138304|BEHAVIORAL|Video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.
40951981|NCT03138304|BEHAVIORAL|Educational program|Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
40951982|NCT03864770|DEVICE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy is a mechanical sound wave that generates energy by extremely high-frequency vibration to compress the medium. Low-energy extracorporeal shock waves can be used for cell regeneration and pain control therapy; medium-high energy can be used to treat patients with poor bone healing; high-energy can be used to lithotrite. In recent years, extracorporeal shock waves have been applied on the musculoskeletal diseases, such as: epicondylitis, plantar fasciitis, chronic pelvic pain, chronic heel pain syndrome, lymphedema, burns, pressure sores, calcific tendinitis and myofascial pain syndrome. This treatment is a non-invasive and safe treatment.
40951983|NCT03864770|PROCEDURE|General physical therapy|The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.
40951984|NCT00142935|BEHAVIORAL|Pre-release Initiation of MMT|Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
40951985|NCT00142935|BEHAVIORAL|Post Release Initiation of MMT.|Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
40951986|NCT00142935|BEHAVIORAL|Standard of Care Plus|Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
40951987|NCT00669396|DRUG|Copper T380 IUD|Copper T380 IUD
40951988|NCT00669396|DRUG|levonorgestrel|1.5 mg
41134442|NCT04968509|DRUG|Statins with or without ezetimibe|Patients in control group are only treated with conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
40760574|NCT00237627|DRUG|Velcade|Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
40760575|NCT06570707|OTHER|Brighter Bites|Families will receive a distribution of fresh fruits and vegetables (FV) (\~20lbs., 50 servings/family/distribution) for \~16 weeks during the school year using primarily donated produce from local food banks. Nutrition education will be implemented for children using the evidence-based Coordinated Approach to Child Health (CATCH) program and for parents using bilingual nutrition handbooks and fun food experiences such as healthy FV recipe tastings for families during produce pick-up time will be conducted.
40760576|NCT03720808|OTHER|Balloon Blowing|The parents of the children in this group were asked whether their children had the latex allergy or not and the children without the allergy were included in the group. The children's skills of blowing balloon were observed before the procedure. Before starting the venous blood sampling procedure, the children were asked to choose a balloon in the color they preferred and to start blowing the balloon at least 20 seconds before the procedure. Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
40760577|NCT03720808|OTHER|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
40760578|NCT03720808|OTHER|Coughing|The children included in this group were asked to cough after taking a deep breath during the venous blood sampling procedure. Before the procedure, the researcher showed the children how they should cough and asked them to imitate. The venous blood sampling was not performed until the child successfully completed coughing. The child was directed by the researcher during the procedure. Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
40760579|NCT03720808|OTHER|Control|No intervention was performed to reduce pain and fear in the control group.
40760580|NCT05308641|PROCEDURE|radial extracorporeal shockwave therapy_4000_20|application of radial extracorporeal shockwave therapy (rESWT) with 4000 pulses and 20 Hz
40760581|NCT05308641|PROCEDURE|radial extracorporeal shockwave therapy_500_2|application of radial extracorporeal shockwave therapy (rESWT) with 500 pulses and 2 Hz
40951989|NCT05570383|DRUG|Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).|The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
40951990|NCT00934479|DRUG|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
40760582|NCT05308641|PROCEDURE|standard multimodal pain therapy|standard multimodal pain therapy
40760583|NCT05318443|DRUG|SIBP04|SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
40760584|NCT05318443|DRUG|Avastin|Avastin, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
40760585|NCT05318443|DRUG|Paclitaxel|Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.
40760586|NCT05318443|DRUG|Carboplatin|Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.
40760587|NCT03747237|OTHER|Edema measurement methods|A correlation between the results of the first and second methods will be examined.
40760588|NCT03374332|DRUG|Gemtuzumab Ozogamicin (GO)|Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.
40760589|NCT03374332|OTHER|Donor Leukocytes|The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.
40760590|NCT02951819|DRUG|Daratumumab|"For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks."
41134443|NCT05752370|DEVICE|High flow oxygen|Use of HFO
41134444|NCT05752370|OTHER|Usual care|Room air or normal flow oxygen
40760591|NCT02951819|DRUG|Cyclophosphamide|Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m\^2 ) on Days 1, 8, 15, and 22 for every 28 days.
40760592|NCT02951819|DRUG|Bortezomib|Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
40760593|NCT02951819|DRUG|Dexamethasone|Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
40760594|NCT03851952|DEVICE|Optilume Drug Coated Balloon|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
40760595|NCT03688763|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).
40760596|NCT01399645|DRUG|Liraglutide-metformin vs insulin-metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU."
40760597|NCT00660231|DRUG|bexarotene|Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
40951991|NCT06045780|OTHER|nothing|disease
40760598|NCT00660231|DRUG|gemcitabine hydrochloride|Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
40951992|NCT02266498|DRUG|BIBB 515 BS|
41134445|NCT00005962|BIOLOGICAL|sargramostim|
41134446|NCT00005962|DRUG|cyclophosphamide|
40760599|NCT00370578|DEVICE|repeated thrombus aspiration during primary PCI|
40951993|NCT02266498|OTHER|Standard breakfast (40 g fat)|
41134447|NCT00005962|DRUG|cytarabine|
41134448|NCT00005962|DRUG|gemtuzumab ozogamicin|
41134449|NCT00005962|DRUG|liposomal daunorubicin citrate|
41134450|NCT00005962|DRUG|topotecan hydrochloride|
41134451|NCT03642834|DRUG|ICP-105|25mg, 100mg capsule
41134452|NCT02003872|DEVICE|Spatz 3 intragastric balloon|Intra gastric balloon implanted using gastroscopy
41134453|NCT03784105|DRUG|Codeine Phosphate|30 mL of codeine phosphate 10mg/5mL
41134454|NCT03784105|DRUG|Siripus simplex|Sugar syrup
41134455|NCT00972920|PROCEDURE|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
41454300|NCT02416180|DEVICE|Placebo MDI|Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
41454301|NCT01939535|OTHER|No intervention|Evaluation of an imaging technique ic MRI
40951994|NCT01554436|BEHAVIORAL|neuropsychological assessment|"The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.~The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test"
41289437|NCT01702012|DIETARY_SUPPLEMENT|Almased Meal Replacement Powder|Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
40760600|NCT00894010|DRUG|carbamazepine 400mg|
41289438|NCT01702012|BEHAVIORAL|Group-Based Lifestyle Intervention|
41289439|NCT05190575|DRUG|TST001|TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
40760601|NCT00894010|DRUG|levetiracetam 1000mg|
40760602|NCT01366274|OTHER|Protective manual hyperinflation|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels
41134456|NCT05366478|DRUG|Autologous tumor infiltrating lymphocytes (TILs)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.
41134457|NCT02160301|DRUG|Gabapentin|PO
41134458|NCT02160301|DRUG|Acetaminophen|PO
41134459|NCT02160301|DRUG|Acetaminophen|IV
41289440|NCT02846077|OTHER|No intervention. Observation only|No intervention. Observation only
41289441|NCT04388735|BEHAVIORAL|Questionnaire|Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
41454302|NCT04092595|DRUG|PF-06651600|PF-06651600: 200 mg dose provided as four 50 mg oral tablets
41454303|NCT04092595|DRUG|Rosuvastatin|10 mg oral tablet
41454304|NCT00487435|DRUG|Tapentadol (CG5503) Extended Release (ER)|100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
41454305|NCT00003795|PROCEDURE|quality-of-life assessment|
40760603|NCT01366274|OTHER|Usual method of MHI|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
40760604|NCT05284617|DRUG|HU6|HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).
40760605|NCT05284617|DRUG|Placebo|Placebo
40760606|NCT06569420|OTHER|Drug: Foritinib Succinate|SAF-189s: 160 mg QD, 21 days a cycle
40760607|NCT06569420|OTHER|Drug: Crizotinib|Crizotinib: 250 mg BID, 21 days a cycle
40760608|NCT05752838|OTHER|No intervention|This is a survey study, and there were no intervention
40951995|NCT01910961|PROCEDURE|limb RIPC|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
40951996|NCT02904993|OTHER|L2 paravertebral block|nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
40951997|NCT02904993|OTHER|periarticular injection group|periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
41134460|NCT02160301|DRUG|Celecoxib|PO
40951998|NCT03730675|PROCEDURE|Portal irradiation stent placement|The irradiation portal vein stent was designed as two separate parts that consisted of an outer seeds-loaded-stent and an inner self-expandable metallic stent
40951999|NCT03730675|PROCEDURE|TACE|TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.
41289442|NCT05083208|DRUG|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II: Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib within the first 8 weeks (including the treatment received in Phase Ib).~Maintain treatment: 2.5mg orally every day continuously, at approximately the same time every day, without food restriction, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
41289443|NCT05083208|DRUG|Chidamide|"Phase Ib: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast.~Phase II: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast until disease progression, death or unacceptable toxicity developments."
41289444|NCT04312997|DRUG|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
40952000|NCT03730675|DRUG|Sorafenib|Sorafenib is a kinase inhibitor drug approved for the treatment of advanced hepatocellular carcinoma.
41134461|NCT02160301|DRUG|Dexamethasone|IV
41289445|NCT04312997|DRUG|Placebo|Sterile saline for inhalation
41289446|NCT00754767|DRUG|L-carnitine L-tartrate|Given orally
41289447|NCT00754767|OTHER|placebo|Given orally
41454306|NCT00951535|OTHER|questionnaire administration|
41454307|NCT00951535|PROCEDURE|quality-of-life assessment|
40952001|NCT04812171|PROCEDURE|non-surgical endodontic treatment|standard non-surgical endodontic treatment performed by endodontic specialist
40952002|NCT00293527|DRUG|Interferon Alpha-2b|
40952003|NCT02494674|BEHAVIORAL|Bite Counter tracking|Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
40952004|NCT01361568|DRUG|CR845|Single i.v. dose (0.04 mg/kg) administered preoperatively
40952005|NCT01361568|DRUG|Placebo|Single i.v. dose administered preoperatively
40952006|NCT01361568|DRUG|CR845|Single i.v. dose (0.04 mg/kg) administered postoperatively for pain
40952007|NCT01361568|DRUG|Placebo|Single i.v. dose administered postoperatively for pain
41134462|NCT02160301|DRUG|Oxycodone|PO
40952008|NCT05928793|BEHAVIORAL|mindfulness practices|"Mindfulness, according to Kabat-Zinn, is to pay attention to the present moment in a purposeful way, without judgment. Being conscious involves both attention and awareness. Conscious awareness is an observer in the background of the state of consciousness, constantly observing the inner and outer environment. It is to direct our awareness and attention to our experiences in the present moment in an accepting way with our whole body and thoughts."
41134463|NCT06132009|PROCEDURE|Surgery of endometriosis|Cystectomy or unilateral oophorectomy due to endometriosis
40952009|NCT04564495|BEHAVIORAL|Seated exercise|Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
41289448|NCT02112266|OTHER|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
41134464|NCT01005615|DEVICE|Non-FES Upper Extremity Exercise|While undergoing the non-FES exercise intervention, the subjects will receive a specific, individualized exercise regimen, consisting of strengthening, stretching, splinting and any other therapeutic interventions that do not use electrical stimulation. Than a 1 month washout period,the subjects will remain seated in their primary wheelchair throughout the treatment. The subjects will exercise for 60 minutes/session, three times a week for 4 months.
41289449|NCT02112266|OTHER|no mail support|follow-up without mail support
40952010|NCT00121381|DRUG|Pimecrolimus plus topical corticosteroid (TCS)|Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
41289450|NCT02726867|DRUG|levetiracetam|Treatment will consist of LEV 4000 mg i.v. over 10 minutes.
41289451|NCT02726867|DRUG|lacosamide|Treatment will consist of LCM 600 mg i.v. over 10 minutes
40952011|NCT00121381|DRUG|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)|twice daily administration
41134465|NCT01005615|DEVICE|RT300-SLSA, from Restorative Therapies, Inc.|They will undergo 4 months of FES assisted upper extremity ergometry followed by 1 month was out period, than by 4 months of a specific, individualized, non FES assisted exercise regimen
41289452|NCT02726867|DRUG|Ketamine|Treatment will consist of KET 2.5 mg/kg over 10 minutes
40952012|NCT03239184|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
40952013|NCT03239184|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
40952014|NCT02623140|DEVICE|Biofreedom|PCI with Biofreedom stent
40952015|NCT02623140|DEVICE|Orsiro|PCI with Orsiro stent
40952016|NCT03845777|DIAGNOSTIC_TEST|Using Antiseptic solution|Using of iodine including antiseptic solutions. The investigators investigate the urine iodine status of staff before and after the using of antiseptic solution
40952017|NCT01589978|DEVICE|PROMUS Element Plus Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
40952018|NCT01589978|DRUG|Aspirin|Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
41134466|NCT04789174|DRUG|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
41134467|NCT04789174|DRUG|Placebo|Placebo
41289453|NCT02726867|DRUG|Phenobarbital|Treatment will consist of PHB 15 mg/kg mg i.v. at 100 mg/minute rate
41289454|NCT02355912|DEVICE|Powered knee and ankle prosthesis|A powered knee and ankle prosthesis developed by Vanderbilt University.
40952019|NCT01589978|DRUG|P2Y12 antagonist|"Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~* Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~* Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided.~* Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)"
41289455|NCT00372164|PROCEDURE|American Society of Interventional Pain Physician Guidelines|
40952020|NCT01424709|DRUG|Gemcitabine, Docetaxel, CPT-11,Cisplatin|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
40952021|NCT01424709|DRUG|gemcitabine/cisplatin|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
40952022|NCT06212154|BIOLOGICAL|ThisCART19A|Participants will receive ThisCART19A cell infusion after preconditioning, and they need to be closely monitored for 28 days following CAR-T cell infusion.
40952023|NCT04273373|BIOLOGICAL|Low Dose Albumin|20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours
40952024|NCT04273373|BIOLOGICAL|Standard dose Albumin|20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours (duration of infusion 6 hours).
40952025|NCT04712383|COMBINATION_PRODUCT|Fitbit Care intervention arm|Entire suite of Fitbit Care.
40952026|NCT01820065|PROCEDURE|Cataract surgery with IOL implantation|Phacoemulsification with implantation of single piece Acrysof IOL
40952027|NCT00398788|DRUG|OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine|
41289456|NCT00022711|DRUG|temozolomide|150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
40952028|NCT03493620|PROCEDURE|Device arm|Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.
40952029|NCT03493620|PROCEDURE|Sham arm|Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
40952030|NCT01085474|OTHER|1|In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
40952031|NCT01085474|OTHER|2|The best intervention used in the pilot study will be chosen and included in the main study.
40952032|NCT05239442|OTHER|Taste Commission|"Evaluation of the daily meal once a week:~Introduction on the different sensory dimensions of the food, hedonic rating for each component, indicate what pleases/what could be improved in the recipe."
40952033|NCT05239442|OTHER|Evaluation of the taste commissions|"At 0, 3, 6 months:~* Food intake measurement, satisfaction measurement, and food waste measurement performed on 2 days (same week but not necessarily consecutive)~* Assessment of nutritional status using the Mini-Nutritional Assessment (MNA)"
40952034|NCT05239442|OTHER|Entretien SWOT|Individual semi-guided face-to-face interview with an experimenter. They will allow us to identify the positive and negative effects of the taste commissions in the establishment as well as the levers and difficulties encountered during the implementation of the taste commissions. These interviews will be recorded using an audio device (dictaphone). Their content will then be transcribed in full.
40952035|NCT04058873|DRUG|Levonorgestrel 1.5mg|Levonorgestrel 1.5mg for pericoital use
40952036|NCT00002854|BIOLOGICAL|filgrastim|
40952037|NCT00002854|DRUG|carboplatin|
40952038|NCT00002854|DRUG|cisplatin|
40952039|NCT00002854|DRUG|cyclophosphamide|
40952040|NCT00002854|DRUG|etoposide|
40952041|NCT00002854|DRUG|ifosfamide|
41289457|NCT05110586|OTHER|Electrotherapy|Applications will be applied for 4 weeks, 5 days a week
41289458|NCT03925844|OTHER|Classification according to the cardiovascular risk|All patients are cognitively assessed at the beginning of the study and their cardiovascular risk is calculated. After 5 years of follow-up, patients are re-evaluated cognitively and their cardiovascular risk is recalculated.
40952042|NCT00002854|DRUG|mesna|
40952043|NCT00002854|DRUG|paclitaxel|
40952044|NCT00002854|PROCEDURE|peripheral blood stem cell transplantation|
40952045|NCT03166059|DEVICE|CaveoVasc® Thrombolysis Protection System|CaveoVasc® Thrombolysis Protection System for Femoral Artery Access and Protection in Patients Treated with Thrombolysis for Limb Ischemia
40760609|NCT02416479|BEHAVIORAL|SystemCHANGE|SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.
40760610|NCT02416479|BEHAVIORAL|Patient-education attention control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
40952046|NCT03890315|DIAGNOSTIC_TEST|Functional MRI|"In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses."
40952047|NCT05332730|DRUG|BAT2506 injection|50 mg, subcutaneous administration
40952048|NCT05332730|DRUG|Simponi® (EU commercially available product)|50 mg, subcutaneous administration
41289459|NCT05640986|BEHAVIORAL|BART-EEG at V1 + V2|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 + V2 for Parkinsonian patients
40760611|NCT03696693|DEVICE|acoustic vocal analysis|Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)
40760612|NCT04862403|PROCEDURE|Umbilical cord clamping distance|Intervention group I: Umbilical cord clamped at a distance of 2cm Intervention group II: Umbilical cord clamped at a distance of 3cm Control group: Usual care (clamped without measurement).
40760613|NCT03624556|DIETARY_SUPPLEMENT|EGCG FontUp|Intake of 10mg/kg/day of EGCG, in the form of a dietary supplement (FontUp), two times a day.
40760614|NCT03624556|OTHER|Placebo FontUp|Intake of placebo, in the form of a dietary supplement (FontUp) (without EGCG), two times a day.
40760615|NCT03624400|BEHAVIORAL|Internet-based CBT-I|The adapted Internet-based CBT-I for adolescents with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 8 weekly modules and each module consists of several website pages that will be presented in a fixed order, with preprogrammed modules containing information, interactive questionnaires, descriptions of exercises and movies.
40760616|NCT03624400|BEHAVIORAL|Internet-based psychoeducation|Internet-based psychoeducation contains information about ASD, sleep difficulties and aspects of sleep hygiene. The intervention takes place in 8 weeks modules.
40760617|NCT03186157|PROCEDURE|Decompressive craniectomy|Decompressive craniectomy is a surgical procedure used to treat patients with acute intractable intracranial hypertension. It includes removing a large portion of lateral skull wall in order to alleviate the effects of increased intracranial pressure and allow the brain to expand.
40760618|NCT03186157|PROCEDURE|Cranioplasty|Cranioplasty is a routine neurosurgical procedure to repair the continuity of the bone tissue of the skull with autologous bone or synthetic bone flap from heterologous material.
40760619|NCT01714063|DEVICE|Pressurized Metered-Dose Inhaler|Pressurized Metered-Dose Inhaler
40760620|NCT04645030|DIAGNOSTIC_TEST|Ultra low-dose computer thermography|The ULD-CT scan will be executed according to a standardized predeveloped technical protocol. The technical protocol will differentiate between patients with BMI \<25 and \>25 to insure optimal ULD-CT image quality.
40760621|NCT04645030|DIAGNOSTIC_TEST|lung ultrasound|"LUS will be performed by trained researchers. Before inclusion researchers preforming LUS scans, will undergo a training program and will complete 25 supervised LUS scans to be certified in LUS. At the end of the training program, researchers will be tested to insure proficiency in LUS.~LUS will be performed according to LUS protocol with seven scanning's zones on each side; 2 anterior, 2 lateral and 3 posterior."
40760622|NCT03189927|DEVICE|BD-Covered esophageal stent|a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures
40760623|NCT02172261|DRUG|BI 10773|
40760624|NCT02172261|DRUG|Glimepiride|
41289460|NCT05640986|BEHAVIORAL|BART-EEG at V1 only|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 only for healthy volunteers
41454308|NCT00951535|RADIATION|image-guided radiation therapy|
40760625|NCT02098473|DRUG|RPC4046|
40760626|NCT02098473|DRUG|Placebo|
40760627|NCT00438282|BEHAVIORAL|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
40760628|NCT06209372|PROCEDURE|Group PENG|Pericapsular Nerve Group Block (PENG)
40952049|NCT05332730|DRUG|Simponi® (US commercially available product)|50 mg, subcutaneous administration
40952050|NCT00195546|DRUG|DVS-233|
40952051|NCT00061477|DRUG|Pemetrexed|
40952052|NCT00061477|DRUG|Gemcitabine|
40952053|NCT04298515|DIAGNOSTIC_TEST|Nesfatin-1|Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
41454309|NCT00951535|RADIATION|intensity-modulated radiation therapy|
40760629|NCT06209372|DRUG|Group C|Tramadol infusion
40952054|NCT04402918|DIAGNOSTIC_TEST|biological samples day of delivery|mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration
40952055|NCT04295551|DRUG|Lopinavir / ritonavir tablets combined with Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
41454310|NCT00951535|RADIATION|radiation therapy treatment planning/simulation|
41454311|NCT03886363|BEHAVIORAL|MBSR|Described previously
41454312|NCT03464045|DRUG|empagliflozin|drug
41454313|NCT03464045|DRUG|DPP-4 inhibitors|drug
41134468|NCT01965990|OTHER|NEP|A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
41134469|NCT05178706|OTHER|upper extremity rehabilitation program|Patients with FSHD who have undergone and have not undergone surgery will be given activity training by the same physiotherapist after they agree to participate in the study. Both groups will be given the same exercises, the same number of repetitions and the same frequency. A two-phase exercise protocol will be established and progression will be performed after 4 weeks. The exercises will be based on the upper extremity and will include various types of exercises and the primary affected November muscles in the upper extremity. It is planned that the exercises will be accompanied by a physiotherapist 2 days a week, with a total of 16 sessions for 8 weeks. It is planned that there will be a total of 8-10 exercises in 10 repetitions in the exercise program. The total length of the exercise session will be 30 minutes. It is planned that the same physiotherapist will be one-on-one with the patient from the beginning to the end of the exercises.
41134470|NCT05178706|DIAGNOSTIC_TEST|Results of assessment|The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.
41134471|NCT03673605|DRUG|Rivaroxaban 15 mg|Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
41134472|NCT03673605|DRUG|Warfarin|Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
41134473|NCT01755559|DRUG|Artesunate-amodiaquine|antimalarial ACT
41134474|NCT01755559|DRUG|Dihydroartemisinin-piperaquine|antimalarial ACT
41134475|NCT01755559|DRUG|Artemether-lumefantrine|antimalarial ACT
41134476|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
41134477|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
41134478|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
41134479|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
41134480|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
41134481|NCT05899699|DRUG|DAP-FLU ME|Combination therapy of topical anti-inflammatory agent (Dapsone 5%) and anti-androgenic agent (Flutamide 2.5%) with anti-bacterial agent of micro-emulsion component (tea tree oil 5%)
41134482|NCT05899699|DRUG|Adapalene .1% gel|Adapalene .1% gel
41134483|NCT05142774|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1%, applied daily to affected areas by subjects or their caregivers based on vIGA-AD. Subjects are advised to choose the application time they prefer and apply the study drug at that approximate time each day of study participation.
41134484|NCT03764020|DRUG|Placebo oral capsule/placebo comparator|3 mg placebo capsule one hour before bedtime for three weeks along with life style modification according to ACC/AHA 2013 guideline
41134485|NCT03764020|DRUG|Melatonin/experimental|Melatonin ,capsule, 3 mg, one dose one hour before bedtime, for three weeks along with life style modification according to ACC/AHA 2013 guideline.
41134486|NCT00475241|BEHAVIORAL|Prolonged Exposure therapy for PTSD|exposure-based treatment for PTSD
41134487|NCT00475241|BEHAVIORAL|Present centered therapy for PTSD|present focused coping and problem solving for PTSD
41134488|NCT00687869|BEHAVIORAL|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
41134489|NCT00687869|BEHAVIORAL|Case management|Usual stroke aftercare plus patient-information-notes
41134490|NCT01534091|BEHAVIORAL|Pedometer with supervision|
41134491|NCT01534091|BEHAVIORAL|Pedometer without supervision|
41134492|NCT05581251|BEHAVIORAL|Food and cooking skills|The researchers collected the study data using the face-to-face interview method through a questionnaire including the Descriptive Information Form, Cooking Skills and Food Skills Scale, and Three-Factor Eating Questionnaire-R21.
41134493|NCT02590094|DRUG|Intravitreal bevacizumab or intravitreal ziv-aflibercept|Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
41134494|NCT00952640|DIETARY_SUPPLEMENT|vitamin A|high dose vitamin A, 200.000 IU
41134495|NCT02502526|DEVICE|Centurion® Vision System, 45° Balanced Tip|
41134496|NCT02502526|DEVICE|Centurion® Vision System, 45° MFK Tip|
41134497|NCT02502526|DEVICE|lnfiniti® Vision System, 45° MFK Tip|
41134498|NCT02502526|DEVICE|INTREPID® Ultra infusion sleeve|
41134499|NCT02502526|DEVICE|Ultra infusion sleeve|
41134500|NCT00828126|PROCEDURE|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
41134501|NCT02734706|DIETARY_SUPPLEMENT|LRC™ capsule|Twice per day (BID), 9 weeks
41134502|NCT02734706|OTHER|Placebo capsule|Twice per day (BID), 9 weeks
40952056|NCT04295551|DRUG|Lopinavir/ritonavir treatment|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
41134503|NCT03977805|DRUG|Hetrombopag Olamine|a single oral taking
40952057|NCT05295056|DEVICE|AFGen1 Device Wear Test|Participant wears the device for 7 days
41289461|NCT03235440|BEHAVIORAL|Kids N Fitness Program|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
41289462|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
41454314|NCT03464045|DRUG|SGLT-2 inhibitors|drug
40952058|NCT05295056|DEVICE|AFGen 1 Device Single Use|Participant wears the device in conjunction with a standard ECG
41454315|NCT00734825|OTHER|Omnipaque|oral contrast for CT scan
40760630|NCT05023057|BEHAVIORAL|Multidomain intervention|For 24 weeks, participants will receive cognitive training using the tablet PC application twice a week, exercise 3 times a week, nutrition education 12 times, anthropometric measurements and alcohol and smoking monitoring every 4 weeks, motivation reinforcement training 4 times.
40760631|NCT06352567|OTHER|European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire|"It consists of a total of 20 items each is scored from 1: not at all to 4: very much in a 4-point Likert scale. Individuals are requested to fill out by considering their last week. Sensory, motor, and autonomic subscales are reported within its constructs. A total of 9, 8, and 3 items are referred to as sensory, motor, and autonomic disturbances, respectively"
40952059|NCT00109122|BIOLOGICAL|zoster vaccine live (Oka/Merck)|
40952060|NCT00109122|BIOLOGICAL|Comparator: placebo (unspecified)|
40952061|NCT05169996|OTHER|Real Food|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Food condition, the tangram pieces were tempting food products (i.e., pieces of chocolate). Players had to physically move the chocolate pieces with their hands and puzzle them together.
40952062|NCT05169996|OTHER|Real Nonfood|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of wood). Players had to physically move the wooden pieces with their hands and puzzle them together.
40952063|NCT05169996|OTHER|Virtual reality Food|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together.
40952064|NCT05169996|OTHER|Virtual reality Nonfood|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of virtual wood). Players had to physically move the virtual wood pieces with the grab button on the controller and puzzle them together.
40952065|NCT05169996|OTHER|Virtual reality Food Branded|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together. In the background of the puzzle, a chocolate brand ('Milka') is shown
41454316|NCT04029545|DEVICE|PN40082|1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
41454317|NCT02143596|OTHER|normal saline|the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
41454318|NCT03082586|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
41454319|NCT03082586|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
40760632|NCT04336566|DIETARY_SUPPLEMENT|Melatonin|Melatonin 5mg
40760633|NCT04336566|DIETARY_SUPPLEMENT|Placebo|Comparable Good Neighbor Pharmacy placebo tablet
41454320|NCT03082586|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
41454321|NCT03082586|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
41289463|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
41289464|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 infusion of vvDD-CDSR.~Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u."
40952066|NCT05444101|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
40952067|NCT05444101|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
40952068|NCT05444101|BEHAVIORAL|Values and committed action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
40952069|NCT00579878|DRUG|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
40952070|NCT00579878|DRUG|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day)."
41134504|NCT04740944|BEHAVIORAL|Salutogenic Approach Based Interview|Salutogenic Approach Based Interview has five basic components. (1) Continuity of health, (2) The story of the person, (3) Health promoting factors, (4) Understanding the health promoting power of tension and strain, (5) Active adaptation In traditional therapy recommended for recovery, more emphasis is placed on negative life events, diagnosis and medication. In the salutogenic approach-based interview, the resources and coping potential of the person are discussed and three healing factors are focused on for the recovery process. These factors are that the participants (1) perceive themselves as more than just a diagnosis and disease, (2) self-discovery and respect for other people's self-discovery, (3) control over their own lives. In the intervention, mental health nurses take part as group leaders. The focus in interviews is therapeutic conversations.
41134505|NCT01698541|DRUG|Tacrolimus|Tested generic
41134506|NCT01698541|DRUG|Tacrolimus|Original formulation used as comparator
41134507|NCT02531126|DRUG|RPC1063|
41134508|NCT02766361|BEHAVIORAL|Cognitive Behavioral Rehabilitation|12 weekly sessions of Combined intervention lasting 90 minutes
41134509|NCT02766361|OTHER|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
41134510|NCT02343666|BIOLOGICAL|C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs|Given IV
41134511|NCT02343666|DRUG|Carmustine|Given IV
41134512|NCT02343666|BIOLOGICAL|Filgrastim|Given SC
41134513|NCT02343666|OTHER|Laboratory Biomarker Analysis|Correlative studies
41134514|NCT02343666|DRUG|O6-Benzylguanine|Given IV
41134515|NCT02343666|DRUG|Plerixafor|Given SC
41134516|NCT00195403|DRUG|Etanercept|Etanercept 25mg Injection, 2 times/week
41134518|NCT03547154|BIOLOGICAL|Pegylated interferon alfa-2b|Weekly SC injection of pegylated interferon alfa-2b, 6.0 microg/kg
41134519|NCT03547154|BIOLOGICAL|Interferon alfa-2b|Daily SC injection of interferon alfa-2b, 5 MIU/m\^2
41134520|NCT02431741|DEVICE|Mepilex Transfer Ag|
41289465|NCT00933335|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
41289466|NCT00456937|DRUG|Escitalopram|
41289467|NCT02214979|DRUG|Telmisartan/Ramipril|fixed dose combination tablet
41134521|NCT03940339|OTHER|Suboccipital myofascial release|The MFR technique will be given in the upper cervical region with the patient in supine position. The MFR will be given for three repetitions per session, three times per week for the period of four weeks.
41134522|NCT03940339|OTHER|Conventional Physiotherapy|The control group will be receiving conventional physiotherapy treatment for hamstring tightness which includes static stretching, modified hold-relax stretching and contract relax technique.
41134523|NCT01331772|OTHER|Control arm|Dietetic follow-up only
41134524|NCT01331772|OTHER|Intervention arm|Dietetic follow up + adapted physical activity
41289468|NCT02214979|DRUG|Telmisartan|
41289469|NCT02214979|DRUG|Ramipril capsule|
41289470|NCT02214979|DRUG|Ramipril tablet|
41289471|NCT00205192|PROCEDURE|Cardiac resynchronization pacing|various pacemaker modes used over 1 hour
41289472|NCT04150432|DEVICE|Edmon|New device for exhaled propofol concentration measurements
41289473|NCT05659615|OTHER|Study will not have intervention|Study will not have intervention
41289474|NCT02501356|DIETARY_SUPPLEMENT|ISOThrive Supplement|Consumption of ISOThrive supplements for 3 months
41289475|NCT02501356|DIETARY_SUPPLEMENT|Placebo Supplement|Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
41289476|NCT04171128|BEHAVIORAL|antibiotic stewardship efforts|The local antibiotic team plan to implement procalcitonin use among the hospital physicians. the interventions are not ready yet.
41289477|NCT00663858|DRUG|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
41289478|NCT00663858|DRUG|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
40952071|NCT00579878|DRUG|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
40952072|NCT05896124|DRUG|2mg CS0159|Oral QD
41134525|NCT03620955|OTHER|Justified risk stratification based on MRD after three course chemo therapy|All patients are routinely divided into different risk groups according to the NCCN guild based on cytogenetic and molecular abnormality. Then all patients are treated with anthracycline combined with cytarabine regimens for two courses . The patients without obtaining CR will go on one cycle of salvage therapy and then be bridged to allo-HSCT. Those acquiring CR will be given one more course of HDAC as consolidation treatment and then be detested MRD with flow cytometry after that. The patients with MRD positive would be moved to a higher risk class.The stratified therapy should be considered according to the new risk stratification.
41134526|NCT01439906|PROCEDURE|Surgical correction of the deformity|"Three different surgical techniques are used:~* lumbar fusion vs thoraco-lumbar fusion~* iliac fixation vs fixation to the sacrum~* posterior + interbody fusion vs posterior interbody fusion"
41134527|NCT04559074|DRUG|Amlodipine|Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.
41134528|NCT06195449|OTHER|ALKASITE RESTORATIVE MATERIAL|Restorative material for primary teeth
41134529|NCT06195449|OTHER|Glass Ionomer Cement|Restorative material for primary teeth
41289479|NCT00663858|OTHER|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
41289480|NCT01086683|BEHAVIORAL|Psychosocial rehabilitation course|Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
41289481|NCT05182333|OTHER|Examination|History taking, examination of upper limb
41289482|NCT03768401|OTHER|Education|Seminars about wellness and exercise, and resulting therapeutic programs, while living with a neurological physical disability.
41289483|NCT03768401|BEHAVIORAL|Trial Exercise Modalities|Wellness/exercise clinics located at Mayo Clinic, Rochester will be offered to persons with neurological physical disabilities on a regular basis, at least monthly, during the last half of the trial period.
41289484|NCT04912531|DEVICE|Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG|The investigators will use a DeepReality VR with biofeedback using a Microsoft Hololens, Empatica HR wristband and EEG. The Empatica HR wristband will measure HR and the EEG will measure alpha and theta brain waves. To monitor the physiologic data in real-time, data from the EEG and heart rate monitor will be streamed and processed in an Android Application that the investigators previously developed. During data collection, the Android app sends data via OSC to a specific IP and port, which is then collected in the game engine, Unity 3D and processed to adapt the virtual environment. Importantly, each device is inexpensive and can be sanitized and reused by multiple patients.
41454322|NCT03082586|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
40952073|NCT05896124|DRUG|Placebo|Oral QD
40952074|NCT05559398|DRUG|Glenzocimab|"Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0.~It is supplied for clinical trial use in vials containing 50 mL of the drug product at a concentration of 10 mg/mL.~Each vial contains 500 mg of glenzocimab. Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g.~Glenzocimab is intended to be administered as an IV infusion over 6 hrs, with 1/4 of the dose administered by a 15-minute bolus and 3/4 of the dose administered by 5h45min-slow infusion."
40952075|NCT05559398|DRUG|Placebo|Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
40952076|NCT02738034|OTHER|Cogmed|The Cogmed is computer software designed to train visuospatial and audio-verbal working memory, and other functions associated with working memory: attention, focus and impulsiveness. It has three versions adapted to different age groups: Cogmed for younger children, about 4-7 years, which are not yet so familiar with numbers and letters; Cogmed for children over 7 years and adolescents; and Cogmed for youth and adults over 18 years. In this study we will use the version for youth and adults over 18 years.
40952077|NCT05884788|OTHER|free interview, and questionnaires in a second time|"After inclusion in the study, patients will be met for a free interview. The interview will be conducted using an open-ended interview method with the patients to allow free expression of their life history, using open and broad questions to avoid the influence of the interviewer as much as possible.~Each interview will be conducted by the same person to allow for better interpersonal reproducibility.~After the interview, the patients will be seen again to complete two questionnaires:~* An attachment questionnaire: Relationship Scales Questionnaire~* A questionnaire on symptoms: Distress thermometer"
40952078|NCT02987556|DEVICE|Continuous Glucose Monitoring|Collection of glucose data
40952079|NCT02987556|DEVICE|External Insulin Pump|insulin delivery
41289485|NCT04912531|DEVICE|Essence Olfactory Necklace|The Essence Olfactory Necklace holds a small, lightweight 7 ml capsule that contains an essential oil. Within the capsule is a piezo electric transducer which allows us to control the release of scent via Bluetooth using a smartphone app. Each Essence Necklace will be paired with a google phone that the investigators will use to control the frequency and intensity of scent for each patient. The investigators will limit the frequency to one burst of scent every 20 seconds to avoid habituation. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water). The investigators chose lavender because in our previous studies, \>97% of users enjoyed the lavender scent. The Essence Necklace is powered with a 3.7V Lithium Battery and has a battery lifetime of approximately 6 hours. The RC can easily recharge the Essence Necklace through a USB micro connector. Additionally, the Essence Necklace can be easily sanitized and reused by multiple patients.
40952080|NCT02987556|OTHER|telemdecine|Remote follow up by care health providers team
40952081|NCT02987556|DEVICE|The Diabeloop Software (Model predictive control)|Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
40952082|NCT00689780|DRUG|AZD1940|Oral solution Multiple ascending dose given orally once daily at day 1-12
40952083|NCT00689780|DRUG|Midazolam|Oral solution given orally once daily on day -1 and day 14
40952084|NCT04634383|DEVICE|WFMA - wireless floating microelectrode array|Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.
40952085|NCT04108871|PROCEDURE|Prostate Biopsy|Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
40952086|NCT02389517|DRUG|Ixazomib Citrate|Given PO
40952087|NCT02389517|DRUG|Lenalidomide|Given PO
40952088|NCT02389517|DRUG|Dexamethasone|Given PO
40952089|NCT05493332|PROCEDURE|HAIC(FOLFOX)|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of chemotherapy drugs.
40952090|NCT05493332|DRUG|Oxaliplatin|85mg/m2 IVdrip from hour 0 to 2 on D1，Q3W
40952091|NCT05493332|DRUG|Leucovorin|400mg/m2 IVdrip , from hour 0 to 2 on D1 to D2，Q3W
40952092|NCT05493332|DRUG|Fluorouracil|400mg/m2 , bolus at hour 3 ; and 600mg/m2 IVdrip over 46 hours on D1 to D2，Q3W
40952093|NCT05493332|DRUG|Toripalimab|240mg IVdrip，D3, Q3W
40952094|NCT05493332|DRUG|Donafenib|0.1g. P.O, BID, continuously
41454323|NCT03082586|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
41454324|NCT03891095|DRUG|Oxytocin|intranasally administrated
41454325|NCT03891095|DRUG|L-DOPA|orally administered
41454326|NCT03891095|DRUG|Placebos|intranasally administrated and orally administered
41454327|NCT01653405|OTHER|Multifaceted behavioral intervention|The intervention included access to a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
40952095|NCT02765269|DEVICE|Intelligent Pain Management System|A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
40952096|NCT06421116|PROCEDURE|Synovial ultrasound-guided biopsy Intestinal biopsy|Patients will undergo biopsies if needed for standard-of-care follow-up and after clinical indication.
40952097|NCT01864941|PROCEDURE|Catheter venography with balloon venoplasty|All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
40760634|NCT01652404|BEHAVIORAL|Procalcitonin-guided treatment|The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
40952098|NCT01864941|DEVICE|Catheter venography with balloon venoplasty and balloon|
40952099|NCT04136366|DRUG|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
40952100|NCT04136366|OTHER|Standard surgical care procedure|Standard surgical care performed upon completion of pars plana vitrectomy
40952101|NCT06556524|BEHAVIORAL|observation|Behavioral observation and trauma measurement in live mannequin application
41454328|NCT03285438|DRUG|Reduced dose of DOAC|The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
40760635|NCT01652404|BEHAVIORAL|Conventional treatment|The antibiotics duration will be determined by treating physician.
40952102|NCT04239053|DRUG|Bupivacaine|Measuring the plasma concentration level of bupivacaine after applying ESPB
40952103|NCT00074984|BIOLOGICAL|Fabrazyme (agalsidase beta)|1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
40952104|NCT00074984|BIOLOGICAL|Placebo|1 mg/kg placebo intravenously every 2 weeks
40952105|NCT04544085|BEHAVIORAL|noise management|The intervention mainly includes the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.(1) control of noise source:equipment maintenance,alarm management,set quiet time,etc.;(2)control of noise transmission:improvement of architectural design;(3)personal protection of noise receiver:providing patients with earmuffs or earplugs.
40952106|NCT00826046|DRUG|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
40952107|NCT03555435|OTHER|Moving Forward On Your Own|Participants in this group will use the online program on their own for 6 weeks.
40952108|NCT03555435|BEHAVIORAL|Moving Forward with Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
40952109|NCT03555435|BEHAVIORAL|Wait|Participants in this group will wait 6 weeks.
40952110|NCT04676698|BEHAVIORAL|Three Good Things|"The treatment phase will last 3 weeks. However, participants will complete surveys at baseline and up to 6 months. At the end of the trial the study team will also select a limited number of entries from participants to share some of the good things which people listed. These will be edited to ensure writer anonymity and participants will be informed of this plan in the study introduction."
40952111|NCT04676698|BEHAVIORAL|Wait list control arm and then Three Good Things|Surveys will be completed for 3 months prior to treatment and then after treatment.
40952112|NCT02234570|DRUG|Oxfendazole|A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
41289486|NCT04912531|DEVICE|Bedside Olfaction Device|The bedside olfaction device can be clipped on to the side of the patient's bed or beside table. The RC will turn on the night-time olfactory device at 7 pm and will turn off the device at 7 am. When turned on, the device releases scent once every 60 seconds. However, the frequency and intensity of the scent will be adjusted to the patient's preferences. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water).
40952113|NCT02234570|OTHER|Placebo|Normal Saline administered with an oral dosing syringe. Group 1- Group 6
40952114|NCT04212871|OTHER|watch food video 1|A 2 minutes video, with food content. The first study used a ramen mukbang here, the second study used a hotpot mukbang.
40952115|NCT04212871|OTHER|watch food video 2|A 2 minutes video, with food content (different content from video 1). The first study used a donut mukbang here, the second study used a hotpot cooking show here.
41289487|NCT02369510|DRUG|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
41289488|NCT02369510|DRUG|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
41289489|NCT02369510|DRUG|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
41289490|NCT06442241|BIOLOGICAL|LYB005 low dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
41289491|NCT06442241|BIOLOGICAL|LYB005 middle dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
41289492|NCT06442241|BIOLOGICAL|LYB005 high dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
41289493|NCT06442241|BIOLOGICAL|LYB005 low dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
41289494|NCT06442241|BIOLOGICAL|LYB005 middle dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
41289495|NCT06442241|BIOLOGICAL|LYB005 high dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
41289496|NCT06442241|BIOLOGICAL|Placebo|0.9% sodium chloride injection. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
41289497|NCT06442241|BIOLOGICAL|Positive control|AREXVY. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
40952116|NCT04212871|OTHER|watch a non-food content video|a 2 minutes video without food content. The first study used a documentary introducing the forbidden city, the second study used a documentary introducing Cornell University.
40952117|NCT02509481|DRUG|Ivermectin|
40952118|NCT02509481|DRUG|Albendazole|
40952119|NCT03140228|DEVICE|I-Gel|I-gel is the single use supraglottic airway from intersurgical, UK (Intersurgical Ltd, Wokingham, Berkshire, UK) with an anatomically designed mask made of a gel like thermoplastic elastomer to fit over perilaryngeal and hypopharyngeal structures. It is designed to separate the gastrointestinal and respiratory tracts and also allow a gastric tube to be passed into the stomach.
41289498|NCT02675517|DRUG|Spiolto Respimat|Tiotropium bromide + Olodaterol
41289499|NCT02502630|DEVICE|microwave ablation|pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
40952120|NCT03140228|DEVICE|LMA|The AmbuAuraOnce (Ambu A/S, Ballerup, Denmark) is a supraglottic airway device with an inflatable cuff. It is a disposable device as well, but unlike I-gel, it does not feature a gastric channel.
41289500|NCT05026229|DRUG|dasatinib plus consolidation chemotherapy with vincristine and prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
41289501|NCT05026229|DRUG|dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
41289502|NCT05888337|DEVICE|Contoura LASIK with Phorcides planning strategy|Bilateral treatment with topography guided LASIK
41289503|NCT05888337|DEVICE|Contoura LASIK with manifest refraction planning strategy|Bilateral treatment with topography guided LASIK
41289504|NCT02113748|OTHER|Downhill walking training|Walk on a treadmill with a negative inclination.
41289505|NCT02113748|OTHER|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
40952121|NCT05894226|PROCEDURE|laparoscopic ventral mesh rectopexy|patients are treated by laparoscopic ventral mesh rectopexy for anterior rectocele
40952122|NCT06002126|DIAGNOSTIC_TEST|Xpert HPV|The Cepheid Xpert HPV Assay (Xpert HPV) is a qualitative, real-time polymerase chain reaction (PCR) assay for the detection of hrHPV DNA. The assay is formatted in a single-use, Xpert HPV test cartridge and is run on the Cepheid Xpert® System, a multi-analyte, random access, molecular-diagnostic platform ranging in capacity from 1 to 80 test processing modules. Importantly, a single hrHPV DNA test can be completed in one hour, permitting same-day screening and diagnosis (e.g. colposcopy) or treatment (e.g. cryotherapy), reducing the potential for loss to follow-up in lower-resource settings. It uses liquid-based cytologic media and yields five separate results or channels: HPV16, HPV18/45, HPV 31/33/35/52/58, HPV51/59, HPV39/68/56/66 all with a corresponding cycle threshold.
40952123|NCT06002126|DIAGNOSTIC_TEST|S5 DNA methylation classifier|The S5 classifier is a combination of DNA methylation levels of the late regions of the L1 and L2 proteins from HPV16, HPV18, HPV31, and HPV33, as well as DNA methylation of the promotor region of the human tumor suppressor gene, Erythrocyte Membrane Protein Band 4.1 Like 3 (EPB41L3).
40952124|NCT02961673|BIOLOGICAL|HU-014 Inj|Clostridium botulinum type A
40952125|NCT02961673|BIOLOGICAL|Botox Inj|Clostridium botulinum type A
41289506|NCT05414968|DEVICE|Non-pharmacological Heat, Pressure, and Vibration|The innovation central to this approach is in the multifactorial combination of pressure, heat, and vibration stimuli to improve foot sensation. The heat stimuli will be provided with commercially available heating elements. The pressure stimuli will be provided via pneumatic garment. Lastly, the vibrotactile stimuli will be provided with commercially available vibrotactile motors. The non-pharmacological DPN device will be able to safely and consistently control temperature to 100-105°F within 1°F, control pressure to 50 mmHg within 5 mmHg at 0.25 Hz, and provide 5 distinguishable vibrational stimuli to 5 zones on the leg and foot.
41289507|NCT04115397|DRUG|Zoledronic Acid|Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
41289508|NCT04115397|DRUG|Placebo|Placebo
41454329|NCT03285438|DRUG|Full dose of DOAC|The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
41454330|NCT01927016|PROCEDURE|Esophagectomy|Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
41454331|NCT06154993|OTHER|static opening with slider+ Conventional PT|"Patient supine Maintaining neck flexion + contralateral flexion and rotation and applying median nerve slider mobilization while maintaining the neck static in mentioned position.~Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
41454332|NCT06154993|OTHER|dynamic opener with slider + Conventional PT|"Patient supine Neck flexion + contralateral flexion and rotation. And sliding the median nerve along with neck movement from contralateral flexion+rotation to neutal position in repetitive manner, by releasing tension from median nerve when bringing neck in neutral to ease tension from affected side.~Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
41454333|NCT01206751|OTHER|Chest imaging technique and case presentation|
41454334|NCT06089330|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
41289509|NCT03288467|PROCEDURE|Root canal treatment with 5% NaOCl|
41289510|NCT03288467|PROCEDURE|Root canal treatment with 1% NaOCl|
41289511|NCT00520689|DEVICE|Silicone Hydrogel Contact Lens|use of lens over 2 days
41289512|NCT04374994|DRUG|Avanafil 50 MG|Oral phosphodiesterase type 5 inhibitors
41289513|NCT04374994|DRUG|Placebo oral tablet|lactose and maize starch, Egypt
41289514|NCT03247998|DRUG|General Anesthesia|Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
41289515|NCT03247998|DRUG|Conscious Sedation with Remifentanil|Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
41289516|NCT00310245|PROCEDURE|STI (structured Treatment Interruption)|
41289517|NCT06157151|BIOLOGICAL|PRGN-2009 plus Pembrolizumab|Subjects randomized will receive PRGN-2009 (5 x 10\^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.
41289518|NCT06157151|DRUG|Pembrolizumab alone|Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.
41454335|NCT06089330|DRUG|SG001|240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
41454336|NCT06089330|DRUG|Irinotecan|180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).
41454337|NCT06089330|DRUG|Regorafenib (Stivarga)|160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
41454338|NCT01285713|DRUG|5% Dextrose (D5) in Normal Saline (NS)|D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
40952126|NCT04569903|DEVICE|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
40952127|NCT00562471|OTHER|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
41289519|NCT02707094|DEVICE|Biomodulator|The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.
40952128|NCT00562471|OTHER|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
40952129|NCT04470544|DRUG|Camostat Mesilate|Given PO
40952130|NCT04470544|OTHER|Standard of Care|At Investigator discretion
40952131|NCT05689710|DIETARY_SUPPLEMENT|Inositol and alpha-lactalbumin|The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
40952132|NCT01469312|OTHER|modified pasta|50 grams carbohydrate as a single breakfast meal
40952133|NCT05586893|DEVICE|Acupuncture therapy and Electroacupuncture|"We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher."
40952134|NCT05405465|DRUG|Exposure to golimumab|Retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
40952135|NCT03788629|OTHER|Talocrural joint MWM mobilization|There were two groups for this study. In addition to Bobath Concept, talocrural joint mobilization was performed.
40952136|NCT03788629|OTHER|Subtalar joint MWM mobilization|There were two groups for this study. In addition to treatment of control group, subtalar joint mobilization was performed.
40952137|NCT04185948|BEHAVIORAL|Mediterranean diet guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
40952138|NCT04185948|BEHAVIORAL|UK Eatwell guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
40952139|NCT05959733|PROCEDURE|Bridging Reconstruction using BioBrace|Patients in the reconstruction group will undergo maximal repair with interposition bridging using BioBrace. This technique will follow a previously described technique by the principal investigator with differences allocated to the graft, it's preparation and insertion. The bursa will be debrided, and rotator cuff edged will be shaved down to stable tissue. BioBrace is bioinductive scaffold composed of highly porous type I collagen and bio-resorbable poly (L-lactide) (PLLA) microfilaments, and will be used as the graft in this trial.
40952140|NCT05959733|PROCEDURE|Repair|Patients in the maximal repair group will undergo a SCOI-row rotator cuff repair with adequate tension as described previously, with recreation of the rotator cable. Briefly, the SCOI-row rotator cuff repair uses one triple loaded suture anchor for each 1.2cm of torn tendon. This technique has been completed in a previous randomized controlled trial.
40952141|NCT04325646|OTHER|Human Biological samples|Blood samples for serological tests
40952142|NCT04325646|OTHER|Human Biological samples|Blood samples, saliva, nasopharyngeal swab for serological tests
41454339|NCT01285713|DRUG|Normal Saline (NS)|NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS
40952143|NCT05788120|OTHER|Follow up by phone call|Centralized review of ECGs by the Pitié-Salpêtrière rhythmology department and collection of vital status at 12 months (if information not available, telephone call to the patient)
40952144|NCT03062007|DRUG|BI-CON-02|BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
40952145|NCT02024555|DRUG|Levofloxacin|
41454340|NCT05064007|BEHAVIORAL|A: 40 Hz music|The participant will listen to the 40 Hz music playlist one hour each day, 5 days a week for 4 weeks
41454341|NCT05064007|BEHAVIORAL|B: 40 Hz sound|The participant will listen to the 40 Hz sound playlist one hour each day, 5 days a week for 4 weeks
41454342|NCT05064007|BEHAVIORAL|C: Preferred music|The participant will listen to the preferred music playlist one hour each day, 5 days a week for 4 weeks
41454343|NCT03005366|DRUG|Vernakalant|Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.
41454344|NCT03005366|DRUG|Flecainide|2 mg /kg (max 150 mg) intravenously over 10 minutes.
41454345|NCT04518553|DRUG|active comarator using antiviral drug of nucleoside analogues|using antiviral drug of nucleoside analogues without additional active interference to control Hepatitis B virus.
41454346|NCT04518553|DEVICE|HA+purification|Based on antiviral drug of nucleoside analogues, plasma purification is added to control hepatitis B virus every three months. After three months, plasma purification will continue if hepatitis B virus DNA titer is still higher than cut-off normal value. plasma purification process lasts 2.5-3 hours each session.
41454347|NCT03453554|OTHER|Digital Notebook app|Training in use of Digital Memory Notebook app
41454348|NCT03453554|OTHER|Smart Home Prompting|Smart-home sensor based activity-aware prompting to support digital memory notebook app use
41454349|NCT04968951|DRUG|Metronidazole|Antibiotic treatment - 250 mg every 6 hrs for 5 days
40952146|NCT02024555|DRUG|Ethambutol|
40952147|NCT02024555|DRUG|Azithromycin|
40952148|NCT02024555|DRUG|Rifampin|
40952149|NCT02024555|DRUG|Placebo|This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
40952152|NCT00169793|OTHER|evaluation of kidney stone risk after bariatric surgery|24 hour urine collections done pre and post surgery
40952153|NCT00169793|OTHER|Evaluate risk of kidney stones after bariatric surgery|24 hour urine collections are done before and after surgery
41134530|NCT05674981|DIETARY_SUPPLEMENT|Probiotic group|Two-strain probiotic supplement includes Lactobacillus reuteri ADR-1 (alive) and Lactobacillus rhamnosus GM-020 ( alive).
41134531|NCT05674981|OTHER|Placebo group|Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
41134532|NCT01003743|DEVICE|endolumenal tissue approximation|
41134533|NCT05785325|DRUG|RC48-ADC plus Bevacizumab|Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.
41134534|NCT05168397|OTHER|RV4857A|RV4857A formula CD2110 is a sunscreen product
41134535|NCT05680857|OTHER|Placebo|Product doesn't have active ingredients i.e. marine collagen peptide and Coenzyme Q10.
41134536|NCT05680857|OTHER|Product containing marine collagen peptide and Coenzyme Q10.|Product containing marine collagen peptide and Coenzyme Q10.
41134537|NCT00078156|BEHAVIORAL|Behavior Therapy|
41134538|NCT04275167|DEVICE|Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope|Either the Tethered Capsule Endomicroscope or the Transnasal Endomicroscope will be deployed in the subject. Once the capsule is swallowed /TNE device is inserted, the device will naturally be moved to the duodenum via peristalsis. Once in the duodenum, imaging will be performed. For subjects receiving the TNE device, brushing samples will be collected through the introduction tube.
41134539|NCT02206867|BIOLOGICAL|LBAL|Anti-inflammatory agents
41134540|NCT02206867|BIOLOGICAL|Humira|Anti-inflammatory agents
41134541|NCT03946956|BEHAVIORAL|Prebooking|Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
41134542|NCT03946956|BEHAVIORAL|Pictured invitation|Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
41134543|NCT00372476|DRUG|Imatinib and Vinorelbine|
41134544|NCT04913103|DRUG|Polatuzumab vedotin|treatment by a study drug polatuzumab-vedotin, i.v.
41134545|NCT04913103|DRUG|Bendamustine Hydrochloride|treatment by a study drug bendamustin i.v.
41134546|NCT04913103|DRUG|Rituximab|treatment by a study drug rituximab, i.v.
41134547|NCT03352713|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
41134548|NCT03393390|DIAGNOSTIC_TEST|Clinical Assessment Visit|Subjects will meet with a clinician who will determine if they meet diagnostic criteria for an externalizing disorder.
41134549|NCT03393390|OTHER|fMRI scan|Subjects will undergo an fMRI scan where images will be taken for observational purposes only, not as a means of diagnosis.
41134550|NCT04696016|PROCEDURE|Skin conductance guided antinociception|The value of skin conductance guides the titration of sufentanil
41289520|NCT02707094|OTHER|Usual Care (Medication + Exercise)|The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
41289521|NCT03046238|DRUG|Dexmedetomidine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
41289522|NCT03046238|DRUG|placebo|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
41289523|NCT01919372|DEVICE|Telemedic assistance with a technological system|
41289524|NCT01919372|OTHER|Standard care|
41289525|NCT05969080|BEHAVIORAL|Treatment for Self-Injurious Behaviors|Treatment for Self-Injurious Behaviors (T-SIB) incorporates evidence-based approaches to replace NSSI with behaviors that improve psychosocial functioning.
41289526|NCT05969080|OTHER|Treatment As Usual|Participants randomized to the TAU condition will be provided with referrals to both Durham VA and local community mental health resources and offered a consult for Durham VA mental health services.
41289527|NCT03100331|OTHER|Neuropsychological testing|Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
41289528|NCT05982977|OTHER|Acupuncture|The patient was placed in a supine position, selected Lianquan, Fengchi, and acupoints.
41289529|NCT05982977|BEHAVIORAL|Conventional rehabilitation|swallowing training included breathing training, masticatory muscle training, oral movement training and feeding training.
41134551|NCT04696016|PROCEDURE|Standard care antinociception|The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
41134552|NCT00082966|DRUG|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|Given IV
41289530|NCT01738139|DRUG|Imatinib Mesylate|Given PO
41289531|NCT01738139|BIOLOGICAL|Ipilimumab|Given IV
41289532|NCT04697719|DRUG|Aspirin 81mg|81mg oral capsule
41289533|NCT04697719|DRUG|Aspirin 325mg|325mg oral capsule
41289534|NCT01483846|DRUG|AV-101|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
41289535|NCT01483846|DRUG|Placebo|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
41289536|NCT02278185|DRUG|Enzalutamide|Given PO
41289537|NCT02278185|DRUG|leuprolide acetate|Given SC or IM
41289538|NCT02278185|DRUG|goserelin acetate|Given SC or IM
41289539|NCT02278185|DRUG|histrelin acetate|Given SC or IM
41289540|NCT02278185|DRUG|triptorelin|Given SC or IM
41289541|NCT02278185|DRUG|degarelix|Given SC or IM
41289542|NCT02102230|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This is a group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains.
41454350|NCT04968951|DRUG|Placebo|Placebo treatment
41454351|NCT04968951|DRUG|Vancomycin|Antibiotic treatment - 125 mg every 6 hrs for 5 days
41454352|NCT04968951|BIOLOGICAL|Fecal Microbiota Transplantation|Encapsulated biologically active human fecal material (donor stool) is provided in capsule form. The fecal material is homogenized with sterile saline, then pelleted and re-suspended in sterile saline/40% glycerol. Participants will receive 15 FMT capsules per day for 3 consecutive days. Capsule are to be swallowed under direct supervision.
41454353|NCT04303624|OTHER|Health sciences survey|Large scale demographic survey evaluating attitudes of population towards organ donation for the self vs. family
41454354|NCT01739647|DRUG|AZD3293|Oral solution
41134553|NCT04221659|DEVICE|Transcranial Direct Current Stimulation|Participants will receive 16 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, on alternate days (3 times a week). The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². The cathode, reference electrode (5x7cm), will be positioned in the occipital region. These parameters are within the safe limits established in previous human studies.
41454355|NCT01739647|DRUG|Placebo|Oral solution
41134554|NCT06342700|DRUG|Rilzabrutinib crystalline form|Pharmaceutical form:Film coated tablet Route of administration:Oral
40952154|NCT03822182|DRUG|liposomal bupivicaine|"The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline"
40952155|NCT03822182|DRUG|Dexamethasone|steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
40952156|NCT01599195|DEVICE|AudioDoc|AudioDoc will be used to identify the carotid and femoral bruit
40952157|NCT03691935|DRUG|Ropivacaine|Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control
40952158|NCT03691935|DRUG|Normal saline|Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
40952159|NCT03567577|DRUG|Solnatide 25 mg powder for reconstitution for solution for inhalation|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
40952160|NCT03567577|DRUG|0.9% Saline Solution|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
41307808|NCT04941352|BEHAVIORAL|6-session Interpersonal Relations Theory-based Motivational Interviews and 3 month follow-up.|6-session Interpersonal Relations Theory-based Motivational Interviews were applied to the individuals in the study group. All sessions were conducted face-to-face in the form of individual interviews. Each interview lasted an average of 30-40 minutes. With this intervention, it was aimed to increase treatment cooperation and motivation in individuals with schizophrenia, to increase insight, to improve adherence to treatment, daily living skills and social functionality.Study data were collected using a personal information form, the Functional Remission of General Schizophrenia Scale (FROGS) and the Scale for Assessing the Three Components of Insight (SAI). The data were analyzed on the basis of pre-intervention, post-intervention and 3 months after the intervention.
40952161|NCT03812120|PROCEDURE|Dural closure with L-PRF|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair
40952162|NCT03812120|PROCEDURE|Dural closure with classical fibrin sealants|Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair
40952163|NCT01928173|BEHAVIORAL|Abbreviated cognitive behavioral therapy|see arm description
40952164|NCT01928173|BEHAVIORAL|Sleep education/sleep hygiene|see arm description
40952165|NCT03490708|DRUG|Tranilast|Subjects will be treated with tranilast
40952166|NCT01902823|BEHAVIORAL|Services from a Nurse Navigator|Services from a Nurse Navigator
40952167|NCT03477136|DIAGNOSTIC_TEST|ELISA to evaluate serum and seminal vitamin D level|Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen
40952168|NCT04069962|BEHAVIORAL|CGA coordination by geriatric team including intensive patient coaching and follow-up|In the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching. This intervention aims to support patient empowerment by improving self-efficacy and supporting self-management of existing age-related problems before systemic therapy or occurring during systemic therapy, and includes an individual counselling session at start of systemic therapy to discuss the recommendations with the patient and to determine their priorities.
40952169|NCT06253975|BIOLOGICAL|adipose tissue derived extracellular vesicles (AT-EVs)|Extracellular vesicles from patient's adipose tissue together with HA
40952170|NCT06253975|DRUG|Hyaluronic acid|Use HA only as a placebo
41134555|NCT06342700|DRUG|Rilzabrutinib amorphous form|Pharmaceutical form:Film coated tablet Route of administration:Oral
41134556|NCT00705159|DRUG|loteprednol etabonate and tobramycin|Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
40952173|NCT05763693|DRUG|Azithromycin at Baseline|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
40952174|NCT05763693|DRUG|Azithromycin at Day 21|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
40952175|NCT05763693|OTHER|Placebo at Baseline|this group will be randomized to receive Placebo at baseline
40952176|NCT05763693|OTHER|Placebo at Day 21|This group will be randomized to receive Placebo at the day 21 visit
40952177|NCT04954287|BIOLOGICAL|CVXGA1 low dose|see arm/group description
40952178|NCT04954287|BIOLOGICAL|CVXGA1 high dose|see arm/group description
40760636|NCT03615131|DIAGNOSTIC_TEST|MRI-TRUS fusion prostate biopsy|First an advanced MRI prostate image is obtained, annotated and recorded by the Radiology of the Kantonsspital Winterthur. Next, using special fusion technology, the recorded MRI image is fused with a live transrectal ultrasound by the Urologist who performs a MRI/TRUS fusion biopsy.
40952179|NCT05642767|DIAGNOSTIC_TEST|culture on cetrimide agar|Samples will be inoculated on cetrimide agar using the plating out technique.
40952180|NCT05642767|DIAGNOSTIC_TEST|Staining with Gram stain|colonies on cetrimide agar will be spread on glass slide and stained by gram stain
40952181|NCT05642767|DIAGNOSTIC_TEST|Antibiotic sensitivity testing|Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI
40760637|NCT00000709|DRUG|Zidovudine|
40952182|NCT05642767|DIAGNOSTIC_TEST|Molecular detection to efflux genes and some virulence genes|Molecular detection to efflux genes and some virulence genes by conventional PCR
40952183|NCT00282100|DRUG|Gefetinib (Iressa)|
40952184|NCT00001067|DRUG|Lamivudine|
40952185|NCT00001067|DRUG|Stavudine|
40952186|NCT00001067|DRUG|Zidovudine|
41134557|NCT00705159|DRUG|loteprednol etabonate|Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
41134558|NCT00705159|DRUG|Tobramycin|Topical ocular administration of Tobramycin QID for 14 days.
41289543|NCT02102230|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)|This is a mobile-app-augmented, group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains. The mobile-app augmentation substitutes a smartphone-based sleep diary with time-stamping of records to mitigate the common postponement of diary recording and consequent loss of validity. The app also records the sleep prescription, making it, along with links to web-based psychoeducational materials, easily accessible to users. The app also provides plots of bed times, wake times, and sleep efficiency over time, with the goal of promoting adherence.
41289544|NCT02102230|BEHAVIORAL|Desensitization Treatment for Insomnia|"This is a group-delivered version of the sham sleep improvement treatment developed by Edinger which purports to desensitize the patient to the various aspects of the sleep experience which are presented as distressing."
41289545|NCT05721261|DEVICE|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.
41289546|NCT05721261|DEVICE|Sham Temporary Peripheral Nerve Stimulation System|Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.
41289547|NCT00994565|BEHAVIORAL|Activity monitoring and distance counseling|The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
40952187|NCT02028143|DEVICE|Biosense Webster irrigated tip catheter|The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
40952188|NCT02028143|DEVICE|Biosense Webster irrigated tip catheter|Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
40952189|NCT02028143|PROCEDURE|Pulmonary vein isolation|
40952190|NCT02028143|PROCEDURE|ICE catheter placed through one of two existing 8F sheaths|
40952191|NCT00657358|DRUG|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
40952192|NCT04961307|DRUG|Trastuzumab|30 female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase
40952193|NCT01426438|DRUG|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
40952194|NCT01426438|DRUG|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
40952195|NCT01426438|DRUG|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
40952196|NCT03985059|OTHER|Transcranial Doppler|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet."
40952197|NCT00167648|DRUG|Leuprolide or goserelin|Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
40952198|NCT00167648|DRUG|Transdermal estradiol|Estradiol patches, six at 0.1 mg each, changed every 3-4 days
40952199|NCT00834223|DEVICE|Aquashunt|A shunt which is implanted into the suprachoroidal space.
41289548|NCT03690518|OTHER|Cardiac rehabilitation|Educational/Counseling/Training : Rehabilitation, , cardiovascular rehabilitation in congenital heart disease
41289549|NCT05227846|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
41289550|NCT00340327|DRUG|IMA-638|
41289551|NCT03557372|RADIATION|Mathematical Model-Adapted Radiation Fractionation Schedule|"* Re-irradiation with 35 Gy delivered over 2 weeks, based upon reference dosing of 35 Gy in 10 Fractions over 2 weeks~* Radiation therapy is delivered on Monday-Friday during standard clinic hours in our department. Each treatment may take 20-40 minutes.~* Treatment will be once daily for the first 7 days of treatment and then three-times daily for the last three days of treatment."
40952200|NCT05942560|BEHAVIORAL|Cognitive behavioural therapy-based intervention|"A specifically designed CBT-based intervention consisting of 8 weekly sessions with group format.~Each group will be comprised of 4-10 participants, and each session will last 1.5 hours.~The content of the weekly sessions will be based on Beck's cognitive theory and the cognitive therapy in groups guidelines.~The framework of every session will follow a pre-determined structure."
40952201|NCT05942560|BEHAVIORAL|Educational group|The educational sessions are consisting of 8 weekly sessions with a group format. These sessions will focus on cancer-related information and care knowledge which will be delivered in daily routine care.
41289552|NCT05992779|OTHER|Measuring the vocal audiometry of patients.|Measuring vocal audiometry at 6 months, 1 year and annually until the last date of follow-up
41289553|NCT05992779|OTHER|Measuring data loging|Measuring data loging at 6 months, 1 year and then annually until last date of follow-up
41289554|NCT00400387|DRUG|Fragmin P Forte (dalteparin sodium)|subcutaneous injection, once daily supported by multivitamine supplement and close monitoring
40952202|NCT01050283|PROCEDURE|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
41454356|NCT01662011|DEVICE|mode of neurally adjusted ventilatory assist|patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
40952203|NCT02179866|DRUG|RO5285119|Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) \[14C\]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
40952204|NCT03531983|PROCEDURE|fixation of tochentric fractures by gamma nail|• Thirty patients with recent traumatic extracapsular proximal femoral fractures were treated using a short gamma nail of third-generation assembly
40952205|NCT00121095|DRUG|Samarium Sm-153 lexidronam + Docetaxel|1 mCi/kg Sm153 + 75 mg/m2 docetaxel
40952206|NCT02210650|PROCEDURE|Symptomatic stone removal|Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy
40760638|NCT01063569|DRUG|Solu-Cortef (hydrocortisone)|Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
40952207|NCT02210650|PROCEDURE|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy
40952208|NCT01321060|PROCEDURE|Aspiration|
40952209|NCT01321060|PROCEDURE|Catheter drainage|
40952210|NCT01321060|DRUG|Conservative treatment|Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
40952211|NCT02683720|DIETARY_SUPPLEMENT|ONS|randomized clinical trial involving different ONS strategies
40952212|NCT05773443|DEVICE|Digital biomarkers|Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor
40952213|NCT04166500|PROCEDURE|Hysteroscopy|outpatient hysteroscopy after the first menstrual cycle in the follicular phase (9-12 days).
40952214|NCT05511194|OTHER|Enhanced Recovery After Surgery therapeutic protocol|Feeding and early ambulation, double short IV antibiotic regimen.
40952215|NCT05511194|OTHER|Conventional management|Delayed feeding and ambulation, triple short IV antibiotic regimen.
40952216|NCT04966832|DRUG|XW10508|XW10508 capsules or tablets
40952217|NCT04966832|OTHER|Placebo|Placebo capsules or tablets
40952218|NCT00590135|DRUG|atorvastatin (Lipitor)|atorvastatin 40 mg by mouth once daily
40952219|NCT04667481|OTHER|Aerobic Exercise Intervention|Participate in aerobic exercise intervention
40952220|NCT04667481|OTHER|Resistance Exercise Intervention|Participate in resistance exercise intervention
40952221|NCT04667481|OTHER|Exercise Intervention: Digital copies and outline of sessions|Receive digital copy of AE and RE sessions and an outline of sessions
40952222|NCT04667481|OTHER|Questionnaire Administration|Ancillary studies
40952223|NCT04667481|OTHER|Quality-of-Life Assessment|Ancillary studies
40760639|NCT01063569|DRUG|Cortef (hydrocortisone)|Oral treatment 3 times a day. Weight adjusted doses.
40760640|NCT00124358|DRUG|Buprenorphine|
40952224|NCT04746248|OTHER|Outpatient labor induction|The participants stay at home during til labor induction process and are admitted to hospital at the onset of labor or if a complication occur. Outpatient consultations once a day.
40952225|NCT04746248|OTHER|Inpatient labor induction|The participants are induced following standard inpatient care
40952226|NCT05934578|OTHER|Exercise training|Aerobic and light muscle resistance exercise by online cardiovascular rehabilitation
40952227|NCT06557018|DRUG|liposomal bupivacaine|liposomal bupivacaine group
40952228|NCT06557018|DRUG|traditional peri-articular injection|traditional peri-articular injection group
40952229|NCT00423722|DRUG|Saline|1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
40952230|NCT00423722|DRUG|Saline|100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
40952231|NCT02836392|BEHAVIORAL|Questionnaire|
41289555|NCT00400387|DIETARY_SUPPLEMENT|Multivitamin supplement|general pregnancy support by multivitamin supplementation and close monitoring
41289556|NCT06227923|DEVICE|PRO-HOME intervention|Patients are transferred to the apartment inside the hospital setting and are evaluated and assessed also using technological devices
41289557|NCT05215210|OTHER|Bitter-gourd|12-week intervention of 3.6 grams of dried bitter-gourd supplements
41289558|NCT05215210|OTHER|Cucumber|12-week intervention of 3.6 grams of cucumber supplements
40952232|NCT05353179|DRUG|Meperizumab injection|Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
41289559|NCT04311905|DEVICE|Diode laser|Diode laser activated irrigation
41289560|NCT04311905|OTHER|Placebo|mock Laser activated irrigation
41289561|NCT04475094|DRUG|Rubidium-82|Consented subjects will undergo a rest/regadenoson stress myocardial perfusion PET study.
40952233|NCT05353179|DRUG|NUCALA®|NUCALA® is a humanized monoclonal antibody of IgG1 injection
40952234|NCT05291325|DRUG|3L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
40952235|NCT05291325|DRUG|3L PEG|Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
40952236|NCT05291325|DRUG|2L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
40952237|NCT05148065|DEVICE|BIS|Bispectral index monitoring
40952238|NCT05148065|DEVICE|PSi|Patient state index monitoring
40952239|NCT02923596|PROCEDURE|History of prior Surgery|History of prior Surgery will be reviewed
40952240|NCT02923596|RADIATION|History of Radiation Therapy|History of prior radiation therapy will be reviewed
40952241|NCT04894695|DIAGNOSTIC_TEST|biomarkers detection in different groups|Biomarkers of urine exosomes in different groups were identified by sequencing technology，then biomarkers were validated using urine samples of different groups
40952242|NCT04771312|BEHAVIORAL|Mobile app information-only intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants can respond to daily questions in a diary. Participants can also use a locator tool to find where PrEP can be found near them.
40952243|NCT04771312|BEHAVIORAL|Mobile app social support network intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants are shown an online chatting tool where they can discuss with each other and answer daily questions. Participants can also use a locator tool to find where PrEP can be found near them.
40952244|NCT03082482|BEHAVIORAL|Self-help materials|Self-help smoking cessation materials
40952245|NCT03082482|DRUG|nicotine patch|Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke \<10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
40952246|NCT03082482|BEHAVIORAL|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
40952247|NCT03082482|OTHER|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
40952248|NCT04098614|BEHAVIORAL|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
40952249|NCT04920344|PROCEDURE|Transoral Surgery|Patients will undergo transoral surgery
40952250|NCT04920344|RADIATION|External Beam Radiation Therapy|Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
41289562|NCT04475094|BEHAVIORAL|Seattle Angina Questionnaire-7|Consented subjects will complete a SAQ-7.
41289563|NCT04475094|BEHAVIORAL|Rose Dyspnea Scale|Consented subjects will complete a RDS.
41289564|NCT01379586|DRUG|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
41289565|NCT01379586|DRUG|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
41289566|NCT03172650|DIAGNOSTIC_TEST|glomerular filtration rate|collection of blood sample 5 milliliter for calculation of glomerular filtration rate
41289567|NCT02165852|PROCEDURE|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
40952251|NCT04920344|DRUG|Cisplatin|Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.
41289568|NCT02165852|PROCEDURE|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
41289569|NCT05294042|OTHER|Navigation|The intervention in this study is a model of navigation for families seeking services at the two mental health agencies collaborating on this study. Navigators (PP and CM) will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
41289570|NCT01917825|DRUG|MDT-15|
41289571|NCT03009695|DEVICE|High frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically high-frequency rTMS (18 Hz) enhances cortical excitability.
41289572|NCT03009695|DEVICE|Low frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically low-frequency rTMS (1 Hz) inhibits cortical excitability.
41289573|NCT03009695|DEVICE|Sham|Sham stimulation will be performed by an H-sham-coil. The H-sham-coil is designed to mimic the auditory artifacts and the scalp sensation evoked by the real coil, without stimulating the brain itself. As in the other groups, in each patient the rMT will be determined before each repetitive dTMS session. The sham stimulation will be performed either at high frequency (50% of subjects) or at low-frequency (50% of subjects), according to the previously described methodologies. All obese people in this group will be submitted at the sight of food preferred (cue).
40952252|NCT04920344|PROCEDURE|Incisional Tumor Biopsy|Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
40952253|NCT04920344|OTHER|Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment|Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
40952254|NCT04920344|OTHER|MD Anderson Dysphagia Index|MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.
41289574|NCT05841849|DRUG|Aprepitant|oral aprepitant capsules 125mg for D1 before chemotherapy, 80mg for D2 and D3
40952255|NCT04920344|OTHER|University of Washington Quality of Life Questionnaire|University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
41289575|NCT05841849|DRUG|Palonosetron|oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;
41289576|NCT05841849|DRUG|Fosaprepitant|intravenous fosaprepitant 150mg for D1 before chemotherapy
40952256|NCT04920344|OTHER|Euro-QOL 5 dimension scale questionnaire|A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
40952257|NCT04920344|DIAGNOSTIC_TEST|Modified barium swallow (MBS) evaluation with aspiration-penetration scale|"The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms.~The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration."
40952258|NCT04057508|OTHER|Modulation of muscle sympathetic nerve activity|Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
40952259|NCT04627246|BIOLOGICAL|Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)|"SOC: Subgroup1: intravenous mFOLFIRINOX for twelve 14-day cycles. Subgroup2: intravenous gemcitabine twice, on days 1 and 8, and oral capecitabine for 14 days of 21-day cycles, for eight cycles.~PEP-DC vaccine: At least 5 subcutaneous vaccinations starting on cycle 8 (subgroup1) or cycle 5 (subgroup2) of chemotherapy: Subgroup1: every 4 weeks, on day 3 of every second 14-day cycle, and then every 4 weeks starting from the first nivolumab administration. Subgroup2: Every 3 weeks, on day 9 of each 21-day cycle, and then every 4 weeks starting from the second nivolumab administration.~Nivolumab: intravenous, starting after the last chemotherapy cycle. Administered as a flat dose of 240mg every 2 weeks during the vaccination period until the last vaccine dose or at least for 8 weeks after the end of last chemotherapy cycle if vaccination stops earlier. Then, as a maintenance therapy at 480 mg every 4 weeks until appearance of new lesions or unacceptable toxicity for a maximum of 2 years."
41289577|NCT00482001|DRUG|donepezil|
40952260|NCT04326673|OTHER|Testosterone Measurements in healthy volunteers after fasting|salivary testosterone measurements taken in morning and evening and a single blood test for testosterone taken
40952261|NCT04326673|OTHER|Testosterone Measurements after glucose loading|salivary tstosterone and blood testosterone measurements
41289578|NCT00482001|DRUG|Placebo (cornstarch)|
41289579|NCT04277702|DRUG|Montelukast 10mg|Oral administration of 10mg of montelukast daily for 12 months
41289580|NCT04277702|PROCEDURE|Endovascular treatment|Percutaneous transluminal angioplasty combined with bare-metal stenting of lower limbs arteries
41289581|NCT04277702|DRUG|Standard anti-platelet treatment|Standard antithrombotic treatment for patients undergoing endovascular procedures
41289582|NCT04814823|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-11)
41454357|NCT01662011|DEVICE|Mode of pressure support ventilation|Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
41454358|NCT01216254|DEVICE|classic v high-frequency electrocoagulation|During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
40760641|NCT00124358|BEHAVIORAL|Integrated HIV care and office-based opioid dependence treatment|
41289583|NCT06274359|BEHAVIORAL|Digital storytelling|Caregivers will receive text messages with embedded digital stories and messaging to encourage influenza vaccination.
41289584|NCT01571271|PROCEDURE|Laser Lithotripsy|Laser Lithotripsy
41289585|NCT01571271|PROCEDURE|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
41307809|NCT05838833|DRUG|INV-001|Patient will be assigned to one of three arms.
41307810|NCT02199301|PROCEDURE|Transplantation Conditioning for BMT|Transplantation Conditioning for BMT (POD#-7\~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6\~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5\~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschränkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)
41307811|NCT05213468|DEVICE|PainDrainerTM|Self management digital tool for chronic pain
41307812|NCT02260245|BEHAVIORAL|Team training using the TeamSTEPPS model|Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
40952262|NCT04394975|COMBINATION_PRODUCT|Biological : Toripalimab Drug: Axitinib|Biological: Toripalimab, Intravenous infusion Drug: Axitinib, oral tablet
40952263|NCT04394975|DRUG|sunitinib|Drug: Sunitinib, oral capsule
40952264|NCT03663946|OTHER|Non-Interventional|Non-Interventional
40952265|NCT02437812|DRUG|Metformin|Metformin with standard chemotherapy
41289586|NCT00390923|DRUG|Selegiline + nicotine replacement therapy|Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
41289587|NCT00390923|DRUG|placebo + nicotine replacement therapy|Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
40952266|NCT02437812|DRUG|Paclitaxel|Standard chemotherapy
40952267|NCT02437812|DRUG|Carboplatin|Standard chemotherapy
40952268|NCT06558045|DRUG|Rivaroxaban 20 mg film-coated tablet|One tablet of the test drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
40952269|NCT06558045|DRUG|Xarelto 20 mg film-coated tablet|One tablet of the reference drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
40952270|NCT04743076|PROCEDURE|Endovascular treatment|Endovascular treatment
41289588|NCT02292381|OTHER|Isometric exercise|
41289589|NCT02291380|DRUG|Botulinum Toxin Type A for Injection|In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.
40952271|NCT04743076|OTHER|Standard medical treatment|Standard medical treatment
40952272|NCT02840721|DRUG|PF-06480605|PF-06480605 500 mg IV Q2W x 7 Doses
40952273|NCT06454019|BEHAVIORAL|Phone Outreach|Phone outreach to individuals losing Medicaid and auto-enrolled into Covered California plan to nudge them to act
40952274|NCT06454019|BEHAVIORAL|Standard Notice|Standard notification letter without phone outreach to individuals losing Medicaid and auto-enrolled into Covered California plan to nudge them to act
40952275|NCT06201364|PROCEDURE|The external oblique intercostal block|chest wall will be systematically scanned. Initially the probe will be placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle will be identified at the level ribs 6 and 7 in line with the xiphoid process to confirm correct identification of the external oblique muscle, the probe will be moved in the caudad direction following the external oblique muscle. At the subcostal level, the ultrasound probe will be rotated 90° to see the convergence with the internal oblique and transversus abdominus muscles. The probe will be then moved back to the initial identification point for the external oblique muscle. The EOI plane will be identified deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles. Local anesthetic agent will be 20 ml volume (10 ml bupivacaine, 10 ml saline) will be injected under ultrasound guidance and this will be done bilaterally.
40952276|NCT06201364|PROCEDURE|Paravertebral block|involve injection of local anaesthetic in a space immediately lateral to where the spinal nerves emerge from the intervertebral foramina. This technique is being used increasingly for not only intra-operative and post-operative analgesia but also as a sole anaesthetic technique for carrying out various procedures.
41289590|NCT02291380|DRUG|Placebo|In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
41289591|NCT00306891|DRUG|Cediranib|45 mg oral dose
40952277|NCT04066647|DRUG|Dexamethasone 4mg|1 mg IV dexamethasone will be pushed and miRNA levels will be checked at baseline just before injection and then at 15, 30, 45, and 60 minutes after injection.
41289592|NCT00306891|DRUG|Cediranib 30 - 90 mg|oral tablet dose escalation
41289593|NCT01745055|DRUG|CP-690,550 (tofacitinib)|CP-690,550 30 mg q12h for 5 days
40952278|NCT04267822|DRUG|RV521 oral tablet|Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
40952279|NCT04267822|DRUG|Placebo oral tablet|Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
40952280|NCT05954702|PROCEDURE|Supercharged TRAM esophagectomy|Esophagectomy, immediately followed by supercharged esophagogastroplasty. Use the transverse rectus abdominis myocutaneous (TRAM) flap transfers to surgically create a new anastomosis in the left gastroepiploic vessels.
40952281|NCT05954702|PROCEDURE|Conventional Esophagectomy|Esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty.
40952282|NCT05401968|BEHAVIORAL|Osteoporosis patient education|During osteoporosis patient education the participants get knowledge about e.g. osteoporosis, medication, and diet, and they participate in physical exercises. Though, differences between municipalities exist. The participants meet in groups and face-to-face.
40952283|NCT06057077|DRUG|Semaglutide weekly injection|semaglutide is Glp1 AGONIST WHICH IS NEW CHALLENGE IN DIABETES DISEASE TREATMENT EITHER TYPE 2 AND IS APPROVED BY FDA FOE children aged above 12 years at obesity
40952284|NCT05412875|OTHER|Best Practice|Given usual care
40952285|NCT05412875|DRUG|Nicotine Replacement|Given JUUL
41289594|NCT01745055|DRUG|Methotrexate (MTX)|individual dose of methotrexate (stably dosed)
41289595|NCT03670862|OTHER|CT|Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
40952286|NCT05412875|OTHER|Quality-of-Life Assessment|Ancillary studies
41289596|NCT02234115|DRUG|Leuprolide Mesylate|Subcutaneous injection of 50mg Leuprolide Mesylate
41289597|NCT05346757|DIAGNOSTIC_TEST|miRFec test|The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression
41289598|NCT03029962|BEHAVIORAL|Girl2Girl|"Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted."
40952287|NCT05412875|OTHER|Questionnaire Administration|Ancillary studies
40952288|NCT05968456|OTHER|Data collection|Observational study in patients undergoing thoracic, cardiac and vascular surgery.
41289599|NCT06260150|DEVICE|Intermittent Pneumatic Compression Devices|During use, the pressure is gradually reduced from large to small, and pressure is applied in steps, starting from the calf and moving up to the thigh. Every 30 minutes, the patient's skin color of the lower extremities is observed for any abnormalities, and the blood supply status of the distal ends of both lower limbs (palpation of the dorsalis pedis artery pulse) is noted. If any special conditions occur, the procedure must be immediately stopped.
40952289|NCT00778544|DRUG|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
41289600|NCT04685473|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) Capsule
41289601|NCT05776537|DEVICE|Fibreoptic bronchoscopy|different endoscopies used for confirmation of diagnosis
41289602|NCT04155385|OTHER|Measurement|The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.
41289603|NCT04155385|OTHER|Feedback|The feedback system is a web-based dashboard that displays current and historical results in each of the outcome and goal domains that is measured; it is available to addiction treatment clinicians who are working with patients enrolled in the study.
41289604|NCT05331989|OTHER|patient group/ healthy group|Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index
41289605|NCT01791439|OTHER|lidocaine|Application of lidocaine to the glossopharyngeal nerve.
41289606|NCT01791439|OTHER|placebo|
41289607|NCT04879446|PROCEDURE|Concentrated growth factor(CGF)|Concentrated growth factor(CGF) liquid applied to the implant cavity and implant surface.
41289608|NCT04879446|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity and implant surface.
41289609|NCT04879446|PROCEDURE|Control side of concentrated growth factor study group|Traditional implant methods applied.
41289610|NCT04879446|PROCEDURE|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied.
41289611|NCT03148171|OTHER|WERK Supportive Contact|Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
40952290|NCT01903174|DEVICE|AeroForm Breast Tissue Expander|Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
40952291|NCT00808626|DRUG|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
40952292|NCT01790425|PROCEDURE|to infuse water into colon to open the lumen for water infusion colonoscopy|
40952293|NCT01790425|PROCEDURE|Air colonoscopy|
40952294|NCT01632917|DRUG|ATX-101 - U.S.|US ATX-101, 10 mg/mL, one dosing session in the submental area
40952295|NCT01632917|DRUG|ATX-101 - EU|EU ATX-101, 10 mg/mL, one dosing session in the submental area
41289612|NCT05488301|OTHER|chest physiotherapy|"chest physiotherapy session including:~* nasal ventilation~* decrease of respiratory rate without increasement of Tidal volume~* abdomino-diaphragmatic ventilation"
41289613|NCT06246552|BIOLOGICAL|JTM201|"JTM201 20U in 0.5mL~: JTM201 will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"
41454359|NCT05591105|DRUG|Control Group|At the end of surgery, they will continue receiving analgesia according the schedule and, addicionally, lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minute as part of postoperative analgesia.
41454360|NCT05591105|DRUG|Placebo|At the end of surgery, they will continue receiving analgesia according the schedule.
41454361|NCT05723796|PROCEDURE|nasal endoscopy|nasal endoscopy and mucosal biopsy
40952296|NCT05489757|DEVICE|SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software|Perfusion assessment with SPY Q-ICG system
40952297|NCT00719108|BIOLOGICAL|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
40952298|NCT00719108|BIOLOGICAL|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
40952299|NCT02029170|PROCEDURE|Early weightbearing|Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast
40952300|NCT02029170|PROCEDURE|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
40952301|NCT06061354|DRUG|Teriparatide|mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® or 1g of Bio-Oss® will be mixed with 0.72ml of saline solution.
41454362|NCT02674711|BEHAVIORAL|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
41134559|NCT00705159|DRUG|Vehicle of Zylet|Topical ocular administration of the vehicle of Zylet QID for 14 days.
40760642|NCT01123187|PROCEDURE|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
40760643|NCT03462121|DRUG|RPh201|RPh201 is a well-defined extract from a botanical source
40760644|NCT03462121|OTHER|Placebo|Inactive placebo consisting of the therapeutic vehicle
40760645|NCT00000845|BIOLOGICAL|P3C541b Lipopeptide|
41134560|NCT02061124|DRUG|Sevelamer 1600 mg TID for 7 days|
41134561|NCT02061124|DRUG|Placebo 1600 mg TID for 7 days|
41134562|NCT02025504|DEVICE|ColoWrap|ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
41134563|NCT03963466|DRUG|tranexamic acid|Oral tranexamic acid group(menstrual period\>2days) 250mg bid（exclude menstrual period ）
41454363|NCT00147134|PROCEDURE|open colectomy|Procedure/Surgery: open colectomy
41454364|NCT00147134|PROCEDURE|laparoscopic colectomy|Procedure/Surgery: laparoscopic colectomy
40952302|NCT06061354|PROCEDURE|Maxillary Sinus Augmentation|Local anesthesia will be performed, mucoperiosteal flap will be raised to access the anterior wall of the maxillary sinus. Access to the maxillary sinus will be done through osteotomy, using a piezosurgery under irrigation with saline solution. Subsequently, the Schneider's membrane will be carefully lifted and, according to the randomization process, the graft material (Bio-Oss® mixed with saline solution or Bio-Oss® mixed with Forteo®) will be delivered for placement on the sinus floor maxilla below Schneider's membrane.Next, the access window to the maxillary sinus and Schneider's membrane will be protected. The mucoperiosteal flap will be repositioned and closed.
40952303|NCT06061354|PROCEDURE|Dental Implant Installation|Local anesthesia will be performed a mucoperiosteal flap will be raised in the area for implant placement and a bone core 10 mm high and 2 mm in diameter will be removed with a 2 mm trephine bur. The bone biopsied through this nucleus is part of the region where the implant will be installed, and the height of the sample depends on the surgical planning carried out previously (3-month radiographic control). The sequence of drills to place the implant will continue, installation of the implant itself and, finally, verification of the insertion torque and measurement of the resonance frequency in the already installed implant. The mucoperiosteal flap must be repositioned and sutured.
40952304|NCT06061354|COMBINATION_PRODUCT|Bone graft|One arm:mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® In other arm: 1g of Bio-Oss® will be mixed with 0.72ml of saline solution.
40952305|NCT02233114|OTHER|Yogic exercises|Yogic exercises (YE) - 2 hours per week, 1h in each session
40952306|NCT02233114|OTHER|Physiotherapy|Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
40952307|NCT06557096|DRUG|Osimertinib 80 MG|Osimertinib is taken orally at a dose of 80mg daily for a 28-day treatment period, followed by a sequential treatment of osimertinib 80mg daily taken orally for another 28 days.
40952308|NCT06557096|DRUG|Bevacizumab|Sequential combination therapy with bevacizumab administered intravenously at a dosage of 7.5mg/kg of body weight on the first day of each cycle, with medication given once every 3 weeks, for a continuous treatment duration of 21 days.
40952309|NCT01453725|BIOLOGICAL|Golimumab|Golimumab 50 mg SC injection every 4 weeks
40952310|NCT01453725|BIOLOGICAL|Placebo|Placebo SC injection every 4 weeks
40952311|NCT01484275|DRUG|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
40952312|NCT01484275|DRUG|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
40952313|NCT00066365|BIOLOGICAL|sargramostim|given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.
40952314|NCT00066365|PROCEDURE|conventional surgery|thoracotomy
40952315|NCT06294782|RADIATION|STereotactic Arhythmia Radioablation (STAR)|STereotactic Arhythmia Radioablation (STAR)
40952316|NCT05923606|DEVICE|Active tACS|Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
41454365|NCT04260035|DRUG|Vasoactive Intestinal Polypeptide (VIP)|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
40760646|NCT00500331|DRUG|GSK189075|Experimental Drug
40760647|NCT00500331|DRUG|pioglitazone|Active Control
40952317|NCT05923606|DEVICE|Placebo tACS|Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
40952318|NCT02694809|DRUG|Conjugated Estrogens/Bazedoxifene|Given PO
40952319|NCT02694809|OTHER|Laboratory Biomarker Analysis|Correlative studies
40952320|NCT02694809|OTHER|Pharmacological Study|Correlative studies
40760648|NCT00500331|OTHER|Placebo|Placebo Comparator
40760649|NCT03436732|DRUG|LMB-100|administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles
40760650|NCT03436732|DRUG|SEL-110|administered on day 1 of each cycle for up to 4 cycles
41289614|NCT06246552|BIOLOGICAL|Placebo|"Placebo 20U in 0.5mL~: Placebo will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"
41289615|NCT00872898|DRUG|Memantine - Extended Release (ER)|Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.
40952321|NCT02694809|OTHER|Placebo|Given PO
40952322|NCT02694809|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
40952323|NCT02694809|OTHER|Questionnaire Administration|Ancillary studies
40952324|NCT05968131|OTHER|Conventional Physical Therapy|"The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions."
41289616|NCT00872898|DRUG|Placebo|Placebo capsules, once daily, oral administration.
41289617|NCT03162718|BEHAVIORAL|Exercise|single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
41307813|NCT02834546|BIOLOGICAL|Sorafenib plasma concentration 4 weeks after treatment initiation|Sorafenib plasma concentrations will be assessed at 4, 8 and 16 weeks by high performance liquid chromatography. The pharmacology Unit of Bordeaux university hospital (Pr Molimard) is a French Center of reference for the dosage of TKI in the plasma
41307814|NCT00000944|DRUG|Indinavir sulfate|
41307815|NCT00000944|DRUG|Lamivudine|
41307816|NCT00000944|DRUG|Zidovudine|
41454366|NCT04260035|DRUG|Sterile saline|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
41134564|NCT03963466|RADIATION|1064-nm Q-Switched fractional laser|Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
41134565|NCT03963466|RADIATION|1064-nm Q-Switched laser|Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
41134566|NCT03701906|DIETARY_SUPPLEMENT|Lactobacillus PS11603 & Bifidobacterium PS10402|Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L.salivarius PS11603 and 1\*10E8 CFU of B.longum PS10402.
41134567|NCT03701906|DIETARY_SUPPLEMENT|Placebo|8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
41134568|NCT03267537|BEHAVIORAL|Telemedicine CBT-I|Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits
41134569|NCT03267537|BEHAVIORAL|Conventional office-based CBT-I|Conventional office-based CBT-I
41134570|NCT03363945|BIOLOGICAL|MDR-101|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
41134571|NCT03233152|DRUG|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|"Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec."
41134572|NCT03233152|DRUG|Nivolumab (OpdivoTM, 40 mg/4mL solution)|First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
41289618|NCT03228251|OTHER|Stroke team simulation training|"The participating centers identify 3-4 senior staff of different professional backgrounds (e.g. senior neurologist, neurointerventionalist, head nurse) who will design a stroke team algorithm tailored to the local circumstances of the stroke center. The centers will be invited to a joint train-the-trainer seminar at the sponsor's institution where they present their algorithm to the participants of all seven stroke centers for discussion to invite suggestions for streamlining and improvement. The teams will be introduced to the concept of simulation-based stroke team training. After the seminar, the principal investigator and the stroke team trainer will visit all centers for one on-site stroke team training and provide teaching materials. Afterwards, each center will be invited to schedule two additional stroke team trainings with the stroke team trainer that will be led by e.g. the senior neurologist from the stroke unit with use of a simulation manikin."
41454367|NCT05651698|DEVICE|HeartMan Intervention group|The system uses wrist-band sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
41454368|NCT03202251|OTHER|It's is a cohort|It is a prospective, observational, cohort study
40760651|NCT01821014|OTHER|Telemedicine|Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
40760652|NCT01821014|OTHER|In-person physician interaction|Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
41289619|NCT05452720|DEVICE|Surgical Right Ventricular Outflow Tract Reconstruction|Surgical replacement of the Pulmonary Valve or a previously implanted prosthetic with the investigational device (MASA Valve)
40952325|NCT05968131|OTHER|Conventional Physical Therapy with Proprioceptive Training Exercises|"Interventional group will receive strengthening intervention as well as proprioceptive training for 32 sessions. ROM and Strengthening exercise will be performed same as in control group.~Exercises For Proprioceptive Training: Intervention group will practice an additional 24 minutes of proprioceptive training (two minutes rest prior to performing this training). A circuit with different floor texture composed of 6 stations of exercises to stimulate the sole of foot where participant had to improve gait by stepping with alternate feet marker placed on ground and progression will be done by modify the speed and direction. Material used to build the circuit are in following order: 10 cm thick foam, a wood box with beans, a 2 cm thick mat with density lower than foam, a wooden box filled with sand, balance board to train the lateral balance reactions, a wooden box filled with cotton. Duration of this training is 24 minutes; patient will spend 4 minutes on each station."
41454369|NCT05532631|PROCEDURE|Percutaneous coronary intervention|The studied intervention will be percutaneous coronary angioplasty with drug eluting stent implantation. Percutaneous coronary intervention may be performed during one single procedure or during staged procedures. The decision will be left at the investigator choice. PCI will be performed using drug eluting stent exclusively. The techniques for bifurcation lesions and chronic total occlusion angioplasty will be left at the operator choice. The choice of the drug eluting stent used will be left at the operator's choice. Anti-platelet therapy will be given to all patients randomized to PCI. The choice of the anti-thrombotic regiment and its duration will be left at the investigator choice (after assessment of initial presentation, bleeding and ischemic risks) but will have to comply with the European Society of Cardiology guidelines.
41454370|NCT05532631|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines
41454371|NCT03531060|DRUG|IRL790|IRL790 capsule 10 mg
41454372|NCT03531060|DRUG|Placebo|Placebo capsule
40760653|NCT06466655|OTHER|MitoTempol|Two intradermal microdialysis probes will be inserted into the dermal layer of the ventral forearm and perfused with either lactated Ringer's solution (control) or MitoTempol (0.5 mM) to scavenge mitochondrial-derived superoxide.
40952326|NCT01315184|BEHAVIORAL|Recovery Line Support System|"Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.~The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback."
40952327|NCT05270512|DEVICE|Dermal Cooling System|Controlled localized cooling may be applied to lesions using the Dermal Cooling System.
40952328|NCT04744831|DRUG|DS-8201a 5.4 mg/kg Q3W|DS-8201a for injection will be administered intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W)
40952329|NCT04744831|DRUG|DS-8201a 6.4 mg/kg Q3W|DS-8201a for injection will be administered intravenously (IV) at a dose of 6.4 mg/kg every 3 weeks (Q3W)
40952330|NCT00353665|DRUG|Memantine (Ebixa)|10 mg bid
40952331|NCT00353665|DRUG|riluzole|riluzole 50 mg bid
41454373|NCT02095522|DRUG|Colchicine|Colchicine 1mg per day for one month
40952332|NCT00353665|DRUG|Placebo|
40952333|NCT01786655|DRUG|Neosaxitoxin in saline|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
40952334|NCT01786655|DRUG|NeoSTX + bupivacaine 0.2%|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
40952335|NCT01786655|DRUG|NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml|Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
40952336|NCT01786655|OTHER|Saline placebo|Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
41454374|NCT02095522|DRUG|Placebo|Placebo
41454375|NCT05886127|DEVICE|A novel hemostatic agent (Purastat®)|A novel hemostatic agent (Purasta®) will be applied on cutted ampulla of Vater
41454376|NCT04762069|DRUG|Berubicin|Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
40952337|NCT06026709|BEHAVIORAL|EmoEase|"The online interventionEmoEase integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program."
41454377|NCT04762069|DRUG|Lomustine|"Lomustine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an alkylating agent."
40760654|NCT02698787|DEVICE|Experimental sound coding strategy (FAST)|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
40760655|NCT02698787|DEVICE|Commercially available ACE sound coding strategy|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
40760656|NCT00385112|PROCEDURE|Echocardiogram|2D echocardiogram with Doppler flow
40760657|NCT00553969|DRUG|carvedilol phosphate|Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
41454378|NCT02344849|DRUG|mesenchymal stem cell|Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
41454379|NCT00453258|OTHER|Eye Examination|Subjects receiving eye examination
40760658|NCT00553969|DRUG|lisinopril|tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
40760659|NCT00553969|DRUG|carvedilol phosphate and lisinopril|carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
40760660|NCT00553969|DRUG|placebo and placebo|capsule once daily for 9 months; dosage unknown
40952338|NCT04022434|DIETARY_SUPPLEMENT|Placedo|Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
40952339|NCT04022434|DIETARY_SUPPLEMENT|Alanine|Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
40952340|NCT05231304|PROCEDURE|Total Talus Replacement (TTR)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement device.
40760661|NCT05722002|DRUG|NSAID|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~* Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~* Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)"
40760662|NCT05722002|DRUG|Opioid|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~* Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~* Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses"
40952341|NCT05231304|PROCEDURE|Total Ankle Total Talus Replacement (TATTR)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device.
40952342|NCT05231304|PROCEDURE|Total Ankle Total Talus Replacement + Subtalar Fusion (TATTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device with concurrent subtalar fusion.
40952343|NCT05231304|PROCEDURE|Total Talus Replacement + Subtalar Fusion (TTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement (TTR) device with concurrent subtalar fusion.
41289620|NCT03260738|DEVICE|Rehabilitation program with Poppy robot|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks. Among those 3 hours, patients receive 30 minutes of physical exercises dedicated to mobility of the spine supervised by robot Poppy.
41289621|NCT03260738|OTHER|Usual rehabilitation program|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks.
41289622|NCT05266638|OTHER|Data collection (radiological parameters, outcome information) from electronic patient files in hospital data system|Collection of medical data and medical images (MRI, radiographs) of the lumbar spine and pelvis of patients having received TLIF with degenerative spinal diseases from the years 2015-2020 and statistical analysis of the coded data.
41289623|NCT06273865|DIAGNOSTIC_TEST|Several assays|Standard blood draw by venipuncture is performed in all study participants to collect blood samples in four 2.7 mL citrated blood tubes. Tube one is a dummy tube and is discarded. Tube two is used for the FVIII activity and thrombin generation assay on the EnzySystem. Tube three is used to perform conventional FVIII activity and thrombin generation assays. Tube four is used for duplicate measurements of the conventional assays and measurement of prothrombin F1+2 antigen levels, ADAMTS13 activity, FVIII antigen, VWF (von Willebrand Factor) antigen and von Willebrand ristocetin cofactor activity levels.
41289624|NCT04678167|DIAGNOSTIC_TEST|Caloric test|Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
41454380|NCT02832960|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
40952344|NCT01030536|DRUG|CAT-8015 20 mcg/kg|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
40952345|NCT01030536|DRUG|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
40952346|NCT01030536|DRUG|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
40952347|NCT01030536|DRUG|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
40760663|NCT05722002|DRUG|Acetaminophen|Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
40760664|NCT00814983|PROCEDURE|Naive T-cell Depleted Stem Cell Transplant|"The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant."
40952348|NCT01030536|DRUG|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
40952349|NCT05383521|DRUG|Tinidazole 56|Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
40952350|NCT05383521|DRUG|Tinidazole 42|Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
40952351|NCT05613361|DRUG|Colistin|added for infection with multi drug resistant bacteria
40952352|NCT05613361|DRUG|Curcumin|added for the possible nephroprotective effect
40952353|NCT03827265|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
41289625|NCT04678167|DIAGNOSTIC_TEST|Measurement of the speed of Nystagmus|A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
40760665|NCT00814983|PROCEDURE|Stem Cell Transplant No Manipulation|These patients will be transplanted with unmanipulated peripheral blood stem cells.
40760666|NCT00814983|DEVICE|Isolex device from Baxter|
40760667|NCT05369975|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
40760668|NCT05369975|OTHER|Normal Transplantation Routine|Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
40760669|NCT01291160|DEVICE|Epiflo|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
40760670|NCT01291160|OTHER|Moist Wound Therapy|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
40760671|NCT05559047|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
40760672|NCT05559047|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
40760673|NCT06497829|DIETARY_SUPPLEMENT|geranylgeraniol|GG Pure (Extendlife Natural Products) containing GG gold®30 Annatto Extract, 500 mg capsule, use for 3 months, once daily
40760674|NCT00087672|DRUG|CC-5013|10 mg orally (2 capsules) daily
40760675|NCT06357715|OTHER|"slumpposition"|"neurodynamic sliding mobilisation in the slump position"
40760676|NCT06357715|OTHER|"no slump position"|placebo
40952354|NCT04188587|DRUG|177 Lu-PSMA-I&T|All patients were intravenous injected with single dose 2.0-8.0 GBq. The time of the next treatment cycle is determined according to the patient's condition, and it is recommended to treat once every 8-12 weeks.
41289626|NCT04678167|DIAGNOSTIC_TEST|Angle of deviation at Fukuda|The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
41289627|NCT04678167|DIAGNOSTIC_TEST|Alexander's degree of nystagmus|"there are 3 degrees:~* Degree I: nystagmus that exists only when the eyes are turned to the right.~* Degree II: also exists when the eyes are to the right or to the front.~* Degree Ill: exists when the eyes are on the right, front, or left"
41289628|NCT04678167|OTHER|EHTEV questionnaire|Handicap Scale for Balance Disorders and Vertigo
41289629|NCT04678167|OTHER|EEV questionnaire|European Vertigo Assessment Questionnaire
40952355|NCT05836181|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|Effects of Eye Movement Desensitization and Reprocessing on Anxiety, Depression, Quality of Life, Blood Pressure and Heart Rate Variability in Patients with Hypertension.
41289630|NCT04678167|OTHER|anxiety VAS|visual analog scale of anxiety
41289631|NCT02714946|DEVICE|Percutaneous Laser Ablation|Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
40952356|NCT06180746|BEHAVIORAL|Knowledge mobilization to facilitate the structuring of health mediation|"The ECEMSo intervention involves knowledge mobilization to facilitate the structuring of health mediation throughout French territory, and the development of a co-designed effective action plan to facilitate cancer screening uptake by people living in informal housing.~The action plan will, consider territorial specificities at the regional level. The ECEMSo project team will organize a seminar and three workshops. The aim of the seminar and workshops is to mobilize knowledge to facilitate i) the structuring of health mediation in the regions, and ii) the development of an action plan with health mediators and other stakeholders to foster organized cancer screenings uptake by underserved people. This action plan must match with the needs of people living in informal housing, and must be coordinated, suitable and feasible to implement, in terms of knowledge about people living in informal housing specificities and specific local collaborations"
40952357|NCT02912078|OTHER|Pocket-warming|Pocket-warming of epidural medication
40952358|NCT02912078|OTHER|Standard of Care Labor Epidural|Labor epidural medication administered per standard of care; no pocket warming.
41289632|NCT02714946|DEVICE|Percutaneous Radiofrequency Ablation|Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
40952359|NCT03558087|DRUG|Nivolumab|Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
41289633|NCT05437029|DRUG|Q-Griffithsin 3.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of low dose Q GRFT intranasal spray DP
41289634|NCT05437029|DRUG|Q-Griffithsin 6.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of high dose Q GRFT intranasal spray DP
41289635|NCT04661319|PROCEDURE|video editing training|"1. The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~2. Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~3. Select a random experimental group.~4. For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~5. Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation."
41289636|NCT06304272|PROCEDURE|Irrigating Traumatic Wound with Drinking Water|Irrigating Traumatic Wound with Drinking Water and Normal Saline
41289637|NCT01056107|DRUG|ROSE-010|The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
41289638|NCT01056107|DRUG|Placebo|Placebo subcutaneous injection daily
41289639|NCT04911101|DEVICE|Excision with 7G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
40952360|NCT03558087|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four 21-day cycles.
40952361|NCT03558087|DRUG|Cisplatin|Cisplatin 70mg\^m2 will be administered on Day 1 for four 21-day cycles.
41289640|NCT04911101|DEVICE|Excision with 10G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
40952362|NCT03189420|PROCEDURE|Tumor resection|The tumors will be resected in routine therapeutic surgeries
41134573|NCT03762278|DIETARY_SUPPLEMENT|Leucine|Participants will ingest 15g of leucine supplementation/day during the immobilisation period. Leucine supplementation will be administered in powdered form (Infinit Nutrition, Canada) and participants will be required to consume 5g of leucine mixed with 250-300 ml of water during each meal. Leucine is a dietary supplement according to the US FDA. This supplementation protocol has been demonstrated in humans (Murphy et al., 2016, AJCN) with no reported side effects. The quantity of leucine supplementation falls well within the safe limits outlined by Rasmussen et al. (2016). Infinit Nutrition Leucine is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Infinit Nutrition Leucine is not a medicinal product.
41289641|NCT04661618|DEVICE|Gym Tonic programme and Gym equipment|12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
41289642|NCT01188018|BEHAVIORAL|Brief Advice (BA)|Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.
41289643|NCT01188018|BEHAVIORAL|Motivational Interviewing (MI)|Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).
41289644|NCT01188018|BEHAVIORAL|Health Education (HE)|Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
40952363|NCT05837585|DEVICE|Air quality sensors|The air quality sensors detect air quality, including temperature, humidity, carbon dioxide, respirable suspended particulates (PM10 or PM2.5), total volatile organic compounds (TVOC) and formaldehyde (HCHO), which may influence health of residences. The managers of the service unit will decide the changes of activities to improve air quality and long-term measures based on the detected air quality indexes. The care staff will follow these decisions.
41289645|NCT04476771|BEHAVIORAL|Feliz-Mente (third generation psychotherapy)|The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
41289646|NCT04291014|DEVICE|SunRay Light Boxes|SunRay light boxes will be used to administer the light therapy.
41289647|NCT00029796|DRUG|soy isoflavones|
41289648|NCT02144220|OTHER|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
41289649|NCT01571882|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
41289650|NCT01571882|OTHER|2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
41289651|NCT01571882|OTHER|3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)|3- Intervention with active control product (1,6 g of plant sterol/ day)
41289652|NCT05506371|DRUG|Az+SRP|Azithromycin as an adjunct to scaling and root planning in the treatment of periodontitis
40952364|NCT01386008|DEVICE|senfilcon A contact lens|senofilcon A spherical contact lens worn in a daily wear modality
41289653|NCT05506371|DRUG|SRP|Scaling and root planning (SRP) treatment of periodontitis
41289654|NCT05506371|DRUG|No interventions|Diagnostocs to confirm the healthy state of the gingiva
41289655|NCT00129077|PROCEDURE|plastic wrap over eye & lubrication applied q6 hrs|
41289656|NCT02844608|OTHER|Quality of Life Questionnaires|Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
40952365|NCT01386008|DEVICE|investigational enfilcon A|investigational enfilcon A, worn daily wear modality
40952366|NCT00630370|DRUG|Placebo|2 Placebo tablets, TID, orally, 58 days
40952367|NCT00630370|DRUG|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
40952368|NCT00630370|DRUG|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
40952369|NCT00630370|DRUG|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
40952370|NCT01554683|DRUG|Low/High/Placebo Dose Keppra (Levetiracetam)|Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
40952371|NCT05038943|DEVICE|Paragonix SherpaPak Cardiac Transport System|Transportation of cardiac allografts in a device maintaining constant optimal temperature to minimize freezing tissue injury
40952372|NCT01882348|BEHAVIORAL|CEASE Intervention|The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)-including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
40952373|NCT01723657|DRUG|Ara-C|"* Intermediate dose during induction phase to remission.~* High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20."
40952374|NCT01723657|OTHER|Autologous peripheral blood stem cell transplantation.|"* In patients with favorable cytogenetics with a Leukocyte index above 20.~* Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor."
40952375|NCT01723657|OTHER|Allogeneic matched related or unrelated donor transplant.|-Patients without favorable/intermediate characteristics.
40952376|NCT01723657|DRUG|G-CSF|"* Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~* Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L."
41454381|NCT02832960|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
41454382|NCT00003223|DRUG|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
40952377|NCT01723657|OTHER|CD34+ selection.|-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.
41454383|NCT01932905|DEVICE|deep rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
40952378|NCT01723657|OTHER|Mylotarg purging before autologous PBSC transplantation|Patients without favorable/intermediate characteristics and without matched related donor.
40952379|NCT05444621|RADIATION|Ultrasound and doppler|All patients are then assessed by transthoracic echocardiography to measure Left ventricle and Right ventricle function and to assess LVOT-VTI and SV. Doppler Ultrasound assessment of carotid arteries to assess corrected flow time (FTc), velocity time integral (VTI) and respirophasic variation in carotid artery blood flow peak velocity (ΔVpeak). The patient will be assessed pre- and post- passive leg raising (PLR) and after fluid challenge of 30 mL/Kg of IV crystalloid
40952380|NCT01173354|DIETARY_SUPPLEMENT|Free balanced amino acid mixture|7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.
40952381|NCT01173354|DIETARY_SUPPLEMENT|Free essential amino acid mixture|7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
40952382|NCT00889408|BIOLOGICAL|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
40952383|NCT05084014|OTHER|Deep Stripping|The deep longitudinal stripping can be applied on adhesions and knots in muscles. The lengthening stokes are parallel to muscle fiber and applied in an oblique direction with the help of the thumbs of hands/ elbow/ knuckles
40952384|NCT05084014|OTHER|Kneading|kneading lifts the muscle in circular movements with the help of the hands. It lifted, rolled, and squeezed muscle
40952385|NCT02001103|DRUG|Memantine|"Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.~The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3."
40952386|NCT02001103|DRUG|Placebo|Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
40952387|NCT04710602|PROCEDURE|Minimally invasive surgical fixation of unstable rib cage|Minimally invasive and muscle sparing surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes).
41134574|NCT03762278|DIETARY_SUPPLEMENT|Placebo|"Participants will ingest 15g of placebo supplementation/day during the immobilisation period. Placebo supplementation will be administered in powdered form and participants will be required to consume 5g of placebo supplementation mixed with 250-300 ml of water during each meal (3x/day).~Placebo supplementation will contain 5g of non-essential amino acids (Infinit Nutrition, Canada) and will be calorically matched to the leucine supplementation.This supplementation protocol has been demonstrated previously in humans, with no reported side effects (Murphy et al., 2016, AJCN)."
41134575|NCT02502019|DEVICE|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
41289657|NCT03984760|DRUG|Ferric Citrate|Take the capsules with meals or immediately after meals.
41454384|NCT01841060|PROCEDURE|Percutaneous radiofrequency ablation (RFA)|Computed tomography (CT) was used to treat tumors under general anesthesia. Thoracic epidural anesthesia was administered in case of contraindication to general anesthesia mostly due to poor respiratory function. All patients were treated with the same multitine electrodes (LeVeen; Boston Scientific, Nattick. MA) measuring 3, 3.5, or 4 cm in diameter and at least 10 mm larger than the diameter of the target tumor. Multiple overlapping ablations were performed, when needed, in different parts of the tumor in order to cover the entire volume.
41454385|NCT04880876|DRUG|25mg Eluxadoline|Oral Tablets
41454386|NCT04880876|DRUG|100mg Eluxadoline|Oral Tablets
40952388|NCT04710602|PROCEDURE|Large incision surgical fixation of unstable rib cage.|Surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes). Large non muscle sparing incision with simultaneous thoracotomy.
40952389|NCT05101785|DRUG|Lidocain hydrochloride 2 % with epinephrine|Local anesthesia infilteration in children
40952390|NCT05101785|DRUG|Articaine chloride 4% with epinephrine|Articaine chloride 4% with epinephrine
40952391|NCT03148314|DRUG|vaginal misoprostol|(800µgm.x 2 doses 3 hours).
40952392|NCT03148314|DRUG|buccal/sublingual misoprostol|200 µgm.x4 hrs.x 6 doses
40952393|NCT04783818|RADIATION|Adjuvant Radiotherapy|PMRT
40952394|NCT05905900|COMBINATION_PRODUCT|Emergent IV Dye Preparation|Diphenhydramine 50 mg IV once, famotidine 20 mg IV once, and dexamethasone 10 mg IV once
40952395|NCT06139965|OTHER|Validity and Reliability|Assessment study
40952396|NCT05815641|DIETARY_SUPPLEMENT|food (breakfast)|The breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds
40952397|NCT00419276|PROCEDURE|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
40952398|NCT00062946|DRUG|(18F)fallypride|
40952399|NCT01754870|DRUG|Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance|
40952400|NCT06441669|DRUG|Letermovir|Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
40952401|NCT01138839|DRUG|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
41134576|NCT03645161|DIAGNOSTIC_TEST|rat and mouse skin test|Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients
40952402|NCT01138839|DRUG|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery
40952403|NCT06049043|OTHER|Intervention to Help Orient Men to Excel (IN-HOME)|A multi module online training
40952404|NCT06049043|OTHER|"AARP's English Care at Home resource webpage"|Caregiver information from the American Association of Retired Persons
40952405|NCT01330680|DIETARY_SUPPLEMENT|Coffee|40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
40952406|NCT01330680|DIETARY_SUPPLEMENT|Decaffeinated coffee|40 mL dose of decaffeinated coffee
40952407|NCT01999153|DRUG|20 mL topically used during alginate dressing NAROPEINE|20 mL topically used during alginate dressing
40952408|NCT01999153|DRUG|20 mL topically used during alginate dressing NaCl|20 mL topically used during alginate dressing
40952409|NCT03334591|DRUG|Apatinib|Apatinib 500mg with Docetaxel 60mg/m2
40952410|NCT01966601|DRUG|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
41134577|NCT05532553|DEVICE|Carotid Doppler U/S|Measurement of carotid intima media thickness by carotid doppler ultrasound
41134578|NCT01629420|DRUG|KLH-2109|
40952411|NCT01966601|DRUG|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
40952412|NCT01966601|DRUG|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
41134579|NCT01629420|DRUG|KLH-2109|
41134580|NCT01918176|DRUG|Palbociclib alone|Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
41289658|NCT03984760|DRUG|Sevelamer Carbonate|Take the tablets with meals.
40952413|NCT01966601|DRUG|Placebo|Placebo continuous intravenous infusion
40952414|NCT06142708|DRUG|Dual trigger (human chorionic gonadotropin plus GnRH-agonist)|Human chorionic gonadotropin will be added to GnRH-agonist as a dual trigger in participants previously having had a suboptimal response to GnRH-agonist trigger only
40952415|NCT06142708|DRUG|GnRH-agonist only trigger|GnRH-agonist only will be used for final maturation
40952416|NCT05888454|OTHER|Integrative Group Program|The integrative group program consists of 6 in-person sessions directed by a health coach and occurring every other week, and 6 asynchronous educative sessions during a period of 12 weeks.
40952417|NCT05888454|OTHER|Conventional treatment for T2DM|Conventional medical treatment for T2DM
40952418|NCT00390065|DRUG|Nitric Oxide|Early low dose (5ppm) NO inhalation Placebo
40952419|NCT03835871|DRUG|Placebo|Intervention: Drug: placebo
40952420|NCT03835871|DRUG|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg HFA per day
40952421|NCT03835871|DRUG|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg HFA per day
40952422|NCT03835871|DRUG|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg HFA per day
40952423|NCT04108234|DRUG|HR071603|HR071603 monotherapy ,nasal spray
40952424|NCT04108234|DRUG|placebo|placebo,nasal spray
40952425|NCT04087265|DIAGNOSTIC_TEST|Transabdominal ultrasound|Transabdominal ultrasound will be performed 30 minutes before colonoscopy
40952426|NCT04765215|BIOLOGICAL|CoronoVAC|SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
40952427|NCT00643331|BEHAVIORAL|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
41289659|NCT05018910|OTHER|Skin to Skin|During routine Skin-to-skin sessions, the heart rate variability of the infant will be measured.
41289660|NCT00354549|DRUG|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
40952428|NCT06025825|DRUG|Articaine Hydrochloride + Epinephrine|"Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction."
40952429|NCT06025825|DRUG|Lidocaine Hydrochloride + Epinephrine|Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group
40952430|NCT00961649|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
40952431|NCT00961649|DRUG|Brinzolamide ophthalmic suspension, 1%|
41134581|NCT01918176|DRUG|Palbociclib + Rabeprazole|Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
41134582|NCT03900585|BEHAVIORAL|Interval walking|Interval walking administered by an app on the patient's telephone. Interval walking for 150 minutes/week for 10 weeks.
41134583|NCT02446275|OTHER|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression. The patient's head was passively moved into contralateral rotation and the patient was asked to relax completely. Sustained pressure was then applied to the sternocleidomastoid muscle until the pain threshold was reached. During the application of pressure, pain decreases so the pressure was gradually increased over a duration of 1 minute. The pressure was then reduced progressively.
41134584|NCT02446275|OTHER|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid. Subsequently stretching was performed, whereby the therapist supported the patient's head and performed passive contralateral inclination and ipsilateral rotation of the head. The therapist placed one hand over the patients shoulder while the other hand performed the stretching and simultaneously controlled the position of the head to achieve suitable stretching
41134585|NCT03142867|OTHER|non-applicable|non-applicable
41134586|NCT01945372|OTHER|EEG NeuroFeedback|
41134587|NCT04093609|GENETIC|XIST gene deletion|detection of XIST gene deletion by fluorescence in situ hybridization
41134588|NCT01603108|DRUG|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
41134589|NCT01603108|DRUG|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
41134590|NCT00236847|DRUG|topiramate|
41134591|NCT05277285|DRUG|Sodium Thiosulfate 25% Solution for Injection|The drug will be administered via continuous infusion after being diluted to a concentration 12.5 gr/100ml
41134592|NCT03908164|BIOLOGICAL|Pertussis containing vaccine|Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
41454387|NCT03493633|DEVICE|EzyGain|"Each patient performs a minimum of 3 sessions per week with the investigator / APA investigator, for 4 weeks, each walk for a few minutes (\<60 min).~Evaluation of the spontaneous physical activity of the patient by actimetry for seven days QAPPA (questionnaire of physical activity for elderly person) a week and a month after the training phase of four weeks"
40952432|NCT00961649|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
40952433|NCT00961649|OTHER|Vehicle|Inactive ingredients used as placebo
40952434|NCT04403360|PROCEDURE|ESPB|Ultrasound guided performance of ESPB at T12 level after the induction of anesthesia but before the start of the surgery
40952435|NCT04403360|PROCEDURE|Local infiltration by the surgeon|Local infiltration of anesthetics at surgical site after skin incision
41134593|NCT03683576|DRUG|GB001|film-coated oral tablet
41134594|NCT03683576|DRUG|Placebo|film-coated oral tablet
41307817|NCT04978467|DEVICE|Exoskeleton|Participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
40952436|NCT02994134|BEHAVIORAL|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
41134595|NCT02759575|DRUG|Pembrolizumab|200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
41134596|NCT02759575|RADIATION|Radiation Therapy|70 Gy in 35 fractions over 7 weeks
41454388|NCT00015691|DRUG|Metformin hydrochloride|
41454389|NCT00015691|DRUG|Rosiglitazone maleate|
41454390|NCT00004216|BIOLOGICAL|salmonella VNP20009|
41454391|NCT00004216|DRUG|cefixime|
41454392|NCT00004216|DRUG|ceftriaxone sodium|
41454393|NCT00004216|DRUG|ciprofloxacin|
41134597|NCT02759575|DRUG|Cisplatin|100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
41134598|NCT01630304|BEHAVIORAL|WelTel SMS service|"Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician."
41454394|NCT00004216|DRUG|trimethoprim-sulfamethoxazole|
41454395|NCT02955901|OTHER|3 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
41454396|NCT02955901|OTHER|1 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
41134599|NCT04818632|DRUG|AZD9833|Part A: AZD9833 monotherapy dose escalation.
41134600|NCT04818632|DRUG|AZD9833|Part B: AZD9833 monotherapy dose expansion
41134601|NCT04818632|DRUG|AZD9833 with palbociclib|Part B: AZD9833 with palbociclib dose expansion
41134602|NCT04818632|DRUG|AZD9833 with everolimus|Part B: AZD9833 with everolimus dose expansion
41134603|NCT05361356|RADIATION|Spectral CT scanning|Volunteer accept spectral CT scanning
41134604|NCT05655000|PROCEDURE|Neonatal thymus transplantation|The donor's neonatal thymus vessels will be dissected right after the routinary partial thymectomy. These vessels will be anastomosed into the recipient's penetrating vessels within the radial forearm by using a supermicrosurgical technique. The graft will be explanted at day 14-21 after the procedure.
41289661|NCT00354549|DRUG|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
40760677|NCT06455631|PROCEDURE|Facilitated Tucking, Oral Breast Milk , Kangaroo Care|Before data collection, the researcher will inform families of newborns meeting the sample criteria about the study and obtain written consent from participating parents. Newborn and parent information will be recorded. Procedures will occur between 08:00 and 16:00, with one researcher, two nurses, and a preterm newborn present during tape removal. Tape removal will be done by the same nurse. Physiological and behavioral responses will be recorded before, during, and after tape removal. Breast milk will be orally administered during tape removal, with the amount adjusted based on gestational age. Measurements will be taken at specified time points, including heart rate, respiratory rate, oxygen saturation, and PIPP-R score. These procedures will also apply to the control group. PIPP-R scores will be recorded by two evaluators based on video recordings.
40760678|NCT00413712|DRUG|Calcium Channel Blocker & Adenosine|
40760679|NCT01697501|OTHER|Interleukin 28B testing|Blood sampling for IL28B genotyping
40760680|NCT05088525|PROCEDURE|MRI|MRI for standard of care meniscus root repair surgery - noting with an added stabilization suture if it is able to successfully slow down the progression of osteoarthritis versus a standard root repair surgery.
40760681|NCT05732870|PROCEDURE|Relevant orthopaedic surgery|Inclusion criteria is purposefully broad to examine a range of discarded bone waste. Therefore, a large number of surgical interventions are relevant.
40760682|NCT02065986|DRUG|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
40760683|NCT05254860|PROCEDURE|LPS Ventral Rectopexy|Continuous Locked Suture vs Traditional 6-points suture for Laparoscopic Ventral Rectopexy to verify if the operative time of a standard laparoscopic ventral rectopexy for the treatment of severe rectal prolapse could be further reduced using continuous locked suture vs traditional 6-points suture for mesh fixation
40760684|NCT04629521|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
40760685|NCT04629521|PROCEDURE|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
40760687|NCT03066180|DEVICE|Viveve SUI treatment|Non-ablative radiofrequency treatment with surface cooling
40760688|NCT04053426|OTHER|Implementation of agitation care algorithm|Following the agitation care algorithm care professional adapt their behavior regarding agitation
40760689|NCT04269863|DRUG|Aspirin|control - 81mg. treatment - 81-325mg.
40760690|NCT02462057|OTHER|Email message regarding the HealthyFood benefit|
40760691|NCT01681849|DRUG|Placebo|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
40760692|NCT01681849|DRUG|Paroxetine|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
40952437|NCT02994134|BEHAVIORAL|High intensity exercise.|High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
41134605|NCT06418074|DIETARY_SUPPLEMENT|Ketone Monoester (KE4)|Each subject will receive beta-hydroxybutyrate boned to R 1,3 Butandiol (KE4) 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.
41134606|NCT06418074|OTHER|Placebo|Each subject will receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
41454397|NCT01828294|DRUG|Subcutaneous immunoglobulins|Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
41289662|NCT02112604|DEVICE|Ventilator|Mechanical ventilator used to replace or assist spontaneous breathing.
40760693|NCT01681849|OTHER|Positron Emission Tomography (PET) Imaging|Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
40760694|NCT03748472|PROCEDURE|Continuous gavage feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
40760695|NCT03748472|PROCEDURE|Bolus feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
40760696|NCT06501313|DEVICE|Photobiomodulation|Soft laser therapy
40760697|NCT03554330|OTHER|Radiofrequency catheter ablation|(1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).
40760698|NCT03554330|OTHER|Balloon atrial septostomy|Graded balloon atrial septostomy is performed in all patients.
40760699|NCT05559385|DEVICE|Robot-Assissted Therapy|Houston Bionics ExoRehab X brand/model device was used for improving the upper extremity in subacute stroke.
40952438|NCT05123196|DRUG|MT-8554|Oral Capsule
41454398|NCT04487184|OTHER|Kinesiology taping|Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
40952439|NCT05123196|DRUG|Placebo|Oral Capsule
40952440|NCT01408264|DEVICE|Conventional 0.035 guidewire|0.035 guidewire
40952441|NCT01408264|DEVICE|Olympus Visiglide 0.025 guidewire|0.025 guidewire
40952442|NCT04582370|BEHAVIORAL|theater program|10-week theory-based theater program designed to improve their physical functioning and reduce emotional stress.
40952443|NCT02029001|DRUG|Nilotinib (400 mg BID)|Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
40952444|NCT02029001|DRUG|Everolimus (10 mg QD)|Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).
40952445|NCT02029001|DRUG|Sorafenib (400 mg BID)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
40952446|NCT02029001|DRUG|Lapatinib (1500 mg QD)|Patients whose tumor harbors mutations or amplifications of HER2
40952447|NCT02029001|DRUG|Pazopanib (800 mg QD)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT\* or amplification /translocation of the genes and/or of the ligands.
40952448|NCT02029001|DRUG|Olaparib (300 mg BID)|"ATM, BAP1 et BRIP1 Mutation only if double hit documented; BRCA2, BRCA1, RAD51C, PALB2, RAD51D Mutation; BRCA1, BRCA2, ATM and BAP1 Loss; BRCA1, BRCA2, ATM and BAP 1 : mutation and heterozygote deletion. except for patients eligible to olaparib's available labels and reimbursements in France.~NOTE : only prostate cancer with RECIST 1.1 evaluable disease are eligible until the French price and reimbursement"
40952449|NCT02029001|COMBINATION_PRODUCT|Durvalumab + Tremelimumab|Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.
40952450|NCT02100800|OTHER|MR and CT measurements of emphysema quantification|
40952451|NCT06557993|OTHER|Serratus Posterior Superior Intercostal Plane Block|The serratus posterior superior muscle is located deep to the rhomboid major and minor. Ligamentum nuchae starts from the processus spinosus of C7-T3 vertebrae and extends to the 2nd-5th. In the ribs, the angulus ends at the upper edge of the rib. Serratus posterior superior -intercostal plane block (SPSİPB) is a newly defined block, and C7-T7 spread has been shown in cadaver studies
40952452|NCT03702517|DEVICE|lateral stair walking exercise|15 minutes of lateral stair walking exercise
41134607|NCT01228734|DRUG|Cetuximab|Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
41134608|NCT01228734|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
41134609|NCT01228734|DRUG|Folinic Acid|FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
41134610|NCT01228734|DRUG|5Fluorouracil|5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
41289663|NCT02112604|DEVICE|Alice PDx|Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.
41289664|NCT02112604|OTHER|Pulmonary function test|The pulmonary function tests are used to study upper airway patency.
41454399|NCT04744467|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
40952453|NCT03702517|DEVICE|traditional physiotherapy|strengthening exercise, balance training and gait training
40952454|NCT06367361|DRUG|Oxfendazole|Human studies have shown that doses up to 60 mg/kg (approximately 3.6 g for a 60-kg human, which is considered the average weight of an adult in developing countries) are safe and that repeated doses of 15 mg/kg (approximately 900 mg for a 60-kg human) daily for 5 days are safe. A single dose of OXF results in significant plasma drug concentrations that reach a Cmax plateau after doses of 15 mg/kg.75 The dose to be studied in this trial is 20 mg/kg (1200 mg maximum dose), a dose only slightly higher than that achieving a Cmax plateau. This dose was conservatively selected to account for interindividual variation in plasma levels and deemed well tolerated and safe based on laboratory and ECG evaluations.
41134611|NCT04927078|OTHER|Observation of breathing pattern|Observations will be collected using a remote vision based patient monitoring and management system.
41134612|NCT03607591|OTHER|rTMS|rTMS is a non-invasive and safe brain stimulation technique, that uses a magnetic pulse, administrated through a coil, set on the DLPFC
41134613|NCT03776760|DEVICE|Fingerstick GeneXpert HCV RNA quantitative assay|All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly
41134614|NCT03776760|DRUG|sofosbuvir/velpatesvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
41134615|NCT03776760|DRUG|glecaprevir/pibrentasvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
41289665|NCT02112604|OTHER|Muscle strength tests|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
40952455|NCT06367361|DRUG|Triclabendazole|The standard of care for the treatment of fascioliasis according to the same guidelines is two 10 mg/kg doses of TCBZ 24 hours apart administered with a fat containing meal. The subjects in one of the arms of the study will receive this treatment as the standard of care. Subjects from any of the arms that fail to achieve parasitological cure will receive rescue treatment off the study with two doses of TCBZ as recommended by the Peruvian guidelines.
40952456|NCT01910948|DRUG|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
40952457|NCT05487352|OTHER|hyperglycemia exposure in the first trimester|The exposure means the hyperglycemia identified by the 75g oral glucose tolerance test before the 14 weeks of gestation
40952458|NCT03781843|DRUG|Genicular nerve block with lidocaine|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
40952459|NCT03781843|DRUG|Genicular nerve block with saline|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
40952460|NCT03781843|DRUG|Genicular nerve block with dextrose|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
40952461|NCT00966771|DRUG|Copper T380 IUD|copper T 380 IUD
40952462|NCT00966771|DRUG|Oral levonorgestrel|1.5 mg
40952463|NCT00454623|BEHAVIORAL|drawing serum adiponectin level|
40952464|NCT03023462|DRUG|Oksykodonhydroklorid|Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
40952465|NCT03023462|DRUG|Ondansetron and Droperidol|When nausea and vomiting: Ondansetron 4mg and droperidol 0,625 mg intravenously
40952466|NCT03023462|DRUG|Ropivacaine|Local anesthetic for the block
40952467|NCT01952145|DRUG|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
40952468|NCT01952145|DRUG|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
40952469|NCT04805177|PROCEDURE|hematoma evacuation|early minimally invasive image guided hematoma evacuation in patients suffering from ICH
41134616|NCT01590134|DIETARY_SUPPLEMENT|Dietary supplement of iron|1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
41134617|NCT01590134|DRUG|Ferrous sulphate|200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
41134618|NCT02971215|DEVICE|iLux Laser|"Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy)~+ Physical Therapy protocol."
41454400|NCT01093560|DIETARY_SUPPLEMENT|fat feeding|Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
41454401|NCT04202705|DRUG|SYD1875|SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
40952470|NCT04249531|DRUG|Amikacin Inhalation Dry Powder|Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg
40952471|NCT04249531|DRUG|Amikacin Injectable Product|patient wil receive one dose of 400 mg amikacine intravenously in week 1
40952472|NCT05341687|OTHER|No applicable|No applicable
40952473|NCT05922111|DEVICE|cervical ripening balloon for one hour|The cervical ripening balloon will be left in place for one hour and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
40952474|NCT05922111|DEVICE|cervical ripening balloon for twelve hours|The cervical ripening balloon will be left in place for for twelve hours and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
40952475|NCT01701921|DRUG|Pregabalin 75mg|Pregabalin 75mg by mouth one hour before surgery
40952476|NCT01701921|DRUG|pregabalin 150 mg|pregabalin 150mg by mouth one hour before surgery
40952477|NCT01701921|DRUG|Placebo|Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
40952478|NCT00411528|DRUG|Patupilone|
40952479|NCT00411528|DRUG|prednisone|
40952480|NCT00411528|DRUG|docetaxel|
41134619|NCT02971215|DEVICE|Sham ilux Laser|Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
41134620|NCT03451422|DRUG|Efavaleukin Alfa|Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
41134621|NCT03451422|DRUG|Placebo|The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
41134622|NCT01847859|PROCEDURE|Ultrasound examination by nurses|Focused examination of the pleural space and inferior vena cava.Reference method: Cardiologists performed ultrasound examinations.
41134623|NCT02553148|OTHER|Need for children's palliative care|Need for children's palliative care
41134624|NCT03372252|DEVICE|Electroencephalography|Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.
41134625|NCT00040105|DRUG|Zarnestra (R115777)|"Starting Dose:~300 mg by mouth (PO) Twice daily"
41134626|NCT00040105|DRUG|Gleevec (Imatinib mesylate)|"Starting Dose:~300 mg By Mouth (PO) daily"
41134627|NCT02802566|DIETARY_SUPPLEMENT|BMI-based prenatal vitamin|The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
40952481|NCT05708170|DRUG|Ferinject|"Ferinject Therapy Group: each patient's Iron need for repletion by the Ferinject will be determined using product SPC dosing based on patient's body weight and Hb level. Accordingly, the appropriate dose of Ferinject will be administered while ensuring that a single administration will not exceed:~* 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)~* 1,000 mg of iron (20 mL Ferinject) The cumulative dose of Ferinject per week will not exceed 1,000 mg of iron (20 mL Ferinject)."
40952482|NCT05708170|DRUG|Ferrous Sulfate 200 MG|Active Control Group (standard care excl. IV Iron): Oral Ferrous sulphate 200 mg three times daily.
40760700|NCT05559385|PROCEDURE|Conventional Rehabilitation|It is an upper extremity rehabilitation program prepared in line with individual needs.
40952483|NCT05636644|DRUG|Taxol|All patients received TAC regimen: both groups received AC (epirubicin 75 mg/m ² and cyclophosphamide 500mg/m ²)， Group A was treated with docetaxel for 6 cycles every 3 weeks (75 mg/m on the first day ²)； Group B received six cycles of nab paclitaxel (125 mg/m ²)， every 3 weeks is a course of treatment.
40952484|NCT00318058|BIOLOGICAL|influenza vaccine Fluarix, Adjuvanted Fluarix|
40952485|NCT01987635|DEVICE|MEMO 3D ring|The experimental MEMO 3D ring is placed.
40952486|NCT01987635|DEVICE|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
40952487|NCT01987635|PROCEDURE|3D Echocardiography|
40952488|NCT06378138|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
40952489|NCT06378138|DRUG|Orelabrutinib|Eligible patients will receive Orelabrutinib orally as per the protocol，once daily for every 28 days as one treatment cycle
40952490|NCT03562910|OTHER|HelpSteps application|Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
40952491|NCT03298906|DRUG|Esketamine|Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.
40952492|NCT03298906|DRUG|Ticlopidine|Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
40952493|NCT05116215|DRUG|Hydrogen|Hydrogen supplement
40952494|NCT04203329|DEVICE|Femoral Venous Vascular Closure|Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
40952495|NCT02037022|BEHAVIORAL|Pivotal Response Treatment Package (PRT-P)|
41134628|NCT02802566|DIETARY_SUPPLEMENT|Standard prenatal vitamin|Standard prenatal vitamin
41134629|NCT02136654|BEHAVIORAL|Culturally tailored diabetes program|Includes family member and peer support Includes communication training
41134630|NCT06402552|DIAGNOSTIC_TEST|bp-MRI prostate|Biparametric MRI is considered less comprehensive compared to multiparametric MRI (mp-MRI), which includes additional parameters like dynamic contrast-enhanced MRI (DCE-MRI). However, bp-MRI offers a simpler, faster, and often less expensive alternative that still provides critical diagnostic information, particularly in the detection of clinically significant prostate cancer. It's commonly used where less comprehensive assessment is sufficient or in situations where contrast use is contraindicated.
41134631|NCT06402552|DIAGNOSTIC_TEST|mp-MRI prostate|Multiparametric MRI is highly valued for its ability to improve the detection and characterization of clinically significant prostate cancer, aid in biopsy guidance, and help in treatment planning and monitoring. Its comprehensive approach provides crucial insights that are not as readily available through simpler imaging modalities like biparametric MRI (bp-MRI).
41134632|NCT04847258|OTHER|Standard rehabilitation|Patients follow standard municipal rehabilitation
41134633|NCT00198185|PROCEDURE|Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery|
40760701|NCT03982810|DRUG|Antibiotics|Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
40760702|NCT04747431|DRUG|PBFT02|PBFT02
40952496|NCT04286399|DRUG|Renin-angiotensin-aldosterone system inhibitors|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
40952497|NCT04286399|DRUG|Beta blocker|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
40952498|NCT04286399|DRUG|SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
40952499|NCT01398553|DEVICE|Armeo Spring|30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
41134634|NCT01857999|DRUG|Losartan|
41134635|NCT01857999|DRUG|Placebo|
40952500|NCT01398553|OTHER|conventional physiotherapy|30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
41134636|NCT00745875|DRUG|ZD4054|10mg oral tablet, once daily
41134637|NCT00745875|DRUG|Pemetrexed|500mg2/m IV infusion
41289666|NCT02112604|OTHER|Grip strength measurement|Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.
40952501|NCT06460922|PROCEDURE|Radial osteotomy|3D printing models and personalized guides in surgical planning in distal radius osteotomies for Kienböck´s disease. Osteosynthesis with a plate in distal radius.
40952502|NCT05979506|PROCEDURE|Cutaneous wraps|"The topical treatment that will be used in this study are:~* For the body, an emollient cream with a high lipid content: Cold cream~* For the scalp and feet, an emollient preparation with keratolytic action: 10% or 30% urea, depending on the scalp and feet damage~Each of the 3 treatments (body, scalp and feet) will be carried out as follows:~* Application of different topicals all over the body and face, after taking a lukewarm therapeutic bath of 20 minutes~* Occlusion by wrapping the patient in a plastic film, then covering with a blanket~* After 1 hour, the unabsorbed excess cream is removed with a towel"
40952503|NCT04553185|OTHER|Study procedure|All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.
40952504|NCT03117920|DRUG|Minnelide|Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
40952505|NCT04393285|DRUG|Abemaciclib|Abemaciclib 150mg orally twice a day
40952506|NCT04393285|DRUG|Letrozole|Letrozole 2.5mg orally once a day
40952507|NCT04436159|PROCEDURE|Addition of 360 fundoplication after crural closure|A total fundoplication was constructed in which the right and left part of the wrap was brought together in front of, and slightly to the right of the esophagus, and sutured with three interrupted stitches of 2-0 unabsorbable sutures from the GEJ and cranially to attain a length between the top and bottom sutures of at the most 2 cm. At least one wrap suture included the esophageal muscle-wall.
40952508|NCT04436159|PROCEDURE|Addition of 180 posterior fundoplication after crural closure|"The wrap was pulled dorsally around the distal part of the esophagus and GEJ, which was encircled approximately 180-200 degrees. First, the wrap was anchored with Gore-tex sutures, dorsally to the left crus with 3 sutures and then to the right crus with another 3 sutures.~Finally, the wrap was completed with 3-4 sutures, between the edges of the wrap and the right and left side of the esophageal wall, respectively."
40952509|NCT06287008|PROCEDURE|robot-assisted kidney transplantation|The interventional surgery is a robot-assisted kidney transplantation and its efficacy will be measured against that of open kidney transplantation
40952510|NCT04755153|OTHER|Practice Facilitation|Tailored interventions provided by a trained Practice Facilitator
40952511|NCT04755153|OTHER|Non-Practice Facilitation|Implementation support without using Practice Facilitation
40952512|NCT04734951|OTHER|Power/resistance exercise program|participants will complete a power/resistance program during 14 weeks. The exercise program will consist of training to improve muscle strength, neuromotor skills, flexibility, endurance, and a greater emphasis on maximum strength and power. The intensity will be set according the estimated repetition to failure.
41289667|NCT02112604|DRUG|Sedatives and muscle relaxants given in the ICU|Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
41289668|NCT04038775|BEHAVIORAL|Volunteering|Subjects recommended volunteer by their provider.
40952513|NCT04734951|DIETARY_SUPPLEMENT|HMB supplementation|Daily oral supplementation with 237 ml of a polymeric nutritional formula added with 1.5 g of HMB (Ensure Advance®)
40952514|NCT05465460|DRUG|Banana Blossom|Banana Blossom 225 mg tablet orally four times per day for 14 days
40952515|NCT05465460|DRUG|Placebo|Placebo tablet orally four times per day for 14 days
40952516|NCT00163878|PROCEDURE|Sensory Stimulation|
40952517|NCT00163878|DEVICE|Sesnory Modality Assessment and Rehabilitation Technique|
41289669|NCT01756976|DEVICE|OrthoPat Advance|The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
41289670|NCT06211348|DEVICE|Genomic Sequencing|Individuals who request prenatal diagnostic testing with standard chromosomal microarray will be offered genomic sequencing (GS) as an option to assess for additional disease risk.
41289671|NCT01024465|DEVICE|ReShape Duo Balloon|ReShape Duo Balloon
41289672|NCT03798561|DRUG|ASN008 TG|ASN008 TG
41289673|NCT03798561|DRUG|Placebo TG|Placebo TG
41289674|NCT00552539|OTHER|'educational video'|'educational video'
40952518|NCT02221687|DIETARY_SUPPLEMENT|Synbiotic formula|Standard milk formula enriched with a prebiotic fiber and a probiotic strain
40952519|NCT02221687|DIETARY_SUPPLEMENT|Control formula|Standard milk formula without pre and probiotic
40952520|NCT05704231|BEHAVIORAL|Behavioral: Motivational Interviewing with WhatsApp video call|The intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interviews will be applied every two weeks, 6 times in total.
40952521|NCT05447897|OTHER|Qualitative Group Interviews|One time interview, 60-90 minutes
41289675|NCT05784389|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
41289676|NCT05673902|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
41289677|NCT04260724|DEVICE|TMS|"* stimulation intensity : motor threshold 100%~* stimulation frequency : 1600 pulses for 20 minutes~* stimulation duration :for four weaks, 20 minutes/day, 5 days per week (Monday - Friday )"
41289678|NCT04260724|DEVICE|sham coil stimulation|no stimulation Although the sound from device during stimulation is similar, no stimulation is applied.
41289679|NCT02719483|DEVICE|Swiss DolorClast|"Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied."
40952522|NCT05447897|OTHER|Stakeholder advisory group|The team will meet with the stakeholder advisory group four times for 1-2 hours each
40952523|NCT02692222|OTHER|Calculation of PPV and CO with two methods|
41454402|NCT04495543|BEHAVIORAL|Brief Skills for Safer Living|Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.
40952524|NCT01811225|DRUG|Low-dose Progesterone|"The low progesterone dose is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM)."
40952525|NCT01811225|DRUG|High-dose Progesterone|"The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM)."
40952526|NCT00900237|DRUG|Eslicarbazepine acetate|Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9
40952527|NCT00900237|DRUG|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
40952528|NCT02707107|DRUG|Intravenous infusions of WCK 5222|
40952529|NCT02707107|DRUG|Placebo|
40952530|NCT01126970|DRUG|Velneperit 400 mg|Velneperit 400 mg q.d.
40952531|NCT01126970|DRUG|Orlistat 120 mg|Orlistat 120 mg t.i.d
40952532|NCT01126970|DRUG|Orlistat Placebo|Orlistat Placebo t.i.d.
40952533|NCT01126970|DRUG|Velneperit Placebo|Velneperit Placebo q.d
40952534|NCT01126970|OTHER|Reduced Calorie Diet|Reduced calorie diet
40952535|NCT02651831|OTHER|Focus groups and individual interviews|Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
40952536|NCT02651831|OTHER|Questionnaire|Health related quality of life questionnaire (FACT-ICM) to be completed by patients
40952537|NCT00955318|DRUG|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
40952538|NCT03867344|OTHER|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.
40952539|NCT03867344|OTHER|Normoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.
40952540|NCT04965727|PROCEDURE|Device implantation|The intervention involves the insertion of lead electrodes (Medtronic SenSight Directional Lead) in the right and left lateral hypothalamus through craniotomy and an implantable pulse generator (Medtronic Model B35200 Percept™ PC) in the upper part of the pectoralis major (under the clavicle).
40952541|NCT05727930|BEHAVIORAL|High-intensity, task-specific (i.e., walking) interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve higher cardiovascular intensities
40952542|NCT05727930|BEHAVIORAL|High-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve higher cardiovascular intensities
41289680|NCT02719483|PROCEDURE|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
41289681|NCT02941731|DRUG|HIP1403|Oseltamivir 6mg/mL
41454403|NCT05026736|OTHER|Quality-of-Life Assessment|Ancillary studies
41454404|NCT05026736|BIOLOGICAL|Sintilimab|Given IV
41454405|NCT02940613|BEHAVIORAL|Visual feedback of symptom frequency|Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
40952543|NCT05727930|BEHAVIORAL|Low-intensity, task-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve lower cardiovascular intensities
40952544|NCT05727930|BEHAVIORAL|Low-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve lower cardiovascular intensities
40952545|NCT01500889|PROCEDURE|Group I: Conventional Lateral internal sphincterotomy:|LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
40952546|NCT01500889|PROCEDURE|GroupII: V-Y advancement flap|"GroupII: V-Y advancement flap:~The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide."
40952547|NCT01500889|PROCEDURE|GroupIII: Tailored LIS with V-Y advancement flap|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
40952548|NCT00079768|DRUG|Alemtuzumab (Campath)|
40952549|NCT00446862|DRUG|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
41134638|NCT00745875|DRUG|Placebo|10mg oral tablet, once daily
41134639|NCT03246750|DRUG|B-MAD chemotherapy|B-MAD chemotherapy
41289682|NCT02941731|DRUG|HGP0919|Oseltamivir phosphate 6mg/mL
41454406|NCT00535912|PROCEDURE|Stem cells autograft|Treatment by Intensive Chemotherapy and autograft
40952550|NCT05712434|OTHER|Long Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 2 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 6-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
41289683|NCT02018250|DRUG|MMB4 DMS|Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
40952551|NCT05712434|OTHER|Mid-length Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 4 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 4-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
40952552|NCT05712434|OTHER|Short Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 6 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 2-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
40952553|NCT04435587|DRUG|Ivermectin Pill|3 days of once daily oral ivermectin 600mcg/kg/d
40952554|NCT04435587|DRUG|Combined ART/hydroxychloroquine|"1. Day 1 hydroxychloroquine 400mg bid, Day2-5 hydroxychloroquine 200mg bid~2. Darunavir/ritonavir (400/100mg) q 12 hours for 5 days"
40952555|NCT00779740|DRUG|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
40952556|NCT00779740|DRUG|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
40952557|NCT03761693|OTHER|Fasting test|"The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~* blood glucose concentration drops \< 3.6 mmol/L;~* the child shows symptoms/signs of a low blood glucose concentration;~* patients parent(s) or guardian(s) request end of fast."
40952558|NCT00633750|DRUG|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
40952559|NCT00633750|GENETIC|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
41289684|NCT02018250|DRUG|Placebo|Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
41289685|NCT04681287|DRUG|inetetamab and PD-1 inhibitor combined with chemotherapy.|"1. Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;~2. The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks~3. PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause.~The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued."
41307818|NCT05523063|OTHER|Quality of life questionnaire|"The quality of life questionnaire will be performed in routine practice by the CAMI during the initial assessment.~The 3-month visit is part of the routine patient visit to CAMI. During this visit, the quality of life questionnaire will be completed a second time by the patients, through a phone call given by the investigator."
41454407|NCT00385736|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.
41454408|NCT00385736|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
41454409|NCT00385736|BIOLOGICAL|placebo|Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
41454410|NCT03117244|OTHER|Exercise for Foot Strengthening|Stabilization exercises of the longitudinal arch of the foot
41454411|NCT03117244|OTHER|Exercise for Foot Strengthening and Electrostimulation|Exercise for the Strengthening of the Foot associated with Electrostimulation
41454412|NCT03595462|OTHER|Snack|"Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be \~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be \~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat."
41454413|NCT03595462|OTHER|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
41454414|NCT00083772|DRUG|Nesiritide|Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
40952560|NCT00633750|GENETIC|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
40952561|NCT00633750|OTHER|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
40952562|NCT00633750|OTHER|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
40952563|NCT00633750|OTHER|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
40952564|NCT00633750|OTHER|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
40952565|NCT00633750|OTHER|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
40952566|NCT00633750|PROCEDURE|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
40952567|NCT04558580|DRUG|Rufinamide|Rufinamide
40952568|NCT02285647|DRUG|Rolapitant - Oral|Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
40952569|NCT02285647|DRUG|Rolapitant - IV|IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
40952570|NCT04977674|DRUG|Naltrexone|Pre-treatment with naltrexone 45 min before the ketamine infusion.
40952571|NCT04977674|DRUG|Placebo|Pre-treatment with placebo 45 min before the ketamine infusion.
40952572|NCT04977674|DRUG|Ketamine|Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
40952573|NCT01773252|DEVICE|Flow Detection System|
40952574|NCT00371072|PROCEDURE|trabeculectomy with mitomycin-C|
40952575|NCT05642988|DEVICE|LifeSignals 1AX Biosensor|Biosensor worn by patients for 30-days after intra-abdominal or pelvic surgery on discharge from hospital
41454415|NCT01616550|OTHER|Assessment of pain using the Brief Pain Questionnaire|Patients will complete this questionnaire daily from surgery until discharge from the hospital
41454416|NCT01616550|OTHER|Assessment of pain relief using a Verbal Numeric Scale (VNS)|Patients will assess their pain daily from surgery until discharge from the hospital using the VNS
40760703|NCT00586937|BEHAVIORAL|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
40952576|NCT01431170|DRUG|Besivance Treatment Group|Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.
40952577|NCT01431170|DRUG|Polytrim Treatment Group|Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
40952578|NCT02218749|OTHER|Initially triaged to physiotherapist|
40760704|NCT04573738|PROCEDURE|Robotic assisted transanal total mesorectal excision|Robotic assisted transanal total mesorectal excision for rectal cancer patients
40760705|NCT04573738|PROCEDURE|Laparoscopic assisted transanal total mesorectal excision|Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients
40952579|NCT02218749|OTHER|Initially triaged to physician|
40952580|NCT03074955|DEVICE|leg wrapping with tension|"1. Apply elastic bandages with tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages."
40952581|NCT03074955|PROCEDURE|Trendelenburg position|"1. Apply Trendelenburg position positon of 10 degree after injectin propofol~2. After 3 minutes, change to supine position"
40952582|NCT03074955|DEVICE|leg wrapping without tension|"1. Apply elastic bandages without tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages"
40952583|NCT03074955|PROCEDURE|supine position|1.maintain supine position
40952584|NCT04436731|OTHER|Hypoxia Exposure|Systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
40952585|NCT04436731|DRUG|Phenylephrine|Phenylephrine (0.0625 mcg/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
41454417|NCT01616550|OTHER|Assessment of patient' satisfaction with pain relief|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
40952586|NCT04436731|DRUG|Dexmedetomidine|Dexmedetomidine (12.5 ng/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
40952587|NCT04436731|DRUG|Phentolamine|Phentolamine will be locally infused via brachial artery catheter for 10 min before baseline measurement (12 mcg/dL/min) and the infusion will continue at a maintenance rate (5 mcg/dL/min) during acute normoxia and hypoxia.
40952588|NCT04436731|DRUG|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
40952589|NCT01442454|OTHER|chronic pancreatitis|No intervention, subjects followed through surgery
40952590|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 1)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112011), intramuscularly injected into the lateral deltoid muscle of the upper arm.
40952591|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 2)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112012), intramuscularly injected into the lateral deltoid muscle of the upper arm.
40952592|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112013), intramuscularly injected into the lateral deltoid muscle of the upper arm.
40952594|NCT02006888|DRUG|IBI-10090|
40952595|NCT02006888|DRUG|Placebo|Placebo
41454418|NCT01616550|OTHER|Nurse's satisfaction with patient's pain relief and recovery|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
40952596|NCT04548037|OTHER|PET-CT examination|The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.
40952597|NCT05274061|BEHAVIORAL|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy|AIM-CBCT consists of an accelerated, 2-day delivery of the first 7 sessions of CBCT for PTSD and is comprised of (a) psychoeducation about PTSD and relationship functioning; (b) instruction in conflict management skills; (c) instruction in effective communication skills with an emphasis on the identification and sharing of emotions to decrease emotional numbing and increase emotional intimacy; (d) discussion of the importance of approaching, rather than avoiding, difficult situations and identification of places, situations, people, and feelings that the couple has heretofore avoided as a result of PTSD; (e) instruction in identification of thoughts and related feelings that can maintain PTSD and relationship distress and strategies to increase cognitive flexibility, and (f) instruction in problem-solving skills to generate couple-level approach behaviors and guidance in how to select activities that double as opportunities to approach feared situations and engage in positive bonding.
40952598|NCT00940160|DRUG|QAX576|
40952599|NCT00940160|DRUG|QAX576|
40952600|NCT00940160|DRUG|QAX576|
40952601|NCT00940160|DRUG|Placebo|
40952602|NCT02736994|DRUG|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).|Probiotic
40952603|NCT02736994|DRUG|Corega Tabs Anti-bacteria®|Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
40952604|NCT02736994|OTHER|Water|Water
40952605|NCT03715101|DRUG|Rosuvastatin|Open-label, one-sequence, multiple administration
40952606|NCT03683160|OTHER|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
40952607|NCT00435864|PROCEDURE|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
40952608|NCT02812173|DEVICE|suprapubic tube ex 2 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
40952609|NCT02812173|DEVICE|suprapubic tube ex 5 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
40952610|NCT02812173|DEVICE|transurethral catheter ex 5 day|transurethral catheter withdrawal removal on the fifth day after the surgery
40952611|NCT04450888|OTHER|The strategic use of messages in risk communication|The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.
40952612|NCT03317340|OTHER|Background Sounds|Background music or sound of running water
40952613|NCT01681940|DRUG|Lamazym|ERT, i.v. infusions weekly
40952614|NCT06306820|OTHER|Fixed PEEP|Patients will receive a fixed positive end-expiratory pressure (PEEP) of 5 cmH2O throughout the surgical procedure.
40952615|NCT06306820|OTHER|Ultrasound-guided lung recruitment|Patients will receive ultrasound-guided lung before pneumoperitoneum, after pneumoperitoneum then once an hour, until the end of surgery. Alveolar recruitment will be conducted the same as that for the conventional manoeuvre with a simultaneous continuous ultrasound assessment if atalectasis is detected until no collapsed areas are visualized. When the collapsed lung areas are absent on the sonogram, positive end-expiratory pressure (PEEP) can no longer increase at this point. Subsequently, the pressure will be maintained for approximately 10 breaths.
40952616|NCT06306820|OTHER|Individualized PEEP|Patients will receive individualized positive end-expiratory pressure (PEEP). After the first recruitment Maneuvere (RM), titration of PEEP will be performed by setting the initial PEEP to 5 cm H2O, then increasing PEEP according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing PEEP, until the calculated Cstat shows a downward trend, the we set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEP for this patient. The highest PEEP is limited to 15 cmH2O.
40952617|NCT03039452|BEHAVIORAL|High intensity interval training|Each training session will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
40952618|NCT02922855|BEHAVIORAL|0 dollars group|Those assigned to the $0 group will not receive an incentive for visiting their PCP.
40952619|NCT02922855|BEHAVIORAL|50 dollars group|Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
40952620|NCT02922855|BEHAVIORAL|25 dollars group|Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
40952621|NCT05877768|DIAGNOSTIC_TEST|Photon Counting Detector Coronary Computed Tomography Angiography|Clinically indicated Photon Counting Detector Coronary Computed Tomography Angiography for the suspicion of coronary artery disease or the progression thereof.
40952622|NCT06220773|DRUG|BR1019A|Subjects take the investigational products once a day for 12 weeks.
40952623|NCT06220773|DRUG|BR1019B|Subjects take the investigational products once a day for 12 weeks.
40952624|NCT06220773|DRUG|BR1019C|Subjects take the investigational products once a day for 12 weeks.
40952625|NCT06220773|DRUG|BR1019A-1|Subjects take the investigational products once a day for 12 weeks.
40952626|NCT06220773|DRUG|BR1019B-1|Subjects take the investigational products once a day for 12 weeks.
40952627|NCT06220773|DRUG|BR1019C-1|Subjects take the investigational products once a day for 12 weeks.
40952628|NCT03564431|DEVICE|Magnetic resonance|magnetic resonance spectrum of brain
40952629|NCT00638482|DRUG|Hydrochlorothiazide|Hydrochlorothiazide
40952630|NCT01076920|GENETIC|Mesenchymal stem cells|60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
40952631|NCT02688049|BIOLOGICAL|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
40952632|NCT02688049|BIOLOGICAL|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
40952633|NCT05804084|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
40952634|NCT05804084|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
40952635|NCT02213640|DEVICE|transcranial direct current stimulation (tDCS)|Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
40952636|NCT02213640|DEVICE|Control: placebo stimulation|electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
40952637|NCT00108433|DRUG|Cefazolin IV|
40952638|NCT00108433|DRUG|Linezolid IV|
41307819|NCT00586391|GENETIC|CD19CAR-28-zeta T cells|"Intravenous injection~Dose Level 1:~CD19CAR-28zeta - 2x10\^7 cells/m\^2~Dose Level 2:~CD19CAR-28zeta - 1 x10\^8 cells/m\^2~Dose Level 3:~CD19CAR-28zeta - 2x10\^8 cells/m\^2"
41454419|NCT03292705|BEHAVIORAL|PEP|The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains. For instance, if music is among a person's lifelong interests, the system provides access to multiple music genres through jukebox, karaoke and therapeutic music applications that can be tailored to a particular activity and by individual interest (for instance, a preference for classic jazz). As another example, for someone who likes travel or visiting new places, the interface offers access to Google Earth, guided tours, slide shows and regional facts and history.
40952639|NCT00108433|DRUG|Vancomycin (IV)|
40952640|NCT03611491|DEVICE|Princess FILLER Lidocaine|Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.
40952641|NCT02293161|DRUG|GSK2618960|GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
40952642|NCT02293161|DRUG|Placebo|It is Sodium Chloride Intravenous Infusion
40952643|NCT04672395|BIOLOGICAL|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22
40952644|NCT04672395|BIOLOGICAL|Placebo; 0.9% saline|Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22
40952645|NCT04672395|BIOLOGICAL|SCB-2019 vaccine|Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant
40952646|NCT04672395|BIOLOGICAL|SCB-2019 vaccine for Placebo|Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart
40952647|NCT03945214|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
40952648|NCT03945214|BEHAVIORAL|Healthy Eating|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
40952649|NCT03945214|BEHAVIORAL|Meditation + healthy eating|10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
40952650|NCT01495975|OTHER|Diabetes Transitions Tool Kit|Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
40952651|NCT00628485|DEVICE|BION|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated."
40952652|NCT00628485|DEVICE|BION|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each."
40952653|NCT00628485|DEVICE|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
40952654|NCT01975714|DRUG|Preservative-free latanoprost|
40952655|NCT01975714|DRUG|Preservative-free bimatoprost|
40952656|NCT05834569|DRUG|Acetaminophen and Ibuprofen|Patients in the Maxigesic group will be administered a total of 5 doses of the drug (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthetic induction.
40952657|NCT05834569|DRUG|Normal saline|Patients in the control group will be administered equal amounts of normal saline at the same time points.
40952658|NCT00098956|DRUG|topotecan hydrochloride|Given IV
40952659|NCT00098956|DRUG|7-hydroxystaurosporine|Given IV
40952660|NCT00344708|PROCEDURE|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
40952661|NCT05658913|DRUG|AV-1451|This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants.
40952662|NCT02275858|DEVICE|Stiffening wire|Stiffening wire
40952663|NCT02275858|DEVICE|Placebo wire|Placebo wire
40952664|NCT00407329|PROCEDURE|transurethral resection of the prostate|resection of prostate
40952665|NCT04167969|DRUG|(64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots|Patients will be injected with approximately 5 mCi (+/- 10%) of a copper-64 (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
40952666|NCT04167969|DIAGNOSTIC_TEST|PET/MRI|Imaging will be performed using the GE Signa PET/MRI.
40952667|NCT04167969|OTHER|Blood and urine sampling|Staff will perform the IV blood draws and collect urine samples
40952668|NCT04167969|PROCEDURE|laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection|Surgery will be performed within 24 h of the third PET/MRI scan.
40952669|NCT05929794|DRUG|Metronidazole 0.75% Topical Gel|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
40952670|NCT05929794|DRUG|Metronidazole 0.75% Topical Cream|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
40952671|NCT05929794|DIAGNOSTIC_TEST|Transdermal water loss measurement|Baseline measurements of transepidermal water loss will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied).
41289686|NCT01483040|DEVICE|colonoscopy system (PeerScope B System™)|Cancer of the colon and rectum is second only to lung cancer as the leading cause of cancer-related deaths in the United States.Each year, about 1.23 million new cases of bowel cancer are diagnosed worldwide, 333,000 in Europe alone. Colorectal cancer almost always starts in a benign growth called a polyp. Polyps originate in the inner lining of the colon, where they may be visible in a screening test known as colonoscopy. Recent research has shown that appropriate screening and treatment can alleviate much of the suffering associated with colorectal cancer and reduce the number of deaths caused by this malignancy
40952672|NCT05929794|DIAGNOSTIC_TEST|Electrical Resistance|Baseline measurements of electrical resistance will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied). In all study periods the measurements will also be repeated at 48 hours and 96 hours, when metronidazole product and occlusive coverings are removed from the skin.
40952673|NCT05929794|DIAGNOSTIC_TEST|Skin color measurement|Baseline measurements of skin color will be made at 3 sites on the upper arm.
40952674|NCT05929794|OTHER|Micropatch application|All subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm (color only measured at baseline). Two sites will have micropatch application + metronidazole product with occlusive covering. One site will have micropatch application + occlusive covering, no metronidazole product. Micropatch application will only occur on day 1 (a micropatch is a patch of 50 microneedles). Transepidermal water loss and electrical resistance are repeated after micropatch application and removal. At 48 hours occlusive coverings and metronidazole are removed; electrical resistance measurements are repeated. Metronidazole product and fresh occlusive patches are reapplied. At 96 hours patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis.
40952675|NCT01540266|PROCEDURE|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
40952676|NCT01540266|PROCEDURE|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
40952677|NCT01224964|DRUG|Montelukast|Montelukast, 10 mg
40952678|NCT01224964|DRUG|long acting beta2 mimetic|ICS+long acting beta2 agonist: twice daily
41289687|NCT03390231|COMBINATION_PRODUCT|Stem Cell Educator therapy|It briefly cocultures the patient's lymphocytes with CB-SCs in vitro, induces immune tolerance through the action of autoimmune regulator (AIRE, expressed by CB-SCs), returns the educated autologous lymphocytes to the patient's circulation, and restores immune balance and homeostasis.
40952679|NCT06215807|PROCEDURE|Femtosecond laser arcuate keratotomy|The patient will receive femtosecond laser arcuate keratotomy and femtosecond laser-assisted cataract surgery with implantation of a monofocal intraocular lens in one eye.
40952680|NCT06215807|PROCEDURE|Toric intraocular lens implantation|The patient will receive femtosecond laser-assisted cataract surgery with implantation of a Toric monofocal intraocular lens in the contralateral eye.
40952681|NCT03600701|DRUG|Atezolizumab|Given IV
40952682|NCT03600701|PROCEDURE|Biopsy|Undergo biopsy
40952683|NCT03600701|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40952684|NCT03600701|DRUG|Cobimetinib|Given PO
40952685|NCT03600701|PROCEDURE|Computed Tomography|Undergo CT scan
40952686|NCT03600701|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40952687|NCT05058235|OTHER|Active Release Technique|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Active release Technique 5 reps/ 1 set/ (6 days/ week)~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
40952688|NCT05058235|OTHER|Bent leg raise|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Bent leg raise 5 sec hold/ 5 sec stretch/ 3 reps/ 1 min rest interval/ 1 set/ (6 days/ week).~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
40952689|NCT00722423|BEHAVIORAL|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
40952690|NCT00722423|BEHAVIORAL|Usual Care Model|
40952691|NCT03943160|DEVICE|Diamondback 360 Extended Length Orbital Atherectomy System|All patients undergoing peripheral vascular intervention (PVI) via transradial access (TRA) and for whom TRA has been successfully achieved and peripheral lesion deemed appropriate for treatment via TRA per physician discretion.
41289688|NCT00443560|OTHER|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
40952692|NCT02505906|RADIATION|Simultaneous Integrated Boost Technique|
40952693|NCT00837356|DRUG|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
40952694|NCT00837356|DRUG|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
40952695|NCT02394483|DRUG|F901318 safety|Safety assessments
40952696|NCT02394483|DRUG|F901318 tolerability|Tolerability assessments
40952697|NCT02394483|DRUG|F901318 pharmacokinetics|Pharmacokinetic assessments
40952698|NCT02394483|OTHER|Placebo safety|Safety assessments
40952699|NCT02394483|OTHER|Placebo tolerability|Placebo tolerability
40952700|NCT02394483|OTHER|Placebo pharmacokinetics|Plaacebo pharmacokinetics
40952701|NCT04099407|DRUG|Pirfenidone|Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.
40952702|NCT04099407|OTHER|Standard of care|All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.
41134640|NCT03189303|DEVICE|Primary Uncemented Total Hip Arthroplasty|The study devices are the Pinnacle Hip System acetabular cup with a Summit, Actis, or Corail femoral stem
41134641|NCT05100797|DEVICE|Vyntus CPX|To study the validity, precision and accuracy of the Vyntus CPX metabolic cart using both, in-vitro and in-vivo (i.e., human study) measures.
41134642|NCT02969200|DRUG|Enzyme replacement therapy|All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
41134643|NCT05689606|BEHAVIORAL|Exercise|Exercise includes acute high-intensity interval training.
41134644|NCT04136990|PROCEDURE|Isolated ACL reconstruction|Isolated ACL reconstruction using the bone-patellar tendon autograft.
41134645|NCT04136990|PROCEDURE|ACL + LEAT reconstruction|ACL reconstruction using the bone-patella-tendon-bone autograft combined with LEAT using the mini Lemaire technique.
41134646|NCT02466958|DRUG|levomilnacipran|antidepressant
41134647|NCT02466958|DRUG|Placebo|an inactive drug
41134648|NCT03169933|RADIATION|Combined, intensified and modulated adjuvant radiotherapy|
41134649|NCT00022672|DRUG|trastuzumab (Herceptin®)|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
41134650|NCT00022672|DRUG|anastrazole (Arimidex®)|1 mg tablet taken orally daily
41134651|NCT04425980|OTHER|Modified Constraint-Induced Movement Therapy|intensive use of more affected arm in structured setting
40952703|NCT06012487|DRUG|Low BPV Regimen|Each the patients' physician will invite patients to complete a 48-hour ABPM, then undergo cross-titration from their current antihypertensive regimen to a low BPV regimen, consisting of Amlodipine and Indapamide. Study staff will suggest to the treating physician to initially start patients on Amlodipine 5mg daily, with uptitration to 10mg daily to a goal systolic blood pressure (SBP)\<130 mmHg. Indapamide will be suggested to be added at 1.25mg daily and increased to 2.5mg daily, as needed to meet target SBP. Other antihypertensive medications will be suggested to be discontinued as the SBP target is reached. Patients not meeting target SBP on maximally tolerated Amlodipine and Indapamide will be suggested to have a long acting angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker (ARB) added to their therapy. Patients will complete another 48-hour ABPM after 1 week at target SBP on the low-BPV regimen.
40952704|NCT05059639|OTHER|Almond|Consume 2 ounces of almond daily for 8 weeks
41289689|NCT05868967|DRUG|[14C]DWP14012|Each subject will receive a single oral dose of \[14C\]DWP14012 suspension (containing approximately 40 mg/80 μCi \[14C\]DWP14012) under fasting conditions.
41289690|NCT00091390|RADIATION|High Dose brachytherapy boost|19 Gy in two fractions (on day of placement and 6-24 hours later) before or after external beam radiotherapy, such that all study treatment occurs within 8 weeks.
41289691|NCT00091390|RADIATION|External beam radiotherapy|45 Gy as 1.8 Gy five days a week for five weeks.
40952705|NCT05059639|OTHER|Pretzel|Consume comparative amount of pretzel daily for 8 weeks
40952706|NCT00885287|DRUG|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
40952707|NCT00000546|BEHAVIORAL|meditation|
40952708|NCT05211115|PROCEDURE|Split thickness flap|Palatally displaced crestal incision at the edentulous site, combined with the split thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a micro-blade, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
40952709|NCT05211115|PROCEDURE|Full thickness flap|Palatally displaced crestal incision at the edentulous site, combined with the full thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a fine periosteal elevator, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
40952710|NCT05211115|PROCEDURE|Autogenous sub epithelial connective tissue graft|Harvest of a sub epithelial connective tissue graft using a double incision technique, approximately 2-3 mm apical to the palatal gingival margins of the first and second premolars. Graft dimension standardised as 10mm (mesio-distally) by 6-8mm (apico-coronally) by 1,5mm (thickness). Graft stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
40952711|NCT05211115|PROCEDURE|Volume stable collagen matrix|Geistlich Fibro-Gide® matrix shaped at a standardised dimension of 10mm (mesio-distally) by 6-8mm (apico-coronally) by 6mm (thickness). Matrix stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
40952712|NCT04704544|OTHER|Tele-rheumatology|Participants will receive virtual visits via video conferencing and/or phone.
41134652|NCT05901532|DRUG|Szechwan Lovage Rhizome, Biod Magnolia Bud, Taiwan Angelica Root, Wild Mint Herb, Baikal Skullcap Root, and Borneol|The bilateral nasal cavity was irrigated with a plastic bottle containing 1 gram of Szechwan Lovage Rhizome, 1 gram of Biod Magnolia Bud, 0.5 gram of Taiwan Angelica Root, 0.5 gram of Wild Mint Herb, 1.5 gram of Baikal Skullcap Root, and 0.5 gram of Borneol dissolved in 240 ml of warm normal saline once a day for 2 months.
41289692|NCT02583750|BEHAVIORAL|OGTT after deprived sleep first|Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
41454420|NCT03292705|BEHAVIORAL|CCI|VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
41454421|NCT00310674|BIOLOGICAL|Meningococcal C Conjugate Vaccine|
41454422|NCT05227677|OTHER|GA guided anti-diabetic therapy adjustment|The GA concentration will be measured at 4-week intervals in both groups. The anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.
41454423|NCT05227677|OTHER|current guidelines to adjust treatment|The GA concentration will be measured at 4-week intervals. Investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
41454424|NCT03408730|BIOLOGICAL|Hepatitis B Vaccination|Hepatitis B Vaccination
41454425|NCT01590563|DEVICE|IUD|Insertion of a spherical IUD, one year follow-up
41454426|NCT03690349|OTHER|Skin test|Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens
41454427|NCT05290896|DEVICE|Phacoemulsification|Phacoemulsification for senile cataract.
41454428|NCT02664792|OTHER|Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma|
41454429|NCT02889393|DRUG|Teduglutide|Daily 0.05 mg/kg Teduglutide administered subcutaneously.
41454430|NCT02889393|OTHER|Standard of Care|The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.
41454431|NCT01426568|BEHAVIORAL|Multi-Convergent Therapy|Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
41454432|NCT05909696|DRUG|rocuronium|Advanced intravenous injection of rocuronium before the succinylcholine injection
41454433|NCT03130335|PROCEDURE|BMA Injection|Bone marrow will be aspirated from the iliac crest and injected into the knee.
41454434|NCT03130335|BIOLOGICAL|BMA|Bone marrow will be aspirated from the iliac crest.
40952713|NCT04479930|OTHER|Pulmonary Care Web-Based App (HappyAir App)|The HappyAir app reminded the HappyAir group daily to use the app, indicating that they record medication intake, daily exercise time (minutes), level of tiredness after the exercises (good, little tired, very tired, or exhausted), and daily mood (happy, little sad, sad, or very sad). The HappyAir integrated plan was designed as a model of a therapeutic program based on communication that introduced the figure of the therapeutic educator (physiotherapist or respiratory coach) in order to design interventions focused on the patients and their needs, with minimal intervention and presence, making the patients responsible for their self-care and management of their illness. Patient and educator shared responsibility.
40952714|NCT01685034|BIOLOGICAL|"Allergy immunotherapy (allergy shots)"|
40952715|NCT06134492|DRUG|Acyclovir|"Dosage: 10mg/kg (current) body weight every 8 hours, dose adjustment to renal function according to technical information.~Mode of administration: intravenous (i.v.)"
40952716|NCT01128842|DRUG|Neratinib|240 mg once daily by mouth.
40952717|NCT01128842|DRUG|Capecitabine|1500 mg/m\^2 twice daily by mouth.
40952718|NCT04638660|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
40952719|NCT04638660|DRUG|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
40952720|NCT01443208|DRUG|desvenlafaxine|one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
40952721|NCT01443208|DRUG|desvenlafaxine|one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
40952722|NCT01443208|DRUG|desvenlafaxine|two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
40952723|NCT01970657|BIOLOGICAL|No treatment specified|No intervention
41289693|NCT02583750|BEHAVIORAL|OGTT after sufficient sleep first|Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
40952724|NCT01970657|BIOLOGICAL|No treatment|None specified
40952725|NCT02221024|PROCEDURE|Flushing with positive pressure|Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
40952726|NCT02221024|DRUG|Normal saline|
40952727|NCT02221024|DEVICE|MicroClave ICU Medica|
40952728|NCT05901454|DRUG|Yellow Fever Vaccine|vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)
40952729|NCT05616975|OTHER|test-retest reliability|Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests.
40952730|NCT05616975|OTHER|construct validity|Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests.
40952731|NCT05616975|OTHER|normative data|Collection of normative SWAY Balance, Functional, and Cognitive data.
40952732|NCT01020383|DRUG|ALX-0081|4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
41289694|NCT06511427|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
40952733|NCT01020383|DRUG|ReoPro®|0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
41289695|NCT06511427|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
41289696|NCT01588301|BEHAVIORAL|Attending for cervical cytology|A further invitation to attend for cervical cytology are going to be sent by mail to women
40952734|NCT00179543|BEHAVIORAL|Relaxation response|
40952735|NCT03546062|OTHER|patients treated by HTx|From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
40952736|NCT00292396|DRUG|Anti IL-12 monoclonal antibody/ABT-874|Please see Arm Description for intervention description and details.
40952737|NCT00292396|DRUG|placebo|12 doses
40952738|NCT05236296|BEHAVIORAL|EASE-CG|EASE-CG is an adapted brief psychotherapeutic intervention with relational support and trauma-based cognitive behavioral therapy (CBT) components.
40952739|NCT05371730|DRUG|NCR300|Intravenous infusion of NK cells（NCR300）
40952740|NCT01551901|DEVICE|Spinal fusion|Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
41289697|NCT01588301|BEHAVIORAL|Kit for Self-collected vaginal sample|Kit for self-collected vaginal sample are going to be directly sent at women's home
41289698|NCT04599816|DRUG|levosimendan at a dose of 3 mcg/kg|levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction
41289699|NCT04599816|DRUG|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
40952741|NCT04213729|BEHAVIORAL|Diet Counseling|Standard of care diet counseling provided at clinic visit 1.
40952742|NCT04213729|OTHER|CD LFD|Daily breakfast, lunch, dinner and snacks LFD catered meals. Meals will have approximately 20% calories from fat, a goal ratio close to 1:1 omega-6/omega-3 fatty acids, and approximately 25-35 grams of fiber per day.
40952743|NCT04213729|BEHAVIORAL|Dyadic Psychological Support (DPS)|The dyadic psychosocial support (DPS) intervention will be provided for a total of 12 weeks. The 12-week DPS intervention consists of eight sessions (main sessions) and two booster sessions. The intervention will incorporate psychoeducational components that combine didactic and behavioral regulatory procedures to promote healthy diet behavior for self-determined reasons.
40952744|NCT06132516|OTHER|HIIT|High Intensity Interval Training On semi-recumbent ergocyclometer, after a symptom-limited graded exercise Test
41289700|NCT04599816|DRUG|levosimendan at a dose of 12 mcg/kg|levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction
41289701|NCT01516801|OTHER|PSA flyer|A mailed low-literacy informational patient flyer about the PSA test
40952745|NCT06132516|OTHER|LIGT|Low Intensity Group Training Group gymnastics, mainly with short static stretching/strengthening tasks.
40952746|NCT05412095|OTHER|Ultrasound of the abdominal wall muscles|the measurements will be performed during inspiration and expiration to take into account variability during the respiratory cycle. The examination is performed bilaterally and comparatively and lasts between 3 and 5 minutes.
40952747|NCT05412095|OTHER|Ultrasound quadricipital|The examination is performed bilaterally and comparatively and takes between 3 and 5 minutes.
40952748|NCT05412095|OTHER|Ultrasound of the diaphragm|The examination is performed bilaterally and comparatively and takes between 5 and 10 minutes.
41289702|NCT05409976|DEVICE|GORE® VIAFORT Vascular Stent|Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.
40952749|NCT05412095|OTHER|Ultrasound of the inter-costal muscles|measurements performed bilaterally on a patient in a half-sitting position at 45° and in spontaneous ventilation
40952750|NCT05412095|OTHER|Ultrasound of the inter-costal muscles|In spontaneous ventilation, lying down, arms by the side of the body, palms up, head down
40952751|NCT00003970|DRUG|irinotecan hydrochloride|Given IV
40952752|NCT02935842|OTHER|Specific SL-therapy|Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
40952753|NCT02935842|OTHER|Rhythmic Balance-Movement Training (rBMT)|Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
40952754|NCT04534972|OTHER|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Intervention for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \> 100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
40952755|NCT05051995|DRUG|Open-label placebo|Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.
40952756|NCT05051995|OTHER|No-treatment|During the no-treatment phase, participants receive no treatment for 2 weeks.
41289703|NCT05421377|DIAGNOSTIC_TEST|clinical assessment|screening of patients at risk for developing unilateral or bilateral lower limb lymphedema
41289704|NCT04486521|DRUG|Interleukin 6 (IL6) Antagonist|anti-IL6 alone
41289705|NCT04486521|DRUG|Interleukin 6 (IL6) Antagonist and corticosteroids|anti-IL6 + corticosteroid combination
41289706|NCT04486521|DRUG|corticosteroid alone|"dexamethasone, hydrocortisone, methylprednisolone, prednisone. All steroids  other than dexamethasone will be converted to dexamethasone equivalent"
41289707|NCT01292772|PROCEDURE|contract-enhanced MRI|Patients will have contrast-enhanced MRI of the breasts.
41289708|NCT01292772|RADIATION|Unilateral Adjuvant Radiation Therapy|The study group will consist breasts receiving post-operative radiation, and the control group will consist of the patient's breasts on the non-radiated side. In this way, patients will act as their own control.
41454435|NCT03681938|PROCEDURE|Autograft|Autograft
41289709|NCT01380756|DRUG|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
41289710|NCT01380756|DRUG|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
41289711|NCT01248806|RADIATION|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
41289712|NCT06343350|DEVICE|OPTDR01 software application|Retinal images will be sent to the OPTDR01 software application for mtmDR and vtDR detection
41289713|NCT02297217|DRUG|Carboplatin and Taxol (paclitaxel)|Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
41289714|NCT02297217|RADIATION|External Beam Radiation|Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
41289715|NCT05243329|DRUG|Psilocybin|10 mg or 25 mg oral aqueous psilocybin solution
41289716|NCT04985773|DEVICE|Lacrosse NSE ALPHA coronary dilatation catheter|The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.
40952757|NCT01847378|PROCEDURE|Catheter ablation|During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
40952758|NCT04123275|OTHER|No intervention wil be done. Patient characteristics and the standard care before and after withdrawal of life-sustaining treatment in all potential cDCD donors, will be studied. .|
40952759|NCT01163331|OTHER|Singing Therapy|Singing therapy as a way to improve voice quality
40952760|NCT06002607|OTHER|Antibiotic duration|The patient will be enrolled in a 48-hour course of antibiotics.
40952761|NCT06002607|OTHER|Antibiotic duration|The patient will be enrolled in a 7 day course of antibiotics.
41289717|NCT02868502|DEVICE|Goldmann tonometer|IOP measurement in the sitting position and lateral decubitus
41289718|NCT02868502|DEVICE|Pneumatonometer|IOP measurement in the sitting position and lateral decubitus
40952762|NCT05578079|OTHER|Music|"Intervention-1 group will listen to the classical music that the Arts of Fugue by Bach."
40952763|NCT05578079|OTHER|Music|Intervention-2 group will listen to lullaby.
41289719|NCT02868502|DEVICE|Tonopen XL|IOP measurement in the sitting position and lateral decubitus
41289720|NCT02868502|DEVICE|ICare rebound tonometer|IOP measurement in the sitting position and lateral decubitus
41289721|NCT03863444|OTHER|Prenatal Preparation Education|Intervention, provided by researchers, includes video, counseling, and skill practices. Video contains (1) Newborn Reaction, including rooting reflex, correct latch-on posture, assuring newborn having enough milk intakes; (2) Newborn Care, including holding, dipper-changing, clothes-changing, and swaddle the newborn; and (3) Partner Support, including the importance of partner support and the content how partner provide support to the postpartum women. After watching the video, the researcher will provide participants counseling, and then each pair of participants will have skill practice.
40760706|NCT01586715|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
40952764|NCT05340465|DRUG|Darbepoetin Alfa|Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.
40952765|NCT05340465|DRUG|Low Molecular Weight Iron Dextran|Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
40952766|NCT05340465|DRUG|Ferumoxytol injection|Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
40952767|NCT05340465|DRUG|Oral iron supplements|Infants in group 1 will receive standard care in the UW NICU with iron started on day 7 if tolerating 100 mL/kg/day enteral feeding. Iron supplements are adjusted every 2 weeks based on ferritin, zinc protoporphyrin to heme ratio and complete blood count (CBC).
41307820|NCT00586391|DRUG|Ipilimumab|For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
41289722|NCT03863444|OTHER|Routine care|Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.
41289723|NCT02561377|BEHAVIORAL|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
41289724|NCT02561377|BEHAVIORAL|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
41289725|NCT02185599|DEVICE|DySIS|Colposcopy performed with the DySIS digital colposcope
41289726|NCT02342171|OTHER|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
41289727|NCT05431556|OTHER|Virtual mind-body group exercise classes|"Pre-operative period (baseline/intake day to day before surgery): mid- to high intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)~* Immediate post-operative period (post-operative hospitalization to 2 weeks after surgery): low- to mid-intensity classes focusing on relaxation, stress management and low-impact physical activity (classes: Chair Yoga, Dance Therapy, Meditation, Music Therapy)~* Late post-operative period (3-12 weeks after surgery): mid- to high-intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)"
41289728|NCT05431556|OTHER|Enhanced usual care|EUC arm will be referred to MSK's multimedia page on the Integrative Medicine website to access pre-recorded mind-body videos on their own time. These videos are 15-60 minutes in duration and consist of educational and self-care videos, including guided meditation and Tai Chi.
41289729|NCT04059809|DEVICE|Photobiomodulation|Photobiomodulation will be with the Cicatrillux (Cosmedical®) LED that contains 36 red light emitters in a 10x12 cm neoprene plate with 650 nm LED wave length whose optical spot diameter is 5 mm and with an average wave length of 2 \~ 5 mw for 10 minutes that will be placed over the area that will be irradiated for 10 minutes;
40760707|NCT04393935|BEHAVIORAL|Pharmacy Delivered PrEP Intervention|Men who are eligible and agree to the clinical screener will be provided with a pre-packaged kit of self-administered tests for HIV, rectal chlamydia, syphilis and gonorrhea and creatinine and directed back to the private area of the pharmacy to perform their screenings. Participants will be asked to return the screening tests to the pharmacy technician. The pharmacy technician will process/ interpret the results of the rapid HIV test first in case a treatment referral needs to be set up. Then s/he will process/interpret the results of a rapid rectal chlamydia, syphilis, gonorrhea and rapid finger prick creatinine test. HIV negative customers will be provided with their results and be given a 30-day prescription for PrEP, culturally appropriate PrEP counseling and a follow-up appointment with a PrEP prescribing physician. Participants will be contacted after 3 months to determine whether they continued PrEP use.
41289730|NCT04722978|DRUG|Gemcitabine and carboplatin plus antibiotic (moxifloxacin)|Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)
41289731|NCT04722978|DRUG|Gemcitabine combined with carboplatin plus placebo|Standard chemotherapy (gemcitabine and carboplatin) plus placebo
41289732|NCT05484986|OTHER|A questionnaire with 47 items|A form consisted of questions on introductory characteristics (age, sex, and class, among others), Big Five Inventory (BFI) to evaluate personality traits, and Management of Workplace Violence Competence Scale for Nursing Students in Areas of Clinical Practice.
41289733|NCT00003530|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41289734|NCT02202811|BEHAVIORAL|Forced Desynchrony|all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
41289735|NCT01805700|OTHER|Caffeine enhanced energy drink|Comparison of different energy drinks
41289736|NCT01805700|OTHER|Glucose drink|Glucose drink (containing 84mg glucose alone)
41134653|NCT05901532|DRUG|edible caramel|The bilateral nasal cavity was irrigated with a plastic bottle containing edible caramel dissolved in 240 ml of warm normal saline once a day for 2 months.
41134654|NCT00002281|DRUG|Filgrastim|
41134655|NCT00002281|DRUG|Epoetin alfa|
41134656|NCT00002281|DRUG|Zidovudine|
41134657|NCT05701579|PROCEDURE|"ACL decompression"|"The technique of ACL decompression by the means of longitudinal incisions and evacuation of extrafibrous mucoid tissue."
40760708|NCT01491919|DRUG|Lisinopril|Subjects will be randomized to Low, Medium, or High dose of Lisinopril
41134658|NCT02725697|OTHER|TCM treatment|
41134659|NCT02140879|DIETARY_SUPPLEMENT|Capsule 1 or Capsule 2|Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.
41134660|NCT02140879|DIETARY_SUPPLEMENT|Capsule 2|Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .
41134661|NCT00220532|DRUG|Folic acid with riboflavin|
41134662|NCT06238310|DIAGNOSTIC_TEST|Comparison of two external marker substance for measuring glomerular filtration rate|Two external marker substance compares for measuring GFR.
40952768|NCT06068023|DRUG|Folfirinox|"Patients meeting the criteria of post-operative adenocarcinoma of the ampulla of Vater will be enrolled, with adjuvant chemotherapy commencing within 8 weeks of recovery from surgery. Those undergoing palliative intent surgery or palliative chemotherapy are ineligible for the ADAPTA study.~The ADAPTA study's adjuvant chemotherapy involves 8-12 FOLFIRINOX cycles (Arm 2) repeated 2 weeks. Given patient outcomes, 8 cycles of FOLFIRINOX are deemed sufficient due to completion challenges in prior research. FOLFIRINOX regimen mirrors the modified version from the ACCORD/PRODIGE trial for metastatic pancreatic cancer. This trial adapts mFOLFIRINOX for standard practice."
40760709|NCT04535362|DRUG|Nicotine|session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes.
41134663|NCT05869331|PROCEDURE|Early mobilization|Patients randomized to nonoperative treatment have already received treatment using early mobilization in the original trial, and all fractures have been confirmed healed. Mobilization consisted of 5 repetitions of full finger extension followed by maximum finger flexion, and 5 such sets of 5 were required per day for the first 6 weeks. Buddy taping or resting splint was offered if the patient experienced difficulty, and mobilization was performed by all patients in this treatment arm.
40952769|NCT06068023|DRUG|Capox|or 8 CAPOX cycles (Arm 1) every 3 weeks.
41289737|NCT04214795|OTHER|Observational study. Postnatal variables are recorded|Postnatal evolution is analyzed in both groups
41289738|NCT01411410|DRUG|Paclitaxel|"Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~* The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~* Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted."
41134664|NCT05869331|PROCEDURE|Operative treatment|Patients randomized to operative treatment have already received treatment using open reduction and internal fixation (ORIF) with cortical screws in the original trial, and all fractures have been confirmed healed. Surgery was performed under general anaesthesia through a dorsal incision centered over the fractured metacarpal. Reduction was performed under visual inspection and fixation performed using 2 or more cortical screws (Synthes Compact Hand 2.0) as first option. At the surgeons preference fixation using plate and screw fixation was also allowed. Postoperatively patients were put in a plaster cast for two weeks and then hand therapy was initiated.
41134665|NCT01217099|DRUG|methylprednisolone|treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
41134666|NCT01217099|DRUG|azithromycin|control patients were iv azithromycin for 5 days.
41134667|NCT04958720|PROCEDURE|Surgery|Surgery
41134668|NCT04958720|DRUG|Chemotherapy, anti-targeted agents and immunotherapy|Chemotherapy, anti-targeted agents and immunotherapy
41134669|NCT04958720|RADIATION|Radiotherapy|Radiotherapy
41134670|NCT00241826|PROCEDURE|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
41134671|NCT00241826|PROCEDURE|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
41134672|NCT02263105|DRUG|CDDP|
41134673|NCT02263105|DRUG|Temozolomide|If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
41134674|NCT02761317|DRUG|standard preparation (2L PEG-ELS)|Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
41134675|NCT02761317|DRUG|low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)|Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
41134676|NCT02761317|DRUG|high-volume preparation (4L PEG-ELS)|Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
41134677|NCT03540329|DEVICE|Internal Osteogenesis distractor|Internal distraction osteogenesis in mandible
41134678|NCT03540329|DEVICE|External Osteogenesis distractor|External distraction osteogenesis in mandible
41134679|NCT03488043|PROCEDURE|Needle lung biopsy|Needle lung biopsy
41134680|NCT03597152|DIETARY_SUPPLEMENT|WelTract|Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D
41134681|NCT03597152|DIETARY_SUPPLEMENT|Placebo|Inert placebo custom manufactured for the sponsor
41289739|NCT01411410|DRUG|Copanlisib (BAY80-6946)|BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
41289740|NCT03345212|OTHER|Exercise training|The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.
41289741|NCT06293898|DRUG|BL-M07D1|Drug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized.
41289742|NCT02253875|DRUG|Tipranavir (TPV)|
40760710|NCT05488964|BEHAVIORAL|Exercise|Supervised endurance training with moderate-to-high intensity 3-4 times weekly.
40760711|NCT00680914|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (Synflorix)|3 doses administered intramuscularly.
40760712|NCT00680914|BIOLOGICAL|Prevenar|3 doses administered intramuscularly.
40760713|NCT00680914|BIOLOGICAL|GSK Biologicals' Hiberix™|3 doses administered intramuscularly.
40760714|NCT03348462|DRUG|ethosomal preparation of anthralin|once daily with short contact topical application
40760715|NCT03348462|DRUG|liposomal preparation of anthralin|once daily with short contact topical application
41289743|NCT02253875|DRUG|Ritonavir|
41289744|NCT02253875|DRUG|Omeprazole|
40952770|NCT03673579|DEVICE|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
40952771|NCT00853346|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
40952772|NCT00853346|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
40952773|NCT04686695|DEVICE|taVNS|taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 20 Hz with pulse duration ≤ 1 ms, for 30min,administered twice daily.
40952774|NCT01689636|DRUG|Tc 99m EC20|
40952775|NCT05335629|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose
40952776|NCT03798197|DRUG|30 mg estetrol (E4)|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).
40952777|NCT02489760|BIOLOGICAL|Adalimumab|The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
40952778|NCT02489760|BIOLOGICAL|Etanercept|The control arm will continue etanercept 25 mg subcutaneously twice a week
40952779|NCT02969330|DEVICE|Stimulator|
40952780|NCT02969330|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g glucose
40952781|NCT01685866|DEVICE|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
40952782|NCT00566111|DRUG|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
40952783|NCT00566111|DRUG|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
40952784|NCT01517620|DRUG|Total Glucosides Paeony Capsules|Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
40952785|NCT05925465|PROCEDURE|Maxillary and mandibular nerve block|receive bilateral combined maxillary and mandibular nerve block
40952786|NCT05925465|OTHER|Control|not receive any nerve block
40952787|NCT03664180|DRUG|Bivalirudin|IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
40952788|NCT03664180|DRUG|Enoxaparin|40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
40952789|NCT03664180|DRUG|Unfractionated heparin|IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
40952790|NCT03664180|DRUG|Bivalirudin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
40952791|NCT03664180|DRUG|Enoxaparin placebo syringe|Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
40952792|NCT03664180|DRUG|Unfractionated heparin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
40952793|NCT06454435|DRUG|Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel|"Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: Fruquintinib Fruquinitinib 4mg/d, QD, PO, D1-D14, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles."
40952794|NCT06454435|DRUG|Sintilimab + S-1 plus nab-paclitaxel|"Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles."
40952795|NCT05869760|OTHER|Carotenoid Intake|Carotenoid intake calculated from food diary records reported by guardians.
40952796|NCT05869760|OTHER|Serum carotenoid concentrations|Serum carotenoid concentrations measured by HPLC.
40952797|NCT00065208|BEHAVIORAL|Reiki|Energy therapy - 8 biweekly sessions of 30 minutes
40952798|NCT00065208|BEHAVIORAL|Pretend Reiki|Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes
40952799|NCT00065208|BEHAVIORAL|Rest / Guided Imagery|4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
40952800|NCT02585154|PROCEDURE|Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
40952801|NCT02585154|PROCEDURE|closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|Deep Brain Stimulation, which is applied depending on ongoing brain activity.
40952802|NCT02585154|PROCEDURE|Deep Brain Stimulation off|Deep Brain Stimulation is turned off.
40952803|NCT02585154|DEVICE|local field potentials and electroencephalography recordings|Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
40952804|NCT03816488|DRUG|Metformin|Metformin (usual dose) administered 2 h before surgery
40952805|NCT03816488|DRUG|Salsalate|Salsalate 1.5 g administered 2 h before surgery
40952806|NCT02938429|OTHER|Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days|
40952807|NCT04088942|OTHER|High-intensity smoking cessation intervention|"1. Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~2. Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~1. A hotline is established which the high-intensity group can call.~2. Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~   d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking."
40952808|NCT04088942|DRUG|Low-intensity smoking cessation intervention|Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
40952809|NCT03801460|OTHER|Remotely administered physiological reconditioning program|Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.
40952810|NCT02984111|DRUG|normal saline|
40952811|NCT02984111|DRUG|erythropoietin|
41289745|NCT03211130|BEHAVIORAL|SystemCHANGE™|During the intervention phase, the PI will visit both groups of participants at home at baseline and telephone them three times (day 3 ±2 days and months 1 and 2). Refer to tables 1 and 2 for intervention details. Treatment participants will implement SystemCHANGE™ activities related to medication taking with the assistance of the PI while attention-control participants will receive patient education materials on stroke. Perceived health data will be collected during the intervention phase. A 1-month maintenance phase follows the intervention phase. Electronic medication monitoring continues, but no intervention is delivered to either group.
41454436|NCT04316962|OTHER|Complex cancer rehabilitation|"The program is conducted as group rehabilitation, organized by four hour weekly over 12 weeks (approximately 50 hours) with 8-10 participants in each group over three years. The program is located in Askøy Municipality's 'Health Central' and conducted by a multidisciplinary team.~The content of the program is based on prior research and clinical experience, consisting of five elements:~1. Individual goal-setting~2. Physical activity (2 hours/week) focusing on balance/coordination, cardio and strength.~3. Psychoeducation: Five teaching sessions and discussions focusing on physical activity, fatigue and late-effects, nutrition, coping, social support and work/studies. In addition, two sessions (first and last) will also include next of kin.~4. Individual follow-up: Mandatory session at the start and end of the program, otherwise based on individual request and need.~5. Peer support."
41454437|NCT04817969|DEVICE|Zimmer Biomet Persona Ti-Nidium Total Knee System|Primary Knee Total Arthroplasty
41454438|NCT03105193|DRUG|IV Saline bolus and infusion|Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
41454439|NCT03105193|DRUG|IP Saline bolus and infusion|Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
41454440|NCT03105193|DRUG|IV lignocaine bolus and infusion|Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
41454441|NCT03105193|DRUG|IP Lignocaine bolus and infusion|Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
41289746|NCT03211130|BEHAVIORAL|Attention-Control|An experienced stroke nurse will deliver the attention control intervention. Table 3.2 shows the 2-month attention-control intervention. The stroke materials were developed by the Saint Luke's Marion Bloch Neuroscience Institute and are given to every stroke patient prior to dismissal. The PI will call participants at day 3 ±2 days, and months 1 and 2 to review chapter(s) from the book and answer questions about it. Interval, frequency, and setting are all exactly the same for the intervention and control groups. If the control participant raises questions about medications or medication-taking, PI will refer them to their Neurologist.
41289747|NCT03216265|OTHER|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
40952812|NCT03078400|DRUG|SPL-108|Subcutaneous injection of 150 mg administered either one time or two times per day.
41289748|NCT03216265|OTHER|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
41289749|NCT03216265|OTHER|No treatment|No treatment.
41454442|NCT06070480|OTHER|Spinal Anesthesia Group|Effect of spinal anesthesia on intraocular pressure
41454443|NCT06070480|OTHER|Desflurane Group|Effect of general anesthesia with desflurane on intraocular pressure
41454444|NCT06070480|OTHER|Propofol Group|Effect of general anesthesia with propofol on intraocular pressure
41289750|NCT00307229|BIOLOGICAL|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
41289751|NCT02021968|BIOLOGICAL|TetraVax-DV-TV003|TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10\^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
41289752|NCT02021968|BIOLOGICAL|rDEN2∆30-7169|The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
41289753|NCT02021968|BIOLOGICAL|Placebo|The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
41289754|NCT06140407|DRUG|Cisplatin|Receive Cisplatin
40952813|NCT06297317|DIAGNOSTIC_TEST|Ultrasound measurement of triceps surae muscle-tendon architecture|The resting plantar-flexors MTU architecture assessment was performed using a conventional B-mode and extended-field-of-view (EFOV) ultrasound imaging. Achille tendon cross-sectionnal area, Medial gastrocnemius thickness, pennation angle, fascicle length and muscle length were collected on the dominant lower limb.
40952814|NCT03623555|BEHAVIORAL|Trier Social Stress Test|"The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback."
41289755|NCT06140407|DRUG|Carboplatin|Receive Carboplatin
41289756|NCT06140407|DRUG|Etoposide|Receive Etoposide
41289757|NCT06140407|BIOLOGICAL|Pembrolizumab|Receive Pembrolizumab by IV
41289758|NCT06140407|PROCEDURE|Computed Tomography|Undergo Computed Tomography
41289759|NCT06140407|PROCEDURE|Positron Emission Tomography|Undergo Positron Emission Tomography
41289760|NCT06140407|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
41289761|NCT06140407|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41289762|NCT06140407|RADIATION|Radiation Therapy|Undergo Radiation Therapy
41289763|NCT02865044|OTHER|Wax Ester Marine Oil|Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules) consumed once, in clinic, at t=0.
41289764|NCT02865044|OTHER|Ethyl Ester Marine Oil|Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule), consumed once, in clinic, at t=0
41289765|NCT01943630|DRUG|15% AS101 gel|Administration of Topical 15% AS101 once a day (overnight)
41289766|NCT01943630|DRUG|Vehicle|Administration of Vehicle once a day (overnight)
40952815|NCT03623555|BIOLOGICAL|Salivary cortisol|Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST
41134682|NCT04529928|DEVICE|Carillon Mitral Contour System|Eligible subjects will be implanted with the Carillon Device, utilizing the Carillon Mitral Contour System. The device is a permanent implant in the coronary sinus/great cardiac vein, designed to cinch the mitral annulus. The implant procedure is minimally invasive, conducted via catheter placement.
41134683|NCT00900900|DIETARY_SUPPLEMENT|dehydroepiandrosterone (DHEA)|one-time 400mg oral dose of DHEA
41134684|NCT00900900|DIETARY_SUPPLEMENT|pregnenolone|one-time 400mg oral dose of pregnenolone
41289767|NCT02536482|DIETARY_SUPPLEMENT|Amix|Treat the children with cow's milk allergy for 5 months.
41289768|NCT03838250|BIOLOGICAL|Cellgram™ (Bone marrow-derived MSCs)|Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
41454445|NCT06028477|DEVICE|Stanford Glove|The non-invasive neuromodulation hardware system comprises two wireless controllers/battery packs which are fastened to the top of each hand via an adjustable elastic strap. Each controller is equipped with four vibrotactile fingertip stimulators, also known as tappers. There is a total of eight tappers (for index, middle, ring and pinkie of each hand) per system.
41454446|NCT04651036|DRUG|QL0605|a pegfilgrastim biosimilar to US Neulasta.
41289769|NCT06242925|DEVICE|AbCLO (Abdominal Wall Closure) Device|They will receive the standard of care (Lahey bag covering the bowel, 2 drains in the subcutaneous tissue and Ioban covering everything). The AbClO device has two Rectus Muscle Splints (RMS) to stabilize the rectus abdominis (preventing buckling of these muscles and stabilize the circumferential dynamic retainer (CDR)). The CDR is passed behind the patient's back. The RMSs are positioned on the abdominal wall approximately 2 cm lateral to the wound edges on each side. Additional padding can be applied underneath the RMS. The CDR is passed between the cross bar and the locking strip of each RMS and stretched until taut. The locking strips are locked in position. Four tensioners bridge across the OA from one RMS to the other. Gauze packs should be interposed between the undersurface of the tensioners and the surface of the temporary abdominal coverage to prevent friction. The Tensioners are tightened progressively until complete facial closure.
41289770|NCT05377905|DRUG|Microneedle Array Doxorubicin (MNA-D)|The Microneedle array patch is loaded/prepared with a total dose of 50 micrograms of Doxorubicin and is applied to a single selected cSCC remnant for a period of 20 minutes for a total of 4 weekly applications
41289771|NCT05161962|COMBINATION_PRODUCT|One group received standard oral care.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
41454447|NCT04651036|DRUG|US Neulasta|US Neulasta
40952816|NCT00967629|DRUG|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
40952817|NCT00967629|DRUG|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
41289772|NCT05161962|COMBINATION_PRODUCT|It was applied to the other group by aspiration.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
41289773|NCT03787433|DEVICE|ARC - Assisted Rehabilitation Care|"ARC is a platform based on wearable inertial sensors and machine learning algorithms, designed to bring the rehabilitation at post-stroke patients' home, following hospital discharge.~The product has been created with the purpose to improve physical skills and patient independence accordingly, in the six months following the acute event. ARC aims to optimize, ease and make more accessible the path of post-stroke rehabilitation during post-acute phase, in real life settings."
40952818|NCT05944887|DRUG|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
41454448|NCT06420063|BIOLOGICAL|CD123/CD33 CART|"The intervention in this clinical trial involves a novel approach using CD22/123-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD33/123-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD33/123-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD33/123 CAR-T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
41454449|NCT04548544|BEHAVIORAL|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
40952819|NCT05944887|DRUG|Saline administration as placebo|administration of a bolus of saline solution as a placebo
40952820|NCT05944887|DRUG|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol
40952821|NCT05944887|PROCEDURE|gastroscopy|esogastroduodenoscopy
40952822|NCT03631875|DRUG|Ketamine|use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
40952823|NCT00394160|DRUG|MK0476, Montelukast Sodium /Duration of Treatment : 14 Days|
40952824|NCT06132295|OTHER|Nursing care|"1. Consistent Schedule for the Replacement of Positioning Line Pens~2. Tailored Educational Content~3. Hypoallergenic Adhesive Patches~4. Enriched Treatment Care Platform~5. Participants with BMI \> 25 and an education level of high school or below, without specific caregivers, were identified by placing a red dot on the treatment record and on the patient's happiness card. Patients with BMI \< 25 and an education level of high school or above, with specific caregivers, were identified by placing a green dot on their records.~6. Individual interventions, educational pamphlets prepared in-house were added, to assess the maintenance status of the positioning marks."
40952825|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
40952826|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
40952827|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
40952828|NCT05228860|BEHAVIORAL|Vida Sana (a Group Lifestyle Intervention)|"Vida Sana is a Group Lifestyle intervention that has been shown to be effective among patients with type 2 diabetes (T2DM). Vida Sana includes 23 group sessions with a trained health coach:~* Months 1-4: 1 family-wide orientation + 12 weekly sessions~* Months 5-6: 4 bimonthly group sessions~* Months 7-12: 6 monthly group sessions~All regular primary care and diabetes care will remain as usual."
41134685|NCT00900900|DRUG|Placebo|one-time dose oral dose
41289774|NCT06295783|OTHER|MDASI-HN|Given by Questionnaire
41289775|NCT06295783|OTHER|EORTC QLQ-C30|Given by Questionnaire
41289776|NCT06295783|OTHER|EORTC HN35|Given by Questionnaire
41289777|NCT06148519|DIAGNOSTIC_TEST|2WIN-S portable refractor|All participants will be tested by 2WIN-S portable refractor without eye dilatation. If the 2WIN-S reports non-referral, participant will be tested visual acuity by optometrist. If the 2WIN-S reports referral, participant will be tested cycloplegic refraction by pediatric ophthalmologist, then tested by 2WIN-S again. The participant whose result is abnormal will be referred to the hospital for further management.
41289778|NCT00178412|BEHAVIORAL|Care Project for Hospitalized Elders & Family Caregivers|"Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)~Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home"
41289779|NCT00178412|BEHAVIORAL|Comparison Group|"Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.~Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center."
41289780|NCT06449625|DRUG|Semaglutide Pen Injector [Ozempic]|Semaglutide active drug
41289781|NCT06449625|DRUG|Placebo|semaglutide placebo
41289782|NCT01654497|DRUG|Dexanabinol|"Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg"
41289783|NCT04036136|BEHAVIORAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
41289784|NCT04036136|BEHAVIORAL|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
41289785|NCT04958564|DEVICE|DCP|"1. Dynamic compression plating to compress the fracture~2. Intramedullary device to share the load."
41289786|NCT04086940|DRUG|Esmolol|preventive
41134686|NCT05260866|OTHER|national population-based study|No intervention
41289787|NCT05878444|DIETARY_SUPPLEMENT|Probiotic|Resistant gastrointestinal capsules will be provided daily to the participants.
41289788|NCT01278628|OTHER|exercise training|exercise class once a year
41134687|NCT02094534|BIOLOGICAL|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
41289789|NCT04239560|DRUG|Boron-based Gel (Fibore)|During each radiotherapy session, 15 minutes before radiotherapy, the gel used and patients followed up.
41289790|NCT04239560|DRUG|Placebos|During each radiotherapy session, 15 minutes before radiotherapy, the Placebo gel which be free of any chemical used and patients followed up.
41289791|NCT04022369|BEHAVIORAL|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The weekly motivational phone calls structured according to the empowerment model and home visits when necessary were repeated. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. The program was established on evidence-based recommendations for the cardiac rehabilitation of patients with HF. Each session included warm-up and cool-down exercises, moderate walking, and balance exercises.
41289792|NCT00449059|DRUG|acute infusion of nitroglycerine into the pulmonary artery|
41289793|NCT04555655|DIETARY_SUPPLEMENT|Chicken extract supplement|70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.
41289794|NCT04555655|DIETARY_SUPPLEMENT|Peptide Supplement|70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.
41289795|NCT04555655|OTHER|Placebo|70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.
40760716|NCT06540495|BEHAVIORAL|Salaso Virtual Exercise Program|Salaso is a digital health technology company that has online, mobile and telehealth solutions enabling providers to 'prescribe' evidence-based exercise programs for patients to complete virtually.
40760717|NCT04550845|BEHAVIORAL|Focus group analyses|Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.
40760718|NCT06570330|DIETARY_SUPPLEMENT|SuperHMO|Super HMO Prebiotic Mix: five major types of human milk oligosaccharides including 2'-Fucosyllactose (2'-FL), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), 6'-Sialyllactose (6'SL), and 3'-Sialyllactose (3'SL)
41134688|NCT02094534|OTHER|Placebo|Fish oil capsules, identical in appearance to the experimental intervention.
41134689|NCT00853255|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine administered by nasal spray
41134690|NCT04658888|DEVICE|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cancer cells for screening purposes.
40952829|NCT05228860|BEHAVIORAL|Supplemental Healthy Food Deliveries|"Participants will receive 12 weeks of weekly food deliveries from Dig Deep Farms.~Each delivery will include a selection of seasonal fresh vegetables and a rotation of either a whole grain or a whole-grain food (3+ grams of fiber/serving). Whole grains will include brown rice, oatmeal, barley, quinoa; whole grain foods will include cereal, pasta, tortillas, bread, crackers. Delivery sizes will be scaled to the three corresponding household sizes: 2-3 people; 4-5 people; or 6 or more people.~Food will be delivered by Dig Deep Farms, which already has an established food subscription delivery system.~(Control group participants will receive the same delivery schedule, but delayed to begin 6 months after their study enrollment.)"
41134691|NCT04463394|DRUG|Vasopressin|Vasopressin administered intravenously
41289796|NCT06316323|DRUG|Silver diamine fluoride|38% Silver Diamine Fluoride (SDF) is a topical antimicrobial and remineralizing agent which was cleared by the FDA as a Class II medical device to treat tooth sensitivity. In certain circumstances, SDF may be used as a non-restorative treatment to arrest carious lesions on primary and permanent teeth
41289797|NCT06316323|DRUG|Sodium fluoride|Fluoride varnish to apply on tooth surface, so that the tooth becomes more resistant to caries attack. The active ingredient of fluoride varnish is 5% sodium fluoride, (22,600 ppm fluoride)
41289798|NCT03211078|PROCEDURE|super-D ENB guided-PDT|PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
41289799|NCT00418262|DRUG|Atomoxetine|Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
41289800|NCT05717907|DEVICE|suction catheter|a suction catheter will be first inserted through the ETT so that about 10 cm of the catheter was protruding from the distal end of the tube. The tip of the catheter is then inserted through the selected nostril until it passes to the pharynx. If resistance is felt to the passage of catheter, the other nostril will be tried. The nostril with less resistance to the catheter passage will be chosen for the completion of the procedure. The Endotracheal tube is then advance over the catheter through the nasal passage while holding the catheter proximal to the tube to prevent its advancement with the tube. After the tube tip reach to the pharynx, the suction catheter is withdrawn and tracheal intubation will be completed.
41289801|NCT06512324|DEVICE|Ampa One TMS System|Transcranial Magnetic Stimulation
41289802|NCT03532555|DIETARY_SUPPLEMENT|Zinc Acetate|Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
41289803|NCT03532555|OTHER|No supplemental zinc|Infants will receive standard of care, which is currently no supplemental zinc
41289804|NCT02571179|DRUG|intranasal fentanyl 50 microg dose up to 250 microg|When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
41289805|NCT01918215|DEVICE|ICD|
41289806|NCT01918215|DEVICE|ILR|
41134692|NCT05538000|OTHER|Face to face and telephonic interviews|"face to face interview : before the first chemotherapy treatment (M0), then at 3 months (M3), 6 months (M6) and 9 months (M9) after the first chemotherapy treatment.~Telephonic interview : every month between two face-to-face interviews, i.e. at 1 month after the first treatment (M1), at 2 months (M2), at 4 months (M4), at 5 months (M5), at 7 months (M7) and at 8 months (M8) after the first chemotherapy treatment."
41289807|NCT01458340|DRUG|TD-9855|Once daily
41289808|NCT01458340|DRUG|TD-9855|Once daily
41134693|NCT00787709|BEHAVIORAL|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
41289809|NCT01458340|DRUG|Placebo|Once daily
41289810|NCT01662973|OTHER|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1\*10E6 UC-MSC/kg body weight for 12 weeks.
40760719|NCT06570330|DIETARY_SUPPLEMENT|Non-GMO corn Maltodextrin, Rapid Absorption|he composition and absorption properties are similar to the investigational product and will be given in the same dosage (2.1g/day for days 1-5 and increasing to 4.2 g/day for days 6-30) and route of administration as the investigational product.
40760720|NCT00949065|BIOLOGICAL|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
41134694|NCT02311413|DRUG|Cat-PAD|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
41134695|NCT02311413|DRUG|Placebo|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
41134696|NCT06079736|DRUG|PGN-EDO51|IV infusion
40760721|NCT06570291|DRUG|Mesenchymal progenitor cells|Allogenic adipose tissue-derived mesenchymal progenitor cells administrated for intra- articular use
40760722|NCT06570291|DRUG|Sodium Hyaluronate Injection|Sodium Hyaluronate administrated for intra-articular use
41289811|NCT01662973|OTHER|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
41289812|NCT05706467|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
41289813|NCT05706467|DEVICE|Non-invasive continuous positive airway pressure ventilation|Non-invasive positive airway pressure ventilation is carried out through non-invasive ventilator.
41289814|NCT03069768|DEVICE|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
41289815|NCT03069768|DRUG|Chantix|For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
41289816|NCT06021795|DEVICE|Sound Treatment|Customized sound audio track delivered via standard commercially available bone conduction headset
41289817|NCT01417286|RADIATION|External beam radiation therapy|Hypofractionated accelerated radiation therapy over 11 days
41454450|NCT01726803|OTHER|Early Physical Therapy with Usual Care|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
40760723|NCT06569381|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fasting condition, 1 tablet at a time, once a day.
40952830|NCT00697788|DRUG|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine \[in ug/kg/hr\], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
40952831|NCT02540109|DEVICE|HD-tDCS (Soterix Medical, Active)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
41134697|NCT05014607|BIOLOGICAL|Personalized multi-peptide vaccine|"Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 1-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen.~Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned.~Treatment schedule:~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses."
41134698|NCT02851498|OTHER|Food product: high-protein pasta and cereal|
41134699|NCT02722434|OTHER|Laboratory Biomarker Analysis|Correlative studies
41134700|NCT02722434|OTHER|MC5-A Scrambler Therapy|Undergo Scrambler therapy
41134701|NCT02722434|OTHER|Questionnaire Administration|Ancillary studies
41134702|NCT02722434|OTHER|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
41134703|NCT02669576|BEHAVIORAL|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
41134704|NCT02669576|OTHER|Usual care|Patients continue usual care by their practitioner
41134705|NCT06051799|OTHER|Myofascial trigger points pressure release|Patient lying down in the supine position, Therapist do a first and second finger pincer grasp is performed on the myofascial trigger points located on the upper trapezius muscle and sternocleidomastoid muscle, this pressure will be increased as the therapist perceives a reduction in soft tissue resistance under the finger over a period of 90 seconds. Previous studies indicate no difference between 60 and 90 seconds of pressure. It will be performed on as many trigger points as we find in each muscle associated with the study.
41134706|NCT06051799|OTHER|Therapeutic exercise and postural hygiene|"Therapeutic exercise and postural hygiene: A progression of exercises with contraction of the deep neck flexor muscles will be included in the first session. Subjects will be taught to perform a slow and controlled craniocervical flexion. Subjects will then be trained to be able to progressively maintain craniocervical flexion through feedback from an air device (Stabilizer™, Chattanooga Group Inc., Chattanooga, TN) placed behind the neck. This sensor monitors the slight flattening of the cervical curve that occurs with contraction of the craniocervical deep flexor musculature. It should be performed at least once a day during the treatment regimen.~Also Postural correction exercises carried out regularly throughout the day, especially when seated. Indications are given to avoid pelvic retroversion and maintain a natural lumbar lordosis while performing retraction and adduction of the scapulae and gently lengthening the spine."
41289818|NCT02859415|DRUG|Mithramycin|Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
41289819|NCT01863563|DEVICE|QuickClot|1 application of treatment to each tonsil/adenoid removal area
41289820|NCT05621512|OTHER|Preventive sessions|Preventive sessions between the pregnant employee, her manager and a midwife.
41454451|NCT01726803|OTHER|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
41454452|NCT03853187|RADIATION|Zr-89 labelled durvalumab PET/CT|Patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and in- and ex-vivo In-111-oxine or in-vivo \[89zr\]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.
41454453|NCT03853187|DRUG|Durvalumab (MEDI4736)|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC.
41454454|NCT05992454|DEVICE|EOLIFE|Measurement of ventilatory parameters during manual ventilation by professional rescuers during out-of-hospital cardiac arrest
40760724|NCT06569381|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
40760725|NCT03607110|DRUG|Ketamine|sedation drugs
40760726|NCT03607110|DRUG|fentanyl|sedation drugs
40760727|NCT03607110|DEVICE|patient control analgesia|patient control analgesia
40760728|NCT03270228|OTHER|Nonspecific pleuritis after VATS thoracoscopy|Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.
40760729|NCT00530257|DRUG|Placebo|Placebo (sugar pill)
40760730|NCT00530257|DRUG|OROS-methylphenidate|18 mg to 54 mg once a day for 1 week
41289821|NCT00806117|RADIATION|Radiotherapy (RT)|"External irradiation 50Gy/5 weeks~* Lateral: 2 cm lateral to the bony margin of the pelvis~* Superior: Between L5 and S1~* Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)"
41289822|NCT00806117|OTHER|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
41289823|NCT00806117|OTHER|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135\~175mg/m2 over 3 hours Cisplatin 60\~75mg/m2
41289824|NCT03894904|DRUG|Papaverine|0.12 mg/mL papaverine administered as soon as the arterial catheter is placed and secured, and 0.12 mg/mL papaverine administered one hour after initial dose
41289825|NCT03894904|DRUG|Heparin|2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
40952832|NCT02540109|DEVICE|HD-tDCS (Soterix Medical, Sham)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
40952833|NCT01447433|DRUG|Calcium Carbonate|tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks
41134707|NCT01278030|PROCEDURE|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
41289826|NCT03894904|DRUG|Rescue papaverine, as needed|If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
41289827|NCT06077422|DRUG|bupivacaine liposome injectable suspension|Bupivacaine liposome injectable suspension (Exparel) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
40760731|NCT05193383|BEHAVIORAL|Imaginal exposure|Session 1 (Day 1): Participants receive repeated exposure to mental imagery of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
41134708|NCT00826956|PROCEDURE|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
41134709|NCT02894099|OTHER|Prolonged sitting time|Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
40760732|NCT05193383|BEHAVIORAL|Exposure|Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.
40760733|NCT05193383|BEHAVIORAL|Approach-avoidance conflict|Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).
40760734|NCT05193383|BEHAVIORAL|In vivo exposure|Session 1 (Day 1): in vivo exposure. Participants receive repeated exposure to film clips of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
40760735|NCT00385515|DRUG|SNX-1012 (meclocycline sulfosalicylate)|tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
40760736|NCT00385515|DRUG|placebo|Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
40760737|NCT05043831|DEVICE|DSLT|Direct-SLT is applied via the limbus to the trabecular meshwork
40952834|NCT01447433|BEHAVIORAL|Energy restriction|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
40952835|NCT00369824|BIOLOGICAL|Different formulations of GSK Biologicals' HPV vaccine (580299)|Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
41134710|NCT02894099|OTHER|PST+Light intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
40952836|NCT00369824|BIOLOGICAL|Menactra TM|One dose of vaccine administered intramuscularly
40952837|NCT00369824|BIOLOGICAL|Boostrix TM|One dose of vaccine administered intramuscularly
40952838|NCT01457222|BEHAVIORAL|Mindfulness intervention|Web-based guided mindfulness meditation 10 minutes daily
40952839|NCT01457222|BEHAVIORAL|Music relaxation|Music relaxation 10 minutes daily
40952840|NCT02344862|DRUG|FYU-981 High dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
40952841|NCT02344862|DRUG|FYU-981 Middle dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
41289828|NCT06077422|DRUG|Bupivacaine Hydrochloride|Bupivacaine HCl (Marcaine) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
41289829|NCT01452425|DEVICE|Tourniquet|Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
41289830|NCT01452425|DEVICE|INVOS assessment|Near Infraread spectroscopy, non invasive
41289831|NCT01452425|DEVICE|EMG assessment|Electromyography, non invasive
41289832|NCT02654106|RADIATION|Fractionated Stereotactic Radiotherapy|The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.
41289833|NCT02654106|DRUG|Temozolomide|concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2\*5d, q28d, 6cycles
40760738|NCT06564701|DEVICE|Phonak Roger TouchScreen Microphone|Transmitter microphone system operating on the 2.4 GHz band, which allows for low-delay and reliable long-range broadcast to a compatible Roger receiver, desgined to be used in educational settings. It features six microphones and adaptive technology in which speech signals are increased when background noise increases to ensure that the speech signal is always above the noise level.
40952842|NCT02344862|DRUG|FYU-981 Low dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
40952843|NCT02344862|DRUG|Placebo, (Oral daily dosing for 8 weeks)|Subjects randomized to the placebo arm receive placebo.
40952844|NCT04207021|DIETARY_SUPPLEMENT|Experimental: Curcumin derivate|two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
40952845|NCT04207021|DIETARY_SUPPLEMENT|Placebo|two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
40952846|NCT04759573|BEHAVIORAL|Early Vocal Contact|Mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.
40952847|NCT04759573|BEHAVIORAL|Behavioral Observation|Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
41134711|NCT02894099|OTHER|PST+Moderate intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.
41134712|NCT02894099|OTHER|PST+Moderate intensity Long bouts PA|Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.
41134713|NCT02792855|DEVICE|snifﬁng Position(place a 7-cm cushion under head )|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
41134714|NCT02792855|DEVICE|Simple Head Extension(without cushion)|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
41134715|NCT02243449|PROCEDURE|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
41134716|NCT02243449|PROCEDURE|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
41134717|NCT05032716|OTHER|Balance exrcises|the group (20 children) received traditional exercise program with instructions given to the children for 60 min aiming to improve posture control and balance. Tools of traditional physical therapy exercises were; special tools were used for traditional physical therapy exercises include vestibular board, rolls of different sizes, blocks and wedges of different heights
41289834|NCT06074510|DRUG|Piflufolastat F 18 Intravenous Solution [PYLARIFY]|Participants will receive a single dose of 333 MBq (9 mCi) \[296 MBq-370 MBq (8 mCi - 10 mCi)\] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing
41289835|NCT04431999|DRUG|Whole blood transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 whole blood bags for the 1st and 2nd pack. The later packs will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
40952848|NCT05818098|DEVICE|Intravascular Lithotripsy System of Shanghai MicroPort Rhythm|The Intravascular Lithotripsy System is a single-use, sterile, disposable balloon angioplasty catheter that contains a series of unfocused, electrohydraulic lithotripsy emitters, which convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within vascular plaque.
40952849|NCT03482765|DIETARY_SUPPLEMENT|Probiotic 1|The product under investigation is a unique probiotic.
40952850|NCT03482765|DIETARY_SUPPLEMENT|Probiotic 2|The product under investigation is a unique probiotic.
41289836|NCT04431999|DRUG|Fractionated blood products transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
41289837|NCT04618705|BEHAVIORAL|Smoking Cessation|Participants will start a smoking cessation program.
41289838|NCT04393181|PROCEDURE|Heart transplantation 1|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with left ventricular dysfunction, defined as an ejection fraction less than 50% or regional hypokinesia.
41289839|NCT04393181|PROCEDURE|Heart transplantation 2|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with normal function, according to the recommendations from The International Society for Heart and Lung Transplantation (ISHLT).
41289840|NCT01410591|DEVICE|8-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
41289841|NCT01410591|DEVICE|10-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
41289842|NCT02438072|DRUG|Omeprazole (10 mg, A02BC01)|The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
41289843|NCT03268174|OTHER|AO+Mist|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
41289844|NCT03268174|OTHER|Placebo|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
41289845|NCT03331172|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
41289846|NCT02553915|OTHER|Placebo|Soybean oil placebo
41289847|NCT02553915|DRUG|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
41289848|NCT02553915|DRUG|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
41289849|NCT02553915|DRUG|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
41454455|NCT04151368|PROCEDURE|Robotic Nipple-Sparing Mastectomy (RNSM)|RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
41454456|NCT04967469|DRUG|Calcitriol|end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy
40760739|NCT06564701|DEVICE|Phonak Partner Mic|Wireless microphone that uses Phonak proprietary AirStream technology to connect to Phonak hearing aids. It uses a fixed directional microphone, and is paired to the hearing aids such that the hearing aid microphones are attenuated at a fixed level when the microphone is in use.
40760740|NCT04464538|BEHAVIORAL|WALC-R|Initial group education session and individualized coaching (remote)
40952851|NCT03482765|OTHER|Placebo|Microcrystalline Cellulose
40952852|NCT05844410|DRUG|Corticosteroid|Adults patients admitted to the hospital after a confirmed COVID-19 infection, irrespective of the stage and severity of the disease, were included in the study. Only those receiving corticosteroids as a treatment were in the study sample, with no preferences based on race or ethnicity
40952853|NCT02470832|DRUG|RG1662|
40952854|NCT02470832|DRUG|itraconazole|
40952855|NCT02700113|OTHER|No intervention|Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
40952856|NCT05159284|DRUG|Hydrocortisone Ophthalmic|1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.
40952857|NCT05159284|DEVICE|MGD Rx EyeBag® eyelid warming device|Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.
40952858|NCT05159284|DEVICE|Lephanet® lid wipes|Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.
40952859|NCT05159284|DEVICE|Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%|Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.
40952860|NCT01691131|OTHER|Exercise training|Comparison of high intensity exercise training on land versus water.
40952861|NCT00265629|DEVICE|RF catheter ablation|RF ablation using mesh device
40952862|NCT06556836|DEVICE|Doppler color and M-Mode ultrasound|A diagnostic test intervention using color Doppler and M-Mode ultrasound will be conducted to localize the catheter within the epidural space and compared with epidurography.
40952863|NCT06556836|DEVICE|Epidurography|An epidurography is an imaging procedure used to visualize the epidural space of the spine. The process involves inserting an epidural catheter, through which a contrast dye is injected. Fluoroscopy or X-rays are then used to capture real-time images of the contrast flow, helping to ensure the catheter's correct placement and to detect any localization anomalies. In this study, the epidurography will be performed in the radiology department by a radiologist and a pain management interventionist.
40952864|NCT01390649|BIOLOGICAL|IgPro10|IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
40952865|NCT02439060|OTHER|Acellular Cadaveric Dermal Matrix|Undergo intraperitoneal prophylactic mesh placement
40952866|NCT01790854|DRUG|Prasugrel dose 5 mg/day|
40952867|NCT01790854|DRUG|Prasugrel dose 10 mg/day|
40952868|NCT03539328|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy.
40952869|NCT03539328|DRUG|Gemcitabine|Chemotherapy medication
40952870|NCT03539328|DRUG|Paclitaxel|Chemotherapy medication
40952871|NCT03539328|DRUG|Liposomal Doxorubicin|Chemotherapy medication
40952872|NCT04053075|OTHER|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
40952873|NCT04053075|OTHER|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
40952874|NCT00802087|DRUG|hydrocodone|Extended Release tablet
40952875|NCT00802087|DRUG|hydrocodone & acetaminophen combination|Immediate Release tablet, hydrocodone and acetaminophen combination product
40952876|NCT06213246|BEHAVIORAL|Sleep Hygiene Strategies|"The sleep hygiene strategies will be applied for all seven days of Week 3 and will involve the following guidelines recommended by the National Sleep Foundation~* Maintain a consistent wake-up and bedtime schedule during workdays.~* Do not delay/advance excessively (no more than 2 hours) the wake-up and bedtime - schedule during weekends.~* Keep the bedroom temperature below 22°C.~* Avoid sources of light and noise in the bedroom.~* Use the bed only for sleeping, avoiding other activities before bedtime.~* Avoid daytime naps during workdays.~* Refrain from using electronic devices (PC, laptop, cellphone, television) at least 30 minutes before bedtime.~* Expose yourself to natural light in the morning and reduce artificial lights in the evening.~* Avoid consuming alcoholic beverages and caffeine in the afternoon.~* Have a moderately sized dinner at least 3 hours before bedtime."
40952877|NCT02932202|OTHER|Longitudinal Nutritional Counseling|
40952878|NCT02932202|OTHER|Standard Care|
40952879|NCT04590131|PROCEDURE|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.|Under local anesthesia, a standard endovascular approach is performed. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Immediately after the stenting procedure, under local anesthesia, access to the distal part of the SFA at the outlet of Hunter's canal and 1 portion of the popliteal artery is performed. The lamina vastoadductoria is dissected. The wound is sutured in layers. An aseptic bandage is applied. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
41134718|NCT05032716|OTHER|Balance exrcises and Treadmill training|the group (20 children) received the same traditional physical therapy program as the same applied in group of balance exercises, in addition to treadmill training (30 min). The child walked on the treadmill (motorized treadmill, ENTRED, Enraf-Nonius) at 75% of over-ground speed and individually prescribed low-endurance walking at 0% incline for 20 min, three times a week for 8 successive weeks. The walking area of the treadmill is made from heavy steel with a minimum 8-inch thickness and is available with cushioning in case of accidental impacts. Before the walking session, each child underwent 5 min of active stretching exercises that include prolonged and progressive stretching of the hamstrings, quadriceps muscles, and Achilles tendon.
41134719|NCT01841385|OTHER|Pilates method|Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
41134720|NCT06477549|DRUG|Bendamustine Hydrochloride|Days -7 through -6: Bendamustine 90 mg/m2 iv x 2 days
41134721|NCT06477549|DRUG|Ruxolitinib|Days -7 through -2: ruxolitinib 5 mg tid per os
40952880|NCT04590131|PROCEDURE|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.|Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
40952881|NCT00850070|DRUG|sapropterin|Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
40760741|NCT04464538|OTHER|Information leaflet|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
40952882|NCT00850070|DRUG|Placebo|Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
40952883|NCT03996733|OTHER|Lecture|Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.
40952884|NCT03996733|OTHER|Demo Video|Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.
41289850|NCT05010681|DRUG|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
41289851|NCT05010681|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
40952885|NCT03996733|OTHER|UltrasoundImaging|Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.
40952886|NCT03996733|OTHER|ModelTraining|"Participants will exercise the proper punction of juguler vein with USG guidance on the homemade jugular venous catheterization training model.~Training model will include carotid artery, trachea and plaure in accordance with the real anatomy."
40952887|NCT03828994|BEHAVIORAL|Tech-PN|"* text messaging(daily medication reminders and tri-weekly messages following the 14-day treatment period)~* enhanced community health nurse visits on day 3-5, 14 and 30~* field based treatment visits~* clinical assistance with notification, testing and treatment"
41289852|NCT04224558|DRUG|Mesna|"Stem Cell Mobilization: Infused according to institutional guidelines;~Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol."
40952888|NCT00654121|DRUG|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
40952889|NCT05738603|DEVICE|Hypotension Prediction Index|Hemodynamic perioperative monitoring with the Hypotension Prediction Index
40952890|NCT00079248|BIOLOGICAL|therapeutic progesterone|
41289853|NCT04224558|DRUG|Cyclophosphamide|"Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)"
41289854|NCT04224558|DRUG|Filgrastim|"Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;~Post-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of \>1000/μL"
40760742|NCT02105012|DRUG|BD MDI 320 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
40952891|NCT00079248|DRUG|conjugated estrogens|
40952892|NCT04004546|BEHAVIORAL|Health literacy-based intervention|Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
40952893|NCT00684099|DRUG|Docetaxel|Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
41134722|NCT03578965|DRUG|Cefazolin|-If patient has a penicillin allergy then clindamycin will be used. Prophylactic antibiotics should be administered prior to skin incision
40760743|NCT02105012|DRUG|BD MDI 160 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
40760744|NCT02105012|DRUG|BD MDI 80 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
40760745|NCT02105012|DRUG|BD MDI 40 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
40760746|NCT02105012|DRUG|Placebo MDI|Placebo MDI administered as 2 inhalations BID
40952894|NCT00684099|DRUG|Pemetrexed|Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
40952895|NCT02835742|DRUG|Sargramostim|
40952896|NCT02835742|DRUG|Placebo|
40952897|NCT02980783|DEVICE|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.
40952898|NCT03363269|DRUG|ID1201|
40952899|NCT02877134|DRUG|JNJ-64304500|Participants will receive JNJ-64304500 Subcutaneously.
40952900|NCT02877134|DRUG|Placebo|Participants will receive placebo Subcutaneously.
40952901|NCT02877134|DRUG|Ustekinumab|Participants will receive ustekinumab as per the dosing regimen.
40952902|NCT01874600|DEVICE|Brain Sentinel Seizure Detection Device and Warning System|The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
40952903|NCT06267248|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
40952904|NCT01216631|DRUG|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
40952905|NCT01216631|DRUG|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
40952906|NCT01216631|DRUG|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
40952907|NCT01287078|DRUG|Cyclosporine Inhalation Solution|sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
40952908|NCT05089279|DRUG|D113|QD, PO
40952909|NCT05089279|DRUG|CKD-349|QD, PO
40952910|NCT00039078|RADIATION|yttrium Y 90 glass microspheres|
40952911|NCT00001966|DRUG|Mind-body therapy|
40952912|NCT02343237|PROCEDURE|Osteopathic treatment|osteopathic sessions of 20 minutes
40952913|NCT02343237|PROCEDURE|Factitious osteopathic treatment|6 factitious osteopathic sessions of 20 minutes
41289855|NCT04224558|PROCEDURE|Apheresis catheter placement|Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.
41289856|NCT04224558|PROCEDURE|Leukapheresis|Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10\^6 CD34+ cells/kg body weight.
41289857|NCT04224558|DRUG|Fludarabine|Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.
41289858|NCT04224558|DRUG|Methylprednisolone|Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines
40952914|NCT04851457|DRUG|Intravenous tirofiban combination therapy|Patients will enter the tirofiban treatment protocol immediately within half an hour after randomization and prior to the femoral artery puncture. Tirofiban is administered as an intravenous bolus dose of 10 μg/kg injection within 3 min and then by an intravenous infusion at a rate of 0.1 μg/(kg·min) for 24 hours.
40952915|NCT02650427|DRUG|Sitagliptin|100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
40952916|NCT05532917|OTHER|Gupta score|The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (\>130 mmol/L or \>1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The frequency of cardiology consultation requests will be investigated according to the use of the Gupta score.
41134723|NCT01920126|DRUG|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
41134724|NCT01920126|DRUG|Saline|
41134725|NCT05402566|DIAGNOSTIC_TEST|Deuterium metabolic imaging|MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
41289859|NCT04224558|DRUG|Diphenhydramine|Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines
40952917|NCT04459624|PROCEDURE|Erector Spina Plane Block|Group E (ESP block) will be applied 20 ml of % 0.25 bupivacaine between the erector spina muscle and transverse process at the 8th thoracic level. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
40952918|NCT04459624|PROCEDURE|Quadratus Lumborum Block 2|Group Q (QLB2 block) lumbar interfacial triangle (LIFT) will be applied 20 ml of % 0.25 bupivacaine. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
41134726|NCT06466083|OTHER|no intervention|this is an observation study,no intervention
41134727|NCT03251456|OTHER|Tertiary care|"1. Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders~2. The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines~3. Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
41134728|NCT03251456|OTHER|Usual Care|"1. Inform the parents that there are abnormalities after eye disease screening of their children~2. Inform the parents that they should take their children to the hospital for further consultation~3. Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
41134729|NCT02705976|OTHER|Experimental|The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.
41134730|NCT02705976|OTHER|Active Comparator|Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
41134731|NCT02588521|DRUG|AL-794|
41134732|NCT02588521|OTHER|Placebo/Vehicle|Suspension vehicle without active drug
41134733|NCT06308406|DRUG|Bevacizumab； HRS-1167|Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral
41134734|NCT00074607|DRUG|Gemcitabine|"Schedule~Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).~In the absence of disease progression or DLT, patients may proceed to consolidation.~Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.~Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year."
41134735|NCT00951132|DRUG|rosuvastatin|10mg tablets, once daily in three months
41134736|NCT00951132|DRUG|Placebo|tablet, once daily, three months
41134737|NCT03572894|DEVICE|PVI and RPVI measurements|"PVI and RPVI measurements during variations of the tidal volume (Vt challenge) and a recruitment maneuver in anesthetized and mechanically ventilated patients.~* T0 : Vt 6 mL/kg of predicted body weight (PBW) during 5 minutes~* T1 : Vt 8 mL/Kg of PBW during 5 minutes~* T2 : Vt 10 mL/kg of PBW during 5 minutes~* T3 : Vt 6 mL/kg of PBW during 5 minutes~* T4 : A single recruitment maneuver~Data will be recorded at each step."
41134738|NCT03510416|DRUG|Apatinib|apatinib is a kind of Inhibitor of VEGFR-2
41134739|NCT03510416|RADIATION|TACE|Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
41289860|NCT04224558|DRUG|Acetaminophen|Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines
41289861|NCT04224558|DRUG|anti-thymocyte globulin (rabbit)|Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.
41289862|NCT04224558|DRUG|lymphocyte immune globulin|Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia \& Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.
41289863|NCT04224558|BIOLOGICAL|Peripheral Blood Stem Cell Infusion|PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.
41289864|NCT04224558|DRUG|Cytoxan|Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.
41289865|NCT03766997|DRUG|Compound Betamethasone Injection|local injection
41289866|NCT03766997|DRUG|Hydrocortisone Butyrate 0.1% Cream|topical use
41289867|NCT04095416|DEVICE|ACE compression wrap|Bilateral lower extremity ACE compression wraps
41454457|NCT04967469|DRUG|Alfacalcidol 0.5 MCG Oral Capsule|end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy
41289868|NCT06510517|OTHER|Calculation of Mechanical Power.|"Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP)."
40952919|NCT06556290|OTHER|Gluten free and casein free diet|Parents will be advised for three months to ensure that children with autism spectrum disorder follow a casein-free and gluten-free diet during this period.
41289869|NCT06510517|OTHER|Measurement Diaphragmatic Excursion after first SBT|Chest ultrasound to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT. The DE at 0 min, 5 min, and 30 min of SBT was respectively named as DE0, DE5, and DE30. The variation of right DE between each time point was named as ΔDE30-5 and ΔDE30-0. (7)
41134740|NCT01784809|BEHAVIORAL|Multimedia WORTH|"The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. \*\*\*To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:~http://ccnmtl.columbia.edu/projects/worth/presentation"
41289870|NCT06268899|OTHER|First mobilization protocol|The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed \>60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
41289871|NCT03412630|RADIATION|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
41289872|NCT05370248|OTHER|Tidal volume 6 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
41289873|NCT05370248|OTHER|Tidal volume 10 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
41289874|NCT04250493|BIOLOGICAL|Homeostasis Model Assessment of insulin resistance (HOMA)|Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index
41289875|NCT04250493|BEHAVIORAL|MOntreal Cognitive Assessment (MoCA)|Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)
41289876|NCT04250493|BEHAVIORAL|Clinical characteristics of AMS patients|Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)
41289877|NCT04250493|PROCEDURE|Brain Magnetic Resonance Imaging (MRI)|Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume
41289878|NCT04250493|BIOLOGICAL|Blood sampling|Optional blood sampling for the constitution of a biological collection
41289879|NCT04950985|OTHER|Observational Study|Observational study
41289880|NCT04016493|PROCEDURE|Connective tissue graft|The patient received 600 mg of ibuprofen (paracetamol 1 g in case of allergy) prior to surgery, and chlorhexidine mouthwash 0.2% was provided for 2 min. Patients received local anaesthesia at the donor and recession sites (articaine hydrochloride 7200 mg/1.8 ml, adrenalin 1800 mcg/1.8 ml). CTG harvesting was performed prior to the preparation of the reception site to avoid any bias. The graft dimension was calculated according to the recession dimensions; a minimum of 3 mm of the graft was submerged mesially, distally and apically. The CTG was harvested from the palate with single edge incision and sutured with 4.0 silk. The patient was subsequently assigned randomly to the control (CAF+CTG) or the test group (TUN+CTG).
41289881|NCT01851473|DRUG|cocaine|25 mg IV on days 1, 5, and 10
41289882|NCT01851473|DRUG|quinine|80 mg orally on days 7-10
41289883|NCT01851473|DRUG|acetazolamide|15 mg orally on days 2-5
41289884|NCT02377934|RADIATION|Cardiac Magnetic Resonance Imaging (MRI)|
40760747|NCT03766906|BEHAVIORAL|Talk STEM Familia app|The Talk STEM Familia app will be used to improve access to sound instruction in scientific academic vocabulary through the development of a technology-enhanced, culturally responsive smart-speaker tool that engages Latino families in culturally responsive academic language acquisition and practice in the home setting.
40952920|NCT03566862|DIAGNOSTIC_TEST|Leicester Cough Monitor (LCM)|The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
40952921|NCT05232071|DRUG|IVA337|800 mg
40952922|NCT05232071|DRUG|Placebo|Placebo to match
41454458|NCT06559761|PROCEDURE|Hepatectomy|According to guideline recommended procedure of hepatectomy
40952923|NCT05232071|DRUG|Empagliflozin|10 mg
41454459|NCT05236062|BEHAVIORAL|Exercise|aerobic and resistance exercise
41454460|NCT05236062|BEHAVIORAL|Attention control|stretching
41454461|NCT00796874|OTHER|active surveillance|Correlative Study
41454462|NCT00796874|OTHER|imaging biomarker analysis|Correlative Study
40952924|NCT04447794|BEHAVIORAL|Step Away Chatbot|"The Step Away chatbot utilizes AI technology to provide mobile, web-based, person-centered, behavioral-based interventions and timely support for individuals seeking to reduce their alcohol use. Participants interact with the chatbot through interactive text.~The Step Away chatbot is informed by the following theoretical constructs: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. It uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. It proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
40952925|NCT04447794|BEHAVIORAL|Step Away App|"The Step Away app is a smartphone-based mobile intervention system.~It is informed by three theoretical constructs that are considered the most important active ingredients for person-centered, behavioral-based intervention and treatment in addictions: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. Step Away uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. Step Away proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
40952926|NCT02607930|DRUG|ABC/DTG/3TC|600/50/300 milligrams (mg) tablets administered orally, once daily
40952927|NCT02607930|DRUG|B/F/TAF|50/200/25 mg tablets administered orally, once daily, without regard to food
40952928|NCT02607930|DRUG|ABC/DTG/3TC Placebo|Tablets administered orally, once daily
40952929|NCT02607930|DRUG|B/F/TAF Placebo|Tablets administered orally, once daily
40952930|NCT00507091|DRUG|ZD6474 (vandetanib) 100mg|once daily oral tablet
40952931|NCT00507091|DRUG|Irinotecan|intravenous infusion
40952932|NCT00507091|DRUG|5-Fluorouracil|intravenous infusion
40952933|NCT00507091|DRUG|Leucovorin|intravenous infusion
41289885|NCT05995522|DIETARY_SUPPLEMENT|Vitamin K2|100 µg per day for 90 days
40952934|NCT00507091|DRUG|ZD6474 (vandetanib) 300mg|once daily oral tablet
40952935|NCT04689009|DEVICE|EmoLED|The treatment with EmoLED, in addition to the SOC, will be performed during each visit for 60 seconds on each 5 cm diameter sub-area of the selected lesion.
40952936|NCT04689009|PROCEDURE|current Standards Of Care|"The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out."
40952937|NCT00027716|DRUG|bortezomib|
40952938|NCT02760797|DRUG|Emactuzumab|Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.
40952939|NCT02760797|DRUG|RO7009789|RO7009789 will be administered IV every 3 weeks (every cycle).
40952940|NCT06378151|OTHER|TLT training|"Emergency clinicians assigned to the intervention group will receive the following training and resources.~1. The TLT Conversation Guide: The structured conversation guide entails discussing patients' values and goals, prognosis, and shared decision-making to use a trial of intensive care. Originally used in ICU settings, we systematically refined the guide to be used in the ED incorporating inputs from patient advisors' and emergency clinicians' inputs.~2. Clinician Training: The clinician training will include a one-hour didactic on research methodologies and serious illness communication skills, followed by a four-hour communication training with trained actors.~3. EHR Documentation: An EHR template for documenting the TLT conversation findings has been developed.~4. Intensivist Communication: A standard template to communicate the TLT conversation findings to the intensivists has been developed."
40952941|NCT02281201|BIOLOGICAL|BE1116 (Prothrombin Complex Concentrate)|
40952942|NCT00550121|DRUG|vitamin C|
40952943|NCT00550121|DRUG|placebo|
40952944|NCT04458207|PROCEDURE|Oral prosthetic rehabilitation|Individual treatment options will be discussed with the participants individually and rehabilitation will be provided as agreed by the dentist and the participant. The rehabilitation will include fixed prosthodontics. The procedures will involve a control phase involving scaling, root planing oral hygiene instructions etc., extractions and bone augmentation when needed and temporary removable dentures. Restoration of the lost vertical dimension (if needed) with occlusal splints, tooth preparations, placement of dental implants (if needed) and finally cementation of dental crowns. The rehabilitation phase is estimated to take approximately 3-18 months, or more.
40952945|NCT03505190|DRUG|RO7062931|RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
40952946|NCT03505190|DRUG|Placebo|Matching placebo will be administered subcutaneously (SC).
41289886|NCT05995522|OTHER|Cornstarch|500 mg per day for 90 days
41289887|NCT00042081|DRUG|CGT003 (E2F Duplex Decoy)|
41289888|NCT04965012|BEHAVIORAL|Online CBT with MET treatment|The CBT with MET treatment condition will begin with an MET-therapist guided introduction to the program and first module. After this guided introduction, they will have access to the remaining 7 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
41307821|NCT03965832|DEVICE|HFNT during exercise|"6-minute walking test performed initially on HFNT. HFNT will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) as at baseline conditions during exercise.~Participants will then cross-over to repeat the test on baseline conditions."
41307822|NCT03965832|DEVICE|Standard oxygen therapy/RA|6-minute walking test performed on baseline conditions. Participants will then be cross over to repeat the test on HFNT
41289889|NCT04965012|BEHAVIORAL|CBT without MET treatment|The CBT without MET treatment condition will begin with a brief non-MET trained research assistant welcome to the program, and will not include working through the first module together. After this welcome, they will have access to the 8 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
41289890|NCT01479088|DRUG|Cinacalcet HCl|The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value \<180 pg/mL as tolerated by the patient
41289891|NCT01956643|OTHER|gum chewing|gum chewing
40760748|NCT01518179|DEVICE|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
40760749|NCT01518179|OTHER|Routine follow up and treatment|Control
40760750|NCT01251757|OTHER|Interactive Voice Recognition (IVR) phone calls|"The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population."
40952947|NCT06034847|DEVICE|Mechanical thrombectomy in proximal large vessels|mechanical thrombectomy with retrievable stents to remove clots in proximal large vessels, combined or not with distal aspiration, combined or not with IV thrombolytics
40952948|NCT06034847|DEVICE|Rescue mechanical thrombectomy in distal vessels|In addition to mechanical thrombectomy in proximal large vessels, mechanical thrombectomy in distal vessels with small stent retrievers combined or not with contact aspiration, or intra-arterial perfusion of thrombolytics such as tPA or uPA or tenecpeplase
41289892|NCT01956643|OTHER|Control|Routine care during NPO
41134741|NCT01784809|BEHAVIORAL|Traditional WORTH|The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
41134742|NCT01784809|BEHAVIORAL|Wellness Promotion|
41134743|NCT03794219|OTHER|Kinesio Tape|To all patients,750 mg/day oral naproxen is administered for 10 days. Additionally, in intervention group kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions.
41134744|NCT03794219|DRUG|oral naproxen|750 mg/day oral naproxen is administered for 10 days.
41134745|NCT05667311|DEVICE|ECG|Finapres electrocardiography machine
41289893|NCT04185610|OTHER|Qi Gong|Guided Qi Gong class
41289894|NCT00320671|DRUG|Aripiprazole|The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.
40952949|NCT02802943|BIOLOGICAL|Peptide Vaccine|Individualized multi-peptide cocktail consisting of 300 μg each of 5 HLA class I and 4 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 30 different peptides restricted by the 6 most common HLA class I allotypes (A\*01, A\*02, A\*03, A\*24, B\*07, B\*08) and 4 HLA class II peptides. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.
40952950|NCT02802943|DRUG|Imiquimod|All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.
40952951|NCT02235805|DIETARY_SUPPLEMENT|Magnesium Citrate|One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks
40952952|NCT02235805|DIETARY_SUPPLEMENT|Placebo|One capsule thrice daily that contains placebo at breakfast, lunch and dinner for 24 weeks
40952953|NCT03301701|PROCEDURE|Radical prostatectomy|Radical prostatectomy
40952954|NCT03301701|RADIATION|HDR (19Gy) or SBRT (35-40Gy)|Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
40952955|NCT02422472|DEVICE|Ultrasound guided peripheral IV placement|Accucath™ 20 Gax 5.7cm catheter
40952956|NCT05501275|BEHAVIORAL|psychotherapy|Psychotherapy and psychoeducation in patients after stroke.
40952957|NCT04135742|DEVICE|Transcranial Alternating Current Stimulation|Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.
40952958|NCT04135742|BEHAVIORAL|Cognitive Training|Cognitive training includes memory, reasoning, processing speed and role playing, etc.
40760751|NCT01251757|OTHER|Educational mailings and follow-up for nonadherence|Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
40760752|NCT02717624|DRUG|Acalabrutinib in combination with BR|
40760753|NCT02717624|DRUG|Acalabrutinib in combination with VR|
40952959|NCT04214184|BEHAVIORAL|Increased sleep duration|Participants will increase their nightly time in bed by 2 hours per night for 4 weeks to target the recommended 7 hours of sleep per night.
40952960|NCT00772304|DRUG|Olopatadine 0.6% / Azelastine 137 mcg|single dose; 2 sprays per nostril
40952961|NCT02933606|DRUG|BNC210|
40952962|NCT02933606|DRUG|Placebo|
40952963|NCT04721730|BEHAVIORAL|PLH-YC|There will be 5 weekly 2-hour sessions. The optimised PLH-YC uses a participatory, non-didactic approach to engage parents. Parents learn positive parenting skills and how to manage child behaviour problems. The program includes Session 1: One-on-One Time and Say What You See, Session 2: Praise and Rewards, Session 3: Instructions, Redirect, Rules, and Routines, Session 4: Ignore and Consequences, Session 5: Reflection and Moving On. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
40952964|NCT04721730|BEHAVIORAL|Lecture|Lecture on parenting. This is a 26-slides power-point presentation that was developed by the University of Bremen for the purpose of this study. Duration: 1 to 1.5 hours. Content: 1) Stages of child development; (2) Potential risk factors for child emotional or behaviour problems; (3) Resources and protective factors; (4) Tips: What parents can do to promote children's development.
40952965|NCT01253473|DRUG|Budesonide|Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed
40952966|NCT01253473|DRUG|budesonide/formoterol|Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily
40952967|NCT01253473|DRUG|Ipratropium/albuterol|Inhaled ipratropium/albuterol combination 2 puffs four times daily
40760754|NCT00049946|DRUG|talnetant|
40952968|NCT01751893|DRUG|Henna|natural henna in the form of paste
40952969|NCT01751893|DRUG|Placebo|placebo
40952970|NCT02819739|DRUG|medical oxygen|
40952971|NCT01195246|BIOLOGICAL|HEPLISAV|Intramuscular (IM) injection on Day1
40952972|NCT01195246|BIOLOGICAL|Engerix-B|Intramuscular (IM) injection on Day 1
40952973|NCT01195246|BIOLOGICAL|Fendrix|Intramuscular (IM) injection on Day 1
40952974|NCT03720353|DRUG|SAS2094AH and SAS2094BH|SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.
41307823|NCT01952730|BIOLOGICAL|GVAX|
40952975|NCT03720353|DRUG|SAS2094AL and SAS2094BL|SAS2094AL and SAS2094BL for 10 days
40952976|NCT03720353|DRUG|Placebo|Placebo for 10 days. Capsules will mimic active treatments.
40952977|NCT02384161|OTHER|Isometric exercise Intermittent|Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
40952978|NCT00705926|DRUG|Highly Active Antiretroviral Therapy (HAART)|Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
40952979|NCT00705926|OTHER|No treatment|Participants in this group will not receive treatment at this stage of their infection.
41454463|NCT00796874|PROCEDURE|biopsy|Tissue Removal
40760755|NCT00049946|DRUG|risperidone|
40760756|NCT05880784|OTHER|Reinforcement of Peer coaching and clinical audit|The goal of the proposed research study is to test the effectiveness and feasibility of an intervention to enhance peer coaching and clinic audit activities to facilitate the implementation of the Package of Essential Non- Communicable Diseases (PEN) in Nepal.
40760757|NCT05880784|OTHER|Continuation of usual practice without intervention|No intervention will be carried out, instead usual practice will be evaluated at the start and the end of the study period.
40952980|NCT05324722|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
40952981|NCT05324722|OTHER|cross body stretch|crossbody stretch performed by an individual
40952982|NCT06029738|BEHAVIORAL|Metacognitive Training for Obsessive-Compulsive Disorder (MCT-OCD)|MCT-OCD is a group education for OCD patients.
40952983|NCT02741856|DRUG|Carboplatin|For more information please see the arm descriptions section.
40952984|NCT02741856|DRUG|Paclitaxel|For more information please see the arm descriptions section.
40952985|NCT02741856|DRUG|Cisplatin|For more information please see the arm descriptions section.
40952986|NCT02741856|DRUG|Capecitabine|For more information please see the arm descriptions section.
40952987|NCT02741856|RADIATION|Radiotherapy|For more information please see the arm descriptions section.
41454464|NCT00796874|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
40952988|NCT04304274|PROCEDURE|Paravertebral block-ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
40952989|NCT04304274|PROCEDURE|Paravertebral block-saline|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% saline infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
40952990|NCT04304274|DRUG|patient controlled analgesia with morphine|Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
40952991|NCT00448838|BIOLOGICAL|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
40952992|NCT00448838|DRUG|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
40952993|NCT00448838|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
40952994|NCT02183896|BIOLOGICAL|Platelet-rich plasma (PRP)|
40952995|NCT02183896|DRUG|Saline|
40952996|NCT02389985|DRUG|CRLX101|
40952997|NCT02389985|DRUG|Paclitaxel|
40952998|NCT04516330|GENETIC|miRNA|miRNA's expressed in breast cancer
40952999|NCT06129877|DEVICE|CHAMP App|CHAMP App software platform will have been used in other research studies to be included in the Feeding difficulties repository
40953000|NCT02404220|DRUG|Entospletinib|
41454465|NCT00796874|PROCEDURE|magnetic resonance imaging|Radiolical Medical Imaging
40953001|NCT02404220|DRUG|Vincristine|
40953002|NCT02404220|DRUG|Dexamethasone|
40953003|NCT02404220|DRUG|CNS Prophylaxis|
40953004|NCT01346579|OTHER|laboratory biomarker analysis|Correlative sciences
40953005|NCT06382948|DRUG|Everolimus|Patients will receive 7.5 mg of everolimus orally once daily.
40953006|NCT06382948|DRUG|Elacestrant|Patients will receive elacestrant 345 mg orally once daily
40760758|NCT06372080|DIETARY_SUPPLEMENT|Resistance training with hydrolyzed collagen ingestion in healthy young men|"Participants in this intervention will be healthy young men. The information of nutritional supplements is below.~Hydrolyzed collagen: 30 grams unflavored hydrolysed collagen (HC) (Myprotein, Cheshire, UK) 30.5 grams unflavored maltodextrin (Myprotein, Cheshire, UK) 50 milligrams vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK) 3 grams non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
40953007|NCT06382948|DRUG|Placebo|Patients will receive placebo orally once daily
40953008|NCT06382948|DRUG|Auxiliary Medicinal Product - Dexamethasone|10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.
40953009|NCT06382948|DRUG|Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues|According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.
40953010|NCT05342792|DRUG|PD-1 antibody|Tislelizumab：200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
40953011|NCT05342792|DRUG|Capecitabine|Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
40953012|NCT03128827|DEVICE|RAM sensor|Acoustic Respiration Monitor
40953013|NCT05247801|BEHAVIORAL|Psychoeducational intervention for safe medication use at home + Medication dosing device|"The intervention is yet to be defined. Psychoeducational intervention based on virtual reality, demonstrations, and psychoeducational content using virtual reality. Contents:~Most frequent medication errors at home. Approaches to risk management in the home. Correct use of the most common medications in different patient profiles. Strategies to avoid medication errors. Guidance to alleviate the burden of responsibility suffered by women as a result of the gender bias derived from assuming the caregiver role.~Other."
40953014|NCT05247801|DEVICE|Medication dosing device|Use of medication dosing device.
40953015|NCT02390908|BEHAVIORAL|Immediate PLUS intervention|The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.
41454466|NCT00796874|PROCEDURE|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
41454467|NCT05136469|OTHER|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
41454468|NCT05136469|OTHER|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
41454469|NCT01020825|DRUG|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
41454470|NCT01020825|DRUG|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
40953016|NCT02390908|BEHAVIORAL|Wait-list PLUS intervention|In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
40953017|NCT06069908|OTHER|Complex Decongestive Treatment|Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach. It will be applied 5 days a week for 3 weeks
40953018|NCT06069908|OTHER|Sham transcutaneous vagus nerve stimulation|In sham transcutaneous vagus nerve stimulation application, the device electrode will be placed in the superior scapha region of the outer ear, where the vagus nerve has no innervation, and no current will be given.Complex Decongestive Therapy and sham transcutaneous vagus nerve stimulation.It will be applied 5 days a week for 3 weeks.
40953019|NCT06069908|OTHER|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation will be applied in addition to Complex Decongestive Therapy.It will be applied 5 days a week for 3 weeks.
40953020|NCT06069908|OTHER|Exercise|Patients will undergo lymphedema-specific exercises 5 days a week for 3 weeks.
40953021|NCT04443699|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
41454471|NCT01020825|DRUG|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
40953022|NCT01286233|DRUG|Metformin|
41454472|NCT05008380|PROCEDURE|prone positioning|3-6 hours of prone-positioning twice a day
41454473|NCT05548335|PROCEDURE|Ocular Ultrasound|1. Patients presenting to the emergency department and have a normal head and/or ocular computed tomography scan will be considered for inclusion in this study. Study staff will discuss the study with the patient and obtain consent. At that point, operator will perform ocular ultrasound. Procedure will start with either the linear or microconvex probe. A single-use sterile gel packet will be used to apply gel to one closed eyelid. The probe will be placed with minimal pressure on the eye. A transverse measurement of the ONSD will be taken. In this same view the maximal transverse diameter of the eyeball will also be measured. Images of the eye with ONSD and ETD measurements will be captured. Repeat until three measurements have been obtained resulting in an average ONSD and ETD for that eye. Repeat for other eye. Switch probe and repeat on both eyes.
40953023|NCT01286233|DRUG|Placebo|
40953024|NCT06400303|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
40953025|NCT06400303|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
40953026|NCT03470961|DRUG|Anti-Tlymphocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
40953027|NCT03470961|DRUG|Anti-Thymocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
40953028|NCT00594048|DEVICE|Resperate|Use of the device 15 minutes a day for 9 weeks
40953029|NCT00594048|DEVICE|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
40953030|NCT00678093|OTHER|Application of the SNAG technique|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
41134746|NCT01051869|PROCEDURE|Simple decompression|"Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.~In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken."
41454474|NCT04285073|DEVICE|Paclitaxel-eluting graft|Implantation of e-PTFE Grafts inner surface-treated with paclitaxel as access for hemodialysis
41454475|NCT02102919|DEVICE|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
41454476|NCT02102919|DEVICE|Virtual Games (VG)|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
41289895|NCT00320671|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
41289896|NCT04408157|BEHAVIORAL|Self-management booklet (SWitCh: Stay well during COVID-19)|The purpose of this booklet is to support adjustment to the current circumstances of the COVID-19 pandemic and facilitate the development and maintenance of healthy behaviours at home. The booklet covers a range of topics, including understanding bodily sensations and symptoms of COVID-19, managing the uncertainty surrounding COVID-19, physical activity, sedentary behaviour, sleep, social support and isolation, nutrition and alcohol consumption, sex and intimate relationships, and coping with children at home. The booklet will provide structured guidance on the various topics through the use of effective behaviour change techniques, in particular self-monitoring, goal setting, and problem solving and signposting to additional helpful resources, such as drinking or nutrition tracking apps.
41289897|NCT02795767|DRUG|Emicizumab|Emicizumab will be administered as per the schedule specified in the respective arm.
41289898|NCT00824538|DRUG|sunitinib malate|
41289899|NCT00824538|OTHER|flow cytometry|
40760759|NCT06372080|DIETARY_SUPPLEMENT|Resistance training with hydrolyzed collagen ingestion in healthy young women|Participants in this intervention will be healthy young women. The same nutritional supplements in Arm 1 wil be used in Arm 2.
41134747|NCT01051869|PROCEDURE|anterior subcutaneous transposition|In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
41134748|NCT03709797|PROCEDURE|Dry needling in infraspinatus muscle|Dry needling technique with multiple rapid needle insertion.
41134749|NCT01259570|DIETARY_SUPPLEMENT|Group 1|Skimmilk enriched with VD encapsulated in CM
41134750|NCT01259570|DIETARY_SUPPLEMENT|Group 2|VD will be dissolved in milkfat and homogenized into skimmilk
41134751|NCT01259570|DIETARY_SUPPLEMENT|group 3|3% fat milk wherein the VD will be in CM
41134752|NCT01259570|DIETARY_SUPPLEMENT|Group 4|Placebo: un-enriched skimmilk.
41134753|NCT01079806|DRUG|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
41134754|NCT01079806|DRUG|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
41134755|NCT00536120|BIOLOGICAL|BG00002 (natalizumab)|
41134756|NCT00536120|BIOLOGICAL|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
41134757|NCT00536120|BIOLOGICAL|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
41134758|NCT02358304|DRUG|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
41134759|NCT02358304|DRUG|Placebo|
41134760|NCT03360617|DEVICE|Syringe IV Push over 2-3 minutes|IV antibiotics will be administered by Syringe IV Push over 2-3 minutes
41134761|NCT03360617|DEVICE|Piggyback over 30 minutes|IV antibiotics will be administered by IV Piggyback over 30 minutes.
41134762|NCT03385759|PROCEDURE|Unicompartmental knee arthroplasty|Implant to replace the medial compartment of a patient with knee osteoarthritis
41134763|NCT03385759|PROCEDURE|Total knee arthroplasty|Implant to replace the knee joint of a patient with knee osteoarthritis
41289900|NCT00824538|OTHER|immunohistochemistry staining method|
41289901|NCT00824538|OTHER|laboratory biomarker analysis|
41289902|NCT01378754|DRUG|Fospropofol (Lusedra®) 6.5|Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
41289903|NCT01378754|DRUG|Fospropofol (Lusedra®) 10|Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
41289904|NCT01378754|DRUG|Fospropofol (Lusedra®) 12|Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
41454477|NCT02102919|OTHER|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.
41454478|NCT02102919|DEVICE|Aktiv Tramp (Swiss Frei AG, Switzerland)|Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
41289905|NCT00173953|PROCEDURE|immune response|
41289906|NCT05658029|DRUG|ARINA-1|Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
41289907|NCT05174572|PROCEDURE|IMR|Patients undergoing coronary sinus reducer implantation (Reducer) undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up.
41289908|NCT00275379|DRUG|ERB-041|
41289909|NCT05018338|DEVICE|Brain shift monitoring|For use to monitor brain shift during craniotomy
41289910|NCT02551848|DRUG|Botulinum toxin type A|
41289911|NCT03047460|OTHER|multimodal evoked potentials|
41289912|NCT01786018|DRUG|Thiotepa|
41289913|NCT01786018|DRUG|Busulfan|
41289914|NCT01786018|DRUG|Fludarabin|
41289915|NCT01786018|PROCEDURE|transplant (HCT)|Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10\^7 CD3 cells/kg recipient weight and cryopreserved.
41289916|NCT01786018|RADIATION|Cytoreduction|Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
41289917|NCT01786018|DRUG|Immunosuppression|Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
41289918|NCT01786018|DRUG|Cyclosporine|"CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below."
41289919|NCT01786018|DRUG|Methotrexate|Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
41289920|NCT01786018|DRUG|ATG|(FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
41289921|NCT01786018|PROCEDURE|Collection and infusions of Donor PBSC|Collection and infusions of Donor PBSC
41289922|NCT02135601|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
41289923|NCT02828319|DRUG|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
41289924|NCT02368444|BEHAVIORAL|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
41289925|NCT01920139|PROCEDURE|Fine needle aspiration and core biopsy of lymph node|Ultrasound guided fine needle aspiration of an abnormal lymph node followed by ultrasound guided core biopsy of the same node followed by clip placement into the node.
41289926|NCT01920139|PROCEDURE|Axillary surgery|Patients underwent axillary node dissection or excision of setinel axillary nodes at the time of surgical treatment of their breast cancer.
41289927|NCT01920139|OTHER|Titanium marker|A titanium marker was deposited into the lymph node that was percutaneously biopsied , immediately after the last tissue sample obtained.
41289928|NCT01038492|BEHAVIORAL|p16 Methylation and Lung Cancer Education|"* patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details~* patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~* a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~* patients are called again at three months and asked about any changes in their attitudes or smoking habits."
41454479|NCT05947266|BEHAVIORAL|an adaptation of the iENGAGE|Haitian immigrant iENGAGE (H-iENGAGE) is an adaptation of the iENGAGE intervention culturally adapted for Haitian immigrants with HIV that will be tested in a quasi-experimental pilot for preliminary efficacy among recently diagnosed or nonvirally suppressed adults across two Federally Qualified Health Centers (FQHCs) in Miami.
40760760|NCT03129997|DIETARY_SUPPLEMENT|Gluten test food|Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
40760761|NCT02869009|DRUG|clopidogrel|
41289929|NCT04163198|DEVICE|Insufflation|Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.
41289930|NCT04163198|DEVICE|Exsufflation|Patients will receive different exsufflation pressures at fixed insufflation pressure.
41289931|NCT05617092|OTHER|Physiotherapy treatment|physiotherapy individualized treatment according to the needs of the patient and clinical findings and symptoms
41289932|NCT05650229|DRUG|KL1333|Twice daily
41289933|NCT05650229|DRUG|Placebo|Twice daily
41289934|NCT06205134|DRUG|A: Epinephrine injection|Autoinjector for intramuscular, single-use, 0.3mg
41289935|NCT06205134|DRUG|B: FMXIN002 3.6mg|Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
41289936|NCT06205134|DRUG|C: FMXIN002 4.0mg|Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril
41289937|NCT01411540|DIETARY_SUPPLEMENT|Whole grains|Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
41307824|NCT00636376|PROCEDURE|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
41454480|NCT01951209|DRUG|Rifaximin|550mg orally twice daily for 12 weeks
41454481|NCT01951209|DRUG|Placebo|Matched placebo
40760762|NCT02869009|DRUG|Aspirin|
40953031|NCT05431660|OTHER|education and exercise protocol about diabetic foot|In diabetic foot school education, foot anatomy and functions, biomechanics, diabetic foot causes, epidemiology, causes of pain will be explained and treatment methods, ergonomic information, exercises to be done, sensory education, appropriate positions in daily life activities, risky situations, points to be considered and foot care. information will be given.
40953032|NCT05431660|OTHER|control group|diabetic foot school information booklet and weekly video conference meeting
40953033|NCT03267836|DRUG|Avelumab|-10mg/kg IV
41289938|NCT02935738|DRUG|Prednisolone treatment|Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
40953034|NCT03267836|RADIATION|Proton Therapy|-Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).
40953035|NCT03267836|PROCEDURE|Surgery|-Standard of care
40953036|NCT02678975|DRUG|Disulfiram|Disulfiram 400 mg daily
40953037|NCT02678975|DIETARY_SUPPLEMENT|Copper|nutritional supplement with copper, 2 mg daily
40953038|NCT02678975|DRUG|Alkylating Agents|Alkylating antineoplastic agent
41289939|NCT03976232|DEVICE|Trans cranial Direct Current Stimulation (tDCS)|Active tDCS will be applied for 20 minutes with 2 mA intensity. Anode will be placed at left dorsolateral prefrontal cortex and cathode will be placed at the right cerebellar cortex.
41289940|NCT03976232|OTHER|Craniosacral therapy (CST)|Craniosacral therapy will be given to all the participants which includes release of all major diaphragm, frontal lift, parietal lift, occipital lift, CV4 and dural tube rocking.
41289941|NCT03976232|OTHER|tDCS+ CST|This group will receive tDCS along with CST
40953039|NCT01824875|DRUG|temozolomide|Given PO
40953040|NCT01824875|DRUG|capecitabine|Given PO
40953041|NCT01141452|DRUG|Extra-fine hydrofluoroalkane beclomethasone MDI|Step-up in baseline BDP-equivalent ICS dose
40953042|NCT01141452|DRUG|Chlorofluorocarbon beclomethasone metered dose inhaler|Step-up in baseline BDP-equivalent ICS dose
41289942|NCT06229678|DRUG|Empagliflozin 25 MG Oral Tablet|Empagliflozin 25MG will be administered orally once per day for 3 months
41289943|NCT06229678|DRUG|Placebo|The placebo will be administered orally once per day for 3 months
41289944|NCT06229678|DRUG|Acipimox 250 Mg Oral Capsule|subjects will be started on acipimox 250mg every 6 hours for 8 days while on continued empagliflozin/placebo therapy. This will be added at the end of 3 months after they finished baseline studies
41289945|NCT02388776|DEVICE|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
41289946|NCT02050932|DIETARY_SUPPLEMENT|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
41289947|NCT05781399|DRUG|JNT-517 Suspension|JNT-517 in on-site compounded suspension
40953043|NCT01141452|DRUG|Fluticasone propionate metred dose inhaler|Step-up in baseline BDP-equivalent ICS dose
40953044|NCT01141452|DRUG|Fluticasone propionate metred dose inhaler|Initiation of ICS therapy
40953045|NCT01141452|DRUG|Hydrofluoroalkane beclomethasone metred dose inhaler|Initiation of ICS therapy
41289948|NCT05781399|DRUG|Placebo Suspension|On-site compounded placebo suspension
41289949|NCT05781399|DRUG|JNT-517 Tablet|JNT-517 tablets, 25 mg and 75 mg
41289950|NCT05781399|DRUG|Placebo Tablet|Matching film-coated placebo tablet
41289951|NCT00062738|DRUG|paroxetine|Paroxetine CR 12.5 - 25 mg q hs
41289952|NCT00062738|DRUG|Nortriptyline|nortriptyline 25 - 75 mg q hs
41289953|NCT00062738|OTHER|placebo|matching placebo
41289954|NCT00668525|DRUG|Escitalopram|Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
41289955|NCT00668525|DRUG|Placebo|Placebo, oral administration, once daily dosing for 8 weeks
41289956|NCT00668525|DRUG|Escitalopram|Escitalopram high dose, oral administration, once daily dosing for 8 weeks
41289957|NCT03507140|OTHER|Multiple sampling|"Bile, saliva, feces, urine et blood samples before and after liver transplantation in recipients.~Bile, saliva, feces, urine et blood samples during liver removal in donors."
40953046|NCT01141452|DRUG|Chlorofluorocarbon beclomethasone dipropionate|Initiation of ICS therapy
40953047|NCT00193258|DRUG|Bevacizumab|10mg/kg IV infusion every 2 weeks
40953048|NCT00193258|DRUG|Erlotinib|150 mg po daily
40953049|NCT00193258|DRUG|Imatinib|400-600mg daily
40953050|NCT05668975|DEVICE|Inspiratory Muscle Training|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training.
40953051|NCT01020149|OTHER|MR Imaging|MRI is used to evaluate nerve regeneration after traumatic transsection and nerve repair.
40953052|NCT06277557|OTHER|Virtual Reality|Virtual reality learning platform as intervention in this study
40953053|NCT04746339|DRUG|Apixaban 2.5 MG|Apixaban 2.5mg twice daily for 30 days
40953054|NCT04746339|DRUG|Placebo|placebo twice daily for 30 days
40953055|NCT02447939|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).
40953056|NCT02447939|DRUG|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
40953057|NCT01227317|OTHER|Prognostic value of Biomarkers|Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
41289958|NCT05804110|OTHER|Mindful Caring Education Program|A four-session education plan was prepared under the nature of action research. The Theory of Unitary Caring Science is transferred to practice through Caritas processes. In this context, ten Caritas processes and caring-healing modalities (meditation, reflection, etc.) were used in the study. The pilot study was carried out with six nurses face-to-face. The education program was conducted on an online platform. Each education took approximately 2.30-3 hours. The evaluation process in action research is an essential part of the change.
40953058|NCT04903678|DRUG|Melphalan|Melphalan is performed for intrathecal chemotherapy
40953059|NCT03097913|DEVICE|video-stylet|recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
40953060|NCT04310046|PROCEDURE|PCI before TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
41289959|NCT05113823|PROCEDURE|Simulation Training|Simulation Training using High and Low Fidelity Simulator
41289960|NCT04246229|DIAGNOSTIC_TEST|Transcutaneous bilirubinometry|use of transcutaneous bilirubinometry a non-invasieve measurement of skin bilirubin levels
41289961|NCT04246229|DIAGNOSTIC_TEST|Serum bilirubin|use of blood draws to measure serum bilirubin level
41289962|NCT03517722|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
41289963|NCT03517722|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
41289964|NCT03517722|DRUG|Ustekinumab 90 mg|Participants will receive 90 mg ustekinumab via SC route.
41289965|NCT06449105|BEHAVIORAL|1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
41289966|NCT06449105|BEHAVIORAL|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
40953061|NCT04310046|PROCEDURE|PCI after TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
40953062|NCT00795847|DRUG|Preminent (losartan/hydrochlorothiazide combination drug)|Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
40953063|NCT03047655|BEHAVIORAL|Lifestyle intervention (physical activity)|Dietary treatment with or without additional motivation on more physical activity
40953064|NCT03047655|DIETARY_SUPPLEMENT|Lifestyle intervention (PUFA/isomaltulose-enriched muffin)|
40953065|NCT00004397|DRUG|heme arginate|
40953066|NCT00004397|DRUG|tin mesoporphyrin|
40953067|NCT05037461|RADIATION|High-dose-high precision MR-guided radiotherapy|MR-guided radiotherapy as described in the group information
41289967|NCT06449105|BEHAVIORAL|Session 3: Unraveling the Knots of Desire and Patterns Agenda|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
41289968|NCT06449105|BEHAVIORAL|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
40953068|NCT06041997|BEHAVIORAL|Smartphone restriction|The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.
41289969|NCT06449105|BEHAVIORAL|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
40953069|NCT06541847|DRUG|HLX-1502|Participants will take an oral dose three times a day (with or without food) for up to 24 cycles (A cycle is defined as 28 days)
40953070|NCT04211402|OTHER|No Intervention|There is no intervention for this study
40953071|NCT02587884|PROCEDURE|TACE|Patients will treated by TACE in 4 or 8 weeks after operation.
41289970|NCT06449105|BEHAVIORAL|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
41289971|NCT06449105|BEHAVIORAL|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
41289972|NCT06449105|BEHAVIORAL|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
41289973|NCT03224637|PROCEDURE|radiofrequency|radiofrequency done in the three genicular nerves upper medial and upper lateral and lower medial
41289974|NCT03224637|DRUG|Paracetamol (conventional)|
41289975|NCT03224637|DRUG|Ketorolac Tromethamine (conventional)|
41307825|NCT06495307|DRUG|rhPRG4|Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride \& 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated
41307826|NCT05398419|OTHER|Music listening intervention|Participants will listen to the music at bedtime and overnight for 7 consecutive nights. The music will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
40953072|NCT05224089|DRUG|Liposomal Bupivicaine/Bupivacaine Admixture|60mL of 0.25% Bupivacaine (150mg)+ 20 mL of 1.3% Exparel (266 mg)+20mL NS=100mL
40953073|NCT05224089|DRUG|Bupivacaine HCL|80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL NS= 100mL
40953074|NCT03519971|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
41289976|NCT04902950|DRUG|Tranexamic acid|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The Tranexamic acid soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
40953075|NCT03519971|OTHER|Placebo|Placebo IV (intravenous infusion)
40953076|NCT03519971|DRUG|Cisplatin/ Etoposide|Cisplatin/ Etoposide, as per standard of care
41289977|NCT04902950|DRUG|Saline|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The saline soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
41289978|NCT02614794|DRUG|tucatinib|300 mg orally twice daily
41454482|NCT00759707|DRUG|L-N^G monomethyl arginine (L-NMMA)|L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein \[arterial\] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
40760763|NCT00202241|PROCEDURE|testosterone injection|
40760764|NCT05757219|DRUG|Itacitinib|Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
40953077|NCT03519971|DRUG|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
40953078|NCT03519971|DRUG|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
40953079|NCT03519971|DRUG|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
40953080|NCT03519971|RADIATION|Radiation|5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
40953081|NCT02472873|PROCEDURE|Aspiration and Sclerotherapy of endometriomas.|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
40953082|NCT02472873|PROCEDURE|cystectomy of endometriomas.|cystectomy of endometriomas during laparoscopy
41289979|NCT02614794|DRUG|capecitabine|1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
41454483|NCT02957331|DRUG|Propranolol|
41454484|NCT03858933|DEVICE|eBrainFit Platform|Alpha/Theta regulation with eyes open
40953083|NCT02472873|DRUG|Ethanol|
40953084|NCT03945266|BEHAVIORAL|Intervention group|During the intervention, all participants will start out at the Baseline level. The baseline level will last 2 weeks and there will be an assessment to determine weight gain over those 2 weeks. If weight gain has succeeded the recommended amount, participants will be adapted up to a new level of intervention that includes education on GWG, healthy eating and physical activity. After every 4 weeks, an assessment will be performed and adaptations up will be made if necessary. Adaptations include addition of exercise sessions, healthy eating recipe demonstrations, and meal replacements. Participants will weigh themselves daily, wear an activity monitor, record their diet, and complete paper and online surveys.
40953085|NCT03945266|BEHAVIORAL|Control group|Participants will follow the same self-monitoring/assessment schedule but will not receive the GWG, healthy eating, and physical activity education or adaptations.
40760765|NCT05757219|BIOLOGICAL|Chimeric antigen receptor (CAR) T-cell therapy|Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
40953086|NCT03172169|OTHER|no Intervention|no Intervention
40953087|NCT03459261|DIAGNOSTIC_TEST|blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4)|Laboratory analyses of peripheral venous blood on admission (blood sample ADD), 24 hours after surgery (blood sample POD1) and fourth-day after surgery (blood sample POD4) included biochemical analysis, complete blood count, C-reactive protein (CPR), procalcitonin (PCT), albumin/protein level, prothrombin time and international normalized ratio (INR) (only on admission) and for determination of cytokines: tumor necrosis factor alpha (TFN-α), interleukin-6 (IL-6), interleukin-10 (IL-10).
40953088|NCT06142032|BEHAVIORAL|Metaverse support group|"Delivery method: Online, virtual platforms. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
40953089|NCT06142032|BEHAVIORAL|In-Person support group|"Delivery method: In-Person, traditional. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
40953090|NCT05434078|DEVICE|Orthofeet Shoes|Participants will wear a pair of Orthofeet shoes to wear for 6 weeks
41289980|NCT02614794|DRUG|trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
40953091|NCT02273232|OTHER|Remote Ischemic Preconditioning|Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles
40953092|NCT02273232|OTHER|Supervised Exercise|constructed extra excessive for peripheral vascular diastase patients
40953093|NCT02273232|OTHER|Standard Care|Standard Care for peripheral vascular disease patients including advises regarding exercises
40953094|NCT00017199|DRUG|bortezomib|
41289981|NCT02614794|DRUG|placebo|Oral dose twice daily
40760766|NCT06571825|DRUG|Venetoclax|The consolidation therapy involves a regimen of intermediate-dose cytarabine (Ara-C) combined with Ven, specifically Ara-C at 1.0 g/m²/day for 3 days (days 1-3) and Ven at 400 mg/day for 10 to 14 days (days 1-10 to 14), with each cycle lasting 4 to 6 weeks, for a total of 3 consolidation cycles. This is followed by maintenance therapy with azacitidine (AZA) at 50 mg/m²/day for 5 days (days 1-5), with each cycle lasting 4 weeks, for a total of 6 maintenance cycles.
40760767|NCT06571825|DRUG|Allogeneic transplant|"The consolidation therapy involves allo-HSCT, with the choice of conditioning regimens typically using reduced-intensity conditioning such as the Fludarabine+Busulfan (FluBu) or Fludarabine+Melphalan (FluMel) regimens commonly used by centers, which can also include Ven.~FluBu regimen: Flu 30 mg/m²/day from day -10 to day -5, Bu 3.2 mg/kg/day from day -6 to day -5 or day -7 to day -5, antithymocyte globulin (ATG) (e.g., rabbit ATG at a total dose of 6-7.5 mg/kg, administered from day -4 to day -1), and Ven from day -10 to day -4.~FluMel regimen: Flu 30 mg/m²/day from day -10 to day -5, Mel 50-70 mg/m²/day from day -4 to day -3, ATG and Ven from day -10 to day -4.~12 weeks (±4 weeks) post-HSCT maintenance begins with AZA at 32 mg/m²/day for 5 days (days 1-5), with each lasting 6 weeks, for a total of 6 cycles. Donor lymphocyte infusion is allowed in cases of minimal residual disease (MRD) positivity."
40760768|NCT01202357|BEHAVIORAL|Community Case Management|Community case management for psychosis by designated key-worker according to specified protocol
40760769|NCT04020185|DRUG|IMSA101|IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
40760770|NCT04020185|DRUG|Immune checkpoint inhibitor (ICI)|Administered according to product label
41289982|NCT04220047|PROCEDURE|Left Atrial Appendage Resection and Marshall Ligament Amputation|Left Atrial Appendage Resection and Marshall Ligament Amputation during the cardiac surgery
41454485|NCT03858933|DEVICE|eBrainFit Platform|Amygdala regulation with eyes open
41454486|NCT04237220|DIAGNOSTIC_TEST|stomach biopsies|To determine the diagnostic performance in the detection of Helicobacter pylori in biopsies taken only from the gastric antrum for the determination of the positive predictive value, the negative predictive value, and sensitivity and specificity.
41289983|NCT05552599|PROCEDURE|woolen blanket|Woolen blanket: The people in the experimental group were treated with a standard hospital woolen.
40953095|NCT02191137|DRUG|Riociguat (Adempas, BAY63-2521)|Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
40953096|NCT02885207|BIOLOGICAL|Focal epilepsy of unknown cause|"Male or female 18-65 years presenting focal epilepsy on the following arguments:~* Crisis with clinical symptoms indicating focal seizure~* \& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~* No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~* No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~* No argument for metabolic or neurodegenerative genetic epilepsy.~* Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines)."
40953097|NCT00994071|DRUG|Temozolomide|
40953098|NCT00994071|DRUG|ABT-888|
40953099|NCT03695744|DRUG|Daratumumab|Daratumumab
41289984|NCT01819688|PROCEDURE|laparoscopic liver resection|
41289985|NCT06513715|DIETARY_SUPPLEMENT|Control|This intervention will be made with a placebo
41289986|NCT06513715|DIETARY_SUPPLEMENT|Jubanine|This intervention will be made with jubanine or prickly pear extract
41289987|NCT05446246|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
40953100|NCT03695744|DRUG|Bortezomib|Bortezomib
40953101|NCT03695744|DRUG|Dexamethasone|Dexamethasone
40953102|NCT04629807|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|Intra-Operative Anterior Lumbar Interbody Fusion (ALIF)
40953103|NCT02236403|DRUG|Ivermectin 0.1% Metronidazole 1%|
40953104|NCT02236403|OTHER|None intervention|Volunteers with no signs of blepharitis and with eyelashes with no demodex. Symptoms and signs will be compared with experimental group
40953105|NCT04103983|DEVICE|Sensory retraining device|All participants will be given a device to keep at home and will be asked to use it for 60 minutes each day, as one block, or as multiple shorter sessions of 20 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will be asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.
40953106|NCT00766025|DRUG|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
40953107|NCT00303901|PROCEDURE|cryosurgery|
40953108|NCT00303901|PROCEDURE|positron emission tomography|
40953109|NCT00002688|DRUG|cyclosporine|
40953110|NCT00002688|DRUG|etoposide|
40953111|NCT00002688|DRUG|mitoxantrone hydrochloride|
41454487|NCT02485938|DRUG|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
41454488|NCT01116505|DIETARY_SUPPLEMENT|Gluten-free diet|gluten-containing cereals removed from diet
40760771|NCT04020185|DRUG|Immuno-oncology (IO) therapy|Administered according to product label
40953112|NCT03231657|DIAGNOSTIC_TEST|Placental biomarkers|sFlt1 and P1GF levels and sFlt1/PlGF ratio
40953113|NCT01913678|OTHER|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
40953114|NCT01913678|OTHER|Complete diet|The participants will be given all dietary items in their diet with no additional products.
40953115|NCT01913678|OTHER|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
41134764|NCT01121328|BIOLOGICAL|Autologous cord blood transfusion for preterm neonates|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of blood within the first 14 postnatal days to maintain Hb level above 10gm%.
41289988|NCT04020874|BEHAVIORAL|HuTT-2x|tackling and blocking training twice/week
41289989|NCT04020874|BEHAVIORAL|HuTT-4x|tackling and blocking training four times/week
41289990|NCT03232723|DIAGNOSTIC_TEST|Whole-cortex MEG System (with optional EEG)|"Whole-Cortex MEG System non- invasively measures the magnetoencephalographic (MEG) signals (and, optionally, electroencephalographic EEG signals) produced by electrically active tissue of the brain. These signals are recorded by a computerized data acquisition system, displayed, and may then be interpreted by trained physicians to help localize these active areas. The location may then be correlated with anatomical information of the brain. MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain."
41289991|NCT04981340|BEHAVIORAL|Diaphragmatic breathing|Same as previously described
41289992|NCT04981340|BEHAVIORAL|Standard urotherapy|Same as previously described
41454489|NCT03044873|DRUG|BMS-986165|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
41289993|NCT04646317|DRUG|Dexmedetomidine injection|Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.
40760772|NCT05010005|DRUG|Ruxolitinib|Ruxolitinib 20mg BID
40760773|NCT05010005|DRUG|Duvelisib|Duvelisib 25mg, 50mg, or 75mg BID
41289994|NCT04646317|DRUG|Normal Saline|0.9% as placebo
41289995|NCT00325572|DRUG|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
41289996|NCT00325572|OTHER|oral Placebo|Each child will be provided separate Placebo suspensions C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
41289997|NCT03333369|DRUG|200 mg levodopa/50 mg benserazide|
41289998|NCT03333369|DRUG|Dextrose|
41289999|NCT03058458|DRUG|PIN201104|IV or SC administration
40953116|NCT06403228|OTHER|Mindfulness Based Structured Nursing Interventions|In the study, 8 days of mindfulness-based structured nursing interventions were applied to high-risk pregnant women. The program lasts 60 minutes each day. The program includes short body scanning meditation, breath awareness meditation, sitting meditation, compassion meditation.
41290000|NCT03058458|DRUG|Placebo|IV or SC administration
41290001|NCT03333356|RADIATION|pelvic radiotherapy|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
41290002|NCT03893903|DRUG|IDH1R132H peptide vaccine|"The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.~Patients receive 3 doses in two week intervals for 6 weeks, followed by re-resection. 4 weeks after surgery, treatment will be resumed consisting of 5 additional vaccinations in 4 week intervals, followed by maintenance vaccines until progression in three months intervals after a pause of 16 weeks."
41290003|NCT03893903|DRUG|Avelumab|"Avelumab is a humanized anti-PD-L1 antibody approved for patients with Merkel cell carcinoma and urothelial cancer. It is applied by i.v. infusion with 10 mg/kg per dose.~Patients receive 3 doses of Avelumab in 2week intervals for 6 weeks, followed by re-resection. Avelumab will be administered in monthly intervals starting 4 weeks after the surgery until progression."
41290004|NCT05182203|DRUG|biologic/targeted therapy|TNF inhibitors or the JAK inhibitors
41290005|NCT05870007|DRUG|Atorvastatin 20 Mg Oral Tablet|Atorvastatin 20mg
41290006|NCT05870007|DRUG|Sodium Bicarbonate 600 Mg Oral Tablet|Sodium bicarbonate would be titrated up to 1800mg per day according to metabolic acidosis severity during clinical follow-up
41290007|NCT01134484|DRUG|Velcade|"* INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)~* REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)"
40760774|NCT01518036|DRUG|somatropin|2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
40760775|NCT01518036|DRUG|somatropin|4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
40760776|NCT05240976|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.
40760777|NCT05240976|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
40760778|NCT04672811|DEVICE|Study App and Apple Watch|Study App and Apple Watch
41290008|NCT01134484|DRUG|Thalidomide|"* INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70"
41290009|NCT01134484|DRUG|Dexamethasone|"* INDUCTION THERAPY~  1. VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)~ 2. TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)~* AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)~  1. VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)~ 2. TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)"
41290010|NCT01134484|PROCEDURE|Peripheral Blood Stem Cell (PBSC) collection|"* Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)~* G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection"
41290011|NCT01134484|PROCEDURE|First Autologous Transplantation|"* HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days"
41290012|NCT01134484|PROCEDURE|Second Autologous Transplantation|"* HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days"
41290013|NCT01904461|DEVICE|Vacuum device|
41290014|NCT01904461|PROCEDURE|Conventional surgery|
41290015|NCT04390815|DRUG|Insulin|Adding insulin to conventional wound treatment
41290016|NCT06275165|OTHER|acupressure|In the experimental group, routine nursing care and acupressure (Neiguan and Zusanli points) were performed from the 1st to the 5th day after the postoperative transfer from the ward to the hospital room. Twice a day, 3 minutes each time, 12 minutes in total.
41290017|NCT03090737|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
41290018|NCT00521963|BIOLOGICAL|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
41290019|NCT05569577|DRUG|Additional hCG injection|An additional hCG injection of 2000-5000IU would be given 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone.
41290020|NCT05569577|DRUG|estrogen and dydrogesterone|estrogen and dydrogesterone
41290021|NCT02688855|DEVICE|Active Combined Magnetic Field OL1000 Bone Growth Stimulator|Active CMF OL1000 Device
41290022|NCT02688855|DEVICE|Sham Combined Magnetic Field OL1000 Bone Growth Stimulator|Sham CMF OL1000
41290023|NCT01183858|DRUG|Erlotinib [Tarceva]|Single daily oral dose
41290024|NCT06444581|BEHAVIORAL|Super Skills Schools|Super Skills Structured and manualized intervention with a manual for the therapist and a workbook for the children. The intervention will be administered by Super Skills-trained clinical psychologists. Sessions will take place once a week for twelve weeks, with each session lasting approximately fifty minutes. The program includes emotional education and social skills training. These contents are learned through playful exercises, activities, readings and role-playing. The intervention modality will be face-to-face.
41290025|NCT04832438|DRUG|9-ING-41|15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle
41290026|NCT04832438|DRUG|Carboplatin|Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle
41290027|NCT00844246|OTHER|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
40760779|NCT04412239|BEHAVIORAL|Patient-centred advice on Telephone Consultation in TB Patients:|The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.
40760780|NCT00214526|PROCEDURE|Bronchial thermoplasty with the Alair System|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
40760781|NCT00214526|DRUG|Conventional therapy with ICS+LABA|Conventional therapy with ICS+LABA.
40760782|NCT01407614|PROCEDURE|external lumbar drainage (ELD) of cerebrospinal fluid|Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
40760783|NCT05642975|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
41290028|NCT00844246|OTHER|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
41307827|NCT05398419|OTHER|Non-musical sounds listening intervention|Participants will listen to the non-musical sounds at bedtime and overnight for 7 consecutive nights. The non-musical sounds will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
41307828|NCT03750032|PROCEDURE|Stapler appendectomy|The patients randomised for this intervention will undergo stapler appendectomy.
41290029|NCT02235285|PROCEDURE|primary breast augmentation|With the patient under sedative anesthesia, wide preparation and draping by using povidone-iodine are performed with using talc-free gloves and povidone-iodine gauze nipple shields. Tumescent solution is infiltrated in the precise plane. Pockets are developed precisely with blunt dissection with fingers and instruments under both direct and indirect visions simultaneously, if needed, with using endoscopy, while careful hemostasis done. After dissection, two pockets are irrigated with 300ml of single antibiotic solution without active evacuation of the irrigation. When re-draping and re-preparation by using povidone-iodine are performed before implant insertion, a new pair of talc-free gloves is used and cleansed with the single antibiotic solution.
41290030|NCT06223425|BEHAVIORAL|virtual reality Situation-Based Flipped Learning|Situation-Based Flipped Learning, and Gamification have gained attention as promising tools to engage nursing students and promote a deeper understanding of complex concepts. This study aims to investigate the effectiveness of combining these strategies in a virtual reality Situation-Based Flipped Learning environment with elements of Gamification on nursing students' learning attitudes, problem-solving abilities, and empathetic skills.
41290031|NCT03790735|DIAGNOSTIC_TEST|FISH|Targeted chromosomal aberrations detection
40760784|NCT04484428|DRUG|K-285|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
40760785|NCT04484428|DRUG|Menthol|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
41290032|NCT02004990|PROCEDURE|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
41290033|NCT02584569|DRUG|TAK-915|TAK-915 oral suspension
41290034|NCT01350700|OTHER|Scars assessment & QOL|Scar assessment and quality of life questionnaires
41290035|NCT03648645|DEVICE|Self measurement of blood pressure|"Patients will perform the measurement of blood pressure at home, on a daily basis, in complying with the rule of 3 stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient."
41290036|NCT02057237|DRUG|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
41290037|NCT05275218|PROCEDURE|Implementation of the KDIGO bundle)|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"
41290038|NCT03342443|DRUG|Memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
41290039|NCT03342443|DRUG|Placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
41290040|NCT01001585|DRUG|sevoflurane|During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
41290041|NCT04263922|DRUG|Huaiqihuang granules|Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
41290042|NCT04263922|DRUG|Valsartan capsule|Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
41290043|NCT00318708|DRUG|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
41290044|NCT00318708|DRUG|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
41290045|NCT00318708|DRUG|placebo clarithromycin|placebo clarithromycin twice daily
40760786|NCT00272246|PROCEDURE|deep brain stimulation of the internal globus pallidus|
40760787|NCT04954989|BIOLOGICAL|Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously
40760788|NCT04954989|BIOLOGICAL|Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously
41290046|NCT06512766|DRUG|Hydroxychloroquine|Patients in this group were treated with hydroxychloroquine (HCQ), a systemic medication commonly used as a first-line treatment due to its ease of use and established safety profile. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
41307829|NCT03750032|PROCEDURE|Endoloop|The patients randomised for this intervention will undergo appendicular stump closure using Endoloop.
41290047|NCT06512766|DRUG|Methotrexate|This group consists of patients treated with methotrexate (MTX), a systemic medication often used as a second-line treatment for its effectiveness in reducing inflammation and controlling autoimmune responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
41290048|NCT06512766|DRUG|Cyclosporine A|Patients in this group were treated with cyclosporine A (CsA), a potent immunosuppressive agent used for its effectiveness in controlling severe inflammatory responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
41290049|NCT06512766|DRUG|Retinoids|This cohort includes patients treated with retinoids, which are used for their ability to modulate cell growth and differentiation. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
41290050|NCT01595204|PROCEDURE|Diagnostic laparoscopy|"Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.~After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers."
41290051|NCT06128837|DRUG|Irinotecan hydrochloride liposome Injection|Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk
41290052|NCT06128837|DRUG|Topotecan|Topotecan 1.2 mg/m² intravenously Days 1-5 q3w
41290053|NCT03291327|DIETARY_SUPPLEMENT|Probiotics|Lozenges for Home use
41290054|NCT03412227|BEHAVIORAL|Individual Behavioral Activation Therapy (IBAT)|IBAT is a manual-based, individual behavioral activation plus exposure therapy aimed at treating youth with anxiety, depression, and anger. The program consists of 10-14 weekly 60 minute sessions. It uses behavioral activation (BA) strategies to target avoidance by helping youth identify stuck points in their lives through functional assessment of numerous life domains, including family and peer interactions, school, extracurricular activities, and health and self-care.
41290055|NCT03412227|BEHAVIORAL|The PASCET Program for Youth Depressive Disorders|The Primary and Secondary Control Enhancement Therapy (PASCET; Weisz, Southam-Gerow, Gordis, \& Connor-Smith, 2003; Weisz, Southam-Gerow et al., 2009; Weisz, Thurber, Sweeney, Proffitt, \& LeGagnoux, 1997) is a brief (usually 11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of, and beneficial treatments for, youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b).
41454490|NCT03044873|DRUG|Rosuvastatin|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
41454491|NCT01476358|DIETARY_SUPPLEMENT|Vitamin A (retinyl palmitate).|"Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth"
41454492|NCT05006573|BIOLOGICAL|Benralizumab|Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
41454493|NCT05006573|BIOLOGICAL|Placebo to Benralizumab|Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
41454494|NCT04950426|DRUG|Propranolol|One administration of propranolol, once a week during six weeks. Reading by the participant of his/her traumatic story, 75 minutes (+/- 15 min) after propranolol intake.
41454495|NCT03271125|BEHAVIORAL|Treadmill|Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
41290056|NCT03412227|BEHAVIORAL|The Coping Cat Program for Youth Anxiety Disorders|"The Coping Cat program (Kendall \& Hedtke, 2006; Kendall, Choudhury, Hudson, \& Webb, 2002) has received substantial empirical support for its efficacy in both children (9-13 years old) and teens (12 - 17 years old) (Kendall, 1994; Kendall et al., 1997; Kendall et al., 2008) and involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward."
41454496|NCT03271125|BEHAVIORAL|Resistance|Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
41454497|NCT03058640|OTHER|PKSA karate class|"Participants will attend at least 20/24 PKSA karate classes over a 12 week period, completing standard karate training lessons. Participants will also be encouraged to practice on their own at home.~• Participants must attend at LEAST 20/24 classes"
41454498|NCT02386007|DRUG|DW-3101_150mg|
41454499|NCT02386007|DRUG|DW-3101_300mg|
41454500|NCT02386007|DRUG|DW-3101_600mg|
41134765|NCT01121328|BIOLOGICAL|Autologous cord blood transfusion|"After delivery of the baby and before placental delivery in vaginal delivery. After delivery of the baby the placental will be taken out in cesarean section. sterilization of the umbilical cord will be done. Puncture of the umbilical cord vein with the needle of blood transfusion bag will be done.~Blood will be kept in the blood bank. Blood grouping, haematocrit and CBC will be done for the cord blood.Maternal sample will be analysed simultaneously.~Mononuclear layer will be separated within 6 hours and transfused to the preterm neonate immediately.~RBCs will be separated and kept till need (Hb less than 10 gm%)."
41290057|NCT03412227|OTHER|14-week waitlist (WL) condition|Youth assigned to the 14-week WL will receive no specific therapeutic services from study therapists during the 14-week WL period. However, participants will be assigned a WL Liaison whom families can contact in the event of clinical deterioration. The Liaison will also be responsible for sending links to, and monitor completion of, weekly and mid-WL online surveys (Qualtrics). Independent Evaluators will conduct post-WL diagnostic interviews at the completion of the 14-week WL. WL participants will receive compensation for completion of assessments. After completion of the WL, participants will be invited to continue in the study and be randomly assigned to one of the three behavioral treatments (IBAT, PASCET, or Coping Cat).
41134766|NCT02481856|DRUG|SQ tree SLIT-tablet|
41290058|NCT05828940|DRUG|Losartan Potassium|oral tablet, over-encapsulated
41290059|NCT05828940|DRUG|Placebo|oral tablet, over-encapuslated
41290060|NCT04596657|DIETARY_SUPPLEMENT|Vitamin D supplementation|Daily vitamin D3 supplementation (5000 IU)
41454501|NCT02386007|DRUG|Placebo|
41454502|NCT06038760|PROCEDURE|Resection|Patients undergo a resection from a lesion, and give 40mL of blood
41134767|NCT02481856|DRUG|Placebo|
41290061|NCT05720078|RADIATION|Adaptive, two-phase RT|Participants in this arm will be treated with an adaptive, two-phase radiation therapy approach
41290062|NCT05171530|DRUG|Lenvatinib plus taxane drugs|"* Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX~* Drug: Docetaxel Dose: 75mg/m2 Other Name: FA~* Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA"
41290063|NCT01823653|DEVICE|Liposonix System (Model 2)|Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
41290064|NCT00234117|DRUG|Rabeprazole|
41290065|NCT04736810|BIOLOGICAL|AK105|IV infusion
41290066|NCT04736810|DRUG|Cisplatin|IV infusion
41290067|NCT04736810|DRUG|Gemcitabine|IV infusion
41290068|NCT04736810|DRUG|Anlotinib hydrochloride|Oral administration
41454503|NCT01909024|PROCEDURE|Coil embolisation|transjugular coil embolisation of pelvic veins
41454504|NCT01909024|PROCEDURE|endovenous treatment of leg recurrent varicose veins|endovenous treatment of leg recurrent varicose veins
41454505|NCT06316557|DEVICE|rTMS group|5Hz rTMS in lesion contralateral cerebellar hemisphere, once a day for a total of five days
41454506|NCT06316557|DEVICE|control group|shame rTMS in lesion contralateral cerebellar hemisphere, once a day for a total of five days
41454507|NCT05682963|OTHER|Square Step Exercises Program|Intervention description: patient will be treated for eight weeks, two days a week, one session a day, and total 16 session. Each session will be 45 minute.
41454508|NCT05682963|OTHER|Home Exercise Program|Frenkel's coordination exercises will be applied as a home program for 8 weeks, 2 days a week, with each exercise session 15-30 minutes excluding rest periods.
41454509|NCT02118324|BEHAVIORAL|Exergaming Program|Participants will exercise through exergaming play.
41454510|NCT02708758|BEHAVIORAL|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
41290069|NCT06384339|DIAGNOSTIC_TEST|CSIV, Social motive|The CSIV is a self-report measure and assesses interpersonal values using eight octant scales, which are aggregated into overall communion and agency scores, ranging from -4 to +4 .
41290070|NCT06384339|DIAGNOSTIC_TEST|Interpersonal messages and behavior|"The Impact Message Inventory - Circumplex (IMI-C) Brief Version is a self-report transactional inventory designed to measure a target person's interpersonal behavior on four octant scales dominance, hostility, submissiveness, and friendliness by assessing the covert responses or impact messages of another person. Each subscale consists of 7 items, with each item scored on a 4-point Likert scale from 1 (not at all) to 4 (very much so). The minimum score per scale is 7 and the maximum score is 28."
40953117|NCT06101511|PROCEDURE|Intraoperative ventilation with individualized high PEEP titrated to the lowest ΔP with RMs|The intervention is intraoperative ventilation using the available ventilator with individualized high PEEP titrated to the lowest ΔP with RMs. After abdominal insufflation, patients randomized to the individualized high PEEP with RMs group will receive a RM followed by a 'decremental PEEP trial'. This is followed by a second RM after which PEEP is set at the level indicated by the decremental PEEP trial
41290071|NCT06384339|DIAGNOSTIC_TEST|CCS, Social motive|The CCS is a elf-report inventory, that measures tendencies towards competitiveness versus caring in social interactions. The minimum score for the two subscales competitiveness and caring are 9 and the maximum score is 90.
41290072|NCT03245476|OTHER|Physical therapy focus on manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
40760789|NCT00178828|DRUG|sertraline|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
40953118|NCT01601860|OTHER|Use of non-pharmacological|"Other: Non-pharmacological resources~A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Walking (with cervical dilation between 4 and 5 cm)~* Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm)~* Shower (with dilation\> 7 cm);"
41134768|NCT01317966|DRUG|rhIL-11|Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
41290073|NCT03245476|OTHER|Physical therapy focus on education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
41290074|NCT03778229|DRUG|osimertinib|osimertinib (80 mg oral OD).
41290075|NCT03778229|DRUG|savolitinib|savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)
41290076|NCT03778229|DRUG|placebo|placebo to osimertinib (oral OD)
41290077|NCT00598962|DRUG|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
41290078|NCT00598962|DRUG|Rifabutin/rifampin|
41454511|NCT05285358|DRUG|Cisplatin|Given IV
40953119|NCT01601860|OTHER|Other: Routine care|Other: Routine care Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
40953120|NCT02095223|DEVICE|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
40953121|NCT02095223|BEHAVIORAL|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
40953122|NCT04716907|GENETIC|Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region|DNA extraction from blood samples, PCR and Sequencing
40953123|NCT04716907|BIOLOGICAL|Blood sample|Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
41134769|NCT05407051|BEHAVIORAL|Family Centered Treatment|In the Family-Centered Treatment Arm, parents would be given the same list of mental health referrals and crisis numbers, but in this condition, they would authorize researchers to share their contact information with the partner agency, Catholic Charities, and would then be linked directly to bilingual adult mental health services there with a behavioral health provider who would provide collateral therapy to parents via telehealth. Although parents will be referred to the community partner for therapy as a part of the research intervention, the behavioral health providers at the community partner will be providing therapy as they usually do for these participants in line with their usual job duties.
41134770|NCT05407051|BEHAVIORAL|Treatment as Usual|"All participants (parents) would receive follow-up calls from a MetroHealth research personnel at 3 months and 6 months to measure changes in parent mental health outcomes, as well as satisfaction.~Children of parents in both conditions will receive treatment as usual which includes brief consultation for 3-5 sessions with an integrated MetroHealth behavioral health provider which is already standard practice in the clinic. Sessions typically occur monthly. Teens will be re-administered the Patient Health Questionnaire -9 by the integrated behavioral health provider as a part of clinical practice to measure treatment progress and this information will be obtained at the end of 6 months of treatment via chart review (see data sheet). Repeated measurement of patient's symptoms over the course of several months of treatment is common in clinical practice to measure patient's symptom improvement."
41134771|NCT03559959|BEHAVIORAL|Vouchers for HIV self-testing kits|Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.
41134772|NCT01227746|PROCEDURE|Tumor biopsies|
41134773|NCT01394835|DRUG|Alpha -1 Antitrypsin|Inhalation twice daily of 160mg
41134774|NCT01394835|DRUG|Alpha-1 Antitrypsin|Inhalation twice daily .Dosage 160mg
41134775|NCT01394835|DRUG|AAT|Inhalation twice daily' 160mg
41134776|NCT01540591|DRUG|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
41134777|NCT01540591|DRUG|Saline|Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
41134778|NCT01478594|DRUG|Tivozanib|Capsules for oral administration
41290079|NCT04705298|DIETARY_SUPPLEMENT|Prebiotic|Oligofructose-enriched inulin. 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
41290080|NCT04705298|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
41290081|NCT05644730|DEVICE|Fusion closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
41290082|NCT03940105|BEHAVIORAL|Packout|Each packout provided during 3 of the 4 snack patterns will contain a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. There are 3 different packouts that will be provided for 3 nonconsecutive weekdays (for a total of 9 packouts). Each packout contains the same calories and types of foods. However, they differ in packaging size and variety.
41290083|NCT02696512|DRUG|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
41290084|NCT02696512|DEVICE|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
40953124|NCT04716907|DIAGNOSTIC_TEST|CT Scan|Thymus and lung imaging
41134779|NCT01478594|DRUG|Bevacizumab|Solution for intravenous infusion
41134780|NCT01478594|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
41454512|NCT05285358|DRUG|Gemcitabine|Given IV
41454513|NCT05285358|DRUG|Nab-paclitaxel|Given via PIPAC
41454514|NCT05285358|OTHER|Quality-of-Life Assessment|Ancillary studies
41454515|NCT05285358|OTHER|Questionnaire Administration|Ancillary studies
41454516|NCT01201694|DRUG|Surface-Controlled Water Soluble Curcumin|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
40760790|NCT00178828|DRUG|bupropion|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
40760791|NCT05905198|DEVICE|Programming|programming the implanted DBS device to adjust the parameter and switch stimulation mode between Variable-Frequency settings and High-Frequency settings.
40760792|NCT06435858|DRUG|Empagliflozin|Empagliflozin 10mg
40760793|NCT06435858|DRUG|Placebo|Placebo capsule
40760794|NCT03510533|OTHER|Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation|blood samples (12ml) and stool samples (30g) collections
40760795|NCT06070350|BIOLOGICAL|Low Titer Group O Whole Blood (LTOWB)|LTOWB is whole blood from group O donors with low titer (\<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.
40953125|NCT04716907|BIOLOGICAL|Bronchial fibroscopy|Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
40953126|NCT03881475|OTHER|questionnaire|"During consultations in occupational medicine (periodic visit and / or visit at the request of the employee), the nurses (or physicians) will propose the passation of the questionnaire to the voluntary agents.~The questionnaire, composed of 79 items with 2 validated questionnaires (HAD and MBI), will be filled using a digital tablet (via the REDCAP software).~Time required to complete the questionnaire 10 minutes."
40953127|NCT04289142|DRUG|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
41134781|NCT00070317|DRUG|Isosulfan Blue|Undergo lymphangiography using isosulfan blue or methylene blue
41134782|NCT00070317|PROCEDURE|Lymph Node Mapping|Undergo lymphatic mapping
41134783|NCT00070317|PROCEDURE|Lymphangiography|Undergo lymphangiography using isosulfan blue or methylene blue
40760796|NCT06070350|DRUG|Placebo|Placebo will be provided to the research pharmacy at each of the clinical sites
40760797|NCT06070350|DRUG|Tranexamic Acid (TXA)|TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure.
40760798|NCT06070350|BIOLOGICAL|Component Therapy (CT)|Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo
40760799|NCT02475993|OTHER|SMART app|Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
41454517|NCT01201694|DRUG|Surface-Controlled Water Soluble Curcumin MTD|Dose will be maximum tolerated dose (MTD) from Arm 1.
41454518|NCT05305586|DEVICE|Splint retained by Bulk-fill flowable|Luxated teeth were splinted with bulk-fill flowable composite
41454519|NCT05305586|DEVICE|Splint retained by Packable Composite|Luxated teeth were splinted with packable composite
41454520|NCT05001698|BIOLOGICAL|Anifrolumab|intravenous infusion (IV)
40953128|NCT04882280|BEHAVIORAL|Light|10 hours of light exposure during the daytime, starting 2 hours after habitual wake time
41134784|NCT00070317|DRUG|Methylene Blue|Undergo lymphangiography using isosulfan blue or methylene blue
41134785|NCT00070317|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
41134786|NCT00070317|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo complete pelvic and low para-aortic lymphadenectomy
41134787|NCT00070317|RADIATION|Technetium Tc-99m Sulfur Colloid|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
41134788|NCT00070317|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical hysterectomy
41134789|NCT01933100|OTHER|Experimental Diet|Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
41134790|NCT03605082|DRUG|UCB0107|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
41134791|NCT03605082|OTHER|Placebo|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
41134792|NCT01531413|OTHER|Oxygen Insufflation|At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
41134793|NCT01087710|OTHER|medical food with EPA and GLA, vitamins and minerals|1 8oz serving per day for 12 weeks
41134794|NCT01087710|OTHER|medical food minus EPA and GLA, antioxidant vitamins/minerals|1 8oz serving a day for 12 weeks
41454521|NCT04443049|DRUG|Lenvatinib|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is \> 60 kg
40953129|NCT05432375|DRUG|Tinostamustine|infusion given over 60 minutes
40953130|NCT00237172|DRUG|Imatinib Mesylate|once daily
40953131|NCT01914757|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
40953132|NCT01914757|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
41134795|NCT04666181|BEHAVIORAL|Dual-task training|See descriptions under arm description. The dual-task training will occur across a total of 5 consecutive workday visits.
41134796|NCT01758549|OTHER|Aggressive Intravenous Hydration Group|Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
41134797|NCT01758549|OTHER|Standard Fluids Arm|Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
40953133|NCT04218695|DRUG|Ceftriaxone|Antibiotic
41134798|NCT02124252|BEHAVIORAL|Community-based testing with standard linkage to care|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
41134799|NCT02124252|BEHAVIORAL|Community-based HPV testing with enhanced linkage to care|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
41134800|NCT05935605|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.
41134801|NCT05935605|DIAGNOSTIC_TEST|Lung ultrasound|A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.
41134802|NCT05030415|DRUG|Ixekizumab Auto-Injector|160 mg week 0 followed by 80 mg every two weeks
41134803|NCT00451711|DRUG|Liposomal amphotericin B|
41134804|NCT05380115|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|weekly one on one video or telephone interviews with a study coach
41134805|NCT03340415|OTHER|Accelerated Rehabilitation plan|early weight bearing after surgery
41134806|NCT01433185|OTHER|Text message|Text messages sent to women before and after delivery
41134807|NCT00362960|DRUG|Olmesartan medoxomil|
41134808|NCT00362960|DRUG|Losartan|
41134809|NCT04106739|DEVICE|Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)|"This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary."
41134810|NCT01942954|OTHER|Mobile health cognitive stimulation|
41134811|NCT02980588|DEVICE|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
41134812|NCT00123409|BEHAVIORAL|Telephone disease management|Telephone based care management
41134813|NCT00123409|BEHAVIORAL|Usual Care|Usual care
41134814|NCT01338506|BEHAVIORAL|Concurrent Treatment with Prolonged Exposure (COPE)|12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).
41134815|NCT05406947|OTHER|Prospective observational study, no intervention|Prospective observational study, no intervention
41134816|NCT02698956|DEVICE|TAVI (Transcatheter Aortic Valve Implantation)|Edwards SAPIEN 3 Transcatheter Heart Valve (S3 THV) and Edwards Commander Delivery system (transfemoral) and Certitude Delivery system (transapical/transaortic). The Edwards S3 THV is indicated for use in patients with severe, symptomatic, calcific aortic stenosis with STS Score ≥ 8 or Logistic EuroSCORE ≥15
41454522|NCT04443049|DRUG|Mebendazole|mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
41454523|NCT04443049|OTHER|Placebo|Placebo (Tab Mecovit) orally twice a day (BD) daily
41454524|NCT05481931|DRUG|prabotulinumtoxinA|Botulinum toxin Type A powder for solution for injection
40953134|NCT04218695|DRUG|Normal saline|50cc intravenous once daily
40953135|NCT05757596|DRUG|VSA001 injection|The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.
40953136|NCT05757596|DRUG|Placebo|0.9% Saline, volume matched
40953137|NCT00347360|DRUG|lisinopril|
40953138|NCT00347360|DRUG|carvedilol controlled release formulation|
40953139|NCT05188170|DRUG|Niclosamide|Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
40953140|NCT00001963|PROCEDURE|hemoglobin-transported nitric oxide|
40953141|NCT02646514|DEVICE|Radiofrequency ablation with stenting|"Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.~After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage."
40953142|NCT02646514|DEVICE|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
40953143|NCT03404232|DEVICE|Dynesys DTO device (Zimmer Spine, Inc.)|All patients receive posterior hybrid instrumentation.
40953144|NCT06057844|OTHER|Additional blood sampling|Once you have been informed and have given your consent, 2 tubes of venous blood (citrated tubes of approximately 5 milliliters (ml) each) will be taken after the blood donation to enable in vitro thrombus formation. The entire sample will be used, and no surplus will be kept in the bank.
40953145|NCT03676192|DRUG|CT-16|15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
40953146|NCT03676192|DRUG|Avastin|15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
40953147|NCT01497717|DRUG|Adalimumab (Humira)|"Open label pilot trial.~The study includes 3 phases :~1. Open label treatment period of 24 weeks.~2. Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.~3. Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks."
40953148|NCT05594056|PROCEDURE|Transorbital ultrasound of the optic nerve sheet|Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).
40953149|NCT05748080|OTHER|Eating apples|the eating of 2 apples a day for a period of 6 weeks
40953150|NCT05312372|DRUG|Combination (S095033 + paclitaxel)|"Phase 1- dose escalation S095033 ; paclitaxel started at 80 mg/m²,(IV)~Phase 2 - S095033 at RP2D; paclitaxel started at 80 mg/m²,(IV)"
40953151|NCT03098121|DRUG|grazoprevir and elbasvir|For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily for 12 weeks.
41454525|NCT01751919|DRUG|Imatinib mesylate tablet 400 mg, 1 Tablet|
40953152|NCT05426772|OTHER|exercise and kinesiotaping|"Exercise: Aerobic exercise will be performed on the treadmill for 20 minutes with a maximum heart rate of 55%-65% and a perceived exertion of less than 3. The Moxy muscle oxygen monitor will take measurements over the quadriceps femoris muscle at this time.~Kinesiotaping: After 3 days, the same participants will be called for kinesiotaping application. The application will be applied to the quadriceps femoris muscle with the facilitation technique by a physiotherapist who has a kinesio taping training certificate."
40953153|NCT01435902|DRUG|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
40953154|NCT01435902|DRUG|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
40953155|NCT01870050|DRUG|Dapsone gel - verum|
40953156|NCT05306392|DEVICE|Moderate Hypothermia|moderate hypothermia will be induced using the heat controller of the VV-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 48 hours followed by a progressive reheating (0.2±0.1°C/h) to reach 36 °C. Temperature at 36°C will be maintained during 48 hours after having reached 36 °C.
40953157|NCT05306392|DEVICE|Normothermia|Temperature at 36°C will be maintained during 48 hours after having reached 36 °C
40953158|NCT03350165|DRUG|K-877|0.2mg tablet
40953159|NCT03350165|DRUG|Placebo|K-877 matching placebo tablet
40953160|NCT02938312|BEHAVIORAL|Weight Loss Only|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
41134817|NCT05443698|DEVICE|Transvaginal ultrasound|Adult women in the U.S. who are eligible for the ultrasound trial on the basis of the inclusion/exclusion criteria will complete an at home transvaginal ultrasound guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.
41134818|NCT00347061|DRUG|afuzosin|
41134819|NCT01379651|OTHER|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
41134820|NCT00774878|DRUG|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
41134821|NCT00774878|DRUG|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
41134822|NCT03838549|PROCEDURE|Prophylactic mastectomy with immediate breast reconstruction|It is an endoscopic approach for prophylactic mastectomy using an axillary single port
41454526|NCT01751919|DRUG|Glivec film-coated tablet 100 mg, 4 Tablets|
41290085|NCT02696512|DIETARY_SUPPLEMENT|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
41290086|NCT02696512|OTHER|Standard of Care|Standard of Care treatment
41307830|NCT03750032|PROCEDURE|Hem-O-Lock|The patients randomised for this intervention will undergo appendicular stump closure using Hem-O-Lock.
41307831|NCT00436566|BIOLOGICAL|trastuzumab|
41307832|NCT00436566|DRUG|cyclophosphamide|
41307833|NCT00436566|DRUG|doxorubicin hydrochloride|
41307834|NCT00436566|DRUG|lapatinib ditosylate|
41307835|NCT00436566|DRUG|paclitaxel|
41307836|NCT00436566|GENETIC|gene expression analysis|
41307837|NCT00436566|GENETIC|reverse transcriptase-polymerase chain reaction|
41307838|NCT00436566|OTHER|fluorophotometry|
41307839|NCT00436566|OTHER|laboratory biomarker analysis|
41307840|NCT00436566|OTHER|mass spectrometry|
41307841|NCT00436566|PROCEDURE|adjuvant therapy|
41307842|NCT00436566|PROCEDURE|quality-of-life assessment|
41290087|NCT06265896|OTHER|Kinesio taping|Tape will be applied on rectus abdominis muscles using muscles facilitation technique from origin to insertion of muscle with a tension between 15-35%. Band will start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xiphoid process. Tape will be applied on the right and left external oblique muscles; the procedure will start without tension from bottom and of 6-12 ribs, then the hip will be placed in flexion and rotation to opposite direction and the tape will be attached to pubic bone with tension between 15-35%. Finally, the tape will be performed on the right and left internal oblique muscles; the procedure will start without tension from anterior superior iliac spine and then the hip will be placed in extension position and the tape will be attached to lower 4 ribs and linea alba with tension between 15-35%.
40953161|NCT02938312|BEHAVIORAL|Weight Loss Plus|Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
40953162|NCT00431288|BEHAVIORAL|diet high in fruits, vegetables, and dairy|
40953163|NCT00431288|OTHER|Routine nutrition care|
40953164|NCT00002561|BIOLOGICAL|bleomycin sulfate|10 units/m2
40953165|NCT00002561|DRUG|dacarbazine|375mg/m2
40953166|NCT00002561|DRUG|doxorubicin hydrochloride|25mg/m2
40953167|NCT00002561|DRUG|vinblastine|6mg/m2
40953168|NCT00002561|RADIATION|radiation therapy|35Gy in 20 fractions (daily)
40760800|NCT06321029|BEHAVIORAL|Diabetes Tune-Up Group|The eDTU and iDTU interventions will consist of 6 weekly group sessions lasting 90 minutes per session offered over a 6-8 week period. Each series will be co-facilitated by one diabetes care and education specialist and one behavioral health interventionist. Enrollment in each series will consist of 4-10 patients per group. The intervention components integrate key strategies that have been demonstrated to be effective in previous studies: motivational interviewing and introduction to stages of change; diabetes education; cognitive behavioral therapy with a particular emphasis on identification of cognitive distortions, thought stopping and cognitive reframing; emotional regulation; social support and miscarried helping; and behavioral strategies to support diabetes self-management. Each session will involve a psychoeducational portion, group discussion, and take-home assignments to be completed between sessions.
40953169|NCT04471246|DRUG|Cephalexin|1000 mg PO QID for 7 days
40953170|NCT04471246|DRUG|Cephalexin|500 mg PO QID plus oral placebo for 7 days
40953171|NCT01810731|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (QIV)|
41290088|NCT06265896|OTHER|Pelvic floor exercise training|The intervention will be applied by a trained physical therapist. First of all, each participant will be instructed to relax thighs, bottom and abdomen musculature, then squeeze pelvic floor muscles 'focus on tightening without flexing abdomen, thighs or buttocks- avoid holding breath' 10 repetitions, 3 to 5 times a day (morning, afternoon, and night). Rest for 4 seconds and then repeat each contraction. Build up pelvic floor musculatures strength until each participant be able to do 10 slow contractions each time, holding them for 10 seconds each with rests of 4 seconds in between. Then do not hold your breath or tighten your stomach, bottom or thigh muscles at the same time. Will instruct participants to try holding each squeeze for a few seconds.
41290089|NCT00677261|PROCEDURE|Sciatic Nerve Block|Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.
41307843|NCT04586114|DRUG|Corticosteroids and Derivatives|Any systemic corticosteroid treatment administrated during ICU stay
41454527|NCT02032927|DRUG|Codeine/paracetamol|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
40760801|NCT00002171|DRUG|Nelfinavir mesylate|
40953172|NCT01810731|BIOLOGICAL|Inactivated Polio Vaccine|
40953173|NCT01810731|BIOLOGICAL|Double Dose QIV|
40953174|NCT05273333|DEVICE|Ultra-gyn®|Ultra-gyn® ovule intravaginal application, every evening before bedtime for a 10 days period.
40953175|NCT02343107|BEHAVIORAL|e-coaching|connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
40953176|NCT03643107|DRUG|Irofulven|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
40953177|NCT03643107|COMBINATION_PRODUCT|Prednisolone 10 mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
40953178|NCT04429048|DEVICE|Acupressure elastic band (Sea-Band)|The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy
40953179|NCT04429048|DEVICE|General elastic band (no bud)|general elastic band was put over bilateral PC6 acupoints
40953180|NCT00076206|DRUG|CCI-779|
40953181|NCT00076206|DRUG|Placebo|
40953182|NCT02547324|RADIATION|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
40953183|NCT02547324|RADIATION|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
40953184|NCT02761070|DRUG|Temozolomide|
40953185|NCT02761070|DRUG|Bevacizumab|
40953186|NCT03750461|DEVICE|Mesh Implantation|Implantation of permanent mesh (BARD Soft Mesh) into the abdominal wall for reinforcement to prevent hernia formation
40953187|NCT00292214|DRUG|Paracetamol (acetaminophen)|
40953188|NCT03307785|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
40760802|NCT02842346|OTHER|ultrasonography|
40760803|NCT00178659|OTHER|Blood/saliva samples for protein/molecular analysis|Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
40760804|NCT04447222|OTHER|Quality-of-Life Assessment|Ancillary studies
40953189|NCT03307785|DRUG|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
41290090|NCT00677261|PROCEDURE|Posterior capsule infiltration with local anesthetic|Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.
41290091|NCT00677261|PROCEDURE|Sham sciatic block and sham posterior infiltration|Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
41454528|NCT02032927|DRUG|Oxycodone/naloxone|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
41454529|NCT00106886|DRUG|Folic acid, vitamin B6 and B12 or placebo|
40953190|NCT03307785|DRUG|Carboplatin-Paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer \[NSCLC\], ovarian cancer, endometrial cancer, and head and neck cancer.
41290092|NCT00402350|DRUG|Inhaled Placebo|Inhaled Staccato Placebo, same number of doses as active comparator in that arm
41454530|NCT06235203|PROCEDURE|endoscopic surgery|The tumor was resected by endoscopic nasopharyngectomy.
41454531|NCT06235203|DRUG|Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy|Two courses of Toripalimab Injection and two courses of Toripalimab Injection and Gemcitabine based chemotherapy were given before endoscopic surgery.
41290093|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg|Inhaled Staccato Fentanyl, 25 mcg x 1 dose
41290094|NCT00402350|DRUG|Intravenous Fentanyl 25 mcg|Intravenous Fentanyl 25 mcg, single dose
41290095|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 2|Inhaled Staccato Fentanyl, 25 mcg x 2 doses
41290096|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 4|Inhaled Staccato Fentanyl, 25 mcg x 4 doses
41290097|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 6|Inhaled Staccato Fentanyl, 25 mcg x 6 doses
41290098|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 12|Inhaled Staccato Fentanyl, 25 mcg x 12 doses
41454532|NCT06235203|DRUG|Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy|Eight courses of Toripalimab Injection and two to four courses of chemotherapy, or until unacceptable side effects.
40760805|NCT04447222|OTHER|Questionnaire Administration|Ancillary studies
41134823|NCT00821288|BEHAVIORAL|Survivorship Intervention|"Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker)."
41134824|NCT00821288|BEHAVIORAL|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
41134825|NCT00001004|DRUG|Tumor Necrosis Factor|
41134826|NCT00001004|DRUG|Interferon gamma-1b|
41134827|NCT04256395|OTHER|mobile internet survey on self-test|1. make a questionnaire, the content of which refers to the new coronavirus diagnosis and treatment guidelines released by the National Health Commission; 2. develop the mobile applet and carry out internet propagation; 3. background data could be identified according to computer technology, de duplication and de privacy; 4. once registered, the applet can automatically remind the self-test twice a day, and encourage to adhere to 14 days; 5. automatically compare with the standards and highly suspected population could be given medical guidance and encouraged to go to the fever clinic of the designated hospital for definite diagnosis.
41134828|NCT05527808|DRUG|Tislelizumab|200 mg ,intravenous injection ,Q3W 2-4 cycles
41134829|NCT05527808|DRUG|pemetrexed|500 mg/m2,intravenous injection ,Q3W 2-4 cycles
41134830|NCT05527808|DRUG|cis-platemum|60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles
41134831|NCT05527808|DRUG|or carboplatin|AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles
41134832|NCT05569382|DRUG|Verapamil|"1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
41134833|NCT05569382|DRUG|Bisoprolol|"1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
41134834|NCT05569382|DRUG|Placebo|"1. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
41134835|NCT01334840|DIETARY_SUPPLEMENT|Bicarbonated mineral water|"Volunteers fasted overnight consumed:~0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal"
41134836|NCT01334840|DIETARY_SUPPLEMENT|Mineral water low in mineral content (control)|"Volunteers fasted overnight consumed:~0.5 L of the control water without meal or, 0.5 L of the control water with meal"
41454533|NCT06235203|DRUG|Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy|Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.
40760806|NCT04447222|OTHER|Survey Administration|Complete survey
40760807|NCT04202094|DIAGNOSTIC_TEST|Physical examination|A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).
41454534|NCT04558450|DIAGNOSTIC_TEST|carotid-femoral pulse-wave velocity|early vascular aging tests
41454535|NCT00264134|DRUG|Docetaxel|
41454536|NCT00264134|DRUG|Irinotecan|
41454537|NCT00264134|DRUG|Carboplatin|
41454538|NCT00544492|DEVICE|catheter for AV fistula cannulation|catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
41454539|NCT01169753|DRUG|Placebo|Oral tablet every morning for 2 weeks
40953191|NCT03307785|DRUG|Bevacizumab|Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
41454540|NCT01169753|DRUG|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
41454541|NCT04196062|DEVICE|EndoMASTER EASE Robotic system for ESD|EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery
40953192|NCT03307785|DRUG|TSR-022|"TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.~TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth."
40953193|NCT03307785|DRUG|Carboplatin-Pemetrexed|Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients
40953194|NCT03307785|DRUG|Carboplatin-Nab-Paclitaxel|Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.
40953195|NCT00812682|DRUG|Symbicort|
40953196|NCT06043882|PROCEDURE|flexible bronchoscopy|fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination
41134837|NCT02630186|DRUG|Rociletinib|A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
40760808|NCT04202094|DIAGNOSTIC_TEST|Scrotum ultrasound|A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.
40760809|NCT04202094|DIAGNOSTIC_TEST|Blood sample|A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.
40953197|NCT04284358|OTHER|Technology integrated instruction neuromuscular training warm-up workshop|Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application. This occurs for every exercise and occurs in pairs in which participants can discuss and evaluate an exercise by an exercise's key execution components.
41134838|NCT02630186|DRUG|MPDL3280A|A human IgG1 monoclonal antibody administered intravenously (IV)
41134839|NCT04447898|DRUG|PPV-06 10 μg|Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
41134840|NCT04447898|DRUG|PPV-06 50 μg|High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
41134841|NCT04447898|DRUG|Placebo|Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
41134842|NCT03078205|OTHER|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
41134843|NCT03078205|OTHER|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
41134844|NCT03905278|BEHAVIORAL|Parental guidance|A psychological intervention including 4 sessions to assess how participants communicate with their children about the disease and take stock of their questions and difficulties. To identify children's reactions and needs. Practical situation are analyzed and worked through role play centered on communicational difficulties to enhance communicational self-efficacy and mutual support among participants. Emotional regulation strategies are learned through relaxation exercises. A relaxation booklet is given to the participants to practice at home too. Moreover, all participants receive an informational booklet containing age-appropriate recommendations on communication with children about cancer.
41454542|NCT00748787|DRUG|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
40953198|NCT06276673|DEVICE|Delfi|Cuffs will be worn throughout the entire training session. Training session consist of lower intensity wall squats. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
41134845|NCT06196164|PROCEDURE|EUS-BD|We observe the bile duct through endoscopic ultrasound, then puncture through the gastric or duodenum wall and place a guide wire, expanding along the guide wire, finally place a stent between the bile duct and the stomach or intestine for drainage.
41134846|NCT06196164|PROCEDURE|ERCP-BD|We use a Duodenoscopy to pass through mouth down to the small opening where the bile duct and pancreatic drain. A small narrow catheter is passed through the scope to gain access to the drainage duct , followed by advancement of a wire deep into the duct. A small cut is made at the bile duct opening to help facilitate a stent placed in the bile duct.
41134847|NCT03479918|DRUG|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
41134848|NCT03479918|DRUG|R-BL-M-04|R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
41134849|NCT03479918|DRUG|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
41454543|NCT00748787|DRUG|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
41454544|NCT05753904|PROCEDURE|Conjoint Tendon Resection|For conjoint tendon resection in the experimental group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved.
41134850|NCT03479918|DRUG|R-BL-M-04 + auto-SCT|R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
40760810|NCT04202094|DIAGNOSTIC_TEST|Semen analysis|A semen analysis to evaluate ejaculate volume, sperm concentration, sperm motility, and sperm morphology. If sperm is found in the semen sample, an anti-sperm antibody test and a sperm DNA fragmentation test will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.
40760811|NCT04642209|DEVICE|Aggregometry|"After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test.~If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia.~If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS \<4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation."
41454545|NCT01316536|OTHER|provide headphones with music playing|Participants will be provided with music through headphones
41134851|NCT00016107|DRUG|estramustine phosphate sodium|Given orally
41134852|NCT00016107|DRUG|docetaxel|Given IV
41134853|NCT00016107|BIOLOGICAL|bevacizumab|Given IV
41134854|NCT00016107|OTHER|laboratory biomarker analysis|Correlative studies
41134855|NCT00838461|DRUG|HSD-016|
41134856|NCT00838461|DRUG|placebo|
41134857|NCT01529632|DRUG|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
41134858|NCT01529632|DRUG|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
41454546|NCT01316536|OTHER|Sounds|recorded ICU sounds will be provided to participants through headphones
41454547|NCT04237415|PROCEDURE|EMG biofeedback training|
41454548|NCT00004985|DRUG|Capravirine|
41454549|NCT00004985|DRUG|Nelfinavir mesylate|
41454550|NCT01604239|DRUG|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
41454551|NCT04920695|DRUG|Nitric Oxide|Pulmonary vasodilator (gas).
40760812|NCT06571578|DEVICE|Threshold Inspiratory muscle trainer|threshold inspiratory muscle trainer device Each subject will breathe through a separate mouthpiece through attach the mouthpiece firmly While putting a nose clip and inhale deeply through the mouthpiece to generate an inspiratory pressure greater than the indicated presetting threshold pressure to compress the spring and open the valve. Using High - intensity interval training technique
40760813|NCT06571578|OTHER|posture correction exercises|"conventional exercise consists of~* Cervical isometric exercises will be performed in the sitting position by resisting at the forehead (cervical ﬂexion, extension, rotation and side bending) for 10 seconds with 15 seconds breaks between holds with 10-15 repetitions in a progressive manner 3time/week for 12 weeks.~* Postural correction exercise consists of gently rolling of pelvis forward to an upright neutral sitting position, followed by scapular correction and occipital lift. Also, for the sub-occipital muscles stretching~* stretching exercises for scalene and levator muscles"
40760814|NCT00974532|DIETARY_SUPPLEMENT|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
40760815|NCT00974532|DIETARY_SUPPLEMENT|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
40760816|NCT02118246|DEVICE|Dry Needling|Dry needling was performed for one week, three times a week.
40760817|NCT02118246|DEVICE|Kinesio Tape|Kinesio tape was performed for one week, three times a week.
40760818|NCT04847037|PROCEDURE|Connected tools|Use of connected tools in postoperative bariatric follow-up vs no use of connected tools.
40760819|NCT02458027|DIETARY_SUPPLEMENT|Hemp Shake|Hemp Protein
40760820|NCT02458027|DIETARY_SUPPLEMENT|Hemp|Hemp Protein Shake
40760821|NCT02458027|DIETARY_SUPPLEMENT|Soybean Shake|Soybean Protein
40760822|NCT02458027|DIETARY_SUPPLEMENT|Soybean|Soybean Protein Shake
40953199|NCT06239025|OTHER|ultrasound-guided Transversus Thoracis Muscle Plane Block|block with ropivacaine 0.5 %, 30 mL
41134859|NCT01529632|DRUG|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
41134860|NCT01529632|DRUG|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
41454552|NCT04920695|DRUG|Placebo|medical grade normoxic gas (FiO2 = 0.21)
40760823|NCT02458027|DIETARY_SUPPLEMENT|Control|Non-Protein Shake
40760824|NCT05681949|OTHER|ADBoard|Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors
40760825|NCT06500598|DRUG|Evinacumab|
40760826|NCT04938531|OTHER|Exercise|Participants will perform an entry passive exercise test within 48 hours of onset of severe sepsis. Patients then will perform 30-60 min supine passive cycle ergometry exercise 5 days/week.
40760827|NCT06411041|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT) and yoga|The experimental group participants will be instructed to perform the practice session four days a week. The four days per week practice times (PFMT 15 minutes/day; yoga 40 minutes/day.) will result in weekly practice times for pelvic floor muscle training (PFMT) of 60 minutes and for yoga of ≥150 minutes.
41134861|NCT00001628|DRUG|Angiotensin II type 1 receptor antagonists|
40760828|NCT03288857|DEVICE|NeilMed Naspira|NeilMed Naspira is a nasal-oral aspirator
40760829|NCT02067598|OTHER|scapular exercise|
40760830|NCT03386058|DEVICE|Temporary device deactivation|Patient-controlled, temporary deactivation of implanted device
40760831|NCT04431284|OTHER|Questionnaires|The two groups (23 patients per group) will be contacted by phone or e-mail to participate to the CIO study. Once their agreement received, each patient will be asked to complete the same set of online questionnaires : weight, HAD (Hospital Anxiety and Depression scale), BES (Binge Eating Scale), YFAS (Yale Food Addiction Scale), DEBQ (Dutch Eating Behavior Questionnaire), IPAQ (International physical activity questionnaire), COVID 19 questionnaire Penn State, items from the Do-It questionnaire, general questions on the lifestyle during the lockdown (custom questionnaire), COVID stress evaluation (custom questionnaire)
40953200|NCT03063242|DRUG|Sargramostim|Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.
40953201|NCT03063242|BIOLOGICAL|Blood samples|Blood samples will be drawn at baseline and during each subsequent visit
41134862|NCT02959385|RADIATION|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
41454553|NCT02571257|DRUG|Gemcabene|1-300 mg tablet, QD, 56 days
41454554|NCT02571257|DRUG|Gemcabene|3-300 mg tablets, QD, 56 days
41454555|NCT02571257|DRUG|Placebo|
41454556|NCT05080387|OTHER|Blood sample|Blood samples will obtained for measurement of neopterin level through ELIZA
41134863|NCT02959385|PROCEDURE|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
41454557|NCT01049464|DRUG|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
41454558|NCT01049464|DRUG|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
40760833|NCT01448304|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
40760834|NCT04060355|BEHAVIORAL|Savvy program|Caregiver program (Savvy) is an evidence-based dementia family caregiver psychoeducation program. Provided to groups of 8-12 (typically) individuals caring for family members living with Alzheimer's disease or related dementias (PLWD), Savvy employs a mechanism of action based in Social Cognitive theory to promote caregivers' solution-focused coping behaviors through the acquisition of appropriate knowledge, skills, and outlook and the enhancement of caregiving mastery.
40760835|NCT04060355|BEHAVIORAL|Semi-structured video interviews|Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials
41134864|NCT05453630|BEHAVIORAL|Patient Navigation|Patients will receive navigation from a trained lay navigator at a community-based nonprofit organization that supports access to high quality healthcare. The patient navigator will work with patients to schedule their colonoscopy and identify, explore, and overcome barriers. They will educate patients about the colonoscopy procedure and preparation, provide resources, and coach and motivate patients.
41134865|NCT05453630|BEHAVIORAL|Usual Care Control|Educational brochure about colonoscopy
41290099|NCT02725255|DIETARY_SUPPLEMENT|Ujiplus|Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
41454559|NCT04252716|DEVICE|OVD|Intraocular administration
41454560|NCT02964039|BEHAVIORAL|Error reduction|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.
41454561|NCT02964039|BEHAVIORAL|Error augmentation|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.
41454562|NCT02964039|BEHAVIORAL|Activity matched control|During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
41454563|NCT00069758|DRUG|SDX-105|
41454564|NCT06339437|OTHER|ERAS Protocol|Ehanced recovery after surgery protocols were applied
41454565|NCT04404907|OTHER|no intervention|This is a secondary analysis of registry data.
41454566|NCT02708251|DRUG|glyceryl trinitrate cream|
40760836|NCT04859075|OTHER|Bifidobacterium longum 35624|1 capsule daily
41290100|NCT02725255|DRUG|Albendazole|400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
41290101|NCT02725255|DIETARY_SUPPLEMENT|uji|maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
40953202|NCT04692493|DRUG|targeted synthetic DMARD class|Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
41134866|NCT03624283|DRUG|Betahistine|Betahistine is used in the treatment of and vertigo.
41290102|NCT04799782|DRUG|Mirtazapine|15 mg dose before bed-time
40760837|NCT02914067|OTHER|Neurocognitive testing|
40760838|NCT02914067|DEVICE|rsfcMRI|The imaging protocols will be a combined version of a standard of care (SOC) protocol with a research portion. The SOC portion of the pre-surgical scans includes a 3D T2-weighted (T2w) scans and 3D pre- and post-contrast T1-weighted (T1w) images, both at high resolution (1.0 mm3) for use in the intraoperative navigation system. This scan also includes a DTI portion for definition of fiber bundles of interest. The SOC portion of the post-surgical scans includes transverse FLAIR and post-contrast T1w images in all 3 planes. The research portion of the scan will be identical at all 3 time points and include 15 min of rsfcMRI during which the non-sedated subjects will be asked to stay still and awake while looking at a fixation cross
40760839|NCT06569329|DEVICE|GentleWave System Root Canal Therapy|This device has 510k market approval for its intended use within this study.
40760840|NCT06569329|DEVICE|EdgePro Laser Root Canal Therapy|This device has 510k market approval for its intended use within this study.
40760841|NCT06569329|DEVICE|The ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy|This device has 510k market approval for its intended use within this study.
40760842|NCT01903590|PROCEDURE|TVT surgery TOT surgery|
40760843|NCT04913090|DRUG|XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
40760844|NCT04913090|DRUG|Placebo to match XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
40760845|NCT04913090|DRUG|XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
41290103|NCT04799782|DRUG|Placebo|One placebo pill before bed-time
41454567|NCT02708251|DRUG|lidocaine cream|
41454568|NCT02708251|DRUG|placebo cream|
40760846|NCT04913090|DRUG|Placebo to match XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
40760847|NCT04913090|DRUG|"XZP-5610 Tablet （for Part C1）"|Tablet(s) administered fasted orally once daily for 1 Day
40760848|NCT04913090|DRUG|"XZP-5610 Tablet for Part C2"|Tablet(s) administered after a high-fat meal orally once daily for 1 Day
40760849|NCT01514422|DRUG|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
40760850|NCT02918630|DRUG|Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
40953203|NCT04692493|DRUG|non-TNFi-biologic class|Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
40953204|NCT04635228|DEVICE|Biodesign Otologic Repair Graft|The Biodesign Otologic Repair Graft is intended for use as grafting material for tympanic membrane perforation closure.
40953205|NCT06557148|DIAGNOSTIC_TEST|18F-Fluoroestradiol PET/CT|Scanned at baseline and again posttreatment within 2 weeks of the restaging FDG PET/CT
41134867|NCT03624283|BEHAVIORAL|Exercise-based vestibular rehabilitation|Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.
41134868|NCT03332875|BEHAVIORAL|OurRelationship Online Program|OurRelationship.com is an online program designed to improve distressed romantic relationships.
41134869|NCT01249209|DEVICE|lifestyle advice|
41134870|NCT05405244|DRUG|Placebo|2 capsules, orally administered once
41134871|NCT05405244|DRUG|Bromocriptine-QR|1.6mg (2 0.8mg capsules), orally administered once
41134872|NCT00509756|DRUG|FXR-450|capsule, single oral doses from 10 mg to 450 mg
41290104|NCT04315363|BEHAVIORAL|Motivational MRI and Behavioral Intervention|Motivational messaging delivered during a functional brain MRI scan and with daily messaging
41290105|NCT04315363|BEHAVIORAL|Control MRI and Behavioral Intervention|Control messaging delivered during a functional brain MRI scan and with daily messaging
41290106|NCT00883194|DRUG|PRF-108|Ropivacaine
41290107|NCT00883194|DRUG|Placebo|PRF-108 Placebo
41290108|NCT00883194|DRUG|Ropivacaine|Solution
41290109|NCT00883194|DRUG|PRF-110|
41454569|NCT04706637|DRUG|Evogliptin|evogliptin 5mg + metformin, oral administration once a day for 48 weeks
41454570|NCT04706637|DRUG|Dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
41454571|NCT02355262|OTHER|Informational Intervention|Receive CATCH-UP intervention
40953206|NCT02759484|BEHAVIORAL|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
41454572|NCT04888767|OTHER|Interval Training Hight Intensity Program|"* Rehabilitation stay in hospitalization with 18 days of training sessions~* Training on an ergometer~* Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist~  * Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold~ * Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible"
41454573|NCT04807777|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.
41454574|NCT04720547|DRUG|Zolpidem|A nonbenzodiazepine hypnotic
40760851|NCT02918630|DRUG|E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
41454575|NCT04720547|OTHER|No Treatment|The Control condition in which participants do not receive medication.
41454576|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
40760852|NCT05007639|OTHER|Public Health intervention programme|The public health intervention programme combined 3 actions : a simple dissemination of information via the regional Unions of private practice physicians and the local correspondents of the regional networks (action 1), an action in the form of oral communication during regional meetings of professionals (action 2) and an action focused on each surgeon for whom the pathologist has diagnosed soft tissue sarcoma (action 3).
40760853|NCT05007639|OTHER|No public Health intervention programme|
40760854|NCT01922895|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
40760855|NCT01922895|DRUG|Placebo for Probiotic|Capsule manufactured without active ingredients.
40760856|NCT05664711|DRUG|Bupivacaine Injection|"Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug."
40760857|NCT03968406|OTHER|Quality-of-Life Assessment|Ancillary studies
40760858|NCT03968406|RADIATION|Radiation Therapy|Undergo radiation therapy
40760859|NCT03968406|DRUG|Talazoparib|Given PO
41454577|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
40760860|NCT06255626|DRUG|CD40.RBDv vaccin (SARS-Cov2 Vaccin)|1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))
40953207|NCT02759484|BEHAVIORAL|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
41134873|NCT00509756|DRUG|Placebo|capsule similar to active drug
41134874|NCT05918107|DRUG|PM8002|IV infusion
40953208|NCT04793867|DIAGNOSTIC_TEST|Xenon|"Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose."
40953209|NCT04565470|OTHER|online questionnaire|Web-based questionnaire about use of self-management strategies
40953210|NCT04639167|BEHAVIORAL|Paths to everyday life (PEER)|The intervention consists of a 10-week group course and the opportunity of individual companionship to e.g. local activities in civil society, municipal social services, education, health and employment. The 10-week group sessions are delivered by two volunteer peers with their own experiential knowledge of mental vulnerability and mental health difficulties. The aim is to form a constructive community through group sessions where exchanges of lived experiences, mutuality and opportunities for social network development can develop.
40953211|NCT02962388|DRUG|Anagrelide|Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
40953212|NCT02962388|DRUG|Ruxolitinib (JAKAVI®)|Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
40953213|NCT02962388|DRUG|IFNα/ PegIFNα|IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
40953214|NCT02552992|BEHAVIORAL|Yoga|
40953215|NCT02552992|BEHAVIORAL|Self-Directed Mind-Body Program|
40953216|NCT03791138|OTHER|online patient decision aid|An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
40953217|NCT05508971|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
41454578|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
40953218|NCT05508971|PROCEDURE|Adenotonsillectomy|Tonsil and adenoid removal
40953219|NCT06166485|OTHER|take a bath|The effects of two different bathtub bath methods on physiological parameters will be compared in babies divided into 2 different groups.
40953220|NCT01585870|DRUG|Sorafenib (Nexavar, BAY43-9006)|"Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).~If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort."
40953221|NCT01585870|DRUG|Eribulin|Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
40953222|NCT04763356|OTHER|Symptom Care at Home with NP follow up|In the SCH-NP group all participants will report their CIPN related symptoms daily via the app, website or phone tree. Any concerning symptoms will trigger a call back from a nurse practitioner who will use a consensus and evidence based algorithm to prescribe therapies for the CIPN symptoms.
40953223|NCT01061411|DRUG|Dalteparin|Given SC
41454579|NCT02281539|DEVICE|Neuromotus|
40760861|NCT04105257|DIAGNOSTIC_TEST|All patients|Comparison of the results of the CTP with MRI
40953224|NCT01061411|OTHER|Pharmacological Study|Correlative studies
40953225|NCT01061411|DRUG|Sunitinib Malate|Given PO
40760862|NCT05652218|DEVICE|LB-CRT|LB-CRT (DDD 60-130, LV lead turned off) (active intervention #1)
40760863|NCT05652218|DEVICE|BIV-CRT|BIV-CRT (DDD 60- 130, LV lead turned on) (active intervention #2).
40760864|NCT01044719|DRUG|Ceftazidime|Ceftazidime 2g TDS IV
40953226|NCT00912860|DRUG|Interferon beta-1a|serum free Avonex given IM once a week
40953227|NCT06309186|OTHER|Evaluation of midwifes' burnout|Burnout evaluated by questionnaires
40953228|NCT00239304|DRUG|Gefitinib|
40760865|NCT01044719|DRUG|Tobramycin|Tobramycin 7mg/kg/day OD IV
40760866|NCT01044719|DRUG|Meropenem|Meropenem 2g TDS IV
40760867|NCT04348058|BEHAVIORAL|Telephone recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program instead of traditional, paper invitation
40760868|NCT04348058|BEHAVIORAL|Combined methods recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program in participants, who did not respond to traditional, paper invitation
40760869|NCT02120248|OTHER|Telephone-based breastfeeding peer counseling|
40760870|NCT00324857|BEHAVIORAL|Decision Aid Video|"The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
40760871|NCT00324857|BEHAVIORAL|Motivational Interviewing|The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.
40760872|NCT00324857|BEHAVIORAL|MI plus Decision aid|Patient viewed the video and then underwent MI.
40760873|NCT00324857|OTHER|Attention control|patients received a booklet.
40760874|NCT04238247|BEHAVIORAL|Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Basic Intervention|"A bilingual emergency department (ED)-based precision prevention intervention grounded in Self-Determination Theory. The Basic TCBD/ABCB intervention integrates one personalized counseling session based on principles of motivational interviewing (MI) and eHealth components including a tailored mobile-friendly educational website and short message service (SMS) text message communications with the goal of improving child passenger safety.~Participants receive monthly text message requests to submit photographs depicting the child as they usually travel. Feedback is provided via text message to correct any observed errors or misuse. Tailored informational and motivational text messages are sent twice each month."
40760875|NCT04238247|BEHAVIORAL|Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Enhanced Intervention|The Enhanced TBDC/ABCB Intervention includes a second motivational interviewing session. Basic Intervention text messages continue with an additional 1-2 tailored text messages per month.
40760876|NCT01585207|DRUG|vigabatrin|3 tablets, bid for 8 weeks
40953229|NCT00239304|DRUG|Cisplatin|
40953230|NCT00239304|PROCEDURE|Radiotherapy|
40953231|NCT05330572|OTHER|No interventions were administered to the patients as a part of this study.|No interventions were administered to the patients as a part of this study. Patients who were under topical steroid regime as a part of their management plan for lichen planus will be enrolled on the study. Details of prescribed topical steroid regime for lichen planus: type of corticosteroid, formulation, frequency of application, duration of treatment will be recorded.
40953232|NCT04089475|DEVICE|Dermoscope|Dermoscopy is a noninvasive diagnostic tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic clinical dermatology and microscopic dermatopathology.
40953233|NCT04553679|BEHAVIORAL|Mindfulness online intervention|A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
40953234|NCT03105804|OTHER|FT21039|An electronic cigarette
40760877|NCT01475825|DRUG|mipomersen sodium 200 mg|Subcutaneous mipomersen 200 mg once weekly
40760878|NCT01475825|DRUG|Placebo|Placebo vehicle for subcutaneous injection.
40760879|NCT01475825|DRUG|mipomersen sodium 70 mg|Subcutaneous mipomersen 70 mg thrice weekly
40953235|NCT03105804|OTHER|FT21041|An electronic cigarette
40953236|NCT03105804|OTHER|FT21044|An electronic cigarette
40953237|NCT03105804|OTHER|FT21042|An electronic cigarette
40953238|NCT00921401|BEHAVIORAL|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
40760880|NCT01968278|OTHER|Baked milk|
40760881|NCT02399566|DRUG|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
41134875|NCT05918107|DRUG|Pemetrexed|IV infusion
41290110|NCT01119040|PROCEDURE|Natural Orifice Translumenal Endoscopic Surgery|"Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery."
41290111|NCT05198167|OTHER|Hyperoxygenated fatty acids|Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
40760882|NCT05776004|DRUG|CAL02|CAL02 consists of a mixture of 2 liposomes and is a non-biological bacterial virulence neutralizer.
40760883|NCT05776004|DRUG|Placebo|Physiological 0.9% sodium chloride solution for iv administration
41290112|NCT05198167|OTHER|Hydrocolloid dressings|Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
41290113|NCT00338936|DRUG|Valsartan + Hydrochlorothiazide|
41290114|NCT01855789|DRUG|Tocilizumab (TCZ)|TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to \[\>/=\] 100 kilograms \[kg\]) or every 2 weeks (if body weight was less than \[\<\] 100 kg).
41290115|NCT01855789|DRUG|Methotrexate (MTX)|MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
41290116|NCT01855789|DRUG|Placebo (PBO)|PBO matching to MTX will be administered orally.
41290117|NCT00092911|DRUG|DVS-233 SR|
41454580|NCT06225245|DEVICE|Epidural Spinal Stimulation (ESS)|ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) \[31-33\]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
40760884|NCT05497245|OTHER|mobile app-based breastfeeding education|"The main screen of the application used to be six screens. These six screens; Breastfeeding, Expressing, Contingencies, Frequently asked questions and my Breastfeeding Log and Breastfeeding diary. Mothers could record the number and duration of breastfeeding, milking status, the baby's height and weight, if it was a measure, the breastfeeding problem and solutions they encountered, on the Breastfeeding Introduction tab, and they could follow their breastfeeding status in the Breastfeeding Diary tab."
41134876|NCT05918107|DRUG|Cisplatin|IV infusion
41134877|NCT05918107|DRUG|Carboplatin|IV infusion
41134878|NCT00154609|DRUG|Gu-Sui-Bu (Davallia Divaricata)|
41134879|NCT02764970|DRUG|Ivabradine 7.5mg orally|additive use to the standard medication with bisoprolol
41290118|NCT05457530|DRUG|DOR/3TC/TDF|100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF
41290119|NCT05457530|COMBINATION_PRODUCT|DOR + FTC/TAF|100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)
41290120|NCT05457530|DRUG|BIC/FTC/TAF|Bictegravir sodium 50 mg, emtricitabine 200mg, tenofovir alefenamide fumerate 25mg
41290121|NCT01122810|PROCEDURE|Coronary scanner|The ECG-gated contrast-enhanced multidetector computed tomography coronary angiography will be performed with a 64 or 256-row CT Philips, Brilliance. The contrast medium mean quantity used is 80-100 ml. The CT scan parameters, adapted to the patient's weight, include 120 kV, 800mA, 0.625 mm slice thickness, 0.42-s rotation time and 0.2 pitch. To determine X-Ray exposure, Dose Length Product (Gycm) will be measured. Reconstruction will be performed at 40 and 75 % of the cycle using ECG gating. A semi quantitative analyse of coronary narrowing will be performed blindly to coronary angiogram results by two experienced radiologists. The CT quality will be determined using a quality scale from 1 to 5. A Calcification score will also be determined. A segment analyse will be performed according to AHA classification. Only more than 1.5 mm diameter vessel segments will be analysed.
41290122|NCT05948878|DEVICE|Novel Taping Method|Subjects will be asked to have the novel taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
41290123|NCT05948878|DEVICE|BCH Emergency Department Taping Method|Subjects will be asked to have the BCH emergency department taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
41290124|NCT05948878|DEVICE|Chevron Taping Method|Subjects will be asked to have the Chevron taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
41290125|NCT02997189|DRUG|OTO-104|12 mg dexamethasone administered intratympanically
41290126|NCT04086134|OTHER|Fruit Products|Fruit Products with the potential to improve constipation-related outcomes
41290127|NCT02634164|DIETARY_SUPPLEMENT|Leucine Supplement|For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution
41290128|NCT02634164|DIETARY_SUPPLEMENT|Isoleucine Supplement|For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
41290129|NCT02634164|DIETARY_SUPPLEMENT|Leucine Supplement combined with Isoleucine Supplement|For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
41290130|NCT02233725|DEVICE|Definity Perflutren Injectable Suspension|a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
41290131|NCT00599586|OTHER|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
41290132|NCT00436670|BIOLOGICAL|AMG 317 75 mg|75 mg SC weekly injection
41290133|NCT00436670|BIOLOGICAL|AMG 317 150 mg|150 mg SC once weekly injection
41290134|NCT00436670|BIOLOGICAL|AMG 317 300 mg|300 mg weekly SC injection
41290135|NCT00436670|BIOLOGICAL|Placebo|Placebo SC once weekly injection
41290136|NCT03245788|OTHER|Lay Navigation|Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
41290137|NCT00705510|DRUG|0.05% cyclosporin eye drop|use the medication twice daily for 3 months
41290138|NCT02412007|OTHER|Individualized comprehensive home centred activity based programme|"Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~1. Standing up from squatting position to catch an object of interest.~2. Squatting from standing position to pick an object of interest.~3. Walking to reach an object of interest.~4. Climbing up steps to get an object of interest.~5. Climbing down steps to keep the above object of interest.~6. Cycling~7. Kicking a football~8. Dancing"
41290139|NCT02021812|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|
40953239|NCT04785248|PROCEDURE|Three-step disinfection|"Three step disinfection method can be divide in three part. The first step of disinfection: scalp dandruff removal + disinfection The second step of disinfection: whole head Use 2% iodine tincture to smear the whole head skin, the assistant helps to lift the head to expose the surgical field, from both eyebrows to the occipital hairline, from both sides to the neck, after the iodine tincture dry out, use 75% alcohol to deionize. Then placing more than 4 layers of operation towel under the head.~The third step of disinfection: neck chest abdomen disinfection."
41290140|NCT00539786|DRUG|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
41290141|NCT02625519|DRUG|Urinary follicle-stimulating hormone|Ovarian stimulation with highly purified urinary follicle-stimulating hormone
41290142|NCT02625519|DRUG|Recombinant follicle-stimulating hormone|Controled ovarian stimulation with recombinant follicle-stimulating hormone
41290143|NCT02097836|DEVICE|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
41290144|NCT06316089|BEHAVIORAL|PrEPared for Release|A multilevel, behavioral and navigation intervention administered over two sessions to promote PrEP initiation, adherence and linkage to PrEP care in the community for incarcerated men with a history of injection drug use.
41290145|NCT00843622|DRUG|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
41290146|NCT00843622|OTHER|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
41290147|NCT04194931|BIOLOGICAL|Autologous BCMA CAR-T cells and CD19 CAR-T cells|Autologous BCMA CAR-T cells and CD19 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
40953240|NCT01848496|PROCEDURE|Gingival displacement|Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
40953241|NCT02005731|DEVICE|Low intensity linear focused shockwave device ('Renova')|
40953242|NCT02551861|DRUG|Daclatasvir|
40953243|NCT02551861|DRUG|Sofosbuvir|
40953244|NCT02551861|DRUG|Ribavirin|
40953245|NCT01265251|DEVICE|Computerized neuropsychological test|Computerized neuropsychological test battery.
40953246|NCT01265251|OTHER|Conventional neuropsychological test|Conventional neuropsychological test (paper and pen)
40953247|NCT02171065|DEVICE|sham|
40953248|NCT02171065|DEVICE|ABSORB BVS|
41290148|NCT03546556|DRUG|Fluorothymidine (FLT)|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
41290149|NCT01810991|DEVICE|Nd:YAG Laser|Nd:YAG 1440nm Laser
41290150|NCT01171521|DEVICE|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
40760885|NCT05308459|BEHAVIORAL|Data-driven health promotion at Vocational Education and Training schools (Data Health VET)|"The intervention consists of the following steps:~1. A local health profile is conducted among all students~2. Results are shortly hereafter presented and discussed with all student and staff, and the school decide what health problem they will work with during the next year~3. A participatory group model process based on a dynamic systems approach is conducted to develop sustainable and system changing activities to address the chosen health problem~4. The activities are implemented~5. A new health profile is conducted to a) evaluate the effects of the implemented activities and to b) determine if a new health problem warrant focus and new activities are needed (the process repeats itself)."
40953249|NCT00002982|BIOLOGICAL|filgrastim|
40953250|NCT00002982|DRUG|carboplatin|
40953251|NCT00002982|DRUG|carmustine|
40953252|NCT00002982|DRUG|cytarabine|
40953253|NCT00002982|DRUG|etoposide|
40953254|NCT00002982|DRUG|ifosfamide|
40953255|NCT00002982|DRUG|melphalan|
40953256|NCT00002982|PROCEDURE|autologous bone marrow transplantation|
40953257|NCT00002982|PROCEDURE|peripheral blood stem cell transplantation|
40953258|NCT00002982|RADIATION|radiation therapy|
40953259|NCT01890746|DRUG|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects \> 60 years: daunorubicin dose was adjusted to 60mg /m2.
40953260|NCT01890746|DRUG|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
40953261|NCT01890746|DRUG|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were \<100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were \<100 Gi/L.
40953262|NCT01890746|DRUG|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were \<100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were \<100 Gi/L.
40953263|NCT00731068|BIOLOGICAL|PRGF|injection of 6cc into injured area of tendon
40953264|NCT00731068|BIOLOGICAL|placebo|injection of 6 cc of saline into injured area
41290151|NCT03450850|DEVICE|NOVOTTF-200A|NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate \>= 75% (\>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.
41454581|NCT04912739|BEHAVIORAL|Targeted health dialogues|"Before the targeted health dialogue, the participants fill in a questionnaire about health behaviors, background characteristics and self-rated health. Samples for blood glucose and total cholesterol are taken. BMI, waist-to-hip ratio and blood pressure are measured. The results are summoned in a health curve, which is discussed with specially trained healthcare personnel in a Targeted heath dialogue. In a sub-group, blood samples are collected for molecular analyses."
41454582|NCT00073580|DRUG|Angiomax (bivalirudin) anticoagulant|): 250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of the procedure with the option to increase or decrease the infusion rate in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT+) \>300 seconds. A low-dose infusion could be administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. An initial dose of 0.1 mg/kg IV bolus followed by an IV infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
41454583|NCT05635630|OTHER|ctDNA and adjuvant therapy|Patients of ctDNA positive group receive individual adjuvant chemotherapy. The ctDNA status are evaluated every 2 months.
41454584|NCT05635630|OTHER|ctDNA|Patients of ctDNA negative group are monitored by ctDNA every 3 months.
40760886|NCT04526457|OTHER|Standard of Care|Randomized to standard of care with lipid testing only.
40760887|NCT04526457|OTHER|Genetic Testing|Randomized to genetic testing.
40953265|NCT02112006|PROCEDURE|0.5% bupivacaine injected in the forearm|Median, Ulnar, and Radial nerve blocks performed in the forearm
40953266|NCT02112006|PROCEDURE|20-30ml of 0.5% bupivacaine.|supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
40953267|NCT04121975|RADIATION|Radiotherapy|Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.
40953268|NCT04121975|DRUG|Endostar|30 mg/d was administered on days 1-5 every two weeks for 4 cycles.
40953269|NCT04121975|DRUG|Cisplatin|30-40 mg/m2 was administered day 1, 8, 15, 22 and 29.
40953270|NCT00215748|DRUG|Dexamethasone|
40953271|NCT05449119|BIOLOGICAL|Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data|at T0, T3 months, T6 months, T9 months and T12 months
40953272|NCT05449119|OTHER|Body Mass Index (BMI)|Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months
40953273|NCT05449119|OTHER|24-hour food and beverage record|at T0, T3 months, T6 months, T9 months and T12 months
40953274|NCT05449119|OTHER|Mini Nutritional assessment (MNA)|at T0, T3 months, T6 months, T9 months and T12 months
40953275|NCT05449119|OTHER|Measurement of muscle mass by bioelectrical impedance analysis (except for participants with a pacemaker)|at T0, T3 months, T6 months, T9 months and T12 months
40953276|NCT05449119|OTHER|Measurement of sensorimotor functions|at T0, T3 months, T6 months, T9 months and T12 months
41454585|NCT04298216|DIAGNOSTIC_TEST|Ultrasound Analysis of Inferior Vena Cavae (IVC)|Novel Operators will attempt to visualize the Inferior Vena Cavae through two different views on the patient's body. The images taken will be interpreted by an expert ultrasound user to determine if the novel operator was successful in locating and evaluating the IVC.
40760888|NCT04835597|BEHAVIORAL|Behavioral Assessment|Complete movement assessment
40760889|NCT04835597|OTHER|Electronic Health Record Review|SAE data is collected
40760890|NCT03004677|BEHAVIORAL|Continuous skin-to-skin contact|Infants will rest in skin-to-skin contact on parents' chest 24 hours a day alternating between the parents. The parents will note who provides the SSC and if and for how long they are off SSC for any reason.
40760891|NCT03004677|OTHER|Standard Care|Infants will receive regular care in the NICU. Parents may practice SSC if they like. Parents will note if, with whom, and for how long they provide SSC.
40760892|NCT00449852|BEHAVIORAL|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
40760893|NCT05849246|DRUG|Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed|"Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
40760894|NCT05849246|DRUG|Sintilimab+Carboplatin or Cisplatin+Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
40760895|NCT05849246|DRUG|Tusamitamab ravtansine+Sintilimab|"Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
40760896|NCT05391958|BEHAVIORAL|base on Lean Body Mass Pattern|PTC(post-tetanic count) was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on lean body weight mass pattern once when PTC \> 2.
40760897|NCT05391958|BEHAVIORAL|base on Actual Body Weight|PTC was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on actual body weight once when PTC \> 2.
40760898|NCT05391958|GENETIC|obese patients|obese patients with elective laparoscopic colorectal surgery were selected，and the inclusion criteria were as follows: age 18-65, body mass index (BMI) 30-35, waist circumference (WC) : female ≥80cm, male ≥90cm, and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
40760899|NCT05391958|GENETIC|normal patients|normal patients with elective laparoscopic colorectal surgery whose body mass index (BMI) 18-24 were selected,and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
40760900|NCT03359395|DRUG|Alfentanil|Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
40760901|NCT03359395|DRUG|Placebos|Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
40760902|NCT00001784|DRUG|Mexiletine|
40760903|NCT05280145|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, the patient is examined with EchOpen to detect the presence or absence of pyelocaliceal dilatation or hepatic steatosis
40760904|NCT05280145|DEVICE|Ultrasound device routinely used in the department|Patient who was first examined with EchOpen, is secondarily examined with an ultrasound probe used routinely in the department to detect pyelocaliceal dilatation or hepatic steatosis
40760905|NCT05280145|PROCEDURE|Ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating. If the latter is not available to carry out the third ultrasound scan within a timeframe deemed clinically acceptable, then the evaluation will be carried out in a delayed manner, using the video loops and image captures saved during the two initial ultrasound scans.
40760906|NCT01028560|BIOLOGICAL|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
40760907|NCT01028560|OTHER|Standard of care|standard of care asthma and allergy treatment
40760908|NCT05024214|DRUG|Lenvatinib + Envafolimab|"Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle."
40760909|NCT05024214|DRUG|Sunitinib|Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
40953277|NCT05449119|OTHER|Measurement of cognitive functions|at T0, T3 months, T6 months, T9 months and T12 months
40953278|NCT00085709|DRUG|gemtuzumab ozogamicin|Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses \>/= 28 days apart
40953279|NCT00085709|OTHER|observation|No treatment given
40953280|NCT00085709|DRUG|Cytosine arabinoside|IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
40953281|NCT00085709|DRUG|Daunomycin|IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
41290152|NCT00764894|DEVICE|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
41290153|NCT00542828|BIOLOGICAL|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
41290154|NCT02875522|OTHER|Individualized, non-linear aerobic exercise training|Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
41290155|NCT05089305|DRUG|Ozone plasma|Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications, as well as recommendations on the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07. You must record in your diary the start time, end and eventualities (in case of presenting them).
41290156|NCT01803802|BEHAVIORAL|Expressive writing|Five sessions of 30 minutes of expressive writing
41290157|NCT05073770|DEVICE|Titan Condom|"The test condoms have the following specifications throughout the study:~1. The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm.~2. The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm."
41290158|NCT02961764|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
41290159|NCT02961764|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
41290160|NCT00396227|DRUG|vildagliptin|vildagliptin as add-on to metformin
41290161|NCT00396227|DRUG|thiazolidinedione (TZD)|TZD add-on to metformin
41290162|NCT03887832|OTHER|SMBI digital app|Digital platform on the smartphone for the media package
40953282|NCT06390033|DEVICE|Prosthetic foot|A low-cost prosthetic foot designed to enhance gait mechanics and physical performance in individuals who have undergone traumatic unilateral transtibial amputation, as compared to the traditional K2 - K3 prosthetic feet currently available on the market, during both indoor and outdoor activities, whilst satisfying the users' satisfaction levels after traumatic unilateral transtibial amputation.
40953283|NCT03913468|DRUG|Intravenous Ascorbic Acid|1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
40953284|NCT00227006|BEHAVIORAL|Behavioral lifestyle/weight-loss intervention|
40953285|NCT00000315|DRUG|Cocaine|
40953286|NCT03593096|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
40953287|NCT03593096|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
40953288|NCT02999074|OTHER|Resistance exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
41290163|NCT03887832|BEHAVIORAL|media package|The SMBI app contains a \<1 minute video of a mother and baby or just mother, a reflection question about the video, a few questions about their mood and stress, and some prompts and suggestions on what to do if they have problems.
41290164|NCT03887832|OTHER|standard newborn and infant care|Recommended standard pediatric primary care will be provided for infants up to 6 months.
41290165|NCT05084989|BIOLOGICAL|Part1:Recombinant two-component COVID-19 vaccine (CHO cell)|2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection
41454586|NCT03997890|PROCEDURE|Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs|After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
41454587|NCT00748696|DIETARY_SUPPLEMENT|Fortimel Extra®|260kcal and 20g protein per day
41454588|NCT00748696|OTHER|resistance training|3 sessions of resistance training per week
41454589|NCT00748696|OTHER|combined treatment|260kcal and 20g protein per day 3 sessions of resistance training per week
41454590|NCT01753362|DRUG|liraglutide|
41454591|NCT01753362|DRUG|placebo|
41454592|NCT00787605|DRUG|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
41454593|NCT00787605|DRUG|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
41454594|NCT00787605|DRUG|Aliskiren|Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
41454595|NCT04348422|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
41454596|NCT04348422|DIAGNOSTIC_TEST|COVID-19 Serology|Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
41454597|NCT04348422|OTHER|Symptoms questionnare|Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
41454598|NCT02790658|DIETARY_SUPPLEMENT|Intake of grumixama juice|In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
41454599|NCT01622764|RADIATION|Molecular imaging with 89Zr-RO5323441|Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
41454600|NCT03960762|OTHER|ESP block (Group ESP)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block
41454601|NCT03960762|OTHER|SAP block (Group SAP)|In group B, after lateral positioning, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be enjected for correction. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
41454602|NCT06352762|OTHER|Conventional physiotherapy|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions.
40760910|NCT04427345|OTHER|Predictive factors for clinical response in patients with COVID-19.|Identify the risk factors for intra-hospital mortality in patients hospitalized in the COVID + hospital wards of the San Gerardo hospital and build a prognostic score through which it is possible to define a stratification that immediately guides the therapeutic choices and the intensity of care .
41290166|NCT05084989|BIOLOGICAL|Part1: Placebo|2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
41290167|NCT05084989|BIOLOGICAL|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati
41290168|NCT05084989|BIOLOGICAL|Part2: COVID-19 Vaccine, mRNA|1 dose. Intramuscular injection, 30 μg/0.3 mL.
40760911|NCT04556773|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
41290169|NCT02417415|OTHER|Passive heat stress|Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at \~44ºC continuously for 2 hr.
41290170|NCT02417415|OTHER|Control (non-heating)|Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
41290171|NCT04837404|PROCEDURE|Ultrasound guided femoral access for complex PCI|Ultrasound guided femoral access for complex PCI
41290172|NCT04837404|PROCEDURE|Fluoroscopy guided femoral access for complex PCI|Fluoroscopy guided femoral access for complex PCI
41290173|NCT04354051|DRUG|Sodium Nitrite|Intravenous nitrite sodium infusion, dose 70μmol, of 5 minute duration (14μmol /min-1).
41290174|NCT01373177|DIAGNOSTIC_TEST|Bayley Scales of Infant Development-II|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).
41290175|NCT01373177|DIAGNOSTIC_TEST|Bayley Scales of Infant Development-III|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
41290176|NCT04722133|DRUG|HERZUMA+mFOLFOX|Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
41290177|NCT05823493|BEHAVIORAL|Schroth exercise therapy|The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis.
41290178|NCT05823493|DEVICE|laser therapy|Laser therapy was performed w ith a dual wavelength, high power IR laser (Multiwave Locked System (MLS®) laser, Mphi, ASA srl, Vicenza, Italy) and the laser acupuncture points include DU2, GB30, DU9, SP6, LR8, DU6, DU4, DU12. Laser puncture acupuncture points had been identified according to Traditional Chinese Medicine (TCM) and treated with handpiece optical group following the detailed treatment parameters: 900Hz, FPW mode, 60 s per point, 29.12J, spot size 3 cm2, energy density 27J/cm2. All treatments are performed five times in a week for 4 consecutive weeks.
41290179|NCT00004934|DRUG|carboplatin|
41290180|NCT00004934|DRUG|epirubicin hydrochloride|
41290181|NCT00004934|DRUG|paclitaxel|
41290182|NCT00004934|PROCEDURE|conventional surgery|
41454603|NCT06352762|OTHER|Robotic Rehabilitation|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions. An additional 30 minutes of robotic rehabilitation was applied to the conventional physiotherapy program. Robotic rehabilitation was applied after each session of conventional physiotherapy applications.
40760912|NCT04556773|DRUG|Durvalumab|Durvalumab: administered as an IV infusion
40760913|NCT04556773|DRUG|Paclitaxel|Paclitaxel: administered as an IV infusion
40760914|NCT04556773|DRUG|Capivasertib|Capivasertib: administered orally
40760915|NCT04556773|DRUG|Anastrozole|Anastrozole: administered orally
40760916|NCT04556773|DRUG|Fulvestrant|Fulvestrant: administered as an IM injection
40760917|NCT04556773|DRUG|Capecitabine|Capecitabine: administered orally
40760918|NCT00836901|DRUG|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
40760919|NCT00836901|DRUG|Augmentin®|400 mg-57 mg chewable tablet
41290183|NCT03272477|DRUG|Perjeta Injectable Product|Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
41290184|NCT03272477|DRUG|Herceptin|Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
41290185|NCT03272477|DRUG|Tamoxifen|20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
41290186|NCT03272477|DRUG|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
41290187|NCT03272477|DRUG|Epirubicin|12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
41290188|NCT03272477|DRUG|Cyclophosphamide|12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
41290189|NCT03272477|DRUG|Anastrozole|1mg per day for a total of 40 weeks in adjuvant therapy phase
41290190|NCT03272477|DRUG|Letrozole|2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
41290191|NCT03272477|DRUG|Exemestane|25mg/day for a total of 40 weeks in adjuvant therapy phase
41290192|NCT03272477|DRUG|Leuprorelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
41290193|NCT03272477|DRUG|Goserelin|3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
41290194|NCT03272477|DRUG|Anastrozole|1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
40760920|NCT05474716|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|Topical Brimonidine tartrate 0.2% bid ophthalmic solution. A selective alpha 2 adrenergic agonist with ocular hypotensive and neuroprotective properties used in glaucoma and ocular hypertension.
40760921|NCT03552445|BIOLOGICAL|Tetanus-diphtheria (Td) and PCV13|154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0
40760922|NCT03552445|BIOLOGICAL|PCV13 alone|154 PCV13 recipients: one vaccine injection administered on Day 0
40760923|NCT03552445|BIOLOGICAL|Td alone|437 Td recipients: one vaccine injection administered on Day 0
40760924|NCT04164186|OTHER|Automatic detection and segmentation of NSCLC tumors|an automated deep learning detection and segmentation software for non-small cell lung cancer (NSCLC) that can automatically detect and segment tumors on CT scans and thus reduce the human variation.
41290195|NCT03272477|DRUG|Letrozole|2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
41290196|NCT03272477|DRUG|Exemestane|25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
40760927|NCT01334567|DRUG|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
40760928|NCT04717739|DEVICE|TTFields|Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
40760929|NCT06215157|DEVICE|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
40760930|NCT06215157|DEVICE|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
40760931|NCT00911157|DRUG|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (\< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
40760932|NCT00911157|DRUG|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
41290197|NCT03272477|DRUG|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
41290198|NCT03272477|DRUG|Tamoxifen|20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
41290199|NCT03272477|DRUG|Leuporelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
41290200|NCT03272477|DRUG|Goserelin|3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
41290201|NCT03272477|DIAGNOSTIC_TEST|Biopsy|Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
41290202|NCT03272477|PROCEDURE|Surgery|Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
41290203|NCT01170156|DEVICE|Hi-Lo Evac tube (Mallinckrodt Inc, USA) (Instilled blue dye)|The cuff pressure will be first checked and reset at 30 cm H2O if needed. Next, blue dye will be instilled just above the cuff through the lumen ending in the subglottic area of the Hi-Lo Evac tube. Then a suctioning manoeuvre will be performed with a suction pressure of - 400 mbar through a 16 French suction catheter. Thereafter, a fiberoptic bronchoscopy will be performed, looking for the presence of blue dye in the trachea and/or the bronchi.
41454604|NCT05262322|DRUG|Edoxaban|This was a non-interventional, observational study. No drug was administered in this study.
41454605|NCT05262322|DRUG|Apixaban|This was a non-interventional, observational study. No drug was administered in this study.
40953289|NCT02999074|OTHER|Aerobic exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.
40953290|NCT02999074|OTHER|Usual care during neoadjuvant chemotherapy/Exercise after surgery|The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
40953291|NCT01182610|DRUG|Panitumumab|Panitumumab 9mg/kg on Days 1, 22, and 43
40953292|NCT01182610|DRUG|Paclitaxel|Paclitaxel 200mg/m2 on Days 1 and 22
40953293|NCT01182610|DRUG|Carboplatin|Carboplatin AUC=6 on Days 1 and 22
41454606|NCT05262322|DRUG|Rivaroxaban|This was a non-interventional, observational study. No drug was administered in this study.
41454607|NCT01826760|OTHER|Using training and testing groups to construct ANN based on laboratory tests|
41454608|NCT00279045|DRUG|Rosiglitazone|
41454609|NCT00279045|DRUG|glyburide|
40760933|NCT04437823|BIOLOGICAL|Intravenous Infusions of Stem Cells|Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30
40760934|NCT02180672|DRUG|Nasal Fluticasone|One spray per nostril, per day.
40760935|NCT02180672|DRUG|Placebo|One spray per nostril, per day.
40760936|NCT00775671|DRUG|placebo|Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
40760937|NCT00775671|DRUG|Nebivolol|Nebivolol 5 mg by mouth daily for 12 weeks.
40760938|NCT00775671|DRUG|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
40760939|NCT06058351|BEHAVIORAL|ABI-motion program|The ABI-motion program strengthens the cooperation between outpatient rehabilitation professionals and community care providers.
40760940|NCT03242070|OTHER|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
40760941|NCT03087149|DIETARY_SUPPLEMENT|monitored vit D supplementation|The vit D supplementation dose start from dose 500IU from 7th day of age and is modified based on vit D measurement at 4 week of age for infants born \<30 GA, at 8 week of age for infants born \<26 GA at 35+/-2 weeks PMA(postmenstrual age), +/-at 40+/-2 weeks PMA according to the protocol.
40760942|NCT03087149|DIETARY_SUPPLEMENT|standard vit D supplementation|The vitamin D supplementation dose is 500IU from 7th day of age.
40760943|NCT04132427|COMBINATION_PRODUCT|vancomycin, magnesium citrate, microbiota|10 days of oral vancomycin, then 1 day of oral magnesium citrate, , then 4 days of high-dose oral microbiota, followed by 12 weeks of low-dose oral microbiota
40760944|NCT04132427|COMBINATION_PRODUCT|placebo vancomycin, real magnesium citrate, placebo microbiota|10 days of oral placebo vancomycin, then 1 day of oral real magnesium citrate, , then 4 days of high-dose oral placebo microbiota, followed by 12 weeks of low-dose oral placebo microbiota
40953294|NCT01182610|DRUG|5FU|5FU 225mg/m2/day on Days 1-15 and 22-36
40953295|NCT04264338|DIAGNOSTIC_TEST|Thyromental height test|Assessment of difficult airway
40953296|NCT00092807|DRUG|MK0653, ezetimibe|
41290204|NCT01231191|DRUG|Intravenous acetaminophen|Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.
41290205|NCT01231191|DRUG|Intravenous placebo|Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
41454610|NCT00279045|DRUG|metformin|
41454611|NCT02822716|PROCEDURE|IRE treatment|The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
41454612|NCT02822716|DEVICE|Ultrasound|
41454613|NCT00136448|DRUG|cytosine arabinoside (ara-C)|
41454614|NCT00136448|DRUG|daunomycin|
41454615|NCT00136448|DRUG|interleukin-2|
41290206|NCT04875520|OTHER|Screening testing strategy|The intervention we are evaluating is the use of weekly screening testing among students and staff.
41290207|NCT04875520|OTHER|No screening testing strategy|a group of schools will not receive screening testing.
41290208|NCT02031146|PROCEDURE|Lumbar puncture|
41290209|NCT00050713|DRUG|Sirolimus|
40953297|NCT00092807|DRUG|Comparator: placebo|
40953298|NCT05981430|BIOLOGICAL|Fecal microbiota transplant|Active comparator will receive infusion of 125mL fecal suspension via enema
41290210|NCT03385668|DRUG|Pirfenidone|Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).
40760945|NCT01436890|DRUG|Revamilast|Tablet. Low dose, Once daily for 12 weeks
40953299|NCT05981430|BIOLOGICAL|Sham fecal microbiota transplant|Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
40953300|NCT03760055|DEVICE|nGoggle|The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
40953301|NCT05715697|PROCEDURE|Sham procedure and maintenance of heart failure medications|Sham intervention, maintenance of heart failure medications
40953302|NCT05715697|PROCEDURE|Renal denervation and maintenance of heart failure medications|Renal denervation and maintenance of heart failure medications
40953303|NCT05732246|OTHER|First rib mobilization with balloon breathing exercises|Patient was in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation.
40953304|NCT05021263|DRUG|IV Medications|IV magnesium sulfate, used to replete magnesium stores
40953305|NCT05021263|OTHER|placebo|placebo
41290211|NCT05101291|DRUG|Bupivacain|Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
41290212|NCT03049540|DRUG|Tadalafil 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
40760946|NCT01436890|DRUG|Revamilast|Medium dose, Once daily for 12 weeks
40953306|NCT00185068|DRUG|Olmesartan medoxomil|
41290213|NCT03049540|DRUG|Placebo 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
41290214|NCT03158545|DIETARY_SUPPLEMENT|Olive oil Placebo|olive oil
40760947|NCT01436890|DRUG|Revamilast|High dose, Once daily for 12 weeks
40760948|NCT01436890|DRUG|Placebo|Placebo tablet in triple dummy format, Once daily for 12 weeks
40760949|NCT04380740|DRUG|Placebo|During the extended dosing of abatacept, those randomized to receive 4 doses will receive a placebo consisting of an equal volume of normal saline solution.
40953307|NCT00185068|DRUG|Olmesartan medoxomil/hydrochlorothiazide|
40953308|NCT00185068|DRUG|Hydrochlorothiazide|
41290215|NCT03158545|DIETARY_SUPPLEMENT|EPA-rich|EPA-rich omega-3 oil
41290216|NCT03158545|DIETARY_SUPPLEMENT|DHA-rich|DHA-rich omega-3 oil
41290217|NCT00003820|DRUG|Rituximab|Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
41290218|NCT01348919|DRUG|CEP-18770|CEP-18770 will be administered per dose and schedule specified in the arm description.
41290219|NCT01348919|DRUG|Lenalidomide|Lenalidomide will be administered per dose and schedule specified in the arm description.
41290220|NCT01348919|DRUG|Dexamethasone|Dexamethasone will be administered per dose and schedule specified in the arm description.
40953309|NCT01686308|PROCEDURE|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
40953310|NCT01686308|PROCEDURE|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
41290221|NCT04044638|OTHER|Resistance trainining|Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G \* Tech-branded automatic digital device (MASTER model).
41290222|NCT03008512|DRUG|Genexol-PM|
41290223|NCT03324256|OTHER|energy drink|16 oz cold commercially-available energy drink
41290224|NCT03324256|OTHER|caffeinated drink|16oz cold commercially-available caffeinated drink
41290225|NCT03324256|OTHER|Energy gum|2 pieces of commercially-available energy gum
41290226|NCT03324256|OTHER|placebo gum|2 pieces of commercially-available placebo gum
41290227|NCT03324256|OTHER|Control drink|16oz cold control drink
41290228|NCT03324256|OTHER|Total sleep deprivation|24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
41290229|NCT01450371|DEVICE|Interferential|The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
41290230|NCT01450371|DEVICE|Interferential Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
41290231|NCT00283829|DRUG|docetaxel|chemotherapy
41454616|NCT00868998|DRUG|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
41454617|NCT02375750|DEVICE|GBO and GBG|Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
41454618|NCT02375750|OTHER|Standard treatment|Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
41454619|NCT06036121|DRUG|ADRX-0706|Antibody drug conjugate targeting Nectin-4
41454620|NCT04181463|DRUG|Isopropyl Alcohol|Given via nasal inhalation
40760950|NCT04380740|DRUG|Abatacept|Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
40953311|NCT05069610|BIOLOGICAL|AD17002|A recombinant protein
41454621|NCT04181463|OTHER|Placebo|Given via nasal inhalation
40953312|NCT05069610|BIOLOGICAL|Placebo (Formulation buffer)|Formulation buffer
41290232|NCT00283829|DRUG|IL2|immunotherapy
41290233|NCT04601272|BEHAVIORAL|Decision aid|Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.
41290234|NCT00846612|DRUG|Doxil|1 cycle: 3 weeks; 30 mg/m\^2, IV, every cycle
41290235|NCT00846612|DRUG|Bevacizumab (Avastin)|1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
41454622|NCT04181463|OTHER|Questionnaire Administration|Ancillary studies
41454623|NCT04701216|DRUG|SHR8735|SHR8735 is an thrombopoietin receptor agonist to promote platelet production.
41454624|NCT02050165|DIETARY_SUPPLEMENT|KIND Bars|Consumption of KIND Bars for 12 weeks
41454625|NCT02050165|DIETARY_SUPPLEMENT|Typical American Snack|Consumption of typical American snacks for 12 weeks
41454626|NCT00894855|BEHAVIORAL|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
41454627|NCT00894855|BEHAVIORAL|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
41454628|NCT00894855|OTHER|dermatologist skin exam|Full body skin exam.
41454629|NCT01374646|BEHAVIORAL|JOIN Intervention|Behavioral group treatment for overweight and obese children and teens, that focuses on decreasing energy dense foods and sedentary behaviors.
41290236|NCT03910192|BEHAVIORAL|Mindfulness-based coaching|16 week mindfulness-based protocol focused on home-based and weekly group practice of mindfulness meditation and mindful movement.
41290237|NCT03910192|BEHAVIORAL|Dietary cardiovascular risk reduction coaching|Regular in-person meetings, phone calls, or email from study coordinator instructing them on how to integrate exercise and dietary changes in their lifestyle to reduce their risk of future cardiovascular events.
41290238|NCT02795910|BEHAVIORAL|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
41290239|NCT02795910|BEHAVIORAL|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
41290240|NCT01483092|DIETARY_SUPPLEMENT|inulin|20g/day for 4 weeks
41290241|NCT01483092|DIETARY_SUPPLEMENT|maltodextrin|20g/day for 4 weeks
41454630|NCT01090245|BEHAVIORAL|Contingency management: voucher/monetary incentives for treatment attendance|Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
40953313|NCT01103336|DRUG|pretreatment with intravenous nicorandil vs. placebo before coronary angiography|"* Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~* Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography"
40953314|NCT00754065|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
40953315|NCT00754065|DRUG|Ortho Tri Cyclen Lo|Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
40953316|NCT05914012|OTHER|Telerehabilitation based on Otago Exercise Program|It took a total of 21 sessions, 7 days a week for 3 weeks. The sessions lasted 30 minutes. It is recommended to do exercises with comfortable shoes at least 1 hour after a meal. Each of his exercises will be videotaped and numbered and delivered to the intervention group via social networks and the Internet or by memory. In each exercise session, the physiotherapist followed the exercise sessions through social networks and answered questions from the older adults.
40953317|NCT01975961|DRUG|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC|For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
40953318|NCT05377879|DEVICE|OPT-IVF dosage|Dosage predicted for each patient by the decision support tool OPTIVF
40953319|NCT05182866|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 640 mg/m\^2 IV infusion followed approximately 24 hours later by photoimmunotherapy
40953320|NCT06434012|OTHER|registry|This is registry for Infective Endocarditis
40953321|NCT01582204|DRUG|124IcG250|Pts will undergo baseline disease assessment with CT scans (chest, abd \& pelvis), 124I-cG250-PET/CT \& Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan \& 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, \& pelvis with contrast after cycles 2, 3, 4 \& 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline \& week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, \& serial blood sampling, following the lst inj of 124I-cG250.
41454631|NCT01090245|BEHAVIORAL|Information|Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
40760951|NCT03397641|DRUG|HBI-3000|Small molecule, multi-ion channel blocker
40760952|NCT03397641|OTHER|Placebo|Normal Saline
40760953|NCT01890538|DRUG|Administration of 100 mg dimenhydrinate intravenous|
40760954|NCT01890538|DRUG|2 g piracetam intravenous|
40760955|NCT03913286|DEVICE|Cortimo|The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
40760956|NCT05151419|PROCEDURE|bronchoscpe|bronchoscopic biopsy from lung mass using cryobiopsy and forceps
40953322|NCT01212458|DRUG|Rufinamid|Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.
40953323|NCT05207254|DIAGNOSTIC_TEST|Ultrasonic test|Ultrasonic test to the patient's head, neck and jaw area.
41290242|NCT04762355|DRUG|Palovarotene|ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3
41290243|NCT04762355|DRUG|Vehicle|Placebo-to-match palovarotene ophthalmic solution vials
41290244|NCT03000114|PROCEDURE|Percutaneous Needle Aponeurotomy|
41290245|NCT03000114|DRUG|XIAFLEX|
40953324|NCT01881074|DRUG|Triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
40953325|NCT01881074|DRUG|Non-triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
40953326|NCT05584332|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)|0.5 ml injection in 3 dosing regimen
40953327|NCT05584332|BIOLOGICAL|Placebo|0.5 ml injection in 3 dosing regimen
40953328|NCT01319357|DRUG|Saxagliptin|orally 5 mg/d for 6 weeks
40953329|NCT01319357|DRUG|Placebo|orally for 6 weeks
40953330|NCT06127615|DEVICE|ClearFit|Implantation of ClearFit Longeviti Craniectomy Cover
40953331|NCT01811680|DEVICE|Variable Speed and Sensing Treadmill|open label study on variable speed and sending treadmill training for hemiplegic gait training.
40953332|NCT04046198|OTHER|Educational program|The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.
40953333|NCT03904732|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
40953334|NCT01470937|DRUG|Acarbose|acarbose 100 mg PO once daily
40953335|NCT01470937|DRUG|Placebo|acarbose placebo
40953336|NCT00239538|DRUG|telmisartan combined with hydrochlorothiazide (80/12.5 mg)|
40953337|NCT00239538|DRUG|valsartan combined with hydrochlorothiazide (160/12.5mg)|
41454632|NCT06209255|PROCEDURE|Pelvic Osteotomy - Ganz Procedure|Ischial osteotomy was performed on the pubic arch; this was followed by iliac osteotomy, performed using Schanz screws in the iliac wing. The osteotomized acetabulum was overturned, and inclination was reduced.
41454633|NCT00314288|DRUG|Sarizotan HCl|
41454634|NCT06449690|PROCEDURE|Dog-assisted therapy|Dog-assisted therapy consists of the search for positive interactions resulting from the intentional human-animal relationship in the educational, therapeutic or social fields, practices as they are conducted in educational and medico-social institutions for example.
40760957|NCT02018679|PROCEDURE|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
40760958|NCT02018679|PROCEDURE|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
40760959|NCT00165607|DRUG|MENATETRANONE|
40760960|NCT05475002|OTHER|care empowerment program|dementia care e-books, dementia virtual reality activity and family support group
40760961|NCT05475002|OTHER|dementia education|dementia education manual and family support group
40760962|NCT05007158|OTHER|procalcitonin blood test|blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
41454635|NCT06449690|PROCEDURE|Occupational activities|Occupational activities consist of origami, relaxation, sports or board games sessions.
41454636|NCT01070745|DRUG|Indomethacin|Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
40760963|NCT00608790|DRUG|Salbutamol|Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.
40953338|NCT03108274|DRUG|Danicopan|Oral tablet.
40953339|NCT03108274|DRUG|Midazolam|Oral syrup.
40953340|NCT03108274|DRUG|Fexofenadine|Oral tablet.
40953341|NCT03108274|DRUG|Mycophenolate Mofetil|Oral tablet.
40953342|NCT02146664|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
40953343|NCT02146664|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
41454637|NCT01070745|DRUG|Ibuprofen|10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
41454638|NCT04172480|OTHER|Blood sampling|Peripheral blood sampling on EDTA
41290246|NCT05012696|DEVICE|Non-invasive ventilation (NIV)|Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.
41290247|NCT05012696|DEVICE|High-flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
41290248|NCT05537428|BEHAVIORAL|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
41290249|NCT06128512|OTHER|Auricular acupuncture|Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch containing the needle will remain in place until the student completes the examination.
41290250|NCT06128512|OTHER|Sham Auricular acupuncture|Sham Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, without a needle. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch will remain in place until the student completes the examination.
41290251|NCT05255614|DEVICE|Virtual reality Simulator|LapSim is a device designed by Surgical Science Device \& software at Swedan
41290252|NCT05255614|DEVICE|Pelvic trainer:|Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught
41290253|NCT02976467|DRUG|Fulacimstat (BAY1142524)|25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
41290254|NCT02976467|DRUG|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
41290255|NCT06246825|DIAGNOSTIC_TEST|Polysomnography|Patients with a high likelihood of having obstructive sleep apnea will undergo a polysomnography, as recommended by the guidelines
40953344|NCT02807519|GENETIC|collection of salivary cytokines|Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
40953345|NCT06308367|DRUG|Betaine|50mg/kg for 12 weeks
40953346|NCT06308367|DRUG|Placebo|Placebo
40953347|NCT01682954|BEHAVIORAL|Lifestyle counseling|16-week nutrition, physical activity and behavioral intervention
40953348|NCT04377243|BIOLOGICAL|V8|one pill per day either V8 or placebo
40953349|NCT00134030|DRUG|Cisplatin|Given IV
41290256|NCT05094440|BEHAVIORAL|Dialectical behavioral therapy skills training (DBT-ST)|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.
41290257|NCT04110834|DRUG|itraconazole gel once daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
41290258|NCT04110834|DRUG|itraconazole gel twice daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
41290259|NCT04110834|DRUG|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
41290260|NCT04493749|DIAGNOSTIC_TEST|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings Move ECG and ECG signal for the reference 12-lead ECG
41307844|NCT03978819|DEVICE|ANI|"ANI profiles during IPNS (bradycardia/asystole) or excessive analgesia.~During surgery continuous monitoring of ANI, HR and Remifentanil effect site concentration was done and recorded. Event markers were placed at the onset of bradycardia, asystole and the coincidence of ANI\>80 + Remifentanil \>6ng/mL). ANI values of 1 min before and 1 min after the event were used for analysis."
41454639|NCT01247103|DRUG|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
41454640|NCT01247103|DRUG|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
41454641|NCT01247103|OTHER|Placebo|Placebo to match AZD4316
41454642|NCT06561308|DRUG|Pucotenlimab|Pucotenlimab is administered at 200mg, q3w，intravenous infusion
41454643|NCT06561308|DRUG|Carboplatin|AUC=4-6，q3w，intravenous infusion
41454644|NCT06561308|DRUG|Paclitaxel|175 mg/m2，q3w，intravenous infusion, administered over 30min.
41454645|NCT06561308|PROCEDURE|Surgery|Transabdominal hysterectomy + bilateral adnexectomy + pelvic lymph node dissection + pelvic-abdominal tumor resection +/- para-abdominal aortic lymph node dissection
40953350|NCT00134030|DRUG|Doxorubicin Hydrochloride|Given IV
40953351|NCT00134030|DRUG|Etoposide|Given IV
40953352|NCT00134030|DRUG|Ifosfamide|Given IV
40953353|NCT00134030|DRUG|Methotrexate|Given IV
40953354|NCT00134030|BIOLOGICAL|Peginterferon Alfa-2b|Given subcutaneously
40953355|NCT00134030|OTHER|Quality-of-Life Assessment|Ancillary studies
41290261|NCT02795598|PROCEDURE|Single injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist."
41290262|NCT02795598|PROCEDURE|Double injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread."
41290263|NCT05728801|DIAGNOSTIC_TEST|Ageing|Using comprehensive cognitive tests to quality the domain-specific cognitive changes during ageing.
41290264|NCT05101421|DIETARY_SUPPLEMENT|Rice ceramide supplementation|At the dosage of 40mg daily for 3 months
41290265|NCT06163781|DEVICE|Blood culture prediction tool|Machine learning based predicition tool
41290266|NCT02001350|OTHER|Ultrasonography|
41290267|NCT03670173|DRUG|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
41290268|NCT01788085|DEVICE|Bravo pH monitoring procedure|Bravo pH monitoring procedure
41290269|NCT03705494|OTHER|Home-based peer counselling (web-based) intervention|The intervention consists of 5-6 home based visits (web-based) over 6 months by trained peer counsellors who will focus on breastfeeding among mothers who have already decided to breastfeed and are interested in this programme.
41290270|NCT00060892|GENETIC|HGF plasmid|Intramuscular injections into index leg on Days 0, 14, and 28
41290271|NCT00222846|BEHAVIORAL|Attention control|Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.
41290272|NCT00222846|BEHAVIORAL|Intervention|Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
40953356|NCT00134030|OTHER|Questionnaire Administration|Ancillary studies
41290273|NCT06187415|BEHAVIORAL|Mobile app to reduce harm of chemsex|Access to the mobile app which includes PrEP diary, demistification of chemsex urban legends, information on the location of needle and syringe services program, and alert sending to emergency contact.
41290274|NCT00045838|DRUG|VCR-HIVDNA006-00-VP|
41290275|NCT06377969|DEVICE|ECAP (Evoked Compound Action Potential)-controlled Closed-Loop Spinal Cord Stimulation|The patients will receive externalized epidural leads connected to external pulse generator for 5-14 days during trial phase. If the trial results in \>50% reduction in pain, they will undergo a minor surgery to receive implantable spinal cord stimulator
41290276|NCT02350829|OTHER|Cardiac magnetic resonance sequence T1 mapping|Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
41290277|NCT04334148|DRUG|Hydroxychloroquine|oral self administered tablet
40760964|NCT00608790|DRUG|Sodium chloride 5%|30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
40953357|NCT00134030|PROCEDURE|Therapeutic Conventional Surgery|Undergo amputation or limb salvage surgery
40953358|NCT05661123|OTHER|Complete decongestive therapy|"1. Education.~2. Skin care .~3. Pneumatic compression device .~4. Manual lymph draining .~5. Multilayer short stretch compression bandages.~6. Exercises."
40760965|NCT06167746|OTHER|Digital Health Information (DHI)|Digital health information websites.
40760966|NCT06167746|BEHAVIORAL|Virtual Health Coach for You|Study participants in the intervention group will receive 10-session virtual health coaching intervention session delivered over 6 months with the goal of improving caregiver self-care and coping, decreasing stress, and improving the hospital-to-home experience The 10 sessions are on average 60 minutes and cover the following topics: care transitions, caregiving demand, self-care, and coping.
40760967|NCT00908908|DRUG|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m\^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
40760968|NCT01894646|RADIATION|Positron Emission Tomography (PET) Imaging|
40760969|NCT06501573|DRUG|SGB-9768|SGB-9768 for sc injection
40760970|NCT06501573|OTHER|Placebo|sterile normal saline (0.9% NaCl) for sc injection
40953359|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (1)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
40953360|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of saline via MicronJet600 microneedle device|Intradermal administration of 100 µL saline (registration number РN002134/01 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the right arm, followed by the insertion of 18G catheter in a cubital vein immediately after the saline administration.
41290278|NCT04334148|DRUG|Placebo oral tablet|oral self administered tablet
41290279|NCT02940665|OTHER|ERAS|Patients in the ERAS group received the ERAS protocol
41290280|NCT01526226|DEVICE|Respiratory support HFNC|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
41290281|NCT01526226|DEVICE|Respiratory support NCPAP|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
40953361|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (2)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
40953362|NCT05108714|PROCEDURE|Intravenous cannulation after without prior interventions|insertion of 18G catheter in a cubital vein without prior interventions.
40953363|NCT04029506|OTHER||this is an obsevational study which needs no interventions
41290282|NCT02681887|DRUG|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
41290283|NCT02681887|DRUG|Placebo|placebo tablet identical to circadian
41290284|NCT05783869|DEVICE|Echocardiography|echocardiographic study of both groups
41290285|NCT04391868|DRUG|Viagra Tablet|50 mg tablet on Day 1 of each period
41290286|NCT04391868|DRUG|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
40760971|NCT03290677|PROCEDURE|Cryoablation|This involves passing a special needle into the body (cryoprobe) to freeze tumor and kill a small part (not all) of the cancer. The immune system will respond to the damage caused by freezing part of the tumor.
40953364|NCT05263375|DEVICE|Innovalve TMVR system|Innovalve TMVR system
40953365|NCT02718066|DRUG|HBI-8000 in combination with nivolumab|"Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice."
41290287|NCT04391868|DRUG|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
41290288|NCT05260255|DRUG|vitamin D2 ( calciferol )|add on vitamin D2( calciferol ) 40,000 IU/wk ( 2 cap) for 12 weeks
41290289|NCT05260255|DRUG|Placebo|add on placebo ( 2 cap ) for 12 weeks
41290290|NCT03270085|DRUG|Colesevelam|Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
41290291|NCT03270085|OTHER|Placebo|A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
41290292|NCT05253807|DRUG|Pemigatinib|13.5 mg tablet
41290293|NCT03063255|DRUG|Obturator block|Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
41290294|NCT03063255|DRUG|Neuromuscular block|Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
40953366|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment A: GK1-399 200 mg. Oral administration, twice per day.
40953367|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment B: GK1-399 800 mg. Oral administration, once per day.
40953368|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment C: GK1-399 800 mg. Oral administration, twice per day.
40953369|NCT01474083|DRUG|Placebo|Dose-matched placebo. Oral administration.
40953370|NCT01138774|DIETARY_SUPPLEMENT|Double blind dietary intervention with EPA and lipoic acid|Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
40953371|NCT06033053|DEVICE|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.
41290295|NCT03280550|DRUG|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
41290296|NCT03280550|DRUG|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
41290297|NCT00444210|DEVICE|DL6049 (injectable poly-L-lactic acid)|
41307845|NCT05078463|DEVICE|Microneedle|Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.
41454646|NCT02538549|BEHAVIORAL|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
41454647|NCT03555695|BEHAVIORAL|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief.
41290298|NCT05195359|BEHAVIORAL|Dein Schlaf. Dein Tag. sleep improvement application powered by SleepScore|The Dein Schlaf. Dein Tag. application powered by SleepScore is a validated sleep measurement application using sonar technology that also provides evidenced-based sleep advice and sleep education content based on a user's objectively measured nightly sleep data. As participants engage with the app, the Dein Schlaf. Dein Tag. application provides personalized and dynamic sleep content and sleep and circadian rhythm improvement advice based in the principles of sleep hygiene, sleep-circadian science, and cognitive behavioral psychology. Participants will also receive personalized sleep challenges tailored to improve their sleep and circadian rhythms. Each challenge lasts for 7 tracked nights, ranging from optimizing sleep habits to limiting caffeine intake, and more. Additional sleep improvement features embedded within the app include sleep sanctuary bedroom checks, sleep sounds, smart alarms, bedtime reminders, and sleep education blogs and science content.
41290299|NCT06257004|GENETIC|Saliva collection (screening of all participants)|All participants will give a salive sample (self-sampling kit) - selection of 25% extremes (UMC and AMC) participants for WGS and linkage analysis
40953372|NCT05943028|DRUG|Subanesthetic dose of esketamine|Both groups were given NI-guided propofol-refentanil dual-channel closed-loop target-controlled infusion under general anesthesia with a laryngeal mask/endotracheal intubation. The experimental group (EEG feedback index 36+N) and the control group (EEG feedback index 36) were intravenously injected esketamine 0.2mg∙kg-1 before anesthesia induction, followed by continuous 5μg∙kg-1∙min-1 infusion to maintain anesthesia for 30 minutes, and the maximum cumulative dose allowed was 100mg. In both groups, the infusion was stopped 30 minutes before the end of surgery.
40953373|NCT00668707|DIETARY_SUPPLEMENT|melatonin|20 mgs ingested nightly
41290300|NCT06257004|GENETIC|Bloodsampling|Based on the results of the WGS, a selection will be made of the 5% most extremes (UMC and AMC) participants for the iPSC-VSMC generation
41290301|NCT00693719|DRUG|Etoposide|50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
41290302|NCT00693719|DRUG|Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
41290303|NCT06097585|DRUG|SGLT2 inhibitor|case control study in which group will receive SGLT2I and group will not , to detect impact of the drug in changing NYHA class for heart failure and echographic parameter
41454648|NCT03555695|BEHAVIORAL|Pre-Intervention Focus Group|At the pre-intervention focus group, the study logistics will be reviewed, informed consent process will occur, the subject will complete a brief, individual pre-intervention assessment focused on overall mobility, gait, balance, mood, neurological status, and quality of life, and the subjects will be prompted to share aloud their thoughts on exercise, balance, and mindfulness practices in general and in PD specifically, and any expectations or preconceptions that they have regarding karate classes for PD.
40760972|NCT03290677|PROCEDURE|Biopsy|Removing a small piece of the affected area to confirm cancer
40760973|NCT06332352|BIOLOGICAL|PRP|Intra-articular hip injection of PRP, Blood Collection 45mL, Processed Neutrophil-Poor PRP, 1 injection to one hip joint.
40953374|NCT00668707|DIETARY_SUPPLEMENT|placebo|similar to experimental in all ways except for lack of active ingredient
40953375|NCT03758443|DRUG|TD-1473 Dose A|See Arm description
40953376|NCT03758443|DRUG|TD-1473 Dose B|See Arm description
40953377|NCT03758443|DRUG|TD-1473 Dose C|See Arm description
40760974|NCT01756742|OTHER|Respiratory physiotherapy|"The respiratory physiotherapy intervention included:~* Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)~* Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry."
41290304|NCT00375934|DRUG|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
41290305|NCT00375934|DRUG|Placebo|Oral placebo capsule, every 6 hours
41290306|NCT02924675|DRUG|Pregabalin|150mg daily in three doses during three weeks
41290307|NCT02924675|DRUG|Placebo|Three doses daily with lactose
40953378|NCT03758443|DRUG|Placebo|See Arm description
40953379|NCT01354587|DRUG|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
40953380|NCT06556589|BEHAVIORAL|Collaborative Care|Collaborative care components include patient-centered team care, population-based care, measurement-based treatment to target, evidence-based care, and accountable care.
40953381|NCT03412526|DRUG|Fludarabine|Reduced intensity, myeloablative, lymphodepleting regimen (25 mg/m2 for 3 days)
40953382|NCT03412526|RADIATION|Radiation|Total Body Radiation (TBR) (2 Gray in a single treatment) for 1 day
40953383|NCT03412526|BIOLOGICAL|TIL administration|TIL Administration
40953384|NCT03412526|DRUG|IL-2|bolus high-dose (720,000 IU/kg) IL-2 is administered to the patients every 8 hours, to tolerance. A maximum of 10 doses are given to the patients.
40953385|NCT01135602|DRUG|Topiramate|Topiramate 50-300 mg/day Orally Twice per day
40953386|NCT00983437|DRUG|Armodafinil|
40953387|NCT00287365|DRUG|ozone|2 hour exposure to 0.4 ppm ozone
40953388|NCT01847742|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|
40953389|NCT01788046|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
40953390|NCT01788046|DRUG|Placebo|Administered intravenously (IV) three times per week.
41454649|NCT03555695|BEHAVIORAL|Post-Intervention Focus Group|At the post-intervention focus group, the pre-intervention assessments will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
41454650|NCT04942496|DRUG|Chlorhexidine Gluconate|Antimicrobial Skin Wash
41454651|NCT04942496|DEVICE|Hibi Universal Bathing System|Cloths used for patient bathing
41454652|NCT04942496|OTHER|0.1% SLS|Positive control
40953391|NCT05259358|OTHER|exercise|exercises that increase muscular endurance
40953392|NCT02538081|DRUG|Risperidone plus Placebo|Standard of care including Risperidone plus Placebo
40953393|NCT02538081|DRUG|Risperidone plus DMXB-A|Standard of care including Risperidone plus DMXB-A
40953394|NCT04877691|DRUG|Medi-546|Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
40953395|NCT04877691|DRUG|Placebo|Solution for injection in aPFS
40953396|NCT02882412|OTHER|observational|
40953397|NCT06103539|DEVICE|Cardiac catheterization and evoked response to cardiac stimulation|Cardiac catheterization with a combined elecrtophysiology and pressure sensing catheter to perform multisite stimulation and measure the evoked pressure response in a connected software.
40953398|NCT02649270|BIOLOGICAL|T1h|Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
40953399|NCT06450821|PROCEDURE|PRIOR [Proactive Intensive Oral Review & Treatment]|Intervention Arm: Professional Oral Health Care (POHC) referred to as PRIOR \[Proactive Intensive Oral Review \& Treatment\] prior to chemotherapy.
40953400|NCT06341075|DEVICE|Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)|MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
40953401|NCT05531331|BEHAVIORAL|At home education via video conferencing|Educational booklets are given according to the type of stoma. The individual with the stoma was told that the researcher was always reachable by phone and could communicate if he had any problems. The individuals with stoma in the experimental group received the training of the company representative that sells stoma materials, which is routinely given in the hospital. After discharge, training was given by the researcher via video conference in a total of four interviews. The first interview was done on the 5th day after discharge, the second on the 10th day, the third on the 15th day, and the fourth on the 2nd month. A post-test was conducted at the end of the 4th training interview, which was administered via video conferencing.
40953402|NCT04958668|OTHER|Post-operative intensive care using volatile sedation|Patients admitted after valve surgery are receiving intensive care using volatile sedative per anaesthetic conserving device. The subject of the study is medical and nursing time management..
40953403|NCT03137420|DIAGNOSTIC_TEST|Numeric Scale of Family Distress|Questionnaires at 1, 3, 6 and 12 months
40953404|NCT05430152|DRUG|Low-Dose Naltrexone|"Study drug dosing schedule (LDN):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
40953405|NCT05430152|OTHER|Placebo|"Study drug dosing schedule (Placebo; capsules made to match LDN doses):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
40953406|NCT01669135|OTHER|Spinal Anesthesia with cerebral oxygen saturation monitoring|
41134880|NCT03105960|DRUG|garlic with lime mouth wash|garlic with lime juice is herbal antimicrobial 10 ml (undiluted) for 30s and then expectorate for 14 days.o prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract.
41454653|NCT04942496|OTHER|Distilled Water|Negative Control
41454654|NCT01968031|DRUG|Istradefylline 40 mg|Istradefylline 40 mg and placebo
41454655|NCT01968031|DRUG|Istradefylline 20 mg|Istradefylline 20 mg and placebo
41290308|NCT01003587|BEHAVIORAL|District health information package|"The intervention package consists of:~* A report on disease burden, disease control priorities and health system performance in India~* Condensed fact sheet based on the report~* District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~* Customized speech for district level officials detailing key actions to reduce deaths~* Reminder materials including poster version of the DRCs and video on key points and actionable messages"
41290309|NCT05565677|DEVICE|micro-computed tomography scanning of lung tissue specimens|Micro-computed tomography will be utilized to scan surgically resected lung tissue specimens.
41290310|NCT02362412|DRUG|FK949E|A tablet containing 50 mg or 150 mg of quetiapine taken orally.
41290311|NCT03709433|BEHAVIORAL|ACT groups and mobile app|See arm description.
41454656|NCT01968031|DRUG|Placebo|Placebo
41454657|NCT00259896|DRUG|exenatide|
40953407|NCT03254979|BEHAVIORAL|Healthy lifestyle prescription|"3 actions for the prevention of DM2 in the clinical setting are recommended:~1. A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~2. With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~3. A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits."
40953408|NCT06043726|DIAGNOSTIC_TEST|Laboratory testing: D-dimeer and astrup|Standard care: Laboratory result (D-dimer and astrup). CT scan for pulmonary embolism if indicated
41134881|NCT03105960|DRUG|chlorhexidine|hlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days.
41134882|NCT01959958|OTHER|Questionnaire/Interview|Participants will each complete an interview with questionnaires assessing nocturnal enuresis, health-related quality of life, emotional and behavioral functioning, family functioning, and stressful life events. Participants who report nocturnal enuresis will also be asked to identify interventions they have used in the past, along with barriers to intervention implementation.
41134883|NCT02955966|DEVICE|imaging 18F-FDG-PET/CT|18F-FDG PET Scan at Day 0, W6 and W12
41134884|NCT02955966|BIOLOGICAL|Blood collection|Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
41134885|NCT04336618|DEVICE|Liver MultiScan|The LiverMultiscan is a quick 15 minute, contrast free, non-invasive MRI scan that provides 3 liver metrics
41134886|NCT06028659|OTHER|Coffee|Decaffeinated coffee with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
41290312|NCT02347358|DEVICE|JRecanTM blood FR device|JRecanTM blood flow recanalisation device
41290313|NCT02347358|DRUG|IV r-tPA|intravenous recombinant human tissue plasminogen activator
41290314|NCT03756012|DEVICE|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
41290315|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method A|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
41290316|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method B|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
41290317|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method C|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
41290318|NCT04930250|OTHER|Placebo Comparator: Minimally-processed oat bran (Positive Control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
41290319|NCT04930250|OTHER|Placebo Comparator: Readily-digestible carbohydrate (negative control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
41290320|NCT01665781|DRUG|Erythropoietin|
41454658|NCT02924649|PROCEDURE|Early Intensive mobilisation|The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
41454659|NCT06445478|OTHER|Blood Flow Restrictive Exercise and Isokinetic Exercise|"Before providing exercise training, the muscle strength, circumference measurement, joint range of motion, agility and quality of life of female football players will be determined. Muscle strength measurements will be evaluated with the Kineo Intelligent Load Isokinetic Device for the BFR-RE and ID-RE groups. Then, both groups will be given 4 weeks of resistance exercise training. After this training, all evaluations will be made again. After this evaluation, another 4 weeks of training will be given and the evaluations will be re-applied at the end of the 8th week.~The Informed Volunteer Consent Form will be read and signed by 30 selected participants."
40953409|NCT04099095|BEHAVIORAL|Immediate Appointment|The participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
40953410|NCT04099095|BEHAVIORAL|Delayed Appointment|After a period of delay (control) the participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
40953411|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
40953412|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
40953413|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
40953414|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
40760975|NCT01756742|OTHER|Conservative treatment|Conservative medical treatment intervention for pleural effusion.
40760976|NCT05734807|DRUG|Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)|Subjects will receive NrtIs therapy for 24 weeks.
41454660|NCT03428750|BIOLOGICAL|EN3835|Collagenase clostridium histolyticum
40760977|NCT05734807|DRUG|HH-003 and NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W and NrtIs therapy for 24 weeks.
40760978|NCT05734807|DRUG|HH-003, NrtIs and PEG-IFN-α|Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.
40953415|NCT00491764|DRUG|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
40953416|NCT00491764|DRUG|Placebo|Placebo for 24 weeks.
40953417|NCT04710173|PROCEDURE|ECMO|VV-ECMO
40953418|NCT03441269|DRUG|Oral Ibuprofen|Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
40953419|NCT03451578|DEVICE|Alpha MSH assay|Assay to detect levels of alpha MSH in intraocular fluid.
40953420|NCT04555421|DEVICE|Lumen|Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
40953421|NCT02983565|DEVICE|Intelligent oxygen therapy system (iO2Ts)|
40953422|NCT01613300|DRUG|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
40953423|NCT03918473|OTHER|Mobilization with Movement|The MWM group will receive manual therapy with the following protocol: the participant will be relaxed and standing in a staggered stance with the involved foot on an eight-inch step and both feet facing forward. The clinician will be positioned in front of the participant's leg and a non-elastic belt will be placed around the distal leg of the participant and the clinician's pelvis. The clinician will then apply a sustained posteroanterior glide to the tibia through the belt by leaning backwards, while stabilizing the fixed talus and forefoot with both hands. The participant will perform a slow lunge until the end range of motion without their heel lifting off the ground. The belt will be kept perpendicular to the tibia throughout the movement and 2 sets of 10 repetitions will be applied.
40953424|NCT03918473|OTHER|Thrust Mobilization|The talocrural joint TM will be a high velocity low amplitude manual therapy technique. This technique will be applied with the participant in the supine position on a plinth. The clinician grasps the foot with one hand with the fifth finger contacting the anterior surface of the ankle at the talus. The other hand reinforces the contact points and both thumbs are placed on the sole of the participant's foot. The clinician gives slight caudal traction focused on the talocrural joint with the ankle dorsiflexed and everted. The therapist then applies a high-velocity thrust distraction technique to the talocrural joint. Only one thrust will be applied and no audible cavitation is required. This manual therapy technique will be performed once.
40953425|NCT00630643|BIOLOGICAL|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
40953426|NCT00630643|DRUG|Placebo|Placebo
40953427|NCT01086722|DRUG|"karolinska cocktail"|"The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol"
41134887|NCT06028659|OTHER|Water|150 mL of hot water with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
41134888|NCT00355745|DEVICE|Ultrasound breast scanning|breast scanning
40760979|NCT05603780|BEHAVIORAL|exploratory protocol|physiological and cognitive evaluations
40760980|NCT06255782|GENETIC|ECUR-506|ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.
40760981|NCT02412982|DRUG|Enoxaparin 40 mg q12h|Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
40760982|NCT02412982|DRUG|Enoxaparin 30 mg q8h|Patients receive enoxaparin 30 mg every 8 hours.
40953428|NCT01117948|DRUG|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
41290321|NCT03299023|OTHER|Medibyte Portable Monitor|Patients will be provided with the portable monitor in order to measure their apnea/hypopnea index.
41290322|NCT06513169|PROCEDURE|Group 1: LEE|"Patients will be in supine position during induction with a 12 wedge placed at the level of the Achilles tendon (LEE)"
41290323|NCT03339427|OTHER|vitamin D|different doses of vitamin D supplementation
41290324|NCT03339427|OTHER|control|control group
41290325|NCT05690633|DEVICE|Pulse oximetry|Noninvasive method of measuring the saturation of oxygen in the blood.
41290326|NCT04950231|OTHER|The questionnaire survey|Questionnaires were issued and collected by 6 competent nurses with strict training, data entry by 2 researchers, statistical analysis by 1 researcher, and quality control by the other 2 researchers throughout the process.
41290327|NCT01092442|PROCEDURE|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
41134889|NCT01131546|DRUG|Levamlodipine besylate|Once daily, 7AM - 10AM
41290328|NCT05539053|DRUG|N Acetylcysteine A|paclitaxel + N-Acetylcysteine orally short course
41290329|NCT05539053|DRUG|N Acetylcysteine B|paclitaxel +N Acetylcysteine orally long course
41290330|NCT00564629|DRUG|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
41290331|NCT00564629|DRUG|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
41290332|NCT00564629|BIOLOGICAL|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
41290333|NCT02060825|DEVICE|Regional saturation monitor|
41290334|NCT03210285|DIAGNOSTIC_TEST|Whole exome sequencing|Whole exome sequencing
41290335|NCT01067638|DRUG|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
41134890|NCT01131546|DRUG|Amlodipine maleate|Once daily, 7AM - 10AM
41290336|NCT02447107|OTHER|Electronic Diary|The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
41290337|NCT02447107|OTHER|Questionnaire|Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
41134891|NCT02734355|DRUG|Telmisartan 80 mg and amlodipine 5 mg|
41290338|NCT02373930|DRUG|DTG 50 mg|Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
41290339|NCT02373930|DRUG|RPV 25 mg|Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
40760983|NCT03759197|DRUG|188-0551 Spray|Topical Spray containing active drug
40760984|NCT03759197|DRUG|Vehicle Spray|Topical Spray containing no active drug
41134892|NCT02734355|DRUG|Placebo (for telmisartan and amlodipine)|Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet
41134893|NCT04596488|DRUG|Efavirenz 400mg|HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
41134894|NCT01472159|BEHAVIORAL|CGM Family Teamwork Intervention|The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
41134895|NCT00268333|DRUG|fluorouracil|
41134896|NCT00268333|DRUG|leucovorin calcium|
41134897|NCT00268333|DRUG|oxaliplatin|
41134898|NCT00268333|PROCEDURE|neoadjuvant therapy|
41134899|NCT03876184|OTHER|Aesthetic archwires|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
41134900|NCT03876184|OTHER|Control group|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.This group will not answer the questionnaire.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
40953429|NCT01117948|DRUG|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
40953430|NCT05490784|OTHER|Lee Silverman Voice Treatment BIG|Patients assigned to experimental group will get Lee Silverman Voice Treatment BIG along with conventional treatment.
40953431|NCT05490784|OTHER|conventional treatment|patients in this group will get conventional treatment program encompassing set of exercises such as complex motor sequences, stretching, dual tasking, mental imagery and core stability.
40953432|NCT05292378|OTHER|2500 ppm Carbon Dioxide|2.5 hour exposure to 2500 ppm carbon dioxide
40953433|NCT05292378|OTHER|600 ppm Carbon Dioxide|2.5 hour exposure to 600 ppm carbon dioxide
40953434|NCT03181035|RADIATION|(18)F-Fluoroazomycin arabinoside|FAZA PET diagnostic testing
41134901|NCT03958526|DEVICE|active tDCS|Patients in active group will receive 10 sessions of anodal tDCS delivered over primary motor cortex (M1) contralateral to the most painful side with a constant current of 2 miliAmpers for 20 minutes.
40760985|NCT06421441|OTHER|Self Management Skills Training|Nursing students will be given self-management skills training for a total of 12 hours, two days a week, two hours a day (60 min. + 60 min.) for three weeks.
40953435|NCT03181035|DRUG|Pimonidazole|oral pimonidazole hypoxia labeling
40953436|NCT00216476|DRUG|Aripiprazole|10-30 mg oral once daily for 104 weeks
40953437|NCT00216476|DRUG|Risperidone Long Acting Injectable (LAI)|25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
40953438|NCT00216476|DRUG|Quetiapine|Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
41134902|NCT03958526|DEVICE|sham tDCS|Same protocol (electrode montage,session duration) will be used for sham stimulation. But the device won't be active for full 20 minutes.
40953439|NCT06358131|DEVICE|Endoscopy|upper and lower endoscopy
40953440|NCT02053870|OTHER|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
40953441|NCT02053870|DRUG|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
40953442|NCT01331122|DRUG|droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
40953443|NCT06378580|DRUG|Surufatinib combine immune checkpoint inhibitor|"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~Chemotherapy regimens that were combined with surufatinib included AG or FOLFIRINOX regimens. The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxalip"
40953444|NCT06378580|DRUG|AG/FOLFIRINOX|"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity."
41134903|NCT00143286|DRUG|varenicline (CP-526,555)|
41134904|NCT05290090|DRUG|Rituximab, Lenalidomide, Zanubrutinib and RCHOP|"chemo free period (21 days as a cycle, a total of 2 cycles): rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~Immunochemotherapy period: RCHOP regimen (21 days as 1 cycle, a total of 4 cycles): rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
41290340|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AS|DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
41290341|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AM|DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
41454661|NCT03428750|BIOLOGICAL|Placebo|Placebo
40760986|NCT05885594|DRUG|[18F]NOS|\[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.
41290342|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AQ|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
41290343|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AK|DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
41290344|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AR|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
41290345|NCT02435628|OTHER|Questionnaires|All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
41290346|NCT04021862|DRUG|Bermekimab Monoclonal Antibody|Bermekimab 400 mg or 800 mg will be administered subcutaneously.
41290347|NCT04021862|DRUG|Placebo|Placebo will be administered subcutaneously.
41290348|NCT00030758|BIOLOGICAL|filgrastim|
41290349|NCT00030758|BIOLOGICAL|pegfilgrastim|
41290350|NCT01972425|OTHER|Biomarker-based diagnostic|The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
41290351|NCT03299504|OTHER|Exercise|5 days per week, 2.5 hours per day strength, balance and endurance training on an outpatient basis
41290352|NCT03348514|DRUG|CPX-POM - 30 mg/m^2|CPX-POM
41290353|NCT03348514|DRUG|CPX-POM - 60 mg/m^2|CPX-POM
41290354|NCT03348514|DRUG|CPX-POM - 120 mg/m^2|CPX-POM
41290355|NCT03348514|DRUG|CPX-POM - 240 mg/m^2|CPX-POM
41454662|NCT01584882|BEHAVIORAL|CATI Tool|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a CATI tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
41454663|NCT04615741|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
41454664|NCT04615741|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
41290356|NCT03348514|DRUG|CPX-POM - 360 mg/m^2|CPX-POM
41290357|NCT03348514|DRUG|CPX-POM - 600 mg/m^2|CPX-POM
41454665|NCT02943538|DEVICE|Telemedicine|Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
41290358|NCT03348514|DRUG|CPX-POM - 900 mg/m^2|CPX-POM
41454666|NCT02943538|DEVICE|Telephone|A telephone control of their state and evolution will be made through the nursing staff of the unit.
40760987|NCT02062008|DEVICE|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
41290359|NCT03348514|DRUG|CPX-POM - 1200 mg/m^2|CPX-POM
41290360|NCT01663740|DRUG|Valganciclovir|Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
41290361|NCT03420677|DEVICE|Application of tones|During NREM sleep, tones (max. 60 dB) will be played using a portable, safe, in-home device. This device records biosignals (e.g. brain activity) and precisely times the tones during NREM sleep. It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic
41290362|NCT03420677|DEVICE|No application of tones|This is the sham-control intervention; The device will only record biosignals but will not play tones.
41290363|NCT05983302|DRUG|Platelet-Rich Plasma-Fibrin Glue|The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
41290364|NCT05983302|DRUG|Repairing Gel|The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
40953445|NCT01880619|DRUG|Tamsulosin|Patients in this arm will receive Tamsulosin 0.4 mg daily
40760988|NCT01229202|DRUG|Bevacizumab|single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
40953446|NCT01880619|DRUG|Solifenacin|Patients in the arm will receive Solifenacin
40953447|NCT01880619|DRUG|Control|Patients in this are will receive placebo
40953448|NCT04736693|DRUG|Raloxifene|Raloxifene dispensing claim is used as the reference group.
40953449|NCT04736693|DRUG|Zoledronic Acid|Zoledronic Acid dispensing claim is used as the exposure group.
40953450|NCT05019976|RADIATION|Radiation - Dose Level 0|"Dose Per Fraction (Each Radiation Treatment): 3.2Gy to 2.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 44.8Gy to 33.6Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 14"
41290365|NCT05983302|DRUG|Repairing Gel and Platelet-Rich Plasma-Fibrin Glue|The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
40953451|NCT05019976|RADIATION|Radiation - Dose Level 1|"Dose Per Fraction (Each Radiation Treatment): 4.2Gy to 3.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 42Gy to 32Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 10"
41290366|NCT05983302|OTHER|Classical wound irrigation (control)|For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.
41290367|NCT00619541|DRUG|Infusional 5-Fluorouracil|5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
41454667|NCT02943538|OTHER|Conventional care|Conventional care provided in the unit to patients with IBD -high moderate complexity.
41454668|NCT03555136|DRUG|Vortioxetine|Treatment with vortioxetine as per local SmPC
41454669|NCT00450658|DRUG|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
40953452|NCT05019976|RADIATION|Radiation - Dose Level 2|"Dose Per Fraction (Each Radiation Treatment): 5.2Gy to 4.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 39.2Gy to 29.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 7"
40953453|NCT05019976|RADIATION|Radiation - Dose Level 3|"Dose Per Fraction (Each Radiation Treatment): 6.8Gy to 5.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 34Gy to 27Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 5"
40953454|NCT05019976|RADIATION|Radiation - Dose Level 4|"Dose Per Fraction (Each Radiation Treatment): 10Gy to 7.8Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 30Gy to 23.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 3"
40953455|NCT00841919|DRUG|Glargine insulin|"The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
40953456|NCT00841919|DRUG|NPH insulin and regular insulin|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
41454670|NCT00450658|DRUG|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
41454671|NCT00028613|RADIATION|iodine I 131 monoclonal antibody Lym-1|
40760989|NCT00637156|DEVICE|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
40760990|NCT00637156|DEVICE|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
40760991|NCT03790956|PROCEDURE|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
41134905|NCT00253266|DRUG|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
41134906|NCT00253266|DRUG|Quetiapine|Quetiapine up to 200 mg/d for four weeks
41134907|NCT02773862|DEVICE|HS-1000|
41290368|NCT00619541|DRUG|Sorafenib (Bay 43-9006)|Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
40760992|NCT05027789|BEHAVIORAL|Self-Guided|People in this arm will come to 15 information sessions. These sessions will provide training and education on memory support strategies and healthy lifestyles. You will decide how you want to implement this information into your daily life.
40760993|NCT05027789|BEHAVIORAL|Structured Group|People in this group will come to 15 information sessions. The study will provide recommended behavior targets (like how much exercise you should have each week). Participants in this group will either receive an iPad or have a special application installed on their own personal device. They will receive training on how to use the application, and will be asked to use the application to record their activities and receive reminders.
40760994|NCT05545527|DRUG|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
40953457|NCT00841919|DRUG|lispro insulin|"Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
40953458|NCT00408538|DRUG|UC-781 microbicide gel (0.1% and 0.25%)|
40953459|NCT00408538|DRUG|placebo|
41134908|NCT04547660|BIOLOGICAL|Convalescent Plasma|Fresh frozen plasma collected by apheresis from recovered COVID-19 patients added to best supportive care.
41290369|NCT04044547|DRUG|Rotigotine, extended-release microspheres|"Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
40760995|NCT05545527|DRUG|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
40760996|NCT05545527|DRUG|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
40760997|NCT03078231|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
40760998|NCT03078231|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
40760999|NCT06136299|OTHER|Neuromuscular Training|This intervention uses the FIFA 11+ Kids program as a warm-up during soccer practice sessions.
40761000|NCT03333200|OTHER|Palliative Care|Collecting information about the natural progression of these diseases
40761001|NCT03333200|BIOLOGICAL|Hematopoetic Stem Cell Transplantation|Following patients who have received HSCT as part of their clinical care.
40761002|NCT04154332|OTHER|Sample collection|Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
40761003|NCT05612945|OTHER|High-intensity interval training group (HIIT)|"Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
40761004|NCT05612945|OTHER|Low-to-moderate intensity training group (LowMod group)|"Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
40761005|NCT00111735|DRUG|Thyroxine|
41290370|NCT04044547|DRUG|Placebo, extended-release microspheres|"Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
41290371|NCT02586207|DRUG|pembrolizumab (MK-3475)|200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.
41290372|NCT02586207|DRUG|Cisplatin|Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36
41290373|NCT02586207|RADIATION|Radiation|70 Gy fractionated over 35 days
41290374|NCT02316444|BIOLOGICAL|Hepatitis B vaccine|An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol
41290375|NCT01381107|DRUG|ALKS 5461|Sublingual administration once daily for 7 consecutive days.
41290376|NCT01381107|DRUG|Placebo|Sublingual administration once daily for 7 consecutive days.
41290377|NCT02252952|OTHER|Beverage Consumption|
41290378|NCT04172831|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
40953460|NCT00515177|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
41290379|NCT04172831|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
41290380|NCT03248466|BIOLOGICAL|PRG combined with BMMSCs transplantation|PRG combined with BMMSCs transplantation
41290381|NCT01470339|DRUG|duloxetine|duloxetine 60mg once a day for 5 weeks
41290382|NCT06511414|DEVICE|duramesh|Duramesh™ non-absorbable polypropylene suture is a hollow core, microporous, cylindrical suture made off in polypropylene filaments that are loosely braided and bonded to each other with heat and pressure
41290383|NCT06511414|DEVICE|Control|standard closure of fascia
41290384|NCT06513260|PROCEDURE|Surgical extraction of impacted lower third molars.|Surgical extraction of impacted mandibular third molars in the mesioangular position, according to the Tetsch and Wagner classification
41290385|NCT02897908|PROCEDURE|vibration controlled transient elastography (VCTE)|Once on the examination table, the subject will be instructed to place the right arm under their head and to cross their right ankle over the left ankle. The subject will then be asked to slightly bend to the left side to open the intercostal space. Subsequently, a handheld probe is placed in the intercostal space overlaying the right hepatic lobe. The velocity of returning shear waves, measured at a depth of 25-65 mm, is converted into a liver stiffness measurement (LSM). The LSM obtained from a given VCTE exam is the median value of at least 10 successful measurements. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.
41290386|NCT02477865|DRUG|PEX168(100µg)|100µg,Subcutaneous injection,once a week. continued for 52 weeks
41290387|NCT02477865|DRUG|PEX168(200µg)|200µg,Subcutaneous injection,once a week. continued for 52 weeks
41290388|NCT02477865|DRUG|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
40953461|NCT00515177|DRUG|eszopiclone|"One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use"
40953462|NCT04275934|BEHAVIORAL|Health Management; Blood Pressure|Pharmacists will work with the patient/study subject, referred to as the participant hereafter, and the participant's other health care providers to manage their blood pressure, making recommendations for medication and lifestyle adjustments as needed.
40953463|NCT00005865|DRUG|vinorelbine tartrate|
41290389|NCT00621023|DRUG|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
41134909|NCT04547660|OTHER|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
41134910|NCT05538572|DRUG|PRT3645|PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
41134911|NCT00263757|DEVICE|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
41134912|NCT00263757|OTHER|Usual Care|Subjects randomized to this arm received medical management as prescribed by their cardiologist.
41134913|NCT00655785|BIOLOGICAL|VEGFR1-1084, VEGFR2-169|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
41134914|NCT00655785|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
41134915|NCT04346914|BIOLOGICAL|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide|ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1\~3，q3w
41134916|NCT03884413|OTHER|questionnaires|Longitudinal observational study. Collection of health data using self-administered questionnaires online.
41134917|NCT00278135|DIETARY_SUPPLEMENT|DHA (nutritional supplement) or placebo|oral 900mg/day
40953464|NCT03005418|BIOLOGICAL|Human Acellular Vessel (HAV)|The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
40953465|NCT05720208|DEVICE|SCiP|Noninvasive Spinal Cord Neuromodulator
41290390|NCT03725046|OTHER|Optimized information transmission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
40953466|NCT05154396|DRUG|Neratinib|Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
40953467|NCT05189080|OTHER|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who no-showed for their well child visits.
40953468|NCT05189080|OTHER|Interviews|Interviews will be conducted with a subset of participants to identify the top one or two performing text messages.
41290391|NCT05989880|DEVICE|SafeLM as a supraglottic airway device with video capability|The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
41307846|NCT05078463|DRUG|1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)|1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
40953469|NCT05189080|OTHER|Survey|Alongside notification text messages regarding no-showed visits, participants will be invited to participate in a survey about their experience with the health system. This survey will assess reasons for missing the WCV and primary caregiver's perspective on the experience at the prior visit.
40953470|NCT05012033|OTHER|No intervention - prednisolone is taken as part if routine clinical care.|Prednisolone given orally prior to taking timed samples for levels
40953471|NCT05819281|DIETARY_SUPPLEMENT|Probiotic blend|(Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 1010 CFU/day).
40953472|NCT05819281|DIETARY_SUPPLEMENT|PLACEBO|Maltodextrin
40953473|NCT00000209|DRUG|Buprenorphine|
40953474|NCT00171743|DRUG|Cyclosporine microemulsion|
40953475|NCT00119431|DRUG|C1 inhibitor concentrate|
40953476|NCT03431766|DEVICE|placebo gel|On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
41307847|NCT05078463|DRUG|1 Finger Tip Unit (FTU) EMLA (15-minute application time)|1 Finger Tip Unit (FTU) EMLA applied for 15 minutes on the dorsal surface of the IV cannulated hand
40953477|NCT03431766|DEVICE|0.20% chlorhexidine gel|On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
40953478|NCT01967342|BEHAVIORAL|Pain Ed|A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
40953479|NCT01967342|BEHAVIORAL|CBT for Pain|A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
40953480|NCT01967342|OTHER|Usual Care|A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
40953481|NCT00341055|DRUG|Epoetin alfa|
40953482|NCT05446441|PROCEDURE|Endoscopic surgery;|Endoscopic thyroidectomy group is the papillary thyroid carcinoma patient group who underwent endoscopic thyroid surgery using a gasless, trans-axillary approach.
41134918|NCT06476769|OTHER|blow bottle technique|There were 20 patients in group A received blow bottle device and postural drainage for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
41307848|NCT05078463|DRUG|0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)|0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
40953483|NCT02387138|DRUG|S-1|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels)."
40953484|NCT02387138|DRUG|Irinotecan|Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
40953485|NCT02387138|DRUG|Oxaliplatin|Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
40953486|NCT02387138|OTHER|G-csf|G-csf : d8 to d13 systematically
40953487|NCT05952596|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acelluar Pertussis-Hepatitis B-Sabin Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
40953488|NCT05952596|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-poliomyelitis(inactived)-Haemophilus influenzae type b vaccine)
40953489|NCT05644769|OTHER|Determine the presence of Human sequence Ang-(1-12) on no medication|Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.
40953490|NCT05644769|DRUG|Human sequence Ang-(1-12) on Lisinopril 40mg every day|Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.
40953491|NCT01854242|OTHER|Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
40953492|NCT04150055|BEHAVIORAL|Mindfulness Coach|Mindfulness Coach is an mHealth delivered mindfulness therapy.
41290392|NCT05989880|DEVICE|SafeLM as a supraglottic airway device without video capability|The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
40761006|NCT06481072|OTHER|Digital patient education|This educative intervention includes both medical and psychological explanations, as well as basic strategies to manage pediatric FAPD. The medical information spans the topics of pain, functional abdominal pain and general advice in terms of child health, and the psychological information is based on cognitive-behavioural and pain management theoretical approaches. The intervention consists of six short, animated films with a total run-time of approximately 30 minutes. The films each cover one of the following topics; Why and how do we feel pain? What is functional abdominal pain? How to help: general advice, Thoughts, feelings and behaviour, Goals and strategies. The films are accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform that is recognised by the care provider as meeting current safety criteria and standards.
40761007|NCT06481072|OTHER|Digital patient education and iCBT|This includes the educative intervention and a fully digital, four session version of the Aim to Decrease Anxiety and Pain Treatment (ADAPT), a CBT treatment program for FAPD. The treatment focuses on pain-management through the following core elements; The Pain-Gate Theory, breathing and relaxation strategies, calming statements, activity pacing, problem solving and behavior activation. This intervention is also accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform.
40761008|NCT03325855|OTHER|None - Observational|None - Observational
40761009|NCT04104477|OTHER|Range of Motion Tasks|Participants will perform range of motion (thumb only) to evaluate fine and gross motor function.
40761010|NCT04104477|OTHER|Strength Tasks|Participants will perform strength (pinch and grip) tests to evaluate fine and gross motor function.
41307849|NCT05078463|DEVICE|Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of a size of 1cm x 1cm will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid on the dorsal surface of the IV cannulated hand for blood transfusion.
40761011|NCT02117076|DRUG|Gabapentin immediate release|up to 1200 mg per day
40761012|NCT02117076|DRUG|Gabapentin enacarbil extended release|up to 1200 mg per day
40761013|NCT01287208|DEVICE|Activity monitor|The activity monitor is an accelerometer that records steps, distance, calories, and sleep
40761014|NCT01287208|DEVICE|Activity device|Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
40761015|NCT03235986|DRUG|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)|Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
40761016|NCT03235986|DRUG|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)|Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)
40761017|NCT03235986|OTHER|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)|Nasal continuous positive airway pressure alone
40761018|NCT03235986|OTHER|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)|nasal continuous positive airway pressure alone
40953493|NCT04478981|OTHER|No intervention|This concerns a natural history study; no interventions will be used
40953494|NCT03656107|BEHAVIORAL|Cognitive Training|Lumosity© is a commercially available software, developed by a group of neuropsychologists, which has been used across several studies of brain training and disciplines. The brain training software targets multiple brain areas, is based online, and is relatively easy to use and administer. It has been designed to adapt to the individual's memory performance to personalise the training program to their needs. Brain exercises will be selected with the support of Lumosity© to target the following brain areas; attention, memory, visuospatial, verbal fluency, and language.
40953495|NCT00963222|DRUG|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
40953496|NCT00963222|DRUG|placebo|1 cap placebo/day for 3 month
40953497|NCT03175757|DIETARY_SUPPLEMENT|Turmeric and Black Cumin Seed|Turmeric and Black Cumin Seed formulation
40953498|NCT03175757|DIETARY_SUPPLEMENT|Placebo|Placebo
40953499|NCT00992277|PROCEDURE|Ablation and skin resurfacing|
40953500|NCT05253638|DIAGNOSTIC_TEST|Macrophage migration inhibitory factor|Assessment of disease activity: This assessment will be performed using the systemic lupus erythematosus disease activity index (SLEDAI). The SLEDAI is an index designed to assess disease activity in the preceding 10 days, with 24 weighted clinical and laboratory variables corresponding to 9 different organs/systems. The SLEDAI score ranges from 0 to 105 Renal activity will be evaluated with the renal-SLEDAI (rSLEDAI), which represents the sum of the renal items of the SLEDAI. The rSLEDAI includes the following items: proteinuria, pyuria, erythrocyturia, and urine casts; each one is scored with 0 meaning absence or 4 points meaning presence; therefore, the maximum rSLEDAI is 16
40953501|NCT05539131|DEVICE|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) suppresses excitability and regulates excitability of neurons by injecting a small amount of current through electrodes attached to the scalp.
40953502|NCT01275040|OTHER|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
41290393|NCT05989880|DEVICE|SafeLM as a conduit for intubation using an endotracheal tube with video capability|The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again.
41290394|NCT05989880|DEVICE|SafeLM as a conduit for intubation using a bougie with video capability|The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation.
41290395|NCT00398528|DRUG|Glatiramer acetate, (Copaxone®)|
41290396|NCT00398528|DRUG|IFN-β-1a, (Avonex®)|
41290397|NCT04908072|DEVICE|Orbis-FundamentalVR MSICS Simulator|Cataract surgery training device, using virtual reality software combined with existing gaming technology for simulated surgery
41290398|NCT02613572|DRUG|alpha lipoic acid|
41290399|NCT02613572|DRUG|Placebo|
41290400|NCT03084159|BEHAVIORAL|Education worksheet|Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
41290401|NCT03715257|DEVICE|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
40953503|NCT01275040|OTHER|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
40953504|NCT00929123|PROCEDURE|neural mobilization|manual therapy technique known to directly stress the median nerve
40953505|NCT00929123|PROCEDURE|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
40953506|NCT00929123|OTHER|healthy controls|People without carpal tunnel syndrome for comparison
40953507|NCT05615779|OTHER|Placebo Comparator: Randomized pectin diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin
40953508|NCT05615779|OTHER|Randomized B-fructan diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan
40953509|NCT05615779|OTHER|Personalized pectin diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline
40953510|NCT05615779|OTHER|Personalized B-fructan diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan based on personal host (biopsy) and microbe (stool) response at baseline
40953511|NCT02883686|BEHAVIORAL|Alma|Alma peer-mentoring
40953512|NCT04007926|BEHAVIORAL|Aerobic exercise programme|Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
40953513|NCT04007926|BEHAVIORAL|Resistance exercise programme|Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
40953514|NCT03344133|BEHAVIORAL|Exercise|4-week moderate intensity exercise programme
40953515|NCT04576429|PROCEDURE|venous puncture|"Venous punctures will be performed:~for patients of cohort A and B1:~* before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~* between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~* each 3 months up to 12 months.~for patients of cohort B2:~* before the radiotherapy;~* within the 6 weeks after the end of radiotherapy;~* at the 2 following evaluations (every 3 months)."
40953516|NCT04576429|PROCEDURE|tumoral biopsy|Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
40953517|NCT05143281|DRUG|Dexamethasone 0.4 MG [Dextenza]|Ophthalmic Intracanalicular Insert
40953518|NCT02597231|DIETARY_SUPPLEMENT|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
40953519|NCT02597231|OTHER|Placebo|Patients in this group will receive a matching placebo pill.
40953520|NCT04137029|DRUG|Formoterol|The participants will receive inhalation of formoterol 12 micrograms
41290402|NCT03715257|DEVICE|Tube changing catheter|"Tube changing catheter Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
40761019|NCT00916526|PROCEDURE|bronchial provocation test with mannitol|"Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.~1. Apply nose clip and subject should be directed to breathe through the mouth~2. Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)~3. The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration~4. At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip~5. At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)~6. Insert 5 mg capsule into inhalation device, and proceed as above~7. Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered."
40953521|NCT04137029|DRUG|Tiotropium Bromide|The participants will receive inhalation of tiotropium bromide 18 mkg once
40953522|NCT04137029|DIAGNOSTIC_TEST|metacholine test|The participants will receive inhalation of metacholine once
40953523|NCT01593085|BEHAVIORAL|interview with a doctor for evaluating suicide risk|"patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)~--------------------------------------------------------------------------------"
40953524|NCT03378661|DRUG|Benznidazole|Benznidazole tablet
40953525|NCT03378661|DRUG|E1224|E1224 capsules
40953526|NCT03378661|DRUG|E1224 Placebo|E1224 matched placebo capsules
40953527|NCT03378661|DRUG|Benznidazole Placebo|Benznidazole matched placebo tablets
41290403|NCT03303430|DIAGNOSTIC_TEST|MRI|Diffusion weighted imaging 24 hours after revascularisation
41454672|NCT04983862|DRUG|Illuminare-1|Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Dose levels of the agent will be administered starting at 0.25mg/kg, with increases in dose between cohorts of no more than 0.75 mg/kg until a maximum dose of 3.0mg/kg is reached, if needed. At the dose identified to have the acceptable NMR and no associated DLTs, Illuminare-1 will be studied in up to 20 additional patients at this dose to optimize the imaging protocol and provide additional safety data.
40761020|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers contingent on drug abstinence with values the same across all patients
40953528|NCT02910115|OTHER|Cold laparotomy sponges|Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline
41454673|NCT04983862|DEVICE|Karl Storz D-Light C photodynamic diagnostic (PDD)|The Storz PDD system will be used as the hardware system in this phase 1 study due to its proven safety profile.
40953529|NCT02910115|DRUG|Pitocin|Pitocin is administered intravenously according to the usual protocol.
40953530|NCT06129162|DEVICE|Conventional Syringe|Dental local anesthesia injection is given by conventional syringe by two injection methods inferior alveolar nerve block and buccal infiltration.
40953531|NCT06129162|DEVICE|STA Single Tooth Anesthesia® System.|Dental local anesthesia injection is given by STA device by two injection methods inferior alveolar nerve block and buccal infiltration.
41290404|NCT01373645|DEVICE|Yinyi stent|subjects with Yinyi stent implantation
41290405|NCT06281873|PROCEDURE|closure by PRF membrane|Oral fistulectomy was done with proper curettage. EMMA was performed. closure of the OAF by application of PRF membrane and covering it with an acrylic splint
41454674|NCT05121194|BEHAVIORAL|Cognitive Behaviour Therapy|Group-based cognitive behaviour therapy (CBT) is an evidence-based treatment that allows service providers to interact with high volumes of individuals who need mental health support. CBT is the most well-researched and well-recognized of all psychotherapies, and is often considered the gold-standard in psychotherapy treatment. While CBT has shown efficacy in the treatment of a range of mental and substance use disorders, it has also been shown to be useful in building resiliency, being used as a tool to better cope during stressful life situations even among individuals who do not have an existing mental illness. Furthermore, research suggests that gains achieved in mental health during CBT are maintained long after treatment completion.
40761021|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
40761022|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers earned independent of cocaine use
40761023|NCT06188247|DEVICE|NightOwl home-monitoring|The NightOwl™ system consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl™ software. The sensor is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl™ sensor acquires accelerometer data and reflectance-based photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
41290406|NCT04623931|OTHER|Quality-of-Life Assessment|Ancillary studies
41290407|NCT04623931|OTHER|Questionnaire Administration|Ancillary studies
41290408|NCT04623931|RADIATION|Radiation Therapy|Undergo radiation therapy
41454675|NCT01715922|DRUG|Fluconazole|Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
41454676|NCT01715922|DRUG|Flucytosine|Flucytosine (100 mg/kg/j) for 2 weeks
41454677|NCT01715922|PROCEDURE|lumbar punctures|lumbar punctures to control intracranial pressure
41454678|NCT05204420|PROCEDURE|Gastric wide local excision for bleeding mass|Laparoscopic partial gastrectomy for gastric submucosal mass
40761024|NCT02407938|OTHER|Rice meal|
40761025|NCT06564038|DRUG|AZD0486|AZD0486 will be administered as either SC injection (substudies 1 and 2) or IV infusion (substudy 3).
40761026|NCT06564038|DRUG|Acalabrutinib|Acalabrutinib tablet will be administered orally twice daily.
41290409|NCT04623931|DRUG|Temozolomide|Given PO
41290410|NCT02732158|OTHER|Nutrition Products|a sachet containing AN777and amino acids; a carotenoid capsule
41290411|NCT02842814|OTHER|Drug free|Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.
41290412|NCT02842814|DRUG|HCQ|Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d
40953532|NCT06129162|DEVICE|Star Pen anesthesia device.|Dental local anesthesia injection is given by Star Pen anesthesia device by two injection methods inferior alveolar nerve block and buccal infiltration.
40953533|NCT00969696|DRUG|Placebo|8Mg a day of a sugar pill
40953534|NCT00969696|DRUG|Galantamine|8mg of Galantamine
40953535|NCT03354078|PROCEDURE|interrupted sutures|The way of closing subcutaneous tissue either by interrupted
40953536|NCT03354078|PROCEDURE|continous sutures|The way of closure of subcutanous tissue is by continous sutures
40953537|NCT00951548|DIETARY_SUPPLEMENT|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
40953538|NCT00951548|DIETARY_SUPPLEMENT|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
40953539|NCT00910026|PROCEDURE|low tidal volume ventilation|6 ml/kg tidal volume ventilation
40761027|NCT06564038|DRUG|Prednisone|Prednisone will be administered either oral or IV infusion as per standard of care.
40953540|NCT00910026|PROCEDURE|high tidal volume ventilation|12 ml/kg tidal volume ventilation
40953541|NCT02325986|DRUG|fluorouracil|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
41454679|NCT05025033|DRUG|PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate|PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
40761028|NCT06564038|DRUG|Rituximab|Rituximab will be administered as IV infusion as per standard of care.
40953542|NCT02325986|DRUG|Cisplatin|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
41454680|NCT01456949|DEVICE|Medtronic Arctic Front® Cardiac CryoAblation System|Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
41454681|NCT02570854|BIOLOGICAL|CSJ137|Starting dose is 0.010 mg/kg and dose escalation will proceed with semi-log increase steps to a maximum dose level 10 mg/kg. Subjects receive the treatment via up to 30 minutes intravenous infusion.
41454682|NCT02570854|DRUG|Placebo|Subjects will be dosed with a matching placebo (vehicle control) via up to 30 minutes intravenous infusion.
41454683|NCT05882526|DEVICE|BURSTONE T-LOOP|Split mouth study one side using elastomeric power chain and other side using T loops
41454684|NCT03163160|PROCEDURE|Pelvic floor manual therapy group|Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.
40761029|NCT06564038|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as IV infusion as per standard of care.
40953543|NCT02325986|RADIATION|Intensity-modulated radiation therapy|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
40953544|NCT05681663|OTHER|Electroshock Wave therapy|Randomized- Controlled trial
40953545|NCT01475409|BIOLOGICAL|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
40953546|NCT00740571|DRUG|amitriptyline|strategy in which the patient starts with amitriptyline, during 8 weeks
40953547|NCT00740571|DRUG|pregabalin|Strategy in which patient starts with pregabalin
40953548|NCT03101787|PROCEDURE|Extracorporeal cardiopulmonary resuscitation (ECPR)|"In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.~The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.~Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.~Time from arrest to start of cannulation is \< 60 minutes."
40953549|NCT01846104|BIOLOGICAL|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
40953550|NCT01047670|DRUG|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
40953551|NCT00578383|DEVICE|Low Field Magnetic Stimulation Device|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
40953552|NCT02875912|BEHAVIORAL|Family Care Rituals|"Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.~Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.~Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.~Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver"
40761030|NCT06564038|DRUG|Vincristine|Vincristine will be administered as IV infusion as per standard of care.
40761031|NCT06564038|DRUG|Doxorubicin|Doxorubicin will be administered as IV infusion as per standard of care.
40761032|NCT05962138|BEHAVIORAL|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online. In addition participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.
40761033|NCT02624687|BEHAVIORAL|Intervention|Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..
40761034|NCT02624687|OTHER|No intervention|No contact control
41290413|NCT02842814|DRUG|GC+HCQ|Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
41290414|NCT03254667|BIOLOGICAL|Brodalumab|Brodalumab
41290415|NCT03254667|DRUG|Comparator Drug (non-biologic IL-17 inhibitors)|Comparator subjects treated with non-biologic IL-17 inhibitors
41290416|NCT03000452|DRUG|DARATUMUMAB|DARATUMUMAB
41290417|NCT03000452|DRUG|DURVALUMAB|DURVALUMAB
40761035|NCT05148247|BEHAVIORAL|The Perceive, Recall, Plan and Perform System of Intervention|The aim of the PRPP intervention is to enhance mastery in performance of needed or desired occupations, and extend traditional task training. Systematic instructions to support the clients' cognitive capacity to think about doing in different tasks and contexts are given by the OT, based on the results of PRPP Assessment stage 2. Further, the OT uses graded verbal, visual or physical prompts and cues directly during the participants task performance, progressing from content-free meta-prompts 'Stop' to alert the participant to process information required for the task, and for errorless learning. Then the OT prompt 'sense/attend, think and do', to more specific behavioural prompts selected by the therapist based on the components from the PRPP Assessment stage 2. At best the skills are generalized throughout all everyday activities, and the OTs' role as a cognitive mediator fades as the person internalize the strategies.
40761036|NCT05748834|DRUG|Tucatinib|Participants will receive tucatinib 300mg by mouth twice daily continuously (days 1-28) of each 28 day cycle.
40761037|NCT05748834|DRUG|Doxil|Participants will receive Doxil 40mg/m2 intravenously on day 1 of each 28 day cycle (with a maximum cumulative dose of 550mg/m2).
40761038|NCT00748527|DRUG|carboplatin|Given IV
40761039|NCT00748527|DRUG|decitabine|Given IV
40761040|NCT02231580|DRUG|BN82451B|BN82451B capsule
40761041|NCT02231580|DRUG|Placebo|Placebo capsule
40761042|NCT02088086|BEHAVIORAL|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
40761043|NCT02088086|BEHAVIORAL|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
40761044|NCT02088086|BEHAVIORAL|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
40761045|NCT03701074|DRUG|Ibuprofen and acetaminophen|Intravenous ibuprofen given concomitantly with oral acetaminophen
40761046|NCT03701074|DRUG|Ibuprofen and placebo|Intravenous ibuprofen given concomitantly with oral placebo
40761047|NCT06258512|OTHER|Intervention with a narrative approach.|"Health social workers will carry out a intervention with a narrative approach, through its training profile based on transversal skills, which will consist of 10 sessions carried out over five months. The interval between sessions will be of two weeks with a specific duration of fifty minutes per session. This type of intervention, with the objective of reorienting and redefining the demand or the initial problems that motivated the consultation, gives space to the patient\&#39;s subjective complaint, as well as to locate the understanding of the discomfort and the symbolic meaning of the symptoms.~That is, recognizing the physical symptoms while listening to stories of chaos to legitimize both the user and his symptoms, an encounter that allows return the user to its context without feeling rejected or judged by the health system."
41290418|NCT01873950|DRUG|Ranolazine|
41290419|NCT01873950|DRUG|Dofetilide|
41290420|NCT01873950|DRUG|Verapamil|
41290421|NCT01873950|DRUG|Quinidine sulfate|
41290422|NCT01873950|DRUG|Placebo|
41290423|NCT02224846|DRUG|Tadalafil|Administered orally
41290424|NCT02984878|DEVICE|Revanesse Ultra|Nasolabial Fold correction
41290425|NCT01478750|DIETARY_SUPPLEMENT|administration of fat (sunflower oil), emulsified|40 ml sunflower oil, in the presence of the emulsifier tween-80.
41290426|NCT01478750|PROCEDURE|Insertion of nasoduodenal tube|A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
41290427|NCT00370656|DRUG|Pregabalin|capsule, 150mg bd, 300mg bd
41290428|NCT00370656|DRUG|Duloxetine|Capsule, 60mg on, 60mg bd
41290429|NCT00370656|DRUG|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
41290430|NCT04635735|DRUG|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
41290431|NCT03331341|DRUG|Dacarbazine|Given IV
41290432|NCT03331341|DRUG|Doxorubicin Hydrochloride|Given IV
41290433|NCT03331341|OTHER|Laboratory Biomarker Analysis|Correlative studies
41290434|NCT03331341|BIOLOGICAL|Pembrolizumab|Given IV
41290435|NCT03331341|DRUG|Vinblastine|Given IV
41290436|NCT03763279|COMBINATION_PRODUCT|Triclosan-coated barbed suture|Use of Triclosan-coated Polydioxanone barbed suture
41290437|NCT03763279|COMBINATION_PRODUCT|Triclosan-coated monofilament suture|Use of Triclosan-coated Polydioxanone monofilament suture
41290438|NCT03763279|DEVICE|Monofilament suture|Use of Polydioxanone monofilament suture
41290439|NCT01845389|DEVICE|Epidural (B. Braun)|20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
41290440|NCT01845389|DEVICE|Spinal (Wiley Spinal Catheter)|The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
41290441|NCT00188994|DRUG|Insulin Cardioplegia|
41290442|NCT05099991|DEVICE|Single Foley Balloon|Foley Balloon will be placed through the cervix and inflated with 30mL of saline or water on the day prior to the procedure
41290443|NCT05099991|DEVICE|Dilapan-S|Dilapan S will be placed through the cervix on the day prior to the procedure
41290444|NCT05016128|DRUG|S-ketamine|S-ketamine is used for preventing postoperative hyperalgesia,thus reducing the patient's acute postoperative pain
41290445|NCT05016128|DRUG|saline|saline is used for control
41290446|NCT04127136|BEHAVIORAL|Multi-disciplinary obesity management therapy|In twenty weeks, trainings by the physician, dietitian, psychologist and physiotherapist are conducted about medical information about obesity, using the technology to aid weight loss, what, when, how and why to eat, nutrition groups, ration management, water consumption, self-awareness, stress management, obesity and the association between the psychological processes, warming up and mobilization, correct stance and posture, and adequate physical activity. In addition to group meetings, in monthly individual meetings, the progress of the patients are evaluated.
41134919|NCT06476769|OTHER|percussion|Group B: There were 20 patients in group B received postural drainage with percussion for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
41134920|NCT04855747|DRUG|REL-1017|REL-1017 tablet
41134921|NCT04855747|DRUG|Placebo|Placebo tablet
41134922|NCT04700202|OTHER|Observational|Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP
41134923|NCT03553225|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors
40953553|NCT04828239|DEVICE|laser acupuncture|400 mW, near-infrared, continuous wavelength, 810 nm. about 24J/cm2
40953554|NCT04828239|OTHER|acupuncture|Needle type: C\&G, gauge and size: 0.25x40mm
40953555|NCT04828239|DEVICE|Sham laser acupuncture|This laser pen is the same device with a red light was pasted on the acu-points in the same way, using the same protocol as for the active laser stimulation, but the laser apparatus was not switched on.
40953556|NCT05356078|DRUG|Antidepressant|"Delirium event reported in the World Health Organization global database in subjects aged over 65 years taking antidepressants, comparative analysis by antidepressant class"
40953557|NCT02272075|DEVICE|Mobile OCT M3 scope|
40953558|NCT05730283|DRUG|ORC-13661|High-dose intervention (30mg daily)
40953559|NCT05730283|DRUG|ORC-13661|Low-dose intervention (12mg daily)
40953560|NCT05730283|DRUG|Placebo|Placebo intervention
40953561|NCT03710005|PROCEDURE|Ascent|Dehydrated Cell and Protein Concentrate injection
40953562|NCT03710005|PROCEDURE|Standard|Standard corticosteroid injection
40953563|NCT01197664|DRUG|paricalcitol|Given PO
41290447|NCT01269567|PROCEDURE|Laying and management of the drain (strictly randomized arm with drainage)|At the end of intervention, the surgeon will position an aspiration drain in order to permit a postoperative pelvic drainage. The drain will be positioned forward sacrum, behind anastomosis. The drain will be leaved in place between 3 and 5 days. The criteria of drain ablation are the absence of haemorrhagic liquid and/or un daily debit \< 100ml. Nursing care will be daily with change of bottle for collect pelvic serosity, accounting of quantity of collected liquid and realization of a dried bandage through contact with penetration of the drain.
41290448|NCT01269567|PROCEDURE|No pelvic drainage|no aspiration drain at the end of intervention
40953564|NCT01197664|RADIATION|radiation therapy|Undergo radiotherapy
40953565|NCT01197664|OTHER|laboratory biomarker analysis|Correlative studies
41134924|NCT03553225|DIETARY_SUPPLEMENT|Concord Grape extract 1|1 g Concord Grape extract in 2 capsules
41290449|NCT04052958|DEVICE|IMT - inspiratory muscle training|respiratory strength or indurance training with respiratory therapy device
41290450|NCT00477451|DRUG|Inhaled placebo|Inhaled Staccato Alprazolam Placebo
41290451|NCT00477451|DRUG|Inhaled alprazolam 1 mg|Inhaled Staccato Alprazolam 1 mg
41290452|NCT00477451|DRUG|Inhaled alprazolam 2 mg|Inhaled Staccato Alprazolam 2 mg
41290453|NCT00477451|DRUG|IV doxapram|0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
41454685|NCT03163160|PROCEDURE|Pelvic floor electrolysis group|"An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.~One weekly session for four weeks."
40953566|NCT01197664|DRUG|fluorouracil|Given PO
40953567|NCT01570166|PROCEDURE|HR|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
41134925|NCT03553225|DIETARY_SUPPLEMENT|Concord Grape extract 2|500 mg Concord Grape extract in 2 capsules
41134926|NCT00399685|DRUG|Ortho Tri-Cyclen LO|Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
41134927|NCT00399685|DRUG|Ortho Cyclen|Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
41134928|NCT00399685|DRUG|Ortho Cyclen + Efavirenz|Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
41134929|NCT00399685|DRUG|Ortho Cyclen|Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
41290454|NCT03693027|DIETARY_SUPPLEMENT|PTx800 lozenges|PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.
41290455|NCT03693027|DIETARY_SUPPLEMENT|Placebo control|The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
41290456|NCT03341468|DEVICE|Urethral catheter immobilization|"Subjects assigned to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial.~Subjects will be asked to fill out a symptom-based questionnaire prior to leaving the office. This will conclude their participation in the study."
41290457|NCT04250805|DRUG|Lidocaine|Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
41290458|NCT04250805|DRUG|Ropivacaine|Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.
41290459|NCT03524872|DEVICE|Original CAD/CAM prosthetic abutment|Original (Sweden\&Martina) CAD/CAM abutments will be screwed to the implants at 32N/cm.
41454686|NCT02939573|DRUG|Colchicine|Randomized to colchicine 0.6 mg x 2/day
41454687|NCT02939573|DRUG|Dapsone|Randomized to dapsone 150 mg/day
40953568|NCT01570166|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
41134930|NCT01567852|DRUG|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
41134931|NCT01567852|DRUG|Methohexital|Methohexital (1.5mg/kg) will be given for induction
41134932|NCT04000399|BEHAVIORAL|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
40953569|NCT03938467|DRUG|Antiseptic Cleanser|Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation. The mechanical action of the Irrisept system removes bacteria and debris without harming underlying tissues. Irrisept has demonstrated broad spectrum bactericidal activity against antibiotic-resistant strains. Its contents are wrapped in two sequential sterilization wraps which repel water blood, and saline, making it effective against both air and water borne bacteria.
40953570|NCT01374841|DRUG|Cyclophosphamide|14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
40761048|NCT05524480|BEHAVIORAL|Salud en Mis Manos - Dissemination and Implementation Assistance|The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).
40953571|NCT01374841|OTHER|Hematopoietic Stem Cell Transplantation,|Hematopoietic Stem Cell Transplantation,
40953572|NCT02959983|DRUG|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
40953573|NCT02959983|DRUG|Placebo|Placebo matching eluxadoline oral tablets BID with food.
40953574|NCT05791955|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
40953575|NCT05791955|BEHAVIORAL|Acknowledgement of personal responsibility|"The message will contain a request for the participant to take personal responsibility for their health by either clicking on the link to make an appointment or replying noted to the text message."
40953576|NCT05791955|BEHAVIORAL|Planning prompt|The message will prompt people to either click on the link to make an appointment now or text back when they plan to close their health gap
40953577|NCT00785928|BIOLOGICAL|LY2127399|Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
40953578|NCT00785928|DRUG|Placebo|Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
40953579|NCT03580993|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound and Echocardiography used to derive parameters for prediction of successful SBT.
40953580|NCT02362581|OTHER|prophylaxis treatment, on demand treatment|
40953581|NCT00408460|DRUG|imatinib mesylate|Given PO
40953582|NCT00408460|DRUG|paclitaxel|Given IV
40953583|NCT00144690|DRUG|E2007 (perampanel)|
40953584|NCT00144690|DRUG|Placebo|
40953585|NCT05276531|DRUG|subcutaneous progesterone|clinical pregnancy rates
41134933|NCT00713596|DRUG|Fibrinogen|One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.
41134934|NCT00713596|PROCEDURE|Septorhinoplasty|Septorhinoplasty to correct nasal deviation.
40953586|NCT05276531|DRUG|vaginal progesterone|clinical pregnancy rates
40953587|NCT05212922|DRUG|YH001 + Toripalimab|YH001 + Toripalimab
40953588|NCT04423276|DRUG|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
40953589|NCT04423276|DRUG|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
40953590|NCT04330274|OTHER|Bipedal with open eyes|Standing bipedal with open eyes on force platform
40953591|NCT04330274|OTHER|Bipedal with closed eyes|Standing bipedal with closed eyes on force platform
40953592|NCT04330274|OTHER|Bipedal with open eyes and with platform|Standing bipedal with open eyes and with platform under heel of prosthetic foot on force platform
40953593|NCT04330274|OTHER|Bipedal with closed eyes and with platform|Standing bipedal with closed eyes and with platform under heel of prosthetic foot on force platform
40953594|NCT02643602|OTHER|Hydration with bicarbonate in addition to theophylline|0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
40953595|NCT02643602|OTHER|Hydration with sodium chloride in addition to theophylline|0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
40953596|NCT02705872|DRUG|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
40953597|NCT02705872|DRUG|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
40953598|NCT05977712|OTHER|Questionnaire|The questionnaire includes information on socio-demographics (age, sex, education, occupation, marital status), behavioural (smoking, alcohol consumption, social functioning), and health-related factors (morbidities, treatment, sleep disturbance, eye diseases, frailty, falls).
40953599|NCT05977712|OTHER|Clinical examination|This includes earing test, cognitive tests (mini-mental status examination, MemScreen), body mass index, waist circumference, blood pressure and blood tests (biomarkers of Alzheimer's disease, neurodegeneration, and other dementias).
40953600|NCT05977712|OTHER|Accelerometer port|Participants will be wearing an accelerometer for 9 days.
40953601|NCT05977712|OTHER|Eye examination|Eye fundus photo, OCT and OCT-A exams
40953602|NCT03221699|OTHER|Formula with ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
40953603|NCT03221699|OTHER|Formula without ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
40953604|NCT03055182|OTHER|Physical rehabilitation program|Patients participate during 4 weeks to a physical rehabilitation program.
40953605|NCT03216187|DRUG|Pregabalin|pregabalin 150 mg capsules
40953606|NCT03216187|DRUG|Placebos|capsules identical to pregabalin but without active drug
41134935|NCT00713596|PROCEDURE|Taping after septorhinoplasty.|Simple taping over the nose following nasal surgery.
40953607|NCT01152983|DEVICE|Rapid Ring|Rapid Ring is a ring-shaped device that encircles the distal phalanx of the middle finger and blocks the arterial blood to quickly and passively withdraw blood following a finger stick, and to reduce the pain of the lancet.
40953608|NCT03332290|BEHAVIORAL|sport practice|the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
40953609|NCT02058693|DRUG|mixed salts amphetamine|adjunctive to ADT
40953610|NCT02433561|PROCEDURE|Intraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound within the brachial plexus between C5 and C6
40953611|NCT02433561|PROCEDURE|Extraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound 2 mm away from the lateral part of the brachial plexus
40953612|NCT04067882|OTHER|Genetic signature|The RNA will be extracted from the tumor sample with a special kit and a q-PCR will be performed. In order to quantify the genetic expression, the comparative method called Cycle threshold or Crossing point will be used.
40953613|NCT05248737|DIETARY_SUPPLEMENT|DHA/EPA bioenhanced chicken|Chicken fed on a high DHA/EPA diet
40953614|NCT05248737|DIETARY_SUPPLEMENT|25(OH)D bioenhanced chicken|Chicken fed on a high 25(OH)D diet
40953615|NCT03352479|OTHER|Opioid Return|Calculate the percentage of prescribed to returned opioids
40953616|NCT03951714|BEHAVIORAL|Marketed experience application on adherence|To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence
41290460|NCT03524872|DEVICE|Compatible CAD/CAM abutment|Compatible (New Ancorvis) CAD/CAM abutments will be screwed to the implants at 32N/cm.
40953617|NCT03531931|DRUG|Apatinib/Capecitatine|Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2), now being developed by Jiangsu Hengrui Medicine (China). Even at a low concentration apatinib can still perform magnificent VEGFR2 inhibitory activities, meanwhile at little higher concentration it can inhibit PDGFR and kinases as well, such as c-Kit and c-Src .The action sites of apatinib are the intracellular ATP binding site of the protein tyrosine receptor. Pharmacodynamical study shows that apatinib is able to inhibit the tyrosine kinase activity of VEGFR, block signal conduction after the combination of VEGF, finally contribute to stopping new blood vessel formation in tumor tissue.
40953618|NCT00310648|BIOLOGICAL|Influenza vaccine|
40953619|NCT01268150|DRUG|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
40953620|NCT06404645|DEVICE|Near-infrared spectroscopy detection|Cranial CT confirm intracranial haematoma. Then the near-infrared spectroscopy device to collect date by red sensor probe in the corresponding position on the scalp and blue sensor probe on the opposite side of the hematoma. Collect data for 10 minutes.
41290461|NCT03524872|PROCEDURE|Local anesthesia|Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).
40953621|NCT03320317|OTHER|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
40953622|NCT03320317|OTHER|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
41134936|NCT00713596|PROCEDURE|Cast applied to the nose after nasal surgery|A molded cast will be placed on top of the nose following nasal surgery.
41290462|NCT03524872|DRUG|Painkillers|Patients will be prescribed ibuprofen 600 mg three times per day for five days
40953623|NCT03320317|OTHER|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
40953624|NCT03320317|OTHER|Learning session 4|Feedback report, Best practice symposium
40953625|NCT00001624|DRUG|Insulin|
40953626|NCT05772208|DRUG|Camrelizumab|camrelizumab 200mg q3w
40953627|NCT05772208|DRUG|Nimotuzumab|nimotuzumab 200mg qw
40953628|NCT05772208|DRUG|neoadjuvant chemotherapy and CCRT|the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
40953629|NCT02218255|DEVICE|Eeva™ results|
41290463|NCT03524872|DRUG|Mouthwashes|Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
41290464|NCT03524872|DEVICE|Implant placement|Dental implants (Sweden \& Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.
41290465|NCT00772395|DRUG|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
40953630|NCT05783375|OTHER|ADUNU program for delivery of RHD care services|The ADUNU program will be deployed by the Ugandan Ministry of Health and the involved District Health Offices to include echocardiography integrated into primary healthcare to screen for RHD and a registry-based care system to keep patients linked to care and prophylaxis.
40761049|NCT05524480|BEHAVIORAL|Salud en Mis Manos- Usual Implementation Practice|The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.
41134937|NCT00713596|OTHER|Saline|Approximately 0.5 cc to 2 cc normal saline will be applied after the operation before the nasal taping and casting.
41134938|NCT02662816|DEVICE|Proton magnetic resonance spectroscopy (1H MRS)|
41134939|NCT02662816|OTHER|a protein rich breakfast at home|
41134940|NCT02662816|OTHER|a protein rich lunch at the Clinical Investigation Center|
40761050|NCT04498767|RADIATION|Stereotactic body radiotherapy|Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size \& location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.
40761051|NCT04498767|RADIATION|Palliative RT|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).
40953631|NCT02925832|PROCEDURE|Deep Topical Fornix Nerve block anesthesia|DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.
40953632|NCT02925832|DRUG|Ropivacaine|0.75% ropivacaine soaked sponges
40953633|NCT02925832|DRUG|Bupivacaine|0.5% bupivacaine soaked sponges
41134941|NCT03110536|DIAGNOSTIC_TEST|Copenhagen Burnout Inventory|"A questionnaire based on Copenhagen Burnout Inventory will be completed by each participant to the study, at the beginning of the triage shift and after 2, 4 or 6 hours.~The questionnaire also contains clinical cases that require triage coding."
40953634|NCT02925832|DRUG|Proparacaine|For anaesthetising conjunctiva
41290466|NCT00772395|DRUG|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
41290467|NCT03356314|OTHER|MRI between 30-35 GA|MRI between 30-35 GA
41290468|NCT03356314|OTHER|Pediatric surgeon meeting|Pediatric surgeon meeting
41290469|NCT03356314|OTHER|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal
41290470|NCT03356314|OTHER|+/- prophylactic surgery|+/- prophylactic surgery
41290471|NCT00404768|DRUG|GSK221149A|6mg/h and 12 mg/h
41290472|NCT00404768|DRUG|Placebo|Matched Placebo to Drug
41290473|NCT00162877|DRUG|Rabeprazole vs. Esomeprazole|
41290474|NCT05126225|BEHAVIORAL|Stigma reduction|The intervention is modularized to have eight weekly sessions of 2-hour group discussions, led by a trained facilitator. The facilitator applies the principle of CBT and provides psychoeducation to promote the awareness and understanding of HIV stigma as well as training to help participants acquire alternative coping skills, such as relaxation techniques.
41290475|NCT04664660|OTHER|Retrospective analysis of obstetrics outcomes|Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
41290476|NCT02062177|DRUG|Propofol|70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
41290477|NCT02062177|DRUG|Midazolam|70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged \< 70, 0.03 mg/Kg if aged \> 70.
40761052|NCT00023595|PROCEDURE|CABG surgery plus MED|CABG plus standard medication management for Coronary Artery Disease
41134942|NCT03110536|OTHER|Triage scoring efficacy|The triage scores of the first 5 and the last 5 cases assessed by the investigated nurse will be compared with the triage codes of an expert evaluator (nurse involved in designing The National triage Protocol).
41290478|NCT00857246|DRUG|Cetuximab|
41290479|NCT00857246|DRUG|Irinotecan|
40761053|NCT00023595|DRUG|Active Medication Alone|Standard medication for coronary artery disease and heart failure management.
40953635|NCT04276337|DIAGNOSTIC_TEST|LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)|LiquidSCAN : detection of circulating DNA CancerSCAN : detection of somatic mutation using tumor tissue
40953636|NCT06557980|OTHER|toothpaste|group of patients with hypersensitive areas will use the calcium silicate toothpaste twice per day (morning and bedtime) the toothpaste will be applied uniformly using medium toothbrush to the hypersensitive surfaces for 30seconds. After that, the patient will rinse their mouth with plain water. the other group of patients will use the sodium fluoride toothpaste twice per day (morning and bedtime). The toothpaste will be applied uniformly using a medium toothbrush to the hypersensitive areas for 30 seconds after that the patients will rinse their mouth with plain water
41290480|NCT00857246|DRUG|Cisplatin|
40953637|NCT01515878|DEVICE|Hemocontrol|Blood Volume Tracking system using biofeedback
41290481|NCT00857246|PROCEDURE|Surgery|
41290482|NCT00857246|DRUG|5-FU|
41290483|NCT00857246|RADIATION|Radiation|
41290484|NCT03356847|DEVICE|Fitting of ocular implant|Removal of natural lens and replacement with a SISA monofocal intraocular implant
41134943|NCT00140491|DEVICE|Vision Restoration Therapy (NOVAVISION)|
41290485|NCT03320733|DIAGNOSTIC_TEST|Dual energy CT scan with subtraction imaging|"The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.~Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT."
41290486|NCT02163330|DRUG|Acetazolamide|
41290487|NCT02163330|DRUG|sugar pill|
41290488|NCT01927562|DEVICE|Fractyl Duodenal Remodeling System|
41290489|NCT01915875|OTHER|sophrology sessions at home|The sophrology is a dynamic method of physical and psychical relaxation
41290490|NCT03690414|DRUG|Experimental BHVI2|Experimental BHVI2 eye drops
41290491|NCT03690414|DRUG|Atropine sulfate 0.02% eye drops|Atropine eye drops
41290492|NCT03690414|COMBINATION_PRODUCT|Combination eye drops|Combination eye drops with experimental BHVI2 plus 0.02% atropine
41290493|NCT05021614|DEVICE|Valveclip® Transcatheter mitral valve repair|Transcatheter mitral valve repair system
41290494|NCT04795180|DRUG|Irrigations trough the efferent limb of loop ileostomy|Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
41454688|NCT02939573|DRUG|Azathioprine|Randomized to azathioprine 2 mg/kg/day
41454689|NCT01962298|DRUG|sugammadex 2mg/kg|
41454690|NCT01962298|DRUG|neostigmine|
41290495|NCT01154725|BEHAVIORAL|Patient education and rehabilitation|Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.
40761054|NCT00023595|PROCEDURE|CABG plus MED and SVR|H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
40761055|NCT05598515|BEHAVIORAL|Time-Restricted Feeding|Participants will be asked to eat for only 8 hours out of 24 hours in a day.
40761056|NCT03070834|DEVICE|Cook 'Celect' retrievable inferior vena cava filter|Cook 'Celect' device will be deployed If randomized to rIVCF insertion
40761057|NCT00298155|DRUG|goserelin with dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
40761058|NCT00298155|DRUG|goserelin with bicalutamide and dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
40761059|NCT00298155|DRUG|goserelin with bicalutamide and dutasteride and ketoconazole|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
41134944|NCT02423005|DEVICE|Neurotech Vital Compact|Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
40761060|NCT00273780|BEHAVIORAL|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
40761061|NCT00273780|DEVICE|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
40953638|NCT03071146|DEVICE|Bard® LifeStent® 5F Vascular Stent System|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
40953639|NCT02505763|PROCEDURE|Strategy with thoracic ultrasound|This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
40953640|NCT05396846|BEHAVIORAL|Eating Plan 1|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
40953641|NCT05396846|BEHAVIORAL|Eating Plan 2|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
40953642|NCT05396846|BEHAVIORAL|Eating Plan 3|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
40953643|NCT01193530|OTHER|Bright Light Therapy|30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.
41454691|NCT01962298|DRUG|sugammadex 4mg/kg|
40761062|NCT01715870|BEHAVIORAL|Life style and food habits questionnaire|
40761063|NCT01435642|OTHER|No treatment given|Subject will fill out a questionnaire when entering the non-interventional study
41134945|NCT02423005|DEVICE|itouch Sure Pelvic Floor Exerciser|Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
41134946|NCT03949257|DEVICE|colonic transendoscopic enteral tubing|Colonic transendoscopic enteral tubing (TET) is a novel, safe, convenient, and reliable way for fecal microbiota transplantation (FMT) and the whole-colon enema treatment.
41134947|NCT05716438|RADIATION|Forearm anteroposterior and lateral plain radiograph|2 view plain film of forearm after valving a short arm cast.
41290496|NCT01154725|BEHAVIORAL|habitual patient education|habitual patient education
41290497|NCT00417612|DRUG|Paricalcitol|Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
41290498|NCT00417612|OTHER|Placebo|Placebo sugar pill
41290499|NCT00090649|DRUG|DVS-233 SR|
41290500|NCT00554294|BEHAVIORAL|environmental and behavioral change|In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
40761064|NCT06478589|BEHAVIORAL|Adapted Patient Priorities Care (PPC) approach|Step 1 is a PPC facilitation encounter, at which the facilitator will help the participant identify patient priorities, such as clarifying values (what matters most); setting meaningful, specific, and realistic outcome goals; describing healthcare preferences (care that is helpful and/or burdensome) and tradeoffs; and discussing priorities with clinicians. The participant's healthcare priorities are then documented and transmitted to clinicians, in order to facilitate changes in the patient's care plan to align it with his/her priorities. In step 2, the clinician considers patient's priorities and potential healthcare options (options might include starting or stopping treatments; adding or removing medications; ordering more or fewer tests; recommending or removing self-management tasks). In step 3, the clinician discusses care options with the participant, using strategies for aligning care with patient priorities.
40761065|NCT06478589|OTHER|Usual Care|Usual care for breast cancer survivorship includes regular visits with the oncology provider and yearly mammograms for surveillance.
40761066|NCT06572020|OTHER|education|simulation-based training on blood pressure and ECG measurement
41290501|NCT03476850|PROCEDURE|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
41454692|NCT01962298|DRUG|placebo|
41454693|NCT01962298|DRUG|Single rocuronium dose|
41454694|NCT01962298|DRUG|Repeated rocuronium dose|
41454695|NCT01962298|DRUG|Continuous rocuronium infusion|
41454696|NCT01090505|DRUG|Drug: S-1 and oxaliplatin|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
41290502|NCT03476850|PROCEDURE|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
40953644|NCT01193530|OTHER|Dim Red Light Therapy|From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
40953645|NCT01193530|BEHAVIORAL|Questionnaires|Weekly
40953646|NCT01193530|BEHAVIORAL|Study Diaries|Daily logs
41290503|NCT01070615|DRUG|Prucalopride|
41290504|NCT03063385|BEHAVIORAL|Parental Communication intervention|In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.
41290505|NCT03063385|BEHAVIORAL|Health promotion control condition|"In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents."
41290506|NCT01103050|DRUG|QAV680 + Cetirizine Placebo|
40953647|NCT01193530|DEVICE|Red Light Litebook|Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.
40953648|NCT01193530|DEVICE|Bright Light Litebook|Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
41290507|NCT01103050|DRUG|QAV680 + Cetirizine|
41290508|NCT01103050|DRUG|Cetirizine + QAV680 Placebo|
40953649|NCT01049568|BEHAVIORAL|Cell Phone Intervention|"Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
40953650|NCT04184544|OTHER|Improving of quality of care at health facility and outreach level|Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes
41290509|NCT01103050|DRUG|QAV680 Placebo + Cetirizine Placebo|
41307850|NCT06553950|DRUG|Botox injection|"Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.~A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle."
41307851|NCT06553950|DRUG|Mandibular stabilization splint|Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
40761067|NCT06569628|COMBINATION_PRODUCT|Envita Stories Methodology in Long-term care Centres for old adults|Collaborative intervention program in long-term care Centres for old adults between professionals, old adults, families and volunteers that aims to foster person-centered care and promote meaningful relationships through the digitization of life stories and life project methodologies in a timeline.
40761068|NCT06569628|BEHAVIORAL|Contact Methodology in Long-term Care Centres for old adults|Professionals know and use Envita Stories Methodology but do not apply it directly with these people.
40761069|NCT01149460|DRUG|Valacyclovir|Test 1000 mg Tablet
40761070|NCT01149460|DRUG|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
40953651|NCT05945628|BEHAVIORAL|Different cognitive and memory demands during the memory experiment|Study conditions will involve attempting to memorize visual scenes, attempting to memorize arrays of visual objects, viewing in a self-directed manner, viewing in a passive other-directed manner, and making memory judgments about whether stimuli are studied versus novel.
40761071|NCT01604798|OTHER|Serum proteomics|magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
40761072|NCT02593214|DEVICE|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
40953652|NCT05945628|OTHER|Different electrical stimulation parameters during cognitive and memory demands|Study conditions will involve different parameters for electrical stimulation delivered through iEEG electrodes, including the presence of stimulation (no stimulation versus stimulation) and the location of stimulation (hippocampus versus amygdala).
40953653|NCT01782547|BEHAVIORAL|Telehealth Intervention|Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;
40953654|NCT01782547|OTHER|Usual Care|Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
40953655|NCT00028782|DRUG|etanidazole|Given IV
40953656|NCT00028782|PROCEDURE|therapeutic conventional surgery|Undergo surgery
40953657|NCT00028782|OTHER|laboratory biomarker analysis|Correlative studies
40953658|NCT01971840|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
40953659|NCT06323187|DIAGNOSTIC_TEST|Cervical Sampling|Each participant will provide a sample of fluid or mucus collected from the uterine endocervix.
40953660|NCT03534362|DEVICE|Nasopore|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract
40953661|NCT03534362|DEVICE|Propel|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
40953662|NCT02110238|DEVICE|Supartz|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
40953663|NCT02110238|DEVICE|Euflexxa|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
40953664|NCT02083081|BEHAVIORAL|Community level intervention|Community intervention plus individual counseling
40953665|NCT01088750|DRUG|cyclophosphamide|
40953666|NCT01088750|DRUG|prednisolone|
40953667|NCT01088750|DRUG|vinblastine sulfate|
40953668|NCT01088750|OTHER|watchful waiting|
40953669|NCT01088750|PROCEDURE|therapeutic conventional surgery|
40953670|NCT04230395|BEHAVIORAL|CAP|4-session combination Motivational Enhancement Therapy and Cognitive Behavioral Therapy alcohol reduction intervention. The intervention will also include 3 booster sessions.
40953671|NCT04230395|OTHER|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
40953672|NCT03950479|DIAGNOSTIC_TEST|3D and 4D Transperineal Ultrasound|The evaluation of Pelvic Floor Muscles with 3D and 4D transperineal ultrasound using A Voluson E6 system (GE Healthcare, Zipf, Austria) with RAB 8-4-MHz volume transducer for all acquisitions. Measurements will be performed in axial planes. The levator hiatus area (LHA), the antero-posterior (AP) diameter and the left-right (LR) transverse diameter will be analyzed at rest, during pelvic floor contraction and on maximal Valsalva maneuver.
40953673|NCT04575623|DIAGNOSTIC_TEST|Duration Pattern test (DPT) /Dichotic Digits Test (DDT) /Auditory fusion test-revised (ART-R)/|"Central auditory function evaluation including:~* Duration Pattern test (DPT) designed to test temporal ordering abilities.~* Dichotic Digits Test (DDT) it assesses binaural integration skills.~* Auditory fusion test-revised (ART-R) to measure temporal resolution.~* speech in test to assess central auditory function."
40953674|NCT04575623|DEVICE|Dual band pure tone audiometer (Orbiter 992). -Impedance audiometer (AT 235h). -Sound treated booth (industrial acoustic company IAC model 1602-A-t) -Panasonic stereo CD player SA-AK 240.|"Cognitive function evaluation including:~-Recording of event-related potentials (ERPs) by using odd ball paradigm auditoryP300 wave in evaluating cerebral information processing.~Equipment:~* Dual band pure tone audiometer (Orbiter 992).~* Impedance audiometer (AT 235h).~* Sound treated booth (industrial acoustic company IAC model 1602-A-t)~* Panasonic stereo CD player SA-AK 240."
40953675|NCT05565131|DEVICE|Guided placement with PYTHEAS® ODYSSEE|Pre-surgery, the surgeon generates a 3D model of the spine from a preoperative CT scan During the perforation and insertion of the implant, the system indicates the orientation of the pedicle path and the current orientation of the instruments (perforation tool) with the orientation sensor (inertial sensor). The system also displays the position of the entry point of the planned pedicle path on the views.
40953676|NCT05007210|OTHER|Prenatal massage therapy|Pregnant women in the intervention group had a whole body prenatal massage therapy every week between 30th and 34th gestational weeks (once a week, 5-weeks in total and 60-minutes each).Session content for the prenatal massage therapy group was created by the researcher who was 640-hours trained massaging midwife.It included 12 different massage techniques (Osborne 2015, Osborne 2021).Also, the session, which included deep tissue and Sweden massage methods, had been applied.Each session began with the pregnant woman in a side-lying position with standart special pillows (30-minutes for left, 30-minutes for right).EFM, BPP, vital signs, FHR evaluation were carried out for all participants per visiting the hospital for the study.BPP before and after prenatal massage therapy was evaluated by an obstetrician.A phone number was set for the study, and this phone number was used by the massaging midwife.The service has been provided for pregnant women to reach her whenever they want.
41290510|NCT05132738|DRUG|Ripretinib treatment|"Ripretinib: 4-week (28-day) cycle of oral administration of 150 mg q.d. For patients who completed up to 6 consecutive treatment cycles in a the clinical investigator decided whether to perform the operation or not, the specific time and other matters.~The above medications can be adjusted according to the adverse reactions of subjects according to the protocol at the investigator's discretion. Subjects will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or discontinuation of treatment as judged by the investigator, and the investigator will decide whether to perform early surgery or subsequent treatment regimen."
41290511|NCT02641899|DRUG|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.
40953677|NCT04609371|BEHAVIORAL|self-care tools|self-care tools only
40953678|NCT04609371|BEHAVIORAL|lay telephone coaching|coaching
40953679|NCT05393011|DRUG|human chorionic gonadotropin|10000 IU when at least three follicles become more than 16 mm
40953680|NCT06391320|OTHER|other|Observational studies do not involve intervention
40953681|NCT02864602|DRUG|IV dexamethasone|An infusion of IV dexamethasone
40953682|NCT05824988|OTHER|Drug exposure|Drug concentrations will be measured after one-month antimycobacterial treatment. Area under drug concentration-time curve (AUC) and maximum concentration (Cmax) will be calculated.
40953683|NCT00547235|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40953684|NCT00547235|PROCEDURE|allogeneic bone marrow transplantation|
40953685|NCT00547235|RADIATION|total-body irradiation|
40953686|NCT00875979|DRUG|Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
40953687|NCT00875979|DRUG|Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
40953688|NCT00875979|DRUG|Pertuzumab 420 mg|Pertuzumab was provided as a single-use formulation.
40953689|NCT00499239|DRUG|GS-9219|"GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.~GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days."
40953690|NCT05449548|DRUG|Lenalidomide 10 mg|All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
40953691|NCT02284269|DRUG|SGLT2 Inhibitors|Ipragliflozin (Suglat®), Dapaglilozin (Forxiga®), Tofogliflozin (Deberza® / Apleway®), Luseogliflozin (Lusefi®), Canagliflozin (Canaglu®), Empagliflozin (Jardiance®)
40953692|NCT04001933|OTHER|CPOP Intervention|The intervention consists of two 15-minute interactive modules (maternal and infant OH), integrated into 2 group prenatal care sessions. Led by trained prenatal care providers (facilitators), the maternal module includes discussion of common OH problems during pregnancy, importance of OH, importance and safety of OH care during pregnancy, hands-on skills-building activities of learning and practicing proper tooth brushing and self-assessment of gum health, and presentation of illustrated flossing and OH promotion guides. The infant module includes discussion of infant oral hygiene, avoiding saliva sharing, proper nutrition, and importance of a dental visit by the first birthday. Activities in both modules utilize separate tool kits including tooth brushes, fluoride toothpaste, and other supplies.
40953693|NCT04367233|OTHER|General anesthesia|General anesthesia with fentanyl, propofol and remifentanil.
40953694|NCT04367233|OTHER|Transverse abdominal block|Transverse abdominal block with ropivacaine 0,25% 0,2 ml/kg at the end of general anesthesia with fentanyl, propofol and remifentanil
41290512|NCT02641899|DRUG|Acetaminophen|Oral acetaminophen 1000 mg on Day 1 and Day 27
40953695|NCT04367233|OTHER|Quadratus lumborum block|At the end of general anesthesia with fentanyl, propofol and remifentanil, patients will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg
40953696|NCT06419738|BEHAVIORAL|Cognitive behavioral treatment (CBT)|Cognitive behavioral treatment includes education about the disorder, proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients are also consulted on changing habits, adjusting behavior, exercising. Patients are instructed to adjust their behavior: quit harmful habits to limit pain in daily functional activities, maintain scientific sleep, maintain good head, neck and shoulder activities, soft diet and avoid hard foods, do exercises twice a day: open mouth wide combined with cool compresses and warm compresses.
41290513|NCT02641899|DRUG|Atorvastatin|Oral atorvastatin 40 mg on Day 2 and Day 28
41290514|NCT02641899|DRUG|Lisinopril|Oral lisinopril 20 mg on Day 2 and Day 28
41290515|NCT02641899|DRUG|Warfarin|Oral warfarin 25 mg on Day 2 and Day 28
41290516|NCT02641899|DRUG|Digoxin|Oral digoxin 0.5 mg on Day 2 and Day 28
41307852|NCT06553950|DRUG|Muscle relaxant|Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
40953697|NCT06419738|RADIATION|Low level laser therapy combined with CBT (LLLT+CBT)|LLLT may facilitate the release of endogenous opioids, tissue repairment and cellular respiration, increase vasodilatation and pain threshold, and decrease inflammation. Diode low-energy laser machine (Sirolaser blue, Dentsply) are set the default mode according to the correct parameters before use: wavelength 660nm, energy level 2.5 J/cm2, power source 100mW. The projection head is placed perpendicular to the muscle being projected. The laser light is shined on the pain point at the beginning of the treatment, then it will shine on muscle points in turn: temporal muscle (anterior, middle, posterior), masseter muscle (upper, middle, lower), 5 points around the temporomandibular joint area (superior, anterior, lateral, posterior, posterior subcondylar). Each masticatory muscle area is treated for 20 seconds, 3 sessions /week (different days), 10 sessions total. In addition, patients are still instructed CBT as group 1.
40953698|NCT06419738|DEVICE|Occlusal Splint combined with CBT (OS+CBT)|Maxillary occlusal splints are made of hard acrylic after taking impressions of the upper dental arches, recording of centric relation (Okeson). Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night at least 8 hours/day for a period of 8 weeks.In addition, patients are still instructed CBT as group 1.
41290517|NCT04385030|DEVICE|TRANSCRANIAL DIRECT CURRENT STIMULATION AND MIRROR THERAPY|The study will consist of 12 sessions, carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
40953699|NCT06049953|DRUG|Antipsychotics|Antipsychotic medications are widely prescribed for severe mental illness such as affective and non-affective psychosis, mood stabilization, and augmentation of unipolar depression.
40953700|NCT06049953|DRUG|Non-antipsychotic medication|Psychotropic medications are typically prescribed to manage symptoms of anxiety, depression, psychological distress, and/or insomnia.
40953701|NCT06049953|OTHER|No Medication|Non-psychotropic medications
40953702|NCT02657538|OTHER|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
41134948|NCT02265107|OTHER|exercise training|The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
41134949|NCT05235685|OTHER|Medical air|Exercise under medical air, both arms exposed.
41134950|NCT05235685|OTHER|Hyperoxia|Exercise under hyperoxia, only experimental arm exposed.
41134951|NCT02446106|DIETARY_SUPPLEMENT|Soup with MSG|0.5% MSG + 0.48% salt
41134952|NCT02446106|DIETARY_SUPPLEMENT|Control soup no MSG|Negative control match for sodium (no MSG + 0.635% salt)
41134953|NCT03224806|OTHER|Wholegrain bread|156.8g wholegrain bread
40761073|NCT02826785|BEHAVIORAL|Cognitive strategy training|The intervention teaches strategies in a way that promotes generalization and enhances daily function . It includes four core elements known to enhance learning transfer: (1) self-generation of broadly applicable strategies, (2) practice across multiple contexts and activities, (3) emphasis on metacognition, and (4) use of meaningful everyday activities.
40761074|NCT06571227|PROCEDURE|Anterior cruciate ligament reconstruction|Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
40761075|NCT05274477|DRUG|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
40761076|NCT05274477|DRUG|Placebo|no active component
40761077|NCT01251211|DRUG|botulinum toxin type A|BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
40761078|NCT06211517|OTHER|Semi-structured interviews with visual mediations|Semi-structured interviews with visual mediations / An hour-long interview
40761079|NCT06211517|OTHER|Semi-structured interviews|Semi-structured interviews
40953703|NCT02657538|OTHER|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
40953704|NCT02657538|DEVICE|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
40953705|NCT02657538|OTHER|Visual examination and bitewing (BW) radiography|established diagnostic methods
40953706|NCT06289569|OTHER|Home telerehabilitation therapy|Occupational therapist prescribed hand/arm exercises will be assigned to patients. Records of each subject's motor tasks, number of repetition and level of performance will be kept. Standard of care home therapy will be performed Monday-Friday for approximately 4 weeks, followed by 4 weeks of application-driven home teletherapy. It is expected that approximately 20 treatments will be finished in 4weeks, however the amount of therapy completed will be recorded to accommodate patients' schedules. Treatment times can be broken up into multiple treatment periods to accommodate patient and caregiver preferences.
40953707|NCT01460017|PROCEDURE|Deep Sclerectomy|Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.
40953708|NCT01460017|PROCEDURE|Combined Trab|Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
41134954|NCT03224806|OTHER|White bread|122.6g white bread
41134955|NCT03224806|OTHER|15% fiber-rich bread|139.2g bread made with 15% added wheat bran
41134956|NCT03224806|OTHER|30% fiber-rich bread|166.5g bread made with 30% added wheat bran
41290518|NCT02355379|DRUG|LV5FU2 or capectitabine|
41290519|NCT02355379|DRUG|FOLFOX4 or XELOX|
41290520|NCT02355379|OTHER|Observation|
41290521|NCT02355379|DRUG|LV5FU2 or capecitabine|
40953709|NCT03363997|DRUG|Estriol 0.125 mg/day|Application of one vaginal ring
40953710|NCT03363997|DRUG|Estriol 0.250 mg/day|Application of one vaginal ring
40953711|NCT03363997|DRUG|Estriol 0.500 mg/day|Application of one vaginal ring
40953712|NCT04687995|PROCEDURE|Endoscopic myringoplasty|Endoscopic myringoplasty by using two different grafts one each time
40953713|NCT00748735|PROCEDURE|Implantation of a cardiac resynchronization therapy device|
41290522|NCT03515980|DRUG|BMS-986231|Intravenous (IV) administration
41290523|NCT04910412|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be use for the intervention. Anodal and sham tDCS will be applied in 2 mA through a pair of saline-soaked surface sponge electrode 35 cm square for 20 minute over the primary motor area for modulating the cortical excitability before apply the rehabilitation training
41290524|NCT00519532|DRUG|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"
41290525|NCT06511609|PROCEDURE|double-flap technique（DFT）; double-tract reconstruction(DTR),|DFT (experiment group). Patients receive double flap technique after laparoscopic proximal gastrectomy. DTR (control group). Patients receive double-tract reconstruction after laparoscopic proximal gastrectomy.
41290526|NCT04952389|DEVICE|Acupuncture Therapy|Consists of two treatments per week for five weeks
40761080|NCT00745667|PROCEDURE|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
40761081|NCT00745667|PROCEDURE|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
40761082|NCT05532163|DRUG|Natalizumab|Administered as specified in the treatment arm
40761083|NCT01299961|DRUG|abatacept|125 mg once a week up to 12 months.
40953714|NCT00748735|PROCEDURE|Echocardiography (myocardial deformation imaging)|
40953715|NCT02555774|BEHAVIORAL|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
40953716|NCT02555774|BEHAVIORAL|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
40953717|NCT01747226|OTHER|Fluoride rinse|rinse with 15 ml for 1 minute
41290527|NCT04952389|DRUG|Budesonide|Twice daily nasal rinses with steroid medication (budesonide)
41290528|NCT04952389|OTHER|Olfactory Training|involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)
41290529|NCT03952923|BIOLOGICAL|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
41290530|NCT05087823|DIETARY_SUPPLEMENT|Lipid Challenge|For the lipid challenge, participants consume 100 grams of a long chain triglyceride emulsion in the form of liquid drink, which is the commercially available brand called Calogen, from Nutricia, Inc.
41290531|NCT05087823|DIETARY_SUPPLEMENT|Glucose Challenge|For the glucose challenge, participants consume 75 grams of glucose in 200 milliliters of water, which is the World Health Organization (WHO) recommended drink for the Oral Glucose Tolerance Test.
41290532|NCT05087823|DIETARY_SUPPLEMENT|Mixed Meal Challenge|For the mixed-meal challenge, participants consume 237 milliliters of the Ensure Enlive nutrition drink , which contains 11 grams of fat, 22 grams of sugar and 20 grams of protein.
40953718|NCT01747226|OTHER|Halita|rinsing with 15 ml for 1 minute
40953719|NCT01747226|OTHER|Meridol Halitosis|rinsing with 15 ml for 1 minute
40953720|NCT01747226|OTHER|Water|rinsing with 15ml for 1 minute
40953721|NCT05146193|OTHER|Nude back photo|Nude back photo at baseline and at follow-ups for each patient and visual severity and curve type classifications
40953722|NCT03820180|DRUG|Test Product|2 inhalations of Test and Reference product in each study period
40953723|NCT03820180|DRUG|Reference Product|2 inhalations of Test and Reference product in each study period
40953724|NCT04221178|OTHER|Cessation of continuous matinenace therapy|Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation
40953725|NCT00737243|DRUG|Paclitaxel|175 mg/m2, 1-3 hour IV infusion Day 1
40953726|NCT00737243|DRUG|Carboplatin|AUC 6.0 IV Day 1
40953727|NCT00737243|DRUG|Bevacizumab|15 mg/kg IV infusion Day 1
40953728|NCT00737243|DRUG|Erlotinib|150 mg PO
40953729|NCT00737243|OTHER|Treatment determined by physician|Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
40953730|NCT04748146|OTHER|Brain stimulation|Theta-burst stimulation will be applied to selected regions of distributed networks to test whether distal stimulation can modulate hippocampus-mediated episodic recollection.
40953731|NCT03523130|DIAGNOSTIC_TEST|Imaging|Macrophage-specific inflammation
40953732|NCT05862831|BIOLOGICAL|PM1003 Injection|Subjects will receive PM1003 by intravenous administration.
40953733|NCT02735408|OTHER|Kinesiotape (KT)|
40953734|NCT01634061|DRUG|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
40953735|NCT01634061|DRUG|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
40953736|NCT01634061|DRUG|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
40953737|NCT01634061|DRUG|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
40953738|NCT03461978|DEVICE|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
40953739|NCT05948787|BEHAVIORAL|Psychosocial intervention|A structured sessions for families that promotes improving communication, bonding, and improved parenting techniques in managing stress within the family setting.
40953740|NCT01439633|DEVICE|MGH OFDI marking|Imaging of esophagus with OFDI system
40953741|NCT04094129|DIETARY_SUPPLEMENT|Wismemo|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.
41134957|NCT03892915|COMBINATION_PRODUCT|evidence-based depression treatment|We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9\>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
41134958|NCT00947895|DRUG|Methylprednisolone|IV 1000 mg daily for 3 days
41134959|NCT00947895|DRUG|ACTH|IM ACTH 80 mg/day for 5 days.
41290533|NCT04272125|BIOLOGICAL|CD123 CAR-T cells|A single infusion of CD123-CAR-T cells will be administered intravenously
41290534|NCT00639067|DEVICE|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
41290535|NCT03691558|OTHER|Ketogenic diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). Macronutrients percentage is 68% fat, 26% protein and 6% carbohydrate Paoli et al. 2013). Very low carbohydrate foods that simulate carbohydrates taste food like croissants, bread and cracked slices made by Le Gamberi Foods (Forlì, Italy), are used for a better compliance to the dietary intervention
40761084|NCT03097978|DEVICE|Commercial system|Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
40953742|NCT04094129|DIETARY_SUPPLEMENT|Placebo|placebo
40953743|NCT03901885|OTHER|Female Sexual Function Index questionnaire|Assessment of FSFI (Female Sexual Function Index) questionnaires preoperatively and postoperatively (4 months).
40953744|NCT05929157|DRUG|artesunate-pyronaridine|Pyronaridine and Artesunate are antimalarial agents with a history of clinical use, and Artesunate has been used clinically in combination with other drugs also. The action of Artesunate is a rapid knock down of the parasites, after which, the drug is quickly cleared as it has a short systemic half-life. Pyronaridine is also rapidly effective in the short term but has a long blood half-life thus providing a more sustained schizonticidal effect.
40953745|NCT03992014|DRUG|Linerixibat tablet|Linerixibat will be available as white to slightly colored film-coated round tablet to be administered as two tablets taken in the fasted state in the morning with 240 milliliter (mL) of room temperature water.
40953746|NCT03992014|DRUG|[14C]-linerixibat intravenous infusion|\[14C\]-linerixibat will be available as clear, colorless solution free from visible particulates to be administered 25 mL IV over 3 hours immediately after the oral dose.
40953747|NCT03992014|DRUG|Linerixibat oral solution|Linerixibat will be available as clear, colorless solution free from visible particulates to be administered 60 mL solution in the fasted state in the morning.
40953748|NCT01363648|DRUG|choline alfoscerate|Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
40761085|NCT03097978|DEVICE|RIC arm system|Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
40953749|NCT01363648|DRUG|placebo (for choline alphoscerate)|Pill manufactured to mimic choline alfoscerate 400mg tablet
40953750|NCT01724931|DRUG|LD-aminopterin|
40953751|NCT01724931|DRUG|placebo|
40953752|NCT03318666|BEHAVIORAL|Supporting Our Valued Adolescents (SOVA)|"The SOVA intervention includes:~* a welcome email to the websites (adolescents also get a SOVA intro video and mobile app)~* adolescents will have access to the website specifically for adolescents: sova.pitt.edu~* parents will have access to the website specifically for parents: wisesova.pitt.edu~These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion. Parents and adolescents cannot log on to each other's sites. The sites are moderated by our research team.~The SOVA websites include articles composed by SOVA Peer Ambassadors who are adolescents and young adults who have experienced symptoms of depression or anxiety and contribute monthly articles and regular comments."
41290536|NCT03691558|OTHER|Western Diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). The diet macronutrient percentage distribution is the following: protein is 25% of TDC (total daily calories), fat is 20% of TDC and carbohydrates represented the 55% of TDC
41134960|NCT00947895|OTHER|IV placebo|IV placebo (saline) daily for 3 days.
41134961|NCT00947895|OTHER|IM placebo|IM placebo (saline) daily for 5 days.
41134962|NCT03093064|DRUG|Natalizumab|Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
40761086|NCT03097978|OTHER|Direct Control|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.
40761087|NCT03097978|OTHER|Pattern Recognition|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
40761088|NCT03590548|DIAGNOSTIC_TEST|gausher disease|lab investigation and radio logical
41134963|NCT03093064|OTHER|Placebo: normal saline|Normal saline, intravenous infusion
40761089|NCT05722769|BEHAVIORAL|CSTOP Now!|Child sex trafficking stops with you. Implement and evaluate the effectiveness of a multi-level bystander-informed program (CSTOP Now!) aimed at Kentucky public middle school staff. Participants will be trained to use the See It To Stop It Indicator Tool (SITSII) by using tiers of concern (clear concern, possible concern, and monitor of emerging concern). The SITSII tool directs the bystander actions to Decide, Directly Intervene, Disrupt, Delegate, and Document.
40761090|NCT05722769|BEHAVIORAL|Prevent Child Abuse Kentucky Online Training|The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed videos we invite active comparator schools to review which also include how to identify and report child sex trafficking.
40761091|NCT01842347|OTHER|Fecal microbiota|
41134964|NCT04715815|OTHER|No intervention (only interview)|Interview
41134965|NCT03233542|BEHAVIORAL|Cognitive Behaviour Therapy|Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
41134966|NCT03443999|DEVICE|Supraflex Family Sirolimus-eluting Coronary Stent System|Patient implanted with at least one Supraflex Family sirolimus-eluting stent as a part of planned clinical care
41134967|NCT05960669|PROCEDURE|3D model guided secondary resection|A prostate model was 3D printed from preoperative pelvic MRI data and used during robot-assisted radical prostatectomy to mark a positive surgical margin and guide secondary resection.
41134968|NCT01972906|DEVICE|moxibustion|apply moxibustion according to traditional Chinese medicine
41134969|NCT01972906|DRUG|Ibuprofen Sustained Release Capsules|apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
41290537|NCT00243893|DRUG|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
41290538|NCT00243893|DRUG|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
40761092|NCT05533437|DEVICE|dry needling|the dry needle inserted to area of pain
40761093|NCT05533437|OTHER|kinesio taping|kinesio taping
40761094|NCT04200963|DRUG|IK-175|Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
41134970|NCT03844685|DRUG|Promensil|1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months
41290539|NCT02796144|DRUG|Lorcaserin|Max dose of 10 mg BID
41290540|NCT02796144|DRUG|Metformin|Max dose of 1,000 mg BID
40761095|NCT04200963|DRUG|IK-175 and nivolumab|Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.
40761096|NCT02445365|DEVICE|AutoRIC device|
40761097|NCT06437457|RADIATION|ceus|MRI was performed by using a superconducting magnet scanner operated at 3.0 T (GE discovery MR750w, USA) and the CEUS examination (Mindray, China), ultrasound was performed first in B-mode to identify the suspicious lesions and then switched to contrast mode prior to the injection of the contrast medium.
40761098|NCT04059822|OTHER|Slow and deep breathing|Please see arm description
40761099|NCT04954898|DEVICE|Study Lens: TECNIS Multifocal Toric 1-piece lens, Model ZMT|Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with TECNIS Multifocal Toric 1-Piece IOL.
41134971|NCT03844685|DRUG|Placebo Oral Tablet|Placebo tablet (80 mg) (without active principle) given once a day for 24 months
41134972|NCT04465721|BEHAVIORAL|TRE|The TRE intervention will be administered and monitored via the study app. It combines self-monitoring behavior, daily eating window reminders, positive reinforcement based on number of log entries or based on meeting eating widow target, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring, and to reducing the eating window.
41290541|NCT02796144|DRUG|Placebo|Matching placebos will be administered for each drug.
41307853|NCT05633147|DRUG|Linaprazan glurate|"Investigational Medicinal Product: Linaprazan glurate (tablets).~Part I:~Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10.~Part II:~Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days."
41307854|NCT05633147|DRUG|Drug drug interaction (DDI) - Clarithromycin (Part I)|Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
41307855|NCT05633147|DRUG|Drug drug interaction (DDI) - Midazolam (Part 2)|Substrate for CYP3A. Midazolam 2.5 mg once daily (2.5 mL oral solution).
40761100|NCT02115971|OTHER|Jumping exercise|Total 120min exercise
40761101|NCT02115971|OTHER|Strength exercise|Total 120 min exercise
41454697|NCT03058107|DIETARY_SUPPLEMENT|Nutrition Therapy|At the time of diagnosis, patients will immediately be screened and started with Nutrition Therapy if assigned to group A. This regimen will stay in place for 6 weeks to 3 months, after which a switch will be made towards normal dietary counselling. Nutrition Therapy can be given orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status and aims at matching Caloric Intake with Resting Energy Expenditure. Moreover, a switch between these modalities is possible. Afterwards, standard dietary counselling will be given during the remainder of the study. Follow-up will last one year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
41454698|NCT03058107|DIETARY_SUPPLEMENT|Control Therapy|At the time of diagnosis, patients will immediately be screened and started with standard dietary counselling for 1 year if assigned to group B. Dietary intervention can be orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status. Moreover, a switch between these modalities is possible. Follow-up will last 1 year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
41454699|NCT01939080|PROCEDURE|Exercise training with supervised sessions|
41454700|NCT00621660|PROCEDURE|Acupuncture|"Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a cun in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred."
40761102|NCT03093415|DRUG|elbasvir-grazoprevir (50 mg/100 mg)|12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
40761103|NCT02777190|DRUG|Misoprostol|Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
40761104|NCT00353119|DRUG|Placebo comparator|Patients received placebo subcutaneously twice weekly
40761105|NCT00353119|DRUG|Etanercept|Patients received etanercept 50 mg subcutaneously twice weekly
40761106|NCT05973656|DRUG|Alcohol|Alcohol dose given orally that will result in a 0.03% blood alcohol concentration (BAC).
40761107|NCT05973656|PROCEDURE|Biospecimen Collection|Undergo saliva, mouthwash, and cheek brush collection
40761108|NCT05973656|PROCEDURE|Breath Test|Undergo breathalyzer testing
41134973|NCT04465721|BEHAVIORAL|HABIT|The HABIT intervention will be administered and monitored via the study app. It combines self-monitoring behavior, positive reinforcement based on number of log entries, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring.
41134974|NCT02715518|DEVICE|PCI using 2nd generation drug-eluting stent|"Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~1. FFR-guided strategy arm~2. Angiography-guided strategy arm"
40761109|NCT02402647|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Treatment (CREST)|"Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
40761110|NCT02402647|BEHAVIORAL|Exposure Therapy (ET)|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
40761111|NCT03424733|DRUG|Plegridy|Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
40761112|NCT03424733|DRUG|Prednisone|Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
40761113|NCT03424733|DRUG|Tylenol Pill|Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
41454701|NCT00621660|PROCEDURE|Sham|Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.
41454702|NCT00591760|DRUG|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
40761114|NCT02463435|BEHAVIORAL|Nutritional intervention|Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
40761115|NCT02463435|OTHER|Nutritional intervention plus olive oil|Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
40761116|NCT02463435|DIETARY_SUPPLEMENT|Olive oil|Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
41134975|NCT02790632|DRUG|EG-1962 (nimodipine microparticles)|Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
41134976|NCT02790632|DRUG|Enteral Nimodipine|Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
41134977|NCT02405000|OTHER|Intraoperative CT imaging|Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
41134978|NCT00349232|BEHAVIORAL|lifestyle intervention (diet and physical activity)|
41134979|NCT04768569|DRUG|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
41134980|NCT04768569|DRUG|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
41454703|NCT01488448|DRUG|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
41454704|NCT01488448|DRUG|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
41454705|NCT04425577|DIAGNOSTIC_TEST|Transabdominal Ultrasound|Transabdominal Ultrasound
41454706|NCT01717313|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week.
41454707|NCT01717313|DRUG|Placebo to Omarigliptin|Placebo to omarigliptin capsule administered orally once a week
41454708|NCT01717313|DRUG|Metformin|If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
41454709|NCT01717313|DRUG|Placebo to metformin|During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
41454710|NCT01717313|DRUG|Glimepiride|If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
40761117|NCT01139970|OTHER|Laboratory Biomarker Analysis|Correlative studies
40761118|NCT01139970|OTHER|Pharmacological Study|Correlative studies
40761119|NCT01139970|DRUG|Temozolomide|Given PO
40761120|NCT01139970|DRUG|Veliparib|Given PO
41454711|NCT02349854|PROCEDURE|Biopsy|1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm \& 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
41454712|NCT05836311|DEVICE|One Perclose Proglide Suture|One Perclose Proglide Suture
40761121|NCT01327729|DRUG|pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg|YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
40761122|NCT03828526|OTHER|High Fidelity Simulation|Teaching strategy based on high fidelity simulation, which simulates the reality of health care to promote meaningful learning.
40761123|NCT03828526|OTHER|Traditional teaching strategy|Classroom-based strategy
40761124|NCT05555329|DRUG|Pomalidomide 4 mg every day in cycle 1|Pomalidomide 4 mg every day, on days 1-21 in a cycle of 28 days
40761125|NCT05555329|DRUG|Pomalidomide 4 mg every other day in cycle 2|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
40761126|NCT05555329|DRUG|Pomalidomide 2 mg every day in cycle 2|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
40761127|NCT05555329|DRUG|Pomalidomide 2 mg every day in cycle 3|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
40761128|NCT05555329|DRUG|Pomalidomide 4 mg every other day in cycle 3|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
41454713|NCT05836311|DEVICE|Two Perclose Proglide Suture|One Perclose Proglide Suture
41454714|NCT03257228|GENETIC|comparative semiquantitative immunohistochemistry|
41454715|NCT05790863|DEVICE|Ergometer cycling|Paticipants will receive 21 sessions (3 sessions/week) of training for 7 weeks with the arm-leg cycle ergometer (SCIFIT, REX7000, US)
40761129|NCT03683082|DRUG|Oxygen supplementation|40% FiO2 via Venturi mask
40761130|NCT03683082|DRUG|Sham O2 (medical air)|Medical air supplementation via Venturi mask
40761131|NCT06569745|OTHER|Verbal Explanation|In the verbal explanation group, a researcher wearing white coat provided oral and dental health education for 3 minutes using a jaw model
40761132|NCT06569745|OTHER|Animation Video Display|"In the animation group, oral and dental health education was presented to the children in the form of a cartoon lasting 1 minute and 17seconds. The animation video was created by the researcher using the test version of www.vyond.com. The animation featured a character voiced by one of the researchers, informative texts, and background music. The character conveyed information about oral and dental health education, using both voice and text content."
40761133|NCT06569745|OTHER|Peer-Led Reels Video Display|In the peer-led reels group, oral and dental health information was presented for 1 minute using a video created on the Instagram platform. The video showed oral hygiene information being provided to a child of a similar age to the target audience with the child then demonstrating the behaviour with music in the background. The video included some text, but did not feature the child's voice or information.
40761134|NCT03196778|RADIATION|Low Dose Radiotherapy|Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks
40761135|NCT05984862|DEVICE|Bandage|To determine if using bandage versus no-bandage, plays a role in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure
41134981|NCT04561089|DIAGNOSTIC_TEST|COVIDSeq Test|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
41290542|NCT04859127|OTHER|effects of neck pain|Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology, questioning of the status of the inquiry Neck Disability Survey, stars in the evaluation of balance dynamic balance test, stand on one leg Test in the evaluation of static balance, dynamic balance and physical performance Term rise and walk test, gait speed for the assessment of the 10-meter walk test and dual-task for the evaluation of the motor-the motor and motor-Cognitive dual-task will be used for the evaluation.
41290543|NCT05422144|DEVICE|Antimicrobial Skin & Wound Cleanser (AWC)|BIAKŌS™ Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKŌS™ Antimicrobial Skin and Wound Cleanser is a pure, colorless, isotonic cleanser that is safe. The preservative, polyhexamethylene biguanide (PHMB), at a concentration of 0.1% w/w is added to the product to inhibit the growth of microorganisms such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA). and fungus Candida albicans within the product.
41290544|NCT05422144|DEVICE|Antimicrobial Wound Gel (AWG)|"BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial polyhexamethylene biguanide (PHMB).~BIAKŌS Antimicrobial Wound Gel:~* Resists microbial colonization within the gel during shelf storage.~* Provides an amorphous gel covering.~* Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
41290545|NCT06511726|DRUG|Cadonilimab|Induction chemotherapy and immunotherapy: Cadonilimab + cisplatin + albumin-bound paclitaxel, for a total of 2 cycles (cisplatin 75 mg/m² + albumin-bound paclitaxel 260 mg/m² q3w, Cadonilimab 10 mg/kg q3w).
41290546|NCT04581187|OTHER|Quality of life assessment|Quality of life questionnaires
41290547|NCT02432677|DRUG|Remifentanil|Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
41290548|NCT02432677|DEVICE|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
41454716|NCT05776901|DEVICE|C-STRESS|Participants were asked to use the C-STRESS app daily for 6 weeks to participate in Cognitively Based Compassion Training (CBCT) lessons, watch guided meditation videos, complete short reflective exercises, and engage with other content provided in C-STRESS (i.e., attending drop-in sessions, journaling, completing mood and wellbeing check-ins, and reading educational articles on depression, anxiety, and stress)
41454717|NCT01929187|DRUG|Phytonail|
41454718|NCT01929187|DRUG|Loceryl|
41454719|NCT04956848|DEVICE|iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed for transfer.
41454720|NCT00191490|DRUG|Gemcitabine|
41454721|NCT00191490|DRUG|docetaxel|
41454722|NCT00191490|DRUG|cisplatin|
41454723|NCT01207856|BEHAVIORAL|specific cognitive rehabilitation|"Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and paper-and-pencil tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises)."
41454724|NCT01207856|BEHAVIORAL|non specific cognitive rehabilitation|A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
41454725|NCT01207856|OTHER|no intervention|no intervention
41290549|NCT02432677|DEVICE|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
41454726|NCT02761122|PROCEDURE|Human biological samples|"* Blood sample~* Skin or mucosal brushing~* Skin or mucosal biopsy"
40761136|NCT03856918|PROCEDURE|PEEP 3 cm of water|PEEP of 3 cm of water will be applied during one-lung ventilation.
40761137|NCT03856918|PROCEDURE|PEEP 6 cm of water|PEEP of 6 cm of water will be applied during one-lung ventilation.
40761138|NCT03856918|PROCEDURE|PEEP 9 cm of water|PEEP of 9 cm of water will be applied during one-lung ventilation.
40761139|NCT06569589|DIAGNOSTIC_TEST|23NaMRI Scan|23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.
40761140|NCT06549647|OTHER|low caloric diet|A low caloric diet of 1200 Kcal will be followed by participant for 3 months. The dietary intervention follows a macronutrient ratio of 15% protein, 30% fat, and 55% carbohydrates. Participants are advised to consume 170-240g of complex carbohydrates, 60-100g of fat, and 55-93g of protein per day, with 20-35g of fiber. Patients are also advised to limit salt, tea, and caffeine intake, and receive supplemental vitamins to prevent deficiencies.
40761141|NCT06549647|OTHER|Placebo laser acupoint stimulation|Placebo laser acupoint stimulation will be used for all participants in group (A).
40761142|NCT06549647|OTHER|Laser Acupuncture|Eazyone EZ1 level laser will be used for the treatment procedures for all participants in group (B) only. Every participant in group (B) will be instructed briefly about the effect of laser acupoints therapy to gain her confidence and co-operation. It will be applied with infrared laser with 830 nm wavelength, 5 W power output and 0.5 J energy on the following acupoints while the patient lie in supine lying position. The head of the machine will be applied perpendicularly on each point for 1 min (17 min total), 3 times/ week for 4 weeks.
40761143|NCT05305573|BIOLOGICAL|COVID-19 Vaccine HIPRA 40 ug/dose|Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)
40761144|NCT05305573|BIOLOGICAL|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|Subjects will receive one injection of Comirnaty Vaccine
40761145|NCT03038919|DRUG|Testosterone cypionate|Bi-weekly intramuscular injection of testosterone cypionate 200mg.
40761146|NCT03038919|OTHER|Standard nutrition and physical therapy at ICU|follow-up of the patient without use of testosterone cypionate
40761147|NCT04798339|DRUG|Canakinumab Injection|Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose
40761148|NCT04798339|DRUG|Darbepoetin Alfa|Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle
40761149|NCT06571175|DIAGNOSTIC_TEST|High frame rate echocardiography|Conventional transthoracic echocardiography will be performed, with added 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.6) and in validated machine learning algorithms.
40761150|NCT06571175|DIAGNOSTIC_TEST|MRI|Cardiac MRI will be performed. In all patients without contraindications, a gadolinium-based contrast agent will be given.
40761151|NCT06571175|DIAGNOSTIC_TEST|Blood test|Conventional brachial venous blood samples will be drawn. Hematocrit value {in %} will be used to calculate CMR-derived exttracellular volume (ECV)
40761152|NCT06571175|DIAGNOSTIC_TEST|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
40761153|NCT06571175|DIAGNOSTIC_TEST|6 min walking test|6 MWT will be performed, and the findings will be related to findings from CMRI/echocardiography.
41454727|NCT00150683|DEVICE|vibration and passive standing versus passive standing alone|
41454728|NCT03279250|DRUG|Abiraterone Acetate|Given PO
41454729|NCT03279250|DRUG|Apalutamide|Given PO
41454730|NCT03279250|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given IM
40761154|NCT01564329|DRUG|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
40761155|NCT01417988|DRUG|Experimental: Empiric TB treatment|Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
40761156|NCT01417988|DRUG|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
41134982|NCT01580306|DRUG|BI 201335|Relevant treatment dose capsule (A) for oral administration
41134983|NCT01580306|DRUG|BI 201335|Relevant treatment dose capsule (B) for oral administration
41290550|NCT02432677|DRUG|Placebo|Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
41454731|NCT03279250|DRUG|Prednisone|Given PO
41454732|NCT03279250|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
41454733|NCT01127087|DRUG|Oxazyme|"Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
41454734|NCT00400452|BEHAVIORAL|wheelchair skills training|
41454735|NCT05557656|DRUG|Regorafenib 40 MG|participants who received the treatment of Regorafenib
41454736|NCT03828539|BIOLOGICAL|Erenumab|70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks
41290551|NCT03471221|BEHAVIORAL|Therapy Dog Visit|"Animal Assisted Activities (AAA) provide opportunities for motivational, educational, recreational, and/or therapeutic benefits to enhance quality of life. AAA are delivered in a variety of environments by specially trained professionals, paraprofessionals, and/or volunteers, in association with animals that meet specific criteria.~Key features of AAA are as follows:~1. Specific treatment goals are not planned for each visit.~2. Volunteers and treatment providers are not required to take detailed notes.~3. Visit content and activities are spontaneous.~4. Visit length can be as long or as short as needed."
41290552|NCT03733678|BEHAVIORAL|Price discounts for SARCs|SARCs are offered free to the client
40761157|NCT05715762|BEHAVIORAL|prone postion|ventilation at prone positioning
40761158|NCT05715762|DRUG|NO inhalation|NO inhalation at 20 ppm
41290553|NCT03733678|BEHAVIORAL|Price discounts for LARCs|LARCs are offered at lower prices to the client
41290554|NCT03733678|BEHAVIORAL|Sequential vs. simultaneous recommendations|Top ranked methods are presented to the client sequentially or simultaneously
41290555|NCT03854162|DEVICE|SMART Guide|The device manufactured according to a digital plan based on patient anatomy. Guiding sleeves are used, through which bone drills are applied. These sleeves sit in a plastic template that is a negative of the patient's dentition, so that the guide is properly stabilized during the operation. The position of the sleeves is calculated from the surgical plan in a way that they guide the drills in the planned position.The material of the template is medical plastic, the sleeves are made of medical steel.The device is applied by the dentist during the implant surgery. The template is placed on the remaining dentition of the patient and stabilized this way. By this, the sleeves are also stabilized in their planned position. Access through the soft tissue can be prepared through the given sleeve with a circular trephine, but the system also supports flap surgery. As access has been established, the dentist performs the surgical protocol as planned.
41290556|NCT05581576|DRUG|Pitolisant|Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
41290557|NCT00999752|DRUG|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure \<140/90
41290558|NCT00999752|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
41290559|NCT03131297|PROCEDURE|treatment by radiofrequency|Radiofrequency might destroy fistula tract without lesion of anal sphincter.
40761159|NCT00414557|PROCEDURE|Quadriceps strengthening|
40761160|NCT02920047|DRUG|Fimasartan/Amlodipine|Treatment B
40761161|NCT02920047|DRUG|Fimasartan + Amlodipine|Treatment A
40761162|NCT06240286|BEHAVIORAL|Sitting workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station in a seated position.
40761163|NCT06240286|BEHAVIORAL|Standing workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while standing.
41290560|NCT03667131|DRUG|Enalapril Maleate|Enalapril Maleate 5 mg tablet, every 12 hrs for 90 days.
40761164|NCT06240286|BEHAVIORAL|Stepping workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while utilizing a stepper.
40761165|NCT06240286|BEHAVIORAL|Walking workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while walking on a treadmill.
40761166|NCT00138242|DRUG|carboplatin|
40761167|NCT00138242|DRUG|docetaxel|
41454737|NCT03828539|DRUG|Topiramate|"Film-coated tablet taken orally:~25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase."
41290561|NCT03667131|DRUG|Placebo|Placebo 5 mg tablet, every 12 hrs for 90 days.
41290562|NCT03205969|DEVICE|Functional mobile game|Functional mobile game for chemotherapy side effect education
41290563|NCT02360943|OTHER|4 blood samples|PK and / or PD measurements during hospitalization
41290564|NCT02365532|DRUG|GS-6615|GS-6615 tablets administered orally
41290565|NCT02365532|DRUG|Placebo to match GS-6615|Placebo to match GS-6615 tablets administered orally
41454738|NCT03828539|BIOLOGICAL|Erenumab matching placebo|Erenumab matching placebo pre-filled syringue administered every 4 weeks
40761168|NCT00138242|PROCEDURE|adjuvant therapy|
40761169|NCT05548361|COMBINATION_PRODUCT|active chlorhexidine and placebo probiotic|the randomized patients will be receive active chlorhexidine rinse and placebo probiotic
40761170|NCT05548361|COMBINATION_PRODUCT|placebo chlorhexidine and active probiotic|the randomized patients will receive placebo chlorhexidine rinse and active probiotic
40761171|NCT05548361|COMBINATION_PRODUCT|active chlorhexidine and active probiotic|the randomized patients will receive active chlorhexidine rinse and active probiotic
40761172|NCT02419911|PROCEDURE|Laparoscopic surgery|gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
40761173|NCT02419911|DEVICE|FloShield Defogging and Cleaning System|Sterile, single-use in vivo device to clean and defog the laparoscope camera lens
40761174|NCT02419911|DEVICE|Clearify Defogging and Cleaning System|Single-use, ex vivo device to clean and defog the laparoscope camera lens
40761175|NCT01557244|DRUG|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
41290566|NCT02365532|DRUG|Placebo to match dofetilide|Placebo to match dofetilide capsules administered orally
41290567|NCT02365532|DRUG|Dofetilide|Dofetilide 500 μg capsules administered orally according to the current prescribing information
41290568|NCT04370262|DRUG|SOC + Intravenous Famotidine|Standard of Care treatment plus IV famotidine
41290569|NCT04370262|DRUG|SOC + Placebo|Standard of Care treatment plus IV placebo
40761176|NCT01557244|DRUG|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
40953753|NCT03318666|OTHER|Enhanced Usual Care|A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.
40953754|NCT01252147|OTHER|No treatment|No treatment (intervention) will be provided in this study
40953755|NCT06364475|BEHAVIORAL|16:8 Time-Restricted Intermittent Fasting Group|Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have a feeding window 8 hours and eating plan of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). Participants in the time-restricted eating group were allowed to drink calorie-free. They were expected to follow their diet for two months during the study.
41290570|NCT04251312|OTHER|Oral Hygiene Education and Oral Hygiene Packets|Patients will be educated on oral hygiene and will be given packets containing toothpaste, mouth rinse, floss and a toothbrush
41290571|NCT02565823|OTHER|Exercise bout|Participants will exercise for 45min at 75% of VO2peak
40761177|NCT01557244|DRUG|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
40761178|NCT01557244|DRUG|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
40761179|NCT01557244|DRUG|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
40761180|NCT01557244|DRUG|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
40761181|NCT01557244|DRUG|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
40761182|NCT03527979|PROCEDURE|IVF/ICSI|IVF/ICSI
40761183|NCT06207851|DEVICE|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
40761184|NCT05116345|DRUG|DEXTENZA|Intracanalicular Dexamethasone ophthalmic insert (0.4mg)
40761185|NCT05116345|DRUG|Topical Dexamethasone|topical dexamethasone drops
40761186|NCT03794635|BEHAVIORAL|Weekly 45 minute Sessions|"The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study:~1. A culturally tailored version for Latinx participants refined during Phase 1 of this study (available in English and Spanish)~2. A version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. The culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants will be used. Interventions will occur weekly with a plus three-week window.~Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention."
40761187|NCT03977155|DRUG|BOS-589|oral tablets
40761188|NCT03977155|DRUG|Placebo|oral tablets
40761189|NCT00276315|BIOLOGICAL|Botulinum toxin type A|
40761190|NCT04020263|DRUG|Levosimendan 2.5 MG/ML Injectable Solution|Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
40761191|NCT04020263|DRUG|Placebo|Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
40761192|NCT03345225|DEVICE|SureFire Infusion System|Surefire is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
40761193|NCT03345225|DEVICE|Standard Endhole Microcatheter|A Microcatheter with a single hole at the end for a infusion.
40761194|NCT01460277|PROCEDURE|Hydrokinesiotherapy Intervention|The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
40761195|NCT01460277|PROCEDURE|Land-based exercise intervention|The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
41290572|NCT05308485|OTHER|Events exposure questionnaire|Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period
41290573|NCT05185232|OTHER|Impact of gaps in care/loss to healthcare follow-up|There will not be a discrete intervention as part of this study but study investigators will be examining a set of primary and secondary outcomes in patients who have followed recommended cardiac care vs. those who have not.
41290574|NCT00124423|PROCEDURE|Megavoltage CT scan|
40953756|NCT06364475|BEHAVIORAL|Energy-Restricted Six-Meal Group|Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have an eating plan three meals and three snacks of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). They were expected to follow their diet for two months during the study.
40953757|NCT03789396|OTHER|Targeted Normoxia (oxygen saturation 90-96%)|The intervention (post-implementation) group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation
40953758|NCT03789396|OTHER|Usual Care Oxygenation|The control (pre-implementation) group will be trauma patients admitted to the ICU during the 12 months prior to the targeted normoxia implementation
40953759|NCT02364726|PROCEDURE|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
40953760|NCT02364726|BEHAVIORAL|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
40953761|NCT02364726|BEHAVIORAL|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
40953762|NCT06389500|DRUG|Adebrelimab|Adebrelimab, IV
40953763|NCT06389500|DRUG|Lenvatinib|Lenvatinib, PO
40953764|NCT06389500|PROCEDURE|Hepatic Arterial Infusion Chemotherapy|GC regimen±5-FU
40953765|NCT05760560|DRUG|Sugammadex|At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.
40953766|NCT02829060|DRUG|Nitrofurantoin 100 MG, 7d|7 day course, 100 mg twice daily, PO
40953767|NCT02829060|DRUG|Gentamicin, 5mg/kg|Peri-operative dose: 5 mg/kg of ideal body weight, IV
40953768|NCT02829060|DRUG|Ampicillin 2g|Peri-operative dose: 2 grams, IV
40953769|NCT02829060|DRUG|Nitrofurantoin 100 mg, 48 hrs|48 hour course, 100 mg twice daily, PO
40953770|NCT02829060|DRUG|Gentamicin, 80 mg, 7d|7 day course, 80 mg daily, IM or IV
40953771|NCT02829060|DRUG|Gentamicin, 80 mg, 48hr|48 hour course, 80 mg daily, IM or IV
40953772|NCT01780571|PROCEDURE|CPAP 5 cm H2O + PSV 5 cm H2O|Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
41290575|NCT06133777|OTHER|Respiratory variability monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
41290576|NCT05295160|BEHAVIORAL|weight loss by very low energy diet intake which may differ in protein or carbohydrate content|The anthropometric, endocrine and metabolic status is tested before, after 7 days and after 15 kg weight loss
41454739|NCT03828539|DRUG|Topiramate matching placebo|Topiramate matching placebo administered daily
41290577|NCT06512220|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with or without risperidone 1 mg. It will also be administered in conjunction with supportive therapy.
41290578|NCT06512220|DRUG|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with psilocybin 25 mg. It will also be administered with supportive therapy.
40761196|NCT03969030|OTHER|PEBRA model|"The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:~1. ART Refill~2. SMS notifications~3. Support"
41290579|NCT03388177|BEHAVIORAL|Yoga-based therapy|
41290580|NCT03388177|OTHER|Treatment as usual|
40761197|NCT04731597|DRUG|drug interaction|when two drugs are taken together
41290581|NCT05785338|DIAGNOSTIC_TEST|Posterior angle of the hard palate|Fetal ultrasound
41290582|NCT03352856|OTHER|Barley starch|Highly purified barley starch
41290583|NCT03352856|OTHER|Maize starch|Maize starch
40761198|NCT05596812|OTHER|New Care Pathway|The New Care Pathway will include continuation of lifestyle and dietary modification, self-blood glucose monitoring, and routine prenatal care.
41290584|NCT02167555|DIETARY_SUPPLEMENT|Active Comparator|Wild Blueberry Beverage
41290585|NCT02167555|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo Beverage
41290586|NCT06410391|DEVICE|Ultrasound|"Gestational age, biparietal diameter and head circumference are measured. then 2 techniques are used according to the 2007 International Society of Ultrasound in Obstetrics and Gynecology guidelines for a US evaluation of the fetal central nervous system (CNS) (10) : 1- the axial transventricular technique including the posterior portions of the lateral ventricles, falx, CSP, and Frontal horn 2- the trans-cerebellar technique, including the cerebellum, cisternal magna, cerebellar peduncles, CSP, and FHs. CSP visualization and width, FH width, anterior horn width (AHW), center from the horn distance (CFHD), upside and downside measurement.~The corpus callosum is identified in the midsagittal plane. The image selected for CC measurement in addition to cerebellar vermis and cisterna magna"
41290587|NCT02685150|DEVICE|Endoscopic Tri-Modal Imaging|Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).
41290588|NCT02685150|DRUG|Omeprazole|Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.
41290589|NCT02685150|OTHER|Analysis of gastric juice|Analysis of gastric juice including routine, biochemical and microbiological analysis.
41290590|NCT03927729|DRUG|Methoxyflurane|Pain will be treated with inhaled methoxyflurane (Penthrox®).
41290591|NCT05522114|PROCEDURE|TMJ injection using patient specific guide|Prefabricated patient specific guide used to guide the needle into the superior joint space of TMJ while real time MSCT evaluate the accuracy of needle position. Sodium hyaloronate injected within the superior joint space.
41290592|NCT02061995|DRUG|PREOB® Intravenous Infusion|Each patient will undergo a single intravenous administration of PREOB®.
41454740|NCT05943522|OTHER|Asciminib|There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
41290593|NCT06053411|DRUG|Diclofenac|25 mg capsule
40761203|NCT05335057|BEHAVIORAL|VR Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab
40761204|NCT05335057|BEHAVIORAL|VR Alone|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone
40761205|NCT05335057|BEHAVIORAL|VR Stranger|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger
41290594|NCT06053411|DIETARY_SUPPLEMENT|curcumin|2,000 mg tablet
41290595|NCT02778880|DRUG|Ketamine|
41290596|NCT02778880|DRUG|Fentanyl|
41454741|NCT04046562|BEHAVIORAL|PAW|Pain and Weight Treatment plus standard of care
40761206|NCT05335057|BEHAVIORAL|Video Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool
40761207|NCT06570421|DEVICE|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct transcutaneous, electrical stimulation of the peroneal nerve
41290597|NCT04397055|DIETARY_SUPPLEMENT|Cottonseed Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Cottonseed Oil
41454742|NCT04046562|BEHAVIORAL|Pain Education|Pain Education plus standard of care
41454743|NCT02886676|DRUG|Spirulina capsules|Spirulina capsules 2gm daily for 1 month
41290598|NCT04397055|DIETARY_SUPPLEMENT|Olive Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Olive Oil
41290599|NCT04345939|DIAGNOSTIC_TEST|Detection method|Different methods for pathogen diagnosis
41290600|NCT01507545|DRUG|MORAb-004|MORAb-004 8mg per kg IV once a week
41454744|NCT03498560|DEVICE|PSG|PSG data to be collected on the night before surgery to establish level of preexisting sleep disturbance.
41454745|NCT00799162|OTHER|Psychophysical testing, questionnaires, and genetics|pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
40761208|NCT06549452|DEVICE|mHealth Intervention|Our HIPPA-compliant texting platform is linked to the Fitabase Interface. Real time activity data are transmitted from the participant's smartphone to Fitabase via cellular network. Participants will receive 3-5 texts/day in sync with their preferred schedule defined at enrollment and taking into account school schedules as relevant. These texts use personal, disease-specific, and provider information to deliver two types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
40761209|NCT06549452|DEVICE|Usual Care|Routine medical care
40761210|NCT04833738|DRUG|Hyaluronic acid|
41134984|NCT04300244|BIOLOGICAL|UV1 vaccine + leukine|The mode of action of UV1 is to activate the immune system to induce T cells directed against telomerase (hTERT). UV1 vaccination amplifies the pool of hTERT specific tumor-reactive T cells from the naive repertoire and has the potential to increase the breadth and diversity of the tumor-reactive T cell response (epitope spreading). Vaccination with UV1 can thus provide the basis for increased efficacy of checkpoint inhibition therapy, by augmenting the pool of tumor specific T cells in patients with limited or insufficient numbers of T cell clones spontaneously primed by tumor antigens. Reciprocally, the efficacy of UV1 vaccination may be enhanced in combination with checkpoint inhibitors, since the clonal expansion and effector activity of UV1 induced T cells will otherwise be restricted by intrinsic immune regulatory and tumor induced suppressor mechanisms.
41134985|NCT04300244|BIOLOGICAL|ipilimumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
41134986|NCT04300244|BIOLOGICAL|nivolumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
41134987|NCT03511144|DEVICE|Unity Knee™ TKR using measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
41134988|NCT03511144|DEVICE|Unity Knee™ TKR using ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
41134989|NCT00518206|BIOLOGICAL|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
41134990|NCT00518206|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
41134991|NCT04412005|OTHER|No intervention|No intervention
41134992|NCT06466759|DEVICE|Mc Grath Videolaryngoscope|Use of Videolaryngoscope with Mc Grath versus direct laryngoscopy
41134993|NCT05534971|PROCEDURE|Central venous catheter insertion|The clinical team will use the technique to establish central venous access
41134994|NCT02202317|DEVICE|PET/CT Scan|Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
41134995|NCT01038934|PROCEDURE|samples collected by buccal cytobrush|
41134996|NCT06510855|DEVICE|DurAVR™ THV System|DurAVR™ THV System - Transcatheter Aortic Valve Implantation (TAVI) Procedure
41134997|NCT01446718|BIOLOGICAL|Gardasil vaccine|0.5ml of intramuscular vaccine in three doses
41454746|NCT03357380|DRUG|Semaglutide|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
41454747|NCT03357380|DRUG|Placebo|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
41454748|NCT06561581|BEHAVIORAL|Acuity|Enhancement to Motivity product for clinical decision support
41454749|NCT05826093|PROCEDURE|Ultrasound-guided subcostal transversus abdominis plane block (US-TAP)|US-TAP is a peripheral nerve block applied for postoperative pain relief. Subcostal refers to the approach which can also be lateral or posterior. In this trial the subcostal approach was used.
40761211|NCT04833738|DRUG|Corticosteroids Triamcinolone Acetonide|triamcinolone acetonide, 40 mg/ml, single dose
40761212|NCT04833738|OTHER|Electrotherapy|electrotherapy
40761213|NCT02607163|DRUG|dexmedetomidine|Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
41454750|NCT01121744|DEVICE|Supralimus-Core™ Sirolimus eluting Coronary Stent|Supralimus-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Sirolimus Drug concentration is 1.4 µg/mm2.
41454751|NCT01896934|DRUG|Sertraline|50-200mg daily
41454752|NCT02756858|DRUG|ANAVEX2-73|
41454753|NCT05026320|DRUG|Naproxen gel|10%, bid for 5 days (final application on morning of Day 6)
41134998|NCT01450397|BIOLOGICAL|XIAFLEX|One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
40761214|NCT02607163|DRUG|saline|same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
41134999|NCT03121885|BEHAVIORAL|30-minute movement activity|The subjects arrive in the CRU after a 12 hours overnight fast to perform a 30-minute movement activity with individually adapted exercise intensity on the treadmill.
41135000|NCT03121885|OTHER|Hypoxia|The 30-minute movement activity on the treadmill will be completed by each subject once under normobaric normoxic and once under normobaric hypoxic conditions (equivalent to approximately 3000 meters above sea level) in a randomized episode.
41135001|NCT01240590|DRUG|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
41135002|NCT01240590|DRUG|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
41135003|NCT06094166|DIAGNOSTIC_TEST|MRI|Quantitative imaging MR parameters
41135004|NCT01670799|DRUG|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
41290601|NCT01507545|DRUG|Placebo|Placebo - normal saline IV once a week
41290602|NCT01507545|OTHER|Best supportive care|Best supportive care to improve quality of life
41290603|NCT05978284|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
41454754|NCT05026320|DRUG|Diclofenac gel|2.32% bid for 5 days (final application on morning of Day 6)
40761215|NCT00670514|BEHAVIORAL|Nix Individual|Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.
41135005|NCT03498365|BEHAVIORAL|MCDA|Experimental decision support
41135006|NCT03498365|BEHAVIORAL|Delphi|Standard support
41135007|NCT03407976|DRUG|Apatinib|Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.
41135008|NCT03407976|DRUG|Pembrolizumab|200 mg Q3 weeks IV
41135009|NCT05483166|BEHAVIORAL|ImPACT|"During the ImPACT program, the childhood cancer survivor and at least one parent collaborates on:~1. Becoming aware of the child's core strengths and difficulties~2. Helping the child to be optimally responsive to the guidance of the parent(s), and~3. Creating compensatory strategies to respond to real-world manifestations of the child's difficulties and helping the child implement these strategies at home."
41135010|NCT06510673|DRUG|Platelet rich plasma|Platelet-rich plasma for the heel
41135011|NCT06510673|OTHER|High power LASER|High power LASER sessions for the heel
41135012|NCT06510673|OTHER|Shockwave therapy|Shockwave therapy sessions for the heel
41135013|NCT06510673|OTHER|Ice application|Ice application for the heel
41135014|NCT06510673|OTHER|Sham LASER|Sham LASER for the heel
41135015|NCT04566172|BEHAVIORAL|Inspiratory Muscle Training (IMT)|Participants will receive an inspiratory muscle training that they will do leading up to the day of their surgery.
41290604|NCT05760456|DRUG|DIDALA hard capsules|DIDALA is given orally with a dose of 2 capsules, 3 times per day for 12 weeks
41290605|NCT05760456|DRUG|Metformin|Metformin 500mg, 1 tablet twice a day, immediately after breakfast and dinner for 12 weeks
41454755|NCT05026320|DRUG|Placebo gel|bid for 5 days (final application on morning of Day 6)
41454756|NCT04651816|BEHAVIORAL|Financial Incentives|Participants will be entered into a lottery to receive a gift card for class attendance.
40953773|NCT03830242|DIAGNOSTIC_TEST|<Sup>18<Sup>F-FDG PET/CT dynamic scan|The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
41135016|NCT02268240|BEHAVIORAL|Stepped Care|Intervention will include : 1) care management; 2) cognitive-behavioral therapy (CBT); 3) psychiatric medication consultation in addition too receiving standard care through their medical team. Care management will include initial consultation to determine participants' and families' concerns and areas of difficulty, followed by brief interventions to connect them with care providers as needed . If participants do not show adequate symptom reduction, they will be engaged in structured CBT. CBT will be delivered in 4 to 12 structured sessions, each ranging from 30-60 minutes in length. Psychiatric medication consultation will be offered on an as-needed basis for participants not adequately responding to prior stepped care interventions. MD providers with expertise in psychopharmacological treatment of youth will provide consultation for participants' primary care provider regarding the prescription of psychiatric medications.
41135017|NCT03926806|OTHER|Plain yoghurt|cups of 200 g yoghurt
41135018|NCT03926806|OTHER|Vitamin B yoghurt|cups of 200 g yoghurt
41454757|NCT04651816|BEHAVIORAL|Motivational Message|Participants will be sent motivational messages through out their participation in the PSH DPP program.
41135019|NCT06254976|BEHAVIORAL|exercise|2 weeks of home exercise
41135020|NCT06254976|BIOLOGICAL|intraarticular knee PRP injections|2 doses of intra-articular platelet rich plasma (PRP) injection, 1 week apart
41454758|NCT04651816|BEHAVIORAL|DPP Program|All Participants will be enrolled in the DPP program.
41454759|NCT04784416|DEVICE|Active tPBM-2.0|The NIR continuous wave (average irradiance = 300 mW/cm2) will be used. The duration or irradiation will be for \~11 minutes (666 seconds).
40761216|NCT00670514|BEHAVIORAL|Fimpa dig fri|"One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program (Fimpa dig fri). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires."
40761217|NCT05215236|OTHER|Opiate Sparing|Subjects will receive non-opiate medications for pain control
40761218|NCT05215236|OTHER|Opiate Based|Subjects will receive opiate based medications for pain control
40761219|NCT02202577|DRUG|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
41290606|NCT05739617|OTHER|Comprehensive Respiratory Training Exercise Program|This comprehensive respiratory training exercise program consists of four main components, including oropharyngeal muscle training, respiratory muscle training, aerobic exercise, and sleep hygiene education.
41290607|NCT05739617|OTHER|Sleep hygiene education|Sleep hygiene education
40761220|NCT02202577|DRUG|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
41290608|NCT04660903|PROCEDURE|Autologous fat cell transplantation|Up to 75 ml of fatty tissue mixture fluid
40761221|NCT06564740|DRUG|Stem Cell|UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC/kg.
40761222|NCT06564740|OTHER|Control|In this group, UC-MSC will not be administered. This group serves as a passive control. The standard treatments that are routinely provided to these patients will continue to be administered.
41135021|NCT03533894|DEVICE|colic capsule|colic polyp diagnosis
41135022|NCT01212913|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
41454760|NCT04784416|DEVICE|Sham tPBM-2.0|"The sham mode (0 mW/cm2) will be used. The duration or sham irradiation will be for \~11 minutes (666 seconds)."
41454761|NCT04784416|DRUG|18F-MK-6240|PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments
41454762|NCT02881541|PROCEDURE|Enhanced support|
41454763|NCT02881541|PROCEDURE|Usual care|
40761223|NCT02054728|OTHER|RHC and IMT|"Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).~The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters."
40761224|NCT04105361|PROCEDURE|Posterior neurectomy|Cut of posterior nasal nerve
40761225|NCT01373411|DRUG|ticagrelor|ticagrelor 90 mg BID for 90 days
40761226|NCT01373411|DRUG|Placebo|Placebo 1 pill BID for 90 days
40761227|NCT04838652|DRUG|Pembrolizumab plus Chemotherapy (ICE or DHAP)|Pembrolizumab (200mg) alone or in combination with ICE (or DHAP in case of PET positive findings after P-ICE) will be admistered. 6 additional courses of pembrolizumab will be administered after the completion P-ICE or P-DHAP
40761228|NCT00005626|DRUG|Irinotecan|Irinotecan as outlined in treatment arm
41135023|NCT01212913|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
41135024|NCT01212913|DRUG|Insulin aspart|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
40761229|NCT01711099|DEVICE|device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy|
40761230|NCT02695186|PROCEDURE|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
40761231|NCT01396876|BEHAVIORAL|clown|a distraction technique is performed by a clown during venipuncture
40761232|NCT06005636|DIAGNOSTIC_TEST|Test delirium state|use scale to test whether ischemic stroke patients have post-stroke delirium
40761233|NCT00257933|DRUG|Prednisolone high dose|4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
41454764|NCT03997253|OTHER|blood and urine samples|various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12 and intraoperative bile collection
41454765|NCT01151280|DEVICE|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
41454766|NCT02337322|DRUG|Dolutegravir|
41454767|NCT02337322|DRUG|Darunavir/r|
41135025|NCT01179802|OTHER|Strenuous Endurance exercise|"Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters."
41135026|NCT06510868|RADIATION|Peptide receptor radionuclide therapy (PRRT)|Specialized type of radionuclide therapy used to treat neuroendocrine tumors.
41307856|NCT02960048|DEVICE|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
41135027|NCT06510868|DIAGNOSTIC_TEST|Blood collection|Patients will have approximately 5 ml of blood drawn 6,12,24,36,48, 60 months and at the time of MDS/AML diagnosis on follow up. Genomic DNA will be extracted from serum sample using the Qiagen QIAamp DNA Mini Kit. Single-molecule molecular inversion probes (smMIPs) will be used to detect mutations. Single nucleotide variants (SNVs), short insertions and deletions (indels), and mutated myeloid genes will be captured (e.g PPM1D, DNMT3A, TET2, TP53).
41135028|NCT04684095|BEHAVIORAL|electronic patient report outcome|ePRO was conducted every two weeks in addition to routine follow-up
41135029|NCT02262988|PROCEDURE|Total knee replacement|Total knee replacement (TKA)
41454768|NCT05346172|DEVICE|PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the PanOptix or PanOptix Toric IOL in both eyes.
41454769|NCT03126292|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
40953774|NCT03830242|DIAGNOSTIC_TEST|B-ultrasonography|The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
40953775|NCT05727436|DIETARY_SUPPLEMENT|Dentoblis|Dissolve the tablets in the mouth once a day for 4 weeks
40953776|NCT05727436|DIETARY_SUPPLEMENT|Placebo|Dissolve the tablets in the mouth once a day for 4 weeks
40953777|NCT04750512|PROCEDURE|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.2% according to randomization): bilateral injection of 30ml (60ml total) under US guidance between the deep fascia of erector spinae muscle and the the two transverse process at the level of the 10th thoracic vertebrae
40953778|NCT04750512|PROCEDURE|TAP block|"US guided TAP block (saline solution vs Ropivacaine 0.2% according to randomization):~bilateral injection of 30ml (total 60ml) under US guidance in the plane between the internal oblique and transversus abdominis muscles at the level of the midaxillary line in the Petit triangle."
40953779|NCT00492531|DRUG|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
40953780|NCT00492531|DRUG|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
40953781|NCT04275570|BEHAVIORAL|Motivational interview|The motivational interview is integrated in a structural theoretical mark. This method is a person-centered counseling style that increases the intrinsic motivation of the patient to behavioral changes through spirit, acceptance, compassion and evocation.
40953782|NCT00214110|DRUG|Tamoxifen|
41135030|NCT05156606|DRUG|AndroGel|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
40953783|NCT01610531|OTHER|SAMScore questionnaire|Patients assessed at high risk according to the SAMScore
40953784|NCT02124161|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
40953785|NCT02124161|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
40953786|NCT02124161|OTHER|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
41135031|NCT00729898|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
41454770|NCT03126292|OTHER|Child Safety Handout|Handout regarding early child safety
41454771|NCT04502706|DRUG|GS-0189|GS-0189 will be administered intravenously.
41454772|NCT04502706|DRUG|Rituximab|Rituximab will be administered intravenously.
41135032|NCT01453959|DRUG|Fludrocortisone|Fludrocortisone in a dose of 0.4 mg/day for 7 days
41454773|NCT01676064|DRUG|ringer lactate solution|
40953787|NCT02124161|OTHER|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
41290609|NCT00200148|PROCEDURE|Normovolemic Hemodilution (ANH)|For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
41290610|NCT00200148|PROCEDURE|Standard of care|An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
41290611|NCT00765869|OTHER|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
41290612|NCT00765869|OTHER|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
41290613|NCT00765869|OTHER|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
41290614|NCT05134298|DRUG|Piperacillin/tazobactam, Meropenem|This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
41290615|NCT01304862|BEHAVIORAL|eSMART-MH intervention|Involves simulated interactions between participants and the virtual health care providers (avatars).
41290616|NCT01304862|BEHAVIORAL|Educational videos about healthy living|20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
41290617|NCT04472104|BEHAVIORAL|MBCT-S|Group mindfulness treatment for sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
41290618|NCT04472104|BEHAVIORAL|SexEd|Group sex education on sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
41290619|NCT01363895|PROCEDURE|Percutaneous closure of LAA|Percutaneous closure of LAA
40761234|NCT00257933|DRUG|Prednisolone lower dose|2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
40761235|NCT04377919|DIETARY_SUPPLEMENT|Cranberry|The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks
41290620|NCT01363895|PROCEDURE|Catheter ablation of AF|Catheter ablation of AF
41290621|NCT00691197|DEVICE|Carboxymethylcellulose sodium and Glycerin|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
41290622|NCT00691197|DEVICE|Carboxymethylcellulose sodium|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
41290623|NCT02004652|DRUG|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
41290624|NCT02004652|DRUG|Placebo|Vitamin, 50mg, tablet.
40953788|NCT02124161|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
41290625|NCT02213757|DRUG|Premarin vaginal estrogen cream|
41290626|NCT02213757|DRUG|Placebo vaginal cream|Inactive vaginal cream manufactured to mimic Premarin vaginal cream
41307857|NCT02960048|DEVICE|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
41454774|NCT01676064|OTHER|restrictive fluid regime|
40953789|NCT02124161|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
40761236|NCT04377919|DIETARY_SUPPLEMENT|Placebo|The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks
40761237|NCT03757117|DRUG|Feminizing hormone therapy|"Estradiol valerate was initiated at 2 mg PO daily and increased to 4 mg after 4 to 12 weeks~Antiandrogen therapy with spironolactone started at a dose of 50 mg PO daily and increased every 4 weeks to 200 mg daily"
40761238|NCT03757117|BEHAVIORAL|Peer navigation|Transgender women community peer navigation
40953790|NCT05600660|DRUG|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6 cycles during induction treatment.~Daily Orelabrutinb will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
40953791|NCT05600660|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy.
40953792|NCT05600660|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
40953793|NCT04034628|DEVICE|Peritoneal Catheter Insertion - Laparoscopic|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
40953794|NCT04034628|DEVICE|Peritoneal Catheter Insertion - Percutaneous|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
40953795|NCT02515643|OTHER|Endothelial dysfunction|"One month before surgery and one year after, the following procedures will be performed in donors and recipients:~1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.~2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.~3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor~4. Estimation of glomerular filtration rate by Iohexol method"
40953796|NCT00627185|BEHAVIORAL|Internet-delivered continuing professional development|Interactive motivational website for dentists and hygienists with practice improvement resources, discussion forum, and educational cases on cessation counseling with email reminders.
40953797|NCT00627185|OTHER|No intervention arm|
40953798|NCT02675985|OTHER|Physical Therapy|Early Intensive Physical therapy in the ICU
40953799|NCT04798638|DRUG|TY-9591 Tablets under Fasted Condition - Arm1|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
40953800|NCT04798638|DRUG|Osimertinib Mesylate Tablets under Fasted Condition - Arm1|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
41135033|NCT01453959|OTHER|Diet cycles|Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
41135034|NCT05461755|COMBINATION_PRODUCT|Fractional radiofrequency and topical Tretinoin|Treatment of striae with fractional radiofrequency and topical tretinoin in combination
41135035|NCT05461755|DRUG|Topical Tretinoin|Treatment of striae with topical tretinoin alone
41135036|NCT05461755|DEVICE|Fractional radiofrequency|Treatment of striae with fractional radiofrequency alone
41135037|NCT01779700|DRUG|Fingolimod|0.5mg each day of 8 week cycle
40953801|NCT04798638|DRUG|TY-9591 Tablets after a High-fat Meal - Arm1|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
40953802|NCT04798638|DRUG|Osimertinib Mesylate Tablets under Fasted Condition - Arm2|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
40953803|NCT04798638|DRUG|TY-9591 Tablets under Fasted Condition - Arm2|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
40953804|NCT04798638|DRUG|TY-9591 Tablets after a High-fat Meal - Arm2|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
40953805|NCT03144921|BEHAVIORAL|psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
41135038|NCT01779700|DRUG|placebo|1 tablet each day of 8 week cycle
41135039|NCT01281657|DRUG|fingolimod|
41135040|NCT06148636|DRUG|[212Pb] VMT-α-NET|Up to 2 infusions with \[212Pb\] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage.
41135041|NCT06148636|DIAGNOSTIC_TEST|[203Pb] VMT-α-NET SPECT/CT|The \[203Pb\] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . \[203Pb\] VMT-α-NET, a radioactive tracer drug.
41135042|NCT01571557|DRUG|dexamethasone 700 ug intravitreal implant|dexamethasone 700 ug intravitreal implant administered according to standard of care.
41135043|NCT03846037|OTHER|Proprioceptive exercise on the vibratory platform|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the vibratory platform
41135044|NCT03846037|OTHER|Proprioceptive exercise on the ground (stable surface)|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the ground
41135045|NCT01319058|PROCEDURE|Tonsillectomy, laser tonsillotomy, debrider tonsillotomy|Each arm will be treated by one of the three methods in addition to adenoidectomy
41290627|NCT01079715|DRUG|Propranolol|"Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).~In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.~In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.~In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:~* Atropine.~* Isoproterenol hydrochloride (isoprenaline.~* Terlipressin.~* Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular)."
41290628|NCT00675285|DRUG|montelukast sodium|one tablet 5 mg once/day for 4 weeks
40761239|NCT06638645|PROCEDURE|VATS/RATS anatomical lung resection|Perioperative care according to the ERAS protocol for lung surgery
40761240|NCT02256033|DRUG|Istradefylline|One 40 mg-tablet administered on Day 1
40761241|NCT01931410|DRUG|Misoprostol|
40761242|NCT05384483|DRUG|Cariprazine|Cariprazine 1.5 to 3 mg per day
40761243|NCT05384483|DRUG|Placebo|Matching placebo
41135046|NCT00609050|BEHAVIORAL|Self-Regulated Exercise with Telephone Reinforcement|The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
41290629|NCT00675285|DRUG|placebo|one tablet 5 mg once/day for 4 weeks
40953806|NCT01660204|OTHER|Preferred empirical treatment|The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
40953807|NCT00892047|DRUG|venlafaxine XR plus aripiprazole|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
40953808|NCT00892047|DRUG|venlafaxine plus placebo|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
40953809|NCT01686061|OTHER|No intervention- only one time survey|
40953810|NCT01034631|DRUG|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
40953811|NCT01034631|DRUG|BNC105P|BNC105P, up to 16 mg/m\^2
40953812|NCT06487416|DRUG|Tiotropium Bromide Inhalation Powder|By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
41290630|NCT06085365|DRUG|Immunonutrition （Su yusu)|Immunonutrition （Su yusu） 250ml oral twice a day d1-d21
40953813|NCT06487416|DRUG|Spiriva®Handihaler®|By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
40953814|NCT05578911|OTHER|"medical students group"|medical student in general practice or in specialty medicine
40953815|NCT03934684|DRUG|Drug: Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~* Carfilzomib will be administered as a 30-minute infusion.~* Dexamethasone will be taken by mouth or intravenously."
40953816|NCT03934684|DRUG|Drug: Carfilzomib + Lenalidomide + Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~* Carfilzomib will be administered as a 10 minute infusion.~* Lenalidomide will be taken orally.~* Dexamethasone will be taken by mouth or intravenously."
40953817|NCT01254292|DRUG|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
40953818|NCT01254292|DRUG|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
40953819|NCT01706822|DEVICE|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
40953820|NCT06422767|DRUG|Bepirovirsen|Bepirovirsen will be administered.
40953821|NCT06422767|DRUG|Placebo|Placebo will be administered.
40953822|NCT00137683|BEHAVIORAL|one-on-one education, group education, small media|
40953823|NCT03186495|DRUG|Somapacitan|All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
40953824|NCT05040048|OTHER|Clinical, biological and imaging assessment|
40953825|NCT02423993|BEHAVIORAL|Education by structured programme|"Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time (CGM-RT); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients."
40953826|NCT02423993|DEVICE|CSII|The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
41290631|NCT06085365|DRUG|fluorouracil based chemotherapy regimens|fluorouracil based chemotherapy regimens
40953827|NCT02423993|DEVICE|CGM-RT|"Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month."
41290632|NCT02640612|DRUG|BI 695501|
41290633|NCT06104345|BIOLOGICAL|Oral typhoid fever vaccine|Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.
41290634|NCT06104345|BIOLOGICAL|Oral cholera vaccine|Oral cholera vaccine (Dukoral®) on Days 0 and 7.
40761244|NCT03112928|DEVICE|Phantom Motor Execution|"Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~1. Pain evaluation~2. Placement of the electrodes and fiducial marker~3. Practice of motor execution in Augmented Reality (AR)~4. Gaming using phantom movements~5. Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours."
40953828|NCT02423993|PROCEDURE|Screening for Complications|To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
41135047|NCT00609050|BEHAVIORAL|Standard Treatment|The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
40761245|NCT03112928|DEVICE|Phantom Motor Imagery|The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
40761246|NCT00605657|DRUG|Valproic Acid|Oral administration of valproic acid
40953829|NCT02423993|PROCEDURE|Glycaemic control assessment|Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
40953830|NCT02423993|PROCEDURE|QoL assessment|"For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~1. The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~2. The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003)."
40953831|NCT02423993|PROCEDURE|Knowledge assessment|For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
40953832|NCT03080454|DEVICE|sham Doublestim|PathMaker MyoRegulator device
40953833|NCT03080454|DEVICE|anodal Doublestim|PathMaker MyoRegulator device
41290635|NCT05440955|DEVICE|left fronto-temporal transcranial Direct Current Stimulation (tDCS)|"The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session."
41290636|NCT05127772|DRUG|HEC93077|Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
40761247|NCT00605657|PROCEDURE|CT Scan|CT scans were done before and after treating the patient with valproic acid
40953834|NCT04344548|BIOLOGICAL|Allogeneic NK transfer|Three doses of allogeneic NK cell transfer
40953835|NCT00219739|DRUG|Imatinib mesylate 400 mg|
40953836|NCT00219739|DRUG|Imatinib mesylate 600 mg|
40953837|NCT00219739|DRUG|Imatinib 400 mg + Peg-Interferon|
40953838|NCT00219739|DRUG|Imatinib mesylate 400 mg + Cytarabine|
40953839|NCT03489148|BEHAVIORAL|Tamarkoz®|Tamarkoz® techniques includes six key elements: clearing the mind, breathing exercises, Movazeneh® (movement and balance exercises), deep relaxation, and visualization.
40953840|NCT03489148|BEHAVIORAL|Stress management resources|Use of the campus health center's stress management resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, pet-an-animal a week, and online reading material about self-care for stress management.
40953841|NCT01937754|DIETARY_SUPPLEMENT|Nitric Oxide supplement|Lozenge consisting of beetroot and 75 mg caffeine
41290637|NCT05127772|DRUG|Placebo|Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
40761248|NCT00605657|PROCEDURE|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
40953842|NCT01937754|DIETARY_SUPPLEMENT|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
40953843|NCT02966769|OTHER|Overall survival|Compare overall survival between both groups.
41290638|NCT06511882|DRUG|Azacitidine|Standard of Care Intravenous (IV) infusion
41290639|NCT06511882|DRUG|Decitabine|Standard of Care Intravenous (IV) infusion
40953844|NCT01951937|DIETARY_SUPPLEMENT|Fish Meals|Meals containing salmon
40953845|NCT01951937|DIETARY_SUPPLEMENT|Placebo|No fish meals
40953846|NCT06259123|DRUG|[177Lu]Lu-PSMA I&T|2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy for patients with oligometastatic prostate cancer
40953847|NCT00913380|RADIATION|Diagnostic CT|2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
40953848|NCT00913380|RADIATION|Diagnostic CT|8 mSv in an average patient (Standard-dose CT)
40953849|NCT05194657|DEVICE|enhanced depth of focus IOL|Acrysof IQ Vivity, enhanced depth of focus IOL
40953850|NCT05194657|DEVICE|monofocal IOL|Acrysof IQ, monofocal IOL
41135048|NCT00609050|BEHAVIORAL|Qualitative Approach|A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
41135049|NCT02562612|DRUG|SM-88|Daily SM-88 in multiple ascending doses over 6 months
40953851|NCT04736446|DEVICE|I-gel® supraglottic device|Use of an i-gel® supraglottic device to deliver ventilations
40953852|NCT04736446|DEVICE|Face mask ventilation|Use of a face mask to deliver ventilations
40953853|NCT04910945|DEVICE|VENUS AIME (RoboCor)|VENUS AIME is a micro-coring device of the skin that can potentially help to reduce visible skin scarring, improve skin laxity and reduce wrinkles.
41135050|NCT05574309|DEVICE|Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer|Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test
41135051|NCT05574309|DEVICE|GAITRite Device|Walking parameter measured during a 10 m walking test with GaitRite device
41135052|NCT01411657|DRUG|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
41135053|NCT01419808|PROCEDURE|Vascularized Bone Graft|Vascularized bone graft in the treatment of Scaphoid Non-Union
41135054|NCT01419808|PROCEDURE|Non-Vascularized Bone Graft|Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
41135055|NCT04459572|DIAGNOSTIC_TEST|suPAR|Soluble Urokinase Plasminogen Activator Receptor (suPAR)
41135056|NCT03682614|DRUG|HCG|we will use the catheter to pass through the cervix, and after that, the experiment Group will accept 40 μl 500 IU HCG injection into the uterine cavity 2 days before the blastocyst transfer.
41135057|NCT03682614|OTHER|culture medium|The placebo group will accept 40 μl of culture medium injection into the uterine cavity 2 days before the blastocyst transfer.
41135058|NCT06287957|PROCEDURE|Labrida BioClean|Debriding the tissue around the implant with Labrida Bioclean
41135059|NCT06287957|PROCEDURE|EMS Handy 3.0 Perio Premium|Debriding the tissue around the implant with Air-Flow Device
40953854|NCT03829839|DRUG|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin
40953855|NCT03829839|DRUG|Lorazepam 1 mg|Oral administration of 1mg lorazepam
40953856|NCT03829839|DRUG|Placebo nasalspray|The placebo nasalspray contain identical ingredients except for the active agent itself.
41135060|NCT05025813|DRUG|Pembrolizumab|Delivery of neo-adjuvant Pembrolizumab
41135061|NCT01642719|BEHAVIORAL|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
41135062|NCT01642719|BEHAVIORAL|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
41135063|NCT04069806|DIETARY_SUPPLEMENT|preoperative oral carbohydrate, preOp|Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.
41135064|NCT04755504|DIAGNOSTIC_TEST|EEG behind the ear|2 additional electrodes behind each ear will record EEG
41135065|NCT05062343|DEVICE|Dilapan-S|Osmotic dilator
41135066|NCT05062343|DEVICE|Cook Cervical Ripening Balloon|Double balloon catheter for cervical ripening
41135067|NCT04350619|OTHER|Genetic screening. No therapeutic intervention|Genetic screening using NGS technique. No therapeutic intervention
41135068|NCT06509685|OTHER|Ladder Training|9 participants will perform only Ladder training exercise protocol. The training schedule included exercises such as Two foot run, Ladder traps, Lateral angle leg hops, Single leg forward hop, two-foot lateral run, Fight shuffle, Skiers, Carioca, Lateral in out, two in two out, Intermediate high knee run, Straddle squat hops, two foot laterals hop in \& out, Two-foot lateral hop, Ali shuffle, 180 Degree rotation, jumping jacks' variation, Advanced in in out, Quick hops cotch, Icky shuffle etc. For each session, ten stations were used and participants change the partner after every end of steps jumping exercise and continued each exercise at least 3 set, depending on the class design(22).
41135069|NCT06509685|OTHER|balance training|9 participants will perform balance training protocol. The balance training program includes exercises based around balance development in unilateral dynamic balancing positions. The program included balance and landing activities incorporating wobble boards and change of direction activities.
41135070|NCT00428805|BEHAVIORAL|classroom curriculum|"classroom curriculum for 3 \& 4 year old children includes activities to increase intake of fruits, vegetables, \& whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.~Teachers are trained to carry out the classroom curriculum."
41290640|NCT06511882|DRUG|Venetoclax|Standard of Care PO (By Mouth)
40953857|NCT03829839|DRUG|Placebo Oral Tablet|The placebo pill contain identical ingredients except for the active agent itself.
41290641|NCT04859491|DIETARY_SUPPLEMENT|Carbohydrate|Participants have a one in three chance of consuming a carbohydrate beverage between two bouts of high-intensity exercise.
40761249|NCT04316650|BEHAVIORAL|Evaluation Scales|"* PATHOS / PEACCE : hypersexuality diagnostic scale~* PDQ-4+: Personality Diagnostic Questionnaire version 4~* AUDIT~* Life trajectory : THQ~* Cognitive function (MoCA, Stroop)~* ISDSS: and self report of sexual activity and desire~* BARS: Brief Adhesion Rating Scale (treatment observance)~* SF-36 scale : quality of life~* BDI-II : Beck Depression Inventory~* BSSI ; Beck suicidal Inventory~* Cognitive functioning evaluation : Molest and Rape Scale~* Empathy: EMPAT~* Evaluation of Cognitive functioning: denial evaluation and Mc Kibben minimization~* Baratt Impulsivity Scale~* CSBI~* Static 99 and Stable 2007"
40953858|NCT04384783|DRUG|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
40953859|NCT06349018|OTHER|Dietary Supplement: High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
40953860|NCT06349018|OTHER|Dietary Supplement: No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
40953861|NCT05451225|BEHAVIORAL|Targeted Educational Campaign|"Correction Officers will be exposed to the Targeted Educational Campaign (TEC) with the aim to increase their knowledge about the early symptoms of psychosis, and how to make a referral to the Correction Health Services staff, their self-efficacy to detect symptoms of psychosis and make referrals, and their expectations about their ability to be successful in making that referral (and for referrals to result in beneficial outcomes).~Correction Officers will be approached and recruited during roll call and in the staff canteen where they take their meal breaks, or at a time/location agreed upon by the Department of Correction, to complete brief surveys at three different times; pre-exposure, after 6 months, and after 12 months from the beginning of the TEC."
40953862|NCT06535165|DIETARY_SUPPLEMENT|Red Beetroot Juice|200ml/d for 14 days
41290642|NCT04859491|DIETARY_SUPPLEMENT|Carbohydrate-Protein|Participants have a one in three chance of consuming a carbohydrate-protein beverage between two bouts of high-intensity exercise.
40953863|NCT06535165|OTHER|Placebo|200ml/d for 14 days
40953864|NCT05065281|OTHER|Education|Training for health care professionals on how to identify and manage cases of elder abuse among their patients
40953865|NCT02718560|BEHAVIORAL|Writing|Writing exercise with or without cues for 1 hour per day for 4 days at week for 4 weeks
40953866|NCT01403181|DRUG|Boceprevir|"In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.~Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data."
40953867|NCT00865670|DRUG|Azithromycin Monohydrate 600 mg Tablets|
41290643|NCT04859491|DIETARY_SUPPLEMENT|Placebo|Participants have a one in three chance of consuming a placebo beverage between two bouts of high-intensity exercise.
41290644|NCT02021123|DRUG|Anidulafungin 100mg single dose iv|Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
41290645|NCT03614624|DEVICE|Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips|Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
40761250|NCT04316650|OTHER|osteodensitometry|Osteodensitometry
40761251|NCT04316650|BIOLOGICAL|blood samples|"* Lipid profile (total cholesterol, triglycerides, HDL cholesterol)~* Liver function (ASAT, ALAT, total bilirubin, transferase gamma-glutamyl et alcalin phosphatases~* Kydney function~* Blood count~* Biological Measurements and Measurement of Systematic Plasma Testosterone and TeBG Levels in Sex Offenders check for pathology of the Gonadotropin Axis~* Biological Measurements of Plasma Prolactin level"
40953868|NCT00865670|DRUG|Zithromax (azithromycin dihydrate) 600 mg Tablets|
41290646|NCT04838912|BEHAVIORAL|Cool Kids (Chilled) Anxiety program adapted to children and youths with autism and anxiety disorders.|CBT program for anxiety in teenagers with autism
41290647|NCT01847144|DRUG|Gliclazide 80mg OD|Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
41135071|NCT00428805|BEHAVIORAL|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
41135072|NCT00428805|BEHAVIORAL|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
41290648|NCT01847144|DRUG|Sitagliptin 100mg OD|Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
41290649|NCT03320148|BEHAVIORAL|Physiotherapist-led primary care model for back pain|"1. Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination~2. Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~3. Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~4. Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
41290650|NCT03320148|OTHER|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
41290651|NCT05386433|DRUG|Paxlovid|"Paxlovid contains two medicines: nirmatrelvir and ritonavir. Nirmatrelvir \[PF-07321332\] is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV2 3CL protease inhibitor) that works by inhibiting viral replication in the early stages of the disease to prevent progression to severe COVID-19.~Ritonavir is co-administered with nirmatrelvir to help slow its metabolism in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus."
41454775|NCT04848090|DIAGNOSTIC_TEST|Neonate WGS Testing|"Neonates will undergo whole genome sequencing, and analysis with a targeted panel of genes likely to cause genetic disorders in the first year of life. If no diagnosis is identified, sequenced data will be analyzed using a whole exome filter. Performed in a CLIA-certified lab. Pathogenic, likely pathogenic, and VUS in genes related to the phenotype will be returned to the care team and family.~Parents will be enrolled for the purpose of trio analysis with the child to assist in determining the pathogenicity of variants in genomic sequencing. Pathogenic and likely-pathogenic findings will be reported to the parents in the setting of genetic counseling.~Sibling will be enrolled and have samples collected for use in the genetic analysis only if deemed essential. Results will be reported to the parents in the setting of genetic counseling."
41454776|NCT03124758|DEVICE|Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))|Measurement of Noninvasive Hemoglobin (SpHb)
41454777|NCT01909713|DRUG|Facial Cleanser and Moisturizer SPF 30|Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
41454778|NCT04576936|OTHER|AIRVO|Daily, at-home device use of AIRVO device in moderate to severe COPD patients.
41454779|NCT06026163|DRUG|Caffeine citrate|Caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base)
40761252|NCT04316650|OTHER|ECG|ECG (heart rate, search for cardiac conduction disorders or cardiac arrhythmias)
40761253|NCT04316650|GENETIC|Blood and saliva samples|Blood and saliva samples
40761254|NCT00247039|DIETARY_SUPPLEMENT|Solgar Israel|Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
41290652|NCT05386433|DRUG|standard-of-care|standard-of-care of COVID-19
41290653|NCT02792777|OTHER|Interviews|Patients will be engaged in open-ended, semi-structured qualitative interviews, which will be performed one-on-one either in person or over the phone (depending on the healthcare setting that they are recruited from). Qualitative interviews will be audio recorded, with the patient's permission, transcribed, de-identified and entered into NVivo software for coding and analysis.
41454780|NCT06026163|OTHER|Placebo|Equivalent volume of saline
41454781|NCT00452348|DRUG|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
41454782|NCT00452348|DRUG|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
41454783|NCT02123823|DRUG|Everolimus|10mg dose
41454784|NCT02123823|DRUG|Everolimus|at recommended dose as per Phase I data
41454785|NCT02123823|DRUG|Everolimus|Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg
41454786|NCT02123823|DRUG|Exemestane|Fixed dose at 25mg
41454787|NCT02123823|DRUG|BI 836845|Human monoclonal antibody at recommended dose as per Phase I data
41454788|NCT02123823|DRUG|BI 836845|Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I. 2 dose levels (high or low) depending on the dose cohort explored
41454789|NCT02123823|DRUG|Exemestane|Fixed dose at 25mg
41454790|NCT02123823|DRUG|Exemestane|Fixed dose at 25mg
41454791|NCT02227238|DRUG|DTG|DTG is supplied as 50 mg tablets
41454792|NCT02227238|DRUG|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
40761255|NCT00247039|OTHER|Placebo capsules|placebo capsules
41135073|NCT00428805|BEHAVIORAL|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
41454793|NCT02227238|DRUG|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
41454794|NCT02937207|DRUG|Ke Chuan Liu Wei Mixture|Experience formula of famous traditional Chinese professor Yingen Wu
41454795|NCT02937207|DRUG|Chuan Xiong Ping Chuan Mixture|Experience formula of famous traditional Chinese professor Changrong Shao
40761256|NCT06240455|DRUG|WP1302|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
40761257|NCT06240455|DRUG|WP1302 placebo|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
40761258|NCT06240455|COMBINATION_PRODUCT|methimazole|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
41454796|NCT02937207|DRUG|Xie Wu Capsule|Experience formula of famous traditional Chinese professor Jianhua Hu
41454797|NCT02937207|DRUG|Dan Ma Jia Tablet|Experience formula of famous traditional Chinese professor Xiaopu Xu
40761259|NCT05703165|BEHAVIORAL|animal-assisted intervention|horse-assisted intervention
40761260|NCT05703165|BEHAVIORAL|watching the countryside|just watching the countryside
41135074|NCT00428805|BEHAVIORAL|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
41454798|NCT02937207|DRUG|Zhi Chuan Capsule|Experience formula of famous traditional Chinese professor Yingen Wu
41454799|NCT02937207|DRUG|Bu Shen Na Qi Granule|Experience formula of famous traditional Chinese professor Changrong Shao
41454800|NCT02937207|DRUG|Ke Chuan Liu Wei Mixture placebo|Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
41454801|NCT02937207|DRUG|Chuan Xiong Ping Chuan Mixture placebo|Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
41454802|NCT02937207|DRUG|Xie Wu Capsule placebo|Low dose combination for treating prescription of Xie Wu Capsule
41454803|NCT02937207|DRUG|Dan Ma Jia Tablet placebo|Low dose combination for treating prescription of Dan Ma Jia Tablet
41454804|NCT02937207|DRUG|Zhi Chuan Capsule placebo|Low dose combination for treating prescription of Zhi Chuan Capsule
41454805|NCT02937207|DRUG|Bu Shen Na Qi Granule placebo|Low dose combination for treating prescription of Bu Shen Na Qi Granule
41454806|NCT01437735|DRUG|QAW039|QAW039 po
40953869|NCT04794309|OTHER|Circuit training exercise|"circuit training exercise start with 5 minutes of warming-up then followed by a 30-minute conditioning protocol formed 20 minutes of aerobic exercise and 10 minutes of resisted exercise. The cool-down period is doing in form of walking on a treadmill in low intensity for 5 minutes.~Aerobic exercise will be performed on an electronically-braked cycle ergometer (Quinton Excalibur, QuintonInstrument Company, Bothell, WA). resistance exercise (RT) in the form of eight different exercises will be performed during each workout: military press, leg extension, bench press, standing leg curl (ankle weights), lateral pull-down, dumbbell triceps push-down, dumbbell seated biceps curl, and sit-ups (abdominal curls).~The participant will do 10 minutes for Aerobic exercise followed by 10 minutes of resistance exercise then 10 minutes for Aerobic exercise. This cycle training will perform five days per week for eight weeks."
41454807|NCT01437735|DRUG|Montelukast|Montelukast 10 mg po
40761261|NCT05185453|BEHAVIORAL|Strengthening Connections for Change|Strengthening Connections for Change is a 12-session curriculum designed to strengthen adolescent-adult support networks, build leadership skills, foster community engagement, and challenge attitudes and behaviors that foster violence involvement. During the program, youth ages 13-17 years invite their self-identified key adult supports to jointly participate in programming including youth-focused, adult-focused and jointly focused activities. Towards the end of programming participants design and carry out a community project to strengthen intergenerational connections and promote community engagement.
40761262|NCT05185453|BEHAVIORAL|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
40761263|NCT05967065|DIAGNOSTIC_TEST|vibration induced nystagmus test|Vibration induced nystagmus test by bone transducer B250.
40761264|NCT05836909|DIETARY_SUPPLEMENT|Swisse plus cholesterol capsule|Swisse plus cholesterol capsule per day orally for 12 weeks
40761265|NCT05836909|DIETARY_SUPPLEMENT|Placebo|Placebo
40761266|NCT05547542|DRUG|CVL-354|Oral solution/capsule
40761267|NCT05547542|DRUG|[11C]-LY2795050|IV injection
40761268|NCT05547542|DRUG|[11C]-carfentanil|IV injection
40761269|NCT01527955|OTHER|Kelee Meditation|The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.
40761270|NCT01817946|OTHER|Genetic Testing|Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
40761271|NCT03517358|OTHER|Service of care|Subjects will be receiving care from case management or clinical pharmacy.
40761272|NCT01166698|DRUG|AZD9819|Inhaled single doses of suspension via SPIRA nebuliser
40761273|NCT01166698|DRUG|AZD9819|Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
40761274|NCT01166698|DRUG|Placebo|Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
40761275|NCT01430715|OTHER|Active vido games and outdoor play|Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, \> 5th % to \< 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
40761276|NCT05198661|BIOLOGICAL|Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.|"Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC.~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7\*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection"
40761277|NCT01787747|DRUG|AVP-786 Dose 1|
40761278|NCT01787747|DRUG|AVP-786 Dose 2|
40761279|NCT01787747|DRUG|AVP-786 Dose 1/Q Dose 1|
40953870|NCT04794309|DIETARY_SUPPLEMENT|Healthy high Fiber diet|The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.
41135075|NCT00428805|BEHAVIORAL|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
41135076|NCT00428805|BEHAVIORAL|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
41454808|NCT01437735|DRUG|Placebo|Placebo
41454809|NCT06177743|DEVICE|Coroflex ISAR NEO stent|Percutaneous coronary intervention with Coroflex ISAR NEO stent
41454810|NCT03138044|PROCEDURE|Combined Treatment|This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (\> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.
40761280|NCT01787747|DRUG|AVP-786 Dose 1/Q Dose 2|
41290654|NCT02792777|OTHER|Concept Mapping (CM)|"The CM process consists of 3 steps that take place over 3 sessions:~Step 1: Generation of Ideas- Participants brainstorm and generate responses to the focus statement. Once the group agrees that no new statements are being generated, the list of statements is reviewed within the group.~Step 2: Structuring of Statements- Each participant is given a set of sort cards and asked to sort the statements into piles. Participants then rate each idea regarding importance. Research staff enters this information into the CM software.~Concept Systems Global Software generates point maps using a technique that detects underlying similarities/differences between statements. The CM software then uses hierarchical cluster analysis to draw boundaries around the point map to create conceptual clusters.~Step 3: Interpretation- The CM group revises the concept map. Participants review the cluster names suggested by the software and decide upon final naming of each cluster as a group."
40761281|NCT01787747|DRUG|AVP-786 Dose 2/Q Dose 2|
40761282|NCT01787747|DRUG|AVP-923|
41290655|NCT03341403|DIETARY_SUPPLEMENT|Probiotical®/Bactecal®|"Probiotical/Bactecal® is composed of: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill."
41290656|NCT03341403|OTHER|Placebo|pills containing placebo
41290657|NCT01729832|PROCEDURE|breast reconstruction|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
41290658|NCT01729832|PROCEDURE|intraoperative imaging|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
41290659|NCT03451825|DRUG|Avelumab|Participants received an intravenous infusion of avelumab 10mg/kg intervention (IV) once every 2 weeks until confirmed progression, death, unacceptable toxicity, or any criterion for withdrawal occurred.
41290660|NCT03451825|DRUG|Avelumab|Participants received an intravenous infusion of avelumab 20mg/kg intervention (IV) once every 2 weeks until confirmed progression, death, unacceptable toxicity, or any criterion for withdrawal occurred.
40761283|NCT01100580|DIETARY_SUPPLEMENT|low salt diet|Daily salt intake less than 4 g/day
40761284|NCT01100580|DIETARY_SUPPLEMENT|water therapy|abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
40761285|NCT06164301|DIETARY_SUPPLEMENT|Elemental amino-acids|mono peptide oral protein formula
40761286|NCT02399995|BEHAVIORAL|HRQoL questionnaires.|"Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~* Baseline sociodemographic and clinical variable data sheet (RSA)~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Post surgical follow up disease status and treatment assessment questionnaire~* At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone."
40761287|NCT02995200|BEHAVIORAL|Accelerometer Based Feedback|
40761288|NCT05753228|OTHER|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.
40761289|NCT05753228|OTHER|Chalder Fatigue Scale|The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.
40761290|NCT05753228|OTHER|Health Questionnaire (EQ-5D-5L)|"The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems."
40761291|NCT05753228|OTHER|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
40761292|NCT01652157|BIOLOGICAL|ULTRESA|pancreatic enzyme replacement therapy
40761293|NCT01652157|BIOLOGICAL|PANCREAZE|pancreatic enzyme replacement therapy
40761294|NCT01652157|BIOLOGICAL|CREON|pancreatic enzyme replacement therapy
40761295|NCT01652157|BIOLOGICAL|ZENPEP|pancreatic enzyme replacement therapy
40953871|NCT01145625|DRUG|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
41135077|NCT02412904|DRUG|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
41290661|NCT03427775|COMBINATION_PRODUCT|multimodal perioperative pain protocol (MP3)|administration of gabapentionoid, acetaminophen, non steroidal anti-inflammatory drugs around the clock in addition to the peripheral nerve block offered before surgery
41290662|NCT00480194|DRUG|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
41290663|NCT01253460|DRUG|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
41290664|NCT01253460|DRUG|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
41290665|NCT01253460|DRUG|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
40761296|NCT01652157|BIOLOGICAL|other non-sponsor pancreatic enzyme replacement therapy|pancreatic enzyme replacement therapy
40761297|NCT01652157|BIOLOGICAL|PERTZYE|pancreatic enzyme replacement therapy
40761298|NCT01652157|OTHER|No pancreatic enzyme replacement therapy|Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
40953872|NCT01145625|DRUG|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
41290666|NCT05882162|PROCEDURE|Coronectomy|Removal of crown part of the mandibular third molar
41290667|NCT05882162|PROCEDURE|Pulp Capping with calcium silicate|Application of a pulp capping material (BiodentineTM, Septodont, St Maur-des-Fosses, France) on pulp tissue to preserve the vitality of the residual pulp and prevent inflammation
41290668|NCT06065722|DRUG|Akynzeo|OLANZAPINE
41290669|NCT06361459|BEHAVIORAL|Stop smoking|Sine fuma program is offered. nicotine is checked in urine
41290670|NCT05430659|OTHER|observational study|Retrospective observational study
41290671|NCT02240498|DRUG|Methylene Blue|Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
41290672|NCT02240498|DRUG|20% I.V. Fat Emulsion|The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
40761299|NCT05580679|OTHER|Abdominal massage|"Application time of the massage: 30 minutes after meals, twice a day, at 10:00 in the morning and at 16:00 in the evening.~Application time of the massage: 15 minutes each Materials needed: Gloves, Liquid Vaseline, Paper Towel Massage methods used: Efflorage, Petrissage, Vibration"
40953873|NCT02652832|DEVICE|non invasive brain stimulation|non invasive brain stimulation
40953874|NCT02866708|DEVICE|Intermittent negative pressure device|This intervention study will be designed as a randomized cross-over study.
40953875|NCT05568823|OTHER|Blood sampling|Measurement of markers of disease evolution
40953876|NCT03212924|BEHAVIORAL|Pupillometry|Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.
40953877|NCT03212924|BEHAVIORAL|Evaluation of speech comprehension in quiet|Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
40761300|NCT02254460|DIETARY_SUPPLEMENT|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
40761301|NCT02254460|OTHER|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
40953878|NCT03212924|BEHAVIORAL|Evaluation of speech comprehension in noise|Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
41290673|NCT02240498|DEVICE|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
41290674|NCT02240498|DEVICE|Laser illumination, 5 minutes|Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
41290675|NCT02240498|DEVICE|Laser illumination, 10 minutes|Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
40761302|NCT01338597|PROCEDURE|endoscopic thyroidectomy|endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
40953879|NCT03212924|BEHAVIORAL|MOCA|The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.
40953880|NCT03212924|BEHAVIORAL|auto evaluation of listening effort in quiet|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
40953881|NCT03212924|BEHAVIORAL|auto evaluation of listening effort in noise|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
41290676|NCT02240498|DEVICE|Laser illumination, 15 minutes|Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
41290677|NCT02240498|DEVICE|Laser illumination, 20 minutes|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
41290678|NCT02240498|DEVICE|Laser illumination, 25 minutes|Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
41454811|NCT06227741|OTHER|Concept Mapping: as a Tool for Problem Based Learning|Concept mapping is a visual representation and organizational tool that illustrates the relationships between concepts, ideas, and information. It involves creating a graphical depiction of knowledge, typically using nodes or boxes to represent concepts and connecting lines or arrows to signify the relationships between them. The central concept or main idea is often positioned in the center of the map, with subsidiary concepts branching out from it. These maps serve as a comprehensive overview of a subject, highlighting the hierarchical structure and interconnectedness of various elements.
41454812|NCT04401137|DRUG|Topiramate|Topiramate
40953882|NCT03380715|DEVICE|Nasal nebulisation into the right nostril|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
40953883|NCT03380715|DEVICE|Nasal Spray into the right nostril|Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray
41454813|NCT00466531|BIOLOGICAL|therapeutic autologous lymphocytes|
41290679|NCT02240498|DEVICE|Laser illumination, 30 minutes|Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
41290680|NCT02240498|DEVICE|Optical spectroscopy measurement|A fiber-optic probe that has undergone high-level disinfection will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity white light will be delivered by a tungsten halogen lamp by a single fiber within the probe, and detected by eight other fibers within the probe. Following this, low-power laser light will be delivered by a fiber-coupled laser diode at 640 nm in order to excite methylene blue fluorescence. Emitted fluorescence will similarly be collected by the eight detection fibers contained within the probe. Upon completion of these measurements, the fiber-optic probe will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
41454814|NCT00466531|DRUG|cyclophosphamide|
41454815|NCT04156737|DEVICE|TECNIS Symfony plus IOL Model ZHR00V|IOL replaces the natural lens removed during cataract surgery
41454816|NCT04156737|DEVICE|Trifocal Intraocular lens|IOL replaces the natural lens removed during cataract surgery
41454817|NCT04174560|BIOLOGICAL|Norovirus GII.4 Challenge Pool|Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.
41454818|NCT02764853|BEHAVIORAL|Experimental Intervention (STEP-AD)|This experimental intervention will consist of 10 sessions- 1 session of Lifesteps (problem solving for medication adherence) and 9 sessions of an intervention specifically tailored for Black women living with HIV to address trauma/abuse, racial discrimination, HIV stigma, and gender roles expectations in order to improve health outcomes (e.g., medication adherence, viral load), increase resiliency, and enhance adaptive coping strategies.
41454819|NCT02764853|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the E-TAU condition will receive 1 session of Lifesteps (problem solving for medication adherence) and appropriate services and referrals as needed
41454820|NCT02867358|DRUG|KT07 Capsule|
41454821|NCT02867358|OTHER|Placebo|
41454822|NCT05128136|DEVICE|Impact of ring size on adherence|The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.
40761303|NCT03539614|DRUG|Prazosin|This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.
40761304|NCT03539614|DRUG|Placebo|This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
40761305|NCT03366831|BEHAVIORAL|Thirty Million Words Initiative Newborn Intervention|The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.
40761306|NCT02909114|RADIATION|Stereotactic body radiotherapy|"All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT"
40761307|NCT06477601|OTHER|Assigning cooling agent type cigarettes|This study is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol cigarettes but allows cooling agent cigarettes.
40761308|NCT06477601|OTHER|Assigning traditional tobacco type cigarettes|This comparison group is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol and cooling agent cigarettes.
40761309|NCT06477601|OTHER|Assigning menthol type cigarettes|This comparison group is for where the Food and Drug Administration does not ban menthol cigarettes.
40761310|NCT01882829|DRUG|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
40761311|NCT01821872|DRUG|Administration of paracetamol|Administration of 1g intravenous paracetamol
40761312|NCT01641055|DIETARY_SUPPLEMENT|Salmon protein hydrolysate|2.5g salmon protein hydrolysate per day for 8wk.
40761313|NCT01641055|DIETARY_SUPPLEMENT|Herring protein hydrolysate|2.5g herring protein hydrolysate per day for 8wk.
40761314|NCT01641055|DIETARY_SUPPLEMENT|Cod protein|2.5g cod protein per day for 8wk.
40761315|NCT01641055|DIETARY_SUPPLEMENT|Milk protein|2.5g milk protein per day for 8wk.
40761316|NCT04126785|OTHER|High Intensity Interval Exercise in Heated Water-Based|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
40761317|NCT04126785|OTHER|Continuous Moderate Exercise in Heated Water-Based|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light)level of RPE.
40761318|NCT04126785|OTHER|Control Group|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the until xiphoid process level for 30 min.
40953884|NCT02434978|DEVICE|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
40953885|NCT02434978|DRUG|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
41135078|NCT02412904|DRUG|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
41135079|NCT03066921|DIETARY_SUPPLEMENT|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
41135080|NCT03066921|DIETARY_SUPPLEMENT|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
41135081|NCT03590496|DIETARY_SUPPLEMENT|Calcium-Propionate 500mg|Calcium-Propionate capsules
41135082|NCT03590496|OTHER|Placebo|Placebo capsules without any active ingredient
41135083|NCT03590899|DEVICE|Optical coherence tomography angiography (Zeiss Cirrus HD OCT 5000 AngioPlex)|Non-invasive, non-contact optical coherence tomography angiography scans of the retina are done per built-in device protocol using the Zeiss Cirrus HD OCT 5000 AngioPlex machine.
41135084|NCT02191670|DRUG|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
41135085|NCT05673551|OTHER|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
41135086|NCT00666705|DRUG|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
41135087|NCT00666705|DRUG|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
41135088|NCT00666705|DRUG|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
41135089|NCT00666705|DRUG|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
41135090|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
41135091|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
41135092|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
41135093|NCT00637858|DIETARY_SUPPLEMENT|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
41135094|NCT00637858|OTHER|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
41290681|NCT05518591|BEHAVIORAL|Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR)|Study participants in the experimental arm of the study are being asked to take part in a 6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining. Each group session lasts less than two hours, per week.
41290682|NCT01212328|OTHER|Care Coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
40953886|NCT02434978|OTHER|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
40953887|NCT02040948|DEVICE|- Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)|
40953888|NCT03823508|DEVICE|anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and a high density EEG. The anode will be placed over F3 in order to stimulate the left dorsolateral prefrontal cortex and the cathode over the right supraorbital area.
40761319|NCT06569225|DRUG|Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig|: Patients will receive prior to surgery: 2 cycles of combinational therapy with Gemcitabine (800mg) /Cisplatin (25mg) /Nab-Paclitaxel (100mg) and Rilvegostomig (Q3W). Post-surgical resection, adjuvant therapy will consist of 4 cycles of Gemcitabine (1000mg) /Cisplatin (25mg) and Rilvegostomig (Q3W). Rilvegostomig (Q3W) will be continued for a total of 12 months in the adjuvant phase
40953889|NCT03823508|DEVICE|sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
40953890|NCT04696055|DRUG|Pembrolizumab|Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).
40761320|NCT01933555|BEHAVIORAL|Empowerment Program|
40761321|NCT05270031|DEVICE|Balloon dilation of the eustachian tube|Balloon dilation of the eustachian tube
40953891|NCT04696055|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.
40953892|NCT04057612|OTHER|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
40953893|NCT04057612|OTHER|Carotid artery temperature monitoring|Measuring temperature on skin near to carotid artery using 3M™ Bair Hugger™ temperature monitoring system
40953894|NCT00398918|DRUG|zonisamide|zonisamide (100 mg)one time
40953895|NCT00398918|DRUG|Placebo|Placebo Comparator
40953896|NCT06209931|PROCEDURE|RIRS|RIRS with tip flexible pressure-controlling ureteral access sheath versus mini PCNL for the treatment of 2-3-cm kidney stones
40953897|NCT02056938|DRUG|Anti-Thymocyte Globulins treatment|
40953898|NCT02056938|DRUG|Basiliximab treatment|
40953899|NCT03198078|DRUG|Brexpiprazole (OPC-34712)|Once-daily, tablets
40953900|NCT03198078|DRUG|Aripiprazole|Once-daily, tablets
40953901|NCT03198078|DRUG|Placebo|Once-daily, tablets
40953902|NCT00659048|DRUG|Ciclesonide|Ciclesonide 200µg versus Placebo
41135095|NCT04072133|BEHAVIORAL|Meditative Movement|Intervention will be taught by a certified Tai Chi Easy (TCE) group practice leader. The TCE movements will be repeated in differing sequences and time-frames during the course of the study. The variety and combination of the exercises will begin easy and progress to more advanced movements and/or intensities as the study progresses and participants become more experienced and comfortable with the routine. Participants spend one hour in class each week for a total of eight weeks.
41135096|NCT01232166|OTHER|Auscultation|
41135097|NCT01232166|OTHER|Observation of symmetric chest movements|
41135098|NCT01232166|OTHER|Tube depth|
40953903|NCT00659048|DRUG|Placebo|placebo
40953904|NCT04824352|DRUG|apatinib|Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA \< 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
41135099|NCT01232166|OTHER|All three|
40761322|NCT04990947|OTHER|lifestyle / RYGB|No intervention, just 2 different groups will be included
40761323|NCT04106635|PROCEDURE|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
40953905|NCT05456165|DRUG|GRT-C901|An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.
40953906|NCT05456165|DRUG|GRT-R902|An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.
40953907|NCT05456165|DRUG|Atezolizumab|Dose of 1680 mg administered once every 4 weeks (Q4W) via intravenous (IV) infusion at Visits 1-13.
41135100|NCT02533232|DRUG|Minocycline|Minocycline 200mg per day
41135101|NCT05958966|OTHER|E-cigarette e-liquid self-administration|Participant will self-administer an experimenter-provided e-cigarette.
41135102|NCT01147471|DEVICE|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
40953908|NCT05456165|DRUG|Ipilimumab|Dose of 30 mg administered via subcutaneous (SC) injection only with the first dose of GRT-C901 at Visit 1 and GRTR902 at Visit 2.
40953909|NCT05456165|DRUG|Adjuvant chemotherapy|Administered according to standard of care.
40953910|NCT05059795|DRUG|Albumin|Type of resuscitation fluid, dose and use of inotrope
40953911|NCT03421535|PROCEDURE|Sleeper Stretch|Internal Range of motion of dominant shoulder
41135103|NCT01147471|PROCEDURE|operative rib fixation surgery|
41290683|NCT01212328|OTHER|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
40953912|NCT03421535|PROCEDURE|Opposite SI joint Stretch|Internal range of motion of dominant shoulder
40953913|NCT05668884|COMBINATION_PRODUCT|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
40953915|NCT00957554|DRUG|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
40953916|NCT00957554|DRUG|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
40953917|NCT04862117|DEVICE|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
40953918|NCT04773756|DRUG|Sofosbuvir 400 MG/ Daclatasvir 60mg|Giving these two drugs for treatment of COVID patients
40953919|NCT03572244|DEVICE|Laser-Lok|A microgrooved abutment will be placed
40953920|NCT03572244|DEVICE|Machined|A machined transmucosal healing abutment will be placed
40953921|NCT04078178|DIETARY_SUPPLEMENT|Niagen|Vitamin B3
41290684|NCT02127112|PROCEDURE|Block Allograft plus Matrix Allograft|A cancellous block allograft plus a demineralized bone matrix allograft will be used as the positive control treatment.
41290685|NCT02127112|PROCEDURE|Moldable Matrix Allograft|The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
40761324|NCT04106635|PROCEDURE|Cricoid pressure|To apply cricoid pressure, the cricoid cartilage is compressed by 30N force with a single-handed three finger maneuvre towards the vertebral bodies.
40761325|NCT03921528|BIOLOGICAL|SRK-015|SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.
40761326|NCT06571552|PROCEDURE|Single Plasma Exchange followed by Double Filtration Plasmapheresis|Double Filtration Plasmapheresis followed by Single Plasma Exchange
40761327|NCT04706325|OTHER|ACUTE KIDNEY INJURY|KDIGO LEVELS
40761328|NCT03989284|BEHAVIORAL|Community-based depression interventions|We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
40761329|NCT04910165|DRUG|Exparel|Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
40761330|NCT04910165|DRUG|Ropivacaine|Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
40761331|NCT04005833|DIAGNOSTIC_TEST|spirometry|The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.
40761332|NCT00456365|DRUG|pravastatin|Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
40761333|NCT00456365|DRUG|Placebo|Placebo daily
40761334|NCT00310141|BEHAVIORAL|Smoking cessation intervention|6 weeks of computer delivered treatment for quitting smoking
40761335|NCT00310141|OTHER|Counseling intervention|In-person counseling (5 sessions)
40761336|NCT00310141|DRUG|Nicotine patch|6-week supply of the nicotine patch
40761337|NCT01017900|PROCEDURE|local excision|surgical excision by orthopaedic surgeon under local anesthesia
40761338|NCT04067622|DEVICE|Exersides|A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.
40761339|NCT03002857|DEVICE|LMA-C|LMA-C will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
40761340|NCT03002857|DEVICE|Baska Mask|Baska Mask will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
40953922|NCT04988139|OTHER|individualized educational training|50 min per session, one session per week, 4 sessions per month, of individualized educational training to preschool children with developmental delays under traditional rehabilitation programs
40953923|NCT04261868|DEVICE|Virtual Reality|New treatment for amblyopia therapy using playing games
40953924|NCT04261868|OTHER|Patching|Patching
41290686|NCT00499993|DRUG|lanreotide (Autogel formulation), duration of treatment 46-48 weeks|
41290687|NCT04245124|OTHER|Strategic Memory Advanced Reasoning Training|SMART focuses on three metacognitive strategies: Strategic Attention, Integrated Reasoning and Innovation.
40761341|NCT03002857|DEVICE|I-gel|I-gel LMA placement will be done as suggested in supine position with a standard gel pillow under patients head.
40761342|NCT06569095|OTHER|Multiparametric Flow Cytometry for the detection of Myelodysplastic syndromes with Measurable residual disease|To observe whether multiparametric flow cytometry for the detection of bone marrow and peripheral blood MRD monitoring can predict the prognosis of MDS patients
40761343|NCT05498909|OTHER|Multidisciplinary joint diagnosis and treatment mode|Multidisciplinary joint diagnosis and treatment mode,break down barriers and treat the heart and brain together
40761344|NCT00434811|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|200 ml suspension of allogenic human purified islets
40761345|NCT00434811|BIOLOGICAL|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
40761346|NCT00434811|DRUG|Sirolimus|Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
40953925|NCT02037360|BEHAVIORAL|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
40953926|NCT02037360|BEHAVIORAL|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
40953927|NCT06442280|DRUG|Dapagliflozin tablet|Dapagliflozin 10 mg 1 tablet once daily
40953928|NCT06442280|DRUG|Hypertonic Saline Solution, 1 Ml|Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
40953929|NCT06442280|DRUG|Furosemide Injection|Furosemide 20 mg
40953930|NCT02703831|PROCEDURE|Dual attending|Two attending spine surgeons perform surgery
40953931|NCT02703831|PROCEDURE|Single Attending|One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
40953932|NCT00931879|DRUG|omega-3-ethyl esters|Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (\>500 mg/dL) triglyceride (TG) levels in adult patients.
41454823|NCT04807595|OTHER|None (Observational study)|The data source for this project will be HER2 IHC historical scores, local lab rescoring of historical HER2 fixed tissue slides, independent central retesting or local lab retesting (under special occasions) of HER2 IHC status for enrolled patients who have available tissue, other biomarker testing results based on historical testing and/or testing of archived tissue samples when available, and curated patient-level data. Real-world data sources include electronic health records/electronic medical records (EHR/EMR) and biobank registries. Data from EHR/EMR sources will be curated. Biobank tissue for enrolled patients who have multiple samples available will be selected consecutively when possible and will start with the latest available samples then move backward in time.
41454824|NCT01618513|DRUG|Sandostatin® LAR|Intramuscular injections, dosage based on either GH or IGF-I levels.
41454825|NCT01173536|DRUG|GDC-0449|Oral repeating dose
40761347|NCT00434811|DRUG|Tacrolimus|On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
40761348|NCT00434811|BIOLOGICAL|Etanercept|Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
40761349|NCT00434811|PROCEDURE|Islet Transplantation|Transplantation of pancreatic islet cell
40761350|NCT00434811|BIOLOGICAL|Basiliximab|Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
40761351|NCT06232954|DEVICE|Mossie-Go containing treated transfluthrin disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with repellent discs impregnated with transfluthrin and a carrier oil. These discs sit above a fan that is powered by a small motor charged by solar energy. The device is expected to both prevent bites and cause some mortality to mosquitoes when switched on for 8-12 hours overnight for up to 1 calendar month. The discs then need to be replaced.
40761352|NCT06232954|DEVICE|Mossie-Go containing untreated blank disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with a blank untreated disc. These discs sit above a fan that is powered by a small motor charged by solar energy. The device containing the untreated disc is not expected to prevent mosquito bites. The discs will still be replaced monthly for blinding purposes.
41135104|NCT06144437|DIAGNOSTIC_TEST|Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Gastroscopy will be completed and reported by experienced endoscopists, requiring no more than 1 month between gastroscopy and ultrasound examination, and patients should fast for at least 8 hours before gastroscopy."
40761353|NCT00982579|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
40761354|NCT06253312|PROCEDURE|Open surgery|Patients with complex TASC C and D aortoiliac occlusive disease undergoing open surgery: aortobifemoral bypass, crossover bypass, axillobifemoral bypass, aortoiliac endarterectomy, iliofemoral bypass
40761355|NCT06253312|PROCEDURE|Hybrid repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing simultaneous open surgical femoral artery reconstruction (endarterectomy, bypass, profundoplasty) and stenting of the iliac axis
40761356|NCT06253312|PROCEDURE|Endovascular repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing total endovascular repair using different material: bare metal stents (self and balloon expandable), stent-grafts (self and balloon expandable), covered endovascular reconstruction of aortic bifurcation (CERAB), simple plain old balloon angioplasty (POBA)
41290688|NCT04245124|OTHER|Traditional Cognitive Rehabilitation|Participants randomized to the TCR condition will participate in a clinician-directed intervention that provides manualized, traditional clinician-directed cognitive rehabilitation that was developed for the SCORE trial (Cooper et al., 2017)
41290689|NCT03993743|BIOLOGICAL|CD147-CART|Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
41290690|NCT01586663|DEVICE|Serial night time position splint|This group will use a serial night time position splint, adjusted monthly, during three months.
41454826|NCT01173536|DRUG|moxifloxacin|Oral single dose
41454827|NCT01173536|DRUG|placebo|Oral repeating dose
41454828|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
41454829|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
40761357|NCT01310751|DRUG|iloprost nebuliser solusion|50 ng/kg/min inhalation for 10 minutes, q2h for 2 days
40761358|NCT01310751|DRUG|distilled water|2 ml per session
40761359|NCT04996745|BEHAVIORAL|Tablet-based educational intervention|"POSNA's Orthokids website and the article on pediatric forearm fracture will be provided on a tablet. The article provided has two separate tabs, labeled Condition and FAQs, that caregivers will be able to read through. Those who speak Spanish will have the Spanish translated version of Orthokids."
40761360|NCT02848027|BIOLOGICAL|Regenexx SD® procedure|Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
40761361|NCT05440565|DIAGNOSTIC_TEST|Fecal immunochemical test|Fecal immunochemical test can concentrate the high-risk population.
40761362|NCT05440565|DIAGNOSTIC_TEST|APCS score|APCS score can concentrate the high-risk population.
40761363|NCT05552573|BIOLOGICAL|low-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of low-dose(30µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
40761364|NCT05552573|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO Cell)|This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.
40953933|NCT00931879|DRUG|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
40953934|NCT00400764|DRUG|Dulanermin|Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
40953935|NCT00400764|DRUG|Rituximab|Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.
40953936|NCT01581775|DRUG|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
40953937|NCT01629992|OTHER|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
40953938|NCT02187744|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
40953939|NCT02187744|DRUG|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
40953940|NCT02187744|DRUG|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
41135105|NCT05489913|OTHER|cardiac rehabilitation support program|First of all, a preliminary interview was made with the patients in the experimental group, and their information needs were evaluated individually. Which trainings he should receive and his priorities were determined with the patient. After the training requirements were determined, the general introduction of the website was made and they were allowed to register. Experimental group patients received both training on the website and counseling over the phone for 12 weeks after they started working. A total of 3 phone calls were made with the patients in the first week, 4th and 8th weeks. The interviews lasted an average of 20 minutes. In each phone call, patients were informed and reminded. When patients needed, an average of 2-3 more phone calls were made and information was provided on the subjects they needed.
41135106|NCT06228053|DRUG|SX-682|Specified dose twice daily
41135107|NCT06228053|DRUG|Enzalutamide|Specified dose once daily
41135108|NCT01429285|DRUG|Hydromorphone|0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose
41135109|NCT01429285|DRUG|Usual care|Attending administers any IV opioid in any dose he chooses
41290691|NCT01586663|DRUG|Drug treatment|This patients will keep there drug treatment and will receive their splints on the end of the study.
41290692|NCT06019143|BEHAVIORAL|Goal Attainment Scaling (GAS) with a goal inventory|Goal Attainment Scaling (GAS) with a goal inventory (list of common goals) as a behavioral interventional tool
40761365|NCT05552573|BIOLOGICAL|high-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of high-dose(60µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
40761366|NCT05040932|DRUG|YH004|IV infusion once every 3 weeks (Q3W).
40761367|NCT04323566|DRUG|Rituximab|"Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~* administered iv over a course of max 180 minutes~* at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)"
40761368|NCT00517114|DRUG|Rabeprazole 20mg twice daily|
40761369|NCT06284304|RADIATION|De-escalated radiotherapy|5 fraction de-escalated dose SBRT protocol
40761370|NCT05313373|OTHER|Virtual Reality|In addition to the routine procedure, virtual reality glasses will be applied to the women in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After being taken to the gynecological table for the HSG procedure, the women included in the experimental group will be made to watch a video lasting an average of 10 minutes with virtual reality glasses until the procedure is completed. While watching the video, the relaxing music of the video will be played.
40761371|NCT06511648|DRUG|Erdafitinib monotherapy|Patients will receive treatment with erdafitinib alone (cohort 1)
40761372|NCT06511648|DRUG|Cetrelimab and Erdafitinib combination|Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
40761373|NCT05114057|OTHER|Renal Angina Index (RAI)|Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury
40761374|NCT05544409|DEVICE|MAKv1|1 hour sessions with the MAKv1 exoskeleton, thrice per week during 1 month
40761375|NCT04309266|DEVICE|Amadeo by Tyromotion|Distal upper extremity/hand robot for robot-assisted therapy
40761376|NCT04309266|BEHAVIORAL|Active Learning Protocol for Stroke|Metacognitive approach involving active problem solving for using the affected upper extremity in motoric activities. Also includes a home program.
40761377|NCT03582085|BIOLOGICAL|Bacillus Calmette Guerin Vaccine|Experimental
40761378|NCT03582085|BIOLOGICAL|Saline Injection|Placebo
40761379|NCT04421001|DEVICE|I-port use|patient will use I-port device fo 2 months
40761380|NCT05292703|OTHER|Participatory activity based on art and olfactory stimulation|practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities.
40953941|NCT02187744|BIOLOGICAL|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
40953942|NCT02187744|DRUG|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
40761381|NCT05292703|OTHER|practicing art virtually in conjunction with olfactory identification|"For the remote group, , they will receive the connection link to the internet application and an individual connection code.~The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop.~The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks."
40761382|NCT01927848|DIETARY_SUPPLEMENT|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
40761383|NCT01927848|DIETARY_SUPPLEMENT|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
40953943|NCT02187744|DRUG|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
40953944|NCT04032652|PROCEDURE|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
40953945|NCT04032652|DRUG|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
40953946|NCT01139983|GENETIC|DNA analysis|
41135110|NCT02661932|DRUG|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis."
41135111|NCT03909100|DEVICE|CoolSculpting® System|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
41290693|NCT06019143|BEHAVIORAL|Goal Attainment Scaling (GAS) without inventory|Goal Attainment Scaling (GAS) without a goal inventory (list of common goals) as a behavioral interventional tool
41290694|NCT01354691|DRUG|ladostigil hemitartrate|Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
40761384|NCT02679274|DRUG|Placebo|Intermittent intramuscular injections of saline (males and females).
40761385|NCT02679274|DRUG|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
40761386|NCT00989495|DEVICE|Brace|Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
40761387|NCT05320952|DEVICE|WellO2|The WellO2 breathing training device performs back-pressure steam breathing training during the inhalation and exhalation phases.
40761388|NCT01177306|DRUG|extended release guanfacine|1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
40761389|NCT05172596|BIOLOGICAL|PHE885|Intravenous (IV) infusion
40953947|NCT01139983|GENETIC|RNA analysis|
40953948|NCT01139983|GENETIC|fluorescence in situ hybridization|
40953949|NCT01139983|GENETIC|microarray analysis|
40953950|NCT01139983|GENETIC|polymerase chain reaction|
40953951|NCT01139983|GENETIC|reverse transcriptase-polymerase chain reaction|
40953952|NCT01139983|OTHER|laboratory biomarker analysis|
40953953|NCT06311825|OTHER|Horticultural Therapy|"One week before horticultural therapy (HT) interventions, face-to-face interviews will be held with the individuals in the experimental group and the forms will be filled in as a pretest.~HT will be applied to the experimental group. The application period was determined as a total of 6 weeks with 50-minute sessions twice a week.~Before starting the HT sessions, area preparations will be made and a safe therapeutic garden will be established.~Medicinal and aromatic plants will be selected that can grow in Turkey, are not harmful to human health, are fragrant and colorful in order to stimulate the senses, and according to air temperature and physical conditions.~HT sessions will consist of gardening activities (group meeting, introduction of plants and cultivation).~After HT interventions, the forms will be filled as a post test. The forms will be filled again 4 weeks after the end of the interventions for follow-up."
40953954|NCT04531839|BEHAVIORAL|Evidence-based collaborative quality improvement|Evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation and collaborative learning
40953955|NCT02077478|DEVICE|Remifentanil and propofol administration using TCI|
40953956|NCT02077478|DEVICE|Remifentanil and propofol administration using MCI|
40953957|NCT01646307|DRUG|Atorvastatin|
40953958|NCT01646307|DRUG|Rosuvastatin|
41290695|NCT01910662|OTHER|KLH 0.1 mg|KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
40953959|NCT04015492|BIOLOGICAL|Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Single dose, 50 IU/kg BAY94-9027 (IU: international Units)
40953960|NCT04015492|BIOLOGICAL|Rurioctocog alfa pegol (Adynovi)|Single dose, 50 IU/kg Adynovi
40953961|NCT01471678|DRUG|Dutasteride (0.5mg)|This study is an open-label, randomized, single dose, four-period cross-over study.
40953962|NCT01471678|DRUG|FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
40953963|NCT01471678|DRUG|Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)|a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
41290696|NCT01910662|OTHER|KLH 5 mg|KLH will be administered as single SC injection of 5 mg
40953964|NCT04158752|DRUG|Galcanezumab|Injection of study drug at 3 timepoints (day 30, day 60, day 90)
40953965|NCT06270771|DEVICE|OURA Ring|The OURA ring (https://ouraring.com) is a light-weight wearable device in the form of a ring that has several microsensors enabling detection of heart rate, blood oxygen level, skin temperature, and movement. The OURA ring and application can synthesize the sensory data to generate physiologic information such as sleep, activity level, resting heart rate, heart rate variability, respiratory rate, and more. The OURA ring is water resistant and has up to 5-7 days of battery life and can be fully charged in 20-80 minutes. It communicates with the OURA app and commonly used Smartphone health apps via Bluetooth connectivity with automatic syncing every week.
40953966|NCT00915122|RADIATION|Dose Escalated IMRT|Patients will receive external beam RT 55.1Gy in 29 once daily fractions to pelvic lymph nodes/prostate/seminal vesicles followed by 24.7Gy in 13 once daily fractions to the prostate/seminal vesicles using intensity modulated radiation therapy.
40953967|NCT06115252|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing with peer dyads starts with an open-ended exploration of the dyad's hazardous drinking behavior via personal stories about alcohol use. It includes a values clarification task and age-matched norms along with personalized feedback regarding the dyad's alcohol use. The goal of the session is to engage the dyad in a thoughtful conversation about drinking and the implications it may have on their lives, with an eye to bolstering and supporting inherent drive for behavior change.
40953968|NCT05734300|PROCEDURE|Combined Endoscopic Laparoscopic Surgery (CELS)|"The main surgical advantage in this procedure is the ability to view the colon intra- and extraluminal simultaneously. The laparoscopic approach enables manipulation and mobilization of the colon, while the endoscopic view secures that the resection is complete and not overlapping the ileac valve or creating stenosis.~Compared to the traditional oncological colon resection, the CELS resection is a minimally invasive procedure - organ sparing procedure leading to a reduced surgical stress response."
40953969|NCT05734300|PROCEDURE|Standard resection|In this study standard resection of the colon will be performed according to complete mesocolic excision (CME) principles.
40953970|NCT01727401|DRUG|Fondaparinux|Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
40953971|NCT05340075|PROCEDURE|Patients who underwent percutaneous nephrolithotomy|Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the percutaneous nephrolithotomy operation
41135112|NCT01052766|PROCEDURE|PET/CT and BH PET/CT|First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (\~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
41135113|NCT00384514|DEVICE|VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors|
41135114|NCT04419779|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.
40761390|NCT06424119|BEHAVIORAL|Traditional Cardiac Rehabilitation|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to TCR arm, they will attend 36 sessions of the program at one of three locations.
40761391|NCT06424119|BEHAVIORAL|Intensive Cardiac Rehabilitation|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to ICR arm, they will attend 72 sessions of the program at one of three locations.
40953972|NCT06022393|BEHAVIORAL|Cognitive Reappraisal|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to cognitively reappraise fear or anger inducing situations and are encouraged to implement this strategy into their daily lifes.
41290697|NCT01910662|OTHER|PBS (0.1 mL)|PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
41290698|NCT01910662|OTHER|Tuberculin PPD|Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
41454830|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
41290699|NCT02137551|OTHER|ABM|The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
41290700|NCT00649298|PROCEDURE|haemodialysis|Comparison of different weekly duration of haemodialysis treatment
41290701|NCT03873350|OTHER|Consumption of kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of living kombucha daily for three weeks.
41290702|NCT03873350|OTHER|Consumption of heat-sterilized kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of heat-sterilized kombucha daily for three weeks.
41290703|NCT04577768|DEVICE|HD-tDCS 2 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 2 mA
41290704|NCT04577768|DEVICE|HD-tDCS 1.5 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1.5 mA
41290705|NCT04577768|DEVICE|HD-tDCS sham|sham stimulation of the right primary motor cortex
41290706|NCT00929578|DRUG|Fluphenazine|Intralesional injection of Fluphenazine
41290707|NCT00929578|DRUG|Placebo|Intralesional injection of placebo
41290708|NCT02065440|DRUG|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
41290709|NCT02065440|DRUG|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
41290710|NCT04379518|OTHER|Best Practice|Receive standard of care
41290711|NCT04379518|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
41290712|NCT04379518|DRUG|Rintatolimod|Given IV
40761392|NCT06424119|OTHER|C2life® Food|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to ICR arm with food, they will receive the food at the beginning of the second week of their respective program. Food will be delivered by mail weekly for a total of 11 weeks to the patient's home address.
40953973|NCT06022393|BEHAVIORAL|Reflection|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to reflect on certain topics of their day.
40953974|NCT04613050|OTHER|Respiratory Training|"Respiratory training in form of :~Diaphragmatic breathing,Segmental breathing, Incentive spirometer:"
41290713|NCT02718677|DRUG|Refacto AF|Observational - Non-Interventional Study
41290714|NCT02119208|BEHAVIORAL|Intensity and timing of exercise|
41290715|NCT03742245|DRUG|Olaparib|PARP inhibitor
41290716|NCT03742245|DRUG|Vorinostat|HDAC inhibitor
41290717|NCT00942201|DRUG|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
40761393|NCT03895476|DIAGNOSTIC_TEST|palatal wound will be cover with collagen and sutures|after harvesting the graft from the palate, a collagen sponge will be sutured to cover the harvested site
40761394|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with platelet rich fibrin|after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
40761395|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with a collagen sponge and cyanoacrylate|after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
40953975|NCT04613050|OTHER|Aerobic training|aerobic exercises are customized according to the patient's underlying disease and residual dysfunction. These exercises will include walking on treadmill. After an initial, 5-minute warm-up phase performed on the treadmill at a low load, each endurance training session lasted 30 minutes and ended with 5-minute recovery and relaxation phase. A total of 3-5 sessions are carried out per week. Patients who are prone to fatigue should perform intermittent exercises
40953976|NCT03474861|BIOLOGICAL|anticancer medication A01; immune cells IC01|"The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.~The subjects will be observed for any side effects during this time and all the adverse events will be recorded."
40953977|NCT02334358|DEVICE|YVOIRE Classic s|
41290718|NCT00942201|DRUG|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
41290719|NCT04993742|BEHAVIORAL|MOMS Intervention|Behavioral: Mentors Offering Maternal Support (M-O-M-S) 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
41290720|NCT05176028|OTHER|conventional physiotherapy|For individuals of control group, hot pack applied for 20 minutes in the sitting position, Interferential Current was applied for the analgesic effect at a constant 100 Hz frequency on the anterior, posterior, superior and inferior part of the operated shoulder. By increasing the current slowly, the dosage of the current was adjusted to such a degree that the patient could tolerate it.
41290721|NCT05176028|OTHER|fascial release|Fascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the cervical, thoracolumbar and upper extremity areas until tissue loosening and releasing were felt.
41290722|NCT00956644|DRUG|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
41290723|NCT00956644|DRUG|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
41290724|NCT04392011|DRUG|Midazolam HCl|Oral syrup, 2 mg/mL
41290725|NCT04392011|DRUG|Dextromethorphan HBr|Oral liquid capsules, 15 mg
41290726|NCT04392011|DIETARY_SUPPLEMENT|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
41290727|NCT02413255|DRUG|TAK-020|TAK-020 oral solution
41290728|NCT02413255|DRUG|TAK-020 Placebo|TAK-020 placebo-matching oral solution
41290729|NCT04150458|DRUG|18F-fluorocholine PET/CT.|18F-fluorocholine positron emission tomography / computed tomography
41290730|NCT06320951|DRUG|Vericiguat 10 MG|The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.
41290731|NCT06320951|OTHER|Placebo|The subject will be randomized, in a double-blind manner to placebo once daily for a period of 12 weeks.
40761396|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with a stent|after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
40953978|NCT01536470|OTHER|noradrenaline|The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
40953979|NCT01536470|OTHER|Ephedryne chorydrate|
41135115|NCT04419779|DEVICE|Duodenal Mucosal Resurfacing (Sham)|The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 48 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
41135116|NCT03667833|OTHER|Shoulder brace|Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.
41290732|NCT06320951|OTHER|Insulin Sensitivity Test|An assessment of the insulin sensitivity will be done using the Euglycemic Hyperinsulinemic Clamp, at baseline and after 12 weeks of pharmacological interventions.
41290733|NCT06320951|OTHER|Resting Energy and Exercise Energy Expenditure Assessment|Each participant's Energy Expenditure will be determined using a metabolic cart, at baseline and after 12 weeks of pharmacological interventions.
40761397|NCT04562519|DEVICE|TENS|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
40761398|NCT02791581|DIAGNOSTIC_TEST|Cardiac MRI|"Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months."
40761399|NCT03551119|BEHAVIORAL|Exercise|See previous description
40761400|NCT03551119|OTHER|Enhanced usual care|See previous description
40761401|NCT04808011|DEVICE|Intelligent Dialysis Assistant (IDA)|The IDA is intended for home dialysis for subjects who are stage 5 kidney diease patients and who perform Peritoneal Dialysis. The system is used deveral times a day for approximately 20 minutes for each cycle. During the interventional period, subjects will use only the investigational IDA system for their in/out exchanges.
40761402|NCT02957019|DRUG|L19-IL2 - Ph I|Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
40761403|NCT02957019|DRUG|L19-IL2 at RD - Ph II|Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
40761404|NCT02957019|DRUG|Rituximab|Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
40761405|NCT01887197|OTHER|Absorptive clearance scan|Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
40761406|NCT01887197|DRUG|inhaled hypertonic saline (7%)|nebulized hypertonic saline (7%)
40761407|NCT01887197|DRUG|mannitol inhalation powder|mannitol inhalation powder
40761408|NCT05300607|OTHER|Cross-cultural adaptation, validity, and reliability|evaluation, translation, cultural adaption, validation, and investigation of the reliability of Arabic version of The Western Ontario Rotator Cuff Index (WORC) to be used in Arabic countries.
40761409|NCT03075228|DEVICE|IntelliCap|Sampling of the small intestine using a samling capsule.
40761410|NCT02694263|DRUG|Canagliflozin|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
40761411|NCT02694263|DRUG|Repaglinide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
40761412|NCT02694263|DRUG|Pioglitazone|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
40761413|NCT02694263|DRUG|Gliclazide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
40761414|NCT02694263|DRUG|Glimepiride|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
40761415|NCT00934388|PROCEDURE|Pre peritoneal mesh placement|
40761416|NCT00934388|PROCEDURE|Laparoscopy|
40761417|NCT04576559|OTHER|Modified dental visual aids|Modified Dental visual aids in the form of pictures created by the main investigator
40953980|NCT05933148|DEVICE|Siemens 7T MRI|The active neurofeedback session will be done within the 7T MRI.
41135117|NCT00623337|BEHAVIORAL|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy \& 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify \& refer sick babies
41290734|NCT06320951|OTHER|White Adipose Tissue Biopsy|Participants who consent to participate in the exploratory aim will undergo WAT biopsy to assess UCP1 gene expression from the collected biospecimens, at baseline and after 12 weeks of pharmacological interventions.
40761418|NCT04576559|OTHER|Regular dental visual aids|Regular dental visual aids
40761419|NCT03206450|PROCEDURE|Biospecimen Collection|Undergo collection of blood and provide saliva and semen samples
40761420|NCT03206450|OTHER|Laboratory Biomarker Analysis|Correlative studies
40761421|NCT03206450|OTHER|Questionnaire Administration|Ancillary studies
41290735|NCT06320951|OTHER|MRI-PET Scan for Brown Adipose Tissue Volume Assessment|Participants who consent to participate in the exploratory aim will undergo PET/MR to BAT volume at baseline and after 12 weeks of pharmacological interventions.
41290736|NCT02990884|DRUG|ketamine|
41290737|NCT01500174|DEVICE|ultraviolet therapy UV254|three times per week until wound closure or patient discharge from hospital
41290738|NCT01500174|DEVICE|Placebo ultraviolet therapy UV254|Three times per week irradiation of wound base and periwound skin
41290739|NCT00984659|DRUG|Fluticasone propionate/salmeterol combination product|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks
41290740|NCT00984659|DRUG|Salmeterol|Salmeterol 50mcg DISKUS twice a day for 8 weeks
40953981|NCT05933148|DEVICE|Sham Neurofeedback|The sham Neurofeedback resembles the active condition but participants will not see their own brain activity and will instead view a past participant's active feedback from their same population group.
40953982|NCT04521660|DEVICE|Virtual reality glasses|Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety. In this study, VR glasses will be worn on the intervention group just before the procedure begins and patients will continue to wear their glasses until the procedure is completed.
40953983|NCT04203654|BEHAVIORAL|cognitive-behavior group therapy|cognitive-behavior group therapy Frequency: thrice a week Treatment duration: 16 week
40953984|NCT04203654|BEHAVIORAL|Individual supportive psychotherapy|Individual supportive psychotherapy 3 sessions during the 16-week treatment period
40953987|NCT02041078|PROCEDURE|Intrahepatic division of the right hepatic vein.|Ligation and division of the entrance of the right hepatic vein into the suprarenal cava vein are done at the end of transection of the liver parenchyma with CUSA.
40953988|NCT02041078|PROCEDURE|Extrahepatic vein division|Standard surgical procedure with extrahepatic ligation/division of the right hepatic vein prior to parenchymal division with CUSA.
40953989|NCT03831789|DEVICE|Cerebellar targeted rTMS|10 Hz cerebellar rTMS (250 pulses)
40953990|NCT03601078|BIOLOGICAL|bb2121|bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
40953991|NCT03601078|DRUG|Lenalomide|Specified dose on specified days
40953992|NCT03601078|DRUG|Talquetamab|Specified dose on specified days
40953993|NCT00880984|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
40953994|NCT00133913|PROCEDURE|Phlebotomy|Peripheral blood draws for testing of circulating tumor cells
40953995|NCT01984788|DRUG|BCX4161|
41135118|NCT01554267|DEVICE|Laser-Assisted ICG Dye Angiography (SPY System)|7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
41135119|NCT02976272|OTHER|bortezomib|
41290741|NCT00984659|DRUG|Placebo|Placebo DISKUS twice a day for 8 weeks
41290742|NCT04293848|OTHER|Vibroacoustic therapy|listening to low-frequency sound of 40 Hz with biorhythmic sequential modulation combined to music
41290743|NCT04293848|OTHER|Only music (no vibrations)|listening to music, no vibrations
41135120|NCT04514081|DRUG|Chidamide; Decitabine; Camrelizumab|"Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.~Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.~Camrelizumab is a humanized anti-PD-1 monoclonal antibody."
41135121|NCT04514081|DRUG|Decitabine+Camrelizumab|Decitabine+Camrelizumab
41290744|NCT00270920|BEHAVIORAL|Lactation counseling|
41290745|NCT05247177|DRUG|dexmedetomidine, ketamine co-administration with sevoflurane for general anesthesia|co-administration of sevoflurane, iv. dexmedetomidine and iv. ketamine to maintain a predefined EEG density spectrum array pattern for general anesthesia
41290746|NCT05247177|DRUG|Conventional general anesthesia by administration of sevoflurane alone|Administration of sevoflurane alone to maintain anesthesia with a bispectral index between 40-60
41290747|NCT06429631|DEVICE|mobile application on telephone|"when patient discharge from the hospital, mobile application downloaded their telephone. then researcher give feedback about patients CIC outputs.~also mobile application include 2 animations, videos, frequently asked questions and ask the expert section."
40953996|NCT01984788|DRUG|Placebo|
40953997|NCT00810914|DRUG|bupivicaine epidural|bupivicaine continuous epidural infusion
41290748|NCT03453086|PROCEDURE|Thoracic paravertebral block(TPVB) group|"Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior"
40953998|NCT00810914|DRUG|bupivicaine epidural infusion patient epidural|bupivicaine
40953999|NCT00810914|DRUG|bupivicaine|patient controlled anesthesia only
40954000|NCT03656770|OTHER|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.
40954001|NCT03114774|DEVICE|The bispectral index (BIS) monitoring|
40954002|NCT03114774|BEHAVIORAL|Ramsay Sedation Scale (RSS) Score monitoring|
40954003|NCT00480285|PROCEDURE|Laparoscopic Nissen Fundoplication|
40954004|NCT00480285|PROCEDURE|Laparoscopic anterior partial fundoplication|
40954005|NCT03254875|BEHAVIORAL|Individually tailored nurse navigation|The intervention consists of systematic report of symptoms to the nurse and up to six individual, manual-based, face-to-face or telephone nurse navigator sessions depending on individual needs.
40954006|NCT03320057|DRUG|Mifepristone|Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
40954007|NCT03320057|OTHER|Training on mifepristone dispensing|Pharmacists were offered a training on medication abortion and mifepristone dispensing
40954008|NCT00285233|BIOLOGICAL|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
40954009|NCT03622073|OTHER|Misoprostol treatment by Midwife|Medical management of incomplete abortion
40954010|NCT03622073|OTHER|Misoprostol treatment by Doctor|Medical management of incomplete abortion
40954011|NCT03328767|BEHAVIORAL|Early activity and Mobilisation intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
40954012|NCT06557629|DIAGNOSTIC_TEST|Ultrasound assessment|Ultrasound assessment of gastric residual volume
41290749|NCT03453749|DIETARY_SUPPLEMENT|Salovum|Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
41290750|NCT05585385|DEVICE|Backward Walking Training|The subjects in this group will receive BW training program on an electric treadmill. The subject will be asked to walk, arms beside, in a backward manner on a level treadmill, zero inclination, with a warming up and cooling down period (5 minutes for each period). The subject walks at his self-selected and comfortable walking speed. A warm-up and cool-down period, in form of light jogging on a treadmill, will be done at speed of 1-2 m/sec. The total training is 30 minutes, three times a week for six consecutive weeks.
41290751|NCT05585385|DEVICE|Balance Training|"Subjects in this group will receive balance training on Biodex Balance System for 3 sessions/ week, over 6 weeks period. Each subject will be instructed to stand with both legs on the locked platform. The researcher advances the platform to an unstable state while instructing the subject to focus on the visual feedback screen. Arms are free at the side of the body and not grasping handrails.~After selecting the stability training program (dynamic balance training), Stability levels are changed depending on the subject's ability to maintain balance, and subjects are instructed to maintain their Center of Pressure (COP) in the smallest concentric rings (balance zones) of the Biodex Balance System monitor, named A zone.~The stability level of the platform is set at level plate stability 8 (the most stable) for the first two sessions. After that, the plate stability is decreased by one level every two sessions to increase the difficulty in training."
41290752|NCT05585385|OTHER|Conventional treatment|Patients in this group will receive the traditional physical therapy program only for 3 sessions/ week, over 6 weeks period. The traditional physical therapy program is (evertors strengthening, short foot ex, heel raise ex, and calf stretch).
40761422|NCT06190379|OTHER|Essential oil blend|an aroma stick containing a blend of essential oils
41290753|NCT03372057|DRUG|Duvelisib|Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
41290754|NCT03372057|DRUG|Duvelisib|Duvelisib PO 75 mg BID in 28-day cycles.
41290755|NCT03372057|DRUG|Duvelisib|Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase)
41290756|NCT00659685|DRUG|Ondansetron|ODT, single-dose, fasting
41290757|NCT00659685|DRUG|Zofran ODT|
40761423|NCT06190379|OTHER|Placebo|an aroma stick containing an inert blend of oils
40761424|NCT05216380|BEHAVIORAL|ActivityLink|"ActivityLink is an implementation program using:~1. Didactic and experiential training sessions for clinic staff to conduct referrals~2. Secure electronic referral webform to refer patients using their email address and phone number~3. Messaging sent to the patient and provider that they have been referred to a program~4. Clinic visual cues (flyers and paper prescription pad) to reinforce referrals~5. Motivational messaging and booster sessions from study staff to encourage referrals and troubleshoot"
40761425|NCT04370886|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
40761426|NCT05499819|OTHER|Canned black beans, drained and rinsed|Canned black beans, drained and rinsed and consumed in a tortilla wrap
41290758|NCT01486238|DRUG|Macugen® pegaptanib sodium|"Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.~Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert."
41290759|NCT02574299|OTHER|E-learning|Management of auditory processing disorders with serious game (E-learning)
41290760|NCT02574299|DEVICE|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
41290761|NCT02494908|BEHAVIORAL|Playing a computer game simulating a car race|Playing a computer game simulating a car race
40761427|NCT05499819|OTHER|Canned red kidney beans, drained and rinsed|Canned red kidney beans, drained and rinsed, drained and rinsed and consumed in a tortilla wrap
41135122|NCT05832593|OTHER|Immunohistochemistry|Immunohistochemical expression of ERCC1
41135123|NCT04486820|OTHER|Analysis Immunohistochemical|Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
41135124|NCT04346875|PROCEDURE|Regularly changing of dressing|Conventional dressing
41135125|NCT04346875|PROCEDURE|No application|No dressing change
41135126|NCT01788605|DRUG|ramosetron|
40954013|NCT03614364|DRUG|nanoxel|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
40954014|NCT03614364|DRUG|herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
40761428|NCT05499819|OTHER|Extra-lean ground beef|Extra-lean ground beef, pan-fried and consumed in a tortilla wrap
40761429|NCT03158246|DRUG|Generic Zoledronic Acid|Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
40761430|NCT03158246|DRUG|Original Zoledronic Acid|Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
40761431|NCT03158246|DIETARY_SUPPLEMENT|calcium|600mg/d calcium for oral daily
40954015|NCT00191269|DRUG|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
40761432|NCT03158246|DIETARY_SUPPLEMENT|vitamin D|925IU/d vitamin D for oral daily
40761433|NCT06568393|OTHER|Calisthenic exercise|Calisthenic exercise program was included: jumping jack, burpee, mountain climber, squat thrust, squat, squat jump, split and alternate exercises.
40954016|NCT00191269|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
40954017|NCT01168141|DRUG|ZD4054|10mg ZD4054 daily in tablet form
41135127|NCT04305340|DEVICE|Myant SKIIN Device|"1. Supine position: Participant lays on a bed on their back for 5 minutes~2. Sitting position: Participant sits on a chair for 5 minutes~3. Standing position: Participant stands for 5 minutes.~4. Exercise measurement: treadmill exercise test - the protocol entails increases of 0.5 mph every minute with zero change in the incline. Starting point would 1.5 mph. The test will be interrupted if the target heart rate of 190 beats per minute is reached or if symptoms and/or arrhythmias and ST depression would be observed. Patient will be monitor during recovery for 5 minutes.~5. Cool-down: Participants cool-down for 5 minutes"
41135128|NCT02930317|DRUG|Recombinant Factor VIII (50 IU/kg)|
41290762|NCT05689827|DRUG|Ethyl methyl hydroxypyridine succinate + Meldonium|Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration), then Ethyl methyl hydroxypyridine succinate - 250.0 mg, meldonium dihydrate based on dihydrate without adsorption moisture - 250.0 mg (oral capsules)
41290763|NCT05689827|DRUG|Placebo|Placebo was used in the same way
40761434|NCT00140920|DRUG|MK0966; rofecoxib|
40761435|NCT00140920|DRUG|Comparator: diclofenac 2x 75 mg|
40761436|NCT00833274|BEHAVIORAL|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
40761437|NCT03110510|DRUG|Fluorouracil|5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
40761438|NCT03110510|DRUG|Irinotecan Hydrochloride|Irinotecan 180 mg/m2
40761439|NCT03110510|DRUG|leucovorin calcium|Leucovorin 200 mg/m2
40761440|NCT01666366|PROCEDURE|Coronary artery bypass grafting|
40761441|NCT06362889|COMBINATION_PRODUCT|Microneedling with CBD|Cannabidiol (CBD) Isolate- 90-100mg / 1mL of carrier oil Organic Hemp Seed Oil- used as carrier oil for CBD isolate in Combination with Microneedling Device
40954018|NCT04790773|OTHER|Amazon Alexa based voice recording patient education|Amazon Alexa based voice recording of medication education material
40761442|NCT06478693|DRUG|MT-303|MT-303
40761443|NCT00803374|DRUG|AntiCD137|Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
40761444|NCT00803374|DRUG|AntiCD137|Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
40761445|NCT00803374|DRUG|AntiCD137|Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
40954019|NCT05061706|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
40954020|NCT05061706|DRUG|Placebo|Matching capsules administered orally, once daily.
41135129|NCT02930317|DRUG|Recombinant Factor VIII (On-demand treatment)|
41135130|NCT05028465|PROCEDURE|Endoscopic Papillectomy|A snare devicewas inserted via the working channel, and the endoscopist adjusted the snare to securely grasp the lesion, which was then excised by using standard electrocautery.
41135131|NCT05028465|PROCEDURE|Endobiliary Radiofrequency Ablation|The RFA catheter was then placed under fluoroscopic guidance across the distal common bile duct. An ERBE VIO200D generator (ERBE Elktromedizin, Tubingen, Germany) was connected for RFA at 10 W for 90 seconds.
41135132|NCT03094546|DIETARY_SUPPLEMENT|Polyamine|12 months of polyamine supplementation (6 capsules/day)
41135133|NCT03094546|DIETARY_SUPPLEMENT|Placebo|12 months of placebo intake (6 capsules/day)
41135134|NCT04318691|BIOLOGICAL|Blood sampling|Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.
40761446|NCT00803374|DRUG|AntiCD137|Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
40761447|NCT00803374|DRUG|AntiCD137|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
40761448|NCT00803374|DRUG|Ipilimumab|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
40761449|NCT00000373|DRUG|olanzapine + fluoxetine|
40761450|NCT00000373|DRUG|placebo + fluoxetine|
40761451|NCT05899959|DEVICE|Corsano CardioWatch 287-2|Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.
40954021|NCT05821478|DRUG|ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy|a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin
41290764|NCT05929326|DIAGNOSTIC_TEST|complete blood count, PT, aPTT, fibrinogen tests|Pregnant women who are eligible for the study will have their blood collected to run complete blood count, PT, aPTT, fibrinogen tests
41454831|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
40761452|NCT01440751|DEVICE|Use of ologen Collagen Matrix in trabeculectomy (ologen)|Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
40761453|NCT01440751|DRUG|Use of Mitomycin-C (MMC) in trabeculectomy|After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
40761454|NCT00745355|BEHAVIORAL|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
40954022|NCT05821478|DRUG|Lymecyclin and corresponding placebos of the experimental arm|12-week course of oral lymecycline.
41290765|NCT04018287|OTHER|HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)|"HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation."
41290766|NCT04512885|OTHER|Survey|Survey via questionnaire
41290767|NCT04644107|DRUG|Marizomib|Marizomib will be administered via IV
41290768|NCT05286398|PROCEDURE|Palatoplasty|Surgical closure of palatal defect
41290769|NCT05286398|DIAGNOSTIC_TEST|Addition silicone impression|diagnostic impression for maxillary arch
41290770|NCT01765712|PROCEDURE|Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft|
41290771|NCT01765712|BIOLOGICAL|Platelet Rich Plasma|
41290772|NCT01549847|DRUG|L-carnitine and piracetam|L-carnitine/piracetam (990mg/810mg) PO BID
41290773|NCT01549847|DRUG|Placebo|Placebo PO BID
41290774|NCT03865069|OTHER|Mode of ventilation (Volume Guarantee)®|This is a volume-targeted mode of ventilation aimed at delivering the set tidal volume of gas by automatically adjusting the peak inspiratory pressure (PIP) on a breath-by-breath basis. Theoretically this should minimise variation in tidal volume delivery as lung compliance and the infant's condition changes. This function is achieved by an automated servo-controlled mechanism. The upper PIP limit can be set by the clinician as a safety mechanism.
41290775|NCT03865069|OTHER|Mode of ventilation (Volume control Ventilation)|Volume-Controlled ventilation (VCV) is a type of 'volume targeted' mode. It aims to target be supported the desired tidal volume by delivering a set volume (chosen by the clinician) irrespective of the underlying lung mechanics. The ventilator will generate whatever peak inspiratory pressure is necessary to deliver this volume. There is constant inspiratory flow pattern (a square flow waveform) and peak volume and inspiratory pressure delivery are achieved at the end of inspiration. During the 'control period' of 12 hours without VG, infants will using VCV A/C (assist control) as is our current clinical standard.
41290776|NCT00579904|DIETARY_SUPPLEMENT|walnuts|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
41290777|NCT00579904|DIETARY_SUPPLEMENT|almonds|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
41290778|NCT01556919|PROCEDURE|Standard of care endoscopy|standard of care endoscopy
41290779|NCT02904967|BIOLOGICAL|Extra Blood Draw|
41290780|NCT04372329|BEHAVIORAL|CPAP4HealthySleep system|Tailored multimedia messages and tailored feedback messages delivered via web-based system to participants' phones to motivate them to use their CPAP therapy
41290781|NCT04779021|OTHER|Hospitalisation for SARS-COV2 infection|Patients hospitalized for SARS-COV2 infection
41290782|NCT01070303|BIOLOGICAL|Adalimumab 40 mg eow or ew|Adalimumab 40 mg by subcutaneous injection every other week or every week
41290783|NCT01292395|OTHER|Dietary Protein Intake|Protein intakes within the current recommendation
41290784|NCT04210713|DRUG|Minocycline|200 mg/day
41290785|NCT04210713|DRUG|Sugar pill|Matched placebo
41290786|NCT00005860|DRUG|floxuridine|
41290787|NCT00005860|DRUG|leucovorin calcium|
41290788|NCT00005860|DRUG|oxaliplatin|
41290789|NCT06195553|BEHAVIORAL|STEPPS plus Family Connections|The intervention will be based on cognitive and behavior treatment using STEPPS for the patients and dialectical and behavior treatment using Family Connections for the families. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Main components Family Connections: psychoeducation, skills training and peer support.
41290790|NCT06195553|BEHAVIORAL|STEPPS|The intervention will be based on cognitive and behavior treatment using STEPPS for the patients. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Waiting list group: Participant's relatives of this group will be able to receive the Family Connections intervention after the research end.
41290791|NCT00196937|BIOLOGICAL|Cervarix|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
41290792|NCT00841724|DRUG|Fludarabine, Busulfan, Thymoglobuline|
41290793|NCT04724590|RADIATION|IMRT(IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY )|Evaluation the optic neuropathy in nasopharynx cancer patients treated in our clinic.
41290794|NCT06359249|BEHAVIORAL|change of habits|change of habits
41290795|NCT06359249|OTHER|change of habits + auto abdominal massage|change of habits + auto abdominal massage
41290796|NCT00360022|OTHER|Joint visits|Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
41290797|NCT02762864|OTHER|platelet (P2Y12) reaction units|VerifyNow P2Y12 assay point-of-care testing
41290798|NCT02762864|DRUG|ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
41290799|NCT02762864|DRUG|Comparator|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
40954023|NCT01086085|DRUG|Adefovir|Adefovir 10 mg po once daily for 36 weeks
41290800|NCT06339229|OTHER|proteinuria|dipstick proteinuria values negative, trace, 1+, and ≥2+
41290801|NCT06177613|PROCEDURE|Blank culture transfer|A maximum of 0.1 ml of gassed embryo culture medium preheated to 37°C is injected into the uterine cavity transcervically using an embryo transfer catheter placed just beyond the internal os, two to 3 days before transfer of the thawed embryo
41290802|NCT06177613|PROCEDURE|Sham transfer|An intermediate transfer step is added two or three days before the planned transfer of the frozen embryo but with an empty catheter.
40954024|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
40954025|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
40954026|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
40954027|NCT02398396|BIOLOGICAL|4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics|4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
40954028|NCT04539353|OTHER|Heart Rate Variability|Heart Rate Variability will be measured with a Polar device.
40954029|NCT04539353|OTHER|Pain intensity|Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale
40954030|NCT02747290|DRUG|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
40954031|NCT06256965|DIAGNOSTIC_TEST|Detection of peri-operative atrial fibrillation|atrial tissue and plasma from patients with atrial fibrillation detection were analyzed for determine lipid and protein oxidation, and detect markers of myocardial injury.
40954032|NCT05751265|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
40954033|NCT05751265|DRUG|5Fu|Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w
40954034|NCT05751265|DRUG|Paclitaxel injection|Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w
40954035|NCT00042900|DRUG|pyroxamide|
40954036|NCT02585843|DRUG|Spironolactone 100mg|2 capsules of study medication consist of 100mg, PO (oral) for 7 days
41135135|NCT04318691|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage at admission to the ICU with analysis of cytological, bacteriological, viral and anatomopathological, and test of NETs.
41135136|NCT03960645|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
41135137|NCT03186248|PROCEDURE|Per oral endoscopic myotomy|General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.
41135138|NCT05201599|DEVICE|Flexible ureteroscope with intelligent control of renal pelvic pressure|After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscope without basket.
41135139|NCT04865718|DIAGNOSTIC_TEST|ICGA imaging|subjects undergoing intraoperative ICGA imaging
41135140|NCT00506896|DRUG|intraarticular injection|Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
41135141|NCT05794074|DIETARY_SUPPLEMENT|luteine and zeaxanthine|luteine and zeaxanthine
41135142|NCT05794074|DIETARY_SUPPLEMENT|luteine|luteine
41135143|NCT05794074|DIETARY_SUPPLEMENT|zeaxanthine|zeaxanthine
41135144|NCT05794074|DIETARY_SUPPLEMENT|Placebo|Placebo
41135145|NCT00089791|DRUG|placebo|Placebo administered by subcutaneous injection
41135146|NCT00089791|DRUG|Denosumab|Denosumab 60 mg administered by subcutaneous injection
41135147|NCT02576691|DEVICE|percutaneous coronary intervention|
40954037|NCT02585843|DRUG|Spironolactone 25mg|25mg/day of spironolactone
40954038|NCT03011710|DEVICE|ProVari v2.5 (E-cigarette)|An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.
41135148|NCT00382941|DEVICE|Red and near infrared LED phototherapy device|
41135149|NCT05522309|DRUG|ET0111|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0111 administered, once daily (QD).
41135150|NCT04755972|OTHER|Inhalation of N-acetylcysteine|Group 1 will receive N-acetylcysteine inhalation every 12 hours from the beginning of invasive mechanical ventilation.
41135151|NCT04755972|OTHER|Inhalation of 5% sodium chloride|Group 2 will receive inhalation with a 5% sodium chloride solution every 12 hours from the beginning of invasive mechanical ventilation.
41135152|NCT04755972|OTHER|Inhalation of 8,4% sodium bicarbonate|Group 3 will receive inhalation of 8.4% sodium bicarbonate every 12 hours from the beginning of invasive mechanical ventilation.
41135153|NCT03056378|BIOLOGICAL|Standard RBCs|Transfusion of standard pRBCs that are matched for C, E and K
41135154|NCT01044446|DRUG|Icodextrin|one exchange daily
40761455|NCT01834378|BEHAVIORAL|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
40954039|NCT03011710|DEVICE|Marlboro Gold (Conventional cigarette)|Conventional cigarette
40954040|NCT03011710|DEVICE|Cigarette tip|Placebo device
40954041|NCT00115739|DRUG|Imatinib|Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
40954042|NCT03252860|OTHER|Observation of compliance with the World Health Organisation Surgical Safety Checklist|Observation of use and compliance with the surgical safety checklist and associated perioperative surgical outcomes
40761456|NCT01834378|BEHAVIORAL|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
40761457|NCT06569680|DRUG|Mosunetuzumab|"Mosunetuzumab will be administered via subcutaneous (SC) injection using a step-up dosing model. Participants will receive Mosunetuzumab on days 1, 8, and 15 of Cycle 1, and on day 1 of Cycles 2 through 8 as follows:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 45mg~* Cycle 1 Day 15: 45mg~* Cycles 2 through 8, Day 1: 45mg"
40954043|NCT03658239|OTHER|Inversion|Inversions will be done while the subject is on the inversion table. The subject will be inverted to 135, 150 and 165 degrees. There inversion will not last longer than 3 minutes at a time. The inversion will be terminated if the subject's blood pressure drops below 50 mmHg diastolic or if the subject's blood pressure increases more than 50 mmHg systolic.
40954044|NCT05490303|OTHER|recording of the probe position|For each patient, a cardiac ultrasound acquisition will be performed with an optical tracking system (infrared) recording the probe's position in real time.
40954045|NCT01338103|DRUG|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
40954046|NCT05285072|RADIATION|PET-CT scan|PET-CT scan using 68Ga-DFO
40954047|NCT02125968|OTHER|interactive video game|short- and medium-term therapeutic effects
40954048|NCT02125968|OTHER|therapeutic exercise|short- and medium-term therapeutic effects
40954049|NCT03022435|BIOLOGICAL|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
40954050|NCT03022435|BIOLOGICAL|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
40954051|NCT03022435|BIOLOGICAL|LAIV|Live, attenuated influenza vaccine for Intranasal Spray
40954052|NCT00242437|DEVICE|Hemostatic matrix|
40954053|NCT00242437|DEVICE|bovine thrombin|
40954054|NCT00546104|DRUG|Dasatinib|An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
40954055|NCT02834728|BEHAVIORAL|telephone interview|
40954056|NCT05797259|DRUG|Danosumab|60 mg subcutaneous Danosumab
40954057|NCT05797259|OTHER|Normal Saline|Placebo comparator arm
40954058|NCT03949309|OTHER|Exploring health literacy levels and patients' informal needs or individual relationship between caregivers and patients.|It is a cross-sectional study coupled with a qualitative ancillary study conducted within patients hospitalized for one of the two acute cardiovascular diseases (acute coronary syndrome or acute heart failure). All patients hospitalized at Hospices Civils de Lyon for one of these two diseases and whom are going back home will be enrolled. Few patients will be interviewed during the follow-up visit at 1-month post hospitalisation. Caregivers from cardiology units will also be interviewed.
40954059|NCT02933723|PROCEDURE|Blood Draw|Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
40954060|NCT05435495|PROCEDURE|Single-photon emission computed tomography|Imaging procedure
41290803|NCT04741243|DEVICE|Extracorporeal Shock wave|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level
41454832|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
40761458|NCT01730729|DRUG|cabergoline|Given orally
40761459|NCT03474601|OTHER|Dynamic hormone study and Magnetic resonance imaging|"1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue"
40761460|NCT06126900|OTHER|Smartphone medication intake reminder + educational and motivational text messaging|The intervention includes the use of a smartphone-based medication intake reminder, along with two educational and motivational text messages during the therapy period.
40761461|NCT06068192|OTHER|no intervention|no intervention
40954061|NCT05435495|PROCEDURE|Blood Draw|Blood draw for future research tests (45-60 mL).
40954062|NCT05435495|PROCEDURE|Tumor Biopsy|Guided biopsy of lesion
40954063|NCT02322476|OTHER|No intervention will be performed|No intervention will be performed
40954064|NCT00431769|DRUG|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m\^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m\^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
40954065|NCT01033760|DRUG|raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine|raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
40954066|NCT01033760|DRUG|darunavir; ritonavir; emtricitabine/tenofovir|darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
40954067|NCT06246175|DRUG|HRS9531|Receive a single dose of HRS9531 injection
40954068|NCT03423082|DRUG|18F fluciclovine|Each subject will receive one IV dose of 18F fluciclovine for PET scanning
40954069|NCT03423082|DEVICE|18F fluciclovine PET|Each subject will undergo one 18F fluciclovine PET scan on a hybrid PET/MRI scanner
40954070|NCT00935948|DRUG|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
40954071|NCT00935948|DRUG|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
40954072|NCT02021227|PROCEDURE|Early chair sitting exercise|A chair sitting exercise will be done at least once a day and for \> 1 hour
40954073|NCT03680560|BIOLOGICAL|ACTR T Cell Product|Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)
40954074|NCT03680560|DRUG|Trastuzumab|monoclonal antibody targeting HER2
40761462|NCT01355666|DEVICE|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
40954075|NCT04312581|DEVICE|Extracorporeal shock wave therapy|3 sessions of radial- extracorporeal shock wave therapy rESWT one week apart, 2000-3000 impulses at 0.25-0.84 millijoule /mm2with a pressure 2.8 bar and 15 Hz frequency.
40954076|NCT04312581|OTHER|Conventional rehabilitation|physical \& occupational therapy
40954077|NCT00183989|DRUG|Fludarabine, Mitoxantrone and Rituximab|
40954078|NCT02706184|DRUG|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
40954079|NCT02706184|DRUG|Placebo|Placebo
40954080|NCT01887665|BEHAVIORAL|incentives|A structured system of prize-based financial incentives rewards attendance at treatment visits.
40954081|NCT01784757|DRUG|ODM-201 Tablet A|Tablet A formulation of ODM-201
40954082|NCT01784757|DRUG|ODM-201 Tablet B|Tablet B formulation of ODM-201
40954083|NCT01784757|DRUG|ODM-201 capsule formulation|Capsule formulation of ODM-201
40954084|NCT00956969|BEHAVIORAL|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
41454833|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
40761464|NCT06184880|BEHAVIORAL|behavioral|International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,
40761465|NCT06184880|OTHER|Sedentary|Actimetry (cumulative time without movement over 24h, prolonged sedentary periods \>30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5
40761466|NCT01588925|DEVICE|Cochlear Implantation|Cochlear implantation using Hybrid L24 Implant
40761467|NCT01588925|DRUG|Cochlear Implantation+dexamethasone|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
40761468|NCT01588925|DRUG|Cochlear Implantation+dexamethasone+hyaluronic acid|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
40761469|NCT00052897|BIOLOGICAL|HspE7|
40761470|NCT01754740|DRUG|Uréia|"The subjects were randomly divided into two groups:~1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months."
40761471|NCT01754740|DRUG|Placebo|Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
40761472|NCT02562703|DEVICE|Transcutaneous Vagus Nerve Stimulation|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
40761473|NCT03868280|PROCEDURE|Antegrade femoral nailing Supine Position|Antegrade femoral nailing in Supine Position using a Fracture Table
40954085|NCT00956969|BEHAVIORAL|Relaxation Training|Teaches patients relaxation training
40954086|NCT01783431|DRUG|Poly ICLC|Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
40954087|NCT01783431|PROCEDURE|leukapheresis|Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
40954088|NCT05067777|PROCEDURE|Massage Therapy|Receive SMT
40954089|NCT05067777|OTHER|Questionnaire Administration|Ancillary studies
40954090|NCT05067777|PROCEDURE|Sham Intervention|Receive light touch control procedure
40954091|NCT03773263|DRUG|sequential IVM system|The immature oocytes will be cultured in sequential oocyte IVM medium 1 for 6 hours (37℃, 5% CO2). After flushed 3 times, COCs were removed into sequential oocyte IVM medium 2 for further cultivation.
40954092|NCT03773263|PROCEDURE|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
41135155|NCT01044446|DRUG|glucose-based peritoneal dialysate|original exchange frequency
40954093|NCT03773263|PROCEDURE|Thawed embryo transfer (TET)|Patients administrates oestrogen (Progynova) 3mg twice a day for 10 to 12 days. From the day when endometrium reach a thickness of 8 mm and above, luteal phase support will be given with 10 mg progesterone (Dydrogesterone Tablets,) triple per day and utrogestan (Laboratories Besins International, Paris, France) 0.2g triple per day, until 14 days after embryo transfer.
40954094|NCT03773263|DRUG|traditional IVM system|COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed.
40954095|NCT02787382|DEVICE|echocardiographic examination|"Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection."
40954096|NCT04203797|DRUG|dupilumab|Pre-filled syringe administered by subcutaneous (SC) injections
40954097|NCT04203797|DRUG|Matching placebo|Pre-filled syringe administered by subcutaneous (SC)
40761474|NCT03868280|PROCEDURE|Antegrade Femoral Nailing Lateral Position|Antegrade femoral nailing in Lateral Position using a Free drape
40761475|NCT06554730|OTHER|Merck Belzutifan PAS in adult patients|There is no intervention for this study. This study will be collecting data from the EMR of consenting subjects who are taking Belzutifan.
40761476|NCT02126891|PROCEDURE|Tests|Individual parameters of echocardiography and heart rate variability
40954098|NCT05704062|PROCEDURE|Diffusion Weighted Imaging|Undergo DW-MRI
40954099|NCT05704062|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
40954100|NCT03836248|OTHER|Osteopathic treatment|"5 osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and treatment of necessary elements and a control of osteopathic treatment at the end of the session."
40954101|NCT03836248|OTHER|Sham osteopathic treatment|"5 sham osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and only contacts for no intent to treat. At the end of the session a control of the sham osteopathic treatment is performed."
40954102|NCT03836248|OTHER|Current practice Medication treatment|Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
40761477|NCT05023902|OTHER|Pilates|Pilates has been performed to all participants two times a week in order to compare the effects of NIA
40761478|NCT05023902|OTHER|Neuromuscular Integrative Action|NIA was the experimental group of this study.
40761479|NCT04270019|DRUG|Polyethylene Glycol 3350|In order to prepare PEG 3350 50% weight/volume, 25 grams of the sterilized PEG 3350 will be measured out and placed into a sterilized glass bottle then 25 mL of sterile water will be added. The solution will be allowed to rest for 10 minutes so that dissolution may occur. More sterile water will then be added so the total volume is 50mL. This solution will then be sterilized by the Halifax Health Infirmary pharmacy department using a liquid autoclave cycle of 120 degrees Celsius for 20 minutes in a glass vial. The 50 mL solution will be portioned into 2mL sterilized glass vials using a standard aseptic technique. The solutions will be kept at a solid frozen state between negative 25 degrees Celsius and negative 10 degrees Celsius for a maximum of 45 days. The solutions will be removed from storage on the day of surgical utilization in order to ensure storage guidelines are kept to the highest standards.
40761480|NCT04270019|DRUG|Normal Saline|Standard solution of sterile normal saline.
40954103|NCT06192784|PROCEDURE|DEB-TACE|transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
40954104|NCT06192784|DRUG|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
40954105|NCT00753571|DRUG|Cistanche Total Glycosides|"Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2"
40954106|NCT03476278|OTHER|Questionnaire|Postoperative questionnaire, and records of complications in the peri-operative period
40954107|NCT06489925|DRUG|Cerebrolysin|The Cerebrolysin will be administered at least one hour after the standard treatment and no later than 24 hours after the stroke symptom onset.
40954108|NCT02118883|OTHER|Essentia Water|
40954109|NCT02118883|OTHER|Bottled water|
40954110|NCT05026411|DIAGNOSTIC_TEST|T 0 Diffusion Tensor MR|Magnetic resonance images has been taken from 20 individuals with eating disorders before fixed orthodontic treatment
40954111|NCT05026411|DIAGNOSTIC_TEST|T 1 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders after 12 months of orthodontic treatment.
40954112|NCT05026411|DIAGNOSTIC_TEST|T 2 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders 6 months after orthodontic treatment finished
40954113|NCT05944211|DRUG|Hetrombopag Olamine|"The subjects will initiate treatment with 7.5 mg hetrombopag once a day, starting orally 24 hours after the end of chemotherapy. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts once every two weeks, and maximum dose should not exceed 15 mg daily. Subjects whose platelet count \<25×109/L for 2 weeks, the hetrombopag dose will be increased by 2.5mg. If subjects whose platelet count ≥100×109/L or who had received hetrombopag for 28 days, hetrombopag can be stopped. Hetrombopag Olamine is sponsored by Jiangsu Hengrui Pharmaceuticals Co., Ltd.~Emergency treatment: When the platelet count was less than 20×109/L, platelet transfusion was given according to the evaluation of the investigator."
40954114|NCT02135770|DRUG|Unfractionated heparin|10 unit/kgBW/hour continuous infusion for 72 hours
40954115|NCT01696695|DRUG|Capecitabine|First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
41290804|NCT03340805|DRUG|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
40954116|NCT01696695|DRUG|Chemotherapy|First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
40954117|NCT01950169|DRUG|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
40954118|NCT01950169|OTHER|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
41135156|NCT00739934|DRUG|voriconazole (Vfend)|"Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~1. If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~2. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
41135157|NCT06253299|OTHER|marble stone|"Marble stones with dimensions of 4x5 cm will be used for cold application. When placed in the freezer compartment of the refrigerator at -10°C (Celsius) for 4 minutes, they cool down to 11°C. Subsequently, in 1 minute, the temperature rises to 12°C when held in the palm. After being placed on a table at room temperature, it reaches 18°C in 5 minutes."
41135158|NCT01164488|DRUG|danoprevir|Repeated daily doses
40761481|NCT04083079|DRUG|PEG-rhG-CSF|Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
40761482|NCT04083079|DRUG|rhG-CSF|Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.
40761483|NCT00967486|PROCEDURE|Carotid endarterectomy with routine shount|
40761484|NCT00967486|PROCEDURE|Carotid endarterectomy with selective shunt|
40761485|NCT03673930|DIETARY_SUPPLEMENT|Zanthozylum armatum|Zanthozylum armatum MCT oil extract
40761486|NCT03673930|DIETARY_SUPPLEMENT|Placebo|sunflower oil matched for appearance
40761487|NCT04628208|DIAGNOSTIC_TEST|Spartan COVID-19 v2 System|A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.
40761488|NCT04066829|BEHAVIORAL|Default setting intervention|The new default settings will be implemented only for patients in the experimental arm.
40761489|NCT02184286|DRUG|Nevirapine|200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28
40761490|NCT02184286|DRUG|Saquinavir-sgc|1600 mg b.i.d. from pre trial to day 28
40761491|NCT01460615|DRUG|Hydrocortisone|
40761492|NCT00959049|BIOLOGICAL|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
40761493|NCT00959049|BIOLOGICAL|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
40761494|NCT03647137|OTHER|Detailed motor testing, including FoG, in PD subjects|"Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state."
40761495|NCT05679934|OTHER|Exercise Program|Stretching and strengthening exercises will be applied to the participants
40761496|NCT02007161|DRUG|Diclofenac potassium 50 mg|Diclofenac potassium 50 mg
40761497|NCT06570226|DIETARY_SUPPLEMENT|hibiscus tea|Some cell and animal experiments have pointed out that drinking tea may be related to hypotension, body composition and vision problems, and there are more and more related advertisements, especially for hibiscus tea, which is rich in anthocyanins.
40761498|NCT03795519|DRUG|[14C]-olinciguat|oral capsule
40761499|NCT04586023|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
40761500|NCT04586023|DRUG|Teriflunomide|Participants will receive teriflunomide.
40761501|NCT04586023|DRUG|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
40761502|NCT00228956|DRUG|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
40761503|NCT02199912|PROCEDURE|Biopsy of adipose and muscular tissue|
40761504|NCT02199912|OTHER|Blood sampling|
40761505|NCT02199912|OTHER|Calorimetry|
40761506|NCT02199912|OTHER|Impedance measure|Evaluation of physical composition (non-invasive method)
40761507|NCT02199912|OTHER|Evaluation of nutritional status|"Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia"
40761508|NCT02199912|OTHER|Evaluation of physical performance|"This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french"
40761509|NCT02199912|OTHER|Evaluation of muscular strength|Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
40761510|NCT02199912|OTHER|Evaluation of emotional status|The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
40954119|NCT01950169|DIETARY_SUPPLEMENT|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
40954120|NCT01263977|DEVICE|Picco- thermodilution catheter|Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
40954121|NCT04234022|DRUG|Zn-DDC|Zn-DDC added to myeloma samples for culturing
40954122|NCT04234022|DRUG|Lanalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
40954123|NCT04234022|DRUG|Pomalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
41135159|NCT01164488|DRUG|ketoconazole|Repeated daily doses
41135160|NCT01164488|DRUG|ritonavir|Repeated daily doses
41135161|NCT02418689|DRUG|NOV120101 (Poziotinib)|NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
41135162|NCT00005826|DRUG|rubitecan|
41135163|NCT00513071|DRUG|saracatinib|Given orally
41135164|NCT00513071|OTHER|laboratory biomarker analysis|Correlative studies
40954124|NCT04745884|DEVICE|Non-invasive bilateral monitoring of ICP waveform|Brain4care non-invasive bilateral monitoring of ICP waveform
40954125|NCT04330053|OTHER|Experimental|"* Training will address issues such as: environmental security, identifying hazards that can lead to a fall, psychological support, getting up from a fall, standing techniques and calling for help.~* The exercise program will last for six months and will be based on the OTAGO exercise program, which includes five exercise groups: general warm-up, muscle strengthening exercises, balance exercises, range of motion and stretching exercises. The program will be performed individually or in groups of two people at most and will be conducted once a week in one of the 5 outpatient clinics under the supervision of a specialized OTAGO trainer, while seniors should repeat the exercises twice a week alone at home and also walk twice a week for at least half an hour."
40954126|NCT04330053|OTHER|Control|"* Information / Education about falls The participants in this group will receive the same information - education as the participants of the 1st group.~* They will be given a leaflet with general gentle exercises (not fall prevention specific) for the home."
40954127|NCT02158975|DRUG|MLN9708|
40954128|NCT03641339|OTHER|One vector feeding|Participants will undergo one feeding by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies)
41135165|NCT04546451|BEHAVIORAL|Music practice|Patients will be trained to play a simple instrument (tongue-drum) in a group setting using different musical styles.
41135166|NCT04546451|BEHAVIORAL|Psychomotor therapy|Patients will be trained in body awareness and a wide range of of movement activities.
41135167|NCT04907929|BEHAVIORAL|targeted speech and cognitive therapy|One month of targeted speech and cognitive therapy with a speech therapist and with home exercice at home by using a numeric solution
41290805|NCT03340805|DRUG|Normal saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
41290806|NCT05329792|DRUG|L19IL2/L19TNF|Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks
40761511|NCT02199912|OTHER|Evaluation of functional status|The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
40761512|NCT02645370|DRUG|Danzhen|
41290807|NCT02201810|BEHAVIORAL|Rate reduction intervention|
41290808|NCT02201810|BEHAVIORAL|Recycling Group|
41290809|NCT02201810|BEHAVIORAL|Choice Group|
41290810|NCT02201810|BEHAVIORAL|Proactive QL|
41290811|NCT00537745|DRUG|Vivitrol (Medication Therapy)|Vivitrol 380 mg/monthly
41290812|NCT00537745|OTHER|Medication Management Therapy|Medication Management Therapy once a month.
40761513|NCT02645370|DRUG|Topiramate|
40761514|NCT01407341|PROCEDURE|musculoskeletal complications management/prevention|Receive beta tricalcium-phosphate bone graft
40761515|NCT01407341|PROCEDURE|bone graft|Receive beta tricalcium-phosphate bone graft
40761516|NCT01407341|PROCEDURE|quality-of-life assessment|Ancillary studies
40761517|NCT01407341|OTHER|questionnaire administration|Ancillary studies
40761518|NCT01962753|DRUG|18FAV45|Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
40761519|NCT01838226|BEHAVIORAL|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
40761520|NCT06501209|BEHAVIORAL|5A-5R-based counselling session|"The 5As (Ask, Advise, Assess, Assist, Arrange) summarize all the activities that a healthcare provider can do to help a tobacco user (both smoking within 3-5 minutes in a primary care setting. This model can guide you through the right process to talk to respondents who are ready to quit tobacco use and deliver advice.~The 5 R's - relevance, risks, rewards, roadblocks, and repetition - are the content areas that should be addressed in a motivational counseling intervention to help those who are not ready to quit."
40761521|NCT06501209|BEHAVIORAL|Counseling through mobile phone call and text message|Participants will get weekly a phone call and a text message
40761522|NCT00336063|DRUG|Azacitidine|Given SC
40761523|NCT00336063|OTHER|Laboratory Biomarker Analysis|Correlative studies
40761524|NCT00336063|OTHER|Pharmacological Study|Correlative studies
41135168|NCT00989755|OTHER|Fax to Quit (F2Q)|Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
41290813|NCT04241003|DEVICE|SmartDrive Mx2+|Rear-mounted power assist
40761525|NCT00336063|DRUG|Vorinostat|Given PO
40761526|NCT02274233|DRUG|SP-420|
40761527|NCT00767208|OTHER|oral glucose load|oral ingestion of 13C labeled glucose
40761528|NCT05634343|OTHER|experimental group 1|Laughter therapy, also called therapeutic laughter, is used to relieve pain and stress and to promote a general sense of well-being. Laughter therapy is simply a method of 'laughing for no reason' in which the person interacts in a group setting with improvisation or pantomime-like exercises and childish games without humour, jokes or funny events. The aim is thus to benefit from laughter.
40954129|NCT03641339|OTHER|Four vector feeding|Participants will undergo four feedings by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies), each about 2 weeks apart, with the same vector type.
40954130|NCT03700593|DEVICE|Single Port Robotic Colorectal Surgery|Single Port Robotic Colorectal Surgery
40954131|NCT05437900|PROCEDURE|Pressure Microcatheter guided strategy - PIOS MC|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
41290814|NCT00165568|DRUG|Bevacizumab|
41290815|NCT03549624|OTHER|Standardised protocol for the perioperative management in patients in need of an acute laparotomy|A standardised protocol for the perioperative management of patients including early start of antibiotics and swift surgical intervention as well as an emphasis on repeated monitoring of physiological parameters pre- and post-operatively.
40954132|NCT05437900|PROCEDURE|Pressure Wire guided strategy - PIOS - PW|Use of Pressure Wire during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
40954133|NCT05437900|PROCEDURE|Pressure Microcatheter guided strategy - Standard of care|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive standard of care treatment.
40954134|NCT05437900|PROCEDURE|Pressure Wire guided strategy - Standard of care|Use of Pressure Wire during PCI. After the PCI, the patient will receive standard of care treatment.
40954135|NCT02550262|DRUG|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
40954136|NCT02550262|DRUG|Fentanyl|0.0625% Bupivacaine plus fentanyl 2mcg/ml
40954137|NCT02550262|DEVICE|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
40954138|NCT03493607|DRUG|AMO-01|Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
40954139|NCT05820607|BIOLOGICAL|Microbiome, metabolome, transcriptome, genome|Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome
40954140|NCT05993819|OTHER|pilates based core stability training and congnitive therapy|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all.the patients also will receive cognitive behavioural therapy.The CBT manual was written specifically for this trial. The sessions were collaborative in style, and the therapist used Socratic questioning wherever possible. The main aim was to challenge any behavioral, cognitive, emotional and external factors that may be contributing to MS fatigue.
40954141|NCT05993819|OTHER|Pilates based core stability training|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all. The exercises were gradually made more difficult to increase the stabilization of the trunk by gradually reducing the support surface, increasing the extremity loading, and adding various materials.Exercises were progressed every 2 weeks in both groups and were performed with 10 repetitions for the first 4 weeks and 15 repetitions for the next 4 weeks.
40954142|NCT03012009|DEVICE|full ablative CO2 laser|ablation to the level of de dermal papilla
40954143|NCT03012009|DEVICE|fractional ablative CO2 laser|180 micron HP, pulse 8ms, 15% overlay, 30 W (943J/cm)
40954144|NCT03012009|DRUG|MAL|
40954145|NCT03012009|DEVICE|LED lamp|peak wavelength 630 nm, 37J/cm2
40954146|NCT03012009|DRUG|lidocaine hydrochloride 2% with epinephrine|
40954147|NCT06227260|OTHER|Thai massage, Thai massage with pure coconut oil, Thai massage with oil mixed with Snake fruit extract, Control, Facial mask with Snake fruit extract, Control jelly, Jelly with Snake fruit juice|Interventions among the 3 studies were categorized as other.
40954148|NCT05720169|DIAGNOSTIC_TEST|Doppler ultrasound|Doppler ultrasound at 13, 16, 20 and 26 weeks for assessment of uterine arteries according to ISUOG criteria.
40954149|NCT05720169|DIAGNOSTIC_TEST|Blood sample|Blood sampling at 13, 16, 20, 26 weeks of gestation to determine the sFlt-1/PlGF ratio
40954150|NCT05720169|DIAGNOSTIC_TEST|Blood sample|Blood sampling at week 13 for DNA extraction for genomic studies
40954151|NCT05720169|DIAGNOSTIC_TEST|Doppler ultrasound|Fetal morphological ultrasound at 13, 16 and 20 weeks.
40954152|NCT01739309|DRUG|Abemaciclib|Administered orally
40954153|NCT01194466|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
40954154|NCT02164214|DRUG|etanercept Treatment|
40954155|NCT02911220|GENETIC|demonstration of genetic mutations causing non-atopic asthma|recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
40954156|NCT04725422|DRUG|Methotrexate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
40954157|NCT04725422|DRUG|Sulfasalazine|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
40954158|NCT04725422|DRUG|Leflunomide|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
40954159|NCT04725422|DRUG|Pamidronate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
40954160|NCT04725422|DRUG|Zoledronic acid|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
40954161|NCT04725422|DRUG|Etanercept|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
40954162|NCT04725422|DRUG|Adalimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
40954163|NCT04725422|DRUG|Certolizumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
40761529|NCT05634343|OTHER|experimantal group 2|Mindfulness is purposefully drawing attention in the desired direction so that we can stay in the present moment without judgment. It is also defined as a conscious understanding of what is happening in the moment we live in with an open and loving attitude. According to another definition, mindfulness includes paying attention to what is happening in the present moment, noticing the quality of this attention, and accepting what is noticed without judgment. With conscious awareness, the individual discovers how to live in harmony with all the events that take place in the present moment, place and time, without any evaluation, rather than the sorrows and regrets of the past, the anxieties and worries of the future. Mindfulness helps us to relate to our experiences by enabling us to see the positive-negative, good-bad experiences we have had objectively.
40761530|NCT03988439|DRUG|IDP-118 Lotion|Topical
40761531|NCT03644758|DIAGNOSTIC_TEST|socio-demographic data and personal medical history|Socio-demographic data and personal medical history is a self-administered questionnaire.
40954164|NCT04725422|DRUG|Infliximab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
40761532|NCT03644758|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire. This score evaluates sleep disturbances.
40761533|NCT03644758|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale is a self-administered questionnaire. This score evaluates excessive drowsiness.
40954165|NCT04725422|DRUG|Golimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
40954166|NCT04725422|DRUG|NSAID|first-line treatment
40954167|NCT05101642|PROCEDURE|Guided Creeping Technique (GCT)|Guided Creeping Technique (GCT) is a novel minimally invasive blind tunnel
40954168|NCT01196507|DRUG|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
40954169|NCT01196507|DRUG|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
40954170|NCT05405868|DRUG|Nicotinomide|Nicotinamide tablets (750mg)
40954171|NCT05405868|DRUG|Matching placebo|Matching placebo
40954172|NCT03137342|BEHAVIORAL|Pepped on PrEP Package|A counseling and problem-solving adherence intervention with a Behavioral Activation approach to re-engage participants in safe but pleasurable activities in life and addresses stimulant abuse as well as associated factors, including depression, as barriers to optimal PrEP adherence.
41135169|NCT06071052|PROCEDURE|TACE and HAIC Combined With Regorafenib|TACE and HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer who failed the second line treatment regimens
41290816|NCT03436589|BEHAVIORAL|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
41290817|NCT02634515|DRUG|Julphar Insulin R (soluble human insulin, biosimilar)|investigational insulin, Julphar Insulin R (soluble human insulin)
41290818|NCT02634515|DRUG|Huminsulin® Normal (soluble human insulin, reference)|marketed product, Huminsulin® Normal (soluble human insulin
41290819|NCT01050062|DRUG|Telmisartan 80mg|Combination tablet
41290820|NCT01050062|DRUG|Telmisartan 40mg|Combination tablet
41290821|NCT01050062|DRUG|Hydrochlorothiazide 12.5mg|Combination tablet
41290822|NCT02332915|BEHAVIORAL|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
41290823|NCT00058799|BIOLOGICAL|Dose Level 1|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5
41290824|NCT00058799|BIOLOGICAL|Dose Level 2|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5
41290825|NCT00058799|BIOLOGICAL|Dose Level 3|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 4.2 x 10\^7
41290826|NCT05590403|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose administered intramuscularly at Day 1.
41290827|NCT05590403|DRUG|Placebo|One dose administered intramuscularly at Day 1.
41290828|NCT01654575|DRUG|Methotrexate|Methotrexate 25mg/week for 16 weeks
41290829|NCT01654575|DRUG|Placebo|Placebo tablets once a week for 16 weeks
41290830|NCT04410783|BEHAVIORAL|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of ED-based sedation, and the objectives of the research. Education will include in-services and lectures focused on the importance of sedation protocols on patient outcome. The use of sedation will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based sedation protocols.
41290831|NCT04410783|OTHER|Standard post intubation sedation practices|Usual care sedation provide in the ED
41290832|NCT03375710|DEVICE|Cordella™ Heart Failure System|"The Cordella™ Heart Failure System collects, records, and transmits physiologic data and communications from the patient at home to clinicians for assessment, patient communication, and patient-centered heart failure management. The system consists of the following components:~1. myCordella™ Patient Management Portal~2. myCordella™ Hub~3. myCordella™ Peripherals, including the Cordella™ Pulmonary Artery Sensor System (CorPASS)"
41290833|NCT02502422|DEVICE|Classic laryngeal mask airway|"1. measurement of head and neck~   * Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip\~sternal notch), modified mallampati classification under sitting position, thyromental distance.~2. laryngeal mask airway insertion and measuring cuff pressure by pressure transducer~   * # 4.0 for female, #5.0 for male~  * initial cuff volume(air) : maximum volume recommended by the manufacturer~  * check pressure : if it exceed 60cmH20, we will remove air until 60cmH20~  * remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured."
41290834|NCT03242759|DRUG|nintedanib|Drug
41290835|NCT03242759|DRUG|pirfenidone|Drug
41290836|NCT05013060|DIETARY_SUPPLEMENT|Probiotics and microcapsulated sodium butyrate|The patients who give their consent to take part in this study, will receive an oral microencapsulated sodium butyrate and a mixture of probiotics formulation 2 times a day for a period of 12 weeks.
41290837|NCT05013060|DIETARY_SUPPLEMENT|Maltodextrin|The patients who give their consent to take part in this study will receive an oral maltodextrin as placebo 2 times a day for a period of 12 weeks.
41290838|NCT02616822|DIETARY_SUPPLEMENT|Trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
41290839|NCT02616822|OTHER|Placebo|Used for placebo substance single dose
41290840|NCT05153395|OTHER|Carbon dioxide breathing|Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
41290841|NCT05153395|OTHER|Neurovascular Coupling|Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.
41290842|NCT05153395|DRUG|Human insulin|Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
41290843|NCT01768299|DRUG|Mifepristone|200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
41290844|NCT01768299|DRUG|Misoprostol|200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
41290845|NCT00834119|DRUG|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
41290846|NCT00834119|DRUG|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
41290847|NCT06158672|BEHAVIORAL|Emotional freedom technique group|Menopausal women in the emotional freedom technique group will be administered the emotional freedom technique by the researcher a total of 4 times at one week intervals.
41290848|NCT06158672|BEHAVIORAL|Sham emotional freedom technique group|Menopausal women in the sham emotional freedom technique group will be administered sham emotional freedom technique by the researcher a total of 4 times with one week intervals.
41290849|NCT01236885|OTHER|computer-assisted intervention|Undergo blood glucose management using Glucommander
41290850|NCT04320303|BIOLOGICAL|expanded NK cells|Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.
41290851|NCT03526640|DEVICE|The BioSentry Tract Sealant System|The BioSentry Tract Sealant System consists of a delivery system and a coaxial adapter with Bio-Seal™ plug. The hydrogel plug is deployed in the tract created by the lung biopsy needle and self-expands upon contact with moist tissue.
40761534|NCT03644758|DIAGNOSTIC_TEST|Insomnia Severity Index (ISI)|Insomnia Severity Index (ISI) is a self-administered questionnaire. This score evaluates insomnia severity.
40761535|NCT03644758|DIAGNOSTIC_TEST|stop-BANG questionnaire|Stop-BANG is a self-administered questionnaire. This score evaluates Obstructive Sleep Apnea (OSA).
40954173|NCT04617587|BEHAVIORAL|Early Intervention|The early intervention (EI) is delivered during the NICU stay. It is a multisensory intervention which consists in three parts: parental training, massage therapy and visual interaction. The EI is first focused on parental training, according to PremieStart Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior through the identification of infant's behavioral states; adopt principles of graded stimulation; sustain infant's attention and respond to infant's cues; optimize interactions and avoid overwhelming infants through facilitation strategies. The program is held in eight main sessions and one additional post-discharge session. In addition, parents are trained and invited to daily promote preterm baby massage therapy and visual interaction (visual fixation/tracking and visual attention).
40954174|NCT02407795|RADIATION|conventional radiotherapy|1x8Gy
40954175|NCT02407795|RADIATION|stereotactic radiotherapy|1x20Gy or equivalent dose fractionation schedule
40954176|NCT06107504|DRUG|Sucralfate|2g of sucralfate powder and 1g of tranexamic acid powder will be sprayed after EST
40954177|NCT03922126|OTHER|Peer counseling|Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake
40954178|NCT03922126|DIAGNOSTIC_TEST|HIV/STI self-testing kits|Kits to self-test for HIV/STIs
40761536|NCT05684198|DEVICE|subcutaneous NPWT|Following fascia closure, NPWT system will be inserted into subcutaneous tissue, continuous negative pressure of 120 mmHg will be applied.
40954179|NCT00078182|DRUG|Tenofovir DF|
40954180|NCT02751866|DIETARY_SUPPLEMENT|Berry fruit powder OR nutritional ketosis|Daily supplementation with berry fruit powder OR carbohydrate restriction to achieve nutritional ketosis
40761537|NCT06458998|BEHAVIORAL|Patient Navigation|Clinical Resource Hub (CRH) providers include a small group of nurses, advance practice providers, and physicians who work to improve care across a range of measures using virtual PN. CRH providers will 1) use existing dashboards to identify at-risk Veterans, 2) conduct Veteran outreach (two calls, one letter) to provide education, problem solve, and offer screening, 3) order and schedule HCC or CRC screening tests, and 4) provide reminders and follow up on results.
40761538|NCT06458998|BEHAVIORAL|Implementation Facilitation|Facilitators will provide 20 hours of virtual facilitation to site teams, through 1-hour meetings every other week and ad hoc meetings, over 12 months. They will guide site teams through a seven-step playbook called Getting To Implementation (GTI), which uses a series of tools to select context-specific strategies.
40761539|NCT03497702|DRUG|Doxorubicin|60mg/m2 IV every 3 weeks for 4 cycles
40761540|NCT03497702|DRUG|Cyclophosphamide|600mg/m2 IV every 3 weeks for 4 cycles
40761541|NCT03497702|DRUG|Docetaxel|75mg/m2 IV every 3 weeks for 4 cycles
40761542|NCT03497702|DRUG|Letrozole|2.5 mg once daily preoperably
40761543|NCT03497702|DRUG|leuprorelin|3.75 mg SC every 4 weeks for premenopausal patients
40761544|NCT06539260|DRUG|Vitamin D|Take 400 units of vitamin D3, twice daily, for a duration of 3 months.
40761545|NCT06539260|DRUG|Placebo|Take a placebo that is identical in appearance and weight to 400 units of vitamin D3, twice daily, for a duration of 3 months.
40761546|NCT01000116|PROCEDURE|Fibrin glue|Tissucol 2 ml
40761547|NCT01000116|PROCEDURE|Tacks|Protacks
40954181|NCT02751866|DIETARY_SUPPLEMENT|Placebo powder OR higher carbohydrate|Daily supplementation with placebo powder OR higher carbohydrate intake
40761548|NCT03917901|OTHER|Anxiety Sensitivity Training|Computerized Single-Session Anxiety Sensitivity Reduction Program
40761549|NCT03917901|OTHER|Health Control|Computerized Single-Session Health Information Control
40761550|NCT01392066|BEHAVIORAL|questionnaire|"Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.~The questionnaire is administered at baseline and 5- and 12-months follow up."
40761551|NCT02953431|DEVICE|CPAP|CPAP will be administered with a CPAP machine
40761552|NCT06428357|DIETARY_SUPPLEMENT|Recombinant Bovine Lactoferrin|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
40761553|NCT06428357|DIETARY_SUPPLEMENT|Bovine Milk-Derived Lactoferrin|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
40761554|NCT06428357|DIETARY_SUPPLEMENT|Placebo|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
40954182|NCT01449539|DRUG|Hyperbaric Oxygen Therapy|Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
40954183|NCT06033144|DIAGNOSTIC_TEST|Diagnosis of Tapia's Syndrome|"The diagnostic includes :~* Lingual clinical examination~* Nasofibroscopy~* Ultrasonography"
40954184|NCT03353246|DEVICE|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
40954185|NCT00516074|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
40954186|NCT00516074|DRUG|placebo|subcutaneous injection, volume equivalent to active, twice a day
40954187|NCT01225692|BEHAVIORAL|Head Injury Guideline|
40954188|NCT03532061|BEHAVIORAL|FamCare Program|6 in-person sessions of biweekly home care problem-solving skills training (FamCare) delivered by a health educator.
40954189|NCT03532061|OTHER|Caregiver Support Group|6 in-person caregiver support group sessions held biweekly and moderated by a health educator.
40954190|NCT01595607|OTHER|Diet Treatment|Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
41290852|NCT03636594|OTHER|Dance|The dance program consisted of one-hour dance classes delivered twice a week for 8 weeks. The classes featured different dance types (such as partnered and non-partnered) and genres (such as salsa, ballroom and jazz) with increasing complexity.
40954191|NCT04016064|PROCEDURE|Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery|"1. Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~2. Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~3. Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~4. Conventional surgical method was applied with hand instruments and gingivectomy knives."
40761555|NCT05327569|OTHER|Myofascial Chain Release Techniques|Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.
40954192|NCT06248060|OTHER|preanaesthetic classical physical consultation|Pre-anaesthetic classical consultation before teleconsultation implementation
41135170|NCT03494413|DIAGNOSTIC_TEST|Transpharyngeal Doppler sonography (TPS)|Usage of transpharyngeal Doppler to assess cerebral perfusion during cardiovascular surgery
40761556|NCT03139721|DEVICE|Mosaic model 305, model 310, and ultra model 305|Aortic or mitral valve replacement
40761557|NCT01988558|DRUG|DL - Lactic Acid|Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
40761558|NCT01988558|DIETARY_SUPPLEMENT|Raspberry flavored syrup|Placebo group to receive Raspberry flavored Syrup
40761559|NCT04976855|DRUG|INDV-2000|Capsule for oral administration
40761560|NCT04976855|DRUG|Placebo|Capsule for oral administration
40761561|NCT04976855|DRUG|SUBOXONE® sublingual film|Administered either under the tongue (sublingual) or between the gum and cheek (buccal)
40761562|NCT03844035|DIAGNOSTIC_TEST|Periimplant crevicular fluid (PICF) collection|Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.
40761563|NCT04722315|DIETARY_SUPPLEMENT|Modified Atkins diet|12 weeks of modified Atkins diet
40761564|NCT04016610|DEVICE|Soliton's Acoustic Scar Reduction (SAR)|Treatment of keloid scars for the temporary improvement in appearance.
40761565|NCT06570889|DIETARY_SUPPLEMENT|Cholecalciferol D3|Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
40761566|NCT06570889|OTHER|Olive oil|Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
40761567|NCT03347669|DEVICE|Sudoscan®|Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.
40761568|NCT05052892|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
40761569|NCT02196974|PROCEDURE|cryobiopsy|
40954193|NCT06248060|OTHER|preanaesthetic teleconsultation|Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
40954194|NCT05771012|DRUG|0.05% cyclosporin (Restasis®, Allergan Inc)|study the efficacy of topical 0.05% cyclosporin eye drops (Restasis®, Allergan Inc) in management of grade 1 and 2 acquired punctal stenosis (group A)
40954195|NCT05771012|DEVICE|mini-monoka stent|insertion of mini-monoka stent in the lower punctum in management of grade 1 and 2 acqquired punctal stenosis (group B)
41135171|NCT03494413|DIAGNOSTIC_TEST|Conventional colour-coded Duplex sonography (CDS)|Usage of conventional colour-coded Duplex sonography (CDS) to assess cerebral perfusion during cardiovascular surgery
41135172|NCT03829553|RADIATION|Hypofractionated radiotherapy|4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast
41135173|NCT03829553|RADIATION|Conventional radiotherapy|5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast
41135174|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Montanide|
41135175|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Montanide + Imiquimod|
41135176|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Imiquimod|
40954196|NCT02304718|BEHAVIORAL|Stationary bike|
40954197|NCT06438302|DEVICE|EEG activity measurement|"The nasal ventilation device (placed as part of the research) (AIRVO 2; Fisher and Paykel Healthcare, Auckland, New Zealand) will be positioned via nasal cannulas adapted to the patient's anatomy. The FiO2 will be set at 21% and the flow rate will be fixed at 0 L/min at the inclusion visit. The temperature of the humidified nasal oxygenator will be set at 37°C.~Six 30-minute experimental conditions will be performed successively: 1) 0 L/min flow, FiO2 21%, 2) 30 L/min flow, FiO2 21%, 3) 30 L/min flow, FiO2 100%, 4) 60 L/min flow, FiO2 21%, 5) 60 L/min flow, FiO2 100%, 6) Negative control.~At the end of each condition, a 10-minute thoracic electrical impedance tomography recording, a 10-minute EEG recording, a 10-minute cerebral NIRS recording and an instantaneous temporal Doppler velocity measurement will be performed. A blood gas (1.5 mL) will also be taken at the end of each condition."
40954198|NCT03460275|DRUG|Osimertinib Mesylate Tablets|Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)
40954199|NCT04258865|DRUG|CKD-348 F1|QD, PO
41290853|NCT05047393|OTHER|Current blood vitamin D level and painDetect questionairre score will be detected|PainDETECT neuropathic pain questionnaire will be used to evaluate the presence of nociceptive, mixed and neuropathic pain in patients. Patients with a total questionnaire score of 12 or less are considered nociceptive pain without a neuropathic pain component. If the total score is in the range of 13-18, the result is uncertain, but it is accepted that the neuropathic component can be found in the mixed type, and in the scores of 19 and above, it is accepted that the neuropathic pain component is present. Patients with previously obtained and finalized vitamin D levels \< 20 ng/mL, 20-30 ng/mL, and ˃30 ng/mL will be grouped as deficiency, insufficiency and normal, respectively.
41290854|NCT04169828|DRUG|Methotrexate|Children in both the intervention and control group will receive Methotrexate dosed as prescribed by the attending rheumatologist
40954200|NCT04258865|DRUG|CKD-348 F2|QD, PO
41290855|NCT04169828|DRUG|Ondansetron|"Children in the intervention group will be prescribed premedication with oral ondansetron.~Children in the control group will be prescribed ondansetron ONLY if the child reports nausea/vomiting during regular treatment care with Methotrexate"
41290856|NCT04169828|DRUG|Folic/folinic acid|Children in both intervention and control group will receive folic acid or folinic acid dosed as prescribed by the attending rheumatologist.
41454834|NCT00850447|OTHER|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
41454835|NCT00850447|OTHER|Videogame|Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
41454836|NCT04429113|DEVICE|Maxillary expansion with conventional Quad Helix bonded on molars.|Maxillary expansion with conventional Quad Helix bonded on molars
41454837|NCT04037488|DIAGNOSTIC_TEST|Inbody 320|Total Skeletal muscle mass (SMM), Skeletal muscle index (SMI), Relative Skeletal muscle mass index (RASM), Fat body mass (FBM), Body mass index (BMI), Body fat percentage, Body water content, Edema Value were calculated by Inbody 320
41454838|NCT01426854|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
41454839|NCT01426854|OTHER|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
41454840|NCT01080703|OTHER|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
40761570|NCT01390103|OTHER|Assessment following hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
40761571|NCT05507437|BIOLOGICAL|TIN816 70 mg lyophilisate powder|Recombinant human CD39 enzyme
40954201|NCT04258865|DRUG|CKD-828, D097, D337|QD, PO
40954202|NCT05840380|DEVICE|instrumental soft tissue mobilization|Individual supine for application will be deposited. The Graston instrument glides over the tissues of the individual. cream will be applied to make it easier, then the physiotherapist will will stand on its side at the level and graston for 5 minutes. superficially on the thoracolumbal fascia between the sacrum and T12. will be applied
41135177|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 intra nodal injection|
41135178|NCT03428438|OTHER|Rehabilitation at home via SMS|Cardiac rehabilitation
41135179|NCT05137366|DIAGNOSTIC_TEST|Transthoracic ultrasound scan|"An ultrasound scan of the thoracic aorta will be performed using an ultrasound machine with 2 MHz phased array transducer. The patient will lay supine on an ultrasound scan couch.The measurements will be taken in B-mode but colour Doppler imaging may be used to identify the thoracic aorta if it is obscured by artefacts. The measurement will be taken inner wall to inner wall and several images will be taken to check reliability.~Three different acoustic windows will be used to image the thoracic aorta:~1. Suprasternal window~2. Parasternal long axis window~3. Apical two chamber views~Ultrasound assessment will be considered satisfactory when at least two of the three regions of the descending thoracic aorta were visualised, partially satisfactory when a single view was obtained and inconclusive when none of the three windows could be obtained."
41135180|NCT05165420|OTHER|Cosmetic product|RV4941A is a face cream product
41290857|NCT03322657|DRUG|Neostigmine|Neostigmine injection
41290858|NCT03322657|DRUG|Glycopyrrolate|Glycopyrrolate injection
41290859|NCT03322657|DRUG|Sugammadex|Sugammadex injection
41290860|NCT02924753|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
41290861|NCT02924753|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
41290862|NCT02924753|BIOLOGICAL|CART-19 cells|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
40954203|NCT05571670|DRUG|Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor|Participants will be treated with PI3K/AKT/mTOR inhibitors by their treating oncologist based on standard of care. This study will prospectively monitor bile acids and parameters of insulin resistance before and during treatment with these drugs.
41290863|NCT01644045|DEVICE|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
41290864|NCT05099601|COMBINATION_PRODUCT|Silymarin|The patients will use topical silymarin 0.7% cream on the face twice daily(home use).
41290865|NCT05099601|PROCEDURE|Microneedling|Patients will be subjected to microneedling sessions on one side of the face. Three consecutive sessions, 4 weeks apart (0, 4, 8 weeks), will be performed by dermapen. Sessions will be done by well trained physician.
40954204|NCT02856035|OTHER|Neural feedback plus FES and motor training|We are not testing the feasibility of the imaging methods; that has been well established and is used clinically. We are testing the feasibility of using neural feedback clinical imaging methods in a neural feedback paradigm which involves sequential rtfMRI (phase I) and rtfNIRS (phase II) training; Neurally-triggered, peripherally-directed FES-assist practice of wrist and finger extension will be combined with rtfNIRS training in Phase II; up to 60 total sessions, including additional motor learning sessions without brain neural feedback will be provided in Phase III.
40954205|NCT05367427|DIETARY_SUPPLEMENT|Heat treated postbiotic Bifidobacterium Longum consumption|Regular consumption in breakfast of heat treated postbiotic B. longum
40954206|NCT05367427|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
40954207|NCT00539656|BIOLOGICAL|Ex vivo expansion of cord blood|Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused
41290866|NCT02081469|OTHER|TDF|To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
41290867|NCT04640597|DEVICE|BioMimics 3D Vascular Stent System|Patients with BioMimics 3D Vascular Stent System
41290868|NCT01588080|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
41290869|NCT01588080|DEVICE|SiPAP - placebo|The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
41290870|NCT06448780|DRUG|Caffeine citrate 20 mg/kg|Following loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
41290871|NCT06448780|DRUG|Caffeine citrate 30 mg/kg|Following loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
41290872|NCT05400460|PROCEDURE|Anatomical single-bundle reconstruction（ASBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the ASBR group to receive anatomic single-bundle reconstruction.We used hamstring as an autograft in the operation, and we chose the anatomical footprint of the anterior cruciate ligament for the positioning of the bone tunnel.Arthroscopic ASB ACL reconstruction was conducted with AMP technique.
41454841|NCT03715751|OTHER|ASV|Adaptive Support Ventilation
40954208|NCT03300284|BEHAVIORAL|Questionnaires|Quality of Life Questionnaires
40954209|NCT05248490|OTHER|pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization
40954210|NCT04496700|PROCEDURE|Whole blood donation and transfusion|"The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only."
40954211|NCT05932966|DEVICE|Insulin closed-loop delivery system|Insulin closed-loop delivery system
40954212|NCT06557967|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
40954213|NCT01480089|DRUG|Intraperitoneal Ropivacaine (AIR)|Ropivacaine 2 mg/kg per lean body mass up to no more than 200mg total dose will be atomized and delivered into the peritoneal cavity at the completion of surgery.
40954214|NCT01480089|DRUG|Atomized Intraperitoneal Saline (AIS)|Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
40954215|NCT03525366|OTHER|Radiofrequency ablation|Radiofrequency Ablation (RFA) as an intervention is part of standard of care at Memorial Herman Hospital, Houston.
41454842|NCT03715751|OTHER|Lung Protective Ventilation|Targeted tidal volume of 6cc/Kg, Positive Inspiratory Pressure titrated per ARDS guidelines.
41454843|NCT02127216|BEHAVIORAL|MOSES|MOSES is an integrated system between a patient, peer patients, and healthcare providers.
41454844|NCT02840669|PROCEDURE|Cardiac magnetic resonance imaging (CMR)|
40954216|NCT05343442|PROCEDURE|Percutaneous tracheostomy|"Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable."
40954217|NCT00547495|DRUG|tadalafil|5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
40954218|NCT00547495|DRUG|placebo|placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
40954219|NCT00547495|DRUG|tadalafil|10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
40954220|NCT00547495|DRUG|tadalafil|20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
40954221|NCT06334458|DIAGNOSTIC_TEST|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile
40954222|NCT04816266|DEVICE|Iol master|Iol master measures the distance between anterior pole of the cornea and the anterior surface of the lens to calculate the anterior chamber depth
40954223|NCT04816266|DEVICE|Pentacam|The Pentacam HR calculates Anterior chamber depth from the corneal endothelial layer along a line from the apex of the cornea to the anterior surface of the lens
40954224|NCT00227448|DRUG|intravenous saline|
40954225|NCT00227448|DRUG|intravenous phenylephrine|
40954226|NCT00227448|DRUG|intravenous levophed|
40954227|NCT00227448|DRUG|oral midodrine|
40954228|NCT01804023|OTHER|HEC placebo gel applicators|"Participants will handle, but not insert, 4 applicators containing HEC placebo gel.~Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators."
40954229|NCT01846390|DRUG|Gemcitabine|Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.
40954230|NCT01846390|DRUG|Dexamethasone|40 mg D1 - D4
40954231|NCT01846390|DRUG|Cisplatin|75 mg/m2 D1
40954232|NCT01846390|DRUG|Romidepsin|Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.
41290873|NCT05400460|PROCEDURE|Double-bundle reconstruction （DBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the DBR group to receive double bundle reconstruction.The hamstring autograft is still used for double-bundle reconstruction. The surgical approach is to treat the native ligaments as anteromedial bundles and posterolateral bundles and restore the structure of the two bundles of ligaments in the process of a
41454845|NCT02840669|PROCEDURE|Exercise-stress test|
41454846|NCT02840669|PROCEDURE|Echocardiography (ECHO)|
40954233|NCT06044454|OTHER|qXR|a software product that uses artificial intelligence to triage, prioritise, and (for tuberculosis only) diagnose based upon identified abnormalities within the CXR.
40954234|NCT00250055|PROCEDURE|Colposcopy, Spectroscopy, and Biopsy|During the colposcopy or LEEP (Loop Electrical Excision Procedure) procedure, or during pelvic exams before surgery after the doctor applies 3% acetic acid to the cervix, the doctor then positions the colposcope to take pictures of the patient's cervix. Digital pictures are taken of the patient's cervix under white light using a colposcopy imaging system. These pictures are annotated by the doctor during the appointment to mark the spectroscopy sites.
40954235|NCT01389271|DRUG|Ventavis inhaled (Iloprost, BAYQ6256)|Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
41454847|NCT02840669|PROCEDURE|Cardiac-related blood studies|
41454848|NCT01732562|OTHER|Patient e-Learning educational tool|Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
41454849|NCT04793633|COMBINATION_PRODUCT|LINFU™ Technique|Non-focused ultrasound excitation of the pancreas with IV Lumason and IV secretin injected during the ultrasound procedure.
41454850|NCT00216060|DRUG|Risedronate|Daily oral risedronate combined with androgen deprivation
40954236|NCT00769210|DRUG|Simvastatin|Simvastatin 40 mg tablet
40954237|NCT05114070|OTHER|Decision of hypothermia|Decision of hypothermia thanks to EEG signal
40954238|NCT03659734|BEHAVIORAL|Motivational Interviewing and Guided Opioid Tapering Support|Following surgery, participants will undergo motivational interviewing with a trained member of the study staff. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
40954239|NCT03659734|BEHAVIORAL|Enhanced Usual Care|Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
40954240|NCT00194883|DRUG|Recombinant Human Growth Hormone|
40954241|NCT05306977|DEVICE|Open-label accelerated 1 Hz repetitive transcranial magnetic stimulation|Patients will receive a 5-day course of accelerated 1 Hz rTMS (8x session x 600 pulses/session) to the right intraparietal sulcus. Subjects will receive a continuous train of 1 Hz stimulation. They will receive a total of 600 pulses per train. Trains will be separated by \~50 min rest intervals.
40954242|NCT03315546|RADIATION|radiotherapy delivery in deep-inspiration|Radiotherapy delivery i deep-inspiration versus free-breathing
41135181|NCT00491101|OTHER|Polish Version of PAQLQ(S) by Juniper|Polish Version of PAQLQ(S) by Juniper
41135182|NCT00491101|OTHER|spirometry|spirometry
41135183|NCT00786188|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.
41135184|NCT00786188|DRUG|Sugar pill|Subjects will receive a sugar pill.
41454851|NCT00216060|DRUG|Placebo|Daily oral placebo combined with androgen deprivation
40954243|NCT04396301|DRUG|Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE).|Fydrane®. The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide type local anaesthetics) for each 0.2 ml dose, equivalent to 0.2 mg of tropicamide, 3.1 mg of phenylephrine hydrochloride and 10 mg of lidocaine hydrochloride for 1 ml.
40954244|NCT02315989|RADIATION|proton therapy|proton therapy
40954245|NCT04304742|PROCEDURE|hip standard radiography/ CT scan/ MRI|hip standard radiography/ CT scan/ MRI
41290874|NCT05400460|PROCEDURE|Central axial single-bundle reconstruction（CASBR group）|"406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to CASBR group.Arthroscopic ASB ACL reconstruction was conducted with transtibial technique and using Hamstring as autograft.Single-bundle reconstruction is used in CASBR reconstruction surgery.~The footprint of the implant on the lateral femoral condyle was chosen to be the location of the AMB bone canal in DB reconstruction surgery while the footprint of the implant on the tibial plateau was chosen to be the location of the bone canal of the PLB in DB reconstruction surgery."
40954246|NCT05719376|DRUG|Monofer (experimental)|Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day\~OP-1day
40954247|NCT05719376|DRUG|control group|Ferritin\<100, TSAT\<20 : Monofer 200mg IV, twice/ Ferritin 100\~200, TSAT\<20 : Monofer 200mg IV, once / Ferritin 201\~500, TSAT\<20 : Monofer 100mg IV, once / Not administer in any other case
40954248|NCT01948661|DIETARY_SUPPLEMENT|Mirtoselect® + Meriva®|
40954249|NCT01948661|DIETARY_SUPPLEMENT|Placebo|
40954250|NCT04765982|DIAGNOSTIC_TEST|Checking diabetes development in follow up at 3 month|An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
40954251|NCT03884959|BIOLOGICAL|HepaStem Infusion|HepaStem will be infused intravenously into the portal vein, either (1) via a permanent mesenteric PAC inserted surgically in an affluent of the portal vein; or (2) through a transient percutaneous transhepatic catheter inserted in to the portal vein under radio guidance.
40954252|NCT04061265|DRUG|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|Local anesthetic agent
40954253|NCT04061265|DRUG|lidocaine hydrochloride 2% and epinephrine 1:100000|Local anesthetic agent
40954254|NCT03849248|OTHER|Maternal scent cloth|The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
40954255|NCT03026361|GENETIC|global proteomic profiling|Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.
41290875|NCT05400460|OTHER|rehabilitation training protocol|The rehabilitation program for all patients followed a standardized Process. The first day after surgery, quadriceps sets, straight-leg raises, and prone hangs were initiated. All of the patients were allowed to walk with crutches and braces but with no weightbearing. The range of motion (ROM) progressed from 0 to 90 degrees 3 to 7 days postoperatively and reached 115 degrees within fourth week. Closed kinetic chain exercises and full weightbearing were started in the sixth week. Patients progressed to running without braces at 4 to 6 months.
41454852|NCT05139628|DIAGNOSTIC_TEST|microbiological identification of samples (skin and blood samples)|"Samples will be plated on blood culture plates and will be confirmed biochemically.~Complete Bacteriological diagnosis will be done. The TTP of each BC bottle will be recorded"
40954256|NCT04111575|BEHAVIORAL|Music Therapy|Music Therapy
40954257|NCT02418650|DRUG|ODM-201 300 mg tablet|
40954258|NCT02418650|DRUG|intravenous14C-ODM-201|
40954259|NCT02418650|DRUG|300 mg 14C-ODM-201 oral solution|
40954260|NCT01703325|DRUG|0.1% triamcinolone , 0.05% clobetasol propionate ointment|"Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~* Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~* Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~* Group C: Controlled group"
40954261|NCT00936156|DRUG|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
40954262|NCT04040205|DRUG|Abemaciclib|Abemaciclib 200 mg will be taken by mouth twice daily.
40954263|NCT00311844|DRUG|desloratadine|
40954264|NCT03428932|DEVICE|Closed Loop (Medtronic 670G)|A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized
40954265|NCT03428932|OTHER|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months.
40954266|NCT01880281|OTHER|Meat and vegetable diet|After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
40954267|NCT00385710|DRUG|valproic acid|Depakine
40954268|NCT00385710|DRUG|Placebo|Placebo
40954269|NCT06483178|DEVICE|Attune knee implant|Attune cementless cruciate retaining rotating platform implant (DePuy Synthes) with a standard gap balancing cruciate sacrificing surgical technique
41290876|NCT05400460|OTHER|Educate patients on return to sports and the importance of quadriceps strength|"Patients were interviewed by telephone preoperatively, 6 months postoperatively, and 1 year postoperatively to ask about Tegner scores and to encourage reasonable return to sports from 6 months postoperatively.~Inform patients of the possibility of osteoarthritis in patients undergoing ACL reconstruction preoperatively, 6 months postoperatively, and 1 year postoperatively in telephone interviews.Tell the patient that return to sports and quadriceps strength is a must if the knee cartilage damage is to improve."
41454853|NCT03975439|DIAGNOSTIC_TEST|Hemoglobin A1C|Finger stick hemoglobin A1C
41454854|NCT03975439|DIAGNOSTIC_TEST|Urinalysis|Urinalysis by dip stick looking for urine protein level
40954270|NCT06483178|DEVICE|Triathlon knee implant|Triathlon cementless condylar stabilised implant (Stryker) with a standard gap balancing cruciate sacrificing surgical technique
40954271|NCT05376462|DIAGNOSTIC_TEST|Quantra System with the QStat Cartridge|Whole blood viscoelastic test system that provides an assessment of the patient's coagulation status.
40954272|NCT05376462|DIAGNOSTIC_TEST|Standard Laboratory Tests|Laboratory tests that provide information about a patient's coagulation status.
40954273|NCT01595711|DEVICE|Pain Monitor|Measurement of cutaneous conductance
40954274|NCT04926142|DEVICE|Implantation of Holter device|Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm
40954275|NCT04926142|PROCEDURE|Percutaneous PFO closure|Patients will undergo percutaneous closure of patent foramen ovale
40954276|NCT00876057|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy
40954277|NCT00876057|PROCEDURE|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
40954278|NCT05846204|BEHAVIORAL|Progressive Muscle Relaxation|"The PMR exercise, which includes the systematic relaxation of the main muscle groups of the body aimed at physical and psychological relaxation, was applied twice a day, every weekday, for eight weeks.~DB exercises training was given to the patients in this group individually by face-to-face interview. During the application, the importance of deep and comfortable breathing was explained and correct breathing technique was taught."
40954279|NCT05846204|BEHAVIORAL|Deep Breathing Exercise Group-DBE|Breathing exercise is an exercise to improve breathing and functional performance. deep breathing exercise; It is a nursing intervention that helps to increase the function of respiratory muscles and improve ventilation and oxygenation.
40954280|NCT00106197|DRUG|Bupropion|Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
40954281|NCT03694002|DRUG|Carboplatin|Given IV
40954282|NCT03694002|DRUG|Paclitaxel|Given IV
40954283|NCT03694002|BIOLOGICAL|Ramucirumab|Given IV
40954284|NCT00310401|DRUG|Albuterol|5 mg nebulized q4h
40954285|NCT00310401|DRUG|Saline|1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
40954286|NCT06428422|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis Bl-04|4 x 10\^9 cfu/g/day Bifidobacterium animalis subsp. lactis Bl-04 for 12 weeks
41135185|NCT02481804|OTHER|Dietary intervention|"Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.~Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts."
41135186|NCT02481804|OTHER|Standard treatment|Standard treatment will be continued
41290877|NCT01145105|PROCEDURE|neural dynamics techniques treatment|Treatment group- will receive neural mobilizations techniques, to improve movement of the sciatic nerve.
41454855|NCT03975439|DIAGNOSTIC_TEST|Whole blood creatinine level|Finger stick looking for serum creatinine as an estimate of renal function
41454856|NCT03136562|DIAGNOSTIC_TEST|Synacthen test|250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
40761572|NCT05507437|OTHER|Placebo|0.9% sterile sodium chloride solution
40954287|NCT06428422|OTHER|Plasebo|1 g/day maltodextrin for 12 weeks
40954288|NCT00808990|DIETARY_SUPPLEMENT|BioFemale|BioFemale 6 months.
41454857|NCT05541198|OTHER|Pressure Injury Prevention Care Bundle|"1. Risk Assessment~2. Skin Assessment~3. Skin Care~4. Positioning~5. Regulation of Nutrition and Liquid Management"
40954289|NCT04057365|DRUG|Nivolumab|Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
40954290|NCT04057365|DRUG|DKN-01|DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
40954291|NCT05446896|DEVICE|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide with the same text and images as in the printed manual, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
40954292|NCT02974283|OTHER|Normobaric oxygen therapy|"In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .~Other Names:"
40954293|NCT06556381|PROCEDURE|TAP block|Women will receive TAP block.
40954294|NCT06012474|OTHER|Power breath plus|Power breath plus use a variable load calibrated spring. It can be adjusted from the lowest load setting (17cmH2O) when training began and increased as the patient breathing muscles adapt and become stronger (maximum load setting 274cmH2O). Use a comfortable chair, preferably straight-back so that the spine is straight at all times during the exercise. patients will be instructed to exhale calmly, followed by a maximal forced inspiration to total lung capacity using a mouthpiece and a nasal clip as an aid to prevent air leaks and will ask to make 10 breaths for 3 sets once daily for 7 days with 2min rest between sets
40954295|NCT06012474|OTHER|Incrementing the training load|The resistance will be increased incrementally, based on the rate of perceived exertion (RPE) scored by the patient on the modified Borg Scale. If the RPE is less than 5, the resistance of the inspiratory trainer will be increased incrementally by 2cmH2O. The resistance will not change if the level of perceived exertion is rated from 6 to 8, and the resistance will be decreased by 1 to 2 cmH2O if the level of perceived exertion is rated 9 or 10.
40954296|NCT06012474|OTHER|Diaphragmatic breathing exercises|"Training by using incentive spirometer:~* Loosen any tight clothing, especially around neck.~* Each patient will be instructed to sit upright with placing incentive spirometer at the same level of his mouth to promote optimal lung expansion while using the spirometer.~* The patient will be instructed to exhale letting all the breath out.~* patient will asked to close the lips around the mouthpiece of the spirometer.~* patient will be instructed to inhale slowly, breathing in until unable to do any more, this would raise the balls to the top of the column.~* patient will be asked to hold the breath as long as possible (at least five seconds) then exhale slowly.~* Session will be in the form of 30 times in sets, each set consist of 5-6 repetitions with rest 1 minute between sets.~* Intensity of exercise will be increased by increasing time of session, time of holding the breath and numbers of repetitions according to patient's status."
40954297|NCT03531125|PROCEDURE|Endoscopic Ultrasound|Endoscopic ultrasound for tumour biopsy collection
40954298|NCT03531125|PROCEDURE|Pancreaticoduodenectomy|Surgery to remove pancreatic tumour
40954299|NCT01072383|DRUG|BT061|administration of BT061 either intravenous or subcutaneous
40954300|NCT01072383|DRUG|placebo treatment|administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
40954301|NCT01275820|DIETARY_SUPPLEMENT|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
40954302|NCT05403788|DEVICE|Intervention with virtual reality|"VR intervention with OCULUS QUEST2 (OCULUS VR, USA) consiste on a VR helmet positioned over subject head. The software consisted of a 3D environment with exercises of upper limbs and visual feedback for the treatment of cognitive and motor dysfunction. The therapist have real-time access to the activities in the 3D environment vby real-time video transmission of the helmet activity.~The program include a single session. Each session is monitored on safety aspects of the subjects with emphasis on possible side effects of virtual reality."
40954303|NCT02178735|PROCEDURE|Anterior vaginal tailored mesh surgery|Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
40954304|NCT02178735|PROCEDURE|Posterior vaginal tailored mesh surgery|Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
40954305|NCT03985254|OTHER|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]), and in subsequent weeks the goal will be the development of muscle strength (load\> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
40954306|NCT03985254|OTHER|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]). However, in subsequent weeks the goal will be to develop strength (load\> 70% 1RM) and muscle power (load between 40-60% 1RM).
40954307|NCT01206075|DRUG|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
40954308|NCT01206075|DRUG|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
40954309|NCT01206075|DRUG|Mozobil|Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
41135187|NCT05544305|OTHER|Digital Home Based Care pathway|The digital version of the pathway includes an integrated data platform with an automated patient flow management system, digitised patient-reported outcome on web-based patient portal, and AI-based automated reporting for clinical decision support.
41135188|NCT06261905|DRUG|[11C]-PHNO|PHNO is used as a tracer for in-vivo imaging.
40761573|NCT05740826|DEVICE|Algometer|The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain
41135189|NCT06261905|DIETARY_SUPPLEMENT|Calcitriol|Calcitriol is an active form of Vitamin D and is given in 3 0.5mcg capsules per dose.
40954310|NCT06038214|OTHER|core exercises|"1.5 minutes walking 2. Stretching exercise~* hallowing in supine and side lying position~* Bracing in supine and side lying position~* Bracing on the prone and forearms~* Bracing in the crawling position~* Bracing in laptop, half-lap and standing position~* Heel slide exercise~* Bridge building exercise~* Unilateral limb flexion exercise in crawling position~* Reciprocal heel slide exercise in supine position~* Bilateral lower extremity lifting exercise~* Unilateral lower extremity flexion in bridging position~* Side bridging exercise with knees extended~* Unilateral lower extremity extension in crawling position~* Contralateral lower and upper extremity lift in the crawling position~* Straight and oblique trunk flexion~* Straight and oblique trunk flexion with hip and knee flexed to 90°~* bracing on the ball~* squat~* bracing while walking"
40954311|NCT06038214|OTHER|home exercises|"Right and left rotation of the head~* lateral flexion of the head~* Flexion and extension of the head~* Stretching the neck extensors~* pectoral stretch~* Stretching the hip extensors~* Hamstrig stretching~* Stretching the lumbar extensors~* Abdominal strengthening~* bridging~* Hip abduction strengthening~* hip extension strengthening~* Upper extremity resistant flexion~* Upper extremity resistant abduction~* Upper extremity relaxation exercise~* Capsule stretching~* Stretching the hip flexors~* Stretching the lower extremity adductors~* relaxation exercise"
40954312|NCT05425641|BEHAVIORAL|Goal Setting|"Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?."
40954313|NCT05425641|BEHAVIORAL|Action Planning|"Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?"
40954314|NCT05425641|BEHAVIORAL|Self-Monitoring of Behavior|"Individuals will receive daily text messages that include the Self-Monitoring behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Self-Monitoring BCT is Check your fitbit for yesterday. Type in the number of steps you did yesterday."
40954315|NCT05425641|BEHAVIORAL|Feedback on Behavior|"Individuals will receive daily text messages that include the Feedback behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Feedback BCT is Your goal is to walk 1000 steps more than your baseline average. Yesterday you did not meet your goal. If you think this is incorrect you can check your step count from yesterday on your Fitbit app to confirm. "
40954316|NCT02573168|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
41135190|NCT06261905|OTHER|Placebo Control|A placebo is an inert capsule, which contains no active ingredients. The placebo will be given in 3 0.5mcg capsules per dose.
41290878|NCT01145105|PROCEDURE|placebo treatment|Control group- will receive placebo treatment that will include mobilization to the upper limb. After the placebo treatment, these patients will receive neural mobilizations techniques.
41290879|NCT05405543|DRUG|MYK-224|Specified dose on specified days
41290880|NCT05405543|OTHER|Placebo|Specified dose on specified days
41290881|NCT06320197|OTHER|In situ simulation assessment|Unannounced in situ simulation assessment during working hours
41290882|NCT02944747|BEHAVIORAL|Education & paper based calendar|The participants will be counseled on importance of remembering LMP. In addition, they will be provided a free calendar to record their LMP dates.
41135191|NCT06261905|PROCEDURE|PET Scan|A high resolution PET Scan performed using a NeurExplorer CT scanner.
41290883|NCT02944747|BEHAVIORAL|Education & SMS system|The participants will be counseled on importance of remembering LMP. They will be asked to send the LMP date via SMS. Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
41290884|NCT02944747|BEHAVIORAL|Education & smart-phone application|The participants will be counseled on importance of remembering LMP. Participants will be asked to record the LMP on a calendar app. This will be transferred to central server via internet Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
41290885|NCT05661136|DEVICE|Warm air blower|Lower body blanket with warm air blower set at 44 deg c started after spinal anesthesia when patient placed in supine/left lat position
41290886|NCT05661136|OTHER|Control: Lower body blanket not attached to warm air blower|Control: Lower body blanket placed, not attached to warm air blower
41290887|NCT00875771|DRUG|Capecitabine+Irinotecan+Bevacizumab|"* Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~* Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~* Bevacizumab: 5 mg/kg day 1, every 2 Weeks~Treatment will be given until disease progression or unacceptable toxicity."
41454858|NCT00841022|OTHER|Information with comics|Information of children with comic leaflet
40761574|NCT00004665|DRUG|dehydroepiandrosterone|
40954317|NCT02573168|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
40954318|NCT02573168|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
40954319|NCT00227838|BEHAVIORAL|Behavior Therapy|
40954320|NCT00699764|BIOLOGICAL|Herpes simplex candidate vaccine- adjuvanted GSK208141|Intramuscular injection, 3 doses
40954321|NCT00699764|BIOLOGICAL|Placebo injection|Intramuscular injection, 3 doses
40954322|NCT03726944|BEHAVIORAL|Calm App Meditation|The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.
40954323|NCT03726944|BEHAVIORAL|Unnamed Consumer-Based App Meditation|The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.
40954324|NCT03726944|OTHER|Educational Control|The educational control consisted of an educational handout that was provided to participants. This control lasted for 4 weeks.
40954325|NCT06208865|PROCEDURE|lumbar erector spinae plane block|All procedures were performed under ultrasound (US) guidance. The patient was monitored in the operating room and placed in the prone position under a sterile drape. A 2-6 MHz convex US probe was used during the procedure. The transverse processes of the lumbar vertebrae were visualized and then a 22 gauge spinal needle was advanced to the transverse process of the L3 vertebra. After contacting the transverse process, a total of 15 mL of drug consisting of 2 mL of methylprednisolone and 6 mL of 0.025% bupivacaine was injected into this area, and the spread of the drug in the craniocaudal area was visualized. The patients were followed up for possible complications after the procedure.
40954326|NCT01848730|DRUG|CNV2197944|
40954327|NCT01848730|DRUG|Placebo|
40954328|NCT02917850|PROCEDURE|Isokinetic hip flexors strengthening|Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
40954329|NCT02917850|PROCEDURE|Conventional rehabilitation|Conventional rehabilitation 10/w during 6 weeks
40954330|NCT05136703|BEHAVIORAL|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months.
40954331|NCT05136703|BEHAVIORAL|Antiretroviral Therapy (ART) Adherence Counseling|"This treatment involves a single session integrating CBT for depression with CBT for adherence following our Life-Steps approach."
40954332|NCT00335361|DEVICE|Intra Vas Device (IVD)|
40954333|NCT04545385|DRUG|TEV-48574|subcutaneous infusion
40954334|NCT04545385|DRUG|Placebo|Matching Placebo
40954335|NCT00246753|DRUG|lapatinib ditosylate|1500 mg, daily until disease progression
40954336|NCT04793087|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Comparing 3D T1 versus coronal T1 MRI in detecting Optic Neuritis
40954337|NCT03138603|DRUG|Metoprolol Tartrate|Patients will be randomly assigned to receive up-to-three intravenous doses of 5mg metoprolol tartrate (over 15-minutes) at the end of their surgical procedure, and a scheduled oral dose regimen of 25mg metoprolol approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
40954338|NCT03138603|DRUG|Placebo|Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
40954339|NCT06556940|BIOLOGICAL|LMN-401|Orally delivered tablets and capsules
41454859|NCT02382224|BEHAVIORAL|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
40954340|NCT00124228|DRUG|Human Albumin|albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
41135192|NCT06510400|OTHER|OMNICHROMA|supra nano filled composite
41454860|NCT02382224|BEHAVIORAL|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
41454861|NCT02795026|PROCEDURE|Manual therapy|Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
40761575|NCT04760236|BIOLOGICAL|Oral Cholera Vaccine Simplified (OCV-S)|"* Manufacturer: EuBiologics Co., Ltd.~* Oral administration"
40954341|NCT04187677|PROCEDURE|Sensory Training|The sensory training group includes sensory-oriented interventions and exercises unlike the other classical hand therapy group.
40954342|NCT04187677|OTHER|classical hand therapy|classical hand therapy
40954343|NCT04640857|DEVICE|Silk'n Toothwave|patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
41135193|NCT06510400|OTHER|Ceram. x spectra|nano hybrid composite resin
40761576|NCT04760236|BIOLOGICAL|Shanchol™|"* Manufacturer: Shantha Biotechnics~* Oral administration"
40954344|NCT03442101|DRUG|Patients with psychosis will be treated with known antipsychotic medication|Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.
40954345|NCT03973710|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
40954346|NCT03973710|DIETARY_SUPPLEMENT|Placebo controls|placebo with a similar appearance to probiotics supplement
40954347|NCT05608759|BEHAVIORAL|Multimodal prehabilitation|4 weeks of an supervised, pre-operative exercise prescription augmented by a wearable fitness device.
40954348|NCT00443092|OTHER|proprietary cherry juice blend (food)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
41290888|NCT02263339|BEHAVIORAL|Aerobic Exercise|Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.
41290889|NCT02263339|BEHAVIORAL|Stretching|Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
40954349|NCT00443092|OTHER|control juice (kool aid blend)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
40954350|NCT02211625|DRUG|Open-label TRV734 125 mg|125 mg
41135194|NCT00296790|DRUG|zolpidem tartrate|
40761577|NCT06496607|DRUG|Biological: Solrikitug Low Dose|Solrikitug Low Dose subcutaneous injection
40761578|NCT06496607|DRUG|Biological: Solrikitug Mid Dose|Solrikitug Mid Dose subcutaneous injection
40761579|NCT06496607|DRUG|Biological: Solrikitug High Dose|Solrikitug High Dose subcutaneous injection
40761580|NCT06496607|OTHER|Placebo|Placebo subcutaneous injection
40761581|NCT03662529|BEHAVIORAL|Four-Session Mind Freedom Plan|Problem-solving-focused individualized cognitive behavioral therapy (CBT) that featured homework-worksheets to reinforce session-concepts.
40954351|NCT02211625|DRUG|TRV734 blinded|blinded, multiple ascending dose
40954352|NCT02211625|DRUG|Oxycodone IR 10 mg|
40954353|NCT02211625|DRUG|Placebo|TRV734-matched and oxycodone placebo
40954354|NCT00319501|DRUG|Placebo|Intramuscular autoinjector; administered at onset of an episode
41135195|NCT06358794|DIAGNOSTIC_TEST|Machine learning-based predictive model|The clinical features of participants were used to train, test and validate the machine learning models. Various evaluation metrics including area under the ROC (AUC), accuracy, etc. were used to evaluate the predictive performance of 8 machine learning models.
41135196|NCT03034278|OTHER|Not applicable - no intervention|Not applicable - no intervention, observational survey study.
41454862|NCT02795026|PROCEDURE|Trigger point dry needling|Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
41454863|NCT05789121|DEVICE|walking 25 m in 4 different conditions|"The protocol consisted of walking 25 m in 4 different conditions in the following order:~Gait1, RAS-Slow, RAS-fast, Gait2.~* Gait 1 : preferred cadence without auditory stimulation~* RAS-Slow : Gait with low tempo rhythmic auditory stimulation by music (68.5 per minute).~* RAS-Fast : Gait with fast tempo (10% above each Gait1 cadence).~* Gait2 : preferred cadence without auditory stimulation"
40954355|NCT00319501|DRUG|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
40954356|NCT02566447|DEVICE|Solana Trichomonas Assay Testing|Specimen collection of urine and/or vaginal swabs for testing
40954357|NCT06239831|DEVICE|ExSpiron and ActivPAL Monitors|ExSpiron chest monitor will be placed on the chest ActivPAL accelerometer will be placed on the chest and thigh
40954358|NCT03270371|DEVICE|Medium cut off dialysis|Hemodialysis
40954359|NCT03270371|DEVICE|Standard High Flux Dialyzer|Hemodialysis
40954360|NCT04116788|DEVICE|Artefact IRM assessment|IRM
40954361|NCT00532558|DRUG|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
40954362|NCT00532558|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
40954363|NCT00951444|BIOLOGICAL|dalotuzumab|Given IV
40954364|NCT00951444|DRUG|carboplatin|Given IV
40954365|NCT00951444|DRUG|gemcitabine hydrochloride|Given IV
40954366|NCT02633605|DEVICE|First Sense Medical®|
40954367|NCT02527993|DRUG|Glucobay (acarbose)|Se arm description
40954368|NCT02527993|DRUG|Januvia (sitagliptin)|Se arm description
40954369|NCT02527993|DRUG|Verapamil HEXAL (verapamil)|Se arm description
40954370|NCT02527993|DRUG|Victoza (liraglutide)|Se arm description
40954371|NCT02527993|DRUG|Signifor (pasireotide)|Se arm description
40954372|NCT02527993|DEVICE|Continuous glucose monitoring (CGM)|Continuous glucose monitoring will be performed during 6 days of the treatment period.
40954373|NCT02527993|DIETARY_SUPPLEMENT|Meal tolerance test (MTT)|A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
40954374|NCT06232226|OTHER|Patients suffering from the co-occurrence of ADHD and addiction(s)|All eligible patients over 15 years and 3 months (age limit between child psychiatry and adult psychiatry), presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)
41454864|NCT05516953|DRUG|Baclofen Tablets|10 mg oral baclofen 1 h before anesthesia
41454865|NCT04703166|DEVICE|Samsung Galaxy Watch Active2|The Samsung wearable device will collect data; photoplethysmography (PPG) waveforms, heart rate, heart rate variability, step counts, oxygen saturation levels, sleep pattern and quality.
41454866|NCT01891357|PROCEDURE|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
41454867|NCT01891357|DRUG|paclitaxel|
41454868|NCT01891357|DRUG|lapatinib|
41454869|NCT01891357|DRUG|trastuzumab|
40954375|NCT06533917|DEVICE|Main Group|Thoracolumbar spine AP, Thoracolumbar spine LAT
40954376|NCT02083965|BIOLOGICAL|rFVIIIFc|Administered as specified in the treatment arm.
40954377|NCT00768183|DRUG|KADIAN Capsule + alcohol (under fasting conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
40954378|NCT00768183|DRUG|KADIAN Capsule + water (under fasting conditions)|Capsules 100mg + 240 mL in 4 shots of 60 mL
40954379|NCT00768183|DRUG|morphine sulfate IR oral solution + water|Morphine sulfate IR oral solution + water (under fasting conditions)
40954380|NCT00768183|DRUG|KADIAN Capsule + alcohol (under fed conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
40954381|NCT02972671|DEVICE|MiStent (MT005) Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
40954382|NCT02972671|DEVICE|Xience Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
40954383|NCT02831140|BEHAVIORAL|Early exercises|"In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes."
40954384|NCT02831140|BEHAVIORAL|Removing urinary probe and all catheters.|In postoperative phase : Removing urinary probe and all catheters.
40954385|NCT02831140|BEHAVIORAL|Early alimentation|In postoperative phase :Early alimentation: in the first hour to the second hour .
40954386|NCT02831140|BEHAVIORAL|commun interventions|"* In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~* In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~  , preservation of Serratus anterior and the front part of Latissimus Dorsi ).~* In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour."
40954387|NCT05046899|DEVICE|BIOpH+ Psoriasis Medical Bath|20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
40954388|NCT05046899|DEVICE|Cetaphil Moisturizing Lotion|Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
40954389|NCT05840783|DEVICE|Open ended needle irrigation|irrigation during root canal shaping and cleaning using an open-ended needle
40954390|NCT05840783|DEVICE|side vented needle irrigation|irrigation during root canal shaping and cleaning using a 30-guage side-vented needle
40954391|NCT05840783|DEVICE|Sonic activation|Agitation of root canal irrigation solution with a sonic activation device (Endoactivator).
41290890|NCT02263339|BEHAVIORAL|Aerobic Exercise- Healthy Subjects|Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
41290891|NCT04176822|OTHER|Educational animated movie group|Watching educational animation movie which were designed by the researcher before operation for fear and pain.
41290892|NCT04176822|OTHER|Documentary movie group|Watching documentary movie about trees before operation for fear and pain.
41290893|NCT00135434|DRUG|Atazanavir/Ritonavir/Lopinavir/ritonavir|
41290894|NCT00842517|BEHAVIORAL|Contingency Management|
41290895|NCT01675037|OTHER|Biological evaluation|Complete hypothalamic-pituitary hormonal evaluation
41290896|NCT01952015|BIOLOGICAL|Secukinumab|Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).
41290897|NCT04089124|PROCEDURE|surgery of zone II cut flexor repair|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture
40761582|NCT03662529|BEHAVIORAL|Treatment as usual therapy|Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed.
40761583|NCT02784496|OTHER|Long-term Follow-up|Undergo follow-up assessment
41290898|NCT00565500|DRUG|celecoxib|celecoxib capsules 200 mg bid for 1 week
41290899|NCT00565500|DRUG|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
41290900|NCT00565500|DRUG|placebo|placebo capsules tid for 1 week
41290901|NCT03553017|DEVICE|Binocular OCT|Participants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.).
41454870|NCT05534113|DRUG|Almonertinib Envafolimab|"Subjects will receive Almonertinib treatment for 6-8 weeks after enrollment, and receive ctDNA detection and radiography assessment again.~If the EGFR mutation is positive, according to the patient's condition and clinical actual situation, subjects will receive combination therapy scheme, follow-up once every 6 weeks. The treatment will continue until the disease progress assessed by radiography.~If the EGFR mutation turns negative and stable radiographically deep response, stop Almonertinib treatment and receive the relevant assessment before immunotherapy and receive Envafolimab treatment，and follow-up once every 6 weeks. The treatment of Envafolimab will continue until the EGFR mutation is positive again or disease progress assessed by radiography."
41454871|NCT01720953|OTHER|Mentalization Based Therapy|Fifty female patients diagnosed with BPD will undergo a year of intensive Mentalization Based Therapy that is designed to target domains of BPD pathology. The patients will be assessed at baseline and every 6 months over the treatment period.
40761584|NCT02784496|OTHER|Quality-of-Life Assessment|Ancillary studies
40761585|NCT02784496|DRUG|Ruxolitinib|Given PO
40761586|NCT02398799|BEHAVIORAL|Psychoeducational support|"The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.~Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort."
40761587|NCT00661687|DEVICE|Currently Marketed PureVision Contact Lens.|Contact lens for continuous wear
40761588|NCT00661687|DEVICE|Alternate Design of the PureVision Contact Lens.|Contact lens for continuous wear
40761589|NCT00662038|DRUG|pirfenidone|Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
40954392|NCT01414608|RADIATION|Brachytherapy|Undergo brachytherapy
40954393|NCT01414608|DRUG|Carboplatin|Given IV
40954394|NCT01414608|DRUG|Cisplatin|Given IV
40954395|NCT01414608|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
40954396|NCT01414608|DRUG|Paclitaxel|Given IV
40954397|NCT01414608|OTHER|Quality-of-Life Assessment|Ancillary studies
40954398|NCT06440902|DRUG|Cetuximab|Cetuximab is given In patients with NeoRAS WT
40954399|NCT01443182|BEHAVIORAL|STAIR|Skills Training in Affective and Interpersonal Regulation
40954400|NCT01443182|BEHAVIORAL|MPE|Modified prolonged exposure (MPE)
40954401|NCT01443182|BEHAVIORAL|EMDR|Eye movement desensitization and reprocessing
41290902|NCT04441931|DRUG|LY3832479|Administered IV.
41290903|NCT04441931|DRUG|Placebo|Administered IV.
41290904|NCT05091710|OTHER|HF follow up care|The intervention will consist of follow up phone calls and visits during which the CHWs will remind patients about upcoming visits, ensure patient has sufficient medications, review medication schedule and provide education as needed.
41290905|NCT05091710|OTHER|HF Standard of Care (SOC)|SOC after discharge for HF is to notify patients of a follow-up visit at the hospital/clinic - about 7 days after discharge and provide patients about 30 days of medications at discharge. If a patient does not return for a follow-up appointment, there are no systems to track this missed visit, or to trigger active attempts to contact patients. For patients who come back to their scheduled 7-day visit, there is generally a 14-day visit followed by a 28-day visit.
41290906|NCT00362388|PROCEDURE|Intramyocardial injection of autologous bone marrow cells|
41290907|NCT03327922|DEVICE|Vicryl absorbable suture|Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
41290908|NCT03596125|DRUG|N-acetylcysteine|N-acetylcysteine supplementation
41290909|NCT03596125|DRUG|Placebo|per os: jelly tablets Intravenous Route: Glucidion G5
41290910|NCT03750162|DEVICE|VDW Ultra|supplementary disinfection technique
41290911|NCT03750162|DEVICE|AMD picasso|supplementary disinfection technique
41290912|NCT03750162|DEVICE|ProtaperNext X3 gutta-percha|supplementary disinfection technique
41290913|NCT02917863|DRUG|L-Thyroxine (tablet, per os)|
41290914|NCT02917863|DRUG|L-Thyroxine (oral drops, solution)|
41290915|NCT03662022|DRUG|Rifampicin|Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
41290916|NCT03890224|DEVICE|home ventilators|The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.
41290917|NCT05154747|DRUG|Cabotegravir, Rilpivirine Drug Combination|"Cabotegravir LA 600mg as a 3mL IM injection. The product is packaged in a 3mL USP Type I glass vial. Each vial is for single-dose use. CAB LA injectable suspension is to be stored according to the product label at room temperature (\<30oC). CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol3350, mannitol, and water for injection.~Rilpivirine LA 900mg as a 3mL IM injection. Each single-dose vial contains 900mg/3mL rilpivirine. RPV LA injectable suspension should be stored according to the product label refrigerated at 2-8oC and should be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, and water for injection.~Cabotegravir Long-Acting (CAB LA) will be given IM into one buttock, and Rilpivirine Long-Acting (RPV LA) will be given IM into the opposite buttock."
41290918|NCT05154747|DRUG|TLD|Dolutegravir 50mg oral with tenofovir disoproxil fumarate (245mg) and lamivudine (300mg) in a fixed dose combination or Dolutegravir 50mg oral with tenofovir alafenamide fumarate (25mg) and lamivudine (300mg) (l/TAF) oral in a fixed dose combination
41290919|NCT06322433|DIAGNOSTIC_TEST|no drugs used for this study|tomographic, angiographic and clinical follow up
41290920|NCT01638689|DRUG|Escitalopram|20 mg p.o.
41290921|NCT00722059|PROCEDURE|Breast Tomosynthesis|3D breast imaging
40761590|NCT02095457|BEHAVIORAL|Frequent monitoring and feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
41290922|NCT02076672|DRUG|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
41290923|NCT03505866|BEHAVIORAL|Community home-based care intervention|HIV-positive people who received community home-based care intervention on a monthly basis for six months after they enrolled in the program.
41290924|NCT05336370|BEHAVIORAL|Hypnosis|The hypnosis will be conducted by clinical psychologists who have the formal competence and training in hypnosis. We will be using a tailored hypnosis script designed for this particular study, with a duration of 10-15 minutes. The script involves a hypnotic induction (relaxation-based), imagery (suggestions for pleasant visual imagery), a deepening procedure, and symptom-specific suggestions. The introduction begins by having the hypnotist debunk many of the common myths and misconceptions that patients may hold about hypnosis, and provide a description of hypnosis. Hypnosis is described as focused attention and concentration - like being so lost in a book or movie that it is easy to lose track of what is going on around you. Once the patient is deeply hypnotized, the therapist offers suggestions to reduce distress and improve pain tolerance.
41290925|NCT05336370|DEVICE|Vagus nerve stimulation|A CE approved tVNS device will be used to stimulate the afferent auricular branch of the vagus nerve located medial of the tragus at the entry of the acoustic meatus \[36\]. A standardized intensity of 10 mA with a pulse width of 250 μs and a consistent stimulation frequency of 25 Hz will be used for optimal stimulation. The stimulation will constantly alternate between active stimulation for 30 seconds, followed by a break of 30 seconds \[37\], and will have a duration of 15 minutes. Active tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing downward. The bipolar stimulation electrode is placed correctly within the concha of the left ear. Participants are instructed to breathe normally while not talking or making any movements during their session.
41290926|NCT05336370|DEVICE|Sham control|Sham tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing upward. The bipolar stimulation electrode is placed correctly within the concha of the left ear, but no actual stimulation will be performed. The electrode will be left on for 15 minutes. Participants are instructed to breathe normally while not talking or making any movements during their session
41290927|NCT04939896|OTHER|observation|Observed patients' compliance with rehabilitation at different time
41290928|NCT02900677|BEHAVIORAL|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks
41290929|NCT01486680|PROCEDURE|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
40954402|NCT03886480|DEVICE|SaeboVR|Use of the SaeboVR rehabilitation system for approximately 1 hour, 3 times per week for 4 weeks. Each intervention session will consist of the participant engaging in a series of virtual occupations involving their affected upper extremity and will include a 5 minute warm up activity followed by 3, 15 minute sessions of virtual occupation practice separated by 2, 5 minute breaks. The virtual occupations will include: grocery shopping, grocery storage, breakfast preparation, pet shopping, pet feeding, pet bathing, garden planting, garden harvesting, dinner preparation, closet organizing, and soup kitchen volunteering.
40954403|NCT02225561|PROCEDURE|pharmaco- mechanical optimization|"Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.~As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:~* Using a pomping needle and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.~* The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.~* Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect."
40954404|NCT02225561|PROCEDURE|mechanical optimization only|Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
41290930|NCT01486680|PROCEDURE|Laparoscopic Sleeve gastrectomy|Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
41290931|NCT05328778|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
41454872|NCT06298123|DRUG|Anti-PD-1 monoclonal antibody|The independent risk factors for hepatocellular carcinoma (HCC) patients undergoing adjuvant immunotherapy after hepatic resection surgery were analysed by retrospectively collecting patient data from the Centre for Liver Surgery, Tongji Hospital, during the period of February 2019 to February 2023, and comprehensively evaluating the patients' demographic characteristics, oncological parameters, surgical details, and response to immunotherapy, and establishing a prognostic model based on these factors.
41290932|NCT02650778|PROCEDURE|Breast ultrasound|automated whole breast ultrasound
41454873|NCT02963350|DRUG|BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)|
41454874|NCT01354470|DRUG|Modafinil|600 mg Modafinil capsule
41454875|NCT05348616|OTHER|epidemiology|To review of medical records to describe diagnosis and severity of the disease.
41454876|NCT05348616|OTHER|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
41454877|NCT02933060|OTHER|Normal saline (1000 mL)|
40761591|NCT05680636|DIAGNOSTIC_TEST|temperature measurement|Differential Leg Skin Temperature Measured With Handheld Low-cost Infrared Thermometers.
41454878|NCT02933060|OTHER|Control|
41290933|NCT05372705|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
41290934|NCT05753306|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
40761592|NCT05937243|BEHAVIORAL|Base self-help CBT program|"The self-help app will deliver 12 modules that will be based on Chris Fairburn's Overcoming Binge Eating self-help book, the most widely used self-help resource for binge eating over 12 weeks. Treatment modules will aim to 1) provide psychoeducation on maintenance factors for binge eating, 2) teach CBT skills designed to interrupt these maintenance factors, and 3) coach participant to set personalized goals each week. Modules will be completed in succession over the course of 12-weeks and a new module will be made open each week. In addition, participants will track their eating and eating disorder behaviors using the self-help app."
40761593|NCT05937243|BEHAVIORAL|Just-in-time, adaptive intervention (JITAIs) system|When JITAIs are turned ON, the base self-help app will be used to deliver targeted, personalized and automated interventions during algorithm-identified moments when participants could benefit from receiving an intervention for improving two key areas including 1) treatment adherence, and 2) skills utilization based on responses (or lack thereof) in self-help app. When JITAIs are turned OFF, participants will not receive interventions in real-time on the base self-help app.
40761594|NCT05937243|BEHAVIORAL|Advanced Digital Data Sharing (ADDS) with Coaches|When Advanced DDS with Coaches is turned ON, coaches having a bachelor's degree in health-related fields will have access to a secure web portal called the clinical portal. The portal will also mimic four key behavior change techniques typically employed by an expert clinician including 1) gather data on target behaviors from the base self-help app (i.e., uptake of weekly module, self-monitoring compliance, and skills use), 2) synthesize participants' behavioral data on treatment targets, 3) flag data to indicate behaviors needing improvement and 4) use sophisticated algorithms to generate recommendations for intervening on identified data patterns. Using this information, the coaches will send one weekly email to facilitate improvement in treatment targets over 12 weeks. When Advanced DDS with Coaches is turned OFF, participants' will not have their data shared and will not receive emails from the coaches.
40786501|NCT00827177|DRUG|Treatment with ARQ 197 in combination with sorafenib|"Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If \< 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid)."
40954405|NCT00972582|DIETARY_SUPPLEMENT|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
40954406|NCT02680535|DEVICE|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
40954407|NCT02628470|PROCEDURE|cervical manipulation|cervical high-velocity low-amplitude thrust manipulation
41290935|NCT05753306|DRUG|Cisplatin|Given via HIPEC
41290936|NCT05753306|PROCEDURE|Computed Tomography|Undergo CT scan or PET/CT
41290937|NCT05753306|DRUG|Docetaxel|Given via HIPEC
41290938|NCT05753306|PROCEDURE|Gastrectomy|Undergo robotic gastrectomy
41290939|NCT05753306|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
40954408|NCT02628470|PROCEDURE|cervical control exercises|Exercises of flexion, extension and rotation of the cervical spine
40761595|NCT02808884|GENETIC|Circulating tumor DNA assay|Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
40954409|NCT02628470|PROCEDURE|Oscillatory mobilization technique|Joint mobilization technique type III according Maitland
40954410|NCT04544423|OTHER|Block group|Patients received lumbar erector spinae plane Block before operation
41290940|NCT05753306|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40761596|NCT02542215|DRUG|Cobiprostone|Cobiprostone 30 mcg oral spray
40954411|NCT02454725|BEHAVIORAL|Social Network|Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.
41290941|NCT05753306|PROCEDURE|Positron Emission Tomography|Undergo PE/CT
41290942|NCT05753306|OTHER|Questionnaire Administration|Complete questionnaire
41290943|NCT00537823|DRUG|Cetuximab|
40761597|NCT02542215|DRUG|Placebo|Matching placebo oral spray
40954412|NCT02454725|BEHAVIORAL|Comparison|All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
40954413|NCT00395681|DRUG|Diprivan|Propofol 200 mg versus 350 mg
40954414|NCT02168361|DRUG|Pegylated Interferon alfa-2b|1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
40954415|NCT02168361|DRUG|Simeprevir|150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks
40954416|NCT02168361|DRUG|Ribavirin|1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir
40954417|NCT02168361|DRUG|Sofosbuvir|12 weeks of combination sofosbuvir and simeprevir
40954418|NCT04905888|COMBINATION_PRODUCT|Hyperbaric oxygen therapy|Subjects randomized to treatment will receive up to ten 90 minute treatments with hyperbaric oxygen over a 2-3 week period.
40954419|NCT03084731|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food (MDCF)|"For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period."
41290944|NCT00537823|DRUG|Bevacizumab|
41290945|NCT00537823|DRUG|Leucovorin|
41290946|NCT00537823|DRUG|Oxaliplatin|
41290947|NCT00537823|DRUG|Fluorouracil|
40761598|NCT02542215|DRUG|Standard Care - Chemotherapy|Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
40761599|NCT02542215|RADIATION|Standard Care - Radiation|Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.
40954420|NCT04139668|DRUG|Naltrexone 380 MG [Vivitrol]|Three 4ml intramuscular injections of naltrexone 380mg (Vivitrol) administered over 12 weeks (one injection every 4 weeks)
40954421|NCT04139668|BEHAVIORAL|Motivational Enhancement Therapy and Cognitive Behavioral Therapy|Weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT), based upon the Brief Counselling for Marijuana Dependence Manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA), for 12 weeks
40954422|NCT04808544|DRUG|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
40954423|NCT04808544|DRUG|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
40954424|NCT04432285|DEVICE|DBS-device, implanted in GPi bilaterally|Chronic/continuous bilateral GPi-DBS
40954425|NCT04432285|DRUG|Botulinum toxin|Repeated intramuscular injections at regular intervals of around 3 months
41290948|NCT00184054|DRUG|Arsenic Trioxide (ATO)|Arsenic Trioxide .25 mg/kg/day
41290949|NCT00184054|DRUG|Ascorbic Acid|Ascorbic Acid 1000 mg every other day for 25 days
41290950|NCT02832440|OTHER|Exercise programmes|
41290951|NCT05077189|OTHER|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale|"4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~1. Demographics Survey~2. DC/TMD Symptom Questionnaire (SQ)~3. Graded Chronic Pain Scale (GCPS)~4. Jaw Functional Limitation Scale-20 (JFLS-20)"
41290952|NCT02120586|OTHER|Inspiratory Muscle Training (IMT).|"Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10."
41290953|NCT02120586|OTHER|Peripheral muscle training|"The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10."
41290954|NCT01330446|DRUG|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
41290955|NCT01330446|OTHER|Placebo|1 by mouth every morning for a 28 day cycle.
41290956|NCT01330446|BEHAVIORAL|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
40761600|NCT03060265|DRUG|Paracetamol|Administrating Paracetamol IV pre-cesarean section
40761601|NCT03060265|DRUG|PLACEBO|Administrating SALINE IV pre-cesarean section
40761602|NCT04665765|DRUG|Carboplatin|Given IV
40761603|NCT04665765|DRUG|Etoposide|Given IV
40761604|NCT04665765|DRUG|Ifosfamide|Given IV
40761605|NCT04665765|DRUG|Polatuzumab Vedotin|Given IV
40761606|NCT04665765|BIOLOGICAL|Rituximab|Given IV
40761607|NCT05558085|BEHAVIORAL|Expanded Food and Nutrition Education Program (EFNEP)|Subjects will participate in nine hands-on EFNEP lessons to teach nutrition, healthy lifestyle choices, physical activity, food preparation, food safety, and food resource management.
40761608|NCT04179084|DRUG|fruquintinib|5mg qd, 2weeks on, 1week off
40761609|NCT04179084|DRUG|Sintilimab|200mg q3w
40761610|NCT04653376|PROCEDURE|Tonsillectomy surgery|The tonsillectomy procedure was performed under general anesthesia using the classical dissection method. Extracted tonsil tissue samples were sent to the medical genetics department in tubes to investigate the ER stress and apoptosis.
40761611|NCT00979407|BIOLOGICAL|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
40761612|NCT00979407|BIOLOGICAL|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
40761613|NCT05720351|PROCEDURE|Lachmann maneuver|Patients undergone the Lachmann recruitment maneuver (30 CmH2O PEEP for 30 seconds)
40761614|NCT05720351|PROCEDURE|Staircase maneuver|Patients undergone Undergone staircase recruitment maneuver (stepped increase in PEEP by 2 CmH2O every five breaths until reach upper deflection point
40761615|NCT03020316|BEHAVIORAL|Peer Mentor|A volunteer with a similar disease as the subject
40761616|NCT03020316|BEHAVIORAL|Transcendental Meditation|A meditation technique
40761617|NCT02319915|DRUG|Tranexamic Acid|
40761618|NCT02319915|DRUG|Adrenalin|
40761619|NCT00879372|DRUG|tianeptine|tianeptine 12,5mg TID
40954426|NCT04432025|PROCEDURE|Bariatric surgery + goal directed medical therapy|Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
40954427|NCT04432025|PROCEDURE|Bariatric surgery|Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
41135197|NCT03690804|DEVICE|Evaluation of Autonomic nervous system indices|The ECG signal, respiration rate, SpO2 and NIPΣ or ANI are recorded simultaneously on a computer with a capture card. The other indices of HRV will be analyzed offline: SDNN (standard deviation of all NN intervals), pNN30 (NN30 count divided by the total number of all NN intervals), pNN50 (NN50 count divided by the total number of all NN intervals), RMSSD (quadratic mean of successive R-R intervals), SD1 (standard deviation), SD2 (standard deviation), LF (low frequencies), HF (high frequencies), VLF (very low frequencies), SDANN (standard deviation of the averages of NN intervals in all 5 min segments of the entire recording), ratio LF/ HF, Ptot, Poincaré plot (plot points corresponding to each R-R space of a record).
41135198|NCT03842332|BEHAVIORAL|Life Skills and Resilience Program|The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
40761620|NCT00879372|DRUG|Placebo|Placebo 12.5 mg TID
40761621|NCT04974476|OTHER|HIIT Exercise Training|The HIIT total session duration will be approximately 30 minutes and will be composed of 10 sets of 60 seconds of high-intensity exercises, \>80% of maximum heart rate (MHR), interspersed with a recovery period of 60 seconds of low-intensity exercise at 60% of MHR.
40761622|NCT01040026|OTHER|Treatment with in vitro expanded haploidentical NK cells|10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at \<1x10e5/kg
40761623|NCT05867888|OTHER|conventional therapy|conventional therapy ( instructions, ice application, deep tissue massage, stretching exercises, joint mobilization and isometric exercises )
40761624|NCT05867888|OTHER|shock wave therapy|Acoustic waves (shock waves) that can carry energy and can propagate through tissues promote healing effects.
40761625|NCT05867888|OTHER|low level laser therapy|The application of light to a biologic system to promote tissue regeneration, reduce inflammation and relieve pain.
40761626|NCT01205412|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations
40761627|NCT06416982|OTHER|Perineal massage|2 minutes of perineal massage as described in arm/group descriptions.
40761628|NCT05363930|DEVICE|Novel motorized spiral enteroscopy|Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
40761629|NCT05363930|DEVICE|Single balloon enteroscopy|Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
40761630|NCT01408108|PROCEDURE|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique)."
40786502|NCT01424943|BEHAVIORAL|Stepping Stones Triple P|10-12 session manualized intervention delivered in client homes
41135199|NCT04541199|DEVICE|closed loop|RR and VT will be selected according to the respiratory mechanics by closed loop algorithm
40954428|NCT02498132|OTHER|Behavioral Activation|BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, \& Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).
40954429|NCT02498132|OTHER|Cognitvie Based Therapy|CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
40954430|NCT02498132|OTHER|Treatment as Usual|Individuals will be provided with one on one therapy sessions
40954431|NCT00305214|PROCEDURE|T Wave Alternans Test|
40954432|NCT00963131|DRUG|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
40761631|NCT01408108|PROCEDURE|Laparoscopic primary posterior crural repair|"Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.~In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used)."
40954433|NCT02043080|OTHER|Xpert MTB/RIF Tuberculosis diagnostic tool|This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
40954434|NCT03869983|OTHER|Omnipaque™ (iohexol) Injection|755 mg/mL iohexol (350 mgI/mL), 80 mL infused intravenously over approximately 20 seconds
40954435|NCT03869983|OTHER|CE-Iohexol|755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL, 80 mL infused intravenously over approximately 20 seconds
40954436|NCT00507923|DEVICE|Actigraph|Wear actigraph
40954437|NCT00507923|OTHER|Best Practice|Receive usual care
41290957|NCT04957498|BEHAVIORAL|Guided Self-Help for Family Based Treatment|A online website provided to parents containing information learned in Family Based Treatment and up to 12 coaching sessions with a therapist.
41454879|NCT06268457|PROCEDURE|Chemoembolization with Doxorubicin|"* Identification of the main vessels afferent to the metastasis to be treated.~* Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters.~* Injection of embolizing material (hydrogel microspheres with doxorubicin)~* Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature)."
40954438|NCT00507923|OTHER|Quality-of-Life Assessment|Ancillary studies
40954439|NCT00507923|OTHER|Questionnaire Administration|Ancillary studies
40954440|NCT00507923|OTHER|Sleep Diary|Complete sleep diary
41290958|NCT04957498|BEHAVIORAL|Family Based Treatment|Standard Family Based Treatment provided for up to 15 sessions.
41290959|NCT01542372|DRUG|Medication augmentation|
40954441|NCT00507923|OTHER|Stretching|Participate in stretching sessions
40954442|NCT00507923|PROCEDURE|Yoga|Participate in Tibetan yoga
40954443|NCT01796483|DEVICE|Clonidine (Catapressan)|Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
40954444|NCT01796483|DEVICE|Placebo 90 minutes before EEG|Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
40954445|NCT03877549|DRUG|Dexamethasone|Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
40954446|NCT05706493|OTHER|Non surgical periodontal treatment|Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes
40954447|NCT03757156|OTHER|Withdrawal of aspirin|People who are taking aspirin stop to taking aspirin.
41135200|NCT04541199|DEVICE|conventional|RR, VT, Ti will be selected by the clinician according to the respiratory mechanics
41135201|NCT03263611|DRUG|Placebo|single intradiscal injection
41135202|NCT03263611|DRUG|AMG0103|single intradiscal injection
41135203|NCT02109913|DRUG|Everolimus plus Exemestane|Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
41135204|NCT00989118|PROCEDURE|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
41290960|NCT01542372|BEHAVIORAL|CBT|
41290961|NCT01848444|OTHER|Breastmilk|to measure levels of contaminants in human breastmilk samples
41290962|NCT06513156|BEHAVIORAL|Integrated Infectious Diseases and Medication for Opioid Use Disorder Clinic (IC)|Integrated medication for opioid use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.
41290963|NCT06513156|BEHAVIORAL|NavSTAR-CHOICE (NS)|Patient-centered social support intervention including motivational interviewing and patient navigation designed to overcome the barriers in accessing the recommended follow-up opioid use disorder treatment and medical care services for 6 months.
41454880|NCT01155531|DRUG|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
41290964|NCT03134963|OTHER|Transcranial doppler ultrasonography|Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.
41290965|NCT03134963|OTHER|Blood pressure monitoring|Continuous blood pressure recording
41290966|NCT03134963|OTHER|Heart rate monitoring|Continuous heart rate monitoring
41454881|NCT05031455|DRUG|Aspirin Challenge|"Dupilumab is a fully human monoclonal antibody that blocks the receptor component for IL-4 and IL-13, which are key drivers of type 2 inflammation. All subjects will be prescribed this at standard 300mg subcutaneous dosing every 2 weeks. The intervention will be the response to aspirin challenge.~All 16 subjects will receive dupilumab. All subjects will undergo an aspirin challenge/desensitization procedure. It is estimated that 50% of subjects will have a respiratory reaction to aspirin and 50% will not. There will not be any randomization."
41454882|NCT04842019|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
41290967|NCT03134963|OTHER|End tidal CO2 monitoring|Continuous ETCO2 monitoring
41290968|NCT03134963|OTHER|Addenbrooke's cognitive examination|Performance of a memory test
41290969|NCT04795440|PROCEDURE|Testicular biopsy|Performance of a testicular biopsy with the intention of obtaining spermatozoa for the insemination of oocytes with the ICSI technique.
41290970|NCT04238663|DRUG|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
41290971|NCT04238663|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
41290972|NCT04238663|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
41290973|NCT03074175|RADIATION|radiotherapy|The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 \<25%, lung V30 \<18%, spinal cord \<36 Gy.
41290974|NCT02513940|DRUG|Testosterone|Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
41290975|NCT02513940|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
41290976|NCT02513940|DRUG|Placebo|Subjects will receive placebo transdermal gel and placebo (lactose) capsules
41290977|NCT02513940|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
41290978|NCT06315335|DRUG|UCB9741|Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
41290979|NCT06315335|DRUG|Placebo|Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.
41454883|NCT03500094|DRUG|Migalastat HCl 150 mg|migalastat HCl 150 mg capsule
41454884|NCT05423873|OTHER|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants twice daily
41454885|NCT04912726|DRUG|Sildenafil Injectable Product|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
41454886|NCT00021541|DRUG|tipifarnib|Given orally, 200 mg/m\^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
40954448|NCT05325060|DEVICE|Electromagnetically navigated total knee arthroplasty|The navigated group had surgery using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
41290980|NCT03311178|DRUG|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
41290981|NCT06512727|BEHAVIORAL|PROACTIVE Intervention|Duration: Once-weekly face-to-face sessions Session Time: 1.5-2 hours Intervention: (1) culturally congruent SM education and + SM resource toolkit, (3) active prayer support, and (3) financial counseling/insurance navigation Reinforcement: daily ecological momentary intervention support using Apple smartwatches
40761635|NCT04593745|DEVICE|Intraocular pressure measurment|Intraocular pressure measurmentt using iCare devise: TONOPEN
40761636|NCT01566565|DRUG|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
40954449|NCT05325060|DEVICE|Conventional total knee arthroplasty|The conventional group received surgery using conventional instrumentation and jigs from the implant manufacturer (Zimmer Inc, Warsaw, IN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
41290982|NCT03587909|PROCEDURE|Phacoemulsification Cataract SUrgery|Phacoemulsification in eyes with shallow anterior chamber (\<2.5mm depth)
41290983|NCT03587909|PROCEDURE|Femtosecond Cataract Surgery|Femtosecond Cataract Surgery in eyes with shallow anterior chamber \< 2.5mm
40954450|NCT03602430|DRUG|Cholecalciferol|Native vitamin D dose of 200IU to be given once per month to hemodialysis patients
40954451|NCT03602430|DRUG|Placebo|A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
41290984|NCT03014661|OTHER|Quality of life under or after therapy with Pollinex quattro|To measure Quality of life using the DLQI-index in year one, year two, year three or six month after therapy with Pollinex quattro plus.
41290985|NCT01842464|PROCEDURE|Anterior Sacro-Spinous|Anterior Sacro-Spinous
41290986|NCT06125210|BEHAVIORAL|early bedside rehabilitation|① electrical diaphragm stimulation, ② electrical muscle stimulation, ③ passive limb movement, ④ respiratory rehabilitation.
41290987|NCT06125210|DIETARY_SUPPLEMENT|nutrition program|(1) nutrition department consultation, (2) MDT to develop individualized nutritional pathways, nutrient formulations and use methods, and achieve the target nutritional level within 2 weeks
40761637|NCT04577703|DRUG|CT053PTSA|CT053PTSA will be administered daily in fasting state
40761638|NCT02990702|OTHER|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
40761639|NCT02990702|OTHER|Ultrasound guided coracoid infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
40761640|NCT02990702|DRUG|Bupivacaine|
40761641|NCT02990702|DEVICE|Ultrasound|
40954452|NCT04848571|COMBINATION_PRODUCT|Fetal Protection Pill|A Chinese medicine used in pregnant women for fetal protection, including mainly Rehmannia glutinosa.
40786503|NCT01424943|OTHER|BabyNet Services As usual|BabyNet services as usual based on IFSP
40786504|NCT04915508|DRUG|Hormone Therapy|Receive hormonal therapy
41290988|NCT06125210|PROCEDURE|tracheotomy|early tracheotomy for special diseases (e.g central nervous system diseases) receiving mechanical ventilation 14-21 days recommended tracheotomy
41290989|NCT02585804|DRUG|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
41290990|NCT05662358|DRUG|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection
41290991|NCT05662358|DRUG|Alendronate|oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
41290992|NCT05662358|DRUG|Placebo|oral placebo weekly
41290993|NCT01347697|PROCEDURE|Reconstruction with an acellular porcine dermal collagen implant (biological mesh)|Reconstruction of floor of lesser pelvis with an acellular porcine dermal collagen implant (biological mesh) after extended excision of rectum including levator muscles in advanced low rectal cancer.
41290994|NCT01347697|PROCEDURE|Reconstruction with a gluteus maximus myocutaneous flap|Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
40786505|NCT04915508|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
40954453|NCT02927327|DEVICE|Zero Echo Time (ZTE) scan for head attenuation|"The GE SIGNA PET/MR MP26 software platform includes the zero echo time (ZTE) scan for head attenuation and Q.Static. The ZTE MR software feature has the potential to enable better visualization of bones, including those in the head, by employing optimal head attenuation correction in PET/MR.~PET/MR ZTE MRAC"
40954454|NCT02927327|DEVICE|Q.Static (Q. MRAC) for respiratory motion correction|"An improved Q.Static feature with Q. MRAC, where phase matching the MRAC with the quiescent phase is employed to get more accurate attenuation correction for our Q.Static PET images.~PET/MR Q Static (Q. MRAC)"
41290995|NCT06350162|DRUG|Serplulimab|4.5mg/kg,IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days.
41290996|NCT06350162|RADIATION|Chest Radiation|30Gy-45Gy/QD/3Gy
40954455|NCT05138107|OTHER|Synochi Scar Spray Cosmetic|Application of the cosmetic on each skin graft in a blinded fashion in different sections for a 9 month duration.
40954456|NCT05138107|OTHER|Synochi Scar Spray Placebo|Application of the placebo on each skin graft in a blinded fashion in different sections for a 9 month duration.
40954457|NCT04540588|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
40954458|NCT04722172|DRUG|Acalabrutinib|Acalabrutinib for a minimum of 13 cycles and maximum 26 cycles.
40954459|NCT04722172|DRUG|Obinutuzumab|Obinutuzumab will be administered during Cycles 2-7.
40954460|NCT03473171|DEVICE|Nasal non-invasive ventilation with RAM cannula|Pediatric Pulmonary Team will be consulted on inpatient or outpatient patients that fail to wean from chronic respiratory support (CPAP, BiPAP, High flow Nasal Cannula) in whom long-term ventilation is considered. Pediatric Pulmonary Team, as a consultant, will consider patient history, physical examination, previous imaging and laboratories and previous attempts to wean from respiratory support and causes of failure to wean. The Pulmonary team will determine which patients would potentially benefit from use of NIV/RAM-NC for long-term respiratory support and will recommend initiation of NIV/RAM-NC.
40954461|NCT05232045|DRUG|Automated urinary output collection system group (tight monitoring of urine output)|Automated urinary output collection system group (tight monitoring of urine output)
40954462|NCT01539083|DRUG|Thalidomide|Thalidomide 100 mg tablet, orally.
40954463|NCT01539083|DRUG|Bortezomib|Bortezomib 1.3 milligram per square meter (mg/m\^2) solution for injection subcutaneously (SC).
40954464|NCT01539083|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m\^2 orally.
40954465|NCT01539083|DRUG|Dexamethasone|Dexamethasone 20 mg orally.
40954466|NCT01539083|DRUG|Prednisolone|Prednisolone 50 mg orally.
40954467|NCT00417118|DRUG|Saredutant|oral administration (capsules)
40954468|NCT00417118|DRUG|Escitalopram|oral administration (capsules)
40954469|NCT00417118|DRUG|Placebo|oral administration (capsules)
40954470|NCT05806086|DRUG|Panfoshu+Conventional Treatment（program-A）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
40954471|NCT05806086|DRUG|Panfoshu+Conventional Treatment（program-B）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
40954472|NCT05806086|OTHER|Conventional Treatment|Patients in this group were treated with only the conventional treatment.
41290997|NCT04508309|BIOLOGICAL|Cecolin®|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine
41290998|NCT04508309|BIOLOGICAL|Gardasil®|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine
40954473|NCT02424760|DEVICE|Shoulder hemi-arthroplasty|
40954474|NCT06303908|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
40954475|NCT01403311|DRUG|5-Aminolevuline Acid|5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
40954476|NCT05306145|PROCEDURE|High freqnence Irreversible electroporation|High freqnence Irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with benign prostatic hyperplasia
41290999|NCT05638711|DEVICE|Built-in calculator to calculate Filtration fraction|A calculator built in electronic CVVH prescription system to calculate Filtration fraction
41291000|NCT05555069|OTHER|Menthol-flavored electronic cigarette|Participants will receive 12 weeks of menthol -flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
41291001|NCT05555069|OTHER|Tobacco-flavored electronic cigarette|Participants will receive 12 weeks of tobacco-flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
41291002|NCT01816646|DRUG|Cidofovir|2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
41454887|NCT00021541|OTHER|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
40954477|NCT05306145|PROCEDURE|Trans Urethral Resection Prostate|Trans urethral resection prostate will be performed under general anaesthesia to the patient with benign prostatic
40761642|NCT05272774|BEHAVIORAL|FOREST+|The intervention will be delivered as an online stress recovery intervention consisting of six weekly modules. Modules include an introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These modules have been chosen after considering the themes that could be most useful for healthcare workers under high stress. Each module consists of a psychoeducational and an exercise component.
40761643|NCT06023498|OTHER|Manual Therapy and Exercise|"The 20-minute manual therapy procedures will include:~* Distraction-manipulation: manually assisted segmental lumbar traction manipulation using a specialized treatment table~* Neural mobilization: rhythmic stretches of the sciatic and femoral nerves75~* Hip, sacroiliac and lumbar facet mobilizations to improve joint mobility~* Soft tissue mobilization of lumbopelvic and lower extremity muscles using manual pressure over taut bands/myofascial trigger points and post-isometric (contract-relax) stretching techniques."
40761644|NCT06023498|OTHER|Intramuscular Electroacupuncture|As described previously
40761645|NCT06085729|DRUG|ADI-PEG 20|Given by Injection
40761646|NCT06085729|DRUG|Cabazitaxel|Given by IV (vein)
40761647|NCT06085729|DRUG|Carboplatin|Given by IV (vein)
40954478|NCT05267288|DRUG|afatinib|afatinib 40mg oral, bevacizumab 15mg/kg iv, every 21days, until progression disease, untolerated toxicities, or patient death.
40954479|NCT05023707|BIOLOGICAL|anti-FLT3 CAR-T|Single intravenous infusion of anti-FLT3 CAR-T cells
41291003|NCT01816646|DRUG|Probenecid|2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
41454888|NCT02722187|PROCEDURE|subinguinal microscopic varicocelectomy|
41454889|NCT02722187|PROCEDURE|laparoscopic varicocelectomy|
41454890|NCT04332198|OTHER|biological test|dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation
41454891|NCT02670551|DRUG|Cariprazine|
41454892|NCT02670551|DRUG|Placebo|
41454893|NCT01756313|PROCEDURE|Laser+Methylaminolevulinat|It's a single arm study. Intervention as described in detailed description.
41454894|NCT03591276|DRUG|Chemotherapy Drugs, Cancer|IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
41454895|NCT06433232|PROCEDURE|ROOT CANAL TREATMENT|ROOT CANAL TREATMENT
41454896|NCT00165919|OTHER|None. Not a clinical trial. Specimens taken for basic research in laboratory.|
41454897|NCT01102127|DEVICE|Elastography|Performance of US, elastography and FNA.
41454898|NCT01277510|DRUG|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
41291004|NCT03854487|BEHAVIORAL|Mirror therapy|A mirror is placed at the midsagittal plane of the patient. The patients in the mirror therapy group watched the mirror illusion of the non-affected arm in the mirror and moved together with the affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
41291005|NCT03854487|BEHAVIORAL|Sham mirror|A transparent glass wall is placed at the midsagittal plane of the patient. The patients in the sham mirror group watched the movements of the affected arm through the transparent glass wall and moved together with the non-affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
41291006|NCT03854487|BEHAVIORAL|Covered mirror|A covered mirror is placed at the midsagittal plane of the patient. The patients in the control group watched the movements of the non-affected arm and moved together with the affected arm behind the covered mirror. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
41291007|NCT00227877|BEHAVIORAL|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
41291008|NCT00227877|BEHAVIORAL|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
41291009|NCT02349230|OTHER|Astym treatment|Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
41291010|NCT03176966|DRUG|Vitamin E|Patients will take 400 IU vitamin E nightly for 3 months.
41291011|NCT03176966|DRUG|Ropinirole|Patients will take 0.5mg ropinirole nightly for 3 months.
41291012|NCT03176966|OTHER|Muscle cramp survey|Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.
41291013|NCT00077181|DRUG|cytarabine|Given IV
41454899|NCT01277510|DRUG|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
41454900|NCT01277510|DRUG|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
40761648|NCT00322218|DRUG|Zevalin|"Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one \[90Y\]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m\^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m\^2 immediately followed by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes."
40954480|NCT04916821|DIETARY_SUPPLEMENT|propolis|Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules
41291014|NCT00077181|DRUG|triapine|Given IV
41291015|NCT00077181|OTHER|laboratory biomarker analysis|Correlative studies
41291016|NCT02687113|DEVICE|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
41291017|NCT04110249|PROCEDURE|Photoacoustic Imaging|Undergo PAI
41454901|NCT03141580|DIAGNOSTIC_TEST|Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)|Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
41454902|NCT05139563|OTHER|Placebo injection: Intralipid 20% fat emulsion|placebo intralipid 20% intramuscular (IM) injection
41454903|NCT05139563|OTHER|Placebo implant|placebo subdermal implant rod
41454904|NCT02573779|OTHER|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
41454905|NCT02454595|BEHAVIORAL|Registry|Physician will complete a series of four questionnaires to capture the treatment decisions based upon standard clinical-pathological information and with the addition of the result of genomic testing (Prolaris test).
41454906|NCT04552665|DEVICE|KODEX-EPD system|To evaluate the performance of the KODEX-EPD system and collect procedural data and medical images for Philips' internal research and development activities (R\&D)
40954481|NCT04727073|DRUG|Experimental: Spironolactone|Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was \> 30 mL/min/m2 and potassium \< 4.5 mmol/L.
40954482|NCT04727073|DRUG|Placebo Comparator|Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
40954483|NCT03500575|DEVICE|photopheresis|• Treated group will receive ECP with Therakos online system. Each session consists in 1 treatment for 2 consecutive days. First session stars within 72 hours after transplantation followed by a session weekly for 3 time and 2 sessions for the next 2 months (6 sessions = 12 treatment)
40954484|NCT06271213|OTHER|observational only - no interventions as part of study|Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.
40954485|NCT06424574|BEHAVIORAL|motivational interview|"The sample of the second phase of the study consisted of 74 parents with Type 1 diabetes children, 37 of which were in the study group and 37 in the control group. İn the collection of data process, Descriptive Information Form, University of Virginia Parent Low Blood Sugar Scale, BAKAS Care-Giving Impact Scale, Fatigue Severity Scale, Parental Version Of The Diabetes-Specific Self-Compassion Scale SCS-(Dp) was used. The scales were applied at the beginning of the study and 10 weeks after the first data. After the first test data were obtained from each parent in our research group, four face-to-face motivational interviews were conducted at two-week intervals. In the xvii interviews, attempts were made to change and improve the behaviors and skills that parents felt inadequate within the scope of fear of hypoglycemia, caregiving, fatigue and self-compassion."
40954486|NCT05761041|DRUG|Sodium Fluoride Varnish (5%)|Applied at baseline
40954487|NCT05761041|BEHAVIORAL|Motivational Interviewing|Two MI sessions: face-to-face at baseline and phone call at 3 months
40954488|NCT05761041|DRUG|SDF|Applied bianually
41291018|NCT04110249|PROCEDURE|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
41291019|NCT04297163|OTHER|Telemedicine|Remote CPAP monitoring, mobile app and voice mail
41291020|NCT04297163|OTHER|In Hospital|Face-to-face follow up
41291021|NCT03778255|PROCEDURE|Sentinel Lymph Node Biopsy|"1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining."
41291022|NCT01853228|DRUG|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
41291023|NCT01853228|DRUG|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
41291024|NCT01853228|DRUG|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
41291025|NCT05847972|PROCEDURE|MWM (Mobilization with movement)|This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.
41291026|NCT05847972|DEVICE|Plantar orthoses|"Procedure: MWM All participants will undergo MWM. This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.~Procedure: Plantar orthoses The moulds will be taken immediately after the manipulation. The PO will be made of resin (0.8mm +1.2mm), 2mm hard EVA heel stabiliser, 3mm semi-hard EVA cover. The PO should be worn for 3 months to obtain the results of the study."
40761649|NCT00694590|DRUG|plerixafor|"Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.~Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses."
40761650|NCT03888287|DEVICE|Watch Rx system|The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
40954489|NCT02413970|DEVICE|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
40954490|NCT03609879|DEVICE|Ambu Perfect ACE|patient with a fitted cervical collar (Ambu Perfect ACE) established by an experienced instructor. Cervical collar set up for 20 minutes
40954491|NCT03609879|DEVICE|Philly One-Peace Collar|patient with a fitted cervical collar (Philly One-Peace Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
40954492|NCT03609879|DEVICE|Necloc Collar|patient with a fitted cervical collar (Neclock Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
40954493|NCT03609879|DEVICE|NexSplit Plus|patient with a fitted cervical collar (NexSplit Plus) established by an experienced instructor. Cervical collar set up for 20 minutes
41291027|NCT05535673|DRUG|ThisCART19A|In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
41291028|NCT04853667|OTHER|Interview|Semi-structured interview, lasting a maximum of one hour
41291029|NCT03964415|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.
40954494|NCT03609879|DEVICE|NECKLITE|patient with a fitted cervical collar (NECKLITE) established by an experienced instructor. Cervical collar set up for 20 minutes
41291030|NCT03964415|BIOLOGICAL|Clade C and Mosaic gp140 HIV bivalent vaccine|Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.
41454907|NCT00258024|DRUG|IPT-sulphadoxinepyrimethamine|
40954495|NCT02560909|BIOLOGICAL|FLUAD® influenza vaccine|MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.
40954496|NCT02560909|BIOLOGICAL|FLUVIRAL®|Standard 2015-2016 nonadjuvanted vaccine
40954497|NCT00261222|DRUG|Amodiaquine|
40954498|NCT02903641|BEHAVIORAL|Personalized information|"During a prior study in June-July 2016, we collected anthropometric measures on the index children, including the children's height. Based on these data, for households assigned to the information treatment, enumerators provided personalized information to the children's primary caregiver about the index child's current height, during a baseline household visit. The enumerators carried a display card that visually showed where the child's height fell compared to healthy children of the same age and gender like those in East Africa. The enumerators emphasized to the caregivers that short stature is due to poor chronic malnutrition and is not just attributable to genetics or a recent illness. During this visit, the enumerators additionally pointed out that chronic malnutrition is not immediately life-threatening."
40954499|NCT02903641|BEHAVIORAL|Labeled cash transfer|Households received a cash transfer labeled for child food consumption and were told the money is designed to cover additional spending for food for the index child (and any other younger children in the household) over the next six weeks. Though it was given as a single, lump sum payment, the transfer was evenly split and handed to the household in six sealed envelopes, to help the households better allocate the money. To further encourage them not to spend the money all at once, each envelope was labeled with a number, the index child's name, and the dates for the week the money in the envelope should be spent. Enumerators clearly stated that this is a one-time money transfer.
40954500|NCT02432482|BEHAVIORAL|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
40954501|NCT02432482|BEHAVIORAL|Standard care|Brief advice to quit (\<5 minutes) Self-help brochure Offer of nicotine patches
40954502|NCT03109730|DRUG|ABI-H0731|A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
40954503|NCT03109730|DRUG|Placebo for ABI-H0731|Sugar pill manufactured to mimic the ABI-H0731 tablet
40954504|NCT03109730|DRUG|Entecavir|An antiviral medication used in the treatment of hepatitis B virus infection
40954505|NCT03109730|DRUG|Tenofovir Disoproxil Fumarate|An antiviral medication used in the treatment of hepatitis B virus infection
40954506|NCT03109730|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
40954507|NCT02028754|DRUG|Sodium Carboxymethylcellulose|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
41291031|NCT03964415|BIOLOGICAL|Placebo|Participants will receive matching placebo.
40954508|NCT02028754|DRUG|Levofloxacin|Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
40954509|NCT02028754|DRUG|Prednisolone|Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
40954510|NCT04608929|BEHAVIORAL|Kegel exercise-focused interventions|After the patients in the intervention group were interviewed on the telephone, the second home visit. During this visit, the patients were trained on Kegel exercises and they were administered the ICIQ-SF. Six weeks after the second visit, the third home visit was paid to determine whether the patients did the Kegel exercises and whether they did them accurately, to assess the perceived impact and to re-administer the ICIQ-SF. After the 2nd and 3rd visit, the patients were called once a week for 6 weeks to monitor if they kept up with doing the Kegel exercises as they were taught. Six weeks later, the 4th home visit were paid to the patients. During this visit, whether the patients did the Kegel exercises and whether they did them accurately was determined, the perceived impact was assessed and the ICIQ-SF was re-administered.
40954511|NCT04608929|OTHER|Home visit and scale evaluations|After the 1st visit, the patients included in the control group were called by phone and the 2nd home visit was planned. During the second home visit, the ICIQ-SF was administered to them. At the 3rd home visit paid 6 weeks after the 2nd visit, the ICIQ-SF was re-administered to the patients and the perceived impact assessment was performed. During the 4th home visit paid 6 weeks after the 3rd home visit, the ICIQ-SF was re-administered to the patients, assessment of the perceived impact was performed, and finally they were given training on Kegel exercises.
40954512|NCT05622695|DEVICE|catheterization|Swan-Ganz catheterization (also called right heart catheterization or pulmonary artery catheterization) is the passing of a thin tube (catheter) into the right side of the heart and the arteries leading to the lungs. It is done to monitor the heart's function and blood flow and pressures in and around the heart.
40954513|NCT03144765|PROCEDURE|Transanal Total Mesorectal Excision (taTME)|Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
41291032|NCT02917486|OTHER|blood sample|
41291033|NCT00317070|DRUG|dimethyl sulfoxide|intravesical installation 50 ml
41291034|NCT00317070|DRUG|IC Cocktail|"* Heparin 10,000 units~* Gentamicin 80 mg~* Hydrocortisone sodium succinate (Solucortef) 100 mg~* Lidocaine hydrochloride 1% 10 ml~* Sodium Bicarbonate 8.4% 5 ml"
41291035|NCT02400346|DRUG|Adjunct brexpiprazole|"Weeks 1-4 titration from 0.5 up to 2 mg once daily, in weekly steps. For the rest of the 26 treatment weeks, maintenance with 1-3 mg once daily.~Tablets for oral use once daily during 26 weeks. Tablet strengths: 0.5 mg, 1 mg, 2 mg and 3 mg."
41291036|NCT02400346|DRUG|ADT|Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine, agomelatine, bupropion; dosing according to label
41291037|NCT02711748|DEVICE|electrostimulation|Electrostimulation using manual defibrillator
41291038|NCT02711748|DEVICE|cardiopulmonary resuscitation|CPR according to guidelines of European Resuscitation Council. Cardiopulmonary resuscitation using manual defibrillator
40954514|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
40954515|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
40954516|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
40954517|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
40954518|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Low Dose (Formulation 2)|0.5 mL, Intramuscular
40761651|NCT03888287|OTHER|Parkinson's Disease Inpatient Clinical Knowledge and Management Program|Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
40954519|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
40954520|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Middle Dose (Formulation 3)|0.5 mL, Intramuscular
40954521|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Middle Dose (Formulation 4)|0.5 mL, Intramuscular
40954522|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
40954523|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
40954524|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
40954525|NCT05310838|BEHAVIORAL|Behavioral Activation for First Episode Psychosis|Sessions will be offered weekly and dyads can complete the intervention during a 6-month period to accommodate competing demands encountered by the population.
40954526|NCT05310838|BEHAVIORAL|Treatment As Usual|Given this condition, patients may also receive individual rehabilitation and/or group psychosocial interventions as part of typical clinic care.
40954527|NCT02957929|DRUG|APX001 single IV dose|
40954528|NCT02957929|DRUG|APX001 single oral dose 1|
40954529|NCT02957929|DRUG|APX001 single oral dose 2|
40954530|NCT02957929|DRUG|APX001 single oral dose 3|
40954531|NCT02957929|DRUG|APX001 single oral dose fasted|
40954532|NCT02957929|DRUG|APX001 single oral dose fed|
40954533|NCT02957929|DRUG|APX001 multiple oral doses 1|
40954534|NCT02957929|DRUG|APX001 multiple oral doses 2|
40761652|NCT00567229|BIOLOGICAL|rituximab|
40954535|NCT02957929|DRUG|APX001 multiple oral doses 3|
41291039|NCT04311476|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy|Evaluate Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
41291040|NCT04311476|DRUG|0.9% Sodiun Chloride|0.9% Sodiun Chloride in control group
41291041|NCT01001494|DRUG|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
40761653|NCT00567229|DRUG|lenalidomide|
40761654|NCT00567229|GENETIC|microarray analysis|
40761655|NCT00567229|OTHER|flow cytometry|
40954536|NCT02957929|DRUG|Cytochrome P450 substrates|
40954537|NCT02957929|DRUG|Matching placebo control|
40954538|NCT02429843|DRUG|TRC105|Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
40954539|NCT05057182|BIOLOGICAL|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
40954540|NCT03855228|DRUG|Mometasone furoate nasal spray (MFNS)|Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
40954541|NCT03855228|DRUG|Loratadine|Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
40954542|NCT03855228|DRUG|Placebo nasal spray|Daily dose of placebo administered as a nasal spray for 15 days.
41291042|NCT01001494|DRUG|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
41291043|NCT01001494|DRUG|Placebo|Placebo twice-daily by inhalation for 24 weeks
40954543|NCT03855228|DRUG|Placebo tablet|Daily dose of placebo administered as an oral tablet for 15 days.
40954544|NCT01957774|DRUG|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
40954545|NCT01957774|DRUG|Placebo|
40954546|NCT01355120|DRUG|Ipilimumab|Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
40954547|NCT06350396|DEVICE|active rTMS treatment|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
40954548|NCT06350396|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
40954549|NCT00569465|DRUG|Arginine|1200 mg, once a day
40954550|NCT00569465|DRUG|Acetylcysteine|600 mg twice a day
40954551|NCT00569465|DRUG|Placebo|3 vials a day
41291044|NCT02956889|DRUG|Vismodegib|Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
40954552|NCT01021930|DEVICE|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
40954553|NCT05428631|DEVICE|Implantation of the CARDIOMEMS™ HF device|The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
40954554|NCT05944289|BEHAVIORAL|Acceptance and Commitment Therapy|a four-week workshop based on the principles and procedures of Acceptance and Commitment Therapy
40954555|NCT05944289|BEHAVIORAL|Caregiver Support Group|Caregiver support group to run parallel to the ACT intervention group.
41291045|NCT02956889|RADIATION|Radiotherapy|Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
41291046|NCT02542449|DIETARY_SUPPLEMENT|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
41291047|NCT02542449|DIETARY_SUPPLEMENT|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
41291048|NCT02599467|OTHER|ULNT 1 and EMG recording|While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
41291049|NCT01267435|PROCEDURE|Anterior cruciate ligament reconstruction|reconstruct the anterior cruciate ligament rupturing
41291050|NCT00174161|BEHAVIORAL|self-care, health behavior|
41291051|NCT00052429|DRUG|cisplatin|
41291052|NCT00052429|DRUG|fluorouracil|
41291053|NCT00052429|PROCEDURE|adjuvant therapy|
41291054|NCT00052429|RADIATION|radiation therapy|
40761656|NCT00567229|OTHER|laboratory biomarker analysis|
41291055|NCT00033839|DRUG|Civamide (Zucapsaicin)|
41291056|NCT01691729|DEVICE|Ostomy accessory|Wearing each of the devices for 10 days each
41454908|NCT03340545|OTHER|Custom Magnetic Resonance Elastography Device|Magnetic Resonance Elastography is an imaging method to measure mechanical properties of tissues.
41454909|NCT03819088|DIETARY_SUPPLEMENT|Zinc|Given PO
41291057|NCT02522910|DRUG|BAY 1000394 (Roniciclib) in combination with docetaxel|The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
41291058|NCT05574504|DRUG|avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin|"Avelumab 800 mg IV q 2 weeks (days 1,15, and 29 every 6 week cycle ) (premedication includes a H1 blocker, H2 blocker and Tylenol) Lurbinectedin 3.2 mg/m2 administered as a 1-h intravenous infusion once every 3 weeks (day 1 and 22 every 6 week cycle )~1 cycle= 6 weeks~Premedication for lurbinectedin:~* Corticosteroids (dexamethasone 8 mg intravenously or equivalent)~* Serotonin antagonists (ondansetron 8 mg intravenously or equivalent) Granulocyte-colony stimulating factor (G-CSF) or equivalent per ASCO guidelines per investigator discretion"
41291059|NCT05978895|OTHER|Targeted canteen menus|"The nutritional intervention consisted in the development of targeted menus aiming at the needs of individuals with ASD and in assessing their acceptance of the targeted menus.~The revision of the standard menus was carried 1) balancing energy and macronutrient content, according to LARN 2014; 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus according to CREA 2018; 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population was evaluated through meal evaluation forms. These results were compared with the ones collected during the first observational phase (WP1). In fact, referring to the results of WP1, new canteen menus were drafted according to the nutritional and sensory needs of the population."
41291060|NCT04976075|OTHER|no interventions|no interventions
41291061|NCT02399475|DRUG|Levothyroxine|Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
41291062|NCT02399475|DRUG|Liothyronine|Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
41291063|NCT02399475|DRUG|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
41291064|NCT03562273|RADIATION|Quality Of Life Sizing Nomogram|"If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care."
41291065|NCT01873664|BEHAVIORAL|Jaw-tapping|to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
41291066|NCT05746780|PROCEDURE|Elective bilateral neck dissection in cN0 patients|Radical modified type 3 selective bilaterale elective neck dissection
40954556|NCT05682365|BEHAVIORAL|prevANS intervention|prevANS intervention will be self-guided and can be implemented from the prevANS web or from the participants' Smartphone (through an APP). The prevANS intervention will have different intensities depending on the risk level of the population, evaluated from the already validated risk algorithm for anxiety: predictA. Participants will be classified as moderate-high or low risk of anxiety. Both groups of risk will receive information on their level and profile (risk factors) of anxiety and psychoeducational information periodically; also, they will work towards manage stressors and enhance protective factors. However, participants with moderate-high risk of anxiety will also receive a cognitive-behavioral training (problem solving, decision-making, handling thoughts / concerns and emotions and communicational skills).
40954557|NCT04871971|DIETARY_SUPPLEMENT|10 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g NUTRALYS®S85 Plus pea protein.
40954558|NCT04871971|DIETARY_SUPPLEMENT|20 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g NUTRALYS®S85 Plus pea protein.
40954559|NCT04871971|DIETARY_SUPPLEMENT|10 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g Whey protein concentrate.
40954560|NCT04871971|DIETARY_SUPPLEMENT|20 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g Whey protein concentrate.
41291067|NCT03201653|PROCEDURE|Stump closure using NU-KNIT SURGICEL|We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
41291068|NCT02239094|DRUG|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
41291069|NCT05559866|DEVICE|Apollo ESG with ERBE HAPC|Utilizing two approved devices in combination to assess durability of suturing.
41291070|NCT05559866|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label.
41291071|NCT00193310|DRUG|Paclitaxel|
40954561|NCT04871971|DIETARY_SUPPLEMENT|50 g Glucose|To determine the glycaemic response and insulinaemic response to 50g Glucose
40954562|NCT04312750|DRUG|Lidocaine topical system 1.8%|
41291072|NCT00193310|DRUG|Carboplatin|
41291073|NCT03721081|DRUG|Lidocaine 1%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Lidocaine 1%/Epi 1:200000 Inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
41291074|NCT03721081|OTHER|Na Cl 0.9%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Na CI 0.9%/Epi 1:200000 inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
41291075|NCT06425744|OTHER|self-myofascial release combined reformer Pilates|"The self-myofascial release combined reformer Pilates group performs 10 minutes of self-myofascial release using the BALLance© method before beginning 20 minutes of Reformer Pilates. The 6-week program includes warm-up and breathing, main supine exercises 1 and 2, and movements targeting the sacroiliac and hip joints.~All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants attend twice a week for 6 weeks, for a total of 12 sessions.~And all participants performed home exercise program follows the guidelines of Geroge et al (2021) and includes myofascial release and Pilates Reformer exercises, as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed."
41291076|NCT06425744|OTHER|Reformer Pilates|"The reformer Pilates group will do 30 minutes of Pilates on the Reformer. All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants also attend twice a week for 6 weeks, for a total of 12 sessions.~The home exercise program follows the guidelines of Geroge et al (2021) as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed."
41291077|NCT05533242|DRUG|Lu-177 labeled 6A10-Fab-fragments|The antibody 6A10 is a specific CA12 Inhibitor, a highly specific glioma cell-associated enzyme; all tumor cells are CA12-positive, while its expression in normal brain is very low, and Lu-177 has a comparable β-emission, but a significantly low γ-Emission.
41291078|NCT00607646|DRUG|Dehydroepiandrosterone|Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
41291079|NCT00607646|DRUG|Placebo|Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
40761657|NCT04679987|DIAGNOSTIC_TEST|Holter ECG|all patients will be monitored for paroxysmal Af by holder ECG
41454910|NCT01927380|OTHER|steep trendelenburg position with pneumoperitoneum|ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
40761658|NCT00941395|OTHER|Survey Administration|Complete surveys
40761659|NCT06405529|OTHER|Early and intensive mobilization protocol at the ICU and Rehabilitation post-hospital discharge|"During hospitalization in the ICU and ward, you will perform 30 to 60 minutes of exercises per day, according to the IMS scale.~After hospital discharge, participation in a supervised exercise program twice a week for 8 weeks at the Rehabilitation Center - CER of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto."
40761660|NCT04538482|BEHAVIORAL|DASH Diet|Participant will receive foods following the DASH dietary pattern for 28 days.
40761661|NCT04538482|BEHAVIORAL|standard American diet|Participants will receive foods following the standard American diet for 28 days.
40761662|NCT00879398|DRUG|Toviaz treatment|4 mg starting then can be followed by 8 mg
40761663|NCT00099905|DRUG|vildagliptin|
40761664|NCT03757715|DRUG|Bupivacaine|20 mL of 1.3% bupivacaine
40761665|NCT03757715|DRUG|Dexamethasone|2 mg dexamethasone
40761666|NCT02071732|DEVICE|real repetitive Transcranial Magnetic Stimulation|
40761667|NCT02071732|DEVICE|sham repetitive Transcranial Magnetic Stimulation|This sham stimulation is not true stimulation.
40761668|NCT06023446|DIAGNOSTIC_TEST|Optical Coherence Tomography|The retina is imaged using infrared light. Images collected in light are compared to those collected in darkness to extract information about function.
40761669|NCT06230991|DIETARY_SUPPLEMENT|SIM05|SIM05 contains a blend of food-grade Bifidobacterium and Lactobacillus strains plus prebiotics
40761671|NCT01772693|DEVICE|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR Guided Focused Ultrasound
40761672|NCT01772693|DEVICE|Sham ExAblate Transcranial MRgFUS|Sham ExAblate Transcranial MR Guided Focused Ultrasound
40761673|NCT00153790|DRUG|PhosphoLean|
40761674|NCT00536705|DRUG|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
40761675|NCT04753359|OTHER|Med|Mediterranean diet
40761676|NCT04753359|OTHER|WL|Measuring change in weight
40761677|NCT03295942|DRUG|OMP-336B11|OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
40761678|NCT06430684|DRUG|Empagliflozin 10 MG|Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older
40761679|NCT01993680|DRUG|Pyridostigmine bromide|"Drug doses during the trial:~Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days"
40761680|NCT01993680|DRUG|fludrocortisone|drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
40761681|NCT02167347|BEHAVIORAL|Family intervention|This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
40761682|NCT03918291|OTHER|Addition of whole-body vibration to squat training|
40761683|NCT03918291|OTHER|Squat training|squatting exercises for 12 weeks, 3x/week
40761684|NCT06327165|OTHER|observation|The ANI monitor calculates heart rate variability mediated by changes in the parasympathetic nervous system.
40761685|NCT05802134|DIETARY_SUPPLEMENT|Fruit and vegetable supplement|Weekly food kits including culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) and staple items to support DASH diet compliance
40761686|NCT05802134|BEHAVIORAL|Dietary and chronic disease management education|Intensive education for chronic disease management: participants will receive education on hypertension management, which will include an interprofessional health appointment with a medical professional to discuss medication compliance, and resources from an occupational therapist for chronic disease management strategies, and 2 nutrition appointments with a Registered Dietitian regarding the DASH Diet (initial education and follow-up at 2 weeks)
40761687|NCT02380235|BIOLOGICAL|PEG-somatropin|0.20mg/kg/w
40761688|NCT02380235|BIOLOGICAL|PEG-somatropin|0.12mg/kg/w
40761689|NCT00382863|DEVICE|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
40761690|NCT00382863|DRUG|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
40761691|NCT03412552|DRUG|MgSO4|Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip
40761692|NCT04297735|OTHER|Standard of care group|Visits every 6 months is standard of care.
40761693|NCT04297735|BEHAVIORAL|Telemedicine group|Conduct monthly telemedicine 'skype' visit
40761694|NCT04297735|BEHAVIORAL|Telemedicine|Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.
40761695|NCT05414799|OTHER|figure eight vision exercise|figure 8 vision exercise is performed in sitting position focus on a point 10 feet away, trace an imaginary horizontally figure 8 with eyes. keep tracing figure eight.
40761696|NCT05414799|OTHER|chin nodding|chin nodding performed in sitting for keeping head placed straight over spine, place finger on chin and tuck-in the chin while head straight back until a stretch is felt at base of head.
40761697|NCT05414799|OTHER|neck stretching|"trapezius : neck flexion with opposite side bending and same side rotation for both sides.~sternocleidomastoid : neck extension with opposite side bending and same side rotation for both sides."
40954563|NCT03909646|DRUG|Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram|A layer of methylaminolevulinc acid 160 mg/g cream (about 1 mm thick) is applied to the lesion, with a clinical margin of 5-10 mm surrounding of normal skin and then covered by an occlusive dressing. After 3 hours the occlusive dressing will be removed and the area is illuminated with Omnilux or Actilite (Galderma). After PDT the treatment site is covered again with the above mentioned occlusive dressings during 48 hours. Treatment is performed by an authorized nurse in the hospital. Two sessions should be administered with an interval of one week between sessions.
41135205|NCT04796792|DEVICE|Break Wave Lithotripsy and Ultrasonic Propulsion|Novel ultrasound technologies to facilitate passage of stones.This includes Burst Wave Lithotripsy (BWL), a technology to noninvasively fragment urinary calculi within the kidney and ureter, and ultrasonic propulsion, a technology to non-invasively reposition stones within the kidney and ureter. BWL uses short multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression/tensile cycle of high amplitude (shock) waves to achieve stone fracture. Ultrasonic propulsion uses long multi-cycle bursts of low amplitude ultrasound to move stones within the collecting system.
41135206|NCT04970602|DRUG|Methylene Blue|Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
40761698|NCT05489458|PROCEDURE|Resection|Type A BR-PDAC patients who had a favorable tumor/vascular structures relationship confirmed during surgical exploration underwent resection.
40761699|NCT05489458|PROCEDURE|No Resection|Type A BR-PDAC patients who did not have a favorable tumor/vascular structures relationship confirmed during surgical exploration did not undergo resection.
40761700|NCT03165500|DRUG|Diazepam|"Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
41454911|NCT00609557|DRUG|duloxetine|Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
41454912|NCT01491464|DEVICE|rhBMP-2/ACS/INTER FIX™|The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
40761701|NCT03165500|DRUG|Midazolam|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
40761702|NCT03165500|DRUG|Nitrous Oxide + Oxygen Gas|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971)."
40954564|NCT03909646|DRUG|5Fluorouracil|5-FU is applied on the treatment area by the patient in a thin layer twice daily during 4 weeks.
41135207|NCT02615132|BEHAVIORAL|iPad|Using iPad speech therapy apps on patients with post-stroke communication deficits
41135208|NCT02958566|DRUG|Acetaminophen|
41135209|NCT02958566|DRUG|Gabapentin|
40954565|NCT03909646|OTHER|Surgical excision|Local anesthesia with lidocain 1% (1-2ml) will be used before performing standard surgical excision with 5 mm safety margin followed by routine histological examination. The skin will be closed using cutaneous sutures, which will be removed after 1-2 weeks. The surgical excision will take place in the hospital by the treating physician
41291080|NCT00916721|DRUG|Propranolol|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
41291081|NCT00916721|DRUG|Placebo|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
40954566|NCT02518074|OTHER|Hearing and Vestibular Interactions|in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
41454913|NCT01491464|DEVICE|Autogenous bone/INTER FIX™|The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
41454914|NCT03959150|DRUG|Capecitabine|Oral fluorouracil
40954567|NCT06114160|OTHER|Data collection|Data collection
40954568|NCT03204201|DRUG|Indocyanine Green Solution|Urethral instillation of ICG (Indocyanine Green) mixed with urethral lubricant
40954569|NCT02883959|OTHER|music therapy|Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
40954570|NCT05822661|DIETARY_SUPPLEMENT|Black Seed Oil|Dietary supplement
41454915|NCT02399462|DRUG|Acthar|"Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly\* Weeks 1 and 2~H.P. Acthar Gel 80 units SC twice weekly\* Weeks 3 through 24~H.P. Acthar Gel 80 units SC once weekly\* Weeks 25 through 26~H.P. Acthar Gel 40 units SC once weekly\* Weeks 27 through 28~\*Injections are to be spaced 72-96 hours apart (+/-6 hours)."
41454916|NCT02646488|BEHAVIORAL|Million Hearts ABCS 6 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
40954571|NCT05822661|DIETARY_SUPPLEMENT|Placebo|placebo capsules same odor, color and size as the drug but without the active ingredient
40954572|NCT03824288|DIAGNOSTIC_TEST|Intraoral ultrasound|The ultrasound transducer (either Hockey Stick or Burr-Hole N11C5s transducer from BK Ultrasound) is placed on the palatoglossal arch on the affected side and sweeped from the cranial to caudal end of the tonsil to look for an abscess cavity identified as a hypoechoic area with ill-defined margins.
40954573|NCT03824288|PROCEDURE|The landmark technique|A 14G needle aspiration is inserted blindly in the superior tonsil pol where pus aspiration is attempted.
40954574|NCT03477097|OTHER|Nutrition, exercise and social network intervention|
40954575|NCT04382300|DRUG|pyrotinib combined with thalidomide|Single Group Assignment
40954576|NCT04238416|DRUG|Branched chain amino acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
41454917|NCT02646488|BEHAVIORAL|Million Hearts ABCS 9 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
41454918|NCT02646488|BEHAVIORAL|Million Hearts ABCS 12 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
41454919|NCT02646488|BEHAVIORAL|Million Hearts ABCS 15 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
40761703|NCT03165500|PROCEDURE|Third molar extraction|Anxious patients in need of third molar extraction
40954577|NCT04238416|DRUG|Lactulose|Oral lactulose will be given to patients in both arms
40954578|NCT03879395|PROCEDURE|Abdominal surgery with metastasectomy|Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma
40954579|NCT02465645|DRUG|Carvedilol|
40954580|NCT02465645|DRUG|Carvedilol + Simvastatin|
40954581|NCT03764007|DRUG|18F-Fluorocholine|Given intravenously
40954582|NCT03764007|PROCEDURE|Positron Emission Tomography (PET)|Imaging technique that uses radioactive agents known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
40954583|NCT02504684|DEVICE|Endovenous 1920-nm diode laser|Patients with saphenous veins treated with a new 1920-nm diode endolaser.
40954584|NCT02504684|DEVICE|Endovenous 1470-nm diode laser|Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
41135210|NCT02958566|DRUG|Orphenadrine|
41454920|NCT02646488|BEHAVIORAL|Standard Care Regimen 9 Months|
41454921|NCT02646488|BEHAVIORAL|Standard Care Regimen 12 Months|
40761704|NCT03193138|DRUG|Hormonal therapies: G03, H01C and L02 in the ATC classification|Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
40761705|NCT01005979|DRUG|Lenalidomide, Rituximab, and Cyclophosphamide|"COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~Patients will receive a total of 6-8 cycles."
40954585|NCT00354861|BIOLOGICAL|hepatitis B antigen (without alum) plus IMP321|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
40761706|NCT03508479|BIOLOGICAL|RG-HRV16|0.25 mL inoculum intranasally delivered into each nostril (0.5 mL total delivered). Total cumulative dose of 1000 median tissue culture infective dose at 50% of cells inoculated (TCID50).
40761707|NCT03449147|DRUG|Placebo|Placebo tablet administered orally BID
40761708|NCT03449147|DRUG|Gefapixant 15 mg BID|Gefapixant 15 mg tablet administered orally BID
40954586|NCT00354861|BIOLOGICAL|hepatitis B antigen alone (without alum)|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
40954587|NCT00354861|BIOLOGICAL|Engerix B|20 µg hepatitis B antigen absorbed on alum
40954588|NCT00252746|DRUG|ZD6474 (vandetanib) 100mg|once daily oral dose
40954589|NCT00252746|DRUG|ZD6474 (vandetanib) 200mg|once daily oral dose
40954590|NCT00252746|DRUG|ZD6474 (vandetanib) 300mg|once daily oral dose
40954591|NCT05468060|DRUG|PA1010|Placebo as control
40954592|NCT04111198|RADIATION|Cardiac MRI|Cardiac MRI
41135211|NCT02958566|DRUG|Lidocaine|
41291082|NCT05754827|DIAGNOSTIC_TEST|RDW to platlet count ratio|RDW to platlet ratio will be measured for all patients and results will be compared between groups
41454922|NCT02646488|BEHAVIORAL|Standard Care Regimen 15 Months|
40761709|NCT03449147|DRUG|Gefapixant 45 mg BID|Gefapixant 45 mg tablet administered orally BID
40761710|NCT05830539|DRUG|IN10018+PLD|IN10018 orally once daily; PLD 40mg/m2, Q4W
40761711|NCT05830539|DRUG|IN10018+PLD+Toripalimab|IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W
40761712|NCT04279587|BEHAVIORAL|Residential camp|Intensive education at a residential camp.
40761713|NCT02422108|DRUG|Denosumab|
40761714|NCT03453242|OTHER|Bone measurement by HR-pQCT and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites one measurement will be performed by HR-pQCT to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
40761715|NCT02229682|RADIATION|Mild-dose IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
40761716|NCT04535115|PROCEDURE|Starting LRM (Lung Recruitment Maneuver)|The LRM is performed first for 30 seconds (an insufflation pressure of 30 cmH2O for 30 seconds is applied). After a free interval of 3 minutes, the VtC is done during 1 minute. For VtC, tidal volume is increased from 6 to 8 ml.kg-1 of predicted body weight. Finally, after a new free interval of 3 minutes, the fluid challenge (consisting in fluid administration of 250 ml of Ringer Lactate) is started for 10 minutes (in aim to determine which patients are responders). This sequence is repeated every 30 minutes (maximum four times).
41291083|NCT04914130|OTHER|Study specific testing procedures|Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc
41291084|NCT00002221|DRUG|Peripheral blood stem cells|
41454923|NCT02646488|BEHAVIORAL|Standard Care Regimen 18 Months|
41454924|NCT02646488|BEHAVIORAL|Standard Care Regimen 21 Months|
41454925|NCT02646488|BEHAVIORAL|Standard Care Regimen 24 Months|
41454926|NCT02646488|BEHAVIORAL|Standard Care Regimen 27 Months|
41291085|NCT05165394|DRUG|Placebo|Tablets for oral administration
41291086|NCT05165394|DRUG|NBI-1065846|Tablets for oral administration
41291087|NCT04988126|OTHER|Interventions|Observational study, not applicable
41291088|NCT02847611|DEVICE|Dynamometer LABIN|LABIN is a prototype of dynamometer containing a handle of metal strength, connected with a sensor of pressure registering(recording) the applied strength and transmitting the data in a computer showing an IT curve of the strength according to time.
40954593|NCT03847714|DIETARY_SUPPLEMENT|Omni-Biotic Stress Repair|The probiotic supplement is a commercially available food for special medical purposes and includes 9 bacterial strains with at least 7.5 billion organisms (7.5 × 109 Colony Forming Units/g) per 1 portion (= 3 g).
40761717|NCT04535115|PROCEDURE|Starting VtC (Tidal Volume Challenge)|The VtC is performed first for 1 minute. After a free interval of 3 minutes, the LRM is done for 30 seconds. Finally, after another free interval of 3 minutes, the fluid challenge is started for 10 minutes. This sequence is repe-tead every 30 minutes (maximum four times).
41291089|NCT00607360|BEHAVIORAL|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
41291090|NCT02418403|BEHAVIORAL|Financial incentive|Offer of money designed to overcome barriers to advance care planning.
40954594|NCT03847714|DIETARY_SUPPLEMENT|placebo|similar looking and tasting powder
40954595|NCT04741711|PROCEDURE|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.
40954596|NCT04741711|PROCEDURE|Usual care without ultrasound guidance|Usual care (i.e. without ultrasound guidance)
40954597|NCT00076843|DRUG|Hu MiK-Beta-1|
40954598|NCT00087503|DRUG|Edotecarin|
40954599|NCT05024604|DRUG|Progesterone Only Product in Oral Dose Form|mini pills as a contraceptive method
40954600|NCT05024604|OTHER|office hysterscopy|office hysteroscoy
40954601|NCT05351502|DRUG|Nitric Oxide 25,000 ppm|Intratumoral injection of 25,000 gNO
40954602|NCT05351502|DRUG|Nitric Oxide 50,000 ppm|Intratumoral injection of 50000 gNO
40954603|NCT05351502|DRUG|Nitric Oxide 100,000 ppm|Intratumoral injection of 100,000 gNO
40954604|NCT05351502|DRUG|Nitric Oxide selected dose|Intratumoral injection of selected does on gNO
41291091|NCT02418403|BEHAVIORAL|Educational website|"Research-verson of the Prepare for your care website (www.prepareforyourcare.org)"
40954605|NCT05981339|OTHER|breathing exercises|For the diaphragmatic breathing exercise, patients are asked to perform a nasal inspiration and expiration that moves predominantly the abdomen by reducing the movement of the thorax in the semi-supine position. To give tactile stimulation, one hand of the patient is placed on the chest with the other hand on the abdominal region. Continue this exercise for three minutes.
41135212|NCT02958566|DRUG|Marcaine|
41135213|NCT02958566|DRUG|Ketamine|
41135214|NCT02958566|DRUG|Methadone|
41135215|NCT02958566|DRUG|Tramadol|
41135216|NCT02958566|DRUG|Ketorolac|
41135217|NCT02958566|DRUG|Morphine Sulfate|
41135218|NCT02958566|DRUG|Fentanyl|
41135219|NCT02958566|DRUG|Dilaudid|
41135220|NCT02958566|DRUG|Hydrocodone-Acetaminophen Tab 5-325 MG|
41135221|NCT02958566|DRUG|Morphine Sulfate|PCA
41135222|NCT02958566|DRUG|Fentanyl|PCA
41135223|NCT02958566|DRUG|Dilaudid|PCA
41291092|NCT00538603|DRUG|pegylated liposomal Doxorubicin (CAELYX) & Carboplatin|Chemotherapy
40954606|NCT05981339|OTHER|osteopathic manual therapy techniques|"* Sacral release: While the patient is in the side lying position, the physiotherapist goes behind the patient, one hand is placed on the lower abdominal area, and the thenar and hypothenar areas of the other hand are placed on the basis of the sacrum. It is waited until a general relaxation is felt in the tissue under the hands (Stone, C., 2006).~* Bladder mobilization: Two hands are placed just above the pubic region and gently pressed down first to test the surface protrusion of the uterus. During the application, the pressure of the hand is adjusted according to the tension of the tissue. Hand contact is not interrupted until the fascial tissue under the hand is relaxed (Stone, C., 2006)."
40761719|NCT00088699|DRUG|Ketamine|
40761720|NCT00088699|DRUG|Placebo|
40761721|NCT06570915|DRUG|Daratumumab Injection|Daratumumab was administered once a week at a dose of 16 mg/kg for a total of 4 times (Day1,8,15,22 ) in one cycle.
40954607|NCT03506789|DRUG|Dexamethasone|Dexamethasone 24 mg
40954608|NCT03506789|DRUG|Placebos|Isotonic saline
40954609|NCT02543580|OTHER|transcutaneous electric acupoint stimulation|electrodes are attached o the skin and electric stimulation is given
40954610|NCT02543580|OTHER|electrode attached but no stimulation|electrodes are attached o the skin but no stimulation is given
40954611|NCT02653872|DRUG|AZD7986|Oral solution, single dose, dilution from concentrate
40954612|NCT02653872|DRUG|Verapamil|Extended release tablet for oral use
40954613|NCT02653872|DRUG|Itraconazole|Oral solution
40954614|NCT02653872|DRUG|Diltiazem|Extended release capsule
40954615|NCT00003661|BIOLOGICAL|anti-thymocyte globulin|
40954616|NCT00003661|DRUG|busulfan|
40954617|NCT00003661|DRUG|cyclosporine|
40954618|NCT00003661|DRUG|melphalan|
40761722|NCT03226665|DIAGNOSTIC_TEST|ultrasound|"definition of prevalence of US detected obstruction in patients referred to an emergency facilities with symptoms potentially suggestive for such diagnosis.~Moreover, which clue, if any, could reinforce the need of US intestinal study, such as anaemia, CRP, NLR, hypotension.~This information is not yet available elsewhere. Moreover, in this context, sensitivity and specificity of ultrasound vs. confirm by CT and other procedures will make more sense and will be consequently assessed."
40761723|NCT02985138|PROCEDURE|TLIF and unilateral pedicle screw fixation|TLIF combined with posterior unilateral pedicle screw fixation
40761724|NCT02985138|PROCEDURE|TLIF and bilateral pedicle screw fixation|TLIF combined with posterior bilateral pedicle screw fixation
40761725|NCT02985138|DEVICE|Pedicle screw and cage|Pedicle screw and cage
40761726|NCT06549608|DRUG|Mavacamten|As per product label
40761727|NCT04855435|DRUG|MBS8(1V270)|The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
40761728|NCT03428347|BIOLOGICAL|GamEMab|drug for emergency prevention of Ebola based on recombinant monoclonal antibodies
40761729|NCT06188975|DRUG|DRUG: ABBV-CLS-484|
40761730|NCT01760863|OTHER|Oral Antibiotics|Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
40954619|NCT00003661|DRUG|methylprednisolone|
40954620|NCT00003661|PROCEDURE|umbilical cord blood transplantation|
40954621|NCT00003661|RADIATION|radiation therapy|
40954622|NCT04321070|DRUG|Clindamycin Phosphate|A thin film of investigation product will be applied to the affected areas of the face once daily
40761731|NCT04085731|PROCEDURE|Catheter ablation|Driver-guided catheter ablation of persistent atrial fibrillation
40761732|NCT05494619|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and \<100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
40761733|NCT05494619|DRUG|Placebo|Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to \< 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
40761734|NCT05494619|DRUG|Intravenous immunoglobulin therapy|All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
40761735|NCT00944645|DRUG|niacin (+) laropiprant (Source 1)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
40761736|NCT00944645|DRUG|Comparator: niacin (+) laropiprant (Source 2)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
40761737|NCT00070083|BIOLOGICAL|oblimersen sodium|
40761738|NCT00070083|BIOLOGICAL|rituximab|
40761739|NCT00070083|DRUG|cyclophosphamide|
40761740|NCT00070083|DRUG|doxorubicin hydrochloride|
40761741|NCT00070083|DRUG|prednisone|
40761742|NCT00070083|DRUG|vincristine sulfate|
40761743|NCT01926509|DRUG|MK-8892|
40761744|NCT01926509|DRUG|Placebo for MK-8892|
40954623|NCT04321070|DRUG|Clindamycin Phosphate RLD|A thin film of investigation product will be applied to the affected areas of the face once daily
40954624|NCT04321070|DRUG|Placebos|A thin film of investigation product will be applied to the affected areas of the face once daily
40954625|NCT03134404|OTHER|No Intervention|No Intervention is required for this study
40954626|NCT00876525|DEVICE|Surgical Replacement of the diseased native aortic heart valve with the Freedom SOLO Valve prosthesis|The Freedom SOLO prosthesis is designed for implantation in a supra-annular, sub-coronary position, with a single suture line.
40761745|NCT05292287|DEVICE|Polar Ignite Wearable Activity Monitor|A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality. The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.
40954627|NCT01373242|DRUG|Liquid peanut extract (Peanut SLIT)|Liquid peanut extract will be administered under the tongue
40954628|NCT03493074|DIAGNOSTIC_TEST|Noninvasive pulse wave analysis sensor, ECG-sensor|The sensors are noninvasively attached
40954629|NCT00408629|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
40954630|NCT00408629|BIOLOGICAL|placebo|Matching Placebo for prefilled syringe, 40 mg,
40954631|NCT03417323|OTHER|Compression|Participants in the treatment group wear compression garment after intense WB-EMS application for 24 h, and 12 h for day 2, 3, 4 post WB-EMS.
40954632|NCT00481143|DRUG|ICL670/Deferasirox|
40954633|NCT00586625|DRUG|Bepreve|One drop, both eyes, twice a day
40954634|NCT00586625|DRUG|Placebo|One drop, both eyes, twice a day
40761746|NCT01003327|DEVICE|I-gel|intubation with I-gel airway
40761747|NCT01003327|DEVICE|LMA-Unique|LMA-Unique airway is inserted first, then the I-gel
40761748|NCT02370342|PROCEDURE|Robot-Assisted Laparoscopic Surgery|Undergo robot-assisted laparoscopic HIFU ablation
40761749|NCT02370342|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo robot-assisted laparoscopic HIFU ablation
40761750|NCT02370342|PROCEDURE|Therapeutic Laparoscopic Surgery|Undergo laparoscopic partial nephrectomy
40761751|NCT02370342|DEVICE|Sonatherm 600i Ultrasonic Lesion Generating System|Device used for high-intensity focused ultrasound ablation
40761752|NCT06198777|DEVICE|Magnetometer|Inspection equipment for magnetocardiography
40954635|NCT06223074|OTHER|IV Methylprednisolone administration|Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse
40954636|NCT06223074|DRUG|Nasal Methylprednisolone (MT)|Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse
40954637|NCT05890950|DRUG|K-757 and K-833|Both administered orally
40954638|NCT05890950|DRUG|Matching placebo to K-757 and K-833|Both administered orally
40954639|NCT05923749|DEVICE|Biatain Ag|Biatain with silver
40954640|NCT05923749|DEVICE|Cutimed Siltec Sorbact|comparator device
40954641|NCT03086993|COMBINATION_PRODUCT|Melphalan/HDS|Melphalan/HDS treatment for up to six cycles, followed by a re-induction of CisGem.
40954642|NCT03086993|DRUG|Cisplatin and Gemcitabine|continuous treatment with Cis/Gem until disease progression
40954643|NCT04680091|DRUG|Pyrotinib Maleate|single oral dose, 400 mg, fed.
40954644|NCT04680091|DRUG|Efavirenz|single oral dose, 600 mg, fasted, at bedtime.
40954645|NCT02850601|DRUG|Dexamethasone|Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
40954646|NCT00679666|DRUG|Riboflavin|01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
40954647|NCT00679666|DRUG|Placebo|Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
41291093|NCT00538603|DRUG|Paclitaxel & Carboplatin|Chemotherapy
41291094|NCT04153812|DEVICE|vagus nerve stimulation|Vagus nerve stimulation (VNS) is a new technique for stimulating the left cervical vagus nerve through implanted lead and a programmable pulse generator.
41291095|NCT00638066|DRUG|botulinum toxin|500 units of botulinum toxin for the second arm
40761753|NCT02392169|DRUG|Methylphenidate|Patients used Retina or Concerta twice a day lasting for one year.
40761754|NCT02531451|DRUG|Ibuprofen|
40761755|NCT02531451|DRUG|Acetylsalicylic acid|
40761756|NCT00548691|DRUG|Ferric Carboxymaltose|
40954648|NCT01052571|PROCEDURE|lumbar transforaminal epidural injections|with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
40954649|NCT00866788|DRUG|omalizumab|Administered by subcutaneous injection
40954650|NCT00866788|DRUG|placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study.
40954651|NCT00866788|DRUG|H1 antihistamines|Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
40954652|NCT00866788|DRUG|Diphenhydramine|Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
41291096|NCT00638066|DRUG|botulinum toxin A|250 units of botulinum toxin A once
41291097|NCT02908477|RADIATION|Adjuvant Radiation Therapy|60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)
40761757|NCT00548691|DRUG|Standard Medical Care (SMC)|
40761758|NCT01629498|RADIATION|Image Guided Radiation Therapy|Undergo image-guided IMRT
40761759|NCT01629498|RADIATION|Image Guided Radiation Therapy|Undergo image-guided IMPT
40954653|NCT03738033|OTHER|educational platform|The platform would be opened before they entered the study.
40954654|NCT02980497|OTHER|Listerine Zero Mouthwash (without alcohol)|20 ml of rinse for 30 seconds, twice a day
40954655|NCT02980497|OTHER|Listerine Antiseptic Mouthwash (with alcohol)|20 ml of rinse for 30 seconds, twice a day
41291098|NCT02908477|DRUG|Docetaxel|15 mg/m2. Experimental arm only.
40954656|NCT04576325|DRUG|Voriconazole Inhalation Powder|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules for a given dose must be inhaled over a maximum 10-minute period. Cohort 1 will receive 40 mg BID and Cohort 2 will receive 80 mg BID. Both Cohorts will administer study drug for 3.5 days (7 days total).
40954657|NCT04576325|DRUG|Placebo|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).
40761760|NCT01629498|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image-guided IMRT
40954658|NCT05087108|DEVICE|OsciPulse system|The OsciPulse system is an intermittent pneumatic limb compression system. The OsciPulse sleeves that are applied to the top portion of the user's calves and are periodically inflated with rapid bursts of compressed air to create frequent pulses of venous return.
41291099|NCT02908477|DRUG|Cisplatin|40 mg/m2. Standard arm only.
40761761|NCT01629498|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image-guided IMPT
40761762|NCT01629498|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
40761763|NCT01629498|RADIATION|Photon Beam Radiation Therapy|Undergo image-guided IMRT
40761764|NCT01629498|RADIATION|Proton Beam Radiation Therapy|Undergo image-guided IMPT
40761765|NCT01629498|OTHER|Questionnaire Administration|Ancillary studies
40954659|NCT05087108|DEVICE|Reference Therapy 1|The Venaflow Elite is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Venaflow system sleeves cover the entire calf region of the user and contain two bladders that are inflated sequentially to induce venous return.
40761767|NCT02940119|DEVICE|Multi Radiance Medical®|Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
40761768|NCT01182246|DRUG|AXP107-11|"The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa."
40761769|NCT02106546|DRUG|Carboplatin|Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.
40954660|NCT05087108|DEVICE|Refence Therapy 2|The Kendall SCD device is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Kendall SCD sleeves cover the entire calf region of the user and contain three bladders that are inflated sequentially to induce venous return.
40954661|NCT02002091|OTHER|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
40954662|NCT05552755|DRUG|REC-4881|REC-4881 4mg capsules
40954663|NCT05552755|DRUG|Placebo|Placebo capsules
41454927|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 21 Months|
41454928|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 24 Months|
41454929|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 27 Months|
41454930|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 30 Months|
41454931|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 33 Months|
40954664|NCT01592682|BEHAVIORAL|Smokefree counseling|Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
40954665|NCT03431870|OTHER|Trans-esophageal echocardiography|Perform a trans-esophageal echocardiography before and after anesthesia.
40954666|NCT02137265|DRUG|Clomiphene|Clomiphene citrate 50 mg orally daily
40954667|NCT02137265|DRUG|Placebo|One pill every other day
40954668|NCT05629078|DEVICE|Toric intraocular lens Zeiss AT TORBI|Intraocular lenses are medical devices that are implanted in patients during cataract surgery. At Plymouth University NHS trust the standard lens is a monofocal non-Toric lens unless the patient has astigmatism greater than 4.00D. This study involves implantation of a toric lens in the intervention group where astigmatism is greater than 1.00D. The lens is called the toric IOLS- Zeiss AT TORBI, will be implanted bilaterally instead of standard monofocal IOLs- Zeiss CT ASPHINA, used in routine cataract surgery within NHS.
41135224|NCT02958566|DRUG|HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET|Breakthrough
41135225|NCT00002294|DRUG|Fluconazole|
41135226|NCT06509191|DRUG|Intervention 1|Melatonin 5mg/day
41135227|NCT06509191|DRUG|Intervention 2|Melatonin 8 mg/day
40761770|NCT02106546|DRUG|Veliparib|Capsules taken orally twice a day, 12 hours apart.
40761771|NCT02106546|DRUG|Paclitaxel|Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².
40761772|NCT02106546|DRUG|Placebo to veliparib|Capsules taken orally twice a day, 12 hours apart.
40761773|NCT03410745|BEHAVIORAL|Exercise.|Moderate to heavy intensity resistance exercise consisting of leg press.
40761774|NCT04526925|DEVICE|Respiratory filter in-line placed with the standard mouthpiece|The respiratory filter is a device that removes solid/large particles from gas
40761775|NCT04526925|OTHER|Standard mouthpiece|The mouthpiece is the interface that is placed on participant's face in order to measure all the breathing physilogic responses
40761776|NCT04775979|DRUG|diphenylcyclopropenone (DPCP)|Depigmenting agent
40761777|NCT06466096|OTHER|no intervention|this is an observation study, no intervention
40954669|NCT00553943|DRUG|Rituximab|375 mg/m2 D1
40954670|NCT00553943|DRUG|Cytarabine|50 mg D3
40954671|NCT06021288|OTHER|Effluent dose of CRRT|The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
40954672|NCT05978778|DEVICE|wii sports game|wii sports is a collection five sports game stimulation,which have been designed to demonstrate the motion sensing capabilities of wii remote
40954673|NCT05978778|OTHER|pre-hand writing skills|pre-hand writing skills
41135228|NCT06509191|OTHER|Control|Placebo
41307858|NCT06370936|OTHER|Standardized diet with commercially available animal meats (comparator products)|Fully controlled standardized diet with commercially available meats from animal origin. Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
40761778|NCT06131112|DIAGNOSTIC_TEST|64Cu-DOTATATE PET/CT scan|Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.
40761779|NCT01344655|DRUG|Atimos®|Formoterol 12 μg pMDI
40954674|NCT06534710|DEVICE|electronic moxibustion apparatus|The experimental group used the electronic moxibustion instrument every day on the basis of the control group
40954675|NCT05962957|DRUG|carbidopa-levodopa|Levodopa is typically prescribed to a patient with Parkinson disease once symptoms become more difficult to control with other anti-parkinsonism drugs. The drug can also be used for postencephalitic parkinsonism and symptomatic parkinsonism due to carbon monoxide intoxication
40954676|NCT05962957|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy via suppression of the TLR4/NF-κB network signaling pathway. Moreover, Pentoxifylline has a potential antioxidant capacity mostly via nuclear erythroid 2-related factor 2 (Nrf2) activation with subsequent up-regulation and expression of several antioxidant enzymes
40954677|NCT05962957|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
40954678|NCT01981980|OTHER|Carboxytherapy|Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
40954679|NCT01981980|OTHER|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
40761780|NCT01344655|DRUG|Serevent™|Salmeterol 25 µg pMDI
40954680|NCT01497457|PROCEDURE|MR saline peritoneography|Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
40954681|NCT02846831|OTHER|12-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day before the start of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 12 days.~Participants will have been previously shown how to use the study insulin pump."
40954682|NCT02846831|OTHER|12-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 12 days."
40954683|NCT02846831|DEVICE|Insulin pump|Tandem Diabetes Care
41291100|NCT02132338|BEHAVIORAL|The Education Health Program|The operation of the educational program for the group under intervention will consist of groups operating with the triad of diabetes mellitus (pathophysiology of the disease, physical activity and diet), to be held in five times (cycles) approach, an interval of three months being held between them . In each session, participants will be the same (under multidisciplinary team intervention), the content will also be the same, however, using different educational strategies. During the intervals between cycles these users will be monitored by phone by equity and / or nursing students of the Federal University of São João Del Rei properly trained to do so. The educational program will be developed in five times (T0, T3, T6, T9, T12) and with an interval of three months. At every moment the educational process will be conducted with three consecutive meetings with one week interval. In summary, 15 educational sessions with the experimental group will be held.
40954684|NCT02846831|DEVICE|Continuous glucose monitoring system|Dexcom G5 Platinum
40954685|NCT02846831|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
40954686|NCT02990689|DEVICE|Trifocal Intraocular Lens|bifocal intraocular lens (IOL)
40954687|NCT02990689|DEVICE|Bifocal Intraocular Lens|trifocal intraocular lens (IOL)
40954688|NCT02990689|DEVICE|Low Addition Bifocal Intraocular Lens|low near addition intraocular lens (IOL)
40954689|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
40954690|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
40954691|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
40954692|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
40954693|NCT01235689|BIOLOGICAL|Adalimumab|If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
40954694|NCT01235689|DRUG|Prednisone|The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
41291101|NCT04959019|BEHAVIORAL|Supervised combined endurance and resistance training (CERT)|Subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
41454932|NCT06478745|OTHER|Retrospective and prospective cohort|"* Retrospective study: Population-based retrospective cohort study with RWD. Patients ≥60 years old with 2 or more chronic diseases diagnosed before 01/01/2012, users of the public health system of the participating Autonomous Communities, will be included. Those who have had no contact with primary care defined as contact in a medical or nursing consultation in the previous two years (2010-2012) will be excluded.~* Prospective longitudinal observational open cohort study developed in the context of the MULTIPAP and LOXO studies.Patients over 65 years of age with multimorbidity (3 or more chronic pathologies) and polypharmacy (5 or more drugs taken during at least the last 3 months before inclusion in the study) under follow-up from primary care in Madrid, Aragon and Andalusia."
40761781|NCT01344655|DRUG|Placebo|placebo
40954695|NCT01235689|DRUG|Azathioprine|Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
40954696|NCT00502944|BEHAVIORAL|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
40954697|NCT00502944|BEHAVIORAL|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
40954698|NCT06557044|DRUG|Ropivacaine|PENG block with ropivacaine
40954699|NCT06557044|OTHER|Physiological saline|Placebo control
40954700|NCT05619250|BEHAVIORAL|Unsupervised home-based exercise group without motivational intervention (UNSUP)|UNSUP will receive a non-supervised physical exercise intervention using a mobile app at home. The UNSUP training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised groups, but is adapted to be performed at home with the use of elastic bands and the participant's own body weight. The exercise program will be divided into 3 different levels. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
40954701|NCT05619250|BEHAVIORAL|Unsupervised home-based exercise group with motivational intervention (UNSUP+)|UNSUP+ will receive a non-supervised physical exercise intervention using a mobile app at home. The UNSUP+ training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised groups, but is adapted to be performed at home with the use of elastic bands and the participant's own body weight. The exercise program will be divided into 3 different levels. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks. Further, motivational strategies will be applied based on self-determination theory.
40954702|NCT05619250|BEHAVIORAL|Supervised center-based exercise group without motivational intervention (SUP)|SUP will attend the university facilities and will perform training in small groups, being supervised by an exercise professional. The SUP training program comprises the same exercise structure and is based on the same muscle groups and movements as the unsupervised groups, but is performed in a center using the equipment available at the facility (weight machines, free weight, stationary bikes, etc.). The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises (for upper and lower limbs), 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
40954703|NCT05619250|BEHAVIORAL|Supervised center-based exercise group with motivational intervention (SUP+)|SUP+ will attend the university facilities and will perform training in small groups, being supervised by an exercise professional. The SUP+ training program comprises the same exercise structure and is based on the same muscle groups and movements as the unsupervised groups, but is performed in a center using the equipment available at the facility (weight machines, free weight, stationary bikes, etc.). The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises (for upper and lower limbs), 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks. Further, motivational strategies will be applied based on self-determination theory.
40954704|NCT06556498|PROCEDURE|Proflor group|evaluate the surgical outcomes of patients underwent to laparoscopic inguinal hernia repair with Proflor mesh.
40954705|NCT06556498|PROCEDURE|Progrip group|evaluate the surgical outcomes of patients underwent to laparoscopic inguinal hernia repair with Progrip mesh.
40954706|NCT00393354|DRUG|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
40954707|NCT00393354|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
40954708|NCT06324812|DRUG|Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)|subcutaneous injection，611 450/600mg (loading dose) + 300mg once every 2 weeks/4 weeks
41291102|NCT04959019|BEHAVIORAL|Delayed supervised combined endurance and resistance training (CERT)|After a 6-week delay period (no-exercise control), subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
41291103|NCT05873140|BEHAVIORAL|application LINE|Online lifestyle modification education for weight loss
41291104|NCT00107107|DRUG|pramlintide acetate|Syringe vial and Pen-cartridge
41291105|NCT03946566|PROCEDURE|Acupuncture|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
41291106|NCT04188366|BEHAVIORAL|FAMES|Participants will receive three distinct and revolving components - early, continuous, and motivational contact - that incorporate motivational techniques and the Diagnostic and Statistical Manual of Mental Disorders 5TH Edition (DSM-5) Cultural Formulation Interview (CFI).
40761782|NCT02440165|BEHAVIORAL|Nursing nutrition intervention|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~* Information and advice;~* Examples of energy and protein rich meals;~* patients will be asked to register their nutritional intake for two days at home;~* after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
41291107|NCT04188366|BEHAVIORAL|Treatment-as-Usual|Participants will receive usual services and family-based treatment offered
41291108|NCT05398874|COMBINATION_PRODUCT|Ginkgo biloba extract + standard treatment( paracetamol+Diclofenac100mg SR)|120 mg leaf extract , twice daily in addition to Diclofenac 100 mg Once daily + paracetamol 1g Twice daily
41291109|NCT05398874|COMBINATION_PRODUCT|placebo in addition to the standard treatment|placebo in addition to the standard treatment
40761783|NCT01397591|BIOLOGICAL|Ofatumumab|Given intravenously
40761784|NCT01397591|DRUG|Bortezomib|Given intravenously
40761785|NCT06116526|DRUG|Dupilumab - Discontinuation|Drug injections are discontinued.
41291110|NCT06399081|OTHER|Observational|Observational
41291111|NCT00955110|DRUG|Oxymorphone ER|15mg or 30mg
40761786|NCT06116526|DRUG|Dupilumab - Dose Reduction|The drug is given as a subcutaneous injection.
40761787|NCT06116526|DRUG|Dupilumab - Standard Dose|The drug is given as a subcutaneous injection.
40761788|NCT00157261|DRUG|tenecteplase|
40761789|NCT05531942|DRUG|Ginkgo Diterpene Lactone Meglumine Injection|The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.
40954709|NCT03974243|DRUG|Chiauranib|"In the lead-in period, patients take 50mg Chiauranib capsules on the forth day .~In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle."
40954710|NCT03974243|DRUG|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8,11,15,18,22 and 25 of each cycle. 28 days as a cycle
40954711|NCT05975879|DIETARY_SUPPLEMENT|undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)|"Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
40954712|NCT05975879|DIETARY_SUPPLEMENT|Placebo|Release form: capsules with an average weight of 585 mg. No active ingredients.
40954713|NCT02915796|BIOLOGICAL|G-CSF + CD133(+) cells|Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
40954714|NCT02915796|BIOLOGICAL|G-CSF|Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
40954715|NCT02915796|PROCEDURE|percutaneous transluminal angioplasty (PTA)|Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
40954716|NCT02915796|BIOLOGICAL|Placebo infusion|Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
41454933|NCT06478745|OTHER|Focus group, semi-structured interviews and Photovoice|The participants will be people with multimorbidity over 60 years of age recruited from Primary Care centers in Spain. A theoretical sampling will be carried out. Data will be collected through video and audio recordings from a total of 16 focus groups and 20 interviews in 7 regions, and will finally be transcribed for a triangulated thematic analysis. Two groups will be carried out with participation-action research methodology - Photovoice.
40761790|NCT05531942|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
40761791|NCT06564480|DEVICE|MI-R1 lower limb walking machine assisted training device|The training is conducted under partial weight support training conditions, performing passive movements on the lower limbs through motor drive, improving the joint activity of the patient's hip and knee joints, and achieving sitting, standing, and walking functions.
40761792|NCT06564480|OTHER|Walking rehabilitation training under the guidance of therapists|Each patient undergoes training under the guidance of a rehabilitation therapist
40761793|NCT04796805|OTHER|Topical essential oil application|We applied black pepper essential oil to the participants in experimental group before the catheter insertion procedure
41291112|NCT00955110|DRUG|Oxycodone CR|30mg or 60mg
41291113|NCT00955110|DRUG|Placebo|The placebo was a sugar pill.
41291114|NCT00955110|DRUG|Hydromorphone|8 mg
41454934|NCT06478745|OTHER|Systematic review|No patient recruitment required
41454935|NCT03528486|BEHAVIORAL|Music Training I|Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
41454936|NCT03552328|OTHER|Lunch with Medical Student|Each student will bring provided lunches once a week to their elder participant's residence, and they will share lunch together for an hour once a week for six weeks. Students will enroll as Meals on Wheels volunteers and participate in the Meals on Wheels pre-program training. On the day of their scheduled lunch, students will first arrive at the Meals on Wheels designated meal-drop location and pick up two lunches, one for them and one for their assigned elder. They will then drive to their assigned elder's residence and eat lunch with them for one hour.
41454937|NCT03552328|OTHER|Control|Students will not bring provided lunches to an elder participant's residence. The elder participants in this arm will simply continue receiving daily meals from Meals on Wheels with no accompanying student.
40761794|NCT01501500|DRUG|BOTOX|once injection of BTA 3oU into hallux oblique and transverse heads each
40761795|NCT01501500|DRUG|Normal Saline (0.9% NaCl)|Normal saline 0.3ml to oblique and transverse heads each
40761796|NCT06564532|BEHAVIORAL|Evaluatively conditioning participant to like partner|The intervention is a computerized learning task that leads the participant to associate the partner with positive stimuli
40761797|NCT06564532|BEHAVIORAL|Evaluatively conditioning partner to like participant|The intervention is a computerized learning task that leads the partner to associate the participant with positive stimuli
40761798|NCT04854473|DEVICE|Exero Medical Leak Detection System|"the Exero Leak Detection System components used in this study are:~* Smart drain - a surgical drain with added sensing electrodes~* Transceiver /Recording Unit (TRU) - a wearable placed outside the body on intact skin and is connected to the implanted electrodes. The unit also acts as a wireless connection to the Monitoring Subsystem.~* Monitoring Subsystem - a tablet or a computer connected wirelessly to the transceiver providing logging, applying analysis algorithms on the logged signals and providing indication/alerts to the medical staff derived from the signals recorded by the electrodes."
40761799|NCT03202303|DRUG|Cannabidivarin|Weight-based dosing of 10 mg/kg/day of CBDV
40761800|NCT03202303|DRUG|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo
41291115|NCT04323709|OTHER|Data collection|Clinical data are collected from the medical record of the institution. At admission, date were collected on age, gender, body mass index, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment, hypertension, diabetes, hypercholesterolemia, smoking, history of stroke or congestive heart failure, coronary or peripheral artery disease, renal failure with dialysis, Left Ventricular Ejection Fraction(LVEF), Tricuspid Annular Plane Systolic Excursion, mean arterial pressure, heart rate, central venous pressure, ScvO2, presence of an intra-aortic balloon pump and biochemical parameters. During hospitalization data were collected on reason for initiation of VA-ECMO and its characteristics (duration, type, flow L/min, RPM, FiO2), length of stay in ICU, catecholamines and inotropes maximal dose and length of administration, patients with heart transplantation or LVAD. In patients with levosimendan treatment, timing of administration regarding ECMO canulation was collected
41291116|NCT04323709|OTHER|Data analysis|Continuous variables were presented as mean ± standard deviation and compared using Student's t-test or Mann-Whitney U-test depending on their normality. Categorical variables were presented as counts and percentages and compared using Pearson's chi-squared test or Fisher's exact test, as appropriate. Survival at day 28 was estimated using the Kaplan-Meier method and compared using the log rank test. Investigators conducted a multivariable logistic regression with propensity score matching, which was defined as the probability of exposure to levosimendan. Results were reported as odd ratios (ORs) together its 95%CI assuming a 5% level of statistical significance. All analyses were carried out using STATA 15.0 (Stata Corp, College Station, Texas 77845 USA).
40786506|NCT05011149|DRUG|Ibuprofen|"Pharmacotherapy, when indicated (ie, for severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness), will be provided in the form of ibuprofen as first line agent at a standard dosing of 10 mg/kg followed by 2 doses of 5mg/kg every 24 h. The route of administration may be intravenous or enteral, as determined by the treating team.~For treated infants, follow-up echocardiography will be conducted at the end of the 3-day course and second course of treatment will be initiated if they still fulfill study treatment criteria as mentioned above. If any treatment-eligible infant has a contraindication to ibuprofen, use of acetaminophen will be permitted as an alternative agent."
41291117|NCT06509152|BEHAVIORAL|Theory of mind-based social competence group intervention|"The ToM-SCGI is designed as a group intervention, with 60-minute sessions held weekly, either once or twice, and led by trained therapists. Two caregiver meetings are conducted in the middle and end of the interventions.~The intervention process for each session is as follows:~1. Warm-up Activities(5-10 minutes): review the previous group session and prepare for the current group activities.~2. Theory of Mind Instruction(10-15 minutes): based on the developmental stage of the children's theory of mind, using thought bubbles to teach corresponding elements of theory of mind development.~3. Social Skills Group Games(30-35 minutes): design social scenario-based group games that allow children to practice applying the acquired theory of mind abilities into expressions and applications of theory of mind and social competence.~4. Summary(5-10 minutes): summarize the children's performance in the group and assign homework."
41291118|NCT03074305|DEVICE|PCI for in-bioresorbable scaffold stenosis|"In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~1. DEB strategy~2. DES strategy"
41291119|NCT03531957|DRUG|ASN002|Daily dose of ASN002 for 12 weeks
41454938|NCT03655977|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before external beam radiation therapy (EBRT).
41454939|NCT03655977|DEVICE|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.
40786507|NCT02471313|DRUG|[18F] FMISO|\[18F\] Fluromisonidazole, 1 h-(3-\[18F\]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of \[18F\] FMISO PET imaging post TACE procedure.
41454940|NCT03655977|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before brachytherapy (BT).
41454941|NCT03655977|DEVICE|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.
40786508|NCT03335202|DIAGNOSTIC_TEST|analysis of microbiome|microbial profiling by next generation sequencing
40786509|NCT05407805|OTHER|Electronic Diary|Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.
41291120|NCT03531957|DRUG|Placebo Oral Tablet|Placebo of ASN002 for 12 weeks
41291121|NCT06162026|BEHAVIORAL|RACS app|risk assessment questions, symbol matching task, voice tasks
41291122|NCT03337841|DRUG|Pembrolizumab|Each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.)
41291123|NCT00611130|DRUG|vigabatrin|Tablets twice a day for 9 weeks
41291124|NCT00611130|DRUG|placebo|tablets twice daily for 9 weeks
41291125|NCT06298097|DEVICE|Connectivity measures|Electroencephalography connectivity measures will be collected and compared in both stroke patients and healthy participants. Connectivity measures will be extracted using these devices: high-density electroencephalography (using either a 128-channel or a 256-channel system) and magnetic resonance imaging.
41291126|NCT00719810|DRUG|delafloxacin|300 mg intravenous every 12 hours
41291127|NCT00719810|DRUG|delafloxacin|450 mg intravenous every 12 hours
40786510|NCT00710892|BIOLOGICAL|Allodepleted T Cells|"Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity."
41291128|NCT00719810|DRUG|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
41454942|NCT06403150|DRUG|Levetiracetam Injection|Levetiracetam at 60 mg/kg (max dose 4500 mg) will be intravenously administered in 100mL of normal saline at an administration rate of 2-5mg/kg/min or over 10 minutes. After 30 minutes following Levetiracetam needle time reassessment of the patient will be done to determine the outcomes.
40954717|NCT05921201|BEHAVIORAL|Relax, Reflect, and Empower mobile application|Participants in the RRE group will select an Avatar from a pool of 20 Avatars as their companion over the 3 months. The Avatar wellness check-in in the RRE group includes a daily wellness check-in of 5-minute/day (4 days/week), and a weekly full wellness check-in of 15 minutes/week for 3 months. The daily brief check-in includes a wellbeing and mood check and a 3-minute relaxation meditation. The weekly full wellness check-in includes reflection activities in addition to the daily check-in activities.
40786511|NCT04186325|PROCEDURE|DIAPHRAGMATIC exercising|inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
40954718|NCT05757102|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered.
40954719|NCT05757102|DEVICE|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler
40954720|NCT05757102|DRUG|FF/VI|FF/VI will be administered.
41291129|NCT05247580|OTHER|Hicks self-confidence scale, Karasek survey, Maslach Burnout Inventory|Questionnaires (Hicks self-confidence scale, Karasek questionnaire, Maslach Burnout Inventory) sent to hospital staff caregivers before and after (at 3 and 6 months) their SUrVIS training.
41291130|NCT01716260|DRUG|Chloroquine|
41291131|NCT01716260|DRUG|Primaquine|
41291132|NCT02297893|BEHAVIORAL|Dexterity training program (HOMEDEXT)|The dexterity training program contains 7 exercises which focus on improving fine motor skills.
41291133|NCT02297893|BEHAVIORAL|Theraband training program|The Theraband training program contains 7 exercises which focus on improving upper limb strength
41291134|NCT03246269|DIAGNOSTIC_TEST|MoCA|
41291135|NCT05342831|OTHER|Biological Nutrition Technique|Biological nutrition technique woman trying Biological feeding technique was applied after each breastfeeding. Breastfeeding self-efficacy and breastfeeding success were assessed at regular intervals.
41291136|NCT00676559|DRUG|Efalizumab|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
41291137|NCT00676559|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
41307859|NCT06370936|OTHER|Standardized diet with commercially available PBMAs (intervention products)|Fully controlled standardized diet with commercially available Plant-Based Meat Analogues (PBMAs). Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
41291138|NCT05198986|OTHER|Prone Position during Extra Corporeal Membrane Oxygenation (ECMO)|Pronation will be executed according to a predefined protocol: 4 caregivers will be required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube and the ventilator lines. The others will stand at each side of the bed. In the first step, the direction of the rotation will be decided giving priority to the side of the central venous lines. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. In the third step, the patient will be moved in the sagittal plane and maintained in that position for a short while to attach the cardiac electrodes to her/his back and to set a new bed sheet. In the last step, the patient will be turned to the complete prone position.
40954721|NCT03463174|PROCEDURE|Mandibular overdenture|Placement of an implant in the mandibular midline.
40954722|NCT03463174|OTHER|Mandibular complete denture|No intervention.
40954723|NCT03348137|OTHER|Questionnaire Administration|Ancillary studies
40954724|NCT06260813|DIAGNOSTIC_TEST|Radiography|X-rays of the ankle; anterior-posterior, lateral, Mortise view and hindfoot alignment view. Standard weight bearing x-rays of the foot; anterior-posterior, lateral and oblique view.
41291139|NCT06142747|DIAGNOSTIC_TEST|Super-Resolution Ultrasound Imaging of Erythrocytes (SURE)|Research ultrasound sequence for tracking erythrocytes and thereby generating a super-resolution image of the vasculature.
40786512|NCT02015403|DRUG|Standard Care + NAC (N -ACETYLCYSTEINE)|
41291140|NCT06028776|BEHAVIORAL|MS Ballroom Fitness|A personalized dance-based concept focusing on balance, walking capacity, and well-being.
40786513|NCT02015403|DRUG|Standard Care (in control arm)|
40786514|NCT01159093|BEHAVIORAL|Family Decision Support|Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.
41307860|NCT01599468|DRUG|Tranexamic Acid|10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
40786515|NCT01159093|BEHAVIORAL|Clinician Decision Support|Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.
40786516|NCT01159093|OTHER|Family Decision Support and Clinician Decision Support|This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).
40954725|NCT06260813|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the posterior tibial tendon to see if there is an irritation, elongation or rupture.
40954726|NCT06260813|DIAGNOSTIC_TEST|MRI|MRI when ultrasound is not conclusive to identify an irritation, elongation or rupture of the posterior tibial tendon.
40954727|NCT06260813|DIAGNOSTIC_TEST|CT-scan|CT-scan to identify arthritis of the tibial-talar, subtalar and/or Chopart joints.
40954728|NCT06260813|DIAGNOSTIC_TEST|Gait analysis|This lab is equipped with a 10-meter walkway surrounded by a passive optoelectronic motion analysis system consisting of 10 cameras to track the motion of markers. In the middle of the walkway, a force plate is integrated, with a pressure plate placed on top.
41135229|NCT02586467|BEHAVIORAL|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
41135230|NCT02586467|BEHAVIORAL|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
40761801|NCT04383639|OTHER|No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)|The subjects will receive, after overnight fasting, a high-fat high-sugar breakfast. In treatment A, they will not receive any additional product; in treatment B, they will receive at the same time a mixture of coca and carob; in treatment C, they will receive the mixture of coca and carob 10 h before breakfast. A total of 6 blood samples will be collected during each visit: 0-30-60-120-180-240-270 min. Urine samples will be collected during the permanence of the subjects in the Unit of Human Nutrition. Feces will be collected the first time they are generated after treatments A and C. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
40761802|NCT05579327|DRUG|Tiratricol|Tiratricol tablets are flat tablets that contain 350 µg tiratricol. Treatment will be administered orally or via percutaneous endoscopic gastrostomy (PEG) tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable.
40761803|NCT05579327|DRUG|Placebo|Placebo tablets will be identical in appearance to tiratricol tablets but contain no tiratricol. Treatment will be administered orally or via PEG tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable. During the Randomized Treatment Period, participants will receive the same number of tablets as the stable dose of open-label tiratricol they were receiving before randomization.
40761804|NCT00918398|DRUG|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
41291141|NCT02172612|OTHER|Arm 1 Education Session|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
41291142|NCT00971646|OTHER|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
41291143|NCT00971646|OTHER|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
41291144|NCT00971646|OTHER|EuroQol-5D|This questionnaire grades the health condition of the subject.
41454943|NCT06403150|DRUG|Fosphenytoin Injection|Fosphenytoin at 20 mg/kg (Phenytoin equivalent dose of 15 mg/kg) will be intravenously administered in 100mL of normal saline at an administration rate not exceeding 3mg/kg/min or 150 mg/min. After 30 minutes following the Fosphenytoin needle time reassessment of the patient will be done to determine the outcomes.
41454944|NCT05212116|DRUG|SDI-118|SDI-118 is presented as low dose, and high dose capsules.
41454945|NCT05212116|DRUG|Placebo|The Matching Placebo for SDI-118 is mannitol in capsules.
41454946|NCT00000680|DRUG|Zidovudine|
41291145|NCT00971646|OTHER|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
41291146|NCT06022679|OTHER|CBCT|CBCT examination in supine position A computerized 3D-analysis using Dolphin Imaging 11.95 software was performed in each CBCT.
40761805|NCT00918398|DRUG|AZD1981|514 mg oral solution, single dose
40761806|NCT00918398|DRUG|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
40761807|NCT00918398|DRUG|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
40786517|NCT01159093|OTHER|Control|Usual care
40786518|NCT00442923|DRUG|Coreg|
41291147|NCT03720080|DEVICE|OpenAPS|A self-constructed OpenAPS system will be worn contemporaneously to a Medtronic Minimed 670G hybrid closed loop system. Both systems will calculate recommended basal rate insulin adjustments but only the Minimed 670G system will inject insulin. The maximum treatment period will be 2 weeks per patient
41307861|NCT01599468|DRUG|saline serum|The Placebo group received normal saline with the same volumes
41307862|NCT00704743|DEVICE|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
41307863|NCT00704743|DEVICE|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
41307864|NCT00704743|DEVICE|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
41307865|NCT04439344|DRUG|Binimetinib|Given PO
41307866|NCT05841602|OTHER|descriptive|This research was conducted to evaluate nursing care from the perspective of hospitalized children during the Covid-19 pandemic process and to determine their feelings during this process.
41307867|NCT02347241|OTHER|Educational intervention|Educational Debriefings and High frequency training and team reflection
41454947|NCT00000680|DRUG|Aldesleukin|
41454948|NCT00396162|DRUG|probiotic containing L.rhamnosus R0011 strain|500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
41454949|NCT00396162|OTHER|Placebo|Placebo pill
41454950|NCT00393276|BIOLOGICAL|Twinrix|Combined hepatitis A and hepatitis B immunization
41454951|NCT00393276|BIOLOGICAL|Decavac|Diphtheria and tetanus toxoid vaccine
41454952|NCT05963464|DEVICE|SCOUT® Radar occult breast lesion Localization|The SCOUT® Radar occult breast lesion Localization (SRL) uses non-radioactive micro-impulses to guide surgical excision in real time.
41454953|NCT04224662|OTHER|No intervention|There is no intervention for this study
41454954|NCT01993940|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
41454955|NCT01993940|DRUG|Placebo|Placebo tablet taken orally once a day
41454956|NCT05673707|DIAGNOSTIC_TEST|Thyromental Height|its measure between thyroid and mentum
41454957|NCT01889758|DRUG|Prograf|Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
40761808|NCT06569836|OTHER|12-week intervention|"Rehabilitation Exercise Plan Week 1-4 For No Symptom Group: Therapeutic home exercise prescription(2 sessions, 60 minutes per session) For Mild \& Moderate Group: Rehabilitation Plan provided by Physiotherapist (4 sessions, 60 minutes per session)~Enhancement of Self-Management Capacity Week 5-8 For No Symptom Group: Educational Workshops provided by Physiotherapist (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Self-management group provided by Social Worker (4 sessions, 60 minutes per session)~Exercise Maintenance Week 9-12 For No Symptom Group: Mobilized Intervention (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Exercise Maintenance provided by Exercise Mentor (4 sessions, 60 minutes per session)"
40786519|NCT03927261|DRUG|PRGN-3006 T Cells|Participants will receive up to 2 intravenous (IV) administrations of PRGN-3006 T Cells with or without lymphodepletion and will be monitored for safety, efficacy, and correlative endpoints for up to 12 months following infusion.
41454958|NCT01889758|DRUG|Tacrolimus|Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
41454959|NCT01889758|DRUG|Tacrolimus|Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
40786520|NCT00869167|DRUG|Ramelteon|melatonin agonist
41454960|NCT00901524|DRUG|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
41454961|NCT04858126|DEVICE|ECOM cardiac output|Measure cardiac output during perioperative period and compare to pulmonary artery catheter thermal dilution cardiac output measurement.
41454962|NCT02864836|PROCEDURE|Samples collection|5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
41454963|NCT03577561|OTHER|Proficiency Based Progression Training in Phlebotomy|Trainees will receive an online didactic education package and a simulation skill training module. Both of these education and training platforms will be derived from the procedure characterisation and benchmarked on experienced practitioner's performance. Trainees will be required to engage with the education and training platforms in a process of deliberate practice learning until they demonstrate the requisite performance benchmark. Proficiency demonstration will be mandatory before progressing to ward proctored skill supervision on real patients. In addition, the doctors in training will receive ongoing and proximate feedback on their sampling mislabeling.
41454964|NCT03879187|DIETARY_SUPPLEMENT|High-fat, high-energy diet|Participants consumed a diet that was high in fat and high in energy
41454965|NCT00417677|DRUG|Combination of Temsirolimus and Sunitinib|
41454966|NCT04816773|DEVICE|EVOLUTION® NitrX™|EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
41454967|NCT02096692|DEVICE|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
41291148|NCT05575804|DRUG|GQ1001+pyrotinib|GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.
41135231|NCT02586467|BEHAVIORAL|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
41291149|NCT05575804|DRUG|pyrotinib+capecitabine|pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
41291150|NCT01548664|OTHER|Wii Fit|15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
41291151|NCT01548664|OTHER|Lower Extremity Exercise|Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
41291152|NCT00364546|DRUG|CG 5503;tapentadol|
41291153|NCT02281058|DRUG|Abatacept|self-injected subcutaneous biologic medication
41291154|NCT04278729|DRUG|Apixaban 5 MG|1 - 5 mg tablet taken orally twice a day
41291155|NCT01396525|DEVICE|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
41291156|NCT04763382|OTHER|experimental group: Training of caregivers|Pre-test, post-test, retention test, education, guide booklet delivery, android application installation and urinalysis
41291157|NCT04763382|OTHER|Control gruop|Pre-test, post-test and urinalysis
41291158|NCT05564624|OTHER|Fasting mimicking diet (FMD)|The ProLon(TM) Fasting Mimicking Diet regimen is a meal replacement plan that mimics water only fasting. It consists of 100% natural ingredients, which are generally regarded as safe (GRAS). It is comprised of bars, soups, and beverages aiming to achieve consistent and effective short-term calorie restriction, while providing adequate micronutrients. The very low protein and very low sugar content are essential characteristics of the diet. Complex carbohydrates and polyunsaturated fatty acids are its main components.
41291159|NCT03453060|DRUG|E-WE Thrombin- Dose 1|Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
41291160|NCT03453060|DRUG|E-WE Thrombin- Dose 2|Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
41291161|NCT03453060|DRUG|E-WE Thrombin- Dose 3|Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
41291162|NCT03453060|DRUG|E-WE Thrombin- Dose 4|Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
41291163|NCT03453060|OTHER|Placebo|Participants received a single intravenous dose of placebo.
40761809|NCT06569836|OTHER|12-week attention control|The attention and waitlist control group will have weekly educational and virtual workshops for 12 weeks. Three topics will be covered, including online exercise class, cognitive training, leisure and recreational activities. Each session will be 30-45 minutes and each topic last for four weeks. Participants could access the virtual sessions by their electronic devices.
41291164|NCT05138120|BEHAVIORAL|Common Elements Toolbox|An unguided online single-session intervention with four modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.
41291165|NCT04072640|DRUG|Voriconazole 200mg|Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
41291166|NCT04072640|DRUG|amphotericin B deoxycholate (0.4-0.5mg/kg/d)|Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
41291167|NCT04072640|DRUG|Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)|Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
41291168|NCT06378710|PROCEDURE|Optimized PEEP|Optimized PEEP
41291169|NCT05577715|DRUG|MORAb-202|Specified dose on specified days
41291170|NCT02609893|OTHER|modified directly observed therapy (mDOT)|
41291171|NCT02609893|OTHER|unobserved dosing|
41291172|NCT02609893|OTHER|Motivational Interviewing-based counseling|Motivational Interviewing-based risk reduction and medication adherence counseling
41291173|NCT02609711|DRUG|Candesartan cilexetil|
41291174|NCT02538146|DIETARY_SUPPLEMENT|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
41291175|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
41454968|NCT02096692|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
41291176|NCT01272180|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
41291177|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
41454969|NCT01459601|DRUG|Cabergoline|0,5mg per week
40761810|NCT02825563|DRUG|Anlotinib|in the fasting state
40761811|NCT02825563|DRUG|Anlotinib|in the high fat diet
41291178|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
41291179|NCT00391638|DRUG|TRUVADA (EMTRICITABINE + TENOFOVIR DF)|Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
41291180|NCT00391638|BIOLOGICAL|PEGASYS 180μg (Interféron pégylé alpha -2a)|Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
41454970|NCT00419224|BIOLOGICAL|inactivated split-virus influenza vaccine|
41454971|NCT01160640|DRUG|Ceftriaxone|ceftrixone 250mg IM single dose
40954729|NCT05086926|COMBINATION_PRODUCT|Exercises and CSI|"Corticosteroid injection:~The project manager will give the participants one injection with cortisone and lidocaine in the lateral hip at baseline. The procedure will be performed aseptically.~Home exercise program:~The exercise programis based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of 8 weeks. Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled."
40954730|NCT00508755|DEVICE|Gait Robot|gait training with the use of a gait robot
40954731|NCT00508755|DEVICE|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
40954732|NCT05577780|PROCEDURE|internal fixation|Patients with femoral neck fractures are treated with pinning or hip arthroplasty, depending on the age of the patient and the presence and degree of displacement
40954733|NCT03947203|BEHAVIORAL|Social media|Provided pamphlet and a private Facebook group where informational messages and content relating to oral health will be shared
40954734|NCT03583697|DRUG|BMN 111|Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol
40954735|NCT03583697|DRUG|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
40954736|NCT05593588|DRUG|Fisetin|20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
40954737|NCT05593588|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
40954738|NCT05885997|BEHAVIORAL|Supported HBPM program plus multifaceted implementation strategy|"Supported HBPM Program:~* Patients are loaned a wireless home BP device or use their own device~* Navigator or app support for onboarding and engaging patients in HBPM~* Nursing or app support for monitoring and triaging home BP data for extreme readings~* EHR integration of order for program and home BP data, with weekly feedback of home BP results to clinicians within the EHR~Multifaceted implementation strategy:~* Clinician education about the benefits of the program as well as training in how to refer and manage patients who are enrolled~* Prompts and reminders to increase clinician referrals~* Instructional materials for patients and clinicians~* Problem-solving meetings to tailor implementation for individual practices"
40954739|NCT05885997|OTHER|Usual care|Usual care
40954740|NCT00799383|DRUG|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
40761812|NCT03374956|DRUG|Phentermine-Topiramate|Extended Release at dose of 7.5/46 mg oral daily
40761813|NCT03374956|DRUG|Liraglutide|dose of 3 mg subcutaneous daily
40954741|NCT00799383|OTHER|Placebo|
40954742|NCT02898805|OTHER|Placebo|
40954743|NCT02898805|OTHER|Prescribed Diet|
40954744|NCT02898805|DIETARY_SUPPLEMENT|LopiGLIK®|
40954745|NCT02898805|DIETARY_SUPPLEMENT|Armolipid Plus|
40954746|NCT02432495|OTHER|ANTERIOR SCREW FIXATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
40954747|NCT02432495|OTHER|HALOV VEST IMMOBILIZATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
40954748|NCT01722123|OTHER|Hypothetical scenarios and related decisions|Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
41454972|NCT01160640|DRUG|Doxycycline|Doxycycline 100 mg PO bid x 14 days
40954749|NCT03005145|OTHER|7 days of adequate antibiotic treatment|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
40761814|NCT03374956|DRUG|Naltrexone/bupropion|Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
40954750|NCT03005145|OTHER|14 days of adequate antibiotic treatment.|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
41291181|NCT03531372|DEVICE|Mipolixin®|1.55g chewable tablet 5 times a day for 2 weeks
41454973|NCT01160640|DRUG|Metronidazole|metronidazole 500 mg PO bid x 14 days
41454974|NCT01160640|DRUG|Placebo Oral Capsule|placebo oral capsule PO bid x 14 days
40954751|NCT02714374|BIOLOGICAL|GL-ONC1|"Dose and Regimen:~1. Single dose group: Cohort 1 dose is 1 × 109 pfu~2. Multiple dose groups:~   * Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~  * Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~  * Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection."
40954752|NCT05075902|BEHAVIORAL|Aerobic training|The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.
40954753|NCT02009306|DRUG|PecFent and Epistatus|"PecFent will be supplied by Archimedes Pharma as two strengths of nasal spray solution at 1000 or 4000 mcg/mL fentanyl (as citrate). One spray contains 100 mcg or 400 mcg fentanyl (as citrate). Each bottle contains 1.55 ml ensuring delivery of 8 sprays of 100 or 400 mcg fentanyl (as citrate). PecFent is a commercially available product and packaging will be in accordance with the manufacturing authorisations (EU/1/10/644/001, EU/1/10/644/002, EU/1/10/644/005, EU/1/10/644/003, EU/1/10/644/004, EU/1/10/644/006).~Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
40954754|NCT02009306|DRUG|Standard subcutaneous medication|"Subcutaneous as needed medication will include:~* Opioids for pain or dyspnoea~  * Diamorphine~ * Oxycodone~ * Fentanyl~* Benzodiazepine and / or anti-psychotic for agitation~  * Midazolam~ * Levomepromazine~ * Haloperidol Anti-emetic for nausea~* Cyclizine~* Metoclopramide~* Haloperidol~* Levomepromazine~* Anti-secretory drug for respiratory secretions~* Glycopyrronium~* Hyoscine butylbromide~* Hyoscine hydrobromide"
40954755|NCT02009306|DRUG|Epistatus Alone|"Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
41291182|NCT03531372|DEVICE|Poliprotect®|1.55 g chewable tablet 5 times a day for 2 weeks
41291183|NCT06065956|DRUG|Intravenous morphine|"Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation.~The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation."
41291184|NCT00389415|DRUG|Vildagliptin|
41291185|NCT05448534|DIAGNOSTIC_TEST|Eletroencephalography|We used Sinek and Young Scale to classify electroencephalographic patterns and cognitive outcome with MOCA score.
41291186|NCT03414918|DRUG|Clarithromycin|Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
41291187|NCT04283032|PROCEDURE|Multiparametric magnetic resonance|MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
41454975|NCT04448730|DIAGNOSTIC_TEST|serum marker levels|two groups comparisons
41454976|NCT06271005|DIETARY_SUPPLEMENT|NeuroTears|Over-the-counter supplement
41454977|NCT06271005|DIETARY_SUPPLEMENT|Placebo|Oral placebo pill
41454978|NCT01569113|DRUG|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
41454979|NCT01569113|DRUG|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
41454980|NCT06128824|OTHER|MR Imaging|Serial magnetic resonance imaging (MRI)
41454981|NCT03909633|BEHAVIORAL|a series of tests|all patients in every group will do a series of tests,including DSST、DST、MoCA、WCST、HADS
41454982|NCT02086617|OTHER|ultrasound of aorta|
40761815|NCT03374956|DRUG|Phentermine|15-37.5 mg oral daily
40761816|NCT04366531|BEHAVIORAL|START-VET|prison reentry program
41291188|NCT04776369|DRUG|Lidocaine IV|single-bolus of lidocaine IV 4 mg/kg
41291189|NCT04776369|DRUG|Magnesium Sulfate Injection|single-bolus of magnesium sulfate IV 30 mg / kg
41291190|NCT04776369|DRUG|IV saline|Saline IV 50 ml
41291191|NCT03622411|DEVICE|speech app|language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app
41291192|NCT03622411|DEVICE|brain games|language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games
41291193|NCT03622411|BEHAVIORAL|aphasia therapy|language exercises provided by the speech therapist in hospital
41291194|NCT03633071|OTHER|Web-knee brace|Web -Knee Brace
41291195|NCT00100555|DRUG|zoledronic acid|
41291196|NCT00711451|BEHAVIORAL|Manual removal|Manual removal of placenta during cesarean delivery
41454983|NCT06099158|OTHER|HeartLogic|HeartLogic alerts will be managed according to a standardized alert management guide to ensure uniform reactions to HeartLogic alerts.
41454984|NCT02409797|OTHER|Flexion-Distraction (non-thrust) spinal manipulation|Enrolled participants will receive chiropractic care over a 2-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
41454985|NCT05203835|DRUG|Acebilustat|By mouth, once a day, 100 mg capsule
41454986|NCT05203835|DRUG|Placebo|Placebo to match acebilustat by mouth, once a day
40954756|NCT05705388|DEVICE|POSE2.0 Endoscopic Gastric Remodeling|The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
40954757|NCT05705388|DRUG|Liraglutide injection|Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
40954758|NCT04142632|PROCEDURE|clinical and paraclinical examination|Physical examination of the penis, ultrasonography of the bladder end the testis, Biological sample for endocrine assessment
40954759|NCT04520412|DRUG|GV-971|Administered PO
40954760|NCT04520412|DRUG|Placebo|Administered PO
40954761|NCT06366932|DRUG|Second-line systemic treatment|Patients with moderate to severe atopic dermatitis refractory to topical medication, who also have previous experience with cyclosporine and an unsatisfactory response, or in whom the use of cyclosporine is considered inappropriate due to contraindication or intolerance, are candidates for treatment with other alternatives (Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib).
40954762|NCT06366932|OTHER|Folllow-up of second-line systemic treatment already started|If the patient is receiving second-line therapy at the moment of the inclusion, data will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.
40954763|NCT03854110|DRUG|GP-2250|GP-2250 monotherapy for pharmacokinetics and safety; GP-2250 plus gemcitabine for safety, tolerability, pharmacokinetics, and biomarker assessments
40954764|NCT03484377|DEVICE|Anodal tDCS|The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
40954765|NCT03484377|DEVICE|Sham tDCS|The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.
40954766|NCT05138211|DEVICE|Exoskeleton assisted gait on a treadmill|"The experimental protocol is divided in three sessions. During all of them, the patient will walk on a treadmill for 6 minutes while wearing a safety harness and the robotic exoskeleton in the paretic leg.~1. - Training session: The patient will wear the robotic exoskeleton to familiarize with the action of the device.~2. - Ramp Velocity Session: the session will be divided into five trials: (a) Pre, the patient will not wear the device; (b) Free, the patient will wear the robot but it is mechanically decoupled so it will enable the free knee movement; (c) Active, the robot will assist the gait until 75% maximum gait velocity ; (d) MaxActive, the robot will assist the gait until maximum gait velocity ; and (e) Post, the patient will repeat the Pre condition. Velocity will increase from comfortable velocity to the maximum and then come back to the comfortable one.~3. - Random Velocity session: the session will be divided into the same trials than the Ramp Velocity Session."
40954767|NCT04374071|DRUG|Methylprednisolone|IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days
41291197|NCT00711451|PROCEDURE|Expressed removal|Surgeon will perform an expressed delivery of the placenta
41291198|NCT05604105|OTHER|Questionnaire|The questionnaire includes a section for socio-demographic data, a section to detect their general awareness of oral cancer as a disease, a section about their awareness of its signs and symptoms and lastly, a section about its risk factors and habits.
41291199|NCT03045484|DRUG|Controlled-release oxycodone|CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
41291200|NCT03045484|OTHER|Chemoradiotherapy|Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
40761817|NCT04366531|OTHER|Treatment as usual|This intervention involves no additional services above what is provided by the local health care system
40761818|NCT05315752|PROCEDURE|Bariatric surgery|"Bariatric surgery includes (but is not limited to)~* Gastric bypass: surgical bypass of the entire stomach, duodenum and approximately 1 m of the proximal small intestine~* Sleeve: a large part of the stomach is removed laparoscopically, the open vertical edges are put back in place to leave a sleeve-like tube.~Bariatric surgery is considered a treatment option~* for patients with a BMI \>40 kg/m 2 , assuming the patient has previously participated successfully in a group weight management programme (weight loss \>7%) or~* for patients with a BMI of 35-40 kg/m 2 when the obesity is associated with type 2 diabetes or hypertension, or OAS (with CPAP therapy) or severe musculoskeletal disease"
40761819|NCT05454007|BEHAVIORAL|Step length asymmetry training|Participants will engage in four, five-minute periods of step symmetry training during session 2. This training uses established sensorimotor adaptation-based methods (e.g. split-belt treadmill walking, walking with unilateral leg weighting) to elicit motor aftereffects of more equal step lengths. Two minute sitting rest breaks will be given between training blocks or at the participant's request. A video recording will be taken of the first and final two minutes of training.
40761820|NCT01228032|OTHER|Care team|The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
41291201|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
41291202|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
40761821|NCT05550428|OTHER|home-based-exercise|"All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.~sessions."
40761822|NCT05550428|DEVICE|active pulsed electromagnetic field（PEMF）therapy|Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 PEMF sessions per participant, each leg receiving 8 exposures.
40954768|NCT04121026|OTHER|External validation of the PAANTHER TB treatment decision algorithm|"The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:~* history of contact~* suggestive TB symptoms~* tachycardia~* chest radiography~* abdominal ultrasound~* Xpert MTB/RIF Ultra. A score of \>100 is highly predictive of TB. In children with a score \>100, anti-TB treatment will be initiated immediately. In children with a score of \<100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up."
40954769|NCT04362254|DRUG|Spesolimab|Spesolimab
40954770|NCT04558944|DEVICE|Extracorporal Shock Wave Therapy|Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
40954771|NCT06125561|OTHER|Probing depth and Clinical attachment loss|CPTIN probe will be used for the clinical examination
40954772|NCT03254290|BIOLOGICAL|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted.
40954773|NCT03254290|BIOLOGICAL|Formocresol|Control group
40954774|NCT04259320|DEVICE|Beeswax containing barrier|Use beeswax containing barrier on each nipple after each breastfeeding.
40954775|NCT04259320|BIOLOGICAL|Breast milk|Apply breast milk on each nipple and areola after each breastfeeding.
40954776|NCT02183142|DRUG|Mobic, China, 7.5 mg|
40954777|NCT02183142|DRUG|Mobic, Germany, 7.5 mg|
40954778|NCT00876421|DRUG|Placebo|Placebo / 12 weeks
40761823|NCT05550428|DEVICE|shame pulsed electromagnetic field（PEMF）therapy|Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 sham PEMF sessions per participant, each leg receiving 8 exposures.
41291203|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
40761824|NCT04348630|OTHER|Simulated heatwave exposure|Older adults are exposed to a 8-hour simulated exposure
40761825|NCT01772771|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva/buccal swab samples
40761826|NCT01772771|OTHER|Genetic Testing|Correlative studies
41291204|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
41454987|NCT04092387|OTHER|Varying the nicotine content of cigarettes|1) Altering the nicotine content of the tobacco research cigarettes
40761827|NCT01772771|OTHER|Medical Chart Review|Review of medical records
40761828|NCT02320071|OTHER|Examination of abdominal wall strength changes over time|
40954779|NCT00876421|DRUG|Tolterodine|4mg / 12 weeks
40954780|NCT00876421|DRUG|ONO-8539|low dose / 12 weeks
40761829|NCT05530304|DEVICE|Triple inner branched arch stentgraft|New findings regarding treatment planning and management of patients with aortic arch pathologies.
40761830|NCT04775108|DEVICE|Epygon™ Transcatheter Mitral Valve System|"The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.~The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent."
40761831|NCT00850330|OTHER|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
40954781|NCT00876421|DRUG|ONO-8539|medium dose / 12 weeks
41291205|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
41291206|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
41291207|NCT01343719|DRUG|BI 661051|high dose solution for oral administration
40954782|NCT00876421|DRUG|ONO-8539|higher dose / 12 weeks
40954783|NCT05675176|DRUG|BCG|Intravesical Instillation
40954784|NCT00398411|DRUG|moxifloxacin|400 mg p.o. per day
40954785|NCT00398411|DRUG|placebo|one tablet per day p.o.
40954786|NCT01199965|DRUG|MAP0004|1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
40954787|NCT01199965|DRUG|IV DHE|IV DHE administered at Visit 2 or 3 as per protocol
41291208|NCT01343719|DRUG|BI 661051|high dose solution for oral administration
41291209|NCT01343719|DRUG|BI 661051|low dose tablet
41291210|NCT01343719|DRUG|Placebo|solution for administration
41291211|NCT01343719|DRUG|BI 661051|medium dose tablet
41454988|NCT04092387|OTHER|E-Cigarettes|Comparing effects of combining RC2 with EC 1 versus EC2
40954788|NCT05554588|PROCEDURE|Intrathrombus Thrombolysis During Primary PCI|Intrathrombus Thrombolysis During Primary PCI
40954789|NCT05554588|PROCEDURE|Aspiration Thrombectomy During Primary PCI|Aspiration Thrombectomy During Primary PCI
41454989|NCT04298151|DRUG|Zirconomer Improved|glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
40954790|NCT02652065|OTHER|Acetylcholine iontophoresis|Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
40954791|NCT02652065|OTHER|Sodium Nitroprussiate iontophoresis|Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
40954792|NCT02652065|OTHER|ppi water iontophoresis|ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
41291212|NCT01426048|OTHER|Gynaecological examination and a supine stress test, questionnaires|Gynaecological examination and a supine stress test, questionnaires
40954793|NCT02652065|OTHER|Laser Doppler recording|Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
41291213|NCT02143271|DRUG|KHK7580|Oral administration
41291214|NCT04383977|DRUG|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
40954794|NCT03585231|BEHAVIORAL|Immediate access to novel messaging program intervention|The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.
40954795|NCT03585231|BEHAVIORAL|Immediate access to standard of care messaging program intervention|The immediate control intervention uses a standard of care messaging program for smoking cessation.
40954796|NCT03585231|BEHAVIORAL|Delayed access to novel novel messaging program intervention|The delayed control intervention uses the novel messaging program for smoking cessation.
40954797|NCT05499858|OTHER|Spiced|Vegetables provided to volunteers will be spiced.
40954798|NCT05499858|OTHER|Plain|Vegetables provided to volunteers will be plain.
40954799|NCT05115669|DEVICE|Wortie freeze plus|treatment of common and plantar warts
41291215|NCT04383977|DRUG|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
41291216|NCT01286844|DRUG|GSK2190915A 5mg|Oral powder for dispersion in water
41291217|NCT01286844|DRUG|GSK2190915A 10mg|Oral powder for dispersion in water
41291218|NCT01286844|DRUG|GSK2190915A 25mg|Oral powder for dispersion in water
41291219|NCT01286844|DRUG|GSK2190915A 50mg|Oral powder for dispersion in water
41291220|NCT01286844|DRUG|GSK2190915A 100mg|Oral powder for dispersion in water
41291221|NCT01471873|PROCEDURE|Corneal Collagen Cross-linking (CXL)|"The same surgical procedure was applied to all CXLG patients that included:~Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well."
41291222|NCT05783401|OTHER|Data acquisition: Speech acquisition|Speech test with synchronized audio and video recording. The speaking exercises and the audio and video recording will be done using a tablet computer and an application developed in-house. Freely available images showing different scenes will be integrated and displayed on the tablet to be described by the patient. The goal is to have at least two and maximum four of them described with several sentences by each patient per session. Parameters will be extracted from the patient's audio data to estimate the changes in distress and frailty.
41291223|NCT05783401|DIAGNOSTIC_TEST|Data acquisition: G8 Screening tool|The G8 screening tool consists of seven items dealing with food intake, weight loss, mobility, neuropsychological problem, body mass index, prescription drug, and self-perception of health, from the Mini-Nutritional Assessment (MNA) questionnaire and was developed specifically for elderly cancer patients. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.
41291224|NCT05783401|DIAGNOSTIC_TEST|Data acquisition: Distress Thermometer|The distress thermometer (DT) is a measure of psychological distress in cancer patients. The instrument is a self-reported tool using a 0-to-10 rating scale.
41291225|NCT04050007|OTHER|Preventive initiation of fluid removal|"Preventive initiation of fluid removal will be started right after the randomization with intravenous diuretics according to a predefined algorithm based on the urine output every three hours.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
41291226|NCT04050007|OTHER|Curative initiation of fluid removal|"The initiation of fluid removal will be considered by the attending physician only in case of failure to the spontaneous breathing trial with a clinical suspicion of weaning induced pulmonary edema.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
41291227|NCT03286569|DEVICE|Upper arch Wilson quadhelex appliance|Upper arch Wilson quadhelex appliance
41291228|NCT01477632|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
41291229|NCT01477632|DRUG|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
41291230|NCT01477632|DRUG|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|A single oral dose of 1 tablet under fasting conditions
41291231|NCT03133897|DRUG|Dexamethasone|experimental group will receive 2 day treatment
40761832|NCT01579877|DIETARY_SUPPLEMENT|Herbal extract granule|The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
40954800|NCT03247751|DEVICE|intraocular lens|Implant NIDEK intraocular lens after cataract surgery
40954801|NCT01264783|DRUG|RNS60|RNS60 for intravenous administration
40954802|NCT01264783|DRUG|Placebo|0.9% normal saline for injection
40954803|NCT04444362|DEVICE|Inspiratory Muscle Training|IMT underwent 5 days of 30 breaths twice daily at 50% (+5% increase each week) of maximum inspiratory pressure (MIP)
40954804|NCT00225550|DRUG|ADH -1 (Exherin™)|
40954805|NCT01689103|BEHAVIORAL|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
40954806|NCT01689103|BEHAVIORAL|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
41291232|NCT03133897|DRUG|Prednisone|control group will receive 4 day treatment
41291233|NCT00988962|BEHAVIORAL|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
41291234|NCT02911363|DEVICE|Captivator cassette|The Captivator tissue cassette has an effect on the preservation of tissue histology.
41291235|NCT02911363|OTHER|Standard of Care|The specimen will be processed following the College of American Pathology Standards.
41291236|NCT05715086|PROCEDURE|Ureteroscopy|Upfront ureteroscopy
41291237|NCT02691065|DRUG|Integrase Inhibitor|Raltegravir
41291238|NCT01651260|OTHER|Experimental ET Tube Securement Device|Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
41291239|NCT03699839|BIOLOGICAL|High-dose influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
41291240|NCT03699839|BIOLOGICAL|MF59-adjuvanted influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
40954807|NCT03158896|BIOLOGICAL|MSCTC-0010 Dose Escalation|"Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)~Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD"
40954808|NCT05456009|OTHER|No intervention|No intervention
40954809|NCT05617950|OTHER|salicylic acid|Salicylic acid is applied once daily by the patients (or parents) for a maximum of 12 weeks.
40954810|NCT05617950|OTHER|cryotherapy|Cryotherapy is delivered by a technician up to a maximum of four treatments 3 weeks apart.
41291241|NCT03699839|BIOLOGICAL|Standard intramuscular influenza vaccine|The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
41291242|NCT05091801|BEHAVIORAL|Intervention|Participants will have one week of increased chewing time (chew food until they reach an apple sauce consistency)
41291243|NCT01666873|PROCEDURE|patients that undergo a total knee prosthesis|
41291244|NCT01589120|BEHAVIORAL|Video decision aid|Video decision aid of the goals of care
41291245|NCT02988986|DRUG|TAK-228|MTORC1/2 inhibitor
41291246|NCT02988986|DRUG|Tamoxifen|Non-steroidal anti-estrogen
41291247|NCT02948231|DEVICE|Mistral implantation|Mistral Implant is implanted in the Mitral valve
41291248|NCT00882713|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
41291249|NCT02734121|BEHAVIORAL|pre-consultation educational group intervention|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (40 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (20 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteers (30 mins) questions and answers about their personal experience"
41291250|NCT00309777|DRUG|Pitavastatin|Pitavastatin once daily
41291251|NCT00309777|DRUG|Simvastatin|Simvastatin once daily
41291252|NCT00823329|DEVICE|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
41291253|NCT05263882|DRUG|Gemcitabine combined with eribulin|"* Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~* Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~* The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur."
41291254|NCT04327570|OTHER|Patient sampling|Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
41454990|NCT04298151|DRUG|Ketac Molar quick Aplicap|highly viscous glass ionomer with improved mechanical properties than the conventional GI
40954811|NCT01484223|BEHAVIORAL|Cognitive Behavioral Therapy|Four Cognitive behavioral group sessions. Each session will last two hours a week
40954812|NCT01849783|DRUG|dexamethasone|Given PO
40954813|NCT01849783|DRUG|cisplatin|Given IV
40954814|NCT01849783|DRUG|doxorubicin|Given IV
40954815|NCT01849783|DRUG|cyclophosphamide|Given IV or PO
40954816|NCT01849783|DRUG|etoposide|Given IV
40954817|NCT01849783|DRUG|bortezomib|Given IV
40954818|NCT01849783|DRUG|thalidomide|Given PO
40954819|NCT01849783|DRUG|melphalan|Given IV
40954820|NCT01849783|PROCEDURE|autologous stem cell transplant|
41291255|NCT01364467|DRUG|Placebo|Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.
41291256|NCT01364467|DRUG|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
41291257|NCT01965548|PROCEDURE|Treatment of splenic injury|"There are four possible treatments of splenic injury in this study:~* splenectomy~* splenic artery embolisation~* non-operative management~* any combination of the three treatments mentioned"
41291258|NCT03511638|DEVICE|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
41291259|NCT03511638|DEVICE|Alcon VISCOAT®|Ophthalmic viscosurgical device
41291260|NCT03176186|COMBINATION_PRODUCT|Xenon|50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
41291261|NCT03626467|BIOLOGICAL|HPV9v|Single-arm, phase 4 study. Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24
40954821|NCT03027102|BIOLOGICAL|DNT cells|DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
41291262|NCT06447922|OTHER|Metal ion level testing|Patients will undergo a pre- and post-operative blood draw to analyze metal ion levels (Cobalt, Chromium, Titanium and Nickel)
40954822|NCT02025322|BEHAVIORAL|Peer Mentoring|"Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.~Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors."
40954823|NCT05249101|DRUG|Ivaltinostat|Ivaltinostat (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate) is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase (HDAC).
40954824|NCT05249101|DRUG|Capecitabine|Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).
40954825|NCT00324610|DRUG|capecitabine|
41291263|NCT04728971|DRUG|Micafungin Sodium 50 MG Injection|Give Micafungin 150 mg/d within 24 hours after liver transplantation.
41291264|NCT04728971|DRUG|Caspofungin Acetate|Give Caspofungin 35 mg/d lasts 1 week after liver transplantation.
41291265|NCT00813956|DRUG|gemcitabine plus carboplatin plus BSI-201|iv, 3 week cycles
41291266|NCT02441803|DRUG|Busulfan|Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
41291267|NCT02441803|DRUG|Fludarabine|Fludarabine 10 mg/m2 by vein on Days -6 to -3.
41291268|NCT02441803|DRUG|Clofarabine|"Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3."
41291269|NCT02441803|RADIATION|Total Body Irradiation (TBI)|Total body irradiation (TBI) delivered at 2Gy on Day -2.
41291270|NCT02441803|DRUG|Thymoglobulin|Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
41291271|NCT02441803|BIOLOGICAL|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or \>3.0 X 108 marrow mononuclear cells/kg if bone marrow.
41291272|NCT02441803|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
41291273|NCT02441803|DRUG|Tacrolimus|Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
41291274|NCT02441803|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
41291275|NCT02441803|DRUG|Decitabine|20 mg/m2 by vein on Days 1 - 5.
41291276|NCT02441803|DRUG|Cytarabine|1 g/m2 by vein on Days 6 - 10.
41291277|NCT02441803|DRUG|Idarubicin|10 mg/m2 by vein on Days 6 - 8.
41291278|NCT01360164|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
41291279|NCT02831868|DEVICE|HAVAI|implantation of the HAVAI device to correct the IMA angle
40761833|NCT01579877|DIETARY_SUPPLEMENT|Placebo herbal extract granule|The Yukmijihwang-tang_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
41291280|NCT01623778|DRUG|Interferon Alfa-2a add on ADV|Interferon add on ADV for 48 weeks
41291281|NCT05841498|DEVICE|Immunoadsorption|Immunoadsorption (IA) is a well-established extracorporeal therapy for several autoimmune diseases such as systemic lupus. Its therapeutic effect is based on the removal of antibodies (ABs) from the plasma including auto-ABs and it is used if an immediate response to therapy is necessary. Side effects (SE) of the IA are rare, but angiotensin-converting enzyme (ACE)-inhibitors are prohibited concomitant medication. Notable SE may include increased susceptibility to infection, transient disorders of blood coagulation, or allergic reactions to materials of the adsorber or tubing system. To ensure an effective therapy, a blood flow of at least 45 ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins but in most patients is the placement of a central venous catheter necessary. Central venous catheter placement carries potential risks such as injury to the lung or mispuncture of the carotid artery.
41135232|NCT02586467|BEHAVIORAL|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
41291282|NCT05841498|DEVICE|Sham-apheresis|Sham-apheresis is a procedure without any known therapeutic effects. As there are no known therapeutic effects there are also no known side effects excepted the risk of an allergic reaction to materials of the tubing system or to citrate, which is necessary to prevent clotting inside the extracorporeal system. To ensure a smooth operation a blood-flow of at least 45ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins. However, in most patients, placement of a Shaldon catheter into the internal jugular vein is necessary. Shaldon catheter placement carries other potential risks such as injury to the lung resulting in pneumothorax or mispuncture of the carotid artery. However, since the catheter placement is sonography-guided, the risks for such adverse events are minimized.
41291283|NCT00004778|DRUG|betamethasone|
41291284|NCT00004778|DRUG|dexamethasone|
41291285|NCT00004778|DRUG|thyrotropin-releasing hormone|
41291286|NCT00177346|DEVICE|CAS with cerebral protection|
41291287|NCT00177346|DEVICE|CAS without cerebral protection|
41291288|NCT02435173|DRUG|CDZ173|CDZ173 10 and 70 mg capsules for oral administration.
41291289|NCT02435173|OTHER|Placebo|Placebo capsules for oral administration
41291290|NCT06038448|PROCEDURE|Urinary catheter balloon size|The investigators will collect 120 participants divided into two groups ,in different procedure(stone procedure, herniarraphy, nephrectomy), and the investigators used different urinary catheter balloon size(10ml and 5ml), tp investigate the patient with the severity of catheter-related bladder discomfort.
41291291|NCT06130384|DRUG|Use of bromfenac 0.09% to reduce intravitreal injection pain|The eyedrop (bromfenac) will be given to the assigned eye.
41291292|NCT06130384|DRUG|Use of artificial tears to reduce intravitreal injection pain|The eyedrop (artificial tears) will be given to the assigned eye.
41291293|NCT03246035|BEHAVIORAL|Intervention Group|For the intervention arm, a specialized heart failure nurse practitioner will contact the patient or their primary caregiver by telephone within 5 days post-discharge and send them an education packet by mail. During the telephone call, the nurse will (1) confirm the patient's scheduled follow-up appointment in cardiology, (2) provide recommendations for heart failure self-care behaviors that were found to be deficient at baseline. Patients will then be referred to a Geriatrics Assessment Team, who will provide individualized recommendations for frailty domains that were found to be deficient at baseline. The technique used to provide educational recommendations will be motivational interviewing.
41291294|NCT03246035|OTHER|Control Group (Standard Care)|For patients randomized to the Control Group (Standard Care), they will receive their follow-up visits, medications, diet and physical activity advice as they normally would. This is the care they would receive even if they were not enrolled in the study
41291295|NCT02275572|PROCEDURE|Pharmacist Intervention|
41291296|NCT00358592|DEVICE|Mobius™ retractor|
41291297|NCT00358592|DEVICE|traditional metal retraction instruments|
41291298|NCT00414622|DRUG|DMXB-A|
41291299|NCT00693381|DRUG|Tacrolimus|oral
41291300|NCT00693381|DRUG|Mycophenolate Mofetil|oral
41291301|NCT00693381|DRUG|methylprednisolone and prednisone|IV and oral
41291302|NCT04072770|DIETARY_SUPPLEMENT|Pea|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
41291303|NCT04072770|DIETARY_SUPPLEMENT|Casein|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
41291304|NCT00893503|PROCEDURE|colonoscopy|Patients will provide stool and urine samples and will be scheduled to undergo a colonoscopy. The colonoscopy will be done per standard of care - no study specific procedural requirements imposed.
41291305|NCT04649281|DEVICE|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
41291306|NCT00190463|DRUG|Amphotericin B|
41291307|NCT06232122|DIAGNOSTIC_TEST|68Ga-FAPI-46|Intravenous injection of one dosage of 2 mCi 68Ga-FAPI-46
41291308|NCT06232122|DIAGNOSTIC_TEST|18F-FDG|Intravenous injection of one dosage of 5-10mCi 18F-FDG
41291309|NCT01095484|DRUG|Rotigotine patch|1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
41291310|NCT04194593|OTHER|PCR (Polymerase Chain Reaction)|"Biological testing of FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples of tumors will be led. These tissues have been collected during the treatment of patients (for diagnostic purposes).~A molecular analysis (polymerase chain reaction) is led on DNA extracted from FFPE/frozen conserved tissues, and a result is produced by the algorithm."
41291311|NCT00067522|BEHAVIORAL|User-independent contraception program|
41291312|NCT00067522|BEHAVIORAL|Future Planning Perspectives program|
41291313|NCT00123201|DRUG|Dronabinol MDI|
41291314|NCT03103750|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis
41291315|NCT03103750|DRUG|PHNO|Used as a tracer for in vivo imaging.
41135233|NCT02586467|BEHAVIORAL|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
41135234|NCT03342820|PROCEDURE|Muscle fatigue|Isokinetic quadriceps muscle fatigue of the paretic lower limb
41291316|NCT03103750|DIETARY_SUPPLEMENT|calcitriol|three 0.5 mcg capsules
41291317|NCT03103750|DRUG|Placebo oral capsule|three 0.5 mcg capsules
41291318|NCT03103750|PROCEDURE|high-resolution research tomography|A functional imaging technique that is used to observe metabolic processes in the body.
41291319|NCT03103750|DRUG|Dextro Amphetamine|Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
41135235|NCT00826826|PROCEDURE|Catheter ablation|(Pulmonary vein isolation)
41291320|NCT00002056|DRUG|Pentamidine isethionate|
41454991|NCT03256864|DRUG|Tacrolimus and Everolimus|"In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL."
41135236|NCT00826826|DRUG|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
41135237|NCT00826826|DRUG|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
41291321|NCT02094105|PROCEDURE|Endoscopy examination with iodine staining|Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
41291322|NCT00667277|DRUG|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
41291323|NCT00716937|PROCEDURE|karydakis flap|Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft
41291324|NCT00716937|PROCEDURE|laying open|laying open the site of excision of sinus or cyst without any flap
41291325|NCT03311685|DEVICE|vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.
41454992|NCT01505049|DRUG|quadrivalent HPV vaccine|For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
41291326|NCT06399263|DRUG|Psilocybin|The psilocybin will include two dose administration sessions, first a 20mg administration, and second a 30mg administration.
41454993|NCT05530811|DRUG|Dexamethasone|The suprazygomatic maxillary nerve block approach will be performed with a 27-gauge 38-mm needle following aseptic preparation of the skin and using the anatomical landmarks. The puncture site will be at the frontozygomatic angle formed by the zygomatic arch and posterior orbital rim. After inserting the needle perpendicular to the skin and contacting the greater wing of the sphenoid (approximately 20 mm deep), the needle will be partially withdrawn, reoriented approximately 20° anterior and 10° inferior, and advanced 35 to 38 mm to direct the needle into the pterygopalatine fossa. After negative blood aspiration, the prepared solution will be injected over 20 s on each side. Massage of injection point with pressure for 2 min will be done. No additional local anesthetic will be injected by the surgeon either peri-incisional or submucosal.
40954826|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Pilot (two iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screen Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
41135238|NCT00233714|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
41454994|NCT05530811|DRUG|Bupivacaine|0.5% bupivacaine
41454995|NCT02186353|BEHAVIORAL|Partial feeding study|Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
41454996|NCT02125149|OTHER|Exercise Intervention|
40761834|NCT05768672|BEHAVIORAL|Experimental Task|The main task is an olfactory version of a traditional Go/No-Go task (Albayay et al., 2019): it includes the delivery of either an odour or clean air prior to the presentation of a visual target Moreover, all participants will be assessed with the italian version of the Stroop color and word test (Caffarra et al., 2004) to evaluate inhibition, together with selective and sustained attention. This neuropsychological test consists of three tables, showing color words (W), colored circles (C), and color words printed in incongruent ink (i.e., red printed in blue ink, CW), respectively. The Stroop effect consists of a delayed response when words have to be named according to the color of the ink, ignoring the meaning of the printed word.
41135239|NCT00233714|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
41135240|NCT06269497|PROCEDURE|Scaffold placement|The scaffold is placed in the alveola following extraction
41454997|NCT01912807|DRUG|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
41454998|NCT01912807|DRUG|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
41454999|NCT05062460|OTHER|1 hour Blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 1-hour postprandial blood glucose monitoring.
41455000|NCT05062460|OTHER|2 hour blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 2 hour post prandial blood glucose monitoring
41455001|NCT05172687|BEHAVIORAL|Overprescribing letter to attributed physician|Letter telling patient's attributed physician they were under review for high prescribing
41455002|NCT05172687|BEHAVIORAL|Placebo letter to attributed physician|Letter to patient's attributed physician about unrelated Medicare regulation
41455003|NCT03480880|DEVICE|Bispectral Index|Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.
41135241|NCT06269497|RADIATION|CBCT|A Cone Beam Computer Tomography (CBCT) is taken of the area of interest after surgery
41291327|NCT06399263|BEHAVIORAL|Preparation and Integration Sessions|The psilocybin therapy will include three preparatory sessions, two dose A integration sessions, and four final integration sessions.
41291328|NCT02383329|DIETARY_SUPPLEMENT|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
41291329|NCT01223911|DRUG|NNC 0151-0000-0000|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
41291330|NCT01223911|DRUG|placebo|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
41291331|NCT01129791|BEHAVIORAL|Raw Milk|Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
40761835|NCT04076657|BEHAVIORAL|Brock String Therapy|Oculomotor exercise to improve binocular vision function
40761836|NCT04076657|BEHAVIORAL|Standard of Care|patient engages in normal behavior to manage vision issues, such as breaks with reading and screen use
41291332|NCT01129791|BEHAVIORAL|Pasteurized Milk|Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
41291333|NCT01129791|BEHAVIORAL|Non-dairy milk|Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
40761837|NCT06474962|BEHAVIORAL|Pause|7 days of no e-cigarette consumption
40761838|NCT01505985|DIETARY_SUPPLEMENT|Oral nutritional Supplement|Specialized nutritional supplement for seniors
40761839|NCT01505985|DIETARY_SUPPLEMENT|Placebo|placebo product with no specific nutrients
40761840|NCT00563316|DRUG|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
40954827|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Pre-Injury (one iteration)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
41291334|NCT00547937|DEVICE|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
40761841|NCT00563316|DRUG|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
41291335|NCT02205385|PROCEDURE|Targeted Muscle Reinnervation|
40761842|NCT02757963|OTHER|Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool|The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score \>=3) and meet all other eligibility requirements will be enrolled in Part I of the study.
41291336|NCT02205385|PROCEDURE|Traction Neurectomy|
40761843|NCT02757963|OTHER|International Prostate Symptom Score (IPSS) screening tool|The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score \>=8) and meet all other eligibility requirements will be enrolled in Part I of the study.
41291337|NCT01977534|DEVICE|Absorb BVS|The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating \[formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating\].
41291338|NCT00749099|DRUG|pancrelipase|"The test drug (PANCRECARB® \[pancrelipase\] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
41291339|NCT00749099|DRUG|placebo|"5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
41291340|NCT00839098|OTHER|Instruction Group: Power seat function usage instruction- verbal and written instruction|Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
40954828|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Post-Injury (up to three iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report thee most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
41135242|NCT00284752|DRUG|Abraxane|This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA
41291341|NCT00839098|OTHER|Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach|Subjects assigned to the Instruction \& Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
41291342|NCT05000606|OTHER|A home visit program|A home visit program including education and counseling was applied. A total of five home visits over three months were performed.
41455004|NCT04323527|DRUG|Chloroquine diphosphate|150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
41455005|NCT05213052|OTHER|Topical cream|Topical cream applied to painful joint or muscle
40761844|NCT05727891|DRUG|Tonabersat|Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
41455006|NCT00978536|OTHER|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
41455007|NCT00685854|DRUG|Ranibizumab|
41455008|NCT00860262|DRUG|amlodipine|amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
41291343|NCT02627846|DEVICE|EVLA|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
41291344|NCT02627846|DEVICE|ClariVein®|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
41291345|NCT02627846|DRUG|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
41291346|NCT02627846|DRUG|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
41291347|NCT02627846|DRUG|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
41291348|NCT02627846|DRUG|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
41291349|NCT03890276|OTHER|HMS EL&C training module|No additional information
41291350|NCT03890276|OTHER|Videos used to supplement live trainer|\[Cherrie to add\]
41291351|NCT06216691|OTHER|Coach-guided smartphone delivered CBT program.|All eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.
41291352|NCT01728259|DRUG|pomalidomide|Given PO
41291353|NCT01728259|DRUG|bortezomib|Given IV
41291354|NCT01728259|DRUG|dexamethasone|Given PO
41291355|NCT01728259|OTHER|Laboratory Biomarker Analysis|Correlative studies
41291356|NCT00247481|DRUG|Gefitinib|
41291357|NCT00247481|DRUG|Docetaxel|
41291358|NCT04388657|DIAGNOSTIC_TEST|Echo-Doppler|Utrasound Doppler of the lower limbs
41291359|NCT02410369|DRUG|S-588410|Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
41291360|NCT02410369|DRUG|Placebo|Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
41291361|NCT02194881|DRUG|CF patients with a G551D mutation and treated with Ivacaftor|
41291362|NCT04710940|BEHAVIORAL|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
41291363|NCT04710940|BEHAVIORAL|Usual Care|Participants will receive usual care for DSMT.
41455009|NCT00860262|DRUG|telmisartan|telmisartan 80mg for the 8w, no titration required
41455010|NCT00860262|DRUG|telmisartan and amlodipine|telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
41455011|NCT05774522|OTHER|Measurement of pharyngeal critical airway closing pressure|The Pcrit will be measured on an automatic controlled device specially designed by the engineers of the inserm neophen team capable of varying the pressures from +4 to -20 centimeters of water, by a nasal mask whose pressures are connected to a pneumotachograph. The measurements will be performed in supine position.
41135243|NCT03695549|PROCEDURE|CAF + (A-PRF)|advanced platelet rich fibrin prepared by low speed centrfugation concept(LSCC) together with coronally advanced flap .
41135244|NCT03695549|PROCEDURE|CAF+SCTG|cornally advanced flap plus subepithilial connective tissue graft harvested from the palate
40761845|NCT05727891|OTHER|Placebo|Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
40761846|NCT02414841|DRUG|Vonapanitase|
40761847|NCT02414841|DRUG|Placebo|
40761848|NCT05737706|DRUG|MRTX1133|KRAS G12D Inhibitor
40761849|NCT00185614|PROCEDURE|Autologous hematopoietic cell transplant (Auto-HCT)|The target cell dose is 2.6 x 10e6 CD34+ cells/kg
41291364|NCT01933672|DRUG|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
40954829|NCT05111925|OTHER|PREPARE Optimized Clinical Assessment|"Participants will complete an optimized set of clinical assessments that may include semi-automated field-expedient functional movement quality, joint ranges of motion, and/or psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
40954830|NCT04125888|DRUG|Allergy immunotherapy (AIT)|Immunotherapy for different types of allergies
41455012|NCT05774522|OTHER|Acoustic pharyngometry|Acoustic pharyngometry is an non-invasive technique consisting of the propagation of an acoustic wave from the lips to the larynx providing information on the lengths, cross-sectional areas and volumes of the air spaces.
40954831|NCT01182142|DRUG|Capecitabine|1,250 mg/m2 orally twice a day, days 1-14
40954832|NCT02008318|DRUG|Galunisertib|Administered orally
40954833|NCT02008318|DRUG|Placebo|Administered orally
40954834|NCT06085378|DRUG|Urinary Kallidinogenase for injection|The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days
40954835|NCT06085378|OTHER|Placebo|The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.
40954836|NCT01095211|DRUG|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
40954837|NCT02728596|OTHER|Preventive Intervention|Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN
40954838|NCT02728596|OTHER|Quality-of-Life Assessment|Ancillary studies
41135245|NCT02165202|DRUG|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
41455013|NCT05774522|OTHER|Upper airway ultrasound|Airway ultrasound is a non-invasive imaging allowing visualization and measurements of the tongue base and retrovascular fatty infiltration. Its main interest remains the evaluation of the tongue base which is clinically difficult.
40761850|NCT00185614|PROCEDURE|Allogeneic hematopoietic cell transplant (Allo-HCT)|The target cell dose is 5 x 10e6 CD34 cells/kg
40761851|NCT00185614|DRUG|Cyclophosphamide|Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
40761852|NCT00185614|DRUG|Filgrastim|"* Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~* Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~* Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)"
40954839|NCT02728596|OTHER|Questionnaire Administration|Ancillary studies
40954840|NCT06095804|DEVICE|Percutaneous Ultrasound Jejunostomy|Placement of a jejunostomy tube using the PUMA-J System
40954841|NCT00570570|PROCEDURE|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
40954842|NCT00570570|OTHER|conventional physiotherapy|trice a week during 6 weeks
40954843|NCT00270439|PROCEDURE|removal of omentum|patients with type 2 diabetes had their omentum removed
40954844|NCT02105883|OTHER|Use of identification badge during scenarios|
40954845|NCT01869517|OTHER|intrastromal corneal ring segments (Keraring) implantation|
40954846|NCT01869517|OTHER|Intrastromal corneal continuous ring (Myoring) implantation|
40954847|NCT05915221|PROCEDURE|SMS|Receive SMS
40954848|NCT02318537|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
41291365|NCT01933672|DRUG|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
41291366|NCT01933672|DRUG|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
40954849|NCT02318537|DRUG|Placebo Solution|A matching oral solution containing no cannabidiol.
40954850|NCT03485391|BEHAVIORAL|Prolonged Exposure|Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
40954851|NCT03349697|DIETARY_SUPPLEMENT|Phyllantus amarus|
40954852|NCT03349697|OTHER|Placebo|
40954853|NCT05118243|OTHER|Control cracker|The gut symptoms caused by control crackers are studied in IBS persons
41291367|NCT02203838|DRUG|RBP-7000|"120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner."
41291368|NCT03742804|BIOLOGICAL|Intratumoral G100|G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
41291369|NCT02950623|OTHER|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
41291370|NCT02950623|OTHER|rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
41455014|NCT00045162|DRUG|cisplatin|"Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles~Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles"
41291371|NCT04450355|DRUG|Nefopam 80mg/day|continuous nefopam infusion
41291372|NCT04450355|DRUG|Normal saline|continuous normal saline infusion
41455015|NCT00045162|DRUG|etoposide|100 mg/m2 IV (over 30-60 min) on Days 1 , 2 \& 3. Q 3 weeks x 4 Cycles
41291373|NCT06438367|DRUG|[14C]TGRX-326|Healthy subjects will be given TGRX-326 60 mg orally on day 1.
41455016|NCT00045162|DRUG|irinotecan hydrochloride|60 mg/m2 IV (over 90 min)on Days 1, 8 \& 15. Q 4 weeks x 4 Cycles
41455017|NCT03342339|OTHER|cognitive examination|mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
41455018|NCT03342339|OTHER|viewing of video|viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
41291374|NCT02749370|DRUG|Etanercept|Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
41291375|NCT05296421|PROCEDURE|Biopsy|Undergo biopsy
41455019|NCT03342339|OTHER|Iowa Gambling Task|Test of Iowa Gambling Task
40761853|NCT00185614|DRUG|Melphalan|Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT
40761854|NCT00185614|RADIATION|Total body irradiation (TBI)|200 centigray (cGy) total body irradiation delivered on Day 0
41291376|NCT05296421|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40761855|NCT00185614|PROCEDURE|Cyclosporine (CSP)|Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56
40761856|NCT00185614|DRUG|Mycophenolate Mofetil (MMF)|Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
41291377|NCT05296421|OTHER|Uniformly-labeled [13C]glucose|Given IV
41291378|NCT06031467|DEVICE|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|The laser group received mechanical therapy followed by Er;Cr;YSGG laser. Laser application was performed using the bottom-up technique. Therefore, the tip was retracted about 1 mm after it was placed on the bottom of the pocket and slowly moved in the coronal direction to the parallel to the implant surface.
41291379|NCT06031467|DEVICE|Non-surgical mechanical therapy|Traditional non surgical mechanical therapy Mechanical instrumentation in all groups was made with titanium curettes.The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt.
41291380|NCT02018614|OTHER|algoplus|
41291381|NCT02806765|DIETARY_SUPPLEMENT|(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol|25 micrograms of (1S,3Z)-3-\[(2E)-2-\[(1R,3aS,7aR)-7a-methyl-1-\[(2R)-6-methylheptan-2-yl\]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene\]ethylidene\]-4-methylidenecyclohexan-1-ol every day for 6 months
41291382|NCT02806765|OTHER|Control|Placebo in Softgel form
41291383|NCT02928237|DEVICE|transcranial direct current stimulation tDCS|A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
41291384|NCT02947451|OTHER|Manual Therapy|"In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once."
41291385|NCT02947451|OTHER|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
41455020|NCT03211351|DRUG|Liposic|one eye of the participant recieved Lipoic
40954854|NCT05118243|OTHER|Enzyme-treated cracker|The gut symptoms caused by enzyme-treated crackers are studied in IBS persons
41455021|NCT03211351|DRUG|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
41455022|NCT00913276|DRUG|Propofol|
41455023|NCT00913276|DRUG|Sevoflurane|
41455024|NCT03734354|DRUG|Brexpiprazole|Brexpiprazole , single/oral/with fasting
41455025|NCT06410157|BEHAVIORAL|Daily practice|Participants will be asked to undergo daily practice to regulate (either increase or decrease) heart rate oscillation
41455026|NCT04785963|BEHAVIORAL|Music with Suggestion|A nonpharmacological, short-term treatment that poses minimal risk and places very limited burden on patients seems ideal for this population, and music with suggestions is one such treatment option.
40761857|NCT06351020|DRUG|LM-302|LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle
41291386|NCT05111119|BEHAVIORAL|Making PrEP Smart|"The Making PrEP Smart intervention is a mobile-based application with the following components:~* Notification-based PrEP Reminders and Adherence Self-Monitoring~* HIV self-testing facilitation, interpretation of results, and testing support~* HIV partner testing facilitation, interpretation of results, and testing support~* Nearby HIV clinic contact information"
41455027|NCT04785963|BEHAVIORAL|Pain Information|The comparison condition of informational recordings about chronic pain are structured to account for non-specific effects of general time and attention and to evaluate whether the treatments of music alone, and music in combination with suggestion are effective in the reduction of pain intensity more than an appropriate control group.
41455028|NCT04785963|BEHAVIORAL|Music|The comparison condition of the music only is structured to account for the effect of music listening, and to evaluate whether the addition of suggestion optimizes its effectiveness in the reduction of pain intensity.
41455029|NCT04987645|PROCEDURE|Water-only infusion technique|During a routine colonoscopy, a resident in the study will use water only infusion technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
41455030|NCT04987645|PROCEDURE|Water infusion and air insufflation|During a routine colonoscopy, a resident in the study will use water infusion and air insufflation technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
41455031|NCT05757960|PROCEDURE|Physiotherapy|Various physiotherapeutic techniques are used in three defined sessions. Before the first session, a dental examination is performed and a clinical functional status is obtained to assess the extent of temporomandibular dysfunction. The results are recorded on validated questionnaires.
40954855|NCT01146990|DRUG|ASQ-3, Bayley III, Neurologic exam|Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
41291387|NCT01233219|DRUG|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.~Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS\<4 maximum x 3 daily.~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h)."
41291388|NCT04086303|OTHER|LSST test|LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
41291389|NCT04841668|DRUG|Metformin|Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)
41455032|NCT05995769|DRUG|Psilocybin|Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
41455033|NCT05187884|DRUG|Darovasertib|Oral Darovasertib 300 mg tablets twice daily
41455034|NCT04381871|DIETARY_SUPPLEMENT|Acacia Senegal|Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
41455035|NCT04381871|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
41455036|NCT01175330|DRUG|Omega-3 fish oil emulsion (Omegaven)|Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
41455037|NCT01175330|DRUG|Intralipid|Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
41291390|NCT00304590|DRUG|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
41291391|NCT06339996|DIETARY_SUPPLEMENT|Male supplement|Participants will be administered supplements for a three-month treatment period
41291392|NCT05308095|OTHER|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Initially, a euglycaemic state (5.0 - 8.0 mmol/L) is established and blood glucose is then declined to hypoglycaemia (3.0 - 3.5 mmol/L) by administering insulin. Thereafter, blood glucose is raised again to euglycaemia (5.0 - 8.0mmol/L). During the procedure, driving data is recorded. Additionally, eye movement, head pose, facial expression, heart rate, skin conductance, and CGM values are recorded throughout the glycemic trajectory. Participants are blinded to the blood glucose values during the procedure.
40954856|NCT03364933|BEHAVIORAL|Primary intensivist and nurses|"Primary intensivist will have no active role in the daily management of patients. The primary intensivist should facilitate decision-making, be a liaison between the patient/family and PICU team, and be a resource of information for all. Responsibilities of primary intensivist:~* Weekly check-in with and availability to patient/family~* Attendance at family meetings~* Availability to PICU team~Primary nurses will be a team of up to 7 ICU nurses who will provide as much of the bedside care as possible. Responsibilities of primary nurses:~* Maintain a primary nurse binder (paper format) for on-going communication about the patient among the team members; it will be their discretion what is information is communicated.~* The Primary Nurse or delegate will be involved in all team/family meetings and will be expected/given an opportunity to speak during these meetings."
40761858|NCT06351020|DRUG|Apatinib|The subjects will receive Apatinib orally,qd
40761859|NCT06351020|DRUG|Irinotecan|The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle
40761860|NCT06499961|BEHAVIORAL|Digital version of Holistic Healthy Life Education|Participants need to attend a two-day workshop related to (1) health risk appraisal and self-care; (2) exercise, fitness and self-acupressure; (3) emotion and stress management; (4) the whole food plant-based (WFPB) diet; and (5) meditation and mindfulness practices, led by a multi-disciplinary team. Before the intervention commences, they will take pre-blood test and further receive the e2HLE with Hera Leto for three months. During the intervention, participants will attend (1) nine weekly workshops pertaining to WFPB diet, exercise, fitness and self-acupressure, and meditation and mindfulness and followed by weekly tele-counselling sessions; (2) three process evaluation practice sharing sessions in the format of focus group, making up a total of twelve sessions. The process evaluation practice sharing sessions will be audio-recorded; (3) mutual support networking platform will be held between case managers and participants within Hera Leto system.
40761861|NCT06499961|OTHER|Waitlist control|usual care first, then switch to receive the intervention
41291393|NCT00262262|DRUG|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
41291394|NCT00006168|DRUG|Methotrexate|
41455038|NCT05094596|DRUG|Standart treatment group|Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.
41455039|NCT05094596|DRUG|Montelukast sodium 10 mg treatment|Group 2 (n=60) received 10 mg/day oral montelukast in addition to standard treatment
41455040|NCT05094596|DRUG|Montelukast sodium 20 mg treatment|Group 3 (n=60) were given 20 mg/day oral montelukast in addition to standard treatment.
40954857|NCT03400566|BEHAVIORAL|Narrative|Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).
41455041|NCT01588743|DRUG|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
40761862|NCT02565459|BIOLOGICAL|Mesenchymal Stromal Cells|
40761863|NCT06564727|PROCEDURE|Uniportal VATS approach|Uniportal VATS resection for simple pulmonary aspergilloma
40761864|NCT06564727|PROCEDURE|VATS approach|VATS resection for complex pulmonary aspergilloma
40954858|NCT03400566|BEHAVIORAL|Experiential|Children will receive hands on experience with the vegetable. They will get to listen, see, feel, touch and smell the actual vegetable during the two familiarization phases.
40954859|NCT02248701|DRUG|Testosterone Enanthate|Subjects receive testosterone (125 mg/week) by intramuscular injection
40954860|NCT02248701|DRUG|Finasteride|Subjects receive finasteride (5 mg/day) orally
40954861|NCT02248701|DRUG|Placebo injection|Subjects receive placebo (weekly) by intramuscular injection
40954862|NCT02248701|DRUG|Placebo pill|Subjects receive placebo pill (daily) orally
40954863|NCT05723302|DIAGNOSTIC_TEST|MIP/MEP|MIP/MEP
41291395|NCT01183962|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 3000 IU daily
41291396|NCT01183962|OTHER|No medication|No intervention
41291397|NCT04535011|BEHAVIORAL|PPKAY (brief intervention)|PPKAY is a nurse-administered, one-on-one, 15-minute brief intervention (BI) for alcohol use using FRAMES motivational interviewing techniques. The BI is a four-step discussion: 1) Raise the Subject of Alcohol, 2) Provide Feedback, 3) Enhance Motivation 4) Negotiate and Advice.
41291398|NCT04535011|BEHAVIORAL|Standard Booster|After discharge from the hospital, a standard motivational text message will be sent to their cell phone twice monthly for the duration of the study. In a rotating fashion, one of four standard motivational texts translated into Swahili will be sent to their cell phones.
41291399|NCT04535011|BEHAVIORAL|Personalized Booster|After discharge from the hospital, a personalized motivational text message will be sent to participant cell phones twice monthly for the duration of the study. In a rotating fashion, one of four personalized motivational texts will be sent to their cell phones. Personalized texts will be created with the content obtained from the motivational interview sessions. At each session, the research nurse conducting the intervention will record four messages based on the content of the session to be sent as the Personalized Booster.
41291400|NCT03777956|DRUG|Lacosamide|Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
41291401|NCT03777956|DRUG|Placebo|Identical placebo are given as capsules and taken orally twice a day.
41455042|NCT00857558|DRUG|saxagliptin|orally administration at 1 mg once a day for 12 weeks
41455043|NCT00857558|DRUG|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
41455044|NCT00857558|DRUG|saxagliptin|orally administration at 5 mg once a day for 12 weeks
41455045|NCT00857558|DRUG|placebo|orally administration once a day for 12 weeks
41455046|NCT02252016|DRUG|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
41455047|NCT02252016|DRUG|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
40954864|NCT04566861|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) for anxiety during pregnancy|Women who are randomized to the intervention group will receive six core Cognitive Behavioral Therapy (CBT) sessions for anxiety during pregnancy (and possible booster sessions) to treat symptoms of anxiety.
41291402|NCT01690949|DRUG|PUR118|inhaled PUR118, BID
41455048|NCT00789464|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10\^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
41455049|NCT00789464|DRUG|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
40761865|NCT06036524|DIAGNOSTIC_TEST|Multi-modal, multi-parametric, multiscale imaging of the myofascial unit|Study Participants will undergo four study procedures at one visit, including magnetic resonance imaging (MRI), surface electromyography (sEMG), fiber-optic imaging and sensing, and questionnaires.
40761866|NCT04114825|BIOLOGICAL|RV001V|RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
40761867|NCT04114825|OTHER|Placebo|Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
40761868|NCT05078437|BEHAVIORAL|Medication therapy management|The proposed deprescribing intervention is using a patient-centered framework by: (1) balancing the risks and benefits, and addressing the specific needs of each individual patient, (2) considering the individual patient and the caregiver's preferences and values, and (3) empowering the patient and the caregiver to take responsibility and fully participate in the decision-making process as equal team players.
40761869|NCT03403738|BEHAVIORAL|Bounce Back Now|web/smartphone-based intervention for disaster victims
41455050|NCT06149962|PROCEDURE|FLEXOR TENDON REPAIR|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture under WALANT technique and brachial plexus block.
41455051|NCT01538550|PROCEDURE|Flexible sigmoidoscopy|Flexible sigmoidoscopy screening is offered once only
40761870|NCT03403738|BEHAVIORAL|enhanced usual care|enhanced usual care with list of resources
40761871|NCT04662320|DEVICE|Checkpoint BEST System|"Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair.~Other Name: Checkpoint BEST System"
40761872|NCT05949892|BEHAVIORAL|Expanded Health Belief Model-Based Intervention|A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance
40761873|NCT05663554|BEHAVIORAL|WW Intervention|The core of the WW food program is the SmartPoints® system. Briefly, the SmartPoints® system assigns each food and beverage a SmartPoints® value per volume based on four components: calories, sugar, saturated fat, and protein. Certain foods have a SmartPoints® value of zero (ZeroPoint foods). These foods (e.g., lean sources of protein such as skinless chicken breast and vegetables) form the basis of a healthy eating pattern, are at low risk for overconsumption and do not have to be weighed, measured or tracked. Participants were assigned a personalized SmartPoints® Budget, based on reported food and lifestyle preferences, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure.
40761874|NCT05663554|OTHER|Usual Care|The Usual Care group will continue to receive routine medical care by their provider, in addition to receiving one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments.
40761875|NCT06633549|OTHER|Home Accidents Prevention Training|Mothers in the education group who participated in the study were informed about the research and their written consent was obtained. Mothers filled out the 'Information Form' then completed the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6 Years'. Mothers were helped when filling out the form and their questions were answered. The training program was organized so that there would be a maximum of 5 mothers in each group. The trainings were conducted face-to-face with a PowerPoint presentation and lasted about 40-45 minutes. Question-answer and discussion methods were used during the training. After the training, the mothers were asked to fill out the same scale again one month later. One month after the training, the mothers were interviewed face-to-face and the scale was filled in again and the changes they made at home were recorded.
40954865|NCT05444517|PROCEDURE|Interscalene Block|"Ultrasound-guided brachial plexus block injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml in the Interscalene groove.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
40954866|NCT05444517|PROCEDURE|Infraclavicular - Anterior Supraescapular Nerve Blocks|"Ultrasound-guided combined infraclavicular-anterior suprascapular block of the brachial plexus, injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an ultrasound-guided injection of 3 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml under the omohyoid muscle. If the anterior suprascapular nerve could not be identified after five minutes of insonation time, an upper trunk block will be carried out with the same amount of local anesthetic.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
41455052|NCT01538550|PROCEDURE|iFOBT|Biennial screening with iFOBT
41455053|NCT00576654|DRUG|Irinotecan Hydrochloride|Given IV
41455054|NCT00576654|OTHER|Laboratory Biomarker Analysis|Correlative studies
41455055|NCT00576654|OTHER|Pharmacological Study|Correlative studies
41455056|NCT00576654|DRUG|Veliparib|Given PO
41455057|NCT00213850|PROCEDURE|EFR|
41455058|NCT01929681|DEVICE|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
41455059|NCT04534985|BEHAVIORAL|Dietary|Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted
41291403|NCT02714634|DRUG|Methotrexate + targeted therapy administration|"* Methotrexate or leflunomide + adalimumab or~* Methotrexate or leflunomide + certolizumab or~* Methotrexate or leflunomide + etanercept or~* Methotrexate or leflunomide + golimumab or~* Methotrexate or leflunomide + infliximab or~* Methotrexate or leflunomide + abatacept or~* Methotrexate or leflunomide + rituximab or~* Methotrexate or leflunomide + tocilizumab or~* Methotrexate or leflunomide + sarilumab or~* Methotrexate or leflunomide + filgotinib or~* Methotrexate or leflunomide + upadacitinib or~* Methotrexate or leflunomide + Tofacitinib or~* Methotrexate or leflunomide + baricitinib"
41291404|NCT02714634|DRUG|methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration|
41291405|NCT00225368|DEVICE|Insecticide treated bednets|
40761876|NCT06633549|OTHER|Control Group|Mothers in the control group were informed about the research and the 'Informed Consent Form' was signed. The mothers filled out the 'Information Form' and this process took about 15-20 minutes. Mothers were helped when filling out the form and their questions were answered. In addition, mothers were asked to complete the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6' by introducing. A month later, they were informed that they had to fill out this scale again. A month later, the mothers were interviewed face-to-face and allowed to fill out the scale again. After the last test, the mothers in the control group were given 'Home Accidents and Prevention Training for Children in the 0-6 Age Group' and the output of the training presentation was distributed.
41291406|NCT04489524|BEHAVIORAL|individualized counselor-led MI sessions|Intervention consisted of four 60-min in-person sessions of AMI counseling and a packet of self help smoking cessation materials.
41291407|NCT04489524|BEHAVIORAL|general health education session|four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco.
41291408|NCT04489524|BEHAVIORAL|NRT|nicotine replacement therapy
41291409|NCT02444169|DEVICE|Ultherapy|Focused ultrasound energy delivered below the surface of the skin.
41291410|NCT02444169|DRUG|Incobotulinumtoxin A|An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
41291411|NCT02444169|DEVICE|Radiesse|An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).
41291412|NCT02444169|DEVICE|Belotero Balance|An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
41291413|NCT04923971|OTHER|Purdue Pegboard|Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.
41291414|NCT06040567|OTHER|Validity and reliability of outcome measures in polyneuropathy|Patients will be tested, answer patient reported outcome measures, and wear accelerometer at baseline after 2-4 weeks and after 1-2 years.
41291415|NCT06040567|OTHER|Healthy controls|Healthy controls will be tested, answer patient reported outcome measures, and wear accelerometer at baseline visit. There is no follow-up in the healthy control group.
41455060|NCT02623218|DEVICE|Acupuncture|An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.
41455061|NCT02623218|DEVICE|Sham Acupuncture|Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.
41455062|NCT01497743|DRUG|Lactobacillus|All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
40954867|NCT06224257|DRUG|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
40761877|NCT06571604|DIAGNOSTIC_TEST|Dislocation|One episode of total hip dislocation diagnozied on Xray within 2 years of surgery
41291416|NCT04196842|DEVICE|Telemonitoring devices|Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
41291417|NCT05743023|BEHAVIORAL|Ayurvedic lifestyle protocol|"Based on each participant's current mind-body imbalance determination, a personalized 12-week intervention lifestyle protocol will be given.~Each protocol will mainly address diet and daily routine, quality of food, food combinations, and living in harmony with natural rhythm for balancing the predominant imbalance based on Ayurvedic principles. In addition, the lifestyle protocol will also include stress-reducing methods and more specifically, participants will be recommended to learn and practice the Transcendental Meditation technique."
41291418|NCT04291300|DRUG|Lutetium-177-PSMA-I&T|4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
41291419|NCT04589494|DRUG|Tramadol Hydrochloride|tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily
41291420|NCT06480929|OTHER|Contrast TTE procedure, the SonoVue ultrasound agent|The intervention involved using contrast-enhanced transthoracic echocardiography (TTE) to improve the detection of left ventricular thrombus in patients with anterior ST-elevation myocardial infarction (STEMI).
41291421|NCT01566344|OTHER|PVC suppression therapy|Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
41291422|NCT01175239|GENETIC|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
41455063|NCT00260715|BEHAVIORAL|Community-Popular Opinion Leader Model|
41455064|NCT00260715|BEHAVIORAL|Diffusion of Innovations|
40761878|NCT06571604|DIAGNOSTIC_TEST|No dislocation|No experience of dislocation within two years post-surgery
41291423|NCT02713750|OTHER|reversible contraceptive methods|"1. Consistent male condom use only~2. Consistent female condom use only~3. Hormonal contraception, combined oral contraceptive pills and male/female condom~4. Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom~5. Hormonal contraception , progestin only hormonal implant and male/female condom~6. Intrauterine device and male/female condom"
41455065|NCT03146143|PROCEDURE|ultrafiltration|ultrafiltration after cardiopulmonary bypass
40761879|NCT04551586|DRUG|ACH-0145228: Immediate Release|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
40761880|NCT04551586|DRUG|ACH-0145228: Powder-in-capsule|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
40761881|NCT02320552|OTHER|No intervention|no intervention
40761882|NCT06187714|PROCEDURE|caudal block rate|optic nerve sheath diameter measurement according to caudal block rate
40761883|NCT04910022|DRUG|NMS-03305293|Route of administration: Oral
40761884|NCT04910022|DRUG|Temozolomide|"Route of administration: Oral~Commercially available temozolomide"
40761885|NCT01681641|OTHER|A psycho-social intervention|
40761886|NCT06567262|DEVICE|CAD/CAM metallic removable partial denture|"Make digital scans using an intraoral scanning device. Scan the maxillary (antagonistic scan) and mandibular (pre-preparation scan) arches, as well as an initial digital record of the inter-occlusal relation (occlusal scan).~Analyse the digital cast using CAD software. Primary electronic surveying will be carried out to ensure if the tooth preparations will be needed.~Make a definitive intraoral scan only of the prepared teeth and record the maxillary-mandibular relationship.~The virtual cast is digitally surveyed and the design of the framework is done using computer software. The wax pattern 3D framework information will be converted into a standard tessellation language (STL) file and transfer to a rapid prototyping (RP) system to be printed and finally cast using the conventional technique to produce RPD framework."
40761887|NCT06567262|DEVICE|Conventional metallic removable partial denture|"Primary impressions will be taken, the impressions will be poured to construct a study casts.~Maxillary Face-bow record and diagnostic bite will be taken. The study casts will be mounted on semi adjustable articulator to check inter-arch space.~Surveying of the study cast will be done. Required mouth preparation will be carried out then secondary impression will be taken using special tray.~Secondary impression will be poured to obtain master cast which will be surveyed to confirm proper mouth preparation, blocked out and then wax pattern will be designed and constructed.~A metallic framework will be obtained using the conventional lost wax technique and casting.~Intraoral try in of the framework will be done followed by bite registration record.~The next step will be teeth setting and try in. Heat cured acrylic resin denture base will be processed, finished and polished conventionally."
40761888|NCT04269265|BIOLOGICAL|Yellow Fever Vaccine|YF-VAX®, Yellow Fever Vaccine, for subcutaneous use
40761889|NCT02500836|DRUG|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
40761890|NCT02500836|DRUG|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
40761891|NCT02500836|DRUG|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
40761892|NCT03906071|BIOLOGICAL|Nivolumab|Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.
40761893|NCT03906071|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
40761894|NCT03906071|DRUG|Docetaxel|Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.
41455066|NCT02842723|RADIATION|Protontherapy|59,5 Gy (1,7 Gy daily, 5 fractions per week).
40761895|NCT05692011|DEVICE|blood purification(PS)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days
40761896|NCT05692011|DEVICE|blood purification(AN69ST)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days
40761897|NCT03478488|DRUG|KN035 plus Gemcitabine & oxaliplatin|KN035 a programmed death ligand immune check inhibitor Per Investigator decision
41291424|NCT04309721|DRUG|Perampanel|Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
41291425|NCT04309721|DRUG|Placebo|Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
40954868|NCT06557694|OTHER|Data collection|Data collected included maternal demographics, medication during pregnancy, the gestational week when COVID-19 was diagnosed, antenatal diseases occurring after COVID-19 detection during pregnancy, intrauterine growth retardation (IUGR), small for gestational age (SGA), fetal distress, intrauterine fetal demise (IUFD), intrapartum complications, gestational age (GA) at delivery, mode of delivery, postpartum hemorrhage (PPH), admission to the maternal ICU, birth weight, admission to the NICU, and the indication for NICU hospitalization Pregnancy outcomes included mode of delivery, gestational age at delivery, pre-eclampsia, and postpartum hemorrhage (defined as an estimated blood loss of 1,000 mL or greater).
40954869|NCT00092573|DRUG|MK0653, ezetimibe|
41291426|NCT03897712|DEVICE|Custom Samfilcon B Contact Lenses|Contact lens
41291427|NCT03897712|DEVICE|Alden Optical HP Sphere Contact Lens|Hioxifilcon D, 54% water, Alden Optical HP Sphere lens
41291428|NCT03897712|DEVICE|ReNu MultiPlus Lubricating and Rewetting Drops|For use as needed during the study.
40761898|NCT03478488|DRUG|Gemcitabine & oxaliplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
40954870|NCT00092573|DRUG|Comparator: fenofibrate monotherapy|
40954871|NCT01332370|DRUG|Rosiglitazone + Metformin|At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
40954872|NCT01332370|DRUG|Sitagliptin + Metformin|At least 180 days of continuous therapy with STG+MET after the first Rx for STG
41291429|NCT03897712|DEVICE|Biotrue Multi-Purpose Solution|For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
41291430|NCT05382676|DEVICE|Eyeswift Pro|assessment of visual function parameters
41291431|NCT00388752|PROCEDURE|Acupuncture|
41291432|NCT05632497|BIOLOGICAL|Stool and blood samples|Stool and blood samples
41291433|NCT06252714|DEVICE|Defecation Posture Modification Device|Patients will be asked to use the defecation posture modification device with each bowel movement for two weeks.
41291434|NCT02648815|PROCEDURE|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
40954873|NCT00003257|BIOLOGICAL|Ad5CMV-p53 gene|
40954874|NCT03777488|DRUG|Tranexamic Acid 1 gram intravenously|Intravenous tranexamic acid crossover to oral and intramuscular arms
41455067|NCT01225523|DRUG|Paclitaxel; Cisplatin; 5-Fluorouracil|Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
41455068|NCT01225523|DRUG|Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine|Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
40761899|NCT03775109|DRUG|Canakinumab 150mg/ml solution for injection|Canakinumab 150mg/ml solution for injection
40761900|NCT03775109|DRUG|Placebo|100ml 5% Dextrose
40761901|NCT06375499|DEVICE|T2769|Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
41291435|NCT02648815|PROCEDURE|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
41455069|NCT00079287|DRUG|carboplatin|
41455070|NCT00079287|DRUG|docetaxel|
41455071|NCT00079287|DRUG|gemcitabine hydrochloride|
41455072|NCT00079287|DRUG|paclitaxel|
40761902|NCT06375499|DEVICE|Hylo-Forte®|Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
40761903|NCT01157494|OTHER|classification of hand manipulation function|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
40761904|NCT05879055|DRUG|PM8002|IV infusion
40761905|NCT05879055|DRUG|FOLFIRI|IV infusion
40761906|NCT05178654|DRUG|[14C]PF-07321332|Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.
40761907|NCT06053580|DRUG|Valsartan 40 mg|Valsartan 40mg twice daily for 24 weeks.
40761908|NCT06053580|DRUG|Placebo|Placebo twice daily for 24 weeks.
40761909|NCT00167531|BEHAVIORAL|treadmill walking with partial weight support|
40761910|NCT00167531|BEHAVIORAL|assisted overground walking|30 minutes per day of overground walking with the assistance of one therapist
40761911|NCT02796911|DRUG|Xenograft|group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
40761912|NCT02796911|DRUG|Bioactive glass|group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
40761913|NCT02685436|DRUG|Omeprazole and domperidone|wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
40761914|NCT02458118|DRUG|Secretin|Secretin 1 IU/kg over 3 min
40761915|NCT00726479|DRUG|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
40954875|NCT03777488|DRUG|Tranexamic acid 2 grams oral solution|Oral tranexamic acid crossover to intravenous and intramuscular arms
41455073|NCT00079287|DRUG|vinorelbine tartrate|
41455074|NCT03166904|DRUG|Vistusertib(AZD2014)|Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
41455075|NCT05347459|DRUG|Dapagliflozin|usual and customary doses for type 2 diabetes management
41455076|NCT05347459|DRUG|Empagliflozin|usual and customary doses for type 2 diabetes management
41455077|NCT05347459|DRUG|Canagliflozin|usual and customary doses for type 2 diabetes management
40761916|NCT05645146|BEHAVIORAL|Smoking Cessation treatment delivered by Tobacco Free Florida Quitline|Phone counseling with the state tobacco quitline
40954876|NCT03777488|DRUG|Tranexamic acid 1 gram intramuscular|Intramuscular tranexamic acid crossover to oral and intravenous arms
40954877|NCT03407625|OTHER|Foley bulb plus Oral Misoprostol|"Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States."
40954878|NCT03407625|OTHER|Oral Misoprostol|Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.
40954879|NCT05857943|DEVICE|AEYE-DS Software|Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.
40954880|NCT01851460|DEVICE|Cool-tip RF Ablation System|RFA therapy will be administered according to the instructions of the RFA device manufacturer. After infiltration of the skin (for percutaneous approach) with a local anesthetic, the needle probe will be directed into the lesion. For all methods, the needle placement is confirmed to be within the lesion by ultrasound or other imaging modality as appropriate. After confirming needle placement, the lesion will be heated to a target temperature of \>75 (Infinite)c for up to 15 minutes. The exposure time may be varied depending on the temperatures achieved. Depending on the size of the lesion to be ablated, multiple passes of the probe as well as multiple ablation cycles may be performed. Adequacy of ablation will be monitored by ultrasound throughout the procedure. Depending on the size of the lesions and the time required to complete the ablation, multiple lesions may be treated as staged procedures so as to improve safety.
40954881|NCT04074031|DEVICE|Transcranial Ultrasound Therapy (Exablate® 4000 Type 1.1)|The Exablate® 4000 Type 1.1 model designed for noninvasive ablation of brain tissue is an MRI-guided transcranial ultrasound system (MRgFUS). The goal of the Exablate Neuro system is to precisely guide the focus of the ultrasound energy on the target region. The focused ultrasound energy is then repeatedly transmitted to the target until the desired result is achieved. Targeting is performed using MRI acquired during treatment. The treatment process is constantly monitored by closed-loop thermal feedback in real time, under the supervision of the treating physician. Once targeting is complete, the treatment outcome is confirmed by MRI sequences immediately after treatment. The Exablate Neuro is compatible with Siemens 3 Tesla MRI.
40954882|NCT05962671|DRUG|Opioid-sparing based anesthesia|Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.
40954883|NCT05962671|DRUG|Sevoflurane-based anesthesia|Intraoperative sevoflurane-based anesthesia, 0.8 to 1.0 Minimum alveolar concentration will be used combined with fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h and cis-atracurium, to keep bispectral index between 45% to 60%.
40954884|NCT01738542|DRUG|Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
41135246|NCT02165202|DRUG|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
41135247|NCT02447666|DRUG|Azacitidine|
41135248|NCT02159794|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
41135249|NCT01324076|DRUG|doxorubicin-eluting beads|
40761917|NCT05645146|DRUG|Nicotine patch|Participants will be provided with a 12 week supply of nicotine patches
40761918|NCT05645146|DRUG|Nicotine Lozenge|Participants will be provided with a 12 week supply of nicotine lozenges
40761919|NCT05645146|BEHAVIORAL|Motivation and Problem Solving (MAPS) intervention|MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation. Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
40761920|NCT04520230|DRUG|Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid|inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).
40761921|NCT04520230|DRUG|Tiotropium 18 mcg capsule inhaled once daily + Budesonide|inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).
40761922|NCT04520230|DRUG|Formoterol/Tiotropium|long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).
40761923|NCT03864705|DIAGNOSTIC_TEST|Measurement of plasma metformin levels|Subjects on chronic metformin therapy will have their plasma metformin levels measured during a regular check-up with glycated hemoglobin assessment.
40761924|NCT05474859|DRUG|XT-0528|Once Daily
40761925|NCT01881958|DRUG|DiaPep277®|
40761926|NCT03800901|OTHER|Continuing Medical Education|CME or ABIM MOC credits
41135250|NCT01324076|DRUG|sorafenib tosylate|
41135251|NCT01324076|OTHER|laboratory biomarker analysis|
41135252|NCT01324076|OTHER|pharmacogenomic studies|
40761927|NCT03800901|OTHER|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, including national MIPS quality measures.~Cases will cover clinical conditions aligned with MIPS measures that are commonly seen in the primary care setting including: diabetes, hypertension, depression, osteoarthritis, asthma and pain control."
41455078|NCT05347459|DRUG|Sitagliptin|usual and customary doses for type 2 diabetes management
40954885|NCT01738542|DRUG|Antiaggregant therapy|AAS 100mg/d or Clopidogrel 75mg/d
40954886|NCT01738542|DRUG|Statins|
40954887|NCT01738542|DRUG|Antihypertensive therapy|
40954888|NCT05686031|OTHER|No interventions were done between groups|No interventions were done between groups
40954889|NCT04424810|OTHER|High-quality, physician created video|The intervention group will watch a short (2-5 minute) video prior to surgery that will provide them with information about their condition and the procedure they are about to undergo (either carpal tunnel release or trigger finger release).
41135253|NCT01324076|OTHER|pharmacological study|
41135254|NCT01324076|PROCEDURE|quality-of-life assessment|
41135255|NCT05110794|DRUG|LY3502970|Administered Orally.
41455079|NCT05347459|DRUG|Saxagliptin|usual and customary doses for type 2 diabetes management
41455080|NCT05347459|DRUG|Linagliptin|usual and customary doses for type 2 diabetes management
40954890|NCT04424810|OTHER|Standard of care|Patients in the control group will not be asked to do anything differently prior to their surgery
41455081|NCT05347459|DRUG|Vildagliptin|usual and customary doses for type 2 diabetes management
41455082|NCT03549897|DRUG|Placebo|Placebo Product
41455083|NCT03549897|DRUG|90 mcg Reference Product|90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
40761928|NCT04601493|BEHAVIORAL|Choice Architecture Nudge|"During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. PCPs can choose to ignore this, but opening the SmartSet is the default option. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options (e.g., referral to physical therapy or pain clinic)."
40761929|NCT04601493|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
40761930|NCT04887285|DEVICE|Virtual reality|Subjects in the virtual reality group will be offered a variety of immersive environments to choose from (mountains, beach, rainforest and temperate forest) in addition to local anesthetic.
40761931|NCT04887285|DRUG|Intravenous sedation|Sedation will be administered using low-dose midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). Sedation will be titrated to effect by a board-certified or eligible anesthesiologist so that patients remain responsive to verbal stimuli.
40761932|NCT04887285|OTHER|Standard care|Patients will receive superficial local anesthetic with 1% lidocaine. Local anesthetic will be administered by the physician performing the procedure titrated to patient comfort.
40761933|NCT05668624|OTHER|Clean household energy|LPG stoves/fuel for cooking and solar electricity for lighting
40761934|NCT05168592|BEHAVIORAL|Threat conditioning|Day 1: The participant is repeatedly shown two stimulus (CS+,CS-), one at a time. CS+ is paired with an electric shock. CS- acts as a control stimulus. The stimuli consist of photos of two different objects. Stimuli will be counterbalanced between participants.
40761935|NCT05168592|BEHAVIORAL|Imaginal extinction|Day 1: Participants are repeatedly instructed to produce mental imagery of the two stimuli used during threat conditioning. Imagery is prompted through different written instructions presented in pseudo-randomized order on a screen. No shocks will be delivered.
40761936|NCT01906138|DEVICE|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
40761937|NCT06196034|GENETIC|No intervention|No intervention
40761938|NCT04658680|DRUG|BCG vaccination at first health facility contact|"Intradermal injection at first health facility contact: 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine in the left deltoid region.~The strain supplied by the national vaccination programme is provided through UNICEF. Different strains are used interchangeably. The additional BCG vaccines provided through this study will be procured by the Bandim Health Project. Vaccines will be from the WHO list of prequalified vaccines and the same strain will be used in intervention and control health centres."
41455084|NCT03549897|DRUG|180 mcg Reference Product|180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
41455085|NCT03549897|DRUG|90 mcg Test Product|90 mcg Test Product - ALBUTEROL SULFATE HFA \[AMNEAL IRELAND LIMITED\]
41455086|NCT05341492|BIOLOGICAL|EGFR/B7H3 CAR-T|2 × 10\^6/kg CAR-T cells,For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
41455087|NCT00981344|OTHER|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
40954891|NCT01069016|PROCEDURE|Sacral nerve modulation|For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
40954892|NCT01069016|PROCEDURE|Pudendal nerve stimulation|For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
40954893|NCT04846842|DRUG|Gimatecan|Patients will receive gimatecan orally at the fixed dose level on day 1-5 every 4 weeks.
40954894|NCT02241252|DEVICE|iPhone ECG|Please see detailed description for additional information.
40954895|NCT00760422|DEVICE|NIR|Thermometer
40954896|NCT03094403|DRUG|Azelaic Acid 15% topical gel|Gel
40954897|NCT03094403|DRUG|Finacea® (azelaic acid) Gel, 15%|Gel
40954898|NCT03094403|DRUG|Placebo|Gel
40954899|NCT02855073|BIOLOGICAL|ReJoinTM|adipose derived mesenchymal progeinitor cells
40954900|NCT02855073|DRUG|Sodium Hyaluronate|Sodium Hyaluronate Injection
40954901|NCT01406743|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
41291436|NCT05205239|DIAGNOSTIC_TEST|Endoluminal image analysis by capsule endoscopy|Studies will be performed after discontinuation of medications that could affect gastrointestinal motility for at least 48 hours and overnight fast. Endoluminal images were obtained with the Pillcam capsule (Pillcam SB3 video capsule; Medtronic). Images will be obtained at a fixed 2 per second rate and recorded for a total of 8 hours with the subjects lying comfortably on a hospital bed and the trunk raised 30° above horizontal. Forty-five minutes after gastric exit, participants will be instructed to ingest a liquid meal (Ensure HN; Abbott; 300 mL,1 Kcal/mL). Endoluminal images of the small bowel will be analyzed with a computer program specifically developed in our laboratory for the evaluation of intestinal motility. This previously validated program is based on computer vision techniques, which allow the detection and quantification of contractile and non-contractile patterns characterizing small bowel motility.
41291437|NCT06020976|DIAGNOSTIC_TEST|liver biobsy|all pationt will be subjected yo liver biobsy to confirm diagnosis
40954902|NCT05687175|OTHER|Questionnaire|Questionnaire administration (PDQ-M, NRS, SF-36)
41291438|NCT06255977|DRUG|CN-105|Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
41291439|NCT03472534|DRUG|diacerein 1% ointment|diacerein 1% ointment applied to the skin of the infrascapular area of the back under occlusive patch for 21 days.
41291440|NCT01742221|BIOLOGICAL|HemaMax|single subcutaneous 12 microgram dose of HemaMax
41291441|NCT01742221|DRUG|Placebo|single subcutaneous dose
41291442|NCT02481765|DEVICE|High definition transcranial direct current stimulation|
41291443|NCT02563184|BIOLOGICAL|Fluzone|
41291444|NCT04111367|DRUG|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.
41291445|NCT04111367|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.
41291446|NCT06192446|DRUG|Survey using a questionnaire.|An observational study conducted in a cross-sectional manner using a questionnaire.
41291447|NCT00312377|DRUG|Docetaxel|infusion
40954903|NCT04614558|DRUG|Isatuximab|"Isatuximab in IV form (10mg/kg q weekly x 4 doses followed by 10mg/kg q 2 weeks) for a total of 6 month duration. Doses should be initiated at 175 mg/hour up to a maximum of 400 mg/hour.~Isatuximab (SAR) is monoclonal antibody (mAb)."
41291448|NCT00312377|DRUG|Vandetanib|oral
41291449|NCT04530825|OTHER|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
40954904|NCT06016920|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
41291450|NCT04530825|OTHER|PREVENT Tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese adolescent patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
41291451|NCT05153408|DRUG|BLU-701|BLU-701 for oral administration
41291452|NCT05153408|DRUG|osimertinib|Osimertinib tablets for oral administration
40954905|NCT06016920|DRUG|Pembrolizumab|"Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes."
40954906|NCT00392015|BIOLOGICAL|NMRC-M3V-Ad-PfCA|Malaria Vaccine
40954907|NCT00392015|BIOLOGICAL|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA|Malaria Vaccines
40954908|NCT00276497|DRUG|Pioglitazone|
40954909|NCT05757687|DEVICE|Omega device|"The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.~The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra."
40954910|NCT04418674|DRUG|Ketamine|in this group, patient will receive ketamine at 0.3mg/kg intravenously.
40954911|NCT04418674|DRUG|Fentanyl|In this group, the patients will receive fentanyl at 1.5mcg/kg intavenously.
40954912|NCT02210546|OTHER|Magnetic Resonance Imaging (MRI)|
40954913|NCT02210546|OTHER|Mammography (Mx) + ultrasonography (US)|
40954914|NCT04610970|DRUG|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
40761939|NCT03593278|DRUG|ACT-246475|Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
41291453|NCT05153408|DRUG|carboplatin|IV infusion of carboplatin
41291454|NCT05153408|DRUG|pemetrexed|IV infusion of pemetrexed
41291455|NCT02562196|DEVICE|tdcs|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
41291456|NCT02464319|DRUG|hrIL-2 active|1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
40761940|NCT03191331|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy, dietary counseling at each maternity clinic visit given by public health nurse, group meeting with a dietician x2.
40761941|NCT04498273|DRUG|Apixaban 2.5 MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 2.5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
40954915|NCT00567372|DRUG|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
40954916|NCT01823302|DIETARY_SUPPLEMENT|nutrition counseling plus oral milk-based nutritional supplement|Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.
40954917|NCT01823302|OTHER|nutritional counseling|nutritional counseling
40954918|NCT02401022|DRUG|AZD8529|comparison of different dosages of drug
41455088|NCT02082327|DRUG|IV migalastat HCl|
41291457|NCT02464319|DRUG|hrIL-2 placebo|1 million U doses of placebo s.c. injection active group: placebo group =1:1
40761942|NCT04498273|DRUG|Apixaban 5MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
41291458|NCT00010023|DRUG|capecitabine|
41291459|NCT00010023|DRUG|cisplatin|
41291460|NCT06509516|OTHER|Modified Sleeper-Stretch|Self-administered stretch in which the individual remains side-lying on the upper limb to be stretched, keeping the scapula stabilized by his/her own weight, and rolls the trunk 20-30º posteriorly, maintaining a 90º flexion in the shoulder and elbow. Using the opposite hand over the forearm of the limb to be stretched, the individual passively brings the shoulder to maximum internal rotation.
41291461|NCT01105338|BEHAVIORAL|Green tea drink|Green tea drink
41291462|NCT01105338|DIETARY_SUPPLEMENT|green tea capsules|green tea capsules
41291463|NCT01105338|OTHER|Green tea placebo capsules|Green tea placebo capsules
41291464|NCT01105338|DIETARY_SUPPLEMENT|Lycopene capsules|Lycopene capsules
41291465|NCT01105338|OTHER|Lycopene placebo capsules|Lycopene placebo capsules
41291466|NCT01105338|OTHER|Tomato rich diet|Tomato rich diet
41291467|NCT00783510|BIOLOGICAL|adalimumab|As prescribed by treating physician
41291468|NCT00783510|DRUG|Methotrexate|As prescribed by treating physician
41291469|NCT01466725|DRUG|CC-930|
41291470|NCT01466725|DRUG|Placebo|Placebo
41291471|NCT00296283|BEHAVIORAL|integrative behavior couples therapy|
41291472|NCT01073072|PROCEDURE|Conventional technique|Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
41291473|NCT01073072|PROCEDURE|Technique Tutomesh®|Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
40761943|NCT04498273|DRUG|Aspirin|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Aspirin twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
40761944|NCT04498273|DRUG|Placebo|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
41291474|NCT01894282|PROCEDURE|Manual Therapy|Manual Therapy Arm
41291475|NCT01894282|PROCEDURE|Mind Body Intervention|Combination of manual therapy and cognitive behavioral therapy for pain.
41291476|NCT00978575|DRUG|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
41291477|NCT00978575|DRUG|Ferrosulfate|200mg daily for 12 weeks
41291478|NCT00978575|DRUG|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
41291479|NCT05582577|COMBINATION_PRODUCT|Intravitreal bevacizumab injection with subthreshold micropulse laser|Group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser
41291480|NCT05582577|DRUG|Intravitreal bevacizumab injection alone|Group B: Intravitreal injection of Bevacizumab alone
41291481|NCT04055935|PROCEDURE|elevation of full thickness mucoperiosteal flap|A free gingival sulcular incision was done from the distal surface of maxillary second premolar to the mesial side of the maxillary canine. A releasing oblique incision was done including the interdental papilla between maxillary canine and lateral incisor extending to the mucogingival junction just beyond the attached mucosa. The flap reflection extended beyond the canine root apex. A FTMPF reflection was done with mucoperiosteal elevator. Free sulcus incision was done to allow elevation of palatal mucosa by tunneling technique on the palatal gingiva of maxillary canine.
41291482|NCT04055935|DEVICE|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length. LLLT protocol was using active laser tip (bleaching tip)
41291483|NCT03295422|PROCEDURE|RF ablation PVI alone|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
41455089|NCT02082327|DRUG|IV placebo|
41455090|NCT02082327|DRUG|oral migalastat HCl|
40954919|NCT06361160|DEVICE|Active Transcranial Magnetic Stimulation (TMS)|Active rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) at the onset of the Auditory Verbal Hallucinations (AVH).
40954920|NCT06361160|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|"Sham rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) during the onset of the Auditory Verbal Hallucinations (AVH).~An electrical stimulator is synchronised with the magnetic stimulation to recreate the tactile sensation and the coils emits the same noise during sham stimulation as in the active configuration, making it impossible to distinguish between active and placebo magnetic stimulation."
40954921|NCT05409326|DRUG|TQH2722 injection|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
41455091|NCT04194008|DEVICE|Nerivio|A remote electrical neuromodulation (REN) device for the acute treatment of migraines.The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
41455092|NCT04207229|DEVICE|CODMAN CERTAS Programmable Valves|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
41455093|NCT03192397|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
41135256|NCT03347409|OTHER|Changes in preoperative care|Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling
41455094|NCT03192397|DRUG|Cyclophosphamide|Given IV
41455095|NCT03192397|DRUG|Fludarabine Phosphate|Given IV
40761945|NCT00085839|DRUG|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
40761946|NCT00085839|DRUG|Combination carboplatin and paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
41455096|NCT03192397|OTHER|Laboratory Biomarker Analysis|Correlative studies
41455097|NCT03192397|DRUG|Melphalan Hydrochloride|Given IV
41455098|NCT03192397|DRUG|Mycophenolate Mofetil|Given IV
41455099|NCT03192397|DRUG|Sirolimus|Given IV and PO
41455100|NCT03192397|RADIATION|Total-Body Irradiation|Undergo TBI
41455101|NCT04383249|DIAGNOSTIC_TEST|Pathology result|Pathology result of the hernia sac
41455102|NCT05543395|BEHAVIORAL|Domestic Violence Questionnaire|Domestic Violence Questionnaire
41455103|NCT03666143|DRUG|Sitravatinib|Administered orally as a capsule
41455104|NCT03666143|DRUG|Tislelizumab|Administered intravenously
41455105|NCT00044434|DRUG|bupropion (Wellbutrin)|
41455106|NCT03365908|PROCEDURE|Adductor Canal Nerve Block|An adductor canal nerve block with 15 mL of 0.5% ropivacaine will be performed pre-operatively by Anesthesiology.
40954922|NCT05409326|DRUG|Placebo to match TQH2722|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
40954923|NCT00335413|DRUG|Spironolactone|
40761947|NCT02909257|DRUG|Same Bupivacaine Concentration|patient is exposed to the same concentration than previously successful one
40761948|NCT02909257|DRUG|Lower Bupivacaine Concentration|patient is exposed to a lower concentration than previously successful one
40954924|NCT02326792|OTHER|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
40954925|NCT06558292|OTHER|Virtual Reality Group|Students will experience the operating room environment with virtual reality glasses before clinical practice.
40954926|NCT03076619|OTHER|clinical ophthalmoscopy|To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
40761949|NCT06076226|OTHER|No intervention, observation study|No intervention, observation study
40954927|NCT01522248|BIOLOGICAL|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
40761950|NCT06245655|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS 7000 digital TENS unit, a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
40761951|NCT04641975|DRUG|Mirabegron|Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight \< 35 kg or those who cannot be dosed with the tablet will receive oral suspension.
40954928|NCT03070366|DRUG|Chemotherapy|"* cisplatin~* 5FU~* carboplatin~* cetuximab"
40954929|NCT03070366|RADIATION|Stereotactic radiotherapy|Stereotactic radiotherapy
40954930|NCT02815410|DRUG|levetiracetam|Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
40954931|NCT04930874|OTHER|NIRS (Near-Infrared Spectroscopy)|NIRS assessment of cerebral autoregulation and cerebral blood flow
40954932|NCT01770496|BEHAVIORAL|Childhood vaccination reminder / recall notification|
40761952|NCT04641975|DRUG|Placebo|Oral/ Oral Suspension
40761953|NCT05425355|DRUG|Intravenous (IV) acetaminophen + oral placebo|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
40954933|NCT00154635|DRUG|DCB-AD1|
40954934|NCT05274737|DEVICE|Novel sling|The novel sling was designed and created by the principal investigator to address these concerns of the traditional slings that are currently available for postsurgical protection and immobilization after shoulder surgery. It is anticipated that the novel sling will allow the patient to be more active and more comfortable while still providing a safe healing environment after a shoulder injury or shoulder surgery.
40954935|NCT05274737|DEVICE|Traditional abduction sling|An abduction sling is the most common type of sling utilized to protect patients after rotator cuff surgery and total shoulder of arthroplasty and can be considered the current standard of care.
40954936|NCT01907581|OTHER|Quality of life questionnaires|
40761954|NCT05425355|DRUG|Intravenous (IV) placebo plus oral acetaminophen|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
40761955|NCT04606316|DRUG|Nivolumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
40761956|NCT04606316|DRUG|Nivolumab|Given as intravenous (IV) infusion into a vein.
40761957|NCT04606316|DRUG|Ipilimumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
40954937|NCT00618683|PROCEDURE|Cardiac Invasive Electrophysiological Study|Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study
41135257|NCT03347409|OTHER|Changes in intraoperative care|Blended anesthesia is mostly carried out using Total Intra Venous Anesthesia (TIVA) with loco regional analgesia, in particular Thoracic Epidural Anesthesia (TEA) in open surgery and spinal morphine or Transversus Abdominis Plane (TAP) block or quadratus lumborum block for laparoscopic surgical approach, associated to NSAIDs or acetaminophen; control of deep neuromuscular blocking with Train-of-four (TOF) stimulation avoiding residual paralysis. Multimodal prevention of PONV (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.
41455107|NCT03365908|DRUG|Ropivacaine injection|15 mL of 0.5% ropivacaine will be administered for the adductor canal block
41455108|NCT06383130|DIAGNOSTIC_TEST|Oscillometry with reversibility testing|Oscillometry is a test that uses sound waves to measure the mechanical properties in the lungs during tidal breathing
41455109|NCT06383130|DIAGNOSTIC_TEST|Breath volatile testing|We will be optimising and evaluating the sensitivity and specificity of a novel breath volatile organic compound test of a combination of reactive aldehydes using a gas chromatography-ion mobility spectrometry device
41455110|NCT06383130|DIAGNOSTIC_TEST|Nasal eosinophil peroxidase|We will be evaluating the sensitivity and specificity of a novel nasal swab test for eosinophil peroxidase
40954938|NCT00522015|DRUG|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
40761958|NCT04606316|DRUG|Ipilimumab|Given as intravenous (IV) infusion into a vein.
40761959|NCT04606316|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
40761960|NCT05505786|BEHAVIORAL|Normal stance width|Normal self-selected stance width when performing squat exercises.
40761961|NCT05505786|BEHAVIORAL|Wide stance width|Increased stance with (by 20% over their own self-selected stance width) when performing squat exercises.
40761962|NCT01603368|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
40761963|NCT01603368|DIETARY_SUPPLEMENT|Placebo|Oil drops without Lactobacillus reuteri
41135258|NCT03347409|OTHER|Changes in postoperative care|Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV. According to the type of surgery TEA, TAP block , quadratus lumborum block or IT morphine is preferred. Patient is proposed to start drinking clear fluid 4 hours after surgery and to start eating the evening of the surgery, with the introduction of a normal free diet within 24 hours after surgery. It is proposed to chew gum three times daily for at least 15 minutes and eventually to use laxatives to promote a faster bowel function. Early mobilization is started from the evening of surgery.
40761964|NCT03044795|DRUG|Veliparib|Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
40761965|NCT06374979|BIOLOGICAL|Ixekizumab|Participants will receive an initial dose of 160 mg (two injections of 80 mg) ixekizumab subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.
40761966|NCT00383032|DRUG|mifepristone|
40761967|NCT06569797|DIETARY_SUPPLEMENT|oligosaccharides and multiple nutrients|The effect of adding milk oligosaccharides and optimizing multiple nutrients to infant formula on the growth and development of infants aged 0-1 years
41455111|NCT06383130|DIAGNOSTIC_TEST|Handheld capnometry|We will be evaluating handheld capnometry (carbon dioxide breath testing) to diagnose adult asthma
40761968|NCT06569797|DIETARY_SUPPLEMENT|no oligosaccharides and optimizing multiple nutrients|The effect of traditional infant formula milk powder optimized without adding milk oligosaccharides and multiple nutrients on the growth and development of infants aged 0-1 years old.
40761969|NCT06569797|DIETARY_SUPPLEMENT|breastfeeding|The impact of breastfeeding on the growth and development of infants aged 0-1 years old.
40761970|NCT03213951|OTHER|Experimental beta probe|3mCi (or similar) dose of 68Ga-PSMA-11 will be given prior to resection of cancer. Experimental beta probe designed to detect 68Ga-PSMA-11 will be used on prostate tissue after it has been surgically removed.
40761971|NCT03213951|DIAGNOSTIC_TEST|PSMA-PET|PSMA-PET imaging done prior to surgery and compared to whole mount imaging.
40761972|NCT04479852|DRUG|SP-624|Oral capsule
40761973|NCT04479852|DRUG|Placebo|Oral capsule
40761974|NCT03538808|DRUG|Varenicline|Participants will be provided varenicline medication
40761975|NCT03538808|OTHER|Placebo|Participants will be provided placebo medication
40761976|NCT03218475|OTHER|MR Guided Focused Ultrasound|Two treatments of focused ultrasound under MRI guidance
40761977|NCT06041880|DEVICE|Passive calf muscle stretching device|Modified night splints will be used to passive stretch the calf muscle.
40761978|NCT03358173|PROCEDURE|Conservative Treatment|Conservative Treatment
40761979|NCT03358173|PROCEDURE|Operative Plate Fixation|Operative Plate Fixation
40761980|NCT03113188|DRUG|CBP501|CBP501, CDDP plus Nivolumab
40761981|NCT03692169|PROCEDURE|Half-dose photodynamic therapy|Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
40761982|NCT01487161|DRUG|FX006|Single 3 mL intra-articular injection
40761983|NCT01487161|DRUG|TCA IR|Single 1 mL intra-articular injection
40761984|NCT04463927|OTHER|non-nutritive sucking|intervention group received a sterile gloved finger during the examination for retinopathy of prematurity
40761985|NCT05576350|BEHAVIORAL|Smartphone Based Alcohol Monitoring (SAM)|Smartphone-based alcohol monitoring (SAM) using mobile breathalyzers and surveys.
40761986|NCT05576350|BEHAVIORAL|Tracking and Reducing Alcohol Consumption (TRAC)|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage drinking. It requires four 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the four sessions of intervention content, participants will complete smartphone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
40761987|NCT05576350|BEHAVIORAL|TRAC-ER|Ecological momentary interventions (EMI) use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use.
40761988|NCT02264821|DRUG|ropivacaine infiltration|wound infiltration
40761989|NCT02264821|DRUG|intrathecal morphine|100 µg added to the spinal anaesthesia
40761990|NCT02264821|DRUG|placebo|placebo in spinal anaesthesia and in wound infiltration
40761991|NCT01917370|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
40761992|NCT02471677|DRUG|Elonva|corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
40761993|NCT02471677|DRUG|Puregon|follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
40761994|NCT00450840|DRUG|Simvastatin|
40761995|NCT02963818|OTHER|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
40761996|NCT02963818|OTHER|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
40761997|NCT02963818|OTHER|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
40761998|NCT01173003|DRUG|Mifepristone, misoprostol|
40761999|NCT03453515|BEHAVIORAL|HEART|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
40762000|NCT03453515|BEHAVIORAL|Growing Minds|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
40762001|NCT02914873|PROCEDURE|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
40762002|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Alpha|Rhythmic alpha stimulation
40762003|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Theta|Rhythmic theta stimulation applied
40762004|NCT06252532|DEVICE|Sham Direct cortical stimulation (DCS)|Arrhythmic stimulation paradigm applied
40954939|NCT04969874|OTHER|Remote follow-up|"The feeling of swallowing will be assessed at the end of the stay at the rehabilitation center, which corresponds to the first visit, and then every month for 5 months during remote interviews and on discharge with the Deglutition Handicap Index (DHI), a self-assessment questionnaire for the swallowing handicap.~The quality of life will be assessed at the firs visit and 6 months after using the EORTC QLQ 30 quality of life scale and the H\&N annex, a self-assessment questionnaire on the quality of life for people with cancer of the head and neck.~The satisfaction of users and the interest of city health professionals in the use of the MAX Educ tool as part of a monthly monitoring will be collected via the TUQ questionnaire, through the MAX platform at Month 6."
40762005|NCT06252532|DEVICE|Direct cortical stimulation (DCS) In-Phase Theta|Rhythmic in-phase theta stimulation applied
40762006|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Anti-Phase Theta|Rhythmic anti-phase theta stimulation applied
40762007|NCT01613885|OTHER|No Intervention|This study does not involve any intervention other than obtaining blood, nasal/cheek/throat/skin swabs, saliva, sputum, urine, and stool samples, breathing and skin tests.
40762008|NCT02673060|DRUG|MBC-11|0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
40762009|NCT06113367|OTHER|Evaluation of anti-PD-(L)1 immunotherapy efficacy|Non Applicable, research on data
40762010|NCT04555239|PROCEDURE|Fascial Distortion Model (FDM)|"Only treatment of herniated trigger points, continuum distortions, and/or trigger bands will be performed.~* Herniated trigger points are single areas of sharp pain within soft tissue.~* Continuum distortions are single points of sharp pain overlying bony tissues.~* Trigger bands are lines of pain overlying either soft or bony tissues.~Treatment with FDM is performed using firm, direct pressure over the area of the patient's pain with the provider's thumb. This pressure is applied at a single point or area indicated by the patient for herniated trigger points and continuum distortions, and along the indicated line of pain for trigger bands."
40762011|NCT04555239|OTHER|Standard Care|"The usual standard of care for extremity pain varies from provider to provider and varies from patient to patient depending upon their comorbidities but often includes some combination of the following:~* X-rays, if suspicion for fracture exists~* Venous duplex ultrasound, if suspicion for DVT/SVT exists~* Computed tomography (CT) angiogram (CTA), if suspicion for arterial occlusion exists~* C-reactive Protein (CRP)/erythrocyte sedimentation rate (ESR)/arthrocentesis is suspicion if suspicion for septic arthritis exists~* Arthrocentesis if suspicion for gout exists~* Splinting/casting/immobilization~* NSAIDs, Tylenol, or opioids for pain control~* Possibly trigger point injections~* Possibly osteopathic manipulation~* Recommendations to use RICE (rest, ice, compression, elevation) at home~* Physical/occupational therapy referral~* Orthopedic referral"
40762012|NCT01906320|BEHAVIORAL|High-Intensity Resistance training|"Intervention group performed 3 weekly sessions during 8 weeks in the intra-hospital gymnasium. Each session lasted 50-60 min, and started and ended with warm-up and cool-down periods (10-15 min).~The core session included bench press, leg press, lateral row, leg extension, lateral pull-down, abdominal crunch, low back extension, and push-ups exercises. The participants performed three sets of 8-10 repetitions with resting periods of 1-2 min on the weightlifting machines. Load was gradually increased 5-10 % as the participant strength was adapted. The load started at 70% of 6RM.~Functional exercises (abdominal crunch, low back extension, and push-ups) were performed at the end of the session to strengthen the core musculature consisting of 3 sets of 15s of isometric contractions at the beginning of the program and 30 s at the end. Dynamic contractions were added, starting with 10 repetitions at the beginning to 30 repetitions at the end of the program."
40762013|NCT00408174|DRUG|Balsalazide disodium|
40954940|NCT03734575|DEVICE|ClariCore System|The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.
41135259|NCT03601715|OTHER|Coplanar|The coplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
41135260|NCT03601715|OTHER|Contraplanar|The contraplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
41135261|NCT03601715|OTHER|Longitudinal|The longitudinal arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
41135262|NCT00661206|DRUG|Clopidogrel|Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
41135263|NCT00661206|DRUG|Placebo|Patients randomized in this group will receive placebo for 6 months.
40762014|NCT06563674|OTHER|Acceptance-based healthy lifestyles program (intervention group)|The acceptance-based healthy lifestyles program consists of 4 biweekly 60-min face-to-face interactive workshops to cover the knowledge of pneumoconiosis, exercise to maintain lung function, health diet, and home safety.
40762015|NCT06563674|OTHER|Acceptance-based healthy lifestyles program (control group)|The acceptance-based healthy lifestyles program consists of 4 biweekly 60-min face-to-face interactive workshops to cover the knowledge of pneumoconiosis, exercise to maintain lung function, health diet, and home safety.
40762016|NCT04445909|DEVICE|VA-ECMO|Deployment of extracorporeal membrane oxygenation cardiac assist device.
40762017|NCT04656340|OTHER|non-medication, non-interventional therapies|non-medication, non-interventional therapies
40762018|NCT02621944|DRUG|Melatonin|Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
40762019|NCT02621944|OTHER|Magnetic Resonance Imaging|All participants will receive an MRI between 7-12 days of age.
40762020|NCT02621944|OTHER|Pharmacokinetics|All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
40762021|NCT02621944|BEHAVIORAL|Neurological Outcome Assessment|All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
40762022|NCT02367885|DRUG|TAK-850 0.5 mL injection|TAK-850 injection
40762023|NCT02367885|DRUG|TAK-850 0.25 mL injection|TAK-850 intramuscular injection
40762024|NCT04614662|BEHAVIORAL|SPARK Symptom Screening Linked to Feedback to Providers|Symptom screening three times weekly via SPARK, feedback of symptoms to healthcare providers and development of care pathways for symptom management.
40762025|NCT00378287|DRUG|rabeprazole sodium|
40762026|NCT04283279|OTHER|Virtual reality exercise|"Participants will do exercises in a virtual environment, solving tasks that require cognitive efforts and motor/balance efforts. The virtual environment/tasks will be delivered through a head-mounted display (goggles). Difficulty will progress from standing/sitting, to walking on a treadmill. The environments that will be used will be both over-the-counter environments, as well as in-house designed environments."
40762027|NCT04283279|OTHER|Vestibular rehabilitation exercise|Vestibular rehabilitation exercises focus on head and eyes movements, as well as whole-body movements. The aim is to facilitate the use of other sensory organs than the vestibular organs, which will also be relevant to persons who are not receiving sufficient sensory information from the auditory system. The exercises will progress as tolerated, under careful supervision of trained therapists.
40954941|NCT05591807|OTHER|Electroacupuncture|insert the acupuncture needle to SJ3(left side) and connect the electroacupuncture device for 15min, 2mA and 2Hz
40954942|NCT00004431|DRUG|L-baclofen|
40762028|NCT04283279|OTHER|Control|Participants will not be randomised to either of the exercise interventions, but will be adviced to stay active
40762029|NCT05160441|BIOLOGICAL|Platelet Rich Plasma Injection|"Minimum 2cc Leukocyte Poor Platelet Rich Plasma~The PRP will be prepared by drawing 60cc blood from the participant through venipuncture, spinning the blood sample in a centrifuge and then injecting the platelet rich plasma (approximately 2-5cc or max collected) into the study shoulder using ultrasound guidance. This sample will be prepared by the study provider (physician assistant or physician). Any leftover blood will be safely discarded per standard protocols."
40762030|NCT05160441|BIOLOGICAL|Corticosteroid Injection|5cc Normal Saline + 2cc 10 mg/ml Triamcinolone Acetonide (Kenalog)
40762031|NCT05160441|BIOLOGICAL|Delayed Platelet Rich Plasma Injection After Corticosteroid Injection Failure|Participants randomized to the corticosteroid injection (CSI) group who report no improvement in their pain level at the 6 week post-CSI visit will be unblinded to their study injection (CSI) and will be offered the option to stay in the study and receive Platelet Rich Plasma injection.
40762032|NCT03202173|DIAGNOSTIC_TEST|10% fluorescein|The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
40762033|NCT04738266|DIAGNOSTIC_TEST|Amyloid Cardiomyopathy|Echocardiographic red flags of Amyloid Cardiomyopathy to guide the suspicion of disease and to proceed with second level diagnostic work up including cardiac scintigraphy with bone tracers and search of monoclonal component in serum and urine
40762034|NCT04798820|OTHER|Dietary education(nutritional counselling)|Dietary education provided to gastrectomy patients by dietitian.
40954943|NCT01031381|DRUG|RAD001|RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
40954944|NCT01031381|DRUG|bevacizumab|bevacizumab will be administered intravenously (IV) once every 14 days.
40954945|NCT02842359|DRUG|Irbesartan/atorvastatin fixed dose combination|Pharmaceutical form:Tablet Route of administration: Oral
40954946|NCT02842359|DRUG|Irbesartan SR47436|Pharmaceutical form:Tablet Route of administration: Oral
40954947|NCT02842359|DRUG|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
40954948|NCT01816074|DRUG|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
40954949|NCT01816074|BEHAVIORAL|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
40954950|NCT05576675|DRUG|sufentanil + nalbuphine|sufentanil 100 μ g + nalbuphine 40 mg
40954951|NCT05576675|DRUG|Sufentanil|sufentanil 200 μ g
40954952|NCT05576675|DRUG|hydromorphone + nalbuphine|hydromorphone 10 mg+ nalbuphine 40 mg
40954953|NCT02084693|DEVICE|COMPREHENSIVE|Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
41291484|NCT03295422|PROCEDURE|RF ablation PVI plus LPAW|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
41291485|NCT01179763|OTHER|Optical coherence tomography|Spectral domain optical coherence tomography will be conducted once when patients are enrolled.
40954954|NCT03391089|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system.
40954955|NCT04672343|OTHER|Data collection|from D0 to hospital discharge
40954956|NCT04672343|OTHER|Querying the INSEE database|Vital status at 3 months and 12 months
40954957|NCT01015209|DEVICE|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
41291486|NCT04542291|DRUG|Dapagliflozin|Dapagliflozin will be provided for this trial
41291487|NCT04542291|DEVICE|BIOSENSE meters|-Being used in this trial to evaluate utility for assessing breath ketones
41291488|NCT01863758|BIOLOGICAL|Human-cl rhFVIII|Human-cl rhFVIII was provided as a freeze-dried concentrate to be reconstituted in water for injection.
41291489|NCT04606511|DIAGNOSTIC_TEST|Circumference tape measurements|centimeter and volume criterias
40954958|NCT03999593|PROCEDURE|Resection of perihilar cholangiocarcinoma|Resection of perihilar cholangiocarcinoma
40954959|NCT06005571|PROCEDURE|composite restoration repair by traditional acid etch treatment procedure and adhesive.|Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid and adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.
41291490|NCT04606511|DIAGNOSTIC_TEST|Indocyanine green lymphangiography|Presence of dermal backflow
41455112|NCT05638035|DIAGNOSTIC_TEST|Ultrasonografi, Sarcopenia measurement, Zebris|"The rectus femoris muscle thickness of the participants will be performed in B mode via USG (Mindray-UMT 200,USA) with a multifrequency (7-15 MHz) linear probe and the measurement will be reported.~TANITA for sarcopenia, hand grip strength and walking speed will be evaluated.~Gait time-distance parameters and Static balance COP parameters (COP speed (cm/s) and COP length (cm)) will be recorded using Zebris™ FDM-2."
41291491|NCT04606511|DIAGNOSTIC_TEST|bioimpedance spectroscopy|7.5 and 10 L-DEX criterias
41291492|NCT04606511|DIAGNOSTIC_TEST|Symptom score|using lymph-icf, DASH and SF-36 questionnaires
41291493|NCT04681846|PROCEDURE|Staged approach using antibiotic-cement impregnated PMMA spacer|It will be prepared in the following manner. the cement will be mixed with vancomycin in a ratio of 2 gm to each 40 gm of the spacer. The spacer should be shaped into a cylinder before its solidification. The spacer should be as big as possible to fill the whole defect, without compromising the soft tissue and skin closure. Also, cement should wrap the two ends of bone extremities on 2 or 3 centimeters.
41291494|NCT03845998|PROCEDURE|use the three-finger method|The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers.
41291495|NCT03845998|PROCEDURE|use the weight-related method|The size of the laryngeal mask airway was determined by the patient's weight.
41291496|NCT00487279|DEVICE|Defibrillator|ICD(Implantable Cardioverter Defibrillator)
41291497|NCT00487279|OTHER|Control|No Intervention
41291498|NCT03901183|OTHER|Plant-based Diet|Patients are guided to change their nutrition to a plant-based diet.
40954960|NCT06005571|PROCEDURE|Composite restoration repair by acid etching, silane solution application, and then adhesive.|Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.
41455113|NCT01664650|DIETARY_SUPPLEMENT|Genistein|
41291499|NCT00974662|DRUG|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 \& 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
41291500|NCT04608097|BEHAVIORAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
41291501|NCT04608097|BEHAVIORAL|Attention Placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
41291502|NCT02732912|DEVICE|Ear plugs|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
41291503|NCT02732912|DEVICE|Eye Mask|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
41291504|NCT02732912|DRUG|Zopiclone|This night sedation will be given to any patient requesting it, in either group
41291505|NCT00184639|DRUG|insulin detemir|
41291506|NCT02468089|DRUG|Carbepenem|
41291507|NCT02468089|DRUG|Albumin|
41291508|NCT02468089|DRUG|GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .|
41291509|NCT03321617|DRUG|Pomaglumetad methionil|metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
41291510|NCT02378428|DRUG|MIBG|
41291511|NCT01415622|DEVICE|PlasmaDerm|plasma treatment 3 times a week for 8 weeks, 45 sec / cm² of Ulcus cruris size, in addition to standard care.
41455114|NCT01664650|DIETARY_SUPPLEMENT|Placebo|
41455115|NCT06105580|PROCEDURE|Conduction system pacing|Conduction system pacing implant as a Resynchronization therapy.
41291512|NCT01415622|PROCEDURE|standard care of Ulcera crurum|standard care of Ulcera crurum: Mepithel gaze for non-exsudative wounds, Mepilex for exsudative wounds, followed by surgical hose treatment. Additionally, a standardized compression therapy with Ulcer X is applied.
41291513|NCT03940781|BEHAVIORAL|comprehensive rehabilitation|oropharyngeal rehabilitation, cardiopulmonary rehabilitation, and therapeutic exercise
41291514|NCT04524741|DEVICE|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
41291515|NCT01288378|DRUG|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
41291516|NCT05196698|OTHER|High Flow Oxygen Therapy|"HFOT will be delivered validated medical devices and established as follow:~* Patient will be acclimatized to HFOT which will aim to achieve a flow of air of 30L/min at a temperature of 34°C using dedicated nasal canula.~* Once patient acclimatized, oxygen will be entrained in the HFOT device at a flow that will aim to achieve a saturation \> 90%. An arterial blood gas will be performed with such oxygen delivery, flowrate and temperature to ensure a PaO2 ≥ 8kPa"
41291517|NCT05196698|OTHER|Long-term oxygen therapy|LTOT delivery will be performed according to French guidelines
41291518|NCT00416767|DRUG|fluorouracil|
41291519|NCT00416767|DRUG|irinotecan hydrochloride|
41291520|NCT00416767|DRUG|leucovorin calcium|
41291521|NCT01302769|DEVICE|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
41291522|NCT04666961|DRUG|Tamoxifen 20 mg|Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
41291523|NCT04666961|DRUG|Anastrozole 1Mg Tab|Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
41291524|NCT05924360|OTHER|conventional exercise program|The conventional treatment program will be applied to all participants included in the study, consisting of wand, codman, active and passive stretching exercises. This program will be administered to all patients five days a week. Wand exercises will be applied in the directions of flexion, abduction, extension, internal and external rotation, and will consist of 10 repetitions. Codman exercises will be applied in the directions of flexion, abduction, and circular, and will also consist of 10 repetitions. Active and passive stretching exercises will be applied in the directions of flexion, abduction, and external rotation, and will consist of 10 repetitions.
40954961|NCT06005571|PROCEDURE|Composite restoration repair by sandblasting first, then acid etching, silane solution application, and then adhesive.|Recurrent caries surrounding the defective restoration was removed, the old restoration surface were sandblasted, and the tooth and restoration surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was added to repair the old restoration and restore the carious cavity.
41291525|NCT05924360|OTHER|Mulligan application|The mobilization with movement technique, a part of Mulligan applications, will be performed twice a week in the directions of flexion, abduction, and external rotation.
41291526|NCT05924360|OTHER|Maitland application|Maitland Group: The Maitland application will be applied in the anterior-posterior, posterior-anterior, and caudal directions. The Maitland application will be administered at grades 2-3. Patients in this group will receive the application in five sets of 30 seconds, twice a week.
41291527|NCT05924360|DEVICE|TENS|TENS application will be administered for 20 minutes at 100Hz
41291528|NCT03223727|DIAGNOSTIC_TEST|Blood tests|Blood tests for several bone markers (see summary)
41291529|NCT06287125|DEVICE|Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147|"Laboratory investigations:~erythrocyte sedimentation rate (ESR) Serum C-reactive protein (CRP) complete blood picture (CBC) liver function tests (LFT): aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~kidney function tests (KFT): serum creatinine and blood urea. Estimated glomerular filteration rate (eGFR) by CKD-EPI Creatinine Equation (2021).~Complete urine analysis for: proteinuria, urinary casts (hyaline, granular), hematuria (RBCs/ high power field), pyuria (WBCs/ high power field).~24 hour protein in urine and Creatinine clearance. Complement 3and 4(C3,C4). Immunological investigations : Antinuclear antibody (ANA) and Anti-double stranded DNA (ds-DNA).~Serum CD147~Radiological investigations:~* Chest X-ray~* Renal Doppler~* Multi-parametric MRI"
41291530|NCT00806780|PROCEDURE|on table cholangiography|x-ray imaging of common bile duct
41291531|NCT04408521|OTHER|NEUROFEEDBACK|EEG recording during alpha-related TV viewing
41291532|NCT04408521|OTHER|CONTROL|EEG recording during passive TV viewing
41291533|NCT04815629|RADIATION|Radiotherapy|Radiotion therapy squamous cell carcinoma in cancer bladder
41291534|NCT02820610|DRUG|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
41291535|NCT02820610|DRUG|Magnesium Sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
41455116|NCT06105580|PROCEDURE|Biventricular pacing|Biventricular pacing implant
41291536|NCT02820610|DRUG|Normal saline 0.9 %|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
40954962|NCT00219973|DRUG|Bemiparin|Bemiparin 3.500 IU/day for 28 days compared to 8 days
41291537|NCT04842344|DEVICE|ECCO2R|extracorporeal carbon dioxide removal
41291538|NCT02318394|BIOLOGICAL|MEDI0562|Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
41291539|NCT05774691|DRUG|Protamine sulfate|Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin
41291540|NCT05774691|DRUG|Protamine sulfate|Selective protamine administration, in case of (threatening) bleeding
41455117|NCT02472639|DEVICE|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
41455118|NCT02472639|OTHER|No Ostom-i Alert Sensor|Patient will not use device
41455119|NCT05729854|OTHER|acupressure ( traditional and complementary medicine)|Acupressure will be applied to the shoulders, hands and legs of the women in the experimental group by the researcher.
41455120|NCT06200480|OTHER|Telephone by nurse|Patient-initiated follow-up at week 2 and 6
41455121|NCT02025660|DRUG|Mw, 0.3ml x three days sc|
41455122|NCT02025660|DRUG|Placebo|
40762035|NCT01412216|DIETARY_SUPPLEMENT|Fish Oil (Omega-3 Fatty Acids)|fish oil-4.4gm/day x 5 days
40762036|NCT01412216|DIETARY_SUPPLEMENT|Fish Oil (Omega-3 Fatty Acids)|
40762037|NCT04427111|DEVICE|Non-titratable-customized mandibular advancement device|The most comfortable protruded mandibular position situated between 60-75% of MMPV was determined according to patient response with 6mm of the vertical interocclusal dimension between maxillary and mandibular central incisors and registered. The upper and lower acrylic resin splints were secured to each other in the posterior region with auto polymerizing acrylic resin and NTC-MADs were obtained. The patients were instructed to wear their non-titratable-customized mandibular advancement device every night.
40762038|NCT03670433|OTHER|Cost analysis of medication reconciliation|"1. The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).~2. The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS."
40762039|NCT02114944|DEVICE|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
40762040|NCT02114944|DEVICE|CPAP|Patient treated, as per attending physician's decision, with CPAP
40762041|NCT02114944|DEVICE|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
40762042|NCT02114944|DEVICE|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
40762043|NCT04939103|DEVICE|TRUS-FNA|Transrectal Ultrasound Guided Fine Needle Aspiration for rectal tumor
40762044|NCT04805528|RADIATION|Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS)|Twice weekly ALTENS therapy for 12 weeks
40762045|NCT06570382|OTHER|Videos: Taste messaging focused|Participants in this intervention will watch the taste focused videos.
41135264|NCT03673566|DEVICE|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
40762046|NCT06570382|OTHER|Videos: Health messaging focused|Participants in this intervention will watch the health focused videos.
40762047|NCT02748174|BEHAVIORAL|Audio Files|Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
41135265|NCT02022670|DRUG|Placebo|Sugar pill manufactured to mimic sodium nitrite capsules
41135266|NCT02022670|DRUG|Sodium Nitrite|80 mg/d or 160 mg/d
41135267|NCT03029299|DEVICE|FilmArray RP EZ|Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
41135268|NCT02693288|PROCEDURE|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
41135269|NCT04165772|DRUG|TSR-042 or Dostarlimab|Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
41455123|NCT06126939|BEHAVIORAL|Educational training based on the Denver model|In addition to routine health guidance, one-to-one parent classes were conducted to guide parents to interact with children once a week for 1h each time; A group leader was assigned to supervise the formulation of the intervention plan and ensure the quality of the intervention. The intervention lasted for 3 months
41455124|NCT00908180|BIOLOGICAL|alemtuzumab|
41455125|NCT00908180|BIOLOGICAL|donor lymphocytes|
41455126|NCT00908180|DRUG|carmustine|
41455127|NCT00908180|DRUG|cyclosporine|
41455128|NCT00908180|DRUG|cytarabine|
40762048|NCT02248493|DRUG|Paracetamol|
40762049|NCT02248493|DRUG|Placebo (for paracetamol)|
40762050|NCT02248493|DRUG|Ketoprofen|
40762051|NCT02248493|DRUG|Tramadol|Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
40762052|NCT02248493|DRUG|Morphine|administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
40762053|NCT04424251|DRUG|Experimental: stage I：HSK21542 0.4 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
40762054|NCT04424251|DRUG|Experimental: stage I：HSK21542 1 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
40762055|NCT04424251|DRUG|Experimental: stage I：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
40762056|NCT04424251|DRUG|Experimental: stage I：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
40762057|NCT04424251|DRUG|Experimental: stage II：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
40762058|NCT04424251|DRUG|Experimental: stage II：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
40762059|NCT04424251|DRUG|Placebo|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
41455129|NCT00908180|DRUG|etoposide|
41455130|NCT00908180|DRUG|melphalan|
41291541|NCT05567978|PROCEDURE|pupillometry index|Admission to the intensive care unit, measurement of pupillometry index every 4 hours for 7 days or at extubation of brain damaged patients
41291542|NCT00122772|RADIATION|Radiotherapy|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy"
41291543|NCT00122772|RADIATION|Radiotherapy|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy"
41291544|NCT00122772|RADIATION|Radiotherapy/Cisplatin|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly"
41291545|NCT00122772|RADIATION|Radiotherapy/Cisplatin|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly"
41291546|NCT03851341|COMBINATION_PRODUCT|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
41291547|NCT03851341|COMBINATION_PRODUCT|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
41291548|NCT00740506|BEHAVIORAL|Frequency of Intercourse|
41291549|NCT06049420|BEHAVIORAL|Lifestyle counseling and coaching|Each participant will be provided with personalized exercise therapy that is best suited for their personal goals and disease states. Participants in this study will be encouraged to establish accountability through setting SMART goals, and through monitoring their activity using wearable fitness technology provided to them. This program will also aim to create a sense of community as group activity classes will be available for those that wish to attend. Individualized exercise/physical activity prescriptions will be provided and discussed.
41291550|NCT02564822|PROCEDURE|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
41291551|NCT03488810|OTHER|Radiation Therapy|Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
41291552|NCT03488810|DRUG|Apalutamide|240 mg PO daily, started the same day as the first LHRHa injection, for 6 months
41291553|NCT03488810|DRUG|Luteinising Hormone Releasing Hormone analog agonist (LHRHa)|2 injections of a three-monthly LHRH agonist depot
41455131|NCT00908180|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40762060|NCT04160598|DRUG|IV infusion|Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
41135270|NCT04165772|DRUG|capecitabine or 5-FU|Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
41135271|NCT04165772|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
41291554|NCT03488810|DRUG|Non-steroidal anti-androgen|Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
41455132|NCT02300168|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive procedure which consists in creating a narrow tube-like stomach, designed to decrease appetite by reducing the ability of the stomach to distend.
41455133|NCT04728620|OTHER|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention involves a new feature embedded with the My Health At Vanderbilt (MHAV) native app (on Epic's MyChart platform) for mobile devices that allows patients to: (a) receive notifications when the patient is due for certain types of diabetes monitoring and preventative care and (b) initiate an order for the care. Automated notifications will be sent to patients if, according to the evidence-based guidelines, the patients are due for a hemoglobin A1C blood test, microalbumin urine test, diabetes eye exam, or pneumonia vaccination. Once notified patients can initiate orders for the care within the MHAV app. The patient will receive confirmation when the order has been processed and will be provided instructions to receive the relevant care.
41291555|NCT03996018|OTHER|T-cell lymphocyte responses|T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
40762061|NCT04160598|DRUG|intrathecal fentanyl|10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
40762062|NCT02361697|OTHER|DTI-MRI|MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
40762063|NCT06124300|DIETARY_SUPPLEMENT|Female Hormone Balance Supplement|The product contains: Myo-Inositol D-Chiro Inositol Folic Acid Vitamin D Vitamin B12
41291556|NCT01943539|DEVICE|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
40762064|NCT03766399|DRUG|AZD0449|Participants will receive single inhaled AZD0449 nebulizer suspension and single IV dose of AZD0449 solution.
40762065|NCT03766399|DRUG|Placebo|Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).
40762066|NCT02295579|OTHER|lactobacillus (EcoVag)|Probiotic human lactobacillus (L. gasseri and L rahmnosus)
41291557|NCT01441167|BIOLOGICAL|PfSPZ|
41291558|NCT01260181|DRUG|Erlotinib|Erlotinib 150 mg tablet will be given orally daily.
41291559|NCT04988607|DRUG|Osimertinib|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle
41291560|NCT04988607|DRUG|Bevacizumab|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a
40954963|NCT06298331|OTHER|Aerobic Exercise|Aerobic exercise training will be given for 8 weeks, 3 days a week on the treadmill in the clinic under the supervision of a physiotherapist, and 8 weeks, the other 2 days a week outside the clinic. The duration of the walking session is 50 minutes (5 minutes warm-up - 40 minutes load - 5 minutes cool down). Walking speed in the clinic will be determined according to the Heart Rate Reserve(HRR) method. In the warm-up and cool-down phases in the clinic, the walking speed will be adjusted in the range of 20-40% of HRR, while in the loading phase it will be adjusted in the range of 40-60% of HRR. Heart rate will be monitored with a monitor that detects heart rate by hand contact on the treadmill. Outside the clinic, walking speed will be determined according to the level of fatigue perceived on the Borg Scale. Outside the clinic, walking speed will be regulated as 10-12 (light) on the Borg scale during warm-up and cool-down phases and 12-14 (slightly difficult) during the loading period.
40954964|NCT06298331|OTHER|Abdominal Massage|Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.
40954965|NCT06298331|OTHER|Patient Education|Patient education will include information on the definition of constipation, causes of constipation, how constipation occurs, factors affecting constipation, concepts related to constipation, treatment options for constipation, and lifestyle recommendations for constipation, including increasing fluid intake, regulating nutrition, increasing physical activity, and regulating toilet habits.
40954966|NCT03237624|DEVICE|Functional Chitosan Chewing Gum|Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.
40954967|NCT03237624|DEVICE|Control Chewing Gum|Control chewing gum device does not have food additive chitosan in its composition.
40954968|NCT03237624|BEHAVIORAL|Oral hygiene measures|Patients will be given instructions on how to brush and floss routinely (twice per day)
40954969|NCT04053231|OTHER|liver resection|all type of liver surgical procedures
40954970|NCT05476406|OTHER|äKwä skincare system products|The skincare product system tested in this study was äKwä 6-step skincare system from 4Life Research USA, LLC ( https://www.4life.com/6613461/page/äKwä). Product directions state to use the following products morning and night in sequential order: First Wave Oil-to-Foam Cleanser, Glacier Glow Four-Way Toner, Precious Pool Vitamin Essence, Ripple Refine Eye Cream, and RainBurst Moisture Cream.
40954971|NCT05476406|OTHER|competitor products (control)|Participants use whatever their normal daily routine of skincare products, which are commercially available competitor products from the marketplace.
40954972|NCT03598543|OTHER|no intervention|no intervention, this is an obervational study.
40954973|NCT02351999|DEVICE|TSP Crosser Transseptal Access System|for transseptal puncture, left atrial access and catheter navigation.
40954974|NCT02704260|GENETIC|GENETIC ANALYSIS|prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
41291561|NCT04988607|DRUG|Osimertinib|Osimertinib is dosed orally at 80 mg once per day
41291562|NCT00088010|DRUG|Arzoxifene|20mg, oral, tablet, once a day for 36 months
41291563|NCT00088010|DRUG|Placebo|oral, tablet, once a day for 36 months
41291564|NCT00363025|PROCEDURE|Two post-remission strategies|
41291565|NCT00363025|DRUG|Idarubicin versus daunorubicin|
41291566|NCT04549038|OTHER|12-16 hour nutrition|Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.
40954975|NCT05384964|OTHER|Questionnaire|Questionnaire completed by ICU nurses
40954976|NCT04930991|DRUG|Omeprazole|Treatment will consist of Omeprazole 2 weeks prior to surgical therapy of pancreatectomy.
40954977|NCT04941859|BEHAVIORAL|acupoint massage and application|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
41291567|NCT04523792|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
41291568|NCT05767957|OTHER|Rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist using conventional technique alone.
41291569|NCT05767957|OTHER|Cognitive-behavioral therapies in addition to rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist according to conventional technique, with the addition of techniques from cognitive-behavioral therapies.
41291570|NCT03935477|DEVICE|WellBeing catheter|Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension
41291571|NCT00865254|BEHAVIORAL|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
41291572|NCT00865254|BEHAVIORAL|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
41291573|NCT00865254|BEHAVIORAL|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
41291574|NCT03288584|DRUG|Tocilizumab (Actemra®)|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
40954978|NCT03585062|DRUG|S1,|S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
40954979|NCT03585062|DRUG|Paclitaxel-albumin|Paclitaxel-albumin is a drug which showed a survival benefit in Pancreatic Cancer when combined with S1
40762067|NCT04576754|DEVICE|WB001|The WB001 treatment consists of PPD-specific psychoeducational lessons and CBT-specific skills or tools. The lessons teach PPD-specific information to normalize and contextualize postpartum experiences, as well as provide information on effective mood management and mental health promotion in the context of having recently given birth. Patients complete up to 30 psychoeducational lessons. In addition, patients access and apply core CBT-based tools upon endorsing a negative mood. These tools are core to CBT and are considered transdiagnostic. Examples include thought challenging, behavioral activation, mindfulness, and self-care.
41455134|NCT05582343|BEHAVIORAL|MINDBODYSTRONG™|"Digitalized MINDBODYSTRONG™ is designed for self-paced weekly use via an online platform.~MINDBODYSTRONG© Session Content~1. Thinking, feeling, \& behaving, The ABCs of CBT, Mindfulness Skills Building: Positive self-talk/The ABCs~2. Self-esteem \& positive self-talk, Intentional gratitude, Managing change Skills building: Self-esteem \& positive self-talk~3. Stress, Healthy coping, Abdominal breathing Skills Building: Managing stress~4. Problem solving, Setting goals, Steps to problem solving Skills building: Strategies to overcoming barriers~5. Dealing w/ emotions in healthy ways, Using guided imagery, Coping strategies, Effective communication Skills building: Dealing with emotions~6. Coping w/ stressful situations/valuable sleep Skills building: Coping w/ stressful situations~7. Distress tolerance \& added emotional regulation skills Skills bulding: RAIN practice, Self-love skill, Distracting using ACCEPTS~8. Putting it all together for a healthy YOU!"
41455135|NCT03224143|BEHAVIORAL|Doll Therapy Intervention|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
41455136|NCT03224143|BEHAVIORAL|active control group (SI)|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
41455137|NCT03581630|DRUG|naltrexone/bupropion|Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
41455138|NCT03581630|BEHAVIORAL|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
41455139|NCT02119637|DEVICE|Transcranial magnetic stimulation (TMS)|1 Hz rTMS for 20 minutes. TMS sessions were separated by at least 24 hours.
41455140|NCT02119637|DEVICE|MRI|Anatomical MRI, resting state MRI and functional MRI using gentle brushing and finger movement
41455141|NCT01299935|BEHAVIORAL|Transcendental Meditation|The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.
41455142|NCT01299935|BEHAVIORAL|Health Education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
41455143|NCT00890916|DEVICE|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
41455144|NCT00361049|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
41455145|NCT00361049|GENETIC|fluorescence in situ hybridization|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
41455146|NCT00361049|OTHER|immunoenzyme technique|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
40954980|NCT00676338|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
41291575|NCT03288584|DRUG|Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
40954981|NCT00676338|DRUG|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
40954982|NCT00676338|DRUG|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
40954983|NCT00676338|DRUG|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
40954984|NCT06410599|DRUG|Ketamine|Two ketamine hydrochloride (Ketamin Inresa 2 ml) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Ketamine hydrochloride (Ketamin Inresa 2 ml) is applied continuously over a time span of 40 minutes with a subanesthetic dosage of 0.5 mg per kg body weight.
40954985|NCT06410599|DRUG|Placebo|Two times placebo (Isotone E NaCL 0.9 %) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Placebo is applied continuously over a time span of 40 minutes.
40954986|NCT06410599|BEHAVIORAL|CBASP|In addition to standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements, patients in the CBASP conditions receive one CBASP group session (50 min) per week for 12 weeks. The single sessions (one 50 min and one 25 min per week) contents are CBASP-specific.
40954987|NCT06410599|BEHAVIORAL|TAU|Standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements.
40954988|NCT04250922|DRUG|LAM561|"Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment."
40954989|NCT04250922|DRUG|TMZ|"TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles."
40954990|NCT04250922|RADIATION|RT|During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
40954991|NCT02173223|DRUG|Rho-Kinase Inhibitor|
40954992|NCT04368676|OTHER|Sudarshan Kriya Yoga (SKY)|The SKY program is a standardized, easy to learn sequential breathing yoga consisting of regulated breathing techniques followed by a timed rhythmic breathing practice. Participants will learn various exercises including rhythmic breathing, gentle yoga, and guided meditation.
40954993|NCT04368676|OTHER|Health Enhancement Program|HEP is a structured group program designed to help participants with information and instruction how to lead a healthier life. Participants will be provided psychoeducation and support regarding healthy active living using techniques like music therapy, diet control, exercise, and monitoring these via journaling.
40954994|NCT00736424|DEVICE|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
40954995|NCT06374212|DRUG|Anifrolumab|900mg maintenance dose every 4 weeks for 12 weeks then 600mg loading dose every 4 weeks until week 20
40954996|NCT00622284|DRUG|Placebo identical to BI 1356 5mg|Placebo tablet once daily
40954997|NCT00622284|DRUG|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
40954998|NCT00622284|DRUG|BI 1356|5mg, once daily in the morning for 104 weeks
40954999|NCT00622284|DRUG|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
40955000|NCT03095612|DRUG|Selinexor|Selinexor once weekly oral or twice weekly oral
40955001|NCT03095612|DRUG|Docetaxel|Docetaxel once every 3 weeks (75 mg/m2 IV)
41455147|NCT00361049|OTHER|immunohistochemistry staining method|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
41455148|NCT00361049|OTHER|laboratory biomarker analysis|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
40955002|NCT05664490|BEHAVIORAL|Youth Friendship Bench SA|The intervention includes: 5 individual counseling sessions; one optional in-person or WhatsApp-based group counseling session; optional remote counseling sessions; and optional one-way SMS messages to provide reminders about upcoming visits. During the initial session, participants will meet with the trained counselor to discuss mental health challenges, identify problems in their life that affect their mental health and PrEP use, generate alternative solutions, make decisions about the alternatives, and collaboratively decide on a plan to implement the solutions. During follow-up counseling sessions, participants will discuss progress in implementing solutions to address the problems they identified in prior sessions with the lay counselor. They will also discuss any other mental health challenges and problems in their life that affect their mental health and PrEP use which they would like to address.
40955003|NCT00985023|PROCEDURE|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
40955004|NCT00985023|PROCEDURE|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
40955005|NCT02620657|OTHER|Non interventional study|Non interventional study
40955006|NCT02858960|DEVICE|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen in COPD patients involved in a Pulmonary Rehabilitation program.
40955007|NCT02858960|DEVICE|The Venturi Mask|Exercise capacity testing according to the oxygen Mask Venturi in COPD patients involved in a Pulmonary Rehabilitation program.
40955008|NCT06436274|BIOLOGICAL|GARDASIL®9|GARDASIL®9 or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
40955009|NCT06436274|BIOLOGICAL|Menveo®/Menactra®|Menveo®/Menactra® or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
41291576|NCT03288584|DRUG|Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
41291577|NCT05757999|DRUG|Magnesium Sulphate|A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) will be administered to patients 10 min. before induction of anesthesia.
41291578|NCT05757999|DRUG|Saline|The patients will be pretreated with an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min before induction of anesthesia.
41291579|NCT02393651|DEVICE|tDCS|Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
41291580|NCT06513793|BEHAVIORAL|Roots and Shoots|Four-week intervention involving a self-help guidebook to improve mental wellbeing.
40955010|NCT05475561|PROCEDURE|Ultrasound guided Pecto-intercostal- fascial plane block|The probe of the ultrasound will be placed at 2 cm lateral to the lateral sternal border at 5th and 6th rib. On the surface plane subcutaneous tissue is identified, while Pectoralis major muscle, Intercostal muscles and ribs are seen in intermediate plane and lung along with pleura are identified in deep plane. A 22-gauge, 80-mm short bevel echogenic needle is used and advanced in in-plane manner, in a caudal-to-cranial direction, until the tip of the needle is located in the fascial plane between the pectoralis major and internal intercostal muscle, where the local anesthetic will be injected.
41455149|NCT00361049|PROCEDURE|in vitro-treated bone marrow transplantation|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
41455150|NCT00361049|PROCEDURE|management of therapy complications|Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.
41455151|NCT04999280|OTHER|Fiber Croissant (FIBCRO) Group|Subjects will consume for 2 weeks at breakfast a fiber-enriched sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
41455152|NCT04999280|OTHER|Control Croissant (CONCRO) Group|Subjects will consume for 2 weeks at breakfast a sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
41455153|NCT04197908|DEVICE|EUS-guided gallbladder drainage (EGBD)|As listed in the arms description
41455154|NCT00743535|PROCEDURE|Transobturatory correction of anterior defect plus TOT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle"
41291581|NCT06513793|BEHAVIORAL|Waiting list|Four-week waiting list period involving treatment as usual.
41291582|NCT03393962|BIOLOGICAL|OC-EIEs|2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.
41291583|NCT00882869|DRUG|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
41291584|NCT00882869|DRUG|Sorafenib|Sorafenib will be administered at 400 mg BID every day
41291585|NCT00193362|DRUG|Paclitaxel|
41291586|NCT00193362|DRUG|Carboplatin|
41291587|NCT00193362|DRUG|Gemcitabine|
41291588|NCT00193362|DRUG|Vinorelbine|
41291589|NCT01713400|DRUG|Ustekinumab|One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
40762068|NCT04576754|DEVICE|Educational|The Comparison Condition provides educational only material about various mental and physical topics, delivered in an interactive smartphone application that is accessible anytime of day.
40762069|NCT05286112|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|10 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.
40762070|NCT05286112|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
40762071|NCT06518928|OTHER|Artificial Intelligence assisted sperm selection|SiD software for sperm selection
40762072|NCT06569459|DRUG|Trilaciclib Injection [Cosela]|Chemoradiotherapy and immunotherapy with Trilaciclib in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
40762073|NCT06569459|DRUG|Placebo|Chemoradiotherapy and immunotherapy in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
40762074|NCT01531036|DEVICE|3D Ultrasound elastography by means of shear wave propagation into breast tissue|Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
40762075|NCT01055119|DIETARY_SUPPLEMENT|Omega-3 fatty acids|duration: 4 month
40762076|NCT03177798|DRUG|Icatibant|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
40762077|NCT03177798|DRUG|Placebo|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
40762078|NCT01987999|DIETARY_SUPPLEMENT|Acetogenins|
40762079|NCT06570109|OTHER|Frailty|defined as weigh loss (\>4.5 kg in one year), exhaustion, slow gait speed (below 20th percentile for sex and height), weakness (handgrip strength below 20th percentile for sex and BMI), and low physical activity (by the Physical Activity Scale for the Elderly). The presence of three or more out of five criteria is defined as frailty while one to two criteria is prefrailty
40762080|NCT06564688|DIAGNOSTIC_TEST|Swallowing function test|"The oral function score assesses the oral functional performance of chewing in all participants.~The Functional oral feeding Scale (FOIS) was used to assess the ability of all participants to eat.~The standardized swallowing assessment (SSA) was used to assess the global swallowing function of all participants."
40762081|NCT00421967|DRUG|Ropivacaine, Ketorolac, adrenaline|Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
41291590|NCT01713400|DRUG|Placebo|Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
40762082|NCT00421967|DRUG|Ropivacaine Ketorolac|Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
40762083|NCT02298946|DRUG|AMP-224|10mg/kg on day 1 then every 14 days for a total of 6 doses.
40762084|NCT02298946|RADIATION|Stereotactic Body Radiation Therapy(SBRT)|Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days
40762085|NCT02298946|DRUG|Cyclophosphamide|200mg/m(2) IV on day 0.
40762086|NCT00621114|DEVICE|GamCath® central venous catheter|Choice of central venous catheter type
40762087|NCT00621114|DEVICE|GamCath Dolphin® Protect central venous catheter|Choice of central venous catheter type
40762088|NCT05679557|OTHER|Perioperative geriatric assessment and intervention|The intervention will comprise a preoperative, thorough geriatric, multidisciplinary assessment (CGA) and tailored interventions, focused on optimizing health issues of expected importance in further course of surgery. Furthermore, postoperative ward rounds by a geriatric team will be conducted. Thus, the course of treatment for each patient will be a close interdisciplinary collaboration.
40762089|NCT05841771|DRUG|Venetoclax|"Participants will receive maintenance therapy with venetoclax and azacitidine or decitabine after allogeneic stem cell transplantation.~Azacitidine will be administered once daily subcutaneously (32mg/m2/d) on days 1-5, and venetoclax will be administered once daily orally (400mg/day) on days 1-7. If the patient is refractory or allergic to azacitidine, they will receive decitabine. Decitabine will be administered intravenously (5mg/m2/d) on days 1-5. If the patient is treated with CYP450 inhibitors(such as posaconazole or voriconazole), the dose of venetoclax will reduce to 100 mg once daily on days 1-7. Maintenance therapy will start from the 60th to 120th days after allogeneic hematopoietic stem cell transplantation and repeat every 28 days for up to 10 cycles within the first year after transplantation."
41291591|NCT01713400|DRUG|Tacrolimus (TAC)|Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.
41455155|NCT00743535|PROCEDURE|Transobturatory correction of anterior defect plus TVT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
41455156|NCT04228822|OTHER|Low carbohydrate diet|25-35% of carbohydrates from total energy intake
41455157|NCT03069976|DRUG|Metronidazole|Flagyl x 14 days.
41455158|NCT03515707|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
41455159|NCT03515707|DRUG|Busulfan|Given IV or oral
40762090|NCT05841771|DRUG|Azacitidine or decitabine|azacytidine 32mg/m2 or decitabine 5mg/m2
40762091|NCT06041139|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
40762092|NCT06041139|DIAGNOSTIC_TEST|Defocus Curve|Measurement of visual acuity performed from +1.00 to -4.00 in 0.50 diopter steps and with +0.25 and -0.25 added.
40762093|NCT06041139|DIAGNOSTIC_TEST|Halo and Glare testing|Measurement to quantify degree of visual loss caused by either halo and/or glare.
40762094|NCT06041139|OTHER|Patient Questionnaires|Patients will complete a series of questionnaires to record self-reported visual disturbances, visual acuity satisfaction, level of spectacle independence and any issues with glare, halos, and/or starbursts.
40762095|NCT02340546|DEVICE|cardiac resynchronization therapy|cardiac resynchronization by means of biventricular pacing via left ventricular pace from coronary sinus veins combined with conventional any-site right ventricular pace
40762096|NCT04111601|DEVICE|Blue light imaging|Advanced virtual chromoendoscopy
40762097|NCT01520103|DRUG|Vinorebine, Everolimus|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
40762098|NCT01520103|DRUG|Vinorelbine|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
40762099|NCT05039489|DRUG|Antipsychotic drugs|Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
40762100|NCT05039489|DEVICE|cTBS（the left temporoparietal cortex as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
40762101|NCT05039489|DEVICE|cTBS （the left cerebellum Crus II as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
40762102|NCT00467493|DRUG|Anastrozole|
40762103|NCT04903769|BEHAVIORAL|Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)|SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.
41291592|NCT01713400|DRUG|Sirolimus|Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
41291593|NCT03344497|OTHER|VC Group|VC (Conventional Consultation/Video) Group
41291594|NCT01227915|DRUG|Tobracort|tobramycin 0.3% + dexamethasone 1%
41291595|NCT01227915|DRUG|Tobradex|tobramycin 0.3% + dexamethasone 1%
41455160|NCT03515707|DRUG|Etoposide|Given IV
41455161|NCT03515707|OTHER|Laboratory Biomarker Analysis|Correlative studies
41455162|NCT05416424|OTHER|LIFE program|During the nutritionist visits, subjects will be asked to discuss and evaluate their current diet and will be given recommended dietary changes. The recommended dietary changes include focusing on eating nutrient dense foods, staying consistent with the timing of meals, limiting added sugars, aiming to have balanced meals and snacks, being a mindful eater, and aiming to drink approximately 2 liters of water a day. Additionally, they will review the nutrition survey with the registered dietician. During the office visits with a doctor, subjects will be given exercise counseling. They will be asked to do 150 minutes per week of moderate intensity aerobic activity
40955011|NCT05475561|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. Three muscles trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Local infiltration with 2% of lignocaine at the site of needle insertion will be done. Using in-plane approach a 22 G short bevel needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro dissection below the muscle plane. A 20 ml of 0.25% plain bupivacaine will be injected on each side.
40955012|NCT05475561|DRUG|Bupivacain|local anesthetic
40955013|NCT03722069|OTHER|Low sodium diet|Patients received low sodium diet (3g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
40955014|NCT03722069|OTHER|Normal sodium diet|Patients received normal sodium diet (7g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
40955015|NCT02272426|BEHAVIORAL|CARET|Combined Aerobic and Resistance Exercise Training
40955016|NCT02272426|BEHAVIORAL|CTI|Cognitive Training Intervention
40955017|NCT02272426|BEHAVIORAL|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
40955018|NCT02272426|BEHAVIORAL|Sham CTI|Sham Cognitive Training Intervention
40955019|NCT05766852|BEHAVIORAL|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
40955020|NCT01596478|BEHAVIORAL|Treatment as Usual|Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
40955021|NCT01596478|BEHAVIORAL|Cognitive Motivational Behavior Therapy|Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
40955022|NCT01596478|BEHAVIORAL|12-week wait list|Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
40955023|NCT04905758|PROCEDURE|platform switching|reduced implant abutment interface
40955024|NCT04905758|PROCEDURE|platform amtching|matched implant abutment interface
40955030|NCT03921073|DRUG|T-VEC|Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.
40955031|NCT06361433|DRUG|HUFF-01|autologous MSC combined with scaffold
40955032|NCT03596008|DIETARY_SUPPLEMENT|Active drink|The freeze-dried strawberry powder (25 g) in active drink
40955033|NCT03596008|DIETARY_SUPPLEMENT|Placebo drink|Placebo drink
40955034|NCT03851757|DEVICE|waist-shaped interdental brush|use four times each per interdental space
40955035|NCT03851757|DEVICE|cylindric interdental brush|use four times each per interdental space
40955036|NCT04803461|DIAGNOSTIC_TEST|serum and urinary catecholamines|estimation of level of serum and urinary catecholamines before and after excimer light treatment for patient with non segmental vitiligo.
40955037|NCT04537429|DRUG|Eptinezumab|up to four iv infusions of eptinezumab
40955038|NCT01364077|DRUG|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
40955039|NCT01364077|DRUG|Placebo|Matched placebo
40955040|NCT03863665|DEVICE|A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci|Telemetric home monitoring is a promising strategy to facilitate home BP monitoring after stroke, which should improve adherence and optimize medication to better control BP. Telemetry allows patients with hypertension to monitor their own BP and automatically send the information to a secure website, available to their clinicians to monitor and adjust their treatment.
40955041|NCT03217357|DEVICE|Transcranial stimulation in direct current|tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
40955042|NCT05106387|OTHER|Noninterventional|No investigational treatment will be given in this noninterventional extension study
40955043|NCT03078244|OTHER|N/A, observational study|
40955044|NCT04749875|OTHER|blood sample|sampling of blood for research during routine care
40955045|NCT04633577|DRUG|Lidocaine IV|A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.
40955046|NCT04633577|DRUG|0.9% normal saline|0.9% normal saline
40955047|NCT00809354|DRUG|NSAID|IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
40955048|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
40955049|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
40955050|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48)
40955051|NCT00809354|DRUG|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
40955052|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 48)
40955053|NCT00809354|DRUG|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
41455163|NCT03773653|BEHAVIORAL|BMT to be combined with BAT|Specifically, the participants will first receive 40 to 45 minutes of bilateral robotic priming using the BMT. After the robotic priming, participants will receive another 40 to 45 minutes training in tasks focusing on bilateral symmetric movements of both ULs.
40762104|NCT06413069|DIETARY_SUPPLEMENT|Raw whole almonds|Subjects will be supplemented with 60 grams of almonds (treatment) or left untreated (no-nut group) for 16 weeks. Patients of the no-nut group will receive 6,7 kgs of almonds after finishing the study, supporting their compliance as untreated group.
40955054|NCT01332643|GENETIC|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
40955055|NCT03999177|BEHAVIORAL|Kinect-TOLF Training System|This system will teach patients to perform the lymphatic exercises correctly. Like playing the video games, patients follow the avatar model in the video to perform the lymphatic exercises. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback to the user, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly. Patients will be asked to conduct two types of usability testing: heuristic evaluation and end-user testing.
40955056|NCT00194948|DRUG|escitalopram|
40762105|NCT04850963|DEVICE|Transcranial direct current stimulation (Anodal tDCS) + dual-task training|"anodal tDCS 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
40762106|NCT04850963|DEVICE|Transcranial direct current stimulation (tDCS dualsite) + dual-task traning|"tDCS dualsite 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
40762107|NCT04850963|DEVICE|Transcranial direct current stimulation sham + dual-task training|"tDCS sham 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
40762108|NCT05057546|DRUG|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
40762109|NCT00000354|DRUG|Lofexidine|
40762110|NCT05686980|DRUG|ABBV-552|Oral Capsule
40762111|NCT06365346|BEHAVIORAL|Dyadic video-assisted gamified group-based music breathing therapy|Dyadic video-assisted gamified music breathing therapy comprising six 75-min weekly sessions delivered in a group size of 6-8 (first sessions: parents only; reminding 5 sessions: parent-child dyads).
40762112|NCT06365346|BEHAVIORAL|Online educational modules|Six weekly educational modules on ADHD and its management via email.
40955057|NCT00194948|BEHAVIORAL|interpersonal psychotherapy|
40955058|NCT02206542|DEVICE|Upper limb rehabilitation robot|Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.
40955059|NCT02206542|OTHER|Physical therapy|
41291596|NCT01771094|BEHAVIORAL|Effect of sweetness of the beverage in thirst sensation|"Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min."
41291597|NCT00295399|DEVICE|The Jerusalem Telerehabilitation System|
41291598|NCT00514449|DRUG|Valacyclovir|1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
41291599|NCT00514449|DRUG|Placebo|2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
41291600|NCT00745316|DRUG|Tonapofylline|Oral Tonapofylline - 2 capsules bid
41291601|NCT00745316|DRUG|Placebo|Oral placebo - 2 capsules bid
41291602|NCT05718076|PROCEDURE|cataract surgery|Phacoemulsification combined trifocal lens implantation
41291603|NCT01411397|OTHER|SURGERY|REPAIR OF STRANGULATED HERNIA with intestinal resection
41291604|NCT01411397|OTHER|mesh repair|mesh repair of strangulated hernia without resection
41291605|NCT04579393|DRUG|Placebo|Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
41455164|NCT03773653|BEHAVIORAL|BMT to be combined with MT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of mirror therapy.
41455165|NCT03773653|BEHAVIORAL|BMT to be combined with IOT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of impairment-oriented training.
41291606|NCT04579393|DRUG|fostamatinib|The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.
41455166|NCT00028873|DRUG|docetaxel|
40955060|NCT02206542|DEVICE|Electroacupuncture|
40955061|NCT05345977|DEVICE|eMotiph|Mobile application for patients with schizophrenia.
40955062|NCT06169046|DRUG|Clenbuterol|tablets
41291607|NCT00267254|DRUG|torcetrapib/atorvastatin|
40955063|NCT06169046|DRUG|Placebo|tablets
41291608|NCT00267254|DRUG|simvastatin|
41291609|NCT02267785|OTHER|Skill-Based Exercise|The skill-based exercise program is designed to improve skilled function, fine and gross- motor body coordination. The intervention will be focused on acquisition and improvement of complex movements for the whole body and include the following general categories of activities: (1) balance, (2) eye-hand coordination, (3) leg-arm coordination; 4) reaction time to moving objects/persons; (5) dynamic gait and 6) functional activity performance. The treating therapist will direct both general principles of progression and progression specific to each category.
41291610|NCT02267785|OTHER|Aerobic Exercise|The aerobic cardiovascular exercise will consist of 36 1-hour sessions performed 3 times weekly over 12 weeks. Aerobic exercise will consist of cycling on a recumbent stationary bicycle. Each session will begin and end with gentle stretching. Continuous cycling will be performed for 45-50 minutes, with the first and last 5 minutes designated as warm-up and cool-down periods. The intensity of the middle 30 minutes of cycling will be increased progressively from an initial target of 50% maximum heart rate (HR) during week 1 to 75% of maximum HR by week 12. The initial intensity will be set at 50% of maximum HR. Participants will be encouraged to cycle as fast as they can, with a goal of maintaining 90 revolutions per minute (RPM) throughout the middle 30-minute period. Pedaling resistance will be kept low throughout all sessions. Measures of heart rate via heart rate monitors, blood pressure, RPM, and rate of perceived exertion will be recorded at 5-minute intervals.
41291611|NCT02267785|OTHER|Social Contact|The control Social Contact group will consist of an equal amount of social contact as the exercise group. Subjects will have weekly visits at the University of Southern California with the study coordinator. The goal is for 3 hours of social contact every week for a total of 36 hours over 12 weeks. Activities scheduled for the social contact visits will include: (1) support group interactions and (2) social outings such as a trip to a museum, local café for lunch or dinner; (3) book club; (4) sports event. Support group interaction can include discussions among patients and caregivers, presentations from experts in various aspects of PD. They will be instructed to continue with their usual level of activity but refrain from beginning new exercise activities during the study period.
41291612|NCT03141801|DEVICE|DELFI PTS Personalized Tourniquet System for Blood Flow Restriction Training|cuff is inflated to 80% of an individuals limb occlusion pressure
41291613|NCT03141801|OTHER|Eccentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70% of the 1 repetition maximum
41455167|NCT00028873|DRUG|laniquidar|
41455168|NCT00028873|DRUG|paclitaxel|
41291614|NCT03141801|OTHER|Concentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an concentric leg press exercise performed at 70% of the 1 repetition maximum
41291615|NCT00770185|DRUG|ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
41291616|NCT00770185|GENETIC|gene expression analysis|
41291617|NCT00770185|OTHER|immunohistochemistry staining method|
41291618|NCT00770185|OTHER|laboratory biomarker analysis|
41291619|NCT02398123|OTHER|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
41291620|NCT02398123|OTHER|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
41291621|NCT02398123|DRUG|Bupivacaine|
41291622|NCT01410019|OTHER|Gene transfer|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
41291623|NCT06214949|DEVICE|Personalized Repetitive Transcranial Magnetic Stimulation|Treatment will consist of 15 sessions over 3-4 weeks. Specifically, the active or sham treatments will be conducted \~5 times a week during the treatment phase of the study. The treatment protocol parameters (stimulus location, frequency, duration, and intensity) will be derived from the PrTMS software algorithm which incorporates clinical inputs from neurocognitive surveys and quantitative EEG analysis. The mechanical parameters will adhere to the recommended PrTMS parameters for pain treatment: figure of 8 coil that produces biphasic stimulatory pulses to the central zone cortex, frontal zone cortex, Broca's area, and frontal pre-cortex areas at a stimulation depth of 2 cm. Treatment parameters will be unique to each participant but will remain within known ranges. The frequency will be between 8 and 13 Hz, at an amplitude of 20-30% (approximately 30-40% of RMT), and about 3200-7200 pulses per session. Since parameters are specific to each participant, treatment settings will vary.
41291624|NCT06214949|DEVICE|Sham Personalized Repetitive Transcranial Magnetic Stimulation|Treatment will consist of 15 sessions over the course of 3-4 weeks. More specifically, the active or sham treatments will be conducted roughly 5 times a week during the course of the treatment phase of the study. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
41291625|NCT02279329|OTHER|Hyperpolarized Helium MRI|Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
41291626|NCT01650779|BIOLOGICAL|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
41291627|NCT01901133|DRUG|MDV3100|Oral
41291628|NCT03693365|PROCEDURE|PEEP trial|Positive end-expiratory pressure (PEEP) is increased from 5 to 10 cmH2O during one minute.
41291629|NCT03838848|DRUG|KN046|3mg/kg, Q2W, intravenous injection (IV)
41291630|NCT03838848|DRUG|KN046|5mg/kg, Q2W, intravenous injection (IV)
41291631|NCT03838848|DRUG|KN046|5mg/kg, Q3W, intravenous injection (IV)
41291632|NCT03838848|DRUG|Carboplatin|AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
41291633|NCT03838848|DRUG|Pemetrexed|500 mg/m2, Q3W, intravenous injection (IV)
40955064|NCT03821909|PROCEDURE|Endoscopic ultrasound-guided protal venous blood sampling|We wil obtain portal venous blood samples via endoscopic ultrasound(EUS) in patients with suspected pancreatic masses.
41291634|NCT03838848|DRUG|Ningetinib|Oral, QD
41291635|NCT02167204|PROCEDURE|Computed Tomography|Undergo 18F-FLT PET/CT
41291636|NCT02167204|RADIATION|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
41291637|NCT02167204|PROCEDURE|Positron Emission Tomography|Undergo 18F-FLT PET/CT
41291638|NCT02891746|OTHER|non invasive sampling|
41291639|NCT02417220|BEHAVIORAL|Weight Watchers Online 2015 Program|Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.
41291640|NCT02417220|OTHER|Electronic Scale with Feedback|Provision of an electronic scale that automatically transmits body weights to the Weight Watchers Online 2015 program, which generates a weekly feedback message on weight loss progress.
41291641|NCT00726323|DRUG|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
41291642|NCT06405204|DRUG|Myoinositol|an enzymatic isoform of inositol and belongs to the vitamin B complex family
41291643|NCT06405204|DRUG|Co-Enzyme Q10|a lipid-soluble quinone, acting as an effective antioxidant,
41291644|NCT06405204|DRUG|Melatonin|an indoleamine with low molecular weight that is synthesized by different cells and organs in the body. More importantly, melatonin is an outstanding antioxidant
41291645|NCT06405204|DRUG|Folic acid|control
41291646|NCT00196495|DEVICE|Polypropylene Mesh|
40955065|NCT02563171|OTHER|non surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
40955066|NCT02563171|OTHER|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
40955067|NCT04148690|OTHER|Group antenatal care (GANC)|Group antenatal care (GANC) is a service delivery model where women with pregnancies of similar gestational age are brought together for antenatal care (ANC), incorporating information sharing and peer support.
41291647|NCT02499965|DRUG|Ethyl Chloride Topical Aerosol Anesthetic|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
41291648|NCT02499965|DRUG|Nature's Tears Sterile Water|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
41455169|NCT06287216|BEHAVIORAL|Mental Hygiene|Mental hygiene are daily evidence based practices that support mental wellbeing.
40955068|NCT04148690|OTHER|Standard antenatal care|Routine antenatal care as recommended by th Ministry of Health of Tanzania
41291649|NCT02742740|BEHAVIORAL|Chemo Buddy|The Study Buddy ECA acts as an advisor to patients on chemotherapy regimens, promoting protocol adherence and retention, providing anticipatory guidance and answering questions, serving as a conduit to capture information about complaints or adverse events, providing a venue for communicating about updates.
41291650|NCT00038194|DRUG|imatinib mesylate|
41291651|NCT00038194|DRUG|docetaxel|
41291652|NCT05418608|DRUG|Radiotracer|A novel SV2A imaging tracer which is used in conjunction with positron emission tomography scans.
41291653|NCT00754429|DRUG|losartan|losartan 50mg qd for 30 weeks.
41291654|NCT00754429|DRUG|amlodipine|amlodipine 5 mg q.d for 30 weeks.
41291655|NCT02094469|DRUG|Cilostazol|Oral, Bid, 24 weeks
41291656|NCT02740153|OTHER|No Intervention Given|
41291657|NCT04002453|PROCEDURE|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
40955069|NCT05527197|DEVICE|Lapiplasty|The Lapiplasty® System instruments and implants will be retrospectively evaluated in patients previously surgically treated with the Lapiplasty® Procedure for Triplane MTP and TMT joint arthrodesis.
40762113|NCT04879940|DEVICE|Merit Medical Embospheres|Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.
40762114|NCT04879940|RADIATION|Radiation Therapy|Patients will undergo standard of care definitive radiation therapy.
40762115|NCT02261792|PROCEDURE|24 hours Trendelenburg position|Trendelenburg position
40762116|NCT02261792|PROCEDURE|24 hours bed rest|24 hours bed rest after EBP
40762117|NCT02261792|PROCEDURE|EBP|Autologous Epidural Blood Patch
40762118|NCT06638398|PROCEDURE|Computed Tomography|Undergo standard of care Computed Tomography
40762119|NCT06638398|DEVICE|Diagnostic Procedure|Receive a Virtual Nodule Clinic radiomic prediction score obtained in Optellum software.
40762120|NCT06638398|OTHER|Best Practice|Receive standard of care lung nodule management
40762121|NCT06638398|OTHER|Electronic Health Record Review|Ancillary Studies
40762122|NCT02457546|BIOLOGICAL|EVICEL Fibrin Sealant|
40762123|NCT02457546|DEVICE|Hydrogel sealant|
40762124|NCT03491176|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40762125|NCT03491176|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
40762126|NCT03491176|OTHER|Quality-of-Life Assessment|Ancillary studies
40762127|NCT03491176|OTHER|Questionnaire Administration|Ancillary studies
40955070|NCT02721160|OTHER|Nutrition PBF|"Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~* nb of cases screened and referred to HC for acute malnutrition (AM)~* nb of classes promoting good nutrition~HC level~* nb of cases screened and cared for severe and moderate AM~* nb of growth follow-ups~Hospital level~* nb of treated severe AM cases with complications~* length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF."
40955071|NCT02762578|DRUG|insulin degludec/insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
40955072|NCT02762578|DRUG|biphasic insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
40955073|NCT01400763|DIETARY_SUPPLEMENT|Fresh lutein-enriched egg-yolk beverage|Fresh lutein-enriched egg-yolk beverage
40762128|NCT05818930|DIAGNOSTIC_TEST|REMI|Diagnostic monitoring
40762129|NCT02355509|DRUG|Acarbose|"Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months"
40762130|NCT02355509|DRUG|Placebo|Placebo pills are given instead of acarbose in this group
40762131|NCT03635866|DIAGNOSTIC_TEST|Fluciclovine PET/MRI|It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.
40762132|NCT06256939|OTHER|Therapy BRIDGE Program|A standardized education and coaching intervention will be developed to promote optimal neurodevelopmental outcomes through caregiver empowerment. This pilot study will enroll up to 15 infants with IVH and their caregivers during their NICU stay. These infant-caregiver dyads will receive up to 10 sessions utilizing the Therapy BRIDGE program over a four-month period that spans the hospital to home transition.
40762133|NCT04869514|PROCEDURE|spinal manipulation|intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation
40762134|NCT02411045|BEHAVIORAL|Take and send a selfie|Direction to take and send a selfie.
40955074|NCT01400763|DIETARY_SUPPLEMENT|Dried-1 lutein-enriched egg-yolk beverage|Dried-1 lutein-enriched egg-yolk beverage
40955075|NCT01400763|DIETARY_SUPPLEMENT|Dried-2 lutein-enriched egg-yolk beverage|Dried-2 lutein-enriched egg-yolk beverage
40955076|NCT01400763|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage
40955077|NCT00074269|BIOLOGICAL|anti-thymocyte globulin|
40955078|NCT00074269|BIOLOGICAL|filgrastim|
40762135|NCT02411045|BEHAVIORAL|Workout gears|Direction to wear workout gears.
40955079|NCT00074269|BIOLOGICAL|graft-versus-tumor induction therapy|
40955080|NCT00074269|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40955081|NCT00074269|DRUG|cyclosporine|
40955082|NCT00074269|DRUG|fludarabine phosphate|
40955083|NCT00074269|DRUG|melphalan|
40762136|NCT02411045|BEHAVIORAL|Exercise|Direction to complete a 30 minute workout.
40762137|NCT04733495|OTHER|Counseling|Receive group-based behavioral counseling
40955084|NCT00074269|DRUG|methotrexate|
40955085|NCT00074269|PROCEDURE|peripheral blood stem cell transplantation|
40955086|NCT05464693|DIAGNOSTIC_TEST|ERCP biliary culture|"The sample of biliary aspirate will be assessed as follows.~1. Its macroscopic appearance will be analyzed: yellow, black, or purulent.~2. Biliary culture will be performed; if bacterial growth is observed, its identification will be carried out by means of MALDI-TOF MS mass spectrometry and antibiotic susceptibility tests will be carried out, using the automated VITEK system."
40955087|NCT02023593|DRUG|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
40955088|NCT00781274|DRUG|MP-424|750 mg every 8 hours for 12 weeks
40955089|NCT00781274|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
40955090|NCT00781274|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
40955091|NCT03059758|OTHER|fMRI|All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
40955092|NCT05717179|DIAGNOSTIC_TEST|Ultrasound|At baseline and at weeks 12, 24 and 48, patients will undergo an ultrasound examination of 44 joints by one investigator, who is blinded to the strategic arm and all clinical data. The following joints will be assessed: bilateral wrists (distal radio-ulnar joint, radio-carpal, mid-carpal recesses), 1st - 5th MCP, 1st - 5th PIP, elbows, glenohumeral, acromioclavicular, sternoclavicular, knees, ankles and 1st - 5th MTP. At wrists, MCP and PIP joints, palmar and dorsal sites including synovial recess, extensor and flexor tendons will be investigated whereas at feet the dorsal site (plus the lateral aspects of MTP5) including synovial recess and extensor tendons will be evaluated. Further, we will assess the following: at elbows the dorsal and anterior recess, at shoulders the dorsal recess, at knees the suprapatellar as well as the medial and lateral femoro-tibial recess and at ankles the anterior, lateral and medial recess of the tibiotalar joint.
40955093|NCT01868464|BIOLOGICAL|BCG TICE strain|All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.
40955094|NCT01146834|DRUG|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
40762138|NCT04733495|BEHAVIORAL|Dietary Counseling and Surveillance|Receive dietary counseling
40762139|NCT04733495|OTHER|Quality-of-Life Assessment|Ancillary studies
40762140|NCT04733495|OTHER|Questionnaire Administration|Ancillary studies
40762141|NCT04733495|OTHER|Resistance Training|Undergo personalized resistance exercises
40762142|NCT01428713|DRUG|Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
40762143|NCT01428713|DRUG|Oral Contraceptive Pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
41291658|NCT02958163|PROCEDURE|Trans-arterial Chemo-Embolization|Trans-Arterial Chemo-Embolization will be performed with Doxorubicin-Eluting-Beads (DEB-TACE). It will be performed in each arm of treatment.
41291659|NCT02958163|DRUG|Doxorubicin|Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.
41291660|NCT02958163|RADIATION|Stereotactic Ablative Radiotherapy|"SABR schemes will be adapted according to the CP score and the vicinity of surrounding organs at risk. These are the different schemes proposed in this trial:~48Gy = 3x16Gy BED 124.8Gy ( α/β=10) 50Gy = 5x10Gy BED 100Gy ( α/β=10) 48Gy = 6x8Gy BED 86.4Gy ( α/β=10) 40Gy = 5x8Gy BED 72Gy ( α/β=10)~For patients with Child-Pugh (CP) A cirrhosis : the choice of the scheme will be left to each physician. The highest BED should be favored if dose constraints to the organs at risk are respected.~For patients with CP B cirrhosis : only the latter scheme will be allowed: 40Gy = 5x8Gy."
41291661|NCT03300453|DRUG|rAAV2/5-hNAGLU|one-time brain intraparenchymal gene therapy dose
41291662|NCT03873129|BEHAVIORAL|mobile health app (mHealth)|A-CHESS is a mobile health app for participants to interact with their treatment team for 12 months.
41291663|NCT03691012|DIAGNOSTIC_TEST|Circulating tumour DNA testing|Circulating tumour DNA testing
41291664|NCT00759473|DRUG|D-Cycloserine (DCS)|50 mg d-cycloserine or placebo taken orally
41291665|NCT00759473|DRUG|Placebo|
40955095|NCT01146834|DRUG|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
40955096|NCT01146834|DRUG|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
40955097|NCT01146834|DRUG|Plerixafor|plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
41291666|NCT04397133|OTHER|inspiratory muscle training|inspiratory muscle training will be done with Philips Respironics Threshold IMT device starting with resistance of % 50 of MIP value
41291667|NCT04397133|OTHER|sham intervention|in these group the patients will get sham intervention with Philips Respironics Threshold IMT device
41291668|NCT00720707|PROCEDURE|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
41291669|NCT00720707|PROCEDURE|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
41291670|NCT02444637|DRUG|Rivastigmine|
41291671|NCT01388010|OTHER|1-Fermented Probiotic Dairy Product (test)|
41291672|NCT01388010|OTHER|2-Milk-based non-fermented dairy product(control)|
41291673|NCT04844671|DEVICE|da Vinci Surgical Systems|The da Vinci Surgical Systems enable surgeons to perform delicate and complex operations through a few small incisions with robotic assisted surgery.
41291674|NCT03702257|PROCEDURE|bronchoscopy.|gDSAs are studied on cryopreserved biopsies obtained during bronchoscopy. The technique is the one described by Visentin J.
40955098|NCT01323959|BIOLOGICAL|BoostrixTM Polio|Single dose, intramuscular administration.
41291675|NCT02475460|PROCEDURE|Less Invasive Surgery (LIS)|Less invasive HM 3 LVAD surgical implant procedure
41291676|NCT02475460|DEVICE|HeartMate 3™|HM 3 LIS
41291677|NCT06255990|OTHER|Standard of care|Standard of care
41291678|NCT04232501|DEVICE|Cirvo Compression device|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
41291679|NCT04438135|OTHER|Repeated open application test|parallel application of two different types of lotion with and without aluminium.
41291680|NCT03538873|BEHAVIORAL|Physical activity|
41291681|NCT01203462|OTHER|Probiotic strain of Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.
41291682|NCT01203462|OTHER|No Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.
41291683|NCT04085510|DEVICE|Contrast-enhanced mammogram|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
41455170|NCT06287216|BEHAVIORAL|Self-Care|Instructed to do 10 minutes of self-care daily.
40762144|NCT05385289|BEHAVIORAL|A cognitive-behavioral approach of rumination as intervention for overgeneral mode of processing in perfectionism|"The B-experimental phase consists in a 6-session intervention targeting rumination and lasting for 3 weeks. The intervention was derived from 3 manuals: Rumination-Focused Cognitive-Behavioral Therapy for Depression (Watkins, 2016), Overcoming Perfectionism (Shafran et al., 2010), and Cognitive-Behavioral Treatment of Perfectionism (Egan et al., 2014). Participants will attend 2 sessions per week at home. Each week will end with an individual 30 minutes-debriefing session with an experimenter, to ascertain understanding of session content and homework.~Intervention sessions will be given in paper format to participant after the A-baseline-phase. A paper diary was also provided for homework, in addition to the session content caneva. Each session contains (a) theoretical content on ruminations linked to perfectionism, (b) exercises to create alternative habits to ruminations, and (c) homework to become aware of ruminations and to experiment with alternatives."
41135272|NCT04895085|DIAGNOSTIC_TEST|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
40762145|NCT05479227|PROCEDURE|Management of bile duct injury|There are different options for BDI management, we analyzed their utilization and results
40762146|NCT05181696|DIAGNOSTIC_TEST|Chest X-ray|Retrospective analysis of chest x-rays of patients with COVID-19
40762147|NCT06105398|OTHER|clinical evaluation|clinical evaluation tests
40762148|NCT05125172|OTHER|Focus of Attention|Focus of attention instruction and feedback. Focus of attention refers to what people are thinking about during motor tasks. An external focus refers to thinking about an outside outcome or target. An internal focus of attention refers to thinking about how someone is moving their body.
40762149|NCT06569641|DEVICE|Neoneur Feeding System|The Neoneur Feeding System is placed between a nipple and a bottle, and used to measure feeding skill patterns.
40762150|NCT06466642|BEHAVIORAL|Combined Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ©|The intervention combines Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ. This integrated program helps individuals with cognitive impairment improve daily activities and achieve work, social, and daily living goals. CogSMART uses compensatory techniques to enhance prospective memory (remembering to do things), attention, learning/memory, and executive functioning (problem-solving, planning, organization, and cognitive flexibility). BrainHQ complements CogSMART with stimulating, game-like modules focusing on memory, attention, and executive functions. Together, they provide a comprehensive therapeutic tool to support cognitive impairment treatments and can also be used as a brain-training tool to prevent memory loss and maintain cognitive abilities.
40762151|NCT02260232|OTHER|exercise training|
40762152|NCT02408029|OTHER|Observational study - no intervention|
41135273|NCT00622700|DRUG|Teriflunomide|Film-coated tablet Oral administration
41135274|NCT00622700|DRUG|Placebo|Film-coated tablet Oral administration
41455171|NCT03999216|DRUG|Loop Diuretics vs. loop + thiazide diuretics|Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
41455172|NCT04993118|OTHER|Integrated Neuromuscular Inhibition technique|Integrated Neuromuscular inhibition technique At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of integrated neuromuscular inhibition technique . Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
40955099|NCT04781023|DEVICE|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
41455173|NCT04993118|OTHER|Ischemic Compression,Hotpack,TENS|Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
41135275|NCT00395759|DRUG|Optiva artificial tear by Allergan|
41135276|NCT02797587|DRUG|Varenicline|1 week starter kit followed by 1mg twice daily for 12 weeks.
41455174|NCT02611362|BEHAVIORAL|IMB Gaming Intervention|
41455175|NCT03721939|DEVICE|FLEX Scoring Catheter|Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
41135277|NCT02797587|DRUG|Cytisine|Multi-daily dosing, range 3-9 mg daily for 25 days.
41135278|NCT02797587|DRUG|Nicotine Replacement Therapy|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
41455176|NCT02445612|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
40762153|NCT05392283|DEVICE|AERO vacuum cupping device|The treatment consists of 5 sessions (approx. 30 min) of vacuum massage. The vacuum pump provided by the device provides a type of vacuum massage, that can be adjusted according to applied suction and air flow. The resulting massage technique provides a type of soft tissue manipulation similar to the ancient traditional medicine technique of cupping. Nonetheless, this automated technique allows for more precise determination of the massage characteristics.
40762154|NCT06569810|DEVICE|Repeated Low-Level Red Light (RLRL) therapy|In our study, we do not implement any interventions; rather, we collect follow-up information from patients who, due to insufficient response to traditional myopia control therapies, have transitioned to Repeated Low-Level Red Light (RLRL) therapy. The data gathered will reflect treatment patterns as per the approved indications for RLRL therapy, where subjects may have undergone treatment sessions twice daily, each lasting for 3 minutes with a minimum interval of 4 hours between sessions. Our analysis will focus on the real-world outcomes, specifically evaluating the proportion of participants who have achieved effective myopia control (defined as AL elongation of less than 0.1mm per year or SER progression of less than 0.25 diopter per year) after 12 months of documented RLRL therapy use among the collected data from eligible subjects.
41135279|NCT02797587|DRUG|Varenicline Placebo|1 week starter kit followed by 1 pill twice daily for 12 weeks.
41135280|NCT02797587|DRUG|Cytisine Placebo|Multi-daily dosing for 25 days.
41135281|NCT02797587|DRUG|Nicotine Replacement Therapy Placebo|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
40955100|NCT06395129|DEVICE|Low dead-space syringes/needles|LDSS/N are a type of syringe/needle which retains less residual blood following an injecting event when compared to HDSS/N.
41135282|NCT03954860|OTHER|Drainage Tube|The drainage tube drainage to guide the pus, blood and liquid accumulated between human tissues or in body cavity outside the body of High tibial osteotomy'patients.
41455177|NCT01049581|PROCEDURE|aquatic therapy|two hours per week, one hour per time, total 12 weeks
41455178|NCT03227276|DIETARY_SUPPLEMENT|Litramine|2 tablets to be taken 3 times a day after meals
40762156|NCT06409013|OTHER|Non-Interventional Study|Non-interventional study
40762157|NCT04306120|OTHER|Traditional Rehabilitation Therapy|The protocol included range of motion, ambulation, endurance, strengthening, reconditioning exercise, and home program education according to therapists' plans and the patients' ability.
40762158|NCT06290778|BEHAVIORAL|Brief Unified Protocol|The Brief Transdiagnostic Treatment of Emotional Disorders Unified Protocol.
40762159|NCT06290778|BEHAVIORAL|Psychoeducation|Psychoeducation regarding mental health challenges in fire service.
40762160|NCT02913326|DRUG|Dabigatran etexilate|
40762161|NCT02913326|DRUG|Warfarin|
40955101|NCT06395129|DEVICE|Hepatitis C Antibody Rapid Diagnostic Test|Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
41135283|NCT03954860|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
41455179|NCT03227276|DIETARY_SUPPLEMENT|Placebo tablet|2 tablets to be taken 3 times a day after meals
40762162|NCT02235688|DRUG|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
40762163|NCT02235688|DRUG|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
40762164|NCT02235688|DRUG|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
40762165|NCT02235688|DRUG|gemcitabine|
41455180|NCT05198505|DRUG|TQB2868 Injection|TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
40762166|NCT01213251|DEVICE|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
40762167|NCT01213251|DEVICE|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
40762168|NCT00970177|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
40762169|NCT04817436|OTHER|physical activity program (APA)|adapted physical activity program (APA)
40762170|NCT01045733|DEVICE|AcrySof IQ Toric IOL|AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
40762171|NCT01045733|DEVICE|AcrySof IQ Aspheric IOL|AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
40762172|NCT01045733|PROCEDURE|Limbal Relaxing Incision (LRI)|An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
40955102|NCT06395129|DEVICE|HIV rapid Diagnostic Test|Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
41135284|NCT03954860|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
41135285|NCT01860079|PROCEDURE|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
41135286|NCT00293410|DRUG|clofarabine|
41135287|NCT00293410|DRUG|cyclophosphamide|
41135288|NCT04466137|DRUG|YPEG-rhG-CSF|YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
41135289|NCT04466137|DRUG|YPEG-rhG-CSF|YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
41135290|NCT04466137|DRUG|rhG-CSF/PEG-rhG-CSF|rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10\^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.
41135291|NCT00695188|DRUG|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
41135292|NCT00695188|DRUG|methotrexate|25 mg oral administration
41455181|NCT01756716|DRUG|MT-3995 Low|MT-3995 Low dose for 8 weeks
41455182|NCT01756716|DRUG|MT-3995 High|MT-3995 High dose for 8 weeks
41291684|NCT04399278|DIAGNOSTIC_TEST|Diagnostic Test: end-expiratory occlusion (EEO) test|"A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~* T0: baseline.~* T1: At the end of the first EEO (15 sec or 30 sec)~* T2: 1 minute after completion of the first EEO. Return to baseline.~* T3: At the end of the second EEO (15 sec or 30 sec)~* T4: 1 minute after completion of the second EEO. Return to baseline.~* T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~* T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.)."
41291685|NCT02408146|PROCEDURE|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
41291686|NCT02408146|DRUG|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
41455183|NCT01756716|DRUG|Placebo|Placebo for 8 weeks
41455184|NCT00327587|DRUG|Valsartan + amlodipine|
40762173|NCT04725110|DRUG|Instilled T3|The first dose of T3 (50 micrograms in 10 mls volume BID) will be instilled by an investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. T3 doses will be given in 50 mcg doses twice daily for 4 days.
40762174|NCT04725110|OTHER|Placebo Therapy|A placebo therapy will be instilled into the lungs by the investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. Doses will be given twice daily for 4 days.
40762175|NCT02163863|DEVICE|Femoropopliteal stenting|
40762176|NCT00728533|DRUG|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
40762177|NCT00728533|DRUG|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
40762178|NCT00488293|PROCEDURE|Store and forward teledermatology|Standard electronic consult, standardized history, and image set
40762179|NCT06501976|DRUG|Lurbinectedin|2.6 mg/m2 , Given IV, every 21 days
41455185|NCT00327587|DRUG|Valsartan + HCTZ|
41135293|NCT04784650|OTHER|Pre-dialysis population|Pre-dialysis population, consisting of both Diabetes Mellitus (DM) and non-DM patients
40762180|NCT06501976|RADIATION|Radiation Therapy|Thoracic radiotherapy
40762181|NCT00834782|PROCEDURE|IOP measurement|Measuring IOP
41135294|NCT05845398|DRUG|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
41135295|NCT05845398|DRUG|Placebo|0.9% saline for injection.
41135296|NCT03156738|DRUG|MT-2990|Subjects will receive a single IV dose of MT-2990
41135297|NCT03156738|DRUG|Placebo|Subjects will receive a single IV dose of placebo
41135298|NCT05026970|COMBINATION_PRODUCT|Biofeedback+Electrostimulation+Kegel|Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
41135299|NCT05026970|DEVICE|Biofeedback+Tibial Neuromodulation+Kegel|Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
41135300|NCT05026970|COMBINATION_PRODUCT|Biofeedback+Kegel|Biofeedback+Kegel exercises
41135301|NCT06510569|DEVICE|U lab aligners|Aligner group change the aligner every 10 days
41135302|NCT06510569|DEVICE|oramco bracket|changing orthodontic wire every one month
40955103|NCT03775330|RADIATION|Stereotactic Radiosurgery (SRS)|"SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy \> 2 cm and ≤ 3 cm: 15-18 Gy \> 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions \> 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions \> 15 Gy) when patient is randomized to SRS + WBRT arm"
41455186|NCT00327587|DRUG|Amlodipine + HCTZ|
40762182|NCT05792345|PROCEDURE|Transversus Thoracic Muscle Plane Block|The transversus thoracic muscle plane block It is most commonly performed following cardiothoracic surgeries (or any surgeries requiring sternotomy) to provide analgesia to the anterior chest wall. he TTMPB, and thoracic fascial plane blocks, are increasingly being employed as part of enhanced recovery after surgery (ERAS) protocols for cardiothoracic procedures. They have been shown to significantly reduce both the time to extubation and the incidence of acute and chronic perioperative pain
40762183|NCT05792345|PROCEDURE|Control|Infiltration by surgeon
40762184|NCT06570538|DRUG|Ropivacaine|300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL/h of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.
40762185|NCT06570538|DRUG|Sufentanil|Sufentanil 2.0 μg/kg, 0.9% saline diluted to 100 mL, background dose of 2 ml/h, no loading dose, activated after extubation and continued until 48 hours postoperatively.
40762186|NCT05941585|DRUG|Mitoxantrone hydrochloride liposome injection30mg/m2|Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (30mg/m2)
40762187|NCT05941585|DRUG|HomoharringtonineD1-D7(2mg/m2/day)|Homoharringtonine intravenous infusion on D1-D7,2mg/m2/day in a 4-week treatment cycle.
40955104|NCT03775330|RADIATION|Whole brain radiation (WBRT)|WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
40955105|NCT02659293|DRUG|Lenalidomide|"* Cycle 1: 15 mg days 1-21~* Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose~* Cycles 5 and beyond: best tolerated dose days 1-21"
40955106|NCT02659293|DRUG|Carfilzomib|"* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion.~* Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16~* Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16"
41455187|NCT00327587|DRUG|Valsartan + amlodipine + HCTZ|
41455188|NCT05211505|DEVICE|WO 2707|Intravaginal application once daily for 1 week, then twice per week until visit 3 (day 38).
41455189|NCT03508596|OTHER|educational intervention for the supervisors|The educational intervention is based on a systematic literature review as well as focus-group interviews with health care professionals. It will be developed until the end of 2018
41455190|NCT01832922|DRUG|Bendamustine|
41455191|NCT01832922|DRUG|Rituximab|
40762188|NCT05941585|DRUG|Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)|Venetoclax d4-d12 (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)in a 4-week treatment cycle.
40762189|NCT05941585|DRUG|Cytarabine(standard-dose:d1-d7100mg/m2/day)|Cytarabine intravenous infusion on d1-d7 ,100mg/m2/day
40762190|NCT05941585|DRUG|Cytarabine(intermediate-dose:d1-d4100mg/m2/day, d5-d7 1g/m2)|d1-d4100mg/m2/day, d5-d7 1g/m2
40955107|NCT02659293|DRUG|Dexamethasone|"* Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22~* Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22"
41455192|NCT04472039|DEVICE|optical coherence tomography (OCT)|OCT visualizes the retinal layers by backreflection of light
41455193|NCT03655860|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
41291687|NCT02408146|PROCEDURE|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
41455194|NCT03914664|DIAGNOSTIC_TEST|Electroencephalogram (EEG) testing procedure|EEG testing procedure, comprised of somatosensory and auditory event-related potential paradigms, as well as resting state EEG
41455195|NCT03914664|DIAGNOSTIC_TEST|Autonomic function testing procedure|Autonomic function testing procedure, comprised of electrodes to determine heart rate variability and electrodermal activity (EDA)
41455196|NCT01847950|DIETARY_SUPPLEMENT|Short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
40955108|NCT02659293|DRUG|Lenalidomide (Control)|"* Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC ≥ 1,000/µL, platelet count ≥ 75,000/µL, and all nonhematologic toxicity is ≤ grade 1, to 15 mg PO daily (3 capsules per day).~* Cycles 5 and beyond: best tolerated dose days 1-28"
40955109|NCT03051750|OTHER|Complex Physical Therapy plus Pressotherapy|
40955110|NCT03051750|OTHER|Kinesio Taping|
41455197|NCT01847950|DIETARY_SUPPLEMENT|Maltodextrin|
40955111|NCT03959553|DRUG|GV1001|Lyophilized peptide from hTERT
40955112|NCT03959553|DRUG|Normal saline|0.9% normal saline
40955113|NCT04578483|OTHER|PCA group|Patients receiving PCA are allocated in PCA group despite the route of administration. Intravenous PCA is commonly used with morphine or fentanyl while epidural PCA is used with ropivacaine and/or fentanyl frequently.
40955114|NCT04578483|OTHER|ERDS group|After anesthesia, extended-release dinalbuphine sebacate (ERDS) is injected into gluteus maximus with ultrasound guidance.
41455198|NCT02261181|DEVICE|XONRID|The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
40955115|NCT01907243|PROCEDURE|spreader flap|producing of upper lateral cartilage flap as a spreader flap
40955116|NCT01952925|PROCEDURE|Renal Artery denervation|RA denervation performed as part of afib ablation procedure
41135303|NCT05773235|DIAGNOSTIC_TEST|Combined 3- and 7 Tesla-MRI|7 Tesla-MRI including the following sequences: susceptibility weighted imaging (SWI), T1, T2, FLAIR, quantitative mapping sequences (T1mapping, qSM)
41135304|NCT01472406|DEVICE|Sansum Closed-Loop Artificial Pancreas|The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
41135305|NCT01472406|DEVICE|Insulin infusion pump|The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
40955117|NCT01201785|DRUG|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
40955118|NCT01828736|BIOLOGICAL|Trastuzumab|Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
40955119|NCT01828736|DRUG|Gemcitabine|Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
40955120|NCT01828736|DRUG|Carboplatin|Given IV: AUC 5 on Day 1 every 21 days
40955121|NCT01828736|DRUG|Cisplatin|Given IV, 70 mg/m² BSA on day 1 every 21 days
40955122|NCT01156259|RADIATION|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
41135306|NCT01472406|DEVICE|Continuous Glucose Monitor|The CGM, which is an approved device (P050012), measures interstitial glucose.
41135307|NCT01472406|DEVICE|zone-Model Predictive Control algorithm|The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
41135308|NCT01472406|DEVICE|Safety Health Monitoring System|The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
41135309|NCT01662505|DRUG|Volasertib|Patient to receive volasertib
41135310|NCT03771066|BEHAVIORAL|bisphenol A|Vanilla wafer cookie with bisphenol A administered
41135311|NCT03771066|BEHAVIORAL|Placebo|Vanilla wafer cookie with no bisphenol A
41135312|NCT04056754|DRUG|Abiraterone Acetate|Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.
41135313|NCT04056754|DRUG|Placebo|Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.
41135314|NCT04056754|DRUG|Prednisone|Subjects administered 5mg prednisone twice daily in 28-day cycle.
41135315|NCT03397459|DIAGNOSTIC_TEST|Spine teleradiography EOS|
40955123|NCT01156259|RADIATION|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
40955124|NCT00289016|DRUG|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
41455199|NCT05239169|DRUG|Durvalumab|Durvalumab at a fixed dose of 1500 mg as an IV infusion over 1 hour, on day 1 together with the Tremelimumab infusion. Durvalumab only infusion to be repeated every 4 weeks for a maximum of 12 months on day 1 of each cycle.
40762191|NCT05941585|DRUG|Mitoxantrone hydrochloride liposome injection24mg/m2|Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (24mg/m2)
40762192|NCT00396370|BIOLOGICAL|BCG strain Connaught|Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10\^5 CFU vaccine for intradermal administration.
41455200|NCT05239169|DRUG|Tremelimumab|Tremelimumab at a fixed dose of 300 mg as an IV infusion over 1 hour on day 1 of cycle 1.
40762193|NCT00396370|BIOLOGICAL|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 1.2 X 10\^8 colony-forming units (CFU) oral (PO) in 60 mililiters phosphate buffered saline (PBS).
40762194|NCT00396370|BIOLOGICAL|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10\^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
40762195|NCT00396370|OTHER|Placebo|0.1 mL of sterile Sauton medium for intradermal administration.
40762196|NCT00396370|OTHER|Placebo|60 mL of sterile phosphate buffered saline (PBS) for oral administration.
40762197|NCT04883047|OTHER|holistic birth support strategies|"Holistic Birth Support Strategies are composed of birth-supporting practices that were created by Horn and D'Angelo (2017) within the scope of the Algorithm for Coping with Birth Pain and recommended for coping with labor pain. Holistic Birth Support Strategies; It includes four parameters: physical comfort, emotional comfort, informative support and advocacy."
40762198|NCT02455726|DIETARY_SUPPLEMENT|Magnesium oxide|Oral magnesium oxide 300 mg twice a day
40762199|NCT02455726|DIETARY_SUPPLEMENT|Fructose|Oral fructose 10 g twice a day
40762200|NCT02455726|DRUG|Oxycodone|Oxycodone hydrochloride 5 mg at 8 am
40762201|NCT02455726|DRUG|Pregabalin|Pregabalin 25 mg at 8 pm
40762202|NCT01462331|OTHER|Isomaltooligosaccharide (digestion-resistant carbohydrates)|12g/dose; three times a day
40762203|NCT01462331|OTHER|Isomaltooligosaccharide (digestion-resistant carbohydrates)|18g/dose, three times a day
40955125|NCT00437177|DRUG|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
40955126|NCT00437177|DRUG|[(123)I] iodobenzamide|\[(123)I\] iodobenzamide 185 MBq I.V., at discharge.
40762204|NCT01462331|OTHER|Sucrose|12g/dose, three times a day
40762205|NCT03729141|DIETARY_SUPPLEMENT|Added Cholesterol|Participants assigned to the added cholesterol group will receive snacks containing added cholesterol (1g/day) for 3 weeks prior to surgery.
40762206|NCT03729141|OTHER|No Added Cholesterol|Participants assigned to the no added cholesterol group will receive snacks containing no added cholesterol for 3 weeks prior to surgery.
40762207|NCT05638217|COMBINATION_PRODUCT|Silver diamine fluoride 38% followed by Sodium fluoride varnish 5%|"1)Completely drying of the affected area 2)10 microliters of silver diamine fluoride 38% (CaviGuard®) will be placed on the affected area 3)The affected area should be immediately covered with 20 microliters of fluoride varnish 5% (CaviGuard®) 4)Repeat steps 1-3 one or two more times for large caries at intervals of at least 2 days apart 5)Follow up evaluation of treatment success visits will be conducted at 6 and 12 months from the initial treatment.~NOTE: This is a single intervention using the device registered as Caviguard® to apply both products (Silver diamine fluoride 38% followed by Sodium fluoride varnish 5% (®)) in sequence."
40955127|NCT02206074|DIETARY_SUPPLEMENT|Beetroot|
40955128|NCT00011557|DEVICE|Assistance in Voiding|
40955129|NCT00362557|DEVICE|MRI|Magnetic resonance imaging
40955130|NCT02581787|BIOLOGICAL|Fresolimumab|Given IV
41455201|NCT05239169|DRUG|Capecitabine|Capecitabine at 1250 mg/m² p.o. twice a day on days 1 to 14 of a 3-weekly cycle (eight cycles).
41455202|NCT02144805|PROCEDURE|Suturing in a single layer|The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
41455203|NCT02144805|PROCEDURE|Suturing in two layer|The procedure define the use of two sutures for closing the uterine incision following cesarean section
40762208|NCT02002858|DRUG|Nicotine Patch|
40762209|NCT02002858|BEHAVIORAL|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
40762210|NCT02002858|BEHAVIORAL|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
40762211|NCT03161496|GENETIC|detection of genotype|detection of genotype by next generation sequencing
40955131|NCT02581787|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
40955132|NCT00887406|DRUG|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
40955133|NCT00887406|DRUG|GSK961081 3mcg SD|single dose delivered via nebulsier
40955134|NCT00887406|DRUG|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
40955135|NCT00887406|DRUG|Placebo SD|single dose via nebuliser
40955136|NCT00887406|DRUG|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
40955137|NCT00887406|DRUG|GSK961081 200mcg SD|single dose via nebuliser
40955138|NCT00887406|DRUG|GSK961081 300mcg SD|single dose via nebuliser
40955139|NCT00887406|DRUG|GSK961081 100mcg RD|repeat dose via nebuliser
40955140|NCT00887406|DRUG|GSK961081 300mcg RD|repeat dose vai nebuliser
41455204|NCT01712568|DRUG|Test Product (Ropinirole)|"one Tablet at 0 hour"
41455205|NCT01712568|DRUG|Reference Product (REQUIP )|"one Tablet at 0 hour"
40955141|NCT00887406|DRUG|Placebo RD|repeat dose via nebuliser
40955142|NCT01218113|BIOLOGICAL|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
41455206|NCT03147053|DRUG|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
40762212|NCT05515237|BEHAVIORAL|Grade 2-5 CI Therapy + Sensory Components|All participants will receive CI Therapy + Sensory Components over a 2-3 weeks time frame. The treatment intervention will apply all CI Therapy treatment components to include: 1) a behavioral set of techniques called the Transfer Package (TP) to promote carry-over of skills that were gained in the laboratory into the participant's life situation, 2) the use of motor training called shaping to make progress in small approximations 3) the use by the participant of a mitt on the less-affected hand to encourage use of the more-affected hand and 4) home skills and home work will be provided each day for at least 30 minutes. Sensory component training strategies will be added to stimulate sensory input through the more-affected arm an dhand as well as to train sensory discrimination skills.
40955143|NCT01218113|DRUG|Placebo|1 or 3 doses according to protocol schedule
40955144|NCT04878497|DRUG|Warfarin|Initiation of warfarin, identified using prescription fill in pharmacy claims
40955145|NCT04878497|DRUG|Dabigatran|Initiation of dabigatran, identified using prescription fill in pharmacy claims
40955146|NCT04878497|DRUG|Rivaroxaban|Initiation of rivaroxaban, identified using prescription fill in pharmacy claims
40955147|NCT04878497|DRUG|Apixaban|Initiation of apixaban, identified using prescription fill in pharmacy claims
40955148|NCT04878497|DRUG|Edoxaban|Initiation of edoxaban, identified using prescription fill in pharmacy claims
41455207|NCT03147053|DRUG|Placebo|Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
41455208|NCT03224624|OTHER|self-management protocol for hypertension care|participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
41455209|NCT02372006|DRUG|afatinib|
40955149|NCT05334914|BEHAVIORAL|Acceptance Commitment Therapy|"ACT: Consists of 15 sessions, twice per week. Each session is approximately 2.5 hours including breaks. Clients cover 3 modules (OPEN, ACTIVE, AWARE). Any participant who requires access to a device for any part of the study will be provided with one for the duration of the study.~CM: Participants will be given progressive compensation for session attendance via gift cards or e-gift cards amounting to $520.~Motivation Building Session: The study clinician will meet with each of the participants to explain the process of the therapy, reinforce expectations, and address any concerns or hesitations, and build motivation and commitment to fully engage in the program.~ChillTime App Participants rate their emotional state and choose a coping strategy (either physical, emotional, cognitive or spiritual). The app's algorithm learns the individual's strategy preferences over time, allowing for more personalized suggestions. Participants are also able to access coping strategies ad hoc."
40955150|NCT01133873|DRUG|Propoxyphene napsylate (XP20C)|100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
41455210|NCT00096460|DRUG|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
41455211|NCT00096460|DRUG|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
41455212|NCT00096460|RADIATION|Chemotherapy or Radiation therapy|"Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.~Radiation - administered at a rate of \< 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.~Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC \> 500/mm3 x 3 days."
40955151|NCT01133873|DRUG|Placebo|6 times a day in ascending doses until a maximum tolerated dose is identified
40955152|NCT03488732|DEVICE|Transcatheter valvular repair or replacement|Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)
40955153|NCT04118504|DEVICE|Mobile application|Lifestyle intervention on through mobile application
40955154|NCT03820141|DRUG|Durvalumab|programmed cell death-ligand 1 inhibitor
41455213|NCT00096460|DRUG|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
40762213|NCT04804436|GENETIC|Genetic analysis|he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
40762214|NCT01212692|BEHAVIORAL|mentally stimulating activities|The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
40762215|NCT05931822|OTHER|Silver Diamine Fluoride 38%|silver diamine fluoride 38% brushed on the cavity for 1 minute before adding high viscosity glass ionomer restoration in one molar
40762216|NCT05931822|OTHER|fluoride varnish|fluoride varnish brushed after adding the high viscosity glass ionomer restoration in the contralateral molar
40762217|NCT06452511|DRUG|Metformin|In the Metformin arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) and infertility will receive a combination treatment of Letrozole and Metformin. Letrozole, aimed at inducing ovulation, will be administered according to a specified dosage regimen, alongside Metformin, an insulin-sensitizing agent used to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and final evaluation of ovulation rates and pregnancy outcomes at the study's end. This arm seeks to determine the efficacy of Metformin as an adjunct to Letrozole in improving ovulation induction and pregnancy rates among overweight women with PCOS.
40955155|NCT03820141|DRUG|Trastuzumab|anti-HER2 monoclonal antibody
40955156|NCT03820141|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
40955157|NCT01893203|DRUG|BF-200 ALA cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
40955158|NCT01893203|DRUG|MAL cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
40955159|NCT02941991|BIOLOGICAL|hESC-RPE|sub-retinal injection
40955160|NCT02288052|BEHAVIORAL|Writing program|6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
40955161|NCT02288052|BEHAVIORAL|Stretch & Relaxation program|6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
40955162|NCT04262570|DEVICE|Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)|Non-invasive transcutaneous imaging of molecular muscle components
41135316|NCT06006572|PROCEDURE|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive
40955163|NCT04785092|PROCEDURE|All Autologous Cartilage Regeneration|All patients will undergo firstly to a blood sampling and then to the arthroscopic debridement of the damage cartilage and subsequently will be harvested the surrounding healthy cartilage The harvested and healthy cartilage will shredded directly in situ with a shaver. This cartilage will then mixed with the patient's own Platelet Concentrate and may be injected directly into the cartilage defect. The Platelet Concentrate stimulates the healing of the cartilage most effectively. At the same time, the Platelet Concentrate will also used to produce autologous fibrin glue, which can be used to fix the applied cartilage chip / Platelet Concentrate product quickly and safely in the damaged cartilage.
40955164|NCT00487708|DRUG|canakinumab|
41291688|NCT02408146|DRUG|fentanyl citrate+ ondansetron hydrochloride + normal saline|
41291689|NCT02408146|DRUG|celecoxib|
41291690|NCT02457052|DEVICE|DATP|Medical device allowing a custom sitting to help patients with swallowing disorders
41291691|NCT00734929|DRUG|Aprepitant + Dexamethasone|Aprepitant 40 mg + Dexamethasone 10 mg
41291692|NCT00734929|DRUG|Ondansetron + Dexamethasone|Ondansetron 4 mg + Dexamethasone 10 mg
41291693|NCT04418583|DIAGNOSTIC_TEST|Three-dimensional imaging|Three-dimensional surface images, acquired by the Artec Leo
41291694|NCT04510727|DEVICE|Optical Coherence Tomography (OCT)|VivoSight Dx OCT system from Michelson Diagnostics Ltd. OCT will be used to visualize the tumor and lesion in the skin.
41291695|NCT04510727|PROCEDURE|Curettage & Desiccation (C&D) Procedure|Standard of care C\&D where the basal cell carcinoma lesion will be scraped to its base using a Fox dermal curette and an electrodesiccation machine.
41291696|NCT04693247|DEVICE|EQ103|Refraction device
41455214|NCT00096460|PROCEDURE|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
41455215|NCT00096460|PROCEDURE|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
40955165|NCT06004128|DRUG|VYD222|Monoclonal antibody
40955166|NCT01387932|DEVICE|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
40955167|NCT01387932|PROCEDURE|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
40955168|NCT05469035|OTHER|Mobile-based video|Nurses in the experimental group participated in mobile-based video learning.
40955169|NCT05469035|OTHER|Face-to-face|Nurses in the experimental group participated in face-to-face learning.
40955170|NCT06250777|DRUG|Trastuzumab deruxtecan|"Chemotherapy : Every 3weeks as below until withdrawal of patient consent, progression, death or loss to follow-up:~- Trastuzumab Deruxtecan (T-DXd) 5.4mg/kg"
40955171|NCT03948672|DEVICE|CleanHands System|All participants who regularly access the ICUs will wear the CleanHands system wristband while at work for 5 months and the reminding functionality is turned on.
41291697|NCT03628677|DRUG|Domvanalimab|Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
41291698|NCT03628677|DRUG|Zimberelimab|Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
40955172|NCT05009264|PROCEDURE|OMT|OMT will be performed on identified areas of trapezius trigger points
40955173|NCT04085393|DRUG|GRANISETRON EXTENDED RELEASE INJECTION (GERSC)|GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
40955174|NCT00669656|DRUG|Prostate Health Cocktail|3 capsules daily PO up 12 months
40955175|NCT01374828|DRUG|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
41291699|NCT04111822|DRUG|red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate|Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving
41291700|NCT04111822|DRUG|on crystalloid fluid and Tranexamic acid|Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
41291701|NCT03995407|DIETARY_SUPPLEMENT|Peptamen®|Participants in the intervention arm will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements. Those who are not currently taking oral nutritional supplement will be started on Peptamen® while those who are currently on oral nutritional supplements will have to convert to Peptamen® solely. The dietician will determine the amount of Peptamen® required per day based on the recommendations of the product information. Should the participant's daily protein requirement not be met be Peptamen® alone, the dietician will recommend additional whey protein to be added in the form of Beneprotein® Instant Protein Powder. Beneprotein® is a concentrated source of high-quality whey protein that can be added to most foods, liquids or enteral formulas.
41291702|NCT03995407|OTHER|Usual Care|"Participants receive usual care. They will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements (non-100% whey i.e. not on Peptamen® or Beneprotein®). They will consume their regular diet in accordance with the dietician's recommendations."
41291703|NCT00906789|BEHAVIORAL|Software|This is an observer performance study. Radiologists will interpret chest radiographs without and then with the Riverain software, both SoftView (TM) OnGuard (TM) CADe Software with be tested
41455216|NCT00096460|DRUG|Rituximab maintenance therapy|"Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:~Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT"
41455217|NCT00096460|DRUG|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
41455218|NCT02002130|DRUG|Placebo GABA and Placebo GAD-alum|Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
41455219|NCT02002130|DRUG|GABA and Placebo GAD-alum|Oral Active GABA with Placebo GAD-alum
40955176|NCT04597775|DRUG|hydroxychloroquine|hydroxychloroquine
40762218|NCT06452511|DRUG|pep2dia|In the Pep2dia arm of this study, 50 overweight women diagnosed with polycystic ovary syndrome (PCOS) and experiencing infertility will receive a combination treatment of Letrozole and Pep2dia. Letrozole, utilized to induce ovulation, will be administered according to a specified dosage regimen, along with Pep2dia, a peptide-based therapy tailored to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and a final evaluation of ovulation rates and pregnancy outcomes at the conclusion of the study period. This arm seeks to ascertain the effectiveness of Pep2dia as an adjunct to Letrozole in enhancing ovulation induction and pregnancy rates among overweight women with PCOS.
40762219|NCT05686486|OTHER|Tai Chi inspired gymnastics|"The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance."
40762220|NCT06077513|PROCEDURE|CAD-CAM designed and preprinted Ti-Mesh frame|CAD-CAM technology which is the process of designing and manufacturing a custom-made dental device, or a patient-specific dental device from an industrialized product, with the aid of a computer.will be used to plan and preprint a 3-D Ti-Mesh frame prior to the surgery.
40955177|NCT03925857|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution.
40955178|NCT01797731|DEVICE|Digital hand-held surgical navigation system|Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
40955179|NCT01797731|DEVICE|Conventional tibial extramedullary alignment system|This is the standard of care for total knee arthroplasty.
40955180|NCT03062982|DRUG|Fluzoparib|2 doses separated by 7 days.
40955181|NCT03100097|DEVICE|Aspen Horizon 627 LSO|
40955182|NCT06557902|DRUG|Lumateperone 10.5 mg capsule|Lumateperone 10.5 mg capsule, oral administration
40955183|NCT06557902|DRUG|Lumateperone 21 mg capsule|Lumateperone 21 mg capsule, oral administration
40955184|NCT06557902|DRUG|Lumateperone 5 mg ODT|Lumateperone 5 mg ODT, oral administration
40955185|NCT06557902|DRUG|Lumateperone 10.5 mg ODT|Lumateperone 10.5 mg ODT, oral administration
40955186|NCT06557902|DRUG|Lumateperone 15.5 mg ODT|Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration
40955187|NCT06557902|DRUG|Lumateperone 21 mg ODT|Lumateperone 21 mg ODT, oral administration
40955188|NCT00400283|DRUG|NNC 55-0414|
40955189|NCT05492214|PROCEDURE|Delayed cord clamping (30s)|The same as that stated in arm descriptions.
40955190|NCT05492214|PROCEDURE|Delayed cord clamping (60s)|The same as that stated in arm descriptions.
40955191|NCT05492214|PROCEDURE|Delayed cord clamping (90s)|The same as that stated in arm descriptions.
41135317|NCT06006572|PROCEDURE|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive
41135318|NCT03672032|DEVICE|Fork-tip Needle|Fork-tip Needle will be used to obtain biopsy
41135319|NCT03672032|DEVICE|Franseen Needle|Franseen Needle will be used to obtain biopsy
41455220|NCT02002130|DRUG|Active Oral GABA and Active GAD-alum injection|Active Oral GABA and Active GAD-alum injection
41455221|NCT01338090|DRUG|89Zr-bevacizumab|Intravenous injection 120 MBq
40955192|NCT00032955|DRUG|Buprenorphine/naloxone|
40955193|NCT05615168|DIAGNOSTIC_TEST|"Acumen IQ guided hemodynamic optimization"|"Hypotension prediction index (HPI) available with the Edwards Acumen IQ sensor will be used as an early warning system and a diagnostic screen will be used to guide therapeutic interventions."
40955194|NCT05615168|DIAGNOSTIC_TEST|"Flotrac guided hemodynamic optimization"|"Therapeutic interventions guided by real time monitored hemodynamic parameters as measured by Edwards Flotrac sensor."
40955195|NCT04200950|DEVICE|Previse|Machine learning algorithm for early acute kidney injury (AKI) prediction.
40955196|NCT06377475|PROCEDURE|Jaw relation|The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
40955197|NCT06377475|PROCEDURE|Questionnaire|The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
40955198|NCT02074930|DEVICE|Microporation by P.L.E.A.S.E. Professional / Prick needle|
40955199|NCT00049192|BIOLOGICAL|oblimersen sodium|Given IV
40955200|NCT00049192|DRUG|imatinib mesylate|Given PO
40955201|NCT00049192|OTHER|laboratory biomarker analysis|Correlative studies
40955202|NCT01024075|DRUG|Dexamethasone|4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
40955203|NCT01024075|DRUG|Saline|8cc of Saline mixed with Sinufoam
40955204|NCT01132365|DEVICE|any knee joint arthroplasty device|Cohort consist of all consented patients receiving knee arthroplasty
40955205|NCT00993902|PROCEDURE|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
40955206|NCT00993902|PROCEDURE|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
40955207|NCT05265715|OTHER|Low AGE diet|"The recommended daily AGE intake will be either:~* 7,500 kilounits \[ku\], which is a 50% reduction from the average 15,000 ku consumed by most adults or~* a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)"
40955208|NCT05265715|PROCEDURE|Research blood draw|Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)
40955209|NCT03846804|DIAGNOSTIC_TEST|Karius Test|Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
40955210|NCT04511104|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
40955211|NCT04511104|OTHER|Standard of Care|Standard of care rehabilitation
41291704|NCT03178461|OTHER|Body temperature parenteral fluids|2 study groups shall receive the same parenteral fluids but at different temperatures.
41291705|NCT02406872|DRUG|Remimazolam Tosilate|IV pumping for anesthesia
41291706|NCT02406872|DRUG|Propofol|IV bolus for anesthesia
41291707|NCT03698162|DEVICE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo STAR DCE-MRI
40762221|NCT06077513|PROCEDURE|Conventional chairside fabrication of Ti-Mesh frame|A three-dimensional frame or cage of Ti-Mesh or Ti-reinforced d-polytetrafluoroethylene (PTFE) will be fashioned during the surgery to contain, shape and stabilize the bone graft materials (the internal scaffold). This 3-D frame will be custom fabricated from a perforated Ti Mesh sheet material at the time of surgery which takes considerable time and skill.
40762222|NCT05645887|DRUG|Human albumin|Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l.
40762223|NCT05645887|OTHER|Saline solution|Saline solution from day 0 to day 7.
40762224|NCT03510715|DRUG|Alirocumab SAR236553 (REGN727)|"Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)"
40762225|NCT03510715|DRUG|Atorvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
40762226|NCT03510715|DRUG|Simvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
40955212|NCT05357638|BEHAVIORAL|High Intensity Interval Training (HIIT)|8 weeks of HIIT, 2x/week for about 30 minutes/session on a cycle ergometer
40955213|NCT05357638|BEHAVIORAL|Continuous Aerobic Training (CAT)|8 weeks of CAT, 2x/week for about 50 minutes/session on a cycle ergometer
40955214|NCT05357638|BEHAVIORAL|Movement Advice|Weekly step goal, monitored using an activity tracker, +3000 steps/day for 5 days/week, step goal is based on average step count in the 4 weeks of baseline prior to the intervention
40955215|NCT05491720|DRUG|RisperiDONE 1 MG/ML|Patients will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
40955216|NCT05491720|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days
40955217|NCT05491720|DRUG|Placebo|Patients will receive placebo tablet (Galenus pharmaceutical company)
40955218|NCT05491720|DEVICE|sham transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days
40955219|NCT03711318|DRUG|Buprenorphine/naloxone|3 week treatment with buprenorphine/naloxone
40955220|NCT00001071|DRUG|Filgrastim|
40955221|NCT04903444|DEVICE|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system .
40955222|NCT03624985|DRUG|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
40955223|NCT03624985|DRUG|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
40955224|NCT03642119|DEVICE|iButton®|Women with frequently reported hot flashes will be undergo both real world (ambulatory; field tests) and controlled (laboratory) assessments to validate the iButton® as an objective method to assess hot flash dynamics and incidence.
40955225|NCT06490939|DRUG|Efepoetin Alfa|Single-intravenous administration
40955226|NCT02081287|DRUG|IP6|IP6 2,000 -3,000 mg per day given orally in two doses
40955227|NCT02081287|DRUG|Lamotrigine|Dose up to 200 mg per day over 10 weeks
40955228|NCT06263556|BEHAVIORAL|Pelvic floor exercises|"Patients will be informed about pelvic floor muscles functions and written material will be given for home training.~Exercise program will be planned as 1 set, 3 times per day. Each set will include 10 pelvic floor contractions. Patient will be instructed to squeeze their pelvic muscles and keep them contracted for 8 seconds. Due to fatigue and spasticity patients may experience, patients will set their own resting periods between contractions. Patients will be told to avoid contracting abdominal and gluteal muscles and avoid holding their breathe during the exercise.~Patients will be instructed to perform exercise as following:~1. Lie on your back. Take a deep breathe. Relax your abdominal muscles as you breathe out.~2. Focus on your pelvic floor muscles. Squeeze your muscles as you are trying to stop the flow of your urine and stay contracted for 8 seconds, then relax.~3. Repeat when you feel ready. You need to repeat this 10 times.~4. Repeat this exercise 3 times per day"
40955229|NCT06263556|DEVICE|Transcutaneous posterior tibial nerve stimulation|Patients in TTSN group will receive posterior tibial nerve stimulation based on the protocol explained before.
40955230|NCT06263556|DEVICE|Sham stimulation|Patients in sham stimulation group will receive sham stimulation based on the protocol explained before.
40955231|NCT03197454|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
40955232|NCT03197454|OTHER|Commercially available computerized training|Forty-two minutes of training on computerized, casual video games.
40955233|NCT02598960|DRUG|BMS-986156|
40955234|NCT02598960|DRUG|Nivolumab|
40955235|NCT05159219|DRUG|Colchicine Pill|Anti-inflammatory
40955236|NCT05159219|OTHER|Placebo|Inert ingredients
40955237|NCT02698046|DIETARY_SUPPLEMENT|Ferrous sulfate|200mg of ferrous sulfate three times a day for 4 months
41291708|NCT03698162|DRUG|Bevacizumab Injection|Bevacizumab will be give to participants who have recurrent high-grade glioma as part of standard of care.
41291709|NCT04522427|DEVICE|Use Multifocal and Extended Depth-of-Focus Intraocular Lenses(IOLs)|IOLs include AT LISA tri 839MP, AcrySof IQ PanOptix IOL, TECNIS Symfony EDOF
41291710|NCT04522427|DEVICE|Use Monofocal intraocular lenses(IOLs)|Monofocal IOLs include 409(Zeiss), AcrySof, TECNIS IOLS
41291711|NCT06511856|DEVICE|ARROW|Patients included in the study are patients operated with one or more shoulder medical device fabricated by FH ORTHO. Medical devices of interest are CE marked and include ARROW and ARROW prosthesis, Telegraph Evolution humeral nail and STRAPFLEX strapping system.
40762227|NCT03510715|DRUG|Fluvastatin|"Pharmaceutical form: capsule,~Route of administration: oral"
41291712|NCT02426086|DRUG|Imetelstat 4.7 mg/kg|Participants received imetelstat 4.7 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle. Study drug was administered intravenously until disease progression, unacceptable toxicity, or study end.
40762228|NCT03510715|DRUG|Pravastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
40762229|NCT03510715|DRUG|Lovastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
40762230|NCT03510715|DRUG|Rosuvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
40762231|NCT03510715|DRUG|Ezetimibe|"Pharmaceutical form: tablet,~Route of administration: oral"
40762232|NCT03510715|DRUG|Cholestyramine|"Pharmaceutical form: oral suspension,~Route of administration: oral"
40762233|NCT03510715|DRUG|Nicotinic acid|"Pharmaceutical form: tablet,~Route of administration: oral"
40762234|NCT03510715|DRUG|Fenofibrate|"Pharmaceutical form: tablet,~Route of administration: oral"
40955238|NCT02698046|DIETARY_SUPPLEMENT|Placebo starch|200mg of placebo starch three times a day for 4 months
41135320|NCT06157645|DEVICE|Prolene mesh|Application of mesh onlay post stoma closure
41135321|NCT04111159|DRUG|HSK3486|Subjects \< 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
41135322|NCT04111159|DRUG|Propofol|Subjects \< 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
41135323|NCT06062641|DRUG|SR-GDP|Selinexor 40mg/d，po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg，po/iv d1-4 (If patient\>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
41135324|NCT06075030|DRUG|AND017|Oral administration of AND017 capsules three times per week
41135325|NCT06543797|DEVICE|wearable rTMS|Application of inhibitory low-frequency rTMS on unaffected primary motor cortex by wearable rTMS
41135326|NCT03849066|OTHER|Parent-Reported Symptom Assessment|As the basis for PRSA, the investigator will use the PediQuest Memorial Symptom Assessment Scale (PQ-MSAS), which is an adapted pediatric-specific version of the validated adult MSAS that assesses 28 physical and psychological symptoms over the past week. The study instrument is designed to be completed by a full-proxy parent, and 2 versions tailored for specific age groups are available (0-3, 3-18 years-old). Spanish versions are available for both instruments. The PQ-MSAS contains 28 symptom items, each with 4-point scores for domains of frequency, severity, and extent of bother. Based on these components, a global symptom score and individual symptom scores can be calculated (0-100 scale, with 100 being the worst).
41135327|NCT05696405|PROCEDURE|VATS resection of MEPA|VATS resection of mediastinal parathyroid adenoma
40762235|NCT03510715|DRUG|Omega-3 fatty acids|"Pharmaceutical form: capsule,~Route of administration: oral"
41135328|NCT03241550|DRUG|isavuconazonium sulfate - intravenous|IV infusion
41135329|NCT03241550|DRUG|isavuconazonium sulfate - oral|Oral
40762236|NCT00761137|DRUG|0.3 mg tropicamide|0.3 mg tropicamide in intra-oral thin film
40762237|NCT00761137|DRUG|1 mg tropicamide|1 mg tropicamide in intra-oral thin film
40762238|NCT00761137|DRUG|3 mg tropicamide|3 mg tropicamide in intra-oral thin film
40762239|NCT00761137|DRUG|0 mg tropicamide|0 mg tropicamide (placebo) in intra-oral thin film
40762240|NCT05412979|DRUG|ST-1891|ST-1891
40762241|NCT05412979|DRUG|Levothyroxine|Levothyroxine
40955239|NCT05708274|DRUG|CPH + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
40955240|NCT05708274|DRUG|CD-LD + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
40955241|NCT05708274|DRUG|ATX + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
40955242|NCT05708274|DRUG|Placebo + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
40955243|NCT01622231|DRUG|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
40955244|NCT05728021|BEHAVIORAL|Recovery Record Aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (eating disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 5-8 and every other week in weeks 9-16."
40955245|NCT05728021|BEHAVIORAL|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2. Patients from the CG are also assessed at all assessment points.
41291713|NCT02426086|DRUG|Imetelstat 9.4 mg/kg|Participants received imetelstat 9.4 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or study end.
41291714|NCT06286930|DEVICE|anodal trans cranial direct current stimulation (tDCS)|1 20-minute anodal tDCS stimulation
40955246|NCT01545804|DRUG|Lenalidomide|All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
40955247|NCT02469740|DRUG|Ticagrelor|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).
40955248|NCT02469740|DRUG|Clopidogrel|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
40955249|NCT03495037|BEHAVIORAL|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
40955250|NCT03495037|BEHAVIORAL|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
40955251|NCT01872221|PROCEDURE|Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol|
41291715|NCT06286930|DEVICE|cathodal trans cranial direct current stimulation (tDCS)|1 20-minute cathodal tDCS stimulation
41291716|NCT01134887|OTHER|Informational Guide for Patients|"Veterans received a copy of the NIA guide for Talking with Your Doctor. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
41291717|NCT01134887|BEHAVIORAL|Video-Assisted Coaching|Physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients, but before seeing them for follow-ups. The main goal of this video-assisted coaching session was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management.
41291718|NCT01134887|OTHER|Monograph for Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians. The Four Habits provided practical evidence-based advice for improving patient-physician communication."
41291719|NCT01134887|BEHAVIORAL|Educational Coaching|an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor \[Coaching\]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management.
41455222|NCT01338090|DRUG|Everolimus|Oral use, 10 mg per day
41455223|NCT01538160|DRUG|recombinant factor VIIa|single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
41455224|NCT04531527|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 60 μl of Butenafine HCl 1% applied twice to the treated irradiated site and to the treated non-irradiated site for a total application of 240 μl of Butenafine HCl 1%.
40955252|NCT02028819|DRUG|Dolutegravir Sodium Monohydrate|Dolutegravir taken 50mg orally twice daily
41455225|NCT04934254|OTHER|Attitude Scale|26-item related to scale will construct and apply to nurses for creating scale
41455226|NCT01246453|DRUG|Intrapleurally Alteplase vs Intrapleurally Urokinase|Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
41455227|NCT02387762|DRUG|acalabrutinib|
41455228|NCT02387762|DRUG|Placebo|
41455229|NCT02380534|PROCEDURE|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
41455230|NCT05812625|OTHER|Myokinetic stretching technique|Myokinetic stretching technique (MST) is a form of myofascial release, which involves active or passive stretching and movement as well as muscle energy techniques until a desirable release from the taut band is achieved.
40955253|NCT02028819|DRUG|Ibalizumab|Ibalizumab will be administered intravenously at a dose of 800mg once every two weeks.
41291720|NCT01134887|OTHER|Control|"The primary care providers randomly assigned to the Control-Physicians arm did not receive any additional coaching or resources and conducted their practice as usual."
41291721|NCT00000581|PROCEDURE|leukocyte transfusions|
40762242|NCT00721110|DRUG|Lidocaine|Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
40762243|NCT00721110|DRUG|Placebo|Placebo boluses and infusions will be substituted
40762244|NCT00721110|DRUG|Ketamine|Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
40762245|NCT00721110|DRUG|Ketamine + Lidocaine|both Ketamine and Lidocaine will be given
40762246|NCT00772525|DRUG|Nerispirdine|"form: tablet~Route: oral"
40762247|NCT00772525|DRUG|Placebo|"form: tablet~Route: oral"
40762248|NCT05249660|OTHER|Soft tissue release technique|Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
41291722|NCT04247932|BEHAVIORAL|Active labor market intervention|Behavior change intervention
41291723|NCT03421847|DIAGNOSTIC_TEST|Rotatory vestibular test|We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests
41291724|NCT01196910|DEVICE|treatment by HLPFC coil|"DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase."
41291725|NCT05972967|DRUG|OMS906 Study Drug - 3 mg/kg|All patients will receive 3 doses of OMS906 of 3 mg/kg Intravenous (IV) at 8-week intervals. Clinical responders at Week 24 will receive an additional 3 doses of OMS906 only at 8-week intervals (monotherapy). Incomplete responders may receive an additional 3 doses of OMS906 with ravulizumab at 8-week intervals. Non responders will not receive additional OMS906.
41291726|NCT05972967|DRUG|OMS906 Study Drug - 5 mg/kg|All patients will receive 3 doses of OMS906 of 5 mg/kg Intravenous (IV) at 8-week intervals. Clinical responders at Week 24 will receive an additional 3 doses of OMS906 only at 8-week intervals (monotherapy). Incomplete responders may receive an additional 3 doses of OMS906 with ravulizumab at 8-week intervals. Non responders will not receive additional OMS906.
41291727|NCT05972967|DRUG|Ravulizumab|Participants must be on prescribed stable dose of ravulizumab (IV dose per approved summary of medicinal product characteristics) for at least 2 doses (4 months) prior to baseline. During the Run-in period - ravulizumab only. During the Treatment period all patients will receive 3 doses of ravulizumab at 8-week intervals. Clinical responders at Week 24 will not receive additional ravulizumab. Incomplete responders may receive an additional 3 doses of ravulizumab with OMS906 at 8-week intervals. Non responders will return to treatment with ravulizumab or standard of care.
41291728|NCT03088423|RADIATION|SBRT delivers high dose selective irradiation with millimeter precision to a small volume. The Cyberknife® is a robotic SBRT dedicated device that can deliver 100 to 200 photobeams to the target|Seven to ten days before the scheduled CT, 2-4 fiducial markers were implanted percutaneously 2 to 5 cm next to the lesion under sonographic guidance following administration of local anesthesia, thus allowing real-time tracking during treatment. The total dose delivered was 45 Gy on the 80% isodose, in three fractions over 10 days. Gross tumor volume (GTV) was defined as the tumor mass that could be discerned by diagnostic imaging. An isotropic margin of 5 mm was added to account for the microscopic extension (clinical target volume, CTV) and another 3 mm margin was added to compensate for uncertainties regarding the position (previsional target volume, PTV)
41291729|NCT04098926|RADIATION|Dose-integrated accelerated EBRT in pN0 breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy
41291730|NCT04098926|RADIATION|Dose-integrated accelerated EBRT in pN+ breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy Lymph node region: 5 x 5.4Gy
41291731|NCT03947879|DRUG|L-glutamine|15 g of L-glutamine twice daily by mouth for 3 months.
41291732|NCT03947879|OTHER|No L-glutamine|The same patients will be given no L-glutamine for 3 months.
41291733|NCT02273310|BEHAVIORAL|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
41291734|NCT00163722|OTHER|Culture and histology|
41291735|NCT00163722|OTHER|Aspergillus galactomannan and PCR|
41291736|NCT00631722|DRUG|Quatiapine Fumarate|600-750mg/day
41291737|NCT00631722|DRUG|Haloperidol|12-20mg/day
41291738|NCT02231203|DRUG|Omegaven|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
41291739|NCT02231203|DRUG|Placebo|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
41291740|NCT02008240|PROCEDURE|Needle aspiration of hydrosalpinx|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
41291741|NCT02008240|PROCEDURE|Salpingectomy|laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
41291742|NCT05362162|PROCEDURE|cervical plexus block|local anesthetic agent injection into the either Superficial or intermediate area
41291743|NCT02367092|BEHAVIORAL|Exercise Program|They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
41291744|NCT00660140|DRUG|Gemcitabine|
41291745|NCT00660140|DRUG|Carboplatin|
41291746|NCT03829189|DIETARY_SUPPLEMENT|inulin|prebiotic supplement
41291747|NCT03829189|DIETARY_SUPPLEMENT|maltodextrin|placebo supplement
41291748|NCT01120327|DRUG|Placebo|Placebo
41291749|NCT01120327|DRUG|Amlodipine|Amlodipine
41291750|NCT00478660|DRUG|adalimumab (Humira)|
41291751|NCT05212532|DRUG|EOM613|peptide nucleic acid (PNA)
41291752|NCT00519623|OTHER|PassPort(R) Transdermal Insulin Delivery System|The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
41291753|NCT05609422|OTHER|Physical therapy program|"* Stretching exercises~* Strength Training Kneeling exercises~* Standing exercises~* Gait Training"
41291754|NCT05609422|OTHER|scooter board activities|"1. Scooter board bear walk.~2. Scooter board crab walk.~3. Sitting on scooter board, use it to move forward and backward, move the pool rings from one end to another.~4. Cross sitting on scooter board, pulls along the rope using his/her hands~5. Sit with knees pulled into the chest (like a bug pose) and move around with arms only.~6. Prone over scooter board, pulling rope to move forward. Pull self along an anchored rope to retrieve items~7. Scooter rolls outs. Place knees on floor and hands holding the edge of the front scooter board. Push board out a few inches then pull back, the further you roll, the harder it gets.~8. Kneeling, Push self forward and backward with the use of a therapy ball (lots of Motor Planning).~9. Supine flexion on scooter board, Clip clothespins to a rope hanging above."
41291755|NCT01713985|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
41291756|NCT01713985|DEVICE|Thermage|Radiofrequency treatment focusing radiofrequency energy
41291757|NCT02760602|DRUG|Solanezumab|Administered IV
41291758|NCT02760602|DRUG|Placebo|Administered IV
41291759|NCT02947139|DRUG|Co-administration of DWC20155/DWC20156|
41291760|NCT02947139|DRUG|DWC20161|
41291761|NCT03372954|DRUG|BMAC|retrograde administration on non-selected BMAC via coronary sinus
41291762|NCT04575350|GENETIC|reinterpretation of CNV|Reinterpretation of CNV of unknown significance
41291763|NCT02521246|DRUG|Candesartan + Chlorthalidone|
41291764|NCT02521246|DRUG|Candesartan + Chlorthalidone|
41291765|NCT02521246|DRUG|Losartan+hydrochlorothiazide|
40955254|NCT01067690|DRUG|Indinavir in association with Vinblastina +/- Bleomicina|Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
40955255|NCT00843531|DRUG|RAD001|5 mg/day PO (oral)
40955256|NCT00843531|DRUG|erlotinib|100 mg/day (oral)
40955257|NCT05779969|OTHER|Chest CT scan|Comparison of structural damage to the manubriosternal joint (MST) between a population of patients with radiographic axSpA and a control population free of chronic inflammatory rheumatism on chest CT.
40955258|NCT04811885|OTHER|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
40955259|NCT04902131|DRUG|A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL|Single dose cross-over bioequivalence trial
40762249|NCT05249660|OTHER|Comparator: Instrument assisted soft tissue mobilization|Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
40762250|NCT06420336|PROCEDURE|Quadratus lumborum block|After induction of anesthesia and securement of appropriate airway device, the patient will be placed in position for the QL block. Using ultrasound guidance, the pediatric anesthesiology attending will perform unilateral QL block on the side of the anterior iliac bone graft harvest. The dose will be 0.2% ropivacaine, 1 mL per kilogram to a max of 20 mL with an additive of dexamethasone 4 mg. Ultrasonography will be used to identify external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A 50 mm-150 mm block needle will be advanced under ultrasound guidance. Ropivacaine will be injected slowly with frequent aspiration to rule out incorrect needle placement. The anesthetic is deposited at the lateral edge of the QL after penetrating the transversus abdominus aponeurosis. Injection will continue to be observed with real time US guidance.
40762251|NCT06420336|PROCEDURE|Local anesthetic infiltration|After induction of anesthesia and securement of appropriate airway device the patient will be turned over to the surgical team to proceed with the operation. The surgeon will proceed with usual injection of local anesthetic as their standard of care; this medication will be charted by the circulating nurse in the Medication Administration Record with local anesthetic type and amount. At the conclusion of the procedure, to maintain the blind, the patient will have a bandage placed where the QL block would have been performed.
40762252|NCT04197232|OTHER|clinical evaluation|- In children: general clinical evaluation, birth weight, APGAR, ECG, admission to ICU, hospital admissions in perinatal age, presence of malformations; complete blood count, inflammatory index, complement, antibiotic treatment, brain ultra-sound, presence of infection, presence of sepsis, presence of necrotizing enterocolitis, growth curve, presence of recurrent infections, developmental milestones, response to vaccines, admission to hospital in the first year of life.
40762253|NCT05725434|BIOLOGICAL|CT-P47 AI (tocilizumab)|CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2
40762254|NCT05725434|BIOLOGICAL|CT-P47 PFS (tocilizumab)|CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10
40955260|NCT04902131|DRUG|A MENOPUR powder including solvent for solution for injection, 75 IU|Single dose cross-over bioequivalence trial
40955261|NCT02544646|OTHER|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
40955262|NCT06534684|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).
40955263|NCT02938104|DIETARY_SUPPLEMENT|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses"
40955264|NCT02938104|BEHAVIORAL|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
41291766|NCT01430221|BEHAVIORAL|Mindfulness-based Personalized Health Planning|
41455231|NCT05812625|OTHER|Post Isometric Relaxation|Post Isometric Relaxation (PIR) is the effect of the decrease in muscle tone in a single or group of muscles, after a brief period of submaximal isometric contraction of the same muscle.
40955265|NCT02938104|BEHAVIORAL|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD
40955266|NCT01980940|DRUG|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
41291767|NCT01430221|OTHER|Structured & Guided Education|
40955267|NCT01980940|DRUG|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
40955268|NCT01980940|DRUG|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
40955269|NCT01980940|DRUG|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
40955270|NCT01980940|DRUG|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
40955271|NCT01980940|DRUG|Placebo|Placebo gel applied topically.
40955272|NCT01980940|DRUG|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
40955273|NCT01980940|DRUG|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
40955274|NCT03727269|OTHER|Wii Fit Training Experimental Group|Experimental group receiving wii fit game based abdomino-pelvic training. A specific protocol was developed by the researchers. Wii fit games which promote exercises focusing on the abdominopelvic cavity strengthening, using as a therapeutic means a Wii™ console with a Wii Fit Plus™ CD game. The protocol was design that which playing games participant perform different pelvic movements such as anteversion, retroversion, lateral tilt and circumduction that maintain trunk control and stabilization with mild abdomino-pelvic muscle activation. Duration of each game is 5 minutes with 90 seconds interval between them twice a week. After performing the sequence of virtual games, a series of abdominopelvic and lower limb muscle stretching exercises will done.
41291768|NCT05986539|OTHER|Observational|This study is only observational in nature and will not include an intervention.
41291769|NCT02094079|OTHER|biomedical outcomes|Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
41291770|NCT01009385|PROCEDURE|cervical epidural steroid injection|"* After aseptic preparation and skin infiltration with 1% lidocaine~* 20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~* identification of the epidural space confirmed by injection of contrast medium under fluoroscope~* injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~* Post-procedure, patients were observed for any adverse effects and followed with a neurological examination"
41291771|NCT01009385|PROCEDURE|epidural pressure measurement|"* The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~* Identification of the epidural space and measurement of EP was performed with a closed measurement system."
41291772|NCT03550144|BEHAVIORAL|Awe Walk|To examine the effect of weekly awe walks in cognitively healthy older adults.
41291773|NCT03550144|BEHAVIORAL|Control Walk|To examine the effect of weekly walks in cognitively healthy older adults.
41455232|NCT03232762|DIETARY_SUPPLEMENT|Refined Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
41455233|NCT03232762|DIETARY_SUPPLEMENT|Whole Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
41455234|NCT06213792|OTHER|Adaptation of the VOR|Subjects will undergo adaptation of their VOR in virtual reality in two different conditions. The side on which the adaptation will take place and the type of condition with which the patients will start will be randomized. Subject will undergo passive rapid head movements done by an experienced examinator whilst fixing a target in front of them. The movement of the target relative to the movement of the head will increase every 90 seconds by 10% until the movement of the visual scene is twice that of the head movement. In one condition the visual scene will be only a target in a grey void. In the other condition the visual scene will be more complex and represent a target in the room in which the subject is seated. Subjects will undergo both conditions at least 7 days apart.
40955275|NCT03727269|OTHER|Conventional Training|"Control group (n=20) receiving conventional pelvic floor exercises. Conventional exercises includes:~1. Knack Maneuver (Ashton -Miller 1998, 2008)~2. Pelvic floor strengthening: kegel Exercise.~3. -Lumbo-Pelvic Stabilization Exercise.~4. Functional Training/ PFM Contraction during ADL~5. Correction of biomechanical/structural deformities"
40955276|NCT03259217|DRUG|Stem Cell Product|Adipose tissue derived mesenchymal stem cell seeded in Curcumin loaded chitosan nanoparticles into collagen-alginate
40955277|NCT03729466|OTHER|clinical pilates|The intervention group will be performed in clinical pilates 45 to 60 minutes twice a week for 8 weeks.
40955278|NCT02170194|BEHAVIORAL|Resilience Enhancement Training via Smart Phone|
40955279|NCT02170194|BEHAVIORAL|Daily Text Messages|
40955280|NCT04261036|DRUG|Ascorbic Acid 1000 mg|1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
40955281|NCT04261036|OTHER|Placebo|Placebo pills for 14 days post-op after an elective gynecological surgery.
40955282|NCT00993681|BIOLOGICAL|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
40955283|NCT00993681|BIOLOGICAL|TD Vaccine System|placebo
40955284|NCT06429111|PROCEDURE|Epidural analgesia|Consists of a central nerve block by injecting a local anesthetic near the nerves that transmit pain, in the lumbar region, for pain relief during labor.
40955285|NCT06429111|PROCEDURE|Immersion water|Consists of the use of hot water immersion in a birthing tub during labor and/or delivery.
40955286|NCT00366574|DEVICE|Amadeus Microkeratome|
41455235|NCT01971554|DRUG|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
41455236|NCT01971554|DRUG|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
41291774|NCT05025488|DRUG|Peptide-based vaccine|ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only). Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses. Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart.
41291775|NCT05025488|DRUG|Poly ICLC|ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.
41291776|NCT06095674|DRUG|Anti-PD-1 antibody balstilimab|Both antibodies will be neoadjuvantly administered around the cervical tumor.
41291777|NCT03345862|BEHAVIORAL|non-pharmacological multicomponent|Following the proposal of Nicholson \& Shellman, (2013) collected in its CARELINK program, an intervention is proposed that includes: 6 sessions at home \[30-60 minutes\] for 16 weeks (1 fortnightly session) and 5 telephone sessions \[20 min.\] That will be intercalated (in the 16 weeks) depending on the particular characteristics of each person. The first visit, aimed at defining objectives and creating a relationship of trust for future visits.
41291778|NCT01982110|BEHAVIORAL|Mindfulness based smoking cessation|Mindfulness based interventions are provided via a mobile phone application.
41291779|NCT01982110|BEHAVIORAL|Behavioral Smoking Cessation intervention|Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
40955287|NCT00366574|DEVICE|IntraLase|
40955288|NCT03914482|DEVICE|MRI|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality
40955289|NCT02985372|DRUG|Decitabine|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
40955290|NCT02985372|DRUG|Cytarabine|
40955291|NCT05194865|DEVICE|cardiac MRI|assessment of the viability using CMR
40955292|NCT05194865|PROCEDURE|Percutaneous coronary intervention|direct revascularization using PCI
40955293|NCT05004077|DRUG|AMIODARONE|Assess the effectiveness of different dosing strategies of amiodarone.
41291780|NCT03569514|DRUG|AIGIV|Anthrax Immune Globulin Intravenous (Human)
41291781|NCT03334214|DRUG|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
41291782|NCT03334214|DRUG|Placebo|Saline 0.9%
41455237|NCT01685008|DRUG|MOR00208 (formerly Xmab 5574)|
41455238|NCT04603703|OTHER|HVLAT Manipulation|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week), HVLAT manipulation/ 1 rep/ 1set/ (3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
40955294|NCT01932307|PROCEDURE|Neck strengthening exercise program|Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
40955295|NCT01719783|BIOLOGICAL|LAIV H5N2|2 doses provided intranasally
40955296|NCT01719783|OTHER|Placebo|2 doses of placebo provided intranasally
40955297|NCT03651505|OTHER|No intervention|Access to any treatment is through authorized commercial use and not as a part of this DMP
40955298|NCT03717246|BEHAVIORAL|Sleep Smart Latino|A culturally tailored group intervention aimed at improving sleep duration and quality for Latino middle school students.
40955299|NCT03717246|BEHAVIORAL|Basic Sleep Hygiene and Child Health|A group intervention providing sleep hygiene and child health topics education to Latino middle school students.
40955300|NCT00149734|DRUG|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
40955301|NCT00149734|DRUG|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
40955302|NCT03406767|OTHER|GLA:D Canada Program|The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.
40955303|NCT03406767|OTHER|JointEffort Program|The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
41291783|NCT05331365|OTHER|Construction and evaluation of a composite score evaluating post ankle surgery residual instability by completing questionnaires and undergoing physical tests|"Four tests and two questionnaires, each evaluating specific physical or psychological dimensions will be used to construct the composite score Ankle Go Test composite score:~* Foot and Ankle Ability Measure Questionnaire (FAAM)~* Ankle ligament reconstruction-return to sport after injury Questionnaire(ALR-RSI)~* Single Leg Stance Test (SLST)~* Side Hop Test (SHT)~* Star Excursion Balance Test (SEBT)~* Figure-of-8"
41291784|NCT02797366|RADIATION|Proton radiotherapy|
41291785|NCT05416606|PROCEDURE|transurethral bipolar enucleation and resection of the prostate|transurethral bipolar enucleation and resection of the prostate
41291786|NCT05416606|PROCEDURE|open surgical transvesical prostatectomy|open surgical transvesical prostatectomy
41291787|NCT03373812|PROCEDURE|Blepharoptosis repair|levator advancement or mullerectomy
41291788|NCT03446170|BEHAVIORAL|Graphic cigarette warning labels, plain packaging|This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging
41291789|NCT01376739|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
41291790|NCT04159727|OTHER|stool and blood analysis|High throughput sequencing and quantitative PCR
40955304|NCT00914173|DEVICE|Scanlaf Circulator and water bath|Cold Pressor Test
40955305|NCT00914173|DEVICE|Medoc TSA 2000|Thermal stimuli pain
41291791|NCT03855254|BEHAVIORAL|communication type|Positive and negative communication types are the way that the practitioner communicates to the participant about the potential effectiveness of the osteopathic treatment. The control is a neutral communication condition.
41291792|NCT05895175|OTHER|Questionnaires|Questionnaires
40955306|NCT02421471|DRUG|Ingenol mebutate 0.015 percent or 0.05 percent gel|Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
41291793|NCT05533554|BEHAVIORAL|Brief Intervention Based on the Theory of Planned Behavior to Reduce Alcohol Consumption in University Students|Cognitive-behavioral intervention where the key concepts of the Theory of Planned Behavior were operationalized from which two intervention sessions were formed and the most appropriate techniques were chosen to influence the key concepts of the theory: behavioral beliefs, subjective norms, perceived behavioral control and self-efficacy. The program is made up of 3 evaluation sessions (pre and post a month later) and 2 intervention sessions with a duration of 120 minutes each.
40955307|NCT05020678|BIOLOGICAL|NKX019|NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10\^8 NK cells (6 × 10\^6/kg for patients \< 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.
40955308|NCT03301805|DRUG|BLEX 404|"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~* 28 days a cycle."
40955309|NCT03725137|OTHER|Analysis of T-lymphocytes|Analysis of T-lymphocytes regarding the development of cognitive function after stroke
40955310|NCT00385762|DRUG|paroxetine|paroxetine 10-40mg daily x 5 weeks
40955311|NCT02317588|DIETARY_SUPPLEMENT|Flax Oil|Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).
41291794|NCT04034979|BEHAVIORAL|decision aid|One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
41291795|NCT02439385|DRUG|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
40955312|NCT02317588|DIETARY_SUPPLEMENT|Fish Oil|Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
41291796|NCT02439385|DIETARY_SUPPLEMENT|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
41291797|NCT04820985|OTHER|Vaginal swab|Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing
41291798|NCT04820985|OTHER|Blood test|Blood sample to measure plasma dose of progesterone
40955313|NCT05436470|DEVICE|PK Papyrus|The PK Papyrus is a balloon mounted stent that will be administered during standard of care treatment of pseudoaneurysms.
41291799|NCT03640897|DEVICE|Liniderm|Cleaning of the diaper area with Liniderm at each diaper change during 28 days
41291800|NCT03640897|OTHER|Wipes|Cleaning of the diaper area with wipes at each diaper change during 28 days
41291801|NCT03640897|OTHER|Water|Cleaning of the diaper area with water and cotton pads at each diaper change during 28 days
40955314|NCT06557382|BEHAVIORAL|Cognitive tests and reading-related evaluations|Tests assessing cognitive status and reading were administered. (Frankfurter; MVPT-3, TILLs; etc.)
40955315|NCT03128034|DRUG|Cyclosporine|Given PO or IV
40955316|NCT03128034|DRUG|Fludarabine Phosphate|Given IV
40955317|NCT03128034|OTHER|Laboratory Biomarker Analysis|Correlative studies
40955318|NCT03128034|DRUG|Mycophenolate Mofetil|Given PO or IV
40955319|NCT03128034|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
40955320|NCT03128034|OTHER|Pharmacological Study|Correlative studies
40955321|NCT03128034|RADIATION|Pretargeted Radioimmunotherapy|Given 211\^At-BC8-B10 IV
40955322|NCT03128034|RADIATION|Total-Body Irradiation|Undergo TBI
40955323|NCT02554695|DRUG|placebo|subcutaneous saline injection
40955324|NCT02554695|DRUG|denosumab|single subcutaneous injection of denosumab 60 mg
40955325|NCT04047329|OTHER|general anesthesia or neuraxial anesthesia|
40955326|NCT05938842|BEHAVIORAL|Online DBT-Mindfulness Intervention|"The whole intervention exists of 10 sessions, one session a week for at least one hour and a half. The session 1 is tailored to address specific issues to people with MS, whereas the sessions 2 to 7 are based on DBT and mindfulness contents, and in sessions 7 to 10 introduced some contents of ACT. The program is based in teaching two different sets what and how (Linehan, 1993). The first skill what, teaches patients to simply observe; in a second level, to describe, which implies the ability to put the name to what one has observed; and in the third, what skill patients learn to fully participate in their actions in the current moment and without self-consciousness (Soler et al., 2012). In the other hand, the skills of how are related to how observe, how to describe and how to participate. Moreover, some mindfulness skills such as Observing the breath, Half-smiling, Awareness are practice introduced as homework tasks."
40762255|NCT05555693|OTHER|Collecting clinical data, EGG，Brain Metabolomic Characteristics(with Magnetic Resonance Spectroscopy), blood gas data and blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），Magnetic Resonance Spectroscopy data (before induction of anesthesia and first day after surgery)blood gas data(before induction of anesthesia and first day after surgery) and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
40955327|NCT05938842|BEHAVIORAL|Online psychoeducational intervention|The active control group intervention will be based on a psycho-educational framework and will involve MS-related topics (Oz \& Oz, 2020). The psychoeducational intervention will be conducted by a psychologist with experience in working with pwMS through group videoconference and will follow similar format as the DBT-Mindfulness intervention, except for the homework tasks. The participants will receive information about different aspects related to the disease (e.g., disease progression, disease-symptoms, stress management, nutrition, sleep hygiene, physical activity, social relationships). The content of the sessions of the psychoeducation program was created based on the current literature about MS. Similar psychoeducational programs were used in other studies before (Oz \& Oz, 2020; Dowd et al., 2015).
40955328|NCT03805425|RADIATION|PiXL|The system is set to deliver 30 mW/cm2 UVA irradiance in pulsed intervals of 1 second on and 1 second off to 5 to 9 mm diameter corneal annulus. Total energy delivered is 15J.
40955329|NCT00432419|PROCEDURE|autologous peripheral blood cell transplantation|
40955330|NCT00434954|DRUG|exenatide twice daily (BID)|subcutaneous injection (5 mcg or 10 mcg), twice a day
40955331|NCT00434954|DRUG|premixed insulin aspart twice daily (BID)|subcutaneous injection (titrated appropriately), twice a day
40955332|NCT01717911|DRUG|Insulin|In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
41291802|NCT04713345|OTHER|Virtual Reality Observations|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
41291803|NCT04713345|OTHER|Relaxation|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
40955333|NCT01717911|DRUG|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
40762256|NCT01443026|DRUG|Lycopene 30mg|Lycopene 30 mg.
40762257|NCT01443026|DRUG|Placebo|Placebo
40762258|NCT01631500|BEHAVIORAL|Conventional treatment|Conventional treatment
40955334|NCT01717911|DRUG|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was \<70mg /dl, discontinued the study if blood glucose was still \<70mg/dl under sitagliptin 50mg per day.
40955335|NCT03037775|OTHER|Baseline|measurement of baseline hemodynamic parameters
40955336|NCT03037775|DEVICE|e-cigarette without nicotine|measurement hemodynamic parameters during smoking e-cigarette without nicotine
40955337|NCT03037775|DEVICE|e-cigarette with nicotine|measurement hemodynamic parameters smoking e-cigarette with nicotine
40955338|NCT03037775|DEVICE|traditional cigarette|measurement hemodynamic parameters smoking traditional cigarette
40955339|NCT01580085|OTHER|polysomnography|full night supervised laboratory polysomnography
40955340|NCT01372592|PROCEDURE|Surgery|Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
40955341|NCT00334685|DRUG|[S,S]-Reboxetine + Pregabalin|\[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
40955342|NCT00334685|DRUG|Pregabalin|Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
40955343|NCT05692128|OTHER|Hematological and chemistry tests|Laboratory tests
40955344|NCT02202187|DRUG|GSK2140944|Investigational Study Drug
40955345|NCT02202187|OTHER|Placebo|Placebo
40955346|NCT02148159|DEVICE|Cachexia Acupuncture-A (Peace Classic Needles® )|Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
40762259|NCT01631500|OTHER|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
40955347|NCT02148159|DEVICE|General Acupuncture-B (Peace Classic Needles®)|Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
40955348|NCT03947892|DIAGNOSTIC_TEST|PET-CT|A PET-CT scan will be performed systematically for all patients included with the SUVmax, SUV peak, MTV of the lesion, and up to 3 suspicious ganglia during the visual analysis.
41291804|NCT03656640|DRUG|Gammanorm|Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
40955349|NCT04861909|DEVICE|AT LISA tri 839MP|Non interventional study
40955350|NCT03260101|OTHER|non intervational|Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
40955351|NCT02432742|DEVICE|Restylane Perlane|Intradermal injection
40955352|NCT02432742|DEVICE|Restylane|Intradermal injection
40955353|NCT03248336|PROCEDURE|office-based vergence/accommodative therapy|one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
40955354|NCT05964387|DEVICE|SDF|38% SDF will be applied to the hypoplastic area of the enrolled first permanent molar.
40955355|NCT05964387|DEVICE|Placebo|An inert liquid will be applied to the hypoplastic area of the enrolled first permanent molar.
40955356|NCT01170143|DRUG|Trastuzumab QW, Trastuzumab Q3W|two arms using Trastuzumab QW vs Q3W
40955357|NCT05664074|DRUG|Rectal indomethacin|"Dosage based on subject's weight:~\>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg"
40955358|NCT05664074|DRUG|IV ketorolac|Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
40955359|NCT00659750|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
40762260|NCT01631500|OTHER|Therapeutic acupuncture|Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
40955360|NCT00659750|DRUG|Placebo|placebo
40955361|NCT03329508|DRUG|P2B001 0.6/0.75 mg|Fixed low dose extended release combination capsule of pramipexole and rasagiline
40955362|NCT03329508|DRUG|Rasagiline 0.75 mg|Rasagiline 0.75 mg oral extended release capsule, component
40955363|NCT03329508|DRUG|Pramipexole 0.6 mg|Pramipexole 0.6 mg oral extended release capsule, component
40955364|NCT03329508|DRUG|Marketed Pramipexole ER|Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet
40955365|NCT03555760|BEHAVIORAL|Observation of informed consent form readings of all patients who are scheduled for surgery|All patients who are scheduled for surgery will be observed for their initial reflex of inform consent form readings.
40955366|NCT01611155|DRUG|venlafaxine|Given PO
40955367|NCT01611155|DRUG|placebo|Given PO
40955368|NCT01611155|OTHER|questionnaire administration|Ancillary studies
40955369|NCT01611155|OTHER|quality-of-life assessment|Ancillary studies
40955370|NCT05991167|DEVICE|EndeavorRx|EndeavorRx® is an FDA cleared digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. EndeavorRx is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
40955371|NCT00229593|DRUG|Nestorone gel|2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
41291805|NCT03631667|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
40955372|NCT00229593|DRUG|Testosterone Gel|100 mg Testosterone gel daily for 3 weeks
40955373|NCT02123342|BEHAVIORAL|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
40955374|NCT02284516|DRUG|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
40955375|NCT02284516|DRUG|Placebo|Placebo to match active treatment, BID for 84 days
40955376|NCT00761631|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
40955377|NCT02364492|DRUG|MAG-TN3 + AS15|
40955378|NCT06151132|PROCEDURE|Direct current cardioversion|Direct current cardioversion to maintain sinus rhythm during rhythm control strategy
40955379|NCT00004488|DRUG|alendronate sodium|
40955380|NCT00004488|DRUG|calcium carbonate|
40955381|NCT00004488|DRUG|cholecalciferol|
40955382|NCT02964975|PROCEDURE|Percutaneous coronary intervention|Recanalisation of chronic total occlusion of coronary artery
40955383|NCT02964975|DRUG|Optimal medical therapy|Medical threatment according to guidelines
40955384|NCT00237094|BEHAVIORAL|Nurse Practitioner led multidisciplinary team approach|
40955385|NCT00016159|BIOLOGICAL|filgrastim|
40955386|NCT00016159|BIOLOGICAL|lintuzumab|
40955387|NCT00016159|DRUG|arsenic trioxide|
40955388|NCT00016159|DRUG|idarubicin|
40955389|NCT00016159|DRUG|tretinoin|
40955390|NCT04076475|DEVICE|neuromuscular electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
40955391|NCT05350410|BEHAVIORAL|HALT-AD|HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.
40955392|NCT03154593|OTHER|Stage 2 - Bariatric Surgery|This observational study follows patients after routine bariatric surgery.
40955393|NCT01509092|PROCEDURE|vitrectomy surgery|"pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole"
40955394|NCT06192368|DEVICE|INSPIRE|Virtual reality application for relaxing.
40955395|NCT06192368|DEVICE|Tablet|Gaming tablet
40955396|NCT00827528|PROCEDURE|Traditional correction of anterior vaginal wall prolapse|"Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
40955397|NCT00827528|PROCEDURE|Biologic Graft (SIS)|"Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
40955398|NCT05875428|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Be given intravenously at 20 mg/m\^2 on days 1 of each treatment cycle.
40955399|NCT06285708|BEHAVIORAL|Prolonged exposure|PE therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure (repeated recounting of the most disturbing traumatic memory) followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure (approaching trauma-related situations); psychoeducation about PTSD; and controlled breathing training. Between sessions, participants listen to audio recordings of the imaginal recounting daily and complete in-vivo exercises. Typically, PE is delivered weekly for 10-12, 90-minutes sessions. For this study, participants will complete daily 60-minute sessions for 10 consecutive weekdays during a 2-week period.
41291806|NCT03631667|DRUG|[14C]-benzo[a]pyrene plus phenanthrene|Oral micro-dose of 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene plus 1250 ng phenanthrene
41291807|NCT01837082|DRUG|ferric carboxymaltose|
41291808|NCT01837082|DRUG|Placebo|
41291809|NCT01895010|DEVICE|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
41291810|NCT01895010|DRUG|tropisetron|only tropisetron 6mg before TACE
41291811|NCT00048906|DRUG|DRX005B|
40955400|NCT03828175|PROCEDURE|spinal anesthesia monitoring|"After attaching all standard monitors (ECG, NIBP, pulse oximeter) and the COP bio-impedance monitor recording basal data (COP, CI, SV, CPI, Do2, DO2I, SVR, SVV.~During sitting position intrathecal anesthesia was conducted in the sitting position under complete aseptic condition using heavy bupivacaine 15mg (3ml) plus 10 mic dexamedatomedine 25G needle after 2 ml Lidocaine skin infiltration. lithotomy position till anesthesia level documented T4 and fixed and lower urinary tract endoscopy then shifting the patient to prone position and after adjustment of the prone position precautions 2 bellows one under the chest and one under the pelvis with pliable free moving abdomen jell ring under the patient head knees and in front of heels, then the basal data recording and after that data recording every 10 minutes till end of the operative procedure. Blood sampling at basal, postoperative"
40955401|NCT04967378|BEHAVIORAL|HEPPI|10 weekly individual sessions, 90 minutes each, at the participants' homes. The content of sessions includes psychoeducation, cognitive training, psychotherapeutic intervention, and compensatory strategy training.
41291812|NCT00950352|DRUG|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
40955402|NCT01976338|DRUG|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
40955403|NCT01976338|OTHER|Sham injection|Sham intravitreal injection
40955404|NCT02322346|OTHER|Group S|"Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
40955405|NCT02322346|DRUG|Group LL|"Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
40955406|NCT02322346|DRUG|Group HL|"Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
40955407|NCT00066638|DRUG|Romidepsin|Given IV
40955408|NCT00066638|OTHER|Laboratory Biomarker Analysis|Correlative studies
40955409|NCT03468803|DIAGNOSTIC_TEST|Beta D Glucan test|Measurement of BDG before, during and after surgery
40955410|NCT06036823|DRUG|Insulin regular|Intravenous insulin
41291813|NCT00950352|DRUG|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
41291814|NCT00945191|DRUG|CS-1008|CS-1008 intravenous (IV) infusion 10 mg/kg on Day 1 of Cycle 1 and 8 mg/kg once every 3 weeks (1 cycle) for Cycle 2-6
41291815|NCT00945191|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
41291816|NCT00945191|DRUG|Carboplatin|Carboplatin (target area under the concentration versus time curve of 6.0 mg/mL/min using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
41455239|NCT04603703|OTHER|Conventional Physical Therapy|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
40955411|NCT06036823|DRUG|Dextrose 50|to be given to both arms
40955412|NCT06036823|DRUG|salbutamol|to be given to all patients
40955413|NCT04234074|DEVICE|Volusense paediatric monitoring device|Comparison of Volusense paediatric monitoring device to full cardiorespiratory polysomnography.
40955414|NCT02620722|DEVICE|Personalized Tourniquet Instrument|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.
40955415|NCT02620722|DEVICE|Handheld Doppler ultrasound|Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
40955416|NCT05850065|OTHER|Hu-Friedy 212 clamp|Hu-Friedy 212 clamp is normally used for the retraction with rubber-dam
40955417|NCT05850065|OTHER|dental floss using the simple knot tie method|Dental floss using the simple knot tie method is normally used for the retraction with rubber-dam
41291817|NCT02446652|DRUG|Hydralazine/Magnesium|(Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
41291818|NCT02446652|DRUG|Placebo|Placebo (orally) starting 1 week before the first day of the QT
41291819|NCT02446652|DRUG|Carboplatin|5 AUC 1 hour/day 1 for every 21 days for 6 cycles
41455240|NCT04883996|DRUG|1% EXP039|1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),
41455241|NCT04883996|OTHER|Saline control|Saline
40955418|NCT05850065|OTHER|Coltene B4 clamp|Coltene B4 clamp is normally used for the retraction with rubber-dam
40955419|NCT01555450|OTHER|Patient Navigation|Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
40955420|NCT06341101|DRUG|Perindopril|In case of side effects Perindopril will be replaced by Valsartan
40955421|NCT02925117|DRUG|Upadacitinib|Tablet for oral use
40955422|NCT02925117|DRUG|Placebo|Tablet
40955423|NCT00647361|DEVICE|Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).|Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
40955424|NCT01228643|BIOLOGICAL|Pancreatic enzimes|- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
40955425|NCT01228643|DEVICE|Creon ®|- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
40955426|NCT02055833|DIETARY_SUPPLEMENT|Intensive nutritional counseling|Intensive nutritional counseling: nutritional counseling + oral nutritional supplements
40955427|NCT02055833|OTHER|Nutritional counseling|Nutritional counseling
40955428|NCT03766568|DEVICE|JGG endoscope(R)|The JGG endoscope(R) is attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.
40955429|NCT00686283|BEHAVIORAL|PEP intervention|This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
40955430|NCT02144623|DRUG|Valproate|
40955431|NCT03159221|BEHAVIORAL|BFST for Teens with Type 2 Diabetes|BFST for Teens with Type 2 Diabetes: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
40955432|NCT02969564|OTHER|scintigraphy 99mTc-MDP-SPECT/CT.|SPECT/CT will be performed for every patient in the frame of their clinical follow up
40955433|NCT02969564|OTHER|18F-NaF-PET/MR|a 18F-NaF-PET/MR will be performed, in the frame of this clinical study, to the patients to assess the difference of sensitivity of the 2 exams
40955434|NCT02898129|OTHER|Questionnaire|
40955435|NCT02898129|DEVICE|Lung function test|Basic lung function test performed with a micro-spirometer, without broncho dilatator
40955436|NCT00607984|DRUG|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
40955437|NCT00797771|DEVICE|"Adi Insulin pump"|insulin delivery will be defined by the physician
40955438|NCT01573260|OTHER|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
40955439|NCT01573260|OTHER|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
40955440|NCT06557226|OTHER|oral and nutritional examination|Participants will receive a comprehensive oral examination, nutritional examination and will fill an oral health related quality of life questionnaire.
40955441|NCT05100459|DIETARY_SUPPLEMENT|Pasture-raised whey protein|25 grams of protein delivered 3 times daily
40955442|NCT05100459|DIETARY_SUPPLEMENT|Conventional whey protein|25 grams of protein delivered 3 times daily
40955443|NCT05100459|DIETARY_SUPPLEMENT|Placebo|Iso-caloric placebo taken 3 times daily like the protein supplementation
40955444|NCT06134908|BEHAVIORAL|Multifaceted Intervention|The multicomponent intervention elements include education for clinicians and patients as well as a shared decision-making program among clinicians and patients. A shared decision-making booklet and a mobile application will be used to promote osteoporosis management and fracture practice.
40955445|NCT01713608|DRUG|OZ439|OZ439 x mg once daily for 3 days with milk
40955446|NCT06356909|OTHER|Survey of sedo-analgesia practices before laryngoscopy|The survey will evaluate adequation to the French best practice guidelines to improve their dissemination and to identify current practices of premedication before laryngoscopy in neonates in French units (agents, dosing, efficacy, safety)
40955447|NCT03878953|DRUG|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; \[mg/dL\] = serum calcium \[mg/dL\] +0.8\*\[4-serum albumin (g/dL)\]) is \>2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is \>2.97 mmol/L (\>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
40955448|NCT04530526|PROCEDURE|Regenerative Peripheral Nerve Interface|The regenerative peripheral nerve interface (RPNI) has emerged as a novel strategy to treat neuromas in peripheral nerves. The RPNI consists of the residual peripheral nerve end implanted in a skeletal muscle graft, following surgical resection of the injured terminal nerve portion (neuroma). The free muscle graft is separated from its native nerve innervation, leaving open neuromuscular junctions for ingrowth and attachment of nerve fibers from the implanted nerve.
40955449|NCT03519178|DRUG|PF-06873600|PF-06873600 tablet for oral dosing
41291820|NCT02446652|DRUG|Paclitaxel|175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
41291821|NCT00804440|DRUG|Ibuprofen Tablets, 800 mg|
41291822|NCT04893837|DEVICE|Standard care plus infrascans|Hourly infrascans to detect expanding intracranial hematomas
41291823|NCT03446547|DRUG|Durvalumab|durvalumab 1500 mg i.v. every fourth week for 12 months
41291824|NCT00723658|BIOLOGICAL|rituximab|
41291825|NCT00723658|DRUG|bortezomib|
41291826|NCT00723658|DRUG|carmustine|
41291827|NCT00723658|DRUG|cisplatin|
41291828|NCT00723658|DRUG|cyclophosphamide|
41291829|NCT00723658|DRUG|cytarabine|
41291830|NCT00723658|DRUG|dexamethasone|
41291831|NCT00723658|DRUG|doxorubicin hydrochloride|
41291832|NCT00723658|DRUG|etoposide|
41291833|NCT00723658|DRUG|melphalan|
40955450|NCT03519178|DRUG|Endocrine Therapy 1|Endocrine Therapy 1
41455242|NCT03692455|PROCEDURE|Roux-en-Y Gastric Bypass|The Roux-en-Y gastric bypass procedure involves creating a stomach pouch out of a small portion of the stomach and attaching it directly to the small intestine, bypassing a large part of the stomach and duodenum. Not only is the stomach pouch too small to hold large amounts of food, but by skipping the duodenum, fat absorption is substantially reduced.
40955451|NCT03519178|DRUG|Endocrine Therapy 2|Endocrine Therapy 2
40955452|NCT04442113|PROCEDURE|Pulmonary vein isolation plus ablation guided by novel STAR mapping™|Catheter ablation for persistent AF consisting of pulmonary vein isolation plus additional ablation guided by the novel STAR mapping™ software on a computer device.
40955453|NCT04442113|PROCEDURE|Pulmonary vein isolation|Catheter ablation for persistent AF consisting of pulmonary vein isolation (the standard treatment for AF)
40955454|NCT00325273|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
40955455|NCT02399553|OTHER|Soccer boot intervention|
41291834|NCT00723658|DRUG|thalidomide|
41291835|NCT00723658|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|
41291836|NCT00723658|PROCEDURE|peripheral blood stem cell transplantation|
41291837|NCT00044044|DRUG|Lurasidone 20 mg|Lurasidone 20mg/day tablets
41291838|NCT00044044|DRUG|Lurasidone 40mg|Lurasidone 40mg/day tablets
41291839|NCT00044044|DRUG|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
41291840|NCT00044044|DRUG|Haloperidol 10mg|Haloperidol 10mg/day tablets
41291841|NCT00044044|DRUG|Placebo|Matching Placebo to Lurasdione and Haloperidol
41291842|NCT01332929|DRUG|Bevacizumab|"5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week."
41291843|NCT00205972|DEVICE|Humerus Nail or LC Plate|
41291844|NCT05051085|BEHAVIORAL|"Internet-delivered treatment: SpilleFri."|The guided internet program consists of 8 modules over a period of 10 weeks. The content is written psychoeducation, videos with patients and experts, and exercises (encouraging reflection, cognitive restructuring, and exposure). The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 10 weeks.
41291845|NCT06430268|PROCEDURE|implant decontamination with titanium curette|Titanium curettes (Hu-Friedy, Chicago, Illinois, USA) will be used for supra and submucosal around the implant, with and without flap elevation.
41291846|NCT06430268|DEVICE|implant decontamination with Air-Flow device|Air-polishing (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) will be carried out with AIR-FLOW powder PLUS (EMS) containing erythritol (sugar alcohol, 14 μm), amorphous silica and 0.3% chlorhexidine to decontaminate implants with and without flap elevation. The device will be adjusted to a power setting of 5 bar static pressure and a maximum level of irrigation with water.
41291847|NCT00265941|DRUG|cetuximab|Cetuximab 400 mg/m\^2 IV loading dose 5-7 days before start of radiation therapy, then 250 mg/m\^2 IV weekly for 7 weeks
41291848|NCT00265941|DRUG|cisplatin|Cisplatin 100 mg/m\^2 IV on days 1 and 22
41291849|NCT00265941|RADIATION|Accelerated Fractionation by Concomitant Boost|3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks
41291850|NCT00265941|RADIATION|Intensity-modulated radiation therapy|70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.
41291851|NCT02796950|DRUG|Acipimox|P.o. administration of 250 mg acipimox
41455243|NCT03692455|PROCEDURE|Vertical Sleeve Gastrectomy|VSG surgery restricts food intake and decreases the amount of food used. Most of the stomach is removed during this surgery, which may decrease ghrelin, a hormone that prompts appetite. Lower amounts of ghrelin may reduce hunger more than other purely restrictive surgeries, such as AGB.
41455244|NCT05719467|DRUG|Buscopan 20 MG/ML Injectable Solution|1 mL intravenously
41455245|NCT05719467|DRUG|Sodium bicarbonate|4 g orally
40762261|NCT04264845|OTHER|Provider Focus|The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
40955456|NCT01953107|OTHER|Oral Ferrous Fumarate|
41455246|NCT05719467|DRUG|Placebo|4g orally
40955457|NCT01953107|OTHER|Placebo|
40955458|NCT04693988|BEHAVIORAL|Case Management|a case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as provide advice about cardiac symptoms and behavioral life style changes
40955459|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
40955460|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
40955461|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
40955462|NCT00942448|OTHER|Placebo s.c.|1 single injection at day of dental surgical extraction
40955463|NCT04211181|OTHER|The multifaceted interventions|"1. An evidence-based clinical guideline and pathway in hospital.~2. A series Written care protocols for the implementation of performance measures.~3. A computer-based clinical decision support system(CDSSs) and a computerized reminder, which was referred to as a key element to enhance VTE assessment and prophylaxis. A well-designed computer program will be integrated into the Electronic Medical Record(EMR) of intervention group and By processing, analyzing, summarizing and representing crucial information, physicians can be altered.~4. A full-time quality coordinator~5. A trained physician or nurse in each intervention cluster will be acted as a quality coordinator. The responsibility of the quality coordinator includes:"
40955464|NCT04211181|OTHER|Routine VTE prophylaxis|Patients randomized to the Routine VTE prophylaxis (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices
40955465|NCT01577368|DRUG|Piperacillin-Tazobactam continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
40955466|NCT01577368|DRUG|Piperacillin-Tazobactam intermittent infusion|Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
40955467|NCT03685123|BEHAVIORAL|Physical activity recommendations|Participants in the PA-REC group will exercise at 550 MET min. per week in a supervised format
40955468|NCT03685123|BEHAVIORAL|Weight maintenance recommendations|Participants in the WM-REC group will exercise at 970 MET min. per week in a supervised format
40955469|NCT03685123|BEHAVIORAL|OPTIFAST weight loss|Participants will participant in an OPTIFAST medical weight loss program and exercise training
40955470|NCT05662345|DIAGNOSTIC_TEST|CellSearch Circulating Tumor Cells|Serial CTC enumeration
40955471|NCT03837860|DRUG|Oxycodone/Placebo|Oxycodone 20 mg plus placebo
40955472|NCT03837860|DRUG|Oxycodone/Risperidone|Oxycodone (20mg) plus Risperidone (2 mg)
40955473|NCT03837860|DRUG|Oxycodone/Ziprasidone|Oxycodone (20mg) plus Ziprasidone (80 mg)
40955474|NCT01817829|DRUG|paracetamol|500 mg oral tablet
40955475|NCT01817829|DRUG|placebo|
40955476|NCT02418078|PROCEDURE|local infiltration anesthesia and sedation|the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents
40955477|NCT04105582|BIOLOGICAL|Neo-antigen pulsed Dendritic cell|Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide
40955478|NCT04815993|DRUG|SYN-020 delayed release capsule|SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
40955479|NCT01601730|DRUG|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
40955480|NCT01601730|DRUG|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
41291852|NCT03806569|BEHAVIORAL|MAC-cbt group treatment for adult ADHD|Psychotherapeutic intervention to treat adult patients with ADHD to be mindful, accept the symptoms and disturbances and commit with the situation or the possibility to change.
40955481|NCT01601730|DRUG|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
40955482|NCT01601730|DRUG|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
40955483|NCT06465095|GENETIC|Baseline|Measurements and sampling
40955484|NCT04432259|DRUG|Dexamethasone|4 mg bid for 4 days
40955485|NCT04432259|DRUG|Placebo|oral placebo
40955486|NCT06409715|OTHER|Enhanced Care with PMRT and Acupressure|Progressive Muscle Relaxation Training (PMRT) is a structured strategy created to reduce psychological and physiological stress by alternating muscle contraction and relaxation.Rooted in traditional Chinese medicine's meridian theory, acupressure employs manipulative techniques on distinct acupoints to induce therapeutic effects 18. Targeting enhanced circulation, pain relief, muscle relaxation, and systemic regulation, acupressure's efficacy as both a preventive and therapeutic modality in complementary and alternative medicine is well-established
41291853|NCT03806569|BEHAVIORAL|Jacobson|Relaxation treatment in technique of Jacobson in 8 sessions
41291854|NCT06119178|DEVICE|EX-PRESS P-50 filtration device|FDA-approved, stainless steel device with a 50-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
41455247|NCT05719467|DRUG|Nacl 0.9%|1 mL intravenously
41455248|NCT02829684|OTHER|Data collection|This register will follow the evolution of the clinical practices and their consequences in the health of the patients, in all regions of France in order to have a national register. for Children and adults.
41455249|NCT00684801|OTHER|questionnaire administration|Patients complete questionnaires.
41455250|NCT00684801|PROCEDURE|quality-of-life assessment|Patients undergo quality-of-life assessments.
41455251|NCT02527213|DRUG|Sodium thiosulfate|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
41455252|NCT02527213|DRUG|Placebo|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
41455253|NCT06408727|DRUG|CNM-Au8|CNM-Au8 (cellular energetic nanocatalyst). Faceted clean-surfaced catalytically-active Au nanocrystals.
41455254|NCT06270745|DRUG|indocyanine green|Whether to use ICG to assess anastomotic perfusion during digestive system surgery
41455255|NCT00132457|PROCEDURE|Self-collected vaginal swab for chlamydia testing|
41455256|NCT00633698|DRUG|Nicotinic acid (niacin)|oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
41455257|NCT00633698|DRUG|Placebo|Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
41455258|NCT02707016|OTHER|Sevoflurane 8%|Sevoflurane 8% (high dose) during anesthesia induction
41455259|NCT02707016|OTHER|Sevoflurane 5%|Sevoflurane 5% (low dose) during anesthesia induction
41455260|NCT03433404|PROCEDURE|Soft Tissue Mobilization|The technique has been described previously in other descriptions. However, the main goal of this treatment is to address the LDSIL in the manner described previously in order to mobilize the soft tissue in the area.
41455261|NCT03433404|PROCEDURE|Soft Tissue Massage|For sMass, the subject will be positioned on her side opposite to the most painful side of the lumbosacral spine with the hips flexed to 45 degrees and knees flexed to 90 degrees (with a pillow positioned between them). The investigator will perform superficial (light stroke) massage to the painful side of the lumbosacral region for 5 minutes
41135330|NCT00587886|BEHAVIORAL|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
41455262|NCT01146080|DEVICE|Promus Element|Promus Element implanted to treat coronary artery lesions.
41455263|NCT01146080|DEVICE|Promus|Promus stent implanted to treat coronary artery lesions
41455264|NCT00746460|BEHAVIORAL|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
41455265|NCT05665387|DRUG|0.1% STN1013600 ophthalmic solution|0.1% STN1013600 ophthalmic solution 1 drop BID for 2 months
41291855|NCT06119178|DEVICE|EX-PRESS P-200 filtration device|FDA-approved, stainless steel device with a 200-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
41455266|NCT05665387|DRUG|0.3% STN1013600 ophthalmic solution|0.3% STN1013600 ophthalmic solution 1 drop BID for 2 months
41455267|NCT05665387|DRUG|Placebo|Placebo ophthalmic solution 1 drop BID for 2 months
41455268|NCT05046951|BEHAVIORAL|Should I Screen website|The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
41455269|NCT05046951|BEHAVIORAL|Should I Screen print booklet|The Should I Screen print-based education will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
41455270|NCT02539628|DRUG|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
41455271|NCT03950674|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
41455272|NCT03950674|DRUG|Cisplatin|IV infusion
41455273|NCT03950674|DRUG|Carboplatin|IV infusion
41455274|NCT03950674|DRUG|Pemetrexed|IV infusion
41455275|NCT03950674|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
41455276|NCT03950674|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
41455277|NCT03950674|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
41455278|NCT03950674|DRUG|Saline solution|IV infusion
41455279|NCT04318808|PROCEDURE|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
41455280|NCT00160524|BIOLOGICAL|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
41455281|NCT01145157|DEVICE|Signature Knee Guide|Total Knee Arthroplasty performed using Signature Knee Guide
41455282|NCT01145157|DEVICE|Conventional Instrumentation|Total Knee Arthroplasty performed using Conventional Instrumentation
41455283|NCT01145157|DEVICE|Computer Assisted Navigation|Total Knee Arthroplasty performed using Computer Assisted Navigation
41455284|NCT03006835|DRUG|Clopidogrel|
41455285|NCT02699866|DEVICE|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
40955487|NCT06409715|OTHER|standard care|vital sign monitoring, positional support, dietary management, pain control, psychological support, functional training, and educational initiatives on health matters.
40955488|NCT06429488|OTHER|no intervention, questionnaires were used|"The following psychological assessment tools were used:~Obsessive-Compulsive Inventory-Revised (OCI-R): An 18-item self-report questionnaire measuring symptoms across six subscales: washing, checking, neutralizing, obsessing, ordering, and hoarding. A score of 21 or higher indicates likely OCD.~Depression Anxiety Stress Scales-21 (DASS-21): A set of three self-report scales assessing stress, depression, and anxiety over 21 items. This shortened version is widely used for research and clinical purposes and is easy to administer.~Patient Health Questionnaire-9 (PHQ-9): A nine-item scale for assessing depressive symptoms. Scores are categorized as: 1-4 (no/minimal), 5-9 (mild), 10-14 (moderate), 15-19 (moderately severe), and 20-27 (severe depression).~Generalized Anxiety Disorder-7 (GAD-7): A seven-item tool measuring anxiety symptoms and the severity of generalized anxiety disorder (GAD)."
40955489|NCT00752180|BIOLOGICAL|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
41291856|NCT03089567|DRUG|Sodium Fluoride|5% Sodium Fluoride Varnish used for dental caries prevention and desensitizer
40955490|NCT00752180|BIOLOGICAL|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
40762262|NCT04264845|OTHER|Patient Interview|A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
41135331|NCT00587886|BEHAVIORAL|Questionnaire|"The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers."
41291857|NCT03089567|DRUG|Silver diamine fluoride|38% Silver Diamine Fluoride used for dental caries prevention and desensitizer
40762263|NCT04264845|OTHER|PROs/Clinical Data Integration|A plan has been developed that will integrate PRO scores into patient medical records. Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic. All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
41291858|NCT03528044|PROCEDURE|Bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
40762264|NCT06297902|RADIATION|Dose painting|Dose painting
40762265|NCT06443242|DEVICE|Low-Dose Laser Acupuncture (LLA)|The intervention utilizes the xS-998D06 semiconductor laser acupoint therapeutic device specifically designed for targeted acupoint therapy. This device is critical in delivering precise low-dose laser therapy at a controlled wavelength and power. The laser treatment is directed towards enhancing neurological function and potentially alleviating symptoms of insomnia and depression by stimulating specific acupoints associated with mental health and sleep.
40762266|NCT06443242|DEVICE|Sham Laser Acupuncture (SLA)|Sham laser acupuncture serves as a control to assess the placebo effect of the laser treatment. It involves the same procedure as LLA but uses a non-emitting laser probe. This intervention is designed to mimic the LLA setup without delivering actual laser therapy, allowing for an evaluation of the psychological and physiological effects of the placebo compared to the active laser treatment.
40955491|NCT03892187|BEHAVIORAL|Intervention Group|Walking prescriptions plus weekly coaching calls prior to surgery.
41135332|NCT03515369|DRUG|Babaodan oral capsule|On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
41135333|NCT03515369|DRUG|Placebo oral capsule|On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
41135334|NCT06305143|DRUG|Conbercept|participants with diabetic macular edema (DME) combined with severe non-proliferative diabetes retinopathy (sNPDR) were assigned to anti-VEGF therapy over 12 months.
41135335|NCT03775213|BEHAVIORAL|Decision Support Tool with Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including active monitoring and surgery options.
41135336|NCT03775213|BEHAVIORAL|Decision Support Tool without Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including surgery options only.
41135337|NCT03072888|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation will be apply
41135338|NCT02157948|DRUG|Denosumab (CP2)|Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
41135339|NCT02157948|DRUG|Denosumab (CP4)|Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
41291859|NCT03546478|BIOLOGICAL|99mTc-ABH2|99mTc-ABH2 were injected into the patients before the SPECT/CT scans
41135340|NCT06313632|DRUG|Bupivacaine injection|Erector spinae plane block with bupivacaine (0.5%) 30 mL once
41291860|NCT02018510|BIOLOGICAL|1 mg/kg, single dose IV administration of 3BNC117|1 mg/kg, single dose IV administration of 3BNC117
41135341|NCT06313632|DRUG|Placebo|ESP with matching saline placebo
41291861|NCT02018510|BIOLOGICAL|3 mg/kg, single dose IV administration of 3BNC117|3 mg/kg, single dose IV administration of 3BNC117
41291862|NCT02018510|BIOLOGICAL|10 mg/kg, single dose IV administration of 3BNC117|10 mg/kg, single dose IV administration of 3BNC117
41291863|NCT02018510|BIOLOGICAL|30 mg/kg, single dose IV administration of 3BNC117|30 mg/kg, single dose IV administration of 3BNC117
41291864|NCT02018510|BIOLOGICAL|10 mg/kg, two doses IV of 3BNC117|10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
41291865|NCT02018510|BIOLOGICAL|30 mg/kg, two doses IV of 3BNC117|30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
41291866|NCT00299884|DRUG|Lipitor 20 mg|A/A for 6 weeks
41291867|NCT00299884|DRUG|Combination Ezetrol 10 mg and Lipidil Supra 160 mg|a/a for 6 weeks
41291868|NCT01048515|DRUG|Caffeine|Caffeine capsule 6 mg/kg given 1 hour before test
41291869|NCT02439762|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
41455286|NCT03614728|DRUG|GSK3326595|GSK3326595 will be administered.
41455287|NCT03614728|DRUG|5-Azacitidine|5-Azacitidine will be administered.
41455288|NCT04654429|DRUG|IV Ondansetron 4mg|IV ondansetron 4mg
41455289|NCT04654429|OTHER|Higher OT temperature range|OT temperature set to 19-22 degree celsius
41135342|NCT06313632|OTHER|Monitored Anesthesia Care|Standard monitored anesthesia care
41135343|NCT00198419|DRUG|Vitrase|
41135344|NCT03369457|BIOLOGICAL|Isolation of multipotent cells|Isolation of multipotent cells from patient's cells. Analysis of CFU and differentiation potential
41291870|NCT02439762|BEHAVIORAL|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
41291871|NCT00751881|DRUG|Placebo|"Film-coated tablet~Oral administration"
41291872|NCT00751881|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
41291873|NCT01369693|PROCEDURE|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
41291874|NCT00181688|DRUG|Iressa (ZD1839)|
41291875|NCT00181688|DRUG|Arimidex (Anastrozole)|
41291876|NCT05137522|DRUG|Chidamide combines with VP-16 and methylprednisolone|Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
41291877|NCT05597046|OTHER|Interview|Interviews
41291878|NCT06512701|OTHER||This study is an observational study without any intervention measures.
41291879|NCT03559985|DRUG|paracetamol|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
41291880|NCT03559985|OTHER|Placebo comparator|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
41291881|NCT00928915|DRUG|Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)|intravenous, repeated until INR ≤ 1.2
41291882|NCT03188211|OTHER|E-learning educational program|A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.
41291883|NCT03188211|OTHER|Control|Any educational program will be delivered to clinicians assigned to control arm
41291884|NCT03141307|BEHAVIORAL|EICI Movie|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
41455290|NCT04654429|DRUG|Placebo|IV Normal Saline 2cc will be given
41455291|NCT04654429|OTHER|Lower OT temperature Range|OT temperature set to 17-19 degree celsius
41455292|NCT05633251|BEHAVIORAL|Variable (random) interval|Using Variable (Random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
41455293|NCT05633251|BEHAVIORAL|Variable (non-random) interval|Using Variable (Non-random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
41455294|NCT05633251|BEHAVIORAL|Variable (random) interval with table tents|Using Variable (Random) Interval Reinforcement Schedules and Table Tents with Health-related Messages to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
41455295|NCT05633251|BEHAVIORAL|Control|No intervention
41455296|NCT01260805|DRUG|Reference Drug|Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
41455297|NCT01260805|DRUG|Test Drug|Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
40955492|NCT05580393|DIAGNOSTIC_TEST|RFLP analysis of SSU rRNA|"1. Genomic DNA will be extracted from Blastocystis-positive fecal samples using a specific DNA Stool Mini Kit according to the manufacturer's instructions and will be stored at -20°C until use.~2. PCR will be used to amplify a region of Blastocystis small subunit ribosomal RNA (SSU rRNA) gene.~3. The amplified products for the SSU rRNA gene will be digested to determine the strain subtype of Blastocystis spp. using specific restriction enzymes."
40955493|NCT02513342|BIOLOGICAL|Endostar|Endostar 30mg continuous intravenous injection pump,d1-d7；
40955494|NCT02513342|DRUG|Docetaxel|d4 Docetaxel，75（mg/m2），iv；
40955495|NCT02513342|DRUG|Cisplatin|d4，cisplatin，75（mg/m2），iv；
40955496|NCT01210469|OTHER|Strengthening and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
40955497|NCT01210469|OTHER|Stretching and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
40955498|NCT02917733|DRUG|LY3039478|Administered orally
40955499|NCT03754569|PROCEDURE|Peritoneal biopsies after complete macroscopic cytoreduction|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
40955500|NCT00508365|DRUG|Carvedilol CR capsules|The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.
40955501|NCT00508365|DRUG|Placebo|Placebo capsules to match each dose level will be provided.
40955502|NCT00508365|DRUG|Lisinopril|Lisinopril will be available as 10 milligrams tablets administered orally once daily.
40955503|NCT00785265|BEHAVIORAL|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
41291885|NCT03141307|BEHAVIORAL|EICI App|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
41291886|NCT03141307|BEHAVIORAL|Control|Standard of care, paper-based brochure
41291887|NCT02769871|BEHAVIORAL|Neuroimages of stroke|Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
41291888|NCT02769871|BEHAVIORAL|standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
41455298|NCT05385835|OTHER|Training|A training module was prepared by explaining the theoretical and practical parts of the application of blood pressure measurement from the brachial artery with a slide presentation and an animation video. The knowledge and skills of nurses in blood pressure measurement before education were measured. The training module was delivered to the nurses from the online system. At the end of the two-week training period, the knowledge and skill levels of the nurses will be measured again.
41455299|NCT04262245|PROCEDURE|Traditional Irrigation|irrigation with syringe
41455300|NCT04262245|DEVICE|Xp-endo Finisher (XPF)|irrigation activation file
40955504|NCT00785265|BEHAVIORAL|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
40955505|NCT02989545|DEVICE|Anal Tape|
41291889|NCT01469923|DRUG|AZD2820|Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
40955506|NCT04395404|DIAGNOSTIC_TEST|MRI|Patients with unilateral ASS, with and without the prosthesis in situ, are analysed by 3D- magnetic resonance imaging (MRI) with 64 channel head coil using T1 and T2 weighted, DIXON/ IDEAL, and T2 inversion recovery sequences.
40955507|NCT06405958|OTHER|gut microbiome|Obtaining new gut microbiome data in organ transplantation
40955508|NCT03922997|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.
40955509|NCT03191188|DRUG|Levothyroxine Sodium|Thyroid hormone supplement
40955510|NCT03191188|DRUG|Placebo Oral Tablet|Placebo
40955511|NCT04333550|DRUG|Deferoxamine|Intravenous infusion of Deferoxamine
40955512|NCT06556992|BEHAVIORAL|FIT Teens|This intervention will consist of 16 in-person and remote group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
40955513|NCT00487175|DRUG|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
40955514|NCT01006369|DRUG|hydroxychloroquine|hydroxychloroquine 200 mg po BID daily
40955515|NCT03894800|DRUG|Methoxyflurane (M)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention inhalation of metoxyflurane 3 ml and NaCl i.v. will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
40955516|NCT03894800|DRUG|Fentanyl (F1)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.025 mg i.v. and NaCl for inhalation will be administered(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
40955517|NCT03894800|DRUG|Fentanyl (F2)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.05 mg i.v. and NaCl for inhalation will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
40955518|NCT03894800|DRUG|NaCl (C)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
40955519|NCT02300246|PROCEDURE|Platelet-Rich Fibrin|Alveolar socket preservation with Platelet-Rich Plasma
40955520|NCT03373292|PROCEDURE|Venous stenting for internal jugular vein stenosis|"After confirming the diagnosis of IJVS by Jugular Vein Doppler Ultrasound, Magnetic Resonance Venography (MRV) and/or Computed Tomography Venography (CTV), and excluding external compression-induced stenosis as well as other causes of intracranial pressure elevation, patients will be divided into two groups randomly (30 for each group: group-1 and group-2).~Patients in Group-1 will receive Digital Subtraction Angiography (DSA) immediately after enrollment, and trans-stenotic pressures (∆MPGs) will be measured, balloon angioplasty bridging venous stenting will be performed when their ∆MPGs of jugular veins are equal to or greater than 5.44 cmH₂O (4 mmHg)."
40762267|NCT06443242|DRUG|Standard Medication Management (Control Group)|This intervention involves the continued use of standard pharmacological treatment with SSRIs for managing symptoms of depression. It serves as a control to evaluate the effects of laser acupuncture against conventional medical treatment without the introduction of additional therapeutic modalities. Participants' adherence to their prescribed medication regimen is monitored and documented, ensuring an accurate comparison of treatment effects across groups.
40762268|NCT06383013|BIOLOGICAL|BB-101|Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.
41291890|NCT01469923|DRUG|Placebo|Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
41291891|NCT04729530|DEVICE|Dyson Pure Cool - Active Purifier|Free standing air purifier
41291892|NCT04729530|DEVICE|Dyson Pure Cool - Placebo purifier|Placebo air purifier
40762269|NCT05809700|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|"This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded."
40955521|NCT03373292|PROCEDURE|One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis|"Patients in Group-2 will receive routine medical treatment for one month. Afterwards, they will undergo DSA (the procedure is the same as that in Group-1).~Notably, patients in Group-2 with medical uncontrolled intracranial hypertension will be provided stenting of their jugular veins at any time during the one-month routine medical treatment, in attempt to reduce their intracranial pressure and ameliorate visual damages in time."
40955522|NCT05271461|RADIATION|Low level laser Therapy|Pin pointed application of low level laser on 15 acupuncture points each point 1 min time of application 15 min.
41291893|NCT02815631|DEVICE|Cardiogoniometry (CGM)|
41291894|NCT02815631|DEVICE|Fractional Flow Reserve (FFR)|
41291895|NCT05677789|DIAGNOSTIC_TEST|Medical observation|Likely suitable for home treatment
41291896|NCT05677789|DIAGNOSTIC_TEST|Supportive treatment (BSC)|Consider hospital supervised treatment
41291897|NCT05677789|DIAGNOSTIC_TEST|Intensive care management|Manage in hospital as severe pneumonia
40762270|NCT04403685|DRUG|Tocilizumab|Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
40762271|NCT00489359|DRUG|Pemetrexed - Phase 1|500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
40762272|NCT00489359|DRUG|Carboplatin - Phase 1|area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
40762273|NCT00489359|DRUG|Pemetrexed - Phase 2|Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles
40762274|NCT00489359|DRUG|Carboplatin - Phase 2|Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles
40762275|NCT05571514|DIETARY_SUPPLEMENT|Mother-of-pearl|"The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone.~The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation."
40762276|NCT05571514|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate is a source of calcium.
41291898|NCT04886830|PROCEDURE|laparoscopic appendectomy using a single endoloop for appendiceal stump closure|laparoscopic appendectomy using a single endoloop for appendiceal stump closure before resecting the appendix
41291899|NCT04886830|PROCEDURE|laparoscopic appendectomy using two endoloops for appendiceal stump closure|laparoscopic appendectomy using a two endoloops for appendiceal stump closure before resecting the appendix
41455301|NCT04262245|DEVICE|Passive Ultrasonic Irrigation|irrigation activation method
41455302|NCT04262245|DEVICE|EndoActivator|irrigation activation method
40762277|NCT01892189|DRUG|Ketamine|Ketamine intravenous administration.
40762278|NCT01892189|DRUG|TAK-063|TAK-063 tablets
40955523|NCT05271461|OTHER|Circulatory exercises|"Active assisted or against mild resistance. Supine with leg up position 18degrees measured by the bed water balance in side rails.~If patient is not comfortable according to the modified Borg scale or contra indicated for the position then assume the supine position.~The subject will have A 3 min rest period to acclimatize themselves to each position.~The ankle pumping exercises consisted of simple repetitions of dorsiflexion 1 sec and planter- flexion for 1 sec with three different exercise intervals:~* repeated dorsiflexion and planter-flexion with no rest (no rest exercise).~* repeated dorsiflexion and planter-flexion with a 2 sec rest period (2 sec rest exercise).~* repeated dorsiflexion and planter-flexion with 4sec rest period (4sec rest exercise).~Subjects will have practiced ankle pumps before the exercise to get familiar and be educated about the procedure."
40955524|NCT05143385|OTHER|Virtual reality|"* Those patients who are randomly assigned as the intervention group will be given an explanatory session on the use of the video game console, controllers and game accessories.~* The intervention will begin 15 calendar days after admission.~* The intervention will be carried out once a week with a duration of 20 minutes with one of the games chosen by the patient together with the physiotherapist.~* The end of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions completed in order to participate in the study.~* The intervention will be carried out with an average of six sessions in each patient, including in the study those who perform a minimum of four sessions. However, the interventions will continue until hospital discharge.~* After completion of the clinical trial, a registry table will be drawn up quantifying the number of sessions for each patient and the type of session:"
40955525|NCT03724032|DEVICE|HD-tDCS*|Non-invasive brain stimulation (active protocol)
40955526|NCT03724032|DEVICE|Sham HD-tDCS*|Non-invasive brain stimulation (sham protocol)
40955527|NCT00769392|DRUG|Proparacaine Ophthalmic|Drops of Proparacaine on the eye, administered as described in the package insert
40955528|NCT00769392|DRUG|Tetracaine Ophthalmic|Drops of Tetracaine on the eye, administered as described in the package insert
40762279|NCT01892189|DRUG|TAK-063 Placebo|TAK-063 placebo-matching tablets
40762280|NCT05175001|DRUG|Diprospan|Diprospan combined with ropivacaine in ultrasound-guided thoracic paravertebral nerve block
40762281|NCT05175001|DRUG|Ropivacaine|Only ropivacaine in ultrasound-guided thoracic paravertebral nerve block
40762282|NCT06569927|PROCEDURE|Utilization of a perioperative position management protocol for congenital microtia patients based on the ADDIE model.|Key elements included formation of a multidisciplinary team，perioperative postural management, preoperative sleeping posture adaptability training, neck movement training, standardization of head position angles and head suspension time during surgery, use of protective headrests, attention to transfer and handover procedures, and specially designed pillows.
40762283|NCT06549985|BEHAVIORAL|PEEPS|Participants will participate in the PEEPS program in addition to usual care.
41455303|NCT00405262|DRUG|Ketorolac|0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
40762284|NCT06549985|BEHAVIORAL|Education|Participants will receive an educational handout on endometriosis in addition to usual care.
40762285|NCT00543127|DRUG|Fulvestrant|500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
40762286|NCT00543127|DRUG|Anastrozole|1 mg oral Anastrozole per day during 5 years.
40955529|NCT00769392|DRUG|Lidocaine 4%|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
40955530|NCT00769392|DRUG|Lidocaine 2% Injectable Solution|A subconjunctival injection of Lidocaine 2%
40955531|NCT01548287|DRUG|AZD5213|AZD5213 doseA daily
40955532|NCT01548287|DRUG|AZD5213|AZD5213 doseB daily
40955533|NCT01548287|DRUG|AZD5213|AZD5213 doseC daily
40955534|NCT01548287|OTHER|Placebo|Placebo tablet daily
40955535|NCT03236285|BEHAVIORAL|High-intensity interval exercise training in the fed state|High-intensity interval exercise training in the fed state
40955536|NCT03236285|BEHAVIORAL|Continous exercise training in the fed state|Continous exercise training in the fed state
40955537|NCT03236285|BEHAVIORAL|High-intensity interval exercise training in the fasting state|High-intensity interval exercise training in the fasting state
40955538|NCT03236285|BEHAVIORAL|Continous exercise training in the fasting state|Continous exercise training in the fasting state
41291900|NCT04886830|PROCEDURE|laparoscopic appendectomy using a clip for appendiceal stump closure|laparoscopic appendectomy using an endoclip for appendiceal stump closure before resecting the appendix
41455304|NCT00405262|DRUG|Bupivacaine|0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
40762287|NCT03843073|DEVICE|Connected Urinary Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
40762288|NCT03823482|DRUG|Lidocaine|Administration of lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation.
40762289|NCT03968042|DRUG|Nerve Growth Factor|Intramuscular injection for 2 weeks
40762290|NCT03968042|DRUG|Edaravone|Intravenous injection for 2 weeks
40762291|NCT03968042|DRUG|Combination of vitamin B1, B6, C, E and mecobalamine|Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
40762292|NCT06459583|OTHER|eHealth Platform|The eHealth Platform consists of the ADWebPortal and ADChatbot for receiving Alzheimer's-related test results
40955539|NCT01203631|DRUG|NNC 0142-0000-0002|A single dose administered subcutaneously (s.c., under the skin)
40955540|NCT01203631|DRUG|Placebo|A single dose administered subcutaneously (s.c., under the skin)
40955541|NCT05234996|DEVICE|3 Virtual Reality headset (VR Headset),|The VRE will administer through the use of 3 Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics.
40955542|NCT04678856|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
40955543|NCT04678856|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
40955544|NCT06040840|PROCEDURE|BAX|Injection of 30 mL of lidocaine (10 mg/ml) around the median, radial, ulnar and musculocutaneous nerves.
40955545|NCT06040840|PROCEDURE|Tourniquet|Inflation pressure 75 to 100 mmHg above the patient's systolic blood pressure.
40955546|NCT06040840|DRUG|Lidocaine|Axillary block with Lidocaine (10 mg/ml).
40955547|NCT06040840|PROCEDURE|WALANT|"Preparation of a mixture of 20 ml of lidocaine (10 mg/ml) with epinephrine (0.005 mg/ml) + 3 ml Na bicarbonate (84 mg/ml) + 17 ml sterile normal saline.~The ultrasound probe will be placed to obtain a transverse image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 5 ml of the solution posterior and then anterior to the median nerve under the annular carpal ligament.~Then the ultrasound probe will be placed to obtain a longitudinal image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 15 ml of the solution anterior to the median nerve towards the carpal tunnel.~At last, a local infiltration with 5 ml of the solution will be performed around the surgical incision."
40955548|NCT06040840|DRUG|Lidocaine + Epinephrine|WALANT technique with lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine.
40955549|NCT01296217|PROCEDURE|lymph nod detection|
40955550|NCT01853423|DRUG|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
40955551|NCT03604484|PROCEDURE|Tricuspid annuloplasty|Tricuspid annuloplasty
40955552|NCT03556735|DEVICE|Treatment with PEMF equipment|Treatment with PEMF in 8 weeks
40955553|NCT06284031|PROCEDURE|3 fractions HDR brachytherapy|"The 3 fractions of HDR brachytherapy may be delivered in the following ways:~Option 1: 3 insertions over 2 non-consecutive days:~Option 2: 3 insertions over 3 non-consecutive days"
40955554|NCT00366132|DEVICE|Extracorporeal Shockwaves|
40955555|NCT02904889|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
40955556|NCT02904889|OTHER|Usual care|Homecare professionals will get no training and their clients will receive usual homecare.
40955557|NCT03875365|PROCEDURE|POPE|Patients who have undergone Per-oral Plication of the Esophagus (POPE) procedure.
40955558|NCT01282632|DRUG|Risperidone|Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
40955559|NCT01282632|DRUG|Olanzapine|Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
40955560|NCT03533296|PROCEDURE|Positive end expiratory pressure (PEEP)|The different levels of PEEP, 5 cmH2O, 8 cmH2O and 12 cmH2O, are applied serially. Mean respiratory compliance and intratidal compliance-volume profile are evaluated.
40955561|NCT05614232|RADIATION|Chest X-ray|Chest radiographs
40762293|NCT06459583|OTHER|Videoconference Telehealth Platform|Participants will have a video telehealth visit with a healthcare provider to receive Alzheimer's-related test results
40955562|NCT02664259|PROCEDURE|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
40955563|NCT02664259|PROCEDURE|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
40955564|NCT02664259|PROCEDURE|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
40955565|NCT03459170|BIOLOGICAL|BPX-501 T cells|Biological: T cells transduced with CaspaCIDe® safety switch
40955566|NCT03459170|DRUG|rimiducid|administered to eliminate BPX-501 cells in the event of GVHD
40955567|NCT02229383|DRUG|Exenatide|2 mg weekly suspension injection
40955568|NCT02229383|DRUG|Exenatide matching placebo|Once weekly Placebo injection
40955569|NCT00255112|BEHAVIORAL|family based cognitive behavior therapy|newly developed family based cognitive behavior therapy for children with separation anxiety disorder over 5 years old
40955570|NCT01741090|BIOLOGICAL|mesenchymal stem cell injection|Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
40762294|NCT02881216|DEVICE|Synergy Stent|Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
40955571|NCT06086171|DRUG|Methadone Hydrochloride|Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia
40955572|NCT06086171|OTHER|Placebo|Saline solution
40955573|NCT03504059|BEHAVIORAL|Long-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
40955574|NCT03504059|BEHAVIORAL|Short-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
40955575|NCT01004965|OTHER|laboratory biomarker analysis|
40955576|NCT03208712|DRUG|Atezolizumab|Atezolizumab 1200 mg IV once every 3 weeks
40955577|NCT03208712|DRUG|Radium-223|Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
41291901|NCT00148590|DRUG|Memantine|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
40955578|NCT05207046|OTHER|Mechanical Ventilation|Patients will be assessed and measurements will be taken during controlled ventilation (most likely \<72 hours of ICU admission), during partially assisted ventilation, and until spontaneous unassisted breathing is reached.
40955579|NCT03855865|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
40955580|NCT03855865|DRUG|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
40955581|NCT03855865|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
40955582|NCT01864655|DRUG|saracatinib|oral drug given to experimental group
40955583|NCT01864655|DRUG|Placebo|Placebo given to placebo group
40955584|NCT05599191|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
40955585|NCT05599191|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
40955586|NCT05213481|DRUG|Tepotinib|Participants received Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.
40955587|NCT05213481|DRUG|Carbamazepine|Carbamazepine 100 mg twice daily at Day 8 and 9, 200 mg twice daily at Day 10 and 11, 300 mg twice daily from Day 12 to 32.
40955588|NCT05374733|DIAGNOSTIC_TEST|Coronary Physiology assessment|"1. Pd/Pa, diastolic pressure ratio (dPR), resting full cycle ratio (RFR), FFR, coronary flow reserve (CFR), and index of microvascular resistance (IMR) measurements in the coronary of interest before the valvular intervention.~2. Pd/Pa, dPR, RFR, FFR, vFFR, CFR and IMR measurements in the coronary of interest after the valvular intervention."
40955589|NCT04999488|DRUG|BPM31510|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
40955590|NCT04999488|OTHER|Placebo|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
40955591|NCT02774954|BEHAVIORAL|Change the Cycle|See previous response
40955592|NCT04383483|OTHER|COVICU|COVICU
40762295|NCT02881216|DEVICE|Currently common drug-eluting stent (DES)|Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
40762296|NCT04661358|DRUG|Fenofibrate|Participants begin with a dose of either 160mg or 54mg fenofibrate, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
40762297|NCT04661358|OTHER|Placebo|Participants begin with a dose of either 160mg or 54mg placebo, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
40762298|NCT04246749|DRUG|[14C]-CRN00808|Investigational drug
40762299|NCT04246749|DRUG|CRN00808|Investigational drug
40955593|NCT02732756|BEHAVIORAL|Healthy Sleep Duration|This study examines healthy sleep duration as related to improved functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are able to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep). Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
40955594|NCT02732756|BEHAVIORAL|Shortened Sleep Duration|This study examines shortened sleep duration as related to poorer functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are in bed for 6.5 hours per night. Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
40955595|NCT00645112|DRUG|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
40955596|NCT00645112|DRUG|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
40955597|NCT00268788|DRUG|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
40955598|NCT00268788|DRUG|Intravenous immunoglobulin|Individual dose and frequency
40955599|NCT05212519|OTHER||For observational research
40955600|NCT01634334|BEHAVIORAL|Real-Time Intervention|Lights and Sound Brief Coaching
40955601|NCT01634334|BEHAVIORAL|Usual Education|Participants will receive usual education about secondhand smoke and thirdhand smoke.
40955602|NCT04456257|DEVICE|fractional picosecond 1,064 nm laser|The parameter of laser was 8-mm spot size, 0.6 mJ/cm2, 750 ps, 10 Hz, 2 passes. The treatment was done in every 4 weeks for 4 sessions.
40955603|NCT04676178|DRUG|PRA023|PRA023
40955604|NCT04676178|OTHER|Placebo|Placebo
40955605|NCT04372082|OTHER|Standard of care (SOC)|SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen...) during the whole study duration
40762300|NCT05646693|DIETARY_SUPPLEMENT|Drusen Mega®|It consists of a dietary supplement composed of Vitamin C 60.0mg, Vitamin E 30.0mg, Zinc 12.5mg, Copper 1.0mg, Astaxanthin 4.0mg, Zeaxanthin 2.0mg, Lutein 10.0mg and Omega 3 Acids 500.0mg. It is suggested to consume one capsule per day, preferably with food. This supplement is indicated for nutritional deficiencies and in patients with ophthalmological pathologies.
40762301|NCT05646693|DRUG|Sertraline|It consists of a drug capsule composed of Sertraline Hydrochloride 50mg. In adults it is suggested to consume one to four capsule(s) per day, administering (preferably) the highest dose in the evening, before going to bed. This drug is indicated in the treatment of depressive states with anxiety or moderate to severe agitation, which are accompanied by tension, excitement, insomnia, obsessive and hypochondriac traits. It is also indicated in obsessive-compulsive disorder, panic attacks, stress disorder, post-traumatic disorder, social anxiety disorder and used to relieve the symptoms of premenstrual dysphoric disorder.
40955606|NCT04372082|DRUG|Hydroxychloroquine|200 mg x 3 per day during 10 days in addition to SOC
40955607|NCT04372082|DRUG|Association of diltiazem and niclosamide|niclosamide 500 mg x 4 at J1 then 500 mg x 2 per day + diltiazem 60 mg x 3 per day during 10 days in addition to SOC
40955608|NCT06435676|DRUG|HRS9531|Single dose escalation of HRS9531 tablets in healthy subjects
40955609|NCT06435676|DRUG|Placebo|Single dose of placebo in healthy adults
40955610|NCT06435676|DRUG|HRS9531|Multiple dose escalation of HRS9531 tablets in healthy subjects
40955611|NCT06435676|DRUG|Placebo|Multiple dose of placebo in healthy adults
41291902|NCT00148590|DRUG|Placebo|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
40762302|NCT05646693|DRUG|Placebo|It consists of a placebo capsule composed of Magnesium Oxide 100mg. This component is inert in the dose at which it will be administered.
40762303|NCT05218434|DRUG|AX-158|Oral administrations of AX-158
40762304|NCT03696186|DRUG|Luminal type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
40955612|NCT00223015|DRUG|Fluvastatin, Tacrolimus, Mycophenolat Mofetil|
40955613|NCT03775629|DRUG|Polmacoxib and Tramadol combination|Tramadol hydrochloride , Polmacoxib
40955614|NCT03775629|DRUG|Polmacoxib|Polmacoxib
40955615|NCT03775629|DRUG|Tramadol hydrochloride|Tramadol hydrochloride (HCl)
40955616|NCT04846296|OTHER|Questionnaire|The QLPSD, developed in Spain, was the first questionnaire designed to evaluate HRQoL in adolescents with spinal deformities. It has shown good validity and reliability. English, French and Persian versions of the QLPSD have been developed and validated. Good reliability and ease of use are mentioned in these versions. The QLPSD was designed to examine adolescents with spinal deformities and measure the effect of orthotic and surgical treatments on QoL.
40955617|NCT02323243|DEVICE|"Allium  Bulbar Urethral Stent  (BUS) system"|
40955618|NCT00180050|DRUG|Budesonide|
40955619|NCT03006107|PROCEDURE|intraligamentary injection piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
40955620|NCT03006107|PROCEDURE|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
40762305|NCT03696186|DRUG|Luminal type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
40955621|NCT05596344|OTHER|Hospital Anxiety and Depression Scale|The basic information, anxiety and depression, treatment and prognosis of these patients were collected.
40955622|NCT02501226|OTHER|Treatment as usual|Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
40955623|NCT02501226|BEHAVIORAL|ENVIE psychoeducational program|"The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.~The sessions may be carried out remotely, by videoconference."
41291903|NCT01527604|OTHER|Avenanthramide-enriched oats|avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
40762306|NCT03696186|DRUG|Neuroendocrine type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
40955624|NCT01822171|OTHER|Discharge medication counseling from a pharmacist|Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
40955625|NCT01822171|OTHER|Home medication if needed|Patient will be provided with medication to take home, when needed.
40955626|NCT01822171|OTHER|Follow-up visit at Medication Therapy Management clinic|This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
41291904|NCT01527604|OTHER|Refined flour absent avenanthramides|refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
41291905|NCT03271827|DEVICE|Apnoeic oxygenation|3 L/min of oxygen by nasal cannula during as apnoeic oxygenation during airway management.
40762307|NCT03696186|DRUG|Neuroendocrine type-2|Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
40762308|NCT03696186|DRUG|Atypical type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
40762309|NCT03696186|DRUG|Atypical type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
40762312|NCT04781972|DRUG|Methylphenidate|single dose of 10 mg or 15 mg
40762313|NCT04781972|DRUG|Placebo|Matching placebo
40762314|NCT05152485|DRUG|BIIB104 Reference Formulation|Administered as specified in the treatment arm
40762315|NCT05152485|DRUG|BIIB104 Test Formulation|Administered as specified in the treatment arm
40762316|NCT02150863|DEVICE|Ultrapulse Carbon Dioxide Laser|
40955627|NCT06114225|COMBINATION_PRODUCT|metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy|participants first receive concurrent SBRT and penpulimab (PD-1 blockade) and two cycles of GP regimen (gemcitabine d1,d8 and Penpulimab d8 per a 21-day cycle), followed by complete pulmonary metastasectomy. After surgery, participant receive another 4 cycles of GP regimens followed by Penpulimab monotherapy maintenance. The rationale is that pre-operative SBRT could boost the immune microenvironment, leading to a long-term effect of immunotherapy post-metastasectomy and eventually resulting in better long-term survivorship compared to the histological control for pulmonary resectable recurrence of osteosarcoma .
40955628|NCT00386048|BEHAVIORAL|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
40955629|NCT01931592|DRUG|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
40955630|NCT01931592|DRUG|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
40955631|NCT00894166|DRUG|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
40955632|NCT00894166|DRUG|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
40955633|NCT00894166|DRUG|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
40955634|NCT00894166|DRUG|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
40955635|NCT00894166|DRUG|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
40955636|NCT00894166|DRUG|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
40762317|NCT02150863|DEVICE|Cellutome epidermal harvesting system|
40955637|NCT00894166|DRUG|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
40955638|NCT02737397|DRUG|JMI-001 (SJP-304 and SJP-223)|
40762318|NCT01893450|DRUG|Methimazole|
40762319|NCT01893450|DRUG|Bromocriptine|
40762320|NCT01893450|DRUG|Pentoxifylline|
40955639|NCT02737397|DRUG|SJP-304|
40955640|NCT02737397|DRUG|SJP-223|
40955641|NCT02737397|DRUG|placebo|
40955642|NCT05954975|COMBINATION_PRODUCT|BabyCheck and pulse oximetry|"The BabyCheck is a validated scoring system to grade the severity of acute systemic illness in infants up to six months of age. Severity of illness is graded by using a weighted score of a combination of nineteen signs and symptoms. The higher the score, the higher the chance of severe illness.~Nellcor PM10N is a pulse oximeter which is cleared for use in young infants. A sensor for infants will be used, so reliable oxygen saturation and heart rate can be obtained."
40955643|NCT01095926|DRUG|doxorubicin|blood sampling before, during and after doxorubicin administration
40955644|NCT05244304|DRUG|Tinlarebant|Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
40955645|NCT05244304|DRUG|Placebo|Not active drug
40955646|NCT00695409|BIOLOGICAL|rituximab|Given IV
40955647|NCT00695409|DRUG|carmustine|Given IV
40955648|NCT00695409|DRUG|cytarabine|Given IV
40955649|NCT00695409|DRUG|etoposide|Given IV
40955650|NCT00695409|DRUG|melphalan|Given IV
40955651|NCT00695409|PROCEDURE|ASCT|Undergo autologous peripheral blood stem cell transplant
40955652|NCT00695409|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
40955653|NCT01942343|DRUG|Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration|
40955654|NCT01842022|DIETARY_SUPPLEMENT|Isomaltulose|Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
40955655|NCT01842022|DIETARY_SUPPLEMENT|Sucrose|Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
40955656|NCT01842022|DIETARY_SUPPLEMENT|Glucose|Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
40955657|NCT02217878|DRUG|Morphine|IV bolus injection
40955658|NCT02217878|DRUG|Placebo|IV bolus injection
40955659|NCT02217878|DRUG|Ticagrelor|180 mg loading dose
40955660|NCT03831399|DIETARY_SUPPLEMENT|Leucine|Administration 6 g/day of leucine at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
40955661|NCT03831399|DIETARY_SUPPLEMENT|Placebo|Administration 6 g/day of lactose at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
40955662|NCT03582189|OTHER|MRI|Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
40955663|NCT01965821|DEVICE|Continuous control of Pcuff followed by manual control|continuous control of tracheal cuff pressure using an electronic device for 24 h followed by manual control of cuff pressure using a manometer
40955664|NCT01965821|DEVICE|Manual control of Pcuff followed by continuous control|24 h of manual control using a manometer followed by 24 h of continuous control using an electronic device
40955665|NCT05142111|BEHAVIORAL|Therapy|Discussion with therapist
40955666|NCT04840004|DRUG|PVT-1|Since there is no specific dose range is available for testing the anti-tumor effects of PVT-1 in clinical trials settings, in the present study the dose of PVT-1 will be up-titrated 250/160/160 mg to maximum 1000/640/640 mg as described in study methodology section.
40955667|NCT00382304|DRUG|tolevamer potassium-sodium (GT267-004)|
40955668|NCT03690531|DEVICE|Take-Pause virtual reality|Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.
40955669|NCT03690531|DEVICE|Passive Distraction|Standard or passive distraction technique, lasting 5 minutes.
40955670|NCT02158234|DRUG|Cisplatin|Cisplatin 15 mg/m\^2 prior to each fraction
40955671|NCT02158234|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
40955672|NCT03030807|DIAGNOSTIC_TEST|Right heart catheterization (in case of suspected PH)|
40955673|NCT03802760|DEVICE|Transcranial Doppler (TCD) ultrasound measurement|Non-invasive measurement of cerebral embolic load and blood flow using TCD
40955674|NCT01760720|BEHAVIORAL|MMT CARE|
40955675|NCT05919888|DRUG|Povidone-Iodine|Applied to skin incision.
40955676|NCT05919888|DEVICE|SURGX Wound Gel|Applied to skin incision.
40955677|NCT02796469|DRUG|Pentoxifylline|
40955678|NCT02796469|DRUG|Corticosteroid|
40955679|NCT02796469|DRUG|Placebo|
40955680|NCT01358045|DRUG|Diclofenac|Application on the lesion 2 times a day 8 weeks.
40955681|NCT01358045|DRUG|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
40955682|NCT01358045|DRUG|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
40955683|NCT00589992|DRUG|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
40955684|NCT05009654|DIETARY_SUPPLEMENT|L-carnitine|
40955685|NCT05009654|DIETARY_SUPPLEMENT|L-leucine|
40955686|NCT02293057|BEHAVIORAL|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
40955687|NCT02293057|BEHAVIORAL|Girl Health Group|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
40955688|NCT00455078|PROCEDURE|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
40955689|NCT00455078|OTHER|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
40955690|NCT00455078|PROCEDURE|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
40955691|NCT00455078|PROCEDURE|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
40955692|NCT00455078|PROCEDURE|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
40955693|NCT05139121|DRUG|MR-100A-01|Transdermal contraceptive delivery system
40955694|NCT04532970|BEHAVIORAL|Cessation Counseling|Two different types of smoking cessation counseling
40955695|NCT00014937|DRUG|lopinavir/ritonavir|
40955696|NCT00014937|DRUG|lamivudine/zidovudine|
40955697|NCT00014937|DRUG|efavirenz|
40955698|NCT00014937|DRUG|lamivudine|
40955699|NCT00014937|DRUG|stavudine|
40955700|NCT00014937|DRUG|zidovudine|
40955701|NCT00014937|DRUG|didanosine|
40955702|NCT03623841|OTHER|Dual-task training|Participants in experimental group will do dual-task training via exer-game which combined with treadmill
40955703|NCT03623841|OTHER|Treadmill training|Participants in control group will do treadmill training only
40955704|NCT03763175|DRUG|SYN-010 21 mg|21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
40955705|NCT03763175|DRUG|SYN-010 42 mg|42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
40955706|NCT03763175|DRUG|Placebo|A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
40955707|NCT01064596|OTHER|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
41455305|NCT00405262|DRUG|ketorolac + bupivacaine|"0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter"
41455306|NCT06209996|BEHAVIORAL|L4 weight management intervention|he key goals of the intervention are to: (i) teach knowledge of weight loss benefits and health risks of obesity, (ii) offer skill-based dietary and physical activity advice, (iii) develop an achievable weight loss goal and plan, (iv) enhance weight management self-efficacy, (v) provide access to exercise equipment and resources, and (vi) teach strategies for managing cravings. The L4 intervention is a therapist- delivered intervention involving a registered dietitian and a cancer exercise specialist. Participants allocated to the intervention arm will be provided with a schedule to attend the L4 intervention within four weeks post-baseline via phone. They will receive five intervention sessions (120 min each) on a weekly basis, and will be given home-based practices and reading to practice the skills learnt in each session. The intervention sessions will be delivered in a group format with a maximum of 5 individuals per group, which is likely to enhance accountability.
40955708|NCT01765907|DEVICE|HIFU|
40955709|NCT06251648|DRUG|Lenalidomide|Patients exposed to LEN
40955710|NCT00143182|DRUG|Asenapine|Asenapine , 9 weeks
40762321|NCT03791060|DRUG|Secukinumab|Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
40955711|NCT00143182|DRUG|Olanzapine|Olanzapine, 9 weeks
40955712|NCT03314194|OTHER|Plant Based Diet|Plant Based Diet for 4 Days Compared to Habitual Diet
41455307|NCT06209996|BEHAVIORAL|Active control|A video-based intervention is selected as a low-touch alternative with expected benefits beyond a no treatment control. Participants allocated to the active control arm will receive five educational videos designed to promote a balanced diet and reinforce regular physical activity, weekly through instant messaging, and be encouraged to follow the advice covered in the videos. The materials will be developed based on the existing dietary and physical activity guidelines for cancer survivors. Participants in this arm will be arranged to attend to the L4 intervention upon completion of the study.
40955713|NCT02201641|RADIATION|Cone Beam computed tomography (Morita Accuitomo)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
40955714|NCT02201641|RADIATION|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
40955715|NCT02201641|DEVICE|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
40955716|NCT02201641|DEVICE|glass ionomer cement ( Fuji IX™)|glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
40955717|NCT00870441|DRUG|ASP2151|Oral
40955718|NCT00870441|DRUG|Valacyclovir|Oral
40955719|NCT00870441|DRUG|Placebo|Oral
40955720|NCT05759078|DRUG|Ferinject|The first dose of FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4 and 8 months (visits V2, V3) for: haemoglobin, serum ferritin and TSAT. They will receive an additional dose of 1000 mg of FCM during these visits if ferritin \<100 ng/mL or/and TSAT \<20% (ferritin cannot exceed 400 ng/dL, TSAT cannot exceed 40%, haemoglobin cannot exceed 15 g/dL). If these criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.
40762322|NCT06561776|OTHER|Physical Evaluations of individuals|Participants will be evaluated on cough strength, physical activity and balance. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
40955721|NCT05759078|DRUG|Sodium Chloride 0.9% Inj|The first dose of placebo will be administered during the first visit on the day of randomisation (V1). During visits V2 i V3 (at 4 and 8 months) they will receive next dose of placebo.
40955722|NCT04470141|DRUG|SHC014748M treatment|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
40955723|NCT04252781|OTHER|Exhaustive exploration|"* clinical investigations~* imagery~* blood assessment~* functional respiratory investigations~* muscle function / skeletal muscle index"
40955724|NCT00871533|DRUG|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
40955725|NCT00871533|DRUG|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
40955726|NCT00871533|DRUG|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
40955727|NCT00871533|DRUG|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
40955728|NCT00880542|DRUG|sorafenib|Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
40955729|NCT00880542|DRUG|Ifosfamide|Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
40955730|NCT00423904|BEHAVIORAL|Brief intervention|
40955731|NCT01796509|OTHER|Medical, psychological, social|After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
40955732|NCT02771431|OTHER|Tele-rounding in post operative care|Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
40955733|NCT03094429|DRUG|NaBen®|2000 mg/day or 1000 mg/day, twice daily
40955734|NCT03094429|OTHER|Placebo|0 mg total, twice daily
40955735|NCT03651544|BIOLOGICAL|GamFluVac|1 dose (0,5 ml)
40955736|NCT00334321|RADIATION|IMRT|
40955737|NCT00334321|RADIATION|Intracavitary vaginal brachytherapy|
40955738|NCT00334321|DRUG|Paclitaxel|
40955739|NCT00334321|DRUG|Carboplatin|
40955740|NCT04341077|DRUG|SHR3162|A single oral dose of fluzoparib on Day 1
40955741|NCT01651039|DRUG|Panobinostat|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
40955742|NCT01651039|DRUG|Lenalidomide|Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
40955743|NCT01651039|DRUG|Dexamethasone|Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
40955744|NCT05145595|DEVICE|Thermal Sensory Analyzer|Thermal stimuli: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
40955745|NCT05145595|DEVICE|Pressure Stimuli|Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
40955746|NCT05145595|DEVICE|Mechanical Stimuli|Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture.
40955747|NCT05145595|BEHAVIORAL|Pain Ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
41455308|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
41455309|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
41455310|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
40762323|NCT01027351|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
40762324|NCT01027351|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
40762325|NCT03442972|DRUG|Teduglutide|Teduglutide
40762326|NCT03442972|DRUG|Placebo|Placebo
40762327|NCT05078411|BEHAVIORAL|Test treatment|"Test treatment will consist of a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on periodontal risk level (as calculated with the PerioRisk tool proposed by Trombelli et al. 2009) and profile (i.e., the magnitude of the contribution of each PerioRisk parameter to generate the patient risk level); (iii) information on treatment plan and oral hygiene instructions, with emphasis to treatment goals based on the PerioRisk output.~The operators will be trained to administer test treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
40762328|NCT05078411|BEHAVIORAL|Control treatment|"Control treatment will consist in a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on treatment plan and oral hygiene instructions, and treatment goals. Although the general concept of risk of periodontitis incidence/progression will be explained, no mention will be made to the patient risk level as calculated with PerioRisk or any other tool.~The operators will be trained to administer control treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
40762329|NCT02997007|DEVICE|active tDCS|Participants will receive active tDCS over the angular gyrus on five consecutive days
40762330|NCT02997007|DEVICE|sham tDCS|Participants will receive sham tDCS over the angular gyrus on five consecutive days
40762331|NCT05988281|PROCEDURE|Type I Dental implant placement.|Placement of dental implant.
40762332|NCT05988281|PROCEDURE|Type II Dental implant placement.|Placement of dental implant.
40762333|NCT05988281|PROCEDURE|Type III/IV dental implant placement.|Placement of dental implant.
40762334|NCT06564922|OTHER|Counselling|Counselling was given for treatment group.
40762335|NCT05635084|DRUG|YN001|Dose ranges from 2-90mg
40762336|NCT05635084|DRUG|Placebo for YN001|5% dextrose injection to mimic the YN001
40762337|NCT04245098|PROCEDURE|Carpal tunnel syndrome surgery|Biopsy
40762338|NCT03587090|DIAGNOSTIC_TEST|echocardiography|echocardiography by subcostal and transhepatic views
40762339|NCT01996046|OTHER|FDG PET/CT scan|\[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
40762340|NCT03285360|COMBINATION_PRODUCT|Sylc|a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment
40762341|NCT03285360|COMBINATION_PRODUCT|fluoride varnish (Bifluorid 10)|It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
40762342|NCT06407401|DRUG|Duloxetine 60 MG|"Patients randomized to the duloxetine arm will take duloxetine orally daily, with or without food, on a continuous dosing schedule.~Initial dose is 30 mg daily for 1 week, followed by 60 mg daily for a total of 6 months of treatment, followed by a taper off the medication of 30 mg daily for 1 additional week."
40762343|NCT06407401|DRUG|Furosemide 40 mg|Patients randomized to the furosemide arm will take furosemide 40 mg orally daily, on an empty stomach with plenty of liquid, on a continuous dosing schedule.
40762344|NCT06407401|BEHAVIORAL|Booklet for healthy behaviors|All patients will receive usual care, including a booklet focused on healthy behaviors, particularly physical exercise, to manage endocrine therapy side-effects.
40955748|NCT05145595|BEHAVIORAL|Thermal pain thresholds|Cold and heat pain thresholds (CPT and HPT, respectively) will be determined \[22; 55\]. Thresholds are determined by continuous ramping of temperature from 32°C baseline temperature until the participant press a button at the first moment he/she feels pain from the stimulus. Cut-off temperatures are 0°C and 50°C, to minimize potential damage to the skin. The baseline temperature to which the thermode returns before each test is 32°C. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
40955749|NCT05145595|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
41455311|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
41455312|NCT01583530|BIOLOGICAL|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
41455313|NCT01583530|BIOLOGICAL|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
40762345|NCT01145183|DRUG|Doxazosin|Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
40762346|NCT01145183|DRUG|Placebo|Matched placebo daily dosing
40762347|NCT04369105|OTHER|Prone position|The patients will be put in prone position while receiving invasive mechanical ventilation and the investigators will monitor changes in mechanical power applied to the respiratory system and compare with supine position
40762348|NCT03728686|OTHER|Different given time|Fentanyl 2mcg/kg (F) was given at either 1,2,3 minutes before intubation
41455314|NCT02030535|DRUG|olodaterol|free combination with tiotropium
40762349|NCT03517800|OTHER|Arterial embolization and/or surgical management.|Arterial embolization and/or surgical management.
40762350|NCT06195956|OTHER|exercise|Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months
40762351|NCT05316740|OTHER|No intervention|Repeated clinical evaluation and sample collection
41455315|NCT02030535|DRUG|tiotropium|free combination with olodaterol
40955750|NCT05145595|BEHAVIORAL|Mechanical temporal summation|A pinprick stimulus with standardised intensity (#6.10 or #6.45 von Frey filament) and a flat contact area of 0.25mm diameter will be used. In this test, participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli. The 10 identical pinprick stimuli are applied with a frequency of 1 s-1 within an area of 1 cm2. Immediately following the single stimulus and series of stimuli, an evaluation of the pain will be collected. The difference in pain ratings evoked with the one stimuli vs. the 10 stimuli is the temporal summation value.
40955751|NCT05145595|BEHAVIORAL|Conditioned pain modulation (CPM) efficiency|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information. CPM testing includes the application of a test stimulus without conditioning (control run) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run). Heat-CPM and pressure-CPM. Heat and pressure CPM will be tested in random order.~The difference between the pain ratings/thresholds of the test stimulus with vs. without the concomitant conditioning stimulus is the CPM magnitude. CPM\<0 (reduction in pain) implies efficient inhibitory pain modulation of spatial filtering."
40955752|NCT05145595|BEHAVIORAL|Offset analgesia efficiency|"Offset analgesia (OA) paradigm assesses endogenous inhibitory pain modulation efficiency of temporal filtering of nociceptive information. The mechanisms underlying OA are distinct from the CPM mechanisms \[41\]. OA is characterized by a disproportionately large reduction in pain perception after a small decrease in temperature during noxious thermal stimulation.~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). The T1 will be noxious heat (44-48°C) delivered to the hand or leg. During the OA paradigm, real time pain intensity ratings will be obtained using the computerized VAS.~The difference between the pain ratings of the 10-20 seconds noxious stimulus in the OA paradigm compared to a control paradigm (30 seconds of T1) is the OA magnitude. OA\<0 (reduction in pain) implies efficient inhibitory pain modulation of temporal filtering."
40955753|NCT05145595|BEHAVIORAL|Cold pain tolerance|Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold (4-12°C) water bath. Tolerance will be defined by the time of hand withdrawal. VAS ratings of cold pain intensity might be obtained periodically, and both pain intensity and pain unpleasantness will be recorded upon hand withdrawal. Limb immersion in the cold water bath will be terminated after 120 s if participants do not withdraw their hand before then.
40955754|NCT02385942|DEVICE|Smart phone|"* measure the Live assessed wound size and the transmitted Smart phone-based wound size~* determine dressing materials using Smart phone-based tele-consultation"
40955755|NCT06187584|DRUG|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen 0.15mg/kg PO q6
40955756|NCT06187584|DRUG|Acetaminophen|15mg/kg PO q6 hours
40955757|NCT06187584|DRUG|Ibuprofen|10mg/kg PO q6 hours
40955758|NCT03673046|DEVICE|Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)|12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
40955759|NCT03998930|OTHER|Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R)|Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task
40955760|NCT00479726|DRUG|duloxetine hydrochloride|
40955761|NCT05140915|BEHAVIORAL|Peer Messaging|Peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit.
40955762|NCT05140915|BEHAVIORAL|Peer Coaching via Text|Peer coaching, facilitated by texting
40762352|NCT05902975|DEVICE|Fiber reinforced composite resin space maintainer|Bonding of fiber reinforced with composite resin on primary second molar and primary canine under rubber dam isolation
40762353|NCT04715581|DIETARY_SUPPLEMENT|Preoperative nutritional optimization|"1. Indication for oral nutritional supplementation: Patients at risk of malnutrition (MNA-SF 8-11) or with malnutrition (MNA-SF 0-7).~2. Protocol of nutritional optimization: Enteral nutritional powder (Ensure for patients without diabetes and Glucerna for patients with diabetes) twice a day. The target protein intake is 1.5-1.8 g/kg/d. Patients with iron deficient anemia (hemoglobin \<130 g/L for men and \<120 g/L for women) will be given oral iron therapy.~3. The duration of nutritional optimization: The day admitted to the hospital to the surgery to one day prior to the surgery."
40762354|NCT04715581|BEHAVIORAL|Preoperative exercise training|"1. The respiratory training will be performed for at least 2-3 times per day. Respiratory training include thoracic breathing exercise and cough training.~2. Aerobic exercise will be performed for at least 1-2 times per day. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Every training should be last for 45 minutes to 1 hour. If the patient can not tolerate, the training time should be reduce to 30 minutes.~4. The duration of exercise training: The day admitted to the hospital to the surgery to one day prior to the surgery."
40762355|NCT04715581|BEHAVIORAL|Postoperative exercise training|"1. Muscle strength training in the bedside and walking in the ward.~2. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Exercise training is performed under the supervision of physiotherpists durign hospital stay, and is reminded by regular telephone calls and phone messages after hospital discharge."
40762356|NCT06570356|DIAGNOSTIC_TEST|Geriatric Depression Scale - 15|a validated screening tool designed to identify depression in older adults. It consists of 15 simple yes/no questions that assess depressive symptoms.
40955763|NCT05140915|BEHAVIORAL|Gamification|Gamification, designed to motivate participation
41455316|NCT02030535|DRUG|Placebo|
41455317|NCT02030535|DRUG|tiotropium|fixed dose combination with olodaterol
41455318|NCT02030535|DRUG|olodaterol|fixed dose combination with tiotropium
41455319|NCT01600313|DIETARY_SUPPLEMENT|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
40955764|NCT05140915|OTHER|E-Cigarette Cessation Materials|Written e-cigarette cessation materials by the Research Coordinator at the time of study enrollment. The written materials will consist of two pamphlets from Journeyworks, selected based on: (1) their clear and attractive layout designed for a low-literacy audience, and (2) their providing both information re: e-cigarette use with a strong message about nicotine and nicotine addiction, E-Cigarettes: 8 Things Everyone Should Know, and support in quitting, How to Quit Vaping.
40955765|NCT06258941|BEHAVIORAL|MF-HIIT|Two 10-min MF-HIIT sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
40955766|NCT06258941|BEHAVIORAL|HIIT-only|Two 10-min HIIT-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
40955767|NCT06258941|BEHAVIORAL|MF-only|Two 10-min MF-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
40955768|NCT06258941|BEHAVIORAL|Sedentary activity|Two 10-min sedentary sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
40955769|NCT04997083|DEVICE|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
40955770|NCT04997083|DEVICE|Petit face mask|The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion. It consists of forehead cap, chin cap, and cross bar.
40955771|NCT05979259|OTHER|Serious game nutrition education intervention|"Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will play the Foodbot Factory nutrition education serious game for 10-15 minutes. The Foodbot Factory serious game and lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide."
40955772|NCT05979259|OTHER|Conventional nutrition education intervention|Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will use conventional learning activities, such as worksheets, sourced from an online teaching resource repository. The lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide.
40955773|NCT03807518|BEHAVIORAL|Standard Exercise Program|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing neo adjuvant therapy and for a six week period when deemed fit post surgery.
40955774|NCT00762060|DEVICE|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
40955775|NCT00762060|DRUG|Patient controlled analgesia|IV opioids delivered via PCA
40955776|NCT05893576|DRUG|HRS9531|Receive a single dose of HRS9531 of original formulation.
40955777|NCT05893576|DRUG|HRS9531|Receive a single dose of HRS9531 of new formulation.
40955778|NCT05540457|DEVICE|Intermittent Non-InvasiveBlood Pressure Monitor|"Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis."
41135345|NCT04923022|OTHER|Vegan Diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
40762357|NCT05095285|OTHER|Swaddling|"* Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.~* Common procedure steps:~  * Legal representatives of the infants will sign an informed consent form.~ * İncubator cover and nesting~ * Endotracheal suction(ES) was performed in the supine position.~ * ES was done at the time of care the baby needed.~ * No painful procedure was applied until 2 hours before ES and 15 minutes after ES.~ * Aspiration was performed sterile at 80 mmHg pressure.~ * A second nurse assisted in the suction process and the procedure took no more than 15 seconds.~ * The amount of oxygen taken by the baby was increased by 10% 30 seconds before the suction procedure and returned to its original value 60 seconds after the procedure.~ * Beginning 3 minutes before the ES procedure, during the procedure and until 15 minutes after the procedure, the infants' behaviors and bedside monitor indicators were video recorded."
40762358|NCT05095285|OTHER|Oropharyngeal colostrum|"* Common procedure steps~* In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue."
40955779|NCT01924000|DRUG|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
40955780|NCT01924000|DRUG|Placebo|
40955781|NCT03045185|PROCEDURE|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.|"First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin."
40955782|NCT00842582|DRUG|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
41135346|NCT04923022|OTHER|Therapeutic exercise|Individuals in the therapeutic exercise group will perform therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.
40955783|NCT00842582|DRUG|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
40955784|NCT00842582|DRUG|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
40955785|NCT00511446|DRUG|docetaxel, oxaliplatin, capecitabine|"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
40955786|NCT06199154|DRUG|Misoprostol|Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.
40955787|NCT04149379|DRUG|Hyperbaric oxygen|20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
40955788|NCT00316992|DRUG|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
40955789|NCT05175508|DRUG|Azacitidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle 28 days
40955790|NCT05175508|DRUG|all trans retinoic acid|ATRA 20mg tid by po on days 1-21 of every cycle 28 days
40955791|NCT04207320|DEVICE|αβ+ T-cell depletion with Miltenyi CliniMACS system|Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads.
40955792|NCT03728920|OTHER|Muscle strength measurement|Patients awaiting hip arthroscopy will undergo muscle strength testing pre- and post-operatively. There will be no deviation of treatment from their NHS care. Validated outcome measure questionnaires will be completed at five months post-operatively. Magnetic resonance imaging and electromyography tests will be performed on a subset of patients post-operatively.
40955793|NCT06365112|PROCEDURE|Endoscopy assisted|Endoscopy
40955794|NCT00540774|DEVICE|detection of oral pathology|detection of oral pathology
40955795|NCT01577420|OTHER|Reflexology Sessions|One session per week performed by certified reflexologist for four consecutive weeks.
40955796|NCT01577420|OTHER|Placebo Sessions|One session per week performed by research aide for four consecutive weeks.
40955797|NCT03789214|DRUG|Placebo oral capsule|Placebo Sleep Medication
40955798|NCT03789214|DRUG|Low Dose Suvorexant|Low Dose Suvorexant
40955799|NCT03789214|DRUG|High Dose Suvorexant|High Dose Suvorexant
40955800|NCT05395689|BIOLOGICAL|House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
40955801|NCT05395689|BIOLOGICAL|Placebo|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
40955802|NCT05961579|DRUG|Barrier Renew|RoC Skincare (New York, New York, USA) has developed a gentle cleanser and moisturizer that are free of exfoliants, astringents, and other abrasive ingredients. The moisturizer contains emollients, humectants, and silicones to improve the functioning of the skin barrier while antioxidants protect against environmental damage and inflammation
40955803|NCT00446251|DRUG|Rituximab|Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).
40955804|NCT00446251|DRUG|Mycophenolate mofetil (MMF)|Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.
40955805|NCT02655640|OTHER|Questionnaires|Questionnaires will be provided to patients
40955806|NCT00384657|DRUG|iron sucrose|"Patients in Group I will receive iv iron sucrose, as described in the study protocol.~Patient in Group II will receive conventional treatment for chronic heart failure."
40955807|NCT04239859|BIOLOGICAL|secukinumab|Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.
40955808|NCT04239859|DRUG|Methotrexate|Oral tablet up to 15mg per week
40955809|NCT04239859|DRUG|Cyclosporin A|Oral capsule up to 200mg per day
40955810|NCT04239859|DRUG|Acitretin|Oral capsule up to 25mg per day
40955811|NCT00025363|DRUG|vincristine sulfate|Given IV
40955812|NCT00025363|DRUG|irinotecan hydrochloride|Given IV
40955813|NCT00025363|DRUG|cyclophosphamide|Given IV
40955814|NCT00025363|DRUG|doxorubicin hydrochloride|Given IV
40955815|NCT00025363|DRUG|ifosfamide|Given IV
40955816|NCT00025363|DRUG|etoposide|Given IV
40955817|NCT00025363|DRUG|tirapazamine|Given IV
40955818|NCT00025363|BIOLOGICAL|filgrastim|Given SC
40955819|NCT00025363|BIOLOGICAL|sargramostim|Given SC
40955820|NCT00025363|OTHER|pharmacological study|Correlative studies
40955821|NCT00025363|OTHER|pharmacogenomic studies|Correlative studies
40955822|NCT00025363|OTHER|laboratory biomarker analysis|Correlative studies
40955823|NCT01278836|PROCEDURE|fasciocutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
40955824|NCT04930822|OTHER|Table Top Visual Intervention|Table top visual interventions and exercises.
40955825|NCT04930822|DEVICE|Bioness Integrated Therapy System Visual Intervention|Digital visual interventions and exercises.
40955826|NCT05186025|DRUG|MATA trees or MATA grass|Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
40955827|NCT02399371|BIOLOGICAL|Pembrolizumab|Given IV
40955828|NCT02399371|OTHER|Laboratory Biomarker Analysis|Correlative studies
40955829|NCT02399371|OTHER|Pharmacogenomic Study|Correlative studies
40955830|NCT01355757|DEVICE|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
40955831|NCT01355757|DRUG|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
40955832|NCT03740633|BEHAVIORAL|passive ankle pump motions on the day of surgery|Passive ankle pump motions include flexion and extension, circumduction, which will be conducted by caregiver on the day of surgery.
40955833|NCT03740633|BEHAVIORAL|active ankle pump motions and abdominal breathing training on the 1-3 day after the surgery|Active ankle pump motions include flexion and extension, circumduction, which will be conducted by patient on the 1-3 day after the surgery. On the same time, the patient is given abdominal breathing training.
40955834|NCT03740633|COMBINATION_PRODUCT|Regular care|Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization
40955835|NCT05801133|DRUG|Pirfenidone|200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
40955836|NCT02182102|DRUG|BIBF 1120|
40955837|NCT02182102|DRUG|Pemetrexed|
40955838|NCT03555916|DRUG|BOTOX®, Allergan|50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
40955839|NCT03555916|DRUG|Placebo|2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
40955840|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm1|Arm1: GI tumor beyond CRC, ESCC, BTC and GC\&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)
40955841|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm2|Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.
40955842|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm3|"Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.~OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator."
40955843|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm4|Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks. OR Irinotecan: 120 mg/m2 iv, day 1and day 8 and Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks (by investigator's choice)
40955844|NCT04480008|BEHAVIORAL|Resilient Living Program|Participants will be given the journal Resilient Living with Dr. Sood: Building Strength for Difficult Days to use throughout the study. The initial session with one of the investigators will be an introduction and a review of Module 1: Gratitude, and will last 30-60min. Three follow-up sessions will occur approximately every two weeks and the participants should view the videos before those virtual meetings (Session 2 will review Module II: Mindful Presence; Session 3 will review Module III: Kindness; Session 4 will review Module IV: Resilient Mindset). The videos will take approximately 30 minutes each to review and virtual sessions will each take 30-60 minutes.
40955845|NCT05157438|BEHAVIORAL|virtual reality device|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, it has been used to manage cases of phobia and extreme fear through the use of exposure-based treatment programs. The virtual reality system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment into which the child can be entirely immersed. It works to distract the brain from the painful procedure and reduce the perception of pain stimuli
40955846|NCT05157438|BEHAVIORAL|screen programs|the screens are used for distraction during dental treatments. they could be on tablets, iPads or televisions.
40955847|NCT02459301|DRUG|IPH2201|
40955848|NCT01446315|BEHAVIORAL|Use of Asthma APGAR system and tools|Practices will use the Asthma APGAR control questionnaire and the care algorithm.
40955849|NCT01446315|BEHAVIORAL|Asthma APGAR tools|Usual care
40955850|NCT03087643|OTHER|Passive mobilization - PM|
40955851|NCT04674644|BEHAVIORAL|The psychosocial effects of COVID-19 pandemic on dental professionals|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals using the Turkish version of the Fear of COVID-19 and Coronavirus Anxiety Scales
40955852|NCT00456248|DRUG|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
40955853|NCT05749107|DIAGNOSTIC_TEST|Echocardiography|Identify AF patients at risk of developing moderate/severe STR and those who will benefit from restoring the normal sinus rhythm
40955854|NCT05749107|COMBINATION_PRODUCT|Proteomic analyses|To identify the mechanisms leading to moderate/severe STR during AF.
40955855|NCT05108285|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)|OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
41135347|NCT03270709|DRUG|Vitamin D3 450,000 IU orally|Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
41135348|NCT05437666|OTHER|Education and booklet|The education program was given both an educational presentation accompanied by a physiotherapist once a week for six weeks and a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
41135349|NCT05437666|OTHER|Booklet|The control group will be given a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
41135350|NCT05715684|OTHER|Exercise Training|Virtually supervised exercise training for four weeks prior to cystectomy
40955856|NCT01630057|DRUG|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
40955857|NCT01630057|DRUG|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
40955858|NCT03629431|PROCEDURE|Prophylactic non-invasive ventilation|"The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions."
40955859|NCT03629431|PROCEDURE|postoperative standard care|Standard care received postoperatively
40955860|NCT03359772|OTHER|Kinesthetic Ability Trainer|Kinesthetic Ability Trainer
40955861|NCT02204956|BEHAVIORAL|Sustained Care|The Sustained Care intervention includes four main components: 1. a 40-minute individual session about quitting smoking during the hospital stay; 2. a 90-day telephone-based and text messaging program that provides support regarding smoking and nicotine patch use; 3. the opportunity, during the automated calls and texts to be transferred to quit smoking resources, including live telephone quit coaching counseling, web and text-based quit coaching resources; and 4. an 8-week supply of nicotine patches, provided at no cost.
40955862|NCT02204956|BEHAVIORAL|Usual Care|Usual Care includes a brief, 5 - 10 minute education session about quitting smoking, delivered by a hospital nurse during the hospital stay. Written handouts to reinforce the educational session will also be provided.
40955863|NCT04397601|DRUG|Folfiri/Bevacizumab|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with bevacizumab (5 mg/kg) on day 1 of each 14-day cycle.
40955864|NCT04397601|DRUG|Folfiri/Aflibercept|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with aflibercept (4 mg/kg) on day 1 of each 14-day cycle.
40955865|NCT01993706|DRUG|VRC-HIVMAB060-00-AB|
40955866|NCT02002273|PROCEDURE|Switching level of suction|
40955867|NCT05371431|OTHER|Traditional rehabilitation training|The non-BFR group undertook traditional rehabilitation training only. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
40955868|NCT05371431|OTHER|Blood flow restriction combined with traditional rehabilitation training|BFR group completed the traditional rehabilitation training with a medical grade tourniquet applied on the upper arm. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
40955869|NCT02279446|OTHER|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
40955870|NCT02699593|DEVICE|Test Contact Lens|
40955871|NCT02699593|DEVICE|Control Contact Lens|
40955872|NCT03538002|DEVICE|Blue-light filtering spectacle lenses|This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
40955873|NCT04534543|RADIATION|MRI/Spectroscopy|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
40955874|NCT01479478|DRUG|Placebo|One placebo capsule daily.
40955875|NCT01479478|DIETARY_SUPPLEMENT|Probiotic dietary supplement|Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
41135351|NCT05715684|DIETARY_SUPPLEMENT|Nutritional Intervention|Patients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively
41135352|NCT00655109|DRUG|Olopatadine|Ophthalmic solution
41135353|NCT00655109|DRUG|Fluticasone|Nasal spray
40762359|NCT03135067|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
40955876|NCT04153942|BEHAVIORAL|Mobilization|Any movement out of bed
40955877|NCT01776411|DRUG|forodesine hydrochloride|
40955878|NCT03214315|PROCEDURE|Visceral adipose tissue specimen|specimen
40955879|NCT00037596|DRUG|Gemtuzumab Ozogamicin|
40955880|NCT00037596|DRUG|cytarabine.|
40955881|NCT00702039|OTHER|No Music|No music will be played in patients in arm 2 of the study.
40955882|NCT00702039|OTHER|Music Therapy|Classical music being played during intravitreal injection.
40955883|NCT00150709|DRUG|Levetiracetam|"* Pharmaceutical form: Oral tablets and oral solution~* Route of administration: Oral use"
40955884|NCT02587793|OTHER|not interventional study|
41135354|NCT00655109|DRUG|Saline|Nasal spray
41135355|NCT00655109|DRUG|Artificial tears|Ophthalmic Solution
41135356|NCT05449366|DRUG|Intraperitoneal Paclitaxel Solution (Ml)|Weekly cycles of intraperitoneal paclitaxel monotherapy
41135357|NCT01933997|DRUG|Metadoxine (MG01CI )|
41135358|NCT04378413|OTHER|exercise|exercise for low back pain
41135359|NCT01738698|DRUG|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
40955885|NCT02234232|BEHAVIORAL|Exercise|Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
40955886|NCT00003710|DRUG|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
40955887|NCT00003710|DRUG|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
40762360|NCT05490056|OTHER|no intervention|the study will not apply on intervention
40762361|NCT04545892|DRUG|Capsaicin|One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
40762362|NCT03526666|OTHER|Peripheral blood collection|Peripheral blood collection for the measurement of ascorbic acid levels and banking of plasma and buffy coat for future resrearch.
40762363|NCT05615220|DRUG|Ecopipam Hydrochloride|Selective dopamine D1 and D5 receptor antagonist
40955888|NCT02509273|DRUG|Clonidine|
40762364|NCT03557905|DEVICE|RM 0.5|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
40762365|NCT03557905|DEVICE|RM 0.3|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.3.
40955889|NCT02509273|DRUG|Midazolam|
40955890|NCT05899257|BEHAVIORAL|Immersive Training using EYME|Psychological assessment based on the RGT with EYME-Explore Your Meanings, a digital platform to explore the structure and content of personal identity with Virtual Reality.
40955891|NCT04525846|OTHER|PFMT|"* program of PFMT consist of contract and hold pelvic floor muscle 10 seconds and relax 10 seconds 20 times per set totally 3 set per day~* follow up by telephone once a week about compliance of program PFMT, general symptoms, notice recording book~* at third trimester evaluate UI by questionaire (UDI-6, IIQ-7)"
40955892|NCT04525846|OTHER|non PFMT|Randomized to non PFMT group follow up and evaluate UI at third trimester sames as intervention group
40955893|NCT03342963|DRUG|ASC-01|Aripiprazole 3 mg/sertraline 100 mg combination drug
40955894|NCT03342963|DRUG|Aripiprazole and sertraline|Aripiprazole 3 mg and sertraline 100 mg
40955895|NCT04710056|DRUG|REGN4461|
40955896|NCT03402646|BEHAVIORAL|Reminder module (SMS and Phone call)|Same as described under arm/group descriptions
40762366|NCT02067156|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
40762367|NCT06039800|OTHER|No intervention|No intervention
40762368|NCT01686321|DRUG|Bendamustine and subcutaneous rituximab|
40762369|NCT06570668|DRUG|CDD-2101|All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.
40762370|NCT05629572|DIAGNOSTIC_TEST|i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity|Paired whole blood and plasma samples collected at multiple time points.
40762371|NCT03163329|PROCEDURE|TAVR|Transcatheter Aortic Valve Replacement
40762372|NCT03163329|PROCEDURE|SAVR|Surgical Aortic Valve Replacement
40955897|NCT03402646|BEHAVIORAL|Photovoice|Same as described under arm/group descriptions
41135360|NCT01738698|DRUG|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
41135361|NCT01738698|DRUG|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
41135362|NCT01738698|DRUG|Placebo|Oral administration once-daily for 12 weeks
41135363|NCT06015256|BIOLOGICAL|blood sample|Blood sample (56mL) taken in a heparin tube
40955898|NCT00645385|OTHER|MRS Spectroscopy|"Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI."
40955899|NCT02566486|DEVICE|Reciprocating system|Different root canal instrumentation systems
40955900|NCT02566486|DEVICE|Rotational system|Different root canal instrumentation systems
40955901|NCT04996017|DRUG|Atezolizumab 1200 mg in 20 ML Injection|Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.
41135364|NCT03840096|DEVICE|Breg Flex|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation using Breg Flex device on the affected leg to guide and monitor of knee HEP during the 6 weeks prior to surgery and 12 weeks following surgery.
40762373|NCT06008795|DRUG|Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone|Each PPF-active nerve block will consist of 20mg (4ml) ropivacaine plus 4mg (1ml) dexamethasone
40762374|NCT06008795|PROCEDURE|Placebo Pteryogpalatine Fossa Injection|Each placebo PPF-injection will consist of 5ml normal saline
40762375|NCT03362632|DRUG|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment.
40762376|NCT01974947|OTHER|Blood sample, sperm sample and clinical examens|Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
40762377|NCT03509480|PROCEDURE|Surgical Curettage for benign bone lesion|Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used
40762378|NCT03676270|OTHER|Phase I|Chemotherapy, ITK, Hormotherapy, Immunotherapy
40762379|NCT02722330|DEVICE|Baha 5 SuperPower on Baha Attract System|The Investigational device involves the following parts: the sound processor unit, an actuator unit and a cable that connects the sound processor and actuator units. The actuator unit is attached to the Sound Processor Magnet (SP Magnet) of the Baha Attract System which is pulled towards the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant. The actuator unit can also be connected to the Baha Softband via a snap coupling.
40762380|NCT02816112|DRUG|Ciprofloxacin|Antibiotic
40762381|NCT02816112|DRUG|Neupogen|Granulocyte-colony stimulating factor
40762382|NCT05739994|OTHER|Theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
40762383|NCT05739994|OTHER|Sham theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.
40762384|NCT05410314|DRUG|Myo-Inositol and D-Chiro-Inositol (MIC)|Both groups were followed up for 12 months, in T0 (during first evaluation), and T12 (after twelve months) with blood test for AMH (ng/ml).
40762385|NCT02659371|DIETARY_SUPPLEMENT|Low energy diet|
40762386|NCT03150888|DRUG|Antihypertensive Agents|Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
40762387|NCT03150888|OTHER|Cardiovascular risk factors|Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
40762388|NCT01416831|OTHER|Radiation therapy and high-dose IL-2|Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.
40762389|NCT01416831|DRUG|High-dose IL-2|IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
40762390|NCT00236665|DRUG|topiramate|
40762391|NCT03213405|BIOLOGICAL|rBCG-N-hRSV 1/100|5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
40762392|NCT03213405|BIOLOGICAL|rBCG-N-hRSV 1/10|5x10\^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
40762393|NCT03213405|BIOLOGICAL|rBCG-N-hRSV full dose|1x10\^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
40762394|NCT03213405|BIOLOGICAL|Conventional BCG full dose|2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
40955902|NCT04996017|DRUG|Placebo|Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
40955903|NCT01453361|BIOLOGICAL|Vigil™ Vaccine|
40955904|NCT04792008|BIOLOGICAL|YQ23|Single dose of 120 mg/kg YQ23 via intravenous route will be evaluated
40955905|NCT04792008|BIOLOGICAL|Matching placebo|Single dose of 0.9% normal saline via intravenous route as matching placebo
40955906|NCT00503295|BIOLOGICAL|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
40955907|NCT04164355|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
40955908|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
40955909|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
40955910|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
40955911|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
40955912|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
40955913|NCT00457301|BEHAVIORAL|HUI score card|Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
40955914|NCT03081533|OTHER|Circle Dance Program (CircleCare)|Circle Dances derives from folk dances, but their current repertoire encompasses traditional and contemporary dances from diverse nations and cultures around the world. Most of the choreographies are danced with the participants placed in a circle, holding hands, repeating a pattern of steps to the rhythm of the music.
40955915|NCT03000569|DRUG|SAGE-217|
40955916|NCT03000569|DRUG|Levodopa|Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).
40955917|NCT03000569|DRUG|Antiparkinsonian Agent(s)|Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.
40955918|NCT02564549|PROCEDURE|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
40955919|NCT02564549|PROCEDURE|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
40955920|NCT01644539|DIETARY_SUPPLEMENT|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
40955921|NCT01644539|DIETARY_SUPPLEMENT|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
40955922|NCT01644539|DIETARY_SUPPLEMENT|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
40955923|NCT05487846|BEHAVIORAL|Patient Navigation|Receive peer navigation services
40955924|NCT05487846|OTHER|Genetic Counseling|Receive genetic counseling
40955925|NCT05487846|OTHER|Survey Administration|Ancillary studies
40955926|NCT05487846|OTHER|Best Practice|Receive standard care
40955927|NCT05487846|OTHER|Genetic Counseling|Receive genetic counseling
40955928|NCT05487846|OTHER|Survey Administration|Ancillary studies
40955929|NCT06437496|DRUG|68Ga-AAZTA-093|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.
40955930|NCT06437496|DRUG|68Ga-PSMA-11//68Ga-PSMA-617|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11//68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
40955931|NCT02996578|DIETARY_SUPPLEMENT|polyphenol rich chocolate bar|High polyphenol content chocolate bar. Each participant will consume 581.4mg of polyphenols
40955932|NCT02996578|DIETARY_SUPPLEMENT|polyphenol rich cocoa powder|High polyphenol content cocoa powder. Each participant will consume 6g containing 554mg of polyphenols
40955933|NCT02996578|DIETARY_SUPPLEMENT|low polyphenol content chocolate bar|Low polyphenol content matched chocolate bar. Each participant will consume 198.5mg of polyphenols
40955934|NCT02996578|DIETARY_SUPPLEMENT|low polyphenol content cocoa powder|Low polyphenol content cocoa powder. Each participant will consume 6g containing 191.2mg of polyphenols
40955935|NCT02647242|BEHAVIORAL|Auto rehabilitation program of gait with Beat Health device.|The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
40955936|NCT02245984|OTHER|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
40955937|NCT02245984|OTHER|electronic nursing process|for each of the groups separately-training program aimed to education the nursing process and how to do it (including the definition of the nursing process, advantages and its implementation and how to collect data using patient assessment forms Gordon) in the form of workshops a day (5 hours) will be implemented. Nursing process education in the two groups will similar but two hours of the program in each groups is devoted to practical training on how to implement. After completing the training program, students learn about the nursing process will be determined in the same way. Then for two weeks, students in Group A and Group B will be implemented paper and electronic nursing process for patients.
40955938|NCT00882063|DRUG|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
40955939|NCT05913258|DEVICE|Er:YAG laser system (Doctor smile, Pluser, Italy)|The Er:YAG laser offers a virtually painless alternative to conventional methods of caries removal, and its adoption in clinical practice could greatly reduce children's fear of going to the dentist. Caries removal is one of the leading reasons for dentist visits among children, and many children become fearful at the mere thought of a drill touching their teeth, before they even hear the sound. Laser caries removal could go a long way toward eliminating children's fear of going to the dentist; it is virtually painless, and most children are able to get through the entire procedure without needing local anesthesia.
40955940|NCT05913258|DEVICE|Master Torque high/low-speed air rotor handpiece (KaVo Dental, Charlotte, North Carolina, USA)|Mechanical removal of carious lesions with a rotating handpiece and bur instruments is the most often used approach for treating dental caries because it is cost-effective, timesaving, and simple. However, these procedures have many drawbacks, including the potential for removing healthy tooth structures, vibration and noise, which can cause the patient anxiety and pain, thus necessitating local anesthesia.
40955941|NCT05577065|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in the form of a sachet with a daily dose of 3E+9 Colony Forming Unit (CFU) per day for 26 weeks.
40955942|NCT05577065|DIETARY_SUPPLEMENT|Placebo|Matching placebo in the form of a sachet once daily for 26 weeks
40955943|NCT04873115|OTHER|Placebo|Sialanar placebo
41455320|NCT04779736|BEHAVIORAL|A set of implementation strategies to reduce sexual stigma|The intervention will be finalized based on formative interviews and consultation with an advisory board. It is likely to include an educational mHealth component followed by an in-person workshop for skills development, then supportive coaching components (i.e., coaching calls and an optional email listserve) to encourage and respond to the implementation of recommended practices.
41455321|NCT00662272|BIOLOGICAL|Fluzone vaccine with JVRS-100 adjuvant|One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
41455322|NCT00662272|BIOLOGICAL|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
41455323|NCT00662272|BIOLOGICAL|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
40955944|NCT04873115|DRUG|Sialanar|Sialanar - a licensed glycopyrronium bromide product
40955945|NCT04873115|OTHER|Oral Rehabilitation|Standard oral rehabilitation for provided drooling
41455324|NCT03576040|DEVICE|Whole Body Dynamic 68Ga-DOTATOC PET/CT|"68Ga-DOTATOC PET-CT will be performed in the nuclear medicine department of the University Hospital of Brest on a Biograph mCT S64 machine (Siemens medical, Erlangen, Germany) Time of Flight system after intravenous injection of 150MBq of 68Ga-DOTATOC. In the usual conditions for performing this exam, the patient must remain at a strict rest for 60 minutes following the injection of the tracer and before a static 3D acquisition. For this protocol, a complementary 4D dynamic acquisition (15-60 minutes post-injection) will be performed during this usual rest period."
40955946|NCT00436241|DRUG|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
40955947|NCT00436241|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
40955948|NCT04664192|OTHER|Patient Biospecimen Registry (observational and blood sampling)|Clinical data collected at every blood sample collection visit.
40955949|NCT05424302|BEHAVIORAL|Standard Vestibular Rehabilitation with Adjunct At Home Virtual Reality Vestibular Rehabilitation|The virtual reality intervention will involve standard vestibular rehabilitation as described above and adjunct at home virtual reality video game. This video game will be projected on an android or apple device accommodated into a VR headset for 20 minutes daily until the vestibular rehabilitation is complete. This video will be congruent to current vestibular rehabilitation program exercises. Point-of-view games compatible with both Android and iOS devices will be evaluated by professionals to determine the game that is most representative of current evidence based exercises.
40955950|NCT05424302|BEHAVIORAL|Standard Vestibular Rehabilitation with Adjunct Auditory Intervention|The control intervention will involve standard vestibular rehabilitation as described above and adjunct audio intervention while wearing the VR headset for 20 minutes daily until the vestibular rehabilitation is complete.
40955951|NCT00576784|DRUG|pioglitazone and glimepiride|switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
40955952|NCT02655133|DRUG|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
40955953|NCT02655133|DRUG|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
40955954|NCT01747148|DRUG|AVI-7100 versus placebo|dose-escalating AVI-7100 versus placebo
40955955|NCT04437563|BEHAVIORAL|HERMES|Via an app, the caregiver answers 14 questions about his/her need for (more) information. The caregiver presents his/her answers (i.e., need for information) to the health care professionals (HCPs), and the HCPs provide the caregiver with the lacking information.
40955956|NCT03302650|DRUG|Angiotensin II|Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
40955957|NCT03302650|DRUG|Normal saline|Patients will receive normal saline.
40955958|NCT03302650|DRUG|Norepinephrine|patients will receive norepinephrine infusion adjusted according to blood pressure
40955959|NCT02646657|DRUG|Vedolizumab 300 mg|Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
40955960|NCT04862429|OTHER|Contrast enhanced mammography guided biopsy (diagnostic procedure)|With visible contrast-enhancement, stereotactic biopsy will be performed under CESM guidance. After administration of an additional dose of iodized contrast-enhancement (Omnipaque), the insertion of the biopsy needle and the biopsy sampling will be targeted on the area of greatest enhancement in the context of calcifications. In the absence of contrast-enhancement, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area. At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).
40955961|NCT04862429|OTHER|Mammography guided biopsy (diagnostic procedure)|"For all lesions, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area.~At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice)."
41455325|NCT05492448|DIETARY_SUPPLEMENT|Placebo|Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.
40955962|NCT05081765|DRUG|Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)|correlation between C through and taken drug
40955963|NCT05081765|DEVICE|Lynparza|correlation between C through and taken drug
41455326|NCT05492448|DIETARY_SUPPLEMENT|L. salivarius AP-32 and L. reuteri GL-104|Subjects take one pack containing L. salivarius AP-32 and L. reuteri GL-104 twice daily after breakfast and dinner.
40762395|NCT04714255|OTHER|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of images attractive that need to be colored, created as a book called TICK-B. This book was created with the instructions and recommendations of a pediatric psychiatrist and a professional drawing teacher at a children's school.Distraction with TICK-B began 1-3 min. before the intravenous cannula procedure and lasted until the end of the procedure.
40762396|NCT03928015|DRUG|Adjunctive dronabinol|5mg BID and adjusting within the range of 2.5mg - 10mg BID, minimum of 48 hours, as an adjunct to systemic analgesics
40762397|NCT03928015|DRUG|Systemic analgesics|multimodal analgesia including opioid and non-opioid analgesics
40762398|NCT02489487|DRUG|VM-1500|VM-1500 40 mg
40762399|NCT02489487|DRUG|Darunavir|Darunavir 600 mg
40762400|NCT02489487|DRUG|Ritonavir|Ritonavir 100 mg
40762401|NCT02489487|DRUG|Raltegravir|400 mg Raltegravir
40762402|NCT02117271|DEVICE|continuous positive airway pressure|device to treat obstructive sleep apnea using positive airway pressure with a nasal mask
40762403|NCT02117271|OTHER|Breathe Right ®|Nasal dilator strip treatment used during sleep to open the nasal airway
40762404|NCT05143619|OTHER|Survey Administration|Complete surveys
40955964|NCT03267017|OTHER|posture changes|Following induction of general anesthesia and initiation of positive pressure ventilation, patients will be tilted 15 degrees head up for 5 minutes with positive end expiratory pressure of 8 cm H2O, and then 15 degrees head down for 5 minutes with positive end expiratory pressure of 3 cm H2O
40955965|NCT04693455|DRUG|ZD03|ZD03 capsule
40955966|NCT04693455|OTHER|Placebo|placebo capsule
40955967|NCT05899985|COMBINATION_PRODUCT|FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System|"FerroTrace will be injected peri-tumorally during the surgeons staging endoscopy, with an MRI conducted 12h to 28 days after injection. The MRI will be blinded to the clinical team and will assess the location of the primary draining lymph nodes (sentinel lymph nodes or SLNs).~Patients will proceed to standard of care neoadjuvant therapy and/or surgery. During surgery, indocyanine green (ICG) will be used to identify draining lymph nodes. Following surgery, pathologists will use FerroMag to identify SLNs which will undergo standard H\&E assessment, and if negative ultras-staging (fine serial slice and immunochemistry)."
40955968|NCT04766060|OTHER|Fluorescent Imaging|Fluorescense imaging used to evaluate blood perfusion
40955969|NCT01193699|DRUG|PEG-P-INF alpha-2b (P1101)|µg (starting with 50 µg), subcutaneously, 2-weekly administration
40955970|NCT02059408|OTHER|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm will recommend using creatinine, cystatin C and albuminuria for screening and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage. Recommendations are sent to the primary care provider via an electronic note.
40955971|NCT02059408|OTHER|Screen-Educate and Intensify Treatment|This arm adds option of a pharmacist. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys \<45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
40955972|NCT05962931|BIOLOGICAL|Bioengineered Artificial Mesenchimal Sheet (BAMS)|Each patient assigned to the experimental treatment group will receive 4 BAMS (1 BAMS/week) at a concentration of about 360,000 cells/cm2.
40955973|NCT05962931|PROCEDURE|Standard treatment (Control)|Each patient assigned to the control group will undergo a standard treatment procedure for uncomplicated venous ulcers.
40955974|NCT05556330|PROCEDURE|computer guided autogenous cortical shell technique|computer guided autogenous cortical shell technique
40955975|NCT00699569|DIETARY_SUPPLEMENT|hyperimmune colostrum|hyperimmune colostrum
40955976|NCT00699569|DIETARY_SUPPLEMENT|Placebo|
40955977|NCT05866406|BEHAVIORAL|Time restricted eating|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
40955978|NCT05866406|BEHAVIORAL|Extended eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 14-hour window for 12 weeks.
40955979|NCT05866406|BEHAVIORAL|Healthy diet|Participants will be provided nutrition education and counselling to follow a diet consistent with the existing guidelines for chronic disease prevention.
40955980|NCT04391361|DRUG|Scopolamine, atropine, edaravone and dexmedetomidine|The patients were treated with scopolamine, atropine, edaravone and dexmedetomidine dissolved in saline.
40955981|NCT04391361|DRUG|Edaravone|The patients was treated with edaravone dissolved in the same volume of saline as the intervention applied in the experimental group.
40955982|NCT00831025|BIOLOGICAL|Immunotherapy with modified extract of Olea europaea pollen|Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
40955983|NCT00831025|BIOLOGICAL|Placebo|Placebo for subcutaneous monthly administration
40955984|NCT04167982|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
40955985|NCT04167982|DRUG|Oral conventional-dose isotretinoin|Conventional-dose isotretinoin
41455327|NCT05492448|DIETARY_SUPPLEMENT|L. reuteri GL-104|Subjects take one pack containing L. reuteri GL-104 twice daily after breakfast and dinner.
40955986|NCT04167982|DRUG|Oral low-dose isotretinoin|low-dose isotretinoin
40955987|NCT05227183|BEHAVIORAL|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
40955988|NCT04041297|OTHER|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~Education to bronchial drainage techniques as well as directed coughing."
40955989|NCT05552521|DIAGNOSTIC_TEST|Echocardiography|Echocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission
40955990|NCT01706146|DRUG|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
41135365|NCT04160559|OTHER|green tea|The investigators require patients to regularly drink green tea during the trial period.
41135366|NCT00076674|DRUG|Intravenous Levodopa|
41455328|NCT05156086|DRUG|COVID-19 vaccine, booster|Additional dose of COVID-19 vaccine (booster shot)
41455329|NCT03989141|PROCEDURE|Repeated cannulation Buttonhole.|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
41455330|NCT03989141|PROCEDURE|Single cannulation Buttonhole.|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
41455331|NCT03699930|DEVICE|tDCS|Anodal or sham tDCS will be applied to the scalp.
41455332|NCT03699930|BEHAVIORAL|Speech and language therapy|A trained speech pathologist will administer the speech and language therapy.
41455333|NCT01780051|DRUG|Repaglinide/Metformin combination, Repaglinide, Metformin|"Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2."
40955991|NCT05216783|BEHAVIORAL|Motivational Interviews|The qualitative research studies performed on the traumatic childbirth experiences indicated that the pregnant women's interaction and communication with the midwives were more effective than the medical intervention methods that were applied.
41455334|NCT01780051|DRUG|Repaglinide/Metformin combination, Repaglinide, Metformin|"Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2."
41455335|NCT02701101|DEVICE|Use of SEM200 Scanner daily|From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels
40955992|NCT04370223|BIOLOGICAL|Ozone auto-hemotherapy|ozone auto-hemotherapy
40955993|NCT06051370|PROCEDURE|Ultrasound-guided glenohumeral space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach
40955994|NCT06051370|PROCEDURE|Ultrasound-guided subacromial space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the subacromial space through the anterolateral approach
40955995|NCT05744284|DEVICE|electrocautery|advantages reported in this study in terms of wound infections, healing time, postoperative pain and cosmetic results in association with economic gain for saving in the purchase of scalpels, represent a formidable motivation for the surgeons to abandon the scalpel in favors of diathermy
40955996|NCT03619278|OTHER|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 doses of 10-1074 antibodies and 3 doses of romidepsin
40955997|NCT03619278|OTHER|placebo|Participants will receive 5 vaccines of placebo of HIVACAR01, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
40955998|NCT02195336|DEVICE|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
40955999|NCT02195336|DRUG|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
40956000|NCT02195336|DRUG|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
40956001|NCT02721485|OTHER|Ringer's Lactate|After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
40956002|NCT02721485|OTHER|Normal Saline|After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
40956003|NCT04732143|OTHER|Inspiratory muscle training|At least 2 weeks prior to surgery, participants will be given a Vyaire incentive spirometer device and provided with formal training on proper inspiratory muscle breathing exercise using the device. They will be instructed to perform 4 sets of these exercises per day for 14 days prior to surgery.
40956004|NCT01519232|RADIATION|Liver Irradiation|Patients already scheduled to undergo radiation treatment
40956005|NCT01172522|DRUG|Fexofenadine|Fexofenadine 1%
40956006|NCT01172522|DRUG|Placebo|Placebo
40956007|NCT03919331|DIAGNOSTIC_TEST|Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)|After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days
40956008|NCT05509036|OTHER|No interventions|No interventions
40956009|NCT01586065|DEVICE|Continuous Glucose Monitor (CGM)|CGM during 24-hr CRC stay.
40956010|NCT04600141|DRUG|Tocilizumab|Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.
40956011|NCT04600141|DRUG|Heparin - Therapeutic dosage|Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
40956012|NCT04600141|DRUG|Heparin - Prophylactic dosage|Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.
40956013|NCT04486911|DRUG|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
40956014|NCT03115086|DRUG|Cholbam|Cholbam prescribed according to the approved label.
41455336|NCT02701101|OTHER|Assessment and treatment of Pressure Ulcers using SOC|Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
41455337|NCT04193150|DIAGNOSTIC_TEST|Full pulmonary specialist assessment|Please see description for the intervention arm.
41455338|NCT02579226|DRUG|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
41455339|NCT00740896|BEHAVIORAL|Smoking|Active Comparator: Participants smoke 8 cigarettes in 4 hours.
41455340|NCT00740896|BEHAVIORAL|Smoking|Sham Comparator: Participants are not allowed to smoke for 4 hours.
41455341|NCT02810223|BIOLOGICAL|CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
41455342|NCT00388219|DRUG|Transtec (R) PRO (buprenorphine)|
40956015|NCT02672800|BEHAVIORAL|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
40956016|NCT04450446|DRUG|Low molecular weight heparin|Anticoagulation therapy
40956017|NCT05435677|DRUG|IcoSema|One single dose of IcoSema administered subcutaneously, S.c. into the left thigh
40956018|NCT05435677|DRUG|insulin icodec|One single dose of insulin icodec administered subcutaneously, S.c. into the left thigh
40956019|NCT05435677|DRUG|semaglutide|One single dose of semaglutide administered subcutaneously, S.c. into the left thigh
40762405|NCT05833542|BEHAVIORAL|Health education materials|Participants will receive informational material (designed to be self-guided), including a video and an information sheet about current HIV treatment options (i.e., long-acting injectable and daily oral antiretroviral therapy). These materials will provide a comparison of the risks and benefits of long-acting injectable and oral regimens, set expectations about clinic visits, present information about side effects, and provide additional resources for patients to assist them in preparing to discuss HIV treatment and support options with their medical case manager and clinical provider. Participants receiving this intervention will be offered/pointed to these materials by a medical case manager or patient navigator and will be encouraged to review the materials on their own, but may also go over the materials with staff during a medical case management visit.
40956020|NCT05401357|DRUG|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
40956021|NCT05401357|DRUG|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
40956022|NCT06057831|RADIATION|Total Neo-adjuvant Therapy|"* TNT incorporates chemotherapy with concurrent chemoradiotherapy (CRT) in any order.~* Radiotherapy includes 5000 cGy/25 fractions over 5 weeks.~* Chemotherapy regimen for Concurrent CRT: Capecitabine~* Chemotherapy regimens used with TNT are: FOLFIRINOX x 6 cycles, 8-9 courses FOLFOX or 5-6 courses of CAPEOX delivered over 4-6 months.~* The chemotherapy regimen or the order of treatment will be decided at the discretion of the patient's medical oncologist"
40956023|NCT06057831|OTHER|18FDG-PET/MRI scan|18FDG-PET/MRI scan within 4 weeks of commencing chemo-radiation and within 1 - 2 weeks before radical rectal cancer surgery.
40956024|NCT02440971|DEVICE|S9-Autoset CS-A|The S9-Autoset CS-A is an adaptive servo-ventilation (ASV) machine. It adjusts the level of inspiratory support automatically in response to the patient's respiratory effort. Inspiratory support is increased in the presence of hypoventilation and decreased in the presence of hyperventilation.
40956025|NCT02153333|PROCEDURE|Serum sample|Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
40956026|NCT02202980|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
40956027|NCT02202980|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
40956028|NCT02202980|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
40956029|NCT02202980|DRUG|VOX|100 mg tablet administered orally once daily with food
40956030|NCT04497935|DRUG|PLENVU|Bowel preparation for a colonoscopy
40956031|NCT04497935|DRUG|MoviPrep|Bowel preparation for a colonoscopy
40956032|NCT01481597|DRUG|deuteporfin|deuteporfin 1 mg/kg IV as a single dose
40956033|NCT01481597|DRUG|deuteporfin|deuteporfin 2.5 mg/kg IV as a single dose
40956034|NCT01481597|DRUG|deuteporfin|deuteporfin 5 mg/kg IV as a single dose
40956035|NCT01481597|DRUG|deuteporfin|deuteporfin 7.5 mg/kg IV as a single dose
40956036|NCT01481597|DRUG|placebo|Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
40956037|NCT04014946|DEVICE|ICD implantation|implantation of the Lumax 540 single/dual chamber ICD or successor
40956038|NCT03350581|PROCEDURE|FAM 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by FAM alone.
40956039|NCT03350581|PROCEDURE|FAM-CT 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by the integration of the FAM with CT or MRI.
40956040|NCT01485575|PROCEDURE|Use of intraoperative filters in vitrectomy|During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
40956041|NCT03892070|DIETARY_SUPPLEMENT|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB will be provided for 12 weeks twice daily
40956042|NCT03892070|DIETARY_SUPPLEMENT|Mannitol|1.5 g twice daily for 12 weeks
40956043|NCT04314726|DRUG|Amelogenin|amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction
40956044|NCT04314726|DRUG|Placebos|placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
40956045|NCT01468675|OTHER|Intervention|risk assessment survey; decision support for providers for prevention based on risk
40956046|NCT05140785|DIAGNOSTIC_TEST|Advanced MRI sequences|Advanced MRI sequences which look to a) determine structure of a primary brain tumour and b) metabolism within a primary brain tumour
40956047|NCT05049616|DRUG|ACE Inhibitors and Diuretics|Hctz/Lisinopril (brand name: Zestoretic)
40956048|NCT05049616|DRUG|NIFEdipine ER|Extended release nifedipine
40956049|NCT01206348|DRUG|Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide|Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
40956050|NCT00761904|BEHAVIORAL|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
40956051|NCT06177522|DRUG|Adebrelimab|1200mg，i.v. , q3w
40956052|NCT06177522|DRUG|albumin-bound paclitaxel|125 mg/m2, i.v.,d1,d8, q3w
40956053|NCT06177522|DRUG|Gemcitabine|1.0 g/m2, i.v.,d1, d8, q3w
40956054|NCT05570292|DRUG|Domperidone|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of domperidone tablet
40956055|NCT05570292|DRUG|Folic acid|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of folic acid tablet
40956056|NCT00736944|DRUG|Abraxane|100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
40956057|NCT00736944|DRUG|Cetuximab|400 mg/m2 IVPB, Day 1, cycle 1
40956058|NCT00736944|DRUG|Cetuximab|250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
40956059|NCT00736944|DRUG|Cisplatin|75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
40956060|NCT00736944|DRUG|5-FU|750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
40956061|NCT00736944|RADIATION|Radiation (Post induction)|Monday-Friday, weeks 1-7
40956062|NCT00736944|DRUG|Cisplatin|(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
40956063|NCT00736944|DRUG|Cetuximab|(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
41455343|NCT02484716|DRUG|Timolol nasal spray|Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
40956064|NCT06454682|DRUG|RJK002 Intrathecal injection|Eligible subjects will receive a single intrathecal administration of investigational product with dose 6E13 vg/person, 1.2E14 vg/person, and 2.4E14 vg/person sequentially.
40956065|NCT05075460|DRUG|Tucidinostat, Azacitidine combined with CHOP|"Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~* Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~* Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~* Vinoresin (VDS) 4mg intravenous infusion, day 1;~* Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment"
40956066|NCT03361163|BIOLOGICAL|emm75 Streptococcus pyogenes (GAS M75, strain 611024)|Direct oropharyngeal application by swab following immersion in a solution containing a specified concentration (dose) of GAS M75.
40956067|NCT00981201|DRUG|Celecoxib|"Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
40956068|NCT00981201|DRUG|Celecoxib|"Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
40956069|NCT00981201|DRUG|Placebo|"Months 1-3:~By mouth twice daily."
40956070|NCT00981201|DRUG|Placebo|"Months 4-6:~By mouth twice daily."
40956071|NCT05597371|OTHER|the use of the platform|the use of the platform
40956072|NCT02488161|OTHER|No intervention|
40956073|NCT00469378|DRUG|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
40956074|NCT00443495|DRUG|Chitin microparticles by nasal route|
40956075|NCT04010695|DIAGNOSTIC_TEST|SD Biosensor G6PD Analyzer|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
40956076|NCT04010695|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
40956077|NCT04010695|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
40956078|NCT00044083|OTHER|Placebo|Placebo: One capsule 3 times a day from Day 1 to Day 7
40956079|NCT00044083|DRUG|Tolcapone|Tolcapone: One capsule 3 times a day from Day 1 to Day 7
40956080|NCT04843137|DEVICE|Cervical Transcutaneous Electrical Spinal Cord Stimulation|Surface electrodes are placed over the cervical spinal cord. Constant current is delivery through these electrodes. Stimulation frequency and electrode configuration are manipulated, and outcome measures are recorded.
40956081|NCT03998488|DRUG|Fecal Microbiota Transplantation|"The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery."
40956082|NCT03998488|DIETARY_SUPPLEMENT|Psyllium Husk Powder|"All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon (approximately 5 grams) of psyllium husk powder twice a day (morning and night) for 8 weeks, beginning 3 days prior to Week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat."
40956083|NCT01549678|OTHER|Total contact insole|EVA insole shaped on patient´s foot.
40956084|NCT01549678|OTHER|placebo insole|EVA insole flat
40956085|NCT02707939|OTHER|Observation|Patients will be observed before and after they receive anesthesia
41455344|NCT02484716|DRUG|Placebo nasal spray|Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
41455345|NCT05278403|OTHER|Virtual reality and video games|Use of a software in stroke patients' rehabilitation.
40956086|NCT06088108|DEVICE|Cornell treadmill exercise protocol|Study participants are asked to undertake the Cornell treadmill exercise protocol which they complete to voluntary exhaustion.
40956087|NCT03519620|OTHER|SWWSV|Behaviours to prevent child obesity
40956088|NCT01330030|DRUG|Selegiline|6mg/24 hrs for 8 weeks
40956089|NCT01330030|OTHER|matching placebo|placebo/24hrs for 8 weeks
40956090|NCT02067130|PROCEDURE|Fibroscan|Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
41455346|NCT05278403|OTHER|Neurological physiotherapy|Application of conventional physical therapy techniques.
40956091|NCT04420442|PROCEDURE|Scar Transformation Group|Surgical excision of the NSSI scars followed by IntegraTM transplantation and wound closure with a negative pressure wound system. After 21 days the silicone layer of the IntegraTM will be removed and split thickness skin will be transplanted. After suture removal a compression therapy by individually tailored garments will be started for 12 months.
40956092|NCT03802695|BIOLOGICAL|OrcaGraft (Orca-Q)|engineered donor allograft
40956093|NCT00557128|DRUG|COREG CR and lisinopril (FDC)|
40956094|NCT06354309|OTHER|Virtual reality game|Pre and post control study after use virtual reality game
40956095|NCT06240871|OTHER|Pulmonary artery pressure measurements|The investigators will compare noninvasive measurements of right sided pressure measurements with invasive RHC performed in 3 steps:at rest, with agitated saline and with agitated echo contrast, Optison. This was not a clinical trial and there were no intervention arms per se. All patients received agitated saline and echocardiographic contrast.
40956096|NCT04021771|OTHER|Educational Curriculum Intervention|The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
40956097|NCT03766074|DIETARY_SUPPLEMENT|vitamin D supplement|The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly.
40956098|NCT03766074|DIETARY_SUPPLEMENT|Placebo|placebo
40956099|NCT03113071|DRUG|Decitabine|Decitabine will be administered in combination with Digoxin
40956100|NCT03113071|DRUG|Digoxin|Decitabine will be administered in combination with Digoxin
40956101|NCT02255903|OTHER|ultrasound and Doppler examination|ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
40956102|NCT05364190|DRUG|Canagliflozin|Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
40956103|NCT05364190|DRUG|Empagliflozin|Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
40956104|NCT01349088|DRUG|Ixabepilone|Patients will receive ixabepilone at 40 mg/m2.
40956105|NCT01349088|DRUG|Capecitabine|Patients will receive capecitabine at 2000 mg/m2.
40956106|NCT01349088|DRUG|Motesanib|Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
40762406|NCT05833542|BEHAVIORAL|Patient-provider decision tool|Participants will receive a shared patient-provider assessment and decision-making tool, utilizing techniques from Motivational Interviewing and based on the Ottawa Patient Decision Aid framework, for weighing each patient's treatment options and their fit to patient interests, needs, assets, and constraints. The tool will facilitate and record patient-provider agreement on an antiretroviral treatment and support-services plan, to be integrated into the broader existing medical case management care plan signed by both patient and provider. The tool will be administered during a medical case management visit and completed by the participant and a patient navigator or medical case manager.
40956107|NCT01409434|DRUG|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
40956108|NCT00369707|DRUG|Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
40956109|NCT00369707|DRUG|bortezomib|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
40956110|NCT04282642|BEHAVIORAL|Cognitive Training|Participants (n=20) provided game console with cognitive training games and activities.
40956111|NCT04282642|BEHAVIORAL|WLC (Waitlist Control)|Participants (n=20) will receive the cognitive training intervention later, following week 8 assessments.
40956112|NCT04312048|DRUG|Isosorbide mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
40956113|NCT04312048|DRUG|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
40956114|NCT05400746|BIOLOGICAL|Pfs48/45 in Matrix-M|Three doses of Pfs48/45 in Matrix-M at different doses
40956115|NCT02632331|DRUG|ASP8825|Oral
41455347|NCT04440696|DRUG|Lanthanum Polystyrene Sulphonate Powder|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
41455348|NCT04440696|DRUG|Lanthanum Carbonate 500 MG|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
41135367|NCT04958837|OTHER|FIFA 11+ protocol with additional Core training exercises|Slow paced running exercises of 8 minutes' duration (2 rounds each), followed by Strength, plyometric and balance exercises including 3 sets of 20-30 sec of The Bench, Sideways Bench each side, Nordic Hamstring strengthening, single leg stance balance training, squatting and high speed running. The protocol will end with additional core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge. Each exercise plan will be progressively increased. Core training will be followed by 30 sec stretch of major muscle groups.
41455349|NCT04440696|DRUG|Placebo|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
41455350|NCT06229912|DRUG|Revumenib|Given by PO
41455351|NCT03920280|DEVICE|LID015385 contact lenses|Investigational silicone hydrogel contact lenses
41455352|NCT03920280|DEVICE|Comfilcon A soft contact lenses|Commercially available silicone hydrogel contact lenses
40956116|NCT00529334|RADIATION|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
40762407|NCT01582581|BEHAVIORAL|Telephonic CBT|Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
40762408|NCT01582581|BEHAVIORAL|Wait List Control|Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
40762409|NCT02233569|PROCEDURE|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
40762410|NCT02233569|PROCEDURE|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
41291906|NCT06365333|PROCEDURE|Fluoroscopic-guided air-enema reduction (FGAR)|A hand-held pump facilitated the delivery of atmospheric air, while pressure was monitored using a digital gauge. A two-way Foley's balloon catheter, ranging from 18oF to 24oF in diameter depending on age, was inserted rectally to introduce air. Following insertion, the balloon was filled with 10cc of saline to prevent air leakage, with patient immobilization ensured by leg straps and hand positioning above the head for abdominal exposure. Under intermittent fluoroscopy, the surgeon operated the pump with the right hand, inflating the catheter to 80 to 120 mmHg, simultaneously palpating the intussusceptum with the left hand, employing a deep gliding motion for deep and fixed cases. Successful reduction, indicated by air entry into the small bowel, was confirmed under fluoroscopy, with a subsequent brief rotating abdominal massage ensuring uniform air distribution throughout the small intestine, confirming complete reduction.
41291907|NCT03988114|DRUG|Abemaciclib|Administered orally
41291908|NCT03988114|DRUG|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole administered orally or anastrozole administered orally (physician choice)
41291909|NCT06480474|DEVICE|Deprexis|The internet-based self-help program used in this study, Deprexis, contains 10 modules ( based on different psychotherapeutic approaches, consistent with a cognitive-behavioral perspective) and accessible at any time via regular internet browsers on laptops, computers, tablets, or smartphones through a secure website. Participants can repeat all modules as often as they wish after completing the full sequence once.
41455353|NCT03920280|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting system
41455354|NCT05508490|DIAGNOSTIC_TEST|renal chemistry, serum electrolyte,|detection of renal chemistry affection and electrolyte disturbance in diabetic ketoacidosis
41455355|NCT06124690|DEVICE|Catheter ablation|Pulmonary vein isolation and ablation of low voltage areas.
40762411|NCT02233569|DEVICE|Ventralight ST implant|
40762412|NCT02233569|DEVICE|ETHICON PHYSIOMESH®|
40762413|NCT02168699|OTHER|Ultrasound examination of the axilla|
40762414|NCT01515215|DEVICE|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specific brain regions. (MagPro X100)
40762415|NCT01688791|DRUG|Vintafolide|
40762416|NCT01688791|DRUG|Carboplatin|
40762417|NCT01688791|DRUG|Paclitaxel|
40762418|NCT03151668|DRUG|Dexmedetomidine|
40762419|NCT01415687|DRUG|Polyethylene Glycol-Based Lavage|"Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours."
40762420|NCT01415687|DRUG|Pico-Salax (Magnesium Citrate) plus Bisacodyl|"If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre."
40762421|NCT03960346|PROCEDURE|Ablation with cryoenergy|Esophageal temperature-guided ablation using cryoengery and an esophageal temperature probe.
40762422|NCT00459550|DRUG|GSK933776|"Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg"
40762423|NCT00459550|DRUG|Placebo to match GSK933776|Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
40762424|NCT04174482|PROCEDURE|morphological and functional evaluation of adult flat foot|Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique
40956117|NCT02487433|DRUG|Tofacitinib MR 22 mg (Fed)|A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal
40956118|NCT02487433|DRUG|Tofacitinib MR 22 mg (Fasted)|A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
40956119|NCT02061774|DRUG|Acetaminophen|1 gram of intravenous Acetaminophen
40956120|NCT02061774|DRUG|Placebo comparator|placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
40956121|NCT04776109|PROCEDURE|erector spinae block|"Bilateral erector spinae catheters will be placed at T8 level. an ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles and the transverse Processes. Next, 2-3 ml of 2% lidocaine will be infiltrated .~A 16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the ultrasound beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle, 10 ml of saline 0.9% will be injected lifting the muscle of the transverse process. A catheter will be inserted into the newly formed space underneath the ES muscle and secured. The procedure will be repeated on the contralateral side. bupivacaine (20 ml of bupivacaine 0.25%) solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours."
40956122|NCT04343469|PROCEDURE|Bariatric Surgery (RYGB or LSG)|Morbidly obese subjects will receive either RYGB or LSG, and the effect of bariatric surgery-induced weight loss on brain inflammation will be assessed
40956123|NCT05956691|DIETARY_SUPPLEMENT|AllerPops|Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.
40956124|NCT00017446|DRUG|CP4071|
40956125|NCT00440414|DRUG|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
40956126|NCT00440414|DRUG|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
40956127|NCT03321266|DEVICE|Cook Biodesign® Fistula Plug|The Cook Biodesign® Fistula Plug is for implantation to reinforce soft tissue for repair of Anorectal fistulas.
40956128|NCT05257655|PROCEDURE|MRI after ganglionic local opioid analgesia (GLOA)|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius
40956129|NCT02298530|OTHER|Combination of caffeine and theanine|Beverage containing caffeine and theanine
40956130|NCT02298530|OTHER|Caffeine|Beverage containing caffeine
40956131|NCT05962437|DEVICE|Self-guided digital Acceptance and Commitment Therapy|Smartphone-based mobile health application (app) that delivers a self-guided, evidence-based ACT program tailored to the management of FM. This investigational digital therapeutic, referred to herein as STANZA, was inspired by a web-based ACT program for FM validated by University of Manitoba and was recently granted De Novo clearance by the U.S. FDA. The app delivers ACT in 15- to 20-minute daily doses over the course of 12 weeks without the involvement of healthcare providers. The program consists of interactive educational materials that teach ACT skills which are reinforced experientially via values exploration and identification, mindfulness, and relaxation exercises. Values-based assignments follow each lesson to assist patients in incorporating ACT skills into their daily lives. Uniquely, STANZA teaches additional skills, including self-guided physical exercise and pacing daily activities via a personally customized stepwise, gradual approach.
40956132|NCT05962437|DEVICE|FM symptom tracking app (FM-ST)|Based on the same platform as STANZA, FM-ST enables self-guided daily tracking of patient-reported symptoms and functioning. Symptom tracking is commonly used in chronic pain management. FM-ST also provides access to educational materials relevant to FM and general health but does not provide any psychotherapy or healthcare professional involvement. This app mitigates potential expectation, treatment time and attention, and healthcare provider interaction biases that often occur in chronic pain studies that utilize passive comparison conditions.
40956133|NCT05962437|BEHAVIORAL|Treatment as Usual (TAU)|Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)
40956134|NCT02242266|DRUG|Tiotropium low dose|inhalation powder, hard PE capsule
40956135|NCT02242266|DRUG|Tiotropium medium dose|inhalation powder, hard PE capsule
40956136|NCT02242266|DRUG|Spiriva® HandiHaler® high dose|Tiotropium inhalation powder, hard gelatine capsule
40956137|NCT02242266|DRUG|Placebo via the blue HandiHaler®|oral inhalation via the blue HandiHaler®
40956138|NCT02242266|DRUG|Placebo via the grey HandiHaler®|oral inhalation via the grey HandiHaler®
40956139|NCT03643354|DIAGNOSTIC_TEST|Epley maneuver/Barbeque maneuver|Subjects will be rotated using the Rotundum Device to perform the previously described maneuvers Epley/Barbeque to evaluate the presence of BPPV.
40956140|NCT00384501|DEVICE|Intacs|
40762425|NCT00431379|DRUG|Tenecteplase|
40762426|NCT04649905|PROCEDURE|Surgical Treatment|Surgical standard-of-care treatment for knee OCD
40762427|NCT04649905|PROCEDURE|Nonoperative Treatment|Nonoperative standard-of-care treatment for knee OCD
40762428|NCT05220202|BEHAVIORAL|Behavioral Intervention Group (MOTIVATE)|Behavioral: Behavioral Intervention Group (MOTIVATE) The behavioral intervention is designed for older Veterans with musculoskeletal pain and depression and will include 8 individual telephone sessions delivered by health coaches (for up to 5 months total), accounting for additional time between sessions (if needed).
40762429|NCT04598087|BEHAVIORAL|Prehabilitation|The multi-phasic prehabilitation intervention involves three phases: Phase 1: Before surgery (typically \~25 days); Phase 2: The in-hospital phase (typically 10-14 days); Phase 3: Discharge to 6-weeks after surgery.
40762430|NCT03811119|DEVICE|MANTA vascular closure device|Collagen based vascular closure device
40762431|NCT03811119|DEVICE|Suture based vascular closure device|Suture based vascular closure device (ProGlide)
40956141|NCT01635335|BEHAVIORAL|Latino STYLE|7-hour family-based workshop with 3-hour follow-up booster 3 months later
40956142|NCT04751526|DEVICE|BreEStim 240|240 BreEStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
40762432|NCT01589640|OTHER|Blink Tears lubricating Eye Drops|2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
40762433|NCT01589640|OTHER|Blink Gel Tears Lubricating Eye Drops|2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
40762434|NCT01589640|OTHER|Systane Balance Lubricant Eye Drop|2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
40762435|NCT02752035|DRUG|gilteritinib|Tablet, oral
40762436|NCT02752035|DRUG|azacitidine|Subcutaneous injection or intravenous infusion
40762437|NCT06638138|DEVICE|Flexband|Artelon FLEXBAND is a commercially available, polycaprolactone polyurethane urea (PCL/PUUR) multipolymer synthetic knitted mesh that is used for soft tissue reinforcement procedures. The device is biocompatible and degradable and has been used as an augmentation device in over 50,000 Orthopedic tendon and ligament reconstructive procedures. The FLEXBAND kits contain the device and all of the instrumentation needed to insert the device.
40956143|NCT04751526|DEVICE|EStim 240|240 EStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
40956144|NCT00132652|DRUG|Lamivudine|
41291910|NCT06480474|DEVICE|Deprexis with online forum|Those in this group will have access to deprexis ( same as the first group) as well as an online forum built for the study. This forum will feature a general discussion page where participants can ask and answer questions, and they will be divided into groups of 10 to share experiences if they wish. Additionally, there will be subforums related to specific modules of the program. Participants can share their experiences and ask questions related to the modules. A moderator will regularly check to ensure no personal or sensitive information is disclosed and will ask questions weekly to encourage contributions to the forum.
40762438|NCT02793050|DRUG|Trabectedin|Collection of data on the clinical use of Trabectedin
40762439|NCT05708521|DRUG|Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery|POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.
40956145|NCT00132652|DRUG|Telbivudine|
41135368|NCT04958837|OTHER|FIFA 11+ protocol|Slow paced running exercises of 8 minutes' duration including running straight, running with hip out, running hip in, running circling partner, running shoulder contact and running quickly forward and backwards (2 rounds each), followed by Strength, plyometric and balance exercises including The Bench, Sideways Bench each side, Nordic Hamstring strengthening and single leg stance balance training, squatting and jumping. All exercises will be progressively increased as per established protocol. The final phase of the study includes fast running for 2 minutes.
40956146|NCT02564796|DRUG|Epoetin Alfa and Iron|Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
40956147|NCT02564796|DRUG|Iron|Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
40762440|NCT05708521|DRUG|Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery|SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
40762441|NCT06323083|OTHER|Emotional Freedom Technique|Emotional freedom techniques is a psychophysiological intervention that combines psychological methods from traditional therapies with somatic stimulation. EFT involves tapping acupuncture points to desensitize negative emotions by focusing on the emotion.
40762442|NCT02046876|OTHER|Multimodal Physiotherapy Program|Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
40762443|NCT02768246|DEVICE|BVGA|The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation
40762444|NCT02768246|DEVICE|Face Mask|Classic face mask
40762445|NCT05930535|BEHAVIORAL|Parenting for Lifelong Health for Parents and Teens|"PLH will be delivered over 6 sessions as a group-based family program with both adolescents and caregivers attending, with joint and separate core sessions framed by joint introductions and endings. It will include activities such as: building positive parent-child relationships; developing problem-solving skills; stress-management and stress-reduction skills; improving effective limit-setting and discipline by parents; talking about feelings and regulating emotions.~The PLH program will also include a peer support component and incentive boosters. The Helping Adolescents Thrive comic chapters will be provided as homework activities. The comics, developed by UNICEF, cover adaptation to new situations, stress management, problem-solving, communication skills, risky choices and being there for each other."
40956148|NCT01590459|DRUG|VX-509|50 mg oral tablet
40956149|NCT01590459|DRUG|VX-509 matching placebo|0 mg oral tablet
40762446|NCT02268656|DRUG|propofol concentration|First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
40762447|NCT02075684|PROCEDURE|Renal Biopsy|
40762448|NCT01795157|DEVICE|CCADSS|Questionnaire is transferred wireless to the physician's PC
40762449|NCT01795157|DEVICE|pen-paper|Questionnaire completed and transferred to the physician using standard methods
40762450|NCT04692597|DEVICE|Phoenix Thera-Lase System|Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes per affected hand.
40762451|NCT04692597|DEVICE|SHAM Phoenix Thera-Lase System|Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes per affected hand.
40762452|NCT00781898|DRUG|Depot naltrexone|Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
40762453|NCT00781898|OTHER|Treatment as Usual (TAU)|Treatment as Usual (TAU) community treatment provided to the participant
40762454|NCT04585581|BEHAVIORAL|time-restricted eating|Participants will be asked to limit the time-window for their daily energy intake to a maximum of 10 hours.
40762455|NCT04585581|BEHAVIORAL|high intensity exercise|Participants will be encouraged to exercise with high intensity 2-3 times per week
40762456|NCT04585581|OTHER|Standard Care|Standard clinical care
40956150|NCT02722369|DRUG|Gemcitabine|Chemotherapy
40956151|NCT02722369|DRUG|Carboplatin|Chemotherapy
40956152|NCT02722369|DRUG|Etoposide|Chemotherapy
40956153|NCT02722369|DRUG|Hydroxychloroquine|Maintenance Agent
40956154|NCT04067700|PROCEDURE|Invasive coronary treatment|Coronary artery bypass surgery or percutaneous coronary intervention.
40956155|NCT01558739|DRUG|INC424|Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
40956156|NCT03041883|PROCEDURE|Crosslinking with riboflavin of the corneal graft-support|Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique
40956157|NCT03041883|PROCEDURE|De-epithelisation of the corneal graft support with instillation of riboflavin|Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
40956158|NCT00884169|DRUG|M518101|Proper quantity twice a day
40956159|NCT00884169|DRUG|placebo|Proper quantity twice a day
40956160|NCT01631110|BIOLOGICAL|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
40956161|NCT05236400|DEVICE|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|Subjects who have passed the screening test will receive the test device (LMECA.A1000) within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through bronchoscopy before application for clinical trials and 72 hours after application.
41135369|NCT03843606|OTHER|Modified ketogenic diets|Different diet composition
40762457|NCT05597605|DEVICE|The SHINE SYSTEM|The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
40762458|NCT00800345|DRUG|Oral Topotecan|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
40762459|NCT00800345|DRUG|Pazopanib|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
40762460|NCT02437526|OTHER|Analytic treatment interruption|
40762461|NCT03891446|DRUG|Bimatoprost SR|Intraocular implant
40762462|NCT03891446|OTHER|Standard of Care|Standard of care treatment based on investigator's judgement.
40762463|NCT06057090|BEHAVIORAL|Therapy Dog|Certified, volunteer therapy dogs and their handlers will be present in the room during procedures in the experimental arm to see if their presence reduces anxiety and improves behavior in pediatric dental patients.
40762464|NCT02160808|DRUG|Secretin|Drug to stimulate pancreatic secretion
40762465|NCT02160808|DRUG|Placebo|
40956162|NCT05236400|PROCEDURE|Manual phlegm suction system|Subjects who have passed the screening test will receive a manual phlegm suction system procedure using a catheter by professional medical staff within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through a bronchoscopy before application to clinical trials and 72 hours after application.
40956163|NCT04209192|DRUG|Fosfomycin Tromethamine 3G Sachet|Is the prophylactic drug which will be used in the intervention group.
40956164|NCT04209192|DRUG|Amikacin|Is the prophylactic drug which will be used in the control group.
40956165|NCT04925661|DRUG|HEC53856|Either dose of HEC53856 will be administered after fasting .
40956166|NCT04925661|DRUG|Roxadustat|Roxadustat will be administered after fasting .
40956167|NCT04925661|DRUG|Placebo|Either dose of placebo will be administered after fasting .
40956168|NCT02740556|OTHER|HepCure ToolKit|"HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources."
40956169|NCT02740556|DEVICE|AdhereTech Active Features|AdhereTech, a wireless pill monitoring device that measures the dosage and time a medication was taken. It is a HIPAA-compliant, FDA-registered Class I medical device. Using cellular technology, AdhereTech can be used passively to collect data on when a medication is taken, when a refill is needed, and how often the bottle is opened. AdhereTech also can be used actively to monitor adherence and provide feedback to subjects using the device. When actively monitoring, AdhereTech can be set up to provide live feedback to a subject by lighting up, sounding chimes, and sending phone/text/email alerts to remind patients to take their medication.
40956170|NCT02740556|OTHER|AdhereTech Passive Monitoring|AdhereTech passively monitors adherence (no chimes or reminders)
40956171|NCT04937231|OTHER|Aerobic exercises|"For Week 1 and 2 : Treadmill 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 10-20 minutes For Week 3 and 4; Cycle ergometer 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 30-40 minutes"
40956172|NCT04937231|OTHER|Resistance exercises|"For Week 1 and 2; 2 x 10 rep (unilateral leg press) 4x 12 reps (Bilateral leg press~1 x 8 rep ( unilateral arm curls For Week 3 and 4; 1 x 10 reps Shoulder press~1 x15 rep Bilateral knee extension~1 x 10 reps Bilateral arm curls"
40956173|NCT04937231|OTHER|Combined training|For Week 1 and 2; Aerobic exercise on Treadmill along with dumbbell to perform upper limb exercises (biceps curls, side curls extensions, upright row, back fly) and used Thera band to perform lower limb exercises for 10-20 minutes For Week 3 and 4; Aerobic exercise on Treadmill along with dumbbell and Thera band to perform upper limb and lower limb exercises for 30-40 minutes
40956174|NCT01223131|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
40956175|NCT01223131|DRUG|NPH insulin|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
40956176|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.05%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.05%.
40762466|NCT06502119|OTHER|Designed Questionnaire|Participants in this study, comprised solely of obstetricians and gynecologists practicing in Egypt, will complete a self-administered questionnaire designed to assess their knowledge, attitudes, and practices related to operative vaginal birth. The questionnaire includes four sections: the first gathers demographic data such as name, gender, and years of experience in childbirth care; the second focuses on participants' practices regarding the frequency and types of operative vaginal birth used (forceps, ventouse) and reasons for their use; the third evaluates knowledge of outcomes associated with operative vaginal birth through multiple-choice questions; and the fourth explores attitudes towards operative vaginal birth, including opinions on hospital rates and policy appropriateness. Completion and return of the questionnaire, which takes approximately 5 to 10 minutes, will be considered as consent to participate in the study.
40762467|NCT05471128|PROCEDURE|Standard of Care Biopsy|Patients will be evaluated with multiparametric MRI prostate followed by ExactVu micro-ultrasound to identify target lesions all of which will be biopsied by the examiner
40762468|NCT04045145|DRUG|Crinecerfont|Crinecerfont administered orally for 14 consecutive days.
40762469|NCT01339091|DRUG|Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
40762470|NCT01339091|DRUG|Vancomycin / Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
40956177|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.1%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.1%.
41135370|NCT03345095|DRUG|Marizomib|Intravenous administration of Marizomib
41135371|NCT03345095|DRUG|Temozolomide|Oral Administration of Temozolomide
40956178|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.5%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.5%.
40956179|NCT05932693|OTHER|E-liquid coolant (WS-3, 1.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 1.0%.
40956180|NCT05932693|OTHER|E-liquid coolant (WS-3, 2.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 2.0%.
41135372|NCT03345095|RADIATION|radiotherapy|60 Gy in 30 fractions over 6 weeks
41135373|NCT02483468|BEHAVIORAL|Cognitive Behavioral Therapy for Pain|Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.
41135374|NCT02483468|DEVICE|Transcranial Direct Current Stimulation|Electrical stimulation of the prefrontal cortex using 2mA of direct current
41135375|NCT02483468|DEVICE|Sham Transcranial Direct Current Stimulation|Sham stimulation of the left dorsolateral prefrontal cortex
41135376|NCT04652869|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
40956181|NCT05932693|OTHER|E-liquid coolant (menthol, 0.05%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.05%.
40956182|NCT05932693|OTHER|E-liquid coolant (menthol, 0.1%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.1%.
40956183|NCT05932693|OTHER|E-liquid coolant (menthol, 0.5%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.5%.
40956184|NCT05932693|OTHER|E-liquid coolant (menthol, 1.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 1.0%.
40956185|NCT05932693|OTHER|E-liquid coolant (menthol, 2.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 2.0%.
40956186|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.05%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.05%.
40956187|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.1%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.1%.
40956188|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.5%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.5%.
40956189|NCT05932693|OTHER|E-liquid coolant (WS-23, 1.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 1.0%.
40762471|NCT04206943|BIOLOGICAL|Car-T Cell Therapy|"Lymphodepletion Protocol:~* -6. Day: Cyclophosphamide 300 mg / m\^2 i.v.~* -5. -4. and -3. Days: Fludarabine 30 mg / m\^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements."
40762472|NCT02132260|DRUG|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks
41291911|NCT04467541|BIOLOGICAL|Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell)|Inactivated Enterovirus Type 71 (EV71) Vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
40956190|NCT05932693|OTHER|E-liquid coolant (WS-23, 2.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 2.0%.
40956191|NCT05932693|OTHER|E-liquid coolant (WS-23, 4.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 4.0%.
40956192|NCT00158574|DRUG|sulphadoxine-pyrimethamine|
40956193|NCT00158574|DRUG|mefloquine|
40956194|NCT00158574|DRUG|Chlorproguanil-dapsone|
40762473|NCT02132260|DRUG|Naftin® (Naftifine Hydrochloride) Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
40762474|NCT02132260|DRUG|Placebo Topical Cream|Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
40762475|NCT01143636|DEVICE|Transcranial Direct Current Stimulation|Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
40762476|NCT00153933|DRUG|Bortezomib|Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
40956195|NCT00158574|DRUG|Placebo|Placebo
40956196|NCT00158574|DRUG|Sulphadoxine-pryrimethamine|IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg
40956197|NCT00158574|DRUG|IPTi mefloquine|IPTi doses 1 \& 2 at ages 2 \& 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg
40762477|NCT00153933|DRUG|CC-5013|Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
40762478|NCT00692328|BEHAVIORAL|Levodopa or acupuncture|Comparison of subject expectancy of receiving levodopa or acupuncture.
40762479|NCT01737723|DEVICE|Neurokeeper stroke detector|Monitoring stroke patients
40956198|NCT00158574|DRUG|Chlorproguanil dapsone|IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone
40956199|NCT05241743|OTHER|radiological examination, pain, nomophobia, phone addiction|120 patients who applied to the clinic with the complaint of neck pain and were diagnosed with cervical hypolordosis by radiological examination will be included in the study. After giving the necessary verbal and written information about the study, a link will be sent to the phones of the patients whose informed consent was obtained. Patients will access evaluation questions and survey questions via this link. Personal information with the Sociodemographic Data Form prepared by us; pain severity by Visual Analogue Scale (VAS); phone addiction level with the Smartphone Addiction Questionnaire (Young Population); nomophobia levels will be evaluated with the Nomophobia Scale.
40956200|NCT02736760|DRUG|Daylight photodynamic therapy using Methylaminolevulinate (MAL)|"In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months."
41291912|NCT00778323|PROCEDURE|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
41291913|NCT01770353|DRUG|Ferumoxytol|Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.
40762480|NCT06570902|DEVICE|WCD|An FDA-approved, CE marked WCD will be prescribed for up to 3 months of use after hospital discharge, with the option for longer use under physician discretion
40956201|NCT02736760|PROCEDURE|Cryosurgery|In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
40956202|NCT03068455|BIOLOGICAL|nivolumab|Specified Dose on Specified Days
40956203|NCT03068455|BIOLOGICAL|ipilimumab|Specified Dose on Specified Days
40956204|NCT05947045|OTHER|Cognitive training via iPad|Participants will complete five sessions of the Cogmed training program on an iPad. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
40956205|NCT05947045|OTHER|Cognitive training via virtual reality|Participants will complete five sessions of the Cogmed training program within virtual reality. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
40956206|NCT00667160|DRUG|tacrolimus ointment|topical
40956207|NCT00667160|DRUG|pimecrolimus cream|topical
40956208|NCT04970784|OTHER|Activities of Daily Living (ADL) questionnaire (The Katz index )|"For patients cared for by the geriatric sector, questionnaire will be filled in at admission D0 and by phone at D30, for the classic emergency patients questionnaire will be submitted by phone the day following the consultation D1, and D30."
40956209|NCT03745807|BIOLOGICAL|NKTR-214|Specified dose on specified days
40956210|NCT03745807|BIOLOGICAL|Nivolumab|Specified dose on specified days
40762481|NCT01877057|DIETARY_SUPPLEMENT|Saturn|
40762482|NCT06563752|OTHER|Participants will use 3D glasses to view VR educational information|"Participants will use 3D glasses to view VR educational information, which includes:~1. Understanding of psychiatric symptoms, including symptoms, disease course, treatment, and prognosis.~2. Knowledge about medications, their relationship with symptom stabilization, and handling of side effects.~3. Schizophrenia as a chronic illness, with analogies to other chronic diseases.~4. Signs of disease relapse.~5. How to manage ongoing psychiatric symptoms of schizophrenia, including delusions, hallucinations, paranoia, and negative symptoms.~6. Strategies for interacting and communicating with patients.~7. Stress management and adjustment, as well as suicide prevention.~8. Available resources."
40956211|NCT05285800|DRUG|0.5% Hyperbaric Bupivacaine|In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
40956212|NCT01956383|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
40762483|NCT06563752|OTHER|routine care|Before discharge, provide routine discharge preparation instructions and offer a disease education booklet with relevant health information. Follow up with two phone calls after discharge, on the 7th and 30th days.
40956213|NCT00391729|DRUG|ABT-089|Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
40956214|NCT00391729|DRUG|Placebo|Subjects will take placebo QD, BID for 4-6 weeks
40956215|NCT06201520|PROCEDURE|manual acupuncture|manual acupuncture
40956216|NCT06201520|DEVICE|laser acupuncture|laser acupuncture therapy
40956217|NCT06201520|DEVICE|sham laser acupuncture|sham laser acupuncture
40956218|NCT06201520|DEVICE|wrist splint|wear wrist splint at night
40956219|NCT00061347|PROCEDURE|Fiducial marker placement|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
41291914|NCT01770353|DRUG|MM-398|MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
40956220|NCT06088875|DRUG|Nebulization|Patients will be nebulized with mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg by using wall nebulizer for 15 min before awake fiberoptic intubation. Patients in group S will receive saline 10 ml nebulization
40956221|NCT06088875|DRUG|Spray-as-you-go|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization. Patients in group N will receive saline via spray-as-you-go technique
40956222|NCT06406114|DRUG|Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing|Percutaneous and intradermal skin testing will be performed in all participants. Concentrations for percutaneous testing; cefazolin (330 mg/ml), cefuroxime (90 mg/ml), cefotaxime (100 mg/ml), ceftazidime (100 mg/ml), ceftriaxone (100 mg/ml), cefepime (200 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (6 mg/ml). Concentrations for the first intradermal testing; cefazolin (3.3mg/ml), cefuroxime (1 mg/ml), cefotaxime (1 mg/ml), ceftazidime (1 mg/ml), ceftriaxone (1 mg/ml), cefepime (2 mg/ml), pre-pen (undiluted), penicillin G (1000 U/ml), ampicillin (20 mg/ml), and histamine (0.1 mg/ml). Concentrations for the second intradermal testing; cefazolin (33mg/ml), cefuroxime (10 mg/ml), cefotaxime (10 mg/ml), ceftazidime (10 mg/ml), ceftriaxone (10 mg/ml), cefepime (20 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (0.1 mg/ml). Histamine and saline will be used as positive and negative controls.
40956223|NCT06406114|DRUG|Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge|After double-blind skin testing, participants will undergo a 3-step double-blind placebo-controlled drug challenge to their culprit cephalosporin (the cephalosporin they are suspected to be allergic to, either cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime). The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
41291915|NCT01347567|OTHER|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
41291916|NCT00479440|DRUG|SAM-315|
41455356|NCT02827097|DRUG|denogan and rectus sheath block|administration of denogan and rectus sheath block with 0.375% ropivacaine
41455357|NCT02827097|DRUG|denogan|administration of denogan
40762484|NCT00991978|OTHER|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
40762485|NCT00260338|BIOLOGICAL|stem cell|mesenchymal stromal cell
40762486|NCT00859885|DRUG|Antithrombotic treatment|antiplatelets, anticoagulants
40762487|NCT00859885|DEVICE|percutaneous device closure of PFO|umbrella device for PFO closure
41455358|NCT03563443|DIAGNOSTIC_TEST|Genomic Imprinting Testing|The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)
41455359|NCT01232244|OTHER|GLP-1 infusion|1 pmol/kg/min
41455360|NCT01232244|OTHER|Glucagon infusion|3ng/kg/min
41455361|NCT01232244|OTHER|Oxyntomodulin infusion|3 pmol/kg/min
41455362|NCT01232244|OTHER|GLP-1 and glucagon infusion|1 pmol/kg/min 3 ng/kg/min
40762488|NCT01548326|DRUG|Atorvastatin|one 40 mg Atorvastatin tablet orally per day for 10 days
40762489|NCT01548326|DRUG|placebo|one Placebo tablet orally per day for 10 days
40762490|NCT02125422|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
40762491|NCT06025708|DEVICE|Diagnostic Test: Quantra QStat Cartridge|Whole blood coagulation testing system
40762492|NCT03409770|OTHER|Therapeutic hypothermia|Whole body cooling using a servo controlled device
41455363|NCT01232244|OTHER|Placebo|NaCl 9 g/L infusion
41455364|NCT00965731|DRUG|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
41455365|NCT00965731|DRUG|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
40762493|NCT00773591|DRUG|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|"NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge."
41455366|NCT00965731|DRUG|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
41455367|NCT01402050|DRUG|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
41455368|NCT01402050|DEVICE|FOLEY BALLOON|INDUCTION OF LABOR
40762494|NCT05059665|DIAGNOSTIC_TEST|Helio Liver Test|De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).
40762495|NCT00055185|DRUG|CD4-IgG2 (PRO 542)|
40762496|NCT06124924|DRUG|SGLT2 inhibitor|a starting dose of a SGLT2i will be prescribed for the participant for pickup at discharge via the UMMC discharge pharmacy. The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills, but this can be adjusted to other SGLT2i or other doses in the outpatient setting by either Dr. Murphy or by the participants' established providers, typically based on insurance company preferences among the three FDA-approved SGLT2i.
40762497|NCT05136027|OTHER|Combined training|Low-intensity interval training and resistance exercise
40762498|NCT06563596|DRUG|Zanubrutinib|Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol.
40762499|NCT06563596|DRUG|Rituximab|Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard.
40762500|NCT06563596|DRUG|Epcoritamab|Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol.
41455369|NCT03113396|DRUG|Baclofen|baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
41455370|NCT03113396|DRUG|Placebo oral capsule|placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
41455371|NCT06306391|DRUG|Intravenous naloxone|Nyoxid 1.8 mg nasal spray, solution in single-dose container. Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
41455372|NCT06306391|DRUG|Intranasal naloxone|Naloxone Kern Pharma 1 mg in total (from 0.4 mg/mL injectable solution). Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
41455373|NCT04872608|DRUG|Letrozole|Letrozole will be given daily on days 1-28.
40762501|NCT03377322|DRUG|Probiotic Capsule|Probiotic - one capsule a day for four weeks
40762502|NCT03377322|DRUG|Placebo Capsule|Placebo - one capsule a day for four weeks
40762503|NCT04575688|DRUG|Exparel|Exparel will be administered by periarticular injection to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
40762504|NCT04575688|DRUG|Bupivicaine|Bupivicaine will be administered by popliteal block to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
40762505|NCT06471673|BIOLOGICAL|BC1 cell line|BC1 cell line is a different experimental, HER-2 positive, allogeneic, whole cell BC cell lines designed to secrete GM-CSF in situ and augment dendritic cell activity. Similar to the SV-BR-1-GM cell line (NCT03328026, IND 10312), the BC cell line is derived from the BC parent cell line, SV-BR-1, which expresses multiple tumor associated antigens (TAAs)
41135377|NCT04652869|BEHAVIORAL|Mindfulness|Mindfulness is a type of meditation in which you focus on being intensely aware of what you're sensing and feeling in the moment, without interpretation or judgment.
40762506|NCT06471673|BIOLOGICAL|Bria-OTS regimen and CPI (tislelizumab)|"Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation."
40956224|NCT06406114|DRUG|Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge|Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that shares a similar side chain with their culprit. This will be cefepime for those allergic to ceftriaxone, cefaclor for those allergic to cephalexin, cefixime for those allergic to cefdinir, cefdinir for those allergic to cefixime, cephalexin for those allergic to cefaclor or cephadroxil, and ceftriaxone for those allergic to cefepime, cefuroxime, or cefpodoxime. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
40956225|NCT06406114|DRUG|Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge|Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that has a dissimilar side chain to their culprit. This will be ceftriaxone for those allergic to cefazolin, and cefazolin for those allergic to any other cephalosporin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
41455374|NCT04872608|DRUG|Palbociclib|Palbociclib will be given daily on days 1-21 and held on days 22-28, as per standard FDA-approved dosing guidelines.
41135388|NCT06240351|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib is a Janus kinase (JAK) inhibitor
41135389|NCT02644122|DRUG|SF1126|
41135390|NCT02978183|BIOLOGICAL|ST266|One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
41135391|NCT02978183|DRUG|Saline (0.9% NaCl)|One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
41291917|NCT00716404|DEVICE|Targeted Renal Therapy|Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
41291918|NCT00707018|DEVICE|External rotation shoulder sling|The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
41291919|NCT00707018|DEVICE|Internal rotation shoulder sling|The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
41455375|NCT04872608|DRUG|Onapristone ER|Onapristone will be given daily on days 1-28.
41291920|NCT01742351|BEHAVIORAL|Guided internet-based cognitive behavior therapy|
41466402|NCT06613048|OTHER|Breathing exercise|"The researcher has a certificate in breathing exercises. Those who consent to participate in the study that meets the research criteria will be given training with a prepared training brochure about correct breathing technique, introduction and function of the diaphragm muscle, box breathing technique, diaphragm breathing technique and benefits of correct breathing before the exercise.~Box breathing technique will be applied in addition to standard treatment, 3 sets per day (morning, noon and evening) for 6 weeks, 10 repetitions in each set.~Diaphragm breathing exercise will be applied in addition to standard treatment, lasting 2 minutes in the first week, then increasing each week and reaching 12 minutes in the 6th week, as 3 sets (morning, noon and evening)."
40762507|NCT06471673|BIOLOGICAL|Bria-OTS regimen and CPI (tislelizumab) expansion cohort|"Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation."
40956226|NCT06406114|DRUG|Amoxicillin double-blind placebo-controlled drug challenge|Participants will optionally undergo a 3-step double-blind placebo-controlled drug challenge to Amoxicillin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. The order of challenge to similar vs. dissimilar cephalosporin will be randomized as well.
40956227|NCT01566734|OTHER|Cefazolin irrigation|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
40956228|NCT01566734|OTHER|Normal Saline Irrigation|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients and in the last group
40956229|NCT04046055|DEVICE|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
40956230|NCT04046055|DEVICE|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
40956231|NCT04046055|DEVICE|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
40956232|NCT00239109|DRUG|Ziprasidone|
40956233|NCT00239109|DRUG|Olanzapine|
40956234|NCT00239109|PROCEDURE|Scales|
40956235|NCT00239109|PROCEDURE|measures of the body (Weight...)|
40956236|NCT00239109|PROCEDURE|Serum analysis|
40956237|NCT04694781|DRUG|LVGN6051|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
40956238|NCT04694781|DRUG|Pembrolizumab|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
40956239|NCT05170464|BEHAVIORAL|Acute Exercise|Brisk walking on a treadmill at ⅔ maximum heart rate as defined by 220-age (in years).
40956240|NCT05170464|DRUG|Caffeine Powder|Participants will receive powdered caffeine dissolved in one cup of water (1.2mg/kg)
40956241|NCT00503529|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
40956242|NCT03266731|DRUG|Aspirin|evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset
40956243|NCT04392752|OTHER|Dieting intervention|This study includes four laboratory testing sessions over the 50-week period. Testing sessions will be performed over one week. Time points include testing before the diet or the control period start (PRE), one week before the competition (MID), after the competition (COMP) and after a recovery period (POST), during which the participants are advised to continue their normal training regimen, but to stop competition dieting. Participants will spend three hours in the laboratory between 0700-1300. The control group will be advised to maintain their normal physical activity diet throughout the study. The participants will be given identification numbers and the research group is blinded so that they do not know which group participants belong to. All measurements will be conducted at the same time (always within max ±1 hour) due to the importance of standardizing the time of the day of measurements.
40956244|NCT00807170|DRUG|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
40956245|NCT00807170|RADIATION|Whole Brain Radiotherapy (WBRT)|
40956246|NCT00807170|DRUG|ZD6474|200 mg as a once daily oral dose, 21 days
41466403|NCT01334957|DRUG|Intravenous ibuprofen|800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
41291921|NCT00761124|BEHAVIORAL|Intervention Session|A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
40956247|NCT00807170|DRUG|ZD6474|300 mg as a once daily oral dose, 21 days
40956248|NCT06402630|DRUG|STS01|Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
40956249|NCT06402630|DRUG|Placebo|Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
40956250|NCT00241943|PROCEDURE|Hepatitis C educational video|
40956251|NCT06311786|DRUG|[14C]-BIIB091|Administered as specified in the treatment arm.
41135392|NCT05122026|DRUG|Rifapentine|As included in arm/group description
41135393|NCT05122026|DRUG|Isoniazid|As included in arm/group description
40762508|NCT05269797|BEHAVIORAL|Nurse-led health coaching re: heart failure self-care management|A focus group meeting will be arranged with the nurse participants to provide training on the study intervention specific to the Nurse-led health coaching intervention. The intervention involves identifying barriers and finding strategies and solutions to self-care management, while employing a self-care HF management tool of adjusting diuretic dosing (ADD) according to the congestive cardiac calendar (designed in collaboration with nurses in Phase 1). It will be essential for the nurses to document key information pertaining to the rationale for these decision-making strategies or solutions. This is in comparison to the standard of care in primary health care of nurses not taking a standardize approach towards health coaching and the patient being instructed by the practitioner to take a set diuretic dosing (SDD).
40762509|NCT04133038|OTHER|Questionnaire|Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.
41291922|NCT00761124|BEHAVIORAL|Printed Material|General prostate cancer pamphlet
40762510|NCT05688384|DRUG|Propofol + Alfentanil|In addition to LA, patients in the study group are able to self-administer a combination of propofol and alfentanil using a patient-controlled sedation pump. The pump enables the patient via a hand-held button to trigger the release of a single bolus of 0.5ml containing 4.5mg propofol and 25µg alfentanil under an 10second period. This results in a maximal possible amount of 6 bolus doses per minute.
40762511|NCT06181058|BEHAVIORAL|escape room game|Participants will be informed about the game (15 minutes). They will complete the game by solving puzzles within the framework of the oncology patient scenario (approximately 30 minutes). There will be a debriefing session at the end of the escape game (15 minutes).
40762512|NCT01486329|BIOLOGICAL|VXM01|Live anti-angiogenic cancer vaccine drink solution, escalating dose
41291923|NCT05914220|DEVICE|AI Insights Application|Predictive AI Model Risk score
40762513|NCT01486329|BIOLOGICAL|Placebo|Drink solution
40762514|NCT05138822|DRUG|GSK3882347|GSK3882347 will be administered on each dosing day.
40762515|NCT05138822|DRUG|Nitrofurantoin|Nitrofurantoin will be administered on each dosing day.
40762516|NCT05138822|DRUG|Placebo|Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
40762517|NCT05067985|PROCEDURE|covid 19 spinal anesthesia|this group description covers that all the covid 19 pregnant women which we gave spinal anesthesia for cesarean section procedures. The investigators analyzed them retrospectively.
41291924|NCT04634669|DRUG|AXS-05 (dextromethorphan-bupropion)|- AXS-05 tablet, taken daily (up to 15 months)
41291925|NCT01059604|DRUG|Sumatriptan|Sumatriptan
41291926|NCT01059604|DRUG|Naratriptan|Naratriptan
41291927|NCT01059604|DRUG|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
40762518|NCT02669641|DIETARY_SUPPLEMENT|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
40762519|NCT03906084|PROCEDURE|Corticotomy and low laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
40762520|NCT03906084|PROCEDURE|Corticotomy facilitated Orthodontics|Corticotomy is carried out under local anesthesia in right side.
40956252|NCT06069505|DIAGNOSTIC_TEST|Aspergillus PCR|Aspergillus PCR will be performed on different volumes of serum and plasma of patients with hematological malignancies with suspicion for invasive fungal infection.
40762523|NCT05153317|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules or tablets for oral administration.
40762524|NCT05153317|DRUG|IVA|Granules or tablets for oral administration.
40762525|NCT05665751|DRUG|TLC-3595 Dose 1|Tablets administered orally
40762526|NCT05665751|DRUG|TLC-3595 Dose 2|Tablets administered orally
40762527|NCT05665751|DRUG|Placebo|Tablets administered orally
40762528|NCT05222945|OTHER|Biopsies and bloood samplings|blood samples, rectal biopsies, nodes biopsies, cutaneous fat tissues biopsies, semen sample
40762529|NCT04620668|DEVICE|Wysa|Wysa is an AI-based mental health chatbot. It uses evidence-based techniques to help users build mental resilience skills and improve their mental health.
40762530|NCT03460704|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d. dosing).~The 1 MIU/ml CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (11 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d. (morning and evening) over aperiod of 12 month.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g. salbutamol/albuterol), supplied by the Sponsor, could be taken to improve tolerability."
40762531|NCT03460704|OTHER|Placebo|1 mL saline solution 0.45%. The placebo was made up of identical empty glass vials to which the same saline solution diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to mantain the blind.
40762532|NCT01706315|DRUG|GSK2140944|GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
40762533|NCT01706315|DRUG|Placebo|Matching placebo will be available
40956253|NCT03344796|BEHAVIORAL|Goal attainment|After reviewing daily UV exposure in the prior 10 days, participants will be randomized to structured (select strategies from a list of 7 items) or unstructured (submit a free text description of a strategy) goal attainment.
40956254|NCT04027543|COMBINATION_PRODUCT|Neoadjuvant chemoradiotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
40762534|NCT05398666|DEVICE|White LED light|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
40762535|NCT05398666|DEVICE|Green LED light|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
40956255|NCT04027543|PROCEDURE|Oesophagectomy|Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic,and the appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
40956256|NCT04027543|DRUG|Neoadjuvant chemotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
40956257|NCT00639431|BEHAVIORAL|direct observation|direct observation of another person's foot moving
40956258|NCT00639431|BEHAVIORAL|mental visualization|mentally imagining moving one's phantom foot/feet
41291928|NCT05030623|DRUG|Tadalafil 5Mg Tab|Tadalafil 5Mg Tab plus Fluoxetine 20 mg capsule
41291929|NCT05030623|DRUG|Placebo|Placebo Tab plus Fluoxetine 20 mg capsule
41291930|NCT00593112|DRUG|OROS methylphenidate|Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
41291931|NCT00593112|OTHER|No intervention|No intervention
40762536|NCT03769948|OTHER|risk factors for diabetic retinopathy|Demographic variables: gender, race, marital status, urban rural status. Co-morbidity variable: neuropathy, nephropathy, peripheral circulatory, ketoacidosis, hyperosmolarity Lab tests variables: alanine aminotransferase (ALT), albumin serum, anion gap, aspartate aminotransferase, blood urea nitrogen, calcium serum, chloride serum, creatinine serum, glucose serum plasma, hematocrit, hemoglobin, mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MPV), potassium serum, protein total serum, red blood cell (RBC) count, sodium serum, white blood cell (WBC) count
40762537|NCT05200338|DRUG|Engerix-B|Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.
40762538|NCT00100893|DIETARY_SUPPLEMENT|IH636 grape seed proanthocyanidin extract|Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
40956259|NCT03873025|COMBINATION_PRODUCT|Pembrolizumab and CXD101|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allow the immune system to destroy these cancer cells. CXD101 is a histone deacetylase (HDAC) inhibitor which kills cancer cells by blocking the vital functions of HDAC enzymes.
40762539|NCT06449547|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
40956260|NCT00515489|DRUG|Risperidone|as prescribed
40956261|NCT04810871|PROCEDURE|Brain Surgery|Undergo surgery
40956262|NCT05036590|OTHER|control group|The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.
40762540|NCT03889535|DEVICE|Resin strip crowns|"Technique:~I.Select shade of resin-based composite II.Rubber dam isolation III.Select primary incisor celluloid crown form with mesiodistal width similar to the tooth to be restored and trim the selected crown form to fit.~IV.Remove decay with slow speed round bur. Perform pulp therapy, if indicated. V.Reduce incisal edge by 1.5 mm VI.Reduce interproximal surfaces by 0.5 to 1.0 mm with feather edge at gingival margin. The interproximal walls should be approximately parallel.~VII.Reduce buccal surface by 1.0 mm and lingual surface by 0.5 mm with feather edge at gingival margins.~VIII. Round line angles IX.Etch for 15 to 20 seconds, rinse and air dry X. Apply bond and polymerise XI. Fill crown form to 2/3 full with composite resin and seat onto the tooth. Remove excess material with hand instrument. Polymerise.~XII. Remove celluloid crown form with scaler XIII. Finish and polish"
41291932|NCT04630340|DEVICE|STEADES-2|In this arm, the subjects will use a novel exhaled breath carbon monoxide measurement instrument (STEADES-2) for self surveillance of their smoking status. In addition, the subjects will download the STEADES-2 mobile phone application to pay serious games relating to smoking cessation, receive push-though motivational messages and e-coaching from trained healthcare professionals.
41291933|NCT05414123|DEVICE|CNSide|The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
41291934|NCT00670917|OTHER|questionnaire administration|
41291935|NCT00670917|PROCEDURE|acupressure therapy|
40956263|NCT05036590|OTHER|Intervention group|The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.
41291936|NCT00670917|PROCEDURE|biopsy|
41135394|NCT03120026|DIETARY_SUPPLEMENT|Experimental product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
41291937|NCT00670917|PROCEDURE|bone marrow aspiration|
41291938|NCT00670917|PROCEDURE|pain therapy|
41466404|NCT01456429|PROCEDURE|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
41291939|NCT00005592|BIOLOGICAL|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
40956264|NCT06468852|PROCEDURE|Goal-Directed Fluid Therapy|Stroke volume variation (SVV)≤12% and cardiac index (CI)≥2.5L/min/m2 are the goals of Goal-Directed fluid therapy, while the mean arterial pressure (MAP) are kept between 65 and 90 mmHg. 5mL/kg of crystalloids will be infused during induction period, followed by an infusion rate of 2 mL/kg/h to supplement the physiological requirements. If SVV\>12% for more than 5 min, a 250 mL bolus of colloid is given. Another 250 ml bolus of colloid is administrated if SVV was still more than 12% or SV decreased over 10%. If the CI\<2.5 L/min/m2, inotropes are used to achieve this minimum CI, serving as a safety parameter to prevent the patient from being exposure to a low cardiac output state. If SVV and CI reached the s target range but MAP could not maintain the expected level, vasopressors were started. Assess the patients every 5min intraoperatively to ensure that all parameters adhere to the target range according to the study algorithm.
41291940|NCT00005592|BIOLOGICAL|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
41291941|NCT00005592|RADIATION|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
41291942|NCT04440917|DRUG|Camrelizumab|200mg, iv, on day 1, 15, 29, 43
41291943|NCT04440917|DRUG|Apatinib Mesylate|250 mg po, qd, 28 days as a cycle, 2 cycles in total
40956265|NCT03530969|BEHAVIORAL|Self-Efficacy Assessment|"Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training."
40956266|NCT03530969|BEHAVIORAL|UCLA Geriatrics Attitudes Scale|The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.
41291944|NCT02463123|DEVICE|Indirect calorimetry|Resting energy expenditure will be studied using indirect calorimeter CCM Express (Medgraphics Inc, USA).
41291945|NCT04870177|DRUG|AK112|AK112 infusion biweekly
40762541|NCT03889535|DEVICE|Zirconia crowns|I.Choose appropriately sized crown based on tooth's dimension; evaluate occlusion. II.Rubber dam isolation. III.Remove decay, perform pulp therapy if indicated. IV.Prep mesial half of incisal edge to complete thickness of 001 donut bur. V.Prep and blend distal half of incisal edge to create uniform incisal reduction. VI. Create chamfer margin at gum line at least half the thickness of bur tip. VII. Taper incisal half lingually to create a thin incisal edge. VIII. Remove cingulum and 0.75-1.25mm of lingual enamel; blend together forming smooth, slightly concave surface extending to tissue. IX. Thin incisal half. X.With 004 flame bur, remove chamfer margin at tissue level. Keep bur parallel to long axis of tooth. Remove chamfer in incremental steps, XI. Extend tip of bur full 2mm subgingivally. While hugging bur axially along root surface, make 3 circumferential passes. XII.Clean tooth and control bleeding. XIII.Cement crown with pure glass ionomer cement
40762542|NCT06541119|OTHER|Selective Peroneus longus excercise|Weight bearing peroneus longus exercise
40762543|NCT06541119|OTHER|Conventional physical therapy programme|"* Passive abduction of the Hallux with traction~* short foot exercise~* toe spread outs"
40762544|NCT01717274|PROCEDURE|Hot saline irrigation|The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
40762545|NCT00400322|DRUG|Valganciclovir (Valcyte)|
40762546|NCT00400322|OTHER|Placebo|
40762547|NCT06312254|DRUG|Topical lidocaine 5%|Drug is used to pharmacologically modulate peripheral sensory afferents
40956267|NCT03530969|BEHAVIORAL|Course Evaluations|The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.
40956268|NCT03530969|BEHAVIORAL|The Consultation and Relational Empathy (CARE) questionnaire|The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.
40956269|NCT03530969|BEHAVIORAL|Consumer Assessment of Health Care Providers and Systems Program (CAHPS)|"Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)"
40762548|NCT06312254|DRUG|Topical Phenytoin 10%|Drug is used to pharmacologically modulate peripheral sensory afferents
40762549|NCT06312254|DRUG|Topical Mepyramine 2%|Drug is used to pharmacologically modulate peripheral sensory afferents
40762550|NCT06312254|OTHER|Topical Placebo|Drug is used as control
40762551|NCT03747263|PROCEDURE|Catheter ablation|Electrophysiology studies are performed during conscious sedation using boluses of midazolam and fentanyl and a continuous infusion of propofol. Vital parameters are continuously monitored. One 7F standard diagnostic catheter is positioned inside the coronary sinus (CS) via the femoral vein. One 8,5-F sheath is advanced to the left atrium (LA). After transseptal catheterization, intravenous heparin is administered to target an activated clotting time of ≥300 seconds. PV angiographies are obtained for each PV and PV recordings are registered at baseline in SR. The 8.5F transseptal sheath (TS) is changed over the wire for a 12F steerable TS.
40762552|NCT04832152|OTHER|OT4ASD|Occupational therapy will focus on education and coaching of families/caregivers of children with autism spectrum disorder to help them adapt their daily routines to address their child's sensory needs.
40762553|NCT05001113|PROCEDURE|the subxiphoid approach thoracoscopic thymectomy|A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.
40762554|NCT05001113|PROCEDURE|the lateral intercostal approach thoracoscopic thymectomy|"Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.~Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces."
40762555|NCT00958425|DEVICE|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
40762556|NCT00958425|DEVICE|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
40762557|NCT06305403|DIAGNOSTIC_TEST|serum creatinin level|Serum creatinine and urine amounts will be checked for five days.
40762558|NCT04633330|DRUG|AHCC®capsules|AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.
40762559|NCT04633330|DRUG|Simulation of AHCC®capsules|TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
40762560|NCT03186820|OTHER|Susceptibility Weighted Imaging as 3D SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
40956270|NCT03530969|BEHAVIORAL|Patient activation measure (PAM) scale|The PAM scale contains 22 items that assess patient engagement in their care process.
40762561|NCT02941029|OTHER|Plasma Blood collection|Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
40762562|NCT04878185|OTHER|Exercise|Preoperative exercise
40956271|NCT06180720|DRUG|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
40762563|NCT06047587|BEHAVIORAL|VR-TrAC|Virtual Reality Training for Aggression. The training consists of 16 twice-weekly sessions, with a duration of 60 minutes each.
40956272|NCT06180720|DRUG|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
40762564|NCT06047587|OTHER|Care as Usual|Care as usual as provided in prison.
40762565|NCT04751357|DIAGNOSTIC_TEST|ECA-Test (Clot-Pro)|Thrombelastometric ECA-Test performed on Clot-Pro
40762566|NCT03412591|DRUG|Suvorexant 20 mg|Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.
40762567|NCT04854499|DRUG|Magrolimab|Administered intravenously
40762568|NCT04854499|DRUG|Pembrolizumab|Administered intravenously
40762569|NCT04854499|DRUG|Docetaxel|Administered intravenously
40762570|NCT04854499|DRUG|5-FU|Administered intravenously
40956273|NCT05879679|BEHAVIORAL|Food craving induction|Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.
40762571|NCT04854499|DRUG|Cisplatin|Administered intravenously
41291946|NCT02500030|PROCEDURE|Glossopharyngeal Breathing|Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
40762572|NCT04854499|DRUG|Carboplatin|Administered intravenously
40762573|NCT04854499|DRUG|Zimberelimab|Administered intravenously
41135395|NCT03120026|DIETARY_SUPPLEMENT|Isocaloric placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
40956274|NCT03665454|DRUG|PF-06412562|PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
40956275|NCT03665454|DRUG|Standard of Care Placebo|25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
40956276|NCT02008175|RADIATION|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (\<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
40956277|NCT03940287|OTHER|Muscle Energy Technique|"Muscle energy technique will be given in two different position. For anterior in- nominate rotation and posterior in- nominate rotation patient position will be in supine lying position.~For weakened muscle,piriformis application the patient should be side-lying position, close to the edge of the table, affected side uppermost, both legs flexed at hip and knee.~The therapists stand facing the patient at hip level,then patient should be close enough to the edge of the table for the therapist to stabilize the pelvis against his trunk. The angle of hip flexion should not exceed 60°, and then places one hand on the contralateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis.~Isometric contraction should be hold for 3-5 second and that particular method will be repeated for 7-10 times."
40956278|NCT03940287|OTHER|Kinesiotape application|"Kinesiotaping will be applied to piriformis muscle and Sacroiliac joint (SIJ). This tape will be applied in I shape to both sides of the spine from sacrum to Anterior Superior Iliac Spine. For SIJ taping same 5 cm KT tape will be used, it will be applied from below posterior sacroiliac spine to opposite side. Here patient should be in standing position.~For Piriformis application patient will be in side lying position where the affected leg will be placed uppermost with hip in flexion, adduction, and internal rotation , then the application will be performed. The base of the tape will be placed over contralateral part of sacrum and then make a Y strip with no tension will be attached over the greater trochanter of femur."
40956279|NCT03940287|OTHER|Conventional physiotherapy|Hydro-collator pack will be used superior to the affected area for at-least 15 minute to reduce the stiffness. Hydocollator pack will be wrap twice with a thick towel and then it will be placed to the affected part.
40956280|NCT00365222|DRUG|Temozolomide|temozolomide 75 mg/m2 /d
41291947|NCT02500030|PROCEDURE|Air Stacking|Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
41291948|NCT00281411|PROCEDURE|Computed Tomography Angiography|Computed Tomography Angiography
41291949|NCT00281411|PROCEDURE|Magnetic Resonance Angiography|Magnetic Resonance Angiography
41291950|NCT00126464|DRUG|fulvestrant|
41291951|NCT00126464|DRUG|tamoxifen citrate|
41291952|NCT00126464|PROCEDURE|conventional surgery|
41291953|NCT00126464|PROCEDURE|neoadjuvant therapy|
41291954|NCT03384511|DRUG|Apatinib|Patients will accept apatinib therapy and undergo baseline 18F-ALF-NOTA-PRGD2 PET/CT scans of the whole body after having met all eligibility criterias.
40762577|NCT05704322|OTHER|Wim Hof Methode|The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.
40762578|NCT06640322|OTHER|Reliability and validity|Reliability and validity of Craniocervical Dysfunction Index in Turkish Patients With Non-specific Neck Pain
40762579|NCT02542371|OTHER|Arterial Imaging|
40956281|NCT03645564|OTHER|Specialized nurse consultation|The purpose of this consultation is to establish a partnership between the patient and the nursing staff. Tools were set up (notebook, movie) to answer the questions of the patient. In case of specific question, an expert will meet the patient (doctor of the service, psychologist, pharmacist or hematologist).
40956282|NCT01086761|BIOLOGICAL|MP0112|Single intravitreal injection of MP0112 in the study eye.
40956283|NCT02599896|BIOLOGICAL|VRC-HIVMAB080-00-AB (VRC01LS)|VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
40956284|NCT02599896|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
40956285|NCT00851630|DRUG|Fixed dose combination zidovudine/lamivudine/abacavir|All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
40762580|NCT03163667|DRUG|Placebo|oral tablets
40762581|NCT03163667|DRUG|CB-839|oral tablets
40762582|NCT03163667|DRUG|everolimus|oral tablets
40762583|NCT05475925|DRUG|DR-01|DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
40956286|NCT02537106|PROCEDURE|1.5% NaCl|After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
40956287|NCT02537106|PROCEDURE|3% NaCl|After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
40956288|NCT01865097|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
40956289|NCT01865097|BEHAVIORAL|Relaxing music|An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
40956290|NCT04571320|BEHAVIORAL|Summer STRIPES|See arm description.
40956291|NCT04571320|OTHER|Enhanced School Services as Usual|see arm description.
40956292|NCT00004857|BIOLOGICAL|alemtuzumab|30 mg subQ injection tiw for 6 weeks
40956293|NCT00004857|DRUG|fludarabine phosphate|25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
41466405|NCT03477383|DIAGNOSTIC_TEST|donor-derived cell-free DNA (dd-cfDNA)|Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously
41466406|NCT05695417|DRUG|OTX-TKI|Injection of OTX-TKI
41466407|NCT05695417|DRUG|Sham|Sham Injection of OTX-TKI
40762584|NCT06640023|BEHAVIORAL|Default Intervention|For new orders of oral Z-drugs tablets (zolpidem, zolpidem CR, zaleplon, and eszopiclone), the EHR dispense quantity default will be changed to 10 pills with 0 refills for all dosage levels. Dispense quantities for Z-drug reorders and renewals will not be changed.
41135396|NCT04888052|DEVICE|Acute ACL injury|Quantification of the preoperative deficits, by an isokinetic dynamometer, in order to adapt the care management of patients found with a muscle deficiency. Patients with preoperative knee extensor deficits \> 15% will benefit from an additional preoperative rehabilitation protocol (8 weeks).
40956294|NCT03697473|OTHER|Nordic hamstring exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
40956295|NCT03697473|OTHER|Hip extension exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
40956296|NCT01122771|DRUG|Liposomal amphotericin B|Ambisome i.v. 5mg on days 1, 3 and 5
41135397|NCT02684032|DRUG|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
41135398|NCT02684032|DRUG|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
41135399|NCT02684032|DRUG|Letrozole|Letrozole at 2.5 mg daily
41135400|NCT02684032|DRUG|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
40956297|NCT01122771|DRUG|liposomal amphotericin B + miltefosine|Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
40956298|NCT01122771|DRUG|liposomal amphotericin B + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
40956299|NCT01122771|DRUG|Miltefosine + Paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
40956300|NCT04002739|DIAGNOSTIC_TEST|Polygraphy|Patients will perform polygraphy during the CCU stay (baseline) and, if found to have a diagnosis of Obstructive Sleep Apnea (OSA) syndrome, will complete the study with a follow-up visit at 90-day (follow-up). Diagnosis of OSA syndrome will require an Apnea / Hypopnea Index (AHI) more than 5 events per hour.
40956301|NCT01402765|DEVICE|Summit first|Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
40956302|NCT01402765|DEVICE|Nimbus 3 first|Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
40956303|NCT04789083|OTHER|Propholis extrate|Plassebo
40956304|NCT03820271|OTHER|SuperMELD|"The population of this arm will consist of patients newly enrolled in the National Liver Transplantation Waiting List for decompensated cirrhosis, whose liver function and MELD score are assessed at enrollment and then routinely reassessed at least quarterly during the waiting phase.~Patients will be followed from their listing to transplantation or discharge or death."
40956305|NCT06334887|DEVICE|Use of esTOCma|"Participants of the experimental group will use the esTOCma mobile app until completion, within a set period of 10 days.~EsTOCma is a a serious game with 10 missions where users have to free 10 characters who have been imprisoned by a monster called esTOCma, which metaphorically represents the stigma in OCD. With each mission, users will gain knowledge about OCD and free an imprisoned character until the tenth mission, when they will defeat the monster. This game has three modules: (1) Psychoeducation (missions 1-5), where general information about OCD, OCD treatments and where to seek help is provided; (2) Indirect Contact (missions 6 and 7), which consists of a series of audio-visual recordings in which OCD patients report their symptoms and the impact the disorder has had on their lives; and finally, (3) Cognitive Restructuring (missions 8-10), where common dysfunctional beliefs about OCD and OCD treatment are challenged."
40956306|NCT00751933|BIOLOGICAL|Vaccine Vivotif + Vaccine Dukoral + oats|"Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.~One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months."
40956307|NCT00751933|BIOLOGICAL|Vaccine Vivotif + Vaccine Dukoral|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
40956308|NCT00751933|DIETARY_SUPPLEMENT|Oats|One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
40956309|NCT00751933|OTHER|Placebo|Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
40956310|NCT02500160|DEVICE|Patient specific instrumentation (MRI)|
40956311|NCT02500160|DEVICE|Patient specific instrumentation (CT)|
40956312|NCT05085730|DEVICE|InMode Morpheus8 System|The InMode Morpheus8 System is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis and neoelastogenesis.
40956313|NCT01533077|DRUG|BIA 9-1067|50 mg of BIA 9-1067 (single-dose)
40956314|NCT01533077|DRUG|Sinemet® 100/25 mg|immediate-release levodopa/carbidopa 100/25 (single-dose).
40956315|NCT03410329|OTHER|Resistance training|Physical activity
40956316|NCT01488370|DEVICE|Endotracheal intubation|Endotracheal intubation
40956317|NCT05084131|OTHER|Use of an online questionnaire as follow-up after abdominal colorectal surgery|Patients were asked to complete a questionnaire via the institutional patient portal. Participants were also asked to upload a photo of their respective incisions. Participants then had an in-person follow-up visit.
40956318|NCT00687960|DIETARY_SUPPLEMENT|Resistant starch type 4 - raw|Dose: 80g bar containing Resistant Starch Type 4 - raw
40956319|NCT00687960|DIETARY_SUPPLEMENT|Resistant Starch Type 4 - Cooked|Dose: 80g bar containing Resistant Starch Type 4 - cooked
40956320|NCT00687960|DIETARY_SUPPLEMENT|Dextrose|Dose: 7 oz of oral glucose tolerance beverage
40956321|NCT00687960|DIETARY_SUPPLEMENT|Puffed Wheat|Dose: 80g bar containing puffed wheat cereal
40956322|NCT05964101|DRUG|Nivolumab Injection [Opdivo]|Neoadjuvant treatment stage: Nivolumab +Carboplatin AUC+ paclitaxel
40956323|NCT00342940|BIOLOGICAL|influenza surface antigen inactivated vaccine|
40956324|NCT00090168|DRUG|MK0653A , ezetimibe (+) simvastatin|
40956325|NCT00090168|DRUG|Comparator: atorvastatin|
40956326|NCT00090168|DRUG|Duration of Treatment: 6 weeks|
40956327|NCT03661671|DIAGNOSTIC_TEST|LCI+white light|Firstly use white light to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
40956328|NCT03565978|DEVICE|BAMA solution|Use of BAMA cardiac post-discharge management solution for patients education and follow up management
40956329|NCT04786938|DRUG|Saccharomyces Boulardii-Containing Product in Oral Dose Form|S. boulardii CNCM I-745 (approximately 22.5 x109 CFU)
40956330|NCT00182884|DRUG|Donepezil|
40956331|NCT06066125|DRUG|AK111|AK111 regimen 1- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
40956332|NCT06066125|DRUG|AK111|AK111 regimen 2- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
40956333|NCT06066125|DRUG|Placebo|Placebo- subcutaneous injection at week 0,1,2, 3, 4 and week 8. AK111 regimen 2-subcutaneous injection every 4 weeks from week 12 to week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
40956334|NCT04994600|OTHER|Reduces number of question items|The number of alarm fatigue questions are reduced to about 15 in the CFA_2nd_phase group.
40956335|NCT01131611|BEHAVIORAL|CBPT|Cognitive-Behavioral Based Physical Therapy
40956336|NCT01131611|OTHER|Control-Attention|Standard of Care + weekly phone calls
41291955|NCT05975567|OTHER|Three-dimensional imaging of the collected cardiac specimens|The cadaveric coronary artery segments will first be scanned with intravascular imaging modalities, namely optical coherence tomography (OCT) and intravascular ultrasound (IVUS), and then with micro-computed tomography (micro-CT) and light sheet fluorescence microscopy (LSFM). The thrombotic specimens aspirated from patients with ST-elevated myocardial infarction, will also be scanned using micro-CT. The surgically removed aortic valves will undergo scanning with micro-CT and LSFM. Traditional histopathological assessment will also be performed on the scanned specimens.
41291956|NCT06180551|DIAGNOSTIC_TEST|DKK-3|DKK-3-Urine measurement
41291957|NCT05772650|BEHAVIORAL|e-Health Program|Lifestyle modification for health and disease management using digital solutions
40956337|NCT00154622|BEHAVIORAL|work hardening program|
40956338|NCT03960814|DRUG|Insulin detemir|No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
40956339|NCT02479607|DEVICE|Smartphone or tablet|
40956340|NCT05210907|BIOLOGICAL|SNUH-CD19-CAR-T|SNUH-CD19-CAR-T is an autologous CAR-T from T cells collected from each patient. Administer a single dose of SNUH-CD19-CAR-T to patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia, and evaluate safety and efficacy of SNUH-CD19-CAR-T for 12 months after the infusion.
40956341|NCT00545766|DRUG|Vinflunine|Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
40956342|NCT04824950|OTHER|Circulating tumor DNA monitoring|Monitoring of circulating tumor DNA after 2 and 4 cycles of chemotherapy
40956343|NCT00306189|DRUG|100 mg AMG 162|100 mg AMG 162 (denosumab) SC every 6 months
40956344|NCT00306189|DRUG|60 mg AMG 162|60 mg AMG 162 (denosumab) SC every 6 months
40956345|NCT00306189|DRUG|14 mg AMG 162|14 mg AMG 162 (denosumab) SC every 6 months
40956346|NCT00306189|DRUG|Placebo|Placebo SC every 6 months
40956347|NCT03872154|OTHER|Checklist-guided shared decision-making|"Physicians will receive a checklist and a decision aid for shared decision-making during code status discussion.~Ancillary project: Physicians will receive a checklist to communicate the futility."
40956348|NCT03892096|DIAGNOSTIC_TEST|Blood-based cell-free cfDNA qPCR assay|Up to 30mL of blood via venipuncture
40956349|NCT01041326|RADIATION|Radiation|Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
40956350|NCT01041326|PROCEDURE|Radical Prostatectomy|Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
40762585|NCT06640023|BEHAVIORAL|Accountable Justification|"For qualifying Z-drug orders, an EHR alert will suggest removing the Z-drug, adding a CBT-I referral, or both. If the alert recommendation is not followed, clinicians will be asked to provide a justification for their decision when the order is signed. The justification will display in the After Visit Summary.~The alert suggestion depends on the recent history of Z-drug prescriptions for a given patient. When a Z-drug is being ordered for patients with 180 days supply of Z-drugs or fewer in the last 365 days, the alert will prompt removal of the Z-drug and addition of a CBT-I referral to the order. When a Z-drug is being ordered for patients with 181 days supply of Z-drugs or more in the last 365 days, the alert will only prompt addition of a CBT-I referral to the order.~If a CBT-I referral is already in the current order or has been ordered for a patient in the past 180 days, the alert to add a CBT-I referral to the order will not display."
40956351|NCT05097612|DEVICE|Placebo LiftSuit Exoskeleton|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). In this condition the EES are removed from the device to create a placebo device.
40956352|NCT05097612|DEVICE|LiftSuit Exoskeleton (low support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
40956353|NCT05097612|DEVICE|LiftSuit Exoskeleton (medium support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
40956354|NCT05097612|DEVICE|LiftSuit Exoskeleton (high support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
40956355|NCT04912960|DEVICE|Mechanical ventilation|Optimum PEEP
40956356|NCT02672826|PROCEDURE|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
40956357|NCT03273270|RADIATION|transcranial magnetic stimulation|transcranial magnetic stimulation
40956358|NCT00985478|DRUG|SLV342|25 mg once daily - Maximal Tolerated Dose
40956359|NCT00985478|DRUG|placebo|matching placebo
40956360|NCT01315665|DIETARY_SUPPLEMENT|Broccoli sprouts|Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
40956361|NCT01072422|BEHAVIORAL|smoking cessation|Use of trying to quit smoking instrument and quit smoking advice
40956362|NCT03948581|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
40956363|NCT00816296|OTHER|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
40956364|NCT00816296|OTHER|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
40956365|NCT00816296|OTHER|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
40956366|NCT00816296|OTHER|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
40956367|NCT06013397|DIETARY_SUPPLEMENT|Ketogenic diet|"Ketogenic diet (KD) is a high-fat, low-carbohydrate and moderate protein diet pattern, suitable for refractory epilepsy, glucose carrier protein 1 deficiency, pyruvate dehydrogenase deficiency, tumors and some genetic metabolic diseases. The ketogenic diet has been used to treat epilepsy for nearly 100 years, and its safety has been recognized by the medical community. In 2015, the ketogenic diet was included in the Clinical Diagnosis and Treatment Guidelines - Epilepsy Volume and became a commonly used treatment for refractory epilepsy."
40762586|NCT05056818|OTHER|Electronic Health Record Review|Review of medical records and past imaging examinations
40762587|NCT04669197|DRUG|Paclitaxel protein bound|combination therapy
40762588|NCT04669197|DRUG|Gemcitabine|combination therapy
40762589|NCT04669197|DRUG|Cisplatin|combination therapy
40956368|NCT06284421|DEVICE|Shore durometer|The durometer will be held on the exterior of the lower uterine segment and fundus to measure the hardness reading at each location.
40956369|NCT06203171|OTHER|Observational|Routine laboratory parameters requested from patients; Direct lung Radiograph and Electrocardiography results were evaluated and preoperative consultations and recommendations requested from the patients were recorded. Type of anesthesia, operation performed, operation duration, intraoperative blood and fluid losses, intraoperative and postoperative complications that develop within the first 24 hours, additional problems that develop (pain, postoperative nausea and vomiting, hypothermia, change of consciousness, bleeding and unplanned transfer to the intensive care unit). postanesthesia recovery The length of stay in the room, length of hospital stay, and method of discharge were recorded. The effects of preoperative laboratory, imaging methods and required consultations on intraoperative and postoperative complications in the first 24 hours were evaluated.
40956370|NCT00593502|DRUG|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; \> 40 kg, 75 mg twice daily, for 5 days
40956371|NCT00593502|DRUG|placebo|The dosage of placebo will be similar to the active drug
41291958|NCT05335525|DEVICE|Closure of the femoral arterial puncture site|Patient will undergo a diagnostic or interventional endovascular procedure, compatible with the use of Angio-Seal™ VIP VCD.
40762590|NCT04669197|DRUG|Hydroxychloroquine|combination therapy
40956372|NCT02428270|DRUG|GSK2256098|Small molecule inhibitor of focal adhesion kinase (FAK)
40956373|NCT02428270|DRUG|Trametinib|Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
40956374|NCT01186965|BEHAVIORAL|eHealth program in the Virtual Environment (VE) platform Second Life|determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.
40956375|NCT04592978|BEHAVIORAL|Pain-Alcohol Personalized Feeback Intervention|The intervention will be designed to enhance knowledge regarding adverse pain-alcohol-opioid interrelations as well as increase motivation and intention to reduce hazardous drinking and positive attitudes and intentions regarding concurrent use of alcohol and prescription opioid medications.
41291959|NCT02333955|DRUG|GCS-100|3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
41291960|NCT02827552|OTHER|skin biopsy|skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
41291961|NCT01016483|DRUG|Pimasertib|
40762591|NCT01816399|PROCEDURE|Routine coronary angiography|
40762592|NCT02743221|DRUG|Trifluridine/tipiracil + bevacizumab|Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion.
40762593|NCT02743221|DRUG|Capecitabine + bevacizumab|Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion.
40762594|NCT02078726|DRUG|Glucagon|glucagon (hormone produced by the body)
40762595|NCT03536858|BEHAVIORAL|COACH (Communicating about Choices in Transplantation)|COACH is a behavioral communication intervention designed specifically for ESRD patients pursuing kidney transplantation. The COACH program consists of four modules: 1) Kidney transplant options, 2) Discussing your transplant options, 3) Requesting living donation, and 4) Maintaining positive relationships. The content and teaching strategies were guided by the concepts of social cognitive theory as well as principles of adult learning and communication skill acquisition. We believe that patients will transfer these skills to other patients at the hemodialysis clinic who are on their shift.
40956376|NCT04592978|BEHAVIORAL|Control Personalized Feedback Intervention|The control intervention will incorporate personalized feedback relevant to exercise and nutrition but not address drinking reduction or pain-alcohol-opioid interrelations.
40956377|NCT00261274|BIOLOGICAL|A-ECO|
40956378|NCT00261274|BIOLOGICAL|Saline|
40956379|NCT01049100|PROCEDURE|lymphadenectomy|paraaortal and pelvic lymphadenectomy laparoscopic or open
40956380|NCT01049100|OTHER|Standard Staging|clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--\> CT controlled biopsy
40762600|NCT02719730|BEHAVIORAL|Reimbursement for whole grain purchases|All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
40762601|NCT05819801|OTHER|Non-fasting|Instructing patients to eat before their local-only procedure
40762602|NCT05819801|OTHER|Fasting|Instructing patients to fast before their local-only procedure
40762603|NCT05644132|DEVICE|InDx Implant for the carpometacarpal joint|Treatment of thumb base joint arthritis with the InDx Implant
40762604|NCT06186284|DIAGNOSTIC_TEST|nerve conduction study|sensory and motor nerve conduction study of both median nerves and ulnar nerves
40762605|NCT06186284|DIAGNOSTIC_TEST|ultrasonography wrists|assess the cross-sectional area of the median nerves and the ulnar nerves
40762606|NCT06186284|DIAGNOSTIC_TEST|Boston carpal tunnel questionnaire|assess the severity of symptoms and the functional impact related to carpal tunnel syndrome
40956381|NCT05886504|OTHER|Community-based psychiatric intervention|intervention will take place in CBO offices instead of mental health department, medication will be given freely and psychiatric consultations will be free. Trained CBO members will provide individual and collective support including recall of appointments and tracing of those lost to follow-up, information on mental health, main psychiatric disorders, psychiatric medication, their potential side effects and expected benefits, contact with families and continuous support
40956382|NCT06445296|OTHER|High-fat meal containing beef|High-fat meal (eggs cooked in butter, croissant) with 80% ground beef.
40956383|NCT06445296|OTHER|High-fat meal containing Beyond Meat|High-fat meal (eggs cooked in butter, croissant) with Beyond Meat Cookout Classic.
40956384|NCT01869439|DEVICE|"gold standard LxW manual ruler measurement technique"|"Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length)."
40762607|NCT06186284|DIAGNOSTIC_TEST|clinical provocative tests for carpal tunnel syndrome|Tinel and Phalen's test to evaluate the presence of carpal tunnel syndrome
41291962|NCT01016483|DRUG|Gemcitabine|
41291963|NCT01016483|DRUG|Placebo|
41291964|NCT03763487|DIAGNOSTIC_TEST|venous blood sampling|Venous blood samples to determine memory B lymphocytes.
41291965|NCT03763487|PROCEDURE|spleen volumetry|Ultrasound examination of spleen to scaled the size.
40762608|NCT05497206|DEVICE|One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System|Total Hip Arthroplasty
40762609|NCT06263179|BEHAVIORAL|Target Heartrate Aerobic Exercise|Exercise program
41291966|NCT04817540|DRUG|Herzuma|8mg/kg IVF loading dose at first cycle -\> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
41291967|NCT04798417|DIETARY_SUPPLEMENT|Probiotic supplement|Use of a probiotic sachet
41291968|NCT04798417|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic sachets
41291969|NCT04798417|DIETARY_SUPPLEMENT|Maltodextrin|Placebo comparator
41291970|NCT03742492|DIETARY_SUPPLEMENT|Meal containing canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
40956385|NCT01869439|DEVICE|WMMS ImageReview software's LxW measurement technique|This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
40956386|NCT01869439|DEVICE|WMMS ImageReview software's Visual External Wound Trace|This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
40956387|NCT01869439|DEVICE|WMMS ImageReview software's External Wound Trace Overlay|This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradient), mean, and the mode of the thermal wound bed can be measured.
40956388|NCT01521546|DRUG|eplerenone|25mg tablet, once daily by mouth for 12 months
40956389|NCT01521546|DRUG|placebo|one tablet by mouth daily for 12 months
40956390|NCT06376292|DRUG|Intrathecal Injection of Thiotepa+Radiation+Systemic Treatment of Primary Diseases|Participants will receive a comprehensive treatment plan consisting mainly of whole brain 30Gy/10F radiotherapy combined with intrathecal injection of Thiotepa. The injection was administered by qualified individuals (certified personnel in the radiotherapy department of our hospital) twice a week for a total of 4 weeks. Thiotepa was injected 10mg each time, mixed with cerebrospinal fluid, and then injected slowly for 5-10 minutes.
40956391|NCT01649804|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
40956392|NCT00018031|DRUG|Peginterferon alfa-2b|Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
40956393|NCT00018031|DRUG|Ribavirin|Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.
40762613|NCT01506726|DRUG|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
40762614|NCT01506726|DRUG|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
40762615|NCT01019915|DEVICE|CRT|Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
40762616|NCT01734122|OTHER|Questionnaires / Observational Assessments|Includes QUEST, PDQ-39, FTM, and Neuropsych evaluation
40956394|NCT03848429|PROCEDURE|Surgery for mechanical complications of acute myocardial infarction|Surgical treatment of post-AMI left ventricular free-wall rupture: sutured and sutureless repair. Surgical treatment of post-AMI ventricular septal defect: infarctectomy and infarct exclusion repair. Surgical treatment of post-AMI papillary muscle rupture: mitral valve repair and replacement
40956395|NCT01044875|PROCEDURE|Pan retinal photocoagulation laser treatment|Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
40956396|NCT04728399|DIETARY_SUPPLEMENT|Experimental group|Take 1 bag a day with warm boiling water. Intervention: 2g Soybean peptide, 3g CLA and ng protein. They will complete all baseline, 12-weeks, and 24-weeks visits
40956397|NCT04728399|DIETARY_SUPPLEMENT|Control group|Take 1 bag a day with warm boiling water. Intervention: 2g+N protein and 3g Soybean oil. They will complete all baseline, 12-weeks, and 24-weeks visits
40956398|NCT02866916|DRUG|SXL01|Treatment will be administered continuously over 24h through the subcutaneous route.
40956399|NCT00860444|BEHAVIORAL|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
40956400|NCT00860444|BEHAVIORAL|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
41135401|NCT04920799|DIETARY_SUPPLEMENT|Nitrate rich beetroot juice|Participants will drink nitrate rich beetroot juice (2.4 floz ; Beet It Sport Nitrate 400 concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
41135402|NCT04920799|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Participants will drink nitrate depleted beetroot juice (2.4 floz ; Beet It placebo concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
41135403|NCT03269500|OTHER|use of nutrition education tools|"Use of different nutrition education tools :~* General advice: feeding seniors~* Oral supplementation: instructions for use~* Information about enriched food~* Food modified in texture: chopped masticatory disorders, chopped swallowing disorders, co-mingled~* How should I drink? : With stimulus, texture syrup / nectar, velvety texture, texture compote / cream~* Recipe booklets for people to easily eat (chewing disorders) or recipe with molded texture (swallowing disorders)"
41135404|NCT04275583|DRUG|TQB3602|This is a kind of proteasome inhibitor.
40762617|NCT05787041|OTHER|high-fat diet group（AD16 20mg）|AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
40762618|NCT05787041|OTHER|fasted group（AD16 20mg）|Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
40956401|NCT04336293|DEVICE|sTMS|"sTMS will be delivered following NeoSync guidelines using the device user~manual"
40956402|NCT04336293|DEVICE|sham sTMS|sham sTMS will be delivered following NeoSync guidelines using the device user manual
40956403|NCT00768950|PROCEDURE|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
40956404|NCT00768950|PROCEDURE|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
40956405|NCT06378931|OTHER|Quality of life progression after parathyroidectomy|Study the progression of quality of life.
40956406|NCT02040571|DEVICE|Closed Loop|A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
41135405|NCT00872859|PROCEDURE|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
41135406|NCT02417350|OTHER|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
40762619|NCT03939065|DEVICE|Sensor Augmented Pump Therapy|Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
40956407|NCT02040571|DEVICE|Open Loop|"The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.~In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.~Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants."
40956408|NCT00667407|DRUG|Levalbuterol 1.25 mg|"levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days"
40956409|NCT00667407|DRUG|Racemic Albuterol Sulfate|"Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days"
40956410|NCT02592525|BEHAVIORAL|IP-SDM training for health professionals|Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
40956411|NCT00677131|OTHER|Reading the package insert of the drug|package insert of the drug
40956412|NCT00677131|OTHER|Reading the education information provided by the Pharmacy of NTUH|education information
40956413|NCT00677131|OTHER|Oral education provided by the pharmacist|Oral education provided by the pharmacist
40956414|NCT01674114|PROCEDURE|TAP block|
40956415|NCT01674114|PROCEDURE|control|
40956416|NCT03875339|BEHAVIORAL|Navigator Guidance|Use of a dedicated Navigator to determine if follow-up and compliance rates can be improved for those infants initially demonstrating an abnormal hearing result.
40956417|NCT03095885|OTHER|Test Meal|
40956418|NCT06144892|DEVICE|Proactive Therapy|Uses AI to make predictions and preventions of future apneic events.
40956419|NCT02007993|OTHER|PDT|"A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5"
40956420|NCT02007993|OTHER|Tongue Scraper|The pacient will scrap the tongue 10 times.
40956421|NCT05664607|OTHER|for excise, nutrition consultant, nutrition supplement and psychologic intervention.|for excise, nutrition consultant, nutrition supplement and psychologic intervention.
40956422|NCT03055156|DEVICE|Low rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
40956423|NCT03055156|DEVICE|High rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
40956424|NCT01805375|DRUG|DI-B4|DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
41135407|NCT02417350|OTHER|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
41135408|NCT04565717|DRUG|ALN-HSD|ALN-HSD will be administered by subcutaneous (SC) injection.
41135409|NCT04565717|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.
41135410|NCT00252382|DRUG|SNS-595 Injection|Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
41135411|NCT05400759|OTHER|IOP monitoring data|
41135412|NCT05743426|OTHER|Survey|Patient Reported Outcome (PRO) questionnaire
41135413|NCT05743426|OTHER|Toxicity Assessments|Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).
41135414|NCT04343898|OTHER|No intervention|Observational
41135415|NCT00487240|DRUG|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
41135416|NCT00487240|DRUG|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
41135417|NCT04474496|OTHER|Assessing the impact of COVID-19|Surveying Marshallese adults in the U.S. to determine the impact of COVID-19
41135418|NCT03912909|DRUG|Empagliflozin Oral Tablet [Jardiance]|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
41135419|NCT03912909|DRUG|Placebo Oral Tablet|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
41135420|NCT03739606|BIOLOGICAL|Anti-CD123/CD3 Monoclonal Antibody MGD006|Given IV
41135421|NCT01579318|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
41291971|NCT03742492|DIETARY_SUPPLEMENT|Meal containing canned tuna + soybean oil|Meal containing canned tuna + soybean oil
41455376|NCT05276986|OTHER|DOMS protocol|For a maximum repetition of the trunk muscles, two measurements were made with a 45-second rest interval.The values were recorded in Newtons by taking the maximum value of the two repetitions measured. DOMS was formed by eccentric contraction with 80% of this determined value.To generate DOMS in the trunk, participants were seated on the bench with the knees flexed at 90° and the soles of the feet in full contact with the floor, keeping the weight at 80% of the predetermined maximum repetition.The participants were asked to perform trunk extension with eccentric contraction of the trunk in 5 seconds, and trunk flexion with concentric contraction in 3 seconds.Two-minute rests between sets and 45-second rests between repetitions were given.The date and time of the created DOMS were recorded and the measurements were repeated at the 24th and 48th hours.
40956425|NCT06275347|OTHER|Low-fat normoprotein Controlled Ketogenic Diet.|Frank ketosis will consist of between 650 and 730 kcal/day in 5 meal times, based on commercial and vegetable preparations with low glycemic index, an average of 1.2 g of protein/kg of ideal weight/day, 20 g/day of lipids based on essential fatty acids and less than 60 g/day of absorbable carbohydrates. Patients will receive vitamin and sodium chloride, magnesium oxide, calcium carbonate. Mixed Ketosis one or two intakes of commercial preparations will be progressively replaced by proteins, which will increase by 100 to 150 Kcal/day, supplementation of vitamins and minerals will continue. Transition Stage simple carbohydrates and some complex carbohydrates are added to the previous program, in an approximate proportion of 30 to 35% protein, 25% fat and 40 to 45 % carbohydrates. Integral and maintenance phase: may vary between 1300 and 2250 kcal/day, with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats.
40956426|NCT06275347|OTHER|Hypocaloric Balanced Diet|Balanced hypocaloric diet (caloric intake 20% below basal metabolic expenditure measured by Multifrequency Bioelectrical Impedance or calculated according to the FAO/WHO/UN formula (FAO/WHO/UNU (1985). Energy and Protein requirements. Technical Report Series No 724, World Health Organization, Geneva). The usual caloric intake of a balanced hypocaloric diet is between 1,200 and 1,400 kcal per day with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats, according to the Diogenes study
41455377|NCT04449341|DEVICE|Oculus Go headset with Ocean Rift application|Information already included in arm description
40956427|NCT00844675|DRUG|rabeprazole|The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
40956428|NCT00844675|DRUG|placebo|The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
40956429|NCT03605407|OTHER|Patient visit prior to hospital admission|Patient and family receiving one visit prior to hospital admission for surgery
40956430|NCT05235048|PROCEDURE|Tooth extraction|Atraumatic tooth extraction without flap elevation
40956431|NCT05235048|PROCEDURE|Tooth extraction and socket seal with connective tissue graft|Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)
40956432|NCT05235048|PROCEDURE|Tooth extraction and socket seal with BRG and connective tissue graft and|Atraumatic tooth extraction without flap elevation, position of a bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
40956433|NCT05235048|PROCEDURE|Tooth extraction and socket seal with membrane placement, BRG and connective tissue graft|Atraumatic tooth extraction without flap elevation, position of a collagen membrane and bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
40956434|NCT03449875|DEVICE|TREOVANCE® Stent-Graft with Navitel® Delivery System|Endovascular repair of abdominal aortic aneurysms.
40956435|NCT02599714|DRUG|AZD2014|The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
40956436|NCT02599714|DRUG|Palbociclib|cyclin dependent kinase inhibitor
41455378|NCT04643691|DRUG|Losartan 50 mg and Spironolactone 25 mg pillules oral use|Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
41455379|NCT06094140|DRUG|Durvalumab|"Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure."
40956437|NCT02599714|DRUG|Fulvestrant|Fulvestrant hormonal therapy as background
40956438|NCT01542320|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
40956439|NCT01542320|OTHER|Placebo|Solution without active Lactobacillus reuteri
40956440|NCT06558409|BEHAVIORAL|" Safer Still  Interactive Intervention"|An interactive intervention will be developed to help promote safe storage of firearms during the critical period immediately following high-risk care transitions.
40956441|NCT06558409|OTHER|Enhanced Usual Care (EUC):|Families randomly assigned to the control condition will receive a psychological placebo that will feature an education only website developed by NCH's web design team. This website will cover warning signs for suicide, the leading methods of suicide - so that both conditions have content that features information about firearms - and locating professional help. The control website will NOT feature these three behavioral economic strategies--namely (a) multiple suggested alternatives for means restriction, (b) requests to justify inaction regarding means restriction, and (c) normative feedback about means restriction.
40956442|NCT01136148|BEHAVIORAL|A medical and mental health unit|A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.
40956443|NCT02270008|OTHER|Pelvic floor training|Baseline muscle strength will be measured with the modified Oxford scale. The intervention group will undergo an in-person standardized pelvic strength training session by a trained nurse practitioner.
41291972|NCT06093880|DEVICE|monofocal intraocular lens|monofocal aspheric hydrophilic-hydrophobic intraocular lens
41455380|NCT06094140|DRUG|Oxaliplatin|85mg/m2 intravenously on day 1
41455381|NCT06094140|DRUG|Irinotecan|150mg/m2 intravenously on day 1
41455382|NCT06094140|DRUG|Calcium folinate (leucovorin)|50mg as an intravenous bolus
40956444|NCT02116946|BIOLOGICAL|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
40956445|NCT02116946|OTHER|Saline + exercise|Peritendinous saline injection plus 12 week exercise program.
40956446|NCT00533897|DRUG|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
40956447|NCT00533897|DRUG|Placebo|Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
40956448|NCT00436839|DRUG|Docetaxel|75mg/m² intravenously (day 1) every 21 days
40956449|NCT00436839|DRUG|Mitoxantrone|12mg/m² intravenously every 21 days
40956450|NCT00436839|DRUG|Prednisone|10mg orally given daily
40956451|NCT06169384|DEVICE|Endoscopic adenoidectomy|Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .
40956452|NCT01821196|PROCEDURE|biopsy|biopsies will be evaluated with immunohistochemistry and gene expression studies
41135422|NCT01579318|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
40956454|NCT01930123|DRUG|intravenous fructose challenge|"Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO (nothing by mouth) after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have had an historical standard of care liver biopsy in the past and will have IV fructose Magnetic Resonance biomarker measures in the morning."
40956455|NCT01930123|OTHER|Blood Draw|Fasting bloodwork will be obtained before and after the IV fructose challenge.
40956456|NCT01164800|DRUG|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
40956457|NCT01164800|DRUG|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
40956458|NCT02988843|DRUG|Brentuximab Vedotin|Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
40956459|NCT02988843|DRUG|Bevacizumab|15 mg/kg every 21 days
40956460|NCT01551992|PROCEDURE|Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
40956461|NCT03975036|DRUG|Anlotinib|Anlotinib Hydrochloride Capsules
40956462|NCT03975036|DRUG|pd-1 antibody|Pembrolizumabinjection
40956463|NCT00673504|DRUG|Gemcitabine + Sunitinib|Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
40956464|NCT00673504|DRUG|Gemcitabine|1.000 mg/m2 d1,8,15q4weeks
40956465|NCT05898685|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
40956466|NCT05898685|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air)
41135423|NCT05847699|OTHER|MRI sequences and biopsies|Addition of a contrast injection and optimized SWI sequences during the pre-DH MRI examination performed as part of the care Addition of two 1x1 cm biopsy samples of cortex in two different non-functional ischemic areas, one of which is within the SWI hyposignal remodeling, during the DH. This will be a cold pial dissection without the use of coagulation.
40956467|NCT02562534|DEVICE|MRI compatible ElectroCardioGraph|MRI with ECG control for people with healthy heart or heart diseases
41135424|NCT05559697|DEVICE|Sponsor incisional negative pressure wound therapy device and dressing|A sponsor incisional dressing placed on the knee and connected to a sponsor disposable negative pressure therapy device
41135425|NCT05559697|DEVICE|Standard of Care incisional negative pressure wound therapy system|The control incisional negative pressure wound therapy system represents the standard of care system and market leader. It consists of a disposable negative pressure therapy device and incisional dressing.
41135426|NCT00444743|DRUG|MM-093|60 mg, administered subcutaneously, weekly
41135427|NCT00444743|OTHER|Placebo|Placebo
41135428|NCT00367653|DRUG|Azithromycin plus Chloroquine|Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
41135429|NCT00367653|DRUG|Mefloquine|Mefloquine 1250 mg PO given as a split dose (750 mg \[three 250 mg capsules\]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
41135430|NCT06213311|DRUG|Glofitamab|Given by IV
41135431|NCT06213311|DRUG|Obinutuzumab|Given by IV
41135432|NCT06213311|DRUG|Axi-cel|Given by IV
41135433|NCT00630500|DRUG|Memantine|Tablets, 5 or 10 mg, twice daily
41135434|NCT00630500|DRUG|Placebo|Tablets corresponding to 5 or 10 mg, twice daily, 6 months
41455383|NCT06094140|DRUG|Fluorouracil|2400mg/m2 by continuous infusion via pump over 46 hours starting on day 1
41455384|NCT06094140|DRUG|Pegylated G-CSF|6mg by subcutaneous injection to be given on day 3 of each cycle.
41455385|NCT00125385|BIOLOGICAL|GC1008|0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
41455386|NCT00125385|BIOLOGICAL|GC1008|1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
41455387|NCT00125385|BIOLOGICAL|GC1008|2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
40956468|NCT04874584|BEHAVIORAL|CTNSM|The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .
40956469|NCT04874584|BEHAVIORAL|Standard of Care Chemotherapy Education|Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
40956470|NCT01955564|DRUG|NW-3509a|single dose
40956471|NCT05600452|OTHER|Heat acclimation|Repeated heat exposures with light exercise sufficient to elevate deep body temperature to \~ 38.5C
40956472|NCT03196856|BEHAVIORAL|Resistance and Plyometric Exercise|12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
40762620|NCT03939065|DEVICE|Standard of Care with CGM|Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
40762621|NCT06271616|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40956473|NCT03196856|DIETARY_SUPPLEMENT|Greek Yogurt (0% Plain)|200g 3x/day for 12 weeks.
40956474|NCT03196856|DIETARY_SUPPLEMENT|Placebo - Study Designed Supplement|Iso-energetic to yogurt. 3x/day for 12 weeks.
40956475|NCT03704480|DRUG|Durvalumab|1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent
40956476|NCT03704480|DRUG|Tremelimumab|300mg by IV infusion on D1 at cycle 1 only
40956477|NCT06535386|DRUG|Dexmedetomidine 0.004 MG/ML|Incidence of polyuria during the intraoperative period, associated with dexmedetomidine .
40956478|NCT04075760|PROCEDURE|Coils + Cyanoacrylate Group + beta-blocker|"EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group."
40956479|NCT04075760|DRUG|beta blocker therapy|A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
40956480|NCT02544399|OTHER|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
40956481|NCT02015754|DRUG|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
40956482|NCT02015754|DEVICE|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
40956483|NCT02015754|PROCEDURE|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
40956484|NCT05267886|DRUG|Dobutamine|Dobutamine administered according to its clinical dose stage for cardiogenic shock
40956485|NCT05267886|DRUG|Milrinone|Milrinone administered according to its clinical dose stage for cardiogenic shock
40956486|NCT05267886|DRUG|Normal Saline|Normal saline running at a standardized rate
40956487|NCT00828412|DEVICE|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
41135435|NCT03331536|PROCEDURE|Roux en Y Gastric Bypass Pre-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
41291973|NCT02988804|DEVICE|endotracheal tube|"In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
41455388|NCT00125385|BIOLOGICAL|GC1008|4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
41455389|NCT00125385|BIOLOGICAL|GC1008|8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
40956488|NCT00828412|DRUG|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
40956489|NCT05333016|BEHAVIORAL|Multimodal exercise|Multimodal exercise programming including aerobic, resistance, balance, and flexibility exercises
40956490|NCT05265416|PROCEDURE|Piezosurgery|Three vertical incisions will be made (3-mm depth and 8-10 mm length) after anesthesia. The cuts will be performed mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar.
40956491|NCT05265416|OTHER|Low-level laser therapy|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal.
40956492|NCT05265416|DEVICE|Traditional treatment|The canine retraction in this group will be performed in conventional method. Closed nickel-titanium coil springs applying 150 g of force per side will be used for retraction of the upper canine.
40956493|NCT05235555|DEVICE|Transcatheter heart valve (THV) with CE approval|TAVI trough femoral access or alternative routes
40956494|NCT03691181|DEVICE|Ventilation|monitoring with the use of the Life2000 Ventilation System for a period of six months
40956495|NCT01809106|DRUG|Morphine|60 mg /24 ore
40956496|NCT01809106|DRUG|Fentanyl|25 microg/h
40956497|NCT01809106|DRUG|Buprenorphine|35 microg/h
40956498|NCT01809106|DRUG|Oxycodone|40 mg /24 ore
40956499|NCT02911857|BIOLOGICAL|Canakinumab (AIN457)|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution
40956500|NCT06455176|PROCEDURE|alveolar cleft Grafting from the symphysis|grafting using particulate bone from the symphysis
40956501|NCT06455176|PROCEDURE|alveolar cleft Grafting from the iliac cancellous bone|grafting using iliac cancellous bone
40956502|NCT05373277|DRUG|Placebo|one tablet of placebo twice daily for two days
40956503|NCT05373277|DRUG|Ticagrelor|Intervention Description: 90 mg tablet twice daily for two days
40956504|NCT05373277|DRUG|Rosuvastatin|10 mg tablet, single dose
40956505|NCT02264561|OTHER|Food|Active group
40956506|NCT02264561|OTHER|Food|Control group
40956507|NCT04417361|DRUG|Galcanezumab Prefilled Syringe|Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
40956508|NCT04417361|DRUG|Placebo|Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
41455390|NCT05269238|OTHER|performing lumbar punctures by students with standard training|performance of the puncture by the student have been previously trained with standard training
40762622|NCT06271616|PROCEDURE|Echocardiography|Undergo echocardiography
40762623|NCT06271616|DRUG|Ibrutinib|Given PO
40762624|NCT00195728|DRUG|Hydrocodone/Acetaminophen on Extended Release|2 tablets twice daily
40762625|NCT01245023|PROCEDURE|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
40956509|NCT03824730|DEVICE|Stenting of the Common and/or External Iliac Arteries|"Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries."
40956510|NCT01866774|OTHER|Fecal calprotectin level|
40956511|NCT03525171|DIAGNOSTIC_TEST|euglycemic hyperinsulinemic clamp|In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
40956512|NCT03385200|DRUG|SonoVue|As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.
40956513|NCT05625802|PROCEDURE|Erector Spinae Plane Block (ESPB)|Up to 30 Cubic Centimeter (cc) of 0.5% ropivacaine administered by local injection into the erector spinae plane under ultrasound guidance
40956514|NCT05625802|DRUG|Ropivacaine|0.5% ropivacaine
40956515|NCT01956435|DEVICE|Excimer Light Treatment|Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
40956516|NCT00716703|OTHER|CT Scan using IV contrast alone|CT scan using IV contrast alone
40956517|NCT02605070|DRUG|Bravelle|"Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.~From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.~At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis."
40956518|NCT03844932|DRUG|ST-0529|ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
40956519|NCT04515394|DRUG|Tepotinib|Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
41455391|NCT05269238|OTHER|training students augmented reality simulator|performance of the puncture by the student have been previously trained using the augmented reality simulator
40956520|NCT04515394|BIOLOGICAL|Cetuximab|Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m\^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
40956521|NCT05106517|DRUG|Denosumab|Denosumab 60mg/6 months subcutaneously + placebo iv
40956522|NCT05106517|DRUG|Zoledronic acid|Iv zoledronic acid and placebo /6 months subcutaneously
40956523|NCT01185756|RADIATION|MIBG for diagnostic purpose|All patients will undergo the diagnostic test specific to the study.
40956524|NCT06150482|OTHER|No intervention|No intervention
40956525|NCT01429415|DRUG|Magnesium Sulfate Sandoz|Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
40956526|NCT01429415|DRUG|Sodium Chloride , USP PPC|Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
40956527|NCT02244112|DRUG|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
40956528|NCT02244112|DRUG|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
40956529|NCT06273085|BEHAVIORAL|Patient education|3 sessions of education over phone at 1, 3 and 5 months after discharge, each session includes an overview of benefits and side effects of GDMT, inquiries about reasons of not using optimal doses of GDMT medications, and encouraging adherence to visits with providers.
40956530|NCT02944032|OTHER|CogmedRM|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
41455392|NCT04541264|DIAGNOSTIC_TEST|radiomic of chest CT|radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.
41455393|NCT01959828|DRUG|IK-3001|
40956531|NCT02944032|OTHER|Mobymax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
40956532|NCT04017078|OTHER|diagnosis of carotid artery calcification on digital panoramic radiograph|Suspected carotid arty calcifications findings were defined as one or more radiopaque mass adjacent to the cervical vertebrae at or below the intervertebral space between C3 and C4 on the DPR.
40956533|NCT03104543|BEHAVIORAL|Education|30 minute education session; 15 minute booster session at 4 months
41455394|NCT04805840|DEVICE|CoV-SCAN rapid COVID-19 antigen test|SARS-CoV-2 rapid antigen screening test
40956534|NCT03104543|BEHAVIORAL|Test results only|The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
40956535|NCT02324257|DRUG|RO6958688|RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.
41135436|NCT03331536|PROCEDURE|Roux en Y Gastric Bypass Post-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
41135437|NCT03331536|PROCEDURE|Sleeve Gastrectomy Pre-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
41455395|NCT00857038|DRUG|Doxycycline|Doxycycline tablets, 100mg daily
41455396|NCT00857038|DRUG|Placebo|Placebo tablets 100mg
41455397|NCT00834158|PROCEDURE|TACE|1 time
40762626|NCT01245023|PROCEDURE|Placebo-surgery|skin incisions without laparoscopy or related procedures
40956536|NCT02324257|DRUG|Obinutuzumab|Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
40956537|NCT02324257|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.
41455398|NCT00834158|PROCEDURE|PVE|1 time
40956538|NCT00731627|DRUG|placebo|one tablet a day for up to 21 days
40956539|NCT00731627|DRUG|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
41455399|NCT04967170|BIOLOGICAL|Autologous Platelet-Rich Plasma (PRP)|Two intralesional injections of approximately 5-6mL given approximately 6 weeks apart
41455400|NCT04967170|OTHER|Sham Procedure|Intralesional needle insertion without any injectate.
41455401|NCT01501448|DRUG|Levonorgestrel and ethinylestradiol|30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
41455402|NCT01501448|DRUG|Estradiol valerate|4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
40956540|NCT01334164|BEHAVIORAL|Recovery Management Checkups|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
40956541|NCT01334164|OTHER|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own
40956542|NCT00094172|DRUG|Atorvastatin|atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
40956543|NCT00094172|DRUG|Placebo|tablet form
40956544|NCT00244062|BEHAVIORAL|counseling|
40956545|NCT02167087|PROCEDURE|Sentinel node mapping|Through transabdominal access via laparoscopic ports indocyanine green solution is injected around the tumor (25 mg indocyanine green dissolved in 9 ml sterile water and 1 ml 20% human albumin). This is done by the construction of two small boluses of 0.5 mL each into the colonic wall just orally and anally to the tumor margin, but not within the tumor itself. When the bolus is injected the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner.
40956546|NCT05020782|DRUG|Belimumab|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
40956547|NCT04894448|BIOLOGICAL|COVID-19 Vaccine|Any COVID-19 vaccine (1 or more doses)
40956548|NCT05862142|OTHER|No intervention|No intervention
40956549|NCT06110078|DRUG|Acetazolamide|Oral rinse with acetazolamide (not taken orally)
40956550|NCT00543010|DRUG|MK0767|
40956551|NCT05775354|DIAGNOSTIC_TEST|Early diagnosis strategy|RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
40956552|NCT05267847|OTHER|Cryotherapy|local anesthetic injection with articaine 4% 1:100,000 epinephrine then an application ice packs
40956553|NCT05267847|OTHER|Traditional local anesthesia|local anesthetic injection with articaine 4% 1:100,000 epinephrine
40956554|NCT03226860|DEVICE|Gait Myoelectric Stimulator|Electrical stimulation during gait for children with CP
40956555|NCT03226860|OTHER|5210|Children will eat 5 fruits/vegetables each day, watch 2 hours or less of screen time, perform 1 hour or more of physical activity, and drink 0 sugar-sweetened beverages.
40956556|NCT02527135|BEHAVIORAL|Weekly HIV sensitization text messages|"Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase Get tested for HIV."
40956557|NCT03569085|DRUG|Sevoflurane|The patient will receive Sevoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
41135438|NCT03331536|PROCEDURE|Sleeve Gastrectomy Post-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
41135439|NCT03429816|PROCEDURE|Biopsy|Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.
41135440|NCT01068977|DRUG|bevacizumab|Repeating intravenous dose
40956558|NCT03569085|DRUG|Isoflurane|The patient will receive isoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
40956559|NCT01142271|PROCEDURE|Billroth-I|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.
40956560|NCT01142271|PROCEDURE|Roux en Y|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
40956561|NCT04478266|DRUG|Amcenestrant-matching placebo|Pharmaceutical form: Tablets Route of Administration: Oral
40956562|NCT04478266|DRUG|SAR439859|Pharmaceutical form: Tablets Route of Administration: Oral
41135441|NCT01068977|DRUG|MetMAb|Repeating escalating intravenous dose
41135442|NCT01068977|DRUG|MetMAb|Repeating intravenous dose
41135443|NCT03208465|DRUG|Empagliflozin|In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
40956563|NCT04478266|DRUG|Palbociclib|Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
40956564|NCT04478266|DRUG|Letrozole|Pharmaceutical form: Capsules Route of Administration: Orally
41135444|NCT03208465|DRUG|Sitagliptin|In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
41135445|NCT00148122|DRUG|Docetaxel|Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
40956565|NCT04478266|DRUG|Goserelin|Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
40956566|NCT04478266|DRUG|Letrozole-matching placebo|Pharmaceutical form: Capsules Route of Administration: Orally
40956567|NCT05346874|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
40956568|NCT05346874|DRUG|Teysuno|Oral S-1, 40mg-60mg, day 1-14 for four 21-day cycles.
40956569|NCT05346874|PROCEDURE|Transarterial chemoembolization (TACE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1.
40956570|NCT02004483|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
41291974|NCT02988804|DEVICE|Laryngeal mask|"In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
41291975|NCT02571361|DRUG|Paracetamol (1g x 4)|Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively
40956571|NCT04802317|DIAGNOSTIC_TEST|Identification of the composition of the intestinal microbiota|Identification of the composition of the intestinal microbiota
41135446|NCT00148122|DRUG|Capecitabine|Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
41135447|NCT01869465|OTHER|Pre-treatment snack|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
41291976|NCT02571361|DRUG|Ibuprofen (400 mg x 4)|Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
41291977|NCT02571361|DRUG|Paracetamol (0,5 g x 4)|Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively
41291978|NCT02571361|DRUG|Ibuprofen (200 mg x 4)|Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
41291979|NCT02571361|DRUG|Placebo (x4)|Given in 6 hour intervals the first 24 hours postoperatively
41291980|NCT02512016|OTHER|Study Procedures|"* Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)~* Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.~* Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.~* Measures of strength and body habitus:~  8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index~  1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod~* Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings."
41291981|NCT03415464|OTHER|Exercise|neuromuscular training
40956572|NCT00875264|DRUG|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
40956573|NCT04433663|OTHER|Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis|"To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome."
41291982|NCT03955848|BIOLOGICAL|Alloreactive NK cell infusion|Alloreactive NK cell infusion
41291983|NCT03154450|DEVICE|EncoreAnywhere with data available to review|Encore Anywhere will be installed and available for review by the clinical team
41291984|NCT03154450|DEVICE|EncoreAnywhere with no data available to review|Encore Anywhere will be installed but not available for review by the clinical team
41466408|NCT03730181|DRUG|Rifapentine|Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.
40956574|NCT03722823|DRUG|Tucatinib|300mg oral single dose
40956575|NCT00619736|DRUG|NSA-789|
40956576|NCT00619736|OTHER|Placebo|
40956577|NCT02911714|DRUG|Lumason Contrast-Enhanced Ultrasound|In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.
41455403|NCT05306496|DEVICE|Pre-shaped 4DMESH®|The 4DMESH® mesh is semi-resorbable parietal reinforcement implant made of 25% Polypropylene (non-resorbable) and 75% Poly-L-Lactic Acid (resorbable). 4DMESH® meshes are designed for the repair and reinforcement of inguinal and femoral hernias. 4DMesh is a CE-marked, class III medical device manufactured by Cousin Biotech.
41455404|NCT01266902|DRUG|Rilpivirine|25 mg once daily
41455405|NCT04659096|DRUG|ION537|ION537 will be administered by IV injection.
41455406|NCT02627274|DRUG|RO6874281|RO6874281 will be administered as per the schedule specified under arm description.
41455407|NCT02627274|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified under arm description.
41291985|NCT06378073|DIAGNOSTIC_TEST|Incentive Spirometer|"Specificity and sensitivity: Incentive spirometry is a specific type of spirometry that aims to encourage people to breathe deeply intentionally but does not provide a measurement or inform management of chronic lung diseases. Less than 5 repetitions per day (sensitivity 93%, specificity 77%) and less than 2 balls per repetition (sensitivity 93%, specificity 77%) were predictive of postoperative pulmonary complications. (1) Validity and reliability: Incentive spirometry can be used as a simple mean to follow lung function, especially VC, in the postoperative period in spontaneously breathing patients. Incentive spirometry is noninvasive and can be performed repeatedly at the bedside in the intensive care setting. (2)~Interpretation:~There are only three numeric values that are required to interpret spirometry:~* Forced Vital Capacity (FVC)~* Forced Expiratory Volume (FEV1)~* FEV1/FVC ratio."
40956578|NCT02606448|DRUG|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
41455408|NCT02627274|DRUG|Cetuximab|Cetuximab will be administered as per the schedule specified under arm description.
41455409|NCT02161705|DRUG|Ropivacaine|0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
41455410|NCT02161705|DRUG|Saline|Up to 0.8 mL/kg of normal saline administered
41455411|NCT01669460|OTHER|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
41455412|NCT06206148|DEVICE|Given novel electronic pain recording device|Patients in this arm will be given a custom-built pain recording device to see if the method of self-reported data collection has any effect on how many data points are collected.
41455413|NCT06206148|OTHER|Given Hand-written pain journal|Patients in this arm will be given a hand-written pain journal to see if the method of self-reported data collection has any effect on how many data points are collected.
41455414|NCT06206148|OTHER|Smartphone app|Patients in this arm will be given a research smartphone with survey app to see if the method of self-reported data collection has any effect on how many data points are collected.
41455415|NCT00247013|BEHAVIORAL|Breast Cancer Screening Compliance|
41455416|NCT02184936|OTHER|standard of care|
41455417|NCT00108043|PROCEDURE|FES-evoked functional upright gait|
41455418|NCT03341013|DRUG|MEDI0382 Formulation 2|Sequence 1 Period 1 and Sequence 2 Period 2.
40762627|NCT02959346|PROCEDURE|Sham Acupuncture|"Procedure:~Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.~All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
41455419|NCT03341013|DRUG|MEDI0382 Formulation 3|Sequence 1 Period 2 and Sequence 2 Period 1
41455420|NCT02665780|PROCEDURE|Periodontal debridement|teeth cleaning
41455421|NCT02665780|OTHER|Cetylpyridium chloride|mouthrinse
40956579|NCT02606448|PROCEDURE|Femoral nerve block|Pre-operative femoral nerve block
40956580|NCT02606448|DRUG|Ropivacaine|Ropivicaine was used in all femoral nerve blocks
40956581|NCT00298584|PROCEDURE|Percutaneous Suprapubic Aspiration|
40956582|NCT00298584|PROCEDURE|Urethral Catheterization|
40956583|NCT00691314|DEVICE|Stent implantation (Wingspan, Coroflex, and TiTAN2)|"Stent Implantation:~Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex\&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent~Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .~Arms: 1"
41455422|NCT05882630|DRUG|Surufatinib,Serplulimab,Etoposide,Carboplatin|"In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w＋Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed."
41455423|NCT03141853|OTHER|Equine-assisted Therapy|Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
41455424|NCT03141853|OTHER|Arthritis Exercise Education|Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
41455425|NCT05937126|DIAGNOSTIC_TEST|FilmArray Pneumonia Panel|FDA-approved/cleared molecular, multiplex device that rapidly identifies viruses, bacteria, and antimicrobial resistance genes in sputum-like and bronchoalveolar lavage (BAL)-like specimens obtained from individuals with signs of a lower respiratory tract infection.
41455426|NCT05937126|DIAGNOSTIC_TEST|Culture and antimicrobial susceptibility testing|Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.
41455427|NCT03171064|BEHAVIORAL|Resistance and Endurance Exercise|Machine-based, 2x/week endurance and resistance training for 12 weeks
41455428|NCT04862806|DIAGNOSTIC_TEST|COVID-19 serology|Immune response to BNT162b2 mRNA vaccine is assessed on the basis of anti covid19 IgG levels. A centralized assessment of the serological response for 4 medical centers is performed on serum samples stored at -60 °C using Abbott-SARS-CoV-2 IgG quant (Positive value \> 151; range 0-40.000). The other 4 medical centers performed the test locally using DiaSorins-LAISISON SARS-CoV S1/S2 IgG test (positive value \>15 range 15-400). In the central virus laboratory at the Chaim Sheba Medical center the test was done by Elisa-RDB (positive value \>1.1; range 1.1-10).
41455429|NCT00014469|DRUG|busulfan|
41455430|NCT00014469|DRUG|melphalan|
41455431|NCT00014469|DRUG|methotrexate|
40762628|NCT02959346|PROCEDURE|Acupuncture|"Procedure:~Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.~The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
40762629|NCT06260774|DRUG|TTX-MC138|The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.
40762630|NCT05901831|DRUG|Finerenone|Dose A, Dose B, oral
40762631|NCT05901831|OTHER|Placebo|Oral
41291986|NCT06378073|DIAGNOSTIC_TEST|Numeric Pain Rating Scale|"Sensitivity: The area under the receiver operator characteristic curve for the NRS as a test for pain that interferes with functioning was 0.76, indicating fair accuracy. A pain screening NRS score of 1 was 69% sensitive for pain that interferes with functioning. (4) he diagnostic value of different NRS cut-off values for administering analgesics is determined by an ROC curve. Sensitivity of NRS \> 3 for 'unbearable' pain in older patients was 72% with a specificity of 97·2%. With a cut-off point NRS \> 4, sensitivity increased to 83%, while specificity was 96·7%. (5) Validity and reliability: The numerical rating scale is a reliable and valid tool for pain assessment in patients with musculoskeletal impairments. (3)~Measurement (circle): Categorical /Numerical /Both:~Numerical:~The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine or worst pain imaginable)"
41291987|NCT00478972|DRUG|Rimonabant|Tablet, oral administration
41291988|NCT00478972|DRUG|placebo (for Rimonabant)|Tablet, oral administration
41291989|NCT00478972|OTHER|Diet and exercise|Target daily caloric intake: Ideal body weight × 25 kcal
41291990|NCT05671120|PROCEDURE|Transcutaneous levator recession|recession of the upper and lower eyelid retractors can improve the upper eyelid contour if the patient has lateral flare (common in TED). The choice of procedure depends on severity of lid retraction and associated features like proptosis, status of extraocular muscles, and corneal condition
41291991|NCT00784784|BIOLOGICAL|Fluviral|One dose
41291992|NCT00784784|DRUG|Zanamivir|10 mg, OD, for duration of influenza season (10-23 weeks)
41291993|NCT01288040|BEHAVIORAL|Split Belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to get at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same speed or both going slightly different speeds.
41291994|NCT02236585|PROCEDURE|Patient-controlled epidural analgesia|Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
41291995|NCT02236585|PROCEDURE|Continuous epidural analgesia|Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
41291996|NCT05798962|PROCEDURE|Biopsies|Biopsies from the pathological muscle and healthy, unaffected muscle
41291997|NCT01125891|DRUG|gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
40762632|NCT03136302|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation
40762633|NCT06192966|DIETARY_SUPPLEMENT|Food supplement|Probiotic formulation containing Lactobacillus plantarum, cranberry and vitamine C for 6 months 1 capsule/day
41455432|NCT00014469|DRUG|tacrolimus|
41455433|NCT00014469|PROCEDURE|allogeneic bone marrow transplantation|
41455434|NCT04807062|PROCEDURE|surgery|tunnel bone tamps method (TBTM) was used to reduce the depressed articular fragments and then structural bicortical autologous ICBG was used to fill the valley tunnel.
41455435|NCT01083329|BEHAVIORAL|training|the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
41455436|NCT01083329|DRUG|nicotinic acid|Obese subjects will receive nicotinic acid or placebo for 16 weeks
41455437|NCT01083329|DRUG|Placebo|Obese subjects will receive nicotinic acid or placebo for 16 weeks
41455438|NCT02063139|DRUG|Flutiform 50/5 ug (2 puffs bid) pMDI|
41455439|NCT02063139|DRUG|Fluticasone 50 ug (2puffs bid) pMDI|
41455440|NCT02063139|DRUG|Beclometasone Autohaler 50 ug (2 puffs bid)|
41455441|NCT01251068|DEVICE|near infrared spectroscopy: invos 5100|duration:six hours
41455442|NCT01251068|DEVICE|INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
41466409|NCT03730181|DRUG|Isoniazid|Isoniazid. 25mg/kg
41466410|NCT00545688|DRUG|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
40762634|NCT06192966|DIETARY_SUPPLEMENT|Placebo|Placebo composed of maltodextrin for 6 months 1 capsule/day
40956584|NCT00691314|DRUG|Standard medical treatment|Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
40956585|NCT02717520|DEVICE|EQUIA Forte and Tetric EvoCeram|"GC cavity conditioner (20% polyacrylic acid) will be applied for 10 sec, rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 min 30 sec after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat will be applied to the surfaces and light cured with D-light for 20 sec.~Enamel will be etched with 37% orthophosphoric acid for 10 sec. After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (1200 mW/cm2, slow mode) for 10 sec. The composite resin will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece and polished."
40956586|NCT00332280|DRUG|AMT2003|
40956587|NCT04817631|OTHER|tuboovarian abscess|Evaluating the surgical and medical management of tuboovarian abscess
41135448|NCT01869465|BEHAVIORAL|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
40762635|NCT02661347|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
41135449|NCT05733559|DEVICE|QIAstat-Dx® Respiratory Panel Plus (RPP)|An observational prospective performance evaluation study of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target against a marketed comparator, using NPS collected per the manufacturer's instructions and eluted in Universal Transport Media (UTM) from subjects with signs and symptoms of respiratory infection
40762636|NCT02661347|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
40762637|NCT04812015|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS) 15 minutes|Sham 60 minutes and taVNS active stimulation for 15 minutes
40762638|NCT04812015|DEVICE|taVNS 30 minutes|Sham 45 minutes and taVNS active stimulation for 30 minutes
40762639|NCT04812015|DEVICE|taVNS 45 minutes|Sham 30 minutes and taVNS active stimulation for 45 minutes
40762640|NCT04812015|DEVICE|taVNS 60 minutes|Sham 15 minutes and taVNS active stimulation for 60 minutes
40762641|NCT04812015|DEVICE|taVNS 75 minutes|Sham 0 minutes and taVNS active stimulation for 75 minutes
40762642|NCT04812015|DEVICE|taVNS 0 minutes|Sham taVNS 75 minutes
40762643|NCT04111536|DRUG|liothyronine|Each treatment period of liothyronine was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo.
41455443|NCT01251068|DEVICE|near infrared spectroscopy device|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
41455444|NCT05066334|DRUG|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal cells
41455445|NCT05066334|PROCEDURE|Sham|local anaesthesia, no disc injection, no placebo injection
40762644|NCT04111536|OTHER|Placebo|Each treatment period of placebo was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - LT3.
40762645|NCT01179555|BEHAVIORAL|Behavioral Activation|Baseline assessment plus 4 in-home problem solving therapy sessions.
40762646|NCT01179555|BEHAVIORAL|Supportive Therapy|Baseline assessment plus 4 in-home sessions of supportive therapy.
40956588|NCT00365508|DRUG|nicotine lozenge|nicotine lozenge
40956589|NCT00365508|DRUG|nicotine patch|transdermal nicotine patch
40762647|NCT03960736|OTHER|ESP block (Group A)|US probe will be placed longitudinally 2-3 cm lateral to the T5 transvers process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position 20G catheter will be inserted 5 cm in caudal direction. 20 ml %0.25 bupivacaine will be administered for block.
40956590|NCT04872582|DRUG|PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab|combined
40956591|NCT01788228|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
40956592|NCT03859778|OTHER|survey|French pharmacy students will be contacted by email thanks to the student associations and scolarity departments. Answer to the survey will be done online
40956593|NCT00462566|DEVICE|motor cortex stimulation|
40956594|NCT01766596|PROCEDURE|Optical Coherence Tomography|
40956595|NCT03840174|BIOLOGICAL|V160|V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)
40956596|NCT03840174|OTHER|Placebo|Saline solution (0.9% sodium chloride \[NaCl\] administered as a 0.5 mL IM injection
40956597|NCT06047483|DRUG|HRF2105 patch|HRF2105 patch ，external use，once a day
40956598|NCT06047483|DRUG|Loxoprofen patch|Loxoprofen patch ，external use，once a day
40762648|NCT03960736|OTHER|TEA group (Group B)|Local infiltration with 2% of lidocaine under the skin, in T4/T5 intervertebral space will be administered. An 18 G Tuohy needle will be inserted at T4/T5 intervertebral space to identify epidural space using the loss of resistance technique. 20G catheter will be inserted 3-4 cm in caudal direction in the epidural space. Bolus dose of 0.125% bupivacaine 10 ml will be administered through the catheter after the negative aspiration for blood or cerebrospinal fluid
40956599|NCT06047483|DRUG|placebo|placebo ，external use，once a day
40956600|NCT01752270|DRUG|Diane-35 pretreatment|Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
40956601|NCT01752270|DRUG|Diane-35 pretreatment|
40956602|NCT06267105|PROCEDURE|Longitudinal incision|Incision performed longitudinally
40956603|NCT06267105|PROCEDURE|Transverse incision|Incision performed transversally
40956604|NCT05534529|DRUG|Rezafungin Acetate|This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.
40956605|NCT03928119|BEHAVIORAL|public education and network construction|Publication education includes multiple methods of acute myocardial infarction knowledge education. Network construction includes regional connection of ST-Segment Elevation Myocardial Infarction patients transfer for percutaneous coronary intervention treatment, as well as physicians skill improvement in primary hospital.
40956606|NCT06556979|RADIATION|Radiotherapy|Review imaging and medical record of head and neck cancer patient who recieve radiotherpy to find out the incidence of ischemic cerebrovascular event and carotid artery stenosis. The risk factor that influence new carotid artery stenosis was claculated
40956607|NCT04809285|DEVICE|Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app|Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.
40956608|NCT01172236|DRUG|Lactoferrin|"Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.~Control group: newborns (group B) will receive only standard therapy and they will be used as controls."
40956609|NCT01172236|DRUG|Lactoferrin|Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
40956610|NCT01059591|DRUG|GSK424887|GSK424887 2mg, 10mg, 50mg, 100mg capsule
40956611|NCT01059591|DRUG|Placebo|Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
40956612|NCT01059591|RADIATION|PET|Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose
40956613|NCT05694767|DRUG|CM313 Injection|"intravenous CM313 administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
40956614|NCT06097169|DRUG|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
40956615|NCT06097169|DRUG|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
40956616|NCT02573688|BEHAVIORAL|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
40956617|NCT06394830|DRUG|VNX001|Intravesical administration of VNX001
40956618|NCT05195190|OTHER|Clinical test|The 2 minutes walking test, the time up and go test and the 30 second sit and stand test will be applied to the patients in order. Each test will be repeated 2 times after the familiarization test and the average of the tests will be taken. There will be a 10-minute rest period between tests. For the re-test, the tests will be repeated after the patients are given a rest period of 2 hour. Testing will be conducted by a single therapist with at least 5 years of experience blinded to the study.
41455446|NCT05131516|DIAGNOSTIC_TEST|Alveolar recrutment maneuver|alveolar recruitment maneuver (30 mmHg for 30 seconds)
40762649|NCT06569524|DRUG|TQA2225/AP025 or TQA2225/AP025 Placebo 25mg|To evaluate the efficacy and safety of TQA2225/AP025 (25mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
40762650|NCT06569524|DRUG|TQA2225/AP025 or TQA2225/AP025 Placebo 50mg|To evaluate the efficacy and safety of TQA2225/AP025 (50mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
40956619|NCT01509365|DRUG|clopidogrel|2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
40762651|NCT03345550|DRUG|Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
40956620|NCT01509365|DRUG|clopidogrel|1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
40956621|NCT04038684|BEHAVIORAL|Mindfulness-Based Weight Control (MBWC)|Mindfulness-Based Weight Control will be administered over 12 group-based sessions with weekly home practice (e.g., mindfulness exercises, dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Sessions will include BWC and mindfulness components. BWC components include: 1) a dietary plan based on a balanced, caloric deficit diet; 2) increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting); and 4) minimal parent involvement (i.e., 3 parent sessions). Participants will be taught core mindfulness exercises (e.g., breath-awareness, body scan, mindful eating) while focusing attention on the present moment and non-judgmentally acknowledging thoughts, emotions, or sensations. Participants will learn informal mindful strategies for daily living, which are designed to increase awareness of emotions and their relation to emotional eating.
40956622|NCT04038684|BEHAVIORAL|Standard Behavioral Weight Control (SBWC)|Standard Behavioral Weight Control will be administered over 12 group-based sessions with weekly home activities (dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Group sessions will include SBWC component, including: 1) a balanced, caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting, motivation, problem-solving, etc.); and 4) minimal parent involvement (i.e., 3 parent sessions).
40956623|NCT03206411|DIAGNOSTIC_TEST|Renal and liver function tests , ECG , Sex Hormones Profile|Renal Function tests as creatinine , Uric Acid , Blood urea. Liver Function tests as AST , ALT, ALP ECG (Electrocardiogram recording) SEX hormones as LH , FSH , and Testosterone
40956624|NCT02902432|DRUG|Endostar|The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
40956625|NCT01890473|DRUG|Abatacept|
40956626|NCT06105931|BIOLOGICAL|Hyperinsulinemic-euglycemic clamp|Hyperinsulinemic-euglycemic clamp will be used to assess insulin resistance. After IVs are placed, participants will be transitioned to intravenous insulin administration for the baseline portion of the study. Stable Isotope Tracer Infusions will assess rates of glucose, lipid metabolism, and beta-hydroxybutyrate turnover during the last 30 minutes of the baseline equilibration period and again during the last 30 minutes of the stepped IV insulin infusion periods.
40956627|NCT06105931|OTHER|High Fat Mixed Meal Tolerance Test|After a 12 hour overnight fast, baseline levels of the lipoproteins will be drawn. The YCCI Bionutrition Service kitchen will prepare the standardized high-fat meal. Participants will administer their bolus insulin per their home regimen for the carbohydrates in the high-fat meal, and then they will consume the meal within a 15-minute timeframe.
40956628|NCT02715180|RADIATION|low dose chest computed tomography|All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
40956629|NCT00282412|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
40956630|NCT00282412|DRUG|Fludarabine|inhibits DNA synthesis or repair
40956631|NCT00282412|DRUG|Cyclophosphamide|Causes prevention of cell division by forming adducts with DNA
40956632|NCT00282412|DRUG|Campath 1H|humanized monoclonal antibody against CD52 antigen
40956633|NCT00282412|DRUG|GCSF|Hematopoietic growth factor
40956634|NCT00282412|DRUG|Cyclosporins|immune suppressive drug
41135450|NCT04192357|BEHAVIORAL|WLM3P|18 months behavioral weight loss program divided into three phases (first and second phase of weight loss, during 1 month and 5 months, respectively; and a third phase of weight maintenance, during 12 months).
40956635|NCT00282412|DRUG|Mycophenolate Mofetil|immune suppressive drug
40956636|NCT02489162|DEVICE|MyotonPRO|MyotonPRO measurements of the biomechanical properties of facial mimic muscles
40956637|NCT02489162|DEVICE|non-invasive electromyography (EMG)|Gold standard technique for measuring muscle
40956638|NCT04760821|DRUG|Trimetazidine|Trimetazidine 35mg bid in patients with GFR above 60mL/min. Trimetazidine 35mg od in patients with GFR between 30 and 60mL/min.
40956639|NCT03576612|BIOLOGICAL|AdV-tk|Given IT
40956640|NCT03576612|DRUG|Valacyclovir|Given PO days 1-14; 1-3 days post surgery
41291998|NCT01125891|DRUG|ON 01910.Na|The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
41291999|NCT03921229|BEHAVIORAL|Tele-coaching|"Patients will meet with a tele-coach, who is a care team member, via video-calling, on a regular basis for six months to identify and address treatment adherence concern(s)."
41292000|NCT02037945|PROCEDURE|18F-FCH PET Scan|
41292001|NCT02241018|DRUG|CD25 monoclonal antibody|
40956641|NCT03576612|RADIATION|Radiation|Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks
41135451|NCT04192357|BEHAVIORAL|Low-carb diet|18 months behavioral weight loss program divided in two phases (first of weight loss during 6 months and a second phase of weight maintenance during 12 months).
41135452|NCT01686152|DRUG|Imiquimod Cream, 3.75%|
41135453|NCT01686152|DRUG|Zyclara®|
41135454|NCT01686152|OTHER|Vehicle of Test Product|
41292002|NCT02241018|DRUG|calcineurin inhibitors|
40762652|NCT03345550|DRUG|Placebo - Cap|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
40956642|NCT03576612|DRUG|Temozolomide|Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)
40956643|NCT03576612|BIOLOGICAL|Nivolumab|day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks
40956644|NCT03576612|OTHER|Laboratory Biomarker Analysis|correlative studies
40956645|NCT05638178|OTHER|No intervention|No intervention, cohort study.
40956646|NCT05707975|OTHER|Identifying a relationship between the intensity of eco-anxiety and the severity of suicide risk in adolescents|Relationship between the intensity of eco-anxiety with the 13-item CAS score, and the seriousness of the suicide risk with the C-SSRS score
40956647|NCT01197560|DRUG|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
40956648|NCT01197560|DRUG|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m\^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m\^2 IV days 1 and 15 every 28 days for 6 Cycles
40956649|NCT01197560|DRUG|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m\^2 IV day 1 for 21 days for 6 Cycles
40956650|NCT01197560|DRUG|Rituximab|Suggested starting dose for Rituximab is 375 mg/m\^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
40956651|NCT01197560|DRUG|Etoposide|"Suggested starting doses for Etoposide are:~100 mg/m\^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m\^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-10 every 28 days for 6 Cycles"
40956652|NCT05711797|DRUG|ZX-7101A 80mg|ZX-7101A a drug to treatment influenza in Chinese adults
40762653|NCT04021745|BEHAVIORAL|App-based mindful eating|This is a mindful eating smartphone application comprised of twenty-eight modules of 10-15 minutes each designed to teach mindfulness for binge eating. The feature that is being tested will ask individuals to do a mental exercise when they're craving and will measure their satisfaction related to the experience.
40956653|NCT03158025|DRUG|Zolpidem tablets|Zolpidem 3 x 10 mg tablets will be administered orally.
40956654|NCT03158025|DRUG|Suvorexant tablets, over-encapsulated|Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
40956655|NCT03158025|DRUG|Lemborexant tablets|Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
40956656|NCT03158025|DRUG|Placebo lemborexant|Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
40956657|NCT03158025|DRUG|Placebo zolpidem|Placebo 3 x 10 mg zolpidem tablets will be administered orally.
40956658|NCT03158025|DRUG|Placebo suvorexant|Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
40956659|NCT00261456|DIAGNOSTIC_TEST|PSA test|Patients tested for their level of Prostate Specific Antigen.
40956660|NCT00261456|PROCEDURE|Prostate Biopsy|A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
40956661|NCT01284101|DEVICE|Use of the Tan Endoglide to insert the donor graft|Using the Tan Endoglide to insert the donor graft into the eye
40956662|NCT01284101|DEVICE|Forceps for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye.
40956663|NCT00324792|DRUG|intensive insulin therapy|
40956664|NCT05510375|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
40956665|NCT05510375|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
40956666|NCT05510375|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
40956667|NCT05510375|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
40956668|NCT00077961|DRUG|CAMPATH (alemtuzumab)|
40956669|NCT01817530|OTHER|Elagolix placebo|oral coated tablet
40956670|NCT01817530|DRUG|Elagolix|oral coated tablet
40956671|NCT01817530|DRUG|0.5 mg estradiol / 0.1 mg norethindrone acetate|oral hard capsule
40956672|NCT01817530|DRUG|1 mg estradiol / 0.5 mg norethindrone acetate|oral hard capsule
40956673|NCT01817530|DRUG|E2/NETA placebo|oral hard capsule
40762654|NCT06335706|BEHAVIORAL|Fit of underpants worn|Tight or loose-fitted underpants
40762655|NCT04672616|BEHAVIORAL|Group psychotherapy|The intervention is a group psychotherapeutic offer for mentally burdened adolescents and young adults to support their professional integration.
40956674|NCT02010710|DEVICE|INFANT software|The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
40956675|NCT05178771|OTHER|Platelet rich fibrin|"1. Intravenous blood (obtained by venipuncture of the antecubital vein) will be collected in two 10-mL sterile tubes without any anticoagulants and will be immediately centrifuged at 3,000 revolutions (400 × g) per minute for 10 minutes.~2. A structured fibrin clot in the middle of the tube, just between the red corpuscles (RBCs) at the bottom and the acellular plasma at the top, will be separated from the RBCs using sterile tweezers and scissors and transferred on a sterile PRF box.~3. The PRF will be then brought to a thickness of 1 mm by gently compressing in PRF box. Standardized PRF pieces will be obtained by measuring by a periodontal probe and cutting into 3 × 5 mm dimensions.~4. The PRF pieces will be inserted into the periodontal pockets by filling the pockets from the base up to the gingival margin. A modified gingivectomy knife, of which the tip is made blunt, will be used.~The PRF volume will be calculated by recording how many pieces will be inserted."
40956676|NCT05543967|BEHAVIORAL|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
40956677|NCT05543967|OTHER|Olfactory function measurements|Olfactory Threshold, Odor Identification Score, Odor Memory Score.
40956678|NCT05543967|OTHER|Functional magnetic resonance imaging|resting-state fMRI, odor-induced fMRI.
41292003|NCT02241018|BIOLOGICAL|MSCs|
41466411|NCT00545688|DRUG|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
41292004|NCT04765462|BIOLOGICAL|Allogeneic γδ T cells|"Phase 1:Enrolled patents will be administered allogeneic γδ T cells from 2x10\^6/kg, 1 x10\^7/kg to 5x10\^7/kg every 2-4 weeks to determine the recommended dose level.~Phase 2: Enrolled patents will be administered allogeneic γδ T cells at the recommended dose level to confirm the efficacy.~Whether or not in combination with other therapies will be determined by research physicians according to the disease status of enrolled patients."
41455447|NCT02694653|DRUG|Placebo|100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
41455448|NCT02694653|DRUG|Acetaminophen|1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
40956679|NCT05331651|DRUG|Glycopyrronium in Combination With Tropisetron|Glycopyrronium (0.2mg) in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
40956680|NCT05331651|DRUG|Normal Saline in Combination With Tropisetron|Normal Saline in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
40956681|NCT03676283|OTHER|Web-based psycho-educational support for family caregivers|A website including potentially modifiable topics shown to be associated with preparedness. The topics cover areas such as knowledge about medical issues including symptoms and symptom relief, communication within the couple, how to spend the time before death, being partner or caregiver, planning of the moment of death and considerations of the partner's future, including psychological issues, logistical issues, economy, and the care for children.
40956682|NCT06558305|OTHER|blood sample|Total RNA will be extracted from the whole blood using a commercial extraction kit (RNA Extraction Kit, applied biotechnology Co.Ltd, Egypt) according to the manufacturer's instructions. RNA will be stored at -80°C.The extracted RNA will be used for cDNA synthesis using commercial kits (cDNA Synthesis Kit, applied biotechnology Co.Ltd, Egypt), according to the manufacturer's instruction.
40956683|NCT02939430|DRUG|Sugammadex intravenous|Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
40956684|NCT02939430|DRUG|Intravenous neostigmine and atropine|
41135455|NCT01703546|PROCEDURE|LAGB & LGCP|All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band \& Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
41135456|NCT06096116|DRUG|Human plasma derived antithrombin|A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma
41135457|NCT06096116|DRUG|Placebo|Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ
41135458|NCT04266821|OTHER|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and FAQ handout) meant to mimic what physicians will receive in the real-world market as they learn about the Ethos technology.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the Ethos test at the clinically-appropriate point in each case."
41135459|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 7.5 µg administered IM
41135460|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 15 µg administered IM
41135461|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 30 µg administered IM
41135462|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 31.25 µg administered SC
41135463|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 62.5 µg administered SC
41135464|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 125 µg administered SC
41135465|NCT04183491|BIOLOGICAL|Placebo|Placebo (administered either IM or SC)
41292005|NCT03584802|OTHER|Therapeutic plasma exchanges|The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.
41455449|NCT02913924|DRUG|Clonazepam|fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
41455450|NCT02913924|DRUG|Placebo|
41455451|NCT03196557|DRUG|Prenisolone|Specified dose on specified days
41455452|NCT03196557|DRUG|Placebo|Specified dose on dose on specified days
40956685|NCT03889106|DRUG|Ribavirin|Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.
40956686|NCT01289080|DRUG|OPC-34712|administered orally
40956687|NCT03151343|DRUG|Empagliflozin|Empagliflozin tablet
40956688|NCT03151343|DRUG|Placebo Oral Tablet|Sugar pill, visually identical to active comparator
40956689|NCT04749706|BEHAVIORAL|Physical training alone|The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.
40956690|NCT04749706|BEHAVIORAL|physical training + protein intake|"The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.~15 women with constitutional leanness will, on top of the physical training, received a daily protein supplementation corresponding to 20 grams of proteins + 10 grams of Maltodextrine"
40956691|NCT02086292|PROCEDURE|2 ml 1% Lidocaine|
41135466|NCT00357994|DRUG|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
41135467|NCT00357994|DRUG|Placebo gel|
41135468|NCT00357994|DRUG|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
40762656|NCT03123679|RADIATION|pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT|"1. Patient referred to radiotherapy treatment are evaluated with a baseline PFT \[Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), Alveolar gas volume (VA)\].~2. RT simulation at the radiotherapy department and treatment planning.~3. Baseline evaluation of pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT.~4. Radiotherapy."
40762657|NCT00802906|DEVICE|subthreshold micropulselaser|on demand if leakage is persistent or recurs after initial treatment
40762658|NCT00802906|DRUG|bevacizumab|1.5 mg initial intravitreal injection
40762659|NCT05311423|DIAGNOSTIC_TEST|QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra|Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
40762660|NCT06541132|OTHER|Observational study without human intervention|Observational study without human intervention
40762661|NCT04502108|BEHAVIORAL|Covid19|Impact of the COVID19-pandemic on physical activity, nutritional habits and sleeping behavior during an extraordinary period of confinement and social distancing, during the loosening phase and social distancing and the phase after the pandemic.
40762662|NCT00002809|BIOLOGICAL|anti-thymocyte globulin|
40762663|NCT00002809|BIOLOGICAL|filgrastim|
40762664|NCT00002809|BIOLOGICAL|sargramostim|
40956692|NCT02086292|PROCEDURE|1 ml 2% Lidocaine|
41135469|NCT00357994|DRUG|Placebo (PBO) oral capsules|
41135470|NCT00357994|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
41135471|NCT00357994|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
41135472|NCT00357994|DEVICE|J-tube|jejunal tube
41135473|NCT00853411|DRUG|prednisone|Druing asthma exacerbation, subjects will be dosed to prednisone.
41135474|NCT01702376|DRUG|Retosiban 100 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
41135475|NCT01702376|DRUG|Retosiban 800 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
41292006|NCT03584802|OTHER|Conventional treatment of AE-IPF|Conventional treatment of AE-IPF
41292007|NCT00083824|DRUG|Estrogens, Conjugated (USP)|0.625 mg/day QID for 3 years
41292008|NCT00083824|DRUG|Medroxyprogesterone 17-Acetate|2.5 mg/day QID for 3 years
41292009|NCT00083824|DRUG|Placebo|2 pills/day QID for 3 years
40762665|NCT00002809|BIOLOGICAL|therapeutic immune globulin|
40762666|NCT00002809|DRUG|cyclophosphamide|
40762667|NCT00002809|DRUG|methotrexate|
40762668|NCT00002809|DRUG|tacrolimus|
40762669|NCT00002809|PROCEDURE|allogeneic bone marrow transplantation|
40762670|NCT00002809|RADIATION|radiation therapy|
40762671|NCT03925077|OTHER|Movement-to-Music|The M2M program has been developed for onsite instruction and will be repurposed into an eHealth version. The program is based on the positive effects of exercise and music on both physiological and psychosocial outcomes in people with disabilities. Investigators aim to advance our current M2M program by enabling more robust personalization features, allowing people with SCI to individualize their M2M program. Movement and tempo-based adaptations will also be available. A typical M2M session will consist of tailored movement routines starting with a warmup using range of motion exercises, followed by muscle strengthening, cardiorespiratory, and/or balance routines, and ending with a cool down emphasizing breathing and mindfulness.
40956693|NCT03356756|DIAGNOSTIC_TEST|simultaneous combined 18F-FDG PET and cardiac MRI imaging|Patients will undergo a research study performed with an integrated whole-body PET/MRI imaging system designed for simultaneous PET and MRI acquisition, immediately after standard of care PET/CT exam.
40956694|NCT02836093|BEHAVIORAL|FACIT-Fatigue 52-point questionnaire|
40956695|NCT02234388|OTHER|Observation|There are no interventions associated with this registry as it is purely observational.
40956696|NCT05247775|PROCEDURE|Profilometry|Profilometry was performed in 43 patients before open retropubic radical prostatectomy.
40956697|NCT03748693|PROCEDURE|Hysterectomy|Surgery performed on women with a variety of gynecological indications
40956698|NCT03748693|PROCEDURE|Colporrhaphy|Surgery performed on women with POP
40956699|NCT02369432|DRUG|Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy|
40956700|NCT05663567|BEHAVIORAL|solution oriented approach|Implementing a solution-focused approach to support breastfeeding
41135476|NCT01702376|DRUG|Placebo|Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
41135477|NCT01702376|DRUG|Moxifloxacin 400 mg|Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
41135478|NCT04592926|DEVICE|Accuro SpineNav3D|The intervention will consist of a pre-procedural scan of the lumbar spine using the handheld image guidance device, Accuro, to determine spinal landmarks and anticipated depth of the intrathecal space.
41135479|NCT04592926|OTHER|Sham|The sham group will receive a pre-procedure sham scan (the handheld image guidance Accuro device will be placed on the back, but it will be turned off) followed by sham marking on the subject's back.
41135480|NCT01095848|BIOLOGICAL|DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG|Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.
41292010|NCT04073823|DEVICE|Flexitouch Plus|Flexitouch Plus full arm and core treatment
41292011|NCT04073823|DEVICE|Flexitouch Plus FT with software modification|Flexitouch Plus full arm and trunk/chest treatment
41292012|NCT00687050|DIETARY_SUPPLEMENT|peroral high-caloric supplemental nutrition|HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
40956701|NCT04912193|DRUG|Antithrombin III|In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.
40956702|NCT03057678|OTHER|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
40956703|NCT01963273|PROCEDURE|Video Assisted Ablation of Pilonidal Sinus|
40956704|NCT00560105|DEVICE|Lung Flute|8 weeks home use, twice daily
40956705|NCT00560105|DEVICE|Acapella|8 weeks home use, twice daily
41455453|NCT03051945|DRUG|Ketamine Hydrochloride|Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
40762672|NCT03925077|OTHER|Standard Exercise Training|The SET program is based on the NCHPAD 14-Weeks to a Healthier You program launched in 2008. Exercise videos including range of motion, muscle strengthening, cardio and balance routines performed both seated and standing have been developed and will be restructured for use in this study. The SET program will be delivered through the same platform as M2M.
40762673|NCT04804345|OTHER|standard of care|retrospective study: standard of care
40762674|NCT05444439|GENETIC|detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent H.Pylori genotypes by polymerase chain reaction amplification(PCR) in gastric biopsies :|Extraction of DNA, using Wizard® Genomic DNA Purification Kit (Promega-USA), will be done following the manufacturer instructions. For detection of vacuolating cytotoxin A and cytotoxin-associated gene A gene, polymerase chain reaction amplification will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 60˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. For detection of vacuolating cytotoxin A (S1/S2, m1, m2), PCR will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 56˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. Amplified DNA will be analyzed by agarose gel electrophoresis. A positive sample will give bands at DNA fragment 138-bp for cytotoxin-associated gene A, at 259/286-bp for vacuolating cytotoxin A s1/s2, and 290-bp and 352-bp for m1 \& m2, respectively
40956706|NCT00478231|DRUG|Maraviroc|Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
40956707|NCT00850343|DRUG|Certolizumab pegol|Subcutaneous (SC) injection
40956708|NCT00113503|DRUG|Azathioprine weight-based dose|
40956709|NCT00113503|DRUG|Azathioprine individualised dose|
41135481|NCT02309294|DEVICE|Novel lubricant Miami w/ fragrance|0.2 ml aliquot on occlusive patch
41135482|NCT02309294|DEVICE|Novel lubricant Miami no fragrance|0.2 ml aliquot on occlusive patch
41135483|NCT02309294|DEVICE|KY Liquid lubricant|0.2 ml aliquot on occlusive patch
41135484|NCT02309294|DEVICE|Astroglide Gel lubricant|0.2 ml aliquot on occlusive patch
41135485|NCT02309294|DEVICE|Wet Platinum lubricant|0.2 ml aliquot on occlusive patch
41135486|NCT01488084|PROCEDURE|Coronary Artery Bypass Graft Surgery|Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery
41135487|NCT01488084|PROCEDURE|Conventional open SVG harvesting|SVG harvested using conventional open technique and manually distended with crystalloid solution
41135488|NCT02075723|DIETARY_SUPPLEMENT|Overfeeding (130 % of energy requirements )|Overfeeding (130 % of energy requirements )
41135489|NCT02075723|BEHAVIORAL|Sleep restriction (4 hours per night)|Sleep restriction (4 hours per night)
41135490|NCT01670877|DRUG|Neratinib|
41135491|NCT01670877|DRUG|Fulvestrant|
41135492|NCT01670877|DRUG|Trastuzumab|
41455454|NCT03051945|OTHER|Normal saline|Placebo
41455455|NCT02761915|OTHER|Leukapheresis|
41455456|NCT02761915|DRUG|Cyclophosphamide|
41455457|NCT02761915|DRUG|Fludarabine|
40956710|NCT01045525|PROCEDURE|Phlebotomy|From 300 to 400mL for women; From 350 to 450mL for men
40956711|NCT01045525|BEHAVIORAL|Lifestyle and diet advices|2 Booklets with Dietary and physical activity advices
40956712|NCT06492967|BEHAVIORAL|Systematic Lifestyle Intervention|Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
40956713|NCT06492967|BEHAVIORAL|Flexible Lifestyle Intervention|Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
41135493|NCT01670877|PROCEDURE|Tumor biopsy|-Optional at baseline and disease progression
41135494|NCT01670877|PROCEDURE|Research blood sample|-Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)
41135495|NCT01706159|DRUG|catridecacog|Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg
41135496|NCT01706159|DRUG|placebo|Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
41135497|NCT05826496|OTHER|Exercise|The supervised high-intensity interval training is conducted on bicycle ergometers at 85-95% maximal workload. The high-intensity interval sequences will be separated by two steady state sequences. Blood samples are collected at baseline, 2 min and 60 min post-exercise.
41135498|NCT02333318|DRUG|VVZ-149 injection|Colorless, transparent liquid in water for injection
41135499|NCT02333318|OTHER|Placebo|water for injection
41135500|NCT05785650|DIAGNOSTIC_TEST|osteopathic palpation|comparaison of ultrasound caracteristics of areas with ad without TP
41135501|NCT05325099|DRUG|Azacitidine|azacitidine (Vidaza) 1mg/BW(kg) (subcutaneous injection) QOD x 3 times
41135502|NCT05325099|DRUG|Placebo|Placebo (subcutaneous injection) QOD x 3 times
41135503|NCT04629950|DRUG|Rimegepant|Active Agent
41135504|NCT04629950|DRUG|Placebo|Placebo Comparator
41455458|NCT02761915|GENETIC|1RG-CART|
41455459|NCT01703754|GENETIC|Ad-RTS-hIL-12 and Veledimex|Oral activator ligand with adenoviral vector injection of cancer lesions
41455460|NCT01703754|DRUG|Palifosfamide|Small molecule chemotherapy, IV administration
40956714|NCT04883229|DEVICE|Halo Neuroscience Neurostimulator|"Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks."
40956715|NCT00231842|DRUG|Ifosfamide|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
40956716|NCT00231842|DEVICE|Radiation Therapy|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
40956717|NCT00231842|DRUG|Cisplatin|dosage is 20 mg/m2/day for 5 days, ever 3 weeks.
40956718|NCT03499977|BEHAVIORAL|Sitting|10 min bouts
40956719|NCT03499977|BEHAVIORAL|Light-Intensity Cycling|10min bout
40956720|NCT03499977|BEHAVIORAL|Moderate-Intensity Cycling|10 min bout
40956721|NCT03499977|BEHAVIORAL|High-Intensity Cycling|10 min bout
40956722|NCT03780543|DRUG|standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)|Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
40956723|NCT04242329|PROCEDURE|Surgical metastasectomy|Surgical removal of metastases aimed at R0 resection.
41455461|NCT05376449|BEHAVIORAL|HealthPartners NeuroWell Exercise Program|A 12-week exercise program geared towards individuals with neurological disorders or injuries run by the Regions Hospital Rehabilitation department at the HealthPartners Neuroscience Center. The exercise programming will be designed by the exercise physiologists and adapted to individuals' abilities. Exercise prescriptions will be designed based on established guidelines, level and completeness of injury, individual functional ability, individual goals, and baseline exercise assessments. Program will consist of strength and endurance adaptive exercise.
40762675|NCT05444439|DIAGNOSTIC_TEST|Culture and sensitivity of endoscopic gastric biopsies:|During endoscopy, three biopsies will be taken from antrum and/or corpus of and will be examined by rapid urease test also known as Campylobacter-like organism test (Kimberly-Clark,USA). Culture of the bacterium on Columbia agar plus 5-7% defibrinated horse or sheep blood and selective Dent supplement under microaerophilic condition at 37degree Celsius for 3-5days.
41292013|NCT00687050|DIETARY_SUPPLEMENT|peroral supplemental nutrition|Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
41292014|NCT04962165|DEVICE|Mandibular Advancement Device|The device maintain opened upper airway by moving the lower jaw slightly forward while sleeping.
40762676|NCT05444439|OTHER|Histopathological examination endoscopic gastric biopsies:|Histological sections from the antrum and body regions will be stained with Giemsa stain. Giemsa stain working solution was prepared as follows: 40 ml Giemsa stock solution with 60 ml of distilled water. Giemsa stock solution will be prepared as follows: Giemsa powder 4 g, glycerol 250 ml and methanol 250 ml. Histological sections will be examined by a gastrointestinal pathologist to standardize the classification of gastritis. Histopathological classification will be recorded as following (acute gastritis, mild-moderate- severe chronic gastritis, Glandular atrophy or Intestinal metaplasia).
40762677|NCT05444439|PROCEDURE|Upper endoscopy|it will be done patient before start empirical therapy and multiple antrum and/or corpus biopsies will be taken . Patient will be fasting at least 8 hours.Upper and findings will be recorded in the report as presence of gastroesophageal reflux disease, diffuse or localised gastric and/or duodenal redness, mucosal swelling, atrophy of mucosa, nodularity, intestinal metaplasia, erosions or ulcers.
40762678|NCT05444439|DRUG|empirical H.pylori regimens|Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)). Follow up after 2 weeks after finishing regimen by Stool Ag in stool
40762679|NCT05444439|DIAGNOSTIC_TEST|H.Pylori Ag in stool|"Any symptomatic patient is above 18 years old with H pylori infection patients diagnosed by positive H pylori Ag in stool will be included.~assessment of laboratory response, 2 weeks after finishing empirical therapy."
40762680|NCT04497155|DRUG|Norepinephrine|Trauma patients with prehospital or arrival to the trauma center hypotension, defined as a systolic blood pressure \<100 mmHg, that received norepinephrine during prehospital transport or in the resuscitation unit.
41455462|NCT00041860|PROCEDURE|Controlled Exposure to Environmental Contaminant|
40956724|NCT04242329|DRUG|Immunotherapy|Continued PD1-inhibitor treatment according to current treatment standards.
40956725|NCT03566888|DEVICE|Blood pressure assessment|Validation of an automated blood pressure device
40956726|NCT05133752|DRUG|Nemonoxacin|500 mg, oral administration, once daily for 7-10 days.
40956727|NCT05993377|OTHER|Logistic regression Cross validation Area under the RIC curves Machine learning analysis. .|we will use robust machine learning approaches, such as Random Forest and XGBoost.
41455463|NCT05772559|OTHER|Collection of blood sample of bone marrow (cohort 1)|"* 3 additional tubes of blood sample (cohort 1), at diagnosis and upon relapse if relapse occurs~* Bone marrow aspirate : 3 additional tubes (cohort 1), at diagnosis and upon relapse if relapse occurs"
40956728|NCT01188421|DRUG|Buprenorphine/naloxone|up to 8/2 mg Sublingual (SL) per day
40956729|NCT01188421|DRUG|Clonidine|up to 0.8 mg per day (oral)
40956730|NCT01188421|DRUG|Tramadol ER|up to 600 mg per day
40956731|NCT00286312|DRUG|Atorvastatin|
40956732|NCT06098092|OTHER|Long-term non-invasive Blood pressure monitoring|All measurements during the experiment include only non-invasive Blood pressure and Heart rate measurements. Measurements will be taken using a smartwatch attached to the wrist and a digital tonometer with a cuff placed on the other arm. Paired readings will be compared.
41292015|NCT04300218|BEHAVIORAL|internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)|"The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study."
41292016|NCT04300218|OTHER|Care as usual (CAU)|Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
41292017|NCT02194296|DRUG|Ambroxol hydrochloride - lozenge|
41292018|NCT02194296|DRUG|Ambroxol hydrochloride - syrup|
41292019|NCT00152373|DRUG|Levetiracetam|
41292020|NCT06135818|DIAGNOSTIC_TEST|IRISA-TB|ELISA-based assay that detects interferon-gamma concentrations in extrapulmonary fluid in active TB.
41292021|NCT01618955|DEVICE|VIBEX MTX|Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
41292022|NCT04281927|DEVICE|Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)|Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).
41292023|NCT04174963|BEHAVIORAL|eToke + TPsy|Combination of brief computerized intervention (eToke) with Information-Motivation-Behavior based text messages tailored to young adults in psychiatric treatment
41292024|NCT05956574|BEHAVIORAL|Nutrigenomix, personalized dietary plan|Personalized dietary plan.
41292025|NCT05956574|BEHAVIORAL|Physical Activity|Participate in an exercise program to work up to 300 min/week of moderate-intensity activity.
41292026|NCT05956574|BEHAVIORAL|Behavioral counseling|Review behavioral counseling videos and participate in worksheets to assist with behavioral change.
41292027|NCT05956574|BEHAVIORAL|Standard Dietary plan|Receive a standard dietary plan
41455464|NCT05772559|OTHER|Collection of blood sample of bone marrow (cohort 2 and 3)|"* 1 additional tube of blood sample (cohort 2 and 3 at inclusion)~* Bone marrow aspirate: 1 additional tube (cohort 2 and 3 at inclusion)"
41455465|NCT03487939|DRUG|FOLFOXIRI|IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
41455466|NCT01971645|DRUG|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
41455467|NCT01971645|DRUG|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
40762681|NCT00609349|DEVICE|ETED, CPET, RHC|"exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)~right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values"
40762682|NCT06229093|DEVICE|Gamma|For the OAg group, the visual component of multimodal stimulation will have the same properties as for the other group, except it will also be additionally amplitude-modulated in the gamma-band (30-60 Hz) range, resulting in a detectable flicker over-and-above the beat-level modulation.
41292028|NCT00636623|OTHER|Pilates exercises|15 FM patients participated in the PE programme three times a week during a 4-week period
41292029|NCT00636623|OTHER|Connective tissue massage|21 patients received CTM, three times a week during a 4-week period
41292030|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 100mg
41292031|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 200mg
40762683|NCT06229093|DEVICE|Synchrony|For the OA group, the lights will be tuned to delta-band frequencies (1-4 Hz) in the music, which corresponds to the beat-level frequency in most music. Thus, the lights automatically adapt to the rhythm of the music, pulsing on the beat and changing color on strong beats.
41292032|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 300mg
41292033|NCT01557010|DRUG|Control|Tablets, oral administration, Placebo
41292034|NCT03279237|DRUG|Irinotecan|May help shrink tumor before surgery.
41292035|NCT03279237|DRUG|Oxaliplatin|May help shrink tumor before surgery.
41292036|NCT03279237|DRUG|Leucovorin|May help shrink tumor before surgery.
41292037|NCT03279237|DRUG|5-Fluorouracil|May help shrink tumor before surgery.
41292038|NCT03279237|DRUG|Paclitaxel|Paclitaxel may stop cancer cells from growing and spreading.
41292039|NCT03279237|RADIATION|Radiation Therapy|May help shrink tumor.
41455468|NCT03113227|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length
41455469|NCT03113227|DIAGNOSTIC_TEST|Vaginal examination|Vaginal examination will be done for assessment of Bishop score
41455470|NCT05965479|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.
41455471|NCT03369535|OTHER|CARB rich diet|Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
41455472|NCT03369535|OTHER|MUFA rich diet|Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
41455473|NCT03369535|OTHER|PROT rich diet|Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
41455474|NCT02117505|DRUG|Formulation 2|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
41455475|NCT02117505|DRUG|Formulation 1|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5\*30 mg tablet=150 mg) in one of the treatment periods.
41292040|NCT03279237|DRUG|Carboplatin|Carboplatin may stop cancer cells from growing.
41292041|NCT00006669|BIOLOGICAL|rituximab|
41292042|NCT00006669|BIOLOGICAL|sargramostim|
41292043|NCT00006669|DRUG|EPOCH regimen|
41292044|NCT00006669|DRUG|cyclophosphamide|
41292045|NCT00006669|DRUG|doxorubicin hydrochloride|
41292046|NCT00006669|DRUG|etoposide|
40762684|NCT02579057|DRUG|Furosemide Injection Solution (SCP-101)|
40956733|NCT06198283|OTHER|Low Level LASER Therapy with Pressure Garment|This group will be treated by low level laser therapy with pressure garment (8-10hrs a day) by Laplace' s Law method because it is more accurate since the range of pressures that can be delivered to a particular range of body circumferences varies depending on the fabric used and its particular tension- extension profile, the method is difficult to utilize manually and till present there is no available design tool to aid in its application. Pressure garments generate an increase in subdermal pressures in the range 9- 90 mmHg depending on the anatomical site. Garments over soft tissues generate pressures ranging from 9 to 33 mmHg. Over bony prominences the pressures range from 47 to 90 mmHg. 25mmHg pressure will be provided by garments and garments will be replaced in every 2 months
41292047|NCT00006669|DRUG|prednisone|
41292048|NCT00006669|DRUG|vincristine sulfate|
40956734|NCT06198283|OTHER|Low Level LASER Therapy without Pressure Garment|This group will receive low level LASER therapy (422-800nm) without pressure garment only for the duration of 6 weeks (3 days in a week with 20-30 minutes per session).
41455476|NCT03050424|DRUG|Ferric Carboxymaltose|Ferric Carboxymaltose injectable Product
40956735|NCT01803061|BEHAVIORAL|WebCan|Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
40956736|NCT03989700|DRUG|Thiamine Mononitrate|Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
40956737|NCT05637879|DRUG|Glecaprevir/pibrentasvir|Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection
40956738|NCT05637879|OTHER|Placebo|Compounded, inactive pill equal in appearance to active study drug
40956739|NCT05128500|PROCEDURE|Total Shoulder Arthroplasty with Permedica's MIRAI|Total Shoulder Arthroplasty with Permedica's MIRAI Modular Shoulder Prosthesis System
40956740|NCT06323057|DEVICE|Single pulse TMS to the frontal cortex|Single pulse TMS will be delivered to the left frontal cortex, and stimulation intensity will be at 110% of resting motor threshold.
40956741|NCT00705289|BIOLOGICAL|Infliximab|Infliximab used in line with current clinical practice and local guidelines.
40956742|NCT00734175|BIOLOGICAL|H6N1 Teal HK 97/AA ca recombinant vaccine|Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
40956743|NCT04259567|DEVICE|Cytokine absorption|Use of CytoSorb absorber
40956744|NCT01998776|DRUG|Misoprostol|Misoprostol 200ug four times daily
40956745|NCT01998776|DRUG|Placebo|Placebo Starch four times daily
40956746|NCT05919589|OTHER|Care Integration for Children With Special Health Care Needs|The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers
40956747|NCT04521816|BEHAVIORAL|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
40956748|NCT00259610|DRUG|methotrexate|varies
41292049|NCT03500107|DEVICE|Blue Light Emitting Diode (LED) 401 +/- 5nm|The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
41292050|NCT02229994|OTHER|Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.|"Evaluation will be performed on a group of 200 patients deriving from 4 samples.~* From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).~* From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment."
41292051|NCT02773992|BEHAVIORAL|The IoT|"For the IoT group, three plus two type pulmonary nodule diagnosis： ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform."
41292052|NCT01225068|DRUG|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
41455477|NCT03050424|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9%
41455478|NCT05943613|DRUG|Clonidine|compare the effect of intrathecal Clonidine and Neostigmine as adjuvants to Bupivacaine in elective cesarean section
40762685|NCT02579057|DRUG|Furosemide Injection Solution, USP|
41292053|NCT01225068|DRUG|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
41292054|NCT03488940|DEVICE|24-hours group|"Daily amount of feeding were continuously pumped for 24 hours. Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes(GRV) is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
41292055|NCT03488940|DEVICE|16-hours group|"Daily amount of feeding were continuously pumped for 24 hours.Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
41292056|NCT03488940|DEVICE|intermittent group|"Daily amount of feeding were divided into four meals, each meal are pumped within 60mins through stomach tube.~Enteral nutrition preparations pumping scheme: the initial pumping speed is 200ml/h, and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
41292057|NCT05283083|DRUG|Dexmedetomidine|A highly-selective alpha-2 agonist with sedative, analgesic, and sympatholytic effects.
41292058|NCT02436798|DRUG|Ondansetron|All patients will be receiving treatment with ondansetron as part of standard care.
41292059|NCT03538392|DEVICE|Serranator® Alto|Serranator® Alto PTA Serration Balloon Catheter
41292060|NCT02817542|DEVICE|percutaneous coronary intervention|Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
41455479|NCT03419260|OTHER|Clinically indicated EEG monitoring.|Children enrolled in the study will be undergoing clinically indicated EEG monitoring. Some children will undergo clinically indicated electrographic seizure management.
41455480|NCT01714141|BEHAVIORAL|Multi-component, technology based intervention|Motivational sessions were adapted from work done with young adults with HIV (MESA).
41455481|NCT01714141|BEHAVIORAL|Asthma education active control|
40762686|NCT00000397|BEHAVIORAL|Behavioral insomnia therapy|
40762687|NCT03001739|DRUG|Urapidil Hydrochloride Injection|Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
40762688|NCT04692779|OTHER|Lung Ultrasound (LUS)|Enrolled subjects will undergo LUS 1 hour before and 1 hour after prone positioning by a trained clinician and will be assessed using a LUS score based on LUS pattern. LUS will then be performed again 1 hour before supination (16 hours) and assessed by a LUS score. This process will be repeated on the first 3 prone sessions. Patients will be enrolled in the study for 4 weeks in order to observe patient outcomes.
40762689|NCT02970058|OTHER|Platelet-rich Plasma|The active group will receive Platelet-rich Plasma following spinal injection
40762690|NCT02970058|OTHER|Control|The control group will receive saline as a placebo
40762691|NCT00238329|BIOLOGICAL|PEG-interferon alfa-2b|
40762692|NCT00238329|DRUG|thalidomide|
40762693|NCT00020007|DRUG|isolated perfusion|
40762694|NCT00020007|DRUG|paclitaxel|
40762695|NCT00020007|PROCEDURE|hyperthermia treatment|
40762696|NCT01909245|BIOLOGICAL|Allogenic Human Islet Cells|Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
40762697|NCT01909245|DRUG|Immunosuppressive Agents|Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
40762698|NCT01909245|DRUG|Gastrin 17|Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).
40762699|NCT03312543|DEVICE|Active Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the active light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
40762700|NCT03312543|DEVICE|Sham Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the sham light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
40762701|NCT02034565|DRUG|Apixaban|
40762702|NCT02578537|DRUG|Ticagrelor|Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
40956749|NCT00259610|DRUG|sulfasalazine|varies
40956750|NCT00259610|DRUG|hydroxychloroquine|varies
40956751|NCT00259610|DRUG|etanercept|varies
40956752|NCT01007539|DIETARY_SUPPLEMENT|CDP-choline|The subjects will be given 1g citicoline twice daily for a total of 8 weeks.
40956753|NCT01007539|DIETARY_SUPPLEMENT|Placebo (fructose)|The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.
40956754|NCT00929383|DEVICE|Wingspan Stent System with Gateway PTA Balloon Catheter|"The Wingspan Stent System is used in conjunction with Gateway PTA Balloon Catheter to improve cerebral artery lumen diameter in patients with intracranial atherosclerotic disease.~The Gateway Balloon Catheter is indicated for balloon dilation of the stenotic portion of intracranial arteries prior to stenting the artery for the purpose of improving intracranial perfusion."
40956755|NCT04289623|BEHAVIORAL|Email|Email
40956756|NCT04289623|BEHAVIORAL|Loss frame|Email
40956757|NCT04289623|BEHAVIORAL|Testimonial (medical expert)|Email
40956758|NCT04289623|BEHAVIORAL|Testimonial (rank-and-file)|Email
41455482|NCT04507698|OTHER|Intensive Exercise Intervention|INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC), randomised to either the supervised exercise arm or the self-directed exercise arm.
40762703|NCT02578537|DRUG|Clopidogrel|Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
40956759|NCT04289623|BEHAVIORAL|Social norms (percentage)|Email
40956760|NCT04289623|BEHAVIORAL|Social norms (number)|Email
40956761|NCT02331342|DEVICE|NICOM cardiac output measurement|
40956762|NCT02331342|DEVICE|Innocor cardiac output measurement|
40956763|NCT02430623|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.
40956764|NCT02430623|DEVICE|NanoKnife|
40956765|NCT00939640|BEHAVIORAL|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
40956766|NCT02412995|OTHER|Meal sequence 1-2-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
40956767|NCT02412995|OTHER|Meal sequence 1-3-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
40956768|NCT02412995|OTHER|Meal sequence 2-3-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
40956769|NCT02412995|OTHER|Meal sequence 2-1-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
40956770|NCT02412995|OTHER|Meal sequence 3-1-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
41135505|NCT03067337|DEVICE|Stainless Steel Crown (Group A)|Full coverage restoration for multi-surface carious teeth
41135506|NCT03067337|DEVICE|NuSmile Zirconia Crowns (Group B)|Full coverage restoration for multi-surface carious teeth
41292061|NCT02727114|OTHER|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® \& VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
41455483|NCT05376423|BIOLOGICAL|OBI-833/OBI-821|OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.
41455484|NCT05919901|OTHER|HPV Vaccine Communication Strategy|The intervention will include health promotions materials and provision of HPV vaccine
41455485|NCT00396630|BIOLOGICAL|Rotarix|Two-dose oral vaccination.
41455486|NCT00396630|BIOLOGICAL|Placebo|Two-dose oral administration.
41455487|NCT02812381|PROCEDURE|KT|to aplicate neuromuscular bandage technique(KT)
40956771|NCT02412995|OTHER|Meal sequence 3-2-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
40956772|NCT04690933|OTHER|Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients|Signing of consent at the time of the pre-transplant consultation (1 month before grafting). Inclusion of patients during conditioning (around D-8 of transplantation). Samples related to the cohort:one blood sample from the donor (only familial donors) for genetic SNPs analysis. 5 samples: D-8, D20, D100, D200 (+/-10 days), 1 year : 1 tube of 7ml of whole blood on EDTA: Biobanking of whole blood for genetic SNPs analysis (D-8) of specific transporters for GCV, and of plasma for TTV viral load at all times. In routine care:samples taken in the event of a therapeutic escape (2 x 7 ml EDTA tubes, for resistance genotype, and ganciclovir dosage, 3 x 1 ml for Quantiferon CMV, according to CNR Herpesvirus recommendations. 1 x Paxgene tube (2.5 ml) for subsequent CMV genomic and transcriptomic studies. Cell preservation plasma and whole blood for biocollection (2 tubes EDTA de 7ml). Samples stored by the centers' virology laboratories are periodically sent to the CNR for analysis.
40956773|NCT03076320|COMBINATION_PRODUCT|PDF+M-DDO|Participants with moderate and severe acne will be treated two times a day on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Zaxcell (Pirfenidone with M-DDO) in form of a gel. Patients have to wait 20 min without cover those sites.
40956774|NCT03076320|COMBINATION_PRODUCT|A+PBO|Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Effezel (Adapalene with benzoyl peroxide) in form of a gel. Patients have to wait 20 min without cover those sites
40956775|NCT05409248|OTHER|Personalized cognitive stimulation|Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser. Performance feedback will be shown after each activity.
40956776|NCT05409248|OTHER|Sham cognitive stimulation|Non-therapeutic online games based on artistic tasks designed to not train the specific cognitive abilities at test. The time of each session will match that of the experimental group. Performance feedback will be shown after each game.
40956777|NCT00463112|DRUG|Sibutramine|
40956778|NCT04974983|OTHER|Observation of neurological deficits|Observation of neurological deficits
40762704|NCT01839409|BEHAVIORAL|vestibular stimulation|Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
40762705|NCT05214508|DIAGNOSTIC_TEST|interleukin 6|assessment of serum IL-6 by ELISA
40762706|NCT04548219|DRUG|Mirikizumab|Reference and test formulations of mirikizumab administered as a SC injection.
40762707|NCT06267430|BEHAVIORAL|Kleuter Extra training program|The intervention was described in the included arm/group explanation.
40762708|NCT00240019|DRUG|Addition of furosemide 20 mg oral bid to baseline regimen|
40956779|NCT04939116|DRUG|ANG-3070|Orally administered tyrosine kinase inhibitor capsule
40762709|NCT05933603|DRUG|Atomoxetine and Oxybutynin (ato-oxy)|0.5 mg/kg atomoxetine (max 40 mg) and 5 mg oxybutynin by mouth nightly
40956780|NCT04939116|DRUG|Placebo|Orally administered placebo capsule
40956781|NCT05057975|DEVICE|Sunrise|Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.
40956782|NCT05057975|DEVICE|polysomnography|Reference protocol to diagnose OSA (in-lab or outpatient PSG)
40956783|NCT03047876|PROCEDURE|aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
40956784|NCT03944421|OTHER|Red and Processed Meat|Integration of 240 grams (raw weight) of red and processed meat into daily diet for 2 week period.
40956785|NCT03944421|OTHER|Quorn|Integration of 240 grams (uncooked weight) of Quorn into daily diet for 2 week period.
40956786|NCT01972100|DEVICE|Low-level laser therapy (808nm)|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise
40762710|NCT04922879|BEHAVIORAL|Individualized lung rehabilitation|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
40762711|NCT04573504|DRUG|Augmentin/Flagyl or Augmentin/Clindamycin|Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
40762712|NCT04573504|DRUG|Placebo|Placebo
40956787|NCT01972100|OTHER|isokinetic exercise|
40956788|NCT01972100|DEVICE|Placebo low-level laser therapy|
40956789|NCT06278519|BIOLOGICAL|Blood, urinary and feces collection|Blood, urinary and feces collection, at inclusion during acute phase of STEMI, and one year after inclusion visit.
40956790|NCT06278519|DEVICE|Cardiac MRI|Cardiac MRI at the acute phase of STEMI (Day 5 +/- 3) and at 1-year follow-up
40956791|NCT06278519|OTHER|Quality of life and cognitive status questionnaire|Quality of life and cognitive status questionnaire at the acute phase of STEMI and at 1-year follow-up
40762713|NCT05061823|DRUG|Bintrafusp alfa|Participants who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) per dose in a parent protocol, will receive an intravenous infusion of bintrafusp alfa at the dose specified based upon the participant's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Participants who are entering the rollover study after discontinuation of treatment in a parent study will receive bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
41455488|NCT02812381|PROCEDURE|SCS|To aplicate strain-counterstrain above trigger point
40956792|NCT05740124|BEHAVIORAL|slip recovery training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after slipping.
41292062|NCT02267499|OTHER|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
41292063|NCT04770155|DIETARY_SUPPLEMENT|Dietary Nitrates 400 mg|The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.
41292064|NCT04770155|DIETARY_SUPPLEMENT|L-citrulline 3 g|Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.
41292065|NCT04770155|DRUG|Sildenafil 100 mg|Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.
40956793|NCT05740124|BEHAVIORAL|alternative balance training|Participants practice standing and walking under varied sensory conditions.
40956794|NCT04211883|BEHAVIORAL|ACTIVE intervention|The Project ACTIVE intervention was adapted to suit workflow demands of our busy inner-city clinic: (1) identify patients who could most benefit from improvements in adherence to evidence-based preventive care, (2) use a validated mathematical model to quantify and rank the estimated amount of health benefit that would arise from improved adherence to each USPSTF preventive care guideline, (3) communicate this information in a manner informed by risk communication studies relevant to patients from disparate cultural groups and with low literacy and numeracy, (4) engage the patient in a shared decision making process in which the patient identified which preventive health goals aimed to achieve, and (5) set particular action steps for the next visit that were congruent with these goals .
41292066|NCT04770155|DRUG|Bosentan 125 mg|Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
41292067|NCT02158221|DRUG|PACAP|Pituitary adenylate cyclase-activating polypeptide (PACAP)
41292068|NCT03576677|DRUG|Levosimendan|"Levosimendan, 2.5 mg/mL concentrate for dilution. 5 mL of the study drug will be injected into a 245 mL isotonic glucose solution.~Patients will receive a 6 hours infusion of this study drug at an infusion rate of 0.2 µg/kg/min."
41292069|NCT03576677|DRUG|Placebo|"The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group."
41292070|NCT03085732|DRUG|Irrigation with Saline Solution|During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
41292071|NCT01157858|DRUG|Everolimus|2.5 mg every day orally
41292072|NCT01157858|DRUG|Octreotide LAR|40 mg every 28 days IM
41292073|NCT05385614|BEHAVIORAL|de:)press|Patients will receive de:)press for the duration of six weeks. They will be encourages to use the app at least three times a week, up to once per day.
41292074|NCT04275310|BEHAVIORAL|Microeconomic Intervention|The intervention will consist of six sessions on six different days. Sessions will be held at VCU or at one of VCU's community partners. Each session will last for around 2 ½ hours (around 15 hours total). There will be breaks and food will be provided. During the sessions the facilitators will provide education on a variety of topics, including economic services that are available to people living in Richmond, job skills (such as creating a resume and dealing with discrimination at work), personal finance education, gender transition ideas, and HIV prevention. The sessions will occur in a group of about 4-10 transgender women.
41292075|NCT05712031|PROCEDURE|Insertion of 1 Nucleoss T4 dental implants in posterior mandible|Nucleoss T4 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
41292076|NCT05712031|PROCEDURE|Insertion of 1 Nucleoss T5 dental implants in posterior mandible|Nucleoss T5 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
40956795|NCT05600803|PROCEDURE|Single-operator cholangioscopy|SpyGlass (Boston Scientific Co, Marlborough, USA) which enabled the direct visualization of the pancreaticobiliary system for the evaluation of intraductal lesions
40956796|NCT01234441|DIETARY_SUPPLEMENT|Control|A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.
40956797|NCT01234441|DIETARY_SUPPLEMENT|Protein|A whey protein beverage will be administered before dialysis sessions 3 times per week.
40956798|NCT01234441|BEHAVIORAL|Protein + Exercise|A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
40956799|NCT04686214|PROCEDURE|heating|patients were aggressively warmed using multiple heating methods such as pressurized air heater and intravenous fluid heater
40956800|NCT06199336|BIOLOGICAL|JHM03|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.5 ml,0.1 ml per site.
40956801|NCT06199336|BIOLOGICAL|BOTOX®|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
40956802|NCT06199336|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
40956803|NCT03772925|DRUG|Belinostat|Given IV
40956804|NCT03772925|DRUG|Pevonedistat|Given IV
40956805|NCT05070195|DRUG|SKLB1028|SKLB1028, capsule, oral
40956806|NCT05070195|DRUG|Midazolam|Midazolam Maleate, tablet, oral
40956807|NCT03207477|DIAGNOSTIC_TEST|Visual acuity measurement|visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
41292077|NCT05712031|PROCEDURE|Insertion of 2 Nucleoss T4 dental implants posterior mandible|2 freestanding Nucleoss T4 dental implants is used to support 3 unit fixed partial dentures
41292078|NCT06387238|DIAGNOSTIC_TEST|PSMA PET/CT|pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy.
41292079|NCT00003210|BIOLOGICAL|recombinant interleukin-12|Given subcutaneously
41292080|NCT00003210|OTHER|laboratory biomarker analysis|Correlative studies
41292081|NCT06203145|DRUG|Bortezomib|A reduction in serum FLCs level of more than 80% by day 14 of BCD is defined BCD-AutoHSCT group; A reduction in serum FLCs level of less than 80% by day 14 of BCD is defined BCD-KPD-AutoHSCT group.
41455489|NCT03097198|OTHER|Plum-blossom Needle|"* acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~* plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding."
41455490|NCT03097198|DRUG|Tropicamide Eye Drops|Instill one drop in both eyes every night before bed.
41455491|NCT02436200|DEVICE|Neuromuscular Electrical Stimulation|Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
41455492|NCT00189553|DRUG|Pegylated liposomal doxorubicin|30 mg/m² every 4 weeks during 6 cycles or until progression
40762714|NCT02133872|DRUG|Minocycline dose escalation|Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.
40956808|NCT00255125|DRUG|Soy Supplement|Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
41292082|NCT01858428|DEVICE|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
41292083|NCT01858428|DEVICE|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
40762715|NCT05757050|DIETARY_SUPPLEMENT|"Re-Focus Verum Tablets"|The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
40762716|NCT05757050|DIETARY_SUPPLEMENT|"Re-Focus Placebo Tablets"|The placebo will be a matched control.
40762717|NCT00979758|DRUG|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
40762718|NCT06334796|DIAGNOSTIC_TEST|Virtual Assistant|Stage 1 focused on safety, using only medical information from clinical records for the virtual assistant. In Stage 2, which evaluated accuracy, participants interacted with the virtual assistant post-medical stabilization. Additionally, participants also provided initial symptom details for Chat-GPT input. Nine neurologists specializing in emergency participated in the study. In Stage 1, they assessed the virtual assistant's performance using clinical history information. In Stage 2, they analyzed the results from participant interactions with the assistant and performed a comparative evaluation of Chat-GPT. The virtual assistant functioned as a chatbot on WhatsApp and Telegram, using Spanish and incorporating advanced algorithms, decision trees, and large language models for interaction. For comparison, we utilized Chat-GPT versions 3.5 and 4, employing two prompt types in natural Spanish: one incorporating clinical record data and the other based on participant narratives.
40762719|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10\^4 TCID50
40762720|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10 \^5 TCID50.
40762721|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10\^6 TCID50.
40762722|NCT05272605|BIOLOGICAL|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
40762723|NCT05272605|BIOLOGICAL|SARS-CoV-2 beta variant RBD mRNA vaccine|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
40762724|NCT05272605|OTHER|Normal Saline|Placebo comparator
40762725|NCT05328622|BEHAVIORAL|Aqueduct Contingency Management Platform|"All individuals who consent to participate will engage with the Aqueduct contingency management system. Once participants are enrolled, they accumulate points in Aqueduct for each prenatal/postpartum appointment they attend. They also earn points for attending pregnancy and birth related classes, monitoring their health (e.g., blood sugar, blood pressure), and taking prescribed medications. Participants then redeem their points for money on a Visa gift card.~Enrolled participants also receive daily text messages that contain motivational and mini-educational content regarding pregnancy from trusted sources such as the American College of Obstetricians and Gynecologists, Evidence Based Birth, and Postpartum Support International. These texts serve as reminders to participants to remain engaged in their pregnancy care."
40762726|NCT03066739|DRUG|Remifentanil|0.1 micrograms/kg/mL
40762727|NCT03066739|DRUG|Remifentanil+ Placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
40762728|NCT03066739|DRUG|Remifentanil +ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
40762729|NCT04846699|PROCEDURE|per-cutaneous stone extraction|percutaneous nephrolithotripsy for renal stones by different renal access
40956809|NCT00255125|DRUG|Placebo|Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
40956810|NCT03636984|DRUG|recombinant TNF-α receptor: IgG Fc fusion protein|50mg weekly
40956811|NCT02693119|DRUG|elamipretide (MTP-131) 1% topical ophthalmic solution|
40956812|NCT02693119|DRUG|Vehicle topical ophthalmic solution|
41135507|NCT04085952|PROCEDURE|dermal graft (ARCUS repliform) for anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with dermal graft augmentation
40762730|NCT02695888|BEHAVIORAL|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
40762731|NCT02695888|BEHAVIORAL|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
40762732|NCT03502200|DEVICE|JUUL|Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.
40762733|NCT03502200|OTHER|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.
40762734|NCT03376529|DRUG|SPR741|400 mg IV over 1 hour
40762735|NCT03376529|DRUG|Ceftazidime|1.0 gram IV over 1 hour
40762736|NCT03376529|DRUG|Piperacillin/tazobactam|4.5 grams IV over 1 hour
40762737|NCT03376529|DRUG|Aztreonam|1.0 gram IV over 1 hour
40762738|NCT04467255|OTHER|Rehabilitative training|4 weeks aerobic treadmill training compared to endurance training with elastic thera band
40762739|NCT01628952|DRUG|Transversus Abdominis Plane|PIA coelioscopic
40762740|NCT01628952|DRUG|Curare|IAP coelioscopic
40762741|NCT02771327|DEVICE|CPAP plus Gas|
40762742|NCT02771327|DEVICE|ventimask plus gas|
40762743|NCT06326541|BEHAVIORAL|music therapy|Listening to the Holy Quran.
40956813|NCT04346082|BEHAVIORAL|online mindfulness group|Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.
41292084|NCT03288974|DRUG|POMALYST® (Pomalidomide)|The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
41292085|NCT00722540|DRUG|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
41455493|NCT00189553|DRUG|Carboplatin|AUC 5 every 3/4 weeks during 6 cycles or until progression
40762744|NCT06570785|DEVICE|Intra-Operative Positioning System (IOPS)|This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the use of contrast dye and radiation exposure for patients and healthcare professionals alike. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The console is operated by a technician under a physician's instruction. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.
40956814|NCT02654314|DRUG|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
40762745|NCT06570785|DEVICE|Conventional group|This group will be treated using standardised materials (wires, catheters) during EVAR.
41455494|NCT00189553|DRUG|Paclitaxel|175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
40762746|NCT05770180|BIOLOGICAL|Recombinant COVID-19 variant vaccine (Sf9 cell)|WSK-V102
40762747|NCT05770180|BIOLOGICAL|Recombinant COVID-19 vaccine (CHO cell)|control 1
40762748|NCT05770180|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|control 2
40956815|NCT02654314|OTHER|Placebo|Blue capsule matching the melatonin arm
40956816|NCT03566784|PROCEDURE|Inguinal hernia repair|Standard procedure for inguinal hernia repair
41135508|NCT04085952|PROCEDURE|suture based anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with a suture based repair
41135509|NCT01990625|DEVICE|Antenatal Ultrasound Scan|Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
41292086|NCT00722540|DRUG|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
41292087|NCT00722540|DRUG|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
41455495|NCT01690260|DRUG|Bone Morphogenetic Protein 2|12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
41455496|NCT01690260|PROCEDURE|Autologous bone graft|Autologous bone graft in connection with bone docking operation.
41466412|NCT00545688|DRUG|Pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
41466413|NCT00337558|DRUG|Solifenacin succinate|tablet
41466414|NCT00337558|BEHAVIORAL|Simplified bladder training|Instructions
40956817|NCT01902199|BEHAVIORAL|TRAA intervention|The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
40956818|NCT00728793|DRUG|CUDC-101|Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
40956819|NCT02327689|DRUG|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
40956820|NCT04817735|PROCEDURE|TAVI|TAVI sizing with dedicated algorithm
40956821|NCT05004103|OTHER|Cosmetic products application|Female healthy volunteers applied cosmetic products (cleanser and moisturizer) in the morning and afternoon for 1 month. Seven days wash out period will be conducted prior study starts. The evaluation will be conducted before, two weeks after treatment starts, and at the end of the study.
41292088|NCT00722540|DRUG|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
41466415|NCT02388698|PROCEDURE|Cervical swab|"Cervical Swab at baseline.~HPV testing at recurrence, if applicable."
40762749|NCT04627974|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
40762750|NCT04755387|DRUG|Ticagrelor 90mg|Standard strategy initially receive ticagrelor 90mg twice daily for 12 months.
40762751|NCT04755387|DRUG|Ticagrelor 60/45mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60/45mg twice daily after discharge for 12 months.
40762752|NCT00123942|DRUG|MEDI-507|
40956822|NCT02283619|OTHER|None - no intervention, observational study|No intervention, observational study
40956823|NCT00897208|OTHER|high performance liquid chromatography|
40956824|NCT00897208|OTHER|laboratory biomarker analysis|
40956825|NCT00897208|OTHER|mass spectrometry|
40956826|NCT00897208|OTHER|medical chart review|
40956827|NCT00897208|PROCEDURE|evaluation of cancer risk factors|
41135510|NCT02196610|OTHER|Applanation tonometry|Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
41292089|NCT00722540|DRUG|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
41292090|NCT00722540|DRUG|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
41292091|NCT00722540|DRUG|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
41292092|NCT00722540|DRUG|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
40762753|NCT06548724|OTHER|assessment of quality of life before and after anal surgery|"Preoperatively, the state of continence will be assessed using Wexner Incontinence Score (WIS) . Also, the basal state of quality of life (QoL) will be assessed using a validated disease-specific tool known as Quality of Life in patients with Anal Fistula Questionnaire (QoLAFQ) (Ferrer-Márquez et al., , faecal incontinence quality of life (FIQL)~Surgical Techniques:~The selection of surgical technique depends on the type of fistula , patient choice and commitment to guidelines . Follow-up Patients will be followed-up in the outpatient clinic weekly in the first month, then every two weeks in the second month, then at 3, and 6 months postoperatively. The continence state and QoL change will be assessed using QoLAF-Q and GIQLI 3 months and6 months postoperatively."
40762754|NCT01767987|DRUG|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
40762755|NCT01767987|DRUG|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
40762756|NCT00196612|DRUG|emtricitabine, FTC (drug)|
40762757|NCT00196612|DRUG|didanosine, ddI (drug)|
41292093|NCT00722540|DRUG|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
41292094|NCT00722540|DRUG|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
40956828|NCT04944420|BEHAVIORAL|Health enSuite Caregivers|"Advice within Health enSuite Caregivers is organized into 5 priority areas: Taking Care of Yourself (Self-care), Support for You (Support), Supporting the Person Living with Dementia (Characteristics of Persons Living with Dementia), Communication, and Time Management.~Under My Priority Areas, participants will see these in order from highest to lowest need, based on their answers to the needs assessment. Each priority area contains small subtopics and specific tips for things to Try or Avoid. Navigation through the priority areas is user directed and at the participant's discretion. The goal is to make the information they need easy to access."
40762758|NCT00196612|DRUG|efavirenz (drug)|
40762759|NCT06571643|OTHER|Lower Abdomen MRI|The patients will undergo a lower abdomen MRI to assess the size of the psoas muscle and derive the PMI
40762760|NCT02731482|OTHER|Training Group|"Three sessions per week, each lasting 50 minutes, during eight weeks.~* Aerobic training in stepping training.~* Resistance training: Three sets of eight repetitions each, in both simultaneous members, using an elastic band. The trained muscles are quadriceps, hamstrings, deltoid and biceps.~* Once a week, patients will receive a phone call and every two weeks, patients will get a visit of the researcher at his home."
40762761|NCT02731482|OTHER|Control Group|"* The participants will receive verbal and written information about the importance of physical activity and walk in moderate intensity, at least, three times a week for 30 minutes.~* Participants will not receive any supervised physical training.~* Once a week, patients will receive a phone call to provide support and general advice."
40762762|NCT06569485|DRUG|Trilaciclib+R-CHOP|This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Trilaciclib in DLBCL patients treated with R-CHOP.
41292095|NCT03391518|PROCEDURE|Water drinking test|Ingestion of 800 ml water in less than 5 minutes.
41292096|NCT00570739|DRUG|Metformin HCl and Colesevelam Placebo|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks
41292097|NCT00570739|DRUG|Metformin HCl tablets and Colesevelam tablets|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks
41292098|NCT00570739|DRUG|Colesevelam placebo|Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks
41292099|NCT00570739|DRUG|Colesevelam|Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
41292100|NCT01677611|DRUG|Trans-resveratrol extract from Polygonum Cuspidatum|Starting dose of 500 mg daily of either resveratrol to be administered on Day 1 and increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
41292101|NCT01677611|DRUG|Placebo|
41292102|NCT03988751|BEHAVIORAL|Ambulation|Variation in ambulatory intensity.
41466416|NCT02388698|RADIATION|PET-CT|PET-CT will be completed 3 month post chemoradiation.
40956829|NCT01259765|DRUG|VHH batch 203027|The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
40762763|NCT03057340|BIOLOGICAL|Dribble vaccine|DRibble vaccine with DC/CIK(The experimental group) DRibble vaccine will be administered at day1,22,55
40762764|NCT01381679|DRUG|Ezetimibe|Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
40762765|NCT06569316|PROCEDURE|Biospecimen Collection|Undergo blood or saliva and leftover tissue sample collection
40956830|NCT01259765|DRUG|Placebo product|The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
41292103|NCT02040246|DRUG|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
41292104|NCT02040246|DRUG|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
41455497|NCT05471596|DEVICE|NeuWave Microwave Ablation System|The NEUWAVE System supports target ablation or linear coagulation in surgical liver resection procedures. The System offers a versatile probe portfolio, multi-probe synchrony and CO2 cooling to help control the shape, size and burn pattern of your ablations.
41455498|NCT03724682|DEVICE|Carry Life UF device|Treatment with the Carry Life UF device compared to standard PD therapy
40762766|NCT06569316|OTHER|Communication Intervention|Receive care plan recommendations
40762767|NCT06569316|OTHER|Genetic Testing|Undergo genetic testing
40762768|NCT06569316|OTHER|Survey Administration|Ancillary studies
40762769|NCT05255666|DRUG|Pembrolizumab|400 mg intravenously
40762770|NCT05255666|DRUG|Liposomal Irinotecan|Starting at 50 mg/m\^2. The dose may be increased to 70 mg/m\^2 if tolerated or dose reduced to 35 mg/m\^ if treatment-emergent severe adverse event (TESAE) occurs.
40762771|NCT00380146|DRUG|sulfadoxine-pyrimethamine|
40762772|NCT02895984|BEHAVIORAL|Single-session alcohol intervention (BMI)|The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
40762773|NCT02264756|OTHER|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
40762774|NCT06468943|DRUG|Polatuzumab Vedotin|1.8mg/kg/21d（d0） Intravenous infusion
40956831|NCT00573183|BEHAVIORAL|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
40762775|NCT06468943|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
40762776|NCT06468943|DRUG|Rituximab|375mg/㎡/21d（d0） Intravenous infusion
40762777|NCT06468943|DRUG|Cyclophosphamide|750mg/㎡/21d（d1） Intravenous infusion
40762778|NCT06468943|DRUG|Doxorubicin|50mg/㎡/21d（d1） Intravenous infusion
40762779|NCT06468943|DRUG|Prednisone|100mg PO （d1-d5）/21d
40762780|NCT00661180|DRUG|Nexavar (Sorafenib, BAY43-9006)|Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
40956832|NCT00573183|BEHAVIORAL|Treatment as Usual|
40956833|NCT06272201|DEVICE|POSE2.0 procedure with g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|POSE2.0 (g-Cath EZ snowshoe suture anchors placed in the mid + distal body without placement in the fundus), with a moderate intensity diet and exercise program
40762781|NCT06062355|DRUG|HRS-9815 injection|HRS-9815 injection
40762782|NCT04506892|BEHAVIORAL|Meditation|meditation
40762783|NCT05603637|PROCEDURE|Catheter ablation using SmartTouch radiofrequency ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using radiofrequency energy with SmatTouch ablation catheter (Biosense Webster, USA)
40762784|NCT05603637|PROCEDURE|Catheter ablation using Farawave pulsed-field ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using pulsed-field energy with Farawave ablation catheter (Boston Scientific, USA)
41455499|NCT00157521|DRUG|L-arginine|
40762785|NCT06570057|BEHAVIORAL|Participatory, learning and Action (PLA) Based intervention|An PLA based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after completion of 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
40762786|NCT04072939|OTHER|Patients having had a lens surgery|Dilated fundus exam
40762787|NCT02821650|OTHER|TEJ (Traditional stove to Efficient stove in Jhuggi)|TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
40762788|NCT04511741|OTHER|no intervention, it is an observational study.|no intervention, it is an observational study.
40762789|NCT06437366|BEHAVIORAL|Nurse-Led Heart Math Training Program|"he nurse-led HeartMath training program consists of several key components designed to enhance resilience, sense of coherence, and emotional adjustment:~Heart-Focused Breathing Techniques: Patients are taught specific breathing techniques that help synchronize heart and brain activity, leading to a state of physiological coherence.~Emotional Regulation Skills: The training includes exercises that help individuals recognize and shift from negative to positive emotional states, thereby improving emotional stability and reducing stress."
40762790|NCT04011241|DRUG|BI 1323495|Tablet
40762791|NCT04011241|DRUG|Itraconazole|Oral solution
41455500|NCT02491853|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator
41455501|NCT00397657|DRUG|extended release niacin|Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
41455502|NCT00397657|DRUG|ezetimibe|Ezetimibe 10mg once daily
41292105|NCT05829577|OTHER|Executive Function Strategies and Training|will be conducted by primary investigator and trained therapist ,EF strategies will be implemented during DLS and SI training and these strategies will target following area which proved by evidences within the context of functional training: Using monitoring system for each child , Improving sense of time, Externalize important information , Externalize Motivation, Provide consequences: Immediately, more frequently, Higher magnitude and more powerful, Richer degree of incentive, Rotated or changed more frequently, Personalize the command, praise, instruction, reprimanding, Process training, remediation and training on executive function skill
40762792|NCT04648085|DEVICE|Trigeminal Nerve Stimulation|Applied to to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve.The device generates electrical impulses allowing to stimulate the trigeminal nerve.
41292106|NCT05829577|OTHER|Daily Life skill training|each child will receive 25 minute of DLS training which will focus on training children on Grooming, feeding, dressing undressing, toileting and community reintegration tasks aligned with facilitation fine motor skills for children and Using several techniques for ADL training including : prompting, shaping, forward and backward chaining, and modeling ,training children based on level of independency identified by WeeFIM score
41455503|NCT03901690|DRUG|Betaglucin soluble gel 0.2%|With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
40956834|NCT03951155|BEHAVIORAL|Muscle Relaxation|"* Ask the child to lie down in a comfortable position. Ask him/her to notice how their muscles feel in each part of the body. Taking one area of the body at a time (face, shoulders, arms, hands, fingers, abdomen, legs, feet, and toes).~* Instruct the child to contract the muscles for 5 seconds, take a deep breath, and release.~* Next, instruct the child to contract all muscles simultaneously, hold for 5 seconds, then release.~* Finally, ask him/her to notice how his/her muscles feel after the exercise."
41455504|NCT03901690|DRUG|Imiquimod 5% cream|With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
41466417|NCT02388698|BIOLOGICAL|Plasma HPV|Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
40762793|NCT05544695|DEVICE|intravesical sodium hyaluronate (Cystistat®)|Cystistat will be instilled into the bladder according to the instructions for use and in line with the routine clinical practice.
40762794|NCT04632173|OTHER|non interventional study|There is no intervention
40956835|NCT04734938|DIETARY_SUPPLEMENT|Huel Powder|Huel is made of an ultra-fine blend of sustainable ingredients. Oats, rice, peas, coconut, flaxseed, and our unique mix of vitamins and nutrients to provide you a meal with all the carbohydrates, protein, essential fats, fibre, and all the 26 essential vitamins and minerals your body needs to thrive. Volunteers will consume only Huel as their food source for the final four weeks of the study.
40956836|NCT03677921|DIETARY_SUPPLEMENT|Investigational Product (Bio-Germanium)|"* Ingredient: Bio-Germanium~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks"
40956837|NCT03677921|DIETARY_SUPPLEMENT|Control Group - Placebo Product|"* Ingredient: Corn starch~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks"
40956838|NCT00293033|DRUG|BEMA™|BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
40956839|NCT00293033|DRUG|Placebo|
40956840|NCT04279405|DRUG|YY-20394|YY-20394 80mg tablet administered orally once daily
40956841|NCT04774796|OTHER|Cognitive Behavioural Therapy|Participants will take part in a one day, or two half-day group CBT workshop for parents of children with food allergy. The workshop will included understanding difficulties using a CBT model, psychoeducation on common psychological issues (e.g. anxiety) and the development of skills to help deal with maladaptive cognitions and behaviours relating to managing a child's food allergy.
40956842|NCT05276037|OTHER|Liver transplantation|Both groups will receive the same advantages on the LT waiting list (SE points)
40956843|NCT03190590|PROCEDURE|tDCS-NeuroConn.|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
40762795|NCT00831883|BEHAVIORAL|Partner-Specific IMB-based HIV risk reduction intervention|5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
40956844|NCT03190590|PROCEDURE|TMS - Magstim.|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry \[this is not repetitive TMS and so does NOT modulate brain excitability
40956845|NCT03190590|PROCEDURE|Sham tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
40762796|NCT00831883|BEHAVIORAL|Healthy Lifestyle|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
40762797|NCT00216385|DRUG|Gatifloxacin combined regimen|
40762798|NCT04744792|OTHER|Short Form - 36|"Medical outcomes: 36-item short form health survey (SF-36)~The SF-36 was used as a measure of health-related QoL because it is an internationally recognized global measure. It comprises 36 items that measure perceived health on eight scales (i.e., physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health) with higher scores (range 0-100) reflecting better perceived health. Additionally, two summary scores can be obtained: the physical component summary score (PCS) and the mental component summary score (MCS).~In addition, this tool has been validated in Turkish patients"
40762799|NCT04744792|OTHER|WHODAS-II|"The World Health Organization disability assessment schedule II (WHODAS-II)~The WHODAS-II is an instrument developed by the World Health Organization to assess behavioral limitations and restrictions regarding participation in specific activity domains experienced by an individual independent of their medical diagnosis. The conceptual frame of reference of this instrument is the International Classification of Functioning, Disability, and Health (ICF). Specifically, the instrument is a 36-item, generic, multidimensional questionnaire designed to evaluate the functioning of the individual in six activity domains (i.e., understanding and communicating, getting around, self-care, getting along with people, life activities, and participation in society). This questionnaire has been validated in Turkish patients."
40762800|NCT04883203|DRUG|Vit-D 0.2 MG/ML Oral Solution [Calcidol]|ARM 1 : Cholecalciferol 200,000 IU / 1 mL .
40762801|NCT04883203|DRUG|Physiological Irrigating Solution|ARM 2 : placebo
40762802|NCT06495099|OTHER|Russian electrical stimulation|Type of Medium frequency current with 2500 Hz frequency modulated at 50 Hz with 50% Duty cycle training protocol is (10 sec. on time - 50 sec. off time - 10 minutes total time)
40762803|NCT01743144|DRUG|Magnesium Sulfate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
41455505|NCT04438434|DRUG|Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
41455506|NCT04438434|DRUG|Chlorhexidine mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
41455507|NCT04438434|OTHER|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
41292107|NCT05829577|OTHER|Sensory Integration /Processing training|each patient will receive 20 min of SI/SP training Manualized SI/SP intervention which will be used is based on the principles of sensory integration as outlined by Ayres ,such as deep pressure, brushing, weighted vests, and swinging will used , individually-tailored treatment activities might include activities such as using a carpeted scooter board while in the prone position to pull oneself up a ramp, then working to turn the scooter board around to ride down the ramp and land in a cushioned area of mats and pillows that are covered with various textures. Intervention is contextualized in play with active involvement of the child will be conducted in a large gym equipped with mats, a variety of suspended swings, large balls, a climbing wall, carpeted barrels, large inner tubes and foam blocks with opportunities for active, guided, sensory motor play.
41455508|NCT04935580|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
41455509|NCT00509301|DRUG|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
41455510|NCT03790163|DRUG|Levobupivacaine|Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
41455511|NCT05499728|OTHER|Telerehabilitation; physical therapy via telecommunication device (i.e. online video conferencing)|Postoperative physical therapy performed through online video conferencing with a licensed physical therapist while the patient remains remote/at home rather than in person
41455512|NCT00065962|DRUG|secretin, synthetic porcine|
41455513|NCT00065962|DRUG|secretin, biologically derived porcine|
41455514|NCT01643434|DRUG|Spironolactone|Spironolactone (titrating dose from 12.5 to 50mg SID)
41455515|NCT01643434|DRUG|Clonidine|Clonidine (titrating dose from 0.100-0.300mg BID)
41455516|NCT04391829|DIAGNOSTIC_TEST|Ejaculated semen sample|SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.
41455517|NCT06251349|RADIATION|Radiation|Single dose radiation with 7-8 Gy
40762804|NCT01743144|DRUG|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
40762805|NCT03333889|OTHER|Vita Enamic hybrid crown|hybrid ceramic material in the form of mesoblocks where the ceramic block is attached to a ti base .The whole assembly is screw retained superstructure.
40762806|NCT03333889|OTHER|emax hybrid crown|high srength glass ceramic that can be milled in sections up to 1mm .
40762807|NCT02006290|DRUG|PF-06412562|single oral split dose 30+20 mg QD
41135511|NCT04594525|OTHER|Low-Intensity Psychosocial Interventions through Telemental health|Low-Intensity Psychosocial Interventions through Telemental health (Thinking healthy): The intervention will include six sessions. Each session may last to 45 min as a max, and it will be provided through telehealth. The first session will be an introduction, while the other five sessions will be covering the period from the second pregnancy trimester to the first year of the infant's life.
40762808|NCT02006290|DRUG|Placebo|tablet, matching placebo, QD
40762809|NCT04884360|DRUG|Olaparib|Olaparib tablets 300 mg oral twice daily
40762810|NCT04884360|OTHER|Matching placebo|Matching placebo tablets taken orally at a dose of 300 mg twice daily
40762811|NCT06489431|DRUG|Chlorhexidine|Irrisept is a self-contained jet lavage that contains chlorhexidine gluconate (CHG) as a preservative to offer broad-spectrum activity against various microorganisms in the bottled solution
40762812|NCT06489431|DRUG|Gentamicin|Aminoglycoside antibiotic irrigation
40762813|NCT06489431|DRUG|Rifampin|Antibacterial known to inhibit DNA-dependent RNA polymerase
40762814|NCT02072057|DRUG|Ruxolitinib|
40762815|NCT05540184|DRUG|Trimetazidine 35 mg|Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
40762816|NCT05540184|DRUG|Allopurinol 300 MG|allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
40956846|NCT05165836|PROCEDURE|Erector Spinae Plane block without Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL saline will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
41135512|NCT06407648|OTHER|Personalized Assessments|Personalized CBT will use individualized OCD symptom networks to guide CBT strategies to target central symptom nodes in contemporaneous networks.
41135513|NCT06407648|OTHER|Standard of Care|The standard CBT condition will use standard-of-care approaches to guide CBT strategies to target OCD symptoms.
41135514|NCT02066155|BEHAVIORAL|Parish nurse|On-going support following diabetes self-management education provided by Parish Nurse
40762817|NCT05540184|DRUG|Normal saline|rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
40762818|NCT03559530|DRUG|Antimicrobial|Antimicrobial therapy according to A. baumannii susceptibility profile
40762819|NCT06570590|PROCEDURE|Minimally invasive lapidus procedure with no arthroscopy|The two procedures, with and without arthroscopy, only differ by the method of assessing cartilage removal. Cartilage removal will be assessed arthroscopically in the procedure with arthroscopy. In the procedure without arthroscopy, cartilage removal will be assessed via direct visualization through a mini arthrotomy procedure. After use of the cartilage burr the surgeon will make a small dorsal portal and use this opening to ensure that the cartilage is removed and all debris removed. The incision will be 2 cm long and centered over the dorsal medial aspect of the joint.
40762820|NCT06570590|PROCEDURE|Minimally invasive lapidus procedure with arthroscopy|After removal of the cartilage with the cartilage burr, a 3.0 arthroscope will be inserted to inspect the joint for all cartilage removal. Any residual cartilage pieces will be removed to ensure complete cartilage debridement from the subchondral bone and fragments removed from the joint.
40762821|NCT02458729|DRUG|Tranexamic Acid 5%,5ml/amp (intraoperative)|tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
40762822|NCT02458729|DRUG|Tranexamic Acid 5%,5ml/amp (3 hours after operation)|tranexamic acid 1g administered intravenously 3 hours after operation
40762823|NCT02458729|DRUG|0.9% Normal Saline (intraoperative)|0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
40956847|NCT05165836|PROCEDURE|Erector Spinae Plane block with Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
41135515|NCT02066155|BEHAVIORAL|Peer Support|On-going support following diabetes self-management education provided by a trained person with diabetes
41292108|NCT01954628|DRUG|AQX-1125|Synthetic SHIP1 activator
40762824|NCT02458729|DRUG|0.9% Normal Saline (3 hours after operation)|0.9% Normal Saline 20ml administered intravenously 3 hours after operation
40762825|NCT02458729|DRUG|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
40762826|NCT02624856|DRUG|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
40762827|NCT02624856|DRUG|Bupivacaine plus dexamethasone|Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
40762828|NCT05226052|DIETARY_SUPPLEMENT|Saccharomyces boulardii (Floratil 600mg)|PGIC and PGIS assessment
40762829|NCT05226052|DIETARY_SUPPLEMENT|3 capsules of placebo|PGIC and PGIS assessment
40762830|NCT03236883|DRUG|Gemcitabine|Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.
40956848|NCT04046692|OTHER|Hospital School Experience, point of view of the children|Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.
40956849|NCT04046692|OTHER|Hospital School Experience, point of view of the hospital teachers|operators interview hospital teachers and make them complete a questionnaire (CEESQ)
40762831|NCT03236883|OTHER|GPBSC|immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)\*10\^8/kg,once a month,repeated every 4weeks,three times in all.
40762832|NCT01751425|DRUG|Dasatinib|Given PO
40762833|NCT01751425|DRUG|Imatinib Mesylate|Given PO
40762834|NCT01751425|DRUG|Nilotinib|Given PO
40762835|NCT01751425|DRUG|Ruxolitinib|Given PO
40762836|NCT00601445|BEHAVIORAL|Amount of sleep and wake|4 groups with different patterns of sleep and wake
40762837|NCT04215458|OTHER|sample collection (swap or tape strip)|collection of swap or tape strip to determine yeast colonization in skin
40956850|NCT04046692|OTHER|Hospital School Experience, point of view of the non hospital teachers|operators interview the teachers and make them complete a questionnaire (CEESQ)
40956851|NCT04046692|OTHER|Hospital School Experience, point of view of parents|Operators interview parents
40762838|NCT04756232|DRUG|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
40956852|NCT05912244|DRUG|IO102/IO103|IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.
40956853|NCT05912244|DRUG|Nivolumab-Relatlimab|Nivolumab-relatlimab will be administered as a single infusion 160mg relatlimab and nivolumab 480 mg for all participants. Both agents will be combined in a single fixed-dose combination (FDC) as an intravenous 30-minute infusion every four weeks.
41455518|NCT06251349|DRUG|Diclofenac|postoperative treatment with diclofenac to prevent HO
40762839|NCT04756232|OTHER|Placebo Comparator Challenge|Matching placebo oral pill administered once
40762840|NCT06225544|DRUG|Lumasiran|Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
40762841|NCT06225544|DRUG|0.9% Sodium Chloride (placebo)|Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
40762842|NCT06157593|PROCEDURE|NAVA|weaning from mechanical ventilator using neurally adjusted ventilatory assist
40762843|NCT01455090|DRUG|BMS-650032|
40762844|NCT01455090|DRUG|BMS-790052|
41292109|NCT01954628|DRUG|Placebo|Placebo control
41455519|NCT03021876|DRUG|L-carnitine|treatment with oral L-carnitine, 1500 mg/body per day
41455520|NCT03021876|OTHER|usual intake|baseliner
40762845|NCT01455090|DRUG|BMS-791325|
40762846|NCT01455090|DRUG|Ribavirin|
40762847|NCT06548438|PROCEDURE|Transurethral resection of the bladder performed with PDD tecnique and Hexvix|For the execution of PDD cystoscopy in blue light, it is necessary to use the study drug (Hexvix) which, after intravesical instillation, causes an accumulation of porphyrins in the lesions of the bladder wall at the intracellular level. The intracellular porphyrins are photoactive fluorescent compounds that emit red light when excited with blue light. Consequently, the preneoplastic and neoplastic lesions will emit a red luminescence against a blue background, allowing for better visualisation and subsequent resection.
40762848|NCT04722809|DRUG|Botulinum toxin injection|Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
40762849|NCT04722809|OTHER|QOL-Brux|Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
40762850|NCT04722809|OTHER|Muscular strength of the jaw|"Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.~At inclusion and 1 month post-injection."
41135516|NCT03310255|DIAGNOSTIC_TEST|H pylori Faecal Antigen|All patients will be screened for H. pylori using fecal Ag and positive patients will do endoscopy and biopsy.
41135517|NCT03560804|DRUG|Olmesartan|Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
41135518|NCT03560804|DRUG|Chlorthalidone|Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
41292110|NCT05092581|DRUG|casirivimab+imdevimab|Single dose weight-based equivalent administered intravenously (IV)
41455521|NCT03256149|DRUG|Dexamethasone|
41455522|NCT03256149|DRUG|Placebo|Normal saline (IV placebo)
40762851|NCT04722809|OTHER|Intensity and frequency of episodes of nocturnal bruxism|Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
40762852|NCT04722809|OTHER|visual analogue pain scale|Evaluation of jaw pain. At inclusion and 3 months post-injection
40762853|NCT04722809|OTHER|Endobuccal and linea alba photographs|"anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).~At inclusion"
40762854|NCT05208437|BEHAVIORAL|Complete oral feeding intervention|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale by trained nurses. Assess the premature infants by using the Feeding Preparation Scale. If the premature infant does not meet the oral feeding standard, let the premature infant use the non-nutritive sucking for 3 minutes before the nasal feeding. If the premature infant meets the oral feeding standard, use the non-nutritive sucking for 3 minutes, and refer to the feeding schedule for the premature infant.
40762855|NCT05208437|BEHAVIORAL|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding.
41292111|NCT00562510|DRUG|Raltegravir|Raltegravir 400 mg BID added to stable HAART
41292112|NCT00562510|DRUG|Placebo|Placebo BID added to stable HAART
41292113|NCT00186238|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
41455523|NCT01994915|OTHER|Occupational therapy|Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
41292114|NCT01701791|OTHER|Computerized Decision Support System|
41455524|NCT01963663|DRUG|Metformin|metformin 1000 mg daily in two divided doses of 500 mg tablets
41292115|NCT02272205|OTHER|Retrospective analysis of records|
41292116|NCT03057873|DIETARY_SUPPLEMENT|High protein, high fiber dietary supplement|Dry powder to be mixed with 10 ounces of cold water
41455525|NCT01963663|DRUG|Pioglitazone|pioglitazone 30 mg daily in two divided doses of 15 mg tablets
40762856|NCT05605197|DRUG|U87 CAR-T|Subjects will be pretreated with cyclophosphamide 250\~500 mg/m2( body surface area) for 3 days prior to Intravenous injection of U87, followed by intraartery of U87 14 days later with intravenous IL-2. Researchers can perform intratumoral injection based on their judgment.This study will explore two dose of dose 1 (DL-1): 1×106 (±20%) to dose 2 (DL-2): 1×107 (±20%),each group was enrolled in 3\~6 patients.
40762857|NCT00539500|DRUG|Carboplatin|Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.
40762858|NCT00539500|DRUG|Etoposide|300 mg/m\^2 by vein over 24 hours for 4 days
40762859|NCT00539500|DRUG|Melphalan|70 mg/m\^2 Intravenous Bolus for 3 Days
40762860|NCT00539500|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10\^8 TNC cells/kg CD133+ selected) on Day 0.
40762861|NCT00539500|DEVICE|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
40762862|NCT05938569|DEVICE|Hair restoration|The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
40762863|NCT04473196|OTHER|weightbearing|immediate weightbearing
40762864|NCT03035214|DRUG|Dexamethasone (Steroids)|Is to describe the use of integrated assessment of respiratory physiology using Targeted Neonatal Echocardiography, assessment of optimal Functional Residual Capacity and the tolerance of lung oxygen uptake at different oxygen levels, and hence early prediction of Bronchopulmonary Dysplasia and the underlying pathophysiology by periodic application of the oxygen tolerance test; which may help early targeted treatment of this common disease.
40762865|NCT00130390|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily for 28 days
40762866|NCT00130390|OTHER|Placebo|One placebo tablet twice daily for 28 days
40762867|NCT02779231|OTHER|Bi-directional texting|
40762868|NCT06569511|DIAGNOSTIC_TEST|N-terminal pro-B-type natriuretic peptide (NT-proBNP)|In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit
40762869|NCT06569511|DIAGNOSTIC_TEST|high sensitive cardiac troponin T (hs-cTnT)|In patients diagnosed with Acute coronary syndrome, serum high-sensitive cardiac troponin T (hs-cTnT) levels were measured on admission to the Emergency Department.
40762870|NCT01055340|DRUG|Oxyntomodulin (OXM)|Single infusion of OXM 3.0 pmol/kg/min by IV
40762871|NCT01055340|DRUG|Comparator: Oxyntomodulin (OXM)|Single infusion of OXM 0.6 pmol/kg/min by IV
40762872|NCT01055340|DRUG|Comparator: Placebo [ hemaccel-containing saline]|Single Placebo infusion of hemaccel-containing saline by IV
41135519|NCT02802111|DRUG|Albuterol|Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
41135520|NCT02802111|DRUG|Levalbuterol|Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
41135521|NCT03543332|DIAGNOSTIC_TEST|Measures of physical activity and kinesiophobia|Groups will be compared regarding kinesiophobia with TSK heart.
41135522|NCT00168506|DRUG|SSRI|
41135523|NCT00168506|DRUG|CBT|
41135524|NCT00168506|DRUG|CBT/SSRI|
41135525|NCT02744066|DEVICE|NEATCAP|Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
40762873|NCT01648322|DRUG|F-627|subcutaneous injection given 1 per chemotherapy.
40762874|NCT01648322|DRUG|Neulasta® (pegfilgrastim)|Single dose injection given once per chemotherapy cycle.
40762875|NCT05061836|DRUG|Ringer acetate|Patient will receive Acetate Ringer's solution (Acetar) infused at maintenance rate
40762876|NCT05061836|DRUG|1.25%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ¼ of maintenance rate
40762877|NCT05061836|DRUG|2.5%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ½ of maintenance rate
40762878|NCT05061836|DRUG|Dextrose 5|5%dextrose in normal saline (5%DNSS) infused with maintenance rate
40762879|NCT06355141|OTHER|oral assessment|observational oral assessment
40762880|NCT04477837|DRUG|Apixaban 5 MG|frequency of heavy menstrual bleeding
40762881|NCT04477837|DRUG|Rivaroxaban 20 MG|frequency of heavy menstrual bleeding
40762882|NCT04477837|DRUG|Edoxaban 60 MG|frequency of heavy menstrual bleeding
40762883|NCT04477837|DRUG|Dabigatran 150 Mg Oral Capsule|frequency of heavy menstrual bleeding
40762884|NCT06230341|OTHER|Health Services Research|MSPs benefit from a learning system. The learning system combines an individualised support programme provided by a regional support structure for quality and safety in health care (QualiREL Santé) and the provision of a web platform. Based on the 4 dimensions of the Shortell model, the support programme includes initial training (6 months) and personalised methodological support (18 months) for each MSP. A web platform is provided to MSPs to enable them to implement the full approach of the Risk Management Support Programme. It provides support for reporting, analysis and management of PSIs.
40762885|NCT01162785|DRUG|SCH 721015|Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
41135526|NCT01337752|DRUG|BHQ880|
41135527|NCT01337752|DRUG|BHQ880 Placebo|Intravenous infusion
41135528|NCT01337752|DRUG|bortezomib|intravenous injection
41135529|NCT01337752|DRUG|dexamethasone|Oral
41135530|NCT01703598|DEVICE|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
41135531|NCT01703598|PROCEDURE|DBS surgery|Placement of DBS electrodes
41135532|NCT03730038|DRUG|Treatment of pitavastatin 4 mg qd for 12 weeks|Treatment of pitavastatin 4 mg qd for 12 weeks
41135533|NCT03730038|BEHAVIORAL|Life-style modification|Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min
41135534|NCT03371225|DEVICE|Active tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. 20 minutes of tDCS will be applied.
41292117|NCT03057873|DIETARY_SUPPLEMENT|Placebo|Dry powder to be mixed with 10 ounces of cold water
40956854|NCT03366038|PROCEDURE|Shark Mouth Modified Pancreaticojejunostomy|"The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant）, which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis.~The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis."
40956855|NCT01443078|DRUG|pemetrexed|
40956856|NCT01443078|DRUG|cisplatin|
40956857|NCT01443078|DRUG|Carboplatin|
40956858|NCT01443078|DRUG|Gemcitabine Hydrochloride|
40956859|NCT01443078|DRUG|Vinorelbine Tartrate|
40956860|NCT01443078|DRUG|Docetaxel|
40956861|NCT00531271|DRUG|ABI-008 (nab-docetaxel)|ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
40956862|NCT01010373|DRUG|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
40956863|NCT04755790|DEVICE|Point Digit|Patient is fit with Point Digit partial hand prosthetic system
40956864|NCT04813640|DEVICE|Spectacles|Novel spectacles for myopia control
40956865|NCT01830231|DRUG|Cabazitaxel|Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
40956866|NCT01830231|DRUG|Vinflunine|"Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~* 280 mg/m2 in patients aged \>75 - ≤80 years or with PS 1 or prior pelvic radiation,~* 250 mg/m2 in patients aged \>80 years."
40956867|NCT06154187|DRUG|PBK_L2201|Abaloparatide-SC 80 μg was to be self-administered daily using a Pen Injector device.
40956868|NCT06154187|DRUG|Placebo|Placebo was formulated similar to abaloparatide-SC.
41292118|NCT03945331|DEVICE|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
41292119|NCT03945331|DEVICE|Epidural spinal cord stimulation system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
41292120|NCT02119104|DRUG|Prevenar (13v)|Prevenar (13v)
41292121|NCT06292481|OTHER|Brunnstorm movement therapy|this group received Brunnstorm Movement therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
41292122|NCT06292481|OTHER|Combined Brunnstorm Movement therapy and low level laser therapy|this group received Combined Brunnstorm Movement therapy and low level laser therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
40956869|NCT00354822|DRUG|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts\>150x10\^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10\^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
40956870|NCT00965315|DRUG|Rosuvastatin,SFC fenofibrate|"1. Rosuvastatin 10 mg once daily~2. Rosuvastatin 5 mg + SFC fenofibrate 160 mg"
40956871|NCT04334057|DRUG|Turoctocog alfa pegol|Patients will be treated with commercially available Esperoct® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
40956872|NCT02449252|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~Involved-site radiotherapy (ISRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week."
41292123|NCT01748695|DRUG|V158866|
41292124|NCT01748695|DRUG|Placebo|
41292125|NCT02996305|DRUG|OV101 Regimen 1|
40956873|NCT02449252|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.~Involved-field RT (IFRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week."
40956874|NCT02449252|DRUG|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
40956875|NCT02449252|DRUG|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
40956876|NCT02449252|DRUG|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
40956877|NCT02449252|DRUG|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
40956878|NCT05205525|OTHER|Restrictive antibiotic strategy|Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
40956879|NCT05205525|OTHER|Aggressive antibiotic strategy|Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
41292126|NCT02996305|DRUG|OV101 regimen 2|
41292127|NCT02996305|OTHER|Placebo|
41292128|NCT06141408|BEHAVIORAL|MPowerment Stigma-reduction Intervention|"In-person events will focus on five specific goals: Fostering a sense of community acceptance and social connection among Black sexual minority men (BSMM), promoting self-acceptance of sexual identity, teaching skills for coping with experiences of racism, reducing PrEP stigma, and providing education on HIV risk. In accordance with the MPowerment model, In collaboration with the PI, the BSMM core group and volunteers would lead the development, implementation, and evaluation of all intervention events. Both peer leaders and the primary investigator (all BSMM) will collaborate to develop specific events (M-Groups), guided by the findings in both the quantitative and qualitative studies. M-Groups will be held once every month. Events will be 2 hour in-person activities focused on the aforementioned goals."
41292129|NCT03932136|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.
40762886|NCT01138306|GENETIC|gene expression analysis|
40956880|NCT00509444|BEHAVIORAL|Educational materials|
41292130|NCT03932136|COMBINATION_PRODUCT|Placebo|The placebo is safe, with no therapeutical effect, and has same appearance and similar smell and taste with active tablet.
40762887|NCT01138306|GENETIC|mutation analysis|
40762888|NCT01138306|OTHER|flow cytometry|
40762889|NCT01138306|OTHER|laboratory biomarker analysis|
40762890|NCT01557569|DRUG|Atomoxetine|During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)
41292131|NCT02975154|DEVICE|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
41292132|NCT00397228|DRUG|ALTROPANE®|ALTROPANE® SPECT imaging
40762891|NCT01557569|DRUG|placebo|participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
40956881|NCT00509444|BEHAVIORAL|educational materials, plus patient navigation|
40956882|NCT04716465|OTHER|Dysautonomia|Indicators of dysautonomia
40956883|NCT00916942|DRUG|capsaicin 8%|High concentration capsaicin 8% dermal patch applied for one hour
41292133|NCT01094899|RADIATION|Radiography|Radiography, microscanner, osteodensitometry
41292134|NCT01094899|OTHER|Urine and Blood sampling|mainly dosage of bones metabolism
41292135|NCT01094899|OTHER|Echography|body bones echography
41292136|NCT05632939|DRUG|ASKB589 +CAPOX+Sintilimab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~ASKB589 is administered intravenously at a fixed dose. the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
40762892|NCT05986487|DEVICE|CPAP or usual practice|CPAP (continuous positive airway pressure) is a machine that uses mild air pressure to keep breathing airways open while you sleep.
40762893|NCT05986487|DEVICE|Monitoring and intervention in follow-up|Each participating center can incorporate monitoring and intervention in the follow-up of patients into their work dynamics. Through the use of mobile applications, you can monitor the variables of: weight, diet, lifestyle, exercise and sleep. This intervention will help the patient to improve in different aspects of their health.
40762894|NCT00657683|BIOLOGICAL|Monovalent GBS-CRM glycoconjugate vaccine|1 dose of GBS conjugate vaccine
40762895|NCT00657683|BIOLOGICAL|Placebo|1 dose of placebo
40762896|NCT00219726|DRUG|Imatinib mesylate|
40762897|NCT03777020|BEHAVIORAL|Service Dog Training Program|Participate in 8 weekly dog training sessions using a positive reinforcement method and curriculum under the direct supervision of trainer at the Warrior Canine Connection facility in Boyds (Montgomery County) MD.
40956884|NCT00916942|DRUG|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
40956885|NCT06184386|OTHER|NIDCAPARENTALIM|PARENTALIM practice that strengthens the NIDCAP. It is proposed in a routine way in the NICU since 2019. PARENTALIM supports and monitors parental implication in nursing care. It is led by a speach language therapist specialized in early feeding development who proposes 5 individualized interviews and uses an educational booklet on eating development care with a lot of illustrations and few words.
40956886|NCT06184386|BEHAVIORAL|SOFS|SOFS is a behavioral practice of orofacial stimulations. Il has been mainly carried out by nurses or a speach language therapist specialized in early feeding development. SOFS has been applied through routine protocol in the NICU until 2018.
40956887|NCT02506465|DEVICE|iTIND|Temporary Implantable Nitinol Device (iTIND)
40956888|NCT02506465|PROCEDURE|Sham Arm|Foley catheter will be placed and immediately removed.
40956889|NCT05167929|BEHAVIORAL|Self-determination Enhancement Group|The self-determination enhancement group - Each group has eight participants. There will be 10 sessions per group and each session will last 1.5 hours.
41135535|NCT03371225|PROCEDURE|Active Exercise|Participants will walk briskly in a treadmill (as to keep at 60-70% maximum heart rate) for 30 minutes
40956890|NCT05167929|BEHAVIORAL|Self-determination Enhancement Plus Group|The self-determination enhancement PLUS group - Each group has eight participants and their caregivers. There will be 10 sessions per group and each session will last 1.5 hours. Meanwhile, their caregivers will attend four sessions separately and each session will last 1.5 hours.
40956891|NCT05167929|BEHAVIORAL|Leisure activity group|Leisure activity group - Leisure activity group is the comparison group. Each group will consist of eight adults with mild intellectual disability. There will be 10 sessions for the group and each session will last for 1.5 hours.
40956892|NCT06556264|DRUG|Dupilumab|Dupilumab 300mg every 2 weeks for 24 weeks
40956893|NCT06556264|OTHER|Placebo|Placebo 300mg every 2 weeks for 24 weeks
40956894|NCT02292121|PROCEDURE|Intestinal permeability|5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
40956895|NCT02292121|OTHER|a solution of mannitol and lactitol|
40956896|NCT06372301|DIAGNOSTIC_TEST|Dobutamine stress echocardiography|Patients will be investigated with dobutamine stress echocardiography (increasing doses of dobutamine infusion and simulatneous echocardiogarphic evaluation) to assess aortic valve area and projected aortic valve area.
40956897|NCT03070028|PROCEDURE|crystallised phenol|crystallised phenol will be applied to sinus cavity
40956898|NCT03070028|PROCEDURE|Platelet rich plasma|platelet rich plasma will be applied to sinus cavity
40956899|NCT06313489|PROCEDURE|Biopsy of EPL tendon and muscle during the operation|Biopsy of EPL tendon and muscle
40956900|NCT01810861|OTHER|There is no intervention in this study|This is a non-interventional study.
40956901|NCT05821400|OTHER|observational study|observational study
40956902|NCT00251784|DRUG|Sildenafil|
40956903|NCT01414660|PROCEDURE|transplantation|transplantation of islet, kidney or liver
40762898|NCT03777020|OTHER|Dog Training Education|Learn about training dogs by watching 8 weekly dog training online modules programs at the Warrior Canine Connection facility in Boyds (Montgomery County) MD. After completing this education the participants will participate in the service dog training program.
41135536|NCT03371225|DEVICE|Sham tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. Only 30 seconds of current will be applied for the sham condition.
40956904|NCT06326385|OTHER|no intervention|no intervention
40956905|NCT03398044|DRUG|Dexamethasone|Dexamethasone will be administered to patients randomised into the active treatment arm, in order to determine the influence upon PONV incidence.
40956906|NCT03398044|DRUG|Placebo|Placebo will be administered to patients randomised into the control group arm.
40956907|NCT01102517|PROCEDURE|video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery
40956908|NCT01102517|PROCEDURE|axillary thoracotomy|axillary thoracotomy lobectomy
40956909|NCT04822324|OTHER|Spencer Muscle energy technique with conventional Physiotherapy|"shoulder extension with elbow flexion. shoulder flexion with elbow extension. circumduction with compression circumduction with distraction shoulder abduction and internal rotation with elbow flexion. shoulder adduction and external rotation with elbow flexion stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.~conventional therapy Joint mobilization~Exercise therapy:~Self stretching and strengthening exercises"
41135537|NCT03371225|PROCEDURE|Sham Exercise|Participants will walk in a treadmill (as to keep at 10% within their baseline heart rate) for 30 minutes.
41135538|NCT06435481|DRUG|3D printed chewable formulation of hydrocortisone|Administration of a novel hydrocortisone formulation provided as chewable tablets. Each tablet, manufactured with a volume dosing device (3D printer), contains a precise dosage of hydrocortisone.
41135539|NCT06435481|DRUG|Oral suspension of hydrocortisone|Administration of a standard hydrocortisone oral suspension. The solution, based on simple syrup, contains 1mg of hydrocortisone per milliliter.
41135540|NCT03615833|DRUG|Cholecalciferol|Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
40762900|NCT06564857|DRUG|Remifentanil|Age \< 70 years: Bolus of 4 μg/kg Ideal Body Weight remifentanil at anaesthesia induction; Age \>= 70 years: Bolus of 2 μg/kg ideal Body Weight remifentanil at anaesthesia induction
40762901|NCT06564857|DRUG|Rocuronium|Bolus of 0.6 mg/kg Ideal Body Weight rocuronium at anaesthesia induction
40762902|NCT01424137|DEVICE|Easyhaler type A|Easyhaler type A inhaler, 3 consecutive inhalations
41292137|NCT04913324|BEHAVIORAL|Virtual Care|Infants randomized at 4 months of age to the intervention arm will participate in virtual care visits for 16 weeks in addition to standard of care in-hospital visits.
40762903|NCT01424137|DEVICE|Easyhaler type B|Easyhaler type B inhaler, 3 consecutive inhalations
40762904|NCT01424137|DEVICE|Diskus inhaler|Diskus inhaler, 3 consecutive inhalations
40762905|NCT06454188|DRUG|Upadacitinib 15 MG [Rinvoq]|15mg tablet once per day.
41292138|NCT04368130|BEHAVIORAL|SIGNAL|"SIGNAL is a smartphone-based mobile health intervention designed to improve important outcomes in cancer patient patients (e.g., symptom burden, physical functioning).~Patients will download the adapted Beiwe app for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
41292139|NCT06139380|DRUG|Ketamine|This is medication which is commonly used for sedation in the emergency department. At the analgesic dose, this medication can be used to reduce the pain via other routes such as intranasal.
40762906|NCT06454188|DRUG|Placebo|15mg tablet once per day.
40762907|NCT05050669|OTHER|No Intervention for this observational study|No Intervention for this observational study
40762908|NCT02002715|DRUG|Inhaled budesonide|inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
40762909|NCT06279182|BEHAVIORAL|Barre Stretching Intervention|The Barre stretching intervention will consist of a 15-minute recorded video session with static and isometric movements focused on the hands, wrists, shoulders, and neck combined with breathing exercises throughout each movement. A 15-minute Barre stretching video will be selected for this study because static and isometric stretching should be held for 10-15 seconds per movement and repeated 2-3 times for increasing blood flow and circulation which can improve heart rate variability (HRV), increase muscle suppleness in preparation for muscle activation through patient care, and reduce stress levels through regulation of the rate, depth, and pattern of breathing. The duration of 15-minutes provided the participants with adequate time to complete each stretching movement for a total of 45 seconds with 15 seconds rest between movements. There will be fifteen targeted stretching movements focused on the hands, wrists, shoulders, and neck region.
40762910|NCT02512939|PROCEDURE|blood test, not yet marketed, no trade name|blood test using the new TB diagnostic test
40762911|NCT03941561|DRUG|S-1 for 9 months|S-1 for 9 months after D2 resection
40762912|NCT03941561|DRUG|S-1 for 1 year|S-1 for 1 year after D2 resection
40762913|NCT00020176|BIOLOGICAL|filgrastim|
41292140|NCT06139380|DRUG|Sterile water|Intranasal sterile water was administered via syringe.
41292141|NCT04982913|DRUG|HEC116094|Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
40762914|NCT00020176|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40762915|NCT00020176|DRUG|cyclophosphamide|
40762916|NCT00020176|DRUG|cyclosporine|
40762917|NCT00020176|DRUG|fludarabine phosphate|
40762918|NCT00020176|PROCEDURE|peripheral blood stem cell transplantation|
40762919|NCT06569940|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 42 minutes.
40762920|NCT05192070|OTHER|Percussive Massage Group|Quadriceps, hamstring and gastrocnemius muscles of the participants will done massage for 3 minutes with a hypervolt massage device.
40762921|NCT05192070|OTHER|Dynamic stretching group|Dynamic stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
40762922|NCT05192070|OTHER|Static stretching group|Static stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
41292142|NCT06096194|DIETARY_SUPPLEMENT|vitamin D-enhanced egg|"In our study, the vitamin D3-enhanced eggs were produced by hens that received 23,500 IU of vitamin D3 per kg of feed. Which does not confer them any harm or danger of intoxication. This experiment was carried out at the Center for Teaching, Research and Extension in Poultry Production (CEIEPAv, FMVZ-UNAM) and lasted 40 weeks.~This ensured that the hens eggs were enhanced with vitamin D achieving a final concentration of approximately 400 IU of vitamin D"
41292143|NCT06096194|OTHER|Control|Unfortified eggs were used for the control group with a concentration of approximately 43 IU of vitamin D
40762923|NCT04742023|DEVICE|Continuous Glucose Monitor Application|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied and values interpreted by nursing.
40762924|NCT04742023|DIAGNOSTIC_TEST|Finger Stick Glucose Measurement|Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.
40762925|NCT04742023|DRUG|Insulin|Insulin will be administered.
40762926|NCT04742023|DEVICE|Continuous Glucose Monitor Placebo Applied|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied however values will not be interpreted.
40762927|NCT00742690|DRUG|terlipressin given by intravenous boluses and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
40762928|NCT00742690|DRUG|terlipressin given by continuous intravenous infusion and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
40956910|NCT04822324|OTHER|Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique|"Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess."
40956911|NCT01538511|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
40956912|NCT01538511|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
40956913|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ TNBC patients|"Standard adjuvant chemotherapy + additional chemotherapy:~* BRCA positive patients: standard adjuvant chemotherapy + olaparib~* BRCA negative patients: standard adjuvant chemotherapy + capecitabine~In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once."
40956914|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ HER2+ patients|"Standard adjuvant chemotherapy + intensive targeted therapy:~* Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP~* Adjuvant therapy patients: AC-T/TCb + HP~In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once."
40956915|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ ER+ patients|"Standard adjuvant chemotherapy + intensive endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib.~* Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib.~In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once."
41135541|NCT01668394|BEHAVIORAL|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
41135542|NCT01668394|OTHER|Control arm|Usual care. Teaching style: deductive.
40762929|NCT00892866|OTHER|Cytology Specimen Collection Procedure|Correlative studies
40762930|NCT00892866|OTHER|Laboratory Biomarker Analysis|Correlative studies
40762931|NCT05145491|PROCEDURE|Immediate Vitrectomy|Surgery to remove epiretinal membrane (ERM). Vitrectomy will be performed on eyes within 1 month of randomization
40762932|NCT05145491|PROCEDURE|Deferred Vitrectomy|"Vitrectomy may be performed only if at least one of the following criteria is met:~1. Decrease in visual acuity ≥10 letters from baseline at a single visit presumed to be from ERM~2. Decrease in visual acuity ≥5 letters from baseline at two consecutive visits presumed to be from ERM~   a. Visits must be at least one month apart~3. Participant actively requests surgery due to worsening symptoms~4. Complication requires prompt surgical intervention (e.g., macular hole, retinal detachment, non-clearing vitreous hemorrhage)"
41135543|NCT02296593|DEVICE|comparison of blood lactate and glucose levels|comparison of blood lactate and glucose levels with the reference method (co oxymetry) and a new central veinous catheter microdialysis system provided by MAQUET. (Critical Care AB, Solna, Sweden.)
40762933|NCT05886478|DRUG|No intervention|As this is an observational study, no intervention will be administered.
40762934|NCT02333292|DRUG|Telaprevir|Initiation of a regimen containing TVR
40762935|NCT02333292|DRUG|Boceprevir|Initiation of a regimen containing BOC
40762936|NCT02333292|DRUG|Sofosbuvir|Initiation of a regimen containing SOF
40762937|NCT02333292|DRUG|Simeprevir|Initiation of a regimen containing SMV
40762938|NCT02333292|DRUG|Daclatasvir|Initiation of a regimen containing DCV
40762939|NCT02333292|DRUG|Ledipasvir|Initiation of a regimen containing LDV
40762940|NCT02333292|DRUG|ritonavir-boosted Paritaprevir/ Ombitasvir|Initiation of a drug combination of PTV/OTV
40762941|NCT02333292|DRUG|Dasabuvir|Initiation of a regimen containing DBV
40762942|NCT02333292|DRUG|Velpatasvir|Initiation of a regimen containing VPV
40762943|NCT02333292|DRUG|Elbasvir|Initiation of a regimen containing EBV
40762944|NCT02333292|DRUG|Grazoprevir|Initiation of a regimen containing GZR
40762945|NCT04037137|OTHER|Questionnaire|Caregiver Difficulties Scale, Impact on Family Scale, WHOQOL-BREF Quality of Life Assessment, Nottingham Health Profile, Fatigue Severity Scale, Beck Depression Scale
40762946|NCT03847519|DRUG|ADXS-503|A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
40762947|NCT03847519|DRUG|Pembrolizumab|a programmed death receptor-1 (PD-1)- blocking antibody.
40762948|NCT04171895|OTHER|Questionnaires|Will be filled out before and after the training so investigators can evaluate the skills learned and how they can be used them in advanced care planning. Questionnaires will be available in both paper form and electronic via REDCap.
40762949|NCT04171895|OTHER|Communication training Part 1 (no longer recruiting)|1.5 hour Communication Training will be delivered through videoconferencing using the WebEx or Zoom platforms. The Training consists of a 30-minute lecture watched independently, and two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) completed as part of a virtual meeting. The lecture will be pre-recorded by Drs. Applebaum and Parker and will be sent via REDCap to ICs prior to the training to watch idependently. REDCap will log when ICs watch the lecture so that study staff know the participant has completed this aspect of the training. For the second part of the training ICs will participate in a virtual meeting for approximately 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs.
40762950|NCT04171895|OTHER|Enhanced usual care|"Participant will complete a survey on distress and receive feedback about distress and given a resource packet with support information and targeted referrals based on needs. The participant will also receive a physical or electronic copy of a book entitled Cancer Caregiving A to Z published by the American Cancer Society. At the conclusion of their participation in the study, EUC participants will be given access to the pre-training video and Advanced Care Planning forms sent to Communication Training participants."
40762951|NCT04171895|OTHER|Communication training Part II|Part II The communication training developed in Part 1 will have two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) and consist of a 20-30 minute lecture and 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs. Realistic scenarios were created and tailored according to ICs' reported concerns. After training, ICs will be coached through setting a SMART goal related to conducting ACP conversations, which emphasize Specific, Measurable, Attainable, Relevant and Time-bound steps that motivate and direct behavior change. Two weeks post training, a booster phone call will be made to ICs to check progress toward their SMART goal, address barriers with problem-solving and review skills as indicated.
40956916|NCT05345860|OTHER|The MRD strategy for low risk and MRD- TNBC patients|"Standard adjuvant chemotherapy: AC-T/TC/TCb/AC.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in The MRD strategy for high risk or MRD+ TNBC patients will be added for at most twice."
41292144|NCT01690234|PROCEDURE|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
40762952|NCT06020079|OTHER|laughter yoga|"According to the literature and the training received on laughter yoga, the time required for the treatment of depression is 50 minutes. The first 10 minutes includes relaxation, stretching and warm-up exercises. The next 30 minutes includes laughing exercises, and finally, the last 10 minutes includes relaxation exercises.~Steps of laughter yoga sessions:~1. Clapping hands and warm-up exercises: Participants clap their hands, fingers and palms. Then, sounds like ho-ho and ha-ha are added to the clapping exercises along with the rhythm.~2. Deep breathing exercises: Breathing exercises should be repeated 3-4 times while standing~3. Childlike games: Arms are raised, imitating the funny and clumsy behavior of a child.~4. Laughter exercises: The researcher names the exercise, explains how to do it, and the group performs the exercise together.~Dance and Relaxation"
40762953|NCT00666042|DRUG|Vigamox - administration in spray form|Vigamox will be administered in a spray form
40762954|NCT00666042|DRUG|Vigamox eye drops|Vigamox eye drops
40762955|NCT04098146|PROCEDURE|Surgical Resection and Reconstruction|"One stage reconstruction: Osseous reconstruction is performed in the same surgery of the tumor/mandibular resection. It is also known as immediate or primary reconstruction.~Second stage reconstruction: Osseous reconstruction is performed after the tumor/mandibular resection surgery as an independent surgery. After the mandibular resection a temporary alloplastic bridging might be put in place. It is also known as delayed or secondary reconstruction."
40762956|NCT06502418|OTHER|Acupuncture therapy|7 acupuncture points will be used to managed pain and improved patient's experience
40762957|NCT03975946|PROCEDURE|Rheopheresis procedure|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
40762958|NCT03975946|BIOLOGICAL|Blood Sample|Biological analysis
40762959|NCT03975946|PROCEDURE|Shamapheresis procedure|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
40762960|NCT06638255|OTHER|Sequence A involves administering Low PEEP for 12 hours, followed by High PEEP for 12 hours.|"Patients will first receive the Low PEEP protocol for 12 hours, followed by the High PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies.~Description: Patients will first receive the High or LOW PEEP protocol for 12 hours, followed by the Low or HIGH PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies."
41292145|NCT01690234|PROCEDURE|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
40762961|NCT06638255|OTHER|Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.|Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.
40762962|NCT06570174|DIETARY_SUPPLEMENT|oral protein supplements|Participants in this group received an oral protein supplement providing 18g of protein per day. The supplement was administered postoperatively and continued throughout the study period. The goal was to assess the impact of protein supplementation on protein intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed. These outcomes were measured at three specific time points: before surgery, at discharge, and during the outpatient visit.
40762963|NCT06570174|GENETIC|placebo|Participants in this group received a placebo supplement containing carbohydrates instead of protein, which was identical in appearance and taste to the protein supplement to maintain the study's double-blind design. The placebo was administered postoperatively and continued throughout the study period. The aim was to serve as a control to evaluate the effects of the protein supplement on outcomes including nutrient intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed, measured at three key time points: before surgery, at discharge, and during the outpatient visit.
40762964|NCT04874597|DRUG|Ocrelizumab|Ocrelizumab treatment will be administered in accordance with the product characteristics approved in Turkey.
40762965|NCT02565394|OTHER|Micro Break with Dynamic Exercise Activities|Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
40762966|NCT05246839|BEHAVIORAL|Brief Video|Videos about colorectal cancer screening.
40762967|NCT05246839|BEHAVIORAL|Brief Video Plus|Videos about colorectal cancer screening and modalities.
40762968|NCT04073420|DEVICE|Surgical Heart Valve Repair Products|Surgical heart valve repair products.
40762969|NCT04073420|DEVICE|Surgical Heart Valve Replacement Products|Surgical heart valve replacement products.
40762970|NCT06371378|PROCEDURE|PEEP 0|PEEP 0 CMH20 will be used During Surgery
40762971|NCT06371378|PROCEDURE|PEEP 4|PEEP 4 CMH20 will be used During Surgery
40762972|NCT06371378|PROCEDURE|PEEP 8|PEEP 8 CMH20 will be used During Surgery
40762973|NCT05176665|DRUG|EMB-01|EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).
40762974|NCT06529237|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
40762975|NCT06529237|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|Routine malaria rapid diagnostic tests
40762976|NCT06641960|DRUG|Probiotics|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction with probiotic lozenges.
40762977|NCT06641960|PROCEDURE|Traditional treatment|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction without probiotic lozenges.
40762978|NCT06637514|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
40762979|NCT06637514|OTHER|Placebo|Placebo Tablet: BID
40762980|NCT06637514|DRUG|JNT-517 Tablet|JNT-517: 150 mg BID
40762981|NCT06132659|OTHER|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with the real neurofeedback. Visit 4 will take place one month after visit 3 and will include a follow-up interview with a trainer assessor as well as questionnaires. Additionally, 2 weeks after visit 3 participants will also complete some questionnaires online.
40956917|NCT05345860|OTHER|The MRD strategy for low risk and MRD- HER2+ patients|"Standard adjuvant chemotherapy + standard targeted therapy:~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H.~* Adjuvant therapy patients: AC-T/TC/TCb/wP + H.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in The MRD strategy for high risk or MRD+ HER2+ patients will be added for at most twice."
40762982|NCT06132659|OTHER|fMRI with Sham-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with feedback that looks similar to real neurofeedback, but is computer generated. Visit 4 will take place 2 weeks after visit 3 and participants will complete more questionnaires.
40762983|NCT02082977|DRUG|GSK2816126|GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
40762984|NCT06637748|PROCEDURE|Echocardiography|"Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening)"
40762985|NCT06637748|PROCEDURE|Electrocardiography|"Standard 12-lead ECG recording~• Parameters assessed:~* Heart rate and rhythm~* P-wave morphology~* PR interval~* QRS complex duration and morphology~* ST-segment changes~* T-wave abnormalities~* QT interval"
41292146|NCT01464697|DRUG|Oral micronized progesterone|300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
40956918|NCT05345860|OTHER|The MRD strategy for low risk and MRD- ER+ patients|"Standard adjuvant chemotherapy + standard endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR.~* Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in The MRD strategy for high risk or MRD+ ER+ patients will be added for at most twice."
40956919|NCT03949972|OTHER|Biosampling|Biosampling at initial visit and follow-up visits
40762986|NCT04583553|DIAGNOSTIC_TEST|Vikor Scientific Urine-IDTM|Urine samples will be collected for both standard laboratory culture at KUMC Lab and expedited delivery to Vikor Scientific Lab for Urine-IDTM analysis. Vikor Scientific will cover all costs associated with sample delivery. If insufficient urine volume is collected for both standard laboratory culture at KUMC Lab and Vikor Scientific Urine-IDTM, urine will be preferentially used for standard laboratory culture at KUMC Lab.
40762987|NCT06207019|DEVICE|Hyflex EDM , The XP-endo Shaper, Primary WaveOne Gold|rotary single files
40762988|NCT04204915|PROCEDURE|Aortic valve replacement|Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.
40762989|NCT05938283|DEVICE|Implantable Cardioverter Defibrillator implant|ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation
40956920|NCT03180073|DIAGNOSTIC_TEST|Ziopatch Pre discharge|Ziopatch applied 2 weeks prior to procedure
40956921|NCT03180073|DIAGNOSTIC_TEST|Ziopatch at Discharge|Ziopatch applied at discharge from hospital to be worn for 2 weeks
40956922|NCT03180073|DIAGNOSTIC_TEST|Ziopatch at 2 months|Ziopatch applied 2 months from procedure to be worn for 2 weeks
40762990|NCT03249649|BEHAVIORAL|Comprehensive Healthcare Needs Assessment|Questionnaire focused on existing healthcare communication, treatment and services plus community needs in those three areas.
40762991|NCT06643013|DRUG|XBD173|4 weeks treatment
40762992|NCT06645158|DEVICE|Transcutaneous bilirubin level monitoring|self-monitoring by parents long-term: from birth to 30 days of age
41292147|NCT01464697|DRUG|placebo|placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
40762993|NCT06642649|PROCEDURE|General Anesthesia (control group)|Only General Anestesia
40762994|NCT06642649|PROCEDURE|General Anesthesia + Spinal anesthesia combined|General anesthesia + spinal anesthesia with local anesthetic and morfine
40762995|NCT06642649|PROCEDURE|General Anesthesia + Spinal anesthesia combined|General anesthesia + spinal anesthesia with local anesthetic, morfine and fentanyl
40762996|NCT03284385|DRUG|Adavosertib|Given PO
40762997|NCT03660449|COMBINATION_PRODUCT|Moderately hypofractionated conformal radiation combined With S-1|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
40956923|NCT04493073|PROCEDURE|Trabectulectomy|decrease IOP
40762998|NCT06488833|BEHAVIORAL|Komtü Programme (Komtü)|"Mainly, 4 actions will take place:~* Training with reflective practice exercises. This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~* Healing spaces to generate a collective restorative experience, offering tools that facilitate emotional management~* Individual support for teachers to offer them resources, tools, and intervention strategies to help improve educational practice and the emotional and relational well-being of the school community~* Coaching for the school management team to help them establish some objectives together and offer them the necessary resources and tools so that they can achieve them successfully."
40956924|NCT04493073|DRUG|Mitomycin|Decrease bleb failure
40956925|NCT04493073|DEVICE|Ologen Collagen Implant|Ologen Collagen Implant (Aeon Astron Europe, Netherlands)
40956926|NCT04493073|DEVICE|Mitomycin-C Kyowa®|Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)
40956927|NCT01995110|OTHER|high-fat meal A|
40956928|NCT01995110|OTHER|high-fat meal B|
41135544|NCT04976829|DEVICE|Antibiotic stewardship and healthcare-associated infections surveillance assisted by computer|Implementation - in our tertiary care university hospital - of a computerized-decision support system (CDSS) facilitating antibiotic stewardship and of an electronic surveillance software (ESS) facilitating infection prevention and control activities
40956929|NCT01995110|OTHER|high-fat meal C|
41292148|NCT06242340|OTHER|Preterm group bathing 24 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
40762999|NCT06488833|BEHAVIORAL|Komtü Training and Reflective Practice|"This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~No other actions will take place in this group."
41135545|NCT00310609|DRUG|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
40763000|NCT01946880|DRUG|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
41292149|NCT06242340|OTHER|Preterm group bathing 48 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
40956930|NCT01785264|PROCEDURE|Non-operative treatment|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none. Patients randomized to non-operative treatment will have a cast applied within 3 days from injury.
40956931|NCT01785264|PROCEDURE|Open surgery|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
40763001|NCT01946880|DRUG|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
40763002|NCT01946880|DRUG|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
40763003|NCT06272487|DRUG|Zilebesiran|Zilebesiran administered by subcutaneous (SC) injection
40956932|NCT01785264|PROCEDURE|Mini-invasive surgery|"We will use the technique developed by Dr. Amlang and Professor Zwipp from Dresden, Germany. They have developed a protocol of mini-invasive surgery using specially adapted proprietary instruments.~All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none."
40763004|NCT06272487|DRUG|Placebo|Placebo administered by SC injection
40763005|NCT06191198|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
40763006|NCT06191198|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
40763007|NCT06640426|BEHAVIORAL|Two Messaging Nudges|This intervention involves receiving one personalized email and one personalized text message, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
40763008|NCT06640426|BEHAVIORAL|Five messaging nudges|This intervention involves patients receiving up to five personalized email and text messages, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
40763009|NCT06638268|PROCEDURE|Acute TAVI|TAVI must be performed as soon as possible and within 12 hours of admission to the heart center.
40763010|NCT06638268|OTHER|Stabilization and subacute TAVI|Patients are stabilized according to target parameters. Treatment may include vasopressor, mechanical ventilation, renal replacement therapy, and blood transfusion. TAVI is then performed no earlier than 72 hours of admission to heart center.
40763011|NCT06642467|DEVICE|BGEM|BGEM is an ai driven model to predict blood glucose using ppg sensor
40763012|NCT04396574|DRUG|Lasmiditan|Administered orally
40956933|NCT03221270|DEVICE|tACS treatment week|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 20 minutes twice for 5 consecutive days.
40763013|NCT05777863|BEHAVIORAL|Multidomain lifestyle intervention|A multidomain lifestyle intervention including the following lifestyle domains: (1) diet, (2) physical activity, (3) sleep, (4) stress/mindfulness, and (5) cognitive training.
40763014|NCT06641622|DIAGNOSTIC_TEST|Prediction of delayed graft function|Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence
40763015|NCT06145711|OTHER|hiPSC-DAP|Using hiPSC-DAP for the treatment of the patients of Parkinson's diease
40763016|NCT05996185|DRUG|Mogamulizumab|Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.
40763017|NCT05996185|DRUG|DA-EPOCH Protocol|EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
40956934|NCT03221270|DEVICE|tACS sham week|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds twice a day for 5 consecutive days.
40956935|NCT03221270|DEVICE|Maintenance tACS|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes once a weekly for 8 weeks.
40956936|NCT03221270|DEVICE|Maintenance Sham tACS|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds once a week for 8 weeks.
40763020|NCT06642090|BEHAVIORAL|Educational intervention for patients undergoing hemodialysis in Morocco|This is the first educational intervention in Morocco to improve the knowledge, self-care, and biological characteristics of patients undergoing hemodialysis.
40763021|NCT06638918|DEVICE|Virtual Reality|The virtual reality (VR) intervention administers graded motor imagery (GMI) treatment for phantom limb pain. It consists of three stages: left right sorting task (a sorting task where participants sort images of left and right feet), explicit motor imagery (a series of guided imagery exercises administered via audio to facilitate focus on the phantom limb), and the limb simulation task (where participants perform a series of exercises with virtual legs to create the illusion of movement in their phantom limb). The limb simulation stage can also be conducted with leg trackers to generate a higher degree of illusion in the virtual legs.
40763022|NCT02059499|DRUG|imiquimod|Given intra-anally
40763023|NCT02059499|DRUG|fluorouracil|Given intra-anally
40763024|NCT02059499|OTHER|questionnaire administration|Ancillary studies
40763025|NCT02059499|OTHER|laboratory biomarker analysis|Correlative studies
40763026|NCT01653314|DRUG|Megavec|
40763027|NCT01653314|DRUG|Glivec|
41292150|NCT06242340|OTHER|Early term group bathing 24 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
40763028|NCT04813120|BEHAVIORAL|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|For the UM-UT group, the participants will be seated in front of the new MT system, and will be instructed to watch the real-time image reflection of movements of the non-affected arm and hand on the screen carefully. At the same time, the patients will need to imagine that the movements were performed by their affected arm and hand. In this group, only the non-affected arm and hand will need to perform the movements, but the affected one will not need to move.
40763029|NCT04813120|BEHAVIORAL|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|During the UM-BT, as similar as the first group (UM-UT), the participants will be also seated in front of the new MT system, and be instructed to watch the real-time image reflection of the non-affected arm and hand's movements on the screen carefully and imagine that the movements were performed by the affected arm. However, in this UM-BT group, the bilateral training mode is emphasized, and thus both arms and hands will need to move. That is, during therapy, the patient's affected arm and hand will be required to move at his/her best motor ability with the non-affected arm and hand at the same time.
40763030|NCT04813120|BEHAVIORAL|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|For the BM-BT group, the participants will be seated in front of this new MT system, and be instructed to observe the real-time image reflection of the non-affected arm and hand's movements transformed and superimposed on both arms and hands (i.e., bi-MVF), and to imagine that the movements were performed by both arms and hands. In this group, bi-MVF and bilateral training mode are emphasized, and thus both arms and hands will also need to move. The patient's affected arm and hand will be required to move as could as possible simultaneously.
40956937|NCT01435278|DEVICE|Glucosanol|2 tablets taken 3 times a day.
40956938|NCT02921542|DEVICE|Laser Atherectomy|The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
40956939|NCT00006111|DRUG|cisplatin|
40956940|NCT00006111|DRUG|fluorouracil|
41135546|NCT04335474|PROCEDURE|Surgical drainage strategy|A laparotomy is performed and the operative approach to pancreatic trauma can consist of laparotomy with drainage of the peripancreatic area, distal pancreatectomy with or without preservation of the spleen, Rouxen-Y pancreaticojejunostomy, and, more seldom, pancreaticoduodenectomy. The type of operation depends on the grade of the pancreatic lesion. Spleen-preserving surgery will be attempted to avoid the lifelong increased risk of infections after splenectomy. In case of trauma where multiple organs are involved and an acute laparotomy is performed, the damage control surgery must be applied and the pancreatic resection will be done as part of a staged surgery.
41292151|NCT06242340|OTHER|Early term group bathing 48 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
41455526|NCT03821974|PROCEDURE|wet suction technique|"For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
41455527|NCT03821974|PROCEDURE|dry suction technique|"For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
40763031|NCT04813120|BEHAVIORAL|Traditional MT using a mirror box|During traditional MT, the participants will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm and hand of the participants will be placed inside the mirror box, and the non-affected arm and hand will be in front of the mirror. As similar to the UM-UT group, the participants will be instructed to watch the mirror reflection of the movements performed by the non-affected arm and hand carefully and to imagine that the movements were performed by the aﬀected arm and hand. In this group, the patient's affected arm and hand inside the mirror box will not need to move.
41455528|NCT00349765|BEHAVIORAL|higher fat, high polyunsaturated fat diet|
41455529|NCT00349765|BEHAVIORAL|higher fat, high saturated and trans fat diet|
41455530|NCT00349765|BEHAVIORAL|lower fat diet|
40956941|NCT00006111|PROCEDURE|conventional surgery|
40956942|NCT00006111|RADIATION|radiation therapy|
41455531|NCT01476904|DRUG|Placebo|0 mcg/inhalation, 2 inhalations QID
41455532|NCT01476904|DRUG|Primatene Mist|220 mcg/inhalation, 2 inhalations QID
41455533|NCT01476904|DRUG|Epinephrine inhalation|125 mcg/inhalation, 2 inhalations QID
40956943|NCT00799422|DEVICE|Complete Easy Rub|Commercially marketed contact lens solution for contact lens care
40956944|NCT00799422|DEVICE|ReNu MultiPlus|Commercially marketed contact lens solution for contact lens care
41135547|NCT04335474|PROCEDURE|Percutaneous drainage strategy|The nonoperative management consists of close monitoring of the patient's clinical condition; repeated radiological investigations such as CT, ultrasound, and MRCP; monitoring of the amylase and lipase levels, initiation of post-pyloric enteral nutrition and parenteral nutrition. In addition, ERCP with the placement of a stent in the damaged pancreatic duct is used as part of the non-operative approach. Besides, percutaneous catheter drainage (PCD) management including ultrasound or CT-guided drainage of abdominal and peripancreatic fluid collections and pancreatic pseudocysts is applied to the HGPT patient.
41135548|NCT03015220|DRUG|Semaglutide|Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).
41135549|NCT03015220|DRUG|Dulaglutide|Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).
41135550|NCT02867982|PROCEDURE|Subcrestal implant placement|Dental implants placed 2 mm below the alveolar ridge
40956945|NCT00799422|DEVICE|Clear Care|Commercially marketed contact lens solution for contact lens care
41135551|NCT02867982|PROCEDURE|Paracrestal implant placement|Dental implants placed flush to the alveolar ridge
41135552|NCT02867982|DRUG|prophylactic antibiotics|amoxicillin was used before and after implant surgery for prophylactic reasons
41135553|NCT02867982|DEVICE|dental implant|dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
41135554|NCT02867982|RADIATION|x-ray examination|radiographies were taken before treatment and at different time point during the follow-up period
41292152|NCT02584621|BEHAVIORAL|Check Yourself App with Feedback|
41292153|NCT01210950|BIOLOGICAL|cell and RPR injection|mesenchymal cells and Plasma reach Protein are injected to the callus center
40763032|NCT06641258|OTHER|Control Group (Standard Procedure)|"Application in Control Group: After the theoretical lesson, the nurses in the control group determined and classified the pressure injuries in their patients using the  Braden Risk Assessment Scale, which has been accepted as valid and reliable. The nurses in the control group, who determined the pressure injuries using the scale, were given training on the determination and classification of pressure injuries using written material, the content of which was prepared by the researchers. After the training, the Satisfaction with the Training Method Survey was applied to the nurses. One week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied. After the completion of the application, volunteer nurses from the control group were subjected to pressure injury detection and classification with the deep learning model and trained with the mobile application."
40956946|NCT00799422|DEVICE|Contact lenses|Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
41292154|NCT03177876|PROCEDURE|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles with simultaneous implant placement
41292155|NCT03177876|PROCEDURE|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
41292156|NCT06337370|BEHAVIORAL|Chronic Disease Self Management Program|"CDSMP is a group-based chronic disease self-management education intervention comprised of 2.5-hour sessions, including time for a break and snack. The maximum number of participants per session ranges from 12 to 16. In total the program consists of 6 sessions that take place once a week for a total duration of 6 weeks. The development of each of the sessions is standardized and scripted; two group leaders previously trained by a Master Trainer, who in turn was trained to train leaders with Stanford University, guide the sessions. In the case of the present study, the main researcher and a nursing professional with experience in health education will receive the training from a Master Trainer of the program. Participants receive the book Taking Control of Your Health at the beginning of the program."
41292157|NCT06337370|BEHAVIORAL|Conventional Care Group|"The conventional intervention consists of education provided by the nursing staff when the patient is admitted to the RA Clinical Care Center (C3AR); patients receive a pharmacological and allergy reconciliation form; the C3AR care pathway; an educational pamphlet and a disease diary. The education provided is oriented to the disease, pharmacological treatment, adherence, healthy lifestyles and guidance on administrative procedures. Group educational sessions are held twice a year with patients, family members and caregivers.~Follow-up is carried out either in person, virtually or by telephone to strengthen tools, agree on self-care goals, promote healthy lifestyles, improve adherence and mitigate risks related to the disease and its management at home."
41292158|NCT03741439|DEVICE|Treatment|Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter
41292159|NCT03741439|DEVICE|Sham|Sham treatment
41292160|NCT02117050|DRUG|Rebif®|Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
41292161|NCT05196932|DEVICE|Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies|"A drop of blood obtained by both finger-prick and venipuncture will be placed on the test card, which has been activated by the addition of diluent. Visual clumping of red blood cells (RBCs) will be seen within minutes if SARS-CoV-2 antibodies are present. Additionally, the COVID card is semi-quantitative, meaning that the yielded hemagglutination pattern will correlate with the concentration of antibodies in the serum.~A research team member will be present at bedside to provide their interpretation based on an established visual agglutination scoring system."
41455534|NCT04121533|DIETARY_SUPPLEMENT|Placebo|Placebo supplement for vitamin D (cholecalciferol), glucosamine sulfate, and omega-3 fatty acids. Supplement was taken orally every day for 84-days.
40763033|NCT06641258|OTHER|Experimental Group|"Application in the Experimental Group: After the theoretical course, the nurses in the experimental group detected and classified pressure injuries in their patients with the Deep Learning Model. In the experimental group, a mobile application developed by the researchers was installed on the phones of the nurses who detected pressure injuries using the deep learning model and training was applied. Thus, the nurses were provided with the patient's care and treatment according to the developed mobile application according to the pressure injury stage detected by the deep learning model. After the training, the Satisfaction Survey with the Training Method was applied to the nurses. 1 week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied"
40763034|NCT04826341|DRUG|Berzosertib|Berzosertib will be supplied as 20 mg/mL M6620 to be diluted with 5% dextrose in water solution before intravenous infusion.
40763035|NCT04826341|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles.
41455535|NCT04121533|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Vitamin D (cholecalciferol). Supplement was taken orally every day for 84-days.
40763036|NCT06637501|DRUG|Sonrotoclax|Administered orally
40763037|NCT06637501|DRUG|Zanubrutinib|Administered orally
40763038|NCT06464913|RADIATION|With or without chest wall RT|Supraclavicular and infraclavicular lymphatic drainage area radiotherapy with or without chest wall RT
40763039|NCT05142319|BIOLOGICAL|Homologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
40763040|NCT05142319|BIOLOGICAL|Heterologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
41455536|NCT04121533|DIETARY_SUPPLEMENT|Glucosamine sulfate and omega-3 fatty acids|Glucosamine sulfate and omega-3 fatty acids supplement was taken orally every day for 84-days.
41455537|NCT03431636|OTHER|immersion|cold water immersion
41455538|NCT03431636|OTHER|ice pack|ice packs through the body
40956947|NCT05520112|BIOLOGICAL|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction
40763041|NCT05142319|BIOLOGICAL|COVAXIN|Single intradermal injection at 6ug (0.5ml) per dose.
40763042|NCT05142319|BIOLOGICAL|Nuvaxovid|Single intradermal injection at 5mcg (0.5mL) per dose.
40763043|NCT05454982|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
40956948|NCT05520112|OTHER|Standard treatment according to the clinical protocols|Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
40956949|NCT05293743|DEVICE|Foot abduction bracing for clubfoot with novel dynamic bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares the standard straight bar in a foot abduction brace to our novel dynamic bar. This group uses the novel bar.
40956950|NCT05293743|DEVICE|Foot abduction bracing for clubfoot with standard straight bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares the standard straight bar in a foot abduction brace to our novel dynamic bar. This group uses the standard bar.
40956951|NCT03046758|DRUG|A combination of fosfomycin, metronidazole and GM-CSF i.p.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed.
40956952|NCT05123170|DRUG|Dexmedetomidine Injectable Solution [Dexdomitor]|two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries
40956953|NCT05123170|DRUG|Lidocaine IV|Intravenous regional anaesthesia
40956954|NCT05624281|DRUG|nintedanib|nintedanib, for patients with fibrosing interstitial lung disease (ILD); in this EAP limited to children and adolescents
40956955|NCT01778972|OTHER|Otago home exercise programme|"Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
41455539|NCT03431636|OTHER|rest|seated rest
40763044|NCT06636903|OTHER|Acupressure|Before pressing directly on the point for acupressure, a gentle warming, relaxing and preparatory process of approximately 15 seconds should be performed on the point area. In this case, manual pressure with the thumb, index finger and/or middle finger will be applied sequentially (in the rhythm of breathing) without lifting the finger for an average of 1.5 minutes on each point, at a frequency that does not disturb the person, does not cause pain and has a calming effect. Before the suturing procedure, acupressure will be applied to the HT7 and Li4 points by a researcher (EB) who has an acupressure certificate.
40763045|NCT06636903|OTHER|Acupressure|Before and after acupressure, vital signs and before acupressure, anxiety scores will be checked using the Spielger State Anxiety Scale. In addition, vital signs and anxiety scores will be checked again immediately after the stitching procedure.
40763046|NCT01660373|DRUG|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
40763047|NCT01660373|DRUG|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
40956956|NCT01778972|OTHER|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
40956957|NCT01790932|DRUG|BKM120|
40956958|NCT00069940|BIOLOGICAL|sargramostim|
40763048|NCT03380273|BEHAVIORAL|Implementation of the AO Trauma SSI Prevention Bundle|"AOT SSI Prevention Bundle~Preventive measure~1. Antibiotic prophylaxis~2. Perioperative antibiotics~3. Oxygen administration~4. Patient temperature~5. Surgeon protective wear~6. Patient operative skin preparation~7. Suction drains~8. Blood glucose level~9. Red cell transfusion~10. Dressing changes"
40956959|NCT00069940|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
40956960|NCT03805399|DRUG|Pyrotinib with Capecitabine|If patients were LAR subtype with HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)
40956961|NCT03805399|DRUG|AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)|B1: if patients were LAR subtype without HER2 gene activated mutation, but had PI3KCA mutation, she would receive everolimus 10mg qd combined with AR inhibitor SHR3680 240mg qd continuously ; B2: if patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with CDK4/6 inhibitor SHR6390 150mg qd (three week on one week off); B4: If patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with EZH2 inhibitor SHR2554 300mg bid continuously
40956962|NCT03805399|DRUG|anti PD-1 with nab-paclitaxel|If patients were IM subtype, she will receive PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw (three week on one week off).
40956963|NCT03805399|DRUG|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation, she will receive PARP inhibitor SHR3162 150mg bid and famitinib 20mg qd continuously .
40956964|NCT03805399|DRUG|BLIS with anti-VEGFR included therapy|"If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation , she will receive:~E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off); E3: famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off); E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w"
41292162|NCT05701852|OTHER|reward learning task|during usual follow-up patients will complete a remard learning task questionnaire. This questionnaire cannot be assimilated to a clinical intervention.
40956965|NCT03805399|DRUG|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation,she will receive famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off).
40956966|NCT03805399|DRUG|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation, she will receive mTOR inhibitor 10mg qd continuously combined with nab-paclitaxel 100mg qw (three week on one week off).
41292163|NCT05886192|DRUG|norepinephrine+vasopressin|Norepinephrine combined with vasopressin to maintain blood pressure
41292164|NCT05886192|DRUG|Norepinephrine|norepinephrine
40956967|NCT04751565|OTHER|Bleeding on Probing change reduction following peri-implant mucositis non surgical therapy|Statistically significant different in terms of Bleeding on Probing will be recorded between groups.
40956968|NCT04210596|PROCEDURE|Soft tissue augmentation at the buccal aspect of single implants|Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.
40956969|NCT02336373|DRUG|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
40956970|NCT03928496|DRUG|AbobotulinumtoxinA|Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck
40956971|NCT03928496|DRUG|Normal saline|Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck
41292165|NCT02983903|PROCEDURE|transbronchial biopsy|
41292166|NCT05537363|OTHER|Health education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.
41292167|NCT05537363|OTHER|Multicomponent training|Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
41292168|NCT05537363|OTHER|Agility training|The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
41292169|NCT00003995|BIOLOGICAL|trastuzumab|
41292170|NCT00003995|DRUG|irinotecan hydrochloride|
41292171|NCT00985452|OTHER|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
41292172|NCT00985452|OTHER|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
41292173|NCT00790296|DRUG|Thyrotropin releasing hormone (TRH)|0.5mg and 1.5mg
41292174|NCT00790296|DRUG|Placebo|Saline
41292175|NCT00517686|OTHER|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
40956972|NCT03172442|DEVICE|Vacuum plate|Vacuum plate with two hooks between lateral incisor and canine in each side will be applied on the lower arch.
40956973|NCT03172442|DEVICE|Rapid maxillary expander|Rapid maxillary expander will be applied in the maxilla to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
40956974|NCT03172442|DEVICE|Class III elastics|Class III elastic traction from upper first molar to the hook in both side will be applied.
40956975|NCT01626430|DIETARY_SUPPLEMENT|Gamma delta TRF|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
41292176|NCT00336193|BEHAVIORAL|Home visitation|Home visitation to improve maternal health and well-being and parenting practices
41292177|NCT04689646|BEHAVIORAL|Mind Body Intervention 1|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
41292178|NCT04689646|BEHAVIORAL|Mind body intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
41292179|NCT00935233|GENETIC|DNA analysis|
41292180|NCT00935233|GENETIC|polymorphism analysis|
41292181|NCT00935233|GENETIC|protein analysis|
41292182|NCT00935233|OTHER|laboratory biomarker analysis|
41292183|NCT00935233|OTHER|questionnaire administration|
41292184|NCT00935233|OTHER|survey administration|
41292185|NCT05859620|OTHER|Patient assessment and follow-up|There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.
41292186|NCT04641546|PROCEDURE|Therapeutic Exercise|Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.
41292187|NCT04641546|PROCEDURE|Occupation-Based Intervention|Collecting and placing items in cabinets, washing windows and tables, and hanging clothes on a clothesline.
41292188|NCT03667651|DRUG|EpiCeram|Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
41292189|NCT06508996|DIAGNOSTIC_TEST|Xpert HCV|Detection of HCV RNA by Xpert HCV test
40956976|NCT01626430|DIETARY_SUPPLEMENT|Placebo|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
40956977|NCT03294759|OTHER|Bio ACL|Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex
40956978|NCT03294759|OTHER|Control|Normal ACL reconstruction technique with either patella or hamstring autograft
40956979|NCT01483300|DRUG|lobaplatin|Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks
40956980|NCT01483300|DRUG|cisplatin|Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
41292190|NCT02991950|DRUG|Parnaparin Sodium|Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
41292191|NCT00997412|DRUG|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
41292192|NCT00997412|DRUG|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
41292193|NCT04332692|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
41292194|NCT04332692|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
41292195|NCT04332692|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital
41292196|NCT04332692|PROCEDURE|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital
41292197|NCT04332692|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
41292198|NCT04036058|OTHER|Universal gloving|The intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing universal gloving (non-sterile gloves) for all patient contacts in the units that are randomized to receive the intervention. If a patient in the intervention unit is known to have CDI or a multidrug-resistant organisms, both gowns and gloves will be used as is currently recommended. Signage denoting what type of precautions are needed will be utilized.
41292199|NCT03264638|DRUG|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
41292200|NCT03264638|DRUG|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
40763049|NCT06570525|BEHAVIORAL|NurseNET|"Nurse-Delivered Narrative Exposure Therapy (NurseNET). Narrative Exposure Therapy (NET) is a brief, low-cost, trauma-focused treatment modality that is effective in treating mobile populations with complex PTSD. In NurseNET, NET is facilitated by a clinically experienced nurse, while peers/program support specialists offer scaffolded support, fostering trust, engagement, and retention. NurseNET begins with administration of a diagnostic battery and psychoeducation. Then, in subsequent NurseNET sessions, using gradual imaginative exposure, the nurse guides the participant to verbally express and re-frame their personal trauma narratives to shift unhelpful beliefs/symptoms around trauma. NurseNET utilizes a racism-conscious approach to create relational spaces in which narratives of WEH are positioned to challenge dominant social narratives. Each NurseNET session offers a brief soulfulness-based stress reduction activity to prompt emotional/affective grounding."
40763050|NCT06570525|OTHER|PAL|"Peer Active Listening (PAL). In the PAL active comparator/control, peers/program support specialists meet individually with participants in active listening sessions, along the same visit sequence as NurseNET. During PAL sessions, peers/program support specialists allow participants to set each conversational agenda while practicing the tenets of active listening, including attending to body language, paraphrasing the participant's verbal expressions, reflecting feelings, and using tactful repetition. PAL sessions are not intended to center on topics of trauma, but rather designed to offer a supportive relationship (attentional control)."
40763051|NCT05793502|DEVICE|Solia S and Selectra 3D Developed by BIOTRONIK|LBBaP with Solia S and Selectra 3D Developed by BIOTRONIK
40763052|NCT06505395|DRUG|SYHX2008 injection|The patients will accept SYHX2008 injection by subcutaneous administration every cycle.
40763053|NCT06505395|DRUG|Sandostatin LAR@|The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.
40763054|NCT05144737|BEHAVIORAL|The Diabetes Prevention Program|The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.
40763055|NCT06640348|OTHER|No intervention|No intervention
40763056|NCT06077773|DRUG|Oral EP262|Once daily
40763057|NCT06077773|DRUG|Placebo|Once daily
41292201|NCT03264638|DRUG|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
41292202|NCT01176851|DRUG|Glycopyrrolate|Single administration of Glyco pMDI 100 µg
41292203|NCT01176851|DRUG|Glycopyrrolate|Single administration of Glyco pMDI 100 µg after charcoal ingestion
41292204|NCT01176851|DRUG|Glycopyrrolate|Single intravenous injection of glycopyrrolate 100 µg
40956981|NCT02420522|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
40956982|NCT02420522|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
40956983|NCT03209531|BEHAVIORAL|Operant Conditioning|Active encouragement and feedback to increase motor evoked response when stimulated.
40956984|NCT03209531|BEHAVIORAL|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
40956985|NCT03209531|DEVICE|Single Pulse Transcranial Magnetic Stimulation|Transcranial magnetic stimulation to elicit a motor evoked response from the quadriceps muscles.
40956986|NCT02176343|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
40956987|NCT03605589|DRUG|Blinatumomab|Continuous IV infusion
40956988|NCT03605589|DRUG|Pembrolizumab|IV infusion
40956989|NCT05473507|DIAGNOSTIC_TEST|Digital Dermoscopy|Digital Dermoscopy will be performed every 3 months.
40956990|NCT05473507|DIAGNOSTIC_TEST|Reflectance confocal microscopy (RCM)|Reflectance confocal microscopy (RCM) will be performed every 3 months.
40956991|NCT05473507|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) will be performed every 3 months.
40956992|NCT05473507|DIAGNOSTIC_TEST|Dermtech tape-stripping|Dermtech tape-stripping for genetic analysiswill be performed every 6 months.
41292205|NCT05385705|DRUG|Cyclophosphamide|Cyclophosphamide at a single dose of 600mg/m2 IV between days -5 and -3 before NK cell infusion for preconditioning the tumoral microenvironment by reducing the levels of lymphocyte T regulators (Tregs FOXP3+, CD3+, CD4+, CD25+).
41292206|NCT05385705|DRUG|Trastuzumab|Trastuzumab at a dose of 8mg/kg IV for the loading dose on Day 1, and 6mg/kg IV for the maintenance dose every 3 weeks (Q3W).
41292207|NCT05385705|DRUG|Pertuzumab|Pertuzumab at a dose of 840mg IV for the loading dose on Day 1, and 420 mg IV for the maintenance dose every 3 weeks (Q3W).
41292208|NCT05385705|BIOLOGICAL|NK cells|NK product is a cellular investigational product comprising a live cell suspension of allogenic NK cells derived from a compatible donor that will be infused on Day 2.
41292209|NCT05385705|DRUG|Interleukin-2|IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.
41292210|NCT05476692|OTHER|AOFAS score and VAS|Clinical outcome by the Visual analogue scale (VAS) and the American Orthopaedic Foot and Ankle (AOFAS) score.
41292211|NCT03564249|DEVICE|MiniCap|The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan
41292212|NCT04593498|DIAGNOSTIC_TEST|Holter recording|Holter recording with Zenicor Flex ECG during 14 days.
41292213|NCT04593498|DIAGNOSTIC_TEST|Echocardiography (Echo)|Echocardiography: Comprehensive transthoracic echocardiography with special focus on atrial dimension and function.
41292214|NCT04593498|DIAGNOSTIC_TEST|Blood sample|Blood sample: 2 x 10 ml EDTA plasma sampled from venous blood at index and at 21 months. Troponin T, NTproBNP, Na, K, Creatinine. Sample for Biobank for future analysis.
41292215|NCT04593498|DIAGNOSTIC_TEST|24 hour ambulatory blood pressure monitoring And Arteriograph|To assess artery stiffness.
41292216|NCT03015272|BEHAVIORAL|Auditory-Motor Mapping Training|AMMT is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums, designed to help minimally verbal children between the ages of 5.5 and12.0 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in the method.
40956993|NCT05473507|DIAGNOSTIC_TEST|Total Skin Examinations|Total Skin Examinations will be performed every 12 months.
40956994|NCT05890508|DEVICE|Acupuncture|Disposable acupuncture needles (0.20 mm in diameter) are are used in the study. The acupoints are GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). Electrical stimulation will be delivered with waves at 2-5 Hz from an electroacupuncture device. The needles will be retained in position for 30 minutes.
40956995|NCT05890508|DEVICE|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
41292217|NCT03015272|BEHAVIORAL|Speech-Repetition Therapy|SRT is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT.
41466418|NCT05626387|DRUG|Mycophenolate Mofetil plus prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms. Mycophenolate mofetil (MMF) is an immunosuppressive drug that acts by inhibiting the proliferation of T-lymphocytes and suppressing the recruitment of lymphocytes and monocytes into the sites of inflammation.
41466419|NCT05626387|DRUG|Prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms.
41466420|NCT01017939|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
40956996|NCT01631773|GENETIC|microRNA|Biological samples will be taken from subjects w/ Nasal polyps \& AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
40956997|NCT05798065|PROCEDURE|Inpatient gastrointestinal endoscopy|all inpatient endoscopy procedures (gastroscopy, colonoscopy, ERCP, sigmoidoscopy) during 2016-2022.
40956998|NCT00246623|DRUG|Exubera (inhaled insulin)|
40956999|NCT00246623|PROCEDURE|8-point glucose diary (to assess pre- and post prandial glucoses)|
40957000|NCT00246623|PROCEDURE|Meal Tolerance Test|
40957001|NCT00246623|PROCEDURE|24-hour continuous glucose monitoring (at select sites)|
40957002|NCT00246623|PROCEDURE|Pulmonary Function Testing|
40957003|NCT00246623|PROCEDURE|Hypoglycemic Event Monitoring|
40957004|NCT00246623|PROCEDURE|Laboratory Assessments|
40957005|NCT00246623|BEHAVIORAL|Nutritional Counseling and Diabetes Education|
40957006|NCT00023946|DRUG|ixabepilone|Given IV
40957007|NCT00023946|OTHER|laboratory biomarker analysis|Correlative studies
40957008|NCT06068608|DRUG|TNM005|single,intramuscular injection
40957009|NCT06068608|DRUG|Placebo|single,intramuscular injection
40957010|NCT06068608|DRUG|VariZIG|a single dose of VARIZIG 625 IU,intramuscular injection
40957011|NCT03750955|DEVICE|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene cessation utilizing localized stent-induced biofilm overgrowth model (SIBO), will manipulate the participants' oral environment by leading to reversible inflammation of the gingival tissues.
40957012|NCT03750955|DEVICE|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene has been maintained by tooth brushing with fluoride toothpaste and flossing twice daily.
41455540|NCT02391233|BEHAVIORAL|E-WORTH|E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
40957013|NCT00593008|DRUG|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
40957014|NCT00593008|DRUG|Gemcitabine|Given intravenously every other week of each 28-day cycle.
40957015|NCT03764696|DEVICE|tight-fitting simple facemask|Oxygen will be administered by facemask at 10 L/min oxygen. The therapy will continue until after delivery
40957016|NCT04208633|PROCEDURE|Horizontal placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
40957017|NCT04208633|PROCEDURE|Vertical placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
41455541|NCT02391233|BEHAVIORAL|Streamlined HIV Testing|In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
41466421|NCT01017939|DRUG|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
40763065|NCT06642038|PROCEDURE|Transbronchial Endoscopic Thermal Vapor Ablation|Transbronchial Endoscopic Thermal Vapor Ablation
40763066|NCT05752487|DEVICE|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|Participants will undergo catheter ablation with the PF /RF ablation system consisting of the TRUPULSE Generator (delivers RF or PF energy through the study catheter) and the THERMOCOOL SMARTTOUCH SF (STSF) Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a Generator, for cardiac ablation).
40763067|NCT05815199|OTHER|E-cigarette (EC)|Fixed dose. Participants are to use the EC as replacement for smoking combustible cigarettes. Participants will vape the EC.
40763068|NCT05815199|OTHER|Nicotine Replacement Therapy (NRT)|Includes nicotine patches and lozenges. NRT use recommendations will follow the guidelines of the product, e.g. one patch per day.
40957018|NCT06136078|OTHER|rate of appropriate and inappropriate transfers from Methodist interfacility transfers|Evaluating rate for patients experiencing traumatic intracranial subarachnoid hemorrhage or spontaneous bleeds
40957019|NCT00855673|DEVICE|Intermittent Mechanical Compression|FM220 device
40957020|NCT00855673|DRUG|Control|Standard medical treatment
40957021|NCT02050243|DRUG|5ALA|20mg/kg of oral suspension of 5ALA
40957022|NCT00693849|DRUG|Escitalopram|10 mg/day as a single dose, increased to max 20 mg/day
40957023|NCT00693849|DRUG|Sertraline|50 mg/day as a single dose, increased to max of 200 mg/day
40957024|NCT00693849|DRUG|Venlafaxine-XR|75 mg/day given once daily; increased to 150-225 mg/day
40763069|NCT05815199|BEHAVIORAL|Harm-Reduction Counseling|At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Up to five additional sessions will be delivered, 15\~20 minutes each.
40763070|NCT05815199|BEHAVIORAL|Ecological Momentary Intervention (EMI) Text Messaging|EMI can be defined as delivering tailored interventions via electronic messages (i.e., regular text messages) that include personalized feedback based on real-time assessment responses and other contextual factors. EMI will take place throughout the intervention period.
40763071|NCT00833703|DRUG|Clopidogrel|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
40763072|NCT00833703|DRUG|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
40957025|NCT03823456|OTHER|Self-acupressure|We teach participants how to using self-acupressure to manage insomnia, depression, and anxiety. Six acupoints are included in our acupressure protocol which are Baihui, Yintang, Fengchi, Neiguan, Shenmen, and Taichong. Participants are requested to stimulate each acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from Anxiety and Depression Association of American.
40763073|NCT06294990|DRUG|Testosterone gel|Two years treatment with testosterone
40763074|NCT06294990|OTHER|Placebo|Two years treatment with placebo
40763075|NCT04961580|DRUG|Ceftazidime Avitbatan Sodium|For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
40763076|NCT06641206|DRUG|Triamcinolone Acetonide|1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain
40763077|NCT06641206|DRUG|Bupivacaine Hydrochloride|20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain
40763078|NCT06641206|DRUG|Dexmedetomidine|Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
41292218|NCT05777811|PROCEDURE|Vertically coronally advanced flap combined with connective tissue graft.|The exposed root surfaces are planed with Gracey 1-2 curettes. An intrasulcular incision is made with a blade on the buccal aspects of the involved teeth. The incision is extended horizontally to the adjacent papilla. Then, slightly divergent vertical releasing incisions are carried 2 mm beyond the mucogingival junction. A full-thickness flap is raised with a periosteal elevator towards the mucogingival junction. After that, a partial-thickness dissection is carried out in the apical direction to release muscle tension and provide coronal advancement of the flap. The adjacent papillae are de-epithelialized. The connective tissue graft (CTG) is harvested from the lateral palate using the de-epithelialized gingival graft technique. After harvesting, the connective tissue graft is sutured to the recipient bed. Finally, the flap is positioned 2 mm over the cementoenamel junction and sutured with 6-0 polypropylene sutures. No periodontal dressing is applied.
40763079|NCT06643819|DRUG|sacubitril/valsatran(dose maintenance)|"During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day."
40763080|NCT06643819|DRUG|sacubitril/valsartan(dose increasing)|"During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day."
40763081|NCT06643819|DRUG|Valsartan|During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
40763082|NCT01251055|DRUG|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1(500) 4# BID
40763083|NCT01251055|DRUG|Placebo|starch
41466422|NCT01017939|DRUG|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
40763085|NCT03546257|DEVICE|magnifying endoscopy with narrow band imaging (ME-NBI)|A system consisting of a magnifying endoscope combined with narrow-band imaging (NBI), with the spectral band width narrowed by optical filters, was developed to enhance visualization of mucosal surface structure and vascular architecture. There were some reports that the magnifying endoscopy with narrow band imaging (ME-NBI) is superior to predict the histologic differentiation, depth of invasion and lesion margin than WLE.
40763086|NCT05500521|DIAGNOSTIC_TEST|Caloric irrigation|In a healthy ear irrigation with warm and cold water should give rise to an intense sensation of vertigo and involuntary eye movements called nystagmus. This nystagmus can be measured and thereby give an indication of the vestibular function in that ear.
40763087|NCT05500521|DIAGNOSTIC_TEST|vHIT|This test measures the vestibular ocular reflex in all six semicircular canals (three in each ear). By performing a fast head thrust in the direction of the canal the eye response can be detected by a high-velocity video camera. A slower response indicates impaired function in that canal.
40763088|NCT05500521|DIAGNOSTIC_TEST|VEMP|Utricular and saccular function can be measured by VEMP. Sound is presented in one ear at a time and the evoked myogenic potential in the sternocleidomastoid and the superior oblique muscles can be measured respectively. This gives a measurement of the function of the sacculus (cVEMP) and utriculus (oVEMP).
40763089|NCT06554587|DIAGNOSTIC_TEST|Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)|Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance
40763090|NCT05250934|DEVICE|Robotic rehabilitation|The upper limb rehabilitation will be carried out with the planar rehabilitation robot Icone (a CE Class IIA medical device manufactured by Heaxel). The proposed exercises require the patient to move a cursor on the screen using the end-effector of the robot to reach specific points (planar reaching exercises). When the patient is able to perform these exercises independently, the robot assists the movement by minimizing the interaction force applied to the hand and limiting itself to acquiring the kinematic and dynamic parameters of the exercise, which are useful in determining the state of motor skills. Icone assist the subject by applying a force to his hand that helps him complete the task in the phases where the patient plans the movement correctly but is unable to complete it. As a result, the system will enable you to perform planar elbow and shoulder movements in active, passive, or active-assisted modes, with visual and acoustic feedback.
41466423|NCT01017939|DRUG|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
41466424|NCT01794754|OTHER|Care as usual|
40957026|NCT03823456|OTHER|Sham Self-acupressure|We using a sham acupressure protocol to teach participants in this group. Six sham acupoints are included in the protocol. The sham acupoints are located 2-5cm away from the true acupoints. Participants are requested to stimulate each sham acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from the Anxiety and Depression Association of American.
40957027|NCT00153907|DRUG|Navelbine|Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
40763091|NCT06637241|BEHAVIORAL|Risk stratification care|In this group, Taiwanese adolescent baseball players are categorized into high-risk, medium-risk, and low-risk groups based on injury risk from a previous study. High-risk players receive sports protection education and physician referrals for shoulder and elbow assessments, with further imaging if necessary. Common issues like Little League shoulder and elbow are managed with conservative treatments. The sports protection education includes the Modified Yokohama Baseball-9 (mYKB-9), a program that significantly reduces injuries with exercises targeting shoulder and elbow health. Medium-risk players receive mYKB-9 education only, while low-risk players are observed without changes to their training methods.
40763092|NCT04147286|DRUG|Atorvastatin 40mg|12 weeks of 40 mg atorvastatin therapy per os
40763093|NCT04147286|DRUG|Placebo oral tablet|Identical placebo
40763094|NCT06641635|COMBINATION_PRODUCT|Moderated hypofractionated online adaptive radiotherapy|"Radiation: Moderated hypofractionated online adaptive radiotherapy (oART)+ High-dose rate (HDR) Brachytherapy~Experimental group: 43.35Gy/17F external beam radiotherapy with oART + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
40957028|NCT00153907|DRUG|Capecitabine|Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
40763095|NCT06641635|COMBINATION_PRODUCT|Conventional radiotherapy|"Radiation: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy~Contral group: 45Gy/25F EBRT + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
40957029|NCT03768232|OTHER|ultrasound asessment|US diaphragm measurements within 36 hours of initiation of MV. Measurements will be repeated daily for the duration of MV for the first week, then every 48 hours and 24 hours after the extubation.
40763096|NCT06640400|DEVICE|Cardiovascular ultrasound|Participants in the intervention group will be treated with a medical LIPUS device (838C-M-L-I/II, Shenzhen, China) for 10 days in addition to conventional medical treatment. The ultrasound therapy instrument is equipped with a sound head comprising 5 transducer units, operating at an ultrasonic frequency of 0.84MHz with a sound intensity range of 1 W/cm2 -1.25 W/cm2. The therapeutic ultrasound sessions necessitate a controlled environmental temperature. Patients will assume the supine position, exposing the precordial region, with the five-pronged head positioned parallel to the heart\&amp;amp;amp;amp;#39;s long axis, covering the entire precordial region including the right and left coronary arterial trunks and the aortic root. The ultrasound therapy device operates in a pulsed mode, with each treatment session lasting 20 minutes, comprising 2 daily sessions for a total of 20 treatments.
40763097|NCT06108544|DRUG|TAK-279|Specified drug on specified days.
40763098|NCT06108544|DRUG|Placebo|Specified drug on specified days.
40763099|NCT06108544|DRUG|Apremilast|Specified drug on specified days.
40763100|NCT06640582|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
40763101|NCT06640582|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
40763102|NCT06640582|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
40957030|NCT02223312|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
41292219|NCT05777811|PROCEDURE|Free gingival graft|A partial-thickness flap is elevated (using a blade #15c) with horizontal incisions at the cemento-enamel junction (CEJ) level of the adjacent teeth. Then, two vertical incisions extending to the apical are made from the two ends of the horizontal incision. The epithelium in the framed region is removed with a scalpel, and the underlying connective tissue is exposed. To achieve the best vascularization of the free gingival graft from the recipient site, bed preparation is completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region. The free gingival graft is stabilized using interrupted sutures and a sling suture.
41292220|NCT00941772|OTHER|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
41292221|NCT00004184|BIOLOGICAL|monoclonal antibody 4B5 anti-idiotype vaccine|
41292222|NCT00004184|BIOLOGICAL|sargramostim|
40763103|NCT06640582|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
40763104|NCT06640582|DRUG|Pembrolizumab|Intravenous (IV) infusion
40763105|NCT05928390|DRUG|Pasireotide Diaspartate|Injectable ampoules
40763106|NCT06642220|DEVICE|Y-90 Selective Internal Radiation Therapy (SIRT)|Y-90 radioembolization will be performed using glass spheres to treat non-metastatic RCC within the kidney.
40957031|NCT03939026|GENETIC|ALLO-501|ALLO-501 is an allogeneic CAR T cell therapy targeting CD19
40957032|NCT03939026|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
40763107|NCT05543174|DRUG|TAK-625|TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily
40763108|NCT03034811|DEVICE|Persona Partial Knee system|Fixed bearing partial knee
40763109|NCT02967692|BIOLOGICAL|Spartalizumab|Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks
40763110|NCT02967692|OTHER|Placebo|Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks
40763111|NCT02967692|DRUG|Dabrafenib|Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.
40763112|NCT02967692|DRUG|Trametinib|Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
40763113|NCT06639204|DEVICE|Electrical stimulation|A removable appliance will be used to accelerate orthodontic tooth movement by emitting electrical stimulation.
40763114|NCT06639204|PROCEDURE|Orthodontic treatment without acceleration|No additional appliances will be used. Only the traditional fixed appliances (braces).
40957033|NCT03939026|DRUG|Fludarabine|Chemotherapy for lymphodepletion
40957034|NCT03939026|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
41135555|NCT03803150|PROCEDURE|PRA approach|A preauricular incision will be made that extends downwards in a curvilinear fashion in the cervicomastoid skin crease, though any variation in this incision will suffice. The great auricular nerve will be preserved and the flap raised in the subdermal fat plane, superficial to the superficial musculoaponeurotic layer to allow access to the masseter adjacent to the anteroinferior edge of the parotid gland, just below the parotid duct. Branches of the facial nerve will be readily identified and avoided with or without loupe magnification, on the surface of the masseter muscle.
41292223|NCT00004184|DRUG|alum adjuvant|
40763115|NCT04729114|DRUG|PRL-02 injection|abiraterone decanoate for intramuscular injection
40763116|NCT04729114|DRUG|prednisone|Oral dose
40763117|NCT04729114|DRUG|dexamethasone|Oral dose
40763118|NCT04729114|DRUG|enzalutamide|Oral capsule
40957035|NCT00644228|DRUG|Bortezomib|Given IV
40957036|NCT00644228|DRUG|Dexamethasone|Given PO
40957037|NCT00644228|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
40957038|NCT00644228|DRUG|Lenalidomide|Given PO
40957039|NCT00270335|DRUG|Propofol|
40957040|NCT01228474|OTHER|Select the Number of embryos to transfer|Select the Number of embryos to transfer
41292224|NCT05738213|DEVICE|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
40957041|NCT00089414|DRUG|Ethinyl Estradiol/Drospirenone|Drug administered dependent upon arm.
40957042|NCT00089414|DRUG|Placebo|
41292225|NCT05738213|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
41292226|NCT05738213|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
41292227|NCT05738213|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
41292228|NCT05738213|BEHAVIORAL|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
41292229|NCT05738213|BEHAVIORAL|PedMIDAS (Pediatric Migraine Disability Assessment)|Adolescents with migraine will complete questions regarding their headache frequency. Migraine disability will be assessed using PedMIDAS (Pediatric Migraine Disability Assessment). This self-reported questionnaire assesses the number of days that headaches affect participant's daily activities. This is a widely used, reliable and validated tool to assess migraine disability.
41292230|NCT05738213|DIAGNOSTIC_TEST|Hormonal assessment|Blood samples (approximetly 2 tablespoons) will be collected for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone).
40957043|NCT00089414|DRUG|CDB 2914|
41292231|NCT05738213|OTHER|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-Wave 3 survey, which allows for differentiation between pre-, early-, late-, and post-pubertal status. Early puberty is defined as a score of 3 and no menarche, mid-puberty is defined as 4 and no menarche, late pubertal is defined as a score of 7 points or less and with menarche, and post pubertal is defined as a score of 8 and menarche. For boys, pubertal maturation status will be determined by the Physical Development Scale using the body hair growth voice change and facial hair questions. Early puberty is defined as a score of 4-5, mid-puberty is defined as a score of 6-8, late pubertal is defined as a score of 9-11 points, and post pubertal is defined as a score of 12.
41292232|NCT01541254|DEVICE|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
41292233|NCT05574946|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Anterior Cruciate Ligament Reconstruction with four strand semitendinosus graft
41292234|NCT04326322|DIETARY_SUPPLEMENT|Methionine Intake|Intakes will be randomly chosen from a list of 7 doses of methionine. Each intake will will be repeated approximately 5 times.
41292235|NCT02242539|BEHAVIORAL|Height measurement poster|Each household is provided with a poster which study personnel help to hang on the wall. The poster clearly indicates height-for-age benchmarks and stunting cut-offs for study-age children. Parents are provided training on how to measure their children at regular intervals, and interpret height readings to determine whether their child is developing normally or is stunted.
40957044|NCT05737589|RADIATION|Whole-brain radiotherapy|Radiotherapy is administered to the patient's brain lesions, and the subject's specific treatment plan is developed by two specialized physicians.
40957045|NCT04792320|DIETARY_SUPPLEMENT|Active bamboo charcoal|4g particle
40957046|NCT04792320|DIETARY_SUPPLEMENT|probiotics|0.8g powder
40957047|NCT05409495|PROCEDURE|periodontal surgical procedure (open flap debridement)|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed The IBD area in the control group was closed without applying any material. Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
40957048|NCT05409495|PROCEDURE|periodontal surgical procedure (OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF))|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed (Figure 2a). The blood supply of the defect areas was taken into account. At the test site, IBDs were filled with T-PRF and T-PRF membranes were adapted over the defects both buccally and lingually, in addition to OFD (Figure 2b). Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
40957049|NCT04528732|BEHAVIORAL|Group Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
41135556|NCT03803150|PROCEDURE|RT approach|The incision for the retromandibular approach begins 5mm below ear lobe and continues 3 to 3.5cm inferiorly. Initial incision begins through skin and subcutaneous tissues,platysma muscle ,(SMAS), parotid capsule Dissection is continued until the only tissue remaining on the posterior border of the mandible will be the periosteum of pterygomassetric sling,then the fracture site will exposed and reduced.
41135557|NCT02128893|DRUG|Isavuconazole|oral
41135558|NCT02128893|DRUG|Esomeprazole|oral
41135559|NCT02124356|OTHER|Evaluation of functional performance|
41135560|NCT04559698|BEHAVIORAL|LGBTQ-affirmative CBT training|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week.
41135561|NCT04809623|DRUG|Edecesertib|Tablets administered orally
41135562|NCT04809623|DRUG|Placebo|Placebo to match edecesertib tablets administered orally
41135563|NCT04809623|DRUG|Standard of Care|Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)
41135564|NCT00000269|DRUG|Pergolide|
41135565|NCT00786864|OTHER|exercise programme|Specific low back pain exercise programme for children
41135566|NCT00043589|DRUG|donepezil|
41135567|NCT00043589|PROCEDURE|Memory-training class|
41135568|NCT01021748|DRUG|MK-2206|Oral tablets
41135569|NCT01021748|DRUG|AZD6244|Oral capsules
41135570|NCT04743388|BIOLOGICAL|BNT162b2|Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies
41135571|NCT04743388|BIOLOGICAL|Other vaccine against SARS-Cov-2|Any other vaccine authorized and administered by the Greek Ministry of Health against SARS-Cov-2
41135572|NCT04373967|DRUG|Victoza®.|Patients will receive Victoza®. Both products will be provided as pen-injector.
41135573|NCT04373967|DRUG|Metformin Hydrochloride|Patients who were receiving metformin prior to study will continue to receive it during the study.
41135574|NCT04373967|DRUG|TQZ2451|Patients will receive TQZ2451.Both products will be provided as pen-injector.
41135575|NCT05485493|BEHAVIORAL|Internet-Based Solution Focused Short-Term Group Counseling|Sessions will be held online once a week, with an average duration of 60-90 minutes, in the form of 6 sessions, via video-conference applications.
41135576|NCT05485493|OTHER|healthy nutrition education|60-minute single session healthy eating training
41135577|NCT05224232|DEVICE|Access Socket|During a period of 4 weeks, patients will live in their usual environment with the soft socket (Access-Socket)
41135578|NCT05224232|DEVICE|Rigid socket|During a period of 4 weeks, patients will live in their usual environment with their usual rigid socket
41135579|NCT03200574|DIAGNOSTIC_TEST|4D Cardiac CT Scan|4D CT scan obtained at minimum of 1 month after the discontinuation of the anticoagulation or dual antiplatelet therapy
41135580|NCT03200574|DEVICE|LivaNova Bioprothetic Aortic Valve Implant|Study includes patients that have received the commercially approved LivaNova bioprosthetic aortic heart valve Perceval, as standard of care.
41466425|NCT01794754|OTHER|Occupational therapy|Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
41135581|NCT01888484|BIOLOGICAL|octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
41135582|NCT05474950|DRUG|minocycline|minocycline capsule (100mg) per day orally
41135583|NCT03737110|DRUG|Rilonacept|Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly
41466426|NCT02354807|DRUG|Mirabegron|One-time dose of 100mg of Mirabegron
41135584|NCT03737110|DRUG|Placebo|Placebo SC injections once weekly
41135585|NCT01894399|DRUG|HM61713|Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian
41135586|NCT02317172|OTHER|Gel-based artificial saliva|Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
41135587|NCT05071677|PROCEDURE|Discussion|Participate in treatment planning meeting
41135588|NCT05071677|OTHER|Interview|Participate in interview
41135589|NCT05071677|OTHER|Survey Administration|Complete survey
41135590|NCT05420584|PROCEDURE|Arterial chemoembolization|The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.
41135591|NCT05420584|DRUG|Tislelizumab Injection|Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.
41135592|NCT05420584|DRUG|XELOX|Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.
41135593|NCT05420584|DIAGNOSTIC_TEST|Pelvic MRI|Pelvic MRI to evaluate efficacy
41466427|NCT02354807|OTHER|Cold exposure|Exposure of subjects to cold temperature to induce non-shivering thermogenesis
40957050|NCT04528732|BEHAVIORAL|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
40957051|NCT06161870|DRUG|individualized vancomycin dosing based on the population pharmacokinetics (PK) model|The experimental group will be guided at the bedside with individualized vancomycin dosing by a drug dosimetry software tool that incorporates a PK model developed by Roberts JA et al. for data from sepsis patients. The model developed by Roberts JA et al. has been validated in multiple centers to have a good ability to predict the concentration-time data of patients. Once the basic information of participants such as gender, age, body weight, and creatinine clearance rate (CCR) is entered, the software tool can calculate the dosing regimen that is estimated to achieve the pharmacodynamic (PD) target. The area under the curve (AUC24) of 400-600mg·h/L is identified as the PD target of vancomycin.
40957052|NCT06161870|DRUG|empirical vancomycin dosing|The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
41135594|NCT05420584|PROCEDURE|Laparoscopic radical resection of rectal cancer|Surgical treatment for patients who meet the surgical conditions
41135595|NCT06172036|DRUG|irinotecan liposome + oxaliplatin + 5-FU / LV|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
41135596|NCT06172036|DRUG|Adebellizumab|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
41135597|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT|Standard approach for SMC strategy used by the Ministry of Health (without directly-observed therapy) and without any interference of the study team. Implemented over 4 rounds, carried out in June-October 2023 with \~30 days between rounds.
41135598|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT|SMC will be implemented with the same number of rounds and the same timing as in active comparator arm but village health workers will visit the participants at home to administer each dose of study treatment (with DOT-directly-observed therapy)
41135599|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT|SMC will be implemented as in arm 2 but age of participants is extended up to 10 years: each dose of study treatment (with DOT-directly-observed therapy) distributed at home by village health workers.
41135600|NCT04468191|DEVICE|Experimental expiratory muscle strength training (EMST)|The experimental EMST will involve blowing into a device with a spring-loaded valve set to 50% of the patient with ALS' maximum expiratory pressure.
41135601|NCT04468191|DEVICE|Sham expiratory muscle strength training (EMST)|The sham EMST will involve blowing into a device without a spring-loaded valve (0% resistance).
41135602|NCT04493359|DRUG|Renin-angiotensin system inhibitors|switch anti-hypertensive class
41135603|NCT02052440|DRUG|Baclofen|Treatment arm: baclofen 10mg tid
41135604|NCT02052440|DRUG|Placebo|Sugar pill by mouth three times daily
41292236|NCT02242539|BEHAVIORAL|Community-based monitoring|"Once every three months, villages are visited by study staff who measure children's heights and weights, and parents are informed if their children are below the reference measures established by the World Health Organization. If a child's weight is such that the child is classified as severely malnourished, the child is referred to the nearest health center for treatment. If the child is stunted (height-for-age z-score more than 2 standard deviations below the reference median), we provide parents with a supply of Yummy Soy powder, a fortified soy and maize mix popular among parents and widely available in local super markets. Parents are instructed to give one or two tea spoons of the mix to the child each day."
41292237|NCT03667677|DRUG|Tandospirone + Amlodipine|The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
41292238|NCT03667677|DRUG|Tandospirone placebo + Amlodipine|The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
41292239|NCT03667677|DRUG|Tandospirone + Amlodipine placebo|The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
41292240|NCT03667677|DRUG|Tandospirone placebo + Amlodipine placebo|The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
41292241|NCT06207877|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
41292242|NCT06207877|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
41292243|NCT06207877|DRUG|Placebo|Placebo will be administered subcutaneously.
40763119|NCT06641713|PROCEDURE|TACE|TACE was carried out under the guidance of digital subtraction angiography, and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The emulsion of the selected drug and the embolization agents was therefore injected infused into tumor-feeding arteries via the selective microcatheter. A final arteriography confirmed the success of the procedure. The endpoint of the TACE procedure was reached when there was no flow in the tumor-feeding vessels.
41135605|NCT01683669|OTHER|Noisy-PSV 1|Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
41292244|NCT05874245|DRUG|oral Dexmedetomidine|will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
41292245|NCT05874245|DRUG|oral ketamine|will receive 6 mg/kg oral ketamine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia
41292246|NCT05874245|DRUG|oral Midazolam|will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
41292247|NCT04370249|OTHER|pulmonary ultrasound|pulmonary ultrasound on admission
41292248|NCT02891993|OTHER|IMPROVED|"The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden."
41292249|NCT02891993|OTHER|Usual Care|Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
41292250|NCT04546256|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
41292251|NCT04546256|DRUG|ADVAIR DISKUS® 500/50|2 inhalations of Test and Reference product in each study period
41292252|NCT04156646|DRUG|Balovaptan|Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)
41292253|NCT04156646|DRUG|Esomeprazole|Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
41292254|NCT01827501|DEVICE|PulsioflexTM Monitoring|Fluid and catecholamine management according to PulsioflexTM measurements
41292255|NCT01949493|DEVICE|mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.
40957053|NCT02236442|OTHER|Recommendation to use global headache treatment protocol|"The global treatment protocol is :~1. Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~2. Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~3. Provide a sound-proof helmet to the patient.~4. Provide a light-blocking google to the patient.~5. If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~6. If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient."
40957054|NCT03857399|DRUG|Caspofungin|Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
41135606|NCT01683669|OTHER|Noisy-PSV 2|Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
41135607|NCT02430259|DRUG|Weekly INH / RRT given by DOT|weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
41135608|NCT00815100|DRUG|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
41135609|NCT00815100|DRUG|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
41135610|NCT05873205|BIOLOGICAL|Isatuximab|All participants enrolled on the study will receive isatuximab intravenously as a single agent
41135611|NCT01159600|DRUG|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
41135612|NCT01159600|DRUG|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
40763120|NCT06641713|PROCEDURE|HAIC|HAIC was carried out under the guidance of digital subtraction angiography, 990and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
41135613|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily high dose open label
41135614|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily high dose
41135615|NCT01159600|DRUG|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
40763121|NCT06643026|OTHER|Food preference|Evaluate the impact of chemotherapy on the dietary preferences of patients with digestive cancer using a dietary and quality-of-life questionnaire at the beginning, middle and end of the chemotherapy/immunotherapy treatment.
40763122|NCT06639295|DRUG|611|611 subcutaneous (SC) injection.
40763123|NCT06639295|DRUG|Placebo|Placebo subcutaneous (SC) injection.
40763124|NCT06636786|DRUG|Cyclobenzaprine HCl|TNX-102 SL (cyclobenzaprine HCl sublingual tablets) taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
40763125|NCT06636786|DRUG|Placebo|Placebo sublingual tablets taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
41135616|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily low dose
41135617|NCT01159600|DRUG|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
41135618|NCT05332613|BEHAVIORAL|TRE plus SOC|Participants will undergo time restricted eating (TRE) each day for 12 weeks and will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
41135619|NCT05332613|BEHAVIORAL|SOC|Participants will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
41292256|NCT01949493|OTHER|Care as usual|Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
41292257|NCT03476551|DRUG|Hydrochlorothiazide|Patients are tested for their normal prescription hydrochlorothiazide medication
40957055|NCT06217341|OTHER|In the study, bispectral index monitoring and follow-up will be applied to both groups.|Perioperative Bispectral Index Monitoring (BIS) monitor and Bispectral Index suppression Rate (BIS-SR) monitoring will be applied. The duration and magnitude of BIS-SR values will be examined together with BIS values in terms of recovery agitation.
40957056|NCT01153074|DEVICE|Closure of bronchopleural fistula with Occlutech Figulla|Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
40957057|NCT00815698|PROCEDURE|suture|suture for mesh fixation
40957058|NCT00815698|PROCEDURE|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
40957059|NCT05429060|PROCEDURE|Hemorrhoidal surgery|All surgical interventions under general or local anesthesia, either in the office or operation room, including any type of injection, excision, ligation, ablation, mucopexy and suturation.
40957060|NCT01496248|DIETARY_SUPPLEMENT|Korean Red Ginseng|100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.
40957061|NCT03574831|DEVICE|Stretta|Stretta
40957062|NCT06322680|PROCEDURE|Main pancreatic duct and biliary duct external drainage|"Pancreaticojejunostomy:~Assess pancreatic texture and duct diameter, preparing a 2 cm pancreatic remnant, and securing it to the jejunum's muscular layer using 3-0 prolene for U-shaped anastomosis. A patented drainage tube is inserted into the jejunum for effective drainage. Anastomoses are performed with 4-0 prolene between the pancreatic duct and jejunal mucosa, both posteriorly and anteriorly, with additional reinforcement at the pancreas and jejunum's anterior walls. A Fr6 silicone tube is placed in the distal jejunal remnant and secured.~The drainage system, featuring a one-way valve, connects the internal and external silicone tubes to a drainage bag.~Choledochojejunostomy:~The common bile duct's diameter is noted, and an opening in the jejunum is made for hepatobiliary tract formation with 4-0 absorbable sutures. A Fr10 silicone tube is inserted into the afferent limb and secured. This tube, too, connects to the external drainage system with a one-way valve."
40957063|NCT06322680|PROCEDURE|Main pancreatic duct and biliary duct internal drainage|"Pancreaticojejunostomy:~Assess the pancreatic texture and pancreatic duct diameter, and reserve the length of the pancreatic remnant to about 1.5 cm. Open the transverse mesocolon and bring the distal small intestinal remnant to the side of the pancreatic remnant. Perform a 2 cm side-to-side pancreaticojejunostomy with an invagination technique. Use a simple full-layer suturing method, 4-0 PDS plus continuous suturing, insert a plastic strip into the pancreatic duct, and fix the pancreatic duct stent with 3/0 Vicryl.~Choledochojejunostomy:~Record the diameter of the common bile duct, about 10 cm away from the pancreaticojejunostomy, and open the jejunum. Form the hepatobiliary tract and perform interrupted anastomosis with 4-0 absorbable sutures."
40957064|NCT03817879|PROCEDURE|VivaSight double-lumen tube for single-lung ventilation|Procedure using a tube with a camera
40957065|NCT03817879|PROCEDURE|Conventional double-lument tube for single-lung ventilation|Procedure using a tube without a camera
40957066|NCT03606512|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as IM injection at a dose of 2.5\*10\^10 vp.
40957067|NCT03606512|BIOLOGICAL|Placebo|Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.
40957068|NCT03606512|BIOLOGICAL|Nimenrix|Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.
40957069|NCT02221830|DRUG|Oxytocin|Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
40957070|NCT02221830|DRUG|Placebo|This intervention utilizes a Placebo Camparator
40957071|NCT03726307|BIOLOGICAL|DCreg: 0.5 million cells/kg+SOC|"DCreg 0.5 (±0.1) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
41135620|NCT05332613|BEHAVIORAL|TRE|Participants will undergo time restricted eating (TRE) each day for 12 weeks plus 4 extra visits with the registered dietician and repeat Fibroscan, InBody composition scan, and MRI-PDFF.
41135621|NCT06365892|DRUG|open-label placebo|Placebo will be supplied as a 330mg tablet (manufactured by Consolidated Midland Corporation). Patients will take placebo with each oral opioid intake and 3 additional times per day beginning on POD 1.
41135622|NCT06365892|OTHER|Treatment as usual|Each oral opioid dose is a 5mg Oxycodone tablet. Investigator shall never prescribe ibuprofen. Investigator shall always prescribe Tylenol 625mg every 8hrs (PRN).
41135623|NCT05177432|DEVICE|QPOP|QPOP will be used as a clinical decision support platform to identity suitable patient-specific drug combinations across a range of breast cancer patients, which are derived from drug sensitivity tests using patient-derived materials.
41292258|NCT03425799|DRUG|Sodium Chloride 0.9% Inj|Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
41292259|NCT03425799|DRUG|Tranexamic Acid|Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
41292260|NCT03043365|DRUG|control fish oil|4 capsules, 3 times a day after meals
41292261|NCT03043365|DRUG|LCMUFA-rich saury oil|4 capsules, 3 times a day after meals
41292262|NCT02172222|DRUG|BI 10773|
41292263|NCT02172222|DRUG|Linagliptin|
40957072|NCT03726307|BIOLOGICAL|DCreg: 1.2 million cells/kg+SOC|"DCreg 1.2 (±02) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
41292264|NCT02492711|BIOLOGICAL|Margetuximab|15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,
41292265|NCT02492711|BIOLOGICAL|Trastuzumab|8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion on day 1 of each 21 day cycle
41466428|NCT01121588|DRUG|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
40763126|NCT03850301|DRUG|XBD173|7 days treatment
40763127|NCT03850301|DRUG|Etifoxine|7 days treatment
41292266|NCT02492711|DRUG|Physician's choice of chemotherapy.|Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle
40763128|NCT06640907|BEHAVIORAL|Personalized e-Perinatal mHealth intervention integrated in maternal routine care|The mHealth app provides psychoeducational materials, video-guided physical activities, mood tracking features, personalized recommendations, and community features. Additionally, professionals involved in this group are specifically trained to incorporate the mHealth app into their routine care practices, enhancing their ability to support mental health during the perinatal period.
40763129|NCT06640907|OTHER|Usual perinatal care with general prenatal and postnatal health information|Usual prenatal and postnatal health care, including regular health check-ups. They also gain access to public health resources and perinatal information distributed via email.
40763130|NCT05856526|DRUG|Spesolimab - solution for infusion|Solution for infusion
40763131|NCT05856526|DRUG|Placebo matching to spesolimab - solution for infusion|Solution for infusion
40763132|NCT05856526|DRUG|Spesolimab - solution for injection|Solution for injection
40763133|NCT05856526|DRUG|Placebo matching to spesolimab - solution for injection|Solution for injection
40763134|NCT05938270|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) given orally once daily
40763135|NCT05938270|DRUG|Darolutamide|Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
40763136|NCT05938270|OTHER|No Treatment|No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
40763137|NCT03849144|BEHAVIORAL|Therapy dog activity|Visiting therapy dogs and their owners, evaluated and registered as therapy dog teams with Pet Partners will be spread around a large room on the Aetna campus. Employees will arrive at scheduled times to visit with the dogs for 15 minutes, talking to the dogs and owners and petting the dogs
40763138|NCT03849144|BEHAVIORAL|Low impact exercise|The low impact exercise will consist of stretching exercises conducted by a member of Aetna's wellness team in the same room for 15 minutes.
40763139|NCT06634823|DRUG|Triamcinolone Acetonide Injectable Suspension|Triamcinolone injection into deltoid muscle (arm)
40763140|NCT06634823|DRUG|Saline injection|Saline injection into deltoid muscle (arm)
40763141|NCT04089111|OTHER|Minute volume target of 100%|Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).
40763142|NCT04089111|OTHER|Minute volume target to reach PaCO2 less than 45% (high tidal volume)|Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.
40763143|NCT00273585|DEVICE|Personally-tailored educational software program|
40763144|NCT06643000|DRUG|furmonertinib|furmonertinib (240 mg/d,po) combined with bevacizumab (15 mg/kg, every 3 weeks, ivgtt) and pemetrexed (50 mg) intrathecal chemotherapy / pemetrexed (500 mg/m²) intravenous chemotherapy, administered every 3 weeks.
40763145|NCT06502028|DEVICE|Video laryngeal mask airway|The airway is secured with a video laryngeal mask airway.
40763146|NCT06502028|DEVICE|Endotracheal tube|The participant is intubated with an endotracheal tube via direct laryngoscopy.
41292267|NCT05014074|OTHER|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
40763147|NCT06640452|OTHER|RecoveryFun system|The system components were: VR headset; wereable biosensors, clinical platform, caregiver app and smart services.
40763148|NCT06639126|DIETARY_SUPPLEMENT|Wild thyme extract|All patients will be randomized (1:1) to receive the active thyme extract (600 mg/capsule/day or 600 mg/capsule/day of microcrystalline cellulose) in the form of capsules, administered orally and daily for 2 months
40763149|NCT06639126|OTHER|Placebo|600 mg/day microcrystalline cellulose
40763150|NCT04798768|DEVICE|mCRM Therapy System|Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.
41135624|NCT05413993|RADIATION|photobiomodulation|Laser application intraorals and extraoral points in the region of the salivary glands bilaterally
41135625|NCT03486509|DRUG|Afatinib|afatinb 40mg po bid
41466429|NCT05549050|OTHER|interdialytic weight gain|interdialytic weight gain during hemodialysis
41466430|NCT00478049|DRUG|Gefitinib|250 mg oral tablet
40763152|NCT06634862|OTHER|Normatec Air Compression|Intermittent pneumatic pressure has been used in other studies, usually for deep vein thrombosis and vascular disorders. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
40763153|NCT06634862|OTHER|Soft Tissue Mobilization|The soft tissue mobilisation technique has been investigated in other studies in terms of its effect on soft tissue and its role recovery. In this way, there is no comparison with other recovery interventions for post-exercise recovery applications.
40763154|NCT06634862|OTHER|Percussive therapy|Percussive therapy has been investigated in device research and athlete health. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
40763155|NCT04878757|BEHAVIORAL|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
40763156|NCT06571812|DEVICE|TSX|Treatment of tooth loss with TSX dental implants
41135626|NCT02802488|PROCEDURE|Blood sampling|"A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care."
40957073|NCT03726307|BIOLOGICAL|DCreg:2.5 to 5.0 million cells/kg+SOC|"DCreg 2.5 to 5.0 million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
40957074|NCT00860483|OTHER|observational|PET Scan
40763157|NCT04023058|PROCEDURE|Mitral surgery|Guidelines approved mitral surgery
40957075|NCT04899102|BEHAVIORAL|Time-Restricted, Intermittent Fasting|A special type of diet for 6 weeks, called time-restricted, intermittent fasting.
40957076|NCT04882384|PROCEDURE|Pericapsular Nerve Group Block|This will be a peripheral nerve block.
40957077|NCT02351375|OTHER|diet|A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
40957078|NCT02351375|DEVICE|IntelliCap® system|
40957079|NCT04033575|DRUG|Colgate Total SF|1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
40957080|NCT04033575|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
40957081|NCT05868395|DRUG|Polatuzumab, bendamustin und rituximab|"* Polatuzumab vedotin 1.8 mg/kg i.v. on day 2 of cycle 1, then on day 1 of each subsequent cycle~* Bendamustine 90 mg/m2 i.v. day 2 \& 3 of cycle 1, then on day 1 \& 2 of each subsequent cycle~* Rituximab 375 mg/m2 i.v. on day 1 of each cycle~* Each cycle is 21 days long~* Up to 6 cycles per patients planned"
40957082|NCT04286750|DRUG|ACT-1004-1239|ACT-1004-1239 administered as hard capsules for oral use.
40957083|NCT04286750|DRUG|Placebo|Matching placebo administered as hard capsules for oral use.
40957084|NCT05739188|BIOLOGICAL|Anti-GPRC5D CAR-T cells infusion|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10\^6 /kg±20%; Dose level two:6.0×10\^6 /kg±20%; Dose level three:1.0×10\^7 /kg±20%."
40957085|NCT06099366|DRUG|induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate|vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate
40957086|NCT06099366|DRUG|Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000U/m2 Intrathecal Methotrexate
40957087|NCT06099366|DRUG|Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate
40957088|NCT06099366|DRUG|Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate
40957089|NCT06099366|DRUG|Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate
40957090|NCT06099366|DRUG|Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate
41135627|NCT01412606|PROCEDURE|scratching|scratching endometrium on day 21-26 of a spontaneous menstrual cycle
40763158|NCT04575298|DIETARY_SUPPLEMENT|Acceptability, tolerance study for an infant formula with human milk oligosaccharides|Prospective study
41466431|NCT00478049|DRUG|Docetaxel|intravenous infusion
40957091|NCT06099366|DRUG|Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
40957092|NCT06099366|DRUG|Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
40957093|NCT02695901|DRUG|Chlorhexidine gluconate 0.12% (PerioGard®)|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
41135628|NCT03192709|DRUG|Sildenafil vaginal suppositories|Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.
41135629|NCT03192709|OTHER|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.
41135630|NCT03192709|OTHER|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
41135631|NCT00120549|PROCEDURE|Assisted embryo hatching|
41135632|NCT02409043|OTHER|Blood draw|Blood drawn for comparison with other groups
41466432|NCT05713227|DIETARY_SUPPLEMENT|White rice|185 g Jasmine (white) rice boiled in 356 g water
41466433|NCT05713227|DIETARY_SUPPLEMENT|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
41466434|NCT04377906|BEHAVIORAL|Modification Lifesyle|high protein-fiber and exercise
40763159|NCT06252584|DRUG|Vaccines, Peptide|Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
40763160|NCT06096857|DRUG|Roseomonas mucosa (RSM2015) and Cardamom seeds|Freeze dried packet to be reconstituted in water
40763161|NCT06096857|DRUG|Placebo (sucrose)|Freeze dried packet to be reconstituted in water
41292268|NCT02440724|DEVICE|Winged stent (partially covered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
41292269|NCT02440724|DEVICE|Winged stent (uncovered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
41292270|NCT02746679|OTHER|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
41292271|NCT01118143|BEHAVIORAL|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
41292272|NCT02158143|DIETARY_SUPPLEMENT|vitamin D3|
41292273|NCT01309425|DRUG|tapentadol (CG5503) ER two 100-mg TRF|200mg TRF single oral dose
41292274|NCT01309425|DRUG|tapentadol (CG5503) ER 50-mg TRF|50mg TRF single oral dose
41292275|NCT01309425|DRUG|tapentadol (CG5503) ER 25-mg TRF|25mg TRF single oral dose
41292276|NCT01309425|DRUG|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
41292277|NCT00312351|DRUG|Pegaptanib sodium|
41292278|NCT01818375|PROCEDURE|Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided|
41292279|NCT01818375|OTHER|Standard fluid therapy|
41292280|NCT04583865|OTHER|teleconsultation|In the pandemic period linked to COVID, pediatric pre-anesthesis consultations should preferably be carried out by teleconsultation. This is to assess the effectiveness of these teleconsultation and the satisfaction of parents.
41292281|NCT03461692|DRUG|patients under 14 years of age using Reduning injeciton|To assess in patients using Reduning injection's clinical features and drug adverse reaction during patients' hospital stay. The registry procedure will only for patients under 14 years of age using Reduning injection,observed from February 2018 to December 2018.
41292282|NCT02013193|DEVICE|Ranger DCB|After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.
41292283|NCT02013193|DEVICE|uncoated PTA balloon|The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
41292284|NCT03955029|OTHER|Progressive Interval training|heating up 7 minutes at 15 watt, then alternating 30% of the maximum power reached by the patient at Vo2 max for 3 minutes and first peak at 40% of max power, second at 45%, third at 50%, fourth at 55 % and fifth to 60%, then return to calm 3 minutes at 15 watt. Total duration of the endurance session: 30 minutes. The powers of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session).
41292285|NCT03955029|OTHER|Conventional Interval training|warm up 7 minutes at 15 watt, then alternating between plateau at 30% of the max power reached by the patient at VO2 max for 3 minutes and peak at 60% for 1 minute, return to calm 3 minutes at 15 watts. Total duration of the endurance session: 30 minutes. The power of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session)
41292286|NCT03366844|DRUG|Pembrolizumab|checkpoint inhibitor
41292287|NCT03366844|RADIATION|RT Boost|The second dose of pembrolizumab will be given in conjunction with an RT boost, consisting of 8 Gy for 3 fractions.
41292288|NCT02012972|BEHAVIORAL|Referral for NCD care|Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
41292289|NCT00818038|DRUG|BG0002 (natalizumab)|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
41292290|NCT01147965|BIOLOGICAL|AD5 CEA Vaccine|AD5\[E1-, E2b-\]-CEA Vector Vaccine
40957094|NCT02695901|DRUG|Nanoparticle solution of M. alternifolia oil (0.3%).|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
41135633|NCT02409043|OTHER|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
41135634|NCT06369155|DRUG|Azenosertib|Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.
41292291|NCT04634968|BEHAVIORAL|Brief Motivational Interviewing interaction|Telephone peer counselling+ Brief Motivational Interviewing interaction, and telephone-based interview after receiving all information.
41292292|NCT04634968|BEHAVIORAL|General health communication|Telephone peer counselling+ General health communication, and telephone-based interview, and telephone-based interview after receiving all information.
41292293|NCT03649776|OTHER|Mental Health First Aid|Mental Health First Aid (MHFA) is listed in the Substance Abuse and Mental Health Services Administration's National Registry of Evidence-based Programs and Practices. The program also teaches the common risk factors and warning signs of specific types of illnesses like anxiety, depression, substance use, bipolar disorder, eating disorders, and schizophrenia. Participants are introduced to local mental health resources, national organizations, support groups, and online tools for mental health and addictions treatment and support.
41292294|NCT04151563|BIOLOGICAL|nivolumab|Specified dose on Specified days
41292295|NCT04151563|BIOLOGICAL|ipilimumab|Specified dose on Specified days
41292296|NCT04151563|DRUG|cabozantinib|Specified dose on Specified days
41292297|NCT04151563|BIOLOGICAL|docetaxel|Specified dose on Specified days
41292298|NCT04151563|BIOLOGICAL|ramucirumab|Specified dose on Specified days
41292299|NCT04151563|DRUG|lucitanib|Specified dose on Specified days
41292300|NCT01251575|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
41292301|NCT01251575|DRUG|Cyclosporine|Given PO or IV
41292302|NCT01251575|DRUG|Fludarabine Phosphate|Given IV
41292303|NCT01251575|OTHER|Laboratory Biomarker Analysis|Correlative studies
41292304|NCT01251575|DRUG|Mycophenolate Mofetil|Given PO
41292305|NCT01251575|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
41292306|NCT01251575|DRUG|Sirolimus|Given PO
41292307|NCT01251575|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
41292308|NCT06166576|PROCEDURE|Ablative radioembolization|The interventional radiologist utilizes a pre-test with 99mTc-MAA SPECT-CT and cone-beam CT for procedural planning. For tumors confined to a single segment, the treatment area is planned to receive a radiation dose of over 400 Gy using the single-compartment MIRD technique. For tumors extending beyond a single segment, the multi-compartment MIRD technique is used to plan a radiation dose of 700 Gy (± 20%) to the tumor. The upper limit for the estimated lung dose is set at 25 Gy, and the upper limit for the perfused non-tumoral liver dose is 250 Gy. In cases where tumors extending beyond a single segment cannot receive the planned dose of 700 Gy (± 20%) due to limits on lung or normal liver dose, the plan is adjusted to deliver the maximum dose to the tumor within the permissible range for lung and normal liver doses. Radioembolization is typically performed in a single session, and any methods not mentioned here should follow the instructions for use of TheraSphere.
41292309|NCT00399802|DRUG|ZA|Single ZA 4 mg IV infusion at the start of treatment
41292310|NCT00399802|DRUG|Odanacatib|Once-daily odanacatib 5 mg tablet for 4 weeks
41292311|NCT00399802|DRUG|Odanacatib matching placebo|Once-daily odanacatib matching placebo for 4 weeks
41292312|NCT00399802|DRUG|ZA matching placebo|Single IV infusion of ZA matching placebo given at the start of treatment
41292313|NCT06512597|BEHAVIORAL|Primary Intervention for Combination Therapy - IBD Coping Strategies Program|psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
41455542|NCT05128396|BEHAVIORAL|Cognitive Stimulation|During the initial session, a member of the research team will visit the subject's home and introduce the subject to the Cogmed training program (www.cogmed.com). Individuals will start at the same low difficulty level. As training proceeds, task difficulty will be individually adjusted based on performance by increasing/decreasing the number of items individuals have to remember, such that a participant reaches approximately 60% correct per day for each task. Each training session will start at the task difficulty level where the participant ended in the previous session. Performance and reaction time data will be continuously recorded while subjects are doing the task, and these data will be sent via the internet to the research team after each session. A member of the research team will communicate with each subject on a weekly basis (via phone call or email) to provide feedback and address any questions or concerns.
41466435|NCT01487629|DRUG|Bevacizumab|Bevacizumab, 1.5 mg, intravitreal, throughout the study
41466436|NCT01487629|DRUG|Ranibizumab|Ranibizumab, 0.5 mg, intravitreal, throughout the study
40763162|NCT06111742|DEVICE|Bedside Entertainment and Relaxation Theater (BERT)|BERT is a Nebula Capsule Max portable projector that creates a familiar theater experience designed for children to divert attention away from procedures. It is fitted with a remote control that can be utilized to manage on-screen activities. BERT can be used with any wall, ceiling, or projector screen to create the theater experience with a large screen. It can also be used with assist devices, such as steering wheel and noise-canceling headphones.
40763163|NCT02758626|DRUG|ataluren|Powder formulation
40763164|NCT02758626|DRUG|Placebo|Powder formulation
40957095|NCT06044831|BEHAVIORAL|Expanded Population Health Model|This intervention includes the current population health model in addition to expanded programming from a local community organization. The current population health model with Baylor Scott \& White Health and Wellness Center includes access to primary care, general wellness programs such as cooking classes and nutritional counseling, and evidence-based disease management and prevention. The additional programs from a local community organization focus on human essentials integral to improving health and quality of life and include: health and wellness, economic stability, safe and affordable housing, transportation, a sense of belonging, education, and access to fair credit.
41292314|NCT06512597|BEHAVIORAL|Time and Attention Control - IBD Support Program|psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
41292315|NCT05712668|BEHAVIORAL|Preoperative counseling|Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.
41292316|NCT05712668|BEHAVIORAL|Asynchronous telemedicine|An asynchronous video will be delivered by Mytonomy. This platform allows investigators to track user analytics relating to the time, frequency, or duration watched by the user.
41292317|NCT00664274|BEHAVIORAL|Cognitive remediation therapy|36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
41292318|NCT00664274|GENETIC|COMT Genotyping|One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
41292319|NCT02292134|DEVICE|earplug and sleep mask|Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
41292320|NCT03312673|OTHER|Interview and tests of drawing.|The intervention will take place with patients followed for asthma at the Croix Rousse hospital. Patients agreeing to participate in the study will come to the hospital for one hour and a half. They will answer questionnaires and tests of drawing. Results Restitution Session (optional) is proposed to patients within the next 4 weeks during a routine consultation.
41292321|NCT03482310|DEVICE|Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
41292322|NCT03078725|DRUG|Glyburide|oral hypoglycemic agent
41466437|NCT02136706|PROCEDURE|Myocardial Perfusion imaging with 10 minute waiting period|After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
40957096|NCT01531595|DRUG|Bevacizumab plus alternating Xelox/Xeliri|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
40957097|NCT04130022|DEVICE|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
40957098|NCT04292483|DRUG|Nitric Oxide|Inhaled vasodilator to increase pulmonary capillary perfusion
40957099|NCT04614220|BEHAVIORAL|Presence of Family member|The correlation between presence of the Family member and the consent for regional anaesthesia for Caesarean Section
41292323|NCT03078725|DRUG|Metformin|oral hypoglycemic agent
41292324|NCT01221051|PROCEDURE|active management of the third stage of labor|early cord clamping, administration of oxytocin 10 IU, controlled cord traction, uterine massage after placenta expulsion
41292325|NCT01221051|PROCEDURE|expectant management of the third stage of labor|early cord clamping, administer saline solution 2 mL i.v,wait for signs of placenta detachment, encourage the woman to push ot placenta by her own effort, uterine massage after placenta expulsion
41292326|NCT04095910|BEHAVIORAL|Planet Nutrition program|"1. - Nutritional education sessions: The study team previously worked on the development of a handbook called Planet Nutrition which contains around 26 topics of nutrition and health. Interns from the Nutritional Sciences Degree of the University of Sonora implemented the sessions. 2 classes of 1 hour were given weekly, adding 18 sessions in total, during regular school hours. The program contemplates the establishment of different objectives.~2. - Physical activity: The classes were designed and implemented by interns from the Bachelor of Physical Culture and Sport from the University of Sonora along with a teacher from the study team. 3 weekly sessions of 1 hour were provided. The activities were held on the schoolyard court during normal school hours, independent of the physical activity classes of the school.~3. - Indirect family participation: Six information brochures with different nutrition and health topics were sent to parents."
40957100|NCT04076878|DEVICE|Mollii|The Mollii method is provided in a tight fitting, whole body suit with multiple electrodes that can be set individually. The Mollii method uses low frequencies and low intensities that evokes sensory input but does not directly elicit muscle contractions. The theoretical background of this treatment method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle through the activation of the disynaptic reciprocal Ia inhibitory pathway.
40957101|NCT03334539|BIOLOGICAL|HL036 ophthalmic solution|HL036 ophthalmic solution
41292327|NCT03714412|DEVICE|Implantation|Implantation of the Cardiovalve transfemoral mitral valve replacement system
41292328|NCT05930925|DRUG|[phenyl-14C]ARV-471|Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth
41292329|NCT05930925|DRUG|[oxoisoindolin-14C]ARV-471|Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth
41292330|NCT01616615|DRUG|Aspirin|150 mg/day oral use
41292331|NCT01616615|DRUG|placebo|1 capsule / day oral use
41292332|NCT05546788|PROCEDURE|scaling and root planing|subgingival Depridement
41292333|NCT05546788|DRUG|hydroxylated poly methoxy flavones|Received hydroxylated poly methoxy flavones extract solid dispersion incorporated into sodium carboxymethylcellulose gel
41292334|NCT05546788|DRUG|chlorhexidine|Received chlorhexidine gel
41455543|NCT05128396|BEHAVIORAL|Mindfulness training|"The mindfulness meditations will be narrated by one guide and the tasks will be narrated by a different guide. We will have 7 mindfulness tasks in total, whose order of presentation will be counterbalanced across sessions: 1. mindful observing of place, 2. mindful eating, 3. mindful observing of object, 4. mindful observing of person, 5. mindful walking, 6. mindful listening, and 7. mindful writing with the non-dominant and dominant hand.~At the end of each session, participants will write brief reflections stored via the website (e.g., an estimate of the amount of time subjects experienced their thoughts as wandering) both as an integral part of the mindfulness process and as a means of increasing the likelihood that subjects fully participate in each session. Each session will be structured as follows: Login, Mindfulness Meditation Session, Mindfulness Task 1, Mindfulness Task 2, Mindfulness Task 3, Write Log Reflection, Logout."
40957102|NCT03334539|OTHER|Placebo vehicle solution|Placebo vehicle solution
40957103|NCT02056977|OTHER|Titration|Individualized PEEP according to PEEP titration monitored by EIT
40957104|NCT02056977|OTHER|control|PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
40957105|NCT05065814|OTHER|Systemic lupus erythematosus group|Demographic information of systemic lupus erythematosus who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
40957106|NCT05065814|OTHER|Systemic sclerosis group|Demographic information of Systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
40957107|NCT05065814|OTHER|Healthy control group|Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
40957108|NCT00816595|BIOLOGICAL|bevacizumab|Given IV
40957109|NCT00816595|BIOLOGICAL|pegfilgrastim|Given subcutaneously
40957110|NCT00816595|BIOLOGICAL|rituximab|Given IV
40957111|NCT00816595|DRUG|cyclophosphamide|Given IV
41292335|NCT05546788|DRUG|placebo|Received placebo gel
41292336|NCT03595215|DEVICE|TENS|Transcutaneous electrical nerve stimulation
41292337|NCT02325999|PROCEDURE|ESD AND LRLD|A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
41292338|NCT02251223|DRUG|Tipranavir low dose|
41292339|NCT02251223|DRUG|Tipranavir medium dose|
41292340|NCT02251223|DRUG|Tipranavir high dose|
41292341|NCT02251223|DRUG|Ritonavir low dose|
41292342|NCT02251223|DRUG|Ritonavir high dose|
40763165|NCT06060509|DIETARY_SUPPLEMENT|Phytosterol-rich Wheat and Corn Germ Blended Oil|Blending of corn germ oil and wheat germ oil supplied by Yihai Kerry to obtain germ blended oil with high phytosterol content.
40763166|NCT06060509|DIETARY_SUPPLEMENT|Peanut oil|Participants in the control group consumed peanut oil daily for cooking.
40763167|NCT03890094|DRUG|Sufentanil|Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
40763168|NCT06637319|DEVICE|Ultrasound|Ultrasound scan of blood vessels where front of neck access vertical incision would take place in a cant intubate cant oxygenate scenario
40957112|NCT00816595|DRUG|pentostatin|Given IV
40957113|NCT03416725|DEVICE|Otoscope|Otoscopic examination will be done to find the presence or absence of perforation, granulation tissue and cholesteatoma.
40763169|NCT00205985|DEVICE|Scaphoid screw|Conservative treatment versus application of scaphoid screw
40763170|NCT03443401|PROCEDURE|Standard physical therapy care|standard plan of care delivered to patient with chronic low back within scope of licensure
40763171|NCT01254929|DEVICE|F-18 PET bone scan|Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
40763172|NCT01254929|DEVICE|Tc-99m bone scan|Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
40763173|NCT06641466|DRUG|Rimegepant|Rimegepant 75 mg ODT for 7 days
40763174|NCT06641466|DRUG|Placebo Comparator|Matching placebo oral disintegrating tablets for 7 days
40763175|NCT06641466|DRUG|Standard of Care|Standard of care for acute treatment as needed
40763176|NCT06641466|DRUG|Rimegepant|Rimegepant 75 mg ODT for acute treatment as needed
40763177|NCT06193382|BEHAVIORAL|PCIT|Participants will receive the adapted Pocket PCIT Online via a web-based learning platform for up to 5 weeks. Participants will engage in this intervention weekly for about 1 hour per week. During engaging with the adapted Pocket PCIT Online version of PCIT, caregivers will learn positive parenting skills to increase the warmth of the parent-child relationship as well as strategies to effectively set limits. Participants will also participate in 15-minute check-in phone calls with a therapist each week throughout the course of treatment.
40763178|NCT06172465|OTHER|EOIP|Ultrasound guided External oblique intercostal block will be performed bilaterally.
40763179|NCT06172465|OTHER|OSTAP|Ultrasound guided oblique subcostal transversus abdominis plane block will be performed bilaterally.
40763180|NCT02732496|BEHAVIORAL|Targeted Cognitive Training (TCT)|The instructors have selected a set of computer exercises designed to specifically target working memory, which is a cognitive construct relevant to ADHD and Tourette Syndrome. The tasks were designed to benefit subjects through principles of learning-dependent plasticity.
40763181|NCT02732496|OTHER|Youth Appropriate Online Games|Engaging games not designed to improve cognition.
40763182|NCT05549362|OTHER|Dial Health Research Study|To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.
40957114|NCT05993689|OTHER|BUNDLE|An integrated model of community-based doulas and clinical obstetric providers
40957115|NCT05993689|OTHER|Usual Care|Standard of care for pregnancy and pregnancy-related issues by the obstetric provider
40957116|NCT04084431|RADIATION|Radiation|WBRT will be applied in 10 fractions with single doses of 2 Gy (Arm 1) to the whole brain
40957117|NCT04084431|OTHER|OSC|optimal supportive Care (OSC) alone
40763183|NCT06637436|BEHAVIORAL|Motivational Interviewing (MI)|This telehealth MI intervention seeks to increase intrinsic motivation and self-efficacy for starting or restarting pre-exposure prophylaxis (PrEP) in session one. Session two focuses on concomitant risk behaviors such as substance use and CAS.
40957118|NCT06503913|BEHAVIORAL|Cognitive Muscular Therapy|Psychologically informed physiotherapy which integrates training to reduce overactivity of postural muscles which can interfere with the mechanics of breathing.
40957119|NCT06503913|BEHAVIORAL|Breathing visualisation|Breathing visualisation; Data from two 3D camera are combined and used to calculate respiratory volumes. These volumes are then used to drive an animation of breathing so that the patient can understand how their breathing pattern compares to an optimal pattern. Note this is not a medical device as data from this system is only used for education and not for diagnostic or treatment decisions.
41135635|NCT01566890|DRUG|regadenoson infusion with contrast-enhanced ultrasound|Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
40763184|NCT06637436|BEHAVIORAL|Contingency Management (CM)|Provides incentives for initiating PrEP care ($50) and filling a PrEP prescription ($50) in the three months following randomization.
40763185|NCT06640179|OTHER|Standard medical care|Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
40763186|NCT06640179|BEHAVIORAL|Monitoring Contacts|Participants will receive brief conducts (\<10 minutes) remotely (telephone or video platform) with the research staff at weeks 6, 12, and 18.
40763187|NCT06640179|BEHAVIORAL|Behavioral Sessions|Participants will be provided weekly individual behavioral sessions during the 6-month intervention to assist in supporting recommended changes in energy intake (diet) and physical activity.
40957120|NCT02371148|DRUG|Bortezomib-Rituximab-Bendamustine|"Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22\* Rituximab: 375 mg/sqm i.v. day 1\*\* Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles \*In case of toxicity is omitted~\*\*In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8"
41135636|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
41135637|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
41135638|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
41135639|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
41135640|NCT00131404|DRUG|taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
41135641|NCT00131404|DRUG|Comparator: Placebo|Placebo capsule once daily. 52 week treatment period.
41135642|NCT02808832|BEHAVIORAL|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
41135643|NCT01892007|BEHAVIORAL|Cogmed RM - Online adaptive working memory training|
41135644|NCT01892007|BEHAVIORAL|Cogmed RM - Online non-adaptive (placebo) working memory training|
41135645|NCT00068107|DRUG|Replagal|enzyme replacement therapy
41135646|NCT04660799|DRUG|Rituximab IV|Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m\^2 (milligram per square meter).
41135647|NCT04660799|DRUG|Rituximab SC|Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).
41466438|NCT06320158|OTHER|clinical evaluation of sarcopenic obesity|completion of scales and questionnaires, venous blood sampling, muscle ultrasound scan
41135648|NCT04660799|DRUG|Rituximab IV|Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m\^2.
41135649|NCT04660799|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2
41466439|NCT02604576|DRUG|FDC Bromopride 10 mg and Simethicone 80 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
41466440|NCT02604576|DRUG|Bromopride 10 mg|Bromopride 10 mg
41135650|NCT04660799|DRUG|Doxorubicin|Doxorubicin will be administered IV at a dose of 50 mg/m\^2
41135651|NCT04660799|DRUG|Vincristine|Vincristine will be administered IV at a dose of 1.4 mg/m\^2
41135652|NCT04660799|DRUG|Prednisone|Prednisone will be administered orally at a dose of 100 mg/day
41135653|NCT04660799|DRUG|Paracetamol|All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab
40763188|NCT06640179|BEHAVIORAL|Diet|An energy balanced diet to meet energy needs that will allow for weight maintenance will be prescribed. This will be estimated using the Mifflin-St. Joer equation to estimate resting metabolic rate and for most participants we anticipate using a physical activity correction of 1.3 to account for energy needs for physical activity. This will provide the initial estimate of energy intake needs to maintain weight stability; however, the prescribed level of energy intake will be adjusted at 4-week intervals across the intervention based on the observed changes in weight, eating behaviors, and physical activity patterns in an effort to prevent excessive weight gain. Within the context of this level of energy intake, we will prescribe a diet that is consistent with the dietary recommendations of the National Kidney Foundation.
40763189|NCT06640179|BEHAVIORAL|Physical Activity|Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress in 4-week intervals from an initial amount of 50 minutes per week to 150 minutes per week across the initial 6 months of the intervention. Moderate intensity will be prescribed, and will be anchored using RPE (rating of perceived exertion) to allow intensity to be self-regulated according to the participant's capacity. Physical activity will be prescribed in the form of walking; however, the participant will be permitted to engage in other forms of physical activity that meet the recommended dose and intensity.
40763190|NCT06499181|DRUG|Liposomal bupivacaine|The primary objective is to examine differences in post-operative opioid consumption between the two groups.
40763191|NCT06499181|DRUG|Bupivacain|Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
40957121|NCT04661904|DEVICE|Continuous theta burst stimulation (cTBS)|Our active treatment will consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions. All enrolled patient in the cTBS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes during the hospitalization after the surgery. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
41135654|NCT04660799|DRUG|Diphenhydramine hydrochloride or alternative antihistamine|All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab
40957122|NCT04661904|DEVICE|Sham stimulation|The sham stimulation group will receive a sham cTBS (600 pulses per session, 3 sessions per day, ISI ≥ 30mins, 4 days) with the coil set at 90 against the skull. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
41135655|NCT01197924|OTHER|IRMf Bold|IRMf BOLD of the working memory
41135656|NCT03510195|OTHER|MEDICORP HO PREPARATORY MODULE|3 DAY course module to prepare medical graduates to become house officers
41135657|NCT03864237|BEHAVIORAL|Alcohol texts|A text message each day for 10 weeks, containing factual information about campus drinking norms.
41466441|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 1|Low dose, approximately 10\^3 TCID50/mL
41135658|NCT03864237|BEHAVIORAL|Attention control|"A text message each day for 10 weeks, containing this day in history facts."
41455544|NCT05128396|BEHAVIORAL|Physical Activity|Aerobic exercises will include relatively low impact activities like walking, jogging, or running in place, which will aim to put limited demands on balance. Each exercise will be explained and demonstrated in the video. All exercises can be done standing, sitting, or next to a chair that provides balance support as demonstrated in the videos. After the first session, for each subsequent session the difficulty level will start at one level below the previous session's average difficulty level (e.g. if they exercise at the most difficult level for most of the time during one session, the next session will start at the medium difficulty level). Each exercise will be explained and demonstrated in the video.
41455545|NCT05128396|BEHAVIORAL|Control Group|Individuals in the control group will participate in the same computerized Cogmed training program as described above. The main difference is that for the control group task difficulty will remain at the same low starting level, rather than increasing over time. The instructions given to subjects will be identical to the ones used in the cognitive training intervention.
41455546|NCT04206462|OTHER|Questionnaire of eating habits|frequency and type of aliments
41455547|NCT00617825|OTHER|cyrotherapy as a cool gel wrap|A cool gel wrap made of a hydrogel with silicon will be applied to the lower leg of skin affected by venous disorders for 30 minutes each day for 30 days during the study
41455548|NCT01799850|DRUG|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
41455549|NCT01799850|DRUG|placebo|placebo assigned randomly, double blind
41455550|NCT02604641|DIETARY_SUPPLEMENT|Placebo group|Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
41455551|NCT02604641|DIETARY_SUPPLEMENT|Quvital LD group|Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
41455552|NCT02604641|DIETARY_SUPPLEMENT|Quvital HD group|Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
41455553|NCT06372119|PROCEDURE|Letrozole-stimulated cycle strategy|"Letrozole (Femara® 2.5 milligrams, Novartis, Switzerland or Lezra® 2.5 milligrams, Actavis, Rumani) 5 milligrams/day for 5 days, starting on the second to fourth day of the menstrual cycle.~Post-letrozole, ultrasound checks follicle growth. If ≥18mm, Ovitrelle® 250 mcg (Merck, Kenilworth, New Jersey, USA) induces ovulation.~Luteal phase support with vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day starting two days post-hCG.~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: no follicle development on day 21 from the day of starting letrozole, spontaneous ovulation, letrozole intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
41455554|NCT06372119|PROCEDURE|Artificial cycle strategy|"Oral estradiol valerate (Progynova® 2 milligrams, Bayer Pharma AG, Germany or Valiera® 2 milligrams, Laboratories Recalcine, Chile) 6 milligrams/day for 10 days, starting on the second to fourth day of the menstrual cycle.~Post-estradiol, ultrasound checks endometrial thickness. If ≥7mm, start vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day. If \<7mm, increase the dose of oral estradiol valerate to 8 milligrams/day (5-6 days) and 12 milligrams/day (5-6 days).~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: endometrial thickness \<7mm on day 21 of using estradiol, spontaneous ovulation, oral estradiol valerate intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
41455555|NCT00510848|PROCEDURE|autograft tendon|Reconstruction with an autograft tendon (hamstrings)
41455556|NCT00510848|PROCEDURE|allograft tendon|Reconstruction with an allograft tendon (tibialis posterior)
41455557|NCT00266487|DRUG|Folic acid|
41455558|NCT00266487|DRUG|Vitamin B12|
41455559|NCT00266487|DRUG|Vitamin B6|
41455560|NCT03407222|OTHER|Text messages|Text messages which encourage the increment of daily step count
41455561|NCT02156219|OTHER|Separation of women and men in the metro of Mexico City|"The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.~The implementation of the measure of separation of men and women on the subway consists of three operational tasks:~1. Control: Surveillance that men do not use cars corresponding to women.~2. Dosage: Regulation of entry women.~3. Assignment: Of the women, to the part of the platform where the first wagons stop."
41455562|NCT02789839|PROCEDURE|Blood test|Blood test of 30mL
41135659|NCT00222898|PROCEDURE|DNA analysis of pancreatic cyst fluid / buccal swab|
41135660|NCT04901416|BIOLOGICAL|DVX201|"Based upon the occurrence of DLT (does limiting toxicity), the MTD will be estimated as the highest dose at which the toxicity probability is the closest to the target probability (denoted pT=0.30) following up to 2 doses of DVX201. The corresponding dose allocation methodology is a modified toxicity interval design based upon (Ji et al., 2010; Ji et al., 2013).~All patients who have at least one dose initiated will be included in the safety analysis. Patients who are enrolled but never exposed to investigational product will be replaced for all analyses. Patients who get exposed to lymphodepleting chemotherapy will be followed and reported for outcomes overall, but for determination of safety and efficacy, only those subjects who have been exposed to the investigational agent will be included."
40957123|NCT06143813|DIAGNOSTIC_TEST|Selective nerve root block (SNRB)|CT/Fluoroscopy guided nerve root block
40957124|NCT01602120|DRUG|Lampalizumab|Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
41135661|NCT05851898|DRUG|Duloxetine 30 mg|Duloxetine 30mg daily prescribed at discharge
41135662|NCT04329598|OTHER|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
41455563|NCT02789839|PROCEDURE|Medullar test|Medullar test for 2-5mL and a smear
41455564|NCT03543735|BEHAVIORAL|Wisepill+SMS|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox and generate relapse prevention messages that can be later delivered during non-adherent windows; 2) use of the Wisepill device during the intensive treatment program and after discharge; and 3) three forms of tailored SMS messages paired with Wisepill device use: a) supportive messages with medication compliance, b) reminder messages for early non-adherence (e.g., 1 hour late) and c) relapse-prevention messages after longer periods of non-adherence (e.g., several hours).
41455565|NCT03543735|OTHER|Wisepill-only|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox; 2) use of the Wisepill during the intensive treatment program and after discharge.
41455566|NCT06332690|DEVICE|dexamethasone implant|Intravitreal dexamethasone implant (Dex) slowly releases steroids into the vitreous over a period of up to 6 months. Dex 0.7 mg (Ozurdex™; Allergan, Irvine, CA, USA) has been used to reduce ME in patients with DR and RVO and its efficacy in terms of best corrected visual acuity (BCVA) improvement and central macular thickness (CMT) reduction has been demonstrated in many different studies.
41455567|NCT06138561|BEHAVIORAL|Geriatric-8 Survey|A screening tool to evaluate frailty and at-risk participants by covering multiple domains that contribute to frailty, including mobility, functional status, pharmacologic burden, and underlying psychologic burden. A total score ranges from 0 to 17 with participants scoring \> 14 points are more likely to be fit, or having a better health status, while those scoring 0 - 14 would benefit from further comprehensive geriatric assessment.
41455568|NCT06138561|BEHAVIORAL|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)|Patient reported, sixteen question survey focused on evaluation of quality of life in patients with bladder cancer.
41455569|NCT06138561|BEHAVIORAL|Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)|Patient-reported questionnaire that evaluates cancer-specific toxicity, developed based upon Common Terminology Criteria for Adverse Events.
41455570|NCT00525746|BEHAVIORAL|Interview|Interview lasting about 50 minutes.
41455571|NCT01598896|DRUG|Dronabinol|Dronabinol titrated to 5 mg three times daily
41455572|NCT01598896|DRUG|Clonidine|Clonidine 0.1 mg twice daily
41455573|NCT01598896|DRUG|Placebo|One placebo capsule by mouth twice daily
41455574|NCT04021160|DEVICE|High frequency repetitive transcranial magnetic stimulation (rTMS)|10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
41455575|NCT04021160|DEVICE|Sham stimulation|A sham coil will be used that is shielded so that it produces sounds and sensations similar to the active coil but does not produce therapeutic effects. 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
41455576|NCT02821676|PROCEDURE|PECI/SPB Block with Active Anesthetic + Placebo Multilevel Intercostal Nerve Block followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of 0.5% Ropivacaine with 1:200,000 epinephrine preoperatively via an ultrasound guided PECI/SPB regional block and 5mL of Normal Saline intraoperatively as an intercostal nerve block to each of the T2-T7 nerve segments
41455577|NCT02821676|PROCEDURE|Placebo PEC/SPB Block + Multilevel Intercostal Nerve Block with Active Anesthetic followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of Normal Saline via an ultrasound guided PECI/SPB block and 5mL of 0.5% Ropivacaine with 1:200,000 epinephrine as an Intercostal nerve block to each of the T2-T7 nerve segments
40957125|NCT04709107|OTHER|Quality of life assessment - elective|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. To assess reliability and systematic shift and variation between the two assessments, elective patients will be asked to fill the VascuQoL-6 again at the admission to hospital, as well as 1 week after the 30-days follow-up vie an e-mail link for a test-retest assessment. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
41135663|NCT04329598|OTHER|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
41135664|NCT04338919|PROCEDURE|Percutaneous coronary intervention|PCI with stent implantation
41135665|NCT04338919|DRUG|Ticagrelor plus aspirin|Ticagrelor plus aspirin
41455578|NCT00178711|DEVICE|Hypothermia|Induction of moderate hypothermia to 33 degrees celsius, within 2.5 hours from time of injury and maintained for 48 hours
41455579|NCT06285448|DRUG|Lecanemab|Bi-weekly infusions of lecanemab \[exposure\].
41455580|NCT00252161|PROCEDURE|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
41455581|NCT00252161|DRUG|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
41455582|NCT02218216|DEVICE|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
41455583|NCT06481813|OTHER|Blood Sampling (2*8mL Tubes)|Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)
41455584|NCT06481813|OTHER|PBMC Sampling (1*8mL Tubes)|Patients will be sampled from 1 x 8 mL PBMC
41455585|NCT06481813|OTHER|Paxgene Sampling|Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube
41466442|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 2|Medium dose, approximately 10\^4 TCID50/mL
41466443|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 3|High dose, approximately 10\^5 TCID50/mL
41466444|NCT01004315|DRUG|KUC-7483|
41466445|NCT01004315|DRUG|Placebo|
41466446|NCT01004315|DRUG|Tolterodine|
41455586|NCT03342196|DRUG|Melphalan|"Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
41455587|NCT03342196|DRUG|Thiotepa|"Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
41292343|NCT04934202|OTHER|Teleconsultation|"Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms:~* General signs: Anorexia, fatigue, new hospitalization, weight loss,~* Respiratory signs: recent dyspnoea, chest discomfort, chest pain, new cough, abnormal lung CT scan since discharge~* Neurological signs: headache, paraesthesia, anosmia, limb paralysis~* Digestive signs: abdominal pain, diarrhoea, constipation, nausea, vomiting~Edition 2021~◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties"
41455588|NCT03342196|DRUG|Fludarabine|"Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness."
41292344|NCT04934202|OTHER|Outpatient clinic|"During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment.~* General clinical examination~* Assessment of the state of health~* Respiratory assessment~* Pulmonary CT assessment~* Cognitive evaluation~* Cardiological evaluation~* Renal assessment~* Immunological evaluation"
41292345|NCT00851110|PROCEDURE|stem cell reinfusion|hematopoietic stem cell reinfusion
41292346|NCT00851110|DRUG|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
41292347|NCT02049528|DRUG|CC-122|CC-122
41292348|NCT02049528|DRUG|CC-122|CC-122
41292349|NCT02049528|DRUG|CC-122|CC-122
41292350|NCT06513195|PROCEDURE|endoscopic ultrasound-guided portal pressure measurement|The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.
41292351|NCT00492622|DRUG|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
41292352|NCT00492622|DRUG|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
41292353|NCT00259805|DRUG|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
41292354|NCT02778776|DRUG|Metformin|Metfomin in tablet presentation of 500 mg
41455589|NCT01640041|DEVICE|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
41455590|NCT01096745|DRUG|Gemcitabine, Cisplatin|D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
41455591|NCT01096745|DRUG|S-1, Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
41455592|NCT04779827|BEHAVIORAL|Online Social Network and Collective Intelligence Intervention|The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.
41455593|NCT04779827|BEHAVIORAL|Independent Control|Independent control aims to test the baseline of population understanding of health behaviors and choices. Participants will respond to health questions independently without getting any feedback from others.
41455594|NCT00685334|DRUG|Olanzapine|Participants will take olanzapine daily for 12 weeks.
41455595|NCT00685334|DRUG|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
41455596|NCT00697827|DEVICE|Interspinous Spacer device|Device: In-Space
40763192|NCT06499181|DRUG|Epinephrin|Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
41292355|NCT02778776|DIETARY_SUPPLEMENT|Agave inulin|Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
41292356|NCT02778776|OTHER|Placebo of agave inulin|Calcinated magnesia powder
41292357|NCT02778776|OTHER|Metformin placebo|Calcinated magnesia tablet
41292358|NCT02797041|DRUG|Bortezomib|Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment
41292359|NCT04827056|DRUG|Placebo|Placebo will be administered orally, as individual films in the SL space.
41292360|NCT04827056|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL 501 40µg will be administered orally, as individual films in the SL space.
41292361|NCT04827056|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL 501 80µg will be administered orally, as individual films in the SL space.
41292362|NCT04827056|PROCEDURE|Ethanol Infusion|Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).
41292363|NCT04827056|BEHAVIORAL|PTSD Reactivity Condition|Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).
41292364|NCT04827056|BEHAVIORAL|Alcohol Cue Reactivity|Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.
41292365|NCT04205591|PROCEDURE|split bone block technique|A graft surgery using autogenous bone chips surrounded by a rigid framework made over the atrophic sites of the mandible and maxilla to obtain bone augmentation to support dental implants
41292366|NCT01589094|DRUG|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
41292367|NCT02688010|BEHAVIORAL|Noise reduction and cycled light|Reduced noise exposure (sound levels \<45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
41292368|NCT03016715|DRUG|Sirolimus 2%|
41135666|NCT02499094|OTHER|Behavioral-data driven support|Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
41292369|NCT03016715|DRUG|Vehicle|
41292370|NCT04967755|DRUG|Jing-Si-Herbal-Tea|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
41292371|NCT01749735|DEVICE|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
41292372|NCT01749735|DEVICE|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
41292373|NCT01749735|DEVICE|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
41292374|NCT03909685|BEHAVIORAL|Mobile Mental Health App|The Mobile Mental Health App is an app that utilizes artificial intelligence to identify symptoms and provides targeted, tailored solutions for its users.
41292375|NCT02813330|OTHER|Subcutaneous sterile water injection|sterile water injection in two points of low back pain
41292376|NCT02813330|OTHER|saline injection|Saline injection in two points of low back pain
41292377|NCT02278146|DEVICE|ParaPatch|A device for the treatment of urinary incontinence
41292378|NCT00023907|DRUG|paclitaxel|
41292379|NCT05330442|BEHAVIORAL|Written Exposure Therapy (WET)|The WET protocol for primary care settings consists of six, 30-minute sessions. The first session consists of psychoeducation of PTSD and treatment rationale. Written narratives are conducted in sessions 2-6, following specific writing instructions and 20 minutes of writing in each session.
41135667|NCT01556594|DRUG|Nasal Glucagon 1 mg|
41135668|NCT01556594|DRUG|Nasal Glucagon 2 mg|
41292380|NCT02109003|DEVICE|Pressure easy® device|Continuous control of tracheal cuff pressure using a mechanical device for 24h followed by manual control of cuff pressure using a manometer.
41292381|NCT02109003|DEVICE|Manual control of Pcuff followed by continuous control.|Control 24h with manual control using a manometer followed by 24h of continuous control using a mechanical device.
41292382|NCT00229840|PROCEDURE|Functional MRI, Diffusion Tensor Imaging|
41455597|NCT00697827|DEVICE|Interspinous Process Distraction Device|Device: X STOP
40763193|NCT06256120|DIAGNOSTIC_TEST|Restrictive|3 mL/kg/hour Ringer Lactate will be given peroperatively to the restrictive group (Group R).
41135669|NCT01556594|DRUG|SC Glucagon|
41292383|NCT02077322|DEVICE|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
41292384|NCT02077322|DEVICE|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
41292385|NCT01088815|DRUG|Gemcitabine, nab-Paclitaxel, GDC-0449|"1. One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~2. Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"
41292386|NCT06318923|OTHER|Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment|"The demographic questionnaire collects demographic information: gender, age, level of education, laterality, history of psychiatric or neurological disorders.~The moral judgment task consists in completing 20 vignettes of moral dilemmas. Cognitive disorders will be assessed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery. If the patient has taken the BICAMS battery recently (less than 6 months), and with no change in pathology since then, the results of these tests will be used in this study.~Affective disorders will be assessed using the following tests:~* The Beck Depression Inventory-Fast Screen (BDI-FS) to assess the level of depression,~* State trait anxiety inventory-Y (STAI-Y) to assess anxiety,~* Toronto Alexithymia Scale-20 (TAS-20)to assess alexithymia,~* The Empathy Quotient-8 (EQ-8) to assess participants' level of empathy,~* The Dot Probe Task to assess participants' emotional information processing style."
41292387|NCT06318923|OTHER|MS questionnaire|This questionnaire collects key information on the participant's pathology: clinical form, date of first symptoms, diagnosis, last attack, as well as latest EDSS and functional scores.
41292388|NCT06318923|OTHER|MONTREAL COGNITIVE ASSESSMENT (MoCA) test|The MoCA is a screening tool for neurocognitive impairment, designed primarily to detect milder impairment. The MoCA is a short-answer questionnaire that includes a number of tasks to be completed by the individual. The items assessed are grouped into six subsections: short-term memory, visuospatial skills, executive functions, attention, concentration, working memory, language and orientation in time and space. The tests proposed are often more complex than those found in the mini-mental state examination (MMSE).
41292389|NCT01377467|DRUG|Denosumab (Prolia)|60 mg s.c. injection at baseline and after 6 months
41292390|NCT02892097|DEVICE|tDCS|tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
41292391|NCT02892097|DEVICE|sham tDCS|Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
41292392|NCT02892097|BEHAVIORAL|Repetitive task-specific practice (RTP)|Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
41292393|NCT06094712|DRUG|CORT125134|CORT125134 150-mg capsule
41292394|NCT05536648|OTHER|Comparing the plaque removal ability of triple head tooth brush versus single head tooth brush among school based cerebral palsy children: A Randomized Control Trial|To compare the plaque removing ability of two different tooth brushes in school going cerebral palsy children.
41455598|NCT01101386|DRUG|Voriconazole|Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
41455599|NCT02545179|OTHER|web-based daily care training|12 week interactive web based caring training education
41455600|NCT06486389|DEVICE|reading fairy tales|Reading fairy tales during inhaler medication administration.
41455601|NCT06486389|DEVICE|painting|painting during inhaler medication administration
41455602|NCT00735319|DEVICE|Transcutaneous Bilirubinometer|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
41455603|NCT01427036|PROCEDURE|MISS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate."
41455604|NCT01427036|PROCEDURE|PHS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a  L  detaching the vastus lateralis to expose the external surface of the femur on the length of the plate."
40763194|NCT06256120|DIAGNOSTIC_TEST|Liberal|7 ml/kg/hour Ringer Lactate will be given peroperatively to the liberal group (Group L).
41455605|NCT04606550|DEVICE|Microablative Fractional CO2 Laser Therapy|Microablative Fractional CO2 Vaginal Laser Therapy
41455606|NCT02428348|OTHER|Interview about prototype EEG-cap|
40763195|NCT01321684|OTHER|lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.
40763196|NCT01321684|OTHER|lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column
41135670|NCT01556594|DRUG|Nasal Glucagon 3 mg|
41455607|NCT02342873|PROCEDURE|NS-guided interscalene block|Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
40763197|NCT05989477|OTHER|At-home Breast Oncology care Delivered with E-health solutions - ABODE|The development and implementation of the Breast Cancer Treatment Application (BCTA) will facilitate a secure approach to virtual care for Breast Cancer patients, provide patient specific treatment education and facilitate evaluation of Patient Reported Outcome Measures.
40957126|NCT04709107|OTHER|Quality of life assessment - emergent|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
41292395|NCT00942877|DRUG|AZD2171|Cediranib (AZD2171), a vascular endothelial growth factor (VEGF)/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with Alveolar Soft Part Sarcoma (ASPS).
40763198|NCT06639984|DRUG|Psyllium (0.7 g/year of age per day)|Psyllium (0.7 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
40763199|NCT06639984|DRUG|Psyllium (0.5 g/year of age per day)|Psyllium (0.5 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
40763200|NCT06639984|DRUG|Placebo|Placebo (0.7 g/year of age glucose) (Staleydex 333; Tate \&amp; Lyle, Staley, London, UK)
40763201|NCT06639984|OTHER|fructans|Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
40763202|NCT06639841|DEVICE|Virtual Reality Psychotherapy|"Participants in this VR-facilited psychotherapy group will receive their treatment via Oculus Quest 2 and HTC Vive Flow wireless, standalone headsets systems to provide a comfortable immersive environment. The more hardware-intensive experiences will be carried out on Oculus Rift S headsets powered by high-end laptops.~Sessions will last 30-60 minutes each, ranging from six to ten sessions within two to four weeks. The treatment will include reducing anxiety and improving emotion regulation through Cognitive-Behavioural techniques such as mindfulness, acceptance and commitement therapy, exposure therapy and 4-7-8 breathing. The same investigator will conduct all sessions to ensure uniformity. Additionally, subjects will undergo unsupervised VR at home with pre-programmed headsets to minimize investigator bias and maintain cosistancy of the relaxation and cognitive-behavioral strategies."
40957127|NCT05134675|DIETARY_SUPPLEMENT|Homemade beer|The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.
40957128|NCT00581243|DRUG|SLV-313 SR|sustained relase tablets taken once daily for 14 days
40957129|NCT01430000|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
40957130|NCT02537119|PROCEDURE|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
40957131|NCT02537119|PROCEDURE|Massage therapy|Rubbing on hamstrings
41292396|NCT00968578|DRUG|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
41292397|NCT00968578|DRUG|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
40957132|NCT00149201|DRUG|5-FU continuous infusion|
40957133|NCT00149201|DRUG|MTX + 5-FU sequential therapy|
40957134|NCT00289133|DEVICE|total knee arthroplasty|Gamma Vacuum Foil polyethylene tibial insert
40957135|NCT00289133|DEVICE|total knee arthroplasty|cross-linked polyethylene tibial insert
40957136|NCT03993795|OTHER|A19010-W|A snus product
41455608|NCT02342873|PROCEDURE|US-guided interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
40957137|NCT03993795|OTHER|B19010-F|A snus product
40957138|NCT06000332|DEVICE|InogenOne Rove 6 Portable Oxygen Concentrator|overnight use of Portable Oxygen Concentrator, 6 hours minimum
40957139|NCT03185871|DRUG|Celecoxib|Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
40957140|NCT05536050|OTHER|Migraine diary and Questionnaires|Patients who already have a prescription for low-dose naltrexone will be administered questionnaires twice during the trial. Additionally, patients will maintain migraine diary for the duration of the trial.
40957141|NCT00690274|DRUG|BF2.649|up to 20mg per day
40957142|NCT00690274|DRUG|Placebo|up to 20mg per day
40957143|NCT01529502|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
40957144|NCT01529502|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
40957145|NCT01529502|DRUG|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
40957146|NCT00412542|DRUG|Thalidomide|100 mg PO (by mouth) daily for 8 weeks
40957147|NCT00412542|DRUG|CPT-11|125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
40957148|NCT00412542|PROCEDURE|MRI Scan|Dynamic MRI scan with dye injection through vein, every 6 weeks
41135671|NCT03819543|DEVICE|Transcranial Direct Current Stimulation|Application of transcranial direct current stimulation via scalp electrodes over presumed epileptogenic focus for 20 minutes at 2.0 mA.
40957149|NCT00412542|PROCEDURE|Quantitative Sensory Tests (QST)|QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
40957150|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
40957151|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
40957152|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
40957153|NCT01534962|DRUG|Placebo|Oral administration, BID; for a maximum of 112 days.
40957154|NCT06074601|DIAGNOSTIC_TEST|Mirvie Predictive Test for Adverse Pregnancy Outcomes|This is a proprietary biomarker and clinical factor-based algorithm for predicting which pregnancies are at greatest risk of developing a variety of adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)
41135672|NCT03592407|DRUG|Epacadostat|Given PO
41135673|NCT03592407|OTHER|Laboratory Biomarker Analysis|Correlative studies
41135674|NCT03592407|BIOLOGICAL|Pembrolizumab|Given IV
41135675|NCT03592407|OTHER|Pharmacodynamic Study|Correlative studies
41135676|NCT02413138|DRUG|Somavaratan (VRS-317)|Long acting recombinant human growth hormone
41135677|NCT01522014|DEVICE|Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head|
41292398|NCT00364039|DRUG|AV650|
41455609|NCT05863026|BEHAVIORAL|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
41455610|NCT00522223|BEHAVIORAL|Questionnaire|"Participants who are treated with radiation therapy: Questionnaires 5 times.~Participants who undergo a radical hysterectomy: Questionnaires 4 times."
41455611|NCT06129123|BEHAVIORAL|Live Free From E-cigarettes|This is a 30-minute online educational program that focuses on providing information about e-cigarette and smoking social norms, harms of e-cigarettes and cigarettes, and ways to quit or reduce using e-cigarettes.
40957155|NCT02420340|BEHAVIORAL|"HOPES Program (Helping Older People Experience Success)"|Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
40957156|NCT02128971|DIETARY_SUPPLEMENT|Ferrochel® 90 mg|Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
40957157|NCT02128971|DIETARY_SUPPLEMENT|Sumalate® 90 mg|Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
40957158|NCT02128971|DIETARY_SUPPLEMENT|Ferrous fumarate 90 mg|Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
40957159|NCT02128971|DIETARY_SUPPLEMENT|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
40957160|NCT02128971|DIETARY_SUPPLEMENT|Ferric Glycinate 90 mg|Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
40957161|NCT02128971|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
40957162|NCT03159117|DRUG|PF-06688992|(PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
40957163|NCT04118439|OTHER|Motor Imaginery and Action Observation|A set of tasks done with the shoulder, first with an Action Observation perspective and then asked to perform this tasks with motor imaginery
40957164|NCT06044610|OTHER|GENPOP Passive dehydration (75% reduction in fluid intake|Over 24-hours
40957165|NCT06044610|OTHER|GENPOP Ad lib fluid intake|Over 24 hours
40957166|NCT06044610|OTHER|EXERCISE without fluid replacement|90-min standard cycling exercise trial in heat chamber
40957167|NCT06044610|OTHER|EXERCISE with fluid replacement|90-min standard cycling exercise trial in heat chamber
40957168|NCT02568774|OTHER|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
40957169|NCT02568774|OTHER|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
40957170|NCT00091442|DRUG|Docetaxel|Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
40957171|NCT00091442|DRUG|DOXIL|DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
40957172|NCT01890941|DRUG|KCT-0809 ophthalmic solution|
40957173|NCT01890941|DRUG|Placebo|
40957174|NCT04453722|DEVICE|Oxalert Monitor Mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO. Using the Oxalert in monitor only mode.
40957175|NCT04453722|DEVICE|Oxalert Normal mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO using the Oxalert in monitor in normal mode
40957176|NCT01463488|DRUG|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
40957177|NCT01463488|DRUG|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
40957178|NCT05684705|DRUG|BV100|Intravenous infusion
40957179|NCT05562414|BEHAVIORAL|HIIT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will perform six high-intensity intervals (95% HRmax) at high pedalling rates of 80-100 rounds per minute (rpm) for 60-90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20 watts, 60-80rpm) aimed to return to 60% HRmax (approximately 1.5-2 min). The duration of the HIIT bout is approximately 21 minutes."
40957180|NCT05562414|BEHAVIORAL|MCT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will continuously train at 60% HRmax and pedal at 60-80 rounds per minute. The duration of the MCT bout is 26 minutes."
41135678|NCT01522014|DEVICE|Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head|
41135679|NCT05081726|DIAGNOSTIC_TEST|Functional MRI|Series of MRI scans of the brain
41135680|NCT00869856|DRUG|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
41455612|NCT00000380|DRUG|GHRH|
41455613|NCT03956420|BEHAVIORAL|Premedication visit|detailed information about surgery, anaesthesia and postoperative period
41455614|NCT03956420|DIETARY_SUPPLEMENT|Preoperative period|avoidance of prolonged fasting, intake of fluids with carbohydrates before surgery
41455615|NCT03956420|DRUG|Preoperative period|administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre
40957181|NCT05493475|BEHAVIORAL|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at court sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
40957182|NCT05200832|OTHER|Online questionnaire|Participants will be asked to complete an online questionnaire about their health and quality of life since the start of the pandemic.
40957183|NCT05200832|OTHER|Semi-structured interview|20 participants (10 from each group) will be randomly selected to participate in a semi-structured interview focusing on their perception of their health and quality of life since the start of the pandemic.
40957184|NCT06438588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41292399|NCT01625169|DRUG|Etravirine pharmacokinetics in breast milk and plasma|HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
41292400|NCT01771679|BIOLOGICAL|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
41292401|NCT04359446|PROCEDURE|NC ( Non- Compliant) Balloon dilatation|NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
41292402|NCT04359446|PROCEDURE|Laser Excimer + NC Balloon|Laser Excimer + NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
41292403|NCT04977999|OTHER|Exercise|Both arms/conditions use varying forms of exercise as the intervention.
41292404|NCT04362267|OTHER|self-administered questionnaire|Every14 days, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
41455616|NCT03956420|OTHER|Postoperative period|Fluids 1 ml/kg/h; Discontinuation of propofol at the moment of drainage and cardiovascular system stabilization; Fluids administered orally 2 hours after extubation; Early mobilisation
41455617|NCT03956420|OTHER|Intraoperative period|deep temperature (necessity to maintain normothermia during the stay in the operating theatre 36 °C. Normothermia should be maintained rather than restored.
41455618|NCT03956420|DRUG|Intraoperative period|Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.
41455619|NCT03956420|DRUG|Intraoperative period|Ketamine 30 mg i.v. after induction of anaesthesia
41455620|NCT03956420|DRUG|Intraoperative period|Sevoflurane 1.5 MAC higher in patients \< 60 years old
41455621|NCT03956420|DRUG|Intraoperative period|Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field
41455622|NCT03956420|DRUG|Intraoperative period|Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
41455623|NCT03956758|OTHER|Semi-directed interview|Semi-directed interview on ChemSex practice
40957185|NCT06438588|OTHER|Dietary Intervention|Given FMD
40957186|NCT06438588|OTHER|Educational Intervention|Receive educational guidelines
40957187|NCT06438588|OTHER|Electronic Health Record Review|Ancillary studies
41455624|NCT03865225|OTHER|Biofeedback|9 x 10 minutes biofeedback sessions over period of three days
41455625|NCT03865225|OTHER|Sham-Biofeedback|9 x 10 minutes sham-biofeedback sessions over period of three days
41455626|NCT01941069|BEHAVIORAL|Friends for Life|Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
41455627|NCT01941069|BEHAVIORAL|Coping Power Program|The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
41455628|NCT06277076|PROCEDURE|Computer Implant guided Surgery|Dental implant placed using printed guide after a digital planification on a superimposed 3D surface scan and a 3D Cone Beam imaging of the jaw.
41455629|NCT01644422|BIOLOGICAL|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
41455630|NCT01644422|BIOLOGICAL|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
41455631|NCT01644422|OTHER|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
41455632|NCT01044433|DRUG|lapatinib ditosylate|Given orally
41455633|NCT01044433|DRUG|capecitabine|Given orally
41455634|NCT03313713|DIETARY_SUPPLEMENT|Beta-glucans|Placebo consumption at breakfast (3 g per day)
41455635|NCT03313713|DIETARY_SUPPLEMENT|Placebo|Placebo consumption at breakfast (3 g per day)
41455636|NCT01485068|DEVICE|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
41455637|NCT02581527|DRUG|Rifampicin|Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
41455638|NCT02581527|DRUG|Isoniazid|Isoniazid 75mg - all arms
41455639|NCT02581527|DRUG|Ethambutol|Ethambutol 275mg - all arms
41455640|NCT02581527|DRUG|Pyrazinamide|Pyrazinamide 400mg - all arms
41292405|NCT04362267|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every14 days, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
41292406|NCT04727216|DEVICE|Dorsal Root Ganglion Stimulation (DRG-S)|Dorsal Root Ganglion stimulation will be delivered with continuous dosing and 2 different ON/OFF periods to compare effects for each patient.
41292407|NCT04755400|OTHER|isotonic saline 9%|1 Liter of Isotonic saline administered I.V.
40763203|NCT06639841|BEHAVIORAL|Yoga|"The Yoga group members will be guided in a yoga class focused on managing performance anxiety. The interventions will consist of body exercises (Asanas), breath (Pranayama) and meditation to increase relaxation, consciousness and resilience; typical yoga postures like Surya Namaskar, Padahastasana, Virabhadrasana, Bhujangasana and Shavasana will be included in the session, as will breathing movements like Ujjayi (Victory Breath).~Each class will be 60-90 minutes long, and 6-10 classes will be taught in two to four weeks. The technique will be progressive, from the basic to more advanced postures as participants cultivate confidence and resilience. All classes will conclude with meditation to ease tension and cultivate mindfulness."
40763204|NCT06457217|DIAGNOSTIC_TEST|Magnetic resonance spectroscopic imaging|High-resolution 3D metabolic imaging was performed using the SPICE 1H-MRSI sequence.
41292408|NCT04755400|DIETARY_SUPPLEMENT|Potassium nitrate|24 mmol of Potassium nitrate is the active comparator substance, that is ingested every morning for 4 days before and on the examination day.
41292409|NCT04755400|DIETARY_SUPPLEMENT|Potassium chloride|24 mmol of Potassium nitrate is the placebo substance, that is ingested every morning for 4 days before and on the examination day.
40957188|NCT06438588|OTHER|Interview|Ancillary studies
40763205|NCT03342222|DEVICE|Interference Screws|tibial fixation for ACL reconstruction
41292410|NCT05743543|OTHER|Sphenopalatine ganglion block|The block is performed with a nasoscope and the administration of a local anesthetic.
41292411|NCT01284556|DRUG|Phenobarbital|tablet
41292412|NCT01284556|DRUG|Placebo tablet|tablet
41292413|NCT00909090|DIETARY_SUPPLEMENT|12 mg Lutein + Zeaxanthin|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year
41455641|NCT03567122|OTHER|Internal Focus of Attention|Information already included in arm/group descriptions.
41455642|NCT03567122|OTHER|External Focus of Attention|Information already included in arm/group descriptions.
40763206|NCT05085756|BEHAVIORAL|Puma|One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.
40763207|NCT06555601|DRUG|UCB3101|Study participants will receive UCB3101 as prespecified in each cohort.
40763208|NCT06555601|DRUG|Placebo|Study participants will receive placebo as prespecified in each cohort to maintain the blinding.
40957189|NCT06438588|OTHER|Nutritional Assessment|Receive nutrition counseling
40957190|NCT06438588|OTHER|Questionnaire Administration|Ancillary studies
41292414|NCT00909090|DIETARY_SUPPLEMENT|Visually identical placebo|Visually identical placebo, taken once daily for one year
41292415|NCT02093975|DEVICE|iPad air with 4G/3G SIM card|"iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation"
41292416|NCT02617758|DRUG|Fentanyl|Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
40957191|NCT06544889|OTHER|Sunscreen SPF 70|Participants will topically apply sunscreen SPF 70
41455643|NCT03567122|OTHER|Control|Information already included in arm/group descriptions.
41292417|NCT02617758|DRUG|Fentanyl|Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
41292418|NCT02465034|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator to measure transient cortical excitability. Single pulse transcranial magnetic stimulation applied at low frequencies (not greater than 0.25 hertz (Hz)) will be used. The may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
41466447|NCT00133367|DRUG|Tacrolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
40763209|NCT06642636|DEVICE|Intensive Care Unit-specific Virtual Reality|The Intensive Care specific Virtual Reality (ICU-VR) film is designed so that patients received relevant and truthful information regarding their ICU treatment with the aim to reduce stress and anxiety. The final film lasts approximately 12 minutes. Real ICU nurses and ICU physicians re-enacting a typical day/treatment for a mock patient undergoing ICU treatment. The module will be watched via HMD-VR glasses (PICO G2 VR; Pico Technology, Beijing, China) with the SyncVR Relax \& Distract application (SyncVR, Utrecht, the Netherlands).
40763210|NCT04605146|BEHAVIORAL|Tele-monitoring|"The tele-monitoring will consist in filling in a specific questionnaire once a week in the first 6 months, every 2 weeks until 12 months, and on-demand (in case of upcoming toxicity, at any time). These questionnaires will be reviewed by a coordinating nurse. According to the result of the questionnaire, the coordinating nurse will adapt patients' management, either by giving them a phone call, or inviting them to directly contact their medical department, or even plan an emergency hospitalization if necessary. The coordinating nurse will closely work with the investigator to adapt patients' management.~Quality of life questionnaire (FACT-G) will also be filled in at inclusion, M3 and M12."
41466448|NCT00133367|DRUG|Sirolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
40957192|NCT04841538|DRUG|ES101|The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
40957193|NCT00891592|BIOLOGICAL|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|"Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~* 1xE5 cells/kg~* 2xE6 cells/kg~* 3xE7 cells/kg~* 4xE8 cells/kg"
40957194|NCT00891592|OTHER|Observation Arm|Single infusion of Cord Blood Cells
40957195|NCT05344365|DRUG|Iloperidone|oral tablet
40957196|NCT00145522|DRUG|17ß-Estradiol/Dydrogesterone|1/5 mg/day for 12 cycles of 28 days
40957197|NCT00145522|DRUG|Tibolone|2,5 mg/day for 12 cycles of 28 days
40957198|NCT00092638|DRUG|MK0653, ezetimibe|
40957199|NCT00092638|DRUG|Comparator: ezetimibe, placebo|
40957200|NCT04263077|OTHER|PLACEBO|The diamond shape technique, which is a kinesio tape technique, will be used in the lateral epicondyle region. The ends of the kinesiotapes will be applied tension-free without overlapping.
40957201|NCT04263077|OTHER|50% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 50% tension.
40957202|NCT04263077|OTHER|75% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 75% tension.
40957203|NCT04263077|OTHER|100% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 100% tension.
40957204|NCT02956239|PROCEDURE|Thermocoagulation (device)|Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix
40957205|NCT02956239|PROCEDURE|Cryotherapy (device)|Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix
40957206|NCT02956239|PROCEDURE|LEEP (device)|The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
40957207|NCT02435446|DEVICE|Cone-beam computed tomography|Cone-beam computed tomography
40957208|NCT05995483|OTHER|Early Diagnosis on BSE|the System Which Sends Reminder Notifications Directing Them to the Website Containing BSE Training Along With the Illustrations Created for the Practice Prepared by the Researcher on the Determined Ideal Day.
40957209|NCT01319890|PROCEDURE|Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)|Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
40957210|NCT06295302|DRUG|HWH486|HWH486 capsule was administrated orally
40957211|NCT06295302|DRUG|Placebo|Matching placebo was administrated orally
40957212|NCT05210335|OTHER|Clinical pharmacist's recommendation to physicians about drug related problems|Clinical pharmacist's recommendation to physicians about drug related problems
40957213|NCT05809882|DEVICE|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times
40957214|NCT05809882|DEVICE|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz，60% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. But with no stimulating energy output.
40957215|NCT00383461|BEHAVIORAL|smoking cessation intervention|
40957216|NCT00383461|OTHER|counseling intervention|
40957217|NCT04376463|DIETARY_SUPPLEMENT|Branched Chain Aminoacid|It is an experimental design, controlled with 8 months of supplementation combined with exercise and washout 2 months, totalling 10 month intervention.
40957218|NCT02772107|DRUG|Temozolomide|Temozolomide is a nonclassic oral alkylating agent. Temozolomide will be given alone as maintenance therapy in patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
40957219|NCT02772107|DRUG|first-line chemotherapy|first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）
40957220|NCT02772107|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation was allowed if necessary
40957221|NCT02772107|RADIATION|thoracic radiotherapy|thoracic radiotherapy was allowed if necessary
40957222|NCT01889238|DRUG|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
40957223|NCT00179556|DRUG|Isoflavone supplement|
40957224|NCT04431453|DRUG|Remdesivir|Administered as an intravenous infusion
40957225|NCT04028778|DRUG|Gefitinib|Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
40957226|NCT04028778|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
40957227|NCT04028778|OTHER|Placebo|Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
40957228|NCT02532088|DIETARY_SUPPLEMENT|Oil Palm Phenolics|Palm fruit derived phenolics compound
40957229|NCT02532088|DIETARY_SUPPLEMENT|Placebo|Placebo
40957230|NCT05802212|DRUG|Metformin intervention for 12 weeks|PCOS patients were treated with metformin orally for 12 weeks, and various indicators related to fertility were observed.
40957231|NCT03847246|DRUG|Baraclude® tablets,1.0 mg|oral,once,under fasting condition
40957232|NCT03847246|DRUG|Entecavir tablets,1.0 mg|oral,once,under fasting condition
40957233|NCT00651352|DRUG|4 mg nicotine lozenge|marketed formulation
40957234|NCT00651352|DRUG|2 mg nicotine lozenge|marketed formulation
40957235|NCT00651352|DRUG|2 mg nicotine prototype|2 mg
40957236|NCT00651352|DRUG|4 mg nicotine prototype|4 mg
40957237|NCT04076397|PROCEDURE|autologous transplant reinjection|The patient is placed under loco-regional anesthesia. After sterilization of the upper limb and abdomen, the fat is removed at a fold by micro-incision by the Coleman method. The fat is decanted and micro-reinjected into the pulp of the patient's finger with 2 or 3 punctiform incisions. The quantity of fat injected is 2 to 3 mL. Incision of the abdomen and fingers is closed by points at monocryl 4/0. Finally, a fatty dressing is performed on the finger. Patients will benefit from nursing care every 2 days
40763211|NCT06638632|BEHAVIORAL|Decision aid|Patients with dementia and care partners will receive an iteration of the decision aid and provide feedback.
40763212|NCT04030650|OTHER|Functional analyses|2-minute walking test 200-metre walking test
40763213|NCT04030650|OTHER|3D analysis of walking and balance|Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb
40957238|NCT04076397|OTHER|desensitization|Patients will have to stimulate the pulp of your finger on a daily basis
41135681|NCT04024982|OTHER|Sequence of teaching (Lecture first followed by Simulation)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
41135682|NCT04024982|OTHER|Sequence of teaching (Simulation first followed by Lecture)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
41292419|NCT02465034|DEVICE|Traditional Paired Associative Stimulation|Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
41466449|NCT00133367|DRUG|G-CSF|Given starting on day 5 after transplant until the subjects white blood cell count recovers.
40763214|NCT04030650|OTHER|Functional analyses|400-metre walking test 200-metre walking test
40763215|NCT06640283|DIAGNOSTIC_TEST|ctDNA test|ctDNA involves the collection of peripheral blood samples for the analysis of circulating tumor DNA (ctDNA). The samples are processed using next-generation sequencing (NGS) and/or digital polymerase chain reaction (PCR) techniques to detect specific genetic alterations related to the tumor. The objective is to assess the presence and quantity of ctDNA, providing information on tumor burden and treatment response.
40763216|NCT06640283|DRUG|Pembrolizumab|Participants will receive the institution's standard treatment during Phase I. If ctDNA remains positive between 8 and 12 weeks after the standard treatment, the participant will be invited to proceed to Phase II, which will consist of intravenous immunotherapy for up to 12 months, or until disease progression or unacceptable toxicity occurs. Continuous monitoring with ctDNA testing will be performed during Phase II.
40763217|NCT00515229|DRUG|amitriptyline|"Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch"
40763218|NCT06549335|DRUG|Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)|"Induction therapy:~The ZGR regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 28 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-28;~2. Obinutuzumab, 1000mg, ivgtt, day 1/8/15 (C1), day1 (C2-6);~3. Lenalidomide, 25 mg qd, po, day 2-11.~Maintenance therapy:~1. Obinutuzumab, ivgtt,1000mg, every 3 months for 2 years;~2. Lenalidomide, 25mg, PO, during 1-10 days in every 28 days for 6 cycles."
40763219|NCT02376010|DRUG|rivaroxaban|
40763220|NCT02376010|DRUG|Warfarin|
40957239|NCT03689530|BEHAVIORAL|Peer Support|"Participants will be paired with a peer supporter. They will meet in person one time and then be in contact by phone or texting on a weekly basis for the first 6 months of a year.~During the final six months of the year, the peer supporter and participant will be in touch at least monthly. The peer supporter will help link participants to existing health system and community diabetes prevention programs, support their engagement in formal programs, maintain achieved gains, and support participants to initiate and sustain healthy behaviors to prevent diabetes.~The 95 peer supporters who consented to participate in the study are included in this arm, along with the participants who were randomized to this arm, in the participant flow. The peer supporters were not randomized to the arm; rather, they consented to deliver the intervention. Although 95 consented, only 68 met with at least one peer, the first step in intervention delivery."
40763221|NCT05836025|DRUG|Rapamycin|5mg/week of rapamycin orally for 12 weeks
40957240|NCT03689530|BEHAVIORAL|Enhanced Usual Care|Participants will receive brief education and folder of information and resources.
40957241|NCT00384566|DRUG|Carvedilol|anit hypertensive medication
40957242|NCT00384566|DRUG|Metoprolol|Anti hypertensive medication
40957243|NCT00008372|DRUG|chloroquinoxaline sulfonamide|
40957244|NCT02265874|DRUG|Habitrol|Patch used daily for 28 weeks
40957245|NCT02265874|DRUG|Placebo to Habitrol|
40957246|NCT01083485|DRUG|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
40957247|NCT01083485|DRUG|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
40957248|NCT03308032|BEHAVIORAL|Intervention|SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating
40957249|NCT03308032|BEHAVIORAL|Control|Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
40957250|NCT04538430|DEVICE|SPRINT percutaneous peripheral nerve stimulator placed|Placement of a SPRINT percutaneous peripheral nerve stimulator targeting the bilateral medial branches at the suspected level of pain generation. This procedure is done as standard of care.
40957251|NCT01057095|GENETIC|RNA analysis|
40763222|NCT05836025|OTHER|Placebo|5mg/week of placebo orally for 12 weeks
40763223|NCT06447480|DRUG|ISOtretinoin 5 MG|"The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d.~After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended."
40763224|NCT06447480|DRUG|Topical cream|Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced.
40957252|NCT01057095|GENETIC|gene expression analysis|
40957253|NCT01057095|GENETIC|reverse transcriptase-polymerase chain reaction|
41455644|NCT06059755|OTHER|Cross education|For strength training resistance exercises with a load of 60% of one repetition maximum will be performed targeting the muscle involved in upper limb function. Strength will be measured using the grip strength test/hand held dynamometer. Patients will undergo 45 minute session per day, 3 days per week for 6 weeks.
40957254|NCT01057095|OTHER|laboratory biomarker analysis|
41466450|NCT00133367|DRUG|Antithymocyte globulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
41466451|NCT00133367|DRUG|Thymoglobulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
40763225|NCT06637046|DIAGNOSTIC_TEST|Diagnostic procedures|A 30-gauge 1-inch needle was inserted adjacent to, but not within, the CFN. The infiltrate was delivered at the level of the fibular neck just proximal to where the CPN coursed beneath the deep fascia of the peroneus longus. This was immediately adjacent to the first known anatomical site of compression of the CPN. 0.3cc of the drug was delivered.
40763226|NCT06637046|DIAGNOSTIC_TEST|Lidocaine HCl|This study compares the vasodilatory effects of lidocaine to papaverine after diagnostic infiltration of the Common Peroneal Nerve in patients with demonstrated motor weakness of the EHL (extensor hallucis longus).
40763227|NCT00949039|DRUG|Isolated pelvis perfusion|injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
40763228|NCT00949039|RADIATION|radiotherapy|chemotherapy and/or radiotherapy and/or surgery
40763229|NCT00949039|PROCEDURE|Surgery|
40763230|NCT01127958|DEVICE|PCI with a drug-eluting balloon|PCI with a drug-eluting balloon for in-stent restenosis
40763231|NCT01127958|DEVICE|PCI with a drug-eluting stent|PCI with a drug-eluting stent for in-stent restenosis
40763232|NCT06439810|DIAGNOSTIC_TEST|Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)|Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
40763233|NCT03340506|DRUG|dabrafenib|dabrafenib is available in capsules (50mg and 75mg) taken twice a day
40763234|NCT03340506|DRUG|trametinib|trametinib is available in tablets (0.5mg, 2mg dose)
40763235|NCT06561087|DRUG|Nivolumab|Given by injections
40763236|NCT06643039|BIOLOGICAL|Nasopharyngeal swab|Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant.
40763237|NCT06643039|OTHER|Questionnaire|questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode.
40763238|NCT02304159|DRUG|daclatasvir|
40763239|NCT02304159|DRUG|Sofosbuvir, Sovaldi|
40763240|NCT02304159|DRUG|Ribavirin|
40763241|NCT05468918|DEVICE|Phonak Audeo previous generation hearing aids|Receiver-in-canal (RIC) hearing aids with universal earpieces
40763242|NCT05468918|DEVICE|Phonak Audeo Lumity hearing aids|Receiver-in-canal (RIC) hearing aids with universal earpieces
40763243|NCT06640530|DRUG|BCD-263|BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
40763244|NCT06640530|DRUG|Opdivo|Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
40763245|NCT04305756|DRUG|Enoxaparin|Low molecular weight heparin
40763246|NCT02063438|PROCEDURE|Pericostal suture technique|
40763247|NCT02063438|PROCEDURE|Intracostal suture technique|
40763248|NCT06641661|DRUG|Hybutimibe 10mg QD|Hybutimibe was added to the conventional treatment
40763249|NCT05541861|BIOLOGICAL|BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
40957255|NCT02460445|PROCEDURE|Phlebotomy|Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.
41135683|NCT04117100|PROCEDURE|Polypectomy or myotomy|Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).
40763250|NCT05541861|BIOLOGICAL|BNT162b4 5 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
40763251|NCT05541861|BIOLOGICAL|BNT162b4 10 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
40763252|NCT05541861|BIOLOGICAL|BNT162b4 15 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
40763253|NCT05541861|BIOLOGICAL|BNT162b4 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
40763254|NCT05541861|BIOLOGICAL|BNT162b2 Monovalent (OMI XBB.1.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
40763255|NCT04475380|DEVICE|Percutaneous coronary intervention|PCI for treatment of coronary or bypass graft lesions
41135684|NCT05552105|OTHER|Blood test|Before and after 6-months of anti TNF treatment, blood will be collected using the TruCulture system (2x 1ml in non-stimulated and LPS-stimulated TruCulture tubes) to measure Whole Blood Oxylipin Response, cytokine response, PUFA cell content and gene expression under homeostatic and stimulated conditions (i.e. LPS)
41466452|NCT00133367|DRUG|Fludarabine|Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).
41466453|NCT00133367|DRUG|Melphalan|Given intravenously on day 2 before transplant.
40763256|NCT06639139|BEHAVIORAL|CogFun RG occupational therapy|21 weekly, online group sessions (4-6 participants in each group), lasting 90 minutes. Sessions are structured, comprising opening, collaborative learning, and summary. Session topics include learning about ADHD as a biological disorder of executive functioning, understanding the impact of ADHD on daily life, discovering strategies for coping with ADHD through exploration of life experiences, and preparing for future self management
40763257|NCT04973319|DRUG|Pyrotinib|Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment.
40763258|NCT04973319|DRUG|Trastuzumab|Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
40957256|NCT02460445|DRUG|ethinylestradiol|35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
40957257|NCT02460445|DRUG|Cyproterone Acetate|2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
40957258|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 1
41292420|NCT02465034|DEVICE|Median Nerve Stimulation|Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1 milliseconds (ms) rectangular pulses at an intensity to evoke a 1 millivolt (mV) response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
41292421|NCT02465034|DEVICE|Corticocortical Paired Associative Stimulation|Cortico-cortical Paired Associative Stimulation (CC-PAS) is a combination of TMS and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. The interstimulus interval will range from 5-15 ms depending on site of stimulation.TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This CC-PAS may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
40763259|NCT06641531|OTHER|Screening pap smear test|"The patient put in dorsal lithotomy position and place the feet in stirrups or on foot rests . then, the physician will insert a cusco speculum into the vagina to hold vaginal wall open . The specimens will be collected as follows; firstly, the speculum will be inserted without lubricant. Any mucous, discharge or blood will be removed with dry cotton. A wooden spatula will be used for sampling ectocervix which will be rotated 360 degrees. For sampling endocervix, A brush or a swab will be rotated only 90 degrees as the circumferential bristles will be in contact with the entire surface the moment the brush is inserted.~The samples will be applied to the slides which will be encoded and immediately fixed in 95% ethanol and the samples will be transferred to pathology department to be stained by the standard Papanicolaou stain"
40763260|NCT03802851|PROCEDURE|Holmium Laser Enucleation of Prostate (HoLEP)|Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment use for men with bothersome lower urinary tract symptoms (LUTS) to improve their LUTS. During the procedure a thin telescope-like instrument is inserted into the urethra. The high-powered laser is then inserted through this instrument and used to carefully remove the excess prostate tissue that is causing obstruction of the urethra and contributing to the patient's lower urinary tract symptoms.
40957259|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 2
41135685|NCT01410409|OTHER|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
41135686|NCT01410409|DRUG|Paracetamol|1 g x 4/day
41135687|NCT01410409|DRUG|Burana|400 mg x 3/day for three weeks
41135688|NCT01410409|DRUG|Pantoprazol|20mg x 1/day for three weeks
40763261|NCT05518162|DEVICE|InBloom|The Rose Program (RPv2) application will be built for iOS and Android devices (including tablets) and will feature a video-based Learning Management System (LMS) which provides resources for people with postpartum depression to improve their wellbeing. Each InBloom session will contain 4-5 video modules with specific themes contained in each ROSE session which are 3-5 minutes each.
40763262|NCT05518162|BEHAVIORAL|ROSE|"ROSE will be offered as a psychoeducational course on adjusting to parenthood by a health professional embedded in the obstetric clinics. There are five 90-minute group sessions which provide interpersonal rationale for the program, a review of the course outline, ground rules for the group, and the signs and symptoms of baby blues and postpartum depression, stress management skills. managing role transitions with an emphasis on transition to motherhood and the development of a support system, identifying types of interpersonal conflicts common around childbirth and techniques for resolving them, skills for resolving interpersonal conflicts and an opportunity to review and reinforce the content of the previous sessions."
41135689|NCT01410409|BEHAVIORAL|Dietary counseling|For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
41135690|NCT01410409|BEHAVIORAL|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
41135691|NCT01410409|PROCEDURE|TKR|Surgical treatment with insertion of total knee replacement following standard procedures.
40957260|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 3
40957261|NCT02092831|DRUG|GDC-0941|Single dose Phase 2 tablet formulation
40957262|NCT00843856|DRUG|tacrolimus|tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
40957263|NCT00843856|DRUG|tacrolimus and mycophenolate mofetil|tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
40957264|NCT05248048|BIOLOGICAL|CAR-T infusion|NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
40957265|NCT04544397|PROCEDURE|Catheter Ablation for AF|Pulmonary vein isolation (PVI) is the mainstay goal of atrial fibrillation (AF) ablation procedures, especially in paroxysmal AF (PAF), and is recommended during all AF ablation procedures. PVI can be obtained with different techniques, using 3D-mapping systems guiding point-by-point radiofrequency (RF) ablation procedures or balloon-based ablation systems (cryo- or laser balloon), introduced to simplify catheter ablation for AF. In particular, the 2nd generation of visually guided laser balloon ablation system (LB2) makes use of laser energy to achieve PVI, leading to better PV occlusion and isolation compared to the 1st generation.
40957266|NCT04138810|OTHER|VCE|Videoconference conducted according to a standard script which reviews the following key aspects of post-operative care: bowel functions, voiding functions, presence of vaginal bleeding, pain control, diet status, ambulatory status and any additional concerns. Standard post-operative instructions and precautions are reviewed as well.
40957267|NCT04138810|OTHER|Survey|Measure of satisfaction regarding post-op visit.
40957268|NCT04633018|DEVICE|AsthmaMD mobile application|asthma management app with Spanish-language user interface
41135692|NCT01410409|OTHER|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
40763263|NCT06441188|DIAGNOSTIC_TEST|Thin layer conventional ultrasound coupling gel|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin layer of conventional ultrasound coupling gel.
40763264|NCT06441188|DIAGNOSTIC_TEST|Thick layer of conventional ultrasound coupling gel|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick layer of conventional ultrasound coupling gel.
40957269|NCT04633018|OTHER|Usual care|Asthma management without the app
40957270|NCT05679583|RADIATION|Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy|"1. Preoperative Stereotactic body radiation therapy (SBRT) For the gross pancreatic cancer lesion, 30 Gy/5 fx will be prescribed considering respiratory movement. And 20 Gy/5 fx will be prescribed to the triangle operation area including the common hepatic artery, celiac artery, and portal vein.~2. Pancreatic resection Surgical resection will be performed 2-4 weeks after the end of radiation therapy. The surgical method and resection range depend on the surgeon's judgment at the time of surgery.~3. Adjuvant Chemotherapy Adjuvant chemotherapy will be given under the judgment of the oncologist from 4 weeks after surgical resection, considering the pathological findings (R0 or R1 resection status, etc.) and the patient's medical condition. Adjuvant chemotherapy includes gemcitabine alone, gemcitabine plus capecitabine combination therapy, and mFOLFIRINOX."
40957271|NCT00493025|DRUG|cisplatin|Cisplatin IV
40957272|NCT00493025|DRUG|gefitinib|Gefitinib IV
40957273|NCT00493025|DRUG|paclitaxel|Paclitaxel IV
40957274|NCT00493025|PROCEDURE|adjuvant therapy|Postoperative ZD1839
40957275|NCT00493025|RADIATION|radiation therapy|Radiotherapy
40957276|NCT01550731|BEHAVIORAL|PREPARE website|Advance care planning website and materials plus an advance directive.
40957277|NCT01550731|BEHAVIORAL|Advance directive|The control group will only receive an advance directive.
40957278|NCT02369016|DRUG|Copanlisib (BAY 80-6946)|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
40957279|NCT00868985|DRUG|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
40763265|NCT06441188|DIAGNOSTIC_TEST|Thin conventional ultrasound coupling gel pad|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin conventional ultrasound coupling gel pad.
40957280|NCT00868985|DRUG|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
40957281|NCT06342752|DIAGNOSTIC_TEST|Breath test|Early detection of volatile organic compounds (VOCs) in breath from preterm infants, collected at several timepoints within the first 4 weeks of life to predict BPD before diagnosis is made at 36 weeks PMA.
41135693|NCT01662388|DEVICE|Separation ring|Separation ring placed along with automatrix band
41135694|NCT01662388|DEVICE|automatrix band|band placed with a tightening device
40763266|NCT06441188|DIAGNOSTIC_TEST|Thick conventional ultrasound coupling gel pad|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick conventional ultrasound coupling gel pad.
40763267|NCT06640920|BIOLOGICAL|Cohort A|Administered IV High dose
40763268|NCT06640920|BIOLOGICAL|Cohort B|Administered SC Low Dose
40763269|NCT06640920|BIOLOGICAL|Cohort C|Administered SC Mid Dose
40763270|NCT06640920|BIOLOGICAL|Cohort D|Administered SC High Dose
40763271|NCT06638710|DRUG|oral administration of midazolam or placebo|If the patient is opposed to a treatment (resistance to care ≥3 on the Pittsburgh scale), the nurse administers an oral dose of midazolam or placebo to the patient according to the random allocation.
41135695|NCT02387606|DRUG|Placebo|Participants will receive placebo once daily.
41135696|NCT02387606|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
41135697|NCT04773145|PROCEDURE|Hemiarthroplasty with hydroaxyapatite coated stem|Hemiarthroplasty with non cemented femoral stem, using the hydroxyapatite-coated femoral stem Pharo
41466454|NCT02926651|DRUG|Conventional Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
40763272|NCT01522872|DRUG|TH-302|
40957282|NCT06342752|OTHER|Throat swabs|A throat swab will be taken on several timepoints within the first 4 weeks of life to detect airway mucin expression. A second throat swab will be taken as proxy for the airway microbiome.
40957283|NCT06342752|OTHER|Placental samples|After birth, placental biopsies will be collected for headspace VOCs analysis. A placental swab and a biopsy will be taken for microbiome analysis.
40957284|NCT06342752|OTHER|Vaginal swab|A vaginal swab will be taken before birth for microbiome analysis.
40957285|NCT06342752|OTHER|Endotracheal aspirates|Collection of aspirates, as part of routine care, to detect mucin expression and the lung microbiome.
40957286|NCT06556862|DRUG|Dalpiciclib|100 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
40957287|NCT06556862|DRUG|Tucidinostat|25 mg/BIW, po., q2w. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
40957288|NCT03175978|DRUG|IGF/MTX|765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
40957289|NCT06371443|BEHAVIORAL|Sucking and swallowing exercises|Sucking-swallowing exercises were applied to premature infants in the experimental group (n=41) for 14 days, once a day, 12 minutes before feeding.
40957290|NCT00541684|DRUG|MK0954, /Duration of Treatment : 16 Weeks|
40957291|NCT00541684|DRUG|Comparator : atenolol /Duration of Treatment : 16 Weeks|
40957292|NCT05116878|DIETARY_SUPPLEMENT|Omega-3|One capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
40957293|NCT05116878|DIETARY_SUPPLEMENT|Placebo|One cellulose capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
40957294|NCT02041832|OTHER|Conventional Holter monitoring|Patients undergo 72h Holter monitoring
41292422|NCT02465034|DEVICE|Sham Paired Associative Stimulation|The sham PAS is a combination of TMS and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25 Hz for 12 minutes. TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
40763273|NCT01522872|DRUG|TH-302 and Dexamethasone|
40957295|NCT02041832|DEVICE|Implantable loop recorder|Implantation of loop recorder with follow-up by remote monitoring
40957296|NCT00740389|DRUG|TMC125|
41135698|NCT02745756|PROCEDURE|Autologous Hematopoietic Progenitor Cell Transplant|Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.
40763274|NCT01522872|DRUG|TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib|
40763275|NCT01522872|DRUG|TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide|
40957297|NCT02378961|DRUG|VOX|100 mg tablet(s) administered orally once daily with food
40957298|NCT02378961|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
40957299|NCT01483755|PROCEDURE|Postconditioning|Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.
40763276|NCT06640699|OTHER|exercise|exercises with using neurophysiological facilitation techniques and cardiac rehabilitation.
40763277|NCT03263533|DRUG|Vorinostat Oral Capsule Group 1|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
40957300|NCT01483755|PROCEDURE|Percutaneaous intervention|Conventional primary percutaneaous intervention
40957301|NCT01189604|DRUG|Placebo|Infusion of placebo, same infusion rates as for arm 2
40957302|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
40957303|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
40957304|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
40957305|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
40957306|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
40957307|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
40957308|NCT00578708|DEVICE|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
40957309|NCT04705363|BEHAVIORAL|Dialectal Features Varied|Participants will randomized to interact with a VHA that speaks either Standardized American English, a low level of African American English, or a high level of African American English
40957310|NCT04705363|BEHAVIORAL|Video Intervention|Participants will randomized to either receive a video introduction from the voice actor or receive no introduction
40957311|NCT04705363|BEHAVIORAL|VHA with no voice|virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
41135699|NCT02745756|BIOLOGICAL|KLH and Tumor Lysate Pulsed DC Vaccine|Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
40763278|NCT03263533|DRUG|Vorinostat Oral Capsule Group 2|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
40763279|NCT06636773|BEHAVIORAL|Diet|A reduced energy diet ranging from 1200-2100 kilocalories per day will be recommended for participants.
40763280|NCT06636773|BEHAVIORAL|Aerobic Exercise|Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress from an initial amount of 100 minutes per week to 300 minutes per week across the initial 6 months of the intervention, with this level of physical activity continuing to be recommended between months 7-12.
41292423|NCT04424498|PROCEDURE|Absorbable Rods and Kirschner Wires|A Boyd incision was applied in all patients; olecranon fractures were reduced first and fixed with Kirschner wires. Then, the displaced radial neck fractures were reduced and fixed using absorbable rods.
40957312|NCT06089499|BEHAVIORAL|Get Palliative Care: four educational learning module videos|Organizational Sponsored public domain educational videos
40957313|NCT02438020|DRUG|Metformin|One tablet of 500 mg will be ingested before the main meal
41466455|NCT02926651|DRUG|Multi-Dose Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
40763281|NCT06636773|BEHAVIORAL|Behavioral Sessions|Participants will be provided weekly group-based behavioral session for months 1-6, with these sessions being offered twice per month during months 7-12 to assist in supporting recommended changes in energy intake (diet) and physical activity.
40957314|NCT02438020|OTHER|Placebo|A placebo tablet will be ingested daily before main meal.
40957315|NCT02087735|DIETARY_SUPPLEMENT|Cranberry extract|The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
41292424|NCT06335940|OTHER|Videoregulation|"To encourage the use of video-regulation, several measures will be taken to reinforce its use as much as possible:~* Posters visible to all in the dispatch room.~* Regular mailings to all dispatching physicians.~* On-site presence of interns and the study investigator to help doctors who are not used to video-regulation to get to grips with the computer tool.~* Involvement of ARMs to remind doctors to use video-regulation."
41292425|NCT01379443|OTHER|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
41292426|NCT00906022|DEVICE|Astron Pulsar Stent|Stenting with Astron Pulsar
40957316|NCT00809393|DRUG|tranexamic acid|10 mg/kg
40957317|NCT00809393|DRUG|tranexamic acid|30 mg/kg
41292427|NCT00906022|DEVICE|PTA alone|Balloon angioplasty alone
41292428|NCT05667428|DRUG|leuprorelin|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of leprorelin in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
41292429|NCT05667428|DRUG|normal saline|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of normal saline in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
41292430|NCT01883245|DEVICE|real tDCS|2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
41292431|NCT01883245|DEVICE|sham tDCS|2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
41292432|NCT02400112|DRUG|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
40957318|NCT04226872|BEHAVIORAL|My Tools for Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting.
40957319|NCT05678933|DRUG|Azacitidine|Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
40957320|NCT05678933|DRUG|Chidamide|Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
40763282|NCT06636773|BEHAVIORAL|Aerobic + Yoga Exercise|Physical activity will be recommended in the form of a combination of aerobic types of activity, such as brisk walking, and yoga. Aerobic activity will progress from 60 minutes per week to 180 minutes per week across the initial 6 months of the intervention. Yoga will progress from 40 minutes per week to 120 minutes per week across the initial 6 months of the intervention. When combined this will progress from a total of 100 minutes per week to 300 minutes per week across the initial 6 months of treatment. This level of physical activity will continue to be recommended between months 7-12.
40957321|NCT05678933|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
40957322|NCT05678933|DRUG|Epirubicin|Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
40957323|NCT05678933|DRUG|Vincristine|Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
40957324|NCT05678933|DRUG|Prednisone|Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
40957325|NCT01121653|DRUG|Magnogene ® (magnesium)|evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
41292433|NCT03739983|DEVICE|Vaginal Renewal Program|Therapeutic vibrating wand.
41292434|NCT03370081|DEVICE|CAPNOGRAPHY|MONITORING OF CAPNOMETRY USING ETCO2 METHOD
41292435|NCT00349791|DRUG|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
41292436|NCT00349791|DRUG|Placebo patch|placebo patch replaced twice a week for two years
41292437|NCT01613235|OTHER|Induced hypertension|Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
40957326|NCT05645575|DEVICE|Open-label TMS|Customized, Open-Label Transcranial Magnetic Stimulation
40957327|NCT06097286|PROCEDURE|external oblique intercostal plane block|o EOIP Group (ŋ=25): Patients will receive ultrasound guided External oblique intercostal plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
40957328|NCT06097286|PROCEDURE|erector spinae plane block|o ESP Group (ŋ=25): Patients will receive ultrasound guided Erector spinae plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
40957329|NCT00133328|DRUG|valsartan|
41292438|NCT01852344|DRUG|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
41292439|NCT01852344|DRUG|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
41292440|NCT01852344|BEHAVIORAL|Easy Behavioral Task|Subjects do an easy version of the Letter E Task.
41292441|NCT01852344|BEHAVIORAL|Hard Behavioral Task|Subjects do a hard version of the Letter E Task.
41292442|NCT00359814|DRUG|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
41292443|NCT00359814|DRUG|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
41292444|NCT01202110|DRUG|Propranolol|
41292445|NCT04681664|OTHER|High fat diet|50 % fat
41292446|NCT01628991|BEHAVIORAL|behavioural program|interventional behavioural program
40957330|NCT03476993|BIOLOGICAL|BCD-085|All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.
40957331|NCT03204578|DRUG|AB (Midazolam OD formulation/Dormicum)|Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
40957332|NCT03204578|DRUG|BA (Dormicum/Midazolam OD formulation)|Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
40957333|NCT02697864|DRUG|tafamidis|
40957334|NCT02285842|DEVICE|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
40957335|NCT00169026|DRUG|Clozapine versus typical (conventional) and atypical antipsychotic medications|
40957336|NCT00675948|DRUG|Sativex|"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."
40957337|NCT00675948|DRUG|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
41455645|NCT06059755|OTHER|Mirror Therapy|Participants will be asked to sit in front of a table of appropriate height with their arms resting on the table and a mirror (35 cm × 35 cm) placed between the patient's arms. The non-affected arm will be placed in front of the mirror and the affected arm will be placed and obscured. Appropriate movement tasks will be selected according to the function of the affected upper limb. This exercise will be performed 45 minutes per day, 3 times per week for 6 weeks
41455646|NCT00664053|DIETARY_SUPPLEMENT|DHEA|50mg daily for 6 months
41292447|NCT01628991|DEVICE|Iranian version of vaginal cones|intravaginal device(vaginal cone) for promote the pelvic floor exercises
41455647|NCT00664053|BEHAVIORAL|Yoga|2 sessions per week for 6 months
41455648|NCT00664053|DIETARY_SUPPLEMENT|Placebo|Placebo supplement every day for 6 months
41455649|NCT00664053|BEHAVIORAL|Aerobics|Walking/chair aerobics program 2 sessions per week for 6 months
40957338|NCT03351933|BIOLOGICAL|Immune Globulin (Human)|A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) was administered in healthy subjects.
40957339|NCT05832801|OTHER|( Traditional dietary advice )|traditional dietary advice for IBS which is based on guidance provided by the National Institute for Health and Care Excellence (NICE ) and the British Dietetic Association (BDA). Its principles include adopting healthy, sensible eating patterns such as having regular meals, never eating too little/too much, maintaining adequate hydration, and reducing the intake of (1) alcohol/caffeine/fizzy drinks, (2) fatty/spicy/processed foods, (3) fresh fruit to a maximum of 3 per day, (4) fiber and other commonly consumed gas-producing foods (eg, beans, bread, sweeteners, etc), and (5) addressing any perceived food intolerances (eg, dairy).
40957340|NCT05832801|OTHER|(Pilates exercises)|Pilates exercises will be in the form of Swan, One leg up-down, Leg circles, Single leg stretch, Saw, Side kicks, The hundred,. Pelvic lift on the ball, Sit-ups with the ball, Stretching on the ball. exercise Dose will be First month (first- eighth session) composed of one set of eight repetitions Second month (eighth-sixteenth session) composed of two sets of ten repetitions
40957341|NCT05182190|DIETARY_SUPPLEMENT|White bread|Toasted white bread
40957342|NCT05182190|DIETARY_SUPPLEMENT|Black beans whole boiled|Whole boiled black beans with spaghetti sauce
40957343|NCT05182190|DIETARY_SUPPLEMENT|Knife Mill pasta|Black bean pasta (KM) with spaghetti sauce
40957344|NCT05182190|DIETARY_SUPPLEMENT|Combo Flour Pasta|Black bean pasta (Combo) with spaghetti sauce (medium protein flour)
40957345|NCT05182190|DIETARY_SUPPLEMENT|Cyclone Flour Pasta|Black bean pasta (Cyclone) with spaghetti sauce (low protein flour)
41292448|NCT05218889|DRUG|surufatinib + camrelizumab + nab-paclitaxel + S-1|"phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40mg bid, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1"
41292449|NCT05218889|DRUG|nab-paclitaxel + gemcitabine|nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
41455650|NCT03873805|BIOLOGICAL|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
41292450|NCT00001056|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
41455651|NCT03873805|DRUG|Cyclophosphamide|Given IV
41455652|NCT03873805|DRUG|Fludarabine|Given IV
41455653|NCT03873805|DRUG|Fludarabine Phosphate|Given IV
41455654|NCT02000258|PROCEDURE|Double-bundle ACL reconstruction|
41455655|NCT02000258|DEVICE|Magnetic resonance imaging (MRI)|MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
41455656|NCT03574051|DRUG|Probiotic|Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment
41455657|NCT05017935|DEVICE|Renal Denervation|Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System)
41455658|NCT03748251|OTHER|the patients ate a pizza that fermented for 8 hours|Patients eat pizza prepared with controlled ingredients but fermented 8 hours
41455659|NCT03748251|OTHER|the patients ate a pizza that fermented for 24 hours|Patients eat pizza prepared with controlled ingredients but fermented 24 hours
41455660|NCT00757172|BIOLOGICAL|panitumumab|
41455661|NCT00757172|DRUG|cisplatin|
41455662|NCT00757172|DRUG|docetaxel|
41455663|NCT00757172|PROCEDURE|neoadjuvant therapy|
41455664|NCT00757172|PROCEDURE|therapeutic conventional surgery|
41455665|NCT00757172|RADIATION|radiation therapy|
41466456|NCT05886257|DRUG|Candonilimab|10mg/kg, iv.drip, every 3 week
40957346|NCT06117163|BEHAVIORAL|Collaborative Care Model|"The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication."
40957347|NCT05327426|BIOLOGICAL|Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL) admixed with 0.47µg of recombinant double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant.
40957348|NCT05327426|BIOLOGICAL|Intradermal fractional dose inactivated polio vaccine (fIPV)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL).
40957349|NCT05327426|BIOLOGICAL|Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain|Monovalent oral polio vaccine (OPV) challenge administered as a test of mucosal immunity.
40957350|NCT06438068|OTHER|Modern Colon Hydrotherapy plus probiotic product intake|Colonic cleansing through 3 interventions of Modern Colon Hydrotherapy separated by 48 hours. In addition, a daily intake of a product with prebiotic and prebiotic properties for 30 days.
40957351|NCT04775407|PROCEDURE|blood sampling|IgM og IgG analysis
40957352|NCT02339285|DEVICE|tACS (alpha)|
40957353|NCT02339285|DEVICE|tACS (gamma)|
40957354|NCT02646384|PROCEDURE|Ovarian tissue cryopreservation|Ovarian tissue will be removed
40957355|NCT01388738|DRUG|citicoline|citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\*3 times per day) per os
40957356|NCT01388738|DRUG|L-Alpha glycerylphosphorylcholine|choline alfoscerate IV 1000mg daily 10 days
40957357|NCT01388738|DRUG|cerebrolysin|Cerebrolysin IV 10 ml daily 10 days
40957358|NCT04502433|DRUG|CUROSURF® (poractant alfa)|"Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW."
40957359|NCT04966039|OTHER|No intervention.|There was no intervention.
40957360|NCT03466567|DRUG|Semaglutide|A single dose of 3 mg semaglutide tablet alone will be administered orally. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
40957361|NCT03466567|DRUG|Probenecid|A dose of 500 mg probenecid (2 tablets of 250 mg) will be administered orally twice daily for 3½ days (7 trial product administrations in total). On the 4th day, the last probenecid administration will take place 2 hours prior to administration of a single dose of 3 mg oral semaglutide tablet. The last trial product administrations will take place in the morning after overnight fasting for at least 6 hours.
41292451|NCT01326598|DEVICE|V-Go™|Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
40957362|NCT03466567|DRUG|Ciclosporin|A single dose of 600 mg ciclosporin (6 capsules of 100 mg) will be administered orally 1 hour prior to administration of a single dose of 3 mg oral semaglutide tablet. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
40957363|NCT04482257|DRUG|Irinotecan Liposome Injection combined with 5-FU/LV|Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;
40957364|NCT05528185|OTHER|Direct participation of the family member in the daily rounds|When the team arrives at the participating family member's room, the family member will be invited by a member of the healthcare team to come out of the room. The rounding team and structure will be the same as the usual care group with the following exceptions: (1) the family member will be invited to participate in the rounds outside their relative's room; (2) the family member will be provided with an orientation to the medical team members; (3) the family member will be allowed to engage and participate throughout the rounds; (4) at the end of the rounds, the team will summarize the patient's daily care plan; (5) the family member will be prompted to ask questions.
40957365|NCT01528475|BEHAVIORAL|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
40957366|NCT03711461|DEVICE|endotracheal tube (double lumen)|patients routinely use double lumen endotracheal intubation while they have received thoracoscopy
40957367|NCT03711461|DEVICE|nonintubated|patients receiving nonintubated anesthetic plan while they have received thoracoscopy
40957368|NCT05013489|BEHAVIORAL|Mindfulness and intercare based intervention|"Eight week online program based on mindfulness, compassion and intercare intervention. A two hour synchronic online session every week plus daily homework based on meditation and journaling exercises.~The topics covered in the program are mindfulness meditation, cognitive behavioral therapy exercises, gratitude and acceptance, compassion and self compassion exercises, conservation of resources theory and intercare."
40957369|NCT02184481|BEHAVIORAL|Working memory training|
40957370|NCT02184481|BEHAVIORAL|Placebo training|
40957371|NCT06463834|DRUG|Sintilimab|"Sintilimab: 200mg, iv, D1, Q3W;~DCF chemotherapy:~docetaxel 70mg/m2，iv，d1，Q3W； cisplatin 75mg/m2，iv，d1，Q3W； 5-fluorouracil 750-800mg/m2，iv，d1-d5，Q3W"
40957372|NCT05439941|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
40957373|NCT01112865|DEVICE|Genotropin Pen|Pen provided in 5, 5.3 and 12 mg doses, Dose based on body weight, subcutaneous injection daily for 2 months while in study.
40957374|NCT01112865|DEVICE|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
40957375|NCT01112865|DEVICE|Genotropin Pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
40957376|NCT01112865|DEVICE|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
40957377|NCT02416570|DRUG|Clarithromycin|
40957378|NCT02416570|DRUG|Placebo|
40957379|NCT04396340|BIOLOGICAL|XMT-1592|XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
40957380|NCT04436250|DRUG|Active comparator|The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
40957381|NCT04436250|DRUG|S-Ketamine Low dose|The arm 1 is composed of esketamine 0.2 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
40957382|NCT04436250|DRUG|S-Ketamine High dose|The arm 2 is composed of esketamine 0.4 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
40957383|NCT03949036|OTHER|Crystalloid fluid administration with the target of stroke volume variation ≤ 12%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%
40957384|NCT03949036|OTHER|Crystalloid fluid administration with the target of stroke volume variation ≤ 6%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
40957385|NCT02624609|OTHER|Control without pomegranate juice|Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
40957386|NCT02624609|OTHER|Test with pomegranate juice|The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
40957387|NCT04733404|DEVICE|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
40957388|NCT00846235|OTHER|Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%|moisturising cream twice daily three weeks
40763283|NCT06639711|DRUG|Taurine|Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
40957389|NCT01431989|DRUG|Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL|Test formulation
40957390|NCT01431989|DRUG|Amoxil® 500mg/5mL powder for oral suspension|Reference formulation
40957391|NCT00767962|OTHER|talc pleurodesis under medical thoracoscopy|talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
40957392|NCT00767962|OTHER|pleurodesis under video-assisted thoracoscopy surgery|pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
40957393|NCT04258163|DRUG|Capecitabine|1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days
40763284|NCT02770365|DRUG|estrace cream (Perrigo)|
40763285|NCT02770365|DRUG|estrace cream (Reference)|
40763286|NCT02770365|DRUG|Placebo cream|
40957394|NCT04258163|DRUG|Liposomal doxorubicin|50 mg/m 2 IV day 1, cycled every 28 days
40957395|NCT04258163|DRUG|Gemcitabine|800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days
40957396|NCT04258163|DRUG|Fulvestrant|500mg IH Days 0, 14, 28, then every 28 days
40957397|NCT04258163|DRUG|Anastrozole|1mg PO qd
40957398|NCT04258163|DRUG|Letrozole|2.5mg PO qd
40957399|NCT05191342|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay for PCSK9|Enzyme-linked immunosorbent assay for plasma PCSK9
40957400|NCT05373745|BEHAVIORAL|Active Brains 1|Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
40957401|NCT05373745|BEHAVIORAL|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight and Medical appointments. The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity."
40957402|NCT02780375|PROCEDURE|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
40957403|NCT04401423|DRUG|TXA127|0.5 mg/kg per day
40957404|NCT04401423|DRUG|Placebo|0.5 mg/kg per day
40957405|NCT00989105|OTHER|immunohistochemistry staining method|
40957406|NCT00989105|OTHER|laboratory biomarker analysis|
40957407|NCT00989105|OTHER|pharmacological study|
40763289|NCT06571981|DEVICE|TUP ultraportable US with teleradiology capacities|Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
41292452|NCT05699460|OTHER|This is an observational study.|This is an observational study.
40957408|NCT00989105|PROCEDURE|computed tomography|
41292453|NCT03877185|DIAGNOSTIC_TEST|Live birth rate|Live Birth Rate and Blastulation Rate according to the protocol of COS
40763290|NCT06571981|DEVICE|CUS conventional ultrasound|Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
40763291|NCT00697385|DRUG|Cyclokapron|(2) 500mg tablets taken by mouth every 6-8 hours
40763292|NCT06104306|DRUG|B/F/TAF|Tablets administered without regard to food
40763293|NCT06638684|OTHER|Exercise|Subjects in the two groups preformed 90-100 minutes of exercise at different intensities.
40957409|NCT00989105|PROCEDURE|magnetic resonance imaging|
40957410|NCT00989105|PROCEDURE|single photon emission computed tomography|
40957411|NCT00989105|RADIATION|technetium Tc 99m demobesin-4|
40957412|NCT06556394|DRUG|RAG-17|RAG-17 is a therapeutic small interfering RNA (siRNA).
40957413|NCT06556394|DRUG|Placebo|Placebo will be administered via intrathecal injection
40957414|NCT00087607|DRUG|Ribavirin|1000/1200mg/day po
40957415|NCT00087607|DRUG|Peginterferon alfa-2b (PEG-Intron)|1.5 micrograms/kg sc weekly
40957416|NCT00087607|DRUG|Ribavirin|1000/1200mg/day po
40957417|NCT00087607|DRUG|Peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
40957418|NCT00134082|BIOLOGICAL|KGEL vaccine|Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10\^8 cells per dose. The first dose was given on Day +1.
40957419|NCT00134082|BIOLOGICAL|Filgrastim|5 mcg/kg/day starting on Day +6 until ANC is \>= 1000/mcL.
40957420|NCT00134082|BIOLOGICAL|Rituximab|375 mg/m\^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.
40957421|NCT00134082|DRUG|Cyclophosphamide|50 mg/kg/day on Day -3, -2, -1, and 0.
40957422|NCT03698409|DRUG|Preserved saline in reconstitution of Botox|The intervention consists of using 4 ml of preserved saline for the reconstitution of OnabotuliniumtoxinA prior to its use in subjects with chronic migraine.
40957423|NCT02349061|DRUG|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
40957424|NCT02349061|DRUG|Placebo Infusion|Placebo intravenously at Week 0.
40957425|NCT02349061|DRUG|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
40957426|NCT02349061|DRUG|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
40957427|NCT02349061|OTHER|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
40957428|NCT04996043|DIETARY_SUPPLEMENT|Collagen Peptide Drink|Testing product
41292454|NCT00623012|DRUG|Rapamycin|Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.
41455666|NCT03822949|DEVICE|Day Light|Patients are exposed to daylight for up to 10 days prior to surgery
40957429|NCT04996043|DIETARY_SUPPLEMENT|Placebo drink|Blank
40957430|NCT01041833|DRUG|atRA|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
40957431|NCT01041833|DRUG|Placebo|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
41135700|NCT01192555|BIOLOGICAL|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|"1x10\^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.~Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.~Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol."
41135701|NCT01192555|DRUG|Cytoxan|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
41135702|NCT02517385|DRUG|Phosphatidylcholine|Pharmaceutical form:Paste Route of administration: Oral
41135703|NCT00861003|DEVICE|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
41135704|NCT00065182|DRUG|Topotecan/Docetaxel combination|
41292455|NCT00623012|DRUG|Tacrolimus|Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
41292456|NCT06453551|DRUG|TRN501 - Dose 1|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
41292457|NCT06453551|DRUG|TRN501 - Dose 2|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
40763294|NCT01534221|DEVICE|Biomatrix drug eluting stent|Biomatrix drug eluting stent
40763295|NCT06641414|DRUG|Lisaftoclax (APG-2575)|QD, oral administration.
40763296|NCT06641414|DRUG|Azacitidine Injection|QD, hypodermic or intravenous injection.
40763297|NCT06641414|OTHER|Placebo|QD, oral administration.
40763298|NCT06572774|BEHAVIORAL|C3Link Strategies|Education sessions and community liaison support to link to services
40763299|NCT06241573|DRUG|Spesolimab|Spesolimab
40763300|NCT04250415|PROCEDURE|Surgery|
40763301|NCT01384045|OTHER|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
40763302|NCT02019173|BEHAVIORAL|Boot Camp Balance Training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
40763303|NCT06642857|OTHER|Peripheral blood, tougue coating, saliva, and feces|Peripheral blood, coating, saliva, and feces on the tongue and clinical data of patients with advanced gastric cancer patients who received chemotherapy combined with immunotherapy will be collected.
40763304|NCT06637592|OTHER|Calcaneal taping|Calcaneal taping is a method employed to offer assistance and relieve discomfort in the heel and ankle area. Start with a clean surface and apply first tape from lateral malleolus, pulling calcaneus in medial direction and attach to medial malleolus. Apply two more tapes in the same manner going distally. Apply an anchor tape at back of heel.
40763305|NCT06637592|OTHER|Windlass taping|Begin by anchoring the tape just above the ball of the foot (metatarsal heads). Tear or cut a strip of tape, approximately 2-3 inches long, and place it horizontally around the foot, securing the starting point. Pull the tape diagonally across the bottom of the foot, aiming to support the arch. The tape should be applied with moderate tension to provide support without causing discomfort. While keeping tension on the tape, extend the big toe (great toe) upward. As the toe extends, the tape should tighten, activating the windlass mechanism and providing additional arch support.
40763306|NCT06639347|DRUG|SHR-A2102|SHR-A2102
40763307|NCT06639347|DRUG|Adebrelimab injection|Adebrelimab injection
40763308|NCT06639347|DRUG|SHR-8068 injection|SHR-8068 injection
40763309|NCT00962338|BEHAVIORAL|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
40763310|NCT06638723|BEHAVIORAL|Balance and fall recovery training|Following the video observation described in the arms, participants will undergo training to physically practice the motor tasks. The training will take place over a 2-week period encompassing 40 practice trials for each task over the training sessions. During training, the investigators will continuously monitor the changes in balance and fall recovery task performance, and will provide feedback. Participants can request to re-watch the demonstration video that they were assigned to at any time.
40763311|NCT05908760|DEVICE|CO2 ReHaler|The ReHaler captures expired CO2, which is then re-inhaled. The net effect is a transient increase in CO2.
40763312|NCT06348147|BIOLOGICAL|Daratumumab|Daratumumab is a CD38-directed cytolytic antibody indicated for the treatment of adults with multiple myeloma. 1800 mg will be given subcutaneously according to its standard package insert schedule.
40763313|NCT06348147|DRUG|Lenalidomide|Lenalidomide will be administered, once daily orally on Days 1-21 of a 28-day
40763314|NCT06348147|DRUG|Bortezomib|Bortezomib is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma, will be given subcutaneously once weekly on days 1, 8, and 15 of every 28 day cycle.
40957432|NCT03041857|RADIATION|Observational use of fluoroscopy|
41135705|NCT00065182|DRUG|Docetaxel|
41135706|NCT00570505|DEVICE|LAP-BAND System|Reduction of food intake due to creation of smaller stomach pouch
41135707|NCT05462873|BIOLOGICAL|QEQ278|Intravenous dosing of QEQ278
41466457|NCT05886257|DRUG|Bevacizumab|15mg/kg, iv.drip, every 3 week
40957433|NCT06050005|DIAGNOSTIC_TEST|Diagnostic test through functional tests and comparison of scales applied to participants in the pre-surgical and post-surgical period.|The protocol is based on the ligamentization stages, since the bibliography relates the ligamentization process with rehabilitation. These stages are necrosis, revascularization, cellular priorities and collagen formation, and different care is required for each stage. Taking these aspects into account, the authors developed recommendations to establish a protocol divided by the evaluation phases of the present work. Users should only move on to the next phase if they achieve the expected results, or that makes the total duration of each protocol vary from user to user. tests and scales will be evaluated before surgery, after 6 weeks of surgery and at the end of treatment.
40763315|NCT06348147|DRUG|Dexamethasone|Dexamethasone is a glucocorticoid.
40957434|NCT03386448|DRUG|Scopolamine and naltrexone|participants will receive scopolamine and naltrexone in buccal drops
40957435|NCT03386448|DRUG|placebo arm|participants will receive placebo medications
40957436|NCT02824614|DIETARY_SUPPLEMENT|E967-Xylitol|
40957437|NCT02824614|DIETARY_SUPPLEMENT|E968-Erythritol|
40763316|NCT03184025|OTHER|dentin adhesive|HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
40957438|NCT05097274|OTHER|MRI pelvis or CT imaging under clinical management for Pr Ca|Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
40957439|NCT05097274|OTHER|Whole body bone scan imaging|bone scan of the whole body (under clinical diagnosis).
40957440|NCT05097274|OTHER|PET-CT imaging|Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
40957441|NCT06558123|PROCEDURE|block|Single Level and Two Level Deep Parasternal Intercostal Plane (DPIP) Block
40957442|NCT03985904|OTHER|ART THERAPY|ART THERAPY: Nursing Interventions Classification = 4330 Weekly 2 hour group carried out by a mental health nurse, a social monitor and a museum educator.
40957443|NCT05190588|OTHER|Mesotherapy|Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used.
40957444|NCT06055101|DRUG|DEXMEDETOMIDINE|"DXM is a nonselective α2 agonist. Alpha2 adrenoreceptors, the overall response to α2 adrenoreceptors agonists is related to the stimulation of α2 adrenoreceptors located in the CNS and spinal cord. These receptors are involved in the sympatholysis, sedation, and antinociception effects of α2 adrenoreceptors.~DEXMEDETOMIDINE (DXM) DXM shows a high ratio of specificity for the α2 receptor (α2/α11600: 1) compared with clonidine (α2/α1 200: 1), making it a complete α2 agonist. (76) DXM belongs to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is freely soluble in water."
40957445|NCT06055101|DRUG|Neostigmine|Neostigmine is an indirect cholinomimetic agent. It produces its primary effects by inhibiting the action of AChe, which hydrolyzes acetylcholine (ACh) to choline and acetic acid. By inhibiting AChe, the indirect-acting drug increases the concentration of spinal endogenous ACh. This drug is, in effect, amplifiers of endogenous ACh and act primarily where ACh is physiologically release. It combines reversibly with AChe by the formation of an ester linkage, which lasts about 30 minutes. The pharmacokinetic of neostigmine administered by bolus injection is linear with respect to bolus injection.
40957446|NCT06055101|DRUG|Bupivacaine|"The onset of sensory blockade following spinal block with bupivacaine is very rapid (within one minute); maximum motor blockade and maximum dermatome level are achieved within 15 minutes in most cases.~The conduction of nerve impulses along nerve fibers is related to changes in the electrical gradient across the nerve membrane and movement of predominantly sodium ions (but also potassium ions) from intracellular to extracellular fluid and vice versa. Bupivacaine work by reversibly blocking specific areas of the nerve cell membrane, known as sodium channels. It contains a mixture of ionized and un-ionized particles which, when injected into body tissues, make more un-ionized particles available, which are lipid soluble and able to penetrate the nerve cell membrane."
40957447|NCT05999929|BEHAVIORAL|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
40957448|NCT04898595|PROCEDURE|Discontinuation of CRRT|Discontinuation of CRRT will be guided by an algorithm based on patient current condition.
40957449|NCT03880734|DRUG|Cholecalciferol|ingredients-Cholecalciferol (40,000 IU),Microcrystalline Cellulose (58.1 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
40957450|NCT03880734|OTHER|Placebo oral capsule|ingredients- Microcrystalline Cellulose (303.8 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
40957451|NCT00702923|DRUG|Bicalutamide and CP-675,206 (Tremelimumab)|"Dose level -1 :~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
40957452|NCT00702923|DRUG|Bicalutamide, CP-675,206 (tremelimumab)|"Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
40763317|NCT02019836|OTHER|Determining maternal and neonatal vitamin D levels|
40957453|NCT00702923|DRUG|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
40957454|NCT00702923|DRUG|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
40957455|NCT00702923|DRUG|Bicalutamide, CP-675,206|"Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29"
40957456|NCT03988088|DRUG|Lasmiditan|Administered orally.
41135708|NCT04197037|PROCEDURE|Evaluation of sialorrhea through questionnaires that measure daytime and nighttime sialorrhea and the impact on quality of life.|Sialorrhea will be evaluated by the Nocturnal hypersalivation rating scale (NHRS) and Drooling Severity and Frequency Scale (DSFS)
41135709|NCT03490032|DRUG|[68Ga]-PSMA-R2|radio-labelled PSMA ligand
41455667|NCT03822949|DEVICE|Placebo light|Patients are exposed to placebo light for up to 10 days prior to surgery
40957457|NCT02130297|DEVICE|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
40957458|NCT00666172|BEHAVIORAL|Exercise|
40957459|NCT00666172|BEHAVIORAL|Weight Loss|
40957460|NCT02831452|OTHER|pelvic floor muscle strength evaluation|
40957461|NCT06255964|DRUG|IAP0971|Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times
41135710|NCT06186349|GENETIC|Genomic sequencing|Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
40763318|NCT05130801|DIAGNOSTIC_TEST|pHLIP® ICG NIRF imaging|"Pre-operative research MRI will be performed 1-3 weeks prior to the surgery. single pHLIP® ICG injection will be administered i.v. by a radiologist on the protocol one day prior to scheduled surgery on the occasion of presurgical localization (12-36 hours prior to the surgery).~In Phase I, we propose to investigate 4 different doses:~Dose level 1 = 0.04 mg/kg Dose level 2 = 0.075 mg/kg Dose level 3 = 0.15 mg/kg Dose level 4 = 0.30 mg/kg~In Phase IIa, the researchers propose to administer selected in Phase I dose of pHLIP® ICG. In Phase IIa, the researchers propose to administer pHLIP® ICG at DL2, DL3 or DL4 at different time points prior to surgery ranging from 12-110 hours, with targeted enrollment of 12 patients. Next, the selected optimal dose and timing will be used with targeted enrollment of 28 patients. The total number of subjects in Phase IIa study is 40."
40957462|NCT06255964|COMBINATION_PRODUCT|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder perfusion,Maintain at months 3, 6, 12, 18, and 24Perfusion, once a week, three times in a row.
40957463|NCT06255964|COMBINATION_PRODUCT|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder irrigationNote, progress at months 3, 6, 12, 18, and 24Perform maintenance perfusion once a week, three times in a row.
40957464|NCT05986786|DEVICE|Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule|Patient will receive AVT06 (proposed aflibercept biosimilar) PFS injection
40957465|NCT05792501|DEVICE|Mechanical ventilation|type of therapy that helps you breathe or breathes for you when you can't breathe on your own
41135711|NCT03845699|DEVICE|Diagnostic algorithms that detects/predicts hypoventilation|Produce mild and moderate respiratory depression (hypoventilation) using a controlled intravenous infusion of fentanyl while measuring/recording respiratory rate, tidal volume, body activity, and body position.
41135712|NCT01331174|DEVICE|Pulsed short wave|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.
41135713|NCT05995691|DRUG|ABP 501|SC injection
41135714|NCT05995691|DRUG|Adalimumab|SC injection
41135715|NCT01857076|PROCEDURE|Gastric bypass surgery|Gastric bypass surgery performed laparoscopically
41135716|NCT01857076|PROCEDURE|Surgical ileal transposition with sleeve|Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
41135717|NCT01857076|OTHER|Clinical|The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
41135718|NCT04885673|DEVICE|Vapotherm|flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
41135719|NCT04885673|DEVICE|Apneic oxygenation|Standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
41455668|NCT03822949|DEVICE|ICU Intense Light|ICU Patients are exposed to daylight for up to 10 days after surgery
41455669|NCT03822949|DEVICE|ICU Placebo light|ICU Patients are exposed to placebo light for up to 10 days after surgery
41455670|NCT06381323|DRUG|Finerenone|All eligible subjects enter a 2-week enrollment phase and only take stable doses of controlled-release nifedipine. After completing baseline examinations, subjects with SBP \<180 and ≥140 mmHg and DBP \<120 and ≥90 mmHg enter the follow-up phase of the treatment period. Eligible subjects receive a starting dose of 20 mg qd of Finerenone. If the blood pressure is still ≥140/90 mmHg at week 4, serum potassium is \<5.0 mmol/L, and eGFR has decreased \<30% compared to baseline, the Finerenone dose is adjusted to 40 mg qd.
40957466|NCT04449926|BIOLOGICAL|Bacillus of Calmette and Guerin (BCG)|Prime and boost vaccination
40957467|NCT00232973|DRUG|ICXP007|
41135720|NCT03183804|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention.
41135721|NCT03183804|OTHER|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.
41135722|NCT04436549|PROCEDURE|Stab Avulsion of varicose veins|Stab avulsion is a technique to remove varicose veins. In this procedure, several tiny cuts (incisions) are made in the skin through which the varicosed vein is removed. Removed varicose veins will be collected and analyzed.
41135723|NCT04436549|DIAGNOSTIC_TEST|Histopathologic evaluation of varicose veins|Sample obtained from varicose veins of lower limbs of patients will be collected and immediately fixed in formalin. The tissue fragments will be taken from varicose veins. Subsequently the tissue will be embedded in paraffin and 3-to-4 mm thick sections will be prepared by a microtome. The tissue sections will be processed for histological and immunohistochemical studies of VEGF, MM9, PGP 9.5 AND FRIBRONECTIN. For antibodies the EnVision staining system (Dako EnVision™) will be used. For the analysis of the positive structures detected by immunohistochemistry, a semiquantitative evaluation method will be used.
40957468|NCT04340648|DEVICE|Vital GlucoseDetect|11 time points for blood glucose measurements over 210 min including the ingestion of a standardized meal 30 min after the first blood glucose measurement.
40957469|NCT05146895|DRUG|Imiquimod treatment|As an control arm, for patients with flat warts
40957470|NCT05146895|DEVICE|Local Hyperthermia at 44℃|As an experimental arm, for patients with flat warts
40957471|NCT02702453|BEHAVIORAL|website|The intervention arm will consist of 12 modules, 8 of which are consistent with the trajectory of prostate cancer and its treatment. Four modules address aspects of the prostate cancer experience that are important for patients and partners as well as providers and are designed to optimize the goal of supporting patients and partners in their sexual recovery.
40957472|NCT04360668|OTHER|Muscle Energy Technique (MET)|The Contract-Relax Agonist-Contract (CRAC) technique will be used, which belongs to the broad MET group. The participant will be in the supine position. The therapist will set the cervical segment in the lateral flexion until a slight soft tissue tension is felt. The technique will consist of two stages. In the first phase (contraction phase), the upper trapezius will be activated against the therapist's resistance (shoulder girdle elevation) - 10 seconds. Then the person undergoing the procedure breathes in and out deeply. Then 10 seconds of antagonist group contraction (shoulder girdle depression) will be performed. Next, the therapist will passively move the participant's shoulder girdle towards the depression. Then the second phase will follow (stretching phase), during which the participant will passively lie in the back position for 30 seconds. Both phases will make up the therapeutic cycle. Each participant will have 5 cycles on each side of the upper trapezius.
40957473|NCT04360668|OTHER|Trigger Point Therapy (TPT)|The technique of Positional Release (PR) will be used, which is one of the broadly understood Trigger Point Therapy. It will consist in compressing the trigger point with a simultaneous shortening of muscle attachments (slight lateral flexion towards the relaxed muscle). The muscle on both sides will be treated. The pressure exerted by the therapist's pincer grip will be acceptable to the patient. The duration of the technique will be 2 minutes for each muscle. While performing this technique, the participant will passively lie on his back.
40957474|NCT04360668|OTHER|Muscle Energy Technique (MET) combined with Trigger Point Therapy (TPT)|For this type of intervention, TPT will first be performed on both sides of the upper trapezius muscle, followed by MET, which will also be performed bilaterally. The detailed method of performing the applied therapeutic techniques for the combined procedure will be identical as in the case of isolated (single) methods.
40957475|NCT03864978|DRUG|Rifaximin delayed release 400 mg tablet|Rifaximin delayed release
40957476|NCT03864978|DRUG|Placebo|Placebo
40957477|NCT00032409|BEHAVIORAL|Music therapy-based relaxation/stress reduction|
40957478|NCT01272674|OTHER|exercise training|4 weeks supervised physical exercise training
40957479|NCT00252395|DEVICE|PDA-based Electronic Prescribing Software|
40957480|NCT02918201|DRUG|Tranexamic Acid|TXA 25 mg/ml applied topically to moisten the wound
40957481|NCT02918201|DRUG|saline|Saline solution (0.9% NaCl) applied topically to moisten the wound
40957482|NCT01489397|DEVICE|Confocol laser endomicroscopy|Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
41455671|NCT00365053|DRUG|belinostat|Given IV
40957483|NCT06450353|BEHAVIORAL|Patient Ancestry Questionnaires|Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.
40957484|NCT05849701|DEVICE|Shock wave therapy|using gymna Shock Master 500 with an input voltage of alternating current (AC) 220 Volte, 100 pulses at 0.13 m joule/mm at 3 Hz per session for 6 weeks.
40957485|NCT05849701|DEVICE|Vacuum-assisted closure|Using KCI's Vacuum Assisted Closure Device for six weeks, the pump delivered an intermittent negative pressure of -125 mmHg. The cycle was of seven minutes during which the pump was on for five minutes and off for two minutes, the dressings were changed on the fourth day.
40763319|NCT04925375|DRUG|Abatacept|Abatacept is a selective costimulation modulator, inhibiting T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Orencia solution supplied in a prefilled syringe should be refrigerated at 2C to 8C (36F to 46F). Orencia should not be used beyond the expiration date on the prefilled syringe. The product should be protected from light by storing in the original package until time of use. The prefilled syringe should not be frozen.
40957486|NCT02128802|PROCEDURE|Gastric Bypass|
40957487|NCT02128802|OTHER|Weight Loss Program|
40957488|NCT00189995|DRUG|clozapine|
40957489|NCT00189995|DRUG|haloperidol|
40957490|NCT05000281|DRUG|Ibuprofen|600 mg Ibuprofen 3 times a day for up to six weeks.
40957491|NCT02871414|BEHAVIORAL|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
40957492|NCT02871414|BEHAVIORAL|REST - Late Group|Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
41455672|NCT00365053|OTHER|laboratory biomarker analysis|Correlative studies
41455673|NCT00362635|DRUG|Clevudine|
41455674|NCT00296530|DRUG|fluticasone propionate/salmeterol|
41455675|NCT00296530|DRUG|fluticasone propionate|
41455676|NCT00296530|DRUG|montelukast|
40957493|NCT04022850|BEHAVIORAL|A non-reflective decision assistance strategy|A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).
40957494|NCT04022850|BEHAVIORAL|A both reflective and non-reflective decision information strategy|"This strategy consists of a corporate campaign entitled Stopping Low-Value Prescribing run by the organization (Osakidetza- Basque Health Service) that provides FPs with the evidence-based Clinical Practice Guidelines for the primary prevention of CVD in low-risk patients."
40957495|NCT04022850|BEHAVIORAL|A reflective decision structure strategy|The strategy involves the sending of regular audit/feedback reports with practice- and organizational-level performance indicators regarding PIP of statins and healthy lifestyle promotion to prompt reflection about their own care practice, provided along with intention formation and goal-setting-focused messages.
40957496|NCT01158157|BIOLOGICAL|ACAM2000|Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
40957497|NCT01269411|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
40957498|NCT01269411|PROCEDURE|therapeutic conventional surgery|Undergo surgery
40957499|NCT01269411|OTHER|pharmacological study|Correlative studies
40763320|NCT04925375|OTHER|Placebo|The composition of the placebo for Orencia is the same as the active study drug without the abatacept. The placebo will be packaged and labeled as described above for the Orencia prefilled syringes. To maintain the blind, injection volumes will be the same as the active treatment.
40957500|NCT01269411|OTHER|laboratory biomarker analysis|Correlative
40957501|NCT04257734|OTHER|observation|different serum antibodies status
40957502|NCT01694264|DRUG|Entecavir|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
40957503|NCT01694264|DRUG|Placebo|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
41135724|NCT02732132|DRUG|Ketamine and Midazolam|This group was injected intravenous midazolam 0.1 mg/kg (maximum 4 mg), two minutes later, ketamine 1 mg/kg was given intravenously before the start of endoscopy.
40957504|NCT01831648|OTHER|Blood sample|
40957505|NCT02055417|BEHAVIORAL|Personal Approaches to Treatment Choices for HIV|
40957506|NCT02055417|BEHAVIORAL|Stress Reduction Skills Program|
41135725|NCT02732132|DRUG|Propofol and Fentanyl|This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.
41135726|NCT02551705|OTHER|functional Imaging|Brain responses associated with emotional memory will be investigated
41135727|NCT05626907|OTHER|Diet modification #1|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 130% of estimated daily caloric needs and for the other 7 days, meals will be low in calories, consistent with recommendations for weight loss.
40763321|NCT00684684|DEVICE|Chartis System|Assessment of airway flow and pressure
40957507|NCT01237821|DRUG|BenzaClin|Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks
40957508|NCT01237821|DRUG|Effaclar|Topical, Bid, 12 weeks
40957509|NCT03352297|BIOLOGICAL|Unfiltered Nanofat Graft|Nanofat created from microfat, skipping the filtration step. Intradermal and subdermal injections in post burn scars on the face.
40957510|NCT00334958|DRUG|Placebo|For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
40957511|NCT00334958|DRUG|Rufinamide|For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
40957512|NCT05710042|DEVICE|Revivent TC System|The Revivent TC System is indicated for patients suffering from symptomatic heart failure referred for treatment of left ventricular antero-septal aneurysms/scars that are contiguous and includes both anterior and septal components.
40957513|NCT04352569|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
40957514|NCT03227185|DEVICE|real anodal transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
40957515|NCT03227185|DEVICE|sham transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
40957516|NCT05231057|OTHER|Pilates exercises|Mat, Pilates band or elastic bands, and Pilate's ball
40957517|NCT05231057|OTHER|Conventional physical therapy program|pain relief, increasing flexibility, and mobility, improving muscle strength
40957518|NCT04437186|BEHAVIORAL|Recovery program|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
40957519|NCT00003568|BIOLOGICAL|aldesleukin|
40957520|NCT00003568|BIOLOGICAL|gp100 antigen|
40957521|NCT00003568|BIOLOGICAL|incomplete Freund's adjuvant|
40957522|NCT05514483|DRUG|Placebo|Single intravenous dose of 10 mL of sodium chloride (NaCl) 0.9% over 15 minutes.
40957523|NCT05514483|DRUG|Ondansetron|Single intravenous dose of ondansetron hydrochloride dihydrate 0.15 mg/kg (maximum 16 mg) in 10 mL of NaCl 0.9% over 15 minutes.
40957524|NCT03475823|DIETARY_SUPPLEMENT|Sideritis Scardica|Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
40957525|NCT03475823|DIETARY_SUPPLEMENT|Ginkgo biloba|Ginkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.
40957526|NCT03475823|DIETARY_SUPPLEMENT|Placebo control|An inert encapsulated powder provided by Finzelberg.
40957527|NCT03464071|DEVICE|Hyperinflation with mechanical ventilator|increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
40957528|NCT03464071|DEVICE|Manual hyperinflation|the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
40957529|NCT00608660|OTHER|acupuncture|staging acupuncture
41455677|NCT03494933|PROCEDURE|CRT-P implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-P device.
40957530|NCT00608660|OTHER|acupuncture and moxibustion|staging acupuncture and moxibustion
41455678|NCT03494933|PROCEDURE|CRT-D implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-D device.
41455679|NCT04943107|OTHER|no intervention|no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
40957531|NCT00608660|OTHER|electroacupuncture|staging electroacupuncture
40957532|NCT00608660|OTHER|acupuncture along yangming tendons|staging acupuncture along Yangming musculature
40957533|NCT00608660|OTHER|acupuncture|non-staging acupuncture
40957534|NCT01021046|PROCEDURE|DALK using GCCT|Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
40957535|NCT01021046|PROCEDURE|DALK using FCT|Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
40957536|NCT01543958|DRUG|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
40957537|NCT01543958|DEVICE|Sevelamer carbonate|
40957538|NCT04214171|DIAGNOSTIC_TEST|Gait and muscle strength will be assessed|The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated
40957539|NCT00246155|BIOLOGICAL|Botulinum toxin type A|
41135728|NCT05626907|OTHER|Diet modification #2|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 150% of estimated daily caloric needs and for the other 7 days, meals will be meals will be low in calories, consistent with recommendations for weight loss.
41455680|NCT04345822|PROCEDURE|Decompression surgery|The surgeries aim to relieve the myelopathy from cord compression
41455681|NCT05179122|PROCEDURE|Surgical drain|In this arm a surgical drain will be inserted prior to surgical wound closure
41455682|NCT05797740|DRUG|Mavenclad|This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.
40957540|NCT03453008|OTHER|elbow extension, electromyography|"Two evaluations before the toxin injection (T0 and T1), to quantify cocontractions and to determine the toxin injection pattern.~The first evaluation (T0) will be carried out within a period of between 1 month and 15 days before the injection. This evaluation makes it possible to pose the indication for the realization of injection of Botulinum Toxin A (TBA).~The second evaluation (T1) will be performed on the day of the injection to specify the muscle targets to be injected.~The first evaluation is a Clinical evaluation and second is Instrumental evaluation"
40957541|NCT06193317|DEVICE|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
40957542|NCT05843045|DEVICE|Indoor Air Quality Mitigation|Mitigation of indoor air quality with use of smart thermostat, smart bath fan control, and high quality furnace filters
40957543|NCT05405374|OTHER|OSTEOAMP|OSTEOAMP SELECT Fibers (derived from human bone allograft) rehydrated with bone marrow aspirate (BMA) and combined with local autogenous graft for use in lumbar interbody fusion of the lumbar spine.
40957544|NCT05405374|DEVICE|Infuse|The Infuse Bone Graft/Medtronic Interbody Fusion Device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2, known as dibotermin alfa) placed on an absorbable collagen sponge (ACS). rhBMP-2 is the active agent in the Infuse Bone Graft component. The ACS is a soft, white, pliable, absorbent implantable matrix for rhBMP-2.
40957545|NCT04567498|OTHER|exhaled breath sampling|The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
40957546|NCT01065597|DEVICE|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
40957547|NCT03191422|BEHAVIORAL|LSVT BIG|LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
40957548|NCT01972568|DRUG|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
41292458|NCT06453551|DRUG|TRN501 - Dose 3|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
41455683|NCT03734263|DRUG|sodium phenylbutyrate|Enrolled subjects will receive a four-week period of treatment with sodium phenylbutyrate (oral use)
40763322|NCT06637917|DEVICE|OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System|The Nellcor™ N-600x Pulse Oximetry System with N-600X Pulse Oximeter and Nellcor™ Sensors and Cables with OxiMax technology is indicated for prescription use only for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin and PR. The N-600x Pulse Oximeter is intended for use with neonatal, pediatric, and adult patients during both no motion and motion conditions and for patients who are either well or poorly perfused, in hospitals, hospital-type facilities, intra-hospital transport, and home environments.
40957549|NCT01972568|DRUG|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
40957550|NCT01972568|DRUG|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
40957551|NCT00113022|DRUG|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
40957552|NCT00113022|DRUG|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
40957553|NCT03460938|PROCEDURE|Remote ischemic preconditioning|RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery.
40957554|NCT04338074|DRUG|Tranexamic acid tablets|Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos
40957555|NCT04338074|DRUG|Placebo oral tablet|2 tablets p.o. three times per day x 5 days
40957556|NCT03781427|DEVICE|Cardiac resynchronization therapy|Left ventricular pacing
40957557|NCT00628056|DRUG|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
40957558|NCT04589455|DIETARY_SUPPLEMENT|Hennep extract|Hennep extract from Becanex containing 70 mg CBD
41135729|NCT05626907|OTHER|Diet modification #3|Participants will be provided all meals for a 14-day period to be approximately 100% of estimated daily caloric needs.
40957559|NCT05508711|DEVICE|FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device|Concomitant cardiac output measurement with transesophageal echocardiography and with the FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device in 3 different positions (horizontal supine, Trendelenburg and reverse Trendelenburg position).
40957560|NCT05464810|DRUG|Letrozole|Given PO
40957561|NCT05464810|DRUG|Simvastatin|Given PO
40957562|NCT05482412|DEVICE|transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve|Direct superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]
40957563|NCT01344785|PROCEDURE|Intramedullary nailing|All patients will be treated with Intramedullary nailing
40957564|NCT03719586|DRUG|ZMapp|Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1
41135730|NCT00553332|DRUG|selumetinib|Given orally
41135731|NCT00553332|OTHER|laboratory biomarker analysis|Correlative studies
41135732|NCT03964779|DIAGNOSTIC_TEST|Hormonal assay|Measurement of Thyroid stimulating hormone
41135733|NCT03964779|DIAGNOSTIC_TEST|Antibody assay|antithyroglobulin and antithyroid peroxidase
41135734|NCT01314066|DRUG|Bevacizumab|Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
41135735|NCT01314066|DRUG|Placebo|Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
41292459|NCT06453551|DRUG|TRN501 - Dose 4|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
41292460|NCT06453551|DRUG|TRN501 - Dose 5|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
41292461|NCT06453551|DRUG|TRN501 - Dose 6|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
41292462|NCT06453551|DRUG|TRN501 - Dose 7|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
41292463|NCT06453551|DRUG|TRN501 - Dose 8|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
40957565|NCT03719586|DRUG|Remdesivir|Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg remdesivir 2.5 mg/kg)
40957566|NCT03719586|DRUG|MAb114|50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
40957567|NCT03719586|DRUG|REGN-EB3|150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
40957568|NCT00818480|DRUG|YM155|continuous infusion
40957569|NCT01100671|OTHER|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
40957570|NCT06557746|OTHER|Coca-Cola|100 ml Coca-Cola every 30 minutes during the operation
40957571|NCT06557746|OTHER|Supplemental oxygen|Continuous supply of oxygen (2 L/min) during the operation
40957572|NCT03638609|DEVICE|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
40957573|NCT03137537|DRUG|Ivabradine|lower heart rate in heart failure patients.
40957574|NCT03137537|DRUG|Placebo Oral Tablet|Procedure prescribed to compare the active effect of a medicine.
40957575|NCT03893370|DEVICE|RejuvenAir System|RejuvenAir Metered CryoSpray
40957576|NCT03893370|DEVICE|Sham Control Procedure|Sham Control Procedure
40957577|NCT03493399|BEHAVIORAL|Interference|"The principle of interference-based techniques is to move the resources allocated to the elaboration of intrusive desire thoughts to a competing task (e.g., clay modelling, competitive mental imagery, Tetris) in order to monopolize the resources underlying craving, thus preventing its elaboration and reducing its vividness and overwhelming nature. Several studies (Andrade, Pears, May, \& Kavanagh, 2012; May, Andrade, Panabokke, \& Kavanagh, 2010; Skorka-Brown, Andrade, Whalley, \& May, 2015) have shown the efficacy of such techniques to reduce substance-related craving. Yet, data obtained on clinical samples remain scarce.~Due to the flexibility of the single case design towards each participant, the list of interference-based techniques that will be used in this study cannot be exhaustive. However, the following will be proposed to participants: Tetris (smartphone version), manipulation of a bunch of keys, manipulation of a fidget, mental imagery, reading and memorizing a text."
40957578|NCT03398785|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
40957579|NCT01742000|DIETARY_SUPPLEMENT|Karinat|
40957580|NCT01742000|DRUG|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
41292464|NCT05453370|DEVICE|CALMA m-health app|CALMA is an app for smartphones that provides evidence-based tools to prevent suicide. Out of Crisis modality consists of 4 sections: Moments, Agenda, Profile and Tips. The I need help modality uses DBT skills presented in a card format. The Problem-solving Card is the first one showed and helps the user to know if the problem that triggered the crisis can be addressed through a problem-solving strategy. If not, the next step is to use the CALMA thermometer (to identify the intensity of the emotion) and the DBT Skills Cards. They are based fundamentally in two groups of DBT skills, emotional regulation and distress tolerance. If distress worsens or does not diminish the Emergency Card is activated, offering the user the option to make one or several calls to emergency contacts and providing the option to use the geolocation function to show all emergency services near the user's location so that he/she can consult personally. All participants will also receive mental health treatment.
41292465|NCT05453370|OTHER|Treatment As Usual (TAU)|Participants who do not receive the application will continue the usual mental health treatment (psychotherapeutic and/or psychopharmacological) by their usual treating professionals throughout the duration of the study.
41455684|NCT00214682|DRUG|Folate (400mcg) and Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
41292466|NCT01478347|BIOLOGICAL|Recombinant meningococcal B + OMV NZ|2 injections 2 months apart
41292467|NCT00416351|DRUG|clofarabine|
40957581|NCT05685511|BEHAVIORAL|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
40957582|NCT05685511|OTHER|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
40957583|NCT03243071|BEHAVIORAL|Tailored Website|Participants randomized to the intervention arm will have free access to a password protected interactive culturally and linguistically tailored website via a tablet device. No private identifiable data about you will be collected. Participants will receive a brief 10-minute tutorial by a trained research assistant on login procedures and use of the website.
40957584|NCT03243071|BEHAVIORAL|Standard Website|Participants randomized to the control condition will have free access to the NYU standard clinical trials website. Participants in the control condition will have access to the tailored website at the date of study completion (no later than 6 months' post-date of enrollment).
40957585|NCT00002734|BIOLOGICAL|recombinant interferon alfa|
40957586|NCT00002734|DRUG|chemotherapy|
40957587|NCT00002734|DRUG|paclitaxel|
40957588|NCT00002734|DRUG|topotecan hydrochloride|
40957589|NCT00002734|RADIATION|lutetium Lu 177 monoclonal antibody CC49|
40957590|NCT00002734|RADIATION|yttrium Y 90 monoclonal antibody CC49|
40957591|NCT03816384|DEVICE|Standard of Care|Standard of care urinary drainage system.
40957592|NCT03816384|DEVICE|DLC Group|Urinary drainage system with active drain line clearance and plain silicone catheter.
40957593|NCT03816384|DEVICE|DLCS Group|Urinary drainage system with active drain line clearance and silver-doped silicone catheter.
40957594|NCT00075218|DRUG|Placebo|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
40957595|NCT00075218|DRUG|SU011248|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
40957596|NCT04800744|OTHER|Lavender peppermint elequil aromatab|Lavender peppermint elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
40957597|NCT04800744|OTHER|Sweet almond oil elequil aromatab|Sweet almond oil elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
40957598|NCT05938517|DRUG|Betahistine dihydrochloride|Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.
40957599|NCT05938517|DRUG|Selegiline-hydrochloride|In the second period, each subject was pre-treated with Selegiline (5 mg/day) for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) with at least two days between the different dosages.
40957600|NCT05509114|DEVICE|Virtual Reality Glasses|The intervention group of patients watched a video with virtual reality glasses during the transrectal biopsy process.
40957601|NCT06260215|OTHER|ST|Participants will perform a soccer training (ST) session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
40957602|NCT03584178|DEVICE|Budesonide via MAD device|Delivery through Mucosal Atomization Device
41135736|NCT02263859|DEVICE|aura6000 System|The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).
41135737|NCT04067609|DRUG|Dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
41135738|NCT04067609|OTHER|placebo|100mL of normal saline (placebo)
41135739|NCT02265120|BEHAVIORAL|Questionnaire|The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
41135740|NCT03418922|DRUG|Lenvatinib|Specified doses will be administered orally on specified days.
41466458|NCT05911087|BIOLOGICAL|Phase II:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
40957603|NCT03584178|DEVICE|Budesonide via intranasals Saline Irrigation|delivery via nasal irrigation bottle
40957604|NCT04887844|DRUG|Lidocaine injection|Lidocaine injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
40957605|NCT04887844|DRUG|Corticosteroid injection|Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
40957606|NCT04887844|OTHER|Conventional Physical therapy|The study participants underwent a physiotherapy program that included a one-time 15-minute cold therapy using ice packs and closed-kinetic chain quadriceps strengthening program as follows; isometric quadriceps exercise, isokinetic concentric, and eccentric quadriceps exercises with heel slides and squads. These exercises were repeated ten times a day, seven days per week, for eight weeks in total
41135741|NCT03418922|DRUG|Nivolumab|Specified doses will be administered intravenously on specified days.
40957607|NCT06095947|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.
41135742|NCT02390778|BEHAVIORAL|Group Debriefing|Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.
41135743|NCT02390778|BEHAVIORAL|leisure activity (film showing)|
40957608|NCT03913988|BEHAVIORAL|Lucid Dream|Lucid dream techniques are a set of strategies to induce the ability to obtain conscious awareness during the dream state and include mental suggestions before sleep.
40957609|NCT03913988|BEHAVIORAL|Stress Reduction|Stress reduction techniques are a set of strategies designed to reduce anxiety and include meditation and guided imagery.
40957610|NCT03913988|BEHAVIORAL|Sleep Hygiene Techniques|Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.
40957611|NCT00142298|DRUG|Telbivudine (LdT)|Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
40957612|NCT02946528|DEVICE|urgent-start peritoneal dialysis catheter|Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
40957613|NCT02946528|DEVICE|central venous catheter|Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
40957614|NCT06313775|PROCEDURE|bilateral orchiectomy|Bilateral simple orchiectomy is the surgical removal of both testicles through an incision in the scrotum.
40957615|NCT00313300|DRUG|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
41455685|NCT00214682|BEHAVIORAL|mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
40957616|NCT00313300|DRUG|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
40957617|NCT00313300|DRUG|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
40957618|NCT00313300|DRUG|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
40957619|NCT04536701|BEHAVIORAL|Mood Monitoring and Behavioral Recommendation System|The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships. This includes monitoring for mood and stress and analyzing the significance of monitoring those attributes to dementia patient care and subsequent behavior dynamics between the patient and caregiver. In addition, novel and adaptive behavioral suggestions will be provided to family caregivers via text messages on project Smart phones at the right moments aimed to help improve familial interactions related to caregiving, which over time should ameliorate the stressful effects of the patient's illness and reduce strain on caregivers.
40957620|NCT03267108|COMBINATION_PRODUCT|INOpulse®|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
40957621|NCT03267108|COMBINATION_PRODUCT|Placebo|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
40957622|NCT03267108|COMBINATION_PRODUCT|Open Label Extension|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
40957623|NCT02004522|DRUG|Duvelisib|PI3K Inhibitor
40957624|NCT02004522|DRUG|Ofatumumab|monoclonal antibody
40957625|NCT01814631|OTHER|image quality and resolution|Image quality and resolution will be viewed using Aloka processor
40957626|NCT01814631|OTHER|image quality and resolution|image quality and resolution will be viewed on the EU-me2
40957627|NCT05123820|DRUG|Treatment period A|Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
40957628|NCT05123820|DRUG|Treatment period B|ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
40957629|NCT06315959|PROCEDURE|Bilateral ultrasound guided erector spinae plane block|"Bilateral ultrasound-guided ESP(total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.~Postoperative chronic pain will be assessed using the Brief Pain Inventory(BPI).~Anxiety and depression status will be evaluated using the Hospital Anxiety and Depression Scale (HADS).~The character of pain will be evaluated using the Douleur Neuropathique 4 (DN4) score."
40957630|NCT06315959|DRUG|morphine PCA|IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
40957631|NCT06315959|OTHER|Control group|"Patients in this group will not be performed plane blocks. Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.~Postoperative chronic pain will be assessed using the Brief Pain Inventory(BPI).~Anxiety and depression status will be evaluated using the Hospital Anxiety and Depression Scale (HADS) .~The character of pain will be evaluated using the Douleur Neuropathique 4 (DN4) score."
40957632|NCT06315959|DRUG|morphine PCA|V PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
40957633|NCT04710394|BEHAVIORAL|Smell Training|Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
40957634|NCT03473483|OTHER|SREC|"The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices.~Tank:~* Sealed and disposable~* Minimum 350 puffs per tank~* Volume of e-liquid per tank \~ 3ml~E-Liquid Characteristics:~* Tobacco flavored~* Nicotine concentration: 15 mg/ml~* Propylene Glycol:\~ 50% (wt / wt)~* Glycerin: \~ 50% (wt / wt)~* Cotinine: \<1 μg/g~* Nornicotine: 5 μg/g~* Myosmine : 3 μg/g~* Anabasine: \<1 μg/g~* Anatabine: \<1 μg/g~* Beta:nicotyrine: \<1 μg/g~* Diacetyl: \<2 μg/g~* 2,3:Pentanedione: \<1 μg/g~* Arsenic: \<0.1 μg/g~* Cadmium: \<0.1 μg/g~* Chromium: \<0.1 μg/g~* Lead: \<0.1 μg/g~* Nickel: \<0.1 μg/g~* Mercury: \<0.05 μg/g"
40957635|NCT05654935|RADIATION|Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center."
40957636|NCT05654935|RADIATION|Telerobotic Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet)."
40957637|NCT02408627|DEVICE|EEG|
40957638|NCT00654017|DRUG|placebo|Placebo comparator to be given per protocol.
40957639|NCT00654017|DRUG|sildenafil|oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
40957640|NCT06042504|OTHER|Survey|"Subjects will complete a survey. The survey consists of two parts, A and B. During part A subjects will indicate which of the 5 cohorts they identify as. Successively in part B, subject will complete a survey known as the Perceived Stress Scale (PSS)."
40957641|NCT05629169|OTHER|No intervention applied - observational study only|Observational study only. All head impacts will be assessed using video footage.
40957642|NCT01237743|DEVICE|Transcatheter aortic valve implantation.|Transcatheter aortic valve implantation,femoral access.
41135744|NCT05485441|OTHER|Digital Educational Intervention|"The educational intervention will be provided (at T1) in two ways:~(I) a video lecture in e-learning mode lasting about an hour, aimed at adolescents, using the School Institute's platform for distance education (II) the promotion of 2-minute videopills on the social channels most frequently used by students (dedicated youtube channel/school portal)"
41135745|NCT03383848|DEVICE|Medication Management Software|"The OnTrack Medication Management Software allows patients to track the amount of fertility medication they have at home. When they check off their to do list of medications, it decrements the amount they have at home. It allows them to see when they will run out of medication depending on their current doses (which can change daily). Daily use of the software will be 5-10 minutes daily for approximately 21 days."
41135746|NCT04820491|DIAGNOSTIC_TEST|X-Ray|Shoulder x-rays as felt necessary for standard of care of diagnosis of shoulder dislocation and reduction
41292468|NCT05537181|DEVICE|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
41292469|NCT01983345|PROCEDURE|prenatal surgical repair of fetal myelomeningocele|open surgical repair of myelomeningocele before 26 weeks gestational age
41292470|NCT03902405|BEHAVIORAL|Active CEASAR Intervention|Healthy and stimulant-use related pictures will be presented on a computer screen. Using a joystick, participants will be trained to pull in pictures that are presented in portrait orientation, and push those presented horizontally. In the active experimental condition, pushed pictures will exclusively be stimulant-related pictures.
41292471|NCT03902405|BEHAVIORAL|Placebo CEASAR|In the control condition, stimulant cues and healthy cues will be randomized and stimulant use-related pictures will be equally divided into push and pull conditions.
41292472|NCT05046210|BEHAVIORAL|LHA intervention|The participants in the EG received 4 lessons from a LHA over 4 weeks. Four lessons were taught one-on-one once a week by a certified LHA at the participants' homes. The lessons including understand oral structure, learn oral self-care skills and oral function promotion, understand the status of oral self-care and the relationship between oral diseases and systemic diseases, understand swallowing dysfunction and safe eating skills and review.
40957643|NCT04624646|DEVICE|Discontinuous monitoring|Discontinuous ECG monitoring by finger contact every day
40957644|NCT04624646|DEVICE|Continuous single-lead ECG Patch|Continuous 72hr ECG monitoring by a single-lead patch at 3, 6, 9, 12 months after stroke
40957645|NCT04624646|DEVICE|24-hour Holter monitoring|Continuous 24-hour monitoring by Holter monitor at 1, 6, 12 month after stroke
41135747|NCT04820491|DIAGNOSTIC_TEST|Ultrasound|Initial evaluation with ultrasound; may also evaluate nearby areas for concern of fracture. Order x- rays after ultrasound as seen fit for other injuries of diagnostic uncertainty.
41292473|NCT05046210|BEHAVIORAL|Oral exercise intervention|Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.
40957646|NCT03714971|BEHAVIORAL|WhatsApp embedded in smoking cessation service|The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
40957647|NCT03617185|OTHER|High Intensity Interval Training (HIIT)|Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.
40957648|NCT03617185|OTHER|Routine Exercise|Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
40957649|NCT03617185|PROCEDURE|Bariatric surgery|Patients will undergo bariatric surgery as part of their routine care
40957650|NCT00776204|DEVICE|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
40957651|NCT00776204|DEVICE|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
40957652|NCT00776204|DEVICE|Taxus Libertè|Taxus Libertè stent placed in coronary artery
40957653|NCT06505174|OTHER|Hydroxypropyl Guar-based artificial tears four times per day|Use of hydroxypropyl Guar-based artificial tears four times per day
40957654|NCT01458236|DRUG|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
40957655|NCT01458236|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
40957656|NCT01854658|DRUG|GFF MDI (PT003)|GFF MDI administered as two puffs BID
40957657|NCT01854658|DRUG|GP MDI (PT001)|GP MDI administered as two puffs BID
40957658|NCT01854658|DRUG|FF MDI (PT005)|FF MDI administered as two puffs BID
40957659|NCT01854658|DRUG|Placebo|
40957660|NCT05072704|DRUG|Sufentanil|Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.
40957661|NCT05072704|DRUG|Dexmedetomidine|Pre-operative infusion of dexmedetomidine 1µg/kg in 100ml of normal saline before surgery + per-operative infusion of dexmedetomidine 0.4 µg/kg in 100ml of normal saline during the surgery if needed.
40957662|NCT06555497|DRUG|topical 1% methotrexate gel|topical 1% methotrexate gel
40957663|NCT06555497|DRUG|clobetasol propionate 0.05% ointment|clobetasol propionate 0.05% ointment
40957664|NCT00183677|DRUG|Escitalopram|Escitalopram 10 to 30 mg per day for 12 weeks
40957665|NCT06318429|BEHAVIORAL|stretching exercise group|stretching exercise group
40957666|NCT00579137|BIOLOGICAL|Campath -1H|"Given intravenous on Days -8,-7, and -6~Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients \>15 kg to 30 kg the dose 5 mg; for patients \> 30 kg the dose is 10 mg"
40957667|NCT00579137|DRUG|Fludarabine|"Given intravenous on Days -8,-7,-6,-5, and -4~Dose is 30 mg/m2"
40957668|NCT00579137|BIOLOGICAL|Anti-CD45|"Given intravenous over 6 hours on Days -5,-4,-3, and -2~Dose is 400 microgram/kg"
40957669|NCT00579137|PROCEDURE|Stem cell infusion|stem cells are infused on day 0
41135748|NCT05056194|DRUG|Valiloxybate|XW10172 MR Granules for Oral Suspension
41135749|NCT05056194|OTHER|Placebo|Placebo Granules for Oral Suspension
41292474|NCT01123447|PROCEDURE|Open reduction and internal fixation|Patients will undergo surgery for open reduction of the fracture and internal fixation with an LC-DC plate and screw fixation.
40957670|NCT04232254|BEHAVIORAL|Animal-based Protein Foods|Participants will consume animal-based protein foods.
40957671|NCT04232254|BEHAVIORAL|Skewed Protein Distribution|Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.
40957672|NCT04232254|BEHAVIORAL|Plant-based Protein Foods|Participants will consume plant-based protein foods.
40957673|NCT04232254|BEHAVIORAL|Balanced Protein Distribution|Participants will consume 5 meals per day consisting of 20% of dietary protein per meal.
41292475|NCT01123447|PROCEDURE|Closed reduction and short-arm cast|Patient will undergo a closed reduction and be placed in a short-arm (below-elbow) cast for 6 weeks.
40957674|NCT00092989|DRUG|montelukast sodium|Duration of Treatment: 1 dose
40957675|NCT00092989|DRUG|placebo|Duration of Treatment: 1 dose
40957676|NCT01264757|BEHAVIORAL|Physical Activity Educational Materials|A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
40957677|NCT01264757|BEHAVIORAL|Pedometer|A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
40957678|NCT00932100|DRUG|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
40957679|NCT00932100|DRUG|Heparin|IV dose per standard of care at the local institution
40957680|NCT02893670|PROCEDURE|Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation|"All patients will be assessed for drug levels and metabolites. Patients diagnosed with ileal or ileo-colonic crohn's will undergo an MR Enterography (MRE). In crohn's patients, MRE was shown to have a higher impact on patient management than colonoscopy. Patients diagnosed with either UC, IBD-U or Crohn's colitis will undergo a flexible sigmoidoscopy.~Following re-evaluation each patient will undergo 2 transition meetings with pediatric and adult gastroenterologist as well as a meeting with IBD nurses and social worker."
41135750|NCT05244967|OTHER|vaginal swab|self-sampling, vaginal swab
41135751|NCT05770609|DRUG|SPH3127 Tablets with Dose A|See Arm description
41135752|NCT05770609|DRUG|SPH3127 Tablets with Dose B|See Arm description
41135753|NCT05770609|DRUG|SPH3127 Tablets placebo|See Arm description
41135754|NCT04598139|OTHER|Study group|The study group uses a web-based medication error notification system
41292476|NCT05384743|DRUG|Rituximab Monotherapy|Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).
41292477|NCT01907529|DRUG|docetaxel, epirubicin and cyclophosphamide|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
41292478|NCT01907529|DRUG|docetaxel, epirubicin and cyclophosphamide plus endostar|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
41466459|NCT05911087|BIOLOGICAL|Phase II:SW-BIC-213;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
40957681|NCT05412303|OTHER|data collection|age, gender, body weight, height, personal medical history, ASA score, EuroSCORE2, type of cardiac surgery, the preoperative left ventricular ejection fraction, the duration of CPB, the duration of aortic clamping, the need for intraoperative blood transfusion, norepinephrine, dobutamine, creatinine value, time to extubation (hours), any occurrence of complications during the stay in the ICU or in the hospital, and the LOS in the ICU and hospital
40957682|NCT05561738|DIETARY_SUPPLEMENT|Nicotinamide Riboside Chloride|The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.
40957683|NCT05561738|DIETARY_SUPPLEMENT|Placebo|The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.
40957684|NCT05561738|OTHER|Standard of Care|Standard of Care
40957685|NCT02982668|OTHER|Initial enteral feeding|
40957686|NCT02982668|DRUG|metoclopramide or mosapride|gastrointestinal (GI) motility improving
40957687|NCT04850820|DIETARY_SUPPLEMENT|Novel essential amino acid supplementation|This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
40957688|NCT04850820|DIETARY_SUPPLEMENT|Branched-chain amino acid supplementation (BCAA)|This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
40957689|NCT04850820|DIETARY_SUPPLEMENT|Isocaloric carbohydrate supplementation|This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
40957690|NCT04477889|OTHER|Treatment for COVID-19|Patients treated for COVID-19
40957691|NCT00934089|DRUG|PF-04217329|Topical ocular solution, once-daily for 14 days
40957692|NCT00934089|DRUG|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
40957693|NCT00934089|DRUG|PF-04217329|Topical ocular solution, once-daily for 14 days
40957694|NCT00934089|DRUG|latanoprost|Topical ocular solution, once-daily for 14 days
40957695|NCT02746146|OTHER|Systematic use of a prognostic score|The prognostic score is given in Dusseux et al 2015. It will be used as soon as possible after the initiation of dialysis.
40957696|NCT01164930|BEHAVIORAL|Acceptance and Commitment Therapy|8-week ACT group
40957697|NCT02021773|DRUG|LBR-101 High Dose|Subcutaneously Administered LBR-101 Monthly x 3
40957698|NCT02021773|DRUG|LBR-101 Low Dose|Subcutaneously Administered LBR-101 Monthly x 3
40957699|NCT02021773|DRUG|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
41135755|NCT03004989|BEHAVIORAL|Programme|The participants of this study had participated in one of three different RTW-GPs. These programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. All the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important
40957700|NCT04549857|BEHAVIORAL|aromatherapy|"The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~1. The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~2. The placebo group only used base oil (sweet almond oil).~3. The control group did not provide any interventional measures and only received conventional treatment."
40957701|NCT05058820|OTHER|Post Facilitation stretch|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Post facilitation stretch 15 secs isometric hold/ 15 secs stretch/ 30 secs relax/ 5 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
40957702|NCT05058820|OTHER|Active Isolated Stretching|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Active Isolated Stretching 2 secs hold/ 10 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
40957703|NCT00178633|PROCEDURE|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
41135756|NCT03113175|BEHAVIORAL|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation, medication according to a stepped care model
41135757|NCT03113175|BEHAVIORAL|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
40957704|NCT04389853|PROCEDURE|Flexible ureteroscopy|Retograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
40957705|NCT04389853|PROCEDURE|Mini-percutaneous nephrolithotomy|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs).
40957706|NCT03722966|DRUG|Varenicline|All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.
40957707|NCT03722966|DRUG|Oral Nicotine Replacement Therapy (NRT)|Half of study participants will be randomly assigned to receive oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur) in addition to varenicline.
40957708|NCT03722966|BEHAVIORAL|Medication Reminders|Half of study participants will be randomly assigned to receive automated medication reminders via their smartphones.
40957709|NCT03722966|BEHAVIORAL|Tobacco Cessation Counseling|All participants will be offered 6 weekly tobacco cessation counseling sessions with a Tobacco Treatment Specialist.
40957710|NCT05882942|DIETARY_SUPPLEMENT|Matcha green tea|This is the condition with the Matcha green tea
40957711|NCT05882942|DIETARY_SUPPLEMENT|Placebo|This is the condition with the placebo
40957712|NCT02050841|BIOLOGICAL|octaplas|Octaplas S/D Plasma
40957713|NCT03844880|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
40957714|NCT03844880|BEHAVIORAL|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
40957715|NCT01702961|DRUG|Melphalan|"Given on Day -1~Melphalan is administered according to the current SOP."
40957716|NCT01702961|DRUG|Ara-C|200 mg/m2 IB BID given on Days -5, -4, -3, -2
40957717|NCT01702961|DRUG|VP-16|200 mg/m2 IV BID given on Days -5, -4, -3, -2
40957718|NCT01702961|DRUG|BCNU|BCNU 300 mg/m2 IV given on Day -6
40957719|NCT01702961|DRUG|Rituxan|375 mg/m2 IB given on Days -6, +14, +21, +28
40957720|NCT01702961|DRUG|Stem Cells|Stem cells given on Day 0
41135758|NCT04318483|OTHER|survey|parents' telephone interview to collect medical history
41292479|NCT02140320|DRUG|RV1729 single dose|Safety and tolerability of single dose
40957721|NCT05127616|BEHAVIORAL|Minimal Contact-Cognitive Behavior Therapy|This 4 session largely home-based version of CBT with minimal therapist contact treatment is aimed at improving UCPPS symptoms by teaching symptom self-management skills that modify illness beliefs, information processing strategies, and reactions that aggravate pelvic pain and urinary symptoms.
40957722|NCT05127616|BEHAVIORAL|Patient Education/Support|This 4 session largely home-based treatment is aimed at improving UCPPS symptoms through the provision of support and science-based information about UCPPS symptoms, how it is diagnosed, its causes, impacts, and triggers, treatment options and a collaborative relationship between the patient and clinician.
40957723|NCT00999089|PROCEDURE|Conventional Coronary Artery Bypass|Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest
40957724|NCT00999089|PROCEDURE|Off-Pump Coronary Artery Bypass|Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia
40957725|NCT00999089|PROCEDURE|Pump-Assisted Coronary Artery Bypass|Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
40957726|NCT05459272|DIETARY_SUPPLEMENT|Aquilea Sueno Forte|"The test product consists of a dietary supplement in the form of tablets with three layers containing: melatonin (1.95 mg/tablet) and herbal products (extracts from Griffonia, Passiflora, California poppy, Valerian, Melissa).~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
41135759|NCT00022490|DRUG|cytarabine|Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
41135760|NCT00022490|DRUG|imatinib mesylate|Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
41135761|NCT01420757|PROCEDURE|incisional hernia repair|Tension-free open or laparoscopic incisional hernia repair
41135762|NCT01681823|DIETARY_SUPPLEMENT|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
41135763|NCT00987324|DEVICE|Taxus stent|Implantation of paclitaxel-eluting stent
40957727|NCT05459272|OTHER|Placebo|"The placebo will consist of tablets with three layers and with the same appearance as the dietary supplement under study, but containing no active ingredients.~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
40957728|NCT03400878|BIOLOGICAL|BCG-Japan|One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.
40957729|NCT03400878|BIOLOGICAL|BCG-Russia|One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.
40957730|NCT06547099|DIAGNOSTIC_TEST|Clinical tau PET|Tau PET (flortaucipir)
40957731|NCT06547099|DIAGNOSTIC_TEST|Clinical amyloid test|Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test
40957732|NCT06547099|OTHER|Research blood collection|Research blood assays for amyloid, tau, and neurodegeneration
41135764|NCT00987324|DEVICE|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
41135765|NCT00987324|DEVICE|Conventional Balloon Catheter|Ryuijin, Trek
41135766|NCT05237869|DEVICE|Blood Flow Restriction Device|Occlusion training involves the application of a cuff to the upper arm that is designed to restrict only the low-pressure blood flow in veins. It does not prevent blood flowing from the heart to the arm.
41135767|NCT05237869|OTHER|Standard Physical Therapy|Standard physical therapy protocol for lateral epicondylitis rehab without blood flow restriction.
41135768|NCT03811665|PROCEDURE|Radiofrequency Ablation|RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter. The generator will modulate power up to 150 W in reach average ablative temperature of 105oC. Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.
41135769|NCT03811665|RADIATION|Stereotactive body radiation therapy|The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation. No clinical target volume (CTV) for microscopic disease is necessary. The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT. The planning target volume (PTV) will be a standard 0.5 cm around the ITV.
41292480|NCT02140320|DRUG|RV1729 matching placebo single dose|Safety and tolerability of single dose
40957733|NCT06547099|OTHER|Cognitive assessments|Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)
40957734|NCT00229073|DRUG|dapoxetine|
40957735|NCT02821169|DRUG|ropivacaine|injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach
41135770|NCT02610322|BEHAVIORAL|Whole soy replacement diet|Participants who are allocated to Whole soy group will receive a 30\~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
41292481|NCT02140320|DRUG|RV1729 14 day repeat dose|Safety and tolerability of repeat doses
40957736|NCT02821169|DRUG|saline solution 0.9%|injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach
40957737|NCT01949831|OTHER|Assessment of functional ability in combination with follow-up at home|
40957738|NCT03342677|DIAGNOSTIC_TEST|Primovist MRI|Utility of Gd-EOB-DTPA (Primovist) enhanced Liver MRI in HCC detection and characterization in cirrhotic patients will be studied.
40957739|NCT02050516|OTHER|micro-well group culture dish|an embryo culture dish containing nine micro-wells in the middle.
41135771|NCT02610322|BEHAVIORAL|usual diet|Participants who are assigned to the usual diet group (control group) will receive a 5\~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and \<30% of energy as total fat.
41292482|NCT02140320|DRUG|RV1729 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
41292483|NCT02140320|DRUG|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
40957740|NCT01522508|PROCEDURE|tetanic stimulation|as test stimulus a painful tetanic stimulation is used
40957741|NCT00702195|DRUG|Org 36286 (corifollitropin alfa)|single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
40957742|NCT00702195|DRUG|Placebo|single dose of placebo (administered under protocol 38805)
40957743|NCT00702195|DRUG|recFSH|150 IU recFSH daily (reference group administered under protocol 38807)
40957744|NCT05975892|BIOLOGICAL|Transplantation of allogeneic MSCs in periodontal disease|Oral surgery is performed in patients with periodontal disease, under local anesthesia. An incision will be made on the periodontal lesion, A full-thickness flap is elevated on both the buccal and lingual areas and the inner epithelium of the flap removed. Granulation tissue is removed from bone defect area, and a root planning is performed. MSC construct is placed around the bone defect and a collagen membrane is used to cover and close off the bone defect site. The flap will be repositioned and the wound closed by a suture
40957745|NCT05282329|DEVICE|Transcranial alternating Current Stimulation (tACS)-active|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
40957746|NCT05282329|DEVICE|Transcranial Alternating Current Stimulation (tACS)-sham|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.
40957747|NCT06426810|DEVICE|Electrosurgical bipolar system (LigaSure)|Study participants using a electrosurgical bipolar energy system will undergo sentinel lymph node biopsy using only LigaSure during the surgery.
40957748|NCT04005911|DEVICE|Themography|Using a FLIR camera, a thermographic recording will be taken of the patient while breathing. Simultaneously, the research investigator will record the thoracic impedance-based respiratory rate as well as manually count respirations in one minute.
40957749|NCT01126801|DRUG|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
40957750|NCT01126801|OTHER|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
40957751|NCT02652754|DRUG|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
40957752|NCT04647864|DEVICE|Transcatheter Aortic Valve Implantation|Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.
41292484|NCT02140320|DRUG|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
40957753|NCT05161767|DIAGNOSTIC_TEST|Brain MRI (neuroimaging)|Structural and functional brain scans will be taken.
40957754|NCT04119544|OTHER|Conventional rehabilitation|upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
40957755|NCT04119544|DEVICE|Intensive Visual Simulation|"* First week: observation, mentalization and then attempt to perform the movements on the screen.~* Second and third weeks: production of analytical movements of wrist flexion/extension, pronation/supination, finger flexion/extension, thumb opposition.~* From the 4th week until the end: depending on the patient's motor capacities, continuation of the work of the previous 2 weeks or introduction of more functional work with object manipulation, gripping work.~Conventional rehabilitation upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible."
40957756|NCT04345042|OTHER|Classic Massage (Swedish Technique)|Classic Massage (Swedish Technique); The massage was applied to the paitents with NP in the second group. Massage procedure included 3 strokes, 3 kneads, and 3 strokes to the upper back and neck area. The application was supported by face cradle and carried out in a semi-horizontal position in which the neck was relaxed. The patient was lying in supine position.
40957757|NCT03142178|DRUG|Experimental: 3VM1001 active 2g Cream 3 times daily|3VM1001 2g Cream with active ingredient administered 3 times daily
40957758|NCT03142178|DRUG|Experimental: 3VM1001 active 3g Cream 3 times daily|3VM1001 3g Cream with active ingredient administered 3 times daily
41135772|NCT06390449|OTHER|Kahoot intervention|Kahoot, one of the WEB-2.0 tools, will be applied to students who are second-year students of the nursing department and taking the basic principles and practices in nursing course after the course.
40763323|NCT06637917|DEVICE|LNCS® NEO SpO2 Sensor with RAD-97™ Pulse CO-Oximeter|The Masimo Rad-97™ and accessories are indicated for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin, PR, carboxyhemoglobin saturation (SpCO), methemoglobin saturation (SpMet), total hemoglobin concentration (SpHb), and/or acoustic respiratory rate (RRa). The Masimo Rad-97™ and accessories are indicated for use with adult, pediatric, and neonatal patients during both no motion and motion conditions, and for patients who are well or poorly perfused. In addition, the Masimo Rad-97™ and accessories are indicated to provide the continuous non-invasive monitoring data obtained from the Masimo Rad-97™ and accessories for functional oxygen saturation of arterial hemoglobin and PR to multi-parameter devices for the display on those devices.
40957759|NCT03142178|DRUG|Experimental: 3VM1001 active 3g Cream 4 times daily|3VM1001 3g Cream with active ingredient administered 4 times daily
40957760|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 2g Cream 3 times daily|3VM1001 placebo 2g vehicle Cream administered 3 times daily
40957761|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 3g Cream 3 times daily|3VM1001 placebo 3g vehicle Cream administered 3 times daily
40957762|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 3g Cream 4 times daily|3VM1001 placebo 3g vehicle Cream administered 4 times daily
40957763|NCT06171295|DIAGNOSTIC_TEST|Blood draw|The blood draws in specified time points
40957764|NCT02126917|DRUG|HC-ER + 40% Alcohol|HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
41135773|NCT01399606|DRUG|BF2.649|5,10,20,or 40 mg per day, in a once daily scheme
41455686|NCT00214682|BEHAVIORAL|Mental health literacy|Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
41455687|NCT00214682|DRUG|placebo|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
40763324|NCT06637917|DEVICE|1041PTS (or similar) Kendall™ Neonatal Electrodes with IntelliVue MP5 Portable Patient Monitor|Market-released ECG monitoring system
40763325|NCT03469960|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
40763326|NCT03469960|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
40763327|NCT05293002|DEVICE|Restorer Iliac Stent System|Not applicable (only one intervention)
40763328|NCT05912400|DIAGNOSTIC_TEST|Blood draw|• An additional 10 mL of blood will then be drawn for mitochondrial testing purposes.
41135774|NCT05948995|DEVICE|Abduction external rotation brace|Abduction external rotation brace Arm position : Abduction , External rotation
41135775|NCT00278499|BEHAVIORAL|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
41135776|NCT00278499|BEHAVIORAL|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
41135777|NCT01049152|DEVICE|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
41135778|NCT02338999|RADIATION|PET/CT|The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.
41135779|NCT02338999|DRUG|Pioglitazone|Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.
40957765|NCT02126917|DRUG|HC-ER + 20% Alcohol|HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
41292485|NCT05315310|DEVICE|Soft Exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
40763329|NCT05912400|OTHER|FACIT-F and Pain Scales|• Questionnaires regarding pain and fatigue will be provided for the subject to review and answer.
40957766|NCT02126917|DRUG|HC-ER + 0% Alcohol|HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
40957767|NCT00492141|DRUG|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m\^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m\^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
41135780|NCT02338999|DRUG|Placebo|
41135781|NCT00113308|DRUG|GW406381|
41135782|NCT02326506|DEVICE|VA-ELS pump speed variations|Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
41135783|NCT00364975|BEHAVIORAL|gourmet cooking workshop|
41135784|NCT01354145|DRUG|Chondroitin sulfate|Chondroitin sulphate 1200 mg/day, 24 months treatment period
41135785|NCT01354145|DRUG|Celecoxib|Celecoxib 200 mg/day, 24 months treatment period
41135786|NCT01431118|OTHER|specific dragon boating training intervention|male athletes of the german national dragon boat team performing three specific training units at one day
40957768|NCT00492141|DRUG|L9-NC|"Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3."
40957769|NCT04377620|DRUG|Placebo|Placebo administered BID approximately 12 hours apart
40957770|NCT04377620|DRUG|Ruxolitinib|Ruxolitinb administered BID approximately 12 hours apart
40957771|NCT02178085|OTHER|Flow imaging|Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
41292486|NCT03859999|DIAGNOSTIC_TEST|Analysis of primary radiograph and available demographics|Multivariate analysis of the fracture x-ray features measured by computer, together with the database demographic and outcome data will be used to develop the best model /decision rule to predict likelihood of MUA success
41292487|NCT02768129|DEVICE|transcranial direct current stimulation|active stimulation: 2 milliamp (mA), 20 mins
40957772|NCT00036517|DRUG|PHY906|
40957773|NCT02497339|BEHAVIORAL|Mindfulness training|Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
41292488|NCT02768129|DEVICE|sham transcranial direct current stimulation|sham stimulation
40957774|NCT05096793|DIETARY_SUPPLEMENT|beta alanine|On day 1, all participants completed the 6-MRT corresponding to baseline. Then, on days 2 and 3, each participant performed the 6-MRT with 30 mg·kg-1 and 45 mg·kg-1 of BA (low and high-dose trials, respectively). BA was purchased in powder format from a factory specializing in sports supplements. BA was colorless when diluted in water and had a characteristic taste. This format of BA (powder) allowed personalized dosing for each participant. The research team performed the personalized dosing before the application of the treatment. Between the evaluation days, there was 72 hours difference. The 30 mg·kg-1 or 45 mg·kg-1 BA administration was done with a double-blind method. Thus, on day 2, 50% of the sample performed the 6-MRT supplemented with 30 mg·kg-1 BA, while the other 50% performed the 6-MRT with 45 mg·kg-1 BA. On day 3, those participants who completed the 6-MRT with 30 mg·kg-1 BA now performed with 45 mg·kg-1 BA and vice versa.
40957775|NCT01822795|PROCEDURE|Lung volume reduction coïl treatment|
40957776|NCT01822795|OTHER|Regular medical treatment|
41292489|NCT02504892|DRUG|Everolimus|Everolimus is a commercial agent and is supplied by Novartis.
41292490|NCT02270632|DRUG|F8IL10|F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
41292491|NCT02270632|DRUG|MTX|All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
41292492|NCT02270632|DRUG|Placebo|Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
41292493|NCT02606877|DRUG|nintedanib|
41292494|NCT02606877|DRUG|pirfenidone|
41292495|NCT00051688|DRUG|tezacitabine|
41292496|NCT00051688|DRUG|oxaliplatin|
41455688|NCT00214682|BEHAVIORAL|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
41292497|NCT04272853|OTHER|Interview|Compilation of the interview concerning: demographic data, sports practice, habits on sleep, sexual habits, perception of the relationship between sexual habits and sleep, perception of the relationship between sexual habits and sports practice.
41292498|NCT04797975|BIOLOGICAL|KDS-1000|"Non-randomized part of study:~* At the beginning of each dose level (Cohort), 3 patients will receive KDS-1000. These initial patients will be enrolled in a staggered manner to ensure detection of any early safety signals.~Randomized part of the study (Can start when there are no safety concerns in the non-randomized cohorts):~* Cohort 1: Low Dose, 2x10E8 cells/dose~* Cohort 2: High Dose, 1x10E9 cells/dose"
41292499|NCT04797975|OTHER|Placebo|0.9% Normal Saline
40957777|NCT06403046|DRUG|intraarticular injection|all patients will be subjected to routine (TMJ) arthrocentesis followed by Tenoxicam injection into the superior joint space in the (Tx group) and Meloxicam injection among the patients of (Mx group).
40957778|NCT00000371|DRUG|D-cycloserine|50 mg/daily by mouth
40957779|NCT00000371|DRUG|Placebo|50 mg/day of placebo by mouth
40957780|NCT05950256|DEVICE|N95 mask and surgical mask|Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.
40957781|NCT03954197|OTHER|No hormone|No hormonal injection before oocytes retrieval
40957782|NCT03954197|OTHER|hCG|a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval
40957783|NCT03954197|OTHER|GnRH a|a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval
40957784|NCT00437983|DIETARY_SUPPLEMENT|PS-Omega3|Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
40957785|NCT00437983|DIETARY_SUPPLEMENT|Placebo|Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
40957786|NCT04159571|DEVICE|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; active sham coil (double blinded)
40957787|NCT04159571|DEVICE|Sham cTBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.
40957788|NCT04598230|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.
40957789|NCT04598230|DRUG|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
40957790|NCT00375648|DRUG|Zoledronic acid|
40957791|NCT02462252|DRUG|BL-8040|Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
40957792|NCT02462252|DRUG|horse anti-thymocyte globulin (hATG)|From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
40957793|NCT02462252|DRUG|Methylprednisolone|From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
40957794|NCT02462252|DRUG|Cyclosporine|From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
40957795|NCT02398760|OTHER|Motor Control Exercises|Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
40957796|NCT00926328|DRUG|Triclosan, fluoride|Six Month study, brush twice daily
40957797|NCT00926328|DRUG|Fluoride|twice daily usage
41135787|NCT01431118|OTHER|specific dragon boat intervention|women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
41135788|NCT05113134|PROCEDURE|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder will undergo Transvaginal NOSE
41135789|NCT05197127|DEVICE|exoskeleton-based gait training|Gait training included dynamic over-ground walking (both self-selected and fast-paced), variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
41135790|NCT02791295|OTHER|Diet and physical activity program|A personalized intervention focused on improving diet and increasing physical activity will be implemented at-home with a monthly support by a registered dietician and physical activity educator during 6 months
41135791|NCT05927259|DRUG|n acetyl cysteine|A patients received NAC 140 mg/Kg IV infusion (as a loading dose), then 70 mg/KgIV infusion every 4 hours up to 17 doses
41135792|NCT05927259|DRUG|standard treatment|stabilization and antidotes
41135793|NCT05707598|PROCEDURE|Laparoscopic surgery|The laparoscopic approach was used for the treatment of clinical T4b colorectal cancer
41135794|NCT02302157|BIOLOGICAL|AST-OPC1|One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
41135795|NCT00569439|DRUG|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
40957798|NCT05624593|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
40957799|NCT05624593|DEVICE|Predicate|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
41135796|NCT00569439|DRUG|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
41135797|NCT00569439|DRUG|NS|Normal Saline solution at 125 cc/hr
41135798|NCT01275911|DRUG|Esmolol|Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
40957800|NCT00807378|OTHER|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
41135799|NCT01275911|DRUG|Remifentanil|At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
41135800|NCT02323776|OTHER|Trimodality protocol|neoadjuvant chemoradiotherapy followed by surgery
41135801|NCT04813666|DIAGNOSTIC_TEST|Urinary LAM ELISA:|
40957801|NCT05781620|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks. If the serum 25(OH)D concentration exceeds 48 ng/mL, the intervention remains the same. However, if the serum 25(OH)D concentration is under 48 ng/mL, the dosage would increase by 2,500 IU. The principle remains the same at week 6.
40957802|NCT05781620|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily.
40957803|NCT05279339|OTHER|Exercise|Upper limb exercises using an elastic band.
40957804|NCT03745131|OTHER|Blood draw|Blood draw to obtain serum to determine anti-orthopox antibody titres.
40957805|NCT02609204|DIAGNOSTIC_TEST|Diopsys NOVA|Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
40957806|NCT02518256|PROCEDURE|Lavage of the Cavum uteri and proximal fallopian tubes|
40957807|NCT02114801|DEVICE|manual brushing|Tooth brushing
40957808|NCT02114801|DEVICE|electric toothbrush linked|Tooth brushing
40957809|NCT02114801|DEVICE|off electric toothbrush|Tooth brushing
40957810|NCT00003473|DRUG|Atengenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
40957811|NCT00003473|DRUG|Astugenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
40957812|NCT06447740|DRUG|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
40957813|NCT06447740|DIAGNOSTIC_TEST|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
40957814|NCT06447740|DEVICE|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
40957815|NCT03610282|DRUG|IV Methylphenidate|Subjects will receive a bolus of IV methylphenidate during propofol infusion at one of the study visits.
40957816|NCT03610282|DRUG|Propofol|Subjects will received propofol for up to 100 minutes.
40957817|NCT04179708|OTHER|Pain Neuroscience Education|"Intervention description Patients participate in a back school program including initial and final assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hours of educative initial assessment and ½ hour of educative final assessment.~The content of Pain Neuroscience Education (experimental group) focuses on deconstruction of patho-anatomical and biomechanical believes, and the explanation of pain from the biology. This framework allows the introduction of coping strategies (eg gradual exposure to exercise, activity and physical activity) and regulation strategy (eg fragmentation of activity, stress management, and so on)."
40957818|NCT04179708|OTHER|Conventional education|"assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hour of educative initial assessment and ½ hour of educative final assessment.~The content of conventional education (control grou) focuses on patho-anatomical and biomechanical notions. This framework allows the introduction of protection strategies (eg education on good posture, good handling techniques, physical activity and therapeutic exercise in stretch and strenghten the spine in order to protect it)."
40957819|NCT04080375|DRUG|Dinoprostone 3 mg|the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
40957820|NCT04080375|DRUG|placebo|the patient will take one vaginal tablet of placebo 1 hour before surgery
41135802|NCT01539252|PROCEDURE|Single dialyzer|Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
40957821|NCT01999868|BIOLOGICAL|Ustekinumab|"Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh \<= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh \> 100 kg at study entry will receive 90 mg of ustekinumab."
40957822|NCT01999868|BIOLOGICAL|Abatacept|"Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection"
40957823|NCT01999868|DRUG|UST Placebo|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
40957824|NCT01999868|DRUG|ABA Placebo|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
40957825|NCT04383262|DRUG|Fosamprenavir Calcium|A repurposing approach, prospective, placebo-controlled clinical trial of FOS-SA (used at 1,400 mg fosamprenavir calcium and 24.5 mg sodium alginate, twice daily) for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR (RSI \> 13, RFS \> 7 and MII-pH confirmed laryngeal reflux event\[s\]).
40957826|NCT04383262|OTHER|Placebo|Sodium Alginate: 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate morning and night.
40957827|NCT00372671|BEHAVIORAL|Survey|
40957828|NCT00372671|BEHAVIORAL|Survey and videotape|
40957829|NCT03169543|BEHAVIORAL|Sleep deprivation|36-hours total sleep deprivation
40957830|NCT03258931|DRUG|Crenolanib|Crenolanib will be administered orally
40957831|NCT03258931|DRUG|Midostaurin|Midostaurin will be administered orally
41135803|NCT01539252|PROCEDURE|Two dialyzers|Hemodialysis treatment using a two Baxter dialyzers in parallel.
40957832|NCT03258931|DRUG|Cytarabine|100 mg/m² IV continuous infusion over 24 hours
41455689|NCT00214682|BEHAVIORAL|pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
41455690|NCT04484740|DRUG|Gepotidacin|Single oral dose of 1500 mg gepotidacin
41455691|NCT03173651|DEVICE|Modified Williams airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W
41455692|NCT03173651|DEVICE|Modified Guedle's airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G
40957833|NCT03258931|DRUG|Duanorubicin|90 mg/m2 IV
40957834|NCT06223737|DIAGNOSTIC_TEST|EOS x-ray|After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting
40957835|NCT06223737|DIAGNOSTIC_TEST|Motion capture|"The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand"
40957836|NCT06134622|DRUG|Intravenous thrombolysis plus tirofiban|Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.
40957837|NCT06134622|DRUG|Intravenous thrombolysis plus placebo|placebo (saline)
41135804|NCT04569526|DEVICE|use of intraoperative ultrasound|Ultrasonography guided brain lesions resection intra operatively for good localization
40957838|NCT01622803|PROCEDURE|parallel stent|bilateral parallel stent insertion (right and left side)
40957839|NCT01622803|DEVICE|Y-stent (BONASTENT M-Hilar)|Bilateral Y-stent insertion (stent in stent type)
41135805|NCT01946594|OTHER|Acetaminophen|
41135806|NCT01946594|OTHER|Placebo|
41135807|NCT04784988|DRUG|EHL-FVIII|prophylaxis with EHL-FVIII targeting a 12% FVIII through level based on PK assessment with WAPPS-Hemo
41135808|NCT04784988|DRUG|FVIII concentrate|standard prophylaxis with FVIII concentrate according to current guidelines
41135809|NCT01567150|DEVICE|Novel Dressing|Topical wound dressing
41135810|NCT05371899|DRUG|Chiauranib|Take Chiauranib 50mg orally once daily
41135811|NCT04494399|DRUG|Interferon beta-1b|5-day course of daily subcutaneous injection of interferon β-1b 16 million IU
41135812|NCT04494399|DRUG|Ribavirin|5-day course of oral ribavirin 400mg twice daily
41135813|NCT05848856|BEHAVIORAL|Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up|Study of different types of risk-informed screening approaches and the measurement of patient compliance with screening recommendations based on different approaches to patient engagement
41135814|NCT04251793|OTHER|Observation|Soft tissue implant measurements and radiographs
41135815|NCT01565187|BEHAVIORAL|Questionnaires|Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
41135816|NCT05837806|DRUG|tislelizumab+disitamab-vedotin|patients in group will receive 3 cycles of tislelizumab 200 mg in combination with disitamab-vedotin 120 mg intravenously.
41135817|NCT05205213|OTHER|Surgical Technique (lateral retromuscular preperitoneal)|Open abdominal wall repair through the previous lateral incision for L3-L4 Incisional hernias
41135818|NCT03938272|BIOLOGICAL|Oxabact OC5 - Oxalobacter formigenes Strain HC-1|Live, commensal bacteria
41135819|NCT06368999|DIAGNOSTIC_TEST|EEG|registration of 8 minutes of EEG
41292500|NCT03953560|DIAGNOSTIC_TEST|dyspnea grade ≥ II according NYHA-WHO|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated~Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~1. Pulsioximetry.~2. Electrocardiogram.~3. Blood sample with determination of NT-ProBNP.~4. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~5. V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~6. Right heart catheterization \& Pulmonary CT Scan are required for confirming the diagnosis"
41455693|NCT03173651|DEVICE|LMA MADgic airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
41455694|NCT02740257|OTHER|Photos|Photos will be taken of skin lesion markings using a smart phone or tablet
41455695|NCT02713139|DRUG|Clotrimazole + Metronidazole|Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.
40957840|NCT03668275|PROCEDURE|(partial) oncological home-hospitalization|Patients assigned to oncological home-hospitalization will receive as many as possible parts of their oncological treatment at their homes. These include the required preparatory actions before treatment administration is possible and/or the treatment administration itself in case of subcutaneous cancer drugs.
40957841|NCT04246177|DRUG|Lenvatinib|Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) via oral capsules once a day during each 21-day cycle.
40957842|NCT04246177|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).
40957843|NCT04246177|DRUG|Oral Placebo|Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
40957844|NCT04246177|DRUG|IV Placebo|Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
40957845|NCT04246177|PROCEDURE|TACE|Conducted as a background procedure of chemotherapeutic and embolic agent(s).
40957846|NCT03597880|OTHER|obese patients|underwent bariatric surgery
40957847|NCT05845736|DRUG|Antihypertensive Agents|number of hypertensive drugs
40957848|NCT03841812|DRUG|5mg/kg/h Propofol|5mg/kg/h Propofol continuously infused during intre-operation
40957849|NCT03841812|DRUG|Sevoflurane|1% Sevoflurane continuously using during intre-operation.
40957850|NCT03841812|DRUG|2 mg/kg/h Propofol|2mg/kg/h Propofol continuously infused during intre-operation
40957851|NCT01242462|PROCEDURE|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 \& Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
41135820|NCT01451359|DEVICE|EndoBronchial Valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
41135821|NCT02725372|DRUG|Inhaled Nitric Oxide 75 mcg/kg IBW/hr|Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)
41135822|NCT02725372|DRUG|Placebo|Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
41135823|NCT06475079|OTHER|• FHP app (Pyeongtaek, South Korea) mobile application|FHP app (Pyeongtaek, South Korea) mobile application ,is mobile application to asses cranio vertebral angle
41135824|NCT02082990|BEHAVIORAL|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
41292501|NCT04859803|PROCEDURE|Patients will be received rhomboid intercostal block under ultrasound guidance.|Following endotracheal intubation, patients allotted to the RIB group were positioned in the lateral decubitus position with the chest on the operating side lying superiorly. The ipsilateral arm was abducted from the chest to move the scapula laterally. The RIB was performed as described previously \[8\]. A high-frequency (6-12 MHz) linear ultrasound probe (LOGIQ e ultrasonic system, Deutschland GmbH \& Co. KG, Solingen, Germany) was placed medial to the medial border of the scapula in the oblique sagittal plane. The landmarks, i.e., the trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung, were identified in the ultrasound. Under aseptic conditions, an 80-mm 21-gauge needle was inserted at the level of T6-7 in the ultrasound view. A single dose of 30 ml 0.25% bupivacaine will be injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography.
41292502|NCT04859803|DRUG|conventional intravenous analgesia|Following endotracheal intubation, patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings
41292503|NCT03397420|OTHER|FAM-CARE|Family-centered care, where all HIV-positive family members are seen together as a unit and receive HIV care and treatment services together, for HIV-positive children and their caregivers
41292504|NCT02810002|DEVICE|Experimental infantry boot - DEFINITE-REGULATOR|Training: infantry basic training in the experimental boots
41292505|NCT02810002|DEVICE|Control infantry boot|Training: infantry basic training in the control boots
41292506|NCT02698592|DEVICE|CelsiusTMDS® 8 mm catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.
41292507|NCT02698592|DEVICE|Thermocool® 3.5 mm catheter of irrigated tip|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
40957852|NCT01242462|OTHER|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is \>/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH \>/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
40957853|NCT03385564|DRUG|BI 655064|subcutaneous injection
41292508|NCT02698592|DEVICE|Thermocool® SF catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
41292509|NCT00530699|DRUG|AZD1152|intravenous
41292510|NCT00435539|DRUG|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
41292511|NCT00435539|DRUG|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
40957854|NCT03385564|DRUG|Placebo|subcutaneous injection
40957855|NCT05686889|OTHER|Patient self-report|Simulated patient following structured script
40957856|NCT04821648|DRUG|RJV001|Subcutaneous injection in the abdomen
41292512|NCT00435539|DRUG|Sham Comparator|Intravitreal sham injection
41292513|NCT05808088|OTHER|Hypnotherapeutic sound-files|The participants have access to hypnotherapeutic sound files which they can use as the please.
41292514|NCT03578354|DRUG|4-aminopyridine|an oral drug to be swallowed
40957857|NCT04821648|DRUG|Placebo|The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.
41292515|NCT03578354|DRUG|Atenolol|an oral drug to be swallowed
41292516|NCT03578354|OTHER|Placebo|a masked placebo to be swallowed
41292517|NCT04524975|DRUG|CD-008-0045|CD-008-0045 20 mg capsules
41292518|NCT04524975|DRUG|Placebo|Placebo capsules
40957858|NCT03374969|BEHAVIORAL|Attachment and Biobehavioral Catch-Up|Attachment and Biobehavioral Catch-up (ABC) is a 10-session, weekly intervention delivered in the family's home. ABC addresses three primary issues. First, young children who have experienced early adversity are especially in need of nurturance and parents who behave in synchronous ways and delight in them. Next, when parents behave in frightening ways, it is difficult for children to look to them for reassurance when distressed. This can be particularly difficult for children who have experienced early adversity. Therefore, this intervention helps parents learn how to: 1) behave in nurturing ways when children are distressed; 2) behave in synchronous, delighted ways when children are not distressed; and 3) avoid behaving in frightening or intrusive ways. Interventionists are provided with a manualized protocol, but tailor specific session content to each family's needs. Sessions are videotaped, both for playback to families, and for supervision.
41135825|NCT02082990|BEHAVIORAL|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
41135826|NCT00259792|DRUG|Budesonide/formoterol Turbuhaler|
41135827|NCT06140550|DEVICE|Drug balloon dilated|Through the expansion after the balloon is in place,Release drugs on the surface of the balloon and improve the blood perfusion of nerve vessels to treat stenosis
41135828|NCT06140550|DEVICE|balloon dilated|Through the expansion after the balloon is in place, improve the blood perfusion of nerve vessels to treat stenosis.
41292519|NCT05616949|BEHAVIORAL|Treatment as Usual (TAU) (Arm 1)|Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
41455696|NCT02713139|DRUG|Metronidazole|Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.
40957859|NCT03374969|BEHAVIORAL|Developmental Education for Families|Developmental Education for Families (DEF) is a 10-session, weekly intervention delivered in the family's home. DEF focuses on enhancing gross and fine motor skills, cognition and language development. The age-based protocols (i.e., 6-24 months,) provide information about the developmental themes of focus for each week and suggest activities to enhance the target skills for that week. However, the protocols do not provide a direct script with which to conduct the sessions. Interventionists tailor the developmental program session to the needs of the child and family by considering the child's current gross, fine, cognitive and language skills and creatively preparing several activities that will address the session topics.
41292520|NCT05616949|BEHAVIORAL|Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)|Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services
41292521|NCT04729127|BEHAVIORAL|Project ImPACT|Project ImPACT (Improving Parents As Communication Teachers) is an evidence-based parent-mediated intervention program based on best practices in early intervention. The program is designed for young children up to age six with social communication delays, including autism spectrum disorder. Project ImPACT focuses on social engagement, language, social imitation, and play. Project ImPACT is a naturalistic developmental behavioral intervention (NDBI).
40957860|NCT00428792|DRUG|Methylphenidate 20 mg long-acting capsules|
40957861|NCT01021722|PROCEDURE|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
40957862|NCT04932993|BEHAVIORAL|Writing down goals|Patient will write their health goals down before the visit.
41292522|NCT03418038|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
41292523|NCT03418038|DRUG|Carboplatin|Given IV or PO
41292524|NCT03418038|DRUG|Cisplatin|Given IV or PO
41292525|NCT03418038|DRUG|Cytarabine|Given IV or PO
41292526|NCT03418038|DRUG|Dexamethasone|Given IV or PO
41292527|NCT03418038|DRUG|Etoposide|Given IV or PO
40957863|NCT02654834|OTHER|Exposure to nitrous oxide or other volatile anesthetics|No intervention, but routine work-place exposure to volatile anesthetics
40957864|NCT02423759|DRUG|ciprofloxacin|500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
40957865|NCT02423759|DRUG|ciprofloxacin and gentamycine|standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
40957866|NCT02423759|DRUG|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
40957867|NCT04090866|OTHER|PET/MRI|Positron Emission Tomograph/Magnetic Resonance Imaging - participants will undergo PET/MRI prior to initiation of pulmonary vasodilator therapy and again 4-6 months after initiation of therapy
40957868|NCT04449601|OTHER|clinical assesment|Comparison of Hypertensive group and normotensive group
41292528|NCT03418038|DRUG|Gemcitabine Hydrochloride|Given IV or PO
41292529|NCT03418038|DRUG|Ifosfamide|Given IV or PO
41292530|NCT03418038|OTHER|Laboratory Biomarker Analysis|Correlative studies
41292531|NCT03418038|DRUG|Oxaliplatin|Given IV or PO
40957869|NCT00191139|DRUG|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
40957870|NCT00191139|DRUG|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
40957871|NCT00191139|DRUG|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
40957872|NCT00191139|DRUG|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
41292532|NCT03418038|OTHER|Placebo Administration|Given normal saline IV
41292533|NCT03418038|OTHER|Questionnaire Administration|Ancillary studies
41292534|NCT03418038|BIOLOGICAL|Rituximab|Given IV
40957873|NCT00191139|RADIATION|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
40957874|NCT05334966|OTHER|Maternal Hyperoxygenation|Oxygen is given to mothers at 8L through a non-rebreather mask.
41292535|NCT03418038|DRUG|Decitabine|Given IV
41292536|NCT03418038|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41292537|NCT03418038|PROCEDURE|Core Biopsy|Undergo core needle biopsy
41292538|NCT03418038|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
41292539|NCT03418038|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
41292540|NCT03418038|PROCEDURE|Echocardiography|Undergo ECHO
41292541|NCT03418038|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41292542|NCT03418038|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41292543|NCT03418038|PROCEDURE|Central Venous Cannula Insertion|Undergo PICC placement
41292544|NCT03418038|PROCEDURE|Portacath Placement|Undergo portacath placement
41292545|NCT03418038|PROCEDURE|Computed Tomography|Undergo PET/CT
41292546|NCT03072511|BEHAVIORAL|Spotlight on Smoke-Free Living: Mindsets and Decisions|Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
41292547|NCT03072511|DRUG|Transdermal Nicotine Patch|TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
41292548|NCT04490954|DEVICE|brain biological electrical impedance tomography|Patients diagnosed with brain supratentorial tumors through MRI/CT are evaluated with brain biological electrical impedance tomography. And the brain biological electrical impedance tomography is used to monitor the cerebral edema situation of patients with brain edema
41292549|NCT04490954|DEVICE|MRI/CT|Patients diagnosed with brain supratentorial tumors through MRI/CT
41455697|NCT02713139|DRUG|Clotrimazole|Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
41455698|NCT01102907|OTHER|Liquid Breakfast|The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk
41455699|NCT01102907|OTHER|Solid Breakfast Meal|The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
40957875|NCT05252455|BEHAVIORAL|pelvic and abdominal mechanics exercise|"starting from 24 weeks of pregnancy, participate in the pelvic and abdominal mechanics exercises offered by the Good Pregnancy College of Shanghai Tongren Hospital once a week. Each class lasts one hour until the 38th week of pregnancy (attend at least 10 times)"
40957876|NCT04599140|DRUG|CXCR1/2 Inhibitor SX-682|Given PO
40957877|NCT04599140|BIOLOGICAL|Nivolumab|Given IV
41292550|NCT03340740|DRUG|Cetirizine Hydrochloride 1 MG/ML|Cetirizine oral suspension
41292551|NCT03340740|DRUG|Placebo - Concentrate|Similar-appearing liquid to cetirizine oral suspension
41292552|NCT02430792|BEHAVIORAL|Football|The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.
41292553|NCT06274112|DEVICE|TMS|TMS will be administered in either an active format that induces neuromodulatory effects or a sham comparison format that does not induce neuromodulatory effects.
41455700|NCT02011828|DRUG|Ergocalciferol|50,000 IU/week
41455701|NCT02011828|DRUG|Placebo|Placebo tablet
41135829|NCT04801706|DIAGNOSTIC_TEST|Ultrasound|Association of each ultrasonographic parameter with FIGO clinical grading of placenta accreta and with histopathological diagnosis of placenta accreta in hysterectomy specimens
41135830|NCT02410278|DRUG|dimethyl fumarate|Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally
41135831|NCT02410278|DRUG|montelukast|As described in the treatment arm
41135832|NCT02410278|DRUG|Placebo|Matched placebo
41135833|NCT05750719|GENETIC|BRCA1/2 genetic testing|All patients will undergo genetic testing for BRCA 1 and BRCA 2 germline mutations, employing next generation sequencing (NGS) techniques.
40957878|NCT05457426|PROCEDURE|robotic right hemicolectomy with CME|The distribution of trocars was placed according to the position of Intuitive Surgical Inc. for robotic colectomy. The robot was set to come and dock from theright shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R3), and Cadiere's fenestrated forceps in the right lower quadrant port (R2) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transversemesocolon with the grasp in R2, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R3.
40957879|NCT00012311|BIOLOGICAL|filgrastim|
40957880|NCT00012311|DRUG|CMF regimen|
40957881|NCT00012311|DRUG|carboplatin|
40957882|NCT00012311|DRUG|cyclophosphamide|
40957883|NCT00012311|DRUG|docetaxel|
40957884|NCT00012311|DRUG|doxorubicin hydrochloride|
40957885|NCT00012311|DRUG|etoposide|
40957886|NCT00012311|DRUG|fluorouracil|
40957887|NCT00012311|DRUG|ifosfamide|
40957888|NCT00012311|DRUG|methotrexate|
40957889|NCT00012311|DRUG|thiotepa|
40957890|NCT00012311|PROCEDURE|peripheral blood stem cell transplantation|
40957891|NCT01334346|OTHER|Nike Pegasus|Conventional neutral supportive running footwear. Non minimalist.
40957892|NCT01334346|OTHER|Nike Free 3.0|Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.
40957893|NCT01334346|OTHER|Vibram Five Fingers Shoe|Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
40957894|NCT05512767|OTHER|Best Practice|Undergo self-manual lymphatic drainage
41292554|NCT03726216|DRUG|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
41292555|NCT05707845|DRUG|Medical treatment.|Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).
41292556|NCT05707845|BEHAVIORAL|weight reduction|weight reduction in the form low caloric diet program for 12 weeks.
41292557|NCT05707845|OTHER|exercise|aerobic exercise in the form of walking on treadmill for 30 minutes 3 times a week for 12 weeks.
41292558|NCT02526615|DRUG|Rosiglitazone|Patients received either placebo, metformin or rosiglitazone
41292559|NCT02526615|DRUG|Metformin|Patients received either placebo, metformin or rosiglitazone
41292560|NCT02526615|DRUG|Placebo|Patients received either placebo, metformin or rosiglitazone
41292561|NCT04165265|DEVICE|Constant-Care|"Constant-Care (CC) (https://ibd.constant-care.com) is a web-application and contains an education and a disease monitoring package. An algorithm is established in the disease monitoring package, which consist of two variables; fecal calprotectin (FC) and a disease activity questionnaire (validated), Simple Clinical Colitis Activity index (SCCAI) for UC. The FC is obtained through CalproSmart app (it only takes 18 min) and the questionnaire is filled out in CC. Afterwards, the data are analyzed by CC and presented in a Total Inflammatory Burden Score (TIBS) as well as a visual traffic light of disease for the patients"
40957895|NCT05512767|OTHER|Consensus Auditory-Perceptual Evaluation of Voice|Ancillary studies
40957896|NCT05512767|PROCEDURE|Diagnostic Imaging|Undergo photographs of face and neck
40957897|NCT05512767|OTHER|Lymphedema Management|Undergo skilled lymphedema treatment by a therapist
40957898|NCT05512767|PROCEDURE|Modified Barium Swallow|Undergo swallow study
40957899|NCT05512767|PROCEDURE|Nasopharyngeal Laryngoscopy|Undergo Nasolaryngoscopy
40957900|NCT05512767|DEVICE|Pneumatic Compression Therapy|Undergo compression therapy - Flexitouch Plus System is an advanced pneumatic compression device (APCD) that consists of a 2-piece garment that provides systematic and sequential pressure changes to move fluid to intact lymphatic chains.
40957901|NCT05512767|OTHER|Quality-of-Life Assessment|Ancillary studies
40957902|NCT05512767|OTHER|Questionnaire Administration|Ancillary studies
40957903|NCT05512767|OTHER|Voice Handicap Index-10|Ancillary studies
40957904|NCT05610683|DEVICE|Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer|Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months
40957905|NCT04301037|PROCEDURE|Tension band wires|medial malleolus fracture fixed with tension band wiring): 2 k.wires (1.6 mm) are inserted perpendicular to the fracture site. Again the position is checked under image intensification for the correct direction and length. We drilled a 2.5mm hole with a protection sleeve, 2-3cm above the level of the horizontal joint line, aiming the drill bit slightly inferiorly to avoid screw pullout. We inserted a 3.5mm unicortical screw about 30 mm in length (with or without washer), 2-3mm is left for the wire between the bone and screw head before full tightening. A steel wire is constructed into a figure of eight between the screw the reduction k. wires, then twisted to achieve interfragmentary compression
40957906|NCT04301037|PROCEDURE|Cannulated screws|In group 2 (15 patients with medial malleolus fixed by 2 cannulated screws): Two guide wires (1.6mm) are inserted perpendicular to the fracture site, the appropriate length, proper insertion site including the distance from the articular surface is checked fluoroscopically .the length is measured .drilling of the bone through the threaded guide wire with a cannulated drill bit (3.2mm). A two 4.5mm partially threaded cannulated screws (with or two washers) are inserted through the guide to achieve Compression, the guide wires are then removed
41292562|NCT05649124|BEHAVIORAL|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4, SP6 and ST36 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
41292563|NCT01447173|DRUG|Vitamin D|Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
40957907|NCT04158492|DIAGNOSTIC_TEST|real-time multiplex PCR|Patients will be randomly assigned to receive experimental diagnosis (comprehensive molecular testing added to routine microbiological testing) AND standard diagnosis microbiological procedures
40957908|NCT04158492|DIAGNOSTIC_TEST|Standard diagnostic procedures|Patients who will undergo only the standard microbiological diagnostic procedures: blood cultures, Gram stain and culture sputum when possible, Gram and pleural fluid culture when appropriate, urine determination of the pneumococcal and Legionella pneumophila serogroup antigens type 1. A serological study will be carried out for the etiological agents of atypical pneumonia in the acute and convalescent phases of the infection.
40957909|NCT04152655|DRUG|Idebenone|30mg tablets three times a day
40763330|NCT05878795|BEHAVIORAL|WET-SP|WET-SP will consist of 5 treatment sessions; the first session lasting about one hour and each subsequent session lasting approximately 45 minutes. Each session will include a 30-minute written exposure exercise. The participant will be given general instructions for completing the narrative writings and specific instructions for completing the first session. Participants will be instructed to write about the same suicidal crisis during each session. The therapist will emphasize the importance of delving into their deepest emotions surrounding the suicidal crisis as well as the importance of writing detailed information about the crisis. Following writing, the therapist and the participant will process the writing experience. Subsequent sessions involve the therapist iteratively providing feedback to the patient regarding their writing from the previous session.
40763331|NCT05878795|BEHAVIORAL|TAU|TAU includes initial psychiatric stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily throughout the duration of hospitalization and have structured times for psychoeducation groups, case management, medication management, hygiene, and meals.
40763332|NCT01503177|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given intrapleurally
40763333|NCT01503177|OTHER|laboratory biomarker analysis|Correlative studies
40763334|NCT01503177|PROCEDURE|single photon emission computed tomography|Correlative studies
40763335|NCT01503177|PROCEDURE|computed tomography|Correlative studies
40763336|NCT05910424|OTHER|collection of saliva, gum fluid and/or dental plaque samples|Non-invasive sampling of dental plaque, crevicular fluid and/or saliva, using an examination probe, paper tips and saliva swabs
40763337|NCT01933763|DRUG|REGN1193|
40763338|NCT01933763|OTHER|Placebo|
40957910|NCT04152655|DRUG|Placebo oral tablet|placebo tablets three times a day
40957911|NCT01139931|GENETIC|DNA methylation analysis|
40957912|NCT01139931|GENETIC|gene expression analysis|
40957913|NCT01139931|GENETIC|microarray analysis|
40957914|NCT01139931|GENETIC|polymorphism analysis|
40957915|NCT01139931|OTHER|laboratory biomarker analysis|
40957916|NCT03325127|DRUG|radium Ra 223 dichloride (Xofigo, BAY88-8223)|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injections
40957917|NCT03325127|DRUG|Zytiga|Abiraterone 1000 mg per day orally
40957918|NCT03325127|DRUG|Xtandi|Enzalutamide 160 mg per day orally
40957919|NCT03616275|OTHER|HRV biofeedback|HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
40957920|NCT01507012|DIETARY_SUPPLEMENT|Berry Polyphenols|
41292564|NCT00649519|DRUG|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
41455702|NCT00860145|PROCEDURE|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
40763339|NCT06571162|OTHER|Clinical Pharmacy Team|Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.
40957921|NCT01507012|DIETARY_SUPPLEMENT|Placebo|Placebo control containing sugar and artificial flavouring.
40957922|NCT05218135|OTHER|Intervention|Learning session 1: explain key interventions, explain BIC methodology, retrospective patient record analysis Learning session 2: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 3: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 4: feedback report
40957923|NCT01643356|BEHAVIORAL|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
40957924|NCT03375606|BIOLOGICAL|CSL730|Solution for IV infusion
40957925|NCT03375606|OTHER|Placebo|Saline solution for IV infusion
40957926|NCT02834039|PROCEDURE|Tidal volume 6 ml/kgBW|Tidal volume 6ml/kgBW was given to subjects after endotracheal tube was inserted properly.
40957927|NCT02834039|PROCEDURE|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to subjects after endotracheal tube was inserted properly.
40957928|NCT03840798|OTHER|Child Abuse Clinical Decision Support system|"The investigators are implementing the following aspects of the Electronic Health Record (EHR) based child abuse- clinical decision support (CA-CDS) system.~1. a universal child abuse screen (CAS)~2. an embedded child abuse alert system~3. alerts to physicians and advanced practice providers~4. physical abuse order sets"
41292565|NCT00649519|DRUG|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
41292566|NCT01236222|BEHAVIORAL|Cycling to school|Regular cycling to school
41292567|NCT02226614|DEVICE|University of Edinburgh head cooling device|head cooling
41292568|NCT04385901|BEHAVIORAL|Therapy Intervention|Patients receive 2-4 visits (based on patient presentation and need) of physical therapy, up to 4 visits of occupational therapy, up to 4 visits of speech therapy based on need. Treatment focuses on physical strengthening, pulmonary strengthening/breathing exercises, and cognitive rehabilitation.
41292569|NCT03912467|OTHER|Pressure Ulcer Evaluation|Patient was evaluated according to presence of pressur ulcer or not
41292570|NCT01184989|DRUG|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
41292571|NCT02688075|OTHER|No Intervention|Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
41292572|NCT03870022|DEVICE|Pivot Breath Sensor System|Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
40763340|NCT06571162|OTHER|Usual Care|Patient will receive usual care for their LDL-C management.
40763341|NCT05222789|PROCEDURE|TAP|The transverse abdominal plane (TAP) block is a regional anesthesia technique performed using ultrasound that blocks the afferent nerves of the anterolateral abdominal wall, injecting local anesthetic in the fascial plane between the deep oblique and the transversus abdominis muscles.
40763342|NCT02457793|DRUG|Cobimetinib|Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
40957929|NCT06557590|DIAGNOSTIC_TEST|18F-FAPI-04|18F-FAPI-04 was injected into the patients before the PET/CT or PET/MR scans
40957930|NCT03602820|BIOLOGICAL|AAV2-hRPE65v2|
40957931|NCT02793544|DRUG|Fludarabine|"* Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).~* The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).~* creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted."
41292573|NCT03870022|DEVICE|Similar Carbon Monoxide breath sensor system|Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
40957932|NCT02793544|DRUG|Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|"* Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
40957933|NCT02793544|RADIATION|Total Body Irradiation (TBI) 200cGy on Day -1|"* 200 cGy TBI is administered in a single fraction on Day -1.~* Radiation sources, dose rates, and shielding follow institutional practice."
40957934|NCT02793544|PROCEDURE|Infusion of non-T-cell depleted bone marrow on Day 0|"* On Day 0, the harvested bone marrow is infused.~* Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.~* The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight."
40957935|NCT02793544|DRUG|Busulfan|"* Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM\*min (Perkins et al., 2012))~* Busulfan dosing is based on adjusted IBW (Appendix K)"
40957936|NCT02793544|DRUG|Cyclophosphamide 50mg/kg/day IV on Days -2,-1|"* Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
40957937|NCT02793544|DRUG|Cyclophosphamide 50mg/kg/day IV on Days -5,-4|"* Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
40957938|NCT02793544|RADIATION|Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|"* 200cGy TBI is administered in twice daily on Days -3, -2, and -1.~* Radiation sources, dose rates, and shielding follow institutional practice."
40957939|NCT02793544|DRUG|Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|"* Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~* Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~* Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight."
41292574|NCT06298292|DIETARY_SUPPLEMENT|Zero minis (range of protein substitutes in tablet form)|Intervention: range of protein substitute tablets. Subjects who currently take a protein substitute for the dietary management of either tyrosinaemias or alkaptonuria, homocystinuria, or MSUD will be recruited. Subjects will take the study product for 7 days. Daily questionnaires will be completed (ease of preparation,administration; any problems or gastrointestinal effects). Subjects will replace some or their entire usual protein substitute with the new product suitable for their diagnosed rare metabolic disease. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Additional questions at the beginning and end of the study will record information on organoleptic properties, presentation and packaging of the product. Routine weekly blood samples will be collected and analysed for amino acids typically for the metabolic control of the individual specified metabolic disorders as is usual clinical practice.
41292575|NCT02183298|DRUG|BI 1356 BS - intravenous|
41292576|NCT02183298|DRUG|BI 1356 BS - Tablet|
41292577|NCT02183298|DRUG|Placebo|
41292578|NCT03940144|DEVICE|the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device|Stroke volume variation (SVV)-guided fluid therapy
41292579|NCT00056212|BEHAVIORAL|Yoga|
41292580|NCT00056212|BEHAVIORAL|Exercise|
41292581|NCT01673880|DRUG|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
41292582|NCT05476549|DIETARY_SUPPLEMENT|Lemon verbena|Lemon verbena supplement administered at an estimated daily dose of 15mg/kg
41292583|NCT05476549|DIETARY_SUPPLEMENT|Placebo|Placebo supplement containing carrier material only
41292584|NCT03614715|DRUG|Interferon Beta-1A|A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
41292585|NCT02213198|BEHAVIORAL|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
41292586|NCT02213198|BEHAVIORAL|Standard Care|Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
41292587|NCT00155285|PROCEDURE|computed tomography|
41292588|NCT03418662|DEVICE|EndoRings device|Subjects randomized to undergo a colonoscopy procedure with the EndoRings device will have the device placed on the colonoscope that will be used during their procedure.
40763343|NCT02457793|DRUG|GDC-0994|GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
40763344|NCT06018519|OTHER|Clinical endpoints|"1. Number of epileptic seizures~2. Change in antiepileptic treatment (increase or decrease)~3. Visual analogical scale on a target symptom defined with the parents,~4. CGI,~5. Actimetry data over 24 hours,~6. Podometry data over 24 hours,~7. 6 minutes' walk test,~8. Clinical examination~9. Feasibility of performing an MRI without any anesthesia on a mock scanner"
40957940|NCT02793544|DRUG|Sirolimus|"* Sirolimus dosing is based on adjusted IBW (Appendix K).~* Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.~For subjects ≥ 18 years old:~* A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.~For subjects \< 18 years old:~* A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay."
40763345|NCT06018519|OTHER|Parental questionnaires|"10- Adaptive assessment with Vineland Adaptive Behavior scale II,~11- Mac Arthur questionnaire regarding language,~12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),~13- Dunn sensory profile,~14- Aberrant Behavior Checklist,~15- Nisonger Child Behavior Rating form,~16- Social Responsiveness Scale 2,~17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)"
40957941|NCT02793544|DRUG|Mycophenolate mofetil|"MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD."
40957942|NCT02793544|DRUG|G-CSF|"Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted."
40957943|NCT02793544|DRUG|Pre-HCT Mesna on Days -6 and -5|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
41292589|NCT05497505|DEVICE|Pacmed Critical|For patients in the On-period, Pacmed Critical will be available as decision support after initial eligibility screening for ICU discharge by treatment team
40957944|NCT02793544|DRUG|Pre-HCT Mesna on Days -2 and -1|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
40957945|NCT02793544|DRUG|Pre-HCT Mesna on Days -5 and -4|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
40957946|NCT02793544|DRUG|Post-HCT Mesna|"Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight."
41292590|NCT04292847|OTHER|Referrals Recommendations|All participants will complete the geriatric assessment and receive Referral recommendations based on the assessment.
41292591|NCT03279510|DEVICE|hearing aids|Subjects are fit with hearing aids.
41292592|NCT01784549|DRUG|Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine|
41292593|NCT03704051|BEHAVIORAL|Mode of Feeding (breastfeeding versus bottle-feeding)|Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.
41455703|NCT00860145|PROCEDURE|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
41455704|NCT05936047|BIOLOGICAL|Vertebral bone marrow clot|vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot will be applied on each side of the vertebra according to the number of segments to be fused.
41455705|NCT02939261|BEHAVIORAL|Intervention - 4 Home Visits|4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
41455706|NCT02939261|BEHAVIORAL|Control|monthly emails with general health information
41455707|NCT02705716|OTHER|0.454% w/w stannous fluoride (1100ppm fluoride)|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
40957947|NCT03089320|BEHAVIORAL|Contingency Management Counseling|Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.
40957948|NCT03089320|BEHAVIORAL|Addiction Physician Management|Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.
40957949|NCT03089320|BEHAVIORAL|Motivational Enhancement Therapy|"Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.~MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol."
40957950|NCT05705518|DRUG|Systane Complete PF|3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product
40957951|NCT05705518|DRUG|Refresh Relieva PF|3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product
40957952|NCT05705518|DRUG|Refresh Optive Mega-3 PF|3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product
40957953|NCT05705518|DRUG|CVS Health Lubricant Eye Drop (PG 0.6%)|3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product
40957954|NCT03842514|DIETARY_SUPPLEMENT|Soya lecithin|The lecithin supplement will be soya lecithin granules given as 7.5 g twice daily, incorporated into juices
40957955|NCT06469593|DEVICE|Automated insuling delivery system|Closed-loop insulin pumps including MiniMed 780G, Tandom T2-slim x2 and YpsoCamAPS
40957956|NCT01597401|DRUG|Aes-103|300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
40957957|NCT01597401|DRUG|Aes-103|1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
41455708|NCT02705716|OTHER|0.76% sodium monofluorophosphate (1000ppm fluoride)|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
41455709|NCT01379313|PROCEDURE|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
41455710|NCT01379313|PROCEDURE|1:1 ratio|I:E ratio of 1:1 is applied.
40763346|NCT06018519|OTHER|Quality of life scale|18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
40763347|NCT06018519|OTHER|Cognitive assessments|"19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible~20- CPM-BF~21- Simple reasoning task on tablet (match-to-sample task)~22- Implicit rules learning (modified Brixton),~23- 4 sub-tests from the WPPSI-IV (zoo location to assess spatial memory, block design to assess visuo-constructive abilities, bug search , cancellation),~24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),~25- Elementary visuo-spatial perception (on tablets)"
40763348|NCT06018519|OTHER|Language assessments|"26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),~27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),~28- Automatic language analysis (during a 10 minutes interaction, play)."
40957958|NCT01597401|DRUG|Aes-103|2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
40957959|NCT01597401|DRUG|Aes-103|4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
40957960|NCT01597401|DRUG|Placebo|Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
40957961|NCT01539538|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
40957962|NCT01539538|DRUG|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
40957963|NCT00134459|DRUG|Bifeprunox|
40957964|NCT00134459|DRUG|Placebo|
40957965|NCT05281679|OTHER|Low-intensity resistance exercise with blood flow restriction group (L-BFR)|The blood flow restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 40% of 1-RM. The SB protocol consists of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min recovery interval between sets and 3-min between exercises. Blood flow to the active muscle during training will be restricted by a blood flow restriction band (tourniquet) placed at the proximal end of the lower limbs. When the subjects performed training with BFR, the proximal portions of their lower limbs will be compressed at the pressure of 120-160 mmHg by electronically controlled air pressure belts. The air pressure belt will be inflated before the exercise and will remain inflated during one-minute intervals between the sets and will be deflated during the three-minute interval between the exercise.
40957966|NCT05281679|OTHER|High-intensity resistance exercise without blood flow restriction group (H-BFR).|The high-intensity restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 80% of 1-RM. The SB protocol consist of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min rest interval between sets and 3-min between exercises.
40957967|NCT02874157|BIOLOGICAL|blood draw|
40957968|NCT01460004|DEVICE|patella knee strap|infra patella strap 100% cotton pressure is exerted immediately under the patella
40957969|NCT02805010|DRUG|Abatacept|On Day 1, subjects will receive a single SC dose of abatacept 125mg
40957970|NCT02805010|OTHER|Placebo|On Day 1, subjects will receive a single SC dose of placebo
41292594|NCT00592501|RADIATION|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
41455711|NCT01379313|PROCEDURE|2:1 group|Inverse I:E ratio of 2:1 is applied.
41455712|NCT01379313|PROCEDURE|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
41455713|NCT01450800|DRUG|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
40957971|NCT04512417|DRUG|Camrelizumab+Radiotherapy|The combined treatment group received radiotherapy for recurring or metastatic lesions: at least one or more lesions were irradiated, stereotactic body radiotherapy (SBRT, 8Gy/time, 3-5 times) or conventional radiotherapy (parts not suitable for SBRT, total Dose 30Gy or more); start immunotherapy within 8 weeks after radiotherapy.Until PD or toxicity is intolerable or up to 24 months.
40957972|NCT04512417|DRUG|Camrelizumab|Camrelizumab,200mg,Q3W,Until PD or toxicity is intolerable or up to 24 months.
40957973|NCT01259596|BEHAVIORAL|cognitive behavioral therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
40957974|NCT01259596|BEHAVIORAL|nondirective supportive therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
40957975|NCT01762878|DRUG|GSK2269557|Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
40957976|NCT01762878|DRUG|Placebo|Dry powder for oral inhalation once daily using DIKUS device
40957977|NCT02094183|OTHER|GLP-1|GLP-1
40957978|NCT02094183|DIETARY_SUPPLEMENT|low calorie diet|low calorie diet
40957979|NCT05032664|OTHER|Home-based aromatherapy programme|1 hour individualised face-to-face training to family caregivers, and 3 weeks aromatherapy intervention delivered by family caregivers (aromatherapy inhalation 2 times per day, each for 1 hour, using 2 drops of Lavandula angustifolia essential oil.
40957980|NCT05032664|OTHER|Control Group|Wait-list control, no intervention for 3 weeks, then provide home-based aromatherapy
40957981|NCT05499715|BIOLOGICAL|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
40957982|NCT00236444|DRUG|risperidone|
40957983|NCT00837057|PROCEDURE|crrt|early CRRT (35 ml/kg/h)\& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
40957984|NCT00371826|DRUG|Everolimus (RAD001)|
40957985|NCT00371826|DRUG|Cyclosporine (Calcineurin Inhibitor (CNI))|
40957986|NCT00371826|DRUG|Methylprednisone/prednisone|
40957987|NCT00371826|DRUG|Mycophenolate sodium (MPA)|
40763349|NCT06018519|OTHER|Motor assessments|"29- Kinematic task (specifically designed),~30- Purdue-Pegboard test,~31- Renzi test"
40957988|NCT02187497|DRUG|Low dose of BIBR 277|
40763350|NCT06018519|OTHER|Social assessments|"32- Eye-tracking analysis of social visual scenes and social preference index (movies),~33- theory of mind assessment,~34- ADOS scale (Autism Spectrum Disorder),~35- sensitivity to inequality,~36- pro-social behaviors (help of the psychologist)"
40763351|NCT06018519|OTHER|3T MRI|37- Structural, metabolic and functional data
40957989|NCT02187497|DRUG|Medium dose of BIBR 277|
40957990|NCT02187497|DRUG|High dose of BIBR 277|
40957991|NCT00003433|BIOLOGICAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
40957992|NCT05745493|BEHAVIORAL|Social Engage Coaching (S-ENG)|Social Engage Coaching (S-ENG) involves 10 individual coaching sessions focused on increasing social connection. S-ENG is a stepped, modular intervention that was developed to allow personalization to a given subject's needs, preferences, and individualized barriers to social connection. Early sessions include psychoeducation on the importance of social connection; a values clarification exercise on aspects of connection most important to subjects; and assessment of current social networks and social activities. Together, the coach and subject create a conceptualization of reasons for loneliness and identify personalized activities most likely to impact loneliness. The primary activity is 'action planning,' which involves selecting a social goal for the week, brainstorming ways to meet the goal, identifying barriers, and selecting specific actions to take before the next session. The first 8 sessions are offered weekly and the final two are monthly booster sessions.
40957993|NCT00709761|DRUG|Lapatinib/nab-Paclitaxel|This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
40957994|NCT03433157|DEVICE|Hall technique|Metal Stainless stain crown placed with Hall technique
40957995|NCT03433157|DEVICE|Traditional technique|Metal Stainless stain crown placed with Traditional technique
40957996|NCT04833543|OTHER|Robotic Mobility Device (REX)|A self supporting robotic mobility device (REX) will be utilized. It is a Class I device, and it is classified as powered exercise equipment meant for anyone that requires use of a wheelchair for mobility who has difficulty with standing and walking. The participant will be supported securely within the device using a pelvic harness, and thigh and calf cuffs. The device will be operated under the supervision of a device trained physical therapist and therapy technician. The participant will be transferred into the device in a seated position. Once aligned properly and strapped in, the participant will be passively moved by the device into standing and walking positions. To provide constant vestibular input, a variety of mobility functions will be performed including standing, sitting, walking, turning, shuffling (side-stepping), and backwards stepping.
41292595|NCT00592501|DRUG|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
41292596|NCT00592501|DRUG|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
41455714|NCT01450800|DRUG|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
41455715|NCT02682134|DRUG|xylocaine|First group were given xylocaine
41455716|NCT02682134|DRUG|Dexamethasone|Second group were given Dexamethasone
41455717|NCT02682134|DRUG|Xylocaine and Dexamethasone|Third group were given both Xylocaine and Dexamethasone
40763352|NCT06018519|OTHER|Cardiac assessments|"38- ECG~39- Ultrasound"
40763353|NCT06018519|OTHER|Biological collection|"40- Blood sample~41- Urinary sample~42- Superficial skin biopsy"
40763354|NCT06639074|PROCEDURE|Biopsy|Undergo biopsy
40763355|NCT06639074|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40763356|NCT06639074|PROCEDURE|Computed Tomography|Undergo CT
40957997|NCT04833543|OTHER|Tilt Table|A tilt table is a table with a footplate that can be tilted at different angles. The participant will lie flat on the table and straps will be placed to stabilize the trunk and lower extremities. The inclination of the tilt table will be adjusted from a horizontal to a vertical position to allow the participant to attain and maintain a standing or partial-standing position. Sessions will be supervised by a physical therapist and therapy technician.
41292597|NCT00590681|DRUG|Bevacizumab and Temozolomide|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
41292598|NCT04049188|RADIATION|Single-Fraction Palliative Radiation Therapy|All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.
41292599|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy with the assistance of EndoAngel's polyp detection function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's polyp detection function,which can remind endoscopists of the location of the polyp.
40763357|NCT06639074|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
41292600|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy with the assistance of EndoAngel's quality monitoring function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's quality monitoring function,which can monitor the withdrawal speed of the endoscope.
41292601|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy without the assistance of EndoAngel's any function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's both functions.
40763358|NCT06639074|PROCEDURE|Leukapheresis|Undergo leukapheresis
41292602|NCT03344159|DRUG|Spironolactone|Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
41455718|NCT01401062|DRUG|Fresolimumab|
40763359|NCT06639074|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40763360|NCT06639074|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
40763361|NCT06639074|DRUG|Placebo Administration|Given ID
40763362|NCT06639074|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|Given IM
40957998|NCT00968214|GENETIC|polymorphism analysis|
40957999|NCT00968214|OTHER|laboratory biomarker analysis|
40958000|NCT00552565|DRUG|Rezular 15mg|Oral Tablets
40958001|NCT00552565|DRUG|Placebo|placebo
40958002|NCT00552565|DRUG|Rezular|Rezular 37.5mg 3xday up to 12 weeks
40958003|NCT00552565|DRUG|Rezular|Rezular 75mg 3xday up to 12 weeks
41292603|NCT03344159|DRUG|Placebo|Placebo daily for a total of duration of 12 weeks
40763364|NCT06642896|DEVICE|pupillometer|describe the feasibility of pupillometry measurements in sedated but non-cerebrosed children
40763365|NCT06642896|DEVICE|pupillometer|Pupillometry measurements at 5 and 25 minutes for children treated with osmotherapy, followed by measurements twice a day during hospitalization in the intensive care unit
40763366|NCT03537794|DIAGNOSTIC_TEST|PET scans|PET scans and PHNO scans
40958004|NCT05360602|DIETARY_SUPPLEMENT|Alpha Lipoic Acid plus the standard care for post-PCI MI|Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
40958005|NCT05360602|DRUG|The standard care for post-PCI MI|will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
41292604|NCT03344159|RADIATION|PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82|At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
41292605|NCT03344159|DIAGNOSTIC_TEST|Cardiac MRI (Gadolinium enhanced)|At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
41292606|NCT04615390|BEHAVIORAL|Early rehabilitation|The intervention is primarily focused on the recovery of mobility and functional autonomy. The treatment sessions are dependent on the patient's exercise tolerance.
41292607|NCT04615390|BEHAVIORAL|Subacute rehabilitation|Comprehensive intensive rehabilitation in the hospital
41292608|NCT04615390|BEHAVIORAL|Mindfulness training|The home mindfulness training consists of 2 parts: 1) explanation and reflection of the Mindfulness practice 2) formal and informal practice.
41292609|NCT04615390|BEHAVIORAL|Personalized ambulatory training|Low-intensity walking exercises at home
41292610|NCT05310383|COMBINATION_PRODUCT|Tislelizumab plus radiotherapy|During the period of radiotherapy, patients receiveTislelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Tislelizumab 200mg q3W was administered for up to 35 cycles (up to approximately 2 years) after radiotherapy until disease progression or toxicity.
40958006|NCT04903275|PROCEDURE|Topical fluoride application and Laser irradiation|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth followed by laser irradiation with CO2-laser (Ultra Dream Pulse, DS_40U, Daeshin Enterprise, Seoul, South Korea), emission wavelength 10,600 nm, time on-100 μs, time off-40 ms; average power-0.73 W; peak power-292.73 W; speed of movement-2 mm/s; energy density with movements-5 J/cm2; tip-to-tissue distance-20 mm; tip diameter 700 μm; irradiation time-30 s.
40958007|NCT04903275|PROCEDURE|Topical fluoride application|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth
40958008|NCT01720056|DRUG|Verapamil|
40958009|NCT01720056|DRUG|Kenalog 10|
41455719|NCT01401062|RADIATION|Radiation Therapy|
41455720|NCT03977441|DRUG|Agomelatine or PIacebo|control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
41292611|NCT04995744|PROCEDURE|Pectoralis Major Pedicle Bone Graft|It is aimed to restore the integrity of the medial cortex with the bone pedicle from the insertion region of the pectoralis major muscle in middle-aged patients with Neer type 4 proximal humerus fractures. Researchers aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method. The investigators aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method.
40958010|NCT03277664|BEHAVIORAL|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
40958011|NCT05867303|DRUG|RC198 Injection|RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
40958012|NCT02623023|DRUG|Combigan|brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
40958013|NCT02623023|OTHER|Refresh tears|This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
40958014|NCT00241085|DRUG|valsartan|
40958015|NCT04470323|DIAGNOSTIC_TEST|Flow cytometry|Lymphocyte subsets in peripheral blood were assessed by staining 50 µl of blood sample with 5 µl of Fluoroisothiocyanate (FITC)-conjugated- PD-1, phycoerythrin (PE)-conjugated-CD8, peridinium-chlorophyll-protein (Per-CP)-conjugated-CD4, Peridinium-chlorophyll-protein (Per-CP)-conjugated anti-CD3 and allophycocyanin (APC) conjugated anti-CD28.
40958016|NCT03221283|BEHAVIORAL|Music therapy group|The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.
40958017|NCT05269043|DEVICE|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smart inhaler, spirometer, blood pressure monitor, pulse oximetry device, particulate matter sensor.
40958018|NCT05399654|DRUG|TAC-001|TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC)
40958019|NCT00040573|DRUG|131I-TM-601|
40958020|NCT00055250|DRUG|Gemcitabine|
40958021|NCT00055250|DRUG|LY293111|
40958022|NCT00055250|DRUG|placebo|
40958023|NCT04452682|OTHER|COVID 19 impact|The impact of COVID-19 pandemic on Critical limb threatening ischemia and emergency vascular practice
41292612|NCT01841008|DRUG|Protopic|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
41292613|NCT01841008|DRUG|Placebo : Diprobase|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
41292614|NCT06302322|PROCEDURE|Thin Tissues|Patients with thin tissues received implants 10 years ago and are now followed up after 10 years.
41292615|NCT06302322|PROCEDURE|Thick Tissues|Patients with thick tissues received implants 10 years ago and are now followed up after 10 years.
41292616|NCT06302322|PROCEDURE|Surgically augmented thin tissues|Patients with thin tissues received soft tissue augmentation and implants 10 years ago and are now followed up after 10 years.
41292617|NCT04727112|DRUG|Usual care versus primary care|RCT study
41292618|NCT06067646|BEHAVIORAL|Semistructured interview|Semistructured interview and validated quality of life assesment using EQ5-DL
40958024|NCT05641519|BEHAVIORAL|SERVE OC Intervention|"SERVE OC intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment and discussing prevention/risk reduction 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations such as local churches, parks, community centers, or grocery stores (for field trips) They will also receive messages from them throughout the duration of the study using their preferred method of contact (text, email, webportal/app, phone call) for reinforcement and scheduling meetings"
40958025|NCT05641519|BEHAVIORAL|Enhanced Standard Intervention|Enhanced Standard Intervention will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care
40958026|NCT05205811|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
40958027|NCT05205811|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 7 weeks.
40958028|NCT05205811|DRUG|Placebo bupropion|Placebo bupropion for 7 weeks.
40958029|NCT05205811|DRUG|Placebo zonisamide|Placebo zonisamide for 7 weeks.
40958030|NCT05205811|OTHER|E-cigarette|e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
40958031|NCT05344911|DRUG|Propofol combined with alfentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, alfentanil 20 μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with alfentanil(0.5-2ug/kg/min)
41292619|NCT05652010|DEVICE|Iris - new coupling|"* SenSura Mio Click maxi bag (open, wide outlet), 50mm Ø with new coupling and lock ring~* Baseplate flat: SenSura Mio, click base plate with belt ears, 50 mm, 10-45 mm with improved weld-ing bead~* Baseplate Concave: Item 18510 SenSura Mio Concave, click base plate with ears size Ø50, 10-45 mm"
40958032|NCT05344911|DRUG|Propofol combined with remifentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, remifentanil 1μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with remifentanil(0.1-0.3ug/kg/min)
40958033|NCT01600469|DRUG|DAOI-B|250-1500 mg/day, oral, for 24 weeks
40958034|NCT01600469|OTHER|Placebo|placebo, oral, for 24 weeks
40958035|NCT02257307|PROCEDURE|RetCam retinal imaging used for routine care|De-identified digital images of both eyes, obtained by a non-physician Certified ROP Imager (CRI) using the RetCam Shuttle, will be uploaded to the secure server for remote evaluation by a Trained Reader. The results of the Reader's evaluation will be reported to the Clinical Center.
40958036|NCT01100541|DEVICE|Polymeric plate|Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
40958037|NCT05209360|DEVICE|Medial or Lateral Wedge|A foam wedge that is placed inside the shoe under the CDO, that runs along the length of the foot. The tall side of the wedge will be placed on the medial (Medial Wedge) or lateral (Lateral Wedge) aspect of the shoe to preferentially load the medial or lateral side of the foot.
40958038|NCT05209360|DEVICE|Carbon Fiber Custom Dynamic Orthosis|A device that consists of a proximal cuff that wraps around the leg just below the knee, a posterior strut that runs the length of the leg, and a semi-rigid footplate that goes under the length of the foot.
40958039|NCT05010057|DIETARY_SUPPLEMENT|New Zealand blackcurrants (NZBC)|NZBC capsules containing anthocyanin-rich blackcurrant extract
40958040|NCT05010057|DIETARY_SUPPLEMENT|Placebo (PLA)|Placebo capsules containing microcrystalline cellulose
40958041|NCT03656432|DRUG|CPP-ACP paste|The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
40958042|NCT03571425|OTHER|Oral Placebo|A placebo beverage will be consumed orally
40958043|NCT03571425|OTHER|Oral Protein|A protein beverage will be consumed orally
40958044|NCT03571425|OTHER|Enteral Protein|A protein beverage will be consumed via a naso-gastric feeding tube
40958045|NCT01686828|DRUG|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
40958046|NCT01686828|DRUG|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
40958047|NCT01686828|DRUG|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
40958048|NCT01686828|DRUG|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
40958049|NCT01686828|DRUG|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
40958050|NCT05212571|DRUG|S-ketamine infusion inpatient setting|S-ketamine is administered intravenously for six consecutive days. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
40958051|NCT05212571|DRUG|S-ketamine infusion outpatient setting|S-ketamine is administered intravenously for six hours. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
40958052|NCT02699814|BEHAVIORAL|H3 Services|A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
40958053|NCT05469581|OTHER|A set of preventive interventions to improve adherence in vulnerable elderly people|"* reviewing the list of medications, delivery of an ordered list of medications, and checking medication regimen understanding;~* delivering a leaflet on the correct/safe taking of medications, discussion, explanation, and verification of understanding of the content;~* a counseling about the importance of adherence;~* handing over the medication dispenser (if the elderly person does not have one yet),~* delivering of a personal medication card, which shows the timeline of taking prescribed medication."
41135834|NCT01221532|BEHAVIORAL|SHHE Peridischarge Intervention|"Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus~1. a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;~2. two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;~3. the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care."
41292620|NCT05652010|DEVICE|Sensura Mio Click|"* SenSura Mio Click 2p bag, item #11472. Open, wide outlet, maxi, neutral grey. 50mm with inspection window and circle filter 430~* Baseplate flat: Item #10512 SenSura Mio Click Base Plate with belt ears, 50 mm, 10-45 mm~* Baseplate concave: Item #18510 SenSura Mio Concave, click base plate with ears size Ø50, 10-45 mm"
41455721|NCT05588505|BEHAVIORAL|Cognitive-Behavioral Therapy Targeting Executive Dysfunction in College Students with ADHD|The intervention is 12 weeks long, made up of one 2- hour session each week. These sessions are designed to help the participants develop strategies to improve their executive functioning skills including self- care, time management and organizational skills. These skills will also be applied to specific academic tasks such as note-taking during reading and lectures, organizing and conducting research, and writing papers.
40958054|NCT04707508|DRUG|Valsartan 80 mg and metformin|Valsartan 80 mg once daily in addition to metformin monotherapy
40958055|NCT04707508|DRUG|Metformin|Metformin monotherapy
40958056|NCT03454542|DEVICE|Menicon Modified Lens Design|Randomized in a daily wear, single day (6 hours or more) evaluation
40958057|NCT05219175|DRUG|MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (\~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (\~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (\~80 mg MDMA) to 140 mg MDMA HCL (\~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (\~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (\~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (\~100 mg MDMA) to 180 mg MDMA HCL (\~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (\~280 mg MDMA) to 500 mg MDMA HCL (\~435 mg MDMA)"
41455722|NCT04513860|DRUG|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
40958058|NCT06061536|DRUG|Lipovirtide 10mg|Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
40958059|NCT06061536|DRUG|Lipovirtide 40mg|Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
40958060|NCT06061536|DRUG|Lipovirtide 60mg|Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；
40958061|NCT06061536|DRUG|DTG|DTG +3TC + TDF（once daily）.
40958062|NCT00977860|RADIATION|Stereotactic Body Radiation Therapy|36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
40958063|NCT00168870|DRUG|Gemcitabine|
40958064|NCT00168870|DRUG|Treosulfan|
40958065|NCT04131426|DRUG|Remune|Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD
40958066|NCT04131426|OTHER|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
40958067|NCT00036270|DRUG|exemestane (Aromasin)|exemestane, orally, 25 mg, for 5 years
40958068|NCT00036270|DRUG|tamoxifen + exemestane|tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
40958069|NCT01523535|BEHAVIORAL|repeated cycles of short sleep|- 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
40958070|NCT01365052|DRUG|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
40958071|NCT01365052|DRUG|Placebo|2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
41135835|NCT05119699|DEVICE|MagPro X100/R30 stimulator equipped with the B70 fluid-cooled coil|Subjects will receive 5 consecutive days (always Monday to Friday) of TBS rTMS, administered 8 times daily at 1 hour intervals. Patients will undergo cTBS of the R DLPFC at 110-120% RMT using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for a total of 600 pulses over 40 seconds, followed by iTBS of the L DLPFC at 110-120% resting motor threshold (RMT) using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz with a duty cycle of 2 s on, 8 s off for a total of 600 pulses over 3 min 9 s. Participants will be titrated to 110-120% RMT within the first four treatments to aid with tolerability. If patients tolerate the stimulation well, the target will be 120%. Assessments focused on depressive symptoms will be administered at baseline, after final treatment and four weeks post final treatment.
41292621|NCT01764178|DRUG|Livalo fixed combination drug|Pitavastatin 4mg / Valsartan 160mg
41455723|NCT06485518|BEHAVIORAL|The 5G RHS group receiving audio-video conferencing and effective data management for decision-making via augmented reality platform RealHealthcare System.|The 5G RHS group will receive audio-video conferencing and effective data management for decision-making via augmented reality platform. A total of 14 physicians from SRRSH will be participated in the study, offering remote consultations and instant guidance to the physician.
41455724|NCT02217709|DRUG|phenelzine sulfate|Given by mouth
41455725|NCT02217709|OTHER|laboratory biomarker analysis|Correlative studies
40958072|NCT03641859|DEVICE|virtual reality|"The virtual reality headset can be used for 45 minutes with the need to pause for 5 minutes if the gesture lasts longer. The VR sequence will be complete when the end of the programmed time is reached to preserve the patient's immersion. The patient will be able to see the final sequence at the end of the gesture in order to get used to the real world again. The programs and their durations will be adjusted to the duration of the gesture concerned. Regarding the pain, anxiety and satisfaction visual analogue scales, they will be performed just after the removal of the VR helmet.~Virtual reality videos are from Healthy Mind® software. The videos are contemplative with three kinds of relaxing landscapes accompanied by a sound universe specifically composed to relax the patient. The patient can choose one of three interactive worlds (an Asian garden, a forest or a mountain)."
40958073|NCT00092612|DRUG|MK0653, ezetimibe|
40958074|NCT00092612|DRUG|Comparator: ezetimibe, placebo|
40958075|NCT05814289|OTHER|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
40958076|NCT00180622|PROCEDURE|Spirometry|
40958077|NCT00180622|PROCEDURE|Exhaled Nitric Oxide and Carbon Monoxide|
40958078|NCT00180622|PROCEDURE|Exhaled Breath Condensate|
40958079|NCT00180622|PROCEDURE|Induced Sputum|
40958080|NCT00180622|PROCEDURE|CT Scan|
40958081|NCT00180622|PROCEDURE|Blood test|
40958082|NCT00180622|PROCEDURE|St Georges Questionnaire|
40958083|NCT00180622|PROCEDURE|Bodypletysmography|
40958084|NCT02426944|DRUG|NOAC|Medical arm, patients will be treated by NOAC.
40958085|NCT02426944|DEVICE|Left atrial appendage closure|The patients will be treated by interventional closure of the left atrial appendage.
40958086|NCT00005044|DRUG|Casodex|Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
40958087|NCT00005044|DRUG|Eulexin|Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
40958088|NCT00005044|DRUG|LHRH agonist|LHRH agonist of choice. The manufacturer's instructions should be followed.
40958089|NCT00005044|RADIATION|radiation therapy|\[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
41292622|NCT01764178|DRUG|Pitavastatin, Valsartan|Pitavastatin 4mg, Valsartan 160mg
41292623|NCT03005782|DRUG|REGN3767|
41292624|NCT03005782|DRUG|cemiplimab|
41455726|NCT02217709|OTHER|questionnaire administration|Ancillary studies
41455727|NCT00688844|DRUG|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
40958090|NCT04425512|DIAGNOSTIC_TEST|Complete Blood Count|Complete Blood Count samples
40958091|NCT00875992|DEVICE|ETN with ASLS|Angle stable locking of ETN using ASLS
40958092|NCT00875992|DEVICE|ETN locked with conventional locking bolts|Conventional surgical procedure
40958093|NCT05091359|DEVICE|Study group with absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste|Application of absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate in paste for prevent loosening of Dynamic Hip Screw implant
40958094|NCT05647460|PROCEDURE|computer guided screw holes locating guide and custom-made plates|"Virtual planning and guide fabrication for the study group:~* Preoperative CT.~* Virtual reduction of broken segments on software.~* Gain occlusion.~* Design surgical screw holes locating guide.~* Design the custom-made plates.~* Print the screw holes locating guide and the custom-made plate.~* Surgical guiding tools: screw holes locating guide and custom-made plates.~Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa."
40958095|NCT05647460|PROCEDURE|conventional plates|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
40958096|NCT01217359|DRUG|Interferon Alfa-2b|Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
40958097|NCT04174846|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|SAM children will receive approximately 190 kcal/kg/day of standard RUTF
40763372|NCT03435107|DRUG|Durvalumab|"Study treatment consists of durvalumab 1500 mg Q4W for patients \> 30 kg, and will be repeated every 4 weeks. For patients ≤ 30 kg, weight based dosing of 20 mg/kg durvalumab Q4W will be used.~Response evaluation will be performed every 8 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
40958098|NCT04174846|DIETARY_SUPPLEMENT|Ready-to-use-supplementary food (RUSF)|SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
40958099|NCT00321308|DRUG|pemetrexed|500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
40958100|NCT00321308|DRUG|pemetrexed + PF-3512676|pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
40958101|NCT00293215|DRUG|111-Indium-CMD-193|111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.
40958102|NCT00293215|DRUG|CMD-193|CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
40958103|NCT00917397|DRUG|Sertraline|varies
41292625|NCT02556879|BIOLOGICAL|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
41292626|NCT02556879|BIOLOGICAL|Serum bank|Additional samples for serum bank at each visit if possible
41292627|NCT02556879|BIOLOGICAL|DNA bank|Additional sample for DNA bank at inclusion visit if possible
40958104|NCT00917397|BEHAVIORAL|trauma-focused cognitive behavioural therapy|once a week
41135836|NCT05223959|BEHAVIORAL|Culturally adapted Psychoeducation|This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).
41292628|NCT02556879|PROCEDURE|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
41292629|NCT02556879|PROCEDURE|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
41292630|NCT01834326|BIOLOGICAL|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
41292631|NCT01834326|BIOLOGICAL|POM (Palatal oral mucosa)|POM is a tissue graft harvested from the palate and surgically placed into the defect area
41292632|NCT02532543|BIOLOGICAL|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
41292633|NCT02532543|BIOLOGICAL|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
41292634|NCT02532543|BIOLOGICAL|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
41455728|NCT01345539|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.
40958105|NCT05222269|DRUG|68Ga-PTF|68Ga-PTF will be injected intravenously at three time points during the course of the standard treatment of the patient.
40958106|NCT04242719|DEVICE|Electromagnetic stimulation|Retinal electromagnetic stimulation A high-frequency repetitive electromagnetic stimulation protocol has been defined in the literature and was applied in groups 1 and group 2 via a novel device developed specifically for ophthalmic usage (Magnovision-TM, Bioretina Biyoteknoloji AŞ, Ankara,Turkey). The patients underwent 10 consecutive sessions of rEMS application. Parameters for the treatment were 42 hertz frequency/min, 30 minutes of duration and mild operating cycle. The power of the electromagnetic field was 2000 milligauss, which is a very low dose and within the safety limits of World Health Organisation. In group 2, sub-tenon aPRP injections were also performed immediately after the first, fifth, and tenth sessions of rEMS application.
41292635|NCT02532543|BIOLOGICAL|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
41455729|NCT01345539|DRUG|Chemotherapy|Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
40958107|NCT04242719|BIOLOGICAL|Platelet rich plasma|About 20 ml of blood was drawn from the patient's antecubital vein and inserted into two 10-ml vacutainer tubes that contain trisodium citrate (T-LAB PRP Kit, T-Biyoteknoloji, Bursa, TURKEY). These tubes were placed in a refrigerated (+4 °C) centrifuge (Nüve NF 1200R, Nüve Laboratuar Teknolojileri, Ankara, TURKEY) and spun at 2500 rpm (580×g) for 8 min within 30 min of collection. Three different layers formed in the tubes: red blood cells at the bottom, platelet-rich plasma in the middle, and platelet-poor plasma in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe and immediately injected into the sub-tenon space of each eye after topical anesthesia with proparacaine hydrochloride (Alcaine, Alcon, USA) drops.
40958108|NCT02218320|DRUG|Raltegravir|
40958109|NCT02218320|DRUG|Dolutegravir|
40958110|NCT02218320|PROCEDURE|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
40958111|NCT05382663|DEVICE|Alio Device|Non-invasive device worn over vasculature.
40958112|NCT06467968|OTHER|Cardiac ECG-gated PET imaging will added|Blood sample will be used to measure troponin, BNP and CRP . After 68Ga-DOTATOC PET/CT whole body recording, a cardiac ECG-gated PET imaging will added
40958113|NCT04713930|DRUG|JNJ-61393215|JNJ-61393215 will be administered orally.
40958114|NCT04713930|DRUG|Placebo|Placebo will be administered orally.
40958115|NCT06049238|OTHER|Maitland Mobilization|"* Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation"
40958116|NCT06049238|OTHER|Post facilitation stretch|"* Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation"
40958117|NCT04532047|DRUG|Aldurazyme (laronidase)|Enzyme replacement therapy for lysosomal storage diseases
40958118|NCT02644642|OTHER|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
40958119|NCT01393223|DRUG|LP-08 80mg|Intravesical instillation of 80mg LP08
40958120|NCT01393223|DRUG|Normal saline|Intravesical instillation of normal saline
40958121|NCT01393223|DRUG|LP-08 20mg|Intravesical instillation of 20mg LP08
40958122|NCT04747080|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
40958123|NCT04747080|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
40958124|NCT05856071|DEVICE|goniometer|to measure the range of motion
40958125|NCT05856071|OTHER|clamshells exercises|clamshells exercises
40958126|NCT05856071|OTHER|traditional physical therapy|traditional physical therapy
40958127|NCT01466647|DRUG|AXL1717|A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
40958128|NCT00318422|DRUG|liraglutide|
41135837|NCT02617693|BEHAVIORAL|lifestyle intervention|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.
40958129|NCT00318422|DRUG|rosiglitazone|
40958130|NCT00318422|DRUG|glimepiride|
40958131|NCT04948528|OTHER|Active Comparator: Surgery Pathology or Cystoscopy|Case group will be followed up with surgery pathology or cystoscopy.
40958132|NCT04948528|OTHER|Active Comparator: Clinical Diagnosis|Control group will be diagnosed in clinical.
40958133|NCT02327065|DEVICE|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
40958134|NCT02327065|DEVICE|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
40958135|NCT04066023|DRUG|C213 Microneedle System|The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.
40958136|NCT04066023|DRUG|Placebo|The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm\^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
40958137|NCT05492838|PROCEDURE|Immediate implantation with the Socket Shield Technique|Immediate implant surgery applied with the Socket Shield Technique
41135838|NCT02617693|OTHER|standard antenatal care|Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
41135839|NCT06427239|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
40958138|NCT03119233|DEVICE|PQ Bypass System|Intended use from CLN114 Rev F (CLN114 is the DETOUR2 protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).
40958139|NCT02789995|PROCEDURE|Human biological samples|Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
40958140|NCT03862222|OTHER|Retinal Imaging|Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
40958141|NCT03862222|OTHER|Pupillometry|Participants will complete a task studying pupillary response to light
40958142|NCT03862222|OTHER|Contrast Sensitivity|Participants will complete a task evaluating contrast sensitivity
40958143|NCT03862222|DIAGNOSTIC_TEST|Neuropsychological Evaluation|Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
41455730|NCT01140607|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
41455731|NCT03302598|DIAGNOSTIC_TEST|serum C-reactive protein|
41455732|NCT02986139|DRUG|Commercial Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.
41455733|NCT02986139|DRUG|New Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.
41455734|NCT02121184|DRUG|Routine oxytocin|per regular oxytocin protocols
41292636|NCT03215472|OTHER|DASH Cloud|With DASH Cloud, the investigators will ask participants to track their diet daily using a commercial diet tracking app. The investigators will retrieve the diet data on our DASH Cloud platform and provide tailored feedback about a participant's DASH adherence via fully automated daily or weekly text messages. These feedback messages will describe both an individual's absolute performance and change over time. The investigators also include theory-driven tailored content that reinforces successes, offers motivational strategies, and offers short behavior change tips.
40763373|NCT03283956|DEVICE|Patient records|Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
40763374|NCT02594072|RADIATION|stereotactic ablative radiotherapy|Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.
40958144|NCT03862222|GENETIC|APOE genotyping|APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.
40958145|NCT03862222|OTHER|blood draw|Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis
40958146|NCT03862222|OTHER|Gait Assessment|Gait assessment will be conducted by trained researcher
41292637|NCT03215472|OTHER|Nutritionix Track app|DASH Light Control participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
41292638|NCT00739297|DRUG|Comparator: montelukast|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
41292639|NCT00739297|DRUG|Comparator: placebo|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
41292640|NCT00865462|DRUG|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
41292641|NCT00865462|DRUG|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
41292642|NCT04947566|DRUG|Comparison of Efficacy of Naproxen versus Ibuprofen|Comparison of Efficacy of Naproxen Versus Ibuprofen in the Management of Post-Operative Endodontic Pain in Teeth with Irreversible Pulpitis
41292643|NCT02243124|DRUG|cenersen|cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
41292644|NCT02243124|DRUG|Dexamethasone|Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
41292645|NCT06012604|BIOLOGICAL|allogeneic mesenchymal stromal stem cells|mesenchymal stromal stem cells injection under ultrasound guidance into parotid and submandibular glands
41292646|NCT00068952|DRUG|Edotecarin|
41292647|NCT00068952|DRUG|Temozolomide|
41292648|NCT00068952|DRUG|Carmustine (BCNU)|
41292649|NCT00068952|DRUG|Lomustine (CCNU)|
41292650|NCT00447954|DRUG|NT-501 implant|High Dose
41292651|NCT00447954|DRUG|NT-501 implant|Low Dose
41292652|NCT00447954|OTHER|Sham Procedure|Sham Procedure
41292653|NCT05032833|DRUG|5-MeO-DMT|A single dose of 5-MeO-DMT will be administered intranasally
41292654|NCT05032833|OTHER|Placebo|A single dose of placebo will be administered intranasally
41292655|NCT03237845|DRUG|Rimegepant|75 mg tablet QD
41292656|NCT03237845|DRUG|Placebo|Placebo tablet to match rimegepant dose QD
41292657|NCT02985125|DRUG|LEE011|Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.
41292658|NCT02985125|DRUG|Everolimus|Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.
41292659|NCT00751101|DRUG|Nicotine patch|Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
41292660|NCT00828386|PROCEDURE|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
41292661|NCT00472927|DRUG|Premarin/MPA 0.45 mg/1.5 mg|
41455735|NCT02121184|DRUG|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes initiation of labor analgesia
41455736|NCT02599662|RADIATION|10 Gy Low-KV IORT|: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
40958147|NCT03862222|OTHER|Actigraphy|Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
41455737|NCT02599662|RADIATION|15 Gy Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
41455738|NCT02599662|RADIATION|20 GY Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
41455739|NCT01344018|PROCEDURE|therapeutic conventional surgery|
41455740|NCT01344018|RADIATION|3-dimensional conformal radiation therapy|
41455741|NCT03294122|RADIATION|External beam radiotherapy for prostate cancer|Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.
41455742|NCT03294122|RADIATION|External beam radiotherapy for head and neck cancer|Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
41455743|NCT01064960|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
41455744|NCT03028545|BEHAVIORAL|Collection of the individual narrative, semi-directed interviews|Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
41455745|NCT01539564|DRUG|Minocycline HCl Microspheres|
41455746|NCT05934695|OTHER|Lymphedema severity stratification|"Participants will be stratified into one of three lymphedema severity groups based on the International Society of Lymphology lymphedema severity staging:~Mild (stage 1): swelling with pitting; normal skin and tissue turgor Moderate (stage 2): swelling with pitting; dermal thickening; skin changes without distortional warty-overgrowth Severe (stage 3): swelling with non-pitting; warty overgrowth or elephantiasis folds"
41455747|NCT02050321|DRUG|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
41455748|NCT02050321|DRUG|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
41455749|NCT00280930|DRUG|Letrozole|
41455750|NCT03546049|PROCEDURE|US-guided percutaneous biliary drainage|"Device: metal stent. The self-expandable metal stent is implanted percutaneously by a transhepatic access route.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed).~Length: 6-10 cm. Diameter: 8-10 mm."
41455751|NCT03546049|PROCEDURE|EUS-guided biliary drainage|"Device: metal stent. The transluminal (transgastric, transduodenal or transenteric) implanted self-expandable metal stent is released via echoendoscope.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed) or mixed covered (one half covered, one half non-covered). The mixed covered stent is used for the transhepatic access.~Length: 6-10 cm. Diameter: 8-10 mm."
40958148|NCT06111807|DIAGNOSTIC_TEST|ctDNA|ctDNA will be tested retrospectively, no treatment decisions will be made prospectively
40958149|NCT06081712|DRUG|TNP-2198|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
41135840|NCT06427239|DRUG|Adebrelimab|Adebrelimab will be administrated per dose level in which the patients are assigned
41455752|NCT00306306|DEVICE|Reprieve Endovascular Temperature Therapy System|
41455753|NCT02471027|PROCEDURE|Neoadjuvant chemotherapy|There is no uniform schemer,commonly used drugs including carboplatin,cisplatin,paclitaxel,vincristine,bleomycin,fluorouracil,ifosfamide,mitomycin,gemcitabine,and so on.Methods including intravenous chemotherapy and artery intervention chemotherapy,also has not been unified.
41455754|NCT00204451|DRUG|0.75 levonorgestrel|
41455755|NCT00204451|DRUG|50 mg ethinyl estradiol/0.5 mg levonorgestrel|
41455756|NCT01166529|PROCEDURE|EUS-guided Celiac Plexus Neurolysis|All patients will receive anesthesia. The linear echo-endoscope will be advanced into the proximal stomach. It will be noted whether the tumor is seen in the celiac axis, if there is flow in the celiac artery, and if the celiac ganglia are seen. The celiac ganglia will be injected directly with 10cc of 0.25% bupivicaine followed by 10cc of 98% dehydrated alcohol. If the celiac ganglia cannot be identified, the posterior and anterior aspects of celiac artery take-off will be injected in a similar manner (twice the volume). Flow in the celiac axis will be confirmed. All injections will be performed with a standard EUS injection needle made especially for CPN . Prior to injection, aspiration will be performed through the needle to ensure that no blood is aspirated.
40958150|NCT06081712|DRUG|TNP-2198 Placebo|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
40958151|NCT05406778|DEVICE|SPARK Test|Twenty (20) minutes of resting state EEG data collection.
41135841|NCT06509867|PROCEDURE|DGG+PRF|de-epithelialized subepithelial connective tissue grafts+ L-Platelet Rich Fibrin + Coronally advanced flap
41135842|NCT06509867|PROCEDURE|DGG|de-epithelialized subepithelial connective tissue grafts+ Coronally advanced flap
40763375|NCT02594072|RADIATION|external beam radiation therapy|Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.
40958152|NCT01313858|DRUG|Simponi®|
40958153|NCT01313858|DRUG|Methotrexate|Given concomitantly with Simponi®
40958154|NCT00457925|DRUG|GSK221149A|
41135843|NCT05977985|DRUG|Rotator interval hydro-dissection with dextrose 5%|Single injection of 20ml dextrose 5% into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
41455757|NCT05846139|COMBINATION_PRODUCT|PerioTabs® brushing solution|PerioTabs® contains a non-antibiotic biofilm removal complex called NitrAdine®.Its anti-biofilm action is based on the combination of surfactant-induced protein denaturation and slow release of a non-toxic concentration of hypochlorite (0.02%).
41455758|NCT05846139|COMBINATION_PRODUCT|Chlorhexidine 0.12 %|chlorhexidine 0.12 % toothpaste and chlorhexidine 0.2% mouth rinse
40763376|NCT02594072|DRUG|Zoladex ®|The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
40958155|NCT00389597|DEVICE|Cervical Artificial Disc|Cervical artificial disc mechanical device
40958156|NCT04903990|OTHER|Blood sample|As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
40958157|NCT04054505|DIETARY_SUPPLEMENT|EZPAK|One packet with breakfast for three months
40958158|NCT04054505|DIETARY_SUPPLEMENT|Placebo|One packet with breakfast for three months
40958159|NCT03969732|DRUG|1. amyloid PET；2. T807 PET|"1. Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807 (4 x 300 seconds)"
40958160|NCT01267045|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
40958161|NCT04275531|DRUG|Anesthesia Agent|various anesthetic agents used in both general and regional anesthesia
40958162|NCT00515411|DRUG|Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
40958163|NCT00515411|DRUG|Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen|"Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg\* subcut x 7 d 10-17~\* 300 mcg for weight \< 60 kg, 480 mcg for weight \> 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter."
40958164|NCT00515411|DRUG|Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
40958165|NCT02654743|DIETARY_SUPPLEMENT|Sulforaphane|Children with ASD will receive Sulforaphane in this study
40958166|NCT00919425|OTHER|biologic sample preservation procedure|
40958167|NCT01733784|OTHER|Induced central apneas|
40958168|NCT02925520|DRUG|Omegaven|"Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.~Home Use of Omegaven:~The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider."
41455759|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
41455760|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
41455761|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
40763377|NCT05934396|BEHAVIORAL|Safety Planning|Prior to discharge and following the conclusion of all Virtual Reality (VR) sessions, the participant will develop a safety planning intervention for school settings in collaboration with relevant individuals (e.g., the researcher, a school professional).
41455762|NCT02044939|OTHER|Pulmonary rehabilitation program|Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
41455763|NCT04908449|DRUG|Rectus sheath block with bupivacaine|Rectus sheath block with local anesthetic versus sham block with saline
41455764|NCT01559116|DRUG|tiotropium + olodaterol|low dose + one dose only
41455765|NCT01559116|DRUG|tiotropium|low dose
41455766|NCT01559116|DRUG|olodaterol|one dose only
41455767|NCT01559116|DRUG|tiotropium|high dose
41455768|NCT01559116|DRUG|tiotropium + olodaterol|low dose + one dose only
41455769|NCT01559116|DRUG|Placebo|placebo matching tiotropium+olodaterol FDC
41455770|NCT01559116|DEVICE|Respimat|Respimat inhaler
41135844|NCT05977985|DRUG|Rotator interval hydro-dissection with corticosteroid solution|Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
41135845|NCT03140670|DRUG|RUCAPARIB|Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
41135846|NCT03975465|BEHAVIORAL|Expiratory Muscle Strength Training|8 weeks of EMST at 75% maximum expiratory pressure (MEP)
41292662|NCT04880057|OTHER|Resistance+Aerobic training|"The RT focuses on lower extremity workout, including leg press, hamstring curls, and calf raises. The participants start with intensity at 12 RM and finished with intensity at 8 RM after 3 weeks. There are 8 repetitions, 2 sets for each action. It will take 15 minutes to complete RT.~The AeT is composed by cycling on stationary bikes in the first week, stepping on steppers in 2nd week, and running on treadmills in the last week. Participants are asked to wear a portable heart rate monitor throughout the experiments. They have to maintain their heart rates in 60%-75% of predicted maximal heart rate (moderate intensity exercise), which has been shown to be benefit on cognition\[3\]. It took the participants 25 minutes to complete AeT."
41292663|NCT04880057|OTHER|Agility training|AT program consists of three parts: technical drills, pattern running and reactive agility training. There will be nine sessions over 3 weeks and progress the intensity, complexity or velocity every week.
41292664|NCT02232789|DRUG|Mephedrone|Single oral dose mephedrone
41292665|NCT02232789|DRUG|3,4-methylenedioxymethamphetamine|Single oral dose MDMA
41292666|NCT02232789|DRUG|Placebo|Single oal dose placebo
41292667|NCT00870272|DRUG|Misoprostol|400mcg misoprostol taken sublingually or buccally
41292668|NCT01571674|PROCEDURE|Manipulation + Exercise Group|"First 2 sessions~* High-velocity, low-amplitude manipulations to the thoracic spine.~* Low-velocity mid to end-range mobilizations to the cervical spine.~* Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
41292669|NCT01571674|PROCEDURE|Exercise Group|"First 2 sessions~◦ Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
41292670|NCT05392322|OTHER|Self-help skills|Self-help skills were given to down's syndrome children 3 times per week upto 15 minutes.
41292671|NCT05392322|DEVICE|Virtual video reality gaming|Virtual video reality gaming was given to children with down's Syndrome 3 time per week upto 15 minutes.
41455771|NCT02560051|DRUG|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
40958169|NCT04456530|DRUG|Aveed 750 MG in 3 ML IM Injection|Participants in the Testosterone Group will receive two IM Aveed injections 1 month apart.
41135847|NCT03975465|BEHAVIORAL|Pharyngeal Muscle Strengthening Exercises|8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing
41135848|NCT04862598|DEVICE|Oculus Virtual Reality|The patient will receive standard care, augmented with virtual reality. Their post-operative satisfaction score will be recorded.
41135849|NCT00151866|PROCEDURE|platelet transfusion|
41292672|NCT03044665|DRUG|Rosuvastatin|Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
41292673|NCT03044665|DRUG|Rosuvastatin plus ezetimibe|Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
41292674|NCT04834986|DRUG|Tislelizumab combined with Lenvatinib|"Pre-operation: Tislelizumab, 200mg, iv,d1,q3w, 2-4 cycles; Lenvatinib,8mg/kg,po,qd,d1-d84.~Operation Postoperation: 4-8 weeks after surgery, Tislelizumab, 200mg, iv,d1,q3w; Lenvatinib,8mg/kg,po,qd, up to one year."
41292675|NCT03020524|BIOLOGICAL|Autologous CD4 T-Cells|all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
41292676|NCT00425438|DRUG|Mycophenolate Mofetil|0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
41292677|NCT00425438|DRUG|Corticosteroids|0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
41292678|NCT00425438|DRUG|Azathioprine|100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
41292679|NCT00425438|DRUG|Cyclophosphamide|0.75 g/m\^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m\^2 to maintain a minimum WBC count of ≥ 2500 per mm\^3 from Weeks 5 through 24
41292680|NCT00890968|DRUG|Triamcinolone Acetonide (TAC) DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
41455772|NCT02560051|DRUG|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
41455773|NCT02560051|DRUG|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
41455774|NCT02560051|DRUG|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
40958170|NCT04456530|OTHER|Normal Saline 3 ML IM Injection|Participants in the Control Group will receive two IM normal saline injections 1 month apart.
40763378|NCT05934396|BEHAVIORAL|VR Enhanced Affect Regulation|Participants will receive an overview of affect regulation in VR and then have the opportunity to practice using affect regulation in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
41135850|NCT05474326|DEVICE|intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System)|application of intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System) on lower limbs and its effect on fetal and maternal doppler and amniotic fluid index in women with oligohydramnios. the compression system will be applicated on lower limbs for one hour in which it will produce intermittent compression on lower limbs. amniotic fluid amnout assessment will be done after this including doppler studies in order to detect any change in amniotic fluid amount or dopper.
41292681|NCT00890968|DRUG|Placebo DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
41292682|NCT02616029|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
41292683|NCT02442999|OTHER|Screening for obstructive sleep apnea|
41292684|NCT02442999|DEVICE|CPAP - continuous positive airway pressure|
40958171|NCT01760629|DEVICE|Tecotherm-HELIX|Whole body cooling using Tecotherm-HELIX
40958172|NCT03338010|DRUG|LY2963016|Administered SC
40958173|NCT03338010|DRUG|Lantus®|Administered SC
40958174|NCT02579837|DEVICE|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
41135851|NCT01246635|DEVICE|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
41135852|NCT01246635|PROCEDURE|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
41135853|NCT04698694|DEVICE|Electroporation with voltage amplitude of 40 V (corresponding to an electric field strength of 100 V/cm)|The physician will select the voltage amplitude of 40 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
41135854|NCT04698694|DEVICE|Electroporation with voltage amplitude of 60 V (corresponding to an electric field strength of 150 V/cm)|The physician will select the voltage amplitude of 60 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
41135855|NCT04090502|OTHER|Dry needling in hamstring muscle trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied to this area.
41292685|NCT01463852|DRUG|vincristine|Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
41292686|NCT00541359|DRUG|bortezomib|Given IV
41292687|NCT00541359|DRUG|topotecan hydrochloride|Given IV
41292688|NCT00541359|OTHER|immunohistochemistry staining method|Correlative studies
41292689|NCT00541359|OTHER|pharmacological study|Correlative studies
41292690|NCT02151539|OTHER|medical chart review|Ancillary studies
41292691|NCT02151539|OTHER|quality-of-life assessment|Ancillary studies
41455775|NCT02560051|DRUG|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
41292692|NCT05209243|RADIATION|SBRT|SBRT (all metastatic lesions)
41292693|NCT05209243|RADIATION|STANDARD OF CARE|ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
41292694|NCT03378401|DRUG|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
41292695|NCT03378401|OTHER|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
41292696|NCT04713358|DRUG|Nalmefene|Immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
41292697|NCT04713358|DRUG|normal Saline|Immediately Intravenous injection of normal saline 1ml after surgery
41292698|NCT00779038|DRUG|Fentanyl ITS|40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
41455776|NCT05092464|DEVICE|Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
40958175|NCT02579837|DEVICE|Zeiss Cirrus|optical coherence tomographer (OCT)
40958176|NCT02398578|DEVICE|Amphora OAB Device|Cystoscopic procedure to treat OAB
40958177|NCT00099541|DRUG|zoledronic acid|
40958178|NCT00004762|DRUG|cladribine|
40958179|NCT02899299|BIOLOGICAL|Nivolumab|
40958180|NCT02899299|BIOLOGICAL|Ipilimumab|
40958181|NCT02899299|DRUG|Pemetrexed|
40958182|NCT02899299|DRUG|Cisplatin|
40958183|NCT02899299|DRUG|Carboplatin|
41455777|NCT05563207|OTHER|traditional Chinese medicine health education standard path|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff.During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
41455778|NCT05563207|OTHER|The contents of the health intervention mainly included:Graphic and text education|When the patient was admitted to the hospital, the responsible nurse had a comprehensive understanding of the patient's disease cognition and psychological state, and based on this, an individualized intervention plan was formulated. With the help of publicity boards, brochures and other forms of pictures and texts, to popularize the knowledge and precautions of disease treatment for patients
41455779|NCT05563207|OTHER|The contents of the health intervention mainly included:Language education|adopt one-to-one method to inform patients of the principles, effects and precautions of chemotherapy, eliminate patients' misunderstandings, and repeat language education for many times during the treatment process to strengthen patients' memory
41455780|NCT05563207|OTHER|The contents of the health intervention mainly included:Psychological education|guide patients to express their own emotions, according to the patient's personality, cultural background, etc., after communicating with family members and negotiating, selectively inform the patient's actual condition
41455781|NCT05563207|OTHER|The contents of the health intervention mainly included:Dietary education|instruct patients to follow the principles of light, easy to digest and balanced nutrition
40763379|NCT05934396|BEHAVIORAL|VR Enhanced Cognitive Restructuring|Participants will receive an overview of cognitive restructuring in VR and then have the opportunity to practice using cognitive restructuring in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
40958184|NCT01062204|DEVICE|Altrazeal|Sterile, odorless, crystalline white powder consisting of flakes of freeze dried HEMA and HPMA polymers. For application, the powder is distributed to the surface of the wound or burn where it forms a moist, flexible film and adheres to the surface of the wound.
40958185|NCT01062204|DEVICE|Aquacel Ag|Textile fiber made from sodium carboxy-methylcellulose containing 1.2% silver in ionic form.
40958186|NCT05053100|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40958187|NCT05053100|OTHER|Electronic Health Record Review|Undergo electronic health record review
40958188|NCT01332331|DRUG|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
40958189|NCT01332331|DRUG|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
40958190|NCT01176383|GENETIC|Respiragene test and risk score|This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
40958191|NCT02916589|DIETARY_SUPPLEMENT|Diet|
40958192|NCT02056496|DIETARY_SUPPLEMENT|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
40958193|NCT02056496|DIETARY_SUPPLEMENT|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
40958194|NCT06474702|DEVICE|'Fitbit charge 4' 'smart-watch'-|smartwatch device that collects physiological measures
40958195|NCT01500577|DRUG|nimesulide|Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
40958196|NCT01500577|DRUG|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
40958197|NCT01500577|OTHER|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
40958198|NCT00316472|DRUG|Niacinamide|
40958199|NCT01262911|DRUG|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
41455782|NCT05563207|OTHER|The contents of the health intervention mainly included:Complication education|Actively inform patients about complications in advance, and guide their prevention methods, such as increasing water intake, avoiding activities of affected limbs after chemotherapy, etc. Patients with vomiting, hair loss and other adverse reactions are prone to negative emotions such as anxiety and depression , timely take corresponding measures and appease the patient, inform them that it is a normal phenomenon, and guide them to maintain a good attitude.
40763380|NCT05934396|BEHAVIORAL|VR Enhanced Problem Solving|Participants will receive an overview of problem solving in VR and then have the opportunity to practice using problem solving in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
40763381|NCT05934396|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Worksheets|The researchers will provide instructions for participants to complete a packet of worksheets teaching introduction to cognitive behavioral therapy (CBT), affect regulation, cognitive restructuring, and problem solving.
41135856|NCT04090502|OTHER|Dry needling in hamstring muscle not trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied out of this area.
41135857|NCT06411561|BEHAVIORAL|SLEEP + COG|Combination of SLEEP and COG interventions
41135858|NCT06411561|BEHAVIORAL|COG|Daily 30-minute session of computerized cognitive training
40958200|NCT01262911|DRUG|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
40958201|NCT01681472|DRUG|6R-MTHF (arfolitixorin) 200 mg/m2|i.v. bolus injection
41135859|NCT06411561|BEHAVIORAL|SLEEP|Nighttime use of both ear plugs and eye masks
41135860|NCT06411561|BEHAVIORAL|AC|Educational modules on cognitive and sleep health
41135861|NCT04201314|DIETARY_SUPPLEMENT|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
41135862|NCT04201314|DIETARY_SUPPLEMENT|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
41135863|NCT02941094|DEVICE|needle PLT-805AT|comparing success rate and complications using different needle to US probe angles.
41135864|NCT02941094|DEVICE|Ultrasound|Xario, Toshiba Tokyo Japan
41135865|NCT04207372|DIETARY_SUPPLEMENT|whey protein isolate|whey protein isolate
41135866|NCT04207372|DIETARY_SUPPLEMENT|Zein|zein protein
41135867|NCT04207372|OTHER|protein-free|protein free
41135868|NCT06510959|OTHER|Digital course|The course aims to enhance participants' digital skills concerning the use of smartphones, specifically focusing on daily utility apps such as email apps, eGov apps, mobility apps, etc. The course is structured into the following ten 90-minute weekly lessons.
41135869|NCT02151084|DRUG|Selumetinib|
40958202|NCT01681472|DRUG|Levoleucovorin 200 mg/m2|i.v. bolus injection
41135870|NCT02151084|DRUG|Cisplatin|
41135871|NCT02151084|DRUG|Gemcitabine|
41135872|NCT03742882|DRUG|CC-90001|CC-90001
41135873|NCT01442766|DRUG|Donepezil|5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
41135874|NCT01442766|DRUG|Placebo|Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
41135875|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
41135876|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
41455783|NCT00890864|OTHER|Invitation for breast screening|Invitation for breast screening to women in different age groups
41455784|NCT02643927|BEHAVIORAL|standard 8-weeks MBSR|A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
41135877|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
41135878|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
41135879|NCT00681941|DRUG|Sevelamer carbonate (Renvela®)|Sevelamer Carbonate Tablets Dosed Three Times A Day
41135880|NCT04705051|DRUG|Venglustat GZ402671|Pharmaceutical form: capsule Route of administration: oral
41135881|NCT04511286|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
41135882|NCT03865732|DRUG|Ganaxolone|active drug
41135883|NCT03865732|DRUG|Placebo|inactive
41135884|NCT02372799|DRUG|Vilazodone|
41135885|NCT02372799|DRUG|Placebo|
40958203|NCT01681472|DRUG|6R-MTHF (arfolitixorin) 60 mg/m2|i.v. bolus injection
40958204|NCT01681472|DRUG|Levoleucovorin 60 mg/m2|i.v. bolus injection
40958205|NCT01160315|DRUG|Triptorelin|Triptorelin: intramusculAR injection every 3 months
40958206|NCT01160315|DRUG|Norethisterone acetate|5 mg/day per os until during chemotherapy
40958207|NCT03757325|DRUG|DNL747|DNL747
40958208|NCT03757325|DRUG|Placebo|Placebo
40958209|NCT00252915|BIOLOGICAL|GM-CSF (verum)|sagramostim
40958210|NCT01387620|DRUG|Hyaluronic Acid and hydroxypropylmethylcellulose|Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
40958211|NCT06464796|OTHER|Motor Imagery Techniques|"* Play a video of person doing a toe-raise exercise where carrying a big barbell on his shoulders.~* The individual in the video proceeded from a neutral upright position to a tiptoe standing while loud a heavy barbell; the plantar-flexors are used in this workout.~* The members were said to imagine engaging their ankle flexor muscles in an effort to generate ankle flexion. Both limbs were used during the 10-second imaginary contraction, which was tailed by a 10-second rest. Subsequently five repetitions of the contraction, there was a 30 second pause. Two-minutes of rest were interspersed between five-sets of five-contractions. Fifty imaginary contractions in total."
40958212|NCT06464796|OTHER|Conventional Exercise Therapy|"1. ROM drills for pronation, flexion and extension.~2. Ankle strengthening trainings include stand-up on tiptoe, walking on toe-tip, hopping on single foot, and resistance exercise with a latex elastic band.~3. Proprioceptive exercise include the following exercises: (a) sit on a proprioception board and move the injured limb in a round motion; (b) stand-up with both legs on the board while performing both eyes open and closed; (c) standing with single leg on the board while performing both eyes open; and (d) exercises on a mini-tramp (stand-up on double legs, single leg stances, hops on both left and right legs and on single leg).~4. Strengthening of the muscles of ankle completed with flexible bands at moderate Intensities.~5. Training on a stationary bicycle.~6. lunges forward into a wall.~7. Steps up and down on the transverse or sagittal plane."
40958213|NCT00899769|GENETIC|protein expression analysis|
40958214|NCT00899769|GENETIC|proteomic profiling|
40958215|NCT00899769|OTHER|immunoenzyme technique|
40958216|NCT00899769|OTHER|laboratory biomarker analysis|
41292699|NCT04211324|DEVICE|TENS|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
40763382|NCT06329622|COMBINATION_PRODUCT|low-protein diet + Ketosteril|low-protein diet (0.6-0.8g protein/kg body weight/day) and Ketosteril 0.12 g/kg body weight/day will be prescribed with the target energy intake of 25-30kcal/kg body weight/day.
40763383|NCT06329622|DIETARY_SUPPLEMENT|low-protein diet|low-protein diet (0.6-0.8g protein/kg body weight/day) with the target energy intake of 25-30kcal/kg body weight/day.
40763384|NCT02136355|RADIATION|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
40958217|NCT00899769|OTHER|liquid chromatography|
40958218|NCT00899769|OTHER|mass spectrometry|
40958219|NCT03694587|DRUG|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
40958220|NCT03694587|DRUG|Aktren® 200 mg überzogene Tabletten (Ibuprofen)|one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
40958221|NCT01628978|OTHER|determination by auscultation|determination of depth of endotracheal tube placement by auscultation
40958222|NCT01628978|OTHER|determination by ultrasound|determination of depth of endotracheal tube placement by ultrasound
40958223|NCT04775069|BIOLOGICAL|BNT162b2|Intramuscular injection
40958224|NCT04775069|BIOLOGICAL|CoronaVac|Intramuscular injection
40958225|NCT04775069|BIOLOGICAL|AZD1222|Intramuscular injection
40958226|NCT02051504|BEHAVIORAL|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
40958227|NCT02051504|DIETARY_SUPPLEMENT|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
40958228|NCT02051504|PROCEDURE|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
40958229|NCT02051504|PROCEDURE|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
40958230|NCT02051504|PROCEDURE|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
40958231|NCT02051504|PROCEDURE|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
40958232|NCT02051504|OTHER|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
40958233|NCT01784445|DRUG|Ceftazidime|Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
40958234|NCT05693948|OTHER|Other: Serum X|Serum X contain arbutin and glutathione
40958235|NCT01262131|DEVICE|magnetic therapy protocol A|Application of magnetic fields using the Resonator device Protocol A
40958236|NCT01262131|DEVICE|magnetic therapy Protocol B|Application of magnetic fields using the Resonator device Protocol B
40958237|NCT01262131|DEVICE|placebo therapy|Application of inactive magnetic fields using the Resonator device
40958238|NCT02367443|RADIATION|Radiation|Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
40958239|NCT00717093|DRUG|Varenicline Tartrate|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
41135886|NCT02372799|DRUG|Fluoxetine|
41292700|NCT04211324|DEVICE|electro-acupuncture|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
41292701|NCT06071286|PROCEDURE|Blood samples|Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
41455785|NCT02643927|BEHAVIORAL|4-week shortened MBSR|This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
41455786|NCT03086876|BEHAVIORAL|Level 4 Stepping Stones Triple P (SSTP)|Stepping Stones Triple P is a system of psychoeducational and behavioural approaches to parenting a child with LD and challenging behaviour that aims to increase parental confidence and skills so that parents are able to manage the child's behavior effectively. SSTP comprises different levels based on increasing family complexity.
40763385|NCT06369545|OTHER|EXERCISE|All participants included in this group will receive Exercises
40763386|NCT06369545|OTHER|TENS|All participants included in this group will receive TENS
40763387|NCT06369545|OTHER|ESWT|All participants included in this group will receive ESWT
40763388|NCT06641102|OTHER|Self-Guided Program (Tier 1)|"The study intervention is a smartphone application.~Tier 1: self-guided program, includes videos, guided meditations, and worksheets that are delivered to users in 10 different topical modules. Two modules are delivered per week, with email reminders. It will emphasize that PRT is a practice that requires users to come back to the material regularly to help retrain the brain often (just like how you need to practice and complete exercises between PT sessions)."
40958240|NCT00717093|DRUG|Placebo|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
41292702|NCT01764646|RADIATION|Intensity modulated radiation therapy|Minimize radiation doses to surrounding area
41292703|NCT01764646|RADIATION|Volumetric modulated arc therapy|Highly conformational dose distribution
41292704|NCT01764646|RADIATION|Image guided radiation therapy|Follow target by the use of fiducial markers and ERB
41292705|NCT00005029|DRUG|topotecan hydrochloride|
41292706|NCT01277289|DRUG|Dexamethasone|500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
41292707|NCT02492750|BIOLOGICAL|Anakinra|Given SC
41292708|NCT02492750|DRUG|Dexamethasone|Given PO
41292709|NCT02492750|OTHER|Laboratory Biomarker Analysis|Correlative studies
41292710|NCT02492750|DRUG|Lenalidomide|Given PO
41292711|NCT02492750|OTHER|Placebo|Given SC
41292712|NCT02064218|DRUG|Anti-hypertensive drugs|
41292713|NCT00797927|DRUG|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
41292714|NCT00797927|OTHER|no intervention|keep the original conventional antipsychotic agent for 28 days
41292715|NCT02517112|OTHER|Parabolic flight|
41292716|NCT02517112|OTHER|Cardiovascular parameters measurements|with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
41292717|NCT02517112|DEVICE|3D-BCG sensor|
41292718|NCT05603286|PROCEDURE|Home-monitoring|Questionnaires for home-monitoring will be send to the participants 11 weeks after the baseline visit via e-mail using Castor EDC and can be completed using a computer, tablet or smartphone. Home-monitoring can be done together with a parent or guardian, if needed.
41292719|NCT01797029|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
41292720|NCT01797029|BIOLOGICAL|Placebo|A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
41292721|NCT01312792|OTHER|Amoxycilline, Cephradine followed by follow up on day 3|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
41292722|NCT01312792|OTHER|Injectable ampicillin followed by urgent referral|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
41292723|NCT01206595|DRUG|SKY0402|Single dose of SKY0402 administered as a nerve block
41292724|NCT01206595|DRUG|Bupivacaine HCl|Single dose of 125 mg administered as a nerve block
41292725|NCT02964104|DRUG|Insulin icodec|Administered once weekly subcutaneously (s.c., under the skin) for 35 days
40958241|NCT04923061|OTHER|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected four different points will also be applied to the other extremity, a total of 16 minutes of compression will be applied to each point, provided that it is two minutes. Each nurse's session will be approximately 20 minutes, depending on the preparation and compression time on each point.
40958242|NCT04923061|OTHER|Sham acupressure group|In the sham group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
40958243|NCT02027961|BIOLOGICAL|Durvalumab|Intravenous dose of 3 or 10 mg/kg durvalumab.
40958244|NCT02027961|DRUG|Dabrafenib|Oral dose of 150 mg dabrafenib capsule.
40958245|NCT02027961|DRUG|Trametinib|Oral dose of 2 mg trametinib tablet.
40958246|NCT01577680|DRUG|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
40958247|NCT01577680|DRUG|Inhaled GSK573719|All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
40958248|NCT02269306|DRUG|clomiphen citrate|The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
41455787|NCT02833428|DEVICE|Biomedical equipment (Eclipse Nim, Medtronic®)|"It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.~• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma."
40763389|NCT06641102|OTHER|Coach Assisted Program (Tier 3)|"The study intervention is a smartphone application.~Tier 3: one-on-one coaching program that sets users up with trained PRT coaches who will walk them through the program individually. Users will meet with the assigned coaches once per week for an hour-long Zoom-hosted session that covers the same information as Tier 1, however in a completely personal and individualized way, focusing on the content that is most relevant for the user/patient at the time of the session. Tier 3 users will also receive materials from their coaches (e.g. videos, meditations, etc.) to support their own practice between session."
40958249|NCT06533722|DRUG|Gemcitabine, Vinorelbine, or Eribulin|Gemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days
40958250|NCT05768217|BEHAVIORAL|Community Resiliency Collective Efficacy Intervention (CRCEI)|The Community Resiliency Collective Efficacy Intervention (CRCEI) will involve community members in dialogue on thriving, community leadership, and organizing for social change. Participants in the intervention condition will be asked to participate in 2 sessions of discussions about community thriving and a 7-week training program on the following topics: Building on the Strengths of Your Community, Collective Efficacy and its Effects on Violence Prevention \& Community Mental Health, Non-threatening Peaceful Intervention Principles and Strategies: Part One, Non-threatening Peaceful Intervention Principles and Strategies: Part Two, Safety and Roles of Police and Community in Intervening, Active/Effective listening and non-violent communication skills, and Community Resources and Indirect Intervention.
41292726|NCT02964104|DRUG|placebo|Administered once daily subcutaneously for 35 days
41292727|NCT02964104|DRUG|insulin degludec|Administered once daily subcutaneously for 35 days
41455788|NCT00398593|BEHAVIORAL|Range of electronic pill dispensers with alarms|Patients will be offered 1. Counselling with education and/or 2. Electronic reminders
41455789|NCT01608646|DRUG|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
40958251|NCT05768217|BEHAVIORAL|Health Education Sessions|Comparison neighborhoods will receive health education sessions across a variety of community-identified health topics as a control intervention. (9 sessions)
40958252|NCT04751331|BIOLOGICAL|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113)
40958253|NCT04751331|BIOLOGICAL|Saline|0.9% saline administered as an intravenous bolus
41292728|NCT02964104|DRUG|placebo|Administered once weekly subcutaneously for 35 days
41292729|NCT06092502|OTHER|Graded Motor Imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
41292730|NCT06092502|OTHER|Traditional Physiotherapy Program|This protocol included stretching and strengthening exercises
41292731|NCT03078673|OTHER|training intervention, motor skill training|cross country specific motor skill strength training
41292732|NCT03078673|OTHER|training intervention, maximal strength training|general maximal strength training
41292733|NCT03078673|OTHER|control group|regular training
41292734|NCT05091060|DEVICE|Erchonia HLS|56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.
41292735|NCT03304483|OTHER|246-km running|Spartathlon 2017
40958254|NCT00324909|DRUG|Hyperbaric Oxygen Therapy|
41292736|NCT01108991|BEHAVIORAL|Physical activity self-management|This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.
40958255|NCT02840955|DEVICE|Staphefekt SA.100|
40958256|NCT02840955|OTHER|Placebo|
40958257|NCT02053051|DEVICE|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
40958258|NCT02053051|DEVICE|Standard bolus calculator|
40958259|NCT06246929|BEHAVIORAL|MBCT+w|MBCT+w uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The MBCT+w sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with 90-minute weekly meetings that will focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. MBCT+w uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
40958260|NCT06246929|BEHAVIORAL|ALED|ALED is a behavior change program. ALED offers different options to traditional exercise program to help participants overcome barriers to physical activity and increase their physical activity. The format is a 12-week program with 60-minute sessions that include a short lecture and group discussions to help participants set goals, decrease barriers to exercise, and find an activity they enjoy. The ALED program is conducted in the same format as MBCT+w, but participants are not taught the mind-body, walking or cognitive-behavioral skills. ALED will also use a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
40958261|NCT05018975|DRUG|Tazemetostat|Tazemetostat 800mg BID PO dosing for 15 days
40958262|NCT03562533|DRUG|pegylated liposomal doxorubicin (PLD) + carboplatin (CD)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
40958263|NCT03562533|DRUG|carboplatin + paclitaxel (CP)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
40958264|NCT03884491|DRUG|Vortioxetine IV|an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours
40958265|NCT03884491|DRUG|Vortioxetine SLA|5-25 mg of sublingual formulation A of vortioxetine
41292737|NCT01108991|OTHER|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
41292738|NCT00001761|DRUG|Interleukin-10|
41292739|NCT02619240|PROCEDURE|bronchoscopy|performance of bronchoscopy with BAL
41292740|NCT00006346|PROCEDURE|psychosocial assessment and care|
41455790|NCT03209167|BEHAVIORAL|Questionnaire|Two study-specific questionnaires
40763390|NCT06641102|OTHER|Standard of Care (SOC)|SOC is defined as a comprehensive clinical care plan, including a consultation with physiatrist and prescribed interventions, which will capture a comparison representative of all potential interventions that are recommended for an individual.
40958266|NCT03884491|DRUG|Vortioxetine SLB|5-25 mg of sublingual formulation B of vortioxetine
41292741|NCT00006346|PROCEDURE|quality-of-life assessment|
41292742|NCT04853797|DRUG|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
41292743|NCT04853797|DRUG|Ivabradine|15 mg oral Ivabradine.
41292744|NCT04853797|DRUG|Placebo|Oral placebo (calcium supplements).
41292745|NCT03078101|DRUG|Empagliflozin 10 MG [Jardiance]|administered orally once daily
41292746|NCT03078101|DRUG|Placebo Oral Tablet|administered orally once daily
41292747|NCT02940886|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
41292748|NCT02940886|DRUG|Iron sucrose|"Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial.~Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended."
41455791|NCT04865120|OTHER|cream cyclic merocyanine|cream long-UVA absorber
41455792|NCT04865120|OTHER|placebo|placebo
41455793|NCT01253564|DRUG|RO5185426|960 mg b.i.d. orally
40958267|NCT03884491|DRUG|Vortioxetine SLC|formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg
40958268|NCT05419999|DEVICE|Soterix 1x1 tDCS mini CT|During stimulation, a current flows between the electrodes passing through the brain to complete the circuit. tDCS is hypothesized to modulate intrinsic neuronal activity by enhancing neuronal resting potential, or altering the likelihood that a neuron will (or will not) depolarize.
41455794|NCT03334734|DRUG|PBTZ169|Once a day for 14 days
41455795|NCT03334734|DRUG|Isoniazid|Once a day for 14 days
40958269|NCT05419999|OTHER|Sham Soterix 1x1 tDCS Mini CT|Sham setting is used on the Soterix transcranial electrical stimulator
40958270|NCT05419999|BEHAVIORAL|Written Exposure Therapy (WET)|An exposure-based, behavioral psychotherapy for PTSD.
40958271|NCT00141843|GENETIC|ReFacto AF|
40958272|NCT00141843|GENETIC|B-Domain deleted Recombinant Factor VIII|
40958273|NCT00141843|GENETIC|BDDrFVIII|
40958274|NCT05241912|DRUG|Dobutamine|administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
40958275|NCT04534582|DRUG|HLX14|healthy volunteers receive HLX14 (60mg) once
40958276|NCT04534582|DRUG|EU-Prolia®|healthy volunteers receive EU-Prolia® (60mg) once
40958277|NCT04534582|DRUG|US-Prolia®|healthy volunteers receive US-Prolia® (60mg) once
40958278|NCT04534582|DRUG|CN-Prolia®|healthy volunteers receive CN-Prolia® (60mg) once
40958279|NCT01815801|OTHER|Lungs were not mechanically ventilated during subclavian vein catheterization|Control group
40958280|NCT01815801|OTHER|Lungs were mechanically ventilated during subclavian vein catheterization|Ventilated group
40958281|NCT01667484|DRUG|Adderall XR 5mg|
40958282|NCT01667484|DRUG|Adderall XR 10 mg|
41292749|NCT03731416|PROCEDURE|GBR by xenograft and autogenous bone|Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
41292750|NCT03278730|DRUG|Para-Tyrosine supplementation|Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
41292751|NCT03278730|DRUG|Placebo solution|Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
41292752|NCT04157660|PROCEDURE|Oxygen application|Oxygen application Supplemental oxygen via mask
41292753|NCT04157660|PROCEDURE|Sham room air|Room air will be applied via mask
41292754|NCT02042131|BEHAVIORAL|Treatment As Usual (TAU)|
41292755|NCT02042131|BEHAVIORAL|Standard Crisis Response Plan (S-CRP)|
41292756|NCT02042131|BEHAVIORAL|Enhanced Crisis Response Plan (E-CRP)|
41292757|NCT05603910|DRUG|Lenvatinib|Lenvatinib capsules taken daily by mouth
41292758|NCT05603910|DRUG|Pembrolizumab|200 mg Pembrolizumab administered intravenously (IV) once on Days 1, 22 and 43.
41455796|NCT03431493|BEHAVIORAL|Behavioral Activation - Rehabilitation|"Participants will first receive a home visit from a physical therapist (PT) who will evaluate home safety and establish/verify the participant's exercise prescription. Within 1 week, an occupational therapist (OT) will visit the home to: 1) explain the purpose of behavioral activation (BA); 2) help the participant identify long-term recovery goals regarding valued activities; and 3) then, using the principles of BA, identify short-term goals for the next week and an action plan. The OT will then call the participant weekly (weeks 2-5) to review the status of the prior week's goals and use BA to set new goals for the upcoming week. The PT and OT will repeat home visits at week 6 to assess the participant's progress, and the OT will conduct phone calls every 2 weeks for weeks 8-12."
41455797|NCT02331823|DRUG|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
40763391|NCT06642701|DEVICE|Electrical Impedance Tomography|According to the results of traditional assessment, physiotherapists and clinicians discussed the EIT results to give respiratory rehabilitation chest physiotherapy
40958283|NCT01667484|DRUG|Placebo|
40958284|NCT00986830|DEVICE|FinESS Sinus Treatment|
40958285|NCT01317485|PROCEDURE|Laparoscopic lavage and drainage|"\[CLOSED\] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~\*\*\*This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues"
41292759|NCT05603910|RADIATION|Hypofractionated External Beam Radiation Therapy|HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks.
41292760|NCT04921436|PROCEDURE|cardiac surgery|prophylactic use of antibiotic-inhibitors
41292761|NCT00002195|DRUG|Amprenavir|
41292762|NCT00002195|DRUG|Lamivudine|
41292763|NCT00002195|DRUG|Zidovudine|
41292764|NCT02563873|DEVICE|Tailored pacemaker settings|Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
41292765|NCT00063648|BIOLOGICAL|EBV-specific autologous CTL|
41292766|NCT02747043|BIOLOGICAL|ABP 798|ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
41292767|NCT02747043|BIOLOGICAL|Rituximab|Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100-mg/10 mL or 500-mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
41292768|NCT00000455|DRUG|naltrexone|
41292769|NCT02046915|DRUG|Imnovid (pomalidomide)|
41292770|NCT02046915|DRUG|Dexamethasone|
41292771|NCT02046915|DRUG|Endoxan (Cyclophosphamide)|
41292772|NCT02517047|DEVICE|CareTRx|CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
40958286|NCT01317485|PROCEDURE|Sigmoidectomy with primary anastomosis|\[OPEN\] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
41292773|NCT01019590|DRUG|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
41292774|NCT01019590|DRUG|Benicar HCT ® Tablets 40 mg/25 mg|
41292775|NCT02146807|DEVICE|Picosecond Laser system|Picosecond Laser System for the Treatment of Unwanted Tattoos
41292776|NCT04737122|DRUG|LM-061|Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.
41292777|NCT04737122|DRUG|Toripalimab|For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks
41292778|NCT05805085|DEVICE|Lens A (Hydrogel Daily Disposable Toric Contact Lens)|15 minutes
41455798|NCT02331823|DRUG|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
41455799|NCT06176560|DRUG|Mesalazine|Oral Formulation
41455800|NCT02125760|OTHER|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
41292779|NCT05805085|DEVICE|Lens B (Silicone Hydrogel Daily Disposable Toric Contact Lens)|15 minutes
41292780|NCT00898053|OTHER|laboratory biomarker analysis|Correlative studies
41292781|NCT01988012|BIOLOGICAL|tocilizumab|162 milligram (mg) administered subcutaneously once weekly for 24 weeks
41292782|NCT02241512|DRUG|Ibuprofen|
41455801|NCT02125760|OTHER|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
41455802|NCT01152112|DEVICE|Myomectomy|Removal of fibroids and / or polyps
41455803|NCT02965898|DIETARY_SUPPLEMENT|Vitamin D 100ug|Vitamin D 100 ug from Orion Pharma. Safest highest daily dose of vitamin D.
41455804|NCT02965898|DIETARY_SUPPLEMENT|Vitamin D 10ug|Placebo dose. Minimal recommended dose.
41455805|NCT04229160|DEVICE|Noninvasive mapping (Cardioinsight® system)|Noninvasive mapping (Cardioinsight® system) of the left atria before the Atrial fibrilation ablation procedure
41455806|NCT04229160|DEVICE|long-term cardiac monitoring (LINQ system)|long-term cardiac monitoring (LINQ system) is used to evaluate recurrence rate following AF ablation procedure
41292783|NCT02241512|DRUG|placebo|
41292784|NCT04743414|DRUG|CTP-543|Itraconazole in solution dosage form
41292785|NCT04904146|DIAGNOSTIC_TEST|Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.|The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.
41292786|NCT02805907|DRUG|Calcifediol|
41292787|NCT02805907|DRUG|Placebo|
41292788|NCT06258629|DIAGNOSTIC_TEST|Flowcytometry on bone marrow aspiration|Flowcytometry on bone marrow aspiration
41292789|NCT04921722|DRUG|Percutaneous sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In experimental group, we administrate percutaneous sirolimus. Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
41292790|NCT04921722|DRUG|Oral sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In active comparator group, we administrate oral sirolimus. Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
41292791|NCT01726777|DIETARY_SUPPLEMENT|Control|Normal cheddar cheese
41292792|NCT01726777|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 supplemented cheddar cheese
41292793|NCT05037903|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive and behavioral interventions aimed at increasing behavioral activation, and reducing procrastination and inattentive symptoms.
41455807|NCT04229160|PROCEDURE|Atrial Fibrillation ablation procedure|Atrial Fibrillation ablation procedure is done with standard practice
41455808|NCT04714060|BIOLOGICAL|UB-621|mAb by SC administration
41455809|NCT03647722|OTHER|Assessment of leukocyte function.|The function and phenotype of regulatory B-cells, regulatory T-cells and alternatively-activated monocytes will be assessed directly ex vivo from PBMC.
41455810|NCT01291862|DEVICE|Watchpat 100|Watchpat 100 is a noninvasive portable sleep monitoring device which monitors peripheral arterial tone, pulse, oxygen saturation, snoring, and body position. Patient places one probe at his or her finger and another sensor at front of the chest and Watchpat 100 monitors the patient overnight.
41292794|NCT01495546|OTHER|Early loading|Patients stepping down immediately after THA
41292795|NCT01495546|OTHER|Late loading|Patients stepping down after three weeks of HTA
41292796|NCT05427682|DRUG|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule on Day 1
41292797|NCT04499508|DEVICE|Optima Coil System|Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with
41292798|NCT02255591|DRUG|Lidocaine-adrenaline added gadolinium.|
41292799|NCT05547373|BEHAVIORAL|Infection prevention and control (IPC)|The intervention will be developed by matching behavioral change components identified in the gap analysis stage with the intervention components extracted from a systematic review. The investigators will use the Behavior Change Wheel (BCW) model as a guide to design this infection control prevention and control intervention. In brief, the intervention development processes will follow eight steps based on the BCW. The steps will include defining the problem in behavioral terms, selecting the target behaviors, specifying the target behaviors, identifying what needs to change, identifying intervention functions, identifying policy categories, identifying behavior change techniques, and identifying the mode of delivery.
41455811|NCT05698316|DIAGNOSTIC_TEST|Collection of both retrospective and prospective data collection in 3 visits.|3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.
41292800|NCT04869579|DRUG|Selenium (as Selenious Acid)|Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.
41292801|NCT04869579|OTHER|Placebo|Active comparator arm participants will receive the standard of care therapy plus a Saline-based placebo.
41292802|NCT04389801|DRUG|Desferal 500 MG Injection|iron chelating agent
40958287|NCT01317485|PROCEDURE|Sigmoidectomy with end-colostomy|\[OPEN\] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
40958288|NCT04779125|PROCEDURE|Gluteus plasty enhanced with Progrip self gripping mesh|Intervention group will be compared to historical patients in a case-control setting. Intervention group will have a mesh enhanced gluteus plasty made to reconstruct perineum after abdominoperineal resection.
40958289|NCT00991731|BEHAVIORAL|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
40958290|NCT00991731|BEHAVIORAL|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
40958291|NCT05047835|DIAGNOSTIC_TEST|electrocardiogram|Prone position electrocardiogram
40958292|NCT01204554|DRUG|Indocyanine green (ICG)|a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
40958293|NCT04147702|OTHER|Balance analysis|Balance analysis is assessment method to estimate deterioration of postural control.
40958294|NCT00362310|DRUG|indinavir|
40958295|NCT00945893|BIOLOGICAL|MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]|0.5 mL; (intranasal sprayer)
40958296|NCT00945893|OTHER|Placebo|(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
40958297|NCT01446978|BIOLOGICAL|hepatitis A vaccine|3 doses of hepatitis A vaccine, given at 0+1+6 months
40958298|NCT01446978|BIOLOGICAL|hepatitis A vaccine|Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
40958299|NCT02296320|DRUG|MEDI4893|Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
40958300|NCT02296320|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
40958301|NCT06129175|BIOLOGICAL|Neuroncell-EX|Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.
40958302|NCT06129175|OTHER|Placebo|Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.
40958303|NCT03875404|DIAGNOSTIC_TEST|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
40958304|NCT06166589|DRUG|Zimberelimab|Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
40958305|NCT06166589|DRUG|Oxaliplatin|Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.
40958306|NCT06166589|DRUG|S-1|S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.
40958307|NCT06166589|DRUG|Irinotecan|Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.
40958308|NCT02609009|OTHER|Spinal Manipulation Therapy|Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
40958309|NCT02609009|OTHER|Usual Medical Care|Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
40958310|NCT04868214|DEVICE|coagulation measurements|peak and trough coagulation measurements of patients treated with Xarelto, Eliquis, or Lixiana and coagulation measurements of healthy proband blood spiked with eiter Xarelto, Eliquis or Lixiana.
41292803|NCT04109443|BEHAVIORAL|Young Men & Media Program|The online sexual health media literacy website includes content about (1) male anatomy; (2) HIV/STI prevention; (3) overall sexual health; and (4) sexually explicit online media (SEOM) literacy.
41292804|NCT04109443|BEHAVIORAL|Available websites on safe sex and preventing STIs|Available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections (STIs) including HIV.
41292805|NCT01160367|OTHER|TAILORED Patient Family Decision Making|Patient-family dyads will receive TAILORED intervention on health decision making
41292806|NCT01160367|OTHER|standard of care|Patient-family dyads will receive standard of care in health decision-making
41455812|NCT03284138|DEVICE|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
41455813|NCT03284138|DEVICE|placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
41455814|NCT01614288|PROCEDURE|knee Arthroscopy|Patient undergoes a knee arthroscopy and HTO
41455815|NCT01614288|OTHER|No arthroscopy|Patient undergoes an HTO without knee arthroscopy
41292807|NCT05695846|DEVICE|externally applied cricoid cartilage pressure|
41292808|NCT05953740|DRUG|MK-5720|MK-5720 IM injection
41292809|NCT05953740|DRUG|Placebo to MK-5720|Placebo matched to MK-5720 IM injection
41455816|NCT05547048|BEHAVIORAL|Decision Aid|Decision aid for PrEP tailored for justice-involved women with opioid use disorder
40958311|NCT03352349|DRUG|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
40763392|NCT06642701|BEHAVIORAL|chest physiotherapy|Conventional assessment by physical therapists was followed by respiratory rehabilitation chest physiotherapy.Chest physical therapy for respiratory rehabilitation includes postural drainage, cough technique, forced expiratory technique, positive expiratory pressure, high-frequency chest wall compression, chest tapping, vibration, active breathing cycle technique, etc. All chest physiotherapy was performed by 1 therapist.
40763393|NCT02973022|OTHER|CC&S|Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC\&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
40958312|NCT03549169|BEHAVIORAL|TOMAS|Intervention focused on decision making for the management of symptoms aimed at adults with heart failure.
40958313|NCT03549169|BEHAVIORAL|Regular attention|Regular attention focused on education for therapeutic adherence
40958314|NCT02539446|BEHAVIORAL|stable condition|
40958315|NCT02539446|BEHAVIORAL|unstable condition|
40958316|NCT02539446|BEHAVIORAL|attentional focus|
40958317|NCT00000842|DRUG|Nerve Growth Factor, Recombinant Human|
40958318|NCT02222740|DRUG|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
40958319|NCT02222740|DRUG|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
40958320|NCT03147677|DRUG|Alfacalcidol|
40958321|NCT03147677|DRUG|Irbesartan|
41292810|NCT05953740|DRUG|MK-8189|MK-8189 tablet taken by mouth
40958322|NCT01137396|DRUG|Modafinil|Modafinil 400mg PO QDaily following up-titration for \~8weeks
40958323|NCT01137396|BEHAVIORAL|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
40958324|NCT04465110|DIETARY_SUPPLEMENT|Grape Seed Extract|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day
40958325|NCT01927510|BEHAVIORAL|Early mobilisation|
40958326|NCT03736733|OTHER|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
40958327|NCT03736733|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
41292811|NCT05953740|DRUG|Placebo to MK-8189|Placebo tablet matched to MK-8189
41292812|NCT03749993|OTHER|Screening|Use of bpMRI for opportunistic prostate cancer screening.
40958328|NCT04079946|PROCEDURE|Total Mesocolic Excision with Central Vessel Ligation|sharp dissection of the anatomical layers and the dissection of the visceral plane from the parietal one . In addition a central division of the feeding arteries at their origins is performed at the level of superior mesenteric artery for tumors of the right colon and at the level of inferior mesenteric artery or the aorta for tumors of the left colon .this allows for removal of the maximum number of lymph nodes possible.
40958329|NCT04079946|PROCEDURE|conventional surgery of cancer colon|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
40958330|NCT02044393|DRUG|itraconazole|multiple doses of itraconazole given as capsules
40958331|NCT02044393|DRUG|BI 691751|single dose BI 691751 given as tablet
40958332|NCT02044393|DRUG|BI 691751|single dose BI 691751 given as tablet
40958333|NCT05903170|DEVICE|360J LifePak Monitor/Defibrillator|The LifePak Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 360J.
40958334|NCT05903170|DEVICE|200J Philips HeartStart MRx Monitor/Defibrillator|The Philips HeartStart MRx Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 200J.
41292813|NCT04788719|OTHER|Gait analysis|Gait analysis
41292814|NCT01742962|PROCEDURE|Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
40763396|NCT03489083|OTHER|Strength training|Strength training was performed three times per week for twelve weeks. Supervised (by qualified sport and exercise scientists) exercise was performed in a gym on three non-consecutive days of the week. Each session lasted \~60 min and consisted of a warm up, the resistance exercise training and a cool down. The training programme consisted of a combination of upper and lower body exercises using gym equipments, free weights and body weight as the primary resistance. The twelve weeks of strength training were divided into three mesocycles of four weeks each. The resistance training was performed using two to three sets per exercise at intensities between 12-15 repetition maximum-RM.
40958335|NCT05259514|DEVICE|CytoSorb|The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
40958336|NCT03219138|DEVICE|Acceleromyography|Use of an uncalibrated acceleromyography
40958337|NCT01832974|DRUG|IL-13-PE|IL-13-PE intravenous infusion
40958338|NCT04782661|DRUG|JNJ-70075200|JNJ-70075200 solution or solid formulations will be administered orally.
40958339|NCT04782661|DRUG|Placebo|Placebo solution will be administered orally.
41292815|NCT00450866|BIOLOGICAL|epothilone B|Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
41455817|NCT05547048|COMBINATION_PRODUCT|Athena strategy|eHealth for integrated PrEP/medications for opioid use disorder + decision aid
40958340|NCT03756077|DIAGNOSTIC_TEST|68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT|0.05-0.06 mCi per kilogram bodyweight of 68Ga-PSMA, 0.1-0.15 mCi per kilogram bodyweight of 18F-FDG will be injected intravenously prior to imaging
40958341|NCT04969575|OTHER|Insemination and culture|All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.
40958342|NCT04969575|OTHER|Media refreshment Group 1|Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3).
40958343|NCT04969575|OTHER|Culture media preparation and refreshment|"30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator."
40958344|NCT04969575|OTHER|Embryo grading|Should be done prior to media refreshment. For group 2, embryo grading and media refreshment is done prior to blastocyst biopsy.
40958345|NCT04969575|OTHER|Media refreshment Group 2|Zygote scoring on day 1 (18-20hpi). Culture media refreshment will be done 114-118 hours post insemination (Day5).
40958346|NCT02256657|BEHAVIORAL|Quality Improvement Toolkit|The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
40958347|NCT03607487|DRUG|INCB054707|INCB054707 tablet administered orally once daily at the protocol-defined dose.
40958348|NCT03607487|DRUG|Placebo|Placebo tablet administered orally once daily.
40958349|NCT05899088|OTHER|Mindful Movement|Mindful Movement Program with Researcher Follow-up
40958350|NCT00887874|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
40958351|NCT01216761|DRUG|Iodine tincture|Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
40958352|NCT01216761|DRUG|Chlorhexidine gluconate|2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)
40958353|NCT01216761|DRUG|Povidone iodine|10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
40958354|NCT00853775|OTHER|No intervention, observational study|
40958355|NCT01352546|BIOLOGICAL|BOTOX|150 units of Botox injected intravaginally into the bulbocavernosum, pubococcygeus and puborectalis muscles along the lateral side walls, left and right as a one time injection under anesthesia.
40958356|NCT02425371|OTHER|Screening and treatment of comorbidities|Screening and treatment of comorbidities
40958357|NCT02425371|OTHER|Placebo Comparator|No screening of comorbidities
40958358|NCT05795075|PROCEDURE|Computerized Modified Paramedian Approach Technique|Computerized Modified Paramedian Approach Technique ( CMPAT )
40958359|NCT05795075|PROCEDURE|Conventional Midline Approach Technique|Conventional Midline Approach Technique
40958360|NCT01268969|PROCEDURE|KARYDAKIS GROUP|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
40958361|NCT01268969|PROCEDURE|Lamberg flap technique|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
40958362|NCT04795960|DIETARY_SUPPLEMENT|Low serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
41292816|NCT03199092|BEHAVIORAL|RRT+sat|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. For this study, RRT was delivered in combination with a specific auditory training involving several music games specifically designed for improving auditory processing abilities typically compromised in children with DD.
40958363|NCT04795960|DIETARY_SUPPLEMENT|High serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
40958364|NCT00724932|DRUG|Rocuronium|Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
41292817|NCT03199092|BEHAVIORAL|Abilmente|'Abilmente' method is an intervention for DD that comprises several validated treatments resulting in a proposal tailored to meet individual needs and features.
41292818|NCT02422043|OTHER|Questionnaires and audio-tape interviews|therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
41292819|NCT00001693|DRUG|Celecoxib (SC-58635)|
40958365|NCT00724932|DRUG|Sugammadex|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
41292820|NCT02729311|BEHAVIORAL|Paired PLIÉ Program|The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
40958366|NCT00724932|DRUG|Neostigmine|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
41455818|NCT01368354|BEHAVIORAL|CLTS|CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
40958367|NCT00724932|DRUG|Atropine|After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
40958368|NCT02791997|OTHER|Neuropsychological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
40958369|NCT02791997|OTHER|Neurophysiological tests|Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.
40958370|NCT00822042|OTHER|Samples and procedures|"* Scanner, histomorphometry : at the inclusion and M3 visits~* whole blood samples, cytoponction : at the inclusion and M3 visits"
40958371|NCT04497831|DRUG|Morphine hydrochloride|5 mg milligram(s) per day per two days of dosage
40958372|NCT04497831|DRUG|Placebo|Inhalation use
40958373|NCT04253262|DRUG|Rucaparib|Rucaparib (PO twice daily continuous)
40958374|NCT04253262|DRUG|Copanlisib|Copanlisib (IV day 1, 8, 15; 28 day cycle)
40958375|NCT06254651|OTHER|High resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's xiphoid process in a neonatal manikin.
40958376|NCT06254651|OTHER|Low resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's superior anterior iliac spines in a neonatal manikin.
40958377|NCT04171440|PROCEDURE|robotic pancreaticoduodenectomy|The robotic pancreaticoduodenectomy is performed through small incisions using robotic-assisted technology. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater.
40958378|NCT01593657|OTHER|Mindful Movement and Breathing program|Participate Mindful Movement and Breathing program with an experienced yoga instructor. All movements can be done while in a bed (e.g. turning head, shrugging shoulders, bending knees, etc). Each session lasts approximately 15 minutes.
40958379|NCT01593657|OTHER|Questionnaire administration|Collected at baseline (before surgery), before and after each YST session, and at follow-up (two days after surgery).
40958380|NCT01593657|PROCEDURE|The Observer Mobility Scale|Conducted by nurse and study coordinator prior to surgery and two days after surgery to assess mobility. Will ask patient to turn, sit, stand and walk as they are able.
41292821|NCT05908383|DRUG|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
41455819|NCT00856622|DRUG|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
41455820|NCT00856622|DRUG|timolol 0.5% ophthalmic solution|one drop in the morning and evening
41455821|NCT00856622|DRUG|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
41455822|NCT06063291|DRUG|ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
41455823|NCT06063291|DRUG|Placebo of ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
41455824|NCT02684292|BIOLOGICAL|pembrolizumab|IV infusion
41455825|NCT02684292|BIOLOGICAL|brentuximab vedotin|IV infusion
41455826|NCT05244213|BIOLOGICAL|Sintilimab|200mg Q3W
41455827|NCT05244213|DRUG|Carboplatin|AUC 5, d1 every 3 weeks
41455828|NCT05244213|DRUG|Nab paclitaxel|260 mg/m2, d1 every 3 weeks
40958381|NCT01593657|PROCEDURE|Volumetric Incentive Spirometry|Conducted twice before and after each Mindful Movement and Breathing program to measure lung function. Mean of the two readings used.
40958382|NCT02352129|OTHER|CMR using T1 mapping technique|the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
40958383|NCT00967057|DRUG|asparaginase|Given intramuscularly
40958384|NCT00967057|DRUG|dexamethasone|Given orally
40958385|NCT00967057|DRUG|idarubicin|Given IV
40958386|NCT00967057|DRUG|methotrexate|Given intrathecally
40958387|NCT00967057|DRUG|mitoxantrone hydrochloride|Given IV
40958388|NCT00967057|DRUG|pegaspargase|Given intramuscularly
40958389|NCT00967057|DRUG|vincristine sulfate|Given IV
40958390|NCT02114671|DRUG|Faldaprevir high dose|capsules, oral
40958391|NCT02114671|DRUG|Placebo|capsule, oral
40958392|NCT02114671|DRUG|Ciprofloxacin|tablets, oral
40958393|NCT02114671|DRUG|Faldaprevir low dose|capsules, oral
40958394|NCT05442814|PROCEDURE|Posterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by posterior approach
40958395|NCT05442814|PROCEDURE|Anterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by anterior approach
40958396|NCT03348150|PROCEDURE|Cytoreductive surgery + Gastrecomy|Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.
40958397|NCT03348150|DRUG|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)
40958398|NCT04205968|DRUG|Fluorouracil|Given IV bolus or IV
40958399|NCT04205968|DRUG|Irinotecan|Given IV
40958400|NCT04205968|DRUG|Irinotecan Hydrochloride|Given IV
40958401|NCT04205968|DRUG|Leucovorin|Given IV
40958402|NCT04205968|DRUG|Leucovorin Calcium|Given IV
40958403|NCT04205968|DRUG|Paclitaxel|Given IV
40958404|NCT04205968|BIOLOGICAL|Ramucirumab|Given IV
40958405|NCT01198678|DIETARY_SUPPLEMENT|Boost Nutritional Supplement|Boost- Nutritional Supplement
40958406|NCT05618860|OTHER|Questionnaire|eligible participants in the radiology department waiting rooms will be asked to complete a questionnaire after taking consent.
40958407|NCT00499499|DRUG|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m\^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
40958408|NCT00310167|RADIATION|radiation therapy|
40958409|NCT05679219|PROCEDURE|Structured Pes Planus Exercises|Structured pes planus exercise group; short foot exercise, towel picking exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, picking objects from the ground with the toes, balance exercises on one foot. the purpose of all these exercises; The aim is to increase the medial longitudinal arch by contracting the intrinsic muscles of the foot, and to improve the balance at the same time. Walking exercises will be performed in the form of 10 meters and 10 rounds, other exercises will be performed with 30 repetitions for both feet and the whole session will be 40 minutes in total.
40958410|NCT05679219|PROCEDURE|Wii Based Exergame|Wii-based exergame group, Nintendo wii game console balance games; In the literature, frequently used ones in different disease groups will be selected and played. In this context, Penguin Slide, Tightrople Tension, Tilt Table, Soccer Heading and Balance Bubble games will be played in each session under the supervision of an expert physiotherapist (executive), each game will be 8 minutes and the session will be 40 minutes in total. The motion sensor will be placed directly opposite the Balance Board. All games are played in a standing upright position on a double-footed Balance Board.
40958411|NCT05679219|PROCEDURE|Wii Based Serious Game|The lower extremity strengthening and balance exercises within the Becure Balance System, developed in cooperation with the Physiotherapist, Academician and Engineer, will be performed by the Wii-based serious game group through the Wii Balance Board. Three games, Balance Surf, Balance Adventure and Balance Maze, which are among the balance games within the Becure Balance System application, will be played for 40 minutes in each session under the supervision of an expert physiotherapist (executive). The Wii Balance Board will be connected via Bluetooth from the menu in the Becure application. Then the Person will stand on the Balance Board and transfer weight in four directions in line with the instructions of the game on the screen.
40958412|NCT01940601|DRUG|Balugrastim|Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
41135887|NCT04037033|BEHAVIORAL|Everyday Meaningful Activities (EMA) intervention|"The EMA intervention will include 6 intervention sessions. At session 1, the interventionist and participant will identify 2 meaningful active lifestyle behavior goals using COPM. Last, an action plan will be created for behavior 1. Participants will be asked to implement the action plan everyday.~At session 2, the interventionist and participants will review the daily activity log and the action plan.~At session 3, the interventionist and the participants will review the daily activity log and the action plan.~At session 4, an action plan will be created for behavior 2. Participants will be asked to implement the action plan for behavior 2 everyday.~At session 5, the participants and interventionists will discuss the participant's daily activity log and action plan.~At session 6, the participants and interventionists will discuss the participant's daily activity log and action plan."
41135888|NCT06065930|DEVICE|Subcutaneous microdialysis|"Group with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1."
40763397|NCT03489083|OTHER|No Training|"Control group performed a placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks. To avoid any significant adaptation, all stretching exercises (for large muscle groups only) were performed at very low intensity without any significant discomfort."
40763398|NCT05245058|DRUG|SPH5030 tablets|SPH5030 tablets orally once or twice daily.
40958413|NCT01940601|DRUG|Filgrastim|Filgrastim 5 μg/kg
40958414|NCT04721171|DEVICE|The Bridge device|he Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
40958415|NCT00795145|DRUG|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
40958416|NCT00795145|DRUG|Linezolid 900 mg|Intravenous, 900 mg linezolid, single dose
40958417|NCT00795145|DRUG|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
40958418|NCT00795145|DRUG|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
40958419|NCT00795145|DRUG|Linezolid 600 mg|Intravenous, 600 mg linezolid, single dose
40958420|NCT00795145|DRUG|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
40958421|NCT00795145|DRUG|Moxifloxacin 400 mg|Oral, 400 mg moxifloxacin, single dose
40958422|NCT01437969|GENETIC|genotyping and/or sequencing|genotyping and/or sequencing DNA for IL28
40958423|NCT05406141|DIETARY_SUPPLEMENT|Amino acid formula (Neocate Jr)|"Use Neocate Jr for 4 weeks, either as sole source of nutrition or oral nutritional supplement:~* Sole source of nutrition: as far as possible \>7 days, especially newly diagnosed allergy children~* Oral nutritional supplement (Neocate Jr ≥50% of daily total energy and the rest provided by food)"
40958424|NCT02624752|DIETARY_SUPPLEMENT|Ensure|Comparison of enhanced oral nutrition supplementation versus standard of care
40958425|NCT06273462|DRUG|Palmitoylethanolamide 600mg twice a day|600mg palmitoylethanolamide twice a day
40958426|NCT06273462|OTHER|placebo|visually identical placebo capsule
40958427|NCT02384486|BEHAVIORAL|Training to Reduce Stress in Mothers of Children with (ASD)|The main objective of the proposed study is to examine the effect of implementing the proposed intervention on stress in mothers of children with ASD in SA
40958428|NCT02384486|OTHER|Nothing (treatment as usual)|Mothers in the control group will continue to receive treatment as usual during the trial
40958429|NCT05367492|DRUG|Double Blind Varenicline|"For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks"
40958430|NCT05367492|DRUG|Double Blind Placebo|"For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old, regardless of weight:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks"
40958431|NCT05367492|BEHAVIORAL|QuitVaping|QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
40958432|NCT05367492|BEHAVIORAL|This Is Quitting|A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
40958433|NCT03039140|OTHER|Educational Intervention|Attend weekly educational sessions
40958434|NCT03039140|BEHAVIORAL|Exercise Intervention|Participate in CR program
40958435|NCT03039140|OTHER|Quality-of-Life Assessment|Ancillary studies
40958436|NCT03039140|OTHER|Questionnaire Administration|Ancillary studies
40958437|NCT02000583|OTHER|Aerobic Exercise|Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
40958438|NCT02000583|OTHER|Standard of Care|Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
41292822|NCT05908383|OTHER|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
41292823|NCT01556633|DRUG|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers on dialysis
40763399|NCT06641921|DEVICE|Seerlinq haemodynamically-guided heart failure treatment|Heart failure treatment of participants in the Seerlinq intervention arm will be haemodynamically-guided based on the results from the Seerlinq telemedical monitoring system.
40958439|NCT02538029|BEHAVIORAL|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
40958440|NCT02538029|BEHAVIORAL|Single Task Group|Performing motor or cognitive tasks alone.
40958441|NCT02759783|RADIATION|SBRT|Patients will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC. All patients should commence SOC therapy within 4 weeks of completing SBRT treatment.
40958442|NCT02759783|OTHER|Standard of Care|Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
40958443|NCT04722887|BIOLOGICAL|Alpha-1 15%|Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous infusion
40958444|NCT04722887|BIOLOGICAL|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion
40958445|NCT00330746|DRUG|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
41135889|NCT03205488|DRUG|Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)|2 capsules taken once daily
41292824|NCT01556633|DRUG|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
40763400|NCT06300528|DRUG|Pemigatinib|Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.
40763401|NCT06636331|OTHER|Continuous Suprainguinal Fascia Iliaca Compartment Block|Using PCRA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
40958446|NCT00330746|DRUG|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
40958447|NCT00330746|DRUG|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
40958448|NCT00330746|DRUG|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
41135890|NCT03205488|DRUG|Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)|2 capsules taken once daily
41135891|NCT03205488|DRUG|Placebo|2 capsules taken once daily
41135892|NCT02005172|DEVICE|Alivecor monitor and 14 day event monitor|Alivecor monitor and 14 day event monitor
40958449|NCT04827381|OTHER|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
40958450|NCT04827381|OTHER|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
40958451|NCT02124525|DRUG|N-acetylcysteine|N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
40958452|NCT00765557|DRUG|MiraLAX|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
40958453|NCT00765557|DRUG|Placebos|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
40958454|NCT02564497|BIOLOGICAL|Process E Belatacept|
40958455|NCT02564497|BIOLOGICAL|Process C Belatacept|
40958456|NCT05820945|OTHER|Pharmacist-led medication review|Clinical review by a primary care pharmacist of the primary care clinical history and the pharmacological treatment plan. After the review process, a meeting will be held between the pharmacist and the responsible physician in order to present proposals for pharmacotherapeutic optimization.
40958457|NCT03434197|DRUG|Esflurbiprofen|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
40958458|NCT03434197|DRUG|Diclofenac diethylamine|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
40958459|NCT05232175|DRUG|ALT-BB4|Recombinant Hyaluronidase
40958460|NCT05232175|DRUG|0.9%NaCl|Normal Saline
40958461|NCT03854201|BEHAVIORAL|Personalized Exercise Counseling (PEC)|At the first counseling appointment, PEC-participants answer the physical activity (PA) questionnaire, perform fitness tests and discuss with their exercise instructor. The target is a personalized short-term PA plan including where and when the PA/exercise takes place and what is the mode. Participants may choose instructed group-exercise sessions provided by the municipal sports/leisure sector or exercising alone as preferred. The exercise instructors utilize the fitness test results and feedback data of the research accelerometers by the UKK Institute to guide the participants. The PEC includes 2 more face-to-face sessions and 4-6 phone calls by the instructors aimed at checking the realization of exercise plans and discussing the outcomes provided by the interactive accelerometer.
40958462|NCT06050148|BIOLOGICAL|Feacal microbial transplantation (FMT)|Feacal microbial transplantation (FMT)
40958463|NCT06050148|OTHER|Placebo transplantation (PT)|Transplantation with coloured 0,9% NaCl-solution
40958464|NCT02643680|DEVICE|The novel biocellulose wound dressing|The novel biocellulose dressing will used as a primary dressing at one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
40958465|NCT02643680|DEVICE|Bactigras|Bactigras will used as a primary dressing at another one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
40958466|NCT06178289|DEVICE|3M Cavilon Advanced Skin Protectant|3M Cavilon Advanced Skin Protectant is applied to the study area of partial-thickness wounds (IAD category 2A, peri-wound MASD, peri-stomal MASD). Application of the study device should be according to the manufacturer's IFU. Comprehensive training for nurses will be provided to the study nurses.
40958467|NCT06178289|DEVICE|Standard hospital wound treatment protocol|Comparator: Standard hospital wound treatment protocol
41292825|NCT01056523|DRUG|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
41292826|NCT01056523|DRUG|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
41292827|NCT00832715|PROCEDURE|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
41292828|NCT01198444|DRUG|EE/DRSP (Yasmin Product Family)|One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
40958468|NCT01898637|OTHER|Augmented pulse oximetry using incentive spirometer.|Augmented pulse oximetry using incentive spirometer.
40958469|NCT01898637|DEVICE|Incentive spirometer.|The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
40958470|NCT02758769|BIOLOGICAL|ORENCIA Subcutaneous Injection|
41292829|NCT06497426|OTHER|Study intervention|Participants will be asked to drink water. Water intake will be supervised by a nurse/nurse assistant/dietitian team to ensure adherence, and registered to assess intervention compliance.
41292830|NCT03729869|DRUG|Progesterone|200 mg of exogenous progesterone twice a day
41292831|NCT03729869|DRUG|Placebo|One dose of matched placebo twice a day.
41292832|NCT05725148|DEVICE|CART-I plus|CART-I plus is a ring-type medical device that continuously monitors Atrial Fibrillation, heart rate, oxygen saturation, and blood pressure using PPG and ECG signals.
41292833|NCT06094777|DRUG|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
41292834|NCT04807582|OTHER|PET/MRI|18F-fluoropivalate tracer injection followed by PET/MRI scan
41292835|NCT01968044|DRUG|Gemigliptin|
41292836|NCT01968044|DRUG|Placebo to Linagliptin|
41292837|NCT00635531|OTHER|placebo|Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam
41455829|NCT02463630|PROCEDURE|Posterior Approach Compression Distraction Reduction|Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
40958471|NCT01934946|OTHER|comprehensive rehabilitation|received 14 days hospitalization for comprehensive rehabilitation
40958472|NCT01934946|OTHER|home rehabilitation|6 times home rehabilitation services within 3 months
41455830|NCT01906190|BIOLOGICAL|seasonal influenza vaccine|subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
41135893|NCT05770115|PROCEDURE|Vicryl 1|Double layer closure with split thickness with vicryl 1, in continuous, non-locked, 1 cm apart sutures.
41135894|NCT05770115|PROCEDURE|Vicryl 2/0|Double layer closure with split thickness with vicryl 2/0, in continuous, non-locked, 1 cm apart sutures.
41135895|NCT04574206|BEHAVIORAL|Elaborative Reminiscence (ER)|Parents will be trained to use elaborative communication techniques in conversations with their child.
40763402|NCT06636331|OTHER|Continuous Epidural|Using PCEA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
40763403|NCT02523027|DIETARY_SUPPLEMENT|Oral nutritional supplement (List No S691/Z0)|(List No S691/Z0)
40763404|NCT02523027|DIETARY_SUPPLEMENT|Oral nutritional supplement|(List No- P968/Z0)
40763405|NCT02523027|OTHER|Dietary Counselling|Regular dietary counseling conducted by a trained hospital dietitian.
40958473|NCT02937675|DRUG|Tomivosertib (eFT-508)|eFT508
40958474|NCT04049760|DRUG|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
40763406|NCT06641869|DIETARY_SUPPLEMENT|procyanidin C1|Proprietarily extracted procyanidin C1
40763407|NCT06641869|DIETARY_SUPPLEMENT|Cellumiva|Cellumiva is a novel senolytic complex blend invented by Mrs. Patricia Mayer. It's a complext of grape seed extract(its key active component later identified asPCC1), Pterostilbene and Spermidine.
40763408|NCT06641869|DIETARY_SUPPLEMENT|Placebo|Placebo
40763409|NCT03637816|DRUG|Anamorelin Hydrochloride|Given PO
40763410|NCT03637816|OTHER|Placebo|Given PO
40763411|NCT03637816|OTHER|Questionnaire Administration|Ancillary studies
40958475|NCT01146665|BEHAVIORAL|Computer-based PAF|This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
40958476|NCT01146665|BEHAVIORAL|Computer-based Sham|This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
40763412|NCT03787147|DEVICE|Google Cardboard|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
40763413|NCT03787147|DEVICE|Oculus|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
40763414|NCT03787147|DRUG|Lidocaine Hydrochloride|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
40763415|NCT03787147|DRUG|Bupivacaine|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
40763416|NCT06638502|DRUG|HRX215 capsules|HRX215 capsules 250 mg orally twice daily
40763417|NCT06638502|DRUG|Placebo capsules|placebo capsules matching appearance of HRX215
40763418|NCT03320993|OTHER|Mixed meal with different macronutrient composition|A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
40763419|NCT05599321|DIAGNOSTIC_TEST|Virtual Navigation System|The Virtual Navigator guidance computer is interfaced to the bronchoscopy hardware to tap off the live bronchoscopy and EBUS video feeds. The standard OR medical team (technicians, clinical fellows, et al.) is on hand, and standard clinical facilities (e.g., fluoroscopy, CT/PET image viewer) are available. Our technical team is also present to record all procedural video and computer display information. It also operates the guidance computer during the guided procedure and offers any assistance in case of unanticipated issues. The participant's clinical bronchoscopy will be recorded by the radiology imaging management system.
40958477|NCT01070498|DRUG|Trichuris suis ova (TSO)|Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
41135896|NCT04574206|BEHAVIORAL|Present Tense Talk (PTT)|Parents will be trained to engage their children in conversations, describing activities as they are actually happening.
41135897|NCT00003259|DRUG|vinorelbine tartrate|
41135898|NCT06510972|PROCEDURE|Strategy for continuing oral intake|Patients will be able to ingest liquids or solid food orally, at any frequency and in any quantity they wish, according to their tolerance, with paramedical assistance if necessary.
41135899|NCT06510972|PROCEDURE|Fasting strategy|The patient will not be able to ingest liquids or solid food.
41135900|NCT02102724|DIETARY_SUPPLEMENT|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
41135901|NCT02102724|DIETARY_SUPPLEMENT|Placebo|Gelcaps that contain 1 gram of oleic sunflower oil
40763420|NCT05478837|DRUG|Cyclophosphamide|Given IV
40763421|NCT05478837|DRUG|Fludarabine|Given IV
40763422|NCT05478837|BIOLOGICAL|Autologous Anti-H3.3K27M TCR-expressing T-cells|Given IV
40763423|NCT05516173|DIAGNOSTIC_TEST|Blood Pressure Monitoring, Ambulatory|To monitor the blood pressure during 24 hours.
40763424|NCT05129969|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
41135902|NCT06140888|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract 8 pills three times per day is administrated.
41135903|NCT03213028|OTHER|WHO Decision-Making Tool for Family Planning Clients and Providers|Contraception decision-making tool
41135904|NCT03741621|DIETARY_SUPPLEMENT|Viscous Fibre Blend|High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
41135905|NCT03741621|DIETARY_SUPPLEMENT|Psyllium|Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
40958478|NCT04714840|OTHER|Exercise testing results|Tailored, home-delivered aerobic and strengthening intervention,exercise intolerance,Both groups of participants will be provided with the results of their exercise testing.
40958479|NCT04714840|OTHER|Individually tailored exercise program (INT)|Individuals randomized to receive an individually tailored exercise program will meet with an exercise specialist. Written instructions, videos of each strengthening exercise, a blue tooth enable heart rate monitor, all necessary exercise equipment, and an iPad pre-loaded with heart rate monitor software, exercise videos and ZOOM app (for video conferencing) will be provided. After returning home, the exercise specialist will supervise and provide guidance to the individual via the ZOOM app during the first 2 weeks (3 sessions per week). Supervision will slowly decrease to twice a week in weeks 3-4, once a week in weeks 5-8, every other week in weeks 9-16, and to one time midway between weeks 17-20. The exercise program will be adjusted depending on the individuals progress.
40958480|NCT04714840|OTHER|Generalized exercise recommendations (AC)|Individuals randomized to receive the generalized exercise recommendations will receive a copy of the Physical Activity Guidelines for Americans. At the baseline visit, a study staff will review these guidelines and answer questions about their exercise testing and encourage them to be physically active. The staff will contact them via telephone to complete a short questionnaire weekly during weeks 1-8 and monthly for weeks 9-20.
40958481|NCT04238260|BEHAVIORAL|Enhancing Physical Therapy Usual Care|The protocol is focused on the completion of a minimum of 30 minutes of weight-bearing, walking-related activities that progressively increase in intensity informed by heart rate and step counters over 4 weeks.
40958482|NCT04238260|BEHAVIORAL|Physical Therapy Usual Care|Usual physical therapy
40958483|NCT03681665|OTHER|ultralow dose abdominopelvic CT|In the patient cohort with abdominal abscess, ultralow dose abdominopelvic CT will be performed as a follow-up protocol. Ultralow dose CT has approximately 80\~90% reduced radiation dose compared to standard dose CT.
40958484|NCT00394823|BEHAVIORAL|Set of supportive tools/measures vs. standard care|
40958485|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
40958486|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
41135906|NCT03741621|DIETARY_SUPPLEMENT|Wheat Bran|All Bran cereal (All Bran®; Kellogg Company)
41292838|NCT00635531|DRUG|alprazolam XR|Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
40958487|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
41135907|NCT05075200|DRUG|Tranexamic acid|Participants in both groups will be given single intravenous bolus of TXA 20 mg/kg over 15 min after induction of spinal (or other regional technique) or general anesthesia as per standard of care.
41135908|NCT03744052|OTHER|Motivational Messages|Messages regarding physical activity will be texted to participants.
41135909|NCT01171053|BEHAVIORAL|Internet-delivered CBT|Internet-delivered cognitive behavioral therapy with therapist support.
41292839|NCT00354068|DRUG|imatinib mesylate|
41292840|NCT00354068|DRUG|temozolomide|
41292841|NCT00354068|OTHER|pharmacological study|
40958488|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
40958489|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
40958490|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
40958491|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
40958492|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
40958493|NCT04306848|DEVICE|Temporary Continuous Glucose Monitoring System|This is a feasibility study evaluating the potential to utilize a continuous glucose monitoring system (CGMs) on a temporary basis, during participation in an intensive therapeutic lifestyle medicine program, to help improve the compliance with healthy lifestyle changes for people with Type 2 diabetes (T2DM) and prediabetes (PD).
40958494|NCT04051528|PROCEDURE|aerobic exercise training|The aerobic exercise will first perform 3 minutes of warm-up followed by 25 minutes of resistive aerobic exercise and then 2 minutes cool-down. During the aerobic exercise the target heart rate will be 40 to 70% of maximal heart rate calculated as (208 - 0.7 age). The exercise intensity will be progressed as the participants improve their performance throughout practice. Vital signs and the Borg Perceived Exertion Scale will be monitored and recorded during exercise for each session.
41135910|NCT01171053|BEHAVIORAL|Therapist support|Weekly therapist support without CBT-interventions
41135911|NCT00135018|DRUG|celecoxib and chemotherapy|
41292842|NCT05933278|BIOLOGICAL|SARS-CoV-2 Subunit Recombinant Protein Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT Bio Farma
40958495|NCT04051528|PROCEDURE|computerized cognitive training|The core function of cognitive training will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance. Cognitive training group will use commercialized cognitive based training programs to facilitate several cognitive functions. The core function will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
40958496|NCT04051528|PROCEDURE|guiding training|At the first time in guiding training will focus on introducing the Goal-Plan-Do-Check strategy and identifying initial three goals by the Canadian Occupational Performance Measure. At the second time in guiding training will begin with a review of the Goal-Plan-Do-Check and will apply the Goal-Plan-Do-Check to the first initial goal. Participants will review this goal and plan, describe the execution of the plan (do), and evaluate the execution of the plan (check). After each execution of the plan, the participant will rate his performance using the COPM Performance Scale, producing iterative scores for each activity. The remaining session of guiding sessions will repeat this process, review performance of identified activities, and applying the Goal-Plan-Do-Check strategy to improve performance.
40958497|NCT01857856|DRUG|Eplerenone|eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
40958498|NCT04312880|DRUG|Tranexamic Acid|IV and topical form of TXA will be administered to patients in the respective groups.
40958499|NCT04036019|BIOLOGICAL|CD20-directed CAR-T cells with CliniMACS Prodigy® system|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
40958500|NCT00199875|DRUG|Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)|Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
40958501|NCT03659500|DIAGNOSTIC_TEST|Four-week routine bloodwork|Routine hemodialysis bloodwork done every 4 weeks
40958502|NCT03659500|DIAGNOSTIC_TEST|Six-week routine bloodwork|Routine hemodialysis bloodwork done every 6 weeks
40958503|NCT05749965|PROCEDURE|Unicompartmental knee arthroplasty|medial unicompartmental knee arthroplasty
40958504|NCT06556303|OTHER|Acupressure|Acupressure
40958505|NCT03771820|DRUG|NC-6004|NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.
40958506|NCT03771820|DRUG|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
41135912|NCT02860949|DRUG|0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL|
41135913|NCT02860949|PROCEDURE|Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)|
40763425|NCT06634498|OTHER|real rTMS on the dlPFC|During real rTM session, participants will perform the regulation of craving (ROC). In the rest phase, participants need to relax and rest. In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
40763426|NCT06634498|OTHER|Sham (No Treatment)|During the sham rTMS session, participants will perform the regulation of craving (ROC). In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
40763427|NCT04099290|OTHER|Blood and tumor samples|Blood samples to be obtained at consent, post-operatively, post-adjuvant treatment, and at follow-up or recurrence. Tumor samples to be obtained at surgery and at time of recurrence or post-treatment biopsy, if applicable.
40763428|NCT06570200|PROCEDURE|PMPR+iPRF|locally applied iPRF in the periodontal pocket
40763429|NCT06570200|DRUG|PMPR+iPRF+Vit.D|locally applied iPRF plus vitamin D in the periodontal pocket
40763430|NCT06570200|PROCEDURE|PMPR only|scaling and root planing only will be done for the periodontal pocket for the control group
40763431|NCT06311734|DRUG|LW231 tablets|P.O.
40763432|NCT06311734|DRUG|Placebo|P.O.
40763433|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 440 micrograms sirolimus each.
40763434|NCT00656643|DRUG|Placebo|Two subconjunctival injections of placebo.
40763435|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 220 micrograms sirolimus each.
40958507|NCT04512014|DIAGNOSTIC_TEST|serum lactate|perioperative measurement of lactate levels
40958508|NCT05751434|BEHAVIORAL|Exercise Therapy|The intervention will consist of exercise therapy, individualized, walking delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule, up to 5 individual treatment sessions/week to achieve a cumulative total duration of 225 to 300 mins/wk until the participant's next standard of care prostate biopsy (about 6-12 months).
40958509|NCT04804007|DRUG|Etoposide|etoposide will be provided with prescription for etoposide 50mg orally daily for 21 days out of 28 day cycles. Cycles will be repeated every 4 weeks for a total of 3 cycles.
40958510|NCT02824575|DRUG|Rebastinib|50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
41135914|NCT02860949|PROCEDURE|Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL|
41292843|NCT02162745|DRUG|Isotonic solution (NaCl 0.9%)|
41292844|NCT02162745|DRUG|Hypertonic solution (NaCl 3%)|
40763436|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 880 micrograms sirolimus each.
40763437|NCT04090606|OTHER|FTC Method Smoking Regimen|cigarettes are smoked by drawing 35 mL puff volumes over 2 s, with 60 s interval between puffs and no blocking of filter ventilation holes
40763438|NCT04090606|OTHER|Massachusetts Method Smoking Regimen|45-mL puffs drawn over 2 s, with 30 s interval between puffs and 50% blocking of filter ventilation holes
40763439|NCT04090606|OTHER|Health Canada Intense Smoking Regimen|55-mL puff volumes of 2-s duration, with 30 s interval between puffs and 100% blocking of filter ventilation holes
40763440|NCT05795881|OTHER|Cyclic daytime enteral nutrition|The allocated feeding schedule is followed from the start of enteral nutrition after ICU admission until discharge from the ICU.
40763441|NCT02559856|DRUG|Apixaban|
41135915|NCT04320914|OTHER|High Intensity LASER Therapy|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J Duration of the treatment will be 8 minutes in one session/knee joint for each day for 3 days/week for 8 weeks."
41292845|NCT04675346|OTHER|Questionnaire|Questionnaire
41292846|NCT05606822|OTHER|Observational|Collection of data from electronic health record
40763442|NCT02559856|DRUG|Rivaroxaban|
40763443|NCT03755336|OTHER|Administered Slip Perturbations|Slips will be administered in early, middle or late phases of stance during overground walking.
40763444|NCT04951206|DEVICE|Fractionated CO2-laser|All women will be undergoing FxCO2-laser therapy as this treatment is a criterion for enrollment.
40763445|NCT04951206|DRUG|Clobetasol Propionate 0.05% Ointment|Clobetasol propionate 0.05% ointment obtained from a commercial manufacturer
40958511|NCT02824575|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
40958512|NCT02824575|DRUG|Eribulin Mesylate|Eribulin 1.4 mg/m2 day 1 \& 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
40958513|NCT06282510|DRUG|Povidone Iodine Topical|Topical intranasal povidone iodine (10%) twice daily for 5 days
40958514|NCT01945528|DRUG|US-guided tenotomy with PRP|"Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure"
40958515|NCT01945528|DRUG|US-guided tenotomy with lidocaine|Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
40958516|NCT00811759|DRUG|sorafenib tosylate|
40958517|NCT00811759|DRUG|temozolomide|
40958518|NCT00811759|GENETIC|gene expression analysis|
40958519|NCT00811759|GENETIC|mutation analysis|
40958520|NCT00811759|OTHER|laboratory biomarker analysis|
40958521|NCT00811759|OTHER|pharmacological study|
40958522|NCT00811759|PROCEDURE|biopsy|
40958523|NCT01500031|DEVICE|OffRoad Re-entry Catheter System|Facilitate the placement and positioning of guidewires within the peripheral vasculature.
40958524|NCT01180985|DEVICE|galyfilcon A prototype lens|silicone hydrogel contact lens
40958525|NCT01180985|DEVICE|comfilcon A|silicone hydrogel contact lens
41135916|NCT04320914|OTHER|Ibuprofen gel phonophoresis|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. Each treatment session will last for 8 min with one session each day for 3 days/week for 8 weeks.
41135917|NCT04187482|OTHER|Exercise training|All participants with DM1 will undergo a 12-week aerobic exercise training intervention on a cycle ergometer
41135918|NCT00269815|DRUG|methylphenidate HCl|
40763446|NCT06640517|DRUG|Netakimab|netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks
40763447|NCT06640517|DRUG|Placebo|placebo will be administered subcutaneously at a scheme masking netakimab treatment
40763448|NCT06640517|DRUG|Adalimumab|adalimumab will be administered subcutaneously at weeks 1, 2, and then once every 2 weeks
40958526|NCT04148352|DRUG|Dupilumab|Dupilumab injected every 2 weeks for 18 weeks
40958527|NCT04148352|OTHER|Placebo|Placebo injected every 2 weeks for 18 weeks
40958528|NCT00317512|PROCEDURE|Percutaneous Coronary Revascularization|
40958529|NCT00317512|DRUG|Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)|
40958530|NCT00317512|DRUG|Voluven|
40958531|NCT05745883|DRUG|DISC-0974|DISC-0974 is administered subcutaneously
40958532|NCT05745883|DRUG|Placebo|Placebo is administered subcutaneously
40958533|NCT01523262|PROCEDURE|preconditioning|peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
40958534|NCT01523262|PROCEDURE|Normal surgery, with sham intervention without inflating arm cuff|
40958535|NCT02631759|DRUG|Lévétiracetam|"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
40958536|NCT02631759|DRUG|Placebo|"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
40958537|NCT01655914|DRUG|Flumazenil|
40958538|NCT05361161|DRUG|Transarterial Chemoembolization|Arterial infusion chemotherapy (THP + oxaliplatin + raltitrexed) and THP combined with lipiodol embolization for 2 times, with an interval of 1 month.
40958539|NCT02776865|DRUG|suprascapular nerve block|4ml 2% xylocaine
40958540|NCT02776865|OTHER|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
40958541|NCT02649595|OTHER|Red Cross Respite care|See detailed description.
40958542|NCT02929914|PROCEDURE|Local anesthesia and rubber dam isolation|Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.
40958543|NCT02929914|PROCEDURE|Incomplete caries removal and microbiological samples collection|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.
40763449|NCT06638671|DRUG|Metformin Hydrochloride|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
40763450|NCT06638671|DRUG|Placebo|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
40763451|NCT06314048|OTHER|CGM and RPM|1. Implement the 4T program as standard of care at Stanford Diabetes clinics, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.
40763452|NCT01889251|DRUG|Ocriplasmin|
40763453|NCT01889251|DRUG|Sham injection|
40763454|NCT04875754|GENETIC|ICM-203|Intra-articular injection
40763455|NCT04875754|DRUG|Placebo|Intra-articular injection
40763456|NCT05976633|OTHER|Whole white rice (control)|One serving size (140g cooked on stovetop) of whole white rice will be provided. Cooking time will be consistently maintained throughout.
40958544|NCT02929914|PROCEDURE|Dentin washed with sodium 0.9% saline|The remaining dentin was dipped in sodium 0.9% saline for 2min.
40958545|NCT02929914|PROCEDURE|Antimicrobial Photodynamic Therapy|The remaining dentin was disinfected with aPDT for 2 min.
40958546|NCT02929914|PROCEDURE|Microbiological samples collection and Indirect pulp treatment|A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).
41135919|NCT04158206|OTHER|Maternal voice|Recording in the intensive care unit quiet and separate consultation room. For infants in the 'maternal voice group,' mothers were asked to tape what the mother wants to say to their babies and read of a child book from the independent publish, 'Xiao Qi's yellow persimmon' which talk about the mother who has a premature infants how to take caring of their baby. After reviewing the quality of the recording, the mother's voice recordings are compiled for 13 minutes with Sound Organizer. 2 , and the volume of the sound standard according to the American Academy of Pediatrics guidelines is 60 decibels in the incubator.
41135920|NCT02779426|BEHAVIORAL|Text messages|Daily text messages with information about atopic dermatitis and treatment reminders.
41135921|NCT05437328|BIOLOGICAL|bi-4SCAR GD2/CD56 T cells|Infusion of bi-4SCAR GD2/CD56 T cells at 10\^6 cells/kg body weight via IV
41135922|NCT06227988|PROCEDURE|patients with liver disease who undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
40763457|NCT05976633|OTHER|Whole brown rice|One serving size (140g cooked on stovetop) of whole brown rice will be provided. Cooking time will be consistently maintained throughout.
40763458|NCT05976633|OTHER|Whole wild rice|One serving size (140g cooked on stovetop) of whole wild rice will be provided. Cooking time will be consistently maintained throughout.
40763459|NCT05976633|OTHER|15% Wild rice and 85% Brown rice blend - Stovetop|One serving size (140g cooked on stovetop) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
40958547|NCT00261469|DRUG|topiramate|
40763460|NCT05976633|OTHER|15% Wild rice and 85% Brown rice blend - Microwaved|One serving size (140g cooked in microwave) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
40763461|NCT06642740|OTHER|Platelet count|divide into two groups based on platelet count
40763462|NCT06502158|DRUG|Mifepristone|200 milligrams (mg)
40763463|NCT06502158|DRUG|Misoprostol|600 micrograms (ug)
40958548|NCT03948711|DEVICE|Near-infrared spectroscopy (NIRS) monitoring of cerebral oxygenation|Monitoring before anesthesia to hospital admission. No treatment decisions made based on monitoring.
40958549|NCT05679323|OTHER|KATZ index of independence in activities of daily living|KATZ index measures self-care tasks using a dichotomous rating (dependent-0/independent-1) including; bathing, dressing, toileting, transferring to and from a chair, maintaining continence, and feeding. Six points are considered independent and 0 points are considered fully dependent. Assessment of each patient is made through a phone call at day 1, 3 and 5 after discharge
40958550|NCT05840640|DRUG|Standard Medical Therapy|Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
40958551|NCT05840640|DRUG|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
40763464|NCT04996875|DRUG|bezuclastinib|Bezuclastinib is administered as tablets to be taken orally, continuously in 28-day cycles.
40763465|NCT03368144|DEVICE|ClearLumen II Peripheral Thrombectomy System|Patients will be treated with the ClearLumen Peripheral Stent Graft System
41292847|NCT04565561|DEVICE|Neovas BRS or DCB|"All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis \< 30%; B. no flow limiting dissection or TIMI grade 2-3."
40958552|NCT05840640|DRUG|G-CSF and NAC|Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
41292848|NCT06321744|OTHER|adapted physical activity program (APA Program)|"Content of the APA program:~* Strengthening of the lower limbs: Exercises alternating different regimes of muscular contractions (eccentric, concentric and isometric), with the use of elastics, balls or even body weight. These exercises will mainly work the quadriceps and hamstrings.~* Upper limb strengthening: Exercises focused on eccentric and concentric contraction regimes, in a global movement approach (as opposed to a segmental approach), with the use of elastics, dumbbells, weighted balls, etc. These exercises will work the muscles of the biceps, triceps, pectorals, deltoids and lats.~* Walking: In the room and/or in the corridor, with technical assistance (cane/walker, etc.) or human work~* Balance and proprioception: Balance work in a bi- and uni-pedal situation, statically and dynamically (eyes open and closed) will be offered with the use of proprioception boards and/or mats combining if possible work in dual task."
41455831|NCT01924364|DEVICE|Tissue Genesis Cell Isolation System™ (TGI CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
40958553|NCT00072566|BIOLOGICAL|Bevacizumab|Given IV
40958554|NCT00072566|DRUG|Cyclophosphamide|Given PO
40958555|NCT00072566|OTHER|Laboratory Biomarker Analysis|Correlative studies
40958556|NCT00318448|DRUG|Zolpidem (SL800750)|
40958557|NCT03154164|DEVICE|Ultrasonic tissue coagulation dissection|ultrasonic coagulation for dissection during laparoscopic cholecystectomy
40958558|NCT00415168|DRUG|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
40958559|NCT00415168|DRUG|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
40958560|NCT03812471|DEVICE|3D volume acquisitions|2 abdominal volumes 2 thigh volumes 2 head volumes
40958561|NCT03812471|DEVICE|2D standard measurements and 3D volumes acquisitions|"* 1 abdomen circumference measurement~* 1 femur length measurement~* 1 head circumference measurement~* 1 bi-parietal diameter measurement~* 1 abdominal volume~* 1 thigh volume~* 1 head volume"
40958562|NCT05246683|OTHER|observational|registry
40958563|NCT03218709|COMBINATION_PRODUCT|High-dose multi-vitamins with minerals|The high-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.37mg,vitamin C 0.27mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
40958564|NCT03218709|COMBINATION_PRODUCT|Low-dose multi-vitamins with minerals|The low-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.20mg,vitamin C 0.50mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
40958565|NCT03218709|COMBINATION_PRODUCT|Hypouricemic tablets|The hypouricemic tablets contained skipjack,salvia and rosemary extract.
40958566|NCT03218709|COMBINATION_PRODUCT|Placebo|The placebo tablets contained maltodextrin and tartrazine.
40958567|NCT06557707|OTHER|Childhood stress|Based on stress-related information, participants will be divided into those who were exposed to adversity during childhood and those who were not exposed.
40958568|NCT01389388|DRUG|Rosuvastatin|All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
40958569|NCT01918384|DRUG|NPC-14|"NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~* An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~* After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14"
40958570|NCT01918384|DRUG|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
40958571|NCT02465515|BIOLOGICAL|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
40958572|NCT02465515|BIOLOGICAL|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
40958573|NCT02465515|BIOLOGICAL|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
40958574|NCT05977140|DRUG|CDI-988|SARS-CoV-2 3CL protease inhibitor
40958575|NCT05977140|DRUG|Placebo|matching placebo
40958576|NCT01964430|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m\^2 on Days 1, 8, and 15 of every 28 day treatment cycle by intravenous (IV) administration for a total of 6 cycles.
40958577|NCT01964430|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.
40958578|NCT01999114|DRUG|Buprenorphine transdermal patch|Buprenorphine patch applied transdermally
40958579|NCT01999114|DRUG|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
40958580|NCT01999114|DRUG|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
41292849|NCT04591665|OTHER|swallowing examination|patients received swallowing examination, including high resolution impedance manometry and Video-Fluoroscopic swallowing study.
40958581|NCT01999114|DRUG|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
40958582|NCT00000430|DRUG|Alendronate|
40958583|NCT00000430|DRUG|Estrogen/progestin therapy|
40958584|NCT03966144|DEVICE|RoboHear Device|Delivery of haptic sensations followed by testing to assess the ability to interpret stimuli as sounds and words
40958585|NCT00034541|BIOLOGICAL|cetuximab|400 mg/m2 i.v. over 120 minutes
40958586|NCT00034541|DRUG|paclitaxel|225 mg/m2, infusion
40958587|NCT00034541|DRUG|carboplatin|30-minute AUC = 6, infusion.
40958588|NCT05542160|DIETARY_SUPPLEMENT|Pumpkin seed extract (IRK-19)|Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
40958589|NCT05158465|BEHAVIORAL|Motivational Interviewing|Intervention will include 3 one-on-one motivational interviewing sessions and 3 follow-up calls with a trained MI health educator. These sessions aim to promote better oral hygiene and oral health.
40958590|NCT03532841|DRUG|an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
40958591|NCT03532841|DRUG|Placebo Oral Tablet|placebo tablet of the same shape,color and taste will be given in the placebo arm
41135923|NCT06227988|PROCEDURE|patients with liver disease who do not undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
41135924|NCT01249638|DRUG|Capecitabine|Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
41135925|NCT01249638|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1 q day 21
41455832|NCT01924364|PROCEDURE|Standard of care fat grafting|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
40958592|NCT02027883|DEVICE|Nominal T shock setting|Nominal Parameter Set 1 Programming Values for EnTrust
40958593|NCT02027883|DEVICE|Educated T shock setting|Experimental Parameter Set 2 Programming Values
40958594|NCT03209661|DRUG|E-cigarette|E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.
40958595|NCT03209661|DRUG|Nicotine 0%|E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.
40958596|NCT03209661|DRUG|Menthol Inhalant Product|Menthol inhaler will be administered to determine the effects on vascular function.
40958597|NCT01604408|BIOLOGICAL|LY2495655|Administered SC
40958598|NCT01604408|DRUG|Placebo|Administered SC
40958599|NCT00057889|BIOLOGICAL|ipilimumab|
41292850|NCT00775372|DRUG|Clarithromycin 250mg/5mL|
41292851|NCT03723265|DEVICE|Cardiac Resynchronization Therapy|
41292852|NCT03527901|DIAGNOSTIC_TEST|GCF collection with aMMP-8 chair side test|
41292853|NCT03527901|OTHER|Saliva collection|
41455833|NCT02219009|DEVICE|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
40958600|NCT05960552|DIAGNOSTIC_TEST|The PReTEE group|Prior to clinical application of PReTEE, all participants designated must receive professional training. They need to receive lectures focusing on the clinical thinking flowchart of rescue transesophageal echocardiography, in conjuntion with the simulator-based training. The discriminating ability of PReTEE will be further assessed in real clinical scenario, that is, within the specified 120 seconds participants in the PreTEE group need to provide the leading causes with regard to difficult separation from cardiopulmonary bypass in high-risk cardiac surgical procedures. All examinations will be supervised by a TEE expert owning to safety considerations but without help in views acquirement or interpretation. After completion of study assessments, the TEE expert will perform a standard comprehensive TEE, the results of which was reported to the attending cardiac anesthesiologist in charge of the patient and the recorders.
41135926|NCT01249638|DRUG|Capecitabine|Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
41135927|NCT01249638|DRUG|Irinotecan|Irinotecan: 200 mg/m2 day 1 , q day 21
41135928|NCT01249638|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1, q day 21
41135929|NCT02964793|OTHER|intervention group|"The intervention will include~1. clinician training sessions, designed to raise awareness of the importance of monitoring for FGR and standardizing SFH measurements~2. the use of SFH charts and EFW customised charts, built with the same software allowing all information to be recorded on an unique document~3. the use of the EFW values mentioned on US report, to plot EFW on the customised chart~4. and explicit recommendations about interpretation of longitudinal values of SFH and EFW measurements. If slopes through consecutive plots are not parallel to either of the predicted centile lines (90th, 50th, 10th) on the chart, and either of the centile lines are 'crossed', fetal biometry by ultrasound scan will be recommended."
41135930|NCT00130091|DRUG|clonidine|2 mcg clonidine added to local anesthetic
40958601|NCT05960552|DIAGNOSTIC_TEST|The conventional TEE group|Before cardiopulmonary bypass separation, conventional TEE examinations will be performed within the specified 120 seconds. Then, the expert will also perform a standard comprehensive TEE; the leading cause should also be presented to the attending anesthesiologists and recorders.
40958602|NCT05747430|DRUG|IRX-101|IRX-101 is a novel ocular anti-septic
41135931|NCT04317885|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
40958603|NCT05747430|DRUG|Providone-Iodine|5% Providone-Iodine
40958604|NCT06222190|RADIATION|online-adaptive radiotherapy|A conebeam CT is taken to determine the current tumour extent and the deformations occurring in comparison to the dose distribution to be applied. Normal tissues heart, lung and tracheal tree are automatically contoured by the Ethos therapy system in that cone-beam CT. A specialist physician and a physicist are present during this process. These organ contours are used to determine the extent of the current target volume and the adaptive radiotherapy plan is adjusted to the new target volume. If the current tumour extent is not sufficiently covered by the initial radiotherapy plan planned for the series with its planned tolerances, or if the surrounding normal tissue is exposed to too much radiation, then the online adaptive radiotherapy plan for the current treatment is selected by the specialist. Otherwise, the initial radiotherapy plan is used for IGRT.
40958605|NCT01921387|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
40958606|NCT01921387|DRUG|Carmustine|Given IV
41135932|NCT03830320|DRUG|[64Cu]FBP8|Injection of Copper-64 radiopeptide to detect thrombosis
41135933|NCT03830320|DEVICE|PET/MR|Whole body imaging using Siemens mMR PET/MR scanner
41135934|NCT03830320|PROCEDURE|Blood Collection|A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
40958607|NCT01921387|DRUG|Cytarabine|Given IV
40958608|NCT01921387|DRUG|Etoposide|Given IV
40958609|NCT01921387|OTHER|Laboratory Biomarker Analysis|Correlative studies
40958610|NCT01921387|DRUG|Melphalan|Given IV
41135935|NCT03830320|PROCEDURE|Electrocardiogram|A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
41135936|NCT04326478|DRUG|Azithromycin|Enrolled children in the intervention arm of this study will receive a single weight-based dose of azithromycin (20 mg/kg, to a maximum dose of 1 gram) administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
41135937|NCT04326478|BIOLOGICAL|Placebo|Enrolled children in the placebo arm of this study will receive a single dose of non-antibiotic placebo administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
41135938|NCT03800368|OTHER|Exercise|Indoor cycling exercise intervention
41135939|NCT03800368|OTHER|Non-exercise|Psycho-education
41135940|NCT03097549|DEVICE|Tät®II Information app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
41455834|NCT06292364|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
40958611|NCT01921387|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
40763466|NCT06642948|OTHER|Motor rehabilitation based on ai visual recognition|Patients in the intervention group will engage in a home-based exercise program in addition to standard rehabilitation guidance. Initially, patients will be provided with exercise materials developed by the intervention team, one-on-one guidance via the AI rehabilitation platform, and a detailed explanation of the exercise intervention program (including its components, foundational knowledge, and benefits).The aerobic warm-up routine includes activities such as marching in place, full-body stretches, jumping jacks, side steps with arm circles, and squats with alternating punches. For the elderly, the warm-up routine is similar but also incorporates chest expansion exercises, abduction exercises, overhead reaches, lateral movements, hip extension exercises, calf raises, and additional full-body stretches.Functional training should be done 3 to 5 times per week at an intensity of RPE 3 to 4, with each session lasting 15 to 30 minutes.
40763467|NCT05704088|DRUG|Dapagliflozin tablet|randomized control trial, study group will receive dapagliflozin tablets
40958612|NCT01921387|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
40958613|NCT02564237|BIOLOGICAL|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
40958614|NCT02564237|BIOLOGICAL|Hepatitis B vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
40958615|NCT02564237|BIOLOGICAL|Hepatitis A vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
40958616|NCT02564237|BIOLOGICAL|Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
40958617|NCT05022082|OTHER|Chest Physiotherapy- Aspiration- Inhaler drugs group|In the intensive care unit where the study was conducted, the patients who have a respiratory disorder and receive supplemental oxygen therapy with non-invasive mechanical ventilation or an oxygen mask are first administered an inhaler drug therapy placed in the physician's order. It is followed by chest physiotherapy and then oropharyngeal and nasopharyngeal aspiration. However, in practice rendered by the researcher, it is suggested that when chest physiotherapy and aspiration are administered in the first place and then followed by an inhaler drug therapy, it might have a more positive impact on the patient's physiologic parameters.
41135941|NCT03097549|DEVICE|Tät®II Treatment app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
41135942|NCT00701415|BIOLOGICAL|Agalsidase beta|Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks
41135943|NCT00701415|BIOLOGICAL|Agalsidase beta|Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
41135944|NCT01429454|DRUG|Omega-3 Long Chain Fatty Acid|: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
41135945|NCT01429454|DRUG|Placebo|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
41135946|NCT02315118|DRUG|T-cell therapy + Rituximab + IL-2|"* T cells collection~* T cells expansion and modification in the laboratory~* T cells infusion back to the patients"
41135947|NCT02267109|BIOLOGICAL|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z|IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
41135948|NCT02267109|BIOLOGICAL|Booster-MVA-BN® Filo or saline placebo|IM injection of Booster-MVA-BN® Filo or saline placebo
41135949|NCT00955565|PROCEDURE|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
41135950|NCT00955565|PROCEDURE|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
41135951|NCT03608436|PROCEDURE|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
41135952|NCT03608436|DRUG|Rocuronium Bromide|Deep (PTC 1-2) versus moderate (Tof count 1-2) neuromuscular block
41135953|NCT02434705|OTHER|Antigen (wheat base soy sauce) spray|Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
41455835|NCT06292364|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
40958618|NCT05352100|DIAGNOSTIC_TEST|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
40958619|NCT04649320|OTHER|questionnaire|"1. 13-item questionnaire about cancer patient's distress and everyday life,~2. EORTC-QLQ-C30"
40763468|NCT05704088|DRUG|placebo|randomized control trial, control group will receive placebo tablets
40763469|NCT05811949|DRUG|Dimethyl Fumarate 240 MG [Tecfidera]|DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.
40763470|NCT06643585|DRUG|Trastuzumab-Deruxtecan|Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier
40763471|NCT06643585|OTHER|Physicians Choice (PhC).|Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib)
40763472|NCT04295928|BEHAVIORAL|PPP|Personalized Pharmaceutical Plan on therapeutic adherence to immunosuppressive treatments after the transplantation
40763473|NCT04681885|DEVICE|Tapered bristles A|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week .
40958620|NCT03024060|DRUG|ALA|20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
40958621|NCT03024060|DRUG|Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
40958622|NCT03024060|DEVICE|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
40958623|NCT03024060|DEVICE|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
40958624|NCT05095597|PROCEDURE|Injection of hUC-PRP by hysteroscopy|PRP previously frozen at -80ºC (6±2 mL) will be defrozen after checking donor-receptor compatibility and viral safety study. PRP (4±2 mL) will be activated with 5% CaCl2 and immediately injected (4±2 mL) in the sub-endometrial wall via hysteroscopy.
40958625|NCT05095597|DRUG|Oestraclin|Patients will receive estrogenic therapy, based on estradiol, for 10±2 days (oestraclin, topical cream, 5µg daily for 10±2 days).
40958626|NCT05095597|PROCEDURE|Umbilical cord blood collection|The SCU will be collected using a blood collection bag containing anticoagulant. This step will be performed by the medical and nursing staff of the obstetrics service of the HUP La Fe. The blood collection bags will be the following, or similar: Cord Blood Collection Bags from MACOPHARMA; CPD Umbilical Cord Bag from GRIFOLS.
40958627|NCT05095597|PROCEDURE|Endometrial biopsy|Biopsies will be taken by specialized medical personnel by aspiration with an intrauterine cannula (pipelle or cornier). Samples will be collected in 15 mL tubes (or in a larger capacity container if needed) containing PBS or RNA later until frozen at -80ºC, at the IVI Foundation facilities. Prior to freezing (in a 1.8-2 mL cryotube) the PBS will be removed and the sample cleaned in a Petri dish if needed.
40958628|NCT00725374|DRUG|tibolone|one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).
41135954|NCT04686617|DIAGNOSTIC_TEST|Mechanical Vibration|Oral B HummingBird device (Procter\&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks.
40763474|NCT04681885|DEVICE|Tapered bristles B|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
40763475|NCT04681885|DEVICE|End rounded bristles|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
40763476|NCT03896568|BIOLOGICAL|Oncolytic Adenovirus Ad5-DNX-2401|Given IA
40763477|NCT03896568|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40763478|NCT03829501|DRUG|KY1044|A human anti-ICOS monoclonal antibody
40763479|NCT03829501|DRUG|KY1044 and atezolizumab|A human anti-ICOS monoclonal antibody in combination with anti-PD-L1 monoclonal antibody (atezolizumab)
40763480|NCT06644170|BEHAVIORAL|Behavioral Intervention|Attend individual visits
40763481|NCT06644170|BEHAVIORAL|Group Therapy|Attend group visits
40763482|NCT06644170|DRUG|Psilocybin|Given PO
40958629|NCT00725374|DRUG|placebo|Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
40763483|NCT06644170|OTHER|Questionnaire Administration|Ancillary studies
40763484|NCT03314896|PROCEDURE|Laparoscopic surgery|
40958630|NCT04337268|DRUG|Glucagon-Like Peptide 1|Intravenous infusion (1.5 pmol/kg/min) for 60 min.
40958631|NCT04337268|DRUG|saline 0.9%|Intravenous infusion for 60 min.
40958632|NCT02628938|OTHER|Miswak extract mouth wash|50% Miswak extract mouth wash (5ml) twice a day for 7 days
40958633|NCT02628938|OTHER|Miswak stick|Miswak stick twice a day for 7 days
40958634|NCT02628938|OTHER|Chlorohexidine gluconate|5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
40958635|NCT03195764|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
40958636|NCT03483025|OTHER|Skin Testing of Hair cleansing products|6 different commercially available shampoos
40958637|NCT01435603|BEHAVIORAL|Standard Lifestyle Advice|Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
40958638|NCT01435603|BEHAVIORAL|Advice Plus Lifestyle Intervention|Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
40958639|NCT00352339|DRUG|Rispridoen and Aripiprazole|Start with risperidone and switch it to aripiprazole. Flexible dose
41135955|NCT05991882|BEHAVIORAL|Condition 1: Craving daily+PBS daily|Participants in this condition will complete ecological momentary assessment (EMA) for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily, until the end of the six-week period.
41292854|NCT04740593|OTHER|Orthoptic care with the prescription of glasses from age 12-18 months onwards|Children assigned to the intervention group (group 1) will receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, and glasses, based on accurate determinations of refractive error by retinoscopy in cycloplegia by the study orthoptists at age 12-18 months. The spectacles for the children in this study will be provided by the study via their optician without costs.
40958640|NCT00352339|DRUG|Risperidne|Start with risperidne and keep it through the end of study. Risperidne:flexible dose
40958641|NCT00352339|DRUG|Abilify|Start with abilify and keep it through the end of study
40958642|NCT06315348|PROCEDURE|flapless alveolar decortication with augmentation|piezocision-assisted orthodontics, concomitant to soft tissue grafting (volume-stable collagen matrix), with piezocision-assisted orthodontics, concomitant to bone grafting with a xenograft and a native collagen membrane. Piezocisions will be performed using a piezoelectric device.
40958643|NCT02272660|DRUG|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
40763485|NCT06640608|BEHAVIORAL|ICBT - Internet Based Cognitive Behavioral Therapy|The study (intervention) group received 6 consecutive sessions utilizing ICBT techniques to overcome Fear of childbirth
40763486|NCT06640634|DEVICE|active in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|"Active in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days."
40763487|NCT06640634|DEVICE|sham in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|Sham in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. In the sham tDCS groups, the duration and electrodes application were the same of active in therapeutic tDCS (Th-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
40763488|NCT06640634|DEVICE|active in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|"Active in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days."
40763489|NCT06640634|DEVICE|sham in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|Sham in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. In the sham tDCS groups, the duration and electrodes application were the same of active in preventive tDCS (Pr-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
40763490|NCT06637384|DRUG|Hyaluronic Acid (HA)|Gengigel Gingival Gel 20ml, Ricerfarma, Milan, Italy
40763491|NCT06637384|DRUG|Corticosteroid Injection|Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals, Pakistan
40763492|NCT06641674|DRUG|18F-LF13|18F-LF13 PET/CT: after intravenous injection of 1.85 - 3.7 MBq/kg body weight of quality-controlled 18F-LF13, a Siemens Biograph PET/CT scan will be applied within 0.5 h, and the scan range will be from the top of the head to 1/3 of the upper thigh, 2 h to 4 h delayed scanning can be added if necessary.
40763493|NCT02107989|DEVICE|MRI|MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.
40958644|NCT02272660|DRUG|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
41292855|NCT04740593|OTHER|Orthoptic care without the prescription of glasses from age 12-18 months onwards|Children with high refractive error in the control group (group 2) will also receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, but they will not receive glasses.
40958645|NCT05203432|DEVICE|Red Light Intervention|Repeated Low-Level Red-Light Therapy
40763494|NCT02107989|DEVICE|MEG|MEG/EEG: Magnetoencephalography (MEG) is commonly used during epilepsy pre-surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only.
40763495|NCT00811850|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
41455836|NCT00695110|DRUG|Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)|Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
40958646|NCT05203432|DRUG|Atropine|0.01% atropine
40958647|NCT05223933|BEHAVIORAL|Proactive community case management|CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature ≥ 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.
40958648|NCT05714059|DEVICE|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
40958649|NCT03108677|OTHER|Blood samples|15 ml peripheral blood
40958650|NCT00450255|BIOLOGICAL|ziv-aflibercept|Given IV
40958651|NCT00450255|OTHER|pharmacological study|Correlative studies
40958652|NCT04273204|DIAGNOSTIC_TEST|one leg standing test, gross motor function measurement, pedobarographic measurement|OLST:During the OLST,the participants were asked to shoes off,place both hands on their hips and look at a point on the wall at eye level.A recording stopwatch was used to assess their standing duration on one leg while keeping the other leg in 90 degrees of knee flexion.The test was stopped when the contralateral foot touched the ground or when the participant broke 90 degrees of knee flexion.The OLST was repeated three times for each leg.GMFM:To assess standing and walking,running and jumping functions of the UCP group,the D and E dimensions of GMFM were utilized by a certificated physiotherapist.Each item was tested by three trials and the best trial was used.Pedobarography:The participants' plantar pressure was analyzed using pedobarography.For each participant, the pedobarography was calibrated before the assessment.During the pedobarographic analysis, the participants walked barefoot in 90 BPM cadence. Three steps were analyzed for each side.
40958653|NCT06535646|OTHER|Home exercise program using Physitrack exercise program and a smart watch|Participants wear a smart watch to monitor activity levels while using a web based exercise program to follow along for 8 weeks.
40958654|NCT05498012|COMBINATION_PRODUCT|placebo dental gel, placebo toothpaste|"* Placebo dental gel applied by dentist after oral hygiene; without cannabidiol.~* Placebo toothpaste; without cannabidiol. For daily use by patient."
41292856|NCT04740593|OTHER|First measurement only|Children who have no or mild refractive error (group 3), the majority of all children, will be examined by the study orthoptists only once at the age of 12-18 months, after which youth health care (YHC) physicians and nurses will continue standard vision screening at CHCs, as part of screening for general health disorders and vaccinations. Visual acuity is measured routinely at 42-48 months as part of standard vision screening.
41292857|NCT04185467|OTHER|Intervention (rehabilitation exercise)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
41292858|NCT05502848|BEHAVIORAL|Internet Cognitive Behavior Therapy|ICBT helps change patterns of thinking (cognitions) and behaviors of psychological distress, including relaxation, stress management, while using ICBT can increase personal tolerance for negative thoughts and negative emotions, help patients reduce negative perception of the disease due to long-term recurrent itching, and break the vicious cycle
41292859|NCT00855530|DRUG|amibegron (SR58611A)|oral administration of 300 mg twice daily
41292860|NCT02424370|PROCEDURE|TAVR|Percutaneous aortic valve replacement
41292861|NCT06488326|DRUG|Mulberry leaf extract 6 mg capsule|Take one capsule of the sample one time.
41455837|NCT00695110|DRUG|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)|Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
41292862|NCT06488326|DRUG|Mulberry leaf extract 12 mg capsule|Take one capsule of the sample one time.
40958655|NCT05498012|COMBINATION_PRODUCT|Cannabidiol dental gel, Cannabidiol toothpaste|"* Cannabidiol dental gel applied by dentist after oral hygiene; containing 1 % (w/w) cannabidiol.~* Cannabidiol toothpaste; containing 1 % (w/w) cannabidiol. For daily use by patient."
40958656|NCT05498012|COMBINATION_PRODUCT|Placebo toothpaste, Corsodyl dental gel|"* Corsodyl dental gel; containing 1 % (w/w) chlorhexidini digluconatis applied by dentist after oral hygiene.~* Placebo toothpaste; without cannabidiol. For daily use by patient."
41292863|NCT06488326|DRUG|Mulberry leaf extract 18 mg capsule|Take one capsule of the sample one time.
41292864|NCT06488326|DRUG|Placebo capsule|Take one capsule of the sample one time.
41292865|NCT00906256|DRUG|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
41292866|NCT00906256|DRUG|Placebo|Placebo
41292867|NCT01789073|DIETARY_SUPPLEMENT|Oral Impact, Nestlé Health Science|Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
41292868|NCT03298854|DEVICE|99mTc-MDP SPECT/CT|Delayed whole body images, using Symbia-T-Siemens dual headed gamma camera, will be obtained 2-3 hours after injection of 15-25 mCi of Tc-99m MDP (Methylene diphosphonate) followed by SPECT images of the lumbar spine and pelvis.
41292869|NCT03395171|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Supplementation of subjects who meet the inclusion criteria and test to have below the threshold of vitamin D in their blood.
41292870|NCT03321929|COMBINATION_PRODUCT|LUM Imaging System|Drug: LUM015 Device: LUM 2.6 Imaging Device
41292871|NCT00428727|DRUG|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
41455838|NCT00695110|DRUG|Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)|Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.
41455839|NCT00695110|DRUG|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)|Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
41455840|NCT00019487|BIOLOGICAL|aldesleukin|
41455841|NCT00019487|BIOLOGICAL|gp209-2M antigen|
41455842|NCT00019487|BIOLOGICAL|incomplete Freund's adjuvant|
41455843|NCT04677517|DEVICE|Modification of active microphone positioning|"Patient will pass the experimental tests described above with 3 different active microphone positions :~* on the cochlear implant processor;~* on the antenna~* in front of the external ear canal~Patient will pass the tests 1 week after each microphone position change, so that they can get used to the new position in their everyday life."
41455844|NCT04677517|BEHAVIORAL|SPHERE protocol|"Patient's 3D localization in noise will be assessed thnks to a 3D localization system called SPHERE based on virtual reality.~Data from spatial hearing perception will be recorded in three-dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D (the 3d-D value), hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure."
40958657|NCT01186536|DIETARY_SUPPLEMENT|Whey Protein supplement|40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)
41455845|NCT04677517|BEHAVIORAL|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value
40958658|NCT01186536|DIETARY_SUPPLEMENT|Soy Protein Supplement|40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)
40958659|NCT01186536|DIETARY_SUPPLEMENT|Carbohydrate supplement|40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
41135956|NCT05991882|BEHAVIORAL|Condition 2: Craving daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
41135957|NCT05991882|BEHAVIORAL|Condition 3: Craving trigger+PBS daily|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages that will be delivered based on responses to signal-contingent EMA questions and PBS delivered once daily.
41135958|NCT05991882|BEHAVIORAL|Condition 4: Craving trigger+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered based on responses to signal-contingent EMA questions.
41292872|NCT00428727|DRUG|placebo patch|daily application during 90 days
41292873|NCT00042185|BEHAVIORAL|Dissonance Eating Disorder Prevention Program|In this intervention, participants voluntarily engaged in verbal, written, and behavioral exercises in which they critiqued the thin-ideal ideal. These exercises were conducted in sessions and in homework activities. For example, they wrote a counter-attitudinal essay about the costs associated with pursuit of the thin-ideal and engaged in a counter-attitudinal role-play in which they attempted to dissuade facilitators from pursuing the thin-ideal.
41455846|NCT04677517|BEHAVIORAL|Quality of life questionnaire|The Speech, Spatial and Qualities of Hearing Scale short-form with 15 items (SSQ15) questionnaire is performed in order to evaluate auditory abilities of patients in different daily life situations.
41455847|NCT04677517|BEHAVIORAL|Likert scale|This subjective evaluation will be added to evaluate difficulties and self-confidence felt by participants during the SPHERE protocol and the French Matrix Test.
41292874|NCT00042185|BEHAVIORAL|Healthy Weight Intervention|In this intervention, participants were encouraged to make gradual healthy and lasting changes to their diet and physical activity to balance their energy needs with their energy intake, and thereby achieve a healthier weight and body satisfaction. With support from the facilitator and group members, they initiated an individual lifestyle change plan to reduce intake of fat and sugar and to increase exercise using behavioral modification principles. Food and exercise diaries were used to identify behaviors to target in this lifestyle modification and to monitor change. Motivational enhancement activities were used to promote motivation for behavior change.
41292875|NCT00042185|BEHAVIORAL|Expressive Writing Control Condition|In this condition, which is based on the work of Pennebaker (1997), participants wrote about emotionally significant topics in three individual weekly 45-minute sessions. They were told that research indicates that body dissatisfaction is linked to emotional issues and that expressive writing helps resolve these issues. Sample topics included relationships or goals. They were told that their work would not be read and were asked to write continuously for the duration of the session about an emotionally important topic.
41455848|NCT01972841|DRUG|Solifenacin succinate|Oral tablet
41455849|NCT01972841|DRUG|Mirabegron|Oral tablet
41455850|NCT01972841|DRUG|Placebo to match solifenacin succinate|Oral tablet
41455851|NCT01972841|DRUG|Placebo to match mirabegron|Oral tablet
41455852|NCT02270697|DEVICE|Array|Applications of oligonucleotide array in diagnosis.
40763496|NCT00811850|DRUG|fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
41455853|NCT00383916|DRUG|pantoprazole|
41455854|NCT06476600|DRUG|Dexmedetomidine injection|All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
41455855|NCT06476600|DRUG|Nalbuphine Injection|All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
41455856|NCT03947658|PROCEDURE|Surgical crown lengthening|Surgical lengthening of teeth with short clinical crown and prosthetic rehabilitation
40958660|NCT03533868|DIAGNOSTIC_TEST|Point-of-care viral load monitoring test|For enumerating viral load for patients in the POC arm, we will use the Cepheid Xpert® HIV-1 Viral Load test, a quantitative assay with a quantification range of 40 to 10,000,000 copies/mL. Based on the GeneXpert® technology, Xpert HIV-1 VL automates the test process, including RNA extraction, purification, reverse transcription and cDNA real-time quantitation in one fully integrated cartridge. The pre-loaded disposable single-use cartridges provide a visual read-out within 90 minutes. The assay requires 1 mL of plasma using a precision pipette (1.2 mL using a transfer pipette).
41455857|NCT04260373|DRUG|[14C]SHR4640|Patients will receive single dose of orally \[14C\]SHR4640 on Day 1.
41455858|NCT00372996|DRUG|CP-751,871|CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
40763497|NCT06642324|DIAGNOSTIC_TEST|Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing|Histopathology for carcinoma detection, Immunohistochemistry for carcinoma-related protein expression, Real-Time PCR for HPV association and HPV typing, Sequencing for genetic study or mutation analysis.
41455859|NCT00372996|DRUG|exemestane|Exemestane given at 25 mg orally once a day.
40763498|NCT05707260|BEHAVIORAL|CKD SMS|The intervention begins with a face-to-face or digitally assisted session, entry into improving the knowledge and self-management of CKD through, using the four sources of manipulation of self-efficacy (achievement of performance, indirect experience, verbal persuasion, and self-evaluation). In this session, participants will be asked to identify their problems related to CKD and establish, based on these two goals, that they are real and achievable according to their priorities. These goals will be recorded in the monitoring format and will be monitored in the telephone or WhatsApp follow-ups. This using the performance achievement manipulation source, said session lasts 60 minutes, as does the final session at week 16.
40763499|NCT06638970|DRUG|Secretome|3 ml Injection of secretome for 4 times two weeks apart
40763500|NCT05862584|OTHER|Questionnaires|Distribution of questionnaires to patients to be completed on a weekly basis.
40763501|NCT05356130|BEHAVIORAL|Written Educational Material on BLT|Participants in both Arms 2 and 3 will receive written information about how to obtain the greatest BLT benefit, including recommended day/time usage, session duration, eye distance from light box, the length of time to continue using, and the small risk of emergent mania or BD and how to recognize this. Written best practices for ideal BLT will be provided in both Arms 2 and 3 via secure EHR message, email, and/or USPS. PDFs of best practices for BLT will also be available for download on our study website.
40763502|NCT05356130|BEHAVIORAL|Enhanced BLT Encouragement and Adherence Promotion|BLT phone coaches will follow a four-step approach in engaging with Arm 3 participants: (a) provide encouragement to consider using BLT; (b) provide guidance regarding light box purchase and assist with obtaining compensation for purchase; (c) educate participants about ideal BLT use to obtain maximum benefit; and (d) provide ongoing brief telephonic adherence promotion and motivational interviewing (MI) where warranted to maximize persistent and appropriate BLT use.
40763503|NCT00576745|PROCEDURE|Vicryl Suture|A 4-0 vicryl suture will be used to close the subcuticular layer
41292876|NCT06497985|DRUG|Tucidinostat|30mg orally BIW
41292877|NCT06497985|DRUG|Sintilimab|200 mg intravenously (IV) Q3W
41292878|NCT06497985|DRUG|Bevacizumab|7.5mg/kg intravenously (IV) Q3W
41292879|NCT06497985|DRUG|Fruquintinib|5mg orally QD
41455860|NCT00372996|DRUG|exemestane|Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
41292880|NCT01970579|DEVICE|Paclitaxel coated balloon|"* Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting"
41455861|NCT00372996|DRUG|Fulvestrant|Used for salvage therapy and administered according to the local label and standard clinical practice.
41455862|NCT03730558|COMBINATION_PRODUCT|aflibercept + FOLFIRI|aflibercept + FOLFIRI
41292881|NCT01970579|DEVICE|uncoated PTA catheter|"* Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting."
40763504|NCT00576745|DEVICE|3M TM S Surgical Skin Closure System|These steri-strips will be applied to close the skin in this cohort of patients
40763505|NCT06085872|BEHAVIORAL|REThink Life Game|REThink Life Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of four levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change and positive bias.
41292882|NCT04969393|DEVICE|High intensity laser therapy|"Fifteen treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 5 weeks in succession via EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. Patients in group (A) received HILT along with the conventional physical therapy program. The session involved 3 subphases: (1) The Initial phase Analgesic phase, (2) In the intermediate phase Trigger point phaseand (3)The final phase Bio-stimulation phase was applied for 6 minutes with a slow scanning in several parallel longitudinal lines."
40763506|NCT06085872|BEHAVIORAL|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress. The efficacy of the app adjunct to other therapeutic tools within the platform in our projects will be tested."
40763507|NCT06085872|BEHAVIORAL|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
40763508|NCT04773457|OTHER|Surgical Site Infection|infection at the site of the surgery (spine or abdomen)
40763509|NCT05896202|OTHER|taVNS Video|One third of the participants will see the taVNS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
41292883|NCT04969393|OTHER|Conventional Physical Therapy|Fifteen treatment sessions that involved using a neutral custom volar splint alongside neural and tendon gliding exercises. the splint was used at night and while performing strenuous activities during the day for 5 weeks. While nerve and tendon gliding exercises was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
41292884|NCT06408194|DRUG|CD22CART infusion|CD22CART will be administered after Standard of Care (SOC) administration of tisagenlecleucel.
41455863|NCT03454737|PROCEDURE|mesenchymal stem cells|"Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.~The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration"
40763510|NCT05896202|OTHER|Educational materials|Participants will receive sample consent forms and brochures for taVNS and TMS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.
40763511|NCT05896202|OTHER|TMS Video|One third of the participants will see the TMS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
40763512|NCT03695315|DEVICE|Continuous Positive Airway Pressure|CPAP is a noninvasive treatment for sleep apnea
40763513|NCT06033859|DIAGNOSTIC_TEST|Clinical measurements|With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
40763514|NCT06033859|DIAGNOSTIC_TEST|Radiographic measurement|A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
40763515|NCT06033859|PROCEDURE|Dental prophylaxis or maintenance|Dental prophylaxis or maintenance will be performed every 3 months.
40763516|NCT06097897|DEVICE|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
40763517|NCT06363981|DEVICE|Active rTMS over the left DLPFC and over the left DMPFC|Active rTMS over the left DLPFC and over the left DMPFC to induce the long term potentiation of stimulated areas.
40763518|NCT06363981|DEVICE|Active rTMS over the left DLPFC|Active rTMS over the left DLPFC to induce the long term potentiation of stimulated area.
41292885|NCT06408194|DRUG|Tisagenlecleucel|All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.
41292886|NCT06228183|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
41292887|NCT06228183|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
41292888|NCT06228183|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
41292889|NCT03690622|DRUG|Dexmedetomidine|Instillation of eyedrops
41292890|NCT03690622|DRUG|Balanced salt solution|instillation of eyedrop
41292891|NCT04059133|DEVICE|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm|Sham treatment (shock wave probe w/o energy)
41455864|NCT03454737|PROCEDURE|Pure platelet-rich plasma|"Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.~The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%."
41455865|NCT06219980|COMBINATION_PRODUCT|SBRT+chemoimmunotherapy|All eligible patients will receive SBRT (6Gy\*3 fractions, qod) to the primary site and metastatic lymph nodes. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics.
41455866|NCT01679327|DRUG|Oxaliplatin|
41455867|NCT01679327|DRUG|Xeloda|
41455868|NCT01679327|DRUG|Calcium folinate (CF)|
41455869|NCT01679327|DRUG|5-FU|
41455870|NCT01679327|DRUG|Bevacizumab|
41455871|NCT06230094|OTHER|moderate intensity|Arm Circles, Leg Swings, Lunges, brisk walk
41455872|NCT06230094|OTHER|high intensity|Arm circles, Leg swings, Lunges, skipping rope
41455873|NCT06348316|OTHER|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
41466460|NCT05911087|BIOLOGICAL|PhaseIII:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
41292892|NCT04059133|DEVICE|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm|Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
41292893|NCT05045755|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
41292894|NCT06408831|BEHAVIORAL|Classroom Teaching University Students Intervention Group|Web-based cyber sexual violence training and counseling will be provided to female classroom teaching students, who are the intervention group, and the effect of the intervention on cyber sexual violence experience, sensitivity and cyber security will be examined.
40763519|NCT06363981|DEVICE|Sham rTMS|Sham rTMS over the left DLPFC or over the left DLPFC and over the left DMPFC for placebo.
40763520|NCT06642766|DIETARY_SUPPLEMENT|Fiber supplement|"Subjects that meet the inclusion criteria and with symptoms appropriate for fiber supplementation are eligible to participate. Participants will be instructed to use the fiber product (NutraLieve) as currently labeled; start with a dosage of 4-5 grams per day (one heaping teaspoon), initially taken once daily, increasing up to 3 heaping teaspoons a day (maximum dose 15 grams/day) on an as needed basis.Participants will be prospectively assessed for symptoms at baseline and at 6 weeks.~* The primary endpoint, number of bowel movements, will be assessed by bowel movements in the last 72-hour period at baseline and at 6 weeks, by patient recall/diary.~* Secondary endpoints, reduction in bloating or gas, or any adverse events will be assessed using analog scales, also by 72-hour recall at baseline and at 6 weeks, by patient recall/diary."
40763521|NCT05668923|BEHAVIORAL|Speech sound stimulation|Behavioral-, electrophysiological-, and magnetic resonance imaging-based speech sound testing
40763522|NCT00997659|DIETARY_SUPPLEMENT|chromium picolinate|1000 mg per day
40763523|NCT05855759|OTHER|Acellular Dermal Matrix|Patinets will be treated with acellular dermal matrix with standard arthroscopic technique performed as per normal clinical practice. For the tendon repair the acellular dermal matrix patch will be placed over the repaired tendon with dedicated sutures and anchors.
41292895|NCT03616769|DRUG|antiplatelet drugs ,statins ,antihypertensive drugs|According to the international guidelines, we treated patients who suffered from different disease.
41292896|NCT06438276|BEHAVIORAL|Psychiatric outreach nurse service|Mental health service provided by psychiatric outreach nurses for 12-16 year old students in secondary schools
41292897|NCT01264965|DRUG|long acting oxycodone|10mg twice daily
41292898|NCT01264965|DRUG|extra strength acetaminophen|1,000 mg twice daily
41292899|NCT03189225|OTHER|Capillary And Venous Accuracy|Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference instrument and LifeScan reference instrument (YSI 2300)
41292900|NCT00828867|DRUG|100 mg GSK investigational drug|
41135959|NCT05991882|BEHAVIORAL|Condition 5: PBS daily+ PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive PBS messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
40763524|NCT05855759|OTHER|Acellular Dermal Matrix with autologous orthobiologics|Patinets will be treated with acellular dermal matrix enriched with autologous humeral bone marrow concentrate and subacromial bursa with standard arthroscopic technique. Humeral bone marrow concentrate will be harvested from the proximal humeral head inthe operating room and concentrated by an automatic close system.
40763525|NCT03242031|PROCEDURE|monospot panretinal photocoagulation|panretinal photocoagulation with monospot laser
40763526|NCT03242031|PROCEDURE|multispot panretinal photocoagulation|panretinal photocoagulation with multispot laser
40958661|NCT05764421|BEHAVIORAL|motor-cognitive intervention|The intervention included physical activity and integrated cognitive training. The training was conducted in three sessions. The first session was a warm-up and wake-up preparation, in which participants massaged facial acupoints in a seated position to light music. In the middle phase of aerobic exercise, participants raised their legs in a standing position and performed mental exercises to fast-paced music. Session 1: tapping the five fingers of each hand in turn; Section 2: The thumb of both hands in turn to tap the rest of the fingers; Third section: hands five fingers cross fist; Section 4: The five fingers of both hands are stretched out in turn, and then retracted in turn. The final session was a relaxation session in which participants performed inspiratory and expiratory exercises to light music. The integrated cognitive training consisted of 15 minutes of attention training, 15 minutes of memory training, and 15 minutes of executive function training.
40958662|NCT03233607|PROCEDURE|Blood Draw|On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
41135960|NCT05991882|BEHAVIORAL|Condition 6: Craving daily+Craving trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and craving reduction trigger messages that will be based on responses to signal-contingent EMA questions.
41135961|NCT05991882|BEHAVIORAL|Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered once daily and non-repetitive craving reduction and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
41135962|NCT05991882|BEHAVIORAL|Condition 8: No daily or trigger craving or PBS|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will not receive any further intervention strategies.
41292901|NCT00828867|DRUG|200 mg GSK investigational drug|
40763527|NCT06088979|DRUG|TOUR006 - 20 MG|TOUR006 20 MG
40763528|NCT06088979|OTHER|Placebo|Placebo
40763529|NCT06088979|DRUG|TOUR006 - 50 MG|TOUR006 - 50 MG
40763530|NCT06641648|DRUG|NK cell|Drug: Donor NK cells injection is a non-genetically modified natural killer cells therapy derived from a healthy donor.
41135963|NCT02813304|BEHAVIORAL|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.
41135964|NCT02813304|BEHAVIORAL|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
40763531|NCT06641154|DRUG|GT-UGT1A1-AAV8-02|Intravenous infusion, single dose
40763532|NCT06641596|DIETARY_SUPPLEMENT|Placebo|2 capsules of Placebo, once daily after breakfast for 12 weeks
40763533|NCT06641596|DIETARY_SUPPLEMENT|Cr-400|1 capsule of Cr-400 + 1 capsule of Placebo, once a day after breakfast for 12 weeks
40763534|NCT06641596|DIETARY_SUPPLEMENT|Cr-800|2 capsules of Cr-400, once a day after breakfast for 12 weeks
41135965|NCT01929291|BIOLOGICAL|Boostrix|Single intramuscular injection
41135966|NCT01929291|OTHER|Safety data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
41135967|NCT04057261|DRUG|Liraglutide Pen Injector [Victoza]|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
40763535|NCT06641596|DIETARY_SUPPLEMENT|PE-500|1 capsule of PE + 1 capsule of Placebo, once a day after breakfast for 12 weeks
40763536|NCT06641596|DIETARY_SUPPLEMENT|PE-1000|2 capsules of PE-500, once a day after breakfast for 12 weeks
41135968|NCT04057261|DRUG|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
41135969|NCT02445404|DRUG|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks
41135970|NCT02445404|DRUG|fractionated ICED|ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
41135971|NCT01499979|PROCEDURE|In situ hypothermic perfusion|In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
41135972|NCT04851665|OTHER|No Intervention - this was a qualitative analysis|No Intervention - this was a qualitative analysis
41292902|NCT00828867|DRUG|400 mg GSK investigational drug|
41292903|NCT00828867|DRUG|800 mg GSK investigational drug|
41292904|NCT00828867|DRUG|2000 mg GSK investigational drug|
40763537|NCT02522273|DEVICE|EKF Diagnostics 'SensPoint' Lactate Meter|
40763538|NCT05805189|PROCEDURE|pulmonary vein (PV) isolation|The settings used during ablation will be for both groups: 15W, unipolar; 5ml/min baseline irrigation, 35ml/min irrigation during inflation/RF application; 55°C target electrode temperature; RF application time 60s for anterior electrodes, 20s for posterior electrodes. The catheter insertion in Pulmonary vein and ablation workflow will be different for two groups.
40763539|NCT00403052|DRUG|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
41292905|NCT00828867|DRUG|1500 mg GSK investigational drug|
40763540|NCT06640686|OTHER|Exercise training|Inspiratory muscle training for increase strength of inspiratory muscle.
40763541|NCT03809533|DRUG|sofosbuvir/velpatasvir|12-week, oral, fixed-dose
40763542|NCT00970710|BEHAVIORAL|Vaasa Childhood Obesity Primary Prevention Study|Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
40763543|NCT01561469|DRUG|Linezolid|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
40763544|NCT01561469|DRUG|Vancomycin|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
40763545|NCT04543617|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
41135973|NCT00756574|DEVICE|Surgical mask|Surgical mask worn for patients with febrile respiratory illness
41135974|NCT00756574|DEVICE|N95 mask|N95 mask worn for patients with febrile respiratory illness
41135975|NCT02314975|DEVICE|AcceleDent vibrational device|Supplementary vibrational force with fixed appliances
41135976|NCT02314975|DEVICE|Sham AcceleDent device|Supplementary sham-vibrational device with fixed appliances
41292906|NCT00828867|DRUG|800mg fed GSK investigational drug|
41292907|NCT00828867|DRUG|3000mg GSK investigational drug|
41292908|NCT00828867|DRUG|4000mg GSK investigational drug|
41292909|NCT06048016|DIAGNOSTIC_TEST|Scaling and Root Planning|Scaling and Root Planning by using ultrasonic scaler ,and Gracy currettes.
41292910|NCT01392989|DRUG|CIK cells|Standard of care
41292911|NCT01392989|DRUG|Cyclosporine|5 mg/kg, po
41292912|NCT01392989|DRUG|Mycophenolate Mofetil|15 mg/kg, oral
41292913|NCT01392989|DRUG|Thymoglobulin|7.5 mg/kg, IV
40763546|NCT04543617|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
40763547|NCT04543617|DRUG|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
41292914|NCT01392989|RADIATION|Total Lymphoid Irradiation (TLI)|
41292915|NCT04979572|DRUG|TS-172|"* Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner"
41135977|NCT02314975|OTHER|Fixed appliance only|Fixed appliance treatment only
41292916|NCT04979572|DRUG|Placebo|"* Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner"
41292917|NCT01803165|PROCEDURE|Single shot femoral and sciatic nerve block|Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
41292918|NCT02177669|OTHER|quick Contrast Sensitivity Function test|
41292919|NCT04513808|DRUG|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia, titrated to clinical need.
40763548|NCT04543617|DRUG|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
40763549|NCT02395627|DRUG|Tamoxifen|
40763550|NCT02395627|DRUG|Vorinostat|
41135978|NCT01934452|DRUG|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
41135979|NCT01934452|DRUG|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
41135980|NCT03102892|PROCEDURE|Scaling root planing|Treatment by scaling and root planing alone.
41135981|NCT03102892|PROCEDURE|Antimicrobial photodynamic therapy|Treatment with methylene blue dye and red laser
41135982|NCT03713580|DRUG|Venetoclax|"Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor."
41135983|NCT05097638|DIAGNOSTIC_TEST|spirometry|Patient do spirometry
41292920|NCT04513808|DRUG|Sevoflurane intravenous anesthesia|Sevoflurane intravenous anesthesia, titrated to clinical need.
41135984|NCT01463475|PROCEDURE|Bone marrow aspirate|A single bone marrow aspirate procedure is planned.
41292921|NCT02595060|DRUG|inhaled molgramostim (rhGM-CSF)|
40763551|NCT02395627|DRUG|Pembrolizumab|
40763552|NCT06487936|DEVICE|TransLoc 3D SI Joint Fusion System|Satisfaction survey will be administered to collect real world evidence on patients that previously received the TransLoc 3D System commercially.
40763553|NCT06563687|DEVICE|Dexcom ONE+|In all the neonates recruited CGM sensor and transmitter will be placed soon after study enrollment. The sensors will be inserted in the lateral thigh and continuous measurements will be recorded for all the duration of therapeutic hypothermia.
40763554|NCT01793233|OTHER|Laboratory Biomarker Analysis|Correlative studies
40763555|NCT01793233|OTHER|Questionnaire Administration|Ancillary studies
41135985|NCT00075998|DRUG|"Interferon gamma-1b (Actimmune)"|200 mcg, SQ, 3x per week
41135986|NCT01040312|DRUG|CPT-11|CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
41135987|NCT01040312|DRUG|Platinum analogues|Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
41135988|NCT00463944|BEHAVIORAL|Effect of an electronic voting system|
41135989|NCT02499809|OTHER|Recovery mode|After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).
41135990|NCT01915888|OTHER|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
41135991|NCT00296309|DRUG|Tacrolimus|Immunosuppression
41135992|NCT03346733|DIETARY_SUPPLEMENT|Psyllium Fibre|Viscous soluble psyllium fibre
41135993|NCT01018550|DRUG|AMG 853|AMG 853 5 mg (BID)
41135994|NCT01018550|DRUG|AMG 853|AMG 853 200 mg (QD)
41292922|NCT02595060|DRUG|inhaled placebo|formulated as the active substance without molgramostim
41292923|NCT03080922|BIOLOGICAL|hematopoietic stem cell|high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
41292924|NCT05478018|BEHAVIORAL|High Intensity Interval Training|Supervised high-intensity interval training for 12 weeks three times per week
41292925|NCT03609229|PROCEDURE|Burch|polyglactin suture was passed through the Cooper's ligament bilaterally with the guidance of the valve
41292926|NCT03609229|PROCEDURE|Abdominal Sacrocolpopexy|"* By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~* The right-handed operator double gloves, and places the left hand in the vagina.~* With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~* Place three Ethibond J-shaped sutures on either side of the urethrovesical junction."
41292927|NCT04897412|DRUG|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
41292928|NCT04897412|OTHER|Placebo|Sodium Chloride (0.9% NaCl) placebo for injection
41292929|NCT05665985|DRUG|Moringa Oleifera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
40763556|NCT03982693|DRUG|Edetate Disodium|The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.
40763557|NCT03982693|OTHER|Placebo|Placebo infusions consist of 500 ml normal saline.
40763558|NCT01484756|DIETARY_SUPPLEMENT|daily multi micronutrient supplement|Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
40763559|NCT01484756|DIETARY_SUPPLEMENT|Placebo|calcium carbonate 500 mg
40763560|NCT05892393|DRUG|Zirconium Zr 89-DFO-YS5|Given IV
40763561|NCT05892393|PROCEDURE|Positron Emission Tomography / Computed Tomography (PET/CT)|Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image
40763562|NCT05892393|PROCEDURE|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)|Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.
40763563|NCT05892393|OTHER|Fludeoxyglucose F-18|Given IV
40763564|NCT06358508|DEVICE|Sapphire 3 Coronary Dilatation Catheter|To pre-dilate Chronic Total Occlusion (CTO) lesions in coronary arteries during the subject's index procedure with Sapphire 3 0.85mm, 1.0mm, and 1.25mm diameter Coronary Dilatation Catheters.
40763565|NCT06639308|PROCEDURE|Endoscopic Flexor Hallucis longus tendon transfer to tendon achilles|The endoscopic FHL tendon transfer is usually performed with the scope introduced through the posterolateral portal and instruments through the posteromedial portal. The FHL tendon must be identified during hindfoot working area creation. First, the calcaneoplasty is completed as described. Next, the FHL tendon is harvested. A tunnel was created into calcenous the tendon is introduced into the tunnel and the tendon is secured with an interference screw of same size than the tunnel
40763566|NCT06639308|PROCEDURE|Open Flexor Hallucis longus transfer to tendon achilles|The FHL tendon can be approached through the posterior longitudinal incision The FHL is confirmed by digital retraction of the tendon, watching for flexion of the hallux. Dissection of the FHL tendon is followed to the posterior talus and FHL tunnel, remaining lateral to avoid the neurovascular bundle. Release of the fibro-osseous tunnel along the posterior talus is necessary to gain length. With the hallux and ankle plantar flexed, the FHL tendon is transected as distally as possible. The tendon is fixed to the calcaneus just anterior to the Achilles stump insertion by an interference screw.
40958663|NCT06301334|DRUG|Bupivacaine 0.25% Injectable Solution|Group CTB (n=30): patients included in this group will receive unilateral US-guided CTB after general anesthesia. The CTB will be performed by using 20 ml bupivacaine 0.25% Group ESPB (n=30): patients included in this group will receive unilateral US-guided ESPB after general anesthesia. The ESB will be performed by using 20 ml bupivacaine 0.25%
41135995|NCT01018550|DRUG|AMG 853|AMG 853 25 mg (BID)
41135996|NCT01018550|DRUG|AMG 853|AMG 853 100 mg (BID)
41135997|NCT01018550|DRUG|Placebo|Placebo
41135998|NCT03177226|DEVICE|Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
41135999|NCT03177226|DEVICE|Non-Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
41136000|NCT02404844|DRUG|BKM120|daily oral
41136001|NCT02404844|DRUG|Tamoxifen|daily oral
41136002|NCT03795532|PROCEDURE|SWL|Shock wave lithotripsy
40958664|NCT02875054|BEHAVIORAL|Constraint induced movement therapy (CIMT)|Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
40763567|NCT01248819|DRUG|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
40763568|NCT01248819|DRUG|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
41292930|NCT03059303|DRUG|Simeprevir 75 mg|"Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.~Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2."
41455874|NCT06348316|OTHER|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
41292931|NCT03059303|DRUG|Odalasvir 25 mg|"Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.~Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2."
41292932|NCT03059303|DRUG|Odalasvir 12.5 mg|Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
41292933|NCT03059303|DRUG|Odalasvir 75 mg|Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
41292934|NCT03059303|DRUG|AL-335 800 mg|"Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.~Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2."
41292935|NCT03059303|DRUG|Lansoprazole 30 mg|30 mg lansoprazole once daily from Day 1 to Day 5.
41455875|NCT05397444|OTHER|No intervention|This is an observational study with no intervention.
40763569|NCT05267600|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
40763570|NCT05267600|OTHER|placebo|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
40763571|NCT05267600|DRUG|Prednisone|Oral Prednisone
40763572|NCT05199844|DEVICE|Apple Watch|Apple Watch device measures heart rate and oxygen saturation
40763573|NCT06097299|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
41292936|NCT03059303|DRUG|Omeprazole 20 mg|20 mg omeprazole once daily from Day 1 to Day 5.
41292937|NCT05359627|DRUG|Polymyxin B|Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.
41292938|NCT01595646|DRUG|Saline|Saline, administered intranasally twice per day for a 16 week duration
41292939|NCT01595646|DRUG|Insulin detemir|20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
40763574|NCT06097299|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
40763575|NCT06258668|DRUG|Deucravacitinib|As per product label
40763576|NCT03379584|DRUG|SGN-CD48A|Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
40763577|NCT03439072|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
40763578|NCT03439072|DRUG|Lilly Glucagon|1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\])
40763579|NCT06637761|DRUG|NeoMTA2|Bio-active bio-ceramic mineral trioxide aggregate
40763580|NCT06637761|DRUG|WMTA|White Mineral trioxide aggregates
40958665|NCT02875054|BEHAVIORAL|Hand-arm bimanual intensive training (HABIT)|Facilitates the translation of gains to improve goal-directed bimanual performance.
41292940|NCT01595646|DRUG|Insulin|20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)
41292941|NCT04953455|OTHER|no intervention|no intervention
41455876|NCT04064827|DRUG|Paricalcitol|Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser
40763581|NCT06637475|DEVICE|Electric stimulation|"Patients with baseline assessments will be followed up for 8 weeks within a planned treatment program. Treatment protocol for the ES group:~external ES wearable apparatus will be applied three days a week for 30 minutes with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 s contraction and 5 s rest, with a current intensity ranging from 0-100 mA while the patients are in the supine position. The device will be attached to the patients in such a way that it wraps around the upper thigh, the electrodes will be attached to the anterior and posterior of the right and left thigh, the right-left pelvic side and the right-left gluteal region. The current intensity in each session will be determined as the maximum current intensity that will not cause pain and discomfort in individuals."
40763582|NCT02510248|DRUG|AL-704|JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
40763583|NCT02510248|DRUG|Placebo|Placebo to match AL-704
40763584|NCT04570943|COMBINATION_PRODUCT|Gabrinox|"Regimen: GEMBRAX~Other Names:~Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m²~Regimen: FOLFIRINOX~Other Names:~Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²~Gembrax + Folfirinox = GABRINOX"
40763585|NCT04570943|RADIATION|MRI-GUIDED STEREOTACTIC RADIOTHERAPY|"Radiotherapy will start between 5 and 6 weeks after the last injection of chemotherapy (FOLFIRINOX regimen) in non-progressive patients after Gabrinox.~Stereotactic adaptive radiotherapy in five fractions: prescription of five fractions of 10 Gy/each on the planning target volume (PTV). At least two sessions/week should be performed. An interval of at least 18 hours between fractions is recommended."
40763586|NCT04448847|DIETARY_SUPPLEMENT|Bif195|Active trial product with minimum 100 billion CFU daily dose
40763587|NCT04448847|OTHER|Placebo|Placebo similar to trial product but without Bif195
40958666|NCT05251246|BEHAVIORAL|recovery management program|The recovery management program consists in training the nurses and physicians during a 15-day training course to optimize their recovery abilities : sleep management according to the schedules by anticipation and recovery, and stress management through cardio-feedback techniques (cardiac coherence) also called controlled breathing techniques and mental imagery.
40763588|NCT05535569|DRUG|Nivolumab, Paclitaxel|Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.
40958667|NCT01162460|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Week 1 and 2 either 400mg/day Eslicarbazepine acetate (ESL) or 200mg/day Carbamazepine controlled release(CBZ-CR); Week 3 onwards either 800mg/day Eslicarbazepine acetate or 400mg/day CBZ-CR; this dose then to be maintained unless a subject has a seizure.~Subjects experiencing a seizure will have their assigned treatment dose increased to ESL 1200mg/day or CBZ 800mg/day.~Should a subject have another seizure, their assigned treatment is to be increased to ESL 1600mg/day or CBZ 1200mg/day.~Subjects who remain seizure free for 26 weeks at any dose in an Evaluation Period will continue to receive the allocated treatment under double-blind conditions."
40958668|NCT02856178|DRUG|F901318|F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
41292942|NCT03687034|DRUG|Temozolomide|Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
41292943|NCT03687034|DEVICE|Optune|Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.
41292944|NCT01144689|BEHAVIORAL|Mindfulness Training|8 sessions of behavioral treatment for smoking cessation
41292945|NCT01144689|BEHAVIORAL|Smoking Cessation Therapy|8 sessions of behavioral treatment for smoking cessation
41292946|NCT03870581|BEHAVIORAL|AI-based social software management model|a AI-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
41292947|NCT03870581|BEHAVIORAL|Human-based social software management model|a Human-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
41292948|NCT02558699|PROCEDURE|physician's personal experience|physician's personal experience
41292949|NCT02558699|PROCEDURE|Virtual rotor mapping|Virtual rotor mapping
41292950|NCT00856427|RADIATION|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
41455877|NCT05237830|PROCEDURE|Use of Cell Salvage in revision of total hip arthroplasty|The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.
41455878|NCT01071551|BEHAVIORAL|Life-style intervention|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
41455879|NCT01071551|BEHAVIORAL|Physical activity only|Children allocated to this group will attend 20 physical activity classes.
41455880|NCT03081897|DRUG|SPRANC Block group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
41455881|NCT03081897|DRUG|SPRANC Control group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
41455882|NCT00301327|DRUG|Summers 5% L.A.|
41455883|NCT03372317|DRUG|18F-MK-6240|Results of the 18F-MK-6240 PET scan will be correlated with other observations.
41455884|NCT02024230|DRUG|Rivaroxaban or Warfarin|a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin
41455885|NCT02763631|OTHER|Experimental: Treatment|Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
41455886|NCT02763631|OTHER|Experimental: Run In Phase|Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
41455887|NCT02763631|OTHER|Sham Comparator: Stand Care Arm|No change will be made to participants care
41292951|NCT00856427|PROCEDURE|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
41455888|NCT04202484|DRUG|Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules|Toripalimab: 240mg IV Q3W;Tegafur,Gimeracil and Oteracil Porassium Capsules: 40mg/m2 Bid PO×14d Q3W;Oxaliplatin: 130mg/m2 IV Q3W
41292952|NCT02812030|OTHER|National Eye Institute Visual Functioning Questionnaire|Routine treatment plus visual functioning questionnaires
41292953|NCT00918723|DRUG|Fludarabine Phosphate|Given IV
41292954|NCT00918723|DRUG|Cyclophosphamide|Given IV
41292955|NCT00918723|BIOLOGICAL|Rituximab|Given IV
41292956|NCT00918723|DRUG|Vorinostat|Given PO
41292957|NCT01133639|DRUG|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
41292958|NCT01133639|DRUG|Placebo|Placebo plus standard of care
40958669|NCT02856178|DRUG|Caspofungin|Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
40958670|NCT06385951|DIAGNOSTIC_TEST|Procedure for patients|We will screen patients who undergo an MRI and neuropsychological examination as part of their diagnostic workup. If inclusion and exclusion criteria are met, patients will be asked to undergo additional investigations (FDG-PET, lumbar puncture, tau and amyloid PET and the ALLO iVR task).
40958671|NCT06385951|DIAGNOSTIC_TEST|Procedure for healthy controls|Healthy controls will be asked to undergo a neuropsychological examination, the ALLO iVR task, an MRI, FDG-PET and tau-PET.
40763589|NCT06639269|OTHER|fertility health education program|"The intervention group will be implemented with a fertility health education program for which a literature information document will be created. In the training; booklets and brochures will be prepared. The control unit will include information on programming and data collection forms to be used. Those selected from the intervention group will be divided into groups of 10-15 people. The training program will consist of 3 sessions. Training sessions will be planned on days and hours that are convenient for the researcher, classrooms and students. For students who cannot attend group training, make-up training will be provided within a week. In this study, the time between sessions will be planned as 1 week. The sessions in this study will be planned to be in groups of 10-15 people and will last 50 minutes."
40763590|NCT05422573|BEHAVIORAL|post-test cardiovascular genetic counseling with pre-test education by video|post-test cardiovascular genetic counseling with pre-test education by video
40763591|NCT05422573|BEHAVIORAL|required phone call with genetic counselor pre-test|REQUIRED phone call with genetic counselor pre-test.
41455889|NCT00301964|BIOLOGICAL|bevacizumab|Given IV
40763592|NCT05422573|BEHAVIORAL|optional phone call with genetic counselor pre-test|OPTIONAL phone call with genetic counselor pre-test
40763593|NCT06538012|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
40763594|NCT06538012|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
40763595|NCT06538012|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
40958672|NCT04336540|OTHER|Menu configuration (presence of energy labelling)|Restaurant menus are altered to accommodate energy labelling intervention
40958673|NCT04336540|OTHER|Menu configuration (more lower energy options added)|Restaurant menus are altered to include more lower energy options
41455890|NCT00301964|OTHER|laboratory biomarker analysis|Correlative studies
40763596|NCT06538012|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
40763597|NCT06538012|DRUG|Pembrolizumab|Intravenous (IV) infusion
40763598|NCT05538208|DRUG|Mycophenolate Mofetil|MMF dosed 600mg/m2 body surface area per dose about every 12 hours
40958674|NCT06210607|DRUG|HS-10511 Tablets|HS-10511 tablets for 5\~6 SAD cohorts and 4 MAD cohorts
40958675|NCT06210607|DRUG|HS-10511 Tablets Placebo|HS-10511 tablets placebo for 5\~6 SAD cohorts and 4 MAD cohorts
40958676|NCT03916991|OTHER|Exercise|Hip focused Neuromuscular Activation Exercise
40958677|NCT02768363|BIOLOGICAL|aglatimagene besadenovec|Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
41455891|NCT04600635|PROCEDURE|Bariatric surgery|Some patients in the cohort are followed by a multidisciplinary team in preparation for bariatric surgery. Others have already undergone bariatric surgery and are being followed up postoperatively.
41455892|NCT00884390|DRUG|moroctocog alfa (AF-CC) (ReFacto AF)|Providing moroctocog alfa (AF-CC) as test article for use during this study.
40763599|NCT05538208|DRUG|Mycophenolate Mofetil|MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA \>=60-70 mg\*h/L
41292959|NCT05215392|BEHAVIORAL|Family Connections program|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app. Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
41292960|NCT05187338|DRUG|ipilimumab +pembrolizumab +durvalumab|"This study has 3 subgroups:~1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
40958678|NCT02768363|BIOLOGICAL|placebo|Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
40763600|NCT06643624|OTHER|Vision Training Program|Vision training (experimental) group; vision training program was applied in addition to routine training programs. For 8 weeks, 5 sessions per week for a total of 40 sessions of vision training were applied by a physiotherapist. In the first 2 weeks, each movement was applied for 1 minute for a total of 10 minutes. In the 3rd week, each movement was practiced for 1.5 minutes for a total of 15 minutes. In weeks 4-8, each movement was performed for 2 minutes each for a total of 20 minutes.
40763601|NCT06643624|OTHER|Routine Training Program|All athletes performed their routine training for wrestling 6 days a week.
40763602|NCT06639113|BEHAVIORAL|Self-administration medicines|Management of drugs' administration by the patient
40763603|NCT06640777|DRUG|LEAF-4L6715|LEAF-4L6715: Administration at a dose of 200mg , for up to 10 days every 12 hours for the first 2 days, followed by once-a-day dosing for the next 8 days (days 3 through 10).
40958679|NCT02768363|DRUG|valacyclovir|Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
41292961|NCT03991377|BEHAVIORAL|Eye movement desensitization and reprocessing therapy|"EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~1. Patient history.~2. Patient preparation.~3. Patient assessment.~4. Memory desensitization.~5. Installing the positive cognition.~6. Body scan.~7. Closure.~8. Reevaluation."
40958680|NCT00806351|DRUG|Active Anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
41455893|NCT00884390|PROCEDURE|Laboratory tests|Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
40958681|NCT00806351|DRUG|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
40763604|NCT06640777|DRUG|Supportive Care|Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
40958682|NCT04185064|DEVICE|Game Ready ATX shoulder wrap; Game Ready GRPro 2.1|the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.
40958683|NCT04185064|OTHER|Standard Care|Participants will undergo post-surgical cryotherapy using the treating surgeons preferred method of cryotherapy, which can include rest, ice, and compression using standard ice packs or bag of ice, a cryocuff, or other such device.
40763605|NCT06638346|OTHER|Shortened FIFA 11+ warm-up exercise program|"The shortened FIFA11+ incorporates 5 exercises from the original FIFA11+ part 2 and 3: Sideways bench, single-leg stance, squats, jumping and plant and cut (refer to FIFA 11+ manual). All exercises, except plant and cut, have three levels of difficulty. Difficulty progression will follow FIFA11+ guideline option C where all players progress to the next level of all exercises after 3 or 4 weeks. This program is done on artificial turf.~Coaches will be trained on FIFA guidelines by the primary investigator and provided with explanatory placards and the FIFA 11+ manual. The primary investigator will conduct checks twice a week with the coaches to address any questions and review the program. Only the shortened FIFA11+ group will receive verbal feedback as per FIFA11+ guidelines."
40763606|NCT06638346|OTHER|Brazilian warm-up exercise program|"The control group engages in a Brazilian warm-up. The warm-up consists of exercises performed in standing and while running including the following:~* Performed in standing: Circular Arms (20-30 sec total), Opening and closing of the hips (20-30 sec total).~* Performed while running back and forth on the field: Jogging (2 times), high kicks (2 times), glute kicks (2 times)~* Performed while running forward (exercise), then small jog back without performing the exercise: hand-to-heel touches (2 times), knee and heel touches (2 times each side), side leg swings (2 times) and progressive sprint 80-90% speed (2 times).~Coaches will supervise the session but will not be allowed to give verbal feedback. This program is done on artificial turf."
40763607|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinol + geranylgeraniol|Combination of ubiquinol and geranylgeraniol
40763608|NCT06640465|DIETARY_SUPPLEMENT|Geranylgeraniol|Geranylgeraniol alone
40958684|NCT02008760|DIETARY_SUPPLEMENT|Omega Krill with D3|
40958685|NCT02287857|DRUG|Domestic Tenofovir Disoproxil Fumarate Tablets|1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
40958686|NCT02287857|DRUG|Tenofovir Disoproxil Fumarate Tablets of Gilead|1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
40958687|NCT00561457|DEVICE|Bard Luminexx Iliac Stent and Delivery System|Iliac Stenting
40958688|NCT02675283|DEVICE|Simtomax|Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
40958689|NCT03307967|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
41455894|NCT04071613|DRUG|Tenecteplase|Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset
40763609|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinol|Ubiquinol alone
41455895|NCT04071613|DRUG|Intravenous tissue plasminogen activator (tPA)|Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset
41455896|NCT00966160|DRUG|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
41292962|NCT03991377|DRUG|Treatment as usual|Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
41292963|NCT02760407|DRUG|Olokizumab 64mg q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
41292964|NCT02760407|DRUG|Olokizumab 64mg q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
40958690|NCT05073601|DIAGNOSTIC_TEST|ELISA,DNA extraction|quantitative measurement of (Thyroid stimulating hormon (TSH), free triiodothyronine (FT3)\& Free tetraiodothyronine(FT4)) measured using ELISA . Serum 25-OH vitamin D measured using ELISA. Serum 25-OH vitamin D will be classified based on 2012 American Endocrine Society guidelines into deficient (\< 20ng/ml), insufficient ( 21 -30 ng/ml) and sufficient (\> 30 ng/ml).vitamin D receptor polymorphisms was done in 3 steps: a) DNA extraction from whole blood using Gene Jet gene DNA Purification kits . b) PCR: three Vitamin D receptor polymorphisms were tested \[Taq I (restriction enzymes according to single nucleotide polymorphism ) (rs731236), Apa I (rs7975232) and Bsm I (rs1544410)\] using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genomic DNA was amplified using certain primers
41292965|NCT02760407|DRUG|Adalimumab 40mg q2w|0.4 or 0.8 mL prefilled, single-dose syringe
40958691|NCT03392467|BIOLOGICAL|PNEUMOSTEM|human umbilical cord blood-derived mesenchymal stem cells
41292966|NCT02760407|DRUG|Placebo q2w|sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
40958692|NCT03392467|OTHER|Placebo|normal saline
40958693|NCT03734042|BIOLOGICAL|Platelet rich plasma intrauterine infusion|platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11
40958694|NCT03734042|BIOLOGICAL|Normal saline|Intrauterine infusion of normal saline at day 11
41292967|NCT03475407|DRUG|Ozurdex intravitreal injection|"1. Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline~2. AC paracentesis at 6 wk~3. intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk"
41292968|NCT02881307|DIETARY_SUPPLEMENT|Whey Protein&Prebiotic Supplement|Dietary supplement (protein drink) commercially available protein shakes
41292969|NCT02881307|BEHAVIORAL|Dietary Counseling|Dietary Counseling
41455897|NCT00966160|DRUG|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
41455898|NCT01684280|GENETIC|gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
41455899|NCT03141216|DEVICE|VCV+PSV|invasive mechanical mechanical modes by volume cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
40958695|NCT06045546|PROCEDURE|5-5-5-8 technique|the new technique of 5-5-5-8 for laparoscopic cholecystectomy
40958696|NCT06045546|PROCEDURE|10-10-10-5 technique|the standard technique of 10-10-10-5 for laparoscopic cholecystectomy
40958697|NCT02486523|BEHAVIORAL|Hygiene promotion sessions|Hygiene promotion sessions are provided weekly to the caretakers at the health center level. They contain 7 main messages this study is trying to get across: Allocate a protected space for children to play, limiting the likelihood of them ingesting soil or animal feces; Wash the child with soap (hand, face) when outside the protected area; Cleaning and rapid burial of children's stools; Key times for hand washing with soap for the child caretaker; Store drinking water in a closed container located in an elevated place out of reach of animals; Drinking water provided to the child should be treated with chlorine or boiled; Once weaned, avoid giving to the child leftover food, or only after warming it again.
40958698|NCT02486523|DEVICE|Household WASH package|The content of the kit: 200 g soap, aquatab 67 g, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
40958699|NCT02486523|BEHAVIORAL|Household visit|A household visit conducted by village's community health volunteers and ACF intervention staff during and after the treatment, to provide refresh training on the messages and the use of the kit.
41292970|NCT02881307|BEHAVIORAL|Dietary recommendations|recommendations for one meal per day including lean protein and vegetables
41455900|NCT03141216|DEVICE|PCV+PSV|invasive mechanical mechanical modes by pressure cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
40763610|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinone|Ubiquinone alone
40763611|NCT06640465|OTHER|Placebo|Placebo capsule
40763612|NCT04154163|DIAGNOSTIC_TEST|Dried blood Spot (DBS)|Dried Blood Spot filter paper and sponges
40763613|NCT04154163|DIAGNOSTIC_TEST|Venous blood sampling|Venous blood
40763614|NCT05910554|DRUG|Metformin|Patients randomized to metformin will be assigned the active arm.
40763615|NCT05910554|DRUG|Cellulose|Patients randomized to cellulose will be assigned the placebo arm.
40763616|NCT04418479|DRUG|Aspirin|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients being treated with dual antiplatelet therapy (DAPT) at high risk for recurrent ischemic events who have been over 12 months after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period."
40763617|NCT04418479|DRUG|Clopidogrel|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients being treated with dual antiplatelet therapy (DAPT) at high risk for recurrent ischemic events who have been over 12 months after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period."
40763618|NCT05798663|DRUG|Atezolizumab|Atezolizumab will be given to participants either intravenously at a dosage of 1200mg or subcutaneously at a dosage of 1875 mg on Day 1 of each 21-day cycle for Arms A, B, and C, and on days 1 and 22 of concurrent chemoradiotherapy for Arm C only.
40763619|NCT05798663|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 600 mg on day 1 of each 21-day cycle (Arms B and C), and on days 1 and 22 of concurrent chemoradiotherapy (Arm C only).
40763620|NCT06641219|DRUG|One single intravenous injection of [177Lu]Lu-BQ7876|One single intravenous injection of 600-800 MBq \[177Lu\]Lu-BQ7876 in prostate cancer patients.
40763621|NCT04788615|DRUG|Ofatumumab|20mg Subcutaneous injection
40763622|NCT04788615|DRUG|First line DMT|any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg
40763623|NCT03085290|OTHER|Autologous serum eye drops|Autologous serum eye drop doses will be 6 times daily in each eye
40763624|NCT03085290|OTHER|Allogeneic serum eye drops|Allogeneic serum eye drop doses will be 6 times daily in each eye
40763625|NCT03053232|DEVICE|Purse string suture device|Using purse string suture device to close gastrointestinal perforation under endoscopy.
40958700|NCT02486523|BEHAVIORAL|Group discussions after successful discharge|Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
40958701|NCT02486523|PROCEDURE|Outpatient Therapeutic Programme|Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
40763626|NCT03053232|DEVICE|Endoclips|Using endoclips to close gastrointestinal perforation under endoscopy.
41455901|NCT05336097|OTHER|Pathways to Empowerment|Pathways to Empowerment (PTE) is a program for person-centered intervention. PTE is rooted in the Strengths Model by Rapp and Goscha (2011), and in the Social Quality Approach as described by Van der Maesen and Walker (2005). The general aim of PTE is to improve the quality of the daily lives of persons who experience loss of control in their lives by focusing on their strengths and stimulating their personal agency, participation in society, and self-direction in life. The main task of professionals is to help create the conditions in which growth and recovery are likely to occur.
41455902|NCT06064149|BEHAVIORAL|CARE-PC Web-Based Application|The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects CV and prostate cancer-related risk variables and CV care access data from prostate cancer patients receiving ADT.
40763627|NCT06637813|OTHER|Blood sampling for evaluation of biomarkers|Non-routine diagnostic test evaluations
40958702|NCT00726375|DRUG|Etanercept (Enbrel)|Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
41455903|NCT02069951|OTHER|Practice a procedural module on a simulator|
41455904|NCT03086434|OTHER|Culturally Tailored Intervention|School-based substance use prevention
40763628|NCT06641284|DRUG|Spironolactone|All patients will receive Spironolactone as a part of their GDMT for Heart Failure
40763629|NCT04349098|DRUG|Selinexor|Participants will receive 20 mg of selinexor.
40763630|NCT04349098|OTHER|Placebo|Participants will receive 20 mg of placebo matched to selinexor.
40958703|NCT00105417|DRUG|IL-7|
40958704|NCT01404858|BEHAVIORAL|There is no intervention; this is a survey only study|There is no intervention; this is a survey only study
40958705|NCT04209517|OTHER|Filming|Behavioural markers selection from video-recordings of the interview
40958706|NCT04674410|DRUG|Antibiotic|Empiric antibiotic therapy, subdivided according to Community Acquired Pneumonia coverage vs Hospital Acquired Pneumonia coverage
40958707|NCT05607615|DRUG|Hydroxypropyl Beta Cyclodextrin|Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days
40958708|NCT05607615|DRUG|Placebo|0.5N saline as an intravenous (IV) infusion once every 28 days
40958709|NCT05274880|DRUG|CKD-393|PO, QD
40958710|NCT04290780|OTHER|nosocomial infection/hospital acquired infection|"When there is suspicion of a community-acquired case (admission of an infected patient) or nosocomial case (infection of a patient already hospitalized), a case report form including demographic data, medical history, and clinical and biological data on the infectious episode will be completed for each case, either patient, caregivers or health care professionals, presenting clinical signs or symptoms compatible with SARS-CoV-2 infection. The suspected cases will undergo nasopharyngeal swab collection and detection of SARS-CoV-2 in nasopharyngeal swabs will be done by real-time RT-PCR assay.~Hygiene measures applied by the service will be collected using a questionnaire as well as recommendations of the learned societies within the country regarding the risk of infection by coronavirus. In addition, data characterizing the service and hospital will also be collected (specialty, number of beds, number of nurses, doctors, etc.)."
41136003|NCT01682928|DRUG|IV/Oral Hydration and Bedrest|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs"
41136004|NCT01682928|OTHER|Hydrotherapy|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs~* HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
41136005|NCT03026166|DRUG|Ipilimumab|Administered by intravenous infusion
41455905|NCT03086434|OTHER|Standard Substance Abuse Education|Class room program
40763634|NCT05860985|DEVICE|ZEISS disposable|a comparison will be done between the present lenses used (reusable RESIGHT lenses and disposable Vitreq contact lens) and the new disposable RESIGHT lenses.
40763635|NCT00830531|DRUG|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
40763636|NCT00830531|DRUG|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
40763637|NCT06640036|OTHER|Rapeseed oil|During 1 week, 46 % of total energy intake will come from rapeseed oil, using pre-prepared and blinded meals.
40958711|NCT00397345|BIOLOGICAL|Trovax|1ml IM injection 2-8 weeks apart.
40958712|NCT00397345|BIOLOGICAL|Placebo|Placebo
40958713|NCT00397345|BIOLOGICAL|Standard of care therapy|subcutaneous low dose IL-2, interferon-α or sunitinib
40958714|NCT01441180|DRUG|GS7977|drug intervention
40958715|NCT01441180|DRUG|RBV|drug intervention
41136006|NCT03026166|DRUG|Nivolumab|Administered by intravenous infusion
40763638|NCT06640036|OTHER|Butter|During 1 week, 46 % of total energy intake will come from butter, using pre-prepared and blinded meals.
41136007|NCT03026166|DRUG|Rovalpituzumab tesirine|Administered by intravenous infusion
41136008|NCT02522104|DRUG|Siklos|
41136009|NCT05802849|DRUG|Acetazolamide|Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.
41292971|NCT05930873|BEHAVIORAL|Immersive room|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented on one of the four walls of the immersive room and a set of stimuli, including the target stimulus, which the subject will have to touch within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
41292972|NCT05930873|BEHAVIORAL|stimuli in a paper format|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented in a paper format and a set of stimuli, including the target stimulus, which the subject will have to indicate within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
41292973|NCT04346823|DRUG|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3minutes. Then, parturients breath 1% of sevoflurane in a mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min.~Thirty seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure.The duration of ECV in addition to the level of difficulty estimated by obstetricians will be recorded. Usually, the duration of ECV does not exceed 10 minutes.~The intervention will be stopped if the woman reported severe pain, if version could not be achieved readily, or if prolonged fetal bradycardia, uterine bleeding or placental abruption occurred.~Parturient will be kept in Post Anesthesia Care Unit (PACU) for 45minutes. CTG will be monitored during PACU stay."
41455906|NCT02541227|DRUG|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
40958716|NCT01544283|DRUG|Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch|Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
41455907|NCT06245603|DEVICE|Hydeal Cyst®|"BCG or MMC will be started within 1-2 weeks from randomization (within 4-6 weeks after TURB).~BCG or MMC will be administered once a week by intravesical instillation: BCG will be abministered for 6 weeks and MMC for 8 weeks. (induction cycles) Before instillations a physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes.~IPSS questionnaire and QoL questionaire will be administered to the patient at week 1, 4 and 6/8 (6 for BCG and 8 for MMC) of treatment.~48 hours after post BCG or MMC intravesical instillation, patients of Arm A will undergo Hydeal Cyst intravesical instillation.~BCG patiens will received 6 Hydeal Cyst intravesical instillation; MMC patiens will received 8 Hydeal Cyst intravesical instillation."
40958717|NCT01544283|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
40990560|NCT04417920|PROCEDURE|Express implant device|"Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock."
41292974|NCT04904042|DEVICE|Use of plasma of neutral argon|"Evaluation of the mesentery or peritoneum area infiltrated by miliary implants that is going to be treated. Determination of the PCI. Collection of several samples of the mesenteric peritoneum or parietal peritoneum with tumor involvement (implants between 1-2.5mm of diameter).~It will established a matrix which will be divided into 12 quadrants where the tissue with implants will be placed and it will be treated according to specific power (80-100%), and for an action time of 2-4 seconds or until macroscopic tumor destruction. For each power, application of Plasmajet at 1, 2 and 3 cm from the target tumor tissue.~The in-vivo effect will be evaluated with the use of ball-tip in terms of damage to the serosa or vascularization of the mesentery."
41292975|NCT02061007|DRUG|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
40958718|NCT05799170|OTHER|regional trauma care|Study intervention is the establishment of in-hospital trauma treatment centers and the formation of regional trauma care system. Regional trauma care system refers to both the establishment of unified and standardized pre-hospital and in-hospital trauma triage and injury classification warning mechanism and the development of unified trauma treatment process and standard in a main government district (population within 1 million), with secondary general hospitals and above that have strong treatment capability as the trauma treatment centers. Regional trauma care system will strengthen both pre-hospital emergency care and in-hospital emergency treatment while reinforcing the information exchange between in-hospital emergency treatment and specialized treatment. Taking 5 to 6 hospitals with certain trauma treatment capacity as the trauma treatment point, the trauma treatment network is formed relying on the treatment point hospitals within the range of one trauma treatment center.
40958719|NCT00654680|DRUG|Vardenafil (Levitra, BAY38-9456)|5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
40958720|NCT00654680|DRUG|Placebo|Matching placebo
40958721|NCT03719612|DRUG|DEFINITY®|All subjects will receive a single dose of DEFINITY®
41292976|NCT02061007|DRUG|Optional 18F-FMISO PET scan (18F-fluoromisonidazole)|All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
40763639|NCT06640036|OTHER|Coconut oil|During 1 week, 46 % of total energy intake will come from coconut oil, using pre-prepared and blinded meals.
40763640|NCT01889446|DIETARY_SUPPLEMENT|Calcium propionate|
40958722|NCT01945281|DRUG|Caspofungin|
41455908|NCT03290807|DEVICE|SPECT/CT|Combined single photon emission computerized tomography and conventional computerized tomography (SPECT/CT) is a hybrid imaging modality, which combines a 3D bone scintigraphy (SPECT) and a conventional CT into one imaging procedure. The use of SPECT/CT offers the benefit of combined anatomical, mechanical (CT) and functional imaging (SPECT)
41455909|NCT00005967|DRUG|tipifarnib|
41455910|NCT01780350|DEVICE|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
40763641|NCT06472856|PROCEDURE|Acupuncture|Acupuncture will be given using single use sterile stainless steel 34 gauge (Japanese size: 0.20 X 30 mm) filoform needles. Skin will be swabbed with an alcohol prep pad before acupuncture is administered. Needles will be inserted 0.5 to 1.0 centimetres deep into the skin and gently manipulated to create the deqi sensation. No electrical stimulation will be used.
40763642|NCT01799135|OTHER|DCE-MRI scan|
41455911|NCT00090753|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
40763643|NCT01799135|RADIATION|Stereotactic Body Radiation Therapy|
40763644|NCT01799135|OTHER|4D-CT scan|
40763645|NCT03807765|DRUG|Nivolumab|480 mg intravenous Nivolumab administered every 4 weeks.
40763646|NCT03807765|RADIATION|Stereotactic Radiosurgery|"Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy."
40763647|NCT06640712|DIAGNOSTIC_TEST|Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria.|The same psychiatrist administered the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) to all participants. Oral health examinations were performed by a trained dental student and a specialist dentist using a portable dental chair, artificial light, and a dental mirror. Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria. This index included the number of decayed, missing (due to caries, excluding 3rd molars), and filled teeth in the permanent dentition. The oral health examiners were blinded to each participant's substance use type and sociodemographic information.
40763648|NCT06640712|DIAGNOSTIC_TEST|Substance Use Disorder Diagnosis|This intervention involves a psychiatric evaluation conducted by a licensed psychiatrist to diagnose Substance Use Disorder according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The psychiatrist performs a comprehensive assessment of each participant's substance use history and related behaviors. This diagnosis step is essential for identifying participants with specific substance use disorders, such as Methamphetamine, Cannabis, or Polysubstance Use Disorders, before proceeding with the dental health examination.
40763649|NCT01822379|PROCEDURE|Melanocyte Keratinocyte transplantation|Transplantation of cells prepared with dispase
40763650|NCT06639516|DIETARY_SUPPLEMENT|Bifidobacterium longum|Bifidobacterium longum
40763651|NCT06639516|DIETARY_SUPPLEMENT|Placebo|Placebo
40958723|NCT01945281|DRUG|Amphotericin B Deoxycholate|
41455912|NCT00090753|DRUG|Epoetin alfa|Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
40763652|NCT06639516|COMBINATION_PRODUCT|Standard clinical treatment|Fasting, gastrointestinal decompression, rehydration, inhibition of pancreatic fluid and pancreatic enzyme secretion, improvement of microcirculation, and support of organ function if organ dysfunction occurs at a later stage (mechanical ventilation, continuous renal replacement therapy, and the use of vasoactive drugs).
40763653|NCT06211374|BEHAVIORAL|Communication Bridge|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
40763654|NCT06642142|PROCEDURE|ESP block|"The ESPB will be performed at the T4 level, monolaterally (according to the surgical side), with 30ml volume of 0.5% Ropivacaine injected with a 20-gauge, 50-mm-long needle. The technique used is the standard ultrasound-guided, sterile procedure.~Soon after performing the block, a timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block until 40 minutes or until general anaesthesia is induced, the cold sensitivity of the chest will be explored."
40763655|NCT04844606|DRUG|Mirikizumab|Administered SC
40763656|NCT04844606|DRUG|Mirikizumab|Administered IV
40763657|NCT04272034|DRUG|INCB099318|INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.
40763658|NCT06156384|DEVICE|FITBONE® Lengthening Nail|"The patient is installed on a standard orthopaedic table, intramedullary reaming is performed through a metal working tube. The osteotomy is performed percutaneously and then an osteotome according to the postage-stamp technique. Once the FITBONE lengthening nail is placed in the desired location, it should be connected to the subcutaneous receiver. The receiver should be placed close enough to the skin surface to ensure the energy transfer from the external transmitter.~After 5 to 10 days after surgery, the lengthening mechanism is operated by the patient, using the transmitter. An elongation of approximately 1 mm/day takes place. The attending physician determines the rhythm of lengthening in each case. When the desired elongation length is reached, the consolidation phase begins, which is necessary for bone regeneration. The FITBONE lengthening nail can be removed once the bone has consolidated, approximately one to one and a half years after implantation."
40763659|NCT06397768|BIOLOGICAL|RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
40958724|NCT05191771|DEVICE|Neovis Total Multi|1 drop in each eye, 4 times per day
40958725|NCT05191771|DEVICE|Systane Balance|1 drop in each eye, 4 times per day
41136010|NCT00610337|DRUG|Cethrin® (BA-210)|Intraoperative epidural administration during spinal decompression surgery
41136011|NCT00610337|PROCEDURE|placebo|Spinal decompression surgery without administration of Cethrin® BA-210
41455913|NCT00090753|DRUG|Epoetin beta|Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
41455914|NCT00090753|DRUG|Darbepoetin alfa|Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
41455915|NCT02803879|DEVICE|Cardiogoniometry|
41455916|NCT00382187|BIOLOGICAL|MF59 adjuvanted H5N1 influenza vaccine|"* MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~* non-adjuvanted influenza vaccine containing 15 ug of H5N1"
41455917|NCT02736019|DRUG|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
41455918|NCT02736019|DRUG|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
41455919|NCT02736019|DRUG|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
40763660|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
40763661|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
40763662|NCT06397768|BIOLOGICAL|Hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
40763663|NCT06397768|BIOLOGICAL|Streptococcus pneumoniae vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
40763664|NCT06397768|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form:Oral solution-Route of administration:Oral
40763665|NCT06397768|BIOLOGICAL|Measles, mumps, and rubella vaccine|Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular
41455920|NCT02736019|DRUG|Placebo 2|Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
40763666|NCT06397768|BIOLOGICAL|Varicella virus vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular
40763667|NCT06397768|BIOLOGICAL|Placebo|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
41136012|NCT04439825|DRUG|Botulinum Neurotoxin|glabella, forehead lines and/or lateral canthal lines
41136013|NCT04439825|DRUG|Placebo|Saline solution (preservative free)
41455921|NCT02378909|DEVICE|Electrical stimulation device.|In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
41455922|NCT02697708|DIETARY_SUPPLEMENT|Potassium control diet|No additional potassium.
41455923|NCT02697708|DIETARY_SUPPLEMENT|Potassium gluconate diet|1000 mg K from potassium gluconate.
41455924|NCT02697708|DIETARY_SUPPLEMENT|Potato Diet|1000 mg K from potatoes.
41455925|NCT02697708|DIETARY_SUPPLEMENT|French Fries Diet|1000 mg K from French Fries.
40763668|NCT00751985|OTHER|Personalised normative feedback (PNF)|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
40990561|NCT03209427|DRUG|Morphine 100 μg|Intrathecal injection of morphine100 μg
41136014|NCT02066636|DRUG|Nivolumab|
41136015|NCT01070537|DEVICE|Bonfils fiberscope intubation|
41455926|NCT03192813|DEVICE|Symetis ACURATE neo™ transfemoral TAVI system|Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
41292977|NCT02061007|PROCEDURE|Surgical Resection of Melanoma Metastases|Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
41292978|NCT04578145|DIAGNOSTIC_TEST|HIV self-testing among female sex workers|"Barriers faced by FSWs in terms of undergoing HIV blood test seemingly overcome through the implementation of alternative strategy of testing, by using OFT self-testing (Ora-Quick).~Ora-Quick test used in this study measures antibody in oral fluid of participants. The oral fluid is collected used a test swab from participant's gum by wiping upper and lower gums once. The specimen mixed with buffered developer solution in test tube. Test result will appear in a short time, by 20 to 40 minutes and leading to interpret."
41292979|NCT05519761|DEVICE|Implantation of veinous access ports|"The surgeon, anaesthetist and interventional radiologist should be thoroughly familiar with the surgical procedure, instruments, and device characteristics prior to performing the implantation.~The nurse has also to be familiar with the implantable port since he/she intervenes in it at the time of the Huber needle puncture and solution injection."
41292980|NCT03403972|DRUG|Vancomycin 250Mg Capsule|Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
40763669|NCT00751985|OTHER|Self-help material|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
40763670|NCT00751985|OTHER|Control|The participant is being informed about their allocation to the control group.
40763671|NCT05453539|DRUG|DSPE-DOTA-Gd Liposomal Injection|Single dose, intravenous infusion
40763674|NCT06639373|OTHER|Specialized clinical service access|A new model of addiction care that will offer comprehensive and coordinated service delivery
40763675|NCT04660344|DRUG|Atezolizumab|Participants will receive 1680 mg intravenously every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
40763676|NCT04660344|OTHER|Placebo|Participants will receive placebo intravenously Q4W on Day 1 of each 28-day cycle
40763677|NCT06637852|BEHAVIORAL|SUFICS-PACT|SUFICS-PACT includes sexual and urinary dysfunction screening, collaborative treatment of sexual and urinary dysfunction, and care managers who are mental health professionals with training in psychosexual counseling. Mental health professionals will facilitate a comprehensive approach to sexual dysfunction, as emphasized by the biopsychosocial model of sexual health. SUFICS-PACT also emphasizes close follow up, which is important for sexual function recovery after prostate cancer treatment.
40990562|NCT03209427|DRUG|Morphine 200 μg|Intrathecal injection of morphine 200 μg
41455927|NCT03192813|DEVICE|Medtronic CoreValve Evolut R TAVI System|Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
41455928|NCT05772858|OTHER|Training on CIFFTA competencies using Family Therapy Training and Implementation Platform (FTTIP)|An Innovative Web-based Tool to train mental health therapists in family therapy competencies with animated families and provided recorded video responses to receive feedback from trainers.
40763678|NCT06637670|OTHER|Kinesiology taping|'Y shaped' kinesiology taping was applied on quadriceps femoris muscle, based on facilitation technique with 25-50% stretching.
40763679|NCT06637670|OTHER|Placebo taping|A tape without tension was applied perpendicular on the quadriceps femoris muscle.
40763680|NCT03808077|DRUG|Rocuronium 0.3mg/kg/hr|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).
40763681|NCT03808077|DRUG|Rocuronium 1.5mg/kg/hr|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
40763682|NCT05988619|DEVICE|Transcranial Magnetic Stimulation|TMS is a noninvasive method of brain stimulation administered by physicians in the UCLA TMS Clinical and Research Service. It is an FDA-approved treatment for Major Depressive Disorder.
40763683|NCT05988619|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy|This Way Up is an internet-based cognitive behavioral therapy (iCBT) for depression and anxiety. Participants learn about depression and anxiety symptoms, as well as behavioral strategies for addressing these symptoms. Participants are provided with homework exercises designed to help them engage in these strategies regularly.
40763684|NCT05988619|BEHAVIORAL|Psychoeducation|Stories of the Mind is an educational program that is freely available through the Public Broadcast Service (PBS). Participants view video testimonials in which individuals describe their personal experiences across a variety of mental health concerns.
40763685|NCT06637904|DIAGNOSTIC_TEST|TriVerity Test|Participants in the post-phase of the study will have a 2.5 ml whole blood draw obtained via venipuncture into a PAXgene® Blood RNA tube. Blood samples will be processed using the TriVerity Cartridge on the Myrna Instrument located in the ED.
40763686|NCT04519567|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
40763687|NCT04519567|BIOLOGICAL|Placebo|Placebo Comparator
40763688|NCT05833139|DRUG|BI 1810631|BI 1810631
40763689|NCT05833139|DRUG|Itraconazole|Itraconazole
40958726|NCT01223430|DRUG|Si-Ni-Tang/ Placebo of Si-Ni-Tang|The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
40958727|NCT03534414|DIETARY_SUPPLEMENT|Portfolio Dietary Pattern|"Portfolio Dietary Pattern consisting of 4 food components, including:~1. plant sterols (sterol-enriched margarine or supplement)~2. viscous soluble fibres (oats, barley, psyllium, eggplant, okra, etc)~3. plant protein (soy products and pulses), and~4. nuts (tree nuts and peanuts)"
40958728|NCT03534414|DIETARY_SUPPLEMENT|NCEP Based Diet|A low saturated fat, low cholesterol diet.
41136016|NCT00790569|DRUG|nicotine|Given transdermally and orally
40958729|NCT00760123|OTHER|Early Physical Therapy and Educational strategy|"Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy"
40958730|NCT03703622|BEHAVIORAL|Video-debriefing with standard HBB training compared with standard HBB training only|"We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, \& OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances."
40958731|NCT03004742|DIETARY_SUPPLEMENT|Flavonoid|Flavonoid rich supplement
40958732|NCT03004742|DIETARY_SUPPLEMENT|Placebo|Placebo
40958733|NCT01695187|DRUG|NB-001 (0.3%)|Topical administration at least five times throughout the day
40958734|NCT01695187|DRUG|Placebo|
40958735|NCT01529047|BEHAVIORAL|Personalized Feedback Intervention|Printed or electronic form containing personalized information about health-relevant behaviors
41292981|NCT04013581|DRUG|TZD group|Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg
40958739|NCT03460730|BIOLOGICAL|Pneumovax|23-valent pneumococcal polysaccharide vaccine
40958740|NCT06441448|BEHAVIORAL|case focus groups|The study is in a monocentric, exploratory, participatory study conceptualization phase. Within the study, a mixed-methods assessment involves various interview and group exercise formats among scientists, medical personnel, affected individuals, and their caregivers to develop components for a future psychotherapeutic program for ALS patients and their caregivers. Therapists provide an overview of therapy forms by presenting components based on format, content, and applied techniques. Case studies and focus groups are used for practical experience for the participants. Participants qualitatively assess the significance of therapeutic approaches and make a quantitative prioritization to establish a ranking of therapy components.
40958741|NCT00622817|DRUG|xylometazoline HCL 0.05%|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
40958742|NCT00622817|DRUG|Epinephrine 1mg|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
40958743|NCT00531973|DRUG|liposomal doxorubicin|5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
41292982|NCT04013581|DRUG|SGLT-2 group|Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
41136017|NCT00790569|DRUG|varenicline|Given orally
41136018|NCT00790569|OTHER|placebo|Given orally
41136019|NCT02695199|PROCEDURE|Laparoscopic varicocelectomy|Traditional laparoscopic varicocelectomy assisted by laparoscopic Doppler ultrasound
41292983|NCT03664817|BEHAVIORAL|social capital intervention|The social capital intervention will focus on developing skills and group-work that culminate in participant-derived photovoice projects. Each group of YBMSM will be encouraged to complete a 30 day photovoice challenge. The 30 day challenge is based on a prior community action project done as a part of our Centers for AIDS Research (CFAR)-funded research, which was a Photovoice project conducted by Dr. Hussen. Photovoice is a participatory action research methodology in which groups of individuals from a population of interest are given cameras to document events, people and places of significance in their lives.
41292984|NCT03664817|BEHAVIORAL|group-based health promotion intervention|"The control arm will participate in a health education intervention that will be delivered in a group, but without a specific goal of creating group cohesion or social capital. The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)."
41455929|NCT05772858|OTHER|Training on CIFFTA competencies using Training and Coaching as Usual (TCAU).|Therapists receive training using the traditional face to-face training method for 2.5 days followed by coaching.
41136020|NCT02695199|PROCEDURE|Microscopic Subinguinal varicocelectomy|Infertile patients with clinically palpable varicoceles were selected to receive microscopic Subinguinal varicocelectomy
40763690|NCT06637930|OTHER|Edentulous Alveolar Ridge In Mandible|"implant retained mandibular overdenture using telescopic attachment system. all the patients received 2 implants at the canine region bilaterally using sterelithographic guide , then healing period for 3 months for proper osseointegration , then digital intraoral scanning was performed to detect implant position using scannable bodies , abutments which act as primary crowns were designed on cad software then milled using premilled titanium abutments.the study grouping was performed then virtual model was done for the designing of the frameworks then milled according to the grouping of the study. Try in of the frameworks was done and overdentures were inserted.~* Retention force test was done using digital force gauge.~* Probing depth using Teflon coated periodontal probe.~* Marginal bone level and bone density were measured using digital periapical x-ray"
40763691|NCT01550887|OTHER|No intervention|No intervention will be performed on this study
40763692|NCT06640673|DIAGNOSTIC_TEST|Hd-EEG|Subjects undergo a clinical and neuropsychological assesment, then a Hd-EEG both during resting state and execution of tasks, and structural Magnetic Resonance Imaging
40763693|NCT05127265|OTHER|Video Monitoring|continuous video monitoring
40763694|NCT05127265|OTHER|Accelerometer Monitoring|continuous accelerometer monitoring of patient movements
40763695|NCT05127265|OTHER|Noise Level Monitoring|continuous environmental noise monitoring
40763696|NCT05127265|OTHER|Light Level Monitoring|continuous environmental light monitoring
40763697|NCT05127265|OTHER|Air Quality Monitoring|continuous environmental air quality monitoring
40763698|NCT05127265|OTHER|EKG Monitoring|continuous EKG monitoring
40763699|NCT05127265|OTHER|Vitals Monitoring|continuous vitals monitoring (heart rate, oxygen saturation)
40763700|NCT05127265|OTHER|Biosample Collection|blood and urine samples collected once on Day 1 and once on Day 2
40763701|NCT05127265|OTHER|Delirium Motor Subtyping Scale 4 (DMSS-4)|done daily on delirious patients to subtype delirium
40763702|NCT02014103|DRUG|Prograf|Administration of each formulation will be determined by sequence.
40763703|NCT02014103|DRUG|Tacrolimus, Sandoz|Administration of each formulation will be determined by sequence.
40763704|NCT02014103|DRUG|Tacrolimus, Reddy Laboratory|Administration of each formulation will be determined by sequence.
40763705|NCT02014103|DRUG|Tacrolimus, Mylan|Administration of each formulation will be determined by sequence.
40763706|NCT02014103|DRUG|Tacrolimus, Accord|Administration of each formulation will be determined by sequence.
40763707|NCT02014103|DRUG|Tacrolimus, Pancea Biotech Limited|Administration of each formulation will be determined by sequence.
40763708|NCT00837135|OTHER|Screening|"A. SCREENING~1. Consent~2. Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)~3. Physical Exam, History, Blood Tests~4. Skin Test (for allergy to saccaromyces cerevisiae) yeast.~5. Collection of Blood for research~B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)~C. ENROLLMENT INTO ACTIVE PART OF STUDY~1. Consent~2. Chemotherapy~3. GI-4000 Vaccine #1 + Prevnar + Activated T Cells~4. GI-4000 Vaccine #2~5. Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B."
40763709|NCT00837135|BIOLOGICAL|GI-4000 Vaccine|"1. Chemotherapy and Radiation~2. GI-4000 Vaccine #3~3. GI-4000 Vaccine #4"
40763710|NCT00837135|BIOLOGICAL|GI-4000 Vaccine + Activated T Cells|"1. Apheresis #2~2. Chemoradiation~3. Activated T Cells + GI-4000 Vaccine #3~4. GI-4000 Vaccine #4"
40763711|NCT00837135|BIOLOGICAL|Surgical Evaluation after Vaccine #4|"SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.~B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR."
40763712|NCT03755154|DRUG|S65487- initial scheme|S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.
40763713|NCT03755154|DRUG|S65487 - alternative scheme|S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
40763714|NCT02946983|OTHER|Fructose|Intragastric administration of fructose (25g dissolved in 250ml distilled water)
40763715|NCT02946983|OTHER|Control|Intragastric administration of distilled water
40763716|NCT06150898|PROCEDURE|Prospective data and sample collection|Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity
40763717|NCT06150898|DRUG|Ketorolac 10 Mg Oral Tablet|Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
40763718|NCT06150898|DRUG|Pregabalin 75mg|Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
40763719|NCT04704648|PROCEDURE|Surgical|"The treatment involves excision only of the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP).~As part of the study patients will be asked to return for follow-up evaluation 1 week, 6 weeks, 6 months, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough ocular history as well as a history of AIDS-defining illnesses and perform a slit-lamp examination of both eyes, complete with templated drawings of the conjunctiva, and careful examination of the cornea for limbal stem cell deficiency."
40763720|NCT03215160|BEHAVIORAL|Exercises|mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
41136021|NCT02666404|OTHER|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
41292985|NCT00029315|DRUG|Recombinant Tissue Plasminogen Activator (rt-PA)|
41292986|NCT00006418|PROCEDURE|DNA collection|
41292987|NCT02933515|OTHER|yoga and occupational therapy|group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
40763721|NCT05634174|DRUG|Mirabegron|Single dose, 100mg oral mirabegron
40763722|NCT05912634|PROCEDURE|Conservative TAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
40763723|NCT05912634|PROCEDURE|Extensive TAAD- R|Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
40763724|NCT01198691|DEVICE|Insorb absorbable staples|Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
40763725|NCT01198691|DEVICE|Insorb|Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
40763726|NCT03713411|PROCEDURE|urethral catheter placement|urethral catheter placement to provide low-pressure urinary bladder by providing active drainage of the bladder
40763727|NCT06641557|DRUG|200mg of Ikt-148009|4 50mg capsules
40763728|NCT06641050|DIAGNOSTIC_TEST|Triage+ Score|The TriAGE+ score is used to evaluate the risk of cerebrovascular disease in patients presenting with dizziness. The score assists in determining the necessity of advanced diagnostic evaluation for stroke, potentially improving diagnostic accuracy and patient outcomes.
40763729|NCT06211868|BEHAVIORAL|Digital wearable and AI-human symbiotic lifestyle intervention|Digital wearable and AI-human symbiotic lifestyle intervention
40763730|NCT04642430|DRUG|Apixaban|Refer to Apixaban group
40763731|NCT04642430|DRUG|Rivaroxaban|Refer to Rivaroxaban group
40763732|NCT06643078|DRUG|HL231 Solution for Inhalation|HL231 Solution for Inhalation, 3ml:261 μg/141μg, once per day via PARI BOY nebulizer, consisting of a fixed dose combination of indacaterol 261µg and glycopyrronium 141µg, treatment period; 52-weeks fixed dose.
40763733|NCT06643078|DRUG|Ultibro 110μg/50 μg|Ultibro capsule for inhalation once per day via Breezhaler, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, treatment period; 52-weeks fixed dose.
40958744|NCT00531973|DRUG|epirubicin|5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
41292988|NCT02077049|DEVICE|serious games|"Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.~The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.~This serious games program is instructed individually by experienced physiotherapists."
41292989|NCT02077049|OTHER|Conventional self-training|Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
40958745|NCT06063278|BEHAVIORAL|l Group Therapy for BN.|9 to 10 group sessions of 90 to 120min each
40958746|NCT04896541|BIOLOGICAL|AZD7442 300 mg IM(male)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
41455930|NCT05772858|OTHER|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA).|CIFFTA has three major components: Family Therapy, Individual Therapy, and Psycho-educational Modules, delivered over 16 weeks in a two session (60 minutes each) per week format. One session will typically be a family session which may include Family Therapy or Psychoeducational modules designed for the family or parents alone. The other session is typically with the adolescent alone which may include individual treatment or Psycho-educational modules designed for the adolescent.
40958747|NCT04896541|BIOLOGICAL|AZD7442 600 mg IM (male)|Single dose of 600 mg of AZD7442 or saline placebo on Day 1.
40958748|NCT04896541|BIOLOGICAL|AZD7442 300 mg IV (male and female)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
40958749|NCT04896541|BIOLOGICAL|AZD7442 1000 mg IV (male)|Single dose 1000 mg of AZD7442 or saline placebo on Day 1.
40958750|NCT04302896|DRUG|dolutegravir oral tablet 50mg|"Tivicay® (dolutegravir, DTG), a HIV-1 integrase strand transfer inhibitor (INSTI), is FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 30kg. Tivicay® 50mg tablets \[GlaxoSmithKline\] are yellow, round, film-coated, biconvex tablets debossed with SV 572 on one side and 50 on the other side. The inactive ingredients in each tablet are D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide."
40958751|NCT04302896|DRUG|emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg|"Descovy® (emtricitabine/tenofovir alafenamide, FTC/TAF) is a combination of two HIV nucleoside analog reverse transcriptase inhibitors (NRTIs) FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg. Descovy® 200 mg/25 mg tablets \[Gilead\] are blue, rectangular-shaped, and film-coated with GSI debossed on one side and 225 on the other side. The inactive ingredients are croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide."
40958752|NCT04302896|DRUG|tenofovir disoproxil fumarate oral tablet 300mg|"Viread® (tenofovir DF, TDF) is a nucleotide analog HIV-1 reverse transcriptase inhibitor and a hepatitis B reverse transcriptase inhibitor FDA-approved for the treatment of HIV-1 infection in combination with other antiretroviral agents and for the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg. Viread® 300mg tablets \[Gilead\] are almond-shaped, light blue, film-coated tablets containing 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil, are debossed with GILEAD and 4331 on one side and with 300 on the other side. The inactive ingredients in each tablet are croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. Viread® 300mg tablets are coated with Opadry II Y-30-10671-A, which contains FD\&C blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin."
40958753|NCT04302896|DRUG|lamivudine oral tablet 300mg|"Lamivudine (Epivir®, 3TC) is a nucleoside analogue reverse transcriptase inhibitor FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients at least 3 months of age. Lamivudine 300mg tablets \[Apotex Inc.\] are gray, modified diamond-shaped, film-coated, and engraved with LMV 300 on one side and APO on the reverse side. Inactive ingredients are black iron oxide, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose anhydrous, magnesium stearate, polyethylene glycol, and titanium dioxide."
40958754|NCT02516046|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
40958755|NCT02516046|PROCEDURE|PET Scan|positron emission tomography (PET) scan
40958756|NCT01553383|DEVICE|"nasal peep valve Provent"|application of nasal peep valve vs dental device and cpap
40958757|NCT00395304|DRUG|fluticasone propionate + montelukast|Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
40958758|NCT00395304|DRUG|fluticasone propionate|Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
40958759|NCT00395304|DRUG|fluticasone propionate + salmeterol|Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
40958760|NCT04614597|BIOLOGICAL|Sabin strain inactivated polio vaccine|Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.
40958761|NCT06245031|DEVICE|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
41292990|NCT05690594|OTHER|Self or straight administered questionnaire|"Self or straight administered questionnaire with 5 parts:~* General questionnaire (to collect socio-demographic data)~* ICIQ score to evaluate urinary continence~* FLQI score to evaluate fecal continence~* FSFI score to evaluate sexuality in women or IIEF-5 score to evaluate sexuality in men~* SF-12 score to evaluate quality of life The questionnaire will be sent to patients by email and/or mail. Patients will be able to either complete the questionnaire alone and return it to the primary investigator, or to request a telephone interview to help them to complete the questionnaire. The questionnaire is administered only once and the estimated response time to the questionnaire is between 30 minutes and one hour."
40958762|NCT02014571|DRUG|GSK2878175|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
40958763|NCT02014571|DRUG|Placebo|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
40958764|NCT05412615|PROCEDURE|Meniscus Allograft Transplantation with Proximal Row Carpectomy|Supplementing the wrist reconstruction with a meniscal allograft to improve wrist function and pain scores.
40958765|NCT05412615|PROCEDURE|Proximal Row Carpectomy|Standard proximal row carpectomy with no tissue or synthetic adjuncts
40958766|NCT01685944|DIETARY_SUPPLEMENT|Live Pediococcus pentosaceus LP28|
40958767|NCT01685944|DIETARY_SUPPLEMENT|Heat-killed Pediococcus pentosaceus LP28|
40958768|NCT01685944|DIETARY_SUPPLEMENT|Placebo|
41455931|NCT05772858|OTHER|Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP)|The FTTIP agency readiness work begins with a pre-recorded FTTIP introduction webinar presented separately to each agency which presents overall goals of the project and the different FTTIP components, and key decisions agencies often make when seeking to sustain a new EBT.
40763734|NCT06108609|OTHER|Administration of the French version of the COSI and IOI-HA questionnaires|"Inclusion (D0):~* Audiometry (as part of treatment)~* Clinical evaluation (as part of treatment)~* Passing the French version of the COSI and IOI-HA questionnaires Visit 1 (D0 +3±1 week): only for 35 patients Second administration of the French version of the COSI and IOI-HA questionnaires either by telephone, or during a second consultation or hospitalization, if this occurs within a compatible time frame."
40763735|NCT06498687|DRUG|CYR-064|Theophylline Nasal Spray
40763736|NCT06637735|OTHER|education|pregnant women will be given a 4-week training and the pre-test post-test will be analyzed
40763737|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+8Gy x 3f|Radiotherapy: 8Gy x 3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
40763738|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+16Gy x 1f|Radiotherapy: 16Gy x 1f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
40763739|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+2.67Gy x 15f|Radiotherapy: 2.67Gy x 15f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
40763740|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f|Radiotherapy: 0.5Gy x 12-18f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
40763741|NCT06642844|DRUG|Avastin, 25 Mg/mL Intravenous Solution|"Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity."
40763742|NCT06640439|DEVICE|photobiomodulation|830 nm LED was used to irradiate the post-extraction area
40763743|NCT06640439|DRUG|Antibiotic|ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery
40763744|NCT06636825|OTHER|Graded hypercapnia|Volunteers breathe 0%, 2%, 4%, 6%, and 8% CO2 (with 21% O2, balance nitrogen) for 12 minutes each
40763745|NCT06636825|DRUG|Caffeine|400 mg caffeine capsule taken in a single dose 1 hour prior to graded hypercapnia
40763746|NCT06636825|DRUG|Placebo|Placebo (microcrystalline cellulose) capsule taken in a single dose 1 hour prior to graded hypercapnia
40763747|NCT06640868|BEHAVIORAL|MyChart nurse message|Receipt of a MyChart nurse message around 34 weeks encouraging RSV vaccination
40763748|NCT06640868|BEHAVIORAL|SMFM video|Receipt of SMFM video around 34 weeks encouraging RSV vaccination
40763749|NCT06640868|BEHAVIORAL|Visual aid|Receipt of a visual aide encouraging RSV vaccination at 28-30 wks
40763750|NCT06038175|DEVICE|Video Head Impulse Testing|During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient. (Interacoustics EyeSeeCam vHIT 3rd Generation Tests: VOR of lateral, RALP, \& LARP canals. SW: 3rd generation VE525 software. HW: laptop PC, lightweight monocular video goggles). Subjects will be instructed to maintain fixation at a target from 1 m distance. A study team member will deliver at least 5 head impulses per side (10-20° angle, duration 150-200 ms, peak velocity of \>150°/s) in the horizontal and vertical planes with unpredictable timing and direction. A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity. The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team. In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is \<0.8 in the presence of refixation saccades .
40763751|NCT06038175|OTHER|Standard of care neurologic evaluation|A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.
40763752|NCT06289582|DRUG|[F-18]DPA714 administration IV|brain PET/MRI imaging after \[F-18\]DPA-714 administration
40763753|NCT04275284|BIOLOGICAL|PCV10|0.5 ml injection
40763754|NCT04275284|BIOLOGICAL|PCV13|0.5 ml injection
40763755|NCT06340867|DEVICE|CEREC primescan intra-oral scanner|intra-oral scanner
40763756|NCT06634901|OTHER|Health Literacy Educational Session- Comparator|During the pre-to-post-test interval for the Knowledge, Attitudes, and Practices (KAP) measure, participants in this arm will take a break and have lunch.
40763757|NCT06634901|BEHAVIORAL|Health Literacy Educational Session|The Intervention is a 90 minute small group (n=6-10) session with an expert epilepsy provider reviewing fundamental information about epilepsy being a treatable neurologic condition, with topics including epidemiology, causation facts and myths, treatment and the importance of consistent medication, stigma, barriers to care and well-being. These topics will be covered in the first 45 minutes, leaving the second 45 minutes for Q\&A with the expert. This session provides the basic health information relevant to people with epilepsy, communication of which is often sacrificed in overcrowded clinics found in low resource settings.
40763758|NCT00835042|DRUG|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
40763759|NCT00835042|DRUG|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
41455932|NCT05772858|OTHER|Agency Engagement and Orientation as Usual|Work with the agency leaders will consist of the traditional engagement of the leadership so that they agree to collaboration with the study team, with the training team, and with the study procedures.
40958769|NCT02265068|DRUG|Ticagrelor|Treatment of ACS patients with Ticagrelor
40958770|NCT00171483|DRUG|Tegaserod|
40958771|NCT06558266|OTHER|Since this was an observational study, no intervention was performed.|Since it is an observational study, only evaluation will be made. Each participant s mental imagery ability will be evaluated with the Movement Imagery Vividness Questionnaire-2 four times, follicular phase, ovulation, luteal phase and menstrual phase. In addition, the pain intensity experienced during menstruation will be evaluated with the Numerical Classification Scale-11, and the symptoms experienced due to menstruation will be evaluated with the Menstruation Symptom Scale.
40958772|NCT06082492|DIAGNOSTIC_TEST|18F FDG PET/CT|Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
40958773|NCT06082492|DIAGNOSTIC_TEST|CT scan|CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
40958774|NCT01723345|DRUG|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
40763760|NCT06640218|DEVICE|sealer activation with Eddy sonic and AF max|activation of sealer after cleaning and shaping, before the obturation
40958775|NCT00763711|DEVICE|Needle Guided Periurethral Injection|Bulking Agent injection using a needle guide
40958776|NCT05239208|OTHER|Oral Nutrition Supplement (ONS) Group|Oral nutritional supplement specifically designed for nutritionally-at risk children and dietary counseling
40958777|NCT05239208|OTHER|Control Group|Dietary counseling
40958778|NCT02283385|BEHAVIORAL|PROTECT|8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
40958779|NCT00820846|BIOLOGICAL|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
40958780|NCT00820846|BIOLOGICAL|Placebo|1 mL of sodium chloride for injection
40958781|NCT00820846|BIOLOGICAL|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
40958782|NCT03918148|DRUG|SGLT-2i|Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
41455933|NCT02686567|PROCEDURE|with TDT|After completion of the anastomosis and further DS construction if necessary, the surgeon would be notified to implement the intervention based on the randomizing results. In this group, a silicone tube (28Fr, Sumitomo Bakelite Co, Japan) was inserted through the anus and the tip of the tube was placed approximately 5 cm above the anastomosis at the end of the surgery in patients from the TDT group. The tube was fixed with a skin suture and connected to a drainage bag. TDT was planed to remove 3-7 days after surgery and early removal was allowed if the patient experienced intolerable pain.
41455934|NCT02686567|PROCEDURE|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
41455935|NCT00962494|BEHAVIORAL|Cancer: Thriving and Surviving Online Workshop|
40763761|NCT06640218|OTHER|without AF max or Eddy sonic sealer activation|sealer without activation
40958783|NCT03918148|DRUG|DPP-4i|Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
40958784|NCT05176743|BEHAVIORAL|Unconditional Cash Transfer (UCT)|The UCT consists of three $100 VISA merchandise cards provided monthly via mail to participants randomized to the intervention arm. Merchandise cards can be used anywhere that VISA is accepted. Participants in the UCT arm will also receive Usual Care, including referral to the patient support services team and nutritional pamphlets.
40763762|NCT02584738|DRUG|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
41292991|NCT06131645|DIAGNOSTIC_TEST|IASLC grading system|A cohort of 2160 patients with invasive nonmucinous EGFR-mutant LADCs were retrospectively collected and classified according to the IASLC grading system. The role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy was investigated.
40763763|NCT02584738|DRUG|Nebulized isotonic saline|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
40763764|NCT02584738|DRUG|Nebulized Salbutamol|Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
40763765|NCT02584738|DRUG|Ipratropium bromide|Nebulized ipratropium bromide 250 mcg
40763766|NCT02584738|DRUG|Methylprednisolone or Prednisolone|Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
40763767|NCT02465112|DRUG|In111-Pentetréotide|
40763768|NCT02465112|OTHER|simple monitoring without active therapy|
40763769|NCT05403268|DEVICE|DeltaScan|Twice daily DeltaScan observations
40958785|NCT04970355|BIOLOGICAL|Erenumab|Pre-filled syringe; s.c. injection
40958786|NCT04970355|DRUG|Placebo|Pre-filled syring; s.c. injection
40958787|NCT02004119|DRUG|KHK4577|
40958788|NCT02004119|DRUG|Placebo|
40958789|NCT04340180|DRUG|Standard of Care (SOC) gadolinium Breast MRI|Standard of Care (SOC) gadolinium Breast MRI
40958790|NCT04340180|DRUG|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
40958791|NCT00133029|DRUG|Timing of prophylactic antibiotic administration|
40958792|NCT05947383|DRUG|Psilocybin|Psilocybin 25 mg oral capsule
40958793|NCT05947383|DRUG|Placebo|Niacin 100 mg oral capsule
41292992|NCT02152423|DRUG|LOVENOX|LMWH
41455936|NCT04142658|DRUG|Apixaban 5 MG|"For patients that do NOT meet the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)"
41455937|NCT04142658|DRUG|Apixaban 2.5 MG|"For patients that meet at least 2 of the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)"
41455938|NCT04142658|DRUG|Warfarin|Active Control Intervention
41292993|NCT02152423|DRUG|ENOXAMED|LMWH
40958794|NCT04102787|OTHER|cardiac educational program|"Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management."
40958795|NCT00313261|DRUG|Clevudine|
40958796|NCT02639767|DRUG|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m\^2 for pemetrexed in combination with 75 mg/m\^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
40958797|NCT02639767|RADIATION|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
40958798|NCT02639767|DEVICE|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
40958799|NCT00825682|OTHER|Reflexology treatment.|Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.The treatment includes manual pressure on specific points of foot soles and massage of the calf area, adapted individually to each patient.
40958800|NCT00303173|BEHAVIORAL|Guided Imagery|
40958801|NCT05039073|DRUG|Brentuximab Vedotin|Given IV
40958802|NCT05039073|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
40958803|NCT05039073|BIOLOGICAL|Nivolumab|Given IV
40958804|NCT05039073|OTHER|Quality-of-Life Assessment|Ancillary studies
40958805|NCT05039073|OTHER|Questionnaire Administration|Ancillary studies
40958806|NCT06062134|PROCEDURE|Pericapsular nerve group block|Ultrasound-guided injection of local anesthetic mixed with contrast agent underneath the iliopsoas muscle, lateral to the iliopsoas tendon.
40958807|NCT06062134|DRUG|18 mL ropivacaine 0.5% + 2 mL radiopaque contrast|20 mL of injectate: 18 mL ropivacaine 0.5% + 2 mL radiopaque contrast (Iomeron 300: 61.24% w/v of iomeprol equivalent to 30% iodine or 300 mg iodine/mL)
40958808|NCT02500420|OTHER|Diagnosis examens|"* Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~* Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
40958809|NCT00496470|DRUG|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
40763771|NCT06639490|DEVICE|RUS GA|he RUS GA (Endoscopic Imaging Treatment Planning Software, E04010.01(2)) is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the actual intra-abdominal surgical environment, allowing for the visualization of vascular structures and intra-abdominal organs during the surgical planning process and the operation. RUS GA utilizes preoperative CT images of the patient to segment organs and blood vessels and reconstructs them into a 3D model. Although there is no direct intervention with the patient, the surgeon uses RUS GA as a surgical navigation tool to simulate the surgery before performing the actual procedure.
40763772|NCT06639490|PROCEDURE|standard treatment|Only standard treatment is performed.(Robot-assisted gastrectomy will be performed using without software RUS GA.)
40763773|NCT04421963|DRUG|Olaparib|300 mg olaparib (2×150 mg tablets) twice daily
40958810|NCT00496470|DRUG|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
40990563|NCT04462809|DRUG|Talazoparib|"Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment."
41292994|NCT04523779|BEHAVIORAL|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
41292995|NCT01408537|BIOLOGICAL|JEVAC|Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).
41292996|NCT04498910|DRUG|LY3451838|Administered IV
41455939|NCT04142658|DEVICE|On-X Aortic Mechanical Valve|Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
41455940|NCT02143258|PROCEDURE|Stenting of the venous sinus|Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
41455941|NCT02928627|OTHER|Analysis of microRNA expression|sample analysis
41455942|NCT02233751|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Randomization then administration of combination product study medication according to group assignment
41136022|NCT01617707|DRUG|Midazolam plus propofol|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
41292997|NCT04498910|DRUG|Placebo|Administered IV
41292998|NCT06111326|DRUG|BC3402 injection|Intravenous infusion, once every 2 weeks, 4 weeks/cycle.
41292999|NCT06111326|DRUG|Durvalumab injection|Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
41293000|NCT02502877|DRUG|Midazolam|The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.
41293001|NCT02502877|DRUG|Propofol|The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.
41293002|NCT02502877|DRUG|Standard|The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
40958811|NCT05998044|OTHER|Pilates Based Exercises|"The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively. Participants will be asked to open the video recording each time they exercise and follow them to do the exercises.~Exercise Program:~* Arm Circles~* Toe Touch~* bridge~* Shoulder Bridge~* Chest Lift~* Hundred~* Roll Up~* Leg Circles~* Chris Cross~* Side Kick~* Side Leg Circles~* one leg kick~* double leg kick~* Swan~* Single leg Stretch~* Double leg Stretch~* saw~* Spine Stretch"
40958812|NCT05998044|OTHER|control|They will be asked not to participate in any regular exercise for 8 weeks.
40958813|NCT02569658|DRUG|Tranexamic Acid|
40958814|NCT02569658|DRUG|Placebo|
40958815|NCT00437307|DRUG|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
40958816|NCT02260544|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
40958817|NCT06193057|PROCEDURE|Total ankle arthroplasty|Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.
40958818|NCT00005073|DRUG|zoledronic acid|
40958819|NCT06558591|DEVICE|Telerehabilitation intervention|"Inclusion will take place within the framework of routine care for individuals with chronic diseases in rehabilitation services, hospitals, institutions, etc. The study will be offered to patients with chronic illnesses who are being cared for by their therapists. Data collection will be conducted in two sessions. The period between the two sessions will be determined based on the patient's availability, not exceeding a period of 12 weeks:~1. 1st session at 0 week : Conducting activities and initial evaluation at their usual care center. Therapists will perform the various planned tests and evaluations.~2. 2nd session at 12 weeks : This session will take place under the same conditions as the first one and without any potential health risks to the participants.~3. A final evaluation will be carried out at the 18-week follow-up. A telephone call will be made between sessions to check in and assist participants in case of any issues during the study."
40958820|NCT00519402|OTHER|tonsillar examination and questionnaire completion|
40958821|NCT05410483|DRUG|Docetaxel|Hyperthermic Intraperitoneal Docetaxel
40958822|NCT03056404|OTHER|additional blood sample|
40958823|NCT03056404|OTHER|respiratory functional exploration|
40958824|NCT05561049|DRUG|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
40958825|NCT05433012|DEVICE|Ultrahigh Field MRI at 7T|Assessment of the micro-anatomy of the menisci and cartilage in patients with presumed Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T
40958826|NCT00115752|DRUG|Valdecoxib|
40958827|NCT00115752|DRUG|COX Inhibitor|
40958828|NCT03836599|DRUG|Verinurad|Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.
40958829|NCT03836599|DRUG|Allopurinol|Participants will receive allopurinol 300 mg once daily.
40958830|NCT03836599|DRUG|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
40958831|NCT04043286|DEVICE|Definitive abutment|With two height options available, On1 Base are selected depending on the thickness of the soft tissue. It remains in position from implant placement to finalization, which leaves the soft tissue undisturbed for optimized healing, moved the restorative platform of Nobel Biocare conical connection implants from bone level to tissue level, thereby simplifying the restorative procedures
40958832|NCT03941405|DRUG|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days. resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value \> 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
40958833|NCT01215565|DRUG|Sutent|Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
40958834|NCT04673422|DRUG|Montelukast|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
40958835|NCT04673422|DRUG|Placebo|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
40990564|NCT03796780|DIETARY_SUPPLEMENT|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks
40990565|NCT03796780|DIETARY_SUPPLEMENT|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks
41293003|NCT02502877|DEVICE|SpotOn|Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
41455943|NCT03084562|OTHER|collect examination time, functional and clinical tolerability|Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist
40958836|NCT05639426|BEHAVIORAL|Culturally Responsive Practices (CRP)|The CRP component of the intervention targets pedagogy, curriculum, and potential teacher biases and discriminatory behavior. This component will consist of two intensive 4-hour workshops delivered by Morton and Billingsley in each school's first intervention year as well as one-hour annual boosters (Backpacks for Success and Culturally Relevant Pedagogy). All teachers and school administrators will participate in the workshops. The purpose of Backpacks for Success is to increase participants' awareness of structural racism, empathy for students, and motivation to change, while identifying equity targets and strategies to reach those targets. Culturally Relevant Pedagogy comprises classroom based strategies to promote equity, including use of culturally responsive curriculum, language, attitudes, and actions, with the goal of reducing interpersonal and cultural racism. Ongoing group coaching sessions will provide a space for peer support and learning around increasing CRP.
41455944|NCT03053245|BEHAVIORAL|Mobile Critical Care Program|The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
40958837|NCT05639426|BEHAVIORAL|Culturally-Responsive Schoolwide Positive Behavior Interventions and Supports (C-SWPBS)|We will implement SWPBS according to the equity-focused framework established by the Center on PBIS, with an increased emphasis on community integration. SWPBS involves creating a school team of 6-10 people, including at least one administrator, teachers, and staff members. We will include at least three community stakeholders on each C-SWPBS team to integrate the culture of the community, reducing institutional and cultural racism. Community stakeholders may be parents or other invested members of the local community not employed by the school district. The school climate specialists serve on the C-SWPBS team and provide consultation for the management of violence incidents and mental health concerns.
40958838|NCT02834260|DRUG|Dexamethasone implant OZURDEX|
40958839|NCT05509270|BEHAVIORAL|Letter|Mailed letter about flu vaccination
40958840|NCT05509270|BEHAVIORAL|Patient portal|Patient portal message about flu vaccination
40958841|NCT05509270|BEHAVIORAL|SMS|SMS about flu vaccination
40958842|NCT04931407|OTHER|A 12-week interdisciplinary complex intervention|"The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.~The patient education will include an online 2-hours group-based patient-education sessions in week 1.~The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.~The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.~The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian."
41293004|NCT05391763|PROCEDURE|Fascia pectoralis preservation|A total mastectomy will be performed in the control breast: a procedure which includes removal of the breast glandular tissue including the PF and subcutaneously excision of the nipple-areolar complex, while the pectoralis muscle will be spared. As much of the healthy skin envelope will be preserved to enable the performance of an effective breast reconstruction afterwards. When a nipple-sparing mastectomy is performed, the skin envelope together with the nipple-areolar complex will be spared. The investigational part of the operation is preservation of the PF. Dissection of cutaneous flaps and the breast with or without the PF will be performed with electrocautery.
41293005|NCT05717738|PROCEDURE|TACE|Procedure of TACE is standardized.
41455945|NCT03053245|BEHAVIORAL|Attention Control|Patients in this group will receive regular wellness calls from the research team.
40958843|NCT00531934|DRUG|Doxycline|100mg po daily
40958844|NCT00531934|DRUG|erlotinib [Tarceva]|150mg po daily
40958845|NCT03822078|DRUG|Placebo|Administered by subcutaneous injection
40958846|NCT03822078|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
40958847|NCT05595941|OTHER|tele-yoga|"Each session will include postural exercises (asanas), standing, sitting and lying down, in order to work on balance, muscular strength and endurance, as well as flexibility. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, cushions, blocks (provided free to each participant). In addition, breathing work will accompany these postures. A relaxing passive meditation is practiced at the end of each session, in a lying posture called Savasana. The complexity of the postures, their holding time, or the number of repetitions will increase as the program progresses, relative to the abilities of each participant."
40958848|NCT04510584|DRUG|Atezolizumab|Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.
41455946|NCT04750590|PROCEDURE|en bloc resection, morcellation|Laser en bloc resection with subsequent tumor morcellation will be performed. This tissue will be sent for histology in order to estimate the histological subtype and differentiation grade. Next stage laser resection of the tumor basis will be performed with subsequent histology to determine the depth of invasion and the status of surgical margin.
41293006|NCT05717738|DRUG|Lenvatinib|8mg; p.o.; q.d.
41293007|NCT05717738|DRUG|Anti-PD-1 monoclonal antibody|Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
40958849|NCT04510584|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds VEGF, a secreted factor that stimulates angiogenesis. Bevacizumab prevents the interaction of VEGF with its receptors and neutralizes the biological activity of VEGF.
40958850|NCT00941005|DEVICE|Electroacustimulation|Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
40958851|NCT05182905|DRUG|AZD1390|"Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy"
40958852|NCT00296881|DEVICE|PERIOWAVE|
40958853|NCT05578170|DRUG|Pembrolizumab|Participants receive 200 mg pembrolizumab as a neoadjuvant by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles before surgery.
40958854|NCT03127410|OTHER|Lumbar traction|Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
40958855|NCT01768286|DRUG|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
40958856|NCT01768286|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
40958857|NCT01209611|PROCEDURE|Autologous bone marrow mononuclear cells|Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
40958858|NCT01209611|PROCEDURE|Placebo|Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
40958859|NCT01880502|DRUG|Belviq 10mg|Belviq 10mg single dose administration
40958860|NCT01880502|DRUG|Belviq 20mg|Belviq 20mg single dose administration
40958861|NCT01880502|DRUG|Placebo|Placebo single dose administration
40958862|NCT05947175|BIOLOGICAL|Vertebral bone marrow (vBMA) clot|The clotted vBMA will be obtained from vertebral bone marrow aspirate.The vBMA clot contain mesenchymal stem cells (MSCs), growth factors, platelet and osteogenic and anti-inflammatory mediators.
40958863|NCT05947175|OTHER|Bone allograft chips|Bone allograft chips will be obtained from Musculoskeletal Tissue Bank at IRCCS Istituto Ortopedico Rizzoli.
40958864|NCT00518687|BIOLOGICAL|V710|0.5-mL single injection of V710 (60 µg)
40958865|NCT00518687|BIOLOGICAL|Placebo|0.5-mL single injection of matching placebo
40958866|NCT00078793|DRUG|Enbrel®|Etanercept alone, etanercept plus methotrexate or other DMARDs
40958867|NCT00915278|DRUG|PF-04605412|PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
40958868|NCT01214343|DRUG|Sorafenib with Low-dose FP|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.
40763774|NCT06168006|BEHAVIORAL|Exercise|The experimental group will undergo an exercise program using the Recovery App. Participants will receive guidance from researchers about the functionality of the app. The Recovery App includes flexibility, strength, and aerobic training exercises, aiming for a progressive intensity and volume over the weeks.
40958869|NCT01214343|DRUG|Sorafenib|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.
40958870|NCT06451003|BEHAVIORAL|Exposure to clinical decision support system and education|"Surgeons will receive education regarding post-discharge venous thromboembolism after cancer surgery. An electronic medical record based decision support tool with be initiated that will identify patients who have undergone major abdominopelvic cancer surgery. The tool will permit use of a risk stratification score and advise guideline concordant post-discharge venous thromboembolism prophylaxis strategies.~Patients will receive dedicated venous thromboembolism education at the time of discharge."
40958871|NCT01805440|DRUG|Uridine|Uridine is the active treatment in this clinical trial.
40958872|NCT01805440|DRUG|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
40958873|NCT00530946|DRUG|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
40958874|NCT00530946|DRUG|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
40958875|NCT00530946|DRUG|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
40958876|NCT00530946|DRUG|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
40958877|NCT06484738|OTHER|transcriptomic analysis|to use their biological samples from UC and CD patients, already stored at -80°C for transcriptomic analysis through STOmics Stereoseq
40958878|NCT05915078|COMBINATION_PRODUCT|Iontophoresis and tube placement|Iontophoretic delivery of TYMBION™ otic anesthetic using the Tula Iontophoresis System and tube insertion using the Tula Tube Delivery System
40958879|NCT05303181|DEVICE|Russian Current|"The patient will be placed in sitting position, hip at 90-degree flexion, knee at 60°, the upper body supported by the backrest, cross belt support the trunk and cross belt support the pelvis. The dynamometer rotating axis will be aligned with knee joint axis and the resistance lever arm will place in the distal leg above the malleolus. The angle of the joints adjustment considering the joint's range of motion and the device's user's manual, any movement other than the range of motion determined by the mechanical limit will be not allowed~All electrical induced contraction will last 4 second each, with characteristics of 75 bursts; 4 second time on, 400 μs pulse width and 10 second time off. The greatest electrically induced torque by the quadriceps muscle at the maximum current output from the stimulator will be recorded for each subject to be used in data analysis. The same procedure will be done on the 3rd week and after 6th week."
41293008|NCT05717738|DRUG|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
41293009|NCT05717738|DRUG|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
41293010|NCT05717738|DRUG|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
41293011|NCT05717738|DRUG|Sorafenib|400mg; p.o. bid
41293012|NCT05717738|DRUG|Donafenib|200mg; p.o. bid
41293013|NCT05717738|DRUG|Regorafenib|160 mg; p.o.; q.d.
41293014|NCT02601001|DRUG|Omecamtiv mecarbil|Omecamtiv mecarbil tablets for oral administration
41293015|NCT02601001|DRUG|Placebo|Matching placebo tablets
41293016|NCT03591705|DRUG|TACE-HAIC|transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
41293017|NCT03591705|DRUG|HAIC|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
41293018|NCT00812071|BIOLOGICAL|RiVax|vaccine
41293019|NCT00149929|DRUG|Mycophenolate sodium (enteric coated)|
41293020|NCT02751307|DRUG|metformin 500 mg|metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d
41293021|NCT02751307|DRUG|clozapine 100 mg|Clozapine dose remained unchanged during metformin intervention period in recruited patients.
41455947|NCT04750590|PROCEDURE|piecemeal resection, tissue removal by loop|Tumor piecemeal resection will be performed with electric loop. Then fragments of the tumor will be removed by the loop or Janet's syringe. Fragments from the base of the tumor will be sent separately in order to assess which stage the tumor is at and its surgical margin status.
41293022|NCT03233594|OTHER|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
41293023|NCT03233594|OTHER|Healthy Control Group|Participants will not receive any interventions.
41293024|NCT05970055|PROCEDURE|elective surgery|All elective surgical procedures performed under the study period will be included.
41293025|NCT06077058|OTHER|Nicotine Replace Therapy (NRT) sampling|The intervention involves a Zoom/WhatsApp meeting or face-to-face session with a trained counselor who introduces NRT use, possible side effects, and patch dosage based on a previous RCT guide. An online intervention pack with a pamphlet and 1-week free NRT sample (14mg or 21mg patch) is mailed to participants. After 1 week, the counselor follows up. If participants need more patches, an additional pack is mailed, and they are advised to obtain further patches from smoking cessation services or pharmacies. NRT patch users may experience skin reactions, insomnia, or vivid dreams; if severe side effects occur, they are asked to stop using NRT.
40958880|NCT04897334|DEVICE|tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
40958881|NCT04897334|DEVICE|sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
40958882|NCT04897334|BEHAVIORAL|Cognitive Therapy|During both the treatment and the sham intervention, participants will undero cognitive therapy training by performing the NBack task. In this sequential letter memory exercise participants are presented with sequential stimuli in the form of a series of letters. For each new stimulus they are asked to indicate if the current stimulus matches the stimulus from 2 trials prior. This exercise stimulates cognitive demand in working memory, executive function and attention and is correlated with dorsolateral prefrontal cortex activity.
40958883|NCT05876975|PROCEDURE|laparoscopic pectopexy|Women with pelvic organ prolapse and suitable indications underwent laparoscopic pectopexy.
40958884|NCT04351685|BIOLOGICAL|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Water for injection/vial"
40958885|NCT04351685|BIOLOGICAL|BCG SII|"Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Sodium Chloride for injection/vial Injection"
40958886|NCT03809676|OTHER|periodontal examination|clinical measurements were recorded
40958887|NCT04612673|DRUG|Sintilimab|immune checkpoint inhibitor, 200mg, iv, d1,Q3W
40763775|NCT06168006|BEHAVIORAL|Control|They will receive an exercise booklet based on the Brazilian Physical Activity Recommendations (MINISTRY OF HEALTH, 2021), which recommend 150 minutes of physical activity for adults and seniors.
40958888|NCT01423318|DRUG|lebrikizumab|Dose-level cohorts receiving single subcutaneous dose
40958889|NCT01423318|DRUG|placebo|single dose subcutaneously
40958890|NCT05515081|PROCEDURE|blood sample collection|blood sample colletion at regular intervals
40958891|NCT05399641|DRUG|Ibrexafungerp|Each day dosing will consist of two 150mg tablets taken BID.
40958892|NCT00479193|DRUG|bacitracin/xeroform|single layer, change every 3 days
40958893|NCT00479193|DRUG|Polymem|single layer of Polymen, change every 3 days
40958894|NCT03397537|DRUG|Letrozole 2.5Mg Tablet|letrozole 2.5mg p.o.qd
40958895|NCT03397537|DRUG|GnRH analogue|3.75 mg triptorelin im. q28d
40763776|NCT06641518|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|a therapeutic modality employing electric current to relieve pain by activating peripheral nerves. The evolution of TENS units alongside technological advancements has led to user-friendly interfaces and enhanced portability, with units now small enough to be carried in a pocket.
40958896|NCT03473535|COMBINATION_PRODUCT|BEACON + Problem Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application.
40958897|NCT03473535|BEHAVIORAL|Problem-Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist.
40958898|NCT05339464|OTHER|Family Wellness program|Weekly one-hour online workshops over an 8 week period. Families will also receive text message reminders as part of the intervention.
40763777|NCT02016885|DRUG|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
40763778|NCT02016885|DRUG|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
40763779|NCT02016885|DRUG|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
40763780|NCT02016885|DRUG|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
41455948|NCT05021276|DRUG|Ruxolitinib|Ruxolitinib and basiliximab are both second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disease.
41455949|NCT04816851|PROCEDURE|OZAKI technique|an alternative way of repairing aortic valve, involving the use of autologous pericardium for the aortic leaflet reconstruction. Diseased leaflets are removed carefully. The distance between each commissure is measured with invented sizing apparatus. The new leaflet of the size corresponding to the measured value is trimmed with an original template from glutaraldehyde-treated autologous pericardium. Finally, the annular margin of the pericardial leaflet was running sutured with each annulus. Commissural coaptation was secured with additional sutures. The coaptation of three new leaflets were always insured with direct vision.
40958899|NCT01504620|OTHER|Sugar infusion|Infusion of glucose to achieve high blood glucose levels
40958900|NCT01504620|DRUG|insulin infusion|i.v. infusion of insulin
40763781|NCT02016885|OTHER|Vehicle|Vehicle Topical Wipes
40958901|NCT03136354|PROCEDURE|Endoscopic Submucosal Dissection|
40958902|NCT03136354|PROCEDURE|Laparoscopic assisted Gastrectomy|
40958903|NCT01205204|DRUG|Fentanyl|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
40958904|NCT01205204|DRUG|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
40958905|NCT01205204|DRUG|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
40958906|NCT01205204|DRUG|clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
40958907|NCT00312559|BEHAVIORAL|Yoga Training|
40958908|NCT04794842|DRUG|Tetracaine 5% drops|same as information in the arm/group description
40958909|NCT04794842|DRUG|Phenol 90% concentration|same as information in the arm/group description
40958910|NCT06210971|DRUG|liposomal irinotecan|Liposomal irinotecan: 50mg/m\^2 or 70mg/m\^2
40958911|NCT06210971|DRUG|Capecitabine|Capecitabine: 625mg/m\^2 or 1000mg/m\^2 bid.
40958912|NCT06210971|RADIATION|Radiation threapy|50.4Gy/28 fractions
40958913|NCT01390129|PROCEDURE|Control|Deflated blood pressure cuff placed on upper arm for 30min
40958914|NCT01390129|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
40958915|NCT00913172|OTHER|Treatment|Directly observed treatment (DOT) by health extension workers (HEWs)
40763782|NCT06549816|DRUG|sigvotatug vedotin|Sigvotatug vedotin is a antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to cells expressing integrin beta-6.
40763783|NCT00642759|DRUG|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
40763784|NCT00642759|DRUG|Nab-paclitaxel|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
40763785|NCT00642759|DRUG|Bevacizumab|IV infusion
40763786|NCT06641739|DEVICE|laser assisted SPPF|A full-thickness flaps were elevated. In the test sites after the SPPF access will be performed, root surface debridement will be meticulously performed, followed by intra-marrow penetrations (IMPs), on the defect walls using a 0.25 mm wide half round bur, mounted on a slow-speed handpiece. Following this, low-level laser biostimulation of the defect will be effected with an 940 nm diode laser at 3 W power, with an uninitiated 0.6mm optical fiber tip. The defects will be irradiated for 20 seconds in a continuous noncontact mode and then retracted for 8 seconds. This will be repeated for 3 times so that the defects were effectively lased for about 60 seconds.
40958916|NCT06402071|DIAGNOSTIC_TEST|Ascitic fluid study|Ascitic fluid study will be obtained from all participants
40958917|NCT06477198|OTHER|QLB|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the convex probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the quadratus lumborum muscle, the needle will be punctured and 5 ml of saline will be injected into the posterior border of the quadratus lumborum muscle between QLM and latissimus dorsi muscle.. After the block location is confirmed, 30 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (60 ml totally).
40958918|NCT06477198|OTHER|ESPB|ESP block will be performed. Convex probe will be placed longitudinally 4 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle, 2 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for the block in each side (total 60 mL).
40958919|NCT06477198|OTHER|Postoperative analgesia management|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
40958920|NCT03470870|OTHER|Comparative analysis of the characteristics|"* Predictive nomogram of short-term hospitalization (less than two days after surgery)~* Factors influencing the variations of average stay lenght~* Morbidity of the ERAS program"
40958921|NCT04918173|DRUG|Atenativ|Antithrombin concentrate
41455950|NCT05267444|PROCEDURE|Individualized motion-based interactive game program|The participants will receive a 12-session, 4.5 months home visit service that is provided by the young adults, and supervised by an occupational therapist. Young adults will follow the individualized exercise plan with the older adults, facilitate their use of interactive games, provide psychological and technological support to help older adults cope with their fear of using technologies to perform physical activity.
40958922|NCT01360593|DRUG|Gemcitabine|"Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:~Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles."
40958923|NCT01360593|DRUG|Capecitabine|"Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles."
40958924|NCT01360593|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:~12 Gy x 3 fractions (36 Gy total) This will be given every other day."
40958925|NCT02467400|DRUG|Atenolol|beta blocker
40958926|NCT02467400|DRUG|Nebivolol|beta blocker
40958927|NCT02467400|DRUG|Propranolol|beta blocker
40958928|NCT02467400|DRUG|placebo|placebo
41293026|NCT06077058|BEHAVIORAL|Simple exercise education (SEE)|All participants will be given a handgrip at study enrolment. The SEE includes a Zoom/WhatsApp meeting or face-to-face session including 1) watching a 5-minute video (www.youtube.com/watch?v=mZex2Wwy3fU) showing a chair professor of public health demonstrating the 10s-E, including the simple exercises with and without handgrip. The video also encourages participants to 1) follow the exercise instructions during the video demonstration; 2) perform the exercises whenever they experience craving or an urge to smoke during the quitting process; and 3) increase their exercise frequency and intensity as much as possible, which may also increase their grip strength. Participants will also receive a leaflet with exercise instructions and motivational messages.
41293027|NCT06077058|OTHER|Chat-based instant messaging|Participants will receive individualized chat-based encouragement and support messages about motivation and preparation for quit attempts using WhatsApp for 8 weeks. A trained smoking cessation counsellor will have real-time (synchronous), one-to-one interaction with the participants and provide personalized motivational, behavioural support according to the participants' needs. The conversation intensity will be flexible and depends on the participant. The conversation will also be integrated with brief advice using the Behaviour Change Techniques (BCTs) (18) and the AWARD (Ask, Warn, Advise, Refer, Do-it-again) intervention model (11). The intervention protocol will be similar as that in our previous RCT on CBIM (19). For participants who receive the SEE and NRTS, the trained counsellor shall follow-up on their compliance and provide adequate advice in adhering to these interventions.
41455951|NCT06459960|GENETIC|Hydrotherapy|Heated pool (32°C); Convention rehabilitation + Hydrotherapy
41455952|NCT06459960|GENETIC|Convention|Convention rehabilitation only
40958929|NCT02294435|DEVICE|Visceral Manifold and Thoracic Bifurcation|Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system
40958930|NCT02294435|DEVICE|Unitary Manifold|Unitary Manifold Endovascular stent graft system
40958931|NCT02011971|DRUG|Vinpocetine|Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
40958932|NCT03036007|OTHER|Prescribed Physical Activity|General physical activity prescribed by a physiotherapist
40958933|NCT03036007|OTHER|Exercises with Internet support|Neck-specific exercise with Internet support
40958934|NCT05866783|DIAGNOSTIC_TEST|HCCRecurrencePrognosticScore|Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling
40763787|NCT06641739|PROCEDURE|Platelet Rich Plasma|In the second group, following the SPPF, the defect will grafted with particulated PRF, which will be overlaid with a PRF membrane, without any adjunctive defect management measures. PRF will be prepared by collecting Intra-venous blood (from the antecubital vein) in a 10-ml sterile glass tube without anticoagulant and immediately centrifuged in a centrifugation machine at 3000 rpm for 10 minutes. It will result in the separation of blood into a structured fibrin matrix in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma (platelet poor plasma) at the top. PPP will be discarded. PRF will be easily separated from the red corpuscles base using sterile tweezers and scissors.
40958935|NCT05866783|DIAGNOSTIC_TEST|HCCRecurrenceDiagnosticScore|Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling
40763789|NCT06642818|OTHER|protocolized interview and prevention messages|This care consists of a consultation carried out by an environmental health expert (midwife, environmental health engineer) from the PREVENIR platforms. This consultation is carried out through a protocolized interview already developed which allows the identification of exposure to risk factors on reproduction. During the interview, prevention messages targeted at the exposures identified during the interview are delivered.
40958936|NCT05856032|DEVICE|Acapella device|Acapella is one of the Oscillatory Positive Expiratory Pressure (OPEP) device used in mobilization of peripheral secretions to the central trachea. It consists of a mouth piece and metal strip that is attached to a magnet which oscillates upon exhalation of the patient into the device results in oscillations. This helps in generating positive expiratory pressure (PEP) and oscillations of the magnetic ball assist in mucus collection and expectoration. Pulmonary functions are greatly reduced in patients undergone CABG surgery due to prolong effects of anaesthesia and muscle relaxants administered prior to surgery.
40958937|NCT05856032|OTHER|Conventional Treatment|Conventional chest physiotherapy techniques
40763790|NCT06640192|DRUG|Standardised triple antiretroviral therapy|patients have to use Triple therapy antiretroviral drugs on their usual regimen containing an integrase inhibitor. There are many types of drugs within this group, so they are not specified.
40763791|NCT06640192|DRUG|High doses Triple therapy antiretroviral drugs|dolutegravir 50 mg/12 h, maraviroc 300 mg/12 h and lamivudine 300 mg/12 h
40763792|NCT06638086|DRUG|Acetaminophen Suppositories|Per rectal suppositories
40763793|NCT06638086|DRUG|Acetaminophen Injection|Intra-venous injection
40763794|NCT06382207|DEVICE|Eko Duo electronic stethoscope|A digital stethoscope with 1-lead electrocardiogram (ECG), the DUO, which pairs with a mobile application that allows the clinician to further engage with the device during and after a clinical visit. The application enables the clinician to visualize the sounds and electrical signals coming from the device in real time.
40763795|NCT06382207|DEVICE|CORE 500 electronic stethoscope|The CORE 500 has 3 electrodes that produce a 3 lead ECG, which can be viewed through the Eko app. The CORE 500 also has a user interface screen which provides a number of functions including confirming when all three electrodes have good skin contact, showing a single lead ECG wave, providing heart rate, allowing the user to switch between audio modes, allowing the user to take recordings, and providing AI analysis results for recordings.
40763796|NCT04250051|DRUG|Cytarabine|Given IV
40958938|NCT03751696|BEHAVIORAL|Group Coaching|4 sessions of 1-1.5-hour group coaching intervention within 8 weeks
40958939|NCT03751696|BEHAVIORAL|SMS self-help tips|4 mental well-being tips through sms within 8 weeks
40958940|NCT02420171|OTHER|Adding insulin to In Vitro culture media|We will add insulin for in vitro culture of human embryos
40958941|NCT06310538|BEHAVIORAL|kou sha|Kou sha is one of the most important external treatments in traditional Chinese medicine. By using the kou sha to pat on specific parts of the body or acupuncture points, light or heavy slapping is carried out to produce strong vibrations to relax the meridian qi, promote local blood circulation, and achieve the effect of blood circulation and blood stasis, detoxification and evil spirits.
40958942|NCT06310538|DRUG|Hongjin Xiaojie Capsules|The main group of HongjinXiaojie capsule is divided into anisanglian, Bupleurum, Notoginseng, golden buckwheat, Xiangfu, chicken Yanteng, etc., which has the effect of soft and hard dispersing knot, soothing liver and regulating Qi, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and has a certain effect on the treatment of mammary hyperplasia
40958943|NCT04719286|DEVICE|MinSafeStart app|The intervention is the opportunity of using the MinSafeStart app. Women can register their NVP severity in the app by answering a few questions daily. Based on this, they will get tailored advice on NVP, and get alert when they should see a doctor.
40958944|NCT03334630|DEVICE|DiamondTemp Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
40958945|NCT03334630|DEVICE|TactiCath Quartz Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
40958946|NCT00777114|DRUG|bortezomib, tositumomab|"1. 0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~2. 0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~3. 0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~4. 0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~5. 1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."
40958947|NCT00214344|BEHAVIORAL|family preparation for withdrawing life support|
40958948|NCT03047057|DRUG|Lidocaine|IV Lidocaine infusion
40958949|NCT03047057|DRUG|IV normal saline|IV normal saline infusion
40958950|NCT05346770|BEHAVIORAL|Behavioral Intervention|A behavioral intervention could include changing the time of day a drug is taken.
40958951|NCT05346770|DIAGNOSTIC_TEST|Diagnostic Test|A patient may receive a pharmacogenomic test via cheek swab to find PGx results. This is a benign intervention with little to no risk to the patient.
41455953|NCT05505760|BEHAVIORAL|Quality-Based Digital Messaging|"The impact of MomConnect's models will be evaluated using a randomized controlled trial (RCT). Randomization will be at the individual level, where an individual refers to the unique user, which is defined by the unique phone number used at the time of registration to MomConnect at health facilities. Randomizing control and treatment allocations ensures that the study groups will be comparable in terms of observable and unobservable characteristics in expectation. Therefore, statistical inference can shed light on the likelihood that any differences in outcome variables at the end of the intervention were caused by the intervention as compared to chance. We will also study the treatment effects on different outcomes between the different arms of the experiment - comparing outcomes across different treatment arms or outcomes in the control to outcomes in treatment arms will help us answer the aforementioned research questions."
41455954|NCT01482117|DRUG|Clopidogrel|single oral administration of 300mg of clopidogrel
41455955|NCT01482117|DRUG|Cilostazol|single oral administration of 100mg cilostazol
40763797|NCT04250051|BIOLOGICAL|Filgrastim|Given SC
40763798|NCT04250051|DRUG|Fludarabine|Given IV
40763799|NCT04250051|DRUG|Fludarabine Phosphate|Given IV
40763800|NCT04250051|DRUG|Ivosidenib|Given PO
40763801|NCT01246518|DRUG|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
40763802|NCT02937571|DRUG|Carfilzomib|
40763803|NCT02937571|DRUG|Lenalidomide|
40763804|NCT02937571|DRUG|Dexamethasone|
40763805|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine 2.0 mg (Arm A)|2.0 mg/kg intravenous (IV) every 4 weeks
40958952|NCT05346770|OTHER|Data Analysis|Medication safety reviews, and retrospective or prospective data analysis may occur as a result of participation in a case study.
40958953|NCT03218514|DRUG|Dalteparin|
40958954|NCT01065259|DRUG|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
41455956|NCT01482117|DRUG|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
41293028|NCT06077058|OTHER|Chatbot for smoking cessation|The information and access to the chatbot will be introduced to participants. Through the chatbot service, participants shall access to practical information on smoking cessation 24 hours at any time, such as details on cessation services and skills for tackling cravings. By using the second-generation chatbot, participants could receive personalized risk information and recommendations for smoking cessation, as well as reach to a counsellor through WhatsApp live chat for urgently needed advice.
40763806|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine 2.7 mg (Arm B)|2.7 mg.kg IV every 4 weeks
40763807|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine|2.7 mg.kg IV every 4 weeks
41455957|NCT05796843|PROCEDURE|360 Degrees virtual reality-based mirror therapy|Participants will receive mirror therapy using a virtual reality device (Pico G2 VR 4K, Pico, China). They will be asked to follow tasks that are played in HMD using their paralyzed hand. The video played using HMD will be video taped using 360 degree camera prior to the treatment. The 360MT will last 30 minutes/session, 3 sessions a week for 4 weeks. The tasks are finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions.
41455958|NCT05796843|PROCEDURE|Traditional mirror therapy|Participants will receive mirror therapy using an acrylic mirror (40cm x 40cm x 3cm) that reflects unparalyzed side of them. They will be asked to perform tasks including finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions. They will be asked to follow the reflection on mirror using their paralyzed limb. The TMT will last 30 minutes/session, 3 sessions a week for 4 weeks.
41455959|NCT05796843|PROCEDURE|Conventional Physical Therapy|Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises
41455960|NCT02235870|DEVICE|Obalon Intragastric Balloons|Intragastric Balloon System to aid in portion control.
41455961|NCT02235870|DEVICE|Sham Device|Sham Intragastric Balloon
40763808|NCT05551117|DRUG|Abiraterone|1000 mg once daily
40763809|NCT05551117|DRUG|Enzalutamide|160 mg daily
40763810|NCT05260242|OTHER|Disparities Conversation|The study intervention will be a scripted interaction delivered by an anesthesia healthcare provider to an individual patient admitted to the labor/delivery unit for labor epidural placement and obstetric care. The discussion will highlight current data relating to healthcare disparities in obstetric anesthesia care within underserved groups and will explain various aspects of obstetric anesthesia care in a culturally-sensitive manner.
40763811|NCT04791748|DIAGNOSTIC_TEST|Vestibular tests|Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits
40763812|NCT04791748|OTHER|Virtual reality|Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations
40763813|NCT06640764|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty with SMS Femoral Stem (Medacta)
41293029|NCT02852694|DRUG|Methotrexate|Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children \<20kg: 1x 5mg) is recommended.
41455962|NCT02235870|BEHAVIORAL|Nutrition and Lifestyle Program|Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
41455963|NCT05485727|OTHER|The Lokomat® Pro Hocoma USA & Conventional physical therapy|Lokomat Consists of robotic gait orthosis and an advanced body weight support system, combined with a Treadmill. (used for gait training) and Conventional Physical Therapy
40958955|NCT01065259|DRUG|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
40958956|NCT04067674|BIOLOGICAL|Blood sampling|Blood sampling for biomarker measurement
40763814|NCT01720836|BIOLOGICAL|Vaccine + PolyICLC|The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
41293030|NCT02852694|DRUG|Adalimumab|Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients \< 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
41293031|NCT02852694|DRUG|Azathioprine / 6 Mercaptopurine|Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
41293032|NCT00097422|DRUG|OPT-80|
41455964|NCT05485727|OTHER|Conventional Physical Therapy|Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
41455965|NCT02614898|OTHER|Eculizumab|This study was an observational study. Therefore, the study drug was not provided as part of this study, and the dosing regimen was based solely at the discretion of the treating physician.
41455966|NCT04492696|OTHER|Education|Education
41455967|NCT01887158|DRUG|Polyethylene glycol|
41455968|NCT01887158|DRUG|Bisacodyl|
40763815|NCT06640413|DRUG|[177Lu]Lu-OncoFAP-23|3.7, 7.4, or 11.1 GBq to define the RD
40763816|NCT06640413|DRUG|L19IL2|22.5 Mio IU
40763817|NCT06636916|PROCEDURE|Short Intervals HIIT|Participants will undergo different high-intensity interval training (HIIT) protocols, which involve repeated bouts of exercise at an intensity above 90% of VO2max, followed by recovery periods. The work and rest durations will vary across the protocols to assess the impact on the total time spent at or above 90% of VO2max.
40958957|NCT06487585|DRUG|Angiotensin II|Angiotensin II: Starting dose of 20 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.
40958958|NCT00119834|DEVICE|Mechanical Circulatory Support Device (MCSD)|INTERMACS is an observational registry of adult and pediatric patients with end stage heart failure that receive a legally utilized Mechanical Circulatory Support Device.
40958959|NCT02503657|DRUG|tipelukast|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
40958960|NCT02503657|DRUG|Placebo|Excipients of MN-001/tipelukast
40958961|NCT05164185|PROCEDURE|Remote ischemic conditioning|Brief cycles of ischemia to a limb. A blood pressure cuff was placed around the right thigh and inflated to 200 mmHg for 4 cycles of 5 minutes.
41293033|NCT03370367|DRUG|13-cis retinoic acid|Taken daily.
41293034|NCT03370367|OTHER|Placebo|Placebo
41293035|NCT06434740|RADIATION|Stereotactic Body Radiation Therapy，SBRT|The enrolled subjects will receive SBRT treatment for lung metastases.The dose segmentation is 10Gy/f, with a total dose of 50Gy/5f, once every other day.
41293036|NCT06434740|DRUG|Puterizumab|Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).
41293037|NCT03938662|DIETARY_SUPPLEMENT|formulation containing S-Adenosyl methionine and choline|Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.
41455969|NCT02398734|DEVICE|sonolysis|Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
41455970|NCT04484090|DEVICE|Vertica RF device|The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction
41455971|NCT03354780|OTHER|Survey on first pregnancy after endometriosis diagnosis|rate of miscarriage was noted
41455972|NCT03354780|OTHER|Survey on first pregnancy|rate of miscarriage was noted
40763818|NCT06636916|PROCEDURE|Long intervals HIIT|Participants will undergo different high-intensity interval training (HIIT) protocols, which involve repeated bouts of exercise at an intensity above 90% of VO2max, followed by recovery periods. The work and rest durations will vary across the protocols to assess the impact on the total time spent at or above 90% of VO2max.
40763819|NCT04620980|DIAGNOSTIC_TEST|targeted resequencing|The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).
40958962|NCT02381145|DIETARY_SUPPLEMENT|EGCG+RSV-supplementation|Teavigo (\~300mg/d) Resveratrol (\~80mg/d)
40958963|NCT02381145|DIETARY_SUPPLEMENT|Placebo|
41293038|NCT03938662|DIETARY_SUPPLEMENT|Placebo|Placebo of same appearance, colour and taste,
41455973|NCT04966962|DIAGNOSTIC_TEST|serum and urine metabolomics|serum and urine samples will be collected for metabolomics analysis
41455974|NCT01260623|DRUG|Prednisolone and prednisone|oral, or intravenous prednisone, prednisolone, given the first time for asthma exacerbation
41455975|NCT04893941|DRUG|CM310|IL-4Rα monoclonal antibody
41455976|NCT04893941|DRUG|Placebo|Placebo
41455977|NCT00141505|DRUG|Bifeprunox|
41455978|NCT05721157|OTHER|AI-enabled Chest X-ray-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.
41455979|NCT01536249|DRUG|Dexpramipexole|Single Oral Dose
40763820|NCT03400787|DEVICE|Latera Implant|Treatment with implant
40763821|NCT03400787|DEVICE|Sham Procedure|Sham procedure where the Latera delivery device is inserted but no implant delivered.
40763822|NCT06637267|DIAGNOSTIC_TEST|Proclarix®|The aim of the study is the implementation of new biomarkers (Proclarix®) in order to increase the sensitivity and specificity of PSA-based Prostate cancer early detection avoiding unnecessary prostate biopsies thus decreasing the associated morbidity (infections, bleeding, urinary retention, etc.). PSA values, Proclarix and mpMRI findings will be correlated with the results of the prostate biopsy in order to improve patient selection for future biopsies in order to avoid unnecessary prostate biopsies, but still be able to detect relevant carcinomas at an early stage. The null hypothesis in our observational study is the lack of superiority in PCa early detection when using the Proclarix over PSA alone.
40763823|NCT04096235|OTHER|RAM Nasal Cannula|The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.
40958964|NCT04279457|DEVICE|DyeVert Plus System|The DyeVert Plus System also contains a reusable Contrast Monitoring Wireless Display (CMW) which communicates with the Dye-Vert Plus Disposable to allow real-time monitoring and display of contrast volumes manually injected compared to a predefined, physician-entered contrast usage threshold throughout the procedure. At the end of the procedure, the CMW displays total procedure contrast volume used (mL), % of physician specified limit , total procedure contrast volume saved (mL), and % contrast saved
40958965|NCT04279457|OTHER|Standardized hydration protocol|hydration protocol based up on the Poseidon protocol
40958966|NCT03214146|BIOLOGICAL|HYNRCS-Allo inj|The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10\^6 cells/kg according to the protocol design.
40958967|NCT04981548|OTHER|no intervention|no intervention
40958968|NCT00307645|DRUG|Cyclophosphamide|
40958969|NCT00307645|DRUG|Mycophenolate mofetil|
40958970|NCT00307645|DRUG|Azathioprine|
40958971|NCT00307645|DRUG|Prednisone (and methylprednisolone)|
40958972|NCT01471808|DRUG|CSII|continuous subcutaneous insulin infusion for 2\~4 weeks
40958973|NCT01471808|DRUG|CSII, Metformin, Pioglitazone|CSII for 2\~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
40958974|NCT01471808|DRUG|CSII, Sitagliptin|CSII for 2\~4 weeks combined with sitagliptin 100mg/d for 3 months
40958975|NCT02046161|PROCEDURE|colonoscopic examination in colon cleansing room|All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
40958976|NCT00037804|DRUG|Irinotecan|
40958977|NCT05560360|DRUG|SHR1459 tablet|100 mg/tablet; administered orally
40958978|NCT05560360|DRUG|Efavirenz tablet|600 mg/tablet; administered orally
40958979|NCT00660699|DRUG|Gemcitabine|
40958980|NCT00660699|DRUG|Docetaxel|
40958981|NCT00660699|RADIATION|Radiation|
40958982|NCT02492269|DRUG|Dexmedetomidine|
41455980|NCT01536249|DRUG|Cimetidine plus Dexpramipexole|Multiple Oral Doses
41455981|NCT04317638|OTHER|Lipid profile|3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.
41455982|NCT04860349|OTHER|High Intensity Interval Training|4-weeks of high intensity interval training, 3 sessions/week on alternate days. each session for 20 minutes, excluding the warm-up and cool-down.
40763824|NCT06640244|OTHER|Sunscreen|To be used by all participants throughout the study
40763825|NCT06640244|OTHER|Cosmetic product G18|Cosmetic face care product
40763826|NCT06640244|OTHER|Cosmetic product N70|Cosmetic face care product
40958983|NCT02492269|DRUG|Placebo|
40958984|NCT04489628|DRUG|Vitamin D3 or Placebo|): Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
40958985|NCT04489628|DEVICE|Doctella telehealth monitoring|Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
40958986|NCT03196726|BEHAVIORAL|Brief Cognitive Behavioral Therapy|Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
40958987|NCT03196726|BEHAVIORAL|standard management based on Clinical Practice Guideline|Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
40958988|NCT03365492|DEVICE|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
40958989|NCT03203616|DRUG|KADCYLA 160 MG Injection|Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
40958990|NCT00570765|DRUG|Placebo|Matching placebo tablets were administered orally once daily.
41455983|NCT04348955|BEHAVIORAL|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized|"Quality of life and anxiety questionnaires before the course of chemotherapy (C1 and C4).~Touch-Massage during the course of chemotherapy (from C1 to C3) Anxiety questionnaire at the end of the course of chemotherapy (from C1 to C3)"
41455984|NCT02395809|PROCEDURE|lateral internal sphincterotomy|
40763827|NCT06640244|OTHER|Cosmetic product D79|Cosmetic face care product
40763828|NCT06640244|OTHER|Cosmetic product E84|Cosmetic face care product
40763829|NCT06640244|OTHER|Cosmetic product C68|Cosmetic face care product
40763830|NCT06570720|BEHAVIORAL|Alcohol-focused Support of Survivors in Sororities Training (ASSIST)|A web-based intervention that includes sorority and individual values, personalized normative feedback (adapted to address sexual assault, support, and acceptability of encouraging peer drinking), psychoeducation on sexual assault and alcohol, and skills training in behaviors to support sexual assault survivors without heavy drinking.
41293039|NCT04182191|DRUG|Tenoxicam|After extraction of at least one third molar, 89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed.
41293040|NCT06274346|OTHER|Multiangular Isometric exercise|already were described in arm descriptions
41293041|NCT04408092|DRUG|Granulocyte Macrophage Colony Stimulation Factor|Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
41293042|NCT01277224|BEHAVIORAL|Movi2 Program|In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
41293043|NCT02136394|OTHER|Gastro-esophageal reflux|This is an observational study. The exposure is the gastro-esophageal reflux.
41293044|NCT04116034|DEVICE|alfapump DSR system|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
41293045|NCT01494038|DRUG|Isoniazid (INH)|300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
41293046|NCT01494038|DRUG|Placebo for isoniazid (INH)|Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
41293047|NCT05429684|DRUG|Trastuzumab|Trastuzumab (6mg/Kg, iv.drip, d1, q3w)
41293048|NCT05429684|DRUG|Pertuzumab|Patuzumab (420mg iv.drip, d1,q3w)
41455985|NCT02395809|PROCEDURE|TENS|
41455986|NCT02559076|BEHAVIORAL|Ten Steps leaflet advice for healthy lifestyle|Ten steps leaflet advice for healthy lifestyle
41293049|NCT05429684|DRUG|Nab paclitaxel|nab-paclitaxel (200mg iv.drip, d1,d8, q3w)
41293050|NCT05429684|DRUG|Pyrotinib|Pyroltinib (400mg po qd)
40763833|NCT02363426|DEVICE|INVOcell Culture Device|INVOcell is a vaginal culture device
40763834|NCT02363426|DEVICE|IVF Incubation|IVF Incubator
40763835|NCT06535100|BEHAVIORAL|Art therapy|artistic therapy, wood painting, lithography, jewelry design, mud free shaping, expression workshop and training workshops
40763836|NCT03119129|BEHAVIORAL|Ho'ouna Pono Drug Prevention Curriculum|Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
40763837|NCT03629717|PROCEDURE|Ultrasound-guided core needle biopsy|Tissue collection for this research proposal will be used for research purposes only and will not inform participant care
40763838|NCT03629717|DRUG|Denosumab|Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL
40763839|NCT03629717|PROCEDURE|Blood draw|20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)
40763840|NCT03629717|DRUG|Calcium|1200mg daily
40763841|NCT03629717|DRUG|Vitamin D|800 IU daily
40763842|NCT00527631|RADIATION|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
41293051|NCT05429684|DRUG|Capecitabine|Capecitabine (1250mg/m2, po, bid, d1-d14, q3w).
41293052|NCT05429684|DRUG|T-DM1|T-DM1(3.6mg/Kg, iv.drip, d1, q3w)
41293053|NCT05429684|DRUG|Everolimus|Everolimus (4mg, po, qd)
41455987|NCT02349672|PROCEDURE|blood sample|Blood will be collected to test for concentrations of UCH-L1 and GFAP.
41293054|NCT05429684|DRUG|CDK4/6 inhibitor|Palbociclib (125mg, po, qd)
41293055|NCT05429684|DRUG|AI|Letrozole (2.5mg, qd).
41455988|NCT01418235|BIOLOGICAL|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
40763843|NCT04403776|DRUG|tofacitinib MR 11 mg|Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
40763844|NCT04403776|DRUG|tofacitinib IR 5 mg|Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.
40958991|NCT00570765|DRUG|Obeticholic Acid (OCA)|Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
40958992|NCT05953311|OTHER|Blood analysis|Blood analysis for neurological biomarkers measurements
40958993|NCT05953311|OTHER|Cognitive tests|Questionnaires assessing cognitive function
40958994|NCT01458938|OTHER|treatment plan|Data Collection Study
40958995|NCT04185428|BEHAVIORAL|Integrative Therapy|still meditation, meditative movement, relaxation techniques, and massage therapy
40958996|NCT02362269|DIETARY_SUPPLEMENT|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
40958997|NCT03989895|BIOLOGICAL|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
40958998|NCT00727636|BIOLOGICAL|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
40958999|NCT05834374|OTHER|Contextual variation|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
40959000|NCT05834374|OTHER|Maximum affordances|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
40959001|NCT03633656|DEVICE|Model predictive control|Computer aided dose selection for the treatment of iron deficient anemia.
40959002|NCT03633656|DEVICE|Model Predictive Control of Iron Dosing|Model Predictive Control of Iron Dosing
40959003|NCT02121431|BEHAVIORAL|Triple P--Positive Parenting Program|The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
40959004|NCT00749645|DRUG|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
40959005|NCT00749645|DRUG|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
40959006|NCT01741974|DIETARY_SUPPLEMENT|Karinat|
40959007|NCT01741974|DRUG|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
40959008|NCT01114256|PROCEDURE|FNA Biopsy|
40959009|NCT06188338|COMBINATION_PRODUCT|Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.
41293056|NCT05429684|DRUG|Anti-PD-1 monoclonal antibody|Cindilimab (200mg, iv.drip, d1, q3w)
41293057|NCT05477680|DEVICE|Navigation-guided surgery|Surgeon removes brain lesions and assesses brain shift with neuronavigation
40959010|NCT06188338|COMBINATION_PRODUCT|Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.
40959011|NCT05958667|BEHAVIORAL|Quitxt text messaging or Chat|Mobile intervention using proven social cognitive, motivational interviewing, and brief intervention methods for promoting behavior change - blends bilingual text and social media messaging for smoking cessation tailored to the language and culture of young adult smokers in our vulnerable region of South Texas.
40959012|NCT05958667|OTHER|Usual care|Abbreviated text messaging with smoking cessation-related content and referral to the Texas Department of State Health Services (TDSHS) cessation program Yes Quit.
40959013|NCT03747588|PROCEDURE|Minimally-invasive pancreaticoduodenectomy|Minimally-invasive pancreaticoduodenectomy for resection of pancreatic tumor
40959014|NCT03747588|OTHER|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy for resection of pancreatic tumor
40959015|NCT03550456|OTHER|ECC|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
40959016|NCT03550456|OTHER|ECC with CLE|Continuous Laryngoscopy is endoscopy of the larynx used to obtain a view of laryngeal obstruction during exercise.
40959017|NCT03550456|OTHER|Speech therapy|Patients with diagnosis of EILO will be sent to a speech therapist for at least 6 training sessions.
40959018|NCT02542904|PROCEDURE|mesenteric excision|
40959019|NCT05419869|DRUG|ALTO-100 PO Tablet|Two tablets daily
40959020|NCT00762229|DRUG|Ezetimibe 10 mg|Ezetimibe 10 mg daily for 4 weeks
40959021|NCT00762229|DRUG|Ezetimibe 5 mg|"Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half"
40959022|NCT00670150|DRUG|NRX 195183 (retinoid analogue)|30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
40959023|NCT00670150|DRUG|Arsenic Trioxide|0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.
40959024|NCT03219541|BEHAVIORAL|Interventional Automated mobile phone text|Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.
41293058|NCT00259025|DRUG|lipid emulsion with a high content of n-3 fatty acids|
40959025|NCT03219541|BEHAVIORAL|Control Automated mobile phone text|Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
40959026|NCT05219305|DEVICE|Dental Implant Placement|Placement in an edentulous site that was previously bone grafted in the prior study.
40959027|NCT00491816|DRUG|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
40959028|NCT01000402|DRUG|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
40959029|NCT02983825|DEVICE|Continuous positive airway pressure (CPAP); level changes|as per arm description
40959030|NCT02814578|OTHER|Optical coherent tomography|comparative method for BVS
41293059|NCT00077623|DRUG|epoetin alfa or beta|iv 3 times weekly, as prescribed
41293060|NCT00077623|DRUG|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 2 weeks
41293061|NCT00077623|DRUG|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 4 weeks
41293062|NCT01654562|DRUG|Simvastatin|Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
41293063|NCT00006246|DRUG|busulfan|
41293064|NCT01707823|DRUG|acetylsalicylic acid|Given PO
40959031|NCT02814578|OTHER|IntraVascular UltraSound|The method of goldstandard for decision stent choice
41293065|NCT01707823|OTHER|laboratory biomarker analysis|Correlative studies
40959032|NCT01964833|PROCEDURE|Periodontal treatment|"Periodontal treatment will consist of oral hygiene instructions, with the monitored orientation of brushing technique and recommendation of the daily use of dental floss. Calculus deposits will also be removed using ultrasound equipment with the appropriate tips for periodontics as well as scaling and planing with dental instruments, as recommended by the AAP (2001). Treatment will be carried out in two to four one-hour sessions.~Patient will receive sham PDT."
40959033|NCT01964833|PROCEDURE|Periodontal treatment and PDT|Patients will receive periodontal treatment as previously described and PDT. PDT will be administered at the end of the periodontal treatment session at sites with pocket depths equal to or greater than 4 mm. A diode laser will be used at the 660 nm wavelength, P= 100 mW, 9 J/point, D = 22 J/cm2 (per point). The photosensitizer (BlueMet 0.005 % DMC)will be deposited at the fundus of the periodontal pocket using a syringe. The laser will be applied to the mucosa over the oral epithelium that lines the periodontal pocket using an optical fiber.
40959034|NCT05397431|DRUG|Lanadelumab|Lanadelumab 300 mg, subcutaneous injection every 2 weeks
40959035|NCT05112471|DEVICE|Airflow, Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
40959036|NCT05112471|DEVICE|Ultrasonic debridement and curettes|traditional Scaling and Root Planing with curettes and ultrasonic scaler
40959037|NCT01683383|DEVICE|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
40959038|NCT01683383|OTHER|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
40959039|NCT01610661|OTHER|Diet|Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
40959040|NCT04535648|OTHER|Non-invasive detection method: CRISPR techonology|This study was a laboratory diagnostic study without any intervention.
40959041|NCT01099553|OTHER|Educational video|Instructions to view an educational video about preparing for a colonoscopy
40959042|NCT01099553|OTHER|Written instructions|Written instructions on preparing for a colonoscopy
40959043|NCT02045810|DRUG|Levobupivacaine|
40959044|NCT02045810|DRUG|Saline|
40959045|NCT03804697|DRUG|selective anticoagulation|Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
40959046|NCT00991718|DRUG|GDC-0449 oral capsules (non-labeled)|150 mg oral capsule
40763845|NCT05273736|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
40763846|NCT02834741|DRUG|NYX-2925|NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.
40763847|NCT04963296|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.
40763848|NCT04963296|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.
40959047|NCT00991718|DRUG|GDC-0449 IV injection (labeled)|10 mcg (in 2 mL) IV dose of 14C-GDC-0449
40959048|NCT00991718|DRUG|CDC-0449 oral suspension (labeled)|30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
40959049|NCT03832777|DEVICE|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
40990566|NCT03524807|DEVICE|Electrophysiologic therapy|Pelvic floor electrophysiological therapy is used after common gynecologic surgery to record anal exhaust time and micturition time after surgery and endometrium recovery of intrauterine adhesions.For intrauterine adhesions patients, Drug: Aspirin(low dose of Aspirin after operation)Device: intrauterine balloon (insert intrauterine balloon after operation)
40990567|NCT01237873|DRUG|Ali/Amlo 150/2.5 mg|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
40990568|NCT01147705|DRUG|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
40763849|NCT04963296|DRUG|Acetaminophen/Paracetamol|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
40763850|NCT04963296|DRUG|Diphenhydramine hydrochloride|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
40763851|NCT04963296|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.
41455989|NCT01418235|BIOLOGICAL|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
41293066|NCT03964012|BIOLOGICAL|NmCV-5|Polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysaccharide antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to C reactive material (CRM) protein. The diluent is Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
41293067|NCT03964012|BIOLOGICAL|Menactra|Menactra is available as ready to use solution containing polysaccharide antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine
40763852|NCT05978414|OTHER|Visceral therapy|Visceral therapy will be performed manually by a physiotherapist, a detailed description of the techniques is above. Therapy will be in 2 subgroups with prolapse of the usual genitals and endometriosis.
40763853|NCT05978414|OTHER|Placebo|Placebo will be in 2 subgroups that will not have visceral therapy. The placebo will consist of the physiotherapist holding hands on the patient's pelvis.
40763854|NCT03037749|DRUG|Alcohol beverage|Alcohol beverage measured to have participant achieve a BAC of 0.08%
40763855|NCT03037749|DRUG|Placebo beverage|Placebo beverage measured to mimic the smell and taste of the alcohol beverage.
40763856|NCT06639555|PROCEDURE|PRP( platelet rich plasma)|regenerative therapy with PRP for vertical bone defects
40763857|NCT06639555|PROCEDURE|EMD (Enamel Matrix Derivative)|regenerative therapy with EMD for vertical bone defects
40763858|NCT06639555|PROCEDURE|Guided Tissue Regeneration (barrier membrane)|guided tissue regeneration with barrier membrane alone for vertical bone defects
40763859|NCT06639555|PROCEDURE|Guided Tissue Regeneration(barrier membrane and PRP)|guided tissue regeneration with barrier membrane and PRP for vertical bone defects
40763860|NCT05783466|OTHER|Low-fat dairy products|3-month intervention
40763861|NCT05783466|OTHER|Whole-fat dairy products|3-month intervention
40763862|NCT05783466|OTHER|Milk polar lipid enriched whole-fat dairy products|3-month intervention
40763863|NCT05817344|BEHAVIORAL|Written Exposure Therapy - Integrated|A brief exposure-based psychotherapy for posttraumatic stress disorder integrated with harm reduction strategies for opioid use disorder
40763864|NCT06641804|PROCEDURE|Pessary care, change of pessary|Insertion of a new pessary by gynaecologist if not contraindicated, silicon or polyvinyl chloride pessary of same size, blinded to patient
40763865|NCT06638034|DRUG|68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy|Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22-3.33GBq(60mci-100mCi) 177Lu-FAPI-RGD was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
40990569|NCT01147705|DRUG|Placebo|Same appearance/dosing as active drug.
40763867|NCT03568123|DEVICE|MC polyethylene bearing|"Zimmer Biomet Persona Total Knee System with MC polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
40763868|NCT03568123|DEVICE|CR polyethylene bearing|"Zimmer Biomet Persona Total Knee System with CR polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
40763869|NCT04269785|DEVICE|Cryoballoon ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using cryoballoon catheter (cold therapy)
40763870|NCT04269785|DEVICE|Radiofrequency ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using radiofrequency catheter (heat therapy)
40763871|NCT06640504|DIAGNOSTIC_TEST|serum albumin|Serum albumin ratios were calculated as the ratio between the estimated blood lactate, and serum levels of CRP and PCT divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR), CRP-to-albumin ratio (CAR) and procalcitonin (PCT)-to-albumin ratio (PAR).
40763872|NCT06640504|DIAGNOSTIC_TEST|C-Reactive Protein|The serum levels of C-reactive protein (CRP) are divided by the estimated serum albumin level to get the CRP-to-albumin ratio (CAR).
40763873|NCT06640504|DIAGNOSTIC_TEST|Serum procalcitonin|The serum levels of procalcitonin (PCT) are divided by the estimated serum albumin level to get the PCT-to-albumin ratio (PAR).
40763874|NCT06640504|DRUG|Blood Lactate|The serum levels of blood lactate are divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR).
40990570|NCT01185938|DRUG|Rosuvastatin|One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
41293068|NCT02602873|OTHER|therapeutic drug monitoring|with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
41293069|NCT05592223|DRUG|BCG Vaccine USP|2x10\^6 cfu Tice® BCG (ID)
40763875|NCT01940744|PROCEDURE|Prescriptive Mobilization|"The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits."
41293070|NCT05592223|DRUG|Isoniazid|INH in the dose of 300 mg for three days post BCG injection.
41293071|NCT05592223|DRUG|Rifampin|RIF in the dose of 600 mg for seven days post BCG injection.
40959050|NCT06533254|OTHER|Predicting choice of dialysis|"Language data collected using survey 1, will be analyzed using Scaled Insights Behavioral AI solution to identify personality attributes and values. The resulting individual scores will be plotted on a graph and be used to identify specific personality clusters of patients.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses.~The open-ended questions will gather a natural language sample of 100-300 words for analysis using Scaled Insights Behavioral AI approach. This language sample will be analyzed using Scaled Insights Behavioral AI system to identify personality attributes and values. Patients will also be asked their likelihood of selecting PD over HD."
40959051|NCT06533254|BEHAVIORAL|Behavioral nudges|"Patients with Chronic Kidney Disease, participants will be provided with their predicted personalized nudge to increase their likelihood of either maintaining their choice of peritoneal dialysis, or switching from hemodialysis to peritoneal dialysis.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses."
40959052|NCT00489346|DRUG|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
40959053|NCT00489346|DRUG|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
40959054|NCT03389620|DRUG|dexamethasone|0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
40959055|NCT00569608|OTHER|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
40959056|NCT01259128|DRUG|SER120 Nasal Spray 500 ng/day|SER120 Level 1
40959057|NCT01259128|DRUG|SER120 nasal spray 750 ng/day|SER120 (750 ng/day)
40959058|NCT01771952|DEVICE|Synvisc-One™|A single 6cc injection of Synvisc-One™ will be utilized in this study.
40959059|NCT01771952|OTHER|Sham Treatment|A single needle stick without arthrocentesis or injection.
40959060|NCT05751902|OTHER|Arabic version of OHIP questionnaire|Translated Arabic version of Oral Health Impact Profile questionnaire
40959061|NCT03691259|OTHER|Ballet Classes|Ballet classes will consist of learn the basic positions and combinations used in ballet, including: Plié, Tendu, Degagé, Rond de Jambe, Frappé, Chassé, Sauté, Pas de Bourrée, Glissade, and Révérance. Additional ballet movements and patterns may be employed as well.
40959062|NCT05469191|OTHER|Group 5 STS|"For 8 weeks, 3 times per week and 3 sets of 5 repetitions during the first month, then 5 sets of 5 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
40959063|NCT05469191|OTHER|Group 10 STS|"For 8 weeks, 3 times per week and 3 sets of 10 repetitions during the first month, then 5 sets of 10 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
40959064|NCT03821649|BEHAVIORAL|SOONER Training and Naloxone Kit Kit|Participants are shown our unique overdose response education video and given the associated kit to take home.
40959065|NCT03821649|BEHAVIORAL|Community or Hospital-Based Training|Referral to standard of care for Naloxone training
40959066|NCT05240313|BEHAVIORAL|kiR venezolano|A multi-week intervention focused on drug refusal skills and self-regulation.
40959067|NCT04883931|DRUG|Normal Saline|0.5 ml 0.9% normal saline will drop on both eyes twice in a day.
40959068|NCT04883931|BIOLOGICAL|Breast milk|0.5 ml breast milk from all infant's own mother will drop both eyes twice in a day
40959069|NCT02809612|BEHAVIORAL|Internet-based platform|Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
40959070|NCT03713892|DRUG|CKD-504|orally administered once with investigational drug assigned on 1d morning with 240 mL of water
40959071|NCT03713892|DRUG|Placebo|orally administered
40959072|NCT04343963|DRUG|Pyridostigmine Bromide|One 60mg tablet P.O. once per day for 14 days
40959073|NCT04343963|DRUG|Placebo|One tablet P.O. once per day for 14 days
40959074|NCT00001880|DRUG|methotrexate|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
40959075|NCT00001880|DRUG|Cyclosporin|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
40959076|NCT04464629|DRUG|Dextenza|Intracanalicular sustained release dexamethasone insert 0.4 mg
40959077|NCT04464629|DRUG|Prednisolone Acetate|Topical Prednisolone acetate 1% ophthalmic suspension
40990571|NCT05670392|DEVICE|laser and High intensity Tesla magnetic stimulation|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals followed by Eight (8) HITS therapies) Patients will receive two (2) HITS treatments per week for four (4) weeks(.
41455990|NCT01418235|BIOLOGICAL|DNA-C2 + MVA-C|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
40763876|NCT01940744|PROCEDURE|Pragmatic Mobilization|The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
40763877|NCT03127722|PROCEDURE|Blood draw|Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
40763878|NCT03127722|DEVICE|ESSURE (BAY1454032)|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
40763879|NCT03127722|PROCEDURE|Laparoscopic tubal sterilization|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
40763880|NCT06580990|PROCEDURE|specific neck exercises with the Spinetrack|This group will receive an telerehabilitation exercise programme for the deep neck musculature using the spinetrack
40990572|NCT05670392|DEVICE|laser (without HITS treatment)|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals as described above.
41293072|NCT03514472|DIETARY_SUPPLEMENT|Dried Moringa oleifera leaves|
40763881|NCT06580990|PROCEDURE|specific neck exercises|This group will receive a telerehabilitation programme with exercise for the deep neck musculature
40763882|NCT04115293|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
40763883|NCT04115293|DRUG|Placebo|Daily subcutaneous (SC) injection
40763884|NCT06384352|DRUG|YL211|Patients will be treated with YL211 intravenous (IV) infusion.
40763885|NCT06075277|DRUG|BI 1810631|BI 1810631
40763886|NCT06262607|DRUG|CLE-400|Topical CLE400 gel 0.28% administered once daily
40763887|NCT06262607|DRUG|Vehicle|Topical vehicle gel administered once daily
40763888|NCT04544189|DRUG|Alpelisib|300mg (oral) once daily, in a 28-day cycle
40763889|NCT04544189|DRUG|Fulvestrant|Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
40763890|NCT04544189|DRUG|Placebo|300 mg by mouth once daily, in a 28-day cycle
41293073|NCT04199754|DRUG|Omnipaque 300mg/mL Solution for Injection|Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
40763891|NCT06105255|DRUG|D-1553|D-1553 is a novel, targeted KRASG12C inhibitor.
40763892|NCT05157997|DRUG|Casirivimab and Imdevimab Antibody Cocktail|The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
40763893|NCT04426357|DRUG|JNJ-64417184|Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
40763894|NCT06346119|OTHER|this arm will received relaxing touch (hands, feet, head) during 30 minutes twice a day|Patients who will be included in this arm will receive massage twice a day of the head (10 minutes), feet (10 minutes) and hands (10 minutes)
40763895|NCT06642935|DEVICE|Totally implantable cochlear Implant|Totally implantable cochlear Implant
40763896|NCT05504083|DRUG|D-0120|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
40763897|NCT05504083|DRUG|Benzbromarone|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
40763898|NCT00708981|OTHER|Multifactorial Intervention|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~1. BP control of \<130/80mmHg and renal protection with reduction of proteinuria to \<0.5g/day using therapy with ACE inhibitors and/or ARBs.~2. Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~3. Use of hypolipidemic therapy to achieve targets of LDL \< 70 mg/dl, HDL \> 40/50 mg/dl (M/F)and TG \< 200 mg/dl.~4. Patient enhanced self-management provided by combined diabetes-renal education curriculum.~5. Behavior and social intervention~6. Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
40763899|NCT05872516|DEVICE|Chang Gung Atrial Fibrillation Detecting Software|This software is expected to be used in clinical testing to interpret the static 12-lead ECG of adults who are over 20 years old and suspected of having atrial fibrillation, detect whether there is a signal of atrial fibrillation, and output the results for clinicians Near-instant auxiliary diagnostic use.
40763900|NCT00174629|DRUG|Docetaxel/DDP|
40763901|NCT00174629|DRUG|docetaxel/gemcitabine|
40763902|NCT04799535|PROCEDURE|Ultrasound|Undergo breast ultrasound
40763903|NCT05919498|OTHER|Individual semi-directive interview|"This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour."
40763904|NCT05919498|OTHER|Focus groups|"This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours."
40763905|NCT00022854|PROCEDURE|Single-injection femoral nerve block|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
40763906|NCT00022854|PROCEDURE|Femoral nerve block 60-hour continuous injection|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
40763907|NCT00022854|PROCEDURE|Saline (control) injection into femoral nerve envelope|Nerve block bolus with 30 mL saline, followed by continuous saline infusion
40763908|NCT01955356|PROCEDURE|Scratching|Endometrial biopsy
40763909|NCT06133270|DRUG|NNC0560-0004|NNC0560-0004, Oral administration (taken through the mouth)
40763910|NCT06133270|DRUG|Placebo (NNC0560-0004)|Placebo matching NNC0560-0004, Oral administration (taken through the mouth)
40763911|NCT05538858|PROCEDURE|Mechanical Ventilation|Positive pressure mechanical ventilation
40959078|NCT03260309|PROCEDURE|Semi-closed loop infusion system tactic.|"Semi -closed loop infusion system tactic.Use volume loading test twice (before surgery and 12hrs postoperatively). Computer provides advisory hypotension treatment algorithm. Computer provides advisory anemia treatment algorithm. Programmed iv fluid and blood infusions system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
40959079|NCT03260309|PROCEDURE|Routine infusion therapy tactic|Routine re-hydration bolus before surgery. Routine treatment of hypotension. Routine treatment of anemia.
40959080|NCT03306563|DIAGNOSTIC_TEST|Sample collection|Samples of blood, urine and saliva will be collected at up to five successive time points.
40959081|NCT02012283|OTHER|Food consumption|Cooked vegetables with spices or without spices
40959082|NCT03308201|DRUG|Hemay022+exemestane|"Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets combination with exemestane."
40959083|NCT03308201|DRUG|Hemay022+letrozole|Part two: Hemay022 combination with letrozole.
40959084|NCT03308201|DRUG|Hemay022+ fulvestrant|Part two: Hemay022 combination with fulvestrant.
40959085|NCT02188108|OTHER|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
40959086|NCT05490810|OTHER|Trunk stabilization|"Trunk stabilization exercises with~* Static back: A roll of towel was pressed against the back and the position was held for 10 secs and then released~* Static gluteus: The gluts were pressed inside and hold for 10 secs and then released.~* Abdominal bracing: Brace your abdomen by contracting your entire abdomen. From here Perform different exercises such as raising your arms and then raising your legs.~* Pelvic bridging: In crook lying, engage your gluts and trunk lift your hips towards the ceiling. Hold the position for 10 secs and then release.~* SLR with-hold at 30 and 45 degrees: Ask the supine patient to raise the leg up-to 45 degrees and hold for 10 secs. Then raise the leg up-to 30 degrees then hold for 10 secs."
40959087|NCT05490810|OTHER|Activation exercises|"Activation exercises with~* Upper rectus abdominis (URA) and lower rectus abdominis (LRA): body supine with hips and knees flexed 90°, with feet locked. Participants flexed the trunk (i.e. crunch execution) against resistance at the level of the shoulders..~* External oblique (EO) and internal oblique (IO): side-lying with the hip at the edge of the bench and feet locked by a second operator. Participants performed side-bend exercise against resistance at the level of the shoulder.~* Lower erector spinae (LES) and upper erector spinae (UES): prone position with ASIS at the edge of the bench and feet locked by a second operator. Participants performed a back extension against resistance at the level of the shoulders."
40959088|NCT02124083|DRUG|Vorinostat|Histone deactylase inhibitor
40959089|NCT02577978|DEVICE|Medacta GMK posterior stabilized prosthesis|
41293074|NCT04199754|RADIATION|Cone Beam CT|60 seconds after contrast administration, a Cone Beam CT will be performed.
40763912|NCT06639893|PROCEDURE|Telescopic overdenture|Telescopic overdenture with two dental implants in intraforaminal area for mandible.
40959090|NCT02577978|DEVICE|Medacta GMK Sphere prosthesis|
40959091|NCT00150748|DRUG|Levetiracetam 166 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 166 mg~* Route of Administration: Oral use"
40959092|NCT00150748|DRUG|Levetiracetam 250 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 250 mg~* Route of Administration: Oral use"
40959093|NCT00150748|DRUG|Levetiracetam 500 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 500 mg~* Route of Administration: Oral use"
40959094|NCT00268359|BIOLOGICAL|bevacizumab|
40959095|NCT00268359|DRUG|irinotecan hydrochloride|
40959096|NCT01423370|DRUG|YHD1023|5g oral once daily
40959097|NCT01423370|DRUG|YHD1023|5g oral twice a day
40959098|NCT01423370|DRUG|YHD1023|10g oral once daily
40959099|NCT01423370|DRUG|Cialis|5mg oral once daily
41293075|NCT04199754|RADIATION|Radiation Therapy|Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.
41293076|NCT04199754|DRUG|0.9% Saline|50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
40959100|NCT01423370|DRUG|Placebo|Oral
40959101|NCT01719978|DRUG|3.6mL 2% Mepivacaine with 1:100,000 epinephrine|Local anesthetic with vasoconstrictor
40959102|NCT01719978|PROCEDURE|Lower Third Molar Extraction|Lower Third Molar Extraction with LA + hyaluronidase (or placebo)
40959103|NCT01719978|DRUG|Hyaluronidase|75RTU Hyaluronidase administration concomitant to the local anesthetic
40959104|NCT01719978|DRUG|Placebo|1mL 0.9% saline administration concomitant to the local anesthetic
40959105|NCT04489797|DRUG|Acalabrutinib|Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.
40959106|NCT04489797|DRUG|Rabeprazole|Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.
40959107|NCT03222960|DRUG|propolis-containing toothpaste|participants will use propolis-containing toothpaste for 6 months
40959108|NCT03222960|DRUG|Fluoride-containing toothpaste|participants will use Fluoride-containing toothpaste for 6 months
40959109|NCT04623112|DEVICE|Hearing aid feature: Frequency Compression|FC Deactivated/Activated \& set to default/Activated \& set to hearing loss
40959110|NCT04399226|DRUG|Dexmedetomidine|Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine).
40959111|NCT00283452|BEHAVIORAL|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
40959112|NCT05869266|DEVICE|professional fitting vs. self fitting|Licensed professional fits the hearing aid fitting using professional programing tools and thresholds obtained from the traditional audiometry vs. subject performs self-fitting of the hearing aids using the Tuned App.
40959113|NCT00536562|BEHAVIORAL|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition \& psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
40959114|NCT01393301|BEHAVIORAL|Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
40763913|NCT05395312|OTHER|Online blended stepped-care mental well-being platform|"Participants in experimental group will be stratified according to their level of anxiety and/or depressive symptoms.~Level 2 (normal range)~* Topic-based personal growth articles, exercises, and chatbots~* Webinars and talks on varied mental health related topics~* Virtual support community~Level 3 (mild to moderate)~* Online self-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online skills-based workshops, questions-and-answers sessions, retreats~Level 4 (severe)~* Online coach-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online group therapy, 4-week group cognitive behavioural therapy or 8-week group mindfulness-based cognitive therapy"
40959115|NCT01393301|BEHAVIORAL|Control|Enhanced standard smoking cessation treatment and NRT.
40959116|NCT06192277|OTHER|Screening|Patients are screened to confirm they are low risk for a penicillin allergy
40959117|NCT06192277|DRUG|Low dose Penicillin|Low risk participants are given a low-dose of oral penicillin followed by 60 minutes of observation
40763914|NCT05033561|BIOLOGICAL|nOPV2|Novel Oral Poliomyelitis Type 2 Vaccine
40959118|NCT06192277|DRUG|Standard dose Penicillin|Participants who have taken the low dose of oral penicillin and have had no reaction are provided a second higher dose of penicillin (250mg) and observed for 60 minutes.
40959119|NCT06192277|OTHER|Remove allergy label|Participants who have no reaction after 28 days have their penicillin allergy label removed from their electronic medical record and hospital record.
40959120|NCT05116618|DIAGNOSTIC_TEST|InVisionFirst-Lung ctDNA assay|An enhanced tagged/targeted-amplicon sequencing technology for detection of genomic alterations in 36 commonly mutated genes in plasma ctDNA with a sensitivity of 73.9% and specificity of 99.8%.
40959121|NCT04899154|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.
40959122|NCT04899154|OTHER|stool sampling|Participants will provide one stool sample at inclusion
40959123|NCT03485339|DIAGNOSTIC_TEST|genome testing|blood sampling via venipuncture
40959124|NCT03513458|BIOLOGICAL|Anakinra|A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
40959125|NCT03513458|OTHER|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
40959126|NCT03513458|DRUG|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
40959127|NCT06006741|BIOLOGICAL|MM-specific universal CAR T cells|Infusion of MM-specific universal CAR T cells
40959128|NCT00528463|PROCEDURE|sciatic nerve block|Sciatic nerve block, Labatt approach, with a stimuplex needle and catheter. Once localized, a bolus of 20 mL ropivacaine 1,0% is given through the catheter and is followed by a perfusion of ropivacaine 0,2% 6-10 mL/hre for at least 24 hours pre-op and 48 hours post-op
40959129|NCT03026322|OTHER|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
40959130|NCT03026322|OTHER|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
40959131|NCT06040931|PROCEDURE|Bronchoscopy|Bronchoscopy and broncho-alveolar lavage (BAL) to assess neutrophilic count in BAL as a measurement of airway inflammation
40959132|NCT04312204|DRUG|Sintilimab combined with Gemcitabine and Carboplatin|"The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight \<40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months."
40959133|NCT00113984|BIOLOGICAL|PROSTVAC-V/TRICOM|
40959134|NCT00113984|BIOLOGICAL|PROSTVAC-F/TRICOM|
40959135|NCT00113984|DRUG|MDX-010|
40959136|NCT00113984|DRUG|Sargramostim|
41293077|NCT03070977|OTHER|Interprofessional clinical training unit|"In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.~A facilitator team is responsible for the interprofessional training. In autumn 2016 seven professionals participate in course of facilitating interprofessional collaboration and training. The intervention involved the total staff participation in an initial workshop.~The training unit is based on two educational interventions: Student participation in clinical care teams and interprofessional group tuition sessions."
41455991|NCT01418235|BIOLOGICAL|DNA-C2 + MVA-C + gp140/MF59|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
40959137|NCT03875651|DEVICE|SYNERGY 4.50 mm and 5.0 mm Coronary Stent System|The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
40959138|NCT00454012|PROCEDURE|biophysical profile|
40959139|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
40959140|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
40959141|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
40959142|NCT06317727|DEVICE|Irreversible Electroporation using EndoVE(Endoscopic Vacuum Electrode) and electrical pulses generated using ePORE(electroporation device)|The use of pulsed field ablation via irreversible electroporation delivered during flexible lower gastrointestinal endoscopy
40959143|NCT04737382|DIAGNOSTIC_TEST|biopsy|The formalin fixed material will be processed for molecular analysis in a clinically validated diagnostic pipeline according to ISO 15189 or other acceptable standard
40763916|NCT06117631|BEHAVIORAL|Centering Parenting|See Arm description.
40763917|NCT06117631|BEHAVIORAL|Bright by Text|See Arm description.
40763918|NCT06088914|DEVICE|Anodal transcranial direct current stimulation|Anodal tDCS will be delivered for 5 consecutive days. Participants will receive 2 mA of stimulation for 20 minutes with the anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
40959144|NCT04737382|DIAGNOSTIC_TEST|ctDAN analysis|ctDNA analysis will be performed using the AVENIO ctDNA targeted kit according to the guidelines from the manufacturer with respect to isolation, library preparation and bioinformatics analysis.
40959145|NCT02261896|DRUG|Placebo|Evaluate usefullness of antibiotic prophylaxis
40959146|NCT02261896|DRUG|Ciprofloxacin|Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
40959147|NCT04926428|DRUG|tPA|Selectively catheter thrombolysis with alteplase in each main pulmonary
40959148|NCT02837289|OTHER|Therapy taping|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
40959149|NCT02837289|OTHER|Placebo taping|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
40763919|NCT06088914|DEVICE|Sham transcranial direct current stimulation|Sham tDCS will be delivered for 5 consecutive days. Participants will receive sham stimulation for 20 minutes with the current intensity ramping down after 30 seconds of stimulation. The anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
40959150|NCT03021070|OTHER|Conditional cash transfer|For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
40959151|NCT05791175|DEVICE|Teeth scan with intraoral scanner (Trios, 3 Shape, Denmark)|Intraoral scanner will be use to monitor the changes of the teeth over time. Intraoral scanners are devices that capture three-dimensional images of teeth and are used as an alternative to conventional dental impressions.
40959152|NCT02557555|OTHER|educational information|patients will receive pamphlet on labor analgesia options.
40959153|NCT03718832|OTHER|Fresh Food Farmacy|Patients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
40959154|NCT01372696|OTHER|Sample of polyp|A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
40959155|NCT02453178|BEHAVIORAL|Cycling|The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
40959156|NCT04281303|PROCEDURE|Endoscopic vertical gastroplasty|endoscopic vertical gastroplasty + lifestyle modification
40959157|NCT05500157|PROCEDURE|aspiration sclerotherapy versus laparoscopic fenestration|See arm description
40959158|NCT00053937|DRUG|pirfenidone|
40959159|NCT00084383|BIOLOGICAL|GVAX pancreatic cancer vaccine|"Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination."
40959160|NCT03214939|BIOLOGICAL|Immunotherapy based on dendritic cells|Intravenous injection of cells
40959161|NCT00304291|DRUG|Mitoxantrone|
40959162|NCT00329004|DRUG|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
40959163|NCT03782961|DEVICE|sodium lactate and combination of polymers|sodium lactate and combination of polymers (polycarbophil, carbomer and PVM / MA copolymer)
40959164|NCT00882895|PROCEDURE|Stem cell infusion|
40959165|NCT00882895|PROCEDURE|TLI|
40959166|NCT00882895|DRUG|Anti-thymocyte globulin|
40959167|NCT00882895|DRUG|Solumedrol|
40959168|NCT00882895|DRUG|Tacrolimus|
40959169|NCT00882895|DRUG|Mycophenolate mofetil|
40959170|NCT04638257|BIOLOGICAL|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14|Daily oral Lactobacilli starting at =\<18 weeks of gestation in singleton pregnancy
40959171|NCT04638257|OTHER|Placebo|Daily oral placebo starting at =\<18 weeks of gestation in singleton pregnancy
40959172|NCT04375371|PROCEDURE|Bariatric surgery|Obese patients who haveundergone bariatric surgery as part of routine clinical management within the indication of this intervention.
40959173|NCT04505865|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~1) Elicitation of the Relaxation Response through mind-body techniques; 2) discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and 3) coping strategies and adaptive perspective-taking to promote positive well-being."
40959174|NCT05550285|DEVICE|orbital floor recontriction|Guided Calvarial Graft Harvesting vs 3D Printed Titanium mesh
40959175|NCT04888468|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
40959176|NCT04449081|BEHAVIORAL|Knowledge, Attitude, Practice, Awareness, Preference|KAP, Awareness level and Preference were assessed using questionnaires
40959177|NCT03017495|DRUG|Midazolam|2 mg/mL oral solution
40959178|NCT03017495|DRUG|ACT-541468|Hard gelatin capsules for oral use at a strength of 25 mg
41293078|NCT04791397|PROCEDURE|Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from control group undergo 15 procedures of IHHT, 5 procedures per week for 3 weeks, 1 procedure lasts 40 minutes. IHHT is a protocol which employs passive (the patient is at rest), short (several minutes) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia, and repeated for 40 minutes. During the initial pretreatment test, the patient inhales air with low oxygen content at atmospheric pressure in a continuous mode through a mask. In the interval therapeutic mode that follows, periods of hypoxia (10-14% O2) are interrupted by periods of reoxygenation by hyperoxia (up to 35% O2). Automatic switching of gas flows (SRT technology). Built-in intelligent software automatically identifies and suggests key treatment parameters for the individual treatment program, by adjusting the starting parameters based upon the results of the pretreatment hypoxic test.
41293079|NCT04791397|PROCEDURE|Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from group control undergo simulating procedures of interval hypoxic-hyperoxic training, 15 procedures, 5 procedures per week for 3 weeks. 1 procedure lasts 40 minutes, in normoxia. Before the start of the course, each patient undergoes a test procedure for 10 minute (in normoxia) for simulate procedures IHHT.
41293080|NCT01729364|DRUG|crystalloid|
41293081|NCT01729364|DRUG|colloid|
41293082|NCT04069767|PROCEDURE|ICoreDIST|"The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~1. Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~2. Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~3. Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~4. Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~5. Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~6. Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking."
41293083|NCT04069767|PROCEDURE|Standard Care|According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
41293084|NCT05257577|PROCEDURE|Breast conserving surgery|Patients receive standard of care breast surgery and subsequent whole breast irradiation
41293085|NCT05563532|BEHAVIORAL|dental anxiety and oral hygiene|Evaluation of the effect of mothers' dental anxiety and oral hygiene on children's dental anxiety and periodontal status.
41293086|NCT04885244|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
41293087|NCT01380405|BEHAVIORAL|education intervention|"Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons."
41293088|NCT02404831|OTHER|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
41293089|NCT02404831|OTHER|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
41455992|NCT02293616|DIETARY_SUPPLEMENT|Nitrate Rich Beetroot Juice|Nitrate rich beetroot juice diet supplement will be consumed by subjects.
41455993|NCT02293616|DIETARY_SUPPLEMENT|Placebo|
41455994|NCT02247687|DRUG|Protease inhibitor|"Modification in the antiretroviral treatment~•Switch arm for protease inhibitor : intervention switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling."
41455995|NCT02247687|DRUG|Isentress® (raltegravir)|• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling
40763920|NCT06391086|DEVICE|NaviFUS® Neuronavigation-guided focused ultrasound system|The treatment protocol consists of once daily treatment for consecutive five tFUS sessions.
40763921|NCT00234793|BEHAVIORAL|Problem-Solving Skills Training|
40763922|NCT04467853|BIOLOGICAL|LCAR-C18S cells|Before treatment with LCAR-C18S cells, subjects will receive a conditioning regimen
40959179|NCT02481583|DRUG|Levosulpiride|different formulations of levosulpiride
41455996|NCT02247687|OTHER|Counseling arm|No change of antiretroviral treatment but only counseling
40959180|NCT04042896|BEHAVIORAL|exergame|Exergame is 'exercise + game'.
40959181|NCT04042896|BEHAVIORAL|treadmill exercise|traditional aerobic exercise
40959182|NCT01191229|DEVICE|Tecnis one-piece MF IOL|25 patients to be implanted after cataract surgery
40959183|NCT01191229|DEVICE|Crystalens AO|25 patients that are previously implanted
40959184|NCT05560477|DRUG|AM3101|Injectable drug product.
40959185|NCT05560477|DRUG|Saline Placebo|2 mL 0.9% normal saline
41293090|NCT03197675|OTHER|Acupuncture|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
41293091|NCT06107062|DRUG|Cannabidiol - fsCBD|Full-spectrum (i.e., fsCBD, 7.8mg THC (3.4mg BID)), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used.
41293092|NCT06107062|DRUG|Placebo|Placebo arm
41293093|NCT06107062|DRUG|Cannabidiol - bsCBD|Broad-spectrum (i.e., bsCBD, 0% THC), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used
41293094|NCT00318201|DRUG|Erythromycin|
41293095|NCT00318201|DRUG|Diltiazem|
41293096|NCT05468450|DRUG|Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant|Direct injection Foam sclerotherapy
41293097|NCT05468450|DEVICE|Endovenous Laser Ablation (EVLA)|EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
41293098|NCT01232946|DRUG|liraglutide|1.8mg subcutaneous qd for 3 months
41293099|NCT01232946|DRUG|insulin detemir|5units subcutaneous bid titrated to fasting glucose of \<130mg/dL for 3 months
41293100|NCT01232946|DRUG|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose \<130mg/dL for 3 months.
41293101|NCT03426215|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Changes in size and severity of the main herniated disc causing radiating pain will be evaluated by radiology specialists and Korean medicine doctors (KMDs) and categorized into three groups (improved, worse or no discernible change) in comparison with the immediate previous MRI to track long-term changes and assess for correlations in subjective clinical symptoms and objective physical evaluation and MRI results.
41293102|NCT04134104|PROCEDURE|Surgery for Colorectal malignant diseases either LAR or APR|Patients following LAR or APR were observed for the Bowel, Bladder, and Sexual Dysfunction
41293103|NCT01597193|DRUG|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
41293104|NCT01597193|DRUG|anastrozole|1 mg/day
41293105|NCT01597193|DRUG|exemestane|The exemestane dose is 25mg daily.
40763923|NCT03196479|DRUG|ketamine and propofol mixture with 1:6 ratio|K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
40763924|NCT03196479|DRUG|ketamine and propofol mixture with 1:4 ratio|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
40959186|NCT06202430|PROCEDURE|High Thoracic Erector Spinae Plane Block|High Thoracic-ESPB The patient was placed in the lateral decubitus. The transverse process of T2 was identified. After negative aspiration, hydro dissection using 2 mL of saline was performed. Eventually, 30 mL of the LA bupivacaine 0.25% and epinephrine 5 µg/ mL was injected.
40990573|NCT02374645|DRUG|Volitinib|600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
41293106|NCT01597193|DRUG|fulvestrant|500 mg every 28 days
41293107|NCT01597193|DRUG|enzalutamide|160 mg (4 capsules) taken orally daily.
41293108|NCT01597193|DRUG|exemestane|The exemestane dose is 50 mg daily.
41293109|NCT01378390|DRUG|Expanded autologous adipose-derived adult stem cells (eASCs)|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
41293110|NCT01378390|DRUG|Placebo|Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
41293111|NCT06403774|DRUG|Group that will undergo bowel preparation using laxatives (Two bowel X-M Solution 250 ml.)|A laxatives (Two bowel X-M Solution 250 ml.) will be applied for bowel preparation before hemorrhoidectomy. The drug was given to the patient at 3 o'clock (p.m.)before the surgery by mixing it with 1500ml of water.
41293112|NCT06403774|DRUG|Group that will undergo bowel preparation using enema (Two bowel E.S. Enema )|An enema (Two bowel E.S. Enema ) will be applied for bowel preparation before hemorrhoidectomy.The drug was administered to the patient at 00 o'clock (a.m.) and 06 o'clock (a.m.) before the surgery.
41455997|NCT05562037|OTHER|Stepped Care|Patients meeting a non-response criterion will be stepped up to the next step
41455998|NCT02666482|BEHAVIORAL|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
41455999|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
41456000|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
40959187|NCT06202430|PROCEDURE|Shoulder Block|"Shoulder Block Suprascapular nerve block (SSNB) approach: The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle.~Axillary nerve block technique:~The nerve approach had been described in plane from cranial to caudal. After local infiltration of the skin with 1% lidocaine, the needle tip must be visualized within the fascia below the teres minor muscle and just above the PCHA. After cautious aspiration, 10 ml of 0.5% bupivacaine was injected on the posterior aspect of the humerus."
40959188|NCT00000557|BEHAVIORAL|social support|
40959189|NCT03741062|DEVICE|J. Morita AdvErl Evo Er:YAG laser|"Er:YAG laser perimeters:~Energy = 80 mJ Pulse Rate = 25 Hz Duration = 30 s"
40959190|NCT03741062|DEVICE|Control|Sham treatment with laser unit turned off
40959191|NCT02621697|OTHER|Cognitive motor training|Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
40959192|NCT02621697|OTHER|kinesiotherapeutic conventional treatment|Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
40959193|NCT06053996|RADIATION|Hepatopulmonary radio-sterilization|Hepatopulmonary radio-sterilization - ablation of hepatic and pulmonary metastases
40959194|NCT03342183|OTHER|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation).
40959195|NCT03342183|OTHER|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
40959196|NCT01839123|DEVICE|Prosthetic Suction or Pin Socket|Conventional prosthetic socket utilizing non-vacuum suspension to secure the residual limb to the prosthesis. Non-vacuum suspension includes pin/lock suspension and suction suspension.
40959197|NCT01839123|DEVICE|Prosthetic LimbLogic Vacuum Socket|Prosthetic socket that incorporates conventional vacuum suspension using the commercially available LimbLogic vacuum pump
40959198|NCT00225069|PROCEDURE|Level of sympathectomy|T2 sympathectomy or T2-T3 sympathectomy
40959199|NCT03318510|DEVICE|Laser Speckle Flowgraphy|A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
40959200|NCT03363958|PROCEDURE|Remote Ischemic Preconditioning with Postconditioning|Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
40959201|NCT03363958|PROCEDURE|Sham RIPC procedure|Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
40959202|NCT05248867|DRUG|Placebo|Placebo solution for injection
40959203|NCT05248867|DRUG|AGN-151586|AGN-151586 solution for injection
41293113|NCT05011422|DEVICE|Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus|Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations. It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product
41293114|NCT06005714|DRUG|Mindeudesivir hydrobromide tablets and Clarithromycin tablets|Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and clarithromycin tablets are administered twice from D1 to D10.
40959204|NCT00194285|PROCEDURE|FDG-PET Imaging|
40959205|NCT06139107|DRUG|Abemaciclib|150mg twice a day for 3 cycles prior to radiation.
41293115|NCT06005714|DRUG|Mindeudesivir hydrobromide tablets and Cyclosporine softgels|Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and cyclosporine sofgels are administered once at D4.
40763925|NCT03223987|DIETARY_SUPPLEMENT|Strath® Kräuterhefe Original (liquid)|"The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.~Stool analysis at 2nd visit and last visit. Before-after study."
40959206|NCT06139107|DRUG|Letrozole|Letrozole 2.5mg daily
40959207|NCT03150017|OTHER|SPIRE|Online pain management programme.
40959208|NCT02859168|BEHAVIORAL|Myofascial Induction|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
40959209|NCT02859168|DEVICE|Unplugged pulsed shortwave therapy|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
41293116|NCT01801046|DRUG|mitoxantrone hydrochloride|Given IV
40959210|NCT06157359|PROCEDURE|scalp nerve block|In the SNB group, bilateral scalp nerve blocks will performed using 20 mL of 0.75% ropivacaine after anesthesia induction. To cover the area of surgical incision and skull clamp, seven scalp nerves including the supratrochlear, supraorbital, zygomaticotemporal, auriculotemporal, lesser occipital and greater occipital nerves, are blocked bilaterally by injecting 1-2 ml of the solution using a 25-gauge needle.
40959211|NCT05199155|BIOLOGICAL|NerVFIX|Decellularized, freeze-dried and sterile allogeneic graft of artery or vein from umbilical cord use by the investigator as a nerve regeneration conduit
40990574|NCT02374645|DRUG|gefitinib|250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
40763926|NCT06569732|OTHER|Homemade oral nutrition supplements|The homemade oral nutrition supplement is made of soy milk, whey protein powder, vegetable oil, and fruit juices
40763927|NCT06569732|OTHER|Commercial oral nutrition supplements|The commercial oral nutrition supplement is kidney-specific oral nutrition supplement that is high in energy and protein, but low in electrolytes and fluid
40763928|NCT05627492|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 2 years. Participants and their treatment providers will decide on the frequency of sessions collaboratively. This may include individual and/or skills sessions in addition to phone coaching for those who attend individual sessions at least once per month. DBT consultation will also remain a component of the treatment. Participants may choose skills training, conducted in approximately 60 minute meetings, and individual therapy conducted in approximately 60 minute sessions. Family participation in skills training is highly encouraged. Skills training may include: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets.
40763929|NCT04118920|DRUG|Topical insulin (4 units)|N=6: 100 U/ml; 4 units of insulin per application; 40 microliters per drop
40763930|NCT04118920|DRUG|Topical insulin (20 units)|N=6: 500 U/ml; 20 units of insulin per application; 40 microliters per drop
40990575|NCT03639337|DIETARY_SUPPLEMENT|Multi-strain probiotic|30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63
40763931|NCT04118920|DRUG|Artificial tears|N=3, 40 microliters per drop
40959212|NCT04180358|BEHAVIORAL|Native STAND|Native STAND is a comprehensive sexual health curriculum for Native high school students that focuses on sexually transmitted infections, HIV/AIDS, and teen pregnancy prevention, while also covering drug and alcohol use, suicide, and dating violence. Twenty-seven sessions support healthy decision-making through interactive discussions and activities that promote diversity, self-esteem, goals and values, team building, negotiation and refusal skills, and effective communication. Sessions will be conducted in regular Physical Education and/or Health Education classes during classroom/school hours.
40959213|NCT04180358|BEHAVIORAL|Regular Health/Physical Education Curriculum|General health and physical education curriculum provided by New Mexico's Public Education Department.
40959214|NCT04004130|OTHER|Ultrasound imaging|Ultrasound imaging of the lumbar spine/subarachnoidal space
40959215|NCT05827731|BEHAVIORAL|cesarean section|According to the different outcomes of pregnancy, the patients were divided into natural delivery group and cesarean section group
40959216|NCT04178486|BEHAVIORAL|Hypnosis with amnesia suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
40959217|NCT04178486|BEHAVIORAL|Hypnosis with cognitive rehearsal suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
40959218|NCT04178486|BEHAVIORAL|Hypnosis with memory substitution suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
40959219|NCT04178486|BEHAVIORAL|Hypnosis with induction only|Participants received only hypnotic induction.
40959220|NCT06194630|DRUG|68Ga-A3|Intravenous injection of 68Ga-A3 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-A3 will be used to image organs or lesions which expresses ACE2 by PET/CT.
40959221|NCT04984330|DRUG|Selinexor|Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.
40959222|NCT04984330|DRUG|Dexamethasone|Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).
40959223|NCT04305418|OTHER|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
40959224|NCT04335097|DEVICE|Biosensors|Sensor that detect vital signs
40959225|NCT05574738|OTHER|Observational|
40959226|NCT03405584|DRUG|Esomeprazole|Proton pump inhibitor
40959227|NCT03405584|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
40959228|NCT03405584|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
40959229|NCT04388878|DRUG|PF-07054894|Participants will receive oral ascending doses
40959230|NCT04388878|DRUG|Placebo|Participants will receive matching placebo
40959231|NCT03691155|OTHER|The Crohn's Diet|All recruited participants will be educated on the Crohn's Diet and instructed to adhere to the study diet for 14 days.
40959232|NCT02023281|BEHAVIORAL|Exercise|The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
40959233|NCT00353795|PROCEDURE|MR Imaging of the Coronary Arteries|
40763932|NCT05770245|DEVICE|The novel electrolyzed water spray|The researcher used electrolyzed water or piped water to treat the diseased area two times a day for five days. The trial consists of 7 study visits (day 1-day 7). The reduction in the disease area of discomfort or itching scores and promoting healing of the damaged skin of patients with mild dermatophytosis event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
40763933|NCT04700800|OTHER|Exercise|Acute cycle-ergometer exercise for 45 minutes at 65% of peak oxygen uptake
40763934|NCT04700800|OTHER|Infusion of Amino Acids|Intravenous infusion of mixture of amino acids
40959234|NCT06557187|RADIATION|ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost|hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
40959235|NCT04960631|DIAGNOSTIC_TEST|Double site CT guided needle biopsy|Double site CT guided needle biopsy
40959236|NCT04218422|PROCEDURE|Battlefield Acupuncture|Acupuncture at 5 points on the ears
40959237|NCT04218422|PROCEDURE|Sham Acupuncture|Sham acupuncture in 2 points for liver and 1 point for stomach
40959238|NCT00726869|DRUG|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8.
40959239|NCT03133169|DIAGNOSTIC_TEST|blood sample|blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level
40959240|NCT03133169|DIAGNOSTIC_TEST|Tricuspid regurge velocity|Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
41293117|NCT01801046|DRUG|cytarabine|Given IV
41293118|NCT01801046|PROCEDURE|peripheral blood stem cell transplantation|Undergo HMMACT with G-PBSC
40763935|NCT05856747|DRUG|TBP-PI-HBr|TBP-PI-HBr tablets.
40763936|NCT06564051|OTHER|Non-Interventional Study|Non-interventional study
40763937|NCT03673982|BEHAVIORAL|iCASK|Materials and support to aid transitions
40763938|NCT03742726|DEVICE|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
41456001|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
40763939|NCT03662373|RADIATION|carbon ions radiation therapy|Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
40763940|NCT03662373|RADIATION|protons radiation therapy|Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
40763941|NCT02975115|OTHER|RQ-PCR RNA Analysis|Conventional Q-RT-PCR every 3 months
40763942|NCT05368935|DRUG|Nitazoxanide|500 mg Twice Daily for 7 days
40763943|NCT01390519|OTHER|everolimis|
40763944|NCT04637347|DEVICE|Catheterization approach|In plane infraclavicular subclavian vein VS in plane supraclavicular subclavian vein catetherization
40763945|NCT01929603|PROCEDURE|Pharmacokinetic sampling|Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol
40763946|NCT01929603|DRUG|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
40763947|NCT01929603|DRUG|Olaparib tablet dosing|Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
40763948|NCT00035984|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
40763949|NCT00035984|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
40763950|NCT00035984|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
40763951|NCT00035984|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
40763952|NCT02228330|PROCEDURE|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
40763953|NCT05006755|COMBINATION_PRODUCT|Mineral Trioxide Aggregate|Mineral Trioxide Aggregate stimulates cementoblasts to produce matrix for cementum formation and is biocompatible with the periradicular tissues thus shows a superior sealing ability when used in perforation repair
40763954|NCT05006755|COMBINATION_PRODUCT|Biodentine|Biodentine has a good sealing ability, high compressive strengths, short setting time, biocompatibility, bioactivity and biomineralization properties that make it available to be used in endodontic repair procedures
40763955|NCT00980798|DRUG|OROS hydromorphone HCl|4 to 32 mg taken orally once daily for 16 weeks
40763956|NCT00980798|DRUG|Placebo|placebo tablet once daily for 16 weeks
40763957|NCT03063645|DRUG|AC-1202|60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1
40763958|NCT03063645|DRUG|AC-SD-01 (50 g)|50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
40763959|NCT03063645|DRUG|AC-SD-01 (75 g)|75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
40763960|NCT06294899|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed to patients with suspected lower respiratory tract infections.
40763961|NCT06294899|DIAGNOSTIC_TEST|C-Reactive Protein Test|C-Reactive Protein Test will be performed to patients with suspected lower respiratory tract infections.
40763962|NCT02346279|OTHER|Questionnaires, EDSS, physical test|6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
40763963|NCT03794544|DRUG|Durvalumab|Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
41293119|NCT01801046|OTHER|laboratory biomarker analysis|Correlative studies
41293120|NCT03684083|PROCEDURE|bronchial biopsies|bronchial fibroscopy with bronchial biopsies
41456002|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
41456003|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
40959241|NCT03857893|DEVICE|Dynamic Quadripolar Radio-Frequency treatment|"Novel low-energy Dynamic Quadripolar Radio-frequency thermal treatment through Eva™ Device. Eva™ Device combines both advanced VDR™ technology (Vaginal Dynamic Radiofrequency) and RSS™ (Radiofrequency Safely System) technology."
40959242|NCT03857893|DRUG|pH-Cream|1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
40959243|NCT04010058|DEVICE|LIDCO CNAP device|The LiDCO CNAP device (referred to as CNAP in this document) provides continuous cardiac output non-invasively, without the requirement for an arterial catheter. It uses a dual finger cuff in addition to a standard arm cuff (familiar to everyone who's had their blood pressure checked) and it transforms infrared plethysmographic signals into continuous blood pressure information. It uses an algorithm to derive cardiac output-related parameters. In recognition of the potential difference between the derived values and any measured values, it refers to some of its values as 'nominal' values. It has been evaluated in a range of surgical populations8-11 a post-operative cohort12, and a haemodynamically unstable critical care population13. In a population of patients undergoing endoscopy there was increased detection of episodes of hypotension compared with standard measures.
40959244|NCT01647646|DRUG|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
40959245|NCT03912168|OTHER|Question Prompt List|Question prompt list for common orthopaedic conditions
40959246|NCT03912168|OTHER|3 questions list|3 questions from the AskShareKnow model
40959247|NCT03928158|DRUG|LCZ 696|50-100-200 mg tablet
40763964|NCT03794544|COMBINATION_PRODUCT|Oleclumab|Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
41293121|NCT01479049|DRUG|MP (moderate potassium) group|Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
40763965|NCT03794544|COMBINATION_PRODUCT|Monalizumab|Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
40763966|NCT03794544|COMBINATION_PRODUCT|Danvatirsen|Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
40763967|NCT05165927|DEVICE|BFR|BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.
40763968|NCT06308926|DRUG|MRG-001 (Low-dose)|MRG-001 is subcutaneously administered.
40763969|NCT06308926|DRUG|MRG-001 (High-dose)|MRG-001 is subcutaneously administered.
40763970|NCT06308926|OTHER|Placebo|Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.
40959248|NCT03928158|DRUG|Valsartan|40-80-160 mg tablet
40959249|NCT02930330|BEHAVIORAL|INT|"* 5 min warm-up (40% Pmax\*)~* 30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
40959250|NCT02930330|BEHAVIORAL|CONT|"* 5 min warm-up (40% Pmax\*)~* 30 min moderate intensity continuous training (60% Pmax)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
41293122|NCT01479049|DRUG|HP (High potassium) group|Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
41293123|NCT02959710|DRUG|AC-1204 mixed in water|40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
41293124|NCT02959710|DRUG|AC-1202 mixed in water|60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
41293125|NCT02959710|DRUG|AC-1202 mixed in Ensure®|60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)
41293126|NCT03922399|PROCEDURE|Laser and Surgery|Laser and Surgery in patients with major burn scars Evaluating after three years treatment
40763971|NCT02832531|DRUG|Rivaroxaban (15 mg)|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG."
41456004|NCT02784236|DEVICE|telemedicine|The study population corresponds to patients\> 18 and \<65 years with DM1 of\> 1 year of evolution, and treated with MDI HbA1c\> 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele
40959251|NCT01790880|BEHAVIORAL|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
40959252|NCT01790880|BEHAVIORAL|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
40959253|NCT06264414|DRUG|DTT106|oral route
40959254|NCT06264414|DRUG|Dutasteride-Tamsulosin|oral route
40959255|NCT03191279|PROCEDURE|First aid|Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
40959256|NCT06433908|DRUG|Salbutamol HFA-152a|100 µg (ex-valve), given at 20-second intervals.
40959257|NCT06433908|DRUG|Salbutamol HFA-134a|100 µg (ex-valve), given at 20-second intervals.
40959258|NCT05016999|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion)
40959259|NCT02749071|PROCEDURE|Laparoscopic implantation surgery|Laparoscopic surgery to implant the pulse generator and bipolar lead.
41293127|NCT01941368|DIETARY_SUPPLEMENT|Placebo|
41293128|NCT01941368|DIETARY_SUPPLEMENT|HMB-FA|
41293129|NCT01941368|PROCEDURE|High Intensity Interval Training|
41293130|NCT02133378|DEVICE|Hemopatch|Baxter Hemopatch
41293131|NCT02133378|BEHAVIORAL|Traditional Hemostasis Techniques (dry or wet gauze compression or similar)|
41293132|NCT04128657|DIAGNOSTIC_TEST|MA_LARS|Validation of the MA_LARS and MA_Wexner
41456005|NCT06180915|BEHAVIORAL|The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days.|The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days. The peer educator will create a Whatsapp group with the experimental group participants and a name for the group will be found by mutual decision. The peer educator will schedule a time and date with the group. Each session will last approximately 60 minutes and the total training duration will be planned to be 3 weeks. One week and one month after the training is completed, the participants will fill out the scales again.
40763972|NCT02832531|DRUG|Aspirin|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG."
40763973|NCT05981040|DRUG|ZYIL1 capsules 25 mg and 50 mg Placebo|ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
40763974|NCT05981040|DRUG|ZYIL1 capsules 50 mg and 25 mg Placebo|ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
40763975|NCT05981040|DRUG|ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg|ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
40763976|NCT05981040|DRUG|Matching placebo 25 mg and Matching placebo 50 mg|Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
40763977|NCT01256047|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
40763978|NCT05080478|DRUG|Clopidogrel, Ticagrelor|P2Y12 inhibitors are prescribed following the PCI procedure in patients. Patients are enrolled on the study before administration of the first dose of the drug. Parameters are measured before and after drug initiation.
40763979|NCT01271231|DRUG|Scaling and root planing plus placebo|Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
40763980|NCT01271231|DRUG|Scaling and root planing plus azythromycin|Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
40763981|NCT01271231|DRUG|Prophylaxis plus azythromycin|Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
41293133|NCT05589181|DRUG|High Dose Buprenorphine|32mg of BUP split as 16mg at 0 minutes and 16mg at 30-60 min as an induction dose
41293134|NCT05589181|DRUG|Standard Buprenorphine Dose|12mg of buprenorphine (BUP) split as 8mg at 0 minutes and 4mg at time 30-60 min as an induction dose
41293135|NCT04850911|DRUG|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.
40763985|NCT05670704|BIOLOGICAL|ARGX-119|Patients receiving ARGX-119 IV or SC
40763986|NCT05670704|OTHER|Placebo|Patients receiving Placebo IV or SC
40763987|NCT05674565|DRUG|Magnesium sulfate loading with maintenance dose|4 gm MgSo4 loading over 20 minutes followed by 1 gm per hour maintenance till delivery
40763988|NCT05674565|DRUG|Magnesium sulfate loading dose only|4 gm MgSo4 loading over 20 minutes within one hour before delivery
40763989|NCT05294523|PROCEDURE|Rocuronium priming dose|Add the priming dose of rocuronium after the first supramaximal stimulation data measured
40763990|NCT06636812|DRUG|Losartan potassium|Single dose losartan (25mg or 50 mg, weight-adjusted), encapsulated identically to placebo
40763991|NCT06636812|OTHER|Placebo|Single tablet encapsulated identically to placebo
40763992|NCT03499743|DRUG|hyoscine butyl bromide|intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion
40763993|NCT03499743|DRUG|Celecoxib 200mg|Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
40763994|NCT03499743|DRUG|Placebo Oral Tablet|a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
40763995|NCT03570385|DEVICE|MRI|MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)
40763996|NCT01030809|OTHER|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
40763997|NCT02249949|DRUG|efatutazone|Given PO
40763998|NCT00373360|DRUG|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
40763999|NCT03101267|DRUG|ASP4070|Intradermal vaccination at 2-week intervals
40764000|NCT03101267|DRUG|Placebo|Intradermal vaccination at 2-week intervals
40764001|NCT02499926|DIETARY_SUPPLEMENT|Arginine|"Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.~Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals."
40764002|NCT06639412|BEHAVIORAL|Networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention & control services.|The intervention will be networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention \& control services. In this major activity, the project team will establish the network by incorporating agricultural development agents and parents- teacher associations to the health post as foundational actors for educating the community on NCD prevention and control measures. We will implement tier system training to effectively create awareness on NCD and to enhance the NCD care-seeking behavior of the community.
41293136|NCT04850911|OTHER|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
41293137|NCT05934448|DRUG|Pembrolizumab|Pembrolizumab via iv, dosage and timing per protocol
41293138|NCT05934448|DRUG|Lymphodepletion Chemotherapy|Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC
40764003|NCT06639412|OTHER|Usual care|The community in the control group will get noncommunicable disease prevention and control measures given through the health care system.
40764004|NCT06432998|OTHER|Perineal massage|The technique will be applied for approximately twenty minutes and will be carried out as follows: the vaginal dilator is introduced progressively using crescent-shaped movements. Once the dilator is fully inserted, movements will be made from bottom to top and from one side to the other, and then continue with the crescent-shaped movements.
40764005|NCT06432998|OTHER|Standard treatment|The treatment will consist of the use of vaginal dilators according to the gold standard proposed in the literature. It will consist of introducing the same dilators as for the experimental group, with the same time schedule, but without massage, only introducing the dilator and keeping it in the vagina for 20 minutes.
40764006|NCT03930511|PROCEDURE|Pulmonary Rehabilitation|According to patients' needs and physician referral, individually tailored treatments of respiratory physiotherapy, functional training, exercise training and patient education
40764007|NCT06641440|DRUG|Prednisone|patients will be treated for three months in the two groups with the two different protocols for three months both
40764008|NCT05825001|BEHAVIORAL|Smoking Cessation Intervention|Receive active EFT stimulus
40764009|NCT05825001|BEHAVIORAL|Smoking Cessation Intervention (control)|Receive control EFT stimulus
40764010|NCT05825001|OTHER|Medical Device Usage and Evaluation|Use iCOquit Smokerlyzer carbon monoxide monitor
40959260|NCT02749071|DEVICE|EndoStim stimulation for first six months of study|Lower esophageal stimulation
40764011|NCT03988205|BEHAVIORAL|Outpatient Care Model|Outpatient care model includes a nurse teacher educational program, scheduled outpatient visit protocol, and quality of life surveys for both subjects and caregivers.
40764012|NCT03988205|DRUG|CPX-351|CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
40764013|NCT06644807|PROCEDURE|Motor Cortex Stimulation|Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.
40764014|NCT06644807|PROCEDURE|Spinal cord stimulation|Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.
40959261|NCT02749071|DEVICE|EndoStim stimulation from Month 6 thru end of study|Lower esophageal stimulation
40764015|NCT06644807|PROCEDURE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.
40764016|NCT06644807|PROCEDURE|Dorsal Root Ganglion Stimulation|Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.
40959262|NCT02749071|DEVICE|Sham EndoStim stimulation for first six months of study|"EndoStim device remains off (no stimulation delivered)"
40959263|NCT06349772|DRUG|Zynrelef|Zynrelef will be injected at the 12mm port site
40959264|NCT06349772|DRUG|Exparel|Exparel will be injected at the 12mm port site
40959265|NCT01977742|OTHER|Supervised exercise program|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.
40990576|NCT01809873|BEHAVIORAL|Performance based incentives|Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
41293139|NCT05934448|DRUG|Chimeric Antigen Receptor (CAR) Therapy Infusion|Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.
41293140|NCT05934448|PROCEDURE|Leukapheresis|manufacturing using commercial product as per standard of care (SOC) Cycle 1 Day -21 or earlier
41293141|NCT00612846|PROCEDURE|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy
40959266|NCT01977742|OTHER|Supervised exercise program together with a specific sudden rest-exercise training protocol|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
40959267|NCT02782728|BEHAVIORAL|TIPS-Plus|Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
41293142|NCT00612846|PROCEDURE|Laparoscopic bile duct exploration during cholecystectomy|Laparoscopic bile duct exploration during cholecystectomy
41293143|NCT05782556|DEVICE|Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)|For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
41293144|NCT01355991|DRUG|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
41293145|NCT01355991|DRUG|Salmeterol|50mcg inhalation twice daily for two weeks
41293146|NCT06470737|OTHER|Hypertonic Saline|A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.2 mL
41293147|NCT06470737|OTHER|Histamine|A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
41293148|NCT06470737|OTHER|Cowhage|This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
41293149|NCT06470737|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMS-evoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
41293150|NCT02391727|BIOLOGICAL|SYN004|subjects who have received effective treatment for their cancers are eligible
41293151|NCT03728127|DIETARY_SUPPLEMENT|Brazilian cardioprotective diet|Brazilian cardioprotective diet prescription
41293152|NCT03728127|DIETARY_SUPPLEMENT|Brazilian cardioprotective diet plus 30g/day of mixed nuts|Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
41293153|NCT05441969|OTHER|No intervention/expousure|No interventions/expousure since this is an observational study.
41293154|NCT02399878|DRUG|Inspiratory oxygen|
41293155|NCT02844504|BEHAVIORAL|Low Intensity Exercise Training 1|Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
41293156|NCT02844504|BEHAVIORAL|Low Intensity Exercise Training 2|Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
41293157|NCT04806581|DRUG|Allogeneic Hepatocyte|Allogeneic hepatocyte with cell numbers L,M,H respectively.
41456006|NCT00643305|BEHAVIORAL|Skills Building with Motivational Interviewing|Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk
41456007|NCT00643305|BEHAVIORAL|Skills Building|Participants are provided with information and training in skills critical for reducing HIV risk.
41456008|NCT02263768|PROCEDURE|Oral clinical conditions|Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment
41293158|NCT06064682|OTHER|standard of care biopsy|Image-guided or surgical biopsy of the lesion that is suspected to be osteosarcoma in a patient with localized disease (Group 1)
41293159|NCT06064682|OTHER|standard of care biopsy|Image-guided or surgical biopsy or excision of the lesion that is suspected to be recurrent or metastatic osteosarcoma (Group 2).
41293160|NCT04550728|COMBINATION_PRODUCT|Ankle robot training group|Patients will be seated with the paretic foot strapped to the footplate the knee at full extension. The operator will set up and measure (using the robot) ankle passive DF and PF ROM limits. The robot training will include passive stretching, robot interactive game-based training, and cool-down stretching.
41456009|NCT00114504|DRUG|simvastatin|simvastatin 5-10 mg/day
41456010|NCT03135340|PROCEDURE|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
41293161|NCT04550728|COMBINATION_PRODUCT|Ankle robot training and functional electrical stimulation(FES) group|Patients will use the ankle robot device as the ankle training group. Also, water-based FES electrodes positioned inside a soft garment will be secured over the DF and PF muscles by wrapping the garment around the leg just below the knee joint. Stimulation intensity will be increased to maximal tolerance of each participant. Electrically induced contraction timing will be triggered by the ankle robot in synchrony with the ankle dorsi and plantar flexion movements.
41293162|NCT01797432|DRUG|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
41293163|NCT01797432|DEVICE|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
41293164|NCT00242177|DRUG|ACTOS (Pioglitazone)|
41456011|NCT03135340|PROCEDURE|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
41293165|NCT01205243|DRUG|ZIAGEN®|Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
41293166|NCT05786261|DEVICE|experimental group MIRT|Task 1a: Assessing the effect of MIRT on cortical plasticity tested with rPAS Task 1b: Assessing the effect of MIRT on structural cortical plasticity and brain connectivity tested with MRI Task 1c: Assessing the effect of MIRT on movement-related beta modulation Task 1d: Assessing the effects of MIRT on motor skills formation with reaching tasks Task 1e: Assessing the effects of MIRT on EEG correlates of motor skills formation Task 2a: Assessing the effect of MIRT on muscle synergies during gait Task 2b: Assessing the effect of MIRT on muscle synergies during reaching movements Task 3a: Assessing the effect of MIRT on sleep microstructure
41456012|NCT03135340|DRUG|WALANT Injection|1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
41456013|NCT03135340|DRUG|Regional Anesthetic Injection|0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
41456014|NCT03235141|DRUG|azithromycin eye drops by essex|azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
40764017|NCT06641726|OTHER|Not applicable- observational study|This is non-interventional, cross-sectional observational study and thus there is no intervention.
40764018|NCT05615883|OTHER|AEP Group Walking Sessions|The AEP Program consists in a single walking session on a treadmill lasting 80 minutes
40764019|NCT05615883|OTHER|CEP Group Walking Sessions|The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks.
40764020|NCT05718323|DRUG|Niraparib|200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
40764021|NCT03583294|OTHER|MRI pelvic|Pelvic MRI
40764022|NCT01879826|DEVICE|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
40764023|NCT01879826|DEVICE|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
40764024|NCT06534723|DRUG|Wujia Yizhi granules|Drug: Wujia Yizhi granuless
40764025|NCT06534723|DRUG|Placebo|Placebo
40764026|NCT06340360|DRUG|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
40764027|NCT06340360|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
40959268|NCT02782728|BEHAVIORAL|TIPS-Basic|Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
40959269|NCT00356291|BEHAVIORAL|Skill-Building (SB) plus Motivational Interviewing|SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.
41293167|NCT05786261|DEVICE|EEG task rTMS, fMRI|EEG task rTMS, fMRI
41293168|NCT01594476|DRUG|Levonorgestrel IUS|20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device
41456015|NCT03235141|DRUG|azithromycin eye drops|azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
40959270|NCT00356291|BEHAVIORAL|Skill-Building (SB)|SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
40959271|NCT04770181|DEVICE|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
40959272|NCT04770181|DEVICE|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
40764028|NCT06053320|DEVICE|Prism adaptation therapy (PAT) + Electrical stimulation (E-stim)|PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets. For treating left-sided neglect, a person wears the prism lenses that shift the visual field, including the images of the target and of one's own reaching arm, certain degrees to the right depending on the diopter of the lens (e.g., the 20-diopter lens shifts the visual field by 11.4 degrees). The visual system adapts over the repetitive practice of the arm reaching toward the target. The person eventually achieves success with a leftward movement reaching the actual target. Electrical stimulation (E-stim) involves parameters and settings commonly used in clinical practice as well as research for pain relief and other applications, commonly referred to as transcutaneous electrical nerve stimulation (TENS). TENS and E-stim are delivered using FDA-approved, commercially available portable clinical transcutaneous electrical stimulators (e.g. Empi TENS Unit).
40764029|NCT06053320|DEVICE|Prism adaptation therapy (PAT) + Sham Stimulator|Participants in the PAT with sham stim condition group will receive sham electrical stimulation treatment (electrodes will be attached but the stimulator will not be turned on) to the left upper limb with the same placement of electrodes while undergoing PAT.
40764030|NCT06053320|OTHER|Gait Training|After PAT, participants will complete multiple 30-seconds to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts.
40764031|NCT04589468|OTHER|Exercise|Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
41456016|NCT00323258|BEHAVIORAL|oral education & written tips for remembering medications|Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
41456017|NCT00323258|DEVICE|pill box|Subject is provided a pill box and briefly instructed on how to use the box.
41456018|NCT00323258|DEVICE|pocket medication card|Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
41456019|NCT00323258|BEHAVIORAL|sharing information with community pharmacist|A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
41456020|NCT00323258|BEHAVIORAL|Medication use evaluations by community pharmacist|The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
40764032|NCT02592655|DEVICE|Pneumatic Tourniquet|Automated pneumatic tourniquet, applied to middle upper thigh.
40959273|NCT05898113|OTHER|EXTRA VIRGIN OLIVE OIL|Participants will consume a daily amount of extra virgin olive oil. Can consume the oil either raw or cooked
40959274|NCT05898113|OTHER|OLIVE OIL LOW POLYPHENOL|Participants will consume a daily amount of olive oil low polyphenol. Can consume the oil either raw or cooked
40959275|NCT01016197|PROCEDURE|extensor tendon repair|Surgical repair of extensor tendon with bone anchor and splinting
40959276|NCT01016197|PROCEDURE|Mallet splint for 4 weeks|"The patient will wear a mallet splint for fours weeks and then mobilise their finger."
40959277|NCT05781854|DRUG|Epidural analgesia with bupivacaine and dexmedetomidine|Epidural analgesia with bupivacaine and dexmedetomidine
40990577|NCT00847288|OTHER|Monthly Review Arm|Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
40764033|NCT02592655|DEVICE|One Windlass Tourniquet|One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
40764034|NCT02592655|DEVICE|Two Windlass Tourniquets|Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.
40764035|NCT02592655|DEVICE|Tourniquet Tape 5 cm|Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
40764036|NCT02592655|DEVICE|Tourniquet Tape 10 cm|Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
40764037|NCT06630689|OTHER|Dry Full Body Massage|Applying massage after phototherapy
40764038|NCT06630689|OTHER|Oil Full Body Massage|Oil Full Body Massage
40764039|NCT03752372|PROCEDURE|hematopoietic stem cell transplantation|"1. Reduced intensity conditioning(RIC) chemotherapy regimen before transplantation~2. All patients were cared for in single rooms ventilated with a highly effective particulate air filtration system. All patients received intravenous immunoglobulin and antimicrobial prophylaxis, which included antiviral, antifungal, and Pneumocystis jirovecii prophylaxis with ganciclovir and micafungin, as per routine clinical practice before transplantation.~3. Umbilical cord blood transplantation"
40764040|NCT06641310|PROCEDURE|Endurance Exercise Therapy|"* Exercise: Endurance exercise therapy comprising treadmill walking administered by exercise physiologists via a study-kit which includes a smart-watch (activity tracker), heart rate monitor, blood pressure cuff, body composition scale, and etablet)~* Exercise escalation trial testing 3 exercise levels (150, 225, and 300 minutes per week), with one de-escalation exercise of 90 minutes per week, if required.~* The phase 1b trial will evaluate the highest feasible exercise level and one exercise below identified in the phase 1a study."
40764041|NCT06330493|DEVICE|PCB|Paclitaxel coated PTA balloon catheter
40764042|NCT06330493|DEVICE|PTA|Non-coated FDA cleared standard percutaneous transluminal angioplasty balloon catheter
40764043|NCT01275300|DRUG|Aspirin|
40764044|NCT01275300|DRUG|Placebo|
41136023|NCT01617707|DRUG|Midazolam|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
41293169|NCT05885685|DRUG|Nabilone Oral Capsule|Each oral capsule contains a 0.25 mg dose of nabilone. Participants begin by taking 1 capsule at night then 1 capsule in the morning and 1 at night for the next 2 days. On the 4th day, the dose is doubled. On the 6th day, the dose is doubled again.
40764045|NCT01275300|DRUG|Niacin|
40764046|NCT06207604|PROCEDURE|Open sinus lifting without bone grafting and simultaneous implant placement|no bone graft will be used after open sinus lifting
40764047|NCT06207604|PROCEDURE|Open sinus lifting with bone grafting and simultaneous implant placement|bone graft will be packed palatally after open sinus elevation and before implant placement, then implant placement will took place followed by packing of bone grafts
41293170|NCT03083951|PROCEDURE|Complete mesocolon excision|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
41456021|NCT00323258|BEHAVIORAL|informing physician if patient has stopped a medication|The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
41456022|NCT00323258|BEHAVIORAL|Routine discharge counseling|Both groups received routine discharge counseling performed by the patient-care nurse.
40764048|NCT06638567|OTHER|Basal bolus insulin regimen|Combination of long-acting and short-acting insulin in a proactive schedule for achieving better blood glucose values postoperatively
40959278|NCT01723488|RADIATION|[F18] T808|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
40959279|NCT04720066|DIAGNOSTIC_TEST|Ultrasound test|point of care ultrasound performed by PEM physicians to limping children presenting to the PED compared to radiologist performed ultrasound test.
40959280|NCT00272012|DRUG|Insulin glulisine|
40959281|NCT02582983|DRUG|Enfuvirtide|All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
41136024|NCT00775892|DEVICE|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
40764049|NCT06267768|DIAGNOSTIC_TEST|Various intensities of inspiratory muscle training|Each participant will be asked to perform the lung function test to measure the maximal inspiratory pressure (MIP) after including the study. After the baseline measurement, all participants will be requested to use a nose clip to hold the nose and breathe with the mouth through a pressure threshold inspiratory loading device (POWERbreathe, KH2, England). The inspiratory pressure will be set at 30%, 40%, 50%, 60%, 70%, or 80% of their MIP, in random order. Each MIP intensity protocol consists of 10 breaths. Resting will be allowed between different protocols of contraction intensity (% MIP). During the test, sternocleidomastoid muscle activity will be measured with surface electromyography (sEMG) and diaphragm thickness will be used to assessed with ultrasonography.
40764050|NCT00615160|DRUG|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
40764051|NCT00615160|DRUG|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
40764052|NCT06640881|RADIATION|ablative single-dose PBI|ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.
40764053|NCT06639581|DEVICE|20 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 20-rates per minute
40764054|NCT06639581|DEVICE|30 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 30 rates per minute
40764055|NCT06639581|DEVICE|40 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 40 rates per minute
41293171|NCT03083951|PROCEDURE|Conventional locoregional lymphadenectomy|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
41293172|NCT04308369|BIOLOGICAL|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6). In this study, blood samples will be collected by a nurse of the service and centralized by the laboratory of Medical Biology of the General hospital of Dax.
41293173|NCT01553539|DRUG|therapeutic angiotensin-(1-7)|Given SC
41293174|NCT01553539|OTHER|laboratory biomarker analysis|Correlative study
40764056|NCT06315556|DRUG|Aflibercept (Eylea)|Eylea 40 mg/mL solution for injection in pre-filled syringe.
41136025|NCT01054118|DRUG|JNJ-38431055|Liquid suspension of JNJ-38431055 administered as a single dose
41293175|NCT00722345|BEHAVIORAL|"review of Canada's Physical Activity Guide for Youth"|"The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet"
40764057|NCT05620940|DRUG|Vivitrol Injectable Product|Naltrexone Long-Acting Injection
40764058|NCT05620940|DRUG|IVL3004|Naltrexone Long-Acting Injection
40764059|NCT05620940|DRUG|IVL4002|Naltrexone Long-Acting Injection
40764060|NCT05505500|BEHAVIORAL|Interview|Concept Elicitation Interviews are used to create tools followed by Cognitive Debrief Interviews that are used to review created tools.
40764061|NCT05655078|RADIATION|Proton beam therapy|5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).
41136026|NCT01054118|DRUG|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose
41136027|NCT01054118|DRUG|JNJ-38431055 + Sitagliptin 100 mg|Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
41136028|NCT01054118|DRUG|Placebo|Placebo suspension and placebo capsule administered as single doses
40764062|NCT05609253|DRUG|Itraconazole in capsule form|Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).
40764063|NCT05609253|DRUG|Itraconazole in solution form|Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
40959282|NCT06356519|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w
40959283|NCT03210246|DRUG|Vilaprisan (BAY 1002670)|Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
40959284|NCT03210246|DRUG|Vilaprisan Placebo|Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
40764064|NCT06642116|DEVICE|OCEAN|Biodegradable nasal dressing
40764065|NCT06636955|OTHER|biobank|"* nasopharyngeal swab collection~* nasopharyngeal nasal washes collection, during hospitalization, if any"
40959285|NCT03210246|DRUG|Microgynon|Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
40959286|NCT03210246|DRUG|Microgynon Placebo|For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
40959287|NCT05545709|PROCEDURE|remote robot-assisted spine surgery|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
40959288|NCT01292811|DEVICE|Functional Electrical Stimulation (Compex Motion Stimulator)|Functional electrical Stimulation:Parameters of stimulation: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
40764066|NCT06636955|OTHER|follow up|- one year follow up: after 1 month, 3 months, 6 months et 12 months
40764067|NCT06369662|DIAGNOSTIC_TEST|Flow cytometric immunophenotyping|CD155 expression by flow cytometric immunophenotyping
40764068|NCT06369662|DIAGNOSTIC_TEST|Complete blood count|Complete blood count with peripheral blood smear examination
40764069|NCT06369662|DIAGNOSTIC_TEST|Bone marrow aspiration|Bone marrow aspiration at both diagnosis and follow up of patients
40764070|NCT06369662|DIAGNOSTIC_TEST|Cytogenetic testing|Karyotyping or AML fluorescence in situ hybridization (FISH) panel for diagnosis and risk stratification of AML patients
40764071|NCT06369662|DIAGNOSTIC_TEST|FLT3-ITD using High resolution melting curve (HRM) analysis|Detection of FLT3-ITD mutation in AML patinets
40990578|NCT00847288|OTHER|Quarterly Review Arm|Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
40990579|NCT00817115|DEVICE|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
40990580|NCT01983579|PROCEDURE|Intraocular anti-VEGF injection|
40764072|NCT06045247|DRUG|Prednisone|Given by IV (vein)
40764073|NCT06045247|DRUG|Rituximab|Given by IV (vein)
40764074|NCT06045247|DRUG|Cyclophosphamide|Given by IV (vein)
40764075|NCT06045247|DRUG|Vincristine|Given by IV (vein)
40764076|NCT06045247|DRUG|Epcoritamab|Given under the skin
41293176|NCT00722345|BEHAVIORAL|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current \& past activities; 2) reviewing the pros \& cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
41293177|NCT04807569|OTHER|Peripheral magnetic neuromodulation|"Non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation"
41293178|NCT04807569|DRUG|Taking drug Tamsulosin|Tamsulosin at a dose of 0.4 mg x 1 time per day orally for 1 month.
41293179|NCT02927171|OTHER|IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
40764077|NCT05780606|OTHER|Exposed to UV|Two healthy volunteers will be exposed to UV or visible light in the forearm region. Suction bubbles, and skin biopsies will be performed in test areas, suction bubbles for transcriptome, biopsies for immunohistochemistry
41293180|NCT06456723|DRUG|[18F]-FET-βAG-TOCA|Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA) - maximum injected dose of 370MBq - followed PET/CT imaging.
41293181|NCT01753752|DRUG|Chitosan- N- Acetylcysteine eye drops|
41293182|NCT01753752|DRUG|Placebo|
40990581|NCT01983579|DEVICE|SENSIMED Triggerfish|
41293183|NCT05713305|PROCEDURE|Online-based self-help psychological intervention|Daily members of the intervention group were thought to provide three different forms of daily sessions each day, averaging 10-20 minutes. These sessions included psycho-educational and cognitive-behavioral exercises, music therapy, sleep hygiene, stress relief methods. Weekly online lecture sessions presented by professional mental health therapists
40990582|NCT04577937|DIAGNOSTIC_TEST|LAM patients underwent PSG|Patients with confirmed diagnosis of LAM underwent a whole-night polysomnography. The presence of either acute or chronic respiratory failure or the use of long-term oxygen therapy are considered exclusion criteria
40990583|NCT03541265|DRUG|Exparel|long-acting Bupivacaine extended release liposome compound
41456023|NCT00323258|OTHER|Letter to physician/discharge summary|A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
41456024|NCT03470116|DEVICE|Laryngoscopy with Mac Grath|Patients of this group will benefit MacGrath MAC video laryngoscopy for intubation after curarization
40959289|NCT01292811|OTHER|Conventional Occupational therapy|"The Control group will receive conventional occupational therapy pertaining to hand function \[15\].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
40959290|NCT02499822|DRUG|Nifedipine GITS|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
40764078|NCT03779854|RADIATION|Total-Body Irradiation|Undergo TBI
40764079|NCT03779854|DRUG|Thiotepa|Given IV
40764080|NCT03779854|DRUG|Fludarabine|Given IV
40764081|NCT03779854|DRUG|Cyclophosphamide|Given IV
40959291|NCT02499822|DRUG|Ramipril|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
40959292|NCT02339584|DRUG|Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension|
40959293|NCT02339584|DRUG|Brinzolamide 10 mg/mL eye drops, suspension|
40959294|NCT02339584|DRUG|Brimonidine 2 mg/mL eye drops, solution|
41293184|NCT05713305|PROCEDURE|Provide online mental health knowledge|They will receive official mental health recommendations on how to cope mentally with the pandemic. These recommendations inform about the importance of a daily structure, social contact, acceptance of negative emotions and strengthening of positive emotions, and stimulus control to assimilate SARS-CoV-2 Omicron-related news
41293185|NCT01804205|DRUG|Magnesium Sulfate|MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
41293186|NCT01804205|DRUG|Placebo|100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
41293187|NCT02674607|DIETARY_SUPPLEMENT|Spirulina|
41293188|NCT04963218|DIAGNOSTIC_TEST|AI Algorithm to detect LVEF in ECG|A clinical decision support software as a medical device that detects whether a patient has LVEF less than or equal to 40% based upon the input of one or more ECG vectors at the point-of-care.
40959295|NCT02339584|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
40764082|NCT03779854|DRUG|Busulfan|Given IV
40764083|NCT03779854|PROCEDURE|Allogeneic Bone Marrow Transplantation|Receive unmanipulated T cell replete BM
40764084|NCT03779854|DRUG|Tacrolimus|Given IV
40764085|NCT03779854|DRUG|Methotrexate|Given IV
40764086|NCT03779854|PROCEDURE|Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation|Receive naive T-cell depleted PBSCs
40764087|NCT03779854|PROCEDURE|Echocardiography|Undergo ECHO
40764088|NCT03779854|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
40764089|NCT03779854|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40764090|NCT03779854|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40764091|NCT05633667|DRUG|Zimberelimab (ZIM)|Administered intravenously
40764092|NCT05633667|DRUG|Domvanalimab (DOM)|Administered intravenously
40764093|NCT05633667|DRUG|Sacituzumab govitecan-hziy (SG)|Administered intravenously
40764094|NCT05633667|DRUG|Etrumadenant (ETRUMA)|Administered orally
40764095|NCT05633667|DRUG|Carboplatin|Administered intravenously
40764096|NCT05633667|DRUG|Cisplatin|Administered intravenously
40764097|NCT05633667|DRUG|Pemetrexed|Administered intravenously
40764098|NCT05633667|DRUG|Paclitaxel|Administered intravenously
40764099|NCT05633667|DRUG|Nab-paclitaxel|Administered intravenously
40764100|NCT05633667|DRUG|Docetaxel|Administered intravenously
40764101|NCT05633667|DRUG|Nivolumab|Administered intravenously
40959296|NCT00592215|DRUG|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
40959297|NCT00510497|BIOLOGICAL|Autologous HIV-1 ApB DC Vaccine|Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
41293189|NCT02299908|DRUG|TAP block with Bupivacaine at 0.25%|Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
41293190|NCT02299908|DRUG|Placebo saline solution|Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
41293191|NCT02508714|DEVICE|Orsiro|stents will be implanted in case of significant coronary artery disease
41293192|NCT02508714|DEVICE|Resolute Onyx|stents will be implanted in case of significant coronary artery disease based on coronary angiography
41456025|NCT03470116|DEVICE|direct laryngoscopy|Patients of this group will benefit direct laryngoscopy for intubation after curarization
41293193|NCT03808272|DEVICE|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.
40959298|NCT02391701|BEHAVIORAL|Diet|diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
41293194|NCT02159092|BEHAVIORAL|Contingency Management|Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
41293195|NCT05822999|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
41293196|NCT05822999|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
41293197|NCT03340441|DEVICE|Prizma|sensor unit with mobile application installed on smartphone
41293198|NCT04011189|PROCEDURE|Videotaping|Before the videotaping, patients will be asked on their baseline pain scores. Their face and body pose from a frontal view will be videotaped via a mobile phone with no internet access. The collected videos will be further processed to extract key points, which will be the primary input for modelling algorithms and will further ensure anonymity of the patients in the video sequences.
41456026|NCT03945916|DIETARY_SUPPLEMENT|Dark chocolate|180 g/d dark chocolate for 15 days followed by exercise testing
41456027|NCT03945916|DIETARY_SUPPLEMENT|Placebo|Placebo: 180 g/d imitation dark chocolate for 15 days followed by exercise testing
40764102|NCT05670756|OTHER|Survey|Parents/guardians will complete a survey about when the medication allergy was identified and the exact symptomatology that resulted in determination of the allergy.
40764103|NCT06639464|DRUG|Semaglutide|This intervention will consist of the FDA-approved dosing schedule, with terminal dosage based on manufacturer's recommendation to titrate to 1mg over 12 weeks. Participants will receive 0.25mg for the first 4 weeks, 0.5mg for the next 4 weeks, and 1.0mg for the final 4 weeks. IDS will extract semaglutide an draw the doses into syringes for matching placebo doses to also be produced and maintain blind.
40764104|NCT06639464|OTHER|Placebo|Placebo syringes of saline and matching volume will be produced by IDS.
40959299|NCT02586129|DRUG|YH14755|20/1500mg, QD
41293199|NCT04011189|OTHER|Questionnaires|"Patients will be asked to fill in 1-2 questionnaires before surgery/procedure/consultation (Hospital Anxiety and Depression Scale (HADS) and/or EQ-5D-3L). After surgery/procedure/consultation, patients will be again asked to fill in HADS questionnaire (optional).~For pediatrics patient, only Child Pain Anxiety Symptoms Scale (CPASS) will be administered before the surgery."
41293200|NCT04011189|DEVICE|Empatica E4 wristband|A medical grade wearable device, Empatica E4 wristband, will be used in phase 3 for pediatrics patients to monitor real-time physiological data on heart rate and body temperature.
41293201|NCT01104389|DEVICE|Fluorescence imaging|Intraoperatively acquire fluorescence images of renal tumors
41456028|NCT03953664|OTHER|Experimental-Exercise training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.
41456029|NCT02190786|DRUG|KUX-1151|
40764105|NCT06640543|OTHER|Kinesiotape|Postnatal women with low back pain will be treated with kinesiotape, three times per week for 4 weeks
41456030|NCT00398073|BIOLOGICAL|mouse gp100 plasmid DNA vaccine|
41456031|NCT00398073|DEVICE|The Dermal PowderMed® devices|
41456032|NCT00398073|OTHER|intramuscularly (IM injection)|
40764106|NCT06640543|OTHER|Myofascial release|Postnatal women with low back pain will be treated with myofascial release for 25 minutes three times per week for 4 weeks
40764107|NCT06308211|OTHER|MOTOR IMAGERY+MIRROR THERAPY+ROUTINE PHYSICAL THERAPY|Subjects will be instructed to watch the video provided and recorded by investigator.In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.Participants will be than instructed to carry out the task in verbal commands given whenever necessary.The unaffected limb will be placed in front of the mirror so that the reflected illusion of the limb would be hallucinated to represent the affected limb and routine physical therapy includes passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions).
40959300|NCT02586129|DRUG|Metformin|1500mg, QD
40959301|NCT02586129|DRUG|Rosuvastatin|20mg, QD
40959302|NCT00003165|DRUG|doxorubicin-HPMA conjugate|
40959303|NCT05431192|BEHAVIORAL|Mindfulness Training + Enhanced Usual Care|"Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks. MT involves training in the following (1) Awareness of breath; (2) Body scan; (3) Directing attention to simple activities of daily life; (4) Becoming aware of own thoughts and emotions; (5) Open awareness - a technique by which the participant is invited to direct his/her attention to any event arising in their field of experience at a given moment.~In addition, participants will practice mindfulness techniques for 20 minutes daily on their own with the guidance of a digitally recorded, standardized guided mindfulness practice."
40990584|NCT03541265|PROCEDURE|Adductor block protocol|Adductor block using Exparel
41456033|NCT04909970|OTHER|Self-hypnosis|Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
40990585|NCT03541265|PROCEDURE|peri-articular injection protocol|peri-articular injection using Exparel
40990586|NCT02548247|DIETARY_SUPPLEMENT|Orafti® Inulin|Dietary fiber
41293202|NCT01765647|OTHER|AGY|AGY is a natural health product produced in egg yolks
40959304|NCT05431192|OTHER|Enhanced Usual Care|"Usual care will be enhanced in BOTH conditions with printed education materials provided to all participants using publicly available materials (the Healthier Living with Heart Failure guide available at the AHA Heart Failure Resource Center).66 The guide is organized in 7 chapters containing information on topics such as understanding HF, making healthy lifestyle changes, managing HF symptoms, taking medications, and living well with HF. Printed materials will be mailed weekly to all participants during the first 8 weeks of the study."
40959305|NCT03726411|PROCEDURE|non-surgical periodontal therapy|scaling and root planing
40959306|NCT00544830|DRUG|Bicalutamide|Given PO
40959307|NCT00544830|DRUG|Goserelin Acetate|Given SC
40959308|NCT00544830|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41293203|NCT04100070|BEHAVIORAL|Monitoring of the patients|"Follow-up of the patients during the 12 months study periods including :~* visits with the diabetologist/pediatrician~* contacts with the service provider (nurses' visits) (more in intensive group)~* personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)"
41293204|NCT03090191|BIOLOGICAL|Clostridium difficile vaccine|Toxoid-based Clostridium difficile vaccine
41293205|NCT03090191|BIOLOGICAL|Placebo|Normal saline solution (0.9% sodium chloride)
41293206|NCT05694078|OTHER|Hand Therapy Splinting Protocol|Relative motion splinting protocol
41293207|NCT02088944|DRUG|Infliximab|
40959309|NCT00544830|OTHER|Laboratory Biomarker Analysis|Correlative studies
40764108|NCT06308211|OTHER|MOTOR RELEARNING PROGRAM+ROUTINE PHYSICAL THERAPY|"Motor relearning consists of five components including analysis of task, practice of missing components, practice of task and transference of training. Patient will be asked to practice task in both sitting and standing~* supine to side-lying to sitting~* looking up at ceiling (ensure that centre of body mass does not move back when head is tilted back)~* without moving one's feet, turning to gaze over each other's shoulders and scanning the surroundings for specific items, reaching motions in multiple directions while moving the head and trunk, scooting in bed, altering the base of support (standing with your feet together, in tandem, with one foot on a step, or on one leg)~* squatting to pick up an object and cross over stepping and routine physical therapy includes Passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions)."
40959310|NCT00544830|DRUG|Leuprolide Acetate|Given via injection
40959311|NCT03478657|DRUG|Placebo DPI|Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.
41456034|NCT04909970|OTHER|Control (Waiting list)|Usual practice during the first 16 weeks. At the end of study, the participant will practice Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
40764109|NCT06049797|DRUG|Fezolinetant|Oral
40764110|NCT06049797|DRUG|Paroxetine|Oral
40959312|NCT03478657|DEVICE|ELLIPTA DPI|Subjects will receive placebo DPI via ELLIPTA. ELLIPTA is trademark of GSK
40959313|NCT03478657|OTHER|Ease of use questionnaires|Subjects from both stratum after use of ELLIPTA DPI will be randomized to receive either version A or B of the questionnaires. Subjects will be asked questions on ease of use of ELLIPTA. Parent/guardian will also complete a questionnaire about the ELLIPTA DPI.
40959314|NCT03340688|PROCEDURE|Cervical cerclage|Cervical cerclage indicated by short cervix ≤15mm
40959315|NCT00003805|DRUG|piperacillin sodium|
40959316|NCT00003805|DRUG|piperacillin-tazobactam|
40959317|NCT00003805|DRUG|tazobactam sodium|
40959318|NCT00003805|DRUG|vancomycin|
40959319|NCT04289675|DRUG|Interferon-Beta|Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.
41456035|NCT06503926|OTHER|SARS-COV-2 vaccination|Vaccination
41456036|NCT05122858|PROCEDURE|EUS guided biliary drainage|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.
40959320|NCT04941560|OTHER|No intervention|No intervention
40959321|NCT02012101|DEVICE|niv plus oxygen therapy|NIV given on Philips Respironics BiPAP Vision apparatus.
40959322|NCT02012101|DEVICE|oxygen therapy|
40959323|NCT06044883|PROCEDURE|Injection of Botulinum neurotoxin (BoNT)|"Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum, an anaerobic ,gram-positive bacterium. Poisoning with BoNT can cause botulism, resulting in generalized paralysis, respiratory failure, and death .There are seven serotypes of BoNT: A, B, C1, D, E, F, and G. BoNT-A is the most commonly used serotype for medical purposes.~Since its first use in 1977 for the treatment of strabismus in children, BoNT-A has since been used in aesthetic medicine and for the treatment of a number of disorders associated with overactive striated muscles, such as strabismus, esotropia, exotropia , focal dystonia, spasticity, and movement disorders.~BoNT-A has also been used in the management of some smooth-muscle disorders, such as achalasia, oesophageal spasm , ptyalism, hyperhidrosis, and intrinsic rhinitis, blepharospasm, muscle spasms and spasticity, axillary hyperhidrosis, and neurogenic detrusor muscle overactivity of the urinary bladder."
40959324|NCT06044883|DIAGNOSTIC_TEST|Penile duplex and shear wave elastosonography (SWE).|Penile duplex study using intracavernosal injection of prostaglandin E1 (PGE1) before and after Botox injection (in the follow-up visit in the 6th week after Botox injection). Penile cavernosal arteries diameters and colored waves will be assessed. Shear wave elastosonography will be conducted comparing the stiffness of penile tissues before and after Botox injection
40959325|NCT00868608|DRUG|Inotuzumab Ozogamicin (CMC-544)|Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
40959326|NCT02528396|DRUG|BioChaperone insulin lispro|Injection at t0,or t+15 minutes or t-15minutes with test meal
40959327|NCT02528396|DRUG|Humalog®|Injection at t0,or t+15 minutes or t-15minutes with test meal
40959328|NCT01909674|DEVICE|Switch CPAP mask type|
40959329|NCT01317654|OTHER|Observation|Collection of mortality data at 5 years post trial
40959330|NCT01926015|BIOLOGICAL|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
40959331|NCT01926015|BIOLOGICAL|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
40959332|NCT03566160|DEVICE|Cryobiopsy probe, administered to study participants|Cryobiopsy probe as a tool for gastrointestinal biopsy
40959333|NCT03345914|DRUG|Dupilumab|"Pharmaceutical form: Solution for injection in pre-filled syringe;~Route of administration: Subcutaneous (SC)"
40959334|NCT03345914|DRUG|Matching Placebo|"Pharmaceutical form: Solution for injection;~Route of administration: Subcutaneous (SC)"
40764111|NCT06049797|DRUG|Citalopram|Oral
40764112|NCT06049797|DRUG|Escitalopram|Oral
40764113|NCT06049797|DRUG|Desvenlafaxine|Oral
40990587|NCT02548247|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
40990588|NCT02686879|DEVICE|Multifocal contact lenses|
40990589|NCT02686879|DEVICE|Single vision contact lenses|
40764114|NCT06049797|DRUG|Venlafaxine|Oral
40959335|NCT03345914|OTHER|Background Treatment: Topical Corticosteroids|All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.
41456037|NCT05122858|PROCEDURE|ERCP|A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.
40764115|NCT06049797|DRUG|Gabapentin|Oral
40764116|NCT06049797|DRUG|Clonidine|Oral
40764117|NCT06049797|DRUG|Pregabalin|Oral
40764118|NCT06049797|DRUG|Oxybutynin|Oral
40764119|NCT06049797|DRUG|Any other SSRI/SNRI not already specified|Oral
40764120|NCT06049797|DRUG|Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above|Oral
40764121|NCT06638164|OTHER|Control|No attempt was made to increase knowledge, skills and satisfaction. Standard procedure (oral explanation) was applied.
40764122|NCT06638164|OTHER|Virtual reality glasses|In order to increase knowledge, skills and satisfaction, isolation training was given with virtual reality glasses.
40764123|NCT06240728|DRUG|NPX887|NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years
40959336|NCT03345914|OTHER|Background Treatment: Moisturizers|All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.
40959337|NCT00345839|DRUG|Cinacalcet|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
40959338|NCT00345839|DRUG|Placebo|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
40990590|NCT02935608|DRUG|BIIB074|Administered as specified in the treatment arm
40764124|NCT06642181|DRUG|Guanfacine pharmacotherapy|It is a pharmacotherapy
40764125|NCT06642181|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement (MORE)|It is a mindfulness intervention
40764126|NCT05584137|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
40764127|NCT05584137|DRUG|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
40764128|NCT06642870|OTHER|Non-interventional study|The study will consist of focus groups and a large scale patient survey
40764129|NCT06636799|DEVICE|Microneedling only|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left.
40764130|NCT06636799|OTHER|Microneedling and actives|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left. Group G3 received microneedling associated with active ingredients. This manipulated active ingredient was composed of growth factors (EGF Factor, TGFß3 Factor, and IDP-2 Peptide), Hydroxyprolisilane, and hyaluronic acid.
40764131|NCT06641375|DEVICE|Anti reflux endoscopic theraphy|"o the intervention arm, the area of cardia, along greater curvature will be cleaned first followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC using the H-APC catheter for marking and to prevent excess ablation . After this, the area of cardia, on either side will be injected in sequence using a combination of methylene blue and normal saline using the H-APC catheter jet system using between Effect 30 and Effect 70 on the ErbeJet 2 to raise the mucosa and create a submucosal cushion . Once adequate submucosal cushion is created, the mucosa starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W using the H-APC catheter till golden-brown discoloration of the ablated tissue20~The area of cardia below the Z-line will be treated in a 270-320-degree fashion. Once adequate ablation is achieved and no deeper tissue injury or bleeding is ensured, the procedure will be terminated."
40990591|NCT02935608|DRUG|Placebo|Matched placebo
40959339|NCT04315883|BEHAVIORAL|Quality of Life Assessment|"Evaluation of change of HRQOL survey responses will be performed:~* at baseline (time of treatment) and~* 1 month post treatment~* 6 months post treatment~* 12 months post treatment~* 5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
41456038|NCT04981457|DRUG|Misoprostol and iso sorbide mononitrates|drug
40764132|NCT06641375|OTHER|Endoscopy|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
40764133|NCT03758612|DRUG|TBI-223 50mg|TBI-223 50 mg supplied for oral administration.
40764134|NCT03758612|DRUG|Placebo for TBI-223 50mg|Matching placebo for TBI-223 50mg supplied for oral administration.
40764135|NCT03758612|DRUG|TBI-223 100, 300, 600, 1200, 2000, 2600 mg|TBI-223 100, 300, 600, 1200, 2000, 2600 mg supplied for oral administration.
40764136|NCT03758612|DRUG|Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg|Matching placebo for 100, 300, 600, 1200, 2000, 2600 mg TBI-223 supplied for oral administration.
40764137|NCT03758612|DRUG|TBI-223 300 mg capsule|TBI-223 300 mg capsule supplied for oral administration
40764138|NCT03758612|DRUG|Placebo for TBI-223 300 mg capsule|Placebo for TBI-223 300 mg capsule supplied for oral administration
40764139|NCT03758612|DRUG|TBI-223 Prototype 1 SR Tablet|Prototype 1 TBI-223 600 mg sustained-release (SR) tablet
40764140|NCT03758612|DRUG|TBI-223 Prototype 2 SR Tablet|Prototype 2 TBI-223 600 mg SR tablet
40959340|NCT04315883|RADIATION|Transarterial Radioembolization|"Deliver catheter directed yttrium-90 directly to liver tumors and assess -Progression Free Survival - Local and Metastatic~* Local Tumor Response by calculating the decreases in tumor size and enhancement after treatment. This will be assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST).~* Resection Rate following treatment~* Transplant Rate following treatment~* Histologic Response by assessing tumor histopathology in patients who undergo tumor resection or liver transplant~* Biologic Response by monitoring serum tumor markers (e.g. alphafetoprotein-AFP) in AFP secreting tumors~* Review of clinical course post-treatment-rehospitalization rate"
40959341|NCT00223262|DRUG|Lamotrigine (Drug)|
40959342|NCT05344170|DRUG|30 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.
40959343|NCT05344170|DRUG|300 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.
41136029|NCT02324790|DEVICE|iNAP® Sleep Therapy System|The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
41136030|NCT01097811|DRUG|Erythromycin|250 mg orally q.i.d.
41136031|NCT01097811|DRUG|Neomycin|1 g orally q.i.d.
41136032|NCT03031509|BIOLOGICAL|Human Amniotic Epithelial Cells|Human Amniotic Epithelial Cells transplant after debridement
41136033|NCT03031509|PROCEDURE|debridement|debridement
41456039|NCT04863131|BIOLOGICAL|EXG-5003|COVID-19 self-replicating mRNA vaccine
41456040|NCT04863131|BIOLOGICAL|Placebo|placebo solution
40764141|NCT03758612|DRUG|TBI-223 Prototype 3 SR Tablet|Prototype 3 TBI-223 900 mg SR tablet
40764142|NCT03758612|DRUG|TBI-223 IR Tablet|TBI-223 1000 mg immediate release (IR) tablet
40764143|NCT03924284|DIAGNOSTIC_TEST|PB2 gene RT-PCR; NS gene RT-PCR|PB2 gene RT-PCR: RT-PCR targeting the PB2 gene of influenza A virus NS gene RT-PCR: RT-PCR targeting NS gene of influenza A virus
40764144|NCT05299671|BEHAVIORAL|Video consultation|During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.
41293208|NCT03835208|BEHAVIORAL|High/low carbohydrate distribution|A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.
41293209|NCT02742389|OTHER|Preprocedure Telephone Call|The participants will receive a phone call from the investigators 1 week before their testing to talk about the procedure and answer any questions that patients may have . The investigator calling the participant will document the duration of the phone call and any questions asked by the participant
41293210|NCT02471131|DEVICE|WATCHMAN Device implantation|The implantation of the device will be done into the left atrial appendage according to the guidelines.
41293211|NCT05477238|PROCEDURE|walking tasks|The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.
41293212|NCT01418222|DRUG|5-FU|Intravenous repeating dose
41293213|NCT01418222|DRUG|FOLFOX regimen|Intravenous repeating dose
41293214|NCT01418222|DRUG|Placebo|Intravenous repeating dose
40764145|NCT03633201|DEVICE|Cruciate Retaining|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.
40764146|NCT03633201|DEVICE|Medial Congruent|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
40764147|NCT04759404|OTHER|Deep Oscillation Treatment|Deep oscillation to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
40764148|NCT04759404|OTHER|Myofascial Release Treatment|Myofascial release to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
40764149|NCT03708510|DEVICE|Restorative materials- Filtek Silorane|Filtek Silorane
41293215|NCT01418222|DRUG|bevacizumab [Avastin]|Intravenous repeating dose
41293216|NCT01418222|DRUG|leucovorin|Intravenous repeating dose
40764150|NCT03708510|DEVICE|Restorative materials-Kalore|Kalore
40764151|NCT03708510|DEVICE|Preparation-Er,Cr:YSGG Laser|Er,Cr:YSGG Laser
40764152|NCT03708510|DEVICE|Preparation- Diamond Bur|Bur
41293217|NCT01418222|DRUG|onartuzumab [MetMAb]|Intravenous repeating dose
41293218|NCT01276015|DRUG|Botulinum Toxin Type A|BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
41293219|NCT03531268|OTHER|PGx Testing|Pharmacogenomic (PGx) testing will be administered to all subjects. The results of PGx testing will be evaluated for clinical utility. Subjects will be evaluated based on whether PGx testing has clinical utility or has no clinical utility.
41293220|NCT02629497|DIETARY_SUPPLEMENT|Primrose oil|T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
41293221|NCT02629497|DIETARY_SUPPLEMENT|Fish Oil|T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
41293222|NCT00577330|DIETARY_SUPPLEMENT|Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)|Twice daily
40764153|NCT03004183|BIOLOGICAL|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
41293223|NCT04016363|OTHER|ProbeFix|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
41293224|NCT04016363|OTHER|Manual hold|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
40764154|NCT03004183|DRUG|Valacyclovir|Prodrug of the antiviral drug acyclovir
40764155|NCT03004183|RADIATION|SBRT|Low-dose SBRT
40764156|NCT03004183|DRUG|Pembrolizumab|Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
40764157|NCT06638736|OTHER|Wound Closure with sutures vs staples|Closure of the wound with either sutures or staples depending upon the study arm
40764158|NCT04452877|DRUG|Dabrafenib|Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.
40764159|NCT04452877|DRUG|Trametinib|Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
40764160|NCT05855746|DRUG|Colchicine Pill|"Participant receive, in addition to standard of care therapy, six months of colchicine (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization. The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.~During the six months of the treatment administration, in case of severe adverse reaction (such as nausea and/or diarrhea during five days), a dose reduction could be considered by the investigator: half of the study protocol dose could be accepted (0.5 mg per day in the morning). In case of remaining adverse reactions, the study drug should be stopped."
41136034|NCT02590198|OTHER|ANAES algorithm|care as recommended by ANAES, with ANAES algorithm
40764161|NCT05855746|DRUG|Placebo|"Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision."
40764162|NCT06540014|OTHER|No intervention|No intervention is made, groups are formed just due to the races.
40764163|NCT06637865|DRUG|IMP761|Experimental
40764164|NCT06637865|DRUG|Placebo|Placebo
40959344|NCT05344170|DRUG|Placebo|Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
40959345|NCT00001535|DRUG|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
40959346|NCT05947825|DRUG|Combination of sitagliptin+ gemcitabine + nab-paclitaxel|"Drug1: Sitagliptin will be administered orally once a day at a dose of 100 mg depending on cohort assignment.~Drug2: Gemcitabine will be intravenously administered on Days 1 and 8 of every 21-day cycle at a dose of 1000 mg/m2 depending on cohort assignment.~Drug3: Nab-Paclitaxel will be intravenously administered on Days 1 and 8 of every 28-day cycle at a dose of 125 mg/m2 depending on cohort assignment."
41136035|NCT02590198|OTHER|PCT algorithm|care based on PCT algorithm
41136036|NCT04880837|OTHER|Educational Intervention|Attend educational session
41136037|NCT04880837|OTHER|Informational Intervention|Receive handouts
41136038|NCT04880837|OTHER|Survey Administration|Complete surveys
41136039|NCT03062072|DRUG|Chemotherapy|Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
41136040|NCT02093169|DRUG|Part A: Lu AF35700|One 30 mg single dose for one day; orally
41136041|NCT02093169|DRUG|Part B: Lu AF35700|Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
40764165|NCT06632860|DRUG|68Ga-TATE-RGD|Intravenous injection of 68Ga-TATE-RGD with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses will be used to image lesions of by dual-targeted postive cancers PET/CT.
40764166|NCT06632860|DRUG|18-FDG|Intravenous injection of 18F-FDG with the dosage of 1.8-2.2 MBq(0.12-0.15mCi/kg). Tracer doses will be used to lesions therapy of dual-targeted postive cancers by SPECT/CT.
40959347|NCT01218243|DEVICE|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
40764167|NCT03707340|DRUG|Flibanserin Pill|Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.
40764168|NCT00347971|DRUG|recombinant human interleukin 21 and rituximab|rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
40959348|NCT01918436|BEHAVIORAL|TEAMS intervention|In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
40959349|NCT01918436|OTHER|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
40764169|NCT06639477|OTHER|Treatment As Usual|In this trial, all participants will have depression symptoms and will be receiving TAU from their own doctors.
40764170|NCT06639477|BEHAVIORAL|Active Condition|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
40764171|NCT06639477|BEHAVIORAL|Active Comparator|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
40764172|NCT06638749|DRUG|Tranexamic Acid|Administration of tranexamic acid
40959350|NCT05890885|PROCEDURE|Real left prefrontal tDCS - sham|Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
40959351|NCT05890885|PROCEDURE|Sham - Real left prefrontal tDCS|Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
40959352|NCT01699906|OTHER|Diet regimen to induce weight loss|Diet regimen to induce weight loss
40959353|NCT05094583|BEHAVIORAL|Use of SmokeFree app|Intervention Arm
40959354|NCT03167905|DEVICE|Epidural delivery system|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
40959355|NCT03167905|DRUG|Entonox|Entonox will be given upon request in non-epidural group.
40959356|NCT03167905|DRUG|Meperidine|Intramuscular pethidine (75mg/1.5ml) will be given upon request in non-epidural group.
40959357|NCT03167905|DRUG|Ultiva|Intravenous patient controlled remifentanil (20-40mcg/ml) is only given when the patient rejects or cannot receive pethidine and entonox in non-epidural group..
40959358|NCT03167905|DRUG|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
40959359|NCT03167905|DRUG|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
40959360|NCT06297577|PROCEDURE|Albumin Platelet Rich Fibrin (Alb-PRF) combined with minimally invasive surgical technique (MIST)|Albumin-PRF will be placed into intrabony defect
40959361|NCT06297577|PROCEDURE|Minimally invasive surgical technique (MIST)|MIST will be the surgical access for treatment of Intrabony defect
40764173|NCT06638749|DRUG|Normal Saline|Administration of normal saline
40764174|NCT06640959|PROCEDURE|Procedure - blood, urine and stool sample collection|Samples will be collected (blood, urine, stool and optional rectal swab) at baseline (prior to the start of radiotherapy), weekly during radiotherapy for 4 weeks, 6-8 weeks and 12 weeks from start of radiotherapy, and at 6-month and 12-month follow-up appointments
40764175|NCT06317662|DRUG|Asparaginase Erwinia chrysanthemi|Given recombinant crisantaspase IM or crisantaspase IM or IV
40764176|NCT06317662|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40764177|NCT06317662|BIOLOGICAL|Blinatumomab|Given IV
40764178|NCT06317662|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40764179|NCT06317662|DRUG|Calaspargase Pegol|Given IV
40764180|NCT06317662|PROCEDURE|Computed Tomography|Undergo CT
40764181|NCT06317662|DRUG|Cyclophosphamide|Given IV
40764182|NCT06317662|DRUG|Cytarabine|Given IT or IV
40764183|NCT06317662|DRUG|Daunorubicin|Given IV
40764184|NCT06317662|DRUG|Dexamethasone|Given PO or NG or IV
40764185|NCT06317662|DRUG|Doxorubicin|Given IV
40959362|NCT02903355|DRUG|D-methionine|D-methionine, oral liquid suspension
40959363|NCT02903355|DRUG|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
40959364|NCT01450995|DRUG|Treximet|Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
40959365|NCT01450995|DRUG|Imitrex and two Aleve|Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
40959366|NCT04957004|DEVICE|CPAP|CPAP ventilator was worn at nigh
40959367|NCT01968759|DRUG|Sevelamer|
40959368|NCT01968759|DRUG|Ramipril and Irbesartan|
40959369|NCT01675791|BIOLOGICAL|ALK tree AIT 0.5 DU|
40959370|NCT01675791|BIOLOGICAL|ALK tree AIT 1 DU|
40959371|NCT01675791|BIOLOGICAL|ALK tree AIT 2 DU|
40959372|NCT01675791|BIOLOGICAL|ALK tree AIT 4 DU|
40959373|NCT01675791|BIOLOGICAL|ALK tree AIT 7 DU|
40959374|NCT01675791|BIOLOGICAL|ALK tree AIT 12 DU|
41293225|NCT06279585|OTHER|Physical therapy|Health education sessions and combined therapeutic exercise sessions, based on muscular strength training and cardiorespiratory endurance.
41293226|NCT05496803|OTHER|routine education plus digital video disk|Parents receiving routine education plus digital video disk before their children receiving congenital heart disease catheterization. The DVD content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
41293227|NCT05496803|OTHER|routine education|Parents receiving routine education before their children receiving congenital heart disease catheterization
41293228|NCT03851679|DIAGNOSTIC_TEST|B-Type natriuretic peptide (BNP) serum values|"evaluation BNP serum values:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)"
41293229|NCT03851679|DEVICE|Pulmonary echography|"Pulmonary echography:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)"
41293230|NCT03851679|OTHER|urine collection|6 hour and 24 hour urine collection after Cesarean Section
41293231|NCT04471740|PROCEDURE|CSF shunt diversion|Clinical response to a CSF shunt insertion
41293232|NCT00004429|DRUG|growth hormone|
41293233|NCT06427681|DRUG|BH006 for injection|According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
41293234|NCT06427681|DRUG|Fosaprepitant for injection+Palonosetron hydrochloride injection|According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
40764186|NCT06317662|PROCEDURE|Echocardiography|Undergo ECHO
40959375|NCT01675791|BIOLOGICAL|ALK tree AIT Placebo|
41293235|NCT05790304|DRUG|Camizestrant|Camizestrant 75 mg tablets. Experimental drug.
41293236|NCT02242149|DRUG|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
41293237|NCT02242149|DRUG|Placebo|Sugar pill manufactured to mimic Diacerein
41293238|NCT03126227|BIOLOGICAL|AR101|AR101 powder provided in capsules
41293239|NCT03126227|BIOLOGICAL|Placebo|Placebo powder provided in capsules
41293240|NCT03663985|OTHER|Groupe FALCOn|The objective of the study is to determine what are the anthropo-sociological factors in the surgeon, the oncologists and radiotherapists influencing decision making in ENT carcinology.
40764187|NCT06317662|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
40959376|NCT01201850|DRUG|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
40959377|NCT03963596|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
40959378|NCT05456269|DRUG|Bisantrene Dihydrochloride (high dose)|Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2
40959379|NCT05456269|DRUG|Bisantrene Dihydrochloride (low dose)|IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached.
40959380|NCT05456269|DRUG|Cytarabine Hydrochloride|Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5
41136042|NCT05893615|BEHAVIORAL|Cognitive Behaviour Therapy|The CBT module was adjusted as follows: (1) Health education about paroxysmal atrial fibrillation; (2) Self-awareness training; (3) Exposure training; (4) Habitual reversal training；(5) Correcting cognitive distortion; (6) Behavioral activation (7) Specific training for anxiety; (8) Practice and feedback; (9) Relapse prevention; (10) Review.
40764188|NCT06317662|DRUG|Leucovorin|Given PO or NG or IV
40764189|NCT06317662|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
40764190|NCT06317662|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40959381|NCT05456269|DRUG|Decitabine and cedazuridine|PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
40959382|NCT01742702|DRUG|Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).
40959383|NCT01742702|DRUG|Salbutamol 400 µg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
40959384|NCT01742702|DRUG|L-arginine (10 min infusion, no longer given since January 2017)|From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).
40959385|NCT01742702|DIETARY_SUPPLEMENT|Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)|Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).
40959386|NCT01742702|DIETARY_SUPPLEMENT|Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)|Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed 2011).
40959387|NCT01742702|DRUG|Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)|Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed 2011).
40959388|NCT01896050|DRUG|anastrozole, letrozole, exemestane|Patients were treated with one of the listed anti-hormonal medications for up to one year
40959389|NCT01896050|DRUG|Tamoxifen|Patients were treated with tamoxifen for up to one year
40959390|NCT04853550|DEVICE|Strattice Mesh|Subjects will be restrospectively identified has having undergone ventral hernia repair with Strattice mesh reinforcement. Once identified long term follow-up data will be collected.
40959391|NCT02200432|OTHER|PERSPeCT Recommender System|"PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.~Patient Experience Recommender System for Persuasive Communication Tailoring. PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient."
40959392|NCT01546805|DRUG|Zinc Supplement|The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
40959393|NCT01546805|DRUG|Sugar pill|The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
40959394|NCT02867085|OTHER|Observational|The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
40959395|NCT02543437|DEVICE|Trident Acetabular X3 Insert|
40959396|NCT05195671|OTHER|Review|Reviewing all protocols
40959397|NCT03447704|DRUG|BCD-085|120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
40959398|NCT03447704|OTHER|placebo|2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
40959399|NCT02099708|DRUG|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
40959400|NCT04365296|OTHER|Experimental|The purpose of the study is to evaluate which is more effective aerobic or resistance exercises in reducing plasma liver enzymes level (AST and ALT) post burn. Subjects and Methods: Sixty burned patients with burned body surface area about 30% to 50% will participate in this study. Their ages will be ranged from 20-45 years. They will be selected from Orabi Hospital and will be divided randomly into two equal groups.
40959401|NCT00967603|DRUG|sunitinib|oral sunitinib 37.5 mg daily
40959402|NCT02091960|DRUG|Enzalutamide|Capsules for oral administration
40959403|NCT02091960|DRUG|Trastuzumab|Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country
40959404|NCT06389591|BIOLOGICAL|pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)|pp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously
40959405|NCT06389591|BIOLOGICAL|RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)|personalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously
40959406|NCT03717818|BEHAVIORAL|Good Psychiatric Management - Brief|specific interventions as defined by Gunderson and Links (2014)
40959407|NCT03717818|BEHAVIORAL|treatment as usual|non-specific intervention
40959408|NCT05085873|DRUG|Sodium Oxybate injection|"* Induction dosage : 60 mg/kg by direct intravenous injection.~* Continuous dosage : 45 mg/kg/h by continuous intravenous injection.~* Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.~Sedation maintained until patient death."
40959409|NCT05085873|DRUG|Midazolam injection|"* Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).~* Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.~* Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).~Sedation maintained until patient death."
40959410|NCT00004779|GENETIC|Ad5-CB-CFTR|
40959411|NCT02543710|PROCEDURE|Biomarker (ER/PR) guided lymphadenectomy|"Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with \<50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with \<50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 \<50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up."
40990592|NCT04645407|DRUG|Fuzheng Huayu tablet|Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
40990593|NCT00870896|DRUG|Tiotropium|Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
41136043|NCT04872296|DEVICE|Controlled Ankle Motion (CAM) boot|A CAM boot will be worn on the affected ankle to allow weight bearing
41456041|NCT04327336|DEVICE|Manual Non invasive ventilation titration|Manual Group: during a complete polysomnography, adding transcutaneous capnography and the basic ventilators curves, the ventilators setting will be adjusted in order to correct respiratory events and patient-ventilator asyncrony. A 10 hours face-to-face investigator training meeting is programmed before opening the inclusion period.
40764191|NCT06317662|DRUG|Mercaptopurine|Given PO or NG
40764192|NCT06317662|DRUG|Methotrexate|Given IT or IV or PO or NG
40764193|NCT06317662|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40764194|NCT06317662|DRUG|Pegaspargase|Given IV or IM
40764195|NCT06317662|DRUG|Prednisolone|Given PO or NG
40764196|NCT06317662|DRUG|Prednisone|Given PO or NG
40764197|NCT06317662|DRUG|Therapeutic Hydrocortisone|Given IT
40764198|NCT06317662|DRUG|Thioguanine|Given PO or NG
40764199|NCT06317662|DRUG|Venetoclax|Given PO or NG
41456042|NCT04327336|DEVICE|Automatic Non invasive ventilation titration|Automatic Group: the A40 ventilator in the automatic AVAPS mode will be adjusted in order to achieve 8-10 ml/kg of ideal weight.
40764200|NCT06317662|DRUG|Vincristine|Given IV
40764201|NCT06637826|BEHAVIORAL|Quaternary Ammonium Compound Disinfectants|"Participants are instructed to use quaternary ammonium compound disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation."
40990594|NCT02408939|DRUG|Stress-dose hydrocortisone|Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
40990595|NCT06046456|OTHER|Prenatal Affective CogntiiveTraining|A psychological intervention using computer- and virtual reality based exercises to modify negative cognitive bias and improve emotion regulation
40990596|NCT00629499|DRUG|nab paclitaxel|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
41293241|NCT01413178|DRUG|Busulfan|Test dose (32 mg/m\^2) on day -9 then 130 mg/m\^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
41456043|NCT02898740|BEHAVIORAL|Structural exercise|Exercise instruction and encouragement
41456044|NCT02898740|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
40764202|NCT06637826|BEHAVIORAL|Alcohol-based Disinfectants|"Participants are instructed to use alcohol-based disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation."
40959412|NCT02543710|DRUG|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|"A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression."
40959413|NCT05195580|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
40959414|NCT00327275|BEHAVIORAL|strength training|
40959415|NCT02571777|DRUG|QVM149 150/50/160|
40959416|NCT02571777|DRUG|QVM149 150/50/80|
40959417|NCT02571777|DRUG|QMF149 150/320|
40959418|NCT02571777|DRUG|QMF149 150/160|
40959419|NCT02571777|DRUG|salmeterol/fluticasone|
40959420|NCT02570074|DRUG|Fosfomycin|Broad spectrum antibiotic
40959421|NCT02966431|BEHAVIORAL|Counseling|
40959422|NCT02966431|BEHAVIORAL|No Counseling|
40959423|NCT03445715|GENETIC|ART-I02|Single Intra-articular injection in the wrist joint
40959424|NCT05315544|DEVICE|CSI pVAD system|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
40959425|NCT05612711|DRUG|Dronabinol|All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.
40959426|NCT03949530|DRUG|IDL-2965 Oral Capsule|Investigational drug
41293242|NCT01413178|DRUG|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
40764203|NCT05657171|DRUG|cyproterone Acetate/Ethinyl Estradiol Combination|cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
41136044|NCT04872296|PROCEDURE|Physical Therapy|Standard physical therapy protocol will be started at 6 weeks after surgery
40764206|NCT05603143|DRUG|Obeldesivir|Tablets administered orally without regard to food.
40959427|NCT03949530|DRUG|Placebos|Placebo
40959428|NCT04863040|BEHAVIORAL|MOVI intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 10 at high intensity (85-90% of HR max) followed by 20 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities. To increase the workload, and after evaluation of cardiorespiratory capacity, after 12 weeks of program, the HIIT protocol will be changed to 20 of high intensity work alternating with 10 of recovery."
40959429|NCT04562688|OTHER|CICADAS and then PEERS|Participants will complete sensory processing assessments and neuroplasticity-based social cognitive training (NB-SCT) exercises on a digital device for a total of 40 hours. The CICADAS app captures user-specific sensory processing abnormalities (SPA) through 10 brief computerized assessments. The data from these assessments guide and personalize the delivery of 10 NB-SCT exercises. After 16 weeks, participants will then crossover to PEERS, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians.
40959430|NCT04562688|OTHER|PEERS + CICADAS and then no-contact|Participants will complete both PEERS and CICADAS study activities. Participants will complete sensory processing assessments and neuroplasticity-based social cognitive training (NB-SCT) exercises on a digital device for a total of 40 hours. The CICADAS app captures user-specific sensory processing abnormalities (SPA) through 10 brief computerized assessments. The data from these assessments guide and personalize the delivery of 10 NB-SCT exercises. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
40959431|NCT04562688|OTHER|PEERS + Active Comparator and then no-contact|Participants will complete both PEERS and Active Comparator study activities. Participants will engage in computerized, casual video games for a total of 40 hours. Participants will also complete the 10 sensory processing abnormalities (SPA) computerized assessments. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
40959432|NCT00917566|DEVICE|Airtraq|intubation with airtraq
40959433|NCT00917566|DEVICE|Macintoch|use Macintoch laryngoscope for intubation
40959434|NCT02021578|BEHAVIORAL|Family Cognitive Behavioral Prevention|Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
40959435|NCT02021578|BEHAVIORAL|Written information|Reading materials about depression
40959436|NCT04925583|RADIATION|Stereotactic body radiotherapy (SBRT)|"* level 0 (de-escalation): 10 x 5.0Gy~* level 1 (start): 10 x 5.5Gy~* level 2: 10 x 6.0Gy~* level 3: 10 x 6.5Gy"
40959437|NCT05806450|BEHAVIORAL|Intervention|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
40959438|NCT05806450|OTHER|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
40959439|NCT04253444|BEHAVIORAL|slow deep breathing|Participants in this arm will be asked to do slow deep breathing (4 seconds inhalation and 6 seconds exhalation) for 10 minutes twice a day during the study period.
40959440|NCT04253444|BEHAVIORAL|sham breathing|Participants in this arm will be asked to do sham breathing for 10 minutes twice a day during the study period.
40959441|NCT05116475|DRUG|Darolutamide 300 mg|Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
40959442|NCT05116475|DRUG|Placebo of Darolutamide|Placebo of Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
40959443|NCT05496400|RADIATION|Echocardiographic and Doppler studies|"Echographic and Doppler studies will be performed using machine: model GE Vivid iq premium,WUXI,China and we will measure:~1. Cardiac output:~2. Cerebral, intestinal and renal blood flow velocities:"
40959444|NCT04218630|OTHER|Reformer pilates exercises|The program consisted of 10 minutes warm-up exercises, reformer pilates exercises for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week and applied to be 12-15 repetitions in the last week. Increasing the resistance of the springs and adding different positions were used for progression of exercises.
40959445|NCT04218630|OTHER|Home mat pilates exercises|The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week, and applied to be 12-15 repetitions in the last week.
40959446|NCT02450591|DRUG|Erlotinib|
40959447|NCT02450591|OTHER|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
40959448|NCT04490343|DIAGNOSTIC_TEST|Abdominopelvic low dose CT|Patients with urinary stones will undergo multiple computed tomography (CT) examinations
40959449|NCT01477593|PROCEDURE|circumcision with Shenghuan in Yan's method|The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
40959450|NCT01477593|PROCEDURE|circumcision with Shenghuan in Peng's method|The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
40959451|NCT01477593|PROCEDURE|conventional method with incision|The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
40959452|NCT02592356|PROCEDURE|Computed Tomography|Correlative studies
40959453|NCT02592356|PROCEDURE|Dual X-ray Absorptiometry|Correlative studies
40959454|NCT02592356|PROCEDURE|Physical Examination|Correlative studies
40959455|NCT02592356|OTHER|Quality-of-Life Assessment|Ancillary studies
40959456|NCT02592356|OTHER|Questionnaire Administration|Ancillary studies
40959457|NCT02592356|DRUG|Cabozantinib|
40959458|NCT02592356|DRUG|Lenvatinib|
40959459|NCT02925923|DRUG|Ticagrelor|After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, crushed ticagrelor will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
40959460|NCT02925923|DRUG|Eptifibatide|After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
40959461|NCT02925923|DRUG|Clopidogrel|
40959462|NCT03454711|DEVICE|fMRI|Brain MRI
40959463|NCT03454711|DEVICE|Indirect calorimetry|Resting energy expenditure
40959464|NCT03454711|DEVICE|Bioimpedance|Measurement of body composition
40959465|NCT03454711|BIOLOGICAL|Lipid profile, glucose, HBA1c, metabolomic analysis|Blood sample
40959466|NCT03454711|BEHAVIORAL|YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)|Questionnaires to characterize eating habits and depression
41293243|NCT01413178|OTHER|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
41293244|NCT01413178|DRUG|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
41293245|NCT01413178|DRUG|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
40959467|NCT02230800|DRUG|Tocovid SupraBio plus pentoxifylline|
40764207|NCT05603143|DRUG|Obeldesivir Placebo|Placebo tablets administered orally without regard to food.
40764208|NCT01380132|PROCEDURE|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
40959468|NCT02230800|DRUG|Matching placebos|
40959469|NCT03813849|DIAGNOSTIC_TEST|Sonographic examination of uterus after surgical evacuation|
40959470|NCT06557200|BEHAVIORAL|Digital Infant- parents support|A virtual and in-person, personal and group-based intervention will be delivered-educational information on infant behavior and changes in interpersonal dynamics associated with parenting. Modules aimed at understanding and managing infant behavior include information on infant temperament. Personal support will be provided by face-to-face education and WhatsApp messages and videos. Group support will be provided by mothers and their partners or a support person group discussion.
40959471|NCT02914119|DRUG|Rocuronium|
40959472|NCT02914119|DRUG|Succinylcholine|
40959473|NCT02914119|DRUG|Cisatracurium|
40959474|NCT02914119|DRUG|Mivacurium|
40959475|NCT02914119|DEVICE|Objective neuromuscular monitoring (acceleromyography)|
40959476|NCT02914119|DRUG|Sugammadex|
40959477|NCT02914119|DRUG|Neostigmine|
40959478|NCT04138121|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
40959479|NCT06556732|DRUG|Eplereone|Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
40959480|NCT04489433|DRUG|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~* Dabrafenib, 150 mg, twice daily (BID);~* Trametinib, 2.0 mg, once daily (QD)"
40959481|NCT04489433|DRUG|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
40959482|NCT04489433|DRUG|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
40959483|NCT05620771|DRUG|Atezolizumab and Bevacizumab|Patients will receive atezolizumab + Bevacizumab for 21 days after standard of care therapy is complete.
40959484|NCT05620771|DRUG|Y90 + TKI|Patients will receive TKI for 21 days after standard of care therapy is complete.
40959485|NCT02138682|DRUG|l-123 Ioflupane|5 millicuries of Ioflupane
40959486|NCT01827956|OTHER|Blood sample for identifying the polymorphism|Blood sample for identifying the polymorphism
40959487|NCT01652209|BIOLOGICAL|Hearticellgram-AMI|
40959488|NCT06275724|OTHER|inclisiran|Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.
40959489|NCT05846074|DIAGNOSTIC_TEST|sweat samples and used face mask will be collected|Collection of sweat samples and used face mask will take approximately 15 minutes before or after collection for the SARS-Cov PCR test
40959490|NCT03228433|DRUG|TAK-418|TAK-418 Capsule.
40959491|NCT03228433|DRUG|TAK-418 Placebo|TAK-418 placebo-matching capsules.
41293246|NCT01413178|PROCEDURE|Stem cell transplant|Stem cell infusion on Day 0.
41293247|NCT04936672|BEHAVIORAL|Brisk walking and Tai Chi Chuan|This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.
41293248|NCT02260414|DRUG|Tinzaparin|single subcutaneous injection of 4500 IU tinzaparin
40764209|NCT03511287|OTHER|Inspiratory Muscle Training|Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).
40764210|NCT06636669|DRUG|Probiotic|Culturelle probiotic, one capsule daily to start following SOC surgical treatment for PJI during the initial 6 weeks of SOC antibiotic treatment.
40764211|NCT06636669|OTHER|Standard of care|Standard of care (SOC) treatment includes surgery and antimicrobials.
40764212|NCT06637995|DEVICE|Intraoperative Nerve Monitoring|Observational data collection from Locating, Stimulating, and Monitoring target nerves during a surgical procedure (clinician standard of care)
40764213|NCT06300437|PROCEDURE|jaw thrust|children who will receive jaw thrusting during fiberoptic intubation
40764214|NCT06300437|PROCEDURE|control (sub laxed jaw)|children who will not receive jaw thrusting (just sub laxed open mouth)
40764215|NCT05547464|BIOLOGICAL|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
40764216|NCT05547464|BIOLOGICAL|BNT164b1|RNA vaccine for active immunization against tuberculosis administered as intramuscular injection
40764217|NCT05547464|OTHER|Placebo|Placebo
40959492|NCT02702219|BEHAVIORAL|Mobility of the hamstrings muscles|
40959493|NCT01699360|DRUG|Cyclosporine A, Tacrolimus, Sirolimus|
40959494|NCT06506682|BEHAVIORAL|Constraint Induced Movement Therapy|CIMT is an intensive upper limb therapy for children with unilateral (one sided) cerebral palsy where the child wears a constraint (splint or mit) on their dominant hand so that they use the involved (weaker) side to do activities
40990597|NCT00629499|DRUG|Cyclophosphamide|600 mg/m2 of IV cyclophosphamide
41136045|NCT04851782|DEVICE|ivEAD tubing kit|ivEAD tubing designed to reduce infusion pump alarms do to air in infusion line
41293249|NCT02260414|OTHER|Blood sample|blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
40959495|NCT06506682|BEHAVIORAL|CIMT + VR|Participants in the CIMT+VR group of this study protocol will do everything the CIMT group does PLUS will utilize at least 4 of the following VR technologies each day of intervention: FitMi, Tyromotion Pablo® UpperExtremity, Hocoma Armeo® Spring Pediatric, Nintendo Wii, and Parrot Drone.
40959496|NCT06069882|BEHAVIORAL|Cognitive Rehabilitation|"Cognitive Rehabilitation is a person-centred, goal-oriented, problem-solving therapy aimed at managing or reducing functional disability, mitigating excess disability, and maximising engagement and social participation (Clare et al., 2019, p. 710). For this multiple-baseline SCED, there will be a baseline phase where participants will be assessed on goal attainment without an intervention. This phase will be either 3, 4, 5 weeks long and be determined for the participants using an electronic randomiser programme. Thereafter, facilitators will help participants devise personal rehabilitation plans to achieve one of these goals using evidence-based rehabilitative methods. These methods may include the use of environmental adaptations and prompts, introduction of compensatory strategies, procedural learning of skills, and methods for learning or relearning relevant information. The personal rehabilitation plan is put into practice for 6 weeks during the intervention phase of the study."
40959497|NCT02680717|DRUG|Clobetasol|ointment, twice daily (alternating weeks)
40959498|NCT02680717|DRUG|Calcipotriene|ointment, twice daily
40959499|NCT02680717|DRUG|Tacrolimus|ointment, 0.1%, twice daily
40959500|NCT00392860|DEVICE|Natural-Fit|Ergonomic handrim for wheelchairs
40959501|NCT00392860|DEVICE|PalmRim|Ergonomic handrim for wheelchair
40959502|NCT00392860|DEVICE|Handrim Control Group|Participants were given a new standard handrim to test. This intervention group is the control group.
40959503|NCT02817308|OTHER|samples of blood, saliva and urine|Spot samples of Blood, urine and saliva
40959504|NCT03600818|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
40959505|NCT03600818|DRUG|Sarilumab-matching placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
40959506|NCT03600818|DRUG|Prednisone|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
40959507|NCT03600818|DRUG|Prednisone-matching placebo|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
40959508|NCT03600818|DRUG|Prednisone|Pharmaceutical form:tablets Route of administration: oral administration
40959509|NCT04798963|PROCEDURE|On-clamp partial nephrectomy|Partial nephrectomy will performed with renal artery clamping (less than or equal to 25 minutes)
40959510|NCT04798963|PROCEDURE|Off-clamp partial nephrectomy|Partial nephrectomy will performed without renal artery clamping
40959511|NCT00242320|DRUG|Roflumilast|to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
40959512|NCT00242320|DRUG|Placebo|
40959513|NCT00818597|DEVICE|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
40959514|NCT06247514|BEHAVIORAL|The BEET Diabetes Program|The BEET Diabetes program is an adapted CBT program specifically designed to treat disordered eating and improve diabetes self-management. Participants receive support from BHPs to guide them through the program, maintain motivation, and facilitate appropriate goal setting.
40959515|NCT06247514|BEHAVIORAL|Cognitive Behavioral Therapy Guided Self-Help|"6-session cognitive behavioral therapy delivered through the self-help book Overcoming Binge Eating Self-help by Christopher G. Fairburn.~The manual focuses on reducing binge-eating episodes. Guided support sessions can be provided by personnel with no background training or knowledge of CBT or disordered eating behaviors, as the book acts as the expert."
40959516|NCT02147470|DRUG|Definity ultrasound contrast agent|All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
40959517|NCT01684956|PROCEDURE|Intradermal injection|
40959518|NCT01684956|PROCEDURE|Subcutaneous injection|
40959519|NCT04447651|OTHER|Recommendation for treatment with immunotherapy|Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.
40959520|NCT01343420|BIOLOGICAL|Dog Hair Extract, ALK-Abelló, Inc.|ALK-Abelló dog epithelial 1:10w/v glycerin
40959521|NCT04923438|OTHER|Telerehabilitation|The exercise program will begin with a warm-up, followed by a stretching exercise and an alphabetical exercise game called what's your name, and will end with a cool-down. The exercises will be performed 2 times a week for a total of 12 weeks, and each program will last for roughly 30 minutes. it will last. In what is your name game, 10 5-letter words containing the whole alphabet were produced and children will work out the exercises corresponding to each letter with a word they choose for each day.
40959522|NCT04923438|OTHER|Control|The same exercise program will be prepared and given to the patients who are offered and not accepted telerehabilitation, and they will be asked to do their own exercises at home. This group will also be included in the study as a control group.
40959523|NCT00992290|BIOLOGICAL|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
40959524|NCT00992290|BIOLOGICAL|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
40959525|NCT00934492|DRUG|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
40959526|NCT00934492|DRUG|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
40959527|NCT06095583|DRUG|Tifcemalimab injection|200mg once every 3weeks
40959528|NCT06095583|DRUG|toripalimab injection|240mg once every 3 weeks
40959529|NCT06095583|DRUG|Placebo for Tifcemalimab|every 3weeks
40959530|NCT06095583|DRUG|Placebo for toripalimab|every 3weeks
40959531|NCT04993820|BEHAVIORAL|Physical activity|The goal for week one will be to increase moderate-to-vigorous PA (MVPA) by 90 weekly/mins, and by 120 weekly/mins on week two. This amount of time will provide the participant with an adaptation period. The goal for weeks 3-12 will be to increase MVPA by at least 150 weekly/mins. The prescribed aerobic activities can be performed either: 1) outdoors (e.g., walking or cycling), 2) at home (e.g., in-place jogging, dancing, aerobics), or 3) with available exercise equipment if the participant already has this access. Participants will perform a series of 6 to 8 muscle strengthening (MS) exercises for the major muscle groups using elastic bands and their own bodyweight 3 times per week. All MS activities will be depicted in instructional videos available through the app. Participants will be asked to perform 2 sets of 8 to 12 repetitions (reps) per exercise during weeks 1-3, 3 sets of 8 to 12 reps per exercise during weeks 3-7, and 4 sets of 8 to 12 reps per exercise during weeks 8-12.
40959532|NCT04993820|BEHAVIORAL|Education control|Participants in the education CON group will be asked to perform their usual activities and to not engage in additional PA during the intervention. Participants will receive weekly brochures and reading materials including topics related to living with HIV, healthy eating, stress management, and current Federal PA guidelines for Americans. The brochures and reading materials will be available through the BluejayEngage health web-based platform app.
40959533|NCT06326099|BEHAVIORAL|Brief Online Binge Eating and Drinking Intervention|The intervention is an online mobile phone program developed by our research team. It builds upon efficacious brief alcohol interventions with college students by addressing underlying loss of control, impulsivity, and emotion regulation through the use of videos, interactive activities, and psychoeducation.
40959534|NCT03282682|PROCEDURE|Strength training|The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
40959535|NCT05637866|OTHER|Soy milk|Soya milk or soymilk, a plant-based beverage that can be sweetened or unsweetened.
40959536|NCT02850965|DRUG|BI 695501|
40959537|NCT02850965|DRUG|Humira|
40959538|NCT06191640|DRUG|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|HEMT's are prescribed at the discretion of the treating physician and is not dictated by the principal investigator of this study.
40959539|NCT03307681|OTHER|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
40959540|NCT03307681|OTHER|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
40959541|NCT03307681|OTHER|Mashed potato served hot|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
40959542|NCT03307681|OTHER|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
40959543|NCT03307681|OTHER|Meal skipping|No food given
40990598|NCT00629499|DRUG|Trastuzumab|8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
40990599|NCT02448654|DRUG|Tolcapone|Tolcapone will be compared to sugar pill
40990600|NCT02448654|DRUG|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
40990601|NCT06245291|DRUG|Imdusiran|subcutaneous injection
40990602|NCT06245291|DRUG|Durvalumab|intravenous injection
40959544|NCT02701023|DRUG|MitoGel|The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
40959545|NCT01325961|RADIATION|Intensity-Modulated Radiation Therapy|
40959546|NCT02481908|DEVICE|STI measurements at baseline and under Valsalva maneuver|STI measurements at baseline and under Valsalva maneuver
40959547|NCT00037141|DRUG|dehydrated alcohol|
40959548|NCT05428046|BEHAVIORAL|MHL intervention|The current MHL intervention is a brief online intervention and comprises two modules. The first module is a short video introducing a teenage girl with bulimia nervosa. The second module is an online lecture comprising information about eating disorders including the prevalence, symptoms, type, cause, treatment, a related symptom checker, and sources of help. The above two modules are implemented in a single session lasting approximately 2 hours.
40959549|NCT05428046|BEHAVIORAL|Waiting list|Participants assigned to the waiting list group will not receive any intervention until the end of the 12 weeks follow-up. They received the same intervention as the MHL intervention group after the 12 weeks follow-up test.
40959550|NCT00046878|DRUG|O6-benzylguanine|
40959551|NCT00046878|DRUG|carmustine|
40959552|NCT00002711|DRUG|chemotherapy|
40959553|NCT00002711|DRUG|cisplatin|
40959554|NCT00002711|DRUG|paclitaxel|
40959555|NCT00002711|RADIATION|low-LET electron therapy|
40959556|NCT00002711|RADIATION|low-LET photon therapy|
40959557|NCT05893355|BEHAVIORAL|Acupressure group|"Application to Acupressure Group~* Participants in this group will be interviewed for the first time at postpartum week 1, and for the second time between 4-6 weeks postpartum. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* The VAS, which will be applied to the puerperant women for the first time in the first week of the postpartum week and for the second time between the 4th-6th weeks, will be filled by the participant just before the application to evaluate the back pain.~* The VAS Evaluating Back Pain after the application will be filled in by the participant.~* The participant will be informed that the study has been completed."
40959558|NCT04768101|DRUG|[11C]-PIB|\[11C\]-PIB is a PET radiotracer used to evaluate levels of Αβ burden.
40959559|NCT02202525|DRUG|Micardis®|
40959560|NCT02202525|DRUG|Other hypertensives|
40959561|NCT02561611|BEHAVIORAL|Intervention Group|The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
40959562|NCT05582473|BEHAVIORAL|LST-LC Education|"Testing the LST-LC intervention with cultural adaptations integrated through Stage 2 (Adaptation Design). There are 9 modules.~Session 1, we describe the principles underlying the program (safety, hygiene, dignity, comfort, and independence), discuss self-care, and introduce a vignette of caring for a person with dementia, designed to generate conversation around the caregiving role.~Other modules focus on 1) behavioral and 2) communication challenges in the context of dementia; 3) home safety, transfers, and adaptable medical equipment; 4) managing nutrition needs; 5) swallowing challenges; 6) supporting oral hygiene; 7) dealing with incontinence, including preventing and recognizing urinary tract infections; 8) medication management and 9) managing comorbidities including assessing and managing pain"
40959563|NCT01944696|OTHER|phototherapy|Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
40959564|NCT04204343|DRUG|Bupivacaine 0.7 ml/kg|Bupivacaine 0.25% 0.7 ml/kg
40959565|NCT04204343|DRUG|Bupivacaine 0.5 ml/kg|Bupivacaine 0.25% 0.5 ml/kg
40764218|NCT05845580|OTHER|Red yeast rice extract initial therapy followed later on by statin therapy|Patients will be offered red yeast rice extract to achieve a target LDL-cholesterol level of \<2.6 mmol/L, as recommended by the 2019 ESC/EAS guidelines. If a patient's LDL-cholesterol level remains above the target during follow-up, they will be informed that the natural alternative was ineffective, and they will be prescribed atorvastatin.
40959566|NCT03883711|OTHER|Database|Create a database containing clinical characteristic, clinical presentation, flow indexes and treatment of consecutive incident patients with ACS or myocardial injury.
40959567|NCT03758066|DEVICE|PlusCare|PlusCare is a mobile application designed to be used by youth and young adults with HIV and case managers.
40959568|NCT04636229|BIOLOGICAL|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
40959569|NCT04636229|DRUG|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
40959570|NCT05222737|DEVICE|medency diode laser|intra pocket application of diode laser
40959571|NCT05222737|DRUG|spirazole forte|adminstration of spirazole forte with a dose 17 mg per kg
40959572|NCT01506258|PROCEDURE|Application of Stem Cells|IV infusion of autologous stem cells within the first 48 hours after birth.
40959573|NCT01506258|PROCEDURE|Observation|Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
40959574|NCT06265246|OTHER|Habitual Diet + Milk|1.5 servings of milk \[providing approx. 500 mg Ca/day\] per day (either 1% fat milk, or 2% fat milk)
40959575|NCT06265246|OTHER|Habitual Diet + Yogurt|2 servings of yogurt \[providing approx. 500 mg Ca/day\] per day (either 1% fat plain yogurt, 2% fat plain yogurt, 1% fat flavoured yogurt, 2% fat flavoured yogurt)
40959576|NCT01270516|DRUG|HMB, hydroxymethylbutyrate|Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
40959577|NCT01270516|DRUG|EPA, eicosapentaenoic acid|EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
41466461|NCT05911087|BIOLOGICAL|PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
40959578|NCT01270516|DRUG|Saline|Control
40959579|NCT04524897|DRUG|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation
40959580|NCT00137579|PROCEDURE|Influenza vaccine intramuscular administration route|
40959581|NCT03789474|DEVICE|HUNTLEIGH FLOWTRON ACS900|
40959582|NCT02023606|DRUG|SPN-810M|
40959583|NCT00420693|DRUG|sevoflurane|
40959584|NCT05900271|DEVICE|rTMS|10 Hz repetitive-transcranial-magnetic-stimulation
40959585|NCT05900271|DEVICE|iTBS|neuronavigated intermittent theta burst transcranial-magnetic-stimulation
40959586|NCT02572401|BEHAVIORAL|STAND HIV Risk Reduction Intervention|STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
40959587|NCT02572401|BEHAVIORAL|Text Messaging Intervention|Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
40959588|NCT03391037|DIAGNOSTIC_TEST|Internal Jugular Vein Distensibility|. 40 donor candidates for right lobe hepatectomy for living donor liver transplantation were enrolled. During period of hypovolemia (T0) left IJV scanned and measured. After a given fluid bolus in the form of ringer acetate 5 ml / Kg. ultrasonic and hemodynamic measurements were reassessed 10 minutes (T 10) after the fluid resuscitation
40959589|NCT05902520|BIOLOGICAL|DP CD8 TIL|intravenous infusion of T cell suspension
40959590|NCT05902520|BIOLOGICAL|DP CD8 TIL KD|intravenous infusion of T cell suspension
40959591|NCT05902520|BIOLOGICAL|Low dose IL-2|Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks
40959592|NCT06271122|OTHER|Voluntary activation assessed by magnetic stimulation|"Visits V1 (Day 1) and V2 (Day 28) are identical. The dominant leg will be tested, the patient positioned on the ergometer and EMG electrodes placed on the quadriceps.~The familiarization for femoral magnetic stimulation (FMS) will begin, the stimulation site identified and the supramaximality verified.~After a warm up, the subject will perform 3 maximal voluntary isometric contractions (MVIC; 5s, rest = 30s), 3 MVIC reaching maximal force as quickly as possible, and 4 MVIC during which magnetic stimulation (intensity = 100%) will be applied during the contraction and 2 seconds after the contraction ends.~For transcranial magnetic stimulation, the stimulation area and intensity will be determined. After that, the patient will perform 3 CMIV at 100%, 75%, 50% and 35% of CMIV. During each contraction, magnetic stimulation will be delivered during the force plateau."
40959593|NCT02973061|OTHER|Questionnaires|All participants families will fulfill a periodic questionnaire regarding attention, behaviour.
40959594|NCT04044378|DRUG|Famitinib|famitinib with RP2D orally daily
40959595|NCT04044378|DRUG|Ifosfamide|ifosfamide 1.8g/m2/d d1-3, 15-17 Q4W infusion
40959596|NCT04044378|DRUG|Camrelizumab|camrelizumab 200mg infusion once Q2W
40764219|NCT05845580|OTHER|Statin therapy|Patients will be provided reassurance through a short, semi-structured discussion on the excellent safety profile of statins, similar to a typical interaction between a clinician and patient. They will then be prescribed atorvastatin.
40959597|NCT00303732|DRUG|RAD001 (everolimus)|
40959598|NCT00303732|DRUG|PTK787 (vatalanib)|
40959599|NCT05146167|BEHAVIORAL|Bodhi AIM (intervention group)|"Bodhi AIM (Action In Mindfulness) is a smartphone-based app that teaches users to establish a daily meditation practice via a 30-day path, with each day consisting of a brief audio- or video-guided file. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they may access any time to prepare for particular situations (e.g., attending a party)."
40959600|NCT05146167|BEHAVIORAL|HIB (control group)|"HIB (Health In Balance) is a smartphone-based app that is matched to Bodhi AIM for time and structure, but includes health promotion content (e.g., educational information on substance use) in place of the meditation content featured in Bodhi AIM. Like Bodhi AIM, HIB includes a 30-day path of audio and video files, along with a menu of to go audio files that users may access any time to review key intervention concepts."
40959601|NCT01754701|DIETARY_SUPPLEMENT|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
40959602|NCT01754701|DIETARY_SUPPLEMENT|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
40959603|NCT01489800|BEHAVIORAL|Clear liquid diet|clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
40959604|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and placebo
40959605|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and betamethasone
40959606|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and propionate de clobetasol
40959607|NCT05585060|DIAGNOSTIC_TEST|the changes of end expiratory lung impedence|the changes of end expiratory lung impedence measured by EIT
41466462|NCT05734209|BEHAVIORAL|Virtual food|Virtual food eaten using immersive virtual reality equipment
40764220|NCT06642792|DRUG|AK129|Subjects receive AK129 intravenously.
40764221|NCT06642792|DRUG|AK117|Subjects receive AK117 intravenously.
40959608|NCT05585060|DIAGNOSTIC_TEST|the changes of end expiratory lung volume|the changes of end expiratory lung volume measured by apnea method
41136046|NCT02045498|DEVICE|capnography feedback|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
41136047|NCT05135234|BEHAVIORAL|Muscular Exercise|Sedentary time (muscular inactivity when sitting) will be replaced with low effort muscular activity
41293250|NCT01806870|DIETARY_SUPPLEMENT|Zinc and SAMe|If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
41293251|NCT06106425|DIAGNOSTIC_TEST|EEG|diagnostic tool
41293252|NCT00471471|BIOLOGICAL|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
41293253|NCT00471471|BIOLOGICAL|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
41293254|NCT00471471|BIOLOGICAL|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
41293255|NCT02090582|OTHER|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
41293256|NCT02090582|OTHER|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
41293257|NCT00003264|DRUG|cisplatin|
41293258|NCT00003264|DRUG|gemcitabine hydrochloride|
41293259|NCT00604448|OTHER|Dietary advise|Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.
41293260|NCT00604448|OTHER|Diet enriched with a meal containing pulses|Subjects in pulse group will consume the commercially available pulses for 8 weeks
41293261|NCT00277472|DRUG|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
40959609|NCT00745329|OTHER|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
40959610|NCT06475586|DRUG|Semaglutide|0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks
40990603|NCT01173718|DEVICE|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
41136048|NCT03195803|BEHAVIORAL|Computerized Cognitive Stimulation|All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
41136049|NCT06360978|DRUG|Docetaxel|Our patients will receive docetaxel (15 mg per meter squared) once weekly concurrently with radiotherapy.
41136050|NCT03041961|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
41136051|NCT03041961|DIETARY_SUPPLEMENT|Aronia full spectrum|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
41136052|NCT03041961|DIETARY_SUPPLEMENT|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa)
41293262|NCT00277472|DRUG|HCTZ|25 mg taken once daily orally
41293263|NCT03879863|DRUG|Reproxalap Ophthalmic Solution (0.25%) QID|Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
41293264|NCT03879863|DRUG|Vehicle Ophthalmic Solution QID|Vehicle Ophthalmic Solution administered QID for twelve weeks
41293265|NCT03879863|DRUG|Reproxalap Ophthalmic Solution (0.25%) QID to BID|Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
41293266|NCT03879863|DRUG|Vehicle Ophthalmic Solution QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
41293267|NCT00381316|DRUG|Technetium Tc99m Tetrofosmin injections|Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
41293268|NCT00381316|DRUG|Thallous Chloride T1-201|Myoview SPECT Imaging
41293269|NCT00500149|DRUG|Vyvanse (lisdexamfetamine dimesylate)|Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
41293270|NCT00500149|DRUG|Placebo|Placebo
40959611|NCT05693389|BEHAVIORAL|acceptance and commitment therapy|ACT attempts to encourage psychological flexibility, acceptance of one's own experiences, and dedication to behaviours that are consistent with one's own values. ACT therapies focus on six key processes to improve psychological flexibility: engagement with the present moment, acceptance, defusion, self as context, values clarification, and committed action.
40959612|NCT05693389|OTHER|routine hospital care|the patients with bipolar disorders who receive routine pharmacological treatment
40959613|NCT01725711|DEVICE|OPRA Implant System|
40959614|NCT00217061|DEVICE|Decision Aid Statin Choice|
40959615|NCT05178888|DRUG|MRTX849|KRAS G12C inhibitor
40959616|NCT05178888|DRUG|Palbociclib|CDK 4 and 6 inhibitor
40959617|NCT00746083|BEHAVIORAL|Challenge!|"Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a personal trainer (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer."
40959618|NCT05648383|BEHAVIORAL|mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
40959619|NCT05648383|BEHAVIORAL|Standard care|Participants will receive standard care, including lifestyle recommendations.
40959620|NCT05817643|DRUG|BMS-984923|Oral capsule
40959621|NCT02016001|OTHER|toothpaste 1 with maximum fluoride concentration|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
40959622|NCT02016001|OTHER|toothpaste 2 with 1000 ppm of fluoride|tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
40959623|NCT02021032|DEVICE|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
40959624|NCT04391491|DIAGNOSTIC_TEST|Neuregulin-1β level in plasma|Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP
40959625|NCT04851080|DEVICE|Heart Rate Variability|"Heart rate variability is carried out using the complex of prenosological diagnostics VARICARD 2.51 with the ISCIM 6.2 program is methodically based on the technology of analysis of heart rate variability, it uses the original scientific and theoretical substantiation of HRV indicators, which is based on modern ideas about stress, functional state of the body and assessment of health levels. It is designed to assess the risk of developing diseases in persons who are in states bordering health and disease. A decrease in the adaptive capabilities of the organism is considered as the main risk factor, the results obtained with its help are considered from the point of view of the level of health or stressful effects. It can be successfully used to control the effectiveness of medical intervention. Functionally, the complex is designed to register an electrical signal and form conclusions about the functional state of the body, assess the level of stress and its effect on health."
41136053|NCT04730726|DEVICE|MSOT Acuity Echo|Hybrid optoacoustic and ultrasonography imaging
41136054|NCT03755115|DRUG|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m\^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, 30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m\^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
41293271|NCT05483543|DRUG|Pamiparib|Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
41293272|NCT04093323|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given ID
41293273|NCT04093323|DRUG|Celecoxib|Given PO
41466463|NCT05734209|BEHAVIORAL|Real food|Real food eaten using regular utensils
41293274|NCT04093323|DRUG|PD-1 Ligand Inhibitor|Given IV
40959626|NCT04851080|DEVICE|Spirometry|Spirometry is carried out using the device Spirotest USPTs-01, equipped with liquid crystal indicators. It is non-invasive method for measuring air flows and volumes as a function of time using forced maneuvers. It is intended for functional diagnostics of the lungs, namely, indication and measurement of forced vital capacity and forced expiratory volume in the first second.
40959627|NCT04851080|BEHAVIORAL|Testing of psycho-physiological functions using four questionnaires|Research of the behavioral time preferences by Composite Scale of Morningness (CSM, Smith C.S., Reilly C., Midkiff K., 1989). Translation into Russian by Kolomeichuk S., May 2015), of the chronotype by Munich ChronoType Questionnaire (MCTQ, Roenneberg T., Merrow M., LMU München, 2006, 2008. Translation into Russian by Putilov A.A., Danilenko K.V., approved by the authors October 2007, updated 2010), of the seasonal pattern by Seasonal Pattern Assessment Questionnaire (SPAQ, Rosenthal N.E., Genhart M., Sack D.A., Skwerer R.G., Wehr T.A., 1987.Translation into Russian by Putilov A.A., Danilenko K.V., Korneeva N.I. 1988, 2002), of the sleep quality by Pittsburgh Sleep Quality Index (PSQI, Russian edition Semenova E.A., Danilenko K.V., October 2009)
40959628|NCT05746195|BEHAVIORAL|Dietary intervention via Text Messaging|Text messages will be sent to participants cell phones using the HealthySMS platform
40959629|NCT05746195|OTHER|Survey Administration|Various questionnaires evaluating participants dietary habits and use of study intervention will be administered
40959630|NCT05746195|BEHAVIORAL|Nutrition Education|Participants will receive nutrition education materials
40959631|NCT03572972|DRUG|Apixaban|Treatment for NVAF patients
40959632|NCT03572972|DRUG|Dabigatran|Treatment for NVAF patients
40959633|NCT03572972|DRUG|Rivaroxaban|Treatment for NVAF patients
40959634|NCT03572972|DRUG|warfarin|Treatment for NVAF patients
40959635|NCT03572972|DRUG|Antiplatelets|Treatment for NVAF patients
40959636|NCT04601415|DIAGNOSTIC_TEST|ECG from handheld device|Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment
40959637|NCT05719662|OTHER|Weight bearing exercises|Weight bearing exercises
40959638|NCT05719662|OTHER|Jaffrey's core stability exercises|Jaffrey's core stability exercises
41293275|NCT04093323|DRUG|PD1 Inhibitor|Given IV
41293276|NCT04093323|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
41293277|NCT04093323|DRUG|Rintatolimod|Given IV
41293278|NCT06326229|OTHER|ICF entities assessment|A visual analog scale will be used by the participants to evaluate the relevance of the ICF entities in relation to their musculoskeletal condition. The scale will range from 0 (no problem) to 100 (complete problem).
41293279|NCT05582122|BIOLOGICAL|HPV16 Ct-DNA dosing|"Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.~ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.~ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.~DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma."
41293280|NCT04256746|OTHER|Boiled Rice|
41293281|NCT04256746|OTHER|Boiled Rice+0.37 gr mulberry fruit powdered extract|
41293282|NCT04256746|OTHER|Boiled Rice+0.75 gr mulberry fruit powdered extract|
40959639|NCT00259337|BIOLOGICAL|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
40959640|NCT00934830|DRUG|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
40959641|NCT00934830|OTHER|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
40959642|NCT00847379|DRUG|Ataluren|Ataluren oral powder for suspension will be administered as per dose and schedule specified in the arm.
40959643|NCT00981370|DRUG|deferasirox|Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
40959644|NCT02718157|DEVICE|Comparison between GenePOC PCR and Reference Method|Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
40959645|NCT04858633|DRUG|Hydroxychloroquine (HCQ)|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg )
40959646|NCT04858633|OTHER|Standard care|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
40959647|NCT04858633|OTHER|Placebo|Tablet placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
41293283|NCT04256746|OTHER|Boiled Rice+1.12 gr mulberry fruit powdered extract|
41293284|NCT04256746|OTHER|Boiled Rice+1.50 gr mulberry fruit powdered extract|
41293285|NCT04256746|OTHER|Rice Porridge|
40959648|NCT06346340|DRUG|Miebo|Miebo applied in both eyes 4 times per day for approximately 30 days before cataract surgery. Following the completion of the standard follow up, approximately 30 days after cataract surgery, subjects will begin a second regimen of Miebo , 4 times per day in both eyes, for approximately 30 days.
40959649|NCT02057731|GENETIC|Glycogen Storage Disease markers|Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
40959650|NCT03116360|DIAGNOSTIC_TEST|Diagnostic Ultrasound|The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
40959651|NCT03868046|DRUG|Treatment with immune checkpoint inhibitors.|Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
40959652|NCT03868046|DIAGNOSTIC_TEST|Blood tests.|Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
40959653|NCT05865262|DIAGNOSTIC_TEST|ECG|"A triplicate ECG and a blood test will be done during a medical consultation as part of the usual endocrinology follow-up. Included individuals seen prior to initiation of GAHT, will be assessed a second time (at least one month after GAHT start) with a triplicate ECG and a blood test similar to inclusion visit. Included individuals already on GAHT will be seen only once at the inclusion visit.~Triplicates of 10seconds 12-lead digitized electrocardiogram will be recorded after few minutes of rest in the supine position. Electrocardiograms will be acquired with Mindray ECG BeneHeart R12. For each subject, RR, PR, QRS and QT interval durations will be assessed with a semiautomatic approach using the median representative beats (overlap method) generated from 10seconds ECG with a good quality (CalECG v3.7; AMPS, LLC). The QT interval will be measured and corrected for heart rate by Fridericia's formula."
40959654|NCT05865262|DIAGNOSTIC_TEST|blood test (assessing ionic and hormonal circulating levels)|Blood samples for the determination of serum concentrations of estradiol, progesterone, testosterone, FSH, and LH will be collected on the same day as the ECG, in a dry tube and further assayed in the immunology laboratory of Bordeaux University Hospital (France). Estradiol, progesterone, FSH, and LH plasma concentrations will be assayed by immunochemiluminescence (Architect i2000SR; Roche Diagnostics), and testosterone levels by liquid chromatography mass spectrometry. Kalemia and calcemia will be collected in a BD Vacutainer tube with heparin lithium and separator, further assayed at the biochemistry laboratory of Bordeaux University Hospital by indirect potentiometric measurement (Architect c16000) and Arsenazo III SRM 956 colorimetrie (Architect c16000).
40959655|NCT03552731|BEHAVIORAL|Surveys|GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.
40959656|NCT01559467|OTHER|Cardiovascular Magnetic Resonance Imaging|Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
40959657|NCT01559467|OTHER|Computed Tomography Angiography|Routine clinical care plus computed tomography angiography early in the diagnostic process
40959658|NCT01861860|DEVICE|TAXUS™ Element long stent|Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain \> 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
40959659|NCT06101758|DIAGNOSTIC_TEST|Handgrip strength test|A handgrip strength test using a hydraulic hand dynamometer will be performed
40959660|NCT06101758|DIAGNOSTIC_TEST|total body Dual Energy X-Ray Absorptiometry (DXA)|A total body Dual Energy X-Ray Absorptiometry (DXA) to estimate muscle mass will be performed
40959661|NCT06101758|DIAGNOSTIC_TEST|Muscle ultrasound|A muscular ultrasound of abdominal muscles, forearm muscles, quadriceps and gastrocnemius will be performed
40959662|NCT01802801|OTHER|embryo development|intra- and inter-observator analysis
40959663|NCT03217812|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
40959664|NCT03217812|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2 (if serum creatine is \>2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
40959665|NCT03217812|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
40959666|NCT03217812|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as IV infusion or daratumumab SC, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
41293286|NCT04256746|OTHER|Rice porridge+1.50 gr mulberry fruit powdered extract|
41293287|NCT04487860|DRUG|AS012|oral administration
41293288|NCT04487860|DRUG|Placebo|oral administration
40959667|NCT00242216|DRUG|ritonavir-boosted atazanavir|100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
40959668|NCT00242216|DRUG|ritonavir-boosted fosamprenavir|100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
40959669|NCT03143413|OTHER|Ultrasonography|"Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated."
40959670|NCT01378637|DEVICE|AMES- Leg treatment|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
41136055|NCT05505227|BEHAVIORAL|Stigma-reduction training|While the details will be finalized by the intervention working group after the key modifiable features of OUD-stigma among rural HCPs are isolated in Aim 1, our intervention will include several new elements that distinguish it from existing stigma-reduction interventions. The prototype intervention includes several modules aimed at decreasing stigma, increasing knowledge about medications for OUD, and increasing willingness to prescribe buprenorphine (see Table 3) among rural HCPs currently in practice.
41136056|NCT05505227|BEHAVIORAL|Placebo|HCPs affiliated with clinics in the control arm will receive no training but will be provided with a link to the SAMHSA website where prescribers can learn more about buprenorphine prescribing and apply to receive an X-waiver.
40764223|NCT04804033|DRUG|BHV-3500 (zavegepant)|BHV-3500 (zavegepant) softgel capsule.
40764224|NCT04804033|DRUG|Placebo|Matching placebo softgel capsule.
40764225|NCT03753074|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Tablet, Oral, Daily
40764226|NCT03571633|DRUG|Trastuzumab + Paclitaxel|During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)
40764227|NCT03571633|DRUG|Pegfilgrastim|During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
40764228|NCT06637306|DRUG|Dupilumab|Dupilumab 600mg subcutaneous initial loading dose, 300mg for subsequent doses; administered every 3 weeks for 4 cycles. Immunotherapy drug FDA approved to treat patients with eczema, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Investigational/not yet FDA approved to treat patients with breast cancer.
40959671|NCT06290479|DIETARY_SUPPLEMENT|Air Up® Peach Pod|Participants in this arm will use the air up® drinking system with a peach-flavored pod.
41136057|NCT05494658|DIETARY_SUPPLEMENT|BCAA|600ml drink which contains 18g BCAA was consumed by patients 2-4h before surgery.
41136058|NCT05494658|DIETARY_SUPPLEMENT|water|600ml water was consumed by patients 2-4h before suegery.
41136059|NCT03115099|DRUG|LY3325656|Administered orally
40764229|NCT06637306|DRUG|Pembrolizumab|Pembrolizumab 200mg intravenous every 3 weeks for 4 cycles and one 400mg intravenous dose one week following completion of chemotherapy. Cancer immunotherapy drug FDA approved for the treatment of high-risk, early-stage, triple-negative breast cancer (TNBC).
40764230|NCT06637306|DRUG|Paclitaxel|Paclitaxel 80mg/m2 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
40764231|NCT06637306|DRUG|Carboplatin|Carboplatin AUC 1.5 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
40764232|NCT05691829|DRUG|Pembrolizumab|Pembrolizumab 200mg solution administered intravenously every 3 weeks for 6 cycles followed by maintenance therapy until progression of disease or unacceptable toxicity (standard of care). Administered alongside chemotherapy.
40764233|NCT05691829|RADIATION|Radiation|One-time, up-front radiation delivered at up to five metastatic subsites at a 4 Gy x 5 radiation dose fractionation schedule. Radiation will be delivered within five days before or after initiation of first cycle of pembrolizumab treatment. Radiation modality and technique will be determined at the discretion of the treating radiation oncologist.
40764234|NCT05691829|DRUG|Chemotherapy|Administered alongside pembrolizumab every 3 weeks for 6 cycles per institutional standard of care. For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and paclitaxel or nab-paclitaxel
40959672|NCT06290479|DIETARY_SUPPLEMENT|Air Up® Orangeade Pod|Participants in this arm will use the air up® drinking system with an orangeade-flavored pod.
40959673|NCT03591991|DRUG|Empagliflozin|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin . After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths.
41136060|NCT03115099|DRUG|Placebo|Administered orally
40959674|NCT03591991|OTHER|placebo|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg placebo . After admission, patients were treated with 10 mg placebo once daily for 3 mouths.
40959675|NCT05250778|BEHAVIORAL|Nudge|Room intervention
40959676|NCT01217801|DRUG|Ondansetron (ODFS)|Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
40959677|NCT01217801|DRUG|Ondansetron (ODT)|Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
40959678|NCT01688518|DRUG|Heated Lidocaine/Tetracaine Patch|
41136061|NCT03115099|DRUG|Liraglutide|Administered subcutaneously
40764235|NCT04318080|DRUG|Tislelizumab|200 mg intravenously (IV) every 3 weeks (Q3W)
40764236|NCT06638541|RADIATION|Prostate radical radiotherapy|Radiation: De-escalated radiotherapy to be delivered on the Elekta Unity MR-linac
40764237|NCT05524935|DRUG|Pembrolizumab|Pembrolizumab Day 1 of each 21 day (3 week) cycle
41136062|NCT03115099|DRUG|Sitagliptin|Administered orally
41136063|NCT02322372|DRUG|Femoral blockade|Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
40764238|NCT05524935|DRUG|Olaparib|Olaparib by mouth days 1-21 of each 21 day (3 week) cycle
40764239|NCT06640972|DRUG|RDX-002|Gut-specific microsomal triglyceride transfer protein (MTP) inhibitor
40764240|NCT06640972|DRUG|Placebo|Matching placebo
40764241|NCT06189313|DEVICE|Cleaner Pro Thrombectomy System|"The Cleaner™ Pro Thrombectomy System (Cleaner Pro) is a catheter-based aspiration thrombectomy device comprised of a handpiece, an aspiration catheter, a dilator, and an aspiration canister."
40764242|NCT03735901|DRUG|IMP Levodopa 100mg/Carbidopa 25mg|"Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning."
40764243|NCT03735901|DRUG|Matching placebo|"Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning."
40764244|NCT00330733|DRUG|Salsalate|Participants were randomized to 12-week treatment with up to 4 g/day.
40764245|NCT00330733|DRUG|Placebo|Participants were randomized to 12-week treatment matching the active salsalate arm.
40764246|NCT05928572|OTHER|CGM initiation approach|Use of a nutrition-focused approach versus a self-directed approach during CGM initiation
40764247|NCT06640803|BEHAVIORAL|Stepped-Care including Cognitive Behavioral Case Management|Step 1:assessment and feedback, general engagement strategies, assessment of needs and social determinants of health, begin case management, goal setting. Step 2: TAU. Initiation of team-based care at community clinics and 'enhanced monitoring'. Step 3: atheoretically-based stress management skills (stress thermometer, coping skills and coping plans), problem solving strategies. Step 4: targeted intervention for CHRp. Initiation of formulation-based CBT modules, therapy consultation groups with the UC Davis team (UCD), regular meetings between clinic leadership and UCD. Participants may switch providers to increase level of early psychosis specialization. Step 5: add prescriber consultation groups with UCD. Step 6: assessment of trauma and family conflict then Family-Focused Therapy, Trauma-Focused Cognitive Behavioral Therapy, or CBT for CHR at UCD. Termination: At 24 months, referral to UCD coordinated specialty care clinic or other appropriate service for those still CHRp+.
40764248|NCT06639503|DRUG|Bupivacain|5mL 0.25% bupivacain
40764249|NCT05080790|DRUG|Dinutuximab Beta, Zoledronic acid, Interleukin-2|Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
40764250|NCT06634615|OTHER|VR patient education video|The educational video is created by converting the information provided by the service nurses into a video when the patient is admitted to the ward for surgery. The video will show a 2-3 minute animation of a nurse giving information. In a patient room, the service nurse will come to the newly admitted patient and explain the concept of cholecystectomy, the reasons for removing the gallbladder, how laparoscopic cholecystectomy is performed, the advantages of laparoscopic surgery compared to open surgery, the preparation process before and on the day of surgery, the conditions to be monitored after surgery, the importance of nutrition and fluid intake, defecation, the importance of early mobilization and discharge.
40764251|NCT06634615|OTHER|VR family interview|Patients will have a 5-minute video call with their families in a 360° designed home environment using virtual reality glasses in the operating room waiting area.
40764252|NCT06637618|BEHAVIORAL|up front use of mineralocorticoid receptor antagonist|the sequence of which the four drug classes are prescribed will differ, where the intervention is early use of MRA, where the control group will receive standard care, where MRA are usually prescribed last
40959679|NCT01688518|DRUG|5% Lidocaine Patch|
40990604|NCT01462721|DEVICE|eSVS® Mesh|Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
41136064|NCT02322372|DRUG|Intrathecal anesthesia|Spinal anesthesia with heavy bupivacaine
41136065|NCT03292406|DRUG|Placebo|Non active ingredients of CD11301
41136066|NCT03292406|DRUG|CD11301 0.03%|Topical Gel
41136067|NCT03292406|DRUG|CD11301 0.06%|Topical Gel
41136068|NCT02224755|DEVICE|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
41136069|NCT02224755|DEVICE|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
41136070|NCT06208605|BEHAVIORAL|Transdiagnostic Network Informed Personalized Treatment|Idiographic network analysis is used to determine individuals' top central eating disorder symptoms. Participants then receive modules to address these specific symptoms.
41293289|NCT02384369|DRUG|SNC-102 sustained release tablet|Sustained release oral tablet of SNC-102
40764253|NCT06637943|DIAGNOSTIC_TEST|POC viscoelastic test|applying viscoelastic test (Rotem or TEG tests) to 1 ml arterial blood sample
40764254|NCT06637943|DIAGNOSTIC_TEST|standard central laboratory test|applying central laboratory test to arterial blood sample
40959680|NCT05667844|BEHAVIORAL|interoceptive mind-body exercise|A interoceptive mind-body exercise program in a patient with Generalized Anxiety Disorder and Major Depressive Disorder based on a Multidimensional Assessment of Interoceptive Awareness. Each session of the body-mind intervention lasts 80 minutes and is supervised by physical education professionals. The intervention is divided in 4 parts, that are: Preparatory phase (reception) the subjects will be welcomed through subjective analyzes of the researcher; Initial phase (preliminares) Mindfulness, grounding, sensory stimulation and joint warm-up exercises are performed; main phase (exercises) stretching, mobility, posture and balance exercises are performed with full attention and listening after each exercise; Final phase (relaxation) breathing exercises, stretching exercises, body scanning and relaxation are performed.
40959681|NCT06176521|PROCEDURE|Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Performed Without Mesh|Comparison of pre and postoperative POP-Q values of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy SurgeriesWithout Using Mesh Comparison of pre and postoperative PISQ-12 scores of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Without Using Mesh
40959682|NCT03360604|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention is a diet consisting of a Low GI breakfast, lunch and snack meal.
40959683|NCT03360604|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention is a diet consisting of a High GI breakfast, lunch and snack meal.
40959684|NCT06290661|DEVICE|Active electrostimulation|Maintain the electrical stimulation state, and according to the patient's feeling to set the appropriate stimulation parameter range (pain relief and no obvious numbness and discomfort), the programme will be written into the patient's self-control remote control, by the patient according to their own pain situation for the independent control of the stimulation current.
40959685|NCT06290661|DEVICE|Placebo electrostimulation|No actual electrostimulation
40959686|NCT04516174|PROCEDURE|Transversus abdominis plane block using ropivacaine|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using 0.25% ropivacaine was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
40959687|NCT04516174|DRUG|Dexmedetomidine|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of dexmedetomidine.
40959688|NCT04516174|PROCEDURE|Transversus abdominis plane block using saline|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using saline was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
40959689|NCT04516174|DRUG|Saline|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of saline, dosage and infusion method of saline are consistent with dexmedetomidine.
40959690|NCT01725503|DIETARY_SUPPLEMENT|Creatine and Amino Acid supplement|
40959691|NCT01669226|DRUG|PEip (weekly) and TCiv|IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
40959692|NCT01669226|DRUG|TCiv|IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
40959693|NCT05378178|DRUG|HS-10381|Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2...) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
40959694|NCT04755569|DEVICE|ODOCOR II CCM LEADS|ODOCOR II CCM LEADS Implantation
40959695|NCT04749277|OTHER|CAD EYE® (Fujifilm, Europe, Gesellschaft mit beschränkter Haftung, Dusseldorf, Germany)|"Methods plan~Phase 1. Brief virtual chromoendoscopy training on the characterization of colorectal polyps (WLI, LCI and BLI)~Phase 2. CAD EYE® system applied during colonoscopy retrieval:~2.1. CAD EYE® system OFF: Virtual chromoendoscopy (BLI) - independently characterization of a suspected polyp in WLI and BLI by the first endoscopist and by the second endoscopist (iconographic record) 2.2. CAD EYE® system ON: Characterization mode (BLI): Characterization of a suspected polyp by CAD EYE® and respectively level of characterization (1 to 3) (iconographic record) Phase 3. Histopathological evaluation (pathologist with gastrointestinal expertise): Resection and recovery of a suspected polyp for anatomopathological characterization"
40959696|NCT01676571|DRUG|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
40959697|NCT02419105|DRUG|Testosterone|transdermal gel, 75 mg daily
40959698|NCT02419105|DRUG|Colecalciferol|drink solution, 24000 IU once per month
40959699|NCT02419105|DRUG|Placebo drink solution|drink solution, 0 IU Colecalciferol once per month
40764255|NCT02776176|PROCEDURE|Enhanced Recovery After Surgery Program|optimized peri-operative protocol
40959700|NCT02419105|DRUG|Placebo transdermal gel|transdermal gel, 0 mg testosterone daily
41136071|NCT06208605|BEHAVIORAL|Enhanced Cognitive Behavioral Therapy for Eating Disorders|Manualized CBT-E (Fairburn 2008) including regular eating, self-monitoring, and CBT modules implemented flexibly.
40764256|NCT02776176|PROCEDURE|Traditional Program|traditional standard protocol
40764257|NCT05832151|DRUG|CIN-102 Dose 1|2 capsules twice daily for 12 weeks
40764258|NCT05832151|DRUG|CIN-102 Dose 2|2 capsules twice daily for 12 weeks
40764259|NCT05832151|DRUG|Placebo|2 capsules twice daily for 12 weeks
40764260|NCT04945330|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Follow clinical practice
40764261|NCT02999659|DEVICE|Pupilometer|Device to measure change in pupil diameter due to a defined light stimulus.
40764263|NCT06640738|DRUG|arm 2|"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun."
40764264|NCT06640738|DRUG|arm 1|"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun."
40959701|NCT02358174|PROCEDURE|Hemorrhoidectomy|"Grade III and IV patients were treated with surgery according to Milligan-Morgan (Milligan-Morgan laser optical fibers variant) procedure.~All patients will perform blood sampling for MMPs and NGAL plasma levels evaluation"
40959702|NCT02358174|OTHER|blood sampling|blood sampling for MMPs and NGAL plasma levels evaluation (ELISA test)
40959703|NCT02358174|OTHER|tissue sampling|tissue sampling for MMPs and NGAL tissue levels evaluation (Western Blot)
40959704|NCT03095339|OTHER|Educational package|The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
41293290|NCT00876174|PROCEDURE|Blood sampling of peripheral blood mononuclear cells|Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
41293291|NCT00876174|PROCEDURE|Blood draw, 20ml peripheral blood mononuclear cells|One time blood draw of 20 ml
41293292|NCT03251976|BEHAVIORAL|video|informational video
41293293|NCT03251976|BEHAVIORAL|usual care|usual physician counseling on end of life care
41466464|NCT05283330|DRUG|²¹²Pb-DOTAM-GRPR1|²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
41466465|NCT02988973|DRUG|roxadustat|Oral administration
40959705|NCT04412434|DIAGNOSTIC_TEST|Electroencephalography (EEG)|"Electroencephalography (EEG) is a painless and harmless method to record the bioelectric activity of the brain. Clinically, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time, as recorded from multiple electrodes placed on the scalp This method can be helpful in the diagnosis of many various brain diseases and pathological conditions.~For the examination, electrodes are placed on the head, using a special harmless gel, similar to gel, used in ultrasonographic studies."
40959706|NCT04923256|BEHAVIORAL|AAT-APP: A novel smart-phone approach-avoidance bias modification intervention|Participants allocated to the intervention group will be required to upload photos of drinks they wish to avoid, as well as activities they wish to engage in more, and be trained to avoid and approach by repeatedly 'swiping' images away from and towards themselves, respectively.
40959707|NCT04923256|BEHAVIORAL|Sham training control|Complete an AAT on a weekly basis for four weeks
40959708|NCT02106260|DRUG|CLS003|
40764265|NCT06641947|PROCEDURE|Whipple procedure|Typically used for treating pancreatic cancer, particularly tumors located in the head of the pancreas.
40764266|NCT06637150|DRUG|Dalpicilib|Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years.
40764267|NCT06637150|DRUG|endocrine therapy|standard endocrine therapy
40764268|NCT06642272|DRUG|Empagliflozin 10 MG|Once daily
40764269|NCT06642272|DRUG|Dapagliflozin 10 MG|Once daily
40764270|NCT06637059|OTHER|observational study|observation alone
40764271|NCT02614248|OTHER|Organic, Unrefined Coconut Oil|
40959709|NCT03475368|OTHER|Vegetarian diet|People randomized to this interventional group will take a vegetarian diet (i.e. without animal products, except milk and eggs).
40959710|NCT03475368|OTHER|Low carbs diet|People randomized to this interventional group will take low carbs diet (i.e. with a limited amount of carbohydrates)
40959711|NCT03475368|OTHER|Mediterranean diet|People randomized to this interventional group will take a traditional Mediterranean diet.
40764272|NCT02614248|OTHER|Medline Remedy Phytoplex Z-Guard Skin Protectant|
40959712|NCT04691271|PROCEDURE|Stellate ganglion block|"After the patient entered the operating room, early SGB will be performed by a designated experienced anesthesiologist using the B-ultrasound visualization technique. The intervention site is the ipsilateral side of the planned craniotomy site. After routine disinfection, 0.5% ropivacaine 8-10 mL will be injected into the surface of the longus colli muscle on the medial side of the prevertebral fascia at the level of the C6 anterior tubercle, and then the puncture point will be covered with sterile dressings. The success criteria of e-SGB are Horner's syndrome, which is characterized by a miosis, ptosis, enophthalmos, conjunctival hyperemia and facial reddishness without sweating. For the camouflaging arm, the anesthesiologist only covered the corresponding part of the patient with sterile dressings to confuse the follow-up, without any puncture. All patients will be admitted to the ICU after the operation and then receive the standard of care."
40959713|NCT03538548|BEHAVIORAL|CBT-RP|CBT-RP is a time-limited, manual guided intervention that aims to develop behavioral and cognitive skills needed to initiate abstinence and prevent relapse. The treatment will help individuals analyze the decision making process to minimize the influence of more immediate reinforcement, develop cognitive strategies to promote the attainment of longer-term goals, practice behavioral strategies to reduce the influence of socially mediated threats to abstinence, and outline explicit plans for managing situations that threaten their goal of abstinence.
40959714|NCT03555032|DRUG|Talimogene laherparepvec (T-VEC)|One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
40959715|NCT04715633|DRUG|PD-1 inhibitor plus VEGF inhibitors|Camrelizumab 200mg IV every 3 weeks; Apatinib 250mg QD day 1-14. Rescue chemotherapy: Oxaliplatin 130mg/m2 IV drip Q3W d1+Capecitabine 1000mg/m2 QD d1-d14 Rescue chemoradiotherapy: Long-course radiotherapy +Capecitabine 825mg/m2 QD d1-d14
41466466|NCT02988973|DRUG|DA|Subcutaneous administration
41466467|NCT00000317|DRUG|Risperidone|Risperidone (4mg/day)
41466468|NCT00000317|DRUG|Placebo|Placebo
40764273|NCT04857281|DEVICE|nVNS (gammaCore)|The treatment will be self-administered using nVNS and will be applied for 4 weeks; a member of the study will provide the proper training on the correct use of nVNS. The patient will be instructed to use the nVNS in place of the rescue medications. When the nauseas gets bad enough that they feel to use a rescue medication they will first use the device on one side of the neck for two 2-minute stimulations and wait fifteen minutes to check if the stimulation works. If this does not help either, they will stimulate with an additional 2 stimulations and wait for another fifteen minutes. If there is no improvement rescue medication will be used. nVNS can be used up to, but no more than, 8 times a day.
40764274|NCT05880004|BEHAVIORAL|Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications|The primary intervention is a mobile application (app) which supports food pantries to recruit, train and schedule volunteers; provide a safe, remote form of client choice; and provides a means of sharing real-time status information with clients, pantries, food banks, and emergency operation centers. Following formative work, user centered design, and usability testing, the SAFPAS app will be implemented in three stages, where each stage introduces new features. Pantry clients will be encouraged to download the app and learn its key features at the end of baseline data collection. During the first weeks of each stage, training of participating food pantry directors/staff and Maryland Food Bank (MFB) staff will take place - focusing on use of any new features. Initial training will be follow up by proficiency testing.
40764275|NCT03847012|OTHER|exercise|The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.
40764276|NCT06638879|DRUG|Tacrolimus|Participants will receive a tacrolimus treatment via toothpaste application twice daily for three months.
40764277|NCT05277571|BIOLOGICAL|UCB1381|UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B
40764278|NCT05277571|DRUG|Placebo|Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
40764279|NCT06643403|DRUG|Oxygen 100% Gas for Inhalation|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for max. 45 minutes"
40764280|NCT06640049|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
40764281|NCT02805348|DRUG|Bixalomer|Oral
40764282|NCT05908786|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.
40764283|NCT05908786|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.
40764284|NCT05908786|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.
40764285|NCT05908786|DRUG|Tobemstomig|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1
40764286|NCT02446457|OTHER|Laboratory Biomarker Analysis|Correlative studies
40764287|NCT02446457|DRUG|Lenalidomide|Given PO
41293294|NCT05019183|OTHER|Physical training|The subjects will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) with a target heart rate zone of 60%.
41293295|NCT05019183|OTHER|Virtual reality|The subjects will be able to move freely in virtual environments while training on the indoor rower.
40764288|NCT02446457|BIOLOGICAL|Pembrolizumab|Given IV
40764289|NCT02446457|BIOLOGICAL|Rituximab|Given IV
40959716|NCT01813188|PROCEDURE|ABM seeded onto a porous TCP and DBM|"cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.~Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)"
40959717|NCT01813188|PROCEDURE|autologous bone graft|autologous bone graft
40764292|NCT06638619|BEHAVIORAL|Biofeedback Fixation Training|This training type involves the use of microperimetry. Microperimetry is a visual field test that incorporates perimetry and retinal imaging and is a standard ophthalmic clinical technology. It allows for direct observation of the fundus, but uses an eye-tracking system to compensate for involuntary eye movements. A program designed to train patients to direct and hold their gaze at an eccentric location programmed by the controller will be used. When the participant directs their gaze towards the pre-programmed location, a sound of increasing frequency is emitted to let them know they are approaching the correct location. The sound stabilizes into a solid tone when the patient is gazing directly at the trained location (biofeedback) and they are asked to attempt to hold their gaze at this location for as long as possible.
40959718|NCT01988688|DEVICE|Deep Brain Stimulation (DBS)|Deep Brain Stimulation (DBS) bilaterally in area LC.
41293296|NCT05019183|DEVICE|Single-photon emission computed tomography (SPECT)|SPECT allows the measurement of cerebral perfusion, reflecting the global synaptic activity, via a 3D acquisition of 20 minutes, 15 minutes after injection of 740 MBq of radiotracers (ECD - Neurolite or HMPAo - Cerestab), with iterative reconstruction. The data will be processed at the voxel scale by the SPM12 software, with analysis of brain connectivity.
40959719|NCT06291974|DIAGNOSTIC_TEST|electromyography|"Surface Electromyography (SEMG) is a measurement of the electrical activity in muscles as a byproduct of contraction.~It is the summation of action potentials from the muscle fibers under the electrodes placed on the skin"
40959720|NCT00601211|DRUG|Pilocarpine|
40959721|NCT01645345|DEVICE|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
40959722|NCT01457144|DRUG|RiBVD|"Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2"
40959723|NCT00636558|DRUG|CVA21|IV infusion, dose escalation of one or two infusions of escalating strength
40959724|NCT04861389|PROCEDURE|Arterial access|Arterial access for primary percutaneous coronary intervention in STEMI patients
40959725|NCT00109083|DRUG|RWJ-333369|
40959726|NCT01934023|DRUG|Varenicline|Champix (Varenicline) is an approved smoking cessation medication
40959727|NCT01934023|DRUG|Placebo|
40959728|NCT05491109|DEVICE|Venous Assistance and Contracture Management System (VACOM)|Mimic therapist-assisted on bed passive ankle exercises to preclude the development of ankle joint contracture and facilitate venous flow in lower extremities to reduce DVT risk. Using soft pneumatic extension actuators, which is capable of providing robot-assisted ankle exercises, specifically dorsiflexion-plantarflexion and inversion-eversion movements. Through these natural movements to improve blood flow and venous return and maintain ankle joint flexibility. Furthermore, it can facilitate and stimulate the neurologic recovery in walking by early mobilization.
40959729|NCT05857059|DRUG|Misoprostol 25 mcg|Misoprostol 50 mcg every 2 hours
40959730|NCT05857059|DRUG|Misoprostol 50 mcg|Misoprostol 50 mcg every 2 hours
40959731|NCT03739593|DRUG|AR-1105-CF1|AR-1105 clinical formulation 1 (AR-1105-CF1)
40959732|NCT03739593|DRUG|AR-1105-CF2|AR-1105 clinical formulation 2 (AR-1105-CF2)
40959733|NCT04747509|OTHER|Blackburn exercises|"Experimental group will include Blackburn exercises and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include prone horizontal abduction neutral and with full external rotation, prone horizontal scaption neutral and with full external rotation, prone horizontal external rotation, prone horizontal extension. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
40959734|NCT04747509|OTHER|Conventional Physical therapy|"Control group will include conventional physical therapy and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include push-ups on a stable surface, upward rotation shrugs and resisted scapular retraction. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
40959735|NCT00006477|DIETARY_SUPPLEMENT|mistletoe extract|
40959736|NCT04714957|OTHER|construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.|Construction of a core database of genetic and epigenetic markers, in order to identify predictive biomarkers and potentially actionable targets for controlling the spread of peritoneal carcinomatosis.
41293297|NCT05019183|BIOLOGICAL|Metabolomics|This qualitative approach will aim to identify pathways that are not known (or have not been explored) to optimize the chances of detecting metabolites present depending on the group (physical activity coupled or not with VR). This method is favorable for biomarker discovery.
40959737|NCT01161459|DRUG|Tripterygium wilfordii|Tripterygium wilfordii 120mg/d Prednisone 30mg/d
40959738|NCT01161459|DRUG|FK506|capsule
41293298|NCT05650450|DEVICE|DES+DCB|Hybrid approach is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES for a de novo long (\>38 mm) lesion (located in the larger, more proximal part of the vessel -reference vessel diameter -RVD \>2.75 mm-) and DCB inflation for a concomitant and contiguous de novo small vessel disease (distally located with RVD ≤2.75 mm ≥ 2.0 mm)
41293299|NCT04138524|OTHER|SAFIR©|Early Supportive intervention for families of patients with acquired brain injuries.
41293300|NCT04714463|PROCEDURE|Implant-based breast reconstruction|All types of implant based breast reconstructions
41456045|NCT06280794|DEVICE|Laser acupuncture|"Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy).~In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment."
40959739|NCT02758990|DIETARY_SUPPLEMENT|Vitamin A|Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
40959740|NCT02758990|DIETARY_SUPPLEMENT|Vitamin B6|Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
40959741|NCT02758990|DIETARY_SUPPLEMENT|Vitamin C|Subjects will be asked to increase vitamin C intake by 500 mg per day.
40959742|NCT02758990|DIETARY_SUPPLEMENT|Nicotinamide|Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
40959743|NCT02758990|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
40959744|NCT02758990|DIETARY_SUPPLEMENT|Vitamin E|Subjects will be asked to increase vitamin E intake by 400 International Units per day.
40959745|NCT02758990|OTHER|Broccoli|Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.
40959746|NCT02758990|OTHER|Spinach|Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.
41293301|NCT04714463|PROCEDURE|Autologous breast reconstruction|All types of autologous breast reconstructions
41293302|NCT04714463|PROCEDURE|Combined methods|All types of breast reconstructions combining autologous and implant based techniques
40959747|NCT02758990|DIETARY_SUPPLEMENT|Caffeine|Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
40959748|NCT02758990|OTHER|Coffee|Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
40959749|NCT02758990|DEVICE|Axon Eyewear|Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
40959750|NCT02758990|OTHER|Chocolate|Subjects will be asked to increase chocolate intake by eating 57g per day.
40959751|NCT01492985|BIOLOGICAL|Placebos of GTU-multiHIV B and LIPO-5 vaccines|Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
40959752|NCT01492985|BIOLOGICAL|GTU-multHIV B vaccine and LIPO-5 vaccine|Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
40959753|NCT04219007|DRUG|Vosoritide|After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
40959754|NCT05199181|PROCEDURE|Full pulpotomy|After applying the rubber dam. Caries, and weak tissues were removed, and the endodontic access was prepared with a carbide bur. Most of the pulp was removed with a sterile high-speed diamond bur under sterile saline solution irrigation and amputated to the canal orifices level. Hemostasis was achieved by irrigation of the cavity with the same solution and an application of small cotton pellets for max.10 min. White Mineral Trioxide Aggregate was mixed according to the manufacturer´s instructions and was placed against the wound after successful hemostasis using an amalgam carrier and packed using an amalgam standard condenser. The material was adapted and a moistened cotton pellet was placed directly over the Mineral Trioxide Aggregate. After 15 minutes, the cotton was removed and the tooth was restored with amalgam. A postoperative radiograph was taken after restoration, general care instructions were given to the patients, and the recommendation of three analgesic intakes.
40959755|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
40959756|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
40959757|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
40959758|NCT06021197|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of CIAS
40959759|NCT06021197|DRUG|Placebo Cap|Use of placebo as a comparator
40959760|NCT01752361|DEVICE|Motilis-3D transit|
40959761|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
40959762|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
40959763|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
40959764|NCT03557853|DRUG|Golimumab Injection|Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
41293303|NCT04330235|OTHER|Healthy Default Kids' Beverage Policy|The healthy default kids' beverage policy requires that all restaurants serve only healthy beverages (water, milk, or 100% juice) instead of sugary beverages as the default beverage with children's meals. The policy has been enacted in New York City and Philadelphia and will go into effect in April 2020.
41293304|NCT06169865|OTHER|cross sectional study|cross sectional study to explore magnitude of peripheral vascular diseases and presentations in patients with autoimmune diseases in sohag society.
40959765|NCT06022744|DRUG|LX109|LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye
40959766|NCT02556554|DEVICE|Dexcom G4 or G5 Platinum CGM system|Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
41293305|NCT00089128|DRUG|gemcitabine hydrochloride|
40959767|NCT02556554|DEVICE|Dexcom G4 or G5 Platinum CGM system with Share|Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
41293306|NCT00089128|DRUG|irinotecan hydrochloride|
41293307|NCT05552586|DIETARY_SUPPLEMENT|Melatonin|patients in the melatonin group will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
41293308|NCT05552586|OTHER|placebo|patients will receive capsules of the same size and color
41293309|NCT05601037|PROCEDURE|Axilla dissection + Lymphovenous anastomosis|surgical bypass between lymphatic vessel and vein
41293310|NCT01454089|DRUG|OGX-427 600 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
41293311|NCT01454089|DRUG|OGX-427 1000 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
41293312|NCT01454089|DRUG|Placebo|Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.
41466469|NCT00000317|BEHAVIORAL|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
40764293|NCT06638619|BEHAVIORAL|Saccadic Reading Training|Participants will be assigned to participate in an at-home reading program. The reading exercises consist of worksheets with letter and number combinations of increasing complexity and font sizes. They are intended to increase accuracy in identifying letters and numbers. Worksheets will initially be dispensed with larger font type and spacing and be graded at weekly intervals towards regular, newspaper-size print and spacing over the course of training.
40764294|NCT00267488|DRUG|topotecan|
40764295|NCT01257750|DRUG|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
40764296|NCT04221477|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
40764297|NCT04221477|DRUG|MMF|MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
40764298|NCT04221477|DRUG|Prednisone|Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
40764299|NCT04221477|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
40764300|NCT04221477|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
40764301|NCT04221477|DRUG|Acetaminophen|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
40764302|NCT04221477|DRUG|Diphenhydramine|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
40764303|NCT06284408|OTHER|Centralized Screening Unit Implementation|The CSU provides a proactive and comprehensive population health approach to screening. This includes core functions of a) patient identification, b) contact, c) engagement, education and support, d) referral and navigation to LDCT screening, e) post screening follow-up, and f) retention
40764304|NCT06638229|DEVICE|The StimaWELL 120MTRS system|A standardized current (dynamic deep wave stimulation) was applied to all patients. Additionally, the mat, which reached a temperature of 40°C, provided heat therapy with electrical stimulation
40764305|NCT05064722|DEVICE|Self Forming Magnets (SFM)|To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.
40764306|NCT06642064|BEHAVIORAL|Intervention group|"• Intervention group:~Participants were invited to participate in a 20-minute interactive learning course (PPT lecture) and a 25-minute physical activity.The intervention lasted for 12 weeks, twice a week, 45 minutes each time, for a total of 1080 minutes."
40764307|NCT06642623|DRUG|Enavogliflozin|The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
40764308|NCT06642623|DRUG|Dapagliflozin or Empagliflozin|The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
40764309|NCT06232590|DEVICE|Control Lens (comfilcon A)|Multifocal monthly replacement contact lens for 1 month
40764310|NCT06232590|DEVICE|Test Lens (lehfilcon A)|Multifocal monthly replacement contact lens for 1 month
40764311|NCT00684294|BIOLOGICAL|TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine|Patients with solid tumors will receive TAG Vaccine 1 x 10\^7 cells/ injection or TAG Vaccine 2.5 X 10\^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
41466470|NCT00878787|DEVICE|Transcranial magnetic stimulation|
41466471|NCT05425342|DEVICE|Smartwatch ECG|Self-recorded 9-lead smartwatch ECGs
41293313|NCT01454089|DRUG|Gemcitabine|Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
41293314|NCT01454089|DRUG|Cisplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
40959768|NCT05799586|BEHAVIORAL|Traditional Chinese Medicine health preservation group|The traditional Chinese medicine health preservation intervention for depression was developed based on a previous systematic review and meta-analysis of Traditional Chinese medicine based integrated health interventions for depression, traditional Chinese medicine health preservation textbooks, clinical practice guidelines related to traditional Chinese medicine health preservation and traditional Chinese medicine treatment for depression. The content and structure of traditional Chinese medicine health preservation for depression was achieved among Hong Kong traditional Chinese medicine experts via a Delphi study.
40959769|NCT05799586|BEHAVIORAL|Waitlist control group|Usual care
40959770|NCT00696800|DRUG|Corifollitropin alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
41293315|NCT01454089|DRUG|Carboplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
41293316|NCT05721625|OTHER|Aerobic exercise|The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
40959771|NCT00696800|BIOLOGICAL|RecFSH / Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
40959772|NCT00696800|DRUG|Placebo Corifollitropin alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
41293317|NCT05721625|OTHER|Connective tissue massage|Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While the patients are in the sitting position, this massage will be applied on whole back.
41293318|NCT03403101|DRUG|S1|"Patients are planned to receive the SIRIOX regimen including S-1 (BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; oral twice daily on days 1-7, days 15-21）of every cycle.~• 28 days a cycle."
41293319|NCT03403101|DRUG|Oxaliplatin|"Patients are planned to receive the SIRIOX regimen including Oxaliplatin (OXA, 85 mg/m2; d1,d15) of every cycle.~• 28 days a cycle"
41293320|NCT03403101|DRUG|Irinotecan|"Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle.~• 28 days a cycle"
40959773|NCT00696800|DRUG|Placebo RecFSH / follitropin beta|Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
40959774|NCT00696800|BIOLOGICAL|RecFSH / Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
40959775|NCT00696800|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
40959776|NCT00696800|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
40959777|NCT00696800|BIOLOGICAL|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
40959778|NCT05254886|OTHER|NEMO nurse-led program|"The NEMO nurse-led program will consist of a single nursing consultation conducted on the day of the inclusion visit during which the nurse will:~* Report the presence of pre-existing comorbidities/EIMs~* Detect the presence of risk factors~* Implement recommendations for the detection and/or management of comorbidities/EIMs."
40959779|NCT01005108|DRUG|Gabapentin|Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
40959780|NCT00000409|PROCEDURE|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis
40959781|NCT00000409|OTHER|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.
40959782|NCT00000409|PROCEDURE|Fusion--Instrumented|In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
40959783|NCT00000409|PROCEDURE|Fusion-Non-instrumented|additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
40959784|NCT01907997|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
40959785|NCT01907997|DRUG|normal saline infusion|In group C, the patients receive same volume of normal saline
40959786|NCT05043909|BEHAVIORAL|VR-based training|Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
40959787|NCT03224715|OTHER|DNA Repair Enzyme Cream|ver-the-counter cosmeceutical. We were going to be using it adjunctively before standard treatment of the actinic cheilitis was done
40959788|NCT05853185|DRUG|Pro Root MTA®|Patients in this group will receive the pulpotomy with Pro Root MTA®.
41293321|NCT04803786|DRUG|Transition from Xyrem to Xywav|This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
41293322|NCT00458250|PROCEDURE|Haploidentical hematopoietic stem cell transplantation|
41293323|NCT00458250|DRUG|Busulfan|
40764314|NCT01904279|DRUG|Tocilizumab|Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
41293324|NCT00458250|DRUG|Cyclophosphamide|
41293325|NCT00458250|DRUG|CAMPATH-1H|
41293326|NCT00458250|DRUG|Cyclosporin A|
41293327|NCT00458250|DRUG|Methotrexate|
41293328|NCT01541592|OTHER|Dietary fat|On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of \~1 tablespoon per hour so that the total infusion time will be 6 hours.
40959789|NCT05853185|DRUG|EBRRM®|Patients in this group will receive the pulpotomy with Endo Sequence Bioceramic Root Repair (EBRRM)®.
40959790|NCT01466335|DRUG|Ronacaleret (100mg tablet)|100mg tablet
40959791|NCT01466335|DRUG|Placebo|matching placebo tablet
40959792|NCT06507787|DIAGNOSTIC_TEST|EDIT-B test|"EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact."
40959793|NCT06507787|DIAGNOSTIC_TEST|EDIT-B test (without giving result)|"EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact."
40959794|NCT04565106|DEVICE|Closed-loop control of oxygen supplementation by O2matic|Closed-loop control of oxygen supplementation to achieve a target SpO2 of 92 - 96 %
40959795|NCT06045351|DRUG|Vitamin D|"Intervention Group Initial 12 weeks;~* VD supplementation (600,000 IU I/M) once during the study period~* Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off~* Calcium 1000 mg/day"
40959796|NCT06045351|OTHER|Active Comparator|"Active Comparator (Group B; n=71):~Initial-- 12 weeks;~* Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks~* VD supplementation (600,000 IUI/M) once during the study period~* Calcium 1000 mg/day~* Standard PCOS Continued"
40959797|NCT03885258|DRUG|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
40959798|NCT06492759|RADIATION|Radiation Therapy|Undergo radiation therapy
40959799|NCT06492759|BIOLOGICAL|Pembrolizumab|Given IV
40959800|NCT06492759|DRUG|Nab-paclitaxel|Given IV
40959801|NCT06492759|DRUG|Paclitaxel|Given IV
40959802|NCT06492759|DRUG|Carboplatin|Given IV
40959803|NCT06492759|DRUG|Gemcitabine|Given IV
40959804|NCT06492759|PROCEDURE|Biopsy|Undergo biopsy
40959805|NCT06492759|PROCEDURE|Computed Tomography|Undergo CT
40959806|NCT06492759|PROCEDURE|Bone Scan|Undergo bone scan
41293329|NCT01696877|DRUG|degarelix acetate|Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
40959807|NCT06492759|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40959808|NCT06492759|OTHER|Medical Chart Review|Ancillary studies
40959809|NCT01984411|PROCEDURE|Radial Technical|Vascular Access for cardiac catheterization
40959810|NCT01984411|PROCEDURE|Femoral Technical|Vascular Access for cardiac catheterization
40959811|NCT01984411|DRUG|Omnipaque|
40959812|NCT03069443|OTHER|IHG home training|Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
40959813|NCT05089149|PROCEDURE|Clinical examination centered on congestion|Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
40959814|NCT05089149|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
40959815|NCT05089149|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
41293330|NCT01696877|DRUG|Cyclophosphamide|Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.
41293331|NCT01696877|DRUG|GVAX|GVAX is granulocytemacrophage -colony stimulating factor -secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer
40959816|NCT05089149|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
40959817|NCT05089149|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
40959818|NCT04184713|DIETARY_SUPPLEMENT|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.
40959819|NCT04184713|DIETARY_SUPPLEMENT|Control Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.
40959820|NCT03315806|OTHER|Beetroot juice|140 mL of beetroot juice cointaning approximately 9 mmol of nitrate
40959821|NCT03315806|OTHER|Placebo|140 mL of beetroot juice isent of nitrate
40959822|NCT02370134|DEVICE|Parkinson's glove|Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
40959823|NCT02370134|DEVICE|sham glove|
40959824|NCT03530878|PROCEDURE|Hip Arthroscopy|Intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH
40959825|NCT05309408|DIAGNOSTIC_TEST|Venipuncture|Venipuncture
40959826|NCT05309408|DIAGNOSTIC_TEST|Lumbar Puncture|Lumbar Puncture
40959827|NCT02829697|DRUG|Ropivacaine|Perineural injection.
40959828|NCT02144415|DRUG|EB-1020 400 mg|4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
40959829|NCT02144415|DRUG|EB-1020 800 mg|8 x EB-1020 100-mg capsules
40959830|NCT02144415|DRUG|lisdexamfetamine 150 mg|3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
40959831|NCT02144415|DRUG|d-amphetamine 40 mg|4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
40959832|NCT02144415|DRUG|Placebo|8 x matching placebo capsules
41293332|NCT01595256|BEHAVIORAL|muscular strength|12-week moderate intensity walking program
40959833|NCT01950975|BIOLOGICAL|Peripheral blood samples in EDTA tubes|
40959834|NCT01950975|PROCEDURE|Skin biopsies|
40959835|NCT03806790|DRUG|LEO 90100 foam|Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
40959836|NCT03806790|DRUG|Dovobet® ointment|Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
40959837|NCT02348905|DRUG|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
40959838|NCT02348905|DRUG|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
40959839|NCT05269823|OTHER|Ice-therapy|Ice therapy will be provided prior to intravitreal injection provision
40959840|NCT05269823|OTHER|No Ice-therapy|No additional intervention (i.e.) ice therapy will be provided prior to intravitreal injection provision
41293333|NCT03401177|DRUG|Naproxen 500 Mg|Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy
41293334|NCT03401177|DRUG|Placebo Oral Tablet|Placebo is used, to provide a control to the active group.
41456046|NCT06280794|DRUG|Steroids|Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 9 days.
41293335|NCT03401177|OTHER|Heavy resistance training|Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.
41293336|NCT04628559|DRUG|Dexmedetomidine|dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
41456047|NCT06385301|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
41456048|NCT06385301|OTHER|6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
41456049|NCT01044823|OTHER|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
40959841|NCT04758104|RADIATION|Yttrium90|Intracystic implantation of 90yttrium colloid
41293337|NCT04628559|DRUG|Ketamine|In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
41293338|NCT04628559|DRUG|Saline|Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.
41293339|NCT05228652|OTHER|Questionnaire|Three different questionnaires have been developed. They consist of multiple-choice questions and some open-ended questions.
40764315|NCT06645145|BEHAVIORAL|Orthographic facilitation|Half of participants will receive orthographic support (text support) while learning new verbs. The investigators will compare learning with and without text support to determine if this aids verb learning.
40764316|NCT03533569|PROCEDURE|Intra-articular corticosteroid injection|Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection
40764317|NCT02386072|DRUG|mirabegron|oral
41293340|NCT03415074|BEHAVIORAL|Protein restriction|In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
41293341|NCT01165203|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|intramuscular injection
41293342|NCT01165203|BIOLOGICAL|Placebo|intramuscular injection
41293343|NCT04688567|BEHAVIORAL|Patient-driven iCBT|1) Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment by the time of the randomization call. The participant can choose which of the available treatment programs (targeting anxiety, worry, stress, sleep disorders or depression) they want to undergo, how many modules in the treatment program they want to complete and in what order, for how many weeks they want to complete the treatment as well as how much telephone contact and how much written contact they want to have with their therapist.
41456050|NCT03119662|DRUG|Visipaque|100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.
41456051|NCT03119662|DRUG|Placebos|100 mL saline, followed by a 10 mL saline flush.
41456052|NCT05586386|OTHER|Cherry group|200 mL of DSC juice twice/day supplemented with 3g of DSC powder twice/day for 30 days
41456053|NCT05586386|OTHER|Placebo group|200 mL of placebo juice twice/day
41456054|NCT06265038|DEVICE|ReSpace TiCell Cage|"ReSpace TiCell Cages are anatomically shaped interbody spacer implants with curved contour. These implants intended to be inserted into the intervertebral disc space for intervertebral body fusion. The interbody spacers are designed to restore height and lordotic angle in the spine. The spacers have teeth on the endplate-engaging surfaces to provide stability, resist shear and rotational forces, and to help prevent migration of the spacer within the disc space. The open central cavity on them allows for placement of graft material allowing for subsequent bone growth through the interior of the devices.~ReSpace TiCell Cages are indicated for lumbar spine stabilization (between L.I.-S.I. segments). TLIF spine surgery will be combined with posterior fixation using pedicle screws and rods."
41456055|NCT02584166|BEHAVIORAL|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
41456056|NCT01112462|DRUG|Paracetamol 500 mg/Phenylephrine 5 mg tablets|2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period
41456057|NCT01112462|DRUG|Paracetamol 1000 mg/Phenylephrine 10 mg sachet|1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period
40764318|NCT02386072|DRUG|antimuscarinic medication|oral
40764319|NCT00002515|BIOLOGICAL|filgrastim|
40764320|NCT00002515|DRUG|carboplatin|
40764321|NCT00002515|DRUG|thiotepa|
40764322|NCT00002515|DRUG|topotecan hydrochloride|
40764323|NCT00002515|PROCEDURE|autologous bone marrow transplantation|
40764324|NCT00002515|PROCEDURE|bone marrow ablation with stem cell support|
40959842|NCT06059794|OTHER|PUQE score|The Pregnancy-Unique Quantification of Emesis (PUQE) is a scoring system to quantify the severity of nausea and vomiting of pregnancy (NVP). Based on quantification of the 3 physical symptoms of NVP (nausea, vomiting and retching)
40959843|NCT06059794|OTHER|GAD-7|"The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include not at all, several days, more than half the days and nearly every day"
40959844|NCT06557460|DEVICE|Surgical implantation of the CPCB-RPE1 implant|Surgical implantation of the CPCB-RPE1 implant
40959845|NCT02803255|DEVICE|MAHI Exo-II|
40959846|NCT05853068|DEVICE|Mechanical ventilation|Need for endotracheal intubation and invasive mechanical ventilation
40959847|NCT02422303|DRUG|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
40959848|NCT03539471|DIAGNOSTIC_TEST|interview, Tridimensional Personality Questionnaire|interview of the residents about 15-20 minutes, then use Tridimensional Personality Questionnaire
40959849|NCT00303784|DRUG|Goserelin|3.6mg implant, in pre-filled syringe
40959850|NCT00303784|DRUG|Estradiol|Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
40959851|NCT03424408|DRUG|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin 81 mg daily. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
40959852|NCT04224480|DRUG|Pembrolizumab|200mg of intravenous infusion every 3 weeks
40959853|NCT00399750|DRUG|oxaliplatin|
40959854|NCT00399750|DRUG|fluoropyrimidine|
40959855|NCT00399750|DRUG|bevacizumab|
40959856|NCT03312478|DRUG|Blood draw for insulin auto-anti body tests*|"Pharmaceutical form: N/A~Route of administration: N/A"
40959857|NCT04467606|BEHAVIORAL|a discharge planning using the strategy of motivational interviewing|The experimental group will receive a discharge planning which use the strategy of motivational interviewing. The discharge planning will be provided individually at the following time points: before discharge, on post-discharge days 3, 7, 14, 21, 28, and then each month till one year.
40959858|NCT06278350|DRUG|D-2570|"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."
41293344|NCT04688567|BEHAVIORAL|Standardized iCBT (TAU)|2) Patients who are randomized to the control condition (standardized iCBT) undergo the usual iCBT program available for anxiety disorders for 8 weeks. The psychologist provide weekly feedback on the patient's exercises and interact with the patient via secure encrypted messages in the treatment program. A follow-up telephone call takes place at the middle of treatment and at the end of the treatment.
41293345|NCT05061225|BEHAVIORAL|Physical activity counselling|Educational content on several topics regarding physical activity and its implementation in daily living
41293346|NCT00815984|PROCEDURE|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
41293347|NCT01475292|DRUG|RV568|RV568 50 ug administered via a nebuliser once daily for 14 days
41293348|NCT01475292|DRUG|RV568|RV568 100 ug administered via a nebuliser once daily for 14 days
41456058|NCT00397254|DRUG|rizatriptan|10mg ODT 27 tablets
41456059|NCT00397254|DRUG|rizatriptan|10mg ODT 9 tablets
41456060|NCT02059811|OTHER|DASH Diet|The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.
41456061|NCT02059811|OTHER|Control Diet|The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
40959859|NCT06278350|DRUG|Placebo|"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."
40959860|NCT05808114|BEHAVIORAL|Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
40959861|NCT05808114|BEHAVIORAL|TAU|Individually tailored and delivered specialized child psychiatric care
40959862|NCT04764279|DIETARY_SUPPLEMENT|OPTIFAST dietary supplement|Participants will use Optifast Nutrition Supplement as previously described
40959863|NCT04145557|DEVICE|diode laser 980nm|Procedure: Periodontal therapy with laser Scaling, root planning, oral hygiene instruction and diode laser 980nm treatment of periodontal pockets
40959864|NCT04145557|DEVICE|scaling root planing|scaling and root planing
40959865|NCT00955071|OTHER|Exercise: LVLI|low volume, low intensity
40959866|NCT00955071|OTHER|Exercise: HVLI|high volume, low intensity
40959867|NCT00955071|OTHER|Exercise: LVHI|low volume, high intensity
40959868|NCT04847856|BEHAVIORAL|Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic.|The training sessions and the IEC materials were adapted from John Hopkins University studies on self-care for diabetic patients.
40959869|NCT02241629|DRUG|placebo|placebo of levo phencynonate hydrochloride
40959870|NCT02241629|DRUG|levo phencynonate hydrochloride|levo phencynonate hydrochloride
40959871|NCT03268993|DIETARY_SUPPLEMENT|Avmacol|Avmacol is a dietary supplement available over the counter
40959872|NCT01826877|BIOLOGICAL|AdGMCAIX-transduced autologous dendritic cells|Given ID
40959873|NCT01826877|BIOLOGICAL|therapeutic autologous dendritic cells|Given ID
40959874|NCT01826877|OTHER|laboratory biomarker analysis|Correlative studies
40959875|NCT01970397|DEVICE|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
40959876|NCT01970397|DEVICE|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
40959877|NCT02694965|OTHER|observational|
41293349|NCT01475292|DRUG|Placebo|Placebo administered via a nebuliser once daily for 14 days
41293350|NCT05919056|OTHER|Frequent and automatic cardiovascular risk assessment|The 10-year cardiovascular risk scores using the 2019 World Health Organization (WHO) laboratory-based risk charts will be automatically calculated using the latest health information on an EHR-based system per month.
41456062|NCT03762954|OTHER|Neurocognitive function assessment|Neurocognitive function will be assessed via a phone battery derived from standard cognitive tests proven feasible and valid to assess memory, attention, reasoning, and executive functioning. Functional status will also be assessed via phone. The duration of time required for the patient to complete telephone interview for neurocognitive and functional assessment will be approximately 45 minutes per time point.
40764325|NCT00002515|PROCEDURE|in vitro-treated bone marrow transplantation|
40959878|NCT05499000|BEHAVIORAL|Emotional freedom technique|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the 2nd session, post-test data will be taken with SUE, PMSS."
40959879|NCT02610725|OTHER|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
40959880|NCT03408483|DRUG|Quadratus Lumborum Block (QLB)|Under ultrasound guidance, the needle will be advanced to the posterior border of the quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots, ensuring proper placement of needle tip and appropriate spread of local anesthetic.
40959881|NCT03408483|DRUG|Standard of Care|This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
40959882|NCT06261502|DRUG|CBD Oral Solution|Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.
40959883|NCT06261502|DRUG|Placebo|Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.
40959884|NCT04563611|OTHER|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
40959885|NCT04563611|OTHER|Askling L-Protocol|he protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening. Pain is not allowed to be provoked when performing the exercises.
40959886|NCT04563611|OTHER|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. Hands and arms will be positioned on the chest and the individuals will be held by the physiotherapist at their heels. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed.
40959887|NCT04563611|OTHER|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
41456063|NCT04097444|BIOLOGICAL|Bevacizumab|Given IV
40764326|NCT06642012|OTHER|Cash only|Households received 1 mobile cash transfer per month for 6 months.
40764327|NCT06642012|OTHER|Cash + Social Behavior Change Communication|Households received 1 mobile cash transfer per month for 6 months but mothers also received an SBCC package that included interpersonal communication (1:1 consultations for mothers), bi-monthly group sessions on key health and nutrition topics, and cooking demonstrations.
40764328|NCT06642012|OTHER|Cash + top-up cash|Households received 1 mobile cash transfer per month for 6 months, receiving the base cash amount plus an additional cash top-up amount.
40764329|NCT06149559|DRUG|rozanolixizumab|rozanolixizumab solution for injection
40959888|NCT06556615|BEHAVIORAL|Interview|Interviews, presentation of questionnaires
40959889|NCT04568902|DRUG|H3B-6545|H3B-6545 oral tablets.
40959890|NCT04568902|DRUG|Antihistamine|Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.
40959891|NCT00144391|DRUG|Transdermal Testosterone gel|2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
40959892|NCT00935363|DRUG|glyburide|single oral dose
40959893|NCT00935363|DRUG|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
40959894|NCT00935363|DRUG|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
40959895|NCT00935363|DRUG|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
40959896|NCT03118635|BEHAVIORAL|Intervention|Physical activity programming in accordance with the SPARK - After School curriculum as well as engaging activities provided by local community partners. The intervention proceeded the SFSP lunch meal service, so that children received approximately three hours of physical activity programming daily.
40764330|NCT06638580|DIAGNOSTIC_TEST|Clinical Periodontal Measurements (plaque index, gingival index, bleeding index, clinical attachment level), Optical Coherence Tomographic Measurements, Serum IL1-β, TNF-α, IL-10, TAS, TOS, OSİ levels|"Probing pocket depth (PPD) was measured as the distance between the deepest point of the sulcus (or pocket) and the gingival margin, and clinical attachment level (CAL) was measured as the distance between the base of the pocket and the cementoenamel junction. PPD and CAL were measured at six different points (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) in each tooth, and other index scores were taken at four different points (mesial, distal, vestibular and palatinal).~Serum IL1-β, TNF-α, and IL-10 levels were measured via immunosorbent assay method using human-specific kits according to the kit manufacturer's instructions.~Serum total antioxidant status (TAS) and total oxidant status (TOS) levels were mea-sured by a spectrophotometric method using specific kits.~Retinal and choroidal imaging and measurements were performed with optical coherence tomography (SS-OCT) with swept-source (SS) technology and non-invasive OCT angiography."
40764331|NCT05931718|BIOLOGICAL|cytokine essays|evaluation of immunomodulatory cytokines by ELISA kits on peripheral blood samples
40764332|NCT05931718|BIOLOGICAL|NGS|evaluation of somatic mutations commonly associated with myeloid neoplasm and immunodeficiencies by next generation sequencing on peripheral blood samples
40764333|NCT05931718|BIOLOGICAL|Fecal microbiome|evaluation of fecal microbiome on fecal samples
40764334|NCT05931718|DRUG|Erythropoietin|evaluation of recombinant erythropoietin use, safety and efficacy in patients with autoimmune hemolytic anemia according to clinical practice
40764335|NCT05931718|DRUG|Luspatercept|evaluation of cytokine levels, molecular profile and bone marrow microenvironment by single cell analysis in patients treated with luspatercept according to clinical practice
40764336|NCT05931718|DRUG|Thrombopoietin Receptor Agonist|evaluation of TPO-RA use, safety and efficacy in patients with ITP according to clinical practice
41293351|NCT05919056|OTHER|Dynamic risk monitoring|High-risk individuals will be reassessed by the Dynamic Risk-based Early wArning and Monitoring (DREAM) system to obtain the short-term risk. The DREAM system will send a text message about advice to the high-risk individual every month. The text message includes information on the health status (e.g., current cardiovascular risk, level of blood pressure and lipid) and real-time warning messages (e.g., high short-term risk).
40764337|NCT05931718|DRUG|G-CSF|evaluation of G-CSF use, safety and efficacy in patients with CIN/AIN according to clinical practice
40764338|NCT05863455|DRUG|mild sedation and analgesia|Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation
40764339|NCT05863455|DRUG|control|ntravenous injection of an equivalent volume of saline before radial artery cannulation.
40764340|NCT06450314|DRUG|Discontinuation of the anti-HER2 maintenance therapy|Heroes is a de-escalation study. Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line setting for their HER2-positive metastatic breast cancer with complete response or partial response at last radiological assessment. Patients with ctDNA negative test at baseline will stop their anti-HER2 targeted therapy during the study
40764341|NCT06450314|DEVICE|Monitoring with signatera test|"ctDNA test will be performed at 1.5 month after inclusion and every 3 months during 2 years.~Note: For the ctDNA negative patients who become ctDNA positive: ctDNA test will be performed once, 3 months after restarting treatment (+/-1 week)."
41293352|NCT05919056|OTHER|Regular GP visits|"The general practitioners will communicate with the participants based on the information automatically generated from the DREAM system every three months: each participant's cardiovascular risk score, health status (e.g., diabetes mellitus and/or hypertension), and Chinese guidelines-based recommendations (e.g., for the management of dyslipidemia, to provide clear treatment targets for high-risk participants)."
40959897|NCT04571879|DRUG|Nebulized Lidocaine|Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
40959898|NCT04571879|DRUG|Intranasal Midazolam|Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion
40959899|NCT04571879|OTHER|Placebo|Nebulized normal saline and intranasal normal sline
41293353|NCT01198418|BEHAVIORAL|Experimental|Internet-based intervention that assesses transmission risk and provides prevention messages
41293354|NCT03445039|DEVICE|traditional TSFE|The TSFE procedure is performed by osteotomes (Straumann AG, Basel, Switzland) and mallet as the traditional ways.
40764342|NCT03288935|BEHAVIORAL|TICM|The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R\&P service period (i.e., 60 days).
40764343|NCT03288935|BEHAVIORAL|TICO|The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation \& resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.
40959900|NCT01890369|DIETARY_SUPPLEMENT|15g Mixed Essential Amino Acids|Dissolved in 250ml water.
40959901|NCT01890369|DIETARY_SUPPLEMENT|3g Leucine|Dissolved in 250ml water.
40959902|NCT01890369|DIETARY_SUPPLEMENT|15g Mixed Essential Amino Acid REFEED|Dissolved in 250ml water.
40959903|NCT03050099|OTHER|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
40959904|NCT02508857|DRUG|Ketorolac|Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
40959905|NCT02508857|DRUG|Magnesium|Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
40959906|NCT02508857|DRUG|Saline solution|intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
40959907|NCT03105583|DRUG|Medication use during pregnancy|
40959908|NCT03105583|DIETARY_SUPPLEMENT|Supplement use during pregnancy|
41293355|NCT03445039|PROCEDURE|bone grafting materials|The bone substitute is placed into the siuns under the membrane before the implant placement
41456064|NCT04097444|DRUG|5-fluorouracil|Given IV
40959909|NCT03105583|OTHER|Vitamin status of a pregnant woman|Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
40959910|NCT05305820|BEHAVIORAL|Exercise|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing treatment and for a six-week period when deemed fit post-surgery.
40959911|NCT05305820|BEHAVIORAL|Nutrition|Participants will be screened for their nutritional health and tailored advice and education will be provided on an individualised basis. An online dietary recall tool will be used to track patients' dietary habits. This will occur from diagnosis until point of surgery and recommence for 6 weeks post-surgery once deemed physically fit.
40959912|NCT04505462|OTHER|Therapeutic diet|A special healthy diet for dialysis patients
40959913|NCT01352104|BEHAVIORAL|PEP-TE|"PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the coercive interaction process (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses."
40959914|NCT01397162|DRUG|Fluticasone propionate|Fluticasone propionate
40959915|NCT01397162|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
40959916|NCT01397162|DRUG|BI 54903|BI 54903
40959917|NCT05695352|DRUG|Levonorgestrel 1.5mg|oral synthetic progesterone agonist
40959918|NCT05695352|DRUG|Meloxicam 15 mg|Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes
40959919|NCT05695352|OTHER|Placebo|Each tablet contains Calcium Carbonate 1000 mg
41293356|NCT03445039|DEVICE|TSFE by DASK drills|The TSFE procedure is performed by DASK(Dentium Advanced Surgical Kits) drills (Dentium, Korea), the residual cortical plate of the sinus floor is grinded by the drills.
41293357|NCT03445039|PROCEDURE|without bone grafting materials|The bone substitute will not be placed into the sinus before the implant placement.
41293358|NCT06358885|OTHER|Facilitation (FAC)|The facilitation approach will use a flexible clinic level implementation strategy that helps clinics to address common barriers, such as counselor skills, competing priorities, and resource deficits.
41456065|NCT04097444|DRUG|Leucovorin calcium|Given IV
41456066|NCT04097444|DRUG|Irinotecan hydrochloride|Given IV
41456067|NCT04097444|DRUG|Oxaliplatin|Given IV
41456068|NCT04097444|DRUG|Capecitabine|Given PO
40959920|NCT06144281|BEHAVIORAL|Nudge for PHPC NP Referral|The attending and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for home palliative care services upon hospital discharge will be asked to refer their patient for these services.
40764344|NCT06645405|BEHAVIORAL|AI algorithm|Artificial intelligence algorithms in the automated reconstruction of intracranial large vessel occlusion (LVO)
40764345|NCT04208178|DRUG|Alpelisib|Alpelisib orally taken - continuous once daily, in a 21-day cycle.
41456069|NCT05662605|DEVICE|W-PPMA|"W-PPMA is a digital health tool designed specifically for the postpartum experience and is accessed through a mobile application which delivers evidence-based therapy through brief conversations with a fully automated relational agent called Woebot."
40764346|NCT04208178|DRUG|Alpelisib matching Placebo|Alpelisib matching placebo orally taken - continuous once daily, in a 21-day cycle
41456070|NCT01148225|DRUG|adalimumab|Adalimumab, pre-filled syringe, administered by SC injection
41456071|NCT05014880|BEHAVIORAL|ICR (Intensive Cardiac Rehabilitation)|Participants in this arm will not have to adopt a 10-hour eating window while taking part in UCSD's 9-week ICR program.
40764347|NCT04208178|DRUG|Trastuzumab|Trastuzumab 6mg/kg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
40764348|NCT04208178|DRUG|Pertuzumab|Pertuzumab 420 mg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
40764349|NCT06254482|DRUG|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
40764350|NCT06644248|DIAGNOSTIC_TEST|Colposcopy|The intervention involves the use of colposcopy, a diagnostic procedure to visually examine the cervix using a colposcope. The procedure includes the application of saline, acetic acid, and iodine solutions to enhance the visualization of cervical tissues and identify abnormalities. The dosage form includes applying these solutions directly to the cervical area. The frequency of the intervention is typically a single session per patient, with the duration of the procedure lasting approximately 10-15 minutes. This study aims to utilize an AI model to analyze the colposcopic images obtained during the procedure to improve the accuracy and efficiency of cervical cancer detection.
40764351|NCT03913637|BEHAVIORAL|Strategy Training|Occupational therapists deliver Strategy Training to older adults virtually. Strategy training optimizes engagement in meaningful daily activities through generating self-selected goals, monitoring daily activities, scheduling activities, and problem-solving solutions to barriers experienced when engaging in activities.
40764352|NCT03913637|OTHER|Enhanced Usual Care|In this comparison condition, usual care will be enhanced by connecting older adults with MCI to resources available to meet their needs, and notify appropriate physicians when required. Enhanced Usual Care provides a usual care comparison while providing the participants with close monitoring of changes in symptoms.
41456072|NCT05014880|BEHAVIORAL|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|Participants in this arm will adhere to a daily, consistent 10-hour eating window while undergoing UCSD's 9-week ICR program to see if there is an improvement on cardiometabolic parameters.
40764353|NCT03474107|DRUG|Enfortumab Vedotin|Intravenous infusion
40764354|NCT03474107|DRUG|Docetaxel|Intravenous infusion
41456073|NCT02231957|OTHER|educational text message reminders|
40764355|NCT03474107|DRUG|Vinflunine|Intravenous infusion
40764356|NCT03474107|DRUG|Paclitaxel|Intravenous infusion
40764357|NCT06199882|DRUG|SBRT Sequential Surufatinib Combined With Immunotherapy|"1. SBRT :~   Bioequivalent total dose \> 75Gy, completed within 2 weeks (once daily, 5 times a week).~2. Drug treatment (every 3 weeks is a treatment cycle) :~1) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle."
40764358|NCT06641544|DRUG|Inetetamab|Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.
40959921|NCT00043901|DRUG|lamotrigine|
40959922|NCT01468363|DEVICE|Dry weight adjustment|Dry weight adjustment according to BCM results
41456074|NCT02231957|OTHER|conventional text message reminders|
41456075|NCT05041426|DRUG|Letermovir|Participants who are CMV R+ will receive LET prophylaxis for 6 months, and participants who are CMV D+/R- will receive LET prophylaxis for 12 months. The duration of prophylaxis is per current standard of care. LET will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If LET is co-administered with cyclosporin A (CsA), the dosage of LET should be decreased to 240 mg once daily. All patients will be followed for 12 weeks after completion of LET for the occurrence of CMV infection or disease after prophylaxis. Participants on this protocol will receive acyclovir 400 mg orally BID for the duration of LET therapy for herpes simplex virus and varicella zoster virus prophylaxis.
40959923|NCT04533373|PROCEDURE|DIEP Flap Neurotization|"We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new source) that is being transferred and attaching it to a nerve in the chest wall."
40959924|NCT01704378|DRUG|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
40959925|NCT02846584|BIOLOGICAL|CD19 or CD20 CAR T cells briging HSCT|Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
40959926|NCT05711784|OTHER|Phaseolean (White Kidney Bean Standardized Extract) 1500 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
40959927|NCT05711784|OTHER|Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
40959928|NCT05711784|OTHER|Placebo (Resistant Dextrin) Capsules|Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
40959929|NCT02655796|DEVICE|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
40959930|NCT05133232|DEVICE|SynPhNe physio-neuro platform|"The SynPhNe device training protocol lasting approximately 60 mins:~1. Preparation for setup (\~5 mins)~2. Instruction video led warm up with active single and multi-joint movements - (\~20 mins): • Wrist extension and flexion• Fingers extension and flexion• Arm pronation and supination• Open grasp and close grasp • Open pinch and close pinch• Pronate and close grasp/ supinate and open grasp~3. Rest break - (\~5 mins)~4. Video led task practice as per the tasks below (any 4 tasks only) - (\~30 mins) • Grasp, lift and transfer water bottle using cylindrical grasp• Grasp lift and transfer pen using pinch grip• Flip pages of a book using lateral pinch grip• Use chopsticks to lift, transfer and place a small object• grasp doorknob and turn clockwise/anticlockwise, spoon scoop to pick up macaroni, open/ close a cylindrical jar, put object in pouch while holding it open and close it, fold/crease/tear a A4 size paper or fold handkerchief, reach a basket at different heights with an object."
40959931|NCT00094705|BIOLOGICAL|rDEN2/4delta30(ME) Vaccine|Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
40959932|NCT00094705|BIOLOGICAL|Placebo|Placebo for rDEN2/4delta30(ME) vaccine
40959933|NCT01232595|DRUG|LFF571|
40959934|NCT01232595|DRUG|Vancomycin (POC)|
40959935|NCT04070885|PROCEDURE|Blood sample|A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.
40959936|NCT04070885|PROCEDURE|Urine sample|The urine will be taken from three 15 ml tubes.
40959937|NCT02085122|OTHER|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
40959938|NCT00030290|PROCEDURE|high-intensity focused ultrasound ablation|
40959939|NCT01099137|DRUG|Vildagliptin|Vildagliptin 50mg twice a day, orally, for 24 weeks
40959940|NCT01099137|DRUG|Sulphonylurea dose-up|glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
40959941|NCT03974191|OTHER|Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.|13-year prospective longitudinal cohort study
40959942|NCT05852015|BEHAVIORAL|Treatment-as-Usual (TAU)|TAU consists of weekly outpatient-based group therapy for substance use disorder
40959943|NCT05852015|BEHAVIORAL|Digital Mindfulness Treatment|The digital mindfulness-based treatment is a multimedia app-based program teaching mindfulness skills to facilitate recovery from substance use disorder
40959944|NCT04790422|DIETARY_SUPPLEMENT|Dietary fiber supplement|Dietary fiber
40959945|NCT04790422|DIETARY_SUPPLEMENT|Caseine protein hydrolisate|Dietary supplement
40959946|NCT04790422|DIETARY_SUPPLEMENT|Maltrodextrine|Placebo comparator
40959947|NCT01468883|PROCEDURE|M|Modified radical mastectomy
40764359|NCT06644092|OTHER|Investigation of the Effectiveness of Physiotherapy and Rehabilitation After Osteochondral Allograft Transplantation Operation|The treatment protocol to be applied to the patients after surgery was determined. The protocol includes; cold application, game ready device application, CPM device application, patellar mobilization, soft tissue mobilization application, TENS, conventional TENS and NMES application, ultrasound application, stretching exercises, strengthening exercises, mobilization exercises, balance and proprioception exercises, walking training and kinesio taping.
40959948|NCT01468883|RADIATION|X|Excisional biopsy plus radiation
40959949|NCT02711592|GENETIC|Genetic Panel for Analgesics|All patients will receive genetic test panel to determine individualized optimal pain management following Total Knee Arthroplasty.
40959950|NCT05871775|BEHAVIORAL|Personalized exercise|After selective functional movement evaluation, customized interventions for each patient
40959951|NCT05871775|BEHAVIORAL|Stabilization exercise|Neck stabilization exercise and sensorimotor program
40959952|NCT05871775|BEHAVIORAL|General exercise|General mobility exercise and strength exercise program
40959953|NCT00273546|DRUG|XRP6976 (Docetaxel/Taxotere)|
40959954|NCT00082979|GENETIC|cytogenetic analysis|
40959955|NCT00082979|GENETIC|proteomic profiling|
40959956|NCT00082979|OTHER|cytology specimen collection procedure|
40959957|NCT00082979|OTHER|immunohistochemistry staining method|
40959958|NCT00082979|OTHER|laboratory biomarker analysis|
40959959|NCT00082979|PROCEDURE|breast duct lavage|
40959960|NCT00363883|DRUG|vorinostat|Given orally
40959961|NCT00363883|OTHER|laboratory biomarker analysis|Correlative studies
40959962|NCT03928353|DRUG|PB2452 Infusion|30 minute - 24 hour infusion
40959963|NCT03928353|DRUG|Placebo - Sodium Chloride|30 minute - 24 hour infusion
40959964|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo
40959965|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagrelor 180 mg 24 hours following PB2452 or Placebo
40959966|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo
40959967|NCT03928353|DRUG|PB2452 Infusion|30 minute - 16 hour infusion
40959968|NCT03928353|DRUG|Placebo - Sodium Chloride|Placebo - Sodium Chloride
40959969|NCT05806073|PROCEDURE|Elective neck dissection|patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
40959970|NCT05806073|PROCEDURE|Therapeutic neck dissection|patient underwent Therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
40959971|NCT05281211|DIETARY_SUPPLEMENT|Nutrition|6 weeks nutrition implementation in the form of branched chain amino acids and immune-system boosters twice daily for 4 weeks and once daily for 2 weeks
41293359|NCT06358885|BEHAVIORAL|Experiential Brief Alcohol Intervention (EBAI)|Clinic staff will be offered the experiential BAI prior to implementation. The BAI comprises 2 in-person sessions and 2 booster phone sessions. Clinic staff responsible for delivering the BAI to PWH participants will be offered 3 additional consolidation sessions to integrate their experiences receiving the BAI with their delivery of the BAI.
41293360|NCT01062399|DRUG|concurrent RAD001 10 mg/day|During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
41293361|NCT01062399|DRUG|concurrent temozolomide|During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
40959972|NCT05281211|BEHAVIORAL|Exercise|6 weeks exercise 30 minutes' walk/day or 2000 extra steps daily
40959973|NCT06405451|OTHER|Conventional treatment|Conventional treatment to improve trunk control and stability for 30 minutes, twice a day, and six times per week.
41293362|NCT01062399|RADIATION|Radiation therapy|Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
41293363|NCT01062399|DRUG|concurrent RAD001 2.5 mg/day|During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
40959974|NCT06405451|OTHER|Experimental treatment|"Respiratory muscle training will be conducted using the Threshold IMT-Philips inspiratory training device and the Threshold PEP expiratory training device, both from Respironics®. Participants will be comfortably seated in a chair with their feet on the ground, without back support, and with the trunk at a 90° angle to the hips. A conventional nasal clip will be used to prevent air leaks. During forced expiratory training, participants will use the ThresholdPEP® with a customized mouthpiece and perform forced expiration through the resistance device. Inspiratory muscle training will follow the same procedure using the Threshold IMT® (45).~Both inspiratory and expiratory trainings will be repeated 10-15 times, 5 sets for 20 minutes in one session, with a rest time of 30-60 seconds between each set."
40764360|NCT05634811|BIOLOGICAL|VLA15|6-valent OspA-based Lyme disease vaccine
40959975|NCT03569618|DEVICE|Tablet-based Game|Tablet-based game aimed at improving processing speed and attention.
41293364|NCT01062399|DRUG|concurrent RAD001 5 mg/day|During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
41293365|NCT01062399|DRUG|post-radiation RAD001 10 mg/day|Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
40959976|NCT03625622|DRUG|AR1001|AR1001 Active Oral Tablet
40959977|NCT03625622|DRUG|Placebo|Placebo Oral Tablet
40959978|NCT03404115|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.
40959979|NCT03404115|DRUG|Reproxalap Ophthalmic Solution (0.1%)|Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.
40959980|NCT03404115|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered for approximately twelve weeks.
41293366|NCT01062399|DRUG|post-radiation temozolomide|Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
41293367|NCT04046484|DRUG|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
41456076|NCT05041426|DRUG|Valganciclovir|Historical controls will have received CMV prophylaxis with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
41456077|NCT02093962|DRUG|TH-302 combination with pemetrexed|"400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration."
40959981|NCT00603174|DEVICE|neurally adjusted ventilatory assist (NAVA)|Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
40959982|NCT04821115|DEVICE|Low intensity choc waves therapy (active applicator)|At each of the 4 sessions, 4000 shockwaves will be delivered at level 8 (EFD = 0.133 mJ/mm2), over a period of 15 to 20 minutes. The probe will be applied directly to the plaque, on the flaccid penis. The device will stop automatically after the 4000 shock waves.
40764361|NCT05634811|OTHER|Normal Saline|0.9% sodium chloride solution for injection
40959983|NCT04821115|DEVICE|Sham (sham applicator)|At each of the 4 sessions, a sham applicator will be used. The sham applicator has an internal foam pad that disperses the shockwave energy, but is not visible from the outside. The sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted.
40959984|NCT06557083|BEHAVIORAL|Polyvagal Breathing Exercises|Breathing exercises provided include, square breathing, modified Qigong breathing, and three step breathing
40959985|NCT06557083|OTHER|No Intervention|The control group will not perform any intervention.
40959986|NCT03295084|DRUG|Irinotecan|Dose Escalation
40959987|NCT03295084|DRUG|Capecitabine|Dose Escalation
40959988|NCT04527315|OTHER|Questionnaires|Various questionnaires will be used to assess short and long-term impacts of depression, anxiety, and other indicators of overall mental health and quality of life
40959989|NCT03750708|DEVICE|Ara® KOLIBREE tooth brush|"Use of the Ara® KOLIBREE tooth brush by the child one month before alveolar bone graft up to the time of surgery.~The Ara® KOLIBREE tooth brush saves brush tracking data."
40959990|NCT01721993|DRUG|T121|
40959991|NCT01721993|DRUG|Zoledronic acid|
40959992|NCT05113758|DIAGNOSTIC_TEST|muscle ultrasound|All participants will undergo a muscle ultrasound on admission and at discharge
40959993|NCT05497609|OTHER|no intervention. Care as ususal|No intervention
40959994|NCT05546502|BIOLOGICAL|SARS-CoV-2 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
40959995|NCT05546502|BIOLOGICAL|Active Comparator|Covovax
40959996|NCT04808999|DRUG|Pembrolizumab Injection|200 mg IV infusion
40959997|NCT02343679|DRUG|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
40959998|NCT01397890|DRUG|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
40959999|NCT01397890|DRUG|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
40960000|NCT02485197|OTHER|7 continuous days of aerobic training|For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
40960001|NCT02236975|DEVICE|BuMA Supreme Biodegradable drug coating coronary stent system|
40960002|NCT02236975|DEVICE|Resolute Integrity durable polymer stent system|
40960003|NCT03935360|OTHER|Oakland-Jairath Risk Score|Oakland and Jairath developed a clinical prediction rule for safe discharge among patients with LGIB using data from their UK National Audit. They defined safe discharge as the absence of rebleeding, blood transfusion, need for endoscopic/radiologic/surgical intervention for hemostasis, readmission with LGIB, and death and developed a seven variable risk score: age, sex, previous history of LGIB admission, presence of blood on digital rectal exam, heart rate, systolic blood pressure, and hemoglobin. Using a cut-off score ≤8, they reported excellent discrimination (AUC 0.84, 95% CI 0.82-0.86), good calibration, and a 95% probability of safe discharge.
40960004|NCT01402011|PROCEDURE|25% dextrose in shoulder entheses|injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
40960005|NCT01402011|PROCEDURE|.1% lidocaine in shoulder entheses|injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
40960006|NCT01402011|PROCEDURE|.1% lidocaine subcu. above shouldr enth.|injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
40960007|NCT02657369|DRUG|Lenvatinib 24 mg|
40960008|NCT02957669|BEHAVIORAL|Practice Self-Regulation|PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
40960009|NCT02957669|BEHAVIORAL|Therapy Practice Group|Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
40960010|NCT03642457|DRUG|Bupivacaine|20 cc 0.5%
41136072|NCT00777894|RADIATION|3-dimensional conformal radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
40960011|NCT03642457|DRUG|Bupivacaine liposome|133mg liposomal bupivacaine
41293368|NCT04046484|DRUG|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
40960012|NCT02519257|PROCEDURE|CAD|Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
41293369|NCT00682825|BEHAVIORAL|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
40960013|NCT02519257|PROCEDURE|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
40960014|NCT04669652|DEVICE|Piezo-ICSI|During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjection of a sperm with less psychical stress applied on the oocytes than by the conventional technique.
40960015|NCT04843020|DRUG|ION 682884|Subcutaneous injection every month
40960016|NCT04636190|DEVICE|Triathlon All-Polyethylene Tibia Knee|Triathlon All-Polyethylene Tibia Knee is an all polyethylene resurfacing knee device using either a condylar stabilizing (CS) and posterior stabilizing (PS) device.
40960017|NCT06338774|BEHAVIORAL|Cognitive training|Computerized cognitive training completed on any computer or tablet with internet
41293370|NCT00682825|BEHAVIORAL|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
40960018|NCT06338774|BEHAVIORAL|Exercise|Aerobic exercise intervention with structured exercise sessions prescribed by a study exercise specialist
40960019|NCT04682028|OTHER|professional care|The trained nurses provide professional care for the patients.
40960020|NCT04682028|OTHER|coventional care|nurses provide coventional care for the patients.
40960021|NCT02605824|DRUG|n-acetylcystine|NAC is a mucolytic drug.
40960022|NCT02605824|DRUG|0.9% saline|Normal saline is a placebo agent.
40960023|NCT04456959|DRUG|Inotuzumab Ozogamicin|Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.
41293371|NCT00650429|DRUG|Ziprasidone|IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
41293372|NCT05031325|DEVICE|Endoscopic submucosal dissection with Purastat|Purastat (peptidic gel) application
41293373|NCT03468023|PROCEDURE|Short arm cast|Application of a below-elbow cast
41293374|NCT03468023|PROCEDURE|Long arm cast|Application of an above-elbow cast
41456078|NCT02093962|DRUG|Matched placebo in combination with pemetrexed|"Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration."
41456079|NCT05456451|DEVICE|noninvasive vagus nerve srimulation|Non-invasive Vagus nerve stimulation (VNS) stimulates the vagus nerve through the ear via a headset. VNS is a non-pharmacological intervention with the potential to improve walking, cognition, fatigue, and autonomic functions in the treatment of Parkinson's disease.
41456080|NCT00054834|DRUG|hLL2 (epratuzumab)|
41456081|NCT02201316|DRUG|Reference mosapride citrate (GASMOTIN)|Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
41456082|NCT02201316|DRUG|GR107719B (Formulation 1)|GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
41456083|NCT02201316|DRUG|GR107719B (Formulation 2)|GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
41456084|NCT01296607|DRUG|Urocortin 2|"Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
41466472|NCT05511649|DEVICE|continuous electronic monitor|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital, KaiFeng Central Hospital, and the First Affiliated Hospital of Zhengzhou University will receive 24-hour continuous cardiac monitoring until discharge.
41466473|NCT01884064|DEVICE|rTMS|rTMS
41466474|NCT01884064|DEVICE|Sham rTMS|Sham rTMS
41466475|NCT01151319|BIOLOGICAL|ChAdV63.HIVconsv low dose.|Attenuated chimp adenovirus. 5x10\^9 virus particles.
40960024|NCT01899261|RADIATION|Stereotactic Radiosurgery|Undergo SBRT
40960025|NCT02993757|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC injection at Day 0, Month 6 and 12, respectively.
40960026|NCT02993757|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC injection at Month 1, 7 and 13, respectively.
40960027|NCT02993757|BIOLOGICAL|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, IM injection at Day 0 and Month 6, respectively.
40960028|NCT01219569|DRUG|propofol|Propofol infusion 120 and 160 mcg/kg/min in random sequence during the operative procedure
40960029|NCT01219569|DRUG|Sevoflurane|sevoflurane 1.5% and 2.5% end tidal in random sequence
40960030|NCT04600375|BEHAVIORAL|Verbal consultation|Verbal consultation only without written information before receiving written action plan
40960031|NCT04600375|BEHAVIORAL|Written Action Plan|Written handout of treatment plan and disease management strategies
40960032|NCT01077570|DRUG|repaglinide|Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
40960033|NCT04837261|DRUG|Propranolol|3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
40960034|NCT04837261|DRUG|Flecainide|80 mg/m2/d
40960035|NCT04837261|DRUG|Amiodarone|Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
40960036|NCT03797014|DRUG|B/F/TAF|Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
40960037|NCT00659997|DRUG|Albendazole|Single oral dose of 400mg
40960038|NCT00659997|DRUG|Levamisole|Single oral dose of 2.5mg/kg
40960039|NCT03120000|DRUG|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
41466476|NCT01151319|BIOLOGICAL|ChAdV63.HIVconsv high dose.|Attenuated chimp adenovirus at 5x10\^10 virus particles.
40960040|NCT01642979|DRUG|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
40960041|NCT01642979|DRUG|cyclosporin A+Glucocorticoids|cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
40960042|NCT01642979|DRUG|Glucocorticoids|Glucocorticoids 0.5-1mg/kg every day(prednisone)
40960043|NCT05530759|PROCEDURE|Biopsy Specimen|Undergo collection of tissue samples
40960044|NCT05530759|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal swab samples
40960045|NCT05530759|PROCEDURE|Biospecimen Collection|Undergo collection of archived tissue and blood samples
40960046|NCT05530759|OTHER|Medical Chart Review|Review of medical record
40960047|NCT02900339|DEVICE|Magnetic Resonance Imaging|MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
40960048|NCT05163977|PROCEDURE|Blumgart Anastomosis|The anti-mesenteric border of the jejunal loop proximal to the hepatico-jejunostomy is brought against the pancreatic stump. With the pancreatic stump retracted by the stay sutures, the transected end of pancreatic duct is first identified and secured by means of a blunt tipped probe. Each trans-pancreatic, suture was performed using a single Polydioxanone (PDS) 3 -0 blunt needle. We usually take 4 sutures, 2 on each side of the duct. The process is repeated in the same manner with the remaining sutures which are tightened at the end to approximate the jejunum loop to the stump. A small stab incision is then made at the anti-mesenteric border of the jejunum and a duct to mucosa anastomosis is constructed using an interrupted 5-0 Prolene. The process is completed by placing each of the retained needles through the seromuscular layer of the anterior jejunal wall and each knot is tied over the jejunal wall which is then warped over the cut end of the stump
40960049|NCT05163977|PROCEDURE|Cattell Warren Anastomosis|It is a two layer, interrupted, end to side pancreatico-jejunostomy. First an interrupted sutures between the posterior capsule and the seromuscular layer of the jejunum was constructed using PDS 3-0 , then a duct to mucosa interrupted sutures were taken using PDS 5-0 and finally interrupted sutures between the anterior capsule and the jejunum . The main difference here is that the sutures are taken in a conventional way which is tangential to the pancreatic capsule and parenchyma
40960050|NCT06135753|OTHER|psychosomatic intervention based on cognitive restructuring.|Participants will receive information on psychosomatic phenomena and over-listening of somatic manifestations (Session 1), interpretation and possible catastrophization of somatic manifestations even when they might be well-known health problems or potential physiological or para-physiological manifestations (Session 2), pain-proneness (Session 3) and mental pain and psychological distress in somatizers (Session 4). The second part of each session will be devoted to group cognitive restructuring, thus participants will be stimulated in verifying how the phenomena illustrated are in their lives and how they can be differently conceptualized in order to be less intrusive and less able to reduce their own functioning.
40960051|NCT06135753|BEHAVIORAL|Control condition|The control condition will include 4 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health.
41466477|NCT01151319|BIOLOGICAL|pSG2.HIVconsv|DNA at 4mg per dose.
41466478|NCT01151319|BIOLOGICAL|MVA.HIVconsv|Attenuated poxvirus at 4x10\^8 plaque forming units per dose.
41466479|NCT01151319|OTHER|Placebo|Phosphate buffered saline
41466480|NCT04042649|BEHAVIORAL|environmental intervention|provide environmental intervention (help sleep cycle, provide comfortable environment)
41466481|NCT03436953|DRUG|CX-8998|T-type calcium channel blocker
41466482|NCT03436953|DRUG|Placebo|Placebo comparator
41466483|NCT01543867|DRUG|somatropin|Prescribed at the discretion of the treating physician according to product labelling
40764362|NCT04129021|DEVICE|High-resolution retinal imaging through adaptive optics|The protocol consists of performing retinal imaging using full-field optical coherence tomography. The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
41293375|NCT00844298|DRUG|Nilotinib+mVPD|"1. Induction:~   * Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~  * Vincristine 2 mg iv push (d1, 8, 15, 22)~  * Prednisolone 60 mg/m2/day po (d1-28)~  * Nilotinib 400mg bid/d (d8-)~2. Consolidation A (cycle1)~   * Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~  * Vincristine 2 mg iv (d1, 8)~  * Prednisolone 60 mg/m2/day po (d1-14)~  * Nilotinib 400mg bid/d~3. Consolidation B (cycles 2\&4)~   * Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~  * Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~  * Nilotinib 400mg bid/d~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~  * Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~  * Nilotinib 400mg bid/d~5. Maintenance~   ◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~6. Consider alloHCT"
41293376|NCT00467909|BEHAVIORAL|micronutrients|
40960052|NCT06135753|OTHER|Experimental and control condition: Museum therapy|"Session 5-6-7: preselected painting works from the Uffizi Galleries (Florence) will be presented to the participants in order to trigger reflections and emotional responses on specific pain related topics. Session 8: visit the Galleria di Arte Moderna at Palazzo Pitti, in person. Each session will be aimed at facilitating emotional expressions and partecipants' behavioral activation and identifying thoughts associated with those emotions and, if appropriate, remodulating them in a functional way (cognitive restructuring).~Session 9: share the experience of the previous meetings and to recap strategies and skills which could be implemented in FM participants' daily life to cope with their illness."
41293377|NCT00915967|DRUG|Vancomycin|Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
41293378|NCT00915967|DRUG|Placebo (Saline Solution)|Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
40960053|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)|100 mg subcutaneous (s.c) once
40960054|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)|200 mg subcutaneous (s.c) once
40960055|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)|300 mg subcutaneous (s.c) once
40960056|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
41293379|NCT05372575|BIOLOGICAL|PCV13 PAC study|To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia.
41293380|NCT00292292|DEVICE|Lumbar Artificial Disc|Insertion of the Kineflex Lumbar ArtificialDisc
41293381|NCT00292292|DEVICE|Charite Artificial Disc|Insertion of the Charite
41293382|NCT05845164|DEVICE|tDCS|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~tDCS: The anode and cathode are two large 5 cm by 5 cm gel-based pads which are placed on the scalp. This reduces the risk of burn or irritation and increases conduction. The 2 electrodes are connected to the tKIWI device which delivers a low intensity electrical current (\</=2A), thereby polarizing membrane potential of neurons in the stimulated area. Current that flows from the cathode to the anode has an inhibitory effect on the stimulated area, while current that flows from the anode to the cathode is typically excitatory. We will be initiating bilateral stimulation of the Dorsolateral pre-frontal cortex (DLPFC), which has been shown in the literature to elicit a significant decrease in ambiguous risk-taking behavior in healthy human subjects and a decrease in impulsivity on a non-ambiguous risk task."
41293383|NCT05845164|DEVICE|tDCS Sham|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~The sham group will receive ramped up current from 0.0mA to no more than 0.5mA for the first minute at the initiation of each of the three ramp ups, after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle. The current delivered by tDCS is not strong enough to trigger an action potential in a neuron; instead its sub-threshold changes the pattern of already active neurons."
41293384|NCT03855917|DRUG|Sofosbuvir 400mg [Sovaldi]|Four weeks.
41293385|NCT03855917|DRUG|Glecaprevir/pibrentasvir (300mg/120mg)|Four weeks.
41293386|NCT02632058|OTHER|Cognitive Behavioral Therapy|
41293387|NCT05941884|DIAGNOSTIC_TEST|Immunohistochemistry staining,|"Tissue samples:~* Histopathological examination: Hematoxylin and Eosin slides will be prepared and examined.~  * The only dependable criterion for the diagnosis of bilharzial infestation is the microscopic detection of Bilharzia ova in pathological sections.~ * Pathology (cystitis- cancer and its grade staging will be reported in accordance with the 2022 World Health Organization Classification of Tumors of the Urinary System (17).~* To quantify levels of Nuclear factor kappa B and protein kinase c α:~  * Immunohistochemistry according to the manufacturer's instructions."
41293388|NCT05941884|DIAGNOSTIC_TEST|microscopic examination of urine|"Urine samples:~* Mic roscopic examination (detection of S. haematobium egg - egg counting)~* Detection of HSP 70 Measurements: indirect ELISA will be used to quantify HSP concentrations in urine."
41293389|NCT03078517|DEVICE|I-gel|After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
41466484|NCT05239533|DRUG|177Lu-labeled-girentuximab|"The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. \>/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2~Once the MTD is established, a Simon two-stage optimal design will commence."
41466485|NCT05239533|DRUG|Nivolumab|Nivolumab 240mg q2wk
40960057|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
40960058|NCT05588908|DRUG|Compound Betamethasone Injection (phase II)|1 mL i.m. once on Day 1
40960059|NCT05588908|OTHER|Placebo (phase II)|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
40960060|NCT02592252|BEHAVIORAL|Participatory gender training|10 sessions of participatory gender training
40960061|NCT02592252|OTHER|Microfinance|Microfinance loan
40960062|NCT04574011|DIAGNOSTIC_TEST|Passive leg raising|Raise the patient's lower limb at a 45 degree angle while lying down
40960063|NCT06197971|OTHER|Instrument Assisted Soft Tissue Mobilization|Graston Technique instruments to apply strokes and movements along the length of the muscle fibers. Sweeping strokes, cross-fiber friction, and circular motions patterns will be applied on hamstring muscles.
40960064|NCT06197971|OTHER|Therapeutic Cupping Technique|Stationary cupping technique will be used for a duration of 5-15 minutes with multiple Silicone Cups applied on the Hamstrings.
40960065|NCT00330070|DRUG|IPL512,602 20 mg once daily|
40960066|NCT00330070|DRUG|IPL512,602 Matching Placebo once daily|
41293390|NCT03078517|DEVICE|Laryngeal mask airway protector|After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
40960067|NCT05593926|DIETARY_SUPPLEMENT|Myota Metabolic Regulator|The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
40960068|NCT01517711|DRUG|Tramadol|Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
40960069|NCT01517711|DRUG|Placebo|Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
40960070|NCT04390191|DEVICE|Continuous Positive Airway Pressure|CPAP at fixed pressure (8-10cm H20) for 72 hours continuously (except for daily activities such as eating, personal activities and breaks for ambulation etc).
40960071|NCT00508716|BEHAVIORAL|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
41293391|NCT01382069|DRUG|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
41293392|NCT01382069|DRUG|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
41293393|NCT01747330|DRUG|Pancreatin|Doses of Pancreatin \<2500 lipase u/kg/feed or \<4000 lipase U/g fat/intake or \<10000 lipase U/kg/day given orally are used
41293394|NCT01052012|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; SABER-Bupivacaine /Once
41293395|NCT01052012|DRUG|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
41466486|NCT05239533|DIAGNOSTIC_TEST|89Zr-girentuximab PET/CT|All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration
40960072|NCT06310317|BEHAVIORAL|Applied Behavior Analysis protocol|"The main objective of the experimental protocol is to promote the development of cognitive skills, facilitate the acquisition of new skills and promote the adoption of functional and adaptive behaviors. The use of Applied Behavior Analysis procedures, with the help of technological tools such as a tablet or robot can facilitate the increase of new knowledge and skills.~The criterion is acquired if the subject emits 8 out of 10 independent correct responses (90%) for 3 consecutive sessions.~The objective is to test whether the technological tool used (tablet or robot) can make the proposed learning procedure more effective. The experimental group carries out the procedure by means of stimuli presented on tablets or robots."
40960073|NCT06310317|BEHAVIORAL|Traditional intervention|The main objective of the experimental protocol is to promote the development of cognitive skills, facilitate the acquisition of new skills and promote the adoption of functional and adaptive behaviors. In this group the materials are traditional, such as image printed. The criterion is acquired if the subject emits 9 out of 10 independent correct responses (90%) for 3 consecutive sessions. The control group performs the procedure with images printed on A4 laminated sheets.
40960074|NCT02109380|BEHAVIORAL|Bed rest|
40960075|NCT03747458|DRUG|OPN-375|OPN-375, BID
40960076|NCT01999179|DRUG|Heparin, Low-Molecular-Weight, or direct oral anticoagulants|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
40960077|NCT00786734|DRUG|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
40960078|NCT00786734|DRUG|Pitavastatin|4mg daily for 28 days after PCI
41293396|NCT01052012|DRUG|SABER-Placebo|Injectable Solution; SABER-Placebo/Once
41293397|NCT01073748|DRUG|paracetamol|single dose of paracetamol 15mg/kg.
41293398|NCT04928365|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 therapy
41293399|NCT01319929|DRUG|LY2828360|Administered orally
41293400|NCT01319929|DRUG|Placebo|Administered orally
41293401|NCT01902797|OTHER|Questionnaire|Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
41293402|NCT00000960|DRUG|Zidovudine|
41293403|NCT06211283|DRUG|Sodium valproate|fasted
41466487|NCT05239533|DIAGNOSTIC_TEST|177Lu whole body (WB) planar and SPECT/CT scans|177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab
40960079|NCT02695225|BEHAVIORAL|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
40960080|NCT02695225|BEHAVIORAL|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
40960081|NCT05787275|OTHER|diaphragmatic positioning|Traditional medical treatment plus diaphragmatic strengthening exercises through patient self-positioning in prone on elbows then do diaphragmatic breathing 10-15 min ,twice/day, 7days/ weak
40960082|NCT05787275|OTHER|incentive spirometer|Traditional medical treatment plus diaphragmatic strengthening exercises through using of incentive spirometer 10-15 min ,twice/day, 7days/ weak
40960083|NCT05787275|OTHER|Control|Traditional medical treatment
41293404|NCT06211283|DRUG|Sodium valproate|fed
40960084|NCT04960514|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
40960085|NCT04875182|DIAGNOSTIC_TEST|Evaluation of Delirium development|Postoperative pain scores of the patients will recorded by using a numerical rating scale.
40960086|NCT04765696|OTHER|No intervention is administered|No intervention is administered, the cohort is followed in order to evaluate the impact of housing and relocation on active ageing outcomes.
40960087|NCT06469216|DRUG|Hyaluronic Acid|Hyaluronic Acid to be used as sodium hyaluronate powder plus inactive ingredient (Carboxy methyl cellulose) and to be dissolved in distilled water
40960088|NCT06469216|OTHER|Placebo|Inactive ingredient (Carboxy methyl cellulose) to be used as powder and to be dissolved in distilled water
40960089|NCT04929574|DIAGNOSTIC_TEST|Echocardiogram and Hematological Analysis|Echocardiogram and Hematological Analysis
40960090|NCT04431180|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
40960091|NCT05462483|OTHER|Rice Sock and Instructions to heat the quadriceps.|A rice sock will be provided to the experimental group to heat the quadriceps 3x per day for six weeks. The participants will be encouraged to heat before and after rehabilitation exercises as well.
40960092|NCT05086848|DRUG|Irinotecan liposome、5-fluorouracil、Leucovorin|Irinotecan liposome、5-fluorouracil、Leucovorin
40960093|NCT05984472|PROCEDURE|Edelweiss prefabricated veneers|Individual Randomized Clinical Trial
40960094|NCT05984472|PROCEDURE|Ceram-X Duo SphereTec with U-Veneer|Ceram-X Duo SphereTec with U-Veneer
40960095|NCT02959307|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
40960096|NCT02959307|DEVICE|Sham Transcranial Light Therapy|The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
40960097|NCT01300650|DRUG|Anakinra|Anakinra 100 mg subcutaneous injection daily
40960098|NCT03758001|DRUG|IBI101|0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
40960099|NCT03758001|DRUG|IBI101|1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
40960100|NCT03758001|DRUG|Sintilimab|200mg iv infusion day 1 of every 21 days
40960101|NCT00129428|PROCEDURE|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
40960102|NCT02083783|DRUG|TRI102|formulation containing active moiety (amphetamine)
40960103|NCT02083783|OTHER|Placebo|formulation without active moiety
41293405|NCT01573208|DEVICE|Custom guides|Symbios custom guides for TKA
41466488|NCT05889013|DEVICE|Nasal Nitric Oxide testing|Collection of already performed clinical data and nNO testing
40960104|NCT03851523|OTHER|No intervention|No intervention
40960105|NCT04405414|OTHER|Form|Data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD
40960106|NCT05087459|DRUG|Avatrombopag|On the basis of conventional treatment, Avatrombopag was added, 30×10\^9/L \< platelet count \< 50×10\^9/L patients received Avatrombopag 60mg/d, 50×10\^9/L≤ platelet count \< 75×10\^9/L patients received Avatrombopag 40mg/d for 5 consecutive days, and waited for a period of time after drug withdrawal.Surgery is expected to take place on day 10-13 of the initial dose.
40960107|NCT06233617|DRUG|0.9% Sodium Chloride Injection|biliteral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
40960108|NCT06233617|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|biliteral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
41293406|NCT05585437|PROCEDURE|gastric cancer specialist training program|The gastric cancer specialist training program includes technical training and non-technical training. The technical training includes 1. The whole process of laparoscopic gastric cancer surgery technical teaching 2. Operation practice 3. Operation video review, non-technical training includes 1. Difficult case discussion 2. Specialists Session 3. Lymph node sorting training.
41293407|NCT02298517|PROCEDURE|incentive spirometry|Incentive spirometry to flow and incentive spirometry to volume
41293408|NCT02298517|PROCEDURE|inspiratory load equipment|Threshold and Power breathe
41466489|NCT04186598|DEVICE|CPAP mask system|Intervention group will receive 15cm of H2O of positive end expiratory pressure
41466490|NCT04186598|DRUG|Nifedipine 30 MG|All participants will receive this intervention
40960109|NCT06233617|DRUG|Dexmedetomidine injection|biliteral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
40960110|NCT04953754|DIETARY_SUPPLEMENT|Melatonin|The melatonin group will receive 5mg melatonin nightly
40960111|NCT04953754|DEVICE|Phillips Actiwatch Spectrum Plus|Both groups will be monitored by the FDA-cleared Actigraph
40960112|NCT00919919|DRUG|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
40960113|NCT00919919|DRUG|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
41293409|NCT03195634|DRUG|Carvedilol|an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate \>55 beats per minute, or up to 12.5 mg/day
40960114|NCT04922970|OTHER|Strength training|The interventon consist of 3 weekly, supervised group sessions for 4 months (16 weeks). The sessions consist of progressive full body strength training with a primary focus on lower extremity muscle strength. The leg exercises are leg press, knee extension and leg curl. In addition, participants will perform two upper body exercises. Physical assessment will take place immediately and monthly until 4 months.
40960115|NCT00716534|DRUG|ABT-869|12.5 mg ABT-869
40960116|NCT00716534|DRUG|Placebo for ABT-869|Placebo Comparator (12.5 mg or 7.5 mg)
40960117|NCT00716534|DRUG|ABT-869|7.5 mg ABT-869
40960118|NCT00716534|DRUG|Carboplatin|Carboplatin (AUC 6 mg/mL/min)
40960119|NCT00716534|DRUG|Paclitaxel|Paclitaxel (200 mg/m2)
41293410|NCT02549677|DRUG|Epirubicin|epirubicin, 90mg per square meter, every 3 weeks, day 1
41293411|NCT02549677|DRUG|Docetaxel|docetaxel, 75mg per square meter, every 3 weeks, day 1
40960120|NCT02845934|OTHER|blood sample|additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
40960121|NCT00674362|BIOLOGICAL|Certolizumab pegol|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
40960122|NCT00674362|BIOLOGICAL|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
40960123|NCT03438747|DEVICE|P-15L Bone Graft|The investigational group will be treated with P-15L in an instrumented TLIF
40960124|NCT03438747|OTHER|Local autologous bone in a TLIF with Instrumentation|The active control group will be treated local autologous bone in an instrumented TLIF
40960125|NCT03268369|RADIATION|MRI of the brain|to eliminate a structural intra-cerebral lesion
40960126|NCT03268369|RADIATION|PET scan [18F]F-A-85380|exam performed after iv injection of 200 MBq \[18F\]F-A-85380
40960127|NCT03268369|RADIATION|PET scan [18F]FDG|exam performed after iv injection of 200 MBq \[18F\]FDG
40960128|NCT01630642|DRUG|Torrent's Clopidogrel Tablets USP 75 mg|
41293412|NCT02549677|DRUG|cyclophosphamide|cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
41466491|NCT04186598|DEVICE|CPAP mask system without PEEP|Placebo group will receive high flow oxygen via altered CPAP mask system without providing any positive end expiratory pressure
41466492|NCT04003818|DRUG|TEICOPLANIN|Pharmaceutical form:solution for oral administration Route of administration: oral
41466493|NCT05463406|OTHER|The PLUS algorithm|Combination of a clinical prediction score and LUS, and if needed PCT measurement
40960129|NCT05722197|BEHAVIORAL|Crisis Response Planning and Lethal Means Safety Counseling|Crisis Response Planning is an efficacious, one-session intervention that increases positive affect, decreases negative affect and psychiatric hospitalizations, and reduces suicide attempts by 76% among Servicemembers
40960130|NCT00639678|DRUG|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
40960131|NCT00639678|DRUG|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
40960132|NCT00639678|DRUG|placebo|40 mg/kg placebo, single dose (day 0), Group 4
40960133|NCT00639678|DRUG|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
40960134|NCT05840510|DRUG|Adagrasib|KRAS G12C inhibitor
40960135|NCT05840510|DRUG|nab-Sirolimus|mTOR inhibitor
40960136|NCT00622401|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
40960137|NCT00622401|DRUG|Interleukin-12|Given subcutaneously at dose of 30ng/kg
40960138|NCT00622401|DRUG|Interleukin-12|Given subcutaneously at dose of 100ng/kg
40960139|NCT00459225|DRUG|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
40960140|NCT02467075|DRUG|Iopamidol 300 (Contrast)|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
40960141|NCT02467075|DRUG|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
40960142|NCT01374997|OTHER|micromethod from samples taken from blood spots on filter paper|a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
40960143|NCT03708081|PROCEDURE|ProTaper Next|Root canal instrument
40960144|NCT03708081|PROCEDURE|TF Adaptive|Root canal instrument
40960145|NCT00798980|DRUG|Mirena (BAY86-5028)|Nulliparous Women
40960146|NCT01599767|DEVICE|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
41293413|NCT04789746|BEHAVIORAL|adapted Chicago Run running program|The intervention being piloted is a 6-8 week running program modified from a running curriculum designed for school-aged children. The children will use a RaceRunner device to facilitate their participation, but this device is not explicitly evaluated in this study. Depending on transportation, they may be given access to the device in their home or school between sessions after it has been fit for them. If given access, guardians will be instructed on care and usage.
40960147|NCT06005350|DIETARY_SUPPLEMENT|Niagen|Nicotinamide-Riboside-Chloride Preparation 1000mg/day
40960148|NCT06005350|OTHER|Placebo|Placebo Preperation
40960149|NCT06393829|BEHAVIORAL|Applying the Early Mobilization Program|A mobilization intervention based on the level of function (LOF) ( i.e. patients should be assessed for mobilization status within 24 hours of admission; mobilization should occur at least three times a day, and mobility should be progressive and scaled, tailored to the patient's abilities); The frequency of patient mobilization (primary outcome) will be assessed 20 weeks before implementation, during the 20 weeks of implementation and 20 weeks after the end of implementation (60 weeks in total).
40960150|NCT00404235|DRUG|carboplatin|
40960151|NCT00404235|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
40960152|NCT01375244|DRUG|Lisinopril|Tablets, 10 mg, single dose
40960153|NCT01375244|DRUG|Zestril|Tablets, 10 mg, single dose
41293414|NCT05568043|BEHAVIORAL|COPD Transitions of Care Intervention Bundle: Virtual Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal \[V-TTG\] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.
41293415|NCT05568043|BEHAVIORAL|COPD Transitions of Care Intervention Bundle: In-Person Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.
41293416|NCT02379910|DRUG|AM1030-CREAM or placebo|
41293417|NCT02979067|PROCEDURE|Nasal oxygen flow|Nasal oxygen flow during apnoea
41293418|NCT04770168|BEHAVIORAL|Cognitive Behavioral Therapy Curriculum|"The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient."
41293419|NCT02973646|DRUG|Entecavir or Tenofovir|Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
41293420|NCT02973646|DRUG|Peginterferon Alfa-2B|
41293421|NCT00956241|PROCEDURE|j-pouch coloanal anastomosis|
41293422|NCT00956241|PROCEDURE|side-to-end coloanal anastomosis|
40960154|NCT03573739|PROCEDURE|low-calorie low-protein|In the low-calorie low-protein (Low) group, the calorie target will be 6 kcal/kg/day and the protein target 0.2-0.4 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
40960155|NCT03573739|PROCEDURE|standard-calorie/standard-protein|In the standard-calorie/standard-protein (Standard) group, the first-line calorie target calculated based on body weight is 25 kcal/kg/day and the protein target 1.0-1.3 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
40960156|NCT02723214|PROCEDURE|Brain biopsy|Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.
40960157|NCT04594343|DRUG|Disulfiram|The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
40960158|NCT04594343|DRUG|Placebo|The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
40960159|NCT03954665|BEHAVIORAL|10 km time trial|10 km Cycling time trial test will be conducted to examine the effects of the Exogenous Ketone Salts on time
40960160|NCT03954665|BEHAVIORAL|30s Wingate|30s all-out test to measure peak power output
40960161|NCT03954665|DIETARY_SUPPLEMENT|Ketone|Supplement containing exogenous ketone salts
41293423|NCT06151015|OTHER|Nitrate-rich beetroot juice plus calorie-restricted diet|One daily bottle (70ml) of nitrate-rich beetroot juice with a calorie-restricted diet (1,000kcal deficit).
41293424|NCT06151015|OTHER|Nitrate-rich beetroot juice plus weight-maintenance diet|One daily bottle (70ml) of nitrate-rich beetroot juice with a weight-maintenance diet (energy will be met).
41466494|NCT05463406|OTHER|Usual care|Management as usual
41466495|NCT03432273|DRUG|Nicotine lozenge|Nicotine mint lozenge, 2 mg
41466496|NCT03432273|DRUG|Nicotine lozenge|NiQuitin mint lozenge, 2 mg
40960162|NCT03954665|BEHAVIORAL|Baseline 10 km time trial|A baseline 10 km Cycling time trial test will be conducted
40960163|NCT03954665|BEHAVIORAL|Baseline 30s Wingate|A baseline 30s all-out test to measure peak power output
40960164|NCT00002946|DRUG|penclomedine|
40960165|NCT02122172|DRUG|afatinib dimaleate|Given PO
40960166|NCT02122172|OTHER|laboratory biomarker analysis|Correlative studies
40960167|NCT04586907|DRUG|LY3537021|Administered SC.
40960168|NCT04586907|DRUG|Placebo|Administered SC.
40960169|NCT05209425|DIETARY_SUPPLEMENT|Vitamin D3|Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
40960170|NCT00143637|OTHER|Office dust|airborne office dust spiked with glucan
40960171|NCT00143637|OTHER|clean air|Clean air
40960172|NCT01685892|DRUG|Obinutuzumab|Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
40960173|NCT01685892|DRUG|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
40960174|NCT06547450|BEHAVIORAL|5-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 5-session
40960175|NCT06547450|BEHAVIORAL|8-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 8-session
40960176|NCT03681431|DRUG|Ceftriaxone 4g/ 24h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
40960177|NCT03681431|DRUG|Ceftriaxone 2g/ 12h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
41293425|NCT00121810|DRUG|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
41293426|NCT00121810|DRUG|Corticosteroids|As prescribed
41293427|NCT00121810|DRUG|Calcineurin inhibitors|As prescribed
41293428|NCT00121810|DRUG|Sirolimus|As prescribed
41456085|NCT01296607|DRUG|Urocortin 3|"Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
41456086|NCT03610555|OTHER|new patient centered website|
41456087|NCT02929927|PROCEDURE|Rubber dam isolation|tooth was isolated using a rubber dam in order to avoid the outside microbe
41456088|NCT02929927|DEVICE|aPDT|Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60 s,then irradiation 120 s.
41456089|NCT02929927|DRUG|1% iodine tincture|use 1% iodine tincture to disinfect the crown of the teeth.in order to avoid the outside microbe
40960178|NCT06468566|DIAGNOSTIC_TEST|Ultrasound light scattering imaging equipment|Radiologists use ultrasound light scattering imaging to evaluate the benign and malignant nature of breast nodules
40960179|NCT01850628|DRUG|Paclitaxel|
40960180|NCT01850628|BIOLOGICAL|trastuzumab|
40960181|NCT01850628|BIOLOGICAL|pertuzumab|
40960182|NCT05136404|DRUG|Selpercatinib|Administered orally
40960183|NCT04560036|DIAGNOSTIC_TEST|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
40960184|NCT01995474|OTHER|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
40960185|NCT01995474|OTHER|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
40960186|NCT03737942|DEVICE|monitoring of neuromuscular function|started by percutaneous stimulation of the cubital nerve at the wrist level
41456090|NCT02929927|DRUG|2.5%NaClO|use 2.5% NaClO as irrigants
40960187|NCT01147523|DRUG|Spironolactone/Vitamin E|Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
40960188|NCT01631344|OTHER|"Daily physical activity consultation, Using the Stage of change model"|Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
41293429|NCT00480454|BIOLOGICAL|MVA 85A|intradermal vaccine
40960189|NCT01972113|DIETARY_SUPPLEMENT|Placebo-Control|one placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
40960190|NCT01972113|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
40960191|NCT01972113|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|one 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
40960192|NCT05239975|BIOLOGICAL|SCTV01C|intramuscular injection
40960193|NCT05239975|BIOLOGICAL|Comirnaty|intramuscular injection
40960194|NCT05909644|DRUG|Omaveloxolone|Omaveloxolone Capsules, 150 mg, administered orally
41293430|NCT06074822|OTHER|Residual neuromuscular biopsy|recovery of residual neuromuscular biopsy (nerve ans muscle)
41293431|NCT04761497|OTHER|Actice music therapy|active music therapy sessions for three months
41293432|NCT04761497|OTHER|Watching nature videos|nature videos sessions for three months
41293433|NCT04761497|OTHER|Passive music therapy|passive music therapy for three months
40960195|NCT05909644|DRUG|Efavirenz|Efavirenz Tablet, 600 mg, administered orally once daily
40960196|NCT01227759|DRUG|Drug containing the active ingredient|The topical application is performed once daily during a 12-day treatment.
40960197|NCT01227759|DRUG|Placebo|Placebo containing no active ingredient
40960198|NCT06395545|DEVICE|Electronic injector|At room temperature, 1% lidocaine combined with 1:100,000 epinephrine was used as a local anesthesia. The electronic constant-speed injector, i-JECT® (MediHub Inc., Gyeonggi-do, Korea) (Figure 1) was used, and the injection speed of the injector was set at level 1 (0.25 mL/s) or level 2 (0.4 mL/s). The injection site in a patient was divided into two sides (left and right). The method of local infiltration (manual or using the electronic injector) was randomly assigned to each side of the surgical field, and 2.5 cc (0.5 cc at five separate areas) of local anesthetic was injected individually using a 5 cc syringe with a 31-gauge needle. All injections were administered by a single surgeon (Sung Joo Tommy Hwang) to reduce inter-operator variation.
40960199|NCT01915082|DRUG|Azithromycin|"Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
40960200|NCT01915082|DRUG|Ora-Plus|"Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
40960201|NCT03217656|OTHER|No intervention|
40960202|NCT02554500|PROCEDURE|Remote Ischemic Preconditioning (by Blood Pressure Cuff)|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
40960203|NCT03033004|DEVICE|Conventional Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
40960204|NCT03033004|DEVICE|Contrast Cryolipolysis|Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
40960205|NCT03033004|DEVICE|Reperfusion Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
40960206|NCT01575587|DRUG|Abiraterone: Treatment A|1000 mg abiraterone acetate administered in the fasting state
40960207|NCT01575587|DRUG|Abiraterone: Treatment B|Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
40960208|NCT01575587|DRUG|Abiraterone: Treatment C|Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
40960209|NCT01575587|DRUG|Abiraterone: Treatment D|Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
40960210|NCT02859311|DRUG|Withdrawal of therapy|Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
40960211|NCT01954992|DRUG|Glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
40960212|NCT01954992|DRUG|Fluorouracil|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
41293434|NCT03396471|DRUG|Pembrolizumab|200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.
41293435|NCT03396471|RADIATION|External Beam Radiation Therapy|20-30 Gy over five fractions for up to two cycles.
41293436|NCT05356910|BEHAVIORAL|OPPEN|OPPEN training sessions (three small-group and two one-on-one sessions) build skills for effective peer PrEP outreach through didactic instruction, group discussions, role-play exercises, and goal planning and problem-solving activities.
40960213|NCT05230420|OTHER|Clamping|Clamping of chest tube
40960214|NCT05230420|OTHER|Urine bag|Attachment of a urine bag to chest tube
41293437|NCT05356910|BEHAVIORAL|Control Condition|Control sessions (three small-group and two one-on-one sessions) build skills for diet and nutrition behavior change through didactic instruction, group discussions, and goal planning and problem-solving activities.
41293438|NCT02131467|DRUG|Perampanel|oral drug
41466497|NCT00153205|BEHAVIORAL|computerized physician order entry|
40960215|NCT06444971|PROCEDURE|Post isometric Relaxation|"Post isometric relaxation technique: It is defined as a manual procedure which involves the precisely controlled and specifically directed active contraction of a muscle at varying levels of intensity against a counterforce applied by the therapist.~PIR will be applied to following muscles~1. scalene (anterior, middle and posterior)~2. sternocleidomastoid"
41466498|NCT05629286|DEVICE|McConnell taping|non-stretch rigid McConnell tape will be applied
40960216|NCT05965492|DRUG|Acetaminophen|"Day 1 and Day 2: 1000 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 3000 mg.~Day 3 and Day 4: 825 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 2475 mg.~Day 5: 500 mg two times a day and 325 mg once a day administered via tablet by mouth for a total cumulative daily dose of 1325 mg.~Day 6: 500 mg once a day and 325mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1150 mg.~Day 7: 500 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1000 mg."
40764363|NCT04129021|DEVICE|High-resolution retinal imaging through holographic systems|The protocol consists of performing retinal imaging using a laser Doppler holography. For each system, the participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
40764364|NCT06275867|OTHER|Free high-quality care|Participants are able to take their child to receive free consultations and treatment in a network of contracted private healthcare providers.
40960217|NCT05965492|DRUG|Celebrex|"Day 1: 200 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 400 mg.~Day 2 and Day 3: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 4: 100 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 5: 50 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 100 mg.~Not prescribed on Days 6 and 7."
40960218|NCT05965492|DRUG|Gabapentin|"Day 1 and Day 2: 300 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 900 mg.~Day 3: 200 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 600 mg.~Day 4: 200 mg two times a day and 100mg once a day administered via tablet by mouth for a total cumulative daily dose of 500 mg.~Day 5: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 6: 100 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 7: 100 mg once a day administered via tablet by mouth for a total cumulative daily dose of 100 mg."
40960219|NCT05965492|DRUG|Famotidine|Day 1- Day 7: 20 mg once a day administered via tablet by mouth for a total cumulative daily dose of 20 mg.
40960220|NCT05965492|DRUG|Decadron|"Day 1: 4 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 12 mg.~Day 2: 4 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 8 mg.~Day 3: 2 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 4 mg.~Not prescribed on Days 4 through 7."
40960221|NCT05965492|DRUG|Oxycodone|A prescription of oxycodone as per standard of care will be provided to participants in case of breakthrough pain.
40960222|NCT02710474|BEHAVIORAL|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists in a randomized controlled trial (RCT) model (Part I) or applied unit-wide (either through dedicated staff or bedside nurses in Part II). Under FNI, specialists or nurses will support the parents and facilitate contact between mother and baby during the infant's NICU stay. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
40960223|NCT02710474|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
40960224|NCT02158273|DRUG|Sugar Pill|145 mg/day, oral pill, 9 days
40960225|NCT02158273|DRUG|TRICOR (fenofibrate)|145 mg/day, oral pill, 9 days
40960226|NCT05337137|DRUG|Relatlimab|Specified dose on specified days
40960227|NCT05337137|DRUG|Nivolumab|Specified dose on specified days
40960228|NCT05337137|DRUG|Bevacizumab|Specified dose on specified days
40960229|NCT05337137|OTHER|Placebo|Specified dose on specified days
40960230|NCT04889079|BEHAVIORAL|Contraceptive use (continuation/switching/discontinuation)|Assessing contraceptive continuation/switching/discontinuation over 12-months
40960231|NCT00911547|DRUG|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
41293439|NCT04083911|DRUG|Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF|"Decitabine:20mg/m2/d, d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~9,intravenous infusion; Aclarubicin:10mg/d, d3\~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
41293440|NCT00122746|RADIATION|Radiotherapy alone|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
41456091|NCT02929927|PROCEDURE|root canal preparation|mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer
41456092|NCT02929927|PROCEDURE|root canal obturation|filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation
41466499|NCT05629286|DEVICE|Patella Stabilizer Brace|An orthotic application that wraps the patellofemoral joint, which has a patellar cavity and supports the patella, and provides stabilization with velcro
40764365|NCT06275867|OTHER|Close distance|The network of contracted providers is located close to where participants live.
40764366|NCT06275867|OTHER|Far distance|The network of contracted providers is located far to where participants live.
40960232|NCT00911547|DRUG|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
40960233|NCT00911547|DRUG|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
40960234|NCT00911547|DRUG|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
40960235|NCT00515346|DEVICE|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
40960236|NCT01399515|DRUG|Valproic Acid|One 500mg tablet by mouth daily
40960237|NCT01577108|DIETARY_SUPPLEMENT|Probiotic|oral taking 2 capsules before sleeping per day for 14 days
40960238|NCT01577108|DIETARY_SUPPLEMENT|Placebo|oral taking 2 capsules before sleeping per day for 14 days
40960239|NCT05262608|DRUG|Olaparib|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily
41293441|NCT00122746|RADIATION|Radiotherapy with cisplatin|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
40960240|NCT01253408|DRUG|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
40960241|NCT01253408|DRUG|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
40960242|NCT01186471|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
40960243|NCT01186471|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
40960244|NCT01186471|DRUG|placebo|placebo - three times daily during each treatment period
40960245|NCT00316719|DRUG|LAM group|Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
40960246|NCT00316719|DRUG|ADV group|Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
40960247|NCT06127680|BEHAVIORAL|Brief Health Promotion Advice|Brief Health Promotion advice on exercise and nutrition (protein intake) delivered by a health care professional during routine consultations
40960248|NCT05170984|DEVICE|CACIPLIQ20®|Application of CACIPLIQ20® by spray, directly on the wound surface, after wound cleaning and debridement, twice a week, until wound closure (or up to 20 weeks maximum).
40960249|NCT04889807|OTHER|measure of EtCO2 variation|measure of EtCO2 (end tidal carbon dioxide) variation after an 15 seconds end-expiratory occlusion test
40960250|NCT03208205|PROCEDURE|vitrectomy|Complete 23G PPV with scleral indentation was performed using Constellation system. Posterior vitreous detachment was induced very carefully by the cutter probe using aspiration. The peripheral vitreous was removed in all eyes with 360° of the vitreous base shaved under scleral indentation. After complete retinal attachment was achieved, endolaser photocoagulation was applied around the retinal break(s) as three to four rows of burns or/and cryopexy under HPFCL. Then a HPFCL/air/5000cst silicone oil exchange was performed. In one eye only HPFCL/air exchange was performed. Sclerotomies were sutured when needed with Vicryl 8.0 sutures.
40960251|NCT01274078|BIOLOGICAL|Blueberries|150 grams of frozen blueberries on the same day as exercise
40960252|NCT02208479|OTHER|Non invasive ultrasound measurement of the diaphragm thickness during breathing|
41136073|NCT00777894|RADIATION|intensity-modulated radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
41293442|NCT05699616|PROCEDURE|Repair of perforated peptic ulcer|Repair of perforated peptic ulcer either open or laparoscopic.
41456093|NCT05909436|DRUG|GLS-012|"In the dose escalation stage of GLS-012 monotherapy, RP2D will be determined. All subjects will receive GLS-012 intravenously Q3W.~In the expansion stage of GLS-012 monotherapy, subjects will receive up to 17 doses of GLS-012 at the RP2D administered Q3W.~In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W."
40764367|NCT03153410|DRUG|Cyclophosphamide|"200 mg/m\^2, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
40960253|NCT01235624|GENETIC|genetic analysis|
40960254|NCT02560532|DRUG|Clazosentan|Concentrated solution for intravenous injection
40960255|NCT06557369|DEVICE|reSEES|"The treatment consists of combining SMPL and PBM light therapies to exploit the full advantage of their action. The combination will result in an additive or synergetic effect.~* Treatment sessions are scheduled for three weeks after enrolment (Loading-Phase).~* Two visits per week are needed.~* At the first visit of every treatment week, two treatment sessions will follow each other; PBM is applied at least 15' after SMPL (treatment pairs).~* Only PBM will be administered during the second visit of every treatment week.~Patients will receive:~* 1x SMPL treatment at days 0, 7, and 14 (3 in total),~* 1x PBM treatment at days 0, 3, 7, 10, 14, and 17 (6 in total)~Nine treatments will be delivered within three weeks. The study will be concluded with three follow-up visits at 18, 24, and 54 weeks."
40960256|NCT02295488|PROCEDURE|biological sampling|blood intake for biological sampling during validated desensitization protocol (Alyostall®)
40960257|NCT02295488|BIOLOGICAL|Desensitization protocol (Alyostall®)|Validated desensitization protocol using Alyostall® performed
40960258|NCT00107393|BIOLOGICAL|trastuzumab|
40960259|NCT00107393|DRUG|capecitabine|
40960260|NCT00001381|DRUG|suramin|
40960261|NCT02544360|BEHAVIORAL|Photoaging mobile app promoting poster campaign.|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
41293443|NCT02183467|DRUG|BI 1356, low dose|
41293444|NCT02183467|DRUG|BI 1356, high dose|
41293445|NCT02183467|DRUG|Placebo|
40960262|NCT04920552|DEVICE|Elastic abdominal binder|"The ABDO-SYNCRO 3-BAHNIG is an elastic abdominal binder with a 3-stripes Velcro fastening, capable of developing a 20 ± 2 mmHg pressure on the abdominal wall. This device will be tested as potentially beneficial with respect to the mentioned primary and secondary outcomes. The investigators anticipate to use this elastic abdominal binder, since participants of a previous trial reported this device to be comfortable enough and to have used it regularly during the open-label follow-up phase. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer (SYNCRO-MED GmbH)."
40960263|NCT04920552|DEVICE|Placebo binder|"Clima Care is a simple body warmer, developing maximal 3±2 mmHg pressure on the abdominal wall. This device will be used as placebo comparator of the present clinical trial. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer."
40960264|NCT00003331|DRUG|fluorouracil|
40960265|NCT00003331|DRUG|leucovorin calcium|
40960266|NCT00003331|DRUG|topotecan hydrochloride|
40960267|NCT03857958|PROCEDURE|endoscopic retrograde cholangio-pancreatography|In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.
40960268|NCT04216238|BEHAVIORAL|quasi-experimental Pre-test/Post-test design|surveys to document progress
40960269|NCT04510012|OTHER|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
40960270|NCT01844128|DIETARY_SUPPLEMENT|weight loss|
40960271|NCT00006426|PROCEDURE|Achilles tendon-lengthening surgery|
40960272|NCT04713215|OTHER|Questionnaire|A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.
40960273|NCT03944915|DRUG|Carboplatin|Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.
40960274|NCT03944915|DRUG|Paclitaxel|"During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy."
40960275|NCT03944915|DRUG|Nivolumab|Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.
41293446|NCT02183467|DRUG|Moxifloxacin|
41293447|NCT04473443|OTHER|FEops HEARTguideTM|A patient-specific computer simulation that aims to improve the outcomes after TAVI by suggesting THV platform, THV size and implantation depth with the use of the pre-procedural CT-scan.
41293448|NCT00001542|DRUG|fluconazole|
41293449|NCT04207112|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
41293450|NCT04207112|DRUG|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
41293451|NCT04207112|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
41293452|NCT04207112|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
41293453|NCT04207112|DRUG|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
40960276|NCT03944915|RADIATION|Radiation|Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13
40960277|NCT03944915|DRUG|Hydroxyurea Pill|One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
40960278|NCT03944915|DRUG|5-fluorouracil|5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
40960279|NCT03944915|DRUG|Filgrastim Injection|Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
40960280|NCT03944915|DRUG|Cisplatin|Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
40960281|NCT06416371|DIAGNOSTIC_TEST|Fundus fluorescein angiography, with ultrawide field retinal imaging|Intravenous injection of sodium fluorescein for angiography of retinal blood vessels
41293454|NCT04207112|DRUG|Standard Drugs|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
41293455|NCT04018014|OTHER|CT angiography|CT angiography in detection of pulmonary embolism
41293456|NCT00004048|BIOLOGICAL|filgrastim|
41293457|NCT00004048|DRUG|doxorubicin hydrochloride|
40960282|NCT04253223|BIOLOGICAL|REMD-477|REMD-477 will be administered as a subcutaneous injection for three weekly doses
40960283|NCT00561808|OTHER|In-vitro maturation oocytes|Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
40960284|NCT04299074|OTHER|addiction|questionnaire
40960285|NCT01925534|DEVICE|High-flow humidified nasal oxygen delivery system|During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
40960286|NCT01925534|DEVICE|Standard oxygen therapy|During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
40960287|NCT06034314|DRUG|Dronabinol Capsules|Two 10 mg Dronabinol capsules will be administered orally, for a total of 20mg, on test day.
40960288|NCT01552694|DRUG|Sitagliptin|Oral, 100 mg/day for 2 months
40960289|NCT01552694|DRUG|Placebo|oral, matching placebo daily for 2 months
40960290|NCT05626855|DRUG|Apitegromab|Apitegromab (SRK-015) is an investigational, fully human immunoglobulin G4 monoclonal antibody that specifically binds to human proforms (i.e., inactive precursor forms) of myostatin, pro- and latent- myostatin, with high affinity, inhibiting activation of myostatin, a negative regulator of muscle growth and strength.
40960291|NCT06306781|DRUG|HCL001 cell (homologous allogeneic hepatocytes) injection|The patient will undergo a DSA procedure in the hospital's operating room before infusion. A catheter will be inserted into the femoral artery and guided to the hepatic artery. Upon confirmation through imaging, HCL001 cell injection will be slowly infused through the catheter. During the infusion, the cells should be continuously agitated to prevent clumping. The infusion can be administered as a single dose or multiple doses, and after infusion, the patient will be closely monitored for at least one week.
40960292|NCT03812107|OTHER|Moderate Treatment Approach|The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
40960293|NCT03812107|OTHER|Intensive Treatment Approach|After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
40960294|NCT02994992|DRUG|BAY 987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-100)
40960295|NCT02994992|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
40960296|NCT02321410|OTHER|Contrast enhanced ultrasound of the carotid plaque|visual grading of neovessel
40960297|NCT02321410|OTHER|Dynamic contrast-enhanced carotid plaque MRI|quantitative analysis of gadolinium enchantment in a region of interest
40960298|NCT03507803|OTHER|Gait Biofeedback|Feedback will appear on screen in front of participants during walking. If their foot is too inverted (determined by researcher) the object on the screen will turn red and an audio tone will be heard. If the participant corrects the foot position, the object will turn green and the audio tone will not be heard.
40960299|NCT00727493|DRUG|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
40960300|NCT00727493|DRUG|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
40960301|NCT01466153|DRUG|Rituximab|Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles
40960302|NCT01466153|DRUG|Bendamustine|Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
40960303|NCT01466153|DRUG|MEDI-551|MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
40960304|NCT04457635|BEHAVIORAL|Psychotherapy|
40960305|NCT01418170|OTHER|cervical spinal manipulative therapy|A real cervical spine manipulation will be used for the intervention vs a sham cervical spine manipulation. For the rcSMT the subject's head will be supported by the clinician's forearm. The contact hand of the clinician will contact the C5-C6 spinal segment. A thrust maneuver will be given by the contact hand of the clinician with the supportive hand resting on the subject's zygoma. A rotational inferior drop thrust maneuver will be completed. For the scSMT the subject's head will be rotated to 45 degrees and will be supported by the clinician's forearm, which will lie on top if the headpiece. A thrust maneuver will then be given by the contact hand of the treating clinician to the drop piece with the hand beside the paraspinal musculature simulating a real thrust, the supportive hand will be resting on the subject's zygoma. A inferior drop thrust will be applied to the drop piece (no thrust is made by the contact hand on the cervical spine).
40960306|NCT03469934|BIOLOGICAL|Etokimab|Administered on Day 1 over 1 hour by IV infusion
40960307|NCT03469934|DRUG|Placebo|Administered on Day 1 over 1 hour by IV infusion
40960308|NCT04014816|OTHER|MDR bacteria positivity|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
40960309|NCT04014816|OTHER|negative fluid balance|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
40960310|NCT04882618|DRUG|Indocyanine green|indocyanine green application during LRRP to detect positive lymph nodes. ICG will be injected to prostate lobes via csytoscopy
40960311|NCT03616626|RADIATION|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
40960312|NCT03616626|RADIATION|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
40960313|NCT03616626|RADIATION|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
40960314|NCT04152473|DRUG|Proglumide|oral CCK receptor antagonist
40960315|NCT01203098|DRUG|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
40960316|NCT01203098|DRUG|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
40960317|NCT01203098|DRUG|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
40960318|NCT05536583|PROCEDURE|Laparoscopic sleeve Gastrectomy|Laparoscopic sleeve Gastrectomy
40960319|NCT05021601|PROCEDURE|Bi-atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation and right atrial ablation.
40960320|NCT05021601|PROCEDURE|Left atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation alone.
40960321|NCT06445881|DRUG|Modified Si Jun Zi Tang|Modified Si Jun Zi Tang is a classic formula in traditional Chinese medicine, known for its benefits in unifying and strengthening the spleen.
40960322|NCT00823095|DRUG|Nitric Oxide|Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
40960323|NCT03241875|DRUG|Pregabalin 75mg|In this group, premedication is performed with 2 capsules of pregabalin 2 hours before anesthetic induction.
40960324|NCT03241875|DRUG|Gabapentin 300mg|In this group, premedication is performed with 2 capsules of gabapentin 2 hours before anesthetic induction.
40960325|NCT03241875|DRUG|Placebo oral capsule|In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
40960326|NCT04815681|BEHAVIORAL|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 40-50 minutes.
40960327|NCT04815681|BEHAVIORAL|Active Control|The active control condition includes an online self-awareness program that lasts approximately 40-50 minutes. Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
40960328|NCT01728909|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
40960329|NCT01728909|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
40960330|NCT01238510|PROCEDURE|stent technique: Provisional fKBT|"Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.~Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
40960331|NCT01238510|PROCEDURE|stent technique: Routine fKBT|"Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
40960332|NCT02399722|DEVICE|WICVAC|combined wound therapy
40960333|NCT02399722|DEVICE|VAC mono therapy|mono therapy
41293458|NCT00004048|PROCEDURE|autologous bone marrow transplantation|
40960334|NCT04456946|DEVICE|Low Level Laser Therapy|Low Level Laser Therapy
40960335|NCT04456946|DEVICE|Occlusal Splint Treatment|Occlusal Splint Treatment
40960336|NCT04128085|DRUG|TQB3804|A kind of tyrosine kinase inhibitor.
40960337|NCT02386735|DRUG|Placebo|Three days prednisone 40mg, two days placebo
40960338|NCT02386735|DRUG|Prednisone|Five days prednisone 40mg.
40960339|NCT06467448|DEVICE|EMG Assessement of Recovery of Neuromuscular Function|EMG Train of Four Assessment of Recovery of Neuromuscular Function
40960340|NCT06343740|BEHAVIORAL|COMET-Y|Competitive memory training (COMET) is a transdiagnostic intervention first developed for adults and later adapted to be used in children and adolescents. The adapted version for youth consists of 7 sessions in which participants learn to facilitate activation of functional/positive thoughts instead of relying on dysfunctional/negative thoughts by using positive self-verbalizations, imagery, body posture, and music. In addition, they are challenged to reformulate dysfunctional/negative thoughts into more functional/positive thoughts. As an addition to the original COMET protocol, there is a parent session in which parents receive psycho-education about their influence on self-esteem. Parents learn to be a 'co-therapist' and to support practicing at home and improve generalization.
40960341|NCT05198999|OTHER|Aquatic-based Plyometric Exercises|The Aqua-PLYO group received the aquatic plyometric exercise training for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association
40960342|NCT05198999|OTHER|Standard Physical Therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
40960343|NCT04311502|DRUG|Clofazimine (CFZ)|Administered orally once daily
40960344|NCT04311502|DRUG|Rifapentine (RPT)|Administered orally once daily
41293459|NCT00004048|PROCEDURE|peripheral blood stem cell transplantation|
41293460|NCT00004048|RADIATION|indium In 111 monoclonal antibody MN-14|
41293461|NCT00004048|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
40960345|NCT04311502|DRUG|Isoniazid (INH)|Administered orally once daily
40960346|NCT04311502|DRUG|Pyrazinamide (PZA)|Administered based on weight orally once daily
40960347|NCT04311502|DRUG|Ethambutol (EMB)|Administered based on weight orally once daily
40960348|NCT04311502|DRUG|Rifampicin (RIF)|Administered orally once daily
40960349|NCT04311502|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.
40960350|NCT01657669|DRUG|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
40960351|NCT05163236|DIAGNOSTIC_TEST|Positive fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
40960352|NCT05163236|DIAGNOSTIC_TEST|Negative fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
40960353|NCT05163236|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT) not performed|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
40960354|NCT05002452|OTHER|Search of factors predicting therapeutic effects and prognosis|There factors are collected in preoperative routine blood examination, preoperative radiological imaging and pathological examination.
40960355|NCT03000283|DRUG|Conivaptan|"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."
40960356|NCT04105270|DRUG|Oral Restorative Microbiota Therapy (RMT) Capsules|Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly
40960357|NCT04105270|DRUG|Durvalumab 1500 mg IV|Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab
40960358|NCT04105270|DRUG|Cisplatin/pemetrexed or Carboplatin/pemetrexed|Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W
40960359|NCT04105270|OTHER|Placebo|Sixteen doses of oral placebo capsules given weekly
40960360|NCT05864157|OTHER|Gait training without rhythmic auditory cues|Gait training on treadmill and overground without any rhythmic auditory cues
40960361|NCT05864157|OTHER|TRAC|Metronome set to 85% on treadmill and 115% when walking overground
40960362|NCT05864157|OTHER|dTRAC|Metronome set around 85% on treadmill and around 115% when walking overground
40960363|NCT05747820|OTHER|Observational study|This is an observational study designed to assess the evolution of multiple markers of congestion over 4 weeks after a WHF event treated in an outpatient unit
40960364|NCT03338374|DEVICE|Biventricular pacemaker|All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
40960365|NCT00841646|BIOLOGICAL|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
40960366|NCT01664546|PROCEDURE|Trophectoderm biopsy|
40960367|NCT05581628|DIAGNOSTIC_TEST|Pain location inventory (PLI)|PLI is obtained by questioning the pain in 28 regions in the last 7 days. Total score is between 0-28
40960368|NCT05581628|DIAGNOSTIC_TEST|Symptom Impact Questionnaire (SIQR)|The SIQR score includes a total of 10 different evaluations in the last 7 days, including pain, energy, stiffness, sleep, depression, memory problems, anxiety, sensitivity to touch, balance problems, sensitivity to loud sounds-bright light-smells-cold. Each item is scored between 0-10 and the total score is obtained between 0-100. This total score is divided by 2 to get the SIQR score
40960369|NCT05581628|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire (FIQ)|FIQ measures 10 different features, including physical function, well-being, absenteeism, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety and depression. With the exception of the well-being trait, low scores indicate recovery or less affliction. The maximum possible score of each sub-title is 10. Thus, the total maximum score is 100.
40960370|NCT02615314|PROCEDURE|Particle re-positioning maneuver|Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
40960371|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A
40960372|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
40960373|NCT03673215|DRUG|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
40960374|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
40960375|NCT03673215|DRUG|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
40960376|NCT03673215|DRUG|recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
40960377|NCT03673215|DRUG|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
40960378|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
40960379|NCT03673215|DRUG|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
40960380|NCT00714883|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of lesions in native coronary arteries using standard coronary intervention techniques. Intervention will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
40960381|NCT02886832|DIETARY_SUPPLEMENT|Prostate Health formulation|
40960382|NCT00968201|DRUG|montelukast sodium|one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks
40960383|NCT00968201|DRUG|Comparator: Placebo|one chewable placebo tablet, once daily at bedtime for 12 weeks
40960384|NCT04173559|BEHAVIORAL|Activity Intervention|After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
40960385|NCT00713856|PROCEDURE|Custom PRK with iris registration|PRK
40960386|NCT00713856|PROCEDURE|Conventional PRK|PRK
40960387|NCT06027294|PROCEDURE|Ischemic Conditioning|A cuff will be inflated to a pressure of 225 mmHg.
40960388|NCT00074204|DRUG|carboplatin|Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
41136074|NCT00777894|RADIATION|stereotactic body radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
40960389|NCT00074204|DRUG|docetaxel|"Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.~Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.~In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
40960390|NCT00074204|DRUG|gemcitabine hydrochloride|Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
40960391|NCT00040365|DRUG|Amifostine trihydrate|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
40960392|NCT00040365|RADIATION|Radiation therapy|The treatment will be delivered in at least two phases. The first field reduction will occur after 46Gy and the second field reduction will occur after 70Gy.
40960393|NCT03509558|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of spinal cord over the skin combined with physical therapy to improve walking and standing functions
40960394|NCT03509558|OTHER|Physical Therapy|physical therapy to improve walking and standing functions
40960395|NCT03838952|DRUG|Herbal medicine|Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
40960396|NCT00003487|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Adenocarcinoma of the Esophagus will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
40960397|NCT00903799|DEVICE|Implantation of ENTERRA therapy|Gastric electrical stimulation using Enterra Therapy
40960398|NCT03246893|DEVICE|Noninvasive positive pressure ventilation|"Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:~Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min"
40960399|NCT03246893|DEVICE|High flow oxygen nasal cannula|"High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:~Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%"
40960400|NCT01841788|DEVICE|Thermal Adhesion Patch|
40960401|NCT01841788|DEVICE|Marketed Thermal Adhesion Patch|
40960402|NCT01841788|DEVICE|Placebo Patch|
40960403|NCT04471142|DEVICE|neuromuscular bandage|After the dressing is performed by the nursing team with a sterile gauze covering over the region of the healing points, the 7 cm wide Vitaltape® neuromuscular bandage will be applied. For the application of the bandage, maximum stretching will be performed over the region of the plastron and finished with the two ends, from two to three centimeters, without stretching. As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
40960404|NCT06005480|DRUG|Mepivacaine|Injection of 1.5% Mepivacaine in nerve block
40960405|NCT05613478|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
41293462|NCT00417365|DEVICE|WaterWorks Douching Device|
41293463|NCT05492383|DEVICE|TAVI|Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
41293464|NCT02707705|DEVICE|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|"Intervention Description :~The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.~Data collected :~* T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~* T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~* T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~* T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
40960406|NCT05613478|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
40960407|NCT05613478|PROCEDURE|Postoperative TACE treatment|TACE treatment after radical surgery
40960408|NCT05613478|PROCEDURE|Radical surgery|Radical surgery
40960409|NCT05613478|PROCEDURE|Preoperative TACE treatment|TACE treatment before preoperative camrelizumab combined with apatinib mesylate
41136075|NCT03591588|OTHER|diet|The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.
40960410|NCT00249860|DRUG|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
40960411|NCT00249860|DRUG|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
41456094|NCT05909436|DRUG|GLS-010|"In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W."
40960412|NCT00249860|DRUG|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
40960413|NCT04555343|DRUG|Tranexamic acid|1gm instilled instravesically
40960414|NCT00970060|BEHAVIORAL|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
40960415|NCT04092582|DRUG|MTPS9579A|MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
40960416|NCT04092582|DRUG|Placebo|Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
40960417|NCT05765396|DEVICE|imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope|The imPulse™ Systems are an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
41293465|NCT02707705|DEVICE|Apply a device having no real effect|"The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.~Data collected :~* T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~* T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~* T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~* T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
41293466|NCT02707705|PROCEDURE|Disinfection|The ear is disinfected by applying Chlorhexidine®.
41293467|NCT00004640|DRUG|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
41456095|NCT05000723|OTHER|Standard of care|"Standard of care consisting of~* clearance of infection~* treatment with antibiotics (antisuppressive, DAIR) or surgery (1 stage, 2 stage Girdlestone)~* Radiology: X-ray pelvis and hip, X-ray pelvis with kingmark, CT scan pelvis/hip"
41293468|NCT05579561|OTHER|Diet|Participants, in both groups, will be required to eat a diet that is very low in carbohydrates, moderate in protein, with added healthy fats. They will also have to breath in the device to estimate the level of different exhale gaz.
41293469|NCT01096550|BEHAVIORAL|Outpatient|Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
41293470|NCT01096550|BEHAVIORAL|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
41456096|NCT01554111|DRUG|Picosulfate sodium,|One sachet of picosalax will be given with at least 4 cups of clear fluids.
41293471|NCT00477373|DRUG|depakine chrono|Depakine Chrono 500 mg
41293472|NCT02192710|PROCEDURE|electronic tab|classic use of an electronic tab with age specific games
41293473|NCT02192710|DRUG|Midazolam oral intake|
41293474|NCT05067660|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SABR) is a highly focused radiation treatment that concentrates an intense dose of radiation on the recurrent tumorous lesion while limiting the dose to healthy surrounding tissues.
41456097|NCT01554111|DRUG|phosphosoda rectal enema|The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
41456098|NCT01554111|DRUG|Pico-Salax and Sodium phosphate enema|Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
41456099|NCT06443125|OTHER|Natural psychotherapy|Draw ideas from traditional Chinese culture, learn from the practice of Morita therapy in Japan, and create local practice experience. At the same time, a variety of research methods such as cognitive assessment and brain imaging were used to establish the scientific, professional and objective evaluation indexes of the therapy.
41456100|NCT00144222|DRUG|Telmisartan 40 mg/HCTZ 12.5 mg|
41456101|NCT00144222|DRUG|Telmisartan 40 mg|
41456102|NCT00691704|DRUG|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
40960418|NCT01781975|DRUG|Imatinib Mesylate|
40960419|NCT01781975|DRUG|Placebo (For imatinib mesylate)|
40960420|NCT01370330|DRUG|Metaiodobenzylguanidine (MIBG)|131I-MIBG Therapeutic Administration. Therapeutic 131I-MIBG will be synthesized at Jubilant DraxImage (Quebec, Canada) with specific activities of 9-18 Ci/mmole, or at Progenics with specific activity of 2,500 mCi/mg. The therapeutic dose (8-18 mCi/kg at investigator's discretion; any dose greater than 12 requires stored stem cells) will be diluted in 25-50 ml of normal saline for either preparation, and will be infused intravenously through a patient's central line, if already present, or a peripheral IV if a central line is not present.If Azedra is used, the dose will be infused over 30-60 minutes; the low specific activity preparation from Draximage will be infused over 90-120 minutes. For patients with pheochromocytoma or paraganglioma, the recommended maximum dose is 500 mCI or 12 mCi/kg.
40960421|NCT01332903|DRUG|[14C] AZD5069|Single 120 mg oral dose administered on Day 1
40960422|NCT03128411|DRUG|Bosutinib|All patients will receive bosutinib at a starting dose of 400 mg QD.
40960423|NCT02639065|DRUG|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
41293475|NCT05067660|RADIATION|Current standard template-based salvage therapy|In the group receiving salvage radiotherapy according to current standard of care, radiation will be directed to the prostatic bed and pelvic lymph nodes according to the radiation oncologist's discretion.
40960424|NCT04812899|BEHAVIORAL|Parental guided self-help version of FBT-pre-recorded videos and readings from the book|"Each participant will receive a series of pre-recorded videos of parental guided self help version FBT. There will be10 videos of about 10 minutes each. The videos will include content on empowering parents to renourish their child and interrupt binge/purge behaviors. Readings will be assigned to each participant from the book Help Your Teenager Beat and Eating Disorder. There will be psychoeducational content on the dangers and medical complications of eating disorders. The readings will also contain content on coping skills for young people including relaxation, mindfulness strategies, and distress tolerance skills."
40960425|NCT01637935|DRUG|Pioglitazone|Pioglitazone tablets.
40960426|NCT03289858|DRUG|Exparel|Subcutaneous injection at conclusion of surgical fixation of hip fracture
41293476|NCT01810367|DRUG|ABX Combined With Cisplatin|
41293477|NCT01810367|DRUG|Gemcitabine Combined With Cisplatin|
41293478|NCT01455571|DRUG|HM781-36B|Q1DX14/2W for 3W HM781-36B
41293479|NCT06344520|BEHAVIORAL|pektoralis minor shortnes|One factor that is effective in acceleration during swimming is the force of the arm pulling the water. While the pectoralis minor muscle pulls the crocoid process forward, it pulls its posterolateral corner down, which helps the latismus dorsi to make an extension movement and the lower trapezius to depress the scapula. When the pectoralis minor muscle is short, it prevents maximum reach in the arm because its full function cannot be revealed. It is thought that depression of the scapula will directly affect acceleration in swimming, as it increases the backward thrust of the arm.
40960427|NCT03289858|DRUG|Sodium Chloride|Saline Injection
40960428|NCT00680706|DRUG|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
40960429|NCT00680706|DRUG|Placebo|D5W (50 ml)
40960430|NCT05626985|DIAGNOSTIC_TEST|GAMAD|Blood samples are tested for tumor markers including PIVKA-II (DCP),AFP, ctDNA methylation and biochemical tests.
40960431|NCT05717946|DIETARY_SUPPLEMENT|Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.|We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
41293480|NCT06344520|BEHAVIORAL|Group in which the Pectoralis Minor stretching exercise was performed in a sham manner|In most cases, exercise practices also affect the person psychologically. In order to ignore the psychological effects of the exercises, they were made to perform exercises that were similar to pectoralis minor stretching exercises but did not activate the muscle
41293481|NCT06344520|BEHAVIORAL|The group in which Pectoralis Minor stretching exercise was not applied|The Control Group was not given any exercise and they continued to do their own training.
41293482|NCT04803708|BIOLOGICAL|TP-102|One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).
41293483|NCT00192517|DRUG|MEDI-522|4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
41293484|NCT00192517|OTHER|Placebo|4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
40960432|NCT05717946|OTHER|control group|We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
40960433|NCT02627521|PROCEDURE|PRU guided CABG|Coronary Artery Bypass Surgery
40960434|NCT02627521|PROCEDURE|CABG per standard of care|Coronary Artery Bypass Surgery
40960435|NCT02627521|DEVICE|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
40960436|NCT02627521|DRUG|Ticagrelor|Ticagrelor administration prior to randomization
40960437|NCT03424200|BEHAVIORAL|Routine care|Participants will receive routine care
40960438|NCT03424200|OTHER|Coaching plus routine care|Participants will receive coaching plus routine care
40960439|NCT03291730|BEHAVIORAL|Breathing and journaling exercise|May help reduce anxiety of receiving chemotherapy
40960440|NCT03291730|OTHER|Art-therapy|May help reduce anxiety of receiving chemotherapy
40960441|NCT01847274|DRUG|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
40960442|NCT01847274|DRUG|placebo|
40960443|NCT04868175|DRUG|Timolol|Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production
40960444|NCT04868175|DRUG|Travatan|Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow
40960445|NCT04868175|DRUG|Hypromellose|Placebo eye drop, lubricant
40960446|NCT05650775|DRUG|Concerta|3-week trial of oral methylphenidate extended release
40764368|NCT03153410|DRUG|GVAX Pancreas Vaccine (GVAX)|"5x10\^8 cells, six intradermal (ID) injections~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
40764369|NCT03153410|DRUG|Pembrolizumab|"200 mg, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
40764370|NCT03153410|DRUG|IMC-CS4|"75 mg (dose level 1) or 100 mg (dose level 2), intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
40764371|NCT06643221|BEHAVIORAL|Exercise|After an initial maximal graded exercise test to determine maximal oxygen uptake and peak cycling power, healthy participants will undergo a 20-minute graded exercise test at intensities corresponding to 50, 60, 70 and 80% VO2max (5-minutes per stage)
40764372|NCT06643221|DRUG|Isoproterenol|To determine if pharmacological activation of beta-adrenergic receptors evokes an immune respponse akin to exercise, healthy participants will receive an intravenous infusion of isoproterenol (50ng/kg/min)
40960447|NCT05650775|DRUG|Adderall-XR|3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
40960448|NCT02140086|BEHAVIORAL|Buteyko based Remedial Breathing Therapy|Buteyko based remedial Breathing Therapy after Dr. Buteyko
40960449|NCT00779285|DRUG|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
40960450|NCT02320669|DRUG|Triostat|Bolus of Triiodothyronine followed by infusion for 48 hours
40960451|NCT02320669|DRUG|Placebo|Bolus of Placebo followed by infusion for 48 hours
40960452|NCT03634657|RADIATION|Plain X-ray protection shield|Coronary angiography with mere X-ray protection shield
41136076|NCT06234020|OTHER|To see the frequency of vertebrospinal anomalies in patients presenting with Anorectal Malformation|The patients presenting with anorectal malformation go through x-ray. We will get the reporting of x-ray done to see the vertebral anomalies and the patients presenting with fecal/urinary incontinence will go through MRI for spinal anomalies.
41136077|NCT01008917|DRUG|sorafenib with temsirolimus|Weekly intravenous temsirolimus with daily oral sorafenib
41293485|NCT05900414|BEHAVIORAL|Electronic patient decision aid|Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments
40960453|NCT03634657|RADIATION|Protection shield & X-ray protective strips|Coronary angiography with X-ray protection shield \& X-ray protective strips
40960454|NCT03634657|RADIATION|Protection shield & protective strips & patient cut-outs|Coronary angiography with X-ray protection shield \& X-ray protective strips \& X-ray protection patient cut-outs
41136078|NCT04130490|DEVICE|ANTERION|3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
40764373|NCT06643221|DRUG|Placebo|Healthy participants will consume the placebo 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
40764374|NCT06643221|DRUG|Bisoprolol Fumarate Tablet 10 mg|Healthy participants will consume a 10mg Bisoprolol Fumerate tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
40764375|NCT06643221|DRUG|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|Healthy participants will consume a 80mg Nadolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
40960455|NCT01646723|BEHAVIORAL|Volunteers Adding Life in Dementia (VALID) Program|"The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident."
40960456|NCT04498520|DRUG|Abexinostat Tosylate|Given PO
40960457|NCT04498520|DRUG|Fulvestrant|Given IM
40960458|NCT04498520|DRUG|Palbociclib|Given PO
41293486|NCT05900414|OTHER|Information|Link to website with information about atrial fibrillation treatments
41293487|NCT01266707|BIOLOGICAL|antiangiogenic paptide vaccine|for drugs include administration time frame
41293488|NCT03869073|DRUG|Evolocumab|Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
41293489|NCT03869073|DRUG|Placebo|Preservative free 0.9% sodium chloride. Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
41293490|NCT01563588|BEHAVIORAL|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
41293491|NCT05799144|BIOLOGICAL|DNA Vaccine|Given pBI-11 IM
41293492|NCT05799144|BIOLOGICAL|Human Papillomavirus Tumor Antigen Vaccine|Given into a muscle
41293493|NCT05799144|BIOLOGICAL|Pembrolizumab|Given into vein
41293494|NCT05799144|PROCEDURE|Computed Tomography (CT)|Undergo a CT
41293495|NCT05799144|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo an MRI
41293496|NCT05799144|PROCEDURE|Magnetic Resonance Imaging|Undergo blood sample collection
41293497|NCT05799144|PROCEDURE|Biopsy|Undergo tumor biopsy
41293498|NCT03454139|PROCEDURE|Subcostal transversus abdominis plane block|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
40764376|NCT06643221|DRUG|Carvedilol 50 mg|Healthy participants will consume a 50mg Carvedilol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
40764377|NCT06643221|DRUG|Roflumilast 500 Mcg Oral Tablet|Healthy participants will consume a 500mcg Roflumilast tablet and a 10mg Bisoprolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
41293499|NCT02807909|DRUG|BMS-986177|
41293500|NCT02807909|DRUG|Itraconazole|
41293501|NCT02807909|DRUG|Diltiazem ER|
41293502|NCT00410280|BIOLOGICAL|IMA-638 is a biologic|
40960459|NCT00787384|DRUG|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
40960460|NCT00190671|DRUG|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
40960461|NCT00190671|DRUG|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
40960462|NCT00190671|DRUG|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
40960463|NCT00136799|DRUG|Fluvastatin|
40960464|NCT02443766|OTHER|Meditation Retreat|Weeklong retreat which includes meditation and prayer.
40960465|NCT02892578|OTHER|electrocardiogram|
41293503|NCT00805883|PROCEDURE|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
41293504|NCT01099826|BEHAVIORAL|Tailored counseling|education tailored to baseline beliefs by trained counselor over phone
41293505|NCT01099826|BEHAVIORAL|Motivational Interview|motivational interview by trained MI counselors by phone
41293506|NCT05644210|DRUG|Telitacicept|160mg once a week for 24 weeks
41293507|NCT05644210|DRUG|Rituximab|Patients received 200mg of rituximab intravenously at week 0 and week 2.
41293508|NCT05644210|DRUG|Aspirin|50-100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
41293509|NCT05644210|DRUG|Warfarin|Warfarin should be used in patients with arterial thrombosis, and rivaroxaban should be replaced if the patient cannot reach the standard or cannot tolerate it
41293510|NCT05644210|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed，if tolerated by the patient， the dose should remain constant during the observation period
41293511|NCT05644210|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
41293512|NCT03705104|BEHAVIORAL|EPIO|App for self-management of chronic pain An app consisting of 9 modules focusing on cognitive behavioral pain self-management.
41293513|NCT05571150|BEHAVIORAL|Dyad-focused strategy training intervention|"The program consists of five critical ingredients: shared decision making, self-selected goals, self-evaluation of performance, strategy development and implementation, and therapeutic guided discovery.~Trained research therapists will deliver the intervention to the survivor-caregiver dyads on a one-to-two base at the participants' home or in a quiet room at our collaborative hospitals. The therapist will ask the dyad to identify 3 to 5 shared participation goals and provide them the global strategy (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
41293514|NCT05571150|BEHAVIORAL|Attention-control intervention|The topics of the education will cover: (1) secondary stroke prevention; (2) prevention and management of comorbidities; (3) managing emotions and behaviors; (3) medications and personal care; (4) finances and transportation; and (5) home and community-based participation.
41293515|NCT01285921|OTHER|vestibular test before and after hippocampal surgery|"* Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)~* HIT (testing semicircular canal function at high frequency).Results: Gain in %~* VEMp (testing saccular function). Results: Amplitude in μV and latency in ms~* ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s~* Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S"
41293516|NCT06231940|OTHER|Complex Decongestive Therapy (CDT) in venous insufficiency,|Complex Decongestive Therapy (CDT) is a comprehensive treatment approach primarily used for lymphedema and related conditions, but it's also beneficial for chronic venous insufficiency and other edematous conditions. CDT aims to reduce swelling and maintain the reduction, improve skin condition, and alleviate symptoms. It typically involves two phases: an intensive phase to reduce swelling as much as possible and a maintenance phase to sustain the achieved results. The main components of CDT include: Manual Lymph Drainage (MLD),Compression Therapy, Exercise, Skin Care, Education and Self-Care:
41293517|NCT00363012|BIOLOGICAL|HER-2/neu intracellular domain protein|300mcg (100mcg/peptide) of the HER2 ICD peptide mixture per skin test. This will be injected intradermally on the back at 6 months post active immunization.
41293518|NCT00363012|OTHER|flow cytometry|This is a laboratory test used to assess the antigen specific T cell population.
41293519|NCT00363012|OTHER|immunohistochemistry staining method|This is a laboratory test used to identify CD3+, CD4+, CD45R0+, CD8+, and DC1a+ present in the skin biopsy.
41293520|NCT00363012|PROCEDURE|biopsy|A 3mm punch biopsy is taken of the vaccine site. This is taken for laboratory analysis for immunohistochemical staining.
41293521|NCT00363012|OTHER|Sterile water placement|100mcg of sterile water will be administered intradermally on the back and serves as a negative control for the laboratory analysis. This will be injected intradermally on the back at 6 months post active immunization.
41293522|NCT03421990|PROCEDURE|General anesthesia|general anesthesia and regional anesthesia techniques are used
41293523|NCT06483633|BEHAVIORAL|MICT + CPT, HIIT + CPT, SIT + CPT|Single acute intervention, each exercise mode had a washout period of at least 7 days.
41293524|NCT00001259|DRUG|Leuprolide|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
41293525|NCT00001259|DRUG|Estradiol Patches|Transdermal Estradiol, 100mcg/day by skin patch
41293526|NCT00001259|DRUG|Progesterone|Progesterone suppository, 200mg vaginally twice/day
41293527|NCT00001259|DRUG|Placebo patch|Placebo by skin patch
41293528|NCT00001259|DRUG|Placebo injection|Placebo given intramuscularly monthly
41293529|NCT00001259|DRUG|Placebo suppository|Placebo vaginal suppository
41293530|NCT04756089|DEVICE|Electronic breast pump|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
41293531|NCT04756089|OTHER|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
41293532|NCT04704765|OTHER|abdominal breathing training|The abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time).
40960466|NCT01848691|OTHER|Measurement of carbon monoxide level in exhaled breath|Measurement of end-tidal carbon monoxide concentration
41293533|NCT02313480|OTHER|massage|Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
41293534|NCT06149884|PROCEDURE|Sentinel lymph node biopsy, axillary lymph node dissection|"SLNB was performed using single or dual tracers. For the single tracer technique, Technetium 99, a radioactive substance, was administered periareolarly prior to surgery, and SLNs were identified intraoperatively via a gamma detection system (Neoprobe®). The dual tracer method employed both an isosulfan blue dye and Technetium 99 concurrently. The choice of SLNB technique was contingent upon the surgeon's discretion. SLNs were categorized as one or multiple, and any LN identified by either or both methods was defined as SLN. LNs resected during SLNB without tracer signal were not classified as SLNs.~ALND was characterized by the removal of all LNs in axillary levels I and II. Patients documented to have undergone ALND in surgical records were primarily selected from our registry. Among them, those with fewer than 10 LNs were excluded, based on the assumption that a competent ALND necessitated the removal of 10 or more LNs as defined in previous studies"
40960467|NCT04194580|BEHAVIORAL|Phisical activity intervention|The prevalence of overweight in chilean children in the among the highest in the world and increasing quickly. The investigators recently evaluated an after-school program of recreational physical activity to control overweight, obesity and other cardiovascular risk factors in primary school children Temuco. This program reduced adiposity and increased the fitness.
40960468|NCT00004075|DRUG|tanespimycin|
41293535|NCT03806595|DRUG|Lidocaine 2% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
41293536|NCT03806595|DRUG|Normal Saline Flush, 0.9% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
41293537|NCT04637321|PROCEDURE|Solid organ transplant|Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018
41293538|NCT06487494|PROCEDURE|Circumcision wound closure using 2-octyl cyanoacrylate glue with four interrupted sutures|2-octyl cyanoacrylate glue is a wound closure adhesive which will be used with four interrupted sutures following circumcision for wound closure.
41293539|NCT06487494|PROCEDURE|Circumcision wound closure using continuous sutuing|Continuous suturing is the standard following circumcision for wound closure.
40960469|NCT05944757|DRUG|PRP plasma rich platelets|Twenty patients (20) underwent 0.5 ml 100 % intrastromal injection of PRP plasma rich platelets (first group) every 2 weeks for one month
40960470|NCT05944757|DRUG|Autologous serum|Twenty patients (20) underwent intrastromal injection of 0.5 ml 100 %of autologous serum (second group) every 2 weeks for 1 month
40960471|NCT03815942|BIOLOGICAL|ChAdOx1-MVA 5T4 vaccine|ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10\^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10\^8 plaque forming units
40960472|NCT03815942|DRUG|Nivolumab Infusion [Opdivo]|Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
40764378|NCT06644313|DRUG|Vebreltinib|Neoadjuvant treatment stage: Vebreltinib 200mg, bid, po, 2-4 months in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Vebreltinib 200mg, bid, po, up to 2 years/until the disease progressed. PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
40960473|NCT02273778|PROCEDURE|MRI Scan|
40960474|NCT02273778|PROCEDURE|PET-CT Scan|
40960475|NCT02273778|OTHER|No intervention|
40960476|NCT02753114|DRUG|Ketamine|Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.
40960477|NCT02753114|DRUG|Normal Saline|Intranasal Normal Saline administered via mucosal atomization device.
41136079|NCT03098199|DRUG|300IU Gonal-F|\<1.5 AMH group
41136080|NCT03098199|DRUG|150IU Menopur|\<1.5 AMH group
41293540|NCT03151525|DRUG|Azathioprine|AZA treatment after IFX withdrawal for maintenance of remission
41293541|NCT03151525|DRUG|Infliximab|IFX treatment for maintenance of remission
41293542|NCT00390780|DRUG|miconazole Lauriad|50 mg buccal tablet once a day for 14 days
41293543|NCT00390780|DRUG|Clotrimazole|10mg troches administered Five Times a Day for 14 days
41293544|NCT02019381|DIETARY_SUPPLEMENT|Endocrine Society UL Dosage Vitamin D|Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
41456103|NCT00691704|DRUG|Sequential Maintenance Therapy|"Subjects who achieve \>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \> stable disease (SD) from maintenance (per discussion with physician):~* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~* Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~* Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle."
41136081|NCT03098199|DRUG|225IU Gonal-F|1.6-2.5 AMH group
41136082|NCT03098199|DRUG|75IU Menopur|1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
41136083|NCT03098199|DRUG|150IU Gonal-F|2.6-6.9 AMH group
41136084|NCT03098199|DRUG|75IU Gonal-F|\>7.0 AMH group
41136085|NCT06117215|OTHER|Data collection|data collection
41136086|NCT05766943|DEVICE|Smart Pass ON|Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
41293545|NCT02019381|DIETARY_SUPPLEMENT|Institute of Medicine Dosage Vitamin D|IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
40764379|NCT04785820|DRUG|Lomvastomig|2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.
40764380|NCT04785820|DRUG|Tobemstomig|2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
41293546|NCT02019381|DIETARY_SUPPLEMENT|Calcium|1200mg of CaCO3 supplementation will be given to each participant in both groups
41293547|NCT02003742|DRUG|NX-1207|Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
41293548|NCT02003742|DRUG|Tamsulosin|1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
41456104|NCT01223755|DRUG|Sirolimus|Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
41293549|NCT00746772|DRUG|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
40960478|NCT05452031|BEHAVIORAL|Care2Sleep|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
40960479|NCT05452031|BEHAVIORAL|Sleep Education|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
40960480|NCT05938491|DIAGNOSTIC_TEST|OCT and OCT-A|OCT and OCT angiography for the macula
40960481|NCT00840892|OTHER|INTERdisciplinary COMmunity-based COPD management (INTERCOM)|The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
40960482|NCT05825469|BEHAVIORAL|Nutrition Algorithm|A technology-based platform for a person-centered nutrition program, providing suggested foods and recipes from dietitians.
41293550|NCT00746772|DRUG|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
41293551|NCT02369835|DRUG|Dakin's solution|Apply modified Dakin's solution (0.005 to 0.01%) topically
41293552|NCT02369835|OTHER|Placebo|Applied topically
41293553|NCT02457351|DRUG|Roniciclib (BAY 1000394)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent 21-day cycles:~Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose"
41293554|NCT02457351|DRUG|Itraconazole (Sporanox)|Part 1 \& Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
40764381|NCT04785820|DRUG|Nivolumab|240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
40764382|NCT02607722|DRUG|Nintedanib|
40764383|NCT05155085|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8
40764384|NCT05155085|OTHER|Placebo|Placebo
40764385|NCT04032470|DEVICE|Deep Brain Stimulation Systems (DBS)|Subjects receiving DBS implant for treatment of Essential Tremor
40960483|NCT02895230|OTHER|Standard care|An extraction from French Health Reimbursement Agency database and French hospital discharge database will be performed using a simplified request based on inclusion criteria but the extraction will encompass a 4-year period to ensure sufficient follow-up.
40960484|NCT06409871|OTHER|Physiotherapy treatment.|-Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.
40960485|NCT06409871|OTHER|Physiotherapy treatment and modification of the biorhythm.|"* Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.~* Modification of the biorhythm will consist of eliminating methylxanthine-rich foods and/or beverages from their diet, as well as no exposure to electronic devices two hours before bedtime."
41136087|NCT05766943|DEVICE|Smart Pass OFF|Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
41136088|NCT02630966|DRUG|Vedolizumab|Vedolizumab 300 mg IV infusion
41136089|NCT02630966|DRUG|Placebo|0.9% sodium chloride IV infusion
40764386|NCT06639880|OTHER|usual care exercise|the usual care for the lumbar spine which includes TENS, ultrasound, and myofascial release for the lumbar spine in addition to a core program including bridge, half bridge and clam shell exercise
41136090|NCT02476929|DEVICE|Nasal nitrous oxide|Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
40960486|NCT03727230|OTHER|Blood transfusion|Transfusion with RhD+ blood product rather than rare RhD-negative blood to Asian-type DEL recipients
40960487|NCT00541593|PROCEDURE|Pancreatic Pseudocystgastrostomy|An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
41136091|NCT02476929|DEVICE|Electronic nose|To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
41136092|NCT00681915|DRUG|AZD7325|Oral
41136093|NCT06180226|DIAGNOSTIC_TEST|PET CT with 18 FDG .|Impact exerted by the use of 18FDG PET in the process of functional monitoring of the patient undergoing radiotherapy treatment.
41293555|NCT04187222|OTHER|Mechanical debridements|Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curette and polishing using a rubber bowl and polishing paste.
40764387|NCT06639880|OTHER|triple attack protocol|a modified P-A mobilization, manipulation, and stabilization program (Active and passive) for the thoracic spine in addition to the usual care and the core program for the lumbar spine
40764388|NCT04524000|DRUG|Alpelisib|"\[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1."
40764389|NCT04524000|DRUG|Fulvestrant|Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
40764390|NCT06358326|OTHER|Dry needling|In addition to stretching, nerve mobilization and tendon gliding exercises, a total of 5 sessions of dry needling will be performed for fascial mobilization, 2 days a week for 3 weeks.
41293556|NCT04187222|BIOLOGICAL|Bifidobacterium animalis subsp. lactis|Capsules containing Bifidobacterium animalis subsp. lactis were chubby and subsequently ingested twice a day for 12 weeks.
41293557|NCT05801523|PROCEDURE|laparoscopic ethanol sclerotherapy|ethanol (96%) sclerapy of endometrioma - endometrioma is filled with ethanol via foley catether, left for 10 min and than aspirated, endometrioma is washed with saline
41293558|NCT05801523|PROCEDURE|laparoscopic cystectomy of endometrioma|cystectomy of endometrioma - removal of endometrioma from ovary surgically
41293559|NCT00763204|DRUG|AN2728 Cream, 2%|
41293560|NCT00763204|DRUG|AN2728 Cream, 1%|
41293561|NCT00763204|DRUG|AN2728 Cream, 0.3%|
41293562|NCT00763204|DRUG|AN2728 Cream Vehicle|
41293563|NCT00763204|DRUG|Betnesol®-V Creme, 0.1%|
41293564|NCT06396156|PROCEDURE|Anterior enclavation|Anterior enclavation of iris-claw lens
41293565|NCT06396156|PROCEDURE|Posterior enclavation|Posterior enclavation of iris-claw lens
41293566|NCT03245632|OTHER|Carbapenem-Resistant Klebsiella pneumoniae|no intervention, this is an obervational study.
41293567|NCT02221076|DEVICE|Confocal Laser Endomicroscopy (CLE)|Real-time microscopic imaging of living tissue during the standard procedure
41293568|NCT02335450|BEHAVIORAL|Motivational Interviewing|The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.
41293569|NCT02335450|DEVICE|Wristband physical activity monitor|The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
40764391|NCT06358326|OTHER|Control group|The physiotherapist will teach stretching, neuromobilization and tendon shifting exercises and will be asked to do them regularly for 3 weeks.
40764392|NCT06241014|OTHER|Mulligan Mobilization and Sling Exercises|Mulligan mobilizations along with sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated total of six times having two sessions per week for 3 weeks. For the sling exercise, the sling exercise program will also be applied for 3 weeks, 2 times a week for 20 minutes per day. To perform the exercise, the subjects will be instructed with a demonstration and explanation.
40960488|NCT04534361|OTHER|CBCT measurements|No intervention will be performed on patients for this study. Based on the CBCTs already done previously of the patients in the sample, linear measurements will be taken in order to assess dimensional changes of the alveolar ridge at 1, 3, 5 and 7 mm from the bone crest in the CBCTs taken before and after implant explantation, 4-6 months apart.
40764393|NCT06241014|OTHER|Mulligan Mobilization|Mulligan Mobilization
40960489|NCT01837108|DRUG|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
40960490|NCT01837108|DRUG|Placebo|
40960491|NCT00958100|DRUG|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
40960492|NCT00958100|DRUG|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
40764394|NCT06275074|PROCEDURE|Dry Needling|Insertion of filiform needles into cervicothoracic multifidi, upper trapezius, and suboccipital muscles
40960493|NCT00958100|DRUG|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
40960494|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)|Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).
40960495|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron)|Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).
40960496|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)|Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).
40960497|NCT03685968|DEVICE|Video laryngoscopes|Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.
40960498|NCT04144660|DEVICE|Extracorporeal Membrane Oxygenation|Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
40960499|NCT02019693|DRUG|INC280|Supplied by Novartis as film-coated tablet for oral use.
40960500|NCT01149226|DRUG|chloral hydrate|30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
40960501|NCT00135096|DRUG|insulin glulisine|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
40960502|NCT00135096|DRUG|insulin glargine|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
40960503|NCT06008431|DEVICE|Transcranial direct current stimulation (tDCS) (active)|The tDCS montage is developed to modulate the functional connectivity between the dorsal attention network and the default network.
41136094|NCT03516071|DRUG|Brivanib 800 mg, QD|Brivanib Alaninate 800 mg QD, PO
40764395|NCT06275074|OTHER|Therapeutic Exercise|Therapeutic exercise program provided to all participants with the aim of addressing periscapular strength and postural edurance.
40764396|NCT06031402|PROCEDURE|Endoscopy|Endoscopy
41136095|NCT03516071|DRUG|Brivanib 400 mg, BID|Brivanib Alaninate 400 mg BID, PO
41136096|NCT03682003|DIAGNOSTIC_TEST|blood diagnostic tests|blood tests are performed to determine hepcidin, IL-6, CRP, PCT, serum iron, ferritin, transferrin and transferrin saturation
41136097|NCT00780741|PROCEDURE|Immediate Office Probing|Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.
40764397|NCT06639724|COMBINATION_PRODUCT|Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)|Fostamatinib is a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura but it has not been studied in PDAC. The investigators hypothesize that Syk inhibition reprograms macrophages to an immunostimulatory phenotype in the tumor microenvironment. Thus, Syk inhibition with fostamatinib in combination with chemotherapy could improve outcomes for patients with PDAC while having a favorable safety profile.
40960504|NCT06008431|DEVICE|Transcranial direct current stimulation (tDCS) (Sham)|"The tDCS Acti- Sham montage is developed to recreate the cutaneous sensations associated with tDCS, yet essentially a null electrical field over the networks of interest."
40764398|NCT05509660|BEHAVIORAL|PUMA+|Transdiagnostic CBT
40764399|NCT05509660|BEHAVIORAL|PUMA|Transdiagnostic CBT
40764400|NCT05792462|DRUG|Baricitinib|Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.
40764401|NCT06637540|DEVICE|RescueDoppler|Continous handsfree pulsed wave Doppler of the common carotid artery during cardiac surgery
40960505|NCT00002588|DRUG|etoposide|
40960506|NCT00002588|DRUG|topotecan hydrochloride|
40960507|NCT03994107|DRUG|Pegylated Liposomal Doxorubicin|"First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6."
40960508|NCT03994107|DRUG|Albumin-bound paclitaxel|220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
41136098|NCT00780741|PROCEDURE|Deferred Facility Probing|Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
41136099|NCT02377193|DRUG|Simulect|"Simulect IV 40 mg/day D0 and D4~and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg"
41293570|NCT01775488|DEVICE|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
40764402|NCT06637540|DEVICE|RescueDoppler|Continuous hands-free Doppler ultrasound of the common carotid artery during cardiac surgery
40764403|NCT03880019|PROCEDURE|Computed Tomography|Undergo CT
41293571|NCT01659944|DRUG|Eliglustat|Capsules for oral administration
40764404|NCT03880019|PROCEDURE|Core Biopsy|Undergo tumor biopsy
40764405|NCT03880019|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40764406|NCT03880019|DRUG|Olaparib|Given PO
40764407|NCT03880019|DRUG|Temozolomide|Given PO
40764408|NCT06186401|BIOLOGICAL|E-SYNC T Cells|Given IV
40764409|NCT06186401|DRUG|Cyclophosphamide (non-investigational)|Given IV
40764410|NCT06186401|DRUG|Fludarabine (non-investigational)|Given IV
40764411|NCT06186401|PROCEDURE|Leukapheresis|Undergo leukapheresis
40764412|NCT06186401|PROCEDURE|Surgical resection|Undergo surgical resection of tumor tissue
40960509|NCT03994107|DRUG|Trastuzumab|8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
40960510|NCT00126191|DRUG|Rituximab|Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1
40960511|NCT00126191|DRUG|Cyclophosphamide|Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
40960512|NCT00126191|DRUG|Doxorubicin|Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
40960513|NCT00126191|DRUG|Vincristine|Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)
40960514|NCT00126191|DRUG|Methotrexate|Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
40960515|NCT00126191|DRUG|Leucovorin|Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
40960516|NCT00126191|DRUG|Ifosfamide|High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle
41293572|NCT01659944|DRUG|Metoprolol|Tablets for oral administration
41293573|NCT04743882|OTHER||
41293574|NCT00693355|OTHER|Sodium butyrate|sodium butyrate
41293575|NCT00693355|OTHER|NaCl|NaCl
41293576|NCT01781026|DRUG|Vemurafenib|Single arm trial
41456105|NCT01223755|DRUG|conventional therapy|Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure \<130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
40960517|NCT00126191|DRUG|Etoposide|High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
40960518|NCT00126191|DRUG|Cytarabine|Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
40960519|NCT00126191|DRUG|Mesna|High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
40960520|NCT03651869|DRUG|Cigarette 1|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
40960521|NCT03651869|DRUG|Cigarette 2|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
41293577|NCT03262493|DEVICE|Interventional Group|Use of the feeding tube attachment device (FTAD).
41293578|NCT00339079|DRUG|Fluoxetine|Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
41293579|NCT00339079|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.
41456106|NCT06346535|DIAGNOSTIC_TEST|Cognitive Testing|Digital Cognitive Testing performed at home.
41456107|NCT04602741|BEHAVIORAL|A4i Intervention|6 months of the provision of A4i on the individual's own device.
40764413|NCT05621616|DRUG|mirabegron|"Participants will receive mirabegron prolonged-release microgranula-based oral suspension once daily. The initial dose of mirabegron will be based on the participant's weight.~The initial low dose will be up-titrated to a higher dose at weeks 2, 4 or 8 unless the participant is determined to be effectively treated with the low dose, based on urodynamics and the participants'e-diary."
40960522|NCT03651869|DRUG|Patch 1|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
40960523|NCT03651869|DRUG|Patch 2|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
40764414|NCT05996471|BIOLOGICAL|VH3810109|VH3810109 will be administered.
40764415|NCT05996471|DRUG|Cabotegravir|Cabotegravir will be administered.
40960524|NCT00626223|DRUG|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
40960525|NCT00626223|DRUG|folic acid|5 mg per day of oral folic acid
40960526|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 4mg/kg|IL-6R Monoclonal Antibody Injection 4mg/kg i.v.,single use
40960527|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 6mg/kg|IL-6R Monoclonal Antibody Injection 6mg/kg i.v. , single use
40960528|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 8mg/kg|IL-6R Monoclonal Antibody Injection 8mg/kg i.v. , single use
40960529|NCT05232396|BIOLOGICAL|Tocilizumab Injection 8mg/kg|Tocilizumab Injection 8mg/kg i.v., single use
40764416|NCT05996471|DRUG|Standard of care (SOC)|Pre-baseline SOC antiretroviral therapy (ART) will be administered.
41456108|NCT06078176|OTHER|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility and facilitate bowel emptying. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
40764417|NCT05996471|BIOLOGICAL|rHuPH20|rHuPH20 will be administered.
40764418|NCT06643091|DRUG|Nintedanib|Nintedanib150 mg twice a day for 6 months Or Nintedanib 100mg twice a day in case of dose adjustment Oral route (during meals)
40764419|NCT04503616|DRUG|Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention|Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
40764420|NCT04758988|OTHER|DermLoop Learn|DermLoop Learn is our AI augmented digital online educational system with case training on a library of 10,000+ benign and malignant skin lesion as well as written learning modules for the most common skin lesion diagnosis.
40764421|NCT06076135|RADIATION|Intestinal Low Dose Radiotherapy-1Gy|1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.
40764422|NCT06076135|RADIATION|Intestinal Low Dose Radiotherapy-2-3Gy|ILDR will be administered as single fractions within 10 days. The total dose of radiotherapy will be 2-3 Gy in 2-3 fractions. ILDR design is as above.
40764423|NCT06076135|DRUG|PD-1/PD-L1 Inhibitors|The immunotherapy regimen is the previous ICB therapy regimen or modified by the physician in charge. PD-1/PD-L1 inhibitors will be given 1 day after ILDR at a 3-week interval.
40960530|NCT00378378|DRUG|Mometasone Furoate Nasal Spray (MFNS)|100 mcg nasal spray
40960531|NCT00378378|DRUG|Placebo nasal spray|One spray of placebo nasal spray in each nostril once daily for 4 months.
40764424|NCT03683251|DRUG|PDS Implant with Ranibizumab 100 mg/mL|Will be administered as per the schedule described in individual arm
40764425|NCT06583720|PROCEDURE|Oral hygiene at home|Participant will be taught on how to correctly brush their teeth, use dental floss and scrape their tongues at home.
40960532|NCT00074152|DRUG|chemotherapy|Given within 10 weeks after surgery.
40960533|NCT00074152|RADIATION|radiation therapy|Given within 6 months after surgery
40960534|NCT02109211|DEVICE|Intubation with Magill forceps|
40960535|NCT02109211|DEVICE|Intubation with altered Magill forceps|
40960536|NCT04942899|DRUG|letrozole|concurrent capecitabine 500 mg three times daily in combination with letrozole 2.5 mg orally once daily.
40960537|NCT05488730|DIAGNOSTIC_TEST|passive leg raising test and fluid challenge|"Shocked patients were subjected to echocardiographic examination if (EF \<52%) .baseline LVOT VTI was obtained Then IVC scanning was done through subcostal Window and using M-mode the minimum and the maximum diameters were measured then the collapsibility index was calculated~Then passive leg raising test was done Patients who tolerated the PLR test and did not develop clinical or lung ultrasound signs of fluid overload (lung congestion) were given IV fluid bolus (250 ml normal saline) over 10 minutes followed by measurement of LVOT VTI.~Patients who did not tolerate PLR test or developed clinical or lung ultrasound signs of fluid overload (lung congestion) during PLR test were excluded from the third step (fluid challenge).~The differentiating factor used to allocate patient in which group (non-responder or responder) was LVOT VTI variability after fluid challenge (our gold standard to assess fluid responsiveness)."
40960538|NCT00873197|DRUG|granisetron|"Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only."
40960539|NCT04545060|BIOLOGICAL|VIR-7831 (sotrovimab)|VIR-7831 (sotrovimab) given by intravenous infusion (single dose)
40960540|NCT04545060|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
40960541|NCT04946747|DEVICE|Modern microelectrical mechanical systems (MEMS) head-impact sensors|Both groups will wear our smart head-impact sensor system (MEMS head-impact sensors) to measure their response to training.
41136100|NCT02377193|DRUG|ATG Fresenius|Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
41456109|NCT03105297|DEVICE|Prototype nasal dilator strip|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
41456110|NCT03105297|OTHER|No strip|
40960542|NCT04946747|OTHER|Virtual Reality (VR) Goggle Use with consistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.
40960543|NCT04946747|OTHER|Virtual Reality (VR) Goggle Use with inconsistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Control group will also receive the same CS and the same US as trained group, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge.
40960544|NCT06557447|DIAGNOSTIC_TEST|Immunological and microbiological sample of peri-implant crevicular fluid; clinical evaluation|"Immunological sample collection involves placing a Periopaper strip in the peri-implantar sulcus for 30 seconds. If sample is contaminated with blood, sample will be discarded and another sample will be collected (a different surface of the same implant/tooth can be used).~Microbiological sample collection involves collecting subgingival dental plaque by sliding the end of the STERILE curette (Gracey) inside the peri-implant sulcus. In case of slight bleeding following the first sample, dry the site again before collection. In case of profuse bleeding, collect a sample from another site (by site mean mesial/buccal/distal/lingual) of the same implant.~Both immunological and microbiological samples will be sent for respective laboratories for the analysis.~Clinical evaluation will assess presence of dental plaque, bleeding on probing and gingival status."
40960545|NCT04099147|OTHER|This is an observational study.|This is an observational study. No intervention is planned outside of usual clinical practice.
40960546|NCT03166735|DRUG|BI 1467335|once daily
40960547|NCT03166735|DRUG|Placebo|once daily
40960548|NCT00480883|DRUG|meglumine antimoniate, allopurinol|first drug in injectable, second is in tablet form.
40960549|NCT00480883|DRUG|meglumine antimoniate|injectable 20 mg/kg/day/intramuscular for 21 days.
40960550|NCT00480883|DRUG|meglumine antimoniate, allopurinol|injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
40960551|NCT02378259|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
40960552|NCT02378259|PROCEDURE|Intense conservative treatment|Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
40960553|NCT04958135|DRUG|Acoramidis|Film-coated immediate release oral tablet.
40960554|NCT04165200|DIAGNOSTIC_TEST|Blood and feces samples|"Blood samples are going to be taken by puncturing peripheral vein extraction with 10 ml of venous blood for later biweekly to monitor in person and therefore monitor immune status with biomarkers T lymphocyte subclass CD4 and viral load. A total of four blood samples will be taken at weeks 4, 8, 12 and 24 of recruitment.~A total of four feces samples are going to be required during the study, to evaluate the changes on the microbiota of the patient. 1 week before the patients start their HAART, the same day the patients initiate their HAART, 8 weeks after they started HAART and 24 weeks after HAART."
40960555|NCT05184985|DEVICE|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
41293580|NCT00339079|OTHER|Supportive Therapy|The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
41293581|NCT00339079|DRUG|Placebo|Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
41293582|NCT04621123|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT plasma|Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
41293583|NCT04621123|OTHER|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
41293584|NCT02553720|OTHER|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
40960556|NCT05184985|DEVICE|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
40960557|NCT01727297|DEVICE|REVEAL Implantable Cardiac Monitor|
41456111|NCT01979146|OTHER|Provider Unrelieved Symptom Alert|The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
40960558|NCT03033485|RADIATION|18F-P3BZA|18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
40960559|NCT00180544|DEVICE|Stenting: Renal Artery|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
40960560|NCT04563702|BIOLOGICAL|VXA-CoV2-1|non replicating Ad5 adjuvanted oral tableted vaccine
40960561|NCT01090843|PROCEDURE|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
40960562|NCT01090843|DEVICE|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
40960563|NCT01090843|DEVICE|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
40960564|NCT03675100|PROCEDURE|colonoscopic mucosal biopsy|colonoscopic mucosal biopsy was undertaken for every participant
40960565|NCT05801965|DEVICE|A digital solution for patients with Cancer|A digital program that provides holistic lifestyle intervention as well as disease education.
41293585|NCT02553720|OTHER|aquatic activity plus conventional management|walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
41293586|NCT05513612|BIOLOGICAL|Autologous CAR-T cells|CAR-T cells will be infused intravenously.
41293587|NCT05513612|DRUG|Fludarabine|Administered according to package insert
41293588|NCT05513612|DRUG|Cyclophosphamide|Administered according to package insert
41293589|NCT06512311|DIAGNOSTIC_TEST|CBMed Drug Screening Plattform|The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics.
41293590|NCT06149312|OTHER|Advance Care Planning Intervention|Standardized interview based on The letter Project (Stanford Medicine) and Questions Prompt List
41293591|NCT05197868|PROCEDURE|Intubation with traditional laryngoscope|Participants will be invited to intubate the mannequin with a traditional laryngoscope
41293592|NCT05197868|PROCEDURE|Intubation with a straight blade video laryngoscope|Intubation with a straight blade video laryngoscope
41293593|NCT05197868|PROCEDURE|Intubation with a hyper-angulated video laryngoscope|Participants will be asked to intubate the mannequin with a hyper-angulated video laryngoscope
41293594|NCT01161524|DRUG|Perampanel|2 mg titrated up to 8-12 mg maximum; taken once daily.
40960566|NCT05801965|OTHER|Standard of care for patients with Cancer|Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
40960567|NCT03431428|PROCEDURE|transanal surgery|Transanal surgery could Preserve anus to reduce trauma and improve the quality of life
40960568|NCT03431428|PROCEDURE|Miles surgery|Miles surgery cut off the anus, enlarge the trauma and reduce the quality of life.
40960569|NCT03431428|DRUG|Preoperative chemoradiotherapy|After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.
40960570|NCT04974840|BEHAVIORAL|Treadmill training combined with/ without thera-band|Treadmill walking training with thera-band Treadmill walking training without thera-band
41293595|NCT01161524|DRUG|Placebo|Matching Placebo taken once daily.
41293596|NCT05272059|DRUG|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
40960571|NCT01538043|OTHER|local mud-pack therapy and balneotherapy|local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
40960572|NCT02462239|OTHER|Whole-body FDG PET-CT|
40960573|NCT00880009|DRUG|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
40960574|NCT00880009|DRUG|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
40960575|NCT00880009|DRUG|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
40960576|NCT02828696|DEVICE|"No prep treatment of worn dentition with CAD-CAM composite"|Realization of minimally invasive prostheses in PICN (CAD-CAM composite)for worn dentition. Tooth tissues are preserved: no preparation is performed and ultra-thin restorations are CAD-CAM milled.
40960577|NCT06116760|DEVICE|Anodal or sham tDCS|"Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training."
40960578|NCT06116760|BEHAVIORAL|Audio-visual training|"90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse."
40960579|NCT03166384|DEVICE|electrosurgical bipolar sealing devices|Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.
40960580|NCT03166384|PROCEDURE|conventional suture and tie|the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
40960581|NCT05706532|DIAGNOSTIC_TEST|active standing|Data are acquired with patients resting in supine position for 10 minutes and for 10 minutes during active standing
40960582|NCT01957722|PROCEDURE|Microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
40960583|NCT01957722|BIOLOGICAL|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
41293597|NCT05272059|DRUG|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
41293598|NCT03348631|PROCEDURE|Computed Tomography|Undergo CT scan
41293599|NCT03348631|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40960584|NCT05607901|DRUG|Tacrolimus ointment|tacrolimus is an immunosuppressive drug acting as an immunomodulator to assist manage acute flares and reducing the severity of future flares
40960585|NCT05607901|DRUG|Hydrocortisone 1% cream|Topical corticosteroids (TCS) are the cornerstone for the management of AD to which other treatments are compared.
40960586|NCT00196755|DRUG|Sevelamer Hydrochloride (Renagel®)|Sevelamer hydrochloride three times per day with each meal
40960587|NCT00196755|DRUG|Calcium acetate (PhosLo® )|Calcium acetate three times per day with each meal
40960588|NCT01671800|DRUG|Botulinum Type B|
40960589|NCT01671800|DRUG|Placebo|
40960590|NCT03322631|DRUG|Tirzepatide|Administered SC.
40960591|NCT03322631|DRUG|Placebo|Administered SC.
40960592|NCT06071208|DRUG|Gliflozin|to study whether the use of gliflozin prevented diabetic complications
40960593|NCT00282984|DRUG|placebo|1 mg placebo twice daily by mouth for 12 weeks
40960594|NCT00282984|DRUG|Varenicline|1 mg twice daily by mouth for 12 weeks
41293600|NCT03348631|DRUG|Tazemetostat|Given PO
41293601|NCT03802422|DRUG|Vitamin B12|Ultrasound-guided hydrodissection with 3cc Vitamin B12 (methycobal, 500μg/ml) between carpal tunnel and median nerve.
41293602|NCT03802422|DRUG|Normal saline|Ultrasound-guided hydrodissection with 3cc 0.9% normal saline between carpal tunnel and median nerve.
41293603|NCT06116591|BIOLOGICAL|mPnC candidate|monovalent pneumococcal conjugate candidate
41293604|NCT06116591|BIOLOGICAL|mPnC control|monovalent pneumococcal conjugate control
41293605|NCT00450606|PROCEDURE|Balneotherapy and hydrotherapy|
40764426|NCT06583720|PROCEDURE|aPDT|A weekly aPDT session will be performed for a period of 30 days, with the photosensitizer (PS) annatto manipulated at a concentration of 20% (Fórmula e Ação®). 2 ml (quantity measured with a pipette) will be applied to the middle third and dorsum of the tongue for 2 minutes for incubation (pre-irradiation time). The excess will be removed with a suction device in order to keep the surface moist with the PS itself. Six points will be irradiated with a distance of 1 cm between them, considering the light scattering halo; the LED will be positioned at a distance from the tongue so as to form a 2 cm halo at each point. The device will be previously calibrated with a wavelength of 395-480 nm, for 20 seconds per point, energy of 9.6 J.
40764427|NCT06583720|DIETARY_SUPPLEMENT|Probiotics|Probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®) (OralBiotic; Master Products, Fort Lauderdale, Florida, United States) will be used. Each patient will receive 60 lozenges, which should be allowed to dissolve slowly and completely in the mouth. Patients are instructed to use the lozenges twice a day for a period of 30 days.
40764428|NCT05526157|DRUG|Finerenone (Kerendia, BAY 948862)|Retrospective analysis using secondary data collection from various sources
41456112|NCT03685617|DEVICE|Dual Chamber Pacemaker|1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
41456113|NCT03685617|DEVICE|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
40764429|NCT05526157|DRUG|Sodium-glucose cotransporter 2 inhibitors (SGLT2i)|Retrospective analysis using secondary data collection from various sources
41293606|NCT03996538|DRUG|Metformin Hydrochloride Extended-Release Tablets|Subjects will ingest 1500mg/day of metformin hydrochloride extended release. Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.
41293607|NCT03996538|BIOLOGICAL|Influenza Vaccine|All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
41293608|NCT00568789|DRUG|Ramelteon, zolpidem and placebo|"Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3"
41293609|NCT06098885|OTHER|extraction orthodontic treatment|bilateral upper first premolar extraction orthodontic treatment with moderate anchorage.
41293610|NCT00430781|DRUG|pazopanib (GW786034)|
41293611|NCT00430781|DRUG|lapatinib (GW572016)|
41293612|NCT01362400|DRUG|IPI 504 plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
41293613|NCT01362400|DRUG|Placebo plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
41293614|NCT00933205|DRUG|Tipranavir|
41293615|NCT00370149|DEVICE|Antibiotic-impregnated Catheters (M/R)|Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
40764430|NCT05526157|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|Retrospective analysis using secondary data collection from various sources
41293616|NCT00370149|DEVICE|Non-impregnated Catheters (C/S)|Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
41293617|NCT03474003|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2002 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; RCT conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
41293618|NCT03839433|DRUG|Ciclesonide|
41293619|NCT00212238|BEHAVIORAL|internet behavioral weight loss program|
41293620|NCT05328167|DRUG|Perflutren Protein-Type A Microspheres|Given IV
41293621|NCT05328167|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
41293622|NCT05760937|DRUG|BMS-986447|Specified dose on specified days
41293623|NCT05760937|DRUG|Placebo|Specified dose on specified days
41293624|NCT03425110|OTHER|Modified Ketogenic Diet|
41293625|NCT02110121|DEVICE|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
41293626|NCT02110121|DEVICE|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
41293627|NCT06043310|DRUG|Nω-nitro-L-arginine methyl ester (L-NAME)|L-NAME will be infused locally through microdialysis catheters.
41293628|NCT06043310|DRUG|Acetylcholine|ACh will be infused locally through microdialysis catheters.
40960595|NCT02527161|DEVICE|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
40960596|NCT05120778|BEHAVIORAL|exercise training|as appear in arm description.
40960597|NCT05120778|OTHER|conventional medical treatment|participants will maintain habitual medical treatment prescribed by primary care and specialized physicians from the public health service.
40960598|NCT02493140|DIETARY_SUPPLEMENT|Cashew apple extract (Cashewin)|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
40960599|NCT02493140|DIETARY_SUPPLEMENT|Placebo|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
40960600|NCT05014893|COMBINATION_PRODUCT|multi-modal targeted intervention (e.g., cognitive training, exercise, games)|The Intervention group will be given recommended interventions tailored to individuals based on their risks (e.g., physical exercise programs, cognitive training, dietary advice, control of blood pressure and cholesterol, healthy diet, control obesity, stop smoking,reduce alcohol excess)
40764431|NCT05526157|DRUG|Steroidal mineral corticoid receptor antagonists (sMRA)|Retrospective analysis using secondary data collection from various sources
40764432|NCT05526157|DRUG|Non-steroidal mineral corticoid receptor antagonists (nsMRA)|Retrospective analysis using secondary data collection from various sources
40764433|NCT05125302|DRUG|Ubrogepant|Oral Tablet
40764434|NCT05125302|DRUG|Placebo-Matching Ubrogepant|Oral Tablet
40764435|NCT04821310|DRUG|Full dose Pantoprazole plus matching placebo|Full healing dose of pantoprazole plus matching placebo
40764436|NCT04821310|DRUG|Half Dose Pantoprazole plus matching placebo|Half healing dose of pantoprazole plus matching placebo
40960601|NCT05535699|OTHER|exercises|scapular exercise
40960602|NCT01006174|OTHER|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
40960603|NCT01006174|OTHER|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
40960604|NCT01006174|OTHER|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
40960605|NCT03557697|BEHAVIORAL|Standard of Care|At the end of the study the control group will be provided with the opportunity to receive counseling videos delivered via SMS
40960606|NCT03557697|BEHAVIORAL|SMS Intervention|Participants in the intervention group will receive SMS based video counseling which include both educational and SCT=-based behavioral content. In addition, participants will receive biweekly phone calls from study community health workers to review the video content and clarify questions, set goals, and problem-solve barriers to achieving the goals.
40764437|NCT05516134|BEHAVIORAL|SAFE at Home|The All About Me (AAM) app will consist of Serious Digital Health Games for PWD. The market-ready version of the app will consist of five components. (1) The Fun Facts About Me Game will be used when a PWD is moving into LTC. The goal of the game is to provide an enjoyable way for family members and PWD to provide important information about the PWD's background. (2) The Resident Game Bundle will consist of SDHGs that will allow PWD to learn about one another in an enjoyable way. (3) The My Residents Module will provide staff with a convenient way to view information about a PWD with whom they will be working. Staff will launch this module from any device. (4) The Meet the Staff Module, which will be developed and tested in a future Phase II study, will allow residents to learn about staff members at their community. (5) The AAM Training Modules will provide staff and family members with access to video-based training modules that describe how to use relevant portions of the app
40764438|NCT06643546|OTHER|theoretical training|received only theoretical breastfeeding training
40764439|NCT06643546|OTHER|model simulation training|theoretical breastfeeding training and model simulation training accompanied by scenarios
40764440|NCT06643546|OTHER|live-simulation|theoretical breastfeeding training and live simulation training with scenarios
40764441|NCT06645379|OTHER|Platelet-Rich Plasma (PRP) Injections|Transvaginal or laparoscopic injection for ovarian diseases (Premature ovarian insufficiency and Poor ovarian response). Intrauterine perfusion or sub-endometrium injection for uterine diseases (intrauterine adhesion, thin endometrium, and repeated implantation failure)
40764442|NCT05584566|DEVICE|OSSIX Breeze|barrier membrane
41293629|NCT06043310|DRUG|Sodium Nitroprusside|SNP will be infused locally through microdialysis catheters.
41293630|NCT02553603|DRUG|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
41293631|NCT02553603|DRUG|Placebo Growth Hormone Releasing Hormone|Placebo GHRH to be given once daily for 10 weeks
40764443|NCT05584566|DEVICE|Jason membrane|barrier membrane
40764444|NCT06476509|DRUG|LV232 40mg|oral
40764445|NCT06476509|DRUG|Escitalopram 20 mg|oral
40764446|NCT03409198|DRUG|Ipilimumab|Ipilimumab blocks CTLA-4 and may deplete regulatory T cells
40764447|NCT03409198|DRUG|Nivolumab|Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.
40764448|NCT03409198|DRUG|Pegylated liposomal doxorubicin|Chemotherapy
41293632|NCT04272905|OTHER|Non-interventional study|The participants will be asked to complete a questionnaire on their knowledge of, and attitudes towards the recording of patient care by patients or relatives/friends in the maternity unit. An investigator will be immediately available to facilitate completion of the survey and assist with understanding of the questions. The data recorded will be a mixture of nominal data (selections from a number of options using a tickbox) or ordinal (as above, but graded e.g. yes / yes with qualifiers / no). Free text will be coded and presented as nominal data or presented verbatim to illustrate points that arise.
41293633|NCT03906344|DRUG|INCB052793|
41293634|NCT04940598|OTHER|high intensity interval exercise|HIIT training will be delivered two times per week for 16 weeks (32 sessions). Each session will be separated by at least 24-hrs. Participants will be allowed to choose the days and times that they feel exercise will fit into their schedule. The HIIT protocol will be determined based on peak anaerobic power measures during an arm crank Wingate Cycle test. HIIT will consist of 20 minutes of exercise consisting of four minutes of arm crank exercise at 5% of peak anaerobic power followed by 30 seconds at 30% of the peak anaerobic power; this cycle will be repeated four times, ending with two minutes of recovery at 5% of peak anaerobic power.
41293635|NCT04940598|OTHER|No-exercise control group|No-exercise control group
41293636|NCT02636764|OTHER|exercise|exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
41293637|NCT02636764|DEVICE|interferential current|The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (\<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
40764449|NCT03409198|DRUG|Cyclophosphamide|Chemotherapy
40764450|NCT04790370|DRUG|Anticoagulation with heparin|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
40960607|NCT05204238|DIAGNOSTIC_TEST|Transthoracic Echocardiography|LV dimensions, LV mass and indices of LV function LA area and volume Indices of diastolic function (E/A ratio, E/e' ratio) Heart valve assessment according to GL RV dimensions and indices of RV function PAPs (RV-RA gradient and vena cava dimensions and collapsibility) B-lines at lung ultrasounds (comet lung score) Speckle Tracking analysis of LV (GLS), LA (PALS) and RV (LS of free wall) Optional 3D analysis of left and right ventricle
40960608|NCT04395443|OTHER|medication reconciliation|the emergency clinical pharmacists will start medication reconciliation with the admitted patients and a full diseases and preadmission medications history will be taken.A comparison between the accuracy and completeness of drug history lists already presented in the profile and drug history taken by the clinical pharmacists to detect the medication discrepancies
40764451|NCT04790370|DEVICE|EkoSonicTM Endovascular System|EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]
40960609|NCT03834441|OTHER|Oral HRSN screening|Verbal screening delivered by an RA
40960610|NCT03834441|OTHER|Written HRSN screening|Patient completes written screen on iPad.
40960611|NCT05288244|OTHER|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.
40764452|NCT03424005|DRUG|Capecitabine|Capecitabine will be administered 1250 mg/m\^2 orally twice daily on Days 1-14, of each 21 day cycle.
40764453|NCT03424005|DRUG|Atezolizumab|"For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle."
40764454|NCT03424005|DRUG|Ipatasertib|Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle.
40960612|NCT05288244|OTHER|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.
40960613|NCT05288244|OTHER|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
40764455|NCT03424005|DRUG|SGN-LIV1A|SGN-LIV1A will be administered IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle.
40764456|NCT03424005|DRUG|Bevacizumab|Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
40764457|NCT03424005|DRUG|Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|"Gemcitabine will be administered by IV, 1000 mg/m\^2, along with carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle.~Or~Eribulin will be administered by IV, 1.4 mg/m\^2 on days 1 and 8 of each 21 day cycle."
40764458|NCT03424005|DRUG|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
40764459|NCT03424005|DRUG|Tocilizumab|Tocilizumab will be administered IV, 8 mg/kg infusion on Day 1 of each 28 day cycle.
40764460|NCT03424005|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered by IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.
41293638|NCT02636764|DEVICE|short-wave diathermy|Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
41293639|NCT02636764|DEVICE|Low level laser therapy|Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
40764461|NCT03424005|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
40764462|NCT03424005|DRUG|Abemaciclib|Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
41293640|NCT02636764|DEVICE|Ultrasound therapy|Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
41293641|NCT05283915|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: oral
41293642|NCT04079556|BEHAVIORAL|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
41293643|NCT02942550|DRUG|Methylnaltrexone bromide (Relistor®).|
41293644|NCT02942550|DRUG|Sodium Chloride 9mg/mL|
41293645|NCT02777840|DEVICE|face mask oxygen|oxygen given by face mask as per routine practice
40764463|NCT03424005|DRUG|Fulvestrant|Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
40764464|NCT03424005|DRUG|Ribociclib (dose #1)|Ribociclib tablets will be administered by mouth once daily.
41293646|NCT02777840|DEVICE|High flow oxygen|High flow oxygen given via optiflo machine / device
41293647|NCT05650099|DEVICE|One or two dental implants (Biomet3I dental implant system) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of missing posterior teeth and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
41293648|NCT04809727|PROCEDURE|Cervical biopsy|4 quadrant biopsy
41293649|NCT06512467|DRUG|Donafenib|200 mg BID,oral administration will start before the first HAIC treatment .
41293650|NCT06512467|DRUG|Sintilimab|200 mg Q3W,Intravenous infusion will perform before HAIC treatment.
41293651|NCT06512467|OTHER|HAIC|HAIC,Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours).
41293652|NCT05661565|OTHER|No intervention|We try to find an association between insulin resistance with ovarian hormonal and morphological characteristics in patients with polycystic ovarian syndrome
40764465|NCT03424005|DRUG|Inavolisib (dose #2)|Inavolisib tablets will be administered by mouth once daily.
40764466|NCT03424005|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
40764467|NCT03424005|DRUG|Ribociclib (dose #2)|Ribociclib tablets will be administered by mouth once daily.
40764468|NCT03424005|DRUG|Letrozole|Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).
40764469|NCT03424005|DRUG|Inavolisib (dose #1)|Inavolisib tablets will be administered by mouth once daily.
40764470|NCT03424005|DRUG|Inavolisib|Inavolisib tablets will be administered by mouth once daily.
41293653|NCT00475449|PROCEDURE|percutaneous coronary intervention|
41293654|NCT00475449|PROCEDURE|coronary artery bypass grafting|
41293655|NCT03809572|BEHAVIORAL|Mindfulness Based Cognitive Therapy|See Arm description
41293656|NCT02199522|PROCEDURE|titration induction to propofol|propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
41293657|NCT04302883|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE)|Ultrasound of heart chambers via esophagus
41293658|NCT04302883|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
41293659|NCT01898546|PROCEDURE|Primary angioplasty|Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
41293660|NCT01898546|PROCEDURE|Postconditioning|1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
41293661|NCT05777434|PROCEDURE|Conventional Physical Therapy for Chronic Neck Pain|Conventional physical therapy for Chronic Neck Pain will include hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises. After 2 weeks, functional training will be added. Sets and repetitions will be increased progressively.
40960614|NCT04573712|OTHER|Follow up and Assessment|each patient should wear an actigraph during a week and will be do some tests during 2hours (6min walk, apathy inventory, fatigue severity scale etc...)
40960615|NCT05021497|OTHER|Global Positional Re-education|A series of gentle active movements and postures aimed at realigning joints and stretching shortened muscles. GPR includes 8 therapeutic postures in lying, sitting and standing.
40960616|NCT05021497|OTHER|Conventional Physical Therapy Program|Axial traction will be given for 5 minutes, followed by mobilization of the muscle fascia along with static stretching of the scalene, levator scapulae, upper trapezius, sternocleidomastoid and pectoralis minor muscles.
40960617|NCT00730145|DRUG|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
40960618|NCT03209596|DIETARY_SUPPLEMENT|Orange juice (1L/d)|The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
40960619|NCT03209596|DIETARY_SUPPLEMENT|Control drink (1L/d)|The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
40960620|NCT05490511|DRUG|Tacrolimus single dose|5 mg once
40960621|NCT05490511|DRUG|Epidiolex single dose|Epidiolex 5 mg/kg
40960622|NCT05490511|DRUG|Epidiolex steady-state and tacrolimus single dose|Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
40960623|NCT06292520|OTHER|Portage Guide Protocol|Portage Guide Protocol will be given to this group The study will follow the Randomized control trial study design and a purposive sampling technique will be used. Data will be collected from a special education centre BASES (Behaviour and special education services), Lahore. Children with autism spectrum disorder with mild to moderate severity level will be included in the study. The age range of the children will be from three years to seven years. Children with other neurological disorders or any comorbid conditions will be excluded from the study. The consent form will be filled out by parents of children who meet the inclusion criteria. The autism screening tool will apply by the speech and language pathologist. Half of the total number of children will receive therapeutic intervention under ABL
40960624|NCT06292520|OTHER|ABLLS-R protocol|ABLLS-R protocol will be given to this group
41293662|NCT05777434|PROCEDURE|Scapulothoracic Stabilization Exercises|• Scapulothoracic stabilization exercises in addition to conventional physical therapy will include scapular adduction and shoulder external rotation, B/L shoulder extension with scapular retraction, Eccentric scapular retraction, Brügger exercise and Forward punch. Exercises would be given using latex Thera-Band, or acc. to patient strength for mild to moderate resistance. After 2 weeks, functional training will be added. Sets aand repetitions will be increased progressively.
40960625|NCT02166905|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given via intracutaneous injection
40960626|NCT02166905|DRUG|Epacadostat|Given PO
40960627|NCT02166905|OTHER|Laboratory Biomarker Analysis|Correlative studies
40960628|NCT02166905|OTHER|Pharmacological Study|Correlative studies
40960629|NCT02166905|DRUG|Poly ICLC|Given SC
40960630|NCT04153331|OTHER|Nasal swab|Patient included in emergency with a nasal swab
40960631|NCT01823978|BIOLOGICAL|BPX-201 vaccine plus AP1903|The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
40960632|NCT03699657|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
40960633|NCT03699657|DEVICE|SSM|Monopolar RFA using single switching mode (SSM)
41293663|NCT04442048|BIOLOGICAL|IMM-101|Three doses of IMM-101 on days 0, 14, and 45.
40960634|NCT03699657|DEVICE|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
40960635|NCT01552941|DEVICE|Cyberonics VNS System|Active Implantable Electrical Vagal Nerve Stimulator
40960636|NCT00489138|DRUG|Ertapenem|1g a day by drip of 30 min
41293664|NCT04442048|OTHER|Observation|No active treatment. Observation only
40960637|NCT04850001|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
40960638|NCT01810874|PROCEDURE|Transperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
40960639|NCT01810874|PROCEDURE|Extraperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
40960640|NCT00714181|DRUG|hydroxychloroquine|
40960641|NCT00714181|DRUG|temozolomide|
40960642|NCT00714181|GENETIC|TdT-mediated dUTP nick end labeling assay|
40960643|NCT00714181|GENETIC|western blotting|
40960644|NCT00714181|OTHER|electron microscopy|
40960645|NCT00714181|OTHER|high performance liquid chromatography|
40960646|NCT00714181|OTHER|immunoenzyme technique|
40960647|NCT00714181|OTHER|immunohistochemistry staining method|
40960648|NCT00714181|OTHER|laboratory biomarker analysis|
40960649|NCT00714181|OTHER|mass spectrometry|
40960650|NCT00714181|OTHER|pharmacological study|
41293665|NCT03435029|BEHAVIORAL|Cognitive Remediation Program (REHACOP)|The REHACOP group received cognitive remediation sessions 3 times per week for 3 months in 60 minute per session. The rehabilitation consisted of 39 sessions divided into: attention and concentration unit (sustained, selective, alternating, and divided attention) 4 weeks; learning and memory unit (verbal and visual memory and learning strategies) 3 weeks; language (verbal fluency, syntax, grammar, vocabulary, and comprehension) 3 weeks; and executive functioning (objectives planning and attainment, verbal reasoning, categorization, and conceptualization). In addition, processing speed was trained transversely during all the sessions.
40960651|NCT02277145|BIOLOGICAL|clinical grade umbilical cord mesenchymal stem cells|10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
40960652|NCT00035997|DRUG|Zometa|
40960653|NCT02095093|DEVICE|Intellijoint HIP|Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.
41293666|NCT03435029|OTHER|Occupational Therapy|The control group received occupational group activities (reading the newspaper, drawing, singing or doing crafts) with the same frequency and format as the experimental group.
41293667|NCT00950612|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular injection, 2 doses
41293668|NCT00950612|BIOLOGICAL|Placebo|Intramuscular injection, 2 doses
41293669|NCT06342297|DEVICE|Dermatoscopy|Dermatoscopy used in decision of surgical margin before resection of basal cell carcinoma or cutaneous squamous cell carcinoma
41293670|NCT06164795|DRUG|Zoledronate|intravenous infusion
41293671|NCT06164795|DRUG|Denosumab|subcutaneous injection
41293672|NCT06164795|DRUG|Teriparatide|subcutaneous injection
41293673|NCT06164795|DRUG|Romosozumab|subcutaneous injection
41293674|NCT05347914|BEHAVIORAL|Mindfulness|Participants will be taught a mindfulness exercise and will be instructed to use this exercise (following a mobile app) whenever they experience a food craving to eat for non-homeostatic reasons.
41293675|NCT04222725|DRUG|TRS01 eye drops|Dosed 4 times a day (QID)
41293676|NCT04222725|DRUG|TRS01 eye drops|Dosed QID
41293677|NCT04222725|DRUG|TRS01 eye drops|Dosed QID
41293678|NCT04222725|DRUG|Placebo eye drops|Dosed QID
41293679|NCT05595382|BEHAVIORAL|Emotional Appeal|Participants will be presented with a short vignette about a child undergoing cancer treatment and needing a bone marrow transplant in order to survive cancer.
40764471|NCT04585035|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
40764472|NCT04585035|DRUG|D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other|Standard treatment of solid tumor, NSCLC or CRC
40764473|NCT05917288|BIOLOGICAL|Belimumab|Belimumab will be administered
40764474|NCT05917288|DRUG|Standard of care|Standard of care will be administered
40960654|NCT02095093|DEVICE|Outrigger|The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
41293680|NCT05595382|BEHAVIORAL|Rational Appeal|Participants will be presented with data regarding the importance of considering race/ethnicity when looking for a bone marrow transplant donor and the likelihood of finding a match based on the patient's racial/ethnic background.
41293681|NCT05024838|OTHER|Machine learning methods|This is an observational study of the retrospective collection of patient data. Anesthesia-related factors such as anesthesiologist's expertise, injection site, patient position, the dosage of local anesthetics, needle size, the direction of needle bevel, and basic demographic information of the patients were used for data analysis. Patients less than 18 years old were excluded from this study. Twenty percent of the dataset was used as a testing dataset, and the remaining were used for model training. The investigators will utilize four machine learning algorithms as XGBoost (Extreme Gradient Boosting), AdaBoost (Adaptive Boosting), Random Forest (RF), and support vector machine (SVM). Model performances were evaluated visually with a confusion matrix.
41293682|NCT05121597|DEVICE|HugeMed Videolaryngoscope|Macintosh laryngoscope
41293683|NCT02758145|OTHER|Flu vaccination information in 3 phases|"An oral information is given by the nurse during the recruitment visit at the occupational medicine unit. She initiates the discussion on flu and asks the employee if he usually receives the vaccine. Then she provides a brief standardized information on recommendations concerning flu vaccination, and the annual influenza vaccination campaign in CHUV and PMU. She responds to questions.~After the interview, she gives an informative document with key messages (information about the disease, benefits to be vaccinated, vaccine safety, etc.). The document includes frequently asked questions, website address, and the email address of the occupational medicine unit in case of questions.~The third phase consists of sending to the employee shortly after the start of the next campaign of flu vaccination (November 2016), a postal mail recalling the information provided during the recruitment examination and inviting them to get vaccinated."
40960655|NCT05076292|DRUG|GlucaGen|150 ug or 75\*2 ug glucagon will be administered subcutaneously to the participants before and after exercise.
40960656|NCT05076292|DRUG|Saline|Saline will be used as placebo before and after exercise.
40764475|NCT06511076|DRUG|Zilucoplan|Participants will receive a single sc injection of zilucoplan in the pre-specified sequence.
40960657|NCT06239766|DIAGNOSTIC_TEST|Breast Cancer Risk Assessment|Gail and IBIS Tools will be utilized to calculate mean lifetime breast cancer risk
40960658|NCT05045131|PROCEDURE|Left atrial combined pulmonary vein isolation and posterior wall isolation|
40960659|NCT00190697|DRUG|arzoxifene|
40960660|NCT02969369|DRUG|SEP-363856|SEP-363856 (25, 50, or 75mg/day)
40960661|NCT02969369|DRUG|Placebo capsule|Placebo once daily
40960662|NCT04589078|DEVICE|GI Genius CADe system|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
40960663|NCT05176145|DEVICE|VisioCyt®|"* Cytological and endoscopic examination is planned as part of the usual management of patients under surveillance of Non-muscle invasive bladder cancer (NMIBC), according to the CCAFU guidelines.~* Urine collection for conventional cytology and VisioCyt® test"
40960664|NCT05866796|DIAGNOSTIC_TEST|GlycoTransplantTest|Determination of serum glycomics in the early posttransplant stage, using an optimal cutoff based on statistic modeling.
40960665|NCT00358852|OTHER|No intervention|This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
40960666|NCT06429748|DEVICE|rTMS|repetitive Transcranial Magnetic Stimultion
40960667|NCT03118648|DIAGNOSTIC_TEST|Scale Action Research Arm Test (ARAT)|Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
40960668|NCT04446000|BIOLOGICAL|CSL730|solution for injection and infusion
40960669|NCT04446000|DRUG|Placebo|A solution matching the excipient profile of CSL730 without the active substance
40960670|NCT01475994|OTHER|Grass pollen : Dactylis glomerata|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
40960671|NCT01475994|OTHER|Challenge with clean air|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
41293684|NCT02392546|DRUG|elobixibat|
41293685|NCT02392546|DRUG|placebo|
41293686|NCT01599351|RADIATION|The radiographic-fluoroscopic system|Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
41293687|NCT03041376|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
41293688|NCT04918940|BIOLOGICAL|Determination of COVID-19 vacciantion efficacy|Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection
40764476|NCT06643559|OTHER|cognitive rehabilitation|Cognitive rehabilitation started to one group at the beginning of the antiseizure medicine. Participants underwent computer-based cognitive rehabilitation for 3 sessions per week, with each session lasting an average of 60 minutes. Before the sessions, all participants were given detailed information about the programme and its use. The rehabilitation process was carried out in three areas of cognitive functions: memory, executive functions, and language skills.
40960672|NCT01605162|DRUG|TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
40960673|NCT01605162|DRUG|E7016|"E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle."
40960674|NCT00005639|DRUG|Azacitidine Injection|subcutaneous injection (SC)
40960675|NCT00005639|DRUG|sodium phenylbutyrate|continuous intravenous (CIV)
40960676|NCT03711110|OTHER|Intensive cardiovascular monitoring|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; EKG; Echocardiogram; Biomarkers (troponin and natriuretic peptide); Structured counselling on healthy cardiac practices; Treatment optimization of cardiovascular risk factors and heart diseases; Quality of life (ECOG Performance status and Minnesota questionnaires); Interaction and management of patient care by the cardio-onco-hematology team. Moreover, cardiac MRI in centers participating in the CARTIER-MR sub-study."
40960677|NCT03711110|OTHER|No intervention|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; ECOG Performance status; cardiac patient care based on the onco-hematologist criteria"
41293689|NCT00785746|OTHER|Core|We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
41293690|NCT04354753|OTHER|No Intervention|No intervention
41293691|NCT05707065|OTHER|core strengthening exercises|The core muscles training includes transverse abdominis, multifidus, paraspinals, quadratus lumborum, and obliques.
41293692|NCT05707065|OTHER|Proprioceptive Neuromuscular Facilitation|lower limb PNF technique along with conventional treatment i.e., Rhythmic initiation, slow reversal, stabilizing reversal, and combination of isotones.
41293693|NCT00021853|BEHAVIORAL|constraint-induced movement therapy|
40960678|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
40960679|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
40960680|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
41293694|NCT03059563|DRUG|Varenicline|Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.
41293695|NCT03059563|OTHER|Placebo|A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
41293696|NCT00147108|DEVICE|ExAblate 2000|
41293697|NCT04358250|PROCEDURE|Direct Superior Approach|GROUP II :Patients positioned in lateral decubitus.landmark for incision is the apex of the greater trochanter,and skin, subcutaneous tissue except fascia are incised accordingly. Fibers of gluteus will be separated and not incised.posterior capsulotomy is performed,;femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach. Acetabulum is prepared with burs of increasing diameter, and acetabular cup is impacted. A polyethylene insert and a femoral rasp are subsequently introduced.All remaining definitive implants can be positioned.
41293698|NCT04358250|PROCEDURE|posterolateral approach|GROUP I:patients are positioned in lateral decubitus.Landmark for incision is the apex of the greater trochanter.posterior capsulotomy is performed, femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach.Acetabulum is prepared with burs of increasing diameter,and acetabular cup is then impacted.All definitive implants can be positioned.
40960681|NCT01234285|DRUG|heparin|5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
40960682|NCT00957970|DEVICE|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
41293699|NCT02487745|BEHAVIORAL|Abstinence-contingent wage supplements|Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
40764477|NCT06638203|OTHER|The 2-hour Exemplary Leadership Course (ELC)|"This two-hour course, based on the Five Exemplary Leadership Model, aims to refresh participants' theoretical understanding of leadership while providing insights into effective leader-follower interactions through practical scenarios. The session will begin with an exploration of the nature of leadership, including its philosophical and historical context. The significance of leadership in nursing will be emphasized, highlighting its impact on education, clinical practice, and the profession overall. Participants will examine the key roles of nurse leaders, focusing on modeling the way, inspiring a shared vision, challenging the process, enabling others to act, and encouraging the heart. Content Outline:~1. The Nature and Definition of Leadership (5 minutes)~2. Leadership and Its Importance in Nursing (15 minutes)~3. Transformational Leadership and Its Components (40 minutes)~4. Positive Leader-Follower Interactions (15 minutes)~5. Case Study Discussions (45 minutes)"
40960683|NCT00957970|DEVICE|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
41293700|NCT02487745|BEHAVIORAL|Individual Placement and Support (IPS) supported employment|Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
41293701|NCT04804956|PROCEDURE|Stool sample|One stool sample will be taken at baseline for microbiota characterization
41293702|NCT04804956|PROCEDURE|Rectal mucosa sample|Characterization of tissue microbiota before and after surgery.
41293703|NCT04804956|PROCEDURE|Mesorectal adipose tissue sample|Characterization of tissue microbiota and dysfunction
41293704|NCT04804956|PROCEDURE|Subcutaneous adipose tissue sample|Characterization of tissue microbiota and dysfunction
40764478|NCT06638203|OTHER|The NurseLead in Progress Game|Developed collaboratively by the author and a company, this unpublished game focuses on role-playing leader-follower interactions to navigate scenarios effectively. Designed for five students per session, the game consists of five sections, lasting approximately one hour, with each section corresponding to one of the Five Practices of Exemplary Leadership. In each section, one student takes on the role of leader while the other four act as followers. The main objective is to guide a newly appointed charge nurse in making sound decisions when facing challenges to achieve key goals. Following the game, a debriefing session will allow participants to analyze responses with experts. Performance will not be formally evaluated, as the game serves as a learning experience, enabling students to lead and engage as followers. This activity aims to activate the experiential learning phase of Kolb's Learning Model.
40764479|NCT06193239|DIAGNOSTIC_TEST|OWL-EVO1|EVOC probe
40764480|NCT04621188|DRUG|Lorlatinib|100 mg once daily
40764481|NCT06161181|DEVICE|Decision Support System|"TREAT (TREatment Adherence SupporT) is a web-based DSS that comprises four sections:~i) Metastatic Breast Cancer: contains information about MBC and its physical and psychological consequences;~ii) Adherence to Cancer Therapies: contains information about adherence in the cancer population;~iii) Promoting Adherence: contains information about resources, barriers, and available interventions used to foster adherence;~iv) My Adherence Diary."
40960684|NCT06094595|DIAGNOSTIC_TEST|MAS-p administration|Each patient will be assessed the first time at mealtime by two experienced speech therapists, and scores obtained on the MAS-p will be recorded independently and blinded to each other. The two scales selected for comparison will also be administered at the same time. The assessment with the MAS-p scale will be repeated 48 hours apart, a time considered optimal in order to avoid possible bias related to the clinical improvement of the patient undergoing rehabilitation treatment, by one of the two speech therapists.
40960685|NCT03162588|DRUG|erythropoietin|Epokine®, CJ healthcare, South Korea is used preprocedurally to promote revascularization. Total 120,000 units of EPO is injected for three consecutive days, 40,000 units mixed in IV saline 100 ml over 1 hour. The multiple burrhole procedure is performed in area of hemodynamic insufficiency by D-SPECT. It is performed under local anesthesia.
40764484|NCT04330859|OTHER|NeoRehab Bundle|The NICU rehabilitation program includes six multimodal, GA appropriate, parent-administered interventions (vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy)
40764485|NCT04330859|OTHER|Routine care|Routine NICU care including talking, touching and holding the participant per unit guideline as well as physical therapy, occupational therapy, and speech therapy per unit guideline
40764486|NCT06008093|DRUG|Durvalumab|Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles. Durvalumab will also be given during the maintenance phase q4w until disease progression or unacceptable toxicity and at week 16.
40764487|NCT06008093|DRUG|Tremelimumab|Participants will receive IV Tremelimumab q3w for four 21-day cycles. Tremelimumab will also be given during the maintenance therapy phase at week 16.
40764488|NCT06008093|DRUG|Pemetrexed|Participants will receive IV pemetrexed q3w for four 21-day cycles and q4w until disease progression or unacceptable toxicity. During the maintenance therapy phase, participants may receive an additional cycle of pemetrexed, where applicable, at Week 16.
40764489|NCT06008093|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
41293705|NCT04804956|PROCEDURE|Visceral adipose tissue sample|Characterization of tissue microbiota and dysfunction
40960686|NCT06159985|PROCEDURE|left posterior pericardiostomy|In patients assigned to the study group, a 4-5 cm vertical incision posterior to the phrenic nerve and extending from the left inferior pulmonary vein to the diaphragm is performed.
40960687|NCT01607242|OTHER|Endoscopy of larynx|Endoscopic Laryngeal mobility assessment
40960688|NCT01607242|OTHER|Voice Handicap Index|Subjective Evaluation of Voice disorders
40960689|NCT01607242|OTHER|Swallowing Assesment|Swallowing function questionnaire
40764490|NCT06008093|DRUG|Carboplatin|Participants will receive IV Carboplatin on Day 1 of each 21-day cycle for 4 cycles.
41293706|NCT04804956|BEHAVIORAL|Dietary assessment|Dietary assessment will be taken at baseline
41293707|NCT04691596|BEHAVIORAL|Non-cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day
40764491|NCT06008093|DRUG|Cisplatin|Participants will receive IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles.
40764492|NCT06008093|DRUG|Pemetrexed|Participants will receive IV pemetrexed q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
40764493|NCT06553885|DRUG|Enfortumab Vedotin|Enfortumab vedotin is a type of prescription medicine known as an antibody-drug conjugate.
40764494|NCT05995600|DRUG|Antiplatelet Drug|Clopidogrel ± other antiplatelet drug
40764495|NCT05995600|DRUG|Warfarin|Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
40960690|NCT01594983|DRUG|LCQ908|
40960691|NCT01594983|DRUG|Fenofibrate|Fenofibrate once daily 12 weeks
40960692|NCT01594983|DRUG|Fish Oil|Fish Oil once daily for 12 weeks
40960693|NCT01594983|DRUG|Placebo of LCQ908|Matching placebo of LCQ908
40960694|NCT01594983|DRUG|Placebo of fenofibrate|Matching placebo of fenofibrate
40960695|NCT01594983|DRUG|Placebo of fish oil|Matching placebo of fish oil capsule
40764496|NCT06549777|BEHAVIORAL|SE-group|Psychoeducation and information about treatment possibilities + SE-treatment
40764497|NCT06549777|BEHAVIORAL|Control|Psychoeducation and information about treatment possibilities + Phone
40960696|NCT04568044|PROCEDURE|Blood sample|Peripheral blood sample will be obtained.
40960697|NCT03164135|GENETIC|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
41293708|NCT04691596|BEHAVIORAL|Cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk within a +/-1 hour window of the pre-specified time of their chosen contextual walking cue
41293709|NCT04691596|BEHAVIORAL|Habit Coaching|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit
41293710|NCT04691596|BEHAVIORAL|App use instructions|Received a basic training with the StepUp app
40764498|NCT05688111|DRUG|Tranexamic acid injection|Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours
40960698|NCT00850590|DRUG|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
40960699|NCT03362008|DRUG|Zeropix|administration of Zeropix
40960700|NCT03362008|DRUG|Champix®|administration of Champix®
40960701|NCT04271527|PROCEDURE|cognitive fusion targeted biopsy|A cognitive fusion targeted biopsy
40960702|NCT04745130|DRUG|Sintilimab，regofinib，cetuximab|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
40960703|NCT04745130|DRUG|KRAS BRAF mutant Sintilimab + regafinil|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
40960704|NCT04548583|DRUG|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
40960705|NCT04548583|DRUG|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
40960706|NCT04548583|OTHER|Placebo|Normal saline
40960707|NCT01354678|PROCEDURE|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection of bone marrow mononuclear cells
40960708|NCT01354678|PROCEDURE|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection with placebo
40960709|NCT05084937|OTHER|CeliCAT form|Systematic summary to support transition
40960710|NCT05282862|PROCEDURE|Horizontal bone augmentation|Horizontal bone augmentation of a limited span (1-2 teeth) edentulous ridge with neighboring teeth present.
40960711|NCT00662246|RADIATION|respiratory gated proton beam radiotherapy|- Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
40960712|NCT04977193|BIOLOGICAL|LY011|CAR-T
40960713|NCT01804283|PROCEDURE|ischemic postconditioning|"multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult~Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest."
40960714|NCT01804283|PROCEDURE|double valve replacement|The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
40960715|NCT01804283|DEVICE|heart-lung machine|The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
40960716|NCT01804283|DEVICE|Aortic cross-clamp|a surgical instrument used in cardiac surgery to clamp the aorta
40960717|NCT05276193|OTHER|Observational health care register - no applicable intervention at present|Observational health care register - no applicable intervention at present
40764499|NCT05688111|OTHER|Glucose water 5%|Placebo group 30ml will be received 12 hourly for 48 hours
40764500|NCT06637787|OTHER|Pads|A specially desigend pad is used to collect information about leakage and body movement at night.
40960718|NCT02548416|PROCEDURE|Positive end-expiratory pressure|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI\>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
40960719|NCT02548416|PROCEDURE|Control group, zero PEEP|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
40960720|NCT02798601|OTHER|Hypernatremia|Serum Sodium goal: 150 - 155 milliequivalent/L.
40960721|NCT00608816|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
40960722|NCT00608816|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
40960723|NCT02595463|DRUG|Lidocaine|Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.
40960724|NCT02595463|DRUG|Saline|Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
40960725|NCT06558227|BIOLOGICAL|ZG005 for Injection|10 mg/kg or 20 mg/kg administered intravenously Q3w
40960726|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
40960727|NCT06558227|BIOLOGICAL|Sintilimab|200 mg administered intravenously Q3w
40764501|NCT04516434|DEVICE|Neurometer Neurotron CPT|All participants will undergo CPT testing. A Neurotron catheter (12-French) with electrode will be inserted through the urethra into the bladder. The catheter balloon will be inflated and positioned at the urethrovesical junction to stimulate the urethra 10-14 mm from the bladder neck. For bladder stimulation, the catheter balloon will be deflated and the catheter will be advanced into the bladder. The device will deliver sine wave stimulus pulses at 5, 250, and 2,000 Hz. CPT will be established using an automated forced choice paradigm by the method of levels. Testing order of the bladder and urethra will be randomized between participants.
40764502|NCT04516434|PROCEDURE|Cystometry|After bladder stimulation or during intraurethral stimulation, cystometry will be performed to assess bladder sensation and storage. A dual-chamber 8-French catheter will be passed through the urethra into the bladder for retrograde filling. A second 8-French catheter will be placed in the vagina to measure intra-abdominal pressure. A stimulation electrode catheter will only be inserted in the intraurethral stimulation arm. EMG pads will then be placed at 3 and 9 o'clock on each side of the perineum. The bladder will then be filled with room-temperature sterile saline solution in a retrograde fashion using a pump. Bladder sensation and urgency will be assessed while filling.
40764503|NCT04516434|PROCEDURE|Pressure-flow study|A pressure flow study will be performed to evaluate voiding function after stimulation. The transurethral and intra-vaginal catheters are left in place after cystometry and the participant will be asked to void around them, into a commode. Bladder and abdominal pressures will be recorded, as well as urine flow over time.
40764504|NCT05812170|BEHAVIORAL|Educational online session about PF|The educational online session will last 90 minutes, as follows: 10 minutes of contextualization, 40 minutes of practical content about pelvic floor consciousness and 40 of theoretical content (anatomy and practices related to PFD).
40764505|NCT06053489|OTHER|general anesthesia with remimazolam|general anesthesia with remimazolam in pediatric patients undergoing ophthalmic surgery
40764506|NCT06641570|OTHER|Aquatic Exercise Program|This intervention will include 16 sessions of an aquatic-exercise program, twice a week, over 8 weeks at a water temperature between 32-34°C. Each session will be conducted in groups of 8 to 12 patients and will last about 45 minutes.
40764507|NCT06641570|OTHER|Land-based Exercise Program|This intervention will include 8 sessions in 8 weeks, once a week. Each session will last between 25 to 35 minutes and will be divided into two components: core stability exercises and stretching of the trunk and lower limbs.
40764508|NCT06639152|DRUG|oil-based contrast medium|In oil group, ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml) was used as the contrast medium for hysterosalpingography.
40764509|NCT06639152|DRUG|water-based contrast medium|In water group, Ioversol (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 320 mg/ml) was used as the contrast medium for hysterosalpingography.
40764510|NCT06170242|DRUG|EDP-323 Dose Regimen 1|EDP-323 capsule
40764511|NCT06170242|DRUG|EDP-323 Dose Regimen 2|EDP-323 capsule
40764512|NCT06170242|DRUG|Placebo|Placebo capsule
40764513|NCT06638983|OTHER|Non-extraction Orthodontic Treatment of Angle Class I Malocclusion|Cephalometric radiographs, and extraoral and intraoral photographs, and cast impressions were collected before and after intervention. The weighted PAR Index (Peer Assessment Rating) employed to determine outcome of orthodontic treatment. Also the following soft tissue and bone indexes were assessed before and after intervention
40960728|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
40960729|NCT05703516|OTHER|Capmatinib|There is no treatment allocation. Capmatinib will be prescribed by the physician as per locally approved label. Treatment duration depends on the decision of treating physician. No drug will be dispensed from Novartis
40960730|NCT01236482|DRUG|Oxytocin versus oxytocin-ergometrine|Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
40764514|NCT06643806|BEHAVIORAL|CHAI dyad study|In the CHAI (Cardiovascular Health among Asian Indian immigrants) Dyad study, we plan to Implement and pilot test a peer leader-facilitated 12-week dyadic intervention to decrease CVD risk among first generation AI immigrants;
40960731|NCT05773482|BEHAVIORAL|Breathing and Attention Training (BAT)|BAT is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
40960732|NCT05773482|BEHAVIORAL|Breathing Control|Controlled Breathing (without mindfulness) is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
40960733|NCT03732235|DEVICE|TACE+ systemic Bevacizumab|PEG embolics
40960734|NCT03732235|DRUG|FOLFIRI+Bevacizumab|antiangiogenic factor
40960735|NCT03732235|DEVICE|TACE|PEG embolics
40764515|NCT05811013|DEVICE|Transcranial static magnetic field stimulation (tSMS)|Patients will be randomly assigned to either real or sham tSMS. Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months. Patients will choose whether to undergo stimulation at home or in the hospital on an outpatient setting. Real tSMS will be delivered with two cylindrical neodymium magnets (grade N45) of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), applied with south polarity, each pointing toward the motor cortex. To discharge the weight of the helmet from the head during the sessions, patients will be instructed to rest the back of head and helmet on an inclined surface in a comfortable position. They will be also instructed to rest, minimizing movement, and not to watch audiovisuals during the stimulation sessions.
40764516|NCT05811013|DEVICE|Sham Transcranial static magnetic field stimulation (tSMS)|Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months. Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain).
41293711|NCT05342974|DRUG|Atorvastatin|Oral dose of atorvastatin (80 mg) to swallow at the clinic in the presence of a study provider with additional 6 doses (80 mg each) of atorvastatin to administer at home once daily for the next six days. These 6 pills should be taken orally. Return to the clinic for a follow-up visit approximately 3, 8 and 10 days after enrollment visit. At these visits, trained study clinician will evaluate abortion status using ultrasound and blood draw. At 8-day visit post-enrollment, 800 mcg of misoprostol will be provided to be taken vaginally or allowed to dissolve between cheek and tongue for 30 minutes, within 24 hours of the visit. At the final clinic visit, 10 days post-enrollment, if the termination of pregnancy has failed, standard abortion care at the clinic will be offered. A final phone call to assess any side effects, need for medical care or complications will occur 30 days after enrollment.
41293712|NCT05342974|DRUG|Misoprostol|On Study Day 8, participant will be provided will two doses of misoprostol 800 mcg for vaginal or buccal use. Participant will take a single dose of misoprostol on study day 8 (± 1 day), and be instructed to take an additional 800 mcg vaginal or buccal misoprostol if no significant bleeding consistent with passage of tissue (heavier than a menses) has occurred within 24 hours of first misoprostol dose.
41293713|NCT00384280|DRUG|Rifampin|
41293714|NCT00702312|BEHAVIORAL|Low-salt educational programme|Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
41293715|NCT00702312|BEHAVIORAL|Low-salt Bangladeshi educational programme|A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
41293716|NCT00702312|BEHAVIORAL|Low-salt Bangladeshi educational programme|A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
41293717|NCT04595604|PROCEDURE|Trimodal rehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
41293718|NCT04595604|PROCEDURE|ERAS + nutritional prehabilitation|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
41293719|NCT02211495|DEVICE|GEKO device|Placed on the lateral aspect of the knee, when activated it causes the leg to twitch
41293720|NCT02211495|OTHER|Best Medical Therapy|Seen in outpatient clinic for wound care and ongoing advice
41456114|NCT04266548|PROCEDURE|Superselective Intra-arterial Hepatic Injection of Indocyanine Green (ICG) for Fluorescence Image-guided Segmental Positive Staining|The patients with single HCC which is planned to received laparoscopic hepatectomy were involved. Procedures were performed in conventional angiography room. The celiac trunk was catheterized and a microcatheter was advanced into segmental hepatic artery branches which supplied the HCC. The 5cc 0.125 mg/cc ICG was injected from super-selective hepatic artery in operative room. A Near-Infrared laparoscope was used to detect the fluorescent signal to assess the correspondence between arterial-based fluorescence demarcation and ultrasound-based surgical demarcation.
41456115|NCT04361838|BEHAVIORAL|prayer|receive prayers daily while in ICU
41456116|NCT02297230|RADIATION|Radiation Therapy (RT)|Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
40764517|NCT03090165|DRUG|ribociclib|400mg PO
40764518|NCT03090165|DRUG|ribociclib|600mg PO
40764519|NCT03090165|DRUG|Bicalutamide|150mg PO
40960736|NCT03236025|COMBINATION_PRODUCT|Video+brief smoking cessation+pamphlet|The videos presented the health effects of smoking, especially emphasizing the importance of smoking cessation on pregnant women, fetuses, and newborns.
40960737|NCT03236025|COMBINATION_PRODUCT|Text-message+brief smoking cessation+pamphlet|The text -message contains the same content with the videos
41293721|NCT01818557|BEHAVIORAL|Blood glucose testing|Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
41456117|NCT02297230|DRUG|Capecitabine|Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
41456118|NCT02297230|DRUG|Trastuzumab|Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
41293722|NCT06472570|RADIATION|Stereotactic radiotherapy boost|"A stereotactic radiosurgery boost is given in two cases:~* Upfront boost-on the first day of overall treatment time (OTT) (to 6 days before beginning conventional radiotherapy).~* Direct boost-on Days 43-49 of OTT in relation to conventional radiotherapy to total dose (TD) 70 Gy, i.e., up to 6 days after a dose of 60 Gy.~Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin 100 mg/m2 or 40 mg/m2 in a 21-day or 7-day cycle, respectively~Patients who start the treatment from induction chemotherapy may have a chance to qualify for an upfront or direct boost, depending the evaluation of the response to systemic treatment~Prescribed doses of stereotactic boost are in the range of 10-18 Gy"
41293723|NCT04552236|DEVICE|Ultrasound ELastography|"A standardized liver Elastography is critical to obtain reliable and accurate results . The patient is imaged in supine or slight 30 degrees left lateral decubitus position, with the right arm elevated above the head to open the intercostal spaces and improve the acoustic window to the liver . it is recommended to sample measurements in the right lobe , which has shown the most reliable results. Transducer pressure on the skin should be similar to regular anatomical B-mode imaging.~When using SWE techniques, the acoustic radiation force push pulse should be applied perpendicular to the liver capsule, with measurements obtained 4-5 cm deep to the skin and within a minimum 1-2 cm of liver parenchyma to limit refraction of the pulse. The operator should verify that these areas are free of vascular and biliary structures and rib shadows."
41293724|NCT00474630|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
41293725|NCT00474630|DRUG|Placebo|
41293726|NCT00474630|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
41456119|NCT02297230|DRUG|Paclitaxel|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
40764520|NCT06577675|BEHAVIORAL|Group programme for DBT training|This programme comprises 16 sessions over approximately 5 to 6 months, with one 2.5-hour session every week in a closed group of 8 patients. These sessions will be supervised by two or four carers trained in DBT.
40960738|NCT03236025|OTHER|brief smoking cessation+pamphlet|"The pamphlet showed the general information related to the smoking cessation, the brief smoking cessation only contains a sentence like You'd better quit smoking."
40960739|NCT04096729|OTHER|compression stockings|patients will be prescribed compression therapy for varicose veins of the legs using compression stockings
40960740|NCT03026660|DIETARY_SUPPLEMENT|Moringa Oleifera|
40960741|NCT03026660|DIETARY_SUPPLEMENT|Cabbage Placebo|
40960742|NCT01933061|DRUG|Abraxane|Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
40960743|NCT01933061|DRUG|Abraxane|Abraxane 150 mg/m\^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
41456120|NCT05361057|DRUG|Venetoclax, Azacitidine|The patients were administrated with azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21;
40764521|NCT06641752|DIAGNOSTIC_TEST|Blood drop sampling|The process: blood drop sampling Technique: capillary sampling Frequency: Once Time: 5 minutes Sample collection volume: 1mL Total collection volume: 1 mL
40764522|NCT06539442|DEVICE|Versius Surgical System|Urological minimal access surgery performed with Versius Surgical System
40764523|NCT06445439|DEVICE|Pacing rate of 80 bpm|Pacing rate of 80 bpm
40764524|NCT06445439|DEVICE|Pacing rate of 60 bpm|Pacing rate of 60 bpm
40764525|NCT05501522|BIOLOGICAL|GBP510 adjuvanted with AS03|injection volume of 0.5mL on Day 0
40764526|NCT05501522|OTHER|Placebo (Normal Saline)|injection volume of 0.5mL on Day 0
40764527|NCT06638372|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
40764528|NCT06640946|DRUG|Topical lidocaine|Topical lidocaine cream prior to laser follicle ablation
40764529|NCT06640946|DRUG|Sham cream|Placebo cream without lidocaine will be placed and removed before laser.
40764530|NCT06641609|DRUG|Dose-Escalation (Phase Ia) CFT8919 capsule|Phase 1a，enrolled, eligible patients receive CFT8919 150-900mg twice daily.
40764531|NCT06641609|DRUG|Dose-Expansion (Phase Ib) CFT8919 capsule|Phase 1b，enrolled, eligible patients receive CFT8919 RP2D twice daily.
40764532|NCT06641609|DRUG|Cohort-Expansion (Phase Ic) CFT8919 capsule|Phase 1c，enrolled, eligible patients receive CFT8919 RP2D twice daily.
40764533|NCT06558214|DRUG|Pembrolizumab|Keytruda® is the trade name for pembrolizumab, which will be given as 200mg IV Q3 weeks. This treatment will continue for up to two years.
40764534|NCT06558214|DEVICE|Optune GIO®|".~. Optune GIO® TTFields treatment will begin 3-7 days prior to MLA for Arm1 and 3-10 days prior to MLA for Arm 2."
40764535|NCT06558214|DEVICE|NeuroBlate®|Treatment with NeuroBlate will occur one time at the beginning of the study.
40764536|NCT06021522|DRUG|Ecopipam|Selective dopamine D1 and D5 receptor antagonist
40764537|NCT06640647|DRUG|HDM1005 injection or placebo|HDM1005 injection or placebo isubcutaneous injection once
40960744|NCT04862819|DRUG|new local drug delivery|In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp
40960745|NCT04862819|PROCEDURE|scaling root planing|In the second group, on one side of the dental arch srp will be performed
40960746|NCT06556537|DEVICE|Face-to-face and video-assisted training|"During the first phase, the intervention group will receive face-to-face training over 12 weeks. Each session will last 60 minutes, and there will be five sessions per week, with three supervised and two unsupervised.~In the second phase, there will be 60 work sessions, divided into blocks of four weeks on three occasions, with one month of exercise and two months of non-exercise over the remaining 9 months. This phase will be conducted via video assistance. Each session will include a warm-up of 10-15 minutes, a main part of 20-40 minutes, and a cool-down of 10-15 minutes."
40764538|NCT06108050|DRUG|JZP898|Investigational drug monotherapy
40960747|NCT05656495|DRUG|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly|lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
40960748|NCT05656495|DRUG|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled|lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
40960749|NCT05656495|DRUG|Standard of care|The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
40960750|NCT01637272|DRUG|SOM230|Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 \& 60 mg of pasireotide (as free base) \& solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
40960751|NCT05777746|BEHAVIORAL|12-week plant-based dietary program|a 12-week plant-based dietary program consisting of information via an online platform, online guidance by dieticians and in online peer support groups. Patients will aim to maximize their intake of plant-based products while reducing their of animal products as much as possible.
40960752|NCT05777746|BEHAVIORAL|Usual Diet|Patients in the control group continue with their usual diet and/or usual dietary care. Patients in the control group will be offered access to the online platform at 24 weeks.
40960753|NCT02393183|DRUG|ASTED|A tablet of ASTED will be taken twice a day
40960754|NCT02393183|DIETARY_SUPPLEMENT|Selenium|A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day
40960755|NCT02393183|OTHER|Placebo|A tablet of Placebo (same shape and color) will be taken twice a day
40960756|NCT05210673|OTHER|ERAS|Preoperative: Preoperative explanation of ERAS. Preoperative medical optimization. Smoking cessation 4-8 weeks before surgery. Nutritional status assessment. Preoperative fasting: 2hours for Clear fluids and water, 6hours for Semi-solid foods and 8 hours for Solid food. Preoperative carbohydrate loading. Pre-anesthetic medication: Avoid long active sedatives. Thromboembolic prophylaxis and Compression stockings Intraoperative: Antimicrobial prophylaxis and skin preparation. Epidural analgesia. Prevention of intraoperative hypothermia. Intraoperative fluid management. Minimize incision. Drain strategy Postoperative: Nasogastric intubation. Early oral intake. Early mobilization. Prevention of postoperative ileus through. Prevention of postoperative nausea and vomiting. Multimodal opioid sparing analgesia. Discharge criteria: Patients have resumed adequate oral intake and normal bowel function, Effective oral pain management and No other clinical or biochemical concerns
40960757|NCT05210673|OTHER|Non ERAS pathway|standard preoperative preparation intraoperative: combined general and epidural anesthesia postoperative standard care
40960758|NCT04621630|DRUG|PN-235|Active Drug
40960759|NCT04621630|DRUG|Placebo|Matching Placebo
40960760|NCT05214495|DRUG|topical oral Omega-3 hydrogel|Topical oral Omega-3 hydrogel prepared from fish oil
40960761|NCT05214495|DRUG|conventional preventive treatment|"topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)"
40960762|NCT01496612|DRUG|Buspirone|
40960763|NCT01496612|DRUG|Placebo|
40960764|NCT03019575|DRUG|Corifollitropin alfa|CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight \>60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).
40960765|NCT03019575|DRUG|hCG|hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
41293727|NCT02044484|BEHAVIORAL|Multi-component intervention|"The computer-based intervention (CBI) is offered to patients whose viral load exceeds 1000 copies/mL at enrollment.~Counseling is offered to patients whose viral load does not drop 1-log after the first CBI or remains above 200 copies/mL after completing two CBIs.~The behavioral screener will be conducted of all patients at primary care visits. The patient completes the screener before seeing the provider. Responses are given to their provider who can use it in clinical care of the patient.~At primary care visits, all patients are given a palm card containing 1 of 15 empowering messages before they leave the clinic. Messages cover three domains: adhering to antiretroviral therapy, regular care, and safer sex."
41293728|NCT00756977|DRUG|BLI850|multi-dose preparation for oral administration prior to colonoscopy
41293729|NCT00756977|DRUG|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
41456121|NCT05361057|DRUG|Venetoclax, daunorubicin, cytarabine|The patients were administrated with daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
40960766|NCT01503918|DRUG|Valaciclovir/Aciclovir|2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
40960767|NCT01503918|DRUG|Valganciclovir/Ganciclovir|450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
40960768|NCT01269463|DRUG|Methylphenidate Hydrochloride Extended Release Capsule|An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily
40960769|NCT01269463|DRUG|Placebo|Capsule without active drug
41293730|NCT05938881|PROCEDURE|self-cut mesh procedure|transvaginal mesh procedure using self-cut mesh
41293731|NCT05938881|PROCEDURE|mesh-kit procedure|transvaginal mesh procedure using mesh-kit
41456122|NCT01096641|BEHAVIORAL|immediate CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients
41456123|NCT01096641|BEHAVIORAL|Delayed CBT|After the baseline assessment the fatigued patients will be randomized: this group is to be placed on a waiting list. After 6 months, a second assessment will take place in the group of fatigued patients who received CBT immediately after randomization. This assessment will include the same measurements as at baseline. The fatigued patients on the waiting list will then start with CBT.
40960770|NCT05662150|DIAGNOSTIC_TEST|Low frequency repetitive stimulation|Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
40960771|NCT04404205|DIAGNOSTIC_TEST|Postural stability measurements by Biodex Balance System|Postural stability measurements will be done by Biodex Balance System. Three preprogrammed main tests will be applied. Postural stability, fall index, sensory integration will be calculated. All tests will be done in four conditions; implant off(1), implant on(2), implant on music on(3), and implant off again(4).
40960772|NCT03428724|DRUG|Standard Preparation|standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
40960773|NCT03428724|DRUG|Individualized Preparation|individualized bowel preparation for colonoscopy (either split dose 4L PEG or split 2L PEG + ascorbic acid) based o patient characteristics (history of failed bowel preparation; use of laxative drugs, increased BMI, age\>65, neurologic comorbidities)
40960774|NCT02323867|DEVICE|Alpha Beta T cell depletion|
40960775|NCT01678430|DRUG|Ofatumumab|
40960776|NCT01678430|DRUG|Chlorambucil|
40960777|NCT01678430|DRUG|Bendamustine|
40960778|NCT03210311|DEVICE|compression|a compression stocking is worn, a garment compression class 2, flat knitted
40960779|NCT05056545|BEHAVIORAL|C4 Intervention|"C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors.~The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L\&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW."
40960780|NCT02252913|DRUG|Volitinib|oral administration
40960781|NCT02252913|DRUG|Docetaxel|intravenous injection
40960782|NCT00951223|DRUG|Infergen® (Interferon alfacon-1)|Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
40960783|NCT05386810|BIOLOGICAL|Experimental vaccine|Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml)-investigational vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen (per 0.5ml): type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 2.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate,2 - phenoxyethanol for per injection.
40960784|NCT05386810|BIOLOGICAL|IPV control vaccine|Inactivated Poliovirus Vaccine - control vaccine produced by Sanofi. Inactivated poliovirus antigens: Mahoney strain for type 1 (40DU), MEF-1 strain for type 2 (8DU), Saukett strains for type 3 (32DU) in 0.5 ml mixture of 2- phenoxyethanol,ethanol,formaldehyde,hanks199 medium (containing amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injection),hydrochloric acid or sodium hydroxide (for pH value adjustment),trace amounts of antibiotics (neomycin, streptomycin and polymyxin B)for per injection.
40960785|NCT05386810|BIOLOGICAL|single-person sIPV control vaccine|"Sabin Inactivated Poliovirus Vaccine (Vero cell) (0.5ml) -control vaccine produced by Sinovac Biotech Co., Ltd.~Inactivated Sabin poliovirus antigen: type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 0.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate for per injection."
41293732|NCT04805372|OTHER|VD+VF group|where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
40764539|NCT06108050|DRUG|Pembrolizumab|Approved anti-PD1 antibody
40960786|NCT03434093|DEVICE|Transcranial Magnetic Stimulation (TMS)|Description: This will comprise single and repeated paired-pulses delivered over motor and non-motor areas.
41293733|NCT04805372|OTHER|VD group|where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
40960787|NCT03434093|BEHAVIORAL|Working Memory Task|This will consist in remembering an item presented 1 to 5 steps before the inquiry. This task will span the whole duration of the functional MRI acquisition.
40960788|NCT00230204|PROCEDURE|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
40960789|NCT02226146|BIOLOGICAL|Bertilimumab|
40960790|NCT01634009|DIETARY_SUPPLEMENT|Soy-based RUTF (in double blind design)|Soy-based RUTF will be given in double blind manner
40960791|NCT02346552|DEVICE|AutoLap|
40960792|NCT01787331|DRUG|Itraconazole|Given PO
40960793|NCT01787331|OTHER|Laboratory Biomarker Analysis|Correlative studies
40960794|NCT01787331|OTHER|Pharmacological Study|Correlative studies
41293734|NCT02787512|DEVICE|Stent|Endoscopic biliary stent insertion
41293735|NCT00000711|DRUG|Zidovudine|
41293736|NCT00000711|DRUG|Sargramostim|
41293737|NCT00759512|OTHER|Therapeutic Touch|
41293738|NCT02769260|OTHER|Toothbrushing|Normal toothbrushing without toothpaste or antiseptic mouthwash.
40960795|NCT06535425|OTHER|Platelet-Rich Plasma|The PG and JG were injected with autologous PRP at baseline. The injection was performed by the same clinician with 10 years of experience in knee joint injections. Participants were seated with their knees extended, and the needle was inserted through the joint space into the intra-articular cavity of the knee, administering approximately 2.5 mL of PRP into each knee joint. Thirty millilitres of venous blood were drawn from the participant's elbow vein, and approximately 5 mL of PRP was obtained for bilateral knee joint injection by using a TD5A tabletop low-speed centrifuge manufactured in China. The first centrifugation was performed at 2500 revolutions per minute (rpm) for 3 minutes, followed by a second centrifugation at 2300 rpm for 6 minutes.
40960796|NCT06535425|OTHER|Isometric Contractions of Quadriceps|The IG and JG exercises followed the methods of our previous research, with participants undergoing an 16-week ICQ intervention five times per week. Each session consisted of isometric contractions and relaxations of the quadriceps muscle for 5 seconds each, in sets of 30 repetitions, for a total of 10 sets, with a 30-second rest between sets. During this period, researchers conducted weekly follow-up calls or face-to-face interviews with participants to understand their living conditions, ensuring that they did not change their original lifestyle habits and did not engage in any other form of regular fitness activities. Participants who did not comply were not included in the final data analysis.
40960797|NCT06535425|OTHER|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps
40960798|NCT06535425|OTHER|Control|Initially, all participants received identical health education in the form of thematic lectures once per week for 40 minutes each. The content included the following aspects: emphasising the importance of close cooperation with physicians as key to maintaining health; the process of the occurrence and development of KOA, along with its treatment methods; the role of family and social support in improving the condition; establishing a reasonable daily activity routine, such as protecting the affected knee joint, avoiding long-distance fatigue, mountain climbing, ascending and descending high-rise stairs and various adverse body postures (prolonged standing, kneeling and squatting); and advising those who are overweight to reduce their body weight. On this foundation, the four groups of participants underwent the following interventions.
40960799|NCT06149832|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|The patient's mouth (including buccal mucosa, tongue and lip) was applied with MSCs: MSCs (1×10\^6/ml) dressing was applied 4 times/day for 2 weeks.
40960800|NCT01958333|PROCEDURE|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
40960801|NCT01958333|PROCEDURE|Exercise 2|Medium-intensity, Medium-volume cardiorespiratory exercise and strength training
40960802|NCT01958333|PROCEDURE|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
40960803|NCT05683964|DRUG|Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]|per standard care
40960804|NCT05683964|DIAGNOSTIC_TEST|Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan|Per standard care
40960805|NCT00917995|DEVICE|Polypropylene Mesh, density 25-40g/square meter|colostomy with a prophylactic hernia mesh
40960806|NCT04967144|DIAGNOSTIC_TEST|Nerve conduction study|"Participants with carpal tunnel syndrome will consist of individuals whose diagnosis has been confirmed by an electrophysiological study.~Participants in the control group will consist of those who have been confirmed not to have carpal tunnel syndrome by nerve conduction study."
40960807|NCT04967144|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Test|Montreal Cognitive Assessment Test evaluates eight separate cognitive functions. Thirty is the highest score. The scores equal to or above 26 are considered normal cognitive function.
40960808|NCT04700761|PROCEDURE|Opioid-free anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + single dose of alfentanil for endotracheal intubation Anesthesia maintenance: desflurane (without any opioid) Rescue for hypertension, tachycardia: desflurane and beta blocker/calcium channel blocker
40960809|NCT04700761|PROCEDURE|Opioid-using anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + continuous infusion of remifentanil (TCI, Minto model) Anesthesia maintenance: desflurane, remifentanil Rescue for hypertension, tachycardia: desflurane, remifantanil and beta blocker/calcium channel blocker
40960810|NCT05683769|GENETIC|miRNA|Assessment of miRNA, as potential biomarkers to discriminate erosive hand osteoarthritis from psoriatic arthritis
40960811|NCT01655771|DRUG|TD-1211 Dose 1|
40960812|NCT01655771|DRUG|TD-1211 Dose 2|
40960813|NCT01480752|DRUG|Lornoxicam|PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
40960814|NCT01480752|DRUG|normal saline|PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
40960815|NCT01480752|DRUG|no injection|inject nothing after inferior alveolar injection and before root canal therapy
40960816|NCT02545556|PROCEDURE|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
40960817|NCT03965039|DEVICE|Dipotassium oxalate toothpaste|Experimental dipotassium oxalate (3%) toothpaste
40960818|NCT03965039|DRUG|Stannous fluoride toothpaste|Marketed stannous fluoride (0.454%) toothpaste
40960819|NCT03965039|DRUG|Potassium nitrate toothpaste|Marketed potassium nitrate (5%) toothpaste
40960820|NCT03965039|DRUG|Sodium monofluorophosphate toothpaste|Marketed sodium monofluorophosphate (0.76%) toothpaste
40960821|NCT03746457|BEHAVIORAL|Behavioral intervention|Individual counseling, group intervention, collective advocacy
40960822|NCT04784377|OTHER|high intensity laser in addition to traditional physical therapy exercises|"high intensity laser will be used with 1064 nm wavelength and maximum of 25 W power. Analgesic and biostimulant modes were used in the present study.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
41293739|NCT05376111|DRUG|Venetoclax, Azacitidine|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
41293740|NCT03796169|BEHAVIORAL|Personal notification|Baseline quality indicators of each endoscopist were measured and those were notified individually.
40764543|NCT06645262|OTHER|Cryotherapy|cryotherapy, therapeutic exercises, the use of braces, and the Bowen technique.
40960823|NCT04784377|OTHER|low level laser in addition to traditional physical therapy exercises|"patients will receive low level Laser Therapy in addition to traditional physical therapy exercises.~diode laser device with a wavelength of 850nm, power output of 100mV, continuous wave and 0.07cm2 spot area laser will be used. The laser will be applied with a dosage of 5 joule/cm2 (totally 15-20 joule) at the most 5 painful points for 1 minute at each point over subacromial region of the shoulder.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
40764544|NCT03298737|BEHAVIORAL|Covert Spatial Attention|"During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar."
40764545|NCT06402162|OTHER|exercise|The study will include 40 tennis players diagnosed with rotator cuff lesions who meet the inclusion criteria. The 1st group will be randomly divided into 2 groups as control (n=20) and 2nd group as core exercise (n=20). Unlike the control group, core exercises will be added to the routine exercise program of tennis players once a day, 3 days a week for 8 weeks.
40960824|NCT04784377|OTHER|traditional physical therapy exercises|Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
40960825|NCT02590081|DRUG|Dextrose 5%|
40960826|NCT02590081|DRUG|normal saline|
40960827|NCT00222443|DRUG|Irinotecan|
40960828|NCT03326544|OTHER|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
40960829|NCT03326544|OTHER|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
40960830|NCT00899574|DRUG|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
40960831|NCT04049357|DEVICE|Camera Capsule Endoscopy/ PillCam|Camera Capsule Endoscopy in screening
40960832|NCT01109797|BEHAVIORAL|Transition Social Behavioral Intervention|"If you are assigned to the first group, you will have two all-day Saturday sessions four weeks apart on the KU campus in Lawrence. The objectives of the Saturday programs are to promote positive behavior change with respect to taking ownership of diabetes and its demands by providing transition-specific information, enabling participants to practice the life skills needed to successfully manage diabetes as an adult, and fostering peer-to-peer social networking over the 6-month period of the intervention (and beyond). You will continue to see your current provider of diabetes care outside of the parameters of this study."
41293741|NCT03796169|BEHAVIORAL|Open notification|Quality indicators were measured for 3 months after 1st interventions and those were notified openly
40764546|NCT06644339|DEVICE|Voice assistant|"Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) depending on disease.~Follow-up and management of disease provided by specialists at participating institutions."
40764547|NCT04034927|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40960833|NCT01109797|BEHAVIORAL|Diabetes Transition Clinic|Patients who participate in the transition clinic arm of the study will be seen six times during a six-month time period, as well as receive psychological assessment and intervention, as necessary, prior to the first clinic visit (intake) and as part of visits 2 and 4. Three of the six visits will be standard of care medical visits with either a pediatric or adult provider or both. Three will be individual or group education sessions with diabetes educators focused on transition issues such as, managing the adult health care system, talking with your care provider,and dealing with adult issues (pregnancy, genetic concerns, etc).
40960834|NCT06184932|BEHAVIORAL|HAHE|Participants will self-initiate rehabilitative activities through the HAHE program.
40960835|NCT06184932|BEHAVIORAL|Exergame|Participants will self-initiate rehabilitative activities through the Exergame program.
40960836|NCT04801823|OTHER|Home introduction|Cautious, graded introduction of individual tree nuts
40960837|NCT04801823|OTHER|Multi Nut oral food challenge|In hospital multi nut oral food challenge (almond, cashew, hazelnut, walnut)
40960838|NCT05617469|OTHER|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis
40960839|NCT03748784|BIOLOGICAL|ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
40960840|NCT00261807|DRUG|Daptomycin 6mg/kg/day|
40960841|NCT00896571|DRUG|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
40960842|NCT00811369|DRUG|Fulvestrant + ZACTIMA|ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
40960843|NCT00811369|DRUG|Fulvestrant + Placebo|ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
41293742|NCT03796169|BEHAVIORAL|Education|Quality indicators were measured for 3 months after 2nd interventions and educated the importance of colonoscopy quality by a GI faculty
41456124|NCT05191030|BEHAVIORAL|High-Stress Intervention|Those undergoing the High-Stress will be exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993), which reliably induces cortisol reactivity in most individuals.
41456125|NCT05963841|DEVICE|treatment program|the study aims to set up an artificial intelligence diagnostic assistance program
40960844|NCT02352974|DRUG|GAD-Alum|
40960845|NCT02352974|DRUG|Vitamin D|
40960846|NCT02968797|DEVICE|SafeSed|Monitor respiratory parameters
40960847|NCT06037070|BIOLOGICAL|Platelet Rich Fibrin|PRF will be injected inside the hole that prepared to place dental implant
41456126|NCT05736198|DRUG|Dexmedetomidine|dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
40960848|NCT03918785|DIETARY_SUPPLEMENT|Rice germ|25 g twice a day.
40960849|NCT03918785|DIETARY_SUPPLEMENT|Wheat-based supplement|25g twice a day.
40960850|NCT01317030|DEVICE|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
40960851|NCT01317030|DEVICE|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
40960852|NCT01317030|OTHER|Non-Contact Lens Wear|No intervention
40960853|NCT05250882|OTHER|Enhanced perioperative care protocol|See arm/group description
40960854|NCT04427371|OTHER|the levels of pyroptosis|Blood samples were taken to detect plasma lncRNA NBR2 levels and GSDMD protein level.
40960855|NCT01184391|DRUG|DEPAKOTE® Tablets, 500 MG|1 x 500 mg tablet, under fasting conditions
40960856|NCT01184391|DRUG|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 X 500 mg Tablet, under fasting conditions.
40960857|NCT00842608|BEHAVIORAL|Reduced exposure to anticholinergics|"Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can \& cannot receive Haldol"
40960858|NCT00842608|PROCEDURE|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
40960859|NCT00842608|DRUG|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
40960860|NCT00842608|PROCEDURE|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
41456127|NCT04273438|DEVICE|Visual field testing using Oculus Rift and Humphrey Visual Field Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
40960861|NCT01205906|BEHAVIORAL|Internet-based guided self-help for tinnitus|Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks
41456128|NCT04273438|DEVICE|Visual Field Testing using HUmphrey 24-3 Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
40764548|NCT04034927|PROCEDURE|Computed Tomography|Undergo CT
40764549|NCT04034927|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40960862|NCT01205906|BEHAVIORAL|Cognitive-behavior group therapy for tinnitus|Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks
40960863|NCT01205906|OTHER|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
40764550|NCT04034927|DRUG|Olaparib|Given PO
40764551|NCT04034927|BIOLOGICAL|Tremelimumab|Given IV
40764552|NCT04428905|OTHER|Quality-of-Life Assessment|Ancillary studies
40764553|NCT04428905|OTHER|Questionnaire Administration|Ancillary studies
40960864|NCT00925041|DEVICE|Vedera KXS|one treatment with the Vedera KXS
40960865|NCT01919606|DRUG|EXPAREL|Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.
40960866|NCT00129272|DRUG|Bupropion-SR|150mg tablets taken orally twice daily for 9 weeks.
40960867|NCT00129272|OTHER|Placebo|Matching placebo (to Buproion-SR) twice daily for 9 weeks.
40960868|NCT02687997|OTHER|poligraphy|Sleep study
40960869|NCT00232609|DEVICE|GameCycle Exercise System|
41293743|NCT05365295|OTHER|DRM (Deese, Roediger et McDermott task)|"Eight lists of nine words are presented to the participants. Each list is heard once. Immediately afterwards, the child is asked to recall the words he or she remembers. Each child's response is then repeated one by one and the participant is asked to rate his or her confidence in the response on a five-point scale (from not at all sure to 100% sure). A 5-minute break is given in the middle of the task, after the first four lists are presented. The test takes about 20 minutes."
41456129|NCT03419962|DRUG|MaxSpiolto® Respimat® 160 Characters...|as per the approved SmPC
41456130|NCT01828112|DRUG|Ceritinib|Ceritinib is the investigational treatment and is referred to as the investigational study drug and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.
41456131|NCT01828112|DRUG|pemetrexed|Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m2 every 21 days.
40960870|NCT06262880|DIETARY_SUPPLEMENT|plant derived phenolics|Dietary supplement containing plant derived phenolics
40960871|NCT06262880|OTHER|Microcrystaline cellulose (MCC)|Placebo treatment: Microcrystaline cellulose
40960872|NCT06120296|DEVICE|Acumen Hypotension prediction Index software|In the unblinded HPI group (the intervention group), the arterial waveform and pressure will be displayed on the anesthesia monitor and the HPI on the Hemosphere monitor of Edwards Lifesciences (the study monitor).
40960873|NCT04486105|DIETARY_SUPPLEMENT|sucrose|pure sucrose in water in addition to habitual diet
40960874|NCT00261183|DRUG|Melatonin|
40960875|NCT03266965|DRUG|Carbidopa|All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.
40960876|NCT03266965|DIETARY_SUPPLEMENT|L-Histidine|Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.
40960877|NCT06403449|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R (G-WET) is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete.The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
40960878|NCT06403449|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
40960879|NCT01172431|DRUG|Indapamide|Indapamide SR 1.5mg qd
40960880|NCT01172431|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
40960881|NCT00238004|DRUG|Nicotinic acid|
40960882|NCT00007683|DRUG|Warfarin titrated to an INR of 2.5-3.0|anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
40960883|NCT00007683|DRUG|Aspirin|an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
40960884|NCT00007683|DRUG|Clopidogrel 75|(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
40960885|NCT03713359|BIOLOGICAL|Trial arm (MRVAC)|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
40960886|NCT03713359|BIOLOGICAL|Control arm|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
40960887|NCT00138580|DRUG|vildagliptin|
40960888|NCT00417469|DEVICE|NADGL|
41456132|NCT01828112|DRUG|docetaxel|Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m2 every 21 days.
40960892|NCT01910025|DRUG|ADI-PEG 20|
40960893|NCT01769807|DEVICE|CPAP|CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
40960894|NCT01348165|DRUG|BI 137882|Powder for oral solution
40960895|NCT01348165|DRUG|Placebo|Powder for oral solution
41293744|NCT04912128|DRUG|Anlotinib|"Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.~Stereotactic Radiosurgery Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases"
40764554|NCT04428905|OTHER|Survivorship Care Plan|Receive personalized care plan/resource manual
40960896|NCT00318123|DRUG|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
40960897|NCT04551755|DRUG|Ivermectin and Doxycycline|"1. Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~2. Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes"
40960898|NCT04551755|OTHER|Placebo|Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days
40960899|NCT00372762|DRUG|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
40960900|NCT00372762|DRUG|Bumetanide|Equivalent dose to pre-existing furosemide will be used
40960901|NCT00372762|DRUG|furosemide|20mg to 80mg orally once or twice daily
40960902|NCT00372762|DRUG|bumetanide|0.5mg to 2mg orally once or twice daily
40960903|NCT02476383|PROCEDURE|spinal manipulative therapy|refer to arm descriptions
40960904|NCT04956367|PROCEDURE|Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma|Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.
40960905|NCT04956367|DEVICE|CO2 laser with PRP|CO2 laser with PRP
40960906|NCT04956367|DEVICE|CO2 laser with placebo|CO2 laser with placebo
40960907|NCT03245684|DIAGNOSTIC_TEST|assessment of inflammatory response during PSV|assessment cytokines level in BAL and plasma
40960908|NCT04528108|DRUG|Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine|Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.
40960909|NCT04528108|DRUG|Gong Xue Ning capsules|Participants of Gong Xue Ning capsules group children will be treated with Gong Xue Ning capsules, 2 capsules 3 times a day during the bleeding period. When the bleeding stops, patients will be treated with Zhi Bai Dihuang pills,8 pills 3 times a day. Participants receive this treatment for 3 months.
40960910|NCT02302807|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
40960911|NCT02302807|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
40960912|NCT02302807|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
40960913|NCT02302807|DRUG|Vinflunine|Vinflunine 320 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
40960914|NCT03839979|DIAGNOSTIC_TEST|BIOLINE HCV kits|We used BIOLINE HCV kits to detect the presence of HCV antibodies in stick blood samples of all recruited patients.
40960915|NCT03839979|DIAGNOSTIC_TEST|ACCU-CHEK kits|For all patients, we measured random blood sugar levels by stick blood samples using ACCU-CHEK kits.
40960916|NCT03839979|DIAGNOSTIC_TEST|ErKameter 3000 mercury manometer|For all patients, we measured systolic blood pressure using ErKameter 3000 mercury manometer.
40960917|NCT04345809|PROCEDURE|MESH WHIT OMEGA-3|Mesh placement with Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
40960918|NCT04345809|PROCEDURE|MESH WITHOUT OMEGA-3|Mesh placement without Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
40764555|NCT04428905|OTHER|Telemedicine|Participate in telehealth sessions
40960919|NCT04188847|DRUG|Chemotherapy plus apatinib|"A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~* Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~* Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~* Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6."
40960920|NCT03147560|BIOLOGICAL|Sabin IPV+ bOPV+ bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
40960921|NCT03147560|BIOLOGICAL|Sabin IPV + Sabin IPV + bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
41456133|NCT00062296|BIOLOGICAL|rituximab|
41456134|NCT00062296|DRUG|epirubicin hydrochloride|
41456135|NCT04633122|DRUG|Ripretinib|Oral kinase inhibitor
40960922|NCT03147560|BIOLOGICAL|Sabin IPV + Sabin IPV + Sabin IPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
40960923|NCT05929664|BIOLOGICAL|Cemiplimab|Given IV
40960924|NCT05929664|PROCEDURE|Computed Tomography|Undergo CT scan
40960925|NCT05929664|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40764556|NCT04962113|OTHER|TUBE BATH|Wrap Tube Baht (immersion)
40960926|NCT05929664|OTHER|Quality-of-Life Assessment|Ancillary studies
40960927|NCT05929664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40960928|NCT05929664|PROCEDURE|Biopsy|Undergo biopsy
40960929|NCT00200616|PROCEDURE|Antimicrobial prophylaxis|
40960930|NCT00300274|DRUG|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
40960931|NCT00300274|DRUG|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
40960932|NCT00300274|DRUG|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
40960933|NCT00300274|DRUG|corticosteroids|Corticosteroids standard dose.
40960934|NCT02200211|DEVICE|iPad®|Binocular therapy on iPad®
40960935|NCT02200211|OTHER|Patching 2 hours per day, 7 days per week|
40960936|NCT06074198|BEHAVIORAL|SuCCESs|strengthening and endurance exercises
40960937|NCT00388596|DRUG|SB-751689|
40960938|NCT03380403|RADIATION|PDT|clinical treatment of infected diabetic foot
40960939|NCT03380403|OTHER|Ciprofloxacin|antibiotics and or surgical debridment
40960940|NCT06164678|BEHAVIORAL|OMSC|The OMSC program uses a counselling approach to assist clients with tobacco cessation. If required, nicotine replacement therapy may be offered.
40960941|NCT04379024|DRUG|DUAVEE 0.45Mg-20Mg Tablet|One capsule daily for 6 months (+/- 1 month)
40960942|NCT04590222|OTHER|blood sample|One blood sample of 60 mL (EDTA)
40960943|NCT00548223|DRUG|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid\*1year
40960944|NCT00548223|DRUG|placebo|Capsule, 0.18g, 2#, Bid\*1year
40960945|NCT03069300|DRUG|N-acetyl cysteine (NAC)|
40960946|NCT00004132|BIOLOGICAL|filgrastim|
40960947|NCT00004132|BIOLOGICAL|palifermin|
40960948|NCT00004132|DRUG|cyclophosphamide|
40960949|NCT00004132|DRUG|etoposide|
40960950|NCT00004132|DRUG|ifosfamide|
40960951|NCT00004132|PROCEDURE|quality-of-life assessment|
40960952|NCT00004132|RADIATION|radiation therapy|
40960953|NCT00207350|DEVICE|Interstitial Laser Therapy|Device
40960954|NCT05179798|DEVICE|mobile app|Lifestyle modification, insulin therapy if needed, utilization of a mobile app with personalized recommendations.
40960955|NCT02790931|OTHER|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
40960956|NCT02552875|OTHER|Tetanic stimulation|50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
40960957|NCT02552875|OTHER|Staircase Stimulation|TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
40960958|NCT02541019|DRUG|Ondansetron|4 mg IV, one minute before the anesthesia induction and 4 mg IV three times a day during two days after the surgery.
40960959|NCT02541019|DRUG|Palonosetron|75 mcg IV, one minute before the anesthesia induction.
40960960|NCT03421665|DEVICE|Titan 3D Wedge System|Each subject will undergo an LCL procedure and/or medial cuneiform osteotomy with one or more TITAN 3-D™ Wedges. Ancillary fixation should be used in conjunction with each TITAN 3-D™ Wedge used. This surgical procedure will be performed as standard of care and is not part of the research procedures. Post-operative care and weight-bearing/activity restrictions will be at the discretion of the surgeon as part of their standard of care for the procedure.
40960961|NCT00001190|DRUG|Deslorelin|
40960962|NCT01786668|DRUG|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
40960963|NCT01786668|DRUG|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
40960964|NCT01786668|DRUG|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
40960965|NCT01786668|DRUG|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
40960966|NCT01628133|PROCEDURE|ultrasound|sonographic evaluation of intestinal blood flow
40960967|NCT05089877|DEVICE|Surgical Ablation|The AtriCure cryoICE® cryoFORMTM cryoablation probe is used in the cryosurgical treatment of cardiac arrhythmias by freezing target tissues, creating an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway.
40960968|NCT04459728|BEHAVIORAL|Wellness Element 1: Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
40960969|NCT04459728|BEHAVIORAL|Wellness Element 2: Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
40960970|NCT04459728|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
40960971|NCT04459728|BEHAVIORAL|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on social connectedness; adherence documented online daily
40960972|NCT04459728|BEHAVIORAL|Wellness Element 5 - Nutrition|Daily wellness element focusing on nutrition; adherence documented online daily
40960973|NCT04459728|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
40960974|NCT04459728|BEHAVIORAL|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
40960975|NCT01845493|DIETARY_SUPPLEMENT|Alpha Sprout Homogenate|Alpha Sprout Homogenate
40960976|NCT01845493|DIETARY_SUPPLEMENT|Sulforaphane Homogenate|Active
40960977|NCT04972292|DRUG|FDC of codeine 30 mg/dipyrone 500 mg|Group 1: receive one (1) experimental drug tablet (FCD of codeine 30mg/dipyrone 500mg) + one (1) Tylex® placebo.
40960978|NCT04972292|DRUG|Tylex|Group 2: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
40960979|NCT04655378|OTHER|Mass Sepctrometry|Mass spectrometry (LC/MS) of purified immunoglobulins
40960980|NCT01906398|OTHER|ketogenic diet|KD will consist of 3:1 \[fat\]: \[protein + carbohydrate\] weight ratio, with 1600 kcal restriction
40960981|NCT01208792|PROCEDURE|skin biopsy|The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest
40960982|NCT01208792|OTHER|Blood Sample|a blood sample will be collected
40764557|NCT06645041|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|The hypertensive patients with vitamin D deficiency will receive a Vitamin D capsule with a dose of 25,000 IU. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
40960983|NCT03534960|DEVICE|High Flow Nasal Oxygen Therapy|Nasal cannula flows of 3 to 8 lpm via systems approved to provide increased humidification and warmth to inspired gas
40960984|NCT03534960|DEVICE|Nasal CPAP|"Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O"
40960985|NCT00066885|DRUG|calcitriol + docetaxel|
40960986|NCT03805269|DRUG|TAP block|TAP block: local anesthetics infiltration at trans abdominis plane
40960987|NCT03805269|DRUG|wound infiltration|wound infiltration: local anesthetics infiltration at surgical incision
40960988|NCT00250120|DRUG|L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin|delivery mode: inhalation
40960989|NCT01691209|DEVICE|Phoenix (BAY81-2996)|Topical formulation applied to the skin
40960990|NCT01691209|DRUG|1% Hydrocortison cream|1% Hydrocortison cream applied to the skin
40960991|NCT03909841|BEHAVIORAL|Cambridge Neuropsychological Test Automated Battery (CANTAB)|Cognition using Cambridge Neuropsychological Test Automated Battery (CANTAB)
40960992|NCT03909841|OTHER|Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)|Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
40960993|NCT06043531|OTHER|Experimental: EVOO|Subjects will consume 50g of cold pressed EVOO per day for 28 days.
40960994|NCT04979468|DRUG|DOVATO|Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
40960995|NCT05833074|BEHAVIORAL|Couples HIV testing and counseling|Couples HIV testing follows a CDC published protocol for delivery of HIV testing to relationship partners. HIV test results are obtained from Oraquick (FDA approved for at home HIV testing)
40960996|NCT05833074|BEHAVIORAL|Individual HIV testing and counseling|Individual HIV testing and counseling uses a counseling protocol based on the standard of care for routine HIV pre- and post-test counseling. HIV test results are obtained from Oraquick (FDA approved for at home testing)
40960997|NCT06332911|DEVICE|Shockwave™ Peripheral Intravascular Lithotripsy Balloon M5+|Cracking-not-debulking technique (SHOCKWAVE IVL)
40960998|NCT01954719|PROCEDURE|cervix dilated after surgery|The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.
40960999|NCT01954719|PROCEDURE|control group|surgeon not dilated cervix after surgery
40961000|NCT05824793|COMBINATION_PRODUCT|A-PRF+|A-PRF+ contributes to accelerating the healing process, more rapid revascularization, and reducing the risk of inflammation at the graft site. It leads to a decrease in the severity of postoperative complications. Many authors have mentioned platelet concentrates as an effective adjunction that improves the healing of hard and soft tissue and decreases pain, swelling, and trismus. However, there are still some controversial results in the literature. Recently, it has been demonstrated that the production of PRF with lower centrifugal force and lower centrifugal time has more potential to release several growth factors and facilitate more favorable healing at the site of the application when compared to standard PRF. Promoting the healing process after tooth extraction using A-PRF+ aims to manage patient discomfort as well as postoperation complications.
40961001|NCT02967731|DRUG|480 Mometasone Furoate Sinus Drug Depot|Management of Chronic Sinusitis
40961002|NCT03218644|OTHER|Mobility exercises|Usual treatment and exercises of cervical mobility before a mirror.
40961003|NCT03218644|OTHER|Proprioception exercises|proprioceptive exercises for craniocervical sensorimotor control.
40961004|NCT05864755|DRUG|HAIC+Durvalumab+Tremelimumab+Bevacizumab|Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
40764558|NCT06645041|DIETARY_SUPPLEMENT|Placebo Capsule(s)|The hypertensive patients with vitamin D deficiency will receive a Placebo capsule. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
40961005|NCT02276001|DRUG|K-877|
40764559|NCT06055231|BEHAVIORAL|Vape device|Consume THC via vape defice
40961006|NCT02276001|DRUG|Cyclosporine|
40961007|NCT05561569|PROCEDURE|Pars plana vitrectomy|23 gauge pars plana vitrectomy for managing primary retinal detachment.
40961008|NCT00221403|DRUG|Risperidone oral solution|liquid, BID dosing.
40961009|NCT00221403|DRUG|Valproate Oral Solution|liquid, BID dosing.
40961010|NCT00221403|OTHER|Placebo|liquid, BID dosing.
40764560|NCT06055231|BEHAVIORAL|Joint|Consume THC via joint
40764561|NCT06055231|DRUG|Marijuana via vape device|Given via vape device
40764562|NCT06055231|DRUG|Marijuana via joint|Given via joint
40961011|NCT04324775|OTHER|Exercise + Manual Lymphatic Drainage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, manual lymphatic drainage applied to rectus femoris for 5 minutes
40961012|NCT04324775|OTHER|Exercise + Swedish massage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, swedish massage applied to rectus femoris for 5 minutes
40961013|NCT05572320|DIAGNOSTIC_TEST|Platelet Aggregometry Testing|1.6 ml of blood collected in hirudin-coated tubes before the surgery
40961014|NCT00742430|PROCEDURE|PCI|percutaneous coronary intervention in stable coronary artery disease
40961015|NCT06065943|OTHER|Palpation and Fluoroscopy|Vessel puncture guided palpation and fluoroscopy only
40961016|NCT06065943|PROCEDURE|Ultrasound guidance|Vessel puncture guided by Ultrasound
40961017|NCT03081988|OTHER|chemoradiotherapy|concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
40961018|NCT00016887|BIOLOGICAL|filgrastim|
40961019|NCT00016887|BIOLOGICAL|recombinant interferon alfa|
40961020|NCT00016887|DRUG|carmustine|
40961021|NCT00016887|DRUG|cyclophosphamide|
40961022|NCT00016887|DRUG|cytarabine|
40961023|NCT00016887|DRUG|dexamethasone|
40961024|NCT00016887|DRUG|etoposide|
40764563|NCT06637982|PROCEDURE|ridge splitting with the use of allograft and pericardium membrane|ridge splitting with the use of allograft and pericardium membrane
40764564|NCT06637982|PROCEDURE|ridge splitting with the use of extended platelet rich fibrin|ridge splitting with the use of extended platelet rich fibrin
40764565|NCT06010719|DRUG|Azithromycin|oral azithromycin (20 mg/kg, single directly observed dose, oral suspension),
40961025|NCT00016887|DRUG|melphalan|
40961026|NCT00016887|PROCEDURE|bone marrow ablation with stem cell support|
40961027|NCT00016887|PROCEDURE|peripheral blood stem cell transplantation|
40961028|NCT00016887|RADIATION|radiation therapy|
40961029|NCT06219005|BEHAVIORAL|ultrasound education and simulation workshop|workshop testing emergency physician knowledge and technical skills in performing ultrasound-guided nerve blocks in a simulation model
40961030|NCT03859752|BIOLOGICAL|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
40961031|NCT02998567|DRUG|Guadecitabine|In arm 1 (escalation) and 2 (expansion).
40961032|NCT02998567|DRUG|Pembrolizumab|In arm 1 (escalation) and 2 (expansion).
40961033|NCT02998567|DRUG|ASTX727|In arm B2 (lung expansion) replacing guadecitabine
40961034|NCT05489744|DRUG|[14C]Afuresertib|Suspension containing approximately 125 mg of Afuresertib (containing 150 µCi of \[14C\]Afuresertib) is administered orally on an empty stomach, with approximately 240 mL of water for suspending and drug taking.
40961035|NCT00150202|DRUG|pegaptanib sodium|
40961036|NCT03230097|DRUG|BI 409306|50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
40961037|NCT03230097|DRUG|Placebo|placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
40961038|NCT00993200|GENETIC|warfarin pharmacogenetic dosing|Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface
40961039|NCT00993200|DRUG|Warfarin|Usual care warfarin dosing
40961040|NCT01844440|PROCEDURE|High resolution manometry|Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
40961041|NCT01306903|DEVICE|MECC|Minimized extracorporeal circulation
40961042|NCT01306903|DEVICE|MOPS|Modified and optimized perfusion system Frankfurt
40961043|NCT01306903|DEVICE|Super MOPS|Super modified and optimized perfusion system Frankfurt
40961044|NCT01878279|OTHER|Underlying medical illness|
40961045|NCT02198872|OTHER|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
40961046|NCT02198872|OTHER|Land Group|Patients of this group perform physical training on bicycle.
40961047|NCT00299104|DRUG|folate|Intravenous repeating dose
40961048|NCT00299104|DRUG|methotrexate|Oral or parenteral repeating dose
40961049|NCT00299104|DRUG|methylprednisolone|Intravenous repeating dose
40961050|NCT00299104|DRUG|placebo|Intravenous repeating dose
40961051|NCT00299104|DRUG|rituximab|Intravenous repeating dose
41456136|NCT04633122|DRUG|Sunitinib|second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
40961052|NCT04600557|BEHAVIORAL|Describing a shameful experience using a self-compassionate prompt|Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt
40961053|NCT04600557|BEHAVIORAL|Receiving compassionate responses from confederates|Following the participant's description of a shameful experience, two confederates will respond with compassionate responses
40961054|NCT04600557|BEHAVIORAL|Describing a shameful experience using a neutral prompt|Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt
40961055|NCT04600557|BEHAVIORAL|Receiving no response from confederates|Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
40961056|NCT05780372|RADIATION|Intensity Modulated Radiation Therapy|All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
40961057|NCT05780372|DRUG|Chemotherapy|Chemotherapy will be arranged by the physician-in-charge according to the NCCN guideline, patient's stage and physical condition.
40961058|NCT03245515|DRUG|BMS-986195|specified dose on specified days
40961059|NCT00691860|DEVICE|Mesh (Ultrapro ®)|In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy
41456137|NCT00418158|BEHAVIORAL|use of Airlife (therapy)|
41456138|NCT05118607|DEVICE|IG1|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency.
41456139|NCT01360138|PROCEDURE|Cervical epidural steroid injection|cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
40961060|NCT00691860|PROCEDURE|Conventional sigmoid end colostomy|Patients receiving conventional sigmoid end colostomy, without mesh
40961061|NCT00204230|DRUG|mycophenolate mofetil (drug)|
41456140|NCT01845064|DRUG|DM199|
41456141|NCT01845064|DRUG|Placebo|
41456142|NCT01458886|DRUG|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
41456143|NCT01458886|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
41456144|NCT01458886|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
41456145|NCT01458886|DRUG|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
40961062|NCT01425996|DRUG|Lipotecan® (TLC388)|"* Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT~* Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT~* Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT~* Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)~* Cohort Ax: TLC388 MTD x 6 dose + 3DCRT"
40961063|NCT04269252|OTHER|CHI-907|CHI-907 is a high CBD extract.
40961064|NCT04269252|OTHER|CHI-804|CHI-804 is the placebo formulation.
40961065|NCT02824952|DRUG|Tagrisso|taking orally everyday for 6 or 12 weeks.
40961066|NCT00182286|BEHAVIORAL|Assessment of continuity of care from the patient perspective|
40961067|NCT00182286|BEHAVIORAL|Relationship between continuity of care, patient outcomes, and costs|
40961068|NCT05454098|DRUG|Clifutinib with fed state|40 mg Clifutinib with food
40961069|NCT05454098|DRUG|Clifutinib with fasted state|40 mg Clifutinib without food
40961070|NCT00757497|BEHAVIORAL|Electrical Polarization|
40961071|NCT04257981|DEVICE|Brain stimulator v3.0|Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp, validated by the previous research
40961072|NCT04257981|OTHER|Sham Comparator: Control group|The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies
40961073|NCT00952978|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
40961074|NCT00952978|DRUG|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
40961075|NCT05090007|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
40961076|NCT05090007|OTHER|gut microbiota|gut microbiota
40961077|NCT06044090|DRUG|Minocycline|Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
40961078|NCT06044090|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
40961079|NCT00424983|DRUG|Zoledronic acid|
40961080|NCT00483730|DRUG|Deproteinised hemoderivative of calf blood (Actovegin)|Symptomatic diabetic peripheral polyneuropathy
40961081|NCT01281865|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
40961082|NCT01281865|DRUG|everolimus|Given PO
40961083|NCT01281865|DRUG|imatinib mesylate|Given PO
40961084|NCT04836572|OTHER|3M 1529 Adhesive Tape|5-12 hour adhesive wear
40961085|NCT03968770|DIETARY_SUPPLEMENT|Experimental group|Probiotic (Lactobacillus casei) once daily taken by 6 weeks.
40961086|NCT03968770|DIETARY_SUPPLEMENT|Control group|Placebo of Probiotic once daily taken by 6 weeks.
40961087|NCT03968770|OTHER|Usual medical care|NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
40961088|NCT02477150|BIOLOGICAL|Zostavax|Vaccination of a zoster vaccine (Zostavax)
40961089|NCT02477150|BIOLOGICAL|placebo|placebo administration
40961090|NCT01552200|PROCEDURE|Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Standard Colonoscopy,NaviAid™ G-Eye procedure
40961091|NCT01552200|PROCEDURE|Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy|G-Eye procedure, Standard Colonoscopy
40961092|NCT05141591|OTHER|Anxiety level assessment|To investigate the impact of psychological variables e.g. pre-surgical anxiety on postoperative opioid consumption and pain level, the investigators will perform the STOA, APAIS, PCS and the VAS-A anxiety questionnaires before surgery.
41293745|NCT04645797|DRUG|APR003|This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.
40961093|NCT05911529|BEHAVIORAL|Motivational Interviewing|In our study intervention, patients should receive four session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.
40961094|NCT05911529|BEHAVIORAL|Supportive conversations|"In the control intervention patients should also be given four sessions, in which no MI techniques take place. They will be carried out in the sense of supportive conversations (i. e. conver-sations that do not follow a specific psychotherapy concept).~Since we want to check whether the patients really benefit from the specific intervention and not from getting more speaking time, the patient in the control group will also be given four conver-sations. It is known that supportive conversations can have a certain effect on the well-being and recovery process of patients, as the therapeutic relationship, i.e. appreciation, attention and/or attention, is an important efficacy factor (e. g. Grawe, 1995)."
40961095|NCT01007084|DRUG|Propranolol|40 mg
40961096|NCT01007084|DRUG|Propranolol ER|120 mg twice per day
40764566|NCT06010719|DRUG|Amoxicillin|Standard of Care. A 7-day, twice-daily course of amoxicillin will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
40764567|NCT06010719|OTHER|Placebo|A 7-day, twice-daily course of placebo will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
40961097|NCT01007084|DRUG|Sugar pills|sugar pill
40961098|NCT02318771|RADIATION|Radiation Therapy (RT)|Undergo RT
40961099|NCT02318771|DRUG|MK-3475|Given IV
40961100|NCT00199680|PROCEDURE|PET|
40961101|NCT00259649|DRUG|eletriptan|oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days
40961102|NCT03589560|DRUG|Biodentine|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
40961103|NCT03589560|DRUG|Mineral Trioxide Aggregate|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
40961104|NCT01204437|DRUG|Epirubicin, Cyclophosphamide|4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22
40764568|NCT04103814|DRUG|magnesium-cannabidiolic acid cream|Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.
40961105|NCT01204437|DRUG|Cyclophosphamide, Methotrexate, 5 FU|6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)
40764569|NCT04103814|DRUG|Placebo cream|Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
40764570|NCT06482996|OTHER|Intraocular pressure (IOP) was measured|The Frail Scale was used to assess the frailty of the patients.Intraocular pressure (IOP) was measured before anesthesia, 5 minutes after induction of anesthesia and 1 hour postoperatively. IOP was measured using a Tono-pen tonometer (AccuPen). The normal range of IOP is 11-21 mmHg (mean 16 mmHg) and values above 24 mmHg are pathologic.
40764571|NCT06637293|DEVICE|DeepECG plateform diagnosis & recommendations|EchoNeXT\& ECG-AI algorithm
40961106|NCT01204437|DRUG|Capecitabine, Nab-Paclitaxel|6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
40961107|NCT00672243|DRUG|Erlotinib + sirolimus|Erlotinib \& sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
40961108|NCT03602482|BEHAVIORAL|Standing|Participants will stand and complete cognitive tests.
40961109|NCT03602482|BEHAVIORAL|Supine|Participants will complete cognitive tests while supine.
40961110|NCT04789135|DRUG|Ozone|Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.
40961111|NCT00549081|DIETARY_SUPPLEMENT|DHEA|oral DHEA tablets 75 mg daily
41293746|NCT05663086|BIOLOGICAL|One dose group|The vaccines are to be administrated at day 0. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
41293747|NCT05663086|BIOLOGICAL|Two doses group|The vaccines are to be administrated at day 0 and 28. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
40961112|NCT05229237|DRUG|Conbercept|Intravitral injection of Conbercept (0.5 mg/0.05 mL, Chengdu Kanghong Biotech, Inc.)
40961113|NCT04315909|DRUG|PRP-Fibrin Glue|Platelet-Rich Plasma-Fibrin Glue
40961114|NCT04315909|DIETARY_SUPPLEMENT|Vitamin E and C|Vitamin E and vitamin C
40961115|NCT04315909|OTHER|Placebo|Placebo
40961116|NCT02329912|DEVICE|SmartPill|Application of the SmartPill at the end of surgery
40961117|NCT04138238|DEVICE|Supraflex Cruz Sirolimus-eluting Stent|Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
40961118|NCT04526860|OTHER|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 2 standard deviations of normal WHO weight standards, in order to prevent infant obesity and subsequent childhood obesity.
40961119|NCT05309642|BEHAVIORAL|Intermittent calorie restriction|Recipes will be provided with suggestions of meals that would not exceed the calorie restriction. For the remaining 5 days of the week, they will receive instructions and recipes that follows the Korean Dietary Reference Intakes (KDRIs), with an intake limit of 2,000 kcal/day for women and 2,500 kcal/day for men. The percentage of energy (E%) from different macronutrients in the recipes will be 45-60 E% carbohydrates, 25 E% fat and 10-20 E% protein.
40961120|NCT05309642|BEHAVIORAL|Standard of care|They will receive individualized guidance from a hepatologist on how to choose a healthy diet, to reduce the intake of sweets and saturated fatty acids, increase sources of unsaturated fat, avoid large portions, and to regularly eat 3 meals per day. Each participant will be provided a written summary of the dietary advice.
40961121|NCT02521545|DRUG|BIIB061|Capsule
40961122|NCT01012271|OTHER|MRI|MR arthrography is used to evaluate wrist abnormalities
40961123|NCT01322269|DRUG|HQK-1001|HQK-1001 tablets, once daily for daily 26 weeks
40961124|NCT05122533|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.
40961125|NCT05122533|DIAGNOSTIC_TEST|Clinical limb length measurements|"Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~* bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~* tape measuring:~  * Spina iliaca anterior superior - medial malleolus~ * umbilicus - medial malleolus~ * greater trochanter - lateral malleolus~ * in standing, sitting, resupinate and side position"
40961126|NCT00386659|DRUG|tenofovir + abacavir + lopinavir/ritonavir|
40961127|NCT00386659|DRUG|tenofovir + abacavir + efavirenz|
40961128|NCT04915430|OTHER|Training|
40961129|NCT05436093|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
40961130|NCT03035370|BIOLOGICAL|Viaskin PT 25 mcg|Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
40961131|NCT03035370|BIOLOGICAL|Viaskin PT 50 mcg|Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
40961132|NCT03035370|BIOLOGICAL|Viaskin PT Placebo|Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
40961133|NCT03035370|BIOLOGICAL|Boostrix™|Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
40961134|NCT05384093|DEVICE|High Intensity Stretch Device|High Intensity Stretch and Physical Therapy are used either together or alone to treat study arm.
40961135|NCT03005314|PROCEDURE|chemotherapy|chemotherapy before surgery
40961136|NCT03005314|PROCEDURE|Surgery|chemotherapy after surgery
40961137|NCT05598541|PROCEDURE|Surgical or non-surgical treatment|Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
40961138|NCT05678777|DEVICE|Galvanic Skin Response|The probe will be attached to the patient's finger and the Galvanic Skin Response will be measured
40961139|NCT03243604|DRUG|L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)|Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)
40961140|NCT06405230|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered.
40961141|NCT06405230|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
40961142|NCT06405230|DRUG|Pemetrexed+ (carboplatin or cisplatin)|PBCD consisting of pemetrexed+ (carboplatin or cisplatin) will be administered.
40961143|NCT04489563|DEVICE|i-ACT|Performing exercises with an adapted motion detection device (i.ACT) for 20-30 minutes.
40961144|NCT02761252|DRUG|Bilastine 20mg|
40961145|NCT02761252|DRUG|Montelukast 10mg|
40961146|NCT02761252|DRUG|Placebo Bilastine 20mg|
40961147|NCT02761252|DRUG|Placebo Montelukast 10mg|
40961148|NCT04245852|OTHER|Strength education video|The Strength education video must be watched by the patient at the University of Illinois at Chicago Faculty Practice (UICFP) prior to leaving from the 3rd physical therapy visit. The Experimental Group (EG) will watch the video in the waiting room or other quiet available rooms on the 3rd floor within the UICFP. The video will be watched from an iPad/tablet/laptop/desktop computer device as available in the clinic. The EG will also be provided a handout with a link and quick response code to the video on YouTube.com
40961149|NCT04245852|OTHER|standard PT care|standard PT care
40961150|NCT02107170|DRUG|Sevoflurane|sevoflurane-based general anesthesia
40961151|NCT02107170|DRUG|Propofol|total intravenous anesthesia
40961152|NCT02107170|DRUG|Remifentanil|
40961153|NCT01801878|BIOLOGICAL|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
40961154|NCT01801878|BIOLOGICAL|Normal saline|Normal saline inject to the half of irradiated breast
40961155|NCT00256750|DRUG|Cyclosporine (CsA)|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
40961156|NCT00256750|DRUG|Belatacept LI (less intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
40961157|NCT00256750|DRUG|Belatacept MI (more intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
40961158|NCT00386438|PROCEDURE|Honan balloon application|
40961159|NCT00827333|OTHER|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
40961160|NCT00827333|OTHER|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
40961161|NCT00827333|PROCEDURE|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
40961162|NCT00827333|PROCEDURE|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
40961163|NCT00827333|PROCEDURE|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
40961164|NCT04523220|DRUG|BAY1213790 (Osocimab)|Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
40961165|NCT04523220|DRUG|Placebo|Subcutaneous administration in the same manner as Osocimab.
40961166|NCT05278767|OTHER|E-Mobile Education and Counselling|The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months.
40961167|NCT06558552|OTHER|transcutaneous pulsed radiofrequency|Instead of invasive application of PRF directly to the lesion area or nerve, transcutaneous pulsed radiofrequency (TCPRF) is applied noninvasively.
40961168|NCT06558552|OTHER|extracorporeal shock wave therapy (ESWT)'|A shock wave is created together with sound and pressure waves. Changes at the cellular level with the shock wave include increased collagen production, increased blood flow in the applied area, acceleration of wound healing and cellular proliferation.
40961169|NCT03803995|PROCEDURE|Mapping and Pacing the His Bundle|During the device implant procedure, 3D electro-anatomical mapping of the His Bundle region will be performed using EnSite™ Precision™ mapping system and Advisor™ HD Grid mapping catheter. This procedure might be part of the standard-of-care at the participating centers.
40961170|NCT03803995|PROCEDURE|Placing a guidewire in Coronary sinus for measurement of Q-LV during His Bundle pacing or, if needed, for LV pacing|During the device implant procedure, a VisionWire coronary guidewire will also be placed into a branch of coronary sinus (CS), targeting a lateral branch. This guidewire could be used for collecting local left ventricle (LV) activation time (Q-LV) or pacing the LV. This guidewire could also be used to deliver a LV lead at physician's discretion. This procedure might be part of the standard-of-care at the participating centers.
40961171|NCT01837433|DRUG|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
40961172|NCT01837433|DRUG|Prednisone 6 weeks|Guidelines recommend
40961173|NCT06022939|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Given IV
40961174|NCT06022939|PROCEDURE|Biopsy|Undergo fat pad biopsy
40961175|NCT06022939|PROCEDURE|Biospecimen Collection|Undergo blood and urine specimen collection
40961176|NCT06022939|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40961177|NCT06022939|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40961178|NCT06022939|DRUG|Bortezomib|Given SC
40961179|NCT06022939|PROCEDURE|Computed Tomography|Undergo CT scan
40961180|NCT06022939|DRUG|Cyclophosphamide|Given PO or IV
40961181|NCT06022939|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
40961182|NCT06022939|DRUG|Dexamethasone|Given PO or IV
40961183|NCT06022939|PROCEDURE|Echocardiography|Undergo echocardiography
40961184|NCT06022939|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40764572|NCT05470517|DRUG|Ceftriaxone|"Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed."
40764573|NCT05470517|PROCEDURE|Intra-peritoneal Fluid Aspiration|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
40961185|NCT06022939|DRUG|Melphalan|Given IV
40961186|NCT06022939|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
40961187|NCT06022939|PROCEDURE|Stem Cell Isolation|Undergo stem cell collection
40961188|NCT06022939|OTHER|Survey Administration|Ancillary study
40961189|NCT06021145|DRUG|Empagliflozin|26-week use of automated insulin delivery system with empagliflozin (2.5 mg daily) in individuals with suboptimal time in range.
41293748|NCT05663086|BIOLOGICAL|Aged 18-59 years|The vaccines are to be administrated in the population of 18-59 years.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
40961190|NCT06021145|DRUG|Placebo|26-week use of automated insulin delivery system with placebo (daily) in individuals with suboptimal time in range.
40961191|NCT01876420|DEVICE|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 \& 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
40961192|NCT04742959|DRUG|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
40961193|NCT04742959|COMBINATION_PRODUCT|Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle
40961194|NCT06257797|DIAGNOSTIC_TEST|Skin prick test|Fenugreek wiil be tested by mixing fenugreek seed powder with saline at non-irritating doses and it will be performed by prick-by-prick test. The skin tests will be read 20 minutes after the execution.
40961195|NCT03531697|DRUG|Generic Loteprednol Etabonate|Drug
40961196|NCT03531697|DRUG|Reference Listed Drug (RLD)|Drug
40961197|NCT05636059|OTHER|Therapeutic exercise|32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
40961198|NCT05636059|OTHER|Exercise + cryotherapy|"Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
40961199|NCT05636059|OTHER|Exercise + joint mobilization|"Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
40961200|NCT04401475|BIOLOGICAL|SOC plus 15mg/kg EB05 IV|Standard of care plus single IV infusion of 15mg/kg of EB05.
40961201|NCT04401475|OTHER|SOC plus Placebo IV|Standard of care plus a single IV infusion of placebo.
40961202|NCT05332665|DEVICE|AS-OCT|Anterior segment optical coherence tomography (AS OCT) is an imaging device that can acquire an anterior segment image using a noncontact method with the patient in a sitting position. This device provides reproducible and quantitative measurements of the AC angle and other anterior segment parameters.
40961203|NCT05332665|PROCEDURE|YAG laser PI|medical procedure which uses a laser device to create a hole in the iris, thereby allowing aqueous humor to traverse directly from the posterior to the anterior chamber and, consequently, relieve a pupillary block
40961204|NCT04397783|PROCEDURE|construction of an end colostomy|longitudinal incision in the construction of an end colostomy
40961205|NCT03716037|OTHER|Physical Activity for Life (PAL)|The eight-week exercise program (The PAL Study) will incorporate balance, strength, endurance, and flexibility training. The duration of each exercise session, which will be offered three times a week, will be one hour. The supervised exercise session will include 30 minutes of moderate-intensity aerobic exercise, 15 minutes of resistance training, and 15 minutes of stretching and balance training
40961206|NCT02446483|DRUG|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
40961207|NCT02446483|DRUG|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
40961208|NCT05754931|OTHER|Deep neck flexors training + Conventional therapy|Hold for 10 sec and repeated 10 times.Patients will be treated 3 times a week for 4 consecutive weeks
40961209|NCT05754931|OTHER|Muscles energy techniques + conventional therapy|position of patient is in maximal comfort and lengthening After engaging the barrier use of an isometric contraction Feel the release and lengthen the muscle repeated for 4 time per session Patients will be treated 3 times a week for 4 consecutive weeks
40961210|NCT04920019|PROCEDURE|Thoracic continuous epidural analgesia|"Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M\&H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)~Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)"
40961211|NCT02304679|OTHER|Pre-inclusion questionnaires|"(Month -2)~During this visit, the investigator will:~* Validate the patient's inclusion and exclusion criteria;~* Obtain informed consent from the patient;~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Prescribe 1 month of PDE5i treatment.~* The next visit will be scheduled"
40961212|NCT02304679|DRUG|1 month of PDE5i treatment|5 mg Tadalafil per day for 1 month
40961213|NCT02304679|OTHER|PDE5i follow-up questionnaires|"(Month -1)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).~* The next visit will be scheduled"
40961214|NCT02304679|OTHER|Inclusion questionnaires|"(Day 0)~During this visit the investigator will:~* Verify inclusion and exclusion criteria, and proceed with final inclusion~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Randomize the patient at the end of the visit~* The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit."
40961215|NCT02304679|DEVICE|4 weekly LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
40961216|NCT02304679|DEVICE|4 weekly sham LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
40961217|NCT02304679|OTHER|Follow-up questionnaires 1 month after Wave 1|"(Month 2)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
41456146|NCT01115062|DRUG|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
41456147|NCT01115062|DRUG|LMX 4 Cream|LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
41456148|NCT01115062|DRUG|Placebo Patch|A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
40961218|NCT02304679|OTHER|Follow-up questionnaires 3 months after Wave 1|"(Month 4)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit."
40961219|NCT02304679|DEVICE|8 bi-weekly LIESWT (Wave 2) with the RENOVA device|During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
40961220|NCT02304679|OTHER|Follow-up questionnaires 1 month after Wave 2|"(Month 6)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
40961221|NCT02304679|OTHER|Questionnaires via postal mail|Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
40961222|NCT02304679|OTHER|Final follow-up questionnaires 12 months after Wave 2|"(Month 17)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
40961223|NCT00425295|BEHAVIORAL|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
40961224|NCT03857048|OTHER|Weight Loss|12-wk weight loss intervention using a meal replacement strategy (Health \& Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal
40961225|NCT03857048|OTHER|Exercise training|16-wk supervised endurance exercise training program
40961226|NCT03857048|OTHER|Overfeeding|3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements
40961227|NCT03206775|BEHAVIORAL|Cognitive Assessments (Phase 1)|"Participants will participate in up to 6 assessments in 4 domains of cognition: Processing Speed; Executive Attention; Learning and Memory; and Social Cognition.~Assessments:~* Visual Sweeps~* Sustained Visual Attention~* Associative Learning--Visual~* Associative Learning--Auditory~* Emotion Motion~* Voice Choice"
40961228|NCT03206775|BEHAVIORAL|Cognitive Battery A (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete self-report surveys.~Assessments:~* On trails: Learning~* Line Length Discrimination~* Tap the Emotion~* Sound Sweeps~* BIS/BAS~* TEPS~* Feasibility survey"
40961229|NCT03206775|BEHAVIORAL|Cognitive Battery B (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete the complete self-report surveys.~Assessments:~* Visual Time Order Judgment~* Target Tracker~* Emotional Face~* Auditory Sound Discrimination~* BIS/BAS~* TEPS~* Feasiblity assessment"
40961230|NCT03206775|BEHAVIORAL|Cognitive Battery C (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant willcomplete self-report surveys.~Assessments:~* Stroop 2AFC~* Visual Task Switcher~* Beep Seeker~* Voice Choice~* BIS/BAS~* TEPS~* Feasibility Survey"
40961231|NCT05251987|BIOLOGICAL|PD1+ T Cell Expression|The expression of PD1+ T cells was detected by flow cytometry in peripheral blood
41456149|NCT01751633|PROCEDURE|Surgical|
40961232|NCT02981017|DEVICE|Porcine Intestinal submucosal xenograft|Cook Biodesign ENT repair graft will be used in the experimental group to cover exposed bone in the sinonasal cavity as a result of the Draf III/endoscopic modified lothrop procedure.
40961233|NCT06558565|PROCEDURE|stromal vascular fraction or platelet rich plasma|stromal vascular fraction will be injected in one half of the scalp \& PRP will be injected in the other half
40961234|NCT03796793|PROCEDURE|Wound Edge Debridement|Wound debridement is performed using a sharp, circular disposable curette to remove the slough, non-viable tissue and any fibrous tissue down to the vascular base.
40961235|NCT03796793|OTHER|Standard of Care Treatment|Standard of Care treatment will include foam dressing and 4 layer compression therapy, changed weekly.
40961236|NCT02661659|BIOLOGICAL|Multipeptide vaccine S-588210|
40961237|NCT00209534|DRUG|fospropofol disodium|
41293749|NCT05663086|BIOLOGICAL|Aged 60 years old and above|The vaccines are to be administrated in the population of 60 years old and above.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
41456150|NCT01751633|PROCEDURE|Conservative treatment|
41456151|NCT05314062|DIETARY_SUPPLEMENT|FeSO4|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
41456152|NCT05314062|DIETARY_SUPPLEMENT|Ao iron|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
41456153|NCT06045390|OTHER|App|"App features (App will be used during the office visit):~* Pictorial representation of drops (color-coded) and schedule.~* Quiz to assess understanding of the regimen.~* Narrated instructions (language-concordant) on how and when (frequency and eye laterality) to take each drop.~* Graphical print-out of the regimen."
40961238|NCT04464603|DEVICE|InterFACE (mHealth tool)|"Participants will be asked to perform consecutively two 20-min highly realistic, scripted CPR scenarios (first: PALS-based scenario, second: ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and the 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to Arm A will not be allowed to use any other cognitive support."
40961239|NCT04464603|OTHER|Conventional methods|"Participants will be asked to perform consecutively two 20-min scripted CPR scenarios (PALS and ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to group B will be allowed to use the PALS pocket reference cards and a conventional calculator, but not any other cognitive support or mHealth tool."
40961240|NCT00114530|BIOLOGICAL|mHSCT|Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
40961241|NCT00114530|DRUG|cyclophosphamide|An initial intravenous dose of 500 mg/m\^2 was followed by 11 infusions of 750 mg/m\^2 with mesna given for bladder protection.
40961242|NCT01390805|DRUG|Valaciclovir Hydrochloride.|
40961243|NCT00496652|RADIATION|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
40961244|NCT00496652|DRUG|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
40961245|NCT04848597|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|200mg , once every 3 weeks
40961246|NCT06266910|OTHER|Visual training video|"The video, designed according to the principles of pencil pushups, features a dynamic standard E and is presented on an autostereoscopic 3D display equipment."
40961247|NCT01392443|DRUG|Ruxolitinib|INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).
40961248|NCT06107400|GENETIC|RM-004|Intravenous infusion of gene-edited CD34+autologous hematopoietic stem cells (RM-004) after myeloablative conditioning with busulfan.
40961249|NCT06211166|DIAGNOSTIC_TEST|Digital PCR|digital Polymerase Chain Reaction (dPCR)
40961250|NCT06211166|DIAGNOSTIC_TEST|Quantitative PCR|Real-time Polymerase Chain Reaction (real-time PCR)
40961251|NCT06211166|DIAGNOSTIC_TEST|MFC|Multicolor Flow Cytometry
40961252|NCT03298867|BIOLOGICAL|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
40961253|NCT03298867|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
40961254|NCT05626803|DRUG|Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|The first 10 sentinel subjects will receive open label high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
40961255|NCT05626803|DRUG|Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|50 subjects will receive high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
40961256|NCT05626803|DRUG|Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose|50 subjects will receive Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets; total dose is 1×10 to the power 11 IU/dose
40961257|NCT05626803|DRUG|Placebo|25 subjects will receive matching placebo
41456154|NCT03807830|PROCEDURE|Electrocochlography|Intra-operative ECochG recording via the implant, post operative ECochG measurements. Impedances measured over time.
40961258|NCT04849754|DIAGNOSTIC_TEST|bone scintigraphy|Bone scintigraphy
40961259|NCT00560781|DRUG|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
40961260|NCT01501175|OTHER|consultation with a vascular physician|As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
40961261|NCT01781143|DEVICE|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
40961262|NCT03323541|DRUG|Filgrastim Prefilled Syringe [Zarzio®]|Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils \>1 giga/l)
40961263|NCT02198066|OTHER|Dry Sterile Dressing|Described in Arm Description.
40961264|NCT02198066|OTHER|Metallic Silver Dressing|Described in Arm Description.
40961265|NCT02198066|OTHER|Ionic Silver Dressing|Described in Arm Description.
40961266|NCT00156052|RADIATION|Conventional whole breast radiation schedule|
40961267|NCT00156052|RADIATION|Hypofractionated whole breast radiation schedule|
40961268|NCT02795832|DRUG|ZPL-5212372 1% w/w Ointment BID|
40961269|NCT02795832|DRUG|Placebo Ointment BID|
40961270|NCT04835532|PROCEDURE|guided bone gereration|"guided bone generation: GBR is a procedure that uses barrier membranes with or without particulate bone grafts or/and bone substitutes.~tenting screws: Screws are implanted in the surgical area to prevent the barrier membrane from collapsing.~A-PRF/I-PRF: Obtained by autologous blood centrifugation."
40961271|NCT04731181|BEHAVIORAL|mobile application (little lovely dentist).|mobile application
40961272|NCT02927665|DEVICE|Reshape Integrated Dual Balloon|
40961273|NCT05984095|OTHER|Telerehabilitation|The intervention was administered in a telerehabilitation fashion through a videocall on the phone or tablet, by a physiotherapist, in a one-to-one session.
40961274|NCT06556446|DRUG|Tenecteplase and Alteplase|The timepoints, dose, and type of IVT will be collected as well as any complications occuring.
40961275|NCT00000869|DRUG|Nevirapine|
40961276|NCT00651560|DRUG|ezetimibe (+) simvastatin|ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
40961277|NCT02423876|DRUG|Epidural analgesia|"Receive epidural placement. Standard epidural medications and dosage are as follows:~* 0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate~* 3 mL/hr RN bolus, to be used as needed based on pain ratings~* 3 mL/30 minutes patient bolus, which is available on patient demand."
40961278|NCT02423876|OTHER|Intraoperative Complication Management and Prevention|Undergo ERP
40961279|NCT02423876|PROCEDURE|Pain Therapy|Undergo ERP
40961280|NCT01133522|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
40961281|NCT01133522|BIOLOGICAL|Placebo|Administered by subcutaneous injection
40961282|NCT02356575|OTHER|Acupuncture|
40961283|NCT02356575|OTHER|Cognitive Behavior Therapy|
41456155|NCT03086941|DEVICE|I-gel|To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children. We also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.
40961284|NCT04003012|DRUG|EMLA|EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
40961285|NCT04003012|DRUG|Lidocaine|lidocaine 1%
40961286|NCT02155790|DEVICE|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
40961287|NCT01284829|OTHER|FDG-PET scan|
40961288|NCT06440720|OTHER|ELDOA ,UPPER THORACIC MOBILIZATION AND MOBILITY EXERCISE|Already mentioned
41456156|NCT03013530|PROCEDURE|Decision making for ICU patients' care|Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
40961289|NCT04234750|BIOLOGICAL|mesenchymal stem cell conditioned medium-derived pleiotropic factor|After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.
40961290|NCT03298815|BIOLOGICAL|Amniotic Fluid Eye Drops (AFED)|One drop (0.25 mL) in one eye twice daily for up to 3 months
40961291|NCT03298815|OTHER|Saline Solution|One drop (0.25 mL) in the other eye twice daily for up to 3 months
40961292|NCT06004999|OTHER|Whole body vibration|"All patients will be pedaling for 5 minutes, followed by a warm-up phase with 5 minutes of stretching for the hamstring, gastrocnemius, soleus, and quadriceps muscles.~Afterward, the following exercise program on the vibration platform will be applied to the 1st group.~* Lunge,~* Squat,~* Deep squat,~* Wide stance squat,~* Calves,~* Deep calves. The exercise time will be 6 minutes in the first week, and the exercise time will be increased in the following weeks, and the total exercise time will continue at 18 minutes in the last week."
40961293|NCT06004999|OTHER|The exercise program on flat ground without a vibration platform|"All patients will be pedaling for 5 minutes, followed by a warm-up phase with 5 minutes of stretching for the hamstring, gastrocnemius, soleus, and quadriceps muscles.~Afterward, the following exercise program will be applied to the group.~The exercise program will be applied to the 2nd group (controls) on flat ground without a vibration platform.~* Lunge,~* Squat,~* Deep squat,~* Wide stance squat,~* Calves,~* Deep calves. The exercise time will be 6 minutes in the first week, and the exercise time will be increased in the following weeks, and the total exercise time will continue at 18 minutes in the last week."
40961294|NCT06087081|OTHER|Baseline Treatment along with Mill's manipulation|"Position the patient on a chair with a backrest and stand behind the patient. Support the patient's arm under the crook of the elbow with the shoulder joint abducted to 90° and medially rotated. The forearm will automatically fall into pronation. Place the thumb of your other hand in the web space between the patient's thumb and index finger and fully flex the patient's wrist and pronate the forearm. Move the hand supporting the crook of the elbow on to the posterior surface of the elbow joint and, while maintaining full Wrist flexion and pronation, extend the patient's elbow until you feel that all the slack Has been taken up in the tendon. Step sideways to stand behind the patient's head, Taking Care to prevent the patient from leaning away either forwards or sideways, which would reduce the tension on the tendon.~Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks"
41456157|NCT01447758|DRUG|LEO 29102|Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
41456158|NCT01447758|DRUG|LEO 29102 Cream Vehicle|Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
40961295|NCT06087081|OTHER|Baseline Treatment along with Mill's manipulation and Mulligan's pain relief phenomena|"In addition to Group A mentioned protocols Pain release phenomenon (PRP) was delivered as well. The Pain Release Phenomenon Technique (PRPS) is a technique pioneered by Brian Mulligan for management of Pain. There are different types of Pain release Phenomenon as follows:~1. Stretch PRP: affected muscle is eccentrically contracted.~2. Contraction PRP: affected muscle is concentrically contracted.~3. Compression PRP: affected joint surfaces are compressed together.~4. Distraction PRP: affected joint surfaces are distracted away from each other. The types of PRP are performed along with pertained duration of hold time by the therapist. And always painful PRP technique is chosen for the treatment. In the present study stretch PRP technique was used which provoked pain stimuli and was maintained for 15-20 seconds. Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks"
40961296|NCT04847011|OTHER|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
40961297|NCT01258582|PROCEDURE|Oral HIV screening|Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
40961298|NCT01258582|PROCEDURE|Fingerstick HIV screening|Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
40961299|NCT02018068|OTHER|Remote control|When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.
40961300|NCT02018068|OTHER|At bedside care|When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
40961301|NCT04998786|DRUG|Ixazomib|Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress
40961302|NCT04998786|DRUG|Iberdomide|Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress
40961303|NCT04998786|DRUG|Dexamethasone Oral|Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22
40961304|NCT00843947|PROCEDURE|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
40961305|NCT06147804|PROCEDURE|Surgical managment of Urinary bladder trauma after gynaecological and obstetric operation|How to manage Urinary bladder trauma after gynaecological and obstetric operations by the best method to prevent the occurrnce of vesicouterine fistula
40961306|NCT00700661|DRUG|montelukast|One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
40961307|NCT00700661|DRUG|placebo (unspecified)|Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
40961308|NCT00227097|BEHAVIORAL|Education Notebook for anticoagulant treatment|
40961309|NCT00257374|DRUG|Gatorade, Pedialyte and New Solution|
40961310|NCT00002190|DRUG|Saquinavir|
40961311|NCT00002190|DRUG|Lamivudine|
40961312|NCT00002190|DRUG|Zidovudine|
41293750|NCT04579068|BEHAVIORAL|Screening and Brief Intervention of Problematic Alcohol Use|Provide/enhance knowledge, screening and detection, modify attitudes, motivate and provide skills and resources to reduce alcohol related risk and consumption.
40961313|NCT05495620|DRUG|Carfilzomib|"Intravenous~carfilzomib, lenalidomide, dexamethasone"
40961314|NCT05495620|DRUG|Lenalidomide|Oral
40961315|NCT05495620|DRUG|Dexamethasone|Oral or intravenous
40961316|NCT02285192|RADIATION|18F-Fluorodeoxyglucose (18F-FDG)|
40961317|NCT02285192|DEVICE|PET/CT imaging|
40961318|NCT02285192|DEVICE|PET/MRI imaging|
40961319|NCT01408446|DRUG|Menthol|Capsule 48mg three times a day after meals 8 weeks
40961320|NCT01408446|DRUG|Placebo|Capsule 48mg three times a day after meals 8 weeks
40961321|NCT03478930|DRUG|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.
40961322|NCT03478930|DRUG|Placebo|Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.
40961323|NCT03925974|DRUG|KN026 10 mg/kg QW|10 mg/kg QW as safety run-in dosage
40961324|NCT03925974|DRUG|KN026 20 mg/kg Q2W|20 mg/kg Q2W as target dosage
41293751|NCT06468410|OTHER|long duration Hatha Yoga|60 min of Hatha yoga for 4 weeks. Week One:Participants begin with foundational breathing and yoga practicesOn the second day, Square Breathwork is introduced to foster calm and concentration. After a warm-up, the yoga flow focuses on heart openers to increase chest and shoulder flexibility, ending with a soothing cool-down. Week Two:Advanced breathing techniques and targeted yoga flows are introduced. The second session includes Nadi Shodhana to balance the nervous system. Week Three:The focus remains on heart openers with varied breathing exercises. The second day revisits Full Yogic Breath, followed by a warm-up and another heart opener sequence, concluding with a cool-down. Week Four:The final week integrates additional breathing techniques. The last session features Kapalabhati and Suddhi Pranayama to purify and energize the body. After a warm-up, participants engage in a well-rounded yoga flow combining various poses to enhance overall fitness, concluding with a final cool-down.
41293752|NCT06468410|OTHER|short duration Hatha Yoga|30 min of Hatha yoga for 4 weeks .
40961325|NCT03925974|DRUG|KN026 30 mg/kg Q3W|30 mg/kg Q3W as another target dosage
40961326|NCT00598988|PROCEDURE|traditional Chinese acupuncture|10 treatments over 6 weeks
40961327|NCT00598988|OTHER|standard medical care|standard care as provided by primary physician
40764574|NCT06638463|BEHAVIORAL|My Health Coach app|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
40764575|NCT02392442|OTHER|Saline|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6 hours after 1800 of normal Saline installed in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).
40764576|NCT02392442|BIOLOGICAL|Endotoxin|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.
40764577|NCT05689099|DRUG|Semaglutide B, 1.34 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
40764578|NCT05689099|DRUG|Semaglutide B, 0.68 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
40764579|NCT06061302|OTHER|Immediate yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 1-12.
40764580|NCT06061302|OTHER|Delayed yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 13-24.
40764581|NCT06644755|DRUG|DS-2243a|"Escalation Part: DS-2243a will be administered at escalating doses to determine the RDE~Expansion Part: DS-2243a will be administered at RDE"
40764582|NCT03992872|BIOLOGICAL|Chikungunya|Virus Like Particle
40764583|NCT05665608|DEVICE|Implantable cardioverter-defibrillator (ICD)|"A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing.~The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs."
40764584|NCT05665608|DRUG|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure"
40764585|NCT06134401|DEVICE|saline|nebulised
40764586|NCT06365463|BEHAVIORAL|Telerehabilitation|The training will last for 6 weeks, with two 60-minute sessions of balance and mobility training per week. Two consecutive groups will participate.
41293753|NCT06468410|OTHER|Control group|participants will receive information about physical activity guidelines but will not engage in any structured yoga exercise during the study period.
40764587|NCT06100276|DRUG|AMT-162|AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.
40764588|NCT04812483|DRUG|Eltrombopag (Revolade®)|Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
40764589|NCT04812483|DRUG|standard therapy (without eltrombopag): HD-DXM|standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
40764590|NCT05620134|DRUG|JK08|Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
40764591|NCT05620134|DRUG|Pembrolizumab|Immune checkpoint inhibitor
40764592|NCT05620134|DRUG|Lenvatinib Pill|Multi-kinase inhibitor
40764593|NCT06035120|DEVICE|AeriSeal System|The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.
40764594|NCT06640556|BEHAVIORAL|watching animation show|The intervention group will watch the animation titled 'A Green Future with the Hand of a Midwife' on days 7, 21, and 30 to mothers who have just given birth, and the scale will be evaluated on three separate days in total.
41293754|NCT00170157|DRUG|Bicalutamide|Given orally
41293755|NCT00170157|DRUG|Flutamide|Given orally
41293756|NCT00170157|DRUG|Goserelin Acetate|Given SC
41293757|NCT00170157|DRUG|Ipilimumab|Given IV
41293758|NCT00170157|DRUG|Leuprolide Acetate|Given IM
41293759|NCT00170157|OTHER|Pharmacological Study|Correlative study
40961328|NCT01944592|BEHAVIORAL|Gynaecology Teaching Associates (GTA's)|Two GTA's will conduct the session according to the following structure; Students will receive a short anatomy PowerPoint presentation from the GTA's followed by demonstration of a gynaecological examination on a pelvic manikin. Students will then be taken to the out-patient department where one GTA will demonstrate pelvic examination on the other. Each student will then examine one of the GTAs under supervision by the other. The three non-active students will observe each of their colleagues' examinations. The students will then undergo a role play scenario where they will examine one of the GTAs under supervision of the other and feedback will be given by both GTAs.
40764595|NCT06098508|OTHER|Osteopathic Manual Treatment|This study will be using osteopathic manual therapy as the primary intervention. Osteopathic manual therapy (OMT) is a hands-on treatment that is performed by a specially trained physician known as a Doctor of Osteopathic Medicine (DO). This treatment can be used to diagnose and treat somatic dysfunctions, which are palpable areas of tightness, misalignment, and/or restricted motion within the musculoskeletal system and its related vascular and neural structures. A combination of myofascial release, strain/counterstain, soft tissue, balanced ligamentous release, facilitated positional release and muscle energy techniques will be used for the OMT treatment.
40961329|NCT01944592|BEHAVIORAL|Manikin (conventional) training|Clinical Lecturers in Gynaecology (equivalent to Specialist Registrar experience) will conduct the sessions as follows: Students will receive a short anatomy PowerPoint presentation (the same as used in the GTA training). The Clinical Lecturer will then demonstrate pelvic examination on the pelvic manikin. Each student will then perform the pelvic examination twice supervised by the Clinical Lecturer.
40961330|NCT03813069|OTHER|IR3535|The topical repellent IR3535 (3-\[N-butyl-N-acetyl\]-aminopropionic acid ethyl ester) only
40961331|NCT03813069|OTHER|Permethrin lower dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children of 10-20 kg.
40961332|NCT03813069|OTHER|Permethrin higher dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children more than 20 kg.
40961333|NCT01007266|BEHAVIORAL|Assignment of a Lay Patient Partner|
40961334|NCT05005793|DRUG|Sodium bicarbonate|Oral sodium bicarbonate at 0.5 mEq/kg-lean body weight/day
40764596|NCT06098508|OTHER|Sham Treatment|The sham treatment will include a hands-on evaluation typically used to diagnose somatic dysfunctions, but no treatment will be performed. The sham treatment will assess the upper extremities/scapulae, ribs, cervical spine, thoracic spine, thoracic inlet, and occipital-atlantal regions.
40764597|NCT06476548|BEHAVIORAL|EMI|Participants will complete 3 counseling sessions (30 minutes), download and use a smartphone app for 4 weeks, complete 2 online surveys, and a brief phone call at the end of the study to provide feedback. In the first 3 weeks, participants will use the prototype app every day to complete ecological momentary assessments (EMAs), receive brief mindful skills, and practice formal mindfulness meditations (5-20 minutes). In the final week, participants will continue completing EMAs. Participants will also be provided with nicotine patches.
40764598|NCT06384261|DRUG|Cusatuzumab|CD70 monoclonal antibody
40764599|NCT06384261|DRUG|Venetoclax|BCL-2 inhibitor
40764600|NCT06384261|DRUG|Azacitidine|Hypomethylating agent
40764601|NCT06029010|DRUG|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
40764602|NCT06644794|DRUG|Progesterone-modified natural cycle preparation for frozen embryo transfer|A novel endometrial preparation protocol that optimizes the natural cycle, whereby as long as the thickness of the endometrium is suitable for embryo transfer, vaginal progesterone can be used to transform the endometrium before ovulation and subsequently FET.
40961335|NCT05005793|DRUG|Placebo|Placebo at 0.5 mEq/kg-lean body weight/day
40961336|NCT06471829|DRUG|Lu AG13909|Solution for injection/infusion
40961337|NCT00002307|DRUG|Stavudine|
40961338|NCT00002307|DRUG|Zidovudine|
40961339|NCT02951065|OTHER|Tooth brush without nylon bristles|Subjects will use a bristle-less tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
40961340|NCT02951065|OTHER|Tooth brush with soft nylon bristles|Subjects will use a soft bristled tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
40961341|NCT01826188|DRUG|THC 5mg/ml and CBS 50mg/ml|olive oil containing THC and CBD
40961342|NCT01826188|DRUG|Placebo|olive oil without cannabis
40961343|NCT05627323|BIOLOGICAL|CHM-1101 CAR-T cells|Administered via ICT/ICV dual delivery
40961344|NCT03396185|DRUG|Icotinib|Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
40961345|NCT04406376|DRUG|Prednisone tablet|Treatment of Bell's Palsy with prednisone, with or without tapering down.
40961346|NCT00032123|DRUG|erlotinib hydrochloride|
41293760|NCT00537940|DRUG|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
41293761|NCT00537940|DRUG|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
41293762|NCT00991627|DRUG|Bupivacaine|10 mg of a 5 mg/ml hyperbaric solution, intrathecally
40961347|NCT04453371|DRUG|Tissue plasminogen activator|"In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
40961348|NCT04453371|DRUG|Ringer solution|"In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
40961349|NCT05190237|DIETARY_SUPPLEMENT|TMD21-16 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
40961350|NCT05190237|DIETARY_SUPPLEMENT|TCD21-55 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
40961351|NCT05190237|DIETARY_SUPPLEMENT|TFD21-1 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
40961352|NCT05548816|OTHER|Handheld Dynamometer , Special tests and Modified DASH questionarre .|A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
40961353|NCT00672646|DRUG|AZD1386|95mg, oral solution, single dose
40961354|NCT00672646|DRUG|Naproxen|500mg, capsule, single dose
40961355|NCT00672646|DRUG|Placebo|AZD1386 Placebo oral solution
40961356|NCT04029831|DRUG|Propofol and Ketamine Mixture (Ketofol)|Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1
40961357|NCT06496659|PROCEDURE|Segmentectomy|A segmentectomy is a surgical procedure to remove a segment of the lung. This surgery will be done on patients who have completed neoadjuvant therapy for diagnosis of Non-Small Cell Lung Cancer.
40961358|NCT04899869|OTHER|Faecal microbiota transplantation with active study microbiota first|2x enema with active study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
40961359|NCT04899869|OTHER|Faecal microbiota transplantation with inactive autoclaved study microbiota first|2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with active study microbiota
40961360|NCT04899869|OTHER|Faecal microbiota transplantation with inactive autoclaved study microbiota only|2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
40961361|NCT06411730|DRUG|BMS-986368|Specified dose on specified days
40961362|NCT00814164|DRUG|clofarabine|IV
40961363|NCT00814164|DRUG|daunorubicin hydrochloride|IV
40961364|NCT00814164|GENETIC|cytogenetic analysis|Correlative study
40961365|NCT00814164|GENETIC|protein expression analysis|Correlative Study
41293763|NCT00991627|DRUG|Morphine|200 µg of a 100 µg/ml solution, intrathecally
40764603|NCT06644794|DRUG|Hormone replacement therapy cycle preparation for frozen embryo transfer|A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.
40961366|NCT00814164|OTHER|immunologic technique|Correlative Study
41293764|NCT00991627|DRUG|Lactated Ringer's solution|25 ml/min intravenously
40764604|NCT05711615|PROCEDURE|Biopsy|Undergo tissue biopsy
40961367|NCT00814164|OTHER|pharmacological study|Correlative Study
40961368|NCT04742985|DIETARY_SUPPLEMENT|Green tea combined extracts group|Green tea combined extracts 320 mg/day (main compound 62,5 mg for A group, 125 mg for B group) during 8 weeks
40961369|NCT04742985|DIETARY_SUPPLEMENT|Placebo group|Placebo 320 mg/day during 8 weeks
40961370|NCT02365831|OTHER|Observation of treatment management|Group/cohort
40961371|NCT02095977|PROCEDURE|fluoroscopy|Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.
40961372|NCT02095977|PROCEDURE|synchronized high-voltage shock|"If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.~For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist."
41293765|NCT00991627|DRUG|Ephedrine, continuous infusion|37.5 mg/h intravenously
41293766|NCT00991627|DRUG|Ephedrine, bolus|"6.25 mg IV bolus prn.~Hypotension defined according to study protocol for each arm."
41293767|NCT00991627|DRUG|Atropine|"0.1 mg/kg iv bolus prn~Bradycardia defined as 50% drop in heart rate from baseline values."
41456159|NCT05909046|DIAGNOSTIC_TEST|Immediate inpatient postpartum OGTT|The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
41456160|NCT05909046|DIAGNOSTIC_TEST|Standard of care 4-12 week postpartum OGTT|Standard of care is 4-12 week outpatient postpartum OGTT
40961373|NCT02095977|PROCEDURE|Holter monitor|Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
40961374|NCT04154735|DRUG|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
40961375|NCT04154735|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
40961376|NCT04154735|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
40961377|NCT04154735|DRUG|Alemtuzumab|A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
40961378|NCT04154735|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
40961379|NCT04154735|DRUG|Rifaximin|An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
40764605|NCT05711615|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
40764606|NCT05711615|PROCEDURE|Computed Tomography|Undergo CT scan
41293768|NCT06498102|OTHER|Intermittent Fasting: Time Restricted Feeding During 6 Weeks|Thirty-one healthy, young males (age: 27.5±6 years, body mass: 76.5±8.4 kg, and maximal oxygen uptake \[V̇O2max\]: 43.9±6.6 mL/kg/min) were randomly assigned to either TRF (n=14) or control group (n=17). TRF group followed an 16:8 intermittent fasting diet program for 6 weeks. Body composition, insulin sensitivity, resting substrate oxidation, and fat oxidation during cycling at 40% V̇O2max were assessed before and after the diet program.
41293769|NCT00098345|DRUG|ZD6474 (vandetanib)|oral once daily tablet
41293770|NCT00413569|PROCEDURE|cervical spine surgery|
41293771|NCT05776680|OTHER|Psychological support|60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
40764607|NCT05711615|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40764608|NCT05711615|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
40764609|NCT05711615|DRUG|Peposertib|Given PO
40961380|NCT04154735|DRUG|Tacrolimus|A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
40764612|NCT06637969|BEHAVIORAL|mindfulness-based|The experimental group was also provided with a total of 30 minutes of mindfulness training once a day for seven consecutive days. The content included mindful breathing awareness for 8 minutes while resting and lying in bed, 10 minutes of mindfulness meditation, 12 minutes of mindfulness body scanning, and 10 minutes of mindful walking and breathing. The control group The group received routine care, and a pre-test was conducted before the implementation of the interventional measures (from 7 pm to 9 pm the day before the operation), and a post-test was conducted after the seven-day intervention (from 7 pm to 9 pm on the seventh day of the interventional treatment). Comparison between the experimental group and the control group group differences
40961381|NCT04473391|DEVICE|Cycle-ergometer training assisted by FES for lower extremities|The intervention consists of FES treatment sessions on a cycle ergometer for the lower extremities. Each subject received 24 sessions lasting 45 minutes each and a frequency of 3 sessions per week. The sessions will be applied by a physiotherapist with experience in electrotherapy. A 6-channel FES device (TrainFES, Biomedical Devices SpA, Chile) will be used, which consists of a stimulator unit of 95x50x30mm and 100g of weight coupled to the motorized cycle ergometer (MOTOmed Viva 2, Reck GmbH., Germany), a remote user interface consisting of an android application for the configuration of the stimulation via Bluetooth 3.1, and an inertial measurement unit positioned on the rotation axis of the cycle ergometer to detect the rotations and trigger the synchronized electrical stimulation according to the stimulation pattern pre-configured for the pedaling exercise
40961382|NCT01517074|DRUG|Sirolimus|Subconjunctival injection
41456161|NCT04520243|DIAGNOSTIC_TEST|Visual acuity assessment by ETDRS charts|All participants must complete VA measurement of both eyes using 2 charts including the ETDRS letters chart and ETDRS numbers chart.
41456162|NCT02571309|DEVICE|Asthmatuner|Asthmatuner is an app for self-management of asthma.
40764613|NCT03932201|DRUG|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
41456163|NCT05171660|DRUG|Sintilimab Injection|Sintilimab Injection: 200 mg, i.v., D1, Q3W, 8 courses
41456164|NCT05171660|DRUG|Control Test|XELOX + Bevacizumab
41456165|NCT05624424|DRUG|Rematazolam Besylate|Anesthesia was induced with Rematazolam Besylate 0.3\~0.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 1-3 mg/kg/h until the end of surgery.
41456166|NCT05624424|DRUG|Propofol|Anesthesia was induced with Propofol 2\~2.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 5\~12 mg/kg/h until the end of surgery.
40961383|NCT04546438|DEVICE|miraDry®|"MiraDry is a noninvasive method that uses microwave technology to destroy sweat glands.~In this study we evaluate a higher energy level with a newer generation device, in respect with side effects and number of treatments (one or two interventions)."
40764614|NCT04925024|BIOLOGICAL|Lomecel-B medicinal signaling cells|A single administration of Lomecel-B will be performed via 6-10 intramyocardial injections into the right ventricle during the participant's standard of care stage II palliation. Dosing is based on body weight. Each patient will be given 2.5 x 10\^5 cells per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
40764615|NCT03373513|PROCEDURE|Robotic single-site Hysterectomy|Robotic assisted Periumbilical single incision hysterectomy
40764616|NCT03373513|PROCEDURE|Laparoscopic hysterectomy|Multiport laparoscopic hysterectomy
40764617|NCT04874194|DRUG|Omacetaxine Mepesuccinate|Given SC
40764618|NCT04874194|DRUG|Venetoclax|Given PO
40961384|NCT00808860|DIETARY_SUPPLEMENT|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
41293772|NCT04137172|PROCEDURE|laparoscopic (IPOM) hernioplasty without repair|"Under general anesthesia, supine position, lateral visiport 12mm was inserted at the left anterior axillary line . Other two 5mm ports were inserted under vision. A 30-degree optics were used. Adhesiolysis was done . The contents of hernia were reduced . The borders of the defect were illuminated and outlined. The abdominal wall was marked from outside for measurement of defect size and for corners fixation of mesh with 5cm away from defect edge. Defect with axis from 9 to 12 cm is considered big defect.~Group I:~Proline (1) sutures were applied at the corners of the mesh introduced into the peritoneal cavity. Endoclose passed at the marked site from abdominal wall, sutures hanged and tied subcutaneously, completion of mesh fixation using secure strap ."
41293773|NCT04137172|PROCEDURE|aparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS|"Group II:~Using PDS 0, a stratifix suture (STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device) versus proline 1 , used to repair and plicate the defect then mesh fixation"
41456167|NCT05624424|DRUG|Sevoflurane|Anesthesia was induced with etomidate 0.03 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by 2 %-3 % Sevoflorane until the end of surgery.
41456168|NCT05624424|DRUG|Sufentanil|Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.
41456169|NCT05624424|DRUG|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.
41456170|NCT05624424|DRUG|Remifentanil|After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
40764619|NCT03962647|DIETARY_SUPPLEMENT|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
40764620|NCT03962647|DRUG|Letrozole|2.5 mg taken once daily by mouth
40764621|NCT03897075|DRUG|Tildrakizumab|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
40764622|NCT03897075|DRUG|Placebo|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
40961385|NCT00808860|DIETARY_SUPPLEMENT|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
41456171|NCT03565562|OTHER|Promotion of the e-health tool by local authorities|Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.
41456172|NCT03565562|OTHER|Promotion of the e-health tool by local authorities and GPs|In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
41456173|NCT05024487|DIAGNOSTIC_TEST|Clinical Examination|Given the most frequent causes of AD, the above-mentioned trigger stimuli will be used. All these procedures are commonly used in SCI people.
40961386|NCT05880680|DEVICE|SEAL Device|Using standard interventional endovascular techniques, the device is navigated via the push wire delivery system through compatible neurovascular microcatheters to the aneurysm lumen or target site. The device is positioned into its target aneurysm lumen and is electrically detached by the operator with a hand-held, battery-powered detachment handle designed specifically for the SEAL Embolization System.
40961387|NCT03507231|BEHAVIORAL|Email Message|Participants will randomly receive an e-mail message about the availability of free flu vaccines.
40961388|NCT03507231|BEHAVIORAL|Incentive for Vaccination|$5 gift card offered for vaccination
40961389|NCT03507231|BEHAVIORAL|Incentive for completing a short survey|$5 gift card offered for completing s short survey after one gets vaccinated
40961390|NCT04584151|PROCEDURE|regional analgesia|Insertion of bilateral ESP catheters
40961391|NCT05122832|DIAGNOSTIC_TEST|Blood test|Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott)
40961392|NCT05122832|DIAGNOSTIC_TEST|STEPwise Approach to NCD Risk Factor Surveillance (STEPS)|The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.
40961393|NCT05122832|DIAGNOSTIC_TEST|Spirometry|Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
40961394|NCT00045968|DRUG|Dendritic cell immunotherapy|Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
40961395|NCT02289417|DRUG|Apremilast|
40961396|NCT02289417|DRUG|Placebo|
40961397|NCT06438458|PROCEDURE|Postural change from supine to sitting|Patients go from supine to sitting position in bed (passive)
40961398|NCT06438458|PROCEDURE|Mobilization to a chair|Patients go from the bed to sitting in a chair (active)
40961399|NCT00365911|PROCEDURE|Taking blood sample|A blood sample will be taken.
40961400|NCT02433405|BIOLOGICAL|Fetuin-A|Acute phase protein
40961401|NCT02433405|BIOLOGICAL|Serum Amyloid A|Acute phase protein
40961402|NCT00886574|DRUG|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
40961403|NCT00886574|DRUG|Aspirin|100 mg once a day
40961404|NCT02923960|OTHER|Standard ONS|One serving (237 ml) standard oral nutritional beverage
40961405|NCT02923960|OTHER|Diabetes specific ONS 1|One serving (237 ml) diabetes oral nutritional beverage
40961406|NCT02923960|OTHER|Diabetes specific ONS 2|One serving (296 ml) diabetes oral nutritional beverage
40961407|NCT04123600|DEVICE|Origin Stem and Logical Cup|The Origin Stem is a straight, tapered, HA coated cementless femoral stem, and the Logical Cup is a porous coated acetabular cup mated with a cross-linked polyethylene liner. The components are used as part of a total joint replacement prosthesis.
41456174|NCT02757287|DRUG|FSH-CTP + DESOGESTREL|"Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)~- Quality of Life questionnaire the day after the bolus"
41456175|NCT05838716|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40764623|NCT06643455|BEHAVIORAL|Behavioral Dietary Intervention|Participate in the MIND program
40764624|NCT06643455|OTHER|Best Practice|Participate in SOC
40764625|NCT06643455|OTHER|Electronic Medical Record|Ancillary studies
40764626|NCT06643455|OTHER|Questionnaire Administration|Ancillary studies
41456176|NCT05838716|DIETARY_SUPPLEMENT|D Vitamin|Given PO
41456177|NCT05838716|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
40961408|NCT05497830|OTHER|RISK-INDEX|Presentation of RISKINDEX to the physician after approximately 2 hours. The ML RISKINDEX is a prediction model based on laboratory data from the ED. It is based on date of birth, sex and at least four laboratory data which are sampled within the first two hours of the ED visit. Laboratory data that are used as input include samples that are commonly drawn in patients that require treatment from an internal medicine physician, such as urea, albumin, C-reactive protein (CRP), lactate and bilirubin.
40961409|NCT05892120|BEHAVIORAL|the MedAdhere app|The experimental group downloaded and used the MedAdhere app on their personal smartphones during this 8-week study
40961410|NCT00920712|DRUG|Weiqi decotion|Decoction ,two times a day
40961411|NCT02129114|DEVICE|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
40961412|NCT02129114|DEVICE|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
40961413|NCT02985957|BIOLOGICAL|Nivolumab|Specified dose on specified days
40961414|NCT02985957|BIOLOGICAL|Ipilimumab|Specified dose on specified days
40961415|NCT02985957|DRUG|Cabazitaxel|Specified dose on specified days
40961416|NCT02985957|DRUG|Prednisone|Specified dose on specified days
41293774|NCT04137172|PROCEDURE|laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0|The PDS loop sutures were prepared by cutting the needles, keeping two detached ends and one blind end. A small curved supraumbilical incision was done. The endoclose passed through upper border of incision penetrating the abdominal wall above the defect, hanging the blind end of the PDS Loop to outside. It passed through the lower border of the wound crossing the defect. It hanged one detached end of the PDS Loop suture to outside, passed again through lower border of incision to catch the other detached end. The two ends were hanged not tied to avoid incision closure. The process is repeated by passing 1-2 cm lateral or medial to the previous sutures, then blind ends were divided. Lastly, all sutures are tied. Mesh was fixed as before.
41293775|NCT04295304|DEVICE|Retinal surgery with implantation of epi-retinal device|Retinal surgery and implantation of epi-retinal prosthesis
40961417|NCT00144196|DRUG|tiotropium (Spiriva)|
40961418|NCT00527501|DRUG|Travoprost/brinzolamide|
41293776|NCT04907604|DEVICE|A multi-modal and integrative e-health platform aimed at promoting health and reducing the negative impact of mental problems in the workplace|It addresses six main domains: improving awareness of mental health problems and reducing stigma; reducing psychosocial risk factors in the workplace; improving wellbeing and reducing psychological symptoms; ensuring early detection of mental disorders; promoting healthy behaviours and lifestyles; and facilitating early return to work.
41293777|NCT02698423|DEVICE|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
41293778|NCT02698423|OTHER|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
41293779|NCT05646771|BEHAVIORAL|Partner support|Remotely delivered, partner-supported weight management counseling delivered in group visits every two weeks over 14 weeks (8 sessions)
40961419|NCT05728905|OTHER|Therapeutic exercise|Intervention with therapeutic exercise: coordination, relaxation and disc recapture exercises.
40961420|NCT05728905|OTHER|Orthopedic manual therapy|Intervention with orthopedic manual therapy: traction, ventral sliding and massage.
41293780|NCT03184701|OTHER|Telehealth|Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
40961421|NCT05111873|OTHER|multimodal treatment|combination of medical consultations, psychological therapy, physiotherapy, occupational therapy, disease specific education und progressive muscle relaxation
40961422|NCT02743169|OTHER|Spatially-Optimized|Spatial analysis of retrospective data will be used to optimize the placement of ambulances to decrease response time from the time the call is received until the time the ambulance arrives at the patient's location.
40961423|NCT05775874|DRUG|AZD4547|Initiation dose: 80mg BID,po.
40961424|NCT05775874|DRUG|Tislelizumab|Tislelizumab:200mg Q3W
40961425|NCT02767843|DEVICE|continuous negative external pressure (cNEP)|soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
40961426|NCT00550524|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
40961427|NCT00911560|BIOLOGICAL|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Pts receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, \& 52. Minor schedule adjustments are permitted, as needed. Vaccines must occur a minimum of 6 days apart. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), \& continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic \& bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood \& bone marrow. Phase II treatment schema for patients in 1st CR/VGPR or \>2nd CR/VGPR will be the same for the vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/m2.
40961428|NCT00911560|BIOLOGICAL|oral β-glucan|Phase II Patients will be randomized to starting oral β-glucan (40 mg/kg/day) in week 1 or in week 6.
40961429|NCT01812031|OTHER|medical imaging|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
40961430|NCT05825339|DIAGNOSTIC_TEST|Coronary Flow Reserve|Diagnostic of Microvascular Coronary Dysfunction using continuous thermodilution flow reserve
40961431|NCT03194607|OTHER|Functional walk tests|
40961432|NCT03194607|OTHER|3D analysis of locomotion and posture|
40961433|NCT03194607|OTHER|questionnaires|
40961434|NCT03093883|DRUG|Ferrinemia|Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
40961435|NCT03093883|DRUG|Venofer|Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
41293781|NCT04868240|BEHAVIORAL|Concurrent training program|"The experimental group will perform 16-weeks of exercise. The exercise sessions will occur three times/week.~The participants should conduct their daily activities as usual outside of the study and maintain the same diet."
41293782|NCT02856789|OTHER|Routine hemostasis tests|Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
40764627|NCT05897775|DEVICE|Deep brain stimulation|"Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week."
40764628|NCT03116022|DRUG|Estriol|Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
41136101|NCT04515992|BEHAVIORAL|High Intensity Body-weight Circuit Training (HIBC)|HIBC Exercise Protocol- The HIBC circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10 repetitions), and modified push-ups (5 repetitions). The exercise sessions involved repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Participants were instructed to complete three sessions per week and documented the number of cycles completed. After 3 weeks of consistent training, participants were asked to add a 4th session each week as tolerated. Initially, the HIBC sessions were 5 minutes long, and the duration of the sessions were increased by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session as early as the eighth week of training. Session duration was capped at 10 minutes.
41293783|NCT02856789|OTHER|Fibrin structure (FS)|FS will be determined on STA-R® prototype at Percy and at Stago
40764629|NCT03116022|DRUG|Distal estriol|Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
40764630|NCT03116022|DRUG|Vaginal Gel|Women using a base water gel lubricant during intercourse
40764631|NCT05498090|DRUG|Fenofibrate 145 mg|Fenofibrate 145 mg PO daily for 4 weeks
40764632|NCT06639932|BEHAVIORAL|We-INtervention|The We-INtervention focuses on the relationship dynamics of HIV-serodiscordant male couples. In developing the intervention, we reviewed relevant theories and frameworks, such as the cognitive transactional model, the systemic transactional model, the dyadic illness management model, and the intersectional framework of stigma. The three weekly 60-minute sessions are Session 1: We-disease appraisal. Despite stigma related to their dual minority identities, couples develop a perception of HIV as a shared disease, enhancing illness control. Session 2: Couple communication. Couples undertake skill-building exercises on effective communication techniques to strengthen their relationship. Session 3: Dyadic coping. Couples learn to optimize preference and value assessments in HIV management. A few skill-building exercises help them mobilize and maintain mutual support and develop joint problem-solving skills.
40764633|NCT06639932|BEHAVIORAL|Usual Care Group|The participants in the control condition will receive health information pamphlets. The HIV-seropositive partners will receive information on HIV-related knowledge (e.g., symptoms, comorbidity, stages, and opportunistic infection), treatment (e.g., ART and side effects), and management (e.g., nutrition and mental health). The HIV-seronegative partner will receive information on HIV transmission (e.g., risk factors), prevention (e.g., safe sex and PrEP), and testing.
40764634|NCT02584933|DRUG|ceritinib|hard gelatin capsule or hard tablet for oral use up to 750 mg
40764635|NCT05520567|DRUG|Gilteritinib|Oral
40764636|NCT05520567|DRUG|Venetoclax|Oral
41293784|NCT02856789|OTHER|Thromboelastography (TEG)|Thromboelastography will be processed on TEG® at Percy
41293785|NCT02856789|OTHER|Specialized hemostasis tests|Coagulation factors
41293786|NCT00389077|DRUG|Perifosine|Perifosine 50 mg tablets
40764637|NCT05520567|DRUG|Azacitidine|Subcutaneous injection or intravenous infusion
40764638|NCT03907891|BEHAVIORAL|Motivational social support from nurse|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.
40764639|NCT03907891|BEHAVIORAL|Motivational social support from nurse with additional support from significant other|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.
40764640|NCT03907891|BEHAVIORAL|Attention control|A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
41136102|NCT01448109|DRUG|Hydrocortisone|Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
41293787|NCT04018170|DRUG|Study drug|oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg
41293788|NCT04018170|DRUG|Placebo|oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
41293789|NCT02518178|DEVICE|NFC Necklace|
41293790|NCT02518178|DEVICE|Voice Reminder|Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
40764649|NCT06644898|OTHER|Level walking training|For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
40764650|NCT06644898|OTHER|Downhill walking training|For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
41456178|NCT05838716|DRUG|Placebo Administration|Given PO
41456179|NCT05838716|OTHER|Quality-of-Life Assessment|Ancillary studies
41456180|NCT05838716|OTHER|Questionnaire Administration|Ancillary studies
41456181|NCT04533620|RADIATION|Standardized CIRT|CIRT with a dose of 63 GyE/21 fx
41456182|NCT04533620|RADIATION|Individualized CIRT|A predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
41456183|NCT05452213|DRUG|Ribociclib|"All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion."
41136103|NCT01448109|DRUG|Sterile air filled vial|"the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days"
40764651|NCT06644898|OTHER|Uphill walking training|For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
40764652|NCT06641700|DIAGNOSTIC_TEST|diagnosed with gastric cancer|Pathological biopsy confirmed the diagnosis of gastric cancer.
41293791|NCT02518178|DEVICE|NFC Sticker|NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
41456184|NCT01732328|DIETARY_SUPPLEMENT|Calcium plus vitamin D|
41456185|NCT06297408|DRUG|Relma-cel|CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
41456186|NCT03505008|DRUG|Methotrexate|Route of Administration: Oral
41456187|NCT03505008|DRUG|Adalimumab|Route of Administration: Subcutaneous
41456188|NCT00113061|PROCEDURE|Exercise|
41456189|NCT02774018|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) program|
41456190|NCT04425031|DRUG|Low oxygenation target|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
40764653|NCT04970810|BEHAVIORAL|My Diabetes Goal|Subjects enrolled in the MDG arm will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls.
40764654|NCT04970810|BEHAVIORAL|My Diabetes Goal + CommunityRx|"Subjects enrolled in the MDG arm + CRx will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls. Participants will also receive a HealtheRx (personalized resource prescriptions) for community organizations."
40764655|NCT06256016|OTHER|Neck pain massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, effleurages technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
40764656|NCT06256016|OTHER|Neck and thoracic massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, deep stroke technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
41136104|NCT01947114|DRUG|Propofol|
41136105|NCT01947114|DRUG|Ketamine|
41136106|NCT01947114|DRUG|Remifentanil|
41136107|NCT01581099|PROCEDURE|Digestive Adaptations III surgery|
41136108|NCT02629666|BEHAVIORAL|ERS and/or Self-management Strategies|
41456191|NCT04425031|DRUG|High oxygenation target|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
41456192|NCT06381622|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL Ropivacaine 5 mg/mL (= 150 mg Ropivacaine)
41456193|NCT06381622|DRUG|Lidocaine epinephrine|20 mL Ropivacaine 5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg) / ml (= 100 mg Ropivacaine + 200 mg Lidocaine)
41456194|NCT06381622|DRUG|Ropivacaine 0.75% Injectable Solution|20 mL Ropivacaine 7,5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg)/mL (= 150 mg Ropivacaine + 200 mg Lidocaine)
41456195|NCT01494090|DRUG|Rosuvastatin|5 or 20 mg per day during 6 months
41456196|NCT01494090|DRUG|Placebo|5 or 20 mg per day during 6 months
40961436|NCT06037447|PROCEDURE|3-steps standardized repair-oriented strategy|3-steps standardized repair-oriented strategy, including subvalvular apparatus rehabilitation (leaflet plication if chordae absent on leaflet margin, mal-connected chordae resection if chordae mal-connected to leaflet body, papillary muscle splitting if short chordae or dysplastic or fused papillary muscle etc.), leaflets repair (leaflets plication if functional leaflet prolapse, leaflet cleft closure and patch augmentation for anatomical leaflet defect, etc.) and annuloplasty (posterior annuloplasty for annular dilatation and shallow leaflet coaptation, etc.)
40961437|NCT05644353|DRUG|Mirikizumab|Administered SC.
40961438|NCT00241215|DRUG|Botulinum toxin serotype A|
40961439|NCT04495270|DIAGNOSTIC_TEST|"Analysis of treatment outcomes of teeth with apical periodontitis based on cone-beam computed tomography and estimated by means of Periapical and Endodontic Status Scale"|Patients were examined by cone-beam computed tomography at baseline and in 24 months after endodontic treatment. Treatment outcome was evaluated using estimates of periapical radiolucencies in size, relation with anatomical structures and location.
40961440|NCT03240484|DIAGNOSTIC_TEST|X-Ray Imaging|X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.
40961441|NCT03240484|OTHER|Gait Analysis|Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.
40961442|NCT05746793|PROCEDURE|endometrium biopsy|"The procedure is performed without any anesthesia and takes approximately 5 minutes.~A small plastic pipelle is put through the cervix into the uterine cavity. The endometrial tissue is aspirated into the pipelle."
40961443|NCT05746793|DIAGNOSTIC_TEST|Transabdominal ultrasound|Evaluation of fetal biometry and doppler flow study using ultrasound.
40961444|NCT05746793|DIAGNOSTIC_TEST|Peripheral phlebotomy|single puncture collection of peripheral venous blood.
40961445|NCT05746793|DIAGNOSTIC_TEST|Urine collection|Collection of urine in a plastic cup.
40961446|NCT05746793|OTHER|MOCK frozen embryo transfer preparative cycle.|Start with daily estradiol (progynova, oestrogel) administration at hormonal baseline (day 2 of the cycle or with confirmation using endocrine evaluation). When adequate thickness (≥6.5 mm) of the endometrium is achieved (usually after 10-14 days), progesterone is administered daily. 6 days after progesterone administration, the pipelle biopsy will be performed. When this test cycle has ended and menstruation starts, patients will be asked to collect their menstrual flow, during the first night of heavy/red flow, in a menstrual cup. The next day patients will be asked to bring their collected menstrual blood to our center and they will undergo a blood analysis needed for the start of their ART treatment.
40961447|NCT05746793|DIAGNOSTIC_TEST|Baseline questionnaire|questionnaire the patient has to fill in
40961448|NCT05746793|OTHER|collection of menstrual blood|collection of menstrual blood during the first day of heavy menstrual flow for at least 6 hours
40961449|NCT05746793|DIAGNOSTIC_TEST|nutritional and metabolic work-up|Including body composition analysis by BIA/whole body MRI and analysis of resting energy expenditure (REE).
40961450|NCT05746793|DIAGNOSTIC_TEST|cardiac work-up|Using transthoracic ultrasound.
41293792|NCT05477966|OTHER|Medical records review|The clinical characteristics at the time of diagnosis of rifampin-susceptible pulmonary tuberculosis patients, the Xpert MTB/RIF assay Ct value, the tuberculosis activity score based on AI of the chest image, and treatment results will be collected retrospectively through medical records.
40961451|NCT05746793|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure measurement
40961452|NCT06015672|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will experience three accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
40961453|NCT00845104|DRUG|fludarabine phosphate|Given IV
40961454|NCT00845104|BIOLOGICAL|rituximab|Given IV
40961455|NCT00845104|BIOLOGICAL|bevacizumab|Given IV
40961456|NCT00845104|OTHER|laboratory biomarker analysis|Correlative studies
40961457|NCT00845104|OTHER|flow cytometry|Correlative studies
40961458|NCT00845104|GENETIC|polymerase chain reaction|Correlative studies
40961459|NCT00845104|GENETIC|fluorescence in situ hybridization|Correlative studies
41293793|NCT00680420|PROCEDURE|fine needle aspiration biopsy|One extra biopsy will be taken from the pancreas only in patients who are already undergoing biopsy of a mass or cyst.
40961460|NCT05823129|BEHAVIORAL|Tele-rehabilitation caregiver empowerment enhanced post- discharge rehabilitation directive|The intervention group will receive an implemented TUG test-based telerehabilitation program. The TUG test-based telerehabilitation involves patients routinely doing two TUG tests by themselves twice daily. Each patient will be provided with a unique link to the TUGstopwatch, a prerecorded video outlining instructions on how to properly conduct a TUG test, and support and guidance for patients and caregivers throughout the study period.
40961461|NCT01459081|DRUG|Zanamivir|10 mg inhaled by mouth, twice daily, for 5 days
40961462|NCT01459081|DRUG|Placebo|inhaled by mouth, twice daily, for 5 days
40961463|NCT03194230|OTHER|With cervical dilatator|Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
40961464|NCT05399732|DRUG|Luspatercept|Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.
40961465|NCT01318993|DRUG|GSK1605786A|500 milligrams twice daily
40961466|NCT04578639|DRUG|Rituximab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
40961467|NCT04578639|DRUG|Ocrelizumab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
40764657|NCT06640166|DRUG|encorafenib + cetuximab + FOLFIRI|"encorafenib plus cetuximab beyond progression in combination with irinotecan-based doublet chemoterapy (FOLFIRI) as follows:~* encorafenib 300 mg (75 mgx4 hard capsules) orally once daily;~* cetuximab 500 mg/sqm iv every 14 days;~* FOLFIRI iv every 14 days (Irinotecan 180 mg/sqm, Folinic Acid 400 mg/sqm, 5Fluorouracil 400 mg/sqm iv bolus and 2400 mg/sqm iv continuous infusion over 46-48 hours)."
40764658|NCT05882370|DRUG|Cadonilimab|Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
40764659|NCT05882370|PROCEDURE|transjugular intrahepatic portosystemic shunt (TIPS)|transjugular intrahepatic portosystemic shunt (TIPS)
40764660|NCT06639737|PROCEDURE|preoperative stroke volume optimization|Stroke volume optimization using transthoracic echocardigraphy (sub aortic velocity time integral) before induction of total intravenous anesthesia. Fluids bolus of 250 ml of cristalloids will be successively administered until the sub aortic velocity time integral increase will be \< 10%
40764661|NCT06639737|PROCEDURE|Post induction stroke volume optimization|Optimization of stroke volume following induction of general anesthesia using oesophageal stroke volume measurement. 250 ml bolus of cristalloids succesively administered until the stroke volume increase \<10%
40764662|NCT04225117|DRUG|enfortumab vedotin|intravenous (IV) infusion
40961468|NCT02130232|BEHAVIORAL|Lifestyle Intervention|
40961469|NCT02130232|OTHER|Usual Care|
40990605|NCT04178746|DEVICE|Artemis Neuro Evacuation Device|"The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump.~The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.~The Artemis Device will be evaluated by descriptive statistics in this registry to assess its efficiency and reliability in minimally invasive, mechanical evacuation of hematoma in patients with intracranial hemorrhage under direct visualization and control using a neuroendoscope."
40764663|NCT04225117|DRUG|pembrolizumab|IV infusion
40764664|NCT06120504|DRUG|SGN-35T|Given into the vein (IV; intravenously)
40764665|NCT05076617|DRUG|Staccato alprazolam|"* Pharmaceutical form: Inhalation powder~* Route of administration: Inhalation~Participants will receive Staccato alprazolam during the Treatment Period."
40764666|NCT06281769|DIAGNOSTIC_TEST|3D multi-parametric ultrasound targeted biopsy pathway using PcaVision|The procedure of 3D multiparametric ultrasound consists of 3 components: (1) intravenous administration of ultrasound contrast; (2) rectal multi-parametric ultrasound imaging; (3) PCaVision: artificial intelligence algorithm analyzing the images.
40764667|NCT06281769|DIAGNOSTIC_TEST|MRI targeted biopsy pathway|MRI sequences will include at least T1-weighted, T2-weighted, Diffusion-weighted imaging (DWI) and calculation of apparent diffusion coefficient (ADC) maps. Scoring of suspicion will be performed using the European Society of Urogenital Radiology (ESUR) PI-RADS standardized scoring system. All lesions will be marked and delineated for MRI-TRUS fusion 3D multiparametric ultrasound (mpUS).
40764668|NCT04364672|DRUG|18F-labeled DPA-714 PET scan|One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 within 4 weeks after completing NACT including at least 2 cycles administered; before surgery
40990606|NCT00923559|OTHER|Treatment as Usual at Child Health Centre|Treatment as usual (TAU) involved scheduled nurse calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The nurse is encouraged to promote attachment and to detect postnatal depressions. Mothers might be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment might be initiated by the nurse or the mother. This was registered at the end-point interview.
41136109|NCT03507244|DRUG|Pemetrexed|Pemetrexed, 10 mg,intrathecal injection, plus dexamethasone 5 mg, once per week, 5 to 8 times, 4 to 7 weeks in total.
41136110|NCT03507244|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection, simultaneously with pemetrexed, once per week, 5 to 8 times, 4 to 7 weeks in total.
41136111|NCT03507244|RADIATION|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
41136112|NCT04127552|PROCEDURE|Adrenalectomy|Adrenalectomy accordint to 2016 ESE guidelines
41136113|NCT00778856|PROCEDURE|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
40764669|NCT03038672|BIOLOGICAL|Nivolumab|Given IV
40764670|NCT03038672|DRUG|Varlilumab|Given IV
40764671|NCT06644001|DIETARY_SUPPLEMENT|Bacillus coagulans GBI-30,6086 (BC GBI-30)|2g powder/sachet, consists of bacillus coagulans at a dose of 1x10\^9 CFU, taken once daily before a meal.
40764672|NCT06644001|DIETARY_SUPPLEMENT|Placebo|2g powder/sachet, consists of maltodextrin only, taken once daily before a meal.
40764673|NCT03314584|DEVICE|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
40764674|NCT03314584|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
40764675|NCT03314584|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Brain imaging will be done via MRI prior to the first rTMS/Sham TMS session. Imaging will allow investigators to target specific areas in the brain.
40764676|NCT05774041|DEVICE|SIS System|FDA-cleared software that enhances standard clinical images for the visualization of structures in the basal ganglia area of the brain which are commonly targeted for DBS lead placement.
40764677|NCT06356220|OTHER|Gluten-Free Diet Education|The two groups will receive different gluten free diet education interventions. Currently, virtual GFD education classes are the standard of care for educating children with CeD and their families about GFD at Boston Children's Hospital. Thus, all diet education (including GFFG intervention) will be provided virtually by Registered Dietitians with expertise in GFDs. .
40764678|NCT06525727|OTHER|Falls Decision Rule|The Falls Decision Rule is a rule used to assess the risk of intracranial haemorrhage in geriatric patients and to prevent brain tomography (CT) in low-risk patients. This rule recommends that brain CT is not necessary in patients who do not have significant head trauma, memory loss or newly developing neurological examination disorder after a fall.
40764679|NCT06640361|DRUG|Olverembatinib|Oral administration with meal, QOD, every 28 days for a cycle.
41136114|NCT04427124|OTHER|Multidisciplinary Team Based Care Model|All prospective patients admitted into the study will receive care based on multidisciplinary team collaboration and an institutional protocol for critical limb ischemia.
41136115|NCT00262366|DEVICE|Comparison of automatic CPAP versus fixed CPAP|
41136116|NCT02797743|OTHER|Whole blood|"* Adults ≥18 yrs of age: up to 50 mL (5 tubes)~* Adolescents 12-17 yrs of age: up to 30 mL (3 tubes)~* Children 0-11 yrs of age: single tube (1 tube, 10 mL)"
41136117|NCT00590759|DEVICE|GORE TAG® Thoracic Endoprosthesis|implant
41136118|NCT04108858|DRUG|Copanlisib|Given IV
41136119|NCT04108858|BIOLOGICAL|Pertuzumab|Given IV
41136120|NCT04108858|BIOLOGICAL|Trastuzumab|Given IV
40764680|NCT06511024|OTHER|Blood sample|Serial blood sampling to monitor immune cells in patient with COVID 19 infection and compare with control group who have no evidence of COVID-19 infection
40764681|NCT06450444|DEVICE|PRIMUS|The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.
40764682|NCT06643260|DRUG|piclidenoson|Piclidenoson is a selective A3AR agonist, supplied as tablets.
40764683|NCT06643260|DRUG|Placebo|Inactive control
40764684|NCT04225871|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
40764685|NCT06043011|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
41136121|NCT01535352|BEHAVIORAL|Mom-Net|"The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration."
40961470|NCT02747875|DRUG|Methadone|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
40961471|NCT02747875|DRUG|Fentanyl|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
40961472|NCT02032225|OTHER|Skin biopsy|
40961473|NCT03940222|DEVICE|Interactive Binocular Treatment|The specified system which stimulate the fovea of the amblyopic eye directly by detailed and movable objects, while the fixation of the non- amblyopic eye will be focused on fixed targets.
40961474|NCT03940222|PROCEDURE|Patching Therapy|Patching of the dominant eye with better best corrected visual acuity
40961475|NCT02349529|BEHAVIORAL|Psychosocial Intervention Group|6 group sessions
40961476|NCT02349529|OTHER|Waiting list control|Treatment as usual
40961477|NCT02867462|OTHER|Standard care|standard care
40961478|NCT02867462|OTHER|manipulator consultation radiotherapy added to standard care|
40764686|NCT04547556|DIAGNOSTIC_TEST|BioFire|"A molecular rapid syndromic testing platform, using the following panels:~* BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)~* BioFire FilmArray Pneumonia Panel plus (PP)"
40961479|NCT01372267|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
40961480|NCT01372267|BEHAVIORAL|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
40961481|NCT02584816|BIOLOGICAL|BRV-PV Lot A + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
40961482|NCT02584816|BIOLOGICAL|BRV-PV Lot B + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
40961483|NCT02584816|BIOLOGICAL|BRV-PV Lot C + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
40961484|NCT02584816|BIOLOGICAL|ROTARIX + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
40961485|NCT03734276|OTHER|High intensity activity|Cyclo-ergometer session in high intensity setting
40961486|NCT03734276|OTHER|control arm|Usual care
40961487|NCT05477693|BIOLOGICAL|Experimental 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
40961488|NCT05477693|BIOLOGICAL|Control 23-valent PPV|The control vaccine was manufactured by Merck Sharp \& Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.
40961489|NCT03110094|OTHER|Adalimumab|It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes and use of surplus articular fluid (M0 and M3).
40961490|NCT03110094|OTHER|Healthy volunteers|Collection of 2 tubes of blood. The values of the quantitative study of lymphocyte subpopulations will be compared to those obtained from healthy blood donors to define the standards used in this study.
40961491|NCT06524284|DEVICE|Releaf|10 days/35 minutes per day EVNS (non-invasive electrostimulation) treatment on lower legs and feet by the subject or its caregiver after instruction by the podiatrist.
40961492|NCT04803071|DIETARY_SUPPLEMENT|Experimental group of n-pufas improving cognitive formula|Three times a day, one capsule of n-3pufas improvement cognitive formula capsule (once in the morning, in the evening) and routine treatment for depression, lasting for 12 weeks
40961493|NCT04803071|DIETARY_SUPPLEMENT|General fish oil formula product adjuvant treatment control group|The control group: 1 capsule of general fish oil formula (once in the morning, in the evening) three times a day, plus routine treatment for depression, lasting for 12 weeks
40961494|NCT04803071|DIETARY_SUPPLEMENT|Placebo assisted treatment group|Three times a day, one capsule of placebo adjuvant therapy (once in the morning, one in the evening) and conventional treatment of depression for 12 weeks
40961495|NCT00828932|DRUG|Lorcaserin|
40961496|NCT04167579|DEVICE|Transcutaneous Valve Therapy|Any patient who undergoes an attempted transcutaneous aortic or mitral valve therapy procedure, with an FDA approved device.
40961497|NCT01842321|DRUG|Abiraterone Acetate|Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
40961498|NCT05001256|OTHER|questionnaire study|Participants will be surveyed through face-to-face interviews.
40961499|NCT00418457|DRUG|General anesthesia and opioids|General anesthesia, usually with sevoflurane, and opioid analgesia
40764687|NCT06640127|PROCEDURE|Sinus lifting and implant placement with osteotomes|Osteotomes with increasing diameters were used for sinus membrane elevation and implant insertion
40961500|NCT00418457|DRUG|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
40961501|NCT00287482|DRUG|Essiac|
40961502|NCT02705469|DRUG|ZEN003694|
40961503|NCT05417282|DRUG|MW151|Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.
40961504|NCT00319995|DRUG|loratadine; montelukast|
40961505|NCT02981264|DRUG|Transcricoid Injection|
40961506|NCT02981264|DRUG|Spray as you go|
40961507|NCT02662829|BEHAVIORAL|Community-based intervention|
40961508|NCT02662829|OTHER|Standard of care|
40961509|NCT01814514|DRUG|Timolol-trusopt|
40961510|NCT01814514|DRUG|placebo|
40961511|NCT01530360|DEVICE|cerebral oximeter|INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
40961512|NCT01606800|DRUG|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
40961513|NCT01606800|DRUG|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
40961514|NCT05866900|DEVICE|MiniMed 780G with SmartGuard activated|The MiniMed 780G system consists of a MiniMed 780G Insulin Pump connected to Guardian 4 Sensor or Guardian 3 Sensor, using an automated insulin delivery algorithm called SmartGuard.
40961515|NCT00679432|PROCEDURE|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
40961516|NCT00679432|DRUG|budesonide-MMX® 6 mg|6 mg/day, 6 mg tablets
40961517|NCT00679432|DRUG|budesonide-MMX® 9 mg|9 mg/day, 9 mg tablets
40961518|NCT00679432|DRUG|Placebo|Placebo
40961519|NCT00679432|DRUG|Asacol® 400 mg|2400 mg/day, 400 mg tablets
40961520|NCT01495117|DRUG|Povidone-Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
40961521|NCT01495117|DRUG|Chlorhexidine gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
40961522|NCT04083196|BIOLOGICAL|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle
40961523|NCT04083196|BIOLOGICAL|Placebo|Placebo
40764688|NCT06640127|PROCEDURE|Sinus lifting and implant placement with specifically designed drills|Sequential drills were used for sinus membrane elevation and implant insertion
40961524|NCT01002222|DRUG|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
40961525|NCT01786941|OTHER|Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training|
41136122|NCT01535352|BEHAVIORAL|Coach-facilitated Treatment as Usual|Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
40764689|NCT04874480|DRUG|Decitabine|Given IV
40764690|NCT04874480|DRUG|Tegavivint|Given IV
40961526|NCT01786941|OTHER|GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|
40961527|NCT02696460|PROCEDURE|N2O/O2 analgesia|Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
40961528|NCT02696460|PROCEDURE|Lidocaine/Prilocaine analgesia|Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
40961529|NCT06220565|DEVICE|"sensor and wearable device Graded Exercise"|"The program plans to use rational mechanism to provide safe and targeted exercise interventions to patients at different stages of their lives through three aspects: education, motivation and feedback. Through real-time collection of knee function parameters, real-time feedback on the effect of exercise intervention, and tracking the changes in the functional status of patients' knee joints. On the basis of improving knee function, we further improve patients' compliance with exercise intervention.~Considering the community scenario, we plan to use sensors and wearable devices to realize the function of the knee joint on the basis of the existing technology. wearable devices to realize the digital assessment of knee function to reduce patient's time and cost and improve efficiency. At the same time, this digital assessment will provide a basis for decision-making for patient self-management."
40961530|NCT06220565|OTHER|exercise|exercise
40961531|NCT06220565|OTHER|Educational Manual|Educational Manual
40961532|NCT02088710|BEHAVIORAL|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
40961533|NCT06349330|DEVICE|Test: 3D intra-oral scanner|"3D intra-oral scanner will be used to scan the subjects after plaque staining is performed. Subsequently, a 3D rendered image will be produced. Participants will be given oral hygiene education and instruction before being instructed to brush.~A cooling-off period of 30 minutes is given before participants are instructed to brush."
40961534|NCT06349330|OTHER|Control: Standard oral hygiene|Standard oral hygiene instructions will be delivered using a hand mirror. No 3D intraoral scanner will be used.
40961535|NCT01850875|BEHAVIORAL|Eye-Movement-Desensitization-Reprocessing|
40961536|NCT05121896|DEVICE|MRI Scan|7.0 tesla functional MRI scan
40961537|NCT05581862|BEHAVIORAL|3 meals+3 snacks|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals and 3 snacks for 3 months
40961538|NCT05581862|BEHAVIORAL|3 meals|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals for 3 months
40961539|NCT02742441|DRUG|122-0551 Foam|Topical Foam containing active drug
40961540|NCT02742441|DRUG|Vehicle Foam|Topical Foam containing no active drug
40961541|NCT00013962|DRUG|Vitamin D|
40961542|NCT00592930|DRUG|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
40961543|NCT00592930|DRUG|placebo|
40961544|NCT02509767|DRUG|Subcutaneous depot medroxyprogesterone acetate|Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
40961545|NCT03655509|PROCEDURE|Dynamic test ACTH stimulation|
40961546|NCT01753505|OTHER|64-slice Multidetector coronary CT angiography|
40961547|NCT03471520|BEHAVIORAL|Earplugs and eye masks|Patients in this study will be given earplugs and eye masks to be worn during sleep
40961548|NCT02303366|RADIATION|Stereotactic Ablative Body Radiosurgery (SABR)|Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
40961549|NCT02303366|DRUG|MK-3475|MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
40961550|NCT01796080|OTHER|Mueller manoeuvre|
40764691|NCT06300632|OTHER|geriatric locomotive syndrome|Elderly individuals will be included in the study. Before each elderly person starts the study, they will be informed about the content of the study and they will read and sign the consent form stating that they participate in the study voluntarily. Socio-demographic data (age, body mass index, and family history, fall history, ) of all individuals participating in the study will be recorded.Within the scope of the evaluation, locomotive syndrome evaluation will be made through a survey. Fear of movement will be evaluated with the Tampa kinesiophobia scale, your physical activity level with the physical activity scale for the elderly, your physical performance with the short physical performance battery, your fatigue level with the fatigue severity scale, and your cognitive functions with the Montreal Cognitive Assessment Scale.
40961551|NCT01796080|OTHER|Inspiratory threshold|
40961552|NCT01796080|OTHER|Expiratory apnoea|
40961553|NCT01796080|OTHER|Steady state normal breathing|
40961554|NCT01256801|BIOLOGICAL|cytokine|interleukin 2 2 million unit every week
40961555|NCT00082251|DRUG|Niacin extended release and simvastatin tablets|
40961556|NCT05878288|DRUG|Cemiplimab|Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
40961557|NCT06492317|DRUG|Disitamab Vedotin|Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, Q2W (every 2 weeks)
40961558|NCT06492317|DRUG|Cadonilimab|Cadonilimab: 6mg/kg, d1, ivdrip, Q2W (every 2 weeks)
41136123|NCT04905784|BEHAVIORAL|Differential learning|The patient will be requested to perform different exercises, each exercise one time a day for 3 days in a row before moving to the next exercise. All patient will be asked to do the exercises in the same sequence.
41136124|NCT04905784|BEHAVIORAL|Usual toothbrushing|The patients in this group will be provided with the regular oral health instructions, including the traditional toothbrushing recommendations.
41136125|NCT02826954|OTHER|Upper airway assessment, including nasal biopsy|
41136126|NCT01915914|DRUG|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
41136127|NCT00038038|DRUG|18F-fluoromisonidazole|Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
40961559|NCT01737320|DRUG|short-course antibiotic treatment|"On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~1. Intervention group - antibiotic treatment stopped on day 7~2. Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines."
40961560|NCT01737320|DRUG|accepted prolonged antibiotic treatment|
40961561|NCT02271568|PROCEDURE|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
40961562|NCT02271568|OTHER|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
40961563|NCT03801343|DIETARY_SUPPLEMENT|Nutrakos®|"Nutrakos® Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes."
40961564|NCT01797744|OTHER|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
40961565|NCT00487877|DEVICE|SenseWear Pro3 Armband|
40961566|NCT00487877|DEVICE|i-button DS2191 H|
40961567|NCT04094883|BIOLOGICAL|Meningococcal Group B Vaccine|All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.
40961568|NCT02616081|OTHER|Clean Intermittent Catheterization|Clean intermittent self catheterization is a standard of care.
40961569|NCT02616081|OTHER|Indwelling Catheter|Indwelling catheterization is a standard of care.
40961570|NCT02616081|OTHER|Surgery|Bladder surgery is a standard of care.
40961571|NCT02616081|OTHER|Voiding|Voiding spontaneously is a standard of care.
40961572|NCT00002989|DRUG|busulfan|
40961573|NCT00002989|DRUG|cyclophosphamide|
40961574|NCT00002989|DRUG|idarubicin|
40961575|NCT00002989|DRUG|melphalan|
40961576|NCT00002989|RADIATION|radiation therapy|
40961577|NCT01090271|DEVICE|Isokinetic eccentric training|The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
40961578|NCT01805804|DRUG|placebo/valsartan|
40961579|NCT00349531|DRUG|Pramipexole|
40961580|NCT01705990|BIOLOGICAL|SeV-G(NP) (0.2mL, 2x10^7 CIU)|Delivered intranasally by drops
40961581|NCT01705990|BIOLOGICAL|SeV-G(NP) (0.2mL, 2x10^8 CIU)|Delivered intranasally by drops
40961582|NCT01705990|BIOLOGICAL|Ad35-GRIN (0.5mL)|(1x10\^10 vp) Delivered intramuscularly by standard syringe and needle injection
40961583|NCT06271382|OTHER|Acupressure Group|"In the research, the participant in the acupressure group will receive acupressure application 3 times a week for 2 weeks, a total of 6 times.~Depending on the preparation and pressure time on the 5 selected points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes."
40961584|NCT06271382|OTHER|Sham Acupressure Group|"Depending on the preparation and pressure time on the 5 selected sham points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes.~Patients in the sham acupressure group will receive acupressure 6 times in total, 3 times a week for 2 weeks. The practitioner will do the first acupressure at the Family Health Center, and the person with type 2 diabetes will do the others at home. Ankle Brachial Index evaluation will be performed by the researcher at the Family Health Center a total of 3 times before the intervention, 1 week after the intervention and 2 weeks after the intervention."
40961585|NCT06271382|OTHER|Foot Ankle Exercise Group|Exercise will be performed regularly for 2 weeks, 3 days a week for a maximum of 30 minutes.
40961586|NCT00672932|DRUG|raltegravir|400 mg two times daily for three months
40961587|NCT00788567|DRUG|mycophenolate mofetil|1
40961588|NCT02577549|BEHAVIORAL|Diet & Exercise|Participants will attend exercise and diet classes.
40961589|NCT02577549|BEHAVIORAL|Attention Control|Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
40961590|NCT01948297|DRUG|Debio1347 (CH5183284)|Debio1347 (CH5183284) tablets for oral administration
40961591|NCT01628315|DEVICE|MRI|Annual MRIs as part of participation in the ASA study.
40961592|NCT06304428|OTHER|Deprescribing Care Model|The Deprescribing Care Model is designed to deprescribe fall related medications (FRIDs)
40961593|NCT06304428|OTHER|Bone Health Service Model|The Bone Health Service Model is designed to provide osteoporosis evaluation and management
40961594|NCT06304428|OTHER|Injury Prevention Service Model|The Injury Prevention Service Model provides both the Deprescribing Care Model and the Bone Health Service Model.
40961595|NCT05762198|DEVICE|Rezūm|In the REZUM arm, water vapour treatment is performed for all subjects under local anaesthesia.
40961596|NCT05762198|DEVICE|TURP|In the TURP arm, all men will receive TURP operation under general or spinal anaesthesia
40961597|NCT02959320|PROCEDURE|Hip Hemiarthroplasty|This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
40961598|NCT01205711|DRUG|FOLFIRI regimen|
40961599|NCT01205711|DRUG|fluorouracil|
40961600|NCT01205711|DRUG|irinotecan hydrochloride|
40961601|NCT01205711|DRUG|leucovorin calcium|
40961602|NCT01205711|DRUG|zibotentan|
40961603|NCT01205711|OTHER|laboratory biomarker analysis|
40961604|NCT01205711|OTHER|pharmacogenomic studies|
40961605|NCT02126995|DRUG|MG01CI extended-release tablet|Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
41293794|NCT03708003|DRUG|Ibrutinib|"Patients receive 6 cycles (cycle = 28 days) of ibrutinib monotherapy at the daily dose of 420 mg (3x 140 mg).~Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
40961606|NCT02785120|DRUG|TF0023|TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
40961607|NCT04424888|OTHER|WB-011|WB-011 medical food product.
40961608|NCT04424888|OTHER|Placebo|Placebo Capsules identical to those containing WB-011.
40961609|NCT04424888|DEVICE|Continuous Glucose Monitor|Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.
40961610|NCT02576795|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
40961611|NCT02179489|PROCEDURE|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC|HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.
40961612|NCT04307303|DEVICE|abdominal functional electrical stimulation|functional electrical stimulation of the abdominal muscles
40961613|NCT00261144|DRUG|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
40961614|NCT00261144|BIOLOGICAL|Biological|Collagenase injection
40961615|NCT06216483|OTHER|PDM Alert|passive digital marker (PDM) for postoperative delirium risk
40961616|NCT05248061|OTHER|Group A|"Wand exercises; It will be applied to increase the normal range of motion of the joint. Exercises will be performed in the directions of shoulder flexion, abduction, external and internal rotation. Objects such as a round stick, walking stick and towel can be used to assist patients during exercise.~- \*Pendulum (Codman) Exercises: These exercises will be applied in 90° flexion of the waist, with the healthy hand resting on a solid place, and turning the arm back and forth, to the sides, clockwise and counterclockwise with circular movements.~\*Capsule stretching: Auto stretching (by the patient) will be applied to the posterior region of the shoulder (capsule), pectoralis minor and upper trapezius muscles.~\*Isometric shoulder exercises Isometric exercises will be given in the directions of shoulder extension, abduction, external rotation and internal rotation."
41136128|NCT00038038|PROCEDURE|PET scan|Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
41456197|NCT03025451|BEHAVIORAL|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
40961617|NCT05248061|OTHER|Group B|"The same exercises as in Group 1 will be suitable for the participants.~* PRP will be applied in the first session and 2 weeks later. Exercises will be started 2 days after PRP application.~* Up to 10 cc of blood will be taken from the PRP group patients by the nurse. 25 mL of venous blood will be collected from each patient at a time, using a syringe containing 2.5 mL of the anticoagulant citrate dextrose solution. After the blood taken is transferred to the special PRP kit and centrifuged for 8 minutes at 3000 rpm, in addition to the 5-6 cc platelet-rich plasma remaining in the upper part of the kit, the entire buffy coat is injected into the syringe from the region compatible with the posterior arthroscopy portal (inferior to the acromion posterolateral bone prominence) by the physician. next, from the end point of the posterior fibers of the deltoid muscle, targeting the subacromial space) will be applied. No buffering or activating agents will be used for PRP."
40961618|NCT02563743|BEHAVIORAL|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
40961619|NCT02563743|BEHAVIORAL|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
40961620|NCT05434000|DRUG|Hydroxyurea|Children at risk of developing stroke (TCD values\>200cm/s) will be given 20mg/kg of Hydroxyurea
40961621|NCT00544518|DRUG|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
40961622|NCT00544518|DRUG|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
40961623|NCT01347944|DRUG|lenalidomide|Patients who were prescribed Revlimid from 31October 2008 to present.
40961624|NCT04027062|BEHAVIORAL|Diabetes Continuing Education Intervention|"The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians."
40961625|NCT01989897|DRUG|saline with 1mg/ml Histamine base|
40961626|NCT01989897|DRUG|diluent, saline with HSA--phenol|
40961627|NCT02154178|OTHER|Biomarker group|use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)
40961628|NCT03981770|DRUG|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
40961629|NCT02687633|BEHAVIORAL|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
40961630|NCT06204887|PROCEDURE|Manual dynamic activation|The root canals were filled with irrigation solutions. A main gutta percha cone was positioned 1 mm shorter than the working length and 2 mm coronal-apical direction movement was performed at a rate of 100 strokes per minute during 60 s.
40961631|NCT06204887|PROCEDURE|Passive ultrasonic activation|A non-cutting ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) coupled to an ultrasonic device (DTE S6 Led, Guilin Woodpecker Co., Guilin, Guangxi, China) (mode: E, setting: 6) was used according to the manufacturer's recommendations.
40961632|NCT06204887|PROCEDURE|Laser activation|A 2940 nm Er:YAG-laser device (Lightwalker, Fotona, Ljubljana, Slovenia), equipped with a handpiece (H14, Fotona) holding a 8.5 mm long and 600 µm diameter-tapered fiber tip (SWEEPS 600, Fotona) was used for irrigation activation. The device was set to AutoSWEEPS mode with two ultrashort micropulse durations (25 μs) continuously varying at 0.3 W, 20 mJ, 15 Hz settings. The air and water sprays were turned off.
40961633|NCT06557655|DIETARY_SUPPLEMENT|caffeinate chewing gum|participants either chewed caffeinated gum (CAF) containing 3 mg/kg caffeine or a caffeine-free placebo gum (PLA) for 10 minutes prior to undertaking a series of tests on-ice and off-ice.
40961634|NCT02557711|DEVICE|ultrasound elastography, acoustic radiation force impulse|Two physiatrists will perform ultrasound elastography and ARFI for intra-rater and inter-rater reliability evaluation.
40961635|NCT00460096|DRUG|Kamada-API|
40961636|NCT06262516|PROCEDURE|Nephroureterectomy|Participants will undergo standard-of-care nephroureterectomy for UTUC.
41136129|NCT00154115|DRUG|levosimendan|Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
41293795|NCT03708003|DRUG|Venetoclax|"Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
41293796|NCT01900275|OTHER|Urine collection|Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
40961637|NCT06262516|PROCEDURE|Lymph Node Dissection|Participants will receive lymph node dissection alongside nephroureterectomy for UTUC.
40961638|NCT06504784|DIETARY_SUPPLEMENT|Dietary Fiber Mixture|10g/day of dietary fibre mixture - a mixture of oligo-and polysaccharides
40961639|NCT06504784|OTHER|Placebo|10g/day of placebo (glucose)
40961640|NCT03515278|PROCEDURE|SCNB group|IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
40961641|NCT03515278|PROCEDURE|IACI group|SCNB is a new choice for treatment of frozen shoulder.As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to infiltrate the nerve accurately without injury to the nerves or vessels.
40961642|NCT02318251|OTHER|Involuntary muscle contractions|Physiotherapy program focusing on involuntary pelvic floor muscle fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day). This program includes the standard physiotherapy.
40961643|NCT02318251|OTHER|Voluntary muscle contractions|Physiotherapy program (physiotherapy standard program) focusing on voluntary fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day).
40961644|NCT00714441|BEHAVIORAL|Lifestyle and Activities Education Program (LEAP-AHEAD)|Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
40961645|NCT00714441|BEHAVIORAL|Computer Automated Self-Management (CASM)|CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.
40961646|NCT00714441|BEHAVIORAL|Computer Automated Self-Management and Problem Solving Therapy (CAPS)|Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
40961647|NCT03680690|PROCEDURE|hysteroscopy|office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.
40961648|NCT06064812|DRUG|FWD1802|"Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days."
40961649|NCT06064812|DRUG|palbocilib|"The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days."
41136130|NCT00154115|DRUG|placebo|Placebo
40961650|NCT00705484|BIOLOGICAL|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
40961651|NCT00705484|DRUG|Standard Therapy|The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
40961652|NCT05638581|BIOLOGICAL|LTOWB|Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.
40961653|NCT05638581|BIOLOGICAL|Components|Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.
40961654|NCT04524546|DIAGNOSTIC_TEST|Sterno-mental displacement test|While the patient is in sitting position, (SMD neutral) will be is measured using tape as the distance between upper borders of the manubrium sterni to the mentum with the head in a neutral position. The (SMD extension) will be then measured in the same way with the head extended on the neck. The difference between SMD extension and SMD neutral will be then calculated as sternomental displacement (SMDD).
40961655|NCT03498144|DEVICE|Anterior segment OCT|lower punctum examination by AS-OCT
40961656|NCT03692468|BEHAVIORAL|Psychotherapy|Participants will complete 5, 60 minutes sessions. At each session, participants will learn strategies that have been shown to improve pain functioning and/or mood for patients who have chronic pain. The intervention will be delivered in the patient's primary care clinic.
40961657|NCT03481907|DEVICE|Nuvagen Collagen Powder|Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding
40961658|NCT03355716|DRUG|bupivacaine|Bupivacaine 25 ml (0.25%)
40961659|NCT03355716|DRUG|morphine|Morphine (3.0 mg)
40961660|NCT03355716|DRUG|fentanyl|fentanyl (30.0 Mc)
40961661|NCT03355716|DRUG|Ketamine:|ketamine (0.5 mg/kg).
41136131|NCT00259116|DRUG|Relaxin|
40961663|NCT03543475|DEVICE|arabin pessary|arabin pessary: silicon device
40961664|NCT03543475|DEVICE|no pessary|control group
41136132|NCT01830049|OTHER|Take blood|
41136133|NCT01672684|PROCEDURE|support group therapy|Complete at-home group video calling support sessions
41136134|NCT01672684|OTHER|educational intervention|Receive an educational workbook journal
40961665|NCT05534737|OTHER|MAICP + usual care of social services|The intervention consists of applying a MAICP from the municipal social services involved for 2 years (summer 2022-summer 2024). To this end, the AICP.com project will sign the necessary institutional agreements to contract and integrate, in the municipal Social Services of each territory, an intervention team that will work with them in a coordinated manner, although its specific task is the implementation of the MAICP during the intervention period of the project and the baseline, intermediate and final evaluations of the effectiveness of this model in the study population.
40961666|NCT05534737|OTHER|Control|usual care of social services
40961667|NCT04833010|OTHER|Cardiopulmonary Exercise Test|Participants will complete a Cardiopulmonary Exercise test on cycle ergometer in which they will perform progressive step-exercise cycling to exhaustion
41136135|NCT05727111|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) implemented at the patient home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
40961668|NCT04833010|OTHER|Cognitive Performance Test|Cognitive Performance will be tested using a cognition application on an iPad during the Cardiopulmonary Exercise Test.
40961669|NCT05901428|DRUG|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
40961670|NCT05901428|DRUG|Carboplatin|Carboplatin is a deoxyribonucleic acid (DNA) synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
40961671|NCT05901428|DRUG|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
41136136|NCT05727111|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living."
41136137|NCT05727111|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) at the patient's home|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 1 hour per day (4 hours per week in autonomy and 1 hour per week under supervision).
41136138|NCT05727111|BEHAVIORAL|Usual care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
40961672|NCT05901428|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
40961673|NCT05061732|DRUG|Rabeprazole|20mg bid
41136139|NCT04866160|DRUG|BI 1291583|BI 1291583
41136140|NCT04866160|DRUG|Placebo|Placebo
40961674|NCT05061732|DRUG|Bismuth potassium citrate|0.6g bid
40764692|NCT05815264|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.
40961675|NCT05061732|DRUG|Metronidazole|0.4g qid
40961676|NCT05061732|DRUG|Clarithromycin|0.5g bid
41293797|NCT05811572|DEVICE|measurement of pelvic floor muscle with perinometer|Questions the person's perceptions about low back pain and related disability VAS questions the person's perceptions about low back pain severity
40961677|NCT05061732|DRUG|Levofloxacin|0.5g qd
40961678|NCT05061732|DRUG|Amoxicillin|1g tid
40961679|NCT05061732|DRUG|Metronidazole|0.4g tid
40961680|NCT05061732|DRUG|Doxycycline|0.1g bid
40961681|NCT05061732|DRUG|Tetracycline|0.5g qid
40961682|NCT02530684|OTHER|insole|Insoles available on the market without prescription
40961683|NCT02487667|DEVICE|Therapeutic exercise by fitness machines|Therapeutic exercise program by using 8 exercise machine circuit
40961684|NCT00440583|DRUG|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
40961685|NCT05107674|DRUG|NX-1607|Oral NX-1607
40961686|NCT05107674|DRUG|Paclitaxel|Paclitaxel IV
41293798|NCT01859429|OTHER|Stepped Care|Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
41293799|NCT00015249|DRUG|Amantadine|
41456198|NCT05934539|DRUG|ALG.APV-527|ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells such as CD8+ T cells and natural killer (NK) cells, and the tumor associated antigen 5T4. ALG.APV-527 is being co-developed by Alligator Bioscience AB (Lund, Sweden) and Aptevo Therapeutics Inc. (Seattle, WA, USA) as a cancer immunotherapy.
41456199|NCT05871437|DRUG|Huaier granule|Huaier Granules: oral administration, 10g once, 3 times a day, used for 1 year, or intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that they no longer benefit. If the patient experiences grade 3-5 (NCI CTC AE V5.0) adverse reactions related to Huai'er granules, and the adverse reactions do not recover after 2 weeks (returning to grade 1 or 2), it can be considered to reduce dosage or stop Huai'er granules treatment. If the medication is suspended for more than 2 weeks, the medication can be interrupted according to the judgment of the researcher. If the same adverse reaction occurs again, the Huaier granules will be permanently discontinued.
40961687|NCT02354495|DIETARY_SUPPLEMENT|Changes in energy and protein intake|Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
40961688|NCT00976040|OTHER|Early antiretroviral therapy|"The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.~In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis."
40961689|NCT03859193|BEHAVIORAL|Nutritional Video|A 10 - 15 minute video
40961690|NCT00358371|DRUG|flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
40961691|NCT00358371|DRUG|flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
40961692|NCT02119364|OTHER|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
40961693|NCT03452423|PROCEDURE|ACRFP|Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
40961694|NCT00927602|DRUG|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
40961695|NCT06129838|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a brain \[11C\]-CS1P1 PET scan
40961696|NCT00401531|BIOLOGICAL|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|0.5 mL, IM
40961697|NCT00401531|BIOLOGICAL|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|0.5 mL, IM
40961698|NCT06013904|PROCEDURE|Difficult PIV placement personnel|Patients randomized to this group will have their difficult PIV placed following the usual protocol for pediatric ED patients.
40961699|NCT06013904|PROCEDURE|US-trained PEM Fellows|US-trained PEM Fellows
40961700|NCT02575937|BEHAVIORAL|low glycemic diet|nutrition education-based low glycemic diet intervention
40764693|NCT05815264|BIOLOGICAL|pneumococcal vaccine polyvalent|This vaccine（0.5ml） is produced by Merck Sharp \& Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.
40961701|NCT06392100|BEHAVIORAL|Mindfulness-Based Intervention|Mindfulness-based stress reduction interventions include: breathing awareness, loving-kindness meditation, body scan, walking meditation, sitting body awareness, eating meditation, and deep breathing exercises.
40961702|NCT01419691|DRUG|auranofin|6 mg twice a day for a total of 12 mg total daily dose
40961703|NCT06255106|OTHER|cast treatment|Surgical intervention vs cast treatment
41136141|NCT01584674|DEVICE|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
41136142|NCT06509009|DRUG|Nimotuzumab|nimotuzumab, toripalimab, gemcitabine, cisplatin
40764694|NCT06637280|DEVICE|High - flow nasal cannula|"High flow nasal cannula (HFNC), a device first introduced in neonates and pediatric care, is currently used in a wide range of indications in adult respiratory and critical care medicine (5-7). It is a relatively new method in bronchoscopy with several notable theoretical advantages over low flow oxygen via conventional nasal cannula (CNC):~* High flow up to 60 liters per minute ensures a more stable FiO2 and better matches the increased patient's inspiratory flow~* High flow generates a small positive expiratory airway pressure (up to 5 cm H2O) which could stabilize the upper airways during sedation and have a beneficial effect in the lower airways~* High flow reduces dead space in the upper airways and increases alveolar ventilation."
40764695|NCT06637280|DEVICE|Standard nasal cannula|Standard method for supplementing oxygen during EBUS bronchoscopy
40961704|NCT04352816|DEVICE|Magnetocardiogram|Magnetocardiography (MCG) is a non-invasive, non-contact body-surface method which uses magnetometers to measure and map the magnetic fields generated by the electrical activity within the heart. It offers a better spatial resolution than an ECG recording and opens the possibility of detecting conduction characteristics consistent with arrhythmogenesis.9-15 The application of MCG has been limited by feasibility as devices up to now have been based on superconducting quantum interference devices (SQUID) with supercooled sensors. These machines were often operated in a shielded environment, to decrease magnetic field interference (noise) from electrical devices and other sources of magnetic fields. This was a major limiting factor in deploying these devices in a working environment especially considering, that most hospital wards will have numerous devices that can interfere with the device.
40961705|NCT00653120|DRUG|Propranolol|ER capsules, 160 mg, single-dose
40961706|NCT00653120|DRUG|Inderal-LA|ER capsules, 160 mg, single-dose
40961707|NCT05658120|DRUG|noradrenaline/adrenaline|norepinephrine adrenaline in patients with Swan-Ganz catheter monitoring during liver transplantation
40961708|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
40961709|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
40961710|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
40764696|NCT06641089|DRUG|Sonelokimab|Sonelokimab
40961711|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
40961712|NCT01323283|DIETARY_SUPPLEMENT|Omega-3|This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
41136143|NCT04150809|OTHER|No intervention|There is no intervention for this study
40764697|NCT06641089|DRUG|Placebo|Placebo
40764698|NCT06641089|DRUG|Risankizumab|Active comparator
40764699|NCT06636851|DEVICE|Pacemaker and defibrillator|Permenant pacemaker implantation with lead fixed to the RV Septal location
40764700|NCT06636851|DEVICE|Pacemaker and defibrillator|Description: Permenant pacemaker implantation with lead fixed to the RV Apical location
40764701|NCT05560113|OTHER|Continuous theta burst stimulation (cTBS)|cTBS, a patterned form of TMS, (80% active motor threshold intensity, 3 pulses at 50Hz, 200ms interval, 600 pulses, 40s duration applied over the targeted sensory cortical region using real-time neuronavigation to focally and transiently inhibit neural activity
40764702|NCT05560113|OTHER|Sham continuous theta burst stimulation (cTBS)|This will be a sham intervention. An active/sham stimulating coil will be used for double-blinding of stimulation condition. cTBS is safe and has established safety guidelines that will be strictly adhered to during study conduction.
40764703|NCT06643897|OTHER|Qualitative Interview|40-50 minute-qualitative interview.
40764704|NCT06160791|DRUG|Ruxolitinib|Administered Orally (PO)
41136144|NCT01005030|OTHER|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
41136145|NCT04290741|PROCEDURE|Auricular (Battlefield) Acupuncture|Placement of needles based on battlefield acupuncture protocol which includes up to 5 sites on each ear to treat pain.
41136146|NCT04290741|PROCEDURE|Peripheral Acupuncture|Placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
41136147|NCT04890145|DEVICE|RW-Precision-Coupler|Implantation of the RW-Precision-Coupler together with FMT-VORP 503
40764705|NCT06160791|DRUG|Etoposide|Administered IV
40764706|NCT06160791|DRUG|Dexamethasone|Administered PO or IV
40764707|NCT06160791|PROCEDURE|Non-interventional Imaging|Participants undergo abdominal ultrasound and/or magnetic resonance imaging (MRI)
40764708|NCT06160791|PROCEDURE|Research Biopsy|Bone marrow biopsy and lymph node biopsy will be obtained during screening and as clinically indicated throughout the trial.
40961713|NCT01323283|DIETARY_SUPPLEMENT|Placebo|This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
40961714|NCT00304746|DRUG|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
40961715|NCT00304746|DRUG|Placebo|Placebo
40961716|NCT06018454|OTHER|Handout on PGT-A|Educational handout on PGT-A
40961717|NCT06018454|OTHER|Handout on PGT-A and genetic counseling|Handout on PGT-A and genetic counseling session with a genetic counselor on PGT-A
40961718|NCT05292508|DIAGNOSTIC_TEST|C-reactive Protein Rapid Diagnostic Test|In the intervention arm in addition to Usual Standard of Care, CRP Testing will be performed. In this test, health worker at health post will prick the finger of the patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained. This will be added to specimen dilution buffer. Then the sample will be mixed by inverting the tube upside down 10-15 times. Then the yellow dip area of the dipstick will be placed into the diluted sample. It will be held there until the liquid rises to the result area by capillary action. The the dipstick is removed from the solution and placed in a horizontal position. The timer will be started and result will be interpreted in 5 minutes. Treatment decision making regarding the use of antimicrobials will be conducted with the help of CRP test results and other clinical features.
40961719|NCT03265639|DIETARY_SUPPLEMENT|P-inulin|
40764709|NCT06160791|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40764710|NCT04624633|DRUG|Acalabrutinib|Oral, twice a day, predetermined dosage
40764711|NCT04624633|DRUG|Umbralisib|Oral, once a day, predetermined dosage, each 28 day cycle up to 24 cycles
40961720|NCT03481075|OTHER|Biomechanical computer program|Fusion assisting software for image-guided intervention
40961721|NCT05898360|COMBINATION_PRODUCT|Time Restricted Eating|time restricted eating
40961722|NCT05898360|OTHER|normal diet|normal diet
40961723|NCT00231205|PROCEDURE|Revascularization|
40961724|NCT05494931|PROCEDURE|corneal neurotomy|Classic Gunderson conjunctival flap surgery adjuncted by corneal neurotomy
40961725|NCT01073033|DIETARY_SUPPLEMENT|milk supplement 1|milk supplement with probiotics
40961726|NCT01073033|DIETARY_SUPPLEMENT|milk supplement 2|milk supplement without probiotics
40961727|NCT04247880|BEHAVIORAL|Mentoring program|Apprentice-level female construction workers will be assigned to a mentor who has gone through a rigorous mentorship training. Participants will be asked to meet with a mentor at least 4 times/year in person to discuss the challenges of being a female in construction, learn coping mechanisms, and otherwise discuss the unique challenges of the job environment.
41456200|NCT04893590|BEHAVIORAL|Fatigue self-management SMS intervention|Participants will set up an initial goal for the SMS intervention related to fatigue management, and prior to beginning the intervention they will be trained to use the SMS system. Participants will receive text messages each day, providing tips and techniques to help self-manage fatigue. Weekly the participants will be asked to provide feedback regarding their fatigue levels and their patient activation will be re-assessed at the halfway point of intervention.
40961728|NCT05987228|DIETARY_SUPPLEMENT|Thymus vulgaris|500 mg of Thymus vulgaris (capsules) was given orally twice daily
40961729|NCT03144947|BIOLOGICAL|Trastuzumab IV|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles~Post-randomization phase:~Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
40961730|NCT03144947|BIOLOGICAL|Trastuzumab SC|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;~Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
40961731|NCT03144947|BIOLOGICAL|Pertuzumab|pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)
40961732|NCT03144947|DRUG|Docetaxel|docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
40961733|NCT01029834|BEHAVIORAL|family based lifestyle and behavioral counseling|16 group meetings
40961734|NCT01029834|BEHAVIORAL|counseling focused on the child|16 meetings
40961735|NCT03503175|DEVICE|Novel urinary access system (CystoSureTM)|CystoSureTM is a silicone device that was developed by surgeons to enable easy and standardized cystoscopy. The design of the CystoSureTM catheter has separate channels for draining the bladder and performing cystoscopy, so doctors can perform a cystoscopy without removing the catheter (which can, as described above, potentially lead to a UTI).
40961736|NCT03503175|DEVICE|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and standard rigid cystoscopy.
41136148|NCT01448941|PROCEDURE|Temporary extraarticular plate fixation|Arm 1: Primary arthrodesis TMT 1 Arm 2: Temporary extraarticular plate fixation TMT 1
41136149|NCT01448941|PROCEDURE|Primary arthrodesis|Primary arthrodesis
41136150|NCT01448941|PROCEDURE|Primary arthrodesis TMT 2 and 3|Primary arthrodesis TMT 2 and 3 when instability is present
40764712|NCT04624633|DRUG|Ublituximab|28 day cycle, starting cycle 7 via iv, on at predetermined dosage and timepoints in each cycle
40764713|NCT04478890|DIAGNOSTIC_TEST|Hemodynamic assessment|Hemodynamic assessment of the right ventricle using pressure-volume loop catheter and pulmonary artery catheter
40764714|NCT06644690|BEHAVIORAL|CO-OP with Creative Dance|The CO-OP with Creative Dance intervention integrates the Cognitive Orientation to daily Occupational Performance (CO-OP) approach with structured creative dance sessions. The CO-OP approach focuses on improving cognitive and functional performance through goal-setting, problem-solving, and the use of metacognitive strategies. Creative dance sessions involve simple, rhythmic movements aimed at enhancing motor coordination, memory, and attention. This intervention is administered three times per week for 60 minutes over 8 weeks. The sessions alternate between CO-OP activities and creative dance exercises.
40764715|NCT06644690|BEHAVIORAL|CO-OP Only|The CO-OP Only intervention involves the Cognitive Orientation to daily Occupational Performance (CO-OP) approach, which is designed to improve cognitive and functional performance through structured goal-setting, problem-solving, and metacognitive strategies. Participants engage in activities focused on improving their ability to perform daily tasks by using cognitive tools to develop and execute solutions. The intervention is administered three times per week for 60 minutes over an 8-week period. No additional physical or dance activities are included in this arm.
40764716|NCT06284681|BEHAVIORAL|Weight-focused health coaching|Following the definition of structured lifestyle interventions within the current obesity clinical practice guidelines, the weight-focused health coaching intervention will be delivered as a multi-component behavior change intervention intended to produce clinically-important weight loss through consuming a healthy, energy-restricted diet and increasing physical activity.
40764717|NCT06284681|BEHAVIORAL|Weight-neutral health coaching|Dietary and physical activity prescriptions for the weight-neutral health coaching intervention will be similar to the weight-focused intervention except the diet prescription will be designed to fully meet daily estimated energy requirements rather than creating a negative energy balance and producing weight loss. Health coaches will not emphasize changes in body weight as an explicit goal or as a mediator of improved cardiometabolic health. Rather, health coaches will emphasize achieving diet and exercise behavioral goals as a direct means to improving cardiometabolic health independently of changes in body weight.
40764718|NCT06284681|BEHAVIORAL|Intensify lifestyle approach|Participants identified as non-responders to initial health coaching interventions may be re-randomized to receive a 4-month membership to the local YMCA and health coaches will assist participants in identifying and enrolling in at least 2 weekly group fitness classes at the YMCA.
40961737|NCT04326556|OTHER|Prospective cohort for etiological and prognostic purposes|Subjects benefit from a standardized, comprehensive geriatric evaluation in accordance with the recommendations of good practice during a geriatric consultation. It is completed by a measurement of the gripping force using a dynamometer and a measurement of the respiratory parameters (vital capacity) using a spirometer. The following acts are added to the consultation: the completion of questionnaires, a semi-directed interview focused on the perception of air pollution, the wearing on the chest for one week of an individual mobile physiological signal sensor (DM with CE marking) and the wearing (on the belt or in a bag) for one week of a portable device with two air pollution sensors.
40764719|NCT06284681|OTHER|Augment with enhanced medical management|Participants identified as non-responders to initial health coaching interventions may be re-randomized to meet with the primary care provider and health coach to consider additional or revised medication plans to address their weight and weight-related chronic conditions.
40961738|NCT00453063|DRUG|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
40961739|NCT00453063|DRUG|Placebo|Two sprays in each nostril once daily in the morning
40961740|NCT06382259|OTHER|Movement breaks|Stretching and mobility-based exercises lasting 1-minute each performed 4 times per day on two consecutive days.
40961741|NCT03368794|BEHAVIORAL|Active treatment referral of opioid overdose survivors to long-term treatment|Telephone alert and outreach for inclusion, assessment and intake into long-term evidence-based treatment of the substance use disorder.
40961742|NCT03368794|BEHAVIORAL|Control|Written information from ambulance staff to the patient about how to seek treatment. Patient is able to contact the research treatment facility through a specific phone number, making it possible to study treatment entry in the information-only control condition.
40961743|NCT00443261|DRUG|Azacitidine|SC azacitidine
40961744|NCT00443261|DRUG|Cisplatin|cisplatin 75 mg/m\^2 day 8 every 28 days
40961745|NCT00043771|DRUG|Tolvaptan|
40961746|NCT04439331|DRUG|Defactinib Hydrochloride|Given PO
40961747|NCT04607954|BIOLOGICAL|Durvalumab|Given IV
41136151|NCT03649191|OTHER|The BABEL Approach to Advance Care Planning in Nursing Homes|In intervention nursing homes, eligible residents will: (i) receive The BABEL Approach to Advance Care Planning (ACP), (ii) after these ACP discussions occur, the resident's primary care physician will be notified of the residents' ACP wishes, (iii) a brightly colored document will be placed in a standard location of the NH chart that identifies the resident's ACP wishes, (iv) paramedics will be educated to know about these sheets and where to find them, and that they should be taken with any resident transferred to another care setting.
41456201|NCT06223490|PROCEDURE|Cryolipolysis|To investigate the Effect of Cryolipolysis On insulin resistance and In adult type 2 female patients.
40764720|NCT02088554|DEVICE|Model 400 aortic valve bioprosthesis|
40764721|NCT04557124|BEHAVIORAL|USS|social cognitive training
40764722|NCT04557124|BEHAVIORAL|MovingForward|problem solving training
40961748|NCT04607954|DRUG|Lurbinectedin|Given IV
40961749|NCT00168896|DRUG|Carboplatin plus Irinotecan vs Carboplatin plus Etoposide|
40961750|NCT05509920|OTHER|S-PRG barrier coat|S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.
40961751|NCT06176443|PROCEDURE|One anastomosis gastric bypass with combined fundoplication|FundoRingOAGB
40961752|NCT06176443|PROCEDURE|One anastomosis gastric bypass without combined fundoplication|OAGB
40764723|NCT06484543|OTHER|Maslinic Acid|Consumption of Maslinic Acid for 12 weeks
40764724|NCT06484543|OTHER|Placebo|Consumption of Placebo for 12 weeks
40764725|NCT06635629|DRUG|Desmopressin|Stimulates ACTH release in Cushing disease
40764726|NCT06635629|DRUG|Dexamethasone|Inhibits ACTH release in Cushing disease and healthy volunteers
40764727|NCT06641115|BEHAVIORAL|HOPE Therapy|Helping Opioid Use and PTSD with Exposure (HOPE) therapy is an integrated 10-12 week treatment for opioid use disorder and trauma/posttraumatic stress disorder
41136152|NCT03649191|OTHER|Control group Advance Care Planning|Eligible residents in each control nursing homes will receive the prevalent approach to Advance Care Planning in that nursing home. No elements of The BABEL Approach to Advance Care Planning will be introduced in the control homes.
41136153|NCT06177561|PROCEDURE|Lymphoplasma exchange|The LPE treatment regimen is: LPE\*2 times (20-30ml/kg, treatment interval of 2 days);CD20 monoclonal antibody 375mg/m2\*2 times, gamma globulin 0.4g/kg/d\*5d.
41136154|NCT03340259|PROCEDURE|Exposure(s) of interest: enterostomy|Newborn infants with congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation commonly require surgery and enterostomy. In these infants samples of the enterostomy effluent will be collected and DNA extracted for microbiota identification.
41136155|NCT04018300|DIETARY_SUPPLEMENT|Ferrous sulfate|65 mg Fe as ferrous sulfate
41136156|NCT04018300|DIETARY_SUPPLEMENT|Aspiron|65 mg Fe as iron-enriched koji culture, called AspironTM
41136157|NCT04018300|OTHER|Placebo|Contains maltodextrin.
41293800|NCT04830748|OTHER|Mechanical knee traction|Continuous knee joint mechanical traction will be applied to the patients positioned in supine lying position with the affected knee flexed at 25-30 degrees by a wedge placed under the affected knee. The thigh will be secured with a strap for stabilization and the leg will be held by the specially designed greave with the weight of traction hanging throughout a pulley system. The amount of traction will be set to about 10% of body weight. The treatment will be applied for 20 minutes continuously, once a day, 3 times per week for 4 weeks. The traction force will be progressed gradually during the program ( e.g.: weekly increase force by 1% of body weight if the patient can tolerate the duration of 20 min with the preset force).
40764728|NCT06559540|RADIATION|Hypofractionated radiation|External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes,
41136158|NCT04497337|PROCEDURE|Complete excision to superficial lesions around the ear|Complete excision of these lesions and histopathology
41136159|NCT01201837|DRUG|Placebo|Weekly injection
41136160|NCT01201837|DRUG|CER-001|Weekly injection
41136161|NCT04011930|DRUG|cholecalciferol|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
41136162|NCT04011930|DRUG|Placebo oral capsule|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
40961753|NCT05975242|BEHAVIORAL|Smartphone diabetes management application|The intervention is a smartphone diabetes management application that is combined with structured blood glucose testing.
41136163|NCT04518709|PROCEDURE|Posterior Mitral Annulus Elevation Technique|Posterior mitral annulus elevation technique is performed using a large pledget and non-absorbable braided suture starting from the subvalvular section of the posterior mitral valve sutured to the ring annuloplasty (if in the process of repairing the mitral valve, ring implantation is performed; if without the use of ring annuloplasty, the suture is placed in the left atrial wall / supravalvular of PML), so that the posterior annulus is slightly attracted upward toward the cranial and the PML moves toward the center.
41136164|NCT04518709|PROCEDURE|Conventional Mitral Valve Repair|Conventional mitral valve repair in the pediatric patient using annuloplasty, leaflet resection and plication, sliding-plasty of chordae technique
41136165|NCT05616494|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
41136166|NCT02869802|PROCEDURE|Tumour Biopsy|If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.
41136167|NCT02869802|OTHER|Serial Collection of Plasma and Serum Samples|Participants will undergo serial collection of plasma and serum samples at baseline and every 4 weeks until end of study.
41136168|NCT00386399|DRUG|Mitomycin-C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
41136169|NCT00792337|DRUG|simvastatin|10 mg per oral once daily for 8 weeks
41136170|NCT00792337|DRUG|B1-6-12|1 table per day for 8 weeks
41136171|NCT04022421|DRUG|Hydroxychloroquine|the drug will be taken by one group of the patients daily at a dose of 400mg
41136172|NCT02913300|DRUG|Lignocaine 1% concentration solution|
41136173|NCT02913300|DRUG|Lignocaine 2% concentration solution|
41136174|NCT00637663|DRUG|Entecavir|entecavir 0.5 mg QD
41136175|NCT00637663|DRUG|Lamivudine|lamivudine 100 mg QD
41136176|NCT01282645|DEVICE|PSI in PEEK|A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
41456202|NCT06291454|DIAGNOSTIC_TEST|Routine periodontal examination|In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness \& Löe, 1964), Löe-Sillness's gingival index (GI)(Löe \& Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo \& Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.
41136177|NCT02240472|PROCEDURE|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
41136178|NCT05794841|DIAGNOSTIC_TEST|Tongue coating sample collection and multi-omics analysis|Tongue coating sample collection and multi-omics analysis for building a diagnostic model
41136179|NCT04471844|DEVICE|Optune®|"Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~The study treatment plan will continue for 24 months, if no tumor progression."
41136180|NCT00594282|DEVICE|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
41136181|NCT06001515|DEVICE|Dual scan protocol|one CBCT scan for the patient while wearing the scan appliance and another scan for the appliance alone
40961754|NCT05164796|DEVICE|IVUS assessment of coronary ostia|"For coronary arteries at high-risk of obstruction during TAVI in native valves or valve-in-valve TAVI:~* IVUS analysis before valve implantation (+ coronary angiogram) to detect any leaflet interference with the coronary ostium, existing prior to the transcatheter heart valve (THV) placement~* IVUS analysis (+ coronary angiogram) after valve implantation in absence of acute coronary occlusion, to assess the patency of the ostium at-risk, the presence of native or degenerated surgical leaflet adjacent to the ostium, and the interaction of THV-frame with the coronary ostium.~* In case of CHIMNEY stenting, re-assessment of the stent expansion and coronary ostia patency with IVUS."
40961755|NCT03021460|DRUG|Ibrutinib|Given PO
40961756|NCT03021460|OTHER|Laboratory Biomarker Analysis|Correlative studies
40961757|NCT03021460|BIOLOGICAL|Pembrolizumab|Given IV
40961758|NCT04589806|PROCEDURE|2-stage ridge splitting|two-stage alveolar ridge splitting technique using piezoelectric device with simultaneous implant placement in order to treat narrow posterior mandibular ridges avoiding the risks of malfracture and necrosis of the split part
40961759|NCT05544734|DRUG|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|5 mg/325 mg tablet
40961760|NCT05544734|DRUG|Acetaminophen 1000mg|1000 mg tablet
40961761|NCT05544734|DRUG|Ibuprofen 400 mg|400 mg tablet
40961762|NCT01101880|BIOLOGICAL|filgrastim|Given SC
40961763|NCT01101880|DRUG|clofarabine|Given IV
40961764|NCT01101880|DRUG|cytarabine|Given IV
40961765|NCT04254861|PROCEDURE|Simplified Papilla Preservation Flap (SPPF) and PRGF ENDORET (PRGF ENDORET®-KMU16)|"A simplified papilla preservation flap (SPPF) will be performed. The clot phase of PRGF ENDORET (F2) will be placed in the defect, while the fibrin membrane phase (F1) will cover it.~Blood will be extracted and collected in dedicated tubes and then centrifuged. Up to 8 tubes of 9ml will be extracted. The time from the start of the extraction to the start of the centrifugation of the tubes must not exceed 4mins.~After centrifugation, the blood is separated into three components: Plasma rich in growth factors, White cells or leukocytes, red blood cells: this is the red column occupying the bottom of the tube.~Following BTI's instructions, fractioning of the centrifuged blood will be performed in order to separate Fraction 2 (F2), which contains a greater number of platelets and growth factors and will be used as a clot inside the periodontal defect from Fraction 1 (F1), which will be used as a fibrin member to cover the clot. The flaps will be repositioned and sutured."
40961766|NCT04254861|PROCEDURE|Simplified Papilla Preservation Flap (SPPF) and GTR|A simplified papilla preservation flap (SPPF) will be performed. The defect will then be treated according to the guided tissue regeneration (GTR) principle (control group). A deproteinized bovine bone mineral (DBBM) graft will be placed in the defect and covered by a collagen membrane.
40961767|NCT01895062|DEVICE|Airway Management System (AMS)|"The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.~The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway."
40961768|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles|Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.
40961769|NCT01901120|DRUG|Betanis|oral
41136182|NCT06001515|DEVICE|triple scan protocol|3D facial Scanning for the patients while wearing their dentures in addition to the dual scan protocol
41136183|NCT00772902|DRUG|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
41136184|NCT00772902|DRUG|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
41136185|NCT01209156|DRUG|[18F] PBR111|Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.
41136186|NCT04112810|DRUG|Tildrakizumab|100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.
40764729|NCT06559540|RADIATION|Ultra-hypofractionated breast/chest wall and regional nodal radiation|External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes
40764730|NCT04562805|DEVICE|DynamX Bioadaptor|DynamX Bioadaptor Treatment
40764731|NCT04562805|DEVICE|Resolute Onyx|Resolute Onyx Treatment
40764732|NCT04573478|DRUG|Atrasentan|Film-coated tablet
40764733|NCT04573478|DRUG|Placebo|Film-coated tablet
40961770|NCT04669132|DRUG|Olanzapine|- Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)
40961771|NCT04669132|DRUG|Netupitant|- Netupitanto 300 mg, once daily, on chemotherapy day;
40961772|NCT04669132|DRUG|Palonesetron|- Palonosetron 0.56 mg, once daily, on chemotherapy day;
40961773|NCT05166824|DEVICE|TempSure|Radiofrequency platform
40961774|NCT05166824|DEVICE|Scalpel|Cold knife
40961775|NCT05166824|DEVICE|Bovie|Electrosurgery and electrocautery platform
40961776|NCT05166824|DEVICE|Pelleve|Radiofrequency platform
40961777|NCT03240965|DIAGNOSTIC_TEST|FEES (flexible endoscopic evaluation of swallowing)|Endoscopical swallowing study in stroke patients only
40961778|NCT03240965|OTHER|Sensitivity threshold|Determining sensitivity threshold using a pudendal electrode
40961779|NCT03240965|DIAGNOSTIC_TEST|Taste-/smell-test|Taste-/smell-test
41136187|NCT02111551|DRUG|DMXB-A 150 mg|
41136188|NCT02111551|OTHER|placebo|
41136189|NCT02111551|DRUG|DMXB-A 75 mg|
40961780|NCT03240965|DIAGNOSTIC_TEST|Neuropsychological testing|Neuropsychological testing for neglect, agnosia
40961781|NCT01213329|DRUG|Alemtuzumab|All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
40961782|NCT06142071|BEHAVIORAL|Telephone questionnaire|Telephone questionnaire, which includes questions on participant's demographics, anxiety/depression scores, what support they find helpful and what additional support they feel would be beneficial
40961783|NCT02590003|DRUG|Carboplatin|
40961784|NCT02590003|DRUG|Nab-paclitaxel|
40961785|NCT03795454|BEHAVIORAL|Singing|Infant-directed singing and singing of self-invented songs, especially songs emerging from the interaction with the infant, are especially encouraged. The families will receive audio material of children's songs, lullabies, and lyrics of the lullabies to support them if they feel unable to accomplish the task otherwise.
40961786|NCT06506786|OTHER|Garden-fresh Produce|Participants are asked to consume the USDA-recommended amounts of fruits and vegetables harvested from their gardens.
40961787|NCT06506786|OTHER|Supermarket Produce|Participants are asked to consume the USDA-recommended amounts of fruits and vegetables purchased from a supermarket.
40961788|NCT00828997|BIOLOGICAL|Prevenar vaccination|vaccination with Prevenar vaccine in patients with arthritis
40961789|NCT01302756|OTHER|Placebo|Group 1: Placebo plus standard of care pre-natal vitamins (which include 1 milligram of folic acid) a day for the duration of pregnancy
40961790|NCT01302756|DIETARY_SUPPLEMENT|Folic Acid|Group 2: 4-milligrams of folic acid a day for the duration of pregnancy plus standard of care pre-natal vitamins (which include 1 milligram of folic acid)
40961791|NCT01064310|DRUG|pazopanib|oral anti-angiogenic treatment
40961792|NCT01064310|DRUG|sunitinib|oral anti-angiogenic treatment
40961793|NCT04700371|DEVICE|Interwoven stent|Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
40961794|NCT04700371|DEVICE|Laser-cut stent|Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
40961795|NCT06504914|BEHAVIORAL|Assigned Interventions|Behavioral: RN-CHeFRx The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
40961796|NCT02717585|DEVICE|Continuous Positive Airway Pressure Therapy (CPAP)|Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
40961797|NCT04966624|PROCEDURE|"LUVS ventilatory strategy composed of a bundle of measures"|Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization
40961798|NCT04966624|PROCEDURE|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
40961799|NCT02671305|PROCEDURE|placental circulation intact|bedside assistance with placental circulation intact during first 3 minutes of life
40961800|NCT02671305|PROCEDURE|cord milking|neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
40961801|NCT01251939|DEVICE|Near-infrared spectroscopy (NIRS)|Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
40961802|NCT03092921|DEVICE|F&P Mask Seal|Investigative Mask Seal to be used for OSA therapy
40961803|NCT03092921|DEVICE|F&P Mask|Investigative Mask to be used for OSA therapy
40961804|NCT06409923|DEVICE|Stimulation of mandibular growth.|orthodontic treatment where a retrognathic mandibula is put into an anterior position to stimulate mandibular growth. This will happen by either the MA-invisalign system or the herbst appliance
40961805|NCT04394117|DRUG|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers (ARBs) have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin-II (Ang-II) by competitive antagonism of the angiotensin receptor. ARBs displace ang-II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of ang-II induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response The virus causing COVID-19, SARS-CoV-2, binds to the extracellular portion of Angiotensin-Converting-Enzyme-2 (ACE2) expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms
40961806|NCT04394117|OTHER|Placebo|Placebo
40961807|NCT05541120|DEVICE|Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
40961808|NCT05042154|DEVICE|WatchPAT|The WatchPAT One can detect the presence of OSA based on measurement of peripheral arterial tone (PAT), pulse rate, oxygen saturation, actigraphy, snoring, and body position.
40961809|NCT01178957|OTHER|Hyperglycemia|Hyperglycemia with a blood glucose of 15 mmol/L
41456203|NCT05726162|DEVICE|biofeedback-based music program|The investigators will provide biofeedback-based music, which incorporates the patient's respiratory information. In a biofeedback-based music group, the patient performs an active respiratory intervention session, which induces a slow breathing pattern. If breathing has been slow enough, the automatic mode is activated to provide music based on patient's own breathing pattern. It automatically will be terminated 30 minutes after intervention.
41456204|NCT05726162|OTHER|Control|The investigators will provide noise-canceling earplugs to minimize bias from noise in the ward.
41456205|NCT06382662|DRUG|metaxalone m640|A single dose of micronize metaxalone 640 mg
40961810|NCT01935791|OTHER|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|Temperature
40961811|NCT01935791|DRUG|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Hormone
40961812|NCT01935791|OTHER|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|Temperature
40961813|NCT01935791|DRUG|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|Hormone
41456206|NCT06382662|DRUG|tizanidine|A single dose of tizanidine 8 mg
41456207|NCT00882245|OTHER|Vehicle ointment|Topical vehicle cream
41456208|NCT00882245|DRUG|Ointment|SRD441 Ointment
40961814|NCT01935791|DRUG|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|Hormone
40961815|NCT01935791|DRUG|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|hormone
40961816|NCT01935791|DRUG|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|hormone
40961817|NCT01935791|DRUG|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|hormone
40961818|NCT01935791|DRUG|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|Hormone
40961819|NCT06134752|OTHER|Pulse field ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
40961820|NCT06134752|OTHER|Radiofrequency ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
41456209|NCT04763096|DRUG|Advagraf|"Researchers must check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~10ng/ml of study treatment. Duration of treatment The investigational product will be administered for 24 weeks. (The lowest blood levels shall be adjusted at the discretion of the researchers, taking a blood sample is carried out in the morning before administrated of Investigational Product)~Tacrolimus blood level is 3-10 ng/ml for 6 months prior to screening and during the maintenance therapy.~( ① -1day to enrollment : swich to the day before ADVAGRAF®, ② 0day to enrollment : the day swich to ADVAGRAF® )~Duration of treatment the investigational product will be administered for 24 weeks."
41456210|NCT05767762|OTHER|scale Idiopathic Clubfoot|The Dimeglo and the muscle activity scale will be performed at 3, 6 and 12 months with patient with idiopathic clubfoot
41456211|NCT03183141|BIOLOGICAL|SER-109|SER-109, an oral, biologically derived, live microbiome therapeutic that comprises purified bacterial spores
41456212|NCT06221124|DEVICE|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Sleep stage (bSTAGES) and respiratory event index (bAHI) are estimated.
41456213|NCT00079495|DRUG|NBI-5788|
41456214|NCT03910361|DRUG|Evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd
40961821|NCT00690105|DRUG|tacrolimus 0.1%|ointment
40961822|NCT00690105|DRUG|fluticasone 0.005 %|ointment
40961823|NCT02330237|DRUG|natural gels|whole fruits and vegetables
40961824|NCT02330237|DRUG|Placebo|
40961825|NCT05124314|DRUG|Mifepristone, Oral, 200 Mg|Adding 600 mg of oral Mifepristone to the regular treatment with vaginal Misoprostol 800 mcg
40961826|NCT05124314|DRUG|Misoprostol Pill|Regular treatment with vaginal Misoprostol 800 mcg
40961827|NCT00836485|DRUG|Ketotifen 4.0% Patch|This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
40961828|NCT00836485|DRUG|Placebo|The control is a placebo patch that contains only the inactive ingredients of ketotifen.
40961829|NCT00836485|DRUG|Olopatadine 0.2%|1 gtt/eye on two separate occasions
40961830|NCT00836485|DRUG|Artificial tears|1 gtt/eye on two separate occasions
41293801|NCT04830748|OTHER|Therapeutic exercises|"Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force."
41293802|NCT00972998|DRUG|Phenyephrine|Phenyephrine coated suppositories
40961831|NCT05894408|OTHER|this is no intervention|this is no intervention
40961832|NCT03978000|DRUG|IBP-9414|Oral suspension
40961833|NCT03978000|DRUG|Placebo|Sterile water
40961834|NCT05846971|OTHER|Educational materials on validated methylation assay|Educational materials include overall information on the assay including what the test does, how to use the test and report, and performance metrics on the test.
40961835|NCT03501459|DRUG|Rituximab|
40961836|NCT01979887|PROCEDURE|Meibum Expression|Meibum expression as per protocol. No investigational drug is administered in this study.
40961837|NCT02571075|OTHER|Auricular acupuncture|The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
40961838|NCT02160535|DRUG|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
40961839|NCT06004362|BEHAVIORAL|Complementary and Integrative Medicine online intervention, routine care and book|"The online program takes place in a multiprofessionally guided online group setting once a week for up to 180 minutes (including several breaks) over a period of 10 weeks:~* Basic principles of a plant-based whole-food nutrition~* Procedures of hydrotherapy according to Kneipp~* Self-help strategies (e.g. teas, wraps, compresses etc.)~* Methods of mind-body medicine (mindfulness, meditation, breathing, yoga etc.)~* Methods of extended Complementary and Integrative Medicine (e.g. acupressure)~It is recommended to practice a part of the taught exercises at home for about 30 minutes daily. In addition, the patients receive a book for the treatment of post-covid syndrome complaints. Group 1 additionally uses the already existing routine care (e.g. general practitioner)."
40961840|NCT06004362|BEHAVIORAL|Routine care and book|Participants in the second study arm receive routine care, e.g. from their general practitioner. In addition, the patients receive the same book as group 1 for the treatment of post-covid syndrome complaints. The participants of the second study arm will be offered to participate in the Complementary and Integrative Medicine online intervention after 4 months within the study.
40961841|NCT06004336|DRUG|Pembrolizumab|Given by vein (IV)
41456215|NCT03910361|DRUG|Pioglitazone|pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
41456216|NCT03515473|DEVICE|cochlear implant|cochlear implant surgery
41456217|NCT03985657|DEVICE|CPAP|Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
41456218|NCT02465684|PROCEDURE|unicondylar knee arthroplasty|
41456219|NCT00521508|PROCEDURE|gene transcription and cytometry|samply of 30 ml of blood
40961842|NCT06004336|RADIATION|Radiation therapy|Given by vein (IV)
40961843|NCT04028921|OTHER|No intervention|This is a cross-sectional study; no intervention
40961844|NCT05327257|DEVICE|iTBS rTMS|Repetitive transcranial magnetic stimulation (rTMS) intermittent Theta Burst Stimulation (iTBS)
40961845|NCT02072083|DRUG|Dexmedetomidine|via intranasal route 1 mcg/kg
40961846|NCT02072083|DRUG|Ketamine|via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
40961847|NCT03794271|PROCEDURE|Pupilometer guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
41456220|NCT00784095|OTHER|Life completion and preparation|Subjects will discuss life review, issues of forgiveness and heritage and legacy.
41456221|NCT00784095|OTHER|Attention Control|Subjects will listen to a non-guided relaxation CD.
41456222|NCT01299779|DRUG|PEG-SD|"PEG-SD~* Bisacodyl: two 5-mg tablets at 3 pm day prior~* 1L sports drink\* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~* 1L SD\* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~  * Same flavor, non-red Gatorade® for all patients."
41456223|NCT01299779|DRUG|PEG-ELS|"* 1L + 500 cc clear liquids at 6 pm night prior~* 1L + 500 cc clear liquids starting 4 hours prior to colonoscopy"
41456224|NCT06363591|PROCEDURE|Wise vs wide|Wise vs wide excisions for thin melanoma
40764734|NCT06640621|DRUG|Different concentration of ropivacaine for single brachial plexus block|40 ASA grade I - II patients were selected from the patients who underwent shoulder ligament rupture repair surgery under selective general anesthesia combined with brachial plexus block analgesia in the sports medical center of our hospital. They were randomly divided into two groups: high concentration group (group I) and low concentration group (Group II), with 20 cases in each group. 40 patients underwent a single brachial plexus block under ultrasound guidance before general anesthesia.
40961848|NCT03794271|PROCEDURE|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
40961849|NCT00270790|DRUG|Amifostine|Amifostine will be given at dose of 500 mg IV within one hour before radiation
40961850|NCT00270790|DRUG|Carboplatin|Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
40961851|NCT00270790|DRUG|Taxol|Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
40961852|NCT00270790|DEVICE|Radiotherapy|Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
40961853|NCT04754152|OTHER|θ burst transcranial magnetic stimulation|In addition to drug therapy, TBS supplementary therapy was given every 3 months.The TBS parameters were as follows: 3 pulses, 50 Hz bursts given every 200 ms (at 5 Hz), and an intensity of 70% of the resting motor threshold, as measured from the right first dorsal interosseous muscle using a handheld 70 mm figure-of-eight coil. Take a course every 10 weeks .
40961854|NCT04754152|DRUG|Pharmacotherapy|Stable doses of cholinesterase inhibitors were given and the patients were followed up every three months.
40961855|NCT00194571|BEHAVIORAL|Educational counseling intervention|This intervention involves 5 face to face educational counseling sessions with a specially trained patient educator; sessions are fully manualized and complemented by handouts given to the diagnosed parent.
40961856|NCT01916720|DRUG|SB-480848 40 mg|Study Drug
40961857|NCT01916720|DRUG|SB-480848 80 mg|Study Drug
40961858|NCT01916720|DRUG|Placebo|Study Drug
40961859|NCT02157987|DRUG|bevacuzimab spray|
40961860|NCT04153669|BEHAVIORAL|Exercise-NMES|Exercise-NMES
40961861|NCT04153669|BEHAVIORAL|Exercise-No NMES|Exercise-No NMES
40961862|NCT04749615|DRUG|Periarticular Injection (PAI)|PAI is a widely-utilized, surgeon-performed, analgesic intervention for TKA patients.
40961863|NCT04749615|DRUG|Saline Control Periarticular Injection (PAI)|equal volume of saline will be used in place of analgesics used in PAI injections
40961864|NCT04642443|DEVICE|SENSE Device|The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.
41456225|NCT02119988|PROCEDURE|TIPS|TIPS will be performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
40764735|NCT04408638|DRUG|Obinutuzumab|Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
40764736|NCT04408638|DRUG|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles.
40764737|NCT04408638|DRUG|Rituxumab|Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
40764738|NCT04408638|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).
40961865|NCT02702804|OTHER|High Intensity Interval Training|High Intensity Interval Training
40961866|NCT06457880|PROCEDURE|PENG BLOCK|Preoperative ultrasound guided PENG block (ropivacaine 0.5 % 20 mL)
40961867|NCT06457880|PROCEDURE|Femoral Nerve Block|Preoperative ultrasound guided femoral nerve block (ropivacaine 0.5 % 15 mL)
40764739|NCT04408638|DRUG|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
40764740|NCT04408638|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
40961868|NCT06457880|PROCEDURE|Obturator Nerve Block|Preoperative ultrasound guided obturator nerve block (ropivacaine 0.5 % 5 mL)
40961869|NCT06260332|BEHAVIORAL|Supportive Care (Fitbit)|Wear Fitbit, Use Fitbit application, Receive educational materials, attend coaching calls, Ancillary studies
40961870|NCT05051371|DEVICE|Train of four monitoring|Train of four monitoring in postoperative care unit
40961871|NCT03193203|DRUG|Etanercept|50 mg/mL PFS and AI
40961872|NCT02901405|DEVICE|Negative Pressure Wound Therapy (ActivVAC, KCI)|
40961873|NCT02901405|DEVICE|Standard dressings|Current absorbent dressing is 'tegaderm with absorbent pad' (3M)
40961874|NCT01140893|DRUG|Exenatide|"Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.~From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time."
41136190|NCT05387863|OTHER|Decision Aid (DA) Web Tool|The DA web tool provides information on kidney masses and available treatment options. It uses risk communication, directed teaching, and interactive benefit-harm assessment to present information.
41136191|NCT05387863|OTHER|Institutional Pamphlet|The institutional pamphlet provides information on kidney masses, but does not use risk communication, directed teaching, or interactive benefit-harm assessment.
41293803|NCT04507308|BEHAVIORAL|Single-session sleep intervention drawn from principles of the TranS-C youth protocol|We are providing participants psychoeducation on sleep and will be going over several handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth) to improve sleep.
41293804|NCT00179920|DRUG|Carboplatin|
41293805|NCT00179920|DRUG|VP-16|
41293806|NCT00179920|PROCEDURE|Local Surgery|
41293807|NCT00179920|PROCEDURE|Cryotherapy|
41293808|NCT00179920|PROCEDURE|Laser hyperthermia|
41293809|NCT03120403|PROCEDURE|intrathecal morphine|
41293810|NCT01380496|DRUG|doxycycline monohydrate|tablet, 100 mg, single, oral dose
41293811|NCT01380496|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
41293812|NCT01380496|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
41293813|NCT05624944|DRUG|TS-142 5 mg|Single-dose of 5 mg of TS-142
41293814|NCT06274333|DRUG|Dexmedetomidine 0.5 mic/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,
40764741|NCT04943757|DRUG|Bendamustine Hydrochloride|50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
40764742|NCT04943757|DRUG|Cyclophosphamid|25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
40764743|NCT06639815|OTHER|clinical and radiographic examination|clinical and radiographic examination
40764744|NCT06015438|BEHAVIORAL|Home Exercise Program|Participants will perform a minimum of one exercise from each of the targeted muscle groups at a frequency of every other day, for a total of 3-4 days a week of exercise with a rest day. The entire strengthening exercise routine should take approximately 25-30 minutes to perform, including rest periods. Each muscle grouping of exercises is designed to progress from minimal muscle effort required to moderate to maximal effort. Participants will use a video to perform the exercises as well as a handout with specific instructions.
40961875|NCT01140893|DRUG|Placebo|Placebo
40961876|NCT02124330|DIETARY_SUPPLEMENT|montmorillonite 5 g|5g montmorillonite + 15 g protein (ratio 1:3)
40961877|NCT02124330|DIETARY_SUPPLEMENT|montmorillonite 3 g|3g MONT+ 15 g protein (ratio 1:5)
40961878|NCT02124330|DIETARY_SUPPLEMENT|Montmorillonite 1 g|1g MONT+ 15 g protein (ratio 1:15)
40764745|NCT06015438|BEHAVIORAL|Short Exercise Program|Participants in this group will attend one in-person visit expected to last about 60 minutes. The clinic visit will consist of standard of care procedures and tests for individuals with mild-to-severe HS .
40764746|NCT04003038|PROCEDURE|Negative Pressure Wound Therapy|Receive wound care with NPWT
41293815|NCT06274333|DRUG|Tramadol 1mg/kg|Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
41293816|NCT06274333|DRUG|Paracetamol 10mg/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
41136192|NCT02166684|DEVICE|Do-it-yourself devices|"Medisana Vifit is worn every day all-day by each subject~Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.~Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks~Subjects use Medisana BS 440 BT scale daily~In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.~Subjects self-measure fasting blood glucose twice per week for 13 weeks.~Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120."
41136193|NCT02715388|DEVICE|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
41136194|NCT04648904|RADIATION|Radiotherapy|A total dose of 26 Gy in 5 fractions will be given once daily over 5 consecutive weekdays (or within 10 consecutive weekday to allow for treatment delays, interruptions, logistical problems, scheduling issues and weekends/holidays).
41136195|NCT01847768|BIOLOGICAL|GMP-grade HRV-39|Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
41293817|NCT04080115|BEHAVIORAL|Attention Training Technique|ATT will be administered through a customized Expiwell smartphone application that will be downloaded onto participants' cell phones at the first laboratory session (T2). For the purposes of the proposed study, participants need to complete the intervention once a day, for the six days between their lab sessions; signals will begin the day after their T2 session and they will be notified up to a maximum of five times per day to complete their daily session. The ATT sessions are comprised of three phases. The first is a 5-minute phase during which the participant is instructed to attend to specific sounds in the recording and disregard other sounds. The subsequent 5-minute phase includes instructions to rapidly switch their attention between sounds in the recording. The final phase is a dual attention task lasting 2 minutes wherein the participant is instructed to pay attention to multiple sounds in the recording at once. In total, each session of ATT lasts 12 minutes.
41293818|NCT04080115|BEHAVIORAL|Sham intervention control condition|The sham control condition consists of the same 12 minutes of simultaneous sounds as the ATT technique, but will not include any verbal instruction, thus isolating the effects of intentional orientation of attention.
41456226|NCT02119988|PROCEDURE|Variceal Embolization|Embolization of gastroesophageal collaterals will be conducted via the same jugular vein before TIPS implantation. The major procedures includ (a) angiography of gastroesophageal collaterals after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of gastroesophageal collaterals with coils of varying diameters, which result in the gastroesophageal collaterals disappearing at postembolization angiography.
41456227|NCT06466213|OTHER|single exercise bout about one-leg exercise|cycle exercise includes single leg
41456228|NCT03166527|DRUG|Immune Globulin 10% Intravenous Solution|standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
41136196|NCT01847768|PROCEDURE|Bronchoalveolar Lavage|
40764747|NCT04003038|PROCEDURE|Wound Care Management|Receive wound care with a standard dressing (bandage)
40764748|NCT01189851|DEVICE|Intraoperative Radiotherapy|The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
40764749|NCT06461494|OTHER|baseline treatment|hot pack will be applied for 10 minutes
40961879|NCT05683990|DRUG|Diamyd|4 μg (0.1 mL) of Diamyd administered 1 month apart.
40961880|NCT01040975|BEHAVIORAL|Web-based intervention targeting MD communication; Summary Report|Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
40961881|NCT04502693|COMBINATION_PRODUCT|rMenB+OMV NZ vaccine|rMenB+OMV NZ vaccine was administered intramuscularly.
41456229|NCT04980105|BIOLOGICAL|Platelet-rich plasma|Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.
40764750|NCT04493138|DRUG|Azacitidine|Given SC or IV
40764751|NCT04493138|DRUG|Quizartinib|Given PO
40961882|NCT04502693|BIOLOGICAL|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|MenACWY vaccine was administered intramuscularly.
40961883|NCT04502693|COMBINATION_PRODUCT|Placebo|Placebo was administered intramuscularly.
40961884|NCT04502693|COMBINATION_PRODUCT|MenABCWY-1|Lot 1 of the MenABCWY vaccine was administered intramuscularly.
41456230|NCT04980105|DRUG|Hyaluronic acid|Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection
40764752|NCT05726370|DRUG|Pembrolizumab|Immunoglobulin G4 monoclonal antibody, via IV infusion
41136197|NCT01847768|DRUG|Methacholine Inhalation Challenge|The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
40764753|NCT05726370|DRUG|CISPLATIN|Platinum agent, via IV infusion
41136198|NCT01847768|PROCEDURE|Nasal Lavage|
40961885|NCT04502693|COMBINATION_PRODUCT|MenABCWY-2|Lot 2 of the MenABCWY vaccine was administered intramuscularly.
40764754|NCT05726370|DRUG|Carboplatin|Platinum agent, via IV infusion
40764755|NCT05726370|DRUG|Docetaxel|Antineoplastic agent, via IV infusion.
40764756|NCT03533283|DRUG|Glofitamab|Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
40764757|NCT03533283|DRUG|Atezolizumab|Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
40961886|NCT04502693|COMBINATION_PRODUCT|MenABCWY-3|Lot 3 of the MenABCWY vaccine was administered intramuscularly.
40961887|NCT02282579|DRUG|Pazopanib|Non interventional study
40764758|NCT03533283|DRUG|Obinutuzumab|Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
41456231|NCT04980105|DRUG|Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)|Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
40764759|NCT03533283|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
40764760|NCT03533283|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
40764761|NCT03533283|DRUG|89Zr-Df-IAB22M2C|Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
40764762|NCT05064423|BEHAVIORAL|Clinical Trials Education Program|The Community Health Educator (CHE) will provide CT education and outreach to increase clinical trial knowledge and the importance of clinical trials research and participation. The clinical trials educational activities will include the use of NCI Colorectal Cancer resources and materials, including a PowerPoint presentation, clinical trials information, and online resources. The CHE will tailor the PowerPoint slides to ensure that they are culturally tailored, visually appealing, low-literacy, language appropriate and include appropriate visuals. The CTs educational sessions will be delivered in Spanish and English and will take approximately 45 minutes to 1 hour.
40961888|NCT02548780|DEVICE|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver."
40961889|NCT02548780|OTHER|Pharmacokinetics|Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
40961890|NCT04665700|DRUG|BI 764198|BI 764198
40961891|NCT04665700|DRUG|Placebo|Placebo
41456232|NCT05210049|DIAGNOSTIC_TEST|Esocheck/Esoguard|All enrolled patients will complete the Esocheck screening test. EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus. The collected cell material is examined with a two marker panel combining methylated CCNA1 and VIM. These methylated markers have 95% sensitivity and 91% specificity for detecting BE and EAC with an AUC=0.95 in studies performed among white men. Diagnostic yield of this test among Veterans is unknown.
40961892|NCT05923983|OTHER|Clinical decision support|In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team
40961893|NCT05923983|OTHER|Will not receive Clinical Decision Support|In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation
40961894|NCT01244269|DRUG|Methylphenidate|Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
40961895|NCT01244269|DRUG|Methylphenidate|Methylphenidate 20mg three times daily for a total of 7 doses.
40961896|NCT01244269|DRUG|Placebo 10|Blind gelatin capsule three times daily for a total of 7 doses.
40961897|NCT01244269|DRUG|Placebo 20|Blind gelatin capsule three times daily for a total of 7 doses
40961898|NCT00356473|DRUG|Atorvastatin|
40961899|NCT05394961|PROCEDURE|Treatment in an intensive care unit with a diagnosis of sepsis and/or ARDS and/or covid-19|As above
40764763|NCT06643949|DIAGNOSTIC_TEST|Echocardiography|The registry will focus on the diagnostic and prognostic value of of echocardiographic features of patients with takotsubo syndrome
40764764|NCT05870111|DRUG|Citicoline (cytidine diphosphate-choline)|2000mg/day citicoline, administered orally, for 4 weeks
40764765|NCT05870111|DRUG|Placebo oral capsule|placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
40764766|NCT04511494|DIETARY_SUPPLEMENT|Peanut (bamba)|OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.
40764767|NCT06639451|DEVICE|RANGER™ Paclitaxel Coated Balloon Catheter|A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon coated with paclitaxel at the end of it. When the tube is in place, it inflates to open the blood vessel, so that normal blood flow is restored. The tube is then removed.
40961900|NCT04080128|DEVICE|Contact lenses|Depending on the results of the BLINK Study either a single vision spherical contact lens or a multifocal contact lens.
40961901|NCT05662007|OTHER||no intervention
40764768|NCT04886531|DRUG|Neratinib|120mg for 7 days; 160mg for 7 days ; 240mg for 7 days. 240 mg (up to a maximum of 24 weeks) orally daily\*.
40764769|NCT04886531|DRUG|Letrozole (L) or Anastrozole (A)|L: (2.5 mg) OR A: (1 mg) orally daily (up to a maximum of 24 weeks)\*
40961902|NCT00538291|BIOLOGICAL|cetuximab|
40961903|NCT00538291|DRUG|capecitabine|
40961904|NCT00538291|GENETIC|gene expression analysis|
41456233|NCT00622362|BIOLOGICAL|DEPIGOID Dermatophagoides pteronyssinus|Subcutaneous administration:0.5 ml/month during 1 year
40961905|NCT00538291|GENETIC|microarray analysis|
40961906|NCT00538291|GENETIC|polymorphism analysis|
40961907|NCT00538291|GENETIC|reverse transcriptase-polymerase chain reaction|
40961908|NCT00538291|OTHER|immunohistochemistry staining method|
40961909|NCT04329403|DRUG|Adapalene 0.1% Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
40961910|NCT04329403|DRUG|Differin 0.1% Topical Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
40961911|NCT04329403|OTHER|Placebo|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
40961912|NCT02656732|BIOLOGICAL|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
40961913|NCT02656732|PROCEDURE|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
40961914|NCT04930965|BEHAVIORAL|Community health worker engagement|3-4 in-person or virtual engagements (individual or group sessions) over 1 month, each engagement lasting 30 minutes to 1 hour
40961915|NCT00635674|DEVICE|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
40961916|NCT04342377|DIAGNOSTIC_TEST|Selective Targeted Sampling|Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.
40961917|NCT04342377|DIAGNOSTIC_TEST|Systematic Sampling|All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.
41136199|NCT01847768|PROCEDURE|Nasal Scrapings|This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
41136200|NCT01847768|PROCEDURE|Bronchial Brushings|
41136201|NCT01847768|PROCEDURE|Lung Mucosal Biopsy|
41293819|NCT03088904|BIOLOGICAL|FluMist® Quadrivalent|LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
41136202|NCT01847768|PROCEDURE|Allergen Skin Prick Testing|For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer \& glycerol negative control.
41293820|NCT03088904|BIOLOGICAL|Fluzone® Quadrivalent vaccine|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
40764770|NCT04886531|DRUG|Trastuzumab|All Arms 8mg/kg loading dose followed by 6mg/kg every 3 weeks administered every 3 weeks by IV starting wk 4. Trastuzumab biosimilars may be used per institutional guidelines.
40764771|NCT06643299|DIETARY_SUPPLEMENT|Probiotic Agent|BlueBiology: Ultimate Care probiotic pill taken once daily for a four-month period.
40764772|NCT06643299|OTHER|Placebo|Placebo produced to be identical in taste and appearance to the probiotic agent, taken once daily for a four-month period.
40764773|NCT06446739|DEVICE|Continuous Renal Replacement Therapy (CRRT)|Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).
40764774|NCT05402345|DRUG|GlcNAc-GlcN|GlcNAc powder - weight-dependent dose
40764775|NCT05402345|OTHER|Placebo|Placebo xylose
40961918|NCT02746796|DRUG|ONO-4538|
41136203|NCT01847768|PROCEDURE|Venipuncture|Peripheral blood for assessment of neutralizing antibodies to HRV-39
41136204|NCT01847768|PROCEDURE|Bronchoscopy|A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
41136205|NCT01847768|PROCEDURE|Spirometry|
41456234|NCT00622362|BIOLOGICAL|Polymerized TOL of Dermatophagoides pteronyssinus|Sublingual immunotherapy. Two drops daily during 1 year
40961919|NCT02746796|DRUG|Oxaliplatin|
40961920|NCT02746796|DRUG|Tegafur- Gimeracil-Oteracil potassium|
40961921|NCT02746796|DRUG|Capecitabine|
40961922|NCT02746796|DRUG|Placebo|
40961923|NCT02174250|DRUG|Istradefylline 40 mg|On Day 1, istradefylline 1 × 40-mg tablet administered alone
41136206|NCT05891405|PROCEDURE|Cardiac surgery|Operations for congenital heart diseases
41136207|NCT02231970|PROCEDURE|Endoscopic sleeve gastroplasty|To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
41136208|NCT04945538|OTHER|Scatter radiation exposure measurement|Scatter radiation exposure of the operator and sterile assistant is recorded with digital live dosimeters at 3 locations of the operator (frontal head at eye level, left lateral head, below the left shoulder) and at 2 locations of the sterile assistant (left neck and below the left shoulder)
41136209|NCT03443206|OTHER|anonymous social support|Participants randomized to the intervention condition will be able to communicate with one another and offer social media-based forms of support (e.g., post music, photos, etc).
41136210|NCT03443206|OTHER|psychoeducation|educational materials related to mental health
41136211|NCT03443206|OTHER|online resources|links to online mental health resources
41456235|NCT00622362|BIOLOGICAL|Placebo Comparator|Sublingual immunotherapy. Two drops daily during 1 year
40764776|NCT06638892|BEHAVIORAL|Using PrEP, Doing it for Ourselves (UPDOs)|An e-Health intervention that considers women's lived experiences and uses three components: beauty salons and stylists as opinion leaders (trusted gatekeepers who share health information in the community), theory driven edutainment videos and blogs, and a secure online platform for accessing pre-exposure prophylaxis (PrEP).
41293821|NCT04064684|DRUG|Budesonide|Enrolled patients will be treated with Pulmicort Respules® (Budesonide inhalation suspension), at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator. The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
40961924|NCT02174250|DRUG|Rifampin 300mg BID + istradefylline 40mg Day 8 only|On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
41456236|NCT02817828|DRUG|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
41456237|NCT00674908|BIOLOGICAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
41456238|NCT00674908|BIOLOGICAL|Easy Five|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
40764777|NCT06638892|OTHER|Standard of Care|CDC standard of care, e.g., CDC videos and website.
40961925|NCT00133497|BIOLOGICAL|MF-59|Microfluoridized adjuvant 59 (MF59).
41456239|NCT06044948|DEVICE|Delefilcon A contact lenses|Daily disposable, silicone hydrogel spherical contact lenses
40961926|NCT00133497|DRUG|Placebo|0.5 mL of saline placebo.
40764778|NCT06462183|DRUG|RGT-61159|Oral MYB inhibitor
40961927|NCT00133497|BIOLOGICAL|CMV gB vaccine|CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
40961928|NCT03312101|OTHER|exercise program|functional exercises consisting of a therapeutic exercise program based on concentric strengthening the gluteal muscles (maximus, medius and minimus) , the tensor fasciae latae muscle and the pyramidal muscle; ischiotibial muscle stretching ; and empowerment in eccentric and stretching of the gastrocnemius muscle, soleus muscle, tibialis posterior muscle and flexor of the big toe muscle,
40961929|NCT01245621|BEHAVIORAL|Later entry group|"1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert Information (COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan."
40961930|NCT01245621|BEHAVIORAL|Early palliative care intervention|"1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert information(COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan."
40961931|NCT05960799|DEVICE|CON - Contiplex C™ (CC)|This is a catheter used for peripherical nerve block that is inserted at the same time that the needle is being introduced. When the target is achieved, the needle is retired.
40764779|NCT06638593|PROCEDURE|MIRRORS-FROZEN Protocol.|Initial laparoscopic phase and thorough inspection of the abdomino-pelvic cavity to determine the feasibility of proceeding robotically, followed by robotic excision of the mass(es) and its retrieval in a bag if deemed suitable to proceed robotically. The mass or cyst will be sent for frozen section to determine the extent of the surgery. The surgery will continue robotically, with conversion to laparotomy considered at any point at the discretion of the individual surgeon.
40961932|NCT05960799|DEVICE|CTN - Contiplex|This is the traditional catheter used in this centre for peripheric nerve block. In this catheter the needle is introduced first. When the target is achieved the catheter is then introduced throw the needle and after that the needle is retired.
40961933|NCT06199817|BEHAVIORAL|occupational therapies|music, garden-soil and sports practices for individuals diagnosed with schizophrenic disorder
41136212|NCT03731767|PROCEDURE|Distraction thrust manipulation|Distraction thrust manipulation of the talocural joint in supine position
41293822|NCT04064684|DRUG|Placebo|Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
41456240|NCT03250117|DRUG|Ropinirole oral product|oral immediate-release ropinirole
41456241|NCT03250117|DRUG|Ropinirole Implant|ropinirole hydrochloride/ethylene vinyl acetate
41456242|NCT04811729|BEHAVIORAL|Motivational interview|The participants will apply an approach based on the Motivational Interview (Rollnick, 2008) in patients with excessive alcohol consumption, previously receiving a training program
41456243|NCT04811729|BEHAVIORAL|Medical advice|Usual care
41456244|NCT03241836|DIAGNOSTIC_TEST|trans-perineal ultrasonography|accuracy of trans perineal ultrasonography in identification of female pelvic floor dysfunction
41456245|NCT05757609|DEVICE|Anodal tDCS combined with active physiotherapy|anodal tDCS over prefrontal cortex combined with active physiotherapy
41456246|NCT05757609|DEVICE|Sham anodal tDCS combined with active physiotherapy|Sham anodal tDCS over prefrontal cortex combined with active physiotherapy
41456247|NCT00651183|DRUG|Pramipexole immediate release|
41456248|NCT00001698|DRUG|Ketorolac Rinse|
41456249|NCT00002160|DRUG|Ziconotide|
41293823|NCT04064684|DEVICE|Nebulizer|The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
41293824|NCT03067558|DIAGNOSTIC_TEST|Children's automated respiratory rate monitor|"The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities."
41293825|NCT03067558|DIAGNOSTIC_TEST|MK2 Acute Respiratory Infection (ARI) Timer|The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
41293826|NCT01208662|DRUG|Lenalidomide|oral administration
41136213|NCT03314259|DRUG|Tamsulosin|Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population
40961934|NCT01372137|DRUG|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
40764780|NCT06638593|PROCEDURE|Standard open surgery|A midline abdominal incision will be made from the outset, with intraoperative frozen section assessment to determine the extent of the surgery.
40764781|NCT06645197|DRUG|SNUG01|Recombinant adeno-associated virus serotype 9 capsid containing human SG001 expression cassette
40764782|NCT06302985|PROCEDURE|atomized inhalation ICG before thoracoscope pneumonectomy|"Preoperative preparation ICG solution dissolved in 5ml of normal saline (dose 0.5mg/kg) was inhaled 30 minutes before surgery.~Operation method After entering the chest cavity, the fluorescence endoscope was switched to the fluorescence display mode, and the fluorescence-stained normal lung tissue and non-stained lesion tissue could be clearly displayed through the display screen, and the external boundary of the lesion was marked with an electric hook. The mediastinal pleura and pulmonary pleura were opened along the boundary of the lesion, and the lung tissue was split along the gap between the lesion and the lung tissue with an electric coagulation hook and an ultrasonic knife, and the lesion arteries and bronchi were freed."
40764783|NCT06642779|BEHAVIORAL|VFQ- 25 (Visual Function Questionnaire)|VFQ-25 questionnaire was used to evaluate patient satisfaction at the M3 and M12 visits.
40764784|NCT06642779|DIAGNOSTIC_TEST|Optical Biometry|Axial length, anterior chamber depth and corneal keratometric values K1-K2. All these parameters were measured at the screening visit and at the month 3 follow-up visit, using the ARGOS® Biometer or the ANTERION® Cataract App
40764785|NCT06642779|DIAGNOSTIC_TEST|Slit lamps / Fundoscopy / Biomicroscopy|The fundus and other ocular structures, such as the cornea, anterior chamber, iris, pupil, crystalline lens / IOL alignment, corpus ciliare and choroid were examined at screening visit, on the day of the surgery, and at the follow up visits D1, M1, M3, M6, and M12, using the slit lamp binocular indirect ophthalmoscopy.
41293827|NCT01208662|DRUG|Bortezomib|intravenous or, following protocol amendment, subcutaneous administration
41293828|NCT01208662|DRUG|Dexamethasone|"oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
41293829|NCT01208662|PROCEDURE|Autologous Stem Cell Transplant|Autologous refers to stem cells that are harvested from the participant to be a source of new blood cells after high-dose chemotherapy with melphalan.
41293830|NCT04844047|OTHER|Exercise|refer to arm descriptors
40764786|NCT06642779|DIAGNOSTIC_TEST|UDVA|Monocular and binocular Uncorrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
40961935|NCT01372137|OTHER|Glucose 5%|Placebo
41293831|NCT04844047|OTHER|Exercise|refer to arm descriptors
41293832|NCT02134704|OTHER|Data recording with all sensors|The sensors will be placed in the child body and will allow the collection of all the data of the trial.
41456250|NCT06385158|DRUG|GS1-144 tablet|GS1-144 tablet is an NK3R antagonist.
41456251|NCT04837664|DRUG|Curcumin|Curcumin was bought from Sigma®, USA, and its solution was freshly prepared by mixing curcumin powder with phosphate-buffered saline.
40764787|NCT06642779|DIAGNOSTIC_TEST|CDVA|Monocular and binocular Corrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
40764788|NCT06642779|DIAGNOSTIC_TEST|UIVA / DCIVA|Uncorrected and Distance Corrected Intermediate Visual acuity (UIVA / DCIVA) was evaluated postoperatively at M1, M3, M6 and M12, using an intermediate chart from 67 cm.
40961936|NCT00567307|DRUG|Red Heart Pill 2b (Polypill)|Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
40961937|NCT00567307|OTHER|Standard Practice|Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
40961938|NCT01957930|DRUG|Intensified insulin treatment|The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
40961939|NCT01957930|DRUG|Standard treatment|Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
40961940|NCT00307177|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
40961941|NCT00307177|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
40961942|NCT00607828|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
40961943|NCT02030041|DRUG|Vitamin D|Vitamin D will be given to achieve normal serum levels
40961944|NCT02030041|DRUG|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
40961945|NCT02030041|DRUG|Placebo|Placebo will be provided to the study participants
40961946|NCT06504706|PROCEDURE|Matcha Tea|Japanese tea rich in antioxidants and Catechins
40961947|NCT06504706|PROCEDURE|Green Tea|Green tea rich in catechins
40961948|NCT03963037|OTHER|Blood draw|Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
40961949|NCT03031197|COMBINATION_PRODUCT|Tailored realtime triggered reminder pkg|"Core intervention: 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. Personalized features of the intervention will be selected by each patient and may include 1) reminders sent to the WPC (light or chimes) or to patient's or caregiver's cell phone if dose is late; 2) content of text messages from a menu of options; 3) use of youth-friendly WPC adherence reports for interactive counseling sessions; 4) additional counseling by clinic staff; 5) a buddy system, by choosing someone to review the adherence report with him/her; and 6) a reward message after a pre-selected time period of excellent adherence."
40961950|NCT05887414|OTHER|Baseline|Measure Ottawa Decisional Regret at baseline when patients receive a diagnosis of appendicitis.
40961951|NCT05887414|OTHER|30 Day Follow Up|Measure Ottawa Decisional Regret after 30 days.
40961952|NCT04702061|OTHER|Erector spina plane block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be directed between the erector spina muscle and the transverse process of the T4 vertebra using the in-plane technique. The location of the needle will be confirmed by hydrodissection with saline after touching the transverse process. After the plan open, 5 ml of 2% lidocaine, 10 ml of 0.5% bupivacaine and 10 ml of saline, including hydrodissection, will be given in a total amount of 25 ml. Then a 20-G epidural catheter will be inserted 3-4 cm and fixed.
40961953|NCT04702061|OTHER|Thoracic epidural block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be entered through the T4-5 interspinous space (median or paramedian approach). After reaching the thoracic epidural area by loss of resistance method, the epidural catheter will be advanced and fixed to remain 3-4 cm in the epidural area. Following the test dose (2 ml of 2% lidocaine), 3 ml of 2% lidocaine, 5 ml of 0.5% bupivacaine and 5 ml of saline will be administered intermittently in a total volume of 15 ml.
40961954|NCT03947801|OTHER|Greek Yogurt|Female competitive soccer players (11-16y) will consume 0% plain Greek yogurt immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
40961955|NCT03947801|OTHER|Isoenergetic carbohydrate|Female competitive soccer players (11-16y) will consume an isoenergetic carbohydrate supplement immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
40961956|NCT05230290|BIOLOGICAL|KD6001 Injection|Solution for intravenous injection
41456252|NCT04837664|DRUG|Rose Bengal|Rose bengal was bought from Sigma®, USA, and its solution was freshly prepared by mixing rose bengal powder with phosphate-buffered saline.
41456253|NCT04837664|DRUG|Nystatin|Rinsing with topical nystatin (100,000 UI/mL) suspension for 60 seconds
40764789|NCT06642779|DIAGNOSTIC_TEST|UNVA / DCNVA|Uncorrected and Distance Corrected Near Visual acuity (UNVA / DCNVA) was evaluated postoperatively at M1, M3, M6 and M12, using a near chart from 40 cm.
40764790|NCT06642779|DIAGNOSTIC_TEST|Manifest Refraction|Manifest refraction was the monocular subjective refraction (Sph, Cyl, Axis) giving the best distance corrected visual acuity. It was measured at the screening visit and the follow-up visits Day 1, Month 1, Month 3, Month 6 and Month 12.
41456254|NCT03277248|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
41456255|NCT03277248|DRUG|Teriflunomide|Film coated tablets administered orally.
41456256|NCT03277248|DRUG|Oral Placebo|Administered orally.
41456257|NCT03277248|DRUG|IV Placebo|Administered as an IV Infusion.
41136214|NCT03314259|DRUG|Placebo Oral Tablet|placebo is a tablet made to mimic tamsulosin tablet with same size and colour with no active ingredient
41293833|NCT04091867|DRUG|sEphB4-HSA with chemotherapy|sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
40764791|NCT06642779|DIAGNOSTIC_TEST|IOP|Intraocular pressure (IOP) was measured at all visits (preoperative, D1, M1, M3, M6 and M12), using a non-contact tonometer.
41293834|NCT04091867|DRUG|Cetuximab|Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
41293835|NCT04091867|RADIATION|Radiation Therapy|6930 cGy IMRT starting D15-D18
40764792|NCT06642779|DIAGNOSTIC_TEST|VADC|Visual Acuity Defocus Curve (VADC) was taken monocularly at M3, monocularly and binocularly at M6 and binocularly at M12, using the Multifocal Lens analyzer - MLA application.
41293836|NCT00426751|DRUG|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
41293837|NCT00426751|DRUG|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
41293838|NCT02961647|PROCEDURE|Mitral valve repair|The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
41293839|NCT02296840|DRUG|Ibuprofen|Ibuprofen 10mg/kg/day every 6-8 hours
40764793|NCT06642779|DIAGNOSTIC_TEST|CSDC|Contrast Sinsitivity Defocus Curve (CSDC) was taken under photopic conditions at M6 and M12, using the Multifocal Lens Analyzer - MLA application
40764794|NCT06642779|DIAGNOSTIC_TEST|CSV-1000|"Contrast Sensitivity was measured using the CSV-1000 with distance correction in place at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd). Measurements were taken under four different light conditions:~* Photopic (M3 monocular and binocular, M6 binocular and M12 monocular)~* Mesopic (M6 binocular)~* Photopic with backlight (M6 binocular)~* Mesopic with backlight (M6 binocular)"
40764795|NCT06642779|DIAGNOSTIC_TEST|Tear film stability|Tear film stability was assessed at screening visit and at follow-up visits M1, M3, M6, and M12 using the non-invasive Tear break Up Time (TBUT) with fluorescein dye.
40764796|NCT06642779|DEVICE|IOL implantation|The investigational device (877PEY) and the comparator (877PAY) intraocular lens models were implanted, using sutureless, small-incision phacoemulsification surgery.
40961957|NCT03917238|RADIATION|gallium-68-exendin injection followed by PET/CT scan|After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended
41136215|NCT02994667|DEVICE|Permanent Pacemaker Placement|
41136216|NCT03032198|DEVICE|Imagio OA/US|Diagnostic opto-acoustic gray-scale ultrasound
41136217|NCT05384626|DRUG|NVL-655|Oral Tablet of NVL-655
41293840|NCT02296840|DRUG|Hydrocodone-Acetaminophen|Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
41293841|NCT04822922|GENETIC|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|The hUC-MSCs were injected intravenously on the 1, 4, 7 and 10 days after patients recruitment. The treatment doses include low dose: 4\*10\^5 cells/kg/each time, and medium dose: 8\*10\^5 cells/kg/each time, high dose 12\*10\^5 cells/kg/each time. After 3 groups of patients were enrolled, the group with appropriate safety and effectiveness was selected and the other 4 subjects were included.
41293842|NCT05170945|OTHER|Early bowel preparation for colonoscopy|Early (\<24 hours) bowel cleansing prior to colonoscopy.
41293843|NCT02692053|BIOLOGICAL|blood sampling|additional blood sampling (volume: 18 mL)
41293844|NCT01546220|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
40961958|NCT05972876|BEHAVIORAL|Blood flow restriction training|BFR will be achieved using an automatic personalized tourniquet system (MAD-UP, Angers, France) designed to automatically calculate limb occlusion pressure
40961959|NCT05972876|BEHAVIORAL|Resistance training|Resistance training will be performed without any blood flow restriction
40961960|NCT00380822|DRUG|miglitol|
40961961|NCT06175455|DEVICE|dynamic chest radiography|A recent technological advancement in this field is dynamic chest radiography (DCR), which is a low-dose imaging system capable of producing continuous moving images
40961962|NCT00990405|DRUG|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
40961963|NCT00851370|DRUG|Omalizumab (Xolair)|Bi-weekly
40961964|NCT00851370|DRUG|Placebo|Bi-Weekly
40961965|NCT04933877|PROCEDURE|Fascial plane block|Serratus anterior plane block
40961966|NCT02425020|DIETARY_SUPPLEMENT|Meat Protein|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
40961967|NCT02425020|DIETARY_SUPPLEMENT|Whey protein|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
40961968|NCT02425020|DIETARY_SUPPLEMENT|Carbohydrate|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
40961969|NCT06557564|GENETIC|TruGraf liver gene expression|Blood from the patients undergoing graft liver biopsy will be collected on the day of the liver biopsy, preferable prior to tissue collection or within 48 hours following the biopsy. Two specialized PaxGene tubes containing 2.5mL of blood each will be filled and will be sent to TGI laboratory in USA for processing, storage, and analysis using TGI's proprietary bioinformatics TruGraf will provide UHN with a Liver binary result: ACR or non-ACR. The results data will be batched and sent to UHN at agreed upon timepoints.
40961970|NCT01130454|DEVICE|Universal Electrophysiological Biofeedback Treatment|one 45 minute biofeedback treatment
40961971|NCT01130454|DEVICE|Universal Electrophysiological Biofeedback Treatment|one 45 minute placebo treatment
40961972|NCT05970185|DRUG|PEG-rhG-CSF|Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
40961973|NCT05970185|DRUG|G-CSF|G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
40961974|NCT00509041|DRUG|dasatinib|50 mg PO bid
40961975|NCT05622175|DRUG|F8IL10|"The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular.~Patients with arthritis flare(s) in large joints (shoulders, elbows, knees and ankles, with the exception of hip) and small joints (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per 2010 Rheumatoid Arthritis Classification Criteria \[1\] will be treated with increasing dose of F8IL10 according to the schedule detailed below:~Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10"
40961976|NCT01937416|BIOLOGICAL|autologous bone marrow mononuclear cells|Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
40961977|NCT05332197|BIOLOGICAL|17D Yellow fever vaccine|This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. The exact potency of each batch is released with the certificate of analysis that accompanies each batch and the potency confirmed at time of release closest to internal minimum specification. This vaccine is the same vaccine used by the national EPI program
40961978|NCT00791570|BIOLOGICAL|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
40961979|NCT02363842|DEVICE|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
41136218|NCT04918719|DRUG|Acetylcysteine|The dosing of Acetylcysteine will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours. (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
40764797|NCT04491175|DEVICE|DuoTherm|New multi-modal device comprising a sculpted low back plate with multiple sensory modalities held in place with a neoprene belt capable of being tightened with patient control of variations in sensory modalities.
41136219|NCT04918719|DRUG|Dextrose in Water|The placebo will consist of a 5% Dextrose in Water instead of NAC (dosage and timigs are the same as the NAC arm). (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
41136220|NCT04003792|DRUG|oxaliplatin|intra-arterial oxaliplatin administration
41136221|NCT04003792|DRUG|FOLFIRI Protocol|systemic FOLFIRI chemotherapy
41136222|NCT04003792|DRUG|Bevacizumab|systemic bevacuzimab therapy
41136223|NCT01958385|DEVICE|placement of g-Cath EZ suture anchors|
41136224|NCT01958385|PROCEDURE|Sham procedure|
41136225|NCT01958385|BEHAVIORAL|Diet and Exercise|A structured diet and exercise plan
40764798|NCT04491175|DEVICE|TENS|LG SMART TENS stimulator is a portable electrotherapy devcie featuring transcutaneous electrical nerve stimulation (TENS) therapeutic device, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
40764799|NCT05198934|DRUG|Sotorasib|Sotorasib will be administered orally
40764800|NCT05198934|DRUG|Panitumumab|Panitumumab will be administered as intravenous (IV) infusion
40961980|NCT02363842|OTHER|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
40961981|NCT06065397|PROCEDURE|Goal setting improvement program|A improvement program how to optimalize patient-centered goal setting in rehab care is being implemented.
40961982|NCT03652597|DEVICE|Transcranial magnetic stimulation (TMS)|Subjects receive TMS on several cortical brain locations, while recording the heart rate.
40961983|NCT05820672|OTHER|No intervention|No intervention
40961984|NCT05789160|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
40961985|NCT06504797|DEVICE|automatic massage|automatic massage
40961986|NCT00750815|DRUG|Cyclophosphamide|Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
40961987|NCT00750815|DRUG|Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)|Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
40961988|NCT03681405|OTHER|Informational Intervention|Given information about mindful movement and breathing
40961989|NCT03681405|OTHER|Questionnaire Administration|Ancillary studies
40961990|NCT03681405|BEHAVIORAL|Telephone-Based Intervention|Receive caring attention phone call
40961991|NCT01060813|DIETARY_SUPPLEMENT|Leucine supplements|leucine supplements
40961992|NCT03643796|DRUG|Remifentanil|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
40961993|NCT03643796|DRUG|Ketamine|Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
40961994|NCT03643796|DRUG|Dexmedetomidine|dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
40961995|NCT01095055|BIOLOGICAL|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly
40961996|NCT01095055|BIOLOGICAL|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly
41136226|NCT04685395|DRUG|Ribamipide gargle \benzdymine HCL gargel|ribamipide gargle 6 time daily 5ml dosage
41136227|NCT00059826|BIOLOGICAL|interferon-alfa-2b|IV
40764801|NCT05198934|DRUG|Trifluridine and Tipiracil|Trifluridine and Tipiracil will be administered orally
40764802|NCT05198934|DRUG|Regorafenib|Regorafenib will be administered orally
40764803|NCT03942653|DRUG|Goserelin Acetate|Goserelin Acetate, SQ, Q4W
40961997|NCT05403281|DRUG|DW6012|"Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast"
40961998|NCT00760097|DEVICE|Transcranial direct stimulation|sessions of 20 minutes each
40961999|NCT04639375|BIOLOGICAL|Vaccinated with polio vaccine (IPV)|poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States
40990607|NCT00923559|OTHER|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. In the study, the analysts strived to recruit the baby for an emotional interchange, though this did not imply any belief that the infant would understand verbal communication. Rather, the analyst addressed the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst took care in enrolling the participant mother. This was to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her space to vent her own frustration, depression and anxiety.
41136228|NCT00059826|DRUG|cisplatin|IV
41136229|NCT00059826|DRUG|5-fluorouracil|IV
41136230|NCT00059826|RADIATION|radiation therapy|
41136231|NCT06501027|BEHAVIORAL|Mindfulness Based Self Compassion|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of
40764804|NCT03942653|DRUG|Pembrolizumab|Pembrolizumab, IV, Q3W
40764805|NCT02763033|DRUG|Bob's Red Mill®|Standard bone marrow transplant (BMT) diet + potato-based starch
40764806|NCT02763033|OTHER|Starch Placebo|Standard bone marrow transplant (BMT) diet + corn-based starch
40764807|NCT06640062|OTHER|Erector spinae plane block|Patients received ultrasound-guided erector spinae plane block.
40764808|NCT06640062|OTHER|Oblique subcostal transversus abdominis plane block|Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.
40764809|NCT02914886|DRUG|Apidra|Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
40764810|NCT02914886|DRUG|current insulin|Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
40764811|NCT05558267|DIETARY_SUPPLEMENT|Standard Table Salt|Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.
41293845|NCT04498858|OTHER|Patient interview|"Patient will be interviewed :~* tobacco consumption~* reported question asked by the dentist about his/her tobacco consumption~* presence and nature of reported advices given by the dentist~* presence and nature of actions proposed by dentists for patients reporting tobacco consumption, including prescription of NRT~* presence and nature of the actions carried out or envisaged by these patients, including - smoking cessation~* contact with the general practioner~* Fagerstrom score (2 questions)~* demographic variables, age, sex, level of education~* satisfaction"
40962000|NCT01610570|DRUG|Mithramycin|Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
40962001|NCT03302234|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
41136232|NCT04711291|COMBINATION_PRODUCT|Conversion to Envarsus-XR and use of smart phone app, TransMedAx|"Convert to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours used in combination with the smart phone application, TransMedAx.~Patients in this arm will be trained to use the app along with conversion to Envarsus-XR. Once patient scan the code on medicine bottle and the app will remind them about the time and dose of the medication in their native language."
41136233|NCT04711291|DRUG|Convert to Envarsus XR once daily|Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours
41293846|NCT00003356|BIOLOGICAL|aldesleukin|
41293847|NCT00003356|BIOLOGICAL|rituximab|
41293848|NCT03335631|BEHAVIORAL|Exercise|Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.
41293849|NCT02446639|OTHER|Blood collection|
41456258|NCT05539794|BEHAVIORAL|lifestyle and physical exercise|"the intervention group will follow a physical exercise and health counselling intervention--see below.~The exercise program will be performed in the hospital gymnasium (3 supervised sessions/week of aerobic and muscle strength exercises) or in the patients' room (during phases of treatment-induced immunodepression, where isolation is needed to prevent infections). It will also include specific training of the respiratory ('inspiratory') muscles (e.g., diaphragm) on 5 days/week. The counselling program will include psychological (once weekly), nutritional (twice monthly), support (with survivors of adolescent cancer, twice/month) and educational (for relatives/caregivers, once monthly) sessions."
41456259|NCT06105450|DIAGNOSTIC_TEST|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
41456260|NCT03237156|DRUG|TAK-906|TAK-906 capsules.
41456261|NCT03237156|DRUG|TAK-906 Placebo|Placebo capsules.
41456262|NCT05302193|OTHER|Calm measurement of blood pressure and heart rate (before physical activity)|Simultaneous blood pressure and heart rate measurements at minutes 2 and 5.5 of the experiment.
41456263|NCT05302193|OTHER|Physical activity|Five minutes of physical activity, between times 7.5 min and 12.5 min of the experimental part. Riding on a spinning ergometer with a standardized load of 1 W/kg.
41456264|NCT05302193|OTHER|Calm measurement of blood pressure and heart rate (after physical activity)|Simultaneous blood pressure and heart rate measurements at times 15.5, 17, 20.5 and 22 minutes of the experimental part.
40962002|NCT03302234|BIOLOGICAL|Ipilimumab|Administered as an IV infusion every 6 weeks (Q6W)
41136234|NCT03918096|OTHER|Questionnaire|Questionnaire to the parents after the hospital discharge
41136235|NCT04070105|DEVICE|Compliant Adaptive Energy Storage and Return Foot|The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button
41293850|NCT03554499|PROCEDURE|Bichectomy with hydrodissection|Intraoral removal of buccal fat pads using hydrodissection technique
41293851|NCT03554499|PROCEDURE|Bichectomy|Intraoral removal of buccal fat pads using conventional technique
41293852|NCT00729118|DRUG|lenalidomide|combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
41456265|NCT00577655|DRUG|Albuterol|Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
41456266|NCT00577655|DRUG|Placebo|Placebo HFA MDI four times a day (q.i.d) for 21 days.
41136236|NCT04070105|DEVICE|AllPro|Participants will be fit with a high activity foot designed to be used for walking and running
41136237|NCT03153306|DRUG|albumin|"Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)"
41136238|NCT02345551|BEHAVIORAL|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
40764812|NCT05558267|DIETARY_SUPPLEMENT|Salt Substitute|"Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.~Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis."
40962003|NCT03302234|OTHER|Placebo|Normal saline solution administered as an IV infusion Q6W
40764813|NCT06642805|PROCEDURE|duodenal atresia|surgery for duodenal atresia
41293853|NCT00729118|DRUG|vorinostat|Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
41456267|NCT00577655|DRUG|Proventil® HFA|Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
41456268|NCT03454490|PROCEDURE|Postoperative pseudoaneurysm of the greater palatine artery|Patients had an autogenous connective tissue gingival graft.
40962004|NCT00762385|DEVICE|galyfilcon A|galyfilcon A
40962005|NCT00762385|DEVICE|comfilcon A|comfilcon A
41136239|NCT00315185|DRUG|Cetuximab|
41456269|NCT00584103|DEVICE|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
41456270|NCT00584103|DEVICE|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
41456271|NCT06405854|OTHER|Exercise|Children in the coordinative exercise intervention group will be encouraged to participate in sessions twice a week, each lasting 20 minutes. The foundational movement patterns tailored to the specific purpose were organized in a game format suitable for preschool-aged children. These foundational movement patterns comprise open-ended tasks progressing from simple to complex, with motor planning as a prerequisite. As the exercise intervention was game-based, the sessions were maintained as a fun, active, and social learning environment for the children. Duration of the intervention is eight weeks,
40764814|NCT06643325|DIAGNOSTIC_TEST|Gastric ultrasound|Serial, gastric sonography
40764815|NCT06070012|DRUG|Tebentafusp|An anti-cancer medication used to treat uveal melanoma. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.
40764816|NCT05790031|DEVICE|Intelligent Nighttime Brace|Participants will be invited to undergo a fitting session of intelligent nighttime brace. After the fitting, participants will join a 6-month wear trial of the intelligent nighttime brace. Participants are required to wear the intelligent nighttime brace for 8 hours a day during sleeping and compliance will be recorded by an intelligent monitoring system. Participants will be invited to undergo assessments before the wear trial, after the trials of 3 months and after the trial of 6 months. The measure outcomes of the assessment include 1)ultrasound scanning image, 2)3D body scanning, 3)garment pressure, 4) questionnaires
40764817|NCT06639607|BIOLOGICAL|PEP-CMV vaccine|Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.
40962006|NCT03048331|DEVICE|Functional Electrical Stimulation|"Functional electrical stimulation is applied with stimulators according to the lesion. In case of a upper motor neuron lesion the stimulation operates via nerve. For the stimulation surface electrodes are placed on the skin over the muscle belly. The stimulation of the innervated muscles will be conducted using the following conditions:~300-400 usec, 20-50 Hz, amplitude depends on the quality of muscle contraction (20-80 mA). the duty cycle of the stimulation is 3 sec. ramp up, 5 ec. plateau, 2 sec. ramp down, 10 sec. pause."
40990608|NCT03371992|DRUG|Nivolumab|Nivolumab, pembrolizumab or atezolizumab will be administered as per the established standard of care for the eligible population.
40990609|NCT03371992|DIAGNOSTIC_TEST|3D-EX|Analysis of drug-mediated changes in the tumor microenvironment.
40990610|NCT03371992|OTHER|Evaluation of Response by RECIST|Evaluation of tumor response using the set of published rules to determine if a tumor has responded, is stable or progressed during treatments.
40990611|NCT00847457|BEHAVIORAL|Aerobic exercise|Aerobic exercises completed three to four times per week for 20 to 30 minutes per session
40990612|NCT00847457|BEHAVIORAL|Stretching|Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
40962007|NCT04132258|OTHER|survey|(presence of certain antecedents, weight, height, current or past existence of inflammatory rhinitis) and a second by the specialist doctor (pathology at the origin of the start of biotherapy, year of beginning of treatment, previous biotherapies over the last 3 years).
40990613|NCT03251508|DRUG|Peanut OIT|Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
41136240|NCT00489879|DEVICE|Mobile Health Care System (DrUB)|
41136241|NCT04828109|DEVICE|Virtual Reality|Use of any virtual reality experiences available
41293854|NCT05218447|DEVICE|Robotic Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
40764818|NCT06639607|BIOLOGICAL|Tetanus booster|Td 5 flocculation units, Lf
41293855|NCT05218447|OTHER|Usual Care (UC) Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will complete gait training with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
40962008|NCT02228200|BEHAVIORAL|Nurse-led care|The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.
40962009|NCT02228200|BEHAVIORAL|Routine care|Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
40962010|NCT06415487|DRUG|Cyclophosphamide|Lymphodepleting agent
40962011|NCT06415487|DRUG|Fludarabine|Lymphodepleting agent
40962012|NCT06415487|DRUG|ACE2016|Allogeneic gamma delta T (gdT) cell therapy
40962013|NCT06415487|DRUG|Pembrolizumab|Immune checkpoint anti-PD-1 antibody
40962014|NCT01364649|DRUG|Vortioxetine|Vortioxetine tablets
40962015|NCT01364649|DRUG|Escitalopram|Escitalopram tablets
40962016|NCT01364649|DRUG|Placebo|Vortioxetine Placebo-matching capsules
40962017|NCT00843024|DRUG|Sumatriptan and Naproxen Sodium|Sumatriptan succinate and naproxen sodium
40962018|NCT00843024|DRUG|Placebo|Placebo to match
40962019|NCT05626023|DRUG|Human TH-SC01 cell injection|Single injection of human TH-SC01 cell injection
40962020|NCT05772000|DIAGNOSTIC_TEST|cerebrospinal fluids exams|cerebrospinal fluids will be examined by conventional cytology and flow cytometry
40962021|NCT02403986|DEVICE|Restylane Vital Skinboosters Lidocaine|
40962022|NCT04655638|DEVICE|High Flow Nasal Therapy|High flow nasal therapy will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%.
40962023|NCT04655638|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.
40962024|NCT00469274|DRUG|Antibiotic PEP|Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
40962025|NCT00469274|DRUG|Antibiotic PEP|TMP-SMX DS po BID for 14 days
40962026|NCT02328300|DRUG|FLT PET/MR|Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
41293856|NCT02901717|DRUG|Mino-Lok|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.
41293857|NCT02901717|DRUG|Antibiotic lock|Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
41293858|NCT02016742|DRUG|RDC5|
40962027|NCT05988008|DRUG|CCX168|Administered orally.
40962028|NCT05988008|DRUG|Placebo|Administered orally.
40962029|NCT05453201|BEHAVIORAL|Long COVID Coping and Recovery (LCCR) Intervention|Veterans will participate in a LCCR (1x/week for a total of 16 sessions) via the HIPAA-compliant telehealth platform VA Video Connect (VVC) and/or VA WebEx with two co-therapists.
40962030|NCT03128567|DEVICE|Stimulation of the subthalamic nucleus|Stimulation of the subthalamic nucleus
40962031|NCT04891952|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|Functional precision medicine test to predict response to candidate chemotherapeutic agents
40962032|NCT05329701|OTHER|Individualized treatment duration strategy|As listed under arm description.
41136242|NCT04828109|DEVICE|Fitbit|Use of a Fitbit wearable activity device to track daily step goals.
41136243|NCT01758068|PROCEDURE|Coconut Oil Application|Coconut oil - 4 ml
40764819|NCT06639607|BIOLOGICAL|Nivolumab|Administered intravenously
40764820|NCT06639607|DRUG|Temozolomide|Administered orally
40962033|NCT04946383|DRUG|Dasatinib plus Quercetin|Dasatinib plus Quercetin
40962034|NCT05561699|DRUG|Penpulimab Combined With CRT|"1. Penpulimab: 200mg, intravenous infusion, once every two weeks. After completing two courses of CRT, continue to send Penpulimab 200mg every two weeks on the first and 14th days after the completion of CRT, two courses of treatment, a total of four courses.~2. Radiotherapy 40gy/20fx, once a day from Monday to Friday, completed in 4 weeks;~3. PC regimen: Paclitaxel 50mg/m2, intravenous drip, carboplatin AUC=2mg/ml/min, intravenous drip, once a week during radiotherapy, a total of 4 courses, the specific time is D1, 8, 15, 22 days after the beginning of radiotherapy.~4. Gastrointestinal reactions such as nausea and vomiting should be routinely prevented before chemotherapy. Dexamethasone 10mg should be used 30 \~ 60 minutes before paclitaxel, and intramuscular injection should be stopped immediately in case of drug or infusion reactions."
40962035|NCT01081678|DRUG|Placebo|Administered by subcutaneous (under the skin) injection
40962036|NCT01081678|DRUG|Romosozumab|Administered by subcutaneous injection
40962037|NCT01322139|DRUG|Placebo spray and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
40962038|NCT01322139|DRUG|Sativex spray and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
40962039|NCT01322139|DRUG|Sativex spray and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
40962040|NCT01322139|DRUG|Placebo spray and moxifloxacin|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
40962041|NCT04944251|BEHAVIORAL|Regular Exercise|the third month, for 30 minutes or 1 hour, 3 days a week
40962042|NCT00004730|DRUG|magnesium sulfate|
40962043|NCT06297161|DRUG|Bosulif|chronic myelogenous leukemia patients
41293859|NCT02752308|DRUG|Bupivacaine|Injection of Bupivacaine in the epidural space (0.25%, 0.33mg/Kg)
41293860|NCT02752308|PROCEDURE|General anesthesia|Induction with thiopental sodium 5 mg/Kg, atracurium 0.4 mg/Kg and fentanyl 2 mcg/Kg and maintenance with isoflurane and a combination of oxygen and nitrous oxide
40962044|NCT04893278|OTHER|Virtual reality|Use of Virtual reality goggles during procedure
40962045|NCT05397964|DEVICE|Radiopaque Calcium Hydroxide Composition|Treatment of exposed pulp tissue with radiopaque calcium hydroxide composition as a direct pulp capping material
40962046|NCT03949374|DRUG|CRESTOR, reference formulation of rosuvastatin|Use of ROVASRO for hypercholesterolemia
40962047|NCT03949374|DRUG|ROVASRO, generic formulation of rosuvastatin|Use of CRESTOR for hypercholesterolemia
40962048|NCT03282643|DRUG|Rivaroxaban 10 MG|Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
40962049|NCT03282643|DRUG|Rivaroxaban 20 MG|Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
40962050|NCT03282643|DRUG|Low-molecular-weight heparin|0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
40962051|NCT00880997|DRUG|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17."
40962052|NCT00880997|OTHER|Placebo|Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
40962053|NCT04243681|COMBINATION_PRODUCT|CD 34 and MSC infusion|Combination of stem cells
40962054|NCT04243681|DRUG|Standard of care for Cirrhosis management|Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
40962055|NCT00939770|DRUG|Crizotinib|Given PO
40962056|NCT00939770|OTHER|Laboratory Biomarker Analysis|Correlative studies
40962057|NCT00939770|OTHER|Pharmacological Study|Correlative studies
40962058|NCT00939770|OTHER|Questionnaire Administration|Ancillary studies
40962059|NCT04496271|DEVICE|RIC (Receiver in channel)- device|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
40962060|NCT03787264|DRUG|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
40962061|NCT03787264|BIOLOGICAL|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
40962062|NCT03787264|BIOLOGICAL|Acalabrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o."
40962063|NCT03787264|BIOLOGICAL|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
40962064|NCT05517915|OTHER|Inspiratory muscle training.|Interval inspiratory muscle training was performed using the inspiratory muscle trainer.
40962065|NCT05517915|OTHER|Sham inspiratory muscle training.|Interval inspiratory muscle training was performed using the unloaded inspiratory muscle trainer.
41293861|NCT02752308|DRUG|Dilute epinephrine injection|Injection of 1/100000 epinephrine solution along all incision lines
41293862|NCT02752308|DRUG|Fentanyl|fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
41293863|NCT02752308|DRUG|dextrose plus sodium chloride.|Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution
41293864|NCT02752308|DRUG|neostigmine and atropine|Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.
40962066|NCT05279443|OTHER|yoga-based exercises therapy|Accompanied by a certified yoga instructor, and under the supervision of an PMR specialist and a Sports Medicine specialist, YBEs were administered to our patients included in the study for 8 weeks, 2 sessions a week, and with sessions of 60 minutes, using personal mats and equipment in a 2475 m3 (18mx25mx5.5m) gym area that belonged to our hospital, in the form of group therapy for 5 (five) people and in accordance with the social distancing rules. The exercises program was applied as a exercise program consisting of physical postures (asana) to improve the body's muscle strength and flexibility, breathing exercises (pranayama) to increase respiratory function, and relaxation and meditation (dhyana) techniques.
40962067|NCT04289662|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
40962068|NCT04289662|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
41293865|NCT02752308|PROCEDURE|Hypospadias repair|Surgical repair of hypospadias, using tubularized incised plate technique
41293866|NCT06035380|OTHER|placebo group|aromatherapy
41293867|NCT06035380|OTHER|mint oil group|aromatherapy
41293868|NCT06035380|OTHER|rose oil group|aromatherapy
40962069|NCT04158297|PROCEDURE|ESWL vs SOPIL|To compare the efficacy of single operator pancreatoscopy (SOP) with intracorporeal lithotripsy (SOPIL) to extracorporeal shock wave lithotripsy (ESWL) for the treatment of main pancreatic duct stones (MPDS) in patients with chronic pancreatitis.
41293869|NCT00296348|DRUG|tacrolimus|immunosuppression
41293870|NCT00296348|DRUG|mycophenolate mofetil|oral
41293871|NCT00296348|DRUG|daclizumab|oral
40962070|NCT05780918|OTHER|Best Case/Worst Case-ICU Communication Tool|"This intervention uses scenario planning and a daily report of the interplay between major events and prognosis to illustrate a range of long-term outcomes and treatment experiences. By using a graphic aid to illustrate what we are hoping for, what we are worried about, and the evolution of the patient's story over time, the tool aims to facilitate dialogue among older adult trauma patients, their families, and the trauma team. Because the tool delivers critical prognostic information over the longitudinal course of care, subsequent treatment decisions can be made within the context of the patient's overall health status. This information alerts patients and families to the life-limiting nature of serious injury and provides an entrée for them to consider how comfort-focused strategies might better align with patients' end-of-life goals.~All clinicians will be trained to create, use, and/or reference the graphic aids with patients depending on their roles in the trauma ICU."
40962071|NCT06259747|OTHER|Acutaping|Application of the kinesio tape on finger and forearm flexor tape after localization of the acupoints of application
40962072|NCT06259747|DRUG|Doxylamine and Pyridoxine|traditional medical treatment for nausea and vomiting during pregnancy
40962073|NCT00149162|DRUG|proleukin|"One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months"
41293872|NCT00296348|DRUG|steroids|oral
41293873|NCT03207828|BEHAVIORAL|Behavioral activation|The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, \& Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.
41456272|NCT01021501|DRUG|nifedipine controlled release tablets|nifedipine controlled release tablets 60mg/day for at least 4 weeks
41293874|NCT03207828|OTHER|Usual care|Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
41456273|NCT03544242|OTHER|Control|A saline infusion will be administered during the pre-isolation and post-isolation phases.
41456274|NCT03544242|DRUG|Pre-Isolation Infusion|A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
41456275|NCT03544242|DRUG|Post-Isolation Infusion|A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
41456276|NCT01942616|OTHER|Condition 1: Perpetrator Positive|Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
41456277|NCT01942616|OTHER|Condition 2: Perpetrator Negative|The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
41456278|NCT01942616|OTHER|Condition 3: Placebo|This intervention provides no details for the participant and is for comparison use in the study.
41456279|NCT01723683|DRUG|Surfactant|
41456280|NCT00452543|DRUG|acamprosate|Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
41456281|NCT00452543|DRUG|escitalopram|Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
41456282|NCT00452543|BEHAVIORAL|Medical management|Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
41456283|NCT00452543|DRUG|Placebo|Placebo, 2 capsules PO TID, for 12 weeks
41456284|NCT05363241|PROCEDURE|Cooled radiofrequency in classical targets (CRF-CT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial. The participant will not be able to follow the procedure.
40962074|NCT05912010|DIAGNOSTIC_TEST|NP/OP swab|NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.
40962075|NCT01112358|DRUG|r-FSH|r-FSH will be administered as specified in the arm description.
40962076|NCT01112358|DRUG|r-hLH|r-hLH will be administered as specified in the arm description.
40962077|NCT01112358|DRUG|Analogous GnRH antagonist|Analogous GnRH antagonist will be administered as specified in the arm description.
40962078|NCT01112358|DRUG|r-hCG|r-hCG will be administered as specified in the arm description.
40962079|NCT01112358|DRUG|Progesterone|Progesterone will be administered as specified in the arm description.
40962080|NCT06505122|BEHAVIORAL|Dyadic Life Review|DLR is an intervention that will promote relationship closeness, communication, and psychological distress in both older adults and caregivers.
40962081|NCT04504357|BEHAVIORAL|Tablet based U=U app|"Tablet based app focusing on TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing."
40962082|NCT04504357|BEHAVIORAL|U=U videos played in clinic waiting rooms and integrated into HIV counseling session|TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing.
40962083|NCT04504357|OTHER|Text messages|Monthly text messages reinforcing intervention content
40962084|NCT00354536|DRUG|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
40962085|NCT00354536|BIOLOGICAL|placebo injection|placebo injection
40962086|NCT02591290|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular (2 doses with 8-week interval)
41456285|NCT05363241|PROCEDURE|Cooled radiofrequency in revised targets (CRF-RT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial and recurrent fibular nerves and the infra-patellar branch of the saphenous nerve. The participant will not be able to follow the procedure.
41456286|NCT02737462|DRUG|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
40962087|NCT00560456|OTHER|Chronic sleep restriction and driving simulator|"* One night of normal sleep~* Driving simulator~* Night 1: night of total sleep deprivation~* Night 2: night of sleep recovery~* Night 1 to 5: nights of sleep restriction~* Driving simulator after night 1 to 5~* Night 6: night of sleep recovery~* Driving simulator"
40962088|NCT00133471|BIOLOGICAL|Influenza A/H9N2 vaccine|A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.
40962089|NCT00133471|DRUG|MF59 adjuvant|MF59 adjuvant is an oil-in-water emulsion.
40962090|NCT04105101|DEVICE|Industrial passive shoulder exoskeleton|Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.
40962091|NCT01212523|DRUG|propofol and isoflurane|both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
40962092|NCT04201093|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 mg QD or 15 mg QD tablet once daily orally for 27 weeks.
40962093|NCT04201093|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
40764821|NCT04373551|BEHAVIORAL|Cultural adaptation of a patient-provider communication tool|Adaptation of a patient-provider communication tool for PrEP uptake utilized among AA women and their providers in a pilot pre/post-intervention design.
40764822|NCT06510231|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) targets the inspiratory muscles and is used to improve inspiratory muscle strength.
40962094|NCT04149626|DRUG|Dexmedetomidine|Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)
40962095|NCT04149626|DRUG|Midazolam|Sedation using midazolam (initial bolus dose followed by continuous infusion)
40962096|NCT04149626|DRUG|Remifentanil|Sedation using remifentanil (initial bolus dose followed by continuous infusion)
40962097|NCT01227434|DRUG|PD 0332991 (pre-surgery)|PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression
40962098|NCT01227434|DRUG|PD 0332991|PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles
40962099|NCT01227434|PROCEDURE|Resection as clinical care|Indicated, intended, surgical resection as clinical care
40962100|NCT01225432|OTHER|Gait Training|12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
40962101|NCT03730571|DEVICE|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
41293875|NCT05677945|DRUG|3Mixtatin paste: Simvastatin mixed with modified triple antibiotic|"* Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
41293876|NCT05677945|DRUG|3Mix: Modified triple antibiotic mix in propylene glycol|"* Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
41293877|NCT02965703|DRUG|Aspirin|Given PO
41293878|NCT02965703|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, stool, and rectal swab samples
41293879|NCT02965703|OTHER|Placebo Administration|Given PO
41293880|NCT02965703|OTHER|Questionnaire Administration|Ancillary studies
41456287|NCT05643105|PROCEDURE|Any kind of colectomy|This is a registry of surgical patients with colon cancer that are managed following current clinical practice in each participating center. The aim of this research is studying anastomotic leak rates and posible risk factors.
41456288|NCT02133638|DRUG|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
40962102|NCT01881347|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
40962103|NCT01881347|DIETARY_SUPPLEMENT|Placebo|Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
40962104|NCT02527005|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses
40962105|NCT02527005|DRUG|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
40962106|NCT06383078|DRUG|HR070803|HR070803 60 mg/\^2 D1 over 90 minutes.
41293881|NCT02965703|PROCEDURE|Rectal Biopsy|Undergo rectal biopsy
41456289|NCT02133638|DRUG|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
41456290|NCT03284697|PROCEDURE|Direct Pulp Capping with Ca(OH)2|Calcium hydroxide powder was mixed with saline and placed over the exposed pulp tissue. The cavities were then restored with resin modified GIC liner followed by composite restoration.
41456291|NCT03284697|PROCEDURE|Direct Pulp Capping With MTA|MTA was mixed using1:3 water/ powder ratio and applied to exposure site. Then cotton pellets soaked in normal saline was placed over MTA and cavity was sealed provisionally with IRM. After 24 hours, the patient was recalled and the cavity was restored with resin modified GIC liner followed by composite restoration.
41456292|NCT04425096|OTHER|Skin to skin contact|Skin to skin contact
41456293|NCT01812603|DRUG|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
40764823|NCT06642428|DRUG|Neoadjuvant therapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
40962107|NCT06383078|DRUG|Oxaliplatin|Oxaliplatin 85 mg/\^2 D1 over 2 hours.
40962108|NCT06383078|DRUG|Tegafur|initial dose of S-1 is determined according to the body surface area，orally, D1-7.
40962109|NCT06383078|DRUG|Folinic acid|Folinic acid 400 mg/\^2 D1
40962110|NCT06383078|DRUG|5-Fluorouracil|5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours
40962111|NCT04725461|DEVICE|Low cost lower limb prosthetic socket|"A pre-made 3D printed cylinder used as an outer shell is selected for each subject based on their measurements. The space between the residual limb and the outer shell will be filled with an expanding polyurethane foam (Foam IT 8, Smooth On Inc.) that conforms to the residual limb and bonds with the outer shell to form a strong and lightweight socket. The foam forms a smooth surface against the protective sheath; the socket is fully formed once the foam has hardened to the 3D printed cylinder.~A prefabricated supracondylar suspension cuff made of Dacron or nylon, or a commercially available suspension sleeve may be will be applied to the prosthetic socket to aid in suspension. Commercially available components, including the International Committee of the Red Cross (ICRC) transtibial polypropylene component system will be attached to the bottom of the socket to allow the patient to ambulate in the prosthesis."
41293882|NCT01971879|PROCEDURE|Remote ischemic preconditioning|"A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
40962112|NCT05192109|BEHAVIORAL|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
41293883|NCT01971879|PROCEDURE|Control|"A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
41293884|NCT06352216|DIAGNOSTIC_TEST|Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS)|Each subject is examined for the presence of synovitis using the aforementioned diagnostics.
41293885|NCT00455858|DRUG|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
41293886|NCT00854932|OTHER|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
41293887|NCT03590847|BEHAVIORAL|Intermittent Fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
41293888|NCT06181617|OTHER|Quality of life assessment|Quality of life assessment
41293889|NCT02295098|OTHER|Thoracic epidural catheter placement|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
41293890|NCT02295098|OTHER|Paracostal catheter placement|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
41293891|NCT06340555|OTHER|GUIA ATENCION MULTIDISCIPLINAR SANT BOI|Women with losses attended according to the multidisciplinary intervention proposed at the SJD Hospital de Sant Boi
41293892|NCT06340555|OTHER|USUAL CARE|Women with losses treated at the Hospital Comarcal del l'Alt Penedes.
41293893|NCT02016066|DRUG|CR6261|CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
41293894|NCT02016066|DRUG|Placebo|Placebo will be administered as a single 2-hour intravenous infusion
41293895|NCT06512038|RADIATION|DEXA Scan|If the participant consents to take part in the trial, they will have an additional DEXA scan.
41293896|NCT02047123|DIETARY_SUPPLEMENT|Raw Flaxseed|The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
41293897|NCT01570725|BEHAVIORAL|Virtual reality exposure|"The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.~Patients were exposed to the virtual environment for the entire length of the operation."
41293898|NCT01570725|BEHAVIORAL|Music only|A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
41293899|NCT04239274|DEVICE|transcranial direct current stimulation|Subjects in this arm will receive one session of tDCS for 20 minutes at 2.0 milliamps.
41293900|NCT04239274|DEVICE|transcranial pulsed current stimulation|Subjects in this arm will receive one session of tPCS for 20 minutes at 2.0 milliamps.
40764824|NCT06642428|DRUG|Neoadjuvant therapy|Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
40764825|NCT06627049|OTHER|Focus group|Focus group to evaluate the facilitators and barriers to the use of virtual reality.
40962113|NCT05192109|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
41293901|NCT04239274|DEVICE|Sham-no stimulation|Subjects in this arm will receive one session of sham for 20 minutes.
41293902|NCT01204112|DRUG|Tasocitinib (CP-690,550) plus Rifampin|Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
41293903|NCT00887445|DRUG|SLV341|5 - 1000mg once daily
41293904|NCT00887445|DRUG|placebo|
41293905|NCT02951546|DIETARY_SUPPLEMENT|Mediterranean diet|In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol \<300 mg/day, dietary fiber 25 g/day.
41456294|NCT00421863|DRUG|Triatec 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
41456295|NCT00421863|DRUG|Triatec HCT 5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
40764826|NCT06627049|OTHER|Implementing facilitating strategies|Implement strategies to facilitate the integration of virtual reality into rehabilitation sessions.
40764827|NCT06627049|OTHER|Focus group|Evaluate the strategies used to facilitate VR implementation.
40764828|NCT06627049|OTHER|Interviews|Interviews to evaluate the facilitators and barriers to the use of virtual reality.
40962114|NCT03108183|DIAGNOSTIC_TEST|x-rays|To get further and actual information about periapical lesions, different x-rays will be done (panoramic radiographic, small picture ray, cone beam computed tomography). Furthermore a periodontal status will be performed.
40962115|NCT06535542|GENETIC|Whole Genome Sequencing|Participants in this arm will have their blood sample analyzed by whole-genome sequencing (WGS) and will be given access to Predictiv™ Deoxyribonucleic acid (DNA)-based digital twin platform, a web-based interactive application with WGS results. The platform will include positive monogenic and polygenic Familial Hypercholesterolemia results and pharmacogenomics results on statins and clopidogrel. A report of positive monogenic variants will be included in their medical record. This may also include genes on the American College of Medical Genetics and Genomics (ACMG) secondary findings (SF) version 3.2 list if the participant consents to receive these incidental findings. The report will only include pathogenic, likely pathogenic, and variant of uncertain significance (VUS) results.
40962116|NCT03198247|OTHER|Usual care|"The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
40764829|NCT06627049|OTHER|Interviews|Evaluate the strategies used to facilitate VR implementation.
40962117|NCT03198247|OTHER|PNE + CST|The PNE and CST program will be divided in 3 individual sessions.
40962118|NCT05797675|PROCEDURE|prf + osseodensification|prf+ osseodensification in close sinus lift
40962119|NCT01376284|DRUG|Dutasteride|Collection of safety data
40962120|NCT01760460|DRUG|Anacetrapib|
40962121|NCT01760460|DRUG|Placebo for anacetrapib|
40962122|NCT01595932|DIETARY_SUPPLEMENT|α-galactosidase|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet."
40962123|NCT01595932|DIETARY_SUPPLEMENT|Placebo|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet."
40962124|NCT02428517|PROCEDURE|AlloHCT for Young/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
41136244|NCT01517503|BEHAVIORAL|Cognitive Therapy|This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
41136245|NCT01517503|BEHAVIORAL|Acceptance and Commitment Therapy|This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
41136246|NCT01366456|DEVICE|Moxibustion|Comparison of different kinds of moxibustion
41136247|NCT04012905|DRUG|Corticosteroids for Systemic Use|"Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month"
41136248|NCT02956109|DRUG|Finerenone (BAY94-8862): 1 0mg tablet|10 mg finerenone immediate-release tablet; single dose in the fasting condition
41136249|NCT02956109|DRUG|Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
41136250|NCT02956109|DRUG|Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet|1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
41456296|NCT00421863|DRUG|Lasix 25|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
41136251|NCT05283018|DEVICE|Electroencephalogram recording|Brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
41136252|NCT05283018|OTHER|Auditory stimulation|Monotonous sounds are sent via binaural headphones: a standard item and a distractor item (rough sound). Each stimulus lasts about 300 ms and they are separated by 1.5 to 2 seconds between them; the deviant sound/standard sound ratio is fixed between 1/5 and 1/6.
41136253|NCT05283018|DEVICE|Transcranial Doppler|Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography. For all patients, CFV (unit cm/s) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at inspired oxygen fraction (FiO2) of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period.
40764830|NCT06357377|DRUG|NEO100|"NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol.~NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol."
40764831|NCT06087536|DRUG|OMN6|"Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days"
40764832|NCT06087536|DRUG|Placebo|3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
40764833|NCT05888233|DRUG|Allopurinol|Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then increased to 600mg/daily for an additional 4 weeks.
40764834|NCT03999424|BIOLOGICAL|autologous human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
40764835|NCT04510740|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
40764836|NCT04987775|DRUG|N-Acetyl Cysteine|900mg 2x daily
40764837|NCT04987775|DRUG|Placebo|Matching placebo bid
40962125|NCT02428517|PROCEDURE|AlloHCT for Young/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
41293906|NCT02951546|DIETARY_SUPPLEMENT|Low fat diet|In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.
41136254|NCT05283018|DEVICE|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at FiO2 of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period."
41293907|NCT02951546|OTHER|Aerobic exercise|"A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type)."
41293908|NCT05715125|DRUG|Dose A VTX958|Dose A VTX958
40764838|NCT05359237|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40764839|NCT05359237|DRUG|Vincristine|Given IV per standard of care
40764840|NCT06643663|PROCEDURE|Endodontic Micro-Surgery|Pt with apico-marginal defects with interproximal bone loss receiving Endodontic surgery following failure of non surgical root canal treatment.
41136255|NCT04176952|DRUG|FOLFOX-A|"* nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)"
41136256|NCT04176952|DRUG|AG|"* nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~* Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
41136257|NCT02799849|OTHER|Sleep and metabolism assessment|
41136258|NCT02430766|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
41136259|NCT02430766|DEVICE|NanoKnife|
41136260|NCT01229176|BIOLOGICAL|Vi-CRM197 vaccine|
41136261|NCT01229176|BIOLOGICAL|Vi Polysaccharide (PS) vaccine|
41136262|NCT01229176|BIOLOGICAL|Pneumococcal conjugate vaccine|
41293909|NCT05715125|DRUG|Dose B VTX958|Dose B VTX958
41293910|NCT05715125|DRUG|Placebo|Placebo
40764841|NCT06644963|DEVICE|Impella (5, 5.5 or CP)|Impella (5, 5.5 or CP) as an isolated circulatory support or combined with others Temporary Mechanical Circulatory Support
41293911|NCT02590679|DEVICE|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
41293912|NCT00898144|OTHER|Papanicolaou test|
41293913|NCT00898144|OTHER|laboratory biomarker analysis|
41293914|NCT01401829|BEHAVIORAL|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
40764842|NCT04315922|DIAGNOSTIC_TEST|Microbiome and Plasma Characterisation|Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing
40764843|NCT05715281|BIOLOGICAL|Atezolizumab|Given IV
40764844|NCT05715281|PROCEDURE|Biopsy|Undergo tumor biopsy
40962126|NCT02428517|PROCEDURE|AlloHCT for Old/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
41136263|NCT02356198|DRUG|EXPAREL|transversus abdominis plane injection
40764845|NCT05715281|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40764846|NCT05715281|PROCEDURE|Computed Tomography|Undergo CT scan
40764847|NCT05715281|PROCEDURE|Echocardiography|Undergo ECHO
40764848|NCT05715281|DRUG|Tiragolumab|Given IV
40764849|NCT06640270|DEVICE|Diabetes Treatment|Lucie™ is an innovative medical device for measurement by bio-impedancemetry. It has been developed specifically to meet medical needs in nephrology. The aim of the study is to compare its performance with a reference device validated in nephrology nephrology, the Body Composition Monitor® (BCM) from Fresenius.
40764850|NCT05935150|PROCEDURE|Omit SLNB|All patients enrolled have to receive two or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, axillary surgery will be omitted for eligible patients, and BCS or mastectomy (allowing breast reconstruction) will be chosen voluntarily by the patient under the premise of ensuring therapeutic efficacy, patients receiving BCS must undergo whole breast irradiation (WBI) after surgery, and the radiotherapy target area does not include the axillary region.
41136264|NCT02356198|DRUG|Intrathecal hydromorphone|Intrathecal opioid administration
41293915|NCT01401829|BEHAVIORAL|75 weekly minutes walking|12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
41293916|NCT01401829|BEHAVIORAL|Stretching/Flexibility exercise|12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
41293917|NCT00401583|DRUG|GW786034 (pazopanib)|Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
41293918|NCT00401583|DRUG|Probe drugs|probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).
41293919|NCT02232646|DRUG|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
40764851|NCT04169009|BIOLOGICAL|Zostavax|Intradermal injection of Zostavax
40764852|NCT04169009|BIOLOGICAL|Shingrix|Given to subjects in Arm 4 who've never had a herpes zoster vaccine
40764853|NCT06469021|OTHER|Conservative Approach|Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the individuals. In a one session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises and 10 minutes of balance training will be applied. The exercises will start from an easy level and the level of difficulty will be gradually increased. The assessments will be evaluated in three stages: at the beginning of treatment, at the third month of treatment and at the end of treatment (sixth month).
40764854|NCT06469021|OTHER|Rehabilitative Game Therapy|Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the patients and will be applied to the patients with a conventional approach. In a one-session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises, and 10 minutes of balance training will be applied in the clinical setting. Home exercises will be performing with the SmartPose system differently from the control group. The SmartPose system is a special software system that enables the user to perform movements with a tablet or phone without the need for any sensors.
40764855|NCT06052553|DEVICE|TopSpin360|Helmet training device used to train head to stay stable during jarring impacts through dynamic and multi-planar neck strengthening.
40764856|NCT04467489|OTHER|observational|There is no intervention for any group in this observational study.
40764857|NCT06191445|PROCEDURE|Conventional Landmark Technique|The investigator will perform spinal anesthesia using the conventional landmark technique.
40764858|NCT06191445|PROCEDURE|Ultrasound Assisted Technique|The investigator will perform spinal anesthesia using the ultrasound assisted technique.
40764859|NCT06191445|PROCEDURE|Real-Time Ultrasound Guided Technique|The investigator will perform spinal anesthesia using the real-time ultrasound-guided technique.
40764860|NCT06264596|DRUG|Epinephrine|The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag
40764861|NCT06264596|PROCEDURE|Normal Saline irrigation fluid|The control group will have two 3-L normal saline solution bags prepared with no additive
40764862|NCT06638944|BEHAVIORAL|In-person sEMG-biofeedback|Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions in the clinic and 3 days of home practice per week using the i-Phagia sEMG system. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
40764863|NCT06638944|BEHAVIORAL|Remote sEMG-biofeedback|Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions completed remotely (via telehealth) and 3 days of home practice per week. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients also use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
40764864|NCT06638944|BEHAVIORAL|Standard-of-care treatment|Participants in this intervention will complete the same standardized behavioral swallowing rehabilitation protocol and in the same frequency as the sEMG biofeedback intervention groups but WITHOUT a device. That is, they will complete the protocol for 12 weeks with weekly (once per week) treatment sessions completed in-person and 3 days of home practice per week. For this intervention group, patients use a visual analog scale and a timer as feedback tools, as frequently done in clinical practice where sEMG devices are not widely available.
40962127|NCT02428517|PROCEDURE|AlloHCT for Old/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
40962128|NCT02818400|PROCEDURE|composite tissue allotransplantation|
40962129|NCT06558513|DRUG|XNW5004 tablets|XNW5004 an EZH2 inhibitor, BID, administered in continuous
41293920|NCT03792919|DRUG|Stop current treatment (anti-HBV neucleos(t)ides)|Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
41293921|NCT03792919|DRUG|Keep current treatment (anti-HBV neucleos(t)ides)|Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
41293922|NCT06070623|DEVICE|US|We use elastography and color Doppler from US machine and compare results with CT
41293923|NCT02243527|OTHER|Inspiratory Muscle Training|6-weeks of inspiratory muscle training
41293924|NCT02243527|OTHER|Sham Inspiratory Muscle Training|A sham training procedure that is meant to elicit no physiologic changes
41456297|NCT00421863|DRUG|Micardis 80 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
40764867|NCT05669846|DRUG|Fecal Microbiota Transplant (FMT)|FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by performing a colonoscopy and sigmoidoscopy. The FMT consists of introducing normal bacterial flora contained in the stool collected from a donor into the small intestine. In this case, the donors are patients with advanced metastatic non-small cell lung cancer (NSCLC) who have undergone PD-1 therapy (nivolumab or pembrolizumab) and are currently in a durable remission that is ongoing. The FMT will be performed on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.
40962130|NCT01427686|DRUG|Dobutamine|Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
41136265|NCT04239768|DEVICE|MonoDermà HA gel combined to a low level laser|"Two intradermal injections of the filler were performed during the basal and after 1 month, on the middle and inferior third of the face (1ml for each face side) using a needle (30G).~Immediately after both injection procedures, LLLT session were performed on the same face area for a total of 8 minutes, using three different wavelengths (450 nm, 650 nm and 1064 nm) simultaneously."
41136266|NCT02540369|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
41136267|NCT00426205|BIOLOGICAL|GM-CSF secreting leukemia vaccine|Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.
41136268|NCT00849446|DEVICE|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
41136269|NCT01911559|DEVICE|standing-frame|
41136270|NCT01042184|DRUG|Sequential therapy for 14 days|D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
41136271|NCT01042184|DRUG|Sequential therapy for 10 days|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
41136272|NCT01042184|DRUG|Triple therapy for 14 days|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
41136273|NCT00286325|DRUG|Rituximab|Infusion of 1000 mg of rituximab on day 0 and day 14
41136274|NCT04987528|DIAGNOSTIC_TEST|Aminoterminal type III peptide of procollagen|Serial Measurement of PIIINP in serum and/or BAL
41136275|NCT04987528|DIAGNOSTIC_TEST|Lung computed tomography|Screening for the presence of reticulation or bronchiectasia within lung parenchyma
41136276|NCT04903080|BIOLOGICAL|HER2 Specific CAR T Cell|HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.
41136277|NCT06301620|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
41136278|NCT06301620|BEHAVIORAL|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
41136279|NCT01215747|DRUG|KIACTA (eprodisate disodium)|Orally 1 to 3 capsules (Kiacta 400 mg) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases.
41136280|NCT01215747|DRUG|Placebo|Orally 1 to 3 capsules (placebo) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases:
40962131|NCT01427686|DRUG|Dopamine|Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
40962132|NCT02963792|OTHER|Preventing Professionals burnout|
41136281|NCT05424328|PROCEDURE|ALTF (Anterolateral thigh flap) with preoperative virtual planning|In this study group, using preoperative CTs (head \& neck and thigh ) to virtually plan a guide that can be used during the surgery, this guide will determine the design and dimensions of the Alt flap to be harvested and restore the defect left on the tongue due SCC resection and hemi glossectomy.
41136282|NCT05424328|PROCEDURE|ALTF (Anterolateral thigh flap) with conventional method|ALTF (Anterolateral thigh flap) will be harvested with conventional method which depends on surgeon's own experience in determining the flap design and dimensions needed to reconstruct and restore the defect left on the tongue due SCC resection and hemi glossectomy.
41136283|NCT02188459|DRUG|Bupropion|A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
41293925|NCT04942418|OTHER|Multicolor hybrid ceramic laminate veneers.|Multi shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
41456298|NCT00421863|DRUG|Micardis plus 80/12.5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
41456299|NCT00421863|DRUG|Catapresan TTS 2|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
41456300|NCT00421863|DRUG|Norvasc 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
40962133|NCT03159624|OTHER|Biodesign™ SIS graft|2x3 cm Biodesign™ SIS perforated mesentery graft
41293926|NCT04942418|OTHER|Multicolor fieldspathic ceramic laminate veneers.|the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
40962134|NCT03159624|OTHER|Doyle silastic sheet|Doyle silastic sheet
41293927|NCT06340204|DRUG|Irinotecan Hydrochloride Liposome Injection|Irinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).
41293928|NCT02905773|OTHER|root canal therapy|effect of devices ( ProTaper and Reciprocal Files)
41293929|NCT02905773|OTHER|root canal retreatment|effect of devices ( ProTaper and Reciprocal Files)
41293930|NCT00573131|DRUG|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
41456301|NCT00421863|DRUG|Triatec 5 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
41293931|NCT00573131|DRUG|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
41456302|NCT00421863|DRUG|Pluscor|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
41456303|NCT00776867|DRUG|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
41456304|NCT01965093|PROCEDURE|perioperative desaturation|children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation
41456305|NCT01965093|PROCEDURE|no perioperative desaturation|children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
41456306|NCT02641873|DRUG|BBI608|240 mg twice daily (480 mg total daily dose)
41456307|NCT02641873|DRUG|5-FU|400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
40764868|NCT05669846|DRUG|Pembrolizumab|Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle.
40764869|NCT01225224|DRUG|peficitinib|oral
40764870|NCT01225224|DRUG|Placebo|oral
40962135|NCT02298608|DEVICE|Nano Knife|Percutaneous, CT guided, ablation of renal mass
41293932|NCT00573131|DRUG|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
41456308|NCT02641873|DRUG|Irinotecan|180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
41456309|NCT02641873|DRUG|Levofolinate|200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
41456310|NCT02641873|DRUG|Bevacizumab|5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
40764871|NCT06361836|BIOLOGICAL|SBT777101|Experimental treatment
40764872|NCT06637072|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection of efgartigimod PH20 SC
40764873|NCT06645106|DEVICE|Rapid Point of Care (POC) Syphilis testing|Participants will undergo the point of care (POC) FDA cleared syphilis health check (SHC) POC test by a research staff using 50 microliters or 1-3 drops of whole blood via finger stick. The analyzer is handheld, and all testing equipment is temperature stable and does not need refrigeration. The SHC-Syphilis results will be available within 10 minutes of receipt given the published turnaround time to results of 15 minutes per package insert and will be recorded as a research note in the electronic medical record (EMR) while the provider assigned to the patient and the Houston Health Department will be notified of results and further treatment will be done if results are positive.
40764874|NCT06643286|DEVICE|Digizorg Melanoma app|The Digizorg Melanoma app is a digital survivorship care plan, in which ellaborated information regarding diagnosis, treatment and follow-up and supportive care, adjusted to one's personal preferences and disease characteristics, is offered in the form of a mobile application.
40764875|NCT05755958|DEVICE|HIFU treatment in rectal Endometriosis|HIFU treatment of rectal endometriosis
40764876|NCT05755958|DEVICE|SHAM HIFU procedure|SHAM HIFU procedure
40764877|NCT03258554|BIOLOGICAL|Cetuximab|Given IV
40764878|NCT03258554|BIOLOGICAL|Durvalumab|Given IV
40764879|NCT03258554|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40764880|NCT03258554|OTHER|Laboratory Biomarker Analysis|Correlative studies
40764881|NCT03258554|OTHER|Quality-of-Life Assessment|Ancillary studies
40764882|NCT03258554|OTHER|Questionnaire Administration|Ancillary studies
40764883|NCT04783571|OTHER|Placebo|Auditory stimulation will not be delivered during the nap
40764884|NCT04783571|OTHER|Auditory Stimulation|Auditory stimulation will be delivered during the nap
41293933|NCT00573131|RADIATION|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
41293934|NCT00573131|PROCEDURE|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
41293935|NCT03856073|BEHAVIORAL|Novice|Using the simulate device, the novices in bronchoscopy are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
40962136|NCT05881538|OTHER|Exercise group|Participants will perform a 16-week High Intensity Interval Training exercise program, twice a week. The intervention will be conducted telematically with real time supervision.
40962137|NCT04746963|DRUG|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye (low dose)
40962138|NCT04746963|DRUG|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)
40962139|NCT04746963|DRUG|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye (high dose)
41136284|NCT01501825|DEVICE|5 channels Multiway deep Transcranial Magnetic Stimulator|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
41136285|NCT01501825|DEVICE|five channels Multiway deep Transcranial Magnetic Stimulation|"During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)"
41456311|NCT00327457|BEHAVIORAL|Help with physician office and patient management|
41456312|NCT00327457|BEHAVIORAL|Tailored physician recommendation letter|
40962140|NCT05211362|BIOLOGICAL|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
40990614|NCT00985842|DEVICE|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
40990615|NCT00985842|DEVICE|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
40990616|NCT00985842|DEVICE|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
40990617|NCT00985842|DEVICE|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
40990618|NCT00985842|DEVICE|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
40990619|NCT03475966|OTHER|Exercise|A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)
40990620|NCT03475966|OTHER|Nutrition|Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
40990621|NCT03475966|BEHAVIORAL|Relaxation techniques|Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.
40990622|NCT06528522|DIAGNOSTIC_TEST|Clinical Measurements and Saliva Sample Collection|"Saliva samples will be collected from all participants, and comprehensive clinical parameters will be meticulously documented. The Plaque Index (PI) and Gingival Index (GI) will be measured at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be recorded in detail for each tooth at six sites. The percentage of bleeding areas will be assessed within 20 seconds post-probing using a binary scoring system to indicate presence or absence. All clinical parameters will be recorded by a calibrated periodontologist utilizing manual probing techniques.~Following collection, saliva samples will be stored at -80°C until subsequent analysis. Concentrations of IL-39, IL-41, IL-1β, and TNF-α in the saliva samples will be quantified using specific enzyme-linked immunosorbent assay (ELISA) kits."
40990623|NCT04174287|DRUG|F-18-AV45|The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
40990624|NCT01487590|OTHER|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
40990625|NCT01487590|OTHER|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
40990626|NCT03807011|DRUG|fentanyl group|fentanyl 2 μg/kg
40990627|NCT03807011|DRUG|remifentanil group|remifentanil 0.2 μg/kg/min
40962141|NCT05211362|BIOLOGICAL|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
40962142|NCT04667871|PROCEDURE|cataract surgery|Eyes for cataract surgery
41293936|NCT00632034|OTHER|CD34+ haemopoietic stem cells|Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
40962143|NCT03100500|DRUG|QMF149|QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
41136286|NCT01156454|PROCEDURE|X-ray|surgical specimen taken to radiology and contents x-rayed
41136287|NCT02060084|DRUG|a control group|the same dose of luke warm water
41293937|NCT00000289|DRUG|Ondansetron|
41293938|NCT01050179|OTHER|carbon dioxide|sinusoidal carbon dioxide delivery
41293939|NCT00100373|DRUG|RSV challenge material|
41293940|NCT06082947|DEVICE|CliniMACS®|CliniMACS® αβT cell/CD19+B cell depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
40764885|NCT06413914|BEHAVIORAL|Cognitive behavioral Therapy|"Cognitive behavioral therapy is the psychological approach in this study. It is associated with better outcomes of rehabilitation for long-term pain in general, reduced pain intensity and less use of medication and health services, sustaining factors that provide an understanding of how thoughts and feelings affect the experience of pain. An important aim is also a reduction in pain-related rumination and worry and changed metacognition that maintains inhibiting behavior and thought patterns.~A workbook for pain has been developed. It contains knowledge about pain and pain management, describes measures and homework from session to session. The treatment consists of 8 sessions with 7 weekly sessions + 1 booster session 2 months after the end of treatment.~."
40764886|NCT06645028|BEHAVIORAL|Intensive treatment programme|"Intervention Group: 8-day intensive treatment where each treatment day consists of the following schedule:~Physical activity: 30 minutes Prolonged Exposure (PE): 90 minutes Physical activity: 30 minutes Lunch Physical activity: 60 minutes Eye Movement Desensitization and Reprocessing (EMDR): 90 minutes Physical activity: 30 minutes (omitted on days 4 and 8) Dinner Psychoeducation (omitted on days 4 and 8) Participants stay at the SÄS patient hotel during the treatment (with a three-day weekend break between treatment days 1-4 and 5-8). The treatment concept includes therapist rotation, meaning that participants switch therapists between PE and EMDR sessions. The purpose of this is to increase focus on the processing process rather than the relationship between the therapist and the client."
40764887|NCT06645028|BEHAVIORAL|Treatment as Usual (TAU)|Control group: 16 treatment sessions (90 minutes in duration) either Eye movement desensitisation and reprocessing (EMDR) or Prolonged Exposure (PE) in a standard outpatient format-weekly sessions. Participants can choose to attend 6 sessions of Psychoeducation for PTSD in a group format before starting EMDR or PE.
40764888|NCT06644365|OTHER|Acupresure mat|The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.This practice will continue for three menstrual cycles.
40764889|NCT06644365|OTHER|Basic mat|The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.Participants in this group will also be sent a reminder message similar to the intervention group. This practice will continue for three menstrual cycles.
40764890|NCT06132204|DRUG|HRS-7535 Tablets|HRS-7535 Tablets
40764891|NCT05687578|DIAGNOSTIC_TEST|Measurements Only|This is an observational study only using biospecimen and imaging-based measurements only
40764892|NCT04353492|BIOLOGICAL|Ofatumumab|Subjects will receive ofatumumab injections in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)
40764893|NCT06097260|DRUG|PLN-74809|PLN-74809
40764894|NCT06097260|DRUG|Placebo|Placebo
40764895|NCT04482803|DRUG|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes|Before NST, one of the clinically assesed positive lymph nodes will be subjected to ultrasound-guided CNB or FNA, and a locating clip (Ultraclip, BARD) will be placed. Meanwhile, a small amount of Kanarine (carbon nanoparticles suspension injection, 0.5ml:25mg, H20073246) will be injected into or around the cortex of the locating lymph node and other clinically assessed positive lymph nodes. Preoperative FNA will be performed again for locating clip labelled node.
40764896|NCT06634771|DEVICE|10 Hz transcranial alternating current stimulation (tACS)|10 Hz bi-frontal tACS: Alternating current stimulation is delivered by an XCSITE 100 device (Pulvinar Neuro, Chapel Hill, NC), through three conductive carbon-rubber electrodes. Electrodes are placed over the apex of the head (Cz) and the prefrontal cortex bilaterally (F3 and F4). Stimulation is delivered during the second half of the HABIT Test session. Stimulation parameters: 2mA peak-to-peak 10Hz sine-wave flanked by 10 second linear envelope ramps in and out for a total duration of 30 min and 20 seconds.
40764897|NCT06634771|DEVICE|sham transcranial alternating current stimulation (tACS)|Sham tACS: The procedure for sham stimulation will be identical, but it will last for 2 minutes instead of 30 minutes.
40962144|NCT01337232|BEHAVIORAL|Complex sentence treatment protocol|Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
40962145|NCT02644135|DRUG|Halo Oral Spray|Three sprays per use, total = 9 sprays per day
40962146|NCT02644135|DRUG|Halo Placebo|Three sprays per use, total = 9 sprays per day
40962147|NCT03482544|DRUG|Pragabalin|pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.
40962148|NCT03482544|OTHER|Placebo|empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.
40962149|NCT02376231|DEVICE|Surgery for EOC with trial (PJ) device (PlasmaJet)|Debulking surgery for EOC using PJ device
40962150|NCT06079021|DEVICE|CytoSorb|Application of CytoSorb treatment for 72 hours in patients with ACLF
40962151|NCT04058730|PROCEDURE|Laparoscopic Roux en Y Gastric by pass surgery|
40962152|NCT04058730|PROCEDURE|Laparoscopic Sleeve Surgery|
40962153|NCT04058730|OTHER|Standard Medical Management|
40962154|NCT04833881|OTHER||
40764902|NCT04285567|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
40764903|NCT04285567|DRUG|Venetoclax|Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.
40962155|NCT06404502|BEHAVIORAL|PRISMA|"PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants;~PRISMA has four sessions."
40962156|NCT00675493|DRUG|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
40962157|NCT02784431|DEVICE|Contour Neurovascular System placement|Patients who meet the eligibility criteria will have their target aneurysm treated with the Contour Neurovascular System device via standard endovascular procedure.
40962158|NCT00096798|DRUG|Ethyl-eicosapentanoic acid (ethyl-EPA)|
40962159|NCT06099197|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
40764904|NCT04285567|DRUG|Fludarabine|Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m\^2), IV, on days 1, 2, and 3 of Cycles 1-6.
40764905|NCT04285567|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in a dosage of 250 mg/m\^2, IV, on Days 1, 2, and 3 Cycles 1-6.
40764906|NCT04285567|DRUG|Rituximab|Rituximab will be administered at a dose of 375 mg/m\^2, IV, on Cycle 1, Day 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
40962160|NCT06099197|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
40962161|NCT01063452|DEVICE|Truvalve|Atkinson Product Design urinary slide valve
40962162|NCT01063452|OTHER|Control (catheter drainage bag)|urinary catheter drainage bag
40962163|NCT02877303|BIOLOGICAL|Blinatumomab|Given IV
40962164|NCT02877303|DRUG|Cyclophosphamide|Given IV
40962165|NCT02877303|DRUG|Cytarabine|Given IT and IV
40962166|NCT02877303|DRUG|Dexamethasone|Given PO
40962167|NCT02877303|DRUG|Doxorubicin Hydrochloride|Given IV
40962168|NCT02877303|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
40962169|NCT02877303|OTHER|Laboratory Biomarker Analysis|Correlative studies
40962170|NCT02877303|DRUG|Mercaptopurine|Given PO
40962171|NCT02877303|DRUG|Methotrexate|Given IT, IV, and PO
40962172|NCT02877303|BIOLOGICAL|Ofatumumab|Given IV
40962173|NCT02877303|DRUG|Prednisone|Given PO
40962174|NCT02877303|BIOLOGICAL|Rituximab|Given IV
40962175|NCT02877303|DRUG|Vincristine Sulfate|Given IV
40962176|NCT03044678|BEHAVIORAL|REACH for Success|Exposure-based cognitive behavioral with social skill training (cognitive self control, relaxation, skills for conversations and assertiveness)
40962177|NCT03044678|BEHAVIORAL|Self-Study|Books for youth about anxiety management
40764907|NCT04285567|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m\^2, IV, on 2 consecutive days of Cycles 1-6.
40764908|NCT06511401|OTHER|Pharmacogenomic (PGx) results.|These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
40962178|NCT05970562|DEVICE|Ambulatory Voice Monitoring with Biofeedback (AVM-B)|AVM-B is software on the Voice Health Monitor that uses a neck-placed accelerometer to sense neck skin vibrations during voicing in daily life. The AVM-B consists of cues every time the patient exceeds a subject-specific threshold, \[100% frequency AVM-B\] and/or summary statistics every 2 minutes of voicing \[Summary AVM-B\].
40962179|NCT05970562|BEHAVIORAL|Conversation Training Therapy|CTT is a 4-week (1 45-minute session per week) evidence-based voice therapy for patients with VH, developed primarily to maximize the amount and speed of generalization outside the therapy session. It consists of 3 required targets: Decreased overall auditory-perceptual voice severity, improved discrimination between baseline and improved voicing, and adherence to CTT recommendations in daily life. The three optional targets are decreased overall auditory-perceptual severity across an increased pitch range, loudness range, and decreased rate of speech. All voice-related targets are modified through practicing voicing with increased forward resonance and mean airflow in spontaneous speech/conversation.
40962180|NCT06413563|DIAGNOSTIC_TEST|Complete blood count|"Complete blood count will be done for all patients and then will search about CD4, CD8 T lymphocyte cells surface markers~* CD56 Natural killer cells surface marker~* CD19 Lymphocyte cells surface marker"
40962181|NCT06066164|DEVICE|Transcranial magnetic stimulation (TMS)|Trans-cranial magnetic stimulation (TMS) is a safe and painless technique for evoking activity in neurons in the human brain through the intact scalp and skull To measure cortical excitability
40962182|NCT02914470|DRUG|carbplatin, cyclophophamide, atezolizumab|
40962183|NCT04337801|OTHER|Acupressure|The acupressure for symptom management is performed by pressing and scrubbing-like manipulations at certain points on the acupuncture meridians.
40962184|NCT04337801|OTHER|Placebo|The placebo intervention involves touching to the Pericardium 6 and Large Intestine 4 points without pressing.
40962185|NCT01696084|DRUG|CPX-351|First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
40962186|NCT01696084|DRUG|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2."
40962187|NCT05193370|DRUG|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring hormone of the same name, peptide hormone of the renin-angiotensin-aldosterone system (RAAS), that was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
40962188|NCT05193370|DRUG|Vasopressin|Vasopressin (Vasostrict) is a pharmacologic version of a naturally occurring peptide hormone that serves as a vasoconstrictive agent in the treatment of vasodilatory shock.
40962189|NCT03464578|PROCEDURE|Therapy of proximal humeral fractures (irrespective conservative or operative)|
40962190|NCT05111171|DEVICE|sheath|Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.
40962191|NCT03733470|DRUG|Sildenafil study group|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
40962192|NCT04850521|OTHER|Remote monitoring|patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
40962193|NCT02787668|OTHER|Carbohydrate-restricted diet|Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO \<10%; fat \>65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
40962194|NCT02787668|OTHER|Control, low-fat diet|Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
40962195|NCT00916097|DRUG|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
40962196|NCT00763620|DEVICE|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
40962197|NCT01919593|DRUG|2% chlorhexidine gluconate in 70% alcohol|skin preparation before venipuncture for blood culture in even month
40962198|NCT01919593|DRUG|10%povidone iodine|skin preparation before venipuncture for blood culture in odd month
40962199|NCT03050554|DRUG|Avelumab|Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
40962200|NCT03050554|RADIATION|SBRT|SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
40962201|NCT00006161|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|
40962202|NCT00006161|PROCEDURE|Distal Splenorenal Shunt|
40962203|NCT00004771|DRUG|leuprolide|
40962204|NCT00004771|DRUG|testosterone|
40962205|NCT03072147|DRUG|Teriparatide|20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
40962206|NCT03072147|DRUG|Placebo|20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
40962207|NCT05229406|BEHAVIORAL|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
40962208|NCT03597776|DRUG|Lidocaine|Bolus of lidocaine will be given over 5 minutes before skin incision
40962209|NCT03597776|DRUG|Saline|Bolus of saline will be given over 5 minutes before skin incision
40962210|NCT02971254|DRUG|Sevoflurane|
40962211|NCT02971254|DRUG|Desflurane|
40962212|NCT00848471|DEVICE|Quark RMR|Quark RMR calorimeter (Cosmed)
40962213|NCT00848471|DEVICE|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
40962214|NCT02077920|DRUG|Chlorhexidine|"SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~* Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~* Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving"
40962215|NCT02077920|DRUG|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
40962216|NCT02077920|DEVICE|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
40962217|NCT02077920|DEVICE|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
40962218|NCT00080470|DEVICE|bion|battery powered microstimulator
40962219|NCT02445508|DRUG|Sevelamer|
40962220|NCT02445508|DRUG|Cholecystokinin|
40962221|NCT02445508|DRUG|Sevelamer placebo|
40962222|NCT02445508|DRUG|Isotonic saline|
40962223|NCT00257543|PROCEDURE|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
40962224|NCT03703115|BEHAVIORAL|Fasting|No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours
40962225|NCT04465474|OTHER|Non Intervention|It's an observational study, no intervention involves.
40962226|NCT03886805|OTHER|Dual task with variable- and fixed-priority instructions|The participants were asked to perform dual-task activities focused, interchangeable or simultaneously, on balance (motor tasks) and on cognitive tasks performance, according to the instructional priority established by the physical therapist.
40962227|NCT03886805|OTHER|Dual-task with variable-priority instructions|The participants were asked to spend half the session focused on balance (motor tasks) and half the session focused on cognitive tasks performance, according to the instructional priority established by the physical therapist.
40962228|NCT00592943|DRUG|armodafinil|tablet, taken by mouth, once each study day
40962229|NCT02701400|BIOLOGICAL|Durvalumab|Given IV
40962230|NCT02701400|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
40962231|NCT02701400|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
40962232|NCT02701400|BIOLOGICAL|Tremelimumab|Given IV
40962233|NCT00978198|DRUG|ASP1517|oral
40962234|NCT00978198|DRUG|Placebo|oral
40962235|NCT01695590|DRUG|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
40962236|NCT00905411|BEHAVIORAL|PacDASH intervention|"Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study."
40962237|NCT05066854|PROCEDURE|integron research|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Urine samples will be sent to the laboratory for culture and integron PCR according to routine practice.~Results of the integron search will be given to the investigator. Patients in the experimental group with a positive or uninterpretable PCR will also receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines.~Patients in the experimental group with a negative PCR will receive a treatment with SXT at the recommended dose."
40962238|NCT05066854|PROCEDURE|usual practice|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Patients in the control group will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
40962239|NCT06039397|BEHAVIORAL|Semifowler 30' Right Lateral Body Position|Semifowler 30' Right Lateral Body Position Is a regulation of body position by placing the patient's body in a semi-fowler and lateral resting position of 30 degrees
40962240|NCT05865067|OTHER|Yoga Therapy|The intervention sessions will consist of 12 yoga therapy sessions, each one approximately 30 to 45 minutes long, it will be given once a week (on Saturdays) in a room in the building of the School of Health Professions in the Campus of Medical Sciences from the University of Puerto Rico.
40962241|NCT05865067|OTHER|Exercise|The wait-list control group will be motivated to exercise at home (except for Yoga).
40962242|NCT04370574|DIAGNOSTIC_TEST|Soluble Biomarkers dosage|"1. CytoLyt® fluid will be first processed for routine PDAC diagnosis. In essence, the samples are filtered, tissue fragments and cells are kept for analysis while flow-through is kept until the diagnosis is confirmed. Once this is completed, the samples will be transferred to the lab where the proteins found in the CytoLytR fluid will be precipitated and then solubilized. The protein extracts are stored at -80°C pending proteomic analysis. The remaining CytoLytR fluid supernatant is also stored at - 80°C to be used for metabolomics.~2. Blood sample will be collected from each patient that underwent diagnostic biopsy. Dry tube for serum analysis will be collected at the time of inclusion during the routine blood test. The serum samples are intended for the validation phase (WP4) and will be exclusively dedicated to this study."
40962243|NCT04605445|PROCEDURE|1 visit root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be completed in the same visit or performed in another visit where cleaning, shaping and root filling procedures, temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
40962244|NCT04605445|PROCEDURE|2 visits root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be started, or performed in another visit, lasting 2 visits. In the first visit cleaning and shaping is performed and a medication is put in place in the canals, and the tooth is temporized until the next visit at least one week apart. In the second visit the tooth is root filled and temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
40962245|NCT04405583|DEVICE|Occlutech Atrial Flow Regulator|The Occlutech Atrial Flow Regulator is an interatrial shunt device for transcatheter delivery.
40962246|NCT00502047|DRUG|Plantago ovata husk|
40962247|NCT03800797|DRUG|Loxoprofen sodium hydrogel patch|100 mg per day
40962248|NCT03800797|DRUG|Loxoprofen sodium tablet|60 mg t.i.d.
40962249|NCT03943147|DRUG|BMS-986165|Specified dose on specified days
40962250|NCT03943147|DRUG|Placebo|Specified dose on specified days
40962251|NCT03943147|DRUG|Mycophenolate Mofetil|Specified dose on specified days
40962252|NCT00585143|DRUG|ABT-335|45 mg once daily for 10 consecutive days
40962253|NCT00585143|DRUG|Rosuvastatin|10 mg once daily for 10 days
40962254|NCT03589872|DIAGNOSTIC_TEST|Fine motor dexterity test, nine hole peg test|The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
40962255|NCT00003105|BIOLOGICAL|filgrastim|
40962256|NCT00003105|DRUG|cisplatin|
40962257|NCT00003105|DRUG|doxorubicin hydrochloride|
40962258|NCT00003105|DRUG|gemcitabine hydrochloride|
40962259|NCT00003105|DRUG|ifosfamide|
40962260|NCT00003105|DRUG|paclitaxel|
40962261|NCT01581788|DRUG|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
40962262|NCT02298920|DRUG|AZD0914|Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
40962263|NCT04023435|OTHER|PNE edcuation|The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
40962264|NCT01011777|DRUG|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10\^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10\^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
40962265|NCT01139489|OTHER|procalcitonin-guidance|If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
40962266|NCT04646837|DRUG|Durvalumab|Durvalumab 1000 mg IV Q3W for 2 cycle + Followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 1500mg Q4W for 8 months
40962267|NCT04646837|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 200-260 mg, depending on the patient's physical condition, for 2 cycle
40962268|NCT04646837|DRUG|Carboplatin/Cisplatin|Carboplatin AUC 6 IV Q3W or Cisplatin 80mg/㎡ for 2 cycle
40962269|NCT00263601|BIOLOGICAL|Allergovit 6-grasses|Subcutaneous injections
40962270|NCT00263601|OTHER|Placebo|Subcutaneous injections
41456313|NCT02233374|OTHER|Early MRI and PET/CT - 2 weeks after commencing chemo/RT|Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
40962271|NCT03118115|DEVICE|Measurement of the flap bioimpedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
40962272|NCT02868775|PROCEDURE|cystoscopy, bladder hydrodistention and bladder biopsy|
40962273|NCT02829632|BEHAVIORAL|Group Sessions|Participants will receive a 3-session behavioral lifestyle program for a healthful lifestyle and weight loss.
40962274|NCT02829632|BEHAVIORAL|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.
40962275|NCT02829632|BEHAVIORAL|Self-monitoring|Participants will receive an one-time how to self-monitor using the smartphone session.
40962276|NCT02151110|BIOLOGICAL|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
40962277|NCT02151110|BIOLOGICAL|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
40962278|NCT02151110|BIOLOGICAL|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
40962279|NCT02151110|BIOLOGICAL|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
40962280|NCT02151110|BIOLOGICAL|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
41456314|NCT02233374|OTHER|Late MRI and PET/CT 6 weeks post chemo/RT|Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
41456315|NCT00625339|DRUG|Entecavir|entecavir 0.5 mg QD
41456316|NCT00625339|DRUG|Lamivudine|lamivudine 100 mg QD
41456317|NCT00169130|DRUG|doxorubicin|
41456318|NCT00169130|DRUG|cyclophosphamide|
41456319|NCT00169130|PROCEDURE|Autologous stem cell transplantation|
40962281|NCT02151110|BIOLOGICAL|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
40962282|NCT02151110|BIOLOGICAL|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
40962283|NCT02151110|OTHER|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
40962284|NCT00795860|BEHAVIORAL|Weight loss - diet only|Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
40962285|NCT00795860|BEHAVIORAL|Weight loss plus exercise|Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
40962286|NCT01896102|GENETIC|Lenti-D Drug Product (eli-cel)|Participants received a single IV infusion of Lenti-D Drug Product.
40962287|NCT04511546|DEVICE|BPET Prototype Scan|Scan on the BPET Prototype PET system and qualitative comparison with a PET image acquired on a conventional clinical PET system.
40962288|NCT00989560|PROCEDURE|endoscopy|patients receive best treatment and care with an additional endoscopy
41293941|NCT00907140|PROCEDURE|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
41293942|NCT04901026|OTHER|An in-house manikin|Participants obtain an in-house manikin
41293943|NCT03196050|DEVICE|Handheld Device (Smart Phone)|"Handheld device will be used for 3 tasks:~1x per day: status update (how are you today?)~1x per week: 10 questions on general health status~1x per month: EORTC QLQ-C30 questionnaire"
41456320|NCT01231737|DRUG|prulifloxacin|Prulifloxacin 1 tablet/week for 12 weeks.
41456321|NCT05002140|DRUG|XRD-0394|Single ascending dose
41456322|NCT05002140|RADIATION|Palliative radiotherapy|4 Gy × 5 daily fractions
41456323|NCT00432705|PROCEDURE|Checking stability of ankle|Flexing and walking
40764909|NCT03845036|BEHAVIORAL|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
40764910|NCT03845036|BEHAVIORAL|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
40764911|NCT03369808|BIOLOGICAL|7.5μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
40764912|NCT03369808|BIOLOGICAL|Phosphate Buffer Solution|0.5ml phosphate buffer solution
40764913|NCT03369808|BIOLOGICAL|Aluminum Hydroxide Adjuvant|0.5ml aluminum hydroxide adjuvant
40764914|NCT03369808|BIOLOGICAL|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
40764915|NCT03369808|BIOLOGICAL|30μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
40764916|NCT06063551|PROCEDURE|Testicular Biopsy|Testicular biopsy for clinical storage and laboratory research.
40764917|NCT05359562|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.
40764918|NCT04975646|BEHAVIORAL|Prescribed exercise program|Active or passive exercises for the spastic upper limb, including functional electrical stimulation (FES), performed regularly for two weeks.
40764919|NCT05418426|DEVICE|IVR Dose 1|Estradiol 80 ug/progesterone 4 mg
40764920|NCT05418426|DEVICE|IVR Dose 2|Estradiol 160ug/progesterone 8 mg
40764921|NCT05418426|DRUG|Oral Reference|estradiol 1mg/progesterone 100 mg
40764922|NCT02516813|DRUG|M3814 100 mg|Participants received 100 mg of M3814 as capsule or tablet orally once daily.
40764923|NCT02516813|DRUG|M3814 200 mg|Participants received 200 mg of M3814 as capsule or tablet orally once daily.
40764924|NCT02516813|DRUG|M3814 300 mg|Participants received 300 mg of M3814 as capsule or tablet orally once daily.
40764925|NCT02516813|DRUG|M3814 400 mg|Participants received 400 mg of M3814 as capsule or tablet orally once daily.
40764926|NCT02516813|DRUG|M3814 50 mg|Participants received 100 mg of M3814 as capsule orally once daily.
40764927|NCT02516813|RADIATION|Fractionated RT|Participants received fractionated palliative RT (3 Gray \[Gy\] \* 10 in Arm A and 2 Gy \* 33 to 35, 5 fractions per week \[F/W\]) in Arm B and received a single high dose of RT (10-25 Gy) capsule on Day 1 given on Lesion 1 and a single high dose of RT (10-25 Gy) on Day 2 given on Lesion 2 in ancillary CPoP part.
40764928|NCT02516813|DRUG|Cisplatin|Participants received Cisplatin twice at a dose of 100 mg/m\^2 or weekly at a dose of 40 mg/m\^2.
40764929|NCT06643754|DRUG|SHR-3276|"Dose Escalation: SHR-3276 will be administered intravenously. 4 dose levels are preset.~Dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage.~Indication Expansion: Indications will be selected to evaluate preliminary efficacy."
40764930|NCT06636721|BEHAVIORAL|LuCA Behavioral Intervention|The intervention will integrate aspects of Cognitive Behavioral Therapy (identifying and challenging automatic thoughts, engaging in behavioral activation) and Acceptance and Commitment Therapy (integrating one's values, distancing skills). The intervention will include skills such as problem-solving, communicating with close others and the medical team, and breathing techniques to improve shortness of breath related to lung cancer.
40764931|NCT03452202|DEVICE|Soterix 1x1 line tDCS low-intensity stimulator|Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.
40764932|NCT03452202|DEVICE|Sham|Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
40962289|NCT02955160|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
40962290|NCT02955160|BIOLOGICAL|Tdap|Tetanus, diphtheria, and pertussis vaccine
41293944|NCT02739698|DRUG|Paclitaxel|
41293945|NCT02739698|PROCEDURE|Radical surgery-peritonectomy|
41293946|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
41456324|NCT00866580|BIOLOGICAL|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
41293947|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
41293948|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
41456325|NCT00866580|BIOLOGICAL|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
41456326|NCT00866580|BIOLOGICAL|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
41456327|NCT04785053|DEVICE|transcranial alternating current stimulation (tACS)|The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
40962291|NCT03204019|DRUG|Tegafur and Temozolomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
40962292|NCT03204019|DRUG|Tegafur and Temozolomide combined with Thalidomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
40962293|NCT00566995|DRUG|ZACTIMA (Vandetanib) (ZD6474)|
41456328|NCT02573662|BIOLOGICAL|Blood and Urine sampling|Blood and Urine Sampling
41456329|NCT02573662|RADIATION|DXA scan|Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
41456330|NCT02573662|BIOLOGICAL|OGTT|Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
41456331|NCT04543084|BEHAVIORAL|Logbook|Participants will record practice in a logbook.
40962294|NCT00266734|DEVICE|RPS Adeno Detector|
40962295|NCT00110838|PROCEDURE|Supplementation with fish oil versus placebo|
40962296|NCT02656537|DEVICE|EnSite™ HD Grid Catheter mapping system|
40962297|NCT03702985|RADIATION|Radiation|Pelvic Radiation: 50Gy/25Fx
40962298|NCT03702985|DRUG|Capecitabine|625mg/m2 bid Monday-Friday per week
41456332|NCT03485027|DRUG|the rechallenge regimen|XELOX regimen: Oxaliplatin 130mg/m2, intravenous, on day 1; Capecitabine 1000mg/m2, oral, twice daily, continuously for 14 days; ±bevacizumab 7.5mg/kg, intravenous, on day 1; repeating every 3 weeks. FOLFOX regimen: Oxaliplatin 85mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. FOLFIRI regimen: Irinotecan 180mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours; ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Irinotecan monotherapy regimen: Irinotecan 180mg/m2 on day 1, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Raltitrexed contained regimen: Raltitrexed 3mg/m2 on day 1; ± Bevacizumab 7.5mg/kg, repeating every 3 weeks; Raltitrexed 2mg/m2 on day 1; ± Cetuximab 500mg/m2, repeating every 2 weeks.
40962299|NCT03702985|DRUG|Irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
40962300|NCT03702985|DRUG|Amifostine|400mg/m2 per week
40962301|NCT01435200|DRUG|Intravenous iron|Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
40962302|NCT00531323|DRUG|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
40962303|NCT00531323|DRUG|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
40962304|NCT05063604|DRUG|Citalopram|20 mg tablet one or twice daily for 12 weeks
40962305|NCT05063604|BEHAVIORAL|Psychotherapy|One session weekly for 12 weeks
40962306|NCT00785694|DRUG|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
40962307|NCT03974425|DRUG|Aflibercept Injection [Eylea]|intravitreal injection of Aflibercept in resistant DME.
40962308|NCT01784159|DRUG|Aspirin|Aspirin administration for 7 days
40962309|NCT01991769|BEHAVIORAL|47 min moderate intensity training|
40962310|NCT01991769|BEHAVIORAL|exercise healthy volunteers|
40962311|NCT01991769|BEHAVIORAL|control; no exercise training|
41136288|NCT02060084|DRUG|a probiotic-supplemented group|was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live\>0.5\*107CFU), twice per day, for 2 weeks
41136289|NCT05681611|DRUG|Rocuronium|Rocuronium bolus was administered, according to our protocol, to facilitate surgery and ventilation.
41136290|NCT04284085|OTHER|Psychoeducational intervention|Psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
41136291|NCT01794299|BIOLOGICAL|ATIR|Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
41136292|NCT03610620|PROCEDURE|Vivascope 2500 ex-vivo fluorescent confocal microscope|scanned with the Vivascope 2500
41136293|NCT06412094|OTHER|Standard care|Recommendation of standard treatment plan, according to the clinical severity of the AD, and. are instruction to contact the doctor via messenger for any questions related to treatment recommendations.
41136294|NCT06412094|BEHAVIORAL|"Access to the AtopicApp mobile application"|"Access to the AtopicApp mobile application with 1 day after enrollment."
41136295|NCT06412094|BEHAVIORAL|Virtual oversight through the AtopicApp|Notification of doctor's virtual oversight through the AtopicApp mobile application.
41136296|NCT03679299|OTHER|Observational - No intervention|See outcomes
41136297|NCT03111368|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
41293949|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
41293950|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
41293951|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
41293952|NCT05028023|BIOLOGICAL|Apneic oxygenation - supplemental high flow oxygen administration by an apneic way|In pediatric patients undergoing tracheal balloon dilatation, oxygenation maintenance is essential, while induction in anesthesia, cessation of spontaneous ventilation by neuromuscular relaxant and pediatric i-gel placement are necessary for access to trachea. After i-Gel placement controlled ventilation with 100% oxygen is initiated. Pediatric bronchoscope and balloon dilatation catheter are advanced into trachea to the stenotic area. Overall dilatation duration is 2,5-3minutes, while the balloon is inflated for 60sec. Every dilatation cession consists of three dilatations. First dilatation is performed without oxygen enrichment. During second and third dilatation, a nelaton catheter, connected with high oxygen flow, is advanced into i-Gel canal, together with bronchoscope and balloon catheter. Effects of no oxygenation and apneic oxygenation in regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, arterial blood gases and haemodynamics are recorded and compared.
41456333|NCT01616199|DRUG|PX-866|"Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity."
41136298|NCT05118100|DRUG|Clearfil Protect Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive containing an antibacterial monomer (MDPB)
41136299|NCT05118100|DRUG|Clearfil SE Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive.
41456334|NCT01616199|DRUG|vemurafenib|vemurafenib is a B-Raf enzyme inhibitor
41136300|NCT00162006|DRUG|Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution|
41456335|NCT05296928|PROCEDURE|laparoscopic incision|laparoscopic umbilical trocar entry pathways
40764933|NCT06183541|PROCEDURE|Pericapsular Nerve Group (PENG) Block|Pericapsular nerve group (PENG) block The femoral nerve and obturator nerve terminal branches, which provide sensory innervation of the hip joint, are blocked, thus providing analgesia without creating a motor block.
41136301|NCT00343083|DRUG|Erbitux, Paclitaxel & Carboplatin|"Paclitaxel, 40 mg/m2/week,~1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.~Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.~Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)"
41136302|NCT00343083|RADIATION|Radiation|XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
41136303|NCT03482102|DRUG|Tremelimumab|Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
41136304|NCT03482102|DRUG|Durvalumab|Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
41136305|NCT03482102|RADIATION|Radiation|Radiation therapy is used to shrink cancer cells.
41136306|NCT04284878|GENETIC|PCR-RFLP|PCR-Restriction fragment length polymorphism
41456336|NCT00924963|DEVICE|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
41456337|NCT00924963|DEVICE|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
40962312|NCT02993393|OTHER|Teacher|The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care.
40962313|NCT02993393|OTHER|Student|The students' questionnaire comprised 3 parts: learning content, process and evaluation.
40962314|NCT04303819|DRUG|Exenatide treatment|12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.
40962315|NCT04178564|BEHAVIORAL|Cognitive Stimulation|"The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 60 minutes and they will be developed according to the following structure:~Welcoming to the group (5 minutes) Reality orientation therapy (10 minutes) Main activity (35 minutes) Session evaluation (10 minutes) CS sessions will be conducted in groups. The intervention sessions will include several activities based on different non-pharmacological therapies, whose effectiveness in elderly with neurocognitive disorders has been scientifically proven. Non-pharmacological therapies used encompass therapies such as musictherapy, reminiscence therapy, validation therapy, Montessori method in geriatrics, ADL training, art therapy and the computer software Rehacom."
40962316|NCT02607150|OTHER|Cerebral Oxygenation Changes|Monitor cerebral oxygenation changes in patients receiving blood transfusions who are undergoing spinal fusion surgery.
40962317|NCT01500161|DRUG|Busulfan|Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
40962318|NCT01500161|DRUG|Clofarabine|Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
40962319|NCT01500161|DRUG|Fludarabine|Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
40962320|NCT01500161|DRUG|Melphalan|Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
40962321|NCT01500161|DRUG|Carmustine|BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
40962322|NCT01500161|DRUG|Etoposide|Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
40962323|NCT01500161|DRUG|Cytarabine|ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
40962324|NCT05533684|DRUG|Gabapentin|single preoperative dose of 600 mg gabapentin
40962325|NCT01084083|BIOLOGICAL|cetuximab|Given IV
40962326|NCT01084083|RADIATION|intensity-modulated radiation therapy (IMRT)|Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
40962327|NCT01084083|DRUG|Paclitaxel|Given IV, 90 mg/m\^2 on days 1, 8 and 15
40962328|NCT01084083|DRUG|Cisplatin|Given IV, 75 mg/m\^2 on day 1
40962329|NCT00486200|DRUG|ASP2151|Oral administration.
40962330|NCT00486200|DRUG|valacyclovir|Oral administration of active comparator.
40962331|NCT00486200|DRUG|Placebo|Oral administration of placebo.
40962332|NCT00564772|DRUG|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
40962333|NCT03504657|DEVICE|Drug-coated balloon angioplasty|Angioplasty with a drug-coated angioplasty
40962334|NCT03504657|DEVICE|stenting angioplasty|Angioplasty with a stenting
40962335|NCT00970970|OTHER|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
41456338|NCT00924963|DRUG|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
41456339|NCT01675115|DRUG|BNG-1|BNG-1 3 grams TID for 4 weeks
40962336|NCT06534554|BEHAVIORAL|Patient Navigation|A lay patient navigator working will contact patients seen in the UAB ED via phone within \~72 hours following the ED visit. During this initial phone conversation, the navigators will: 1) conduct a baseline assessment to identify barriers to attending an outpatient visit for gout care and to adhering to gout treatment recommendations and 2) determine the level of support and assistance needed by the patient.
41456340|NCT01675115|DRUG|Aspirin|Aspirin 100 mg QD for 4 weeks
40962337|NCT01939808|OTHER|Splint Neutral|
40962338|NCT01939808|OTHER|Splint Extended|
40962339|NCT04403477|BIOLOGICAL|Convalescent plasma|Apheretic convalescent plasma from a COVID-19 survivor
40962340|NCT05251766|DRUG|Nab paclitaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
40962341|NCT05251766|DRUG|Docetaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
40962342|NCT02915016|BIOLOGICAL|DNA-HIV-PT123 vaccine|Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
40962343|NCT02915016|BIOLOGICAL|Bivalent Subtype C gp120/MF59 vaccine|Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
40962344|NCT02915016|BIOLOGICAL|Bivalent Subtype C gp120/AS01B vaccine|"Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose."
40962345|NCT02915016|BIOLOGICAL|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
41456341|NCT04593160|DRUG|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
41456342|NCT04593160|DRUG|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
40962346|NCT04173585|DRUG|Bortezomib|Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
40962347|NCT04173585|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
40962348|NCT03942666|DRUG|Treatment A|tablet of CHF 6532
40962349|NCT03942666|DRUG|Treatment B|tablet of CHF 6532
41456343|NCT04593160|DRUG|Placebo|Preoperative single dose of placebo
40962350|NCT03942666|DRUG|Treatment C|tablet of CHF 6532
40962351|NCT03942666|DRUG|Treatment D|tablet of CHF 6532
40962352|NCT03942666|DRUG|Treatment E|Placebo tablet of CHF 6532
40962353|NCT03942666|DRUG|Treatment F|tablet of CHF 6532
40962354|NCT01048177|DRUG|Bladder instillation with heparin/ lidocaine|9 bladder instillations in 6 weeks
40962355|NCT00250302|PROCEDURE|autologous mesenchymal stem cells implantation|
40962356|NCT05288920|PROCEDURE|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
40962357|NCT05288920|DRUG|Transforaminal injection of Steroids alone|Transforaminal injection of Steroids alone
40962358|NCT03474770|DRUG|BIS-001ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
40962359|NCT01745133|DRUG|vehicle foam|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
40962360|NCT01745133|DRUG|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks
40962361|NCT01745133|DRUG|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
40962362|NCT03024619|OTHER|Pain and Urinary pH|assess the correlation between urinary pH and Interstitial Cystitis (IC) pain, with emphasis placed on exploring the type and severity of pain
40962363|NCT03989271|DRUG|Quercetin|Placebo
40962364|NCT00316849|OTHER|pharmacological study|
40962365|NCT00316849|PROCEDURE|adjuvant therapy|
40962366|NCT00316849|RADIATION|3-dimensional conformal radiation therapy|
40962367|NCT00316849|RADIATION|intensity-modulated radiation therapy|
40962368|NCT00316849|DRUG|temsirolimus|Given IV
40962369|NCT00316849|DRUG|temozolomide|Given orally
41456344|NCT04153825|DEVICE|Transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.
40962370|NCT00202800|DRUG|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
40962371|NCT06199596|DIETARY_SUPPLEMENT|alpha-s1 casein hydrolysate|150mg of Prelactium per capsule
40962372|NCT06199596|DIETARY_SUPPLEMENT|Maltodextrin|150mg of Maltodextrin per capsule
40962373|NCT04224701|BIOLOGICAL|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|30 µg
40962374|NCT04224701|BIOLOGICAL|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|300 µg
40962375|NCT04224701|BIOLOGICAL|Placebo|Tris NaCl Diluent
40962376|NCT00825578|DEVICE|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
40962377|NCT06327035|OTHER|Gait rehabilitation|"Assessment of gait and balance abilities after stroke during neurorehabilitation from the subacute phase of stroke to 6 months after stroke.~The assessments will be carried out on entrance to the neurological center, then at 1 ,3 and 6 months and on hospital discharge."
40962378|NCT03163264|BEHAVIORAL|Peer Assisted Lifestyle|Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
40962379|NCT03163264|BEHAVIORAL|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
40962380|NCT00677729|DRUG|solution contains 1 mg salbutamol plus 3% hypertonic saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
40962381|NCT00677729|DRUG|solution contains 1 mg salbutamol plus 0.9% saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
40962382|NCT01171430|DEVICE|Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)|"3 Whole Body Dynamic Contrast Enhanced MRI:~* 1 WB-DCE-MRI before induction of chemotherapy(initial MRI).~* 1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).~* 1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI)."
40962383|NCT00941785|DRUG|DHA-PQ|"Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days"
40962384|NCT00941785|DRUG|SP-AQ|"Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg"
40962385|NCT03627247|BEHAVIORAL|Cognitive Behavioral Stress Management|Interactive activities (e.g., role-playing, use of physical props to introduce concepts related to coping and stress) were designed for each class to optimize participant engagement and understanding of the course material while tailoring class content to the stressors commonly reported by participants. Each week, participants were given coping and relaxation skills to practice at home (e.g., cognitive reappraisal, diaphragmatic breathing) and were asked to record their experiences on an activity log that was collected and discussed in class the following week. Course content was taught from a detailed training manual (Urizar \& Kofman, 2012).
40962386|NCT02279563|DRUG|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|"During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days"
40962387|NCT02279563|DRUG|Dymista™ Nasal Spray|
40962388|NCT02279563|DRUG|Placebo|
40962389|NCT02159417|OTHER|Therapeutic Education|"Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:~* Knowledge of the disease~* Food~* Physical Activity and care of feet~* The therapeutics"
40962390|NCT03443375|OTHER|Physical exercise|The interventions proposed in the present trial were based on a safe and well-established exercise training program
40962391|NCT01866293|DRUG|Cabozantinib (XL184)|
40962392|NCT06062082|PROCEDURE|adrenalectomy|laparoscopic exeresis of the adrenal gland
41136307|NCT06162182|DIAGNOSTIC_TEST|electrical impedance device,|The electrical resistance of the residual dentine underneath each measurement point was determined between an electrode and the crown pulp (Prepometer, Hager \& Werken, Duisburg, Germany). Assigning the electrical resistance of the dentin. high values are considered to represent more residual dentine than low values.
40962394|NCT03783364|RADIATION|Radiotherapy|Pre- or postoperative acellerated irradition in 5 fractions
40962395|NCT02192359|BIOLOGICAL|Carboxylesterase-expressing Allogeneic Neural Stem Cells|Given intracranially
40962396|NCT02192359|DRUG|Irinotecan|Given IV
40962397|NCT02192359|DRUG|Irinotecan Hydrochloride|Given IV
40962398|NCT02192359|OTHER|Laboratory Biomarker Analysis|Correlative studies
40962399|NCT02192359|OTHER|Pharmacological Study|Correlative studies
40962400|NCT02337660|PROCEDURE|Liver biopsy|One ultrasound guided liver biopsy
40962401|NCT02337660|OTHER|Pancreatic clamp|I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
40962402|NCT01116115|OTHER|InFat™ based infant formula|High sn-2 palmitic acid oil based infant formula
40962403|NCT01116115|OTHER|Standard vegetable oil based infant formula|Standard vegetable oil based infant formula
40962404|NCT02996513|OTHER|Retinol Isotope Dilution (RID)|13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
40962405|NCT06557837|DIAGNOSTIC_TEST|Questionnaires and pain assessment|Participants complete two questionnaires: the Oswestry Disability Index (ODI) and the EQ-5D-5L. They also rate their low back pain using the Visual Analogue Score (VAS) scale and respond to two additional questions about their posture and gait.
40962406|NCT06557837|DIAGNOSTIC_TEST|Standing sagittal whole spine X-ray|Participants undergo standard preoperative X-ray imaging of the entire spine to capture the upright posture. This imaging is conducted before and after 6-minute of continuous walking to compare changes in spino-pelvic and sagittal balance parameters.
41136308|NCT06162182|DIAGNOSTIC_TEST|Reference test: Digital Radiographic examination|A digital periapical radiograph using paralleling technique was taken
41136309|NCT03488459|BEHAVIORAL|Routine preoperative information from a nurse|Routine preoperative information from a nurse.
41136310|NCT03488459|BEHAVIORAL|Additional information support from a psychologist|Routine preoperative information from a nurse + additional information support from a psychologist.
41136311|NCT00297466|DRUG|transdermal nicotine patches|
41136312|NCT00297466|BEHAVIORAL|Motivational interview|
40962407|NCT06557837|DIAGNOSTIC_TEST|Dynamic test|With the dynamic test, we analyze body movements of participants during gait using 49 reflective markers placed on their bodies according to the Qualisys PAF package: Instituti Ortopedici Rizzoli (IOR) and 10 EMG electrodes on specific leg and back muscles. Participants walk for 6 minutes between two cones set 7 meters apart, while a 12-camera Qualisys Motion Capture System tracks marker movements for comprehensive kinematic analysis. Data are recorded at five key moments: standing before and after the test, and during three phases of gait (at the beginning, middle, and end). Participants are barefoot and dressed in underwear for accurate measurement. Static recordings before and after walking involve stepping on a tensiometric force plate to measure the center of gravity. Before the test, participants perform stretching exercises to ensure consistent preparation.
41456345|NCT04153825|DEVICE|Interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.
41456346|NCT04153825|OTHER|Hydrocollator hot-pack|The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
40764934|NCT06373718|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
40764935|NCT06637579|OTHER|universal exercise unit therapy with task oriented strength training|Leg press, Sit to stand, Half knee rise, Lateral step up, Forward step up.
40764936|NCT06637579|OTHER|Task-oriented training for gross motor functioning|Standing transfer (hip abduction/adduction), Stair climbing (hip extension, calf raise), Walking and gait training, Reaching and grasping activities.
40764937|NCT05537025|DRUG|ARO-MMP7 Inhalation Solution|ARO-MMP7 by inhalation of nebulized solution
40764938|NCT05537025|DRUG|Placebo|Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution
40764939|NCT06644677|DIAGNOSTIC_TEST|HPV integration|Collect late-stage cervical cancer (Stage IIIB and beyond) and post-treatment recurrence and metastasis specimens (TCT, tissue) associated with HPV infection. Utilize third-generation nanopore technology to detect the integration sites of HPV DNA based on the principle of probe hybridization capture. Obtain information on HPV integration and hot spot genes in the samples. By analyzing the integration of HPV in primary and recurrent/metastatic tissues, identify insertions and gene alterations associated with recurrence/metastasis, and develop a predictive formula.
40764940|NCT03338790|BIOLOGICAL|nivolumab|Specified dose on specified days
40764941|NCT03338790|DRUG|docetaxel|Specified dose on specified days
40764942|NCT03338790|DRUG|enzalutamide|Specified dose on specified days
40764943|NCT03338790|DRUG|rucaparib|Specified dose on specified days
40764944|NCT03338790|DRUG|prednisone|Specified dose on specified days
40764945|NCT06645002|DIETARY_SUPPLEMENT|stevia rebaudiana bertoni|effect of short term study (7 days) of stevia leave powder 1000 mg/day in diabetic subjects
40764946|NCT06645002|DIETARY_SUPPLEMENT|stevia rebaudiana bertoni|effect of long term study (60 days) of stevia leave powder 1000 mg/day in diabetic subjects
40764947|NCT05440786|DRUG|Abemaciclib|Orally
40764948|NCT05440786|DRUG|Irinotecan|IV
40764949|NCT05440786|DRUG|Temozolomide|Orally
40764950|NCT05583864|DEVICE|CONDUIT Porous Titanium Spinal Cage|Already included in arm/group descriptions.
40764951|NCT05583864|DEVICE|PROTI 360 Titanium-Coated PEEK Spinal Cage|Already included in arm/group descriptions.
40764952|NCT06643182|OTHER|Back Support|When the sandbag is to be left by the researcher together with the nurse caring for the patient, the patient will be placed in the left lateral position for a short time, a gel-filled orthopedic non-sweating viscose pillow will be placed in the patient's lumbar region and the patient will be placed in a supine position with the head supported.
40764956|NCT02236910|OTHER|Lu-DOTA-TATE|
40764957|NCT06215716|DRUG|Efruxifermin|Administered by subcutaneous injection
40764958|NCT06215716|DRUG|Placebo|Administered by subcutaneous injection
40764959|NCT06644404|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
40764960|NCT06644404|DRUG|DWC202407 1,000mg|1 tablet, Orally, Twice daily
40764961|NCT06644404|DRUG|DWC202408 2mg|1 tablet, Orally, Once daily single dose
40764962|NCT04501705|DRUG|Apatinib Mesylate|"Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator."
40764963|NCT04421664|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
40764964|NCT04421664|DRUG|Placebo oral tablet|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
40764965|NCT02507934|DEVICE|Lubricin|Lubricin 150 µg/ml eye drops
40764966|NCT02507934|DEVICE|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
41456347|NCT04153825|DEVICE|Sham transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.
40962408|NCT06557837|DIAGNOSTIC_TEST|Muscle strength and body composition measurement|Participants have their body composition analyzed and the maximum isometric strength of their paraspinal and abdominal muscles measured using the Dr. Wolff BackCheck device.
40962409|NCT01970215|DRUG|TA-8995|
40962410|NCT01970215|DRUG|Atorvastatin|
40764967|NCT05104736|DRUG|PT-112|PT-112 will be administered intravenously in 28-day cycles, on Days 1 and 15 at a dose of 360 mg/m2 for cycle 1, and on day 1 at 250mg/m2 for each subsequent cycle,
40764968|NCT05588323|DRUG|Naldemedine|Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)
40764969|NCT06637553|COMBINATION_PRODUCT|Adlay formula|The extract will be administered at a dose of 20 grams dissolved in 200cc of hot water once daily
40764970|NCT06637553|COMBINATION_PRODUCT|Placebo|Same weight as the adlay formula but did not include the active compound
40764971|NCT03761641|OTHER|Neurotriage|NeuroTriage binocular handset monitors pupil dynamics \& eye position with infrared cameras. Rubber non-allergenic ocular spacers contoured to eye sockets come in contact with the face \&cushion between the skin \& eyepiece. During pupil dilation tests, an LED briefly illuminates the pupil. The NeuroTriage system measures neurological pupil index, constriction velocity, \& dilation velocity. Total pupil dilation testing time is \< 1 minute. During saccade-tracking tests, patients direct their gaze towards dim LED targets selectable across the range of view. Visual targets involve center-out ocular motion or smooth pursuit following of illusory movement. The NeuroTriage system measures eye position \& movement velocity during these tests. Total saccade-tracking testing takes \< 3 minutes. Ocular measures are non-invasive, are done quickly and commonly used to measure neurological function.
40764972|NCT04899661|DRUG|Molidustat (Musredo, BAY85-3934)|Tablets, administered orally at the discretion of investigators
40764973|NCT05396287|DEVICE|MRI|Participants will undergo an MRI scan while participating in two breathing tests (hypercapnia and hypoxia) to measure brain blood flow.
40764974|NCT05988229|OTHER|Toolkit to improve discharge equity|Linguistically appropriate discharge teaching aids: a medication calendar, pictographics added to the after visit summary (AVS), and an audio recording of the discharge teaching.
40764975|NCT02873052|DEVICE|MyoVista|The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.
40962411|NCT01970215|DRUG|Rosuvastatin|
40962412|NCT01970215|DRUG|TA-8995 0mg (placebo)|
40962413|NCT01970215|DRUG|Placebo Statin|
41456348|NCT04153825|DEVICE|Sham interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
41456349|NCT05963269|OTHER|Computer assisted intramuscular learning game|It is an educational game that can only be opened from the computer, with questions and answers and cases. The game is currently under development by the developers. The researcher will be able to see how many times the students entered the game and how many points they got.
41456350|NCT03345615|DIAGNOSTIC_TEST|30-day ambulatory cardiac event monitor|SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
40962414|NCT03207230|DEVICE|Cardea SOLO|Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.
41456351|NCT00017550|BIOLOGICAL|anti-thymocyte globulin|
40764976|NCT05473715|DRUG|Aflibercept(BAY86-5321, Eylea)|2mg, intravitreal (IVT) injection
40764977|NCT06637033|BEHAVIORAL|Chewing Food|Daily foods like candies and dumplings will be cut into small pieces. Patients will chew them before each feeding and then spit them out, with each training session lasting ten minutes.
40764978|NCT06637033|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
41456352|NCT04000776|DIAGNOSTIC_TEST|FDG Positron emission tomography (PET) scan|"Patients will undergo 18F-FDG and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).~The patient will be measured and weighed before the exam in order to calculate a personalized dose. An intravenous catheter will be put in place in peripheral vein to allow injection of the tracer."
41456353|NCT04000776|DIAGNOSTIC_TEST|PSMA Positron emission tomography (PET) scan|Patients will sequentially undergo 68Ga-PSMA and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).
41456354|NCT04000776|DIAGNOSTIC_TEST|OCTREOTATE Positron emission tomography (PET) scan|"In the case a patient would present at least one PSMA-negative/FDG-positive lesion, he will be referred to undertake a whole-body 68Ga-OCTREOTATE PET/CT within 10 days of the first PET/CT. The delay between this third PET scan and the last one should be minimal (not least than 18 hours, not more than 10 days).~Images and data will be reviewed centrally within 4 days by the Imaging Corelab, which will produce a final report confirming patient's eligibility to Radioligand therapy (RLT)."
40962415|NCT03207230|DEVICE|ActiGraph wGT3X-BT|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.
40962416|NCT03207230|DEVICE|Wavelet Wristband|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
40962417|NCT02211937|DRUG|BI 44847 solution, low dose|
40962418|NCT02211937|DRUG|BI 44847 suspension, high dose|
40962419|NCT02211937|DRUG|BI 44847 tablet, low dose|
40962420|NCT02211937|DRUG|BI 44847 tablet, high dose|
40962421|NCT02211937|OTHER|high fat breakfast|
40962422|NCT03501290|DIETARY_SUPPLEMENT|Fortimel® Protein supplementation|"Patients are supposed to take Fortimel® Protein once daily during the study period. The prescription is one unit a day.~First prescription of the study product will be done for one month. Prescription will be repeated for 2 additional months only after the patient's nutritional status and its global health status, as well as tolerability and compliance to the ONS, were re-assessed during the first follow-up visit at one month."
40962423|NCT04935320|DRUG|HTL0016878.HCl Solution 10 mg|Oral solution fasted
40962424|NCT04935320|DRUG|HTL0016878.Citrate Capsule 10 mg|Oral capsule fed or fasted
40962425|NCT01020175|PROCEDURE|Bone marrow transplantation|Patients received bone marrow transplantation
40962426|NCT01020175|PROCEDURE|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
40962427|NCT01987297|DRUG|ATRA+Arsenic|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses.~MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients."
40962428|NCT01987297|DRUG|ATRA+Chemo|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses.~Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.~MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients."
41456355|NCT04000776|OTHER|Optional Bone or soft-tissue biopsies|Patients presenting FDG-positive/PSMA-negative or Octreotate-positive lesions on imaging will be asked to undergo a biopsy of these lesions (optional) for research purposes. Bone or soft-tissue biopsies will be collected by an interventional radiologist according to site's standard-of-care procedure and sent to the local pathology department for preparation (formalin-fixed and paraffin-embedded); the blocks being sent to the Pathology Corelab.
40962429|NCT00004037|DRUG|docetaxel|
40962430|NCT03593603|DEVICE|Nellcor™ Bedside Respiratory Monitoring System|Nellcor™ Bedside Respiratory Patient Monitoring System with Nellcor™ Respiration Rate Software and the Nellcor™ Adult Respiratory Sensor to provide continuous respiration rate monitoring
40962431|NCT03415568|DIETARY_SUPPLEMENT|LCT oil|LCT muffin was provided to the study participants. The LCT muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was LCT.
40962432|NCT03415568|DIETARY_SUPPLEMENT|MCDG oil|MCDG muffin was provided to the study participants. The MCDG muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was MCDG.
40962433|NCT04916431|DRUG|mRNA-6231|Sterile frozen liquid dispersion for injection
40962434|NCT04893044|BEHAVIORAL|Video|"The video was a 3 minutes and based on inoculation theory to modify behavior towards moderating the effect of alcohol use as opposed to advising no use at all."
40962435|NCT04244682|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|In the rTMS procedure a small plastic coil will be placed next to the participant's head. The position of the coil will be guided by neuro-navigational software utilizing the individual's MRI scan. The coil will be placed over the relevant brain region using the Brainsight TMS-MRI co-registration system for visualizing the coil position with respect to the participant's individual MRI scan. The coil will then generate a series of repetitive magnetic pulses, and stimulation will occur, disrupting typical function of the targeted brain region.
40962436|NCT01457469|OTHER|questionnaire administration|Ancillary studies
41456356|NCT01071876|DRUG|BF2.649|1 capsule in the morning before breakfast
41456357|NCT01071876|DRUG|Placebo|1 capsule in the morning before breakfast
40962437|NCT01457469|PROCEDURE|quality-of-life assessment|Ancillary studies
40962438|NCT01457469|OTHER|counseling intervention|Undergo counseling session
40962439|NCT01457469|OTHER|internet-based intervention|Receive enhanced quitline intervention
40962440|NCT01457469|BEHAVIORAL|telephone-based intervention|Receive enhanced quitline intervention
40962441|NCT01457469|OTHER|educational intervention|Receive usual care plus
40962442|NCT01457469|DRUG|nicotine replacement therapy|Receive nicotine replacement patches
40962443|NCT01457469|OTHER|educational intervention|Receive enhanced quitline intervention
40962444|NCT01519271|DRUG|Exelon Patch (rivastigmine transdermal system)|"The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )"
40962445|NCT01519271|DRUG|Placebo Patches|The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
40962446|NCT01546883|DRUG|Dabigatran etexilate (Pradaxa)|150mg bid or 75mg bid for a period of one year
40962447|NCT01578187|DEVICE|Hair2Go|Treatment with the device once under observation
41136313|NCT02815865|DEVICE|Foley catheter and pitocin|Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
41456358|NCT00645827|OTHER|IICE Dosing|Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
40764979|NCT06637033|BEHAVIORAL|Oral tube feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
40764980|NCT06253858|DEVICE|Catheter Placement with Solopass System|This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
41136314|NCT02815865|DEVICE|Foley catheter and Dinoprostone|Foley catheter will be inserted through the cervix and inflated with 80 ml saline Dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
41136315|NCT02815865|DRUG|Dinoprostone|Dinoprostone 3 mg will be inserted to the posterior fornix
41136316|NCT04431128|BEHAVIORAL|infant feeding position|correlation with allergy, GER or feeding position
41136317|NCT02241785|DRUG|natalizumab|Administered as specified in the treatment arm
41136318|NCT02848625|OTHER|Yoga|Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks
41136319|NCT01267552|PROCEDURE|Non drains will be placed during operation|Non drains will be placed during operation
41136320|NCT01267552|PROCEDURE|Closed suction drainage|Closed suction drainage will be placed during operation
41136321|NCT03087890|DRUG|Cotrimoxazole|Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
41136322|NCT03087890|DRUG|Placebo|Patients will receive 2 tablets placebo daily for 48 weeks
41136323|NCT01852045|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
41136324|NCT06511219|DEVICE|maxillary segmental distalization|maxillary segmental distalization using skeletal anchored digitally printed appliances
41136325|NCT02791204|DEVICE|SPECT/CT imaging following revascularization procedures|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
41136326|NCT02791204|DEVICE|SPECT/CT imaging|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
41136327|NCT02432066|DRUG|GTS-21|GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
41136328|NCT02432066|DRUG|Placebo|Oral placebo pills, compounded by the UF investigational pharmacy
41136329|NCT04053699|DRUG|Von Willebrand Factor-Containing Product|Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
41136330|NCT01434732|PROCEDURE|Umbilical Cord Milking|UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
41136331|NCT01434732|PROCEDURE|Immediate Cord Clamping|The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
41136332|NCT04627168|DEVICE|Non-invasive, surface electrical stimulation device, DS5 Digitimer|Transcutaneous abdominal electrical stimulation will be delivered through the commercially available equipment, a DS5 Digitimer.
41136333|NCT02387385|DEVICE|Whole body cooling (Tecotherm)|Whole body cooling to 33 to 34 C using Tecotherm
41136334|NCT00239967|DRUG|Rimonabant (SR141716)|
41136335|NCT00239967|DRUG|Placebo|
41136336|NCT01760226|DRUG|DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|"Day 1: Rituximab IV~Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.~Day 5: cyclophosphamide will be given in a vein~Days 1-5: prednisone given by mouth twice a day~G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved."
41136337|NCT01760226|DRUG|Methotrexate|"CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.~CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.~DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:~* 2+ extranodal sites~* elevated LDH,~* MYC rearrangement OR~* bone or marrow disease.~ALL OTHERS receive IT MTX cycles 3-6."
41136338|NCT01760226|DRUG|Etoposide|Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
41466500|NCT06461845|OTHER|Whole Body Vibration with conventional therapy|This group will be given WBV training session, by using a WBV platform was conducted to the study group. The wBV program comprises various positions such as the child stands in an erect position, sitting, and in kneeling position on vibrating platform. This platform vibrates horizontally at a frequency ranged from 10 to 25 Hz. The participants had to carry out each position for 2 min in the first month, and then it was increased to 3 min in the second month. The rest period between each position was 1 min in the first month, then it became half a minute in the second month. The duration of the vibration exposure was 10 min.
40764981|NCT04416815|OTHER|Integrating Health promotion with and for Older People - eHealth|The intervention will be delivered for 6 months on top of usual care. It will be provided by HCPs. If needed one home visit to install the digital platform will be conducted. A HCP will introduce how to use the digital platform and create a personal account. The intervention starts with a person-centred phone-call where a health plan is co-created and potential team members to support this are identified and invited. The health plan includes the older persons' goals, internal and external resources, and need of support from health and/or social-services. This plan will be the point of departure for the forthcoming dialogue. A digital platform will open up for extended and safe communication and visualize the health planning between the older person and team-members in different settings. The older person and the HCP and involved team members on the digital platform will regularly evaluate the health plan and commonly agreed goals.
40764982|NCT06644261|DRUG|Bupivacaine injection|Palpation 1 cm superior and medial to ischial spine to locate pudendal nerve. 22 gauge spinal needle with trumpet will be placed at this location. Upon negative aspiration, 10 mL of 0.25% bupivicaine will be injected bilaterally.
40764983|NCT06642376|BEHAVIORAL|Experimental: Breathing Exercise Application Group|The Effect of Breathing Exercise Applied to Intensive Care Nurses on Fatigue and Perceived Stress
40764984|NCT06633991|PROCEDURE|verbal instructions|verbal instructions inducing hope and optimism were administered as experimental condition vs neutral instructions (i.e., instructions not able to induce hope and optimism although realistic ones)
40764985|NCT06644131|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate
40764986|NCT06644131|DIETARY_SUPPLEMENT|Sugar Pill (Placebo)|Placebo - sugar pill
40764987|NCT05517421|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
40764988|NCT05517421|DRUG|Placebo|Matching Placebo
40764989|NCT06643312|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
40764990|NCT03349996|DEVICE|LifeStream Peripheral Stent Graft System|Patients will be treated with the LifeStream Peripheral Stent Graft System
40764991|NCT05823259|OTHER|Hybrid Telehealth Program: Respiratory Muscle Training and Patient Education|"A testing session will be held where subjects will undergo respiratory muscle testing using the Pro2Fit device to measure PIMax and PEmax. During this session, subjects will be instructed in a respiratory muscle training home program utilizing a provided device call the Breather. They will be instructed to perform this program consisting of breathing exercises for 2 sets of 10 repetitions, twice a day at a difficulty level of 5-7 on the Visual Analogue Scale (VAS) scale for 8 weeks. Subjects will be shown how to follow a training program every day utilizing the free companion application to the device Breather Coach. If subjects have issues with using technology, they will be provided a physical log to record when they complete sessions. Ten to fifteen-minute Zoom sessions with the study coordinator will be held once a week to check in on how the program is progressing, compliance, and if the resistance can be increased."
40764992|NCT05823259|OTHER|Standard Physical Therapy Care|A group of patients who receive standard physical therapy care for chronic constipation at the University of Miami that consists of biofeedback therapy, manual therapy, therapeutic exercise, and patient education.
40764993|NCT06644599|DEVICE|wireless monitoring|The monitoring wireless system will continuously monitor the heart rate, oxygen saturation (SpO2), respiratory rate, and blood pressure and in selected patients electrocardiography (ECG).
41136339|NCT01760226|DRUG|Doxorubicin|Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
40764995|NCT06643611|BEHAVIORAL|Continuous Glucose Monitor|Patient will be provided a continuous glucose monitor. Pharmacist will provide information regarding how to best manage type 2 diabetes.
40764996|NCT06643611|BEHAVIORAL|Usual Care|Routine physician office visits and hemoglobinA1c every 3 for those with HbA1c outside goal and every 6 months for those with HbA1c within goal. Medication regimens managed by physicians, nurse practitioners, and physician assistants. Patients are sent reminders on the phone prior to their visits or when they are due for a visit or any physical examination.
41136340|NCT01760226|DRUG|Vincristine|Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).
41136341|NCT01760226|DRUG|Rituximab|Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.
40764997|NCT02652052|OTHER|Standard of Care - Observation Only|Control Arm - Observation only
40764998|NCT02652052|DRUG|Group 2: Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
41136342|NCT01760226|DRUG|Cyclophosphamide|Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.
40764999|NCT02652052|DRUG|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
40765000|NCT06177431|DRUG|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
40765001|NCT06644885|PROCEDURE|TIVAD implantation complications|Follow up and post operative outcome of patients with devices implantation
41136343|NCT01760226|DRUG|Prednisone|Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
41136344|NCT01760226|DRUG|G-CSF|G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
40962448|NCT04274413|COMBINATION_PRODUCT|Beta Adrenergic Sweat Test|"In Beta Sweat Test - sweat secretion will be stimulated by injecting a series of drugs within the skin surface. Small needles will be used to inject minute amounts of each drug. Before and after each skin injection, the skin will be cleaned using an alcohol swab.~1. Two sensor probes will be strapped to the forearm with rubber bands in position just above the injection site.~2. Under the first probe, injection atropine will be given in one small area of the skin.~3. Under the second probe, first injection carbachol will be given in one small area of the skin.~4. Next, at the second probe area, the normal sweating will be stopped for awhile by injecting a drug called atropine.~5. Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail). Using probes, all sweat rate readings will be recorded."
40962449|NCT04526431|DRUG|Dosage Forms Oral|Dosage form of tacrolimus (extended release tacrolimus or immediate release tacrolimus)
40962450|NCT02294955|DEVICE|Catheterablation|Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
40962451|NCT02294955|DRUG|Amiodarone|Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
40962452|NCT02294955|DRUG|Sotalol|Dosage orally 80-160 mg twice daily
40962453|NCT02294955|DRUG|Flecainide|Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
40962454|NCT02294955|DRUG|Propafenone|Dosage orally 300 mg twice daily
40962455|NCT02294955|DRUG|Disopyramide|Dosage orally 250-375 mg twice Daily
40962456|NCT02294955|DRUG|Dronedarone|Dosage orally 400 mg twice daily
40962457|NCT01313793|DRUG|Treatment A-B|Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
40962458|NCT01313793|DRUG|Treatment B-A|Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
40962459|NCT01350492|BEHAVIORAL|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
40962460|NCT01780077|DRUG|RXI-109|Multiple intradermal injections of RXI-109 at incision sites
40962461|NCT01780077|DRUG|Placebo|Multiple intradermal injections of placebo at incision sites
40962462|NCT00783237|DRUG|Mometasone|Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
41136345|NCT04597931|DRUG|Romosozumab|SC Romosozumab 210 mg/monthly
40962463|NCT00783237|DRUG|Placebo|Placebo nasal spray, single dose of 2 sprays per nostril
40962464|NCT04123314|DRUG|Psilocybin|Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
41136346|NCT04597931|DRUG|Zoledronic Acid|IV Zoledronic acid 5 mg
41136347|NCT01157195|BEHAVIORAL|Tele-AutoCITE|Automated, remotely-administered form of CI therapy
41136348|NCT01157195|BEHAVIORAL|CI therapy|CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
41136349|NCT00446368|DRUG|RAD001|Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
41136350|NCT05132049|DRUG|DA-5211|single dose administration (DA-5211 one tablet once a day)
41456359|NCT00645827|OTHER|Healthcare Provider dosing|Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
40962465|NCT05012683|DEVICE|Point Partial|Patient is fit with Point Partial partial finger prosthetic system
40962466|NCT02836730|PROCEDURE|Low back pain surgery|
40962467|NCT04786990|DRUG|SPN-812|Viloxazine extended-release capsule
40962468|NCT01908283|BIOLOGICAL|13-valent pneumococcal conjugated vaccine (PCV13)|Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
40962469|NCT01278979|DEVICE|"Objective measurements of perineal tears with Peri-Rule"|"Four measurements will be used in this study.~1. Depth of tear, from the fourchette into the greatest depth of the perineal body.~2. Length of tear, from the fourchette to the apex of the vaginal tear.~3. Length of tear, from the fourchette along perineal skin towards the anus.~4. Length of the perineal body, from the fourchette to outer margin of anus."
40962470|NCT01278979|OTHER|Visual and digital assessment|Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
40962471|NCT03145233|OTHER|Isometric exercise programme|Exercise programme where the muscle length and joint angle do not change due to the limb being held in a static position
40962472|NCT03145233|OTHER|Isotonic exercise programme|Exercise programme where both the muscle length and joint angle do change, consisting of concentric muscle actions (where the muscle shortens) and eccentric muscle actions (where the muscle lengthens)
41136351|NCT05132049|DRUG|DA-5211-R1 + DA-5211-R2|single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
41136352|NCT04126577|BIOLOGICAL|blood samples|4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
41136353|NCT03652493|DRUG|Carboplatin|Tumoral evaluation every 3 cycles
41136354|NCT03567278|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
40962473|NCT04843293|BEHAVIORAL|Olfactory stimulation|Newborns in the experimental group will be given the smell of breast milk during 3 consecutive feedings and for 3 days in the morning. Smell stimulation will be started 1 minute before gavage feeding and the application of breast milk odor will continue until the feeding ends. A hand-cleaning researcher will drip 15 drops of breast milk on sterile gauze to apply the smell of breast milk. Sterile gauze dripped with breast milk will be placed as close to the newborn's nose as possible and not in contact with the newborn's skin. After the feeding of the newborn is completed, the application of the smell of breast milk will be terminated and the gauze will be removed from the incubator. A new sterile gauze will be used for each feeding, and these processes will be repeated with each smell stimulation for three days.
40962474|NCT05004025|DEVICE|Novocure Optune|Novacure Optune with Opdivo and Yervoy
41293953|NCT06186336|OTHER|Deep Learning-based Vulnerable Plaque Detection and Assessment Tool|"Scanning requirements for the clinically indicated CCTA and ICA with OCT will be performed according to current site(s) guidelines and procedures. Administration of medications (such as contrast agents and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational product. The tool's use is intended for research purposes and is not intended as a substitute for required medical care. The CCTA and ICA with OCT will be processed in real-time using the site's locally available post-processing tools in order to guide the subject's medical care. Once the ICA with OCT is complete, the de-identified CCTA data will be inputted in the investigational tool.~The clinically indicated CCTA and the ICA with OCT will both take approximately 1 hour and will take place within 10 days. No additional imaging is needed as part of the study."
41293954|NCT00000530|DRUG|nifedipine|
40765002|NCT03689179|BEHAVIORAL|Time for Living and Caring (TLC)|"Time for Living \& Caring (TLC) is an online, self-administered intervention. It includes three types of modules: 1) virtual coaching module (defined as a series of prompts, reminders, and suggestions that guide caregivers through assessment, goal setting, and goal review activities) to monitor respite time-use and time-use goals, 2) an interactive calendar that can be used to schedule and track respite time, 3) resource pages (including links, printable forms, video guides) that provide education and resources such as What is Respite?, Why is Respite Important?, How do I Get (More) Respite?, How do I Use Respite?."
40765003|NCT05395754|DEVICE|App Intervention|Use of the PCheck app, an app encouraging STI prevention behaviors.
40962475|NCT05004025|DRUG|Opdivo|Novacure Optune with Opdivo and Yervoy
40962476|NCT05004025|DRUG|Yervoy|Novacure Optune with Opdivo and Yervoy
40962477|NCT00003931|GENETIC|reverse transcriptase-polymerase chain reaction|
40962478|NCT05062356|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution_#2|40cc
40962479|NCT05062356|DRUG|EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge|10cc
40962480|NCT05062356|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#2|20cc
40962481|NCT05062356|DRUG|Ketorolac|15mg
40962482|NCT03668860|DRUG|Dexamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
40962483|NCT03668860|DRUG|Betamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
40962484|NCT03668860|DRUG|Celestone Soluspan 6Mg/Ml Suspension for Injection|Intramuscular. Total dose: 1 mL (6 mg)
40962485|NCT03668860|DRUG|Dexamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
40765004|NCT06429072|BEHAVIORAL|Mindfulness training|• I-MASS begins with one introductory telephone call by a mindfulness coach within 1 week of the patient scheduling surgery to introduce the participant to the Pattern Health app, discuss the benefits of combining mindfulness and acupuncture, discuss how to access the Healthwise educational content, and lead a brief (\~10 min) mindfulness exercise, as desired. Thereafter, participants will complete 4 self-directed mindfulness modules through the Pattern Health app (1 prior to surgery, 3 following surgery). Each mindfulness module is anticipated to last one week and includes a short (4-5 min) introductory video, daily sessions comprised of a 6-8 min guided mediation, and interactive suggestions for how to apply mindfulness within a daily routine (\~10-12 min total per daily session).
40962486|NCT03668860|DRUG|Betamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
40962487|NCT01591759|DRUG|Citicoline|2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
40962488|NCT01591759|DRUG|Placebo|Placebo arm of single-blind study
40962489|NCT04380116|DEVICE|Soberlink|Soberlink is a comprehensive alcohol monitoring system designed to remotely monitor a person's Blood Alcohol Concentration (BAC). Combining a professional grade handheld breathalyzer with wireless connectivity, the technology includes real-time facial recognition, robust tamper detection and real-time alerting.
40962490|NCT04660877|DIETARY_SUPPLEMENT|Cheddar Cheese|20g of protein from cheddar cheese
40962491|NCT04660877|DIETARY_SUPPLEMENT|Milk|20g of protein from milk
40962492|NCT04051866|PROCEDURE|Non-surgical periodontal treatment: Scaling and root planing (SRP)|Removal of dental plaque and dental calculus from the surface of a tooth, from the surface of a tooth apical to the gingival margin accumulated in periodontal pockets, or from the surface coronal to the gingival margin.
40962493|NCT04051866|OTHER|Oral hygiene instructions|Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss
40962494|NCT04566679|DIETARY_SUPPLEMENT|Dibuzin|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
40962495|NCT04566679|DIETARY_SUPPLEMENT|placebo|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
40962496|NCT01764672|DRUG|Methylphenidate|Oral dose 40mg (2 x 20mg)
40962497|NCT01764672|OTHER|Placebo|Oral intake of 2 placebo tablets
40962498|NCT01154582|DIETARY_SUPPLEMENT|Egg snack|subject consume 4 cooked whole eggs, providing 380 kcal
40962499|NCT01154582|DIETARY_SUPPLEMENT|Cottage cheese|Subjects consume 200 g of cottage cheese, providing 380 kcal
41293955|NCT00000530|BEHAVIORAL|biofeedback (psychology)|
41293956|NCT00000530|PROCEDURE|electromyography|
40962500|NCT01044628|DEVICE|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be \>90%
40962501|NCT01044628|DEVICE|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
40962502|NCT03461913|PROCEDURE|Cesarean section|Lower segment elective Cesarean section
40962503|NCT03725852|DRUG|GLPG1205|GLPG1205 will be provided as an oral hard gelatin capsule.
40765005|NCT06429072|OTHER|Acupuncture|This arm also includes up to 8 total acupuncture treatments (1 prior to surgery and up to 7 treatments in the 12 weeks after surgery). Auricular acupuncture will be the preferred form of acupuncture used. This technique involves inserting tiny needles in specific areas of the outer ear to target points believed to influence pain. If participants are unable to tolerate auricular acupuncture, they will have the option to receive peripheral acupuncture.
40765006|NCT06429072|BEHAVIORAL|Enhanced education|• The program consists of education prior to and after surgery for all participants. All of the educational material is delivered via the Pattern Health App. All educational content is from the Healthwise.net Duke Health Library (https://www.healthwise.net/dukehealth/Content) and is carefully selected with input by surgeons to be delivered during the appropriate phase of recovery. Education is in the form of short reading materials or videos, all designed to help safely and effectively recover from surgery. Educational topics include learning how to lift and sit when experiencing pain, proper precautions following surgery, how to ease back into daily activities following surgery, and ways to self-manage pain.
40765007|NCT04519619|DRUG|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
40962504|NCT03725852|DRUG|Placebo|GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.
40962505|NCT03721744|DRUG|GB201|GB201 will be administered orally, twice daily, with doses separated by approximately 8-12 hours. GB201 administration will begin 2-5 days prior to the first infusion of paclitaxel and low-dose gemcitabine
40962506|NCT03721744|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 will be administered intravenously starting on Day 1 of Cycle 1. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle
40962507|NCT03721744|DRUG|Gemcitabine|Low-dose gemcitabine 600 mg/m\^2 will be administered intravenously following completion of paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle.
40962508|NCT03721744|OTHER|Standard of care treatment options|Patients will receive one of the standard of care treatment options assigned by the Investigator for each patient prior to starting protocol treatment, including Gemcitabine, capecitabine, 5-FU/LV, Onivyde plus 5-FU/LV (if Onivyde is available in the country/region) or best supportive care (BSC).
40962509|NCT00620867|DRUG|Ibuprofen|800 mg oral tablet three time daily with meals for 6 weeks
40962510|NCT00620867|DRUG|celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
40962511|NCT00620867|OTHER|placebo|matched placebo orally for 6 weeks
40962512|NCT01292746|DEVICE|Erchonia MLS|The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
40962513|NCT00525330|DRUG|KRP-104 QD Drug: Placebo Drug: Metformin|KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
40962514|NCT00525330|DRUG|Placebo Drug: Metformin|Two tablets 15 to 30 minutes before each meal, morning and evening.
40962515|NCT00525330|DRUG|KRP-104 BID Drug: Placebo Drug: Metformin|KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
40962516|NCT04798664|BEHAVIORAL|Removal of Financial Barriers|Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications
40962517|NCT04798664|BEHAVIORAL|Financial Incentives|Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.
40962518|NCT04798664|BEHAVIORAL|Mobile Health Application|Episodic future thinking tool to overcome temporal discounting of future
41136355|NCT01840722|OTHER|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
41456360|NCT01507662|BEHAVIORAL|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
41466501|NCT06461845|OTHER|conventional therapy|This group will be provided with the conventional physical therapy. To this, stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors; strength training to hip flexor, knee extensor, and ankle dorsiflexor;
40765008|NCT06637956|DRUG|Nitroglycerin (NTG)|Received 1 mg of nitroglycerin intranasally two minutes prior to laryngoscopy and intubation
41136356|NCT00162318|DRUG|Cetuximab + Gefitinib|IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
41136357|NCT02114515|BEHAVIORAL|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
41136358|NCT02114515|BEHAVIORAL|Navigator intervention|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
40962519|NCT00727428|BIOLOGICAL|FluLaval® TF|One IM injection.
40962520|NCT00845858|DRUG|metoclopramide|30 minutes before meals and at bedtime for 4 weeks
40962521|NCT00845858|DRUG|Placebo|30 minutes before meals and at bedtime
40962522|NCT02213367|DRUG|Bilastine|20mg (8 weeks)
40962523|NCT02213367|DRUG|Bilastine|40mg
40962524|NCT02213367|DRUG|Bilastin|80mg
40962525|NCT04978961|BEHAVIORAL|Focused Acceptance & Commitment Therapy (FACT)|FACT is a brief form of Acceptance and Commitment Therapy and in this study, FACT focused on increasing patient functioning through connection with valued activities and increased acceptance.
40962526|NCT04978961|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|This active control intervention included 4 handouts focused on pain management based on cognitive behavioral science.
40962527|NCT02975518|BIOLOGICAL|Administration of radio labelled endothelial outgrowth cells|Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
40962528|NCT03890601|BIOLOGICAL|blood sample|"A single 15 mL blood draw is planned for this study, as follow:~* 10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~* 5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1."
40962529|NCT03210571|DEVICE|eyeWatch system|The eyeWatch device is composed of an AGDD, a control unit and a draining plate
40962530|NCT04468854|DIETARY_SUPPLEMENT|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
40962531|NCT04468854|OTHER|Placebo|mannitol formulated for oral administration (capsules)
40962532|NCT05801874|DIAGNOSTIC_TEST|Movement analysis|Qualitative and quantitative computerized and instrumental assessment of gait and posture.
40962533|NCT02617381|OTHER|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
40962534|NCT00807729|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
41293957|NCT06440304|DRUG|Fosfomycin|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
41293958|NCT06440304|DRUG|Eravacycline|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
41293959|NCT06440304|DRUG|ampicillin/sulbactam|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
40962535|NCT00807729|PROCEDURE|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
40962536|NCT00130598|DRUG|NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)|"control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast."
41293960|NCT01101724|BEHAVIORAL|Mandated Rest, Intervention|"In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating No return to school and No Physical Activity for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury."
41466502|NCT04791956|DIETARY_SUPPLEMENT|Prebiotic|Daily intake of Inulin-type fructans from chicory
41466503|NCT04791956|DIETARY_SUPPLEMENT|Placebo|Daily intake of maltodextrin
40962537|NCT00824720|DRUG|High Dose Device|inserted for 14 days
40962538|NCT00824720|DRUG|Low Dose Device|inserted for 14 days
40962539|NCT00824720|DEVICE|Placebo Device|inserted for 14 days
40962540|NCT02336971|BEHAVIORAL|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
41466504|NCT01435824|DRUG|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
41136359|NCT02114515|BEHAVIORAL|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
41136360|NCT01714076|OTHER|cohort isolation|all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
41136361|NCT04783766|DRUG|CK-3773274|CK-3773274- Tablets
40765009|NCT06639945|DEVICE|transcranial MR-guided focused ultrasound|MRI-guided transcranial focused ultrasound (MRgFUS) combines magnetic resonance imaging (MRI) with focused ultrasound to target specific areas in the brain non-invasively. MRgFUS allows for treatment without surgical incisions, leading to fewer risks and a quicker recovery. MRI provides real-time imaging that helps precisely locate and treat affected brain regions, such as the thalamus or globus pallidus.The procedure allows for continuous monitoring of the treatment effects, enabling adjustments as needed.
40765010|NCT05846230|DRUG|BI 1291583|Tablet
40765011|NCT05846230|DRUG|Placebo matching BI 1291583|Tablet
41293961|NCT05314595|PROCEDURE|bilateral uterine artery ligation|"* Spinal anaethesia with intrathecal morphia~* Transverse skin incision~* Adequate dissection of the bladder.~* Incision of the uterus above placental edge.~* Delivery of the fetus.~* Delayed cord clamping (60 seconds) if the baby appears well.~* Exteriorization of the uterus.~* Start Oxytocin infusion and uterine massage to ensure good uterine contractions immediately after delivery of the fetus. No trials of placental delivery will be made at this point.~* At this point, a gentile trial to deliver the placenta is performed~* A catheter is placed in the cervix from above to secure the cervical opening~* Compression is applied to the site of bleeding from placenta site~* Placental pouch is marked by multiple allies and is closed down to the multiple-8 suture.~* Blood loss is measured using the suction device and coated socked towels. In modified PPC, Bilateral uterine artery ligation will be done after exteriorization of the uterus in order to minimize the blood loss."
40765012|NCT03164993|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
40765013|NCT03164993|DRUG|Pegylated liposomal doxorubicin|Chemotherapy
40765014|NCT03164993|DRUG|Cyclophosphamide|Chemotherapy
41293962|NCT06182527|DEVICE|Free Style Libre Pro IQ|Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded.
41293963|NCT03691623|DRUG|EDP-938 Dose 1|Oral suspension for 5 days
41293964|NCT03691623|DRUG|EDP-938 Dose 2|Oral suspension for 5 days
40765015|NCT03164993|OTHER|Placebo|Placebo
40765016|NCT06289764|OTHER|Bergamot Essential Oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
40765017|NCT06289764|OTHER|Grapefruit Essential Oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
40765018|NCT06289764|OTHER|Sweet almond oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles
40765019|NCT06640751|BEHAVIORAL|Health behavior intervention|The program is a group-based intervention provided by a healthcare team consisting of researchers, cardiologists, family doctors, community healthcare workers, psychologists, and health education specialists. The intervention is structured around three modules-predisposing, enabling, and reinforcing factors-that provide a framework for educational interventions aimed at promoting healthy behaviors in hypertensive patients.
40765020|NCT03653546|DRUG|AZD3759|AZD3759 200mg PO BID.
40765021|NCT03653546|DRUG|Erlotinib|SoC EGFRTKI Erlotinib 150 mg PO Q.D
40765022|NCT03653546|DRUG|Gefitinib|SoC EGFRTKI Gefitinib 250 mg PO Q.D
40765024|NCT05498870|DRUG|Adductor Canal Block (ACB) Only|Patients will receive an ACB with lidocaine skin wheal
40765025|NCT05498870|DRUG|Adductor Canal Block (ACB) + iPACK Block|Patients will receive an ACB with iPACK block
41136362|NCT04783766|DRUG|Placebo|Placebo- Tablets
41136363|NCT04103099|DIETARY_SUPPLEMENT|HLNatural Immune|Vitamin C, Echinacea, Ivy Extract, Zinc, Ginger and Turmeric in a powder form mixed with water
41136364|NCT02548299|OTHER|Nutrition Education|Nutrition classes will be led by a registered dietician.
41136365|NCT02548299|OTHER|Cooking Lecture|
41136366|NCT02548299|OTHER|Cooking Demo|
41136367|NCT02548299|OTHER|Hands-on Cooking|
41136368|NCT02548299|OTHER|e-Coaching|
41136369|NCT01536964|DRUG|morphine|2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later
41136370|NCT01536964|DRUG|saline|2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine
40765035|NCT05796193|OTHER|Alpha-cypermethrin and PBO LLIN|Veeralin Long lasting insecticidal net with Alpha-cypermethrin Pyrethroid insecticide and PBO
40765036|NCT05796193|OTHER|Alpha-cypermethrin and Clorfenapyr LLIN|Interceptor G2 dual active ingredient LLIN with with Alpha-cypermethrin Pyrethroid insecticide and Clorfenapyr
40765037|NCT05796193|OTHER|Alpha-cypermethrin only LLIN|reference: standard pyrethroid LLIN
40765038|NCT05724030|DEVICE|integrated pulmonary index|integarted pumobary index monitoring
40765039|NCT05724030|DEVICE|saturation|saturation monitorization
40765040|NCT06644430|PROCEDURE|Ablation|Ablation including (microwave ablation, radiofrequency ablation, cryoblation), this surgery was conducted under CT guidence. The pulmonary was completely ablated.
40765041|NCT06644430|DRUG|system therapy|Paticipants received systemic therapy according the instructions.
40962541|NCT02336971|BEHAVIORAL|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
41136371|NCT03579407|PROCEDURE|BMA cell therapy injection|The bone marrow aspirate will be injected into the affected knee joint.
41136372|NCT02488798|PROCEDURE|2D grey scale vaginal ultrasound|To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).
40962542|NCT06506721|DEVICE|Double ballon device, Cook|"Cook double balloon will be introduced transcervically. The double balloon will be inflated with sterile 0-9% saline solution (maximum 80 ml in each balloon of the double device), then the catheter will be fixed with a tape at the women's thigh without traction. The catheter will remain in place until spontaneously expelled or start of active labour.~If neither happens, the device will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed."
40962543|NCT06506721|DEVICE|Hygroscopic cervix dilators, Dilapan-S|"A maximum number of 5 hygroscopic cervical dilator rods will be inserted transcervically, after humidification with sterile 0.9% saline solution. They will be fixed in this position by inserting a humidified compress into the vagina. They will remain in place until spontaneously expelled or until start of active labour.~In neither happens, the devices will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed."
40962544|NCT06085612|DIAGNOSTIC_TEST|Automated retinal oximetry|Non invasive standard examination on automated retinal oximetry.
40962545|NCT00244010|DEVICE|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
40962546|NCT03873831|BEHAVIORAL|Animal-assisted intervention|The therapy dog is present during the session.
40962547|NCT03873831|BEHAVIORAL|Social skills group|"The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists."
41136373|NCT02488798|PROCEDURE|3D power Doppler vaginal ultrasound|To assess the endometrium using the IETA group criteria.
41136374|NCT02488798|PROCEDURE|Office hysteroscopy|using the vaginoscopic approach to assess the uterine cavity and take sample.
41136375|NCT05015699|DEVICE|HT Supreme|HT Supreme ( R\&D by Sinomed, Tianjin, China)
41136376|NCT02203032|DRUG|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
40765042|NCT06642727|BEHAVIORAL|laughter yoga|Laughter yoga reduces stress levels through sessions lasting approximately 40 minutes without any invasive or pharmacological interventions. It regulates breathing, relaxes muscles, stimulates circulation, increases pain thresholds, strengthens immunity, lightens the mind, enhances social relationships, promotes mental balance, and boosts self-esteem, hope, energy, and quality of life. The content of a session includes deep breathing exercises, warm-up exercises, childlike games, and laughter exercises.
41136377|NCT02203032|DRUG|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
41136378|NCT02203032|DRUG|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
41136379|NCT02203032|DRUG|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
41136380|NCT04216641|DIETARY_SUPPLEMENT|Adapted food intervention|Adapted food intervention
41136381|NCT05488405|DRUG|Mesalamine Oral Product|Mesalamine oral suspension for oral use
41293965|NCT03691623|DRUG|Placebo|Oral suspension for 5 days
40765043|NCT03617939|PROCEDURE|Biospeciman Collection|Collection of blood, tissue, and other biological samples.
40765044|NCT03617939|OTHER|Survey Assessments|Data taken from patient surveys and assessments, including quality of life.
40765045|NCT03617939|OTHER|Medical Chart Reviews|Data taken directly from the patients' medical charts.
41136382|NCT01970878|DRUG|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
41136383|NCT01970878|DRUG|GP MDI (PT001)|GP MDI administered as two puffs BID
41136384|NCT01970878|DRUG|FF MDI (PT005)|FF MDI administered as two puffs BID
41136385|NCT01970878|DRUG|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
41293966|NCT03691623|DRUG|EDP-938 Dose 3|Oral suspension for 5 days
41293967|NCT03691623|DRUG|EDP-938 Dose 4|Oral suspension for 5 days
40962548|NCT03742830|DEVICE|C-MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
40962549|NCT02725710|DRUG|Gabapentin|600mg Gabapentin administered orally 1-2 hours prior to procedure
40962550|NCT02725710|DRUG|Placebo|Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
40962551|NCT05713175|DEVICE|EVA plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
40962552|NCT05713175|DEVICE|Polypropylene plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
40962553|NCT05713175|DEVICE|Fixtoe device|Fixtoe Device, simulating the metatarsophalangeal stabilization tape technique is worn for one month, prior to definitive treatment consisting of a personalized plantar orthosis.
40765046|NCT05878067|DRUG|ABBV-444|Lubricant Eye drops
40962554|NCT00458211|DRUG|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
40962555|NCT06272760|OTHER|Home-based hand-arm bimanual intensive training (Tele-HABIT)|Hand-Arm Bimanual Intensive Therapy (HABIT) is a therapeutic approach designed to improve the motor skills and functional use of both arms in individuals with conditions such as cerebral palsy. The core principle of HABIT is to encourage voluntary exercise by actively engaging the affected side, which may be weaker or partially paralyzed, in various activities. This approach aims to reduce physical and mental discomfort while maximizing the effectiveness of the training. HABIT has been adapted into a home-based format by ZOOM, referred to as Home-Based HABIT (H-HABIT).
41293968|NCT03691623|DRUG|Placebo|Oral suspension for 5 days
41293969|NCT05888714|DEVICE|Experimental FES cycling|Using the experimental, new FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
41293970|NCT05888714|DEVICE|Comparator FES cycling|Using the comparator, marketed FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
41293971|NCT05888714|OTHER|Conventional physical therapy|Conventional physical therapy for muscle strengthening, for 16 treatment sessions (twice a week, for 8 weeks).
41293972|NCT01391091|PROCEDURE|Radiofrequency catheter ablation|PVAI
41293973|NCT01391091|PROCEDURE|Radiofrequency catheter ablation|PVAI
41293974|NCT01048125|DEVICE|Sympathetic Nerve Activity|Resting Sympathetic Nerve Activity
41293975|NCT01048125|BEHAVIORAL|Mental Stress Test (Color Word Test)|"A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word green is written in blue ink, they will say blue. This mental stress procedure will be used to cause brief changes in heart rate and blood pressure."
41293976|NCT01048125|DRUG|The Modified Oxford Technique for Baroreflex Sensitivity|Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
40962556|NCT06272760|OTHER|Hand-arm bimanual intensive training (In-clinic-HABIT)|Hand-Arm Bimanual Intensive Therapy (HABIT) is a therapeutic approach designed to improve the motor skills and functional use of both arms in individuals with conditions such as cerebral palsy. The core principle of HABIT is to encourage voluntary exercise by actively engaging the affected side, which may be weaker or partially paralyzed, in various activities. This approach aims to reduce physical and mental discomfort while maximizing the effectiveness of the training.
40962557|NCT04173104|DIAGNOSTIC_TEST|PET/MR with [18F]PARPi|One PET/MR study (with up to 3 scan times) with \[18F\]PARPi
40962558|NCT04173104|DRUG|[18F]PARPi|Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
40962559|NCT05899036|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the cerebral vasculature using pulsatile aspiration. The system is comprised of a sterile one-time use 071 catheter, a sterile one-time use tubing set and a multiuse aspiration pump console.
40962560|NCT02201485|DEVICE|Stent|
41293977|NCT01048125|OTHER|Cold Pressor Test|The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.
41293978|NCT01048125|DEVICE|Echocardiographic evaluation|Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
41293979|NCT00644319|DRUG|ibuprofen|
40765047|NCT05257551|OTHER|Observation|No intervention
40765048|NCT06639360|DEVICE|Transcranial Magnetic Stimulation Active|The patients will be treated with cTBS and usual medical treatment after endovascular treatment
40765049|NCT06639360|DEVICE|Transcranial Magnetic Stimulation Sham|The patients will be treated with sham-cTBS and usual medical treatment after endovascular treatment
40765050|NCT03583710|DRUG|Cisplatin|Given IV
40765051|NCT03583710|DRUG|Etoposide|Given IV
40765052|NCT03583710|DRUG|Mitotane|Given PO
40765053|NCT03583710|OTHER|Quality-of-Life Assessment|Ancillary studies
40765054|NCT02393625|DRUG|Ceritinib (LDK378)|
40765055|NCT02393625|DRUG|Nivolumab|
40765056|NCT06638021|BEHAVIORAL|Targeted EHR-based Communication of Diagnostic Uncertainty (TECU)|The Targeted EHR-based Communication about Uncertainty (TECU) strategy will be activated in the electronic health record (Epic) every time an ED clinician enters an uncertain diagnosis for a patient being discharged, and will notify the clinician to counsel the patient about uncertainty while additionally triggering automated 1) insertion and printing of the patient handout and 2) provision of a hyperlink for the clinician-facing checklist to guide the discharge conversation.
40962561|NCT02201485|DEVICE|Balloon|
40962562|NCT01408927|OTHER|Thienopyridine resistance testing|Thienopyridine resistance will be measured by flow cytometry of vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and/or VerifyNow P2Y12 assay, and/or the Chrono-Log Lumi-Aggregometer, and/or the PlaCor PRT 7000 platelet reactivity assay.
40765057|NCT04730271|DEVICE|Total Knee Replacement|Subjects will be implanted with an ATTUNE Primary total knee replacement.
40962563|NCT01408927|OTHER|Aspirin resistance testing|Aspirin resistance will be measured by the VerifyNow aspirin resistance assay.
40962564|NCT01408927|OTHER|Genetic polymorphism assessment|The presence of minor alleles in selected single nucleotide polymorphisms (SNPs) as measured by the Applied Biosystems Open Array system.
40962565|NCT00005571|DRUG|h5G1.1-mAb|
40962566|NCT01197261|DRUG|Oxycodone naloxone prolonged release tablets|2 tablets/ day
40962567|NCT01197261|DRUG|Placebo tablets|2 tablets/ day
40962568|NCT03424863|OTHER|Moderate Intensity Muscle Strengthening|1 session of lower extremity muscle strengthening at moderate intensity (60% of estimated maximal muscle strength). The exercise is performed on one single day.
40962569|NCT02151383|DRUG|Serelaxin|Serelaxin was administered intravenously for up to 48 hours.
40962570|NCT05496530|DRUG|Suprachoroidal triamcinolone acetonide injection|Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.
40962571|NCT01951274|DRUG|VPD-737|NK1 Receptor Antagonist
40962572|NCT01951274|DRUG|Placebo|
40962573|NCT01160978|DRUG|Simvastatin 80mg|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
40962574|NCT01160978|DRUG|Control Rx|The transplant recipients who have received an organ from non-treated donors.
40962575|NCT04229420|DEVICE|Ultrasound guided Rectus sheath block vs Erector spinae plane block|Ultrasound guided Rectus sheath block vs Erector spinae plane block
40962576|NCT05185193|DEVICE|radiofrequency|Radiofrequency of 9.50v, 218.5mA and 2.076W is applied once a day for 30 minutes, a total of 3 times
40962577|NCT05185193|DEVICE|sham stimulation|The appearance is the same as the medical device for clinical trials, and when applied, the sound and the amount of light visible from the outside are designed to be the same as the medical device for clinical trials. The external light was the same, and only the high frequency that stimulates the dermis was blocked. The sham device was applied once a day for 30 minutes, a total of 3 times.
40962578|NCT02685410|OTHER|One Night Stan Prototype|The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
40962579|NCT04532944|DIAGNOSTIC_TEST|imaging of energy dysfunction|7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy
40962580|NCT02616406|DEVICE|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
40962581|NCT02920385|DRUG|Semaglutide|Oral administration once daily alone or together with levothyroxine or Placebo
41136386|NCT01329107|BEHAVIORAL|Multimodal Intervention|"Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.~After operation the intervention group will be mobilised in a fast speed compared to standard care."
41136387|NCT03114215|DRUG|MD1003|capsules 100mg 3 times per day
41136388|NCT03114215|DRUG|Placebo oral capsule|capsules 100mg lactose 3 times per day
41293980|NCT00644319|DRUG|morphine sulfate|
41293981|NCT00644319|PROCEDURE|management of therapy complications|
40765058|NCT03255200|DEVICE|ReActiv8 Implantable Stimulation System|Implantable electrical stimulation system.
40962582|NCT02920385|DRUG|SNAC|Oral administration once daily alone or together with levothyroxine or semaglutide
41136389|NCT02040870|DRUG|LDK378|750 mg once daily
41293982|NCT00644319|PROCEDURE|pleurodesis|
40765059|NCT06642961|DRUG|GR1802 injection|GR1802 will be administered SC.
40962583|NCT02920385|DRUG|Levothyroxine|Oral administration alone or together with SNAC or oral semaglutide
40962584|NCT02920385|DRUG|Placebo|Oral administration once daily together with semaglutide
40962585|NCT00448981|BEHAVIORAL|Hand hygiene and educational material|
40962586|NCT00448981|DEVICE|Mask, alcohol and hand sanitizer|
40962587|NCT03472183|OTHER|biopsies of colon|Removal of additional biopsies of colon during the course of a colonoscopy planned for usual medical follow-up of patient
40962588|NCT01893632|DRUG|gabapentin|
40962589|NCT01893632|DRUG|Placebo|
40962590|NCT00398580|DRUG|Nanomilled testosterone|
40962591|NCT00398580|DRUG|Nanomilled dutasteride|
40962592|NCT00398580|DRUG|commercially available dutasteride|
40962593|NCT04688970|OTHER|no intervention|no intervention
40962594|NCT00361569|DRUG|DR-2041a|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
40962595|NCT00361569|DRUG|DR-2041b|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
40962596|NCT00361569|OTHER|Placebo|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
40962597|NCT00361569|OTHER|Placebo|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
40962598|NCT01606007|DRUG|Saxagliptin|Tablets, Oral, 5mg , Once daily, 24 weeks
40962599|NCT01606007|DRUG|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
41136390|NCT04251988|DEVICE|Oculus Go VR|virtual reality headset
41293983|NCT04494711|BEHAVIORAL|Physical Functional Literacy for Adults|A 5 week physical literacy for program focused on virtual knowledge translation strategies to improve function and mobility for adults with multiple chronic conditions. This is a population -based approach to rehabilitation
40765060|NCT06642961|DRUG|GR1802 injection|GR1802 will be administered SC.
40765061|NCT06642961|OTHER|Placebo|The placebo will be administered SC.
40765062|NCT06346132|DEVICE|Virtual reality application|In this group, virtual reality will be added to usual care
41136391|NCT01930188|DRUG|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
41136392|NCT01930188|DRUG|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
40765063|NCT03403790|DRUG|Quetiapine|Oral (extended-release tablet)
40962600|NCT01606007|DRUG|Dapagliflozin|Tablets, Oral, 10mg , Once daily, 24 weeks
40962601|NCT01606007|DRUG|Placebo matching with Dapagliflozin|Tablets, Oral, 0mg, Once daily, 24 weeks
40962602|NCT01606007|DRUG|Placebo matching with Saxagliptin|Tablets, Oral, 0mg, Once daily, 24 weeks
40962603|NCT02171377|DEVICE|group 2 : quadricipital electrical stimulation|bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)
41136393|NCT01930188|DRUG|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
41136394|NCT01930188|DRUG|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
41136395|NCT04440540|BEHAVIORAL|Dietitian led life style modification intervention|lifestyle changes supervised by dietitians
41136396|NCT04440540|BEHAVIORAL|Conventional care (control)|receive routine care
41136397|NCT02237937|DRUG|Paroxetine|
41136398|NCT02237937|DRUG|Sertraline|
41136399|NCT02237937|DRUG|Citalopram|
41136400|NCT02237937|DRUG|Venlafaxine|
41136401|NCT02237937|DRUG|Amitriptyline|
41136402|NCT02237937|DRUG|Escitalopram|
41136403|NCT02237937|DRUG|Amitriptylinoxide|
41136404|NCT02237937|DRUG|Nortriptyline|
41136405|NCT02237937|DRUG|Trimipramine|
41293984|NCT04303390|DRUG|Cefuroxime|second generation cephalosporin
41293985|NCT04303390|DRUG|Cefazolin|First generation cephalosporin
40962604|NCT02171377|OTHER|pulmonary rehabilitation|exercise training, 3 to 5 times per week, 8 weeks
40962605|NCT02171377|DEVICE|muscular electrical stimulation|Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation
40962606|NCT02171377|OTHER|pulmonary rehabilitation|exercise training, 45 min, 3 to 5 times per week, 8 weeks
40962607|NCT00851747|DRUG|Phosphatidylcholine Deoxycholate|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
41136406|NCT01597674|DRUG|YF476|"There were 4 treatments: 3 dose levels of YF476 (5mg, 10mg, 25 mg) and placebo.~Each treatment taken by mouth once daily for 14 days (Study Days 1-14). Each subject took 1 of the 4 treatments."
41136407|NCT02326220|DRUG|Placebo|
41136408|NCT02326220|DRUG|Alirocumab|
41136409|NCT05004909|DRUG|0.05% Tretinoin|Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
41136410|NCT02123940|DEVICE|lung ultrasound score|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
41136411|NCT05188066|DIAGNOSTIC_TEST|Histology|Collect the placenta and fetal membranes and perfor either tissue culture or fixation for further analyses
41293986|NCT04303390|OTHER|24 hours|Duration of antibiotic therapy
41293987|NCT04303390|OTHER|48 hours|Duration of antibiotic therapy
41293988|NCT00031577|DRUG|paclitaxel|
41136412|NCT03072810|BEHAVIORAL|Positive mindfulness program|4 week program consisting of 8 modules. Each module comprises an introduction video (approx. 10 minutes), a daily meditation (approx. 10 minutes) and a daily activity.
41136413|NCT01049854|DRUG|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
41136414|NCT01049854|DRUG|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
41136415|NCT01049854|DRUG|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
41293989|NCT00031577|RADIATION|radiation therapy|
41293990|NCT01177215|PROCEDURE|Thoracic Surgery|Wedge Resection Segmental Resection Lobectomy
41293991|NCT03623269|PROCEDURE|posterior approach to total shoulder arthroplasty|The posterior approach to total shoulder arthroplasty approaches the patient from the back of the shoulder and spares the rotator cuff.
40962608|NCT00851747|DRUG|Saline|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
40962609|NCT03799770|DIAGNOSTIC_TEST|Optic nerve sheath diameter by ultrasound at 5 minutes post-reperfucion|"Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the ﬁnal ONSD value was calculated by average 4 measured values.~We measured the ONSD at 4 timings: (T1) Post induction and before surgical incision, (T2) Portal vein clamping, (T3) 5 minutes after reperfusion, and (T4) 30 min after reperfusion."
40962610|NCT02100514|DRUG|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection for 52 weeks.
40962611|NCT02100514|OTHER|Placebo|Subcutaneous injection every 2 weeks for 52 weeks.
40962612|NCT01826630|OTHER|CLn BodyWash|Comparing two washes to determine change in bacterial load.
40962613|NCT01826630|OTHER|Cetaphil Daily Facial Cleanser|Comparing two washes to determine change in bacterial load.
40962614|NCT02178371|PROCEDURE|mCIMT|affected upper limb use with constraint of the healthy hand
40962615|NCT02178371|PROCEDURE|Unimanual therapy without constraint UTWC|affected upper limb use without constraint of healthy hand
40962616|NCT03548259|PROCEDURE|Platelet-rich plasma|Platelet-rich plasma injection
40962617|NCT03548259|PROCEDURE|Platelet-poor plasma|Platelet-poor plasma injection
40962618|NCT02272062|OTHER|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
40765064|NCT05941780|DIAGNOSTIC_TEST|Pain classification method|A current clinical algorithm will be used to determine the predominant type of pain in individuals with FMS. The classification to diagnose nociceptive, neuropathic and nociplastic pain will based on a recent method developed by Nijs et al. This method consists of seven steps in total. These steps question the following, respectively: duration of pain, pain distribution, presence of nociceptive pain, presence of neuropathic pain, phenomenon of hypersensitivity, presence of hypersensitization and presence of specific comorbidity. Besides, inter-rater and intra-rater reliability of pain classification algorithm will be determined by two independent researchers.
40962619|NCT00901316|PROCEDURE|Routine Measures Group|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures."
41136416|NCT01049854|DRUG|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
41293992|NCT03152864|BEHAVIORAL|Full Package|Individuals will be randomly allocated to receive the full HealthRhythms package (Rhythm Sensing, Rhythm Trending, and Rhythm Stabilization) program on their smartphones
40765065|NCT06568302|DRUG|SerpinPC|Administered as SC injection.
40765066|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 12|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12
40765067|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 3|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3
41293993|NCT04846153|OTHER|Human-based Quantification of Airway Stenosis|Human-based Quantification of Airway Stenosis From Bronchoscopic Images.
41293994|NCT04846153|DEVICE|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
41293995|NCT03988816|DRUG|Roflumilast|500Mcg Tab, once daily
41293996|NCT03988816|DRUG|Placebo oral tablet|once daily
40765068|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 6|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6
40765069|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 24|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24
40765070|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 21|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21
40765071|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 18|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18
40765072|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 15|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15
40765073|NCT06298058|DRUG|SIBP-A13 formulation for injection|"SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion). Starting from the lowest dose, when the former does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD). The study adopts a 3+3 dose increasing design. Administration period: divided into single administration and multiple administration. Single dose administration: The participants are administered a single dose on the first day for a total of 21 days of observation, and complete the examinations and evaluations specify in the protocol. If dose-limiting toxicity (DLT) does not occur, the participant enters a multiple dosing period. Multiple administration: administration every 3 weeks."
40765074|NCT06040827|DEVICE|Total Knee Arthroplasty|The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.
40765075|NCT06642051|DEVICE|High Intensity focused ultrasound|Sonablate High Intensity Focused Ultrasound system to ablate incompetent veins of the periphery
40962620|NCT00901316|PROCEDURE|Bleach Bath Group (Bleach plus routine measures)|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths."
40962621|NCT03479970|OTHER|GNPT+ Social Cognition|Aplication of a computer based treatment focused on attention, memory, executive functions and social cognition.
41136417|NCT04183023|GENETIC|Collection of a salivary sample|"Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and 4,000 of them will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~A subset of 4,000 individuals will be selected to provide a homogeneous geographic coverage and to avoid inclusion of related individuals who will share large genomic regions. Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data."
41136418|NCT00712413|DRUG|OBMT|Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
40962622|NCT03479970|OTHER|GNPT|It's a computeritzed program of cognitive telerehabilitation
41136419|NCT04358588|DRUG|iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System|Patients will be treated by means of an INOpulse device and cannula. The active study drug, nitric oxide for inhalation (iNO), will be provided in size 0.074 liter aluminum cartridge at a concentration of 6.0 mg/L (4880 ppm).
41136420|NCT02740426|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
40962623|NCT02837328|DRUG|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
40962624|NCT02837328|DRUG|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
40962625|NCT02798874|DRUG|Ticagrelor|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
40962626|NCT02798874|DRUG|Clopidogrel|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
40962627|NCT01748084|DRUG|Rituximab|Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
41136421|NCT04580004|OTHER|Med Optimization Arm|An evidence-based medication recommendation website that is provided to the patients.
41136422|NCT03555812|OTHER|Pelvic inclination measurement|Measurement of pelvic inclination per ultrasound
41136423|NCT04637100|OTHER|Mobile or tablet-based gaming applications|Subject will use their own personal smartphone or tablet device to play from a collection of pre-selected gaming applications. The collection is made of puzzle-type games available on both Android and iOS without excessive ads and with clear or self-explanatory instructions. Subject will be instructed to play for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
40765076|NCT06636864|PROCEDURE|Intrathecal morphine|The patient was asked to lie on the side, the needle insertion point was located under the guidance of color ultrasound, and after local anesthesia, the needle was inserted into the subarachnoid space at the puncture point and morphine was injected.
40765077|NCT06636864|PROCEDURE|Intrathecal saline injection|After the patient was asked to lie on his side, the injection point was determined under the guidance of color ultrasound. After local anesthesia, the needle was injected into the subarachnoid space and then normal saline was injected.
40962628|NCT01748084|DRUG|Placebo (NaCl)|Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
41293997|NCT01266148|DRUG|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
41456361|NCT02043392|DEVICE|Magnamosis|Single-use, sterile device enables creation of a circular compression intestinal anastomosis. Device is comprised of matched pair of self-centering rare earth magnets encased in medical grade polycarbonate. Geometry of magnets' mating surfaces applies force on inside of mated rings to produce compression necrosis of intervening intestinal walls. Lesser force on outside of mated rings produces inflammatory healing of the two co-apted intestinal walls. Internal lumen creates patency of the anastomosis to prevent intestinal obstruction during compression anastomosis creation. In 5-10 days, mated rings with necrotic tissue falls into intestinal lumen and is naturally expelled with stool, leaving a well-healed anastomosis.
41456362|NCT02671474|OTHER|4-dimensional volume-rendered computed tomography|
40962629|NCT03172624|DRUG|Nivolumab|nivolumab 3 mg/kg every 2 weeks
40765078|NCT06636864|PROCEDURE|TAPB|The patient was in a supine position. The rectus muscle was confirmed to be warping under the guidance of color photography, and the needle was injected with bupivacaine liposomes
40765079|NCT06644976|PROCEDURE|femoral neck CRIF|femoral neck fracture CRiF while under noac. no special intervention beside taking blood test for drug levels
40962630|NCT03172624|DRUG|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
40962631|NCT03787732|DRUG|Fluid Bolus|500 milliliters of an intravenous crystalloid solution of the operator's choosing
41136424|NCT04637100|OTHER|Stroke-related educational videos|Subject will use their own personal smartphone or tablet device to watch videos from a collection of pre-selected educational videos. These include topics on stroke recognition, stroke recovery process, patient experiences with stroke, rehabilitation after stroke, activities of daily living equipment instructions. Subject will be instructed to watch for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
41136425|NCT06169566|DIETARY_SUPPLEMENT|synbiotics|synbiotics
41136426|NCT06169566|COMBINATION_PRODUCT|placebo|placebo
41136427|NCT04486703|OTHER|Exercise with music|physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.
41136428|NCT02905292|OTHER|evaluation and treatment maneuver for BPPV|
41136429|NCT01545583|DRUG|LY3016859 intravenous|Administered intravenously
41136430|NCT01545583|DRUG|Placebo intravenous|Administered intravenously
41136431|NCT01545583|DRUG|LY3016859 subcutaneous|Administered subcutaneously
41456363|NCT04157205|DIAGNOSTIC_TEST|Non-invasive ECG imaging - CardioInsight test|"1. Consent session~2. Fitting of ECGi vest and CT scan of the chest~3. Supervised exercise test and Valsalva maneuvre~4. Programmed stimulation via ICD (selected participants)~5. Blood tests - genetics"
41456364|NCT00724958|BIOLOGICAL|Infliximab|Not specified in the protocol.
41136432|NCT01545583|DRUG|Placebo subcutaneous|Administered subcutaneously
41136433|NCT00669474|PROCEDURE|Suction curettage|Suction curettage
40962632|NCT03787732|OTHER|No Fluid Bolus|No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation
40962633|NCT02650856|DRUG|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
41136434|NCT00669474|DRUG|Treatment with Botox|Treatment with Botox
41136435|NCT06269068|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
41136436|NCT06269068|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
41293998|NCT01266148|DRUG|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
41456365|NCT02069262|OTHER|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
40962634|NCT02650856|BIOLOGICAL|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
41136437|NCT06269068|OTHER|Oswestry Low Back Pain Disability Questionnaire|With this scale, it is questioned to what extent the patient is affected by low back pain in selected daily living activities under certain ten headings. In total scoring, disability is expressed as a percentage, and high scores are interpreted in favor of an increase in disability.
41136438|NCT06269068|OTHER|Douleur Neuropathique 4|The questionnaire consists of 10 items; while the nature of pain is questioned in 7 items, the other 3 items include brief sensory examination. Patients with a score of 4 or more out of 10 are considered to have neuropathic pain.
41136439|NCT06269068|OTHER|Visual analogue scale|global pain score on a 0 to 10
41136440|NCT00349206|DRUG|sorafenib tosylate|Given orally
41136441|NCT00349206|DRUG|temsirolimus|Given IV
41456366|NCT00712244|DEVICE|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
41456367|NCT00712244|DEVICE|DuoVisc|Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
40962635|NCT01316796|DRUG|Sodium Nitrite Cream|
40962636|NCT05493046|BEHAVIORAL|Interactive Hand Exercise Game|Interactive Hand Exercise Game to Improve Vascular Maturity and Grip Strength in Patients undergoing Arteriovenous Fistula Surgery
40962637|NCT05493046|BEHAVIORAL|Soft ball exercise ( routine care)|Soft ball exercise ( routine care)
40962638|NCT02041884|BEHAVIORAL|iCBT for Adults with ADHD|A skill training internet-based treatment program based on CBT and DBT interventions .
40962639|NCT02041884|BEHAVIORAL|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
41136442|NCT02368652|DRUG|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
41136443|NCT02368652|DRUG|Amlodipine 10mg, Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
41136444|NCT03497052|OTHER|In vitro culture in medium 1|Oocytes and embryos will be cultured in GEMS media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
41456368|NCT00712244|DEVICE|Healon5|Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
40962640|NCT02041884|OTHER|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
41293999|NCT01266148|DRUG|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
41294000|NCT01266148|DRUG|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
41294001|NCT01266148|DRUG|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
41294002|NCT02255786|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
41294003|NCT00246883|PROCEDURE|Exercise|
41294004|NCT03753568|DEVICE|Electronic medicine reminder system|Electronic surveillance device is attached to the participants push through pill sheet and the smart phone application reminds the participants to take their medicine if they are about to take their daily dosage.
41294005|NCT06404008|BEHAVIORAL|REST|After randomization, individuals will attend an in-person training session in the REST protocol. This is a 15 minute controlled breath protocol that includes 3 yoga breathing techniques: 3-part dirgha breath, alternate nostril breathing, and 2:1 breathing. Each technique will be completed for 5 minutes, for a total of 15 minutes. After the training session, participants will practice the REST protocol for 15 minutes twice a day with guidance from research staff over zoom (Days 1-7) with daily COPD education including inhaler technique, nutrition, vaccinations, tobacco cessation counseling, and exacerbation education. On Day 8, participants will attend the Trial Session where they will complete the REST protocol (15 minutes) while vitals, lung function, and ECG measurements are taken. Surveys will be administered before and after the REST protocol to document patient reported stress and dyspnea.
41294006|NCT06404008|OTHER|Education|After randomization, individuals will attend an in-person education session led by a research coordinator. For the following 7 days, the research staff will call patients daily and provide daily COPD education including inhaler technique, nutrition, vaccinations, tobacco cessation counseling, and COPD exacerbation education. On Day 8, participants will attend the Trial Session where they will do spontaneous breathing (15 minutes) while vitals, lung function, and EKG measurements are taken. Surveys will be administered before and after the spontaneous breathing period to document patient reported stress and dyspnea. After the study, participants will be asked to complete a close out survey and interview over zoom.
40765080|NCT04981912|DRUG|HDMP + rituximab as a means of debulking prior to initiating venetoclax.|"* Patients will receive HDMP + Rituximab for 1 cycle, followed by reassessment of Tumor Burden,~* If Tumor Burden classification is low after HDMP + Rituximab (lymph nodes \< 5cm in diameter AND absolute lymphocyte count \< 25k/uL), patients will initiate venetoclax dose ramp-up, with ramp-up schedule according to venetoclax package insert.~* Patients who still have a disease burden (lymphadenopathy \> 5 cm or ALC \> 25k/iL) that meets criteria for medium or high risk of TLS after 1 cycle of HDMP + Rituximab are given the option to repeat a 2nd cycle of HDMP + Rituximab prior to venetoclax dose ramp-up."
40765081|NCT04456673|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
41294007|NCT00894530|DRUG|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
40765082|NCT04456673|DRUG|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
40765083|NCT04456673|DRUG|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
40962641|NCT02510196|BEHAVIORAL|reminder|
40765084|NCT04456673|DRUG|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
40765085|NCT04456673|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
40765086|NCT06641297|BEHAVIORAL|Music video game|The video game \&#39;Guitar Hero\&#39; will be used as the platform for training for participants to acquire a new \&#39;skill\&#39;
40765087|NCT04914273|DRUG|Inhalation Spray|400 mcg salbutamol administered per metered dose inhaler
40765088|NCT04914273|DRUG|Tablet|8 mg salbutamol administered per tablet for ingestion
40765089|NCT06645236|DEVICE|therascreen® KRAS RGQ PCR Kit|The investigational device, therascreen® KRAS RGQ PCR Kit, will be used to determine the KRAS G12C mutation status of patients during the screening period of Amgen's clinical trial (20210081)
40962642|NCT04232995|OTHER|Balance Training|Balance enhancing exercises
40962643|NCT04232995|OTHER|General Exercises|General Exercises
40962644|NCT05004870|DEVICE|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
40962645|NCT00394368|DRUG|beclomethasone dipropionate plus formoterol fumarate combination|
40962646|NCT00394368|DRUG|fluticasone propionate plus salmeterol xinafoate combination|
40962647|NCT05036759|DRUG|68Ga-FAPI|intravenously injected with 68Ga-FAPI
41294008|NCT00894530|DRUG|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
41294009|NCT04561817|DRUG|Ipatasertib|400mg PO daily: day 1-21 of 28 day cycle
41294010|NCT04561817|DRUG|Paclitaxel|80 mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle
40765090|NCT05013736|DEVICE|Magnetic Resonance Imaging|3 Tesla Discovery MR750 MRI scanner (GE Healthcare, Waukesha, WI) will be used to perform structural imaging, diffusion MRI, relaxometry and microstructural imaging. The exact scan length and parameters of each scan type (T1, T2, DWI) will be set for this study to optimize the quality of data and decrease the length of scanning session for each type of scan. All of the imaging methods have been previously implemented at UW-Madison. Each sequence will take approximately 5-10 minutes.
40765091|NCT05013736|BEHAVIORAL|Behavioral Assessments|The behavioral assessments (GMA: General Movements Assessment; HINE: Hammersmith Infant Neurological Examination; Baby Observation of Selective Control AppRaisal (BabyOSCAR); Bayley-4 / Bayley Scales of Infant and Toddler Development 4th ed; Pediatric Evaluation of Disability Inventory -Computer Adaptive Test (PEDI-CAT)) are infant and age-specific and will be administered by trained pediatric occupational and physical therapists.
40765092|NCT05013736|DEVICE|Non invasive Transcranial Magnetic Stimulation|TMS will be used to assess cortical excitability and circuitry (not as a neuromodulation intervention). Single-pulse TMS (Magstim 200², Magstim, UK) with a scalp surface coil will be used to assess how the brain is developing and how connected the tract is, between the brain and a target muscle on the arm. 10-20 TMS stimulation pulses will be delivered at a range of stimulation intensities (50-100%) increasing by 5% maximal stimulator output (MSO) at each stage. In sum, around 150 stimulation pulses per hemisphere are expected for TMS assessment for each infant.
40765093|NCT05201495|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
40765094|NCT06637696|OTHER|Blood Culture Bundle|In this pre and post intervention study investigators aimed to evaluate the impact of a blood culture bundles on the incidence of blood culture contamination rates in NICU.
40765095|NCT06377319|DIAGNOSTIC_TEST|Cardiac Output Response to Stress (CORS) test|Cardiac Output Response to Stress (CORS) is a novel, non-invasive, easy-to-use test developed by the Newcastle and Coventry Universities. CORS test measures heart function (cardiac output) at rest and in response to short step-exercise using validated electrical signal processing bioreactance technology, similar to an ECG.
40765096|NCT05462496|PROCEDURE|Biopsy|Pre-treatment tumor biopsy
40765097|NCT05462496|DRUG|FOLFIRINOX|"Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows\*:~* Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~* Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~* Leucovorin\*\*: 400 mg/m2 IV over 2 hours on Day 1, followed by,~* 5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3"
40765098|NCT05462496|DRUG|Ciprofloxacin|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
40765099|NCT05462496|DRUG|Metronidazole|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
40765100|NCT05462496|DRUG|Pembrolizumab|Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.
40765101|NCT05462496|PROCEDURE|Surgical Resection|Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.
40962648|NCT02383498|OTHER|Placebo|Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
40962649|NCT02383498|BIOLOGICAL|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
40962650|NCT02383498|RADIATION|Radiotherapy|Standard of care
40962651|NCT02383498|DEVICE|wGT3X-BT Actigraph|wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
40962652|NCT03980041|DRUG|IPI-549 (eganelisib)|IPI-549 (40mg QD) administered orally in 28-day cycles
40962653|NCT03980041|DRUG|Nivolumab|Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
40962654|NCT03980041|DRUG|Placebos|Placebo administered orally in 28-day cycles
40962655|NCT02084654|DRUG|Exenatide 5 and 10 mcg 2 times a day|
40962656|NCT02084654|DRUG|placebo|
40962657|NCT00896246|DRUG|Klean-Prep®|Four litres of solution administered orally as a divided dose.
41136445|NCT03497052|OTHER|In vitro culture in medium 2|Oocytes will be cultured in IRVINE media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
40962658|NCT00896246|DRUG|Moviprep®|Two litres of solution administered orally as a divided dose
40962659|NCT04853212|PROCEDURE|Biopsy|Biopsy during recto-coloscopy
40962660|NCT00115102|DRUG|fentanyl|
40962661|NCT00115102|DRUG|S-ketamine|
40962662|NCT04650711|DIAGNOSTIC_TEST|p16 protein expression|P16INK4A immunohistochemical staining is to be performed in residual cytology samples.
40962663|NCT03783416|DRUG|Ixazomib (NINLARO®) capsules / Matching placebo capsules|Participants will be treated for a maximum of 24 months
41136446|NCT03068312|DRUG|Ivacaftor|IVA 150 mg tablet.
41136447|NCT03068312|DRUG|Placebo|Placebo matched to IVA tablet.
41294011|NCT04704882|OTHER|omental patchwork|the omental flaps were sewn to lesser omentum and hepatorenal ligament to cover all the vessels
41294012|NCT02850614|BEHAVIORAL|gaming application to encourage physical activity|
41294013|NCT02850614|DEVICE|FitBit|
40765102|NCT06643351|OTHER|Standard Intrapartum Glucose Target Range|Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-110mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 110 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
40765103|NCT06643351|OTHER|Liberalized Intrapartum Glucose Target Range|Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-160mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 160 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
40765104|NCT05272488|OTHER|Manual therapy and vagus nerve stimulation|A neurodinamic intervention of vagus nerve through deep breaths involving diaphragm muscle and manual therapy techniques.
40765105|NCT05272488|OTHER|Manual therapy|Manual therapy techniques. Joint manipulation techniques for temporomandibular joints and Soft tissue techniques for the muscles
40765106|NCT04634435|COMBINATION_PRODUCT|BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2|Single dose infusion of BHV-1100 plus CIML NK Cells plus IVIG, followed by low dose IL-2
40765107|NCT05019703|BIOLOGICAL|Atezolizumab|Given IV
40765108|NCT05019703|DRUG|Cabozantinib|Given PO
40765109|NCT06093191|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
40962664|NCT05875363|OTHER|collect data|"The Juvenile Affairs Division provided the records without person-identifiable data (i.e., name, ID) to the researchers. The researchers coded the above data (i.e., the offenders' sociodemographic data, medical history, and criminal history).~Demographic characteristics were collected, which are the offenders' age, gender, occupation, education level, and residence (district). We recorded the offenders' household members (without the name or age), main caregivers (e.g., father, or mother), and the parents' socioeconomic and marital status. We also tracked whether the offenders live with family members with mental illness, whether they are from at-risk families, and whether had been victims of domestic violence. The medical history and deviant (or criminal) behaviors will be collected in the attached measure."
40962665|NCT01962896|DRUG|Erlotinib|
40962666|NCT01962896|DRUG|Sirolimus|
41136448|NCT02955563|OTHER|CSDM Web-Based Tool Intervention|The web and tablet-based tool is designed to help family members become familiar with ICU environment, routines, and clinicians, prepare for family meetings, and learn how to make values-based decisions for their loved one. The tool contains short videos, interactive exercises, and links to other resources. Family members work through the tool shortly after admission to the ICU, before each family meeting, and any other time they wish to during the ICU admission.
41294014|NCT06207175|BIOLOGICAL|Nonavalent HPV study vaccine|A 3-dose regimen administered at months 0, 2 and 6.
41294015|NCT06207175|BIOLOGICAL|GARDASIL® 9|A 3-dose regimen administered at months 0, 2 and 6.
41294016|NCT01284179|BEHAVIORAL|Home Hypnotherapy|Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
41294017|NCT01284179|BEHAVIORAL|Educational|Educational recordings regarding FCP and FGIDs.
41456369|NCT00712244|DEVICE|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
41456370|NCT02731781|OTHER|NONE . OBSERVATIONAL|OBSEVATION AND FOLLOW UP
41456371|NCT04021407|DEVICE|LMA group|patients were ventilated with LMA
41456372|NCT04021407|DEVICE|AirQ group|patients were ventilated with AirQ airway
41466505|NCT01435824|DRUG|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
40765110|NCT06093191|DRUG|Ciprofloxacin 750 MG|Oral ciprofloxacin 750mg twice daily will be prescribed for 2 weeks.
40765111|NCT06093191|DRUG|Oral ciprofloxacin placebo|Oral ciprofloxacin placebo twice daily will be prescribed for 2 weeks.
40765112|NCT06093191|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
40765113|NCT04065399|DRUG|revumenib|revumenib orally
40765114|NCT04065399|DRUG|cobicistat|Phase 1 Arm C participants will receive 150 mg cobicistat daily.
40765115|NCT05250908|DEVICE|INTIBIA Therapeutic|INTIBIA implantable tibial nerve stimulator with therapeutic stimulation
40765116|NCT05250908|DEVICE|INTIBIA Non-Therapeutic|INTIBIA implantable tibial nerve stimulator with non-therapeutic stimulation for 3 months, then therapeutic stimulation
40765117|NCT04203576|DEVICE|FIRE1 System|FIRE1 System
40765118|NCT05064085|DRUG|Cemiplimab|Participants will be given Cemiplimab 350 mg IV day 1 every 21 days
40765119|NCT05064085|DRUG|Capecitabine|Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.
40765120|NCT05138133|DRUG|Anifrolumab|Anifrolumab intravenous infusion (IV)
40765121|NCT05138133|DRUG|Placebo|Placebo intravenous infusion (IV)
40765122|NCT02532452|BIOLOGICAL|Viral Specific VST Infusion|"VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \> 1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy~* Evidence of PML or other CNS infection due to JC virus"
40765123|NCT05821894|OTHER|Observational study|
40765124|NCT06643988|BEHAVIORAL|MemFlex|MemFlex employs cognitive training exercises in self-led sessions to improve 1) switching between specific and general AMs, 2) access to positive AMs, and 3) vividness of positive AMs.
40962667|NCT01201005|DIETARY_SUPPLEMENT|Hydroxycobalamin|Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection
40962668|NCT01201005|DIETARY_SUPPLEMENT|Sham injection|needle injection without any substance given
40962669|NCT05026255|PROCEDURE|alveolar recruitment manoeuvre by pressure step|The application of alveolar recruitment manoeuvres consists of transiently increasing alveolar pressure in order to re-open collapsed alveolar territories and to re-ventilate poorly ventilated or non-ventilated lung areas.
40962670|NCT03752983|DIAGNOSTIC_TEST|blood samples|blood samples
40765125|NCT06644482|OTHER|Exercise group in a hospital setting|Participants will exercise in a group once a week for 16 weeks in a hospital setting.
40765126|NCT05621837|OTHER|MDSC quantification|Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).
40765127|NCT06643494|DIETARY_SUPPLEMENT|N-111|A combination of Acetogenins
40765128|NCT06643494|OTHER|Placebo|Placebo
40765129|NCT02836249|DRUG|TAF|TAF 25 mg tablet administered orally once daily
40765130|NCT02836249|DRUG|TDF|TDF 300 mg tablet administered orally once daily
40765131|NCT02836249|DRUG|TAF Placebo|TAF placebo tablet administered orally once daily
40765132|NCT02836249|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
40765133|NCT06507644|PROCEDURE|light curettage|Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.
40765134|NCT06507644|OTHER|Pre irradiation of 1 hour|A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 1 hour.
40765135|NCT06507644|OTHER|Pre irradiation of 3 hour|A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 3 hour.
40765136|NCT06507644|OTHER|topical application of 8% methyl aminolevulinate photosensitizer MAL|Participants will be treated with 8% topical MAL photosensitizer
40765137|NCT06507644|OTHER|topical application of 16% methyl aminolevulinate photosensitizer (MAL)|Participants will be treated with 16% topical MAL photosensitizer
40765138|NCT06507644|DEVICE|Visible light source|Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm
40962671|NCT06264375|BEHAVIORAL|Physical exercise|see group description
40962672|NCT03423641|DRUG|Direct Acting Antivirals|The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
40962673|NCT02022852|DRUG|Capecitabine|50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
40962674|NCT02022852|DRUG|XELOX|XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
40962675|NCT00158990|DRUG|triiodothyronine|
40962676|NCT00158990|DRUG|sertraline|
40962677|NCT02825056|DRUG|Bupivacaine|Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
40962678|NCT02825056|DRUG|Bupivacaine + Morphine|Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
40765139|NCT02595879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40765140|NCT02595879|RADIATION|Brachytherapy|Undergo LDR brachytherapy
40765141|NCT02595879|DRUG|Cisplatin|Given IV
40765142|NCT02595879|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
40765143|NCT02595879|RADIATION|External Beam Radiation Therapy|Undergo pelvic EBRT
41294018|NCT04448249|BEHAVIORAL|APN intervention|"APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary,~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
40765144|NCT02595879|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT
40765145|NCT02595879|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
40765146|NCT02595879|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40765147|NCT02595879|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40765148|NCT02595879|OTHER|Pharmacological Study|Correlative studies
40765149|NCT02595879|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
40765150|NCT02595879|DRUG|Triapine|Given IV and PO
40765151|NCT05860751|PROCEDURE|Dry Needling with electrical stimulation|Administered for a total of 2 sessions at a frequency of once per week. The target muscles to be needled will include the gastronemius, soleus, vastus lateralis, rectus femoris, anterior tibialis, posterior tibialis, biceps femoris, and gluteus medius.
40765152|NCT06645249|DRUG|Amiodarone (Antiarrhythmic drug)|Comparing 2 regimes of amiodarone pre-electrical cardioversion witn ECG monitoring
40962679|NCT06241833|DRUG|PPI|use of PPI concomitant with DAPT
40962680|NCT02313792|DRUG|Palifermin|
40962681|NCT01325584|DRUG|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
40962682|NCT01036893|DRUG|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
40962683|NCT04250220|DIAGNOSTIC_TEST|e-Health based strategy: PPG-based screening using a smartphone and ECG patch|PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch
40962684|NCT01646762|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
40962685|NCT01646762|OTHER|Laboratory Biomarker Analysis|Correlative studies
40962686|NCT01370356|DRUG|Varenicline Tartrate|Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
40962687|NCT01370356|DRUG|Placebo|Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
40962688|NCT00002133|DRUG|Itraconazole|
40962689|NCT05700097|DRUG|Dengzhanxixin Injection|Experimental arms for low, and high dose for the standard protocol
40962690|NCT05700097|DRUG|Placebo injection|placebo control arm for the standard protocol
41294019|NCT03068026|DEVICE|VitaBreath|The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
41294020|NCT03068026|OTHER|Pursed Lip Breathing technique|Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
40962691|NCT06324669|DIETARY_SUPPLEMENT|Ketone supplement|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
40962692|NCT06324669|DIETARY_SUPPLEMENT|Placebo supplement|Placebo with stevia and bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
40962693|NCT04503785|DIAGNOSTIC_TEST|Manometry|Transnasal Esophageal manometry and Endoflip Balloon distensibility
40962694|NCT02516163|DEVICE|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
40962695|NCT05307146|DEVICE|macro/micro electrode recording|intracranial macro/micro-electrode placement at the cerebral cortex or in deeper brain areas with te use of macro/micro electrode recording. Macro/micro electrodes are placed at the cerebral cortex or in deeper brain areas in order to precisely identify the epileptogenic focus
41294021|NCT06329362|PROCEDURE|Minimally invasive implantation|Specially designed ridge splitting instrumentation by Champions Implant GmbH which is implant shaped expanders.
41294022|NCT06329362|PROCEDURE|Open flap procedure for ridge expansion.|Mucoperiosteal elevation and ridge splitting using conventional ridge expanders.
41294023|NCT01511146|DRUG|Oxaliplatin|oxaliplatin 85 mg/m2 in 10 minutes
41294024|NCT01511146|DRUG|Mitomycin + Gemcitabine|Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
41294025|NCT00658970|DRUG|KX2-391|2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
41294026|NCT00218244|OTHER|Lower Nicotine Smokeless Tobacco Product|Skoal for 50% reduction;Skoal bandits for 75% reduction.
41456373|NCT05766631|BEHAVIORAL|DynamiCare Health|"Participants earn incentives for:~1. CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~2. Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~3. Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~4. The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment."
40962696|NCT03894332|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|"After enrollment, a silicon EIT belt of proper size with 16 electrodes was placed around the patient's chest between the 4th and 6th intercostal spaces, and connected to the EIT device. All patients were ventilated in Pressure Support Ventilation (PSV) mode, with a dedicated ventilator connected to the EIT device.~We acquired 5-min EIT data records at baseline (during PSV), during the first (SBT_0) and the last (SBT_30) 5 minutes of SBT, and, when the patient was extubated, during spontaneous breathing soon after (SB_0) and 30 minutes after extubation (SB_30).~EIT and ventilator data were recorded at a sample of 20 Hz. The last 3 minutes of each record were analyzed.~We measured respiratory rate (RR); Vt changes from baseline, expressed as percent (dVt%); dEELI variations from baseline, expressed in mL; the Global Inhomogeneity index (GI); Impedance ratio (IR) and the Center of Ventilation (CoV)."
40962697|NCT03674684|OTHER|hydroxyethyl starch|After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
40962698|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
40962699|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
40962700|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
40962701|NCT02400333|DRUG|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
40962702|NCT04976660|DRUG|TT-4|TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
40962703|NCT01617200|DRUG|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
41294027|NCT00218244|OTHER|Behavioral Counseling|Behavioral counseling alone for reduction in tobacco use.
41294028|NCT01224353|DRUG|lipoic acid|Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks
41294029|NCT01224353|OTHER|Placebo|Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
41294030|NCT01209208|DRUG|Budesonide|9 mg per day
41294031|NCT01209208|DRUG|Mesalamine|3 g per day
41294032|NCT01209208|OTHER|Placebo|0 g per day
41294033|NCT03026504|DRUG|Baricitinib|4 milligrams oral Baricitinib daily for 52 weeks
41294034|NCT05159232|PROCEDURE|hospital stay|hospital stay in in inguinal hernia repair
41294035|NCT01713036|DRUG|Pimasertib|Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) \[14C\] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries \[mcgCi\]) of \[14C\] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
40765153|NCT06642493|BIOLOGICAL|Fresh frozen plasma|"Intervention Type: Biological~* Intervention Name: Fresh Frozen Plasma (FFP)~* Detailed Description:~* Dosage:Fresh frozen plasma (FFP) will be administered at a dose of 10-15 mL/kg body weight.~* Administration: The FFP will be transfused intravenously under controlled clinical conditions.~* Purpose: The transfusion aims to correct coagulopathy and normalize activated partial thromboplastin time (aPTT) in non-bleeding thrombocytopenic dengue patients.~* Monitoring: Patients will be closely monitored for any adverse reactions or complications during and after the transfusion process. Coagulation parameters, including aPTT, will be measured at baseline, 24 hours, and 48 hours post-transfusion."
40765154|NCT06581237|OTHER|Eat2Win App|Voluntary use of the app will occur throughout the sport season.
40765155|NCT04049214|OTHER|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
40765156|NCT05948943|DRUG|Alpelisib|"In Stage 1: adult participants (≥18 years of age) will receive dose 1 or dose 2 of alpelisib; pediatric participants (6-17 years of age) will receive dose 2 or dose 3 of alpelisib.~In Stage 2: Adult participants will receive alpelisib at the dose selected for confirmatory phase in adult participants; pediatric participants (6-17 years of age) will will receive alpelisib at the dose selected for confirmatory phase in pediatric participants; and pediatric participants of 2-5 years of age will receive dose 3 of alpelisib"
40962704|NCT01617200|DRUG|Placebo Asenapine|2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
40765157|NCT05948943|DRUG|Placebo|In Stage 2, participants will receive matching placebo for 24 weeks of the study
40962705|NCT01617200|DRUG|Olanzapine|15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
40962706|NCT01617200|DRUG|Placebo Olanzapine|15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
40962707|NCT04036890|DRUG|2% minocycline hydrochloride controlled-delivery system (MHS)|The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
40962708|NCT04036890|DRUG|Placebos|It is the same gel as MHS but without active ingredient minocycline hydrochloride.
40962709|NCT03711812|PROCEDURE|Serratus Anterior Plane Catheter|Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
40962710|NCT03711812|PROCEDURE|Thoracic Epidural Catheter|Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
40962711|NCT00433121|DRUG|Risperidone|
40962712|NCT00433121|DRUG|Olanzapine|
40962713|NCT00433121|DRUG|Haloperidole|
40962714|NCT00433121|DRUG|Quetiapin|
40962715|NCT00433121|DRUG|Escitalopram|
40962716|NCT00433121|DRUG|Citalopram|
40962717|NCT00433121|DRUG|Sertralin|
40962718|NCT02579239|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
40962719|NCT02579239|BIOLOGICAL|Placebo|Concentrate for solution for infusion
40962720|NCT06354400|OTHER|Core stabilization training|Isometric exercises of the abdominal muscles in the supine, prone, and squatting positions; isotonic exercises in the supine, prone, squatting, and side-lying positions; isotonic exercises in coordination with the extremity movements in the supine, prone, and crawling positions; and trunk rotation exercises in the sitting position will be performed. The Swiss ball will be used for dynamic exercises. It will include isometric and isotonic exercises of the abdominal muscles. Exercises will start with 3 sets of 20 repetitions, gradually increase in intensity on static and dynamic surfaces, and progress towards difficulty. Each exercise will be performed in coordination with breathing control. Breathing control will be coordinated with every exercise.
40962721|NCT00514111|DRUG|pegylated-interferon, conventional-interferon, ribavirin|Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
40765158|NCT06641011|DEVICE|Immediate restoration (resin- based) after blot-drying silver fluoride application|Blot-drying silver fluoride with cotton pellet followed by resin-based fissure sealant
40765159|NCT06641011|DEVICE|Immediate restoration (GI- based) after blot-drying silver fluoride application|Blot-drying silver fluoride with cotton pellet followed by glass ionomer-based fissure sealant
40765160|NCT06641011|DEVICE|Immediate restoration (Resin based) after rinsing silver fluoride application|Rinsing silver fluoride off followed by resin-based fissure sealant
40765161|NCT06641011|DEVICE|Immediate restoration (GIC) after rinsing silver fluoride application|Rinsing silver fluoride off and blot-drying of fissures followed by glass ionomer-based fissure sealant
40765162|NCT06641011|DEVICE|Resin based fissure sealant restoration one week after silver fluoride (AgF) application|Resin based fissure sealant restoration one week after silver fluoride (AgF) application
40765163|NCT06641011|DEVICE|GI- based fissure sealant restoration one week after silver fluoride (AgF) application|GI- based fissure sealant restoration one week after silver fluoride (AgF) application
40765164|NCT05000788|BEHAVIORAL|Qigong|Eight-Section Brocades Practice: The treatment group will undergo an 8-week Eight-Section Brocades intervention program consists of a total of 16 group training sessions with two 1-hour sessions per week. The treatment group participants will be provided with health qigong exercise in a group format led by qualified qigong instructors. All the health qigong instructors will be trained by a certified Traditional Chinese Medicine (TCM) practitioner with an expertise in health qigong and they are required to pass the certification examination before delivering health qigong intervention at the clinical settings. The Eight-Section Brocades protocol will be used in this study because it is easy to learn by the participants and the clinical effects on psychosocial health were evidenced in previous RCTs. A complete cycle of the Eight-Section Brocades took 12 minutes for completion, which consists of eight sequential and simple forms of movements.
40765165|NCT05000788|BEHAVIORAL|Exercise|Exercise Program: Participants in the control group will attend a physical exercise program for 8 weeks (1-hour sessions, 2 times a week). The exercise program will incorporate aerobic fitness, strength training, body weight workouts, balance training, flexibility and stretching into the training plan. The exercise program is provided in a group format, which will be led by qualified physical trainer.
40765166|NCT06308224|OTHER|Modified-Otago Exercises|"Walking for 15 minutes before or after the strengthening and balance exercises of Modified-Otago.~Strengthening exercises for 10 minutes: Knee extensor, Knee flexor, Hip adductor, Ankle plantar flexors (calf raises), and Ankle dorsiflexion (toe raises).~Balance exercises 20 minutes: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel-toe stand), Tandem walk (heel-toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backward, sit to stand and Stair walking."
40765167|NCT06308224|OTHER|Tai-Chi Exercises|"Warm-up exercises for 10 minutes.~Tai Chi Qigong Exercises for 30 minutes: Commencing form and regulating breathing, Expanding your chest, Painting a rainbow, Circling arms to separate the clouds, Fixed step invert brachial, Row a boat in the middle of the lake, Shoulder the ball, Turning the body to look at the moon, Twisting waist and pushing palms, Horse step and cloud hands, Drag the sea and watch the sky, Undulating waves, Dove spreading wings, Extend arms and punch, Wild goose flying, Flywheel turning, Bounce ball while stepping, Pressing palms in calmness.~Cool-down exercises for 5 minutes."
40765168|NCT06639243|DEVICE|QYM Technique|"The intervention in this study involves the application of the Quick Yielding Modified (QYM) technique for the treatment of complex aortic arch diseases. This procedure consists of two main components:~1. Thoracic Endovascular Aortic Repair (TEVAR): This minimally invasive procedure utilizes a covered stent graft to exclude the diseased segment of the thoracic aorta, providing immediate protection against rupture and controlling blood flow.~2. In Situ Fenestration and Revascularization of Supra-Aortic Branches: Following TEVAR, the QYM technique includes creating fenestrations in the stent graft to allow for the revascularization of the supra-aortic branches (such as the brachiocephalic, left common carotid, and left subclavian arteries). This is achieved through direct puncture and reconstruction of the branch vessels, ensuring adequate blood flow to these critical arteries while preserving their function.~The combination of these techniques aims to achieve effective treatment out"
40765169|NCT06186518|OTHER|PİKSEÇ|"In designing the PİKSEÇ application, the Turkish validity and reliability version of the 'Difficult Intravenous Access Score' and a literal translation of the miniMAGIC instructions were utilized. The application serves as a guideline for nurses during peripheral intravenous catheter insertion, taking into account parameters such as the patient's age, urgency status, anxiety, and vein characteristics, providing tailored suggestions.~By utilizing the application, nurses can follow evidence-based guidelines more efficiently, ensuring a faster and more practical adherence to the PIVC intervention procedure, ultimately contributing to a safer peripheral intravenous catheter insertion process."
40765170|NCT06186518|OTHER|Routine care|The pediatric unit's PIVC insertion process will be routinely performed in routine care.
40765171|NCT06579040|DEVICE|Monoplace Hyperbaric Chamber (Class III medical device)|Participants in the intervention group will be triaged to the closest hyperbaric facility to their address and treated with 40 HBOTs (2.4 ATM for 90 mins, scheduled daily from Monday to Friday). As HBOT is not a service currently offered at Sunnybrook Hospital, all HBOT treatments will be provided at three collaborating outpatient facilities, Halton Hyperbaric Unit, Restore Hyperbaric Oxygen \& Medical Centre (CPSO-certified Level-II OHP), and Rouge Valley Hyperbaric Medical Centre. All three facilities have the exact same hyperbaric chambers, run by anesthesiologists with advanced training, thus treatments will be identical at all sites.
40962722|NCT05747209|OTHER|Observation of Exercise Program Adherence|Observation of a monitored group exercise regimen utilizing standard of care high-load resistance training and functional exercises with compound movements under close supervision and with the goal of improving functional mobility, body composition, and strength after cancer treatment to study adherence and attendance to the exercise program.
40962723|NCT05472831|BEHAVIORAL|BAILAMOS dance program plus MIND diet|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute MIND diet session per week.
41456374|NCT05766631|DRUG|Methadone Treatment-As-Usual|Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
41294036|NCT02307305|DRUG|Duloxetine|"1. Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~2. Phase II (titration): POD#1\~6 (30mg for another 6 days)~3. Phase III (maintenance): POD#7\~13(60mg for 7 days)~4. Phase IV (tapering-1): POD#14\~20 (30mg for 7 days)~5. Phase V (tapering-2): POD#21\~27 (30mg another every day for 7 days)"
40765172|NCT06639776|DIAGNOSTIC_TEST|Questionnaire|"All erection prosthesis placements in post-phalloplasty transgender and gender non-conforming individuals at Ghent University Hospital from start of the gender clinic until June 2023 will be evaluated. All patients that are at least 6 months after erection prosthesis placement and currently have a functioning prosthesis in place are eligible and will be contacted. Upon inclusion and informed consent, the patient's medical files will be used to gather all necessary underlying medical information that is relevant to this study. will receive an email asking them to complete a questionnaire for themselves. At the end of this questionnaire the patient will be asked if they have a sexual partner and if this partner is willing to participate as well. After affirmation, the partner will be contacted in the same way.~Patients will receive a series of questionnaires reviewing recent sexual activity, sexual preference, satisfaction with the erectile prosthesis and quality partner relationship."
40765173|NCT03914326|DRUG|Semaglutide|Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
40765174|NCT03914326|DRUG|Placebo (semaglutide)|Placebo tablets to be taken with water at the same time every morning in a fasting state
41294037|NCT02307305|DRUG|celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone|Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
40765175|NCT06581263|DEVICE|Meta Quest 3|Meta Quest 3 is a virtual reality headset device
40765176|NCT03728478|DRUG|Etanercept|Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).
40765177|NCT03728478|DRUG|Methotrexate|Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
40765178|NCT03728478|DRUG|Intra-articular corticosteroid injections|Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
40765179|NCT06642077|DRUG|LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml|A total of 2 ampoules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml were injected into the sternotomy incision site and around the chest tubes of 30 patients in the experimental group. The total number and dose of opioids, the total number and dose of analgesics used to relieve the pain of the patients in the 24 hours after the injection of 2 ampules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml, and the total number and dose of analgesics were recorded, and the patients were interviewed face-to-face 24 hours later, and PoRI was recorded. No intervention was performed on 30 patients in the control group, and standard treatment and care continued to be applied to these patients.
40765180|NCT06570460|DRUG|17-beta estradiol|Treatment with orally administered estrogen for 6 months
40765181|NCT06570460|DRUG|17-beta estradiol|Treatment with transdermally administered estrogen for 6 months
40765182|NCT06642714|PROCEDURE|weaning by early non-invasive ventilation and progressive high flow oxygen therapy|"Step 1 Clinical stability was confirmed:~(1)Without organ failure;(2)Without sepsis;(3)Stable heart rate and blood pressure without use of vascular active drugs.~Step2 Reduce the support parameters of the ventilator gradually. Step3 SBT when the ventilator mode is pressure support ventilation(PSV),P+PEEP≤16cmH2O for 2 hours.~Step4~①Success of SBT: titrate based HFOT time-------connected with tracheostomy tube ,flow rate and FiO2 able to maintain oxygen saturation as assessed by pulse oximetry monitoring of at least 95%.HFOT was interrupted in cases of sighs or symptoms of distress such as oxygen desaturation, RR\>30bpm, HR\>130bpm,SBP\>180mmHg or \<90mmHg.The time was based HFOT time. When any of these conditions were present the patient was connected again to the ventilator with the same parameters before titration. The duration of SBT was increased progressively over the following day according to patient tolerance. Then gradually extending HFOT time daily according patient condition. Wh"
40962724|NCT05472831|BEHAVIORAL|BAILAMOS dance program plus Health Education|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute Health Education session per week.
41294038|NCT02481518|DRUG|Magnesium|Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
41294039|NCT02481518|OTHER|Control|Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
41294040|NCT00991172|DRUG|REGN475|Single Subcutaneous injection dose level 1
41294041|NCT00991172|DRUG|REGN475|Single subcutaneous injection dose level 2
40765183|NCT06643117|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
40962725|NCT06147362|DRUG|68Ga-NOTA-PEG2-RM26|Single-dose 68Ga-NOTA-PEG2-RM26, a gastrin-releasing peptide receptor antagonist linked with a positron emitting radioisotope intravenously injected into participants before the PET/CT scans.
40962726|NCT00465036|DIETARY_SUPPLEMENT|Whole flaxseeds, flaxseed mucilage, glucomannan|
40962727|NCT03131778|PROCEDURE|Liver resection|liver resections for colorectal liver metastases
40962728|NCT04020380|DRUG|Azithromycin 250Mg Capsule|250 mg OD
40962729|NCT04378556|BEHAVIORAL|Nutritional coaching|Participants were provided with nutrition education and a per-meal protein prescription followed by 9 weeks of nutritional coaching.
40962730|NCT00536185|DIETARY_SUPPLEMENT|Fish Oil|capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
40962731|NCT00536185|DIETARY_SUPPLEMENT|Placebo|capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
41294042|NCT00991172|DRUG|Placebo Injection|Placebo Subcutaneous injection
41294043|NCT02004054|OTHER|measure of pupil diameter|The measure will use infra-red cameras
41294044|NCT04310137|BEHAVIORAL|Therapist-Directed Re-loading|Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.
41456375|NCT03720548|DRUG|LY3372993|Administered IV.
41456376|NCT03720548|DRUG|Placebo|Administered IV.
41294045|NCT00576498|OTHER|NBI-AFI imaging|"Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence."
41294046|NCT00576498|OTHER|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
41294047|NCT05114863|OTHER|Product A1|Usual Brand (UB) filtered, non-menthol cigarette
40765184|NCT06643117|BIOLOGICAL|FYB206|Open-label treatment with FYB206 combined with chemotherapy (Cycles 18-34) to assure treatment continuation for trial patients up to a total of 2 years (a total of 34 treatment cycles)
40765185|NCT06643117|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
41294048|NCT05114863|OTHER|Product B|40007388, A Non-Combusted Cigarette Variant and product use Mode A
41294049|NCT05114863|OTHER|Product C|40007388, A Non-Combusted Cigarette Variant and product use Mode B
41294050|NCT05114863|OTHER|Product D|40007386, A Non-Combusted Cigarette Variant and product use Mode B
41294051|NCT05114863|OTHER|Product A2|Usual Brand (UB) filtered, menthol cigarette
41294052|NCT05114863|OTHER|Product E|40007385, A Non-Combusted Cigarette Variant and product use Mode A
41294053|NCT05114863|OTHER|Product F|40007385, A Non-Combusted Cigarette Variant and product use Mode B
41456377|NCT01897077|DRUG|Peanut Dissolving Film|
40765186|NCT06639334|OTHER|Fasttrack pathway for THA/HE prosthesis reduction|"The purpose of this study is to design a fast-track pathway for patients referred to the University Hospital of Southern Denmark, Esbjerg, with high probability of having a dislocated hip prosthesis with the primary aim to reduce the time from arrival to reduction and the total hospitalization time.~The intervention is changed logistic and work pathways at the hospital that should reduce time to reduction significantly. For detailed description we refer to the uploaded protocol."
40962732|NCT03692130|BEHAVIORAL|Mindfulness, Acceptance and Commitment-Therapy|Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.
40962733|NCT03692130|BEHAVIORAL|Jacobson|Relaxation treatment in technique of Jacobson
40962734|NCT00067405|DRUG|Intravenous micronutrient therapy|
40962735|NCT04617171|DRUG|Benralizumab 30 MG/ML [Fasenra]|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
40962736|NCT04617171|DRUG|Placebos|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
41294054|NCT05114863|OTHER|Product G|40007387, A Non-Combusted Cigarette Variant and product use Mode B
41294055|NCT05114863|OTHER|Product H|40007386, A Non-Combusted Cigarette Variant and product use Mode B
41294056|NCT05114863|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
41294057|NCT02829346|DRUG|Peri-articular tranexamic acid|750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
41456378|NCT04894409|DEVICE|Mouthwash and nose rinse with the AgNPs solution|"The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers"
41456379|NCT04894409|DEVICE|Mouthwashes and nose rinse in a conventional way|The control group was instructed to do mouthwashes and nose rinse in a conventional way
40765187|NCT06639334|OTHER|Standard pathway for THA/HE prosthesis reduction|Standard treatment for a dislocated THA/HA at our institution is education in general anesthesia at the operating theater. For detailed description we refer to the uploaded protocol.
40765188|NCT06638801|BEHAVIORAL|Coach-led caregiver-implemented early literacy and developmental programming|Caregivers will receive training about child brain development in the first 3 years of life. The training will emphasize the areas of spoken words, physical education, pointer-finger concept, focus and label, reading lessons, and mathematics.
40765189|NCT06638801|BEHAVIORAL|Reach Out and Read Training|Reach Out and Read parent training
40765190|NCT06410209|OTHER|Goal Setting|Set physical activity goals
40765191|NCT06410209|OTHER|Interview|Participate in a one-on-one interview
40765192|NCT06410209|OTHER|Interview|Ancillary studies
40962737|NCT02051686|DRUG|Tranexamic Acid|10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
40962738|NCT02051686|DRUG|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
41294058|NCT02829346|DRUG|Intravenous tranexamic acid|750 mg of IV TXA, prior to deflating the tourniquet and wound closure
41294059|NCT00374907|DRUG|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
41294060|NCT00374907|DRUG|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
41294061|NCT00374907|DRUG|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
40765193|NCT06410209|OTHER|Media Intervention|View private social media peer support group content
40765194|NCT06410209|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit physical activity tracker
40765195|NCT06410209|OTHER|Medical Device Usage and Evaluation|Wear a research grade activity measuring device
40765196|NCT06410209|OTHER|Questionnaire Administration|Ancillary studies
40765197|NCT06410209|OTHER|Reward|Receive badges
40765198|NCT06410209|OTHER|Text Message-Based Navigation Intervention|Receive text messages
40765199|NCT06410209|OTHER|Text Message-Based Navigation Intervention|Receive reminders
40765200|NCT06342609|DRUG|Colchicine 0.5 MG|0.5mg per day of Colchicine orally administered
40765201|NCT06519994|DRUG|Artesunate vaginal inserts|Subjects will self-administer 200 mg of Artesunate vaginal insert daily for 5 days, on weeks 1, 3, 5.
40765202|NCT06519994|DRUG|Placebo vaginal inserts|Subjects will self-administer a placebo vaginal insert daily for 5 days, on weeks 1, 3, 5.
40765203|NCT06638489|OTHER|High-Intensity-Focused-Electromagnetic-Therapy (HIFEM)|The HIFEM stimulation was administered using an Emsella instrument (manufactured by BTL Industry Inc., Boston, MA). The frequency ranged between 50 and 60Hz, and the intensity was as high as the patient could tolerate, which was usually up to 100%.
40765204|NCT06638489|OTHER|Pelvic-Floor-Muscle-Training (PFMT)|The PFMT protocol was that outlined by previous study. The participants were instructed to execute 5 rapid contractions over a span of 3 seconds and 10 prolonged contractions, each lasting between 3 to 8 seconds, with intervals of 10 seconds for relaxation in between, all while in a crook-lying position.
40765205|NCT06638008|DRUG|perineural injection|perineural intervention of placental growth factor in one group and PRP in other group
40765206|NCT06641024|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy
40765207|NCT06642168|GENETIC|Whole exome sequencing to detect myocardial genetic mutations (SCA group only)|Whole exome sequencing to detect myocardial genetic mutations
40765208|NCT06546995|DRUG|NMRA-323511|Participants will receive NMRA-323511 orally.
40962739|NCT05881928|DRUG|Sodium Valproate 500 Mg Prolonged-Release Oral Tablet|sodium valproate tablet30 mg / kg / day , maximum 1500mg / day . LTG :
40962740|NCT05881928|DRUG|Lamotrigine|lamotrigine tablet 0.5 mg/kg for 2 weeks in two divided doses , increased in 0.5mg/kg/day increments every 2weeks .
40962741|NCT05881928|DEVICE|E.E.G|device recording of brain activity. During this painless test, small sensors are attached to the scalp to pick up the electrical signals produced by the brain. These signals are recorded by a machine and are looked at by a doctoris
40962742|NCT05792709|OTHER|Oral Motor Therapy|In Traditional therapy we will give cognitive and articulation therapy to the patients.
40962743|NCT03811028|DRUG|SOBI003|weekly i.v. infusion
41136449|NCT02334605|OTHER|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
41136450|NCT02334605|DEVICE|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
41136451|NCT02334605|DEVICE|capsaicin nasal spray|1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
41136452|NCT02506452|OTHER|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
41136453|NCT02506452|OTHER|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
41136454|NCT00529009|DRUG|UDCA|
41136455|NCT02280759|DRUG|Gelatin Tannate|
41136456|NCT02280759|DRUG|Placebo|Placebo consists of an identical formulation, except active substance
41294062|NCT00374907|DRUG|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
41294063|NCT05242588|BIOLOGICAL|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
40765209|NCT06546995|DRUG|Placebo|Participants will receive matching placebo tablets orally.
40765210|NCT06636656|DRUG|BI 3032950 intravenous (Part A)|BI 3032950 intravenous (Part A)
40765211|NCT06636656|DRUG|BI 3032950 subcutaneous (Part B)|BI 3032950 subcutaneous (Part B)
40765212|NCT05619744|DRUG|RO7616789|RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.
40765213|NCT05619744|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
40962744|NCT05564429|DRUG|18F-SF12051|Injected intravenously followed by PET scanning
41136457|NCT01466569|DRUG|AbGn-7|Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
41136458|NCT01466569|DRUG|AbGn-7|Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
41136459|NCT01315977|DIETARY_SUPPLEMENT|Green tea|Each subject will take either green tea (2%w/v), or water, twice a day for twelve weeks, then wash out for twelve weeks and swap onto the other treatment (either green tea of water) for another twelve weeks in addition to their normal food and beverage intake
41136460|NCT05222100|DIAGNOSTIC_TEST|Mammography screening|Breast screening mammograms use X-rays to look for cancers that are too small to see or feel.
41136461|NCT01548703|DRUG|BCI-838|BCI-838 100 mg or matching placebo administered once daily for 7 days
41136462|NCT01548703|DRUG|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
40962745|NCT00289965|BEHAVIORAL|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
40962746|NCT00289965|BEHAVIORAL|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
40962747|NCT00289965|BEHAVIORAL|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
40962748|NCT02085083|BEHAVIORAL|Telephone and email correspondence with an Inflammatory Bowel Disease Nurse|"The IBD pediatric-adult transition nurse will send an email each month containing:~Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.~Direct Nurse Contact: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse~Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.~MyHealth Passport~Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email."
40765214|NCT06344247|DRUG|RAS inhibitors：Losartan®️/Valsartan®️|Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.
40962749|NCT02085083|BEHAVIORAL|Minimal Intervention Arm|Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
41136463|NCT01548703|DRUG|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
41136464|NCT01911156|DRUG|Continue NA treatment|Prescribed NA during the 72 week study period
41136465|NCT01911156|DRUG|Discontinue NA Treatment|Discontinue NA Treatment
40962750|NCT00007865|BIOLOGICAL|rituximab|
40962751|NCT00007865|DRUG|carboplatin|
40962752|NCT00007865|DRUG|etoposide|
40962753|NCT00007865|DRUG|ifosfamide|
40962754|NCT01146418|BIOLOGICAL|Corifollitropin alfa|Single injection of 150 μg corifollitropin alfa administered under protocol P06029
41136466|NCT02386332|PROCEDURE|transplantation|
41136467|NCT02284607|DRUG|MHAA4549A|MHAA4549A single, intravenous dose administration, lower dose level
41136468|NCT02284607|DRUG|MHAA4549A|MHAA4549A single, intravenous dose administration, higher dose level
41136469|NCT02284607|DRUG|Placebo|Matching placebo to MHAA4549A administration
41136470|NCT03735381|DEVICE|Pedometer watch 'Xiomi mi band2'|"1. They receive information on the use of the pedometer.~2. Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~3. Prescription of benefits of walking in pregnancy:~   * Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~  * Receive information on the adequacy of walking with moderate intensity.~4. They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group)."
41136471|NCT03929198|OTHER|Healthy Lifestyle|6 week Diet, Exercise training, Behavioral modification
41136472|NCT03046706|BEHAVIORAL|post operative voice rest|After surgery, a week of total silence. In the second week after surgery talking is allowed for 20 minutes a day.
41136473|NCT03046706|BEHAVIORAL|No voice rest|No limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions
41136474|NCT00259766|DRUG|Budesonide|
41136475|NCT00259766|DRUG|Formoterol|
41136476|NCT00259766|DRUG|Terbutaline|
41136477|NCT04567459|DIETARY_SUPPLEMENT|Premium Amino Acids|after Chemotherapy ang surgery one pack of Premium Amino Acids in the morning and evening
41136478|NCT04267523|BEHAVIORAL|Web parenting intervention|Parents participate in the self-delivered web-based parenting intervention for 6 modules. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
41136479|NCT04267523|BEHAVIORAL|Group parenting intervention|Parents participate in face-to-face a weekly 2-hour group for 4 sessions. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
40765215|NCT06344247|DRUG|dapagliflozin：Forxiga®️|Forxiga®️ : titrated to the target dose (10 mg qd).
40765216|NCT06344247|DRUG|simagliptin：Forxiga®️|Semaglutide®️ : titrated to the target dose (1 mg qw).
40765217|NCT01755403|DRUG|Benznidazole|
40765218|NCT06474182|PROCEDURE|Blood sampling|Blood sampling
40765219|NCT06474182|DRUG|Apixaban|Treatment by Apixaban
41294064|NCT05242588|BIOLOGICAL|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
41294065|NCT03700892|OTHER|Cinnamaldehyde e-liquid|Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
41294066|NCT03700892|OTHER|PG/VG e-liquid|Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
40962755|NCT01146418|BIOLOGICAL|recFSH (follitropin beta)|Daily recFSH 300 IU administered under protocol P06029.
41294067|NCT05259046|DIETARY_SUPPLEMENT|Menaquinone-7 (MK-7) tablet (333 µg)|One MK-7 tablet containing 333 µg MK-7 per day
41136480|NCT05774262|PROCEDURE|Pacemaker implantation|Elective pacemaker implantation (DDDR) for functional AVB according to the 2021 ESC Guidelines for Cardiac Pacing
41294068|NCT05259046|DIETARY_SUPPLEMENT|Placebo tablet|One placebo tablet per day
41294069|NCT06260397|PROCEDURE|serratus anterior plane block|using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the plane between the latissimus dorsi and serratus muscles
41294070|NCT06260397|PROCEDURE|costotransverse block|using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the costotransverse plane of fourth rib
41294071|NCT06260397|PROCEDURE|patient controlled analgesia|PCA pump in the form of 20 mg nalbuphine HCL in 100 ml 0.9% normal saline with basal rate of infusion 5ml/hr. with self-administration bolus of 0.5ml with 15 min lock-out time.
41294072|NCT01311206|OTHER|partial blood flow restriction|Partial Blood Flow Restriction (PBFR) Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side, while receiving PBFR in each exercising limb. The padded belts (65 mm in width and 650 mm in length) of the Kaatsu Master™ PBFR device (Sato Sports Plaza, Tokyo, Japan) will be applied to the proximal thigh as near to the hip joint as is comfortable. Before training each leg, subjects will be seated in a chair where an initial belt pressure of 37-40 mmHg will be applied. The belt then will be iteratively pressurized for 30 seconds and then relaxed for 10 seconds in increments of 20 mmHg from 100 mmHg to the final pressure of 160 mmHg. During exercise, the cuff pressure will be continuously controlled and monitored by the PBFR apparatus
40962756|NCT04091594|DEVICE|Flexible orthotic|Participants will receive the SIAFO to wear
40962757|NCT04091594|DEVICE|Standard orthotic|Participants will received the standard AFO to wear
40962758|NCT03448783|DRUG|Apixaban|Patients are tested for their normal prescription apixaban medication
40962759|NCT04818060|OTHER|Clinical Assessments|A neurological evaluation will be administered to all participants at baseline, 1 year and 2 year follow-up visits. Motor exams and premorbid IQ assessments will be video-recorded for rater reliability assessments conducted randomly throughout the research project.
40962760|NCT04818060|DIAGNOSTIC_TEST|MRI Scan|At baseline and 2 year follow-up all participants will undergo a 60-minute 3T MRI scanning session which will consist of measures of the volume of brain tissue and cerebral spinal fluid, as well as connections in the brain measuring water pathways and pictures of the brain active and at rest.
40962761|NCT04818060|DIAGNOSTIC_TEST|Lumber Puncture (LP)|Participants will be asked to complete a LP at both onsite study visits (baseline and 2 year follow-up). Blood collection following the procedure will consist of about 80mL and will be stored at a repository for biomarker analysis.
40962762|NCT06300931|OTHER|educational lecture|An Educational lecture about SDF
40962763|NCT00962910|OTHER|PFF evidence based pathway|A care pathway, as complex intervention, will be implemented.
40962764|NCT04002713|OTHER|ALT flap reconstruction|Patients who underwent ALT free flap reconstruction after head and neck cancer surgery.
40962765|NCT04002713|OTHER|AMT flap reconstruction|Patients who underwent AMT free flap reconstruction after head and neck cancer surgery.
40962766|NCT05723978|PROCEDURE|Selective extended dissection of pancreaticoduodenectomy|An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
40962767|NCT04141488|OTHER|experimantal group|Control Group
40962768|NCT04923191|OTHER|Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care|percutaneous coronary intervention
40962769|NCT00565045|DEVICE|Neuromuscular electrical stimulator|"Intervention Characteristics Common to Both Groups~• 6-week intervention~1. Home exercise, daily~   1. Exercise (at home) 2 sessions/day~  2. A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~  3. A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~2. Lab therapy, 2x/week~   1. Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible)."
41294073|NCT01311206|OTHER|Low intensity exercise without partial blood flow restriction|Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side in each exercising limb without partial blood flow restriction.
41294074|NCT03564665|DIETARY_SUPPLEMENT|400mg Magnesium Glycinate BID|400mg Magnesium Glycinate BID for 8 weeks.
41294075|NCT03564665|OTHER|Placebo|Placebo BID for 8 weeks.
41294076|NCT01461577|DRUG|INSULIN GLARGINE HOE 901|Pharmaceutical form:solution Route of administration: subcutaneous
41294077|NCT04556604|BEHAVIORAL|Educational meetings and visual prompts|Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts
41294078|NCT01310595|PROCEDURE|Manual mobilization on cervical spine|Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin
41294079|NCT01310595|PROCEDURE|Infra-red therapy with self exercise pamphlet|Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
41294080|NCT00803244|DRUG|300 IR|300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
41294081|NCT00803244|DRUG|Placebo|Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
41456380|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
41294082|NCT00864227|BIOLOGICAL|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 40 mg/m\^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide: 50 mg/kg IV on Day -6~* Total body irradiation: 200 centigray (cGy) on Day -1"
41294083|NCT00864227|BIOLOGICAL|GVHD prophylaxis|"GVHD prophylaxis regimen will consist of:~* Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~* MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm\^3 for three consecutive measurements, each on different days."
40765220|NCT05998759|BIOLOGICAL|Telitacicept|subcutaneous telitacicept 160 mg weekly for 24 weeks.
40765221|NCT05998759|DRUG|Placebo|subcutaneous placebo weekly for 24 weeks.
40765222|NCT06486441|DRUG|Sacituzumab govitecan-hziy|Administered intravenously
40962770|NCT01326143|DEVICE|ORM Narval MRD|
40962771|NCT04452240|DEVICE|thoracic endovascular repair|Repair of thoracic aorta lesions with the application of a dedicatet stent-graft by endovascular way.
40962772|NCT04002661|DRUG|Flibanserin|Flibanserin tablet
40962773|NCT04002661|DRUG|Placebo|Oral Tablet
40962774|NCT06411197|OTHER|Hypertonic saline injection|Injection with hypertonic saline (7%)
40962775|NCT06411197|OTHER|Isotonic saline injection|Injection with isotonic saline (0.9%)
40962776|NCT01091974|DRUG|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
40962777|NCT01091974|DRUG|Placebo Comparator|Placebo for 47 days
40962778|NCT01091974|BEHAVIORAL|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
40962779|NCT00289783|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
40962780|NCT00289783|BIOLOGICAL|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
40962781|NCT00289783|BIOLOGICAL|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
40962782|NCT00289783|BIOLOGICAL|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
40765223|NCT06486441|DRUG|Doxorubicin|Administered intravenously
40765224|NCT06486441|DRUG|Paclitaxel|Administered intravenously
40962783|NCT00289783|BIOLOGICAL|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
40962784|NCT00289783|BIOLOGICAL|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
40962785|NCT00289783|BIOLOGICAL|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
40962786|NCT01448486|DRUG|Raltegravir|Oral raltegravir, 400 mg tablet, twice daily for one year.
40962787|NCT03323710|DRUG|Propranolol|Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
40962788|NCT03323710|DRUG|Sunitinib|Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
40962789|NCT05007392|DRUG|Dotinurad|Dotinurad oral tablets.
41294084|NCT02284906|DRUG|Pioglitazone|Pioglitazone tablets
41294085|NCT02284906|DRUG|Placebo|Pioglitazone placebo-matching tablets
41294086|NCT04356105|DRUG|Minimal stimulation protocol|Letrozole, Recombinant FSH, GnRH antagonist
41294087|NCT04356105|DRUG|Microflare protocol|OCP, GnRH agonist, Recombinant FSH
41294088|NCT04356105|PROCEDURE|IVF/ICSI cycle|Involving ovum pickup and embryo transfer
41294089|NCT01149278|DRUG|maintain mean arterial pressure between 80-85 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
40765225|NCT05734066|DRUG|Lurbinectedin|Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
40765226|NCT04605276|OTHER|No intervention|No intervention
40962790|NCT05007392|DRUG|Febuxostat|Febuxostat oral tablets.
40962791|NCT05007392|OTHER|Dotinurad Matched Placebo|Dotinurad matched placebo oral tablets.
40962792|NCT05007392|OTHER|Febuxostat Matched Placebo|Febuxostat matched placebo oral tablets.
40962793|NCT04524390|DRUG|Maralixibat|A small molecule inhibitor of the ileal bile acid transporter (IBAT)
40962794|NCT04524390|OTHER|Placebo|Identical to maralixibat except for the active drug substance
40962795|NCT04063930|DRUG|LOKELMA 5 GM Powder for Oral Suspension|Sodium zirconium cyclosilicate (a hyperkalemia treatment)
40962796|NCT04063930|DRUG|Placebos|Matching placebo
40962797|NCT04859361|DRUG|Aldara 5% Topical Cream|5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.
40962798|NCT04859361|PROCEDURE|LLETZ|LLETZ will be performed in an outpatient setting with local anesthesia, using KLS Martin Maxium with loop devices ranging from 10 mm to 20 mm in size. The excision will be performed using monopolar current with a cut frequency set to 100-150 W. Treatment success will be evaluated in accordance with our national guidelines 24 weeks after the procedure using a PAP smear with or without a punch biopsy.
40765227|NCT04007679|OTHER|Pain neuroscience education|Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
40962799|NCT03699605|OTHER|VESMP|. The application contains following seven domains: spontaneous speech, comprehension, naming, reading, writing, imitation and automated speech. The programme was developed in Urdu language which contains different daily functional words, phrases and sentences. Treatment stimuli consisted of images of objects along with auditory sounds of person and actions cues. The voice output can operate by pressing the selected picture with index finger. Participants received 1-16 weeks of therapy using software of two domains with different difficulty levels. Specifically the programme included seven domains within the software comprising of eight 30-45 minutes sessions (4 days per week for total 16weeks). The measurement will be taken at 0 week (baseline) after 16 weeks.
40765228|NCT06637644|DEVICE|Right-sided ventricular assist device|Percutaneous device for right heart support
40962800|NCT03699605|OTHER|Traditional Therapy|, All subjects participated in an traditional therapy group in routine and received MIT for 4 months of periods with three sessions per week to improve language skills.
40962801|NCT01399814|BEHAVIORAL|perioperative fluid management|No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000\~1500ml crystalloid was administered on the days following operation
40962802|NCT01399814|BEHAVIORAL|perioperative fluid treatment|500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000\~2500ml crystalloid was administered on the days following operation
40962803|NCT04451850|OTHER|Noninvasive actigraphy monitor|Noninvasive chest-mounted actigraphic device to be worn for 2 hour intervals two times per week during the six month study participation.
40962804|NCT03414060|DEVICE|Menstrual Cup|
40962805|NCT03873974|DIAGNOSTIC_TEST|DualDur dark-field microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Manual evaluation.
40962806|NCT03873974|DIAGNOSTIC_TEST|DualDur dark-field automatic microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Software evaluation.
40962807|NCT03873974|DIAGNOSTIC_TEST|Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
40962808|NCT03873974|DIAGNOSTIC_TEST|Bózsik Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
41294090|NCT01149278|OTHER|maintain mean arterial pressure between 65-70 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
40765229|NCT06640101|OTHER|sham IMT|with 10% maximum inspiratory pressure (MIP) as the training intensity, IMT will be conducted while sitting on the chair.
40765230|NCT06640101|OTHER|target IMT (sitting on a chair)|IMT intensity identified as optimal based on the results of our ongoing study, IMT will be conducted while sitting on a chair
40765231|NCT06640101|OTHER|target IMT (sitting on an unstable surface)|IMT intensity identified as optimal based on the results of our ongoing study, IMT will be conducted while sitting on an unstable surface
40765232|NCT06640101|OTHER|Conventional treatment|The conventional treatment includes limb muscle strengthening exercises, Bobath approach, bridging exercise, balance training in standing, general gait training and activities of daily living training
40765233|NCT02668757|BEHAVIORAL|HeartHab application intervention|The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
40765234|NCT04464759|DRUG|Nivolumab|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
40765235|NCT04464759|DRUG|Hydroxychloroquine|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
40765236|NCT04464759|DRUG|Ipilimumab|Combination of nivolumab, hydroxychloroquine and ipilimumab
40765237|NCT05627921|DEVICE|Extracorporeal Shock Wave Therapy|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex. 1 week after the injection, patients will receive 3 sessions of radial ESWT treatment, 1 session/week. rESWT application will be applied with the 'MODUS ESWT' device and a 35 mm radial soft applicator will be used. rESWT will be applied with a soft applicator. The soft applicator is designed for application to sensitive and painful areas and applications will be painless.Shock waves will be applied at 1500/beat, 8 Hz, 0.030 Mj/mm2, 2 bar per muscle.
40765238|NCT05627921|DRUG|Botilinum Toxin injection|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex.
40962809|NCT03873974|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay (ELISA) IgM and IgG|Standard ELISA test for Lyme borreliosis.
40962810|NCT03873974|DIAGNOSTIC_TEST|DualDur Polymerase chain reaction|DualDur PCR test for Lyme borreliosis.
40962811|NCT06153329|DRUG|THDB0206 injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
41294091|NCT05600712|DEVICE|REDAPT Sleeved Stem|The REDAPT Sleeved Stem is designed to provide secondary proximal support to the distal fixation and enhance implant stability.
41456381|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
41456382|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
41456383|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
40765239|NCT05195840|BEHAVIORAL|Personalized Treatment for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 includes psychoeducation on the network-informed model of personalized treatment and 14 sessions (sessions 5-19) are focused on the top three targets (4-5 sessions per target). Session 20 is a termination and conclusion session.
40962812|NCT06153329|DRUG|Humalog®|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
40962813|NCT06153329|DRUG|BC222insulin lispro injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
40962814|NCT00454883|DRUG|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
40962815|NCT01182675|DRUG|Transplant Conditioning with Mobilization Only|Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant
40962816|NCT01182675|DRUG|Transplant Conditioning with Mobilization and Alemtuzumab|Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant
40962817|NCT03072992|DRUG|Curcumin|Curcumin (CUC-01), 300mg i.v. , once weekly for 12 weeks.
40962818|NCT03072992|DRUG|Paclitaxel|Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.
40962819|NCT03072992|DRUG|Placebo|Placebo i.v. solution, once weekly for 12 weeks
40962820|NCT02671175|DRUG|dihydroartemisinin-piperaquine|Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
40962821|NCT02671175|DRUG|dihydroartemisinin-piperaquine placebo|Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
40962822|NCT02649465|DRUG|Tofogliflozin|The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks
40962823|NCT02649465|DRUG|Glimepiride|Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
40962824|NCT04490850|PROCEDURE|Blood sample|Blood sample
40962825|NCT04456608|DRUG|Aspirin|Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.
40962826|NCT00172133|DRUG|ALX1-11 (drug)|100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
40962827|NCT02840500|OTHER|No intervention|No intervention
41456384|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
41456385|NCT01140672|DRUG|PF-04634817|Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
41456386|NCT06462495|DRUG|[18F]F-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
41456387|NCT06462495|DRUG|[18F]F-PSMA-1007|Each subject receive a single intravenous injection of \[18F\]F-PSMA-1007, and undergo PET/CT imaging within the specificed time.
40765240|NCT05195840|BEHAVIORAL|Cognitive Behavioral Therapy for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 consists of food monitoring, addressing irregular eating, challenging thoughts, making adaptive behavioral changes, and relapse prevention. Session 20 is a termination and conclusion session.
41456388|NCT00001763|DRUG|Interleukin-12|
40962828|NCT01482845|DRUG|ABT-126|Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
40962829|NCT01482845|DRUG|Placebo|Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
40962830|NCT00205881|DEVICE|HiRes 90K Bionic Ear System|Cochlear implant system
40962831|NCT05860478|DEVICE|Wearable device|The wearable device includes a motion sensor, and is worn around the wrist, and the device records a participant's physical activity .
41456389|NCT03059329|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
41456390|NCT04280224|BIOLOGICAL|NK Cells|twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)
41136481|NCT05774262|PROCEDURE|Cardioneuroablation (CNA)|"Experimental method; elective implantable loop recorder (ILR) and biatrial, binodal, atomically and electroanatomically guided CNA with extracardiac vagal nerve stimulation (ECVS) prior and after procedure monitoring (disappearance of ECVS-induced AVB with the goal of achieving post-procedure and maintaining a target heart rate \> 50 beats per minute). CNA procedure is performed with radio-frequency generators and irrigated catheters and with support of 3D-electroanatomic mapping system.~CNA group will receive external ECG recorders. The major reason for external ECG recorders is to provide documentation of clinical AVB, as well as monitoring of patients before and after CNA (or PM implantation, if accepted). In case of severe AVB symptoms always the emergency system will be called."
41294092|NCT06201572|OTHER|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared. The data management platform provides intelligent management of patients' out-of-hospital follow-up, and the dynamic physiological indicators and psychological assessment data of patients are mastered through the hospital port, so as to provide telemedicine guidance for patients, so as to improve the prognosis of hypertensive emergency patients.
40765241|NCT04566731|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. The current, 1.5 mA, is approximately of the same intensity as the current provided by a 9-volt battery. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp.
40765242|NCT04566731|DEVICE|Sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 1.5 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
41294093|NCT03762252|OTHER|Dry needling|A solid filiform needle will be inserted over active trigger points in the scalene muscles for 30 seconds. The aim will be to elicit local twitch responses or the referred pain pattern of the scalene muscles.
40765243|NCT04566731|BEHAVIORAL|Modified Contraint-Induced Language Therapy (mCILT)|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
41136482|NCT00470483|DRUG|Placebo treatment during 8 weeks|comparator
41136483|NCT00470483|DRUG|Paroxetine treatment during 8 weeks|treatment drug
41136484|NCT03278977|BIOLOGICAL|Blood sample for specific analyzes|"Standard management of ALTE~* Hospitalization in pediatric intensive care unit or pediatric emergencies~* Etiologic research~* Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)"
41294094|NCT03762252|OTHER|Manual Therapy|The therapist will apply manual compression over active trigger points in the scalene muscles for 30 seconds
41294095|NCT04813679|DIAGNOSTIC_TEST|Bed side Ultrasound Sonography|Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha
41294096|NCT00204893|DRUG|calcium formate|Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
41294097|NCT02385032|DRUG|Ursodiol|
41456391|NCT05929053|OTHER|Vaccine Education Program Based on Integrated Change Model|Vaccine Education Program Based on Integrated Change Model The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people.
41136485|NCT00927706|DEVICE|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
41136486|NCT00231699|PROCEDURE|Plastic wrap (study group) and cotton (control group) wrap.|
41136487|NCT04638049|OTHER|Collection of human biofluids|Feces, blood and urine: (1) shortly before, (2) during and (3) shortly after RT treatment, as well as (4) one-month post-RT
41136488|NCT04638049|OTHER|Patient reported outcome measures|EORTC QLQ-C30, PR25: (1) shortly before and (2) shortly after RT treatment, as well as (3) one-month post-RT
41136489|NCT00937287|OTHER|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
41294098|NCT02385032|DRUG|URSO Forte|
41456392|NCT01292668|DRUG|methyl-5-aminolevulinate hydrochloride cream|Applied topically
41456393|NCT01292668|DRUG|photodynamic therapy|Undergo light-emitting diode photodynamic therapy
41294099|NCT05958368|OTHER|Avocado|The Hass Avocado group will consume 7 avocados a week (1 / day; \~240 kcals/d).
41294100|NCT05958368|OTHER|Other Fruit(s)|The other fruits group will consume fruit(s) matched to the avocado in energy and form (i.e., solid fruit).
41294101|NCT03553238|DRUG|Chidamide|Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
41294102|NCT03553238|DRUG|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
41456394|NCT01292668|PROCEDURE|laser therapy|Undergo laser light photodynamic therapy
40765244|NCT06119477|OTHER|Bioceramic Putty Apical Plugs|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, then dried, and filled with Ca(OH)2 dressing. Afterward, the incisor will be temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. The Bioceramic Putty will be inserted in the apical 4 mm of the canal using the modified cannula and adapted to the canal walls with a hand plugger. The correct placement and thickness of the apical plug will be verified with a periapical radiograph. Afterward, the remainder of the root canal will be filled with gutta-percha with sealer. Finally, a suitable immediate final restoration was made for each case individually.
40765245|NCT06119477|OTHER|Single Cone Gutta-percha with Bioceramic Sealer|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. A large sized gutta-percha cone (GC) will be inserted to the working length, The GC was ensured to make tag-back with the apical third of the immature canal and confirmed with a periapical radiograph. Then the immature canal will be gently filled with Bioceramic sealer and the GC will be placed again and another apical radiograph will be taken to confirm that the canal was properly filled. Finally, a suitable immediate final restoration was made for each case individually.
40765246|NCT06119477|OTHER|Combination of Bioceramic Putty and Sealer|"Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried.~The immature canal will be gently filled with Bioceramic sealer and then 3 to 5 small balls of BP (diameter of 1 mm) will be inserted into the canal orifice and gently plugged with hand pluggers. Afterward, an apical radiograph will be taken to confirm that the canal was properly filled without gaps and voids. Finally, a suitable immediate final restoration was made for each case individually."
40765247|NCT05771155|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, on Weeks 0, 2 and 6, 14, 22, 30, 38 and 46
40765248|NCT04469686|COMBINATION_PRODUCT|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator
40765249|NCT04469686|COMBINATION_PRODUCT|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator
40765250|NCT04469686|COMBINATION_PRODUCT|Twice daily placebo suppository administered with Sephure applicator|Twice daily placebo suppository administered with Sephure applicator
40765251|NCT06637839|BEHAVIORAL|Moderate-Intensity Locomotor Training Program|The moderate-intensity program prescribes participants to exert 50-59% of their heart rate (HR) reserve, or a score of 13-15 on Borg's rating of perceived exertion (RPE) scale.
40765252|NCT06637839|BEHAVIORAL|High-Intensity Locomotor Training Program|The high-intensity program prescribes participants to exert at least 60% of their heart rate (HR) reserve, or a score of 16-18 on the RPE scale.
40765253|NCT06637839|BEHAVIORAL|High-Step Count Locomotor Training Program|The high step count program prescribes at least 600 steps per session, at less than 50% or HR reserve, or less than 13 RPE.
40765254|NCT06422247|DRUG|Systemic therapy|Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician
40990628|NCT05465551|COMBINATION_PRODUCT|Stress Management Toolkit|The toolkit will be a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home. Potential tools for the toolkit includes low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. The tookit will also include user-safety guidelines and directions on how to use each tool. Tools will be included for participants with dementia and care partners.
41136490|NCT01918033|DRUG|Desloratadine 5 mg|Desloratadine 5 mg tablets
41136491|NCT01918033|DRUG|Placebo|Matching placebo to desloratadine 5 mg tablets
40962832|NCT00844896|BEHAVIORAL|DEF-only|"The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.~In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise."
40990629|NCT02221375|DRUG|BHT low|
41136492|NCT00797056|DRUG|G-CSF|G-CSF 5 mcg/kg/day SQ daily for 10 days
41136493|NCT00797056|DRUG|Placebo|Saline SQ daily for 10 days
41294103|NCT03553238|DRUG|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
41294104|NCT03553238|DRUG|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
41294105|NCT03553238|DRUG|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
41294106|NCT03553238|DRUG|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
41294107|NCT03553238|DRUG|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
41294108|NCT03553238|DRUG|Methotrexate|Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
41294109|NCT03553238|DRUG|6-Mercaptopurine|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
41294110|NCT03553238|DRUG|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
41294111|NCT03553238|DRUG|Cytarabine|AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
41294112|NCT03553238|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
41294113|NCT03553238|PROCEDURE|Intrathecal injection|Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
40990630|NCT02221375|DRUG|BHT medium|
40990631|NCT02221375|DRUG|BHT high|
40990632|NCT02221375|DRUG|BI 54903 XX low|
41136494|NCT00797056|DRUG|Aspirin|Aspirin 75 mg/day for 14 days
41136495|NCT00797056|DRUG|Clopidogrel|Clopidogrel 75mg/day daily for 14 days
41294114|NCT03553238|RADIATION|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
41294115|NCT03553238|GENETIC|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
41294116|NCT03553238|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
40990633|NCT02221375|DRUG|BI 54903 XX medium 1|
40990634|NCT02221375|DRUG|BI 54903 XX medium 2|
40990635|NCT02221375|DRUG|BI 54903 XX high|
40990636|NCT02221375|DRUG|Ciclesonide|
40990637|NCT05096169|DRUG|Clomiphene Citrate 25mg|clomiphene citrate at a dose of 25mg daily
40990638|NCT05096169|DRUG|Clomiphene Citrate 50mg|clomiphene citrate at a dose of 50mg every other day
40990639|NCT00298207|BEHAVIORAL|Walking (behavior)|
41294117|NCT03553238|DIAGNOSTIC_TEST|Flow-MRD|Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
41294118|NCT03553238|DIAGNOSTIC_TEST|FISH|FISH will be performed in PDT-ETP-ALL for bone marrow samples.
41294119|NCT03553238|DIAGNOSTIC_TEST|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.
41294120|NCT03553238|DIAGNOSTIC_TEST|Karyotyping|Karyotyping will be performed in PDT-ETP-ALL protocol.
41294121|NCT03412422|DIAGNOSTIC_TEST|fluid responsiveness assessment|During the procedure, the investigator will be imaging one of the carotid arteries with ultrasound. In expiratory phase, four sets of three video loops will be recorded: before and after PLR and then before and after fluid challenge. There also will be noted hemodynamic parameters measured with PiCCO monitor. The fluid challenge is defined as administration of 500ml of crystalloid in less than 10 minutes. Later, another investigator, who will be blinded to other data, will measure the maximal and minimal diameter of CCA in each loop. The measurements will be averaged and eventually two values (maximal an minimal) from each set will be obtained.
41294122|NCT05602467|DEVICE|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
40962833|NCT00844896|BEHAVIORAL|DEF + COPE|"All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.~For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks."
40962834|NCT05979558|DRUG|ropivacaine with dexmedetomidine|this group received with ropivacaine with dexmedetomidine
40962835|NCT05979558|DRUG|Ropivacaine with placebo|this group received with ropivacaine with normal saline
40962836|NCT03678129|DRUG|AZD7325_10|Single oral dose (10mg)
41456395|NCT04166058|DRUG|Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)|Participants whom are between the ages of 7-11 years old at their time of enrollment will be assigned a dose (72 μg or 145 μg) based on their weight. Randomized doses (145 μg or 290 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
40765255|NCT03829488|DRUG|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
41294123|NCT05602467|OTHER|Treatment as usual (TAU)|Treatment-as-usual (TAU) in the Hong Kong outpatient clinic without TPS intervention was given. They would receive the standard care for mild NCD including counselling, lifestyle modification, cognitive training and antidementia medications occasionally depending on the case doctor's judgement.
41294124|NCT01583192|PROCEDURE|skin preparation|skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
41294125|NCT00620204|DRUG|atorvastatin|atorvastatin 40mg qd for 1 year
41294126|NCT03787004|DRUG|CNTX-6970|Oral dose CNTX-6970
41294127|NCT03787004|OTHER|Placebo|Oral dose placebo
41294128|NCT01422304|DRUG|Sugammadex|Sugammadex 4 mg/kg intravenously
41294129|NCT01422304|DRUG|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
41294130|NCT01422304|DRUG|Placebo to neostigmine|Normal saline (NaCl 0.9%)
41294131|NCT01422304|DRUG|Placebo to sugammadex|Normal saline (NaCl 0.9%)
41294132|NCT05926089|DIAGNOSTIC_TEST|Blood sampling|blood sampling to measure APR
41294133|NCT03556722|DEVICE|Repetitive Transcranial Magnetic Stimulation.|High frequency rTMS on left dorsolateral prefrontal cortex.
41456396|NCT04166058|DRUG|Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)|Participants whom are between the ages of 6-11 years old at their time of enrollment will be assigned a dose of 72 μg. Randomized doses (72 μg or 145 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
41456397|NCT02885441|DRUG|Ketorolac|Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
41456398|NCT05642936|BEHAVIORAL|didactic health education control|didactic classroom-based comparison group that follows standard guidelines for diet, exercise and substance use with no stress reduction component
40765256|NCT03829488|DRUG|0.9% SODIUM CHLORIDE 9g/L injection BP|Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
40962837|NCT03678129|DRUG|AZD7325_20|Single oral dose (20mg)
40962838|NCT03678129|DRUG|Placebo|Single oral dose placebo (capsule)
41294134|NCT03556722|DEVICE|Sham rTMS|Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.
41294135|NCT03746574|BEHAVIORAL|Compassion Curriculum|12 session curriculum offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
41294136|NCT04797013|DRUG|rt-PA|Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
41294137|NCT04797013|DRUG|rhTNK-tPA|Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
41294138|NCT03392519|OTHER|Chronic stroke|MRI data acquisition and behavioral test
41294139|NCT02626052|BEHAVIORAL|Dizziness Handicap Inventory|A standardized questionnaire used to quantify symptoms of dizziness.
41456399|NCT05642936|BEHAVIORAL|Transcendental Meditation technique|a mental technique derived from the Vedic tradition of ancient India and practiced by anyone for 20 minutes twice a day sitting
41456400|NCT04875585|DRUG|neoadjuvant therapy with Pembrolizumab/Lenvatinib|Neoadjuvant therapy for 6 weeks
41456401|NCT04875585|PROCEDURE|Surgery|surgical resection of primary tumor and lymph-node-dissection.
41456402|NCT04875585|DRUG|Adjuvant Treatment Phase|Adjuvant treatment with 15 cycles of Pembrolizumab
40962839|NCT03678129|DRUG|Clobazam|Single dose (5mg)
41294140|NCT02626052|BEHAVIORAL|Global Rating of Change|A standardized questionnaire used to review the overall outcome of the participants condition with physical therapy.
41294141|NCT02626052|BEHAVIORAL|Patient Acceptable Symptom State|A standardized questionnaire used to determine whether meaningful progress has been made
41294142|NCT02626052|PROCEDURE|Spontaneous Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
41294143|NCT02626052|PROCEDURE|Gazehold Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
41294144|NCT02626052|PROCEDURE|Primary Vibration Test|A test used to identify asymmetry that may be present in the vestibular system through 60-100 MHz vibration applied to the mastoid bone. A WAHL massager is used to stimulate the inner ear by vibrating the mastoid bone. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
41294145|NCT01751646|DIETARY_SUPPLEMENT|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
41294146|NCT01751646|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
41294147|NCT02101411|DIAGNOSTIC_TEST|PRU(Platelet reactivity unit)|measure by VeryfyNow.
40765257|NCT00678821|OTHER|Aerobic exercise|Supervised aerobic exercise and educational lectures for 10 weeks
40765258|NCT06069713|BEHAVIORAL|CBD advertisements|Participants will view the 5 images of CBD advertisements in their assigned panel and answer questions about their perceptions of the advertisement.
40765259|NCT06003712|BEHAVIORAL|Mindfulness|Participants will engage in a 10-15 minute mindfulness exercise three times weekly for one month. This mindfulness exercise utilizes guided attention on the breath through an instructional video, aiming to cultivate calmness and alleviate stress.
40765260|NCT06641973|DEVICE|Robotic balance rehabilitation with hunova® robotic platform|The G-Hun will perform robotic balance treatment with the hunova® robotic platform lasting 30 minutes per session, 2 times a week for 5 weeks, in addition to the services provided in their clinical pathway.
40765261|NCT05918029|DRUG|Potassium Citrate Extended Release Oral Tablet|Oral potassium citrate extended-release tablet
40962840|NCT02123888|RADIATION|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
41136496|NCT02906137|OTHER|Peripheral blood and intestinal biopsies will be collected|Blood draw and intestinal biopsies
41294148|NCT01748448|DRUG|Vitamin D|"* prospective interventional randomized double blind placebo controlled trail~* clinical setting (tertiary university hospital)~* investigator driven, no pharmaceutical sponsor~* cutaneous malignant melanoma patients~* add- on study (placebo or vitamin D) on top of optimal standard care~* 1:1 inclusion ratio (placebo:Vitamin D)~* randomisation after informed consent and screening"
41294149|NCT01748448|DRUG|arachides oleum raffinatum|
41294150|NCT05279469|OTHER|no intervention, just observational for D-Dimer level in blood|observation for basal D-Dimer and 48 hours later D-Dimer in blood for ICU SARS.COV.2 patients
41294151|NCT05948267|DRUG|ketamine- dexmeditomidine admixure|ketamine in anesthetic dose mixed with two different doses of dexmeditomidine
40962841|NCT05840367|BEHAVIORAL|Partner present in the operation room|The partner (father, co-mother or other close relative present for the birth) is present in the operation room during the entire category 1 cesarean section. This is standard clinical practice in this particular hospital since June 2021.
40962842|NCT01113567|DIETARY_SUPPLEMENT|Lactose-free milk|3.5 g of lactose
41136497|NCT04019067|DIAGNOSTIC_TEST|MCE first|"Patients randomized to the MCE first group will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours."
41136498|NCT00927849|PROCEDURE|lateral internal sphincterotomy (LIS)|closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
41294152|NCT05948267|DRUG|Propofol, Lidocaine and fentanyl|Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml
41294153|NCT03975972|OTHER|Occupational Therapy Based Literacy Intervention|Use of an occupational therapy-based literacy intervention that utilizes student interest to guide a prescriptive literacy intervention. Addressing reading as an occupation and making the necessary modifications to the literacy task to allows for increased engagement in the task. Increased engagement in literacy tasks, allows for opportunities to work on literacy deficit areas to address proficiency with reading ability.
40765262|NCT05918029|OTHER|Placebo|Placebo capsule identical to active ingredient
40765263|NCT05918029|DRUG|Potassium Citrate and Citric Acid Oral Solution|Oral potassium citrate and citric acid
40765264|NCT06570746|DRUG|Sedative|Sedation is applied before the procedure
40765265|NCT05845255|DEVICE|mjn-SERAS|Using of wearable, non-invasive device for EEG recording and forecasting of epileptic seizures
40962843|NCT01113567|DIETARY_SUPPLEMENT|Whole milk|Whole milk with 24 g lactose
40962844|NCT05417139|OTHER|Immunotherapy+induction chemotherapy+radiotherapy|All enrolled patients received Sintilimab (200mg, d1, q3w) + GP (gemcitabine 1000mg / m2, d1, d8 + cisplatin 80mg / m2, d1, q3w) for 4-6 cycles followed by radiotherapy of primary site and cervical metastasis, and Sintilimab (200mg, q3w) treatment was continued during and after radiotherapy until disease progression or toxicity or up to 2 years.
40962845|NCT05997069|OTHER|Posterior-anterior vertebral mobilizations followed by Prone press-up exercise|"Posterior-anterior vertebral mobilizations of the lumbar spine are achieved by applying a force on to a spinous process in a posteroanterior direction (Back to front).~Prone press-up exercise is started in the prone position (lying on stomach) on a flat surface. Participant keeps hands underneath the shoulders then press up his or her upper body while trying to keep the hips on the floor."
40962846|NCT05997069|OTHER|Conventional physiotherapy|Traditionally used physiotherapy for the treatment of nonspecific low back pain (thermotherapy and general stretching exercises)
40962847|NCT03837197|DEVICE|Kidney-Hypothermic oxygenated|"Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys."
41136499|NCT00927849|DRUG|Glycerin trinitrate (GTN)|All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
41136500|NCT00927849|DRUG|botulinum toxin injection (BTX A)|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
41136501|NCT03496545|DRUG|Bromocriptine 5 MG|Bromocriptine 5 mg every 4 hours PO/NG/FT
41294154|NCT03109951|DRUG|Colonoscopy preparation using polyethylene glycol|Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
41294155|NCT01496261|DRUG|Clopidogrel and Aspirin|Clopidogrel and Aspirin seperate combination, single dose
40765266|NCT06639191|DRUG|[177Lu]Lu-AKIR001|"Patient cohorts of a minimum of three and a maximum of 12 evaluable participants will be opened according to the decision tree defined in the protocol and will be consecutively completed. When one cohort has been completed and fully evaluated, the next cohort will be opened after all participants in the previous cohort have received at least one dose of the IMP without dose-limiting toxicities during a follow-up period of at least six weeks.~The \[177Lu\]Lu-AKIR001 protein mass dose and activity are predefined for each cohort, and could be adjusted according to the results of previous cohort(s) to ensure the safety of participants. The initial design of the trial encompasses five cohorts to escalate both \[177Lu\]Lu-AKIR001 pmd, from 50 mg to 100 mg, and activity, from 0.75 to 3.0 GBq."
40765267|NCT03107182|DRUG|nab-paclitaxel|All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
40765268|NCT03107182|DRUG|Carboplatin|All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
40765269|NCT03107182|DRUG|Nivolumab|"All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses."
40765270|NCT03107182|DRUG|Cisplatin|Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
40765271|NCT03107182|DRUG|Hydroxyurea|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
40765272|NCT03107182|DRUG|5-FU|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
40765273|NCT03107182|DRUG|Dexamethasone|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
41456403|NCT01859260|DEVICE|CPAP/autopap|
40765274|NCT03107182|DRUG|Famotidine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
40765275|NCT03107182|DRUG|Diphenhydramine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
40765276|NCT03107182|DRUG|Paclitaxel|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
40962848|NCT03837197|DEVICE|Liver-Hypothermic oxygenated|"Liver perfusion will be performed through the portal vein at a 5 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers."
40962849|NCT03265769|OTHER|radial access site|radial route
40962850|NCT03265769|OTHER|femoral access site|femoral route
40962851|NCT02849041|DEVICE|medical imaging|Low-dose CT-scanner
40962852|NCT02849041|BIOLOGICAL|Identification of Circulating Tumor Cells|Research of circulating tumor cells in blood
41136502|NCT03496545|DRUG|Acetaminophen 650 MG|Acetaminophen 650 mg every 4 hours PO/NG/FT for 48 hours
40765277|NCT03107182|PROCEDURE|Transoral robotic surgery (TORS)|Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.
40765278|NCT03107182|RADIATION|Adjuvant RT|Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.
41294156|NCT01496261|DRUG|Fixed dose combination of clopidogrel/aspirin|Fixed dose combination of clopidogrel/aspirin
41294157|NCT04304222|DEVICE|3D Printed Denture Framework|The Denture Framework is 3D printed from the digital image obtained from the denture mold.
41456404|NCT03714373|DRUG|DCCR|Once daily oral administration of open-label DCCR tablet(s) during the OLE Period
41456405|NCT03714373|DRUG|DCCR|Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period
41456406|NCT03714373|DRUG|Placebo for DCCR|Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
41136503|NCT03194516|OTHER|Surveillance|The investigators propose an 8-week ketogenic diet intervention with pre-/post-intervention assessment of serum and tissue metabolic and inflammatory biomarkers, including metabolomics analysis, among a sample of 12 overweight or obese prostate cancer patients on active surveillance. There will be no randomization; all patients will receive the diet intervention.
41136504|NCT02203799|BIOLOGICAL|Peanut Oral Immunotherapy (POIT)|The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
41136505|NCT01720706|DEVICE|RFA Loosely wound thermal coil|"This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode."
41136506|NCT05905549|PROCEDURE|extended pancreatic transection during laparoscopic pancreaticoduodenectomy|the pancreatic transection was performed at the pancreatic neck beyond the left side of the mesenterico-portal axis during laparoscopic pancreaticoduodenectomy
41136507|NCT04654390|DRUG|DWP16001 Amg|Tablets, Orally, Once daily
41136508|NCT04891978|BEHAVIORAL|AIRQ|A validated tool designed to identify patients who may be at risk for adverse outcomes from uncontrolled asthma.
41136509|NCT04891978|BEHAVIORAL|Asthma Checklist|A validated, 3-page tool, based on GINA and NAEPP guidelines to assist providers with recognition, evaluation, and optimization of all patients with asthma. In this study, healthcare providers will be required to complete the assess component (page 1) of the Asthma Checklist .
41136510|NCT04891978|BEHAVIORAL|PRECISION Program (Educational Resources)|Educational resources accessible to all providers in the study. There are provider-facing and patient-facing educational materials that can be accessed during the patient visit or as resources for before/after visits. Resources can be downloaded and sent to patients per the discretion of providers.
41136511|NCT05033327|BEHAVIORAL|Nutrition and Exercise app|Personalized, home-based, interactive therapy app
41136512|NCT01885559|DRUG|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
41136513|NCT01885559|DRUG|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
41136514|NCT01885559|DRUG|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
41136515|NCT03560271|DRUG|Cyclo-Z|Cyclo (His-Pro) and zinc
41136516|NCT03560271|OTHER|Placebo|Matching placebo
41136517|NCT05707494|DEVICE|Efferon LPS NEO|Efferon LPS NEO, a medical device, which is a cylindrical body filled with a polymeric hemosorbent that selectively absorbs LPS and excess cytokines. The device is used for extracorporeal therapy to relieve septic shock in the treatment of sepsis.
41136518|NCT06463145|DIETARY_SUPPLEMENT|Vanizem|Aframomum melegueta seed extract standardized to 10% of total Vanilloid and at least 1.5% of 6-paradol
41136519|NCT06463145|DIETARY_SUPPLEMENT|Placebo|Food grade Maltodextrin 12
41136520|NCT03032757|DIETARY_SUPPLEMENT|Essential amino acids|240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.
41136521|NCT02648555|BEHAVIORAL|Daily walking|Participants will be instructed to walk briskly for \>40 minutes, 7 days a week.
40765279|NCT03107182|RADIATION|Chemoradiotherapy|"Patients who have low risk disease with \<50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and \<30% reduction of tumor, patients who have high risk disease and \<50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
40765280|NCT06303427|OTHER|Modified constraint-induced movement therapy|"The unaffected arm will be restricted by using an upper extremity sling that will strap to the child's trunk with a distal end fastened to prevent the movement of the unaffected limb.~The modified constraint-induced movement therapy will include these exercises.~1. Playing with ball.~2. Playing with modeling clay.~3. Playing with LEGOS (building towers or different shapes from the toy bricks).~4. Tearing a paper towel from a roll.~5. Holding and eating biscuits.~6. Eating with a spoon.~7. Drinking from a glass.~8. Combing hair.~9. Brushing teeth.~10. Making bubbles using a bubble blower.~11. Pulling a toy.~12. Placing a hat or piece of cloth on the head.~13. Applying lotion to the trained caregiver."
40765281|NCT06303427|OTHER|Electrical stimulation|The participants in this group will first receive a 20-minute session of electrical stimulation (on time of 10 s, off time of 30 s, pulse rate of 35 Hz, the pulse width of 300 µs).
40765282|NCT06644872|OTHER|Bedrest|Investigation of the effect of short-term bed rest (3 hours) on heart function, measured by cardiac magnetic resonance, in healthy participants ( males and females)
40765283|NCT06162507|BIOLOGICAL|CM310|CM310 injection
40765284|NCT06121856|DEVICE|VerioVue Enhancements BGMS|Blood glucose monitoring system
40962853|NCT02849041|PROCEDURE|Psychological Questionnaires|"The procedure of screening test could be stressful. False positive results can cause anxiety and lead to additional costs, as well as increased exposure to radiation and invasive medical examination. Although this is based on some objective results, there is a high probability of adverse psychological effects in case of false positives; so there is cause for concern in the short term anxiety associated with positive results and the use of additional tests during the intervals between screening phases. There is no data related to psychological distress potentially caused by the discovery of circulating tumor cells."
40962854|NCT06204601|OTHER|Education According to Meleis' Transitional Theory to Patients With Pacemaker|Patients in the experimental group will be trained according to Meleis's Transition Theory.
40962855|NCT05002062|DEVICE|"RehaCom computer-based cognitive training in addition to Conventional physical therapy program"|"Rehacom procedure: It is a computer-based intensive cognitive rehabilitation test used to assess patient's cognitive functions. It includes 32 assessment tasks for attention, memory , logical reasoning\& executive functioning. It composes of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patient enpult (1990-1997) EN/ISO-13485-certified). It is characterized by easy handling, close to reality , motivating for patients."
40962856|NCT05002062|OTHER|Conventional physical therapy program|Conventional physical therapy program for MS patients include aerobic training, resistive training and flexibility program
40765285|NCT06638450|PROCEDURE|Dense Cranial Electroacupuncture Stimulation plus Body Acupuncture (DCEAS+BA)|"DCEAS+BA will be conducted for 2 sessions per week for 8 weeks.~For DCEAS, 6 pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). For body acupuncture, the following acupoints are used: Shenmen (HT7). Neiguan (PC6), Zhongwan (CV12), Guanyuan (CV4), Zusanli (ST36), Sanyinjiao (SP6), and Taichong (LV3).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is conducted to evoke a needling sensation. After that, electrical stimulation is delivered on DCEAS, with continuous waves at 2 Hz through an electrical acupuncture stimulation instrument (Hwarto, SDZ-II). The stimulation lasts 30 minutes."
40765286|NCT06638450|PROCEDURE|Minimal Acupuncture Stimulation (MAS)|"MAS will be conducted for 2 sessions per week for 8 weeks.~The following 6 acupoints are used: bilateral Tongtian (BL07), bilateral Shousanli (LI10) and bilateral Fuyang (BL59). Electrical stimulation will be only performed on bilateral Tongtian (BL07)."
40765287|NCT06642259|RADIATION|Echocardiography|ECHO
40765288|NCT05913167|PROCEDURE|laparoscopic nephrectomy|laparoscopic nephrectomy
40765289|NCT02070211|DIETARY_SUPPLEMENT|omega-3 PUFAs|4 capsules (2 in the morning; 2 in the evening) for a period of 12 weeks. The active treatment is a supplement of yellow gelatine 0.625 g capsules containing concentrated marine fish oil. The daily dose of 4 capsules will provide approximately 700 mg of eicosapentaenoic acid (EPA, 20:5n3), 480 mg of docosahexaenoic acid (DHA, 22:6n3), and 7.6 mg of Vitamin E.
40765290|NCT02070211|OTHER|Standard care|Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.
40765291|NCT02070211|DIETARY_SUPPLEMENT|placebo|4 capsules of 0.7g of paraffin oil (which is not absorbed by the gastrointestinal tract) per day.
40765292|NCT06641336|DEVICE|RehAtt|Each patient received the RehAtt intervention.
40765293|NCT06094855|OTHER|20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest|2 bouts of 20 minutes of pedaling on a stationary recumbent bicycle, 1-2 weeks apart. Subjects will be cooled for one of the bouts and uncooled for the other.
40765294|NCT06386107|BIOLOGICAL|Thrombin Generation Assay (TGA)|Hemostasis is a complex process in which genetic or environmental conditions can cause shifts either towards pro-thrombotic states resulting in thrombosis, or towards pro-hemorrhagic states resulting in uncontrolled bleeding. Tests to assess a more global hemostatic profile, such as the TGA, have appeared as a more reliable alternative to assess the real hemostatic capacity of an individual. TGA is a global dynamic assay simultaneously and continuously measuring thrombin generation. It monitors the cleavage of a fluorigenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample.
40765295|NCT04019327|DRUG|Talazoparib|"Phase I maximum tolerated dose portion:~Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6"
40962857|NCT02195583|DRUG|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
40765296|NCT04019327|DRUG|Temozolomide|"Phase I maximum tolerated dose portion:~Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 \& 4 - 100 mg/m2 QD Days 2-8 Level 5 \& 6 - 125 mg/m2 QD Days 2-8"
40765297|NCT06640010|OTHER|Non-Interventional Study|Non-interventional study
40765298|NCT06638476|OTHER|Perturbation Induced Step training|A sudden lateral displacement of the treadmill.
41294158|NCT02295930|OTHER|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
40765299|NCT06638476|OTHER|Voluntary step training|Voluntary steps emphasizing speed, movement of center of mass and taking larger steps.
41294159|NCT02295930|OTHER|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
40765300|NCT06642558|BIOLOGICAL|Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)|0.25 mL per dose.
40765301|NCT06642558|BIOLOGICAL|Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)|0.5 mL per dose
40765302|NCT06642558|BIOLOGICAL|Placebo (Saline solution)|0.5 mL per dose
40765303|NCT02310269|DRUG|Pasireotide|
40765304|NCT00280202|PROCEDURE|Biopsy of the major carinal area|Biopsy performed intraoperatively
40765305|NCT00280202|PROCEDURE|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
40765306|NCT00280202|PROCEDURE|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
40765307|NCT00280202|PROCEDURE|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
40765308|NCT00280202|PROCEDURE|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
41294160|NCT04459910|PROCEDURE|Arthroscopic Brostrom combined with Arthroscopic Deltoid Repair|After anesthesia and surgical site preparation, traditional arthroscopic portals were performed. A 4.5mm set was used to clean the joint and assess possible associated injuries. Anterolateral and anteromedial impacts were resected when needed. Lateral and medial instability were confirmed arthroscopically, and ligament repairs prepared, starting by the lateral compartment. A traditional Arthroscopic Brostrom was performed, using one anchor and suture passers. Sutures are passed but not tightened. Medial anchor insertion is executed at the medial malleolus, in the quadrant described by Vega et al. Sutures were passed respecting the safe zone illustrated by Acevedo at al. The ankle was positioned in neutral (no posterior drawer) and the lateral sutures tightened with arthroscopic knots. Finally, the medial repair is finalized by tightening the deltoid sutures with the ankle at the same position. Portals were closed and a dressing applied.
41294161|NCT03177837|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
41294162|NCT03177837|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
41294163|NCT02572661|RADIATION|radiation in Squamous Head and Neck Cancer|
40765309|NCT00280202|PROCEDURE|Analysis of lymph nodes|Tissues banked for future analysis
40765310|NCT04589650|DRUG|Alpelisib|"Adult participants (group 1) will receive 125 mg of alpelisib oral tablets once daily. Pediatric participants (Group 2: 6 to 17 years old) will receive 50 mg of alpelisib oral tablets once daily. Pediatric participants (Group 4: 2 to 5 years old) will receive 50 mg of alpelisib oral tablets once daily, Pediatric participants (Group 3: 2 to 5 years old) will receive alpelisib granules at dose determined based on the primary analysis for efficacy, safety and PK of alpelisib in Groups 1 and 2 in addition to the data from Group 4 as available.~Pediatric participants (Group 5: 6 to 17 years old) will receive 125 mg of alpelisib oral tablets once daily."
40765311|NCT04589650|DRUG|Placebo|Participants will receive matching placebo once daily up to week 16.
40765312|NCT02640131|BEHAVIORAL|Biomedical Component|Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
40765313|NCT02640131|BEHAVIORAL|Psychosocial Component|Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
40765314|NCT02640131|BEHAVIORAL|Attention Control|Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
40962858|NCT02195583|DRUG|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
40962859|NCT02195583|DRUG|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
40962860|NCT02195583|DRUG|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
40962861|NCT02195583|DRUG|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
40962862|NCT02195583|DRUG|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
40765315|NCT06637124|DEVICE|Blood Flow Restriction Therapy Device|"Blood Flow Restriction (BFR) therapy involves units use standardized cuffs of varying widths and lengths which are physically attached to the devices and provide the capability of precisely controlling the amount of pressure applied to each limb during exercise or at rest.~We will be using Smart Cuffs® 4.0 which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it will calculate and set the optimal pressure for each participant's limb. There is no need for an external doppler probe or hand pump. Made in the USA, SmartCuffs® are registered with the FDA as a Class 1 Medical Device.~Blood flow restriction therapy is commonly paired with resistive training, so this study will explore the effect of blood flow restriction at rest for patients with osteoarthritis at different restriction levels (50% for first group and 70% for second group)."
40765316|NCT06637124|DEVICE|45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.|Patients assigned to group will receive strengthening of the lower limb musculature through moderate intensity resistance training (60% of 1RM) using a 45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.
40765317|NCT02356653|DEVICE|Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)|Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
40765318|NCT06377852|DRUG|Palbociclib 125mg|Arm 1: Indicated dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle)
40765319|NCT06377852|DRUG|Ribociclib 600mg|Arm 1: Indicated dosing of ribociclib (600 mg orally daily on days 1-21 of 28-day cycle)
40962863|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
41136522|NCT02648555|BEHAVIORAL|Dietary recommendations|"Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.~Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron."
41294164|NCT01891747|DRUG|Bevacizumab|bevacizumab at 10mg/kg IV every 14 days (Phase I \& phase II)
41294165|NCT01891747|DRUG|Temozolomide|150 mg/m2/day for a 5-day regimen per month (Phase I \& Phase II)
41456407|NCT01508065|DEVICE|Glucometer CGM-305|The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.
41456408|NCT06116396|GENETIC|Genetic analysis on isolated cells|Isolation of cells from blood and urine
41136523|NCT01231178|DIETARY_SUPPLEMENT|Alginate beverage|The dosage is 3x500ml daily
41294166|NCT01891747|DIETARY_SUPPLEMENT|Vitamin C|250 mg vitamin C once a day (oral) - Phase I \& Phase II
41294167|NCT03332004|DRUG|Indocyanine Green|0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
41456409|NCT06173960|DEVICE|atherectomy|Jetstream atherectomy in combination with Ranger paclitaxel elution balloon (Drug Coated Balloon (DCB))
41456410|NCT04885751|DRUG|Eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
41456411|NCT04885751|DRUG|Rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
41456412|NCT01656798|DRUG|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
41294168|NCT02666911|PROCEDURE|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
41294169|NCT02666911|PROCEDURE|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
41294170|NCT05979129|OTHER|zero PEEP|zero end-expiratory pressure during face mask ventilation
41294171|NCT05979129|OTHER|low PEEP|4 cmH2O PEEP during mask ventilation
41294172|NCT05979129|OTHER|high PEEP|8 cmH2O PEEP during mask ventilation
41294173|NCT04151940|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
41294174|NCT04151940|PROCEDURE|Computed Tomography|Undergo PET/CT scan
41294175|NCT04151940|DRUG|Chemotherapy|Receive standard of care chemotherapy
41294176|NCT04151940|BIOLOGICAL|Immunotherapy|Receive standard of care immunotherapy
41294177|NCT04151940|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
41294178|NCT02275026|PROCEDURE|Functional magnetic resonance imaging|Diffusion tensor imaging
41294179|NCT03499041|DRUG|LY3314814|Administered orally
41294180|NCT00622934|DRUG|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
41294181|NCT00622934|DRUG|placebo|placebo
41294182|NCT03424330|DEVICE|ReX-C intervention|Patients receive medication by the ReX-C device
41294183|NCT03424330|OTHER|Standard of Care|Patients receive medication as usual
41456413|NCT01656798|DRUG|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
40765320|NCT06377852|DRUG|Ribociclib|Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
40765321|NCT06377852|DRUG|Palbociclib|Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
40765322|NCT03113929|RADIATION|MRI|Research MRI
40765323|NCT06067425|DRUG|SAR442501|Solution for injection; Subcutaneous injection
40962864|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
40765325|NCT03862417|OTHER|Schroth exercises|An exercise program begun individually and then continued in groups.
40765326|NCT05644301|DRUG|Celecoxib|Oral capsule, 200 mg, twice daily, for 12 weeks
40765327|NCT05644301|DRUG|Minocyclin|Oral capsule, 100 mg, twice daily, for 12 weeks
40962865|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
40962866|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
40765328|NCT05644301|DRUG|Placebo|Oral capsule, no active substance, twice daily, for 12 weeks
40765329|NCT05393427|DRUG|BL-B01D1|Administration by intravenous infusion
40765330|NCT06535607|BIOLOGICAL|Volrustomig|IV Infusion
40765331|NCT06639763|DIAGNOSTIC_TEST|Questionnaire|Questionnaire containing a combination of basic epidemiological questions, questions regarding recent sexual activity, questions regarding sexual preference and sexual activity, questions regarding the use of different types of erectile aids, questions regarding satisfaction with the use of these different erectile aid and questions regarding the satisfaction with sexual functioning and the partner relation. Al patients at least 6 months after primary genital gender-affirming surgery and who are sexually active are eligible.
40962867|NCT05478369|BEHAVIORAL|storybook|anxiety and fear during operative
40962868|NCT03616600|OTHER|Breath-O-Correct Lens|Breath-O correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material
40962869|NCT05806281|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
40962870|NCT00441714|PROCEDURE|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
40962871|NCT03231605|BIOLOGICAL|Hepatitis A Vaccine|Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
40765332|NCT03092011|DRUG|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
40765333|NCT03092011|DRUG|Morphine Sulfate|Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
40765334|NCT06406621|PROCEDURE|Laser hair depilation|1 treatment every 4-6 weeks to obtain a total of 5 treatments. The laser treatment group will consist of an Nd:YAG application to teh gluteal cleft
40765335|NCT04785352|DIETARY_SUPPLEMENT|Nutrition Intervention|One egg per day for six months
40765336|NCT04785352|BEHAVIORAL|Grandi Byen|Multicomponent intervention on responsive parenting, nutrition, hygiene + one egg per day for 6 months
40765337|NCT04802590|DRUG|Ibrutinib 560 mg|560mg/d continuously from C1D2 to end C24
40765338|NCT04802590|DRUG|Venetoclax 10 MG Oral Tablet [Venclexta]|20mg/d from C2D1 to C2D7
40765339|NCT04802590|DRUG|Venetoclax 50 MG Oral Tablet [Venclexta]|50mg/d from C2D8 to C2D14
40765340|NCT04802590|DRUG|Venetoclax 100 MG Oral Tablet [Venclexta]|100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
40962872|NCT03047915|OTHER|Music|The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
40962873|NCT02308605|DEVICE|SMARTCap|The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
40962874|NCT01667029|DRUG|Sulfasalazine|
40962875|NCT01667029|DRUG|placebo|
40962876|NCT05482724|BEHAVIORAL|Super Skills for Life|"Structured and manualized intervention with a manual for the therapist and a workbook for the children.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández.~The intervention was administered by a trained clinical psychologist in SSL. Sessions were held after school hours once a week for eight weeks, with each session lasting approximately one hour. The contents of the program were covered through playful activities in groups of 4 to 6 children"
40962877|NCT04739904|OTHER|Normoxia|48 hours experimental protocol conducted at sea level
40962878|NCT04739904|OTHER|Normobaric hypoxia|24 hours experimental protocol conducted in a normobaric hypoxic facility
40962879|NCT04739904|OTHER|Hypobaric hypoxia|72 hours experimental protocol conducted at terrestrial altitude
41136524|NCT01231178|DIETARY_SUPPLEMENT|Control beverage|The dosage is 3x500ml daily
40765341|NCT01639690|GENETIC|Autologous CD34+ cells transduced with TNS9.3.55|Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10\^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10\^6 untransduced CD34+ cells per kg will be preserved for every patient.
40765342|NCT06636734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40765343|NCT06636734|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40765344|NCT06636734|DRUG|Lovastatin|Given PO
40765345|NCT06636734|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40765346|NCT06636734|BIOLOGICAL|Pembrolizumab|Given IV
40765347|NCT06636734|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40962880|NCT00319553|BIOLOGICAL|ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
40962881|NCT00319553|BIOLOGICAL|BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
41136525|NCT03028285|DRUG|arginine sodium succinate|Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
41294184|NCT05762939|BEHAVIORAL|Chatbot|Participants in this condition were asked to use Fido, a Polish therapy chatbot, for two weeks. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
41456414|NCT02768701|DRUG|Pembrolizumab|Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.
40765348|NCT05338320|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block|General anesthesia and Ultrasound Guided Erector Spinae Plane Block
40765349|NCT05338320|DRUG|Intrathecal morphine|General anesthesia and intrathecal morphine
40765350|NCT05338320|OTHER|General anesthesia using intravenous fentanyl (1µg/kg)|General anesthesia using intravenous fentanyl (1µg/kg)
40765351|NCT05419492|DRUG|ETX101|ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.
40765352|NCT03940521|OTHER|Bioclinical evaluation|50-100ml blood extracted for flow cytometry and qPCR
40765353|NCT02759133|DEVICE|Metal wire|Localization technique for breast surgery using metal wire
40765354|NCT02759133|DEVICE|Radioactive Iodine Seed|Localization technique for breast surgery using Radioactive Iodine Seed
40765355|NCT04070040|DRUG|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
40765360|NCT00237159|DRUG|Zoledronic acid|
40765361|NCT05607459|OTHER|Dry Needling|"Dry needling consists of a skilled intervention which uses a thin filiform needle (as those used in acupuncture) to penetrate the skin and stimulate underlying myofascial trigger points (defined as a hyperirritable spot in skeletal muscle that is associated with a hypersensitive palpable nodule in a taut band which is painful on manual compression and can give rise to characteristic referred pain, referred tenderness, motor dysfunction and autonomic phenomena.)~This intervention will be performed targeting the upper trapezius and cervical multifidus muscles"
40765362|NCT05607459|BEHAVIORAL|Therapeutic Exercise|Patients will include a supervised therapeutic exercise program in their daily life, based on strengthening exercises for neck muscles.
40765363|NCT05607459|OTHER|Manual Therapy|Patients will receive a manual compression (30 seconds) over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus muscle.
40765364|NCT05607459|OTHER|Sham Dry Needling|"For the sham DN intervention, a similar approach will be used, but the skin will be not pierced since the material used will be a telescopic Park's sham device.~The guide tube will be pressed against the skin mark and the sham needle will be allowed to drop. The handle will be tapped briskly, but the (blunted) needle tip will not not break the skin."
40765365|NCT00044785|DRUG|triacetyluridine|
40765366|NCT00044785|DRUG|fluorouracil|
40765367|NCT00044785|DRUG|leucovorin|
40765368|NCT00044785|DRUG|camptosar|
40765369|NCT06153108|DEVICE|PAMSys pendant PAMSys wrist sensors|The PAMSysTM sensor consists of a 3-axis accelerometer, battery, and built-in memory for recording long-term data. Accelerometer data is recorded at a sampling frequency of 50 Hz
40765370|NCT04695665|OTHER|Cervical pain|Exercise program for cervical spine according to McGill's approach.
40765371|NCT04695665|OTHER|Thoracic pain|Exercise program for thoracic spine according to McGill's approach.
40765372|NCT04695665|OTHER|Lumbar pain|Exercise program for lumbar spine according to McGill's approach.
40765373|NCT06640231|OTHER|sealer activation after cleaning and shaping with XP-Endo Finisher|activation of sealer before the obturation of root canals
40962882|NCT05999032|BEHAVIORAL|CASE in person version (High Intensity Package)|Controlling Asthma in Schools Effectively (CASE) is a multi-level school-based asthma management program delivered by a Community Health Worker (CHW) that includes 1) staff training involving education on asthma management in school, 2) child-based asthma management education with an emphasis on control of symptoms in the school setting provided in a group setting during the school day, 3) caregiver education after school involving supporting children's asthma control in the school setting, 4), and provision of an Asthma Action Plan (AAP) to the school for child enrollees.
40765374|NCT06640231|OTHER|negative control where canals are obturated directly without sealer activation|sealer after cleaning and shaping before the obturation without using activation method
40765375|NCT06525220|DRUG|Petosemtamab|MCLA-158
40765376|NCT06525220|DRUG|Pembrolizumab|Humanized Antibody
40765377|NCT06402838|DRUG|RO7269162|Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.
40765378|NCT06402838|DRUG|Placebo|Participants will receive daily doses of placebo for up to 72 weeks.
40765379|NCT05074381|OTHER|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leadi
40765380|NCT05074381|OTHER|Sham Needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
40765381|NCT05442216|DRUG|Tagraxofusp (Cycles 1-2)|12 mcg/kg intravenously Days 1-5
40765382|NCT05442216|DRUG|Azacitidine|75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
40765383|NCT05442216|DRUG|Tagraxofusp (Cycles 3-12)|12 mcg/kg intravenously Days 1-3
40765384|NCT06638125|DEVICE|3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping|All patients in Phase I and those randomized to Intervention in Phase II will have preoperative 3D VR reconstructions of their pulmonary anatomy with the target lesion created using the Elucis platform. Segment identification and confidence rating will be collected before and after visualizing the 3D VR reconstruction. Intraoperatively, the surgeon will use this 3D VR model as a guide to determine which inflow and outflow vessels to the involved segment need to be removed. After vascular ligation, a 8mL bolus of ICG solution will be injected into a peripheral vein catheter by anesthesia. The surgeon will mark out the segmental plane based on the fluorescence pattern seen on the infrared mode of the robotic camera. The surgeon will then perform the pulmonary resection and the resected non-fluorescent lung segment will be extracted from the body cavity. Study patients will receive routine postoperative care as non-study patients and will be followed until the 3-4-week mark.
40765385|NCT06638125|DEVICE|3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping|The patients that are randomized to Control in Phase II will undergo the same intervention as above, but instead of using Elucis for 3D VR reconstructions, Synapse 3D will be used for 3D reconstructions.
41294185|NCT05762939|BEHAVIORAL|Control (book)|Participants in this condition were told to read selected chapters from a self-help book during the two-week intervention period. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
41456415|NCT02768701|DRUG|Cyclophosphamide|A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
41456416|NCT04460716|PROCEDURE|Major noncardiac surgery|Vascular, thoracic, visceral, orthopedic, gynecologic, urologic, ENT, maxillo-facial, plastic and reconstructive surgery
41456417|NCT01572662|DRUG|Fludarabine monophosphate|40 mg/m2 by vein on Days -6 through -3.
40765386|NCT02168439|DRUG|Dexmedetomidine|
40765387|NCT02168439|DRUG|Midazolam|
40765388|NCT04083027|DEVICE|MRI|Breast MRI
40765389|NCT06642194|BEHAVIORAL|Education on sunnah of sleeping|The interventions had three session which conducted between 40-60 minutes per session. The session include: 1) introducing the research objectives, definition and benefits on sunnah of sleeping; 2) steps in sunnah of sleeping (early bedtime and early wake up time; perform ablution (wudoo) before going to bed and supplicate; dusting and cleaning the bed before sleeping; sleep position; turning off light before sleep; cover mouth when yawning and reciting some verses such as Ayat Kursi, Al-Ikhlas, Al-Falq and An-Nas); 3) providing mp3 and prayers beads to facilitate Qur'an recitation and zikr. These surat was chosen because the portion of surat concentrate on the absolute divinity of Allah and Allah's blessings to His creatures. The surat brings every Muslim the closeness to Allah, the calmness of the soul, and the cure for many physical and psychological diseases. The steps in sunnah of sleeping can be performed approximately about 10-15 minutes about 30 minutes prior to sleep.
40765390|NCT04100993|OTHER|No intervention used|No intervention used
41136526|NCT05697536|OTHER|Pilates training|"It consists of patients who will receive pilates exercise training sessions 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercise programs follow the basic principles of pilates method but particularly movements with low and medium difficulty levels will be chosen to adapt the program to the physical capacity of the patients.~Protocol will be compromise of 9 modules: postural education, search for neutral position, sitting exercise, antalgic exercise, stretching exercises, proprioceptively improvement exercises and breathing exercises."
41136527|NCT05697536|OTHER|Aerobic Exercise|"It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 45 minutes.~It will include warm up phase, active phase and"
41136528|NCT04498780|DRUG|Sacubitril-Valsartan|Observational study during the clinically indicated treatment
41136529|NCT01479010|DRUG|Anakinra 100 mg subcutaneously daily|Anakinra 100 mg subcutaneously daily
41136530|NCT01738997|DEVICE|Dilation 10 sec|
41136531|NCT01738997|DEVICE|Dilation 2 min|
41136532|NCT01584596|BEHAVIORAL|Adapted Dietary Guidelines|"This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist."
41294186|NCT03760380|DEVICE|Sole 1 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability. This is defined as the location which creates the smallest amount of instability.
41456418|NCT01572662|DRUG|Busulfan|First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
41456419|NCT01572662|PROCEDURE|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
41456420|NCT01572662|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
41456421|NCT01572662|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
41456422|NCT01572662|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
40765391|NCT01462747|DEVICE|KULIST|Twice daily dosing for 8 weeks
40765392|NCT05085834|DRUG|Zinc Gluconate|Two 45 mg capsules once daily
40765393|NCT05085834|DRUG|Placebo|Two placebo capsules once daily
40765394|NCT06637774|DEVICE|Aspirometer|a triaxial accelerometer and a contact microphone affixed with tape to patient neck, a data accrual infrastructure, algorithms that decode swallow physiology noninvasively
40765395|NCT06637774|DEVICE|Videofluoroscopic X-ray|MBS is a fluoroscopic diagnostic test to evaluate swallowing physiology. Its images are judged by humans trained to do so.
40765396|NCT05263167|DRUG|Sodium Aescinate|sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
40765397|NCT05263167|DRUG|Placebo|250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
40765398|NCT02562235|DRUG|Riociguat (Adempas, BAY63-2521)|For children with body-weight \<50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
40765399|NCT06434727|OTHER|observational study|Observational Study
40765400|NCT03740113|BEHAVIORAL|Kids SipSmartER|Kids SIPsmartER is grounded by the Theory of Planned Behavior as well as health literacy, media literacy, numeracy, and public health literacy concepts
40765401|NCT06113289|DRUG|ASTX727|Given by PO
40765402|NCT06113289|DRUG|ASTX029-01|Given by PO
40765403|NCT04427670|OTHER|Group intervention|Group intervention programme designed for stroke survivors with dysarthria and their carers. The programme was eight weeks long, with weekly two sessions, each session lasting for two hours, lead by speech language therapist and was comprised of activities which addressed participants education about their dysarthria and stroke. The role of family , peer and professional was to provide support and communication practice.
40765404|NCT04427670|OTHER|Regular speech therapy|Regular speech therapy will be provided to the controlled group.Regular speech therapy is one to one speech therapy session,conducted twice a week for the duration of eight weeks.This intervention is implemented to patients with dysarthria following stroke in a format of one patient and one therapist per session.
40765405|NCT05675020|BEHAVIORAL|Zoom Intervention|"This educational program will be delivered via a 45-minute presentation via Zoom.~* The educational presentation will be recorded and emailed to participants within 1 week of intervention to re-watch/review.~* The educational program will promote a healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines.~* We will compare the effects of an educational program on healthy lifestyle knowledge and behaviors pre-and post-program (after one month) via a REDCap survey for the adolescent and their parent/legal guardian."
40765406|NCT06377748|OTHER|Facilitated tucking position|Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will administer intramuscular vaccine injection into the vastus lateralis region of the left leg of the infant in the facilitated tucking position according to routine practice.
40765407|NCT06377748|DEVICE|ShotBlocker|Immediately prior to the vaccination procedure, the nurse will place the protruding surface of the ShotBlocker on the neonate's vaccination procedure site (left leg vastus lateralis muscle). The nurse will continue to hold the ShotBlocker at the injection site by pressing against the skin for 20 seconds. At the end of the time, she will grasp the tissue with the ShotBlocker and inject the vaccine through the opening in the center. After the procedure is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin.
40765408|NCT06377748|COMBINATION_PRODUCT|Combined facilitated tucking and ShotBlocker|Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will place the ShotBlocker on the procedure site and apply pressure to the skin for 20 seconds. At the end of the time, the nurse will grasp the tissue with the ShotBlocker and inject the vaccine through the central opening. After the injection is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin. The newborn will continue to take facilitated tucking position until 1 minute after the ShotBlocker is removed.
40765409|NCT03753516|PROCEDURE|Laparoscopic - Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close laparoscopically using an 0-Barbed suture.
40765410|NCT03753516|PROCEDURE|Vaginal- Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close vaginally using an 0-Vicryl suture in a vertical fashion.
40765411|NCT03899428|DRUG|Durvalumab|Durvalumab 1500 mg IV (intravenous infusion)
40765412|NCT03899428|DRUG|Sorafenib|Prescribed by physician.
40765413|NCT03899428|DRUG|Lenvatinib|Prescribed by physician.
40765414|NCT03899428|DRUG|Regorafenib|Prescribed by physician.
40765415|NCT03899428|DRUG|Cabozantinib|Prescribed by physician.
41456423|NCT03368391|DRUG|tetracaine HCl and oxymetazoline HCL|0.4 mL HCl and oxymetazoline HCl administered intranasally
41456424|NCT03368391|DRUG|2% Lidocaine with 1:100,000 epinephrine|2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth
40765416|NCT06154525|OTHER|RO water|Aquafina's reverse osmosis (RO) water, produced by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively. The RO water ampoules are produced using a similar process as the LIVESPO Preg-Mom/ KIDS but contain 5ml of high-quality RO water from Aquafina (proper noun)
40765417|NCT06154525|DIETARY_SUPPLEMENT|LiveSpo Preg-Mom|LiveSpo® Preg-Mom has a registration number 7695/2020/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
41456425|NCT03368391|DRUG|3% Mepivacaine with 1:100,000 epinephrine|2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth
40765418|NCT06154525|DIETARY_SUPPLEMENT|LiveSpo KIDS|LiveSpo® KIDS has a registration number 1537/2023/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
40765419|NCT00538447|OTHER|Database|data base for CML
40765420|NCT06644534|DRUG|TTI-0102|(cysteamine-pantetheine disulfide)
40765421|NCT06644534|DRUG|Placebo|Pearlitol® 100 SD (mannitol)
40765422|NCT06535776|OTHER|Matrix Rhythm Therapy|Individuals in this group will be taught home exercises face-to-face in a single session as in the home-based exercise group and will be asked to perform the exercises themselves at home for 3 non-consecutive days a week for 6 weeks. In addition to home-based exercises, a total of 12 sessions of face-to-face matrix rhythm therapy will be performed, 2 non-consecutive days a week for 6 weeks. Matrix rhythm therapy applications will be applied by a specialist physiotherapist who has received training with the matrix rhythm therapy vibromassage device.
40765423|NCT06535776|OTHER|Home-based Exercise|Home-based exercise program will be explained to patients diagnosed with axSpA by a physiotherapist. All exercises will be repeated with the physiotherapist and explained until understood. Patients will be asked to perform these exercises on their own 3 non-consecutive days a week for 6 weeks. Patients will be called by the physiotherapist on each exercise day and their home exercises will be monitored and recorded in the exercise tracking chart created for each patient. In addition, the patients will be given an exercise follow-up chart and they will be asked to fill in the existing chart and submit it at the end of the 6-week training.
40765424|NCT04381806|DRUG|5-ALA|Patients enrolled in this study will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed. Patients are followed through day 56 for adverse event and efficacy measures.
40765425|NCT06640296|DRUG|Liposomal Amphotericin B (LAmB)|collect data on tolerability and effectiveness of liposomal amphotericin B prophylaxis
40765426|NCT04022213|DRUG|131 I-omburtamab|Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
41136533|NCT01584596|BEHAVIORAL|Adapted Physical Activity Guidelines|The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
41456426|NCT03368391|DRUG|saline intranasal|0.4 mL intranasal saline will be administered as a placebo
41456427|NCT03368391|DRUG|saline infiltration|2.8 mL of saline will be infiltrated at anterior teeth as a placebo
41456428|NCT06166862|OTHER|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
40765427|NCT04022213|RADIATION|WAP-IMRT|Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
40765428|NCT06637631|DRUG|SAR441566|Pharmaceutical form: Tablet Route of administration: Oral
40765429|NCT06637631|DRUG|SAR441566 matching Placebo|Pharmaceutical form: Tablet Route of administration: Oral
41456429|NCT06166862|OTHER|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
41456430|NCT01698736|DEVICE|Membrane filtration|Membrane filtration (Polysulfone)
41456431|NCT01698736|DEVICE|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
41456432|NCT02520193|PROCEDURE|Protocolized early mobilization in ICU|
40765430|NCT05097287|DRUG|Dupilumab|solution for injection subcutaneous
40765431|NCT05097287|DRUG|Placebo|solution for injection subcutaneous
40765432|NCT02764138|BEHAVIORAL|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
41136534|NCT04951791|DRUG|SMOFlipid|will receive intravenous infusion of 2ml\\kg of smoflipid 20%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed
40765433|NCT01644591|OTHER|Quality-of-Life Assessment|Ancillary studies
40765434|NCT01644591|OTHER|Questionnaire Administration|Ancillary studies
40765435|NCT01644591|RADIATION|Stereotactic Radiosurgery|Undergo SRS
40765436|NCT04606290|DEVICE|O2matic HOT|Automated oxygen titration with O2matic HOT
40765437|NCT04606290|DEVICE|Oxygen concentrator|Fixed dose oxygen flow from concentrator
40765438|NCT05781503|BEHAVIORAL|Identity Capital Intervention (Coach + Co-designed Leadership Guide)|Young people randomized to the intervention group will engage in a co-designed leadership guide with their assigned coach. The co-designed leadership guide contains 12 chapters with the overarching aim of enhancing identity capital along with providing strategies to achieve participant-identified goals. Each chapter contains four activities (e.g., self-reflection exercise or listening to a podcast). Ideally, youth will complete one chapter every month. Each young person in this group will meet individually with their coach every two weeks and with a larger group of 10 youth participants and their coach every month.
40765439|NCT05781503|OTHER|Monthly Rent Subsidies|All study participants will receive a monthly rent subsidy ($800 for those living in Toronto; $700 for those living in St. Catharine's or Hamilton due to differences in cost of living) for 12 months.
40765440|NCT03372733|DRUG|control olive oil (COO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
41136535|NCT04951791|OTHER|Normal saline 0.9%|will receive intravenous infusion of 2ml\\kg of normal saline 0.9%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed.
41456433|NCT05123443|BIOLOGICAL|Blood sample provided|Individuals who consent to provide a blood sample will be included in the cross-sectional genetics study.
41456434|NCT05123443|DIAGNOSTIC_TEST|7-T MRI scan|Individuals who consent to receive an additional 7-T MRI scan will be invited to the Sir Peter Mansfield Imaging Centre. This current MRI will be compared against the baseline 7-T scan performed between 2008 - 2012.
40765441|NCT03372733|DRUG|palmitoleate-rich oil (PLO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
40765442|NCT03531541|DEVICE|Application of TENS|The subject's skin will be cleaned with mild soap and water. Two square self-adhesive electrodes (5x5cm) will be placed 1 cm below the olecranon of the ulna and 10 cm above the radiocarpal joint of the dominant hand, maintaining the PPT measurement region between two electrodes. Two identical TENS units will be used: an active and a placebo (Neurodyn Portable TENS, IBRAMED). The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes. Participants will be asked about the intensity of TENS every 5 minutes, and if the intensity has faded, the intensity will be increased again to a strong but comfortable level.
40765443|NCT03531541|DEVICE|CJM|The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust). If the patient does not experience joint cavitation during the maneuver, two more attempts will be made. If no sound occurs on the third attempt, the joints will be considered manipulated.
40962883|NCT05999032|BEHAVIORAL|CASE-V remote version (Low Intensity Package)|CASE-V, the low intensity version of CASE, includes similar child and caregiver-based asthma management education that is provided in a remote format with adaptation to integrate technological feature of Zoom. All CASE-V components (for staff, children, and parents) have been adapted to promote engagement (e.g., use of chat and polling function).
41294187|NCT03760380|DEVICE|Sole 1 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
41294188|NCT03760380|DEVICE|Sole 2 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability.This is defined as the location which creates the smallest amount of instability.
41294189|NCT03760380|DEVICE|Sole 2 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
41294190|NCT05393583|PROCEDURE|Outpatient hysterectomy|Discharge on the day of the hysterectomy
41294191|NCT05393583|PROCEDURE|Inpatient hysterectomy|1 night hospital stay after hysterectomy
41294192|NCT04487847|DIAGNOSTIC_TEST|18F-PSMA-1007 PET/CT|18F-PSMA-1007 PET/CT
41294193|NCT01205490|OTHER|head positions and spinal manipulation|Each subject will then undergo a baseline MRI in a head neutral position (0 degrees rotation). They will then be placed in head rotation (45 degrees) to the non-dominant and undergo a MRI. Maximum rotation to the side with MRI will follow. Finally, each subject will receive an upper cervical rotary manipulation to the non-dominant side with MRI immediately after. A total of 4 test conditions will be evaluated (rest, 45 degree, maximal, post-manipulation). The manipulation will be performed by an experience practitioner on a bed just outside the MRI room in supine position. A controlled impulse load will be applied and the head/neck returned to neutral position. Prior to each maneuver, the subject will be queried on their comfort, condition and willingness to continue
41456435|NCT06340698|BEHAVIORAL|Resilience intervention|"Contents of the first session include:~1. Resilience. Know the concept of resilience.~2. Stigma management. Discuss stigma experience and learn stigma management strategies such as normalizing the disease.~3. Self-efficacy. Learn ways of improving self-efficacy, such as experience of success and social support.~Contents of the second session include:~1. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions. Learn effective communication skills.~2. Acquiring social support. Know people and resources that could provide support when having HIV-related difficulties and mental health problems.~3. Emotional regulation. Understand the physiological responses to emotions. Know a range of emotional regulation strategies, such as cognitive reappraisal and deep breathing."
41456436|NCT06340698|BEHAVIORAL|Adherence intervention|"Contents of the first session include:~1. Adherence behavioral skills. Identify barriers to optimal HAART adherence. Know behavioral skills that can deal with these barriers, such as forgetting, afraid of others' questioning and side effects.~2. Adherence information and motivation. Know how the HIV virus attack human body and the mechanisms of HAART medication. Understand the influence of adherence level on health outcomes.~Contents of the second session include:~1. Adherence motivation. Discuss possibilities and hope of future life, intimate relationship and career.~2. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions concerning HAART medication. Learn effective communication skills.~3. Acquiring social support. Know people and resources that could provide support when having HAART-related difficulties and problems."
41456437|NCT01675973|DRUG|RANEXA|500mg BID up to 1000mg BID
41456438|NCT05212038|PROCEDURE|iliopsoas plane block group|Ultrasound-guided iliopsoas plane block with 0.75% ropivacaine 10 ml and epinephrine 0.05 ml (1:200,000) 10 ml
41456439|NCT05212038|PROCEDURE|sham block group|Ultrasound-guided iliopsoas plane block with normal saline 10 ml
41456440|NCT04225364|DRUG|camrelizumab|Participants will receive camrelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
41294194|NCT01225393|DRUG|MLTA3698A|Subcutaneous repeating dose
41294195|NCT01225393|DRUG|adalimumab|Subcutaneous repeating dose
41294196|NCT01225393|DRUG|leflunomide|Stable dose if not on methotrexate
41294197|NCT01225393|DRUG|methotrexate|Stable dose if not on leflunomide
41294198|NCT01225393|DRUG|placebo|Subcutaneous repeating dose
40765444|NCT03531541|DEVICE|Placebo TENS|The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value. Participants will be informed that TENS can cause a slight tingling sensation or any sensation during the procedure. They will be asked every 5 minutes if they are comfortable, without increasing intensity as in the active TENS group
40765445|NCT03531541|DEVICE|Placebo CJM|Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect. The maneuvers will be carried out by a physiotherapist with more than 5 years of experience in manual therapy. The active or placebo manipulation will be performed on the right or left side according to randomization.
41294199|NCT02890082|DRUG|Tamoxifen stim in early follicular phase|"Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3~* Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)~* Monitoring (ultrasound + blood test E2, LH (luteinizing hormone) and P) every 2 to 3 days +/- dose adjustment of FSH~* Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
40765446|NCT06636942|DEVICE|Intermittent pneumatic compression|Following a soccer match, athletes will be enrolled in a recovery treatment: placebo intervention or intermittent pneumatic compression. Participants will be randomly assigned to each group. Neuromuscular tests (cmj) and perceptual questionnaires (hooper index) will be conducted.
40962884|NCT05999032|BEHAVIORAL|CASE and HARP in person (High Intensity package)|"Children with poorly controlled asthma will receive both the CASE and HARP programs. HARP is a home-visiting program that includes individualized asthma management education and strategies and supplies for environmental remediation. All 3 visits can be conducted by a CHW. The first includes a walk-through to identify triggers. Asthma education and self-management strategies are provided using a structured protocol and low-literacy flip-book (English or Spanish). Referrals and advocacy are offered to address asthma management barriers (e.g., communication with landlord/housing re: code violation). The 2nd and 3rd visits include delivery of supplies (e.g., HEPA vacuum, pest gels, mattress covers), instruction for use, review of AAP, and follow-up on environmental control recommendations provided during the 1st visit."
40962885|NCT05999032|BEHAVIORAL|CASE-V and HARP-V remote version (Low Intensity package)|"HARP-V replicates the content delivered in HARP in a remote format. The first session includes a virtual walk-through in which the educator uses a structured script and checklist to guide the caregiver through the home and show specific components of the environment (e.g., carpeting, area under the kitchen sink, exhaust fan in bathroom) to identify asthma triggers. Asthma education and self-management strategies are provided using a structured protocol and slide overview based on the HARP flip-book. Supplies for environmental remediation are delivered prior to the 2nd visit. The 2nd and 3rd visit include instruction for use of supplies, review of AAP, and follow-up on recommendations and referrals."
40962886|NCT01211470|DRUG|Daptomycin|Active Comparator: Daptomycin.
40962887|NCT01211470|DRUG|PMX-30063-investigational drug|Experimental: PMX-30063
40962888|NCT00211510|DEVICE|Paradigm 722 sensor augmented pump|Subjects use the Paradigm 722 sensor augmented pump
41294200|NCT02890082|DRUG|Tamoxifen stim in late follicular phase|"Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14~* Monitoring (ultrasound + blood test E2, LH and P) until a follicle of 15 mm~* Ovulation induction by OVITRELLE® 250μg.~* Continued monitoring (ultrasound + blood test E2, LH and P) 4 days after OVITRELLE® to the proper stage for the beginning of stimulation.~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
40962889|NCT00211510|DEVICE|Paradigm 715 insulin pump|Subjects use the Paradigm 715 insulin pump
41456441|NCT04225364|DRUG|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound): 260mg/m2(in total), ivgtt d1, d8, q3w，for 2 cycle
40962890|NCT04556188|PROCEDURE|Cardiac surgery|
41456442|NCT04225364|DRUG|Cisplatin|75mg/m2(in total), ivgtt d1-d3, q3w, for 2 cycles
41456443|NCT00566722|BIOLOGICAL|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
41456444|NCT00834236|OTHER|normal subject|biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
41456445|NCT00834236|OTHER|gastric cancer|biomarker in gastric juice, e.g., alpha 1-antitrypsin
41456446|NCT02691676|DRUG|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
41456447|NCT02691676|DRUG|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
41456448|NCT00916045|DRUG|Thiotepa|
41456449|NCT00916045|DRUG|Fludarabine|
41456450|NCT00916045|DRUG|Intravenous busulphan|
40962891|NCT02407860|OTHER|osteopathic treatment|Treatment duration range between 30 to 40 minutes. The infant entire body is evaluated and then manipulative procedures are provided following palpatory results.
40962892|NCT02407860|OTHER|usual breastfeeding counselling|breastfeeding counselling and support by lactation consultant
40962893|NCT06086470|DEVICE|Qidni/D Hemodialysis System|Qidni/D is a hemodialysis device for patients with end-stage renal disease.
40962894|NCT01256008|BEHAVIORAL|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
40962895|NCT01256008|BEHAVIORAL|Clinical Management|"Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible."
41294201|NCT02890082|DRUG|Tamoxifen stim in luteal phase|"Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28~* 1 or 2 Monitoring (ultrasound + blood test E2, LH and P) to check the validity of the post-ovulatory phase~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia"
41294202|NCT06110234|BEHAVIORAL|Episodic Specificity Induction|Recalling complex scenes using the Episodic Specificity Induction
41294203|NCT06110234|BEHAVIORAL|Associative Memory|Recalling word/picture pairs
41456451|NCT00916045|DRUG|Thymoglobulin|
41456452|NCT00916045|DRUG|Ciclosporin|
41456453|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
40962896|NCT04130620|DIAGNOSTIC_TEST|Applied Kinesiology|An Applied Kinesiology muscle test will be supplemented by a single blood draw for validation.
40962897|NCT01193595|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
40962898|NCT01193595|DRUG|bevacizumab|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
40962899|NCT02186990|DRUG|propofol|2,5 mg/kg
40962900|NCT02186990|DRUG|etomidate|0,3 mg/kg
40962901|NCT02186990|DRUG|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
40962902|NCT02231008|DRUG|tasimelteon|
40962903|NCT02231008|DRUG|placebo|
40962904|NCT00534391|DRUG|neomycin sulfate, polymyxin B sulfate and gramicidin|to the effected eye 4 times a day
40962905|NCT00534391|DRUG|Artificial tear|4 times daily
40962906|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
40962907|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
40962908|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
40962909|NCT01382095|BIOLOGICAL|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
41294204|NCT01686204|OTHER|Low fat dairy yogurt|Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
41294205|NCT01686204|OTHER|Soy pudding|Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
41294206|NCT01962259|BEHAVIORAL|Physical activity|
41294207|NCT03281226|DRUG|RIPE (2m) and RI (4m)|Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
41456454|NCT00916045|DRUG|Fludarabine|
41456455|NCT00916045|DRUG|Cyclophosphamide|
41456456|NCT00916045|RADIATION|Radiotherapy|
41456457|NCT00916045|DRUG|Thymoglobulin|
41456458|NCT00916045|DRUG|Ciclosporin|
41456459|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
41456460|NCT00916045|DRUG|Fludarabine|
41456461|NCT00916045|DRUG|Melphalan|
41456462|NCT00916045|DRUG|Thymoglobulin|
41456463|NCT00916045|DRUG|Ciclosporin|
41456464|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
41456465|NCT06067789|PROCEDURE|neuraxial anesthesia|Intervention arm participants will be allocated to neuraxial anesthesia.
41456466|NCT05862987|DIETARY_SUPPLEMENT|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
41456467|NCT05862987|DIETARY_SUPPLEMENT|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
41456468|NCT03416049|DEVICE|PEMF therapy with a high-power PEMF device|The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.
41456469|NCT03416049|DEVICE|PEMF therapy with a medium PEMF power device|The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.
41456470|NCT03416049|DEVICE|PEMF therapy with a low-power PEMF device|The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.
41456471|NCT03416049|DEVICE|PEMF therapy with the sham PEMF device|The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
41456472|NCT01638273|DRUG|Pregabalin 150mg|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
41456473|NCT01638273|DRUG|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
40962910|NCT01434030|BEHAVIORAL|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
40962911|NCT04907903|OTHER|internet-based intervention|Intervention consists in 8 weekly online cognitive-behavioral modules (for a total duration of 2 months).
40962912|NCT01774968|DRUG|Human Regular U-500 Insulin|
40962913|NCT02983344|DRUG|Ropivacaine|Fascia iliaca compartment block using ropivacaine
41136536|NCT00307216|BEHAVIORAL|Graduated Recovery Intervention Program (GRIP)|GRIP is a manual-based comprehensive psychosocial intervention for people recovering from an initial episode of nonaffective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management, substance use, persistent symptoms, and functional recovery.
41294208|NCT03281226|DRUG|RIPE+NAC (2m) and RI (4m)|Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
41294209|NCT02132390|DRUG|Goserelin|
41294210|NCT02132390|DRUG|Toremifene|
41456474|NCT03242980|BEHAVIORAL|Structured adherence counseling|"Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.~Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling."
41456475|NCT01714284|BEHAVIORAL|Informative|The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
41456476|NCT01714284|BEHAVIORAL|Diet and Exercise|The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
41456477|NCT04836182|DRUG|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
40962914|NCT02983344|DRUG|Fentanyl|Intravenous fentanyl
41136537|NCT00307216|BEHAVIORAL|Treatment as usual (TAU)|Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.
41136538|NCT05498051|PROCEDURE|Sentinel lymph node identification|Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.
41136539|NCT03536767|DRUG|AG10|AG10 800mg twice daily, oral administration
41136540|NCT05733494|OTHER|Administration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)|the CADN will be administrated to each patient at the enrolment
41294211|NCT03461965|BEHAVIORAL|3D printed model|A printed 3D model of MMS will be created showing a model of skin, and a tumor to visually depict the surgery
41294212|NCT03461965|BEHAVIORAL|Verbal Counselling|Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
41456478|NCT04836182|DRUG|Placebo|IONIS-AGT-LRx-matching placebo will be administered by SC injection.
40962915|NCT02983344|DEVICE|Ultrasound|Ultrasound-guided fascia iliaca compartment block
41294213|NCT03201328|OTHER|Audio-vestibular examination|Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
41294214|NCT03201328|OTHER|Videonystagmoscopic study|Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
40962916|NCT03438929|DEVICE|Diode laser|Diolaze XL blended modes diode laser
40962917|NCT03173313|DEVICE|Intravascular permissive hypothermia as an adjunct to PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
40962918|NCT00386178|DRUG|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
41294215|NCT03201328|OTHER|Posturographies study|(stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
41294216|NCT02409420|BEHAVIORAL|Physiotherapy informed by Acceptance and Commitment Therapy|PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
41294217|NCT02261480|OTHER|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
41294218|NCT02261480|OTHER|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
40962919|NCT01416272|DEVICE|KeraSoft IC Soft Contact Lenses|Lenses will be worn between 8 and 16 hrs each day, for 12 months
40962920|NCT00313157|DRUG|Metoprolol|
40962921|NCT00313157|DRUG|Diltiazem|
40962922|NCT00313157|DRUG|Verapamil|
40962923|NCT00313157|DRUG|Carvedilol|
40962924|NCT05176730|BEHAVIORAL|Mindfulness meditation|Similar to the information included in arm/group descriptions
40962925|NCT04112784|DEVICE|INVSENSOR00039|Noninvasive pulse oximeter sensor
40962926|NCT02250378|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
40962927|NCT02250378|PROCEDURE|therapeutic conventional surgery|Undergo wedge resection
40962928|NCT02250378|OTHER|laboratory biomarker analysis|Correlative studies
41294219|NCT00950027|DRUG|povidone iodine|oropharyngeal decontamination every 4 hours
40962929|NCT02250378|OTHER|quality-of-life assessment|Ancillary studies
41294220|NCT00950027|DRUG|Placebo|oropharyngeal decontamination every 4 hours
40962930|NCT05999240|DRUG|Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]|Participants will be randomized to take a single dose of either pimavanserin 34 mg or placebo at Visit 2.
40962931|NCT05999240|DRUG|Placebo|Placebo for Pimavanserin Tartrate 34 Mg ORAL CAPSILE \[NUPLAZID\]
40962932|NCT04092400|DEVICE|Micro-invasive Glaucoma Surgical Devices|Safety and efficacy of Micro-invasive Glaucoma Surgical Devices
40962933|NCT02900196|OTHER|1 - Fermented dairy drink|1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
40962934|NCT02900196|OTHER|2 - Acidified dairy drink|2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
40962935|NCT05851066|DRUG|VSA003|sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg
40962936|NCT05851066|DRUG|0.9% NaCl|placebo
40962937|NCT00332163|BIOLOGICAL|Panitumumab|Administered by intravenous infusion
40962938|NCT00332163|DRUG|Irinotecan|Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
40962939|NCT00332163|DRUG|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
40962940|NCT00332163|DRUG|Pre-emptive Skin Treatment|Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
40962941|NCT00332163|DRUG|Reactive Skin Treatment|Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
40962942|NCT01737697|DRUG|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
40962943|NCT01737697|DRUG|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
40962944|NCT01737697|DRUG|Placebo (acute phase)|Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
40962945|NCT01737697|DRUG|Placebo ( subacute phase)|Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
40962946|NCT06166667|PROCEDURE|Fecal Microbiota Transplant（FMT）|Patients involved in the trial received 20 capsules of Enterobacteriaceae (one course) on days 1, 8, and 15, which were provided by Dongyuan Yikang company. Patients were prohibited from taking antibiotics such as amoxicillin and Cefalexin during the trial.
40962947|NCT03863054|DEVICE|NATROX™ Topical Oxygen Therapy System|"A small battery-powered electrochemical oxygen generator to concentrate atmospheric oxygen and feed to wound site through a dressing-like oxygen distribution system"
41294221|NCT03687177|OTHER|With visual cue and nurses informed|Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
41294222|NCT03687177|OTHER|Without visual cue and nurses informed|Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
41456479|NCT01411462|DEVICE|VIBE + drug-eluting balloon|VIBE before and after durg-eluting balloon angioplasty
41456480|NCT01519830|DRUG|Iron carboxymaltose (Ferinject)|Intravenous iron
41456481|NCT01519830|DRUG|Placebo|0.9% NaCl solution
41136541|NCT03288506|BEHAVIORAL|Google Hangout (VC) group|Feasibility and acceptability of online peer support groups for adults with depression. Groups will be delivered using video-conferencing technology (Google Hangouts).
41136542|NCT00163358|DRUG|Ciclesonide|
41136543|NCT00952003|DRUG|Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel|
41136544|NCT04781868|DRUG|Multi-nutrient supplement|Multi-nutrient supplement containing a combination of vitamins, minerals and antioxidants
41136545|NCT04781868|DRUG|Placebo|Placebo
40962948|NCT06394297|RADIATION|SBRT|SBRT to reproduce HDR BT dose distribution in non-operated patients LACC
41136546|NCT05035563|BEHAVIORAL|Intervention. Early and integral communication strategy (EICS)|"This intervention will be implemented in patients since they are hospitalized in the ICU where is expected:~* Facilitate contact and communication between patients, families and the health team.~* Respond to the communication needs of family members.~* Reduce equipment overload and facilitate communication with families and patients, providing tools and timely support.~* Build a positive and trusting relationship of relatives and patients with health teams.~The intervention considers the following actions:~1. - Training in communication to the health team~2. - Written material~3. - Family website~4. - Standardized and daily telephone information~5. - Health Team Support Strategy~6. - Weekly multidisciplinary virtual meeting with the family~7. - ICU diaries for family members"
41136547|NCT03528304|BEHAVIORAL|Contingency management|Contingency management (CM) is a behavioral intervention that uses gift cards, prizes, or access to privileges to reinforce specific healthy behaviors and lifestyle changes. CM has been used successfully for a range of addictive behaviors, including cigarette smoking and heroin, cocaine, methamphetamine, and other illicit substance use, as well as for reducing psychiatric problems and HIV risk. CM has great potential for treating smoking and overweight/obesity, as it reinforces both short- and long-term behaviors. This is important because both smoking cessation and weight loss are highly prone to short-term relapse,
41136548|NCT05985265|PROCEDURE|Fat grafting|Nano fat grafting followed by fractional carbon dioxide laser resurfacing
41136549|NCT04818476|PROCEDURE|diagnostic endoscopic resection|diagnostic endoscopic resection
41136550|NCT04803734|DRUG|Albuterol Sulfate inhalation aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
41136551|NCT04803734|DRUG|Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation|MDI, 2 puffs, single dose, fasting
41136552|NCT00825344|DRUG|Etanercept|50 mg subcutaenous preoperatively
41136553|NCT00825344|DRUG|Saline|Given subcutaneously preoperatively
41456482|NCT04815668|OTHER|Acupuncture group|Sterile single-use stainless steel needles (size 0.35 mm × 55 mm) (YiDaiFu brand, Suzhou Tianyi Acupuncture Instrument Co., Ltd., Suzhou, China) will be utilized. Participants in lateral position, the acupoints area will be sterilized with 75% alcohol. To stimulate SPG, the needles will be inserted in the medial superior anterior direction to a depth of approximately 55 mm33 until the participants report a special sensation radiating toward the nose or the upper teeth. After that, the needle will be withdrew slightly. The needles will be retained for 30 minutes after three stimulation. Rescue medication are permitted when participants feel that their symptoms are intolerable.
40962949|NCT03673449|DEVICE|SilkBridge|SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
40765447|NCT05544760|OTHER|CatchU Intervention|The CatchU Intervention arm will receive individualized recommendations (adapted from the CDC STEADI program) as outlined on the CatchU physician report sent to the participants physicians. These recommendations in combination with falls intervention referrals and falls counseling tips will be monitored and statistical investigation of the impact of CatchU intervention in preventing future falls will be determined.
40962950|NCT05757453|DEVICE|MHealth|Mobile application
40962951|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 1|Liquid formula produced by several food ingredients to provide a balance nutrient intake
40962952|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 2|Liquid formula produced by several food ingredients to provide a balance nutrient intake
40962953|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 3|Liquid formula produced by several food ingredients to provide a balance nutrient intake
40962954|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 4|Liquid formula produced by several food ingredients to provide a balance nutrient intake
40962955|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 5|Liquid formula produced by several food ingredients to provide a balance nutrient intake
40962956|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 6|Liquid formula produced by several food ingredients to provide a balance nutrient intake
40962957|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 7|Liquid formula produced by several food ingredients to provide a balance nutrient intake
40962958|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 8|Liquid formula produced by several food ingredients to provide a balance nutrient intake
40962959|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 9|Liquid formula produced by several food ingredients to provide a balance nutrient intake
40962960|NCT06358716|DIETARY_SUPPLEMENT|Glucose|25 mg of glucose dissolved in 200 mL
40962961|NCT02849431|BEHAVIORAL|Mindfulness-based intervention|A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
41136554|NCT00258115|DRUG|salsalate|
41136555|NCT03784222|DRUG|Blonanserin|patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
41136556|NCT03784222|OTHER|MRI and serum BDNF|60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
41136557|NCT00006203|DRUG|naltrexone (Revia)|
41136558|NCT05504447|OTHER|"Rong-Yang Zhengyifang tea bag"|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
41136559|NCT05504447|OTHER|placebo tea bag|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
40962962|NCT03409835|DRUG|Ramosetron|Ramosetron 0.3 mg is administered after induction of general anesthesia.
41136560|NCT04645849|BIOLOGICAL|Immunomonitoring|"16 patients will be recruited at the end of treatment: an immunoprofiling analysis will be performed out of a blood sample about 1 month, 5 months and 9 months after treatment.~8 patients will be recruited at diagnosis: a immune profile analysis will be performed before the start of treatment. This will give comparative values for the immune system cells and molecules."
41136561|NCT04017299|OTHER|CHOISIR|Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
41136562|NCT01866800|DEVICE|Renal Guard|Renal Guard
41136563|NCT01866800|DRUG|Conventional Treatment|Saline and N-acetylcysteine
41136564|NCT03028805|OTHER|Automatic inclusion of COPD orders in admission orders|Use of real-time data to identify a population of patients with COPD and prompt improved adherence to evidence-based guidelines through the automatic inclusion of a COPD order set in the admission orders.
41136565|NCT03028805|OTHER|Dynamic, end-user order set design|Use of a dynamic order set that has been end-user tested prior to launch rather than designed centrally by a committee to test use of order set components.
41136566|NCT00141232|DRUG|Atorvastatin and Omega-3 fatty acids|
41136567|NCT05588388|DRUG|Bevacizumab|Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM
40962963|NCT03409835|DRUG|Normal saline|Normal saline 2 ml is administered after induction of general anesthesia.
40962964|NCT00371280|PROCEDURE|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
40962965|NCT02761278|PROCEDURE|Endometrial biopsy|
40962966|NCT02560597|PROCEDURE|repetitive transcranial magnetic stimulation|"Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most."
41136568|NCT02673866|DRUG|DS-1971a|
41136569|NCT02673866|DRUG|placebo|
41136570|NCT02673866|DRUG|pregabalin|pregabalin
41136571|NCT02661958|DRUG|S6G5T-3|once a day topical cream
41136572|NCT02661958|DRUG|S6G5T-1|once a day topical cream
41136573|NCT02661958|DRUG|S6G5T-5|once a day topical cream
40765448|NCT05841667|DRUG|Remimazolam besylate|"This is an observational study, meaning that no interventions are actually administered to the participants. However, blood and urine samples will be collected for research purposes.~Participants will receive remimazolam besylate for at least 2 hours during anesthesia and surgery. Blood will be drawn to determine the concentration of remimazolam in the blood at the following time points: (1) before remimazolam administration, (2) after remimazolam administration has lasted at least 2 hours without a change in concentration, (3) immediately before discontinuation of remimazolam if there has been a change in concentration since the second blood draw, (4) within 5 minutes of discontinuation, (5) within 15-60 minutes of discontinuation, and (6) 90 minutes after discontinuation. Urine will also be collected after the end of anesthesia to check for metabolites of remimazolam."
40765449|NCT03579719|DRUG|Balovaptan|"In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20."
40765450|NCT03579719|DRUG|Itraconazole|In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
40765451|NCT05101551|DRUG|Talazoparib|"Talazoparib will be administered in escalating doses based on current dose level.~* Dose Level 1: 400 µg/m2/dose once daily~* Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19"
40962967|NCT06467474|BEHAVIORAL|PEG-D program|PEG-D will be carried out in person, open format, for six consecutive weeks lasting 90 minutes each. An approximate group of 6 to 10 participants will be led by a team of experienced psychologists and psychiatrists. Each group will have a main therapist and a co-therapist to ensure effective support and guidance for participants. Before the start of the group, participants received a booklet containing the content of the sessions.
40962968|NCT06467474|DRUG|TAU|The treatment will start with Sertraline (SSRI) - doses of 50 mg and adjusting as necessary according to the patient\&#39;s profile. After 8 weeks, if the patient experiences remission, they will continue on monotherapy with Sertraline. In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on. In this case, add-on medications will be determined according to the patient profile, by the clinician. If there is a response above 25% of the symptoms, but without remission, the patient will proceed to augmentation with the aforementioned medications and if there is no improvement of at least 25%, the patient will be considered drop-out. Associations with Lorazepam if necessary will be allowed in any phase of the study.
40962969|NCT02406716|OTHER|Biospecimen retention|
40962970|NCT00558558|DRUG|Haelan|4 oz orally twice daily for 8 Weeks
40962971|NCT04741282|OTHER|Pulmonary telerehabilitation|pulmonary telerehabilitation program include breathing exercise,aerobics exercise and upper and lower limbs muscle strengthening exercise
40962972|NCT04741282|OTHER|progressive muscle relaxation training|summarized Jacobson progressive muscle relaxation training method
40962973|NCT03054441|OTHER|Actigraph|Actigraphs worn on wrists
40962974|NCT02256020|OTHER|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
40962975|NCT02256020|OTHER|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
40962976|NCT06008821|PROCEDURE|Bilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrine|60mL of 0.25% ropivacaine will be injected into the PVB at thoracic vertebrae T3/4 level bilaterally (30mL at each site for a total of 2 injections)
40962977|NCT06008821|PROCEDURE|Bilateral sham block with normal saline|10 mL of normal saline will be injected into subcutaneous space at the T3/4 level bilaterally (5 mL at each site for a total of 2 injections)
40962978|NCT04433377|PROCEDURE|Suprascapular nerve block|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 22 gauge 90-mm injector
40962979|NCT04433377|PROCEDURE|Subacromial injection|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 21 gauge 38-mm injector.
40962980|NCT06032468|DEVICE|ARC Intellicare|wearable devices to guide rehabilitation exercise
40962981|NCT06032468|OTHER|Rehabilitation sheets|rehabilitation exercise sheets to guide rehabilitation exercise
40962982|NCT00279305|DRUG|Anti-CD20 (rituximab)|
40962983|NCT00279305|DRUG|Placebo Comparator|Placebo intravenous infusion
40962984|NCT03495219|PROCEDURE|Esophageal Manometry|A catheter inserted through the nares, post appropriate anesthetization. The subject is then given 8 - 10 sips of water or semi viscous fluid during the routine study. At the conclusion of the clinical portion of the examination the manometer catheter is typically removed by the technician at that point. For the purposes of this research study the catheter will remain in place to examine pressures specifically at the lower end of the esophagus during various breathing patterns and training activities to see if pressures can be increased with instruction.
40962985|NCT03132818|OTHER|To evaluate the prevalence of sexual disorders in patients receiving AMP|To evaluate the prevalence of sexual disorders in patients receiving AMP
41136574|NCT02661958|DRUG|S6G5T-6|once a day topical cream
41136575|NCT02661958|DRUG|S6G5T-7|once a day topical cream
40765452|NCT05101551|DRUG|Topotecan|"Administered IV route on Days 1 to 5~* Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5~* Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5"
40765453|NCT05101551|DRUG|Gemcitabine|"Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.~* Dose Level -2: 600 mg/m2/dose once daily by IV days 1~* Dose Level -1: 600 mg/m2/dose once daily by IV days 1~* Dose Level 1: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 2: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 3: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 4: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 5: 1200 mg/m2/dose once daily by IV days 1"
40765454|NCT03463681|DRUG|Cabometyx|cabozantinib 60 mg orally once daily
40765455|NCT05894746|DIETARY_SUPPLEMENT|gluten-free|see info in arm description
40765456|NCT05894746|DIETARY_SUPPLEMENT|probiotic|see info in arm description
40962986|NCT01597960|OTHER|Yoga|Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
40962987|NCT01065285|BIOLOGICAL|Evaluation of vaccines against flu|evaluate efficacy and tolerance
40962988|NCT06304129|DIAGNOSTIC_TEST|Blood ponction|Blood ponction
40962989|NCT03609905|BIOLOGICAL|Adipose-cord mesenchymal stromal cells (A-MSCs)|A-MSCs 5 x 10\~7 diluted on 100 mL of normal saline
40962990|NCT03609905|OTHER|Conventional drugs|5-amino-salicylic acid or glucocorticoid
40962991|NCT01202292|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
40962992|NCT04092439|DIETARY_SUPPLEMENT|Watermelon Juice|100% Watermelon Juice
40962993|NCT06011057|DIAGNOSTIC_TEST|Serum C reactive protein (CRP) level|An immunoturbidimetric method using a Modular P Analyzer will be used to carry out HSCRP assay, with a quantitation limit of 0.5 mg/L.
41136576|NCT02661958|DRUG|S6G5T-8|once a day topical cream
41136577|NCT04990856|PROCEDURE|Exercise|Tumor blood flow after acute exercise
41136578|NCT00788606|DRUG|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
41136579|NCT05906966|OTHER|Phone contact|. All mothers of children of born from cryopreserved oocytes will be contacted by phone and administered a questionnaire, to gather additional information about further psychomotor development of children.
40765457|NCT05894746|DIETARY_SUPPLEMENT|gluten|see info in arm description
41136580|NCT03286907|BEHAVIORAL|Online videos|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 \& 8.
41136581|NCT03286907|BEHAVIORAL|Online videos and MI|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, \& 8.
41136582|NCT03286907|BEHAVIORAL|Control group|Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises
40962994|NCT06011057|DIAGNOSTIC_TEST|Ultrasound|All examinations will be carried out by an experience operator with a transvaginal probe on high-resolution ultrasound machines. Pregnancies will be dated from the LMP. Other measurements will be obtained during the scan as the mean gestation sac diameter, volume of the gestation sac and the embryonic heart rate (FHR).
40962995|NCT01277991|DRUG|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
40962996|NCT01277991|DRUG|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
40962997|NCT01277991|DRUG|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
40962998|NCT01277991|DRUG|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
41136583|NCT01572805|DRUG|melatonin 3mg|To receive sublingual 3 mg melatonin before spinal of anesthesia .
41136584|NCT01572805|DRUG|melatonin 6mg|To receive sublingual 6 mg melatonin before spinal of anesthesia .
41136585|NCT01572805|DRUG|placebo|To receive sublingual placebo tablet before spinal of anesthesia .
41136586|NCT06055491|DRUG|Vitamin D3 or Saline injection at ipsilateral deltoid muscle|study group: 1.0mL Vitamin D3 injection control group: 1.0mL saline injection
41136587|NCT05097534|OTHER|iDSMES|Intensive Diabetes Self-Management Education and Support combined with Addressing Social Determinants of Health
41136588|NCT05097534|OTHER|Standard of Care|Standard of Care for patients with type 2 diabetes
41136589|NCT00300404|DRUG|daraprim|
41136590|NCT00300404|DRUG|pyrimethamine|
41136591|NCT00300404|DRUG|folinic acid|
41136592|NCT00805441|DRUG|LY686017|50 milligrams (mg) daily by oral route for 12 weeks
41136593|NCT00805441|DRUG|Placebo|Daily by oral route for 12 weeks
41136594|NCT03357237|OTHER|medical device|"patients will be assigned, following an external randomization, to two groups:~* Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~* Control or reference group: treatment regimen with oral rehydration solution and placebo"
40765458|NCT05211466|OTHER|Digital healthcare platform|In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.
40765459|NCT06639867|DEVICE|VR-based home physiotherapy|VR-based home physiotherapy
40765460|NCT06639867|OTHER|Standard physiotherapy care|Standard physiotherapy care as prescribed by the treating physiotherapist
40765461|NCT06571240|PROCEDURE|Anterior cruciate ligament reconstruction|Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
40765462|NCT05512143|DEVICE|Transcranial magnetic stimulation|Participants will undergo a standard course of TMS treatment (30 sessions/6 weeks).
40765463|NCT00552279|BIOLOGICAL|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
40765464|NCT00552279|BIOLOGICAL|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
40765465|NCT06641765|DEVICE|Continous Glucose Monitoring|10 days of real time open access to Continous Glucose Monitoring - either at defined time intervals (Group 2) or continuously for 9 months (Group 3).
40765466|NCT06639048|BEHAVIORAL|Questionnaire|Questionnaire including demographic characteristics, social media usage habits, body weight, height, effects of social media on eating behavior scale and eating disorder fear questionnaire.
40765467|NCT05537740|DRUG|BAY3375968|Intravenous (IV) infusion
40765468|NCT05537740|DRUG|Pembrolizumab|IV infusion
40765469|NCT05662722|OTHER|percutaneous needle electrolysis|It´s an intervention of physiotherapy. It´s an invasive technique.
40765470|NCT05662722|OTHER|Dry needling|It´s an intervention of physiotherapy. It´s an invasive technique.
40765471|NCT05662722|OTHER|Sham needling|It´s an intervention of physiotherapy. It´s an invasive technique simulation.
40765472|NCT04569032|DRUG|brentuximab vedotin|1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
40765473|NCT04569032|DRUG|cyclophosphamide|750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
40765474|NCT04569032|DRUG|doxorubicin|50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
40765475|NCT04569032|DRUG|prednisone|100 mg daily administered orally on Days 1-5 of each cycle
40765476|NCT04201873|BIOLOGICAL|Dendritic Cell Tumor Cell Lysate Vaccine|Given ID
40765477|NCT04201873|BIOLOGICAL|Pembrolizumab|Given IV
40765478|NCT04201873|OTHER|Placebo Administration|Given IV
40765479|NCT04201873|DRUG|Poly ICLC|Given IM
40765480|NCT06628960|BEHAVIORAL|Su Jok Therapy|Su Jok Therapy
40765481|NCT06644950|OTHER|Efficacy and safety of administering 1 or two cartridges of anesthesia|"The investigator will administer the first anesthesia for NDI block with a cartridge of 4% articaine anesthetic at 1:100,000 . At the end, an envelope containing the assignment to the experimental or control group will be opened.~In the control group, only the first anesthetic (1.8 mL of articaine 4% 1:100,000) will be injected and a second puncture will be simulated, contacting the syringe without the needle, in the same area, counting up to 30 seconds.~In the experimental group two anesthetic cartridges of articaine 4% 1:100,000 will be administered with the direct technique for the inferior alveolar nerve block."
41136595|NCT03695185|DRUG|Ravagalimab 600 mg|Ravagalimab 600 mg was administered intravenously (IV).
41136596|NCT03695185|DRUG|Ravagalimab 300 mg|Ravagalimab 300 mg was administered subcutaneously (SC).
41136597|NCT03270384|DEVICE|Urotronic Drug Coated Balloon (DCB)|The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
41136598|NCT06466681|OTHER|All included subjects|Administration of the subtest of divided attention of the Test of Attentional Performance (TAP), recording of the event related potentiels N200 and P300, measure of the variation of power in several frequency bands (theta, alpha and beta) and measure of the high-resolution EEG connectivity during an attentional task at several time-points : a first time during interictal period (no seizure for more than 24 hours) and 1, 3, 6 and 24 hours after a focal seizure.
41294223|NCT02967848|OTHER|99mTc-mebrofenin hepatobiliary scintigraphy (HBS)|99mTc-mebrofenin HBS is a SPECT imaging procedure that allows evaluation of global and local liver function. Mebrofenin, bound to albumin, is taken up by hepatocytes in a similar manner to organic anions such as bilirubin. After hepatic uptake, the mebrofenin is excreted into the bile canaliculi. Dynamic imaging tools allow measurement of clearance rates for global function, and 3D SPECT imaging with corresponding CT allows visualisation of the local liver function with respect to anatomy. HBS allows direct visualisation of hepatocyte function.
40765482|NCT06639802|OTHER|Hand Arm Bimanual Intensive therapy including lower extremity (HABIT-ILE)|HABIT-ILE is continuous intervention applied for 50-90 hours over two weeks. We will design the activities based on the findings of the initial assessments (T0) and the customized functional goals that were previously discussed with the parents (e.g., drinking on one\&#39;s own without spilling, using one hand to hold a book while turning pages with the other, removing a t-shirt, etc.). HABIT-ILE activities are presented as games and the whole environment is arranged in such a way that children perceive the therapy as fun. Progression of difficulty depend upon success in performance of current level. Specific bi-manual activities are selected on basis of child's motor abilities, age and interest.
40765483|NCT03878602|PROCEDURE|Delayed umbilical cord clamping|Umbilical cord will be clamped after 1 min after the birth of the newborn
40765484|NCT03878602|PROCEDURE|Immediate umbilical cord clamping|Umbilical cord will be clamped immediately after the birth of the newborn
40765485|NCT01469156|DRUG|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
40765486|NCT04981145|DRUG|Iguratimod Tablets|Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
40765487|NCT04981145|DRUG|Hydroxychloroquine Sulfate Tablets|Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
40765488|NCT04152200|DRUG|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
40765489|NCT06638762|PROCEDURE|surgery|We recruited patients diagnosed with oral squamous cell carcinoma who had received surgical treatment, collected patient follow-up information and postoperative pathological images, enhanced and standardized pathological images, and extracted pathological features through visual transformation model.
40765490|NCT00410657|BIOLOGICAL|alemtuzumab|
40765491|NCT00410657|DRUG|methylprednisolone|
40765492|NCT00410657|DRUG|prednisone|
40765493|NCT00410657|OTHER|flow cytometry|
41294224|NCT02967848|OTHER|Indocyanine Green|ICG is a fluorescent dye injected into the patient. The dye is exclusively excreted by the liver. The ICG clearance rate is measured in the finger of the subject.
41294225|NCT02967848|OTHER|Liver Elasticity|This is an Ultrasound measurement of the elasticity of the liver.
40765494|NCT00410657|OTHER|immunologic technique|
40765495|NCT00410657|OTHER|pharmacological study|
40765496|NCT04717466|BIOLOGICAL|Secukinumab|300mg subcutaneous injection
41294226|NCT01719081|PROCEDURE|Sacroiliac Joint Injection|Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
40765497|NCT01275378|BEHAVIORAL|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
40990640|NCT04824170|OTHER|Neural Glide|hot pack and cervical traction is applied for 10-15 min.Group A received Neural mobilization of median nerve which includes gliding and sliding was given,therapist stood on the patient \& affected side besides the patient, patient'S shoulder was depressed with one hand and elbow was moved in 90 degree flexion, forearm supination, extend the wrist and fingers with other hand. Then patient arm was moved into 90 degree abduction and then sliding or gliding of nerve was applied. Sliding was applied with elbow extension and wrist flexion and elbow flexion with wrist extension. 6 sets were performed. Each set was performed for 60 seconds, for alternative days in week for 4 weeks and then progressed to gliding/tensioning technique when symptoms improved
40765498|NCT01275378|BEHAVIORAL|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
40765499|NCT06637891|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 2 weeks, 3 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
40765500|NCT03697447|PROCEDURE|Endermotherapy|Endermotherapy massage (mechanic massage) of burn scar
40765501|NCT06643273|OTHER|Robotic rehabilitation|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
40765502|NCT06643273|OTHER|Conventional rehabilitation|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
40765503|NCT05078229|BEHAVIORAL|FOCUS|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.
40765504|NCT05078229|BEHAVIORAL|Healthy Living|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.
40765505|NCT06154265|DEVICE|TEE probe|Transesophageal echocardiography, ultrasound probe
40765506|NCT00855335|DRUG|Darunavir|TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
40765507|NCT00855335|DRUG|Ritonavir|100 mg tablet twice daily up to 12 weeks postpartum.
40765508|NCT00855335|DRUG|Etravirine|200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.
40765509|NCT00855335|DRUG|Rilpivirine|One 25 mg tablet once daily up to 12 weeks postpartum.
40765510|NCT00855335|DRUG|Darunavir/Cobicistat (FDC)|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
40765511|NCT06638905|DRUG|Babor Ultimate ECM Repair Serum|The BABOR® Ultimate ECM Repair Serum contains Biogen plant extract, cotton thistle flower, and wakame extract. Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
40765512|NCT06638905|DRUG|Babor Cure Cream|Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
40765513|NCT04441138|DRUG|Durvalumab|Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
41456483|NCT04815668|OTHER|Placebo acupuncture group|The acupuncture procedure will be similar to that of the acupuncture group. After sterilizing the skin, the 0.35 × 25 mm disposable needle will be vertically inserted at SPG acupoint about 3-5 mm. No needle manipulation will be conducted to avoid the deqi response. Rescue medication are permitted when participants feel that their symptoms are intolerable.
41456484|NCT04815668|OTHER|Rescue medication group|Participants in the rescue medication group do not receive acupuncture treatment during the study period. They will be only allowed to use rescue medication. They have the option of 4 weeks (up to 8 sessions) of acupuncture free of charge at the end of the follow-up period.
40765515|NCT02317419|DRUG|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
40765516|NCT02317419|DRUG|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
40765517|NCT02317419|DRUG|gemcitabine|gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
40765518|NCT02317419|DRUG|nab-paclitaxel|nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
40765519|NCT06449378|DEVICE|Transorb™ Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for repair of open ventral hernia.
40765520|NCT02615275|PROCEDURE|Bioelectric Impedance Analysis|Undergo BIA with seca mBCA
40765521|NCT02615275|PROCEDURE|Computed Tomography|Undergo CT
40765522|NCT02615275|PROCEDURE|Positron Emission Tomography|Undergo PET
40765523|NCT02615275|OTHER|Quality-of-Life Assessment|Ancillary studies
40765524|NCT02615275|OTHER|Questionnaire Administration|Ancillary studies
40765525|NCT02615275|RADIATION|Radiation Therapy|Undergo RT
40765526|NCT04737265|OTHER|Biomarker Guided Intervention|NTproBNP above the upper limit of normal will trigger the initiation of heart failure therapy with counseling from a study investigator based on protocol specified algorithm.
41136599|NCT06035354|DRUG|AK120|subcutaneous injection once a week
41136600|NCT06035354|DRUG|AK120|subcutaneous injection once a week
41456485|NCT02816684|BEHAVIORAL|Pegasys-VR|Pegasys-VR uses artificially intelligent avatars and serious game technology to assist children in the acquisition and use of social skills.
41456486|NCT02816684|BEHAVIORAL|Social Effectiveness Therapy for Children|Group social skills training, peer generalization sessions, individual exposure therapy
41456487|NCT01839539|BIOLOGICAL|dendritic and cytokine-induced killer cells|
41456488|NCT02921516|BEHAVIORAL|N'ap Grandi|Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
40765527|NCT03896581|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
40765528|NCT03896581|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points.
40765529|NCT04559581|DRUG|Nintedanib|Capsules
40765530|NCT05183984|DRUG|Chemotherapy|Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period
40765531|NCT05183984|DRUG|Bevacizumab-Awwb|"MVASI (bevacizumab biosimilar) will be administrated by intravenous infusion at the second chemotherapy cycle for 5 cycles.~the administration will continue during maintenance phase. Total bevacizumab duration therapy is 15 months."
41136601|NCT06035354|DRUG|Placebo|subcutaneous injection once a week.
41136602|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
41136603|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
41136604|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
41136605|NCT06035354|DRUG|Placebo|subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.
40765532|NCT05183984|DRUG|Niraparib|niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.
40765533|NCT01687062|OTHER|FeSO4|
40765534|NCT01687062|OTHER|reduction of phytate|
40765535|NCT01687062|OTHER|NaFeEDTA|
40765536|NCT05006040|DEVICE|Hybrid Closed Loop System|Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system \[25, 26\]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days \[30\].
40765537|NCT05219487|DRUG|Risdiplam|"Risdiplam is administered orally once daily and the recommended dosage is determined by age and body weight (see Table 1) \[as outlined in the US Prescribing Information for EVRYSDI™(risdiplam)\].~Table 1 Adult and Pediatric Dosing Regimen by Age and Body Weight: US Prescribing Information~Age and Body Weight (Recommended Daily Dosage): 2 months to less than 2 years of age (0.2 mg/kg); 2 years of age and older weighing less than 20 kg (0.25 mg/kg); 2 years of age and older weighing 20 kg or more (5 mg)"
41456489|NCT02921516|BEHAVIORAL|N'ap Grandi - A|Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
41456490|NCT02921516|BEHAVIORAL|Health Promotion - A|Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
41456491|NCT02032316|DEVICE|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
41456492|NCT02243137|DRUG|acetylsalicylic acid|Administration: one dose of Acetylsalicylic Acid (300mg)
41456493|NCT02243137|DRUG|prasugrel|Administration: one loading dose (60mg)
40765538|NCT06638099|BEHAVIORAL|CGM Toolkit Prescriber Training|A CGM prescription toolkit was created for prescribing clinicians and staff that includes written guidance on CGM eligibility criteria, instructions for screening patients for eligibility using EHR records and during healthcare visits, recommended provider documentation templates to address all required eligibility criteria for insurance coverage of CGM device and supplies (e.g., Medicare, Medicaid), sample scripts for communicating with patients about the purpose and use of CGM, and patient-level frequently asked questions (FAQs), including free resources available to learn more about CGM benefits, where/how to acquire CGM, and determining out-of-pocket costs. The toolkit will be introduced during a 20 minute initial training session and reinforced during a 10 minute booster training approximately one month after initial training
40765539|NCT06640725|DRUG|Avelumab administration at 10mg/kg|"Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Avelumab 10 mg/kg every 2 weeks (±3 days)"
41136606|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks
41136607|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
41136608|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
41136609|NCT03783936|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2
41456494|NCT02243137|DRUG|lysine acetylsalicylate|Administration: one dose (450mg iv)
41456495|NCT04783337|DIAGNOSTIC_TEST|HR-pQCT (high resolution computertomograph)|In addition to determining the bone density, a quantitative bone structure analysis with measurement of the number of thickness and distribution of the trabeculae can also be carried out. In addition, the finite element analysis (FEA) allows strength models of the examined bone to be created from the data of the hr-pqCTs. In this way, the osseous consolidation of the fracture can not only be observed, but also tested for resilience with the help of mathematical models.
41456496|NCT04783337|DIAGNOSTIC_TEST|Blood withdrawal|Bone remodeling blood marker: S-CTX (Crosslaps), S-TRA5b ( tartrate-resistant acid phosphatase), S-PINP (Procollagen type 1 amino-terminal propeptide), BALP, Calcium, parathyroid hormone, 25-OH-Vitamin D3 (HPLC)
41456497|NCT00704249|DRUG|nevirapine|Full-dose nevirapine from baseline (200 mg bid).
41456498|NCT00704249|DRUG|nevirapine|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
41456499|NCT02070523|DRUG|VDCLD regimen|
41456500|NCT01015963|OTHER|laboratory biomarker analysis|Perform DNA sample analysis
41456501|NCT02955628|DRUG|Ibrutinib-RICE|Ibrutinib will be added to RICE regimen for patients not achieving a complete remission at interim PET-2. Ibrutinib will be continued for up to 1 year after autologous transplantation.
41456502|NCT02664415|BIOLOGICAL|VRC01|40 mg/kg; administered IV
41456503|NCT02664415|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection 0.9%, USP; administered IV
41456504|NCT00198133|DRUG|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
41456505|NCT04034277|OTHER|Lee Silverman Voice Therapy|LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize
41136610|NCT03783936|DRUG|Leucovorin|Leucovorin 400 mg/m2
41136611|NCT03783936|DRUG|5 fluorouracil|5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion
41136612|NCT03783936|DRUG|Trastuzumab|Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1
41136613|NCT03783936|DRUG|Avelumab|Avelumab 800 mg
40765540|NCT06640725|DRUG|Cetuximab (Erbitux)|"Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Cetuximab 500 mg/m² every 2 weeks (±3 days) (according to current recommendations \[35\])"
40765541|NCT04603287|DRUG|SI-B001|Administration by intravenous infusion.
40765542|NCT05912725|PROCEDURE|Implant placement|"4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar~4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar"
40765543|NCT06642246|BEHAVIORAL|Intervention|During a 7-week intervention phase, parent-child dyads will be provided a sleep duration goal paired with a loss-framed financial incentive (virtual account) starting with deductions each time the sleep goal is not met, will be sent sleep guidance text messages, and will receive weekly performance feedback text messages.
41294227|NCT03645252|PROCEDURE|Vein interruption before any other surgical manipulation|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner."
40765544|NCT06442891|PROCEDURE|Acupressure Therapy|Self-administer relaxing acupressure
40765545|NCT06442891|PROCEDURE|Acupressure Therapy|Self-administer sham acupressure
40765546|NCT06442891|OTHER|Internet-Based Intervention|Receive access to acupressure mobile app
40765547|NCT06442891|OTHER|Interview|Ancillary studies
40765548|NCT06442891|OTHER|Medical Device Usage and Evaluation|Receive an AcuWand
40765549|NCT06442891|OTHER|Questionnaire Administration|Ancillary studies
40765550|NCT00974272|DRUG|Exenatide|Single subcutaneous injection (10 μg)
40765551|NCT00974272|OTHER|Normal Saline|Single subcutaneous injection
41294228|NCT03645252|PROCEDURE|Arteries interruption before vein interruption|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above."
40765552|NCT04005326|PROCEDURE|quadratus lumborum block; (Anterior QLB or QLB III)|The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
40765553|NCT04005326|PROCEDURE|suprainguinal fascia iliaca block|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
40765554|NCT04005326|PROCEDURE|Subarachnoid block|"Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study."
40765555|NCT06641908|DRUG|M3554|M3554 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose is determined in participants with STS (dose escalation A) and glioblastoma and IDH wildtype (dose escalation B).
40765556|NCT06296355|BEHAVIORAL|Health Warning Label|"Message displayed on warning label is: WARNING: Consuming ultra-processed food and drinks can cause weight gain, which increases the risk of obesity and type 2 diabetes."
40765557|NCT06296355|BEHAVIORAL|Identity Warning Label|"Message displayed on warning label is: WARNING: Ultra-processed food."
40765558|NCT06296355|OTHER|Barcode Label|Barcode is displayed.
40765559|NCT06328569|DEVICE|Virtual Reality Therapy|The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.
41294229|NCT02983981|DRUG|Topicort Topical Spray|open label Topicort spray
40765560|NCT06328569|BEHAVIORAL|Conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
40765561|NCT05516875|DRUG|JM-010|JM-010
40765562|NCT06193681|OTHER|Pedi@ctivity Exercise Mobile Application Exercise Program|The first group of the study received a mobile application (Pedi@ctivity) based exercise program. With the Pedi@ctivity exercise mobile application, the selected exercises and exercise program will be offered personalized to each adolescent for 12 weeks. After 12 weeks, the effectiveness of the Pedi@ctivity mobile application-based exercise program on the evaluation parameters will be investigated.
40765563|NCT06193681|OTHER|Supervised Exercise Group|In the physiotherapist-supervised personalized exercise program, the exercises selected through the Pedi@ctivity exercise mobile application will be applied to adolescents under the supervision of a physiotherapist (2 sessions face-to-face, 1 session online/synchronous).
41136614|NCT05999448|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
40765565|NCT05516147|BEHAVIORAL|SAFE at Home|SAFE at Home will enable community-dwelling PWD to participate in videoconference-based group activities with their peers, that is, other PWD. SaH sessions will be facilitated by highly trained Engagement Professionals.
41294230|NCT04493710|DIAGNOSTIC_TEST|Sarcopenia estimation|Analysis of pre-existing CT imaging
41136615|NCT05999448|BEHAVIORAL|Culturally Informed Cognitive Behavioral Therapy (CICBT), Individual|CICBT-Individual will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
41136616|NCT05999448|BEHAVIORAL|Culturally Informed Cognitive Behavioral Therapy (CICBT), Group|CICBT-Group will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
41294231|NCT05068596|OTHER|expermintal|progressive resistive functional strength training in the plantigrade foot position plus designed physical therapy program
40765566|NCT03603808|DEVICE|Electroporation|Undergo electroporation
40765567|NCT03603808|BIOLOGICAL|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|Given IM
40765568|NCT03603808|OTHER|Laboratory Biomarker Analysis|Correlative studies
40765569|NCT05840913|DRUG|Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge|Local anesthetic injection for intra- operative pain control
40765570|NCT06333652|DRUG|Ravulizumab|Intravenous infusion 100 mg/ml
40765571|NCT06638047|PROCEDURE|robotic-assisted TKA|Robotic-assisted TKA means that TKA surgery is operated with the guidance of robotic system.
40765572|NCT06638047|PROCEDURE|CI-TKA|TKA operated with conventional instruments
40765573|NCT06002477|DRUG|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
41136617|NCT05999448|BEHAVIORAL|Dialectical Behavioral Therapy (DBT)|DBT will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
41136618|NCT05999448|BEHAVIORAL|Durand Sleep Intervention|Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.
40765574|NCT06002477|OTHER|Placebo Comparator Challenge|Matching placebo oral pill administered once
40765575|NCT06638216|OTHER|Geriatric Assessment|"Frailty is assessed using the G8 questionnaire.~Secondary objectives include the assessment of quality of life and financial burden (EORTC-QLQ C30+ H\&N43), swallowing function, cardiopulmonary resilience (6-minute walk test) and the patient's wishes regarding a prehabilitation program. Epidemiological and disease-related data is also collected."
41294232|NCT05068596|OTHER|CONTROL|Designed physical therapy program
41294233|NCT02110134|DEVICE|Revlite Laser System with hydroquinone skin care regimen|Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma
41294234|NCT02110134|OTHER|Hydroquinone skin care regimen|Hydroquinone skin care regimen for the Treatment of Melasma
41294235|NCT02267577|DEVICE|Sphygmo: Automatic Blood Pressure Monitor|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals.
41294236|NCT02267577|DEVICE|GE Dinamap ProCare Automatic Blood Pressure Monitor|This commercially available gold standard blood pressure monitor will be used as a control to assess the accuracy of the Sphygmo device.
41294237|NCT04933097|DEVICE|Microfet2®|"Conducting a day hospitalization including analyses:~1. Quantitative muscular analysis by measuring the DEXA of the whole body, the reference method for measuring body compartments and allowing the diagnosis of sarcopenia (IMMA\<7 in men and 5.5 in women)~2. Qualitative muscular analysis:~   * isokinetic measurement of muscular strength carried out on 3 muscle groups using a manual measurement sensor such as Microfet2 ® : quadriceps, triceps brachii, biceps~  * measurement of grip strength using Jamar® equipment validated as recommended by the EWGSOP~  * a walking test to assess the functional impact of sarcopenia and its severity"
40962999|NCT05433493|BEHAVIORAL|Cognitive stimulation|"The intervention program will have 24 sessions (base scheme of 4 series of 6 sessions), lasting approximately 45 min and will be developed according to the following structure: - welcoming (greeting to the participant) (5 min); - orientation to reality (10 min); - main cognitive stimulation activity (25 min); - return to calm and evaluation of the session (5 min).~The CS sessions will have an individual format and will be conducted by a professional with experience in CS and previously trained in this intervention. The intervention sessions will include several activities based on the CS principles, with evidence suggesting positive participant effects. The CS sessions will be carried out using material, developed by the principal investigator, in digital format (power point presentations). There will be no repetition of activities, and throughout the base CS program, the degree of difficulty of the exercises will be adjusted based on the dementia stage of the participant."
40963000|NCT05081141|DIAGNOSTIC_TEST|Diagnostic test for HHV8 exposure|Venipuncture for blood sampling
40963001|NCT00598104|DRUG|QAX576|
40963002|NCT00598104|DRUG|Placebo|
40963003|NCT02641808|OTHER|follicular flushing|Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.
40963004|NCT02641808|OTHER|no follicular flushing|
40963005|NCT05955105|DRUG|ILB-2109|ILB-2109 tablets will be administered by mouth every day in 21-day cycles
40963006|NCT05955105|DRUG|Toripalimab|Toripalimab injection will be administered via IV every 21 days.
40963007|NCT03982407|DRUG|68Ga-PSMA-11 PET/MRI|The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
40963008|NCT05724563|DRUG|Zimberelimab|Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
40963009|NCT05724563|DRUG|Domvanalimab|Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
40963010|NCT01546207|PROCEDURE|catheter-based ablation|specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
40963011|NCT06266169|OTHER|making artificial intelligence based decisions of gamete, embryo and endometrial potential|The method of Raman spectroscopy is based on the registration of inelastic scattering of photons. Each compound has its own spectral pattern when using a certain type of monochromatic radiation (laser). With this method, it is possible to obtain metabolic fingerprints from the objects being studied. Luminescent spectroscopy is a type of spectroscopy used to register emission from objects that occurred after absorbing the exciting (primary) radiation. Spectrophotometry is the detection of radiation in the visible area of the spectrum. Raman spectroscopy is used for the spent medium and semen to build artificial intelligence model and make prognosis of function for each object. For endometrium, luminescent spectroscopy and spectrophotometry are used to build the model and test its clinical relevance
40963012|NCT05497583|OTHER|Acetone based HEMA -free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. Bioactive composite ( beautifill II ) will be used.
41294238|NCT03391011|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while monitored by clinically approved system.
41294239|NCT01065129|DRUG|G-CSF|
41294240|NCT01065129|DRUG|Plerixafor|
41294241|NCT01065129|DRUG|Azacitidine|
41136619|NCT05999448|BEHAVIORAL|RUBI Intervention|RUBI will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed behavioral analyst.
41136620|NCT05999448|BEHAVIORAL|Naturalistic Communication Intervention (NCI)|NCI will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed behavioral analyst.
41136621|NCT05999448|BEHAVIORAL|Self-Guided Resources|Participants will be provided a self-guided resource notebook that includes 12 weeks of content that parallels the topics examined in other support programs (child behavior management, child sleep, child communication, caregiver mental health, caregiver health behaviors, community connection)
41294242|NCT02195115|PROCEDURE|Laparoscopic Cholecystectomy|
41294243|NCT02195115|DRUG|amitriptyline|
41294244|NCT02195115|OTHER|low-fat and low cholesterol diet|
41294245|NCT01334125|DRUG|Metformin|Metformin 1000 mg once daily by mouth for 9 months
41294246|NCT01334125|DRUG|Placebo|2 capsules once daily by mouth for 9 months
41294247|NCT02163408|OTHER|MRI with/without contrast|Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
41294248|NCT02046564|DRUG|ASC-01|
41294249|NCT02046564|DRUG|Placebo|
41294250|NCT03336840|DRUG|Metformin tablets|0.5g (1 pill) of Metformin tablets administered three times a day orally before meal
40963013|NCT05497583|OTHER|Isopropanol based HEMA- free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. resin composite (Neo Spectra™ ST) will be used.
40963014|NCT02695329|DEVICE|KneeAlign 2|Patients suffering non-severe varus deformity Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
40963015|NCT03153969|DEVICE|SHOFU Beautifil II LS|Placed under manufacturer's instructions
40963016|NCT03153969|DEVICE|3M/ESPE Filtek Supreme|Placed under manufacturer's instructions
40963017|NCT02318147|PROCEDURE|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
41136622|NCT05999448|BEHAVIORAL|Participation Enhancement Intervention (PEI)|"A standardized PEI intervention will be conducted by trained peer coaches who are also rare disorder caregivers. Each peer coach will work with their clients to complete a Change Plan Worksheet and will complete two booster sessions at midpoint and end of treatment. Coaches will also meet with their clients after follow-up data are complete to support connection back to community resources and patient-specific rare disorder communities."
41136623|NCT01166191|RADIATION|Radiotherapy|Radiotherapy
41136624|NCT05748184|DEVICE|ULDCT PACS prototype|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images.
41294251|NCT03336840|DRUG|ProMetS probiotics powder|4g (2 strips) of ProMetS probiotics powder administered orally every night
41294252|NCT03336840|DRUG|1. Metformin tablets; 2. ProMetS probiotics powder|"1. 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
41294253|NCT03873207|DEVICE|PopSole™ offloading device|Offload Device Distribution to remain in use at all times during ambulation and activity instruction to stay off of feet as much as possible for 3 days, then limit ambulation to 10 minutes per hour for 4 weeks and no sports, kicking, running or exercise for 4 weeks. Devices will be provided for both feet to maintain symmetry and gait stability between the two feet.
41294254|NCT03873207|DEVICE|padded insole|the control arm will be provided with standard padded insole to wear inside footwear
41294255|NCT02062151|OTHER|Acupuncture|Acupuncture
41456506|NCT04034277|OTHER|Conventional Treatment|"speech rehabilitation protocol comprehend:~* Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~* Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation."
41456507|NCT02169336|DRUG|Intranasal Dexmedetomidine|
41456508|NCT02169336|OTHER|Intranasal Placebo|
40963018|NCT02318147|DRUG|The traditional treatment|the traditional treatments according to associated guidelines
40963019|NCT06392620|OTHER|Study Group|n individually planned exercise program including stretching, strengthening, respiratory, aerobic and posture exercises will be applied via video conference method
40963020|NCT01698372|DEVICE|Prevena device (Group A)|This portable device is applied to initiate negative pressure therapy to a wound site.
40963021|NCT06556485|PROCEDURE|Catheter ablation|Preventive ablation therapy
40963022|NCT06556485|DRUG|Medical therapy|Optimal medical therapy
40963023|NCT00524862|DRUG|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
40963024|NCT00524862|DEVICE|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
40963025|NCT00568997|DRUG|Pimecrolimus|Pimecrolimus 1% cream
40963026|NCT00920998|DRUG|Z-338|oral
40963027|NCT04902794|DEVICE|Light Emitting Diode|Blue light-emitting diode applied to the female genital region for eight minutes, for five sessions, one per week
40963028|NCT04902794|DEVICE|Sham Light Emitting Diode|Sham Blue light-emitting diode turned off applied to the female genital region for eight minutes, for five sessions, one per week
40963029|NCT04856189|BIOLOGICAL|Pembrolizumab|Given IV
40963030|NCT04856189|DRUG|Selinexor|Given PO
40963031|NCT04645082|DIAGNOSTIC_TEST|x-ray examination|A total of 40 individuals who underwent an axial x-ray examination of the lower extremity following ankle sprain were included.
40963032|NCT03760978|DRUG|Dexmedetomidine|
40963033|NCT04191031|DEVICE|ioveraº|Cryoneurolysis
40963034|NCT04191031|DEVICE|ioveraº sham|ioveraº sham
40963035|NCT01169493|DEVICE|VVI-40|Pacing mode set to VVI-40, RV only pacing
40963036|NCT01169493|DEVICE|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
40963037|NCT01169493|DEVICE|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
40765576|NCT03404960|DRUG|Niraparib + Nivolumab|Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.
41294256|NCT04381000|OTHER|Exercise Group|The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.
41294257|NCT05165329|COMBINATION_PRODUCT|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC: The probiotic to be used is Lactobacillus rhamnosus GG, supplied as a freeze-dried powder. Probiotic will be prepared under strict Food Manufacturing Regulations. The daily dose of 2x10\^10 cfu will be packed individually in sachets. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic must be stored at 4 degrees Celsius
41456509|NCT06562543|DRUG|Fruquintinib|Oral capsules
40963038|NCT00794378|DRUG|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
40963039|NCT00794378|DRUG|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
40963040|NCT00720538|DRUG|Thalidomide|Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
40963041|NCT00720538|DRUG|placebo|placebo capsules
40963042|NCT02499783|BIOLOGICAL|adalimumab|subcutaneous injections of adalimumab
40963043|NCT02499783|OTHER|placebo|subcutaneous injections of placebo
40963044|NCT03674671|DRUG|Intravenous Ketamine|Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
40963045|NCT03674671|PROCEDURE|Electroconvulsive Therapy|Participants will receive ECT treatment thrice weekly for the 3 or 4 weeks. If participant responds, they will continue to receive ECT, with frequency at the discretion of the treating physician based on best practice guidelines for the remainder of the study.
40963046|NCT02250781|DRUG|Oral ONC201|Given PO
40963047|NCT06400862|COMBINATION_PRODUCT|eOCT implantation|eOCT is regarded as an Advanced Therapy Product (ATP).
40963048|NCT04597723|DRUG|oxygen|Patients will be given different concentrations of oxygen.
40963049|NCT04166175|PROCEDURE|botox injection in intersphincteric space|injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position
40963050|NCT04166175|PROCEDURE|lateral internal sphincterotomy|lateral internal sphincterotomy under GA in lithotomy position
40963051|NCT06209177|DRUG|ARO-CFB|ARO-CFB for sc injection
41294258|NCT05165329|COMBINATION_PRODUCT|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
41456510|NCT03630354|BEHAVIORAL|Exercise Intervention|Complete supervised exercise
41456511|NCT03630354|BEHAVIORAL|Exercise Intervention|Complete unsupervised exercise
41456512|NCT03630354|OTHER|Informational Intervention|Receive instructional DVD
41456513|NCT03630354|OTHER|Questionnaire Administration|Ancillary studies
40765577|NCT03404960|DRUG|Niraparib + Ipilimumab|Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
40963052|NCT06209177|DRUG|Placebo|sterile normal saline (0.9% NaCl for sc injection)
40963053|NCT03045315|OTHER|IVF Procedure|
40963054|NCT03543150|DRUG|BOTOX|BOTOX injections will be administered to eligible subjects with diagnosis of spasmodic dysphonia. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
40963055|NCT06505889|OTHER|Local anesthesia methods|Local pain control method before arterial blood sampling procedure
40963056|NCT02530060|DRUG|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC|Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
40963057|NCT01734356|OTHER|Skin biopsies|
40963058|NCT04113109|DRUG|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
40963059|NCT04113109|DRUG|Icatibant|Icatibant will be given intravenously at 100 µg/kg over one hour followed by 20 µg/kg/hr during each study day.
40963060|NCT04113109|DRUG|placebo|Placebo (vehicle) will be given at the same rate as icatibant.
40963061|NCT04113109|DRUG|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
40963062|NCT04113109|DRUG|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
40963063|NCT03517098|PROCEDURE|The ERAS group|"ERAS pathway for orthopedic surgeons:~1. Shortened preoperative fasting from intake.~2. Preoperative tranexamic acid administration.~3. No indwelling catheters.~4. No tourniquet used for TKA.~5. No drainage tube.~6. Application of the low molecular heparin 6 hours after the operation.~ERAS pathway for anesthesiologist:~1. Intravenous 20 mg of dexamethasone before anesthetic induction.~2. Anesthesia will be induced with small dose of long-acting opioids such as sulfentanil, or without long-acting opioids at all.~3. Laryngeal mask for airway.~4. Anesthesia will be maintained with short-acting anesthetic agents such as desflurane, sevoflurane, or propofol, with continuous remifentanil , and BIS value will be kept between 40 to 60 during procedure.~5. Incision infiltration with 40-50ml of 0.2% ropivacaine, and no patient controlled intravenous analgesia devices will be applied."
40963064|NCT03517098|PROCEDURE|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care according to different participating center, and there's no standard protocol for pre-operative management, anesthetic technique or medication choice, postoperative analgesia or food intake, or catheters indwelling.
40963065|NCT03018769|DRUG|Chinese Herb|
40963066|NCT05367622|BEHAVIORAL|Self-regulation health education|"1. Insert the continuous blood glucose monitor~2. Give self-regulation model of health education to assist patients in making a judgmental decision on how to modify health promotion behaviors to reach a good glucose control~3. Use Telecommunications on the modifications of health promotion behaviors for 7 days"
40963067|NCT05367622|BEHAVIORAL|Usual diabetes health education|"1. Practice self-monitoring of blood glucose~2. Give usual diabetes health education"
40963068|NCT02601391|BEHAVIORAL|Adapting STEPPS within forensic inpatient services.|This study will focus upon delivering the STEPPs-HI group within Forensic Healthcare Inpatient Services.
40963069|NCT05465434|DRUG|Zinc Supplement|Zinc sulphate 50 mg
40963070|NCT04858243|OTHER|Home-Based ART|Community-based male-specific counseling followed by home-based ART initiation (or at any location that is convenient for participants) and home-based ART continuation for a 3-month period, followed by linkage to a local health facility for further ART continuation.
40963071|NCT04858243|OTHER|Facility-Based ART|Community-based male-specific counseling followed by linkage to a local health facility for ART initiation and continuation.
40963072|NCT02782637|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: individual interviews to further perform in-depth exploration of prenatal counseling preferences"
40963073|NCT04336306|OTHER|virtual reality-based therapy (VRBT)|"The warm-up was performed using the Just Dance 2015 game, in a sequence previously defined in a pilot study, aiming to increase HR progressively. A multimedia projector (Epson Power Life, H309A, China) connected to a console (Xbox One KinectTM, Microsoft, Redmond, WA) was used to project the game onto a white wall.The conditioning phase was performed using the Shape Up exercise game, in which patients perform exercises following a virtual therapist."
40963074|NCT05236049|BIOLOGICAL|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in support of intraocular implant.
41136625|NCT05748184|DEVICE|PACS viewer prototype|A PACS system mimicking the clinical PACS system used in LUMC.
40963075|NCT03712956|DRUG|Caelyx®|Caelyx® every two weeks for 8 courses
40963076|NCT06248801|DRUG|Vildagliptin and Metformin-Test product|Vildagliptin and Metformin tablets 50/1000 mg manufactured by Mylan Laboratories Limited, India
40963077|NCT06248801|DRUG|Vildagliptin and Metformin-Reference product|Vildagliptin and Metformin tablets 50/1000 mg manufactured by NOVARTIS PHARMA PRODUKTIONS GmbH, Germany.
40963078|NCT01320904|PROCEDURE|NMES|"We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).~We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation."
41136626|NCT05748184|DEVICE|Optimized ULDCT viewer prototype version(s)|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images. Optimized version(s) of previous version.
41136627|NCT05605132|OTHER|Proprioceptive Training Exercise|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~* head relocation~* gaze stability~* eye follow~* saccadic eye movement~* head and eye coordination"
41294259|NCT05165329|COMBINATION_PRODUCT|PEANUT PLACEBO: Peanut Placebo is maltodextrin powder with food colouring and peanut essence that has similar appearance, taste and smell to the active product.|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
41294260|NCT01878006|DRUG|Morphine|
40963079|NCT01320904|PROCEDURE|Closed Kinetic Chain|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
40963080|NCT00536679|DRUG|GSK163090 capsule, fasted|GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
40963081|NCT00536679|DRUG|GSK163090 Tablet, fasted|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
40963082|NCT00536679|DRUG|GSK163090 Tablet, fed|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
40963083|NCT00681083|DEVICE|Heated breathing tube (CPAP with ThermoSmart)|CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
40963084|NCT00681083|DEVICE|Non heated breathing tube (CPAP with conventional humidification)|CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
40963085|NCT06376396|DRUG|albendazole and praziquantel|Combination of albendazole plus praziquantel
40963086|NCT06376396|DRUG|Albendazole|Albendazole alone
40963087|NCT01350297|PROCEDURE|reinnervation|anastomosis between right inferior laryngeal nerve and right phrenic nerve
40963088|NCT03546660|DEVICE|SECM capsule|Subjects will swallow a SECM capsule and the SECM imaging will be performed
40963089|NCT02854631|DRUG|Selonsertib|18 mg tablet administered orally once daily
40963090|NCT02854631|DRUG|Prednisolone|40 mg (4 x 10 mg tablets) administered orally once daily
40963091|NCT02854631|DRUG|Placebo|Selonsertib placebo tablet administered orally once daily
40963092|NCT03367221|DEVICE|NAVA ventilation|Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
40963093|NCT00306215|DRUG|CCX282-B|CCX282-B or placebo capsules
40963094|NCT01478880|PROCEDURE|continuous theta burst stimulation (cTBS)|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)
40963095|NCT01478880|PROCEDURE|sham cTBS|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°
41136628|NCT05605132|OTHER|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
41136629|NCT05605132|OTHER|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
41136630|NCT06272032|PROCEDURE|High-intensity focused ultrasound (HIFU)|Ultrasound is a type of mechanical vibrational wave capable of penetrating living tissues without causing harm to the tissue. As a non-invasive physical modality, ultrasound boasts advantages such as non-invasive safety, excellent directional propagation, strong penetration capability, and optimal focusing effects. It can induce a series of structural and functional changes in tissue cells through actions like cavitation, mechanical force vibration, and heat generation, leading to corresponding clinical effects. Clinical studies have demonstrated that focused ultrasound not only improves symptoms of allergic rhinitis (AR) but also holds certain advantages in preserving the structural and functional integrity of the nasal mucosa.
41136631|NCT06272032|DRUG|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines and other therapies.
41136632|NCT05550441|DRUG|Dapagliflozin|The experimental group received dapagliflozin (10 mg qd) for 1 year.
41136633|NCT05550441|DRUG|Placebo|The Placebo group received placebo for 1 year.
41136634|NCT04393402|PROCEDURE|lung ultrasound (LUS)|Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS
41136635|NCT00001930|DRUG|Amantadine|
41294261|NCT01878006|DRUG|Placebo|
41294262|NCT01750476|DRUG|Mirena|
41294263|NCT01750476|DRUG|Oral contraception|
41294264|NCT01750476|DRUG|Depo-Provera|
40963096|NCT05604677|PROCEDURE|Breast Surgery|Breast-conserving Surgery or modified radical mastectomy
40963097|NCT00705198|DRUG|Temozolomide (for newly diagnosed malignant glioma)|"Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
41136636|NCT02959411|DRUG|Tolvaptan|Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
41456514|NCT05146024|BEHAVIORAL|Way To Serve Plus: Improving Responsible Alcohol Service|Improving responsible alcohol service of owners, managers, and employees of alcohol-serving establishments by developing professional development components to enhance their responsible beverage service skills.
41456515|NCT01877122|DEVICE|Proflex® Mesh Mesh implantation|Implantation of mesh in the incision of inguinal area
40963098|NCT00705198|DRUG|Temozolomide (for relapsed malignant glioma)|"Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
41136637|NCT02959411|DRUG|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
41136638|NCT04008004|DRUG|EDP-514|Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
41136639|NCT04008004|DRUG|Placebo|Placebo to match EDP-514
41136640|NCT03851094|BEHAVIORAL|Wellth app|The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
41136641|NCT00407706|PROCEDURE|blood test|
41456516|NCT01877122|DEVICE|Marlex® Mesh Implant|
41456517|NCT02213887|DRUG|Pantoprazole|40 mg PO QAM
41456518|NCT02213887|DRUG|Pantoprazole|0 mg PO QAM
40963099|NCT00705198|RADIATION|Radiotherapy (for patients with newly diagnosed malignant glioma)|Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
40963100|NCT03372044|DRUG|PF-06865571 Immediate release suspension|Suspension
40963101|NCT03372044|DRUG|PF-06865571 Slow release MR tablets|Modified release tablets
40963102|NCT03372044|DRUG|PF-06865571 Fast release MR tablets|Modified release tablets
40963103|NCT03372044|DRUG|PF-06865571 Immediate release tablets|Immediate release tablets
40963104|NCT06362577|DIAGNOSTIC_TEST|EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG|Diagnostic Test were collected at before surgery, during surgery,2 months, 6 months, 9 months, 12 months, 18 months and 24 months after radical surgery
40963105|NCT00347568|DEVICE|TX-plore|PI has terminated at institution and there is no one available to report.
40963106|NCT00000789|DRUG|Stavudine|
40963107|NCT00000789|DRUG|Zidovudine|
40963108|NCT01010061|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
40963109|NCT01010061|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
40963110|NCT01010061|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
40963111|NCT01750983|DRUG|Ipilimumab|"Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group."
40963112|NCT01750983|DRUG|Lenalidomide|"Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group."
40963113|NCT00256191|DRUG|TPI 287 Injection|
40963114|NCT05366946|OTHER|Prevalence study|Prevalence study of chronic pain in COPD vs healthy controls
40963115|NCT02393170|OTHER|self-training using video-games|"Individuals will receive a video-game console and will be taught how to play the games.~They will be requested to play 60 minutes a day for 5 weeks."
40963116|NCT02393170|OTHER|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
40963117|NCT05981898|DEVICE|OPTIVF dosage|Dosage predicted by Opt-IVf
40963118|NCT05981898|DEVICE|traditional Dosage|Dosage used traditionally by doctors
40963119|NCT04530916|DIETARY_SUPPLEMENT|Blueberry Powder|22 g/day wild blueberry powder
41136642|NCT04017611|DEVICE|INVSENSOR00038|Noninvasive regional oximeter
41294265|NCT04317222|DEVICE|eCRRT|"eCRRT was define as:~1. Initiated within the first 24 post-transplant hours;~2. High volume (35-50ml/kg) hemofiltration;~3. Continuous at least 12 hours per day for 3 days;~4. Standard treatment"
41294266|NCT00001269|DRUG|IL-3|
41294267|NCT03969433|DEVICE|TMSi Porti|Data collections
41294268|NCT03969433|DEVICE|Bloomlife sensor|Data collections
41294269|NCT05501444|OTHER|Topical antiperspirant|The participants will be instructed to use topical antiperspirant (aluminum chloride, 15 percent every evening for four weeks. The PI will contact the participants every week. If the participant experiences that antiperspirant have an effect, the use of antiperspirant will be reduced from daily use to 3 times a week.
41456519|NCT06322251|BEHAVIORAL|Use of instrument to identify exposure to violence in close relationships|Use of instrument to identify exposure to violence in close relationships
40963120|NCT04530916|DIETARY_SUPPLEMENT|Placebo Powder|22 g/day placebo powder
40963121|NCT02621060|DRUG|Placebo|Placebo: 1200 mg per day for three months
40963122|NCT02621060|DRUG|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
40963123|NCT04342156|DRUG|Hydroxychloroquine Sulfate 200 milligram (mg) Tab|Oral tablet of Hydroxychloroquine sulfate
40963124|NCT04992598|OTHER|Hypnosis session|Hypnosis session will precede therapeutic strategies and reduction
41456520|NCT06144034|DEVICE|Air polishing with erythritol powder|Air polishing with erythritol powder utilized for biofilm disclosing and, followed by an ultrasonic scaler to remove calculus if present.
41456521|NCT06144034|DEVICE|Conventional treatment|Rubber cup polishing with prophy paste after biofilm disclosing, followed by ultrasonic scaling of calculus if present.
41456522|NCT06160180|DRUG|Dexamethasone|Submucosal application
41456523|NCT04467619|DEVICE|Functional Proprioceptive Stimulation|Functional Proprioceptive Stimulations (FPS) are applied on the musculo-tendinous junction. FPS mechanically stimulate the muscle spindles, mimicking the sensory signals - Ia fibers of functional movements. This neurosensory trick activates related sensory-motor areas allowing patients to feel natural movements. Because sensory \& motor systems are interdependent, the central nervous system then reacts by initiating corresponding movements.
40963125|NCT04992598|PROCEDURE|Reduction|All dislocation would be reduced Under adequate analgesia and sufficient sedation. All methods for reduction can be used.
40963126|NCT04444388|DIETARY_SUPPLEMENT|cocoa|Sachets of 5 grams of cocoa daily supplementation
40963127|NCT04444388|DIETARY_SUPPLEMENT|Placebo|Sachets of 5 grams of maltodextrin daily supplementation
40963128|NCT02989714|DRUG|Interleukin-2|600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
40963129|NCT02989714|DRUG|Nivolumab|Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
40963130|NCT06359392|OTHER|No message|Participants will not be exposed to a message in this arm of the intervention.
40963131|NCT06359392|OTHER|Culture-centric message|Participants in this arm of the study will watch a 2-minute video on palliative care developed specifically for these American Indian communities.
40963132|NCT06359392|OTHER|General messge|Participants receiving this intervention will watch a 2-minute video developed by the National Hospice and Palliative Care Organization to teach about palliative care.
40963133|NCT00764283|DEVICE|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
40963134|NCT00764283|DEVICE|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
41456524|NCT00822887|DRUG|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
41456525|NCT00822887|RADIATION|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
41456526|NCT00722436|DRUG|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
41456527|NCT00722436|DRUG|saline|Placebo
41456528|NCT00170469|BIOLOGICAL|AVA|
41456529|NCT00170469|BIOLOGICAL|rPA vaccine containing alhydrogel|
40963135|NCT00764283|DEVICE|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
40963136|NCT03906838|DRUG|Ropivacaine injection|Regional Anesthesia Nerve Block: Incremental injections up to total of 20 mL of 0.5% ropivacaine is administered.
40963137|NCT01475357|OTHER|Arm 1: NPO by mouth pre-operative|Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
41456530|NCT04821232|OTHER|yoga|"Content of education;~1. Breath Awareness Training (10 minutes)~   Students will be checked on a routine basis~2. Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced."
41456531|NCT04821232|OTHER|Routin control|Students will be checked on a routine basis
41456532|NCT00754507|DRUG|colesevelam HCl tablets, and atorvastatin tablets|colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
40963138|NCT01475357|OTHER|Arm 2: Fresh Breast Milk pre-operative|Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
40963139|NCT00004211|BIOLOGICAL|PSA RNA-pulsed dendritic cell vaccine|
40963140|NCT01582165|DRUG|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
40963141|NCT01582165|DRUG|Placebo.|Placebo once daily vs rosuvastatin for 6 months
40963142|NCT04355520|DRUG|TQ-B3525|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.
40963143|NCT04355520|DRUG|Fulvestrant injection|Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
40963144|NCT06083662|DRUG|Neratinib Maleate|"* neratinib 240mg po daily~* herzuma 8mg/kg (loading) --\> 6mg/kg q3w"
40963145|NCT01927172|DEVICE|AirSonea|
40963146|NCT03129178|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
41294270|NCT02345369|DEVICE|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
41294271|NCT02345369|DEVICE|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
41294272|NCT02664285|OTHER|closure of subcutaneous tissue|the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.
41294273|NCT02664285|OTHER|No closure of subcutaneous tissue|the subcutaneous fat will not sutured after cesarean section in diabetic patients.
41294274|NCT03662334|DRUG|Rapid Acting insulin with pre-treatment of rHuPH20|Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
40963147|NCT06506110|OTHER|Retrieving of retrospective data from Epic|Retrospective data from Epic will be extracted to determine the Patient Acceptable Symptom State (PASS) for the numeric rating scale (NRS) pain score in the first 48 hours after surgery in patients who received intravenous Patient Controlled Analgesia.
40963148|NCT03895541|DIAGNOSTIC_TEST|SuperSonic image|3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
40963149|NCT03673852|BEHAVIORAL|WE Harambee|WE Harambee is a 6-month intervention, comprised of twice a week group meetings for 12 weeks, followed by a second 12 weeks of individual peer coaching/navigation. WE Harambee aims to enhance access to and engagement in primary care and behavioral health services, as well as improve overall health and well-being, including the 8 dimensions of wellness and social determinants of health.
40963150|NCT03673852|BEHAVIORAL|Behavioral Health Home Enrollment|A BHH is a Center for Medicaid Services program supporting Medicaid beneficiaries with complex needs, typically multiple chronic conditions impacting both physical and behavioral health. Utilizing a team-based clinical approach that includes the patient, his/her providers, and possibly family members, BHH programs target service fragmentation by linking community supports and resources as well as by enhancing the integration of primary and behavioral health care. Care Coordinators oversee and facilitate access to all services an individual needs to stay as healthy as possible, aiming to promote continuous health management not mere resolution of repeated acute episodes.
41294275|NCT03662334|DEVICE|Sham injection|A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
40963151|NCT01862900|BIOLOGICAL|MEDI6469|Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
40963152|NCT03986398|OTHER|Infection prophylaxis|Infection prophylaxis with Urell®, cranberry fruit juice extract (vaccinium macrocarpon)
40963153|NCT02929667|DRUG|Fluoxetine|Standard 6 weeks titration, starting 10 mg per day.
40963154|NCT02929667|DRUG|Placebo|Standard 6 weeks titration.
40963155|NCT01421914|OTHER|Bupivacaine 0,5%|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
41294276|NCT01888354|DRUG|H.P. Acthar Gel (repository corticotropin injection)|Acthar Gel 80 IU
41136643|NCT03155399|OTHER|Proprioceptive based training (PBT)|During the PBT patient will stay in supine position with the upper limbs positioned in symmetric posture. He/She will be asked to move both limbs with the same frequency performing bilateral flexion-extension of one of the upper limb districts according to the available free ROM of the target joint. The movement execution of the affected arm will be supported by the physiotherapist performing passive movement at the same rhythm, as the one executed with the unaffected side. Patient will be asked to focus the attention on the movement performed against gravity, which will be reinforced by a verbal command. Afterwards, the physiotherapist will fully support movement execution coherently with the patient's movement initialization. The active movement performed voluntarily by the patient with unaffected limb will be considered as the reference movement, that the physiotherapist has to emulate passively, by synchronization of passive movement executed in phase with the affected side.
41136644|NCT03155399|OTHER|Conventional neuromotor treatment (CNT).|The patients randomized to the CNT group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity.
41136645|NCT03116191|DRUG|SK-1404|4 weeks of repeated administration of SK-1404 to the patients of nocturia
41136646|NCT03116191|DRUG|Placebo|4 weeks of repeated administration of Placebo to the patients of nocturia
41136647|NCT04413188|OTHER|Warm foot bath|The participants in experimental group were asked to soak their feet in warm water (38-40°C) for 20 minutes one hour before their bedtimes for six weeks. A special foot bath (Beurer FB50 luxury foot bath spa with water heater) was used for this purpose. The bath is 10 cm deep; it keeps water at a constant temperature of 35-48°C for 15-60 minutes, has a display screen for water temperature and duration of use, and turns off automatically.
41294277|NCT03121352|DRUG|Carboplatin|AUC 4.5 IV day 1 of 21-day cycle
41294278|NCT03121352|DRUG|Nab-paclitaxel|75mg/m2 IV days 1, 8 and 15 of 21-day cycle
41294279|NCT03121352|DRUG|Pembrolizumab|200 mg IV every 21 days
41294280|NCT01827540|DRUG|Cenicriviroc|
41294281|NCT01827540|DRUG|Dolutegravir|
41294282|NCT01827540|DRUG|Midazolam|
41294283|NCT02096939|PROCEDURE|Adrenal extirpation|
41294284|NCT02096939|DRUG|Antihypertensive medication|
41294285|NCT01271478|DRUG|captopril plus placebo|This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
41294286|NCT01271478|DRUG|telmisartan plus placebo|Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day
41294287|NCT01271478|DRUG|Telmisartan plus Captopril|Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
41294288|NCT01271478|DRUG|Placebo|Patients in this group will receive 2 tablets of placebo (starch) twice a day.
41456533|NCT00754507|DRUG|colesevelam HCl placebo tablets and atorvastatin tablets|colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
41456534|NCT05432115|DRUG|Tetracyclin|Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
41456535|NCT06127186|DIAGNOSTIC_TEST|Swab test for viral antigens|No intervention except for a routine examination and viral testing is planned.
41456536|NCT00686062|OTHER|Control - computerized age-appropriate prenatal testing educational brochure|Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
40963156|NCT04459533|DEVICE|TOF protocol|"To the introduction of CISATRACURIUM, Initial bolus was at 0.2mg/kg and initial continuous infusion at 0.18mg/kg/h of theoretical ideal weight.~To the introduction of ATRACURIUM, initial bolus was at 0.5mg/kg and initial continuous infusion at 0.5mg/kg/h of theoretical ideal weight.~Introduction of NMBA was associated to deep sedation (RASS - 4 or RAMSAY 6; BIS 40 to 60).~TOF was measured through the electric stimulation of peripheral nerves (facial or ulnar nerve).~The dose of NMB agents was then adapted according to the number of answers to the TOF, per 4 hours:~* If 0 response and no respiratory asynchrony: no change in flow rate~* If \>=1 or respiratory asynchrony: increase of the continuous curare flow by 20% preceded by a bolus identical to the one administered at the beginning of NMB agent, then recheck at H+1."
40963157|NCT04198298|DRUG|EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
41456537|NCT00686062|OTHER|PT Tool - interactive, computerized, prenatal testing decision tool|An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
41456538|NCT01239498|PROCEDURE|Injection of Saline + Lidocaine/Adrenaline|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.~Injection of Saline + Lidocaine 1%"
41456539|NCT01239498|PROCEDURE|Lidocaine/Adrenaline only|Injection of Lidocaine/Adrenaline only
41456540|NCT01091363|BEHAVIORAL|Standard|10 minute brief cessation counseling
41456541|NCT01091363|BEHAVIORAL|Deep Cultural|Deep culturally tailored cognitive behavioral therapy
41456542|NCT00642811|DRUG|Ticagrelor|Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
41456543|NCT00642811|DRUG|Clopidogrel|(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
41456544|NCT00642811|DRUG|Aspirin|Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
41456545|NCT00325780|DRUG|Pitavastatin|Pitavastatin 4 mg once daily
40765578|NCT01321905|DIETARY_SUPPLEMENT|Supplementation with vitamin D2/D3|"Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.~Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
40765579|NCT06168448|OTHER|Oral and written information|Legal oral and written information given by physicians concerning additional examinations
40765580|NCT06168448|OTHER|Video information|Explanatory video applied after physician's formal information
40765581|NCT05144256|DRUG|Mitapivat|Tablets or granules
40765582|NCT05144256|DRUG|Mitapivat-matching placebo|Tablets or granules
40765583|NCT06640140|BEHAVIORAL|Supervised aerobic plus strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training.
40765584|NCT06637085|DEVICE|LLLT|low level laser therapy Probe laser device: (Laserklasse2M, EN60825-1, +A2:2002, W.L= 635-670nm, P\<6mW, German):low level laser therapy It will be used to stimulate vagus nerve .
40963158|NCT04198298|DRUG|ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
40963159|NCT04198298|DRUG|Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
40765585|NCT06637085|OTHER|traditional physical therapy|traditional physical therapy include (phase I cardiac rehabilitation, breathing exercises, modified postural drainage, percussion and vibration)
40963160|NCT05878145|BEHAVIORAL|Structured rehabilitation exercise program|Stretching (10 mins): neck, shoulder, wrist, back; Aerobic exercise (20 mins): cycle ergometer, wheelchair run; Strengthening exercise (15 mins): shoulder press, chest press, front raise, biceps curl, lateral raise, bent over rowing or rowing, bent over lateral raise, triceps extension; Balance training (5 mins); Stretching exercise (10 mins)
40765586|NCT06637085|DEVICE|ACU TENSE|Acu-TENS device (Digital TENS, EAF20, JERF20BD0604, add manufacturing country): It will be used to stimulate vagus nerve throug h the acupoint PC6 .
40765587|NCT06095128|DRUG|Vedolizumab|Vedolizumab IV infusions
40765588|NCT06095128|DRUG|Tofacitinib|Tofacitinib Tablets
40765589|NCT05929079|DRUG|Retatrutide|Administered SC
40765590|NCT05929079|DRUG|Placebo|Administered SC
40765591|NCT06642025|BIOLOGICAL|CAR-T Cell Injection|"Conditioning chemotherapy: Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before intraperitoneal infusion.~On the day of administration, premedication with 500mg of acetaminophen orally and 20mg of promethazine intramuscularly or intravenously (or other non-steroidal anti-inflammatory drugs and antihistamines) should be given 30 minutes before intraperitoneal infusion.~The therapeutic dose of CAR-T cells is defined as intravenous injection of 1.0E6 CAR-T cells/kg as the initial standard dosage."
41456546|NCT05878132|DEVICE|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 30-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
40765592|NCT06639659|PROCEDURE|Sphenopalatine Ganglion Block|patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.
40765593|NCT06639659|DRUG|Dexmedetomidine|patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.
41294289|NCT04545112|DEVICE|CABG|Elective, on-pump coronary artery bypass (CABG) surgery. Each study subject will receive an internal mammary artery (IMA) conduit to the left anterior descending (LAD) coronary artery, one saphenous vein graft and one XABG medical device.
41294290|NCT00614003|BEHAVIORAL|Decision support skills building Intervention|Decision support skills
41136648|NCT05642806|BIOLOGICAL|Mepolizumab|Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
40963161|NCT03921944|DIAGNOSTIC_TEST|CT scan of the shoulders|studies of both operative and nonoperative shoulders
40963162|NCT04795011|OTHER|exercise and manual lymphatic drainage|MLD will be launched with simple neck application. Hemodynamics of blood and lower extremity motoring will be increased by combining active bilateral shoulder-twisting with breathing after effleurage. Cervical lymph nodes will be stimulated. Back-up treatment will be applied for the abdominal area. Suction power in the ductus thoracicus will be increased with breathing exercises. Ventral drainage will be applied to the lower extremity in accordance with the surgery of the patient.
41136649|NCT05642806|OTHER|Placebo|Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
41456547|NCT05878132|OTHER|Conventional therapy|The participants in the control group received similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They were instructed to perform the exercises for the recommended therapy dose and received a weekly therapy consultation as well. To monitor the participant's exercise compliance, they were instructed to record their daily exercise progress in the exercise log.
40765594|NCT06639659|OTHER|General Anesthesia (control group)|patients will be operated under general anesthesia including routine protocol for these cases
40765595|NCT06644781|DRUG|Ifinatamab deruxtecan|Intravenous administration
40765596|NCT06644781|DRUG|Docetaxel|Intravenous administration
40963163|NCT04795011|OTHER|exercise|range of motion and walking exercise
40963164|NCT01814384|DEVICE|prosthesis GMK ® without the ancillary MyKnee ® LBS|
40963165|NCT01814384|DEVICE|Matched patient cutting blocks MyKnee ® LBS|
40963166|NCT01270412|BIOLOGICAL|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml
40963167|NCT01270412|DRUG|Hyaluronic acid|Intra articular injections: 20 mg / 2 ml
40963168|NCT04287829|DRUG|Pembrolizumab|Infusion
40963169|NCT04287829|DRUG|Lenvatinib|Capsule
40963170|NCT05196204|OTHER|Trunk-oriented task training combined with functional electrical stimulation|Training will consist to perform one hour of trunk task-oriented training combined with functional electrical stimulation (FES/T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. FES will be combined with functional and non-functional tasks to work functionality and muscle strengthening. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
40963171|NCT05196204|OTHER|Trunk-oriented task training alone|"The SCI participants who will perform T-TOT training alone will have to perform the same exercises as explained in the previous section (two functional tasks and two non-functional tasks) but they will not receive any functional electrical stimulation.~Training will consist to perform one hour of trunk task-oriented training (T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises."
40963172|NCT00695877|BIOLOGICAL|Ad5.ENVA.48 HIV-1 vaccine|Recombinant adenovirus serotype 5 HIV-1 vaccine
41136650|NCT01381445|DRUG|GW870086 0.2%|White to slightly coloured opaque cream
41136651|NCT01381445|DRUG|GW870086 2%|White to slightly coloured opaque cream
40765597|NCT06644781|DRUG|Paclitaxel|Intravenous administration
40765598|NCT06644781|DRUG|Irinotecan|Intravenous administration
41136652|NCT01381445|DRUG|Clobetasol Propionate|White cream
41136653|NCT01381445|DRUG|Placebo|White to slightly coloured opaque cream
41136654|NCT03692845|PROCEDURE|Transforaminal Lumbar Interbody Fusion either open or minimally invasive|Spinal fusion procedure through the intervertebral foramen
41294291|NCT05655546|OTHER|Access to Cue Health COVID-19 Remote testing and treatment for COVID-19|Participants will receive at home COVID-19 test for themselves and others in their household.
41294292|NCT00878046|DEVICE|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
41294293|NCT01588197|BEHAVIORAL|Attention/Distraction Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
41456548|NCT00616096|PROCEDURE|immunoadsorption|"First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5"
41456549|NCT06179641|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anesthetics around the nerve.
41456550|NCT06179641|PROCEDURE|IPACK block|The IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where nineteen mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anesthetics will be observed above the posterior capsule.
41456551|NCT02966860|DRUG|Oral solution OC/APAP|
41456552|NCT06375187|BIOLOGICAL|Engineering Tumor Infiltrating Lymphocytes|A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.
41456553|NCT05924880|DRUG|durvalumab|Durvalumab 1500 mg as a 60-minute IV infusion in combination with gemcitabine-based chemotherapy Q3W. Upon completing chemotherapy, or discontinuing chemotherapy due to toxicity, durvalumab 1500 mg IV Q4W alone or in combination with gemcitabine.
41456554|NCT02182596|DRUG|Mylotarg|Dose level study
41456555|NCT04736537|DEVICE|4DCT|CT imaging conceptually similar to time-lapse photography.
40765599|NCT05007132|BIOLOGICAL|Panitumumab 20 milligram/ML|Participants receive Panitumumab at 6mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
40765600|NCT05007132|BIOLOGICAL|Bevacizumab|Participants receive bevacizumab at 5 mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
40765601|NCT05007132|DRUG|Trifluridine/Tipiracil Hydrochloride|Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12
40765602|NCT06569992|OTHER|VIS, TIES|The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
40765603|NCT06532799|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
40765604|NCT06532799|DRUG|Cyclophosphamid|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
41136655|NCT03890484|BEHAVIORAL|Peer Type - New Peer|Participants drink with 2 unfamiliar confederate peers
41136656|NCT03890484|BEHAVIORAL|Peer Type - Close Friends|Participants drink with 2 close friends
40765605|NCT06532799|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
40765606|NCT06532799|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
40963173|NCT05518019|DIETARY_SUPPLEMENT|The Daily Supplement|"Each serving of the dietary supplement (defined as 1 softgel) contains the following formulation:~Organic Broad Spectrum Hemp Extract 35mg Bio-Terpene Complex 52mg Palm Monoglycerides Organic Hemp Seed Oil, Clove Bud Oil, Black Pepper Berry Essential Oil Curcumin (Turmeric Root) Essential Oil~Inactive ingredients: Organic Flaxseed Oil, Gel Shell (Modified Tapioca Starch, Glycerin, Purified Water, Maltitol"
41136657|NCT03791190|OTHER|Regional citrate anticoagulation|Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
41136658|NCT03791190|OTHER|No-anticoagulation|Patients accepted CRRT without anticoagulant.
41136659|NCT01640340|DRUG|aprepitant|Given by mouth
41136660|NCT01640340|DRUG|palonosetron hydrochloride|Given IV(intervenous infusion)
41136661|NCT01640340|DRUG|ondansetron|Given PO
41136662|NCT01640340|DRUG|dexamethasone|Given PO
41136663|NCT02813174|BEHAVIORAL|Compassionate Mind Training from Compassion-Focused Therapy|
41136664|NCT01630668|DIETARY_SUPPLEMENT|One-a-Day L. reuteri NCIMB 30242 supplement capsule|Once per day, 12 weeks
41136665|NCT01630668|DIETARY_SUPPLEMENT|One-a-Day placebo capsule|Once per day, 12 weeks
41136666|NCT02323945|OTHER|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
41136667|NCT02323945|OTHER|Walk|30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
41136668|NCT02323945|OTHER|Strength|30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
41456556|NCT01548053|OTHER|PC-DATA tool|The implementation plan consists of educational sessions and a dementia care manager (DCM). The educational sessions consist of two components: a 1.5 hour group-based DATA tool implementation workshop with primary care providers (PCPs); and, a 1 hour follow-up session at study mid-point. The DCM will facilitate application of the DATA tool and provide direct support to PCPs during the study.
41456557|NCT01846091|OTHER|Laboratory Biomarker Analysis|Correlative studies
41456558|NCT01846091|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IT
41456559|NCT00898664|GENETIC|cytogenetic analysis|
40765607|NCT06532799|DRUG|Pembrolizumab|Intravenous (IV) infusion
40765608|NCT06271057|DRUG|golcadomide|golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166
41456560|NCT00898664|GENETIC|gene expression analysis|
41456561|NCT00898664|GENETIC|mutation analysis|
41456562|NCT00898664|GENETIC|polymerase chain reaction|
41294294|NCT01588197|BEHAVIORAL|Stimulus Quality/Severity Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.
41294295|NCT01588197|BEHAVIORAL|Control Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
41136669|NCT05147155|BIOLOGICAL|Mepolizumab|This will be a 2-year prospective study. Patients with uncontrolled severe asthma will receive mepolizumab according to standard of care and best clinical practice, which will be administered as a 100-mg subcutaneous dose every four weeks.
41136670|NCT04432155|DRUG|Xenon|30% xenon, 30% oxygen, and 40% nitrogen
41456563|NCT00898664|OTHER|immunohistochemistry staining method|
41456564|NCT00898664|OTHER|laboratory biomarker analysis|
40765609|NCT03287063|OTHER|Tumor Biopsy|Stereotactic biopsies will be performed prior to resection.
41136671|NCT04432155|DRUG|Placebo|30% oxygen, and 70% nitrogen
40765610|NCT05362305|BEHAVIORAL|Essential Coaching for Every Mother|Daily text messages for the first six-weeks postpartum.
40765611|NCT04096677|PROCEDURE|hysteroscpy|
40765612|NCT03238547|DIAGNOSTIC_TEST|semi-quantitative urine albumin-to-creatinine ratio test|measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
40765613|NCT03238547|DIAGNOSTIC_TEST|standard quantitative spot urine albumin-to-creatinine ratio|measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
40765614|NCT06637163|DRUG|Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy|Benmelstobart: 1200 mg, i.v.gtt , d1, 22; Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week(If the number of patients achieving pCR in this group is ≥ 18 with the first 30 patients enrolled, the subsequent 20 patients will receive a reduced dose of 36 Gy in 20 fractions, 5 days per week.)
41136672|NCT00703352|DRUG|Eplerenone|Eplerenone (coated tablet) 50mg daily during 12 months.
41294296|NCT01174914|OTHER|ARV's + Placebo|Patients continued ARV's plus a placebo nightly for 9 months
41294297|NCT01174914|DRUG|Naltrexone|Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months
40765615|NCT06637163|DRUG|Paclitaxel + Carboplatin + Radiotherapy|Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week
41136673|NCT01052272|DRUG|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
41136674|NCT01052272|DRUG|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
41136675|NCT01052272|DRUG|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
41136676|NCT03967015|OTHER|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
41294298|NCT01174914|DRUG|Naltrexone + ARV's|Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
41294299|NCT05894018|DRUG|Fluzoparib|150mg, orally, bid
41294300|NCT05894018|PROCEDURE|Radioactive particle implantation|Radioactive iodine-125 seeds implantation
41294301|NCT00306566|BIOLOGICAL|CYT004-MelQbG10|
41294302|NCT04556331|BEHAVIORAL|Parenting programme (cognitive behavioural) aimed at reducing generational transmission of anxiety|'Psychoeducation' (psychologically informed information about the topic of transmitting anxiety) and cognitive-behavioural strategies aimed at reducing the transmission of anxiety from parent to young child. These will be shared with a group of maximum 8 remotely delivered, in a didactic format.
41294303|NCT00036218|DRUG|sumanirole|
41294304|NCT00036218|DRUG|ropinirole|
41456565|NCT01721551|OTHER|Exercise|Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
41456566|NCT01721551|OTHER|Usual Treatment|The CON group received no intervention but the usual treatment
41136677|NCT03964974|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.
41294305|NCT03442426|OTHER|Integrated model of primary care|Intervention includes: 1) consistent risk screening and assessment; 2) care coordination and system navigation; 3) patient/caregiver engagement and shared decision-making; and 4) enabling technology supports.
41294306|NCT00001332|PROCEDURE|CHPP with cisplatin|
41294307|NCT00918762|PROCEDURE|assessment of therapy complications|
41294308|NCT00918762|PROCEDURE|diagnostic endoscopic surgery|
41294309|NCT00918762|PROCEDURE|quality-of-life assessment|
41294310|NCT00918762|PROCEDURE|therapeutic conventional surgery|
41294311|NCT00918762|PROCEDURE|therapeutic endoscopic surgery|
41294312|NCT00918762|PROCEDURE|transoral robotic surgery|
41456567|NCT03161197|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
41456568|NCT03187925|PROCEDURE|open, transcervical versus rigid endoscopic treatment|The goal of the project is to perform the first prospective, multi-institutional long-term (5 year) study comparing the outcomes of open, transcervical versus rigid endoscopic treatment of cervical esophageal diverticulum and cricopharyngeal dysfunction in resolving associated symptoms, complications, and recurrence rates of dysphagia surgery. This study will also include cricopharyngeal bar as it pertains to an early Zenker's diverticulum.
41456569|NCT04568707|OTHER|blood sample|blood sample for serum (serology, biomarkers) and DNA
41456570|NCT01480895|BEHAVIORAL|Lifestyle instruction for Jews and Bedouin GDM women.|Every several months the women had instructions and checkups.
41456571|NCT04702789|DRUG|Dorzolamide-timolol-brimonidine and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
40765616|NCT04105283|BIOLOGICAL|Tc99m-MAA|Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
40963174|NCT06270810|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will be performed on the treadmill at 40-60% of the participants' heart rate reserves. Each aerobic exercise session will last for 40 minutes. All participants will be monitored with a heart rate monitor throughout the exercise sessions. During the first three-week, participants will exercise on the treadmill at intensities between 40-50%, and between fourth and eighth weeks, 50-60% of their heart rate reserves. Participants will wear an accelerometer on their non-dominant wrist during the intervention to monitor the physical activity and sedentary behavior data. At the same time, these participants will be asked not to change their routine diet during the intervention period.
41294313|NCT00918762|PROCEDURE|video-assisted surgery|
41294314|NCT03253198|DRUG|Saline|A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative
41294315|NCT03253198|DRUG|Bupivacaine liposome|an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
40963175|NCT06270810|BEHAVIORAL|Increasing non-Exercise Physical Activity|Participants who will carry out this intervention will increase their non-exercise physical activities. Before intervention period, participants will receive face-to-face training to increase their non-exercise physical activities. This training will generally consist of recommendations based on the study which effectively reduced sedentary behavior (SB) with non-exercise physical activities (Sarah Kozey-Keadle et al. 2012). A one-on-one interview will be held with each participant every week to learn about strategies by which the volunteers successfully increased their non-exercise physical activities in the previous week, and the difficulties or barriers they encountered. New strategies to overcome these difficulties and barriers will be discussed and suggestions will be made. Participants will wear an accelerometer on their non-dominant wrist to monitor the physical activity and SB data, and will be asked not to change their routine diet during the intervention period.
40963176|NCT02829528|BEHAVIORAL|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
40963177|NCT05037812|DRUG|Saline injection|Saline
40963178|NCT05037812|DRUG|Multimodal injections|"5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).~2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection)."
40963179|NCT05119517|OTHER|Osteopathic manipulative medicine pedal pump|In this 7 minute intervention, the patient receives 2 minutes of myofascial release of the thoracic inlet and then 5 minutes of the pedal pump technique
40963180|NCT06143644|OTHER|Serial ctDNA monitoring|Baseline blood samples, surgical resected tumor tissue, blood samples after surgery (D5-7), blood samples before adjuvant therapy and blood samples after adjuvant therapy (every 3 months for up to 2 years follow-up) will be collected from colorectal patients.
40963181|NCT03416946|DEVICE|Visionaire|Custom cutting block using MRI to create patient specific instrumentations
40963182|NCT03416946|OTHER|Traditional|Traditional cutting method
40963183|NCT05325788|OTHER|e-Covery|Through the e-Covery app, participants will receive place-specific messages, sent when participants pass locations identified as triggers.
41294316|NCT06070233|RADIATION|stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation|"Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing. Prescription dose is 50 Gy delivered in a single fraction to the target volume, prescribed to whatever isodose line produces optimal falloff (but not less than a 50% isodose line; dmax \<100Gy) .~All radiosurgery treatment will utilize the Varian Edge, Varian TrueBeam STx, or CyberKnife system"
41294317|NCT06070233|OTHER|Sham|Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing.
41456572|NCT04702789|DRUG|Dorzolamide-timolol and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
40963184|NCT05325788|OTHER|Comparator Condition|Through the e-Covery app, participants will receive a single general message sent daily in the morning.
40963185|NCT05037071|DEVICE|Upper body graduated compression sleeve|An over the counter light compression sleeve will be worn during game training
40963186|NCT02099578|DIETARY_SUPPLEMENT|25 g of Freeze-dried Strawberry Powder|Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
40963187|NCT02099578|DIETARY_SUPPLEMENT|50 g of Freeze-dried Strawberry Powder|Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
40963188|NCT02099578|DIETARY_SUPPLEMENT|Placebo Powder|Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
40963189|NCT05337228|DRUG|IN-C006 Peri inj.|IN-C006 peri inj. will be injected continuously for 3 days.
40963190|NCT05337228|DRUG|RPN301|RPN301 will be injected continuously for 3 days.
40963191|NCT04945122|DRUG|Pitavastatin|Pitavastatin 4mg Qn
40963192|NCT04945122|DRUG|Atorvastatin|Atorvastatin 20mg Qn
40963193|NCT03052491|DIETARY_SUPPLEMENT|Stem Cell 100+|Open-Label 10-Component Dietary Supplement
40963194|NCT00275457|DRUG|pramipexole|
40963195|NCT02368015|OTHER|Peripheral intravenous cannula (IVC)|Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
40963196|NCT02368015|DRUG|cefazolin|
40963197|NCT03560232|DRUG|Ceftriaxone|See arm description
40963198|NCT03560232|DRUG|Ampicillin/sulbactam|See arm description
41456573|NCT05755854|BIOLOGICAL|allogeneic γ9δ2 T Cells|dose escalation (3+3) : dose 1 (5 × 10\^7cells/kg) ,dose 2 (1 × 10\^8 cells/kg) ,dose 3 (2 × 10\^8cells/kg)
41456574|NCT05755854|DRUG|Fludarabine|Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition
40963199|NCT03560232|DRUG|Piperacillin/tazobactam|See arm description
40963200|NCT03560232|DRUG|Cefazolin + Gentamicin|See arm description
40963201|NCT03560232|DRUG|Clindamycin + Gentamicin|See arm description
40963202|NCT02339935|BEHAVIORAL|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
40963203|NCT02339935|OTHER|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
40765617|NCT06639399|OTHER|Acupuncture|Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally. Electroacupuncture (EA) was applied to the BL32 and BL54 acupoints at a frequency of 2/100Hz. Each treatment lasting for 30 minutes. Patients received five acupuncture treatments per week for two consecutive weeks
40765618|NCT06639399|OTHER|Acupuncture|Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6). The acupuncture and EA procedure for the lumbosacral acupoints was the same as in Group A. After 30 minutes of treatment, abdominal and lower limb acupoints were selected for an additional 30 minutes treatment.Each treatment lasting for 60 minutes.Patients received five acupuncture treatments per week for two consecutive weeks
40765619|NCT04869527|DEVICE|BIOTRONIK ICDs with DX Technology|The BIOTRONIK DX system offers a single chamber ICD that enables sensing of atrial signals through floating atrial dipoles, using a single ventricular lead. This technology enables enhanced arrhythmia diagnosis based on atrial and ventricular electrograms and, in addition, early diagnosis and automatic transmission of AF and heart failure (HF) diagnostic data. The DX technology provides several features in a single chamber device that are usually only found in dual chamber devices, including atrial diagnostics and SVT discrimination - early detection of SAF, increased diagnostics accuracy, dual-chamber discrimination. Nevertheless, the benefits of a single chamber device are preserved: reduced lead complications, reduced procedure complexity, elimination of costs for atrial lead. The DX system also integrates with BIOTRONIK Home Monitoring, allowing physicians to remotely follow their patients' clinical and device statuses with daily updates.
40765620|NCT00000307|DRUG|Naltrexone|
41294318|NCT02734992|BEHAVIORAL|ACT+ MTAU|Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hour. The control group will receive the ACT intervention following the completion of the 3-months follow-up assessment of the treatment group. Participants in both groups will complete primary and secondary outcome scales, as well as ACT process effects scales at pre, post and 3-months follow-up. The treatment group only will be also assessed at 6 and 12-months follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou \& Karekla, 2015). Techniques will focus on key ACT processes aiming at promoting psychological flexibility for the head pain experience.
40765621|NCT02543385|DRUG|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
40765622|NCT06217081|DEVICE|3M Topical Tissue Adhesive|Application of investigational topical tissue adhesive to trauma laceration or surgical incision.
40765623|NCT06217081|DEVICE|Histoacryl® Blue Topical Skin Adhesive|Application of control topical tissue adhesive to trauma laceration or surgical incision.
40765624|NCT05515224|OTHER|5-Cog Paradigm (5-Cog battery coupled with clinical decision tool)|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. If cognitive concerns are endorsed the 5-Cog battery will be conducted. The 5-Cog battery includes the Picture Memory Impairment Screen, Motoric Cognitive Risk Syndrome diagnosis, and Symbol Match. The simple, \<5-minute cognitive assessment will reliably identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation.
41294319|NCT02734992|BEHAVIORAL|Waitlist Control +MTAU|Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of the 3 months follow-up assessment of the ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.
41294320|NCT04860713|DRUG|aspirin and ketamine|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
41294321|NCT04860713|DRUG|Nurtec (Rimegepant)|Drug: 75 mg of ODT
41294322|NCT05611463|DRUG|Camrelizumab Plus Docetaxel and Cisplatin|Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
41294323|NCT00184912|DRUG|caffeine|
41294324|NCT00184912|DRUG|Technetium-TC99m-labeled Annexin A5|
41294325|NCT00184912|PROCEDURE|ten minutes forearm ischemia|
41294326|NCT00184912|PROCEDURE|ischemic forearm exercise|
41294327|NCT00199511|DRUG|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
41294328|NCT02949661|PROCEDURE|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block
41294329|NCT02949661|PROCEDURE|Local wound infiltration|Patients will receive local wound infiltration
41294330|NCT05828446|DEVICE|MRI|To compare the diagnostic performance of US+/- Constrast-enhanced US and AMRI for HCC detection in an at-risk population
41294331|NCT00004297|DRUG|diazepam|
41294332|NCT00004297|DRUG|lorazepam|
41294333|NCT03271008|DEVICE|Direct laryngoscopy|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a size 4 (or size 3 if necessary) Macintosh blade direct laryngoscope.
41294334|NCT03271008|DEVICE|Vividtrac videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a Vividtrac videolaryngoscope connected to a tablet or smartphone.
41294335|NCT03271008|DEVICE|KingVision videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a KingVision videolaryngoscope.
41294336|NCT02806778|OTHER|BIS Monitor-guided sedation|The patients enrolled in the study will undergo BIS Monitor-guided sedation. Standard BIS Monitor will be used for the procedure to monitor the depth of sedation.
41294337|NCT02806778|OTHER|Jugular bulb catheter|Jugular bulb catheter will be implanted in the patients enrolled in the study.
41294338|NCT03543891|OTHER||
41294339|NCT00400491|DRUG|Cholecalciferol (vitamin D)|Cholecalciferol capsule 20.000 IU twice per week for 6 months
41294340|NCT00400491|DRUG|Placebo|Placebo capsule twice a week, identical to the cholecalciferol capsules
40765625|NCT05515224|OTHER|Enhanced usual care|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. The results will be provided to primary care physicians.
40765626|NCT06641791|RADIATION|Standard Radiotherapy (SRT)|2400 cGy in 3 fractions - day 0/7/21, OR, 2500 cGy in 5 fractions over 1 week
40765627|NCT06641791|RADIATION|Stereotactic Body Radiotherapy (SBRT)|4500 cGy in 5 fractions (twice a week to primary and nodal GTV, OR, 4000 cGy in 5 fractions twice a week if organs at risk.
41294341|NCT02890771|PROCEDURE|Tooth Brushing with Dentifrice|Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
40765628|NCT03073577|DRUG|Antiaging Glycopeptide|Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
40765629|NCT04636073|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
40765630|NCT03711032|BIOLOGICAL|Pembrolizumab|Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization
40765631|NCT03711032|BIOLOGICAL|BCG|BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy
40765632|NCT05020457|DRUG|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
40765633|NCT05020457|DRUG|AP or TP|AP or TP should be administered immediately after SI-B001 is completed. The administration of AP or TP should refer to the drug instructions and standard usage.
40765634|NCT05020457|DRUG|Docetaxel|Docetaxel should be administered immediately after SI-B001 is completed. The administration of Docetaxel should refer to the drug instructions and standard usage.
40765635|NCT02657343|DRUG|Ribociclib|
40765636|NCT02657343|DRUG|T-DM1|
40765637|NCT02657343|DRUG|Trastuzumab|
40765638|NCT02657343|DRUG|Fulvestrant|
40765639|NCT04148911|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 of every 28-day cycle. Day 15: Atezolizumab may be administered on Days 15-18 of each cycle.
40765640|NCT04148911|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle. Day 8: Nab-paclitaxel may be administered on Days 8-11 of each cycle. Day 15: Nab-paclitaxel may be administered on Days 15-18 of each cycle, on the same day with the atezolizumab infusion.
40765641|NCT00336206|DRUG|Alemtuzumab|
41294342|NCT02890771|PROCEDURE|Turmeric Massaging|:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
40765644|NCT05962736|DEVICE|Mirror therapy|The patients received a total of 24 sessions of treatment for 8 weeks, 3 sessions a week, starting from the postoperative 1st day after thorakaotomy. Each treatment session lasts between 60 and 90 minutes.
40765645|NCT06636695|DEVICE|Cellular Matrix|Group 1 (Cellular Matrix): Patients randomized to this group will be treated with two intra-articular injections of Cellular Matrix at D0 and M1.
40765646|NCT06636695|DEVICE|Orthovisc|Group 2 (HA): Patients randomized to this group will be treated with two intra-articular injections of HA alone provided by ORTHOVISC at D0 and M1
40765647|NCT06062472|DIETARY_SUPPLEMENT|Probiotics|Lactobacillus paracasei PS23 will be used in this study
40765648|NCT06062472|DIETARY_SUPPLEMENT|heat-treated of Lactobacillus paracasei HT-PS23|heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use
40765649|NCT06062472|DIETARY_SUPPLEMENT|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use
40765650|NCT04642976|DEVICE|Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters|Ganglionated plexi will be mapped using high frequency stimulation with standard ablation catheters attached to a Natus Cortical Stimulator for high frequency stimulation. Vagal innervation to the heart will be assessed with non-invasive Parasym tragal stimulation.
40765651|NCT03852420|DEVICE|LUMINIZE RF Balloon Catheter|Ablation Therapy with the LUMINIZE RF Balloon Catheter
40765652|NCT02121639|DRUG|Placebo|
40765653|NCT02121639|DRUG|AZD5363|
40765654|NCT06637566|OTHER|Brandt Daroff exercises along with Cawthorne Cooksey exercises|"Brandt Daroff exercises along with Cawthorne Cooksey exercises. The Cawthorne Cooksey exercises include eye and head movements, coordination of eye and head movements (visual-vestibular interaction), postural control exercises, and progressively more difficult balance tasks (eyes open, eyes closed, large base support, uneven base support, while walking, in high visual or noisy environments). Exercises should be done three times a day, with 5 repetitions of each. The exercises will be performed in three sessions per week with 60 minutes each session for eight weeks. The cawthorne Cooksey exercises includes the following:~A: Eye and head movement~B: Head and body movement, sitting down:~C: Standing up exercises:"
40765655|NCT06637566|OTHER|Brandt Daroff exercises|brandt daroff exercises without cawthorne Cooksey exercises. To begin the Brandt-daroff exercise, the patient will sit and swivel the head 45 degrees to one side (left), then instantly lie down on the other shoulder (right). The patient should be instructed to maintain this posture for 30 seconds or until the vertigo subsides. The patient then gradually returns to the starting position, maintaining the left ear rotation until sat upright. Following the same 30 second time limits, the patient turns his head in the opposite way (right) and rests down on the opposite shoulder (left). These exercises will be instructed to perform at home for 3 sets (morning, afternoon and evening) with 5 repetitions approximately for 30 minutes in each session for five weeks
40765656|NCT06642987|DRUG|Vonoprazan Test 20mg|1 tablets orally once a day
40963204|NCT05497154|BEHAVIORAL|Training Arm|The training will be composed of 4 separate training sessions provided every 2 - 4 weeks. During the 1st session (45 minutes), the investigators will educate the physical therapist about the different categories of opioid use including opioid misuse (OM) and the risks associated with OM as well as training to engage the patient in a conversation about opioid use. The 2nd and 3rd sessions (30 minutes each) involve training in procedures to screen and assess patients at risk for OM, respectively. The 4th session (30 minutes) involves training in procedures to refer patients to a specialist or a primary care provider for further treatment if OM is suspected.
40963205|NCT04579575|DEVICE|Trans-abdominal Ultrasound|"All patients will undergo trans- abdominal and trans-vaginal examination (The trans-abdominal US was performed for virgin patients or patients with large tumors that cannot be completely seen by the TV route) performed on the devices available in South Egypt Cancer Institute in supine position.~The most important b-mode parameters (such as gain, frequency, number of foci and their depth, etc.) of the US machines were manually adjusted to obtain similar image impressions.~* The morphological features of each AM, and independently categorized the US images of each AM according to the O-RADS published by ACR and GI-RADS simple rules . The results of consensus reviewing were used to calculate the validity of each US classification system.~* The definite diagnoses of AM were preferentially established based on~Histo-pathological findings and other modalities."
40963206|NCT01906632|BIOLOGICAL|DC-CIK Immunotherapy|
41456575|NCT05755854|DRUG|Cyclophosphamide|Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition
40963207|NCT00005814|BIOLOGICAL|cetuximab|
40963208|NCT00005814|DRUG|cisplatin|
40963209|NCT00005814|RADIATION|radiation therapy|
40963210|NCT02469298|DRUG|GSK1325756 (Danirixin)|It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
40963211|NCT02469298|DRUG|Placebo To Match GSK1325756|It will be supplied as capsule shaped white film coated placebo tablet for oral use
40963212|NCT02469298|DRUG|Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
40963213|NCT02469298|DRUG|Placebo To Match Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
40963214|NCT04372901|PROCEDURE|Digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
40963215|NCT04372901|PROCEDURE|Digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement.
40963216|NCT01389817|DEVICE|Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))|Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
40963217|NCT05776615|OTHER|mobile application|"In the collection of Mobile Application group data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Participants will be asked to provide nursing care using this application once a week for 3 months.Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month;  MıssCare Questionnaire in the Neonatal Intensive Care Unit(NICU); System Availability Scale will be applied."
40963218|NCT02347280|PROCEDURE|Loop Ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
40963219|NCT02347280|PROCEDURE|Total Abdominal Colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
40963220|NCT02267083|DRUG|GPX-150 for Injection|GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
41456576|NCT05755854|DRUG|Zoredronic acid|Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
41456577|NCT01824498|OTHER|Low Fat diet|Low fat diet = 20% fat
41456578|NCT01824498|OTHER|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
41456579|NCT01824498|OTHER|High Fat Diet|High Fat Diet = 40% fat
41456580|NCT00735696|BIOLOGICAL|Ramucirumab|10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
41456581|NCT00735696|DRUG|Paclitaxel|200 milligrams per meter squared (mg/m\^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
41456582|NCT00735696|DRUG|Carboplatin|Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
40765657|NCT06642987|DRUG|Vonoprazan Reference 20mg|1 tablets orally once a day
40765658|NCT05017103|BIOLOGICAL|Sintilimab|Given IV
40765659|NCT05406401|BIOLOGICAL|Zilovertamab Vedotin|IV infusion
40765660|NCT05406401|DRUG|Cyclophosphamide|IV infusion
40963221|NCT00439478|DRUG|Radioiodine|
40963222|NCT02787096|DEVICE|LaxIRM|Dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
40963223|NCT01673217|DRUG|decitabine|Given IV
40963224|NCT01673217|BIOLOGICAL|NY-ESO-1 peptide vaccine|Given SC
40963225|NCT01673217|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
40963226|NCT01673217|BIOLOGICAL|sargramostim|Given SC
40963227|NCT01673217|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
40963228|NCT01673217|OTHER|immunohistochemistry staining method|Correlative studies
40963229|NCT01673217|OTHER|liquid chromatography|Correlative studies
40963230|NCT01673217|OTHER|mass spectrometry|Correlative studies
40963231|NCT01673217|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
40963232|NCT01673217|OTHER|laboratory biomarker analysis|Correlative studies
40963233|NCT01673217|GENETIC|DNA methylation analysis|Correlative studies
40963234|NCT01673217|OTHER|enzyme-linked immunosorbent assay|Correlative studies
40963235|NCT01265368|BIOLOGICAL|MGN1601|Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
40963236|NCT05206578|DRUG|AGT2, AGZ|Tablet, q.d.
40963237|NCT05206578|DRUG|AGT2|Tablet, q.d.
41136678|NCT03964974|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
40765661|NCT05406401|DRUG|Doxorubicin|IV infusion
40765662|NCT05406401|BIOLOGICAL|Rituximab|IV infusion
40765663|NCT05406401|BIOLOGICAL|Rituximab Biosimilar|IV infusion
40963238|NCT05206578|DRUG|AGT4, AGZ|Tablet, q.d.
40963239|NCT05206578|DRUG|AGT4|Tablet, q.d.
40963240|NCT04561466|DRUG|Béfizal|600 mf befizal a day for one year
40963241|NCT00870883|DRUG|N-acetylcysteine and deferoxamine|N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
40963242|NCT03727529|OTHER|Treadmill + VR|Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
40963243|NCT03727529|OTHER|Treadmill|Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
40963244|NCT01849198|DEVICE|accelerometry m. trapezius and m. adductor pollicis|
40963245|NCT04333797|OTHER|Risk and Protective Factors Assessment|First assessment at baseline (T0) - 17 y.o. Follow-up 2 years later (T1) - 19 y.o.
40765664|NCT05406401|DRUG|Prednisone|IV or oral administration (per local guidelines)
40765665|NCT05406401|DRUG|Prednisolone|IV or oral administration (per local guidelines)
40765666|NCT06569472|BIOLOGICAL|CD19-targetd CAR-T|Subjects underwent lymphocyte clearance chemotherapy and then received a single intravenous cell infusion
40963246|NCT06241508|DEVICE|Transcranial magnetic stimulation|A standard 600-pulse TBS \[16\] will be administrated using a MagPro X100 stimulator (MagVenture, Denmark) and a 65-mm figure-of-eight coil. The measurement of the motor hotspot and individual RMT will be in accordance with our established methodology \[3, 9\]. For patients with stroke, the intensity of real stimulation will be 55% or 70% RMT of the unaffected M1 \[17\], depending on their assigned condition. Sham stimulation will be delivered using the same coil with 20% RMT of the unaffected M1 \[4, 6\]. The priming and conditioning sessions will be delivered to the ipsilesional M1 sequentially. In line with previous works, the interval between them will be 10 minutes \[2, 3\]. For healthy adults, the stimulation will be applied exclusively to the non-dominant (right) M1.
40963247|NCT03758209|PROCEDURE|Prehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
40963248|NCT03758209|PROCEDURE|ERAS|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
40963249|NCT03795623|OTHER|Voice-Weaning|Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
40963250|NCT03795623|OTHER|Sham control|Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
40963251|NCT06506448|DIAGNOSTIC_TEST|CT Coronary Angiography|CTCA for anatomical, physiological, plaque composition and inflammatory assessment of coronary arteries
40963252|NCT05570500|BEHAVIORAL|Oral health education|oral health education sessions that aims to improve both knowledge of primary school children regarding bacteria, caries, number of teeth, plaque formation and attitude of primary school children regarding tooth brushing techniques, number of times per day, dietary instructions to avoid dental caries.
40963253|NCT04653961|DEVICE|DreaMed Advisor Pro DSS-MDI algorithm|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
41294343|NCT02890771|PROCEDURE|SRP with turmeric massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
41294344|NCT06337851|OTHER|Simultaneous burr hole craniostomy|Patients in group-1 were fixed in supine position with their heads in neutral and flexion position. Bilateral burr holes were made one after another, the dural surfaces were exposed at the same time, then the outer membranes of both sides opened and hematomas evacuated simultaneously. All the patients underwent a drainage system, performed with the insertion of a silicone tube into the subdural space and tunneled under the scalp to the exit point.
41294345|NCT06337851|OTHER|Consecutive burr hole craniostomy|In group-2, hematoma with a greater thickness was removed first (if thickness was equal on both sides, first incision was made on the right side). The head in supine position was rotated to the side with a smaller hemorrhage thickness. Previously, burr holes were made, the dural surfaces were exposed, the outer membrane opened, and the hematoma was evacuated at one side. Then, drainage system inserted into the subdural space. After the procedure of the first side was completed, as a consecutive process, the head was rotated to the other side, and the same procedure was repeated. The contralateral hematoma was evacuated.
41294346|NCT04514367|DRUG|ANX005|Intravenous Infusion
41294347|NCT00020852|PROCEDURE|conventional surgery|
41294348|NCT00020852|PROCEDURE|cryosurgery|
41294349|NCT02922036|DEVICE|WiSE System|The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
41294350|NCT01568905|OTHER|Low level nicotine cigarette|smoke the study cigarette exclusively for one week
41294351|NCT01568905|OTHER|Intermediate nicotine level cigarette|smoke the study cigarette exclusively for one week
41294352|NCT01568905|OTHER|High level nicotine cigarette|smoke the study cigarette exclusively for one week
41294353|NCT02630277|DRUG|Aflibercept|Intravitreal Aflibercept Injection 2.0 mg
40765667|NCT06568172|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or plasma
40765668|NCT06568172|BIOLOGICAL|Cemiplimab|Given IV
40963254|NCT04527705|PROCEDURE|Non-surgical root canal retreatment|Non-surgical root canal retreatment
40963255|NCT05270343|DRUG|Cholecalciferol (Vit D3) 400Unit Cap|Each subject will take Vit D3 (400Unit Cap) with breakfast for 12 consecutive months, and the initial load will be 140IU/kg qd until the serum 25(OH)D3 is maintained at the upper limit of normal ( 50-80ng/ml\[125-200nmol/L\], ≤100ng/ml\[≤250nmol/L\]), then maintained at 70IU/kg qd, combined with intensive insulin therapy
41294354|NCT01396408|DRUG|Sunitinib|50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)
41294355|NCT01396408|DRUG|Temsirolimus|25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
40963256|NCT00884871|PROCEDURE|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
40963257|NCT02508181|DEVICE|I-gel|supraglottic airway device without cuff
40963258|NCT02508181|DEVICE|LMA Supreme|supraglottic airway device with cuff
41294356|NCT05131178|DEVICE|ON-Q Pump® with continuous infusion of bupivacaine|270 ml of 0.5 % bupivacaine. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
41294357|NCT05131178|DEVICE|ON-Q Pump® with continuous infusion of saline|270 mL of normal saline. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
41294358|NCT02965534|DEVICE|Spectacle/Glasses|
41294359|NCT00034112|PROCEDURE|osteopathic manipulative treatment|
41294360|NCT02703805|OTHER|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
41294361|NCT02703805|OTHER|Standard YMCA membership|A 12 week standard YMCA membership.
41294362|NCT00358189|DEVICE|Deep Brain Stimulation|
41294363|NCT01795040|DIETARY_SUPPLEMENT|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
41294364|NCT03338387|DRUG|Acipimox|Acipimox
41294365|NCT03338387|DRUG|Placebo|Placebo Other Names: Placebo (for Olbetam)
41294366|NCT04006743|BEHAVIORAL|The swaddling group|The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.
40963259|NCT00210483|DRUG|almotriptan malate|
40963260|NCT03781869|DRUG|Anlotinib Hydrochloride; etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1 and Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, repeated every 21 days
40963261|NCT03781869|DRUG|etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, repeated every 21 days
40963262|NCT01437462|DRUG|Sevoflurane|Sevoflurane inhalation anesthesia, sufficient amount to maintain adequate general anesthesia for surgery
40963263|NCT01437462|DRUG|Propofol|Propofol intravenous anesthesia, sufficient amount to maintain adequate anesthesia during surgery
40963264|NCT02054260|DRUG|Surgicel|
40765669|NCT06568172|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
40765670|NCT06568172|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
40765671|NCT06568172|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40765672|NCT06568172|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40765673|NCT06568172|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40765674|NCT06568172|OTHER|Questionnaire Administration|Ancillary studies
40765675|NCT06568172|PROCEDURE|Surgical Procedure|Undergo surgery per SOC
40765676|NCT06568172|PROCEDURE|Surgical Procedure|Undergo response-adaptive surgery
40765677|NCT05268367|BEHAVIORAL|Written Exposure Therapy|A brief exposure-based psychotherapy for posttraumatic stress disorder
40963265|NCT03533543|DEVICE|CEM|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
40963266|NCT02657915|DRUG|Placebo|Administered as specified in the treatment arm.
40963267|NCT02657915|DRUG|BIIB033 100mg/Kg|Administered as specified in the treatment arm.
40963268|NCT04380415|DIAGNOSTIC_TEST|Single lead ambulatory ECG patch|Single lead ambulatory ECG patch worn on the chest
40963269|NCT03859505|DEVICE|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated in a single session and they will receive a total dose of 0 J.
40963270|NCT03859505|DEVICE|Active PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated in a single session and will receive a total dose of 220.05 J.
40963271|NCT02887638|OTHER|Individual Profile Analysis (Physical therapy Intervention)|"The Individual Profile Analysis consists of the following components:~* Analysis of the sitting-posture profile:~  o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~* Analysis of the dural profile before and after the provoking task:~  o Determination of the dural sensitivity by the use of the slump-test~* Analysis of the pain profile before and after the provoking task:~  * Determination of pressure pain sensitivity by the use of pressure algometry~ * Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire"
40963272|NCT03855969|PROCEDURE|Removal of a central venous access device|We are interested in those patients for which a central venous access device was removed.
40963273|NCT02359760|PROCEDURE|Piezocision|Flapless corticotomies
40963274|NCT05314751|BEHAVIORAL|Questionnaire and interview|An online survey and an in-depth interview.
40963275|NCT02295384|OTHER|Retrospective Audit|Retrospective Audit
40765678|NCT02287779|DRUG|SHP626|
40963276|NCT00002914|DRUG|piritrexim|
40963277|NCT03274024|DEVICE|Ahmed Glaucoma Implant|Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube
40963278|NCT03274024|PROCEDURE|Trabeculectomy with Mitomycin C|Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure
41136679|NCT03136822|OTHER|Standard Dressing|Standard dressing is applied for treatment of diabetic foot ulcers
40765679|NCT02287779|DRUG|Placebo|
40963279|NCT05829304|OTHER|MTA based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
40963280|NCT05829304|OTHER|Collagen based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
40963281|NCT02044705|BEHAVIORAL|Active and Healthy Families|Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
41294367|NCT04006743|BEHAVIORAL|The expressed breast milk group|In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
40963282|NCT00481078|DRUG|vorinostat|Given PO
41136680|NCT03136822|DEVICE|DERMALIX|DERMALIX, a class III Medical Device will be applied in addition to standard dressing
40765680|NCT06638775|OTHER|Fesia Grasp|The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
40765681|NCT06638775|OTHER|GLOBUS ELITE|is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
40765682|NCT05051345|OTHER|Informational Intervention|Receive information on the services provided for pregnant women and smoking cessation
40963283|NCT00481078|DRUG|paclitaxel|Given IV
41136681|NCT01535898|OTHER|MRI scanner with sequence|The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
41136682|NCT01579799|DRUG|L-lysine|Dose finding study for L-lysine
41136683|NCT00223600|BEHAVIORAL|Nutritional and life style counseling|
41136684|NCT00958048|DEVICE|non-invasive ventilation|CPAP, BiPAP
41136685|NCT00346320|RADIATION|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
40963284|NCT00481078|DRUG|carboplatin|Given IV
40963285|NCT00481078|OTHER|placebo|Given PO
40963286|NCT00481078|OTHER|laboratory biomarker analysis|Correlative studies
40963287|NCT03990454|DRUG|SLC-391|SLC-391 is an AXL inhibitor
40963288|NCT01299740|BEHAVIORAL|Participation in DBT Skills Group|Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.
40963289|NCT01299740|OTHER|Control Group|Treatment as usual
40963290|NCT04219657|BIOLOGICAL|mesenchymal stem cell application|
40963291|NCT02587260|DRUG|Ticagrelor|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
40963292|NCT02587260|DRUG|Prasugrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
40963293|NCT02587260|DRUG|Clopidogrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
40963294|NCT06049862|BEHAVIORAL|MaRiTensi App|"MaRiTensi is a mobile health-based hypertension self-management application used on Android smartphones.~MariTensi provides facilities for recording blood pressure, BMI, activity, examination results, education about hypertension, consultations, reminders and community chat."
40963295|NCT00713323|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
40963296|NCT01335191|BIOLOGICAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
40963297|NCT01335191|OTHER|Placebo|Two subcutaneous injections of Placebo at Day 0 and Week 3.
40963298|NCT03738683|DRUG|Piperacillin/tazobactam|Dose according to summary of product characteristics (SPC) or local protocols
40963299|NCT00415662|DEVICE|Pulsed Signal Therapy (PST)|
40963300|NCT05909748|DEVICE|GEMINUS Transcatheter Aortic Valve Implantation system|Implantation of the GEMINUS Transcatheter Aortic Valve Implantation system
40963301|NCT00041483|DRUG|Anecortave Acetate 15 mg sterile suspension|
40963302|NCT00041483|OTHER|Photodynamic Therapy (PDT)|
40963303|NCT01796561|DIETARY_SUPPLEMENT|Olive leaf extract liquid|Commercially available polyphenol-rich olive leaf extract liquid
40963304|NCT04175483|OTHER|assessment of subglottic diameter by ultrasonography|assessment of subglottic diameter by ultrasonography
40963305|NCT01651377|DRUG|Pramipexole|Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
41136686|NCT02208843|DRUG|Afatinib|Afatinib tablet once daily until progression
41456583|NCT04827251|DIETARY_SUPPLEMENT|Coffee|"Participants will receive Nespresso coffee maker Essenza model. The coffee Nespresso blend voluto will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over)."
40963306|NCT01651377|DRUG|Placebo|Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
41136687|NCT00000388|BEHAVIORAL|Psychosocial treatment|
40963307|NCT02021331|DEVICE|immediate implant placement without provisionalization|
40963308|NCT02021331|DEVICE|immediate implant placement with immediate provisionalization|
40963309|NCT00495365|DRUG|Epoetin alfa|
40963310|NCT03415334|BEHAVIORAL|behavioral development for change|"1. Social Marketing Principles (4 Ps) Product, price, place and promotion~2. Communication for Behavior Development Approach 1. Interpersonal communication campaigns (IPC) 2. Mass media and public gathering awareness campaigns 3. Public health awareness campaigns 4. A village hotline and local satellite channel 5. School awareness raising events"
40963311|NCT04802291|BEHAVIORAL|HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood|Comparison of 2 educational interventions
40963312|NCT00402415|DRUG|Sunitinib malate|C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off
40963313|NCT00402415|DRUG|Rapamycin|"Dose escalation until MTD as follows:~C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly"
41136688|NCT00000388|DRUG|Anti-ADHD medication|
41136689|NCT00000388|BEHAVIORAL|Assessment-and-Referral|
41136690|NCT01073761|DRUG|darunavir/ritonavir then atazanavir/ritonavir|"Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days"
41136691|NCT01742494|PROCEDURE|Water-jet POEM|Water-jet assisted POEM procedure was performed
41294368|NCT04006743|BEHAVIORAL|The facilitated tucking group|Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.
40963314|NCT00834171|DRUG|Loteprednol etabonate ophthalmic suspension 0.5%|Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician
40963315|NCT00834171|DRUG|Loteprednol etabonate (0.5%) and tobramycin (0.3%).|Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
40963316|NCT05357313|DEVICE|Bright light therapy|Exposure to 10,000lux bright light for 30minutes a day for six weeks
40963317|NCT05357313|DEVICE|Inactive negative ion generator|Exposure to an inactive negative ion generator for 30 minutes a day for six weeks
40963318|NCT06556316|BEHAVIORAL|Cognitive Intervention with the Categorization Program|Cognitive intervention delivered individually. This is a hierarchical cognitive rehabilitation program
40963319|NCT06556316|BEHAVIORAL|Social Cognitive Communication Program|An 11 week group intervention targeting social and cognitive-communication abilities
40963320|NCT06556316|DEVICE|Non-Invasive Brain Stimulation with tDCS|20 minute tDCS intervention as a non-invasive neuromodulation treatment
40963321|NCT06504836|OTHER|Gait training with biofeedback|Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
40963322|NCT06504836|OTHER|Gait training without biofeedback|Gait training include treadmill and overground walking.
40765683|NCT05051345|OTHER|Informational Intervention|Receive tobacco cessation self-help materials
40765684|NCT05051345|OTHER|Informational Intervention|Receive Smoke-Free Homes mailings
40765685|NCT05051345|OTHER|Media Intervention|Download and use the Wellness app
40963323|NCT02221947|DRUG|Bryostatin 1|25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.
40963324|NCT02221947|DRUG|Placebo|Placebo, single dose via intravenous infusion over 1 hour.
41136692|NCT01742494|PROCEDURE|Conventional POEM|POEM were performed by the use of conventional technique using injection and triangle tip knife.
41136693|NCT02843100|OTHER|Modified Exclusive Enteral Nutrition|Two weeks of Exclusive Enteral Nutrition with Modulen
41136694|NCT02843100|OTHER|Crohn's Disease Exclusion Diet|a limited whole food diet
41294369|NCT04006743|BEHAVIORAL|The swaddling and expressed breast milk group|Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
41456584|NCT04013750|OTHER|Modified Constraint Induced Movement Therapy|constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
40765686|NCT05051345|OTHER|Questionnaire Administration|Ancillary studies
40765687|NCT05051345|BEHAVIORAL|Smoking Cessation Intervention|Receive Smoke-Free Homes kit
40765688|NCT05051345|OTHER|Survey Administration|Ancillary studies
40765689|NCT05051345|BEHAVIORAL|Telephone-Based Intervention|Receive telephone counseling sessions
40765690|NCT05051345|BEHAVIORAL|Telephone-Based Intervention|Receive a coaching call from a Baby Steps for Health counselor
40765691|NCT05051345|OTHER|Tobacco Cessation Counseling|Receive telephone counseling sessions
40765692|NCT01048853|PROCEDURE|Lymph Node Mapping|Undergo lymphatic mapping with sentinel lymph node biopsy
40765693|NCT01048853|OTHER|Quality-of-Life Assessment|Ancillary studies
40765694|NCT01048853|PROCEDURE|Salpingo-Oophorectomy|Undergo hysterectomy with or without salpingo-oophorectomy
40963325|NCT03971214|DRUG|PD-1 inhibitor JS-001|The extensive-stage SCLC patients will receive PD-1 inhibitor treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
40963326|NCT03484091|DRUG|Hyruan-One|single dose intra-articular injection
40963327|NCT03484091|DRUG|Hylan G-F 20|single dose intra-articular injection
40963328|NCT03484091|DRUG|Normal saline|single dose intra-articular injection
40963329|NCT06506344|BEHAVIORAL|5S Trial|Participants will receive caring contacts/recruitment outreach, suicide risk screening, suicide safety planning, and, if indicated, connection to healthcare services, resources and the CLASP virtual outreach intervention.
40765695|NCT01048853|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo lymphatic mapping with sentinel lymph node biopsy
40765696|NCT01048853|PROCEDURE|Therapeutic Conventional Surgery|Undergo hysterectomy with or without salpingo-oophorectomy
40765697|NCT00220077|PROCEDURE|Endoscopy|
40765698|NCT06637410|DEVICE|High intensity laser therapy|HILT was performed by a single physiotherapist experienced in using a laser device. During HILT application, the patients were seated comfortably on chairs and their shoulders were in neutral position. The wavelength of the laser light used was 1064 nanometers. In the HILT group, the device was used on the rotator cuff muscles in two stages: phase I and phase II. Pulse method was used in phase I for analgesic effect. A standard frequency of 25 Hz is applied. During the first four therapy sessions, it was aimed to provide an analgesic effect by using 8 W power and 12 J/cm dose. The rays were applied to the rotator cuff muscles area in a circle from outside to inside for 2.5 minutes, for a total energy of 300 J, on an area of 25 cm2. For the biostimulation effect, the continuous wave method was used in phase II. n the next five sessions, biostimulation effect was applied using 7W power. A dose of 100 J/cm was applied longitudinally to the rotator cuff muscles.
40765699|NCT06637410|DEVICE|Ultrasound therapy|US therapy was performed by a single physiotherapist experienced in using US device. Calibration and control of the device are performed regularly. During US therapy, the patients were seated comfortably on chairs and their shoulders were in neutral position. The standard US dose was 1.2 W/cm2. The duration of ultrasound was 8 minutes. Using slow circular movements, the physiotherapist applied the transducer head of US device over the shoulder joint on an area of 25 cm2. US device was used in pulsed mode at a frequency of 1 MHz. The therapeutic ultrasound pulse cycle was 50%.
40765700|NCT06637410|OTHER|Therapeutic Exercise|ROM exercises and Codman exercises, in a level not to increase the severity of the pain of the patient, were given and stretching and strengthening exercises were taught to the patients. They performed these exercises daily in two sets with five repeats in each set underCalibration and control of the device are performed regularly.
40765701|NCT01197300|DRUG|Zoledronic acid|intravenous infusion
40765702|NCT06639646|DIETARY_SUPPLEMENT|Probiotics supplements|"A Dietary intervention group receiving health education message about healthy diet and probiotics supplements ( spores of poly antibiotic resistant Lactobacilli 5 billion in form of capsules registrated by the Egyption drug auyjority EDA and sold in Egyption markets under brand name Lactèol Forte ® capsules by Rameda® company.~The probiotic supplement is recommended to be given twice daily for 12 wks duration."
40765703|NCT06639646|DIETARY_SUPPLEMENT|Health diet|A Control group receiving health education about healthy diet. At the end of the 12 wk. period, the same measurements are repeated
40963330|NCT01524471|PROCEDURE|Per Oral Endoscopic Myotomy|
40963331|NCT04925362|OTHER|Biological specimens|"Biological specimens are collected to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis :~* added for the research : blood, urine, stools~* collected for the research : liver tissue sample, if a liver biopsy is indicated for clinical reasons (standard of care)"
41136695|NCT02843100|OTHER|Partial Enteral Nutrition|25-50% of Energy from formula
41136696|NCT02843100|OTHER|Standard Exclusive Enteral Nutrition|8 weeks of Exclusive Enteral Nutrition
41136697|NCT05161000|OTHER|Oral Nutritional Supplement|ONS plus dietary counseling
41136698|NCT05161000|OTHER|Dietary counseling|dietary counseling
40765704|NCT03757663|BEHAVIORAL|UV Counseling|Participants will self-report their knowledge and attitudes related to UV exposure. They will then wear a dosimeter for 3 weeks. After, the study team will counsel the participants on their UV levels and exposure, creating a personal plan and advice for avoiding sun exposure before letting the participants wear the dosimeter for an additional 3 weeks.
40765705|NCT06641895|GENETIC|BBM-D101|BBM-D101 is a recombinant adeno-associated virus vector-based gene therapy for DMD treatment. It is a suspension for single intravenous (IV) infusion.
40963332|NCT04925362|OTHER|Additional visit|Visits if possible during standard care, otherwise added by the research (If necessary the annual visit will be added by research for the collection of biological samples)
40963333|NCT05139238|DRUG|Labetalol|Intravenous labetalol, a short acting ant-hypertensive
40963334|NCT05139238|DRUG|Nifedipine|Oral nifedipine, a short acting ant-hypertensive
40963335|NCT01212315|DEVICE|Triclosan coated sutures|Subcutaneous and cutaneous sutures coated with triclosan (Vicryl Plus / Monocryl Plus) are used to close the incisions after vein harvesting and sternotomy. All wounds are inspected before discharge from hospital and the patients are instructed to contact the study coordinator if any suspected infection occurs. In addition, all patients are controlled after thirty days by a nurse and contacted by telephone sixty days after surgery to assess postoperative infections by a predefined questionnaire. Infection symptoms are graded according to the Asepsis score and the CDC classification. Patient records including bacterial cultures and antibiotic treatment are collected for all patients with suspected infections.
40963336|NCT05618366|DRUG|Venetoclax|Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.
40765706|NCT03923270|DRUG|Durvalumab|Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.
40765707|NCT03923270|DRUG|Tremelimumab|Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.
40765708|NCT03923270|DRUG|Olaparib Pill|Participants in arm C will be self-administer 300 mg of Olaparib orally.
40963337|NCT05618366|DRUG|Tazemetostat|Tazemetostat 800mg taken orally, twice daily.
41136699|NCT00850915|OTHER|community IPT|"In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.~In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.~All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB."
41136700|NCT04869605|DIAGNOSTIC_TEST|1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin ratio|the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes
41136701|NCT03068988|BIOLOGICAL|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
41136702|NCT03068988|PROCEDURE|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
41136703|NCT05139615|DRUG|APD418|Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
41136704|NCT05139615|DRUG|APD418|Participants will receive a single dose of APD418 as an IV infusion.
41136705|NCT05139615|DRUG|Placebo|Participants will receive a single dose of APD418 matching placebo as an IV infusion.
41136706|NCT03705572|DIETARY_SUPPLEMENT|Lacprodan PL20|Milk protein concentrate that is high in phospholipid content (min 16%).
41136707|NCT03705572|OTHER|Placebo|Placebo milk drink.
41456585|NCT03367260|OTHER|Preference Elicitation|Survey of patient preferences for treatment
41456586|NCT03750591|DRUG|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
40765709|NCT03923270|RADIATION|Thoracic Radiotherapy|Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions
40963338|NCT04568070|DIAGNOSTIC_TEST|mini-BESTest (Mini-Balance Evaluation Systems Test)|Balance evaluation test that has 14 tasks leading to a total possible score of 28 points requires only 10 to 15 minutes to conduct.
40963339|NCT04568070|DIAGNOSTIC_TEST|Berg Balance Scale|The scale is a 14-item objective measure designed to assess static balance and fall risk in adult populations.
40963340|NCT04568070|DIAGNOSTIC_TEST|Timed Up and Go Test|It is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
40963341|NCT04568070|DIAGNOSTIC_TEST|Functional Reach Test|The Functional Reach Test is a single item test developed as a quick screen for balance problems in older adults. A score of 6 or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls.
40963342|NCT00253227|DRUG|galantamine hydrobromide|
40963343|NCT01513343|BEHAVIORAL|Parent and child groups focused on self-regulation of eating|
40963344|NCT04661839|BIOLOGICAL|COVID-HIGIV|COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.
40963345|NCT04661839|OTHER|Placebo (saline)|The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion.
41136708|NCT01676298|DEVICE|Spartan FRX CYP2C19 Test System|
41136709|NCT02216084|DRUG|Recombinant ADAMTS13|"rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3)."
40765710|NCT03923270|DRUG|Tremelimumab|Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose
40963346|NCT04382339|DRUG|SOF/RBV/PegINFα-2|SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
41456587|NCT03750591|PROCEDURE|Chuna manual therapy|"Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.~Chuna manipulation will be administered at the physician's discretion."
41456588|NCT03750591|PROCEDURE|Bee venom pharmacopuncture|"Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test.~Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea)."
41456589|NCT03750591|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea).
41456590|NCT03750591|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41456591|NCT03750591|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41456592|NCT03750591|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
41456593|NCT03750591|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
41456594|NCT02988882|DRUG|Dexamethasone|
41456595|NCT02988882|OTHER|Placebo Vehicle|
40765711|NCT04078373|BEHAVIORAL|Immediate urination|Patients with decreased cognitive ability will be taught to immediately go to the toilet upon feeling the urge to urinate and to be independent in urinating.
40765712|NCT04078373|BEHAVIORAL|Bladder diary|Patients with normal cognitive abilities will be instructed to go to the toilet every 2-3 hours regardless of the urge to urinate
40765713|NCT05421494|BEHAVIORAL|written exposure therapy-revised version|WET-R is a manualized exposure-based therapy program consisting of 5-7 sequential individual sessions. The interval between every 2 consecutive sessions is 0-3 days. There will be 5-7 one to one online sessions in total (only one index trauma will be discussed), and 1-3 weeks to complete. Sessions are scheduled to last for 1 hour in the first session and 50 minutes in other sessions.
41136710|NCT01827761|BEHAVIORAL|Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
41456596|NCT06255145|DEVICE|Bioelectrical Impedance Analysis|"Bioelectrical Impedance Analysis Beurer BF 1000 Super Precision device was used to measure the body composition of the participants. Operating on the principle of BIA, the device allows the body composition to be evaluated by giving an imperceptible electric current to the body.~Fatigue Severity Scale (FSS) Fatigue Severity Scale (FSS) was used to measure participants' fatigue levels. Rivermead Mobility Index Rivermead Mobility Index (RMI) was used to assess the mobility levels of the participants.~Functional Independence Measure Functional Independence Measure (FIM) was used to evaluate the functional status of the participants."
41456597|NCT03645616|DIAGNOSTIC_TEST|6-minute walk test|"First day: Participants undertook 6-minute walk test. There was a 30-minute interval between the first and second test, when the patient was asked to rest. During the resting period, they respond a pain intensity, functional capacity and physical activity level questionnaire.~Second day: the participants repeated the test and questionnaires."
40765714|NCT05421494|BEHAVIORAL|minimal contact control|Participants assigned to MCC will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 3-week MCC period. They will be video-called once per week by a therapist to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MCC participants will also be given contact information to use in case of worsening symptoms or increasing distress.
40765715|NCT06240754|DRUG|Enasidenib|Provided by BMS.
40765716|NCT06636708|COMBINATION_PRODUCT|Nanodropper and Proparacaine HCl 0.5%|The Nanodropper is an eyedrop bottle adaptor that creates smaller eyedrops by coupling to an existing eyedrop bottle. This intervention involves the administration of proparacaine HCl 0.5% using the Nanodropper.
40765717|NCT06636708|COMBINATION_PRODUCT|Standard Eye Drop Bottle with Proparacaine HCl 0.5%|This intervention involves administration of proparacaine HCl 0.5% using a standard eye drop bottle.
40765718|NCT06331468|DRUG|Cisplatin|A total of two IV infusions of cisplatin will be administered on Day 1 and again on Day 8 +/- 1 day. Cisplatin starting dose is 40 mg/m2. Dose reduction is allowed (30 mg/m2) as needed for management of toxicities.
40765719|NCT06331468|RADIATION|intensity modulated radiation therapy (IMRT)|given once daily Monday-Thursday, four fractions per week for 2 weeks. The radiation dose is 4.56 Gy x 8 fractions.
40963347|NCT01565512|DRUG|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
41294370|NCT04006743|BEHAVIORAL|The facilitated tucking and expressed breast milk group|Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
40963348|NCT01565512|DRUG|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
40963349|NCT02312102|DRUG|Lenalidomide|Chemotherapy
40963350|NCT02312102|DRUG|Velcade|Chemotherapy
40963351|NCT04052347|BEHAVIORAL|Shared decision-making with a Decision-aid|A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9
40963352|NCT04052347|BEHAVIORAL|routine shared decision-making|control group
40963353|NCT03964623|DIAGNOSTIC_TEST|OCT-A (Optical Coherence Tomography)|Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception
40963354|NCT01435369|DRUG|CT-011|The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
40963355|NCT03068260|DRUG|Ropivacaine|30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks
40963356|NCT03068260|DRUG|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
40963357|NCT03068260|DRUG|Acetaminophen|1 g orally administered postoperatively
40963358|NCT03068260|DRUG|Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet|orally administered postoperatively
40963359|NCT03068260|DEVICE|ultrasound-guided nerve block|Transmuscular quadratus lumborum block, ultrasound-guided
40963360|NCT03068260|DRUG|Morphine|intravenously administered morphine via PCA-pump
41136711|NCT01903902|DEVICE|SeQuent® Please Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length \< 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
41136712|NCT04943445|DRUG|carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles|Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.
41136713|NCT04943445|RADIATION|Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.|Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.
41136714|NCT04943445|DRUG|Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.|Consolidation immunotherapy
41136715|NCT01341769|OTHER|Dietary Intervention|
41136716|NCT01341769|OTHER|Dietary Intervention|
40765720|NCT06331468|RADIATION|high-dose-rate (HDR) brachytherapy|administered 2x weekly (allow at least 72-hours window between sessions); weekdays only for 2 weeks. The radiation dose is 7 Gy x 4 fractions.
40963361|NCT03068260|DEVICE|Patient-controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
40963362|NCT04458883|PROCEDURE|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging - Cardiac Scan
40963363|NCT04458883|PROCEDURE|Fast Field Cycling - Magnetic Resonance Imaging|Fast Field Cycling - Magnetic Resonance Imaging Cardiac Scan
40963364|NCT04458883|PROCEDURE|Electrocardiogram|Electrocardiogram
40963365|NCT04458883|PROCEDURE|Echocardiogram|Echocardiogram
40963366|NCT00488462|DEVICE|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
40963367|NCT00795496|PROCEDURE|Histamine provocation|A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
40963368|NCT00795496|PROCEDURE|Skin prick tests|Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
41136717|NCT01341769|OTHER|Dietary Intervention|
41136718|NCT01341769|OTHER|Dietary Intervention|
41136719|NCT02659540|DRUG|Nivolumab|Nivolumab was administered as an intravenous (IV) infusion over approximately 30 or 90 minutes, with dosing calculated using body weight.
41136720|NCT02659540|DRUG|Ipilimumab|Ipilimumab was administered as an IV infusion over approximately 30 or 90 minutes, with dosing calculated using body weight. The ipilimumab infusion was initiated approximately 30 minutes after the end of the nivolumab infusion on applicable dosing days.
41136721|NCT02659540|RADIATION|Radiotherapy|RT was delivered in accordance with cohort assignment and institutional practices.
40963369|NCT00795496|PROCEDURE|Serum IgE blood testing|One blood test to measure total serum IgE
40963370|NCT00795496|PROCEDURE|Mantoux-testing|Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
40963371|NCT06321783|OTHER|Assessment|Evaluation of cervical proprioception, hand-eye coordination, postural control and endurance of cervical muscles
40963372|NCT03021941|DRUG|Elelyso 60 units/kg|All patients receive Elelyso 60 units/kg.
40963373|NCT03342365|DIAGNOSTIC_TEST|Evaluation of microbial translocation and microbiota|Blood test from catheter already in place to determine microbial translocation and stool sample taken for microbiota analysis
40963374|NCT04806997|DIAGNOSTIC_TEST|Vascular occlusion test|The VOT procedure was conducted twice in each patient, before and 15 min after intrathecal injection. An NIRS sensor (INVOSTM 5100C Cerebral/Somatic Oximeter; Medtronic, Minneapolis, MN, USA) was attached to the patient's gastrocnemius muscle. A tourniquet (A.T.S ® 3000 Automatic Tourniquet System; Zimmer Inc., Warsaw, IL, USA) was applied to the thigh and inflated to a pressure value 50 mmHg over the patient's baseline systolic blood pressure in the leg and maintained for 5 min. After a 5-min ischemic period, the tourniquet was rapidly deflated to 0 mmHg. The StO2 data was continuously recorded during the VOT procedure. After confirmation of spinal anesthesia using cold sensitivity, the VOT procedure was repeated in the same manner as mentioned above. The occlusion slope and recovery slope were calculated based on the measured StO2 data.
40963375|NCT00903396|DRUG|palonosetron hydrochloride|Given IV
40963376|NCT00903396|OTHER|placebo|Given IV
41136722|NCT00779805|DRUG|Pseudoephedrine hydrochloride 120 mg ER tablets|
41136723|NCT05847452|DRUG|Benralizumab|30mcg ever month for 3 months
41136724|NCT05958537|DEVICE|High flow nasal oxygen|Use of High-flow nasal oxygen at 60% 50 L/min.
41294371|NCT03912571|DIAGNOSTIC_TEST|Structural 3T MRI|measures of global and hippocampal atrophy)
40963377|NCT00900965|DEVICE|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
41456598|NCT03645616|DIAGNOSTIC_TEST|10 meters walk test|"First day: After the second 6-minute walk test the participants perform the 10-meter walk test, the test must be performed three times with a 30-second interval, at the end the average test velocity.~Second day: the participants repeated the test."
40963378|NCT00900965|DEVICE|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
40963379|NCT06557070|OTHER|The Emotional Freedom Technique|Emotional freedom technique (EFT) is a method to help manage emotions and troubling thoughts and lower stress and anxiety. EFT is applying by tapping. To do EFT, you tap your fingertips on certain points on your hand, head, and torso which are used in acupuncture.
40963380|NCT04752475|DRUG|Furosemide|Furosemide 20 mg pill taken daily for 5 days
40963381|NCT04752475|OTHER|Placebo|Identical-appearing placebo pill taken daily for 5 days
40963382|NCT03791489|DEVICE|ClariFix|The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
40963383|NCT04157491|DRUG|anlotinib and anti PD-1 antibody|Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
40963384|NCT03646318|DRUG|Ketanserin|"The dose of 0.75 ug/kg/min is a dose that has been used frequently in critically ill patients. The concentration of the study drug infusion will be 40 mg/40 ml glucose 5%. The maximum dose however will be 4.5 mg per hour for patients with a weight more than 100 kg. The pre-filled 50 ml syringes will be filled with 40 ml of a solution containing 40 mg ketanserin or 0 mg ketanserin in glucose 5%.~The minimum number of ketanserin vials (2 ml with 5 mg/ml) that are needed is 240 (40 mg = 4 vials per patient). Duration of intervention: 8 hours"
40963385|NCT03646318|OTHER|Placebo|Glucose 5% solution
40963386|NCT04963335|BEHAVIORAL|Exergame Training|The individualized exergames were designed for a pressure sensitive plate connected to a personal computer and a frontal screen. The pressure-sensitive plate allows a precise analysis of the user's movements. This concurrent motor-cognitive training aims to improve motor and cognitive functions in an ecological valid setting. The cognitive functions are triggered by specific stimuli in the game scenarios. The video games are controlled via specific (whole body) movements as steps, weight shifting, jumps, and arm movements. The training focus is mainly on multi-tasking, balance and coordination as well as executive functions and attention. Furthermore, the meaningful games (colorful and appealing visuals) were designed to motivate the players to move. As the exergame will automatically adapt (individual progression) during play time, participants are challenged at their individual motor and cognitive level.
41136725|NCT03941106|DEVICE|Accelerated repetitive transcranial magnetic stimulation|Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
41136726|NCT03830151|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
41136727|NCT03830151|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
41136728|NCT04031794|DEVICE|Extra Corporeal Membrane Oxygenator (ECMO)|Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.
41294372|NCT03912571|DIAGNOSTIC_TEST|MRI Based Perfusion Imaging|brain blood flow
41456599|NCT03645616|DIAGNOSTIC_TEST|30 Second Sit to Stand Test|At the end of the tests the participants perform the 30 Second Sit to Stand Test on the first and second day.
40963387|NCT01795209|DRUG|Ranibizumab|"Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg~Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
41136729|NCT03776604|DRUG|PEG-rhG-CSF|"Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were \<45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
41136730|NCT01415206|BEHAVIORAL|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
41294373|NCT03912571|DIAGNOSTIC_TEST|VR-CO2 MRI Scans|reduced vaso reactivity to carbon dioxide
41294374|NCT05515549|OTHER|Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers|"The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group."
41294375|NCT04838444|BIOLOGICAL|VLA1553|Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.
41456600|NCT02542462|DRUG|Rotarix®,|Single oral dose of licensed rotavirus vaccine given alone
41456601|NCT02542462|DRUG|Rotarix®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
41456602|NCT02542462|DRUG|RotaTeq®,|Single oral dose of licensed rotavirus vaccine given alone
41456603|NCT02542462|DRUG|RotaTeq®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
41456604|NCT03709953|DRUG|Apatinib|500 mg，po，QD； 28 days every cycle
40963388|NCT01795209|DEVICE|Sham injection|"Three monthly sham injections followed by retreatment (sham injections) as needed~Stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
40963389|NCT01795209|PROCEDURE|Rescue laser|"In the Lucentis group: performed if BCVA \< 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA \< 20/40 or CFT ≥ 350um from Month 3"
40963390|NCT00804284|BIOLOGICAL|DTaP-IPV/Hib|0.5 mL, Intramuscular
40963391|NCT00804284|BIOLOGICAL|Other DTap Vaccines|0.5 mL, Intramuscular
40963392|NCT03336671|PROCEDURE|Endoscopic Sinus surgery|Endoscopic sinus surgery would be tailored to abnormal findings in the CT scan, as is the standard of care. Radiologists typically examine sinonasal disease of the sinuses, and they would also be requested to comment on the patency of the osteo-meatal unit, as this is a component of the Lund-McKay score. The Lund-McKay score is an objective radiologic grade of the severity of sinusitis. If there is sinus thickening, or narrowing of the OMU, endoscopic sinus surgery would be tailored to this using either balloon sinuplasty or traditional antrostomy. Patient undergoing endoscopic sinus surgery will likely have at least a maxillary antrostomy and anterior ethmoidectomy performed, with frontal sinusotomy, posterior ethmoidectomy, and sphenoidotomy performed depending on CT or endoscopy findings.
40963393|NCT03336671|PROCEDURE|Adenoidectomy|Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
40963394|NCT04550208|OTHER|3D analysis of different landing tasks|General as well as more sport-specific landing tasks are investigated with 3D analysis by using an opto-electronic system
40963395|NCT04767568|DIAGNOSTIC_TEST|Blood sample|"In cohort A: Blood sample n°1 (PBMC, plasma, ctDNA) previous colonoscopy. If no cancer lesions: STOP. If cancer lesion detected : Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery.~In cohort B: Blood sample n°1 (PBMC, plasma, ctDNA) collected before surgery. Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery"
40963396|NCT04767568|OTHER|Tumor tissue|In each cohort, tumor tissue will be collected from the surgical specimen.
40963397|NCT04767568|OTHER|stool collection|In cohort B: Stool sample n°1 collected before surgery. Stool sample n°2 collected 1 month after surgery
40963398|NCT05230303|DIETARY_SUPPLEMENT|Caffeine supplementation|Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
40963399|NCT05230303|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
40963400|NCT06145672|PROCEDURE|follicular unit extraction and implantaion|extract hair follicles as grafts from donor area and implant them in recipient area
41294376|NCT01847638|DRUG|Prolensa (bromfenac 0.07%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
40963401|NCT05907876|OTHER|Functional Test|UULEX uses a table of horizontal parallel lines with 8 levels. Each level is 84 cm wide and 8 cm high. The distance between the levels is 15 cm. The subject is seated on a straight chair with his/her feet on the floor facing the wall with the UULEX table. He/she holds a bar weighing 0.2 kg and lifts the bar at hip level. Keeping his/her arms shoulder-width apart, he/she raises the bar to different levels of the chart. As a warm-up, he/she is instructed to raise the bar to the first level and hold this position for 2 minutes. Then the bar is moved to each level and the levels are increased for 1 minute. The starting and ending point of each level is the hip joint. As the exercise progresses each minute, the weight of the bar is increased by 0.5 kg up to a maximum of 2 kg. During the test, a subject can move up to a maximum of a 2kg bar in a maximum of 12 minutes. The subject is instructed to continue the test until limited by the occurrence of symptoms.
40963402|NCT05717920|DRUG|Part 1 ADX-629 (Open-label)|ADX-629 (250 mg) administered BID for 90 days
40963403|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation A
40963404|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation B
40963405|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation B
40963406|NCT05984966|BEHAVIORAL|Supported Employment|PeerC2T is part of a supported employment program where PWID are trained and supported to provide PWID with job skills to be able to act as Peer Health Worker to facilitate distribution of rapid SARS-CoV-2 testing to other PWID. The effect of the training on the Peer Health Worker themself will be evaluated (Aim 1). In addition, in Aim 2 they will distribute the rapid test kits in places of residence such as tents, shelters, apartments, trailers, or houses or locations where other PWID frequently engage with services such as syringe exchange. The kit is the BinaxNOW COVID-19 Antigen Self Test, which is approved to be used as a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. PWID community members will be offered a free test kit, and the Peer Health Worker will record whether the community member elected to take the test (yes/no), and they will also collect administrative demographic data on the PWID.
40963407|NCT05813951|DRUG|Linezolid|linezolid either continues infusion or standard intermittent dose
40963408|NCT01858389|DRUG|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
41294377|NCT01847638|DRUG|Ilevro (nepafenac 0.3%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
41456605|NCT01156987|DEVICE|Magnetic resonance imaging|"Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~* an IV line is placed by nurse,~* patient is placed in the 4 T MRI scanner at CMRR,~* initial scout images and manual linear shims are adjusted,~* Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~* continuous SWIFT acquisition begins immediately before contrast injection,~* contrast injection,~* continuous SWIFT acquisition continues for 12 min after contrast,~* late enhancement images may also be obtained.~  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods."
40765721|NCT06230640|DIAGNOSTIC_TEST|In vitro medical diagnostic device TEG6s® Platelet Mapping|"Preoperative period:~* Pre-operative blood sampling, according to the usual practices of the unit before surgery~* Collection of the patient's usual demographic characteristics~per operative period :~* After anesthetic induction:a TEG6S platelet mapping® sampled from the arterial catheter routinely placed after anesthetic induction~* During the CPB, 30 min before aortic declamping: performing TEG 6S platelet mapping® (heparinized tube)~* 5 min after heparin antagonization by protamine, after the weaning of the bypass, and before any transfusion: performing a TEG 6S citrate® (citrated tube)~Post-operative period (resuscitation):~• postoperative bleeding at 2 hours and during the first 12 hours."
40963409|NCT01858389|DRUG|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
40963410|NCT04281810|DEVICE|transcutaneous electric diaphragm stimulation|The electrodes were placed on the parasternal region beside the xiphoid process; and the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was set as biphasic waves, frequency of 30 Hz, pulse width of 400 μs, and rise time of 0.7s.
40963411|NCT03019783|DRUG|Atazanavir|The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
40963412|NCT03019783|OTHER|Placebo|The control group will stay on their baseline regimen
40963413|NCT02341365|OTHER|vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors
40963414|NCT02688478|OTHER|Phthalate|Delivered by inhalation on day 1 of the triad
40963415|NCT02688478|OTHER|Filtered Air|Delivered by inhalation on day 1 of the triad
40963416|NCT02688478|OTHER|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
40963417|NCT00999232|DRUG|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
40963418|NCT00999232|DRUG|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
40963419|NCT03990038|DRUG|Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h|Group C receive the intervention Group U receives the placebo See arm description
40765722|NCT05896826|DEVICE|Magnetometer|inspection equipment for magnetocardiography
40963420|NCT03990038|DRUG|Extended Release Capsule|"Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description"
41294378|NCT00667758|DRUG|Cetrorelix|3-5 mg s.c. on days 1-5
41294379|NCT00667758|DRUG|Placebo|3-5 ml NaCl s.c. on days 1-5
41294380|NCT06415578|OTHER|ergonomics training|In this training; What is ergonomics, the importance of ergonomics, the purpose of ergonomics, risk factors for musculoskeletal disorders that can be seen in e-sports players, ergonomic arrangements that can be made in the working environment and methods of protection from musculoskeletal injuries, posture disorders and various ergonomic arrangements that can be made for posture disorders and chair selection, screen selection. selection and rest breaks were included. Participants will be trained twice in total, on the first day of the study and at the end of the 4th week. The training will be carried out interactively, supported by videos and visuals. Training will be done individually and will last approximately 2 hours.
40963421|NCT05759247|DEVICE|BORA Band (wristband)|Wristband collecting patient vital signs and activity
40963422|NCT04361318|COMBINATION_PRODUCT|Hydroxychloroquine plus Nitazoxanide|Both hydroxychloroquine \& nitazoxanide will be administered orally to participating patients
40963423|NCT04361318|OTHER|Standard care|"Oxygen administered via ventilator. In addition, antipyretic paracetamol may be added if necessary"
41456606|NCT04840927|DRUG|E7386|Regimen A: 40 milligram (mg) IR Oral Tablet.
41456607|NCT00052923|BIOLOGICAL|filgrastim|
41456608|NCT00052923|BIOLOGICAL|rituximab|
40963424|NCT03962842|OTHER|Pilates method|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
40963425|NCT01105728|PROCEDURE|Endoscopic resection|Endoscopic resection of the gastric subepithelial mass
40963426|NCT03339908|DEVICE|Thalamotomy by gamma Knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with stereotaxic precision
41456609|NCT00052923|DRUG|carmustine|
41456610|NCT00052923|DRUG|cyclophosphamide|
41456611|NCT00052923|DRUG|etoposide|
41456612|NCT00052923|PROCEDURE|peripheral blood stem cell transplantation|
41456613|NCT00052923|RADIATION|radiation therapy|
40963427|NCT03026400|PROCEDURE|Transumbilical incision|While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
40963428|NCT03026400|PROCEDURE|Subumbilical incision|Considered here as the ''control'' intervention.
40963429|NCT05374369|DIAGNOSTIC_TEST|SDC2 Gene Methylation Test and Q-FIT Test|Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test
40963430|NCT05374369|PROCEDURE|Colonoscopy and/or pathological examination|Subjects underwent colonoscopy and/or pathological examination.
40963431|NCT06234917|OTHER|EEG-based neurofeedback for brain activity modulation|NFB is a type of biofeedback technique for self-modulating brain activities by means of a learning task performed with ongoing sensory (usually visual) feedback to real-time acquisition of either brain imaging or electroencephalographic (EEG) signal, which serves as a biomarker of brain activity
40963432|NCT00966329|DRUG|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
41456614|NCT06504355|BEHAVIORAL|Training program incorporating video aerobic exercise, action video game and resistive action video game|Participants in the experimental group participated in three 60-minute training sessions each week for 12 weeks. One of the session was group training. The other two session were individual training. In the group training session, the participants participate in the video aerobic exercise; in the individual sessions, the participants play action and resistive action video games: Fitness Boxing 2 and Adventure Ring-Fit. All participants in the experimental group wore a hear rate monitoring watch so that the researchers make sure that medium level of physical activities was achieved in each session.
40963433|NCT00966329|DRUG|control group|"HAART regimen including 2 NRTI/NtRTIs plus one of the following :~* 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~* or ATV/unboosted (in a regimen without tenofovir)~* or 1 NNRTI (nevirapine or efavirenz)."
41456615|NCT00106106|PROCEDURE|NMR-spectroscopy|Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
40963434|NCT05543733|BEHAVIORAL|Home exercise program|Participants will complete a 6-month prescription telemedicine-based structured home exercise program. Baseline information will be used to develop a personalized home exercise program. This program will involve downloading the MyDataHelps application on a mobile device to securely collect wearable device information like step counts, activity minutes, and heart rate. Additionally, participants will have multiple virtual visits as well as the 2 in-person visits.
41456616|NCT00106106|DRUG|Oral acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
41456617|NCT01509391|DRUG|keyhole-limpet hemocyanin|Subcutaneous administration keyhole-limpet hemocyanin
41456618|NCT05807763|PROCEDURE|Laparoscopic paraesophageal hernia repair without fundoplication|"Patients undergoing laparoscopic paraesophageal hernia repair will be evaluated for risk of esophageal reflux using intra-operative impedance planimetry and endoscopic gastroesophageal valve grade. Patients deemed low risk for esophageal reflux will then be randomized to partial fundoplication or no fundoplication."
41456619|NCT06466135|DRUG|WAL0921|Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.
41456620|NCT06466135|DRUG|Placebo|Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
41456621|NCT05696548|DRUG|Lenvatinib|Lenvatinib will be administered at a dose of 24mg as oral dose, one a day
41456622|NCT05696548|DRUG|Nivolumab|Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks
40963435|NCT05678569|DIAGNOSTIC_TEST|Dual Energy Xray Absorptiometry|DXA for diagnosis of osteoporosis
40963436|NCT05626725|DEVICE|Automated insulin delivery system|This is an outpatient prospective observational study to evaluate the effect of DIY-AID use on maintaining glucose levels in physically active adult people living with T1D.
40963437|NCT05690373|DIETARY_SUPPLEMENT|Probiotic effect on influenza vaccine response|Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from \>10 to 40 in Ab titre for seronegative subjects.
41136731|NCT01415206|BEHAVIORAL|Usual Care|Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
41136732|NCT01604122|OTHER|No drug|No drug.
41136733|NCT01604122|OTHER|No drug|No drug.
41136734|NCT05663203|OTHER|Internet-Based Intervention|Attend CRCWeb intervention
41294381|NCT06415578|OTHER|Exercises|The exercise training program will be implemented for 8 weeks, 3 days a week, lasting an average of 45 minutes. All participants will be given information about the exercises before the exercise training. The exercise protocol was designed as 3 parts: warm-up, exercise and cool-down. Stretching exercises, mobility and strength exercises will be applied. A rest period of 30-45 seconds was given between sets and 2-3 minutes between exercises. Participants will be given dynamic and static stretching, nerve stretching, postural strength and functional exercises for the upper extremity. Relevant movements will be modified according to the exercise capacity of the participants. Exercise content will also include median, ulnar and radial nerve stretching, neck and thoracic mobility exercises, and functional strength exercises for the shoulder, arm, hand and wrist. Exercise tracking will be checked regularly through online conversations.
41294382|NCT06075004|PROCEDURE|Periarticular Local Anesthetic Infiltration|Sixty milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg will be deposited by the orthopedic surgeon at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.
41136735|NCT05663203|OTHER|Interview|Complete interview
41136736|NCT05663203|OTHER|Survey Administration|Complete survey
41136737|NCT05663203|OTHER|Electronic Health Record Review|Medical records are reviewed
41136738|NCT04604652|DRUG|HTD1801 (BUDCA)|HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
41136739|NCT04541797|DRUG|Empagliflozin 10 MG|Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
40963438|NCT03896386|OTHER|Use of seizure diary|"The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end"
40963439|NCT02160574|DRUG|ChloraPrep|The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.
40963440|NCT02160574|DRUG|0.1% Sodium Lauryl Sulfate|The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
40963441|NCT02160574|DRUG|0.9% Physiological Saline|The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
41456623|NCT00105157|DRUG|Comparator: MK0518|MK0518 oral tablets 200 mg b.i.d, for 24 weeks
41456624|NCT00105157|DRUG|MK0518|MK0518 oral tablets 400 mg b.i.d, for 24 weeks
40963442|NCT02160574|OTHER|ZuraPrep without IPA|Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
40963443|NCT01523171|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
40963444|NCT06192134|DEVICE|CPM device|CPM brace
41456625|NCT00105157|DRUG|MK0518|MK0518 oral tablets 600 mg b.i.d, for 24 weeks
40963445|NCT04137705|OTHER|Multiparametric MRI|A standardised MRI protocol that provides a number of quantitative metrics on liver and other organs relevant to type 2 Diabetes - pancreas, kidneys, spleen, heart, lungs and aorta
40963446|NCT05038631|DRUG|Ribociclib|Patients receive ribociclib
40963447|NCT03274596|DRUG|Vitamin E|
40963448|NCT03274596|DRUG|Placebo|
40963449|NCT00060008|RADIATION|fludeoxyglucose F 18|
40963450|NCT00060008|RADIATION|gadopentetate dimeglumine|
40963451|NCT02043171|DIETARY_SUPPLEMENT|Placebo|A Placebo comparator
40963452|NCT02043171|DRUG|HMB plus Vitamin D|Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
40963453|NCT02043171|BEHAVIORAL|Non-Exercise|This group will not participate in 3 times per week strength training
40963454|NCT02043171|BEHAVIORAL|Exercise|This group will participate in a supervised 3 times per week strength training program
40963455|NCT00786500|DIETARY_SUPPLEMENT|Gynostemma pentaphyllum tea|3 grams twice daily, orally
40963456|NCT00786500|DIETARY_SUPPLEMENT|Placebo tea|3 grams twice daily, orally
40963457|NCT04945954|OTHER|Drug: Cyclophosphamide|"Administer 14.5mg/kg of Cyclophosphamide once a day for 4days. (intravenously)~Blood sampling of pharmacokinetics(PK) of cyclophosphamide will be performed in all patients who have taken the investigational drug for at least 4 days (For 2 days, It will be administered for pretreatment of transplant, for the other 2 days, It will be administered for Post-transplant treatment for the prevention of GVHD)"
40963458|NCT01416064|DRUG|Molindone|The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
40963459|NCT05197556|DRUG|HSG4112|Once-daily oral administration
40963460|NCT05197556|DRUG|Placebo|Once-daily oral administration
40963461|NCT00247897|DRUG|Skin antisepsis|See Detailed Description
40963462|NCT04068935|PROCEDURE|fracture immobilization after reduction of displaced finger fractures|After closed reduction of a displaced finger fracture, fracture immobilization with either Buddy taping or Splint immobilization
40963463|NCT05125757|OTHER|lifestyle modification|for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
40963464|NCT05125757|OTHER|usual lifestyle|the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
41456626|NCT00105157|DRUG|Placebo|Placebo to MK0518, oral tablet b.i.d, for 24 weeks
41456627|NCT04202757|BIOLOGICAL|[21CFR640.30] Plasma from 18 - 25 year old volunteer donors|12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
40963465|NCT04339439|DEVICE|Vessel loop (FDA product code FZZ)|The intervention will be a vessel loop placed below sutures to raise the sutures from the skin of the palm.
40963466|NCT03868020|PROCEDURE|Computed Tomography|Undergo PET/CT
40963467|NCT03868020|RADIATION|Fluciclovine F18|Given IV
40963468|NCT03868020|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40963469|NCT00640601|DRUG|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
40963470|NCT01337700|DRUG|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
40963471|NCT01337700|DRUG|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
41456628|NCT04202757|OTHER|Saline|12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
41456629|NCT00033150|BEHAVIORAL|Fast ForWord|
40963472|NCT04729270|PROCEDURE|Physiotherapy treatment with physium device.|The intervention for this group consisted of 10 sessions with Transcranial Direct Current Stimulation for a month.
40963473|NCT04729270|PROCEDURE|Conventional physiotherapy treatment.|The intervention for this group consisted of 10 sessions with Electrical Nerve Stimulation (TENS) for a month.
41456630|NCT00033150|BEHAVIORAL|Computer Assisted Language Intervention|
41456631|NCT00033150|BEHAVIORAL|Individual Language Intervention|
41456632|NCT00033150|BEHAVIORAL|Academic enrichment|
41456633|NCT02333123|DRUG|Aspirin|Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
41456634|NCT02333123|DRUG|Placebo (for Aspirin)|Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
40963474|NCT05251571|OTHER|Conventional Exercise Group with Telerehabilitation|Exercises such as conventional muscle strengthening and stretching given with telerehabilitation are applied.
40963475|NCT05251571|OTHER|Balance Coordination Group with Telerehabilitation|Functional muscle strengthening, stretching, balance and coordination exercises given with telerehabilitation are applied.
40963476|NCT03606499|DRUG|Ustekinumab|No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
40963477|NCT00813306|DRUG|AZD2066|13 mg oral solution, 1 single dose
40963478|NCT00813306|DRUG|Placebo|Oral solution, 1 single dose
40963479|NCT00813306|DRUG|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
41456635|NCT03391050|DRUG|APR-246|Intravenous infusion
41456636|NCT03391050|DRUG|Dabrafenib|Oral administration
41456637|NCT03391505|BEHAVIORAL|Small-sided soccer game|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
41456638|NCT03391505|BEHAVIORAL|Walking soccer game|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
41456639|NCT03391505|BEHAVIORAL|Rest group watching soccer|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
40765723|NCT06637228|BEHAVIORAL|Move Your Hands, Feet, and Brain: Integrated Exercise Intervention Based on Taipei City Elderly Physical Activity Guidelines|"This video is tailored for fitness exercises for both healthy and sub-healthy elderly individuals and features various physical activity themes, including warm-up routines, balance and coordination drills, aerobic coordination exercises, strength training using chairs and water bottles, and cool-down routines. We selected a 3-month duration with sessions held three times a week to align with established effective intervention periods and to ensure participant adherence.~Integrated exercise sessions were conducted by the staff at the dementia care centers/service bases and lasted 50 minutes. Considering the impact of dementia and aging on the ability of older adults to engage in physical activities, the staff provided simple instructions, and participants performed the exercises while seated to prevent falls. Meanwhile, the control group continued with their usual treatment and daily activities."
41456640|NCT04912063|DRUG|Lemzoparlimab|Intravenous (IV) Infusion
41456641|NCT04912063|DRUG|Azacitidine|Subcutaneous Injection or Intravenous (IV) Injection/Infusion
41456642|NCT04912063|DRUG|Venetoclax|Oral Tablet
40963480|NCT00813306|DRUG|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
40963481|NCT00813306|DRUG|Placebo|Oral solution, 1 single dose
40963482|NCT00477256|BEHAVIORAL|Questionnaires|5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
40963483|NCT02321800|DRUG|Cefiderocol|2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
40963484|NCT02321800|DRUG|Imipenem/cilastatin|1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
40963485|NCT00563498|DRUG|Glutamine|
40963486|NCT05492344|OTHER|Personalized ventilation|"Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings:~* Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O)~* Tidal volume: 6 to 8 mL/kg predicted body weight (PBW)~* Daily prone positioning~LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol.~Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings:~* PEEP ≥ 15 cm H2O~* Tidal volume: 4 to 6 mL/kg PBW~* Daily recruitment maneuver"
40963487|NCT05492344|OTHER|Standard care|"Patient who are randomized in the control group will receive standard care~* Tidal volume: 6 mL/kg PBW~* PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study~* Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is \< 150 mmHg"
41456643|NCT01250730|DRUG|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
41456644|NCT01250730|DRUG|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
41456645|NCT01250730|DRUG|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
41456646|NCT03596710|PROCEDURE|Image Guided Biopsy|Undergo image guided biopsy
41456647|NCT02034513|DRUG|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
41456648|NCT02034513|DRUG|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
41456649|NCT02034513|DRUG|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
41456650|NCT02359539|PROCEDURE|Regenerative therapy|Periosteal pedicle, Platelets rich fibrin
41456651|NCT05456438|OTHER|İntervention 1|Group 1 applied coconut oil to the nipple
41456652|NCT05456438|OTHER|İntervention 2|Group 2 applied tea tree oil to the nipple
41456653|NCT04881188|DIAGNOSTIC_TEST|Survey|Patients with chronic low back pain in in-patient multimodal pain therapy. Three survey times, questionnaires
41456654|NCT01139216|DRUG|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
41456655|NCT01139216|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
41456656|NCT01139216|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
41456657|NCT05636111|DRUG|Paclitaxel|Given by (IV) vein
41456658|NCT05636111|DRUG|Bevacizumab|Given by (IV) vein
41456659|NCT05636111|DRUG|Lurbinectedin|Given by (IV) vein
41456660|NCT01869556|DRUG|Oxytocin|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
41456661|NCT01869556|DRUG|Ergot|Ergot 0.25mg IV
41456662|NCT01869556|DRUG|Carboprost|Carboprost 0.25mg IM
41456663|NCT01886222|OTHER|Long-term mild hypothermia|Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
41456664|NCT01886222|OTHER|Normothermia|Patients assigned to the normothermia group will be kept at 36-37℃.
41456665|NCT05182606|BEHAVIORAL|Pilot study of algorithms implementation package|"The Implementation Bundle will include a link to algorithms in the Electronic Health Record, Smartphrases, audited feedback, and instructions."
41456666|NCT03024268|DEVICE|Figulla Flex Occluder (Occlutech)|Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
41456667|NCT00310492|BIOLOGICAL|subcutaneous immunotherapy|Updosing by 16 injections to 100,000 SQ-U
41456668|NCT03513549|DRUG|Loxapine 10 MG|
41456669|NCT05917119|OTHER|BLT|Bright light therapy delivered via glasses
40765724|NCT06252415|BIOLOGICAL|foetal amniotic fluid sample|At the inclusion visit, during the foetal samples taken for the CMA/ES as part of the care.
40765725|NCT06252415|BIOLOGICAL|blood samples|2 x 5ml blood EDTA tubes for both parents
40765726|NCT06252415|OTHER|semi-structured online interviews|25 included couples will be invited to take part in 2 semi-structured online interviews (by telephone or videoconference)
41136740|NCT04541797|DRUG|Placebo|Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
41136741|NCT04541797|DIAGNOSTIC_TEST|Stress Cardiac Magnetic Resonance|Imaging: All patients will have stress CMR examinations at recruitment.
41456670|NCT05917119|OTHER|s-BLT|sham delivered with bright light therapy glasses to which a neutral density filter has been applied
41456671|NCT05729048|DEVICE|Starling|"Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance. Bioreactance is a measure of the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood.~The Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode.~This information is used to determine cardiac output. The Starling monitor also measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling monitor."
41456672|NCT00000698|DRUG|Ganciclovir|
41456673|NCT04011787|DIETARY_SUPPLEMENT|bolus NGT feeding|Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes
41456674|NCT04011787|DIETARY_SUPPLEMENT|Continuous NGT feeding|Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol
41456675|NCT04011787|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|Both participant groups will have continuous glucose monitoring performed for 5 days while in the study
41456676|NCT04011787|DIAGNOSTIC_TEST|Metabolic Profile|Bloods will be taken to assess all patients metabolic profile
41456677|NCT04011787|RADIATION|Chest X-ray|A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
41456678|NCT06074640|OTHER|MET PIR with Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) MTrPs will be identified and located using flat or pincer palpation method in the Triceps Surae complex of the affected leg. The identified trigger points will be marked with a marker. Piston technique of dry needling is performed on the identified MTrPs in calf muscles. The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
41294383|NCT06075004|PROCEDURE|Posterior Periarticular Local Anesthetic Infiltration plus Pericapsular Nerve Group Block|"From a total of forty-five milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg, 15mL will be deposited by the orthopedic surgeon at the posterior periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure with the remaining 30mL.~After wound closure, an ultrasound-guided pericapsular nerve group block will be performed by an anesthesiologist by injecting 10mL of 0.5% bupivacaine + 5ug/mL epinephrine in the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle."
41294384|NCT01531218|DRUG|azithromycin|azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
41294385|NCT01531218|DRUG|Placebo|
41294386|NCT02145767|DRUG|Progesterone|
41294387|NCT02145767|DRUG|Placebo|
41294388|NCT04705597|DRUG|BGE-175|Drug
41294389|NCT04705597|OTHER|Placebo|Placebo
41294390|NCT00217477|DRUG|gemcitabine hydrochloride|Given IV
41294391|NCT00217477|DRUG|paricalcitol|Given IV
41294392|NCT00593086|PROCEDURE|Pain management|Pain mamagement for burn care procedures.
41294393|NCT00593086|OTHER|Standard of care/no virtual reality game|no intervention for standard of care
41294394|NCT04001751|BEHAVIORAL|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga."
41294395|NCT05814770|DRUG|Finerenone|The participants were randomized in an equal ratio to receive finerenone 10 mg once daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to finerenone 20 mg once daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
41294396|NCT05814770|DRUG|Spironolactone|The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
41294397|NCT02280005|DEVICE|WAK Treatment|Hemodialysis with WAK device.
41294398|NCT04461847|PROCEDURE|subcutaneous mastectomy|Operating subcutaneous mastectomy
41294399|NCT04461847|PROCEDURE|endoscopic subcutaneous mastectomy|Operating endoscopic subcutaneous mastectomy
41294400|NCT00810797|DRUG|exemestane|Given orally
41294401|NCT00810797|OTHER|laboratory biomarker analysis|One year after completion of study treatment
41294402|NCT00810797|PROCEDURE|quality-of-life assessment|One year after completion of study treatment
40765727|NCT06100731|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (FC6, 10-10 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/ out at the beginning and end of the 15-minutes of stimulation over the course of 15 seconds.
41294403|NCT00810797|OTHER|immunohistochemistry staining method|Correlative studies
41136742|NCT05307952|DIAGNOSTIC_TEST|Tone Audiometry|Evaluation of the participants' audiometrical thresholds
41294404|NCT01539265|DRUG|silodosin|
41294405|NCT01539265|DRUG|silodosin|
41294406|NCT01539265|DRUG|placebo|
41294407|NCT01810159|OTHER|Integrated collaborative care|
41294408|NCT01810159|OTHER|Education and Resources|
41294409|NCT02723162|DRUG|Varenicline (VRN)|VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
41294410|NCT02723162|DRUG|N-Acetylcysteine (NAC)|NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
41294411|NCT02723162|DRUG|Placebo|Matched placebo
41294412|NCT06322823|PROCEDURE|direct thawing|Vitrified blastocysts will be thawed directly into 1ml G-TL medium
41294413|NCT06322823|PROCEDURE|Vitrification|Vitrified blastocysts will be thawed using commercially available one-step media.
41294414|NCT03013751|DRUG|Udenafil|Active drug
41294415|NCT02816762|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
41294416|NCT02816762|DRUG|Pharmacological treatment|Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
41294417|NCT02816762|OTHER|Diet|Conventional anti-diabetic diet recommendations
41294418|NCT05106972|DRUG|UC-MSC infusion|UC-MSC infusion by introvenus
41294419|NCT02116972|DRUG|FX006 32 mg|Single 5 mL IA injection
41294420|NCT02116972|DRUG|Placebo|Single 5 mL IA injection
41294421|NCT02116972|DRUG|FX006 16 mg|Single 5 mL IA injection
41294422|NCT00492401|DRUG|decitabine|Given IV
41456679|NCT06074640|OTHER|MET PIR without Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
41456680|NCT05063630|PROCEDURE|Medical treatment plus intracranial stenting|This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
41456681|NCT05063630|DRUG|Medical treatment alone|This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
41456682|NCT01969760|BEHAVIORAL|Healthy Families DC Program|A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
40765728|NCT01584297|DRUG|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
41456683|NCT05206162|DEVICE|theta burst stimulation|TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.
41456684|NCT00796796|DRUG|Temsirolimus|
41456685|NCT00796796|RADIATION|Radiation therapy|
41456686|NCT04891692|DEVICE|StimaWell 120MTRS system|Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.
40963488|NCT03129165|OTHER|Screening and prevention of CVD|"Drug: Pharmacological control of risk factors in agreement with primary physicians.~Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.~Social: Social worker care."
41456687|NCT02604680|DRUG|BLI1100-1|BLI1100-1 Topical gel
41456688|NCT02604680|DRUG|BLI1100-2|BLI1100-2 Topical gel
40963489|NCT01925937|DRUG|Atorvastatin|
40963490|NCT01925937|DRUG|Coenzyme Q10|
40963491|NCT01925937|DRUG|placebo for coenzyme Q10|
40963492|NCT05160493|DRUG|S-ketamine and pregabalin|"S-ketamine and pregabalin~* Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~* Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
40765729|NCT06644859|DEVICE|Daily Activity Patterns Using Wearable Tri-Axial Sensors|This intervention uniquely focuses on the prediction of injurious falls by combining daily life gait (DLG) measures (e.g., gait speed, cadence, variability) with daily life physical activity (DLPA) measures (e.g., activity levels, activity fragmentation). Unlike other studies, this analysis leverages data from a large cohort of older women (n=17,466) enrolled in the Women's Health Study (WHS), where participants wore a tri-axial accelerometer for 1 week. Additionally, the study links accelerometer data to long-term health outcomes, specifically fall-related injuries from Centers for Medicare \&amp; Medicaid Services (CMS) records. This is the first study to explore whether combining DLG and DLPA measures, derived from wearable technology, can predict fall-related injuries in an aging population, applying advanced machine learning techniques to this large, anonymized dataset.
41456689|NCT02604680|DRUG|BLI1100-3|BLI1100-3 Topical gel
41456690|NCT02604680|DRUG|BLI1100-4|BLI1100-4 Topical gel
41456691|NCT02604680|DRUG|Placebo|Placebo - Topical gel
41456692|NCT00475410|DRUG|ASCs (Cx401, company code)|"Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then."
41456693|NCT00475410|DRUG|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
41456694|NCT04284007|DRUG|Perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
41456695|NCT04284007|DRUG|Perineural dexamethasone in addition to levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 4mg dexamethasone diluted in 2 ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
41456696|NCT04284007|DRUG|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 4 mg intravenous dexamethasone diluted in 10 ml saline.
41456697|NCT00404053|DRUG|Clopidogrel|
40765730|NCT06312059|OTHER|Advance Infant Formula Powder|Sole source infant nutrition for the control arm.
40765731|NCT06312059|OTHER|"Kendamil Cow milk test product"|Sole source infant nutrition for the cow milk test arm.
40963493|NCT05160493|DRUG|Normal saline and placebo capsule|Normal saline and placebo capsule
40963494|NCT00033020|BEHAVIORAL|Behavior Therapy|
40963495|NCT02237131|DRUG|Oral contraceptives cyclic|tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
40963496|NCT02237131|DRUG|Oral contraceptives continuous|Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
40963497|NCT02335866|PROCEDURE|test groups|At the test sites, the previously prepared PRF was positioned over the recession defects, the coronal margin of the PRF was placed at the CEJ
41136743|NCT05307952|DIAGNOSTIC_TEST|Spectrotemporal Assessment|Evaluation of the participants' promptness in detecting a modulation of a harmonic complex
41294423|NCT00492401|OTHER|laboratory biomarker analysis|Correlative studies
41294424|NCT00492401|OTHER|pharmacological study|Correlative studies
41294425|NCT00492401|OTHER|high performance liquid chromatography|Correlative studies
41456698|NCT06348576|DRUG|AD-209|PO, Once daily(QD), 8weeks
41456699|NCT06348576|DRUG|AD-2091|PO, Once daily(QD), 8weeks
41456700|NCT06348576|DRUG|AD-209 Placebo|PO, Once daily(QD), 8weeks
40963498|NCT02335866|PROCEDURE|Control groups|Split-full-split thickness flap incisions were performed in a coronal-apical direction. The papillae adjacent to the involved tooth were de-epithelialized to create a connective tissue bed. The gingival flap was repositioned without tension, with its margin located on the enamel, on the test and control sides. It was held in that position with 5-0 resoble sutures
41456701|NCT06348576|DRUG|AD-2091 Placebo|PO, Once daily(QD), 8weeks
40765732|NCT06312059|OTHER|"Kendamil goat milk test product"|Sole source infant nutrition for the goat milk test arm.
40963499|NCT01930864|DRUG|metformin|metformin up to 2500mg/d
40963500|NCT01930864|DRUG|irinotecan|Irinotecan 350 mg/m² IV q21d
40963501|NCT06358820|DRUG|Amino acid peritoneal dialysis solution|Each subject received treatment with 1 bag of amino acid peritoneal dialysis daily and 2-4 bags of glucose peritoneal dialysis solution daily for 6 months
40963502|NCT01666574|OTHER|Test cereal 1, Oat-based|The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
40963503|NCT01666574|OTHER|Test Cereal 2, Oat based|The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
40963504|NCT05152030|DIAGNOSTIC_TEST|'TIB' Olfactory Test|A new smell identification test, 'TIB' Olfactory Test Device (Top International Biotech, Taipei) has been developed in Taiwan. It consists of 16 tests with an odorant embedded in fragrant microcapsules positioned on a strip. The examinee scratches the strip to release the odorant. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors. This process is then repeated with the next odorant on the strip.
41294426|NCT00492401|GENETIC|microarray analysis|Correlative studies
41294427|NCT00492401|GENETIC|RNA analysis|Correlative studies
41294428|NCT00492401|OTHER|mass spectrometry|Correlative studies
41294429|NCT00492401|GENETIC|DNA methylation analysis|Correlative studies
41294430|NCT00492401|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
41294431|NCT01301612|DRUG|Nimotuzumab|Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
41294432|NCT01301612|DRUG|Cisplatin|Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
41294433|NCT01301612|RADIATION|Brachytherapy|"Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week."
41456702|NCT03822858|DRUG|Intrathecal MSC-NP injection|"Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart."
41456703|NCT01016054|BIOLOGICAL|AGS-8M4|IV infusion
41456704|NCT01016054|DRUG|Pegylated liposomal doxorubicin (PLD)|IV infusion
41456705|NCT01016054|DRUG|gemcitabine|IV infusion
41294434|NCT01301612|DRUG|Cisplatin|Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
41294435|NCT01301612|RADIATION|Radiation Therapy|"Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week"
41294436|NCT05189015|DRUG|Olmesartan|- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
41294437|NCT03982459|BEHAVIORAL|decision support tool|computerized online decision support tool
41294438|NCT01926379|BEHAVIORAL|Combination intervention components|"The CIP will contain programmatic, structural, and psychosocial components, including:~1. use of a clinical algorithm by providers;~2. identification of HIV-infected family members eligible for IPT, using an ICAP-developed family care enrollment form (ICAP - International Center for AIDS Care and Treatment Programs);~3. review of monitoring data on IPT initiation and adherence during monthly multidisciplinary team meetings;~4. reimbursement of transportation costs for monthly clinic visits; and~5. real-time adherence support using IVR via mobile phones and trained Peer Educators."
41294439|NCT01926379|DRUG|Isoniazid Prevention Therapy|Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.
41294440|NCT00005628|BIOLOGICAL|vitespen|
41456706|NCT01016054|DRUG|carboplatin|IV infusion
41456707|NCT04608448|DRUG|Rapamycin Topical Ointment|8% topical rapamycin ointment
41456708|NCT04608448|OTHER|Placebo|Petrolatum ointment containing no active ingredient
41456709|NCT02028455|BIOLOGICAL|Patient Derived CD19 specific CAR T cells also expressing an EGFRt|Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
41456710|NCT01940159|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
41456711|NCT01940159|DRUG|Placebo|single oral dose placebo
41456712|NCT06020040|DEVICE|Heterograft|Heterograft (Geistlich, Gegreen, Heal-All) will be used to repair bone defect in the esthetic area of the anterior teeth with simultaneous implant placement. According to the bone particle size, it can be divided into large bone particles(1-2mm) and small bone particles(0.25-1mm).
41456713|NCT00197834|DRUG|Depakote|
41456714|NCT04161950|OTHER|Assessment of the safety and validity of echoendoscope|"1. Ultrasonic and endoscopic image quality assessment~2. Device controllability assessment~3. System safety assessment~4. System stability assessment"
40765733|NCT05633927|BIOLOGICAL|SARS-CoV-2 Vaccine|Analyse humoral and cellular response to SARS-CoV-2 Vaccine.
41456715|NCT00394303|DRUG|Intraoperative continuous insulin infusion|Nomogram specified in appendix
40963505|NCT05152030|DIAGNOSTIC_TEST|Traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC)|The University of Pennsylvania Smell Identification Test (UPSIT), which was developed at the University of Pennsylvania, is one of the most reliable and the most widely used olfactory test.The test consists of four 10-odorant booklets. Each odorant is embedded in 10 to 50 µm urea-formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on a brown strip which is located at the bottom of each page of the test booklet.4 When the examinee takes the test, each of the 40 odorants is released by scratching the strip with a pencil tip. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors.
41136744|NCT05307952|DIAGNOSTIC_TEST|Phoneme and Speech Perception|Evaluation of the participants' understanding of phonemes and short words, both in quiet and in noise
41136745|NCT05307952|DIAGNOSTIC_TEST|Digit Triplet Test|Evaluation of the participants' ability to discern speech in noise
41294441|NCT01245894|DRUG|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
41294442|NCT01245894|DRUG|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
41294443|NCT04004507|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
41294444|NCT04004507|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
41456716|NCT00394303|OTHER|Control|Glucose management according to the discretion of the anesthesiologist aimed to maintain glucose levels \<200 mg.dl, reflecting current practice.
41456717|NCT03682276|BIOLOGICAL|Ipilimumab|Ipilimumab is a monoclonal antibody given as an immunotherapy
41456718|NCT03682276|BIOLOGICAL|Nivolumab|Nivolumab is a monoclonal antibody given as an immunotherapy
41456719|NCT04164758|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily
41456720|NCT04164758|OTHER|Placebo|Placebo (provided as 2 × placebo encapsulated tablets) administered orally as a single dose once daily
41456721|NCT04164758|DRUG|Quetiapine|Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
41456722|NCT03577535|DIETARY_SUPPLEMENT|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;
41456723|NCT01196949|OTHER|Manipulative and Rehabilitative Therapy|Participants will receive 6 treatments over a 3 to 5 week time frame. A minimum of one day and maximum of 3 days between treatments. This group will receive high velocity low amplitude thrust to a minimum of 1 and maximum of 3 restricted segments within the mortise joint, subtalar joint and tarsal along with the same rehabilitation protocol as the other group.
41456724|NCT01196949|OTHER|Rehabilitative Therapy|Participants will receive education and training in the home exercises. This group is only required to attend the treatment facility for outcome measure readings and if they have any questions about the research protocol or check if they are performing their exercises correctly. A Theraband will be utilized for the peroneal muscle strengthening; 3 sets of 12 repetitions. Proprioception will be conducted on a Bosu Ball; 10 minutes per period. This protocol will be conducted everyday at home for the 5 week study. A diary will be required to record compliance and indicate how exercises should be performed.
41456725|NCT01828437|DRUG|Pyridoxine plus prednisolone|
41456726|NCT01828437|DRUG|Prednisolone|
41456727|NCT03859050|OTHER|bronchoscopy with intrabronchial administration of lipopolysaccharide|The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.
41456728|NCT06090708|DIETARY_SUPPLEMENT|yogurt with probiotic bacteria|Children in probiotic study group were received 15 mg/kg of market available fresh probiotic yogurt after stopping vomiting every four to six hours for three consecutive days beside to the standard hospital care and the prescribed medication for acute gastroenteritis.
41456729|NCT03447691|DRUG|Des (volatile anesthetic-desflurane)|Inducing unconciouness with 1.5 to 2 mg/kg of propofol, Intubation is performed 3 minutes after administration of remifentanil 1-2 mcg / kg and rocuronium 0.6 mg / kg. Desflurane concentration is maintained 3-7% (0.7-1.1 MAC) and remifentanil continuous infusion (0.02-0.2 mcg / kg / min).
41456730|NCT03447691|DRUG|TIVA (Total intravenous anesthesia with propofol and remifentanil)|TIVA group is administered with intravenous anesthetic using commercial target controlled infusion (TCI) pump. Anesthesia is induced and maintained with 2-6 mcg / ml propofol and 2-6 ng / ml remifentanil, which are converted to the effect site concentration. After administrating rocuronium 0.6mg/kg, intubation is performed.
41456731|NCT04698551|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation involved in DPN requests from phasing of parental haplotypes by 3rd generation long-fragment DNA sequencing techniques coupled with targeted sequencing of free circulating DNA from maternal plasma.
41456732|NCT04260854|DRUG|Bupivacaine Hydrochloride|Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.
40963506|NCT06505044|PROCEDURE|aerobic exercise|"aerobic exercise.~* Intensity: according to heart rate (60-75% of maximum heart rate) MHR=220-age.~* Heart rate: determined by the sensor of a treadmill.~* Duration: 40-50 min per session. Each session consisted of 5-10 minutes of warming up exercise on a treadmill without increasing speed or intensity and the same for the cooling down phase. There was 30 minutes of conditioning exercise including increasing the treadmill speed till reaching (60-75%) of the maximum heart rate.~* Frequency: 3 times/week for 12 weeks in addition to their usual daily calcium intake."
40963507|NCT06505044|PROCEDURE|resistance exercise|resisted exercise program for 12 weeks
40963508|NCT03873844|BEHAVIORAL|Speed of Processing Training|"Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block."
40963509|NCT03873844|BEHAVIORAL|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
40963510|NCT06557798|DEVICE|Any commercially available transcatheter aortic valve|Redo TAVI will be performed using any commercially available transcatheter aortic valve according to the preferences of the local team in keeping with standard clinical care.
41136746|NCT05307952|OTHER|Personalized fitting|Adjustment of the parameters of the participants' cochlear implants aimed at improving their speech perception
41294445|NCT02288728|PROCEDURE|Gastric tube anastomosis|"In the gastric tube group, the lesser curvature of the gastric remnant approximately 3 cm proximal to the pylorus was removed first by a linear stapling device. An approximately 5-cm-wide tubular stomach was then constructed with preserved right gastric vessels. The length of the tube was consistent with the greater curvature of the residual stomach. The reconstructed gastric tube was lastly anastomosed with the proximal esophageal end.~(Reference: Chen XF, Zhang B, Chen ZX, Hu JK, Dai B, Wang F, Yang HX, Chen JP. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction. Dig Dis Sci. 2012;57(3):738-745.)"
41294446|NCT02288728|PROCEDURE|Double-track anastomosis|"Double-track anastomosis group: First, cut off the jejunum about 15-20 cm away from the Treitz ligament; Second, Roux-en-Y esophagojejunostomy (E-J stomy, first anastomosis) was perform by 25mm circular stapler device; Third, from 30-40cm to the E-J stomy, perform the side-to-side gastrojejunostomy (G-J stomy, second anastomosis). Forth, from 25-30cm to the G-J stomy, perform the jejunojejunostomy (J-J stomy, third anastomosis).~(Reference: Ahn SH, Jung do H, Son SY, Lee CM, Park do J, Kim HH. Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer. Gastric Cancer. 2014;17(3):562-70.)"
41294447|NCT01696409|DIETARY_SUPPLEMENT|400 IU vitamin D3|Take 400 IU once/day for 2 months
41294448|NCT01696409|DIETARY_SUPPLEMENT|2000 IU vitamin D3|2000 IU vitamin D3 once/day for 2 months
41456733|NCT04260854|DRUG|Saline|Normal saline injections.
41456734|NCT02333162|DRUG|Fludarabine Phosphate|Given IV
40963511|NCT06557798|PROCEDURE|Surgical explantation and aortic valve replacement|Surgical explantation and aortic valve replacement will be performed according to the preferences of the local team in keeping with standard clinical care. Any commercially available approved surgical aortic valve may be used. Additional surgery, such as aortic root replacement, root enlargement, CABG, mitral valve repair/replacement, etc. will be performed at the discretion of the local team.
40963512|NCT06557798|OTHER|Conservative management|Conservative treatment, including optimal medical therapy +/- balloon aortic valvuloplasty
40963513|NCT01154790|DRUG|CG100649|6 subjects: study drug 2 subjects: placebo
41456735|NCT02333162|DRUG|Melphalan|Given IV
40963514|NCT01154790|DRUG|Placebo|6 subjects: study drug 2 subjects: placebo
40963515|NCT01154790|DRUG|Naproxen|6 subjects: study drug 2 subjects: placebo
40963516|NCT03147261|OTHER|Lifestyle intervention|Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
40963517|NCT04561830|PROCEDURE|laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision|"We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides."
40963518|NCT03225885|OTHER|Multimedia Information|Is a multi-media mobile application that addresses information about prematurity, resuscitation, and NICU hospitalization.
40963519|NCT03225885|OTHER|Printed Handout|Printed Handout is a gestational age specific handout that addresses resuscitation and prematurity information.
40963520|NCT01095731|DRUG|Tiopronin|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
40963521|NCT01095731|DRUG|Placebo|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
41294449|NCT02943551|OTHER|Online Tutorial|For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
40963522|NCT06127654|DEVICE|Healthy lung sparing treatment plan|CT Ventilation imaging will be used to create a healthy lung sparing treatment plan for patients who will receive radiation therapy treatment for their lung cancer.
40963523|NCT05379738|OTHER|6 sessions of adapted physical activity after stem cell transplant|"physical assessement before and after stem cell transplant:~* weight loss~* brachial muscle circumference~* grip strength evaluation~* short physical battery test~psychometric assessment before and after stem cell transplant:~* quality of life questionary~* physical activities questionary"
40963524|NCT03191994|BEHAVIORAL|Exercise|a structured, supervised eight week moderate intensity exercise intervention
40963525|NCT05032859|DRUG|tapinarof cream, 1%|applied topically once daily
40963526|NCT05032859|DRUG|vehicle cream|applied topically once daily
40963527|NCT05557981|BEHAVIORAL|Coaching|A novel coaching curriculum based in positive psychology with an emphasis on self-reflection, goal setting and adverse event processing.
40963528|NCT05253729|DEVICE|Focused ESWT|F-ESWT (dose 0.01-0.15 mJ/mm2, frequency 4-5 Hz, 1500 shocks) was applied perpendicular to the palmar side of the wrist which was done once a week for a total of three sessions plus conservative treatment.
40963529|NCT05253729|BEHAVIORAL|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
40963530|NCT02059395|OTHER|Mastery based learning|Participants are allowed to follow the course content at their own speed
40963531|NCT02059395|OTHER|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
40963532|NCT01708161|DRUG|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
40963533|NCT01708161|DRUG|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
41456736|NCT02333162|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMTMI
40963534|NCT05947396|DIETARY_SUPPLEMENT|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
41456737|NCT02333162|RADIATION|Total Marrow Irradiation|Undergo IMTMI
40963535|NCT05947396|OTHER|placebo|The placebo is provided by Beijing Jiafurui Biological Technology Co., Ltd. The formula consists of maltodextrin, grapefruit powder, and food coloring. The manufacturing facility has adjusted the appearance, color, solubility, and taste of the placebo to match the intervention agent. There is no risk of unblinding.
40963536|NCT03868124|COMBINATION_PRODUCT|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions
40963537|NCT03868124|DRUG|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
40963538|NCT03945578|OTHER|Pelvic Floor muscle training - PFMT|Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles. The PFMT protocol was divided into four phases. Proprioceptive (2 weeks): where the woman has gained adequate perception of PFM and control of fast and slow contractions; Simple (1 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (1 week): where the exercise evolved into functional exercises of greater amplitude; and Power (1 week): where the control of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and for fast fibers (the list of exercises and a detailed description of them is in Appendix 1).
40963539|NCT03945578|OTHER|Visceral Manual Therapy - VMT|Visceral manual therapy:is a manual treatment intended to the release of visceral fascias. The VMT protocol was based on the work proposed by Vanderheyden-Busquet (2014). To act on the abdominal and pelvic visceral fasciae, the VMT was performed through slow and deep mobilizations, respecting the participant's tissue resistance and painful response, in different regions of the abdômen.
40963540|NCT03945578|OTHER|Manual Sham Therapy - MST|The manual sham therapy protocol was perfomed by gentle techniques applied to the thoracic spine, scapular waist and cervical spine
40963541|NCT04564261|BEHAVIORAL|Personalized Healthy Relationship and Safety Planning Tool|"The app delivers evidence-based information and resources in three sections:~My Relationship: contains a series of activities (e.g., quizzes) to raise awareness of common myths about unhealthy relationships, determine characteristics of healthy relationships, examine the red flags in an unhealthy relationship, and assess risk factors for more severe abuse. Participants are provided with personalized messages about their relationship health and safety based on the answers they endorse.~My Strategies: personalized strategies to increase participants' safety and well-being based on responses in the previous section.~My Resources: direct links to the National Dating Abuse hotline, textline, and chatline, as well as personalized health and safety resources."
41294450|NCT02943551|OTHER|Webinars|"The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants."
40963542|NCT04564261|BEHAVIORAL|Usual Care Teen Relationship and Health Website|The control group website will provide participants with tools to learn about health topics including examining healthy relationships. The resources will be targeted to adolescents. The control group website is not personalized to the participant or their relationship.
40963543|NCT01782222|DRUG|Rotigotine|"Rotigotine, transdermal patches:~10 cm\^2 (2 mg / 24 hours); 20 cm\^2 (4 mg / 24 hours); 30 cm\^2 (6 mg / 24 hours); 40 cm\^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
40963544|NCT01782222|OTHER|Placebo|"Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)"
40963545|NCT00828659|DRUG|Placebo|
40963546|NCT00828659|DRUG|Active Comparator #1|
40963547|NCT00828659|DRUG|Active Comparator #2|
40765734|NCT05798585|PROCEDURE|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.375% according to randomization): unilateral injection of 0,4 ml kg -1 (ideal weight)2 under US guidance between the deep fascia of erector spinae muscle and the two transverse processes at the level of the 5th thoracic vertebrae. Duration approximately 10-15 minutes
41294451|NCT02943551|OTHER|Booster Sessions|"An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette."
40765735|NCT04124419|DEVICE|Treatment with Evolve System|EMS and RF Treatment
40765736|NCT05775042|BIOLOGICAL|CM338|CM338 injection
40963548|NCT00828659|DRUG|Active Comparator #3|
40963549|NCT00828659|DRUG|Lorcaserin Dose #1|
40963550|NCT00828659|DRUG|Lorcaserin Dose #2|
40963551|NCT00828659|DRUG|Lorcaserin Dose #3|
40963552|NCT05019352|DEVICE|CytoSorb cytokine adsorber|device for extracorporeal hemoadsorption
40963553|NCT05019352|DEVICE|CRRT|continuous renal replacement therapy
40963554|NCT04838483|DEVICE|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
40963555|NCT03145974|DEVICE|mechanical ventilation|ventilatory support
40963556|NCT06218485|PROCEDURE|Intravascular ultrasound-guided stent implantation after angiography-derived FFR-based decision-making|"The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making:~1. PCI will be performed if angiography-derived FFR ≤0.80 and will be deferred if angiography-derived FFR \>0.80.~2. If PCI is performed, PCI optimization using IVUS will be performed following the recommended criteria: ① Plaque burden at stent edge ≤55%; ② Minimal stent area ≥ 5.5 mm2, or minimal stent area ≥ distal reference lumen area"
40963557|NCT06218485|PROCEDURE|Fractional flow reserve-guided PCI strategy|"The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy:~1. PCI will be performed if FFR ≤0.80 and will be deferred if FFR \>0.80.~2. If PCI is performed, PCI optimization using FFR will be performed following the recommended criteria: ① Post-PCI FFR ≥ 0.88, or ② Post-PCI ΔFFR (\[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05"
40963558|NCT06505902|OTHER|Exercise|Exercise by bicycle and performing diffusing capacity measurements at the same time with arterial blood gasses.
40963559|NCT02885103|DEVICE|Nasal high flow (NHF)|NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
40765737|NCT06642285|PROCEDURE|Non Invasive Respiratory Support bundle|premature neonates who will receive evidence-based guidelines for prevention of nasal pressure injuries associated with non invasive respiratory support till weaning
40765738|NCT06641401|PROCEDURE|Endoscopic Flexor Hallucis Longus transfer for Acute Achilles tendon rupture|All patients have already undergone the same operation for the same disease. All data are to be collected retrospectively
40963560|NCT02885103|DEVICE|Nebulizer|Inhalation will be done will Nebulizer and via mouth
40963561|NCT06273410|OTHER|Cention N|Cention N will be manipulated using the standard powder: liquid ratio which is, one scoop of powder with one drop of liquid. Powder and liquid will be dispensed on the mixing pad and mixed using a plastic spatula according to the manufacturer's instruction for 45-60 seconds
40963562|NCT06273410|OTHER|Cention N + Adhesive|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds
40963563|NCT06273410|OTHER|Bulk Fill Composite|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds.
40963564|NCT01936805|DRUG|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
40963565|NCT04790929|DEVICE|Muse|Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.
40963566|NCT04790929|BEHAVIORAL|Meditation Coaching|Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.
40963567|NCT00501670|PROCEDURE|Herpes zoster sampling procedure for VZV PCR|Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.
40963568|NCT00501670|PROCEDURE|Blood sampling|Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
40963569|NCT00718952|DRUG|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
40765739|NCT03538457|DRUG|Paracetamol|Patients are tested for their normal prescription paracetamol medication
40963570|NCT00718952|DRUG|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
40963571|NCT00718952|DRUG|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
40963572|NCT04660669|OTHER|ESDM intervention|Early Start Denver Model (ESDM) intervention with remote parental training/ supervision versus intensive ESDM intervention.
40963573|NCT04660669|OTHER|MOOC|Massive Online Open Course: a teaching and learning intervention based on instrumental and interactive teaching situations
40963574|NCT03255798|DEVICE|G2 and G3|Two iStent inject devices and one iStent supra device
40963575|NCT01941875|DRUG|Progesterone Effervescent Vaginal Tablets|Experimental
40963576|NCT00272740|DRUG|Fulvestrant|
41456738|NCT02333162|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
40765740|NCT06645093|OTHER|Fasting|Fasting implies 0 kilojoule. Water ad libitum is permitted.
40765741|NCT01549015|OTHER|oral administration of Sodium [1,2-13C]-Acetate|single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube
40765742|NCT03840889|OTHER|Data collection|"he different modes of active data collection:~* Data collection by telephone~* Data collection by mail~* Collection from discharge database summaries (PMSI)"
40765743|NCT06640257|DRUG|SHR-1314 injection|SHR-1314 injection
40765744|NCT06640257|DRUG|Placebo|Placebo
40765745|NCT02944331|PROCEDURE|Endovenous steam ablation|
40765746|NCT04878471|DRUG|Pudexacianinium chloride|Intravenous
40765747|NCT04878471|DRUG|Placebo|Intravenous
40765748|NCT03809000|RADIATION|Radiation Therapy|daily fractions
40963577|NCT02216734|BEHAVIORAL|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
40963578|NCT01407315|DEVICE|GlucoMenDay|"Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.~An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.~This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once."
40963579|NCT01407315|DEVICE|GlucoMenDay|"Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.~Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.~This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice."
40963580|NCT05471791|DEVICE|Back2Play App|This App uses the Apple watch to monitor activity level and heart rate and combines this with self reported symptoms and stage of recovery to send notifications, suggestions and provide resources to help participants adhere to the guidelines.
40963581|NCT01324908|PROCEDURE|extracorporeal photopheresis|Undergo ECP
40963582|NCT01324908|OTHER|laboratory biomarker analysis|Correlative studies
40963583|NCT02486497|BIOLOGICAL|hENT1|hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
41456739|NCT02333162|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
41456740|NCT02333162|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
40765749|NCT03809000|DRUG|Enzalutamide|tablet
40963584|NCT03311633|PROCEDURE|Percutaneous pinning time|Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
40963585|NCT02066142|DEVICE|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
40963586|NCT02066142|DEVICE|Ultrasound|
40963587|NCT02502578|DRUG|CNT-01 500 mg capsule|After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
40963588|NCT00113620|DRUG|Neurodex|
40963589|NCT01421004|DRUG|TKI258|
40963590|NCT01753271|OTHER|thoracic mobilization & shoulder mobilization & exercise|
40963591|NCT01753271|OTHER|shoulder mobilization & exercise|
40963592|NCT02898883|BEHAVIORAL|Building Resilience after Childhood Emergencies (BRACE)|See arm/group description for details regarding this intervention
40963593|NCT00923156|DRUG|aliskiren|Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
40963594|NCT00923156|DRUG|ramipril|2.5 mg , 5.0 mg or 10 mg once daily
40963595|NCT00923156|DRUG|Placebo to aliskiren|matching placebo to aliskiren in double blind phase
40963596|NCT00923156|DRUG|Placebo to ramipril|Matching placebo to ramipril capsule in double blind phase
40963597|NCT00873015|DRUG|Sodium nitrite|14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
40963598|NCT00873015|DRUG|Saline|14 day continuous infusion of a vehicle control infusion
40963599|NCT02232165|OTHER|Hypotension avoidance|Induced hypertension with MAP \>= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP \>= 65 mmHg is not inferior to induced hypertension.
40963600|NCT02232165|OTHER|Induced hypertension|Induced hypertension with MAP \>= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
41456741|NCT02333162|DRUG|Tacrolimus|Given IV or PO
40963601|NCT04764903|OTHER|No intervention|There is no intervention in this study
40963602|NCT02793921|BEHAVIORAL|Moderate-Intensity Aerobic Exercise Intervention|The intervention is moderate-intensity aerobic exercise. Walking on a motorized treadmill will be the encouraged mode of exercise; however participants may use other equipment or home exercise. Participants will begin by exercising 10-15 minutes for 3 days/week during the first 2 weeks and gradually increase the duration for the following 4 weeks until they reach 40-50 minutes per session/3 days per week. This level is then maintained for the remainder of the 6 months. The rate of increase will be tailored based on baseline cardiorespiratory fitness and response to exercise. All sessions start and end with a vital sign check (in-person) and 5-10 minutes warm-up/cool-down. Trained exercise physiologists will supervise all exercise sessions and closely monitor adherence, intensity, and safety when sessions are completed in-person, or through regular communication when home-based exercise is warranted (due to COVID-19).
40963603|NCT03902288|OTHER|Fresh pomegranate juice|Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG \< 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.
40963604|NCT03280901|OTHER|HD, Magnetic Resonance Imaging (MRI) scans|HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
40963605|NCT03266536|BEHAVIORAL|Western diet|Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with \< 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
40963606|NCT01087138|BEHAVIORAL|exercise|exercise class 3x's/week
40963607|NCT01087138|BEHAVIORAL|exercise and calcium|exercise class 3x's/week and 1500mg calcium intake
40963608|NCT05510440|DIETARY_SUPPLEMENT|Alpha-amino acid derivatives|Alpha-amino acid derivatives mainly citrulline will be used as a supplement to reduce kidneys and other internal organs damage
40963609|NCT05108662|PROCEDURE|Surgery method|Patients were subdivided into two groups according to their prostate volume
40963610|NCT01221792|DRUG|Carvedilol|"Oral, twice daily dosing using 3.125 mg tablets.~1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day)."
40963611|NCT01221792|DRUG|Placebo|Non active comparator
40963612|NCT00118677|PROCEDURE|Treatment interruption|
40963613|NCT02541682|OTHER|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
40963614|NCT01773811|BEHAVIORAL|Narrative Writing: Trauma-Assigned|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
40963615|NCT01773811|BEHAVIORAL|Narrative Writing: Trauma-Spontaneous|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
40963616|NCT06201741|RADIATION|[131I]/[18F]/[68Ga]ZT-111|\[131I\]/\[18F\]/\[68Ga\]ZT-111, single dose
41456742|NCT02333162|DRUG|Mycophenolate Mofetil|Given IV or PO
41456743|NCT02333162|OTHER|Laboratory Biomarker Analysis|Correlative studies
41456744|NCT01282450|RADIATION|Radiotherapy|Radiotherapy
40963617|NCT02416401|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
40963618|NCT02416401|OTHER|Commercially available computerized training|
40963619|NCT02256631|BIOLOGICAL|VRC01|Administered by subcutaneous injection in the thigh
40963620|NCT02256631|BIOLOGICAL|VRC01LS|Administered by subcutaneous injection in the thigh
40963621|NCT02256631|BIOLOGICAL|VRC07-523LS|Administered by subcutaneous injection in the thigh
40963622|NCT04081974|OTHER|Distal leg perfusion|On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.
40963623|NCT00867724|DEVICE|Aer-O-Scope Colonoscopy|Screening Colonoscopy
40963624|NCT06001645|DIAGNOSTIC_TEST|Blood and bronchoalveolar fluid collection and analysis|Blood and bronchoalveolar lavage fluid will be collected within 12 hours after intubation. Blood samples will be centrifuged, and the serum immediately stored at less than 70° C. The following biomarkers will be analysed in the serum and bronchoalveolar lavage fluid: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10). Blood samples obtained from the patients will be placed in specimen tubes containing heparin, centrifuged at 1500 G for 10 minutes, and then the plasma will be aspirated and stored at -70° C. Bronchoalveolar lavage fluid will be centrifuged at 1500 G for 10 minutes to remove cellular contents and stored at -70° C.
40963625|NCT06001645|DIAGNOSTIC_TEST|Chest CT scan|Computed Tomography Scan per normal clinical practice
40963626|NCT01682109|DRUG|Valacyclovir|
40963627|NCT01361152|DEVICE|anatomic modular fixed-bearing|anatomic modular (AMK; DePuy) fixed-bearing prosthesis
40963628|NCT01361152|DEVICE|low contact stress rotating platform mobile-bearing|low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
40963629|NCT04568733|BEHAVIORAL|Pilates exercise session|The Pilates session will consist of warm-up exercises (e.g. breathing, arm circle, cat and camel spinal rotation etc.) and basic mat exercises (e.g. one leg stretching, double leg stretching, the hundred, saw, rolling like a ball, swimming, pelvic curl etc.). The Pilates session will be presented to the participants via pre-recorded video.
40963630|NCT04568733|BEHAVIORAL|Treadmill walking at 3.2 kph|Participants will walk on a treadmill at 3.2 kph (2 mph) speed for 10 minutes.
41294452|NCT02943551|OTHER|Feedback Reports|"During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~* The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~* The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores."
40963631|NCT04568733|BEHAVIORAL|Treadmill walking at 4.8 kph|Participants will walk on a treadmill at 4.8 kph (2 mph) speed for 10 minutes.
40963632|NCT00509015|DRUG|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S\&25mg P/20 kg, 1 day, single dose
40963633|NCT00509015|DRUG|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
40963634|NCT00509015|DRUG|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
40963635|NCT00509015|DRUG|placebo tablets|3 days of lactose tablets (160mg) albochin
40963636|NCT00608686|DIETARY_SUPPLEMENT|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
40963637|NCT00028405|DRUG|LS 11(Taporfin Sodium)|
40963638|NCT00028405|DEVICE|Lumaflex Light Delivery Catheter|
40963639|NCT00039130|BIOLOGICAL|filgrastim|5 ug/kg/day sub Q injection day 7 until ANC\>5000/ul courses II-VII
40963640|NCT00039130|BIOLOGICAL|rituximab|Day 8 course II 50 mg/sq m IV infusion: d 8 course IV \& VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
40963641|NCT00039130|DRUG|cyclophosphamide|200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
40963642|NCT00039130|DRUG|cytarabine|1 g/sq m/day IV infusion Days 4 \& 5, courses II, IV, VI
40963643|NCT00039130|DRUG|dexamethasone|10mg/sq m PO or IV Days 1-5 courses II-VII
40963644|NCT00039130|DRUG|doxorubicin hydrochloride|25 mg/sq m/day IV infusion Days 4 \& 5 courses III,V, VII
40963645|NCT00039130|DRUG|etoposide|80 mg/sq m/day IV infusion Days 4 \& 5 courses II, IV, VI
40963646|NCT00039130|DRUG|ifosfamide|800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
40963647|NCT00039130|DRUG|leucovorin calcium|25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX \<10nM, courses II-VII
40963648|NCT00039130|DRUG|methotrexate|1.5 g/sq m IV infusion Day 1 courses II-VII
40963649|NCT00039130|DRUG|prednisone|60 mg/sq m PO/day Days 1-7 course I
40963650|NCT00039130|DRUG|vincristine sulfate|2 mg IV push Day 1 courses II-VII
40963651|NCT00039130|DRUG|Allopurinol|300 mg/day PO Days 1-14, course I
40963652|NCT00002014|DRUG|Zidovudine|
40963653|NCT00002014|DRUG|Didanosine|
40963654|NCT02826902|DRUG|propofol and remifentanil|Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
40963655|NCT02826902|DRUG|desflurane and remifentanil|Anesthesia is induced and maintained with desflurane and remifentanil
40963656|NCT01807975|OTHER|Forced oscillation|
40963657|NCT00332007|DRUG|Tonabersat|two tablets once daily
40963658|NCT00332007|DRUG|Placebo|two tablets once daily
40963659|NCT05676112|DRUG|nintedanib|nintedanib
40963660|NCT05676112|DRUG|pirfenidone|pirfenidone
41294453|NCT02943551|OTHER|Parent Survey|Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
41456745|NCT00556699|DRUG|rituximab|Escalating intravenous repeating dose
41456746|NCT00556699|DRUG|SGN-40|Escalating intravenous repeating dose
40963661|NCT01471470|DRUG|Docetaxel, Capecitabine, Cisplatin, Bevacizumab|Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
40765750|NCT03809000|DRUG|Bicalutamide|tablet
40963662|NCT05705596|OTHER|Sucrose|10% sucrose corresponding to a regular soft drink
40963663|NCT05705596|DRUG|Hesperetin|increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
40963664|NCT02211040|BEHAVIORAL|My Plan|"The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans."
40963665|NCT04332146|BEHAVIORAL|Mindfulness-based program (MBI-p-R)|The MBI-p-R was developed in line with the model of Mindfulness-based Stress Reducation (MBSR) proposed by Kabat-Zinn. It will be conducted for 1.5 hours for each session, once a week for 8 weeks. There are four key operational components to be included in each session: engagement and introduction, mindfulness practices, daily life application, and consolidation of learning.
40963666|NCT04332146|BEHAVIORAL|Booklet-based psychoeducation|The participants in the control group will be provided a booklet at baseline, including general information in handling every day stress by a new mother, as well as a record for their weekly activities. The contents covered a range of topics including work-stress, balanced diet, physical exercise, sleeping quality, bonding with baby and the treatment for depression. The participants will be contacted by phone call and/or whatsapp weekly for a short talk based on the record and content on the booklet. They will also be asked to record their daily life weekly for discussion.
40963667|NCT05466656|OTHER|Continuous quality improvement cycle model|The continuous quality improvement cycle model consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying barriers to improvements in clinical practice, and drawing up and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
40963668|NCT03874637|DEVICE|Treament|Placement of the FemPulse System with therapy delivery
40963669|NCT03874637|DEVICE|Sham Control|Placement of the FemPulse System without therapy delivery
41294454|NCT01374581|DRUG|Artemether/Lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~Weight in kg Number of tablet per dose Age 5 to \< 15 kg 1 tablet per dose 15 to \< 25 kg 2 tablets per dose 25 to \< 35 kg 3 tablets per dose"
41294455|NCT01374581|DRUG|Artesunate/Amodiaquine|"Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to \< 9kg):1 tablet (25 mg/675mg) for 3 days~1 to 5 years (= 9 kg to \< 18 kg)1 tablet(25mg/67,5mg)for 3 days"
41294456|NCT01374581|DRUG|Quinine + Clindamycin|"this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to \< 11 kg: ½ tablets 12 to \< 19 kg: 1 tablets per dose 20 to \< 27 kg: 1½ tablets per dose 28 to \< 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily"
41294457|NCT03074448|DEVICE|Aquanet|Aquanet bowel cleansing devices
41294458|NCT03074448|DRUG|Sodium Picosulfate|Sodium Picosulfate solution (Picoprep)
41294459|NCT05268094|DEVICE|Ductal Arterial Stent|Drug-eluting ductal arterial stents will be placed by transcatheter method.
40963670|NCT04053101|DEVICE|PET CT|Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).
40963671|NCT01031927|DRUG|N-methyl glycine|staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
40963672|NCT01023620|DRUG|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
40963673|NCT01023620|OTHER|Observation|Participants will be observed for 16 weeks but will not receive drug
40963674|NCT05055362|OTHER|Honey Spice Group|Consume baked good daily for 10 days and provide samples of saliva, urine and dietary habits and spice intake.
40765751|NCT03809000|DRUG|GnRH analog|Injection
40963675|NCT04961931|DRUG|Empagliflozin 10 MG|After qualifying for the study all subjects received oral empagliflozin 10 mg once daily for 7 days.
41136747|NCT05307952|BEHAVIORAL|Personalized training|Self-administered training exercises focused on the speech components the participants are experiencing difficulties into
41294460|NCT05268094|PROCEDURE|Systemic-to-Pulmonary Artery Shunt|A surgical connection will be made between a systemic artery and the pulmonary artery.
41294461|NCT01804361|DRUG|Haporine-S|1 or 2 drops twice a day at 12 hour interval for 12 weeks
41294462|NCT01804361|DRUG|Restasis (cyclosporine 0.05%)|1 or 2 drops twice a day at 12 hour interval for 12 weeks
41294463|NCT04788303|OTHER|School meal, garden, education, and community workshops|"School meal: midday meal provided at intervention schools~School garden: garden used to grow crops (which will be used to supplement the school meal in the full intervention schools)~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
40765752|NCT06642584|DRUG|Semaglutide B|Semaglutide B will be administered subcutaneously.
40765753|NCT06642584|DRUG|Semaglutide J|Semaglutide J will be administered as oral tablets.
40765754|NCT06642584|DRUG|Semaglutide L|Semaglutide L will be administered as oral tablets.
40765755|NCT06642584|DRUG|Semaglutide M|Semaglutide M will be administered as oral tablets.
40765756|NCT06642584|DRUG|Semaglutide N|Semaglutide N will be administered as oral tablets.
40765757|NCT04119037|PROCEDURE|Cordotomy|Undergo cordotomy
40765758|NCT04119037|DRUG|Morphine|Given via injection
40963676|NCT03845985|BEHAVIORAL|Seeking Safety + Signs of Safety toolkit|"Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters."
40963677|NCT03393130|DIAGNOSTIC_TEST|APOE genotyping|APOE genotyping and broad cognitive assessment expressed as a median T-score of the following tests (with cognitive domains assessed in brackets) Trail Making Part A (processing speed), Trail Making Part B (executive function), One Back test (working memory), List Learning Task (Immediate recall, visual learning, delayed recall and recognition discrimination).
40963678|NCT06312345|DRUG|Drug: ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
40963679|NCT02727361|RADIATION|PET (Positron Emission Tomography) imaging|Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
40963680|NCT02727361|OTHER|MRI : Magnetic Resonance Imaging|Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
40963681|NCT05889377|PROCEDURE|Socket preservation|Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.
40963682|NCT04353271|DRUG|Hydroxychloroquine|Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.
40963683|NCT04353271|OTHER|Placebo|Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.
40963684|NCT06374901|DRUG|Tislelizumab|Preoperative treatment with Tislelizumab
40963685|NCT06374901|DRUG|SOX/XELOX|Preoperative treatment with SOX/XELOX
40963686|NCT05675397|DIETARY_SUPPLEMENT|donor human milk|Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding
40963687|NCT00969917|DRUG|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
40963688|NCT00735410|BIOLOGICAL|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
40963689|NCT04915144|DRUG|177Lu-DOTATOC|Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
40963690|NCT03586180|BEHAVIORAL|Medical Clowning for children|Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.
40963691|NCT01744574|OTHER|Placebo|Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
40963692|NCT01744574|DRUG|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
40963693|NCT01744574|OTHER|Smoking Cessation Behavioral Counseling|Subjects will receive weekly smoking cessation behavioral counseling.
40963694|NCT00284583|DRUG|Injection of Steroid into Foot|
40963695|NCT00284583|DRUG|Injection of Alcohol into Foot|
40963696|NCT00284583|DRUG|Injection of Lidocaine into Foot|
40765759|NCT04119037|OTHER|Questionnaire Administration|Ancillary studies
40963697|NCT03123913|DRUG|Testosterone Enanthate|Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.
40963698|NCT03123913|DRUG|Somatropin|Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
40963699|NCT05106686|DIETARY_SUPPLEMENT|Aureobasidium pullulans produced β-glucan group|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
40963700|NCT05106686|DIETARY_SUPPLEMENT|placebo group|Placebo 300 mg/day for 12 weeks
41294464|NCT04788303|OTHER|Garden, education, and community workshops|"School garden: garden used to grow crops~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
40765760|NCT04119037|PROCEDURE|Sham Intervention|Undergo fake cordotomy
40963701|NCT02366052|BEHAVIORAL|Nutritional Counseling|Nutritional counseling by a trained nutritionist for 12 weeks.
40765761|NCT06642402|DIAGNOSTIC_TEST|Kidney biopsy|Patient refered to kidney biopsy independent of the presented study
40963702|NCT02366052|DIETARY_SUPPLEMENT|Lactobacillus casei shirota (LCS)|The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.
40963703|NCT02366052|OTHER|Nutritional Counseling and LCS|Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.
40963704|NCT03217630|OTHER|Fasting 2 h after clear liquid or 6h after a light meal|The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
41294465|NCT02225223|DEVICE|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
40765762|NCT06642402|DIAGNOSTIC_TEST|Urinary extracellular vesicle testing|Urinary extracellular vesicles will be isolated and tested for complement activation and other markers of kidney disease
40963705|NCT01346449|BEHAVIORAL|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
41294466|NCT02225223|DEVICE|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
40765763|NCT06642402|DIAGNOSTIC_TEST|Autoimmunity in plasma|Expected autoimmunity in plasma isolated from blood samples
40765764|NCT05566769|DEVICE|NMOSDCopilot smartphone application|NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladder and bowel dysfunction, depression
40765765|NCT06532565|DRUG|GS-2121|Tablet administered orally
40765766|NCT06532565|DRUG|Zimberelimab|Administered intravenously
40765767|NCT04649749|DIAGNOSTIC_TEST|MRI|MRI scan
41294467|NCT03112837|OTHER|Lactobacillus, Bifidobacterium and Enterococcus|3 pills two times a day during the whole treatment
41294468|NCT04452812|BIOLOGICAL|Convalescent plasma|"Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
41294469|NCT06312007|OTHER|Semi seated position|The patient is positioned 45-90 degrees
41456747|NCT04292691|DRUG|40ml of Ropivacaine 0.5% Injectable Solution|already outlined in the arm/group description
41456748|NCT04292691|DRUG|40ml of Ringer's Lactate|already outlined in the arm/group description
41456749|NCT06482606|OTHER|Flickering Checkerboard Stimulation|This visual stimulation is a succession of alternating black and white squares on a small monitor in the scanner, the black and white checkerboard creates the effect of flickering lights.
40765768|NCT02284893|DRUG|Saxagliptin|administered orally once daily
40765769|NCT02284893|DRUG|Dapagliflozin|administered orally once daily
40765770|NCT02284893|DRUG|Sitagliptin|administered orally once daily
40765771|NCT02284893|DRUG|Placebo matching with Saxagliptin|administered orally once daily
40765772|NCT02284893|DRUG|Placebo matching with Dapagliflozin|administered orally once daily
40765773|NCT02284893|DRUG|Placebo matching with Sitagliptin|administered orally once daily
40765774|NCT05575440|PROCEDURE|Computed Tomography|Undergo a PET/CT scan
40765775|NCT05575440|RADIATION|Fluorine F 18 Tetrafluoroborate|Given IV
40765776|NCT05575440|PROCEDURE|Positron Emission Tomography|Undergo a PET/CT scan
41294470|NCT06312007|OTHER|side lying position|Side lying position
41456750|NCT05626348|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
41456751|NCT05626348|DRUG|Methotrexate|Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
40963706|NCT01346449|BEHAVIORAL|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
40963707|NCT01346449|BEHAVIORAL|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
40963708|NCT01346449|BEHAVIORAL|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
40963709|NCT06052085|OTHER|Pain Neuroscience Education|Four sessions of Pain Neuroscience Education will be applied. The neurophysiology of pain and the ability of the nervous system to modulate the experience of pain will be explained to the patient.
40765777|NCT05575440|OTHER|Survey Administration|Ancillary studies
40765778|NCT06636838|BEHAVIORAL|Spanish-Speaking Provider|Spanish speaking patients will be seen by our Spanish-speaking provider
41294471|NCT00221845|DRUG|ACE Inhibition|ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
41294472|NCT00221845|DRUG|Intensified Blood Pressure Control|Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
41456752|NCT05626348|DRUG|Adalimumab Injection|Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
40765779|NCT06138639|GENETIC|SGT-003|Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)
40765780|NCT06224348|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
40765781|NCT06224348|DRUG|Placebo|Pharmaceutical form: injection solution Route of administration: SC injection
40765782|NCT06224348|DRUG|Topical corticosteroids|Pharmaceutical form: Topical formulation Route of administration: Topical
40963710|NCT06052085|OTHER|Biomedical Pain Education|4 sessions of Biomedical Pain Education will be applied in 6 weeks. Pain will be explained to the patient from a biological point of view.
40963711|NCT06052085|OTHER|Standard Physiotherapy Program|Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks. Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks.
40963712|NCT06506149|DEVICE|Microwave ablation(MWA) device|The device for USG-guided MWA treatment would be performed under USG guidance, aiming to ablate the entire thyroid gland, i.e. the right lobe, left lobe, isthmus and pyramidal lobe.
41294473|NCT00221845|DRUG|Add-on Angiotensin Receptor Blockade|In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
41294474|NCT00723840|OTHER|Observational Studies: participants treated according to the real clinical practice.|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
41294475|NCT04254237|PROCEDURE|Infraumbilical Hasson trocar incision|Infraumbilical Hasson trocar incision
41456753|NCT05626348|DRUG|Leflunomide|Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
40765783|NCT06224348|DRUG|Topical calcineurin inhibitors|Pharmaceutical form: Topical formulation Route of administration: Topical
40765784|NCT04333576|DRUG|Elagolix|Tablet:Oral
40765785|NCT04333576|DRUG|Placebo|Tablet:Oral
40765786|NCT04333576|DRUG|Combined Oral Contraceptive|Tablet:Oral
40963713|NCT00358683|DRUG|Certolizumab pegol|
41136748|NCT01182532|OTHER|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
41294476|NCT04254237|PROCEDURE|Supraumbilical Hasson trocar incision|Supraumbilical Hasson trocar incision
41294477|NCT05715541|OTHER|"mobile applications with the name Set My INR"|"The relevant software company assisted in developing the phone application. The language of the application created with the name Set My INR is Turkish. The application provided an opportunity for patients to share and communicate with their physician after having the INR value measured in a health institution near their place of residence before coming to the hospital"
41294478|NCT01477216|OTHER|ELSA 1-9|Measuring GI and II values for Finnish foods
41294479|NCT04567316|DRUG|[14C]-radiolabelled BI 1358894|Part 1
41294480|NCT04567316|DRUG|BI 1358894|Part 2
41294481|NCT02392208|DRUG|Telavancin|A single 5 mg/kg dose of telavancin is administered intravenously (IV).
41456754|NCT05626348|DRUG|Hydroxychloroquine|Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
40765787|NCT06287073|DRUG|JARDIANCE®|JARDIANCE®
40765788|NCT06507956|OTHER|Characterize the physical activity and sedentary lifestyle profile of adults with cystic fibrosis|Eligible patients will be presented with the study during a routine care visit CF center, at the end of a physiotherapy, adapted physical activity or nurse session, in accordance with the schedule for the day's visit, with no changes induced by this study. After sufficient time for reflection, patients agreeing to participate will be given self-questionnaires. From this visit, a proposal to participate at V2 will be made only to the inactive/hight sedentary patients on the ONAPS-PAQ questionnaire, under elexacaftor-tezacaftor-ivacaftor (ETI). Volunteers will know their participation in either actimetry or a qualitative interview following a draw. At V2, 40 patients will be offered a 7-day longitudinal follow-up by actimetry, and between 10 to 15 patients will take part in an qualitative semi-structured interview identifying motivational barriers and levers for action. At V3, patients monitored by actimetry will be invited to return their actimeter by postage-paid mail.
40765789|NCT04654052|DRUG|Clopidogrel|Clopidogrel during 11 months
40765790|NCT04654052|DRUG|Previous treatment|non-intervention
41294482|NCT02392208|PROCEDURE|Pharmacokinetic Blood Sampling|Blood samples are collected to assess telavancin plasma concentrations.
41294483|NCT03465852|BEHAVIORAL|ChiCAS|Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
41294484|NCT02527876|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Training
41294485|NCT02527876|BEHAVIORAL|Moderate Intensity|Moderate Intensity Training
41294486|NCT02527876|BEHAVIORAL|Delayed Control|Delayed Control
40765791|NCT06639425|DIETARY_SUPPLEMENT|Lactobacillus paracasei LC19 supplementation|Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).
40765792|NCT06639425|DIETARY_SUPPLEMENT|Placebo probiotic milk powder|Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).
40765793|NCT06527872|OTHER|None (Observational study)|Not Applicable since Observational Study
40765794|NCT03537508|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
40765795|NCT03537508|BIOLOGICAL|MenACYW-135 conjugate vaccine|Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular
40765796|NCT03537508|BIOLOGICAL|DTaP-IPV//Hib vaccine|DTaP-IPV//Hib vaccine at 2, 4, 6 and 12 to 15 (Group 1a)/15-18 (Group 1b and Group 2) months of age Intramuscular
40963714|NCT04678245|BEHAVIORAL|Above the Influence-Vaping (ATI-V)|Peer-nominated 8th grade and 9th grade Peer Leaders (PL) will be trained in a half day ATI-V training. Adult Advisors (AA) will attend a half day ATI-V AA training and the PL training. The training day builds leadership skills in the PLs, develops skills for rising above pressure to vape including identification of personal reasons to rise, identification of healthy support people, teaching accurate use statistics, and sharing stories of prior success in rising above negative pressures. The ATI-V team of PLs and AAs then will run four interactive messaging campaigns to reach the rest of the student body. These four campaigns are (1) Introduction to ATI-V and My Reasons to Rise (2) Gain and Loss (3) Who's Got My Back (4) The Facts. Each campaign features a portion in which PLs model healthy norms and behaviors, and a second portion in which all the rest of the students engage in an interactive component to build and demonstrate the target skill.
40963715|NCT03125317|OTHER|Music|a kind of music which the participant likes will be listened using speakers
40963716|NCT03125317|OTHER|Valsalva maneuver|Participant will be asked to take a deep breath and exhale the air out in 15 seconds
40963717|NCT03125317|OTHER|control|No intervention
40963718|NCT06111300|DRUG|Dexmedetomidine|Group D (dexmedetomidine group): Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery. Group C (control group): Patients in this group will receive volum- matched normal saline infusion (NaCL 0.9%) as a placebo.
41294487|NCT02527876|DEVICE|FitBit Flex|Use to measure increase in Physical Activity
41294488|NCT02102061|OTHER|multidisciplinary intervention|"a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from Health at Every Size."
41294489|NCT03832868|BEHAVIORAL|Pre-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
41294490|NCT03832868|BEHAVIORAL|Post-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
40765797|NCT03537508|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular
40765798|NCT03537508|BIOLOGICAL|Pentavalent rotavirus vaccine|Rotavirus vaccine at 2, 4, and 6 months of age, oral solution
40765799|NCT03537508|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine at 2 and 6 months of age, Intramuscular
40765800|NCT03537508|BIOLOGICAL|Measles, mumps, rubella (MMR) vaccine|MMR vaccine at 12 months of age, Subcutaneous
40765801|NCT03537508|BIOLOGICAL|Varicella vaccine|Varicella vaccine at 12 months of age
40963719|NCT03262909|DEVICE|GelrinC|Patients will undergo GelrinC implantation.
40765802|NCT03537508|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine at 15 to 18 months of age
40765803|NCT06319872|DRUG|Oral disulfiram|250 mg/day
40765804|NCT05702450|BIOLOGICAL|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
40765805|NCT06095102|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
40765806|NCT06095102|DRUG|Placebo|Placebo will be administered orally.
40765807|NCT06643598|BEHAVIORAL|Abecedarian Approach|The Abecedarian Approach is an early childhood behavioral education program that aims to improve the learning and cognitive development of children in high-risk or at-risk communities. This study will test the efficacy of implementing this approach in a virtual format.
40765808|NCT01556334|DRUG|Azithromycin|Azithromycin 1g po
40765809|NCT01556334|DRUG|Erythromycin|Erythromycin IV then PO
40765810|NCT05463731|DRUG|Remternetug (IV)|Administered IV
40765811|NCT05463731|DRUG|Remternetug (SC)|Administered SC
40765812|NCT05463731|DRUG|Placebo|Administered IV or SC
40963720|NCT03262909|OTHER|Microfracture historical control arm|Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
40963721|NCT00008203|BIOLOGICAL|aldesleukin|
40963722|NCT00008203|BIOLOGICAL|recombinant interferon gamma|
40963723|NCT00008203|DRUG|carboplatin|
40963724|NCT00008203|DRUG|cyclophosphamide|
40963725|NCT00008203|DRUG|cyclosporine|
40963726|NCT00008203|DRUG|thiotepa|
40963727|NCT00008203|PROCEDURE|autologous bone marrow transplantation|
40963728|NCT00008203|PROCEDURE|peripheral blood stem cell transplantation|
40963729|NCT05810883|DIAGNOSTIC_TEST|Blood Tests; Serum Fasting Insulin and Glucose|"Laboratory results of blood samples, for high-density lipoprotein (HDL), low-density protein (LDL), triglycerides, and total cholesterol (TC) will be evaluated for this study. Fasting Insulin and fasting glucose levels will be used to calculate IR.~Insulin Resistance will be calculated using Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (FPG (mmol/L) × FPI (mU/L)/22.5) \[21\] and defined as HOMA-IR ≥ 3.4"
41136749|NCT01182532|DRUG|TCM Syndrome Differentiation and Treatment|"1. Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.~   Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.~   Dosage: Adjusting by age and weight of patients. Decoction.~2. Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction."
40963730|NCT01136603|DEVICE|TIGR Mesh|TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
40963731|NCT02521870|DRUG|SD-101(1)|SD-101 administered intratumorally at escalating doses (up to 11 doses).
41294491|NCT00862381|DRUG|Hydrocortisone|hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
41294492|NCT00862381|DRUG|Placebo|NaCl 0.9%
40963732|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).
40963733|NCT02521870|DRUG|SD-101(2)|Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
40963734|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
40963735|NCT02521870|BIOLOGICAL|SD-101(3)|Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).
40963736|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
40963737|NCT02609269|OTHER|Decipher Cancer Classifier|The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA \& CAP certified laboratory in San Diego, CA
40963738|NCT02165215|DRUG|Etrolizumab|Participants will receive 105 mg etrolizumab SC injection Q4W.
40963739|NCT02165215|DRUG|Placebo|Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
40963740|NCT00730769|DRUG|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
40963741|NCT06434259|DEVICE|Digi-physical support system|A support system named Evira will be used to provide behavioral treatment.
40963742|NCT00866385|DRUG|AZD8566|Single 6 mg oral solution dose
41294493|NCT00003881|BIOLOGICAL|trastuzumab|
41294494|NCT00003881|DRUG|carboplatin|
41294495|NCT00003881|DRUG|paclitaxel|
40963743|NCT00866385|DRUG|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
40963744|NCT01459471|PROCEDURE|Bariatric surgery|Staple line reinforcement during sleeve gastrectomy
40963745|NCT01783262|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
40963746|NCT01783262|DEVICE|Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|
40963747|NCT04177667|DIETARY_SUPPLEMENT|Proxeed|Treatment with dietary supplement for male infertility for Proxeed Arm
40963748|NCT04177667|OTHER|Placebo|Treatment with placebo for Placebo Arm
40963749|NCT04394286|GENETIC|SHP648|Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
40963750|NCT05827380|BEHAVIORAL|Gait adaptability training|During a period of approximately 5 weeks participants will receive 10 one hour training sessions aimed at improving gait adaptability, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be offered.
40765813|NCT03812848|OTHER|Anticoagulation Stewardship Program|"A clinical-pharmacist led anticoagulation stewardship program that includes:~1. Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients."
40963751|NCT00766337|DRUG|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
40963752|NCT00766337|DRUG|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
40963753|NCT00766337|DRUG|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
40963754|NCT00048321|DRUG|ISIS 104838|
40963755|NCT03903068|DEVICE|NEXALIN ADI AC stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. The three electrodes are placed in this way to enhance the performance of the Nexalin ADI device. When the device is activated, there will be a weak current passing through the forehead electrode and each mastoid electrode. The current intensity of Nexalin ADI treatment defaults to 15.00 mA and the duration defaults to 40 minutes. Both are preset to default parameters and cannot be changed.
40963756|NCT03903068|DEVICE|Pseudo-stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. When the device is started, no current flows through the electrodes, but the instrument's operating procedures, parameter displays, and prompts are the same as for a real instrument.
40963757|NCT00297583|DRUG|Insulin Glulisine|
40963758|NCT04176978|DRUG|Rosuvastatin|Patient in this group will receive Rosuvastatin 20mg daily.
40963759|NCT04176978|OTHER|Treat-to-target strategy|Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.
40963760|NCT02139631|OTHER|Noninvasive ventilation|Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
40963761|NCT03567304|DRUG|Rilpivirine 25 mg|Rilpivirine 25 mg PO OD with meal (and continue 2 back bone of NRTIs)
40963762|NCT05705414|DRUG|Valine|A medical food intended for use under medical supervision
40963763|NCT05705414|DRUG|EEA|A medical food intended for use under medical supervision
40963764|NCT00660309|DRUG|Aliskiren|Aliskiren 300 mg tablets
40963765|NCT00660309|DRUG|Irbesartan|Irbesartan 300 mg tablets
40963766|NCT00660309|DRUG|Captopril|Captopril 25 mg tablet
41136750|NCT01182532|OTHER|Western therapy plus TCM treatment|"1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Syndrome differentiation and treatment adopting the same methods in TCM treatment group."
41136751|NCT03192189|OTHER|monitoring for progression to chronic kidney disease|Collect clinical information and assess risk factors
41136752|NCT05508854|GENETIC|prenatal genetic counselling|Prenatal genetic counseling is a consultancy service that covers the evaluation of the risk status of the baby in the mother's womb in terms of genetic diseases, the tests and risks that can be done for the diagnosis of the disease, the test results and information about the disease in case of illness and the presentation of options.
41136753|NCT05376397|BEHAVIORAL|iTHRIVE 365|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) of interventions with mHealth features, THRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. THRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. THRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of BSMM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
40963767|NCT02872194|DRUG|BAY987516, Y55-170|10 uL in one eye
40963768|NCT02872194|DRUG|BAY987516, X72-151|10 uL in one eye
40963769|NCT02872194|DRUG|BAY987516, Y49-034|10 uL in one eye
40963770|NCT02872194|DRUG|Standard shampoo mixture (control)|10 uL in one eye
40963771|NCT02619175|DEVICE|Stroke Subjects Perturbation-Based Balance Training|
40963772|NCT02619175|DEVICE|Stroke Subjects Weight Shifting and Gait training|
40963773|NCT03167411|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
40963774|NCT03167411|DRUG|Exenatide Injection|Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
40963775|NCT05698797|OTHER|Hip strengthening exercises|Hip abductor and external rotator strengthening exercises were performed for 4 weeks.
40963776|NCT05698797|OTHER|Proprioceptive training|Proprioceptive training consisted of eight exercises was performed for 4 weeks.
40963777|NCT05698797|OTHER|Conventional physical therapy|Conventional physical therapy included interferential therapy and two types of knee-strengthening exercises.
40963778|NCT06504940|DRUG|Orelabrutinib combined with bendamustine and rituximab|they will receive three cycles of Orelabrutinib combined with bendamustine and rituximab (BR: bendamustine 70mg/m\^2 on days 1-2; rituximab 375mg/m\^2 on day 0). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 21 cycles, each cycle 28 days).
40963779|NCT06504940|DRUG|Orelabrutinib combined with obinutuzumab|they will receive six cycles of Orelabrutinib combined with obinutuzumab (G 1000mg iv on days 1, 8, 15 of cycle 1, and day 1 of cycles 2-6; Orelabrutinib 150mg once daily). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 18 cycles, each cycle 28 days ).
40963780|NCT01929005|OTHER|Comprehensive Care|Patients will receive comprehensive medical care from their CCP in clinic and the hospital. For most patients, the ambulatory care provided by the CCP will be in our onsite medicine clinic, but for some patients with subspecialty needs the CCP may be a specialist who will care for the patient in a nearby ambulatory setting (e.g., nursing home, dialysis facility). The CCPs will also supervise the nurses, pharmacists, social workers, and others who are part of the multi-disciplinary care team. Daytime inpatient care will be provided by CCPs in conjunction with our inpatient advanced practice nurses (APNs). These APNs now work with our hospitalists, so they are experienced providing hospital care.
40963781|NCT00959231|DRUG|cyclophosphamide|
40963782|NCT00959231|DRUG|cyclosporine|
40963783|NCT00959231|DRUG|fludarabine phosphate|
40963784|NCT00959231|DRUG|mycophenolate mofetil|
40963785|NCT00959231|OTHER|laboratory biomarker analysis|
40963786|NCT00959231|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
40963787|NCT00959231|PROCEDURE|umbilical cord blood transplantation|
40963788|NCT00959231|RADIATION|total-body irradiation|
40963789|NCT01280175|PROCEDURE|charcoal block|
40963790|NCT01280175|DEVICE|Aerochamber Plus spacer|
40963791|NCT01280175|DRUG|pMDI standard actuator|
40963792|NCT01932112|DRUG|Adenosine arm|After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
40963793|NCT06558032|DRUG|Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia)|One tablet of the test drug was given orally under fasting condition
40963794|NCT06558032|DRUG|Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)|One tablet of the test drug was given orally under fasting condition
40963795|NCT01238471|DRUG|propranolol|2 mg per kg per day divided in 3 doses for 2-4 weeks
41136754|NCT02039999|OTHER|Nebulised citric acid in serial dilutions|Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
40963796|NCT01238471|DRUG|sucrose 5%|2 ml per Kg per day divided in 3 doses for 2-4 weeks
40963797|NCT01804075|DRUG|Methadone|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
40963798|NCT01804075|DRUG|Morphine|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
41136755|NCT02039999|OTHER|Nebulised ATP solution in serial dilutions|ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
40963799|NCT02883270|DEVICE|Robot-assisted Gait Training|Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
40963800|NCT02883270|OTHER|conventional rehabilitation|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
40963801|NCT03013738|BEHAVIORAL|Growing Pro-Social Program|GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
40963802|NCT03013738|OTHER|Treatment As Usual|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
40963803|NCT01486667|DRUG|levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
40963804|NCT01486667|DRUG|sugar pill|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
40963805|NCT05404776|OTHER|Placement of Foley balloon for cervical ripening with tension.|A Foley balloon will be placed for cervical ripening with tension.
40963806|NCT05404776|OTHER|Placement of Foley balloon for cervical ripening without tension.|A Foley balloon will be placed for cervical ripening without tension.
40963807|NCT04449900|OTHER|This is observational study with the examination of OCTA|This is observational study with the examination of OCTA
40963808|NCT03031314|DEVICE|barbed suture|
40963809|NCT03031314|DEVICE|standard suture|
40963810|NCT01774604|DRUG|Indomethacin|100 mg Indomethacin PR x 1
40963811|NCT01774604|DRUG|Placebo|
40963812|NCT01003288|BIOLOGICAL|Adjuvanted influenza H1N1split virion vaccine|"Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)~\* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)"
40963813|NCT06485765|OTHER|Diet planning|Healthy eating planning
40963814|NCT05707767|PROCEDURE|Resection surgery|Patients undergo resection surgery in our hospital.
40963815|NCT02853604|DRUG|ADXS11-001|
40963816|NCT02853604|DRUG|Placebo|
40963817|NCT00961233|DRUG|inhaled/swallowed budesonide|medication will be nebulized and then swallowed
40963818|NCT00961233|DRUG|viscous/swallowed budesonide|viscous suspension of budesonide will be swallowed
40963819|NCT03617497|DIAGNOSTIC_TEST|scalp EEG and polysomnography|48 hour 22 channel EEG with polysomnography
40963820|NCT03617497|DIAGNOSTIC_TEST|scalp EEG with foramen ovale electrodes with polysomnography|long-term scalp EEG with additional foramen ovale electrodes with polysomnography
40963821|NCT03924453|DIAGNOSTIC_TEST|Pearl Powered by Proov|Participants self test in their homes and report back data via uploading onto an app and taking surveys.
40963822|NCT05012332|PROCEDURE|Erector Spinae Plane Block|All volunteers receive an Erector Spinae Plane Block and an MRI.
40963823|NCT05699031|DEVICE|APP|Patients allocated in the app-group will use the newly developed smartphone app te rehabilitate. 5 exercises are provided daily. Daily questionnaires will monitor exercise performance, VAS pain, household activities. Information modules will be sent at specific times.
40963824|NCT05699031|OTHER|PHYSICAL THERAPY|Patients allocated in the physio-group will go, twice a week, to a physical therapist of their choice to rehabilitate. The physical therapist will follow the general guidelines provided by the hospital (surgeon).
40963825|NCT03390816|OTHER|Nutritional assessment|Observational
40963826|NCT01032837|DRUG|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
40963827|NCT01032837|DRUG|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
40963828|NCT01032837|DRUG|Placebo|Matching placebo provided as capsules and as a suspension.
40963829|NCT04847947|DRUG|Cholecalciferol|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks
40963830|NCT04847947|DRUG|Placebo|Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
40963831|NCT01758562|DEVICE|Caphosol|
40963832|NCT06184100|OTHER|Virtual Self-Management Program (SMP)|Four sessions, 60-90 minutes each, will be conducted over eight weeks with a group size of 4-6 participants via videoconferencing platforms such as Zoom or Microsoft Teams. Each session will include Power Point delivered presentations, interactive activities, and group discussions. This is a multifaceted program that includes JIA disease education, self-management strategies, and peer support.
40963833|NCT06184100|OTHER|No Intervention|No intervention. Participant only receives standard of care.
40963834|NCT02703662|DEVICE|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
41294496|NCT06416839|BEHAVIORAL|VR exercise|Participation in high intensity interval training delivered on a virtual reality headset over six-week period. Participants may exercise with others in the multiplayer mode and use any feature of the application.
40963835|NCT02703662|DEVICE|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
40963836|NCT04394260|BEHAVIORAL|Savvy Caregiver Program via Remote Learning|The SCP program is comprised of four pre-recorded Savvy Caregiver videos (each 1 hour and 45 minutes in length). Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of enjoyable involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
40963837|NCT04394260|BEHAVIORAL|Focus group|After watching the Savvy Caregiver videos participants will take part in a focus group to discuss their experience with the SCP and how the course material applies to them as a LGBT caregiver. The semi-structured discussion will include, but not be limited to the following questions: 1) Can you tell me about your role as a caregiver? (Probes: living situation, experiences, challenges). 2) What went well with the SCP, and what could be improved? 3) How relevant to your situation as an LGBT caregiver were the course materials? 4) How well did the questionnaire reflect your experiences with discrimination due to sexual orientation and/or gender identity? (Probe about when working with your care recipient's health care providers, in-home aides/visiting nurses, adult day care staff, respite, etc? 5) What are some of the additional caregiver challenges that should be considered in these questionnaires? (Probes: mental health, physical health, and social life strain, Quality of life, stress).
40963838|NCT06045884|PROCEDURE|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
40963839|NCT06045884|DRUG|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
40963840|NCT06045884|DRUG|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
40963841|NCT05353283|BEHAVIORAL|Motivational Interviewing Counselling|Motivational interviewing-based counseling will be provided to the participant based on the results of the urine test
40963842|NCT05353283|DEVICE|Point-of-care Urine Tenofovir Measurement|Urine will be collected and the presence or absence of tenofovir will be measured with the point-of-care urine tenofovir test.
40963843|NCT05466877|DRUG|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
40963844|NCT05466877|DRUG|Placebo|MG-K10 Humanized Monoclonal Antibody Injection
40963845|NCT00257101|BEHAVIORAL|self-medication monitoring|
40963846|NCT04922775|PROCEDURE|conventional taping|Participants will accept conventional taping before muscle fatigue exercise.
40765814|NCT06641492|BEHAVIORAL|Chatbot-delivered interventions tailored to one's stage of changes|The Chatbot will assess participants' physical activity level and stage of changes regarding physical activity and automatically deliver interventions tailor to their stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
40963847|NCT04922775|PROCEDURE|Chinese medicine technique taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise.
40963848|NCT02316106|DRUG|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
40963849|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
41294497|NCT06513728|OTHER|MPACT Intervention|MPACT has 4 components: accredited training about patient centered, trauma informed methadone treatment, staff education about trauma symptoms with navigation to self screening and treatment or stress management, clinic self assessment tools for trauma informed, patient centered care, and reflective supervision for counselors, case managers and peer staff.
40963850|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
41136756|NCT02039999|OTHER|Nebulised TRPA1 agonist solution in serial dilutions|TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
41294498|NCT03027817|PROCEDURE|Prone Positioning|Noninvasive cardiac output monitoring parameters were recorded before and after prone positioning.
41294499|NCT06132490|DEVICE|Valveless Insufflator with 12 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under low intra-abdominal pressure throughout the surgery.
41294500|NCT06132490|DEVICE|Valveless Insufflator with 8 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under ultra-low intra-abdominal pressure throughout the surgery.
41294501|NCT04237207|DEVICE|Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software|Control cochlear implant sound processor
41294502|NCT04237207|DEVICE|301-M062 sound processor & software|New cochlear implant sound processor
41294503|NCT02385461|DRUG|Low Molecular Weight Heparins (LMWHs)|
40765815|NCT06641492|BEHAVIORAL|Chatbot-delivered standard interventions|The Chatbot will not assess participants' stage of changes. It will assess participants' physical activity level and provides a standard intervention covering general information about physical activity for older adults, which is not tailoring to participants' stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
40765816|NCT06640335|OTHER|Co-ingestion|Subjects co-ingest both (300 g mashed potatoes) and (200 g baby round spinach supplemented with canola oil) in the same time.
40765817|NCT06640335|OTHER|0 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, then directly consume 300 g of mashed potatoes.
40765818|NCT06640335|OTHER|5 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 5 minutes, then consume 300 g of mashed potatoes.
40990641|NCT04824170|OTHER|Rhythmic stabilization technique|"This group was receiving (PNF) Rhythmic stabilization technique with base line treatment.~Subject was lying in spine position on the treatment table and therapist resist an isometric contraction of agonist muscle group.pt maintain this position for 10 sec without trying to move and 12-15 repetitions were performed with 30 sec rest. Each therapeutic session treatment was focused on facilitation of neck stabilizers, improving neck stability, coordination, decreasing pain and improving postural control"
41136757|NCT02539576|DRUG|ABC/DTG/3TC FDC tablet|"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."
41456755|NCT03028792|BEHAVIORAL|Attention Modification Program|"Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe."
41456756|NCT03028792|BEHAVIORAL|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threat material. In this case, the probe randomly replaces the threat or neutral stimulus."
41294504|NCT00202410|BIOLOGICAL|Bacille of Calmette-Guerin|A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).
41456757|NCT02321839|DRUG|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
41294505|NCT00202410|OTHER|placebo|subcutaneous administration of physiologic solution
41456758|NCT01143337|DRUG|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
41456759|NCT01143337|DRUG|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
41456760|NCT05840601|DEVICE|Pointdexter|Commercially available prosthetic hand modified with the investigational Pointdexter finger in place of the usual index finger.
41294506|NCT01682369|BIOLOGICAL|TIV (Aggripal)|
41294507|NCT01682369|BIOLOGICAL|ATIV (Fluad)|
41294508|NCT04726267|DEVICE|Wide-field optical coherence tomography|Merged 4 images of wide-field optical coherence tomography, 2 images of vertical scan and 2 images of horizontal scan.
41294509|NCT03652415|DEVICE|Artificial tears (classified by MHRA as a medical device)|Use of artificial tears
41294510|NCT02421120|DRUG|Ceftolozane/Tazobactam|1 hour intravenous infusion
41456761|NCT05840601|DEVICE|Comparator|Unmodified commercially available prosthetic hand.
41456762|NCT01118767|OTHER|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
41294511|NCT01079793|DRUG|ixabepilone|
41294512|NCT01079793|PROCEDURE|adjuvant therapy|
41294513|NCT01079793|RADIATION|intensity-modulated radiation therapy|
41294514|NCT01080989|OTHER|diagnosis, treatment and education|"Drug:~anti-intestinal parasitic drugs:~1. mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)~2. albendazole(400 mg bid \* 7days) or Ivermectin(200 mcg/kg/day \* 2 days) (For Strongyloidiasis).~Behavior:~1. Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.~2. Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents."
41136758|NCT05689073|DEVICE|Conversational AI system|The conversational AI system based on LLM processes user queries with a sophisticated generation, decision, action, and safety framework to provide optimal feedback. The system has several key features. Firstly, it utilizes retrieval-augmented in-context learning to enhance responses generated by the LLM, sourcing information from trustworthy websites. Secondly, it includes Guardrail module that addresses potential harmful content in the LLM-generated responses by clarifying and validating the content before delivery. Furthermore, the AI system is equipped with Self-checking memory module that retains essential clinical characteristics across multi-turn dialogues, ensuring the continuity and consistency of its interactions with users. The educational content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
41136759|NCT05689073|OTHER|Printed educational Brochure|A printed brochure whose content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
41294515|NCT04277572|PROCEDURE|Aortic valve replacement|Aortic valve surgery
41294516|NCT01753518|DEVICE|Subcuticular suture|subcuticular Monocryl suture closure
41294517|NCT01753518|DEVICE|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
41136760|NCT04417075|BEHAVIORAL|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for Spanish-speaking, Latinx smokers with high anxiety sensitivity and will be built for the Android platform. The app will include components to address and remediate anxiety sensitivity, as well as having smoking cessation components.
41294518|NCT01635556|BEHAVIORAL|Dialectical Behavior therapy|Weekly psychotherapy of both individual and group sessions
41294519|NCT00178321|DEVICE|earplugs|
41294520|NCT03435653|OTHER|OFD with DFDBA|Control Group Open flap debridement with DFDBA Periodontal surgery will be performed in the form of open flap debridement along with placement of demineralized freeze dried bone allograft at the defect site.
41294521|NCT03435653|OTHER|OFD with decortication and DFDBA|Test Group Open flap debridement with decortication and demineralised freeze dried bone allograft Open flap debridement with decortication and placement of demineralized freeze dried bone allograft at the defect site.
41294522|NCT02729454|OTHER|Mental practice and physical therapy|
41294523|NCT02729454|OTHER|physical therapy|
41294524|NCT03874598|PROCEDURE|Ear acupuncture|Patients in the intervention group are treated twice a week for five weeks using semi-standardized ear acupuncture.
41294525|NCT03874598|BEHAVIORAL|Psychoeducation|Patients of the control group receive a 1,5 h psychoeducation group concerning sleep improving behaviour.
41294526|NCT03081325|PROCEDURE|low-dose lymphocyte immunotherapy|Peripheral venous blood (PBMCs) was drawn from the husbands of uRM and RIF patients and then the PBMCs were resuspended and administered intradermally to uRM and RIF patients 3 times at 3-week intervals. Once conceived, the uRM and RIF patients undergo 2 rounds of treatment at 8-week intervals.
41294527|NCT00427388|DRUG|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
41294528|NCT00427388|OTHER|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
41294529|NCT05165810|BEHAVIORAL|Same-day ART initiation [experimental]|Participants assigned to same-day ART initiation will be offered standard, first-line ART on the day of trial enrollment. Participants, will be provided with focused counseling and instructions on where to follow-up for ongoing HIV care (either community-based HIV care or government-based HIV care, depending on randomization).
41294530|NCT05165810|BEHAVIORAL|Standard ART initiation [usual care]|Participants randomized to standard ART initiation will not initiate ART on the day of trial enrollment, but only after linking to their assigned source of HIV care (either community-based HIV care or government-based HIV care, depending on randomization). In standard ART initiation, patients typically, complete an intake visit at the HIV clinic, with baseline laboratory testing, and return to the clinic approximately 2 weeks later to begin ART.
40765819|NCT06640335|OTHER|10 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
40990642|NCT04500210|DIETARY_SUPPLEMENT|Placebo|Placebo in gelatin capsules
40765820|NCT06640335|OTHER|15 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 15 minutes, then consume 300 g of mashed potatoes.
40990643|NCT04500210|DIETARY_SUPPLEMENT|Turmeric|Turmeric in gelatin capsules
40765821|NCT06640335|OTHER|20 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 20 minutes, then consume 300 g of mashed potatoes.
40990644|NCT01618552|BEHAVIORAL|SEE IT training|Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes
41294531|NCT05165810|OTHER|Community-based HIV care [experimental]|Participants randomized to community-based HIV care will be referred to PWID-focused integrated care centers (ICCs) for ongoing HIV clinical management - a prototype of decentralized HIV care in India. ICCs will provide free HIV care that will adhere closely to Indian HIV treatment guidelines and, when relevant, to local HIV treatment standards.
41136761|NCT04417075|BEHAVIORAL|Dejar de Fumar Asistente (Mobile App)|Dejar de Fumar Asistente (English version called: Quit Tracker: Stop Smoking) is a popular, free third party mobile application aimed at helping smokers quit smoking. This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto. This mobile app is well established as a smoking cessation app for Spanish-speaking, Latinx smokers. The app includes smoking cessation components but does not have a specific emphasis on anxiety sensitivity.
41294532|NCT05165810|OTHER|Government-based HIV care [usual care]|Participants randomized to government-based HIV care will be referred to government-based HIV clinics for ongoing HIV clinical management. Government-based clinics provide free HIV care that adheres closely to Indian HIV treatment guidelines
41136762|NCT02279485|DRUG|Perampanel|
41136763|NCT03864159|OTHER|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member. The intervention through the suction cups will be performed with the subject in prone position, on the stretcher. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
41294533|NCT05165810|BEHAVIORAL|Enhanced adherence support [experimental]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to enhanced adherence support will receive an intensive, tailored adherence intervention lasting a maximum of 6 months, with two components: 1) tracking and outreach, and 2) psychosocial support and navigation. These will aim to equip PWID with skills to independently manage their ART using motivational interviewing and strengths-based case management.
41294534|NCT05165810|BEHAVIORAL|Routine adherence support [usual care]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months
40765822|NCT06640335|OTHER|Spinach only / 10 min preload|Subjects consume 200 g baby round spinach WITHOUT canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
40765823|NCT06640335|OTHER|Canola oil only / 10 min preload|Subjects consume 20 g of canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
40765824|NCT03850067|DRUG|CC-90011|CC-90011
40765825|NCT03850067|DRUG|Cisplatin|Cisplatin
40765826|NCT03850067|DRUG|Carboplatin|Carboplatin
40765827|NCT03850067|DRUG|Etoposide|Etoposide
40765828|NCT03850067|DRUG|Nivolumab|Nivolumab
40765829|NCT06267729|BIOLOGICAL|AZD0754|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.~During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion."
40765830|NCT00398879|DRUG|Perifosine|Perifosine 50 mg/d qd
40765831|NCT00398879|DRUG|Capecitabine|Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks
40990645|NCT01618552|OTHER|Knowledge enhancement|Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
40990646|NCT04219982|DRUG|DPI-386 Nasal Gel|Nasal gel
40990647|NCT04219982|DRUG|DPI-386 Placebo Nasal Gel|DPI-386 Placebo Nasal Gel
40990648|NCT04219982|DRUG|Transderm Scop®|Transderm Scop®
40990649|NCT02659527|DRUG|68Ga- PSMA-HBED-CC|Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
40990650|NCT02659527|DEVICE|Biograph mMR, Siemens|All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
40990651|NCT03314155|DIAGNOSTIC_TEST|Cerebral neuroinflammation evaluation|Pet scan following an injection of the radiotracer (\[18F\]DPA-714), to evaluate the neuroinflammation. MRI to evaluate functional and structural integrities. Blood test to analyze various inflammation marker (IL-6, Tumor Necrosis Factor (TNF) alpha, CRPus, and TSPO). And psychological scales to assess the depressive symptoms.
40765832|NCT00398879|OTHER|Perifosine Placebo|Placebo to Perifosine 50 mg/d qd
40765833|NCT06641934|OTHER|No intervention; Observational study|No intervention
40765834|NCT06638931|DRUG|Nivolumab|"The intervention consists of administering Nivolumab 480 mg intravenously every 4 weeks, with a +5 day window for postponement but not for advancement of treatment. Treatment will continue until limiting toxicity, disease progression, or for a maximum period of 12 months (13 cycles) as maintenance therapy, provided the patient maintains stable disease, a partial response, or a complete response. Patients who are off treatment for more than 56 days (2 cycles) due to Nivolumab-related toxicities or other clinical issues will be discontinued from the protocol.~After 12 months of treatment or in the event of study discontinuation for any reason, patients will be followed by the research team via telephone every 60 days, with a +/- 7 day window, until death."
40765835|NCT02220400|DRUG|Ketamine|
40765836|NCT06153264|OTHER|neurodynamic mobilization exercise|Upper extremity neurodynamic mobilization exercises and upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
40765837|NCT06153264|OTHER|strengthening exercises|upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks
40765838|NCT05698498|OTHER|Guaranteed Income|Guaranteed income payments will be disbursed monthly for a total of 24 months to participants who are randomized to the guaranteed income intervention group. Participants will be given the choice to select from one of two different payment strategies (equal monthly payments of $1,000/month vs hybrid payment schedule with initial amount of $6,500 the first month followed by $500/month x 11 months); payment strategy preferences will be re-assessed after 12 months. The choice of payment strategy will be strictly left to participants to specify.
40765839|NCT05698498|OTHER|Public Benefits Information Session|All participants (both the control and intervention groups) will be offered the option of attending a Public Benefits Information Session during which they will receive a comprehensive resource directory of public benefit, assistance, and social service programs available to residents of Santa Clara County, have the opportunity to ask questions about enrolling in those programs, and also have the opportunity to seek additional benefits navigation assistance from our community partner, Sacred Heart Community Service. This session is intended to be optional, with the decision to attend and participant to be left to the discretion of each study participant. Attendance is not required for study participation.
40765840|NCT01448642|DRUG|Atorvastatin|Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
40765841|NCT01448642|DRUG|Placebo|Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
40765842|NCT02637674|PROCEDURE|Uterus Transplant|
40765843|NCT03751982|DEVICE|Transcranial Electrical Neuromodulation (TES)|TES phase-aligned with slow waves or not
41136764|NCT03864159|OTHER|Foam roller|Each session will last 18 minutes, taking place two days a week, in a period of 4 weeks. The intervention will be carried out before starting the training session. The intervention through the self-administration of Foam roller has the objective of increasing the flexibility of the isquitibial musculature. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
41136765|NCT06142838|BEHAVIORAL|community pharmacist intervention|The community pharmacist intervention comprises 2 parts: (1) first prescription counseling (oral and written information), and (2) a follow-up consultation (by telephone or in person) 7-14 days later, to identify problems with adherence/treatment
40765846|NCT06643845|PROCEDURE|arthroplasty|In the surgery arm, patients will have their surgery (arthroplasty), as originally planned.
40765847|NCT06643845|OTHER|Medical and non-medical treatments|In the medical care arm, patients will follow multimodal medical strategies to prevent surgery in a population of patients with knee osteoarthritis having a first indication of knee prosthesis
40963851|NCT02997020|OTHER|EDSPD|The equipment \& conditions for measuring bioelectric changes across the sinus mucosa are based on the standard NPD protocol, including use of agar-filled PE90 tubing for the probing electrode and limiting perfusion solutions to Ringer, Ringer + amiloride (100 µM), chloride-free gluconate with amiloride + isoproterenol (10 µM). The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
40765848|NCT05454566|GENETIC|ICM-203|Intra-articular injection
40765849|NCT06189365|DEVICE|Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder|Subject will receive the Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder.
40963852|NCT01558544|PROCEDURE|surgery to remove ovaries or high dose chemotherapy|oophorectomy to remove a disease ovary.
40765850|NCT06637007|DRUG|Chidamide Tablets combined with AK112|Chidamide Tablets 30mg/day, po.Bid; AK112（10mg/kg or 20mg/kg）, ivgtt, Q3W.
40765851|NCT04278924|DRUG|Placebo|TAK-079 placebo-matching SC injection.
40765852|NCT04278924|DRUG|TAK-079|TAK-079 SC injection.
41456763|NCT02934633|BEHAVIORAL|Keeping Baby Safe 2-DVD package|Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
40765853|NCT05983250|DRUG|TNX-103|oral levosimendan 1 mg
40765854|NCT05983250|DRUG|Placebo|Placebo
40765855|NCT06088043|DRUG|TAK-279|Specified drug on specified days.
40765856|NCT06088043|DRUG|Placebo|Specified drug on specified days.
40765857|NCT06088043|DRUG|Apremilast|Specified drug on specified days.
40963853|NCT03556774|BEHAVIORAL|'WeChat WeQuit' smoking cessation training program|Providing 'WeChat WeQuit' smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.
41136766|NCT04919395|DEVICE|Clip device for Nexplanon Removal|The clip device will be used to assist in the removal procedure to remove the Nexplanon implant from the subject.
40765858|NCT02598973|BEHAVIORAL|Exercise|Aerobic walking
40765859|NCT06179446|BIOLOGICAL|pdmFlu vaccine|Intramuscular injection
40765860|NCT06179446|BIOLOGICAL|Placebo|Intramuscular injection
40765861|NCT06179446|BIOLOGICAL|Licensed influenza vaccine|Intramuscular injection
40765862|NCT06636110|DEVICE|Jun mHealth app|The intervention will be a mHealth app, JUN, across 3 months during pregnancy.
40765863|NCT05289544|BEHAVIORAL|Phone-Based Walk With Ease|6 week phone-delivered Walk With Ease Program
40765864|NCT05645536|DRUG|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months
40765865|NCT05645536|DRUG|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet of solution
40765866|NCT05645536|DRUG|Letrozole tablets|One 2.5 mg tablet taken orally once daily
40765867|NCT05645536|DRUG|Anastrozole Tablets|One 1 mg tablet taken orally once daily
40765868|NCT05645536|DRUG|Exemestane Tablets|One 25 mg tablet taken orally once daily
40963854|NCT03369093|DRUG|Amoxicillin|Twice daily doses of injectable amoxicillin
40963855|NCT00582166|DRUG|Ibritumomab Tiuxetan (Zevalin) + Rituximab|Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
41136767|NCT04919395|PROCEDURE|Standard of Care procedure|The participants Nexplanon will be removed per standard of care.
41136768|NCT05606900|BEHAVIORAL|addiction-focused eye movements desensitization and reprocessing (AF-EMDR)|AF-EMDR includes desensitization and functional reprocessing of the targeted memory or the moment with lateral eye movements. In each session of the psychotherapy, which will be applied as 3 sessions, a memory or a moment that causes alcohol craving will be practised. The processing will continue until the patient becomes desensitized to the memory or the moment that cause the craving. In the first session, a memory of craving will be discussed, in the second session a current trigger that causes craving, and in the third session, a moment that is thought to cause craving in the future will be focused.
40765869|NCT06560138|DRUG|SHR-4602|SHR-4602 will be administered through IV infusion.
40765870|NCT03211546|PROCEDURE|Conservative (non-surgical) treatment|Spica cast Traction Traction and spica cast
40765871|NCT03211546|PROCEDURE|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) Conventional locking intramedullary nail Plating External fixation
40765872|NCT05012124|OTHER|Collaborative care|Receive u-CoCM
40765873|NCT05012124|OTHER|Interview or Focus Group|Participate in an interview or focus group
40765874|NCT05012124|OTHER|Media/technology Intervention with collaborative care|Use t-CoCM digital platform with collaborative care
40765875|NCT05012124|OTHER|Survey Administration|Complete surveys
40765876|NCT05580406|BEHAVIORAL|Outreach messaging|Participants will receive outreach messages via health care system secure messaging and/or phone following a new diagnosis of depression made in primary care if the participant has failed to initiate treatment (pharmacotherapy or psychotherapy) within 30 days of new diagnosis.
40963856|NCT00288054|BIOLOGICAL|cetuximab|"Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles."
40963857|NCT00288054|DRUG|docetaxel|"Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.~20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2."
41136769|NCT02161458|DRUG|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
41294535|NCT01429012|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
41294536|NCT01429012|OTHER|Culture medium without MSC.|2 ml of culture medium.
41456764|NCT02934633|BEHAVIORAL|The Injury Prevention Program (TIPP) sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
41456765|NCT02509260|DEVICE|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
41456766|NCT02509260|OTHER|Standard wound dressings|Control patients with standard wound dressings will have gauze and tape dressings applied
40765877|NCT05054439|DRUG|SI-B001|Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
40765878|NCT05054439|DRUG|Paclitaxel|The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.
40765879|NCT03547973|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously.
41294537|NCT05470582|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine 0.5 mL|Solution for intramuscular injection Сhildren were vaccinated with the Flu-M vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
41294538|NCT05470582|BIOLOGICAL|Vaxigrip, Inactivated split influenza vaccine 0.5 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
41456767|NCT02967926|PROCEDURE|Endoscopic Retrograde Cholangioscopy by SpyGlass (ERCS)|Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal
41456768|NCT01732679|OTHER|rehabilitation|Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
41456769|NCT04513327|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to anterior cruciate ligament reconstruction post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 2 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 2 to 12 weeks post surgery."
41136770|NCT02161458|DRUG|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
41136771|NCT02161458|DRUG|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
41136772|NCT02161458|DRUG|Placebo|Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
41136773|NCT03126604|DIAGNOSTIC_TEST|female sexual function index|evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions
41136774|NCT02397707|DRUG|Voxilaprevir|100 mg tablet administered orally
41136775|NCT00434694|PROCEDURE|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
41136776|NCT02981329|DRUG|Metformin|Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.
41136777|NCT02981329|BEHAVIORAL|Questionnaires|Questionnaires will be completed to assess the impact quality of life
41456770|NCT04513327|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
41456771|NCT00903292|DRUG|erlotinib (Tarceva)|chemotherapy with erlotinib
41136778|NCT04252638|BEHAVIORAL|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment Therapy (ACT) is a newer form of behavioral therapy working with acceptance, and the clarification of personal values. Acceptance, in this case, means the willingness to (temporarily) experience unpleasant sensations such as sleeplessness or tiredness without attempting to control or change them. Aims are, first, to reduce suffering due to unsuccessful control attempts (such as frustration, anger, anxiety) and second, to improve processes that are typically worsened by increased control efforts (such as sleep). Clarification of values means identifying aspects of life that are perceived as rewarding and encouraging approach-behavior in valued aspects of life (instead of avoidance-behavior that is often associated with insomnia and mental disorders).
41136779|NCT04252638|BEHAVIORAL|Cognitive Behavioral Therapy including Sleep Restriction|CBT-I, the gold standard treatment for insomnia, consists of sleep education, relaxation, sleep restriction, and cognitive therapy.
41456772|NCT00903292|DRUG|pemetrexed (Alimta)|Chemotherapy with pemetrexed
41456773|NCT02162615|DEVICE|Restorelle Direct Fix A|
41456774|NCT02162615|DEVICE|Restorelle Direct Fix P|
41456775|NCT02162615|PROCEDURE|Native Tissue Repair Anterior|
41456776|NCT02162615|PROCEDURE|Native Tissue Repair Posterior|
40765880|NCT03547973|DRUG|Pembrolizumab|Administered per package insert
40765881|NCT03547973|DRUG|Cisplatin|Administered per package insert
40963858|NCT00288054|RADIATION|radiation therapy|"Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications."
40963859|NCT00925093|DRUG|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
40963860|NCT00925093|DRUG|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
40963861|NCT00925093|DRUG|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
40963862|NCT03949361|DIAGNOSTIC_TEST|Indirect calorimetry|Resting energy expenditure
40963863|NCT03949361|DIAGNOSTIC_TEST|Skin Temperature|Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer
40963864|NCT03949361|DIAGNOSTIC_TEST|Dual energy X-ray Absorptiometry (DXA)|Body composition
40963865|NCT03949361|DIAGNOSTIC_TEST|Blood Sampling|thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)
40963866|NCT03949361|DIAGNOSTIC_TEST|FDG-PET|Dynamic PET scanning of the neck-region
41136780|NCT01372475|DEVICE|Hymovis Intra-articular Injection|Hymovis Intra-articular injection
41136781|NCT01372475|PROCEDURE|Phosphate Buffered Saline Injection|Placebo Intra-articular injection
40765882|NCT03547973|DRUG|Avelumab|Administered per package insert
40765883|NCT03547973|DRUG|Zimberelimab|Administered intravenously
40765884|NCT03547973|DRUG|Carboplatin|Administered per package insert
40765885|NCT03547973|DRUG|Gemcitabine|Administered per package insert
40963867|NCT03949361|DIAGNOSTIC_TEST|Capillary glucose|Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia
40963868|NCT03949361|DIAGNOSTIC_TEST|Biopsy of supraclavicular adipose tissue (optional)|Ultrasound guided biopsy of the supraclavicular adipose tissue
40963869|NCT06338371|BEHAVIORAL|Pelvic Floor exercise training|The level of sexual function was determined by implementing FSFI for all individuals included in the sample. The participants were divided into two groups, control and training groups, using the randomization program on the computer. Pelvic floor exercise training was given to one group. Trainings were conducted online on different days. Each training lasted 120 minutes. After training was completed, women in the training group were instructed to perform three sets of 8-12 repetitive pelvic floor muscle contractions per day and to use an exercise diary to record their practice. Women in the training group were also given a booklet and the recording of the training video was shared. the training, a brochure explaining how to perform the pelvic floor muscle exercises, which was included in the training content, was prepared and delivered to the training group on the first day of each week. After the training, FSFI was applied to both groups 3 times, in the 1st, 2nd, and 3rd months.
40963870|NCT01603056|BIOLOGICAL|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
40963871|NCT01603056|BIOLOGICAL|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
41136782|NCT00018512|PROCEDURE|Implant-supported denture|
41136783|NCT05667441|COMBINATION_PRODUCT|Standard lifestyle recommendations + dietary supplementation|refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula
41136784|NCT05667441|COMBINATION_PRODUCT|Risk profiling|Personalized risk profiling for lifestyle and genetics.
41136785|NCT05667441|BEHAVIORAL|Coaching|Coaching
40765886|NCT03547973|DRUG|Domvanalimab|Administered intravenously
40765887|NCT03547973|DRUG|Enfortumab Vedotin|Administered intravenously
40765888|NCT03201094|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular electrical stimulation twice daily during study period.
40765889|NCT03201094|DIETARY_SUPPLEMENT|High Protein Supplementation|High protein supplementation with whey protein shakes taken three times a day during study period.
40765890|NCT05983809|DEVICE|Technological rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
41294539|NCT05470582|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine 0.25 mL|Solution for intramuscular injection Children were vaccinated with the Flu-M vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
41456777|NCT03143049|DRUG|PCD|"For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
41456778|NCT03143049|DRUG|PD|"For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
41456779|NCT04428723|OTHER|Entry of demographic and medical history data into a deidentified database|Entry into repository for analysis.
40963872|NCT01471171|DRUG|Aclidinium Bromide|1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
40963873|NCT01471171|DRUG|Placebo|1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
40963874|NCT04079608|BEHAVIORAL|FLASH curriculum|High School FLASH is a 15-session comprehensive sexual health curriculum designed for classroom settings in grades 9 to 12. The basis of High School FLASH is a public health approach to behavior change. The primary strategy used in the FLASH curriculum for preventing teen pregnancy, sexually transmitted diseases (STDs), and sexual violence is to address student behaviors and attitudes. To this end, FLASH uses a harm reduction and behavior change framework, implements best practices as outlined in the research on effective programs, addresses risk and protective factors for program goals, and rests on the theory of planned behavior. The instructional approach of High School FLASH employs key concepts in every lesson, which enables teachers to hone in on the risk and protective factors outlined in the curriculum logic model.
40963875|NCT04079608|BEHAVIORAL|Sexual Health Education for Adolescents|Sexual Health Education for Adolescents is a five-session knowledge-based sexual health curriculum designed for classroom settings. The lessons cover the reproductive system, pregnancy, birth control, abstinence, human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs), and healthy relationships. The goal of the curriculum is to increase student knowledge in all content areas. The primary strategy employed by Sexual Health Education for Adolescents is to address the cognitive learning domain. The curriculum aligns to national health education standards and is intended to be implemented by classroom teachers. The lessons can be delivered according to the schedule that works best for schools (e.g., twice a week, once a week, every days) within a school semester.
41136786|NCT03051568|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
41136787|NCT05528692|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI is a non-invasive imaging modality capable of producing precise soft-tissue images in all body areas. In contrast to CT scanning, MRI does not rely on ionizing radiation. There are no known risks associated with MRI as long as patients with contraindications such as pacemakers are identified and excluded. The MRI scans in this study will be performed without use of contrast media.
41136788|NCT00647400|BIOLOGICAL|adalimumab|Adalimumab 40 mg every other week, subcutaneous
41136789|NCT00647400|BIOLOGICAL|adalimumab|Adalimumab 80 mg every other week, subcutaneous
41136790|NCT01992965|OTHER|Different methods of blood glucose monitoring between groups|Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group
41136791|NCT00446576|DRUG|Epoetin Alfa|
41136792|NCT02662205|OTHER|Psychotherapy Group|Traditional process group
41136793|NCT02662205|OTHER|Yoga class|Yin yoga class
41136794|NCT02662205|OTHER|Yoga Therapy Group|Yoga psychotherapy group integrating yoga and process dialogue
41136795|NCT01289600|DEVICE|Mechanical ventilation|The mechanical ventilator is set to different ventilation modes as described in the individual arms.
40963876|NCT00987675|OTHER|pharmacological study|
41136796|NCT03138629|DRUG|VAL-083|VAL-083 will be administered intravenously
41136797|NCT00000872|DRUG|Abacavir sulfate|
41136798|NCT00000872|DRUG|Nelfinavir mesylate|
41136799|NCT00000872|DRUG|Nevirapine|
41136800|NCT00000872|DRUG|Lamivudine|
41456780|NCT04428723|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing participants with hypoglycemia (both surgical and non-surgical) and healthy controls.
41456781|NCT04428723|DIAGNOSTIC_TEST|Stool sample for microbiome analysis|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
40963877|NCT00987675|OTHER|questionnaire administration|
40963878|NCT00987675|PROCEDURE|assessment of therapy complications|
41136801|NCT00000872|DRUG|Stavudine|
41136802|NCT00000872|DRUG|Zidovudine|
40963879|NCT00987675|PROCEDURE|high-intensity focused ultrasound ablation|
40765891|NCT06001697|BEHAVIORAL|Park prescription|The park prescription given by the patients care-provider includes information about the health benefits of spending time in nature and detailed information about the parks in the neighboring area. As well as access to a web-based platform called ParkRx which includes information and details about events in the parks in the study area. Together with information about the frequency and duration of visits to the parks.
40765892|NCT06001697|BEHAVIORAL|Regular health advice|Regular health advice relating to lifestyle factors that can decrease the risk of chronic disease and/or reducing the burden of an existing chronic disease. Areas included are diet, physical activity, sleep, stress and medications.
41136803|NCT00770874|DRUG|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
40765893|NCT01854762|DRUG|Raltegravir|a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
40963880|NCT00987675|PROCEDURE|quality-of-life assessment|
40963881|NCT05516394|PROCEDURE|Laparoscopic liver resection|Liver tumors are resected with minimally invasive approach, laparoscopically.
40963882|NCT00967590|DRUG|RO5036505|380mg iv infusion once weekly for 8 weeks
40963883|NCT00967590|DRUG|placebo|iv infusion once weekly for 8 weeks
40963884|NCT04199910|OTHER|There is no intervention, only research blood samples are collected|Research blood samples collected
40963885|NCT01499056|BIOLOGICAL|stem cell injection|intra articular inection of mesenchymal stem cell
40963886|NCT00315172|PROCEDURE|Non-Exercise Activity Thermogenesis (NEAT)|
40963887|NCT03067961|OTHER|Salmonella Typhi (S. Typhi)|Investigating the role of typhoid toxin in the pathogenesis of enteric fever
40963888|NCT00545662|DRUG|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
40963889|NCT00545662|DRUG|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
40963890|NCT04460404|BEHAVIORAL|Lifestyle consultation|"Collect relevant data of patients included in the study through outpatient consultation, telephone follow-up, questionnaire follow-up, etc., including:~1. Basic information~2. Digestive tract symptoms:~   A constipation-related symptoms B abnormal symptoms~3. Fecal traits~4. Lifestyle habits~5. Others"
40963891|NCT02642328|OTHER|HIIT Training|Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)
40963892|NCT02642328|OTHER|Control|Continuous aerobic exercise at 65% of VO2Max
40963893|NCT05446805|DRUG|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
40963894|NCT05446805|DRUG|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
40963895|NCT03064984|OTHER|CBS eyedrops|CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
40963896|NCT03064984|OTHER|PBS eyedrops|PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
41136804|NCT00770874|DRUG|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
41136805|NCT06020300|DRUG|Oral Colchicine 0.6 mg|Anti-Inflammatory Effects
41136806|NCT06020300|DRUG|Oral Pyridoxine 10 mg|Colchicine look alike placebo
41136807|NCT01529944|DRUG|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
41136808|NCT01529944|DRUG|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
41136809|NCT05080257|DEVICE|Lung Ultrasonography|"The ultrasonography will be done using the curved probe of the SONOACE R3 SAMSUNG ultrasonography machine, SN: S0GYM3HCC00016M, manufacture date: 12-2012.~Assessment of lung condition using the Lung Ultrasonography Score (total score calculated from the 12 standard examined areas, from 0 to 3 in each area, with a minimum of 0 up to 36)"
41136810|NCT01406106|DIETARY_SUPPLEMENT|Plant stanol esters|The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
40765894|NCT01854762|DRUG|Lopinavir/Ritonavir|The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
40765895|NCT02720094|DRUG|Cabotegravir Oral Tablet|30 mg tablet
40765896|NCT02720094|DRUG|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
40765897|NCT02720094|DRUG|Placebo for TDF/FTC tablets|
40765898|NCT02720094|DRUG|Placebo for cabotegravir oral tablet|
40963897|NCT05238402|DRUG|Statin|Statin on COVID 19 patienst
40963898|NCT00159120|OTHER|maintained antipsychotic treatment vs. stepwise drug discontinuation|maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
40963899|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 2mg|Caffeine 2 mg versus 4 mg/kg or placebo
41136811|NCT01409772|DRUG|Ethanol Lock|Ethanol Lock
41136812|NCT06509386|OTHER|Major Depressive Disorder without treatment or role fulfillment|Read vignette describing the condition and ask stigma questions.
41136813|NCT06509386|OTHER|Major Depressive Disorder with treatment but no role fulfillment|Read vignette describing the condition and ask stigma questions.
41136814|NCT06509386|OTHER|Major Depressive Disorder without treatment but with role fulfillment|Read vignette describing the condition and ask stigma questions.
41136815|NCT06509386|OTHER|Major Depressive Disorder with treatment and role fulfillment|Read vignette describing the condition and ask stigma questions.
41136816|NCT06509386|OTHER|Schizophrenia without treatment or role fulfillment|Read vignette describing the condition and ask stigma questions.
41136817|NCT06509386|OTHER|Schizophrenia with treatment but no role fulfillment|Read vignette describing the condition and ask stigma questions.
41136818|NCT06509386|OTHER|Schizophrenia without treatment but with role fulfillment|Read vignette describing the condition and ask stigma questions.
41136819|NCT06509386|OTHER|Schizophrenia with treatment and role fulfillment|Read vignette describing the condition and ask stigma questions.
41136820|NCT04262115|BEHAVIORAL|AM-EX|AM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
41136821|NCT04262115|BEHAVIORAL|PM-EX|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
41136822|NCT05266300|GENETIC|DPYD genotype|"The SNPs included in this study are the following (dbSNP Reference SNP)~rs3918290(c.1905+1G\>A) rs67376798(c.2846A\>T) rs55886062(c.1679T\>G) rs56038477(75017182)/(c.1236G\>A)"
41136823|NCT05794594|DEVICE|3D printed personalized extendable prosthesis|3D printed personalized extendable prosthesis replacement for limb preservation in children
41136824|NCT01065532|DEVICE|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
41136825|NCT01065532|DEVICE|Xience V everolimus eluting stent|Xience V everolimus eluting stent
40765899|NCT02720094|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
41136826|NCT03941509|BEHAVIORAL|Antimicrobial stewardship|Education, guidelines, communication tools and audit and feedback
41136827|NCT00428714|DRUG|enzastaurin|Administered orally
41136828|NCT00738959|DRUG|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
41136829|NCT04723979|DRUG|Eptacog alfa|Recombinant coagulation factor VII activated
41136830|NCT04723979|OTHER|Standard of care|Patients have been treated according to local routine clinical practice at the discretion of the treating physician.
41136831|NCT01573338|DRUG|Roniciclib (BAY1000394)|oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
41136832|NCT01573338|DRUG|Etoposide|100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
40765900|NCT02720094|DRUG|Placebo for CAB LA|Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
40963900|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
40963901|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 0|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
40765903|NCT04639726|DIETARY_SUPPLEMENT|Whey Protein Micro Gel|The test product is whey protein microgels 10g, reconstituted in 125ml water.
40765904|NCT04639726|OTHER|Water without Whey Protein.|A matching placebo (125ml of water without whey protein) will be used as control.
40963902|NCT04688957|PROCEDURE|oseodensification sinus lifting|application of first densah bur with densifying mood (reverse) counterclockwise, 1200 revolution per minute until the sinus is reached then use a wider densah bur with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.
41136833|NCT01573338|DRUG|Cisplatin|75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
41136834|NCT01573338|DRUG|Carboplatin|Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
41136835|NCT04597866|BEHAVIORAL|Multimodal rehabilitation|A combination of exposure in vivo and interventions directly targeting the cortical reorganization for treating CRPS.
41136836|NCT00829400|BEHAVIORAL|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
41136837|NCT00829400|BEHAVIORAL|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
41136838|NCT01229332|DRUG|Saline|Continuous 24 h administration
41136839|NCT01229332|DRUG|Carbidopa|Continuous 24 h administration
41136840|NCT02118922|PROCEDURE|Brillouin imaging|
41136841|NCT00541996|DRUG|vabicaserin|
41136842|NCT02068053|DRUG|[14C] BMS-986020|
41136843|NCT06021275|OTHER|Microneedling with topical application of regular insulin|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
41136844|NCT06021275|OTHER|Microneedling with topical application of saline|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
40765905|NCT05022316|OTHER|CDS Tool Access|Clinics receiving the intervention will have access to EHR-based CDS tools designed to support social risk-informed care. Prior to tool activation in participating community health centers (CHCs), clinic staff members will be oriented to the CDS tools by an EHR trainer (either on-site or remotely).
40765906|NCT06010251|OTHER|tDCS and bodily illusions|"Participants will be required to perform (in person) 10 interventions over a time frame of 2-4 weeks. They can perform this everyday or for a minimum of 2-3 times per week over 4 weeks.~Two types of illusions will be used 15 min each, the rubber hand illusion and the walking illusion to target upper and lower limbs. These procedures will impact the body representation of the participants resulting in bodily illusions."
40765907|NCT05243797|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
40765908|NCT05243797|DRUG|Lenalidomide|Lenalidomide will be administered orally
40765909|NCT05245071|DRUG|Tusamitamab ravtansine|Pharmaceutical Form: Concentrate for solution Route of Administration: Intravenous infusion
40765910|NCT06555081|DRUG|Ruxolitinib IR|Tablet
40963903|NCT04688957|PROCEDURE|osteotome sinus lifting|drilling implant site with consecutive drills short of the sinus floor by 1-2mm , using osteotome in appropriate size and application of one tap until sinus floor is elevated, using the final drill for the desired implant diameter
40765911|NCT06555081|DRUG|Ruxolitinib XR|Tablet
40765912|NCT06387394|DRUG|BOTOX|Intramuscular Injections
40765913|NCT06387394|DRUG|Placebo|Intramuscular Injections
40765914|NCT02302222|DEVICE|Customizable Dressing with ActiV.A.C. Therapy Unit|
40963904|NCT06491940|DRUG|Losartan|Patients will receives Losartan (LS) 50 mg per day.
40963905|NCT06491940|DRUG|Losartan + Hydrochlorothiazide|Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
40963906|NCT05363644|BIOLOGICAL|BioDFence G3|Placement of a sheet of BioDFence® G3 will be applied to the neurovascular bundle on participants undergoing an elective Full Nerve Sparing Radical Prostatectomy for primary treatment of prostate cancer.
40963907|NCT03119831|DRUG|Alcohol-based Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
40963908|NCT03119831|DRUG|Alcohol-free Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
40963909|NCT03119831|DRUG|C31G|Rinsing with 15ml for one minute twice daily for 14 days
40963910|NCT01294267|DEVICE|Circulatory Support System|Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
40963911|NCT03399721|DEVICE|Chordate S101|Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time
41136845|NCT06465550|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
41136846|NCT03715985|DRUG|EVAX-01-CAF09b|The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
41456782|NCT04428723|DIAGNOSTIC_TEST|Mixed meal tolerance test|For a subset of participants: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
41456783|NCT04428723|DIAGNOSTIC_TEST|Continuous glucose monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
40765915|NCT02302222|DEVICE|Standard of Care Dressing|
40765916|NCT06641778|OTHER|Fecal Microbiota Transplantation|Patients in the experimental group received conventional antibiotic therapy plus fecal microbiota transplantation, and the efficacy was compared with that in the control group
40765917|NCT05319197|OTHER|No Interventions|No Interventions
40963912|NCT03399721|DEVICE|Chordate S101 Placebo|Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
40963913|NCT02598544|OTHER|adipose tissue sampling|adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
40963914|NCT00000883|DRUG|Azithromycin|
41136847|NCT00586755|PROCEDURE|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
41136848|NCT01593644|DRUG|adenosine + dipyridamole|adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
41136849|NCT06061978|PROCEDURE|left bundle branch of His pacing|left bundle branch of His pacing
41136850|NCT06061978|PROCEDURE|right ventricular pacing|right ventricular pacing
41136851|NCT05097105|DEVICE|MRI|MRI sequences: TI. T2 and diffusion weighted
41294540|NCT05470582|BIOLOGICAL|Vaxigrip, Inactivated split influenza vaccine 0.25 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
41294541|NCT02314208|DRUG|Xenbilox|
41456784|NCT04428723|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days, to assess activity, concurrent with CGM sensor wear.
40765918|NCT06635122|PROCEDURE|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. The TIPS-dedicated stent (Gore, Arizona, USA)was emplaced within the liver and gradually expanded utilizing a balloon with a diameter ranging from 6 to 10 millimeters, aiming for a decrease in portal-venous pressure gradient to less than 12 mmHg or achieve a reduction of 25 to 50% relative to the baseline pressure.
40963915|NCT04401085|DIAGNOSTIC_TEST|SARS-CoV-2 diagnostic rapid test|The rapid test detects the presence of antibodies against SARS-CoV-2 in the IgM and IgG class by the immunochromatographic reaction. It cannot detect early infection, the antibodies will probably appear two weeks after possible infection. The collection will be performed by finger puncture.
40963916|NCT04401085|DIAGNOSTIC_TEST|Quantitative analysis of SARS-CoV-2 antibodies|The subsample from Olomouc region (Olomouc, Uničov, Litovel) is based on venous blood sampling and archiving for subsequent quantitative analysis of SARS-CoV-2 antibodies. These tests detect immunoglobulins M and G (IgM and IgG).
40963917|NCT03486223|DRUG|GSK2256294|Drug will be taken daily by mouth for 7 days.
41136852|NCT05943054|OTHER|Temporal perception tasks|"A long temporal perception task in which the duration of the stimulus, around 2 min, is materialized by a video. For each trial, two videos are displayed to the participants, and then the task of the participant is to indicate the longest video and to give his level of confidence in his answer. A short temporal perception task which will take place in the same way as the long task except that the duration of the stimulus, around 2 seconds, is materialized by still frames from the videos used in the previous task."
41136853|NCT00012688|DRUG|Doxycycline HCI 10mg po for 2 weeks|
41136854|NCT00012688|PROCEDURE|Ultrasonic scaling with 0.12% chlorhexidine gluconate|
41136855|NCT04016207|DRUG|Guanfacine|regular treatment
41136856|NCT03879265|DIAGNOSTIC_TEST|Noninvasive chromosome screening|Screening based on MALBAC-NGS technology
41456785|NCT00547625|DRUG|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
41136857|NCT03479892|DRUG|NNC0194-0499|"Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
41136858|NCT03479892|DRUG|Placebo|Participants will receive once weekly injections of NNC0194-0499 matched placebo.
41136859|NCT01828021|BIOLOGICAL|Margetuximab|Anti-HER2 monoclonal antibody
41136860|NCT06323369|DRUG|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41136861|NCT06323369|DRUG|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41136862|NCT06323369|DRUG|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41136863|NCT06323369|PROCEDURE|Surgical resection|Standard of care
41456786|NCT00547625|DRUG|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
41456787|NCT00486434|DRUG|SMC021 Oral Calcitonin|0.8mg SMC021 (Oral Calcitoinin) twice daily
41456788|NCT00486434|DRUG|SMC021 Placebo|Placebo orally, twice daily
41456789|NCT01961817|OTHER|Retromolar Vocal Cord Visualisation|For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack \& Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.
40963918|NCT03486223|DRUG|Placebo oral capsule|Placebo will be taken daily by mouth for 7 days.
41136864|NCT06323369|DRUG|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41136865|NCT06323369|DRUG|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41136866|NCT06323369|RADIATION|Radiation|Recommended, standard of care
41136867|NCT06323369|DRUG|Carboplatin（neoadjuvant）|Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41294542|NCT02314208|DIETARY_SUPPLEMENT|Resveratrol|
40765919|NCT06635122|PROCEDURE|Endoscopic treatment|Endoscopic variceal ligation, endoscopic injection sclerotherapy, endoscopic variceal histoacryl injection therapy , or a combination of several methods were selected according to the location, size, and shape of the patient's varicose veins.Treatment failure can be transferred to TIPS therapy.
41136868|NCT06323369|DRUG|Carboplatin（adjuvant）|Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41136869|NCT04516226|OTHER|Vaginal cleansing with chlorhexidine gluconate solution|Cleansing of the vaginal walls with chlorhexidine gluconate solution for women diagnosed with PPROM
41136870|NCT04528524|OTHER|Questionnaire|QoR-15Dt
41136871|NCT04198922|DRUG|Acalabrutinib|Given PO
41136872|NCT04198922|OTHER|Questionnaire Administration|Ancillary studies
41294543|NCT02314208|DRUG|Tahor|
41294544|NCT02206711|DRUG|BMS-955176|Single dose of drug on Day 1
41456790|NCT01961817|OTHER|Conventional Vocal Cord Visualisation|The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack \& Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
41456791|NCT04483349|OTHER|Survey Administration|Complete survey
40963919|NCT06175910|PROCEDURE|percutaneous nephrolithotomy|"A 7 Fr ureteric catheter was placed into the ipsilateral ureteric orifice. The patients were then placed in the prone position. Opacification of the pelvicalyceal system was performed. The puncture was done by a 22-guage puncture needle was advanced into the posterior lower calyx under fluoroscopic guidance. After successful access is established, a 0.035-inch curved guide wire was advanced through the puncture needle into the kidney. The central Alkane Rod was passed over the guide wire. Under fluoroscopic guidance serial Amplatz dilators up to 30 Fr were advanced over central Alkane rod and guide wire. Then 30 Fr long Amplatz sheath was advanced over the last dilator.~26 Fr rigid long nephroscope used for stone fragmentation and retrieval. Stone fragmentation was done by pneumatic Swiss Lithoclast. Fragments removal was done using toothed peanut stone retrieval forceps."
41136873|NCT01485809|DRUG|Gefitinib|Gefitinib 250mg/day, oral daily q every 4 weeks
41136874|NCT03833752|DIAGNOSTIC_TEST|Diagnostic Flexible Cystosocpy|Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
41136875|NCT03833752|DIAGNOSTIC_TEST|Diagnostic Rigid Cystoscopy|Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
41136876|NCT03860129|DRUG|Isoflurane|Group A: Isoflurane (0.5 MAC)
41136877|NCT03860129|DRUG|Sevoflurane|Group B: Sevoflurane (0.5 MAC)
41294545|NCT05111834|BEHAVIORAL|Supervised resistance training plus nutritional endorsement|resistance training 2x per week, nutritional endorsement/therapy based on individual needs
41294546|NCT05111834|BEHAVIORAL|Nutritional endorsement|nutritional endorsement/therapy based on individual needs
41136878|NCT03860129|DRUG|Desflurane|Group C: Desflurane (0.5 MAC)
41136879|NCT00853593|DEVICE|Pacing Lead|implant and follow-up of study device
41136880|NCT00357019|DRUG|N-acetyl-aspartyl-glutamate (NAAXIA Sine)|
41136881|NCT00686257|DEVICE|Total face mask (interface for NPPV)|NPPV is applied by this mask, as long as NPPV is received.
41136882|NCT00686257|DEVICE|Comfort full or RT040 oronasal mask (interface for NPPV)|NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
41136883|NCT03773497|OTHER|Common Snack Combination|Combination of Chips, Pretzels, and Popcorn.
41136884|NCT03773497|OTHER|Cheesy Broccoli Snack|Oven-roasted, freeze-dried, cheese flavored broccoli
41136885|NCT03773497|OTHER|Cheesy Broccoli with Daikon Radish Snack|Oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder
41136886|NCT03773497|OTHER|Uncooked Broccoli Snack|Uncooked, freeze-dried broccoli with ranch-type dip
41136887|NCT05982366|OTHER|distal radial artery acess side|coronary procedure (coronary angiography and/or coronary angioplasty) by the distal radial artery in the anatomical snuffbox area
41136888|NCT05982366|OTHER|conventional radial artery acess side|coronary procedure (coronary angiography and/or coronary angioplasty) by the forearm radial artery in the anatomical snuffbox area
41456792|NCT03885336|OTHER|No Interventions|There are no interventions in this study. Participants are observed.
40963920|NCT06175910|PROCEDURE|retrograde intrarenal surgery|"urethrocystoscopy was carried out then inserting of a 7F open ended ureteral catheter over the 0.035-inch straight floppy tip guide wire in the working channel of the 22Fr cystoscope under fluoroscopic guidance, access to the ureter was made.~Teflon ureteric dilators are used to dilate the distal ureter till 14 FR. ureteral access sheath placement 12 or 14 Fr. OTU, a disposable digital flexible ureteroscope, is then used then the tip of a 272 m holmium laser fiber is placed on the surface of the stone for fragmentation.~Intra renal lithotripsy was carried out using a 30 W Holmium: YAG laser (Sphinx Jr.) via a 272 m silica quartz laser fiber. 1.9 Fr tipless nitinol baskets were finally used to remove the large fragments. A Double-J (6 Fr) stent is generally applied at the end of the procedure, and a urethral catheter was applied."
41136889|NCT01496339|BIOLOGICAL|MenSCs transplantation|1×10\^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
41136890|NCT01496339|DRUG|exogenous indulin injection daily|traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
41136891|NCT01057082|DIETARY_SUPPLEMENT|Juven|Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
41136892|NCT01057082|DIETARY_SUPPLEMENT|Juven|Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
41136893|NCT03287232|DRUG|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
41136894|NCT03287232|DRUG|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
41136895|NCT04552522|OTHER|shrimp allergy with intend to eat shrimp|shrimp allergy with intend to eat shrimp and treat with oral immunotherapy
41136896|NCT01459952|DIETARY_SUPPLEMENT|Rose hip Liquid|Rose hip Liquid, 20 ml BID
41136897|NCT01296100|BEHAVIORAL|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
41136898|NCT01296100|BEHAVIORAL|Lifestyle intervention (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
40765920|NCT06597513|DRUG|auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab|"Induction:~Two 21-day cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1.~Those without disease progression will advance to consolidation treatment.~Consolidation:~Stem cell mobilization with G-CSF will be start when white blood cell count is at its nadir post-chemotherapy.~After recovery, peripheral blood stem cells will be collected via apheresis, evaluated, and cryopreserved if adequate.~Dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 for two 21-day cycles.~Within 48-72 hours after the first cycle, autologous peripheral blood stem cells will be reinfused with G-CSF.~Further consolidation will depend on hematopoietic recovery with standard-dose EC plus adebrelimab 1200 mg on day 1 for four 21-day cycles.~Maintenance:~Adebrelimab 1200 mg every 21 days will be given until disease progression, intolerable toxicity, death, patient withdrawal, or investigator decision."
40765921|NCT05745285|OTHER|LLS Program|The intervention will be conducted virtually. Participants will receive LLS's free patient and caregiver services including co-pay assistance, transportation and urgent need assistance, a scholarship program for young adult patients and survivors, one-on-one peer-to-peer support, online chats and support groups facilitated by clinical social workers, and nutrition counseling with a registered dietician for 6 months.
40765922|NCT05049824|DEVICE|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact metabolic disease indicators
40765923|NCT06460662|OTHER|Routine Physical Therapy|"Group B: Routine physical therapy Group that includes:~* Calf Stretching~* Hamstring Stretching~* Prone Quadriceps Stretching~* Long-Sitting Knee Flexion and Extension~* Quadriceps setting~* Supine Straight Leg Raises~* Prone Hip Extensions~* Standing Hamstring Curls With Cuff Weights~* Standing Calf Raises~* Treadmill Walking~* Mobilization techniques"
40765924|NCT06351761|DEVICE|Investigational Device (Withings SCT02) 30 second Electrocardiogram recording|30 second ECG recording with investigational device (Withings SCT02)
40765925|NCT06351761|DEVICE|Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording|30 second ECG recording with reference device (Schiller Cardiovit FT-1)
40765926|NCT04289493|OTHER|Language and functional communication therapy|17 therapy sessions in which the patients will be asked to dubb words or sentences from television series previously considered functionally meaningful for them.
40765927|NCT06635226|DRUG|ID110521156|ID110521156 capsules taken orally once daily
40765928|NCT06635226|DRUG|Placebo of 110521156|ID110521156 placebo capsules taken orally once daily
40765929|NCT05837897|DRUG|Vedolizumab IV|Vedolizumab IV infusion
40765930|NCT05837897|DRUG|Placebo|Vedolizumab placebo-matching IV infusion
40765931|NCT06645067|BEHAVIORAL|Measuring energy balance|"The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France.~Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of Heart Rate Reserve (HRR)), concluding with a 2-minute recovery period at light intensity. We will measure the resting ED at the start of the programme and the ED during moderate aerobic exercise in the 5th week of APA."
40765932|NCT06484595|OTHER|Best Practice|Receive SOC supportive care services
40765933|NCT06484595|BEHAVIORAL|Patient Navigation|Receive clinical trial navigator guide services
40765934|NCT05548556|DRUG|Placebo|Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
40765935|NCT05548556|DRUG|RO7204239|Participants will receive SC RO7204239 Q4W
40963921|NCT01714011|DRUG|Ziprasidone|"Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours."
41456793|NCT06110819|OTHER|control|Pregnant women will be contacted by phone and the status of their follow-up in health institutions will be questioned. During these follow-ups, training is provided and monitoring is carried out in line with the Prenatal Care Management Guide of the Ministry of Health.
40765936|NCT06644716|DIAGNOSTIC_TEST|[18F]F-FAPI PET-CT|Each patient will receive a FAPI PET-CT.
40765937|NCT05716087|DRUG|Rocbrutinib|Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
40765938|NCT04909801|DRUG|Abatacept|Abatacept SC (125 mg) once weekly
40765939|NCT04909801|DRUG|Adalimumab|Adalimumab SC (40 mg) once every 2 weeks
40765940|NCT04909801|DRUG|Methotrexate|Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)
40765941|NCT06460155|DEVICE|3 methods intervention|Stu All participants will undergo all three methods being studied: epidurogram (gold standard), CompuFlo CathCheck, and physical exam in PACU following epidural placement.
40963922|NCT01714011|DRUG|Aripiprazole|Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
40963923|NCT03995628|DRUG|Dexamethasone|One dose of dexamethasone (0.5 mg/kg) on post-operative day 3 after tonsillectomy
41456794|NCT06110819|OTHER|Workgroup|"Experimental:~.In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health."
41456795|NCT00464386|DEVICE|Continuous Glucose Monitoring|measure glucose levels on burn patients
41456796|NCT04080999|DEVICE|r-TMS|The interventions have a total administration time of 75 minutes per day.For TMS stimulation, the coil will be positioned tangentially on the target area. Each r-TMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The visual scanning treatment involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities (Pizzamiglio et al.,1992).Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the r-TMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
40765942|NCT06545903|DEVICE|LMA Supreme|The device is inserted and the manikin ventilated
40765943|NCT06545903|DEVICE|SLIPA|The device is inserted and the manikin ventilated
40765944|NCT06545903|DEVICE|I-gel|The device is inserted and the manikin ventilated
40765945|NCT06545903|DEVICE|AuraGain|The device is inserted and the manikin ventilated
40765946|NCT06187961|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
41456797|NCT04080999|DEVICE|SHAM|Device: SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the intervention group.
40765947|NCT06187961|DRUG|Lenvatinib plus cadonilimab|lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
40765948|NCT06645288|OTHER|Emergency Reflex Action Drill|Emergency Reflex Action Drill in performing Emergency Surgical Airway
40765949|NCT06643208|DRUG|TACE-HAIC, Envafolimab and Lenvatinib|TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib
40963924|NCT03995628|DRUG|Placebo|One dose of placebo on post-operative day 3 after tonsillectomy
41456798|NCT01626339|DRUG|Intravitreal Ranibizumab|
40963925|NCT02389361|DRUG|Zaldiar|Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
40963926|NCT02389361|DRUG|Paracetamol-Tramadol|Postoperative analgesia with intravenous Paracetamol and Tramadol
40963927|NCT00306618|DRUG|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
40963928|NCT04729868|DRUG|Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)|evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries
40963929|NCT02154776|DRUG|LEE011|3 weeks on and 1 week off
40963930|NCT02154776|DRUG|Buparlisib|daily
40963931|NCT02154776|DRUG|Letrozole|2.5 mg daily;
40963932|NCT01333254|PROCEDURE|Intermittent urinary catheterisation|Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
40963933|NCT00573612|BEHAVIORAL|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
40963934|NCT00573612|BEHAVIORAL|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
40963935|NCT01929343|DRUG|lidocaine following cue-induced craving|as described in Arm Description
40963936|NCT01929343|DRUG|lidocaine following neutral stimulus|as described in Arm Description
41456799|NCT01626339|DRUG|Intravitreal bevacizumab|
41456800|NCT03410030|DRUG|Ascorbic Acid|combination therapy
40963937|NCT01929343|DRUG|saline|as described in Arm Description
40963938|NCT00064116|BIOLOGICAL|rituximab|Rituximab 375 mg/m² i.v. day 1
40963939|NCT00064116|DRUG|CHOP regimen|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
40963940|NCT01462097|BEHAVIORAL|Aerobic exercise training|12 months of aerobic exercise
40963941|NCT01462097|BEHAVIORAL|Health Education|12 months of health education sessions
40963942|NCT03951571|DRUG|Anlotinib Hydrochloride|Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
40963943|NCT03951571|DRUG|Placebo Oral Tablet|Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
40963944|NCT04592250|OTHER|Survey Administration|Complete survey
40963945|NCT00393029|BIOLOGICAL|anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
40963946|NCT00393029|BIOLOGICAL|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
40963947|NCT00393029|BIOLOGICAL|filgrastim|Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count \> 1.0 x 10\^9/L x 3 days or \> 5.0 x 10\^9/L.
40963948|NCT00393029|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
40963949|NCT00393029|DRUG|fludarabine phosphate|25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
40963950|NCT03256097|DEVICE|XDP sound processing strategy - Period 0|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
40963951|NCT03256097|DEVICE|XDP sound processing strategy - Period 1|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
41456801|NCT03410030|DRUG|Paclitaxel protein-bound|combination therapy
41456802|NCT03410030|DRUG|Cisplatin|combination therapy
41456803|NCT03410030|DRUG|Gemcitabine|combination therapy
40963952|NCT03256097|DEVICE|VG sound processing strategy - Period 1|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
40963953|NCT03256097|DEVICE|XDP sound processing strategy - Period 2|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
41456804|NCT04525898|DRUG|Methadone|The methadone group will receive an intravenous dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
41456805|NCT05081193|DRUG|Testosterone Undecanoate|198mg taken twice daily
41456806|NCT05081193|DRUG|Enzalutamide|160mg taken once daily
40963954|NCT03256097|DEVICE|VG sound processing strategy - Period 2|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
40963955|NCT03256097|DEVICE|XDP sound processing strategy - Period 3|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
40963956|NCT03256097|DEVICE|VG sound processing strategy - Period 3|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
41456807|NCT00974350|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER-Bupivacaine/Once
41456808|NCT00974350|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
41456809|NCT00974350|DRUG|SABER-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
41456810|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
41456811|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
41456812|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
41456813|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
40765950|NCT05761964|BEHAVIORAL|Harmony & Health|Participants will attend group in-person sessions 2 times each week for 8 weeks. The session will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation. Participants will be asked to complete at-home stretching practices 2 times each week for the 8 week intervention period. Participants will also be asked to complete weekly logs to self-monitor their physical activity.
40765951|NCT05761964|BEHAVIORAL|Health Education|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and wellbeing topics.
40765952|NCT06492928|OTHER|Psychomotor Vigilance Task|T0 - at the start of the shift: completion of the 1st PVT / socio-demographic and workstation questionnaire T1 - at the end of the shift: completion of the second PVT and questionnaire on the course of the shift that has just taken place T2 - 1 week after the end of the shift: additional questionnaire sent with scales to assess work-related fatigue (MBI), anxiety (PSS), sleep quality (PSQI) and chronotype (MEQ).
40765953|NCT06638554|BEHAVIORAL|Active Choice|The participant will be send a letter inviting them to complete a SDM visit either in-person or via telehealth.
40765954|NCT06638554|BEHAVIORAL|Telehealth Only|The participant will be send a letter inviting them to complete a SDM visit via telehealth only.
40765955|NCT06638554|BEHAVIORAL|Low Touch Strategy|Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging.
40765956|NCT06638554|BEHAVIORAL|High Touch Strategy|Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging in combination with synchronous telephone-based digital care coordination.
40765957|NCT05073432|OTHER|Experimental|Usability of the Discussion Prioritization Tool (DPT) by completing Geriatric Assessment and Conjoint Analysis
40765958|NCT06360289|OTHER|Standard of Care|This is an observational study. No study drug will be administered as a part of the study, participants will be treated according to the decision of the treating physician.
40963957|NCT03256097|DEVICE|Voice Track|Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
41294547|NCT03114241|BEHAVIORAL|Intervention|Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
41294548|NCT00829166|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
41294549|NCT00829166|DRUG|Lapatinib|Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
41294550|NCT00829166|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
41294551|NCT00987051|PROCEDURE|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
41294552|NCT01511289|DRUG|Imatinib|400mg/Tab, QD
41294553|NCT01511289|DRUG|Radotinib|100mg or 200mg/Capsule, 300mg or 400mg BID
41294554|NCT05673135|DRUG|Anti-Hypertensive|For control of the blood pressure
41294555|NCT05673135|RADIATION|Ultrasound|For assessment of gestational age and fetal weight
40765959|NCT04621877|BEHAVIORAL|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
40765960|NCT04621877|BEHAVIORAL|Master's level clinician-delivered Behavioral Activation|Behavioral Activation as delivered by trained master's level clinicians
40765961|NCT06640894|OTHER|MegaPower training|See arm/group descriptions
40765962|NCT06640894|OTHER|Usual Care|See arm/group descriptions
40765963|NCT05202782|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given IV
40765964|NCT05202782|OTHER|Quality-of-Life Assessment|Ancillary studies
40765965|NCT05202782|OTHER|Questionnaire Administration|Ancillary studies
40765966|NCT05202782|DRUG|Zanubrutinib|Given PO
40963958|NCT01484847|DRUG|PF-00299804|Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
41456814|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
41456815|NCT01898845|DRUG|LEE011|
40963959|NCT02947503|DRUG|Metformin TEVA 850 mg|At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
40963960|NCT02057679|DRUG|Amoxicillin clavulanic|3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
40765967|NCT06642233|DIAGNOSTIC_TEST|Socio-demographic survey|Socio-demographic survey includes: age, sex, time of symptoms, work activity, hours of work activity, work position, activities with loads, physical activity, household chores, missing teeth, dental splints, dentures, smoking, alcohol consumption, whether they can reproduce their symptoms, hours during which they perform focal distance tasks, whether they have visual problems, whether they take painkillers or anti-inflammatory drugs, presence of headaches and their frequency), whether you can reproduce your symptoms, hours during which you perform tasks at focal distance, whether you have visual problems, whether you take analgesics or anti-inflammatory drugs, presence and frequency of headaches.
40765968|NCT06642233|DIAGNOSTIC_TEST|Visual Analogue Scale|VAS scale - The subject must indicate with a horizontal line their perception of pain on a scale (not numbered) of 100 millimetres, with 0 being the absence of pain and 100 the worst pain imaginable. The patient will complete the VAS scale, responding to the average, maximum and minimum pain experienced throughout its duration.
40765969|NCT06642233|DIAGNOSTIC_TEST|The World Health Organization Quality-of-Life Scale-BREF questionnaire|The WHOQOL-BREF questionnaire is used to assess domains quality of life: physical, mental, social functioning and functioning in the environment. Responses are on a 5-point scale (score range 1-5). In each field you can get maximum 20 points. The results of individual areas are positive (the higher the number of points, the higher the quality of life).
40765970|NCT06642233|DIAGNOSTIC_TEST|The International Physical Activity Questionnaire|The International Physical Activity Questionnaire (IPAQ) is a self-reported questionnaire for assessing physical activity and sedentary behavior for adults aged 15-69 years, across a range of socio-economic settings.
40765971|NCT06642233|DIAGNOSTIC_TEST|The Neck Disability Index questionnaire|The NDI evaluates the effect of neck pain on activities of daily living and social relationships. It consists of 10 items with 6 response options that are scored from 0 to 5 points each for a total possible score of 50. The classification of disability is based on the total score obtained, with higher number indicating greater disability.
40765972|NCT06642233|DEVICE|Body composition analysis using TANITA device|"TANITA device - body composition analyzer, the proportion of muscle mass and fat in the upper limbs~* Body height will be determined using a SECA 217 stadimeter.~* General and segmental body composition using the eight-electrode body composition analyzer by TANITA."
40963961|NCT02057679|DRUG|Placebo|1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
41294556|NCT05673135|RADIATION|Doppler ultrasound|Umbilical artery Doppler assessment
41294557|NCT05673135|DIAGNOSTIC_TEST|complete blood count|For assessment of platelet count
41294558|NCT05673135|DIAGNOSTIC_TEST|Body mass index|for assessment of maternal weight during pregnancy
41294559|NCT02436486|DRUG|Placebo|Capsules, orally, single dose
41294560|NCT02436486|DRUG|ldalopirdine 120 mg|Two 60 mg encapsulated film-coated tablets, orally, single dose
41294561|NCT02436486|DRUG|Idalopirdine 360 mg|Four 90 mg encapsulated film-coated tablets, orally, single dose
41294562|NCT02436486|DRUG|Moxifloxacin 400 mg|Encapsulated tablets, orally, single dose
41294563|NCT05378659|BEHAVIORAL|Montreal Cognitive Assessment|Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place
41294564|NCT05378659|BEHAVIORAL|Stroop Test|Evaluates Processing Speed and Executive Control
41294565|NCT05378659|DIAGNOSTIC_TEST|4AT Delirium|Screening tool to test for delirium post surgery
41294566|NCT05378659|BEHAVIORAL|Grooved Pegboard|Evaluation testing for dominant and non dominant sensory-motor speed
41294567|NCT05378659|BEHAVIORAL|NACC Cognitive Battery|A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.
41294568|NCT05378659|DIAGNOSTIC_TEST|ERP Testing|An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.
41294569|NCT05378659|DIAGNOSTIC_TEST|Blood Plasma and Serum sampling|Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.
41294570|NCT05378659|DIAGNOSTIC_TEST|Cerebral Spinal Fluid Sample|At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.
40765973|NCT06642233|DIAGNOSTIC_TEST|Cervical spine AROM (Active range of motion)|"Measurement of cervical spine AROM can be performed using the CROM system (Performance Attainment Associates, Roseville, MN, USA). Flexion, extension, side bending to the right and left, and rotation to the right and left of the cervical spine are examined.~The CROM measuring equipment consists of a helmet-shaped structure with the shape of glasses. These glasses adjust to the nasal septum thanks to the velcro on the back to fit them on the head. Three inclinometers for measuring on 3 cardinal planes were placed in the plastic construction."
40963962|NCT05884996|OTHER|PNF training|Resistance training with elastic bands in diagonals of PNF
40765974|NCT06642233|DIAGNOSTIC_TEST|Sagittal plane UCS AROM (Upper cervical spine active range of motion)|Measurement of sagittal plane UCS AROM can be performed using the CROM system. Flexion and extension of the upper cervical spine are examined.
40765975|NCT06642233|DIAGNOSTIC_TEST|Flexion-Rotation Test|The flexion-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is flexed.
40765976|NCT06642233|DIAGNOSTIC_TEST|Sidebending-Rotation Test|The sidebending-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is in a lateral tilt.
40765977|NCT06642233|DIAGNOSTIC_TEST|Axial rotation test C0-C2|The Axial rotation test C0-C2 can be performed using the CROM system. Rotation of the C0-C2 is examined.
40765978|NCT06642233|DIAGNOSTIC_TEST|Tilting test C0-C1 and C2-C3|The Tilting test C0-C1 and C2-C3 can be performed using a goniometer. Lateral tilt of the C0-C1 and C2-C3 are examined.
40765979|NCT06642233|DIAGNOSTIC_TEST|Craniocervical flexion test|The test measures the level of activation of the deep neck flexors using a pressure biofeedback device, an air-filled manual pressure cuff (Stabilizer TM, Chattanooga Group, INC., USA).
40765980|NCT06642233|DIAGNOSTIC_TEST|Craniovertebral angle|The test measure the craniovertebral angle using a telephone placed on a tripod and a computer program. The CVA measurement is defined as the angle a horizontal line passing the neural spine of C7 in relation to the line connecting the tragus and the neural spine of C7.
40765981|NCT06642129|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Lumboperitoneal shunt (LPS) involves connecting the subarachnoid space of the lumbar spine to the peritoneal cavity through a pressure-adjustable unidirectional valve to shunt the appropriate amount of cerebrospinal fluid from the ventricles to the peritoneal cavity via the spinal canal, where it is absorbed through the peritoneum, to alleviate the increased intracranial pressure caused by the communicating hydrocephalus and the corresponding clinical symptoms.
40765982|NCT05592379|DRUG|Psilocybin|The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).
40765983|NCT05592379|DRUG|Clonidine|Clonidine will be administered orally in a 0.2mg dose
40765984|NCT05592379|OTHER|Saline|The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.
40765985|NCT06637462|DIAGNOSTIC_TEST|Endoscopy|Standard of care endoscopy
40765986|NCT02684474|BIOLOGICAL|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
40765987|NCT04918771|DRUG|Raphamin|"Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved.~On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days."
41136899|NCT04918394|OTHER|Questionnaire of Mold / moisture exposure|"Mold / moisture exposure is assessed by the 5 following questions, whose positive response has been associated with the actual presence of mold in the household (according to data from the literature data), asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home:~* Presence of visible mold~* Impression of dampness~* Apparent dampness~* Existence of recent water damage in the last year~* Presence of a moldy odor"
40765988|NCT04918771|DRUG|Placebo|Oral administration - not with food. Placebo using Raphamin scheme.
40765989|NCT04265651|DRUG|Infigratinib 0.016 mg/kg|"Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
40765990|NCT04265651|DRUG|Infigratinib 0.032 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
40963963|NCT04317131|DIAGNOSTIC_TEST|Research Diagnostic Criteria of Functional Disorders of the Masticatory System BKD / ZCURNŻ - Polish version|Interview and clinical examination of stomatognathic system based on standardized tool BDK/ZCURNŻ.
40963964|NCT04317131|DEVICE|Clinical examination of the stomatognathic system (structural and functional)|Examination with the use of JMA+Analyser (Jaw Motion Analyser) to analyse movement and function of the temporomandibular joints, mandibular position, condyle position (EPA), and access the muscle action potentials through bipolar skin surface electrodes EMG, assessment of occlusion by visual method according to Angle Classification.
40963965|NCT04317131|DEVICE|3D examination of the body posture|Comprehensive, three- dimensional examination of the body posture (static and dynamic) in the area of the spine, lower limbs and feet, performed by photogrammetric method (4th Generation MORA) and non- invasive image acquisition technology with the aid of infrared (Kineod) and The CQElektronik system.
41136900|NCT01130298|DRUG|Testosterone Gel 1.62%|5 grams
41136901|NCT00515242|BEHAVIORAL|massage|therapeutic massage
41136902|NCT00515242|BEHAVIORAL|thermotherapy|heat therapy
41136903|NCT00515242|BEHAVIORAL|relaxing environment|time in a relaxing environment
41136904|NCT05541289|BIOLOGICAL|BBV152|Single Arm; BBV152 (COVAXIN™)
40765991|NCT04265651|DRUG|Infigratinib 0.064 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
40765992|NCT04265651|DRUG|Infigratinib 0.128 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
40765993|NCT04265651|DRUG|Infigratinib 0.25 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
40963966|NCT04317131|DEVICE|Functional assessment of the spine and lower limbs|Functional assessment of the spine and lower limbs mobility trough a wireless motion sensor Moover.
40963967|NCT04317131|DEVICE|Complementary tests|Anthropometric measurements (height, weight, waist and hip circumference, skin folds), foot pressure on the ground and body balance accessed by pedobarograph FreeMed, body mass components measured by the Tanita MC 980 MA (BIA method), evaluation of 7-days of physical activity by accelerometer ActiGraph GT3X-BT, blood pressure measurement by Medel Connect Cardio MB 10 monitor.
40963968|NCT06084234|DIAGNOSTIC_TEST|GALAD|GALAD is a 3 biomarker panel incorporating AFP, AFP-L3% and DCP (all FDA approved), with patient age and sex.
40963969|NCT06084234|DIAGNOSTIC_TEST|Liver Ultrasound with or without AFP|This intervention consists of current standard of care ultrasound based surveillance with or without alpha-fetoprotein measurement.
41136905|NCT03167008|DIAGNOSTIC_TEST|semen sample|-Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
41136906|NCT03167008|DIAGNOSTIC_TEST|blood sample|blood samples will be taken \&the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
41136907|NCT02991118|DRUG|bempedoic acid|bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
41136908|NCT02991118|DRUG|placebo|Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
40963970|NCT05473910|DRUG|SOC + TSC-100|HA-1 positive
41136909|NCT02994004|OTHER|no intervention|
41136910|NCT01798498|DEVICE|Princess® VOLUME|
41136911|NCT00316797|DRUG|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
41136912|NCT00834379|DRUG|pravastatin sodium|40 mg Tablet
41294571|NCT00081289|RADIATION|Radiation Therapy|Pelvic radiation therapy given once daily 5 days a week for 6 weeks, 45 Gy in 25 fractions + boost of 5.4 Gy in 3 fractions for a total dose of 50.4 Gy.
41294572|NCT00081289|DRUG|Capecitabine 1650 mg/m^2/day|825 mg/m\^2 q12 hours (1650 mg/m\^2/day) orally 5 days per week during radiotherapy.
41294573|NCT00081289|DRUG|Capecitabine 1200 mg/m^2/day|600 mg/m\^2 q12 hours(1200 mg/m\^2/day) orally 5 days per week during radiotherapy.
40765994|NCT05103605|DRUG|Osimertinib|Single arm treated by osimertinib
40765995|NCT05521178|DIAGNOSTIC_TEST|Electrocardiogram|ECG to monitor electrical activities of the heart on each visit
40765996|NCT05521178|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram at baseline and 6 months
40765997|NCT05521178|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Cardiac MRI at baseline and 6 months
40765998|NCT05521178|DEVICE|Mobile cardiac telemetry|Mobile cardiac telemetry at baseline and 6 months
40765999|NCT05521178|DIAGNOSTIC_TEST|Blood pressure monitoring|Home blood pressure monitoring three times per week
41136913|NCT00834379|DRUG|Pravachol®|40 mg tablet
41136914|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are guided by a therapist. Treatment is delivered via the Internet."
41136915|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered via the Internet."
41294574|NCT00081289|DRUG|Irinotecan|50mg/m\^2 IV over 1 hour on days 1, 8, 22, and 29
40766000|NCT05521178|DIAGNOSTIC_TEST|Blood draw|Blood draw at baseline, 3 and 6 months
40766001|NCT03453541|DRUG|Ketorolac Tromethamine|Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
40766002|NCT03453541|DRUG|0.9% Normal Saline|0.9 % Normal saline 1ml/60kg up to a maximum dose of 1ml IV bolus (an equivalent volume as per kg Ketorolac Trimethamine dose) at the completion of the tonsillectomy in the operating room.
40766003|NCT06580717|DRUG|enavogliflozin 0.3mg|"Enavogliflozin 0.3mg, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo."
40766004|NCT06580717|DRUG|enavogliflozin Placebo|"A placebo pill identical to enavogliflozin, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo."
40766005|NCT05379946|DRUG|D-1553|D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation
40766006|NCT05379946|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day
40766007|NCT04893811|BIOLOGICAL|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
40766008|NCT06644937|DRUG|TACE combined with Acoradine|"Transcatheter hepatic arterial chemoembolization (TACE) : the treatment interval was 28 days, the window period was ± 7 days. Subjects received a maximum of 4 TACE treatments; reduced and delayed treatment: laboratory tests were performed before the start of each cycle of TACE, with investigator criteria confirming whether TACE treatment was feasible.~Acoradine: 6 tablets bid, taken after meals for 6 months or until intolerable or progressive disease (starting one month after surgery) ."
40766009|NCT03374254|BIOLOGICAL|Pembrolizumab|200 mg Pembrolizumab solution for IV infusion Q3W
40766010|NCT03374254|DRUG|Binimetinib|tablet orally BID at 30 or 45 mg depending upon DLT profile
40766011|NCT03374254|DRUG|Oxaliplatin|85 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m\^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
40963971|NCT05473910|DRUG|SOC + TSC-101|HA-2 positive or HA-1 negative
40963972|NCT05473910|OTHER|Control|SOC alone
40963973|NCT00730405|DRUG|Albaconazole 100mg|Albaconazole for 36 weeks
40963974|NCT00730405|DRUG|Albaconazole 200mg|Albaconazole for 36 weeks
40963975|NCT00730405|DRUG|Albaconazole 400mg|Albaconazole for 36 weeks
40963976|NCT00730405|DRUG|Albaconazole 400mg|Albaconazole for 24 weeks, Placebo for 12 weeks
40963977|NCT00730405|DRUG|Placebo 400 mg|Placebo for 36 weeks
40963978|NCT05476198|PROCEDURE|Brachial plexus block|The effect of brachial plexus block method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
40766012|NCT03374254|DRUG|Leucovorin|400 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
40963979|NCT05476198|PROCEDURE|General anesthesia|The effect of general anesthesia method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
40963980|NCT02179242|OTHER|Cardiac rehab|
40963981|NCT00040482|DRUG|Cyclophosphamide|
40963982|NCT00040482|DRUG|ATG|
40963983|NCT00040482|DRUG|MESNA|
40963984|NCT00040482|PROCEDURE|Radiation therapy|
40963985|NCT06385600|DRUG|Labetalol|Group L will recieve labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient.
40963986|NCT06385600|DRUG|Phentolamine|Group P will receive phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.
40963987|NCT00682162|DEVICE|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, \[22\]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
41456816|NCT01137864|OTHER|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
40766013|NCT03374254|DRUG|5-Fluorouracil [5-FU]|2400 mg/m\^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m\^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
40766014|NCT03374254|DRUG|Irinotecan|180 mg/m\^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m\^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
40766015|NCT06334146|OTHER|Tap dance program|Participants will take part in a weekly adapted tap dance class, for one hour per week, for eight weeks.
41136916|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered in book form."
41136917|NCT02994524|PROCEDURE|Rerouting technique for transsphincteric perianal fistula|
40766016|NCT06636981|DRUG|Cohort2: ATRA+Toripalimab+TPC|Receive 200 mg D1 of Toripalimab via intravenous infusion for a course of 21 days; TPC regimen (monoclonal antibody 10mg/kg D1, 8 intravenous infusions, 1 course of treatment every 21 days; Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days; Gemcitabine 1000mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days); Capecitabine 1000mg/m2, D1-14, oral, one course of treatment every 21 days); All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.
40766017|NCT06636981|DRUG|Cohort1: ATRA+Toripalimab+chemo|Receive 200 mg of Toripalimab via D1 intravenous infusion, with 21 days as one course of treatment; Albumin paclitaxel 100 mg/m2, D1, D8, intravenous infusion, one course of treatment for 21 days; All trans retinoic acid 20 mg bid, oral, D-3-D11, continuous administration for 14 days, cessation for 7 days, 21 days is one course of treatment.
40766018|NCT06644066|PROCEDURE|Partial pressure of Oxygen Control method|During the process of inflation-deflation, by maintaining a lower PaO2, the identifying the intersegmental plane is accelerated
40766019|NCT06643676|PROCEDURE|Targeted Endodontic Microsurgery Using 3d Printed surgical guide using the patient's CBCT data|Patients with apical periodontitis with intact cortex in madibular molars receiving Targeted Endodontic surgery or Guided Endodontic Microsurgery with surgical guide fabricated using the cbct data following failure of non surgical root canal treatment
41136918|NCT05114993|DEVICE|wearing a disposable surgical mask|Physiologic vital signs will be monitored every minute for 5 minutes without a mask, followed by every minute for 15 minutes with a surgical mask.
41136919|NCT01138384|DRUG|Foretinib|Daily oral dosing at assigned dose beginning day 3 of cycle 1
41136920|NCT01138384|DRUG|Lapatinib|Daily oral dosing at assigned dose beginning day 1 cycle 1.
41136921|NCT06231680|DRUG|Camrelizumab|Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity
41136922|NCT06231680|DRUG|Thalidomide 50mg|Thalidomide 50mg，po qd；
41136923|NCT06231680|DRUG|Thalidomide 100mg|Thalidomide 100mg，po qd；
41136924|NCT06231680|DRUG|Thalidomide 200mg|Thalidomide 200mg，po qd；
41136925|NCT06231680|DRUG|Chemotherapy|"Platinum-based chemotherapy:~1. Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;~2. Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD;~3. Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles."
41456817|NCT00978458|DRUG|temozolomide|Given orally
41456818|NCT00978458|RADIATION|3-dimensional conformal radiation therapy|Given once daily 5 days a week for 5½ weeks
41456819|NCT00978458|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 5½ weeks
40766020|NCT06643676|PROCEDURE|Conventional Endodontic Microsurgery with a free hand procedure using bur and CBCT analysis|A conventional endodontic microsurgery using arbitrary localisation technique using the cbct data and performing the surgery with a carbide bur.
40766021|NCT06207162|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task. There will also be a Resting state: Participants are not presented with any specific stimulus.
40766022|NCT06643793|DRUG|Irinotecan liposome (ll) + 5-FU/LV + bevacizumab|"1. Bevacizumab: 5 mg/kg, d1, q2w;~2. Irinotecan Hydrochloride Liposomal Injection (II): 60 mg/m2, d1, q2w;~3. leucovorin: 400 mg/m2, d1, q2w;~4. 5-fluorouracil: 2800 mg/m2, d1, q2w."
40766023|NCT06645483|OTHER|ChatGPT-assisted instruction|"ChatGPT will interactively support students by answering questions, initiating discussions, and providing customized learning materials in line with the course objectives. It will be supervised by the instructor to ensure guidance and prevent misinformation.~Duration: ChatGPT-assisted learning for the first two weeks, followed by traditional teaching for the next two weeks."
40766024|NCT06645483|OTHER|Traditional lecture-based instruction|"Students will learn through a traditional teaching format, where the instructor delivers the course content through lectures and presentations.~Duration: Traditional teaching for the first two weeks, followed by ChatGPT-assisted learning for the next two weeks."
40766025|NCT05044897|DRUG|SI-B001|administration weekly by intravenous infusion（QW）.
40766026|NCT06640790|OTHER|Case Group|Root canal treated were categorized based on the AAE case difficulty assessment form. Endodontic mishaps investigated included over-instrumentation, working length loss, underfilling, overfilling, apical transportation, instrument fracture, and perforation.
40766027|NCT06183567|PROCEDURE|Sedoanalgesia|In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under sedoanalgesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
40766028|NCT06183567|PROCEDURE|general anesthesia|In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under general anesthesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
40766029|NCT06192108|DRUG|Orforglipron|Administered orally
40766030|NCT06192108|DRUG|Dapagliflozin|Administered orally
40766031|NCT06640933|DRUG|BIIB091|Administered as specified in the treatment arm.
40766032|NCT06639633|OTHER|Anatomy Training with Enlarged %100 3D Printed Carpal Model Group|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 1-hour extra-curricular training, 30 minutes theoretical and 30 minutes practical. The training period will consist of 30 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 30-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 100% magnification on a 3D printer for 30 minutes.
40766033|NCT06639633|OTHER|Anatomy Training with Enlarged %50 3D Printed Carpal Model Group|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 1-hour extra-curricular training, 30 minutes theoretical and 30 minutes practical. The training period will consist of 30 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 30-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 50% magnification on a 3D printer for 30 minutes.
40766034|NCT06639633|OTHER|Anatomy Training with Conventional Carpal Models|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 1-hour extra-curricular training, 30 minutes theoretical and 30 minutes practical. The training period will consist of 30 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 30-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. They will then have a 30 minute practical lesson with a standard sized printed model.
40766035|NCT03612531|PROCEDURE|Manual Therapy|Receive manual therapy
40766036|NCT04797481|PROCEDURE|Exercise|Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.
41136926|NCT01814605|PROCEDURE|Infragluteal space group|"Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.~The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
41294575|NCT00081289|DRUG|Oxaliplatin|50mg/m\^2 IV over 2 hours on days 1, 8, 15, 22, and 29
41456820|NCT00510393|DEVICE|XIENCE V everolimus eluting coronary stent system|
41456821|NCT00510393|DEVICE|MULTILINK VISION coronary stent system|
41456822|NCT03609749|BEHAVIORAL|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3)"
41456823|NCT06299280|OTHER|dual task training|students will be given additional cognitive tasks while exercising in physical education class
41456824|NCT06299280|OTHER|single task training|students will exercise in physical education class, without additional cognitive tasks
41456825|NCT03922750|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
41456826|NCT03922750|DRUG|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine OD for 16 weeks
40766037|NCT04797481|PROCEDURE|Self-managed exercise|Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.
40766038|NCT05450237|BEHAVIORAL|Psychometric Evaluations|"The main evaluation scales we will use are the Beck Depression Inventory-II (BDI II), the State-Trait Anxiety Inventory (STAI), The twenty-item Toronto Alexithymia scale- I (TAS-20), The fatigue severity scale (FSS), Modified Fatigue Impact Scale (MFIS), The Multiple Sclerosis Impact Scale (MSIS-29), The Epworth Sleepiness Scale (ESS) (Johns MW. 1991), The Pittsburgh Sleep Quality Index (PSQ1), The Multiple Sclerosis quality of life Inventory (MSQOLI), The work productivity and activity impairment instrument (WPAI), Frailty Index.~These rating scales will be administered in person, by telephone and / or by sending them electronically."
40766039|NCT04938817|BIOLOGICAL|coformulation pembrolizumab/quavonlimab|Intravenous (IV) infusion
40766040|NCT04938817|DRUG|lenvatinib|Oral administration
40766041|NCT04938817|BIOLOGICAL|MK-4830|IV infusion
40963988|NCT00682162|DEVICE|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
40963989|NCT02145780|DIETARY_SUPPLEMENT|2g of grape polyphenol extract|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
40963990|NCT02145780|DIETARY_SUPPLEMENT|Dietary Supplement: 2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
40963991|NCT05654220|BEHAVIORAL|Text Messaging Intervention|A text messaging intervention will be conducted that includes prompts to call trained BenePhilly enrollment specialists to submit applications for benefits programs. Text message prompts will be sent on days 2, 4, 7, 14, and 21 post-discharge from a Penn Medicine emergency department.
40963992|NCT02217267|DRUG|Lidocaine|Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour
40963993|NCT02217267|DRUG|Placebo|
40963994|NCT01393691|BEHAVIORAL|CBT with parent involved play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
40963995|NCT01393691|BEHAVIORAL|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
41136927|NCT01814605|PROCEDURE|Subgluteal space group|Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
41136928|NCT05850793|BEHAVIORAL|Sensorimotor Exercise|Balance, perturbation , aging and strengthing exercise will be performed for knee
41136929|NCT05850793|BEHAVIORAL|Conventional Exercise|Range of motion, strengthing and stretching exercise will be performed for knee
41456827|NCT02837913|DEVICE|VitaHeat underbody heating mattress|Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
41456828|NCT05612750|BEHAVIORAL|Education|Participants will receive one of two educational programs.
40766042|NCT04938817|BIOLOGICAL|coformulation favezelimab/pembrolizumab|IV infusion
40766043|NCT04938817|BIOLOGICAL|R-DXd|IV Infusion
40766044|NCT05987423|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
40766045|NCT05987423|DRUG|Placebo|Placebo will be administered by SC injection
40766046|NCT06641999|DEVICE|Tinnitus Implant System|Implanted with Tinnitus Implant System: Active Implantable Medical Device
40766047|NCT03413995|DRUG|Rucaparib|Continuous dosing
40766048|NCT06435221|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
40963996|NCT01311479|PROCEDURE|Osteopathic Manipulation Therapy|"Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment."
40963997|NCT01960400|DEVICE|transcranial direct current stimulation (tDCS) (active or placebo)|TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
40963998|NCT01960400|DEVICE|Graded motor imagery (GMI)|The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
40963999|NCT01930266|DIETARY_SUPPLEMENT|Experimental|
41136930|NCT05850793|BEHAVIORAL|Progressive Motor Imagery Exercise|Different types of exercises will be applied targeting muscle strength, proprioceptive sense or brain neurons for knee
41294576|NCT00081289|PROCEDURE|Surgery|All patients will undergo surgery four to eight weeks following the completion of radiation therapy. The choice of procedure abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis is at the discretion of the surgeon.
41456829|NCT00914654|DRUG|inhaled formoterol|Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
41456830|NCT02897934|DRUG|Bupivacaine continuous infusion|The use of continuous wound infusion of bupivacaine
41294577|NCT00081289|DRUG|Folinic Acid|400 mg/m\^2 IV over 2 hours Day 1 (postoperatively) ,every 14 days, for nine 14-day cycles.
41456831|NCT06223724|DEVICE|STOP|Software to measure impedance telemetry data
41456832|NCT06223724|DEVICE|MAESTRO|Software to measure impedance telemetry data
40766055|NCT06119204|OTHER|Oviva programme|Total diet replacement for insulin-treated patients
40766056|NCT06119204|OTHER|Usual care|NHS 12 week weight loss programme
40766058|NCT05700617|DRUG|1:1 Randomization to receive milrinone or dobutamine|Randomized to receive either inotropic agent: milrinone or dobutamine
40766059|NCT05700617|DRUG|1:1 Randomization to receive dobutamine or milrinone|Randomized to receive either inotropic agent: milrinone or dobutamine
40766060|NCT06637202|RADIATION|postoperative radiotherapy|50 Gy in 25 fractions
40766061|NCT06290323|PROCEDURE|Quadratus lumborum block|Posterior quadratus lumborum block
40766062|NCT06290323|PROCEDURE|Placebo|Patients in the first group are the control group and after spinal anesthesia, the sensory block is formed, the lithotomy position will be taken for the surgical procedure.
40766063|NCT05200481|DRUG|Brigatinib 180 MG|Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.
40766064|NCT05200481|DRUG|Carboplatin|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
40766065|NCT05200481|DRUG|Pemetrexed|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
40964000|NCT01930266|BEHAVIORAL|Active comparator|
41456833|NCT04506567|DRUG|225Ac-J591|Single cycle of fractionated dose of 225Ac-J591
40766066|NCT06639529|DIAGNOSTIC_TEST|Tests of the expression of CXCL3 in various tissues|1.The expression of CXCL3 in peripheral blood PBMC was detected by RT-qPCR. 2.The levels of CXCL3 in serum and urine were detected by Elisa method. 3.Clinical data collection includes the patient \&#39;s name, gender, weight, height, biochemical indicators, urine test indicators, renal biopsy data, etc. 4.The expression of CXCL3 in renal tissue was determined by immunohistochemistry.
40964001|NCT02099175|DRUG|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
40964002|NCT02099175|DRUG|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
40964003|NCT02099175|DRUG|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
40964004|NCT02099175|DRUG|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
40964005|NCT02099175|DRUG|Adriamycin|20 mg/m2/day - Powder for solution for infusion
40964006|NCT02099175|DRUG|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
40964007|NCT02099175|DRUG|Leucovorin|250 mg/m2/day - Powder for solution for infusion
40964008|NCT02099175|RADIATION|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
40964009|NCT02099175|RADIATION|Radiotherapy - Patients not needing ENI|"1. Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
40964010|NCT02099175|RADIATION|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively."
40964011|NCT00993083|BIOLOGICAL|MVA-NP+M1|Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
40964012|NCT05106283|PROCEDURE|Deep block and Combined Block|Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
40964013|NCT00009997|BIOLOGICAL|trastuzumab|
40964014|NCT00009997|DRUG|cyclophosphamide|
40964015|NCT00009997|DRUG|doxorubicin hydrochloride|
40964016|NCT00009997|DRUG|paclitaxel|
40964017|NCT00009997|DRUG|tamoxifen citrate|
40964018|NCT00009997|PROCEDURE|conventional surgery|
40964019|NCT04174755|DRUG|Semaglutide Injectable Product|Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
40964020|NCT04174755|BEHAVIORAL|Standard of care|Diet and exercise advice for 40 weeks
41294578|NCT00081289|DRUG|Fluorouracil|"5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles.~5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles."
41456834|NCT04506567|DIAGNOSTIC_TEST|68Ga-PSMA-HBED-CC injection|68Ga-PSMA-HBED-CC PET/CT before and after treatment
41456835|NCT04506567|DRUG|225Ac-J591|Single dose of 225Ac-J591 every 6 weeks x 4
40964021|NCT05269498|DEVICE|CORTEXPLORER MED|The CORTEXPLORER MED system is a platform that enables surgical navigation using real-time radiological images of patients. The application software formats patient-specific computed tomography or magnetic resonance images taken before surgery. These are displayed on the screen and through mixed reality from different perspectives (axial, sagittal, coronal, diagonal). Before surgery, the surgeon can then create, save and simulate the course along one or more surgical trajectories. As a visualization aid, the surgeon can also create and edit one or more 3D models of the anatomy. During surgery, the system tracks the position of specific surgical instruments in or on the patient's anatomy and continuously updates the position of the instruments on these images.
40964022|NCT02956421|BIOLOGICAL|RABIPUR®|Biological rabies vaccine
40964023|NCT02956421|BIOLOGICAL|PIKA rabies vaccine|Biological rabies vaccine
40964024|NCT03748147|DRUG|Misoprostol|prostaglandin e1
40964025|NCT02197520|DRUG|Insulin Peglispro|Administered subcutaneously (SC), (U-100 formulation)
40964026|NCT02197520|DRUG|Insulin Glargine|Administered subcutaneously (SC), (U-100 formulation)
40964027|NCT02197520|DRUG|Insulin Lispro|Administered subcutaneously (SC), (U-100 formulation)
41456836|NCT01513395|BEHAVIORAL|Interval bladder emptying|"Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time."
40964028|NCT04962178|PROCEDURE|Primary PCI|The patients assigned to early invasive strategy group will receive the primary PCI.
40964029|NCT04962178|OTHER|Optimal medical therapy with primary PCI not performed|The patients assigned to conservative strategy group will receive optimal medical therapy before primary endpoint accomplished.
41136931|NCT03177707|OTHER|Mindfulness-based Therapy Group for Couples|"Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.~The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital."
41136932|NCT06244914|DEVICE|tDCS stimulation|tDCS 1mA will be applied for 20min. tDCS will be applied around the infract area. taVNS or sham taVNS wil be applied before tDCS. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
40964030|NCT06193291|PROCEDURE|Feet heating|Feet placed in hot water
40964031|NCT06193291|PROCEDURE|Calf heating|Feet to calves placed in hot water
41136933|NCT06244914|DEVICE|taVNS stimulation|taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of taVNS will be adjusted under the patient's pain threshold. After taVNS, tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
41136934|NCT06244914|DEVICE|sham tDCS stimulation|sham tDCS 1mA will be applied for 20min. sham tDCS will be applied around the infract area. The stimulation will be applied for only 10 seconds and no stimulation afterward. taVNS or sham taVNS wil be applied before sham tDCS.The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
40964032|NCT03692247|OTHER|Smartphone-based Music Intervention|The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
40964033|NCT03562832|DRUG|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
40964034|NCT05649397|OTHER|cervical manipulation|provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
40964035|NCT05649397|OTHER|conventional therapy|15 mins moist hot pack Neck Isometric exercise hold for 5-8 seconds and repeat 10 times Cervical range of motion 10 repetitions of movement in rotation within pain free range
40766067|NCT06639009|OTHER|940nm diode laser photobiomodulation|"The surgical handpiece (diameter 0.6cm) will be used without the fibre optic tips in defocused mode and head sanitized before therapy.~Peak Power : 0.3Watts Power density: 1 Watt/cm2 Fluence: 4J/cm2 per cycle Spot size : 0.28cm2 Distance : 2mm from surface Mode: Continuous, Non- contact mode, circular motion, overlapping, in clockwise concentric manner with laser handpiece perpendicular to surface Duration of cycle : 25 seconds with interval of 30 seconds alternating with other side Cycles per sitting: Four for each side Four Sittings: Day 0,3, 7, and 15 Area of intervention: Bilateral buccal mucosa and masseter muscle Total treatment time per day: 430 seconds/ approx 7 minutes Total treatment time for 4 sittings: approx 28 minutes"
40766068|NCT06639009|OTHER|Conventional non -Invasive management in Oral Submucous fibrosis|"Brief behavioral Tobacco, areca nut and alcohol habit cessation counseling as per WHO 5As and 5Rs technique at baseline and each follow up.~Oral prophylaxis Removal of oral irritational factors like sharp teeth, appliances or prosthesis, impacted buccoverted third molars, parafunctional habits Oral hygiene maintenance instructions Oral physiotherapy Control of systemic conditions Removal of all predisposing factors for oral candida infection Advocacy for safe sexual practices Nutrition and diet counseling( seasonal and regional food rich in nutrients, vitamins, antioxidants avoidance of spicy /sour/ hot foods and drinks) Regular surveillance for malignant transformation"
40766069|NCT03073967|DRUG|Pritelivir|100 mg oral tablets
40766070|NCT03073967|DRUG|Investigator's choice|Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
40964036|NCT02862444|OTHER|Culturally Appropriate Intervention|Women in the intervention arm will receive a culturally appropriate intervention that will be provided to them according to the five strategies of culturally appropriate interventions of Kreuter et al. (2003).
40964037|NCT03566147|BIOLOGICAL|Human primary Retinal Pigment Epithelial (HuRPE) cells|HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.
41294579|NCT00081289|DRUG|Oxaliplatin|85 mg/m\^2 IV over 2 hours Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
40964038|NCT04487392|DRUG|Estrogen vaginal cream group (group A)|The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.
41456837|NCT06103760|DRUG|Esketamine Nasal Spray [Spravato]|This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.
40964039|NCT04487392|RADIATION|Photobiomodutation group (group B)|The participants selected for group B will be undergo photobiomodulation with red LED. With the participant in the lithotomy position, the speculum will be introduced into the vaginal canal and a vaginal wash with 0.9% saline will be performed to remove secretions. Afterwards, the speculum will be removed and the device with a red LED inserted up to about 6 cm from the introitus. A non-lubricated condom will be used in the LED device for patient protection. Sessions will take place once a week for 4 weeks.
40964040|NCT03671460|BIOLOGICAL|CD19 CAR-T cells|T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
40964041|NCT01487200|DRUG|FX006 10 mg|single 3 mL IA injection
40964042|NCT01487200|DRUG|FX006 40 mg|single 3 mL IA injection
40964043|NCT01487200|DRUG|FX006 60 mg|single 3 mL IA injection
40964044|NCT01487200|DRUG|TCA IR 40|single 1 mL IA injection
41456838|NCT03973151|DRUG|HL-085|HL-085 is one MEK inhibitor.
40964045|NCT02975336|DRUG|Placebo|Participants received placebo matched to M2951 orally for 52 weeks.
40964046|NCT02975336|DRUG|M2951|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.
40964047|NCT02975336|DRUG|M2951|Participants received 75 mg of M2951 orally QD for 52 weeks.
41456839|NCT05471687|DEVICE|dual-energy dual-layer spectral scanner|Realization of dual-energy dual-layer spectral scanner with stress protocol
41456840|NCT05471687|DRUG|Stress protocol with adenosin during dual-energy dual-layer spectral scanner|Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner
40766071|NCT03901365|OTHER|Neuroscience pain education|In Neuroscience pain education (NPE) sessions, patients were informed about the pain experience and the neurophysiological process about pain. NPE was performed by the method proposed by Louw et al (12). NPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
41294580|NCT01853124|DRUG|Placebo|All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
41136935|NCT06244914|DEVICE|sham taVNS stimulation|sham taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of sham taVNS will be adjusted under the patient's pain threshold. The stimulation was only applied for 5 seconds and no stimulation afterward. After sham taVNS, tDCS or sham tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
41136936|NCT03339544|DRUG|Celebrex premedication|celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
41294581|NCT01853124|DRUG|Lacidofil|All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
40766072|NCT03901365|OTHER|Traditional patient education|In traditional patient education (TPE) sessions were aimed to explain to patients a proposed treatment or efficacy of a certain manual therapy technique or approach, have focused heavily on biomechanical and anatomical models. These models would imply that injury, disease, and muscle guarding may lead to altered movement patterns, asymmetrical loading, and resultant pain and dysfunction. TPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
40964048|NCT02975336|DRUG|M2951|Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
40964049|NCT02975336|DRUG|M2951|Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
40964050|NCT04103658|RADIATION|Near-infrared heating|Same as the arm/group description. The NIR heating group will have the non-melanoma skin cancer lesion excised based on the lesion borders established from application of NIR heat at a distance of 20cm for 10 minutes.
41136937|NCT03339544|DRUG|Placebo|placebo is given as a tablet before initiation of endodontic treatment
41136938|NCT04620252|DRUG|Inactive supplement|Chewable candy (negative control), chewed for 30 seconds.
41136939|NCT04620252|DRUG|Tricalcium phosphate supplement|Chewable tricalcium phosphate supplement, chewed for 30 seconds.
41294582|NCT03562780|DRUG|Fortolin Tab 500mg|Fortolin Tab 500mg is a generic product manufactured by Fortune Pharmacal Co. Ltd.
41136940|NCT04620252|DRUG|Calcium carbonate supplement|Chewable calcium carbonate supplement, chewed for 30 seconds.
41136941|NCT04620252|DRUG|Calcium citrate supplement|Chewable calcium citrate supplement, chewed for 30 seconds.
40766073|NCT03901365|OTHER|Manual therapy|Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
40766074|NCT02945722|DRUG|Decolonization|Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
40766075|NCT02945722|OTHER|No decolonization|Screening of persistent carriers in this arm will be done every 3 months
40766076|NCT03526172|PROCEDURE|High tibial osteotomy|Uni-lateral medial opening-wedge high tibial osteotomy following a minimally invasive approach.
40766077|NCT03526172|DEVICE|Allograft wedge|Insertion of allograft wedge into the osteotomy gap during the HTO procedure
40766078|NCT03526172|DEVICE|Accelerometer|ActivPal accelerometer attached to thigh of patient to collect objective physical activity data at pre-determined intervals before and after surgery
40766079|NCT03526172|OTHER|Questionnaire|Validated clinical questionnaires administered to patients to collect subjective physical activity data at pre-determined intervals before and after surgery
40766080|NCT05121558|OTHER|Yoga|Participants will have instructional yoga classes twice each week over the course of 8 weeks. Each yoga class will be 60 minutes, and it will be taught by an experienced yoga instructor. Participants in the yoga group will also have the option to participate in a recorded final check-in session after they have completed their 16 yoga classes. The discussion facilitator will follow the Semi-Structured Interview Guide to further understand participants' experiences in the yoga group.
40766081|NCT05121558|OTHER|Education control|Participants will have educational sessions over 8 weeks. The sessions will be on the causes and impact of Chemotherapy-Induced Peripheral Neuropathy (CIPN) , how yoga may help with CIPN, and how different therapies may help with CIPN.
40766082|NCT05121558|OTHER|Usual care|Participants in the usual care control group will complete the same assessments as the other two arms. To encourage participation and adherence, patients in the UC group will receive a voucher for sixteen free yoga sessions after completing the study. Patients in the UC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
40766083|NCT05852340|DRUG|Ritlecitinib|"ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)"
40766084|NCT04521361|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).
40766085|NCT03809351|DRUG|[F-18]AV-1451-PET|All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
41136942|NCT04620252|DRUG|Inactive supplement and fluoride mouthwash|A chewable candy chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
41294583|NCT03562780|DRUG|Panadol Caplet 500mg|Panadol Caplet 500mg is manufactured by GlaxoSmithKline (Dungarvan) Ltd.
40766086|NCT03162211|OTHER|Feedback Report|There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.
40766087|NCT06174649|DIAGNOSTIC_TEST|Reveal|Reveal is a rapid AST method, which uses small molecule sensor technology to detect growth of bacterial populations by measuring volatile metabolites, and provides AST results in \~5 hours. Reveal™ is approved for clinical use in the European Union (EU) and Israel and approval is in process in India, and provides minimum inhibitory concentrations (MICs) for 28 antibiotics and 9 Gram negative species, that together account for \~90% of organisms causing Gram negative blood stream infections (BSI).
40766088|NCT05852717|PROCEDURE|AutoSCT OR CAR T-cell Therapy|Autologous stem cell transplant (AutoSCT) or CAR T-cell therapy will be performed after Cycle 3 of receiving epcoritamab and GDP
40766089|NCT05852717|DRUG|GDP|Gemcitabine Cisplatin Dexamethasone
40766090|NCT05852717|DRUG|Epcoritamab|Epcoritamab
40766091|NCT05299320|DIAGNOSTIC_TEST|Neuromuscular fatigue and postural sway evaluation|Neuromuscular fatigue will be established by using the Excalibur Sport Ergometer device and the Wingate Anaerobic Strength Test. Postural sway will be evaluated with Cyst Force Plate Balance device. This device is a precision device that provides objective measurable data.
40766092|NCT04606472|DRUG|SI-B003|Administration by intravenous infusion.
41136943|NCT04620252|DRUG|Calcium carbonate supplement and fluoride mouthwash|A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
40766094|NCT06625931|DRUG|NTCB01-1|3 Days infusion
40766095|NCT06625931|DRUG|NTCB-P|3 Days infusion
40766096|NCT06541678|DRUG|Danuglipron|MR Tablet
41136944|NCT04620252|DRUG|Calcium citrate supplement and fluoride mouthwash|A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
41456841|NCT05953987|OTHER|aerobic combined with diaphragmatic breathing exercise (EXDB)|The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added
40766097|NCT06541678|DRUG|Cyclosporine|Capsule
40766098|NCT06541678|DRUG|Itraconazole|Oral solution
40766099|NCT06626711|DRUG|Propofol|Propofol as a part of total venous anesthesia
40766100|NCT06626711|DRUG|Sevoflurane|Sevoflurane as a part of intravenous anesthesia
40766101|NCT05636176|DRUG|Ziltivekimab|Ziltivekimab subcutaneous (s.c.) injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
40766102|NCT05636176|DRUG|Placebo|Ziltivekimab placebo s.c. injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
40766103|NCT06264154|OTHER|E-cigarettes|All participants are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. Participants will receive an e-cigarette device and flavored nicotine pods according to their randomly assigned flavor.
40766104|NCT04684862|DEVICE|Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)|This infusion system is composed of a Medtronic SynchroMed II programmable pump connected to a Intera tapered catheter. Specifically, the Medtronic pump comes with a small connector that ends in a metal flange. During the operation, under sterile conditions, the distal 1 cm of the flange is severed using a scissor. Then, using a Intera connector pin, the end of the Medtronic catheter is connected to the Intera catheter . Two 2-0 silk ties secure the catheters to the pin. The pump and catheter are then inserted into the patient into the abdominal wall or into the chest wall. The catheter is inserted into an artery within the abdomen (usually the gastroduodenal artery but it depends on the exact arterial branching in the individual patient) that feeds the liver.
40766105|NCT04966585|DRUG|Posaconazole Delayed Release Oral Tablet|Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
40766106|NCT04966585|DRUG|Matching Placebo Tablet|Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
41136945|NCT01385800|BIOLOGICAL|ToleroMune Grass|Intradermal injection 1 x 8 administrations 2 weeks apart
41136946|NCT01385800|BIOLOGICAL|Placebo|Intradermal injection 1 x 8 administrations 2 weeks apart
41136947|NCT00001615|DRUG|Corticosteroid|
41136948|NCT03578978|OTHER|No intervention|No intervention will be given to study subjects. Only blood will be obtained from study subjects.
41136949|NCT00070486|DRUG|carboplatin|given IV
41136950|NCT00070486|DRUG|celecoxib|given PO
41136951|NCT00070486|DRUG|gemcitabine hydrochloride|given IV
41136952|NCT00070486|DRUG|zileuton|given PO
41136953|NCT05247307|BIOLOGICAL|convalescent plasma infusion covid 19|"Operating process~* A single dose of plasma (300 mL) immune anti-coronavirus or not, depending on what corresponds will be infused.~* The collaborating staff will enter the initial and follow-up data in Red Cap based on the information contained in the medical record, or by talking to the patient by telephone to clarify any doubts."
41294584|NCT05208983|BIOLOGICAL|mRNA Vaccines or Viral vector-based vaccines for COVID|Participants receiving an approved COVID vaccine
40766107|NCT06539728|DIAGNOSTIC_TEST|Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces|Participants will drop a saline solution with proteins onto the testing device. They will wait for it to dry and then report on the tactile sensation and overall feel of the surface. Feedback will include comparisons with the two reference surfaces. The primary goal is to determine the presence of mock COVID antigen in synthetic saliva using the device, which aligns with the goals of diagnostic testing.
40964051|NCT03303365|RADIATION|stereotactic radiosurgery (SRS)|"All patients will receive a pre-treatment cranial MRI for diagnostic and treatment planning purposes.~In Arm A, the contrast-based T1-weighted SPACE sequence is utilized for GTV definition. In Arm B, the contrast-based T1-weighted three-dimensional MPRAGE sequence is utilized for GTV definition. In both cases the GTV consists of all contrasted tissue associated with the target lesion and all additional tissue judged by an experienced physician to be part of the suspect target lesion. To the GTV a PTV margin of 1 mm is added by isotropic expansion that can be slightly modified if deemed necessary by the treating physician (e.g. intersection with adjoining OAR).~Dose prescription to the PTV for target lesions will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)"
40766108|NCT06539728|DIAGNOSTIC_TEST|Biomechanical Measurements|Participants may have biomechanical measurements recorded, such as placing samples on a scale to measure downward force or using medical tape with a flexible wire to track finger motion. These measurements are likely aimed at objectively assessing how participants interact with the surfaces and their physical responses to tactile stimuli.
40766109|NCT06539728|BEHAVIORAL|Psychophysical Tasks|Participants may alternatively be asked to perform standardized psychophysical tasks, such as Two Alternative Forced Choice tests, Odd-Man Out tests, or Magnitude Estimation tests. These tasks will provide structured comparisons and quantitative data on participants' perception and preferences regarding tactile qualities. The tasks are designed to evaluate participants' perception and preferences regarding tactile qualities, which involves behavioral responses to sensory stimuli.
40766110|NCT04915612|DRUG|Gemtuzumab Ozogamicin|Given IV
40766111|NCT04915612|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
40964052|NCT03253276|DRUG|Obeticholic acid|Placebo-controlled
40766112|NCT06120842|DRUG|Bimatoprost Implant System (High Dose)|Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL
40766113|NCT06120842|DRUG|Bimatoprost Implant System (Low Dose)|Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL
40766114|NCT06120842|DRUG|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol Maleate Ophthalmic Solution 0.5% BID
40766115|NCT06120842|DEVICE|Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL|Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens
40766116|NCT06120842|DEVICE|SpyGlass IOL|SpyGlass Intraocular Lens
40766117|NCT05392751|DRUG|EA-2353|EA-2353 Ophthalmic Suspension
40766118|NCT06636266|OTHER|Survey using a questionnaire.|This research will examine any potential differences in the professional identity of Scottish chiropractors utilising the Chiropractic Professional Identity Embodiment Scale (CPIES) and the Subtype Orientation Scale (CPISOS).
40766119|NCT05936151|DRUG|Retatrutide|Administered SC
40766120|NCT05936151|DRUG|Placebo|Administered SC
40766121|NCT06608589|OTHER|CoMPAS+ MNCDs Program - Quality improvement program targeting the care transitions of patients living with a major neurocognitive disorder and their caregivers|COMPAS+ is a collaborative approach to improving healthcare quality. It brings together around 30 individuals, including healthcare professionals, deciders, and patient partners, to identify improvement goals, develop action plans, and enhance the prevention and management of chronic diseases. In this study, the investigators adapt COMPAS+ to focus on improving care transitions for patients with major neurocognitive disorders (MNCDs) and their caregivers. Through reflective workshops and collaborative problem-solving, this diverse group will identify best practices and create action plans to enhance care quality.
40964053|NCT03253276|DRUG|Placebos|
40964054|NCT03926169|DRUG|Risankizumab|Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
40964055|NCT03926169|DRUG|Placebo for risankizumab|Placebo for risankizumab is administered as a SC injection in PFS
40964056|NCT03256643|BEHAVIORAL|Exercise|Exercise intervention will consist of 8 exercise classes and exercises at home. A booklet will be given to each person that has a description and photograph of each exercise that designed to work on core strength and balance.
40964057|NCT03256643|BEHAVIORAL|Delayed Exercise|People will be tested up to 40 weeks after beginning the intervention.
41136954|NCT04810832|OTHER|Evoked related potentials|"Evoked related potentials are performed for each patient during each paradigm (neutral voice and expressive voices):~* with scalp electrodes in the department of neurophysiology~* with intracranial electrodes in the department of neurosurgery."
41136955|NCT03507179|OTHER|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional processing
41136956|NCT03507179|OTHER|conventional dentures|conventional dentures
41136957|NCT06470633|DRUG|Adebrelimab|Adebrelimab 1200mg iv q3w
40964058|NCT03256643|BEHAVIORAL|Exercise and enrichment|Exercise and enrichment will consist of the same exercise program described for the exercise intervention. The enrichment protocol consisting of cultural educational program will take place during the exercises and breaks for this group.
40964059|NCT05575531|OTHER|MEWSS and Nursing Guide Application|MEWSS and Nursing Guide application will be used for the patients in the experimental group. According to the Nursing Guide application, patients with MEWS above 4 will be monitored every 5 minutes, while those with a score below 4 will be monitored for 10 minutes. will be followed intermittently. Nursing interventions will be made in accordance with the problems experienced by patients with a score above 4.
41136958|NCT06470633|PROCEDURE|High Intensity Focused Ultrasoun（HIFU）|HIFU treatment at lesion site
41136959|NCT06470633|DRUG|Cyclophosphamide|600mg/m2 iv q3w
41136960|NCT06470633|DRUG|Epirubicin|90mg/m2 iv q3w
41136961|NCT06470633|DRUG|Docetaxel|75mg/m2 iv q3w
41136962|NCT05932303|DRUG|BMS-986278|Specified dose on specified days
41136963|NCT05932303|DRUG|Itraconazole|Specified dose on specified days
41136964|NCT05932303|DRUG|Gemfibrozil|Specified dose on specified days
41136965|NCT05932303|DRUG|Carbamazepine|Specified dose on specified days
40766122|NCT02965313|PROCEDURE|SSLS Procedure|Synthetic suture repair
40766123|NCT02965313|PROCEDURE|BSSVF-M Procedure|Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms
40766124|NCT06625060|BIOLOGICAL|IPN10200|Lyophilised powder
40766125|NCT06625060|OTHER|Placebo|Excipients without active substance, Lyophilised powder
40766126|NCT06625060|BIOLOGICAL|IPN10200 dose A|Lyophilised powder
40766127|NCT06625060|BIOLOGICAL|IPN10200 dose B|Lyophilised powder
40766128|NCT06499350|DRUG|FC084CSA+Tislelizumab combination (dose escalation)|Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy
40766129|NCT06499350|DRUG|RP2D of FC084CSA+Tislelizumab combination (dose expansion)|RP2D of FC084CSA+fixed dose Tislelizumab combination therapy
40766130|NCT05893537|DRUG|Active Comparator CT1812|123 participants will receive a single daily dose of CT1812 (200 mg)
40766131|NCT05893537|DRUG|Placebo Comparator|123 participants will receive a single daily dose of placebo
40766132|NCT04950153|BEHAVIORAL|Peer navigation|Peer navigators will navigate youth with HIV to provide assistance and support to optimize adherence to antiretroviral treatment (ART)
40964060|NCT01340612|DEVICE|endovascular coiling with any type of currently approved coil (first or second generation)|Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
41136966|NCT04217252|DIAGNOSTIC_TEST|PMseqTM high-throughput sequencing technology|high throughput sequencing of infectious pathogens
40766133|NCT04950153|BEHAVIORAL|SMS Text messaging|Short Message System (SMS) text messages to remind and encourage youth to adhere to their ART
40964061|NCT01340612|DEVICE|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.|Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
41136967|NCT02538094|DEVICE|Sham Transcranial direct current stimulation|Delivery of sham stimulation for 30 minutes using Neuro-Conn Direct Current (DC) Stimulator Plus.
41136968|NCT02538094|DEVICE|Anodal Transcranial direct current stimulation|Delivery of transcranial direct current stimulation for 30 minutes.
41136969|NCT02431442|DRUG|RM-493|
40766134|NCT04950153|BEHAVIORAL|Social Media Engagement|HIV testing outreach using social media platforms to promote HIV testing.
40766135|NCT04950153|BEHAVIORAL|Testing Peer Navigation|Peer navigators will conduct HIV testing outreach and linkage to care to at-risk youth
40766136|NCT06371352|DEVICE|iTBS|Active iTBS over the left DLPFC to induce the long term potentiation of stimulated area.
40766137|NCT06371352|DEVICE|cTBS|Active cTBS over the right DLPFC to induce the long term potentiation of stimulated area.
40766138|NCT06371352|DEVICE|Sham|Sham iTBS or cTBS over the left or right DLPFC respectively for placebo.
40766139|NCT06554639|DRUG|MK-5684|Administered via oral tablet per dosing regimen.
40766140|NCT06554639|DRUG|Prednisone|Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.
40766141|NCT06554639|DRUG|Fludrocortisone acetate|Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.
40766142|NCT06554639|DRUG|Diltiazem hydrocholoride|Administered at a dose of 240 mg per dosing regimen via oral capsule (extended-release).
40964062|NCT04168528|DRUG|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
40964063|NCT03041077|DIETARY_SUPPLEMENT|Instaflex Advanced|Joint function
41136970|NCT02431442|DRUG|Placebo|
41136971|NCT02707952|DRUG|ABT-493/ABT-530|Co-formulated tablet
41136972|NCT02707952|DRUG|OBV/PTV/r|Co-formulated tablet
40766143|NCT04855799|DRUG|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
40766144|NCT04625660|DEVICE|PQ Bypass System|Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
40766145|NCT00605189|DEVICE|Powered Suction Pump (VAC Freedom)|continuous foam based negative pressure wound therapy
40766146|NCT00605189|DEVICE|Powered Suction Pump|continuous gauze based negative pressure wound therapy
40766147|NCT00605189|DEVICE|MWT|moist wound therapy
40766148|NCT04205812|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
40766149|NCT04205812|DRUG|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
40766150|NCT04205812|DRUG|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.
40766151|NCT04205812|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
40766152|NCT04205812|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
40766153|NCT04205812|DRUG|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
40766154|NCT04205812|DRUG|nab-Paclitaxel|nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.
40766155|NCT06640842|DIAGNOSTIC_TEST|A combination of various test and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy in brain health in midlife.|Participants will be asked to complete a blood draw, 5-lead ECG, MRI, a series of cognitive assessments, dietary assessments, monitor sleep and physical activity and DXA scan.
40766156|NCT04522739|DRUG|Spironolactone|Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.
40766157|NCT04522739|DRUG|Placebo|A placebo to match spironolactone will be taken orally once per day for 12 months.
40766158|NCT05824728|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
40766159|NCT05043610|BIOLOGICAL|Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)|cGMP grade WJ-MSCs. 10\^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.
40766160|NCT05043610|OTHER|Conventional Treatment|Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
40766161|NCT02946697|BEHAVIORAL|Social support intervention|The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
40766162|NCT06405880|OTHER|Pharmacist-led care pathway|Participants in the intervention arm will receive the care using a shared decision-making pharmacist-led care pathway designed to guide the cardiovascular (CV) risk reduction process. The pharmacist-led care pathway is modelled after the largest CV risk reduction randomized controlled trial in a community pharmacy setting (RxEACH Study), and based upon the latest CV risk reduction guidelines, such as C-CHANGE. This pathway will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to calculate the participant's estimated CV risk. The participant and pharmacist will be guided by the care pathway to review the participant's estimated CV risk and contributing CV risk factors and engage in shared decision-making to manage the participant's CV risk factors using lifestyle changes and/or pharmacological treatment as clinically appropriate.
40766163|NCT05677971|DRUG|Fazirsiran Injection|Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
40766164|NCT05677971|OTHER|Placebo|Participants will receive placebo (sterile normal saline \[0.9% NaCl\]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
40964064|NCT03041077|DIETARY_SUPPLEMENT|Placebo|Placebo
40766165|NCT06589934|DIAGNOSTIC_TEST|Precise Image|Image reconstruction software
40766166|NCT06141733|OTHER|NIRS group|Standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline (NIRS-group) during immediate transition (first 15 minutes after birth) and resuscitation.
40766167|NCT01698905|DRUG|nilotinib|"Nilotinib was dosed by weight or body surface area.~Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water.~No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry."
40766168|NCT06444880|DRUG|Ubamatamab|Given by IV
40766169|NCT06444880|DRUG|Cemiplimab|Given by IV
40766170|NCT06644378|DRUG|[14C]-LY3866288|Administered orally.
40766171|NCT06644378|DRUG|LY3866288|Administered orally.
40766172|NCT06644378|DRUG|[14C]-LY3866288|Administered IV.
40964065|NCT05329610|DIETARY_SUPPLEMENT|Beta-alanine|Slow-release beta-alanine.
41136973|NCT04630119|OTHER|Questionnaires on quality of life, emotional health and presenteeism|After obtaining informed consent, a pro forma consisting of the socio-demographic details and pre-treatment assessment questionnaire (including Visual analog scale The Medical Outcomes Study Short-Form Health Survey The hospital anxiety and depression scale Work functioning impairment scale) was filled for each subject.
41136974|NCT00235937|DRUG|Anastrozole and goserelin|
40766173|NCT06644144|OTHER|No Interventions|No intervention so not applicable.
41136975|NCT05350670|BEHAVIORAL|Perineal massage and cold compress|Using perineal massage and cold compress during the second stage of labor to observe the effect
40964066|NCT05329610|DIETARY_SUPPLEMENT|Placebo|Taste and appearance-matched placebo (tapioca starch).
41456842|NCT05953987|OTHER|aerobic exercise (EX)|The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
40964067|NCT04742998|OTHER|Acoustic-phonetic decoding task (DAP)|Completion of speech-related quality of life autoquestionnaires Routine speech assessment Acoustic-phonetic decoding task (DAP) two lists of 16 pseudo-words
40766177|NCT06557863|BEHAVIORAL|WeCareToFeedDysphagia web tool|The web tool uses written and video content, care-partner testimonials, frequently asked questions, and resource links to provide accurate information (e.g., dysphagia diets), set realistic expectations, identify/support feeding goals (quality of life considerations), acknowledge/support care-partner feelings, and provide competencies/skills for oropharyngeal dysphagia (OD) management.
40766178|NCT02670408|PROCEDURE|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.
40766179|NCT00713492|DRUG|Alcohol|human laboratory alcohol consumption.
40766180|NCT06638788|OTHER|Knee extension|Participants will perform 20, 40, and 60% of thier 1 rep maximum (1RM) at 18, 12, and 6 reps respectively.
40964068|NCT03715530|DEVICE|PAMG-1 immunoassay|The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
40964069|NCT04819074|PROCEDURE|Microsurgery|Microsurgery for unruptured intracranial aneurysm
41136976|NCT04732611|OTHER|Pilates exercises|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
41136977|NCT04732611|OTHER|Walking protocol|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks.
41136978|NCT01083966|DRUG|Bevacizumab (Avastin)|"Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS"
41456843|NCT05953987|OTHER|sedentary control (CON)|The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
41136979|NCT06050941|DRUG|idarubicin|Idarubicin 6mg/m2 d5-7
41136980|NCT06050941|DRUG|Cytarabine|Cytarabine 60mg/m2 d5-9
41136981|NCT02680015|BEHAVIORAL|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
41136982|NCT04672174|DIAGNOSTIC_TEST|Questionnaire: DemTect|Questionnaire is handed out to subjects
41136983|NCT03014791|OTHER|Brief lifestyle/medical history questionnaire|Core Measurement
41136984|NCT03014791|OTHER|Anthropometric measures|Core Measurement
41136985|NCT03014791|OTHER|Blood pressure and arterial stiffness|Core Measurement
41136986|NCT03014791|OTHER|Cardiac output and lung function|Core Measurement
41136987|NCT03014791|OTHER|Heart rate variability|Core Measurement
41136988|NCT03014791|OTHER|Blood sample & spot urine sample|Core Measurement
41136989|NCT03014791|OTHER|24 hour ambulatory blood pressure monitor|Detailed Measurement (Optional for participants).
41136990|NCT03014791|OTHER|24 hour urine collection|Detailed Measurement (Optional for participants).
40766181|NCT06637657|OTHER|No intervention (observational study)|No intervention, only guideline implementation (observational study)
40766182|NCT05745246|BEHAVIORAL|e-health training program|"1. Health letters, 44 issues of 90SecondFire Cancer health letters delivered twice a week during six months to firefighters by text or email~2. A problem-solving asynchronous chat room which encourages mutual support and exchange of ideas via a closed asynchronous bulletin board for peer-to-peer support~3. A brief 45-minute pre-recorded online course; it is intended as a summative exercise rather than providing new information."
40766183|NCT03201380|OTHER|TEP scanner with choline|
40766184|NCT04109482|BIOLOGICAL|MB-102|"The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen.~Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1 will be administered."
40964070|NCT02412618|DRUG|Mifepristone|Progesterone antagonist
40964071|NCT02412618|DRUG|Misoprostol|Prostaglandin E1
40964072|NCT02412618|DIETARY_SUPPLEMENT|Placebo|Tasteless, odorless, sugar based pill
41136991|NCT03014791|OTHER|Echocardiograph: Left ventricular mass|Detailed Measurement (Optional for participants).
40964073|NCT05338515|DRUG|Selpercatinib|Administered orally.
40964074|NCT04474301|OTHER|Survey Administration|Complete survey
40964075|NCT04188782|DRUG|Sevoflurane|Describe how a reiterative anesthesia exposure could induce tolerance to the anesthetic.
41136992|NCT03014791|OTHER|Large artery structure: Carotid intima-media thickness|Detailed Measurement (Optional for participants).
41136993|NCT03014791|OTHER|Small artery structure: Minimum forearm vascular resistance|Detailed Measurement (Optional for participants).
41136994|NCT03014791|OTHER|Large artery endothelial function|Flow- and salbutamol-mediated vasodilatation Detailed Measurement (Optional for participants).
41136995|NCT03014791|OTHER|Small artery endothelial function: Forearm blood flow|Detailed Measurement (Optional for participants).
41136996|NCT03014791|OTHER|Dundee step test|Systolic blood pressure response to submaximal exercise Detailed Measurement (Optional for participants).
40766185|NCT04109482|DRUG|Fludarabine|"Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3~* A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min)."
40964076|NCT04571814|BEHAVIORAL|Psycho-social, computerized intervention targeting error sensitivity|"A psycho-social, computerized intervention for parents and children targeting error sensitivity. This intervention will be based on the constructs in the Child Error Sensitivity Index, as well as other constructs, that relate to the error-related negativity - for example, perfectionism, fear of evaluation from others, and over-valuation of the negative consequences of errors. The parent version of the intervention will include these same basic concepts, but will also target parenting style and provide psychoeducation on the negative impact of over-reacting to children's mistakes.~The parent version will also include examples of how to model appropriate reactivity to mistakes, and provide video vignettes and examples of both critical and adaptive parenting reactions to mistakes."
40766186|NCT04109482|DRUG|Cyclophosphamide|Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
40766187|NCT05463419|BIOLOGICAL|PIKA COVID-19 vaccine|"SARS-CoV-2 spike subunit protein (Also called Recombinant SARS-CoV-2 S-trimer protein), PIKA adjuvant."
40766188|NCT05463419|BIOLOGICAL|Inactivated Covid-19 vaccine|Inactivated SARS-CoV-2 virus
40766189|NCT05718700|DRUG|Bulevirtide|Administered via subcutaneous (SC) injections
40766190|NCT04416958|DEVICE|cardiac implantable electronic device (CIED) implantation|CIED Implantation according to the Guidelines aiming to avoid pacing induced dyssynchrony
41456844|NCT04461587|DRUG|Pirfenidone|see previous entries
40766191|NCT05213234|BEHAVIORAL|Chronotherapy|Chronotherapy is a behavioral intervention that has the intended effect of maximizing therapeutic benefit of a drug by coordinating intake times and biological rhythms.
40766192|NCT06637137|DRUG|Iron|Patients who present a state of hypoferritinemia or a state of reduced transferrin saturation will undergo administration of i.v iron at least 2 weeks before scheduled cardiac surgery, plus acid folic and B vitamin co-administration.
40766193|NCT06641505|BEHAVIORAL|Guiding rehydration|Preoperative fluid rehydration was performed according to 421 fluid rehydration principles
40766194|NCT04379921|DEVICE|Apple Watch and App|Participants in the Apple Watch and App arm will receive an Apple Watch and download an App (NeuroCoach). The Apple Watch and App are used for this study to record patient's mobility information (e.g., step counts, heart rate, stairs climbed, distance traveled) as well as provide an additional platform for patients to complete questionnaires.
40766195|NCT05437055|DEVICE|Mechanical Thrombectomy (Penumbra System with Thunderbolt)|Subject will receive Penumbra System with Thunderbolt
40766196|NCT06518655|OTHER|Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system|Detection of volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
40766197|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
40766198|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
40964077|NCT02126020|DRUG|topical infliximab|topical infliximab administered QID for 3 months followed by BID for 9 months
41136997|NCT03014791|OTHER|Detailed haemodynamic response to submaximal exercise|Detailed Measurement (Optional for participants).
41136998|NCT03014791|OTHER|Cardiopulmonary fitness: Maximum oxygen consumption|Detailed Measurement (Optional for participants).
41136999|NCT03014791|OTHER|Haemodynamic response to mental stress|Detailed Measurement (Optional for participants).
41456845|NCT01129258|DRUG|PF-04991532|Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
40766199|NCT04904549|BIOLOGICAL|Placebo|Pharmaceutical form: liquid. Route of administration: intramuscular administration.
40766200|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
40766201|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
40766202|NCT05897320|DRUG|Eptinezumab|Solution for infusion
40766203|NCT05897320|DRUG|Placebo|Solution for infusion
40766204|NCT04770285|DEVICE|CT-152 - Digital Therapeutic|CT-152 mobile app was used by the participants as per the schedule specified in the respective arm.
40766205|NCT04770285|DEVICE|Sham|Sham mobile app was used by the participants as per the schedule specified in the respective arm.
41137000|NCT03014791|OTHER|Small artery dilatory function: Forearm blood flow|Detailed Measurement (Optional for participants).
41294585|NCT01252888|DEVICE|iStents|Implantation of two iStents through a small temporal clear corneal incision
40766206|NCT04319809|DEVICE|Object recognition subsystem|The object recognition subsystem is an add-on to the Argus II retinal prosthesis system. in the early stage of the study the subsystem will run on a separate processor; in the later stage the subsystem will run in the Argus II user's video processing unit.
40766207|NCT06645015|DEVICE|AI augmented risk-stratification|A state-of-the-art artificial intelligence (AI) model called AIDPRO manual CRC is used as a decision support tool to estimate the 1-year mortality risk for each patient
40964078|NCT02530359|DRUG|Pirfenidone extended release|Pirfenidone extended release 600mg per mouth
40964079|NCT02530359|DRUG|Placebo equivalent|Placebo equivalent per mouth
41137001|NCT01570894|DRUG|Quetiapine Fumarate|25 mg tablet
41294586|NCT05464485|PROCEDURE|ACL hamstring reconstructions using semitendinosus (ST) tendon only|ACL reconstruction with a ST tendon graft received a reconstruction according to the Tape Locking Screw technique (FH Industrie, Quimper, France) with a dedicated interference screw
40964080|NCT04108793|OTHER|Physiotherapy exercises|The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge funded by the study.
40964081|NCT00569881|DRUG|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
40964082|NCT05173805|DRUG|YL-15293|After enrollment, patients will receive oral YL-15293 twice a day until disease progression, unacceptable adverse events, concurrent diseases prevent further study treatment, the investigator decides to withdraw the patient, the patient withdraws consent, the patient is pregnant, or for administrative reasons. After treatment, the patients will continue to be followed up for 30 days. Patients who permanently stop the study treatment for reasons other than disease progression will be followed up for disease evaluation after treatment until the start of new anti-cancer treatment, withdrawal of consent, loss of follow-up, death or until the sponsor stops the study, whichever comes first.
40964083|NCT00003097|OTHER|preventative dietary intervention|
40964084|NCT05142163|OTHER|Intraoperative SVV Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV \<11%, for values \>11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
41456846|NCT01129258|DRUG|Placebo|Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
41456847|NCT01728636|DRUG|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
40964085|NCT05142163|OTHER|Intraoperative PVI Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI \<10%, for values \>10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
40964086|NCT04458597|RADIATION|Image-guided adjuvant pelvic radiotherapy|Image-guided adjuvant pelvic radiotherapy delivered at an SBRT prescription dose of 30 Gy in 5 fractions if feasible, well-tolerated and effective for the adjuvant treatment of high-risk endometrial cancer.
40964087|NCT05812196|DIAGNOSTIC_TEST|Lung function test|Spirometry to assess lung volumes, forced oscillations to measure respiratory mechanics, whole body plethysmography to assess static lung volumes and airway resistance, lung diffusion capacity measurements.
40964088|NCT05812196|BIOLOGICAL|COVID infection|Verified COVID-19 infection.
40964089|NCT03689348|DIETARY_SUPPLEMENT|Avena sativa|A supplement derived from wild green oat
40964090|NCT03689348|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
40964091|NCT02745444|DIETARY_SUPPLEMENT|low-calorie formula diet|
40964092|NCT02745444|DIETARY_SUPPLEMENT|protein-restricted diet|
41137002|NCT04242797|DEVICE|Calmare|Skin is stimulated with an electrical voltage via electrode pads, variably distorted sine wave at \~47 Hz.
41137003|NCT04242797|DEVICE|TENS|Skin is stimulated with an electrical voltage via electrode pads, 300 micro-second rectangle pulse at 47 Hz.
41456848|NCT06298162|OTHER|2 years after RYGB, no intervention. MRI measurement. Observational.|no intervention. MRI measurement. Observation.
41456849|NCT05489497|PROCEDURE|Primary closure with or without omental grafting|Primary closure with or without omental grafting
41456850|NCT05907694|PROCEDURE|Transcatheter PFO closure|"Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient."
41456851|NCT05907694|DRUG|Optimal medical treatment|Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
40964093|NCT04036903|RADIATION|computed tomography|thoracic CT examinations for diagnosis, and/or follow-up.
40964094|NCT02549937|DRUG|surufatinib|orally once daily (QD) in patients with advanced solid tumor.
40964095|NCT02847832|OTHER|Standardized transvaginal ultrasound examination|
40964096|NCT01051323|DRUG|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
40964097|NCT04563351|OTHER|local anaesthetic techniques|The patients were anesthetized with two different local anaesthetic techniques.
40964098|NCT02168634|DRUG|Botulinum Toxins|5U botulinum toxin in 1c.c. normal saline, local injection
40964099|NCT02168634|DRUG|Placebo|1cc normal saline, local injection
40964100|NCT04680130|DRUG|C-11 PiB|Completing PET scan looking for amyloid protein
40964101|NCT04680130|DRUG|AV1451 Tau|Completing PET scan looking for tau protein
40964102|NCT04680130|DRUG|C-11 ER176|Completing PET scan looking for neuroinflammation
40964103|NCT00555971|DRUG|Omalizumab|Subjects randomized to Omalizumab prior to aspirin desensitization
40964104|NCT00555971|DRUG|placebo|Subjects randomized to Placebo prior to aspirin desensitization
40964105|NCT05113017|OTHER|NO Intervention|NO Intervention
40964106|NCT06084663|DRUG|Apremilast 30 mg Tablets|Each film-coated tablet contains 30 mg of apremilast
40964107|NCT06084663|DRUG|Otezla 30 mg film-coated tablets|Each film-coated tablet contains 30 mg of apremilast
40964108|NCT00075959|DRUG|NXY-059|
40964109|NCT05902455|PROCEDURE|Punch biopsy|Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery from each recruited patient.
40964110|NCT05430932|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic resection of a part of the stomach to enable the patient to lose weight.
40964111|NCT00667875|DRUG|Placebo|placebo
40964112|NCT00667875|DRUG|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
40964113|NCT00667875|DRUG|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
41137004|NCT02177292|RADIATION|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
41137005|NCT03055988|DRUG|Tiotropium|Fixed Dose Combination
41137006|NCT03055988|DRUG|Olodaterol|Fixed Dose Combination
41137007|NCT03055988|DRUG|Fluticasone propionate|Fixed Dose Combination
41294587|NCT05464485|PROCEDURE|ACL hamstring reconstructions using semitendinosus and gracilis (ST/G) tendon|ACL reconstruction with a ST/G tendon graft received a reconstruction with the anteromedial portal technique with endobutton fixation (Smith \& Nephew, London, UK).
41294588|NCT01193725|BEHAVIORAL|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
40766208|NCT06449183|DIAGNOSTIC_TEST|VIDAS® TBI Test [GFAP and UCH-L1 assays]|The VIDAS® TBI (GFAP, UCH-L1) test is composed of two automated assays - VIDAS® TBI (GFAP) and VIDAS® TBI (UCH-L1) - to be used on the VIDAS® family of instruments for the quantitative measurement of Glial 15 Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase- L1 (UCH-L1) in human serum using the Enzyme Linked Fluorescent Assay (ELFA) technique. The results of both assays are required to obtain an overall qualitative test interpretation.
40766209|NCT05253196|DEVICE|Use of the foley catheter assistive device|All participants will use the foley catheter assistive device when performing their daily enema
40766210|NCT06397040|DEVICE|provider monitoring and feedback to remote data|provider monitoring of remote data and feedback to changes in remote data
40964114|NCT05045248|DRUG|Apraclonidine Hcl 0.5% Oph Soln|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
40964115|NCT05343845|OTHER|Observational study|After approval of the institution's ethics committee, 100 patients will be divided in two groups as pregnant women who did not smoke during pregnancy and pregnant women who smoked 5 or more cigarettes in a day. The local anesthetic, which dose will adjusted according to height and weight, and 20 µg fentanyl will be administered intrathecally to both groups. Results on the effectiveness of spinal anesthesia will be monitored.
40964116|NCT00002554|DRUG|busulfan|
40964117|NCT00002554|DRUG|cyclophosphamide|
40964118|NCT00002554|DRUG|methotrexate|
40766211|NCT06397040|DEVICE|participant monitoring of remote data|participant monitoring of remote data, based upon post-operative instructions
40766212|NCT06014801|DRUG|Dialysate fluid, Filtration replacement fluid|Dose of continuous hemodialysis and/or hemofiltration
40766213|NCT06639828|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|Following unenhanced (pre-contrast) ultrasound imaging of the target focal liver lesions (FLL), Sonazoid™ will be intravenously administered and a contrast-enhanced examination will be performed.
40766214|NCT03862950|DRUG|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
40766215|NCT03862950|DRUG|Metformin|Active medication
40766216|NCT05719246|BEHAVIORAL|Yoga|The yoga video set that the participants will follow is a brief, at-home, 6-week twice per week Standardized Yoga \& Meditation Program for Stress Reduction (SYMPro-SR) program. The videos feature Sydney Topfer guiding the participants through different yoga poses.
41137008|NCT03055988|DRUG|Salmeterol|Fixed Dose Combination
40766218|NCT05419375|OTHER|Screening platform|The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing.
40964119|NCT00002554|PROCEDURE|allogeneic bone marrow transplantation|
40964120|NCT00002554|RADIATION|radioimmunotherapy|
40964121|NCT03201835|DRUG|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
40964122|NCT03201835|DRUG|Sativex|spray X 4 actuations
40964123|NCT03201835|DRUG|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
40964124|NCT03201835|DRUG|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
40964125|NCT03201835|DRUG|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
40964126|NCT03355820|PROCEDURE|Blood sampling for antibody determination|In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (\~5 mL) will be taken from all the subjects, at Day 1.
40964127|NCT02954731|BEHAVIORAL|UP-CBT|"Psychotherapy in groups based on the Unified Protocol a third generation CBT-type psychotherapy"
40964128|NCT02954731|BEHAVIORAL|Standard-CBT|Psychotherapy in groups based on diagnosis specific, manualized, cognitive behavior therapy
40964129|NCT04332562|OTHER|dietary restriction (salt restriction)|salt restriction for one week after being diagnosed with hypertension
40964130|NCT03426813|OTHER|Historical control group for early mobilization|
40964131|NCT00512005|DEVICE|Percutaneous mitral valve repair|Ventricular reshaping to treat functional mitral insufficiency
40964132|NCT05160103|OTHER|Cosmetic Formulations|Topical emulsions containing anti-aging ingredients
40964133|NCT01369095|DRUG|Duloxetine|Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C\&D)
40964134|NCT01369095|DRUG|Escitalopram|Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C\&D)
40964135|NCT01369095|DRUG|BMS-820836 Placebo|Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)
40964136|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
40964137|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
40964138|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
40964139|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
40964140|NCT02235909|DRUG|Azilsartan Medoxomil Low-dose|
40964141|NCT02235909|DRUG|Losartan|
41137009|NCT04020172|DRUG|Dobutamine|intraoperative fluid administration will be guided by cardiac output monitoring
41294589|NCT01193725|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
41294590|NCT01193725|BEHAVIORAL|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
41294591|NCT04734756|DEVICE|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
41294592|NCT04083742|DEVICE|ANTERION|3 repeat angle measurements performed on each of the 3 Anterion devices and the 3 reference devices
41294593|NCT04748783|OTHER|Water|Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water.
40766219|NCT05614089|DRUG|Insulin Glargine|"Formulation: Available as a clear liquid in a glass cartridge (1 cartridge =3ml=300 units).~Route: Reusable pen~Amount of each dose: varies depending on baseline basal insulin needs~Dose escalation scheme: Participants randomly assigned to glargine will start with a dose that is generally equal to 80% of their total basal human insulin dose prior to the switch (per ISPAD guidelines and the switching guide developed by Life for a Child with the guidance of Dr. Ragnar Hanas and two other ISPAD members familiar with less-resourced settings).~Frequency of dose: once per day (usually administered before bedtime)"
41294594|NCT04748783|OTHER|Peroxyl|Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse
40766220|NCT05614089|DRUG|NPH or premixed 70/30 (human insulin)|"Drug: NPH or Premixed 70/30 Formulation: Available as a liquid in a glass vial or glass cartridge (10ml=1000IU).~Route: Bangladesh = syringes or reusable pens; Tanzania = disposable pens~Subcutaneous injection using insulin syringe and needle Amount of each dose: varies depending on baseline basal insulin needs (per usual care or treating clinician) Frequency of dose: once or twice per day (per usual care or treating clinician)~Duration of therapy: 12 months~Participants in both groups will receive the same frequency of blood glucose testing and same intensity of education and counseling (e.g. titration advice according to fasting glucose targets and strategies to avoid hypoglycemia). Participants in both groups will have equal access to test strips (sufficient to test up to 5 times per day during the active titration phase and after 3 times/day)."
40766221|NCT06497088|DEVICE|Nasotrak System|"Device: The Nasotrak System~The Nasotrak Medical System is intended to aid, in conjunction with institutional protocols, qualified operators in the placement of the Nasotrak's 12 Fr feeding tube into the stomach of patients requiring enteral feeding after insertion and before every feed. The Nasotrak nasogastric tube(NGT) is designed for use with Nasotrak's handheld device (HHD) which is able to detect the tip of the NGT via piezoelectric sensor, which converts ultrasound waves to electronic signals, thus assisting to track its location as an indicator of placement in the stomach. Nasotrak's NGT is intended only to be used with Nasotrak's HHD.~The Nasotrak NGT is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition."
41294595|NCT04748783|DRUG|Periogard|Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.
41294596|NCT04748783|OTHER|Colgate Total Zero|Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
41294599|NCT02963077|DRUG|A4250|
41294600|NCT02963077|DRUG|CRC (A3384)|
41294601|NCT02963077|DRUG|Questran|
41294602|NCT02963077|DRUG|Placebo|
40766222|NCT01542580|DEVICE|Vanguard SSK 360 with PS Bearing|non-constrained tibial bearing
40766223|NCT01542580|DEVICE|Vanguard SSK 360 with PSC bearing|constrained tibial bearing
40766224|NCT01542580|DEVICE|Vanguard DA 360|Dual-articulation device, only cleared in EU
40766225|NCT01542580|DEVICE|Vanguard 360 TiNbN Femur with PS bearing|non-constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
40766226|NCT01542580|DEVICE|Vanguard 360 TiNbN Femur with PSC bearing|constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
40964142|NCT02235909|DRUG|Placebo for Azilsartan Medoxomil|
41294603|NCT05035186|DRUG|Amoxicillin|Anti-H. pylori regimens
41294604|NCT00599430|DIETARY_SUPPLEMENT|Placebo|Inert excipient
41294605|NCT00599430|DIETARY_SUPPLEMENT|Lactobacillus acidophilus NCFM|1e10 CFU/day
41294606|NCT00599430|DIETARY_SUPPLEMENT|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
41294607|NCT01220752|RADIATION|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
41294608|NCT04855721|DRUG|AUR101|Oral ROR-gamma inverse agonist
41294609|NCT04855721|DRUG|Placebo|Placebo
41294610|NCT01270646|DEVICE|Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system|"Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.~Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping."
41294611|NCT04422756|DIAGNOSTIC_TEST|Seated intravenous saline infusion test|"The test will be conducted by infusing two litres of normal saline intravenously over 4 hours with the patient seated.Blood collection (for aldosterone, cortisol, renin, and electrolytes) will be performed at baseline and after completion of the infusion. Following infusion, plasma aldosterone levels \<140 pmol/L will be considered as negative, levels \>280 pmol/L as positive, and levels in between classified as indeterminate."
41456852|NCT01777815|DEVICE|NeoChord DS1000 Artificial Chordae Delivery System|
40964143|NCT02235909|DRUG|Placebo for Losartan|
40964144|NCT02235909|DRUG|antihypertension medication - Add-on Therapy|add-on therapy (e.g., a calcium channel blocker, such as amlodipine, a diuretic, such as hydrochlorothiazide, or a beta-blocker such as metoprolol) per PI's clinical judgment.
40964145|NCT02235909|DRUG|Azilsartan Medoxomil Medium-dose|
40964146|NCT02235909|DRUG|Azilsartan Medoxomil High-dose|
40964147|NCT00052481|PROCEDURE|quality-of-life assessment|
40964148|NCT03435445|BEHAVIORAL|Online platform group|The online platform has social network, gamification and short-text sessions.
40964149|NCT03435445|BEHAVIORAL|Online dietitian coaching|Dietitian coaching refers to individual online sessions between a dietitian and participants to strengthen dietary recommendations
40964150|NCT03435445|BEHAVIORAL|Control group|Minimal intervention with four videos with diet, physical activity and behavior change recommendations
40964151|NCT00006237|BIOLOGICAL|interleukin-2|Given IV
40964152|NCT00006237|BIOLOGICAL|filgrastim|Given subcutaneously
40964153|NCT00006237|BIOLOGICAL|interferon alfa|Given IV and subcutaneously
40964154|NCT00006237|DRUG|cisplatin|Given IV
40964155|NCT00006237|DRUG|dacarbazine|Given IV
40964156|NCT00006237|DRUG|vinblastine|Given IV
40964157|NCT02320383|BIOLOGICAL|GA101 (Obinutuzumab)|"Induction~Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d~Cycle 2 - 6: d1 - 1000 mg i.v., q28d~Maintenance~GA101 iv 1000 mg (flat dose): every 84 days"
40964158|NCT02320383|DRUG|Bendamustine|"Induction~Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d~Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d"
40964159|NCT05433324|OTHER|MRI and PET Scans|All groups will undergo cognitive tests and brain imaging scans (MRI \& PET)
40964160|NCT02647814|BEHAVIORAL|Salud al Día|A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
41456853|NCT01652508|OTHER|Control|Participants in the control group are provided a self-help leaflet on smoking cessation only
40964161|NCT02403492|DEVICE|cPAP|All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial
40766229|NCT05077072|OTHER|Best Practice|Receive SOC
40766230|NCT05077072|OTHER|Counseling|Participate in CHAT counseling intervention
40766231|NCT05077072|PROCEDURE|Electroencephalography|Undergo EEG
40766232|NCT05077072|BEHAVIORAL|Neurofeedback|Undergo NFB intervention
40766233|NCT05077072|OTHER|Questionnaire Administration|Ancillary studies
40766234|NCT06165341|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
40766235|NCT06165341|DRUG|Placebo|Fazirsiran matching placebo.
40766236|NCT06255028|BIOLOGICAL|CNTY-101|CNTY-101 cells for intravenous (IV) infusion
40766237|NCT06255028|BIOLOGICAL|IL-2|IL-2 subcutaneous (SC) injection
40766238|NCT06255028|DRUG|Lymphodepleting Chemotherapy|LDC as prespecified in the protocol.
40964162|NCT02403492|DEVICE|cPAP, Continuation|Participants will be randomized to continue cPAP for a 2 week period
40964163|NCT02403492|DEVICE|cPAP, Discontinuation|Participants will be randomized to discontinue cPAP for a 2 week period
40964164|NCT03331367|PROCEDURE|Blood draw|Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
40964165|NCT03331367|PROCEDURE|Urine sample|Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
40964166|NCT06505564|BEHAVIORAL|AVATAR therapy|In the initial phase of treatment, patients collaborate with therapists to visualize the source of their auditory hallucinations. Therapists adjust their voice to match the hallucinations, prompting patients to recall key statements for future sessions. Subsequent sessions involve dialogues with a computerized avatar. Using the altered voice, therapists interact in real-time through the avatar, engaging patients in role-playing. They alternate between the avatar and supportive therapist roles to empower patients with positive affirmations and discussions. Sessions last approximately 50 minutes, utilizing Oculus Rift VR headsets and noise-cancelling headphones to enhance immersion. HEKA VR software adjusts avatar proximity, and patients have the option to record dialogues for home use and sharing. Therapists receive bi-weekly supervision from HEKA VR-trained colleagues. Participants continue their regular medication prescribed by their psychiatrists alongside this experimental therapy
40964167|NCT04443010|DRUG|Onfekafusp alfa|"This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone."
40964168|NCT04443010|DRUG|Temozolomide|Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
40964169|NCT03693300|DRUG|Durvalumab|Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
40964170|NCT01996852|BEHAVIORAL|Cognitive-behavioral Meetings|"The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.~Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.~Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min."
40964171|NCT01996852|DRUG|sildenafil citrate|"100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study."
40964172|NCT01996852|DEVICE|Vacuum Constriction Device|"The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call."
40964173|NCT06497621|PROCEDURE|Single step PVS impression|Single-step final impression method for complete denture fabrication using medium body PVS for border molding and wash impression in a single-step (i.e., one insertion of impression tray in mouth).
40964174|NCT06497621|PROCEDURE|Conventional two-step PVS impression|Border molding with heavy-body PVS first, followed by wash impression with light-body PVS
40964175|NCT03449797|PROCEDURE|AVS performed with no intraprocedural rapid cortisol assay|AVS performed plus intraprocedural rapid cortisol assay
40964176|NCT03449797|PROCEDURE|AVS performed plus intraprocedural rapid cortisol assay|Adrenal vein sampling performed according to usual clinical practice without intraprocedural rapid cortisol assay
40964177|NCT06505512|DIAGNOSTIC_TEST|No intervention|No intervention
40964178|NCT06497413|DEVICE|Transcranial Photobiomodulation|The transcranial photobiomodulation will be delivered through the Neuradiant 1070 Plus-Programmable 4-Quadrant Photobiomodulation System. This is a commercially available helmet that will be purchased from a commercially available source.
40964179|NCT06497413|DEVICE|Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered|In this condition the participants will wear the Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus); however, the light will not be administered.
40964180|NCT04505189|DRUG|Psilocybin|Psilocybin assisted psychotherapy
40964181|NCT05802056|BIOLOGICAL|Aldesleukin|Given IP
40964182|NCT05802056|PROCEDURE|Biopsy|Undergo biopsy
40964183|NCT05802056|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
40964184|NCT05802056|PROCEDURE|Computed Tomography|Undergo PET/CT
40964185|NCT05802056|PROCEDURE|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
41137010|NCT00125723|OTHER|PI Discretion|PI Discretion
41137011|NCT04317937|OTHER|Jaw opening-closing movements|"Jaw opening-closing movements Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Active jaw movements The patient will then perform maximal Jaw opening-closing movements at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active neck exercises While performing the above movements of jaws, the patient will actively perform active neck exercise (head-neck movements in sagittal plane- Extension- Flexion).~Head-Neck extension on jaw opening (Mandible moves vertically downward); and then from Head-Neck extension to natural flexion movement on jaw closing (Mandible moves vertically upward)."
40766239|NCT06645418|DIAGNOSTIC_TEST|relative Hand grip strength|To perform this study the relative handgrip strength (rHGS) index was used. The rHGSi is defined as the sum of the handgrip strength of both hands divided by body mass index (BMI), and it is considered a better prognostic tool than handgrip strength. rHGS was measured by Jamar hand dynamometer. The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
40766240|NCT06645418|DIAGNOSTIC_TEST|senior fitness test|The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
40766241|NCT06423352|DRUG|Zilebesiran|Zilebesiran administered by subcutaneous (SC) injection
40766242|NCT06423352|DRUG|Placebo|Placebo administered by SC injection
40964186|NCT05802056|DRUG|Fluorouracil|Given IV
40964187|NCT05802056|DRUG|Leucovorin Calcium|Given IV
40964188|NCT05802056|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
40964189|NCT05802056|BIOLOGICAL|Nivolumab|Given IV
40964190|NCT05802056|DRUG|Oxaliplatin|Given IV
40964191|NCT05802056|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
41294612|NCT04422756|DIAGNOSTIC_TEST|Ultra low-dose ACTH stimulation test|"The test will be performed by injecting 0.03 mcg of ACTH intravenously. Blood collection (for aldosterone, cortisol, and renin) will be performed at baseline and after 15 minutes. We expect a positive response to correspond with a plasma aldosterone \>2200 pmol/L and ARR \>220 pmol/L/mIU/L following stimulation."
40964192|NCT00160628|DRUG|Levetiracetam|
40766244|NCT05277532|BEHAVIORAL|High intensity interval training (HIIT)|HIIT performed either in the morning or in the afternoon
40766245|NCT06645184|DIETARY_SUPPLEMENT|Oral nutritional supplement|During 4 test days, 1 bottle (125ML) of High protein ONS with or without fibre and with or without the added nutrients will be consumed by the subjects. During each test day, the subjects will complete questionnaires related to appetite and liking of the product from baseline (-5 minutes of start consumption of study product) until 120 minutes after start consumption of study product.
40766246|NCT06643507|OTHER|Connective tissue graft|regenerative properties
40766247|NCT06643507|BIOLOGICAL|ALB-PRF|regenerative properties
40766248|NCT02704858|DRUG|Perillyl alcohol|Intranasal administration
40964193|NCT03144960|PROCEDURE|Mechanical Thrombectomy|mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption
40964194|NCT04447300|PROCEDURE|high power application|Radiofrequency delivery was performed in a point-by point fashion and continuously (an inter-lesion distance of 6 mm) with 50 W and 70 W and the ablation time for each point is limited to 7s and repeated if needed till the Unipolar signal modification turn to complete positive R wave.
40964195|NCT04447300|PROCEDURE|Standard power application|Standard power application
40964196|NCT04396678|BEHAVIORAL|PrEP standard of care+behavioral intervention|The intervention includes three main components: 1) group PrEP engagement sessions, which include four educational sessions that situate PrEP in a broader framework of access and barriers to care, provider/patient communication, sexual health, HIV/STI education, harm reduction around drug use, stigma, risk compensation and safe sex, and health/science literacy; 2) peer navigation, which aims to help women navigate healthcare engagement with the SPARC nurse practitioner and other providers; and 3) an mHealth component, consisting of a two-way text messaging system through which women will receive automated daily messages and weekly messages requesting adherence reports.
40766249|NCT06639087|DRUG|AZD5462|Participants will receive AZD5462 on top of dapagliflozin once daily.
40766250|NCT06639087|DRUG|Dapagliflozin|Participants will receive dapagliflozin once daily with AZD5462 or placebo.
40766251|NCT06639087|OTHER|Placebo|Participants will receive placebo on top of dapagliflozin once daily.
40766252|NCT06639230|DEVICE|laser therapy|Laser-treated group (test group): This group consisted of ten patients treated using diode lasers. The diode laser was operated in continuous wave mode with an output power of 3 W in contact mode to excise the pyogenic granuloma. The tip was moved around the base of the lesion in circles. The base of the lesion was cut precisely till the whole mass was entirely excised.
40964197|NCT04686071|OTHER|PNF method|Treatment in the study group was conducted with PNF method with a use of indirect training based on irradiation phenomenon. The program included: proprioceptive stimulation of the operated limb, improving trunk stabilization and active control, active foot training, muscle strength facilitation of lower limbs in closed kinematic chain with considering periarticular stabilization within the operated knee joint as well as exercises improving mobility of the operated knee, verticalization and locomotion with emphasis on the stance phase.
40964198|NCT04686071|OTHER|Standard rehabilitation|In the control group standard rehabilitation protocol was used in patients following TKA, which is mainly based on activities in open chains (passive exercises with continuous passive motion (CMP) device, active exercises, isometric, active resistance, patella mobilization, deep tissue massage, verticalization and gait relearning).
40964199|NCT00260481|DRUG|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
40964200|NCT00260481|DRUG|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
40964201|NCT04220320|DIAGNOSTIC_TEST|Vaginal examination.|Cervical properties as evaluated by a vaginal examination.
40964202|NCT04220320|DIAGNOSTIC_TEST|Transvaginal sonography.|Cervical length as evaluated by a transvaginal sonography.
40964203|NCT01217814|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40964204|NCT01217814|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40964205|NCT01217814|DRUG|Golimumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40964206|NCT01217814|DRUG|methotrexate (MTX)|"Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)"
41456854|NCT01652508|BEHAVIORAL|Acceptance and Commitment Therapy|All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
41456855|NCT03407209|OTHER|consumption of local anesthetic measurement|consumption of local anesthetic measurement in both groups
41456856|NCT05274724|DIAGNOSTIC_TEST|No teleconsultation during the ambulance journey|Standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty
40766253|NCT06639230|DRUG|Sclerotherapy|Sclerotherapy-treated group (control group): This group consisted of ten patients treated with injections of sclerosing agent. After anaesthetizing the surgical site with a local anesthetic agent, The lesion was injected with a 2.5% concentration until it leaked out from the surface, leading to necrosis and spontaneous detachment of the lesion.
40766254|NCT05081609|DRUG|TransCon IL-2 β/γ|TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
40766255|NCT05081609|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion
40766256|NCT05081609|DRUG|Chemotherapy drug|SOC chemotherapy will be administered as an intravenous (IV) infusion
40766257|NCT05081609|DRUG|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection
40766258|NCT05081609|PROCEDURE|Surgery|Surgery will take place 4-6 weeks after last dose of study treatment.
40766259|NCT05081609|DRUG|Trastuzumab|Trastuzumab will be administered as an intravenous (IV) infusion
40964207|NCT01217814|DRUG|Folic/folinic acid|"Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard."
40964208|NCT06241534|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
40964209|NCT06241534|BEHAVIORAL|Relaxation-therapeutic recordings|"8 sessions of relaxation-therapeutic recordings in the non-sleep deep rest concept.~The content of the recording is based on the 'body scanning technique', which constitutes the core of the therapy. This approach aims to quiet the overactive sympathetic part of the autonomic nervous system. During therapy, the patients take a 'journey' through their own body from feet to head. Following the voice of the narrator, the patient focuses on specific body parts, tries to feel this place and then relaxes tense muscles. Relaxation of individual body parts (muscle groups) is combined with breathing exercises. Conscious and mindful breathing deepens the state of relaxation. Additionally, the recording includes therapeutic suggestions related to making a choice between: overload and relief, holding on and letting go, acting and sensing. Furthermore, suggestions focus the patient on inner wisdom that allows them to make the best decisions."
41294613|NCT01070550|DRUG|Peginterferon alfa-2a (Pegasys®)|Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
41294614|NCT04340830|PROCEDURE|Free gingival graft|Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.
41294615|NCT03115801|DRUG|Nivolumab|Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
41294616|NCT03115801|DRUG|Atezolizumab|Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
41294617|NCT03115801|RADIATION|Radiation & immunotherapy|Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
41294618|NCT03115801|DRUG|Pembrolizumab|Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
41294619|NCT02975869|OTHER|Standard Leukemia Care|
41294620|NCT02975869|OTHER|Palliative Care|
41294621|NCT00230581|DRUG|DDP225|
40766260|NCT05081609|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine (T-DM1) will be administered as an intravenous (IV) infusion
40766261|NCT05145569|DRUG|Carboplatin AUC 5 and paclitaxel|Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.
40766262|NCT05145569|DRUG|HCW9218|HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.
41294622|NCT00772512|DRUG|PF-04802540|5 mg capsule, single dose
41294623|NCT00772512|DRUG|PF-04802540|15 mg capsule, single dose
41294624|NCT00772512|DRUG|Placebo|Placebo capsule, single dose
41294625|NCT03698240|BEHAVIORAL|Mindfulness-based program|The program includes 9 mindfulness-based sessions for children and their parents.
41294626|NCT03070457|OTHER|Early discharge|Patients randomised to early discharge or not
41294627|NCT03070457|OTHER|Conventional protocol|Discharge as usually done 48-72 hours after surgery
40766263|NCT04516213|OTHER|Enteral Formula With (PHGG)|Pediatric subjects will be fed a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)
40766264|NCT06318169|BIOLOGICAL|Pegozafermin|Subcutaneous injection
40766265|NCT06318169|OTHER|Placebo|Subcutaneous injection
40964210|NCT06241534|DEVICE|Virtual reality therapy|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR TierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.
40964211|NCT06241534|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
40964212|NCT02756013|DRUG|Paclitaxel|80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
41294628|NCT03136211|BEHAVIORAL|EIRA intervention|Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
41294629|NCT03061123|OTHER|Questionnaire|
41294630|NCT04258553|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
41294631|NCT04258553|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
40964213|NCT02756013|DRUG|Carboplatin|area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
40964214|NCT02817256|DIETARY_SUPPLEMENT|Vitamins and Minerals|Multivitamins and Minerals supplementation
40964215|NCT02279537|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
41294632|NCT04258553|DIAGNOSTIC_TEST|Ischemia Modified Albumin(IU/mL)|The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).
41294633|NCT03070730|DRUG|Droxidopa|Droxidopa: 100 mg or 300 mg t.i.d
40964216|NCT04455113|DIAGNOSTIC_TEST|Phosphorus level|infusion
40964217|NCT02949869|OTHER|Spinal Sonography|As described previously
40964218|NCT05479071|DIAGNOSTIC_TEST|Blood test|Screening of antibodies against LDL
41294634|NCT03070730|DRUG|Atenolol|Atenolol: 50 mg Q.D.
41294635|NCT03070730|DRUG|Placebos|Placebo: t.i.d
41294636|NCT04632329|DEVICE|Negative Pressure Treatment via the Mercury Multi-Pressure Dial|Negative Pressure Treatment via the Mercury Multi-Pressure Dial
41294637|NCT01946048|BIOLOGICAL|mesenchymal stem cells|"Procedure: Selected patients were randomly divided into a cell therapy group and a control group.~Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million."
41294638|NCT01996319|DRUG|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
41294639|NCT01996319|DRUG|Placebo|Placebo once a day via Breezhaler® device
41294640|NCT01301911|DRUG|Cipatinib|Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
41294641|NCT04195074|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
41294642|NCT04195074|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
41294643|NCT04195074|DRUG|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
41294644|NCT02114632|DIETARY_SUPPLEMENT|Eye Q|3 months of treatment with a polyunsaturated fatty acids or placebo. At 3 months a one-way treatment crossover of the placebo-group to active treatment was made so that both patient groups received active treatment for the remaining 3 month period.
40964219|NCT02459210|BEHAVIORAL|CLUES|Cognition for learning and for understanding everyday social situations intervention described above
40964220|NCT02459210|BEHAVIORAL|therapy and computer games|Weekly psychotherapy+ computer games such as sporcle
41294645|NCT02786459|DEVICE|ProxiScan|ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.
41294646|NCT02786459|DEVICE|Magnetic Resonance Imaging|Used as a comparative to ProxiScan.
41294647|NCT02786459|DEVICE|SPECT-CT|Used as a comparative to ProxiScan.
41294648|NCT01776099|DIETARY_SUPPLEMENT|Dietary supplement (4 arms, 2 active, 2 placebo)|
41456857|NCT05274724|DIAGNOSTIC_TEST|Teleconsultation during the ambulance journey|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
41456858|NCT00286533|PROCEDURE|Clinical examination (implant stability, gingiva condition, etc.)|Clinical examination (implant stability, gingiva condition, etc.) to follow
41456859|NCT00286533|PROCEDURE|Questionnaires|Questionnaires are used.
41294649|NCT06287424|DIETARY_SUPPLEMENT|Aged Garlic Extract|Subjects will be instructed to continue using their regular home oral hygiene products until the Product Distribution Visit (Visit 2). They will also be instructed not to add or change any of their regular home oral hygiene products during that time.
41294650|NCT06287424|DIETARY_SUPPLEMENT|Placebo|Placebo
41456860|NCT01188590|DEVICE|TOSCA 500 monitor|transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
40964221|NCT04344509|OTHER|Bacterial species isolated|in the respiratory specimen
40964222|NCT03197597|OTHER|Strain isolation from the nasopharynx|B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
40964223|NCT06318182|OTHER|Education|Young men who are included in the research sample and agree to participate in the study will be given training within the scope of the health belief model.
40964224|NCT06309732|DRUG|Pegfilgrastim|6mg at each cycle
41294651|NCT05820295|BEHAVIORAL|Care coordination delivered based on perceived need|If patients in intervention group report on the survey that they experience difficulty coordinating care among their providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
41294652|NCT05820295|BEHAVIORAL|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
41294653|NCT00914628|GENETIC|HSV-Tk|Infusion of approximately 1±0.2 x 10\^7 HSV-Tk genetically modified CD3+ cells/Kg between day +21 and day +49 after haploidentical HCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
40964225|NCT06309732|DRUG|Dactinomycin|1mg/m2
41137012|NCT04317937|OTHER|Specific Active exercises|"Active neck exercises:~Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Note: For Active neck exercise (flexion and extension movements of neck), firstly the patient will perform maximal Jaw opening-closing movements at a pace convenient for his/her for 5 times in order to observe (eyeball observation) the neck extension and flexion as reference point for each individual.~Using this reference points, the patient will ask perform below mentioned active neck exercise.~Active neck exercises: The patient will then perform active neck exercise (flexion and extension of neck) at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active jaw movement: While performing the above movements of neck, the patient will not perform any jaws movements."
41137013|NCT04317937|OTHER|Exercise Therapy|"Isometric strengthening exercises For flexion the starting position will be upright head and neck. The patient will be asked to hold this position.~For extension the starting position will be upright head and neck. The patient will be asked to hold this position.~For rotation the starting position will be upright head and neck. The patient will be asked to hold this position.~• In all above movements ( flexion, extension \& rotation) following method will be followed: Manual resistance will then be applied by the investigator by placing the hand on the patient's forehead, posterior part of the head and lateral part of the head with 6 second hold. 15 repetitions of this exercise will be performed. Three sets with one minute rest in between will be ensured."
41294654|NCT00914628|OTHER|T-cell depleted or T-cell replete strategies|Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10\^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis
41294655|NCT04919993|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|Group presentation
41294656|NCT01588574|BIOLOGICAL|MT10109|Botulinum toxin type A
41294657|NCT01588574|BIOLOGICAL|BOTOX(Registered trade mark)|Botulinum toxin type A
41294658|NCT00418886|DRUG|Vandetanib|oral once daily tablet
41294659|NCT00418886|DRUG|Pemetrexed|intravenous infusion
41456861|NCT06253117|DRUG|Pirfenidone|"Pirfenidone Days 1-7: 267 mg PO TID (801 mg/day) Days 8-14: 534 mg PO TID (1602 mg/day) Day 15 and thereafter: 801 mg PO TID; not to exceed 2403 mg/day~Duration of treatment- total 6 months"
41294660|NCT01081210|OTHER|Ultrasound examination|Screening with bedside ultrasound examination
41294661|NCT00830427|DRUG|PF-00610355|100 mcg, QD, dry powder inhaler
41294662|NCT00830427|DRUG|PF - 00610355|600 mcg, QD, dry powder inhaler
41294663|NCT00830427|OTHER|Placebo|QD, dry powder inhaler
41294664|NCT00830427|DRUG|PF - 00610355|300 mcg, QD, dry powder inhaler
41294665|NCT01032785|DEVICE|no interventions|no interventions
41456862|NCT06253117|DRUG|Placebo|Placebo
41456863|NCT00095537|DRUG|panHer|Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
41294666|NCT02434315|DEVICE|FreeStyle Libre Pro 4 sensor wears, 2 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
41294667|NCT02434315|DEVICE|FreeStyle Libre Pro 6 sensor wears, 4 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
40964226|NCT06309732|DRUG|Methotrexate|Doses are titrated against renal function. Dosage: 30 mins loading plus 12 hour infusion
40964227|NCT06309732|DRUG|Etoposide|90mg/m2 injection for infusion
40964228|NCT06309732|DRUG|Cisplatin|50mg/m2
40964229|NCT06309732|DRUG|Epirubicin|37.5mg/m2
40964230|NCT00944905|BIOLOGICAL|MDX-1203|Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
40964231|NCT06504823|OTHER|Light level|light application
40964232|NCT04387032|OTHER|HVLA Manipulations|The procedure of experimental manipulation: the patient lay on the healthy side with the straight lower limb, and the torso turned towards the dysfunctional side, whose lower limb was bent in the hip and knee joint, and the hands rest on the lower ribs on the same side. The therapist allowed the initial loosening of the tissues and chose the movement barrier with his stabilizing hand. Then, with the treatment hand, he introduced the HVLA thrust through the iliac bone towards the bottom, while giving the iliac bone a posterior or anterior rotation - meaning, the opposite to the occurring dysfunction. If during the manipulation, no cavitation sound was heard, the HVLA thrust was repeated once.
41137014|NCT04317937|OTHER|Supportive Treatment|"Postural Advice and Home Exercise Program with Dairy Postural advice and home exercise program. Postural Advise Maintain upright posture while sitting.~* Avoid prolonged neck bending.~* Avoid twisting movement of the neck.~* Use a suitable pillow to maintain cervical spine.~* Adjust computer screen at eye level.~* Avoid constant use of mobile or similar device to prevent excessive strain over neck joints and muscles.~* Carry light and even weight in both hands while shopping and other chores.•Stay hydrated.~Home Exercise Program (unsupervised) (3 times a day)~* Forward flexion (Self Resisted), 6 sec hold, number of repetitions 15~* Right side flexion (Self Resisted ), 6 sec hold, number of repetitions 15~* Left side flexion (Self Resisted) x 6 sec hold,number of repetitions 15~* Backward flexion (Self Resisted) x 6 sec hold, number of repetitions 15~Home Dairy A home dairy will be provided to maintain home exercise program record."
41137015|NCT02634307|DRUG|ALKS 8700|Administered as specified in the treatment arm.
41137016|NCT06167421|PROCEDURE|Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique|The laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique is defined as a surgical procedure that aims to remove the distal part of the pancreas while preserving the spleen by maintaining the splenic artery and vein (Hepatogastroenterology. 2003;50:2242).
40766271|NCT06162221|DRUG|RMC-6291|Oral tablet
40766272|NCT06162221|DRUG|RMC-6236|Oral tablet
40766273|NCT06162221|DRUG|Pembrolizumab|IV Infusion
40766274|NCT06162221|DRUG|Cisplatin|IV Infusion
40766275|NCT06162221|DRUG|Carboplatin|IV Infusion
40766276|NCT06162221|DRUG|Pemetrexed|IV infusion
40766277|NCT06057623|OTHER|Evaluation of central and peripheral neuromuscular fatigue|To define peripheral and central component of fatigue, the investigators will test, before, during and after the fatigue task, the force produced during a Maximal Voluntary Contraction (MVC) and the force produced by the electrically evoked Resting Twitch (RT) produced, at rest, 5 seconds after the MVC.
41294668|NCT02434315|DEVICE|FreeStyle Libre Pro 3 sensor wears|Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
40766278|NCT06639321|DEVICE|Percutaneous Ventricular Assist System|Percutaneous Ventricular Assist System provides intraoperative circulatory support during high-risk PCI.
40964233|NCT04387032|OTHER|Sham Manipulation|The sham procedure was the same, but no external force was introduced in the form of a therapeutic impulse.
41294669|NCT04611464|DRUG|Misoprostol|Misoprostol is a PGE1 analog
40766279|NCT06639321|DEVICE|extracorporeal membrane oxygenation (ECMO)|ECMO provides intraoperative circulatory support during high-risk PCI.
41294670|NCT04877548|OTHER|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
40964234|NCT02231775|DRUG|Dabrafenib|Given PO
40964235|NCT02231775|OTHER|Laboratory Biomarker Analysis|Correlative studies
40964236|NCT02231775|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40964237|NCT02231775|DRUG|Trametinib|Given PO
40964238|NCT05751460|OTHER|Straight leg raise|Diagnostic test, tool for \*g\*
40964239|NCT04546945|DIAGNOSTIC_TEST|CD56|detection of CD56 by flow cytometry
40964240|NCT01218711|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
40964241|NCT01211730|DRUG|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
41137017|NCT06167421|PROCEDURE|Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique|Warshaw technique laparoscopic spleen-preserving distal pancreatectomy is defined as a surgical procedure that aims to preserve the spleen while removing the distal part of the pancreas. It involves ligating the splenic artery and vein, while preserving the left gastroepiploic artery and short gastric vessels (Arch Surg. 1988;123:550).
41294671|NCT04877548|OTHER|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
41294672|NCT04877548|OTHER|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
41294673|NCT01568580|DRUG|GreenGene|Dose : 10 \~ 50IU/kg Administration method : intravenous infusion or bolus
41294674|NCT01937130|DRUG|IDN-6556|
41294675|NCT01937130|OTHER|Placebo|
41294676|NCT03215888|PROCEDURE|bariatric surgery|Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
41294677|NCT03516799|OTHER|Acupuncture|Acupuncture is a method of Traditional Chinese Medicine that consists of the insertion of thin, sterile, FDA-approved disposable needles on specific acupuncture points (acupoints).
41456864|NCT00057941|DRUG|anastrozole|Given orally
40964242|NCT02215512|DRUG|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
40766282|NCT06564246|DRUG|Vonoprazan 20 mg versus Pantoprazole 40 mg|Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole
41137018|NCT00213759|DRUG|filgrastim|The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.
41137019|NCT00213759|DRUG|dextrose 5%|The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
41137020|NCT03693807|DEVICE|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
41137021|NCT03693807|DRUG|Floxuridine (FUDR)|Please see Detailed Description.
41137022|NCT03693807|DRUG|Gemcitabine|Please see Detailed Description.
41456865|NCT00057941|DRUG|gefitinib|Given orally
41456866|NCT00057941|DRUG|fulvestrant|Given intramuscularly
41456867|NCT00057941|OTHER|laboratory biomarker analysis|Correlative studies
40766283|NCT02960893|DRUG|Troriluzole|Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
40766284|NCT02960893|DRUG|Placebo|Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
40766285|NCT02960893|DRUG|Troriluzole|Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
40964243|NCT00462618|DRUG|Quetiapine|
40964244|NCT00462618|BEHAVIORAL|Cogntive behavioral therapy|
40964245|NCT02515825|DEVICE|CADence|
40964246|NCT03913312|BIOLOGICAL|Unrelated cord blood|Unrelated cord blood comes from Shandong cord blood bank. TNC\>1.5\*107/kg;HLA 4-5/6
40964247|NCT00353262|DRUG|Avastin|7.5mg/kg iv (cycle 3 only)
40964248|NCT00353262|DRUG|Oxaliplatin|130mg/m2 iv (cycles 1, 2 and 3)
40964249|NCT00353262|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid (cycles 1, 2 and 3)
40964250|NCT03365830|DIAGNOSTIC_TEST|FertQol, Beck's Depression Inventory, Beck's Anxiety Inventory|These 3 scale will be given to patients to fill up who takes infertility treatments
40964251|NCT06446167|OTHER|Exercises|All groups received a regimen of daily exercises, including stretches for the plantar fascia and Achilles tendon, and strengthening exercises for the calf muscles and foot intrinsic muscles. Each type of exercise was demonstrated to the participants by the same physiotherapist at the beginning of the treatment process, to be performed twice a day with 10 repetitions each time.
40964252|NCT06446167|OTHER|MLS Laser Treatment|The MLS Laser applied to the treatment group was administered using an ASA brand Mphi model device. Patients in the Laser group were positioned in a prone position. Treatment was applied continuously for 7 minutes along the plantar fascia, sole of the foot, heel area, and Achilles tendon in accordance with the plantar fasciitis treatment program on the device, at a dose of 1.73 J/cm2 and a frequency of 700 Hz. A treatment program was established with 3 sessions per week, totaling 10 sessions
41137023|NCT03693807|DRUG|Oxaliplatin|Please see Detailed Description.
41137024|NCT03693807|DRUG|Irinotecan (CPT-11)|Please see Detailed Description.
41137025|NCT03693807|DRUG|Fluorouracil|Please see Detailed Description.
41137026|NCT03693807|DRUG|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
41137027|NCT01934322|OTHER|Case Management|"Furnish specific assistance and to provide referrals for the patients:~* If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~* If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~* If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~* In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
41456868|NCT06367985|OTHER|Air Oxygen Concentration CAPA-IVM culture|"* Group 1A: COC will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 1B: COCs will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and in the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius."
41137028|NCT03989310|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle
41137029|NCT03989310|DRUG|nab-paclitaxel|Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle
41137030|NCT03989310|DRUG|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
41137031|NCT03989310|DRUG|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
41137032|NCT03461666|BEHAVIORAL|Cognitive Behavior Therapy-Insomnia|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
40766286|NCT06223269|DRUG|Skin Xenotransplant|"realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area."
41137033|NCT03461666|BEHAVIORAL|Focus of Attention|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
41294678|NCT04291417|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
41294679|NCT05566756|OTHER|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
41294680|NCT03664986|DRUG|Liposomal Bupivacaine|The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
41456869|NCT06367985|OTHER|Low Oxygen Concentration CAPA-IVM culture|"* Group 2A: COC will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 2B: COCs will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius."
40964253|NCT06446167|OTHER|ESWT treatment|The treatment group was administered with the Swiss DolorClast Master ESWT device, which produces radial shock waves. Patients in the ESWT group were positioned in a prone position. The most painful point in the heel area was identified through palpation. Gel was applied to this area, followed by the surrounding soft tissues, towards the plantar fascia and the attachment area of the Achilles tendon at the dorsal aspect of the heel. Radial ESWT treatment was applied at a frequency of 10 Hz, pressure of 2.5 bars, and 2000 impulses per session, once a week for a total of 4 sessions
41137034|NCT03461666|BEHAVIORAL|Combined-CBT-I and FOA Group|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
41456870|NCT02373839|OTHER|Measurement of PlGF|If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
41137035|NCT03461666|BEHAVIORAL|Sleep Hygiene|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
41137036|NCT02571868|DEVICE|Optimization CRT-D|
41137037|NCT03480815|DEVICE|Nocturnal Temperature Controlled Laminar Flow Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
41137038|NCT03480815|OTHER|None Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
41137039|NCT00955162|DRUG|Buprenorphine (Subutex)|Sublingual tablet
41137040|NCT00955162|DRUG|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
41137041|NCT01020097|DRUG|fluorine F18 EF5|Given IV
41137042|NCT01020097|PROCEDURE|immunohistochemistry staining method|Correlative study
41137043|NCT01020097|PROCEDURE|biopsy|Correlative study
41294681|NCT02540174|PROCEDURE|integrated addiction treatment program|"At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program."
41456871|NCT04442854|OTHER|cognitive behavioral group therapy|A 8-session cognitive behavior group intervention tailor-made for Mainland Chinese university students in Hong Kong
41456872|NCT02658214|DRUG|paclitaxel + carboplatin|IV infusion
40964254|NCT02321878|DRUG|liraglutide|"Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.~No treatment given."
40964255|NCT03918083|BEHAVIORAL|Wellness|Assess the feasibility of an integrated, prescriptive, and trackable wellness intervention amongst residents at Orange Park Medical Center (OPMC) by combining five wellness elements including: exercise, mindfulness, sleep, social connectedness, and nutrition.
40964256|NCT02667054|DRUG|RX0041 4%|Anesthetic
40964257|NCT02667054|DRUG|Placebo|Placebo Comparator
41137044|NCT01020097|PROCEDURE|Positron Emission tomography|Undergo scan
40964258|NCT02667054|DRUG|RX0041 8%|Anesthetic
40964259|NCT00283400|DRUG|25% human albumin|25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
40964260|NCT00228683|PROCEDURE|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
41137045|NCT04967118|BEHAVIORAL|Skin-to-skin contact|Diaper clad baby will be placed ventral position on bare chest of mother 30 minute prior to the heel lance
41137046|NCT04967118|BEHAVIORAL|Mother's heartbeats as sound and vibration|The mother's heartbeat will be recorded and the heartbeat sounds will be saved to the platform. The platform will be placed under the infant's mattress and the heartbeat will be started 30 minute prior to the heel lance.
41137047|NCT04967118|DRUG|30% oral glucose|The infant will be given 30% oral glucose solution 2 minutes before the injection
41137048|NCT01656512|DRUG|zolendronic acid|"patients will receive calcium \& vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~1. Initial dose: (0.025) mg /kg~2. Subsequent doses ( 0.05) mg /kg.~3. Maximum dose of 4 mg."
41137049|NCT01656512|DRUG|calcium & vitamin D|patients will receive calcium \& vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
41137050|NCT02915783|DRUG|lenvatinib|4 mg and 10 mg capsules
41137051|NCT02915783|DRUG|everolimus|5 mg tablets
41137052|NCT00463502|DRUG|Metformin|
41137053|NCT03316690|DRUG|Metformin treatment|"Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2"
41137054|NCT03316690|DRUG|Placebo treatment|"Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2"
41294682|NCT02540174|PROCEDURE|standard of care|"The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~* At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~* At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption"
40964261|NCT05191524|OTHER|Constrained induced movement|Practice in two sessions per day (supervised) for 3 days per week, for six consecutive weeks. The unaffected limb will be constraint using a knee immobilizer only during practice sessions. We will perform the interventions under the supervision of a trained physiotherapist.
40964262|NCT05191524|OTHER|Proprioceptive Neuromuscular facilitation|Group B will receive PNF intervention given for 30 minutes to the lower limb 3 times a week for 6 weeks
40964263|NCT04144244|OTHER|MicroFluidic Sperm Sorting Chips|sperm selection of IUI treatment
40964264|NCT04144244|OTHER|Gradient-Density Centrifugation|sperm selection of IUI treatment
41137055|NCT03316690|BEHAVIORAL|Physical training|Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
41137056|NCT04148378|OTHER|No intervention|There is no intervention for this study.
41137057|NCT04529824|DEVICE|Dexcom G6 Continuous Glucose Monitor (CGM) System|Participants wear a blinded Dexcom G6 CGM and a Fitbit Charge 3 activity tracker for 10 days.
41137058|NCT03430518|DRUG|Durvalumab|1.12g given IV on day 1 every 21 day cycle
41137059|NCT03430518|DRUG|Eribulin|1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.
41294683|NCT05355363|DIAGNOSTIC_TEST|Standard Colonoscopy|Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
41294684|NCT02284399|OTHER|non-invasive prenatal testing|Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
41294685|NCT05379322|DRUG|Anti-TNF|Upon analysis of the sample, patients that are falling into specific phenotypes (diffuse myeloid or pauci-cellular phenotypes) will be assigned to receive anti-TNF as biologic DMARD medications.
41294686|NCT05379322|DRUG|JAK inhibitor|Upon analysis of the sample, patients that are falling into specific phenotypes (lymphoid- myeloid or pauci-cellular phenotypes) will be assigned to receive JAK inhibitors as biologic DMARD medications.
41294687|NCT01010841|DIETARY_SUPPLEMENT|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
41294688|NCT01010841|OTHER|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
41294689|NCT03369301|DRUG|Gammanorm|Gammanorm given per standard of care
41294690|NCT03369301|DRUG|Other Subcutaneous Immunoglobulins|Other Subcutaneous Immunoglobulins given per standard of care
41294691|NCT06175507|DRUG|Naltrexon|Naltrexone 50mg orally once daily will give for 12 weeks
41294692|NCT06175507|DRUG|Baclofen|Baclofen 10mg orally thrice daily will give for 12 weeks
41294693|NCT03067662|OTHER|Aerobic exercise|
41294694|NCT00000800|DRUG|Methadone hydrochloride|
41294695|NCT00000800|DRUG|Zidovudine|
41294696|NCT02788916|OTHER|No Intervention|
41137060|NCT03086226|DRUG|Fosravuconazole|Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
41137061|NCT03086226|DRUG|Itraconazole|This will be the active comparator
41137062|NCT02941692|DRUG|Oxytocin|
41137063|NCT02941692|DRUG|Placebo|Placebo for Oxytocin
41137064|NCT04728100|OTHER|LQT|Patients with LQT syndrome diagnosis.
41137065|NCT01584648|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily
41137066|NCT01584648|DRUG|Trametinib|Trametinib 2 mg once daily
41137067|NCT01584648|DRUG|Trametinib placebo|Dabrafenib 150 mg twice daily and trametinib placebo
41137068|NCT01230359|DIETARY_SUPPLEMENT|Pyridoxine hydrochloride|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
41137069|NCT01230359|OTHER|Tang orange powder|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
41137070|NCT01404637|DRUG|Tamsulosin 0.4mg|Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
41137071|NCT01404637|DRUG|Tamsulosin 0.2mg|tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
41137072|NCT01838603|OTHER|Qualitative interview|Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
41137073|NCT02802332|BEHAVIORAL|Footlength Card|The footlength card has an image of a baby's foot. The card is to be held up against the baby's foot after birth; if a baby's foot is smaller than the image, or if the woman/family member is concerned about the health of their baby, they can call the number printed on the card and hear a pre-recorded message about basic care for newborn babies
41137074|NCT03462966|DRUG|Rifaximin|Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
41137075|NCT02676726|PROCEDURE|Extraperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
41137076|NCT02676726|PROCEDURE|Transperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
41137077|NCT00310037|DRUG|bortezomib|Given IV
41137078|NCT02394054|DRUG|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
41137079|NCT02394054|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
41137080|NCT06114537|DRUG|Acetazolamide|"The used intervention in this study is acetazolamide, which belongs to a class of drugs known as carbonic anhydrase inhibitors and has been used with other medications to treat high ocular pressure due to certain types of glaucoma~Patients in the treatment group will receive 250 milligrams of oral acetazolamide twice daily for 16 weeks.~Patients randomized to the treatment group will switch to 125 milligrams of oral acetazolamide twice daily for another four weeks when the central foveal thickness (CFT) on OCT is reduced by ≥25% at the evaluation visit at 16 weeks after the baseline visit. These patients will continue with this dose till the end of the study when the CFT on OCT is stable or further reduced. If the CFT on OCT has increased, they switch back to 250 milligrams of oral acetazolamide twice daily for another 12 weeks."
41137081|NCT02742805|DIETARY_SUPPLEMENT|Vitamin D (4,000 IU/day)|High Dose of 4,000 IU/day.
41294697|NCT04766424|BEHAVIORAL|Sleep extension intervention|Participants will receive a fitbit and 8 weekly sleep-related educational materials via email and telephone coaching to review their sleep tracker data, set goals, trouble shoot any problems, and increase motivation.
41294698|NCT04766424|BEHAVIORAL|Health education|Participants will receive 8 weekly health education newsletters delivered via email.
41456873|NCT02658214|DRUG|carboplatin + etoposide|IV infusion
41456874|NCT02658214|DRUG|gemcitabine + carboplatin|IV infusion
41137082|NCT02742805|DIETARY_SUPPLEMENT|Vitamin D (400 IU/day)|Low Dose of 400 IU/day.
41137083|NCT02742805|DRUG|Omalizumab|Standard of care dose.
41137084|NCT00532766|DRUG|Jusline|
41137085|NCT04806906|DRUG|CC-486|Investigational product will be dispensed on Day 1 of each treatment cycle. 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
41137086|NCT02906657|OTHER|Medication reconciliation|The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
41137087|NCT04321109|OTHER|Allograft|Corticocancellous mineralized allograft
41137088|NCT04321109|OTHER|Collagen cone|Collagen matrix
41294699|NCT01270893|DRUG|Nilotinib|400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
41294700|NCT02719418|DRUG|Tinzaparin|3500 Unit or 4500 Unit subcutaneous once daily
41294701|NCT02807116|DRUG|Pacritinib|Subjects received a single oral 400-mg dose of pacritinib
41294702|NCT02807116|DRUG|Rifampin|Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
41456875|NCT02658214|DRUG|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
41456876|NCT02658214|DRUG|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
41456877|NCT02658214|BIOLOGICAL|durvalumab|IV infusion
41456878|NCT02658214|BIOLOGICAL|tremelimumab|IV infusion
41456879|NCT02658214|DRUG|nab-paclitaxel (paclitaxel-albumin) + gemcitabine|IV infusion
41456880|NCT02658214|DRUG|cisplatin + 5-fluorouracil (5FU)|IV infusion
41456881|NCT04262180|OTHER|Base intervention-Fitbit with EHR integration|Every subject will start with a base intervention - Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal
41456882|NCT04262180|OTHER|Coaching Calls|Non-responders to base intervention will be randomized to coaching calls.
41456883|NCT04262180|OTHER|Online Gym|Non-responders to base intervention will be randomized to online gym.
41456884|NCT06492252|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
41456885|NCT06492252|BEHAVIORAL|Adaptation|Auditory adaptation in speech
41456886|NCT06492252|BEHAVIORAL|Adaptation|Auditory baseline in speech
41456887|NCT00640926|DRUG|Radezolid|300 mg/day, orally for 7-10 days
41456888|NCT00640926|DRUG|Radezolid|450 mg/day orally for 7-10 days
41456889|NCT00640926|DRUG|Radezolid|900 mg/day orally for 7-10 days
40964265|NCT05990465|DRUG|Pirtobrutinib|Pirtobrutinib will be administered at 200 mg/day orally starting at least 14 days prior to apheresis as bridging until the start of lymphodepletion and restarted between day 28-120 for up to one year as maintenance post cell infusion.
40964266|NCT05990465|DRUG|LV20.19 CAR T cells|Subjects will receive a dose of 2.5x10\^6 CAR-T cells/kg as a previously identified safe in a Phase 1 protocol at the Medical College of Wisconsin.
40964267|NCT06180772|BEHAVIORAL|FIT FIRST|High intensity sports drills and games
40964268|NCT06083285|OTHER|Implement the CRRT specialist nursing group management program on the basis of routine care|Training the department nurses on CRRT related theoretical knowledge and operation skills; guiding the process of CRRT different treatment modes, solving CRRT nursing problems, evidence-based nursing guidance; consulting CRRT treatment and nursing related treatment, timely understanding the new progress; responsible for CRRT nursing quality control, etc.
41137089|NCT03128099|BEHAVIORAL|Virtual reality social skills training|Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
41137090|NCT04534699|DRUG|KBP-5074|KBP-5074 tablet
41137091|NCT05774626|BEHAVIORAL|Contraceptive usage|Continued use of injectable contraception, administered on a quarterly basis
41137092|NCT03615404|BIOLOGICAL|CMV-DCs with GM-CSF|CMV-DCs are autologous dendritic cells derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF.
41294703|NCT02807116|DRUG|Pacritinib and Rifampin|On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
41294704|NCT00112138|DRUG|gabapentin|
41294705|NCT02568826|DRUG|3-glycosyl-3-Odemethylthiocolchicine derivative|IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
41294706|NCT04197297|DIAGNOSTIC_TEST|CT and MRI Scans|CT and MRI scans will occur before and after radiation therapy.
41294707|NCT04848363|PROCEDURE|Quadratus lumborum block|QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
41294708|NCT03130101|OTHER|Change in their basal insulin rate|Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
41294709|NCT01854567|BIOLOGICAL|Infusion of one MPC expanded cord unit and one unexpanded cord unit|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
41294710|NCT01854567|BIOLOGICAL|Infusion of two unexpanded cord blood units.|Umbilical Cord Blood.
41294711|NCT02458651|OTHER|No intervention|No intervention administered in this study
41294712|NCT05984667|BEHAVIORAL|C-SMART|The C-SMART intervention includes approximately 8 individual therapy sessions, each approximately 60 minutes in length, delivered weekly. C-SMART intervention components include cognitive rehabilitation and mindfulness training.
41294713|NCT04929873|BEHAVIORAL|Closed transdyser|When the average arterial pressure ≥ 50mmHg, it is indicated that the basic blood supply of the lower extremities is satisfied without special treatment, and when the average arterial pressure \< 50mmHg, it indicates insufficient perfusion, by adjusting the pipe position, changing the ECMO flow rate, and properly clamping the artery end to divert part of the blood flow to the side branch circulation, so that the average arterial pressure is maintained above 50mmHg.
41294714|NCT04929873|BEHAVIORAL|Routine monitor|Obtain oxygen saturation, skin color, temperature, etc
41294715|NCT00120796|DRUG|Lamivudine|
41294716|NCT00120796|BIOLOGICAL|Recombinant hepatitis B surface antigen|
41294717|NCT03540368|DRUG|Tranexamic acid injection|Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
41294718|NCT03540368|OTHER|Placebo|Administering placebo or sodium chloride 0,9% intravenously
41456890|NCT05388071|OTHER|Usage of telemedicine and tele-consultation for treatment|Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
41456891|NCT06058806|OTHER|Multimodal Physical Therapy|Multimodal Physical Therapy program consisting of electrophysical agents, manual therapy interventions, and core stability exercises
41456892|NCT05648539|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
41456893|NCT06502951|OTHER|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
40766287|NCT06223269|PROCEDURE|Autograft(ing)|Autograft(ing) is the current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin, i.e. autologous (self) skin harvesting, from an uninjured site on the patient and using it to cover the original burn wound.
40964269|NCT04534959|OTHER|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Interventions for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \>100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
40964270|NCT02026739|PROCEDURE|low supplemental oxygen concentration|low supplemental oxygen concentration would be used during the surgery
40964271|NCT02026739|PROCEDURE|high supplemental oxygen concentration (conventional)|high supplemental oxygen concentration would be used during the surgery
40964272|NCT03437096|OTHER|venipuncture pain|postoperative sleeve gastrectomy patients pain
40964273|NCT02838381|OTHER|Additional biological samples|blood and tissue samples
40964274|NCT00519831|BIOLOGICAL|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
40964275|NCT00519831|DRUG|vinflunine|Vinflunine 320 mg/m² every 21 days
40964276|NCT05214456|OTHER|Dry needling|The method of performing the dry needling technique will be based on the method presented by Dommerholt and Fernandez-de-las-Penas. The length of the needle (Tony, china) for each patient will be selected based on the size of the patient: 1) Multifidus: the patient will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. The needles will be inserted into the lumbar multifidus muscles, 1.5 to 2 cm lateral to the spinous process of all lumbar vertebrates, perpendicular to the lamina (after piercing the skin, needles are directed inferomedially). 2) Quadratus lumborum: The patient will be placed in the side lying position with the side to be treated facing up. After identifying the lateral border of the quadratus lumborum muscle, the needle will be aimed straight downward in the direction of the transverse process, followed by slight anterior, posterior, and caudal needling to explore the entire muscle.
40964277|NCT05214456|OTHER|Mobilization|To perform Maitland's mobilization for lumbar spine, the anterior-posterior mobilization technique will be used and it is performed by pushing the heel (pisiform grip) or thumbs (thumb grip) to the vertebrae and can immediately reduce pain and restore motor function. First, the complete physical orthopedic evaluation of manual therapies will be performed using the Maitland evaluation method. Then, based on the findings of the patient evaluation, the severity, rhythm, duration and the degree of the mobilization and the place of force (spine or lamina) will be determined. To apply mobilization, the person will sleep in a prone position and the physiotherapist will use the heel of the hand or the thumbs to apply force to the first to fifth vertebrae of the lumbar spine. In segments that do not have a problem based on evaluation, first grade of the anterior-posterior Maitland's mobilization will be applied to the spinous process of the segment.
40964278|NCT04186728|DIETARY_SUPPLEMENT|Magnesium glycinate|Daily magnesium capsule.
40964279|NCT04186728|OTHER|Placebo|Daily placebo capsule.
40964280|NCT05993130|OTHER|The patients were not intervened. This is a retrospective study|The patients were not intervened. This is a retrospective study
40964281|NCT00875875|DRUG|Rifaximin|Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
40964282|NCT03296358|DRUG|IV Dexamethasone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).
40964283|NCT03296358|DRUG|Oral prednisolone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
40964284|NCT00777608|DRUG|Comparator: Placebo 5mg (run in)|Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
40964285|NCT00777608|DRUG|Donepezil 5 - 10 mg|"Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
40964286|NCT00777608|DRUG|Comparator: Placebo 5-10 mg|"Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
40964287|NCT00777608|DRUG|Donepezil 10 mg|Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
40964288|NCT06352489|PROCEDURE|Posterior component separation technique.|By dividing the posterior rectus sheath, a posterior plane is reached which can be advanced by dividing the transversus abdominis muscle with reinforcement of the midline with synthetic mesh.
41456894|NCT06502951|OTHER|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
41456895|NCT05710354|DIETARY_SUPPLEMENT|Nutridrink Compact Protein|Oral Nutritional Supplement, a liquid, ready-to-drink, high protein, high calorie blend. Intended for adult patients (from 18 years of age) with malnutrition or risk of its development. Produced by Nutricia
41456896|NCT03100357|OTHER|Thyroidectomy|Thyroid surgery for benign nodular goiter
40766288|NCT05647122|DRUG|AZD9592|Varying doses of AZD9592
40766289|NCT05647122|DRUG|Osimertinib|tablets administered orally
40766290|NCT05647122|DRUG|5-Fluorouracil (5-FU)|IV infusion
40766291|NCT05647122|DRUG|Leucovorin|IV infusion
40766292|NCT05647122|DRUG|Bevacizumab|IV infusion
40766293|NCT05383898|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
40766294|NCT05939544|DIETARY_SUPPLEMENT|Experimental: Milk Fat Globule Membrane-enriched Powdered Ingredient|Milk Fat Globule Membrane-enriched Powdered Ingredient
41456897|NCT02711527|OTHER|Acupunture group A|"Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14)."
41294719|NCT02279589|BIOLOGICAL|Pneumo 23® 0,5|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
41456898|NCT02711527|OTHER|Acupunture group B|"Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion."
40964289|NCT01486732|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
40964290|NCT01486732|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
40964291|NCT01486732|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
40964292|NCT05342194|DRUG|Toripalimab|240 mg IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
40964293|NCT05342194|DRUG|Lenvatinib mesylate capsules|8 mg orally (po) once daily (QD)
40964294|NCT05342194|DRUG|Placebo IV|Placebo IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
40964295|NCT05342194|DRUG|Oral placebo|Oral placebo po QD continuously
40964296|NCT05342194|DRUG|Oxaliplatin for injection|85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles
40964297|NCT05342194|DRUG|Gemcitabine hydrochloride|1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
40964298|NCT05342194|DRUG|Cisplatin|25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
41456899|NCT04841967|BEHAVIORAL|TELL Tool Intervention|A 60-minute session with decision support information delivered digitally to parents at their homes or other private, quiet location.
41456900|NCT04841967|BEHAVIORAL|eBook Attention Control|A 60-minute session with good parenting principles delivered digitally to parents at their homes or other private, quiet location.
41456901|NCT03837171|BIOLOGICAL|Liberal Red blood cell transfusion|"Hemoglobin level will be maintained above 9 g/dL (liberal strategy) for the first 48 hours following randomization. After 48 hours, indications of RBC transfusions will be at the discretion of attending physicians in patients with persistent circulatory failure.~After resolution of acute circulatory failure, a 7 g/dL transfusion threshold will be recommended regardless of the allocation arm. In case of subsequent episodes of septic shock, the transfusion strategy will be at the discretion of attending physicians"
41456902|NCT03837171|BIOLOGICAL|Restrictive Red blood cell transfusion|Hemoglobin level will be maintained above 7 g/dL (restrictive strategy) during all the stay in ICU
41456903|NCT02028416|DRUG|ATG-fresenius|"we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days"
41456904|NCT06357741|DRUG|Denosumab|Desumumab, 60mg single injection
41456905|NCT04777552|OTHER|diazepam (or equivalence if other benzodiazepine)|
40964299|NCT04736030|BEHAVIORAL|Intervention|Twelve weekly sessions will be led by Ms. Schneider and Ms. Montañez supported by Drs. Arredondo and Ayala and student research assistants. Mothers and daughters will participate in weekly virtual 1.5-hour sessions that include didactic teaching, skill building (including PA parenting and communication skills training), interactive discussions, PA, and homework review (homework examples: 30-min walks, practicing communication strategies). Mothers and daughters will attend sessions together, with 10-12 mother-daughter dyads participating in each series. Sessions 2-12 will include at least 30 min PA. Sessions will discuss strategies to engage in PA outside the sessions (goal of 60-min MVPA daily).
40964300|NCT05298631|OTHER|Stabilization exercises|The activation of deep cervical muscle to reduce the activity of surface muscles is known as stabilization exercises
40964301|NCT05298631|OTHER|Dynamic exercises|The exercises in which muscle tension remains constant but muscle length changes is known as dynamic exercises
40964302|NCT02257008|DRUG|BILR 355 BS|
40964303|NCT02257008|OTHER|Grapefruit juice|
40964304|NCT02257008|DRUG|Nelfinavir|
40964305|NCT02257008|DRUG|Atazanavir|
40964306|NCT02257008|DRUG|Ritonavir|
40964307|NCT01885403|DEVICE|non-invasive respiratory parameter measurements|
41294720|NCT02279589|BIOLOGICAL|Pneumo 23® 0,1|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
40964308|NCT02958514|DEVICE|intense pulsed light|Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of \*500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.
41456906|NCT04559841|OTHER|bone substitute; NanoBone®|surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
40766295|NCT05939544|DIETARY_SUPPLEMENT|Placebo Comparator: Control (Placebo) Powdered Ingredient|Placebo Comparator: Control (Placebo) Powdered Ingredient
40964309|NCT02958514|DRUG|Tobramycin and Dexamethasone Ophthalmic Ointment|
40964310|NCT02147236|BEHAVIORAL|Social Skills Training|
40964311|NCT02197247|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
40964312|NCT02197247|DRUG|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
41294721|NCT02279589|BIOLOGICAL|Prevenar13® 0,5|"The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197)."
41294722|NCT02369978|DRUG|Nifurtimox|Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
41294723|NCT02369978|DRUG|Benznidazole|Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
41294724|NCT02369978|DRUG|Placebo|Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
41294725|NCT01022853|DRUG|BI 6727|intravenous each 21 days
40766296|NCT06644625|OTHER|Blood draw for the laboratory assessment|Screening blood sample collection to test for MGUS
40766297|NCT05135260|BEHAVIORAL|Virtual reality therapy|Participants will watch a video allowing them to view nature, dinosaurs, animals, and human interactions in three dimensions during a session lasting 11 minutes.
40766298|NCT05135260|BEHAVIORAL|Questionnaires|Questionnaires will be completed regarding stress, pain and affect
40766299|NCT05135260|PROCEDURE|Measure heart rate|To be measured prior to starting treatment and halfway through the 11 minute Video
40766300|NCT05135260|BEHAVIORAL|Cyber sickness measurement|To be measured using the fast motion sickness scale
40964313|NCT02197247|DRUG|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
40964314|NCT02197247|PROCEDURE|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
40964315|NCT02197247|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
40964316|NCT06081868|BEHAVIORAL|Use of toothbrush/toothpaste/fluoride varnish|Children receive information about the use of toothbrush/toothpaste/fluoride varnish.
40964317|NCT06081868|BEHAVIORAL|Education on nutrition/oral hygiene|Children receive education on nutrition/oral hygiene.
40964318|NCT03800329|DEVICE|Snap40 Monitor|Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.
40964319|NCT03800329|OTHER|No Monitor|Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
41137093|NCT03615404|BIOLOGICAL|Td (tetanus toxoid)|Patients will receive preconditioning with Td in the right groin, and approximately 6-24 hours later, they will receive their first CMV-DC vaccination. Patients will also receive Td preconditioning approximately 6-24 hours prior to their 4th vaccine and subsequent vaccines, if any.
41137094|NCT04337593|DRUG|Basiliximab|20mg d1,8, repeated every 3 weeks
41294726|NCT01022853|DRUG|BIBF 1120|oral continuously
41294727|NCT02199977|OTHER|Free Malaria Rapid Diagnostic Test|Malaria RDT is offered free if patients choose to be tested
41294728|NCT02199977|OTHER|Conditional ACT voucher|"Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug."
41294729|NCT02199977|OTHER|Malaria Rapid Diagnostic test for a charge|Participants can receive a malaria RDT for a set amount (i.e., not for free).
41294730|NCT02229864|DEVICE|Coronary artery stenting: Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm"
41294731|NCT05603624|PROCEDURE|Cervical examination to assess labor|Patients were randomized to receive cervical examinations to assess progression in labor with either sterile or clean gloves.
41294732|NCT03854591|OTHER|No intervention|No intervention
41294733|NCT03119038|DRUG|Bupivicaine + epinephrine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
41294734|NCT03119038|DRUG|Bupivacaine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine
41294735|NCT03119038|DRUG|Ropivacaine|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine
41294736|NCT03119038|DRUG|Ketorolac|Intraoperative periarticular injection of 30 mg
41294737|NCT03119038|DRUG|Clonidine Injection|Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
41294738|NCT03605134|DIAGNOSTIC_TEST|level of cardiac troponin|blood test
41294739|NCT03605134|DIAGNOSTIC_TEST|diastolic function assessment|transthoracic echocardiography
41294740|NCT05360277|DRUG|Tislelizumab + Capecitabine|"Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."
41294741|NCT05360277|OTHER|Best supportive care|Best supportive care
41456907|NCT00080613|DRUG|exemestane|
41456908|NCT00080613|PROCEDURE|adjuvant therapy|
41456909|NCT00080613|PROCEDURE|aromatase inhibition|
40766301|NCT06528418|OTHER|Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system|Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
40964320|NCT02614092|BEHAVIORAL|Water-based Activity + Cognitive Training|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
40964321|NCT00923247|DRUG|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
40964322|NCT00923247|DRUG|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
40964323|NCT04483271|DIETARY_SUPPLEMENT|300 mg of omega3-FA|"The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.~Baseline and follow-up serum levels of IL-1,IL-6, and TNF will be measured."
40964324|NCT03324308|DIAGNOSTIC_TEST|Computed Tomography Angiography|This will be a prospective study comparing the low-dose dynamic vs. static CTP combined with the CTA for detecting hemodynamically significant coronary artery stenosis. Patients will have two 18-20 gauge intravenous lines placed for contrast administration. The following image sequences will be completed: coronary calcium scan (non-contrast), rest coronary arterial imaging (with 4-5 mL/sec intravenous ISOVUE-370 infusion), stress myocardial perfusion imaging 20 minutes after rest acquisition imaging (blood pressure will be checked then an infusion of adenosine will be started for a total of 5 minutes; after 5 minutes of adenosine infusion, CT perfusion imaging will be performed during a 4-5 mL/sec ISOVUE-370 infusion). Total estimated radiation dose: 10.551 mSv.
40964325|NCT03521934|DRUG|Sotagliflozin|"Pharmaceutical form: tablet~Route of administration: oral"
40964326|NCT03521934|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
40964327|NCT00379093|BEHAVIORAL|Brief advice|"The intervention will have the following components:~A) At the time of the recruitment visit, all intervention group patients will receive:~* A personalized risk report;~* An educational booklet titled Healthy Drinking as You Age;~* A drinking diary;~* Brief advice to reduce their drinking by their physicians;~B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.~Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician."
40964328|NCT00450281|GENETIC|chromogenic in situ hybridization|
40766302|NCT06521268|OTHER|Inspiratory muscle training|Inspiratory muscle training
40964329|NCT00450281|GENETIC|gene expression analysis|
40964330|NCT00450281|GENETIC|mutation analysis|
40964331|NCT00450281|GENETIC|polymerase chain reaction|
40964332|NCT00450281|GENETIC|polymorphism analysis|
40964333|NCT00450281|OTHER|fluorescent antibody technique|
40964334|NCT00450281|OTHER|immunohistochemistry staining method|
40964335|NCT00450281|OTHER|laboratory biomarker analysis|
40766303|NCT06521268|OTHER|Decongestive treatment|Decongestive treatment
40964336|NCT00450281|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
40964337|NCT00450281|OTHER|study of socioeconomic and demographic variables|
40964338|NCT00450281|PROCEDURE|study of high risk factors|
40964339|NCT03834597|DEVICE|conventional Macintosh laryngoscope|After closure of surgical, anesthesiologist will perform the conventional Macintosh laryngoscope to assess post-thyroidectomy vocal cord mobility.
40964340|NCT03834597|DEVICE|GlideScope®|Patient will be left for a while until hemodynamic stabilization then examination with GlideScope® will be commenced to assess postthyroidectomy vocal cord mobility by another experienced anesthesiologist
41137095|NCT04337593|DRUG|Pegaspargase|2500IU/㎡, d1,repeated every 3 weeks
41294742|NCT05801926|DEVICE|Heel2Toe[TM] sensor|Heel2Toe is a new generation of wearables that provides real-time auditory feedback when the person takes a good step, one in which the step is initiated with a strong heel strike.
41456910|NCT00080613|PROCEDURE|conventional surgery|
41456911|NCT00080613|PROCEDURE|endocrine therapy|
41456912|NCT00080613|PROCEDURE|hormone therapy|
41456913|NCT00080613|PROCEDURE|neoadjuvant therapy|
41456914|NCT00080613|PROCEDURE|surgery|
40766315|NCT05807945|DRUG|Ropivacaine 0.75% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.75%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
40766316|NCT05807945|DRUG|Ropivacaine 0.2% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
40766317|NCT06412185|BIOLOGICAL|CM383|CM383 Injection
40766318|NCT06412185|OTHER|Placebo|Placebo
40766319|NCT04258631|DRUG|Hydromorphone|Given IT
40766320|NCT04258631|PROCEDURE|Laparotomy|Undergo laparotomy
40766321|NCT04258631|DRUG|Liposomal Bupivacaine|Drug
41137096|NCT02362386|DEVICE|Celution Device|Non-interventional evaluation of Celution Device preparation of ADRCs from thermal burn eschar tissue that would normally be discarded.
41137097|NCT01299285|DRUG|LY3009104|Administered orally
41137098|NCT02444962|DEVICE|HAVD-implant|hydroxy-apatite coated, acid etched implant for extra oral use to reconstruct craniofacial defects with an episthesis
41137099|NCT05878106|DIETARY_SUPPLEMENT|Creatine supplementation|"5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention.~The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily."
41294743|NCT04747808|DRUG|LL-BMT1|Drug-printed contact lens in both eyes
41294744|NCT04174131|DEVICE|Restylane + Lidocaine|Restylane + Lidocaine is a HA gel generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine. It is indicated for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs.
41456915|NCT02629640|OTHER|Medical history questionnaire|Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.
41456916|NCT02629640|OTHER|Clinical assessment and review|History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.
40766322|NCT04258631|OTHER|Questionnaire Administration|Ancillary studies
40766323|NCT06572397|DRUG|H-1337 1.0%|ophthalmic solution
40766324|NCT06631391|BIOLOGICAL|umbilical cord blood NK cells|This is a phase I prospective clinical trial, including phase Ia and phase Ib. Phase Ia include 3 dose levels, utilizing a 3+3 design principle, and each dose level will enroll at least 3 subjects. The recommended dose for phase Ia was used in phase Ib. Each patient receives two courses of umbilical cord blood NK cell therapy (a total of 8 infusions of umbilical cord blood NK cells).
40766325|NCT06638151|DRUG|aspirin + clopidogrel|Enrolled patients with acute ischemic stroke will be randomly assigned to the clopidogrel plus aspirin group (300 mg loading dose of clopidogrel plus 160 mg aspirin on day 1; followed by clopidogrel 75 mg plus aspirin 81 mg daily from day 2-day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated).
40766326|NCT06638151|DRUG|Aspirin|Aspirin 81 mg once daily alone
40766327|NCT06642883|DIETARY_SUPPLEMENT|Prolife|randomized in a 1:1 ratio to treatment :1 vial/day for 60 days.
40766328|NCT06642883|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 vial/day for 60 days.
40766329|NCT06639685|DIAGNOSTIC_TEST|MRI|MR Fingerprinting and ASL
40766330|NCT05130281|BEHAVIORAL|Maya mobile app|The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.
40964341|NCT03273114|BEHAVIORAL|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
40964342|NCT03273114|OTHER|Core Training Exercise and Manual Therapy|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with active exercises will involve contractions of abdominal and back muscles in different functional positions, as well as joint mobilization or manipulation techniques applied to the lower back or pélvis, when necessary. Most patients in this group will receive exercises to perform at home, but not related to CFT.
40964343|NCT01710969|BEHAVIORAL|Individual intervention|34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
40964344|NCT01710969|BEHAVIORAL|Group Intervention|34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
40964345|NCT04214769|DIAGNOSTIC_TEST|Audiometry and tympanometry, vHIT, VEMP, ENG|Diagnostic tests
40964346|NCT03372096|DEVICE|Prostatic Artery Embolization|LC Bead LUMI is a spherical polyvinyl alcohol embolic particle that incorporates radiopaque moieties. Once a catheter has been fluoroscopically guided into the target vessel, the beads are then injected, causing obstruction at the arteriole level until the desired degree of embolization has occurred.
40964347|NCT05154591|GENETIC|Adipose-derived stromal vascular fraction cells|Kidney structural and functional changes in 18 patients after 36 months of treatment with SVF cells.
40964348|NCT05432232|DEVICE|HistoSonics Investigational System|The HistoSonics Investigational System is intended for the non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
40964349|NCT02994212|DIETARY_SUPPLEMENT|Monthly distribution of RUTF|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF.
40964350|NCT00000297|DRUG|Labetalol|
40964351|NCT03824314|DRUG|Midazolam|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
40964352|NCT03824314|DRUG|Fentanyl|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
40964353|NCT06429436|BEHAVIORAL|VENDY|At least 1 machine (vending machine like a snack machine or a machine like a newspaper kiosk) will be placed in the respective community served by the participating organizations. Any person in the community can get naloxone from the machine. The vending machine will require a code that will be placed on the machine for anyone to use. The kiosks are a box that you simply pull open and naloxone can be obtained. Naloxone kits will be provided for free as part of the current naloxone distribution program within each respective organization.
40964354|NCT01433705|OTHER|Rb-82 Pet scans|Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.
40964355|NCT01433705|OTHER|F-18 FDG Pet scans|"Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for viability protocol imaging with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) inflammation protocol imaging using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol."
40964356|NCT01433705|OTHER|N-13 ammonia Pet scans|Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
41294745|NCT04174131|DEVICE|Restylane® Lyft|Restylane® Lyft is a sterile gel of HA with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation (Galderma Laboratories, 2014).
41294746|NCT05413967|OTHER|Mills manipulation in addition to myofasical release therapy|Group A will receive Mills manipulation in addition to myofasical release therapy as baselin
41294747|NCT05413967|OTHER|Nirschl exercises in addition to myofascial release therapy|Group B will receive Nirschl exercises in addition to myofascial release therapy as baseline
41294748|NCT06375330|DEVICE|PoliArt|PoliArt injections
41294749|NCT03502759|BEHAVIORAL|CHICA SUDEP module|CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
41456917|NCT02629640|OTHER|Participant follow-up|Hospital patient management system; regular telephone contact with patient/representative.
40964357|NCT01433705|DRUG|Regadenoson|Regadenoson is used as a stressor; but not to study its effects.
41137100|NCT05878106|OTHER|Resistance training|They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.
40766331|NCT05130281|BEHAVIORAL|Social Support|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message. Participants can identify a person they know to receive updates about their progress and support them throughout their time in the program. Participants will not be required to choose a person they know to receive updates about their use of the program; instead, they can choose to have a member of the study team serve as their social support if they are assigned to this condition.
40766332|NCT05130281|BEHAVIORAL|Gain Framed|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message.
40964358|NCT05276518|PROCEDURE|Closure of cesarean section incision|"After the delivery the first group will undergo Two Layer Uterine Closure:~Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.~The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa."
41294750|NCT01884285|DRUG|Part A: AZD8186 monotherapy|The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
41294751|NCT01884285|DRUG|Part B: AZD8186 monotherapy|Part B will be at a dose(s) and schedule(s) at or below from Part A
40766333|NCT05130281|BEHAVIORAL|Loss Framed|Participants lost points and badges for not completing sessions, homework, and skills on time and receive post session feedback via text message.
40766334|NCT05723263|BEHAVIORAL|Standard Pay-it-forward|400 men who have sex with men (MSM) at 4 clinics will be enrolled. The standard pay-it-forward arm will include free point-of-care gonorrhea testing, as well as a passive community engagement component (such as viewing postcards and materials written by others encouraging gonorrhea/chlamydia testing).
40766335|NCT05723263|BEHAVIORAL|Community Engaged Pay-it-forward|400 MSM at 4 clinics will be enrolled. The community engaged pay-it-forward arm will include free point-of-care gonorrhea testing, as well as an active community engagement component (such as multi-stakeholder co-creation activities to develop essential components of the intervention and implementation strategies; writing postcards; designing fans with stickers; sending out testing promotion messages on social media; and opportunity to donate to support others)
40964359|NCT05614505|DIETARY_SUPPLEMENT|Ready to use therapeutic foods|locally produced therapeutic foods
40964360|NCT01059084|DRUG|Valacyclovir|1000 mg tid
40964361|NCT00197639|DRUG|Ritonavir-boosted indinavir|
40964362|NCT03022136|OTHER|cold sensation method|Complete sensory loss to ice will be evaluated form anterior median line to posterior median line at the end of surgery.
40964363|NCT00002105|DRUG|Doxorubicin hydrochloride (liposomal)|
40964364|NCT00002105|DRUG|Bleomycin sulfate|
41294752|NCT01884285|DRUG|Part C1: Abiraterone acetate combination with AZD8186|Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
41294753|NCT01884285|DRUG|Part D1: AZD2014 combination with AZD8186|Dose \& schedule finding of AZD8186 in combination with AZD2014
41294754|NCT01884285|DRUG|Part D2 AZD2014 combination with AZD8186|Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
41456918|NCT02629640|OTHER|Blood or buccal sample|Codon-129 genotyping; storage for future research.
40766336|NCT05723263|OTHER|Control arm|400 MSM at 4 clinics will be enrolled. The control arm will include a fee-based point-of-care gonorrhea testing (approximately 20 USD per test) and no community engagement component
40964365|NCT00002105|DRUG|Vincristine sulfate|
40964366|NCT00662805|DRUG|Salmeterol/Fluticasone propionate|Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
40964367|NCT02091492|DRUG|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
40964368|NCT02091492|DRUG|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
40964369|NCT04223115|BEHAVIORAL|Digitalized CBT with phone coaching|Digitally delivered CBT intervention with weekly phone coaching
40964370|NCT04223115|OTHER|Psychoeducation about depression|Psychoeducational material about depression in a digitalized form
40964371|NCT00192569|DRUG|Pegylated Interferon alfa 2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
40964372|NCT00192569|DRUG|Ribavirin (HIV conifected patients only)|"* genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg)~* Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients"
40964373|NCT05666609|PROCEDURE|placement of non-cutting seton (silicone)|Treatment of Fistula in ano is conducted according to the institution's treatment guidelines. Silicon seton placement is conducted under general anesthesia. Identification of the FIA is secured by the insertion of a bulb-headed lacrimal probe, on which a silicon vessel loop is attached and pulled through the entire fistulous tract. In case of a perianal abscess, drainage and sphincter-sparing debridement is performed followed by secondary wound healing. The loop is ligated loosely outside the anus without any additional tension to the skin. Duration of placed seton is depending on group assignment and is set to either 4 or 12 weeks.
40964374|NCT00451308|PROCEDURE|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
40964375|NCT00451308|PROCEDURE|Induction of labor with foley balloon with 30cc|30cc of saline in foley
40964376|NCT01724918|DRUG|Lacosamide|
40964377|NCT05969145|PROCEDURE|application of thermophor|The experimental group will be given hot and cold application to the bladder
40964378|NCT00942253|OTHER|Dopamine Agonist and Exercise|Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.
40964379|NCT03991572|DEVICE|repeated transcranial magnetic stimulation with real coil|repeated transcranial magnetic stimulation with real coil is a noninvasive technique to activate and modify the activity of the neurons
40964380|NCT03991572|DEVICE|repeated transcranial magnetic stimulation with sham coil|repeated transcranial magnetic stimulation with sham coil is a placebo
40964381|NCT06436365|PROCEDURE|Locking expert intramedullary nail fixation|"the fracture was reduced to enable the insertion of the guide wire to restore the rotation, length, and angulation. Poller screws were used as control deformity by narrowing the medullary canal and were inserted on the deformity concave side between the nail and bone cortex. A ball-ended guidewire was placed through the entry point to the tibial canal and then to the tibial fracture site under the guidance of fluoroscopy. The guide wire should be inserted centrally within the distal segment on both lateral and anteroposterior views and be far about 1 to 0.5 centimeters from the ankle joint. Reamers with deep fluted and small diameters were used slowly to increase the diameter to reach 0.5 mm till the cortical chatter.~The nail was inserted by attachment of insertion device and locking of the proximal screw to the nail by directing its apex posteriorly. The nail insertion was done by flexing the knee to prevent any patellar impingement."
40964382|NCT06436365|PROCEDURE|Distal locked plate|Cobb dissector was used in creation extra-periosteal subcutaneous tunnel for gentle introduction of a proper plate which was determined by choosing appropriate size and level guided by imaging which helped in prevention of any periosteal damage. Manual closed reduction was performed using the percutaneous clamps. Distal screws were positioned as the following, one was inserted above the medial malleolus, another one was inserted right and below the fracture, and the other screws were inserted to help in anatomical plate positioning. By reduction preservation, proximal screws were inserted by small incisions which was followed by insertion of the remained distal screws.
40964383|NCT05306275|DRUG|CSL312|Factor XIIa antagonist monoclonal antibody for subcutaneous use
40964384|NCT04454294|OTHER|Control|"Common Process Steps:~1. Informed consent forms will be signed by those who wish to take part in the research.~2. The form in which individual characteristics are questioned will be filled.~3. Hands will be washed, gloves will be worn.~4. Before the procedure, body temperature, heart rate, respiratory rate, blood pressure, oxygen saturation and bleeding amount will be recorded.~5. Drains will be kept parallel to the ground and upright.~6. Drainage hoses will not be bent and in-bed position will be provided in accordance with gravity.~7. It will be ensured that all connections between the chest tubes and drainage unit are tight and secure.~8. Dressings of the chest and mediastinum drains will be fixed on the patient's skin, so as not to interfere with drainage.~9. To prevent the tubes from coming out, they will be fixed to the patient bed.~Vital signs, Sp02 and bleeding amount will be recorded every hour for 6 hours after surgery"
41137101|NCT04419207|DIAGNOSTIC_TEST|Breath test|Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).
41137102|NCT05300672|DRUG|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
41456919|NCT02629640|OTHER|Post mortem examination|Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
41456920|NCT01788709|OTHER|preparation cleaning solution|
40766337|NCT06514898|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|"After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.~up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment)"
40766338|NCT06514898|BIOLOGICAL|TTRNA-xALT|All participants will receive a single infusion of T-cells.
40766339|NCT06514898|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #5, #7 and #9.
41456921|NCT04075916|DRUG|Epclusa|All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.
40766340|NCT06514898|BIOLOGICAL|autologous HSCs|All participants will receive a single intravenous infusion of autologous HSCs.
41137103|NCT00895596|DRUG|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
41294755|NCT01884285|DRUG|Part C2: Abiraterone acetate combination with AZD8186|Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
41294756|NCT02678988|DEVICE|AI-1000 G2|The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
40964385|NCT04454294|OTHER|Experimental Group (Absorption Group)|"1. Common process steps~2. Appropriate negative pressure monitoring system of the patient, who is admitted to the intensive care unit with underwater drainage system, will be established.~   * The suction control room combined with the vacuum regulator will be filled with sterile distilled water up to the specified level (20 cm H2O).~  * From the vacuum regulator, the drain or drains will be connected tightly and by preventing the crimping, from the aspirator receptor hoses.~3. Suction will begin with a low level and gradually increase the suction until a slight bubble is noticed in the suction control room.~4. Suction pressure will be maintained between 5 and 15 kPa (kilopascals) or 10-20 cm H20.~5. The application will continue without interruption until the patient's drain need and the doctor's request is ended.~6. During the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
41294757|NCT02678988|DEVICE|PFS-NSD|The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.
41294758|NCT02678988|DRUG|Tocilizumab|Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
41294759|NCT06395142|OTHER|pedal walking|Pedal walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation. A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during pedal walking in stroke participants.
41456922|NCT02450058|DRUG|5-fluorouracil|600 mg/m2 intravenously on day 1, every 21 days for six cycles
41456923|NCT02450058|DRUG|epirubicin|60 mg/m2 intravenously on day 1, every 21 days for six cyles
40766341|NCT06514898|DRUG|Pembrolizumab|Participants will receive PD-1 blockade IV starting with ACT continuing for up to 2 years as long as tolerable and without disease progression.
40766342|NCT06638827|PROCEDURE|Thoracic Sympathectomy|"Bilateral thoracoscopic sympathectomy will be performed with general anesthesia, using single lung ventilation and monopolar cautery for transection of the sympathetic chain.~Persons with PFH who underwent the BTS were classified into three groups, depending the level of transaction of sympathetic chain:~1. transection at the level from the second to the forth thoracic sympathetic ganglion (T2- T4);~2. transection at the level from the third to the forth thoracic sympathetic ganglion (T3-T4)~3. transection at the level from the second to the third thoracic sympathetic ganglion (T2-T3).."
41137104|NCT04895774|OTHER|Probiotic strains|Fresh stools will be cultured in vitro in fermenters with adjunction of probiotic strains
41137105|NCT04895774|OTHER|Polyphenols|Fresh stools will be cultured in vitro in fermenters with adjunction of polyphenols
41294760|NCT06395142|OTHER|visual-deprivation walking|visual-deprivation walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation.A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during visual-deprivation walking in stroke participants.
41294761|NCT04296136|OTHER|Advance Care Planning Discussion|Goals of care discussion with patient, documentation with electronic health record note and advance care planning billing. This will also include: pharmacy review of medications, case management review, and coding specialist review.
41294762|NCT06152263|OTHER|Compare color information and mucosal microvascular density|To investigate the association between the color and mucosal microvascular density of CAG and EGC using linked color imaging.
41456924|NCT02450058|DRUG|cyclophosphamide|600 mg/m2, intravenously on day 1, every 21 days for six cycles
41456925|NCT02450058|DRUG|epirubicin|90 mg/m2 on day 1, every 21 days for four cycles
41456926|NCT02450058|DRUG|paclitaxel|175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
41456927|NCT02761720|OTHER|No Intervention|
41456928|NCT02119936|BEHAVIORAL|Heart Rate Variability Biofeedback Tool|The Heart Rate Variability Biofeedback tool (emWave 2) will capture heart rate variability (HRV) before and after deep breathing exercises are used among participants. Participants will be able to visualize changes in their HRV and then fill-out self-reported anxiety measures to determine if the breathing exercises and visualization of HRV affected anxiety.
41456929|NCT03911115|OTHER|Food preference questionnaire|This is an online questionnaire administrated once to the participants, to assess food preferences after bariatric surgery. The investigating team will also collect data on the type of surgery, anthropometry, nutrition, taste, smell, disgust and intolerance as well as sociodemographic data.
41456930|NCT00613730|DRUG|Gemcitabine|Intravenous administration
41456931|NCT00613730|DRUG|panitumumab|Intravenous administration
40766343|NCT06644443|BIOLOGICAL|BCMA-GPRC5D CAR-T cells|patient was subjected to 2-5×10\^6 BCMA-GPRC5D CAR-T cells/kg
40766344|NCT06637800|DEVICE|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)|The Seraph 100 is part of the Seraph platform technology that was developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens, bacteria, viruses, fungus, and other sepsis mediators from the bloodstream. In addition, it has been demonstrated that Seraph 100 is also capable of removing circulating tumor cells from the whole blood.
40766345|NCT06643715|DEVICE|PANDA PLUS|Using the PANDA PLUS model to assist in image interpretation, radiologists are provided with the model's output classification-non-PDAC, PDAC, or normal-alongside the initial CT image assessment. The radiologists then integrate the information from both the PANDA PLUS output and the original image interpretation to formulate the final report.
40766346|NCT06640660|DEVICE|Mindlenses Professional|MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
40766347|NCT06640660|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
40766348|NCT06445595|OTHER|patients with traumatic brain injury|Patients will be contacted by phone
40766349|NCT04632654|BEHAVIORAL|A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)|A total of 7 weekly intervention sessions will occur in a period of 6 weeks. Week 0 is a setup session conducted at the participant's home, including equipment set up, safety instruction, personalized exergame prescription development, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 1 and 2 are coaching sessions delivered by the interventionist using the FaceTime application in iPad, including exergame minutes and prescription review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Week 3 is a progress session conducted at the participant's home. The personalized exergame prescription will be adjusted. This session also will include exergame minutes review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 4 and 5 are the same as weeks 1 and 2. Week 6 is the final session. Exergame platform will be picked up at the participant's home.
40766350|NCT05119335|DRUG|Oral NKT2152|Oral HIF2α inhibitor
40766351|NCT05763641|PROCEDURE|Target Axillary Dissection|TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection
40766352|NCT06643156|DRUG|GP681 10mg/20mg/40mg|0.5/1/2×20mg power for oral suspension taken orally
40766353|NCT06638190|OTHER|100% Orange juice|250 mL of commercial 100% orange juice containing 25 g of total sugars (glucose, fructose, saccharose).
40766354|NCT06638190|OTHER|50% Orange juice|250 mL of 50% diluted orange juice (100% orange juice) plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
40766355|NCT06638190|OTHER|0% Orange juice|250 mL of water plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
40766356|NCT06638190|OTHER|Glucose|250 mL of water with 25 g of glucose. To determine the glycemic index of the different drinks and to characterize the glucose and insuline response of the participants
40766357|NCT06638190|OTHER|100% Orange juice Rep|Repetition of the 100% orange juice intervention
40766358|NCT06638190|OTHER|0% Orange juice Rep|Repetition of the 0% orange juice intervention
40766359|NCT06099405|BEHAVIORAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
40766360|NCT06099405|BEHAVIORAL|Traditional yoga|Participants will perform controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
40766361|NCT05371379|BIOLOGICAL|CM338 Injection|A humanized monoclonal antibody.
41456932|NCT04584073|PROCEDURE|Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application|Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.
41137106|NCT04895774|OTHER|Fibers|Fresh stools will be cultured in vitro in fermenters with adjunction of fibers
41137107|NCT05630859|BIOLOGICAL|NgG low dose investigational vaccine|Two doses of NgG low dose investigational vaccine, administered intramuscularly.
41137108|NCT05630859|BIOLOGICAL|NgG medium dose investigational vaccine|Two doses of NgG medium dose investigational vaccine, administered intramuscularly.
41456933|NCT00697918|DRUG|RWJ-333369|100 mg to 400 mg twice daily
40964386|NCT04454294|OTHER|Experimental Group (Milking Group)|"1. Common process steps will be applied~2. Operation will start from the area near the drain entrance point~3. Latex tube will be folded into 12 cm long pieces and will be gripped with two hands~4. The procedure will be repeated 3 times by compressing the parts gripped by the nurse hand.~5. This process will be repeated in the distal part.~6. After the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
40964387|NCT01063868|DRUG|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
40964388|NCT01063868|DRUG|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
40964389|NCT01619423|DRUG|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
40964390|NCT01619423|DRUG|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
40964391|NCT01619423|DRUG|PledOx (10 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
40964392|NCT01619423|DRUG|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
40964393|NCT00418015|PROCEDURE|Blood Draw|Blood for OPRM1 analysis
41137109|NCT05630859|BIOLOGICAL|NgG high dose investigational vaccine|Two doses of NgG high dose investigational vaccine, administered intramuscularly.
41137110|NCT05630859|BIOLOGICAL|Placebo|Two doses of placebo, administered intramuscularly.
41137111|NCT05630859|BIOLOGICAL|NgG HTD investigational vaccine|Two doses of NgG HTD investigational vaccine, administered intramuscularly.
41137112|NCT05630859|BIOLOGICAL|NgG below HTD investigational vaccine|Two doses of NgG below HTD investigational vaccine, administered intramuscularly.
41137113|NCT02039401|BIOLOGICAL|VM202|
41137114|NCT03676088|PROCEDURE|root coverage|recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group
41137115|NCT01332552|DRUG|GSK2485852 70 mg|single dose
41294763|NCT05664685|DRUG|Optimized bismuth quadruple therapy|Scheme that have high dosage of amoxicillin, metronidazole and omeprazole, with bismuth. The rationale of this scheme is that in Chile, amoxicillin resistance is low, clinical metronidazole is low in the doses used and the high doses ob Proton Pump Inhibitor enhanced the antimicrobial drugs
41456934|NCT04305535|DIETARY_SUPPLEMENT|Peptidic+Probiotic|"Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics~* Bifidobacterium animalis subsp. lactis BPL1,~* Lactobacillus rhamnosus BPL15,~* Lactobacillus rhamnosus CNCM i-4036~* Bifidobacterium longum ES1"
40964394|NCT04524910|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
40964395|NCT00743483|DRUG|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
40964396|NCT05618197|OTHER|Passive heating|\~3x per week of 1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C) sessions over a period of 6 weeks.
40964397|NCT04370405|DRUG|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
41137116|NCT01332552|DRUG|GSK2485852 420 mg|single dose
41137117|NCT01332552|DRUG|placebo|single dose
41137118|NCT01332552|DRUG|placebo|Repeat dose, once daily for 3 days
41137119|NCT01332552|DRUG|GSK2485852 420 mg|Repeat dose, twice daily for 3 days
41137120|NCT01332552|DRUG|GSK2485852 420 mg|Repeat dose, TIDfor 3 days
41137121|NCT01332552|DRUG|GSK2485852 630 mg|Repeat dose, twice daily for 3 days
41137122|NCT01332552|DRUG|GSK2485852 70 mg + Ritonavir 100mg|single dose, day 1
41137123|NCT01332552|DRUG|GSK2485852 210 mg + Ritonavir 100mg|single dose, day 1
41137124|NCT01332552|DRUG|GSK2485852 210 mg +Ritonavir 100mg|single dose daily for 3 days
41137125|NCT01617811|PROCEDURE|epidural anesthesia and analgesia|"A thoracic epidural catheter (T8-10) was placed in group E. A bolus of 8ml 1% lidocaine with 0.375% ropivacaine was administered 15min before skin incision, followed by 5-8 ml/hr infusion during surgery in group E.~Postoperative analgesia by PCEA in group E (concentration: 0.1% ropivacaine + 0.1μg/ml sufentanil, loading dose: 4ml, infusion rate: 8ml/hr, bolus: 4ml, 1hr limit: 16ml) and lasting for 48hr and PCIA in group G (concentration: 1μg/ml sufentanil, loading dose: 4ml, bolus: 2ml, 4hr limit: 30ml).~Both group received general anesthesia maintaining with 1-2% end tidal sevoflurane together with TCI of propofol (target plasma concentration, 2-3µg/ml), continuous infusion of remifentanil (0.10 - 0.20 μg/kg/min) and cis-atracurium intermittently as needed."
41137126|NCT05643521|OTHER|Dietary composition of macronutrients and calories|Carbohydrate restriction
41137127|NCT03595670|OTHER|standardized questionnaires|standardized questionnaires concerning the perception
41137128|NCT03595670|OTHER|interview|Semi-directive interviews will be conducted. The purpose of this approach is to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inscription in the socio-cultural condition of the patients.
41137129|NCT00927966|DRUG|RAD001|Taken orally once a day.
41137130|NCT00927966|DRUG|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
41294764|NCT05664685|DRUG|Control|Standard eradication therapy using omeprazole, clarithromycin and amoxicillin
41294765|NCT01618981|PROCEDURE|pace make active/inactive cross over|
41294766|NCT05303857|DRUG|Semaglutide Pen Injector|Injection of the semaglutide once weekly
41294767|NCT05303857|DRUG|Placebo|Injection of placebo once weekly
40964398|NCT04712994|OTHER|PrEP Optimization Interventions|A bundle of strategies (video-based PrEP counselling, HIV Self-Testing \[HIVST\] for women undergoing repeat HIV testing, and optimized PrEP delivery and prescription processes) will be implemented in the intervention group.
40964399|NCT05378880|BEHAVIORAL|Behavioural intervention bundle to optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission|The study teams will work with communities and authorities to develop, implement and evaluate a multifaceted intervention bundle that will optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission, by targeting the general public (including farmers) and medicine stores.
40964400|NCT00459628|RADIATION|Conventional radiotherapy|Radiation treatment delivered by conventional linear accelerator using matching fields
40964401|NCT00459628|RADIATION|Tomotherapy|CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
40964402|NCT00120731|DRUG|Potassium Citrate|
40964403|NCT00120731|DRUG|Acetazolamide|
40964404|NCT00120731|BEHAVIORAL|Diet low in oxalate and purines|
40964405|NCT01393496|OTHER|red blood cell transfusion|"Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants"
40964406|NCT01393496|OTHER|red blood cell transfusion|"Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants"
40964407|NCT03379168|DEVICE|Microfragmented Adipose Tissue (Lipogems)|Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections.
40964408|NCT03379168|DRUG|Corticosteroid injection|Cortisone is a standard of care injection to reduce joint inflammation.
40964409|NCT03379168|DRUG|Saline|Sterile saline injection will act as a placebo group.
40964410|NCT04998110|OTHER|Ambulatory Supportive Care|Ambulatory supportive care visits monthly for six months - a monthly visit with an ambulatory palliative care provider educated in kidney disease
40964411|NCT00523562|OTHER|diet intervention|controlled hypercaloric high fructose, high fat, or high fat/high protein diet
40964412|NCT04238702|DRUG|Empagliflozin 10 MG|Empagliflozin 10 MG 7 days intervention period
40964413|NCT04238702|DRUG|Losartan 50Mg Tab|Losartan 50 MG 7 days intervention period
40964414|NCT04238702|OTHER|Placebo|Placebo 7 days intervention period
40964415|NCT06332235|DRUG|Silodosin 8 mg|Dosing schedule: Oral, once daily
40964416|NCT00119106|DRUG|Tenofovir disoproxil|Antiretroviral
40964417|NCT00119106|DRUG|Placebo|Placebo
40964418|NCT04578431|DIETARY_SUPPLEMENT|Artificial sweeteners (acesulfame-potassium, sucralose, saccharine, cyclamate)|The intervention is found in light products ingested by millions of people on a daily basis worldwide
40964419|NCT03743623|DEVICE|Neurocytotron|Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.
40964420|NCT03743623|DEVICE|Placebo|Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field
40964421|NCT01748669|DIETARY_SUPPLEMENT|Garlic oil|Oral administration
40964422|NCT04560660|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
41294768|NCT04050904|DEVICE|ExpHeart|ExpHeart is composed of an Information System (web application) and an algorithm, the Expert System, embedded on the Information System. The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment. The Expert System is based on the analysis of a continuously updated clinical database integrating the patient's electronic medical record (managed by the Information System). The Expert System will generate prescription recommendations directed to the treating investigator through the Information System.
41294769|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Acacia Gum-MMST Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Acacia Gum 336.1 mg/capsule; Monomethylsilanetriol 34.9 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
40964423|NCT04560660|DRUG|Midazolam|FDA approved sedative medication with dissociative effects.
40964424|NCT05845216|DEVICE|ACTIVE Transcranial photobiomodulation (tPBM)|fMRI records before and after ACTIVE Transcranial photobiomodulation (tPBM)
40964425|NCT05845216|DEVICE|SHAM Transcranial photobiomodulation (tPBM)|fMRI records before and after SHAM Transcranial photobiomodulation (tPBM)
40964426|NCT04357132|OTHER|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora Application
40964427|NCT04357132|OTHER|VR-Distraction|Participants will be instructed to use one of four applications
40964428|NCT03959943|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve branch of the lateral cutaneous femoral nerve (LCFN) was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
40964429|NCT06298591|PROCEDURE|co2 laser|laser
40964430|NCT02164500|DRUG|Ruxolitinib|
40964431|NCT01935297|BEHAVIORAL|Exercise|endurance and resistance exercise 3x/week for 8 weeks
40964432|NCT00816530|DEVICE|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density \> 50% is confirmed by routine digital screening mammography, ABUS will be performed.
40964433|NCT04848298|BEHAVIORAL|mHealth Intervention|"The Mobile Health Arm will receive standard of care including tailored prescription of physical activity as well as the mobile health intervention, which will have the following features:~* Goal setting for frequency and duration of exercise sessions~* Graphic feedback and reinforcement with educational and motivational messages tailored to user's exercise adherence.~* Problem-solving support~* Library with educational tips and information regarding physical exercise."
40964434|NCT02430311|DRUG|Olaparib|Tablet-150mg, Oral
40964435|NCT02430311|DRUG|Paclitaxel|Injection
40964436|NCT02430311|DRUG|Olaparib|Tablet-100mg, Oral
40964437|NCT02598804|OTHER|5 educational workshop|
41137131|NCT05897905|BEHAVIORAL|Personalised, holistic follow-up appointments underpinned by self determination theory|"Appointment 1 (two weeks after discharge):~* Address participants knowledge gaps as regards their stroke, medication and secondary prevention.~* Detailed biopsychosocial review.~* Understand participant priorities and jointly set goals.~* Agreeing onward referrals if needed.~* Written summary sent to GP with copy to participant.~Appointment 2 (six weeks):~* Review priorities identified in post stroke review checklist.~* Review goals and plans from first appointment.~* Address any new or persistent information gaps.~* Review hidden impairments that may be impacting on return to work, activities of daily living, relationships or general well-being.~* Agreeing onward referrals and action plan.~* Written summary and plan sent to GP."
41137132|NCT01705756|DRUG|Kineret|Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
41456935|NCT04305535|DIETARY_SUPPLEMENT|Peptidic+Placebo|Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo
41456936|NCT04305535|DIETARY_SUPPLEMENT|Polymeric+Placebo|Polymeric oral nutritional supplement and a placebo
41456937|NCT02614196|DRUG|Galcanezumab|Administered SC
41456938|NCT02614196|DRUG|Placebo|Administered SC
40964438|NCT02598804|OTHER|written information booklet|
40766365|NCT06641583|BEHAVIORAL|LEGO|"The LEGO Therapy intervention in this clinical trial is designed to enhance social skills in children with high-functioning Autism Spectrum Disorder (ASD). The intervention involves the following components:~Group Sessions: The therapy will be conducted in small groups of three children of the same age (10-14 years) with a diagnosis of high-functioning ASD. The sessions are designed to foster collaboration and social interaction between the participants.~Duration: The intervention will last for 3 months, consisting of 12 sessions, with each session lasting 90 minutes. Sessions will take place once a week at the IRCCS Fondazione Stella Maris.~Supervision: The groups will be supervised by trained professionals specializing in neurodevelopmental disorders, ensuring that the therapy is structured and supportive of each child\&amp;amp;amp;#39;s individual needs.~Therapy Structure: During the sessions, children will engage in LEGO-based tasks, where they collaborate to build LEGO models."
40766366|NCT06641583|OTHER|Controllo|This group will also consist of children aged 10-14 diagnosed with high-functioning ASD. However, these children will not receive LEGO therapy. Instead, they will continue their usual treatments in their local settings without participating in the LEGO therapy sessions. This group\&#39;s outcomes will be compared with the experimental group to assess the effectiveness of LEGO therapy.
40766367|NCT04487080|DRUG|Amivantamab|Participants will receive amivantamab intravenously.
40766368|NCT04487080|DRUG|Osimertinib|Participants will receive osimertinib capsules orally.
40766369|NCT04487080|DRUG|Lazertinib|Participants will receive lazertinib tablets orally.
40766370|NCT04487080|DRUG|Placebo|Participants will receive matching placebo orally.
40766371|NCT06411938|OTHER|Self-collection of vaginal swabs|Women will collect vaginal swabs for HPV testing, then undergo standard of care screening for cervical cancer
40766372|NCT05018585|BIOLOGICAL|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
40766373|NCT05018585|DIETARY_SUPPLEMENT|Colecalciferol 2000 IU|Colecalciferol (vitamin D3) 2000 IU (equivalent to 50 microgram vitamin D3).
40766374|NCT05018585|BIOLOGICAL|Placebo|Placebo for Diamyd, Alhydrogel® only
40766375|NCT01245608|DRUG|Polypill|Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
40766378|NCT05728502|DRUG|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
40766379|NCT05728502|DRUG|Standard of Care (SoC)|Dosage at the discretion of the treating physician.
40766380|NCT06405412|OTHER|MUST malnutrition score|MUST malnutrition score
40766381|NCT03738228|DRUG|Atezolizumab|Given IV
40766382|NCT03738228|RADIATION|Brachytherapy|Undergo standard of care image guided brachytherapy
40766383|NCT03738228|DRUG|Cisplatin|Given IV
40766384|NCT03738228|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
40766385|NCT04716946|DRUG|Durvalumab|Patients will receive durvalumab 1500mg durvalumab via IV infusion over 1 hour, once every 4 weeks (Q4W) for up to a maximum of 6 months (up to 6 doses/cycles) unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
40766386|NCT04716946|RADIATION|Stereotactic Body Radiation Therapy|Radiation therapy will be performed with external beam ionizing radiation in accordance with institutional standard practice. 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist.
40964439|NCT01741597|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
40964440|NCT01741597|OTHER|pharmacological study|Correlative studies
40964441|NCT01741597|BIOLOGICAL|tumor-homing peptide iRGD|Undergo tumor-homing peptide iRGD DCE-MRI
40964442|NCT04276571|DEVICE|exergames with GRAIL virtual immersive reality environment|The participants will perform exergames on GRAIL immersive virtual reality to improve balance (e.g. load shifts, exercises with adaptations to motor perturbations). GRAIL can provide proprioceptive and visual feedback to participants.
40964443|NCT01409330|DIETARY_SUPPLEMENT|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
40964444|NCT05043129|BIOLOGICAL|Biological/Vaccine: SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
40964445|NCT04352712|OTHER|blood sampling|blood sampling
41456939|NCT01257451|DRUG|Vildagliptin|vildagliptin 50mg bid
41456940|NCT01257451|DRUG|Placebo|Placebo 50mg bid
40964446|NCT06046885|DEVICE|Neuromuscular electrical stimulation|"As regards the electrodes position, one proximal electrode on the gastrocnemius, which will be located below the popliteal fossa (at least 5cm below it) for a better position on the muscle belly; and one distal electrode, located at least 10 cm from the calcaneus.~This protocol will last 20 minutes per session. The placement of the electrodes is as mentioned above, and the parameters to be used will be the following: a stimulation frequency between 35 and 80Hz, a pulse width between 150 and 200 µs, the intensity will be established individually using an intensity that generate a visible contraction of maximum intensity without generating pain. The duration of the contraction will be of 6 seconds with 30 seconds of rest."
40964447|NCT04927260|DRUG|Patient treated by Avapritinib in real life|"The patients included are treated with Avapritinib as part of their care. There is no change in treatment associated with this study.~Patients must regularly complete various questionnaires: FACT-G, FACT-COG, and a neuropsychiatrist or a trained physician will give them the MoCA."
40964448|NCT01969968|OTHER|Lipophilic Organic Polluants dosage|Urinary, blood and fat dosage of Lipophilic Organic Polluants
40964449|NCT05574790|OTHER|annual follow up|Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality
40964450|NCT02062021|OTHER|No intervention|
40964451|NCT04720469|DEVICE|MRgFUS thalamotomy|Ablation of untreated thalamus using focused ultrasound to abate tremor.
40964452|NCT03621397|DEVICE|brainHQ by Posit Science|This is an online cognitive training program. It consists of 29 online exercises that work out attention, brain speed, memory, people skills, navigation, and intelligence. The current study will focus on the following exercises: attention, brain speed (e.g., processing speed), executive function, and memory.
40964453|NCT01749397|DRUG|Floxuridine|Given IP
40964454|NCT01749397|OTHER|Laboratory Biomarker Analysis|Correlative studies
40964455|NCT01749397|OTHER|Pharmacological Study|Correlative studies
40964456|NCT01749397|DRUG|Veliparib|Given IV
40964457|NCT00099008|DIETARY_SUPPLEMENT|Genistein|oral Genistein twice daily on days 1-84
40964458|NCT00099008|DIETARY_SUPPLEMENT|Placebo|oral Placebo twice daily on days 1-84
40964459|NCT04575116|DRUG|Tafamidis free acid tablet|12.2 mg tafamidis free acid tablet
40964460|NCT04575116|DRUG|Tafamidis meglumine capsule|20 mg tafamidis meglumine soft gelatin capsule
40964461|NCT03335098|DRUG|Bortezomib|Six 4-week cycles
40964462|NCT00963937|DRUG|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
40964463|NCT00963937|DRUG|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
40964464|NCT00963937|DRUG|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
40964465|NCT01897844|DRUG|ITF2984 (100, 2000, 3000 mcg bid)|
40964466|NCT01897844|DRUG|Placebo|
40964467|NCT05729646|DRUG|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
40964468|NCT05729646|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
40964469|NCT05729646|DRUG|S1|S-1 orally intake as perioperative chemotherapy
40964470|NCT05566743|DRUG|Capecitabine|maintenance capecitabine after 4 months of FOLFRINOX
40964471|NCT05566743|OTHER|follow up|follow up after 4 months of FOLFRINOX
40964472|NCT00585247|DRUG|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
40964473|NCT00585247|OTHER|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
40964474|NCT04340778|DRUG|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
40964475|NCT04340778|DRUG|Lidocaine-prilocaine Cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
40964476|NCT04340778|DRUG|placebo|inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
41294770|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Malto-OSA Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Maltodextrin 311.4 mg/capsule; Silicic acid 35.6 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
40964477|NCT02211079|DRUG|JNJ-54861911|JNJ-54861911, 50 mg (2\*25 mg tablets) orally once daily from Day 2 to Day 9.
40964478|NCT02211079|DRUG|Caffeine|Single oral dose of caffeine 100 mg (2\*50 mg tablets), on Day 1, 2, and 9.
40964479|NCT02211079|DRUG|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
40964480|NCT02211079|DRUG|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
40964481|NCT05989750|DEVICE|Ultrasonic scaler|Ultrasonic scaling for subgingival cleaning every 6 months for 2 years according to the manufacturer's procedures.
40964482|NCT05989750|DEVICE|Air-Flow Prophylaxis Master|AIR-FLOW PROPHYLAXIS MASTER with erythritol powder (AIR FLOW Powder Plus) will be used every month for 2 years for subgingival cleaning according to the manufacturer's procedures.
40964483|NCT05780658|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
40964484|NCT01965587|PROCEDURE|novasure mirena IUS combined|novasure mirena IUS combined
40964485|NCT03799081|PROCEDURE|Fetoscopy|Fetoscopy is a procedure that enables viewing of the fetus through use of a hysteroscope
40766387|NCT05715021|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
40964486|NCT03228264|DEVICE|teleSLT|The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
40964487|NCT03228264|DEVICE|teleCT|For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
40964488|NCT04911881|DRUG|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
40964489|NCT04007978|GENETIC|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
40964490|NCT02764060|DEVICE|Tongue scraper|The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
40964491|NCT02764060|DEVICE|Toothbrush|The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
40964492|NCT02587234|DEVICE|peripheral nerve stimulation|Non-invasive stimulation of median, ulnar and radial nerves
40964493|NCT02946944|DRUG|Sildenafil/apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \\ g + 10 mg apixaban 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
40964494|NCT02946944|DRUG|apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
41294771|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Collagen Booster|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 99.9646 g/100 ml; Silicic acid 23.65 mg/100 ml; Monomethylsilanetriol 11.75 mg/100 ml. Silicon content per dose: 10.4 mg.
40964495|NCT02097004|BIOLOGICAL|Peginterferon alfa-2a|once weekly 180 μg subcutaneous injection for 48 weeks
40964496|NCT02097004|BIOLOGICAL|HBV vaccination|1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
40964497|NCT02097004|DRUG|Entecavir|Continue Entecavir(0.5mg) for 100 weeks
40964498|NCT06237829|BEHAVIORAL|Single bump acuity|Investigators will design bumps of varying heights, spacings, diameters, and bump shapes (rounded top, flat top, angled top) which give a precise amount of mechanical stimulus to the finger. Subjects will be asked if they could notice a bump on the surface and instructed to make the judgment quickly (\<2 seconds). A psychometric curve, with a standard braille bump serving as the positive, \~100% success rate control, will be constructed
40964499|NCT06237829|BEHAVIORAL|Optimal spacing between bumps|Investigators will fabricate and characterize two bumps of varying widths (ranging from 150 μm to 3 times the bump width, based on fabrication resolution available in commercial tactile aid machines). Subjects will be asked to run their finger across the two bumps (two bumps always form a line, so investigators do not need to ask subjects to orient their fingers) quickly and asked if they felt one bump or two.
40964500|NCT06237829|BEHAVIORAL|Improving signal from a single bump with designer materials|"Investigators will coat single bumps with our designer materials (with alkyl and amino functional groups) to improve the mechanical stimuli from a single bump. Subjects will then be asked to perform a similar experiment as the single bump acuity test and the optimal spacing between bumps test. (can you notice the bump? or did you feel one or two bumps)."
41137133|NCT04255498|DRUG|Etanercept|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
40766388|NCT06644027|DEVICE|Jefcare Sterile Medical Sheets|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
40964501|NCT04031391|OTHER|Physical activity|"The intervention group: engaged in a therapeutic physical activity program involving low-intensity exercise, strength and balance work for 2 days a week over a 12-week period, with each session lasting 90 minutes. Both the intervention group and the control group separately completed the various baseline surveys which were part of the study. Once the intervention was over, they answered them again, also separately.~The classes were led by an experienced physiotherapist who followed the physical exercise guidelines established by the American College of Sports Medicine (ACSM), although the intensity of the exercises was adapted to the participants' tolerance levels"
40964502|NCT02710396|DRUG|Pembrolizumab|"Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks."
40766389|NCT06644027|DEVICE|Molicare Premium Bed Mat|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
40964503|NCT02710396|DRUG|Carboplatin|Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
40964504|NCT02710396|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
40964505|NCT02710396|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
40964506|NCT05841485|DIAGNOSTIC_TEST|Assessment of coronary microvascular dysfunction using intracoronary pressure-temperature wire|The primary assessment method in this study is the measurement of coronary microvascular dysfunction using a pressure-temperature wire to determine coronary flow reserve (CFR) and index of microvascular resistance (IMR).
41456941|NCT06144398|DEVICE|Single Use Bronchoscope|The interventional procedure is performed with a single use bronchoscope.
40964507|NCT06091267|DRUG|IV Decitabine|The subjects will receive decitabine 20 mg/m\^2 IV daily × 5 days in 28-day cycles.
40964508|NCT06091267|DRUG|Decitabine and cedazuridine|subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles.
41137134|NCT04255498|DRUG|Mifepristone|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
41294772|NCT05116982|DIETARY_SUPPLEMENT|Placebo|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 100 ml.
40766390|NCT06368427|DRUG|budesonide / glycopyrronium / formoterol|"Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension.~The COnCORD study is an observational study that will be conducted in a real-life setting in Romania and is not designed to evaluate medicinal products given according to a specific randomised schedule. Treatment with BGF MDI treatment prescribed as per current practice, according to the SmPC and local market reimbursement criteria"
40766391|NCT05309226|OTHER|Cannabis use in pregnancy or cannabis exposure in utero|Cannabis-related product use in pregnancy. Cannabis-related products will include all forms (e.g., dry flower, edibles, extracts, etc.) and formats of consumption (e.g., joint, bong, capsule, tincture, etc.).
40766392|NCT06629103|DIETARY_SUPPLEMENT|life's Omega 1035DS|A natural triglyceride derived from microalgae with minimum 365 mg DHA, minimum 100 mg EPA, and minimum 520 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
40766393|NCT06629103|DIETARY_SUPPLEMENT|Fish Oil|Commercially available fish oil product MEG-3 1812 TG with a minimum 100 mg DHA/capsule, minimum 160 mg EPA/capsule, and minimum 300 mg/g DHA+EPA. Participants receive 600mg/d of omega-3 fatty acids from the fish oil.
40766394|NCT06629103|OTHER|Placebo|The placebo capsules will be a mixture of corn and soybean oils. Participants receive 600mg/d of omega-3 fatty acids from the corn/soy placebo.
40964509|NCT06091267|DRUG|only Decitabine and cedazuridine|subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles, until disease progression, unacceptable toxicity, or the subject/investigator decides that the subject should discontinue treatment or withdraw from the trial.
41137135|NCT01962597|OTHER|aerobic exercise|
41294773|NCT03268304|OTHER|VR-based training including AO and MI|Virtual Reality-based training intervention including Action Observation and Motor Imagery using the YouGrabber® training device
41294774|NCT04592276|DIETARY_SUPPLEMENT|PS128|Participants took two capsules with PS128 after dinner for 30 days.
41456942|NCT06144398|DEVICE|Standard Bronchoscope|The interventional procedure is performed with a standard bronchoscope.
41456943|NCT04727554|DRUG|AMG 994|Administered as an intravenous (IV) infusion.
41137136|NCT01962597|OTHER|resistance training|
41137137|NCT00983294|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
41137138|NCT00983294|DRUG|Azithromycin|Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
41456944|NCT04727554|DRUG|AMG 404|Administered as an intravenous (IV) infusion.
40964510|NCT02367937|DRUG|PRC-4016 (icosabutate)|"Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description"
40964511|NCT03310775|BEHAVIORAL|Parent-assisted social skills training program for young adult with ASD|The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
40964512|NCT01007773|DRUG|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
40964513|NCT01007773|DRUG|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP \< 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
40964514|NCT01007773|DRUG|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
40964515|NCT01007773|DRUG|Propofol|Propofol will be titrated to an ICP \< 20 mm Hg until achievement of sustained ICP control.
40964516|NCT04356391|PROCEDURE|Connective Tissue Graft Technique|For the sites receiving the control technique (Connective Tissue Graft), the technique described by Langer B. and Langer L. will be started with a sulcular incision followed by a partial thickness flap. A CTG is then harvested according to the technique described by Bruno, the first incision is perpendicular to the 2nd premolar and 1st molar and is 2-3mm apical to their gingival margin as wide as the recipient site, followed by a second incision parallel to the for mentioned teeth, 1-2mm apical to the first incision, then the CTG is raised by periosteal elevator and released from apical and lateral attachments by sharp incision when needed. The graft is then prepared to have a homogenous thickness of 1.5-2mm. The donor CTG is stabilized to the underlying connective tissue interproximally using 4-0 Vicryl sutures. The recipient flap is repositioned coronally, to cover as much as possible of the graft with no tension, 2mm coronal to the CEJ, then sutured with 4-0 Vicryl sutures.
40964517|NCT04356391|PROCEDURE|Pinhole Surgical Technique|For the sites receiving the test technique (Chao Pinhole Surgical Technique) the surgery starts with a small pinhole opening in the alveolar mucosa apical to the mucogingival junction of the affected tooth, the flap is then undermined using special instruments to create a full thickness pouch, followed by extending the pouch horizontally and coronally to undermined the adjacent papilla without incising it and free the flap for its coronal displacement. Then multiple 2x12mm strips of collagen resorbable membrane material (Bio-Gide, Geistlich Pharma AG) are packed under the papilla to secure the flap in a coronal direction. Gentle pressure is applied for 5 minutes to minimize the thickness of the blood clot after each of the procedures. The patients are advised to brush all teeth and sites except the buccal surfaces of the operated-on teeth, which are to be cleaned with 0.12% Chlorhexidine mouth rinse.
40964518|NCT02275468|DRUG|Fu-zheng-qu-zhuo (FZQZ) oral liquid|FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
40964519|NCT05832398|DRUG|FOLFOX , FOLFIRI or FOLFOXIRI regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFOXIRI (irinotecan 150mg/m2, and folinic acid 400mg/m2, oxaliplatin 85 mg/m2, 5-fluorouracil 3200 mg/m2 48-h continuous infusion) for 6 cycle
40964520|NCT05832398|DRUG|FOLFOX or CapeOX regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle CaoeOX (Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
41137139|NCT00983294|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
41137140|NCT03120936|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open-label emtricitabine 200mg/tenofovir 300mg
41456945|NCT00168558|BIOLOGICAL|Measles vaccine|"The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine"
41456946|NCT03718039|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
41456947|NCT03718039|DEVICE|Luer Lock applicator|Applicator for instillation.
41294775|NCT04592276|DIETARY_SUPPLEMENT|placebo|Participants took two capsules without PS128 after dinner for 30 days.
41294776|NCT04220866|DRUG|Ulevostinag|IT injection
41294777|NCT04220866|BIOLOGICAL|Pembrolizumab|IV infusion
41456948|NCT03718039|DEVICE|Vial access device|Device for withdrawal of drug product.
41456949|NCT03718039|DRUG|aprepitant|Aprepitant, three single doses of aprepitant will be administered orally.
41456950|NCT03234127|GENETIC|Whole Genome Sequencing|Whole Genome Sequencing Biomarkers analyses
41456951|NCT01286805|PROCEDURE|Lumbar Plexus Blockade|The lumbar plexus block will be dosed with 30 milliliters of 0.25% bupivacaine with 1:200,000 epinephrine
41456952|NCT01286805|PROCEDURE|Control|The control group will receive only a combined spinal-epidural.
41456953|NCT02324452|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
40766395|NCT06629103|DIETARY_SUPPLEMENT|life's Omega O3020DS|A natural triglyceride derived from microalgae with minimum 210 mg DHA, minimum 300 mg EPA, and minimum 510 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
40964521|NCT00523016|PROCEDURE|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
40964522|NCT00523016|PROCEDURE|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
40964523|NCT01195558|OTHER|Data collection on blindness and sleep problems|Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
40964524|NCT04475991|DRUG|Maraviroc + Currently used therapy|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
40964525|NCT04475991|PROCEDURE|Curently used therapy for COVID-19 non-critical patients|"Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga"
40964526|NCT04475991|DRUG|Favipiravir + Currently used therapy|"Favipiravir tablets 200 mg. given orally for a 7 day period. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)."
40964527|NCT04475991|DRUG|Maraviroc+Favipiravir+CT|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND Favipiravir tablets 200 mg. given orally for the first 7 days. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
40964528|NCT01560793|BIOLOGICAL|VAX161 [STF2.HA5 H5N1]|dose escalating, 2 intramuscular doses given 21 days apart
40964529|NCT02579187|PROCEDURE|tooth extraction|The study tooth will be removed
40964530|NCT02579187|RADIATION|CBCT scan|a CBCT scan limited to the dental arch that includes the study side will be obtained
40964531|NCT02579187|DRUG|Anesthesia|all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
40964532|NCT02579187|OTHER|clinical measurements|After tooth extraction, clinical measurements of the site will be obtained and recorded (keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness
40964533|NCT02579187|DRUG|Biodegradable sponge (type I bovine collagen)|control group subjects will receive a biodegradable sponge (type I bovine collagen) to stabilize the clot
40964534|NCT02579187|DRUG|10µg of pSil-miR200c|subjects in the experimental group will receive a 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
40964535|NCT02579187|PROCEDURE|cross mattress suture|The site will be stabilized with a simplet external, cross mattress suture
40964536|NCT02579187|DRUG|10µg of PMIS miR200a plasmids|subjects in the experimental group will receive a 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
40964537|NCT02579187|DRUG|5µg of pSil-miR200c and 5µg of PMIS miR200a|subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
40964538|NCT02579187|PROCEDURE|Blood|Subjects will have venipuncture performed to obtain a small blood sample (approx. 2 ml) to assess for miR-200c and PMIS-miR-200a expression and liver function (AST, ALT, bilirubin levels)
40964539|NCT02579187|OTHER|Photos/videos|subjects will have photos and/or videos of the extraction site and/or implant taken at each visit.
40964540|NCT02579187|PROCEDURE|Wound fluid|a small sample of wound fluid will be obtained from the extraction site in a minimally invasive manner using a paper point at 1, 2, 3 \& 4 weeks post extraction
40964541|NCT02579187|PROCEDURE|saliva|approximately 2 mls of saliva will be obtained in a minimally invasive manner at the time of extraction and at 14 weeks post extraction.
40964542|NCT02579187|RADIATION|periapical xray|periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point
40964543|NCT02579187|OTHER|PVS impression|PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.
40964544|NCT05343598|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses."
40964545|NCT05343598|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
40964546|NCT00764738|DEVICE|OCT, Multifocal ERG, Microperimetry|"OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.~Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.~Multifocal ERG done at the same monthly visits as the microperimetry."
40964547|NCT00764738|DRUG|Ranibizumab Ophthalmic|0.5 mg ranibizumab vs 2.0 mg ranibizumab
40964548|NCT00453622|DEVICE|Cardiac Resynchronization Therapy-Defibrillator|Implantation of a CRT-D device
41456954|NCT06338410|BEHAVIORAL|Kangaroo Mother Care|KMC is a care system for LBW and preterm infants at birth, based on skin-to-skin contact between the infant and the mother and exclusive breast feeding. The mother carries her Preterm infant for at least one hour per day. Urine collected before and after skin-to-skin contact.
40964549|NCT06014203|DIAGNOSTIC_TEST|Edema measurement|"Subcutaneous fluid measurements will be made 3 times in total, before the surgery, immediately after the surgery and 24 hours after the surgery. Measurements will be made with the MoistureMeterD Compact local edema measuring device.~Points to be measured:~1. Midpoint of the upper trapezius muscle~2. 5 cm distal to anterior acromion~3. 5cm distal to lateral acromion~4. 5cm distal to posterior acromion~5. 3cm medial to the axilla~6. Anterior cubital fossa~7. Carpal tunnel"
40964550|NCT06557005|OTHER|Facilitated Transition to Primary Care|The intervention includes default PCP visit scheduling, tailored nudge messages to patients, ongoing care recommendations sent to the PCP, and a summary of recommendations after pregnancy given to the patient.
40964551|NCT03638297|DRUG|PD-1 antibody + cox inhibitor|"BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency."
40964552|NCT05438264|DRUG|Donepezil|acetylcholinesterase inhibitor
40964553|NCT05438264|DRUG|Placebo|placebo
40964554|NCT03889444|DRUG|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.
40964555|NCT03064997|DIETARY_SUPPLEMENT|Synergy 1|a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet
40964556|NCT03064997|DIETARY_SUPPLEMENT|Placebo|a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
40964557|NCT01405456|DRUG|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
40964558|NCT01405456|OTHER|placebo and lifestyle|placebo pill daily and lifestyle counseling
40964559|NCT00277498|DRUG|Xalacom|
40964560|NCT00277498|DRUG|Xalatan|
40964561|NCT00277498|DRUG|Timolol|
40964562|NCT02456441|OTHER|Intervention group|"The device current generator TENS used was  Neurodyn Portable Tens / Fes  of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 microseconds and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes"
40964563|NCT02456441|OTHER|Placebo group|The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
40964564|NCT03325283|DEVICE|ProtEmbo Cerebral Protection System|A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
40964565|NCT03122769|RADIATION|11C-metformin|200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
40964566|NCT04152278|DIAGNOSTIC_TEST|cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila|three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic and anaerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)
40964567|NCT03290092|DRUG|Taselisib (GDC0032)|The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.
40964568|NCT03290092|DRUG|Taselisib (GDC0032)|The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
41137141|NCT03120936|BEHAVIORAL|PrEP support|HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.
41137142|NCT02427191|OTHER|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
41137143|NCT02427191|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
41137144|NCT03239704|BEHAVIORAL|Telemedicine Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
41137145|NCT03239704|OTHER|Telemedicine Monitoring|Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
41137146|NCT03239704|BEHAVIORAL|30 Day Comprehensive Questionnaire|Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
41137147|NCT04919668|BEHAVIORAL|Simulated grocery shopping exercise|Participants will click a link and simulate an online grocery shopping experience by selecting items for 12 grocery categories.
41137148|NCT03093532|OTHER|ED SBIRT-HTN|"Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
41294778|NCT04716439|PROCEDURE|Spine Surgery|spine decompression and fixation
40964569|NCT01317160|DEVICE|Intermittent pneumatic compression (IPC)|6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.
40964570|NCT02197000|DIETARY_SUPPLEMENT|DIM-Avail 100mg|DIM 100 mg\*1 daily for 2 years
40964571|NCT05758298|OTHER|Non-medicated gum|Non-medicated, regular chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
40964572|NCT05758298|DRUG|NICOTINE 2MG GUM|Nicotine 2mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
40964573|NCT05758298|DRUG|NICOTINE 4MG GUM|Nicotine 4mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
40964574|NCT04243798|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro x100 TMS system (MagVenture, Denmark)."
40964575|NCT04243798|DEVICE|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
40964576|NCT03188315|GENETIC|HPV oncogenes|PCR and oncogenes detection
40964577|NCT04109183|DRUG|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
40964578|NCT05909150|DRUG|Sodium chloride solution 3,5%|Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.
40964579|NCT05909150|DRUG|Sodium chloride solution 0,9%|Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.
40964580|NCT01866930|BIOLOGICAL|Pegylated Interferon Lambda-1a|
40964581|NCT01866930|DRUG|Daclatasvir (DCV)|
40964582|NCT01866930|DRUG|Ribasphere (RBV)|
40964583|NCT05881915|DRUG|Phenylephrine|phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL
40964584|NCT05881915|DRUG|Epinephrine|epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
40766396|NCT01915212|BIOLOGICAL|HSV529|The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).
40964585|NCT03425877|DEVICE|MS Band 2|Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.
40964586|NCT03425877|BEHAVIORAL|Emotion Assessment|The subjects will be subjected to the viewing of 21 video clips depicting 6 different emotional states belonging to the FilmStim database validated by Schaefer's studio and collaborators (Schaefer, Nils, Sanchez, \& Philippot, 2010). When viewing the clip, subjects will wear the Microsoft ® Band 2 .and after each movie clip of an evaluation of the stimulus value and activation level perceived by the Self-Assessment Manikin (Bradley \& Lang, 1994) questionnaire). The presentation of movie clip is randomized and does not follow a fixed effect. Between the presentation of each clip a fixed interval of 15 seconds has been inserted in order to induce artifacts and overlap of physiological signals among different emotional valence video clips.
40964587|NCT03425877|BEHAVIORAL|Single Task|The section includes three tasks which involve upper and lower extremities, and cognitive functions, associated with low cognitive and motor load for their execution. Subjects are required to perform a single task, i.e. without the simultaneous execution of other tasks. Grasping(Motor Upper Limbs): The subject is required to reach an object's dominant limb and grab it. Walking(Motor Lower Limbs): It is required to carry 10 feet of walk. Attention(Cognitive): Signal detection task. The subject is required to detect acute sound between a series of serious sounds (Oddball Paradigm).
41137149|NCT03093532|OTHER|PACHT-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
41137150|NCT01801007|DEVICE|Flow Re-Direction Endoluminal Device (FRED)|
40766397|NCT01915212|OTHER|Placebo|Sodium Chloride 0.9%
40766398|NCT03577470|DRUG|D/C/F/TAF Fixed-Dose Combination (FDC)|Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
40766399|NCT04897568|OTHER|Patient decision aid|Each subject will receive an informational flyer describing lung cancer screening options and smoking cessation from a trained person on the medical staff at each clinic. Staff will lead a shared decision-making discussion with the patient.
40766400|NCT02592863|DRUG|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
40964588|NCT03425877|BEHAVIORAL|Dual Task|This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
40964589|NCT03425877|BEHAVIORAL|Rest|At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .
40964590|NCT00003997|DRUG|irofulven|
40964591|NCT01516346|DRUG|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
40964592|NCT01516346|DRUG|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
40964593|NCT01516346|DRUG|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
40964594|NCT00689234|PROCEDURE|diaphragm plication 6 months after inclusion|thoracotomy
40964595|NCT00689234|PROCEDURE|diaphragm plication at time of inclusion|thoracotomy
40964596|NCT00773656|OTHER|Whole blood sample|70 ml per patient for collection of biological sample
40964597|NCT05147025|OTHER|Revascularization|Regain pulp vascularity for young permenant teeth
40964598|NCT02535117|PROCEDURE|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
40964599|NCT02535117|PROCEDURE|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
40964600|NCT05587803|DEVICE|Neurowave and Sedline indices in view|3 additional electrodes are attached on the patients forehead. After electrode placement, the indices of both the SEDLINE device and the NEUROWAVE device are noted every 5 seconds for 1 minute
40964601|NCT03258437|DIETARY_SUPPLEMENT|DA-9401|
40964602|NCT03258437|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
40964603|NCT04481854|PROCEDURE|cricoid pressure|cricoid pressure during laryngoscopy
40964604|NCT04481854|PROCEDURE|left paratracheal pressure|left paratracheal pressure during laryngoscopy
40964605|NCT02172768|OTHER|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
40964606|NCT02172768|OTHER|daily dosing|micafungin daily for 8 days
40964607|NCT02172768|DRUG|micafungin|
40964608|NCT02792881|PROCEDURE|Laparoscopic completion total gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic completion total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and the anastomotic procedure will be performed extracorporeally through an auxiliary incision.
40964609|NCT01478477|DIETARY_SUPPLEMENT|omega-3 fatty acid supplement|6 capsules per day (4.3 g)x 6 months
40766401|NCT02592863|DRUG|Placebo|Patients will take placebo 3 times per day for 12 weeks
40964610|NCT01478477|OTHER|Placebo|6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
40964611|NCT01478477|OTHER|Clinical assessments|All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
40964612|NCT01478477|OTHER|Assessment of therapy complications|Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
40766402|NCT05725031|DRUG|Ephedrine|70 μg/kg as pretreatment
40766403|NCT05725031|DRUG|Rocuronium 0.6|0.6 mg/kg
40766404|NCT05725031|DRUG|Rocuronium 0.8|0.8 mg/kg
40766405|NCT05725031|DRUG|Rocuronium 1.2|1.2 mg/kg
41294779|NCT03737604|DRUG|Ropivacaine Continuous Infusion Catheter|For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.
40964613|NCT01478477|PROCEDURE|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
40964614|NCT01478477|PROCEDURE|Correlative/special studies|Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
40964615|NCT02673138|DRUG|canagliflozin|basal interruption with canagliflozin
40964616|NCT02673138|OTHER|basal interruption without canagliflozin|basal interruption
41294780|NCT03737604|DRUG|Single Dose Liposomal Bupivicaine|TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.
40766406|NCT02097225|DRUG|Dabrafenib|Given PO
40964617|NCT06504680|PROCEDURE|Repair of flexor tendon injury zone ll using 8- strand|Repair cut flexor zone ll using 8-strand with and without splinting the wrist
40964618|NCT05943015|PROCEDURE|Quadratus Lumborum Block II|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the psoas major and the transverse process adjacent to the quadratus lumborum muscle, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle negative aspiration into the middle layer of the thoracolumbar fascia posterior to the quadratus lumborum muscle, then 0.5-1 ml of saline 20 ml of 0.25% bupivacaine will be injected after hydrodissection is observed. The same will be done to the other side.
40964619|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
40964620|NCT05943015|PROCEDURE|Quadratus Lumborum Block III|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
40964621|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
40964622|NCT05943015|PROCEDURE|Paravertebral Block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. The linear ultrasound probe is placed longitudinally at the T6 level, 2-2.5 cm lateral to the spinous processes. Transverse process, superior costotransverse ligament and pleura are visualized, 22 gauge 80 mm peripheral block needle is passed with in-plane technique, superior costotransverse ligament is passed, negative aspiration into the paravertebral space under the ligament, followed by 0.5-1 ml of saline and hydrodissection of the pleura, followed by 20 ml of 0.25% bupivacaine is injected.The same is done to the opposite side.
40964623|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
40964624|NCT02927730|OTHER|no interventions|no interventions
40964625|NCT04506372|DRUG|Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers|Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
40964626|NCT04506372|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery
40964627|NCT04506372|BEHAVIORAL|Diary to register drug adherence|To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.
40964628|NCT04506372|BEHAVIORAL|Quality of life questionnaire|Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery
41294781|NCT06513325|OTHER|Canadian Occupational Performance Measure|It is a semi-structured scale that helps to identify problematic areas of performance experienced by individuals and to measure their perceived occupational performance and satisfaction. This scale assesses the level of performance of self-care, productivity and leisureoccupations and satisfaction with these performances as perceived by the individual.
40766407|NCT02097225|OTHER|Laboratory Biomarker Analysis|Correlative studies
40766408|NCT02097225|DRUG|Onalespib|Given IV
40766409|NCT02097225|OTHER|Pharmacological Study|Correlative studies
40766410|NCT02097225|DRUG|Trametinib|Given PO
40766411|NCT04471727|BIOLOGICAL|MK-6070|IV infusion
41294782|NCT06023199|DRUG|Voxelotor|Voxelotor is administered orally at a dose of 1500mg daily.
41294783|NCT01706445|OTHER|Other|inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
40766412|NCT04471727|BIOLOGICAL|Atezolizumab|IV infusion
40766413|NCT04471727|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
40766414|NCT05815498|BIOLOGICAL|mRNA-1283.222|Sterile liquid for injection
40766415|NCT05815498|BIOLOGICAL|mRNA-1273.222|Sterile liquid for injection
40964629|NCT04506372|BEHAVIORAL|WHODAS questionnaire|Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
40964630|NCT04974697|DEVICE|JJVC Investigational Multifocal Toric Contact Lens|TEST
40964631|NCT05310461|PROCEDURE|Transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement|Early transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
40964632|NCT05310461|PROCEDURE|Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention|Deferred transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
40964633|NCT02258698|PROCEDURE|Cardiac surgery|Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
40964634|NCT04173988|GENETIC|alloCART-19|"AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~* For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10\^6 CAR+ cells/kg~* For children with body weight \> 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10\^8 CAR+ cells."
40964635|NCT04173988|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
40964636|NCT04173988|DRUG|Fludarabine|Chemotherapy for lymphodepletion
40964637|NCT04993521|PROCEDURE|Block type|Regular block type
40964638|NCT02733432|DRUG|CD101 Vaginal Gel (3%)|CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
40964639|NCT02733432|DRUG|CD101 External gel (1%)|CD101 external gel (1%) applied topically twice daily over 72 hours as needed
40964640|NCT02733432|DRUG|CD101 Vaginal Ointment (6%)|CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
40964641|NCT02733432|DRUG|CD101 External ointment (1%)|CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
40964642|NCT02733432|DRUG|Fluconazole|oral fluconazole (150mg) on Day 1
40766416|NCT05815498|BIOLOGICAL|mRNA-1283.815|Sterile liquid for injection
40766417|NCT05815498|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
40766418|NCT05848817|DEVICE|Contoura LASIK|Subjects receiving Phorcides Planned Contoura LASIK
40964643|NCT00649324|DRUG|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
40964644|NCT00649324|DRUG|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
40964645|NCT03773692|BEHAVIORAL|Passive feedback and JITAI|"Second Phase - PA Level Feedback~A PA recommendation handout based on PA guidelines for individuals with SCI will be provided. Participants continue to use the same sensing equipment as in phase one (baseline). The equipment consists of a smartwatch, a smartphone, and a wheel rotation monitor. Participants can view their feedback whenever they want, but will not be prompted with the information.~Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)~The third phase of the study will be similar to the second phase of the study, but with an additional JITAI component. The JITAI component of the study will include providing proactively-prompted, real-time feedback through the smartphone and smartwatch when the participant performs a bout of moderate PA."
41294784|NCT05415202|DRUG|Remimazolam 20 MG [Byfavo]|Remimazolam will be administered for sedation and efficacy and safety will be recorded
41294785|NCT04650321|DRUG|Ocrelizumab at home|Patients will receive ocrelizumab infusion at home.
41294786|NCT03621969|OTHER|Physical exam and medical history|This will be completed by a medical doctor on the research team
40766419|NCT01266577|OTHER|NSR MAGNETOM 7T|The 7 Tesla scanner is a magnet system used to acquire magnetic resonance imaging and spectroscopy
40766420|NCT01266577|OTHER|1Tx x 32Rx Head Coil|Used to perform proton imaging and spectroscopy in the human heads.
40766421|NCT05296798|DRUG|Phesgo|Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
40964646|NCT03249883|DEVICE|SACH prosthetic foot, 1M10 prosthetic foot|"In the SACH first group - the amputees will wear the SACH feet for three weeks and then switch to 1M10 feet for another three weeks.~In the 1M10 first group - the amputees will wear the 1M10 feet for three weeks and then switch to SACH feet for another three weeks."
40964647|NCT04176497|DRUG|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.
40964648|NCT03138278|OTHER|Telephone support on demand|Dedicated phone number for help and advice for caregivers
40964649|NCT05806411|DIAGNOSTIC_TEST|Analysis of calcific aortic valves|Microbiologic analysis of calcofic aortic valves
41137151|NCT05225337|OTHER|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
41294787|NCT03621969|DIAGNOSTIC_TEST|Assessments|One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)
40964650|NCT04960501|PROCEDURE|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
40964651|NCT04444895|DRUG|Lanadelumab|Lanadelumab SC injection
40964652|NCT05307068|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
40964653|NCT04993248|OTHER|Dialog Circle|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
41294788|NCT03621969|DEVICE|Patient Instruction and use of Device (RePlay)|"1. providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~2. improving assessment and evaluation of patients involved in future interventional studies,~3. producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home."
41456955|NCT05289440|DRUG|Low-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
40766422|NCT05296798|DRUG|Giredestrant|A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.
40964654|NCT00640991|DRUG|glulisine insulin, glargine insulin|IV infusion of glulisine, SC injection of glargine
41456956|NCT05289440|DRUG|High-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
41456957|NCT05289440|DRUG|Saline infusion|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
40964655|NCT01386827|BIOLOGICAL|Mouse brain derived japanese encephalitis vaccine (MB-JEV)|a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml \> 2 years later
40964656|NCT01386827|BIOLOGICAL|Primary and booster immunizations with MB-JEV|2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml \> 2 years later
40964657|NCT01386827|BIOLOGICAL|C) primary immunizations with Ixiaro|2 0.5 ml doses of Ixiaro 28 days apart
40964658|NCT01386827|BIOLOGICAL|S) Ixiaro booster to MBJEV primed|0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
41137152|NCT05225337|OTHER|Daily calorie restriction|25% energy restriction every day Diet counseling provided
41294789|NCT05894993|DEVICE|transient elastograghy|is a non-invasive method proposed for the assessment of hepatic fibrosis in patients with chronic liver disease by measuring liver stiffness. It can be easily performed at the bedside or in the outpatients clinic with immediate results and good reproducibility.
41294790|NCT00780000|DRUG|Alvespimycin|Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
41294791|NCT03645837|OTHER|Compression clamp release|Standard compression clamp is used and will be released at different times according to randomization
41456958|NCT02316054|DEVICE|MPHI|addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
40766423|NCT05296798|DRUG|Docetaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.
41137153|NCT00876005|OTHER|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
41137154|NCT00876005|OTHER|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
41137155|NCT04413526|PROCEDURE|radiofrequency|radiofrequency combined with liver resection
41137156|NCT04413526|PROCEDURE|TACE|only TACE treatment
41137157|NCT04413526|PROCEDURE|TACE+radiofrequency|TACE followed by radiofrequency
41137158|NCT04705649|OTHER|Treatment de-escalation|De-escalation from standard treatment based on molecular profile
41137159|NCT03217123|DEVICE|Deep Brain stimulation|Electrical stimulation at subcortical level
41294792|NCT05181917|BEHAVIORAL|STUDIA app|STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
41456959|NCT02836587|BEHAVIORAL|Balance training|The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
41456960|NCT01186835|PROCEDURE|Combination Botulinum Toxin A and Hyaluronic Acid|One side of subject's face will randomly be assigned combination treatment.
41456961|NCT01186835|PROCEDURE|Botulinum Toxin A|Other side of subjects face with receive Botulinum Toxin A treatment alone.
41456962|NCT06052813|DRUG|BN104|Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.
41456963|NCT03456544|DRUG|Vancomycin|Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
41456964|NCT06083623|BIOLOGICAL|TNM001|single dose intramuscular injection
40964659|NCT05131698|COMBINATION_PRODUCT|Tislelizumab and Lenvatinib|"TACE therapy: For transarterial infusion chemotherapy before or after TACE embolization, each drug will generally be diluted with 0.9% sodium chloride solution or 5% dextrose solution 150-250 mL and injected slowly into the target artery for ≥20 min. Subsequent TACE therapy will be administered on an as-needed basis as assessed by the clinician, with each treatment interval exceeding 6 weeks and no more than 6 treatments in total.~Lenvatinib: The starting dose of lenvatinib will depend on the patient's baseline weight: if baseline weight ≥ 60 kg, patients will receive 12 mg of lenvatinib administered once daily; if baseline weight \< 60 kg, patients will receive 8 mg of lenvatinib once daily. TACE therapy will be given 3 days apart.~Tirelizumab: Tirelizumab 200 mg , intravenous infusion on the same day as the first dose of lenvatinib, once every three weeks.~Translated with www.DeepL.com/Translator (free version)"
40964660|NCT04737083|GENETIC|CGH array|a CGH array is systematically offer to women when the fetus show bilateral clubfoot during prenatal ultrasound screening
40964661|NCT04824066|DEVICE|Device: Wearable Device|A Wearable Device will be placed on the wrist of the patient \~30 days prior to the patient's scheduled surgery, removed during the operation, and replaced for \~180 days post-operatively. The device will record activity in terms of steps, sleep quality, heart rate, etc.
41294793|NCT00840645|DRUG|YM178|Oral
41294794|NCT01656616|DRUG|Cyanide antidote administration|
41294795|NCT01240993|BEHAVIORAL|Mothers and Toddlers Program|This intervention is a short-term attachment-based parenting therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing.
41294796|NCT01240993|BEHAVIORAL|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs and a choice of pamphlets on age-related parenting topics.
41294797|NCT04760795|OTHER|PTSD Check List (PCL) scale|PTSD Check List (PCL) scale will be realized to evaluated post-traumatic stress disorder.
41294798|NCT04760795|OTHER|Brief COPE scale|Brief COPE scale dispositional version will be realized to evaluated usual coping strategies. It was assessed during the teleconsultations and post containment.
41456965|NCT06083623|BIOLOGICAL|placebo|single dose intramuscular injection
40964662|NCT01301352|OTHER|Route of feeding (nasogastric vs. nasojejunal)|Safety and efficacy of feeding nasogastrically vs. nasojejunally while receiving noninvasive positive pressure ventilation
40964663|NCT00533598|DRUG|MK0557|
40964664|NCT01749137|DRUG|Setmelanotide|Daily subcutaneous infusion
41456966|NCT01567527|DRUG|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
41456967|NCT01567527|DRUG|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
41456968|NCT01639664|DEVICE|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization.
41456969|NCT03624868|BEHAVIORAL|Tai Chi|See above description
41456970|NCT03624868|BEHAVIORAL|Wellness Education|See above description
41456971|NCT01680601|PROCEDURE|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
41456972|NCT01680601|PROCEDURE|Placebo|
41456973|NCT03198663|BEHAVIORAL|POSSE|Popular-opinion leader
41456974|NCT05697757|OTHER|Dynamic Lighting|This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.
41456975|NCT05697757|OTHER|Placebo Lighting|We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting
41456976|NCT04416750|DRUG|Imatinib Mesylate|Treatment with Imatinib
40964665|NCT01749137|DRUG|Placebo|Daily subcutaneous infusion
40964666|NCT04329533|OTHER|"Calm is a mindfulness meditation mobile app"|"Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
40964667|NCT02680080|DRUG|Moxifloxacin|a single 400 mg tablet of Moxifloxacin
40964668|NCT02680080|DIETARY_SUPPLEMENT|Grapefruit group|one liter of fresh pink-grapefruit juice
40964669|NCT01938456|DRUG|Trametinib|Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
41294799|NCT04760795|OTHER|GAD-7 (Generalized Anxiety Disorder) scale (during containment)|GAD 7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
41294800|NCT04760795|OTHER|Analog scale|Analog scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
40964670|NCT01938456|DRUG|Docetaxel|Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
40964671|NCT01938456|DRUG|Filgrastim|Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter\^2 or 75 mcg/body
40964672|NCT06119945|DRUG|DWJ1568|One tablet of DWJ1568
40964673|NCT06119945|DRUG|DWC202215|One tablet of DWC202215
40964674|NCT02788812|PROCEDURE|Open modified Lichtenstein repair|Open Lichtenstein Hernioplasty
40964675|NCT02788812|PROCEDURE|Laparoscopic TAPP inguinal hernia repair|Laparoscopic TAPP Hernioplasty
40964676|NCT02385500|DRUG|Fesoterodine|"For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
40964677|NCT02385500|DRUG|Placebo|"For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
41137160|NCT04566185|OTHER|FDG PET|"IV application of F Dopa, 2 MBq per Kg, with a scout view (angle of view 90 °, 120 kV, 30 mAs), then an X-ray scan is performed for the attenuation correction ( 120 kV - 5mAs - pitch 0.531 - thickness // increment: 3.75mm//3.27mm -QAC filter - DFOV 25).~PET acquisition: static in 3D mode for 20 minutes, 8 minutes after the injection of 18 F Dopa, the axial field of view is 25, the matrix in 256 x 256. After OSEM reconstruction 6 iterations and 24 subsets, with correction of attenuation and diffusion, then Gaussian filter of frequency 4, 47 contiguous axial sections of 3.26 mm are obtained."
41137161|NCT04566185|OTHER|CT scan|"Localization propeller without injection: 120kV - mA regulation (Noise Index 15) - pitch 0.969 - thickness // increment: 5mm // 5mm - Soft filter - Asir 60% - DFOV 25.~Acquisition begins 5 seconds after the start of the injection of 60 ml of contrast product (VISIPAQUE) at 4 cc / second without (acquisition characteristics: 80 kV - 100 mAs -- thickness: 5mm // 8 images / rotation - STD filter - Asir 50% display field of view (DFOV) 25 - phase1: 5s then phase2 15s).~Diagnostic quality CT: 120kV - Regulation of mA (Noise Index 15) - pitch 0.531 - thickness // increment: 1.25 // 0.625mm - Soft filter - Asir 60% - DFOV 25."
41137162|NCT04566185|OTHER|Magnetic resonance imaging (MRI)|"If the examination is performed on the SIEMENS SKYRA 3T device: 32 channel head coil antenna, if on the PHILIPPS INGENIA 1.5 T device: DStream HeadSpine Coil antenna.~The sequence begins with an axial, coronal and sagittal Survey topogram, lasting 1 minute.~Then axial sequence T1, Axial T2 \*, Axial cerebral perfusion (Injection of gadolinium (0.1 mmol / kg, 5 cc / second), coronal T2, Axial T2 Flair, Axial DWI b100, Axial 3D T1 gadolinium"
41294801|NCT04760795|OTHER|GAD-7 (Generalized Anxiety Disorder) scale (post containment)|GAD-7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during post containment.
41294802|NCT04760795|OTHER|Big Five Inventory (BFI) scale|Big Five Inventory (BFI) will be realized to evaluated personality.
41294803|NCT04760795|OTHER|Relationship Scales Questionnaire (RSQ)|Relationship Scales Questionnaire (RSQ) will be realized to evaluated attachment style.
41294804|NCT04986293|DEVICE|CPAP|Different settings of CPAP and BiPAP will be tested using a home mechanical ventilator
41294805|NCT00698126|DRUG|soluble human insulin|Observational study; use of the products as in the normal clinical practice conditions
41456977|NCT02375815|OTHER|Statin Choice Implementation|
41456978|NCT05545228|BEHAVIORAL|Link work intervention|Intervention from a link worker to support participants to access dental services.
40964678|NCT00586001|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Cognitive-behavioral treatment in development for emotional disorders
41137163|NCT03735459|BEHAVIORAL|Patient reminders and accountability questionnaires|Participants who are assigned to the patient reminder arm will receive text messages 1, 2, and 4 weeks after enrollment. These text messages will encourage participants to adhere to the provided treatment plan, and ask participants to complete questionnaires to assess their adherence to treatment (in-house Adherence Questionnaire) and severity of eczema (PO-SCORAD) for that week.
41294806|NCT00698126|DRUG|biphasic insulin aspart|Observational study; use of the products as in the normal clinical practice conditions
41294807|NCT06382493|DRUG|Tegoprazan-containing sequential H. pylori eradication therapy|tegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy
41456979|NCT00031954|DRUG|carboplatin|
41456980|NCT00031954|DRUG|gemcitabine hydrochloride|
41456981|NCT00031954|DRUG|paclitaxel|
40964679|NCT04659161|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.
40964680|NCT04659161|DRUG|Placebo|Placebo Capsules twice a day (BID)
40766424|NCT05296798|DRUG|Paclitaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.
40964681|NCT02040493|RADIATION|Intra-operative radiation therapy (IORT)|All subjects will receive IORT at the time of lumpectomy.
40964682|NCT04804969|DEVICE|MyoVista wavECG Test|The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.
40964683|NCT03089866|DRUG|Midazolam (0.02mg/kg)|Quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
40964684|NCT01354340|DIETARY_SUPPLEMENT|Limicol|3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
40964685|NCT01354340|DIETARY_SUPPLEMENT|Limicol|6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
41137164|NCT05583656|PROCEDURE|Pulmonary valve replacement|Surgical replacement of the pulmonary valve using the Edwards Inspiris Resilia prosthesis.
41294808|NCT06382493|DRUG|Esomeprazole-containing sequential H. pylori eradication therapy|Esomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)
41294809|NCT01322607|BEHAVIORAL|High-intensity Treadmill Exercise|High-intensity treadmill walking program
41294810|NCT01322607|BEHAVIORAL|Low-intensity Lifestyle Intervention|A low-intensity lifestyle intervention targeted towards group exercises incorporating balance, coordination, and strength.
41294811|NCT04056130|DRUG|KBL697|"Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral"
41294812|NCT04056130|DRUG|KBL697|"Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral"
41294813|NCT04056130|DRUG|KBL697|"Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral"
41294814|NCT04056130|DRUG|KBL697|"Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral"
41294815|NCT03022656|DEVICE|Active Brace system|
41294816|NCT02717546|DEVICE|Zimmer MotionLoc Screw|Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
41294817|NCT01070784|DRUG|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
41294818|NCT01070784|DRUG|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
41294819|NCT05546996|DEVICE|FlowSense|"Patients will have one or more existing external ventricular drains (EVDs). Phase B patients will additionally have an accessible (shaved) region of skin \>3 cm x 3 cm overlaying the EVD tubing.~Clinical data to be collected include: 1) total drainage volume1 over the 20-minute measurement period; 2) handheld ultrasound measurement of skin thickness2 over the EVD; and 3) an ICP waveform from a standard-of-care transducer, 4) dimensions (inner diameter and outer diameter) of tunneled catheter. Single patients may be measured multiple times during their admission; each measurement will be considered independent for analysis."
41294820|NCT02083445|OTHER|cognitive activities|Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.
41294821|NCT02083445|OTHER|Exercise program|Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.
41294822|NCT02083445|DEVICE|Muscle electro-stimulation|A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks
41294823|NCT02083445|OTHER|Intermittent hypobaric hypoxia|
41294824|NCT02221739|DRUG|Ipilimumab|
40964686|NCT01354340|OTHER|Placebo|6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
41137165|NCT03681132|OTHER|Stop of therapy|The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
41137166|NCT04026256|DRUG|Teriparatide|teriparatide daily subcutaneous injection
41137167|NCT04026256|DRUG|Denosumab|denosumab subcutaneous injection
40964687|NCT03440268|DRUG|N Acetyl Cysteine|Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes
40964688|NCT03440268|DRUG|Placebos|These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
40964689|NCT00160290|DRUG|Lactulose|15 mL / 12 hours
41137168|NCT05922774|DEVICE|Cervical VEMP testing|cervical vestibular evoked myogenic potentials
41456982|NCT05270044|DRUG|Encorafenib and Binimetinib|Encorafenib 450 mg (6 × 75 mg capsules) once daily (QD) and binimetinib 45 mg (3 x 15 mg tablets) twice daily (BID) orally for a maximum of 12 months.
41456983|NCT05270044|DRUG|Placebo to match Encorafenib ; Placebo to match Binimetinib|Encorafenib (6 × 75 mg placebo capsules) QD and binimetinib (3 × 15 mg placebo tablets) BID placebos orally for a maximum of 12 months.
41456984|NCT03951727|DEVICE|Endovascular treatment for PAD|Long femoropopliteal stenting with SuperA devices
40964690|NCT00160290|DRUG|Plantago ovata|3,5 g / 12 hours
41137169|NCT00668226|DRUG|Lactic acid (Dermacid)|
41137170|NCT02298166|DRUG|chemotherapy (Mitoxantrone, Cytarabine)|"Induction therapy:~* Mitoxantrone 10 mg/m² IV, push (8 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT) d 1-3~* Cytarabine 1000 mg/m² IV (500 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT), over 3 hours, d 1-6~Consolidation therapy:~Younger adult patients (18 to 60 yrs):~Cytarabine 1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).~Older patients (\> 60 yrs) and or previous allogeneic HCT:~Cytarabine 1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²)."
40964691|NCT01218373|DEVICE|HOMESWEETHOME Services|Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
40964692|NCT01218373|DEVICE|No HOMESWEETHOME services installed|Normal care and healthcare without HOMESWEETHOME services.
41294825|NCT02221739|RADIATION|Radiotherapy (IMRT or 3-D CRT)|
41294826|NCT05164952|DRUG|Zoledronic Acid 4 MG|(4 mg via 15-min infusion every 6 months) for 24 months
40964693|NCT00647881|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
40964694|NCT00647881|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fed
40964695|NCT06015685|OTHER|Embedded Clinic|Once a week, a Primary Care clinic half-day will be dedicated to multi-disciplinary, team-based DM care. The inter-professional team will include an Internal Medicine attending physician, an Internal Medicine resident, a DM educator, a nurse trained in professional CGM, a behavioral health provider, and a social worker to assist in finding resources for housing, food, and patient assistance programs.
40964696|NCT06015685|OTHER|Routine Care|Researchers will use a 2:1 ratio of control to intervention patients. Using the CDW, researchers will identify a control population \[patients who receive routine care (i.e., referral to subspecialty care)\], who will be a propensity-matched cohort of individuals with similar age, gender, race/ethnicity, zip codes, insurance type, visit dates, and co-morbidities (Charlson Comorbidity Index) as the intervention group.
40964697|NCT01509950|PROCEDURE|Staples|Staples for closure of cesarean section skin incision
40964698|NCT01509950|PROCEDURE|Prolene non-absorbable sutures|Prolene non-absorbable sutures for closure of cesarean skin incision
40964699|NCT01509950|PROCEDURE|Absorbable Sutures|Absorbable sutures for closure of cesarean skin incision
40964700|NCT00000329|DRUG|Opioid-Related Disorders|
40964701|NCT01686529|PROCEDURE|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
40964702|NCT01686529|DRUG|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
40964703|NCT06506656|DEVICE|Hyadrol®|Sterile single-use Medical Device for intra-articular injections
40964704|NCT04556513|OTHER|Paraclinical examination|Respiratory functional tests
40964705|NCT04556513|OTHER|Clinical Examination|Clinical Examination
40964706|NCT04556513|OTHER|Semi-directive interview|By phone
40964707|NCT04556513|OTHER|quality of life questionnaires|SF36, VSRQ, IESR, HADS
40964708|NCT03288129|DRUG|Perampanel|film-coated tablets
40964709|NCT04439110|BIOLOGICAL|Trastuzumab Emtansine|Given IV
40964710|NCT01984177|DRUG|Corticotropin-Releasing Hormone|Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. \~15 minutes after Corticorelin/saline injection, \[11C\]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure (\[11C\]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
40964711|NCT00401596|DRUG|Xolair (omalizumab)|
40964712|NCT05907512|DRUG|Endostar|The dose of 210 mg (14 vials) is administered by intravenous pump from Day 1 to Day 3 of each course, every 4 weeks as a cycle, until disease recurrence, metastasis or intolerable toxicity, and up to 6 courses of administration.
40964713|NCT05907512|DRUG|Toripalimab|3 mg/kg by intravenous drip every 2 weeks (Day 1 and Day 15 of each cycle) in a 4-week cycle until disease recurrence, metastasis, or intolerable toxicity for up to 1 year (about 13 cycles).
40964714|NCT04269447|DIAGNOSTIC_TEST|Structured imaging follow-up|Structured imaging follow-up protocol with ultrasound (US) and computed tomography (CT) examinations as compared to current standard surveillance protocol for individualized estimations of AAA growth.
40964715|NCT00764647|BEHAVIORAL|Education program for family caregivers of frail elders|Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
40964716|NCT00210405|DIETARY_SUPPLEMENT|"Sprinkles containing mulitple micronutrients"|
40964717|NCT00210405|BEHAVIORAL|Education/communication on use of micronutrient sprinkles|
40964718|NCT00210405|DIETARY_SUPPLEMENT|Fortified food aid (corn-soy blend)|This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
40964719|NCT00701675|DRUG|sertraline 50 mg daily|50 mg daily
40964720|NCT00701675|DRUG|sertraline 100 mg daily|100 mg daily
40964721|NCT00701675|DRUG|Placebo 50 or 100 mg|50mg or 100mg matching placebo
40964722|NCT04696315|DIAGNOSTIC_TEST|Multiple features extraction|"In the present study, the gold standard of preclinical AD is amyloid PET. SCD with positive amyloid is the target population for early AD intervention. The investigators aim to extract the diagnostic features from multiple parameter MRI, genetic, blood and clinical data using Max-Relevance and Min-Redundancy (mRMR) algorithm. Then, based on support vector machine (SVM), random forest (RF) and multi-kernel learning (MKL) classification methods, the investigators will construct predicted diagnostic model of preclinical AD."
40964723|NCT04390178|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection
40964724|NCT01550289|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
40964725|NCT01550289|BIOLOGICAL|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
40964726|NCT05460845|BEHAVIORAL|Low-Carbohydrate Diet|Using a meal delivery service and a list of prepared meals and recipes, foods/meals will be delivered to participants weekly to maintain daily net carbohydrate intake to less than 40 grams.
40964727|NCT00826943|DRUG|Cetirizine|Cetirizine 10 mg tab daily x 7 days
40964728|NCT00826943|DRUG|Levocetirizine|5 mg tab daily x 7 days
40964729|NCT00826943|DRUG|Placebo|Placebo tablet daily x 7 days
40964730|NCT03591835|OTHER|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
40964731|NCT03591835|OTHER|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear. Measurements will be recorded as centimeters.
40964732|NCT01994447|OTHER|Student Enrollment|The standard informed consent process is for research nurses to provide verbal explanations of studies. In the intervention arm trained research students will use DVD's made by the studies principal investigator to explain study information in the informed consent process.
40964733|NCT01443871|OTHER|Aromatherapy|Subject will assigned inhale aromatherapy
40964734|NCT01443871|OTHER|Pure water|Subject will assigned inhale Pure water
40964735|NCT03801291|PROCEDURE|Transvaginal repair|Vaginal incision through which plication of the rectovaginal septum is done
40964736|NCT03801291|PROCEDURE|Transperineal repair|Perineal incision through which plication of the rectovaginal septum is done
40964737|NCT00042289|DRUG|atazanavir/cobicistat|atazanavir/cobicistat 300/150 mg q.d.
40964738|NCT00042289|DRUG|darunavir/ritonavir dosage #1|darunavir/ritonavir twice daily 600/100 mg b.i.d.
40964739|NCT00042289|DRUG|darunavir/ritonavir dosage #2|darunavir/ritonavir twice daily 800/100 mg b.i.d.
40964740|NCT00042289|DRUG|darunavir/ritonavir dosage #3|darunavir/ritonavir twice daily 900/100 mg b.i.d.
40964741|NCT00042289|DRUG|elvitegravir/cobicistat|elvitegravir/cobicistat 150/150 mg q.d.
40964742|NCT00042289|DRUG|dolutegravir|dolutegravir 50 mg q.d.
40964743|NCT00042289|DRUG|tenofovir alafenamide fumarate (TAF)|TAF 25 mg q.d. without cobicistat or ritonavir boosting
40964744|NCT00042289|DRUG|TAF w/cobicistat|TAF 10 mg q.d. with cobicistat
40964745|NCT00042289|DRUG|TAF w/cobicistat or ritonavir|TAF 25 mg q.d. with cobicistat or ritonavir boosting
40964746|NCT00042289|DRUG|efavirenz|efavirenz 600 mg q.d.
40964747|NCT00042289|DRUG|darunavir/cobicistat|darunavir/cobicistat 800/150 mg q.d.
40964748|NCT00042289|DRUG|lopinavir/ritonavir dosage #1|lopinavir/ritonavir 800/200mg b.i.d.
40964749|NCT00042289|DRUG|atazanavir/ritonavir/tenofovir dosage #1|atazanavir/ritonavir/tenofovir 300/100/300mg q.d.
40964750|NCT00042289|DRUG|rifampicin|rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
40964751|NCT00042289|DRUG|ethambutol|ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.
40964752|NCT00042289|DRUG|isoniazid|isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
40964753|NCT00042289|DRUG|pyrazinamide|pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
40964754|NCT00042289|DRUG|kanamycin|kanamycin (2nd line TB drug)
40964755|NCT00042289|DRUG|amikacin|amikacin (2nd line TB drug)
40964756|NCT00042289|DRUG|capreomycin|capreomycin (2nd line TB drug)
40964757|NCT00042289|DRUG|moxifloxacin|moxifloxacin (2nd line TB drug)
40964758|NCT00042289|DRUG|levoflaxacin|levofloxacin (2nd line TB drug)
40964759|NCT00042289|DRUG|ofloxacin|ofloxacin (2nd line TB drug)
40964760|NCT00042289|DRUG|ethionamide/prothionamide|ethionamide/prothionamide (2nd line TB drug)
40964761|NCT00042289|DRUG|terizidone/cycloserine|terizidone/cycloserine (2nd line TB drug)
40964762|NCT00042289|DRUG|para-aminosalicylic acid (PAS)|para-aminosalicylic acid (PAS) (2nd line TB drug)
40964763|NCT00042289|DRUG|high dose INH|high dose INH (2nd line TB drug)
40964764|NCT00042289|DRUG|bedaquiline|bedaquiline (2nd line TB drug)
41294827|NCT05964725|DEVICE|Receive traditional medical therapy and transcranial direct current stimulation|Equipment used: Bricon tDCS stimulator, high-precision electrode stimulation method Stimulant dose: 1.5mA Stimulation time: 20 minutes/time, continuous treatment for 5 days Stimulation course: 5 days/course Stimulation target: left auditory cortex area, i.e., under system 10-20, left T3 position.
41456985|NCT01156441|PROCEDURE|surgical mitral valve repair w/ mitral valve annuloplasty|"Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.~Intraoperative transesophageal echocardiography will be performed on all study volunteers."
40766425|NCT05296798|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
40766426|NCT05296798|DRUG|Optional Endocrine Therapy of Investigator's Choice|For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.
40964765|NCT00042289|DRUG|clofazamine|clofazamine (2nd TB drug)
40964766|NCT00042289|DRUG|delamanid|delamanid (2nd line TB drug)
40964767|NCT00042289|DRUG|linezolid|linezolid (2nd line TB drug)
40964768|NCT00042289|DRUG|pretomanid|pretomanid (2nd line TB drug)
40964769|NCT00042289|DRUG|ethinyl estradiol|oral contraceptives formulated with 30-35 μg ethinyl estradiol
40964770|NCT00042289|DRUG|etonogestrel implant|etonogestrel implant contraceptive
40964771|NCT00042289|DRUG|nevirapine|nevirapine 200 mg twice a day
41294828|NCT05964725|DEVICE|Receive traditional medical therapy and sham stimulation|By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
40964772|NCT00042289|DRUG|amprenavir|amprenavir 1200mg twice a day
40964773|NCT00042289|DRUG|abacavir|abacavir 300mg twice a day
40964774|NCT00042289|DRUG|lopinavir/ritonavir dosage #2|lopinavir/ritonavir (Kaletra) 400/100mg twice a day
40964775|NCT00042289|DRUG|indinavir/ritonavir dosage #1|indinavir/ritonavir 800/100mg twice a day
40964776|NCT00042289|DRUG|fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg twice a day
40964777|NCT00042289|DRUG|lopinavir/ritonavir dosage #3|lopinavir/ritonavir (Kaletra) 533/133 mg twice a day
40964778|NCT00042289|DRUG|atazanavir/ritonavir dosage #1|atazanavir/ritonavir 300/100 mg once a day
40964779|NCT00042289|DRUG|didanosine delayed release (Videx® EC)|didanosine delayed release (Videx® EC) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg
40964780|NCT00042289|DRUG|emtricitabine|emtricitabine 200 mg once a day
40964781|NCT00042289|DRUG|tenofovir|tenofovir 300 mg once a day
40964782|NCT00042289|DRUG|nelfinavir dosage #1|nelfinavir \[625 mg tablets\] 1250 mg twice a day
40964783|NCT00042289|DRUG|tipranavir/ritonavir|tipranavir/ritonavir 500/200 mg twice a day
40964784|NCT00042289|DRUG|lopinavir/ritonavir dosage #4|lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day
40964785|NCT00042289|DRUG|raltegravir|raltegravir 400 mg twice a day
40964786|NCT00042289|DRUG|etravirine|etravirine 200 mg twice a day
40964787|NCT00042289|DRUG|maraviroc|maraviroc 150 mg or 300 mg twice a day
40964788|NCT00042289|DRUG|atazanavir/ritonavir dosage #2|atazanavir/ritonavir 400/100mg once a day
40964789|NCT00042289|DRUG|tenofovir/atazanavir/ritonavir dosage #2|tenofovir/atazanavir/ritonavir 300/400/100 mg once a day
40964790|NCT00042289|DRUG|nelfinavir dosage #2|nelfinavir \[625 mg tablets\] 1875 mg twice a day
40964791|NCT00042289|DRUG|indinavir/ritonavir dosage #2|indinavir/ritonavir 400/100 mg twice a day
40964792|NCT00042289|DRUG|rilpivirine|rilpivirine (25 mg q.d.)
40964793|NCT00042289|DRUG|darunavir/ritonavir dosage #4|darunavir/ritonavir once daily 800/100 mg q.d.
40964794|NCT05239247|OTHER|Mckenzie extension exercise|"Hot pack applied on lumbar region for (ten minute). Mckenzie extension exercise performed 02 sets of 05 repetitions with 45 second hold and 15 sec rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
40964795|NCT05239247|OTHER|Eldoa stretch technique|"Hot pack applied on lumbar region for (ten minute). Eldoa stretch performed 02 sets of 05 repetitions with 45 second hold and 15 second rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
40964796|NCT02015572|BEHAVIORAL|Occupational intervention|Early coordinated occupational intervention and supervision in physically activities by a physiotherapist.
40964797|NCT02015572|OTHER|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist coordinated by the patient's general physician
40964798|NCT00469183|DRUG|Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%|Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses
40964799|NCT06431087|OTHER|Mindfulness course|Online or in presence Information on Mindfulness, healthy diet and exercise.
40964800|NCT00495183|DRUG|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
40964801|NCT00495183|DRUG|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
40964802|NCT00495183|DRUG|Placebo|Placebo
40964803|NCT00541710|DIETARY_SUPPLEMENT|genistein|pills of 27 mg, twice per day for 12 months
40964804|NCT00541710|DIETARY_SUPPLEMENT|placebo|sugar pills twice per day for 12 months
40964805|NCT06284291|DIAGNOSTIC_TEST|transcranial magnetic stimulation (TMS)|The STM9000 Standard-BI stimulator with 70 mm refrigerated butterfly stimulator (EB Neuro, Florence, Italy) controlled by Galileo Netbrain 9000 hardware and software (EB Neuro, Florence, Italy) is used. EMG data are recorded from the contralateral dorsal first interosseous muscle using gelled surface electrodes. EEG data are recorded by using the BE PLUS PRO Advanced EEG/EMG/EP amplifier (EB Neuro, Florence, Italy IT).
40964806|NCT00476697|DEVICE|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
40964807|NCT00816764|BIOLOGICAL|AGS-8M4|IV Infusion
40964808|NCT04866225|DRUG|Oral [14C]PF-06865571|Oral radiolabeled PF-06865571
40964809|NCT04866225|DRUG|Oral PF-06865571|Oral PF-06865571
40964810|NCT04866225|DRUG|IV [14C]PF-06865571|IV radiolabeled PF-06865571
40964811|NCT03258268|DEVICE|Standard of Care with EASY DSS|"The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.~Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
40964812|NCT03258268|OTHER|Standard of Care without EASY DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
40964813|NCT01616667|PROCEDURE|Total hip arthroplasty|The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
40964814|NCT03680105|DRUG|RJX|RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
40964815|NCT03680105|DRUG|Placebo|Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
40964816|NCT03292562|DEVICE|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
40964817|NCT03292562|DEVICE|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
40766427|NCT04678258|PROCEDURE|HR electroanatomic mapping and MVG catheter ablation|High resolution CTI mapping using the mini-electrodes at the 8 mm catheter tip followed by voltage guided ablation
40964818|NCT03645798|BEHAVIORAL|"Three good things therapy"|"To maintain an emphasis on the positive experience, participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good thing, participants were required to answer the question: Why did this good thing happen?"
40964819|NCT03645798|BEHAVIORAL|Normal psychological instruction|Normal psychological instruction is a convenient method set by the hospital. Nurses who have stress or psychological problem could find help through this intervention. It was delivered by psychologists.
40964820|NCT02294591|DRUG|N-acetylcysteine|Add-on treatment of NAC
40964821|NCT02294591|DRUG|Placebo|Add-on treatment of placebo
40964822|NCT02803632|BEHAVIORAL|questionnaires|
40766428|NCT04678258|PROCEDURE|Conventional bipolar mapping and linear catheter ablation|Bipolar mapping and conventional anatomic linear catheter ablation
40964823|NCT02803632|DEVICE|actigraphic recording|
40964824|NCT03375775|DRUG|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy|According to standardized clinical protocol
40964825|NCT03375775|OTHER|No immunotherapy, symptomatic treatment|These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
40964826|NCT02940535|DRUG|Diphereline (Triptorelin embonate)|
40964827|NCT02940535|DRUG|Decapeptyl (Triptorelin)|
40964828|NCT02940535|DRUG|human menopausal gonadotropin|
40964829|NCT02940535|DRUG|human chorionic gonadotropin|
40964830|NCT01119417|DRUG|BQ123|Low dose day: 25 nmol/min, single IV infusion for 15 min.
40964831|NCT01119417|DRUG|BQ123|Low dose day: 50 nmol/min, single IV infusion for 15 min
40964832|NCT01119417|DRUG|Bq123|High dose day: 100 nmol/min, single IV infusion for 15 min.
40964833|NCT01119417|DRUG|BQ123|High dose day: 300 nmol/min, single IV infusion for 15 min.
40964834|NCT01119417|DRUG|Saline|2-3 IV saline infusions for 15 min each.
40964835|NCT00833794|DRUG|Tramadol Once a day|
40964836|NCT00833794|DRUG|Placebo|
40964837|NCT04986423|DRUG|ZEN003694|72 mg PO QD
40964838|NCT04986423|DRUG|Enzalutamide|160 mg PO QD
40964839|NCT03384095|DRUG|Hyaluronic Acid (HA)|Dosage form: hyaluronic capsules; Dose: 100 mg; Frequency: twice daily; Duration: 26 weeks
40964840|NCT03384095|OTHER|Placebo|Dosage form: microcrystalline cellulose (MCC) capsules; Dose: approx. 100 mg (determined by weight of HA counterpart); Frequency: twice daily; Duration: 26 weeks
40964841|NCT02185092|DIETARY_SUPPLEMENT|Lactobacillus GG|probiotic supplement
40964842|NCT02185092|OTHER|Sugar pill|placebo
40964843|NCT01600638|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
40964844|NCT04391127|DRUG|Hydroxychloroquine|Hydroxychloroquine: 400 mg PO every 12 hours for one day. Subsequently 200 mg every 12 hours per 4 more days.
40964845|NCT04391127|DRUG|Ivermectin|Ivermectin 12 mg PO every 24 hours for one day (in case of weight less than 80 kg) or 18 mg PO every 24 hours for one day (in case of weight over 80 kg) Subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.
40964846|NCT04391127|DRUG|Placebo|Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
40964847|NCT00779701|DRUG|Insulin|Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
40964848|NCT00822783|DRUG|Omalizumab|
40964849|NCT00822783|DRUG|Placebo|
41137171|NCT02298166|DRUG|Placebo|"Induction therapy:~Placebo to be given as p.o. TID starting d 7+, given continuously thereafter until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with placebo is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with placebo will be given at the same dose tolerated during induction therapy."
40964850|NCT00517816|DRUG|RG1671|Administered iv at escalating doses (with a starting dose of 0.0015mg)
40964851|NCT01116583|DRUG|Gabapentin|"Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)~Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)~Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)~Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)"
40964852|NCT01116583|DRUG|Placebo|"Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4"
40964853|NCT01018966|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
40964854|NCT02034383|OTHER|Control|Controlled diet for 3 weeks with 0 servings/day of almonds.
40964855|NCT02034383|OTHER|Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
41294829|NCT06554366|DEVICE|GentleWave|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the GentleWave procedure will be performed
40766431|NCT05974800|BEHAVIORAL|Emergency department caregivers interview|The interview focuses on several parts of the emergency care process: The first part is regarding the actions that are executed during an emergency department visit. We will establish which actions are executed and why. The second part is regarding the suspected outcome for the patient. The third part will be about any potential improvements to the emergency care process for the patient.
40766432|NCT03173950|DRUG|Nivolumab|Participants will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
40766433|NCT05765175|DEVICE|Varian Cardiac Radioablation (CRA)|Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.
40766434|NCT05765175|PROCEDURE|Catheter Ablation (CA)|Subjects randomized to the CA arm will be treated according to a uniform CA protocol.
40766435|NCT05683977|DRUG|durvalumab|Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
40766436|NCT03662451|PROCEDURE|Robotic assisted hysterectomy|Periumbilical single incision vs multiple abdominal incisions for hysterectomy
40766437|NCT06642688|OTHER|Sacroiliac Joint Manipulation|The patient was asked to tie his arms while he was in the side lying position. The patient's upper knee was flexed and positioned such that it was placed in the popliteal fossa of the lower knee, while the lower knee was in full extension. Pushing maneuver was performed with HVLA from posterior to anterior and from medial to lateral with pelvic rotation. The contact point of the sacroiliac joint was PSIS.
40766438|NCT06642688|OTHER|Cervical Spine Manipulation|Cervical SM was applied supine to restrictions found on motion palpation, according to the technique described by Bergmann and Peterson28 The participant's head and neck were simultaneously rotated and laterally flexed over the contact point-specifically, the posterior supramastoid groove or zygomatic arch (C0-C1), the posterior aspect of the transverse process (C1-C2), or the posterior articular pillar of superior vertebrae (C2-C7) -to the end of passive ROM. Thereafter, a high-velocity, low-amplitude thrust was delivered in the direction of restricted movement. Participants with more ROM restriction in the lateral plane were given more lateral-to-medial directed thrusts; participants with more restriction in rotation were given thrusts in the direction of restricted axial rotation; and participants with more restriction in extension were given more anteriorly directed thrusts.
40766439|NCT05947955|DRUG|Rhu-pGSN|Intravenous administration based on actual body weight
40766440|NCT05947955|DRUG|normal saline|intravenous administration in the same volume as the active therapy
40766441|NCT04139304|DRUG|Cyclophosphamide|Given IV
40766442|NCT04139304|BIOLOGICAL|Daratumumab|Given IV
40766443|NCT04139304|DRUG|Doxorubicin|Given IV
40766444|NCT04139304|DRUG|Doxorubicin Hydrochloride|Given IV
40766445|NCT04139304|DRUG|Etoposide|Given IV
40766446|NCT04139304|DRUG|Prednisone|Given PO
40766447|NCT04139304|DRUG|Vincristine|Given IV
40766448|NCT04139304|DRUG|Vincristine Sulfate|Given IV
40766449|NCT06642597|OTHER|Incremental PD|Incremental PD: Commence PD using goal-directed PD prescription ≤14 exchanges/week for continuous ambulatory PD (CAPD) or ≤21 exchanges/week for automated PD (APD) with no day dwell until an indication for increase in the PD dose (trigger point) is reached.
40766450|NCT06642597|OTHER|Full dose PD|Full dose PD: Commence with 24 hours, 7 days/week PD (i.e., CAPD ≥28 exchanges/week or APD (overnight) with day dwell (i.e., no dry abdomen)).
40766451|NCT05402332|DRUG|AVTX-801|D-Galactose medical grade supplement - 1.5g/kg/day (not to exceed 50 g/day)
40766452|NCT05402332|DRUG|Placebo|placebo equivalent
40766453|NCT06587230|BEHAVIORAL|Teachers Leading the Frontlines|"1. During 3-day training, Knowledge and attitudes toward child mental health care are measured pre-training, post-training, and post-intervention.~2. The teachers select students whom they believe have the highest mental health needs to receive care.~3. Teachers analyze chosen students' symptoms.~4. Teachers analyze students' behavior with the AABC Chart.~5. Teachers develop a targeted response using a behavior plan called the 4Cs plan (Cause, Change, Connect, and Cultivate). In the 4Cs, teachers select therapeutic techniques to deliver from a menu of evidence-based therapeutic options for each category of behavior.~6. Throughout the year, teachers receive supervision through monthly site visits supplemented by as-needed telephone and digital discussions to guide their care from the study team. Teachers encourage the use of the 4Cs plan at home."
40766454|NCT06587230|BEHAVIORAL|Responding to Students' Emotions Through Education|"All processes for RE-SEED are the same as in Tealeaf except...~1. Teachers receive only 1 day of training~2. The study team does not provide supervision to the teachers, allowing only the school counselor to provide supervision~This less resource-intensive approach will allow for an ethical comparator to Tealeaf, where the schools would like for teachers to have some skills to support identified students."
40964856|NCT02034383|OTHER|Roasted Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
40964857|NCT02034383|OTHER|Diced Almonds|Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
40964858|NCT02034383|OTHER|Almond Butter|Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
40964859|NCT01434667|BEHAVIORAL|APOE genotype and Alzheimer's disease risk disclosure|Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
41294830|NCT06554366|DEVICE|EdgePro laser irrigation|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the EdgePro procedure will be performed
40964860|NCT01434667|BEHAVIORAL|Alzheimer's disease risk disclosure|Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
40964861|NCT04674930|OTHER|Exercise program|Home based exercise program including aerobic and resistance training will be carried out for a period of 6 weeks. Duration of aerobic exercise will be starting at 20 min/session, and progress to 30 ruin/session, with an increased pace according to the patient's capabilities. Resistance training with thera-band for 1 set of 10 repetitions twice a week. One RM will be reassessed weekly, and the program will be adjusted accordingly.
40766455|NCT06293183|OTHER|Mobile app|Participants in the intervention group will be expected to watch the training video in the mobile application installed on their phones or tablets and then regularly enter all the food and liquid amounts they consume during the day into this application. In the mobile application data entry area, visuals that will be included in the application showing the amount and types of foods consumed by the participants during the day (1 soup bowl, 1 vegetable dish plate, 1 meat dish plate, 1 water glass, 1 tea glass, tablespoon, dessert spoon, teaspoon, ladle). etc.) will choose through. The mobile application will calculate the total amount of liquid consumed by the participants in 24 hours, and will give a yellow warning when the amount of liquid consumed is 2-2.5 liters, an orange warning when it is 2.5-3 liters, and a red warning when it is 3 liters and above. This will contribute to reducing the amount of fluid intake of participants between two dialysis sessions.
40964862|NCT05878860|BIOLOGICAL|ATSN-201|AAV.SPR-hGRK1-hRS1syn
40964863|NCT04353518|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Subjects randomized to Test arm will receive intraderma Mw in divided doses at least 2 cm away from first injection site in the deltoid region.
40964864|NCT04353518|OTHER|Placebo|Subjects randomized to placebo arm will receive intraderma Placebo in divided doses at least 2 cm away from first injection site in the deltoid region.
40964865|NCT00169598|PROCEDURE|positron emission tomography|
40964866|NCT03953196|BIOLOGICAL|Imvanex|Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.
40964867|NCT03953196|BIOLOGICAL|Shingrix|Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.
40964868|NCT03953196|BIOLOGICAL|LPS|LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.
40964869|NCT03953196|BIOLOGICAL|Candin|Candin 0.1 mL solution for injection will be administered as one intradermal injection.
40964870|NCT03953196|OTHER|Skin Biopsy|3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.
40964871|NCT03953196|OTHER|Saline Control|Saline control solution for injection will be administered as one intradermal injection.
40964872|NCT05132387|OTHER|ECMO assisted CPR in out-of-hospital cardiac arrest|Patients included in the registry will be transferred during LUCAS assisted CPR by the Wroclaw Emergency Medical Services to the Emergency Department of the Wroclaw University Hospital where blood gasses will be assessed. If two or more of the following: end-tidal carbon dioxide (CO2) \> 10 mm Hg, arterial partial pressure of oxygen (PaO2) \>50 mm Hg or oxygen saturation \>85%, and lactic acid \<18 mmol/L will be fulfilled patient will be further transferred to the Cardiac Catheterization Laboratory for V-A ECMO implantation followed by coronary/pulmonary artery angiography and intervention.
41294831|NCT06554366|DEVICE|Irrisafe passive ultrasonic irrigation|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the passive ultrasonic irrigation procedure will be performed
40766456|NCT05525520|DRUG|EP547|Once daily
40766457|NCT05525520|DRUG|Placebo|Once daily
40964873|NCT03493594|OTHER|Nutrition education program|online platform support, workshop, seminar and cooking demo etc
40964874|NCT00307411|DRUG|Growth hormone|
40964875|NCT05120128|DEVICE|Acuvue® Oasys 1-Day|TEST Lens
40964876|NCT03392701|BIOLOGICAL|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
40964877|NCT02014025|PROCEDURE|Open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
40964878|NCT02014025|PROCEDURE|Laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept Laparoscopic Hepatectomy: tumors are totally resected through laparoscopic.
40964879|NCT04460638|BIOLOGICAL|Saliva collection|Saliva samples are regularly collected over a period of up to 30 consecutive days.
40964880|NCT04460638|OTHER|Clinical assessment|The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
40964881|NCT02495298|PROCEDURE|Fascial Manipulation|The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
40964882|NCT02495298|PROCEDURE|Sham Fascial Manipulation|After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
40964883|NCT04047745|DRUG|Liposomal bupivacaine|interscalene nerve block administered before surgery using 133 mg liposomal bupivacaine with 10mL 0.5% ropivacaine
40964884|NCT04047745|DRUG|Ropivacaine injection|interscale nerve block administered before surgery using 30mL 0.5% ropivacaine
41294832|NCT00092144|DRUG|MK0476, montelukast sodium / Duration of Treatment: 4 weeks|
41294833|NCT00092144|DRUG|Comparator: placebo / Duration of Treatment: 4 weeks|
41294834|NCT00480753|DRUG|Nitroglycerin|
41294835|NCT01823796|OTHER|Fibromyalgia women group|Assessment of this group at baseline in order to be compared with a control group.
41456986|NCT04974580|DRUG|Nicotine patch|NRT will be discussed and dosed by the study quit coach during coaching calls per quitline dosing protocols. NRT treatment will consist of up to an 8 week supply of nicotine patch, gum, and/or lozenge. NRT will be sent in two 4 week shipments. Participants may be dosed for a single form of NRT or combination NRT (patch plus gum or lozenge) based on coach assessment of nicotine use and participant preference.
41456987|NCT04974580|BEHAVIORAL|Phone Counseling|Participants in all four arms of the study will receive two proactive phone-based behavioral coaching calls for quitting vaping, which will include making a quit plan, learning to cope with urges to vape, and education on strategies for quitting and staying quit. Calls utilize the quitline evidence-based protocol. The first call lasts approximately 20 minutes, the second calls lasts approximately 10 minutes, and participants are encouraged to call in for ad hoc calls if they would like additional support.
41456988|NCT04974580|BEHAVIORAL|Digital Coaching|Intervention descriptionText-based vaping cessation program that utilizes evidence-based content from the quitline tobacco cessation protocol, as well as links directing participants to additional online educational content (brief videos, audio content, quizzes, and educational activities).
41456989|NCT05885386|DRUG|Temozolomide|TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
41456990|NCT02218541|DEVICE|abutment margin 0.5 mm subgingival|
41456991|NCT02218541|DEVICE|abutment margin 1.5 mm subgingival|
41456992|NCT03513224|OTHER|eDosette|The eDosette is an internet-enabled, medication administration monitoring unit that has been previously tested for feasibility in older adults. The eDosette was designed to be compatible with different types of weekly medication blister packs and dosettes, and monitors medication-taking behaviour in a patient's home. The eDosette securely transmits this information to a secure server where the information is converted to individual medication administration records. Patients can also use the eDosette to notify their primary care team of potential medication side effects.
41456993|NCT01710280|DIETARY_SUPPLEMENT|High-fat meal containing native palm olein|
41456994|NCT01710280|DIETARY_SUPPLEMENT|High-fat meal containing interesterified palm olein|
41456995|NCT00210639|DRUG|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
41456996|NCT05820828|DIAGNOSTIC_TEST|Volume control|Volume control in venous reservoir during extracorporeal circulation.
41456997|NCT02759380|OTHER|Phytoestrogen-rich foods|The patients will be given a package containing food with a high amount of phytoestrogens (≥100 mg isoflavonoids and ≥100 mg lignans) that are to be consumed daily. The food-package contains 30 grams of flaxseed, 25 grams of roasted soybeans and 50 grams of frozen green edamame beans to be consumed daily.
41456998|NCT03330496|OTHER|Pain Measurement|Measurement of infant responses (behavioral and physiological) during a painful procedure.
41456999|NCT01742208|DRUG|Sotagliflozin|Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.
40766458|NCT06448091|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|After consent and randomization into the immediate PGx testing, participants' results will (10-14 days after randomization) go into their EHR and be returned via a laminated results card
40766459|NCT06640205|PROCEDURE|pulpotomy|Removal of coronal pulp tissue and then placing pulpotomy agent
40766460|NCT05602727|DRUG|MK-1942|MK-1942 oral capsule
40766461|NCT05602727|DRUG|Placebo|Placebo oral capsule
40964885|NCT05722782|DRUG|Piroxicam|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
41294836|NCT01823796|OTHER|Healthy women|These women are assessed in order to be compared with fibromyalgia women group.
41294837|NCT01569204|DRUG|Etoposide|
41294838|NCT01569204|DRUG|Cyclophosphamide|
41294839|NCT01569204|DRUG|Doxorubicin|
41457000|NCT01742208|DRUG|Placebo|Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
41457001|NCT01742208|DRUG|Sotagliflozin|Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
41457002|NCT04969562|BEHAVIORAL|Emotional Freedom Technique|Emotional Freedom Technique (EFT, Emotional Freedom Technique) is a psychophysiological interpretation that combines elements of cognitive behavioral therapy (CBT), exposure therapy, and somatic stimulation using acupuncture points.
41457003|NCT03185741|BEHAVIORAL|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
41457004|NCT03185741|BEHAVIORAL|SMS Text Messaging|Patients will receive daily text message reminders about when to take medicines based on UMS intervals.
41457005|NCT00143273|DRUG|lasofoxifene|0.05 mg tablets
41457006|NCT00143273|DRUG|Placebo|0 mg
41457007|NCT00143273|DRUG|Lasofoxifene|0.25 mg tablets
41457008|NCT00143273|DRUG|Lasofoxifene|0.5 mg tablets
41457009|NCT03151954|PROCEDURE|functional endonasal sinus surgery|collect nasal polyps from patients
41457010|NCT03151954|PROCEDURE|nasal septal construction|collect inferior turbinates from patients as control arm
41457011|NCT05511662|OTHER|PRO follow up|On the basis of the routine follow-up group, interactive follow-up was conducted through the chronic disease follow-up system, including the APP for regular follow-up (bound to sign the informed consent form, and the account of the patient and his immediate family who can be familiar with the WeChat applet), SMS reminders, and doctors when necessary. Wechat/platform communication and exchange, inappropriate ECG data upload and other multi-dimensional follow-up, at the same time assisting the ECG integrated follow-up platform for ECG data management and medication guidance
41457012|NCT03008005|DRUG|Placebo Oral Capsule|Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
40766462|NCT02422550|DEVICE|MRI or CT|Participants enrolled on this protocol may undergo multiple MRI or CT examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
41294840|NCT01569204|DRUG|Prednisone|
41294841|NCT01569204|DRUG|Procarbazine|
41294842|NCT01569204|DRUG|Dexamethasone|
41294843|NCT01569204|DRUG|Dacarbazine|
41294844|NCT01569204|DRUG|Brentuximab Vedotin|
41294845|NCT02033551|DRUG|Veliparib|
41294846|NCT02033551|DRUG|Carboplatin|
41294847|NCT02033551|DRUG|Paclitaxel|
41294848|NCT02033551|DRUG|FOLFIRI|combination of Fluorouracil, leucovorin and irinotecan
41294849|NCT04576351|OTHER|Observation|The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.
41457013|NCT03008005|DRUG|Dronabinol Cap 5 milligrams (MG)|Dronabinol (5mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
40766463|NCT06644326|DRUG|100mg IkT-148009 Wet|100mg wet tablet formulation
40766464|NCT06644326|DRUG|200 mg Itraconazole|2 100mg capsules
41457014|NCT03008005|DRUG|Dronabinol Cap 10 milligrams (MG)|Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
40766465|NCT06644326|DRUG|100mg IkT-148009 Dry|100mg dry tablet formulation
40766466|NCT06644326|DRUG|50mg IkT-148009 Wet|50mg wet tablet formulation
41137172|NCT02298166|DRUG|Crenolanib|"Induction therapy:~Crenolanib to be given as p.o. TID starting d 7+, given continuously until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Crenolanib will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with Crenolanib is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with Crenolanib will be given at the same dose tolerated during induction therapy."
41294850|NCT00393289|BEHAVIORAL|Calcium controlled diet|
41457015|NCT02779933|OTHER|Epidemiology od HAP|no intervention
41457016|NCT00721162|BIOLOGICAL|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
41457017|NCT00413049|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
41457018|NCT00413049|DRUG|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
40964886|NCT05722782|DRUG|Acetaminophen|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 1000 mg Acetaminophen per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
41294851|NCT00053846|DRUG|buspirone hydrochloride|The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
40766469|NCT06614933|DEVICE|Biphasic transcutaneous auricular vagus nerve stimulation|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a biphasic current, continuous at 25 Hz, for 1 hour, in-person.
40766470|NCT06614933|DEVICE|Monophasic transcutaneous auricular vagus nerve stimulation|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a monophasic current, with a 50% duty cycle at 25 Hz, for 1-hour, in-person.
40766471|NCT06462456|DEVICE|Verofilcon A spherical soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)
41294852|NCT00053846|DRUG|Placebo|Placebo
41294859|NCT05280015|DIETARY_SUPPLEMENT|microbiotherapy (GynMDD)|multi-target microbiotherapy add-on venlafaxine
41294860|NCT05280015|OTHER|placebo|placebo add-on venlafaxine
41294861|NCT01704872|DRUG|ch14.18/CHO|
41294862|NCT03630614|DRUG|Electronic cigarette without nicotine (ECwN) plus active varenicline tablets|"The ECwN group use EC liquids containing 0 mg/mL of nicotine. Because nicotine delivery can be adjusted according to the user's need, all participants are able to adjust their individual nicotine dose by varying the wattage of their EC, by varying puff frequency and puff volume similarly as they are doing (or used to do) with conventional cigarettes.~EC device:~Mini iStick kit (20 W) Eleaf Clearomiser :GS Air M with resistance of 1.5 ohm, the clearomiser's Pyrex window is of blue colour not allowing to distinguish an eventual coloration of the e-liquid containing nicotine. Liquids for EC use are delivered in white opaque 10 mL vials not allowing to distinguish the color of the liquid.~Varenicline, Champix® 0.50 mg tablets Posology of vareniclin follows varenicline's monograph."
40964887|NCT05722782|DRUG|Placebo|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
41457019|NCT01424020|OTHER|Questionnaire|Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
40964888|NCT06388434|BEHAVIORAL|Protective Arm Balance Response Training|Participants will be trained in the reach to grasp arm balance response while being exposed to unpredictable balance perturbations
40964889|NCT03535610|DEVICE|Uterine Embolization|Uterine Embolization with PVA Microspheres
40964890|NCT02590367|DRUG|FOLFOX regimen|"FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks."
40964891|NCT02590367|DRUG|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
40964892|NCT02590367|DRUG|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
40964893|NCT06455644|OTHER|CT group|After completing the AF ablation, select the appropriate LAA occluder based on preoperative CT measurements for implantation.
40964894|NCT06455644|OTHER|DSA group|After completing the AF ablation, select the appropriate LAA occluder based on intraoperative DSA measurements for implantation.
40964895|NCT03602144|OTHER|Carbohydrate|Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
40964896|NCT03602144|OTHER|Protein|Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
40964897|NCT02194244|DRUG|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
40964898|NCT02194244|DRUG|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
40964899|NCT01650844|OTHER|School-Based Telemedicine Enhanced Asthma Management|
40964900|NCT01650844|OTHER|Enhanced Usual Care|
40964901|NCT01497158|OTHER|Self-help brochure|Self help brochure given at baseline visit.
40964902|NCT01497158|OTHER|Biomarker feedback|Biomarker feedback from urine of adult non-smoker in the home.
41294863|NCT03630614|DRUG|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline|"The ECwoN group receives EC liquids with 0 mg/mL of nicotine on a double blind manner (in identical non-transparent refill bottles of 10 mL).~Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph."
41294864|NCT03630614|DRUG|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline|The ECwN group use EC liquids containing 12 mg/mL of nicotine. Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
41457020|NCT05889039|DEVICE|BEMER|Bio-Electro-Magnetic Energy Regulation (BEMER) is an emerging therapeutic modality that deploys a biorhythmically defined stimulus through a pulsed electromagnetic field and has been shown to reduce musculoskeletal pain.
41457021|NCT05889039|PROCEDURE|OMT|Osteopathic manipulative therapy (OMT) is a form of manual therapy utilized by osteopathic physicians and some allopathic physicians to treat a broad variety of musculoskeletal ailments, including neck pain.
41457022|NCT05889039|PROCEDURE|Sham OMT + Sham BEMER|Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
41457023|NCT02582554|BEHAVIORAL|NutriSTEP|Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
40964903|NCT01540838|DRUG|Infusion with paracetamol|The administration of 250 mg/kg/24 hours cefotaxime during the first 4 days as continuous intravenous infusion, each single infusion lasting for 12 hours (to prevent degradation of the agent), combined with high-dose paracetamol orally; the first dose is 30 mg/kg, then 20 mg/kg every 6 hours for 4 full days.
40964904|NCT01540838|DRUG|Bolus without paracetamol|The control intervention consists of 250 mg/kg/24 hours cefotaxime administered traditionally with intermittent i.v. boluses and the place bo of paracetamol orally, both repeated every 6 hours (qid) for 4 days.
40964905|NCT06506747|DEVICE|Navigated Photogrammetry|Navigated Photogrammetry shall be performed following implant surgery, rather than standard stereophotogrammetry. The patient will then receive a provisional that was manufactured using the data from FastMap Navigated Photogrammetry.
40964906|NCT06506747|DEVICE|Standard Photogrammetry|The patient will receive the existing patient care protocol that includes anatomy information for the manufacturing of the provisional. Specifically, the patient will receive a preoperative IntraOral Scan (IOS) anatomy scan with IOS-compatible fiducials. Following implant surgery, the patient will receive a scan with a standard stereophotogrammetry device. Additionally, they will receive a post-op alignment IOS with IOS-compatible anatomy fiducials and IOS-compatible implant scan bodies. The patient will then receive a provisional that was manufactured using the data from the standard stereophotogrammetry device.
40964907|NCT02165969|PROCEDURE|endoscopic endonasal surgery with UPSIT|
40964908|NCT05473390|OTHER|functional electrical stimulation|functional electrical stimulation on back muscles
40964909|NCT05473390|OTHER|kinesotaping|no intervention
40964910|NCT01233531|BEHAVIORAL|monthly cash transfer payments for attending school|In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
40964911|NCT01233531|BEHAVIORAL|B--No cash transfers|No monthly cash transfers
40964912|NCT01939652|PROCEDURE|Restrictive VS Standard Fluid Regime|
40964913|NCT01939652|DRUG|Drag: Crystalloids and Colloids|
40964914|NCT03615378|DIETARY_SUPPLEMENT|5000 IU D3|Daily
40964915|NCT03615378|DIETARY_SUPPLEMENT|1000 IU D3|Daily
40964916|NCT03615378|DIETARY_SUPPLEMENT|Placebo|lactose/sugar tablet
40964917|NCT00521014|BIOLOGICAL|filgrastim|
40964918|NCT00521014|BIOLOGICAL|rituximab|
40964919|NCT00521014|BIOLOGICAL|sargramostim|
40964920|NCT00521014|DRUG|carmustine|
40964921|NCT00521014|DRUG|cytarabine|
40964922|NCT00521014|DRUG|etoposide|
40964923|NCT00521014|DRUG|melphalan|
40964924|NCT00521014|PROCEDURE|autologous hematopoietic stem cell transplantation|
40964925|NCT05746949|PROCEDURE|oxygenization techniques|to compare the effects of high-flow nasal oxygen and jet ventilation on oxygenation in patients who will receive general anesthesia for endolaryngeal surgery.
40964926|NCT05375370|OTHER|circulating tumor DNA dosage|blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
40964927|NCT02730429|DRUG|Palbociclib/placebo|Palbociclib or a placebo is administered together with standard of care letrozole
40964928|NCT02730429|DRUG|Letrozole|Letrozole is standard of care in both arms
40964929|NCT02546453|BIOLOGICAL|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
40964930|NCT02546453|BIOLOGICAL|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
40964931|NCT04904328|DEVICE|Lumishade® Active Lens|"Migraine episodes are often triggered or exacerbated by environmental factors, particularly light. Active lens has been designed by blocking particular range of wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)"
41294865|NCT06048575|PROCEDURE|Cholecystectomy|Early or late surgery, ambulatory, emergency, or differed.
41294866|NCT01020292|DRUG|Nelfinavir|
40964932|NCT04904328|DEVICE|Lumishade® Sham Lens|"Lumishade® Sham lens has been designed as inactive and not blocking particular range of wavelength. Thus, it will not alleviate or prevent symptoms of migraine.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)"
40964933|NCT00484432|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 week until confirmed evidence of disease progression or unacceptable toxicity occurs
40964934|NCT00484432|DRUG|doxorubicin|Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²
41294867|NCT02151500|BEHAVIORAL|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
41457024|NCT01077505|BIOLOGICAL|albiglutide|albiglutide 50mg weekly subcutaneous injection
40964935|NCT04991415|OTHER|Manual Therapy|
40964936|NCT02576002|DRUG|Assigned pulmonary hypertension medication|As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
40964937|NCT01184300|GENETIC|Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers|Patients found to carry the CYP2C19\*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
40964938|NCT05547685|DIAGNOSTIC_TEST|Methylene blue intradermal injection|Methylene blue intradermal injection
40964939|NCT06055010|OTHER|No interventions|Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.
40964940|NCT01845831|DRUG|Sitagliptin|Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
40964941|NCT01845831|DRUG|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
40964942|NCT01845831|DRUG|Metformin and Sitagliptin|Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
40964943|NCT01845831|DRUG|Glargine|"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."
40964944|NCT01845831|DRUG|Glargine 50%|Glargine will be prescribed at 50% of daily hospital dose.
40964945|NCT01845831|DRUG|Glargine 80%|Glargine will be prescribed at 80% of daily hospital dose.
40964946|NCT02771054|DRUG|TAF/FTC|Change of nucleoside backbone
40964947|NCT01744197|DRUG|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
40964948|NCT03129750|DEVICE|Drug Coated Balloon|Peripheral PTA with a drug coated balloon
40964949|NCT03713086|BIOLOGICAL|Rabipur®|3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
40964950|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202 Dose level 1|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
40964951|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202 Dose level 2|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
40964952|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202 Dose level 3|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
41457025|NCT01077505|DRUG|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
41457026|NCT04311346|DIAGNOSTIC_TEST|Cardiac MR|Cardiac MR diagnostic tool for detection of acute rejection, double blind comparison with invasive cardiac biopsy
41457027|NCT05214716|DIAGNOSTIC_TEST|FilmArray Pneumonia panel|A rapid molecular diagnostic test designed to detect 27 bacterial and viral species and 6 major resistance genes from respiratory specimens.
41457028|NCT05821426|DEVICE|eTrieve PE Kit|Patients will be treated with the eTrieve PE Kit
40964953|NCT04176705|DRUG|Lidocaine Cream|Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
40964954|NCT04176705|DRUG|Triamcinolone Acetonide Cream|Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.
40964955|NCT04176705|DEVICE|Fractional Ablative Laser|Applied to only site that is randomized to laser intervention
40964956|NCT02292797|OTHER|Prevalence assessment|Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis
40964957|NCT05959031|DEVICE|kTMP|a new non-invasive brain stimulation tool
40964958|NCT05959031|DEVICE|Sham kTMP|a new non-invasive brain stimulation tool with sham setting selected
40964959|NCT04034485|DRUG|lerodalcibep|PCSK9 inhibitor
40964960|NCT04034485|DRUG|evolocumab|PCSK9 inhibitor
41294868|NCT01276847|DRUG|Ustekinumab|Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing \> 100 kg on Day 1, and Weeks 4 and 16
41294869|NCT01276847|DRUG|Etanercept|Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
41457029|NCT02272335|BEHAVIORAL|Group Sessions|"10 weekly sessions:~* CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~* CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain"
41457030|NCT05373576|BEHAVIORAL|TACHIDINO|"TACHIDINO is based on two principles a) selective stimulation of a cerebral hemisphere and specific reading strategies, and b) the training of selective visuospatial attention, as well as the perception of rapid movement and the visual characteristics of words even in the presence of so-called visual crowding or crowding, an automatic effect of our perceptual system that leads to obfuscation of the visual areas surrounding the object to be analyzed, to make its vision clearer (as suggested by the Magnocellular theory of dyslexia; Stein et al., 2019)."
40964961|NCT00753467|DRUG|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
40964962|NCT00753467|DRUG|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
40964963|NCT00753467|DRUG|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
40964964|NCT05048784|DRUG|Sotorasib|Oral tablet
40964965|NCT02941198|DEVICE|GyneFix|The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity
40964966|NCT02941198|DEVICE|Cu T380 A|Cu T380 A will be inserted into the uterus
40964967|NCT02920372|DRUG|EPOETIN ALFA|
40964968|NCT02478775|DRUG|Degarelix (GnRH antagonist)|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
40964969|NCT02478775|DRUG|recombinant FSH|Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
40964970|NCT02478775|DRUG|Cetrorelix|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist Cetrorelix will be given subcutaneously.
40964971|NCT02033109|DRUG|PC-1005|Intravaginal use
40964972|NCT02033109|DRUG|HEC gel|
40964973|NCT02035930|DRUG|dexmedetomidine|
41294870|NCT03542240|DIETARY_SUPPLEMENT|Curcumin|500 milligram daily supplement
41294871|NCT02228512|DRUG|Pomalidomide|Part A: 5 mg po daily for 21 days (full course) Part A: 5 mg po daily for 4 days (short course) Part B: 5 mg po daily for 5 days (Phase I/II dose) Part C: Phase I/II dose) po daily Day 1-21 of 28 day cycle for up to 12 cycles.
41294872|NCT02228512|DRUG|Rituximab|Part A: 375 mg/m2 day 22 (full course) Part A: 375 mg/m2 day 5 (short course) Part A: 375 mg/m2 day 1 (omit pomalidomode) Part B: 375 mg/m2 day 1
41294873|NCT02228512|DRUG|Prednisone|Part B: 60 mg/m2/day po x 5 days (day 1-5
41294874|NCT02228512|DRUG|Etoposide|Part B: 50 mg/m2/day CIVI over 24 hrs x 4 days
41294875|NCT02228512|DRUG|Doxorubicin|Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
41294876|NCT02228512|DRUG|Vincristine|Part B: 0.4 mg/m2/day CIVI over 24 hrs x 4 days
41294877|NCT02228512|DRUG|Cyclophosphamide|Part B: 750 mg/m2 Day 5
41294878|NCT05604612|PROCEDURE|Corticision|Incisions in the cortical plate of maxillary bone
41457031|NCT01875107|DRUG|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
40766472|NCT06462456|DEVICE|Verofilcon A toric soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
40766473|NCT05927298|OTHER|Non-interventional|Standard of care intervention
41294879|NCT00903461|BIOLOGICAL|EGFR Antisense DNA|"* Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~* EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment."
41294880|NCT05466149|DRUG|Furmonertinib|240mg QD on a continuous dosing schedule.
40964974|NCT03140943|DRUG|Carfilzomib, Thalidomide and Dexamethasone|"Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.~Thalidomide, 100mg po will be given daily during induction cycles 1-12 only."
40964975|NCT04284670|OTHER|EXERCISE|The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
41137173|NCT02298166|OTHER|Allogeneic stem cell transplantation|"In patients achieving a CR or CRi after salvage-reinduction chemotherapy allogeneic HCT from a matched related or unrelated donor is the preferred form of consolidation. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.~Allogeneic HCT should be conducted at the earliest time point after the start of the last chemotherapy but no later than after 56 days. A delay of transplant beyond this time window need to be discussed with the Coordinating Investigator. Patients can receive allogeneic HCT directly after salvage re-induction chemotherapy with MC, but also later on following consolidation with IDAC."
41137174|NCT02736188|DRUG|Aceneuramic Acid Extended-Release Tablets|
41137175|NCT04291859|DRUG|Lu AF28996|capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences
41294881|NCT01731691|BIOLOGICAL|α1 Proteinase Inhibitor|Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.
41137176|NCT01427517|DRUG|N-acetylcysteine|Single, intravenous administration of N-acetylcysteine
40766476|NCT05018507|OTHER|Data collection only|No intervention, just data collection from system machines
40766477|NCT06402136|DRUG|83-0060|Oral MPro inhibitor
41137177|NCT04787198|DRUG|hypertonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
41137178|NCT04787198|DRUG|isotonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
41137179|NCT03043443|DRUG|Melatonin|Natural health product for sleep problems treatment
41137180|NCT03043443|DRUG|Placebo|Lactose containing pills
41137181|NCT00383383|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
41137182|NCT00383383|BIOLOGICAL|Engerix-B|
41137183|NCT03351504|OTHER|Solar lighting system|consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.
41137184|NCT03587415|DIAGNOSTIC_TEST|preptin and amylin level|we will take both of group blood samples to compare them serum preptin and amylin
41137185|NCT03971552|PROCEDURE|gadolinium-enhanced extracranial magnetic resonance angiogram|288 of the 912 acute ischemic stroke patients received gadolinium-enhanced extracranial MRA additionally to the standardized stroke MRI imaging protocol.
41137186|NCT03637075|OTHER|intranasal insulin|intranasal administration of insulin (160 IU)
41294882|NCT01731691|DRUG|Placebos|Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.
40766478|NCT06402136|DRUG|Placebo|Placebo
40766479|NCT06638437|BEHAVIORAL|Cognitive-behavioral therapy|"The mobile application will include the following modules:~1. Psychoeducation: information about what to expect from each phase of the surgical process (i.e., pre-operative, the surgery itself and the post-operative).~2. Activation control techniques: to teach different activation control techniques such as relaxation, breathing techniques and mindfulness training.~3. Cognitive restructuring and problem solving: to teach how to change maladaptive pain-related beliefs for more adaptive ones and how to better cope with pain.~4. Exercises and tasks: to encourage the use of the learning strategies we will offer a number of exercises and tasks~5. Parent's module: to teach parents about the surgical process and how they can help their children during the process"
40766480|NCT06497140|DRUG|Ethiodized Oil-based emulsion|Embolization of genicular arteries
40766481|NCT06497140|PROCEDURE|Sham-operation|Mimicked catheterization and embolization of genicular arteries
41137187|NCT03637075|OTHER|Placebo|placebo intranasal administration
41457032|NCT04182555|DEVICE|Bilirubin estimates from Smartphone Application|Bilirubin estimates through color analysis of digital images obtained through smartphone application.
41457033|NCT04182555|DIAGNOSTIC_TEST|Bilirubin concentration measured in standard blood samples|Bilirubin measured in total serum bilirubin.
41457034|NCT04182555|DEVICE|Bilirubin estimates from standard transcutaneous device|Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)
41457035|NCT04182555|OTHER|Visual assessment of jaundice|Degree of jaundice will be assessed by Kramer scale
41457036|NCT00157066|DRUG|Ergocalciferol|
40964976|NCT03105791|OTHER|Formal education regarding opioid usage|Participannts watched a 2 minute video and were given educational materials
40964977|NCT04068870|BEHAVIORAL|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
40964978|NCT01230632|DIETARY_SUPPLEMENT|high fat overfeeding|Dietary Supplement:3 days overfeeding
41137188|NCT00407498|DRUG|P276-00|Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day
41137189|NCT00929526|PROCEDURE|Liquid-based cytology (LBC) sampling|LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
41137190|NCT00929526|PROCEDURE|Blood sampling|Blood samples will be collected at Months 36 and 48 for antibody determination
41137191|NCT01910194|DRUG|Luyxumia versus Lantus|
41137192|NCT02142309|DRUG|Glimepiride|Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
41137193|NCT02142309|DRUG|Vildagliptin|Reduce to 50 mg if estimated glomerular filtration rate (eGFR) \<45 mL/min
41137194|NCT02142309|DRUG|Pioglitazone|Start with 15 mg/day and advance to 30 mg/day
41137195|NCT02142309|DRUG|Canagliflozin|Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
41137196|NCT06253962|OTHER|coronary agiongraphy|severity of coronary atherosclerosis
41457037|NCT00000205|DRUG|Buprenorphine|
41457038|NCT01884701|DEVICE|ENABLER-P Catheter System|
41457039|NCT03610607|BEHAVIORAL|Intense education|we will inform patients with their own data including the number of P. gingivalis and ratio of S. cristatus and P. gingivalis detected immediately after periodontal treatment and 3 month after the treatment. Explaining these data in detail, in terms that the patient can understand, are equally as important as teaching the plaque control techniques.
41457040|NCT02930876|BEHAVIORAL|Resistance training|Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
41457041|NCT04536506|OTHER|Bobath Therapy|Bobath group received 45 min of sessions three times weekly for 12 weeks. An individual program was scheduled for each case following pre-assessment. It was targeted to enable normal posture, facilitation of corrective balance and protective responses and development of normal movement patterns
41457042|NCT04536506|OTHER|Vojta technique|Vojta group received the following three times weekly for 12 weeks: 1. Reflex crawling, 2. First stage of reflex turning, 3. Second stage of reflex turning. Stimuli (pressure and stretch) for 30-60 sec were given by using the main stimulus points and auxiliary stimulus points together.
41457043|NCT02421627|DEVICE|moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral). using mild-warm moxibustion，the surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
41457044|NCT02421627|DEVICE|Sham moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral); using sham mild-warm moxibustion，the surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
41457045|NCT00957762|OTHER|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
40964979|NCT05452070|DEVICE|HArmonyCa Lidocaine Injectable Gel|Subdermal or deep dermal injection
41137197|NCT04721483|PROCEDURE|Ramicotomy|We will selectively lesion the gray rami communicantes from T3 and T4 thoracic sympathetic ganglia
41137198|NCT06407375|DIAGNOSTIC_TEST|mpMRI|mpMRI
41137199|NCT02086461|DEVICE|Pneumatic pyloric dilatation|
41137200|NCT02086461|OTHER|15 mm pyloric balloon dilatation|
41137201|NCT06211998|DEVICE|Group 1|Salbutamol inhaler, Omron® CompAIR Pro NE-C900 Compressor Nebulizer (Omron Healthcare Co., Ltd., Kyoto, Japan) was used in Group 1
41137202|NCT06211998|DEVICE|Group 2|Salbutamol inhaler, Mesh nebulizer (Aerogen Solo®, Aerogen Ltd, Galway, Ireland) was used in Group 2
41137203|NCT04877756|DRUG|OLX10010|Lyophilized cake reconstituted with WFI and injected intradermally
41137204|NCT06275594|DRUG|Byfavo|For induction and maintenance of sedation
41137205|NCT06275594|DRUG|Midazolam|For induction and maintenance of sedation
41137206|NCT05962099|BEHAVIORAL|Lifestyle and weight loss advice|Commercially available lifestyle and weight loss intervention
41137207|NCT00462072|DRUG|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
40964980|NCT04997434|BEHAVIORAL|Art-therapy in the emergency department|"The intervention will begin with a 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. Since the art-therapeutic intervention that will be proposed seeks to generate pleasant feelings, it will be important to rely on the patient's tastes. At the end of the interview, modern art therapy will be presented to the patient and several artistic activities will be proposed (origami, drawing, creative writing).~Once the activity has been chosen, the patient will have 15 to 20 minutes to carry it out, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the 15 to 20 minutes of the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session."
40964981|NCT06060743|OTHER|INS-MOBILE: Mobile Application Developed for Insulin Use|After determining the application and control groups in the research, the purpose of the research was explained to both groups. Participants were informed that the application would last 1 month. It was explained that data collection forms would be filled out before the application (Z0), on the 14th day of the application (Z1), and on the 28th day of the application (Z2). On the 0th and 28th days of the follow-up, the participants' insulin administration skills were evaluated face-to-face by the researcher using the Insulin Therapy Skill Observation Form. In addition to the standard training given by diabetes training nurses, a mobile application on insulin use was sent to the application group, while the control group was given standard training only by diabetes training nurses.
40964982|NCT05060471|DRUG|Toripalimab|Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
40964983|NCT04959422|OTHER|Active scheduling|Active scheduling, tracking and rescheduling, if necessary.
40964984|NCT00758836|DRUG|placebo|
40964985|NCT00758836|DRUG|ibuprofen|
40964986|NCT00758836|DRUG|acetominophen|
40964987|NCT00758836|DRUG|telcagepant|
40964988|NCT02192138|PROCEDURE|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
40964989|NCT02192138|DEVICE|Pleural catheter|
40964990|NCT02192138|DEVICE|Pleural manometer|
40964991|NCT04971343|DIAGNOSTIC_TEST|Access HIV_blood donor|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Roche - Cobas - Elecsys® HIV Duo .~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
40964992|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Hospitalized patient|"All samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay for hospitalized patient.~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
40964993|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-1 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay .~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.~In case of discrepant results or concordant negative results between Access and Reference HIV Ag/Ab combo assay among known HIV-1 antibody positive patients, the IB/WB test will be repeated by the site to confirm sample status. If this IB/WB result is negative or indeterminate, the sample will be excluded from the statistical analysis"
40964994|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-2 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay.~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays."
41137208|NCT02433444|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP's performed at Cedars-Sinai Medical Center.
41137209|NCT05866432|DRUG|Datopotamab deruxtecan|Will be given until PD or withdraw
41137210|NCT02875704|OTHER|Anterior Chamber (AC) Tap|Aqueous Samples will be collected for measurement of biomarkers
41137211|NCT06305078|OTHER|Personalized ADHD Medication Experiment|All parent/adolescent dyads will select and complete a medication experiment.
41457046|NCT00893776|OTHER|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
41457047|NCT02964936|DRUG|roxadustat|Oral administration
41457048|NCT00003953|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
41457049|NCT00003953|DRUG|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
41457050|NCT00003953|DRUG|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
41457051|NCT00003953|DRUG|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
41457052|NCT00003953|DRUG|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
41457053|NCT00003953|PROCEDURE|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
40964995|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-1 p24 Ag positive|"All samples will be tested with both Reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFUs/study guide to determine non-reactive (NR), initially reactive (IR), and repeatedly reactive (RR). Reference assay will be Abbott - ARCHITECT HIV Ag/Ab Combo Assay.~* Due to volume constraints, all known HIV-1 p24 Ag positive samples that will be tested during the EU HIV clinical trial will be tested in singulare only with the Reference HIV Ag/Ab combo assay, and in singulare and then in duplicate if IR with Access HIV Ag/Ab combo assay.~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays"
40964996|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_Blood donor|"To fit with Canada's requirements:~* 4,000 additional blood donor samples from geographically distinct regions will be collected and tested. Blood donor sample testing will be equally distributed over three blood donor sites, using 3 different lots of reagents: the first 2,000 blood donor samples from CE-marking study (out of the 6,000 tested) will be used plus the 4,000 additional blood donor samples.~* Retesting of 1000 blood donor samples will be done internally with 1 lot close to expiration to satisfy Canadian requirements"
40964997|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_HIV positive|"To fit with Canada's requirements:~o HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents."
40964998|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_P24 Positive|"To fit with Canada's requirements:~* HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.~* Collection and testing of maximum 210 additional HIV-1 Ag positive sample beyond the 50 required by CTS"
40964999|NCT02437266|OTHER|Scapular mobilization|
40965000|NCT03112395|DEVICE|Pio Medical Device|The Pio device combines the technologies of pulse modulated magnetic fields and light emission locally applied to the wound area.
40965001|NCT03333447|OTHER|MRI|
40965002|NCT05952869|DRUG|Enlicitide Decanoate|Oral tablet
40965003|NCT05952869|DRUG|Placebo|Placebo
40965004|NCT04580069|PROCEDURE|Lymphatic drainage|The interventions follow the validated techniques normally used in international rehabilitation
41457054|NCT00003953|PROCEDURE|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
41457055|NCT00003953|RADIATION|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
41457056|NCT03711253|DRUG|Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg|antiretroviral therapy
41457057|NCT04661280|DRUG|Donepezil|Donepezil 5 mg per day during one month, then 10 mg per day during 5 months.
40965005|NCT00873912|BIOLOGICAL|Monovalent influenza virus vaccine|Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10\^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
40965006|NCT00873912|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
40965007|NCT03533764|BEHAVIORAL|ASMA|ASMA, grounded in social cognitive theory and utilizing motivational interviewing techniques, guides adolescents in their transition to being consumers and teaching them to navigate the health system, including overcoming challenges to health care access. Briefly, it consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
40965008|NCT00299910|DRUG|Montelukast|
40965009|NCT03290872|DEVICE|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring
40965010|NCT03290872|DEVICE|Simplici T Partial flexible mitral annuloplasty ring|Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
41457058|NCT04476277|DRUG|Biotin label|Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
41457059|NCT04903340|PROCEDURE|PET/CT Exam|PET/CT image processing application of reconstruction parameters: scan time, respiratory gating, Q-clear
41457060|NCT06416449|OTHER|kinesiotape application|"In the Star Balance Test, lines are drawn on the ground. The individual stands on their dominant foot and reaches out with the tip of the contralateral foot to touch these lines, and points are recorded. For the T-Agility Test, a course is set up, and the participant is asked to complete it as quickly as possible, with time being recorded.~As implied by its name, cones are placed in a T-shape for the T-Agility Test, and the individual is required to touch the cones and return to the starting point as quickly as possible. In the Vertical Jump Test, the individual is asked to jump as high as possible against a wall-mounted ruler, and the highest point reached is recorded. The Kinesio tape used in the study is designed to reflect the characteristics of the skin and allow for approximately 55-60% elongation of its original length. These tests are first conducted without Kinesio tape and then repeated with Kinesio tape applied. Rest intervals are provided between tests."
41457061|NCT01835548|DRUG|NT0102|NT0102 (methylphenidate polistirex \[MPP\] extended release \[XR\] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
40965011|NCT01297660|OTHER|Video-urodynamic examination|
40965012|NCT04784065|DEVICE|Hand orthosis|An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.
40965013|NCT01352858|DRUG|TolDC|Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
40965014|NCT01352858|DRUG|Arthroscopy & saline irrigation alone|
40965015|NCT00958750|DRUG|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
40965016|NCT04668625|BEHAVIORAL|Participate in a massive musical event|Participate in a massive musical event
40965017|NCT01786083|BEHAVIORAL|Application of Problem Solving Technique|
40965018|NCT04329897|BEHAVIORAL|Software Messaging|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
40965019|NCT02601378|DRUG|LXS196|LXS196 as a single agent
40965020|NCT02601378|DRUG|LXS196 and HDM201|LXS196 in combination with HDM201
40965021|NCT03725930|DRUG|Clonidine|clonidine intranasal premedication in preschool infants
40965022|NCT03725930|OTHER|Placebo|Placebo intranasal premedication
40965023|NCT03556072|OTHER|Routine ERCP|
40965024|NCT01746745|DRUG|[^14C]-LY2940680|Administered as solution by mouth
40965025|NCT05622084|DEVICE|Inperia Advance|Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device
40965026|NCT05069532|RADIATION|MSCT chest|CORAD 4-5 MSCT chest
40965027|NCT05069532|DIAGNOSTIC_TEST|PCR|PCR positive for COVID-19
40965028|NCT03931161|DRUG|Evolocumab Auto-Injector [Repatha]|Auto-Injector, 140 mg every two weeks.
40965029|NCT03931161|DRUG|Placebo Auto-Injector|Matching Placebo for the active comparator (Evolocumab)
40965030|NCT05108155|PROCEDURE|Cemented THA|THA with cement fixation
40965031|NCT05108155|PROCEDURE|Unemented THA|THA with uncemented / pressfit fixation
40965032|NCT02862171|DRUG|Dapivirine Vaginal Ring-004|To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
40965033|NCT01564914|DRUG|TRC105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
40965034|NCT01564914|DRUG|Bevacizumab|IV
40965035|NCT01623583|OTHER|Enhanced Needle Phobia Intervention|"The enhanced intervention will include the standard intervention, with two enhancements:~* The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch~* Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity."
40965036|NCT01623583|OTHER|Standard Needle Phobia Intervention|"The standard intervention will include the following components:~1. Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.~2. Basic training on relaxation breathing~3. Brief video of a patient overcoming needle phobia~4. Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle"
40965037|NCT03746652|DRUG|Daratumumab, Ixazomib, Dexamethasone|Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg
40965038|NCT01251237|DRUG|NRL0706|Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
40965039|NCT05317182|OTHER|Occlusal Splints Analogic-Analogic|Take a conventional impression to the patient and conventional fabrication of the splint.
40965040|NCT05317182|OTHER|Occlusal Splints Analogic-Digital|Take a conventional impression to the patient and digital fabrication of the splint.
40965041|NCT05317182|OTHER|Occlusal Splints Digital-Digital|Take a digital impression to the patient and digital fabrication of the splint.
40965042|NCT00067600|BEHAVIORAL|Diet with increased fruits, vegetables, and calcium|
40965043|NCT00067600|BEHAVIORAL|Increased high impact activity and resistance training|
40965044|NCT05937542|BEHAVIORAL|Qualitative Investigation of Participant Experiences|There is no intervention. This is a retrospective qualitative study.
40965045|NCT05465083|DEVICE|Lungpacer AeroPace Protect System|AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.
40965046|NCT02726152|PROCEDURE|Polymer clips for closure of the appendiceal stump|Application of polymer clips to the appendiceal stump
40965047|NCT02726152|PROCEDURE|Endoloops for closure of the appendiceal stump|Application of endoloops to the appendiceal stump
41137212|NCT05924113|BEHAVIORAL|Latin Dance|Latin dance sessions that include a warm-up routine with music, two choreographed dances, and a cooldown routine with music.
41137213|NCT02451072|DRUG|Placebo|Capsules containing mannitol looking identical to LSD per os
41137214|NCT02451072|DRUG|LSD|100µg per os, single dose
41457062|NCT01835548|DRUG|Placebo|Matching ODT placebo was given once daily.
40965048|NCT03182478|BEHAVIORAL|Rothbaum protocol in individual format|8-week 45 minute session Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
40965049|NCT03182478|BEHAVIORAL|Rothbaum protocol in group format|8-week 90 minute session of Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
40965050|NCT00444912|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
40965051|NCT00444912|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5\*10\^6 CD34+ cells/kg were collected.
40965052|NCT00444912|BIOLOGICAL|rituximab|Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
40965053|NCT01288105|DEVICE|Optical coherence tomography|Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom \>95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with \<95% stent strut coverage will receive perioperative bridging.
40965054|NCT01910857|BEHAVIORAL|Lifestyle counseling|weight reduction, low salt, physical activity, stress reduction
40965055|NCT03918122|OTHER|Self-Assessment via pre and post survey|Master Preceptor Fellows will assess and evaluation professional development, knowledge, clinical practices and master preceptor knowledge before the Master Preceptor Fellowship and After completion of the Master Preceptor Fellowship
40965056|NCT00071097|DRUG|TMC114/rtv|800mg TMC114/100mg rtv once daily
40965057|NCT00071097|DRUG|TMC114/rtv|400mg TMC114/100mg rtv both twice daily
40965058|NCT00071097|DRUG|TMC114/rtv|400mg TMC114/100mg rtv once daily
40965059|NCT00071097|DRUG|TMC114/rtv|600mg TMC114/100mg rtv twice daily
40965060|NCT03008603|DEVICE|XACT Robotic System|The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
40965061|NCT01721655|DRUG|Spironolactone|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
40965062|NCT01721655|DRUG|Placebo|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
40965063|NCT01332955|DRUG|Telaprevir|"Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz"
40965064|NCT01332955|BIOLOGICAL|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
40965065|NCT01332955|DRUG|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
40965066|NCT03830424|PROCEDURE|Pain stimulus|Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure
40965067|NCT03830424|DIETARY_SUPPLEMENT|Non-pharmacological pain relief|Administration of sucrose/mother milk during pain stimulus
41137215|NCT02451072|DRUG|Ketanserin|40mg per os, single dose looking identical to LSD per os
41137216|NCT03734432|DEVICE|IGAR-Breast TeleOp|Upon consent, each participant will undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while the radiologist operates the system from a remote site.
40965068|NCT06515743|OTHER|Delayed surgical obturator|Prosthetic rehabilitation after surgical treatment of mucormycosis is essential for the early restoration of oral function and facial esthetics which is performed by using the surgical obturator.
40965069|NCT06497998|DEVICE|Mechanical characterization|"The oocyte is placed in a culture dish with IVF culture medium. This procedure is similar to that used in the ICSI procedure, except that the injection pipette is replaced by a glass indenter. The indenter (sterile, single-use, blunt-edged glass cylinder, L:16mm, ø:0.85mm, mass:8mg) is completely decoupled from the micromanipulation and microinjection platform and driven by the principle of a magnetic spring with negative stiffness.~The oocyte is immobilized using a restraining pipette to prevent unwanted movement during measurement.~The main objective is to investigate the prognostic value of parameters derived from kinetic measurements of microforces on mature human oocytes in the context of IVF with ICSI.~On each oocyte the mechanical testing is divided in 4 successive loading unloading phase to measure:~* global elasticity of the oocyte.~* global viscosity behaviour of the oocyte.~* local elasticity of the oocyte.~* local viscosity behaviour of the pellucid membrane."
41294883|NCT03408873|DRUG|Abilify Maintena|Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.
41294884|NCT03408873|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
40965070|NCT04948710|DIAGNOSTIC_TEST|Sonography|Sonographic Venous Doppler Imaging
40965071|NCT06461364|PROCEDURE|Assessment of cuspal deflection of bulk-fill restorations|To assess the performance of bulk-fill restorations on premolar teeth in class II cavities using some selected FDI criteria, a total sample size of 30 (10 for each group test) will be sufficient to detect: an effect size of 1.22 at a power (1-β error) of 0.8 and using a two-sided hypothesis test and a significance level (α error) 0.05 for data. Two teeth will be added to each group to compensate drop out samples.
40965072|NCT03641443|DEVICE|Non-invasive measurement of intracranial pressure|Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors
41294885|NCT05232591|DIAGNOSTIC_TEST|The teeth diagnosed with chronic apical periodontitis|GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
41294886|NCT02055027|OTHER|Comparison between groups|Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
40965073|NCT01542125|DRUG|Liposomal Lidocaine|4% Liposomal Lidocaine
40965074|NCT01542125|DRUG|Placebo|Tubes were visually identical to the Liposomal Lidocaine tubes.
40965075|NCT04904562|DRUG|Angiotensin II|Angiotensin II started at 5 ng/kg/min and titrated in 5-10 ng/kg/min increments every 5 minutes up to 80ng/kg/min to achieve target arterial pressure (MAP)
41294887|NCT00306436|PROCEDURE|comprehensive management|
41294888|NCT03237260|DRUG|Vedolizumab|Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
41294889|NCT02484573|DRUG|Propanolol|
41294890|NCT05070949|BEHAVIORAL|Mindful Self-Compassion|Bi-weekly meeting will involve six lessons: What is Self-Compassion , Practicing Self-Compassion, Discovering your Compassionate Voice, Self-Compassion and Resilience , Self-Compassion and Burnout and Making it Count
41294891|NCT00592150|DRUG|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
41294892|NCT00592150|DRUG|Placebo|Placebo infusion for 3 hours
41294893|NCT06008171|OTHER|Patient Decision Aid|A designed tool (by us) that help patients and providers talk and decide together about field-directed treatment options for actinic keratosis.
40965076|NCT04904562|DRUG|Placebo|Placebo
40965077|NCT00000308|DRUG|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
40965078|NCT00000308|DRUG|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
41294894|NCT01254396|DRUG|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
40965079|NCT00000308|DRUG|placebo|placebo
40965080|NCT01371175|BIOLOGICAL|DNA.HIVA|0.5mg DNA.HIVA or placebo
40965081|NCT01371175|BIOLOGICAL|MVA.HIVA|5x10\^6 pfu MVA or placebo
41294895|NCT01254396|DRUG|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
40965082|NCT01371175|BIOLOGICAL|MVA.HIVA|5x10\^7 pfu MVA or placebo
40965083|NCT01371175|BIOLOGICAL|MVA.HIVA|2.5x10\^8 pfu MVA or placebo
41294896|NCT01652677|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
41294897|NCT01341509|PROCEDURE|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
41294898|NCT01341509|PROCEDURE|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
41294899|NCT01341509|PROCEDURE|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
41294900|NCT00970294|BEHAVIORAL|Health Promotion Program|10 week health promotion program 3-4 times per week
41294901|NCT02971644|DEVICE|cobalt alloy pedicle screw implantation|The patients with severe kyphosis deformity undergo cobalt alloy pedicle screw implantation.
41294902|NCT04864977|DRUG|Basal Insulin|Participants administered basal insulin
41294903|NCT03808714|BEHAVIORAL|TOUCHDOWN|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.
41294904|NCT03808714|BEHAVIORAL|Control Group|Alabama Quitline
41294905|NCT04490668|BIOLOGICAL|Human albumin|Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
41294906|NCT01894516|DRUG|GLPG0634|GLPG0634 capsules.
40965084|NCT02801383|DRUG|Yallaferon®， the recombinant human interferon α-2b gel|
40965085|NCT02801383|OTHER|gel without active ingredient|
41137217|NCT00284466|PROCEDURE|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
41137218|NCT04027452|BEHAVIORAL|Traumatic memory reactivation|"125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
41137219|NCT04027452|BEHAVIORAL|Neutral memory reactivation|"125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
41137220|NCT03328637|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) consisting of weekly 12 sessions will focus on moderated and controlled use of smartphone instead of abstinence model.
41137221|NCT02717208|BIOLOGICAL|HL036|
41137222|NCT02717208|BIOLOGICAL|Vehicle|
41137223|NCT03137784|DRUG|NVA237 (glycopyrronium bromide)|In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
41137224|NCT03137784|DRUG|Placebo|In each treatment arm, patient will receive placebo
41137225|NCT05751733|DRUG|Apatinib Mesylate|Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.
41137226|NCT05751733|DRUG|Sunitinib, Imatinib dosage, Dasatinib, Reveratinib|Second-line TKI drugs
41137227|NCT06372600|DEVICE|Extracorporeal shock wave therapy device|In the shoulder pain points, choose 2 to 3 of them for each treatment, apply the coupling agent, which is convenient for the treatment head to stick to the skin, and complete the longitudinal treatment and horizontal treatment. The setting frequency was 4 \~ 8 Hz, the length of the probe was 15 mm, and the pressure was set at 1.5 mJ/mm2. The frequency of each treatment point reached 2 000 \~ 2 500 times, and the hand-held pressure was set to medium-high level. A total of 6 treatments were completed. For patients with unclear pain points or regional pain, the treatment point should be supraspinatus tendon or infraspinatus tendon, and the treatment should be completed with the most severe pain site.
41137228|NCT06372600|BIOLOGICAL|Platelet-rich plasma|Autologous Platelet-rich plasma injection was performed under ultrasound guidance
41137229|NCT06310707|DEVICE|ePatch ® Extended Wear Holter (EWH)|"Diagnostic Test: Extended ECG investigation~• An ambulatory ECG recordings with a duration of 7 days using Philips ePatch (https://www.myheartmonitor.com/device/epatch/) will be applied"
41137230|NCT00969007|BEHAVIORAL|Lifestyle modification counselling|Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
41137231|NCT04946734|DEVICE|PFO closure device|Device PFO closure.
41137232|NCT04946734|DRUG|Aspirin and clopidogrel|Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.
41137233|NCT04946734|DRUG|Triptans|If migraine recurred, Triptans would be administered during the acute phase.
41137234|NCT00986752|DEVICE|Stenting (Smart Stent)|Nitinol stent
41137235|NCT00986752|DEVICE|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
41137236|NCT00986752|PROCEDURE|Atherectomy (SilverHawk device)|Atherectomy
41137237|NCT03542695|PROCEDURE|Computed Tomography|Undergo PET/CT
41137238|NCT03542695|DRUG|Copper Cu-64-DOTA-alendronate|Given IV
41137239|NCT03542695|OTHER|Pharmacokinetic Study|Correlative studies
41137240|NCT03542695|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41137241|NCT03887611|DEVICE|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
41137242|NCT04817345|DRUG|Plerixafor|Subcutaneous
41137243|NCT05227898|DEVICE|Device: Attune™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
41137244|NCT05227898|DEVICE|Device: Cerena™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
41137245|NCT05395481|DRUG|LY3849891|Administered SC.
41137246|NCT05395481|DRUG|Placebo|Administered SC.
41137247|NCT03605420|OTHER|Family visit prior to hospital admission|Family receiving one visit prior to hospital admission for surgery
41294907|NCT01894516|DRUG|Placebo|Placebo capsules.
41457063|NCT00153439|BEHAVIORAL|Motivational enhancements, parent training|
41294908|NCT01229488|DEVICE|Intervention|Project was withdrawn before starting. There were no interventions
41294909|NCT01429246|DIETARY_SUPPLEMENT|Regular Salt|Estimated Household Individual Consumption of 30 grams per day
40766482|NCT06344923|PROCEDURE|Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing|The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. A support rod, made of a 24# silicone drainage tube with a 1ml syringe was passed through the mesentery of the small intestine. The support rod was removed two weeks after surgery. It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches.
41294910|NCT01429246|DIETARY_SUPPLEMENT|Salt Substitute|Estimated 30 grams per day per household member
41294911|NCT00347711|DRUG|Intravitreal injection|
41294912|NCT01796353|OTHER|sexual rehabilitation|exercise plus psycho-education
41294913|NCT01796353|OTHER|Usual care|usual care
40766483|NCT06344923|PROCEDURE|Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing|The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. The seromuscular layer of the ileum or the mesentery was intermittently sutured with peritoneum and the anterior sheath of the rectus abdominis circumferentially with 8-10 stitches (3-0 silk thread). It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches
40766484|NCT06644118|BIOLOGICAL|OL-101 infusion|OL-101 infusion will be administered to patients via IV infusion at the assigned dose.
40965086|NCT02940912|DRUG|Apomorphine|cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.
40965087|NCT02940912|DRUG|Placebo|cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
40766487|NCT06070649|DRUG|0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion|Infusion
40766488|NCT06070649|DRUG|0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion|Infusion
41294914|NCT00923910|DRUG|WT1 Peptide-Pulsed Dendritic Cells|
41294915|NCT00923910|DRUG|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
41294916|NCT00923910|DRUG|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
41294917|NCT00923910|DRUG|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
41294918|NCT00923910|DRUG|WT1 Peptides|dendritic cell vaccine
40766489|NCT06070649|DRUG|25 mg Diphenhydramine (5 min) + Normal Saline|Infusion
40766490|NCT06642454|OTHER|Transcutaneous auricular vagus nerve stimulation|"Stimulation Target: Left cymba conchae.~25 Hz Non-Expiratory Gated taVNS: Stimulation is delivered for 30 seconds at a frequency of 25 Hz, followed by a 30-second interval.~25 Hz Expiratory Gated taVNS: One second of stimulation occurs during exhalation at a frequency of 25 Hz.~100 Hz Expiratory Gated taVNS: One second of stimulation is administered during exhalation at a frequency of 100 Hz."
41137248|NCT02032004|BIOLOGICAL|Allogeneic Mesenchymal Precursor Cells (MPCs)|Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved
40766491|NCT05059327|DRUG|Basimglurant with crossover to Placebo|Basimglurant with crossover to Placebo
40766492|NCT05059327|DRUG|Placebo with crossover to Basimglurant|Placebo with crossover to Basimglurant
41137249|NCT02032004|OTHER|Sham Comparator|The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.
41294919|NCT00923910|DRUG|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
41294920|NCT00923910|DRUG|Diphenhydramine|Pre-medication
41294921|NCT00923910|DRUG|Acetaminophen|Pre-medication
41294922|NCT04072237|BIOLOGICAL|MarzAA (marzeptacog alfa [activated])|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)
41294923|NCT04347811|BEHAVIORAL|Death Cafe|Death Cafés are a specific form of debriefing that focuses on discussing death, dying, loss, and illness. Nourishment in the form of cake is provided. These sessions may allow for reflection on distressing patient events while developing a sense of community and collaboration among hospital employees.
41294924|NCT01177150|DRUG|JNJ-28431754/ Placebo|Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
41294925|NCT01177150|DRUG|JNJ-28431754|Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
41294926|NCT01832311|DRUG|Ketorolac|Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
41294927|NCT05379023|BEHAVIORAL|Face-to-face evaluation (FF)|The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
41294928|NCT05379023|BEHAVIORAL|TeleNP evaluation|The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
41294929|NCT00978445|OTHER|vMetrics protocol|use vmetrics protocol and device or use standard in clinic monitoring
41457064|NCT01268839|DRUG|TMC278|25mg tablet once daily for 28 days
41457065|NCT01268839|DRUG|TMC278|25mg tablet once daily for 14 days
41457066|NCT01268839|DRUG|Efavirenz|600mg tablet once daily for 14 days
40766493|NCT05259501|OTHER|RMIST|"RMIST will involve:~1. A study automated visual recognition web-based platform accessible on the participant's smartphone web browser.~2. A supply of methadone in single use bottles and previously described packaging to be kept securely at the methadone clinic/lab setting."
40965088|NCT02080949|RADIATION|4fx x 5Gy|It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
40965089|NCT04587232|DIAGNOSTIC_TEST|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire (Mini-OAKHQoL) was derived from the Turkish version of OAKHQoL questionnaire, which was developed to assess the quality of life (QoL) in subjects with lower limb osteoarthritis. It includes five subscales: physical activities, mental health, pain, social support, social functioning; with three additional independent items addressing sexual life, professional life, and fear of being dependent. The numerical rating scales in the items range from 0 (worst) to 10 (best). Scores were obtained by computing the means of the item scores in each subscale. The last three items' score (independent items) becomes the corresponding score.
41294930|NCT03827577|PROCEDURE|Surgical removal of primary and/or of all oligometastases|Standard lobectomy or segmentectomy if tumor resectable without pneumonectomy (prefer lobectomy if cardiorespiratory function is not or only moderately compromised, prefer segmentectomy if primary tumor less than 2 cm or cardiorespiratory function is more than moderately compromised but still permissive) Mediastinal lymph node dissection (at least 8 lymphnodes from at least 3 stations including station 7).
40766494|NCT05818254|BEHAVIORAL|HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention|The HOP-STEP Intervention is simple with 3-steps: (1) ascertain and document current pregnancy intention and contraceptive use, (2) patient and provider collaboratively arrive at her optimal contraceptive and/or pregnancy plan using a Decision Guide directed conversation, and (3) create a warm handoff with a patient-specific SLE risk assessment and guideline-aligned recommendations.
40766495|NCT05818254|BEHAVIORAL|Routine Care|Providers will continue to provide reproductive healthcare in their current manner.
40766496|NCT06121752|PROCEDURE|Endoscopic submucosal dissection|Endoscopic resection is recommended for the management of small DNETs measuring ≤10 mm. Various endoscopic techniques have been utilized for the resection of DNETs including endoscopic mucosal resection (EMR), band ligation assisted EMR, endoscopic submucosal dissection (ESD). However, the published studies report a high rate of histologically incomplete resection even with ESD. More recently, device assisted endoscopic full thickness resection (EFTR) has emerged as a safe and effective resection modality in cases with upper and lower gastrointestinal (GI) mucosal as well as submucosal lesions. There is limited data on the outcomes of EFTR in cases with DNETs.
40766497|NCT06121752|DEVICE|EFTR|"Initially, the lesion will be marked circumferentially using the FTRD probe available with the device (Forced Coag, E1, 20W). Subsequently, wire guided balloon dilatation of the pyloric channel will be performed.~The device will be mounted over a therapeutic channel gastroscope and negotiated across the cricopharynx over the guidewire with or without assistance of dilating balloon available with the device.~After reaching the target site, the lesion will be pulled withing the FTRD cap with the help of grasping forceps and gentle suctioning.~The clip will be fired after ensuring the entry of the lesion inside the cap, the premounted snare closed and electrocautery activated to cut the grasped tissue (HighCut 200W, Effect 4)."
40766498|NCT04396236|DRUG|Lasmiditan|Administered orally
40766499|NCT04396236|DRUG|Placebo|Administered orally
40766500|NCT06636422|DRUG|Motherwort injection|Patients will be given motherwort injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
40766501|NCT05605093|DRUG|Shionogi Protease Inhibitor (S-217622)|S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
40766502|NCT05605093|DRUG|placebo|Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
40766503|NCT06424262|DEVICE|CI622D|A dexamethasone-eluting Slim Straight electrode
40766504|NCT06424262|DEVICE|CI622|A standard Slim Straight electrode
40766505|NCT06644573|PROCEDURE|PROSOMNIA Sleep Therapy™ (PSTx)|PROSOMNIA Sleep Therapy (PSTx) is a novel intervention designed to manage homeostatic sleep pressure by leveraging an anesthesia-induced protocol. Using Diprivan/Propofol, PSTx rapidly induces REM sleep, clearing adenosine from the brain and reducing sleep pressure more efficiently than traditional methods. Monitored in real-time via EEG, this therapy personalizes sleep architecture optimization, ensuring deep restorative REM sleep. PSTx stands apart as a promising treatment for chronic insomnia, sleep deprivation, and REM sleep disorders, offering long-term improvement in sleep quality and overall health.
40965090|NCT04587232|DIAGNOSTIC_TEST|Nottingham Health Profile|Standardized questionnaire to investigate the health-related quality of life. NHP is a general is used to measure health problems perceived by the patient. It comprises 6 sections. The sum of the items within each section ranges from 0 to 100, and the total score ranges from 0 to 600. The higher score shows a worse quality of life.
41294931|NCT03827577|RADIATION|Non-surgical LAT|Non-surgical LAT may be carried out either by SABR or SBRT or RFA according to site of metastasis, local expertise and availability of resources.
41294932|NCT03827577|DRUG|Standard medical therapy|platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
41294933|NCT01605305|DRUG|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
41294934|NCT05749822|DRUG|Fenofibrate 200mg|Fenofibrate 200mg/day
41294935|NCT05749822|DRUG|Placebo|1 tablet/ day
41294936|NCT05749822|DRUG|UDCA|UDCA 13-15mg/kg/day
41294937|NCT04014504|DIAGNOSTIC_TEST|Neonatal Hearing Screening Test|neonatal hearing screening test results will be evaluated.
40766506|NCT06644573|PROCEDURE|Anesthesia-Induced Sleep Therapy|"1. Single-Arm, Non-Randomized Design: All eligible participants receive the same treatment PROSOMNIA Sleep Therapy(PSTx), ensuring consistency and homogeneity.~2. Targeted Use of Diprivan/Propofol: The PSTx involves the administration of Diprivan/Propofol, an FDA-approved anesthetic, delivered in a controlled environment under the supervision of an Anesthesiologist.~3. Monitored Anesthesia with Advanced Sleep Assessment: The procedure is monitored according to ASA (American Society of Anesthesiologists) standards, along with real-time EEG to track brain activity during REM sleep.~4. One (1) Hour PPSTx (60-120 minutes): A PSTx is designed to provide immediate results within a controlled timeframe of 60 to 120 minutes.~5. Follow-Up Protocol: Post-treatment follow-ups occur at 24 hours, 7 days, and 30 days after the session to measure outcomes and safety parameters.~6. Focus on Safety and Feasibility: A single-arm approach allows for a concentrated assessment of treatment efficacy."
40965091|NCT04587232|DIAGNOSTIC_TEST|Short form 36|Standardized questionnaire to investigate the general health-related quality of life. The SF-36 questionnaire is a generic quality of life questionnaire and consists of 8 subscales, with 36 items. The scores ranges from 0 to 100 and the high score indicates good health.
40965092|NCT04587232|DIAGNOSTIC_TEST|Western Ontario and McMaster|Standardized questionnaire to investigate the health status of patients with osteoarthritis. The WOMAC OA index assesses the symptomatic severity and disability with pain, stiffness, and physical function domains. Each subscale was summated to a maximum score of 20, 8, and 68, respectively, with the higher scores corresponding worst health status.
41294938|NCT02690480|DRUG|PD-0332991 (Palbociclib)|"Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
41294939|NCT02690480|DRUG|Fulvestrant|"Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
41294940|NCT02690480|DRUG|Placebo|"Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs"
41294941|NCT04590937|DRUG|BI 730357|Film-coated tablet
40965093|NCT04786145|PROCEDURE|Cryoneurolysis|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways by freezing it. Small probe is inserted in order to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve.
40965094|NCT04786145|PROCEDURE|Radiofrequency ablation|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. Small needle with an active heating tip is inserted, to destroy the functionality of the target nerve using heat from radiofrequency energy.
41294942|NCT04590937|DRUG|CRESTOR®|Film-coated tablet
41294943|NCT04590937|DRUG|Lenoxin®|Tablet
41294944|NCT04590937|DRUG|MetfoLiquid GeriaSan®|Oral solution
40965095|NCT04786145|PROCEDURE|Placebo|No active treatment is given.
40965096|NCT04106115|DRUG|Durvalumab|1500 mg IV infusion every 4 weeks for up to 7 doses
41294945|NCT04590937|DRUG|Lasix®|Oral solution
41294946|NCT01835990|DEVICE|geko|The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
41457067|NCT05724173|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
40766507|NCT06644573|DRUG|Diprivan (propofol), Astra-Zeneca|Diprivan/Propofol is a short-acting intravenous anesthetic used in PROSOMNIA Sleep Therapy to induce rapid and controlled REM sleep. Unlike other sleep aids, Propofol works by potentiating GABA_A receptor activity, leading to a deeper and faster transition into sleep. The administration is closely monitored in real-time using EEG to ensure optimal sleep stages are achieved. Propofol is distinct from traditional sedatives due to its precise control, rapid onset, and ability to clear adenosine from the brain, reducing sleep pressure effectively and safely.
41294947|NCT01835990|DEVICE|IPCs|devices that pneumatically compress the leg, resulting in increased venous blood flow.
41294948|NCT00006270|DRUG|cosyntropin|
41294949|NCT00006270|DRUG|metyrapone|
41294950|NCT02731040|DRUG|Bisphosphonate|
41294951|NCT01963117|RADIATION|Combined hyperthermia and radiation therapy|
41294952|NCT04149327|DRUG|amoxicillin 500 mg + metronidazole 500 mg|500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days
41457068|NCT03396354|PROCEDURE|Integrated robotic surgery|Robotic gastrectomy using Single-Site and Firefly technology will be performed. Specifically, two-port surgery using the Single-Site port and an independent trocar along the right flank (for harmonic scalpel) will be used, along with peritumoral injection of indocyanine green via endoscopy the day before surgery to completely visualize the entire lymphatic channel.
41457069|NCT03396354|PROCEDURE|Conventional laparoscopic surgery|conventional laparoscopic gastrectomy will be performed.
41457070|NCT02811341|DRUG|Scopolamine Hydrobromide|
41457071|NCT02811341|DRUG|normal saline|
41457072|NCT03119896|OTHER|The Navigator Tool Intervention|The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
41457073|NCT00838838|DRUG|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients \> 18yrs in medical practices fulfilling all criteria for documentation.
41457074|NCT00656539|DRUG|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
41457075|NCT02621190|DRUG|cabazitaxel|25mg/m2 q3w
40965097|NCT04106115|BIOLOGICAL|S-488210/S-488211|S-488210/S-488211 is given as a 1 mL subcutaneous (SC) injection of S-488210/Montanide emulsion and a 1 mL SC injection of S-488211/Montanide emulsion starting the day after first dose of durvalumab and continuing weekly for 6 doses and then every 2 weeks for a further 9 doses
40965098|NCT05523752|DEVICE|Proseal Laryngeal Mask|insertion of Proseal Laryngeal Mask
40965099|NCT05523752|DEVICE|Classic Laryngeal Mask|insertion of Classic Laryngeal Mask
41294953|NCT04149327|PROCEDURE|non-surgical periodontal and peri-implant treatment|"Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned."
40965100|NCT05523752|DEVICE|I-gel|insertion of I-gel
40965101|NCT05523752|DEVICE|Suprema Laryngeal Mask|insertion of Suprema Laryngeal Mask
41137250|NCT05466630|DIAGNOSTIC_TEST|Serological field test for HAT|Whole blood is tested by lateral flow or agglutination (CATT) for the presence of trypanosome specific antibody. Participants testing positive for at least one of these tests will undergo microscopic examination to detect trypanosomes (lymph, mAECT on blood) and DBS will be prepared for immunological and molecular laboratory testing.
41137251|NCT05466630|DIAGNOSTIC_TEST|malaria rapid test|RDT detecting HRP2 plasmodium antigen.
41294954|NCT01320579|DRUG|Cis-UCA 2.5% emulsion cream|2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
41294955|NCT01320579|DRUG|Cis-UCA 5% emulsion cream|5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
40965102|NCT01269632|BIOLOGICAL|blood sampling, specific biological exams and biobank and self administered questionnaires|"HIV INFECTION at inclusion and annually up to 06 years follow-up~1. clinical and therapeutic evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires~In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)~HIV UNINFECTED at inclusion and after 3 years follow up~1. clinical evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires"
40965103|NCT02891161|DRUG|durvalumab|1500 mg Q4 weekly
40965104|NCT02891161|RADIATION|Radiation Therapy|64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
41137252|NCT05466630|DIAGNOSTIC_TEST|Immunologic laboratory tests|Laboratory tests detecting trypanosoma brucei gambiense specific (VSG) antibodies in DBS. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
40766508|NCT06644573|DEVICE|Continuous EEG Monitoring|Continuous EEG Monitoring is an essential component of PROSOMNIA Sleep Therapy, used to accurately track and optimize sleep architecture in real time. This device provides precise monitoring of brainwave activity, ensuring the patient achieves the necessary stages of REM sleep during therapy. Unlike other monitoring systems, this EEG is used to dynamically adjust the Diprivan/Propofol infusion, allowing for personalized sleep regulation. The continuous data collection helps maintain ideal sleep conditions, distinguishing it from standard sleep therapy interventions that lack real-time neurological insights.
40766509|NCT06150742|DEVICE|Niyad (nafamostat mesylate)|Niyad (nafamostat mesylate) lyophilized
40766510|NCT06150742|DEVICE|Placebo (0.9% NaCl)|0.9% NaCl
40766511|NCT06638359|BEHAVIORAL|moderate exercise|moderate exercise for 47 minutes
40766512|NCT06638359|BEHAVIORAL|interval exercise|interval exercise for 28 minutes
41137253|NCT05466630|DIAGNOSTIC_TEST|Molecular laboratory tests|Laboratory tests detecting Trypanozoon specific nucleic acids. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
40766513|NCT06638359|BEHAVIORAL|Control (placebo) group|without exercise
40965105|NCT02034214|BEHAVIORAL|Life skills education|The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
40965106|NCT02034214|OTHER|Reproductive health services|All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
41137254|NCT00416975|OTHER|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
41137255|NCT00416975|OTHER|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
41294956|NCT01320579|DRUG|Placebo for cis-UCA emulsion cream|The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
41294957|NCT01320579|DRUG|Protopic® 0.1% ointment|0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
41294958|NCT00984802|DRUG|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
40766514|NCT05989997|DRUG|68Ga-NOTA-SNA002|68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
41294959|NCT00984802|DRUG|Placebo control|Vehicle solution for IV administration single dose.
41294960|NCT03633578|BEHAVIORAL|walk test|"The patient will have to walk on a treadmill in four different conditions:~* without distraction at preferential speed~* with distraction at preferential speed~* without distraction at the speed of 130% of the preferential speed~* with distraction at the speed of 130% of the preferential speed"
41294961|NCT03207256|DRUG|TGR-1202|Oral Daily TGR-1202
41294962|NCT03207256|DRUG|TGR-1202 + Ublituximab|Oral Daily TGR-1202 + Ublituximab IV Administration
40766515|NCT06643533|OTHER|Fecal Microbiota Transplantation|The FMT capsules will be prepared by matching the gut microbiome profiles of healthy donors with those of patients who achieved a complete response to the triple therapy. The FMT capsules will be taken orally at a dosage of 30 capsules per day for the first 3 days of each treatment cycle. The FMT intervention will be administered in 6 cycles, with each cycle lasting for 21 days (Q3W). The duration of the treatment will be determined by the response to therapy, with a maximum of 6 cycles or until disease progression, intolerable toxicity, or participant withdrawal of consent. The FMT capsules are intended to modify the gut microbiome to reverse the resistance to the triple therapy and enhance the therapeutic response.
40766516|NCT06643247|DRUG|Drug|1) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.
40965107|NCT02034214|BEHAVIORAL|Economic livelihoods|The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
41294963|NCT00764972|DRUG|Sorafenib and Vinorelbine|"vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe."
40965108|NCT03167190|PROCEDURE|Point-of-care ultrasound|A point-of-care ultrasound machine will be utilized to identify and mark midline and the interspinous space based on visualization of spinous processes.
40965109|NCT03167190|PROCEDURE|Traditional Landmark-based Lumbar Puncture|Palpation of anatomical landmarks to identify midline and interspinous space
40965110|NCT06236672|DRUG|GLP-1 receptor agonist|GLP-1 RA initiated between January 2019 and December 2022
40965111|NCT06236672|DRUG|basal insulin|basal insulin initiated between January 2019 and December 2022
41294964|NCT04333433|DEVICE|PRESERFLO® MicroShunt|Device surgically implanted
41294965|NCT04333433|PROCEDURE|Trabeculectomy|The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.
41294966|NCT05423158|BEHAVIORAL|d-Coaching|"MOVN mobile app: Each participant will be assigned a secure login account that does not include personal information for research only. Participants will be trained on how to access and use the MOVN private social network group.~Annie text messaging: Participants will be registered in the Annie VA text messaging program to receive tailored, interactive push messages with a combination of 1 and 2-way tailored messages on goals, barriers, self-management, etc. (based on data collected in real-time from the Fitbit and barriers identified at baseline).~Fitbit wearable device \& mobile app: The intervention group will be instructed to use the Fitbit for step counts and maximizing the Fitbit mobile app/desktop platform to track all PA, sharing one's Fitbit profile with others (optional leaderboard), and use of all available features."
41294967|NCT00890630|PROCEDURE|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
41294968|NCT00890630|DRUG|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
41294969|NCT04284917|DRUG|Carglumic Acid (Carbaglu®)|"A. Study period: 24 months; treatment period: 12 months.~B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)~C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12. (Check Plasma Amino Acid Analysis, Ammonia, acylcarnitine profile, Urinary organic acid analysis.)~D. Patients should report any adverse event that occur during treatment period.~E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis will be recorded during treatment period."
41457076|NCT01949532|DRUG|Carfilzomib|Carfilzomib was administered by IV injection.
40766517|NCT06643247|PROCEDURE|Electroacupuncture|Electroacupuncture Treatment: Needling acupoints include the Jiaji points corresponding to the spinal nerve segment of the affected area, Ashi acupoints along the affected zone, and bilateral Hegu and Waiguan points. Electroacupuncture will be performed once daily for 30 minutes per session, with a total of 7 consecutive sessions. The Jiaji and Ashi acupoints will be connected to an electroacupuncture device, set to disperse-dense wave stimulation at a frequency of 2/100 Hz, with current intensity adjusted to the patient's tolerance level.
40766518|NCT05571839|DRUG|PF-08046049|Given into the vein (IV; intravenous)
41294970|NCT03138850|DEVICE|Olympus standard bite block|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
40766519|NCT05020769|DRUG|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).
40766520|NCT05020769|DRUG|Osimertinib|Osimertinib is administered at the recommended dose of 80mg daily.
40766521|NCT06641453|BIOLOGICAL|GPC3-CART cells|"Phase 1: Dose escalation (3+3): Dose 1 (1 × 10\^6 cells/kg) with or without FC regimen, Dose 2 (3 × 10\^6 cells/kg), Dose 3 (6 × 10\^6 cells/kg).~Phase 2: Dose at RP2D."
40766522|NCT06641453|DRUG|Fludarabine Phosphate for Injection|Administered intravenously at a dose of 20-30 mg/m²/day on days -5, -4, and -3.
40766523|NCT06641453|DRUG|Cyclophosphamide for Injection|Administered intravenously at a dose of 300-500 mg/m²/day on days -5, -4, and -3.
40766524|NCT05149872|OTHER|Muscle relaxation|Rocuronium will be used to induce partial paralysis
40766525|NCT05149872|OTHER|Reversal|Sugamamdex will be used to reverse muscle relaxation
40766526|NCT05479981|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
40766527|NCT05479981|DRUG|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
40766528|NCT06001749|DRUG|Psilocybin|A tryptamine derivative, capsule, taken orally.
40766529|NCT04163081|BEHAVIORAL|Quit Card Intervention (QCI)|"The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a Quit Card (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist."
40766530|NCT03368742|GENETIC|SGT-001|AAV9 vector containing muscle-specific promoter and microdystrophin construct
40766531|NCT06058949|BEHAVIORAL|Health Protection and Promotion|An adaptive integrated Total Worker Health® program. Virtual 8-week program that's been contextualized to the physical and mental health needs of sign language interpreters. It will examine biomechanics, sleep hygiene, vicarious trauma and burnout, demand-control schema, physical activity, emotional management strategies, proper nutrition and examination of worksite.
40766532|NCT06058949|BEHAVIORAL|General Health Program|Virtual 8-week program that addresses participant sleep hygiene, physical activity and proper nutrition.
40766533|NCT06643130|DRUG|JW0104+C2402|For 8 weeks(PO (Per Oral), QD)
40766534|NCT06643130|DRUG|JW0104+C2403|For 8 weeks(PO, QD)
40766535|NCT06643130|DRUG|C2402|For 8 weeks(PO, QD)
41137256|NCT00416975|PROCEDURE|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
40766536|NCT06352099|DIETARY_SUPPLEMENT|Dietary supplement with micronised diosmin, hesperidin and herbal extracts|Taking a dietary supplement with micronised diosmin, hesperidin and plant extracts 1 or 2 sticks per day, as per the study design.
40766537|NCT05453968|DRUG|Berotralstat|Administered orally once daily at a weight-based dose in up to 4 cohorts
40766538|NCT06645392|DEVICE|visual transparent bladed trocar of|visual transparent bladed trocar of diameter 10 mm and Ternamian bladeless trocar of diameter 10 mm
40766539|NCT06645392|DEVICE|Ternamian bladeless trocar|Ternamian bladeless trocar of diameter 10 mm
41137257|NCT02604251|DEVICE|KLOX BioPhotonic WoundGel System|Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
41137258|NCT02604251|DEVICE|Silicone sheets|Treatment of the surgical wounds with silicone sheets.
41457077|NCT01589835|BEHAVIORAL|Lifestyle changes|Green prescription with support from facilitator
41137259|NCT05694832|BEHAVIORAL|Expressive Writing|Creative writing, discussion and social support, in a group setting via videoconference
41294971|NCT03138850|DEVICE|YX mandibular advancement bite block|Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
41457078|NCT02888756|BIOLOGICAL|iHIVARNA-01|Therapeutic vaccination, followed by treatment interruption
41137260|NCT02504801|DRUG|Budesonide|To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
41137261|NCT02246699|DEVICE|KiOnutrime®-Cs|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
41137262|NCT02246699|OTHER|Placebo|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
41294972|NCT03138850|DEVICE|Optiflow High flow nasal cannula|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
41294973|NCT02125929|PROCEDURE|Robotic surgery|Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
41294974|NCT02125929|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
41294975|NCT02125929|PROCEDURE|Open surgery|Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
41457079|NCT02888756|BIOLOGICAL|TriMix|Therapeutic vaccination, followed by treatment interruption
40965112|NCT03305575|DRUG|Chloroprocaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
40965113|NCT03305575|DRUG|Bupivacaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
40965114|NCT04263220|DEVICE|Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back|Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions
40965115|NCT04263220|OTHER|protocol will be performed without exoskeleton|protocol will be performed without exoskeleton
41137263|NCT05086874|OTHER|butylphthalide|Observational only and no predesigned interventions in this study
41137264|NCT00681109|DRUG|2.5% IL-1Ra|2.5% custom made topical IL-1Ra three times a day in both eyes for three months
41137265|NCT00681109|DRUG|Placebo|custom eye drop to be applied three times a day in both eyes for three months
41137266|NCT00681109|DRUG|5% IL-1Ra|5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
41294976|NCT04871633|DRUG|Remdesivir|Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days
41294977|NCT04871633|DRUG|Conventional|IV Steroids Antibiotics
41294978|NCT04742946|OTHER|Digital Physiotherapy Practice (Telerehabilitation)|Online Physiotherapy services
40965116|NCT04768595|DIETARY_SUPPLEMENT|Placebo|Two, 1g capsules taken daily with food
41137267|NCT02435485|DEVICE|Biodex balance training|1.weight shift training, 2. random control training with Biodex balance system.
41294979|NCT01135953|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to to motor cortex every weekday (5 sessions), at 2mA ,during 20 minutes.Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
41294980|NCT01135953|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to the motor cortex every day of the week during 20 minutes, at 1mA first session, 1.5 mA second and third sessions, and 2mA fourth and fifth sessions, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 30 seconds (to avoid the sensation of a flash).
41457080|NCT02888756|BIOLOGICAL|Placebo|Therapeutic vaccination, followed by treatment interruption
41457081|NCT03415867|DRUG|Glasdegib|A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
41457082|NCT04709757|DEVICE|Intermittent Dosing HF10 30/90|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 120 seconds OFF
41457083|NCT04709757|DEVICE|Intermittent Dosing HF10 30/360|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 360 seconds OFF
41457084|NCT06125002|DRUG|Diosmin750|The ingestion will occur orally, under monitoring by the responsible investigator.
41457085|NCT06125002|DRUG|Placebo|The ingestion will occur orally, under monitoring by the responsible investigator.
41457086|NCT02901730|PROCEDURE|532nm laser group|LPI with 532nm laser.
41457087|NCT02901730|PROCEDURE|561nm laser group|LPI with 561nm laser.
41457088|NCT02531490|DRUG|Labetalol|
41457089|NCT02531490|DRUG|Nifedipine|
41457090|NCT02531490|DRUG|Methyldopa|
41457091|NCT00193492|DRUG|Bevacizumab|
41457092|NCT00193492|DRUG|Rituximab|
41457093|NCT03573544|DRUG|OBI-888|For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
40965117|NCT04768595|DIETARY_SUPPLEMENT|Ceto 10|Two, 1g capsules daily with food
40766540|NCT04050839|OTHER|Pain neuroscience education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week in addition medical treatment similar to control group. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, group sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
40766541|NCT04050839|DRUG|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
40965118|NCT04768595|DIETARY_SUPPLEMENT|Fish oil|Two, 1g capsules daily with food
41294981|NCT01135953|OTHER|Transcranial direct Stimulation (tDCS) and D-cycloserine|"Transcranial Direct Stimulation applied to the motor cortex every day of the week (5 sessions) at 2mA, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).~D-cycloserine, administered orally (capsules), 100 mg, twice a week (Monday and Thursday), prior to the tDCS session."
40965119|NCT02000479|OTHER|training|
40965120|NCT06014268|OTHER|electronic clinical decision support system|"eCDSS will alert clinicians if patients with documented atrial fibrillation are admitted to the hospital under their care.~The eCDSS will consist of prompts appearing on patients' electronic health records asking clinicians to clinically assess the risk of stroke (using CHAD2AD2-VASc tool) and the risk of bleeding (using the ORBIT tool) and record the scores on ePJS. Recommendations include reviewing the stroke and bleeding scores in specific cases, referral to an anticoagulation clinic to reduce AF related stroke risk (a referral template and emails/ telephone of the OAC clinics will be provided) and managing modifiable bleeding risk factors."
41294982|NCT00049413|BIOLOGICAL|rituximab|
41294983|NCT00049413|DRUG|cyclophosphamide|
41294984|NCT00049413|DRUG|pentostatin|
40965121|NCT03792698|OTHER|Aidcube digital app-based platform|Use of customizable, patient-specific mHealth home rehabilitation plan
40965122|NCT03385460|OTHER|ESWL BOTOX|ESWL after intrravesical BOTOX
41294985|NCT04845776|DIETARY_SUPPLEMENT|ANRC Essentials Plus|a vitamin/mineral supplement designed for children and adults with autism
41294986|NCT02533960|OTHER|not applicable (observational study)|Observational study without study related intervention.
41294987|NCT00069082|DRUG|Civamide (Zucapsaicin)|Nasal Solution 0.01%
40965123|NCT02818569|DRUG|Dexmedetomidine|Oral form
40766542|NCT05837481|BEHAVIORAL|Meditation|Guided meditation utilizing breath awareness, body scan and visualization techniques
41294988|NCT00069082|DRUG|Sodium Chloride|Nasal Solution 10%
41294989|NCT02702193|BEHAVIORAL|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
41294990|NCT03632512|DIETARY_SUPPLEMENT|Hericium honey bolus|The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
40766543|NCT03774121|DEVICE|Cryoneurolysis|A cryoprobe will be inserted percutaneously and freeze the target nerves (infrapatellar branch of the saphenous nerve \& anterior femoral cutaneous nerve) guided by ultrasound visualization.
40766544|NCT03774121|OTHER|Neuromuscular exercise (GLA:D)|The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.
41294991|NCT03632512|DIETARY_SUPPLEMENT|Placebo honey bolus|The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.
41457094|NCT03573544|DRUG|OBI-888|For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
41457095|NCT03573544|DEVICE|Globo H IHC Assay|This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.
40766545|NCT03774121|DEVICE|Sham|The sham intervention includes a similar procedure but without freezing temperatures.
40766546|NCT06636760|OTHER|Placebo|The placebo contains the non-active carrier of herbal combination that has no pharmacological activity.
40965124|NCT02818569|OTHER|Saline Placebo|Saline Placebo
40965125|NCT02416921|BEHAVIORAL|Weight-gain Prevention|A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
40965126|NCT02416921|BEHAVIORAL|Women's Health|A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
40965127|NCT05391516|DIAGNOSTIC_TEST|Evaluation of shoulder problems|The developed items and Shoulder Pain and Disability Index-SPADI will be directed to the participants.
40965128|NCT01620671|PROCEDURE|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
40965129|NCT01620671|PROCEDURE|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
40965130|NCT01961193|DEVICE|contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
41294992|NCT04429425|PROCEDURE|epidural anesthesia|epidural anesthesia through epidural injection of a local anaesthetic combined with an opioid
41294993|NCT00469196|PROCEDURE|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
41457096|NCT01151696|DRUG|Atarax (Hydroxyzine)|One milligram per 10 kilogram, intramuscular use
41294994|NCT05034783|DRUG|[68Ga]Ga-HBED-CC-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-HBED-CC-exendin-4. Tracer doses of \[68Ga\]Ga-HBED-CC-exendin-4 will be used to image lesions of insulinoma by PET/CT.
41294995|NCT05034783|DRUG|[68Ga]Ga-NOTA-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-NOTA-exendin-4. Tracer doses of \[68Ga\]Ga-NOTA-exendin-4 will be used to image lesions of insulinoma by PET/CT.
41294996|NCT04655677|BIOLOGICAL|CD19/CD20-directed CAR-T cells|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
41294997|NCT04790006|DRUG|TG103|Administered SC
41294998|NCT04790006|DRUG|Placebo|Administered SC
41294999|NCT00447213|DRUG|Insulin glargine|Patient specific, injected, daily, 24 weeks
41295000|NCT00447213|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
41295001|NCT00447213|DRUG|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
41295002|NCT04871321|DRUG|nab-paclitaxel plus gemcitabine-cisplatin|- gemcitabine 800mg/m2 + cisplatin 25 mg/m2 + nab-paclitaxel 100mg/m2 on day 1 and day 8, every 21 days
41295003|NCT05934799|DRUG|Clopidogrel film-coated tablet 75 mg|Clopidogrel is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 75 mg of clopidogrel.
41295004|NCT05934799|DRUG|Plavix® film-coated tablet 75 mg|Plavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.
41295005|NCT01116245|BIOLOGICAL|ADXS11-001 (Lm-LLO-E7)|ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
41295006|NCT01116245|DRUG|Placebo Control|3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
41295007|NCT01981122|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
41295008|NCT01981122|DRUG|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
41295009|NCT01043523|DRUG|Gadoxetic Acid Disodium (Eovist, BAY86-4873)|Participants have received Primovist/Eovist for liver Magnetic Resonance Imaging (MRI) as part of their routine care at participating institutions and additional diagnostic information are identified retrospectively from institution records
40766547|NCT06636760|DIETARY_SUPPLEMENT|herbal compound|The herbal combination is made up of various medicinal plants and possesses immunomodulator properties. It comprises Phyllanthus niruri, Andrographis paniculata, and Glycyrrhiza glabra, along with Anacardium occidentale leaf and Zingiber officinale rhizome, all recognized for their immunomodulatory properties.
40766548|NCT06399718|DRUG|BOTOX|Intramuscular Injections
40766549|NCT06399718|DRUG|Placebo|Intramuscular Injections
41295010|NCT05269940|DRUG|ZX-101A|oral dosing, once daily
41295011|NCT00619684|DRUG|lenalidomide|Given PO
41295012|NCT00812916|PROCEDURE|RF ablation, using specialized CFAE software|RF ablation
41295013|NCT06014905|DRUG|Hyperpolarized carbon C 13 pyruvate|Given Intravenously (IV)
41295014|NCT06014905|PROCEDURE|Magnetic Resonance Image (MRI)|Imaging procedure
41295015|NCT06014905|OTHER|Saline|Given IV
41295016|NCT03175003|OTHER|Food Product|Each food product will provide similar calories, but a different micro- and macro-nutrient composition
41295017|NCT05574816|DEVICE|Phi-Bra prototype measurements|"The bra prototype will be placed on the patient's breast. The patient will stay in a half-lying position during 15 min, the time duration of the measurements. Measurements will not be painful.~Measurements will only be realized one time during the first and unique visit of the patient."
41295018|NCT04963712|DRUG|Zadaxin|1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.
41295019|NCT02561416|BEHAVIORAL|MBSR|Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
41295020|NCT02561416|BEHAVIORAL|FibroQol|"Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.~Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.~Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).~Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV."
41295021|NCT02561416|DRUG|TAU|In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
41457097|NCT01151696|DRUG|Placebo|Placebo
40766550|NCT05620407|DRUG|Deucravacitinib|Specified dose on specified days
40766551|NCT05620407|OTHER|Placebo|Specified dose on specified days
40766552|NCT03952351|RADIATION|CT Coronary Angiography (CTCA)|CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines
41295022|NCT03319992|DEVICE|Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)|RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
41295023|NCT04786028|OTHER|Isatuximab|Brand name for interventional drug is Sarclisa
41295024|NCT02892851|DEVICE|Deep brain stimulation of the subthalamic nuclei (STN-DBS)|"3 phases :~* Parameter setting~* Cross-over double-bind (ON/OFF)~* Open Phase (ON)"
41457098|NCT03056287|BEHAVIORAL|Aerobic exercise|treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
40766553|NCT06645132|BEHAVIORAL|exercise intervention|Exercise intervention leveraging wearable devices and a custom smartphone application to cue exercise as a reminder during idle time during an inpatient hospital stay, post allogenic bone marrow transplant.
40766554|NCT06639958|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40766555|NCT06639958|BEHAVIORAL|Compliance Monitoring|Receive DST
40766556|NCT06639958|OTHER|Health Promotion and Education|Receive customized printed medication schedules
40766557|NCT06639958|OTHER|Informational Intervention|Receive Patient Supply Kit
40766558|NCT06639958|OTHER|Media Intervention|View MIPE program videos
40766559|NCT06639958|OTHER|Media Intervention|Review booster MIPE videos
40766560|NCT06639958|OTHER|Medical Device Usage and Evaluation|Use MEMS® with TrackCap™
40766561|NCT06639958|DRUG|Mercaptopurine|Given PO
40766562|NCT06639958|OTHER|Questionnaire Administration|Ancillary studies
40766563|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive automated customized electronic reminders via smartphone
40766564|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive additional automated reminder
40766565|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|"Receive electronic reminders with successive alerts (using the snooze function)"
40766566|NCT06639958|BEHAVIORAL|Training and Education|Undergo training for prompting and supervising 6MP
40766567|NCT04905407|DRUG|Tamibarotene|Tamibarotene tablets will be administered per dose and schedule specified in the arm.
40766568|NCT04905407|DRUG|Venetoclax|Venetoclax tablets will be administered per dose and schedule specified in the arm.
41137268|NCT02435485|OTHER|Rehabilitation including core spinal stabilization exercise|Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
41137269|NCT02258178|BIOLOGICAL|Flucelvax (cTIV)|vaccine exposure in routine care (no vaccination per protocol)
41137270|NCT05445050|DIAGNOSTIC_TEST|Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)|"Part A: performing CEUS with the contrast agent SonoVue® at two different doses and two different injection speeds in participants with primary breast cancer~Part B: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants undergoing neoadjuvant chemotherapy~Part C: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants with lesions of unknown dignity"
41137271|NCT05347849|DRUG|BPL-003|A single dose of BPL-003 will be administered intranasally
41137272|NCT05347849|OTHER|Placebo|A single dose of placebo will be administered intranasally
41137273|NCT05738785|OTHER|Document review and scanning|Osteoporosis risk and osteoporotic fracture risk will be calculated by examining the patients' files.
40766569|NCT04905407|DRUG|Azacitidine|Azacitidine injection will be administered per dose and schedule specified in the arm.
41137274|NCT01219127|OTHER|Derma-PACE|ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
41137275|NCT01078272|OTHER|Remote ischemic preconditioning|Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
41137276|NCT01078272|OTHER|Sham Remote Ischemic Preconditioning|Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
40766570|NCT05671861|DEVICE|Trismus Device Prototype|Device is noninvasive and will be inserted between patient's upper and lower teeth
40766571|NCT05671861|OTHER|Questionnaires|Surveys will be administered to participants
40766572|NCT05671861|OTHER|Mobile Application|A study-specific, accompanying secure mobile application for users to track progress will be created.
40766573|NCT04946370|DRUG|225Ac-J591|Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.
40766574|NCT04946370|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.
40766575|NCT04946370|DRUG|Androgen receptor pathway inhibitor|Patients will receive an oral androgen receptor pathway inhibitor (ARPI). Examples include enzalutamide and apalutamide. Dosing will be the standard dosing, as described by the package insert.
40766576|NCT04946370|DIAGNOSTIC_TEST|68Ga-PSMA-11|\[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.
40766577|NCT03228537|DRUG|Atezolizumab|Given IV
40766578|NCT03228537|DRUG|Cisplatin|Given IV
40766579|NCT03228537|PROCEDURE|Extrapleural Pneumonectomy|Undergo EPP
40766580|NCT03228537|DRUG|Pemetrexed Disodium|Given IV
40766581|NCT03228537|PROCEDURE|Pleurectomy|Undergo PD
40766582|NCT03228537|RADIATION|Radiation Therapy|Undergo RT
40766583|NCT06643104|PROCEDURE|Tuina|X-ray mapping guides three days of tailored exercises, including 3D therapy, breathing techniques, and spinal manipulation.
40766584|NCT06645275|GENETIC|POCT test|Patients undergo POCT testing on the day of warfarin administration, and based on the POCT results, the initial and maintenance doses of warfarin are determined according to the IWPC algorithm.
40766585|NCT06644352|PROCEDURE|different thoracic surgical approaches|Right Versus Left Thoracic Surgical Approaches
40965131|NCT01961193|DEVICE|punctal plug|A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
40965132|NCT01481727|DEVICE|BiPAP Pro 2, Phillips Respironics|mechanical ventilation type bilevel at high intensity (\>18mmHg) for at least six hours, nocturnal ventilation.
40965133|NCT01481727|DEVICE|CPAP sham|CPAP sham maneuver (IPAP less or equal to 4cmH2O)
40965134|NCT02555683|DRUG|QAW039|QAW039 150 mg once daily
40965135|NCT02555683|DRUG|QAW039|QAW039 450 mg once daily
40965136|NCT02555683|DRUG|Placebo|Placebo once daily
40965137|NCT05876598|DRUG|antibiotic treatments|The outcome of the study will be to implement Prediction Models to support clinicians for the assessment of risk of having a bloodstream infection.
40965138|NCT02364752|PROCEDURE|Blood Draw|
40965139|NCT02364752|PROCEDURE|Loop Diuretic Withdrawal/Salt Load|
40965140|NCT05038436|DEVICE|Polyglucosamine L112|Two tablets once daily per os
40766586|NCT06645171|DIETARY_SUPPLEMENT|Fibre drink|One drink will be tested
40766587|NCT05660187|OTHER|Multiple Sclerosis Clinical Care Delivery via telehealth|Intervention includes clinical care delivered via telehealth
40766588|NCT05660187|OTHER|Multiple Sclerosis Clinical Care Delivery via standard in clinic visits|Intervention includes clinical care delivered via standard in clinic visits
40965141|NCT05500105|OTHER|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
40965142|NCT04991909|DRUG|HRS4800|HRS4800
40965143|NCT04991909|DRUG|Placebo|Placebo
40965144|NCT05877352|RADIATION|Intraoperative Electron Radiotherapy (IOERT)|IOERT can be defined as the direct application of high-energy electron beam irradiation to a tumour bed during an operative procedure. This approach permits precise delivery of a single large fraction of radiation directly and specifically to high recurrence risk anatomical target areas, which the treating clinicians (surgeon and attending clinical oncologist) predict will be a close or involved margin, while simultaneously displacing and shielding dose-limiting radiosensitive structures such as the small bowel or ureter or any anastomoses, if not involved by tumour.
40965145|NCT05877352|PROCEDURE|Extended Margin Surgery|Surgery intended to remove both a tumour and any metastases
40965146|NCT02968771|OTHER|Non intervention|
40965147|NCT00935571|DRUG|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
40965148|NCT03502083|DRUG|GLP-1 (7-36)Amide|IV infusion
40965149|NCT00189150|DRUG|Mycophenolate mofetil|
40965150|NCT00189150|DRUG|Valganciclovir|
40965151|NCT03558854|DRUG|Acetylsalicylic acid|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
40965152|NCT03558854|DRUG|Placebo oral capsule|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
40965153|NCT04185545|BIOLOGICAL|Rotavirus RV3 Vaccine (Bio Farma)|Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains \> 5x10\^6 fcfu/mL rotavirus vaccine strain RV3
40965154|NCT04185545|OTHER|Placebo|Each 1 mL dose of placebo contains 30% of sucrose in DMEM
40965155|NCT05468827|PROCEDURE|lymphatic mapping with indocyanine green|subserosal injection of indocyanine green near the primary tumour with subsequent assessment of the dye spread along lymphatics
40965156|NCT05095545|DRUG|AV5080|Hard gelatin capsules with a white body
40965157|NCT05095545|OTHER|Placebo|Hard gelatin capsules with a white body
40965158|NCT06172322|DRUG|NTQ1062 with Fulvestrant|"Drug: NTQ1062 tablet(s) ，PO，QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment).~Drug: Fulvestrant Injection 500mg in a 28-day cycle."
40965159|NCT01558232|DEVICE|Tibion Bionic Leg|The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
40965160|NCT00946699|BIOLOGICAL|MEDI-551|0.1 mg/kg
40965161|NCT00946699|BIOLOGICAL|Placebo|0.3 mg/kg
40965162|NCT00946699|BIOLOGICAL|MEDI-551|1.0 mg/kg
40965163|NCT00946699|BIOLOGICAL|MEDI-551|3.0 mg/kg
40965164|NCT00946699|BIOLOGICAL|MEDI-551|10.0 mg/kg
40965165|NCT00946699|OTHER|Placebo|Placebo
40965166|NCT02140372|DRUG|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
40965167|NCT05572450|OTHER|Infectious Titre 1|Approximately 10\^5.5 TCID50/mL (titre may be adjusted based on stock titre)
40965168|NCT05572450|OTHER|Infectious Titre 2|Approximately 10\^4.5 TCID50/mL (titre may be adjusted based on stock titre)
40965169|NCT05572450|OTHER|Infectious Titre 3|To be determined (TBD), depending on outcome of Part A
40965170|NCT05572450|OTHER|Infectious Titre 4|TBD, depending on outcome of Part A
40965171|NCT03715881|DRUG|Oral prednisolone administration 50 mg|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
40965172|NCT03715881|DRUG|Intravenous Erythropoietin injection|1000 units of erythropoietin every 12 hours for three days
40965173|NCT03184831|PROCEDURE|sinus lift, implant placement, sole bovine bone|sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement
41137277|NCT02193932|OTHER|EEG Triggered fMRI using Micro Maglink|
40965174|NCT03184831|PROCEDURE|sinus lift, implant placement, injectable PRF + bovine bone|sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
40965175|NCT03657511|BEHAVIORAL|Educational Interventions to Promote Tobacco Cessation|"Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks."
40965176|NCT05630209|DEVICE|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
40965177|NCT05630209|DRUG|Doxorubicin|Doxorubicin infusion
41137278|NCT02144194|DRUG|Vinorelbine-Docetaxel|Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles
41137279|NCT02144194|DRUG|Vinorelbine|Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
41137280|NCT00863902|DRUG|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
41137281|NCT00863902|DRUG|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
41137282|NCT05770492|DIAGNOSTIC_TEST|anterior segment optical coherence tomography|Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans. Radial scan patterns will be used for acquisition.
41137283|NCT02180932|BIOLOGICAL|periodontal pocket samples|
41137284|NCT00197444|DRUG|CDGP/5-FU combined with radiation|Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
41137285|NCT00197444|RADIATION|Radiotherapy|Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
41137286|NCT01841515|DRUG|Desmopressin administration|
41137287|NCT03210324|DRUG|Mifepristone tablets|Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
41137288|NCT05077475|DRUG|C52R1H Tab. and C52R2 Tab.|Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
41137289|NCT05077475|DRUG|AJU-C52L|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
41137290|NCT03543904|PROCEDURE|Pre-operative physiotherapy education|"Pre-operative education regarding post-operative physiotherapy intervention in children with abdominal surgery which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises"
41137291|NCT03543904|PROCEDURE|Post-operative physiotherapy intervention|"Post-operative physiotherapy intervention which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises"
41137292|NCT02401711|BEHAVIORAL|Education - BIPS course|The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
41137293|NCT02401711|BEHAVIORAL|Formal safety curriculum|The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
41137294|NCT02401711|BEHAVIORAL|Ongoing evaluation and feedback|The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
41137295|NCT01474382|DRUG|OraVerse|1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
41137296|NCT01474382|OTHER|Sham injection|No drug administered, simulation of injection used in same manner as drug
41137297|NCT05584306|DRUG|610 30mg group|610 30mg subcutaneous (SC) Q4W，8 times
41137298|NCT05584306|DRUG|610 100mg group|610 100mg subcutaneous (SC) Q4W，8 times
40965178|NCT05190159|DEVICE|Monster Screw System|Subjects who have undergone a foot and/or ankle procedure involving the index device
41137299|NCT05584306|DRUG|610 300mg group|610 300mg subcutaneous (SC) Q4W，8 times
41137300|NCT05584306|OTHER|Placebo 30mg group|placebo subcutaneous (SC) Q4W，8 times
41137301|NCT05584306|OTHER|Placebo 100mg group|placebo subcutaneous (SC) Q4W，8 times
41137302|NCT05584306|OTHER|Placebo 300mg group|placebo subcutaneous (SC) Q4W，8 times
41137303|NCT03345979|COMBINATION_PRODUCT|Aripiprazole Lauroxil|Intramuscular injection; study drug provided using a pre-filled syringe
41137304|NCT03345979|DRUG|Paliperidone Palmitate|Intramuscular injection
40766589|NCT05902741|BEHAVIORAL|RiSE|RiSE provides participants with a platform to share the emotional impact of race-based stress and to offer supportive listening to their peers. Participants explicitly discuss the experiences they have as African American women, taking into account the ways which the interaction between their racial and gender identities shapes their experiences. Facilitators review difficulties associated with addressing racism and unique experiences of Black women at interpersonal and structural levels, and provide evidence of strategies to promote effective communication and internal emotional regulation regarding experiences of racism. Facilitators provide psychoeducation on intersectionality, structural racism, overt racism, microaggressions, and internalized racism. Following this education, facilitators help participants utilize cognitive-behavioral strategies to understand consequent thoughts, feelings, and actions associated with such experiences.
40766590|NCT05902741|BEHAVIORAL|HEP|The HEP group will consist of classes focusing on wellness promotion. Expert speakers provide the HEP classes (e.g dietician, pharmacist).
40766591|NCT06052358|DEVICE|LAAC with Watchman FLX device|LAAC with Watchman FLX device
40766592|NCT06305754|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg via IV infusion
40766593|NCT06305754|DRUG|Pemetrexed|500 mg/m\^2 via IV infusion
40766594|NCT06305754|DRUG|Carboplatin|AUC 5 mg/mL\*min via IV infusion
40766595|NCT06305754|DRUG|Antihistamine|Administered as rescue medication per approved product label
40766596|NCT06305754|DRUG|H2 Receptor Antagonist|Administered as rescue medication per approved product label
40766597|NCT06305754|DRUG|Acetaminophen (or equivalent)|Administered as rescue medication per approved product label
40766598|NCT06305754|DRUG|Dexamethasone (or equivalent)|Administered as rescue medication per approved product label
40766599|NCT06305754|DRUG|Steroid Mouthwash (dexamethasone or equivalent)|Administered as rescue medication per approved product label
40965179|NCT01292434|BEHAVIORAL|Lunch is in the Bag behavioral intervention|Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
41137305|NCT05314049|PROCEDURE|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
40766600|NCT06638853|BEHAVIORAL|Distress Tolerance Skills Training|"These lessons are adapted from DBT Skills in Schools: Skills Training for Emotional Problem Solving for Adolescents (DBT STEPS-A) by Mazza et al. and include elements of mindfulness training, psychoeducation about emotions, and techniques/skills for managing extreme emotions."
41137306|NCT05314049|PROCEDURE|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
41137307|NCT05314049|DEVICE|inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
41137308|NCT05314049|DEVICE|Heat Therapy|superficial heating for 20 minutes
41137309|NCT03703414|DIAGNOSTIC_TEST|Fecal microbiota composition analysis and blood cytokine level analysis|Fecal microbiota composition analysis and blood cytokine level analysis
41137310|NCT01595867|DRUG|Placebo|Lactose (100 mg) placebo tablets crushed; single dose
41137311|NCT01595867|DRUG|EMBEDA - morphine sulfate/ naltrexone hydrochloride|EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose
41137312|NCT01595867|DRUG|morphine sulfate CR crushed.|Morphine sulfate controlled release 30 mg tablet crushed
41137313|NCT03265756|DEVICE|Multimometer|A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
41137314|NCT05433441|PROCEDURE|ESPark Intervention|The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.
41137315|NCT01331408|DEVICE|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
41295025|NCT00677963|DRUG|sulphur hexafluoride, gadopentate dimeglumine|CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
41295026|NCT03765567|DRUG|Vancomycin|2 vials of Vancomycin 1g powder will be applied topically to the open fracture wound site.
41295027|NCT01283191|BEHAVIORAL|Behavioral Incentives|Vouchers for complying with target behavior of treadmill walking
41457099|NCT03056287|OTHER|Repetitive transcranial magnetic stimulation|Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
41457100|NCT03204851|DEVICE|Wound Healing|Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.
41457101|NCT04899934|BEHAVIORAL|mobile and technology assisted aftercare|The mobile and technology assisted aftercare consists of mobile mental health professionals who travel to participants to provide mental health services including counseling, navigation of community referrals, motivational interviewing, solution focused therapy, psycho-education, and social support. Participants randomized to this condition will also receive 24/7 access to evidence-based behavioral health mobile applications that are recommended based on the participant's diagnostic status, learning style, and goals. Frequency of app use is up to the participant's discretion. However, during weekly aftercare sessions, the CSS may assist the participant with creation of an app use schedule that is realistic for the participant's needs and treatment goals.
41457102|NCT04899934|OTHER|Treatment as usual|Treatment as usual services include a personalized discharge plan, a follow up appointment within a month of discharge for evaluation and connection to other agency services if applicable. Some of these services may include outpatient counseling for behavioral and emotional problems, psychiatric services, group therapy, case management, rehabilitation services, homeless recovery services, employment services, medication-assisted treatment, group-based team building activities, primary care clinic, and forensic services. Individuals may also receive ancillary referrals for applicable healthcare services, access to residential and outpatient substance abuse treatment services, and access to a tablet.
41457103|NCT01105182|PROCEDURE|Radiofrequency Ablation|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
40965180|NCT02955602|DRUG|MBX-8025 2 mg Capsule|"Initial 8-week treatment:~• MBX-8025 2 mg~Extension:~The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
41137316|NCT03900988|DRUG|N-acetyl cysteine|N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
41295028|NCT01283191|BEHAVIORAL|Education Control|Education class
41137317|NCT03900988|DRUG|5% Dextrose|5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
41295029|NCT04525222|OTHER|Health Promotion and Education|Receive motivational messages and smoking cessation information via text notifications
40965181|NCT02955602|DRUG|MBX-8025 5 mg Capsule|"Initial 8-week treatment:~• MBX-8025 5 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
41137318|NCT05749237|OTHER|respiratory exercises|respiratory exercises
41137319|NCT05749237|OTHER|relaxation exercises|relaxation exercises
41137320|NCT03138005|OTHER|target SpO2 98-100%|Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to \~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.
41295030|NCT04525222|BEHAVIORAL|Smoking Cessation Intervention (Actify app)|Use Actify app
41295031|NCT04525222|BEHAVIORAL|Smoking Cessation Intervention (Current Standard Care app)|Use (USCPG) Current Standard Care app
41295032|NCT04525222|OTHER|Survey Administration|Ancillary studies
41295033|NCT04772365|DRUG|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels;
41295034|NCT04772365|DRUG|Placebo|Placebo will be subcutaneously administered with different dose levels;
40965182|NCT02955602|DRUG|MBX-8025 10 mg Capsule|"Initial 8-week treatment:~• MBX-8025 10 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
41295035|NCT00521339|DRUG|Apremilast|20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
41295036|NCT03647943|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation, involving low-levels of electrical stimulation applied to the right and left DLPFC will be used in conjunction with cognitive training for 46 minutes.
41457104|NCT03113357|OTHER|Myofascial release technique|myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist
40766605|NCT03308474|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
40766606|NCT05692180|DRUG|Benralizumab|Benralizumab active solution will be administered SC to the patients.
41457105|NCT03113357|OTHER|conventional exercise therapy|"All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present."
40766607|NCT05692180|DRUG|Placebo|Placebo solution will be administered SC to the patients.
40766608|NCT05442879|BEHAVIORAL|Knowledge Translation Intervention|The KT intervention utilizes the communications between the teams and the researchers to promote implementation of the ACL-IPPs. The meetings will provide opportunities for mutually beneficial learning from the researchers, and feedback from the coaches on how to best implement strategies through local barriers in order to facilitate necessary changes to promote ACL-IPP usage while adhering to clinical practice guideline recommendations.
40766609|NCT05442879|BEHAVIORAL|Educational handout|Educational handout describing a commonly cited ACL-IPP.
40766610|NCT06568562|DRUG|XL092|XL092 will be supplied as a tablet that will be taken at home once a day. Participants should drink at least 8 ounces of water with each dose of XL092. Participants should not eat at least 2 hours before taking the dose and 1 hour after. Participants will be given enough XL092 to take at home for a full cycle.
41295037|NCT03647943|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation, involving no electrical stimulation will be used in conjunction with cognitive training for 46 minutes.
41295038|NCT06377644|DIAGNOSTIC_TEST|Kinesio taping|Kinesio taping is a physiotherapy method employed to provide support and stability to muscles and joints while allowing freedom of movement (ROM). The elastic nature of kinesio tape closely resembles that of human skin. After application, kinesio tape rebounds, generating a pulling force that acts as the primary stabilizer for the specific area. Physiotherapy treatments often involve a combination of stretching and strengthening exercises, along with electrotherapy modalities. Additionally, Joint mobilization is a form of passive movement in a broad spectrum of exercise used to treat painful and stiff synovial joints.
40766611|NCT06175533|PROCEDURE|ultrasound guided 60 degree CRF for plantar fasciitis|ultrasound guided plantar fascia CRF for chronic conditions not responding to treatment
40766612|NCT06643442|DRUG|Empagliflozin Tablets|Empagliflozin 10mg p.o. once daily (commercially available tablet)
40965183|NCT02099994|BIOLOGICAL|Ad35-GRIN|intramuscular administration of Ad35-GRIN 5 x 10\^10 vp or saline placebo
40965184|NCT02099994|BIOLOGICAL|MVA.HIVconsv|IM administration of MVA.HIVconsv 2 x 10\^8 pfu or saline placebo
40965185|NCT02099994|BIOLOGICAL|pSG2.HIVconsv DNA|IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
40965186|NCT02099994|BIOLOGICAL|Electroporated pSG2.HIVconsv|IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
40965187|NCT00830362|DRUG|Propranolol|40 mg administered once
40965188|NCT00830362|DRUG|Placebo|administered once
40766613|NCT02853292|BIOLOGICAL|urine collection|
40766614|NCT03126630|BIOLOGICAL|Anetumab Ravtansine|Given IV
40766615|NCT03126630|OTHER|Laboratory Biomarker Analysis|Correlative studies
40766616|NCT03126630|BIOLOGICAL|Pembrolizumab|Given IV
40766617|NCT03126630|OTHER|Pharmacological Study|Correlative studies
40766618|NCT02851706|OTHER|No Treatment|Survey or Questionnaire Completion with or without Sample Submission
40766619|NCT06551727|OTHER|Intervention group|"After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.~In terms of blood pressure control, medications such as dopamine, metaraminol, or midodrine are used to achieve a systolic blood pressure target range of 160-180 mmHg within 1 h of random assignment and to maintain this target for 7 days (or death, should this event occur earlier). BP measurements are routinely captured using automated devices fitted to the unaffected arm, following the protocol recommended by the standard guideline. The readings are taken at 15-minute intervals for the initial hour, hourly from the first to the sixth hour, every six hours from 6 to 24 hours, and then twice daily for 7 days (or death, if earlier). Subsequently, these data are uploaded into the research database."
40965189|NCT01125267|BEHAVIORAL|multifamily group-adherence|multifamily groups held twice a month for one year focused on improving medication adherence using techniques derived from the Theory of Planned Behavior
40965190|NCT01125267|BEHAVIORAL|multifamily group-standard|multifamily groups held twice a month focused on general problem solving method
40965191|NCT06385639|DIETARY_SUPPLEMENT|Probiotic|This clinical trial will last for 10 days, and each subject will have 4 follow-up visits (Day -1, Day 0, Day 10, Day 20).
40965192|NCT04692571|DEVICE|PSICON Measurement Apparatus|Test apparatus acquires 16 sEMG channels, measure four DoFs of force/moment at the hand-wrist \[hand open-close (Opn-Cls); wrist extension-flexion (Ext-Flx), radial-ulnar deviation (Rad-Uln) and pronation-supination (Pro-Sup)\]. sEMG system used 16 custom encased bipolar electrodes. A commercial LTI EMG amplifier (BE328) conditioned each EMG signal before A/D conversion on a PC. A thermoplastic hand cuff secured the wrist to a six-axis load cell (AMTI, model MC3A-100) for force/moment measurement. A separate hand-grasp one-axis load cell (Omega Engineering Inc., model LCR-150) was Velcro-secured between the fingers and the thumb, to measure power grip forces. The PC acquired and stored the sEMG and load cell data, and commanded a triangular screen target. The subject controlled a second triangular cursor. Left-right movement of the cursor was controlled by wrist Ext-Flx, up-down movement by Rad-Uln deviation, cursor rotation by Pro-Sup and cursor size by hand Opn-Cls forces.
40766620|NCT06551727|OTHER|Control group|After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.
40965193|NCT04430218|DEVICE|iSens|The study involves a surgical implant of cuff electrodes on the nerves in the amputated limb, and muscle recording electrodes the remaining muscles. These will be connected to an implanted stimulator. The stimulator will connect wirelessly to an advanced prosthesis. This may allow a user to move the prosthetic hand intuitively and feel what your prosthesis is touching.
40965194|NCT02781597|DRUG|Tranexamic Acid|Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
40965195|NCT02781597|DRUG|Placebo|Patients will receive 0.9% normal saline
41137321|NCT03138005|OTHER|target SpO2 90-94%|Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.
41137322|NCT04549688|PROCEDURE|high-intensity focused ultrasound, HIFU|see above
41137323|NCT05458466|OTHER|Pilates training|Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.
41137324|NCT00774592|BEHAVIORAL|FOYC|FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
41137325|NCT00774592|BEHAVIORAL|Goal for it (GFI)|GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
41137326|NCT00774592|BEHAVIORAL|Wonderous Wetlands|Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
41137327|NCT00774592|BEHAVIORAL|Caribbean Informed Parents and Children Together (CImPACT)|CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
41137328|NCT00774592|BEHAVIORAL|Bahamian Focus on Older Youth (BFOOY)|10 session HIV prevention program
41137329|NCT00774592|BEHAVIORAL|Health and Family Life Curriculum (HFLE)|Standard Grade 10 curriculum
41137330|NCT03382704|DIAGNOSTIC_TEST|Examination for presence or absence of lanugo hairs|Pre-operative examination for presence or absence of lanugo hairs
41137331|NCT02444195|BEHAVIORAL|Guided Imagery With Audio Media|Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
40766621|NCT06644820|DIAGNOSTIC_TEST|radiology|"Chest x ray posteroanterior view and lateral view.~CT. chest without contrast:~To assess the underlying lung pathology e.g. multiple bullae, interstitial lung disease (ILD) , cavitating lesions or nodules."
40766622|NCT04134936|DRUG|Tafasitamab|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) in addition to R-CHOP
40965196|NCT03483740|BEHAVIORAL|CRGT|Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 8 weekly 3-hour sessions.
40965197|NCT03483740|BEHAVIORAL|HIV group therapy|These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 8 weekly 3-hour sessions.
40965198|NCT03821883|DRUG|Aspirin Tablet|Aspirin 100mg qd
41295039|NCT06377644|DIAGNOSTIC_TEST|Dry Needling|Dry needling is a minimally invasive technique involving the use of a single filament or acupuncture needle to penetrate painful soft tissue areas. From a neurophysiological standpoint, Dry Needling might stimulate A-delta nerve fibers (group III), which could activate inhibitory dorsal horn interneurons containing enkephalin, leading to pain suppression and relief through opioid mechanisms. (DN) may affect microcirculation. Numerous studies have shown that inserting needles into muscles can increase blood flow in both the skin and the muscle in the treated area. It can lead to an immediate reduction in local and referred pains, as well as enhance range of motion (ROM) and correct muscle activity patterns.
41295040|NCT06017232|OTHER|Hybrid telerehabilitation program|"The telerehabilitation program lasts 12 week (3 per week). The program includes aerobic, strength, coordination, balance, flexibility, and breathing exercises, in addition to educational components focused on disease management.~This hybrid program incorporates both supervised and unsupervised sessions. A progressive approach from synchronous (supervised) to asynchronous (unsupervised) sessions is adopted.~Each session is structured into 4 components: Warm-up; Muscle strengthening, coordination, and balance; Flexibility; and Breathing exercises.~Participants are asked to maintain a log of their aerobic activity, recording details such as the type of activity, duration, and intensity. The aim is to align with the recommended aerobic physical activity guidelines (150 min/week). Weekly assessments are conducted to provide personalized guidance based on individual progress.~Also, participants engage in weekly educational videos that cover a diverse range of PD-related topics."
40766623|NCT04134936|DRUG|Tafasitamab plus lenalidomide|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) plus lenalidomide (starting dose 25 mg orally, on Day 1-10) in addition to R-CHOP
40766624|NCT06643169|BEHAVIORAL|home-based fall prevention program with multifactorial|"* Health Education~* Otago Exercises~* Assessing and Organizing the Safe Home Environment"
40965199|NCT03821883|DRUG|Placebo|Placebo qd
41137332|NCT01116609|DRUG|Epinephrine|unilateral leg infusion of Epinephrine 0.4 micrograms/m2/min
40766625|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
40766626|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|up to 1 mg three times a day (increasing from 0.5 to 1 mg)
40766627|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|fixed 0.5 mg three times a day
40766628|NCT01065454|DRUG|Placebo|Placebo three times a day
41137333|NCT00291941|BIOLOGICAL|Henogen HBV vaccine|20µg, Month 0, 2 and 6
41137334|NCT00291941|BIOLOGICAL|FENDRIX|20 µg,Months 0, 1, 2 and 6
41137335|NCT05143099|DRUG|TEC|tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan
40766629|NCT05336565|OTHER|Electronic medical record analysis|"Medical information system (MIS) BARS will be used for inclusion and retrieval of relevant data of cardiovascular patients enrolled in the reimbursement programs in the Tomsk Region. Incidence rates and patterns of PIM prescription, polypharmacy, and PDDIs in the time of COVID-19 pandemic will be studied."
40965200|NCT06505304|PROCEDURE|Colonoscopy|"The colonoscopy will be performed at 3 or 6 months after surgery according to FC:~* In patients with FCP \>=150µg/g at around 3 months after surgery, a colonoscopy will be immediately performed~* In patients with FCP \<150µg/g at around 3 months after surgery, the colonoscopy will be organized at 6 months after surgery~Colonoscopy will be performed using high definition white-light endoscopy (HD-WLE) followed by virtual chromoendoscopy (VCE). The neoterminal ileum, ileocolic anastomosis and right colon will be assessed.~A follow-up colonoscopy will be performed within 18 months after index colonoscopy, as standard of care."
40965201|NCT06505304|PROCEDURE|Intestinal biopsies|During index colonoscopy, at least 2 biopsies from each of the segments will be taken as standard of practice to assess inflammation in post-operative CD. Only in Irish sites, twelve biopsies - four in the area of ileocolonic anastomosis, four in the neo-terminal ileum and four in the colon just distal to the anastomosis- will be taken for research purposes, in addition to standard-of-care biopsies.
40965202|NCT06505304|PROCEDURE|Confocal laser endomicroscopy|pCLE with fluorescein injection will be performed during index colonoscopy, in centres where is available, to assess early alteration of the barrier function.
40965203|NCT06505304|PROCEDURE|Intestinal ultrasound|All patients will undergo a cross-sectional imaging test as part of their standard of care at 3 and 6 months after surgery. A follow-up IUS will be performed within 18 months after index colonoscopy, as standard of care.
41295041|NCT04701255|PROCEDURE|phacoemulsification with intraocular lens implantation|treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.
41295042|NCT04701255|DEVICE|ocular aberrometer assesment|evaluate total ocular wavefront, corneal wavefront \& internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
41295043|NCT05164276|OTHER|Head position|Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.
40965204|NCT06505304|DIAGNOSTIC_TEST|Stool|Stool samples will be collected at 3 and 6 months after surgery and used for faecal calprotectin analysis. Research stool will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for metagenomics (only in Irish sites).
41137336|NCT02286869|PROCEDURE|Three different mechanical ventilation modes|patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.
41295044|NCT02778048|OTHER|MRI (magnetic resonance imaging)|Assessment of the sphincter
41295045|NCT02778048|OTHER|US (ultra sound)|Assessment of the sphincter
41457106|NCT04194333|PROCEDURE|Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy to guide Electromagnetic Navigational Bronchoscopy instead of Standard Fluroscopic guidance using the C-Arm|Instead of the standard fluoroscopy using the C-arm, the intervention will undergo electromagnetic navigation guided bronchoscopy while using Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy.
41457107|NCT01021657|PROCEDURE|trabeculectomies, non penetrating deep sclerectomies|
41457108|NCT00756171|DRUG|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
41295046|NCT02778048|OTHER|FLIP (functional lumen imaging probe)|Assessment of the sphincter
41457109|NCT00756171|DRUG|placebo|2 times 3 625mg tablets daily
40965205|NCT06505304|DIAGNOSTIC_TEST|Blood|Blood will be collected at 3 and 6 months after surgery and used as standard of care. Research blood will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for research - i.e. proteomic, genomic, cell experiments (only in Irish sites).
40965206|NCT06505304|DIAGNOSTIC_TEST|Saliva|Saliva will be collected during the visit of index colonoscopy and at 12 months after surgery for research - i.e. optical spectroscopy (only in Irish site)
41295047|NCT02778048|OTHER|HRAM (high resolution anal manometry)|Assessment of the sphincter
41457110|NCT04803162|DIAGNOSTIC_TEST|High-resolution manometry|The parameters of high-resolution esophageal manometry will be compared between EoE patients and controls.
41457111|NCT04803162|DIAGNOSTIC_TEST|Serum biomarkers|The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared between EoE patients and controls.
41457112|NCT04803162|DIAGNOSTIC_TEST|Gastrointestinal Quality of Life index|The Gastrointestinal Quality of Life index (GIQLI) will be compared between EoE patients and controls.
41457113|NCT04803162|DRUG|Omeprazole 20 MG Oral Tablet|The parameters of high-resolution esophageal manometry and serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs.
41457114|NCT00190541|PROCEDURE|Mesorectal excision with lateral lymph node dissection|Mesorectal excision with lateral lymph node dissection
41295048|NCT02401256|DRUG|Efavirenz|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
41295049|NCT02401256|DRUG|Bupropion|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
41295050|NCT02401256|DRUG|Rosuvastatin|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
41295051|NCT02401256|DRUG|Montelukast|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
41295052|NCT04761380|DIAGNOSTIC_TEST|balloon-based tongue pressure measurement device|The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
41295053|NCT02231216|PROCEDURE|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
41295054|NCT02231216|PROCEDURE|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
41295055|NCT02231216|PROCEDURE|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
41295056|NCT01808703|DEVICE|PeriZone PerioPatch|The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
41457115|NCT00190541|PROCEDURE|Mesorectal excision without lateral lymph node excision|Mesorectal excision without lateral lymph node excision
41457116|NCT03240120|DRUG|Dabigatran etexilate|Pradaxa 150 mg hard capsules
41457117|NCT03240120|DRUG|Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
41457118|NCT02786160|DIETARY_SUPPLEMENT|HMO|
41457119|NCT02786160|DIETARY_SUPPLEMENT|Dextropur|
41457120|NCT02052817|DEVICE|Optimal Medical Therapy Debridement + Toad Brace|
41457121|NCT02052817|OTHER|Optimal Medical Therapy - Debridement|
41457122|NCT04249622|OTHER|Best Practice|Given standard of care pertuzumab-based chemotherapy
41457123|NCT04249622|OTHER|Questionnaire Administration|Ancillary studies
41457124|NCT04249622|DRUG|Rifaximin|Given PO
41457125|NCT00563394|DRUG|ofloxacin|400 mg twice a day for 14 days
41457126|NCT00563394|DRUG|MSI-78|1%/2% topical cream twice a day for 14 days
40766630|NCT06637020|DRUG|HDM1005 injection or placebo|Within each cohort, subjects are randomized in a 4:1 ratio to receive either HDM1005 injection or placebo subcutaneously.
40965207|NCT06505304|OTHER|Clinical follow-up|Patients will be followed-up at 6, 12 and 24 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. The following scores will be repeated: Harvey Bradshaw Index (HBI) and CD Activity Index score (CDAI). Participants will give an update on their medication use.
40965208|NCT00518284|DRUG|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.
40965209|NCT02861300|DRUG|CB-839|Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
41137337|NCT01338532|OTHER|A 12 week supervised exercise program and patient education|"The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.~All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time."
41457127|NCT03057535|DRUG|Sodium Bicarbonate|
41457128|NCT03057535|DRUG|Sodium Chloride|
41457129|NCT00301886|DRUG|ibandronate|
41457130|NCT00301886|DRUG|zoledronate|
41457131|NCT00301886|PROCEDURE|quality-of-life assessment|
41137338|NCT01338532|OTHER|Patient education|All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
41137339|NCT06327282|BEHAVIORAL|education on pain and related knowledge|Before surgery, pain related knowledge was educated.
41457132|NCT04337658|DRUG|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
41457133|NCT04337658|DRUG|Trastuzumab|Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
41457134|NCT04337658|DRUG|Fulvestrant|500mg intramuscular injections at day 1, 15, 28 and 4 weeks thereafter
41457135|NCT04337658|DRUG|Capecitabine|1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
40965210|NCT02861300|DRUG|Capecitabine|capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
41457136|NCT00833625|PROCEDURE|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
41295057|NCT01808703|PROCEDURE|Scaling and root planing alone|Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
40766631|NCT01783288|OTHER|Autonomic Function Testing|"heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.~Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed."
40766632|NCT01783288|OTHER|Posture Study|Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured \& collected in the supine (lying) and upright position for each participant.
40766633|NCT01783288|PROCEDURE|Measurement of Total Blood Volume|Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
40766634|NCT01783288|OTHER|Exercise Capacity Test|Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
40766635|NCT06642532|DEVICE|TCD group|Transcranial Doppler ultrasound to examine bilateral hemodynamic parameters of middle cerebral artery(MCA), terminal internal carotid artery(TICA), (anterior communicating artery)ACA, and posterior cerebral artery(PCA) (Vs, Vd, Vm, PI index, RI index) from temporal window
40766636|NCT05781308|DRUG|Paclitaxel|Paclitaxel 200 mg/m² every 3 weeks
41457137|NCT00833625|OTHER|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
40766637|NCT05781308|DRUG|Bevacizumab|Bevacizumab 15 mg/kg every 3 weeks
40766638|NCT05781308|DRUG|Atezolizumab|1200 mg every 3 weeks
40766639|NCT05616910|DRUG|inhaled nitric oxide|iNO will be provided by ventilator or nasal cannula for 4 hours each day.
40766640|NCT02457598|DRUG|Tirabrutinib|Capsules or tablets administered orally
40965211|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
40965212|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
41137340|NCT05386537|COMBINATION_PRODUCT|MyoMo orthosis and VR games|Combining Wearable Robotic Orthosis with Visual and Haptic Feedback to Enhance the Recovery of Upper Extremity Motor Function and ADL in Persons with Acute SCI
41137341|NCT05386537|DEVICE|MyoPro robot only|Using the MyoPro wearable robotic orthosis only
41137342|NCT05386537|OTHER|Games only|Using VR-video games only
41137343|NCT05386537|OTHER|Control|conventional UE therapy at a rehabilitation facility
41457138|NCT02299869|DEVICE|Verde (Competitor-control)|contact lens
41457139|NCT02299869|DEVICE|Green (CVI-test)|contact lens
41457140|NCT02299869|DEVICE|Cinza (Competitor-control)|contact lens
41457141|NCT02299869|DEVICE|Grey (CVI-test)|contact lens
40766641|NCT02457598|DRUG|Idelalisib|Tablets administered orally twice daily
40766642|NCT02457598|DRUG|Entospletinib|Tablets administered orally
40766643|NCT02457598|DRUG|Obinutuzumab|Administered intravenously
40766644|NCT05887401|BEHAVIORAL|Core|The core intervention will include behavioral lessons, activity tracker, weekly adaptive physical activity goals, weekly tailored feedback summary.
40766645|NCT05887401|BEHAVIORAL|Simplified Nutrition Monitoring (Green)|Simplified diet monitoring using smartphone tracking of green foods using a traffic light approach.
40766646|NCT05887401|BEHAVIORAL|Behavioral: Simplified Nutrition Monitoring (Red)|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
40766647|NCT05887401|BEHAVIORAL|Nutrition Goals (Yes)|Participant will be assigned a personalized weekly nutrition goal related to nutrition monitoring condition.
41137344|NCT04251923|DEVICE|Retro pubic sling|patient after hysterectomy will undergo retropubic sling surgery in the same setting. Retropubic sling will be inserted vaginally in the retropubic area following standard protocol.
40766648|NCT05887401|BEHAVIORAL|Nutrition Goals (No)|Participant will not be assigned a personalized weekly nutrition goal.
40766649|NCT05887401|BEHAVIORAL|Supportive Text Messages (Yes)|Participant will receive up to 5 supportive text-messages from the study staff per week.
40766650|NCT05887401|BEHAVIORAL|Supportive Text Messages (No)|Participant will not receive supportive text-messages.
40766651|NCT05887401|BEHAVIORAL|Lesson Delivery (Once)|All behavioral lessons will be made available to participant simultaneously.
41295058|NCT03634215|DIAGNOSTIC_TEST|fibrinogen plasma concentration, coagulation factor XIII activity|blood sampling for a routine coagulation test
41295059|NCT05326399|BEHAVIORAL|renal biospy|Standard percutaneous biopsy has been performed in all participants. Modification of treatment will be jointly decided by hepatologists and nephrologists based on the pathological results. All participants will be followed up for 96 weeks.
41295060|NCT06203678|OTHER|Kinesio taping|therapeutic tape application
41295061|NCT06203678|OTHER|Exercise|Cervical stretching and strengthening exercises home program
41295062|NCT06203678|OTHER|Sham taping|patch tape application
41295063|NCT01864577|OTHER|Negative Pleural Suction at -20 cm H2O|
41457142|NCT02299869|DEVICE|Esmeralda (Competitor-control)|contact lens
41457143|NCT02299869|DEVICE|Jade (CVI-test)|contact lens
40766652|NCT05887401|BEHAVIORAL|Lesson Delivery (Weekly)|A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.
40766653|NCT04116489|OTHER|Forest walk|Participants will be provided with an educational program about the forest and take a guided forest walk.
40766654|NCT04116489|OTHER|Wildlife rehabilitation|Participants will be provided with education on wildlife rehabilitation and assist with wildlife care such as feeding baby animals.
40766655|NCT04116489|OTHER|Wildlife sanctuary observation|Participants will be provided an educational program on wildlife care and accompany park game keepers during animal feeding and will observe iconic wildlife.
40766656|NCT04116489|OTHER|Bird feeding and watching|Participants will learn about bird identification and safe bird feeding. Bird feeders will be provided at the Soldier On facility for home bird feeding after study conclusion.
40766657|NCT06644300|DRUG|BM230|SC injection
40965213|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
41137345|NCT05548049|DEVICE|Bone harvesting from ramus area with piezosurgery for autogenous bone augmentation|In this invervention, the piezo-surgical device settings were set to irrigation: '4', function: 'cortical', light: 'auto'. After the full-thickness flap was lifted with the periosteal elevator, superior and vertical osteotomies were performed with the OT-12 piezo-surgical tip. Lower horizontal osteotomies were performed using OT8-L or OT-8-R piezo tips according to the studied quadrant, combining the vertical osteotomy.
41295064|NCT01864577|OTHER|Water seal|
40766658|NCT06644300|DRUG|BM230|SC injection
40766659|NCT03329131|DEVICE|Cryotherapy|An Elasto gel™ frozen (4°C) glove and sock
40766660|NCT06198010|OTHER|Best Practice|Receive enhanced usual care
40766661|NCT06198010|OTHER|Educational Intervention|Receive ASCENT guide
40766662|NCT06198010|OTHER|Questionnaire Administration|Ancillary studies
41295065|NCT00693212|DRUG|methylphenidate|Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
41295066|NCT00693212|DRUG|methylphenidate|Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
41295067|NCT00693212|DRUG|placebo|Dosing is identical to the MPH arm except that the pills will contain no active medication.
41295068|NCT02154854|DRUG|Tacrolimus targeted half-dose|
41295069|NCT02154854|DRUG|Tacrolimus targeted plain dose|
41295070|NCT02385695|PROCEDURE|Posterior Dynamic Stabilization|
41295071|NCT02385695|PROCEDURE|Internal Fixation and Fusion|
41457144|NCT02299869|DEVICE|Azul (Competitor-control)|contact lens
41457145|NCT02299869|DEVICE|Blue (CVI-test)|contact lens
40766663|NCT06198010|OTHER|Electronic Health Record Review|Ancillary studies
40766664|NCT06198010|PROCEDURE|Health Telemonitoring|Attend video or phone calls with a CHW and/or PCM
40766665|NCT06198010|BEHAVIORAL|Cancer Pain Management|Receive personalized pain management plan
40766666|NCT05878704|DRUG|GBT021601|Oral
40766667|NCT05154734|DRUG|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
40766668|NCT06095050|DEVICE|Embolization|Superselective arterial embolization of hyperemic vasculature in the symptomatic shoulder (utilizing the IDE approved device: Lipiodol) followed by structured physical therapy sessions.
40766669|NCT06095050|OTHER|Physical Therapy|Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
40766670|NCT06137248|DIETARY_SUPPLEMENT|Energy drink|Participants on this arm will consume an energy drink once daily in addition to their normal diet for 4 weeks.
41295072|NCT04942483|DIAGNOSTIC_TEST|Blood eosinophil count|Peripheral blood eosinophil count will be measured from a finger prick blood sample, using the Haemocue machine, allowing a result in approximately 2 minutes. The test will allow to assess the presence or not of eosinophilia and if it can predict future wheezing exacerbations and response to inhaled corticosteroids (ICS).
41295073|NCT04942483|DIAGNOSTIC_TEST|Atopic sensitization|Skin prick tests will be performed to: (a) house dust mite, (b) grass pollen, (c) tree pollen, (d) cat hair, (e) dog hair, as well as normal saline and histamine which will act as negative and positive controls respectively. In addition, skin prick tests will allow the assessment of which aeroallergen is the most useful predictor of outcomes in preschool children.
41295074|NCT04942483|DIAGNOSTIC_TEST|FeNO (offline method)|The child will breathe normally into a sample bag that will be collected for later analysis of FeNO levels. The test will be performed twice.
41295075|NCT00300872|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
41295076|NCT00300872|DEVICE|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
41295077|NCT00273858|OTHER|There is no Intervention. The study is observational.|The study is observational and the prescription follows the SmPC of etanercept.
41295078|NCT00719732|DEVICE|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
41295079|NCT04997837|DRUG|PD-1 inhibitor|Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
40965214|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
40965215|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
41295080|NCT04997837|DRUG|Oxaliplatin|"CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off."
41295081|NCT04997837|DRUG|Capecitabine|CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
41295082|NCT04997837|DRUG|Tegafur-gimeracil-oteracil potassium|SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
41295083|NCT04997837|DRUG|5-FU|FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
41295084|NCT04997837|RADIATION|Radiotherapy|1.8 Gy/Fx, 45-50.4 Gy
41295085|NCT04997837|DRUG|Chemotherapy|Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
41295086|NCT00434460|BEHAVIORAL|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
41295087|NCT05892185|DEVICE|GELA|GELA glaucoma implant
41295088|NCT05892185|DEVICE|XEN|XEN gel stent implant
40766671|NCT06531018|DRUG|Eltrombopag 25 MG|Eltrombopag 25 mg daily and Prednisolone 1-2mg/kg, selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
40965216|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
40965217|NCT02973217|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|
41295089|NCT03393845|DRUG|Pembrolizumab|Pembrolizumab 200mg IV, 21 day cycles
41295090|NCT03393845|DRUG|Fulvestrant|Fulvestrant, 500mg IM, Loading dose: C1 D1 \& 15. Thereafter, Q4 wks
41457146|NCT02445846|DEVICE|dual HIV/syphilis rapid diagnostics tests|
41457147|NCT01643239|OTHER|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
40766672|NCT06531018|DRUG|Prednisolone|Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
40766673|NCT05053061|BEHAVIORAL|Application program for pulmonary rehabilitation|Exercise videos for pulmonary rehabilitation
40766674|NCT05694611|DIAGNOSTIC_TEST|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
41295091|NCT01969175|OTHER|Low-glycemic-load and milk-free diet|
41295092|NCT04883385|OTHER|medical data collection|collection of medical data from patients' medical records
41295093|NCT04722393|OTHER|Exercise|Exercise training
41295094|NCT00701740|DRUG|oral isotretinoin and Mexoryl SX / XL|20mg, 3/week,continuously for three months
41295095|NCT00701740|DRUG|Mexoryl XL / SX|11 subjects used only the same moisturizer and SPF 60 sunscreen
41295096|NCT02273323|OTHER|Tea|Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.
41295097|NCT02273323|OTHER|Placebo|Placebo: tea flavour, colouring and sugar
40766675|NCT05694611|DRUG|Sulfur Hexafluoride|To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
40766676|NCT05754996|DRUG|Nifuroxazide|Nifuroxazide dosing : 200 mg capsule four times daily
41295098|NCT04135261|DRUG|HBM4003|Intravenous (IV) administration
40766677|NCT05754996|DRUG|Lactulose|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools
40766678|NCT05754996|DRUG|Rifaximin 550Mg Tab|Rifaximin 550 MG twice daily
40766679|NCT04877041|BEHAVIORAL|Intradialytic Cycling|This intervention will consist of intradialytic cycling for 60 minutes 3 times per week for a total of 12 weeks.
40766680|NCT06096337|DEVICE|FARAPULSE™ Pulsed Field Ablation (PFA) System|Subjects will undergo a pulsed field ablation procedure using the FARAPULSE™ Pulsed Field Ablation (PFA) System for the isolation of pulmonary veins and posterior wall.
41457148|NCT01643239|OTHER|Hospital-based mCIT|the mCIT group with individualized intervention
40766681|NCT06096337|DRUG|Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone|Anti-Arrhythmic Drugs (AADs) including, Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone will be prescribed and monitored in accordance with local clinical practice and already established guideline-directed therapy for patients with persistent atrial fibrillation (AF).
40766682|NCT06639035|OTHER|External oblique intercostal plane block|The external oblique intercostal plane block is applied to the patients at the end of the surgery.
40766683|NCT06639035|OTHER|intavenous tramadol|Intravenous tramadol will be administered with patient-controlled analgesia
40766684|NCT06562946|DRUG|Pimicotinib|Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.
40965218|NCT05495490|PROCEDURE|Osseodensification Internal Sinus Lift|"The osteotomy for the Osseodensification internal sinus lift begins with the advancement of a twist drill at 800 rpm and saline irrigation to within 1-2 mm of the sinus floor. The osteotomy is then widened by employing a series of osteotomy drills rotating at 800 rpm. Infracture of the sinus has occurred when the final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation (haptic feedback) occurs. After infracture, the graft material will be injected into the osteotomy site. Using the final osteotomy drill, the graft is guided apically. This procedure is repeated incrementally to raise the membrane. Once sufficient space has been created beneath the antral membrane, the implant will be inserted followed by suturing."
40965219|NCT05495490|PROCEDURE|Osteotome Internal Sinus Lift|"The osteotomy for the Osteotome internal sinus lift will begin with standard drills and saline irrigation to prepare the implant socket with a working length that is 1-2 mm shorter than the residual bone height as determined by radiographic examination. After preparation, a series of osteotomes of varying diameters will be sequentially utilized to widen the osteotomy and elevate the Schneiderian membrane by vertical tapping to create a greenstick fracture. The Valsalva maneuver (nasal blowing test) will be performed to determine the integrity of the Schneiderian membrane. During the osteotomy, the graft material will be injected and slowly placed into the elevated space using osteotomes until the desired depth is reached. Implant placement and suturing will conclude the procedure."
40965220|NCT01696825|DRUG|Diazepam tablet, 5 mg, vaginal|Diazepam tablet, 5 mg, moistened and inserted vaginally
40965221|NCT01696825|DRUG|Diazepam Suppository, 5 mg, vaginal|Compounded diazepam 5 mg suppository administered vaginally
40965222|NCT01696825|DRUG|Diazepam Cream, 5 mg, Vaginal|Compounded diazepam cream, 5 mg, inserted vaginally
40965223|NCT02937883|OTHER|Empowerment intervention|Empowerment intervention for persons with young onset dementia
40965224|NCT00388960|DRUG|Amrubicin|"Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression."
41457149|NCT01643239|OTHER|Hospital-based TR|OT or PT or therapist-based training
41457150|NCT01193387|DRUG|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
41457151|NCT01193387|DRUG|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
40766685|NCT05977439|DEVICE|fMRI-EEG-TMS|Participants will undergo a magnetic resonance imaging (MRI) scan with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
40766686|NCT05977439|DEVICE|fNIRS-EEG-TMS|Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
41457152|NCT06278090|DRUG|Ursodeoxycholic Acid Only Product|Ursodeoxycholic acid treatment, 10-15mg/kg/day for at least 6 months
40766687|NCT05977439|DEVICE|fNIRS-EEG-rTMS Interleaved with CBT|Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and repetitive transcranial magnetic stimulation (rTMS). rTMS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. The accelerated paradigm will consist 6 session a day for 5-6 days. Each rTMS session will be separated by 30 minutes of Cognitive Behavioral Therapy (CBT). rTMS treatment will be delivered at an individualized left DLPFC target based on each participant's individualized scans from prior neuroimaging sessions.
41137346|NCT05548049|DEVICE|Bone harvesting from ramus area with conventional burs for autogenous bone augmentation|In control group, After the full-thickness flap is lifted with the periosteal elevator, using a thin #9 fissure burand the surgical handpiece S-11 Straight tip , the physiodispenser settings are according to the manufacturer's recommendations. The osteotomy was performed after it was adjusted to 40,000 rpm as appropriate. Bone incisions were completed with a round bur to combine the lower horizontal osteotomies and 2 vertical osteotomies. The osteotomies were completed with the help of a thin flat drill, and the block graft was carefully separated from the donor site.
41137347|NCT04693169|DRUG|11C-Choline|1、PSMA137 labeled with \[Al18F\] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the \[Al18F\]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
41137348|NCT04751097|OTHER|CUSH Health Digital platform|Remote mobility monitoring and physiotherapy video app
41137349|NCT02402270|DRUG|NuLYTELY® (PEG 3350)|
41137350|NCT02402270|DRUG|ECP-019|
41137351|NCT02402270|DRUG|MoviPrep® (PEG 3350)|
41137352|NCT00840775|DEVICE|Catheterization, stent deployment|Standard catheterization procedure including Bare Metal Stent deployment.
41137353|NCT04996407|DEVICE|survival thermal blanket|patients were given a thermal blanket
41137354|NCT04996407|DEVICE|draping fabric|Patients were given a draping fabric
41137355|NCT01064609|PROCEDURE|Biopsy by cryoprobes|Transbronchial lung biopsy with cryoprobes.
41137356|NCT01064609|PROCEDURE|Biopsy with conventional forceps|Transbronchial lung biopsy with conventional forceps.
41137357|NCT01260259|PROCEDURE|RIPC|RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.
41137358|NCT01260259|PROCEDURE|Control|In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
41137359|NCT01106885|BEHAVIORAL|Medication Care Management (MCM)|"* Basic physical activity counseling~* Notify PCP and facilitate initiation of antidepressants~* Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks\*~* 1/mo monitoring in continuation phase (mos. 4-12)\*~* Report \& recommendations to PCP after each patient call~* Note: \*average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)"
41137360|NCT01106885|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"* Notify PCP~* CBT Manual~* Weekly CBT focused counseling for 12 weeks\*\*~* Monthly CBT in months 4-12\*\*~* Behavioral physical activity counseling~* Report \& recommendations to PCP after each patient call~* Note: \*\*average of 50 minutes of telephone time each"
41137361|NCT05528809|OTHER|Blood sampling|A blood sampling will be performed during the inclusion visit (day 0).
41137362|NCT05160779|OTHER|Analysis of genetic polymorphisms of vasoactive peptides in COVID-19|Evaluate the frequency of the insertion/deletion (I/D) polymorphism in the ACE gene; to assess the frequency of polymorphism in the bradykinin B2 receptor gene; to assess the frequency of the polymorphism in the CK-M gene and compare the frequencies of these polymorphisms between patients with severe and mild conditions.
41137363|NCT00059384|BEHAVIORAL|Concentration-controlled therapy|
41295099|NCT00450203|BIOLOGICAL|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
41457153|NCT00245739|DRUG|TMC-114|600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
41457154|NCT00003751|DRUG|penicillamine|
41457155|NCT00003751|RADIATION|radiation therapy|
41457156|NCT02214706|DRUG|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
41457157|NCT02214706|OTHER|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
41457158|NCT02214706|DEVICE|Pulsed Dye Laser|
41457159|NCT03400774|OTHER|Stair-climbing|Short bouts of moderate intensity stair-climbing
40766688|NCT03982316|BEHAVIORAL|Telehealth Behavioral Migraine Management|1) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.
40766689|NCT02659241|DRUG|Adavosertib|Given PO
41137364|NCT05099562|DEVICE|Acupuncture|Patients received standardized acupuncture treatment. A blood sample of genomic DNA storage was taken from the back of the hand between the first and second metacarpals. Genotypes were obtained by oligonucleotide ligation/polymerase chain reaction and capillary electrophoresis of peripheral neuropathy-associated SNPs.
41457160|NCT02907125|BEHAVIORAL|SEHER Intervention delivered by TSM|"SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
41457161|NCT02907125|BEHAVIORAL|SEHER Intervention delivered by SM|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
41137365|NCT04864834|BIOLOGICAL|SOK583A1 (40 mg/mL)|IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
41137366|NCT04864834|BIOLOGICAL|Eylea EU (40 mg/mL)|IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
41137367|NCT04738149|DRUG|Bimatoprost|Participants will be receiving 2 drops per 4cm2 twice a week for 12 weeks
40766690|NCT02659241|OTHER|Laboratory Biomarker Analysis|Correlative studies
40766691|NCT06055751|DEVICE|TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473)|No intervention will be done as part of this prospective registry. Implantation of Boston Scientific Loop Recorder (LUX-Dx) will be performed regardless of this research and outside this research protocol per standard of care
40766692|NCT04961996|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
41137368|NCT04738149|DEVICE|Excimer laser|Participants will be receiving excimer laser 2x a week for 12 weeks
41137369|NCT04738149|DEVICE|Microneedling with a dermaroller|Participants will have 4cm2 area pre-treated with dermaroller 2x per week for 12 weeks
41137370|NCT01683409|DRUG|Baricitinib|Administered orally
41137371|NCT01683409|DRUG|Placebo|Administered orally
41137372|NCT04817293|OTHER|Questionnaire|Questionnaire SSD-12 and EQ5D5L
41137373|NCT04817293|OTHER|medical consultation|Medical consultation during the visit with data collection
41137374|NCT03271359|BEHAVIORAL|EMDR|Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
41137375|NCT03271359|BEHAVIORAL|PC|Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
41137376|NCT01588522|DRUG|compound 31543 Calcitriol|topical compound 31543 will be applied to the scalp twice daily 7 +/- 2 days prior to the dose of chemotherapy and continue the application twice daily for 3 months or until termination of chemotherapy treatment.
41137377|NCT05243459|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention away from threat face stimuli.
41137378|NCT05243459|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
41137379|NCT05243459|BEHAVIORAL|Non-Contingent Feedback Training|Participants listen to a musical track they chose while viewing the face matrices. The music is played throughout and is not contingent upon gaze behavior.
41137380|NCT06149299|PROCEDURE|Greater occipital nerve block|Greater occipital nerve block using ultrasound guidance
41137381|NCT06510413|DRUG|Loxoprofen Sodium Patches(reference product)|Single dose of one patch in each period; Apply for 24 hours each time
41137382|NCT06510413|DRUG|Loxoprofen Sodium Patches(test product )|Single dose of one patch in each period; Apply for 24 hours each time
40766693|NCT04961996|DRUG|Endocrine Therapy of Physician's Choice|The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.
41295100|NCT00450203|DRUG|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
41457162|NCT02907125|BEHAVIORAL|Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
41457163|NCT01451541|DRUG|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
40766694|NCT04961996|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
40766695|NCT04961996|DRUG|Abemaciclib|Abemaciclib 150 mg will be administered orally (PO) twice a day (BID) on Days 1-28 during each 28-day cycle for 2 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
41457164|NCT01451541|DRUG|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
41457165|NCT01451541|DRUG|Placebo|Placebo - one dose per nostril
41457166|NCT04482816|DEVICE|Physiological pacing|Pacing of the his bundle or the left bundle branch
40965225|NCT00388960|DRUG|Cisplatin|"Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression."
40965226|NCT00388960|DRUG|Etoposide|Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
40965227|NCT00726986|DRUG|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
40965228|NCT00726986|DRUG|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
40965229|NCT00726986|DRUG|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
40965230|NCT02702154|DEVICE|High-frequency rTMS|20 Hz active stimulation, twice daily
40766700|NCT00720785|DRUG|Bortezomib|Parenteral formulation. It is supplied as a 3.5 mg single use vial containing a sterile lyophilized powder that requires reconstitution.
40766701|NCT00720785|BIOLOGICAL|NK cells|NK Cell Infusion
40965231|NCT02702154|DEVICE|Low-frequency rTMS|1 Hz active stimulation, twice daily
40965232|NCT02702154|DEVICE|Sham rTMS|Sham stimulation, twice daily
40965233|NCT01061177|DRUG|Nilotinib|Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
40965234|NCT00158834|DRUG|Salmeterol/Fluticasone propionate combination product|
40965235|NCT00158834|DRUG|Fluticasone propionate|
40965236|NCT00804674|DRUG|bupivacain|
41295101|NCT00450203|DRUG|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
41295102|NCT00450203|DRUG|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
41295103|NCT00450203|PROCEDURE|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
41295104|NCT00450203|PROCEDURE|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
41457167|NCT04482816|DEVICE|Right ventricular pacing|Conventional pacing; right ventricular pacing
40965237|NCT00804674|DRUG|placebo|
40965238|NCT06060782|DRUG|Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen|"All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days"
40965239|NCT03442205|PROCEDURE|LC + LCBDE + ENBD + primary closure of CBD|LC + LCBDE + ENBD + primary closure of CBD
40965240|NCT03442205|PROCEDURE|ERCP technique + LC|ERCP technique + LC
41295105|NCT00450203|PROCEDURE|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
41295106|NCT00450203|DRUG|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
41295107|NCT06401655|BEHAVIORAL|Financial Coaching for People living with Acquired Brain Injury (FC-ABI)|This is an individualized, in-person 10-session financial coaching intervention program. Each session is 45-minutes. In total, participants will be asked to participate in up to 7 hours and 30 minutes of intervention time with a trained Occupational Therapist. Each session will happen 1-1.5 weeks apart and the financial coaching program will last over 3-4 months. The financial coaching sessions will only be offered in-person (at MBIA Winnipeg location, in their home, at the University of Manitoba/Banntyne Campus, or other community locations acceptable/consented by the participant).
41295108|NCT05420467|DRUG|Docetaxel|75 mg/m2, d1, q3w,6 cycles
41295109|NCT05420467|DRUG|Carboplatin|AUC 6, d1, q3w,6 cycles
41295110|NCT05420467|DRUG|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
41295111|NCT05420467|DRUG|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
41295112|NCT05420467|DRUG|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
40766702|NCT06639789|DIETARY_SUPPLEMENT|Vitamin B12 (B12)|The new formulation of vitamin B12 will be ingested 3 days before and on the day of testing (3 hours before).
40766703|NCT06639789|DIETARY_SUPPLEMENT|PLACEBO (PLA)|The placebo will be ingested 3 days before and the same day of the tests (3 hours before).
40766704|NCT04983030|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
41295113|NCT05420467|DRUG|Epirubicin|90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
41295114|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
41295115|NCT05420467|DRUG|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
40766705|NCT04983030|BIOLOGICAL|MVA-BN-HIV|MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
40766706|NCT04983030|BIOLOGICAL|PGT121|PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
40766707|NCT04983030|BIOLOGICAL|PGDM1400|PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
40766708|NCT04983030|BIOLOGICAL|VRC07-523LS|VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
40766709|NCT06644053|BEHAVIORAL|Quantified analysis of walking during a crossing task through different horizontal openings|Functional test that reproduce a task of daily living
40766710|NCT06533735|BEHAVIORAL|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
40766711|NCT06090799|DRUG|SHR-3032|Single dose at varying dosage levels depending on treatment assignment
40766712|NCT06090799|DRUG|SHR-3032 Placebo|Single dose at varying dosage levels depending on treatment assignment
40965241|NCT03442205|PROCEDURE|LC + LCBDE + primary closure of CBD|LC + LCBDE + primary closure of CBD
40965242|NCT02658903|DEVICE|Oxys Catheter|The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.
41295116|NCT05420467|DRUG|Epirubicin|90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
41295117|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
41295118|NCT05420467|DRUG|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
41295119|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w × 6 cycles
40766713|NCT06643520|DEVICE|19-gauge|"All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 19 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations."
40965243|NCT02658903|DEVICE|Covidien Mona-Therm Foley catheter|The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
40965244|NCT03663998|BIOLOGICAL|CN54ENV DNA|"CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s)."
41137383|NCT01124552|DRUG|RT001 Botulinum toxin type A (Dose A)|RT001 Botulinum Toxin Type A (Dose A)
41137384|NCT01124552|DRUG|RT001 Botulinum Toxin Type A (Dose B)|RT001 Botulinum Toxin Type A (Dose B)
41137385|NCT01124552|OTHER|Vehicle|Vehicle Control
41295120|NCT05493956|RADIATION|chemoradiation|Radiation dose of 54 Gy will be given alongwith concurrent capecitabine
41137386|NCT01124552|DRUG|Placebo|Placebo Comparator
41137387|NCT02104349|BEHAVIORAL|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
41137388|NCT06088576|OTHER|Together|"Tchat : limited to 20-30 minutes per day. With a member of the team Together. For teleconsultations : First teleconsultation, during the first month (1 to 4 sessions/month), are made by nurse and/or educator. After that, it is psychologists who do the teleconsultations (2 to 4 sessions/month). It's during 30 to 45 minutes.~Home visits, individual or group interviews on site are possible after 4 month."
41295121|NCT06499090|DRUG|Mirtazapine 30 MG|patients will receive orally the night before surgery the study medication and daily up to two weeks after Mirtazapine 30 mg tablet
41295122|NCT06499090|DRUG|Placebo|patients will receive orally the night before surgery the study medication and daily up to two weeks after placebo tablet
41295123|NCT06314906|DEVICE|Electroacupuncture|Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz
41295124|NCT06314906|DRUG|Antiemetic Therapy|Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.
41295125|NCT06314906|DEVICE|Sham electroacupuncture|Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group
41457168|NCT01715649|BEHAVIORAL|Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose|In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
40766714|NCT06643520|DEVICE|22-gauge|"All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely.~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 22 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations."
40766715|NCT06637098|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
40766716|NCT06637098|BEHAVIORAL|Oral tube feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
40965245|NCT03663998|BIOLOGICAL|GENEVAX® IL-12 DNA|"GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration."
40965246|NCT06265012|BIOLOGICAL|PHV01|Marburg virus vaccine
40965247|NCT06265012|BIOLOGICAL|Placebo|Lactated Ringer's Solution
40965248|NCT04546061|BEHAVIORAL|Project Uplift|Substance use and mental health treatment for young sexual and gender minorities in Durham and Charlotte, NC in conjunction with intensive wraparound services that address factors that influence substance use and mental health among this population.
40965249|NCT02094677|DEVICE|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
40965250|NCT02094677|DEVICE|etafilcon A|Participants were randomized to wear etafilcon A control lens.
40965251|NCT02094677|DEVICE|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
40965252|NCT05802511|DEVICE|Exablate treatment|Exablate treatment for Neuropathic Pain
40965253|NCT02301000|BIOLOGICAL|Intestinal microbiota therapy|60 ml of ACHIM suspension will be administered through a rectal tube
40965254|NCT02301000|DRUG|Metronidazole|Peroral metronidazole 400 mg t.i.d. for ten days
40965255|NCT06556407|DEVICE|renal denervation|ultrasound based renal denervation
40965256|NCT06373796|DEVICE|Echographic scan|Liver ultrasound exam
40965257|NCT06237998|DEVICE|Telemedicine|Patients receive equipment for report of vital signs and patient reported experience measures (PREMS), automatically transmitted via smartphone/bluetooth for six months (possible extension to 12 months in case of instability). A digital smartphone application is used for registration and transmission of data, including modes for asynchronous (chat) communication with the healthcare provider. Planned titration to OMT or diuretic adjustments may be done remotely depending on clinical assessment. The digital sensors include an electronic scale, pulse and blood pressure monitor for daily measurements by the patient.
40965258|NCT05299710|PROCEDURE|Laparoscopic surgery|Surgery used to remove your child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into your child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of your child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
41295126|NCT06314906|DRUG|Antiemetic Therapy|They will also receive the same antiemetic medications as the experimental group.
41295127|NCT00999128|DRUG|GDC-0941|Oral repeating dose
41457169|NCT06227520|OTHER|decellularized dermal matrix|Application of Wound bed
41457170|NCT04199416|DEVICE|mRehab app|The mRehab app will be an interactive system with a user-friendly graphical user interface to provide multiple motivational functions that engage individuals in their prescribed home exercises. The app will contain video-based lower limb strengthening and aerobic exercise materials, health information, and motivational functions to increase their access to rehabilitation and care resources to augment their self-management ability.
41295128|NCT00999128|DRUG|rabeprazole|Oral repeating dose
41295129|NCT06512857|OTHER|Hand puppet method|Children in the experimental group were shown a hand puppet to distract them during the skin test for allergy.
41295130|NCT06512857|OTHER|Kaleidoscope method|Children in the other experimental group were look at kaleidoscope to distract them during the skin test for allergy.
40766717|NCT06637098|BEHAVIORAL|Gastrostomy feeding|Feeding begins through the gastrostomy tube. A registered dietitian will develop a tailored feeding plan, specifying the type and amount of nutrition. Healthcare providers regularly monitor the patient's tolerance to feeding, checking for any signs of complications. Adjustments to the feeding regimen may be made based on the patient's progress and nutritional needs.
40766718|NCT06464510|DRUG|Early Vasopressin|Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.
40766719|NCT06464510|DRUG|Norepinephrine and Vasopressin for Rescue|Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.
40766720|NCT06493084|DRUG|LAE102 injection|intravenous drip or subcutaneous injection
40766721|NCT06493084|OTHER|Saline|intravenous drip or subcutaneous injection
40766722|NCT05454891|DRUG|Extended bolus of insulin then standard bolus of insulin|For a standardized HFHP breakfast, participants will receive an extended meal bolus of insulin on the first morning and a standard meal bolus of insulin on the second morning of the study.
40766723|NCT05454891|DRUG|Standard bolus of insulin then extended bolus of insulin|For a standardized HFHP breakfast, participants will receive a standard bolus of insulin on the first morning and an extended bolus of insulin on the second morning of the study.
40766724|NCT06045754|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
40766725|NCT06045754|DRUG|Adalimumab|Adalimumab subcutaneous injection.
41295131|NCT06115421|DRUG|Roxadustat|hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs)
41457171|NCT04199416|DEVICE|Sham app|The sham app will only contain educational components and text-based exercise recommendations.
40766726|NCT06045754|DRUG|Ustekinumab|Ustekinumab intravenous infusion.
40766727|NCT06045754|DRUG|Ustekinumab|Ustekinumab subcutaneous injection.
41295132|NCT02416687|DEVICE|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
41295133|NCT06284928|OTHER|Gut Microbiota Analysis|This refers to the procedure of collecting fecal samples from both the hypertension group and the control group, followed by analyzing these samples to assess and compare the gut microbiota composition using methods like gene sequencing.
40766730|NCT06645301|BIOLOGICAL|Group A|BGT007 3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
40766731|NCT06645301|BIOLOGICAL|Group B|BGT007 6.0×10\^8cells,Intravenous infusion，6 subject is planned to be enrolled
40766732|NCT06645119|DIETARY_SUPPLEMENT|Whey Protein Supplement|Examining the independent effect of post-exercise dietary protein ingestion on bone metabolic markers.
40766733|NCT05521269|DRUG|ANX1502|ANX1502 is a prodrug of ANX1439.
40766734|NCT05521269|DRUG|Placebo|Placebo comparator.
40766735|NCT06580275|DEVICE|CLAAS|All eligible subjects will have an LAA closure attempt using the CLAAS device guided by ICE technology.
41295134|NCT00739778|OTHER|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
41295135|NCT00739778|OTHER|food vehicle blank|water blank
41295136|NCT00739778|OTHER|food - sweetener, positive control|4.7% sucrose in water
41295137|NCT00739778|OTHER|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
41295138|NCT02349906|DRUG|Treosulfan|
41295139|NCT02349906|DRUG|Busilvex|
41457172|NCT00353535|PROCEDURE|Total Lymphoid irradiation|
41295140|NCT00352781|DRUG|nicotine replacement therapy|nicotine transdermal patches as per product monograph
41295141|NCT00352781|BEHAVIORAL|behavioural intervention|Smoking cessation counselling and relapse prevention
41295142|NCT04878640|PROCEDURE|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
41295143|NCT04878640|PROCEDURE|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
41295144|NCT04008862|BEHAVIORAL|Partnership-based nursing practice|Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare -primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
41295145|NCT05836012|BIOLOGICAL|HIL-214|2 injections - given at 4 months and the second at 6 months of age.
41295146|NCT05836012|BIOLOGICAL|Placebo|2 injections - given at 4 months and the second at 6 months of age.
41295147|NCT04128592|DEVICE|diagnosing noisy breathing in infants and toddlers|breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
40766736|NCT04543591|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
40766737|NCT04543591|OTHER|Placebo|Matching placebo
40766738|NCT04543591|OTHER|Best supportive care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
40766739|NCT02955082|DRUG|Carboplatin|Intravenous carboplatin infusion every 3 weeks.
40766740|NCT05845671|DRUG|Amivantamab 1050mg|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."
40766741|NCT05845671|DRUG|Amivantamab 1400mg|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."
40766742|NCT05845671|DRUG|Amivantamab (to be determined)|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In"
41295148|NCT05615701|DIAGNOSTIC_TEST|EOSedge imaging|Hip X-ray evaluation in an EOSedge imaging for preoperative assessment for hip replacement or revision surgery
41295149|NCT05186181|BEHAVIORAL|In situ fenestration|Interventional therapy of aortic dissection. In situ needle fenestration of left subclavian artery.
41295150|NCT00156546|DRUG|antibiotic to reduce the recurrence of infection|
41295151|NCT01095250|DRUG|AIN457|
41295152|NCT01095250|DRUG|AIN457|
41295153|NCT01095250|DRUG|AIN457|
41137389|NCT06363604|PROCEDURE|VOMEI + PVI + linear ablation of mitral isthmus|The CS angiography is firstly performed to visualize the vein of Marshall. The ethanol infusion by anhydrous alcohol is then performed by using a guidewire and an OTW ballon. For radiofrequency catheter ablation, the standard procedure of pulmonary vein isolation is performed. All the enrolled persistent AF patients perform the routine linear ablation of mitral isthmus.
41137390|NCT06363604|PROCEDURE|Posterior wall isolation|PWI is additionally performed for experimental group with linear ablation of LA roof and bottom line, and verified by mapping with a multielectrode catheter.
41295154|NCT01095250|DRUG|Placebo|
41295155|NCT05952167|OTHER|Intensive cervical traction protocol|2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
41295156|NCT05952167|OTHER|Intensive cervical traction protocol - placebo|2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
41295157|NCT02022423|BEHAVIORAL|Telephone counseling|4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
41295158|NCT02022423|BEHAVIORAL|Internet-based walking program|Four-month Internet-based walking program consisting of weekly step count goals
41295159|NCT02461485|OTHER|Fermented milk product containing Probiotics|2 pots/day during 28 days
41295160|NCT02461485|OTHER|Fermented Milk Product containing Probiotics + Fibers C|2 pots/day during 28 days
41457173|NCT06335927|DRUG|HAIC-GEMOX+Cadonilimab+Regorafenib|HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)
41457174|NCT04130685|DIAGNOSTIC_TEST|Allosure Test|Venous Blood Draw
40766743|NCT05845671|DRUG|Amivantamab (to be determined)|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In"
40766744|NCT06639256|DRUG|Test Product HY07121|HY07121 should be administered intravenously at recommended dose.
40766745|NCT05681481|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
40965259|NCT05081973|OTHER|A model for predicting extubation success based on extubation readiness estimator and lung ultrasonography score|"Parameters to be recorded before and after extubation to create a new dual extubation model from all babies who met the extubation criteria included in the study:~1. Lung ultrasound score: Lung ultrasound will be performed prior to the extubation and after the extubation. Lung aeration will be scored based on three chest areas for each side (upper anterior, lower anterior and lateral) and a score of 0 to 3 points will be given for each area (Total score ranges from 0 to 18 points).~2. Probability of Successful Extubation: It will be calculated by extubation readiness estimator provided by the website named http://extubation.net/.~This parameter will be calculated only 1 hour prior to the scheduled extubation time."
40766746|NCT05681481|DRUG|Prednisone|Oral Prednisone
40766747|NCT05811832|OTHER|Evaluation|Modified Medical research Council , Saint George Respiratory Two Minute Walk Test,Frail fragility scale ,Prisma-7 Vulnerability scale,Pase,Berg balance scale,manual muscle test,quadriceps muscle strength, hand dynamometer,Fatigue Severity Scale
41137391|NCT00653185|DRUG|SYR-472|SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
41295161|NCT02461485|OTHER|Fermented Milk Product containing Probiotics + Fibers W|2 pots/day during 28 days
41137392|NCT00653185|DRUG|SYR-472|SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
41295162|NCT02461485|OTHER|Non fermented Milk Product|2 pots/day during 28 days
41295163|NCT00065975|PROCEDURE|massage therapy|
41295164|NCT00065975|PROCEDURE|chiropractic|
41295165|NCT00065975|PROCEDURE|acupuncture|
41295166|NCT02375698|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c).
40766748|NCT06418308|DRUG|Dexmedetomidine|5 mcg of dexmedetomidine
40766749|NCT06418308|DRUG|Epinephrine|200 mcg of epinephrine
40766750|NCT06418308|DRUG|Standardized Spinal Mixture|Standardized spinal mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.
40766751|NCT02784210|DRUG|Methylprednisolone|3 days of corticosteroids (intravenous methylprednisolone at 1000 mg/day
41137393|NCT00653185|DRUG|SYR-472|SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
41137394|NCT00653185|DRUG|SYR-472|SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
41137395|NCT00653185|DRUG|Placebo|SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
41137396|NCT06094192|DEVICE|High definition transcranial electrical current stimulation|Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
41295167|NCT02375698|BIOLOGICAL|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
41295168|NCT03509753|DIETARY_SUPPLEMENT|High Fiber|See intervention description.
40766752|NCT02784210|DRUG|Prednisone|3 days of corticosteroids (oral prednisone at 1250 mg/day
41137397|NCT02677766|OTHER|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
41295169|NCT03509753|DIETARY_SUPPLEMENT|Low Fiber|See intervention description.
41295170|NCT04303585|PROCEDURE|SAP block|The anesthesiologist performs SAP block immediately before surgery under ultrasound guide
41295171|NCT04303585|PROCEDURE|ESP block|The anesthesiologist performs ESP block immediately before surgery under ultrasound guide
41295172|NCT03306069|OTHER|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
40965260|NCT03833245|BEHAVIORAL|Patient Navigation|The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
40965261|NCT04556162|DIAGNOSTIC_TEST|fractional sodium excretion|fractional sodium excretion will be compared to urinary sodium/creatinin, sodium/potassium ratio's and sodium concentration.
40965262|NCT04556162|OTHER|risk subgroups|subgroup analysis will be performed to identify the patient groups at risk for sodium depletion
40965263|NCT06110780|OTHER|acupuncture|"The insertion of the needles will be applied to a depth of 1-2 cm according to the thickness of the local tissues according to the standards of Traditional Chinese Medicine. The EA parameter will be set to a frequency of 2 HZ/100 HZ at a current that the patients' tolerance is best between 0.5 mA and 1.2 mA.~The patient will be electrically stimulated for 30 minutes until the patient feels Teh Chi - heaviness, numbness and swelling."
40965264|NCT03599999|DRUG|Adverse events detection|type of adverse events detected during treatment with Temocillin and imputed to Temocillin
40965265|NCT03500952|OTHER|Birth Control After Pregnancy|A 27-page patient decision aid in portable document format (and an accompanying 3-page supporting document in portable document format) hosted online.
40965266|NCT03500952|OTHER|Postpartum Birth Control|A 4-page patient information leaflet in portable document format and text format hosted online.
41137398|NCT02677766|OTHER|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
40965267|NCT03544658|PROCEDURE|Dental prophylaxis|Professional dental prophylaxis including dental scaling and dental polishing with prophylactic paste
41137399|NCT05654285|OTHER|Cola beverage with aspartame and acesulfame K|"Before starting the study: Subjects were asked to avoid non-nutritive sweetener consumption for 48 hours prior to the study sessions. A standardized menu of 346 Kcal was prescribed for dinner and fasting for at least 8 hours prior to each study session. A 7-day washout period was left between each study session.~Session 1: Weight, height, and waist circumference were measured, the BMI was calculated, and sociodemographic data of the participants and information on the habitual consumption of soft drinks were collected.~In each session: The beverages were offered at approximately 4°C, in standardized disposable cups, and the participants were asked to drink them in a maximum time of 10 minutes. Heart rate, respiratory rate, and blood pressure were measured before the intervention and every 30 minutes during the observation period. The subjects who manifested adverse sensations were referred to receive medical attention and withdrawn from the session."
41137400|NCT05654285|OTHER|Cola beverage with sucrose and stevia|
41137401|NCT00620854|DRUG|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
41295173|NCT03306069|OTHER|HIIT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT).~HIIT:~* 2 sessions per week~* 5x1 min at 80-95% HRmax~* time-effort per week: \~30 min"
41457175|NCT03161236|OTHER|home exercise program|Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
41137402|NCT00620854|DRUG|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
41137403|NCT00620854|DRUG|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
41137404|NCT00620854|DRUG|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
41137405|NCT01443572|DRUG|desflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
41137406|NCT01443572|DRUG|sevoflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
41295174|NCT03306069|OTHER|MIIT-HR|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR).~MIIT-HR:~* 2 sessions per week~* 5x1 min at 65-79% HRmax~* time-effort per week: \~30 min"
41457176|NCT03161236|OTHER|non exercise program|continue usual lifestyle
40766753|NCT05749094|DIAGNOSTIC_TEST|Optic nerve sheath ultrasound|The patients are examined in a supine relaxed position. The probe is gently placed on the closed eyelid with a standard ultrasound gel and adjusted to a suitable angle to display the optic nerve entry into the eyeball. Measurements are done 3mm distal to the posterior aspect of the ocular globe. Ultrasosonographic 14L5 probe is used with a safe thermal index, mechanical index and intensity limit. All patients will also undergo a bedside fundoscopic examination. Official ophthalmology consultation will be requested in patients with visual symptoms or abnormal fundoscopy.
40766754|NCT05749094|DIAGNOSTIC_TEST|Standardized GCA assessment|Clinical assesment, blood test review, temporal/axillary artery ultrasound
41457177|NCT03386461|BEHAVIORAL|Exercise training|Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.
41457178|NCT03386461|DIETARY_SUPPLEMENT|omega 3 supplementation|Capsules with high content of omega 3 fatty acids (Calanus oil) will be taken every day with lunch meal. The content of omega-3 fatty acids (EPA, DHA) per day should reach 250 mg.
40766755|NCT05794906|DRUG|Darolutamide (BAY1841788, Nubeqa)|Coated tablet, 300 mg / tablet, oral.
40766756|NCT05794906|OTHER|Placebo matching darolutamide|Coated tablet, oral
40766757|NCT05794906|OTHER|ADT|Luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonists
40766758|NCT03533582|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40766759|NCT03533582|DRUG|Carboplatin|Given IV
40965268|NCT03544658|PROCEDURE|Tooth color assessment by the participant|Tooth color assessment using the VITA Classical shade guide. Assessment will be done with normal light conditions and with a light correcting device
40965269|NCT03544658|PROCEDURE|Tooth color assessment by the investigator|Tooth color assessment using the VITA Classical shade guide and the VITA Toothguide 3D Master. Assessment will be done with normal light conditions and with a light correcting device
40965270|NCT03544658|PROCEDURE|Tooth color assessment with SpectroShade|Tooth color assessment using SpectroShade (dental spectrophotometer). Color will be registered in VITA Classical and VITA Toothguide 3D Master and CIELab parameters
41137407|NCT03123224|BEHAVIORAL|Combined Aerobic and Resistance Exercise + Caregiver Skills Training|The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
41295175|NCT03306069|OTHER|MIIT-LT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT).~MIIT-LT:~* 2 sessions per week~* session 1: 2x4 min / session 2: 5x1 min, each at 105% LT~* time-effort per week: \~30 min"
41457179|NCT03386461|DIETARY_SUPPLEMENT|placebo|Capsules with content of omega 6 fatty acids (sunflower oil) will be taken every day with lunch meal.
40766760|NCT03533582|DRUG|Cisplatin|Given IV
40766761|NCT03533582|DRUG|Doxorubicin|Given IV
40766762|NCT03533582|DRUG|Etoposide|Given IV
40766763|NCT03533582|DRUG|Fluorouracil|Given IV
40766764|NCT03533582|DRUG|Gemcitabine|Given IV
40766765|NCT03533582|DRUG|Irinotecan|Given IV
40766766|NCT03533582|DRUG|Oxaliplatin|Given IV
40766767|NCT03533582|OTHER|Patient Observation|Undergo watchful waiting
40766768|NCT03533582|PROCEDURE|Resection|Undergo surgical resection
40766769|NCT03533582|DRUG|Sorafenib|Given PO
40766770|NCT03533582|DRUG|Vincristine Sulfate|Given IV
40965271|NCT00707720|DEVICE|TERIS procedure|The implantation of the restrictive implant
40965272|NCT03228927|OTHER|comparison of twin A to twin B|Comparison of Twin A to Twin B
40965273|NCT03196102|BEHAVIORAL|BTI|Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
41457180|NCT01927991|BEHAVIORAL|iCBT (internet-based, cognitive-behavioural therapy)|The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
41457181|NCT04385043|OTHER|plasma hyperimmune|patients will receive this as add on therapy
41457182|NCT04385043|DRUG|standard therapy|patients will receive only standard therapy for Covid-19 infection
41457183|NCT05391594|DEVICE|customized posture support|We will provide customized modifications for seated or standing or walking devices based on the child's segmental level of control
41457184|NCT01394133|DRUG|Tenofovir, Emtricitabine, Atazanavir, Ritonavir|Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
41137408|NCT03123224|BEHAVIORAL|Stretching Balance and Flexibility + Caregiver Skills Training|The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
41457185|NCT02311894|DRUG|Somatropin|Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus \[+\]/minus \[-\]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
41457186|NCT00529191|DRUG|Atorvastatin|Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
41457187|NCT00529191|OTHER|Placebo|One out of three subjects will receive a placebo.
41137409|NCT00555932|PROCEDURE|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
41457188|NCT00766493|DEVICE|GORE® Embolic Filter|Embolic protection during carotid stenting
41457189|NCT02707276|DEVICE|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
41137410|NCT04665583|OTHER|Prehabilitation|Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.
41137411|NCT06210152|DEVICE|Radial Extracorporeal Shockwave Therapy|Radial Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. Each session involved the delivery of 1000 pulses at a frequency of 10Hz and an air pressure setting of 1.0 bar.
41295176|NCT02637791|DEVICE|Virtual glove|The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
41457190|NCT02707276|DEVICE|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.
41457191|NCT05856058|DRUG|SHR0302|SHR0302 oral solution 1 time, SHR0302 tablets 1 time
41457192|NCT04203823|DEVICE|Cloud-based Digital Twin and Meal Prediction algorithms|Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms
41457193|NCT04333134|DRUG|SHR3162|Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
41457194|NCT02027337|DRUG|20 mcg ethinylestradiol /3 mg drospirenone|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
40766773|NCT04199026|DRUG|Doxorubicin|Given via microdevice
40766774|NCT04199026|DRUG|Doxorubicin Hydrochloride|Given via microdevice
40766775|NCT04199026|DEVICE|Drug Delivery Microdevice|Undergo percutaneous implantation of drug delivery microdevice
40766776|NCT04199026|DRUG|Everolimus|Given via microdevice
40766777|NCT04199026|BIOLOGICAL|Ganitumab|Given via microdevice
40766778|NCT04199026|DRUG|Ifosfamide|Given via microdevice
40766779|NCT04199026|DRUG|Irinotecan|Given via microdevice
40766780|NCT04199026|DRUG|Pazopanib|Given via microdevice
40766781|NCT04199026|DRUG|Polyethylene Glycol|Given via microdevice
40766782|NCT04199026|DRUG|Temozolomide|Given via microdevice
41137412|NCT06210152|DEVICE|Sham Extracorporeal Shockwave Therapy|Sham Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. In each session, the device was held against the achilles tendon without being powered on.
41137413|NCT06230588|DRUG|TQH3906 capsule|TQH3906 is a kinase inhibitor.
41137414|NCT06230588|DRUG|TQH3906 placebo|Placebo Comparator
41137415|NCT01776320|DRUG|Alprostadil|One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
41137416|NCT05044416|DEVICE|VieScope|intubation with VieScope laryngoscope
41137417|NCT05044416|DEVICE|Videolaryngoscopy|intubation with videolaryngoscope
41137418|NCT04475406|OTHER|PICF (Periopaper)|After the plaques and soft attachments around the implants were removed, the implants were isolated using cotton rolls and dried with an air spray. The PICF was collected from the mesio-buccal region of the implant using periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.
41137419|NCT04475406|OTHER|Subgingival plaque, Gracey curette (Hu-Friedy)|After collecting the PICF, the supragingival plaque was carefully removed using a sterile scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal region of the implant using a sterile plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C until the analysis day.
41137420|NCT04475406|OTHER|Clinical data, williams probe PCPNU (Hu-Friedy)|"A single calibrated examiner performed all (full-mouth and site-specific) clinical measurements (B.K.), including probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL).~The values of PD and BOP were measured from four sites of each implant (mesial, distal, buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal probe. The PD was recorded as the distance from the base of the peri-implant to the side of the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of all patients were taken, and differences in the marginal bone level between radiography images after implant placement and 3 years later were evaluated. Original films and images taken later were taken with the same angle for standardizaton."
41137421|NCT03576092|DIAGNOSTIC_TEST|Lung Ultrasound|Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
41137422|NCT03192501|DRUG|inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.|Choose appropriate targeted drugs according to NGS/IHC results.
41137423|NCT04886284|DRUG|Ertapenem|Adjunctive ertapenem
41137424|NCT04886284|DRUG|Placebo|Saline placebo
41137425|NCT00524069|BIOLOGICAL|bevacizumab|
41137426|NCT00524069|DRUG|capecitabine|
41137427|NCT00524069|DRUG|gemcitabine hydrochloride|
41137428|NCT00524069|OTHER|flow cytometry|
41137429|NCT00524069|OTHER|laboratory biomarker analysis|
41137430|NCT00524069|PROCEDURE|adjuvant therapy|
41137431|NCT00524069|PROCEDURE|computed tomography|
41137432|NCT00524069|PROCEDURE|neoadjuvant therapy|
41137433|NCT02535221|DRUG|Goserelin+TAM+AI|Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
41137434|NCT02535221|DRUG|Epirubicin+CTX+5-Fu|Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
41137435|NCT05582226|PROCEDURE|ACL reconstruction|"Orthopedic surgical operation in which a ruptured anterior cruciate ligament is repaired and reattached to the muscle connection points with a graft, a fashioned ligament that is meant to serve as a replacement for the ruptured muscle tissue."
40766783|NCT04199026|DRUG|Temsirolimus|Given via microdevice
40766784|NCT04199026|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
40766785|NCT04199026|DRUG|Vincristine|Given via microdevice
41137436|NCT05582226|PROCEDURE|Mesenchymal stem cell implantation|Stem cells are to be extracted from tissue at the stump of the ACL attachment point and inserted on the graft in the hopes of improving healing response
41137437|NCT05757674|OTHER|Sample examination|No intervention will be performed
41137438|NCT01483885|DEVICE|Transcutaneous Electric Nerve Stimulation|Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
41137439|NCT01483885|DEVICE|Interferential Current|Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
41137440|NCT01483885|PROCEDURE|Manual Acupuncture|Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
41295177|NCT01582282|DIETARY_SUPPLEMENT|placebo|fiber-free placebo
41295178|NCT01582282|DIETARY_SUPPLEMENT|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
41295179|NCT01582282|DIETARY_SUPPLEMENT|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
41295180|NCT05578651|DEVICE|SternaLock XP|Plating system with cable cerclage bands that is used in the stabilization and fixation of fractures of the anterior chest wall, including sternal fixation following sternotomy
41295181|NCT02625142|OTHER|Family-centered rounds checklist tool|A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
41295182|NCT05293769|OTHER|questionnaire|questionnaire will be filled in by all participants
40965274|NCT03196102|BEHAVIORAL|Cigarette smoking military tailored pamphlet|The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
40965275|NCT03196102|BEHAVIORAL|Standard smoking cessation intervention|This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
40965276|NCT01427972|DRUG|LY2623091|Administered orally
41137441|NCT02271906|DRUG|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
41137442|NCT01528683|RADIATION|Carbon Ion Radiotherapy|Treatment with carbon ion radiotherapy using the rasterscanning technique
41137443|NCT04860999|PROCEDURE|Osteopathic Manipulative Treatment|The osteopathic manipulations focused on treating the asymmetric postural dysfunction that was identified by the initial functional structural evaluation. The manipulation consisted of typical time-honored osteopathic treatments directed at the identified somatic dysfunction(s). These techniques were clinically directed and include: soft tissue, muscle energy, high velocity low amplitude, low velocity high amplitude as well as facilitated positional release as indicated.
41137444|NCT04908930|BEHAVIORAL|On-field activity group - Aim 3|Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure
41137445|NCT06459167|OTHER|The position adopted when patients undergoing procedure or surgery|For patients requiring sedation for procedures or surgery, they are randomly assigned either to supine position or lateral position before they are sedated, and kept during procedure or surgery.
41137446|NCT03806309|DRUG|FOLFIRI|Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2
41137447|NCT03806309|DRUG|OSE2101|subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
41137448|NCT01606098|PROCEDURE|Surgery of the primary tumour|Surgical resection of the colon tumour
41137449|NCT01606098|DRUG|Systemic treatment|"First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)"
41137450|NCT03937609|DRUG|Infliximab|infliximab iv 5mg/kg
41137451|NCT05329519|BEHAVIORAL|Listening music|Patients in both groups underwent VATS with wedge recession and the same surgical methods were employed. After the surgery, the patients in the music group performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player (Goldmaster Goldsmart Mp3-159 Player) and head phones on postoperative days 1, 2, and 3. We prepared a list of popular songs of different genres, including Turkish classical, folk, pop and rock music, classical music and foreign music, and allowed them to choose the song to be listened.
41137452|NCT03885544|OTHER|Controlled Lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian (LOV) diet for 3 weeks. All foods will be provided to subjects during the intervention. Each subject's energy requirement will be estimated using sex-specific equations published by the Institute of Medicine for weight maintenance during the intervention.
41137453|NCT03885544|OTHER|Controlled Unprocessed red meat diet|The unprocessed red meat diet will be the same as the LOV diet except that one 3-ounce portion of unprocessed red meat per day, 7 days per week (21 oz/wk) will be included. The unprocessed red meat will include beef tenderloin and pork loin. All foods will be provided to subjects during the intervention.
41295183|NCT02074215|OTHER|Aerobic exercises|Aerobic exercises + dual task
41295184|NCT02074215|OTHER|Stretch exercise|Stretch exercise
41295185|NCT06173492|PROCEDURE|Dental extraction|After local anesthesia (mepivacaine 2%), the tooth is extracted atraumatically with levers and forceps taking care to preserve the cortex. The roots of multi-rooted teeth are separated before extraction. The pocket epithelium and granulation tissue inside the socket are removed.
41295186|NCT06173492|DEVICE|Platelet Rich Fibrin|The clot obtained by centrifugation is made into PRF cylinders and inserted into the socket and compacted.
41295187|NCT01937208|RADIATION|intensity modulated radiation therapy in both arms|
41295188|NCT01937208|DRUG|concurrent chemotherapy with radiation|docetaxel plus cisplatin were used weekly in both arms
41457195|NCT02027337|DRUG|20 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
40766786|NCT06642909|DRUG|Zuberitamab 600mg|administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
41137454|NCT03885544|OTHER|Controlled processed red meat diet|The processed red meat diet will be the same as the LOV diet except that one 3-ounce portion of processed red meat per day, 7 days per week (21 oz/wk) will be included. The processed red meat will include a variety of beef and pork luncheon meats with different methods of preservation. All foods will be provided to subjects during the intervention.
41457196|NCT02027337|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
41457197|NCT02027337|DRUG|30 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
41457198|NCT02027337|DRUG|35 mcg ethinylestradiol/2 mg cyproterone|1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
40766787|NCT06642909|DRUG|Zuberitamab 1000mg|administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
40766788|NCT06642909|DRUG|cyclosporine|Initial dose of 3.5 mg/kg/d, oral administration, divided into two doses, taken 12 hours apart (Q12h)
41137455|NCT03135782|OTHER|Communication Skills Training|Undergo motivational interviewing training
41137456|NCT03135782|OTHER|Medical Chart Review|Undergo medical chart review
40766789|NCT02394574|OTHER|Clean Cookstove|Ethanol
41137457|NCT03135782|OTHER|Questionnaire Administration|Ancillary studies
41137458|NCT03135782|OTHER|Tobacco Cessation Counseling|Attend phone or in-person motivational interviewing coaching sessions
41137459|NCT01650051|DRUG|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
41137460|NCT01650051|DRUG|Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
41137461|NCT03936699|DEVICE|Transcutaneous Nerve Stimulator (TENS)|"The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet \& Exercise Subjects to be instructed on a healthy 1200 calorie diet."
41295189|NCT05641623|DRUG|OSU6162|OSU6162
41457199|NCT02027337|DRUG|35 mcg ethinylestradiol/2 mg cyproterone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
41457200|NCT05737160|BIOLOGICAL|Telitacicept|Administered as an SC infusion
41457201|NCT05737160|DRUG|Placebo|Administered as an SC infusion
40766790|NCT02394574|OTHER|Traditional Cookstove|Firewood / Kerosene
40766791|NCT06127303|DRUG|Toripalimab|Toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after cryoablation, until occurrence of termination event specified in the protocol.
40766792|NCT06127303|OTHER|Cryoablation|The ablation was performed on the first day of each cycle, and the target lesions were comprehensively screened for cryoablation based on the location and size of the lesions.
40766793|NCT06385353|OTHER|Quantification of deep vein thrombosis burden and assessment of post-thrombotic syndrome|"Post-thrombotic syndrome will be assessed by the Villalta score until 6 months of follow-up.~Data collected from colour doppler ultrasound will be used to calculate the Venous Volumetric Index to quantify deep vein thrombosis burden until 6 months of follow-up."
40766794|NCT05961735|OTHER|PECS II Block|The Pecs II block is applied to the patients after induction of anesthesia .
40766795|NCT05961735|OTHER|Combined Serratus Anterior Plane Block|Combined Serratus Anterior Plane Block is applied to the patients after induction of anesthesia .
41137462|NCT03936699|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
41137463|NCT05093894|DEVICE|Group 1|Microlyte will be cut into strips and placed on the subcutaneous space
41137464|NCT05441176|OTHER|Questionnaires|Scoring of the DASH is performed according to references.
41295190|NCT05641623|DRUG|Placebo|Placebo
41457202|NCT06357416|DEVICE|MV-POCT Sub-study|Point of care blood testing
41457203|NCT06357416|OTHER|Main Man Van Group Sub-study (MV-Eco)|Consent for long-term follow-up of patients
41457204|NCT06357416|OTHER|MV-QualQ Sub-study|Qualitative questionnaire and interview sub-study
41457205|NCT06357416|DIAGNOSTIC_TEST|MV-PRS Sub-study|Patients consenting to polygenic risk score testing
41457206|NCT06357416|OTHER|MV-DNA and MV-UctDNA Sub-study|Patients consenting to collection of DNA and urine for further study.
41457207|NCT06357416|OTHER|Man Van patients|All patients seen in Man Van
41457208|NCT06357416|OTHER|MV-SSI Sub-study|Semi-structured interviews will be conducted with stakeholders involved in the running of or recruitment to the project.
40766796|NCT02019849|DEVICE|Plasmafit® Total Hip Arthroplasty|
40965277|NCT01427972|DRUG|Eplerenone|Administered orally
41457209|NCT06357416|OTHER|MV-TPP Sub-study|Multi-stage qualitative study comprising of interviews and participatory design focus group workshops.
41457210|NCT05995054|DRUG|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 110 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
41457211|NCT05290519|OTHER|plant and animal protein|plant protein: 2 bottle of black soy milk (400 mL/bottle) for 4 weeks animal protein: pork dished for 4 weeks
41457212|NCT06042296|OTHER|Expression of CD44, E-cadherin and PCNA|The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)
41457213|NCT03050866|DRUG|Cabazitaxel|25mg/m2 q3w
41457214|NCT03050866|OTHER|Antihistamine|As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)
41457215|NCT03050866|OTHER|Corticosteroid|As intravenous premedication (dexamethasone 8 mg or equivalent)
40965278|NCT03198572|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention is consisted of diet control and aerobic exercise. calorie restriction: to subtract 500 kcal from daily calorie intake aerobic exercise: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate.
40965279|NCT03198572|DRUG|Placebo|placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks
40965280|NCT03198572|DRUG|Berberine|Berberine tablets 0.5 tid, 30 minutes before each meal, for 48weeks
40965281|NCT01941667|BEHAVIORAL|Daily Messages, Virtual Home Visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
41457216|NCT03050866|OTHER|H2 antagonist|As intravenous premedication (ranitidine or equivalent)
41457217|NCT03050866|OTHER|Antiemetic|Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
41457218|NCT05993390|DRUG|Sugammadex|Intravenous administration of sugammadex 2mg/kg.
40965282|NCT01941667|OTHER|Usual Care|Usual care as defined by by the Cardiology Department.
40766797|NCT06061757|DEVICE|Imaging guidance with TEE and ICE for Left atrial appendage closure|The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.
40965283|NCT00454896|DRUG|VESIcare®|Oral
40965284|NCT00454896|DRUG|placebo|Oral
40965285|NCT04873804|OTHER|Transcranial Direct Current Stimulation|The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
40965286|NCT06506136|DRUG|Fluoxetine|"Participants will receive fluoxetine tablets, 20 mg each, taken orally twice a day (total daily dose of 40 mg) for 12 weeks. Tablets should be taken with water at the same times daily.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~Bisacodyl: 5-10 mg Glycerin Enema: 110 ml Polyethylene Glycol: 10 g Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM."
41137465|NCT02673359|DRUG|Progesterone|Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day
41457219|NCT05993390|DRUG|Neostigmine|Intravenous administration of neostigmine 0.05mg/kg with glycopyrrolate 0.01mg/kg
41457220|NCT05191862|DRUG|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
41457221|NCT05191862|DRUG|PMR 135 mg|Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
41457222|NCT01142908|BEHAVIORAL|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
41457223|NCT00838162|DRUG|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
41457224|NCT00838162|DRUG|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
41457225|NCT00838162|DRUG|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
41457226|NCT00838162|DRUG|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
41457227|NCT00838162|DRUG|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
41457228|NCT00838162|DRUG|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
41457229|NCT02980172|OTHER|Pain evaluation|Evaluation of pain using a numerical scale (1 to 10)
41457230|NCT02997891|DIAGNOSTIC_TEST|everyday activity|To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).
40766798|NCT04197583|DEVICE|Boston Scientific Ureteral Stents, Urinary Diversion Stent|A BSC Ureteral Stent is an implantable device that is used to restore flow of urine from the kidney to the bladder in obstructed ureters. A BSC Urinary Diversion Stent is an implantable device that is used to restore flow of urine from the kidney.
40965287|NCT06506136|DRUG|Placebo|"Participants in the Placebo Control Group will receive placebo tablets that are identical in appearance and taste to the fluoxetine tablets. They will take one placebo tablet orally twice a day for 12 weeks, following the same schedule as the treatment group to maintain blinding.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~Bisacodyl: 5-10 mg Glycerin Enema: 110 ml Polyethylene Glycol: 10 g Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM."
40965288|NCT02197130|DRUG|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
41457231|NCT02997891|DIAGNOSTIC_TEST|cognitive performance|Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.
41457232|NCT03541239|DEVICE|Single Cuff Tourniquet 8000|If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.
41457233|NCT03506594|DEVICE|Radiofrequency non ablative|The application of RF was performed by physical therapist trained in the technique of radiofrequency through the CAPENERGY device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41°C radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
40965289|NCT02197130|DRUG|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
40965290|NCT02197130|OTHER|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
40965291|NCT03704467|DRUG|M6620|Participants received 90 milligrams per square meter (mg/m\^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m\^2, or 40 mg/m\^2.
40965292|NCT03704467|DRUG|Avelumab|Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
40965293|NCT03704467|DRUG|Carboplatin|Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
40965294|NCT03925480|DRUG|Azithromycin 500 mg Oral Tablet x 4|A single prophylactic dose of antibiotic given during labour
40965295|NCT03925480|DRUG|Matching Placebo|Matching Placebo
40965296|NCT06260852|DIAGNOSTIC_TEST|Diagnostic Test: Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
41137466|NCT02673359|PROCEDURE|Cervical cerclage|Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)
40766799|NCT06644014|BEHAVIORAL|Exercise|"Participant will communicate with a chatbot-like proprietary AI to receive exercise instructions. The AI will provide personalized advice according to the user's needs, aiming for 2-3 hours of steady-state zone 2 -effort aerobic exercise. Instructions will also be tailored to the user's exercise preferences and limitations (for example, suggest cycling, if running is not convenient)."
40766800|NCT06644014|BEHAVIORAL|Exercise|Supervised HIIT -cycling twice a week. Intensities for cycling intervals will are based on the participants fitness-level determined at first visit. Intensity will gradually increase over the 12-week period
40766801|NCT06644014|DEVICE|Smart Ring|Participants will only receive an Oura Ring, but will not change anything about their normal physical activity.
40766802|NCT05559359|DRUG|Lebrikizumab|Administered SC
41146813|NCT06244394|RADIATION|intensity-modulated radiotherapy|All patients were staged according to the 8th edition of the TNM classification by the American Joint Committee on Cancer/Union for International Cancer Control and received a standardized treatment regimen including IMRT and concurrent or adjuvant chemotherapy. Inverse IMRT treatment planning was performed on a Varian Inspiration Platform (version 10.0), using the simultaneous integrated boost technique. The prescribed doses were 68-75 Gy to the PTV of the GTVnx in 32-34 fractions; 64-75 Gy to the PTV of the GTVnd in 32-34 fractions; 60 Gy to the PTV of CTV1 in 32 fractions; and 50 Gy to the PTV of CTV2 in 28 fractions. All patients were given one fraction daily 5 days a week. The dose-volume-histograms (DVHs) of the organs at risk were evaluated as described in the radiation therapy oncology group (RTOG) 0225 protocol to prevent violation of the tolerance limits.
41295191|NCT03085810|DRUG|Ocrelizumab|Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
40766803|NCT05559359|DRUG|Placebo|Placebo given SC
41295192|NCT03174743|PROCEDURE|Convential Ventilation 1|High tidal volume, moderate inspired oygen fraction (FiO2).
40766804|NCT05559359|DRUG|Topical corticosteroid|Topical corticosteroid
40766805|NCT01587196|DRUG|Vivitrol|There are monthly injections of depot naltrexone for 3 months.
40766806|NCT04933708|BEHAVIORAL|Labor Podcast|"Listening to podcasts.~Topics include:~Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth"
40766807|NCT06258382|OTHER|Questionnaires and functional test|Data will be collected from different sources. Questinnaires, Medical journal, Obstetrical records and functional tests
40766808|NCT04813926|DRUG|Riociguat (Adempas, BAY63-2521)|Follow clinical practice.
40766809|NCT06643936|BEHAVIORAL|E3 Multidisciplinary Team|The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, community health worker, and dietician working together to overcome barriers to diabetes control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
40766810|NCT06643936|BEHAVIORAL|E3 Self-Guided Type 2 Diabetes Education|Patients will receive timed, mailed educational materials on diabetes monitoring, diet and lifestyle modifications to supplement usual clinic based type 2 diabetes care with their primary care doctor. A registered nurse will ensure patients have glucometers and supplies, and remind patients to obtain A1C readings at 3 months and 6 months via phone call.
40766811|NCT05528588|COMBINATION_PRODUCT|Furoscix|"Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation that is buffered to a neutral pH to enable subcutaneous administration and contained in a prefilled Crystal Zenith® (CZ) cartridge.~Study Device: The Infusor is a compact, ethylene oxide (EtO) sterilized, single-use, electro-mechanical (battery powered, micro-processor controlled), on-body subcutaneous delivery system based on the SmartDose® Gen II 10 mL (West Pharmaceutical Services).~The Furoscix Infusor is an investigational drug-device combination product. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours)."
40766812|NCT05528588|DRUG|Diuretic Therapy|Patients will receive home dose oral furosemide or oral furosemide per standard of care.
41457234|NCT05029427|OTHER|High molecular weight β-glucan oat cookies|Two cookies that contains 4g beta glucan made from oats will be consumed per day.
40766813|NCT05151731|DRUG|Vamikibart|Vamikibart will be administered by IVT injection as specified in each treatment arm.
40766814|NCT05151731|DRUG|Ranibizumab|Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.
40766815|NCT05151731|OTHER|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
41137467|NCT06129981|BEHAVIORAL|Imaginary exposure therapy augmented by vocal feedback|"The procedure specific to the study~* adding inclusion procedures (explanation of the study, verification of inclusion and non-inclusion criteria, signature of informed consent)~* including, in the usual initial V0 visit, psychometric measures specific to the study (RSDI, CGI, PMI, GEW)~* including a single usual psychotherapy session (i.e. not augmented) S1, during which the psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study are used~* adding the VF device and using psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study during psychotherapy sessions S2 to Sn (minimum S6)~* adding, during the last usual end-of-treatment visit, psychometric measures specific to the study (CGI)~* adding psychometric measures specific to the study during the usual follow-up visit at 3 months~* adding a follow-up visit at 12 months (CGI, PCL-5), either by telephone or on-site."
41137468|NCT05928754|DIAGNOSTIC_TEST|care strategy|"Uveitis patients:~* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~* Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~* Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~* Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7."
41137469|NCT03500276|BEHAVIORAL|Yoga program|Yoga classes will be conducted 2xweekly/ 90 minutes and consist of physical exercises (asanas), breathing exercises (pranayama), relaxation and self-enquiry meditation based on Yoga in daily life system.
41137470|NCT03500276|BEHAVIORAL|Arthritis-education|Arthritis-education classes will be conducted 1xweekly/ 120 minutes and led by rheumatology specialists and consist of lectures on arthritis and related issues followed by group discussion.
41295193|NCT03174743|PROCEDURE|Convential Ventilation 2|High tidal volume, high inspired oygen fraction (FiO2).
41295194|NCT03174743|PROCEDURE|Protective Ventilation 1|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
41295195|NCT03174743|PROCEDURE|Protective Ventilation 2|Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
41457235|NCT05029427|OTHER|Control wheat based cookies|Two cookies that made from cream of wheat without beta glucan will be consumed per day.
41457236|NCT04057105|DEVICE|Active High-definition Transcranial Direct Current Stimulation (HD-tDCS)|Stimulation sessions will be conducted once a day on 10 weekdays over a period of 2-3 weeks. Anodal HD-tDCS will be delivered either in Active or Sham mode (as per the randomized order) in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
40766816|NCT03951480|OTHER|Manual medicine|At a rate of 3 sessions of a maximum of 30 minutes each at one week interval. Depending on the clinical evolution, it is possible to stop manual medicine sessions according to the therapist's assessment as in current practice. If the patient has an EVA pain of activity \< 2, manipulations will not be continued. The patient being considered as not very symptomatic.
40766817|NCT03951480|DRUG|Corticosteroids infiltration|A unique echo-guided infiltration of one syringe of 1 mL of cortisone product
40766818|NCT06099002|OTHER|Changed Medical research Council,Mini Mental Test, Quadriceps Femoris muscle strength measurement,2 min walking test, fall effectiveness scale,Fall risk self-assessment scale|"All individuals were given a respiratory function test to evaluate respiratory functions before and after training Modified Medical research Council to evaluate dyspnea, Mini Mental Test to evaluate cognitive status~, Berg Balance Test to evaluate balance, 2-minute walk test to evaluate walking speed. A hand dynamometer will be used to measure QuadricepsFemoris muscle strength, Fall efficiency scale Fall risk self-assessment scale will be used to evaluate falls."
40766819|NCT05348733|DRUG|Kerendia (Finerenone, BAY94-8862)|Decision will taken by the treating physician to initiate treatment with finerenone.
40766820|NCT05810467|OTHER|Active Surveillance|"Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA \<10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, \>50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa."
40766821|NCT06645431|BEHAVIORAL|Water Intake|Previous studies have not observed blood glucose with adequate vs. low water intake in a free-living situation. The use of continuous glucose monitors allows this.
40766822|NCT06560736|BEHAVIORAL|Show Me FIRST coping skills intervention|Show Me FIRST is a flexible, transdiagnostic intervention organized around well-tested principles of youth psychotherapeutic change.
40965297|NCT06028139|BEHAVIORAL|Continuous glucose monitoring and health coaching|"Each CGM device will work for 14 days. The participants will use the CGM devices for the first two-week period in the first three months of the trial, and the first two-week period of the second three months of the trial.~Participants will interact with health coach throughout the study duration."
40965298|NCT06028139|BEHAVIORAL|EMPOWER mobile app|Nudges will be delivered through the EMPOWER mobile app. Participants will log lifestyle information such as diet and physical activity, and clinical information such as medication and HbA1c levels through the EMPOWER mobile app.
40965299|NCT04317469|DIAGNOSTIC_TEST|VWF measurement|Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
40965300|NCT06505590|DEVICE|Educational content|Patients will have access to educational content on the mobile app Resilience © in the format of articles, videos or podcasts on treatment related symptoms and on validated supportive care interventions. This version is currently public available in France and Belgium at www.resilience.care and is considered the control group (education only).
40965301|NCT06505590|DEVICE|Educational material plus self-management program - self-administered version|Patients will have access to the same mobile app (Resilience ©) with its educational content will be powered with a self-guided fatigue self-management program based on a cognitive behavioral therapy approach.
40965302|NCT06505590|DEVICE|Educational material plus self-management program - guided version with mental health professional|Patients will have access to the same mobile app (Resilience ©) with its educational content and the self-management program of arm 2 and weekly calls with a certified mental health professional certified in cognitive behavioural therapy for guided coaching across the self-management program.
40965303|NCT01502930|BEHAVIORAL|IRT|Internet-based IRT with therapist support during 6 weeks
41137471|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
41137472|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
41137473|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
41137474|NCT02443909|DEVICE|Holmium laser device|
41146814|NCT01912599|DEVICE|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
41295196|NCT02645747|DRUG|Aflibercept (Eylea, BAY86-5321)|"Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency."
41457237|NCT04057105|DEVICE|MusicGlove|Both groups will undergo MusicGlove video-game based hand exercises.
41457238|NCT04967950|DRUG|Secukinumab 300 MG|Secukinumab 150 mg s.c. with loading dose at baseline, week 1,2,3,4 and then every 4 weeks from week 5 up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, Secukinumab 150 mg will be with a switch to 300 mg.
41295197|NCT04360330|RADIATION|Stereotactic Ablative Breast Radiotherapy|"Preoperative SABER: Participants will be treated with an assigned dose level of preoperative SABER, delivered in once a day, 5 fractions given on non-consecutive days, over a period of 2 weeks. In this phase I study, starting with dose level II, a dose level of preoperative SABER will be assigned per study dose-escalation design, treating 2 to 6 patients per dose level. The tested doses are the following:~* Dose Level I: 35 Gy (5 fractions of 7 Gy)~* Dose Level II (Starting Dose): 40 Gy (5 fractions of 8 Gy)~* Dose Level III: 45 Gy (5 fractions of 9 Gy)~* Dose Level IV: 50 Gy (5 fractions of 10 Gy)"
41295198|NCT05162612|DIAGNOSTIC_TEST|abtominal CT|standard basic Abdominal Ct scan
41295199|NCT01518192|DRUG|doxycycline|100 mg bid; 15 days
40965304|NCT01502930|BEHAVIORAL|Stress Reduction|Internet-based stress reduction with therapist support during 6 weeks
40965305|NCT00249756|BEHAVIORAL|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments - increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
40965306|NCT00249756|BEHAVIORAL|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
41295200|NCT01518192|DRUG|cefuroxime axetil|500 mg bid; 15 days
41295201|NCT03524365|PROCEDURE|RYGB|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy. Lifestyle modification counselling is provided to each patient.
41137475|NCT03728452|PROCEDURE|Trophic Nutrition|"According to previously published studies of Trophic Nutritions in critically ill patients, an energy goal of 20-30% estimated caloric needs of 20-30 kcal / kg and a protein intake of 1.2 to 2.0 g / kg / day of proteins will be established. at most 72 hours after the start of nutritional therapy.~The rhythm of initiation and increase of enteral contributions will be at the discretion of each participating ICU. Prokinetic or parenteral nutrition (PN) complementary will not be used routinely, leaving its indication at the discretion of the responsible physician.~A hyperproteic nutritional formula (10 g / 100 ml) will be used, with a caloric intake of 1.2 kcal / ml and a non-protein kcal / nitrogen ratio of 52: 1. TN will be administered over 23 hours each day by continuous infusion pump. The head of the patient's bed will rise above 30° as much as possible to reduce the risk of aspiration. The Gastric Residue Volume (GRV) will be measured every 24 hours."
41295202|NCT03524365|PROCEDURE|SG|The SG is created using a linear stapler with two sequential 4.8/60-mm green load firings for the antrum, followed by two or three sequential 3.5/60-mm blue loads for the remaining gastric corpus and fundus. The stapler is applied alongside a 48-Fr calibrating bougie. The resection line is performed avoiding the ''critical area'' by resecting the fundus 1.5 cm from the angle of His. Staple lines are buttressed with bovine pericardial strips. The resected stomach is grasped at the antral tip by a laparoscopic grasper and retrieved through one of the trocar sites. A methylene blue dye test by a nasogastric tube is routinely performed at the end of the procedure. The residual gastric remnant capacity is 60-80 ml. Drains are not routinely placed, and the nasogastric tube is removed at the end of the procedure. Upper gastrointestinal contrast (Gastrografin) study is performed on the first postoperative day. Lifestyle modification counselling is provided to each patient.
41295203|NCT03524365|OTHER|Intensive Lifestyle Modification|"Resting calorie requirements will be calculated via the Harris Benedict equation (24) and an activity factor, and subjects will be instructed not to change their activity level other than that suggested by physicians during the study. The diet will contain 1/3 kcal less than the calculated energy expenditure and 30% fat of which 10% saturated, 55% lower glycemic index carbohydrates and 15% proteins.~The participants will be encouraged to gradually increase their walking to achieve 10,000 steps per day. A moderate intensity physical activity program of 1 hour of aerobic exercise 2-3 hours per week will be recommended to all subjects. Their physical activity will be assessed by IPAQ-SF."
41295204|NCT01450930|DRUG|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
41295205|NCT01450930|DRUG|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
41295206|NCT00002677|DRUG|chemotherapy|
41137476|NCT03038490|DIETARY_SUPPLEMENT|ABOUND|an oral mixture of arginine, glutamine and beta-hydroxy-beta-methylbutyrate
41295207|NCT00002677|DRUG|tributyrin|
41295208|NCT01188798|DRUG|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
41457239|NCT04967950|DRUG|Secukinumab 150 MG|Methotrexate 15 mg po. every week up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, methotrexate with a switch to Secukinumab 150 mg at 12 weeks.
41457240|NCT04967950|DRUG|Methotrexate|methotrexate
41457241|NCT04155840|DRUG|Copanlisib|Given IV
41457242|NCT04155840|BIOLOGICAL|Rituximab|Given IV
41457243|NCT04155840|DRUG|Bendamustine|Given IV
41457244|NCT05791864|GENETIC|RGX-381|One time subretinal dose in study eye
41457245|NCT02609191|DEVICE|"Whole body exam using the Discovery A"|"Whole body exam using the Discovery A machine made by Hologic."
40766823|NCT05553236|DIAGNOSTIC_TEST|Targeted next-generation sequencing|During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee.
40766824|NCT06637397|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
40766825|NCT06637397|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
40965307|NCT02074644|PROCEDURE|Prostatic Arterial Embolization|"The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way."
40965308|NCT02074644|PROCEDURE|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
40766828|NCT01380080|DRUG|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
41137477|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
41457246|NCT02609191|DEVICE|"First whole body exam using the Stratos DR"|"First whole body exam using the Stratos DR machine made by the DMS group."
41457247|NCT02609191|DEVICE|"Second whole body exam using the Stratos DR"|"Second whole body exam using the Stratos DR machine made by the DMS group. This second exam is required for reproducibility purposes."
40766829|NCT01380080|DRUG|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
40766830|NCT01380080|DRUG|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
40766831|NCT01380080|DRUG|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
40766832|NCT01380080|DRUG|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
40766833|NCT01380080|DRUG|Isoniazid|INH 300 mg orally once daily
40766834|NCT03970447|DRUG|Temozolomide|Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
40766835|NCT03970447|DRUG|Lomustine|Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
40766836|NCT03970447|DRUG|Regorafenib|Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
40766837|NCT03970447|RADIATION|Radiation|60 Gy
40766838|NCT03970447|DRUG|Paxalisib|Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles
40766839|NCT03970447|DRUG|VAL-083|Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
40766840|NCT03970447|DRUG|VT1021|"Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri).~Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration."
40766841|NCT03970447|DRUG|Troriluzole|Dosage Form: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.
40766842|NCT03970447|BIOLOGICAL|ADI-PEG 20|Dosage Form: Solution for intramuscular injection Strength: 11.5 ± 1.0 mg/ml Standard Regimen: For newly diagnosed patients, 36mg/m2. For recurrent disease patients, dose as confirmed through the dose finding phase intramuscularly once a week
40766843|NCT05712356|DRUG|LSTA1|LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
40766844|NCT05712356|DRUG|Durvalumab|1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
40965309|NCT00864331|RADIATION|radiation|39 Gy in 13 daily fractions of 3 Gy
41457248|NCT01078350|PROCEDURE|tumor tissue aspiration|
41457249|NCT01078350|PROCEDURE|phlebotomy|
41457250|NCT02342938|PROCEDURE|MEG or fMRI And INtracranial EEG|
41457251|NCT02342938|PROCEDURE|fMRI|
41295209|NCT01188798|DRUG|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
40965310|NCT00864331|OTHER|Chemotherapy and radiotherapy|Chemotherapy followed by low dose palliative radiotherapy
40965311|NCT00864331|DRUG|Chemotherapy|Chemotherapy given alone
40965312|NCT00864331|OTHER|Palliative radiotherapy and chemotherapy|Low dose palliative radiotherapy followed by chemotherapy
40965313|NCT03298165|DEVICE|diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
41295210|NCT02680301|DRUG|0.1% triamcinolone CREAM|Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
41295211|NCT02680301|DRUG|0.1% triamcinolone OINTMENT|Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
41295212|NCT04724486|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
41295213|NCT04724486|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
41295214|NCT04724486|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
41295215|NCT04724486|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
40965314|NCT01382212|DRUG|paricalcitol|Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
40965315|NCT03168854|BIOLOGICAL|Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain|Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
40965316|NCT03168854|OTHER|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
40965317|NCT03978338|DIETARY_SUPPLEMENT|brain polypeptide solution|The experimental group will take the brain polypeptide solution 60ml per day which contains nitrogen 90mg, soybean oil ,glycerin and soybean phospholipids in 84days.
40965318|NCT03978338|OTHER|same package of placebo|The control group was treated with the same package of placebo 60ml per day which contains soybean oil ,glycerin and soybean phospholipids in 84 days.
41295216|NCT03400670|DEVICE|ventilator NCPAP|infants will be randomized into two different NCPAP groups
41295217|NCT02717767|OTHER|Autofluorescence of white corpuscle|Measure of auto-fluorescence of white corpuscles cells harvested from tracheal aspirate and/or bronchoalveolar lavages
41295218|NCT02345434|OTHER|Informative letter|The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
41295219|NCT01058577|DEVICE|Non-invasive CGMS|A non-invasive continuous glucose monitoring device measured was applied at the wrist and measured skin glucose as an indirect measure of blood glucose every 10 min.
40766845|NCT05712356|DRUG|Cisplatin|cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
40965319|NCT01998529|DRUG|Cisplatin|Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).
40965320|NCT01998529|DRUG|Amifostine|Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
40965321|NCT00483639|OTHER|Medical chart review|medical chart review
40965322|NCT00483639|OTHER|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
40965323|NCT00483639|PROCEDURE|management of therapy complications|management of therapy complications
41137478|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel + CPG 10104|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
41137479|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel + GLA-AF|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
41137480|NCT03172975|BIOLOGICAL|Placebo|Physiological sterile saline solution
41137481|NCT03172975|DRUG|Albendazole|Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
41137482|NCT03172975|OTHER|Necator americanus Larval Inoculum|50 infectious Necator americanus larvae applied via dermal application (challenge infection).
41137483|NCT04406532|BEHAVIORAL|PT-Pal|"Participants will be guided through an exercise program in the PT-Pal app. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
41295220|NCT01058577|PROCEDURE|Hyperglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (16.7 mmol/L) for at least 2.5h and euglycemia (5 mmol/L) for another 2.5h. A continuous somatostatin infusion was initiated after 1h to suppress endogenous insulin secretion. A glucose solution was infused to increase the blood glucose towards the hyperglycemic target level. At approximately t=3.5h the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level.
41457252|NCT02726841|PROCEDURE|Open thoracoabdominal aortic repair + abdominal stenting|Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation
41137484|NCT04406532|BEHAVIORAL|Self-guided exercises|"Participants will use the exercise manual to guide the exercise program. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
40766846|NCT05712356|DRUG|Gemcitabine|gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
40766847|NCT05712356|DRUG|FOLFOX regimen|"The following will be given every 14 days:~* oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion~* fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes~* fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)"
40766848|NCT05712356|DRUG|Placebo|Placebo given as a slow IV push over 1 minute when standard treatment(s) are given
40965324|NCT00483639|PROCEDURE|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
40965325|NCT00483639|OTHER|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
40965326|NCT05214885|DIAGNOSTIC_TEST|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
40766849|NCT05396014|BEHAVIORAL|Enhanced Self-Care (ESC)|The Enhanced Self-Care intervention will be comprised of educational modules on evidence-based cognitive-behavioral self-management skills for pain. These modules will be provided digitally for self-administration over a period of 12 weeks. There will be no therapist associated with the delivery of these educational materials; however, after the first four modules, email or text messages will be used to make personalized recommendations for accessing additional modules based upon identified problems from the baseline assessment. Additionally, the walking program module will utilize Fitbit step tracking to allow participants to monitor their walking progress.
40766850|NCT05396014|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a form of cognitive behavioral therapy that is well established for the treatment of chronic pain. The goal of ACT is to build psychological flexibility thereby interrupting pain avoidance behavior patterns. Participants randomized to ACT will take part in 12 sessions over the course of 12 weeks. Sessions will be delivered as a combination of 4 remote face-to-face visits with a therapist and 8 therapist-supported online sessions (self-directed online modules supported by provider coaching). Online sessions will focus on helping participants accept pain, connect with negative thoughts and emotions, develop mindfulness and identify and commit to values and goals that are important to them. During face-to-face sessions with the therapist, participants will be encouraged to share their experience of skills practice and mastery, provide examples of skill use at home, and describe what barriers they encountered.
40766851|NCT05396014|BEHAVIORAL|Evidence-Based Exercise and Manual Therapy (EBEM)|Licensed physical therapists (PTs) or Doctors of Chiropractic (DCs) will rely on evidence-based guidance to direct decision-making on the particular type of manual and exercise therapy that may be best suited to an individual study participant. Special attention will be paid to the clinician's choice of language in regard to the purpose and expected outcomes of manual therapy in order to avoid enhancing catastrophizing ideations or preference for passive interventions. A total of 10 sessions will be provided over an 8-week treatment period. Two sessions per week are provided in the first two weeks followed by weekly sessions over the next 6 weeks. Treatment sessions will last approximately 60 minutes each.
40766852|NCT05396014|DRUG|Duloxetine|Duloxetine is a serotonin norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for use in Chronic Low-Back Pain, and, as such, is included as a recommended therapy in nearly all current treatment guidelines for low back pain. Study participants will be treated with duloxetine for 12 weeks during the active treatment phase. At the time of randomization, the approved drug pharmacy at each study site will dispense between 185 and 192 duloxetine 30 mg capsules and provide to participants. This will ensure enough capsules to maintain up to a 60 mg dosage through the 12-week intervention phase and to taper the dose in the 13th week if needed.
40766853|NCT06644196|DEVICE|Acquisition of images/videos of the bilateral fundus with the holographic doppler laser|Acquisition of images/videos of the bilateral fundus with the holographic Doppler laser
40766854|NCT06643871|OTHER|Adapted physical activity program involving connected bikes|The treatment being studied involves a program (DYNAMO-PSY) of adapted physical activity with an enriched environment (connected bike, visualized and experienced routes in virtual reality) and is supervised, comprising (on average) two sessions per week, a total of 20 sessions to be completed over a maximum of 15 weeks. Each session will last 60 minutes and will be supervised by a case manager. They will be composed of a warm up, session on the bike (around 30 minutes of bicycling) and stretching. They will take place in an adequate room in the clinical research department of Saint Anne Hospital. The usual hygienic-dietetic care is not modified by the study and consists of the care proposed to patients of the GHU Paris Psychiatry and Neuroscience who have had a first psychotic episode and are treated primarily with medication: clinical and biological monitoring, dietary consultations, therapeutic education group concerning diet and lifestyle.
40965327|NCT01694472|BIOLOGICAL|MAGE-A4 TCR Gene-Modified T Cells|The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10\^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10\^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
40965328|NCT05777850|PROCEDURE|Conventional cavotricuspid isthmus ablation|Point-by-point 25-40 W applications at the CTI of unlimited duration until achieving the pre-established Ablation Index.
40965329|NCT05777850|PROCEDURE|High-power short-duration ablation|Point-by-point 90W applications at the CTI ablation during 4 seconds.
41137485|NCT01596686|DRUG|one of two possible colon preparation regimens|Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
41137486|NCT04598646|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
41137487|NCT04598646|BEHAVIORAL|Support|Behavioural support via professionals and peer support and recommended physical activity guidelines for cancer survivors, to encourage physical activity.
41137488|NCT04892251|COMBINATION_PRODUCT|MORE+KAP|Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly
40766855|NCT06352463|OTHER|Denken + Doen = Durven|DDD is an evidence based cognitive behavioural therapy (CBT)-treatment protocol for children with anxiety. This research will use the modular version of DDD, which means that the therapist will decide which modules she will use based on the specific symptoms and needs of the child. DDD consists of four parts. First, there will be psycho education in which the child learns about how anxiety can arise, when anxiety is normal, and how thoughts, emotions, and behaviour are linked. Second, the child will learn coping strategies for dealing with anxiety. Third, there will be cognitive restructuring by which that the child will learn skills to deal with anxious and negative thoughts, through challenging and experimenting. Finally, there will be exposure. In the exposure sessions, the child will face their fears step by step.
40766856|NCT06352463|OTHER|Supportive Parenting for Anxious Childhood Emotions|Parents will follow the SPACE program. SPACE is a theory driven, evidence-based treatment program of 12 sessions. In a structured way, parents are trained to change their own behaviour as a reaction to the symptoms of their child. First, they are trained to recognise family accommodation and slowly reduce this. Second, this program focuses on the increase in supportive reactions from parents. They are taught to accept the child's feelings, fears, and problems and to trust in the ability of the child to cope with and tolerate anxiety-related problems. These two goals are attained via a sequence of steps in the SPACE manual. Furthermore, SPACE includes additional modules that can be implemented if needed. These provide tools for conquering communal challenges that can arise during the treatment process, including dealing with extremely disruptive behaviour of children and improving parental collaboration.
40766857|NCT03602508|DRUG|mirabegron|oral
40766858|NCT03602508|DRUG|solifenacin|oral
40766859|NCT03602508|DRUG|darifenacin|oral
40766860|NCT03602508|DRUG|imidafenacin|oral
41295221|NCT00153634|DRUG|IV amikacin|5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
40766861|NCT03602508|DRUG|tolterodine|oral
40766862|NCT03602508|DRUG|oxybutynin|oral
40766863|NCT03602508|DRUG|trospium|oral
40766864|NCT03602508|DRUG|fesoterodine|oral
40766865|NCT03602508|DRUG|propiverine|oral
40766866|NCT04246086|DRUG|Mosunetuzumab (IV)|Participants will receive IV mosunetuzumab as defined by the study protocol
40766867|NCT04246086|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
40766868|NCT04246086|DRUG|Lenalidomide|Participants will receive oral lenalidomide as defined by the study protocol
40766869|NCT04246086|DRUG|Mosunetuzumab (SC)|Participants will receive SC mosunetuzumab as defined by the study protocol
40965330|NCT02738060|DIETARY_SUPPLEMENT|Baked Milk|"The patients in case group will be received baked milk daily in the form of muffin(30 cc milk (equal to 1/3 of milk's proteins) heated in 350 F or 180 C for 30 mints) for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.~Skin prick test and serum IgE levels will be done at the beginning of the study, at 6 and 12 months. IgG4, being specific for milk allergens, will also measured at the beginning and at 12 months of the study."
40965331|NCT00615511|DIETARY_SUPPLEMENT|placebo pregnenolone|Sugar pill, taken twice a day
41457253|NCT02726841|PROCEDURE|Classic thoracoabdominal aortic repair|Thoracoabdominal aortic dissection (TAAD) repair
41457254|NCT04808362|BIOLOGICAL|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
41457255|NCT02847624|DRUG|tolvaptan|
41457256|NCT05471349|BEHAVIORAL|Flyer and video|Participants will view a flyer and video
40965332|NCT00615511|DIETARY_SUPPLEMENT|pregnenolone|500mg in tablet form taken orally twice a day
40965333|NCT01261910|BEHAVIORAL|Intensive initial education|Participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
41295222|NCT00153634|DRUG|PO azithromycin|250 mg once daily
41295223|NCT00153634|DRUG|IV ceftazidime|50 mg/kg every 8 hours, up to 2 grams every 8 hours
41295224|NCT00153634|DRUG|PO ciprofloxacin|500 mg every 12 hours if weight \<50 kg 750 mg every 12 hours if weight ≥50 kg
41457257|NCT05283954|DRUG|Combination regimen: Fluoxetine, Prednisolone, Ivermectin|"Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days."
41457258|NCT05283954|DRUG|Combination regimen: Albendazole, Vitamin C|"Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days."
41457259|NCT00963495|DRUG|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
40766871|NCT06188741|DRUG|Selumetinib|Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID
40766872|NCT04886856|BEHAVIORAL|Mindful Moms|Twelve 75 minutes weekly group sessions involving gentle yoga practices designed for pregnant women, led by experienced yoga teachers.
40766873|NCT04886856|BEHAVIORAL|Prenatal Education|Twelve 75 minutes weekly group sessions involving prenatal education (for example, what to expect during your pregnancy, during labor and delivery, and after the delivery of your child).
40766874|NCT03100461|OTHER|I2|"A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.)."
40766875|NCT03100461|OTHER|Health Education|Standard of care approach that will provide basic information on CRC screening.
40766876|NCT06413498|DRUG|Anitocabtagene Autoleucel|A single infusion of CAR+ transduced autologous T cells
40965334|NCT02439138|DRUG|GS-1101|Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
41137489|NCT04892251|BEHAVIORAL|MORE|Mindfulness-Oriented Recovery Enhancement
41137490|NCT01240785|DRUG|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
41457260|NCT04965233|BEHAVIORAL|DNA reports|The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.
41457261|NCT04965233|BEHAVIORAL|Information reports|Reports containing general information on eczema
41137491|NCT01240785|DRUG|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
41457262|NCT00352196|DRUG|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
41457263|NCT00352196|OTHER|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
40965335|NCT02801396|DEVICE|Etafilcon A Design 1 (Test 1)|
40965336|NCT02801396|DEVICE|Etafilcon A Design 2 (Test 2)|
40965337|NCT02801396|DEVICE|Etafilcon A (Control)|
41137492|NCT03136861|BIOLOGICAL|AIN457|anti IL-17a monoclonal antibody
40766877|NCT06413498|DRUG|Cyclophosphamide|Administered intravenously
40965338|NCT02794883|BIOLOGICAL|Durvalumab|Given IV
40965339|NCT02794883|OTHER|Laboratory Biomarker Analysis|Correlative Studies
40965340|NCT02794883|PROCEDURE|Surgical Procedure|Undergo surgical tumor resection
41137493|NCT03136861|DRUG|AIN457 Placebo|Placebo matching AIN457
41146815|NCT01912599|DEVICE|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
41146816|NCT02453269|BEHAVIORAL|Transdisciplinary program|
41295225|NCT00153634|DRUG|IV meropenem|40 mg/kg every 8 hours, up to 2 grams every 8 hours
41457264|NCT01100905|OTHER|Iron-containing food product|
41457265|NCT00026416|BIOLOGICAL|recombinant interferon alfa|
41457266|NCT00026416|DRUG|thalidomide|
41457267|NCT00026416|PROCEDURE|adjuvant therapy|
41457268|NCT05496192|DRUG|Nivolumab/rHuPH20|Specified dose on specified days
41457269|NCT05496192|DRUG|Nivolumab|Specified dose on specified days
40766878|NCT06413498|DRUG|Fludarabine|Administered intravenously
40766879|NCT06413498|DRUG|Pomalidomide|Tablet administered orally
40766880|NCT06413498|DRUG|Bortezomib|Administered intravenously or subcutaneously
40766881|NCT06413498|DRUG|Dexamethasone|Tablet administered orally
40766882|NCT06413498|DRUG|Daratumumab|Administered intravenously or subcutaneously
40766883|NCT06413498|DRUG|Carfilzomib|Administered intravenously
40766884|NCT05835323|DEVICE|Robotic-assisted mini-PCNL|Eligible participants will be enrolled to undergo robotic-assisted PCNL using the MONARCH Platform, Urology for the removal of kidney stones. The MONARCH Platform, Urology is a novel flexible robotic device that enables the clinician to obtain both transurethral and percutaneous access to a participant's kidney under continuous visualization for therapeutic application (for example, stone removal).
40766885|NCT06637189|DRUG|Ganirelix|Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).
40766886|NCT06637189|DRUG|Medroxyprogesterone Acetate 10 MG|Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.
40766887|NCT06461507|OTHER|Janda's Approach|For Tightened Structures Stretching applied toIliopsoas and Erector spinal muscles (5 repetitions of stretching with 30-s hold for each muscle). For Strengthening of Weakened Structures; Glute bridge and Abdominal crunch(10 repetitions of each).
40766888|NCT06023264|PROCEDURE|Dry needling|It is a minimally invasive treatment modality. Its effectiveness has been confirmed in numerous studies. It consists of applying an antiseptic in the puncture area and inserting the needle in the required aseptic conditions. During puncture, the patient's physical response is observed at all times, in order to control the local spasmodic responses in each muscle. After applying the technique, we assessed jaw pain, mouth opening, and the appearance of headaches. The adverse effects of the technique are the following: pain after puncture (1.7%), local bleeding at the puncture site (6.1%) and syncopal responses (0.7%).
40766889|NCT05325008|DRUG|Immunosuppression reduction/modification + intravenous immunoglobulin|Participants will receive intravenous immunoglobulin along with immunosuppression reduction/modification.
40766890|NCT05325008|OTHER|Immunosuppression reduction/modification|Participants will receive immunosuppression reduction/modification.
40766891|NCT04931017|PROCEDURE|Biopsy|Undergo biopsy
40766892|NCT04931017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40766893|NCT04931017|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
40766894|NCT04931017|DRUG|Extended Release Metformin Hydrochloride|Given PO
40766895|NCT04931017|OTHER|Questionnaire Administration|Ancillary studies
41146817|NCT05739409|BIOLOGICAL|LILRB4 STAR-T cells injection|The study population was relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia.Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg
40766896|NCT04952753|DRUG|NIS793|Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.
40766897|NCT04952753|DRUG|Bevacizumab|Bevacizumab will be administered IV
40766898|NCT04952753|DRUG|Modified FOLFOX6|5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]
40766899|NCT04952753|DRUG|FOLFIRI|5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]
40766900|NCT04952753|DRUG|Tislelizumab|Investigational drug tislelizumab will be administered intravenously (IV).
40965341|NCT02794883|BIOLOGICAL|Tremelimumab|Given IV
40766910|NCT06554821|DRUG|Rosuvastatin|Participants will receive rosuvastatin (dose 1 or dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2.
40766911|NCT06554821|DRUG|Ticagrelor|Participants in each arm will receive ticagrelor 90 mg orally BID from Day 6 to Day 10.
40766912|NCT05229705|BEHAVIORAL|Resistance exercise|Participants in this exercise group will receive progressive resistance training.
40965342|NCT01007097|DRUG|TAK-875|TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
40965343|NCT01007097|DRUG|TAK-875|TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
40965344|NCT01007097|DRUG|TAK-875|TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
40965345|NCT01007097|DRUG|TAK-875|TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
40965346|NCT01007097|DRUG|TAK-875|TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
40766915|NCT05076175|DRUG|Ozanimod|Specified dose on specified days
40766916|NCT05093621|DRUG|Furosemide|Standard of care diuretic
40766917|NCT05093621|DRUG|Torsemide|Standard of care diuretic
40766918|NCT01534819|DEVICE|EndoAnchor™|Use of the EndoAnchor™ in conjunction with endograft
40766919|NCT01534819|PROCEDURE|endovascular treament|implantation of a device inserted through an artery
40766920|NCT03436849|DRUG|ESN364|ESN364 will be administered orally.
40766921|NCT03436849|DRUG|Placebo|Placebo will be administered orally.
40766922|NCT03724747|DRUG|BAY2315497 Injection|BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
40766923|NCT03724747|DRUG|Darolutamide(BAY1841788)|600 mg (2 X 300 mg tablets), twice daily with food, equivalent to a total daily dose of 1200 mg.
40766924|NCT05287126|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
40766925|NCT06639282|DRUG|Siponimod|Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.
40766926|NCT06639282|DRUG|Placebo|A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
40766927|NCT04144517|DRUG|Nemvaleukin Alfa|Nemvaleukin alfa IV infusion.
40766928|NCT04144517|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
41137494|NCT02916576|DEVICE|Blood-Glucose Monitoring Systems for self-testing|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
41137495|NCT06505993|BEHAVIORAL|Health Communication|Participants will experience a coordinated social marketing campaign including targeted messaging related to vaccine education, self-efficacy, and informative resources to receive the COVID-19 vaccine. The intervention messaging will be strategically layered and disseminated to this intervention arm predominately via Facebook by trusted and local communicators in the study counties.
41146818|NCT03805698|DEVICE|Platelet-rich Plasma (PRP)|The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.
40766929|NCT06293781|DEVICE|Web-based ACT|ACT program delivered online
40766930|NCT06293781|BEHAVIORAL|Treatment as usual|Treatment as usual for major depressive disorder
40766931|NCT06644586|OTHER|videolaryngoscopy|The patients intubated with video laryngoscopy
40766932|NCT06644586|OTHER|Direct Laryngoscopy|The patients intubated with direct laryngoscopy
40766933|NCT05214118|BEHAVIORAL|technology-based program|Participants will be asked to complete three 25-minute modules covering the transition from pregnancy to postpartum, possible neonatal abstinence syndrome (NAS) or neonatal withdrawal syndrome (NOWS), and interactions with child welfare.
40766934|NCT00756509|DRUG|Nilotinib|800 mg/d orally
40766935|NCT06639061|DEVICE|Hippocampal stimulation using repetitive transcranial magnetic stimulation (rTMS)|"We will use fMRI resting state data to personalize a TMS inhibitory stimulation to a cortical location that is the most strongly connected to a deeper left hippocampal target.~5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation."
40766936|NCT06639061|DEVICE|Sham stimulation using repetitive transcranial magnetic stimulation (rTMS)|We will use fMRI resting state data to personalize a TMS sham stimulation to a cortical location with near zero connectivity to a deeper left hippocampal target. 5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.
40766937|NCT06632171|BEHAVIORAL|Cognitive Behavioral Therapy- Based and Motivational Interviewing-Supported Psychoeducation|The aim of this study is to examine the effects of cognitive-behavioral-based and motivational interview-supported psychoeducation on emotional eating and psychological resilience in obese individuals. The study will be conducted in a randomized controlled experimental design. The sample of the study will consist of 102 obese individuals in total, 51 in the experimental group and 51 in the control group, who meet the inclusion criteria. A cognitive-behavioral and motivational interview-supported psychoeducation program will be applied to the experimental group. All patients will be evaluated at three time points: pretest (baseline), posttest (8 weeks), and follow-up test (3 months after the posttest). No intervention will be applied to the control group.
40965347|NCT01007097|DRUG|Glimepiride|TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
40965348|NCT01007097|DRUG|Placebo|TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
40766940|NCT04429919|DRUG|AP-325|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
40766941|NCT04429919|DRUG|Placebo|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
40766942|NCT06644547|BEHAVIORAL|Gezond en goed met elkaar|"The intervention 'Gezond en goed met elkaar' focuses on improving (positive) health literacy and literacy. The six domains of positive health are the focus of the intervention meetings. This intervention has been made available for citizens of Almere, Zwolle, Gouda, Nunspeet and Leusden through collaboration with these municipalities. Lifestyle coaches working in these municipalities implement the intervention."
40766943|NCT06149442|OTHER|Dose of five-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (five incisions).
40766944|NCT06149442|OTHER|Dose of ten-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (ten incisions).
40766945|NCT06149442|OTHER|Dose of fifteen-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (fifteen incisions).
40766946|NCT06501963|BIOLOGICAL|Live Attenuated Influenza Vaccine|The FDA-approved live attenuated seasonal influenza vaccine (LAIV) (FluMist®, AstraZeneca) is licensed in the US for people 2-49 years of age. The approved seasonal LAIV at the time of study enrollment will be obtained from the manufacturer. LAIV will be administered by a study nurse or health care provider at the Hope Clinic as a single 0.2 milliliter (mL) dose given as 0.1 mL spray in each nostril.
40766947|NCT06073119|DRUG|SAR441566|Tablet
40766948|NCT06073119|DRUG|Placebo|Tablet
40766949|NCT06071715|DEVICE|ACTIVE cryoneurolysis|Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium Initial treatment: Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.
40766950|NCT06071715|DEVICE|SHAM cryoneurolysis|SHAM cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.
40766951|NCT06333561|PROCEDURE|Hepatic arterial infusion chemotherapy|Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
40766952|NCT06333561|DRUG|Lenvatinib|12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
40766953|NCT06333561|DRUG|Tislelizumab|200mg intravenously every 3 weeks
40766954|NCT06333561|DRUG|Toripalimab|240mg intravenously every 3 weeks
40766955|NCT06333561|DRUG|Sintilimab|200mg intravenously every 3 weeks
40766956|NCT06333561|DRUG|Camrelizumab|200mg intravenously every 3 weeks
40766957|NCT06082843|DRUG|Placebo|Placebo matching Avenciguat (BI 685509)
40766958|NCT06082843|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
40766959|NCT06643780|DRUG|Denosumab|60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
40766960|NCT06643780|DRUG|Zolendronic Acid|5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
41295226|NCT00153634|DRUG|IV piperacillin-tazobactam|100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
40766961|NCT05916937|DRUG|omalizumab 300 mg every four weeks|"Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
40766962|NCT05916937|DRUG|omalizumab 300 mg every six weeks|"Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
40766963|NCT04233021|DRUG|Osimertinib|Osimertinib 80 mg/d
40766964|NCT05025865|DRUG|Sodium Hyaluronate|Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.
40766965|NCT05025865|DRUG|Placebo|A placebo will be given in capsule form to study participants.
40766966|NCT06067139|OTHER|SHUTi|"Each core includes a variety of interactive features, such as animations, vignettes, myth and reality buttons that reveal common misperceptions and facts about sleep, learn more buttons that provide in-depth information about a topic, and quizzes. All cores follow a similar structure with objectives, main content, homework, and review. Participants are free to revisit cores as many times as they like."
41146819|NCT03805698|OTHER|Standard Arthroscopic Debridement|Standard arthroscopic debridement. No PRP injection.
41146820|NCT01718223|DRUG|photodynamic therapy|Undergo interstitial photodynamic therapy using temoporfin
41295227|NCT00153634|DRUG|IV ticarcillin-clavulanate|100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
40766967|NCT06067139|OTHER|Patient Education|The PE website will present content in a simple, static form, without interactive components; and all content on the website will be provided at once, rather than in modules that unlock over time. The PE website will also not provide personalized or individually tailored treatment recommendations.
40766968|NCT03439449|DEVICE|CLEOS software program|Computer-assisted history taking program
40766969|NCT03439449|PROCEDURE|Physician taken history|Conventional history taking by physicians
40766970|NCT05175105|DRUG|Mitapivat|Tablets or granules
40766971|NCT05175105|DRUG|Mitapivat-matching placebo|Tablets or granules
40766972|NCT05652868|DRUG|MYTX-011|MYTX-011 will be administered as an intravenous infusion every 21 days.
40965349|NCT05341193|DRUG|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
40965350|NCT05341193|DRUG|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
40965351|NCT00791856|DRUG|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
40965352|NCT00791856|DRUG|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
40965353|NCT01602159|PROCEDURE|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
40965354|NCT01602159|PROCEDURE|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
40965355|NCT04051073|DEVICE|Continuous non-invasive blood pressure monitoring|Continuous non-invasive blood pressure monitoring using CNAP
40965356|NCT02050191|BEHAVIORAL|www.princetonlivingwell.com|
40965357|NCT05074667|DEVICE|Continuous Glucose Monitor|Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care
40965358|NCT05074667|OTHER|Patient Reported Outcome Questionnaires|Participants and their parents will be asked to complete patient reported outcome questionnaires at 3 study time points.
40766973|NCT03466151|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
41137496|NCT06505993|BEHAVIORAL|Health Communication + Structural|This multi-level intervention will include the defined health messaging intervention components, as well as a combination of structural-level intervention strategies targeted to better facilitate access to community-based vaccination delivery. Health organizations will receive a toolkit, which will include community-specific resources and training modules such as: up to date evidence-based vaccination guidance that can be delivered to patients; strategies for navigating conversations with patients about vaccination; any applicable reimbursement, insurance, or qualifying enrollment information specific to the healthcare organization; identifying locations that facilitate access for the community members; provided advertising to promote the locations and timing of the vaccinations; and generating community-based branding for all vaccination delivery based on the trusted information sources identified.
41137497|NCT03696056|BEHAVIORAL|Kirtan Kriya meditation|The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.
41137498|NCT03696056|BEHAVIORAL|Music listening program|"The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log."
41137499|NCT01187888|DRUG|Rasagiline|tablet once daily 1 mg 1 year
41137500|NCT01187888|DRUG|Sugar pill|tablet once daily one year
41137501|NCT00074425|DRUG|BufferGel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
41457270|NCT05207605|OTHER|Rhythmic Stabilization (RS)|Group A includes rhythmic stabilization technique. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively. The total duration of RS will be of approximately 33 minutes
40766974|NCT03466151|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
40766975|NCT05524012|DIAGNOSTIC_TEST|Blood sample|longitudinal blood samples for CTC monitoring
40766976|NCT05524012|DEVICE|MRI scan|longitudinal MRI scans (non-contrast enhanced)
40766977|NCT04501120|DRUG|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
40766978|NCT04501120|DRUG|Reduced-dose HHT|1mg IV QD on Days 1-14 (28-day cycle).
40766979|NCT04501120|DRUG|standard-dose HHT|2mg/m\^2 IV QD on Days 1-7 (28-day cycle).
40766980|NCT04501120|DRUG|Azacitidine|75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
40766981|NCT04501120|DRUG|APG-2575|APG-2575 orally once daily for 14 days, every 28 days as a cycle.
41295228|NCT00153634|DRUG|IV tobramycin|2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
41295229|NCT01997567|DRUG|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
41295230|NCT01997567|DRUG|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
41295231|NCT01544595|DRUG|Secukinumab (AIN457)|"Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions."
41295232|NCT01544595|DRUG|Placebo|Placebo
40766982|NCT05479370|BIOLOGICAL|Flublok Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
40766983|NCT05479370|BIOLOGICAL|Fluarix Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
40766984|NCT05479370|BIOLOGICAL|Flucelvax Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
40965359|NCT06341842|DRUG|Dapagliflozin 10mg Tab|Dapaglifloziin 10 mg 1 tab daily
40965360|NCT01072331|DRUG|MP-513|MP-513 10 mg, once a day, for 4 weeks
40965361|NCT01072331|DRUG|MP-513|MP-513 20 mg, once a day, for 4 weeks
40965362|NCT01072331|DRUG|Placebo of MP-513|MP-513 placebo, once a day, for 4 weeks
40965363|NCT02325037|DRUG|GLPG1837 single ascending doses|Single dose, oral suspension
40965364|NCT02325037|DRUG|Placebo single dose|Single dose, oral suspension matching placebo
41137502|NCT00074425|DRUG|PRO 2000/5 Gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
41137503|NCT00074425|DRUG|Placebo gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
41137504|NCT05850624|OTHER|ice massage|active phase when cervical dilatation was 6-8 cm. Ice will apply to the huko point (LI4 area) which is located on the dorsum of the hand, between the first and second metacarpal bones, between the thumb and the index finger for 20 minutes with an ice pack
41137505|NCT05850624|OTHER|virtual reality animation|cervical dilatation was 6-8 cm. Immediately after the second VAS application, the women will be asked about the video they wanted to watch of the sound of waves in the Ocean, rain falling or blooming trees with virtual reality glass. animation will show for a total of 20 min.
41137506|NCT02426931|DEVICE|the tip-flexible ureterorenoscope|Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.
41137507|NCT02426931|DEVICE|the classic flexible ureteroscope|Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
40965365|NCT02325037|DRUG|GLPG1837 multiple ascending doses|Multiple doses, daily for 14 days, oral suspension
40965366|NCT02325037|DRUG|Placebo multiple doses|Multiple doses, daily for 14 days, oral suspension, matching placebo
40965367|NCT04778930|OTHER|Physical Therapy|"FACE-TO FACE SESSIONS: approximately 90 minutes of Goal-directed training (activities for the activation of the muscles of the trunk, pelvis and lower limbs; and training of activities will be carried out in a functional and meaningful context, aimed at specific functional objectives, according to the interests of each participant and agreed with the participants and their families) and gait training on the treadmill for 20 minutes.~TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation."
41137508|NCT01544894|DRUG|Raloxifene|60 mg/d for one year
41137509|NCT01544894|DRUG|Strontium ranelate|2 g/d, for one year
41137510|NCT03146845|DEVICE|ALLEVYN Life Non-Bordered|Foam Dressing
41137511|NCT03146845|DEVICE|Standard Care|Foam Dressing
41137512|NCT05371821|DEVICE|Echocardiography|Echocardiographic parameters in obese and overweight
41137513|NCT00281905|DRUG|carboplatin|
41137514|NCT00281905|DRUG|cisplatin|
41137515|NCT00281905|DRUG|cyclophosphamide|
40965368|NCT04778930|OTHER|THERAPEUTIC EDUCATION PROGRAM|TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation.
40965369|NCT01730469|DRUG|AT1001 150 mg|AT1001 150mg is available as a capsule
40965370|NCT02851095|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
40965371|NCT02851095|DRUG|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
41137516|NCT00281905|DRUG|methotrexate|
41137517|NCT00281905|DRUG|vincristine sulfate|
41137518|NCT00281905|RADIATION|radiation therapy|
41137519|NCT00982527|DRUG|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
41137520|NCT00982527|DRUG|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
41137521|NCT01567007|BEHAVIORAL|individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
41137522|NCT01567007|BEHAVIORAL|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
41137523|NCT01567007|BEHAVIORAL|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
41137524|NCT00978718|DIETARY_SUPPLEMENT|high-selenium baker's yeast|Given orally
41137525|NCT00978718|DIETARY_SUPPLEMENT|selenium|Given orally
41137526|NCT00978718|OTHER|placebo|Given orally
41146821|NCT01718223|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
41146822|NCT01718223|OTHER|laboratory biomarker analysis|Correlative studies
41146823|NCT01718223|DRUG|temoporfin|Undergo interstitial photodynamic therapy using temoporfin
41146824|NCT00551954|DRUG|acarbose|100 mg (tablets) t.i.d.
41146825|NCT00551954|DRUG|placebo|one tablet t.i.d.
40965372|NCT02851095|DRUG|Metformin Extended Release (XR)|Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
40965373|NCT01190345|DRUG|bevacizumab|Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
40965374|NCT01190345|DRUG|no bevacizumab|no bevacizumab
40965375|NCT06208683|BIOLOGICAL|Mumps vaccine, Live (MV)|0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus
41295233|NCT06400602|BEHAVIORAL|Usual ED Care plus Health Coaching|Patients will participate in eight remotely-delivered sessions of health coaching after ED discharge. Patients will receive usual care during their ED visit.
40965376|NCT06208683|BIOLOGICAL|Influenza Vaccine, inactivated, quadrivlent(QIV)|0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.
40965377|NCT00163839|BEHAVIORAL|Dietary Therapy|
40965378|NCT05365178|DRUG|TQB3616 capsule|TQB3616 capsule is a CDK (cyclin-dependent kinases) 4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase
40965379|NCT05365178|DRUG|Placebo|It is a placebo
40965380|NCT05365178|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
40965381|NCT04540029|OTHER|Maternal stress|Prenatal COVID-19-related stress retrospectively self-reported by mothers after delivery.
40965382|NCT01848860|PROCEDURE|Thoracoscopic bullectomy and pleural abrasion|Thoracoscopic bullectomy and pleural abrasion will be performed in a standard fashion under general anesthesia using intubated one-lung ventilation. When blebs are identified, they will be grasped with the ring forceps and excised with an endoscopic stapler. Blind apical stapling was done at the most suspicious area if no bleb could be identified. Thoracoscopic pleural abrasion will be performed at the parietal pleura above the 5th intercostal space by inserting the dissector with a strip of diathermy scratch pad through the port sites in all patients.
40965383|NCT01848860|BIOLOGICAL|Mesh coverage of the staple line|Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
40965384|NCT02221791|DIETARY_SUPPLEMENT|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
40965385|NCT02221791|DIETARY_SUPPLEMENT|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
40965386|NCT02221791|DIETARY_SUPPLEMENT|Placebo|Participants will consume 70g white chocolate + placebo capsules
41295234|NCT06400602|BEHAVIORAL|Usual ED Care plus Education|Patients will participate in eight remotely-delivered sessions of education after ED discharge. Patients will receive usual care during their ED visit.
41295235|NCT03077945|BEHAVIORAL|heart rate variability biofeedback and cognitive reappraisal|
40766985|NCT04952571|DRUG|Camrelizumab and Bevacizumab|"Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total.~Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion."
40965387|NCT00000489|PROCEDURE|coronary artery bypass|
40965388|NCT05963594|DIETARY_SUPPLEMENT|Oligomalt|The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
40965389|NCT05963594|DIETARY_SUPPLEMENT|maltodextrin|The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
40965390|NCT04427566|RADIATION|Radiation therapy|Patients will be treated with a single dose of 80 cGy to the bilateral lungs in a manner that is simplified such that it can be designed and delivered quickly in one session. No specific normal tissue constraints are employed in this protocol.
40965391|NCT02804932|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g/day) for 8 weeks
41295236|NCT03077945|BEHAVIORAL|control tasks|
41295237|NCT06307080|DEVICE|Multi-mode thermal ablation device|The tumor tissue was rapidly frozen until the ice ball exceeded 5mm of the lesion tissue, kept for 5 minutes, then thawed and warmed. Then, complete ablation was performed according to the radiofrequency temperature control mode of multimodal tumor therapy to ensure that the ablation area included a safe range of 5\~10mm around the tumor.
40965392|NCT02804932|OTHER|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 8 weeks
40965393|NCT03708016|DEVICE|Robot gait training|Lokomat robot training was applied to stroke patients.
40965394|NCT03708016|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
40965395|NCT00755092|BEHAVIORAL|Doula|Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
40965396|NCT00755092|BEHAVIORAL|Doula|Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
40965397|NCT06504641|OTHER|Isla for Frailty|"Isla for Frailty - video-based patient records. Isla is a technology company providing a visual patient record platform. The platform allows anyone involved in a patient's care to capture and review visual data (photographs, videos) relating to a patient's health. The platform is web-based (a progressive web application) and supports secure capture of visual data with encrypted storage in the cloud.~Isla interfaces with Electronic Health Record (EHR) systems including Cerner, enabling health professionals to view data held on Isla's servers from within the electronic patient record, via the 'Cerner Red Button'. Health professionals can also view a patient's visual record through a secure weblink requiring an NHS email address and password."
41295238|NCT06307080|DRUG|Intravenous anti-PD-1 and chemotherapy|intravenous anti-PD-1 and chemotherapy
41295239|NCT00830830|DRUG|Hyalgan (sodium hyaluronate)|
41295240|NCT03025191|BEHAVIORAL|Speaker/Listener technique|Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
40965398|NCT04959916|BEHAVIORAL|Group Metacognitive Therapy|Group Meta-Cognitive Therapy (Group-MCT) will consist of six weekly sessions delivered by two trained trainee clinical psychologists over 1-1.5 hours. The aims of the intervention are to help participants develop knowledge that can facilitate control of worry, rumination and attention, and to modify the metacognitive beliefs that maintain these unhelpful patterns of thinking. The treatment follows a manual that has been previously evaluated in the treatment of cardiac patients suffering from anxiety and depression. Sessions include group discussions, experiential learning and homework tasks that participants will be expected to complete between sessions.
40965399|NCT03675477|DRUG|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).
40965400|NCT03675477|DRUG|Placebo|Placebo Oral Tablet
40965401|NCT00224042|DRUG|Sodium Ferric Gluconate complex in sucrose|Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
40965402|NCT00224042|DRUG|Ferrous sulfate tablets|ferrous sulfate 325 mg three times daily for 6 weeks
40990652|NCT04637542|OTHER|Mobile Learning|"The necessary interviews and correspondences were carried out in order to conduct the research. Permission was obtained from Health Sciences University Istanbul Training and Research Hospital Clinical Research Ethics Committee. The purpose of the study was explained to the students as per the sample criteria and their consents were obtained. All of the students participating in the study attended four hours of theoretical lessons in the classroom related to anatomy of the genital system. Following the theoretical training, students were divided into experiment (mobile application) and control (genital organ model) groups. Both groups where then given the Structured Student Presentation Form, Status and trait anxiety inventory and Knowledge Examination (pre-test) on paper.~The didactic content prepared for the institution's standard curriculum (control group) or mobile learning is similar for both training methods."
40990653|NCT06496776|PROCEDURE|Choukroun's technique|Suturing will be done using the method described by Choukroun.
40990654|NCT00979888|OTHER|educational intervention|
40990655|NCT00979888|OTHER|informational intervention|
40990656|NCT00979888|OTHER|psychosocial support for caregiver|
40990657|NCT00979888|OTHER|questionnaire administration|
40990658|NCT00979888|PROCEDURE|dyspnea management|
40990659|NCT00979888|PROCEDURE|management of therapy complications|
41457271|NCT05207605|OTHER|McKenzie technique|McKenzie technique will be guided to conduct four extension exercises and three flexion exercisesAll flexion exercises will be repeated for ten repetitions for two sets. There are three minutes for resting intervals in every set. The McKenzie treatment will lasted for 20-40 minutes.
40990660|NCT03948256|PROCEDURE|Control intervention|Prompt closure of EVD with subsequent observation period
40990661|NCT03948256|PROCEDURE|Experimental intervention|Gradual weaning of EVD with 5 cmH2O increase in drainage resistance daily until complete closure with subsequent observation period
40990662|NCT05195723|DRUG|WP1122|Oral solution
40990663|NCT05195723|DRUG|Placebo|Oral solution
40990664|NCT04390594|DRUG|Nafamostat Mesilate|"Nafamostat mesilate continuous intravenous injection. Daily dose ranging between 0.1 mg/kg/h and 0.2 mg/kg/h, based on the severity and underlying disease of the clinical trial participant.~Administration for 10-14 days based on the severity and underlying disease of the clinical trial participant"
40990665|NCT03837873|DRUG|Rituximab|rituximab 750mg/m2 i.v. on day 0
41146826|NCT01094600|DRUG|Synthetic Human Secretin|Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
41457272|NCT05778890|OTHER|Intervention Group: Physiotherapy program + home exercises program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. In addition to the treatment for control group, intervention group received home exercises program.The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form.
40990666|NCT03837873|DRUG|Etoposide|50mg/m2, continuous i.v. on day 1-4
40990667|NCT03837873|DRUG|Vincristine|0.4mg/m2, continuous i.v. on day 1-4
40990668|NCT03837873|DRUG|Doxorubicin|10mg/m2, continuous i.v. on day 1-4
40990669|NCT03837873|DRUG|Dexamethasone|30mg/day, i.v. on day 1-5 for R-DA-EDOCH regimen; 40mg/day, i.v. on day 1-4 for R(2)-DHAP regimen
40990670|NCT03837873|DRUG|Cyclophosphamide|750mg/m2, i.v. on day5
40990671|NCT03837873|DRUG|Lenalidomide|25mg/day, p.o. on day 0-9
40990672|NCT03837873|DRUG|Cisplatin|100mg/m2 continuous i.v. on day 1
40990673|NCT03837873|DRUG|Cytarabine|2g/m2 q12h, i.v. on day 2
40990674|NCT03018561|OTHER|Exercise and Cognitive testing|Maximal cardiopulmonary test Rest cognitive testing
40990675|NCT03370003|OTHER|Standard medical care|All children will receive nutritional treatment and standard medical care in accordance with the nutritional guidelines of the national protocol, with the exception of the routine distribution of antibiotics.
40990676|NCT02589782|DRUG|Bedaquiline|
40990677|NCT02589782|DRUG|Pretomanid|
40990678|NCT02589782|DRUG|Moxifloxacin|
40990679|NCT02589782|DRUG|Linezolid|
41146827|NCT04153357|DEVICE|airtraq|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
40990680|NCT02589782|DRUG|Clofazimine|
40990681|NCT02589782|DRUG|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
40990682|NCT00003463|DRUG|carmustine|
40990683|NCT00003463|DRUG|irinotecan hydrochloride|
40990684|NCT00003463|DRUG|polifeprosan 20 with carmustine implant|
40990685|NCT00003463|PROCEDURE|surgical procedure|
40990686|NCT05829720|DIETARY_SUPPLEMENT|a2 Full Cream Milk|Mothers in this arm will drink a2 Full Cream Milk twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
40766986|NCT05050279|DRUG|Delgocitinib capsule|oral capsule
40766987|NCT05050279|DRUG|Placebo capsule|oral capsule
40766988|NCT05960604|DIAGNOSTIC_TEST|Passive leg raising|"All patients who met the inclusion criteria will be placed head down flat and feet up at a 45° angle for 30 seconds.~Hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected before, during and after the test until the end of the surgery.~The total duration of the intervention (passive leg raising) is 30 seconds. The total duration of hemodynamic parameters recording is expected to be 60-600 minutes."
40766989|NCT05564052|DRUG|Ibrutinib|Ibrutinib capsules will be administered orally.
40766990|NCT05564052|DRUG|Lenalidomide|Lenalidomide capsules will be administered orally.
40766991|NCT05564052|DRUG|Rituximab|Rituximab will be administered IV.
40766992|NCT05564052|DRUG|Bortezomib|Bortezomib will be administered either intravenously or subcutaneously.
40766993|NCT06434350|DRUG|Enfortumab Vedotin|Given by IV
40766994|NCT06434350|RADIATION|Radiation Therapy|Given by Radiation Therapy
40766995|NCT04227379|BEHAVIORAL|Intervention 1- DD-TXT|Participants in this group were signed up for an interactive, tailored self-management texting protocol (DD-TXT). The DD-TXT protocol consisted of the same daily educational content as the DSE arm augmented by the following: regular two-way check-in messages about diabetes self-management behaviors, an invitation to receive messages written by other Veterans living with diabetes on demand, and a menu of optional and customizable modules (e.g., medication reminders, blood sugar and blood pressure monitoring,: physical activity reminders, weight management, and goal setting) from which participants could select messaging that supported their diabetes self-management goals. Patients could customize the timing and frequency of their messages. DD-TXT participants also received a once monthly message asking whether the messages had been helpful.
40965403|NCT05201703|DRUG|Fycompa|Fycompa 4 mg daily
40965404|NCT05201703|DRUG|Fycompa with a boost|Fycompa 4 mg daily with a boost to 6 mg daily a week before the start of your menstruation cycle until Day 4 of your cycle.
41137527|NCT03604809|OTHER|OT Guided Cognitive Interventions|"RASS is defined as the level of sedation and agitation of a patient. Cognitive interventions are evidence based strategies that enhance the cognition of patients and include memory training using visual imagery; metacognitive training using self-awareness and self-regulation approaches for recovery of executive functioning; and neuropsychological rehabilitation to help improve cognitive and functional deficits. Interventions will be adjusted according to the RASS score. Cognitive interventions include discussion of patient status and education of family around reorientation, cognitive screening and graded exercises according to patient ability. The deepest levels of sedation and highest levels of agitation will be included in the intervention arm.~Interventions will be provided by the Occupational Therapist; Monday to Friday, BID, 20 minutes per session, for the duration of ICU admission."
41137528|NCT05647538|PROCEDURE|Bilateral uterine artery ligation|Bilateral UAL was done 2 cm under the Kerr incision (lower segment transverse). A 2-Vicryl absorbable suture (Ethicon, Neuilly-surSeine, France) was introduced from the anterior to posterior views of the myometrium 2-3 cm medial to the descending part of the uterine vessels within an avascular area in the broad ligament and tied. Following the surgery, the uterine tone and hemorrhage were managed.
41137529|NCT04139486|PROCEDURE|combined EMBOTRAP II or III and Contact Aspiration|refer to title
41137530|NCT04139486|PROCEDURE|Contact Aspiration alone|refer to title
41137531|NCT01181115|DRUG|Avonex|Interferon treatment for MS
41295241|NCT03025191|BEHAVIORAL|Social Support|Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
41295242|NCT03025191|BEHAVIORAL|Problem-Solving|Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
41295243|NCT03025191|BEHAVIORAL|Goal Setting|Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
40766996|NCT04227379|BEHAVIORAL|Comparison - DSE|"Participants in the comparison condition were signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE was comprised of 6 months of once daily one-way text messages covering standard diabetes self-management education content. Starting with the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, created in alignment with VA/DoD diabetes guidelines, we enhanced the educational content by incorporating Veteran input through a co-design process with Veterans living with diabetes and expert clinician review. DSE messages could not be customized. There was no interactive content for the DSE arm other than a once monthly message asking whether the messages had been helpful."
40766997|NCT04344795|DRUG|TPST-1495 twice daily|TPST-1495 administered orally twice daily
40766998|NCT04344795|DRUG|TPST-1495 once daily or on intermittent schedule|TPST-1495 administered orally once daily or on intermittent schedule
40766999|NCT04344795|DRUG|Pembrolizumab|Pembrolizumab dosed per label recommendations
40767000|NCT05975450|DRUG|Abatacept 125Mg/Ml Syringe|"Participants on qualifying belatacept regimen (with low dose tacrolimus, mmf and prednisone) will have their maintenance regimen changed from i.v. belatacept to s.c. abatacept, which will continue through week 52 (month 12) post-transplant:~Costimulation blockade:~- Abatacept 125 mg subcutaneous weekly"
40767001|NCT06641167|PROCEDURE|Shoulder surgery|shoulder surgery by arthroscopic approach under locoregional anesthesia combining an interscalene block and a superficial cervical plexus block
40767002|NCT05705258|DRUG|Aflibercept (Eylea, BAY86-5321)|Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist
40767003|NCT04108156|DRUG|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
40965405|NCT05939440|OTHER|Proactive Cost of Care (P-COC) intervention|As in Arm description
40965406|NCT05939440|OTHER|Usual Care|As in Arm description
41137532|NCT00546156|DRUG|Doxorubicin|Standard chemotherapy regimen
40767004|NCT04108156|DRUG|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
40767005|NCT04108156|DRUG|Ranibizumab refill exchange|Will be administered as per the schedule described in individual arm.
40767006|NCT03471845|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
40767007|NCT05882058|DRUG|BI 764532, formulation 1|BI 764532, formulation 1
40767008|NCT05882058|DRUG|BI 764532, formulation 2|BI 764532, formulation 2
40767009|NCT05712395|BEHAVIORAL|Exercise|Non-Ischemic Exercise (NICE), pain-free exercise program will be compared to the Standard painful exercise program.
40767010|NCT04375826|DEVICE|Epidural patient controlled analgesia|The device is connected to the epidural catheter prior to surgery and drug administration is started during surgery. The continuous infusion rate is 4 ml / hr. When the button is pressed, 2 ml is additionally administered and the lock time is 20 minutes.
40767011|NCT04375826|DEVICE|Preperitoneal analgesia and IV-PCA|During surgery, the preperitoneal analgesia catheters are inserted into the preperitoneal space and these catheters are connected to the pump with ropivacaine.
40767012|NCT05853458|DRUG|Hydroxyurea|Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment
40767013|NCT06643910|BIOLOGICAL|Single drug group A|9x10\^10 BST08 cells, Intravenous infusion，3 subject is planned to be enrolled
40767014|NCT06643910|BIOLOGICAL|Combined treatment group B|9x10\^10 BST08 cells+ Pembrolizumab Injection，200mg，Q3W, Intravenous infusion，6subject is planned to be enrolled
40767015|NCT06641180|BIOLOGICAL|High-Dose trivalent influenza vaccine (Split virion, Inactivated)|Liquid suspension for intramuscular injection
40767016|NCT06641180|BIOLOGICAL|Standard-dose trivalent influenza vaccine (Split virion, Inactivated)|Liquid suspension for intramuscular injection
40767017|NCT03053141|DEVICE|Rhythmia Mapping System|The Rhythmia Mapping System is a 3D electro-anatomical mapping system.
40965407|NCT05769439|OTHER|No intervention in an observational study|This study is an observational study only.
40965408|NCT03003390|DRUG|Enoxaparin|The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given \<24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
40965409|NCT03921671|COMBINATION_PRODUCT|Ramucirumab|Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.
41295244|NCT01892527|DRUG|Tivantinib (ARQ197)|Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.
41295245|NCT00008164|PROCEDURE|umbilical cord blood transplantation|
41295246|NCT05283538|DIAGNOSTIC_TEST|Coronary Artery Calcification Realization|Coronary Artery Calcification Realization
40767020|NCT05870124|DEVICE|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
40767021|NCT05870124|OTHER|Conventional Medical Management|Conventional Medical Management is the best standard of care treatment for the patient
40767022|NCT06644105|DRUG|cefditoren pivoxil tablets|took cefditoren pivoxil tablets 200mg after
40767023|NCT06449222|DRUG|BNT327 Dose Level 1 (DL1)|Intravenous (IV) infusion
40767024|NCT06449222|DRUG|BNT327 Dose Level 1 (DL2)|IV infusion
40767025|NCT06449222|DRUG|Taxane A|IV infusion
40767026|NCT06449222|DRUG|Alkylating agent|IV infusion
40767027|NCT06449222|DRUG|Antimetabolite|IV infusion
40767028|NCT06449222|DRUG|Taxane B|IV infusion
40767029|NCT06643637|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
40767030|NCT06643637|DRUG|Placebo|Capsule with no active ingredients
40965410|NCT06505876|BEHAVIORAL|Basic treatment|including anti-infection therapy, blood pressure and blood glucose control
40965411|NCT06505876|DEVICE|Oral Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
40767033|NCT04965064|DRUG|Capecitabine and Neratinib.|Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
40767034|NCT06284122|DRUG|Mosunetuzumab|5 mg (step-up dosing) Day 1 of C1 45 mg Day 8 and Day 15 of C1, 45 mg Day 1 from C2 to C12, 45 mg Day 1 from C13 to C21
40767035|NCT06284122|DRUG|Lenalidomide|20 mg/day Day 1 to Day 21 from C2 to C12
40767036|NCT06284122|DRUG|Rituximab|when associated to CHOP IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C20
40767037|NCT06284122|DRUG|Obinutuzumab|when associated to CHOP 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C18
40767038|NCT06284122|DRUG|Cyclophosphamide|750 mg/m2 Day 1 from C1 to C6
40767039|NCT06284122|DRUG|Doxorubicin|50 mg/m2 Day 1 from C1 to C6
40767040|NCT06284122|DRUG|Vincristin|1.4 mg/m2 (cap cf. below)$ Day 1 from C1 to C6
40767041|NCT06284122|DRUG|Prednisone|100 mg/day Day 1 to Day 5 from C1 to C6
40767042|NCT06284122|DRUG|Rituximab|when associated to bendamustin IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C18
40767043|NCT06284122|DRUG|Obinutuzumab|when associated to bendamustin 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C20
40767044|NCT06284122|DRUG|Bendamustin|90 mg/m2 Day 1 and Day 2 from C1 to C6
41137533|NCT00546156|DRUG|Cyclophosphamide|Standard chemotherapy regimen
41137534|NCT00546156|DRUG|Paclitaxel|Standard chemotherapy regimen
40965412|NCT06505876|DEVICE|Nasogastric Tube Feeding|The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
41457273|NCT05778890|OTHER|Control Group : Physiotherapy program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
40965413|NCT01412515|DRUG|everolimus|everolimus per os 10mg per day
40965414|NCT05863832|DRUG|Ciprodiazole|Ciprofolxacin 500 mg / Metronidazole 500 mg
41457274|NCT03624751|RADIATION|radioiodine|Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
40965415|NCT05863832|DRUG|Ciprofloxacin Tablets & Metronidazole tablets|Ciprofolxacin 500 mg + Metronidazole 500 mg
40965416|NCT06081205|OTHER|Admission in the Cardiac Intensive Care Unit (CICU)|all patients admitted in the CICU will be enrolled in the study provided they give their informed consent.
40767045|NCT06455033|OTHER|Manual Diaphragm Release Technique|The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. During exhalation, the therapist deepens their contact towards the inner costal margin while maintaining resistance. As the respiratory cycles continues, the therapist progressively increases the depth of their contact within the costal margin.
40965417|NCT03506282|OTHER|Running while listening to a traffic audio track|While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be exposed via earphones to an audio track resembling average outdoor conditions (70 dB).
40965418|NCT03506282|OTHER|Running with music at moderate volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate volume (80 dB)."
40965419|NCT03506282|OTHER|Running with music at moderate-to-high volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate-to-high volume (85 dB)."
40965420|NCT03280498|PROCEDURE|Intubation|elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
40965421|NCT02438332|DEVICE|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
41137535|NCT00546156|DRUG|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
41457275|NCT01093833|DEVICE|BD Continuous glucose monitor (BD CGM)|Continuous glucose monitoring for 12-14 hours
41457276|NCT01093833|DEVICE|YSI Glucose Analyzer|Continuous glucose monitoring for 12-14 hours
40965422|NCT02438332|DEVICE|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
40965423|NCT02438332|DEVICE|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
40965424|NCT02438332|DEVICE|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
41137536|NCT04272385|OTHER|Observational|Observational
41137537|NCT01823406|PROCEDURE|Euglycemic clamp (normal blood sugar clamp) for 4 hours|
41137538|NCT01823406|PROCEDURE|hyperglycemic clamp (elevated blood sugar to 300) for 4 hours|
41137539|NCT03806205|OTHER|regular follow-up|we give a regular follow-up and supervision on the study group
41137540|NCT06041932|DRUG|Carvedilol|Carvedilol
41137541|NCT06041932|DRUG|Pentoxifylline|Pentoxiphylline
41146828|NCT04153357|DEVICE|c-mac|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
41146829|NCT03805789|BIOLOGICAL|Alpha-1 antitrypsin (AAT)|Alpha-1 antitrypsin is a lyophilized product for intravenous administration.
41457277|NCT01093833|DEVICE|Medtronic Guardian CGM|Continuous glucose monitoring for 12-14 hours
41457278|NCT04097041|PROCEDURE|Tympanomastoidectomy|Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).
41457279|NCT04097041|PROCEDURE|Non-Surgery|"Screening performed at outpatient clinic after consultation for management of venous pulsatile tinnitus. Consent and formal recruitment into study performed at preoperative visit or at audiological visit.~The masking device is a hearing aid that provides sound that is aimed to negate the internal sound from the pulsatile tinnitus. Almost all hearing aid can be converted to a masking device for tinnitus. It is externally worn on the ear and provides sound at a desired volume. The benefits of wearing the masking device are that it may reduce the volume of the pulsatile tinnitus. As it is worn on the external ear and is not invasive there are minimal risks but potential risks could include irritation of the external ear and discomfort from wearing."
41457280|NCT00127166|DRUG|Montelukast sodium|Montelukast 5 mg chewable tablet once daily
41457281|NCT00127166|DRUG|Salmeterol xinafoate|Salmeterol 50 mcg dry powder per actuation inhaled twice daily
41457282|NCT00127166|DRUG|Fluticasone propionate|Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
41457283|NCT00127166|DRUG|Montelukast matching placebo|Matching placebo to montelukast oral tablet administered once daily.
41457284|NCT00127166|DRUG|Salmeterol matching placebo|Matching placebo to salmeterol dry powder for inhalation administered twice daily
40767046|NCT06455033|OTHER|Breathing Exercise|"Sit up straight in a chair lengthen the distance between your navel and sternum. Keep your shoulders relax.~Keep the pelvis in neutral position (Sit on your sitting bones). Place your hands at either side of your lower ribs. Breath in slowly through your nose. As you inhale feel your ribs expanding outwards and upwards. During inhalation is generated expansion of the trunk in three directions front , sides and back.~Breath out from your nose. As you exhale feel your lower ribs moving inwards."
40767047|NCT06641076|DRUG|Sonelokimab|Randomized treatment, parallel-group
40767048|NCT06641076|DRUG|Placebo|Randomized treatment, parallel-group
40767049|NCT05715320|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
40767050|NCT05022719|DEVICE|PillCam Colon2 procedure with MB-MMX|Subjects will undergo a bowel preparation (single dose, 4L PEG), including 200 mg Methylthioninium chloride, corresponding to eight 25 mg MB-MMX tablets and 1 tab of Resolor (Prucalopride 1mg). An experienced Gastroenterologist will read the CCE procedure and complete a subjective questionnaire, to evaluate mucosal enhancement during a CCE procedure, when using MB-MMX as a contrast-enhancement technique.
41137542|NCT04338178|BEHAVIORAL|Cognitive Remediation Therapy (CRT)|This intervention consists of mental exercises aimed at improving executive function via practice. Simple cognitive tasks that encourage reflective learning and insight into patient's own thinking process are administered. Exercises target set-shifting (i.e., cognitive flexibility), estimating, organization and planning.
41137543|NCT04338178|BEHAVIORAL|Emotional Skills Training (EST)|EST places emphasis on the improvement of inner emotion awareness, facial and body expression recognition and intra- and interpersonal emotion regulation skills. Different modules and interactive exercises are designed to help patients learn about i) the functions and manifestations of emotions, ii) the identification and labelling of own's and others' emotions, iii) tolerating and communicating emotions, and iiii) balancing between negative and positive emotions.
41137544|NCT04338178|BEHAVIORAL|Cognitive Behavioral Therapy|CBT intervention aimed to manage food craving by teaching group members cognitive (e.g., restructuring of urge-related thoughts) and behavioural strategies (e.g., increasing awareness through food diaries, relaxation skills, identification of cues that trigger craving, avoidance of high-risk situations for craving, distraction).
41146830|NCT03805789|BIOLOGICAL|Placebo|Albumin solution administered intravenously
41146831|NCT05267379|DIAGNOSTIC_TEST|Take blood samples|Blood samples are used to check for polymorphisms in NSAID metabolization genes and to determine the diclofenac levels.
41457285|NCT04392596|DEVICE|Bone Mineral Density and Trabecular Bone score|"structural damage in the cervical and lumbar spine was scored according to the modified Stoke AS Spinal Score (mSASSS) which yielded a final summation score ranging from zero to 72.~BMD was measured using DXA (Lunar Prodigy densitometer, GE Healthcare, Madison, WI, USA).~BMD was measured at the lumbar spine (L1-L4) and the left hip (femoral neck and total proximal femur).~TBS was analyzed using DXA images over exactly the same region as the lumbar BMD assessment (L1-L4). Lumbar spine DXA images were reanalyzed using TBS iNight software version 2.1 (Med-I maps, Merignac, France). Patients were divided in 3 TBS groups according to guidelines for fracture risk \[22\]: any TBS \>1.31 was considered as normal; TBS values between 1.23 and 1.31 were consistent as partially degraded structure; and any TBS \<1.23 was considered as degraded structure."
41457286|NCT00960154|DEVICE|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
40767051|NCT06099665|BEHAVIORAL|Automated alert|Receiving an automated alert via the EHR to highlight that the patient in question presents for severe aortic stenosis or severe mitral regurgitation according to the AHA guidelines and that they are a good candidate for valve intervention. The alert will not list any specific manufacturer's device.
40767052|NCT02695277|DEVICE|AtriCure Bipolar System|
40767053|NCT02695277|DEVICE|Standard Endocardial Ablation with Catheter|
40767054|NCT02695277|DEVICE|AtriClip® PRO LAA Exclusion System|
41295247|NCT02306772|DRUG|TP05 Coating A|One radio-labelled tablet given to subjects
41295248|NCT02306772|DRUG|TP05 Coating B|One radio-labelled tablet given to subjects
41457287|NCT00960154|PROCEDURE|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
40767055|NCT02695277|DEVICE|Endocardial Ablation with Catheter|
40767056|NCT02695277|DEVICE|Repeated Endocardial ablation(s)|
40767057|NCT03190954|DRUG|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to \[11C\]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
40767058|NCT03190954|DRUG|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to \[11C\]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
41457288|NCT06369935|DRUG|Equecabtagene Autoleucel|Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy
41457289|NCT05212987|DRUG|FCN-098|FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.
41457290|NCT02663349|BEHAVIORAL|Social Cognition and Intervention Training|A manualized group therapy that teaches social cognitive skills.
40965425|NCT04676074|DEVICE|Electronic Upper limb( body) ergometer|Electronic pedal for the upper limb using for training the upper body. Intensity, speed and resistance can be adjusted.
40965426|NCT02632981|OTHER|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
40965427|NCT02632981|OTHER|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
40965428|NCT03728790|DEVICE|Remote Patient Monitoring|Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
40965429|NCT00105469|DRUG|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
40965430|NCT00105469|DRUG|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
40965431|NCT03438344|BIOLOGICAL|Multi-antigen CMV-Modified Vaccinia Ankara Vaccine|Given IM
40965432|NCT03438344|OTHER|Laboratory Biomarker Analysis|Correlative studies
40965433|NCT03438344|OTHER|Placebo|Given IM
40965434|NCT06293001|OTHER|No intervention|No intervention
40965435|NCT02774525|BEHAVIORAL|Reinforcement for drug & alcohol abstinence|
40965436|NCT02774525|BEHAVIORAL|Parenting intervention|
40965437|NCT02774525|BEHAVIORAL|Treatment as usual (TAU)|Outpatient substance-abuse therapy plus drug \& alcohol screening plus support for personal goal setting
40965438|NCT06266572|BEHAVIORAL|Overcoming and Addressing Stigma in Substance Use Disorders (OASIS)|Web-based educational platform for clinicians and individuals with OUD that will decrease barriers to care and enhance treatment outcomes
40965439|NCT01815593|DEVICE|Enhanced external counterpulsation|Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.
40965440|NCT03533010|DIETARY_SUPPLEMENT|Ca500mg|subjects receive a daily dose of 500mg elemental calcium
41137545|NCT04338178|PROCEDURE|Multidisciplinary outpatient program|Multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches. Patients are regularly followed and educated about the importance of lifestyle changes including healthy dietary habits and exercise in weight reduction and maintenance. Patients are also usually given information about nutritional value of various foods and few simple exercises for decreasing and maintaining body weight. This program is therefore planned as part of the usual care and responds to the recommendations of good practice for obesity
41137546|NCT06169345|OTHER|Echocardiographic evaluation|Echocardiographic follow-up
40965441|NCT03533010|DIETARY_SUPPLEMENT|VitD800IU|subjects receive a daily dose of 800IU VitD3
40965442|NCT03533010|OTHER|Placebo|subjects receive placebo tablet
40965443|NCT00595530|DRUG|ketamine|"Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~* Patients begin the ketamine infusion at 0.05 mg/kg/hr.~* 4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~  1. patient's pain has not improved to an acceptable level~ 2. side effects remain acceptable~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~* Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation."
40965444|NCT05541172|DRUG|Testosterone Undecanoate|Testosterone undecanoate (1000 mg/4 ml) will be administered at a dose of 1 ml every 12 weeks for 6 months, 2 ml every 12 weeks for 6 months, 3 ml every 12 weeks for 6 months and 4 ml every 12 weeks for 6 months.
40965445|NCT00440713|DRUG|Aripiprazole|
40965446|NCT00440713|BEHAVIORAL|Interpersonal Therapy|
40965447|NCT03522389|PROCEDURE|AOT with gait training|"AOT with gait training composes of program of watching video in different views of normal walk for 5 min.~After that, participants will receive gait training program. The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
40990687|NCT05829720|DIETARY_SUPPLEMENT|Conventional Milk (Weidendorf)|Mothers in this arm will drink Conventional Milk (Weidendorf) twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
41137547|NCT00269022|DRUG|SB-705498|
41137548|NCT00599196|DRUG|Rotigotine|"Rotigotine trans-dermal patches, once daily:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.~After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours."
41137549|NCT00254241|DRUG|Seroquel and Risperidone|
41137550|NCT03131713|DRUG|Acetaminophen|Acetaminophen 1000mg
41137551|NCT06317623|DIAGNOSTIC_TEST|Prenatal and postnatal ultrasound examination|Prenatal ultrasound examination of fetus with urinary tract dilation in second trimester and next in third trimester and when the dilation is persist, the child is managed after birth by pediatric nephrologist.
41137552|NCT02206815|DRUG|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
40965448|NCT03522389|PROCEDURE|Gait training|"To control a total time of training, the gait training group will watch video of Vincent van Gogh's painting for 5 min. After that, participants will training the gait as protocol of experimental group.~The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
40965449|NCT03522389|OTHER|Education|There will be no intervention exercise program provide for the control group. They will receive education about dementia such as definition, etiology, sign and symptom, and caring.
40965450|NCT04260152|DEVICE|Geistlich Fibro-Gide|Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide
40965451|NCT04260152|PROCEDURE|Connective Tissue Graft (CTG|Surgical recession root coverage with coronally advanced flap in combination with CTG
40965452|NCT01666782|BIOLOGICAL|Standard Trivalent Influenza Vaccine|Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.
40965453|NCT01666782|BIOLOGICAL|High-Dose Influenza Vaccine|Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.
40965454|NCT01351922|OTHER|No treatment given|Patients will fill out a questionaire by interview.
40965455|NCT00594659|BEHAVIORAL|Psychotherapy|Nine session treatment
40965456|NCT00594659|BEHAVIORAL|Computerized Psychotherapy|Nine session computer delivered treatment
40965457|NCT00594659|BEHAVIORAL|Motivational enhancement therapy|Two session treatment
40965458|NCT05438394|DRUG|melphalan hydrochloride for injection|Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
40965459|NCT02259881|DRUG|Low dose of BIBT 986 CL, per i.v. infusion|
40965460|NCT02259881|DRUG|Medium dose of BIBT 986 CL, per i.v. infusion|
40965461|NCT02259881|DRUG|High dose of BIBT 986 CL, per i.v. infusion|
40965462|NCT02259881|DRUG|Placebo|
40965463|NCT02259881|DRUG|Lipopolysaccharide (LPS), single i.v. bolus|Endotoxin derived from E. coli bacteria, used for activation of coagulation
40965464|NCT03294902|DEVICE|Pedra Tissue Perfusion Monitor|This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
40965465|NCT02496585|DRUG|Nintedanib|
40965466|NCT02496585|DRUG|Prednisone|
40965467|NCT02496585|OTHER|Placebo|
40965468|NCT05532761|OTHER|self-administered questionnaires|"In order to describe the experience of CAR-T cell therapy of DLBCL patients, a pharmaceutical follow-up is carried out the day before the injection (baseline) and at 1, 3, 6, 9, 12 and 18 months. These follow-ups consist of interviews with the patient and the delivery of self-administered questionnaires. The interviews will investigate drug consumption, the use of self-medication and complementary alternative therapies and the adverse effects of interest. The self-questionnaires will focus on exploring multidimensional quality of life, social and professional life, anxiety-depression or uncertainty tolerance through internationally validated questionnaires.~No supplementary visits will be needed : interviews with the research team will occur at the end of hematologic consultations."
40965469|NCT02873000|BEHAVIORAL|Incentive Spirometry|Incentive Spirometer is a tool that allows for deep breathing in a controlled setting while providing the user with visual feedback demonstrating the inspiratory volume of each breath.
40965470|NCT05487144|BEHAVIORAL|Learning in a Virtual Environment (LIVE)|Phase 1 of the study will be a one-time meeting, either remote or in-person to complete V.E. training and fill out questionnaires. Phase 2 of the study is the 8 week intervention implementation.Participants will access the V.E. community from their homes on a computer with broadband internet. During the first four weeks of the intervention, participants will be required to come into the V.E. at least once per week for at least one hour. For the last four weeks, V.E. participation is strongly encouraged, but not required. The content in the V.E. will focus on psychosocial health and stroke recovery, and the messaging in the VE will be updated bi-weekly to encourage retention and engagement. Group meetings led by the study PI, a psychologist, or another trained member of the research team at least once a week will be offered. During the intervention period, VE-specific data will be collected continuously. Phase 3, will include a survey and a focus group interview via online platform.
40965471|NCT04637230|DIAGNOSTIC_TEST|Electrocardiogram analysis by Artificial Intelligence|1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms
40965472|NCT03204903|PROCEDURE|Laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen (GaAlAs laser diode, 810 nm, 150 mW, pulsed waves), which delivered 0.375 J of energy (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
40965473|NCT03204903|PROCEDURE|Sham laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen without laser output (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
41137553|NCT02206815|DRUG|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
41137554|NCT04334252|OTHER|Questionnaire|Questionnaire
40965474|NCT01756898|DRUG|5 mg ASB17061|Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
41137555|NCT01939509|DRUG|Atenolol|Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
41137556|NCT01939509|DRUG|Bisoprolol|
41457291|NCT04230876|BEHAVIORAL|Auditory Brian Training Games/Activities|Game-based activities that encourage listening to words and sentences in noisy situations. Participants will receive subscriptions to the clEAR online auditory training activities and recommended protocol for those who recently received new hearing aids.
40767059|NCT03190954|DRUG|[11C]NNC-112|\[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
41457292|NCT00158535|PROCEDURE|liver transplantation|
40965475|NCT01756898|DRUG|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
40965476|NCT01756898|DRUG|10 mg ASB17061|Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
40965477|NCT01756898|DRUG|20 mg ASB17061|Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
40965478|NCT03384212|DRUG|Cladribine|
40965479|NCT03384212|DRUG|Fludarabine|
40965480|NCT03384212|DRUG|Busulfan|
40965481|NCT03384212|DRUG|Cytarabine|
40965482|NCT03601975|DRUG|Gemcitabine/Cisplatin|gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
40965483|NCT00004983|BEHAVIORAL|diabetes self-management education|
40965484|NCT05473598|BEHAVIORAL|Stand Down app|Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
40965485|NCT05473598|BEHAVIORAL|Peer-Supported Stand Down|Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approx. 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
40965486|NCT05473598|OTHER|Usual Care|All patients, regardless of condition, will have access to usual care for hazardous drinking in primary care. In this setting, usual care entails a spectrum of alcohol-related services including annual screening for hazardous drinking, brief intervention following a positive screen (advice from a provider to reduce their drinking), and referral (as needed) to specialty AUD treatment.
40965487|NCT03456050|BEHAVIORAL|FRC exercise|The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
40965488|NCT03456050|BEHAVIORAL|Conventional Exercise|The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
40965489|NCT03432702|PROCEDURE|Horizontal ridge augmentation|Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
40965490|NCT02728609|DEVICE|ABThera vacuum device|This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
41457293|NCT00109954|DRUG|cisplatin|
41457294|NCT00109954|RADIATION|brachytherapy|
41457295|NCT00109954|RADIATION|yttrium Y 90 glass microspheres|
40965491|NCT02728609|DEVICE|Blue towel: vacuum pack device|This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
40767061|NCT06634875|DRUG|isunakinra|Isunakinra is a potent IL1R1 inhibitor
40767062|NCT06644846|RADIATION|Spatially fractionated radiation therapy|"Spatially fractionated radiation therapy (SFRT) enables delivery of high-dose radiation to discrete sub-volumes inside a tumour target while restricting the remainder of the target to a safer lower dose. This technique results in generation of intentionally heterogeneous dose distribution with spatial areas of hot and cold spots within the tumour, thereby sparing nearby organs at risk."
40767063|NCT06579092|DRUG|AZD5004|AZD5004 film-coated tablet once daily during 36 weeks
40767064|NCT06579092|DRUG|Placebo|Placebo matching AZD5004 film-coated tablet once daily during 36 weeks
40965492|NCT01794884|DRUG|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
40965493|NCT01794884|DRUG|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
40965494|NCT01644565|BIOLOGICAL|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
40965495|NCT01644565|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|
40965496|NCT01644565|BIOLOGICAL|Modified E. coli heat labile enterotoxin LTR192G|
41146832|NCT05448794|OTHER|injection|ultrasound-guided hydrodilatation with hypertonic Dextrose
41457296|NCT04707963|DIETARY_SUPPLEMENT|Peanut protein powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
41457297|NCT04707963|BEHAVIORAL|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
41457298|NCT05904639|GENETIC|Decoding Your Diet|We will collect information from cardiac patients on their genes at baseline and then expose them to a diet intervention and collect genetic information after the intervention.
40965497|NCT04309539|PROCEDURE|Fascia iliaca block|"A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of bow-tie sign formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia."
40965498|NCT04309539|PROCEDURE|combined LFCN block with PENG block|With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected
40965499|NCT02998944|OTHER||not any intervention for this study
40965500|NCT00251485|DRUG|Cetuximab|Cycle 1: 400 mg/m2 (given as a 2-hour infusion) on Day 1, then 250 mg/m2, Day 8 (given as a 1-hour infusion) subsequent cycles:250 mg/m2, Day 1 and Day 8 (given as a 1-hour infusion)
40965501|NCT00603616|DRUG|Placebo Comparator|Matching oral placebo pills to be taken twice daily for a total of 8 weeks
40767065|NCT05406453|OTHER|Whole Genome Sequencing testing|Whole Genome Sequencing testing, community-based contact tracing
40965502|NCT00603616|DRUG|Rifaximin|Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
40965503|NCT02837601|DEVICE|AirSeal® Insufflation System (AIS)|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
40965504|NCT04193098|BIOLOGICAL|CTL|CTL injection
40965505|NCT04193098|BIOLOGICAL|Toripalimab|Toripalimab injection
40965506|NCT03895385|DRUG|Bimekizumab|Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.
40965507|NCT00684346|OTHER|18-FDG|The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
40965508|NCT02349087|DEVICE|Acute EEG with fast applicable EEG electrode|
40965509|NCT00580021|OTHER|Genotyping|Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
40965510|NCT06050395|BEHAVIORAL|Quality fo Life Questionnaire (FHSI)|Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14). The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much. A lower total score indicates better quality of life.
40965511|NCT06050395|BEHAVIORAL|Vioscreen Food Frequency Questionnaire (FFQ)|Participants will receive a web-based link and information to complete VioScreen, a web-based food frequency questionnaire, which allows participants to choose the average frequency of consumption of food items over a given time frame (1 month, 3 month, 1 year, etc.) on a Likert scale with choices ranging by individual questions. Total energy and nutrient intake is estimated by summing intakes from each food based on the selected portion size, reported frequency of consumption, and nutrient content of each food item. Anti-inflammatory and pro-inflammatory dietary patterns are calculated using the energy-adjusted dietary inflammatory index (DII) score to represent the inflammatory potential of an individual's overall diet, using data from FFQ responses. Higher DII scores represent more pro-inflammatory diets while lower (i.e., more negative) DII scores represent more anti-inflammatory diet.
40965512|NCT06050395|BEHAVIORAL|Educational Handouts|Participants will receive educational handouts on diet.
40965513|NCT06050395|BEHAVIORAL|NutritionCoaching|Participants will receive bi-weekly nutrition coaching on anti-inflammatory dietary patterns and foods.
40965514|NCT06050395|BEHAVIORAL|Follow-Up Survey|Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators. This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree. A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
40965515|NCT06050395|BEHAVIORAL|Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire|The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much. A higher score indicates better appetite and quality of life.
40965516|NCT06050395|BEHAVIORAL|Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire|Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits. The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never. A higher score indicates higher cognitive function.
40767066|NCT02579967|DRUG|Immunosuppression Only Conditioning -Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)
40767067|NCT02579967|DRUG|Reduced Intensity Conditioning|pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.
40767068|NCT02579967|DRUG|Myeloablative Conditioning-Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
40767069|NCT02579967|DRUG|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through 0, +18, +25, or +35 depending on treatment arm and cohort.
40767070|NCT02579967|PROCEDURE|Allo BMT|Allogeneic blood or marrow transplantation
40767071|NCT04046419|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants.~4. Second application of the scales to the participants.~5. Statistical analysis and scaling"
40965517|NCT02798133|PROCEDURE|OLA|PEEP titration trial for best Cdyn after the alveolar recruitment maneuver
40965518|NCT02798133|PROCEDURE|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
40965519|NCT03613844|DRUG|DHA|DHA supplementation
40965520|NCT03613844|DRUG|Placebo|Placebo for DHA
41457299|NCT06167330|OTHER|Progressive rehabilitation program|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
40965521|NCT06504628|DIAGNOSTIC_TEST|screening risk for falling and identifiy the risk level low-intermediate-high|"3 key questions: Any posiitve answer to a) Has fallen in the past year? b) Feels unsteady when standing or walking? or c) Worries about falling? prompts to fall severity step.~if no at the three questions= low level of fall-risk Fall severity: fall with injuires, laying on the ground with no capacity to get up, or a visit to emergency room, or loss of conscienciousness/suspected syncope. or Frailty (Clinical Frailty Scale)= if positive, high risk otherwise, 4 meter-walk test: if =\<0.8m/sec= intermediate risk if \>0.8m/sec=intermediate risk"
40965522|NCT06504628|DIAGNOSTIC_TEST|3 mnth-follow-up|patient's phone call, and data collected from electronic medical record
40965523|NCT03663816|DEVICE|experimental foot device|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in healthy people.
40965524|NCT04008576|BEHAVIORAL|Group Blended Transdiagnostic treatment|The treatment combines group face-to-face and Internet-delivered psychotherapy: 7 group sessions delivered every 3 weeks plus the use of an online treatment platform between sessions. Its goal is to learn and practice adaptive regulation strategies from a mechanistically transdiagnostic approach, with a focus on both negative and positive affectivity. Each group session will focus on one of the following core components: the first group session will focus on CBT traditional strategies such as motivation for change and psychoeducation about emotions; sessions 2 to 5 will focus on strategies to down-regulate negative affect: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, and interoceptive and situation-based emotion exposure; session 6 will focus on strategies to regulate positive affect; the final session will teach relapse prevention techniques. All the treatment components are delivered in 16 online treatment modules.
40965525|NCT02647203|DRUG|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
40965526|NCT05289791|OTHER|ultrasonic activation of bioceramic sealer|activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction
40965527|NCT01003912|BIOLOGICAL|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
40965528|NCT02547844|DRUG|efavirenz + emtricitabina + tenofovir|
40965529|NCT02547844|DRUG|rilpivirina + emtricitabina + tenofovir|
40965530|NCT06075862|PROCEDURE|Decompressive surgery|Decompressive lumbar spinal surgery
40965531|NCT00837642|DIAGNOSTIC_TEST|Transthoracic echocardiography|Full transthoracic echocardiography will be performed.
40767072|NCT05972629|DRUG|SAR444836|Infusion pump, intravenous infusion (IV)
40767073|NCT06644924|COMBINATION_PRODUCT|Intervention: AS MDI|"Drug: Treatment A (Ventolin Evohaler) Randomized participants will receive a single-dose (2 inhalations)~Drug: Treatment B (Placebo MDI) Randomized participants will receive a single-dose (2 inhalations to match AS MDI)~Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007) Randomized participants will receive a single-dose (2 inhalations)"
40767074|NCT06644924|COMBINATION_PRODUCT|Intervention: Ventolin Evohaler|"Drug: Treatment A (Ventolin Evohaler) Randomized participants will receive a single-dose (2 inhalations)~Drug: Treatment B (Placebo MDI) Randomized participants will receive a single-dose (2 inhalations to match AS MDI)~Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007) Randomized participants will receive a single-dose (2 inhalations)"
40965532|NCT01785069|DEVICE|Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection|Surgical implant
40965533|NCT02288897|DRUG|PV-10 (10% rose bengal disodium)|
40965534|NCT02288897|DRUG|Dacarbazine, temozolomide or talimogene laherparepvec|
40965535|NCT02967744|DRUG|NSAID|NSAIDs are among the most common pain treatments for patients with osteoarthritis.
40965536|NCT01966900|BIOLOGICAL|CN54gp140 mixed with GLA-AF|Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
40965537|NCT00687466|DRUG|Insulin|"Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.~Glargine should be administered once daily in the morning and always at the same hour."
41137557|NCT01244997|PROCEDURE|Dental Implant|This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
41137558|NCT01536704|DRUG|Nicotine (2 mg)|2 mg nicotine lozenge in two formulations
40767075|NCT06644924|COMBINATION_PRODUCT|Intervention: Placebo matching AS MDI|"Drug: Treatment A (Ventolin Evohaler) Randomized participants will receive a single-dose (2 inhalations)~Drug: Treatment B (Placebo MDI) Randomized participants will receive a single-dose (2 inhalations to match AS MDI)~Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007) Randomized participants will receive a single-dose (2 inhalations)"
40767076|NCT03888027|BEHAVIORAL|WalkMORE group|Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
40767077|NCT03649503|OTHER|No intervention|
40965538|NCT03969446|DRUG|Decitabine|Given IV
41457300|NCT06167330|OTHER|Stimulation devices|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
40965539|NCT03969446|BIOLOGICAL|Pembrolizumab|Given IV
40965540|NCT03969446|DRUG|Venetoclax|Given PO
40767078|NCT05380947|DRUG|BI 1810631 - trial formulation 1 (TF1)|BI 1810631 - trial formulation 1 (TF1)
40965541|NCT00820560|DRUG|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
40965542|NCT00000688|DRUG|Ganciclovir|
40965543|NCT05476471|BEHAVIORAL|multicomponent exercise training program|One supervised 60 minutes training sessions per week were organized combining warm-up, speed-walking, resistance exercise, static and dynamic balance. Supervised walking sessions were for 10-20 minutes at a target intensity of 13-15 on the Borg scale. Thereafter, 10 resistance exercises targeting lower body, trunk and upper body muscles were performed with elastic band. In addition, participants were instructed to accumulate 150 minutes per week of moderate intensity aerobic activity in bouts of at least 10 minutes, and at least 2-3 days all major muscle groups training.
40965544|NCT00717197|DRUG|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
40965545|NCT03315624|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX Coral 600, FX 600 and FX CorDiax 600
40965546|NCT03677505|DEVICE|KoMAC videolaryngoscope|Double lumen endotracheal intubation was performed with the KoMAC videolaryngoscope
40965547|NCT03677505|DEVICE|Macintosh Laryngoscope|Double lumen endotracheal intubation was performed with the Macintosh Laryngoscope
41137559|NCT01536704|DRUG|Nicotine (4 mg)|4 mg nicotine lozenge in two formulations
41146833|NCT02632630|DRUG|Amino Acids w/Electrolytes in Dextrose|Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
40767079|NCT05380947|DRUG|BI 1810631 - new formulation (NF)|BI 1810631 - new formulation (NF)
40767080|NCT05380947|DRUG|Rabeprazole sodium|Rabeprazole sodium
40965548|NCT01827605|OTHER|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
40965549|NCT01827605|DRUG|BEAM|"BEAM REGIMEN day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~1. Patient collecting ≥6x106 CD34+ cells/kg use \>4x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~2. Patient collecting 4-6x106 CD34+ cells/kg use \>2x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~3. Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc"
40965550|NCT04653545|DIAGNOSTIC_TEST|HbA1c|"Blood will be taken as per requirement for patients being admitted to hospital. A small sample will be sent to the biochemistry department for measurement of HbA1 (by HPLC method).~All patients who are diagnosed with diabetes (or known to have diabetes) will have a foot examination and retinal and renal screening and cardiovascular assessment for diabetes complications."
40965551|NCT02957305|DRUG|Misoprostol 400mcg Tab|400µg of misoprostol (2 tablets)
40965552|NCT02957305|DRUG|Misoprostol 200mcg Tab|200µg of misoprostol (1 tablet)
40965553|NCT06169696|DEVICE|Intervention/Treatment|Non-invasive EEG headband device
40965554|NCT03077178|PROCEDURE|Geriatric assessment|Geriatric assessment, questionnaire assessment
40965555|NCT05817825|BEHAVIORAL|Smart IOP Intervention|Smart IOP is a remotely delivered IOP program in operation since 2016, allowing patients to complete addiction treatment entirely online. The original program, consisting of 72 video modules across 8 different topics, will be adapted and tailored to hospitalized patients with serious infections from injection drug use. Participants will watch video content asynchronously, and will be required to correctly answer knowledge questions to proceed to the next module. The whole treatment program will require approximately 4 weeks to complete. Participants are also asked to answer questions about how to apply the knowledge to their own personal circumstances. The answers to these are reviewed by the peer recovery coach during weekly encounters. Videos can be viewed at a time that is most convenient to the participants. T
40965556|NCT05817825|BEHAVIORAL|Peer Recovery Coach|Peer recovery coach, an individual in sustained recovery (\>5 years) and certified to be a coach, will meet weekly with the participant to review progress, answer questions about the videos, review answers to questions, and encourage continuation of treatment after discharge. These meetings will occur in-person or remotely.
40965557|NCT04476069|DRUG|IBUPROFEN|given to children 30 minutes before extraction / orally for one time only
40965558|NCT00517998|DRUG|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
40965559|NCT03162991|OTHER|Aerobic Exercise Intervention|Aerobic Exercise Intervention- 12-weeks, exercise 3 non-consecutive days/week for \~30-55 minutes per exercise session.
40965560|NCT06284746|DRUG|Tirolizumab+SOX/XELOX|Tirolizumab combined with chemotherapy(SOX/XELOX) regimen. The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
40965561|NCT06284746|DRUG|SOX/XELOX|Simple chemotherapy regimen (SOX/XELOX regimen). The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
40965562|NCT04507737|OTHER|Rapid Response Team Composition_ ICU Nurse|In case of deterioration a Rapid Response Team may be activated. We will be examining the composition of the teams alternating between a MET or a CCOT.
40965563|NCT05071469|OTHER|Kinesiotaping|KT was applied.
40965564|NCT05071469|OTHER|Mulligan Mobilization Technique|MMT was applied
40965565|NCT06354595|DEVICE|Multidimensional Rehabilitation in the Metaverse|Using the multidimensional rehabilitation space in the metaverse, evaluate the platform after use.
40965566|NCT04600128|OTHER|Dairy-based greek yogurt|Plain Greek yogurt (2% M.F; Danone, Boucherville, Quebec, Canada)
40965567|NCT04600128|OTHER|Dairy-based cheddar cheese|Mild cheddar cheese (31% M.F. ; Armstrong, Saputo Dairy Products, Saint-Laurent, Quebec, Canada)
40965568|NCT04600128|OTHER|Plant-based yogurt|Plain Greek yogurt alternative (Daiya, Rupert Street, Vancouver, Canada)
40965569|NCT04600128|OTHER|Plant-based cheese|Medium cheddar style block (Daiya, Rupert Street, Vancouver, Canada)
40965570|NCT01423305|DRUG|Budesonide/formoterol capsule.|Oral administration with concomitant charcoal.
40965571|NCT01423305|DRUG|Budesonide/formoterol capsule for oral adm.|Oral administration without concomitant charcoal.
40965572|NCT00602797|DRUG|Paclitaxel|Given IV
40965573|NCT00602797|OTHER|Quality-of-Life Assessment|Ancillary studies
40965574|NCT00602797|OTHER|Questionnaire Administration|Ancillary studies
40965575|NCT00602797|DRUG|Vinorelbine Tartrate|Given IV
40965576|NCT02863952|OTHER|Single photon emission computed tomography myocardial perfusion imaging|
40965577|NCT02863952|DEVICE|novel cadmium-zinc-telluride (CZT) SPECT cameras|
40965578|NCT05367401|DRUG|Sabatolimab|Solution for intravenous infusion
40965579|NCT05367401|DRUG|Magrolimab|Solution for intravenous infusion
40965580|NCT05367401|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
41457301|NCT00366639|OTHER|Acute Decompensated Heart Failure|Treatment \& outcomes during hospital admission for Acute DHF
40965581|NCT03435484|OTHER|Arm A|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
40965582|NCT03435484|OTHER|Arm B|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
40965583|NCT02716571|OTHER|Leukapheresis or Plasmapheresis|"Leukapheresis: Donate 5x10\^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.~Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE)."
40965584|NCT05956496|OTHER|Allograft Material ADM-S|A piece of the allograft material (ADM-D) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
40965585|NCT05956496|OTHER|Allograft Material ADM-D|A piece of the allograft material (ADM-S) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
40965586|NCT03641430|OTHER|Supportive care with OCT product|Participants will apply over-the-counter product for a certain period with or without light challenge. We will perform clinical assessments of the skin associated with product application as well as assess these changes with and without light challenge. Skin biopsies will be obtained following standard medical practice and will be used to analyze skin markers related to photoaging, pigmentation, oxidative stress, and other dermatologic conditions.
40965587|NCT03823001|DIAGNOSTIC_TEST|virtual biopsy (VB) monitoring protocol|"1. PSA bi-annually or more often according to the discretion of the urologist.~2. Annual DRE.~3. Visit with the urologist bi-annually.~4. Multi-parametric MRI (mpMRI) every year for 3 years.~5. Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
40965588|NCT02607033|OTHER|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
40965589|NCT02607033|OTHER|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
40965590|NCT02711397|OTHER|Observational study|Comparison excretion levels of gluten immunogenic peptides
40965591|NCT06261203|DRUG|Aspirin|To investigate the efficacy of low dose aspirin for prevention of early pregnancy loss in women at high risk of preeclampsia.
40965592|NCT01872377|RADIATION|CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost|Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
41146834|NCT02632630|DIETARY_SUPPLEMENT|Ensure product|Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
40767086|NCT06635642|BEHAVIORAL|Dichotic Interaural Intensity Difference (DIID) Training|A total of five trials will be presented in a sequence and there will be 10 sequences per training session. Each of the 25 consonant-vowel-consonant words or digits 1 through 10 (excluding 7) will be presented to each ear during the session. The pairs will be randomized every time, and a word will never be paired with itself. After a sequence is completed, the difficulty of the task will be adjusted, in real time, based on performance on the prior task. If the child scored 4 or 5 of 5 correct in the poorer ear, then the IID will be decreased by 2 dB making the task more difficult. If the child scores 0, 1, or 2 of 5 correct, then the IID will be increased by 2 dB making the task easier. Last, if the child scores 3 of 5 correct, then the IID will remain unchanged for the next sequence.
40767087|NCT04418154|DRUG|epirubicin hydrochloride|Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
40767088|NCT04418154|DRUG|Cyclophosphamide|Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
40767089|NCT04418154|DRUG|Albumin bound paclitaxel|Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.
40767090|NCT04418154|DRUG|Toripalimab|Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
40767091|NCT06008080|DEVICE|Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System
40767092|NCT06277219|DRUG|LAT010|LAT010 monotherapy
40767093|NCT06277219|DRUG|LAT010 + ICI|LAT010 combination with PD-1 inhibitor
40767094|NCT02763566|DRUG|Abemaciclib|Administered orally
40767095|NCT02763566|DRUG|Anastrozole|Administered orally
40767096|NCT02763566|DRUG|Letrozole|Administered orally
40767097|NCT02763566|DRUG|Placebo|Administered orally
40767098|NCT02763566|DRUG|Fulvestrant|Administered intramuscularly
40767099|NCT02603497|DRUG|ASP015K|oral
40767100|NCT06275958|DRUG|Doublet Chemotherapy, Standard Dose (100%)|Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
40767101|NCT06275958|DRUG|Doublet Chemotherapy, Dose-reduced (75%)|75% of: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
40767102|NCT06275958|DRUG|Monotherapy, Standard Dose (100%)|- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
40767103|NCT06275958|DRUG|Monotherapy, Dose-reduced (75%)|"75% of:~- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)"
40965593|NCT01898806|DRUG|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
40965594|NCT01898806|DRUG|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
40767106|NCT04293432|DRUG|Drugs, Generic|All drugs having ≥10 TdP cases reported in the FAERS database
40767107|NCT05949320|OTHER|e-Motivational Interviewing|"This study evaluates a 90-day mobile phone-based intervention using the e-Motivational Interviewing app for individuals with chronic conditions like hypertension and diabetes. The app provides short conversations with health messages and reflective questions on lifestyle choices, such as physical activity and diet. The intervention incorporates change talk from Motivational Interviewing and principles from Basic Psychological Needs Theory (BPNT) to encourage positive behavior change. Users interact via multiple-choice questions, promoting self-assessment and reflection. The goal is to facilitate sustained lifestyle changes and improved health outcomes."
40767108|NCT05517447|OTHER|Observational cohort study|Observational cohort study
40767109|NCT05517447|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
41146835|NCT02632630|DRUG|Crystalloid solutions|Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
40965595|NCT01898806|DRUG|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
40965596|NCT01898806|DRUG|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
41146836|NCT02632630|DIETARY_SUPPLEMENT|Oral nutritional supplementation|Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
41146837|NCT03846817|OTHER|Physiotherapist-led treatment|12-week of semi-standardized, progressive physiotherapist-led treatment aiming to increase hip muscle strength and load capacity.
40767113|NCT05132491|OTHER|TECH-Prep Intervention|Participants in the treatment program will be asked to complete 10 online training modules (1 hour each), attend 5 online motivational speaker forums (1 hour each), and view 5 coding workshops. The activities will be completed over an 8 week period.
40965597|NCT03326102|DRUG|DHP107|DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
40965598|NCT03326102|DRUG|IV Paclitaxel|IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)
40767114|NCT06027086|DRUG|Durvalumab|Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.
40965599|NCT05113420|DRUG|Detralex|Diosmin+ Hesperidin
40965600|NCT05113420|DRUG|Troxevasin|Troxerutin
40965601|NCT04635462|OTHER|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
40965602|NCT04635462|OTHER|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
40965603|NCT01157260|DRUG|Kremezin|AST-120 2g three times a day
40767115|NCT06027086|DRUG|DRP-104|"Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.~After the first cycle of treatment the study drug may be shipped to the patient's home for future cycles of administration if patients or caregiver can demonstrate at least two observed independent injections of DRP-104 prior to home administration."
40767116|NCT06119217|COMBINATION_PRODUCT|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
40767117|NCT06119217|COMBINATION_PRODUCT|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
40965604|NCT00965042|DRUG|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
40965605|NCT02937909|OTHER|Use of wound care products from a single manufacturer|The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
40965606|NCT05590130|DEVICE|Manual Oxygen titration with Philips oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Philips oximeter
40965607|NCT05590130|DEVICE|Manual oxygen titration with Nonin oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Nonin oximeter
40965608|NCT05590130|DEVICE|Manual Oxygen titration with Philips oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
40965609|NCT05590130|DEVICE|Manual oxygen titration with Nonin oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
40965610|NCT02578316|DRUG|Lenvatinib|"Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.~Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase."
40965611|NCT05731895|DRUG|BI 425809 (iclepertin)|BI 425809 (iclepertin)
40965612|NCT05673889|DRUG|ARV-471|Experimental
40965613|NCT05673889|DRUG|Dabigatran etexilate|Probe substrate
40965614|NCT04901468|OTHER|No Intervention|This is an observational study
41457302|NCT01591720|BEHAVIORAL|Tailored Internet-based CBT for depression and anxiety|"This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
41457303|NCT04181736|DRUG|Guanfacine Pill|Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit hyperactivity disorder (ADHD). It is taken by mouth and will be compounded by a pharmacy to the required doses used in this study.
41457304|NCT04181736|DRUG|Placebo|Placebo masked to mirror the treatment drug dose regimen.
41457305|NCT02203539|OTHER|exposure to normal light|exposure for 60 minutes in duration
41457306|NCT02203539|OTHER|exposure to bright light|exposure to bright light for 60 minutes of duration
41457307|NCT02203539|OTHER|exposure to blue-enriched light|exposure to blue-enriched light for 60 minutes of duration
40767118|NCT06119217|COMBINATION_PRODUCT|Nab-Paclitaxel and gemcitabine|Dose and schedule per protocol
40767119|NCT06270056|DRUG|Misoprostol|Self-administered misoprostol by clients obtaining medication abortion via telemedicine
40767120|NCT05322005|PROCEDURE|partial meniscectomy|Arthroscopic procedure
40767121|NCT05322005|DEVICE|Condrotide® (polynucleotides gel: class III medical device)|Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection
40767122|NCT06645314|BIOLOGICAL|Group A|3.0 × 10 \^ 9 BST06 cells, intravenous infusion，at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
40767123|NCT06645314|BIOLOGICAL|Group B|3.0 × 10 \^ 10 BST06 cells, intravenous infusion, at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
40965615|NCT03810560|DEVICE|laser device Er,Cr:YSGG laser|laser device with open flap debridement
40965616|NCT02552771|PROCEDURE|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
40965617|NCT02552771|PROCEDURE|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
40965618|NCT04022993|DRUG|Lantus Solostar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
40965619|NCT04022993|DRUG|Insulin RinGlar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
40965620|NCT01235351|DRUG|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
40965621|NCT01235351|DRUG|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily
40965622|NCT01102959|DEVICE|Photographic Educational Material|Photographic Educational Material on Carbohydrate Counting
40965623|NCT06111820|BEHAVIORAL|Improving Access to Community Therapies (iACT)|The Low-intensity Acceptance and Commitment Therapy (LIACT) protocol is based on the empirically supported Acceptance and Commitment Therapy (ACT), and is designed by registered clinical psychologists with consultation from local ACT experts from the Association of Contextual and Behavioural Science (Hong Kong Chapter). The LIACT protocol is also piloted and revised by clinical psychologists to ensure its adaptability to local situations. For individual guided self-help LIACT service, an intake assessment will be conducted to assess the presenting problem of the participants at pre-treatment to ensure the suitability to receive LIACT service. Participants will be given the LIACT self-help workbook collaboratively with a Psychological Wellbeing Practitioner (PWP). Between each session, clients will read through the workbook and complete the exercises suggested in the workbook. In subsequent sessions, PWP will guide clients to overcome the difficulties in performing the LIACT exercises.
40965624|NCT00114946|DRUG|Avastin|
40965625|NCT03121638|BIOLOGICAL|VARIVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
40965626|NCT03121638|BIOLOGICAL|ZOSTAVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
40965627|NCT03121638|BIOLOGICAL|NBP6081|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
40965628|NCT03121638|BIOLOGICAL|NBP6082|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
40965629|NCT03121638|BIOLOGICAL|NBP6083|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
40965630|NCT01377532|DRUG|131 I-Metaiodobenzylguanidine (131 I-MIBG)|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions. A radiation safety officer will instruct the patient, family, and caretakers about specific UCSF radiation safety guidelines for both hospitalization and discharge.
40965631|NCT02261155|PROCEDURE|Hypnosis|hypnotic Relaxation without specific analgesic suggestion
40965632|NCT03849196|DRUG|2L PEG-Asc|PEG-Asc powder
40965633|NCT03849196|DRUG|Bisacodyl 10Mg Suppository|bisacodyl 10 mg suppository
40965634|NCT03849196|DRUG|1L PEG-Asc|PEG-Asc powder
40767124|NCT03863574|DRUG|Saroglitazar Magnesium 2mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.
40965635|NCT01088997|DRUG|Milrinone Lactate|Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
40965636|NCT06072846|BEHAVIORAL|Reiki Energy Therapy|Reiki Therapy will be applied to the intervention group
40965637|NCT02613975|DEVICE|positonal device|positional device detects prone positional and will vibrate to cause patient to lie laterally
40965638|NCT06077318|OTHER|Keyhole repair|The keyhole technique involves placing a mesh with a slit in the central hole around the intestinal ring, allowing facilitating the passage of the intestine through the central slit.
40767125|NCT03863574|DRUG|Saroglitazar Magnesium 4mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.
40767126|NCT03863574|DRUG|Placebos|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
40767127|NCT05583721|DRUG|[13N]NH3|Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
40767128|NCT05583721|DRUG|Lexiscan|Given IV prior to PET stress test
40767129|NCT05583721|DIAGNOSTIC_TEST|Positron emission tomography|Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.
40767130|NCT05829044|DEVICE|Pupillometry|Pupillometer measurement of pupil size in response to different light stimuli
40767131|NCT05829044|DEVICE|Light box exposure|Using a light box to produce different wavelengths and intensities of light. Exposure to red light on Night 1 and blue/green light on Night 2 to determine circadian timing and suppression of hormone (melatonin)
40767132|NCT06050252|PROCEDURE|Biopsy|Undergo tissue biopsy
40767133|NCT06050252|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40965639|NCT06077318|OTHER|Sugarbaker repair|The modified Sugarbaker technique uses a mesh to place a patch on the lateralized intestine, effectively preventing herniation of abdominal contents through the stoma.
40965640|NCT02770560|DEVICE|Urokinase locking solution|On basis of the prescription : one single administration of thrombolytic locking solution versus multiple administrations (during 3 consecutive dialysis sessions)
40965641|NCT06096753|DEVICE|Bruxoff gnathological function analysis|The recordings will be carried out for 3 randomly selected nights within 3 weeks, with at least 4 hours of sleep per night.
40965642|NCT02279381|DRUG|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
40965643|NCT02279381|OTHER|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
40965644|NCT02279381|OTHER|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
40965645|NCT01530061|OTHER|Egg Breakfast|Egg, Toast and Jelly
40965646|NCT01530061|OTHER|Bagel Breakfast|Bagel, Cream Cheese and Yogurt
40965647|NCT03748888|BEHAVIORAL|Exercise group|"An antenatal physical activity (APA) programme will be designed for participants in the exercise group.~The APA will last for 20-24 weeks. Participants in the EG must enrol in the APA between their 12-16 weeks of gestation.~The APA programme has a frequency of three times a week, which involves aerobic, strength and stretching exercises. The intensity of the APA programme is individually calculated for each participant based on their pre-pregnancy fitness level. Single sessions of the APA programme last 50-60min."
40965648|NCT00222794|DRUG|Atomoxetine (Strattera)|
40965649|NCT02810197|BEHAVIORAL|Psychopathological assessment|
40965650|NCT02810197|BEHAVIORAL|Neuropsychological assessment|
40965651|NCT02810197|DEVICE|Functional magnetic resonance imaging (fMRI)|
40965652|NCT05687383|DEVICE|Safe breastfeeding pillow|A randomized controlled trial
40965653|NCT01691781|DRUG|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
40965654|NCT00923338|DEVICE|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
40965655|NCT02171520|DRUG|Dabigatran etexilate generation I|
40965656|NCT02171520|DRUG|Dabigatran etexilate generation II|
40965657|NCT00528658|DRUG|Paracetamol|1g qid
40965658|NCT00528658|DRUG|Ibuprofen|400mg tid
40965659|NCT00528658|DRUG|Paracetamol Placebo|equivalent to 1g qid
40965660|NCT00528658|DRUG|Ibuprofen placebo|Equivalent to 400mg tid
40965661|NCT00986557|BIOLOGICAL|adoptive immunotherapy|
40965662|NCT00986557|BIOLOGICAL|alemtuzumab|
40965663|NCT00986557|BIOLOGICAL|in vitro-treated peripheral blood lymphocyte therapy|
40965664|NCT00986557|DRUG|foscarnet sodium|
40965665|NCT00986557|DRUG|ganciclovir|
40965666|NCT00986557|GENETIC|polymerase chain reaction|
40965667|NCT00986557|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40965668|NCT00986557|PROCEDURE|infection prophylaxis and management|
40965669|NCT00986557|PROCEDURE|peripheral blood stem cell transplantation|
40965670|NCT00986557|PROCEDURE|standard follow-up care|
40965671|NCT00986557|RADIATION|radiation therapy|
40965672|NCT03295812|OTHER|standard therapy|standard therapy,non-interventional study
40965673|NCT05680896|BIOLOGICAL|inactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV|the protection of COVID-19 vaccines on breakthrough infection
40965674|NCT02684916|PROCEDURE|Chiropractic treatment|"The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.~The parents and the child are unaware of group allocation."
40965675|NCT02684916|PROCEDURE|Placebo|Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
40965676|NCT02871297|DRUG|Vortioxetine|Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
40965677|NCT01722084|BEHAVIORAL|Theory of planned behaviour (TPB) and social cognitive theory (SCT).|"TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process."
40767134|NCT06050252|DRUG|Cisplatin|Given IV
40767135|NCT06050252|PROCEDURE|Computed Tomography|Undergo CT scan
40965678|NCT06247020|DIETARY_SUPPLEMENT|Supplementation with sodium- butyrrate|Oral supplementation with sodium butyrrate capsules
40965679|NCT06247020|DIETARY_SUPPLEMENT|Placebo|Oral supplementation with placebo capsules
40965680|NCT01587001|DIETARY_SUPPLEMENT|N-acetyl-cysteine|900mg three times daily for 8 weeks
40965681|NCT01587001|DRUG|Placebo|Matching placebo three times daily for 8 weeks.
40965682|NCT04399317|DEVICE|Flow controlled ventilation (Evone-ventilator)|The new ventilation technique will be applied
40767136|NCT06050252|BIOLOGICAL|Durvalumab|Given IV
40767137|NCT06050252|DRUG|Gemcitabine|Given IV
40965683|NCT02228460|DRUG|GZ/SAR402671|Pharmaceutical form: Capsule; Route of administration: Oral
40965684|NCT03519646|DRUG|Eliglustat|"1. This is a 3-year study and the enrollment time of this study is 24 months.~2. The participants have to receive the investigational agent, Cerdelga~3. The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~4. IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~5. No need for fasting before use, but can't take with grapefruit juice.~6. Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test."
40965685|NCT01367002|DRUG|Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
41146838|NCT06406777|DIAGNOSTIC_TEST|Spirometry|Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.
40965686|NCT01367002|DRUG|Trastuzumab|Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
40965687|NCT03569033|DRUG|Gefapixant|Gefapixant 45 mg will be administered orally.
40965688|NCT03569033|DRUG|Placebo|Placebo tablet matching gefapixant will be administered orally.
40965689|NCT04195698|DRUG|Upadacitinib|Upadacitinib will be administered oral as tablet
40965690|NCT05932485|PROCEDURE|Stellate nerve block|Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
41137560|NCT03146026|BEHAVIORAL|Combined Exercise Training|The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
41137561|NCT03978065|DIAGNOSTIC_TEST|Confocal microscopy|"For this purpose live stains will be combined with a confocal imaging setup equipped with 6 laser lines. A major advantage of this technique is that tissue specimens do not need to be fixed prior to analysis. Such an approach does not only allow tissue viability and integrity assessment in an unprecedented speed and accuracy, but also promises to shed new light into quality assessment and prognosis in kidney transplantation. The investigators herein wish to establish the predictive values of this technology in kidney transplantation.~The methodology used in this trial is referred to as BIOPSYCHRONOLOGY - as a reference to dendrochronology, or tree ring dating. Leaving the biopsy sample intact facilitates its analysis, just as drills are used for tree-ring counting."
40767138|NCT06050252|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
40767139|NCT06050252|PROCEDURE|Resection|Undergo surgical resection
41137562|NCT04244032|BEHAVIORAL|Working Memory Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a working memory task designed to utilize individually-adapted difficulty levels.
41137563|NCT04244032|BEHAVIORAL|Inhibitory Control Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in an inhibitory control task designed to utilize individually-adapted difficulty levels.
41137564|NCT04244032|BEHAVIORAL|Bias Modification Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a bias modification task designed to utilize individually-adapted difficulty levels.
41137565|NCT00364988|DRUG|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
41137566|NCT00364988|DRUG|losartan|losartan (100 mg daily)
41137567|NCT00004474|DRUG|Anti-thymocyte globulin|Given via IV over 4 hours
41137568|NCT00004474|DRUG|Cyclophosphamide|Given via IV over 60 minutes on Days -5 to -2
41137569|NCT00004474|PROCEDURE|Bone marrow transplantation|Given on Day 0
41137570|NCT02648841|RADIATION|Adjuvant Concurrent Chemo-radiotherapy|Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.
41137571|NCT02648841|DRUG|Adjuvant chemotherapy for active comparator group|8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
41146839|NCT06406777|DIAGNOSTIC_TEST|Contrast Lung Computed Tomography (CT) Scan|CT scan of the lungs using contrast
40767140|NCT00694850|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
40767141|NCT04331249|PROCEDURE|surgery or catheter based cardiac procedure (catheter ablation)|patients with implanted CIED (pacemaker, ICD or CRT) that undergo any surgery or any catheter based cardiac procedure (e.g. radiofrequency ablation)
40965691|NCT04893538|DIAGNOSTIC_TEST|First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
40965692|NCT04893538|DIAGNOSTIC_TEST|First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
40965693|NCT03131765|BIOLOGICAL|YS-0N-001|Cancer vaccine
40965694|NCT05310890|BEHAVIORAL|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
40965695|NCT05310890|BEHAVIORAL|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
40965696|NCT02412605|PROCEDURE|Trophectoderm embryo biopsy|"Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred."
40965697|NCT00622245|DRUG|Lu AA34893|per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
40965698|NCT00622245|DRUG|Quetiapine fumarate|per oral, once daily, during 12 weeks, followed by a one-week tapering period
40965699|NCT00622245|DRUG|Placebo|per oral doses, twice daily as capsules during 13 weeks
40965700|NCT00674245|DRUG|Pantoprazole|40 mg once daily for 4 weeks
41457308|NCT05233254|BEHAVIORAL|Abdominal Hollowing exercise|Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out. Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out.
41457309|NCT04149301|DIAGNOSTIC_TEST|3D gait analysis|Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.
40767142|NCT03872115|DEVICE|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
41137572|NCT02648841|DRUG|Adjuvant chemotherapy for experimental group|6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
40965701|NCT00674245|DRUG|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
40965702|NCT00674245|DRUG|placebo|40 mg once daily for 4 weeks
40965703|NCT01095783|PROCEDURE|physiotherapeutic intervention|Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks
40965704|NCT01095783|PROCEDURE|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
41137573|NCT02542696|DRUG|APL-130277|"Used to treat up to 5 OFF episodes per day"
41137574|NCT02409407|DRUG|Misoprostol , Prostaglandins E1 analogue|
41457310|NCT04149301|DIAGNOSTIC_TEST|MRI scan|The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
41457311|NCT00358631|DRUG|SSR149415|
41457312|NCT06467032|OTHER|superficial CO2 laser resurfacing|Application of the tested product and comparators on the laser treated side of the back
41457313|NCT06467032|OTHER|Laser untreated side|Application of the tested product and comparators on the laser untreated (control) side of the back
41457314|NCT05970939|OTHER|Development of the Telerehabilitation Usability Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Usability Questionnaire in patients with MS.
41137575|NCT02022293|DRUG|Atorvastatin|Patients in this group will take 20mg per night.
40767145|NCT06247787|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
40767146|NCT06247787|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
40767147|NCT06247787|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
40767148|NCT06247787|DRUG|Cytarabine|Receive IV and IT
40767149|NCT06247787|PROCEDURE|Echocardiography|Undergo ECHO
40767150|NCT06247787|DRUG|Fludarabine|Receive IV
40767151|NCT06247787|DRUG|Hydrocortisone Sodium Succinate|Receive IT
40767152|NCT06247787|BIOLOGICAL|Imetelstat|Receive IV
40767153|NCT06247787|DRUG|Leucovorin Calcium|Receive IV or PO
40767154|NCT06247787|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
40965705|NCT06555536|OTHER|Tele OI|A data collection and Telemedicine tool translated into an APP.
40965706|NCT03090178|OTHER|electronic-Patient Report Outcome and wear of a wristband actigraph|Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
40965707|NCT04080401|DEVICE|Game-based rehabilitation exercise|4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.
40965708|NCT04080401|OTHER|Conventional brochures of rehabilitation exercise|4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
40990688|NCT01733446|OTHER|Continuation of High Frequency Jet Ventilation (HFJV)|In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
41137576|NCT02022293|OTHER|Placebo|
41137577|NCT04307056|PROCEDURE|Radical Prostatectomy|The surgical approach can be open or laparoscopic. The procedure begins with lymph node dissection for the intermediate risk groups (PSA \> 10 ng/mL and/or presence of grade 4 Gleason score). Total prostatectomy includes removal of the seminal vesicles. It can preserve 1 or 2 neurovascular bundles, depending on the cancer stage and/or the choice expressed by the patient. The vesicourethral suture is either a running or interrupted suture, and there is drainage by a bladder catheter for at least 5 days.
40965709|NCT00176228|DRUG|Lamotrigine|"It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.~The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg."
40965710|NCT03310021|BIOLOGICAL|Andexanet alfa|fXa inhibitor antidote
40965711|NCT03310021|DRUG|Apixaban|factor Xa inhibitor
41295249|NCT01494961|BEHAVIORAL|Couple-oriented post-test HIV counseling|COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
41295250|NCT06051253|DRUG|TDM-based infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously given as an induction therapy at a dose of 5 mg/kg at week 0, 2, and 6. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.
41295251|NCT06051253|DRUG|Standard infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
40767155|NCT06247787|DRUG|Methotrexate|Receive IT
41137578|NCT04307056|PROCEDURE|High Intensity Focused Ultrasound (HIFU) Treatment|The treatment with High Intensity Focused Ultrasound (HIFU) evaluated in this study will be delivered by 2 types of medical devices currently available on the market, Ablatherm® and Focal One®. They are both computer-controlled and provided with an endo-rectal probe with integrated ultrasound, enabling planning and the monitoring of treatment of localized prostate cancer in realtime.
40965712|NCT03310021|DRUG|Rivaroxaban|factor Xa inhibitor
40965713|NCT03310021|DRUG|Edoxaban|factor Xa inhibitor
40965714|NCT03310021|DRUG|Placebo|Placebo
40965715|NCT03222336|BEHAVIORAL|Family pedigree and data collection|"1. Enroll first generation (newborn), at least one member from second (parent) and third generation (grandparent) for a complete IVS4 family tree mapping.~2. Collect and analyze medical history, genetic and biochemical assessment data"
41137579|NCT06413888|PROCEDURE|pancreaticoduodenectomy|Surgical removal of the head of the pancreas, duodenum, extrahepatic bile duct, distal stomach, and proximal jejunum. Group A cohort will not have NGT placed in the postoperative period. Whereas, group B will have the NGT retained in the posoperative period
41137580|NCT03266419|DRUG|Deep NMB using rocuronium|"* Drug: rocuronium~* Bolus dose: 0.7 mg/kg~* Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation."
41137581|NCT03266419|DRUG|Moderate NMB using rocuronium|"* Drug: rocuronium~* Bolus dose: none~* Continuous infusion: 0.2-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation."
41137582|NCT01436214|DRUG|APC-100|Daily oral, dose escalation, 28-day cycle(s)
41137583|NCT03211988|DRUG|Entinostat|Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
41137584|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Individual Delivery + No Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). No booster sessions.
41146840|NCT06406777|DIAGNOSTIC_TEST|Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan|MRI will be taken while subject is lying on their back breathing 100% oxygen.
40965716|NCT01243892|DEVICE|NuSpin|Device for administration of doses of somatropin.
40965717|NCT01243892|DRUG|Somatropin|Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
40965718|NCT01701557|OTHER|slow fluid rate|10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
40965719|NCT01701557|OTHER|fast fluid rate|20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
40965720|NCT05013684|OTHER|Particle Repositioning Maneuver|treatment with Particle Repositioning Maneuver
40965721|NCT00006097|DRUG|CC-1088|
41137585|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Group Delivery + No Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). No booster sessions.
40965722|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
40965723|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
40965724|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
40965725|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
40965726|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
40965727|NCT03042624|DIETARY_SUPPLEMENT|Fermented rice|7 g of powder obtained from Lactobacillus paracasei CBA L74
40965728|NCT03042624|DIETARY_SUPPLEMENT|Maltodextrins|7 g of maltodextrins powder
40965729|NCT01980394|PROCEDURE|Esophageal Stump Washout|a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
40965730|NCT06185283|DIAGNOSTIC_TEST|panoramic x-ray|Long cone paralleling technique and a film holder designed specifically for implant imaging were used for intraoral radiograph. To maintain the same film- implant distance and cone implant distance, a modification were carried out for the film holder. This modification is a hole drilled exactly above the implant fixture so the distance were maintained during subsequent film exposures. Through this modification, standardized radiographs were achieved.
40965731|NCT01858298|OTHER|Conservative treatment: pulpectomy and composite resin crown|
40965732|NCT01858298|OTHER|Non-conservative treatment: Tooth extraction|
41137586|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Individual Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). 3 monthly booster sessions.
41137587|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Group Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). 3 monthly booster sessions.
40965733|NCT03425747|DRUG|Calcium Carbonate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
41137588|NCT05454332|DRUG|Early Caffeine administration|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
40965734|NCT03425747|DRUG|Calcium Citrate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
40990689|NCT06284278|OTHER|Diaphragmatic breathing retraining|8 weeks diaphragmatic breathing training
41146841|NCT06406777|DIAGNOSTIC_TEST|129Xe MRI scans|MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.
41146842|NCT03469089|DRUG|Ketamine 0.58|Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)
41146843|NCT03469089|DRUG|Ketamine 0.31|Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)
41146844|NCT03469089|DRUG|Modafinil|Modafinil tablet 100 mg placed in a capsule
40990690|NCT06284278|OTHER|Pelvic stabilization exercise|8 weeks pelvic stabilization exercise training
40990691|NCT06284278|OTHER|pelvic anatomy education|pelvic anatomy education
41146845|NCT03469089|DRUG|Placebo for ketamine|0.9 % NaCl infusion solution
41146846|NCT03469089|DRUG|Placebo for modafinil|Placebo capsule for modafinil capsule
40767156|NCT03855540|DIAGNOSTIC_TEST|ECHOcardiography|"ECHO parameters~1. LA diameter~2. LVEDD~3. LVEF~4. Diastolic dysfunction~5. Valvular disease"
40965735|NCT04753645|BEHAVIORAL|Handwashing stations at the public places and no soap|BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
40965736|NCT04753645|BEHAVIORAL|No activities of the HBCC project and also no soap (Pure Control)|In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
40965737|NCT04753645|BEHAVIORAL|Soap distributed but no activities of the HBCC project|In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
40965738|NCT04753645|BEHAVIORAL|HBCC project and Soap|These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
40965739|NCT00228384|DEVICE|GORE VIABAHN Endoprosthesis|Implantation
40965740|NCT00228384|DEVICE|Bare Nitinol Stent|Implantation
40965741|NCT04189159|BEHAVIORAL|PROMPT|PROMPT treatment is consistent with the principles of motor learning, in that every session includes a blocked pre-practice followed by variable and distributed practice and a gradual, hierarchical increase of complexity. Speech motor goals are integrated in goals for language and functional communication. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided, in order to shape speech movements, to give information on sequencing and timing and to introduce constraints for the reduction of degrees of freedom at the articulators' level in favour of motor control.
40965742|NCT04774315|DRUG|Omalizumab|omalizumab 300mg SQ every 4 weeks as part of standard of care
40965743|NCT05840991|DEVICE|elastic bandage|3M™ Coban™ elastic bandage
40965744|NCT05840991|DEVICE|compression stocking|Class 2 compression full-length stocking (23-32mm Hg)
40965745|NCT02973698|OTHER|chin-down posture maneuver|it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
40965746|NCT02973698|OTHER|Orientations about swallowing|The instructions about feeding were performed. The individuals received all the instructions on a written document.
40767157|NCT03855540|DIAGNOSTIC_TEST|Peripheral blood samples for plasmatic biomarkers|"1. Coagulation~   * D - dimer~  * Fibrinogen~2. Inflammation and fibrosis~   * Hs - CRP~  * AGEs~  * Soluble RAGE~3. Hemodynamics (LA stretch)~   * Apelin~  * NT - proBNP~  * Hs - troponin~4. MiRNA~   * miRNA - 1~  * miRNA - 133~  * miRNA - 29b~  * miRNA - 208a~  * miRNA - 208b~  * miRNA - 499"
40767158|NCT03855540|DIAGNOSTIC_TEST|Athens insomnia scale questionnaire|Athens insomnia scale questionnaire
40965747|NCT02973698|OTHER|Control|No intervention will do
40965748|NCT05948397|DIAGNOSTIC_TEST|Combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and quality of life scale|A combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) and quality of life scale would be given to all patients. The sum of the responses for the third, fourth and fifth questions and quality of life scale scores will be recorded.
40965749|NCT05948397|DIAGNOSTIC_TEST|Bladder diary|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance
40965750|NCT05948397|DIAGNOSTIC_TEST|Pad test|"One-hour pad test.~* the test is started by putting one pre-weighted pad without patient voiding, -patient drinks 500 ml of sodium-free liquid in \<15 min- then sits or rests,~* patient walks for 30 min, including climbing one flight of stairs (up and down),~* patient performs the following activities: standing up from sitting (10 ), coughing vigorously (10 ), running on the spot for 1 min, bending to pick up an object from the floor (5 ), and washing hands in running water for 1 min (this activity program may be modified according to the patient's physical fitness),~* the total amount of urine leaked is determined by weighing the pad. In the analysis of 1-hr pad test, an increase of 1-10 g is classified as representing mild incontinence, 11-50 g moderate and \>50 g severe incontinence. The values for 24-hr pad test are classified as follows: Mild (4-20 g/ 24 hr), moderate (21-74 g/24 hr), and severe (\>75 g/24 hr) incontinence"
40965751|NCT04436120|PROCEDURE|De novo tumor tissue biopsy|De novo tissue biopsy performed following disease progression
40965752|NCT04436120|PROCEDURE|Research blood draws|Blood biospecimens collected following disease progression
40965753|NCT03012165|DRUG|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
40965754|NCT03012165|DRUG|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
40965755|NCT03012165|DRUG|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
40965756|NCT00484874|DRUG|I-131 Tositumomab therapeutic regimen|Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.
40767159|NCT03855540|DIAGNOSTIC_TEST|ECG Holter monitor|Patient receives ECG Holter monitor if included to the control group
40990692|NCT00628433|DRUG|Placebo|Placebo
41457315|NCT00494741|DRUG|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
41457316|NCT00494741|DRUG|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight \> 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
40965757|NCT02036294|OTHER|BREATHE program|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
40965758|NCT02036294|OTHER|Usual Care|Standard Healthcare Services
40965759|NCT06120387|PROCEDURE|Radical surgery|Radical nephroureterectomy
40965760|NCT06120387|RADIATION|Kidney sparing surgery+Postoperative radiotheray|Kidney sparing surgery+Postoperative radiotheray
40965761|NCT03917914|DRUG|Bisoprolol|As in arm description
40965762|NCT03917914|DRUG|Placebo Oral Tablet|As in arm description
40965763|NCT02849678|DRUG|Ropivacaine|0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
40965764|NCT02849678|DRUG|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
40965765|NCT05036824|DRUG|tinzaparin|Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU
40965766|NCT04664166|OTHER|Alpena Otago Telehealth Program|"A physical therapist will use video visits to evaluate the participants and provide exercise instructions from Week 1 to Week 4. Each participant will use the Blue Marble Health in Motion app from a mobile tablet to complete the exercise guided by an avatar at their own pace after receiving the exercise instructions from the physical therapist. Participants are encouraged to exercise three days a week and 30 minutes each day using the app for 6 months. The exercise protocol based on the evidence-based Otago program includes warm up, strengthening, and balance exercise.~3.5. Research Study Design and Data Analyses:"
40965767|NCT04026997|DRUG|CIN-102 Dose 1|CIN-102 Dose 1
40965768|NCT04026997|DRUG|CIN-102 Dose 2|CIN-102 Dose 2
40965769|NCT04026997|DRUG|CIN-102 Dose 3|CIN-102 Dose 3
40965770|NCT04026997|DRUG|Placebo|Placebo
40965771|NCT05884905|PROCEDURE|short hydration|NSS infusion prior to and following cisplatin administration within 6 hours
40965772|NCT05884905|PROCEDURE|conventional hydration|NSS infusion prior to and following cisplatin administration over 24 hours
40965773|NCT02370745|DRUG|GLP-1|GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
40965774|NCT02370745|DRUG|Insulin Actrapid|Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
40965775|NCT02370745|DIETARY_SUPPLEMENT|Oral amino acids|Oral amino acids containing 15 g of amino acids
40965776|NCT02370745|DRUG|GIP|This will be co infused with GLP-1 and intravenous amino acids
40965777|NCT02370745|DRUG|Intravenous amino acids|This will aim to deliver iso equivalent amount to the amino acids administered orally
40965778|NCT05173662|PROCEDURE|Providing education and brochures on non-pharmacological methods that can be applied during the heel blood collection process|Theeduvation initiative was implemented by the researcher at least 12 hours ago in the mothers' room and a brochure was given about the education.
40965779|NCT00791960|DRUG|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
40965780|NCT00791960|OTHER|Placebo|single dose, 10 mL normal saline, IV
40965781|NCT03755297|OTHER|Blood sample analysis of patients treated as standard care|Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
40965782|NCT06025227|DRUG|Etrasimod|tablets
41137589|NCT05454332|OTHER|Control Group|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
40965783|NCT01950741|DRUG|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
40965784|NCT00492037|DRUG|YM087 oral|
41137590|NCT05840185|DEVICE|Test myopia control lenses (DAL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
40767160|NCT03855540|DIAGNOSTIC_TEST|ECG event recorder|Patient receives ECG event recorder for twice daily (or if symptoms), 90 seconds duration ECG monitoring if included to the control group
40965785|NCT01369758|DEVICE|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
40965786|NCT03502980|DEVICE|Bard PowerPICC|PICC Insertion
40965787|NCT03502980|DEVICE|Bard PowerMidline catheter|Midline Insertion
40965788|NCT00547482|DEVICE|TANTALUS(TM) System|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation)."
40767161|NCT06563570|OTHER|yoga (online)|8-week online yoga practices, 2 days a week
40965789|NCT03387332|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
40965790|NCT06387095|PROCEDURE|1. no block|After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
40965791|NCT06387095|PROCEDURE|2. superficial parasternal block|After induction, the patient will undergo an ultrasound-guided superficial parasternal plan block. . After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
40965792|NCT06387095|PROCEDURE|3. deep parasternal block|After induction, the patient will undergo an ultrasound-guided deep parasternal plane block. . After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
40965793|NCT06177730|OTHER|Pre-Hospital ECPR|Implementation of pre-Hospital ECPr in OHCA
40965794|NCT05173883|DRUG|injection ，CU-20401|Subcutaneous injection，cohort A 6 sites
40965795|NCT05173883|DRUG|injection ，placebo|Subcutaneous injection，just one site
40965796|NCT01220050|DRUG|Paricalcitol|Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
40965797|NCT01220050|DRUG|Standard therapy|Standard therapy for hyperparathyroidism for 26 weeks
40965798|NCT00365729|BEHAVIORAL|Smear and biopsy testing for HPV-types and viral load|Smear and biopsy testing for HPV-types and viral load
40965799|NCT05175053|OTHER|Renal replacement therapy|Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)
40965800|NCT05175053|OTHER|Best medical management|The best medical management continues until the patient meets absolute indication of renal replacement therapy
40767162|NCT05234177|OTHER|Observation|No intervention
40767163|NCT04832698|OTHER|Survey Administration|Complete survey
40767164|NCT06641388|DRUG|Ebronucimab|Ebronucimab subcutaneous injection
40767165|NCT06641388|DRUG|Ebronucimab|Ebronucimab subcutaneous injection
40767166|NCT04938830|BIOLOGICAL|Clesrovimab|IM injection
40965801|NCT03923712|BEHAVIORAL|Supervised Exercise Programme|The methodology will be multicomponent, including aerobic, strength, coordination-cognitive and balance-agility. The physical exercise sessions will be designed in such a way that they work the dimensions but being attractive and motivating for the participants. Each session will include 10 minutes of warm-up with smooth running and mobility exercises; 35-40 minutes of aerobic, strength, coordination-cognitive and balance-agility progressively developed; and 10 minutes back to calm at low intensity with stretching exercises. Nutritional intervention will not be included. For quality purposes, we will use small groups (10-15 pers). After each session participants will be asked about their subjective perception of the effort and the intensity will be controlled by heart rate monitors.
40965802|NCT05657444|DRUG|Tenecteplase|intra-arterial tenecteplase during endovascular treatment
40965803|NCT05318755|DRUG|GAHT for transgender men|Testosterone undecanoate
40965804|NCT05318755|DRUG|GAHT for transgender women|Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
40965805|NCT06464068|DRUG|Durvalumab|"All drugs will be administered intravenously. Induction treatment will be administered on a 21-day cycle for four cycles and will consist of:~* etoposide 80-100 mg/m² (administered on days 1-3 of each 21-day cycle);~* investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m² (administered on day 1 of each cycle);~* durvalumab 1500 mg every 3 weeks in combination with chemotherapy (induction phase) followed by maintenance phase with durvalumab 1500 mg every 4 weeks. Patients will continue treatment until disease progression per investigator assessment, unacceptable toxicity, or other discontinuation criteria were met for a maximum of 24 months. Continuation of study treatment after disease progression will be permitted if there is evidence of clinical benefit for a maximum 24 months."
40965806|NCT02879305|DRUG|Daprodustat|Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
40990693|NCT00628433|DRUG|HE3286|daily for 28 days
40767167|NCT04938830|BIOLOGICAL|Palivizumab|IM injection
40767168|NCT04938830|BIOLOGICAL|Placebo|IM injection
40965807|NCT02879305|DRUG|rhEPO|The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
40965808|NCT02879305|DRUG|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
40965809|NCT02879305|DRUG|Iron therapy|Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
40965810|NCT00952575|DRUG|polyclonal anti-D immunoglobulin|single injection of 300 µg
40965811|NCT00952575|DRUG|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
40965812|NCT04180228|OTHER|self-administred questionnaire|On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.
40767169|NCT05497024|BEHAVIORAL|Interviews|"Participants will discuss background, such as race, education, and living situation.~Participants will discuss Prostate cancer Participants will discuss feedback on the educational material"
40767170|NCT05497024|BEHAVIORAL|Surveys|Participants may answer questions that are sensitive in nature.
40965813|NCT04890769|DEVICE|Moisture sensor wound dressing|Clinical procedure for change of wound dressing
40965814|NCT00637338|BIOLOGICAL|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
40965815|NCT00637338|BIOLOGICAL|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
40965816|NCT01888237|DRUG|Double dose of PPI|Lansoprasole (30mg) 2 tab oral BID
40965817|NCT01888237|DRUG|sequence of drug use|lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
40767171|NCT05031897|DRUG|Fludarabine|Given IV
40767172|NCT05031897|RADIATION|Total-Body Irradiation|Undergo TBI
40767173|NCT05031897|PROCEDURE|Donor Lymphocyte Infusion|Undergo DLI
40965818|NCT04059783|DRUG|STW5 (Iberogast®, BAY98-7411)|The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks
40965819|NCT05741632|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
40965820|NCT05741632|DRUG|Levofloxacin Ophthalmic|Levofloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
40965821|NCT04753983|DIAGNOSTIC_TEST|Functional magnetic resonance imaging (fMRI)|Diagnostic imaging measuring the metabolic changes that occur within the brain used for measuring and mapping brain activity
40965822|NCT01152697|DRUG|haloperidol decanoate|Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
40965823|NCT01152697|DRUG|haloperidol|Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
40965824|NCT01152697|BEHAVIORAL|Customized Adherence Enhancement|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
40965825|NCT03808545|BEHAVIORAL|Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)|This is a newly developed Internet website that delivered a Social Cognitive Theory-based behavioral intervention using e-learning and one-on-one video chats approaches for increasing physical activity and improving symptoms, walking impairment, and neurological disability. The intervention will last 16 weeks and will include physical activity information.
41137591|NCT03652610|BIOLOGICAL|MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
40767174|NCT05031897|DRUG|Cyclophosphamide|Given IV
40767175|NCT05031897|DRUG|Tacrolimus|Given IV
40767176|NCT05031897|DRUG|Mycophenolate Mofetil|Given IV
40767177|NCT05031897|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
40767178|NCT05031897|DRUG|Melphalan|Given IV
40767179|NCT05031897|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/ biopsy
40767180|NCT05031897|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
40767181|NCT05031897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40965826|NCT03808545|BEHAVIORAL|BIPAMS + Diet|For 8 weeks a participant will complete the standard BIPAMS intervention. For the subsequent 8 weeks, in addition to the BIPAMS website, participants will receive a diet prescription with instructions and guidance on their one-on-one video calls and will utilize the HealthWatch360 app and/or desktop website to track their dietary intake. The total intervention will last 16 weeks and will include physical activity information and dietary information.
40965827|NCT02114814|BEHAVIORAL|Diabetes self-management program for Hispanics and their families|The intervention group received an 8-weekly culturally tailored diabetes self-management and family support education program delivered in Spanish
40965828|NCT02114814|BEHAVIORAL|General health educational program for Hispanics and their families|The attention control group received 8-weekly education program on general health information
40965829|NCT02457260|DRUG|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
40965830|NCT03794297|DRUG|Dabrafenib Mesylate|Given PO
40965831|NCT03794297|OTHER|Quality-of-Life Assessment|Ancillary studies
40965832|NCT03794297|OTHER|Questionnaire Administration|Ancillary studies
40965833|NCT03794297|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
40965834|NCT02714582|BEHAVIORAL|Bedside shift report|Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson \& Mangino 2006).
40965835|NCT01702805|PROCEDURE|Liberal Cell Transfusion|
40965836|NCT01702805|PROCEDURE|Restricted red cell transfusion|
40965837|NCT00000793|DRUG|Mexiletine hydrochloride|
40965838|NCT00000793|DRUG|Benztropine mesylate|
40965839|NCT00000793|DRUG|Amitriptyline hydrochloride|
40965840|NCT01044771|DRUG|change from tenofovir to raltegravir|Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
40965841|NCT03234933|OTHER|Mobility Tracker|Tracking Patient's movements and calories
40965842|NCT01685281|DRUG|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
40965843|NCT01685281|DRUG|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
40965844|NCT02398175|OTHER|reanimation/intubation|
40965845|NCT00885846|OTHER|Qigong therapy|For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
40965846|NCT00885846|OTHER|Progressive resistance training|For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
40965847|NCT05392296|OTHER|Power ball|experimental group getting the power ball training with conventional treatment.
40965848|NCT05392296|OTHER|isometric hand grip strengthening exercises|conventional treatment (isometric hand grip training exercises)
40965849|NCT00280098|DRUG|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
40965850|NCT06211322|DEVICE|"Urika, a self-management application for patients with gout"|The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
40965851|NCT00629707|OTHER|intravenous fluid treatment|infusion of intravenous fluids (0.9% saline and 0.45% saline)
40965852|NCT05697315|PROCEDURE|Control|No block was performed
40965853|NCT05697315|PROCEDURE|Erector spinae plane block|Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
40965854|NCT04478539|DEVICE|Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter|"Admitted patients will receive at least 1 cycle of extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (Baxter, IL, USA). The number of cycles of blood purification is determined based on multiple biochemical, immunological, coagulation parameters, radiological imaging and overall clinical condition.~The patient is connected to the Prismaflex® oXiris® system via a double lumen catheter placed in the femoral vein or vena subclavia.~Flow rates will be maintained as follow; effluent dose 35 mL/Kg/h, dialysate 14 - 16 mL/Kg/h, blood 150 mL/min, replacement 16 -18 mL/Kg/h; patient fluid removal is tailored to the individual's volume status, ≈ 100 - 250 mL/h.~The oXiris® extracorporeal and organ support modality will be chosen according to the patient's kidney function; continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF) or slow continuous ultrafiltration (SCUF)."
40965855|NCT05475795|OTHER|Metapex|obturation of root canals of primary molars with Metapex
40965856|NCT05475795|OTHER|Endoflas|obturation of root canals of primary molars with Endoflas
40965857|NCT02560571|DEVICE|ultrasound|
40965858|NCT02560571|OTHER|blood test|
40965859|NCT00740831|DRUG|PGL4001|tablets
40965860|NCT00740831|DRUG|leuprorelin|solution for injection
40965861|NCT04286243|OTHER|Community-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the community
40965862|NCT04286243|OTHER|Clinic-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the clinic
40965863|NCT01833013|OTHER|live birth date and quality of life assessment|
40965864|NCT06506266|OTHER|HFA-152a|HFA-152a is administered via oral inhalation
40965865|NCT06506266|OTHER|HFA-134a|HFA-134a is administered via oral inhalation
40965866|NCT06506266|OTHER|Radiolabeled saline solution|Radiolabeled saline solution is administered via oral inhalation
41457317|NCT03416673|PROCEDURE|peCTG+CAF|A connective tissue graft will be reshaped to have extensions mimicking the papillae to augment the inter-dental papillae recessed
40965867|NCT05541952|BIOLOGICAL|BCG|Revaccination with BCG, using the immunobiological used in the Brazilian public health network, strain Russia.
40965868|NCT05469828|DRUG|Crizanlizumab|patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses).
40965869|NCT05469828|OTHER|control|Standard of care
40965870|NCT00329238|DRUG|Dabigatran|Dabigatran 150 mg BID (twice daily)
40965871|NCT00329238|DRUG|Warfarin|Warfarin dosed individually to maintain INR 2.0-3.0
40965872|NCT00824239|PROCEDURE|Intermittent sedation|Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
40965873|NCT00824239|PROCEDURE|Daily interruption of sedation|Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
40965874|NCT04146233|OTHER|Point of care gastric ultrasound|Point-of-care gastric ultrasound will be performed using a low-frequency curvilinear ultrasound probe to assess stomach contents (empty vs. not empty, liquid vs. solid, gastric volume).
40965875|NCT03085381|BIOLOGICAL|HPV vaccine|
40965876|NCT03085381|BIOLOGICAL|Placebo|
40965877|NCT01439269|BEHAVIORAL|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
40965878|NCT01394432|PROCEDURE|PCI and Stem Cells or Placebo injections|Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.
40965879|NCT04533581|DRUG|ME-401|In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).
40965880|NCT05129215|OTHER|Questionnaire|The LARS score is used for assessment of bowel dysfunction after rectal cancer resection.
40965881|NCT01740947|DRUG|Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)|SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
40965882|NCT00596284|BEHAVIORAL|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
40965883|NCT00596284|BEHAVIORAL|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
40965884|NCT01867437|DRUG|Placebo|Sterile solution (vehicle) for subcutaneous infusion
40965885|NCT01867437|DRUG|RM-493|Sterile solution (2mg/ml) for subcutaneous infusion
40990694|NCT02323230|BIOLOGICAL|DPX-Survivac|Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
40990695|NCT02323230|DRUG|Cyclophosphamide|Low dose cyclophosphamide will be taken by mouth
40990696|NCT05876273|DEVICE|Neural-net Artificial Pancreas|NAP is a neural-net implementation of the previously tested UMPC algorithm (below).
41137592|NCT03652610|BIOLOGICAL|Licensed GSK MenACWY vaccine (Menveo)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
41137593|NCT02077374|DRUG|IDN-6556|25 mg BID for 28 days
41137594|NCT02077374|OTHER|Placebo|Placebo BID for 28 Days
41137595|NCT00173706|DRUG|L-Carnitine Injection|
41137596|NCT02054208|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
41137597|NCT02054208|OTHER|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
41295252|NCT03434132|PROCEDURE|Open or robotic radical cystectomy|"ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed."
41295253|NCT06513182|OTHER|No Alexis orthopaedic protector|No Alexis orthopaedic protector will be used during the course of the surgery.
41295254|NCT06513182|DEVICE|Alexis orthopaedic protector|Alexis orthopaedic protector will be inserted after making an initial superficial approach to the shoulder.
41457318|NCT03416673|PROCEDURE|CTG+CAF|A connective tissue graft harvested from the palate will be sutured to the gingival recession site and covered with a coronally advanced flap
41457319|NCT02488057|DRUG|Liraglutide|Active comparator. See arm descriptions.
41457320|NCT02488057|BEHAVIORAL|Weight loss|Active comparator. See arm descriptions.
41457321|NCT01237080|DEVICE|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
41457322|NCT01237080|DEVICE|Fastrach|The Fastrach is an intubation laryngeal mask.
41457323|NCT02763488|DEVICE|DelfiPTS tourniquet system|
41457324|NCT02763488|OTHER|Standard physical therapy|
40965886|NCT04362982|OTHER|ADHD360 platform: An intervention intergrating a serious game along with a mobile application for daily behavioral monitoring.|Clinical trials will include two parts. The first part includes three visits. In the first visit, children and their parents will come to the Laboratory of Medical Physics to be informed regarding the experimental procedures, sign the consent form and familiarize with the scientific staff involved in the project as well as the lab enviroment. In the second visit, children will undergo an neuropsychological assessment delivered by an experienced pscychologist. Afterwards, they will interact with the ADHD360 platfrom for 30-45 minutes. In the third visit, participants will interact with the ADHD360 platfrom for 30-45 minutes. In the second part, participants will use the ADHD360 platfrom two or three times per week for about 30-45 minutes. At the end of the second part, participants will undergo a neuropsychological evalutation following the same procedures as the first one.
40965887|NCT00415831|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
40965888|NCT02936830|DRUG|5% Sodium Fluoride Varnish|5% sodium fluoride varnish applied on the dentin by the dentist
40965889|NCT02936830|DRUG|15% Nanohydroxyapetite paste|15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
40965890|NCT02936830|DRUG|Glycerol|Glycerol with water in a 1: 1 ratio
40965891|NCT04606030|DEVICE|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
41457325|NCT01834027|BEHAVIORAL|Jazz music|Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
41457326|NCT01834027|BEHAVIORAL|No music|In this group no music will be played in PACU
40965892|NCT04606030|PROCEDURE|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
40965893|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 10g BID x 12 weeks
40965894|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 20g BID x 12 weeks
40965895|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 30g BID x 12 weeks
40965896|NCT04603443|DIETARY_SUPPLEMENT|Protein Control|Protein placebo control - all amino acids except for BCAA, 10g BID x 12 weeks
41457327|NCT05790460|OTHER|Telehealth|Enhanced synchronous telehealth nurse navigation, compared to usual care nurse navigation, to increase timely molecularly-informed treatment recommendations through early integration of concurrent molecular testing.
41457328|NCT03510208|PROCEDURE|Near-Infrared Fluorescence Imaging|Undergo NIR imaging
41457329|NCT03510208|BIOLOGICAL|Panitumumab|Given IV
40965897|NCT02523248|PROCEDURE|tonsillectomy|Tonsillectomy with cold steel
41457330|NCT03510208|DRUG|Panitumumab-IRDye800|Given IV
41457331|NCT03510208|DEVICE|POINPOINT-IR9000|"Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table)."
41457332|NCT04444141|BIOLOGICAL|AK104|The subjects will receive AK104 till disease progression or for a maximum of 24 months.
41457333|NCT01916694|DEVICE|Blue tooth enabled glucose meter with smart phone application|
41457334|NCT01916694|BEHAVIORAL|Self home blood glucose monitoring|Fingerprick testing of blood glucose levels before and 2 hours after meals
40965898|NCT02523248|PROCEDURE|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
41137598|NCT04084522|DIETARY_SUPPLEMENT|Saturated Fat- Desi Ghee (Clarified Butter)|Desi Ghee which is also known as clarified butter contains around 70% of saturated fat. in India it is one of the important culinary items which promotes longevity and protects against various diseases, attributing numerous health benefits. Ghee consumption has also significant hypolipidemic and hypocholesterolemic effects.
41137599|NCT04084522|DIETARY_SUPPLEMENT|Soyabean Oil|Soyabean Oil consists of around 84% of unsaturated fat and is the most widely used source of unsaturated fat used in the area.
41137600|NCT02761356|OTHER|Tc99-MAA|To evaluate the fisibility of Tc99-MAA injected intra epatic artery to predict uptake of Yttrium-90 SIRT in patients with liver malignancies
41137601|NCT06274203|DRUG|Vitamin D3|Subjects within SCD as well as healthy controls, received monthly oral vitamin D3 dose, for 6 months, according to the baseline status of vitamin D as follows: sufficient (\>30 ng/mL): 100,000 IU, insufficient (20-29.9 ng/mL): 150,000 IU, and deficient (\<20 ng/mL): 200,000 IU.
41457335|NCT06149949|OTHER|Observational study|the aim of the study is to define the prevalence of rhinosinusitis cronic in intestinal bowel disease patients, to assess how it affects the patient's quality of life, and any correlations between these two entities
41457336|NCT00327691|DRUG|Atorvastatin|
41457337|NCT00526136|DRUG|Placebo|
41457338|NCT00526136|DRUG|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
41457339|NCT00674128|DEVICE|Cyanoacrylate tissue adhesive (Dermabond)|Skin closure will be performed with cyanoacrylate tissue adhesive.
41457340|NCT00674128|DEVICE|Polyglactin 910 suture (Vicryl)|Skin closure will be performed with polyglactin 910 suture.
41457341|NCT04789187|PROCEDURE|High-Intensity-Interval-Training|Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.
41457342|NCT04789187|PROCEDURE|General Physical Activity Recommendations|Patients will be given general physical activity recommendations during chemotherapy.
40965899|NCT02280304|BEHAVIORAL|Inner Resources for Veterans (IRV)|Mindfulness and breath-focused mantra therapy which uses techniques that encourage present moment attention for the purpose of improving self-monitoring and self-regulation
41457343|NCT04857333|DIAGNOSTIC_TEST|CT scan|For patients with low-risk pulmonary nodules, follow-up CT scan is recommended
40767182|NCT05528939|DEVICE|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
40767183|NCT05528939|OTHER|Control video game|The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters. There is progression in difficulty to maintain engagement and expectation of benefit from patients and their caregivers.
40767184|NCT06317909|OTHER|allergen challenge|Patients will undergo inhaled allergen challenge followed by different measures like MRI and induced sputum. At least 4 weeks later patients will undergo segmental allergen challenge followed by different measures like bronchoalveolar lavage.
40965900|NCT02280304|BEHAVIORAL|Essential Skills therapy|This active comparator is adapted from a therapy utilized at multiple VAs as a psychoeducational AND symptom management treatment for PTSD. In it, participants learn about mTBI and PTSD symptoms and coping information for PTSD.
40965901|NCT05745571|OTHER|Blood sample|The study foresees a phase of patient recruitment, in which, in the hours immediately following the blood sampling, the isolation of the PBMCs, their incubation and cytofluorimetric analysis will be carried out and the conservation of the material to be analyzed subsequently by molecular biology and immunochemistry.
40965902|NCT05664971|BIOLOGICAL|Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection|200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
41457344|NCT04857333|DRUG|Antibiotics|For pulmonary nodules with features of infectious disease, antibiotics is recommended
40965903|NCT05664971|BIOLOGICAL|Toripalimab|240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
40965904|NCT05664971|DRUG|Docetaxel|60 or 75mg/m2 via IV infusion on Day 1 of a 21-day cycle, which may be maintained until disease progression
40965905|NCT05664971|DRUG|Pemetrexed|500mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles; Subjects who have disease progression after 4 cycles may continue to receive maintenance treatment with pemetrexed
40965906|NCT05664971|DRUG|Cisplatin|75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
40965907|NCT05664971|DRUG|Carboplatin|AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
40965908|NCT05664971|DRUG|Paclitaxel|175mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
40965909|NCT05664971|DRUG|Etoposide|100mg/m2 via IV infusion on Days 1, 2, and 3 of a 21-day cycle for 4 cycles
41137602|NCT03673618|DRUG|Soluble Corn Fiber|Fiber or placebo
41457345|NCT04857333|PROCEDURE|Surgical Resection|For persistent high-risk pulmonary nodules, surgical resection is recommended
41457346|NCT00004105|DRUG|estramustine phosphate sodium|
41457347|NCT00004105|DRUG|paclitaxel|
41457348|NCT00004105|DRUG|vinorelbine ditartrate|
41457349|NCT04192032|OTHER|Preferred Juul pod flavor (5% nicotine)|Preferred Juul pod flavor (5% nicotine)
41457350|NCT04192032|OTHER|Classic Tobacco Juul pod flavor (5% nicotine)|Classic Tobacco Juul pod flavor (5% nicotine)
40965910|NCT04442867|OTHER|Case management|Based on the clients' problems, individualized and specific health education such as recognition of the early signs and symptoms of an exacerbation or deterioration of disease condition, the frequency, dosage, duration of each health-promoting activity that was of therapeutic value, and the techniques required to perform these activities will be provided by the Nurse Case Manager.
40965911|NCT04442867|OTHER|Social call|Provide social call to participants, such as ask the participants what TV program do you like most, and how are you recently.
40965912|NCT03853408|PROCEDURE|Cholecystectomy|Cholecystectomy (removal of the gallbladder) for acute cholecystitis
41137603|NCT03772132|BIOLOGICAL|mutation and signal pathway activation status analysis Drug: FORFIRINOX|Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy
41137604|NCT03075878|DRUG|ALXN1830|Administered via IV infusion.
41295255|NCT03425565|DRUG|Pembrolizumab|3 weekly cycles of Pembrolizumab administered by IV
41295256|NCT03593304|DRUG|Injection Mecobalamin|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
41295257|NCT03593304|DRUG|Tablet Pyridoxine hydrochlorid|Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
41295258|NCT03593304|DRUG|Normal saline|Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
41295259|NCT03593304|DRUG|Oral Placebo|Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
41295260|NCT00041236|DRUG|exatecan mesylate|
41295261|NCT05601999|BIOLOGICAL|GNR-060|GNR-060 will be administered in an individual dose depending on body weight as a single intravenous bolus
41295262|NCT05601999|BIOLOGICAL|Metalyse|Metalyse will be administered in an individual dose depending on body weight as a single intravenous bolus
41295263|NCT06295510|OTHER|No interventions.|It's only observational study.
41295264|NCT06529289|OTHER|Training|"We conducted one day of training for FCHVs and four different groups of FCHVs from two municipalities. We conducted training on hypertension knowledge and blood pressure measurement skills for FCHVs. Studies from Nepal show that with appropriate training, FCHV has the potential to promote hypertension education and conduct hypertension screening. Access to essential equipment such as digital blood pressure monitors, would improve FCHV performance on measuring blood pressure. Therefore, our training was to provide hypertension knowledge and to train FCHVs to measure blood pressure.~The training had two objectives referring to enhancing knowledge and building skills."
41295265|NCT06004531|BEHAVIORAL|Prompting open-ended question promoting sustainability|This intervention will include active persuasion through prompting participants to answer an open-ended question regarding how they will alter their behavior to become more sustainable and eco-friendly.
41457351|NCT04192032|OTHER|Preferred flavor with HWL|Preferred flavor (5% nicotine) with HWL
40965913|NCT01337739|DRUG|Placebo Comparator|Placebo administration (.9 normal saline sterile)
40965914|NCT01337739|DRUG|Active Comparator|Administration of Dexmedetomidine
40965915|NCT04632810|OTHER|Ketogenic low energy diet|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 75g (25E%), protein 60 g (20E%), fat 73 g (55E%) in 8 weeks
40965916|NCT04632810|OTHER|non-ketogenic low energy diet|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 180g (60E%), protein 60 g (20E%), fat 27 g (20E%), in 8 weeks
41137605|NCT01904097|DRUG|Pregabalin|Pregabalin 150 mg per oral BID (i.e. twice per day).
41137606|NCT01904097|OTHER|Transcranial Direct Current Stimulation|The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
41295266|NCT06004531|BEHAVIORAL|Sustainability Passage|This intervention will include passive persuasion through presenting participants with a passage discussing the serious issue of climate change and the pressing need for systemic and individual change to adopt sustainable practices and lifestyles.
41295267|NCT05678790|OTHER|Passive Stretching|Sustained passive stretching of hamstring, tendo-achilles, and adductors 10 (30 s, with three repetitions, five times per week)
41295268|NCT05678790|OTHER|Mobilization|Grade four mobilizations is a stretching motion performed at the talocrural joint with anterior-posterior gliding. Mobilization was performed once a day, 6 times a day, and 5 times a week, only on both deformed feet of the older sibling
41295269|NCT05678790|OTHER|Muscle strengthening|Abdominal muscle strengthening exercises were given to both siblings once a day, 10 times a day, 5 times a week. In the supine position, the patients were asked to lie on their knees with the knees flexed. The hip extensors were trained in the prone position on the bed by resisting hip extension
41457352|NCT04192032|OTHER|Preferred flavor, 3% nicotine|Preferred flavor, 3% nicotine
41457353|NCT04192032|OTHER|Preferred flavor, 0% nicotine|Preferred flavor, 0% nicotine
41457354|NCT00508651|BIOLOGICAL|MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson\^TM luer slip tip syringes. Each 0.2 mL dose contained 10\^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
41457355|NCT00508651|BIOLOGICAL|Placebo|Placebo was a frozen preparation filled into Becton Dickinson\^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
40965917|NCT03792191|RADIATION|Lumbar Spinal Ultrasonography|Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
40965918|NCT03792191|RADIATION|Sham Ultrasound Procedure|Moving the ultrasound probe on the patient's back with the machine in the freeze position.
41137607|NCT01904097|OTHER|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
41137608|NCT04707807|DIAGNOSTIC_TEST|IIEF-5|IIEF-15 form will be filled out by all participants
41137609|NCT01619319|OTHER|Cognitive Remediation Therapy|auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
41137610|NCT01619319|OTHER|computer games|computer games that that consist of word puzzles
40965919|NCT03792191|PROCEDURE|Conventional Landmark Palpation|Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
40965920|NCT03792191|PROCEDURE|Spinal Anesthesia|Spinal anesthesia using a 25- or 22-gauge spinal needle
40965921|NCT03792191|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
40965922|NCT03792191|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
40965923|NCT05677581|OTHER|iodine nutrition status|iodine nutrition status
40965924|NCT03039283|DEVICE|Nucleus CI532 cochlear implant|Retrospective study of the commercial CI532 cochlear implant
40965925|NCT06263205|PROCEDURE|Non-Dressing of Surgical Wound|In this intervention, participants undergoing gastrointestinal tumor surgery will receive standard wound disinfection and initial postoperative care, which includes the application of dressings immediately after surgery. However, unlike traditional methods, the dressings will be removed 48 hours post-surgery, and the surgical wounds will then be left exposed without any further dressing. This method is intended to evaluate the effects of an exposed surgical wound on healing, pain, and healthcare costs, compared to traditional dressing methods.
41295270|NCT05678790|OTHER|Balance and Coordination|"The following exercises were applied 5 times a week, with 1o repetition once a day.~* Standing on one leg in front of the mirror,~* Tandem walking,~* Rhythmic Dynamic Stabilization,~* Swiss ball sitting (eyes open and closed),~* Counting the alphabet or numbers while marching"
41295271|NCT03065803|PROCEDURE|Buccal plate expansion technique for dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
40965926|NCT06263205|PROCEDURE|Regular Dressing Change of Surgical Wound|This intervention involves the standard postoperative wound care for participants with gastrointestinal tumors. After surgery, the surgical wounds will be disinfected and covered with dressings. These dressings will be changed every 48-72 hours, following traditional wound management practices. The purpose of this intervention is to serve as a comparator for assessing the effectiveness of the non-dressing approach, focusing on wound healing, pain management, and healthcare costs.
40965927|NCT03176498|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cell|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
40965928|NCT03176498|DRUG|Aspirin Enteric-coated Tablets & Atorvastatin Calcium|Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
40965929|NCT04602988|DEVICE|EEG|EEG monitoring of brain rhythms
40965930|NCT03677362|BEHAVIORAL|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (\~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (\~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via group phone callsSkype will be delivered by a professional health educator (HE) to participants in their homes.
40965931|NCT02672865|DRUG|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
40965932|NCT01148472|DRUG|Escitalopram|20mg once daily; orally
40965933|NCT01148472|DRUG|Duloxetine|60mg once daily; orally
40965934|NCT02161081|PROCEDURE|Myocardial CT perfusion|Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
40965935|NCT02848040|OTHER|IDK Bile Acids|colourimetric in-vitro laboratory diagnostic test
40965936|NCT04194398|DEVICE|OCS Lung System|Patients previously transplanted with lungs preserved on the OCS Lung System in the Expand Lung study.
40965937|NCT02634320|DRUG|Aripiprazole Lauroxil|Monthly IM injection
40965938|NCT05888766|DRUG|Rimegepant 75 milligrams|At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.
40965939|NCT00745836|DRUG|statin|
40965940|NCT02661893|DRUG|JNJ-42847922|A single oral dose of 40 milligram (mg) (=2\*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
40965941|NCT02661893|DRUG|Rifampin|Oral dose of rifampin 600 mg (2\*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2\*300 mg) on Days 5 to 12.
41457356|NCT02511860|DIETARY_SUPPLEMENT|Burdock|Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
41457357|NCT02511860|DIETARY_SUPPLEMENT|Placebo|Methylcellulose (inert) tablet taken as placebo
41457358|NCT01525628|DRUG|midazolam|CYP3A probe drug
41457359|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
41457360|NCT01525628|DRUG|tenofovir|nucleoside analogue
40965942|NCT00972868|DEVICE|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
40965943|NCT03438669|OTHER|no intervention|no intervention
41137611|NCT01846715|BIOLOGICAL|Implantation of SRC|
41457361|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
41457362|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
40767185|NCT06073067|RADIATION|GRID therapy|GRID therapy delivers a high dose of radiation to small areas of tumor interleaved with areas that intentionally receive a low dose
40965944|NCT03226483|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.
40965945|NCT01135420|BEHAVIORAL|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
40767186|NCT05508789|DRUG|Donanemab|Administered IV
40767187|NCT05508789|DRUG|Placebo|Administered IV
40767188|NCT04825600|DIAGNOSTIC_TEST|anti-Toxoplasma gondii IgG and IgM dosage|blood sample performed to check the toxoplasma serological diagnosis
40767189|NCT04825600|DIAGNOSTIC_TEST|cellular test|blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis
40767190|NCT06204809|DRUG|PGN-EDODM1 for infusion|Single dose of PGN-EDODM1 by intravenous (IV) infusion
40965946|NCT01135420|OTHER|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
40965947|NCT02794038|DEVICE|Soberlink Cellular Device|BAC breath analyzer
40965948|NCT02794038|DEVICE|BACtrack S80 Pro|BAC breath analyzer
40965949|NCT05006196|DIAGNOSTIC_TEST|Outpatient MRI|"Participation in the study includes up to a maximum of 2 study visits. The visits will include clinical measurements (height, weight, blood pressure), blood tests, MRI scan and patient symptoms and experience questionnaires.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications. These will be managed by the routine clinical care team as part of standard care."
41137612|NCT01085513|DEVICE|PillCam SB2|The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
41137613|NCT04658784|DEVICE|2-0 dioxanone, glycolide and trimethylene carbonate|delayed absorbable, monofilament barbed suture
40767191|NCT06204809|OTHER|Placebo|Administered by IV infusion
40767192|NCT04430738|DRUG|tucatinib|For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.
40767193|NCT04430738|DRUG|trastuzumab|Cohorts 1A and 1B: a 6 mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 Day 1, followed by a dose of 4 mg/kg IV every 2 weeks starting on Cycle 2 Day 1. Cohorts 1C, 1D, 1E, 1F, 1G, 2A, and 2B: an 8 mg/kg loading dose will be administered IV on Cycle 1 Day 1, followed by a dose of 6 mg/kg IV every 3 weeks thereafter.
40767194|NCT04430738|DRUG|oxaliplatin|85 mg/m\^2 given IV every 2 weeks for cohorts using FOLFOX. For cohorts using CAPOX regimen, 130 mg/m\^2 given every 3 weeks.
40965950|NCT01865110|DRUG|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
40965951|NCT01865110|DRUG|R-CHOP / R-HAD|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
40965952|NCT01865110|DRUG|Rituximab|Rituximab SC 1400 mg every 8 weeks for 24 months
40965953|NCT01865110|DRUG|Lenalidomide|Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
40965954|NCT03090802|BEHAVIORAL|Mentoring Adolescent Mothers at School (MAMAS)|Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
40965955|NCT01666496|BEHAVIORAL|Experimental Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
40990697|NCT05876273|DEVICE|University of Virginia Model Predictive Control|A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.
41137614|NCT04658784|DEVICE|2-0 polydioxanone|delayed absorbable, monofilament non-barbed suture
41137615|NCT00885625|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|7-valent pneumococcal conjugated vaccine is given twice with 4 weeks apart
41137616|NCT06196853|DRUG|Aminophylline|Give aminophylline for 5 days to keep serum theophylline level 5-15 mg/dl
41137617|NCT03191448|PROCEDURE|Ridge preservation|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously.
41457363|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
41457364|NCT01525628|DRUG|midazolam|CYP3A probe drug
41457365|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
41457366|NCT01525628|DRUG|pegylated interferon|HCV treatment
40767195|NCT04430738|DRUG|leucovorin|200 (mFOLFOX7) or 400 (mFOLFOX6) mg/m\^2 given IV every 2 weeks. Part of FOLFOX regimen.
40767196|NCT04430738|DRUG|fluorouracil|400 mg/m\^2 (IV bolus after leucovorin) and/or 2400 mg/m\^2 (continuous infusion over 46 hours). Part of FOLFOX regimen.
40767197|NCT04430738|DRUG|capecitabine|1000 mg/m\^2 is taken twice per day orally on Days 1-14 of each 3 week cycle. Part of CAPOX regimen.
40767198|NCT04430738|DRUG|pembrolizumab|400 mg given by IV on day 1 of cycle 1, then every 6 weeks.
40965956|NCT01666496|BEHAVIORAL|Off the Shelf Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
40767199|NCT06645080|OTHER|Focus group or interview participation|90 minute focus group or 60 minute interview participation
40767200|NCT06645080|OTHER|Delphi survey participation|Participation in a modified two-round Delphi technique. Optional third round in the event of insufficient agreement in the second round.
40767201|NCT05748210|OTHER|Symptom management mobile health application with personalised support|"Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
40767202|NCT05748210|OTHER|Wait-list Symptom management mobile health application with personalised support|To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
40767203|NCT02879695|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40767204|NCT02879695|BIOLOGICAL|Blinatumomab|Given IV
40767205|NCT02879695|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
40767206|NCT02879695|BIOLOGICAL|Ipilimumab|Given IV
40767207|NCT02879695|BIOLOGICAL|Nivolumab|Given IV
40767208|NCT05870072|OTHER|Dual task training|In addition to balance exercises, random name-word generation, counting the days of the week forward and backward, counting the months of the year forward and backward, subtracting 3 by 3 numbers from 300 to 900 starting from a random number, adding 7 from 1 to 100 and adding 100 Cognitive tasks such as counting tasks by subtracting 7 will be given. While testing dual-task performance, subjects will be asked to perform both tasks without prioritizing and do their best, and will be warned not to stop thinking. In dual-task training, the additional task to be assigned to the motor task will initially be of low complexity and novelty, and will progress to a high degree of complexity and novelty in the training process.
40767209|NCT05870072|OTHER|Kinesthetic motor imagery training|Kinesthetic motor imagery training will be planned according to the PETTLEP model. In our study, a single standard motor imagery frame will be created for the subjects. Before starting the motor imagery sessions, individuals will be given an introductory motor imagery session. How to visualize from first-person and third-person perspectives will be explained practically. Motor imagery training will be done in a quiet environment with the door and window closed in order to minimize the external factors that will distract the individual and prevent him from focusing, and the individual will be asked to sit in the motor imagery training sessions. a comfortable chair in the position they feel most comfortable in. Individuals will have their eyes closed throughout the entire motor imagery training. At the beginning of the session, approximately 5 minutes of relaxation exercise will be performed to maximize attention during motor imagery.
40767210|NCT05870072|OTHER|Balance exercises|Balance exercises will begin with approximately 5 minutes of warm-up exercises and will end with approximately 5 minutes of cool-down exercises at the end of each session. Balance exercises; Static standing on flat ground for 30 seconds with feet together, standing in tandem position for 30 seconds, standing on one leg for 30 seconds, and toes for 30 seconds, one foot airborne backwards, one foot airborne knee flexion slightly squat, one foot airborne knee extension slightly squat, going on the toes, turning with the heel, and multi-directional stretching exercises with eyes open and closed on one leg on the balance board. Each exercise will be performed with 10 repetitions for both lower extremities. Exercises will be applied once a day, 3 days a week for 6 weeks. The exercise program will be accompanied by a physiotherapist and groups of 6-10 people with similar suitability will be formed for the session hours.
40767211|NCT04112992|PROCEDURE|Any treatment that is used for a defect of any long bone|Any treatment that is used for a defect of any long bone. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
40767212|NCT00847730|DEVICE|V.A.C. Negative Pressure Wound Therapy System|This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds
40767213|NCT05951101|DEVICE|Zenith LAA Occlusion System|LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 17 mm and 25 mm
40767214|NCT06644040|DRUG|TeriQ Patch|"Participants will receive two single doses of either of the TeriQ patch (Strength- 28.2 µg, 56.5 µg, and 113.0 µg) approximately 1 week apart.~Route of administration- Dermal patch"
40965957|NCT00159406|OTHER|Registry and Database|Data Collection
40965958|NCT04978727|BIOLOGICAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
40965959|NCT04978727|BIOLOGICAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
40965960|NCT04978727|BIOLOGICAL|SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
40965961|NCT04546230|PROCEDURE|Low-Thoracic Epidural Anesthesia|"Under aseptic conditions and local anesthesia, an epidural catheter will be inserted using the Prefix Epidural Anesthesia Tray with an 18 G Tuohy needle \& a 20 G catheter at the T7-8 or T8-9 intervertebral space. The epidural catheter will be threaded leaving 3 cm within the epidural space and tapped in place.~Using a mixed preparation of isobaric Bupivacaine 0.5% with Fentanyl 2 μg per ml volume, a bolus dose of 5-10 ml will then be given via the epidural catheter, followed by 5-10 ml/hr as a continuous infusion to be started 1 hour later \& continued throughout the procedure."
40767215|NCT06644040|DRUG|Teribone Inj.|"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"
40767216|NCT06644040|DRUG|Forteo Inj.|"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"
40767217|NCT06331949|OTHER|video assisted training|Ebelik bakımının yanı sıra NST konusunda eğitim içerikleri, eğitim videoları ve broşür destekli eğitimler verilecek. NST cihazı takılacak ve standart olarak işlem başladıktan 5 dakika sonra NST kaydı sırasında cihazdan gelen fetal kalp sesinin şiddeti artırılarak fetal kalp sesinin devam etmesi sağlanacaktır. Transfer edilecek hamile kadın yaklaşık 2 dakika kadar dinlenecektir.
40767218|NCT05371327|BEHAVIORAL|Public deliberation|Public deliberation is a method for engaging the public in collective decision-making. Its goal is to facilitate debate and discussion that: 1) fosters the formation of reasonable and informed opinions, 2) permits participants to revise their perspectives and positions in light of new information and dialogue with others, and 3) encourages participants to consider not only their own preferences but also the greater goal of a policy or resolution that is justifiable for all persons affected by the issue under debate.
40767219|NCT06564194|BIOLOGICAL|JCXH-108|IM injection
40767220|NCT06564194|OTHER|Placebo|IM injection
40767221|NCT05038839|DRUG|Cabozantinib|Given PO
40965962|NCT04546230|PROCEDURE|General Anesthesia|General anaesthesia will be induced with intra-venous administration of Fentanyl (2 μg/kg), Propofol (2 mg/kg), Atracurium (0.5 mg/kg) and Lidocaine (1 mg/kg). After tracheal intubation, balanced anaesthesia will be maintained with isoflurane in oxygen \& infusion of atracurium at a rate of 0.5 mg/kg/hr; and mechanical ventilation will be provided.
40965963|NCT00810030|DRUG|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
40965964|NCT00810030|DRUG|Iron Sucrose|"VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is \>25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height \[m\] x height \[m\].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit."
40965965|NCT00000445|DRUG|naltrexone (Revia)|
40965966|NCT04407364|DEVICE|CoMatryx Surgical Bovine Collagen|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
40767222|NCT05038839|DRUG|Pamiparib|Given PO
40965967|NCT03777774|PROCEDURE|Passive Redon subgaleal drains|Passive non-vacuum subgaleal drains will be placed during closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
41137618|NCT03191448|DEVICE|FDBA|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
41137619|NCT03191448|DEVICE|Collagen wound dressing|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
40965968|NCT03777774|PROCEDURE|Vacuum Redon subgaleal drains|Active vacuum subgaleal drains will be placed during the closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
41295272|NCT03065803|PROCEDURE|Guided bone regeneration technique for post-extraction dental socket preservation|After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
41295273|NCT04338022|DRUG|Evobrutinib|Evobrutinib twice daily (BID) in DBTP.
41295274|NCT04338022|DRUG|Placebo (match to Teriflunomide)|Placebo match to Teriflunomide once daily in DBTP.
40965969|NCT03777774|PROCEDURE|No Redon subgaleal drains|A subgaleal drain will be placed during the closing stage of craniectomy but it will be clamped. The drain will be unclamped if necessary. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
41295275|NCT04338022|DRUG|Teriflunomide|Teriflunomide once daily in DBTP.
41295276|NCT04338022|DRUG|Placebo (match to Evobrutinib)|Placebo match to Evobrutinib BID in DBTP.
40965970|NCT03123718|DRUG|Intrathecal methotrexate|Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
40965971|NCT03123718|DRUG|High-dose intravenous methotrexate|"Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~\* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged \>70 years."
40965972|NCT03630952|BIOLOGICAL|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
40965973|NCT03630952|BIOLOGICAL|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
40965974|NCT03630952|BIOLOGICAL|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
41457367|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
40965975|NCT03018821|DRUG|Standard - Yinchengao Decoction plus Ganlu Detoxification Pill|Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.
40965976|NCT03018821|DRUG|Entecavir or Tenofovir|Western drug for anti-HBV such as Entecavir and Tenofovir
40965977|NCT03018821|DRUG|Standard - Ge Xia Zhu Yu Decoction|Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
40965978|NCT03018821|DRUG|Advanced - Supplemented Taohong Huazhuo Decoction|Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
40965979|NCT03018821|DRUG|Standard - Chaihu Shugan San|Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
40965980|NCT03018821|DRUG|Advanced - Soothe the liver and regulate qi Decoction|Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
40965981|NCT03018821|DRUG|Standard - Xiaoyao powder|Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
40965982|NCT03018821|DRUG|Advanced - Supplemented Ganbi Decoction|Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
40965983|NCT03018821|DRUG|Standard - Yiguan Decoction|Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
40965984|NCT03018821|DRUG|Advanced - Supplemented Zimu Dan|Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
40965985|NCT03018821|DRUG|Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus|Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
40990698|NCT03951194|BIOLOGICAL|Autologous Platelet Rich Plasma (PRP) intra ovarian infusion|Autologous PRP intra ovarian infusion
41295277|NCT00931788|DRUG|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
41295278|NCT00931788|OTHER|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
41457368|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
41457369|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
41457370|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
41457371|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
41457372|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
40965986|NCT03018821|DRUG|Advanced - Guifu Erxian Decoction|Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
40965987|NCT03018821|DRUG|Advanced - Supplemented Ganji Decoction|Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
40965988|NCT01776112|OTHER|Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
40767223|NCT06027905|OTHER|E3 Remote Monitoring and Social Intervention|Patients are enrolled in a 12 week remote blood pressure monitoring program composed of a community health worker, nurse, pharmacist and social worker. Participants will receive a home cellular blood pressure cuff for remote monitoring and will receive tele-health calls from their community health worker to assist with blood pressure taking technique and adherence, medication adherence, education around diet and activity. Social work is available to provide institutional and community resources to patients with social needs. Patients will be screened pre intervention and post intervention for medication adherence and social determinants of health needs. The team nurse monitors and triages home blood pressures on the remote portal. The pharmacist assists with medication reconciliation, adherence, and titration of medications according to standards or care.
40767224|NCT03886636|OTHER|neuroscience pain education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week, before an MT session. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, one-on-one sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
40965989|NCT01776112|OTHER|TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
40965990|NCT03600545|OTHER|Brain Fitness App|Brain exercises using an iPAD
40965991|NCT04876924|DRUG|BBP-711|BBP-711, oral suspension
40767225|NCT03886636|OTHER|manual therapy|In our study, Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
40767226|NCT03886636|OTHER|home exercises|All participants in all groups were assigned the home exercise program. The program aims to increase strength and flexibility of the abdominal, erector spinae, gluteal, quadriceps, and hamstring muscles. The participants were then asked to perform all of the exercises with 10 repetitions of each exercise 3 times a day for 4 weeks.
40767227|NCT06439706|BEHAVIORAL|HPV Self-Sampling|HPV self-sampling kit
40767228|NCT06439706|BEHAVIORAL|Group Education|Small-group education led by bilingual health educator
40767229|NCT04494698|DEVICE|Duotherm VibraCool Back Device|Active New multimodal pain device
40767230|NCT04494698|DEVICE|TENS 8-channel unit|LG Smart TENS unit
40767231|NCT05185622|DRUG|Vamorolone|Oral administration of vamorolone for 12 weeks.
40767232|NCT06442800|BEHAVIORAL|Liver Cancer|Participants will view messages about the risk of liver cancer from alcohol consumption.
40767233|NCT06442800|BEHAVIORAL|Throat and Mouth Cancer|Participants will view messages about the risk of throat and mouth cancer from alcohol consumption.
40767234|NCT06442800|BEHAVIORAL|Colorectal Cancer|Participants will view messages about the risk of colorectal cancer from alcohol consumption.
40965992|NCT04876924|DRUG|Placebo|Placebo matching BBP-711
40965993|NCT05199129|DRUG|HCP1904-3|Take once daily for 8 weeks orally
40965994|NCT05199129|DRUG|RLD2001-1|Take once daily for 8 weeks orally
40965995|NCT05364125|OTHER|Olfactory Training|Four aromatic substances will be used (Citrus limon, Eucalyptus radiata, Pelargonium graveolens, Juniperus virginiana)
40965996|NCT05364125|OTHER|Control|Normal Saline will be used
41137620|NCT05579184|DRUG|[177Lu]Ludotadipep|"Patients will receive 100 mCi of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (up to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"
41295279|NCT06212557|DEVICE|KIOS App|KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during Medication-Assisted Treatment (MAT)
40965997|NCT03673033|PROCEDURE|liver transplantation|calculation of hot and cold ischemia durations from donor artery cut-off time in liver transplantation
40990699|NCT03951194|OTHER|Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion|Autologous PFP intra ovarian infusion
40990700|NCT01644175|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
40990701|NCT01644175|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
41295280|NCT06212557|BEHAVIORAL|KIOS App education|Educational tools provided to participants with opioid use disorder
41295281|NCT06212557|BEHAVIORAL|Treatment as usual|Behavioral counseling in clinic
41295282|NCT01257217|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
40965998|NCT01380275|DRUG|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
40965999|NCT01380275|DRUG|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
40966000|NCT04944069|DRUG|Almonertinib|110 mg oral once daily
40966001|NCT04944069|DRUG|Bevacizumab|15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
40966002|NCT05032560|DRUG|ABX464|Drug: ABX464 ABX464 is a new anti-inflammatory drug
40966003|NCT05032560|DRUG|Placebo|Drug: Matching Placebo placebo matching with ABX464
41137621|NCT01326455|DEVICE|Terumo TR wristband|"A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First deflation of 3cc of air occurred 1 hour after inflation. Deflations occurred every 15 minutes unless bleeding was noted. If bleeding was noted, balloon was reinflated (1-3cc of air) until bleeding stopped. Next deflation occurred 30 minutes later, at which point regular 15 minutes deflations occurred if no bleeding noted. Band was removed 1 hour after final deflation."
41295283|NCT01257217|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
40767235|NCT06442800|BEHAVIORAL|Multiple Cancers|Participants will view messages about the risk of multiple cancers from alcohol consumption.
40767236|NCT06442800|BEHAVIORAL|Liver Disease|Participants will view messages about the risk of liver disease from alcohol consumption.
40767237|NCT06442800|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
40966004|NCT00530244|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
40966005|NCT00530244|DIETARY_SUPPLEMENT|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
40966006|NCT01204853|DRUG|Sitaxentan|sitaxentan sodium 100 mg
41137622|NCT01326455|DEVICE|Terumo TR wristband|"A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First balloon deflation of 3cc of air occurred 15 minutes after initial inflation. Deflations occurred every 15 minutes unless bleeding was noted. If active bleeding was noted, the balloon was re-inflated (1-3cc) until bleeding stopped. The next deflation occurred 15 minutes later. If no bleeding occurred, deflations continued every 15 minutes until the balloon was completely deflated. The band was removed 15 minutes after final deflation."
41137623|NCT01326455|DEVICE|Clo-Sur-P.A.D.|"A hydrophilic dressing has a high affinity for water, and absorbs and controls body fluid. The positively charged 4x4 centimetre pad reacts with the neuraminic acid residue on red blood cells causing agglutination of the cells. The Clo-Sur P.A.D. works outside of the clotting cascade.~The radial catheter was removed and occlusive pressure applied on the radial artery. Pressure was released just until bleeding noted \& the pad was applied with approximately 5 minutes of manual compression. The pad was assessed every 15 minutes for 90 minutes to ensure hemostasis. The pad was removed on post-CATH day 1."
41137624|NCT01122134|DRUG|intravenous artesunate|Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
41137625|NCT03196518|PROCEDURE|PET Imaging|PET/CT study immediately after injection
41137626|NCT03196518|OTHER|18F-tetrafluoroborate (18F-TFB)|administration of a single dose of approximately 5-10 mCi 18F-TFB (mass \<= 50 μg) for imaging purposes
41137627|NCT00487045|DEVICE|Hem-Avert Perianal Stabilizer|Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
41137628|NCT04402476|DEVICE|Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
41137629|NCT03511495|DIAGNOSTIC_TEST|Galilei Corneal Topographer|A series of five measurements via the Galilei corneal topographer of each keratoconic eye in quick succession
41137630|NCT05611710|DRUG|Placebo|"Drug: Placebo, with visually matched clear syringes~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 2 syringes of placebo via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive no more than 1 syringe of placebo via IV route, twice daily for 4 days"
41137631|NCT05611710|DRUG|Anakinra|"Drug: Anakinra~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)"
41137632|NCT02845609|DRUG|Sialic Acid-Extended Release|Oral drug of Sialic acid
41137633|NCT05469165|DRUG|Cyproheptadine 4 Mg Oral Tablet|Cyproheptadine treatment for 3 months
40966007|NCT04134468|DRUG|Pegvorhyaluronidase alfa|IV infusion
40966008|NCT04134468|DRUG|Abraxane|IV infusion
40966009|NCT04134468|DRUG|Gemcitabine|IV infusion
40966010|NCT01099605|DEVICE|placement of a continuous infusion pump|Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.
40966011|NCT01099605|DEVICE|continuous infusion pump of bupivacaine|bupivacaine 0.25% at 4ml/hr for 3 to 4 days
40966012|NCT06379412|OTHER|observational study, no intervention|observational study, no intervention
40966013|NCT02837445|DEVICE|PHC ON|Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
40966014|NCT02837445|DEVICE|PHC OFF|Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
40966015|NCT04972695|DIAGNOSTIC_TEST|Fundus Photographs (retinographies)|Fundus photographs under mydriasis
40966016|NCT06505668|DRUG|Atenolol 25 mg|Patients will be receiving Atenolol 25mg OD for 2 months.
40966017|NCT06505668|DRUG|Ivabradine 10mg|Patients will be receiving Ivabradine 5mg BD for 2 months.
40966018|NCT02646137|DRUG|Transarterial chemoembolization (TACE)|TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
40966019|NCT02646137|PROCEDURE|Radiofrequency ablation combined with TACE|Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
40767238|NCT06442800|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
40767239|NCT06442800|BEHAVIORAL|Drinking Guidelines|Participants will view messages about guidelines for alcohol consumption.
40767240|NCT06442800|BEHAVIORAL|Current Warning|Participants will view the current warning that is required on most alcoholic beverage containers sold in the US.
40767241|NCT06442800|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
40966020|NCT02646137|PROCEDURE|Microwave ablation combined with TACE|Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
40966021|NCT00542555|DRUG|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
40966022|NCT00542555|DRUG|Naproxcinod 375 mg|
40767242|NCT06603493|OTHER|Assessment of sleep disorders|: Sleep disturbances will be assessed with the Pittsburgh Sleep Quality Index
40767243|NCT06603493|OTHER|Assessment of Central Sensitization|Central sensitization will be assessed with the Central Sensitization Inventory
40966023|NCT00542555|DRUG|Naproxen|
40966024|NCT00542555|DRUG|Naproxcinod 750 mg|
40966025|NCT03760783|OTHER|Parabolic flight|Sperm analysis (total motility M/ml; grade a+b sperm M/ml, vitality, DNA Frag and apoptosis) will be measured on ground at 1g before the flight and after flight were sperm samples have been exposed to simulated microgravity
40966026|NCT02885012|DRUG|Ambrisentan|At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
40966027|NCT01581645|DEVICE|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
40966028|NCT00407797|DRUG|Pregabalin|150 to 600 mg/day during 21 weeks
40767244|NCT06603493|OTHER|Assessment of depression, anxiety and stress levels|Depression, anxiety and stress levels will be assessed using the Depression, Anxiety, Stress Scale (DASS-21)
40966029|NCT05050539|BEHAVIORAL|Low Intensity|5 implementation strategies: formal commitments, local champions, implementation blueprint , remind educators (cutting board with WISE EBPs), task-focused facilitation.
40966030|NCT05050539|BEHAVIORAL|High Intensity|Low intensity implementation strategies with the addition of holistic individualized facilitation and tailored educational materials.
40966031|NCT05663190|OTHER|mental foramen location|location of mental foramen in relation to primary molars
40966032|NCT01927874|PROCEDURE|Infiltration|injection of local anesthetic, associated with general anesthesia
40966033|NCT01927874|PROCEDURE|Spinal block|injection of anesthetic
40966034|NCT01927874|DRUG|Bupivacaine|10ml 0.5% bupivacaine.
40966035|NCT01927874|DRUG|10 mg of hyperbaric 0.5% bupivacaine|Spinal punction and injection of local anesthetic
40966036|NCT01830270|DRUG|Epirubicin|8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
40966037|NCT01830270|DRUG|Cisplatin|8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
40966038|NCT01830270|DRUG|Paclitaxel|8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
40966039|NCT01830270|PROCEDURE|gastric surgery|surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
40966040|NCT02079220|DRUG|Arm A|"* Capecitabine~* Oxaliplatin~* Ziv-aflibercept"
40966041|NCT02079220|DRUG|Arm B|Capecitabine Oxaliplatin Ziv-aflibercept
40990702|NCT01644175|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
40990703|NCT00935870|DEVICE|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
40990704|NCT06299774|OTHER|Emergency care at home|A mobile integrated health paramedic under the direction of a remote emergency care physician will arrive at the patient's home and deliver emergency care.
41137634|NCT05469165|OTHER|Placebo|Placebo administration for 3months
40966042|NCT04874298|OTHER|Ginger|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Ginger and Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
40966043|NCT04874298|OTHER|Peppermint|Peppermint
40966044|NCT02158403|OTHER|Clinical Management Recommendations for reducing pump thrombosis|Clinical Management Recommendations for reducing pump thrombosis
40966045|NCT00036712|PROCEDURE|management of therapy complications|
40966046|NCT00036712|PROCEDURE|pain therapy|
40966047|NCT02114216|PROCEDURE|endoscopic mucosal biopsy|endoscopic mucosal biopsy was undertaken for every participant.
40966048|NCT05756491|OTHER|24 months of inclusion of unaccompanied patients|inclusion for 6 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 24 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
40966049|NCT05756491|OTHER|18 months of inclusion of unaccompanied patients|inclusion for 12 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 18 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
40966050|NCT05756491|OTHER|12 months of inclusion of unaccompanied patients|inclusion for 18 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 12 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
40966051|NCT05756491|OTHER|6 months of inclusion of unaccompanied patients|inclusion for 24 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 6 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
40966052|NCT01087645|DRUG|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
40966053|NCT01087645|DRUG|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
40966054|NCT01087645|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
40966055|NCT01087645|DRUG|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
40966056|NCT01087645|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo
40966057|NCT03105895|PROCEDURE|Mesh group|An onlay PDVF mesh will be placed as abdominal wall reinforcement
41137635|NCT03118206|DEVICE|lumbar traction|
41137636|NCT03118206|PROCEDURE|spinal manipulation|
40966058|NCT01926236|OTHER|Active Symptom Control|Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
40966059|NCT01926236|DRUG|L-folinic acid|L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
40966060|NCT01926236|DRUG|5 FU|5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
41137637|NCT03118206|PROCEDURE|surgery|
41137638|NCT00488267|DRUG|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Transdermal patch applied to the knee for 12 hours daily.
41137639|NCT00488267|DRUG|Placebo Matrix/CHADD Patch|Transdermal patch applied to the knee for 12 hours daily.
40966061|NCT01926236|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
40966062|NCT00865696|DRUG|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
40966063|NCT00865696|DRUG|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
41137640|NCT00488267|DRUG|Ketoprofen matrix/placebo CHADD Patch|Transdermal knee applied to the knee for 12 hours daily.
41137641|NCT03241810|DRUG|Seribantumab|Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling
41137642|NCT03241810|DRUG|Fulvestrant|Fulvestrant is an estrogen receptor antagonist with no agonist effects
41137643|NCT03241810|DRUG|Placebo|Placebo
41137644|NCT04620642|BIOLOGICAL|Registry|No specific intervention. Data of the usual care will be collected as the medical history, the demographic data, the biological analyses, imaging report, etc.
41137645|NCT00980616|DRUG|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
41137646|NCT00213278|DRUG|vinblastine sulphate injection|Vinblastine dose: 6 mg/m\^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
41137647|NCT00317928|DRUG|Metformin|
41295284|NCT01257217|DEVICE|Acri.LISA® 366D IOL|Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient
41457373|NCT01525628|DRUG|ribavirin|HCV treatment
41295285|NCT01257217|DEVICE|Acri.LISA® 466TD Toric IOL|Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
41295286|NCT01924897|BEHAVIORAL|Exercise training|
41295287|NCT02995681|OTHER|Balance training|Balance exercises will include: functional lower extremity training, gait training under challenging conditions and training to increase stability during changes in body positions.
41295288|NCT02995681|OTHER|Pulmonary rehab|Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
41295289|NCT02179307|BEHAVIORAL|12-week progressive strength training protocol|Every study participant will complete 12 weeks of progressive strength training with one leg performing 1-set per exercise per session and the contralateral leg performing 3-sets per exercise per session. Allocation of dominant/non-dominant leg to either 1- or 3-set protocol will be done in a stratified, randomized fashion (stratified with regard to sex and baseline strength).
41295290|NCT05555030|DEVICE|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
41295291|NCT05555030|DIAGNOSTIC_TEST|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
41295292|NCT05022992|OTHER|Resistance Training|Both groups will perform a resistance training session consisted of 10 reps x 3 set of upper- and lower-body resistance exercises.
41295293|NCT01564290|DIETARY_SUPPLEMENT|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
41295294|NCT01564290|DRUG|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
41295295|NCT02126111|BIOLOGICAL|DEPIGOID phleum|Subcutaneous Immunotherapy with modified extract of Phleum pollen.
41295296|NCT02126111|BIOLOGICAL|DEPIGOID Placebo|Placebo for subcutaneous administration
41457374|NCT01525628|DRUG|ribavirin|HCV treatment
41457375|NCT01525628|DRUG|ribavirin|HCV treatment
40966064|NCT04999176|DRUG|Rivaroxaban|Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with oral rivaroxaban (10 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
41457376|NCT01525628|DRUG|pegylated interferon|HCV treatment
41457377|NCT01525628|DRUG|ribavirin|HCV treatment
41457378|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
40990705|NCT06299774|OTHER|Emergency care at a brick-and-mortar emergency department|Standard emergency care delivered in a brick-and-mortar emergency department.
41137648|NCT01603836|BIOLOGICAL|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
41137649|NCT04130282|BIOLOGICAL|Pfs25-IMX313/Matrix-M1|3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
41137650|NCT00077558|DRUG|fludarabine phosphate|
41137651|NCT00077558|DRUG|triapine|
41137652|NCT02056847|DRUG|Pitavastatin calcium 4mg|taking once a day
41137653|NCT02056847|DRUG|Pitavastatin calcium 2mg|Taking once a day
41137654|NCT03353961|BEHAVIORAL|Emotion regulation individual therapy|The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
41457379|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
41457380|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
41457381|NCT01525628|DRUG|midazolam|CYP3A probe drug
41457382|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
41457383|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
41457384|NCT01525628|DRUG|ribavirin|HCV treatment
41457385|NCT01229150|DRUG|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
41457386|NCT01229150|DRUG|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
41457387|NCT01229150|DRUG|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
41457388|NCT02054819|OTHER|Induction chemotherapy and concurrent radiation|Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
41457389|NCT02054819|OTHER|Consolidation: Radiation therapy to metastatic sites|At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
41457390|NCT00794053|PROCEDURE|detecting lymph node metastasis by staining|this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
41457391|NCT00769951|OTHER|medical chart review|Data will be obtained from patients medical records at baseline, 6 months, 1 year, and 3 years.
41295297|NCT03836118|PROCEDURE|Homologous intrauterine insemination (IUI)|"Patients were treated with HMG/rFSH according to classic protocols of therapy and monitoring. An injection of uHCG 5000 IU/ rHCG 250 mg was given to trigger ovulation. On the day of insemination, the semen sample was obtained through masturbation after a 2-5 day abstinence period and collected in a sterile cup. TMSC was determined by multiplying grade A or grade A + B sperm motility percentages by sperm volume and concentration. To evaluate sperm viability Eosin and Nigrosin (E\&N) staining was carried out according to WHO standards. Sperm capacitation was performed using density gradient centrifugation or swim-up procedure in order to remove seminal fluids and enhance sperm quality for IUI.~IUI was performed a t36 hours post-HCG. A fraction of the washed motile spermatozoa was inserted up to the uterine fundus and expelled into the uterine cavity. Daily treatment with micronized progesterone was prescribed for 14 days after IUI. Serum ß-HCG was determined 14 days after IUI."
41295298|NCT03952312|BEHAVIORAL|Oncotool Intervention (symptom reporting + TKI education)|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with side effects and improve health-related quality of life. OncoTool provides symptom education and management for dealing with the numerous physical and mental side effects associated with TKIs (e.g., fatigue, nausea, skin toxicity). OncoTool is a website designed to improve TKI adherence by improving quality of life and TKI associated symptom burden, as well as providing a portal for provider-patient communication via a bi-weekly health questionnaire. Both intervention and active comparator conditions are administered to participants for 8 weeks.
41295299|NCT03952312|BEHAVIORAL|Oncotool Control (health information)|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to cancer patients, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar TKI education content as the experimental content but without the side effect education or physician notification. Both intervention and active comparator conditions are administered to participants for 8 weeks.
41295300|NCT05212194|OTHER|examination|Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.
40767245|NCT06644560|BEHAVIORAL|Prehabilitation Intervention|The intervention involves a 3-week prehabilitation program during the participant's preoperative window before cancer surgery. During the intervention, patients will be asked to consume 60 grams of walnuts daily, participate in two 60-minute individualized supervised physical activity training sessions per week, meet with a nutritionist for a 30-60 minute session, and conduct 30 minutes of independent walking per day. The participants will be given pre-portioned walnuts for daily consumption, a pedometer, and educational materials. The participants will track their completion of tasks with a daily log and the study coordinator will also track their attendance at scheduled nutrition and fitness sessions. In addition, the study coordinator will check-in with participants twice weekly and send text reminders about their required activities.
41295301|NCT01512368|OTHER|Supervised Exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
41295302|NCT01652378|DRUG|ondansetron, lidocaine|"Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion)."
41295303|NCT06340737|DRUG|CD22CART Infusion|Dosing and Administration Participants will be hospitalized to receive treatment with CD22CART, if not previously hospitalized, and will remain hospitalized for approximately 5 to 7 (±2) days. Patients may be discharged once all AEs have resolved to Grade 1 or better, or at the discretion of the treating physician. Participants may be discharged with non critical and clinically stable or slowly improving toxicities (e.g., renal insufficiency, cytopenias) even if \> Grade 1, if deemed appropriate by the investigator.
41295304|NCT00308295|DRUG|Fish oil capsules|
41295305|NCT00308295|DRUG|matched placebo capsules|
41295306|NCT05078567|DEVICE|5% Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
41295307|NCT02457897|DRUG|Liothyronine|Oral supplement given every 8 hours
41295308|NCT03940950|BIOLOGICAL|Autologous Adipose-Derived SVF (Stromal Vascular Fraction)|60 ml of fat is collected from subjects abdominal wall and SVF is removed from the fat. The SVF is injected into the knee through a needle.
41295309|NCT03940950|DRUG|Placebo|Saline control that contains no active ingredient
41295310|NCT01417780|DRUG|AB103|AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion
41457392|NCT00769951|OTHER|questionnaire administration|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care. The assessments include the Lawton's nine-item Instrumental Activities of Daily Living (IADL); the Katz's Activity of Daily Living (ADL); the Timed Up and Go Test; the Karnofsky Physician-Rated Performance Rating Scale (KPS); the number of falls in the past 6 months; the Mini Nutritional Assessment (MNA); the Body Mass Index; the percent of unintentional weight loss in the past 6 months; the Medical Outcomes Study (MOS) Social Support Subscale (emotional/information and tangible subscales); the MOS Social Activity Limitations Measures; the Charlson Comorbidity Index; the Cumulative Index Rating Scale Geriatrics (CIRS-G); the ACE-27; the Folstein's Mini-Mental State Examination (MMSE); the Geriatric Depression Scale (GDS); the Functional Pain Scale; and a list of medications.
40767246|NCT03975829|DRUG|dabrafenib|dabrafenib oral, twice daily
40767247|NCT03975829|DRUG|trametinib|trametinib oral, once daily
40767248|NCT06360237|DRUG|Olezarsen|Olezarsen 80 mg administered once monthly by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
40767249|NCT04591080|DEVICE|GUMMETAL Orthodontic Wire|Orthodontic archwire made of TiNbTaZr alloy.
40767250|NCT04591080|DEVICE|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
40966065|NCT04999176|DRUG|Enoxaparin|Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with subcutaneous enoxaparin (40 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
40966066|NCT04083430|DRUG|Yellow Fever Vaccine|"STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.~After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.~Powder and solvent for suspension for injection.~Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution."
40966067|NCT03736447|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
40767251|NCT05546866|DRUG|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
40767252|NCT05878093|DRUG|Dupilumab|solution for subcutaneous injection
40767253|NCT05878093|DRUG|Placebo|solution for subcutaneous injection
40767254|NCT05878093|DRUG|Budesonide|nasal spray (suspension)
40767255|NCT02420314|DRUG|Paclitaxel|"* Administered intravenously (IV)~* Prescribed at 200 mg/m2 (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"
40767256|NCT02420314|DRUG|Carboplatin|"* Administered intravenously (IV)~* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"
40767257|NCT02420314|DRUG|Ascorbic Acid|"* Administered intravenously (IV)~* 75g per infusion~* Two infusions per week~* 1 cycle is 3 weeks~* given up to 4 cycles~* may be given while chemotherapy if delayed due to low counts"
40767258|NCT03699865|OTHER|Nicotine content|Study-supplied cigarettes will contain either intermediate or very low nicotine content
40767259|NCT06025578|DRUG|BMS-986278|Specified dose on specified days
40767260|NCT06025578|DRUG|BMS-986278 Placebo|Specified dose on specified days
40767261|NCT06561126|BEHAVIORAL|Participatory, Learning and Action Based Intervention|The total number of participants exposed to the intervention (adapted from the DMagic trial in Bangladesh) will be determined based on random selection from the community. A PLA-based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
40767262|NCT06267911|OTHER|Cognitive stimulation and psychological support (RGS-ICU)|The RGS-ICU intervention consists of daily 20-minute sessions of early cognitive stimulation and psychological support adjuvant to standard ICU care administered by research staff and supervised by clinical staff each morning in the patient's own room during ICU admission and until ICU discharge or up to a maximum of 28 days after randomization. The sessions consist of orienting the patient to space and time, cognitive training of attention, working memory, learning/memory, executive function and processing speed, viewing of relaxing videos inspired by nature and fantasy scenarios to reduce stress and anxiety, and psychoeducation about the ICU environment and the characteristics of the cognitive, mental and physical state of critically ill patients.
40767263|NCT05001737|DRUG|Emapalumab|Emapalumab iv infusion
40767264|NCT04419519|DRUG|Venetoclax monotherapy|Venetoclax monotherapy
40767265|NCT04419519|DRUG|Venetoclax with anti CD20 monoclonal antibody|Venetoclax with anti CD20 monoclonal antibody
40767266|NCT05052684|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
40767267|NCT05518045|DRUG|LM-108|Administered intravenously
40767268|NCT05518045|DRUG|Toripalimab|Administered intravenously
40767269|NCT04870515|OTHER|Best Practice|Receive standard lifestyle recommendations
40767270|NCT04870515|OTHER|Dietary Intervention|Receive dietary instructions
40966068|NCT03736447|BIOLOGICAL|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
41137655|NCT03353961|BEHAVIORAL|Treatment as usual|Treatment as usual as provided in the community.
40767271|NCT04870515|OTHER|Exercise Intervention|Complete aerobic and strength/resistance exercises
40767272|NCT04870515|OTHER|Quality-of-Life Assessment|Ancillary studies
40767273|NCT04870515|OTHER|Questionnaire Administration|Ancillary studies
40966069|NCT02893943|DIETARY_SUPPLEMENT|Probiotics|
40966070|NCT02893943|DIETARY_SUPPLEMENT|Placebo|
40966071|NCT02944968|DEVICE|THERMOCOOL SMARTTOUCH® SF-5D catheter|
40966072|NCT02249585|DEVICE|Standard abdominal pressure|Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery
40966073|NCT02249585|DEVICE|Low abdominal pressure|Abdominal pressure maintained 8mmHg throughout laparoscopic colon surgery
40966074|NCT02249585|DRUG|Conventional neuromuscular blockade|Anesthesia induction with rocuronium 0.4mg/kg and maintenance with rocuronium 0.15mg/kg to maintain TOF 1-2 twitch
41137656|NCT04976764|OTHER||
41295311|NCT01417780|DRUG|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
41457393|NCT00769951|PROCEDURE|cognitive assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
40966075|NCT02249585|DRUG|Deep neuromuscular blockade|Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
40966076|NCT06266078|DEVICE|Innovative PPE|The healthcare workers will perform tasks using innovative personal protective equipments, such as LightWeight Powered Air-Purifying Respirator (PAPR) or other type of PAPR and a Sealed coverall
40966077|NCT06266078|DEVICE|Traditional PPE|The healthcare workers will perform tasks using usual personal protective equipments, such as N95 mask plus Faceshield and waterproof apron.
40966078|NCT02458040|DRUG|Drug selected in the study|
40966079|NCT03200860|DRUG|Empagliflozin 10 MG|10 mg daily, oral, 30 days
40966080|NCT03200860|DRUG|Placebo Oral Tablet|Matching Placebo, 10 mg daily, oral, 30 days
40966081|NCT04189081|DEVICE|dry mouth rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
40966082|NCT04189081|OTHER|Water Control|negative control
40966083|NCT01802931|DRUG|GSK239512|H3 receptor antagonist, potential victim of drug-drug interaction
40966084|NCT01802931|DRUG|ketoconazole|CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
40966085|NCT03056885|OTHER|Conventional One-Lung Ventilation|Vt 10 ml/kg
40966086|NCT03056885|OTHER|Protective One-lung ventilation|Vt 5 ml/kg
40966087|NCT00404846|PROCEDURE|Hyperbaric Oxygenation Therapy|
40966088|NCT01308671|DRUG|Varenicline|Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
40966089|NCT01308671|BEHAVIORAL|Counseling and psychosocial support|Blank group will receive the same counseling and psychosocial support as varenicline group
40966090|NCT03311724|DRUG|Tirzepatide|Administered SC
40966091|NCT03311724|DRUG|Placebo|Administered SC
40966092|NCT01472302|DEVICE|Adaptive Support Ventilation|Ventilation protocol according to the patients ideal body weight
40966093|NCT01472302|DEVICE|Pressure Controlled Ventilation|Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
40966094|NCT00502645|DEVICE|CS-1 DECISION SUPPORT SYSTEM|
40966095|NCT02517983|OTHER|epidemiology|Relative prevalence of different chronic respiratory disease phenotypes
40966096|NCT04765956|DEVICE|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
40966097|NCT04246450|DEVICE|Implantable Cardioverter Defibrillator (ICD) insertion|Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF\<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF \<35%. In patients in the LVEF \<35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.
40966098|NCT02677532|DRUG|Paracetamol|1 g every 8 hours
40966099|NCT02677532|DRUG|Levobupivacaine wound infiltration|Wound infiltration with 10 ml levobupivacaine 0.5%
40966100|NCT02677532|DRUG|Levobupivacaine epidural bolus|Epidural bolus of 10 ml 0.25% levobupivacaine
40966101|NCT02677532|DRUG|Sufentanil epidural bolus|Epidural bolus of 0.15 mcg/kg sufentanil
40966102|NCT02677532|DRUG|Morphine|Intravenous slow bolus of 10 mg morphine
40966103|NCT02677532|DEVICE|Epidural catheter placement|Thoracic epidural catheter placement in the T7-T8 or T8-T9 intervertebral space
40966104|NCT02677532|DEVICE|Wound infusion catheters placement|Pre-peritoneal placement of two catheters for wound infusion
40966105|NCT02677532|DRUG|Levobupivacaine plus sufentanil epidural infusion|Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
40966106|NCT02677532|DRUG|Levobupivacaine wound infusion|Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
40966107|NCT05188911|DRUG|Abiraterone|Patients would be treated with 1000mg abiraterone qd.
40966108|NCT05188911|DRUG|Prednisone|Patients would be treated with 5mg prednisone bid.
40966109|NCT05188911|DRUG|Androgen deprivation therapy|Patients would get medical or surgical castration.
40966110|NCT00285454|PROCEDURE|Retrograde coronary venous delivery of cells.|
40966111|NCT02454998|OTHER|orthodontic treatment|Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
40966112|NCT05453604|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
40966113|NCT04336085|PROCEDURE|caudal block|Caudal block will be performed using ultrasound guidance, the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the two cornua. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
40966114|NCT04336085|PROCEDURE|pericapsular nerve group block|In PENG group, the patient will be placed in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
40966115|NCT05862415|OTHER|therapeutic Exercise|"The circular training method was used in the resistance training phase. During the aerobic training phase, a series of movements from moderate intensity to vigorous intensity was performed. The step loading periodization principle was taken into account in both resistance training and aerobic exercises.~The RT lasted approximately 20-25 min per session and included two sets of 8-20 repetitions, with a rest interval of 1-2 min. The RT exercises included: squat, barbell bent-over row, overhead press, plank, lateral pull down, triceps push down, barbell curl, leg extension, leg curl, lunge, barbell bench press, crunches etc.~For the aerobic training: Intensity was established between 50-65% and 80-85% of HRmax for both groups (SAG and ASG). Aerobic training includes walking and running periods and was carried out on a 400 m outdoor track. In periodization, especially 1st-4th."
40966116|NCT02716454|PROCEDURE|Ileocaecal resection|laparoscopic ileocaecal resection with primary anastomosis
40966117|NCT00750997|DRUG|hypertonic saline|patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
40966118|NCT02784275|DRUG|Cyclo-Z|
40966119|NCT02784275|DRUG|Placebo|
40966120|NCT05776498|PROCEDURE|immediate implant placement with particulate bone graft using the dual zone technique.|Tooth extraction and immediate implant placement as mentioned, then particulate bone graft will be packed in the gap between the implant and the buccal plate of bone and the tissue (dual zone), then will be covered by a customized healing abutment.
40966121|NCT05776498|PROCEDURE|immediate implant placement with connective tissue grafting|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supraperiosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
40966122|NCT04444102|PROCEDURE|Yoga-based stretching|"Different yoga postures (ASANA) were isolated from conventional yoga practice to stretch different muscle groups.~Muscle groups stretched: hip extensor and adductors, hip \& plantar flexors, shoulder extensors, shoulder horizontal adductors, shoulder extensors-adductor, wrist flexor, trunk extensors, lateral flexors, and trunk rotators."
40966123|NCT02067338|DRUG|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
40966124|NCT02067338|DRUG|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
40966125|NCT03676010|OTHER|Sarcoma and GIST|No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
40966126|NCT03676010|OTHER|Breast cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
40966127|NCT03676010|OTHER|Pancreatic cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
40966128|NCT03676010|OTHER|Renal cell carcinoma|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
40966129|NCT03676010|OTHER|Colon cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).
40966130|NCT03676010|OTHER|Solid tumours undergoing image-guided tumor ablation|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
40966131|NCT04013204|OTHER|Endothelial function guided therapy|To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
40966132|NCT03744091|DRUG|P1|10 mg or 20 mg of THC:THCa
40966133|NCT03628820|BEHAVIORAL|Dog Therapy|5 minutes spent with therapy dog during shift
40966134|NCT03628820|BEHAVIORAL|Coloring|5 minutes spend coloring mandalas during shift
40966135|NCT00810238|BIOLOGICAL|C-Cure|Intraventricular injection
40966136|NCT04959903|BIOLOGICAL|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors at \[Day 4-Day 10\] after T cell depleted allogeneic HSCT
40966137|NCT03748758|COMBINATION_PRODUCT|Drug: OP0201|Drug OP0201
40966138|NCT03748758|COMBINATION_PRODUCT|Drug: Placebo|Placebo
40767274|NCT05022654|DRUG|SI-B001|Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
40966139|NCT05228171|BEHAVIORAL|mCC app|Interviewer use of the mCC app during the 24-hour dietary recall interview.
40966140|NCT01615185|DRUG|full-dose amisulpride|amisulpride 800mg/d
40966141|NCT00769470|BIOLOGICAL|trastuzumab|Given IV
40966142|NCT00769470|DRUG|carboplatin|Given IV
40966143|NCT00769470|DRUG|docetaxel|Given IV
40966144|NCT00769470|DRUG|lapatinib ditosylate|Given orally
40966145|NCT01008488|DRUG|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
40966146|NCT05325671|PROCEDURE|transarticular multimodal drug infiltration|as described previously
40966147|NCT04552847|DRUG|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
40966148|NCT04552847|DEVICE|PET/CT|Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.
40966149|NCT04552847|DEVICE|PET/MR|Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.
40966150|NCT02744690|DRUG|Mitomycin-C (MMC)|Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
40966151|NCT05820178|DEVICE|tDCS|On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
41457394|NCT00769951|PROCEDURE|psychosocial assessment and care|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
40966152|NCT05820178|DEVICE|rTMS|On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
40966153|NCT05282758|OTHER|Free Movement Dance|Free Movement Dance as a physiotherapy intervention
40966154|NCT05282758|OTHER|Modified person-centred progressive resistance exercise|Modified person-centered progressive resistance exercise as a physiotherapy intervention
40767275|NCT05022654|DRUG|Irinotecan|The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.
40767276|NCT04726527|DRUG|Florbetapir F 18|A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.
40966155|NCT06050278|OTHER|Tapestry technology|The study involves the immediate freezing and preservation in liquid nitrogen of a tumor histological sample from surgical resection, obtained from the operating room, within one hour of removal. Surgery is part of the normal clinical practice of patients with lung cancer.
40966156|NCT06498492|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy (LC) has been established as the gold standard of treatment for acute mild biliary pancreatitis.
40966157|NCT04109456|DRUG|IN10018|100 mg or 50mg, orally once daily continuously;
40966158|NCT04109456|DRUG|Cobimetinib|60mg , orally once daily from day 1 to day 21 in a 28-day cycle
40966159|NCT04109456|BIOLOGICAL|Atezolizumab|biweekly 840 mg dose will be used in this study starting from Cycle 2.
40966160|NCT00772291|DRUG|pregabalin|pregabalin 150-600mg/day during 8 weeks
40966161|NCT00772291|DRUG|placebo|placebo drug during 8 weeks
40966162|NCT02206048|DRUG|Proflavine|0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
40966163|NCT02206048|PROCEDURE|High-Resolution Microendoscopy (HRME) Imaging|in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.
40966164|NCT01612481|PROCEDURE|chest radiography|surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
40966165|NCT01612481|PROCEDURE|chest CT|surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
40966166|NCT02468232|DRUG|LCZ696|The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
40966167|NCT02468232|DRUG|Enalapril|The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.
40966168|NCT02468232|DRUG|Placebo to LCZ696|LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
40966169|NCT02468232|DRUG|Placebo to Enalapril|Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
40966170|NCT06443944|DRUG|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
40966171|NCT06443944|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
40767277|NCT04726527|DEVICE|Positron Emission Tomography|PET Scan for brain imaging
40767278|NCT03682484|DRUG|MA-0211|oral
40767279|NCT03682484|DRUG|Placebo|oral
40966172|NCT01445561|DRUG|Interleukin-2 (100,00 IU/m(2) SQ)|100,000 International Units/m2 SQ daily for 5 days
40966173|NCT03445208|DRUG|BMS-986036|Crossover administration to abdomen then upper arm
40966174|NCT02036697|DRUG|Bupivacaine 4.5|Bupivacaine hyperbaric, 4.5 mg
40966175|NCT02036697|DRUG|Bupivacaine 9|Bupivacaine hyperbaric, 9 mg
40966176|NCT02036697|DRUG|Morphine|morphine 150 mcg.
40966177|NCT02036697|DRUG|Fentanyl|15 mcg
40966178|NCT05959005|OTHER|No intervention|There is no intervention.
40966179|NCT06295289|DEVICE|Hybrid Closed-loop Insulin Delivery System|The Hybrid Closed-loop Insulin Delivery System system consisted of a Medtronic pump, a continuous glucose monitoring system（SIBIONICS®）and an open-source algorithm integrated into the phone. Insulin pump therapy group consisted of a Medtronic pump, and a continuous glucose monitoring system（SIBIONICS®). The difference between the two groups is that the artificial pancreas system automatically regulates the basal rate to maintain blood glucose in a target range.
40966180|NCT06295289|DEVICE|Insulin pump|Participants used conventional insulin pumps to control blood glucose, At the same time, a continuous glucose monitoring system was used to monitor glucose changes. Health care providers adjust the insulin dose of patients according to their blood glucose level.
41295312|NCT06286852|BEHAVIORAL|Administration of K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)|Administration of 1) K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)
41295313|NCT06286852|BEHAVIORAL|Administration of ChEDE- Child Version of the EatingDisorder Examination|Administration of ChEDE- Child Version of the EatingDisorder Examination
40966181|NCT00814970|DEVICE|Complete SE Vascular Stent System|Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
40966182|NCT02612727|DEVICE|Filtered-sunlight phototherapy|Infants will receive \>= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
40966183|NCT02612727|DEVICE|Intensive phototherapy|Infants will receive \>= four hours per day of intensive phototherapy for 1 to 10 days.
40966184|NCT01264900|BEHAVIORAL|Psychotherapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
40966185|NCT04615481|OTHER|Elliptical Training Group|The training program will be consisted of total 30 minutes of elliptical cross training (5 minutes warm up + Progressive Training up to 20 minutes of elliptical cross training + 5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
40990706|NCT01746927|OTHER|Glidescope Cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
40966186|NCT04615481|OTHER|Ergo-metric Training Group|The training program will be consisted of total 30 minutes of ergometric training (5 minutes warm up + Progressive Training up to 10 minutes of upper limb ergometric training + Progressive Training up to 10 minutes of lower limb ergometric training+5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
40966187|NCT00567294|BEHAVIORAL|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
40966188|NCT00567294|BEHAVIORAL|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
40966189|NCT00567294|BEHAVIORAL|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
40966190|NCT00838396|DRUG|XP19986 CR|
40966191|NCT00838396|DRUG|Placebo for XP19986 CR|
40966192|NCT03060538|DRUG|BFKB8488A|Administered subcutaneously starting on Day 1 and according to dosing schedule.
40966193|NCT03060538|OTHER|Placebo|Administered subcutaneously starting on Day 1 and according to dosing schedule.
40966194|NCT00729651|DRUG|alendronate sodium (+) cholecalciferol|Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
40966195|NCT00729651|DRUG|Comparator: Alendronate sodium (Fosamax)|Alendronate sodium; tablet, once weekly, for 16 weeks
40767280|NCT06558253|DRUG|Coenzyme I for Injection|Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.
40966196|NCT00729651|DIETARY_SUPPLEMENT|Comparator: Calcium|500 mg oral tablet calcium once daily, for 16 weeks
40966197|NCT02790203|DRUG|Celecoxib|NSAIDS
40966198|NCT02790203|DRUG|Placebo|Placebo
40966199|NCT05544604|DEVICE|Transcranial direct current stimulation|tDCS will be delivered with current strength of 2 mA for 20 min . Current will be applied through two concentric electrodes target electrode; return electrode. First we will fill the electrode cage with an electroconductive gel, and then position the electrodes, with the target electrode over the FDI hotspot, and finally we fasten the electrodes with a tubular net-shaped elastic bandage in mesh tissue, making sure that it will not push the electrode forward or backward. This procedure will aim at reducing contact impedance and at creating a uniform adherence between the whole surface of the electrodes and the scalp, avoiding uneven distribution of the current (Fertonani, 2015). We will position the central electrode (anode) according to the study group over C3 or C4 , the stimulating electrode will be placed on the scalp at T7 or T8 for the insular cortex per the 10-20 (EEG) system.
40966200|NCT02559921|BIOLOGICAL|rhRIG（20 IU/kg）|
40966201|NCT02559921|BIOLOGICAL|rhRIG（40 IU/kg）|
40966202|NCT02559921|BIOLOGICAL|HRIG（20 IU/kg）|
40767281|NCT05581121|OTHER|Standard treatment: Control arm|Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO/ESTRO recommendations.
40767282|NCT05581121|PROCEDURE|Experimental arm|Pre-therapeutic para-aortic lymphadenectomy followed by tailored chemo-radiotherapy and brachytherapy.
40767283|NCT06272890|BEHAVIORAL|motivational interviewing|motivational interviewing
40966203|NCT02559921|BIOLOGICAL|rhRIG（20 IU/kg） and vaccine|
40966204|NCT02559921|BIOLOGICAL|rhRIG（40 IU/kg） and vaccine|
40966205|NCT02559921|BIOLOGICAL|HRIG（20 IU/kg） and vaccine|
40966206|NCT02559921|BIOLOGICAL|placebo and vaccine|
40767284|NCT03913130|DRUG|QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
40767285|NCT06452277|DRUG|BAY2927088|Tablet, oral
40966207|NCT02737696|BEHAVIORAL|Web-based prescription opioid prevention for adolescents|The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
40966208|NCT02737696|BEHAVIORAL|JustThinkTwice.gov website (DEA)|The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
41295314|NCT02797873|OTHER|fMRI - Stroop task|2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
40767286|NCT06452277|DRUG|Pembrolizumab|Intravenous (IV) infusion
40966209|NCT04547569|BEHAVIORAL|Speech adaptation|Sensorimotor adaptation in speech
40966210|NCT04547569|BEHAVIORAL|Vibrotactile Discrimination|Vibrotactile Discrimination
40966211|NCT04547569|OTHER|fMRI|fMRI measurement of brain activity
40966212|NCT04547569|BEHAVIORAL|Speech production|Speech production task
40966213|NCT01805154|DEVICE|CRT Patients|This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
40966214|NCT03962010|DRUG|GX-G6|long acting anti-diabetic drug
40966215|NCT03962010|DRUG|Control|Control
40966216|NCT04638933|OTHER|No intervention|No intervention
40966217|NCT00117481|DRUG|DR-2001a|DR-2001a administered vaginally each month
40966218|NCT00117481|DRUG|DR-2001b|DR-2001b administered vaginally each month
40966219|NCT00117481|OTHER|Placebo|Placebo administered vaginally each month
40966220|NCT00848874|BEHAVIORAL|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
40966221|NCT05477810|DRUG|Treatment A (investigational drug) followed by Treatment B (reference drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
40966222|NCT05477810|DRUG|Treatment B (reference drug) followed by Treatment A (investigational drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
40966223|NCT02100085|BIOLOGICAL|GX-188E|In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
40966224|NCT02876211|DRUG|Paricalcitol|Paricalcitol 2 capsules/three times per week
40767287|NCT06452277|DRUG|Cisplatin|IV infusion
40767288|NCT06452277|DRUG|Carboplatin|IV infusion
40767289|NCT06452277|DRUG|Pemetrexed|IV infusion
40767290|NCT06412146|BEHAVIORAL|Peer Support Group|Participation in an Online Peer Support Group
40767291|NCT06460532|OTHER|Baseline treatment|Transcutaneous Electric Nerve Stimulation (TENS) of Care Vision company will be applied, with a pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the suboccipital region and the trapezius bilaterally.
40966225|NCT02876211|DRUG|Epoetin beta|epoetin 1-3 times per week
40966226|NCT02876211|DRUG|Placebo|Placebo 2 capsules/three times per week
40966227|NCT05180279|BEHAVIORAL|7-day sleep lab|Patients will stay in 7-day sleep lab where light exposure, diet, and activity will be closely monitored. They will have two unprepped flexible sigmoidoscopies with rectal biopsy collection and stool collection. Cycles will be shifted by 12h once on Day 3 of sleep lab and be discharged after an 8 hour sleep session on Day 7.
40966228|NCT05255159|DIAGNOSTIC_TEST|18F-DOPA with furosemide|Diagnostic 18F-DOPA PET/CT scan
40966229|NCT05847920|DRUG|SHR-2010 Injection|SHR-2010 Injection
40966230|NCT05847920|DRUG|Placebo|Placebo
40966231|NCT03060629|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5x10\^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
40966232|NCT03060629|BIOLOGICAL|Clade C gp140|Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
40966233|NCT03060629|BIOLOGICAL|Placebo|Participants will receive matching placebo.
40966234|NCT02244606|DRUG|SCY-078|
40767292|NCT06223555|OTHER|Fixed Mixed Meal Test|a FIXED dose meal that will be 900 kcal of a liquid meal
40767293|NCT06223555|OTHER|Adjusted Mixed Meal Test|"a body weight ADJUSTED dose liquid meal.~(30% of total daily energy requirements)"
40767294|NCT02033941|DRUG|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
40966235|NCT02244606|DRUG|Fluconazole|
40966236|NCT02244606|DRUG|Micafungin|
40966237|NCT00079898|PROCEDURE|Acupuncture|
40966238|NCT04229784|PROCEDURE|Radiofrewuency surgery|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
40966239|NCT01626391|DRUG|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
40990707|NCT02451228|OTHER|Serial blood collection|Serial blood collection from IV for pharmacokinetic and pharmacodynamic analysis. No drug, device, or biologic intervention. Opportunistic.
40966240|NCT01626391|DRUG|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
40966241|NCT01862874|BIOLOGICAL|V501|Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant
40966242|NCT01862874|BIOLOGICAL|Placebo|Formulated with AAHS adjuvant
40966243|NCT04884477|BIOLOGICAL|Convalescent Plasma|Convalescent Plasma
40966244|NCT02669771|DRUG|enzalutamide|oral
40966245|NCT06131567|PROCEDURE|Implantoplasty|Implantoplasty as surface decontamination method
40966246|NCT00506662|DRUG|insulin detemir|Treat-to-target, s.c. (under the skin) injection, once daily
40966247|NCT00506662|DRUG|insulin NPH|Treat-to-target, s.c. (under the skin) injection, once daily
40966248|NCT03937011|DEVICE|Robotic Suturing of gastric sleeve oversew and vaginal cuff closure|"1. Robotic Bariatric Sleeve gastrectomy~2. Robotic Hysterectomy with or without oophorectomy;"
40966249|NCT03478202|DIETARY_SUPPLEMENT|GOLO RELEASE|GOLO RELEASE plus Diet
40767295|NCT02033941|DRUG|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
40966250|NCT06300372|PROCEDURE|M-TAPA plane block|As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied bilaterally (60 ml in total).
40966251|NCT06300372|PROCEDURE|Postoperative pain management|For preemptive analgesia, morphine (Morfin ®) 0.05mg/kg and Ibuprofen 400mg IV (Ibuprofen®) will be administered to all patients before the surgical incision. An additional dose of ibuprofen 400mg IV, meperidine (Aldolan ®), and tramadol (Contramal®) 1mg/kg IV will be administered to all patients 30 minutes before wound closure.10 mcg/ml fentanyl containing PCA will be connected to all patients without infusion and boluses 0,35 mcg/kg,15-minute lockout period, maximum 100 mcg per hour. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®)will be administered as a rescue analgesic.
40966252|NCT06233981|RADIATION|Moderate-dose Hypofractionated Intensity-modulated Radiotherapy|All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
40767296|NCT05206929|OTHER|Self Managed Care|Self Managed Care
40767297|NCT05377411|DEVICE|tDCS|During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue
40966253|NCT06233981|DRUG|Tislelizumab|One week before or during the radiotherapy, patients receive concurrent Tislelizumab at a dose of 200mg. Subsequently, Tislelizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Tislelizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
40966254|NCT03346278|BEHAVIORAL|Text Messaging Intervention|After completing baseline procedures, study staff will activate the intervention in the participant's profile on the text messaging platform if the participant was randomized to the intervention. The text messaging platform will deliver messages by an automated algorithm. Participants will receive 4 messages per week for 6 months.
40966255|NCT00287885|DRUG|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m\^2/day up to dose level 6 of 6.4 mg/m\^2/day
40966256|NCT04007718|BEHAVIORAL|Interpretation bias training|Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
40966257|NCT00627120|DRUG|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
40966258|NCT01312272|DRUG|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
40966259|NCT01312272|DRUG|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
40966260|NCT04068714|PROCEDURE|Type of aneurysm repair|In open surgery repair group, aneurysm repair was performed by open surgery including aortobifemoral bypass, aorto-bi-iliac bypass and tubular aortic bypass. In endovascular repair (EVAR group), aneurysm correction was performed by percutaneous approach, femoral cutdowns and aorto-uni-iliac EVARs with femorofemoral bypass.
40966261|NCT04564937|DRUG|SCT510A|SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
40966262|NCT00838890|DRUG|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
40966263|NCT00838890|DRUG|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
40966264|NCT01955096|PROCEDURE|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
40990708|NCT02710890|DRUG|Lacosamide|"Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
41295315|NCT02797873|OTHER|fMRI - MID task|2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
40767298|NCT05377411|BEHAVIORAL|cognitive training|Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
40767299|NCT03140969|DRUG|QR-110|RNA antisense oligonucleotide for intravitreal injection
40966265|NCT01955096|PROCEDURE|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
40966266|NCT00067665|OTHER|Ultrafiltration|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
40966267|NCT02072018|DRUG|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
40966268|NCT02072018|DRUG|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
40966269|NCT04805541|PROCEDURE|Color Fundus Photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
40966270|NCT04805541|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
40966271|NCT04805541|DEVICE|EyeCheckup - AI Based DR Screening|"Screening for existence of More than mild or Vision-threatening Diabetic Retinopathy, and/or Diabetic Macular Edema."
40966272|NCT06223178|DEVICE|thumb-tack needle|Sterilizing skin and avoiding vessels, the thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The thumb-tack needle will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
40966273|NCT06223178|DEVICE|sham thumb-tack needle|Sterilizing skin and avoiding vessels, the sham thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The sham device will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
40966274|NCT06223178|OTHER|Basic gynecological treatment|Gynecological health care guidance will be provided as patients needed.
40966275|NCT01603498|DRUG|Dexamethasone|Dexamethasone 8mg
40966276|NCT01603498|DRUG|Methylprednisolone|Methylprednisolone 40mg
40966277|NCT03841669|BEHAVIORAL|Aerobic Exercise Group|Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
40966278|NCT03841669|BEHAVIORAL|Physical Activity & Health Information Group|This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits.
40966279|NCT03572764|DRUG|CPX-351|-CPX-351 will be provided by Jazz Pharmaceuticals
40966280|NCT03572764|PROCEDURE|Research skin biopsy|"-And/or buccal swab~* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)"
40966281|NCT03572764|PROCEDURE|Research blood draw|"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"
40966282|NCT03572764|PROCEDURE|Research bone marrow aspirate|"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"
40966283|NCT00913497|DRUG|insulin glulisine|Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
40966284|NCT00913497|DRUG|insulin aspart|Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
40966285|NCT06270667|BEHAVIORAL|Aerobic Exercise|Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)
40966286|NCT06270667|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.
40966287|NCT02420392|DRUG|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
41295316|NCT02797873|BEHAVIORAL|Stop Signal Task|Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
41295317|NCT02797873|OTHER|SCID-II|See Detailed Study Description.
41295318|NCT02797873|OTHER|SDQ|See Detailed Study Description.
40966288|NCT03118258|BEHAVIORAL|'Pap smear' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility."
40966289|NCT03118258|BEHAVIORAL|'Self-collected vaginal swab for HPV testing + pap smear triage' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
40966290|NCT03137290|DRUG|Neostigmine|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
40966291|NCT03137290|DRUG|Sugammadex Sodium|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
40966292|NCT00078442|DRUG|Pegylated interferon alfa-2a|Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment
40966293|NCT00041990|DRUG|decitabine (5-aza-2'deoxycytidine)|
40966294|NCT05063487|OTHER|Return of recent classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a recent classification (i.e., having acquired an HIV infection within the last year) will be returned to study participants during a scheduled 1-month visit following initial HIV diagnosis.
40966295|NCT05063487|OTHER|Return of long-term classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a long-term classification (i.e., having acquired an HIV infection more than one year ago) will be returned to study participants during the scheduled 1-month visit following initial HIV diagnosis.
40966296|NCT05127668|DEVICE|Airglove (TM)|A sterile polythene-balloon was inflated around the forearm using the AirGloveTM to 38.5oC at setting number-3 for 3 minutes, then removed and the degree of venodilation assessed by ultrasound.
40966297|NCT05127668|DEVICE|Warm-water Immersion|The upper limbs (to the level of mid-humerus) of participants were immersed in a container filled with a mix of cold-and warm tap-water to 38.5oC for 3 minutes in the WWI method. Arms were towel-dried, and the degree of venodilation was assessed by ultrasound
40966298|NCT05988099|DIETARY_SUPPLEMENT|Complex product|400 mg of chokeberry extract in liposomal formulation and L-arginine, vitamin E, vitamin A, folic acid, chromium
40966299|NCT05988099|DIETARY_SUPPLEMENT|Chokeberry extract in liposomal formulation|400 mg of chokeberry extract in liposomal formulation
40966300|NCT05988099|DIETARY_SUPPLEMENT|Chokeberry extract in traditional formulation|400 mg of chokeberry extract in traditional formulation
40966301|NCT05988099|OTHER|Placebo|Placebo
41295319|NCT02797873|OTHER|ASRS|See Detailed Study Description.
41295320|NCT02797873|OTHER|AQ|See Detailed Study Description.
41295321|NCT02797873|OTHER|TAS-20|See Detailed Study Description.
41295322|NCT02797873|OTHER|Raven's SPM|See Detailed Study Description.
41295323|NCT02797873|OTHER|Reading ability|See Detailed Study Description.
41295324|NCT02797873|OTHER|Ishihara's tests for colour deficiency|See Detailed Study Description.
41295325|NCT02797873|OTHER|Additional questionnaire|including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
41295326|NCT02797873|OTHER|Brown-ADD|See Detailed Study Description.
41295327|NCT02797873|OTHER|MFQ|See Detailed Study Description.
41295328|NCT02797873|OTHER|STAI-T|See Detailed Study Description.
41295329|NCT02797873|OTHER|BIS|See Detailed Study Description.
41295330|NCT02797873|OTHER|DAWBA|See Detailed Study Description.
41295331|NCT02797873|OTHER|STAI-S|See Detailed Study Description.
41295332|NCT02797873|OTHER|Sleepiness rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
41295333|NCT02797873|OTHER|Motivation rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
41295334|NCT02797873|BEHAVIORAL|FEFA2|Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
41295335|NCT02797873|OTHER|Structural T1 MRI scan|See Detailed Study Description and Outcome Measures.
41295336|NCT02797873|OTHER|Structural T2 MRI scan|See Detailed Study Description.
41295337|NCT02797873|OTHER|DTI MRI scan|See Detailed Study Description and Outcome Measures.
41457395|NCT00769951|PROCEDURE|quality-of-life assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
40966302|NCT02805101|DRUG|Biodentine|Biodentine is going to be used as the sealing agent for the perforation.
41457396|NCT00434590|DRUG|Enteric coated mycophenolate sodium (Myfortic®)|
41457397|NCT04153318|DEVICE|full-field optical coherence tomography|Pancreatic tissue sample obtained by EUS-FNB will be used for FFOCT imaging. The Images will be sent to trained pathologists for diagnosis. The same tissue sample will be sent to the pathology department for routine histological examination. Compare the diagnoses made by the 2 different methods.
40966303|NCT02805101|DRUG|MTA|MTA is going to be used as the sealing agent for the perforation.
40966304|NCT02781831|PROCEDURE|Standard rehab|Standard hospital based rehabilitation for patients with stroke
40966305|NCT02781831|DEVICE|Robot-assisted gait rehabilitation|An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke
40966306|NCT03524898|DRUG|Nab-Paclitaxel|150 mg/m2 / 125 mg/m2
40966307|NCT03524898|DRUG|gemcitabine|1000 mg/m2
40966308|NCT01201018|DRUG|Oshadi D, Oshadi R|Oral administration
40966309|NCT04690998|OTHER|Blood Samples|Genetic, proteomic, neurofilament analysis
40966310|NCT04690998|OTHER|MRI|Spinal and muscular MRI
40966311|NCT04119921|DRUG|prescription topical ketorolac in group 1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
40966312|NCT04119921|DRUG|prescription artificial tear in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
40966313|NCT04119921|DRUG|prescription topical ketorolac in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
40966314|NCT04119921|DRUG|prescription artificial tear in group1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
40966315|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
40966316|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
40966317|NCT02340975|BIOLOGICAL|MEDI4736|MEDI4736 will be administered by IV infusion.
40966318|NCT02340975|BIOLOGICAL|Tremelimumab|Tremelimumab will be administered by IV infusion.
40966319|NCT02340975|BIOLOGICAL|MEDI4736+tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
40966320|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
40966321|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
40966322|NCT01507597|DRUG|NaCl|Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
40966323|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
41137657|NCT06216704|DIAGNOSTIC_TEST|Magnetic resonance relaxometry|Spin-lattice relaxation (T1) relaxometry acquisition consisting of fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
41457398|NCT05718180|OTHER|Transperineal imaging|To measure the difference between ultrasound parameters based on maternal position: to measure the variation of AoP (Angle of progression), MLA (Midline Angle), PAA(pubic arch angle expressed in grades) HSD (head-symphysis distance) HPD(head perineum distance) expressed in millimeters, in the supine position and kneeling squat position in the same woman during the expulsion phase, in the resting step and during the push.
41457399|NCT06123754|DRUG|Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection|The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.It will last about 3-4 cycles before surgery and 16 cycles after surgery.
40966324|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
40966325|NCT01235143|DRUG|Desflurane|Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
41295338|NCT02797873|OTHER|Resting state MRI scan|See Detailed Study Description and Outcome Measures.
41457400|NCT06123754|DRUG|placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection|The subjects received platinum-based doublet chemotherapy on day 1 of every cycle. It's 3 weeks per cycle and lasts 3-4 cycles before surgery.
40966326|NCT01235143|DRUG|Sevoflurane|Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
41457401|NCT02349022|RADIATION|[89Zr]Df-IAB2M|
41457402|NCT03181386|DRUG|Rivaroxaban|Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
40990709|NCT05459922|DEVICE|Wearable bright light therapy device|Light treatment glasses (Re-timer®) will be used to deliver bright light therapy. This device is available commercially and allows participants to freely move around while receiving light from LEDs positioned below the eyes. Re-timer® can be worn over glasses and does not interfere with vision, reading, or computer work.
40990710|NCT05459922|DEVICE|Wearable placebo light therapy device|The placebo Re-timer® emits light intensity to a level that will not impact sleep and circadian timing and appears identical to the original Re-timer®.
40966327|NCT01785927|OTHER|ABCD|Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
40966328|NCT06370650|PROCEDURE|platelet rich plasma, narrow band UVB|Role of PRP in treating stable vitiligo
40966329|NCT05117437|OTHER|Physiological test|This test was conducted to determine the endurance levels of the participants.
40966330|NCT05117437|OTHER|Physical test|Height, weight, and BMI were determined
40966331|NCT05117437|OTHER|Biochemical tests|BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.
40966332|NCT03152071|PROCEDURE|Robot assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is robot assisted thoracic surgery
40966333|NCT03152071|PROCEDURE|Video assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is video assisted thoracic surgery.
40767300|NCT05962775|PROCEDURE|Ethanol Sclerotherapy for Endometrioma|2 gr IV cefazolin sodium will be administered 30 minutes before the procedure. The endometrioma cyst content will be aspirated by a single lumen needle, and the total aspirated volume calculation will be done. The endometrioma will then be washed with saline until the color of the cyst content becomes clear. Then, 96% ethanol will be injected into the cyst. The volume of injected ethanol will be 60% of the first aspirated volume (maximum 100 ml). After 10 minutes all ethanol will be aspirated.
40966334|NCT04035798|DRUG|Memantine or placebo|BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
40966335|NCT05395715|PROCEDURE|Electrical stimulation|Patients with cubital tunnel syndrome will receive either surgery and sham stimulation, or conditioning electrical stimulation 7 days prior to surgery
40966336|NCT03486548|DRUG|bupivacaine and dexamethasone|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound guided popliteal sciatic block with 0.125% bupivacaine 20 ml and dexamethasone 5 mg
40966337|NCT03486548|DRUG|bupivacaine and lidocaine|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound at popliteal sciatic area and subcutaneous infiltration popliteal area with 2% lidocaine 1 ml
40966338|NCT03486548|DEVICE|Ultrasound|ultrasound
40767301|NCT05424276|DRUG|IkT-148009|Oral administration gelatin capsule
40966339|NCT02319993|DRUG|TIAN WANG BU XIN DAN|assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
40966340|NCT02319993|DRUG|Suan Tzao Ren Tang|assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
40966341|NCT02319993|DRUG|Placebo|1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
40966342|NCT04158115|OTHER|Entire Spine Mobilization|8 sessions of Following: -Entire Spinal Mobilization of all spinal segment from C0 to C1 to L5 to S1 (10 reps × 3 sets), - Moist heat: 10 to 15 minutes, - Soft tissue Mobilization, - Exercises : (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
41137658|NCT06216704|DIAGNOSTIC_TEST|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at multiple echo times. Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
41137659|NCT06216704|DIAGNOSTIC_TEST|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and inflammation. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). Additionally, in participants with CF, we will assess inflammation, with a c-reactive protein (CRP), and dysglycemia, with a continuous glucose monitor.
41295339|NCT00430625|BIOLOGICAL|VPRIV ®,|Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
41295340|NCT05547555|DIAGNOSTIC_TEST|embryo selection|The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A
40767302|NCT05424276|DRUG|Placebo|Oral administration gelatin capsule
40767303|NCT05336760|DIAGNOSTIC_TEST|Iowa Oral Performance Instrument (IOPI)|IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.
40767304|NCT05336760|DIAGNOSTIC_TEST|Mann Assessment of Swallowing Ability (MASA)|MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.
40966343|NCT04158115|OTHER|Segmental Mobilization|"8 sessions of following -Segmental Mobilization: All lumbar segment from L1 to L2 to L5 to S1 (10 reps × 3 sets) - Moist heat: (10 to 15 minutes), -Soft tissue Mobilization~- Exercises: (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)"
40966344|NCT05362097|OTHER|The reliability and validity of the Chinese version of CC-QoL|Cc-qol, LCQ, and VCD were repeated 1-2 times before and 1-13 weeks after treatment.
40966345|NCT05371691|DEVICE|Myofunctional appliance|Myifunctional appliance will be used for growing patients who have Cl.II div.1 malocclusion, two types of appliances are involved myobrace and twin=block appliance
40966346|NCT04654117|OTHER|Consultee-centered administrative consultation|The consultee-centered administrative consultation model expressly focuses on supporting providers to increase EBP implementation within their specific setting.
40966347|NCT02116296|BEHAVIORAL|ToyBox-intervention|
40966348|NCT00011076|DRUG|Pirfenidone|
40966349|NCT06505655|DIAGNOSTIC_TEST|trehalase levels|We think that in surgical patients requiring hypotensive anesthesia, acute kidney injury, which may occur due to intraoperative renal hypoperfusion, can be diagnosed early by evaluating the urine trehalase value using the ELISA method
40966350|NCT04603690|DIETARY_SUPPLEMENT|Complementary therapy|A daily supplementation of 168 mg curcumin, 260 mg quercetin and 360 IU of vitamin D3 (cholecalciferol) for 14-days
40966351|NCT04603690|DRUG|Standard of care|This arm will receive standard of care as per the hospital guidelines
40966352|NCT01606475|BIOLOGICAL|Allogeneic islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
40966353|NCT00571948|OTHER|more meat and a vegetable oil rich in omega-3 fatty acids|"The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids)."
40966354|NCT00571948|OTHER|Babyfood with usual meat content and corn oil|The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
40966355|NCT03429686|OTHER|DRT Intervention|The digital reminiscence therapy intervention will run 12 sessions twice per week, for six weeks, for up to an hour at a time (this will depend on the participant's ability and willingness to participate). The sessions of reminiscence therapy will be culturally appropriate and based on the key stages in the life which most people will have experienced. These sessions are individual, face-to-face sessions.
40966356|NCT04955197|DIAGNOSTIC_TEST|exfoliated cytology|Micronuclei (MN) are small chromatin bodies in the cytoplasm formed by chromosome fragments or whole chromosomes that fail to be included in the nuclei during cell division. They are considered as a sensitive indicators of genetic damage. They are usually found in the basal cells of epidermis and are shed as exfoliated cells on maturation. Hence micronuclei assay can be used as monitoring of genetic damage, as it is increased in oral neoplastic conditions. Consequently, detection of micronuclei in exfoliated cells indicates an increased risk for cancer
40966357|NCT06139029|DRUG|3% normal saline|nebulization
40966358|NCT06139029|DRUG|steroid(beclomethasone dipropionate 400 μg/day) and salbutamol with 0.9% normal saline|nebulization
40966359|NCT01130142|DRUG|IPI-926 plus gemcitabine|Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle
40966360|NCT01130142|DRUG|Placebo plus gemcitabine|Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
40966361|NCT05733780|DRUG|Prolectin-M|"Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus"
40966362|NCT02725060|DRUG|phenylephrine|Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
40966363|NCT02725060|DRUG|isoproterenol|Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.
40966364|NCT02725060|RADIATION|25 micro-Ci of radiation|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
40966365|NCT02725060|PROCEDURE|Posture study with blood samples|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.
40966366|NCT02725060|PROCEDURE|24-hour heart rhythm and blood pressure monitoring|Blood pressure, heart rate and ECG monitoring for 24 hours
40966367|NCT02725060|PROCEDURE|Quantitative Axonal Sudomotor Reflex Testing|The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
40990711|NCT05669820|DIETARY_SUPPLEMENT|Salovum|Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
40990712|NCT05669820|DIETARY_SUPPLEMENT|Placebo egg yolk powder|Egg yolk powder derived from hen fed with normal feed.
40966368|NCT02725060|PROCEDURE|Autonomic function tests|The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.
40966369|NCT02725060|OTHER|Rebreathing test|Cardiac output will be measured using the rebreathing technique (Innocor)
40966370|NCT02725060|OTHER|Assessment of splanchnic capacitance|Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves
40966371|NCT02725060|PROCEDURE|microneurography|microneurography will be measured in the peroneal nerve to assess sympathetic activity.
40966372|NCT03899571|DRUG|Oseltamivir Oral Capsule for 5 days post-exposure|Patients will receive oseltamivir for 5 days after last influenza exposure.
40966373|NCT03899571|DRUG|Oseltamivir Oral Capsule for 10 days post-exposure|Patients will receive oseltamivir for 10 days after last influenza exposure.
40966374|NCT02878746|DEVICE|Robotic mirror therapy|2-dimensional
40966375|NCT02878746|DEVICE|Conventional mirror therapy|2- and 3-dimensional
40966376|NCT03217331|DRUG|CRD-102|14 mg CRD-102 capsules administered twice daily orally for 14 days.
40966377|NCT00634374|DEVICE|Rx Medibottle|Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
40966378|NCT02344277|DEVICE|S-ICD System (implantable defibrillator)|"The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.~Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system."
40767305|NCT05336760|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).
40966379|NCT01953263|OTHER|Autologous Muscle Fiber Fragments|Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
40966380|NCT04061213|DIAGNOSTIC_TEST|Tc-99m-DPD scintigraphy|Myocardial scintigraphy
40966381|NCT06093815|DEVICE|Injection|A pre specified amount will be injected in tissue at selected timepoints
40966382|NCT06103123|DIAGNOSTIC_TEST|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives
40966383|NCT06103123|OTHER|Baseline Quality of Life questionnaire|Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study
40966384|NCT02314702|DEVICE|PROFEMUR® L Revision Femoral Stem|Revision Total Hip Arthroplasty
40966385|NCT03478332|DRUG|Yangxinshi pill|0.6g/tablet
40966386|NCT03478332|DRUG|conventional coronary heart disease medicine|the conventional treatment includes medicines treating coronary heart disease
40966387|NCT03478332|DRUG|Placebos|Yangxinshi simulant
40767306|NCT05336760|DIAGNOSTIC_TEST|Respiratory function measurements|Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.
40966388|NCT06495827|OTHER|No different intenvention|No different intenvention
40966389|NCT03338998|DRUG|BAF312 solution|Solution for intravenous (IV) infusion - 4.5mg/4.5mL
40966390|NCT03338998|DRUG|Matching Placebo for BAF312 solution|Solution for intravenous (IV) infusion - 0mg/4.5mL matching placebo
40966391|NCT03338998|DRUG|BAF312 tablet|2 mg film-coated tablet
40966392|NCT03338998|DRUG|Matching Placebo for BAF312 tablet|0 mg film-coated tablet matching placebo
40966393|NCT04071561|OTHER|Posterior retroperitoneal adrenalectomy (PRA)|Minimally invasive adrenalectomy procedure
40966394|NCT04071561|OTHER|Lateral transperitoneal adrenalectomy (LTA)|During posterior retroperitoneal adrenalectomy, the failure to progress or the difficulty of creating or maintaining a pneumoperitoneum are reasons why conversion occurs.
40966395|NCT03940040|OTHER|Usual care|Usual Care
40966396|NCT03940040|OTHER|High flow nasal oxygen|High flow nasal oxygen
40966397|NCT04672993|DEVICE|Urine collection device for men|Use of urine collection device for men
40966398|NCT02478632|DRUG|Subjects do not receive study medication in this study 202094|Participants do not receive study medication in this study 202094.
41137660|NCT06216704|DIAGNOSTIC_TEST|DXA|DXA will be utilized to obtain BMD of the total body, lumbar spine, and hip using a Hologic Horizon densitometer (Hologic Inc, Bedford, MA). Body composition will be obtained from total body scans.
40966399|NCT05527340|DRUG|Iberdomide|Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO)
41137661|NCT06216704|DIAGNOSTIC_TEST|pQCT|pQCT will be utilized to obtain volumetric BMD (mg/cm3) of the left tibia. Measurements using a Stratec XCT 3000 device (Orthometrix, White Plains, NY) will be obtained at multiple locations, in relation to distal growth plate.
41137662|NCT05226728|DRUG|pembrolizumab|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression
41137663|NCT01274507|OTHER|Medical tests|All participants will undergo medical tests and will be observed.
40966400|NCT05527340|DRUG|Dexamethasone|Dexamethasone 40 mg (PO) (or 20 mg (PO) if patient ≥ 75 years old) should be administered on the days 1, 8, 15 and 22 of every 4-week cycle.
40767307|NCT06464640|DEVICE|"Online Interactive Podcast Program Living with Type 1 Diabetes to Grown-Up"|The podcast content was designed based on the results of previous research.Subjects will be randomly assigned to either the experimental group (N=44) or the comparison group (N=44). Comparative analyses will focus on variations in disease control, emotional disturbance,confidence in self-management, self-care behaviors, diabetes knowledge,interpersonal disturbance, and family conflict at baseline, and post-interventions of immediate, 3-month, and 6-month periods.
40966401|NCT05527340|DRUG|Daratumumab|Daratumumab will be given at 1800 mg, every 4 weeks, subcutaneously (SC). Cycles 1 and 2 (C1 and C2): Days 1, 8, 15, and 22 C3-6: Days 1 and 15 From C7 onwards: Day 1 of each cycle Cycles will be of 4 weeks of duration (28 days).
40966402|NCT00404261|DRUG|Fluticasone/Salmeterol HFA|Fluticasone/Salmeterol HFA, 2 puffs twice daily
40966403|NCT01793896|BEHAVIORAL|Control period|Analysis at recruitment and after a month without any intervention
40966404|NCT01793896|BEHAVIORAL|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
40966405|NCT01793896|BEHAVIORAL|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
40966406|NCT01793896|BEHAVIORAL|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
40966407|NCT00804544|DEVICE|SPECT/CT|SPECT/Low-Dose MultiSclice CT
40966408|NCT04946188|DEVICE|Opuz NICGM|A wearable and non-invasive prototype device that allows for measurement of bioimpedance data with the aim to help develop a mathematical model to predict blood glucose levels.
40966409|NCT05608798|DEVICE|ODI-Tech medical device|"The device captures and stores frames of the movement of blood in capillaries and spectra containing information on oxygen saturation. Proprietary software is used to analyse the obtained frames and spectra to calculate microvascular parameters such as functional capillary density and microvascular oxygen saturation.~ODI-Tech can be brought to the patient's bedside and operates non-invasively. The device parts are in contact with the patient for less than 5 minutes."
40966410|NCT05979870|PROCEDURE|Valvuloplasty,|Choice of type of intervention decided on a multidisciplinary conference
40966411|NCT05075122|BIOLOGICAL|UV1|UV1 vaccination (300 μg) UV1 vaccination will be applied in a dense schedule with three vaccinations during one week before initiation of pembrolizumab, followed by 5 additional vaccinations every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14)
40966412|NCT05075122|DRUG|Sargramostim for Injection|75 μg GM-CSF as adjuvant per vaccination. Applied in a dense schedule with three injections during one week before initiation of pembrolizumab, followed by 5 additional injections every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14).
40966413|NCT05075122|DRUG|Pembrolizumab injection|200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
40966414|NCT05712759|OTHER|Influenza-like illness group|"Each patient who present ILI (influenza-like illness) at admission or during hospitalization and who have had a nasopharyngeal swab taken as part of their care for the purpose of diagnosing influenza by Polymerase Chain reaction (PCR) testing.~ILI is defined by fever \> 37,8°C or/and cough or sore throat."
40966415|NCT02006719|BIOLOGICAL|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
40966416|NCT02006719|OTHER|Placebo|Placebo injection
40966417|NCT04445311|DRUG|Ivermectin|3 successive days ttt of ivermectin started within 48 hours of symptoms
40966418|NCT01309594|PROCEDURE|Hematopoietic stem cell transplantation|Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
40966419|NCT01952405|BEHAVIORAL|Dialectical behavior therapy (DBT)|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
40966420|NCT06506565|DRUG|Ketamine|Infusion during wound care
40966421|NCT06506565|DRUG|0.9% NaCl|Infusion during wound care
40966422|NCT03973385|DEVICE|Cryotherapy|patients recieving cryotherapy for skin anesthesia for artérial blood gas
40966423|NCT00621153|DRUG|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
40966424|NCT00621153|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
40966425|NCT00621153|DRUG|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
41137664|NCT01883063|DEVICE|Surgical Treatment|Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
40767308|NCT06464640|DEVICE|E-book|Participants in the active control group will use Ebook.According to the research results from the project leader\&#39;s app effectiveness evaluation (Chiang, 2020-2022), the e-book did not show significant effects on blood sugar control, disease management confidence, self-care behaviors, disease-related knowledge, or interpersonal distress. Therefore, the active control group received a sham treatment in the form of an e-book. The research team extracted content from the CEO APP e-book, with an expert validity of 0.91, and reorganized it into an electronic health education manual titled \&#34;Transitioning from Adolescence to Early Adulthood: The Ins and Outs of Type 1 Diabetes.\&#34;
40767309|NCT04716725|DRUG|68Ga-PSMA-11|Given IV
40966426|NCT01878838|PROCEDURE|Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
40966427|NCT01878838|PROCEDURE|Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
40966428|NCT04176666|DEVICE|NettOpp|NettOpp is a mobile application for adolescents aged 11-16 years who have been exposed to cyberbullying or cyberaggression.
40966429|NCT04821947|OTHER|Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine|"for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula.~After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine"
40966430|NCT01367210|DRUG|Maraviroc, Darunavir/r|Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
40966431|NCT01367210|DRUG|current antiretroviral therapy with 3 drugs|To continue the assumption of previous HAART
40966432|NCT06279091|BEHAVIORAL|Diaphragmatic Breathing|apply breathing exercises to evaluate the effectiveness on anxiety reduction
40966433|NCT06279091|BEHAVIORAL|Bubble Blower Breathing|apply breathing exercises by using bubble blower to evaluate the effectiveness on anxiety reduction
40966434|NCT06279091|BEHAVIORAL|Tell Show Do|apply basic behavioral management technique as control group
40966435|NCT03471130|DRUG|MT-8554 Low dose|Oral, 7 days
40966436|NCT03471130|DRUG|MT-8554 High dose|Oral, 7 days
41295341|NCT03611400|DIETARY_SUPPLEMENT|Probiotic|This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10\^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10\^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.
41295342|NCT03611400|DIETARY_SUPPLEMENT|Placebo|The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
41295343|NCT05301322|BIOLOGICAL|RSVpreF Vaccine|RSV Vaccine
41457403|NCT03181386|DRUG|Dabigatran and Apixaban|Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
41457404|NCT03181386|DRUG|Warfarin|The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
41457405|NCT03121937|BEHAVIORAL|Mobile App|"The mobile app mConnect is an app designed to facilitate psychotherapy for depression and includes mood tracking, goal setting, and communication"
40966437|NCT03471130|DRUG|Placebo|Oral, 7 days
40966438|NCT00756756|DRUG|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
40966439|NCT00756756|DRUG|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
40966440|NCT04255108|DEVICE|Cova Patch|CoVa Patch will measure quasi-continuously, approximately every 5 minutes for a period between 6 to 48 hours
40966441|NCT02069717|OTHER|Not applicable-observational study|
40966442|NCT04736407|OTHER|Observational sampling of CSF timed around routine clinical repositioning, or not|no true intervention
40966443|NCT04100265|DEVICE|Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed during surgery.
40990713|NCT03687203|DIAGNOSTIC_TEST|Functional Activities Questionnaire|The FAQ is an economic and easy to apply activity of daily living scale. We aim to validate the prognostic value of novel FAQ scores, which differentiate cognitive- from motor-driven activity of daily living function.
41295344|NCT05301322|OTHER|Placebo|Placebo
41295345|NCT05301322|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|SIIV
41295346|NCT06077630|OTHER|No intervention|There is no intervention, observational study
41295347|NCT04269512|PROCEDURE|lymph node dissection|At least 10 lymph nodes must be removed.
41295348|NCT02805088|OTHER|Electroencephalographic recordings|
41295349|NCT02805088|OTHER|neuropsychological evaluation|
41295350|NCT02805088|OTHER|clinical evaluation of symptoms|
41457406|NCT01670097|DRUG|Dexamethasone|"Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days."
41457407|NCT01670097|DRUG|Placebo|Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
41457408|NCT01670097|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
41457409|NCT01670097|DEVICE|Spirometer|Patient to blow into spirometry machine 1 time a day to test lung function.
41457410|NCT01670097|OTHER|Phone Calls|Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
41457411|NCT02834390|DRUG|Quizartinib|"\[Induction period, Cycle 1\] Once-daily repeated oral administration Day 8 to Day 21.~\[Induction period, Cycle 2\] Once-daily repeated oral administration Day 6 to Day 19.~\[Consolidation period\] Once-daily repeated oral administration Day 6 to Day 19."
40966444|NCT04100265|DEVICE|Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed upon the manifestation of clinical signs of postoperative ileus.
40966445|NCT03932110|DIAGNOSTIC_TEST|omentin, visfatin|diagnostic blood test
40966446|NCT00188669|DRUG|pentoxifylline|
40966447|NCT00188669|DRUG|alpha-Tocopherol|
40966448|NCT02052531|DRUG|PAC-14028|Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
40966449|NCT02052531|OTHER|Vehicle|Participants received topical Vehicle twice daily for 4 weeks
40966450|NCT01678911|DRUG|Gralise|"Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication)."
40966451|NCT02012075|DRUG|Extended-Release Carvedilol Sulfate|
40966452|NCT02012075|DRUG|Sustained-release Metoprolol Succinate|
40990714|NCT00139828|DRUG|human coagulation Factor IX|
41295351|NCT02816710|DRUG|Conbercept|Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
41295352|NCT05553379|DIAGNOSTIC_TEST|FeNO measurement|FeNO measurement at each visit
41457412|NCT02834390|DRUG|Cytarabine|"\[Induction period, Cycle 1\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 7.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 5.~\[Consolidation period\] Twice-daily intravenous injection of 3.0 g/m\^2 cytarabine at 12-hour intervals on Days 1, 3, and 5."
41295353|NCT04346394|DRUG|Yohimbine HCl|Yohimbine hydrochloride will be used to manipulate the noradrenergic system during some of the assessments. By measuring the amounts of hormones the body produces before and after yohimbine hydrochloride administration, researchers can assess how well the noradrenergic system is functioning
41457413|NCT02834390|DRUG|Idarubicin|"Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 and 2."
41457414|NCT02834390|DRUG|Daunorubicin|"Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 and 2."
40767310|NCT04716725|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET
40767311|NCT03952559|DRUG|Baricitinib|Administered orally
40767312|NCT03952559|DRUG|Placebo|Administered orally
40767313|NCT03952559|DRUG|Topical corticosteroid|Administered as standard-of-care
40767314|NCT04666740|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.
40767315|NCT04666740|DRUG|Olaparib|Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.
40767316|NCT04347538|OTHER|Saline Nasal Irrigation|Saline nasal irrigation BID
40767317|NCT04347538|OTHER|Saline with Baby Shampoo Nasal Irrigation|Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.
40767318|NCT02383823|DRUG|Estrogens|Crossover study of estrogen or placebo in random order in menopausal women
40767319|NCT02383823|OTHER|Placebo|Crossover study of placebo or estrogen in random order in menopausal women
40767320|NCT05995626|DRUG|Hyaluronidase|hyaluronidase injection is used during fluid administration under the skin to help achieve hydration, to increase the dispersion and absorption of other injected drugs, or during some types of urography (imaging of the urinary tract) to help improve resorption of drugs used during the procedure.
40767321|NCT05995626|DEVICE|co2 laser|CO2 lasers use an aiming beam to see where the treatment beam will impact the focus tissue. The focus tissue will then be cleanly incised. They have greater precision for laser surgery and have more flexibility in tip sizes and protocols.
40767322|NCT05848687|DRUG|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
40767323|NCT05848687|DRUG|Mitoxantrone|Given IV
41457415|NCT05890963|DRUG|ART|ART is a combination of three or more drugs from different classes of antiretroviral medication.
41457416|NCT05890963|DRUG|10E8.4/iMab|10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
41457417|NCT05890963|DRUG|VRC07-523LS|VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
41295354|NCT04076072|DEVICE|Utravit High-Speed 10000 cpm Beveled Probe|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
41295355|NCT04076072|DEVICE|standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
40966453|NCT00839891|DRUG|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
41137665|NCT01883063|DEVICE|Non surgical Treatment (Cast or splint)|Patients will be treated for distal radius fractures non surgically with a cast or splint
41137666|NCT04571437|DRUG|Capecitabine|Capecitabine metronomic combined with Letrozole
41137667|NCT04571437|DRUG|Letrozole 2.5mg|Letrozole daily alone
41295356|NCT05518344|DEVICE|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."
41295357|NCT01984593|OTHER|Yoga|"The participants in the Yoga group will get a private doctors appointment (20 minutes) where they get instructions for two yoga exercises to perform at home 15 minutes twice a day.~The two yoga exercises were:~1. Left nostril breathing - deep breaths in and out through the left nostril while sitting or lying down, with the right nostril closed off by the right thumb or an earplug (about 11 minutes); and~2. Spinal flex - movement that alternates between flexing the spine forwards (arching) and relaxing the spine back in time with deep breaths while sitting in a chair (about 4 minutes)."
41295358|NCT00824486|BEHAVIORAL|Injury prevention education (TIPP)|using TIPP materials
41295359|NCT00824486|BEHAVIORAL|Injury prevention education (safe home)|using safe home model
41295360|NCT06258811|DRUG|albumin paclitaxel, cispatin, tislelizumab|Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks for one year)
41295361|NCT04736511|OTHER|Star Excursion Balance Test|"The subject will be in unipodal support (only one foot on the ground) on the tested lower limb in the center of the platform. Three lines forming a Y will be arranged according to the lower limb in charge in three directions : anterior (ANT), posteromedial (PM) and posterolateral (PL). The goal is then to reach the longest distance possible in all three directions with the tip of the foot in relief before returning to the starting position. The subject will have 4 training trials per direction on each lower limb then 3 trials will be recorded in order to keep the average."
41295362|NCT04736511|OTHER|Single leg Drop Vertical Jump|The subject will drop from a step and land on one leg, then jump as high as possible and stabilize again on the same leg. The height of the step is 30 cm. The subject will perform 3 consecutive jumps in the strictest respect of the instructions: drop to the level of the mark on the ground and bounce as high as possible while spending a minimum of time on the ground. The subject must stabilize for 3 seconds during the second contact with the ground so that the instructions and measurements are reproducible.
41295363|NCT04736511|OTHER|Unplanned sidestep cutting manoeuvre|"The objective is to create an unanticipated playing situation, close to the daily actions of the subjects in the practice of handball. The subject will make sidestep cutting manœuvre in front of an opponent simulated by a dummy used during usual training.~The subject will sprint in a straight line and then at the force platform will make a rapid change of direction on the side of his shooting arm or will continue his run in a straight line. A light signal randomly will indicate to the player the direction in which he must carry out his manoeuvre. A computer reconstruction of the kinematics and dynamics (knee moment) will be performed."
41457418|NCT04834336|DEVICE|inspiratory muscle training device|Inspiratory muscle training will be performed with an inspiratory muscle training device.
41457419|NCT04834336|OTHER|Physical training|Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.
41457420|NCT03853499|OTHER|No intervention (observational study)|No intervention (observational study)
40767324|NCT05848687|DRUG|PEG asparaginase|Given IV
40767325|NCT05848687|DRUG|Bortezomib|Given IV
41457421|NCT03134053|DEVICE|extracorporeal shock-wave|to treat painful and retracting scars
40767326|NCT05848687|DRUG|Vorinostat|Taken PO or NG
40767327|NCT05848687|DRUG|Mercaptopurine|Given PO or NG.
40767328|NCT05848687|DRUG|Methotrexate|Given IV, IM or PO
40767329|NCT05848687|DRUG|Blinatumomab|Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction
40767330|NCT05848687|DRUG|Ziftomenib|3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D
40767331|NCT06391268|BEHAVIORAL|Emotional Freedom Technique (EFT) works on cognitive and energetic levels.|Emotional Freedom Technique (EFT) works on cognitive and energetic levels.
40767332|NCT02367040|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
40767333|NCT02367040|DRUG|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
40990715|NCT03911440|DRUG|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
41295364|NCT04736511|OTHER|Tendon vibration|The subject will be asked to stand, motionless in bipodal (both feet on the ground) support on a stable and unstable ground (foam). A tendon vibration (80Hz) will be randomly applied to the subject in the Achilles tendons or paravertebral muscles. This vibration will cause an alteration of proprioceptive information in the vibrated area leading to a disruption of postural balance. Thus, according to the amount of displacement of the center of pressure (CoP), the proprioceptive weighting ratio (dRPW) is calculated to deduce therefrom the weight assigned by the CNS to the various proprioceptive inputs during the postural task.
41295365|NCT06513364|DRUG|WH002|"Group A（ddWH002-ddEC）： Regimen for Group A during Cycles 1-Cycles 4:WH002， 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles."
41295366|NCT06513364|DRUG|paclitaxel injection|"Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles."
41295367|NCT04372693|OTHER|impliminting Online Distance Learning|as a result of (COVID-19) social distancing measures, the Online Distance Learning will be implemented without prior planning for undergraduate nursing students
41295368|NCT04833933|OTHER|Phone survey about smoking cessation process since intervention in DISCO trial|We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.
41295369|NCT05482269|OTHER|no intervention|no intervention
41295370|NCT01904877|BEHAVIORAL|Enhancing HIV testing|SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
41295371|NCT00970203|BIOLOGICAL|androgen ablation (AA)|Lupron 22.5 mg or Zoladex 10.8 mg
41295372|NCT00970203|BIOLOGICAL|DC1 vaccine|3-5 x 10e6 cells total
41295373|NCT04146584|DEVICE|Sofwave Treatments|The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.
41295374|NCT01671085|DRUG|LY3015014|Administered SQ
41295375|NCT01671085|DRUG|Placebo|Administered SQ
41295376|NCT03493503|DRUG|Salbutamol|Intravenous Salbutamol loading dose
41457422|NCT03134053|OTHER|massage|to treat painful and retracting scars
41457423|NCT00009776|BIOLOGICAL|monoclonal antibody Lym-1|
41295377|NCT03493503|DRUG|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
40990716|NCT03911440|DRUG|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
41295378|NCT06313905|DIETARY_SUPPLEMENT|EVADRY|"The EVADRY oral spray and the placebo are produced by Wellnet laboratory.~• EVADRY spray: It is a phytotherapy-based medication in the form of an oral spray. It is a 100 ml bottle containing ALEO BARBADENSIS LEAF WATER (1 ml), Chamomilla Recutita Flower extract (30 mg), TOCOPHEROL (10 mg), hyaluronic acid (2 mg), mentha spicata herb oil (10 mg), and eugenol (40 µg)."
41295379|NCT06313905|OTHER|Placebo|"The placebo corresponds to flavored water (mint extract) with the same taste as EVADRY. It is placed in a bottle with the same appearance as EVADRY.~Both products are administered at a rate of 5 intra-oral sprays per day."
41295380|NCT00443430|DRUG|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
41457424|NCT00009776|DRUG|cyclosporine|
41457425|NCT00009776|DRUG|paclitaxel|
41457426|NCT00009776|RADIATION|indium In 111 monoclonal antibody Lym-1|
41457427|NCT00009776|RADIATION|yttrium Y 90 monoclonal antibody Lym-1|
41457428|NCT04840355|DRUG|Sintilimab Injection|The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.
41457429|NCT06321055|DRUG|Regorafenib (Stivarga, BAY73-4506)|Retrospective analysis.
41457430|NCT00929019|BIOLOGICAL|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
41457431|NCT02775058|DEVICE|synergoss Pxx|dental grafting
41295381|NCT00443430|DRUG|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
40966454|NCT01567124|DRUG|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
40966455|NCT01567124|DRUG|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
40966456|NCT01567124|DRUG|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
40966457|NCT01567124|DRUG|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
41295382|NCT00893113|DRUG|Placebo|Alfuzosin-matched One tablet once daily
41295383|NCT00893113|DRUG|Alfuzosin|10 mg once daily
41295384|NCT02286115|BEHAVIORAL|Life-Stress Interview|A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
41295385|NCT03525587|OTHER|"Use of MAGHD App/MAGHD Framework"|Patients daily related outcomes will be recorded thanks to the development, implementation and validation of a Smartphone app (MAGHD App) integrated with a software framework able to merge patient's daily activities data on well-being status, QoL, physical activities and sexual function with clinical data collected in their record chart (extrapolated from already available Institutional Databases).
41295386|NCT03943667|DRUG|Gemcitabine|1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.
41295387|NCT03943667|DRUG|Paclitaxel|80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.
41295388|NCT01791868|DRUG|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
41295389|NCT01791868|DRUG|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
41295390|NCT05416229|DRUG|Psilocybin|Psilocybin-assisted therapy
41295391|NCT05416229|DRUG|Maltodextrin|Placebo-assisted therapy
40966458|NCT00131118|DRUG|Zoledronic Acid|
40966459|NCT05654337|OTHER|Expert health counseling|Expert advice on dietary education, lifestyle change, and physical exercise schedule
41295392|NCT05544825|DIETARY_SUPPLEMENT|Ice plant group|Ice plant extract 2,000 mg/day for 12 weeks
40966460|NCT00635596|BIOLOGICAL|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
41295393|NCT05544825|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,000 mg/day for 12 weeks
41295394|NCT00016523|DRUG|Inhaled nitric oxide|Started at 5 ppm and could be increased to 10 ppm
41295395|NCT00016523|DRUG|Placebo|Started at 5 ppm and could be increased to 10 ppm
41295396|NCT00758303|DRUG|Low Dose TRIA-662|One Capsule 3 times a day
41295397|NCT00758303|DRUG|High Dose TRIA-662|3 Capsules 3 times daily
41295398|NCT00758303|DRUG|Placebo for TRIA-662|Matching Placebo for TRIA-662 taken 3 times a day
40966461|NCT05866172|PROCEDURE|HAIC|hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h)
40966462|NCT05866172|DRUG|Zoledronic acid|Zoledronic acid 4mg iv.drip
40966463|NCT00708968|BEHAVIORAL|FOCUS Program|Supportive, educative sessions with patients and spouses.
40966464|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|10µg (400 IU) orally daily for 10 weeks
40966465|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|30µg (1200 IU) orally daily for 10 weeks
41295399|NCT06109623|OTHER|observation|To observe the changes and differences of steroid hormones between stress urinary incontinence group and control group.
41295400|NCT06109623|OTHER|sex hormone|Six indicators of steroid hormones (estrogen, testosterone, follicle stimulating hormone, luteinizing hormone, pituitary prolactin, progesterone)
40966466|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|40µg (1600 IU) orally daily for 10 weeks
41295401|NCT02466269|PROCEDURE|The supratemporalis approach|The supratemporalis approach was applied in treatment of diacapitular condylar fractures
41295402|NCT06338059|OTHER|Vitamin B12 Level|Vitamin B12 Level Laboratory measurement of patient's vitamin B12 level in unit of pg/mL 25 OH Vitamin D Level Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
41295403|NCT05409885|OTHER|General anesthesia|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
41295404|NCT05409885|OTHER|Spinal anesthesia|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
41295405|NCT02407574|DEVICE|External Pacing Box|Atrial pacing using an external pacing box
40966467|NCT00536198|DRUG|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
41295406|NCT01008930|PROCEDURE|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
41295407|NCT02452970|DRUG|RRx-001|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
40966468|NCT00536198|DRUG|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
40966469|NCT01626456|DRUG|ALKS 9072, Low|IM injection, given monthly
41295408|NCT02452970|DRUG|Gemcitabine and cisplatin|RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
41295409|NCT03925428|DRUG|Entinostat|Given PO
41295410|NCT03925428|DRUG|Molibresib|Given PO
41295411|NCT00036205|DRUG|sumanirole|
41295412|NCT00779727|PROCEDURE|Placement of drainages|
41295413|NCT01951482|DRUG|Pemetrexed/cisplatin|receive Pemetrexed/cisplatin every 21 days
41457432|NCT01095887|DRUG|Eculizumab|Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
41295414|NCT01951482|DRUG|Bevacizumab and Pemetrexed/cisplatin|receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days
41295415|NCT04933006|DIAGNOSTIC_TEST|Pulsevelocity|arterial stiffness evaluation with pulsewave velocity
41295416|NCT05588492|DRUG|Rifamycin-containing regimen|Rifamycin-containing regimen
41295417|NCT05588492|DRUG|Rifamycin-free regimen|Rifamycin-free regimen
41295418|NCT03622164|RADIATION|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)|CTV54 includes only the ipsilateral neck, including levels 2-4 plus levels 1 and/or 5 as clinically indicated.
41295419|NCT03622164|RADIATION|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)|CTV54 includes the entire surgical bed, including bilateral neck lymphatics at risk of harboring microscopic disease
41295420|NCT00436215|DRUG|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
41295421|NCT00436215|DRUG|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
41295422|NCT02204540|BEHAVIORAL|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
41457433|NCT00928057|DEVICE|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
40966470|NCT01626456|DRUG|ALKS 9072, High|IM injection, given monthly
40966471|NCT01410201|DRUG|Dexamethasone Intravitreal Implant|Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
40966472|NCT01446289|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
40966473|NCT01446289|BIOLOGICAL|Placebo|Pregnant women who received one injection of saline solution administered intramuscularly.
40966474|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
40966475|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation|0.1 mL, Intradermal
40966476|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
41295423|NCT03008590|DRUG|Naltrexone|One 4.5 mg capsule each evening
41295424|NCT03008590|DRUG|Placebo|One capsule each evening
41295425|NCT02341014|DRUG|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .
41295426|NCT02341014|DRUG|Romidepsin|
41295427|NCT02341014|DRUG|Lenalidomide|
41295428|NCT03849469|BIOLOGICAL|XmAb®22841|Monoclonal bispecific antibody
41295429|NCT03849469|BIOLOGICAL|Pembrolizumab (Keytruda®)|FDA-approved humanized monoclonal antibody
41457434|NCT00928057|DEVICE|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
40767334|NCT02367040|DRUG|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
40767335|NCT05678465|PROCEDURE|Non-fixation of the mesh|3D-shaped, anatomical, standard, polypropylene mesh without fixation.
40767336|NCT05678465|PROCEDURE|Fixation of the mesh|Glue fixation of lightweight, macroporous, polypropylene mesh.
40767337|NCT03770286|DEVICE|5% Fluoride Varnish|Topical varnish
40767338|NCT03770286|DEVICE|38% Silver diamine fluoride|Topical varnish
40767339|NCT03770286|DEVICE|Super Floss|Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
41137668|NCT03658915|DEVICE|Smartphone application (Goniometer Pro )|Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.
41137669|NCT00445757|PROCEDURE|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
41137670|NCT00445757|RADIATION|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
41137671|NCT00458094|BEHAVIORAL|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
41137672|NCT00458094|BEHAVIORAL|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
41137673|NCT00986869|PROCEDURE|Doppler echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
41137674|NCT04813991|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg for breakthrough pain.
41137675|NCT04813991|DRUG|OxyCODONE 5 Mg Oral Capsule|OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
41137676|NCT03434600|OTHER|Oxford UKA vs Sigma UKA|
40767340|NCT05036330|OTHER|Clinical Evaluation|Undergo speech and swallow evaluation
40767341|NCT05036330|PROCEDURE|Physical Examination|Undergo examination of TEP and laryngectomy stoma
40767342|NCT05036330|OTHER|Quality-of-Life Assessment|Complete questionnaires
40767343|NCT05036330|OTHER|Questionnaire Administration|Complete questionnaires
40767344|NCT05752032|GENETIC|ICM-203|Long term follow-up
40767345|NCT05752032|DRUG|Placebo|Long term follow-up
40767346|NCT04485104|DRUG|GWP42003-P|Oral Solution
40767347|NCT04024488|BEHAVIORAL|TI-CBT Intervention Arm|"TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial."
40767348|NCT04024488|BEHAVIORAL|Discussion Control Arm|Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
40966477|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation|0.5 mL, Intramuscular
41137677|NCT05056948|OTHER|artificial intelligence (AI) computer assisted design (CAD)|Maxillary right first molar will be removed in the computer and will be designed by artificial intelligence system
41137678|NCT03160976|OTHER|Cryolipolysis|First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done. Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk. In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed. The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas). The applicator will be chosen according to the size of the area of each subject and positioned in the target region. At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
41457435|NCT00928057|DEVICE|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
40767349|NCT06274177|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment
40767350|NCT06524960|DRUG|Denosumab|Denosumab is a sterile, preservative-free, clear, colorless to pale yellow solution. Each 1 mL single-dose prefilled syringe of denosumab contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2.
40767351|NCT06524960|OTHER|Placebo|Placebo is 1 mL of normal saline drawn up in a commercially available syringe.
40767352|NCT06585384|COMBINATION_PRODUCT|etanercept and repeated contrast ultrasound|Strategy combining 9 weeks of etanercept administration (50mg/week) with 5 weeks of repeated contrast ultrasound of 2 sessions per day, 5 days per week (from the fifth week of etanercept treatment)
40767353|NCT06333808|DRUG|Bictegravir|Tablets administered orally without regard to food
40767354|NCT06333808|DRUG|Lenacapavir|Tablets administered orally without regard to food
40767355|NCT06333808|DRUG|B/F/TAF|Tablets administered orally without regard to food
40767356|NCT06333808|DRUG|Placebo to match B/F/TAF|Tablets administered orally without regard to food
40767357|NCT06333808|DRUG|Placebo to match BIC/LEN|Tablets administered orally without regard to food
40767358|NCT04573881|DEVICE|HistoSonics System|The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
40966478|NCT05405205|DIETARY_SUPPLEMENT|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in drinking water
40966479|NCT05405205|DIETARY_SUPPLEMENT|probiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, maltodextrin, sucralose and flavour twice a day resolved in drinking water
40966480|NCT05405205|DIETARY_SUPPLEMENT|placebo|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in drinking water
40966481|NCT02852538|BEHAVIORAL|NEW FED TR|NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
40966482|NCT01991691|DEVICE|Tablet-based questionnaire|tablet-based patient reported outcomes (TabPRO)
40966483|NCT05504031|PROCEDURE|Hybrid coronary revascularization|Coronary revascularization is conducted as a combined MIDCAB (LIMA-LAD grafting through a minimally invasive anterior left thoracotomy) and PCI (of all non-LAD stenoses)
40966484|NCT05504031|PROCEDURE|Conventional revascularization|Conventional revascularization with CABG of all significant stenoses through a sternotomy
40966485|NCT03572062|BIOLOGICAL|Formulation A|RSV vaccine
40966486|NCT03572062|BIOLOGICAL|Formulation B|Adjuvanted RSV vaccine
40966487|NCT03572062|BIOLOGICAL|Formulation C|RSV vaccine
40966488|NCT03572062|BIOLOGICAL|Placebo|Placebo
40966489|NCT03648983|PROCEDURE|arm circumference measurement|Undergo arm circumference measurement
40767359|NCT03966313|DEVICE|ventricular assist device implantation|"Blood sampling in patients under surgery for ventricular assist device implantation at five time points:~* After anesthetic induction~* Before starting the device~* 2h, 6h and 48h after starting the device"
40767360|NCT04895696|DRUG|Afimetoran|Specified dose on specified days
40767361|NCT04895696|OTHER|Placebo|Specified dose on specified days
40767362|NCT06381102|DEVICE|transcutaneous auricular vagus nerve stimulation 30/30|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 30 second on and 30 second off, for 1 hour, in-person.
40767363|NCT06381102|DEVICE|transcutaneous auricular vagus nerve stimulation 10/10|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 10 second on and 10 second off, for 1 hour, in-person.
40767364|NCT04683653|RADIATION|Hypofractionated Radiation|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less often. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
40966490|NCT03648983|DEVICE|Bioimpedance spectroscopy|bioimpedance spectroscopy
40966491|NCT03699098|DIAGNOSTIC_TEST|TSH, T3, T4 and thyroid gland DVH|measuring thyroid functions and DVH parameters of thyroid gland
40966492|NCT02575495|DRUG|7 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
40966493|NCT02575495|DRUG|14 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
40966494|NCT02170597|DRUG|BIBR 1048 MS HPMC capsule|
40966495|NCT02170597|DRUG|BIBR 1048 MS gelatine capsule|
41457436|NCT04485208|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
41457437|NCT05352048|DEVICE|Triggered Electromyography|Triggered electromyography will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded.
40767365|NCT04683653|OTHER|Clinical Follow-Up and Assessments|"At each visit, the subject will be evaluated for any signs of their endometrial cancer or symptoms returning (clinical disease recurrence) and any negative side effects associated with their prior radiation treatment. Study participants will also be asked to fill out a survey regarding bowel/urinary habits and quality of life questionnaires (known as the EPIC questionnaire) during these visits. The data collected during these clinical follow up visits will be used to determine how effective hypofractionated/shortened whole radiation therapy is for treating endometrial cancer."
40966496|NCT05304273|DRUG|Mifepristone|Participants with 1st trimester miscarriage will receive for medical termination
40966497|NCT05304273|DRUG|Letrozole|Participants with 1st trimester miscarriage will receive for medical termination
40966498|NCT02362061|RADIATION|3D ultrasound|ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
40966499|NCT04662125|DRUG|caffeine, paracetamol tablet|oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
40966500|NCT04662125|DRUG|Oral prednisolone|patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .
40990717|NCT05350033|DEVICE|tDCS - tDCS|active-tDCS administered during 10 sessions, in Phase 1 and Phase 2
41295430|NCT04283461|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.
40767366|NCT01969058|DRUG|Isotretinoin|Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
41295431|NCT04329923|DRUG|Hydroxychloroquine Sulfate 400 mg twice a day|Antimalarial compound
41295432|NCT04329923|DRUG|Hydroxychloroquine Sulfate 600 mg twice a day|Antimalarial compound
41295433|NCT04329923|DRUG|Hydroxychloroquine Sulfate 600 mg once a day|Antimalarial compound
41295434|NCT04329923|DRUG|Placebo oral tablet|Placebo
41295435|NCT06283095|PROCEDURE|expansion palatoplasty|surgical procedure
41295436|NCT01447056|BIOLOGICAL|LMP specific T cells|"Three dose levels will be evaluated:~Dose Level 1: 2×10\^7 cells/m2; Dose Level 2: 1×10\^8 cells/m2; Dose Level 3: 2×10\^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection."
41295437|NCT01759784|BIOLOGICAL|Intraventricular injection|intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
41295438|NCT04367337|OTHER|No intervention|Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
41295439|NCT05009472|DEVICE|expander with deferential opening and petit face mask|bonded expander with two screws and vertical hooks for attachment face mask. adjustment face mask with forehead and chin anchorage
41295440|NCT02480075|OTHER|Observational|Observational Study only
40767367|NCT05770570|BEHAVIORAL|Counseling|In-person individual diet and physical activity (PA) counseling
40767368|NCT05770570|BEHAVIORAL|Text Messages|Thrice-weekly diet/physical activity(PA) text messages
40767369|NCT05770570|BEHAVIORAL|Phone calls|Weekly telephone support
40767370|NCT05770570|BEHAVIORAL|Self-monitoring tools|Self-monitoring tools
41295441|NCT01671488|BIOLOGICAL|Treatment|ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.
41295442|NCT01671488|DRUG|5FU|1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days
41295443|NCT01671488|DRUG|Mitomycin|10 mg/m2, day 1 and 29 (day 29 can be + 7 days)
41295444|NCT01671488|RADIATION|IMRT|54 Gy in 30 fractions at 1.8 Gy per fraction.
41295445|NCT02749721|DRUG|vortioxetine|Open-label vortioxetine
41295446|NCT03076008|OTHER|Observational|No intervention
41295447|NCT02575482|DRUG|SUVN-D4010|
41295448|NCT02575482|DRUG|Placebo|
40767371|NCT05026710|DEVICE|Silicone (Coloplast Imajin Hydro) ureteral stent|During the end of the standard of care ureteroscopy the silicone stent will be placed.
40767372|NCT05026710|DEVICE|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer)|During the end of the standard of care ureteroscopy the Non-silicone (Polyurethane/Percuflex) stent will be placed.
40966501|NCT04662125|DRUG|oral pregabalin|patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
40966502|NCT02254252|DRUG|Nicorandil|nicorandil (10mg tablets, two times a day)
40966503|NCT02254252|DRUG|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
40966504|NCT00745823|DRUG|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
40966505|NCT00745823|DRUG|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
41137679|NCT03950661|OTHER|Walking|
40767373|NCT04169243|BEHAVIORAL|New Nordic Diet|The New Nordic Diet conforms with the Nordic Nutrition Recommendations and incorporates environmental sustainability and planetary health. It includes rapeseed oil, whole grain bread, wild fish, seafood and game, potatoes, root vegetables, cabbages, Nordic fruits and berries. A two-week menu including all daily meals has been created to ensure dietary goals of the New Nordic Diet intervention: fish and shellfish intake ≥ 3 times/w (fatty fish at least once per week), ≥ 500 g fruit, berries, vegetables and legumes daily (legumes as main protein source at least twice per week), whole-grain cereal products, rapeseed oil for cooking/dressing and three table spoons of nuts and seeds per day.
40767374|NCT04169243|OTHER|Control|The control women receive diet advice according to usual care, which may be a short meeting with the regular midwife or a short meeting with a dietician. From the study, they will receive a gift certificate that can be used in grocery stores.
40767375|NCT06477692|DRUG|ENI using IMRT with or without chemotherapy|This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
40767376|NCT06477692|RADIATION|INRT|INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
40767377|NCT06477692|RADIATION|ENI|ENI using IMRT with or without chemotherapy
40767378|NCT03735121|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in arm or cohort.
40767379|NCT03735121|DRUG|rHuPH20|rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
40966506|NCT00745823|DRUG|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
40966507|NCT02742480|DRUG|Dabigatran|
40966508|NCT02742480|DRUG|Acenocoumarol|
40966509|NCT05812885|DEVICE|TENS|Active TENS
40966510|NCT01405742|DRUG|rF.VIII|40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
40966511|NCT06478485|DIAGNOSTIC_TEST|No Intervention: MCSM|No Intervention: MCSM
40966512|NCT02746744|DRUG|Rituximab|Infusion of Mabthera/Rituximab every 6 months
40966513|NCT02746744|DRUG|Dimethyl fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
40966514|NCT02746744|DRUG|Sodium Chloride solution|Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
40966515|NCT00016185|DRUG|alvocidib|
40966516|NCT00016185|DRUG|docetaxel|
40966517|NCT02071914|DRUG|CT-P27|Influenza A treatment drug.
40767380|NCT06188806|OTHER|ADDUKTOR CANAL BLOCK|All patients who will undergo adductor canal block are sedated with midazolam 0.03 mg/kg in the preoperative preparation room, after standard monitoring. After 2-3 ml skin infiltration with 2% lidocaine under sterile conditions, a block is applied under USG guidance.To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia )tramadol and paracetamol 10 mg / kg iv (8 hours apart) will be given.
40767381|NCT06188806|OTHER|CONTROL GROUP|No nerve block procedure is applied to patients.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia) tramadol 50 mg at 10 mg / hour basal rate after loading (20 mg bolus dose + 30 minutes lock time) and paracetamol 10 mg / kg iv (8 hours apart) will be given.
40767382|NCT04305691|DRUG|Ixazomib Citrate|Given PO
40767383|NCT04305691|OTHER|Quality-of-Life Assessment|Ancillary studies
40767384|NCT04305691|OTHER|Questionnaire Administration|Ancillary studies
40767385|NCT06636578|DRUG|dexmedetomidine|will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
40767386|NCT06636578|DRUG|ropivacaine|will receive 30 ml of 0.25% of plain ropivacaine for each side.
40767387|NCT06636578|DRUG|fentanyl|will not receive any regional anesthesia and only will receive I.V. fentanyl 1μg/kg/hr.
41295449|NCT04652492|DRUG|Tislelizumab in combination with cTACE|On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
40966518|NCT02071914|DRUG|Placebo|Placebo.
41295450|NCT04223167|DIETARY_SUPPLEMENT|Red Bull Energy Drink|473 ml Reb Bull Energy Drink
41457438|NCT05352048|DEVICE|Mechanomyography|SENTIO MMG ball tip probe will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded, and the accuracy compared to the data from the triggered electromyography.
41457439|NCT05065346|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
41457440|NCT00130949|DRUG|ALGRX 4975|
41457441|NCT01517919|BEHAVIORAL|Peer-Led Self-Management|"The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.~PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants."
41457442|NCT01170715|DRUG|Etanercept|self-administered for 52 weeks
41457443|NCT00001864|DRUG|Atropine|
40767388|NCT05346718|OTHER|Ragweed pollen, birch pollen, clean air (placebo)|Participants are exposed for 4 hours in the Fraunhofer Allergen Challenge Chamber with varying pollen concentrations of ragweed or birch pollen and once with clean air, serving as a placebo exposure.
40767389|NCT05157698|DRUG|Naltrexone and Bupropion Combination|Participants in this intervention will take active naltrexone and bupropion pills.
41295451|NCT04223167|DIETARY_SUPPLEMENT|Water|473 ml Water
41457444|NCT00001864|DEVICE|Patch|
40767390|NCT05157698|BEHAVIORAL|Behavioral Weight Loss|Participants in this intervention will receive behavioral weight loss treatment.
40767391|NCT05157698|OTHER|Placebo|Participants in this intervention will take inactive (placebo) pills.
41295452|NCT03635190|DEVICE|Orbital Circumferential Atherectomy|Remove atherosclerotic plaque and modify vessel wall compliance within peripheral arterial vessels. The therapy is intended for patients who are acceptable candidates for percutaneous transluminal atherectomy.
40966519|NCT02975505|OTHER|Strict blood pressure control|Systolic Blood Pressure Target \< 120 mm Hg (measured at home)
40966520|NCT06324539|DIAGNOSTIC_TEST|Diagnostic Test: Rapid Intestinal anti-TG2 Assay|"Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis."
40990718|NCT05350033|DEVICE|tDCS - Sham|active-tDCS administered during 5 sessions, in Phase 1
40990719|NCT05350033|DEVICE|Sham - tDCS|active-tDCS administered during 5 sessions, in Phase 2
41295453|NCT05014698|GENETIC|WGS|Whole Genome sequencing
41457445|NCT00486993|BEHAVIORAL|Dietary and nutritional modification|
41457446|NCT00486993|BEHAVIORAL|Stop smoking|
41457447|NCT00486993|BEHAVIORAL|Regular physical activities|
41457448|NCT00486993|BEHAVIORAL|Weight reduction to normal ranges|
41457449|NCT00486993|BEHAVIORAL|Regular intake of polyphenols, esp. from Ilex paraguayensis|
41457450|NCT05104996|BEHAVIORAL|Telephone Counseling|The form was used for weekly follow-up of the patients included in the experimental group. Headings were created according to the topics in the training form and/or for other problems and the problems stated by the patients were marked every week. Ongoing or eliminated problems of each patient until the time of next telephone counseling were indicated in the form. General problems in the form included drugs, pain, exercise, wound care, edema, compression socks, corset, nutrition, constipation, bathing, sleep, emergencies, back to work, sexual life, travel, visitors, climbing stairs, alcohol use/smoking, stress/anxiety, check-ups, and other issues.
40990720|NCT05350033|DEVICE|Sham - Sham|sham-tDCS administered during 10 sessions, in Phase 1 and Phase 2
40966521|NCT06324539|DIAGNOSTIC_TEST|Diagnostic Test: Rapid Intestinal anti-TG2 Assay|"Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis."
40767392|NCT03507725|BEHAVIORAL|Meditation|"The brief mind-body intervention, specifically developed for this study, is a combination of mindfulness meditation with a specific cognitive component of guided imagery. Patient intervention, they will be given headphones connected to an MP4 player in the clinic area to listen to a pre-biopsy mindfulness exercise (10 minutes). They will then be brought into the biopsy procedure room and given a second set of headphones, guiding the patient through the mindfulness intervention during the biopsy procedure (10 minutes)."
41457451|NCT01404962|BIOLOGICAL|Haemophilus influenza type b conjugate vaccine|Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
40767393|NCT03507725|PROCEDURE|Prostate Biopsy|Prostate needle biopsy under local anesthesia
40966522|NCT06451601|DEVICE|Intermittent hypoxia-hyperoxia therapy|"Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, occupation, environment, body mass index, nutritional status, abdominal circumference, hip circumference, smoking, alcohol. Also, the patients performed a 6-minute walking test.~Other Names:~* Hydrokinetotherapy~* Hydrothermotherapy~* Electrotherapy~* Massage therapy~* Kinetotherapy"
40966523|NCT05577442|DRUG|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
40966524|NCT00025272|DRUG|carboplatin|
40966525|NCT00025272|DRUG|etoposide|
40966526|NCT00025272|DRUG|topotecan hydrochloride|
41457452|NCT01189747|BIOLOGICAL|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
40767394|NCT03507725|BEHAVIORAL|Questionnaires|Questionnaires completion will be by telephone interview or manual completion of paper or online REDCap instruments, depending on participant preference.
40767395|NCT02618941|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
40767396|NCT05560646|DRUG|OG-6219|OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.
40966527|NCT00025272|RADIATION|radiation therapy|
41457453|NCT01189747|DRUG|normal saline|Injected into bilateral Crow's Feet Line areas on Day 1
40767397|NCT05560646|DRUG|Placebo|Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
40767398|NCT06619990|BIOLOGICAL|XmAb942|Antibody
40767399|NCT06619990|DRUG|Placebo|Placebo
40966528|NCT02871700|BEHAVIORAL|Action observation therapy|The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
40767400|NCT05570253|DRUG|Eribulin|Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.
40767401|NCT05570253|DRUG|SDX-7320|SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis
40767402|NCT05570253|OTHER|Placebo|Placebo
40767403|NCT04153149|DRUG|Vutrisiran|Vutrisiran will be administered by SC injection.
40767404|NCT04153149|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile normal saline (0.9% NaCl) will be administered by SC injection.
40767405|NCT06242795|DRUG|7% Hypertonic Saline via nebulization|Twice a day treatment with nebulized 7% HS for 2 weeks as part of airway clearance
40767406|NCT05078112|DEVICE|Sleep sensor technology|Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output to soothe them to sleep. The device will give this output for first 10 nights, then wean the output the child receives over 10 nights.
40767407|NCT06493253|DIAGNOSTIC_TEST|Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)|Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph- FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite
40767408|NCT03598829|DIAGNOSTIC_TEST|Tryptase, Serum test|Blood draw lab test which measures concentration of Tryptase in the sample. Tryptase is the one of the primary secretions of active mast cells and is used as a measure of inflammatory activity. Normal Reference Value: \&lt;11.5 ng/mL
40767409|NCT03539679|OTHER|Encouraging physical activity.|Encouraging physical activity with motion sensor's feedback.
40767410|NCT06463730|BEHAVIORAL|Serious games|Custom games played using the Equio system, non-custom Wii Fit games played using the Nintendo Wii Balance Board
40767411|NCT05589597|DRUG|EO4010|Sequential assignment
40966529|NCT02871700|BEHAVIORAL|Mirror therapy|The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
41137680|NCT03644082|BEHAVIORAL|Luminosity Trial Memory Match|Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
40966530|NCT02871700|BEHAVIORAL|Customary bilateral UE training|The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
40767412|NCT05857241|DIETARY_SUPPLEMENT|Fasting mimicking diet (FMD)|"D1 will correspond to a pre-fasting phase, with about 800 kcal of intake (approximately 40% of normal caloric intake) from a mono-nutrient diet (fruit, rice or potato according to the patient's preferences). Then D2 and D3 will correspond to the days of actual fasting, with 200-350 kcal of intake (10-18% of normal caloric intake) in the form of 100 ml of broth or vegetable juice (with a teaspoon of linseed oil) three times a day, and vaccination will take place on D4, after returning to a normal diet. 2 to 3 liter of water or unsweetened drink per day is required.Laxatives (unsweetened) will be prescribed and can be taken as during the fasting period."
40767413|NCT03732794|DEVICE|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
40767414|NCT05059236|DRUG|Darolutamide (BAY1841788, Nubeqa)|300 mg per tablet, oral administration with food
40767415|NCT05059236|OTHER|ADT|LHRH agonist/antagonist or orchiectomy
40767416|NCT05508126|DIAGNOSTIC_TEST|DECT examination|DECT examinations will be performed using a 192-slice CT scanner (SOMATOM, Force, Siemens, Forchheim, Germany).
40767417|NCT05508126|DIAGNOSTIC_TEST|mpMRI examination|The examinations were conducted on a 3-T MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany).
40966531|NCT05388331|OTHER|No intervention|No intervention
40966532|NCT00779714|DRUG|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
40966533|NCT00779714|DRUG|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
40966534|NCT00779714|DRUG|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
40966535|NCT06298383|DRUG|Trypsin, Bromelain and Rutoside|Flamogen is a combination of trypsin 48 mgs, bromelain 90mg and rutoside 100 mg in one tablet that provides an anti inflammatory, anti edematous activity. each patient will receive a single dose of 2 tablets one hour before treatment.
40966536|NCT06298383|DRUG|Diclofenac Potassium|Non-steroidal anti inflammatory drug. cataflam is known for its potent anti inflammatory and analgesic properties. each patient will receive one tablet of cataflam 50 mg 1 hour before treatment.
41137681|NCT03644082|BEHAVIORAL|Luminosity Trial Memory Matrix|The purpose id to remember the location of squares on a grid
41137682|NCT03644082|BEHAVIORAL|Luminosity Trial Famliar Faces|The purpose is to create associations between visual and verbal information
41295454|NCT05827146|DRUG|Hepalatide|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
41295455|NCT05827146|DRUG|Hepalatide Placebo|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
40767418|NCT05018481|DRUG|Sodium Hyaluronate|Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
40767419|NCT05018481|DRUG|Placebo|A placebo will be given in capsule form to study participants
40767420|NCT02135133|DRUG|Idelalisib|150 mg BID Oral Daily
40767421|NCT02135133|DRUG|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
40767422|NCT03822468|DRUG|Ribociclib|Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib is supplied as 200 mg tablets as individual patient supply packaged bottles.
40767423|NCT03822468|DRUG|Anastrozole|Anastrozole 1 mg tablets for oral use QD continuously
40767424|NCT03822468|DRUG|Letrozole|Letrozole 2.5 mg tablets for oral use QD continuously
40767425|NCT03822468|DRUG|Goserelin|Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
40767426|NCT06645327|OTHER|a change in operating room table position, which will mimic an IV fluid bolus|"Cardiac Output (CO) measurements will be obtained at two separate time points: prior to sternotomy (opening of the chest) and after separation from cardiopulmonary bypass.~Intervention~1. the participant will be placed in the reverse Trendelenburg position (head up) to 15 degrees for 60-90 seconds. CO measurement will be obtained~2. the participant will be transitioned to the Trendelenburg position (head down) to 15 degrees for 60-90 seconds. CO measurement will be obtained"
40767427|NCT06094621|OTHER|Survey|For the patients who underwent a pre-operative virtual visit, data will be collected through semi-structured interviews conducted by trained research personnel. The interviews will be conducted in a one-on-one format, either in-person or via telephone, according to the participant's preference.
40767428|NCT06576843|DRUG|INDV-6001|Extended-release subcutaneous injection
40767429|NCT06576843|DRUG|Suboxone|Oral sublingual film
40767430|NCT06576843|DRUG|Sublocade|Extended-release subcutaneous injection
40767431|NCT05177536|DRUG|Iberdomide|Iberdomide is a novel potent cereblon E3 ligase modulator
41295456|NCT03671863|OTHER|Invasive analysis (caryotype, CGH array)|Invasive analysis (caryotype, CGH array)
40767433|NCT03517969|DRUG|Berzosertib|Given IV
40767434|NCT03517969|DRUG|Carboplatin|Given IV
40767435|NCT03517969|DRUG|Docetaxel|Given IV
40767436|NCT03517969|OTHER|Laboratory Biomarker Analysis|Correlative studies
40966537|NCT06298383|DRUG|Prednisolone Oral Tablet|Steroids are potent anti inflammatory drugs, patients are going to receive one tablet of 30 mg solupred one hour before treatment
40966538|NCT06298383|OTHER|Placebo|A tablet of Compacted powdered milk
40966539|NCT02447042|PROCEDURE|Fluid challenge with crystalloids|Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
40966540|NCT02447042|DEVICE|Measurement of Pmsf-arm|Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
40966541|NCT00980382|DRUG|S-1, Docetaxel|"* Phase I study~  * S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8~* Phase II study~  * S-1 (80mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (35 mg/m2) iv : Days 1, 8"
40767437|NCT04458857|DRUG|Fremanezumab|Dose A or Dose B subcutaneous
40767438|NCT04458857|DRUG|Placebo|Matching placebo
40767439|NCT06644664|BEHAVIORAL|Health Education|Receive control MMS messages
40966542|NCT00993070|DRUG|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
40966543|NCT00993070|DRUG|placebo|vehicle gel, applied 4 times per day for 8 weeks
40966544|NCT06044428|DEVICE|Steadytemp®|Steadytemp® is a clinical thermometer intended to continuously measure axillary temperature and to display relative changes in axillary temperature to the user. The system consists of a sensor patch and a smartphone application, the body temperature measured by the sensor is transmitted via Near-Field-Communication (NFC) and subsequently displayed in the App.
40966545|NCT05389397|BEHAVIORAL|Outreach|Mailed letter, secure message or telephone outreach will be used depending on arm enrolled
41295457|NCT03671863|OTHER|Prenatal management|Prenatal management
40767440|NCT06644664|OTHER|Interview|Ancillary studies
40767441|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive AR MMS messages
40767442|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive RR MMS messages
40767443|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation resources
40767444|NCT06644664|OTHER|Survey Administration|Ancillary studies
40767445|NCT06644664|OTHER|Text Message-Based Navigation Intervention|Receive check-in text message
40767446|NCT05971173|DRUG|Juven|Nutritional supplements
40767447|NCT05971173|DRUG|Centrum Silver 50+|Over the counter nutritional supplement
40767448|NCT05938946|DRUG|L608 Inhalation Solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
40767449|NCT05938946|DRUG|Placebo solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
40767450|NCT04280588|DRUG|Fingolimod 0.5 mg|Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
40767451|NCT05317936|DRUG|Pirtobrutinib|Given by PO
40767452|NCT05317936|DRUG|Venetoclax|GIven by PO
40767453|NCT05669664|PROCEDURE|Biopsy|Undergo biopsy
40966546|NCT01022229|DIETARY_SUPPLEMENT|Compound Natural Health Product|"* 15-35 mg zinc citrate~* 150-350 mg magnesium lactate~* 30-70 mg pyridoxine hydrochloride~* 150-350 mg calcium ascorbate~Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study"
41295458|NCT05797350|DEVICE|Glaucoma Drainage Device|Both the Paul glaucoma implant (PGI) and Ahmed glaucoma valve (AGV) are types of glaucoma drainage devices (GDDs) used to lower intraocular pressure in patients with refractory glaucoma. Devices will be implanted during a surgical procedure and work by diverting excess fluid from the eye to an external drainage tube, allowing the fluid to drain away from the eye and be absorbed into the surrounding tissue. This will help to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.
41295459|NCT06048003|OTHER|No specific intervention|No specific intervention
40966547|NCT01022229|DIETARY_SUPPLEMENT|Placebo|Placebo
40966548|NCT06505317|DIAGNOSTIC_TEST|AI-based PAD screening intervention|"Providers will receive alerts for a patient that is flagged by model as being high risk for PAD. This will allow the provider to review the alert, check the patient's previous history, develop additional questions to assess the risk of PAD, and initiate orders prior to seeing a patient. Depending on their assessment during the patient visit the provider may choose to order an ABI test (or perform one at bedside) and/or initiate other secondary prevention measures. All patients for which an alert is triggered will be included for secondary analysis."
41295460|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
41295461|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
40966549|NCT01649661|BEHAVIORAL|questionnaire|
41295462|NCT02114203|DRUG|placebo for PDE9i|oral dose, every 12 hours for 28 days
40966550|NCT03919799|DRUG|Belumosudil (KD025)|ROCK-2 Inhibitor
40966551|NCT03919799|DRUG|Placebo|Inactive substance
40966552|NCT03109249|DRUG|SPARC1613|Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
41295463|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
41457454|NCT04587258|BEHAVIORAL|Informational videos and social media campaigns encouraging cancer screening.|Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.
40767454|NCT05669664|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40767455|NCT05669664|PROCEDURE|Computed Tomography|Undergo CT
40767456|NCT05669664|DRUG|Darolutamide|Given PO
40767457|NCT05669664|DRUG|Leuprolide Acetate|Given IM
40767458|NCT05669664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40767459|NCT05974787|BEHAVIORAL|Emergency department cancer patients interview|The interview focuses on several parts of the (pre-)admission process: The first part is regarding the barriers and facilitators encountered during the (pre-)admission process. The second part will focus on the timeline that led to an emergency department (ED) visit. It will be established when and which symptoms were first detected. The third part is regarding the number and type of health care workers that were contacted before visiting the ED. The fourth part will be about the actions and considerations taken before the ED visit.
40767460|NCT05190666|BEHAVIORAL|PACE Weight Loss program|12 month phone-based behavioral weight loss program
40767461|NCT05190666|BEHAVIORAL|Chronic Disease Self-Management|12 month phone-based chronic disease self-management program
40966553|NCT03109249|DRUG|Reference1613|Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
40966554|NCT05279183|DIETARY_SUPPLEMENT|Erythritol|Subject specific dose of erythritol dissolved in 300 mL tap water.
41295464|NCT02523586|OTHER|Oxygen administration|Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
41295465|NCT05805969|OTHER|Accommodating variable-resistance training|"The training was conducted twice weekly for six successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise."
40767462|NCT06098573|BEHAVIORAL|High Alert|Participants assigned to the 'High Alert' condition will complete four interactive modules using their smartphones. These modules are hosted online via the Computerized Intervention Authoring Software, version 3.0 (https://www.cias.app \[CIAS\]). CIAS is a non- commercial, easily modifiable, web-based intervention platform used widely in the digital substance use literature. No identifiable information is requested or stored in CIAS. This program is only intended to deliver the content interactively. None of the questions asked in CIAS will be treated as research data. We will only report on the proportion of questions answered by participants (as a measure of adherence). Individual responses to questions will not be analyzed nor reported on. The purpose of the questions is for participants to engage with the content interactively
40767463|NCT06098573|BEHAVIORAL|Information condition|Participants in the DUIC Information condition will receive a Qualtrics link with six infographics created to educate about DUIC. Four infographics were retrieved from government websites, one was provided by a non-profit (i.e., Arrive Alive Drive Sober), and the research team created the final one. After reviewing each infographic, participants will respond to a few questions about the infographic. Questions asked to the DUIC Info Control will obtain data related to: seeing the infographic before, perceptions on the infographic content, aspects they liked/disliked, and likelihood to share with their peers. All items will be treated as research data.
40767464|NCT06098573|BEHAVIORAL|No contact|Participants in the passive control will receive no contact until the three and six-month follow-ups.
41137683|NCT03644082|BEHAVIORAL|Luminosity Trial Brain Shift|The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.
41137684|NCT03644082|BEHAVIORAL|Luminosity Trial Star Search|The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.
41137685|NCT03644082|BEHAVIORAL|Luminosity Trial Word Bubbles|"The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking."
41137686|NCT03644082|BEHAVIORAL|Luminosity Trial Color Match|The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
41137687|NCT03644082|BEHAVIORAL|Luminosity Trial Ebb and Flow|Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
41137688|NCT03644082|BEHAVIORAL|Luminosity TrialChalk Board Challenge|purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
41137689|NCT03644082|BEHAVIORAL|Luminosiuty Follow that Frog|The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory
41137690|NCT03644082|BEHAVIORAL|Luminosity Train of Thought|purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
40966555|NCT05279183|DIETARY_SUPPLEMENT|Sucrose|30 g sucrose dissolved in 300 mL tap water.
40966556|NCT05279183|DIETARY_SUPPLEMENT|Sucralose|Subject specific dose of sucralose dissolved in 300 mL tap water.
40966557|NCT06024590|DEVICE|Irrisept|Standard of care wound treatment with 150 mL of IrriseptTM irrigation of the wound at each follow up visit.
40966558|NCT06024590|DEVICE|Saline|Standard of care wound treatment with 150 mL ration of Normal saline irrigation of the wound at each follow up visit
40966559|NCT00813735|DRUG|Eszopiclone|Eszopiclone 2mg daily at bedtime
40966560|NCT00813735|DRUG|Placebo|Placebo daily at bedtime
41295466|NCT05805969|OTHER|Standard physical therapy|The program encompassed the standard exercises for patients with juvenile idiopathic arthritis (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
41295467|NCT02482220|BEHAVIORAL|Physical activity intervention|
40966561|NCT00813735|DRUG|Escitalopram|Escitalopram 10mg or 20mg
41295468|NCT01852864|DRUG|240mg degarelix s.c. injection|7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
41295469|NCT02768909|DEVICE|E-Nose|1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.
41295470|NCT02768909|OTHER|Survey & Physical Exam|2. Perform a oriented survey for risk factors and a complete physical exam.
40767465|NCT06188585|DEVICE|UI-EWD|Hemostatic powder administered at index endoscopy
40767466|NCT06188585|DEVICE|Conventional therapy|Conventional endoscopic therapy (bipolar electrocoagulation or clips, with or without epinephrine injection) administered at index endoscopy
41295471|NCT02768909|OTHER|Chest X-ray|Perform anteroposterior chest X-ray
41295472|NCT02768909|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear and Culture in L-J.
41295473|NCT02768909|DEVICE|Follow Up 5 days after beginning of Tx.|"Patients will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
40767467|NCT06644508|OTHER|Strict adherence to European guidelines|"The goal is to maintain a neutral fluid balance throughout the course of intubation if clinical practice allows. Therefore:~* From the start of mechanical ventilation, the maximum maintenance fluids is 65% of the maintenance fluids proposed by the Holliday \& Segar formula. Fluid resuscitation in the first hours after intubation is at the discretion of the attending physician.~* Any other interventions to maintain a neutral fluid balance (e.g., starting diuretics, reducing fluid boluses, decreasing creep fluids, or using more concentrated enteral feeding) are at the discretion of the attending physician.~* Throughout the intervention, the attending physician decides if clinical practice allows for a decrease in fluid balance, and international feeding goals must always be met."
41295474|NCT02768909|DEVICE|Follow Up 15 days after beginning of Tx.|"Patients will be asked to come 15 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
40966562|NCT02092493|DEVICE|ScopeGuide|These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
40966563|NCT03608098|DEVICE|Short Pulse Duration|The holmium laser device will be used on a short laser pulse duration setting (300 μs or 350 μs)
40966564|NCT03608098|DEVICE|Long Pulse Duration|The holmuim laser device will be used on a long laser pulse duration setting (700 μs or 1500 μs)
40966565|NCT02740881|OTHER|Counselor Training Methods|
41295475|NCT02768909|DEVICE|Follow Up 30 days after beginning of Tx.|"Patients will be asked to come 30 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
41295476|NCT02768909|DEVICE|Follow Up 60 days after beginning of Tx.|"Patients will be asked to come 60 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
41295477|NCT01743027|DRUG|AL-4943A ophthalmic solution|
41295478|NCT01743027|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
41295479|NCT01743027|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.1%|
41295480|NCT01743027|DRUG|AL-4943A ophthalmic solution vehicle|
41295481|NCT01132573|DRUG|entinostat|Given PO
41295482|NCT01132573|DRUG|clofarabine|Given IV
41457455|NCT03314376|DEVICE|Prehabilitation program|"The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
41457456|NCT02752334|DRUG|Magnesium Sulphate|Magnesium has antinociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells.
40767470|NCT04391569|DRUG|Ganaxolone|Ganaxolone will be administered.
40767471|NCT04391569|DRUG|Placebo|Placebo will be administered.
40767472|NCT04908046|DRUG|HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .|"Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile.~Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
40767473|NCT05407636|GENETIC|ABBV-RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
40767474|NCT05407636|GENETIC|ABBV-RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
40966566|NCT05686811|OTHER|Myofascial release therapy therapy|Group A was treated with myofascial release therapy and routine physical therapy. For routine physical therapy subjects will first applied TENS, hot pack and neck isometric exercises then myofascial release therapy will be given. For myofascial release therapy subjects was in the supine or possibly sitting position, the examiner was seated at the head of the table, the examiner was used his right thumb to palpate (using flat palpation) the upper trapezius muscles from medial to lateral to establish if any MTrPs are present. The entire mass of the upper trapezius muscle is lifted by the supraspinatus muscle and grasped with a pincer grasp. The muscles at this point rotate between the thumb and forefinger to detect the delicate location of the trigger point. Treatment session longs for 10 minutes of myofascial release on each side
40966567|NCT05686811|OTHER|Post isometric relaxation technique|This group will receive routine physical therapy with myofascial release therapy.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
40966568|NCT03879278|DRUG|NPT189|NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
41137691|NCT05267093|PROCEDURE|Acupuncture|Sterile single-use stainless steel needles (size 0.3 mm × 25 mm) will be utilized. After local skin disinfection with 75% alcohol wipes, acupuncturists will insert needles perpendicularly into the Ashi points to a depth of approximately 2-3 mm; horizontally into the Baxie points toward the wrist to a depth of 5-10 mm; and perpendicularly into Houxi (SI3) and Waiguan (TE5) to a depth of approximately 5-10 mm. The depth of needling will vary based on the participant's body sizes. After insertion, all needles except those in the Ashi points will be manually manipulated to achieve De qi sensations. All the needles will be retained for 30 min and then gently removed. Participants will take acupuncture treatment three times per week for a total of 12 sessions in 4 consecutive weeks.
41137692|NCT05267093|PROCEDURE|Sham acupuncture|The sham needles with blunt tips (size 0.3 mm × 25 mm) will be used in the control group. Acupuncturists will gently lift and twist the sham needles to simulate the treatment procedure, thus blinding the patients to the intervention. Acupuncturist will firstly sterilize the areas of acupoints, then apply the adhesive pads on the surface of Ashi points, Baxie points, Houxi (SI3) and Waiguan (TE5) and insert the sham needles without penetrating. The duration and frequency of treatment sessions will be the same as in the acupuncture group.
41295483|NCT01132573|OTHER|pharmacological study|Correlative studies
40767475|NCT05407636|BIOLOGICAL|Aflibercept (EYLEA®)|"2.0 mg (0.05 mL solution) administered by intravitreal injection approximately every 8 weeks after 3 monthly injections~Other Names:~• Eylea (anti-VEGF agent)"
41295484|NCT01132573|OTHER|laboratory biomarker analysis|Correlative studies
40767476|NCT06643689|DRUG|Tranilast|Tranilast is an anti-allergic agent that is hypothesized to prevent stricture formation in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive 100 mg orally three times a day for 8 weeks.
40767477|NCT06643689|DRUG|Dexamethasone|Prednisone is a corticosteroid used to reduce inflammation and prevent stricture in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive an oral dose of 30 mg once daily for 8 weeks, with a gradual tapering of the dosage as follows: Weeks 1-2: 30 mg daily; Weeks 3-4: 25 mg daily; Weeks 5-6: 20 mg daily; Weeks 7-8: 15 mg daily; and then tapering to 10 mg daily in Week 7 and 5 mg daily in Week 8.
40767478|NCT06546618|BEHAVIORAL|pictorial warning and no flavor|LCC Package with pictorial warning and no flavor
40767479|NCT06546618|BEHAVIORAL|pictorial warning and 'sweet' flavor|LCC Package with pictorial warning and 'sweet' flavor
40966569|NCT04987346|OTHER|Walking on an instrumented treadmill|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
40966570|NCT04987346|OTHER|Walking on an instrumented treadmill while dual-tasking|Participants aged between 6 and 17 years will be asked to walk at comfortable walking speed while playing either a cognitive (Stroop Color and Word Test) or motor (requiring arm swing) game.
40966571|NCT00194597|DRUG|Viagra (sildenafil citrate)|
40966572|NCT03206528|DEVICE|Vital Signs Monitoring System|The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
40767480|NCT06546618|BEHAVIORAL|text-only warning and no flavor|LCC Package with text-only warning and no flavor
40767481|NCT06546618|BEHAVIORAL|text-only warning and 'sweet' flavor|LCC Package with text-only warning and 'sweet' flavor
40966573|NCT05830968|DEVICE|Morpheus8 Applicator Radiofrequency device|Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is \~6 months, depending on subject recruitment rate.
41295485|NCT02286011|BIOLOGICAL|MNC (Mononuclear cells)|"The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.~For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device."
40767482|NCT06343376|PROCEDURE|Biopsy|Undergo tissue biopsy
40767483|NCT06343376|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40767484|NCT06343376|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
40966574|NCT05913492|BEHAVIORAL|Simulation training|"Each volunteer went through two simulation scenarios of difficult airway management: 1) cannot intubate, can ventilate (CI), 2) cannot intubate, cannot ventilate (CICV) with the assistance of the training centre operator. Following the first simulation round, volunteers were trained on the same day in difficult airway management according to DAS guidelines, using the same equipment as during the simulation. The participants repeated the simulation scenarios immediately after the training and six months later."
40966575|NCT03986502|OTHER|Media Intervention|Watch web-based financial literacy video
40966576|NCT03986502|OTHER|Informational Intervention|Receive information on financial counseling and medical cost assistance
40966577|NCT03986502|OTHER|Best Practice|Utilize usual clinic procedures and clinic or community-based financial resources
40966578|NCT03986502|OTHER|Questionnaire Administration|Ancillary studies
41295486|NCT02286011|OTHER|Saline|The placebo, 2ml of saline, will be infused like in the experimental arm.
41295487|NCT03290300|DEVICE|Vivaer Stylus|Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus
41295488|NCT06480071|DRUG|Oxymetazoline, 0.05% Nasal Spray|2 sprays each nostril before the excercise test.
41295489|NCT06151756|BEHAVIORAL|Video Supported Mobile Application|The video-supported mobile application was developed to be interactively utilized on smartphones. T
41295490|NCT01752517|DRUG|NI group|vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
41295491|NCT03544060|DRUG|Volanesorsen|Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
40767485|NCT06343376|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
40767486|NCT06343376|PROCEDURE|Computed Tomography|Undergo CT
40767487|NCT06343376|DRUG|Cyclophosphamide|Given IV
40767488|NCT06343376|PROCEDURE|Echocardiography|Undergo ECHO
40767489|NCT06343376|BIOLOGICAL|EGFRt/19-28z/IL-12 CAR T-lymphocytes|Given IV
40767490|NCT06343376|DRUG|Fludarabine Phosphate|Given IV
40767491|NCT06343376|PROCEDURE|Leukapheresis|Undergo leukapheresis
40767492|NCT06343376|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40767493|NCT06343376|PROCEDURE|Positron Emission Tomography|Undergo PET
40767494|NCT06634719|DEVICE|Juveena Hydrogel System|The Juveena Hydrogel System is a single-use device that is instilled into the endometrial cavity as a liquid and sets up as a gel intrauterine tamponade within seconds.
40767495|NCT06316570|DRUG|Early Dual Antiplatelet Therapy|"Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Ticagrelor (180mg) + Aspirin (100mg), one dose;~Days 2-7: Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day)."
40767496|NCT06316570|DRUG|Placebo|"Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Placebo of Ticagrelor (180mg) + Placebo of Aspirin (100mg), one dose;~Days 2-7: Placebo of Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day)."
40767497|NCT06575868|DIETARY_SUPPLEMENT|Myo-inositol|Patients would begin taking myoinositol upon recruitment
40966579|NCT03986502|OTHER|Quality-of-Life Assessment|Ancillary studies
40966580|NCT01670240|DRUG|Adalimumab|
40966581|NCT01670240|DRUG|Placebo|
40966582|NCT06204445|DIETARY_SUPPLEMENT|Green coffee|Each cup of coffee provides approximately 400 mg of hydroxycinnamic acids.
40767498|NCT06575868|DIETARY_SUPPLEMENT|Myo-inositol placebo|Patients would begin taking placebo upon recruitment
40767499|NCT02233868|OTHER|connectivity|Magnetic resonance imaging (MRI) scans will be done to assess brain structure, functional reactivity and functional connectivity.
40767500|NCT02233868|DRUG|neuroinflammation|The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.
41457457|NCT01483820|DRUG|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
40767501|NCT02233868|OTHER|neurofunction|To assess regional brain glucose metabolism.
40767502|NCT03608631|DRUG|Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA|Given IV
40767503|NCT05936437|DEVICE|Subjects treated with Newest medical device|"Newest is a sterile, non-pyrogenic, viscoelastic gel for single use for intradermal infiltrations. Newest is a medical device containing 2ml of the original association of polynucleotides (10mg/ml) and hyaluronic acid (10mg/ml).~Total number of treatments will consist in 4 Newest administrations: at T0 - basal, at T1- 2 weeks, at T2 - 4 weeks, at T3- 6 weeks."
40767504|NCT02684162|BIOLOGICAL|Donor Lymphocytes|Given IV
40767505|NCT02684162|DRUG|Guadecitabine|Given SC
40767506|NCT02684162|OTHER|Laboratory Biomarker Analysis|Correlative studies
40767507|NCT06643390|DRUG|MK-2225|Subcutaneous administration
40767508|NCT06643390|OTHER|Placebo|Subcutaneous administration
40767509|NCT06373068|OTHER|Resuscitation orders|Resuscitation orders, commonly referred to as Code Status, communicate to the healthcare team the specific medical interventions that patients will receive while hospitalised. These orders are issued by a doctor and require confirmation by at least one other licensed medical professional
40767510|NCT05003856|OTHER|Quality-of-Life Assessment|Ancillary studies
40767511|NCT05003856|PROCEDURE|Radiofrequency Ablation|Undergo RFA
40767512|NCT04209543|DRUG|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily
40767513|NCT04209543|DRUG|Placebo oral tablet|Placebo oral tablet will be administered orally once daily
40767514|NCT04209543|DRUG|Progesterone oral tablet|Progesterone oral tablet will be administered orally once daily
40767515|NCT01175993|OTHER|Elliptical exercise|Each participant with TBI will participate in an exercise intervention which will be done in the home. The exercise device in this protocol will be an elliptical trainer that requires coordinated reciprocal movements of both the legs and the arms. Primary emphasis will be placed on maintaining a near maximal speed of movement and to progressively increase this over time. Mild resistance to the leg motion will be provided initially and will be progressively increased once speed and coordination are optimized. The device will be loaned to them to use in the home, and will be delivered to the home fully assembled. Participants will be monitored by phone the first week and thereafter every two weeks and progressed as indicated. The exercise program will be performed 5 days a week for 30 minutes per session, for a total duration of 12 weeks. All will record the length, speed and resistance of each session on a paper-based log sheet.
40966583|NCT06204445|DIETARY_SUPPLEMENT|Roasted coffee|Each cup of coffee provides approximately 150 mg of hydroxycinnamic acids.
40966584|NCT01895569|DRUG|Metformin|Metformin will be added to therapy for the first threre months.
40966585|NCT01895569|DRUG|Pioglitazone|In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin, pioglitazone will be added.
40966586|NCT01895569|DRUG|Sitagliptin|In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.
40966587|NCT05315401|DIETARY_SUPPLEMENT|Probiotic|This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.
41137693|NCT04778813|DRUG|Artemether-lumefantrine|In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group. Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided. These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups. The treatment to be administered will not be known until after the randomization process. The drugs will be administered based on weight according to the instructions from the drug manufacturer. AL will be administered with fatty food or milk according to the manufacturer's recommendations. All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
41457458|NCT02189603|BIOLOGICAL|Recombinant (E. Coli) Hepatitis E Vaccine|
40966588|NCT05315401|DIETARY_SUPPLEMENT|Placebo|This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.
40966589|NCT05315401|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Patients will be provided with ACT for 12 weeks with treatment as usual. The ACT intervention will be conducted in a group of 10 for each session. The ACT modules covered over 12 sessions, 1 hour in each session. The sessions will be held every week.
41137694|NCT04689932|DRUG|Triferic AVNU|Ferric Pyrophosphate Citrate
41457459|NCT00519103|OTHER|exercise|
41457460|NCT04621045|BEHAVIORAL|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
40767516|NCT04912518|DRUG|Dexmedetomidine (DEX)|The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
40767517|NCT04912518|DRUG|Placebo (Saline)|The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.
41137695|NCT02424968|BIOLOGICAL|Anti-Thymocyte Globulin|Given per standard institutional practice
41137696|NCT02424968|DRUG|Cyclosporine|Given PO
40767518|NCT06638528|OTHER|Walking apnea at High Lung Volume|Walking apnea at High Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
40767519|NCT06638528|OTHER|Walking normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
40767520|NCT04023110|DRUG|Carvedilol|Individually dosed carvedilol
40767521|NCT03894462|BEHAVIORAL|Attempted Suicide Short Intervention Program|ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan.
40767522|NCT03894462|BEHAVIORAL|Zero Suicide Usual Care|Participants will have access to outpatient treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged.
40767523|NCT04809064|PROCEDURE|Arthroscopic Bankart repair procedure|Bankart repair with remplissage consists of arthroscopic anterior inferior capsulolabral repair with arthroscopic infraspinatus tenodesis to the posterior humeral head.
40966590|NCT05662631|DEVICE|BioIntellisense BioSticker|"This study uses the BioIntellisense BioSticker for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.~BioSticker System TheBioSticker ® System is an FDA-approved remote monitoring wearable device intended for continuous collection of physiological data in home and healthcare settings. This includes heart rate, respiratory rate, skin temperature, estimated body temperature, frequency of severe cough episodes, activity level, sleep duration, body position, degree of incline while sleeping, step count, step symmetry, step strength, and on/off body times and other symptomatic and biometric data. Data are securely transmitted using AES-CTR 128 bit encryption via wireless connection from the device for storage, review, and further analysis."
40966591|NCT01304316|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
41295492|NCT01147731|BIOLOGICAL|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
41295493|NCT04892862|PROCEDURE|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY DORSAL APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . LISTER TUBERCULA WITH 3 CM PROXIMAL AND 3 CM DISTAL IN INCISION MADE UNDER THE SKIN. 2,3 EXTENSOR COMPARTMENTS RADIAL 4. THE EXTENSON COMPARTMENT IS EARTHED TO ULNAR A AND THE WRIST JOINT CAPSULE IS REACHED. THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision ON DISTAL UNDER RADIUS metaphyseal area of 2CM. 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
40966592|NCT01703039|DRUG|Riluzole|
40966593|NCT01703039|DRUG|Sertraline|
41295494|NCT04892862|PROCEDURE|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY VOLAR APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . İNCİSİON STARTS 2 CM RADİAL TO SCAPHOİD TUBERCULE EXTENTS ITS 3 CM PROXİMAL . AFTER PASİNG SUBCUTANEOUS TİSSUE , FCR AND RADİAL ARTERY ARE İDENTİFİED AND DİVİDED SEPERATLY THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision WİTH PASSİNG PRONATOR QUADRATUS MUSCLE , ON DISTAL UNDER 2 CENTİMETER OF RADIUS metaphyseal area . 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
41295495|NCT01959555|OTHER|No treatment given|Patients will not be treated with any specific product. Data collection only.
41295496|NCT03384849|DIAGNOSTIC_TEST|MRI examination|The part of the body that is being scanned and the time of the MRI examination are not relevant.
41295497|NCT00177268|OTHER|Blood draw, skin biopsy or urine collection|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
41295498|NCT05319951|DRUG|Oral Rehydration Salts power (iii)|Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
41295499|NCT05319951|DIETARY_SUPPLEMENT|water with white granulated sugar|Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
40767524|NCT04809064|PROCEDURE|Open Bankart|Open Bankart repair consists of anterior capsulorrhaphy with labral repair.
40767525|NCT04809064|PROCEDURE|Latarjet|Latarjet consists of open transfer of the coracoid to the anterior glenoid bone deficiency.
40966594|NCT01703039|OTHER|placebo|
40966595|NCT02349321|BEHAVIORAL|Skhokho Supporting Success for Schools|All information describing each facet of the intervention are included in the arm/group descriptions.
40767526|NCT04809064|OTHER|Post-Operative Rehabilitation|Post-operative rehabilitation will be conducted following surgical procedure-specific rehabilitation guidelines and will be progressed based on individual needs.
40966596|NCT02349321|BEHAVIORAL|Skhokho Supporting Success for Families|All information describing each facet of the intervention are included in the arm/group descriptions.
40966597|NCT04388202|DRUG|Sertraline|FDA approved antidepressant
40966598|NCT04388202|DRUG|Escitalopram|FDA approved antidepressant
40966599|NCT02473432|PROCEDURE|RMT + usual care|Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
41137697|NCT02424968|DRUG|Mycophenolate Mofetil|Given PO
40767527|NCT02508038|PROCEDURE|TCRαβ+/CD19+ depleted Haploidentical HSCT|Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.
40767528|NCT02508038|DRUG|Zoledronate|Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.
40767529|NCT06351371|PROCEDURE|Biopsy|Undergo tumor biopsy
40767530|NCT06351371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40767531|NCT06351371|PROCEDURE|Computed Tomography|Undergo CT
40767532|NCT06351371|DRUG|Erdafitinib|Given orally
40767533|NCT06351371|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40767534|NCT01107496|DRUG|IR Viloxazine|"One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1.~Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6."
40767535|NCT01107496|DRUG|Placebo|Placebo capsules administered orally 3 times a day
40767536|NCT05208762|DRUG|PF-08046054|Given into the vein (IV; intravenously)
40767537|NCT05208762|DRUG|pembrolizumab|200 mg once every 3 weeks given into the vein (IV; intravenously)
40767538|NCT06632080|DRUG|Substance P|The participants will receive a continuous intravenous infusion of 20 mL of substance P (1.5 pmol/kg/min) over 20 minutes.
40767539|NCT06632080|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
40966600|NCT02473432|PROCEDURE|NMES|Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
40966601|NCT02473432|PROCEDURE|Usual care|Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
40767542|NCT03663543|DRUG|Conjugated Estrogen|Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
40767543|NCT03663543|DRUG|Normal saline|Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
40767544|NCT06559176|BIOLOGICAL|PM359|Single dose of PM359 administered autologously by intravenous (I.V.) infusion following myeloablative conditioning with busulfan
40767545|NCT03584490|OTHER|Computerized Talking Touchscreen|"The intervention is a computerized talking touchscreen designed to aid people with low health literacy.~All Participants in both arms will complete a battery of health questionnaires. One group will complete questionnaires in traditional pen-and-paper format. The other group will receive the computerized talking touchscreen, which reads questions to participants on demand."
40767546|NCT03584490|OTHER|Phone Administration of Questionnaires|This intervention will pilot questionnaire administration over the phone with currently enrolled or previously enrolled participants from the original intervention. This method was used during the COVID-19 pandemic.
40767547|NCT04711824|DRUG|Olaparib|Olaparib 100-300 mg twice daily up to 28 days concurrently with stereotactic radiosurgery. Three dose levels of olaparib will be explored in the Phase I portion. Olaparib will start one week prior to SRS and continue during and following SRS for up to 28 days total. One cycle will be given.
40767548|NCT04711824|RADIATION|Stereotactic Radiosurgery|SRS 1-5 fractions will be given per institutional standards
41295500|NCT05319951|DIETARY_SUPPLEMENT|water|Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
40767549|NCT04711824|DRUG|Durvalumab|Durvalumab 1120 mg IV over 60 minutes Day 1 of each cycle 21 day cycle.
40767550|NCT04711824|DRUG|Physicians Choice systemic chemotherapy|Olaparib: 300mg PO BID; Days 1-21 Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8 Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8 Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8 Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8 Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1 Capecitabine: 1000 mg/m2 PO BID; Days 1-14 Gemcitabine: 1000 mg/m2 IV over 30 min; Day 1 and 8 Gemcitabine + Carboplatin: 1000mg/m2 IV over 30-60 min; Day 1 and 8
41457461|NCT04621045|BEHAVIORAL|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
40767551|NCT06469242|DEVICE|Serafilcon A multifocal contact lenses|Investigational multifocal soft contact lenses
40767552|NCT06469242|DEVICE|Senofilcon A multifocal contact lenses|Commercially available multifocal soft contact lenses
41295501|NCT04579081|DEVICE|Contour Neurovascular System|Intrasaccular flow disruptor/divertor
41295502|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 200mg PO is given
40767553|NCT06469242|DEVICE|CLEAR CARE® Cleaning & Disinfecting Solution|Hydrogen peroxide-based contact lens cleaning and disinfection system
40767554|NCT01875601|BIOLOGICAL|Recombinant human interleukin-15 (rhIL-15)|Continuous infusion rhIL15 IV
40767555|NCT01875601|BIOLOGICAL|NK Cell Infusion|Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
40767556|NCT03518060|DRUG|JULUCA|JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
40767557|NCT05745961|RADIATION|TSPO PET scan (11C-PBR28)|PET scan
40966602|NCT03978832|DRUG|PERSERIS|PERSERIS is an extended-release SC injectable suspension administered once-monthly
40966603|NCT03978832|DRUG|Risperidone|Oral risperidone
40966604|NCT06333145|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in adults of different BMI groups undergoing drug-induced sleep endoscopy
41137698|NCT02424968|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant|Undergo nonmyeloablative allogeneic HSCT
40966605|NCT05378204|OTHER|Main study:|"For each included patient, tumor biopsy specimen and blood samples will be collected at baseline visit (before the first dose of PARPi treatment).~During the treatment period: blood samples will be scheduled every 8 weeks (i.e. 2 cycles).~At the time of progression: tumor biopsy and blood samples will be collected."
40966606|NCT05378204|OTHER|Sub-study:|For each included patient, tumor biopsy specimen and blood samples will be collected as soon as possible after progression (before initiation of the post PARPi anti-tumoral treatment).
40966607|NCT05264935|PROCEDURE|Ultrasound-Guided Puncture and Lavage (UGPL)|After local anaesthesia with rapidocain the calcific deposit of the rotator cuff will be punctured and washed out with saline solution.
40966608|NCT02880059|DEVICE|Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy
40966609|NCT02067871|OTHER|Laser Therapy|Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.
40966610|NCT02067871|OTHER|Electrical Stimulation|Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
40966611|NCT02464020|DRUG|Vancomycin|Oral vancomycin: 500mg suspended in prefilled syringes for oral use
41295503|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 400mg PO is given
40966612|NCT00209469|DRUG|alendronate sodium|
40966613|NCT04497493|DEVICE|Transcranial Direct Current Stimulation (tDCS)-active|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type，participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks
40966614|NCT04497493|DEVICE|Transcranial Direct Current Stimulation (tDCS)-sham|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min 5 days per week, for 4 weeks
41295504|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 600mg PO is given
41295505|NCT02644525|DRUG|Placebo|A single dose of placebo pill is given
41295506|NCT03271255|DRUG|Apatinib Mesylate Tablets|Apatinib combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
41295507|NCT03271255|DRUG|Bevacizumab Injection|Bevacizumab combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
41295508|NCT03291782|DRUG|D-0120|oral, single dose
40767558|NCT06187909|PROCEDURE|PECS II BLOCK|The linear probe will be placed transversely between the clavicle medially and above . After identifying the pectoralis major and minor muscles , the probe will be angled caudally to look for the pulsating pectoral branch of the thoraco-acromial artery. The block needle will be inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine will be administered. Then probe will be moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The third and fourth ribs will be detected. The needle will target the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 20 ml bupivacaine.
41295509|NCT02728635|OTHER|Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS)|A DEXA scan for body composition will also be completed. After a MRI safety screening a whole body MRI for the volumetric measurement of visceral fat, subcutaneous fat, liver, kidneys, heart, brain, skeletal muscle and intramuscular adipose tissue (IMAT) and hepatic lipid by MRS will be performed. Whole body imaging will include low resolution positioning images, followed by several sets of 3D images which will be digitally connected to create a 3D image the entire length of the body. The liver spectroscopy will be performed using PRESS (point resolved spectroscopy) and STEAM (Stimulated Echo Acquisition Mode) sequence during the same imaging session, using the whole body images for positioning.
41295510|NCT02728635|PROCEDURE|Adipose tissue biopsies|Two biopsies will be performed to collect fat tissue from the abdomen and thigh region.
41295511|NCT02728635|OTHER|FSIGTT/ RMR|Insertion of two intravenous (IV) catheters for performing a Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT) to measure the acute insulin response to glucose (AIRg) and insulin sensitivity (Si) will be performed. Resting metabolic rate (RMR) will be used to measure metabolic flexibility. Point of care blood glucose measurements will be taken frequently to ensure safety.
41457462|NCT02870686|PROCEDURE|ERCP without the use of fluoroscopy|ERCP removal of stone technique without the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with catheter aspiration of bile, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket- number of stones removed should compare number detected on EUS, (5) confirmation of complete stone clearance with radiocontrast.
41457463|NCT02870686|PROCEDURE|ERCP with the use of fluoroscopy|ERCP removal of stone technique with the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with fluoroscopy images, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket, (5) confirmation of complete stone clearance with radiocontrast.
41457464|NCT03985124|BEHAVIORAL|Tuning in to Kids for Teachers|This is an emotion-focused intervention for teachers giving them skills in emotion coaching children in their care and also understanding and managing their own emotions.
41457465|NCT01459380|BIOLOGICAL|Bevacizumab|Given IV
41457466|NCT01459380|DRUG|Carboplatin|Given IV
41457467|NCT01459380|OTHER|Laboratory Biomarker Analysis|Correlative studies
41457468|NCT01459380|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
41457469|NCT01459380|DRUG|Veliparib|Given PO
41457470|NCT03922139|DRUG|OnabotulinumtoxinA Injection|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
40966615|NCT02859454|DRUG|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
40966616|NCT00171392|DRUG|Enteric-coated mycophenolate sodium|
40966617|NCT03441308|BEHAVIORAL|Educational method of group treatment|
41457471|NCT03234608|BEHAVIORAL|AASPIRE Healthcare Toolkit|The AASPIRE Healthcare Toolkit includes a variety of resources (information, worksheets, checklists, links) for patients and providers. The centerpiece of the toolkit is the Autism Healthcare Accommodations Tool, which allows a patient or their supporter to create a personalized accommodations report for the patient's provider. Intervention patients will use the toolkit and create an AHAT report. Intervention clinics will receive a copy of each patient's AHAT report, place it in the medical record, and share it with the patient's PCP and other staff.
41137699|NCT02424968|BIOLOGICAL|Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells|Receive CD8+ memory T-cells via IV
41295512|NCT04211545|DRUG|Rabeprazole|Rabeprazole
41295513|NCT04211545|DRUG|CC-92480|CC-92480
40966618|NCT01013376|DRUG|MC-1101|MC-1101 1.0%
40966619|NCT01013376|DRUG|Vehicle|Vehicle
40966620|NCT01687998|DRUG|Evacetrapib|Administered Orally
40966621|NCT01687998|DRUG|Placebo|Administered Orally
41295514|NCT02025972|PROCEDURE|Allogeneic umbilical cord blood therapy|
41295515|NCT01208896|DRUG|Reduced_intensity conditioning|The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
41295516|NCT00950781|PROCEDURE|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
41295517|NCT03469245|OTHER|numerical simulation|After patients have been treated by fenestrated endovascular of society Vascutek data will be collected by society Vascutek and send to Predisurge society. They will perform numerical simulation and compare with the method of Vascutek.
40966622|NCT00005045|DRUG|carboxyamidotriazole|
40966623|NCT00528788|DRUG|doxercalciferol|
41137700|NCT02424968|RADIATION|Total Nodal Irradiation|Undergo TLI
41457472|NCT00778453|OTHER|Hospital-based mCIT|restraint of the unaffected arm and practice of the affected arm
41457473|NCT00778453|OTHER|Hospital-based BIT|bilateral symmetric, repetitive arm training
41457474|NCT00778453|OTHER|Hospital-based TR|hospital-based traditional rehabilitation : OT or PT or therapist-based training
41457475|NCT00778453|OTHER|Home-based mCIT|restraint of the unaffected arm and practices of the affected arm
40767559|NCT06187909|PROCEDURE|MTP BLOCK|The block will be performed with the patient in a sitting position ,High frequency linear probe will be placed in a vertical orientation 3 cm lateral to the midline at T2 level in parasagittal plane. We will identify the midpoint between the transverse process and parietal pleura, and the distance from this point to the skin will be measured which will be the measured depth of insertion and will be marked in the block needle. The block needle will be inserted out of plane to the probe and advanced till the marked depth till the point is confirmed, 10 ml of 0.25% bupivacaine will be injected. Similar two injections will be made at T4, T6 levels sonographic identification and level determination by counting from the second rib.
40767560|NCT03408262|BIOLOGICAL|Ad4-EnvCN54|Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
40767561|NCT03408262|BIOLOGICAL|MVA-CN54|Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
40767562|NCT03408262|BIOLOGICAL|CN54gp140/MPLA|Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
40767563|NCT06572293|BEHAVIORAL|Nurse-led intervention|Nurse-led intervention involves patient education, collecting Patient Reported Outcomes (PRO) and evaluating them by specialists nurses, as well as navigating patients to services that can assist with their symptoms. During three-five planned appointments, the nurse will talk with you about adjusting to life after complete the radiotherapy of nasopharyngeal carcinoma, including symptoms of relapse and how to deal with them.In the first year, PROs will be collected every six months on recurrences and late effects, and thereafter every 12 months. PRO will be administered to patients for three years after the nurse appointments are finalized.
40767564|NCT06524739|BIOLOGICAL|IgPro20|IgPro20 is a 20% ready-to-use liquid formulation of polyvalent human immunoglobulin G (IgG) for subcutaneous (SC) administration
40767565|NCT06524739|BIOLOGICAL|Placebo|2% human albumin solution administered subcutaneously as a volume-matched dose to the experimental IMP.
40966624|NCT02444520|BEHAVIORAL|Integrated GP Care|"The overall aims of the intervention are to help the patient:~1. develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;~2. understand factors that may be maintaining the problem;~3. learn how to modify the behavioral and cognitive responses which may be maintaining the problem;~4. adopt a healthy sleep routine which can promote healthy living.~Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed."
40767567|NCT06231264|DEVICE|transcutaneous electrical acustimulation at treatment sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.
40767568|NCT06231264|DEVICE|transcutaneous electrical acustimulation at sham sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.
40767569|NCT06559007|DRUG|HRS-5041 dose level 1|Single dose of HRS-5041 orally administered
40767570|NCT06559007|DRUG|HRS-5041 dose level 2|Single dose of HRS-5041 orally administered
40767571|NCT02531191|DRUG|peficitinib|oral
40767572|NCT06220669|DRUG|LY3541860|Administered IV
40767573|NCT06220669|DRUG|Placebo|Administered IV
40767574|NCT05839951|DRUG|Regorafenib (BAY73-4506, Stivarga®)|Oral multitargeted kinase inhibitor
40767575|NCT05839951|DRUG|TAS-102 (trifluridine and tipiracil, Lonsurf®)|Oral cytotoxic chemotherapy
40767576|NCT05839951|DRUG|Bevacizumab|VEGFR inhibitor
40966625|NCT05148598|DEVICE|ADRCs|Adipose Derived Regenerative Cells (ADRCs) processed with Celution System
41457476|NCT00778453|OTHER|Home-based BAT|bilateral symmetric, repetitive arm training
40767577|NCT05834738|DRUG|Atrasentan|Period A (12 Weeks) - Film-coated tablet, Washout Period: 12 weeks, Period B (24 Weeks) - Placebo
40767578|NCT05834738|DRUG|Atrasentan|Period B (12 Weeks) - Placebo, Washout Period: 12 weeks, Period A (24 Weeks) - Film-coated tablet
41457477|NCT00778453|OTHER|Home-based TR|home-based traditional rehabilitation:OT or PT or therapist-based training
41457478|NCT01134198|DRUG|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
40767579|NCT05834738|DRUG|Placebo|Placebo
40767580|NCT05660538|DRUG|VX-548|Tablets for oral administration.
40767581|NCT05660538|DRUG|Pregabalin|Capsules for oral administration.
40767582|NCT05660538|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
40767583|NCT05660538|DRUG|Placebo (matched to pregabalin)|Placebo matched to pregabalin for oral administration.
40966626|NCT05148598|OTHER|Standard Care|Standard care
41457479|NCT01134198|DRUG|placebo|placebo
40767584|NCT03502785|BIOLOGICAL|INO-5401|INO-5401 (9 milligram \[mg\] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.
41457480|NCT02036398|DEVICE|Double J stent without nephrostomy|Double J stent only left at the end of the procedure without placement of a nephrostomy tube
41457481|NCT02036398|DEVICE|nephrostomy tube and double J stent|Double J stent and nephrostomy tube left at end of procedure
40767585|NCT03502785|BIOLOGICAL|INO-9012|"INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator."
40767586|NCT03502785|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.
40767587|NCT03502785|DEVICE|CELLECTRA™ 2000|IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.
40767588|NCT03340116|PROCEDURE|Burn surgery|Burn surgery including wound debridement, skin grafting
40767589|NCT03340116|DIAGNOSTIC_TEST|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
40767590|NCT06073769|DRUG|Oral azacitidine|Maintenance therapy according to the approved label
40767591|NCT05334940|OTHER|not applicable, observational study|Patients do not receive intervention
40767592|NCT05161195|DRUG|Ribociclib|Participants continue ribociclib as was administered in their parent study
40767593|NCT05161195|DRUG|Letrozole|Participants continue ribociclib in combination with letrozole as was administered in their parent study
40767594|NCT05161195|DRUG|Anastrozole|Participants continue ribociclib in combination with anastrozole as was administered in their parent study
40767595|NCT05161195|DRUG|Goserelin|Participants continue ribociclib in combination with goserelin as was administered in their parent study
40767596|NCT05161195|DRUG|Tamoxifen|Participants continue ribociclib in combination with tamoxifen as was administered in their parent study
40767597|NCT05161195|DRUG|Fulvestrant|All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
40767598|NCT04974398|DRUG|Penpulimab|Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin 80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine 1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per treatment cycle (Q3W), and then followed by penpulimab monotherapy as maintenance treatment, Q3W.
40767599|NCT04974398|DRUG|placebo|Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per treatment cycle and then followed by placebo monotherapy as maintenance treatment, Q3W. Subjects in Arm B will have the opportunity to crossover to open-label treatment with penpulimab monotherapy after radiographic disease progression.
40767600|NCT06405581|OTHER|Edmonton frailty scale calculation|"The frailty status of the patients will be assessed using the Edmonton frailty scale.~According to the Edmonton frailty scale;~* (0-5): not frail~* (6-7): sensitive~* (8-9): slightly fragile~* (10-11): moderately fragile,~* (12-17): extremely fragile"
40767601|NCT06494644|DRUG|AZD6793|Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.
40767602|NCT06494644|DRUG|Itraconazole|Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.
40767603|NCT06494644|DRUG|AZD6793+ Itraconazole|Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.
40966627|NCT05148598|OTHER|Placebo|Placebo visually indistinguishable from ADRCs
41295518|NCT03679481|DRUG|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
41295519|NCT03679481|DRUG|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
40767606|NCT04928846|BIOLOGICAL|Telisotuzumab Vedotin|Intravenous (IV) Infusion
40767607|NCT04928846|DRUG|Docetaxel|IV Infusion
40767608|NCT02941055|OTHER|Fiber diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
40767609|NCT02941055|OTHER|Protein diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
40767610|NCT06350110|BIOLOGICAL|CD19- BCMA CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/BCMA-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/BCMA-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/BCMA-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
40767611|NCT05810597|DRUG|Tirzepatide|Administered SC
41295520|NCT05367804|DIETARY_SUPPLEMENT|Isolated pea protein|The subjects eligible to take part in this study will consume an isolated plant protein for 4 weeks (week 4 to 8), in each week the amount of protein supplementation will increase (0.25 to 1.0 g of protein per kg of body weight). The protein will be provided as a powder in opaque bags and participants will be instructed to dissolve the contained powder in liquids (as water) or on their food (e.g., yogurt, oat porridge). The baseline will consist of 4 visits (1 to 4) to see how stable are the baseline results.
40767612|NCT05810597|DEVICE|Single Dose Pen|Used to administer tirzepatide SC
40767613|NCT05810597|DEVICE|Multi-use Prefilled Pen|Used to administer tirzepatide SC
40767614|NCT06355752|OTHER|Dry needling of lumbar iliocostalis muscle|"Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. Ten incisions will be made in the muscle.~The head will rest comfortably on a pillow"
41295521|NCT00394914|DRUG|Pleconaril|Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.
41295522|NCT00394914|DRUG|Placebo to Pleconaril|Placebo nasal suspension
41457482|NCT04083326|DEVICE|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
40966628|NCT03939260|OTHER|Extracorporeal CO2 Removal|Extracorporeal carbon dioxide removal (ECCO2R), a low flow extracorporeal CO2 removal, may be used in association with ultraprotective mechanical ventilation (tidal volume \< 6 ml/kg and Pplat \<20-25 cmH2O).
40966629|NCT04950998|BEHAVIORAL|Moving Up - A|Moving Up - A is a physical activity smartphone app for persons with mild cognitive impairment or mild forms of dementia. The app includes a personally tailored set of messages, tips, strategies, and tasks designed to increase physical activity levels and disrupt extended periods of sedentary time. Users also have the ability to track their steps and and sedentary behavior time as well as their progress towards activity goals.
41295523|NCT01157871|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
41457483|NCT01633281|PROCEDURE|acupuncture|Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
41457484|NCT03721653|DRUG|Bevacizumab|5 mg/kg iv over 30 minutes day 1
41295524|NCT01157871|DRUG|placebo|"Pharmaceutical form:solution~Route of administration: intramuscular"
41295525|NCT06024005|DRUG|Oral Solifenacin 5mg|Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
41457485|NCT03721653|DRUG|Irinotecan|165 mg/sqm iv over 60 minutes day 1
41457486|NCT03721653|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
41457487|NCT03721653|DRUG|L-Leucovorin|200 mg/sqm iv over 2 hours day 1
41295526|NCT06024005|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)|Application of TTNS twice a week for 6 weeks, with each session for 30 minutes
41295527|NCT03123523|DIAGNOSTIC_TEST|Echocardiography at T0|
41457488|NCT03721653|DRUG|5-fluorouracil|3200 mg/sqm 48 h-continuous infusion
41457489|NCT03721653|DRUG|Atezolizumab|840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
41457490|NCT01537718|DEVICE|REPLY 200|REPLY 200 pacemaker
41457491|NCT02090933|DRUG|Celecoxib|Given PO
41457492|NCT02090933|OTHER|Laboratory Biomarker Analysis|Correlative studies
41457493|NCT02090933|PROCEDURE|UV Light Therapy|Undergo UV-irradiation
41295528|NCT03123523|DIAGNOSTIC_TEST|Exercise test|
41295529|NCT03123523|BIOLOGICAL|Biological assays|Creatinin, hematocrit and BNP assays
41295530|NCT03123523|DEVICE|MRI with contrast agent injection|With injection of gadolinium
41295531|NCT03123523|DEVICE|MRI without contrast agent injection|Without injection of gadolinium
41295532|NCT03123523|DIAGNOSTIC_TEST|Echocardiography at M24|
41295533|NCT00974077|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)
41457494|NCT00730652|BIOLOGICAL|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
41457495|NCT05365698|BEHAVIORAL|Community Health and Nutrition Program|"The Community Health and Nutrition supported by the United States Agency for International Development (USAID) will be implemented by an international NGO, FHI 360. The goal of the Community Health and Nutrition (CHN) program is to improve the nutritional status of pregnant and lactating women (PLW) and children under the age of two years in the target areas of the Hashemite Kingdom of Jordan. The program will fulfill this goal by implementing activities to support improvements in IYCF practices, increase adoption of optimal family planning practices and maternal, infant and young child nutrition (MIYCN) practices, and by improving health care provider support for proper IYCF practices and use of modern contraceptive methods."
41457496|NCT06383845|DRUG|Lido-IV|Intravenous Lidocaine dose loading than a continuous infusion
41457497|NCT06383845|DRUG|ESP Block|ultrasound guided block with injection of Ropivacaine
40767615|NCT06355752|OTHER|Sham dry needling lumbar iliocostalis muscle|"Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. The placebo needle will move 10 times imitating the real procedure.~The head will rest comfortably on a pillow"
40767616|NCT05021835|DRUG|Ziltivekimab B|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
41295534|NCT00974077|OTHER|Waiting List Control|Patients receive MBCT with a delay of 6 months.
40767617|NCT05021835|DRUG|Ziltivekimab C|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
40767618|NCT05021835|DRUG|Placebo (Ziltivekimab B)|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
40767619|NCT05021835|DRUG|Placebo (Ziltivekimab C)|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
40767620|NCT06183528|PROCEDURE|Pericapsular Nerve Group (PENG) Block|With ultrasonography-guided PENG block, the femoral, obturator and accessory obturator nerve branches that provide sensory innervation of the anterior surface of the hip joint capsule are blocked .
40767621|NCT05744063|DRUG|Emapalumab-Lzsg 5 MG/ML [Gamifant]|iv
40767622|NCT06628986|BEHAVIORAL|MBSR|20 minutes once a week for 8 weeks
40767623|NCT06628986|BEHAVIORAL|NLP|NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks
40767624|NCT06628986|BEHAVIORAL|control|control group, no practice,
40767625|NCT06077214|DRUG|Treatment with liposomal bupivacaine|Patients will randomly be treated with either liposomal bupivacaine (study drug) after undergoing bariatric surgery.
40767626|NCT06077214|DRUG|Treatment with standard bupivacaine|Patients will randomly be treated with standard bupivacaine after undergoing bariatric surgery.
40767627|NCT04877366|DIETARY_SUPPLEMENT|Dietary Supplement: Sprinkled Format REDUCOSE.|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
40966630|NCT05091047|DEVICE|Erchonia EVRL|42 procedure administrations with the Erchonia® EVRL™ administered by the subject at home: Twice daily procedure administrations for 3 weeks.
40966631|NCT00963547|DRUG|MK-2206|\[Part 1\]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. \[Part 2\] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
41295535|NCT04175197|DEVICE|Drug Coated Balloon|Legflow Drug Coated Balloon
41295536|NCT02313935|OTHER|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
41457498|NCT05947409|DRUG|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
40767628|NCT04877366|OTHER|Reference control|A placebo matching to the test product will be used as control
40767629|NCT04877366|OTHER|Active comparator|Acarbose 100 mg tablet (provided in open-label format)
40767630|NCT03404713|BEHAVIORAL|Pathways to Health|Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.
40767631|NCT03404713|BEHAVIORAL|Be4U|This intervention is grounded in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Acceptance and Commitment Therapy (ACT). The core elements include regulating eating patterns, self-monitoring, developing openness to an acceptance perspective, fostering a willingness to accept distress, teaching defusion from distressing thoughts and feelings, practicing mindful awareness, fostering self-as-context, and directing patients towards clarifying and focusing on life values. Self-monitoring of eating behaviors and emotions are encouraged using a free app that facilitates electronic self-monitoring of eating patterns and symptoms. For participants who elect not to use this app, paper self-monitoring records are provided.
40767632|NCT04756531|DRUG|PF-07321332 Dose 1|PF-07321332 Dose 1 or Placebo
40767633|NCT04756531|DRUG|PF-07321332 Dose 2|PF-07321332 Dose 2 or Placebo
40767634|NCT04756531|DRUG|PF-07321332 Dose 3|PF-07321332 Dose 3 or Placebo
40767635|NCT04756531|DRUG|PF-07321332 Dose 4|PF-07321332 Dose 4 or Placebo
40767636|NCT04756531|DRUG|PF-07321332 Dose 5|PF-07321332 Dose 5 or Placebo
41295537|NCT02313935|OTHER|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
41295538|NCT02313935|OTHER|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
41295539|NCT02313935|OTHER|VideoGrade|Active cognitive training by use of the VideoGrade software by AUTH.
41295540|NCT02039271|OTHER|Music therapy|This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
41295541|NCT06111573|DIETARY_SUPPLEMENT|Vitamin D|"Study group using Vitamin D for myofascial pain treatment. Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Study group usind Vitamin D for myofascial pain treatment. Medical treatment with Vitamin D (10,000 IU/day) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
40767637|NCT04756531|DRUG|PF-07321332 Dose 4 or Placebo (Fed)|PF-07321332 Dose 5 or Placebo with high fat meal
40767638|NCT05082909|DRUG|Probenecid|Addition of 500mg QDS to oral penicillin.
40767639|NCT05960201|DRUG|[18F]fluoroestradiol (FES)|F-18 FES 111\~222 MBq(megabecquerel) injection
40966632|NCT00963547|BIOLOGICAL|Trastuzumab|Trastuzumab will be administered as a 90-minute IV infusion at a loading dose of 8 mg/kg followed by 6 mg/kg q3wk.
40966633|NCT00963547|DRUG|Lapatinib|Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
40767642|NCT06436781|DRUG|Maolactin|Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
41457499|NCT02749604|PROCEDURE|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
41457500|NCT02749604|PROCEDURE|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
41457501|NCT02218398|DRUG|Albuterol|
40767643|NCT06436781|DRUG|Maltodextrin|Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
40767644|NCT05920252|BEHAVIORAL|Vira|"Intensive outpatient DBT supported by the Vira platform. The Vira app is installed on the patient's smartphone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Patients will be asked to use Vira for the duration of their intensive outpatient treatment. Patients' use of the Vira app is supported by practitioners, who can schedule just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan and DBT treatment. The Vira Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the practitioner's workflow."
40767645|NCT05920252|BEHAVIORAL|Treatment as Usual (TAU)|Intensive outpatient DBT + EARS app (passive data monitoring software)
41137701|NCT04648670|BEHAVIORAL|Cognitive stimulation|The intervention was applied to the experimental group and consisted in 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises..
40767647|NCT05271383|DEVICE|Orthognathic surgery using Global D's implants.|Major or minor participants who will be treated by an orthognathic surgery with ORTRAUTEK® or MINITEK® implant(s).
40767648|NCT02927964|DRUG|Ibrutinib|Given PO
40767649|NCT02927964|RADIATION|Radiation Therapy|Undergo radiation therapy
40767650|NCT02927964|DRUG|TLR9 Agonist SD-101|Given IT
40767651|NCT00685295|DRUG|Fentanyl|Fentanyl rapid dissolving tablet 100mcg
40767652|NCT00685295|DRUG|Lansoprazole|lansoprazole 15mg rapidly dissolving tablet
40767653|NCT00685295|DRUG|Oxycodone|Oxycodone 5/325 mg tablet
40767654|NCT04921865|DEVICE|DPS VA-LCP® Clavicle Plate 2.7 System; DPS VA-LCP® Clavicle Hook Plate 2.7 System|"The DPS VA-LCP® Clavicle Plate 2.7 System is indicated for the fixation of clavicle bone fragments. The system consists of three plate types: lateral, shaft, and medial, each available in different sizes and materials (titanium alloy and stainless steel). Each plate is available in left and right.~The DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 System is indicated or the fixation of lateral clavicle fractures and AC joint dislocations. The Clavicle Hook Plate system consists of three plate types: long, short and button plates."
40767655|NCT06241846|DRUG|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.
40767656|NCT04275518|DRUG|APG-115|APG-115 orally once daily from Days 1 to 7 every 28 days.
41295542|NCT06111573|DRUG|Diclofenac Sodium|"Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Control group using Diclofenac Sodium for myofascial pain treatment. Medical treatment with Diclofenac Sodium (Voltaren 75 mg, 2x1 ) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
40767657|NCT04275518|DRUG|Azacitidine|75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
40767658|NCT04275518|DRUG|Cytarabine|1g/m\^2 IV QD on Days 3-7 (28-day cycle)
40767659|NCT06447272|OTHER|sham inspiratory muscle training|This group will receive conventional treatment + sham IMT (with 10% MIP as the training intensity)
40767660|NCT06447272|OTHER|target inspiratory muscle training|This group will receive conventional treatment + target IMT (the IMT identified as optimal intensity based on the results of our undergoing study).
40767661|NCT06638697|OTHER|Free walking|The free walking training program will last 32 weeks. The intensity of the training will be controlled by the scale of perceived exertion (Borg). The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
40767662|NCT06638697|OTHER|Nordic walking|The Nordic walking training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
40767663|NCT06638697|OTHER|Dance|The Dance training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
40767664|NCT06638697|OTHER|Physical exercise for cognition|The Physical exercise for cognition training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
40767665|NCT06638697|OTHER|Balance|The Balance training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
40767666|NCT06638697|OTHER|Aquatic physiotherapy|The Aquatic Physiotherapy training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
40767667|NCT06638697|OTHER|Multicomponent gymnastics|The Multicomponent Gymnastics training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
41295543|NCT06499506|PROCEDURE|Below knee amputation|trans tibial amputation one hand breadth below tibial tuberosity
41457502|NCT05535998|PROCEDURE|TACE-HAIC|The TACE-HAIC which was performed using 30 mg/m2 of epirubicin mixed with 2-5 mL lipiodol, followed by pure lipiodol. Then, a catheter was placed and fixed in the tumor feeding artery for the FOLFOX-based chemotherapy infusion at the following dosage: 85 mg/m2 of oxaliplatin infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; 400 mg/m2 of 5-FU bolus; and 2400 mg/m2 of continuous 5-FU infusion for 46 hours or 1200mg/m2 of continuous 5-FU infusion for 23 hours, respectively. Repeated TACE-HAIC was performed at intervals of 3-4 weeks.
40767668|NCT06638697|OTHER|Water aerobics|The Water Aerobics training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
40767669|NCT06638697|OTHER|Hydroposture|The Hydroposture training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
40767670|NCT06638697|OTHER|deep water walking|The deep water walking training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
40767671|NCT06638697|OTHER|Weight training|The weight training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
40767672|NCT06638697|OTHER|Mat pilates|The MAt pilates program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
40767673|NCT06583343|DRUG|OnabotulinumtoxinA|Botulinum toxin injections were administered in appropriate doses to the spastic muscles of children with cerebral palsy.
40767674|NCT06583343|OTHER|Conventional Physical Therapy|Conventional rehabilitation program; consisting of walking-balance exercises, range of motion exercises, stretching, and strengthening exercises, was provided for 1 hour, 5 days a week, totaling 30 sessions
40767675|NCT06308237|OTHER|RESISTED EXERCISES|"Patients will perform Chest plank for 30 seconds with 4 repetitions.~Then the Participants will perform these exercises for 1 minute each with 4 repetitions:~Wide grip lateral pull down , Lying triceps press, Sit up squats, Barbell curl each.~And will perform Thigh adduction for1 minute with 2 repititions."
40767676|NCT06308237|OTHER|BALANCE EXERCISES|"Static and dynamic balance exercises will include:~Patients will perform Arm abduction holding a half-kg dumbbell, Opposite arm and leg in a quadruped position, Walking in a tandem stance(forward and backward), Turning and bending to the sides in a standing position, Pass through obstacles in a spiral, for 2 minutes each.~Then they will perform throwing a medicine ball to investigator and back while trying to maintain balance, Tandem stance, Walking backwards, Two-leg bridge as well as single (2 repetitions), Leg bridge (raising the other leg), walking on the heel, performing rhythmic movements while stepping on a circular environment and balance board exercises, for 1 minute each.~And will Walk up and down the stairs for 3 minutes."
40767677|NCT04548661|PROCEDURE|Intraoperative incisional wound irrigation with povidone-iodine solution|Participants randomized to the povidone-iodine irrigation group will have all incisions irrigated once with povidone-iodine diluted in 0.9% sterile normal saline (to a final concentration of 5% povidone-iodine (0.5% available iodine)) delivered through a bulb syringe. The povidone-iodine irrigation should be left on for 60 seconds and then dried with sterile gauze. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
40767678|NCT04548661|PROCEDURE|Intraoperative incisional wound irrigation with saline|Participants randomized to the saline irrigation group will have all incisions irrigated once with 0.9% sterile normal saline delivered through a bulb syringe. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
40767679|NCT05090865|DIETARY_SUPPLEMENT|Liberalized dietary potassium via fruits and vegetables|On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 250 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 2000 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.
41137702|NCT03387826|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg twice daily
41137703|NCT03387826|DRUG|Prasugrel 5mg|Prasugrel 5 mg once daily
41137704|NCT06170125|OTHER|Tiotropium treated patients|Patients who are not satisfied with their COPD treatment and will be on additional tiotropium scheme.
41137705|NCT01524497|DRUG|Trazodone|75mg tablet/150 mg tablet
41457503|NCT05535998|PROCEDURE|TACE|TACE was performed using 30 mg/m2 of epirubicin, 200 mg/m2 of carboplatin, and 4mg/m2 of MMC, mixed with 2-5 mL lipiodol. Up to 20 mL of additional pure lipiodol were injected into the tumor-feeding artery until stasis of blood flow was observed in the target artery. Repeated TACE was performed at intervals of 3-4 weeks.
40767680|NCT05090865|DIETARY_SUPPLEMENT|Standard dietary potassium restriction|Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake \< 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.
40767681|NCT05110261|DRUG|Nirsevimab|Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.
40767682|NCT05110261|DRUG|Placebo|Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)
41137706|NCT01524497|DRUG|Placebo|Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
41457504|NCT05535998|DRUG|Targeted therapy|The TKI therapy used in this study were lenvatinib (12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg), sorafenib (400 mg twice a day) or apatinib (250-500 mg orally once daily). Administration of lenvatinib, apatinib or sorafenib was started on the first post-TACE day, and continually administered until disease progression developed or serious treatment-related toxicity occurred.
40767685|NCT04035486|DRUG|Osimertinib|"Drug: Osimertinib (Oral)~Other Names:~AZD9291"
40767686|NCT04035486|DRUG|Pemetrexed/Carboplatin|Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
40767687|NCT04035486|DRUG|Pemetrexed/Cisplatin|Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
40767688|NCT04318938|DRUG|Brigatinib|Treatment with Brigatinib
40767689|NCT04318938|DRUG|Tyrosine kinase inhibitor|Treatment with any TKI
40767690|NCT06402721|DRUG|BAY3283142|Single oral dose.
40767691|NCT04979143|PROCEDURE|Surgical Approach|The surgical laser used will be randomized. All lasers used during this trial are all FDA approved devices and used per routine clinical care.
40767692|NCT06126172|DIAGNOSTIC_TEST|Multiparametric magnetic resonance imaging (mpMRI)|Detecting and localizing prostate cancers and using radiomics extracted from prostate mpMRI for risk stratification patients of histological aggressiveness as well as to predict very early recurrence of PCA patients within 6 months after radical prostatectomy.
40767693|NCT06024226|PROCEDURE|Tumor samples|Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
40767696|NCT04164927|OTHER|Manual Lymphatic Drainage|"1. Lymphatic correction method was used via the KinesioTaping® to patients group.~2. Standardized 30-minute Manuel Lymphatic Drainage treatment was applied to the MLD group.~3. Control group received only physiotherapy treatment."
40767697|NCT04164927|OTHER|Kinesio Taping|Depending on the size of the leg two or three fan cut tapes were applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Kinesio taping was applied by certified Kinesio Tape practitioner once a week to Kinesiotaping group.
40767698|NCT04164927|OTHER|Control|Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures. These exercises were undertaken in sets of 10 repetitions, 3 times daily; the physiotherapist was present to assist, as required, on 2 occasions per day for the first 3 postoperative days and then once daily from day 4 until hospital discharge.
40767699|NCT01355627|PROCEDURE|TachoSil®|Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
40767700|NCT01355627|PROCEDURE|Current Practice|"Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.~In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®."
40767701|NCT06407232|DRUG|Letermovir|480 mg taken orally once daily, for 84 days
40767702|NCT05601869|DEVICE|RECOVER Prosthetic Ankle-Feet System|The RECOVER prosthetic ankle-feet system includes a single prosthetic ankle joint that can be easily attached to 3D printed feet. The feet are designed to fit specifically within different footwear.
40767703|NCT02003703|BIOLOGICAL|Recombinant Hepatitis B Virus Vaccine|
40767704|NCT06379100|DEVICE|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
41457505|NCT05535998|DRUG|PD-1 inhibitors|PD-1 inhibitors were intravenously administered on the first post-TACE day as follows: camrelizumab 200 mg or sintilimab 200 mg or toripalimab 240 mg or tislelizumab 200 mg, every 3-4 weeks.
41457506|NCT03914898|OTHER|Nurse led intervention group|This program is based on cognitive restructuring tecniques.
41457507|NCT03234907|DRUG|Vedolizumab IV|Vedolizumab IV infusion
41457508|NCT03234907|DRUG|Placebo|Vedolizumab placebo-matching
40767705|NCT05019209|DRUG|House Dust Mite Allergen|D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
40767706|NCT05019209|OTHER|Allergen-free air|No allergen added to room ventilation of allergen challenge chamber
40767707|NCT05573308|DEVICE|Clear Aligners with Dental Monitoring|Dental Monitoring™ (DM ™). This digital technology software allows orthodontists to monitor patients remotely through continuous analytics using control vision technology, metaheuristics, and artificial intelligence.31 This app utilizes a patented artificial intelligence machine learning algorithm to calculate 3-dimensional (3D) tooth movements from intraoral photos and videos that patients capture using their smartphone cameras.
40767708|NCT05573308|DEVICE|Clear Aligners|Removabale orthodontics appliances
40767709|NCT06498648|DRUG|Abemaciclib|Given PO
40767710|NCT06498648|PROCEDURE|Biopsy|Undergo tumor biopsy
40767711|NCT06498648|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40767712|NCT06498648|DRUG|Docetaxel|Given IV
40767713|NCT06498648|OTHER|Fluorothymidine F-18|Given IV
40767714|NCT06498648|DRUG|Gemcitabine|Given IV
41457509|NCT06266741|DIAGNOSTIC_TEST|Lubricin|Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.
41457510|NCT05951088|PROCEDURE|Cardio2U follow-up|During the follow-up period, participants will have access to the application and will be able to explore the different modules. At fixed time points, the application will allow them to fill in questionnaires about the application's usability and patient satisfaction. App user data will track how long and how often patients visit the application and which aspects are mostly used. In addition, at different time points during the study, patients will be asked to complete clinical questionnaires regarding e.g. patients' knowledge and self-care abilities. The results of these questionnaires can be used in a more clinical way as they will be accessible to doctors and nurses in the healthcare provider dashboard and can support targeted patient follow-up and guidance
41457511|NCT04914546|DRUG|LY3819469|Administered SC.
41457512|NCT04914546|DRUG|Placebo|Administered SC.
40767715|NCT06498648|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40767716|NCT04581083|DIAGNOSTIC_TEST|RT-PCR|RT-PCR (Gold standard): Real-time PCR testing with reverse transcriptase (RT-PCR). The test consists of a polymerase chain reaction that has previously had a reverse transcription phase, RT. This test allows the cADN (complementary DNA) to be obtained from a RNA chain. This technique allows the detection and amplification of a sequence from a strand of RNA.
40767717|NCT04581083|DIAGNOSTIC_TEST|LAMP|LAMP: The LAMP technique, like PCR, has the ability to amplify specific DNA fragments (target sequence), allowing for highly sensitive detection of pathogens. Unlike pcr, LAMP requires between 4 and 6 feeders, external F3 and B3 feeders, which hybridte with the outer regions of the target sequence, while the internal FIP and BIP have sequences in both ways that allow the formation of a loop. The LAMP reaction is isothermal, i.e. it takes place at a single temperature. LAMP has been successfully used to detect viral diseases as well as viral pathogens such as West Nile virus, TMR-1, Norovirus, avian influenza, foot-and-mouth disease, classical swine fever, among others.
40767718|NCT04581083|DIAGNOSTIC_TEST|POOL RT-PCR|POOL RT-PCR: This test aims to mix in a single sample the extractions obtained from several people. The joint sample is evaluated and, if negative, it is understood that all are free of COVID-19; if it is positive, an array system is used to detect the affected person. That is, a single PCR (polymerase chain reaction), the diagnostic test used to detect the virus pathogen is applied to a group and repeated individually if positive.
40767719|NCT04581083|DIAGNOSTIC_TEST|POOL LAMP|POOL LAMP: Like the RT-PCR pool test. This test essentially involves mixing in a single sample the extractions obtained from several people. This joint sample is tested and, if it is negative, it is understood that everyone is free of COVID-19; if it is positive, an array system is used to detect the affected person. That is: a single LAMP applies to a group
40767720|NCT06565286|PROCEDURE|inner preputial graft versus transverse preputial island flap in two-stage repair of proximal penile hypospadias|compare outcomes of inner preputial graft versus transverse preputial island flap when used to substitute the urethral plate in two-stage repair of primary proximal penile hypospadias .
40767721|NCT06635850|DRUG|Mosliciguat|Dose level 1, 2, or 3 for inhalation
40767722|NCT06635850|DEVICE|Dry Powder Inhaler|Dry powder inhaler for mosliciguat or placebo delivery
40767723|NCT06635850|DRUG|Placebo|Matching placebo for inhalation
40767724|NCT06241352|DRUG|statin addition to chemotherapy|Chemotherapy was administered along with 80mg of atorvastatin per day. Atorvastatin was discontinued when CA19-9 levels (with CA19-9 negative patients referenced against CEA or CA-125) rose more than 20% above baseline.
40767725|NCT06096363|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Transthoracic Echocardiography to look for evidence of right ventricular (RV) dysfunction and right ventricular-pulmonary arterial (RV-PA) uncoupling.
40767726|NCT04512378|BEHAVIORAL|Behavioural Experiments for Intolerance of Uncertainty|Cognitive-behavioural treatment targeting intolerance of uncertainty using behavioural experiment technique
40966634|NCT02468674|DRUG|bimagrumab|"bimagrumab low dose bimagrumab moderate dose bimagrumab high dose~Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
41457513|NCT06397716|GENETIC|ALDH2 Genotyping|Cheek swab for PCR testing of ALDH2 genotype.
40966635|NCT02468674|DRUG|Placebo|"Placebo~Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
41295544|NCT03920852|DRUG|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
41457514|NCT00758797|OTHER|Photoimmunotherapy|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
41457515|NCT00686764|OTHER|Observational|"Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.~We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36)."
41457516|NCT03255980|DEVICE|Xonrid® gel|Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
41457517|NCT03255980|OTHER|Standard of Care|Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines
41457518|NCT02022306|DRUG|TD-6450|
40990721|NCT00605813|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration."
41457519|NCT02022306|DRUG|Placebo|
41137707|NCT03854565|DIAGNOSTIC_TEST|Glycocalyx measurement，respiratory mechanics measurement|ELASA measure glycocalyx, measure plateau pressure, driving pressure
40966636|NCT05738954|OTHER|Ultrasound|"Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.~The DL/SL algorithms will work in a competitive/collaborative way. Following the 'no-free-lunch' theorem, we shall use the competitive phase to establish the most suitable DL/SL technique for the identification and anomaly detection of each organ, and the collaborative phase to make all the algorithms work together in providing a 'second' opinion."
40966637|NCT03725202|DRUG|Upadacitinib|It will be administered orally.
41137708|NCT04920786|DRUG|TB006|TB006
41295545|NCT01438710|DRUG|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
41295546|NCT01438710|DRUG|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
41457520|NCT04403620|RADIATION|Intensity-modulated Radiation Therapy (IMRT)|Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection
41457521|NCT04150549|BIOLOGICAL|Fecal Microbial Transplants|Healthy donor stool will be processed and placed into capsules.
41457522|NCT04150549|BIOLOGICAL|Fecal Microbial Transplants|Participants stool will be processed and placed into capsules.
41137709|NCT04920786|OTHER|Sterile saline (Placebo)|Sterile saline
41137710|NCT01695291|DRUG|Minocycline|Participants randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline. Participants will take either minocycline or pill placebo for 12 weeks.
41295547|NCT02328573|BEHAVIORAL|Communal singing|
41457523|NCT03675815|DRUG|Darunavir (DRV) 800 milligram (MG) Oral Tablet|800 milligrams (mg) orally once daily for 96 weeks
40966638|NCT03725202|DRUG|Corticosteroid (CS)|It will be administered orally.
41295548|NCT01601392|PROCEDURE|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
41295549|NCT01601392|PROCEDURE|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
41295550|NCT01601392|PROCEDURE|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
41457524|NCT03675815|DRUG|Ritonavir 100 MG Oral Tablet|100 mg orally once daily for 96 weeks
40966639|NCT03725202|OTHER|Placebo|It will be administered orally.
40966640|NCT00680017|DRUG|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
40966641|NCT00680017|DRUG|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
40966642|NCT00001006|DRUG|AS-101|
41457525|NCT03675815|DRUG|N(t)RTIs|Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection
41457526|NCT03675815|DRUG|Dolutegravir 50 MG Oral Tablet|50 mg orally once daily for 96 weeks
41457527|NCT03675815|DRUG|TDF 300 MG Oral Tablet|300 mg orally once daily for 96 weeks
41457528|NCT03675815|DRUG|3TC 300 MG Oral Tablet|300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
41137711|NCT01695291|OTHER|Placebo|A placebo pill will be administered twice a day (BID) for 12 weeks.
41137712|NCT03691441|PROCEDURE|Resection|Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.
41137713|NCT03691441|RADIATION|Radiotherapy|6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible
41137714|NCT03691441|DRUG|Chemotherapy|The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.
41295551|NCT05834959|OTHER|An Educational and Training Program|Education and practical training program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury
40767727|NCT04077320|BEHAVIORAL|Memory Self-Efficacy Training|The intervention will consist of a six-week cognitive behavioral intervention integrating the four pillars of self-efficacy, Mastery, Social Modeling, Coaching, and Physiological Responses (West et al. 2008). Each week will comprise of a 1.5 hour session which focuses on an educational component, discussions and active learning practice activities to apply lesson material. Additionally, participants will be given take home exercises to practice outside a classroom setting. The sessions will be conducted in small groups of 4-6 people.
40767728|NCT04077320|BEHAVIORAL|General Education|The active control intervention will be a general education class consisting of real world knowledge and factual information on various topics unrelated to memory. This intervention will follow the same format as the memory self-efficacy training arm. One 1.5 hours session every week for 6 weeks, in small groups.
40767729|NCT04816721|DRUG|EDP-938|Oral suspension
40767730|NCT04816721|DRUG|Placebo|Placebo oral suspension to match EDP-938
40767731|NCT04300894|DEVICE|Mamma Mia|"Users of the Mamma Mia program progress through the intervention in a sequence of modules.~Every day that a module should be completed, you will receive a notification with a reminder to access the program. By clicking on the reminder, you can access that particular day's session content. Modules involve a variety of information and activities; for example, there are guided mindfulness practices, information on breastfeeding, instructional videos on how to interpret your baby's cries, and discussions on how to have effective discussions with your partner or healthcare provider about your needs."
40767732|NCT04300894|OTHER|Mamma Mia Plus|Participants will use the Mamma Mia program, plus receive contact (phone calls or emails or texts) from study staff every few months.
40767733|NCT04331275|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into solid organ transplant recipients who have evidence of viral infection.
40767734|NCT03275987|BEHAVIORAL|Mammography direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
40767735|NCT03275987|BEHAVIORAL|Usual care|Group received usual care, and direct mail 15 months after treatment group received intervention.
40767736|NCT03275987|BEHAVIORAL|Colonoscopy direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
40767737|NCT06645444|OTHER|immediate implant placement with customized PEEK healing abutment|"* an intraoral examination will be done and a digital impression will be taken by the intraoral scanner (MEDIT i500) for a pre-extraction digital model, and CBCT will be taken for prosthetic-driven planning.~* Once the treatment plan formulated, both STL (Standard Triangle Language) and DICOM (CBCT raw data) files format will be sent to produce the digital surgical guide with metal sleeve.~* Then, a customized PEEK healing abutment will be made mimicking the anatomical cervical contour and pseudo-CEJ will be made by merging the STL and DICOM digitally and the exterior surface of the healing abutment will be designed to resemble a tooth.~* Then, the technicians will mill the customized healing abutment digital design from a pre-milled 14 × 14 mm PEEK block (BioHPP, Bredent®, Bolzano, Italy) with a non-hex connection type, polished it, and sterilized it.~* The digital surgical guide with a metal sleeve will be back for scheduled patient implant surgery."
40767738|NCT06114628|DRUG|GSK3036656|Oral daily dosage of 20mg.
40767739|NCT06114628|DRUG|BTZ-043|Oral daily dosage of 1000mg.
40767740|NCT06114628|DRUG|Bedaquiline (B)|Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
40767741|NCT06114628|DRUG|Delamanid (D)|Oral daily dosage of 300mg.
40767742|NCT06114628|DRUG|Pretomanid (Pa)|Oral daily dosage of 200mg.
40767743|NCT06114628|DRUG|Moxifloxacin (M)|Oral daily dosage of 400mg.
40767744|NCT06114628|DRUG|Linezolid (L)|Oral daily dosage of 600mg for the first 8 weeks.
40767745|NCT06114628|DRUG|Pyrazinamide (Z)|Oral daily dosage of 1200mg-2000mg depending on weight.
40767746|NCT06114628|DRUG|Rifampicin (R)|Oral daily dosage of 450mg-750mg depending on weight.
40767747|NCT06114628|DRUG|Isoniazid (H)|Oral daily dosage of 225mg-375mg depending on weight.
40767748|NCT06114628|DRUG|Ethambutol (E)|Oral daily dosage of 825mg-1375mg depending on weight.
40767749|NCT06079372|DRUG|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
40767750|NCT06079372|DRUG|asfotase alfa|Asfotase alfa will be administered via SC injection.
40767751|NCT06471751|OTHER|Inspiratory and Oropharyngeal Muscle Strengthening|"Patients will conduct the training at home, 5 days a week for 3 months. They will perform 2 sets of 30 inspirations against resistance (POWERbreathe® K5 , Powerbreathe International Limited, UK), equal to 70% Maximum Inspiratory Pressure (MIP). Patients will be guided for oropharyngeal exercises.~The sessions will be supervised by the investigator every 3 weeks. During sessions with the investigator, sessions recorded in the device will be downloaded to verify compliance. A MIP measurement will be performed to adjust the resistance of the device."
40767752|NCT06484881|DIETARY_SUPPLEMENT|Daniel Alain Probiotic Treatment for Androgenetic Alopecia|Probiotic
40767753|NCT06484881|DRUG|Topical minoxidil 5%|Topical minoxidil 5%
40966643|NCT04826991|DEVICE|Active UV Device|Active water treatment system
41295552|NCT00509873|DRUG|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
41295553|NCT00509873|DRUG|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
41295554|NCT05044169|DRUG|Broncho-Vaxom|administration for 6 months after remmission
41457529|NCT03675815|DRUG|FTC 200 MG Oral Cap|200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
40767754|NCT05832047|DRUG|Plasma solution (4-hour aggressive hydration)|Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
40966644|NCT04826991|DEVICE|Inactive UV Device|Inactive water treatment system
40966645|NCT01633853|DRUG|Vitamin D2|Treatment with Vit D2.
41457530|NCT04746976|DRUG|Diroximel Fumarate|As described in the arm.
40966646|NCT01633853|DRUG|1,25(OH)2 Vit D3|Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
40966647|NCT03910374|PROCEDURE|Dural closure|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair
40966648|NCT00739791|BEHAVIORAL|exercise intervention|
40966649|NCT00739791|GENETIC|gene expression analysis|
41137715|NCT03691441|PROCEDURE|Salvage neck dissection|+/- Salvage neck dissection 12±2 weeks after treatment
41295555|NCT05207436|DRUG|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each B-CBCT session.
41457531|NCT04703933|OTHER|EVALUATION OF THE LEVEL OF KNOWLEDGE AND ATTITUDE OF THE OPERATING ROOM NURSES|This descriptive study was conducted with 100 nurses working in the operating room of two university hospitals in Istanbul
41457532|NCT00213122|DRUG|miglitol|
40966650|NCT00739791|GENETIC|polymerase chain reaction|
40966651|NCT00739791|GENETIC|proteomic profiling|
40966652|NCT00739791|GENETIC|reverse transcriptase-polymerase chain reaction|
40966653|NCT00739791|OTHER|laboratory biomarker analysis|
41295556|NCT05207436|BEHAVIORAL|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized B-CBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
41457533|NCT02472834|DIETARY_SUPPLEMENT|Amino acid supplementation NephrAmine®|Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing \~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
41457534|NCT01476969|DEVICE|Remote ischemic postconditioning|the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
41457535|NCT01937689|DRUG|Pyrotinib|Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
40767755|NCT05832047|DRUG|Lactated Ringer solution (4-hour aggressive hydration)|Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
40966654|NCT00739791|OTHER|medical chart review|
40966655|NCT00739791|OTHER|questionnaire administration|
40966656|NCT00739791|PROCEDURE|psychosocial assessment and care|
40966657|NCT00739791|PROCEDURE|quality-of-life assessment|
40966658|NCT00739791|PROCEDURE|support group therapy|
40966659|NCT00739791|PROCEDURE|therapeutic dietary intervention|
40966660|NCT02207296|DEVICE|Plethysmographic variability index|
40966661|NCT04433403|OTHER|pathogenic microorganism|Detection of pathogenic microorganisms in adult severe pneumonia by second generation sequencing
41295557|NCT05366933|DRUG|Vitamin B-Complex Supplement|Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
41295558|NCT05327478|PROCEDURE|NRP|Normothermic Regional Perfusion
41457536|NCT04210544|DIETARY_SUPPLEMENT|Experimental dietary protein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of the experimental protein accompanied by a glass with 50 mL water.
41295559|NCT05327478|PROCEDURE|DHOPE|Dual Hypothermic Oxygenated Perfusion
41295560|NCT05327478|PROCEDURE|COR-NMP|Controlled Oxygenated Rewarming Normothermic Machine Perfusion
40767756|NCT05832047|DRUG|8-hour aggressive hydration|If patients experienced postprocedural abdominal pain Numerical Rating Scale (NRS score\>3) or a worsening of abdominal pain compared with the pain before ERCP, the administration of study fluid continues until 8 hours (3 mL/kg/hr ) regardless of the results of serum amylase/lipase within 4 hours after ERCP because serum amylase/lipase within 4 hours after ERCP may have a result approximately 1-2 hours (5 hours-6 hours after ERCP) after blood sampling
40767757|NCT05896839|PROCEDURE|Biopsy|Undergo tumor biopsy
40767758|NCT05896839|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40767759|NCT05896839|PROCEDURE|Computed Tomography|Undergo CT scan
40767760|NCT05896839|BIOLOGICAL|Ipilimumab|Given IV
40767761|NCT05896839|PROCEDURE|Kidney Biopsy|Undergo kidney biopsy
40767762|NCT05896839|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40767763|NCT05896839|BIOLOGICAL|Nivolumab|Given IV
40767764|NCT05896839|DRUG|Prednisone|Given PO
40767765|NCT05896839|DRUG|Sirolimus|Given PO
40767766|NCT06643650|DIETARY_SUPPLEMENT|CHOLECALCIFEROL ORAL.SOL 25000 IU/2,5ML|Cholecalciferol 25000IU/week for 3 months in both groups. 2nd group continues with 25000IU/month for following 3 months.
40767767|NCT04049474|DEVICE|ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)|See BCI description.
40767768|NCT06318624|OTHER|Mobilisation with Movement and Taping|For MWM for the talocrural joint, the hemiparetic side of the participant is positioned in a standing position on a stool. A non-elastic belt is passed behind the patient's distal tibia and secured around the therapist's pelvis. The patient is asked to perform active knee flexion and ankle dorsiflexion with weight on the hemiparetic side. Meanwhile, the therapist performs forward sliding of the tibia with the help of the belt. For 10 seconds active and painless sliding takes place and then return to the starting position. This application is applied as 10 repetitions, 6 sets, and 1 minute rest between sets. Following the MWM application, Mulligan talus stabilization taping is performed. For this taping, the participants' ankles are placed on a stool at a height of 30 cm and their feet are placed in the dorsiflexion position. The therapist starts taping from the plantar surface of the calcaneus using rigid tape and will wrap and stabilize the talus.
40767769|NCT06318624|OTHER|Sham|During joint mobilization with movement, the therapist will stabilize the ankle while performing knee flexion and ankle dorsiflexion by actively moving the center of mass to the affected side, but the shear force required to slide the tibia forward with the belt will not be given. Placebo taping following the application will be applied in such a way that there is no stabilization effect without tension between the same start and end points.
40767770|NCT04806399|OTHER|Educational Materials and Decision Counseling|Participants in the active comparator arm will receive an introductory letter and lung cancer screening educational materials. A site care coordinator will contact each participant post receiving materials.
40767771|NCT06286046|DRUG|Mitapivat|Tablets
41295561|NCT04792138|DIAGNOSTIC_TEST|VERDICT MRI|Advanced Diffusion Model
41295562|NCT04792138|DIAGNOSTIC_TEST|Luminal Index Imaging|Advanced T2 mapping
40767772|NCT06630130|DRUG|Trastuzumab deruxtecan|"* Neoadjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W for 3 cycles~* Adjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W 16 cycles (up to 12 months)"
40767773|NCT06630130|DRUG|Capecitabine|"* Neoadjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 3 cycles~* Adjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)"
40767774|NCT06630130|DRUG|Rilvegostomig|"(Only Cohort B)~* Neoadjuvant; Rilvegostomig 750mg IV on D1, Q3W for 3 cycles~* Adjuvant; Rilvegostomig 750mg IV on D1, Q3W for 16 cycles (up to 12 months)"
40767775|NCT04696575|BIOLOGICAL|Atezolizumab|Given IV
40767776|NCT04696575|DRUG|Carboplatin|Given IV
40767777|NCT04696575|DRUG|Etoposide|Given IV
40767778|NCT04696575|DRUG|Lamivudine|Given PO
40966662|NCT04073069|DRUG|The DR group|Miscible liquid of diprospan and ropivacaine in this study will be peri-incisional scalp infiltration with 0.5 ml diprospan, 15 ml 1% ropivacaine and 14.5 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
40990722|NCT06238232|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient's weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
41295563|NCT05791799|DRUG|Etonogestrel|Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year
40767782|NCT06251310|DRUG|SW-682|SW-682 tablet administered orally
40767783|NCT06251310|DRUG|Combination Therapy|Appropriate combination therapy
41295564|NCT03477630|BIOLOGICAL|Platelet Rich Plasma|intra-articular infiltration of 8 ml of autologous PRP every 15 days.
41295565|NCT03477630|DRUG|Hyaluronic Acid|intra-articular infiltration of a single dose of HA
41295566|NCT02948192|OTHER|Survey, Sample collection|Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
41295567|NCT00401973|DRUG|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
41295568|NCT00401973|DRUG|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
41295569|NCT00401973|DRUG|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
40767784|NCT05230277|OTHER|the active osteopathic treatment (AOT)|The AOT will first consist of the application of a visceral technique. The patient will lie on their stomach and the osteopath will touch the patient's abdomen with a wide two-handed grip. The action will consist of following the abdominal tissues in directions where tissue mobility is allowed and occurs without restriction, from the surface to the depth of the abdomen. A change in the elasticity of the colon will then be perceived when the mobility restrictions of the tissues are dissipated. The osteopath will then use a technique on the sacrum according toik-g the procedure described by Attali et al. \[8\] which consists in mobilizing the sacrum between the iliac bones.
41295570|NCT00401973|DRUG|zonisamide|Zonisamide, 100-400mg, oral, daily.
41295571|NCT00401973|BEHAVIORAL|Wellness education|weight management
41295572|NCT04331158|OTHER|Dry cupping therapy|Dry cupping therapy application on the patient's skin
41295573|NCT04160403|OTHER|physical therapy intervention|NDT bases on neuroplasticity by which the brain change and reorganize itself and its processes according to practice and experience by a) facilitation of normal postural alignment and movement patterns; b) inhibition of the involvement during developmental and functional activities; and c) using sensory feedback (manual contact, visual integration, somatosensory reinforcement) for recovering function
41295574|NCT04715750|DRUG|[18F]-PI2620|\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
41295575|NCT01370798|DRUG|promestriene|Promestriene cream 1%, 1g per day during 2 months, cutaneous application
41295576|NCT01370798|DRUG|Placebo|Placebo of promestriene cream, 1g per day during 2 months, cutaneous application
41457537|NCT04210544|DIETARY_SUPPLEMENT|Casein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of casein accompanied by a glass with 50 mL water.
41295577|NCT01370798|PROCEDURE|Urethroplasty|Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)
41295578|NCT01370798|RADIATION|Wrist X ray|Wrist X ray to follow the degree of bone maturation
41295579|NCT01370798|PROCEDURE|Blood test|Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH
41457538|NCT04210544|DIETARY_SUPPLEMENT|Water|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of water accompanied by a glass with 50 mL water.
41457539|NCT01485718|DIETARY_SUPPLEMENT|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
40767785|NCT05230277|OTHER|the sham osteopathic treatment|For SOT, the patient will lie on their stomach and the osteopath will use a wide two-handed grip on the patient's abdomen to deliberately mobilize it in an imprecise manner. Next, a technique with no apparent therapeutic effects, the light touch, first described by Licciardone et al. \[13\] and proposed by others to perform simulated bone manipulations \[14\], will be applied to the sacrum
40767786|NCT04183712|DRUG|gemcitabine and oxaliplatin.|GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.
40767787|NCT04183712|DRUG|Afatinib|Target therapy Drug: afatinib
40767788|NCT03884257|DEVICE|Passeo-18 Lux treatment group|Percutaneous endovascular angioplasty with the Passeo-18 lux
40767789|NCT03884257|DEVICE|IN.PACT Admiral treatment group|Percutaneous endovascular angioplasty with the IN.PACT Admiral
41295580|NCT00616239|DRUG|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
41295581|NCT00616239|DRUG|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
40767790|NCT06506474|DIAGNOSTIC_TEST|Provision of any of six different low-value health services for treatment of bronchiolitis|This prospective observational will have six separate primary outcomes acting as exposures, (or interventions).The exposures are the the provision of any of the six low-value health services: 1) respiratory virus testing; 2) chest x-ray; 3) continuous pulse oximetry; 4) short-acting beta-agonists; 5) systemic corticosteroids; and 6) antibiotics.
40767791|NCT06640309|DRUG|Nicotinamide Tablet|Nicotinamide is anti-inflammatory and antioxidant.
41457540|NCT01485718|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
40767792|NCT06640309|DRUG|conventional synthetic antirheumatic drugs|methotrexate- leflunomide- sulfasalazine- hydroxychloroquine
40767793|NCT06212817|OTHER|Dietary intervention|Increase dietary fiber intake
40767794|NCT06284915|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection (in a single-dose vial)-Route of administration:Intramuscular (IM) injection
40767795|NCT06284915|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection (powder or cake in a single dose glass vial and a clear and colourless solvent in a pre filled syringe for reconstitution-Route of administration:Intramuscular (IM) injection
40767796|NCT06477029|DEVICE|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
40767797|NCT06477029|DEVICE|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
40767798|NCT04600973|BEHAVIORAL|Technical assistance or team-based coaching|Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.
40966663|NCT04073069|DRUG|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
40966664|NCT00492908|DEVICE|Helistent Titan2 (Titanium coated stent)|Titan2
40966665|NCT00492908|DEVICE|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
40966666|NCT03223142|DEVICE|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
40966667|NCT06278701|OTHER|late-evening snacks|have an additional meal 1h before bedtime (total calories 200-275kcal, protein 11.5g-18g, complex carbohydrates 25-55g).
40966668|NCT02034201|DRUG|Lisdexamfetamine|
40966669|NCT02034201|DRUG|Placebo|
40966670|NCT05169385|BEHAVIORAL|Parent SMART|Parent SMART experimental intervention
41137716|NCT04848532|BEHAVIORAL|Weight loss treatment|The intervention will consist of group-based, weekly or biweekly weight loss coaching (75 minutes per session), which will occur via Zoom videoconferencing software. This intervention is designed to facilitate a 5-10% weight loss and engagement in up to 250 min/week of moderate-to-vigorous physical activity, which is the standard recommendation in lifestyle modification programs for adolescents. Participants will also be asked to download and utilize the smartphone app, Fitbit, to track eating behavior. Weight loss coaches will be experts in lifestyle modification who have graduate degrees in psychology or a related field. Participants will be given guidance on how to reduce your calorie intake (using a balanced deficit diet) and gradually increase your physical activity. Participants will learn to set goals for diet, weight, and physical activity.
41137717|NCT05320094|DRUG|Mavacamten|Specified dose on specified days
41137718|NCT05320094|DRUG|Activated Charcoal with Sorbitol|Specified dose on specified days
41137719|NCT03708809|DEVICE|Intrauterine system|13.5 mg levonorgestrel-releasing intrauterine system
41137720|NCT03708809|OTHER|Alternative contraception to intrauterine system|Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,
41137721|NCT01951703|DEVICE|senofilcon A|Control, senfilcon A
41137722|NCT01951703|DEVICE|senofilcon A|Test, senofilcon A
41457541|NCT02532192|DRUG|Belinostat|"Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.~Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
40966671|NCT05169385|BEHAVIORAL|Treatment as Usual|Residential treatment as usual
40966672|NCT00309114|PROCEDURE|bacterial interference|
41137723|NCT01691677|DRUG|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days|
41137724|NCT01691677|DRUG|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days|
40966673|NCT05628532|DEVICE|Use of the DBLG1 system|During the treatment period, the patient will use the DBLG1 system (consisting of a DBLG1 handset with an embedded software named loop mode, a TERUMO MEDISAFE WITH patch pump and a Dexcom continuous glucose monitoring (CGM) G6). The main function of DBLG1 System is to adjust the insulin delivery at the correct time in order to maintain the patient's blood glucose in the target range and thus minimize both hypoglycaemic events and long-term complications associated with elevated average glycemia.
40966674|NCT00793091|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
40966675|NCT00793091|DRUG|Placebo|4 drops applied daily for 120 days
41137725|NCT06343493|DRUG|Normal saline heated up to 50 °C|Saline heated up to 50 °C used for irrigation
41137726|NCT01947491|DRUG|DFD01 Spray|
41137727|NCT01947491|DRUG|Comp01 Lotion|
41457542|NCT02532192|DRUG|Rituximab|Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
40767799|NCT06589999|DIAGNOSTIC_TEST|MP2RAGE sequence|Addition of MRI sequence MP2RAGE
40767800|NCT04412746|DRUG|MANAGEMENT OF COVID-19|"MANAGEMENT OF COVID-19 Oxygen therapy to maintain SpO2 target more than 94%. Low molecular weight heparin (LMWH) at preventive doses. Empirical antibiotic treatment.~Specific treatment for COVID-19 (approved by Algerian Ministry of Health) First line: Hydroxychloroquin: 200 mg oral three times a day for 10 days, with association of Azithromycin 250 mg oral : 500 mg the first day and 250 mg once a day for 4 days. Sulfate de Zinc : 220 mg once a day for 5 days. Second line: Lopinavir/ritonavir capsule 200 mg/50 mg, oral 2 capsules each times, twice a day during 5 to 7 days.~IF AGGRAVATION OR CRITICAL ILL CONDITION AT PRESENTATION Increase oxygenation flow. Consider Glucocorticoids. 3. Consider the diagnosis of pulmonary embolism and treat with LMWH at therapeutic doses.~MANAGEMENT OF DIABETES Discontinue metformin. Start or adjust insulin doses according to personalized glycemic target of patient."
40767801|NCT00940121|DRUG|mirabegron|oral tablet
40767802|NCT00940121|DRUG|mirabegron|IV solution
40767803|NCT02239237|DRUG|Compound Kuh-seng Injection|Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
40767804|NCT04728230|DRUG|Carboplatin|Given IV
40767805|NCT04728230|BIOLOGICAL|Durvalumab|Given IV
40767806|NCT04728230|DRUG|Etoposide|Given IV
40767807|NCT04728230|DRUG|Olaparib|Given PO
40767808|NCT04728230|RADIATION|Radiation Therapy|Undergo consolidative thoracic radiation therapy
40767809|NCT06114368|PROCEDURE|Surgery for the treatment of Acute Achilles tendon rupture|Two different surgical techniques were applied in two different patient groups for the same disease. Their outcomes are evaluated and compared
40767810|NCT06642571|DRUG|NNC0519-0130 B|NNC0519-0130 B will be administered subcutaneously.
40767811|NCT06642571|DRUG|NNC0519-0130 C|NNC0519-0130 C will be administered subcutaneously.
40767812|NCT04254627|DRUG|Etanercept|Etanercept 50 mg weekly injection
40767813|NCT04254627|DRUG|Mifepristone|Mifepristone 300 mg pill
40767814|NCT01854775|DRUG|E/C/F/TAF|Tablets administered orally with food.
41137728|NCT01947491|DRUG|Vehicle Lotion|
41137729|NCT01947491|DRUG|Vehicle Spray|
41137730|NCT05790317|PROCEDURE|Surgical Procedure with ERAS Protocol|It covers the period before, during and after the surgery.
41137731|NCT02110407|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
41137732|NCT02110407|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
41457543|NCT02532192|DRUG|Cisplatin|Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
41457544|NCT02532192|DRUG|Cytarabine|"Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.~Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours."
41457545|NCT02532192|DRUG|Dexamethasone|Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
40767815|NCT01854775|DRUG|E/C/F/TAF (Low Dose)|90/90/120/6 mg STR administered once daily orally with food.
41137733|NCT04949399|DRUG|OnabotulinumtoxinA|Injection
40767817|NCT05305651|DRUG|Sotrovimab|Sotrovimab dose and administration per standard of clinical care
40767818|NCT05708859|DRUG|Tirzepatide|Tirzepatide 15mg Subcutaneous Solution
40767819|NCT05708859|DRUG|Placebo|Volume matched Subcutaneous Solution
41137734|NCT04949399|DRUG|Placebo|Injection
41137735|NCT03076853|OTHER|Opening of the Pharmaceutical Record|After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
41295582|NCT06272253|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg|Dose : 1 dose 0.5 ml containing 5 μg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
41137736|NCT05831566|DRUG|Budesonide/Formoterol fumarate dihydrate|"The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders."
41295583|NCT00126451|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|
41295584|NCT00126451|DRUG|Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles|
41457546|NCT02532192|DRUG|Ciprofloxacin|500 mg by mouth twice daily for 10 days.
41457547|NCT02532192|DRUG|Fluconazole|100 mg by mouth daily for 10 days.
40767820|NCT05103332|DRUG|Olmesartan|Olmesartan administered orally
40767821|NCT05103332|DRUG|Amlodipine|Amlodipine administered orally
40767822|NCT05103332|DRUG|Indapamide|Indapamide administered orally
40767823|NCT05103332|DRUG|Placebo|Placebo administered by subcutaneous (SC) injection
40767824|NCT05103332|DRUG|Zilebesiran|Zilebesiran administered by SC injection
40767825|NCT02721732|OTHER|Laboratory Biomarker Analysis|Correlative studies
40767826|NCT02721732|BIOLOGICAL|Pembrolizumab|Given IV
40767827|NCT02721732|OTHER|Questionnaire Administration|Ancillary studies
40767828|NCT06638515|OTHER|Walking apnea at Low Lung Volume|Walking apnea at low Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
40767829|NCT06638515|OTHER|Walking at normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
40767830|NCT05286619|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered on Day 1 every 3 weeks for up to 24months
40767831|NCT05286619|DRUG|Cisplatin|Cisplatin at 35 mg/m2 IV using a split dose regimen on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles.
40767832|NCT05286619|DRUG|Carboplatin|Carboplatin at AUC 5 IV on Day 1 of each 3-week cycle, up to 6 cycles.
41457548|NCT03323411|BEHAVIORAL|Advance Care Treatment Plan|subjects in experimental group are taught information on dementia mechanical ventilation tube feeding and cardiopulmonary resuscitation
40966676|NCT05423145|BEHAVIORAL|self-administered acupressure|The acupressure intervention is self-administered. The intervention group receives an app that instructs them on how to perform a stimulating acupressure protocol, consisting of six acupoints with four of the acupoints performed on both the left and the right sides of the body for a total of ten points. Each of the ten acupoints is to be stimulated for 3 minutes per point for a total treatment time of 30 minutes daily for 6 weeks.
40966677|NCT06440057|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
41137737|NCT03250793|DEVICE|Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer|While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.
41295585|NCT06447181|DEVICE|3D visualization technology ; ICG fluorescence technology .|"Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step.~ICG fluorescence technology is a fluorescent laparoscopic technology that can detect extrahepatic biliary duct misalignment, improving surgical precision and safety."
41137738|NCT01000467|DRUG|probucol|group 3: 250 mg 1 tablet in the morning and evening
41295586|NCT03977402|OTHER|Biological specimen collection|Collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.
41295587|NCT06069557|OTHER|Respiratory exercise|This group will undergo intervention. The participants will be assessed in terms of abdominal distension and shoulder pain in preoperative period. Respiratory exercise training will be given in the preoperative period. At the 1st, 2nd, 3rd, 4th, 5th, 4th, 5th, and 6th hours postoperatively, 10 deep breathing exercises will be performed in semi fowlers 45º position. During this 6-hour period, the patient will be asked to give 10 deep breaths into the incentive spirometer every 2 hours. Patients will be evaluated for abdominal distension and shoulder pain at the 1st, 2nd, 3rd, 4th, 5th, and 6th hours postoperatively and mobilization times will be measured in the first 6 hours.
41295588|NCT06469658|OTHER|The standard practice dietary supplements intervention|Participants receive supplements prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
41295589|NCT06469658|OTHER|The AI-guided practice dietary supplements group|Participants receive DS prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
41457549|NCT01529164|DRUG|Endostatins (Endostar)|7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
41457550|NCT01529164|DRUG|Oxaliplatin|85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
41457551|NCT01529164|DRUG|Leucovorin|200mg/m2 iv d1 ,repeat every 14 days
41457552|NCT01529164|DRUG|5-fluorouracil|400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
41457553|NCT00874549|BIOLOGICAL|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
40966678|NCT02792972|OTHER|A. oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
40966679|NCT02792972|OTHER|70% alcohol|70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
40966680|NCT00380952|DEVICE|Dune Device|
40966681|NCT03178903|OTHER|tDCS|Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
40966682|NCT03178903|OTHER|Sham tDCS|Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
40767833|NCT05286619|DRUG|Gemcitabine|Gemcitabine 1250mg/m2 IV on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles
40767834|NCT06045793|DRUG|TNX-1300 (Injection)|Patients will receive a single IV injection of TNX-1300.
41137739|NCT01000467|DRUG|probucol|group 1: 250 mg
40767835|NCT06045793|DRUG|Placebo (Injection)|Patients will receive a single IV injection of placebo with usual care (UC).
40966683|NCT03178903|BEHAVIORAL|Aerobic Exercise (AE)|Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
40966684|NCT02129400|DRUG|Xenon pro Anaesthesia 100 % (V/V)|Xenon-gas inhalation of indicated concentrations during indicated time
40767836|NCT06634524|DRUG|Dexmeditomidine|Patients who will receive IV infusion of (0.2 µg/kg/hr dexmeditomidine).
40767837|NCT06634524|DRUG|Normal saline|Patients who will receive IV infusion of normal saline, at the same rate of dexmedetomidine infusion.
40767838|NCT06644079|DRUG|Tranexamic acid|Participants will self-apply topical tranexamic acid to the area where their disease is located 3 times daily for 21-28 days prior to their scheduled Moh's or excision surgery.
40767839|NCT03993262|DRUG|Bortezomib|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
40767840|NCT03993262|DRUG|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
40767841|NCT05560399|DRUG|Iberdomide|Route of administration: oral pill. Schedule: Taken Once daily on days 1-21. Dose: will be tested at 1 mg, 1.3 mg, and 1.6mg. 1mg dose may be reduced to 0.75mg if not tolerated.
40767842|NCT05560399|DRUG|Elotuzumab|Route of administration: IV Dose: 10 mg/kg for cycles 1 and 2. 20 mg/kg for cycle 3 and beyond. Schedule: Days 1, 8, 15, and 22 for cycles 1 and 2. Then taken on Day 1 (every 28 days) of each cycle thereafter.
40767843|NCT05560399|DRUG|Dexamethasone|"Route of administration: Oral pill or IV Dose: 36 mg within 24 hrs of day 1 of each cycle and day 8, 15, and 22 of cycle 1 and 2.~40 mg on days 8, 15, 22 of cycle 3 and all subsequent cycles. (20 mg for \> 75 years old).~Schedule: On days that Elotuzumab is administered, Dexamethasone to be taken 28mg orally (for ≤75 years old) or 8mg orally (for \> 75 years old) between 3 and 24 hours before Elotuzumab plus 8 mg IV between 45 and 90 minutes before Elotuzumab for all patients.~On days that Elotuzumab is not administered but a dose of Dexamethasone is scheduled (Days 8, 15, and 22 of cycle 3 and all subsequent cycles), 40 mg orally for ≤75 years older and 20 mg for"
40966685|NCT02129400|DRUG|Aer medicinalis Linde 100%|
40966686|NCT00656383|OTHER|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
40966687|NCT00656383|OTHER|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
40966688|NCT01809483|DEVICE|Bandage contact lens|Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
40966689|NCT01809483|DEVICE|Pressure patching|Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
40966690|NCT02200562|DRUG|ipilimumab and dabrafenib|
40966691|NCT06296966|DRUG|VSJ-110|ophthalmic solution
41137740|NCT01000467|DRUG|probucol|group 2: 250 mg 2 tablets at once in the morning
41137741|NCT00720161|DRUG|Metformin|daily 850 mg
41137742|NCT00720161|DRUG|Placebo|placebo
41137743|NCT01366976|DRUG|Acetaminophen|Acetaminophen 1g every 6 hours for 4 doses over 24 hours
41137744|NCT05208294|DRUG|Sulpiride 400 MG|The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
41137745|NCT05208294|DRUG|Placebo|Participants receive an inactive placebo capsule.
41137746|NCT05208294|BEHAVIORAL|High expectation manipulation|Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.
41137747|NCT05208294|BEHAVIORAL|Low expectation manipulation|Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
41137748|NCT05491291|OTHER|Patients with chronic wound of the lower limbs|The rating scale will be passed at three different times, day 1, day 15 and day 75.
41137749|NCT04181099|OTHER|Implant neck surface|The biofilm formation is tested on discs manufactured of zirconia with different surfaces in vivo using orthodontic devices that the participants carry over 24h
41137750|NCT03281928|DIETARY_SUPPLEMENT|Sodium and Potassium Citrate|Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.
41295590|NCT05305638|OTHER|Exercise|Home-based physical activity programs are very important to strengthen the immune system, which is extremely important in the fight against COVID-19 infection, and to protect physical and mental health. In addition, since the pulmonary rehabilitation sessions carry a high risk of transmission, it is recommended that the program be carried out with applications such as single-session training, tele-rehabilitation or home program. Although the home pulmonary rehabilitation program is adapted to the individual, it generally includes positioning, mobilization, relaxation exercises, respiratory training, respiratory muscle exercises, upper and lower extremity exercises, walking, climbing stairs and cycling exercises. The general opinion is that telerehabilitation practices have many benefits such as increasing the quality of life and physical activity. In addition to these benefits, telerehabilitation applications come to the fore in the Covid-19 period with its complementary feature.
41457554|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
40767844|NCT02096354|DRUG|RRx-001|
40767845|NCT02096354|DRUG|Regorafenib|
40767846|NCT02096354|DRUG|Irinotecan|To be dosed after RRx-001 or regorafenib
40966692|NCT06296966|DRUG|Placebo|ophthalmic solution
40966693|NCT03330730|OTHER|IsereADOM service package|Objects connected to patients' homes (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer), Digital liaison booklet, Sentinel referent, Motivational coaching
40966694|NCT01340885|DRUG|Strattera|10-30 mg b.i.d. for 6 weeks
40966695|NCT01340885|DRUG|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
41137751|NCT03281928|DIETARY_SUPPLEMENT|Placebo|Sodium without Potassium Citrate
41137752|NCT00600353|DRUG|Palonosetron|Palonosetron 0.25 mg IV over 30 seconds
41137753|NCT00600353|DRUG|Aprepitant|Aprepitant 125 mg PO and Aprepitant 80 mg PO
41137754|NCT00600353|DRUG|Dexamethasone|Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
40767847|NCT06643468|PROCEDURE|participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and collagen membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: collagen followed by insertion of nano-crystalline putty hydroxyapatite.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
40767848|NCT06643468|PROCEDURE|participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and ALB- PRF as membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade without vertical releasing incision.~4. Implant placement with copious irrigation.~5. Membranes placement: ALB-PRF followed by insertion of nano-crystalline putty hydroxyapatite..~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
40767849|NCT06643468|PROCEDURE|participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate bone graft and collagen membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: collagen followed by insertion of eta-tricalcium phosphate + calcium sulphate bone graft.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
41295591|NCT03752853|BEHAVIORAL|internet-based intervention for mild to moderate depression|The six-weeks, therapist-guided, internet-based intervention for depression includes expressive writing tasks and further consists of key elements of cognitive behavioral therapy (CBT) for depression. In seven consecutive modules, patients receive psychoeducation and instructions for weekly tasks, and an individualized feedback letter of their therapist after each module. The intervention is effective in reducing depressive symptoms (Zagorscak et al., 2018). In the current study, patients will be randomly assigned to two different conditions with varying orders of modules: 1. patients will receive two modules (module 3 and 4) of behavioral activation, followed by two modules (modules 5 and 6) of cognitive restructuring; 2. patients will receive two modules (module 3 and 4) of cognitive restructuring, followed by two modules (modules 5 and 6) of behavioral activation. All other modules (1, 2 and 7) will be identical across conditions.
41295592|NCT02664246|DEVICE|percutaneous coronary intervention|
41295593|NCT02832726|DIETARY_SUPPLEMENT|Vitamin B12|
41295594|NCT00114114|DRUG|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day
41295595|NCT00114114|DRUG|Goserelin acetate|3.6 gms sc every 4 weeks
41295596|NCT01978912|DRUG|KTP-001|KTP-001 is one time dose intradiscally.
41295597|NCT03809065|DRUG|Nitroglycerin|Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
40767850|NCT06643468|PROCEDURE|participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate bone graft and ALB-PRF membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: ALB-PRF followed by insertion of eta-tricalcium phosphate + calcium sulphate bone graft.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing"
40767851|NCT04670484|OTHER|Wearing Mask|Participants wearing masks as per federal guidelines to prevent Coronavirus spread
40767852|NCT04547075|OTHER|Turkish validity and reliability|"1. Contact with developers and formation of steering committee~2. Translation from English to Turkish~3. Back translation from Turkish to English~4. Comparison of translation~5. Review of translated versions.~6. Reaching consensus and development of pilot version~7. Testing in clinical setting~8. Revision of pilot version~9. Testing of final version"
40767853|NCT01851798|OTHER|Home sleep test administered to all enrolled subjects|
40767854|NCT06591741|DIETARY_SUPPLEMENT|Oral PCA|PCA 1,000 mg BID until surgery, held until anticoagulation, and resumed at 1,000 mg daily for 4 years
40767855|NCT05726968|DRUG|Pilocaine 2% (1.5 ml) and 25 ug fentany|"Patients will be randomly allocated into the study groups according to the list of random numbers. The study groups will be as follows:~* Group P1 (N 15): patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).~* Group P2 (N 15): patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).~* Group P3 (N 15): patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml)."
40767856|NCT04428580|OTHER|Online FBT Training|Therapists will receive online training in Family-Based Treatment (FBT)
40767857|NCT04428580|OTHER|Webinar FBT Training|Therapists will receive webinar training in Family-Based Treatment (FBT)
40767858|NCT03934619|DEVICE|Dolores One|Dolores One, which is a will be applied personal sounds amplification device, will be used to determine if it improves the ability to communication and improves intelligibility
41295598|NCT03809065|DRUG|Labetalol|Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
41295599|NCT00092547|BIOLOGICAL|V501|0.5 mL intramuscular injection of V501
41295600|NCT00092547|BIOLOGICAL|Comparator: Placebo|0.5 mL intramuscular injection of placebo
41295601|NCT02138578|RADIATION|SBRT|
41295602|NCT02138578|RADIATION|RFA|
41295603|NCT04736524|OTHER|Rapid antibody test|Serial serology tests on day 21, 90, 180 and 365 following the first dose of the COVID-19 vaccine to detect the temporal trend of the IgM and IgG production in response to the vaccination.
41295604|NCT06497725|DEVICE|Teleguidance-facilitated Airway Management|tele-guidence will be provided by an experienced airway expert
40966696|NCT01340885|OTHER|Placebo|2-6 pills for 6 weeks
41295605|NCT05322460|OTHER|CUMACA-M Program|The CUMACA-M Program will focus on a web-based tailored intervention, using artificial intelligence, for Long-Term Survivors of Breast Cancer. It will be structured into modules related to the specific needs of LS-BS, including physical, psychological, and social needs
40767859|NCT03616340|DRUG|Shoulder injection|intra articular or subacromial shoulder injection
40767860|NCT03616340|DRUG|knee injection|intra-articular knee injection
40966697|NCT00426790|PROCEDURE|Positive end-expiratory pressure|
40966698|NCT04367428|BIOLOGICAL|Administration of probiotics|Patients will receive the previously mentioned combination of probiotics before and after surgery
40966699|NCT00393393|DRUG|intra-articular injection of Hylan G-F 20|
40966700|NCT06147739|OTHER|Temporary Anchorage Devices|intrusion
41137755|NCT01221402|DRUG|extended-release niacin (Niaspan)|Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
41137756|NCT01446640|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 1x10\^6 MSCs per kg; intrathecal administration of up to 1x10\^6 MSCs per kg.
41137757|NCT04557566|BEHAVIORAL|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
41137758|NCT04348357|OTHER|Telemedicine|A video-call application hosted by Texas Tech University Health Science Center El Paso and easily accessible from mobile phones or video-enabled PCs will be used (webex teams)
41137759|NCT04348357|OTHER|Office visit|Patient comes to the office to receive routine postoperative care
41137760|NCT05395299|PROCEDURE|SQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization|Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )
41137761|NCT04325425|DRUG|FOLFOXIRI Protocol|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
41137762|NCT04325425|DRUG|Cisplatin injection|"Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 \[the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)\];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3"
41137763|NCT03137849|OTHER|Yoga Poses|Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
41137764|NCT03137849|OTHER|Breath Control|"Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration."
41137765|NCT03137849|OTHER|Stretching exercises|Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
41137766|NCT00010868|DRUG|Omega-3 Fatty Acids|
41137767|NCT01080404|PROCEDURE|Bariatric surgery|A standardized laparoscopic gastric bypass using Roux-en-Y technique
41295606|NCT02091622|OTHER|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
41295607|NCT04339946|DIAGNOSTIC_TEST|Three-dimensional rectal water contrast transvaginal ultrasonography (3D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
41295608|NCT04339946|DIAGNOSTIC_TEST|Two-dimensional rectal water contrast transvaginal ultrasonography (2D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution.
41295609|NCT05675280|OTHER|Gluten free diet|All subjects initiated a gluten free diet as mandated by their diagnosis of Celiac disease, regardless of the study
41295610|NCT06394219|PROCEDURE|traditional transperitoneal laparoscopic pyelolithotomy|Performing anterior Pyelotomy.
41295611|NCT06394219|PROCEDURE|modified transperitoneal laparoscopic pyelolithotomy|Performing posterior pyelotomy
40767861|NCT05929313|DEVICE|OrbusNeich Scoreflex TRIO|To dilate coronary arteries during the subject's index procedure with Scoreflex TRIO Scoring PTCA catheters
40767862|NCT05929313|DEVICE|OrbusNeich Scoreflex NC|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
40966701|NCT03641274|OTHER|Case-management intervention for frequent users of the emergency department|The CM intervention to be implemented is an evidence-based practice. It consists of individualized services based on a detailed baseline evaluation using validated scales to identify all of the social and medical needs of each FUED. The CM team provides counseling and education on health care utilization, substance abuse and the social determinants of health directly to the FUEDs, using skills such as motivational interviewing and cross-cultural competences. Additionally, the CM team provides concrete services including, referral to psychiatric or substance abuse treatment, or medical services (such as a GP or medical specialist), on a case-by-case basis. Another key element of the CM intervention is to connect all health care or social service providers within the hospital or in the community, promoting continuity of care and improving the FUEDs' ability to navigate the complex health care system.
40767863|NCT06496477|DEVICE|Ayo wearable|Primary study device - the Ayo wearable which are glasses that emit either bright blue-spectrum white light or dim blue-spectrum white light or Mini motion logger AAM-32 - an actigraphy device work during the first and last week of the study on the participants wrist throughout most of the day, measuring activity. This will be used as an indicator of sleep.
41457555|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
41457556|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
40767864|NCT04538053|DRUG|Oral cefalexin only|High-dose oral cefalexin
40767865|NCT04538053|DRUG|IV cefazolin or IV flucloxacillin followed by oral cefalexin|Standard therapy of IV cefazolin or IV flucloxacillin followed by high dose oral cefalexin
40767866|NCT06503016|DRUG|Phosphocreatine|Administration of Phosphocreatine
40767867|NCT06503016|DRUG|Placebo|Saline solution of NaCl 0.9%
40767868|NCT01950520|DRUG|Propranolol|Propanolol 160mg, oral, by mouth (Cohort 1 only)
40767869|NCT01950520|DRUG|Pindolol|Pindolol 20mg, oral, by mouth (Cohort 1 only)
40767870|NCT01950520|DRUG|Dantrolene|Dantrolene 100mg, oral, by mouth (Cohort 1 only)
41137768|NCT01080404|DEVICE|Continuous positive airway pressure|The patients are given standardized CPAP treatment according to current clinical guidelines.
41137769|NCT01883609|BIOLOGICAL|RTS,S/AS01B|Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
41137770|NCT01883609|BIOLOGICAL|ChAd63 ME-TRAP|ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp
41137771|NCT01883609|BIOLOGICAL|MVA ME-TRAP|MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
41137772|NCT06340984|DRUG|Montelukast 10 Mg Oral Tablet|group modrate and severe acne will receive Montelukast therapy , dose: 10mg/day, duration of therapy: three months., Quantitively assay of level of serum intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA) in group moderate acne vs group severe acne pre Montelukast treatment and after three months of treatment vs control group
41137773|NCT06165978|BEHAVIORAL|Self-monitoring|pedometer/activity band provided to each participant
41137774|NCT06165978|BEHAVIORAL|Goal setting and review|Goal setting and review (weekly: +15% of the previous week's average daily steps or walking time, or +1000 steps/day or +10 minutes walking - to be specified)
41137775|NCT06165978|BEHAVIORAL|Education|Educational sessions (face-to-face: providing a manual/explanatory brochure of the intervention; remote: addressing symptom pathophysiology, symptom management, among other topics)
41137776|NCT06165978|BEHAVIORAL|Feedback|Daily or weekly feedback for patients (emotional/social support)
40767871|NCT01950520|DRUG|Magnesium Sulfate|Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)
40767872|NCT01950520|DRUG|Caffeine|Caffeine 200mg, oral, by mouth (Cohort 2 only)
40767873|NCT01950520|DRUG|Qsymia|Qsymia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)
40767874|NCT01950520|DRUG|Topiramate|Topiramate 200mg, oral, by mouth (Cohort 2 only)
40767875|NCT01950520|BEHAVIORAL|Phentermine|Phentermine 37.5mg, oral, by mouth (Cohort 2 only)
40767876|NCT01950520|DRUG|Naltrexone|Naltrexone 100mg, oral, by mouth (Cohort 2 only)
40767877|NCT01950520|DRUG|Mirabegron 50mg|Mirabegron 50mg, oral, by mouth (Cohort 3 only)
40767878|NCT01950520|DRUG|Mirabegron 200mg|Mirabegron 200mg, oral, by mouth (Cohort 3 only)
40767879|NCT01950520|DRUG|Placebo Cohort 1|Placebo, oral, by mouth (Cohort 1 only)
40767880|NCT01950520|DRUG|Placebo Cohort 2|Placebo, oral, by mouth (Cohort 2 only)
40767881|NCT01950520|DRUG|Placebo for Mirabegron|Placebo for Mirabegron, oral, by mouth (Cohort 3 only)
40767882|NCT04441515|DEVICE|Ipod with music|music of patient's preference provided 2 hours daily
41137777|NCT06165978|BEHAVIORAL|Contact|Contact with patients (face-to-face: for assessments; on remote: 1 -messages: for therapists' daily/weekly feedback or patient reports; 2 - calls: to adjust weekly goals or address doubts or issues)
41137778|NCT06165978|BEHAVIORAL|Exercise|Exercise based on patient preference, explaining how to identify moderate intensity (HRmax=64-76%, Borg 3-6) or vigorous intensity (HRmax=77-95%; Borg 7-8) and monitoring safety parameters (StO2\>88%, HRmax\<96%, Borg\<9)
41137779|NCT06165978|BEHAVIORAL|Report|Daily or weekly reporting for therapists (messages)
40767883|NCT04441515|DEVICE|ipod with books to listen|2 hours of daily listening to books
40767884|NCT04441515|DEVICE|ipod only with usual care|participants given device only
41137780|NCT06165978|BEHAVIORAL|Social support|Support meetings (in-person), parallel to educational sessions
41137781|NCT06165978|BEHAVIORAL|Group activities|Group activities (e.g., walking on familiar routes - parks, monumental areas, etc.)
41295612|NCT02717689|OTHER|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
41295613|NCT04964921|OTHER|Device: ANSiScope Plus|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
41295614|NCT05541692|BEHAVIORAL|Sleep Hygiene Toolkit|The sleep hygiene toolkit includes multiple resources including assistive devices (ie. eye masks and ear plugs), sensory-based tools (ie. aromatherapy, music, meditation, and breathing techniques), cognitive behavioral therapy (CBT) activities (ie. addressing anxiety and worry), and education and training on sleep hygiene.
41295615|NCT01943279|OTHER|Remote Follow-up (RFU)|Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.
41295616|NCT01943279|OTHER|Standard Follow-up (SFU)|Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
41295617|NCT02339298|OTHER|music application|music is applied during anaesthesia using headphones
41295618|NCT02339298|OTHER|only headphones|music is not applied, only headphones are placed
40767885|NCT05868811|BEHAVIORAL|Music Together|The intervention consists of 45-minute weekly classes for 16 weeks. Each class is delivered by a trained Music Together facilitator and includes music activities such as singing, dancing, moving and playing musical instruments. At the start of the program, participants receive materials for home use that consist of a song book and online access code for song recordings used in the class.
40767886|NCT05868811|BEHAVIORAL|Play Group|The play group consists of 45-minute weekly classes for 16 weeks. During each class parents are encouraged to play with their child and interact with other participants using the provided age appropriate toys. At the start of the program participants receive an age appropriate toy for use at home.
40767887|NCT01821755|BEHAVIORAL|Foster parent intervention|parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
40767888|NCT05533775|DRUG|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)
40767889|NCT05533775|DRUG|Glofitamab|"Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)"
40767890|NCT05533775|DRUG|Rituximab|Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
41137782|NCT06165978|BEHAVIORAL|World Health Organization recommendations for being physically active|World Health Organization's recommendations to maintain physical activity levels (i.e., 150-300 minutes/week of moderate to vigorous intensity physical activity; a weekly average of 10,000 steps/day or 100-120 minutes walking, which implies maintaining a pace of 100 steps/minute - corresponding to the average cadence across different age and gender groups).
40767891|NCT05533775|DRUG|Ifosfamide|Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
40767892|NCT05533775|DRUG|Carboplatin|Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
40767893|NCT05533775|DRUG|Etoposide|Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
40767894|NCT05533775|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
41137783|NCT03273894|DIAGNOSTIC_TEST|Coagulation testing|"* body temperature before the intervention~* body temperature during the intervention including the way of measuring, each 15 minutes~* body temperature at the end of surgery, signs of the patient's heat discomfort~* body temperature during resting time in the postanesthesia care~* standard coagulation tests + EXTEM, FIBTEM - after anesthesia induction~* blood sampling for standard coagulation tests (prior to the end of the surgical intervention) + EXTEM, FIBTEM.~* if body temperature is below 34°C, two sets of ROTEM tests are run: one at patient's body temperature, following by another one at a standard temperature (37°C)."
41137784|NCT05771688|DEVICE|FETO therapy|placement of FETO prior to 29 weeks 6 days GA; and removal of the FETO device no later than 35 weeks and 6 days
41137785|NCT01785056|BIOLOGICAL|Privigen|Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
41137786|NCT00606788|DEVICE|SmartCare/PS (Automated Weaning)|Patients received computer-driven protocolized weaning
41137787|NCT00606788|PROCEDURE|Conventional weaning|Patients received physician-directed non-protocolized weaning
41137788|NCT02442037|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10\^6/kg) ,once every week，a total of three times.
41137789|NCT02442037|OTHER|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
41137790|NCT01313884|DRUG|Irinotecan|50 mg/m2/day x 5 days
41137791|NCT01313884|DRUG|Vincristine|2 mg/m2 to a maximum of 2 mg
41137792|NCT01313884|DRUG|Temozolomide|100 mg/m2/day x 5 days followed by 2 weeks treatment-free
40767895|NCT06489509|DEVICE|Positive End Expiratory Pressure 5 H2O|Positive End Expiratory Pressure 5 H2O from CPAP apparatus
41137793|NCT01313884|DRUG|Doxorubicin|Starting dose 75 mg/m2 to a maximum of 450mg/m2
40767896|NCT06489509|DEVICE|Positive End Expiratory Pressure 10 H2O|Positive End Expiratory Pressure 5 H2O from CPAP apparatus
40767897|NCT04084366|DRUG|OBI-999|For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
41137794|NCT01313884|DRUG|Cytoxan|1200 mg/m2
41137795|NCT01313884|DRUG|Pegfilgrastim|6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle
41137796|NCT03985397|OTHER|discharge training|Providing planned discharge training according to the level of knowledge about diet, drug and individual monitoring compliance and cardiovascular risk factors of patients with acute myocardial infarction
41295619|NCT02339298|DRUG|a caudal block|
40767898|NCT04084366|DRUG|OBI-999|For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
40767899|NCT06152172|DRUG|KYV-101|The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
40767900|NCT06152172|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2
40767901|NCT06152172|DRUG|Fludarabine|Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)
40767902|NCT05651711|DRUG|Rocatinlimab|Rocatinlimab will be administered through a subcutaneous (SC) injection.
41295620|NCT05347589|OTHER|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range.
40767903|NCT05651711|OTHER|Placebo|The matching placebo will be administered through a SC injection.
40767904|NCT05358223|OTHER|Music|A standard music determined by us for the 1st and 4th groups will be played during the process.
41457557|NCT02556853|DEVICE|Determination of tube position by ultrasound.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
40767905|NCT05358223|DEVICE|TENS|TENS device will be connected to the 3rd and 5th groups during the process and the process will be done in this way.
40767906|NCT05126303|DRUG|RMC-035|Concentrate for Solution for Infusion
41137797|NCT03072862|DEVICE|Commercial Nucleus Cochlear Implant Systems|Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
40767907|NCT05126303|DRUG|Placebo|Concentrate for Solution for Infusion
40767908|NCT03077061|PROCEDURE|Open flap debridement|Open flap debridement using saline as irrigation
40767909|NCT03077061|DEVICE|Bone replacement graft|Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
41137798|NCT06509529|OTHER|Motivational Interviewing Based on the COM-B Model|Motivational Interviewing Based on the COM-B Model will be applied to the women in the experimental group.
41137799|NCT06193499|PROCEDURE|Platelet rich plasma (PRP)|Intra-articular injection of platelet rich plasma (PRP)
40767910|NCT00645658|DRUG|Testim, 1% testosterone gel|Subjects apply contents of gel packet (Testim, 1% testosterone gel) to skin daily.
40767911|NCT06545617|DRUG|BAT8006 for Injection|Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.
40767912|NCT06013852|DIAGNOSTIC_TEST|"processing the radiography with the Boneview software"|all X-Rays will be analysed with and without the software
40767913|NCT04411069|DRUG|Droperidol|Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol
40767914|NCT06498258|OTHER|Positive Psychotherapy Balance Model Based Psychoeducation|In this study, it can be said that adopting a loving, connected and balanced state of mind in the face of the difficulties experienced and responsibilities undertaken by caregivers will increase the joy, meaning and self-sufficiency in life and as a result, it can positively contribute to their level of well-being. All these results are important for caregivers to be able to recognise their own resources, to maintain their life balance, to develop a positive perspective towards themselves, to make subjective evaluations and to recognise their strengths.
41137800|NCT06193499|OTHER|Placebo|Intra-articular Saline injection (0,6-1ml)
41137801|NCT01053650|DRUG|Paracetamol|Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
41137802|NCT06200090|OTHER|No intervention|No intervention
41137803|NCT00299507|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
41137804|NCT00299507|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
41137805|NCT00299507|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6 month intervals
41137806|NCT04976556|DEVICE|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
40767915|NCT04054180|OTHER|CPAP associated with connected devices: blood pressure monitor , scales and activity monitor|CPAP associated with connected devices: blood pressure monitor , PROMs and activity monitor Patients will use their connected devices for one year. Data from the connected devices will be transmitted to their smartphone application Sefam Access. At the beginning of the study, patients will have a dietary assessment and start a support program for nutrition counselling and physical activity. At each study visit the dietician and physical exercise coach will give the patient advices on diet and for adjusting physical activity.
40767916|NCT06250673|DIETARY_SUPPLEMENT|Diet experiment|For the isotretinoin users
40966702|NCT00967668|BEHAVIORAL|Small change approach to improve physical activity and diet|"The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle."
40966703|NCT00967668|BEHAVIORAL|MOVE! Usual Care|The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
41137807|NCT02500082|DRUG|triheptanoin|Triheptanoin (UX007) is a medium chain triglyceride of three seven-carbon fatty acids (C7), on a glycerol backbone, with a molecular formula of C24H44O6. It is being evaluated as a substrate replacement therapy for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) and for the treatment of seizures associated with Glut 1 DS. Triheptanoin is metabolized to provide substrate replacement for both fatty acid metabolism and anaplerosis (replacement of TCA cycle intermediates) required to restore the efficient generation of energy and the net production of glucose in patients. The mechanism of action of triheptanoin in restoring energy metabolism is dependent on its medium-chain length as well as its odd-carbon properties. Triheptanoin is a highly purified form intended for oral administration.
40767917|NCT02626884|DRUG|Ibrutinib|
40767918|NCT04767048|PROCEDURE|bilateral mucosectomy + tonsillectomy|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
40767919|NCT04767048|PROCEDURE|tonsillectomy|tonsillectomy (unilateral or bilateral at the choice of the investigator)
40767920|NCT06456346|DRUG|Bomedemstat|Oral capsule
40767921|NCT06456346|DRUG|Hydroxyurea|Oral capsule
41137808|NCT03836885|DRUG|Apremilast|Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.
41137809|NCT03836885|DRUG|Placebo|Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
41137810|NCT05953909|DRUG|Eribulin-Based Regimen|Eribulin Mesylate will be administered as a 1.4 mg/m\^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
41457558|NCT02556853|OTHER|Determination of tube position by auscultation.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
41457559|NCT06036550|DIAGNOSTIC_TEST|Doppler ultrasound measurement|Doppler sonographic assessment of the uterine artery was performed transabdominally. Patients underwent six sets of Doppler ultrasounds measurements of both right and left uterine artery.
40767922|NCT06456346|DRUG|Bomedemstat placebo|Oral capsule placebo
41457560|NCT00139815|DRUG|Fondaparinux|fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable
41457561|NCT00139815|DRUG|enoxaparin|enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
40767923|NCT06456346|DRUG|Hydroxyurea placebo|Oral capsule placebo
40767924|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose A|Dose A, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
40767925|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose B|Dose B, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
40767926|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose C|Dose C, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
40767927|NCT06194656|OTHER|HER3 Monoclonal antibodies-Dose D|The optimal recommended dosage (RP2D) of SIBP-03intravenous, infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
40767928|NCT06194656|OTHER|Placebo|SIBP-03 solvent without HER3 antibody, intravenous infusion (IV), once every one weeks, 21 days as a cycle.
40767929|NCT06194656|COMBINATION_PRODUCT|Cetuximab injection|Medications used for combination therapy, intravenous infusion (IV). Administer once a week.
40767930|NCT00610220|DEVICE|Fiberglass short arm cast|Cast will be applied for a 4-week period
40767931|NCT00610220|DEVICE|Prefabricated wrist splint|Splint will be applied for a 4-week period
40767932|NCT06624995|OTHER|chatbot education|elderly patients interacted with Chatbot to discuss general postoperative complication related inquiries
40966704|NCT01101503|DRUG|Intensive multifactorial group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~1. For blood glucose control, target HbA1c \>=5.5%and \<=6.0%,fasting blood glucose \>=5.0 mmol/L and \<=6.0 mmol/L, postprandial 2 hour glucose \>= 6.0 mmol/L and \<= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \< =1.9 mmol/L, triglyceride \< =1.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>=120/70 mmHg and \<= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin."
40767933|NCT06570655|DRUG|Huperzine A injection|intramuscular
40767934|NCT06570655|DRUG|Huperzine A injection|intravenous bolus
40767935|NCT06305429|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 6 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. They will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
40767936|NCT06569446|OTHER|There is no intervention. This a qualitative study to explore barriers to rectal irrigation|"This will involve semi-structured, open-ended questions about hypothesized barriers to rectal irrigation where the interviewer will ask a pre-determined number of questions and the participants will answer which will further initiate discussion allowing new themes to emerge. After the entire list of barriers is discussed, participants will be asked if they have any new barriers to add which have not been discussed. All new barriers identified will be added to the hypothesized barriers list for the next focused group sessions. Focused group sessions will continue until no new barriers are found in two consecutive sessions (thematic saturation).~9.2 Phase - 2 includes Cognitive Interviews This will involve semi-structured, open-ended questions about barriers to rectal irrigation identified during focused group sessions where the interviewer will ask pre-determined number of questions for individual participants to answer."
40767937|NCT06602011|COMBINATION_PRODUCT|TACE, Lenvatinib, combined with Tislelizumab group|TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Tislelizumab (200mg administered intravenous injection on Day 1 of each 21-day cycle). After the triple therapy, surgical resection is an option if assessed by the investigator to be feasible, or continued until disease progression or intolerable if not.
40767938|NCT06060535|BEHAVIORAL|Suicide Attempt Risk Model Care Pathway|The suicide attempt risk model uses documented histories of medical and psychiatric diagnoses, medications, and health service utilization to predict risk of a suicide attempt in the 90 days following an outpatient visit in behavioral health clinics.
41457562|NCT03673514|PROCEDURE|Total hip arthroplasty|Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
40767939|NCT04943679|DRUG|Anti-PD-1/PD-L1|Intravenous injection for up to 2 years
40767940|NCT04943679|DRUG|PEG-Interferon Alfa|3 µg/kg every week by subcutaneous injection for up to 2 years
40767941|NCT06313593|DRUG|INCB160058|Oral; Tablet
40767942|NCT04111354|DEVICE|Pacemaker implantation|Pacemaker implantation
40966705|NCT01101503|DRUG|conventional multifactorial therapy group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~1. For blood glucose control, target HbA1c \>6.5%and \<=7.0%,fasting blood glucose \>6.0 mmol/L and \<=7.0 mmol/L, postprandial 2 hour glucose \> 7.8 mmol/L and \<= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \> 1.9 mmol/L and \< =2.5 mmol/L, triglyceride \> 1.5 mmol/L and \< = 2.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>130/80 mmHg and \<= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin."
41137811|NCT05953909|DRUG|nab-paclitaxel based regimen|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.
41137812|NCT05953909|DRUG|Other Chemotherapy Regimen|"TX：Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m\^2, BID D1-14, Q3W.~GP:Gemcitabine 800-1000mg/ m\^2, D1,8 Q3W+Cisplatin 75mg/m\^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m\^2 D1 Q3W)~T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)"
41457563|NCT04358627|DRUG|Dexmedetomidine Injectable Product|continuous intravenous infusion of dexmedetomidine
41457564|NCT00668577|DRUG|Lactic acid (Dermacid)|
41457565|NCT00387205|DRUG|Pazopanib|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
41457566|NCT03618615|BIOLOGICAL|artericitc surgery|biological sample (leg) from leg amputation surgery used for research
40767943|NCT06596187|PROCEDURE|Continuous passive motion device (CPM) of ankle - fast|Continuous passive motion device (CPM) of ankle at 1HZ(60rpm) for 10 repetitions
40767944|NCT06596187|PROCEDURE|Continuous passive motion device (CPM) of ankle - slow|Continuous passive motion device (CPM) of ankle 0.25HZ (15rpm) for 10 repetitions
41457567|NCT05948072|DRUG|mFOLFOX6 + Cetuximab|Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
41457568|NCT05948072|DRUG|mFOLFOX 6|mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
41457569|NCT01942278|OTHER|BHOMA|A complex health systems, clinical care, and community intervention to improve outcomes
40966706|NCT04193332|DEVICE|NIR optical imaging camera|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery using parathyroid gland autofluorescense
40966707|NCT05651997|PROCEDURE|MACT|"* A biopsy of healthy cartilage is taken from a non-weight bearing area of the knee joint during an arthroscopic procedure.~* The biopsy is processed in the GMP accredited laboratory to isolate and amplify chondrocytes.~* The cells are seeded and cultured on a collagen matrix (Chondro-Gide®, Geistlich Pharma)~* The membrane is implanted and sutured onto the injured site."
41295621|NCT05347589|OTHER|post isometric relaxation of the Quadratus lumborum|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
41295622|NCT00841295|DRUG|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
41295623|NCT00841295|DRUG|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
41295624|NCT04670146|DIAGNOSTIC_TEST|ultrasound of the masseteric muscle|Ultrasound of the masseteric muscle to evaluate the thickness and rigidity of the masseteric muscle before and after oral cancer treatment. There will be no invasive investigation of the muscle.
41295625|NCT01448551|BEHAVIORAL|Tailored Mobile Messages to Enhance Weight Loss for Teens|For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
41295626|NCT00377065|DRUG|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
41295627|NCT04497220|BEHAVIORAL|Negative Connotation Langauge|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The control script includes language containing the wording Poke and a burn said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
40966708|NCT05651997|PROCEDURE|AMT|This treatment combines the microfracture procedure with the application of a bilayer matrix of porcine type I/III collagen (Chondro-Gide, Geistlich Pharma) and the supplementation of autologous bone.
40966709|NCT04298801|PROCEDURE|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing|"A self-administered questionnaire on HIV exposure factors will be offered to all patients of ages 18-64 able to complete it. This questionnaire will be available in a paper-based format, electronic format on the patient phone or can be conducted verbally by the nurse. According to the answers, the nurses will suggest performing a rapid test to patients belonging to key populations. A finger-stick rapid HIV test will be performed and results will be disclosed by the nurse assisted by a physician if necessary.~If needed, a follow-up visit with an infectious disease specialist will be scheduled within 72 hours."
41137813|NCT05484336|OTHER|Glucose as reference food|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose diluted in 250ml, tested two times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
41137814|NCT05484336|OTHER|Beverage containing 4g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 4g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
41137815|NCT05484336|OTHER|Beverage containing 6g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 6g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
41457570|NCT05056519|BIOLOGICAL|Live Attenuated Influenza Vaccine|Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
41457571|NCT05056519|BIOLOGICAL|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
40966710|NCT04298801|OTHER|Physician-directed diagnostic testing|Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.
40966711|NCT00996645|OTHER|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
40966712|NCT05719766|OTHER|education ,psycological support and social support|we would give targeted-education according to our patients' need(reflected via questionnaire; we would provide psycological and social support to patients based on their need reflected by questionnaire
40966713|NCT00192556|BEHAVIORAL|food|
40966714|NCT00892762|DRUG|Travoprost APS 40 micrograms/ml eye drop solution|non-BAK (benzalkonium chloride) medication
40966715|NCT00892762|DRUG|Latanoprost 50 micrograms/ml eye drop solution|BAK-preserved medication
40966716|NCT02779829|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number SR15-40-Z12-006.
40966717|NCT00171353|DRUG|valsartan|
40966718|NCT05041205|DIETARY_SUPPLEMENT|Beauty drink powder|Beauty drink powder is designed as a oral beauty product to provide benefits to skin
40966719|NCT05041205|DEVICE|Cosmetic apparatus|This device is designed to let participants to experience brighter, softer, smoother skin and an energizing facial massage. A synergestic effect when combine with beauty drink powder is expected.
40966720|NCT03706079|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
40966721|NCT03706079|OTHER|Placebo|Placebo subcutaneous injection
40966722|NCT01156870|DRUG|SAR566658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
40966723|NCT04546815|DRUG|Daptomycin|According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
40966724|NCT06214338|DIETARY_SUPPLEMENT|Low dose|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 2.5, separated by 1 hour and 15 min.
40966725|NCT06214338|DIETARY_SUPPLEMENT|High dose|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 5 separated by 1 hour and 15 min.
40966726|NCT05477056|OTHER|PrecivityAD blood test|Clinician Survey post receipt of PrecivityAD blood test result
40966727|NCT00802139|DRUG|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
40966728|NCT00802139|DRUG|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
41457572|NCT06017427|OTHER|Questionnaires|Submission of several questionnaires (Quality of Life and clinical scores) at three time points: before initiation of Dupilumab, after 6 months of Dupilumab treatment, and 6 months after stopping Dupilumab treatment
40966729|NCT04906291|OTHER|Toothpaste use|Brushing three times a day
40966730|NCT06268002|DIETARY_SUPPLEMENT|Vernonia cinerea|Vernonia cinerea is an herb that is claimed in many Thai medicinal formulas. In traditional medicines, they use this herbal to treat diseases such as hypertension, asthma, fever, hepatitis, gallstones, including use to help smoker quit smoking.
40966731|NCT06268002|DIETARY_SUPPLEMENT|Placebo|Sweetener
40990723|NCT05270681|OTHER|Movement to Music|Participants will be educated on how to access prerecorded Move to Improve classes conducted by a professional dance instructor which will be accessible by computer or tablet 24/7 via a hyperlink. Classes last 45 minutes, and participants will be instructed to participate in the activity at least twice weekly, for 12 weeks. Each class uses movement to music combinations across different dance genres that build in intensity and sequence complexity, accompanied by music with faster beats, to encourage participants to achieve a moderate-vigorous level of physical and cognitive activity. Care partners will be present during each class to ensure safety and will also participate in the Move to Improve exercise program. The care partner and participant will be instructed to stand at a counter or behind a chair for safety during exercise.
40990724|NCT02105610|DRUG|desflurane, isoflurane, sevoflurane|
40990725|NCT02105610|DRUG|total intravenous anesthetics|
40990726|NCT00087711|DRUG|pemetrexed|500 mg/m2, IV q 21 days x 6 cycles
41295628|NCT04497220|BEHAVIORAL|Positive Connotation Language|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The experimental script includes language containing the wording this is numbing medication, which will make the rest of the procedure go easier said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
41137816|NCT05484336|OTHER|Beverage containing 8g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
41137817|NCT00254124|DEVICE|The Diet Plate (R) TM portion control plate and bowl|
41137818|NCT02827201|DRUG|FOLFIRI.3|For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)
41295629|NCT03893929|DIAGNOSTIC_TEST|New Biological markers for prostate cancer diagnosis and management|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
41457573|NCT03226613|PROCEDURE|Transcervical Oropharyngeal Ultrasound|One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.
41457574|NCT03226613|PROCEDURE|Oral Rinse Collection|Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit. The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds. The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.
41457575|NCT03226613|PROCEDURE|Blood Draw|A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
41457576|NCT03488108|OTHER|Platelet Rich Plasma|Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.
41457577|NCT03488108|DRUG|Minoxidil Foam|Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.
41137819|NCT02827201|DRUG|nab-paclitaxel+ gemcitabine|For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.
41137820|NCT04883957|DRUG|BGB-11417|Film-coated tablets administered orally as specified in the treatment arm.
41137821|NCT02120807|DRUG|Certolizumab|
41295630|NCT06014827|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40990727|NCT00087711|DRUG|gemcitabine|1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles
40990728|NCT00087711|DRUG|cisplatin|75 mg/m2, IV, q 21 days x 6 cycles
41137822|NCT02120807|DRUG|cisplatin|
41295631|NCT06014827|PROCEDURE|Computed Tomography|Undergo CT or PET/CT scan
41295632|NCT06014827|DRUG|Osimertinib|Given PO
41457578|NCT05683808|DRUG|Apixaban|Open label
41457579|NCT00687206|DRUG|Valsartan 160mg plus HCT 25mg|valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
41457580|NCT03750357|DEVICE|Primary Relief v 2.0|To prove the effectiveness of Post Operative Pain Solution using Primary relief v 2.0 by Percutaneous Electrical Nerve Stimulation in the auricle.
40990729|NCT03686410|BEHAVIORAL|Web-based Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
41137823|NCT02120807|DRUG|pemetrexed|
41137824|NCT02318810|DRUG|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
41137825|NCT02318810|DRUG|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
41137826|NCT02318810|DRUG|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
41137827|NCT02318810|DRUG|Placebo|Patients receive saline
41295633|NCT06014827|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41137828|NCT02169414|DRUG|BIA 9-1067 5 mg|OPC, Opicapone
41295634|NCT06014827|RADIATION|Stereotactic Body Radiation Therapy|Undergo BgRT/SBRT
40767945|NCT06534775|OTHER|Questionnary|"The patients were included in a previous study (PABLOS) - These patients received locoregional anesthesia (LRA) by deep parasternal intercostal block (Deep-PIP) or bilateral superficial parasternal intercostal block (Superficial-PIP), compared with standard management (general anesthesia without LRA) for chronic postoperative pain after cardiac surgery by sternotomy.~In PABLOS 2.0 study, the evaluation focuses on the presence of chronic pain between 12 and 24 months postoperatively. There is no intervention in PABLOS 2.0 study but only a questionnary."
40767946|NCT03569891|GENETIC|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
40767947|NCT03569891|BIOLOGICAL|Factor IX (FIX)|During the lead-in phase, which lasted for a minimum of 26 weeks (i.e., ≥6 months), subjects recorded their use of FIX replacement therapy and bleeding episodes in their dedicated e-diary.
40767948|NCT05398003|DEVICE|Implantation of the WAVEWRITER ALPHA ™ device|"The 12 patients will be implanted by the WAVEWRITER ALPHA ™ device. Then, the order of the three stimulation modes will be randomly selected and will be composed of 5 modalities:~* tonic stimulation LF: In tonic mode, the electrical stimulation of the sensory fibres of the posterior cords of the spinal cord induces local paresthesias~* high frequency stimulation (1000 Hz) High Frequency.~* stimulation in bursts (or Burst)"
40767949|NCT03423979|DEVICE|Optilume™ BPH Prostatic DCB Dilation Catheter|BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
40767950|NCT03423979|DRUG|Paclitaxel|paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
41137829|NCT02169414|DRUG|BIA 9-1067 25 mg|OPC, Opicapone
41137830|NCT02169414|DRUG|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
40767951|NCT01141764|PROCEDURE|Positron Emission Tomography (PET) Scan|"The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.~This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days."
40767952|NCT01141764|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
40966732|NCT04678661|DEVICE|Smartphone application and web portal|"My Dose Coach is indicated for single patient use outside the clinic setting by a previously diagnosed Type 2 Diabetic who has been prescribed a once-daily long-acting basal insulin. MDC is intended as an aid to the patient to provide dose suggestions based upon the HCP's independent professional judgment. Before My Dose Coach can be used, the HCP configures the dose instructions for the specific patient and activates the application using the specific patient Instructions. The application uses the dose plan instructions provided by the patient's HCP to provide dose suggestions of once-daily long-acting basal insulin (i.e. basal insulin titration) that are based on the patient's Fasting Blood Glucose (FBG) as well as hypoglycemia occurrence.~MDC includes a Maintenance Module designed to support patients in maintaining proper insulin dosingby enabling logging of administered doses of prescribed diabetes medications and BGM and providing dosing and measurement reminders."
40966733|NCT04678661|BEHAVIORAL|Standard Insulin Therapy Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
40966734|NCT05636683|PROCEDURE|Root surface debridement|subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
41137831|NCT02169414|DRUG|Placebo|PLC, Placebo
41137832|NCT02169414|DRUG|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
41137833|NCT00145145|BIOLOGICAL|MAGE-3.A1 peptide and CpG 7909|
41295635|NCT06014827|OTHER|Survey Administration|Ancillary study
41457581|NCT05276219|DRUG|Furosemide Injection|A diuretic (iv furosemide) strategy for decongestion in acute heart failure
41295636|NCT01512524|OTHER|MRI scan and endocrinology analysis|Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
41295637|NCT00602862|DRUG|Sorafenib|Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
41457582|NCT05276219|DRUG|Isosorbide Dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure
41457583|NCT05276219|DRUG|Furosemide and isosorbide dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
41457584|NCT05536960|OTHER|68Ga-Dotatate PET/CT|One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
41457585|NCT00393705|DRUG|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
41457586|NCT00393705|DRUG|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
41295638|NCT00602862|DRUG|111Indium-bevacizumab|100 MBq / 1 mg 111Indium/bevacizumab iv
41295639|NCT00602862|DRUG|111Indium-cG250|100 MBq / 10 mg 111Indium-cG250 iv
41457587|NCT00393705|DRUG|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
41457588|NCT00393705|DRUG|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
41295640|NCT00258154|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
41295641|NCT00258154|BIOLOGICAL|Comparator: placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
41295642|NCT00258154|BIOLOGICAL|Comparator: Infanrix(tm) Hexa|3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
41295643|NCT04183257|DRUG|oral vitamin D|oral Vitamin D 400IU will be given and will be escalated every 2 weeks.
40767953|NCT01141764|OTHER|Neuropsychological Testing|"On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on."
40767954|NCT06589128|DIETARY_SUPPLEMENT|Astaxanthin Oral Capsule|Once daily supplementation of oral astaxanthin capsule for 24 weeks
40767955|NCT06589128|DIETARY_SUPPLEMENT|Placebo|Once daily supplementation of olive oil capsule for 24 weeks
41295644|NCT00546819|BIOLOGICAL|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
41295645|NCT00546819|BIOLOGICAL|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
41295646|NCT03153397|OTHER|Nutraflora scFOS|prebiotic fiber (Nutraflora scFOS via Vital AF)
41295647|NCT03153397|OTHER|Osmolite|non-prebiotic fiber containing formula (Osmolite)
41295648|NCT02658162|DRUG|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
40767956|NCT00404911|BEHAVIORAL|MFG therapy|MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.
40767957|NCT00404911|BEHAVIORAL|Standard of Care|Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
40767958|NCT06504966|DRUG|MAB-22|Single subcutaneous dose of 60 mg
40767959|NCT06504966|DRUG|Prolia®|Single subcutaneous dose of 60 mg
40767960|NCT05864469|OTHER|12-week psychosocial dyadic intervention|Comprising six weekly 60-min telephone-based sessions, followed by two weekly and two bi-weekly telephone follow-ups.
40767961|NCT05509127|DRUG|Modified universal adhesive|Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
40767962|NCT05509127|DRUG|Conventional universal adhesive|Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
40767963|NCT02678377|DRUG|OnabotulinumtoxinA (Botox ®) Injections|OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
40767964|NCT02678377|DRUG|Saline Injections|Saline will be injected into the bladder so that investigators are masked to subject randomization.
40767965|NCT03692052|DRUG|AG-348|AG-348 tablet orally BID
40966735|NCT04235985|COMBINATION_PRODUCT|Chlorhexidine Gluconate with HUBS|4% CHG soap will be applied to HUBS following manufacturers recommendation and applied to skin for different application times as dictated by the randomization of the marked sites on the forearm. Followed by a HUBS moistened with water.
41295649|NCT02658162|DRUG|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
40767968|NCT05044819|DRUG|Cannabidiol|Oral Cannabidiol solution 100 mg/mL
40767969|NCT05166499|DIETARY_SUPPLEMENT|Hydroxy Methyl Butyrate|Hydroxy Methyl Butyrate
40767970|NCT05166499|DIETARY_SUPPLEMENT|Balanced Amino Acids|Balanced Amino Acids
41295650|NCT00546858|OTHER|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
41295651|NCT06336824|DRUG|Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid|"The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group."
40767973|NCT00802503|DIETARY_SUPPLEMENT|SPN|SPN : in the treated group, SPN is started if at day 4 energy input by EN is \< 60% of energy target in order to reach 100% of energy target by peripheral or central line.
41295652|NCT06336824|DRUG|IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline|"The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group."
41295653|NCT01732263|DRUG|SSP-004184|All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
41295654|NCT00803088|DEVICE|The Alair System|Treatment of airways with the Alair System
41295655|NCT01167595|OTHER|PEP uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
41457589|NCT06361238|DRUG|Liraglutide injection|Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
40767974|NCT06440538|DEVICE|PCMS + Contralateral Motor Training|PCMS + Contralateral Motor Training will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2 Hz) to the weaker first dorsal interosseous (FDI) muscle immediately before a session of ballistic index finger abduction training at the opposite, stronger FDI muscle.
40767975|NCT06440538|DEVICE|PCMS + Rest|PCMS + Rest will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2Hz) to the weaker FDI followed by a 30-min rest.
40767976|NCT06440538|DEVICE|Sham PCMS + Contralateral Motor Training|360 TMS pulses will be delivered at a location 10-cm posterior to the participant's head (into the air, 0.2Hz) and no PNS pulses will be generated, followed by a session of 30-min ballistic index finger abduction training at the opposite, stronger FDI muscle.
40767977|NCT03914833|OTHER|Inclusion Questionnaires|During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
40767978|NCT03914833|OTHER|Questionnaires at inclusion, M1 and M3|During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
40767979|NCT04603560|BEHAVIORAL|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
40767980|NCT04603560|BEHAVIORAL|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
40767981|NCT01765413|BIOLOGICAL|Varicella-zoster virus|
40767982|NCT01765413|BIOLOGICAL|Yellow Fever Vaccine|
40767983|NCT01765413|BIOLOGICAL|Placebo|
40767984|NCT02082379|BEHAVIORAL|inhaled normal saline using different interfaces.|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
40767985|NCT04474873|PROCEDURE|erector spinae block|we administer 15 cc of 0.5% bupivacaine between the erector spine muscle and the transverse process. The distribution of bupivacain was observed on ultrasound.
40767986|NCT04336969|BEHAVIORAL|4T Education and Care|CGM data will be used to create customized weekly feedback to the participant/family by secure MyChart message.
40767987|NCT06602128|BEHAVIORAL|Experimental: Breathing Exercise Application Group|The Effect of Breathing Exercise on Anxiety, Pain and Life Findings in Patients Undergoing Coronary Angiography
40767988|NCT03014258|BIOLOGICAL|NF54 P. falciparum malaria challenge|Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
40767989|NCT05549622|OTHER|Low-soluble fiber diet|12 older adults (\>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet
40767990|NCT05549622|OTHER|High-soluble fiber diet|12 older adults (\>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
40767991|NCT05065216|DRUG|Recombinant human tissue kallikrein|Treatment is completed by week 3 (Day 21). After dosing is complete, participants will be followed up by the investigator at approximately 30 and 90 days after their first dose.
40767992|NCT04279067|DEVICE|BCI-FES dorsiflexion therapy|"BCI technology enables direct brain control of external devices such as assistive devices and prostheses by translating brain waves into control signals. When BCI systems are integrated with functional electrical stimulation (FES) systems, they can be used to deliver a novel physical therapy to improve movement after stroke. The automated software will analyze the data to generate and calibrate a BCI decoder. In the online phase, the subjects will perform 20-25 BCI-FES runs. In each run, subjects will follow 10 alternating epochs of 10-s long idling/dorsiflexion textual cues, and respond by either idling or attempting dorsiflexion to elicit BCI-FES mediated contractions of the TA muscle."
40767993|NCT04279067|BEHAVIORAL|Physiotherapy one hour|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
40767994|NCT04279067|BEHAVIORAL|Physiotherapy two hours|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
40767995|NCT03231735|DEVICE|Mid frequency ventilation|Mechanical ventilator used at rates \> 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
40767996|NCT03231735|DEVICE|Standard frequency ventilation|Mechanical ventilator used at rates \< 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
40767997|NCT06614582|DEVICE|Self-Supporting Nasopharyngeal Airway (ssNPA)|"The ssNPA device is a flexible, medical-grade silicone, nasal tube that is self-inserted into the airway through one nostril and worn during the night. It can also be used during the day. The device works by supporting collapsed airway muscles and keeping the airway open.~In addition to wearing the device, study team members will call monthly and collect certain data, and medical information and participants will be asked to have a sleep study at the 12-month visit."
40767998|NCT06201611|DRUG|Nebivolol+ Standard care arm|This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24
40966736|NCT01815216|PROCEDURE|Bariatric surgery|Gastric bypass surgery
40966737|NCT01815216|BEHAVIORAL|Brain activity in resting state|Measure of activity in brain networks during resting state
40966738|NCT01815216|BEHAVIORAL|Memory performance|"Assess concentration in 2D-location task (i.e. memory game)"
40966739|NCT01132430|BEHAVIORAL|Motivational interviewing|Brief MI 3x30 minute sessions within 4-6 week period
40966740|NCT01132430|BEHAVIORAL|Usual care|Standard medical care within 4-6 week period
40966741|NCT00277147|DRUG|BB IND 6989|
41295656|NCT02088216|DRUG|N-acetylcysteine|600mg po twice a day for 12 months
41295657|NCT02088216|OTHER|On-demand treatment|receive as-needed therapy
41295658|NCT04524936|DIAGNOSTIC_TEST|blood sample|
41295659|NCT00576693|DEVICE|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl).
41457590|NCT06361238|DRUG|Placebo injection|Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
41457591|NCT00862563|DRUG|Topiramate|Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.
41457592|NCT00862563|DRUG|Zonisamide|Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.
41457593|NCT00862563|DRUG|Levetiracetam|Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.
41457594|NCT00862563|DRUG|Sugar Pill|Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
41457595|NCT00002923|DRUG|KRN5500|
40966742|NCT00488176|DRUG|montelukast|montelukast sodium
40966743|NCT00488176|DRUG|cetirizine|cetirizine
40966744|NCT00488176|DRUG|montelukast and cetirizine|montelukast and cetirizine
40966745|NCT00488176|DRUG|placebo|placebo
40966746|NCT02637739|DEVICE|hysteroscope|Women of PUL with β-hCG \> 1000 IU/L or abnormal β-hCG trend (increase \< 66% or decrease \< 15%) were offered HSC.
41295660|NCT00576693|OTHER|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl)
41295661|NCT06037538|DIAGNOSTIC_TEST|blood glucose measurement by subject|blood glucose measurement by subject using finger tip capillary blood
41295662|NCT06037538|DIAGNOSTIC_TEST|blood glucose measurement with reference|blood glucose measurement with reference method using finger tip capillary blood
41457596|NCT03145987|DIETARY_SUPPLEMENT|Vitis vinifera extract|
41457597|NCT03145987|OTHER|Placebo|
41457598|NCT00966628|DRUG|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
40966747|NCT02688205|OTHER|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
40966748|NCT02688205|DEVICE|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
40966749|NCT02019329|OTHER|Placebo|Oral daily administration from Days 1-12
40966750|NCT02019329|DRUG|RO5545965|Oral daily administration from Days 1-12
40966751|NCT02019329|DRUG|risperidone|13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.
41295663|NCT05846386|BEHAVIORAL|Resistance training|moderate-intensity resistance training: three sessions per week for one month. Participants had been instructed to perform exercises at a 4:2:4 tempo; that is, four sets of concentric contraction, two sets of isometric hold, and four sets of eccentric contraction. Participants had been instructed to complete a single set until volitional fatigue or been instructed to stop by the physiotherapist when the technique falters
41295664|NCT05846386|BEHAVIORAL|Aerobic training|"The exercise program consisted of ten minutes warm-up, 45 minutes of moderate aerobic exercises upper extremity aerobic bulk muscles training and arm ergometer and cool-down in five minutes, respectively. That was done as 3 sessions/week for 4 weeks."
40966752|NCT02933047|PROCEDURE|Total laparoscopic hysterectomy|
40966753|NCT02933047|PROCEDURE|Total laparoscopic hysterectomy|
41295665|NCT03864172|DIETARY_SUPPLEMENT|Usual intake + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice
41295666|NCT03864172|DIETARY_SUPPLEMENT|Usual intake+SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)
40767999|NCT06201611|DRUG|Epalrestat + Alpha Lipoic Acid +Standard care|This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.
40966754|NCT03706456|BIOLOGICAL|Darvadstrocel|Darvadstrocel cell suspension for intralesional injection.
41137834|NCT06465537|GENETIC|BD113vVLP|CRISPR/Cas9 gene editing technology, called BD113vVLP (also BD113 virus-like particle) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down the mutated MYOC gene. The BD113vVLP is administrated by intracamerally injecton (sigle-dose: 4ug/p24) for each target interventional eye.
41137835|NCT00738348|DRUG|sivelstat|sivelstat sodiumhydrate
41137836|NCT00738348|DRUG|glucose|glucose
41137837|NCT04252157|OTHER|Kinesiotaping|Kinesiotape will be applied to the group. During the orbicularis oris muscle, I tape will be applied around the lip with a mechanical correction technique with 50-75% tension. I tape will be applied just below the Hyoid with a 50-75% tension mechanical correlation technique.
41137838|NCT04252157|OTHER|Plesebo Taping|An approximately 5 cm I tape will be applied to the group without applying any tension to the temporomandibular attachment for placebo taping.
40966755|NCT00787852|DRUG|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily~Maintenance x 2 years\*"
40966756|NCT00787852|DRUG|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily Maintenance x 2 years\*"
40966757|NCT02326532|OTHER|PRO data utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
40966758|NCT02326532|OTHER|PRO data not utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
41137839|NCT04252157|OTHER|Control|no kinesio or tape will be applied
41137840|NCT01138657|BIOLOGICAL|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
41137841|NCT01138657|DRUG|Prednisone|Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
41137842|NCT01138657|DRUG|Placebo|Administered by subcutaneous injection
41137843|NCT05330000|DRUG|4 mg/kg Voriconazole|Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
41295667|NCT03864172|DIETARY_SUPPLEMENT|Adequate calcium + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI
41295668|NCT03864172|DIETARY_SUPPLEMENT|Adequate calcium+ SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI
40768000|NCT06201611|DRUG|Standard care alone|Patients in this arm will receive standard care as judged by their treating physicians which is generally pain modifying treatment.
41137844|NCT05330000|DRUG|6 mg/kg Voriconazole|High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
40966759|NCT03523897|PROCEDURE|Robot Assisted Total Knee Replacement|A robotic-assisted surgical procedure to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
40966760|NCT03523897|PROCEDURE|Traditional Total Knee Replacement|A surgical procedure using mechanical guides to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
40966761|NCT03626883|PROCEDURE|single-bundle, single-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with single hamstring tendon
40966762|NCT03626883|PROCEDURE|single-bundle, double-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with 2 hamstring tendons
40966763|NCT03619954|BIOLOGICAL|NK cells infusion|"Pretreatment：patients enrolled in this study will receive 20 mg/kg of cyclophosphamide for solid tumor or 20-60 mg/kg of cyclophosphamide for hematological tumor once daily for 3 times. NK cells infusion is allowed within 2-14 days after treatment.~NK cells infusion：30-60 minutes before infusion，ant-allergic agents are applied (promethazine 25mg,i.m. ; Cimetidine 0.4g i.v. ; diphenhydramine 50mg po.). NK cells are intravenously infused into patients with 15-30 minutes every other day for one to three times. The number of every infused NK cells is 1-3×10\^7/kg, counted as the number of CD56+ cells. Patients with severe pleural or ascites can also receive pleural or abdominal cavity perfusion simultaneously. The total number of infused NK cells is no more than 5×10\^9 cells. 4 hours after NK cells infusion，IL-2 is applied every other day for six times"
40966764|NCT02284984|DRUG|Rituximab with belimumab|Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
40966765|NCT04077268|OTHER|GOS-E|Call at 7 days, patients add a brain trauma to know their sequeals
40966766|NCT00953901|DRUG|Fresh Frozen Plasma Transfusion|
40966767|NCT00064337|BIOLOGICAL|filgrastim|
40966768|NCT00064337|DRUG|cyclophosphamide|
40966769|NCT00064337|DRUG|dexamethasone|
40966770|NCT00064337|DRUG|melphalan|
40966771|NCT00064337|DRUG|thalidomide|
40966772|NCT00064337|PROCEDURE|peripheral blood stem cell transplantation|
40966773|NCT02550990|BEHAVIORAL|Cognitive training|
41137845|NCT04153786|OTHER|Temporary changes in an already-implanted medical device (biventricular pacemaker)|"During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD.~The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD.~However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits."
41137846|NCT05480540|BEHAVIORAL|Serious game|According to the curriculum, as of the third week, a serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which is prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group as of the third week. Students would be informed that they could use the application for two weeks whenever they wanted and as much as they wanted.
41137847|NCT05162469|DRUG|SHR-1909 injection|SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).
41137848|NCT05830279|GENETIC|Pharmacogenetic testing|Genotyping for CYP2D6 and CYP2C19
40966774|NCT02550990|BEHAVIORAL|Aerobic exercise training|
40966775|NCT02550990|BEHAVIORAL|Sequential combination of aerobic exercise and cognitive training|
40966776|NCT03384238|PROCEDURE|Fluorescence Imaging|Undergo fluorescence imaging
40966777|NCT03384238|BIOLOGICAL|Panitumumab|Given IV
40966778|NCT03384238|DRUG|Panitumumab-IRDye800|Given IV
40966779|NCT01818232|DRUG|[14C]-LX4211|
40966780|NCT00027261|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
40990730|NCT03686410|OTHER|Conventional Treatment|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
40768001|NCT06563934|BIOLOGICAL|Oral enterobacterium capsules|Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
40768002|NCT06563934|DRUG|Lenvatinib + PD-1 monoclonal antibody|"Lenvatinib 8mg (≤60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day.~PD-1 monoclonal antibody 200mg i.v. once every 3 weeks."
40768003|NCT06563934|BIOLOGICAL|Oral enterobacterium capsules placebo|Enterobacterium capsules placebo (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
40768004|NCT06259812|OTHER|Parameters of Early Warning Scores|Parameters of Early Warning Scores
40768005|NCT03924895|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
40768006|NCT03924895|PROCEDURE|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
40768007|NCT03924895|DRUG|Enfortumab Vedotin|Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.
40768008|NCT06459804|PROCEDURE|Electro Dry Needling|"Standard Physiotherapy:~It will include Hot pack (10 min), Stretching of levator scapulae (3 times with 30 seconds hold), Scapular stabilization exercises (10 times with 5 seconds hold).~Scapular Stabilization exercises will be comprised of four exercise programs. The participants will sit on the knees in 90° flexion position, and a Swiss ball will be propped up between the stomach and chest."
40768009|NCT06459804|PROCEDURE|Dry Needling|Dry Needling
40768010|NCT05175664|OTHER|Long-term study|No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.
40768011|NCT05175664|OTHER|Short-term study|No intervention. Investigations: blood samples and pupillometry.
40768012|NCT05175664|OTHER|Cross-sectional study|No intervention. Investigations: cognitive tests, pupillometry and actigraphy.
40768014|NCT04627103|DEVICE|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.
40768015|NCT06615219|OTHER|Intergroup contact training|The intervention program uses direct contact and four types of indirect contact as the intervention strategy and general framework, and is divided into three main steps, assessing and reflecting on aging stereotypes, carrying out indirect and direct contact, and evaluating the effectiveness of the intervention. The time period is 12 weeks, with the interventionists comprising the researcher and nursing students. The forms of the intervention include holding mini-lectures, organizing participation in voluntary activities, and nostalgia interviews.
40768016|NCT06615219|OTHER|Regular course training only|The specific process is to sign in the classroom, review the knowledge of the previous class by asking questions, introduce the content of the new class, the teacher explains the knowledge points according to the teaching objectives and teaching content, and finally assigns the post-class homework of the course content. At the end of the experiment, the control group was given compensatory intervention.
40768017|NCT04593680|DRUG|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)|The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP. The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP. The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP. The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
40768018|NCT06559462|OTHER|Focus Group|Open-ended group discussion of potential nudges to elicit constructive feedback on nudge development.
40768019|NCT06559462|OTHER|Discrete Choice|Survey involving choice between two potential nudges to elicit feedback on which nudge version is considered superior.
40768020|NCT05422482|BIOLOGICAL|GC1123|ICV-administered Hunterase, Idursulfase-ß
40768021|NCT03030534|COMBINATION_PRODUCT|Educational package and software package|Using Information and communication technology to deliver health promoting activities
40768022|NCT03030534|OTHER|Health promotion tips|Give general information on health promotion
40768023|NCT00400140|DEVICE|Hyperopic lens|+3 D glasses
41137849|NCT05830279|OTHER|Drug-Drug interaction analysis|Evaluating potential drug interactions with CYP2D6, CYP2C9 and CYP3A4 inhibitors and inducers using the Medical Letter.
41457599|NCT00966628|DRUG|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
40768024|NCT01838733|OTHER|Observational study|
40768025|NCT06269315|OTHER|Cleaning product exposure|Exposure of a small amount of a different household cleaner, hand disinfectant, their ingredients, and control with proper dilution on forearm of donors
40768026|NCT02441400|DEVICE|EndoStim LES Stimulation System|
40768027|NCT06396741|OTHER|The quadriceps muscle will be punctured with ultrasound control|With the subject in the supine position, the quadriceps muscle will be shown by ultrasound. Subsequently, a dry needling technique will be performed at the most hyperalgesic point using ultrasound control.
40768028|NCT06600321|DRUG|ALN-BCAT|Administered by intravenous (IV) infusion
40768029|NCT06600321|DRUG|Pembrolizumab|Administered by intravenous (IV) infusion
41137850|NCT02196259|DRUG|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
41295669|NCT03781193|OTHER|Questionnaires administration|Psychological and quality of life questionnaires
40966781|NCT06140147|OTHER|Protocolised reduction of non-resuscitation fluids|Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)
40966782|NCT06140147|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.~Medications: concentrated per local protocol"
40966783|NCT05180084|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory, self-determination theory and self-compassion therapy for low self-esteem among young adults.
40966784|NCT00192361|BIOLOGICAL|CAIV-T|
40966785|NCT01331915|BIOLOGICAL|Theravac|"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously."
40966786|NCT04360629|DRUG|Tranexamic Acid|Tranexamic Acid will be given through central vein
40966787|NCT04360629|DRUG|normal saline|normal saline will be given through central vein
40966788|NCT00187577|DRUG|Latanoprost (Xalatan)|
40966789|NCT00187577|DRUG|Bimatoprost (Lumigan)|Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
40966790|NCT00187577|DRUG|Topical application of latanoprost solution to eyelid|Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
40966791|NCT02716428|DRUG|Faldaprevir|
40966792|NCT02716428|DRUG|TD-6450|
40966793|NCT02716428|DRUG|Ribavirin|
40966794|NCT00694174|DRUG|sucrose 24% oral solution|sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance
40966795|NCT00694174|DRUG|sterile water|sterile water 2 ml single dose to be administered orally one time prior to heel lance
40966796|NCT03782792|DRUG|Spesolimab|Solution for infusion
40966797|NCT03782792|DRUG|Placebo|Solution for infusion
40966798|NCT01861964|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
40966799|NCT01861964|DIETARY_SUPPLEMENT|Xylooligosarcharide 1.4g|8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
40966800|NCT01861964|DIETARY_SUPPLEMENT|Xylooligosarcharide 2.8g|8 capsules (520 mg/capsule) to be taken in the morning and in the evening
40966801|NCT00039975|DRUG|Indinavir sulfate|
40966802|NCT00039975|DRUG|Ritonavir|
40966803|NCT00039975|DRUG|Amlodipine|
40966804|NCT00039975|DRUG|Diltiazem HCl|
40966805|NCT01306942|DRUG|Dasatinib|
41457600|NCT06363240|DEVICE|Broadband Light|Broadband Light treatment
40966806|NCT01306942|DRUG|Trastuzumab|
40966807|NCT01306942|DRUG|Paclitaxel|
41137851|NCT01653925|OTHER|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.
40966808|NCT05544916|DRUG|XC221|200 mg/day, for 5 days
40966809|NCT05544916|DRUG|Placebo|2 tablets/day, for 5 days
40966810|NCT01341145|BEHAVIORAL|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
40966811|NCT01341145|BEHAVIORAL|Relaxation|12-week progressive muscle relaxation program (active control)
40966812|NCT03220360|PROCEDURE|indirect pulp capping|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
40966813|NCT03220360|PROCEDURE|direct pulp capping|Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
40966814|NCT03220360|PROCEDURE|vital pulpotomy|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
40966815|NCT06276283|DRUG|DZD9008 plus Bevacizumab|DZD9008, 200 mg or 300 mg, once daily plus Bevacizumab 15 mg/kg, once every 3 weeks
41137852|NCT01653925|DRUG|Drug (Dutasteride) intervention first|5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
40966816|NCT04254497|DIAGNOSTIC_TEST|EGFR mutation detection kit|A microsieve membrane filter device to effectively isolate circulating tumor cells from whole blood sample has been developed by the Institute of Bioengineering and Nanotechnology. The device exploits the size difference between cancer cells and blood cells to achieve the cancer cell capture on a microsieve filter with \> 85% recovery rate from 4.5-ml whole blood within 10 min, demonstrated with cancer cells spiked into whole blood samples. The device contains a densely packed pore array (\> 8000 pores/mm\^2) with an optimized pore diameter of 10 µm. Fluid regulation and cell counting are achieved by a simple vacuum pumping and laboratory fluorescence microscope. The captured cells are stained with anti-EpCAM-PE for CTCs, anti-CD45-FITC for white blood cells, and 4',6-diamidino-2-phenylindole (DAPI) for cell nuclei. The CTCs are identified with anti-EpCAM positive, anti-CD45 negative and DAPI positive, characterized using a fluorescence microscope.
40966817|NCT00753415|BIOLOGICAL|V935|A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10\^9 vector genomes/mL) or a HD (1 x 10\^11 vector genomes/mL).
40966818|NCT00753415|BIOLOGICAL|V934-EP|A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
40966819|NCT04503902|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I)，three doses of Donafenib tosylate tablets \[100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID\] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
40966820|NCT04503902|DRUG|Toripalimab Injection|JS001 will be administrated by intravenous (i.v.) infusion once every 21 days
40966821|NCT01209260|DEVICE|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
40966822|NCT01209260|DEVICE|Mechanical Needle|Mechanical needle for transseptal access
40966823|NCT04650490|RADIATION|Stereotactic Radiosurgery|Timing of stereotactic radiosurgery relative to immunotherapy
40966824|NCT04650490|DRUG|Immunotherapy|Physician's choice of immunotherapy per standard of care
40966825|NCT00956020|BIOLOGICAL|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
40966826|NCT06239454|DEVICE|interleaving stimulation|ILS consists of two rapid and alternate stimulation programs with different contacts, amplitudes, and pulse width but the same frequency up to a maximum of 125Hz. Contact selection is determined by postoperative stereotactic computed tomography and clinical evaluation to achieve a balance between motor improvement and tolerable side effects. For example, ILS is successfully applied for PD motor symptoms (stimulation of subthalamic nucleus) as well as dyskinesia (additional stimulation of zona incerta).
40966827|NCT06239454|DEVICE|empirical stimulation|Patients are settled with simple polar stimulation with combined parameters adjustment (monopolar mode, 60\~90µs pulse width, 130\~185Hz frequency and varied voltage) during the follow-up.
41137853|NCT04001777|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.
41137854|NCT04001777|DRUG|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
41137855|NCT02541305|OTHER|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
41137856|NCT02541305|OTHER|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
41137857|NCT04661774|OTHER|reflexology massage|reflexology massage of the foot zone implicated in diaphragm stimulation
41137858|NCT04661774|OTHER|sham massage|traditional massage of the foot
41137859|NCT02865785|DRUG|Intralipid 20%|intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.
41137860|NCT02865785|DRUG|Placebo|saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
41457601|NCT04237350|BEHAVIORAL|Video recording for behaviors|"A domenstic apparatus, scenario, and procedure is applied to record all the behavioral phenotypes.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the mobile phone screen. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for about 3 minutes to ensure that behavioral phenotypes could be completely recorded."
40768030|NCT05964699|PROCEDURE|Minimally invasive periodontal therapy with use of Emdogain|Scaling of root with assisted use of the Videoscope and regrowth of attachment by the use of Emdogain.
41137861|NCT05652114|BEHAVIORAL|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children.
41457602|NCT02992548|DRUG|Pravastatin|
41457603|NCT02832466|OTHER|Functional Test|Observation of physical function in hemodialysis patients during a period of 6 months
41457604|NCT04911205|OTHER|Preoperative training program|Patients of intervention group (N=44) followed a 6-week supervised high-intensity preoperative training program. They had a session of preoperative resistance training five days per week for a period of 6 weeks before TKA. Each session was supervised by a physiotherapist specifically trained in progressive resistance training. The duration of each session was approximately 60 minutes. If a participant missed a training session, it was attempted to substitute the session on an alternative day.
40768031|NCT05964699|PROCEDURE|Minimally invasive periodontal therapy without the use of Emdogain|Scaling of root with assisted use of the Videoscope.
40768032|NCT06068361|DIAGNOSTIC_TEST|EEG|32-electrode EEG (resting state, passive auditory and active visual task)
41137862|NCT00871715|BEHAVIORAL|Accelerated Skill Acquisition Program (ASAP)|A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
41295670|NCT03781193|OTHER|Five Facet Mindfulness Questionnaire (FFMQ)|FFMQ is a 39-item measure consisting of five subscales (observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience).
40966828|NCT04213079|DEVICE|re-adaptation of the vestibulo-ocular reflex|The VOR will be readapted by activating velocity storage with full-field optokinetic motion at 5°/s in a set direction while the head is oscillated with a set frequency and direction. The readaptation training will be conducted in repeated modules, each lasting for 1-5 min. The expected duration of daily sessions varies from 30 to 90 min. A day's session will be terminated if patient no longer feel symptoms of MdDS.
40966829|NCT04213079|DEVICE|Habituation of velocity storage of the vestibulo-ocular reflex|The central (velocity storage) time constant will be reduced by inducing cancellation of two velocity storage-mediated responses: OKN and the VOR. Sinusoidal rotation at 0.017 Hz (1 revolution/min) in darkness advances the slow phase eye velocity of the VOR by 32º. In contrast, the OKN at this frequency has no phase advancement. Thus, to counteract the VOR by OKN, the optokinetic stimulus should be set to 32º phase advance the out of phased head rotation stimulus. Since the conflict stimulus is expected to be overwhelming to patients at higher chair velocities, subjects will be first trained with a 10°/s stimulus. In a previous study, no complaints were reported when subjects were tested at such low velocities. Preliminary testing show signs of symptom improvement when the peak velocity reached 30°/s to 40°/s.
40966830|NCT06394817|OTHER|No intervention|No intervention
40966831|NCT02231944|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
40966832|NCT03600571|PROCEDURE|medial midpatellar (MMP) portal|injection medial under horizontal patella midline was administrated with the lower limb extension
40966833|NCT03600571|PROCEDURE|anteromedial (AM) portal|injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion
40966834|NCT01776892|DRUG|Collegenase injection|"Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent."
40966835|NCT01776892|PROCEDURE|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
40966836|NCT04828252|DEVICE|Low level laser treatment|The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
40966837|NCT01908374|DIETARY_SUPPLEMENT|DHA-rich fish oil versus Phospholipid-rich fish oil|This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
40966838|NCT00226707|DRUG|Pimecrolimus Cream 1%|
40966839|NCT04826575|OTHER|High intensity inspiratory and expiratory muscle training|"Inspiratory Muscle Training will be performed using the Threshold inspiratory muscle trainer device (Threshold IMT®, Philips Respironics, Inc., Murrysville, PA, USA).~Expiratory muscle training (EMT) will be performed using the Threshold positive expiratory pressure device (Threshold PEP®, Philips Respironics, Inc., Murrysville, PA, USA) or Expiratory Muscle Strength Trainer EMST 150TM (Aspire Products), depending on the initial MEP.~Patients will train 2 times a day, 7 days per week, for 2 weeks."
40966840|NCT01024452|DEVICE|DAWN AC|computerized dosing management system for anticoagulation clinics
40966841|NCT01024452|DEVICE|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
40966842|NCT04968301|DEVICE|ultrasound Doppler|A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
40966843|NCT05604352|DEVICE|DiaSole|Diabetic ulcer offloading insole
40966844|NCT00036829|PROCEDURE|pain therapy|
40966845|NCT04943497|OTHER|ribociclib|There is no treatment allocation. Patients administered ribociclib by prescription that have started before inclusion of the patient into the study will be enrolled.
40966846|NCT04943497|OTHER|aplelicib|There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.
41137863|NCT00871715|BEHAVIORAL|Dose-Equivalent Usual & Customary Care - DEUCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
41137864|NCT00871715|BEHAVIORAL|Usual and Customary Care - UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
41137865|NCT01005693|OTHER|questionnaire administration|
41137866|NCT01005693|PROCEDURE|cognitive assessment|
41295671|NCT03781193|OTHER|Langer Mindfulness Scale (LMS)|The LMS Tis a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
41295672|NCT03781193|OTHER|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
40768033|NCT05196776|DEVICE|Portable, handheld point-of-care ultrasound device|The patient will have an ultrasound performed using a handheld, portable device.
40966847|NCT04943497|OTHER|mono endocrine therapy|There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
40966848|NCT04943497|OTHER|chemotherapy|There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.
40966849|NCT01918774|BEHAVIORAL|Cognitive behavior therapy for work success (CBTw)|The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
40966850|NCT05135117|OTHER|NeuroRescue Cooling Collar|Between bouts of exercise subjects will be provided cooling on the neck with the NeuroRescue Collar. The custom sized cooling collar has ice water (which is kept around 2 degrees celsius) that is circulated through a neoprene sleeve that is attached to their neck for the cooling period.
40966851|NCT05135117|OTHER|Ice Towel|Between bouts of exercise subjects will be provided cooling on the neck with a towel. The towel will be kept in ice water (which is kept around 2 degrees celsius) and placed around the neck of the individual during the cooling intervention period.
40966852|NCT03727347|DEVICE|InSeca Stylus|Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).
40966853|NCT03187275|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic massage oil to facilitate making long, smooth strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then covered up before moving onto another part of the body. Primary techniques used in the research protocol therapy are: effleurage, petrissage, tapotement. These will be administered according to a very specific, standardized protocol. The total session time will be 45 minutes."
41295673|NCT03781193|OTHER|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
40966854|NCT03187275|OTHER|Light Touch Intervention|The light-touch research intervention is based on the concept that there will be a noticeable effect with regard to massage when compared to light-touch alone without the massage. The protocol followed will be the same as the massage protocol other than that the therapist will use light-touch only. The total session time will be 45 minutes.
40966855|NCT02657291|DRUG|Ropivacaine|Local anesthetic
40966856|NCT02657291|DEVICE|Ultrasound|Ultrasound guided block
40966857|NCT05367648|DIETARY_SUPPLEMENT|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
40966858|NCT05367648|OTHER|Placebo|Placebo comparator
40966859|NCT05015244|PROCEDURE|3T (Tesla) Magnetic Resonance Imaging (MRI)|Neurological evaluation using MRI and neuropsychological tests
40966860|NCT05698030|OTHER|Food allergy|Oral immunotherapy to pistachio
40966861|NCT03550898|DIAGNOSTIC_TEST|Dynamic Ultrasonography|Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
40966862|NCT02087397|OTHER|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
40966863|NCT02087397|BIOLOGICAL|AD-SVF Cell Injection|Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
40966864|NCT01751178|DRUG|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
41137867|NCT01005693|PROCEDURE|examination|
41137868|NCT01005693|PROCEDURE|management of therapy complications|
41137869|NCT04910256|DRUG|HuaTuo Zaizao pill|Patients take 8g of HuaTuo Zaizao pill three times a day. Treatment lasts for 12 weeks.
41137870|NCT04910256|OTHER|basic treatment|"It accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation."
41295674|NCT03781193|OTHER|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
41457605|NCT01288924|DRUG|Parecoxib|Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
40966865|NCT01751178|DRUG|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
40966866|NCT00185939|DRUG|Augmentin|
40966867|NCT01375556|DRUG|Ethanol|
40966868|NCT01140243|DIETARY_SUPPLEMENT|LCPUFA|premature infant formula supplemented with LCPUFA
40966869|NCT01965301|DRUG|BP1.5375 suspension|single oral dose
40966870|NCT01965301|DRUG|Diphenhydramine|single oral dose of Diphenhydramine 50mg
40966871|NCT01965301|DRUG|Placebo|Single oral dose
41137871|NCT00561249|PROCEDURE|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
41137872|NCT06248255|OTHER|Pads|Single arm design in which each participant act as its own control. Wet or Dry pads are applied to the participants forearms.
41137873|NCT00204399|BEHAVIORAL|Telephone counseling support|
41137874|NCT00893100|DRUG|Diltiazem|2%,3 times daily
41137875|NCT04190485|OTHER|Placebo|Subjects will be randomized to one of two groups, using placebo toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite treatment for 4 weeks.
41295675|NCT03781193|OTHER|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
41295676|NCT03781193|OTHER|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
41295677|NCT03781193|OTHER|Toronto Alexithymia Scale (TAS)|The TSA is a 20-item scale that evaluates the three components of alexithymia: difficulty to identify feelings and distinguish between feelings and bodily sensations of emotional arousal difficulty, describing feelings to others, and a cognitive style that is literal, utilitarian, and externally oriented.
41295678|NCT01775046|DEVICE|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
41295679|NCT04370028|DRUG|Divaza|Oral administration.
41295680|NCT05913557|BEHAVIORAL|Radically Open Dialectical Behavior Therapy (RO DBT)|Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
41457606|NCT01288924|OTHER|Control|NSS 2 ml intravenous before surgery and every 12 hours for two days.
40966872|NCT02908360|GENETIC|double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse|
40966873|NCT00057278|DRUG|gabapentin|
40966874|NCT03670888|BIOLOGICAL|JHL1101|100 mg/10 mL solution in a single-use vial
40966875|NCT03670888|BIOLOGICAL|Rituximab|100 mg/10 mL solution in a single-use vial
40966876|NCT05742594|DRUG|Lazertinib|Lazertinib will be administered orally.
40966877|NCT01297712|DEVICE|Latest generation colonoscopy as diagnostic instrument|this endoscope is used as compared to an older generations cope (classic line) currently in use
40966878|NCT04462445|DRUG|Pazopanib|
40966879|NCT00669227|OTHER|autologous stem cells|intracoronary administration at the same day of cell aspiration using the stop flow technique
40966880|NCT00669227|OTHER|placebo suspension|intracoronary administration at the same day as cell aspiration
40966881|NCT05262127|BEHAVIORAL|Flash Version of EMDR|EMDR and the inclusion of a positive engaging focus generated autonomously by participant
41295681|NCT00224107|DRUG|Silodosin|8 mg daily for 12 weeks
41295682|NCT00224107|OTHER|Placebo|1 capsule daily for 12 weeks
41295683|NCT01128972|DRUG|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
41295684|NCT01128972|DRUG|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
41295685|NCT01128972|DRUG|Sterile water|Sterile water rinse
40966882|NCT04467060|DRUG|Anaprazole Sodium|2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg，fasting oral administration.
40966883|NCT04467060|DRUG|Placebo|single dose, fasting oral administration
40966884|NCT05448183|DRUG|Toripalimab, Gemcitabine,Oxaliplatin|Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), combined withTACE (Gemcitabine 1000mg/m2 , Oxaliplatin 135mg/m2) in a cycle of 3 weeks(q3w).
40966885|NCT05459038|DIAGNOSTIC_TEST|C-Arm Rotational View (CARV)|CARV includes predefined fluoroscopy landmarks of the uninjured side to correct for rotational malalignment of the injured side in which the rotation of the C-Arm Image Intensifier is used
40966886|NCT02042183|DRUG|Lubiprostone|12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1
40966887|NCT02042183|DRUG|Placebo|0 mcg soft capsules of placebo for oral administration
40966888|NCT02981420|BEHAVIORAL|Safety planning|Safety Planning Intervention. This brief one-session intervention, based on cognitive behavioral principles, is designed to help individuals identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of suicidal behavior. In youth who also report nonsuicidal self-injurious behavior (NSSI), the safety plan will address both suicidal and nonsuicidal behavior. The plan helps youth identify possible triggers to SI/crisis including self-monitoring of suicidal thoughts, feelings, and behaviors; advance planning to remove lethal means; determine distress tolerance/emotion regulation skills that may be helpful; identify accessible social supports to target hopelessness/sense of isolation; reinforce the commitment to seek treatment; and, how and where to access emergency care.
40966889|NCT05410691|DEVICE|Handheld US device|Handheld US-guided AVF/AVG cannulation
41295686|NCT02099799|BEHAVIORAL|Pedometer and Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
41295687|NCT04384640|OTHER|Change of posture after Intra Tympanic injection|Seating position after Intra Tympanic injection
41295688|NCT01874782|DEVICE|transcranial electrical stimulation|TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
41295689|NCT05231876|OTHER|Recording of pathology-related information on the Wilson Register|Age, gender, date of diagnosis, clinical symptoms, ethnic charateristics and family tree will be collected and recorded on the Wilson Register during routine clinical care
41457607|NCT03098693|BEHAVIORAL|HIV Self-Testing|Access to home-based HIV self-testing kits for stable couples.
41457608|NCT03098693|BEHAVIORAL|Immediate Access to ART for HIV infected couple members|Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
41457609|NCT03098693|BEHAVIORAL|Access to PrEP for HIV uninfected couple members|Access to PrEP for HIV uninfected couple members.
41457610|NCT04610580|DRUG|ALXN1840|ALXN1840 will be administered orally.
41457611|NCT00504062|DRUG|budesonide|
41457612|NCT00504062|DRUG|fluticasone|
41457613|NCT02319603|DRUG|Low dose WenXin keli|Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
40768034|NCT05196776|DEVICE|Cart-based point-of-care ultrasound device|The patient will have an ultrasound performed using a traditional cart-based model.
40966890|NCT06499597|OTHER|Observation|All individuals included in the study will be included in this group and evaluations will be made.
40768035|NCT06367101|OTHER|AR training with gait and HRV feedback|Use projection-based AR system to train gait and HRV. To give gait and HRV feedback for subjects after AR training.
40966891|NCT01752998|BEHAVIORAL|Treating Opioid Patients' Pain and Sadness (TOPPS)|
40966892|NCT01752998|BEHAVIORAL|Health Education|
40966893|NCT00133952|DRUG|Ruboxistaurin|Administered orally
40966894|NCT00133952|DRUG|Placebo|Administered orally
40966895|NCT04640285|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
40966896|NCT04640285|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions
40966897|NCT04640285|OTHER|Usual Brand Cigarette|Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions
40966898|NCT04640285|OTHER|Nicorette White Ice Mint nicotine polacrilex gum|Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions
40966899|NCT05478785|DRUG|Cisplatin micelle injection (HA132)|HA132 will be administered intravenously (IV), once per 3 weeks.
40966900|NCT06242158|PROCEDURE|arthroscopic assisted mini-open 5 step repair|"First step Identifying the tear size , quality and if reducible on the foot print . minimal removal of the bursa and pulling of the tendon with a grasper to reach the foot print area with gentle mobilization of the tendon .~Step two Acromioplasty Using a probe, the LHBT was palpated and mobilized, looking for any signs of degeneration and fraying or instability . The LHBT was inspected either through the tear by the subacrominal portal or through the glenohumeral portal .~Step three Antero-lateral mini-open approach was used through a longitudinal 4 cm skin incision Step four Transosseous repair using the giant needle was used. 3 to 4 number two fiber wire sutures was passed equidistance through the tendon Step five The subarominal bursa was used for biological augmentation of the repair"
40966901|NCT02397278|DRUG|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
40966902|NCT01758432|COMBINATION_PRODUCT|PRT064445/Apixaban|
41137876|NCT04190485|OTHER|GMNL-143 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-143 probiotic toothpastes toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
41137877|NCT04190485|OTHER|GMNL-464 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-464 probiotic toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
41137878|NCT03770429|DRUG|AZD6738|MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
41137879|NCT02824926|DRUG|Dapaconazole|
40768036|NCT01500135|DRUG|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
40768037|NCT01500135|DRUG|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
40966903|NCT01758432|COMBINATION_PRODUCT|Placebo/Apixaban|
40966904|NCT01758432|DRUG|Placebo|
40966905|NCT05650905|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
40966906|NCT05650905|DEVICE|Fourier domain optical coherence tomography (FDOCT)|Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
40966907|NCT05650905|DEVICE|Optical coherence tomography (OCT)|Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
40966908|NCT05650905|DEVICE|Laser Speckle Flowgraphy (LSFG)|Normalized blur and Relative flow volume will be assessed using the LSFG
40966909|NCT05650905|DIAGNOSTIC_TEST|Proteomics and Metabolites in Plasma, tear fluid and finger sweat|Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
40966910|NCT04694742|OTHER|data collecting|"Within 24h from ICU admission, the ventilatory efficiency will be assessed by the following Ventilatory Ratio equation:~Ventilatory Ratio = \[minute ventilation (ml/min) × PaCO2 (mm Hg)\]/(predicted body weight × 100 × 37.5).~Where PaCO2 is the partial pressure of carbon dioxide in mmHg in the arterial blood.~Tha quasi-static compliance will be calculated according to the equation:~C=Tidal Volume/(Paw plateau - PEEP total)~where Paw plateau is the airway pressure measured during 4 seconds of inspiratory pause, PEEP total is the airway pressure measured during 4 seconds of expiratory pause.~In the same time frame, complete blood count, d-dimer, sequential organ failure assessment score, blood gas analysis, haemodynamic and ventilatory parameters will be collected."
41137880|NCT02824926|DRUG|Ketoconazole|
41457614|NCT02319603|DRUG|High dose WenXin keli|High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
40966911|NCT02530593|BEHAVIORAL|There is no intervention, only observation|
40966912|NCT04269096|OTHER|Protocol Compliance|Compliance with the Prisma Health-Upstate Laparoscopic Cholecystectomy Perioperative Protocol
40966913|NCT06556342|DRUG|FRD001|FRD001 injection is a lipid-based second-generation ultrasound contrast agent. FRD001 injection in ultrasound contrast imaging could enhance the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls.
41137881|NCT02309515|OTHER|Laboratory Biomarker Analysis|Correlative studies
40966914|NCT04334070|DRUG|Lamprene®/Clofazimine|All participants will receive Lamprene/clofazimine 50 mg capsules. The recommended dose of clofazimine for this program is 100 mg once daily, administered orally, preferably with meals. Duration of treatment will be decided by the treating physician. When considering clofazimine for the treatment of NTM infection, clofazimine is to be administered as part of a multi-drug regimen.
40966915|NCT01354990|DRUG|Sitagliptin (JANUVIA®)|Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
40966916|NCT03588039|DRUG|Oraxol|Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
40966917|NCT03588039|BIOLOGICAL|Pembrolizumab|Intravenously administered
40966918|NCT06066983|BEHAVIORAL|DINOSAUR|This intervention aims to treat intolerance of uncertainty and anxiety in young autistic children.
40966919|NCT06066983|OTHER|Psychoeducation|This intervention provides psychoeducation regarding anxiety and autism.
40966920|NCT01747044|DRUG|Milnacipran|100mg/day
40966921|NCT01747044|DRUG|Placebo|
40966922|NCT04620356|DEVICE|DryNites Pyjama Pants|DryNites Pyjama Pants are disposable, absorbent youth pants designed to help children manage bed wetting by absorbing involuntary urine loss and protecting the child's garments and bedding. DryNites Pyjama Pants are underwear-like alternatives that can be discreetly worn beneath pyjamas or nightwear during the bedwetting phase.
40966923|NCT01445262|DRUG|Levocetirizine|
40966924|NCT03568734|OTHER|Fecal transplant|At delivery, i.e. 39-40 weeks of gestation, the newborn infant is given 0.1 g maternal fecal sample (in 0.5 ml of the isotonic saline+10 % glycerol) dissolved in 10 ml of bank milk orally. The sample is given within 2 h of birth. Milk containing fecal sample (2 ml) is given as a part of a total feeding of 5-10 ml.
40966925|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information
40966926|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information.
40966927|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information,
40966928|NCT03228043|DRUG|Apatinib|Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal
40966929|NCT03228043|DRUG|CAPEOX|CAPEOX adjuvant chemotherapy for resectable colorectal
40966930|NCT03053960|DEVICE|Computed Tomography|Undergo helical CT scan
40966931|NCT03053960|DEVICE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
40966932|NCT03053960|DEVICE|Cone-Beam Computed Tomography|Undergo CBCT scan
40966933|NCT03053960|DEVICE|Magnetic Resonance Imaging|Undergo MRI scan
40966934|NCT03053960|PROCEDURE|Therapeutic Conventional Surgery|Undergo resection of tumor
40966935|NCT03053960|PROCEDURE|Histopathologic Examination|Correlative studies
40966936|NCT04360252|OTHER|Gracie Diet|"The patient is going to have an encounter with the nutritionist (either face to face or by phone call) and she will provide patient with the requisite nutritional information and will guide patient on how to properly adhere to the diet.~The session is designed to: answer patient questions, educate patients so that patients understand the underlying nutritional concepts that the diet is based upon, support patients by empowering the patients to make healthy nutritional choices consistent with the diet, educate patients regarding the appropriate combinations of healthy foods, and help patients to develop menu samples based on the Gracie Diet when there is interest."
40966937|NCT03374397|DRUG|Surgiguard|Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
40966938|NCT01941121|BEHAVIORAL|Linkage to PrEP or Care|Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
40966939|NCT00273832|PROCEDURE|coronary artery computed tomography angiogram|
40966940|NCT00273832|PROCEDURE|single photon emission computed tomography|
40966941|NCT05914805|DRUG|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
40966942|NCT05914805|DRUG|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
40966943|NCT03415217|OTHER|Neighbourhood Team Development Program|The Neighbourhood Team Development Program aims to both enhance team development and resident centredness in LTC. The Program has three components, designed to modify the physical environment, the organization and delivery of services, and the alignment of staff members, to function independently and collaboratively in providing resident-centred care.
40966944|NCT02460627|DRUG|Lidocaine adhesive tape|700 mg for 12 hours
40966945|NCT02460627|OTHER|Adhesive tape|For 12 hours
40966946|NCT05014789|DEVICE|Control-IQ technology 2.0|All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor
40966947|NCT01631981|DRUG|PGL2001 + Primolut-Nor 5|"PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up."
40966948|NCT01631981|DRUG|Placebo + Primolut-Nor 5|"Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up."
40966949|NCT04850937|DRUG|Esketamine|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction
40966950|NCT04850937|DRUG|normal saline|The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
40966951|NCT00044278|DRUG|lamotrigine|
41137882|NCT02309515|DRUG|Lenalidomide|Given PO
41137883|NCT02309515|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
41137884|NCT01127737|BEHAVIORAL|Educational Intervention|Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.
41137885|NCT01127737|BEHAVIORAL|Placebo|Completed surveys
41137886|NCT00904085|DRUG|Oxymorphone IR|5 mg
40966952|NCT03627143|OTHER|KTI activities|"The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.~1. Selection of one or more local physician champions from both the ED as well as the cardiology group;~2. Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;~3. Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;~4. Development of local action plan addressing local barriers to implementation;~5. Provision of the free Smartphone App to be developed for the guidelines;~6. Regular reminders provided by the local research staff;~7. Audit and feedback charts of site compliance"
40966953|NCT06052605|BEHAVIORAL|Healthy Aging in People with Epilepsy Program|This a 12-week group educational program providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.
40966954|NCT03146013|DIAGNOSTIC_TEST|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
40966955|NCT03987529|OTHER|sevoflurane|volatile anesthetic
40966956|NCT03987529|OTHER|propofol|intravenous anesthetic
41295690|NCT06324370|DIETARY_SUPPLEMENT|Virgin Coconut Oil|"Virgin Coconut Oil (VCO) will be administered with 240 mL water and standardized food during dosing periods.While the participant is standing up, each dose will be administered orally with at least 240 mL of water and standardized meal after an overnight fast of at least 10 hours on each occasion. The time of dosing will be recorded to the nearest minute in the case report form (CRF).~No other liquid or solid food intake is permitted during this time. Fluid intake will be ad libitum 4 hours post-dose. There will be a washout interval of 7 days between the single- and multiple-dose studies.~Participants will not be permitted to take any prescribed medication or over-the-counter products (including vitamins and herbal supplements) within 14 days prior to dosing or during the course of the study."
40966957|NCT03678298|OTHER|Epidemiological/treatment profiles|All consecutively hospitalized adult patients (older than 18 years of age) undergoing surgery, interventional drainage or conservative treatment, with diagnosis of cIAIs (defined as abdominal infections originating in an organ cavity, extending into the peritoneal space, and forming an abscess or peritonitis, will be included in the study.
40966958|NCT02864498|DRUG|DS107|
40966959|NCT02864498|DRUG|Placebo|
40966960|NCT02467868|BIOLOGICAL|MYL-1401H|During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.
40966961|NCT02467868|BIOLOGICAL|Neulasta|During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
40966962|NCT01363674|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
40966963|NCT03332654|OTHER|Determine prevalence of stress urinary incontinence|
40966964|NCT01755078|DRUG|Sevelamer HCl|Non-metal phosphate binder
40966965|NCT01755078|DRUG|Calcium-based phosphate binder|
40966966|NCT00057317|DRUG|Ro 205-2349|
40768038|NCT06588608|DEVICE|auricular nerve stimulation (aVNS)|The Spark Sparrow system stimulates the auricular branch of the Vagus nerve using a low-voltage electrical signal comprising a 1 Hz - 150 Hz biphasic square wave with a pulse width of 50s - 750s. Stimulation current is controlled with a maximum voltage of 95 V and 1-5 milliamperes (mA) output current. The device is positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Stimulation will occur for 30 minutes. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
40966967|NCT03220178|DRUG|Palbociclib|Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
41295691|NCT00911664|DIETARY_SUPPLEMENT|Vitamin D|Weekly dose of 5600 IU (800 IU per day)
40768039|NCT06588608|DEVICE|sham aVNS|The Spark Sparrow system device will be positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Subjects will wear the device for 30 minutes during which no stimulation will be emitted. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
40966968|NCT03220178|DRUG|Fulvestrant|500mg per use-after first application, again at wk2, then once per month
41137887|NCT02055079|DRUG|Sirolimus|Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.
41137888|NCT02055079|DRUG|Placebo|Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
41295692|NCT00911664|DRUG|No supplementation|Control
41295693|NCT00911664|DIETARY_SUPPLEMENT|Vitamin D|Weekly dose of 11,200 IU (1600 IU per day)
41295694|NCT00929630|PROCEDURE|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
41295695|NCT00929630|PROCEDURE|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
40768040|NCT06210893|OTHER|The cricoid cartilage is located.|The cricoid cartilage is located.
40966969|NCT03220178|DRUG|Anastrozole|1mg per day
40966970|NCT03220178|DRUG|Letrozole|2,5mg/day
40966971|NCT03220178|DRUG|Exemestane|25mg/day
40966972|NCT02400632|DEVICE|MAGIC-TOUCH Drug-eluting Balloon|in-stent restenosis treated with drug eluting balloon
40966973|NCT01247909|DRUG|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
40966974|NCT01482000|OTHER|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
40966975|NCT01482000|OTHER|usual care|The control group will get the usual care with some additional tests for the study.
40966976|NCT03557099|DRUG|Hetrombopag Olamine|once daily
40966977|NCT03756844|BEHAVIORAL|Just Right Challenge Food Club|Systematic desensitization, positive reinforcement and escape extinction at a level of just right challenge.
40966978|NCT01832649|BEHAVIORAL|Exercise|Supervised moderate-vigorous exercise in group, based on strength and calisthenics exercises, 2 times per week during 8 weeks.
40966979|NCT01832649|BEHAVIORAL|Health education|Supervised groups 2 times per week during 8 weeks.
40966980|NCT05449652|OTHER|To prescribe exercise prescription for CVD patients|To prescribe exercise intensity, frequency, session duration, program duration, and exercise type (endurance or strength training) for the same three patient cases
40966981|NCT04048928|BEHAVIORAL|maximal strength training|The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
40966982|NCT00035516|DRUG|Epothilone|
40966983|NCT02614586|DRUG|TAK-058|TAK-058 oral solution.
40966984|NCT02614586|DRUG|Ondansetron|Ondansetron capsule.
40966985|NCT02614586|DRUG|TAK-058 Placebo|TAK-058 placebo-matching, solution.
40966986|NCT02614586|DRUG|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
40966987|NCT03009981|DRUG|Apalutamide|Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
40966988|NCT03009981|DRUG|LHRH Analogue|"Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~   OR:~2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1."
40966989|NCT03009981|DRUG|Abiraterone Acetate|Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
40966990|NCT03009981|DRUG|Prednisone|Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.
40966991|NCT01142349|BEHAVIORAL|Lifestyles A|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain and insomnia
40966992|NCT01142349|BEHAVIORAL|Lifestyles B|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain.
40966993|NCT01142349|BEHAVIORAL|Lifestyles C|Six weekly group sessions that last about 90-120 minutes presenting osteoarthritis education.
40966994|NCT01986283|DRUG|Capsule|Taken once
40966995|NCT01986283|DRUG|PF-00345439|40 mg capsule swallowed whole, taken once
40768041|NCT03274466|DEVICE|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days.
40768042|NCT03274466|DEVICE|Standard of Care Dressing|A standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively.
40966996|NCT01986283|DRUG|PF-00345439|40 mg capsule chewed, taken once
40966997|NCT01986283|DRUG|oxycodone|40 mg solution, taken once
40966998|NCT00766311|OTHER|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
40966999|NCT00766311|OTHER|Knee extension strength|"Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken."
40967000|NCT00766311|OTHER|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
40967001|NCT00766311|OTHER|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
40967002|NCT00766311|OTHER|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
40967003|NCT00766311|OTHER|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
40967004|NCT00766311|OTHER|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
40967005|NCT02150317|PROCEDURE|TACE+Sorafenib|TACE followed by Sorafenib
40967006|NCT02150317|PROCEDURE|TACE|TACE alone
40768043|NCT03757949|OTHER|Laboratory Biomarker Analysis|Correlative studies
40768044|NCT03757949|DIETARY_SUPPLEMENT|Nutritional Intervention|Receive SIM PO
40768045|NCT03757949|OTHER|Placebo Administration|Given PO
40768046|NCT03757949|OTHER|Quality-of-Life Assessment|Ancillary studies
40768047|NCT03757949|OTHER|Questionnaire Administration|Ancillary studies
40768048|NCT03797937|OTHER|Magnetic resonance imaging (MRI)|MRI scanner
40768049|NCT00240266|DRUG|Rosuvastatin|
40768050|NCT02760342|DRUG|peficitinib|Oral
40967007|NCT04779060|DRUG|intrathecal fentanyle|25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
40967008|NCT04779060|DRUG|dexamethasone|8 mg dexamethasone give intrathecally for spinal anaesthesia
40967009|NCT04779060|DRUG|saline|normal saline will be mixed with bupivacaine intrathecally
40967010|NCT04157439|OTHER|Control Group|"Hot fermentation was applied for 10 mints Sustain pressure on trigger point was applied with thumb for 3secs hold and 2 sec release (till pain is reduced).~Self-stretches of cervical muscles (10 reps× 1set) For home plan cervical muscles stretching and postural care was guided"
40967011|NCT04157439|OTHER|Experimental Group|"Hot fermentation was applied for 10 mints. Integrated Neuromuscular Inhibition Technique \[sustain pressure, Post Isometric Relaxation (PIR) and SCS\]. Sustain pressure was applied on trigger points using thumb for 3 sec hold and 2 mints release (till pain is reduced).~Post isometric stretch (MET) was given with 4 repetitions (6-10sec hold). Strain counter strain was given in which upper trapezius shortened position was maintained by slight flexion, same side bending, opposite rotation and shoulder abduction for 90 sec and repeats this procedure till the pain is reduced to 3 out of 10.~Self-stretches for cervical muscles were done at the end of session to maintain the gained ranges (10 reps×1 set) For home plan cervical muscles stretching and postural care was guided"
40967012|NCT05467280|OTHER|Online HIIT Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars and challenges.
40967013|NCT05237531|BEHAVIORAL|Standardized Preoperative Education|"The standardized preoperative education includes a brief video, an interactive quiz, and a written handout.~The video will provide information on the proper use and common side effects of opioid pain medications, the expected effects of a peripheral nerve block, and the concept of multimodal postoperative pain management with non-opioid medications and non-pharmaceutical pain management strategies. The interactive quiz will reinforce the critical components of the video in a question-and-answer format which requires active participation. The written handout will summarize the educational content in a form which can be easily referenced by patients at home."
40967014|NCT05237531|BEHAVIORAL|Standard of care|Education per provider preference (no standardization, current standard of care)
40967015|NCT05237531|BEHAVIORAL|Preoperative and postoperative questionnaires|Preoperative questionnaire: Demographic questions plus specific questions about chronic pain, prior opioid use, and mental health diagnoses Postoperative questionnaire: Questions about pain control after surgery, satisfaction with pain control, healthcare contact since surgery, opioid consumption since surgery, and satisfaction with education
40967016|NCT05444192|DEVICE|CAD/CAM insoles|computer-aided-design computer-aided-manufacture (CAD/CAM) insoles
40967017|NCT05787457|OTHER|Clinical examination|
40967018|NCT05787457|OTHER|Blood testing|
40967019|NCT05787457|OTHER|MRI|
40967020|NCT06091631|PROCEDURE|Magnesium sulfate vaporization|pre-opeative magnesium sulfate vaporization
40967021|NCT04655898|DRUG|[14C]CC-90001|Oral
40768051|NCT02760342|DRUG|Metformin|Oral
40768052|NCT06163404|DEVICE|Implantation of Spirair Nasal Device using the Spirair delivery system.|The Spirair implant is designed to acutely correct cartilaginous septal deviation and maintain the cartilage in a corrected position for a duration sufficient to allow for cartilaginous remodeling.
40967022|NCT02018185|DEVICE|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
40967023|NCT02018185|DEVICE|Sham Transcranial Magnetic Stimulation|Sham stimulation of the brain.
40967024|NCT03980002|DRUG|FCR and Ibrutinib|"Induction treatment:~Patients \<65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count \<10×10\^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~1. FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~2. Ibrutinib:420mg/d"
41295696|NCT00929630|PROCEDURE|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
41295697|NCT00929630|PROCEDURE|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
41295698|NCT00690937|DRUG|Enteric coated sevelamer|Drug treatment
40768053|NCT03782493|BEHAVIORAL|the Enhanced Milieu Teaching-Sentence Focus|Caregivers in the treatment group (EMT-SF) will receive 66 EMT-SF intervention sessions at home over 18 months. They will be taught the intervention strategies using a manualized protocol (Teach-Model-Coach-Review).
40768054|NCT05379972|DRUG|Pembrolizumab|Pembrolizumab 200mg IV every 3 weeks starting C2D1
40768055|NCT05379972|DRUG|Olaparib|Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab
40768056|NCT05379972|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib
40768057|NCT04595201|DEVICE|NIPT|Non-invasive pregnancy testing
40768058|NCT06565039|DEVICE|Supira System|The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a high-risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
40768059|NCT04029662|BEHAVIORAL|Valsalva Maneuver|Performing Valsalva maneuver will reduce the pain intensity during spinal needle insertion.
41295699|NCT00690937|DRUG|Enteric coated sevelamer|Drug treatment
41295700|NCT00690937|DRUG|Colesevelam Cholestagel|Drug comparator
41295701|NCT00690937|DRUG|Placebo|Placebo
40967025|NCT03980002|DRUG|BR and Ibrutinib|"Induction treatment:~Patients ≥65y and ≤75 y or \<65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10\^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d"
40967026|NCT03980002|DRUG|Ibrutinib and Thalidomide|"Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy."
40967027|NCT06064643|OTHER|Online Survey|All participants will be asked to complete an online survey
40967028|NCT06064643|OTHER|Qualitative Interview|30 survey participants will take part in a single one-hour qualitative interview.
40967029|NCT06064643|OTHER|Bleed Diary|50 participants will complete a 30 day bleed diary
40967030|NCT06178939|PROCEDURE|control group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery.
40768060|NCT06362629|BEHAVIORAL|Artificial Intelligence assistant decision-making system (AIADMS) App|Participants will be assisted to use the Artificial Intelligence assistant decision-making system (AIADMS) app during the process of management of AD, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up.
40967031|NCT06178939|PROCEDURE|intervention group|For the intervention group, the entire process is carried out according to the Severance Hospital surgical protocol, and the research team provides education before surgery on the importance of nutrition and exercise before and after surgery. In addition, the cognitive training program developed by Rowan is taught with the goal of performing it for at least 10 hours before the surgery, it is conducted the training program after the surgery.
40967032|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
40967033|NCT00982137|BIOLOGICAL|Yellow fever virus; Live attenuated Japanese encephalitis virus|STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
40967034|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
40967035|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
40967036|NCT03954145|PROCEDURE|Enamel pumicing before bonding the lingual retainer.|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle. Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors."
40967037|NCT03954145|PROCEDURE|Enamel sandblasting before bonding the lingual retainer.|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
40967038|NCT02717611|DRUG|ACP-196 (acalabrutinib)|ACP-196 100 mg to be administered orally (PO) twice a day BID.
40967039|NCT03622944|PROCEDURE|Muscle Energy Technic|post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.
41295702|NCT00690937|DRUG|Placebo|Placebo
41295703|NCT02004756|OTHER|Exercise Program|The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
40768061|NCT06348199|DRUG|SB27|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
40768062|NCT06348199|DRUG|Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
40967040|NCT03622944|PROCEDURE|Deep Friction Massage|deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
40967041|NCT03622944|PROCEDURE|Exercise|spinal stabilization exercise were applied three sessions in a week totally six weeks.
40967042|NCT06025097|DRUG|Combination Solution|Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
41295704|NCT04594408|DRUG|Epinephrine|1 mL of 1:1000 mixed into irrigation bag.
41295705|NCT04594408|DRUG|Tranexamic acid|1 g IV x 1 dose to be administered intraoperatively.
41295706|NCT04594408|DRUG|Epinephrine and Tranexamic Acid|1 mL of 1:1000 epinephrine mixed into irrigation bag, and 1 g tranexamic acid x 1 dose to be administered intraoperatively.
41295707|NCT05914272|DRUG|Osmotic drugs|Patients had used osmotic drugs within 72 hours of admission.
41295708|NCT00644540|BIOLOGICAL|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
40967043|NCT03128554|OTHER|Intervention with Training and Materials|Peer-Led Continuing Medical Education Session and Provider/Patient Handouts
40967044|NCT02454491|DRUG|Heparin|intraradial administration of heparin 5000 ui
40967045|NCT02454491|DRUG|Verapamil|intraradial administration of verapamil 5 mg
40967046|NCT05318170|PROCEDURE|Laparoscopic ultra-radical lymph node debulking|Laparoscopic ultra-radical lymph node debulking using Yasargil clamps
40967047|NCT00724360|DRUG|Herceptin (trastuzumab)|Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression
40967048|NCT03824613|DIAGNOSTIC_TEST|Urinary miRNA|MiRNA detection in urine
40967049|NCT04191720|OTHER|Weighted blanket|Patients that were randomly assigned to the intervention group received a weighted blanket to use at their will to reduce anxiety
40967050|NCT00401453|BEHAVIORAL|Diet: carbohydrate days. (Name: oatmeal.)|Dietary intervention with two days of oatmeal compared to normal diabetes adapted diet in insulin resistant subjects.
40967051|NCT02387398|PROCEDURE|Early Angiography|Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
40967052|NCT03766581|DRUG|BMS-986177|Oral administration
40967053|NCT03766581|OTHER|Placebo|Oral Administration
40967054|NCT03766581|DRUG|Clopidogrel|Oral administration
40967055|NCT03766581|DRUG|Aspirin|Oral administration
40967056|NCT03798483|OTHER|Individualised exercise|The intervention will be comprised of up to 6, one-to-one physiotherapy sessions, over a maximum duration of 3 months. 1 or 2 extra sessions are allowed if deemed essential by the participant's physiotherapist. Less than 6 physiotherapy sessions can be agreed with the participant if they have achieved their goals. Throughout this time participants will be required to perform an exercise programme a minimum of 3 times per week. The exercise programme aims to increase leg muscle strength and facilitate a return to the participant's usual activities. It may include hopping and change of direction tasks if these are activities the participant would normally do. Behavioural change techniques to increase participant adherence to the exercise programme will also be used.
40967057|NCT00587054|DRUG|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|"Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.~Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines."
40967058|NCT05425134|DIAGNOSTIC_TEST|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting Occult Nodal Metastasis of Clinical N0 Non-small Cell Lung Cancer
40967059|NCT01129817|OTHER|Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
41295709|NCT00644540|BIOLOGICAL|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
41295710|NCT03528252|OTHER|Written advice LDL Cholesterol|One A4 paper with written information on both sides
41457615|NCT05386134|DEVICE|Adaptive Optics Retinal Camera|The rtx1 is a non-invasive device functions without making contact with the eye. The fundus of the patient's eye is illuminated with the IR light emitted from the illumination optical system. The device is comprised of an optoelectronic sensor (OES) that measures the optical defects, software that calculates the necessary corrections and a deformable mirror (DM) that constantly adapts its shape to restore the image's clarity. The digital camera, which is built into the instrument, receives the images and then the images are recorded in the computer hard disk. The AO image software registers and averages the captured image series in order to reduce noise and produce a final enhanced image. The rtx1 integrates AO technology in a flood illumination imaging system and enables visualizing the retina with a high transverse optical resolution of 250 line-pairs per millimeter.
41457616|NCT04997551|DRUG|Colchcine|"In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day"
41457617|NCT00508833|BIOLOGICAL|287615 containing HBsAg with adjuvants|
41295711|NCT03528252|OTHER|Written advice Triglycerides|One A4 paper with written information on both sides
41295712|NCT04570449|DRUG|Fluoxetine|20 mg capsule
41295713|NCT04570449|DRUG|Placebo|fluoxetine placebo capsule
41295714|NCT00601289|DRUG|temozolomide|
41295715|NCT00601289|GENETIC|DNA methylation analysis|
41295716|NCT00601289|GENETIC|microarray analysis|
41295717|NCT00601289|GENETIC|protein expression analysis|
41457618|NCT00562718|DRUG|capecitabine|
40967060|NCT01129817|OTHER|Manual therapy and exercise|Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
40967061|NCT06078774|BEHAVIORAL|Virtual Health Coach|"Dyads first session will be 60-minutes, totaling 1 hour. Dyads will participate in weekly 30-minute sessions for weeks 2-12, totaling 5.5 hours.~Dyads will participate bi-weekly 30-minute sessions for 12 weeks, totaling 3 hours.~Dyads will participate in weekly 30-minute exercise sessions for 24-weeks, totaling 12 hours.~Children will have 3, 30-minute visits with their primary care physician (PCP) every 3 months, totaling 1.5 hours.~Parents will have three, 60-minute individual sessions, totaling 3 hours. Total study duration is 24 weeks, with a total of 26 contact hours.~Sessions follow a behavior therapy approach, including guided goal-setting, self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks, maintenance and relapse prevention. Weight is assessed weekly by coaches, with MI-consistent, autonomy-supportive feedback provided. Parent sessions will focus on ways to support their child's weight management."
40967062|NCT01897454|DRUG|Fluorouracil|Given IV
40967063|NCT01897454|DRUG|Gemcitabine Hydrochloride|Given IV
40967064|NCT01897454|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40967065|NCT01897454|DRUG|Irinotecan Hydrochloride|Given IV
40967066|NCT01897454|DRUG|Leucovorin Calcium|Given IV
40967067|NCT01897454|DRUG|Oxaliplatin|Given IV
40967068|NCT06011044|PROCEDURE|Intercostal Nerve Block|The intercostal nerve block test is a medical intervention that involves the administration of a local anesthetic to the intercostal nerves, which are located between the ribs. The intervention involves injecting a small amount of anesthetic solution near the targeted intercostal nerves, which temporarily numbs the area and provides potential pain relief. The intercostal nerve block test is considered a diagnostic tool to help guide further treatment decisions for conditions such as intercostal neuralgia, rib fractures, or postoperative pain. It is generally a safe and well-tolerated procedure, often performed under local anesthesia or with the assistance of image guidance to ensure accurate needle placement. Following the test, the patient's response is evaluated, and if pain relief is achieved, it may indicate that intercostal nerve block injections could be an appropriate treatment option.
40967069|NCT00381485|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
40967070|NCT00381485|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
40967071|NCT00381485|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
40967072|NCT05715034|BEHAVIORAL|Compassionate Care|Single-session web-based program
41295718|NCT00601289|GENETIC|proteomic profiling|
40967073|NCT05715034|BEHAVIORAL|Relaxing with Nature|Single-session web-based program
40967074|NCT01693653|DRUG|Tocilizumab|Intravenous infusions every 4 weeks for 3 doses.
40967075|NCT05923437|OTHER|Feeding model group with a chronobiological approach|"Breast milk will be given to the newborns in the intervention group for 3 days in line with the feeding model with a chronobiologic approach simultaneously with the provision from the mother, and the newborn will be ensured to receive breast milk in accordance with the day cycle. Within the scope of the study, firstly, mothers and nurses in the NICU will be informed about the study. Mothers will be asked to put the milk mothers express between 06:00-17:59 in the daytime breast milk storage bag and the milk mothers express between 18:00-05:59 in the nighttime breast milk storage bag and bring them to the unit. The brought breast milk will be prepared by the nurses by matching day and night milk according to the dates, with the first milk brought in priority, and the newborns will be fed by using the time of day factor (cycle so that the milk collected during the day will be given during the day and the milk expressed at night will be given at night)."
40967076|NCT02063620|DRUG|Ketamine HCL|ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
40967077|NCT06238050|PROCEDURE|introduction of oxygen therapy or not|During hospitalisation, surgeon decides if patient needs and will have an oxygen therapy during this hospitalisation and at home.
40967078|NCT00359060|BEHAVIORAL|Physical activity|
40967079|NCT04838613|DRUG|[18F]CTT1057|Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
40967080|NCT04838613|DRUG|[68Ga]Ga-PSMA-11|Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
40967081|NCT01561170|DEVICE|Active Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive active devices. Both patients and investigator are blinded.
41457619|NCT00562718|PROCEDURE|adjuvant therapy|
40967082|NCT01561170|DEVICE|Placebo Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive placebo devices. Both patients and investigator are blinded.
40967083|NCT04011267|OTHER|Physical therapy by foot-ankle segmental and functional exercises|The physiotherapeutic foot-ankle exercise protocol is based on previous clinical trials. It was designed following three criteria established in a supervised, face-to-face intervention: muscle stretching; strengthening of the intrinsic muscles; and strengthening of the extrinsic foot-ankle muscles and functional exercises, such as balance and gait training. To avoid monotony, game principles were inserted to reward the exercise execution and enhance motivation. The exercises change from session to session, and the maximum duration is no longer than 20 minutes. The exercises should only be done 3 times/week; no more than eight exercises each day; and the individual difficulty is regulated by the effort scale to manage the customized progression. In total, 39 different exercises were chosen, and when including their sublevels of progression, a total of 104 different exercises can be completed.
41295719|NCT00601289|OTHER|laboratory biomarker analysis|
41295720|NCT03223038|OTHER|No intervention|No intervention - exposure is mechanical ventilation in PICU
41295721|NCT02572206|RADIATION|PET/SPECT Scan|PET scan will be performed on a mCT scanner.
41457620|NCT00562718|RADIATION|radiation therapy|
40967084|NCT04148053|DIAGNOSTIC_TEST|TB-antigen responsive T cell markers|A blood test including a series of T cell markers which are responsive to TB antigens
40967085|NCT02622308|DEVICE|FlowOx™|FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
40967086|NCT04664712|DIETARY_SUPPLEMENT|Tendisulfur Pro|Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) \[17, 18\], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)
40967087|NCT04664712|DEVICE|Focused shock wave|We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.
40967088|NCT00970567|BEHAVIORAL|Different insulin therapy at different time points|different insulin therapy after positive blood ketones
40967089|NCT00299975|DRUG|MaZiRenWan (MZRW) Low dose|Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
41457621|NCT06492551|OTHER|Trak exercise prescription protocol|Online treatment based on therapeutic exercise using the Trak software. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques to improve secretion management and respiratory mechanics will also be included.
41137889|NCT01855399|BEHAVIORAL|Peer Coaching|All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
41457622|NCT06492551|OTHER|Conventional rehabilitation plan in the gym|Treatment is based on therapeutic exercise following a conventional rehabilitation plan. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques will also be included to improve secretion management and respiratory mechanics.
41457623|NCT01055886|DRUG|nicotine patch|Nicotine patch, 7-21 mg.
40768063|NCT05881291|DRUG|ciprofol|"induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1."
40967090|NCT00299975|DRUG|MaZiRenWan (MZRW) Median dose|Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
40967091|NCT00299975|DRUG|MaZiRenWan (MZRW) High dose|Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
40967092|NCT02170298|DRUG|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
41295722|NCT02572206|DEVICE|MRI scan|Structural MRI will be obtained to permit co-registration of PET images.
41295723|NCT05776186|DRUG|Spinal anesthesia with heavy bupivacaine|Spinal anesthesia
41295724|NCT02855814|OTHER|Body Composition|No intervention. This is an observational, normative study of body composition variation in preterm infants
41295725|NCT03463265|DRUG|nab-sirolimus|nab-sirolimus, single agent
41457624|NCT01055886|DRUG|placebo patch|placebo patch used from weeks 4-6
40967093|NCT06127953|PROCEDURE|intermediate cleft rhinoplasty|intermediate cleft rhinoplasty using open approach and combined techniques of Tajima, Dibbell and Potter's Rhinoplasty
40967094|NCT03706105|BEHAVIORAL|Cardiac Rehabilitation|3 x week \~1 hour of exercise + education
40967095|NCT05798832|OTHER|Virtually reality training group|BLS Training with VR
40967096|NCT05798832|OTHER|Traditional training group|BLS Training with Traditional
40967097|NCT02392143|OTHER|Printed Education Material|The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test \[18\]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.
41295726|NCT03463265|DRUG|nab-sirolimus + temozolomide|temozolomide, combination
41295727|NCT03463265|DRUG|nab-sirolimus + bevacizumab|bevacizumab, combination
41295728|NCT03463265|DRUG|nab-sirolimus + lomustine|lomustine, combination
41457625|NCT02385760|DRUG|CTX-4430|
41457626|NCT02385760|DRUG|Placebo|
41457627|NCT01199653|PROCEDURE|Operative treatment|Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.
41457628|NCT01199653|PROCEDURE|Non-operative treatment with arm immobilised to a sling|Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
40967098|NCT02392143|OTHER|Academic Detailing|Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.
40967099|NCT02392143|OTHER|Academic Detailing+Telephone Education|PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.
40967100|NCT06261385|BEHAVIORAL|typology-based intervention|A typology-based intervention delivered by smoking cessation (SC) counsellors to prevent smoking relapse in ex-smokers who recently quit
40967101|NCT06230887|BEHAVIORAL|Building Spiritual Strength|Spiritually Integrated group intervention for moral injury
40967102|NCT06230887|BEHAVIORAL|Present Centered Group Therapy|Active control, manualized evidence-based coping skills intervention for PTSD
40967103|NCT04654130|OTHER|Neurofeedback|"NFB is a type of brain training in which a person is given real-time information (or feedback) from their own brain activities to help them potentially change how their brain is functioning (i.e., to work in a healthier or more effective manner). In the current study, we will implement at-home, supervised (via teleconferencing) neurofeedback sessions using the Muse headband paired with the Myndlift software application to conduct alpha-down neurofeedback once per week, for 19 weeks."
40967104|NCT06117657|DRUG|Low dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^11 vg/kg.
40967105|NCT06117657|DRUG|Middle dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 8.0x10\^11 vg/kg.
40967106|NCT06117657|DRUG|High dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^12 vg/kg.
40967107|NCT05532657|OTHER|Hearing intervention|The hearing intervention is best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist for 3 years and will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
40967108|NCT05532657|OTHER|Successful aging/delayed hearing intervention|The successful aging health education program follows the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator, with initial sessions spaced over the 2-3 months post-randomization and semi-annual sessions for 3 years. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
40967109|NCT00065689|DEVICE|high-intensity light therapy|
40967110|NCT06364098|DRUG|Misoprostol|400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion
41295729|NCT03463265|DRUG|nab-sirolimus + marizomib (MRZ)|marizomib (MRZ), combination
40768064|NCT05881291|DRUG|propofol|"induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1."
41295730|NCT03463265|DRUG|nab-sirolimus + temozolomide + radiotherapy|temozolomide + radiotherapy, combination
41295731|NCT03684161|DIAGNOSTIC_TEST|Cardiopulmonary function|Body composition measurements; Pulmonary function tests; Cardiopulmonary exercise test; Force frequency releationship, ultrasound
40967111|NCT04425915|BIOLOGICAL|Convalescent Plasma|Dose-250 ml Frequency - 2 doses on consecutive days Duration -Start by day 3 of symptom onset (of severe COVID-19 as in inclusion criteria) in eligible patients
41295732|NCT05851846|BEHAVIORAL|Amygdala insula retraining|Mind body intrevention
41295733|NCT02251730|BEHAVIORAL|Smoking cessation|Refer for smoking cessation
41295734|NCT04051593|OTHER|Cervical stabilization exercise|The participants followed instructional videos and performed the cervical stabilization exercise program at home for 20 minutes/day, 3 days/week, for 6 weeks.
41295735|NCT00695994|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
41295736|NCT00695994|DRUG|gemcitabine and carboplatin|"Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.~Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.~Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.~Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion."
41295737|NCT02950662|OTHER|Overdenture|Active comparator will be metal housing and peek housing
40768065|NCT06634069|DRUG|Sodium Lactate|0.5M HSL (containing 504mM of sodium and lactate)
40768066|NCT06634069|DRUG|3% NaCl|active compartor 3% NaCl
40768067|NCT06601179|DEVICE|HIFU|high-intensity focused ultrasound treatment of benign prostatic hyperplasia
40768068|NCT05983705|BEHAVIORAL|AFFEKT - a manual based brief parent program for parents of children (aged 6-12 years) with externalizing behaviors.|The AFFEKT program includes five group sessions, two hours each, provided on a weekly basis. The program is delivered by therapist trained in Cognitive and Behavioral Therapy (CBT) and AFFEKT. The participants also receive a participation material, covering the same themes that are addressed in the program and working sheets for the home-assignments that are provided in-between sessions.
40768069|NCT06303453|OTHER|Balance exercises|Balance exercises includes active movements (flexion, extension, abduction, adduction) of one upper extremity and lower extremity, trunk movements (bending forward and rotation), raising heel, raising toes and raising heel. Every move in each session will be hold for 30 seconds. The part B comprises of training i.e., holding positions in standing posture which include moving the ball up and down in a straight line with two upper extremities, moving the ball up and down in an oblique line with two upper extremities, moving the ball forward and backward with left and right lower extremities, moving the ball laterally with left and right lower extremities, throwing the ball against the wall with hand and throwing the ball against the wall with foot.
40768070|NCT06303453|OTHER|Resisted exercises|"The resistance training protocol include shoulder flexion and extension with 1 kg weight, shoulder pulley with 2 kg weight, arm curls with 1 kg weight, wall push-ups, bridging, hip abduction and adduction against resistance band, knee extensions and flexion in sitting position with resistance applied by contralateral limb, knee adduction and abduction with resistance band, mini squats, strengthening exercise for toes flexor and extensor (22), resisted inversion and eversion and straight leg raise (SLR) with 1 kg ankle weight (10).~Every move in each session comprises of 2 sets of 3 reps each and 1 set will be added at 4th and 8th week."
40768071|NCT01285232|DRUG|Anakinra|150 mg sc once daily during four weeks
40768072|NCT06468137|BEHAVIORAL|Swedish I-ACE|Rehabilitative programme with focus on communication strategies and problem solving for people with hearing loss.
40768073|NCT06468137|BEHAVIORAL|Clinical visit|Visit in the clinic with focus on audiologic rehabilitation.
40768074|NCT06468137|OTHER|No follow-up|Participants choosing no follow-up.
40967112|NCT04425915|OTHER|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
40967113|NCT01893164|PROCEDURE|simple decompression|decompression of the ulnar nerve
40967114|NCT01893164|PROCEDURE|anterior subcutaneous transposition|transposition of the ulnar nerve into subcutaneous bed
40967115|NCT01893164|PROCEDURE|anterior intramuscular transposition|transposition of the ulnar nerve into muscular tissue
40967116|NCT01023932|DEVICE|Cochlear Implants|
41137890|NCT01855399|BEHAVIORAL|Decision Aid|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
41137891|NCT01109979|DRUG|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
41137892|NCT01109979|DRUG|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
40967117|NCT02131207|DEVICE|magnetic resonance imaging|Undergo pelvic MRI
40967118|NCT02131207|PROCEDURE|prostate biopsy|Undergo prostate biopsy
40967119|NCT03773991|DIAGNOSTIC_TEST|Lung MRI|Proton Lung Magnetic Resonance Imaging
40967120|NCT03773991|DIAGNOSTIC_TEST|Sodium MRI|Sodium Soft Tissue Magnetic Resonance Imaging
40967121|NCT03773991|DIAGNOSTIC_TEST|Chest CT|High-resolution Quantitative Chest CT
41137893|NCT05657470|DRUG|Tenecteplase|intra-arterial tenecteplase
41137894|NCT04218877|OTHER||There will be no intervention, only observation
41137895|NCT00330785|DRUG|Amlodipine/Atorvastatin|
41137896|NCT03249857|BEHAVIORAL|cognitive tasks + IQ + MINI|"Patients will perform different tasks:~* cognitive tasks : reaction time (Alert TEA, Zimmermann and Fimm, 2005) + Edinburgh laterality questionnaire (Oldfield,1971) + hamilton and young's scale (Tohen et al., 2009) + Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) + experimental task (approach/ avoidance and affordance task).~* Intelligence Quotient (IQ) test (PM38, Raven, 1960)~* Mini International Neuropsychiatric Interview (MINI, Van Vliet et al., 2006)"
41137897|NCT03249857|BEHAVIORAL|cognitive tasks|Healthy volunteers will perform only the cognitive tasks = reaction time alert TEA, Zimmermann and Fimm, 2005 + Edinburgh laterality questionnaire (Oldfield, 1971) + experimental task (approach/ avoidance and affordance task).
41137898|NCT05068232|RADIATION|Ablative Radiation|Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.
41137899|NCT05068232|DRUG|Durvalumab|Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.
41137900|NCT05068232|DRUG|Etoposide|Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
41295738|NCT06385964|DRUG|SHR-4597|SHR-4597 by dry powder inhalation
40967122|NCT03773991|DIAGNOSTIC_TEST|Echocardiography|Transthoracic 2D Speckle-Tracking Echocardiography
40967123|NCT03773991|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide|Fractional Exhaled Nitric Oxide testing
40967124|NCT03773991|DIAGNOSTIC_TEST|Pulmonary Function Tests|Spirometry and Plethysmography
40967125|NCT03773991|DIAGNOSTIC_TEST|Blood Sampling|Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins
40768075|NCT05256537|OTHER|Omission of the drug mycophenolate mofetil|Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
40967126|NCT03773991|DIAGNOSTIC_TEST|Six-Minute Walk Test|Six-Minute Walk Test
40967127|NCT03773991|DIAGNOSTIC_TEST|Dyspnea Questionnaires|Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale
40967128|NCT03695120|OTHER|Change of treatment plan|Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
40967129|NCT06295250|BEHAVIORAL|Manualized Group Based Psychotherapy|Manualized Group Based Psychotherapy. Adapted from the World Health Organization (WHO) Problem Management Plus (PM+) intervention, this intervention includes behavioral activation, enhancing social support, and problem management.
40967130|NCT06295250|OTHER|Poverty Alleviation|This intervention includes Asset transfer, skill transfer, financial literacy education, stipend, savings accounts, veterinary support, feed, and agricultural training
40967131|NCT03570645|DRUG|Dexmedetomidine Group|combination of ropivacaine and dexmedetomidine 100 ug every time
40967132|NCT03570645|DRUG|dexamethasone group|combination of ropivacaine and dexamethasone 10mg every time
40967133|NCT03570645|DRUG|control group|block with only ropivacaine
40967134|NCT00394732|DEVICE|Total Disc Prosthesis|
40967135|NCT00394732|BEHAVIORAL|Multidisciplinary rehabilitation program|
40967136|NCT05228132|DEVICE|Pristine™ Long-Term Hemodialysis Catheter|Placement of the Pristine™ Long-Term Hemodialysis Catheter Placement.
40967137|NCT06178510|DEVICE|INTELLiVENT-ASV.|INTELLiVENT-ASV® is a closed-loop ventilation mode that automatically adjusts respiratory rate and tidal volume according to the oxygen and ventilatory patient needs
40967138|NCT01352910|DEVICE|rTMS|120 pulses 0.2 Hz
40967139|NCT01352910|DEVICE|Sham rTMS|120 pulses 0.2 Hz
41137901|NCT05068232|DRUG|Carboplatin|Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
40967140|NCT01651247|PROCEDURE|Serum sample|Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
40967141|NCT04799431|DRUG|Neoantigen Vaccine with Poly-ICLC adjuvant|"Neoantigen Vaccine with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22. 2 to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
40967142|NCT04799431|DRUG|Retifanlimab|500 mg will be administered as a 30 minute IV. Infusion (-5 min/+15min) on Day 1 of each 28 day cycle every 4 weeks.
40967143|NCT03528772|DRUG|Minoxidil|application of minoxidil forte 5% gel three time per day on the anus for four weeks
40967144|NCT03528772|DRUG|Glyceryl trinitrate|application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
40967145|NCT02495805|PROCEDURE|Continuous proximal adductor canal block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
41137902|NCT02074228|DRUG|Methylphenidate (Concerta)|
41137903|NCT00807599|PROCEDURE|Stem cell transplant x 1 or x 2|"After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.~On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L."
40967146|NCT02495805|PROCEDURE|Continuous femoral nerve block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
40967147|NCT03598283|DEVICE|Ultrasound/transient elastography|The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
40967148|NCT05438056|OTHER|education with mobile application|providing training to mothers of premature babies with a mobile application
40967149|NCT00662012|DRUG|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
40967150|NCT01558271|DRUG|LY2189265|
41295739|NCT06385964|DRUG|Placebo|Placebo by dry powder inhalation
41295740|NCT03453463|OTHER|exercise|3x week predominately resistance exercise for 18 months
41457629|NCT04636541|BEHAVIORAL|Goal Management Training|Goal Management Training® (GMT) has been developed to improve executive functions. It was validated in patients presenting executive dysfunction following many conditions: acquired traumatic brain injury, neurodevelopmental spina bifida, attention deficit and hyperactivity disorder (ADHD), subjective cognitive complaints and multiple sclerosis. GMT includes self-instruction strategies, self-monitoring exercises, cognitive training techniques, psychoeducation on cognitive processes, mindfulness exercises and assignments between sessions. It has been shown to increase patient awareness of deficits and improve cognitive control in goal-directed behaviors. The original GMT is a nine-week program administered to dysexecutive patients in 90-to-120-minute group sessions. Thus, it might be suitable for PD-MCI patients presenting with executive dysfunction.
40967151|NCT01558271|DRUG|Placebo|
40967152|NCT01558271|DRUG|Liraglutide|
40967153|NCT00095901|DRUG|Capecitabine|
40967154|NCT04511169|BEHAVIORAL|digital self-help|The digital self-help program is targeting every-day ADHD symptoms in adults with a diagnosed ADHD
40967155|NCT04541862|OTHER|Intensive care|intensive care for critically ill patients in the intensive care units
40967156|NCT04481867|PROCEDURE|densah bur|osseodensification densah bur
41295741|NCT02175667|PROCEDURE|Global Postural Reeducation|Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
41295742|NCT01207739|DRUG|Doxycycline|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
41295743|NCT01207739|DRUG|Clarithromycin and hydroxychloroquine|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
40967157|NCT01192516|BEHAVIORAL|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
40967158|NCT01192516|BEHAVIORAL|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
40967159|NCT05023772|PROCEDURE|Stereotactic Laser Ablation|MR Guided laser ablation therapy
40967160|NCT05023772|RADIATION|Stereotactic Radiosurgery|Precise delivery of radiation to spinal tumor
40967161|NCT05023772|DIAGNOSTIC_TEST|MRI guided laser ablation|Surgery will take place in intraoperative suite to include operating room and MRI scanner
40967162|NCT01239004|DRUG|Placebo|6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
40967163|NCT01239004|DRUG|Colesevelam|6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
40967164|NCT05680597|OTHER|Balance Tele-Rehabilitation Agility Boot Camp (ABC)|The intervention is tele-rehabilitation conducted by a physical therapist virtually for 60 minutes approximately three times a week for four weeks (12 sessions). Participants will be assessed for seven days pre and post intervention using wearable sensors (APDM wearable technologies) to monitor daily mobility.
41137904|NCT00807599|DRUG|lenalidomide and dexamethasone|Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
41295744|NCT01207739|DRUG|Placebo|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
41295745|NCT01435993|DRUG|GSK1223249|Intravenous infusion
41295746|NCT01435993|OTHER|Saline placebo|placebo intravenous infusion
40967165|NCT05238090|OTHER|Passive and active analytical stretching exercises|"For each stretching technique described, 3 repetitions of 15 seconds duration will be performed of 15 seconds duration each, within the patient's tolerance threshold. In any case, the impossibility of performing any technique due to exacerbation of pain shall be recorded in a patient record created for this study, noting the technique in question and the reason for its technique in question and the reason for its non-application. Passive stretches shall be applied in the same order for all subjects.~The physiotherapists in charge of applying the treatments will be trained in advance in the different techniques to be applied and will not in the different techniques to be applied and shall not intervene at any time in the two previous phases.~Both the control group and the study group will receive their respective treatments two days a week for four weeks. In no case will any other type of treatment be associated treatment during the whole process."
40967166|NCT05238090|OTHER|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
41137905|NCT02340806|DEVICE|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
41137906|NCT01861041|DRUG|Heavy Bupivacaine|7,5 mg intrathecal hyperbaric bupivacain,
41137907|NCT01861041|DRUG|Isobaric Bupivacaine|7.5 mg intratecal isobaric bupivacain
41137908|NCT02056925|OTHER|Echocardiography|
41137909|NCT05149950|BEHAVIORAL|Active internet treatment|The patient gets access to the internet treatment via a secure login to 1177 The care guide e-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
41137910|NCT00128765|BEHAVIORAL|an integrated self-management education program|disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada
41137911|NCT00128765|BEHAVIORAL|regular practice nurse review (monitoring controls)|protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
41295747|NCT02559232|DRUG|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
41295748|NCT04302389|BEHAVIORAL|myWW App, Virtual Workshops, and Private Facebook Group|The 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and a private online community. Participants are given a personalized food plan based on expert healthy eating guidelines and the latest nutritional science, an activity plan designed to promote regular physical activity and techniques to help shift members towards a helpful mindset for lasting change all within the WW app. Participants will attend weekly virtual workshops led by an expert WW Coach. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals each week. Participants will be encouraged to participate in a private Facebook group that gives participants an opportunity to receive motivational support from each other. Participants can post about their journey through photos, videos, and comments.
41295749|NCT02690467|DEVICE|Insupen G34x3,5mm|
41457630|NCT04636541|BEHAVIORAL|Psychoeducation|See the Arm section for full details. For a justification of how we designed this intervention: Many clinical guidelines include general recommendations about giving information to PD patients and family so they can take part into decision process. However, few standardized psychoeducation interventions are available, and they don't include information on PD cognitive decline. Some studies investigated Mindfulness Based Stress Reduction (MBSR) and other related mindfulness interventions in PD patients. In this approach, formal meditative exercises are included to develop non-judgmental attention to experiences in the present moment. In elderly patients with MCI unrelated to PD, mindfulness interventions show positive effects on cognitive functioning, including attention, executive functioning and memory (Gard et al., 2014). Therefore, non-pharmacological interventions for PD-MCI including both education on cognitive symptoms, as well as mindfulness exercises, are promising.
40768076|NCT04212923|BEHAVIORAL|Medical Dashboard based self-management intervention|Before the start of the intervention, chronic kidney disease patients and care providers will receive a face-to-face training session on the use of Medical Dashboard. To avoid contamination, Medical Dashboard will only be made accessible for participants in the intervention group via a secure password-protected registration process.
41137912|NCT00128765|BEHAVIORAL|care at initiative of the patient (usual GP care)|care at initiative of the patient (usual GP care)
41137913|NCT06134193|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W) Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.
41137914|NCT06134193|DRUG|Surufatinib|250mg PO d1, Q3W
41137915|NCT06134193|DRUG|Tislelizumab|200mg IV d1, Q3W
41137916|NCT04718285|DRUG|Montelukast Oral Tablet|3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
41295750|NCT02690467|DEVICE|Insupen G32x4mm|
41295751|NCT04373980|DEVICE|phototherapy|estimate CD4 and CD8 subsets in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
41295752|NCT04099446|OTHER|Non-interventional|There is no intervention for this study
41295753|NCT00013039|BEHAVIORAL|Computer reminders|
41295754|NCT06096233|OTHER|Bouts of Exercise|The participants will run on the treadmill for 10 minutes (short) or 30 minutes (prolonged).
41295755|NCT04045223|OTHER|Blood samples|Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
40768077|NCT06232252|DRUG|BI 765423|BI 765423
40768078|NCT06232252|DRUG|Placebo matching BI 765423|Placebo matching BI 765423
40768079|NCT00516308|DEVICE|NightHawk|
40768080|NCT06632613|DRUG|ENN0403 capsules, low dose|ENN0403 capsules will be orally administered once a day for 5 consecutive days at low dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
40768081|NCT06632613|DRUG|ENN0403 capsules, high dose|ENN0403 capsules will be orally administered once a day for 5 consecutive days at high dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the placebo capsules will be administrated through a nasogastric tube/oral gastric tube.
40768082|NCT06632613|DRUG|Placebo|Placebo capsules will be orally administered once a day for 5 consecutive days based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
40768083|NCT01991873|DRUG|Maintenance Chemotherapy|
40768084|NCT01991873|DRUG|Panitumumab (Within maintenance phase)|
40768085|NCT01991873|DRUG|mFOLFOX6 (Within re-induction phase)|
40768086|NCT01991873|DRUG|Panitumumab (Within re-induction phase)|
40768087|NCT00001481|DRUG|Estradiol|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
40768088|NCT00001481|OTHER|Placebo|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
40768089|NCT00001481|DRUG|Progesterone|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
40768090|NCT05398848|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
40768091|NCT05398848|BIOLOGICAL|Placebo|"Before reconstitution:~Lyophilized powder for reconstitution in single-use vials~After reconstitution with BFA03 adjuvant:~Milk-white solution with no visible foreign matter"
40768092|NCT01066910|BEHAVIORAL|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
40768093|NCT01066910|BEHAVIORAL|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
40768094|NCT06585891|BIOLOGICAL|VRC-HIVMAB0121-00-AB|The CAP256J3LS bispecific antibody (bsAb) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of CAP256V2LS antibody with the light chain linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.
40768095|NCT06456164|DEVICE|Cook Cervical Ripening Balloon|The Cook Cervical Ripening Balloon is a double-balloon catheter designed to mechanically ripen the cervix prior to labor induction when the cervix is unfavorable for induction.
40768096|NCT06021613|BEHAVIORAL|Randomized instructions|"Behavioral: Start: On Cannabis- In this two-day block, participants will be instructed to consume cannabis for one day and avoid cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.~Behavioral: Start: Off Cannabis- In this two-day block, participants will be instructed to avoid cannabis for one day and consume cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis."
40768097|NCT05430321|OTHER|Assessment of physiological parameters|FT implementation begins 3 minutes before the procedures and 10 minutes continuous. After the end of the procedures further 3 minutes was given . Physiological parameters were simultaneously recorded on the registration form
40768098|NCT05430321|OTHER|Assessment of Stress|Newborn Stress Scale (NSS) was used end of the all procedures which means 13th minute.
41137917|NCT04718285|DRUG|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
41137918|NCT04718285|DRUG|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
41137919|NCT01884207|OTHER|MRI|
41137920|NCT02351791|OTHER|Patch 1|Patch 1:standard adhesive with own feces in sleeve
41295756|NCT05610891|DRUG|CLR 131|CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA
41295757|NCT01627756|OTHER|Lung Ventilation|In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
41137921|NCT02351791|OTHER|Patch 2|Patch 2:standard adhesive with own feces mixture in sleeve
41137922|NCT02351791|OTHER|Patch 3|Patch 3: standard adhesive with simulated feces in sleeve
40768099|NCT05430321|OTHER|Assessment of Comfort|Neonatal Comfort Behavior Scale (NCBS) was used end of the all procedures which means 13th minute.
41137923|NCT02351791|OTHER|Patch 4|Patch 4:standard adhesive with simulated feces mixture in sleeve
40768100|NCT05940272|BEHAVIORAL|Hematolo-GIST Training|Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
40768101|NCT05940272|BEHAVIORAL|Participants Appointment|Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
40768102|NCT06596525|OTHER|Conventional physical therapy|"Conventional physical therapy program will include:~1. Stretching exercises (forearm pronators, ulnar deviators, shoulder internal rotators, hip flexors and adductors, and hamstring muscle groups)~2. Strengthening exercises (ankle dorsiflexors, knee extensors, and hip flexor muscle groups)~3. Posture exercises~4. Balance and proprioception exercises~5. Walking training, obstacle crossing training, stair climbing and descending exercises"
41137924|NCT02351791|OTHER|Patch 5|Patch 5:standard adhesive with buffer in sleeve
41137925|NCT02351791|OTHER|Patch 6|Patch 6:standard adhesive with buffer mixture in sleeve
41137926|NCT02469025|OTHER|Manual caudal traction mobilization in resting position|
41137927|NCT02469025|OTHER|Manual caudal traction mobilization in end range position|
41137928|NCT02469025|OTHER|Selftreatment|Each subject is advice to do some exercises at home
41137929|NCT02629809|DRUG|Cyclophosphamide|Given IV
41137930|NCT02629809|DRUG|Fludarabine Phosphate|Given IV
41137931|NCT02629809|DRUG|Ibrutinib|Given PO
41137932|NCT02629809|BIOLOGICAL|Obinutuzumab|Given IV
41137933|NCT06075641|PROCEDURE|Gingival depigmentation|Gingival depigmentation is the most widely used periodontal procedure to remove or reduce the melanotic areas. Various techniques can be employed to effectively carry out the depigmentation procedure, including surgical scraping, scalpel technique, bur abrasion, free gingival graft, gingivectomy, cryosurgery, electrosurgery, chemical therapies, and different types of lasers
41137934|NCT01640951|DRUG|AIN457 150 mg|(1 injection per dose) and placebo to Secukinumab 150 mg
41137935|NCT01640951|DRUG|AIN457 300 mg|Secukinumab 150 mg (2 injections per dose)
41137936|NCT01640951|DRUG|Placebo|
41137937|NCT01141075|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
41137938|NCT04648215|OTHER|lavender oil|aromatherapy--two drops applied to a 2x2 gauze and pinned to subject's gown
41137939|NCT04648215|OTHER|Grapeseed Oil|aromatherapy--two drops applied to a 2 X 2 gauze and pinned to subject's gown
41137940|NCT05959902|OTHER|Forward Walking|During the 8-week treatment, the participants will undertake 10 minutes of forward walking, as well as a 5-minute warm-up and cool-down, three times a week on an even surface at their normal speed as a home exercise plan. During the warmup and cool down periods, the participants were advised to execute ankle toe motions, heel lift exercises, and hamstring and gastrocnemius-soleus stretches.
41137941|NCT05959902|OTHER|Physiotherapy Exercises|"Isometric quadriceps exercise. Straight leg raising (SLR) exercise. Isometric hip adduction exercise.~Terminal knee extension exercise:~Semi-wall squat exercise. Quadriceps drill exercise."
41137942|NCT01008787|BEHAVIORAL|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
41137943|NCT01008787|BEHAVIORAL|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
41137944|NCT01008787|BEHAVIORAL|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
41137945|NCT01008787|BEHAVIORAL|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
41137946|NCT03302091|DRUG|BI 1467335|28 day treatment period
41137947|NCT03051074|BEHAVIORAL|Floating|Floating supine in a pool saturated with Epsom salt for up to 90 minutes
41137948|NCT03051074|BEHAVIORAL|Comparison|Watching a relaxing film for up to 90 minutes
41137949|NCT00615368|DRUG|Epoetin alfa|1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.
41137950|NCT00615368|DRUG|Isotonic NaCl (Placebo)|1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia
41137951|NCT06086548|OTHER|metabolomic on plasma sample|metabolic phenotyping by plasma metabolomic and mitochondrial biomarker profiling
41137952|NCT00836537|DRUG|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fed
41137953|NCT00836537|DRUG|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fed
41137954|NCT05018143|BEHAVIORAL|STARS|This intervention will use an online mobile application for teach life skills, coupled with peer mentoring to support the use of safety planning.
41137955|NCT05018143|BEHAVIORAL|Control condition|In this intervention, participants will receive the safety planning intervention.
41137956|NCT03967197|DRUG|Saline spray|Physiologic saline spray
41137957|NCT03967197|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride 10% spray
41137958|NCT04437004|DRUG|Fenfluramine|The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials.
41137959|NCT05199506|DEVICE|RAP|Treatment of cellulite with RAP device
41137960|NCT01824849|PROCEDURE|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
41137961|NCT01824849|PROCEDURE|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
41137962|NCT03888807|DRUG|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
41137963|NCT03888807|DRUG|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
41137964|NCT06475521|OTHER|Infant Formula|Test group
40967167|NCT06506708|OTHER|Hydrotherapy + massage|The comprehensive Hammam experience will consist of 3 sessions at the Arab baths of Hammam Al Ándalus, Granada -Spain- (once every two weeks). Each session will involve a thermal circuit lasting approximately 75 minutes, following the institution's guidelines, inviting women to explore the warm, hot, and cold water baths, as well as the steam room. The thermal circuit will be complemented by a 15-minute relaxing massage using essential oils. During the final session, massage will be preceeded by a traditional Kessa treatment on a hot stone bed. During sessions, women will be involved in a multisensory experience, including aromatherapy and where they will also have the opportunity to sipping on mint tea and relax on a building all decorated in resplendent Arabian décor. One member of the research team will be responsible for coordinating the sessions in collaboration with the Al Ándalus institution, subject to their availability.
40967168|NCT05501301|OTHER|IS weaning off|IS weaning off will be conducted in recipients with chronic virus infection or side effects of IS
40967169|NCT01271062|PROCEDURE|gastric bypass surgery|
40967170|NCT01271062|PROCEDURE|abdominal surgery|
40967171|NCT01271062|BEHAVIORAL|very low caloric diet|
40967172|NCT01573975|DRUG|5RA-5RCM|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
40967173|NCT01573975|DRUG|5RA-5RCT|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
40967174|NCT01573975|DRUG|10RCA|rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
41137965|NCT04613284|DRUG|Recombinant human endostatin (Endostar)|Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.
41137966|NCT04613284|RADIATION|Thoracic irradiation of 50 Gy with 3DCRT or IMRT|Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.
41137967|NCT04813965|OTHER|Written information about potential chemotherapy-related cognitive symptoms without self-affirmation|
41137968|NCT04813965|OTHER|Written information about potential chemotherapy-related cognitive symptoms with self-affirmation|
41137969|NCT06251791|OTHER|conventional physiotherapy+ IMT|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
41137970|NCT06251791|OTHER|conventional physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
41137971|NCT03528915|OTHER|Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
41137972|NCT03528915|OTHER|whithout Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
41137973|NCT03559296|DIAGNOSTIC_TEST|Ultrasonographic assessment of postmastectomy lymphedema|Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume
41137974|NCT05790759|OTHER|No cueing versus Haptic cueing versus Auditory cueing during parkinson's disease gait|Patients walked in three conditions in a randomized order. During control condition, patients walked without cueing on a rectangular track of 63.2 meters at their comfortable gait speed. During Auditory Cueing Condition (ACC) patients walked on the same track using auditory cueing by the mean of a smartphone app called Soundbrenner thath deliverered rhythmic auditory stimulations through earphones paced 10% faster than each patient's preferred step frequence. During Haptic Cueing Condition (HCC) patients walked on the same track using haptic cueing by the mean of a vibratory device called Soundbrenner Pulse and attached to each patient's wrist located on their most affected side. The Soundbrenner app on the smartphone was connected to the Soundbrenner Pulse by Bluetooth to deliver rhythmic vibratory stimulations also paced 10% faster than each patient's preferred step frequence, the same frequence as during ACC.
41137975|NCT00452114|DEVICE|In-Exsufflator Cough Assist Device|
41137976|NCT00452114|DEVICE|Active Comparator: Flutter Valve Device|Active Comparator
41137977|NCT02383693|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
41295758|NCT01627756|OTHER|Non-ventilated Group|. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
41295759|NCT00279903|DRUG|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
40967175|NCT00025493|DRUG|docetaxel|
40967176|NCT03598530|PROCEDURE|Surgery|Surgical fracture fixation, using osteosynthesis, including single or multiple staged procedures (e.g. primary External Fixation and later conversion to internal fixation).
40967177|NCT04277416|DEVICE|Total Hip Arthroplasty|To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
40967178|NCT01211327|DRUG|Cyclosporine A|Cyclosporine 2% eye drops
40967179|NCT01211327|DRUG|Dexamethasone|Dexamethasone 0,1% eye drops
40967180|NCT03334903|DRUG|Gabapentin|600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
40967181|NCT00187369|PROCEDURE|Method of Delivery|CS or VB
41457631|NCT00376740|DRUG|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
41457632|NCT03635697|BEHAVIORAL|Mindfulness Auditory Intervention|This intervention is a short audio clip that focuses on the practices and principles of mindfulness. The goal of mindfulness is to bring awareness to a person's physical body as well as their thoughts and feelings.
41457633|NCT03770130|DRUG|Dexmedetomidine|Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia
40768103|NCT06596525|OTHER|Barefoot Whole Body Vibration Training (WBVTb)|"Each WBVT session will consist of the following schedule: 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest. Thus a treatment session will last 15 minutes in total. The participants will be barefoot. A specially designed walker will be used to provide support during WBVT for children who are unable to stand independently on the platform and. All exercises and WBVT sessions will be performed under the supervision of a physiotherapist and postural correction will be encouraged through visual feedback (the platform will be placed in front of a mirror) and verbal cueing. One set of WBVT along with the dynamic exercise program to be implemented on the platform is summarized below.~Stage 1: Semi-squat (knees flexed 10-45º) for 1 minute~Stage 2: Semi-squat +Calf raise for 1 minute~Stage 3: Triceps surae stretch for 1 minute"
41457634|NCT03770130|DRUG|Saline|Saline, a kind of crystalloid widely used in clinical treatment
41457635|NCT03885934|BIOLOGICAL|V114|V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration
41457636|NCT03885934|BIOLOGICAL|Prevnar 13®|Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
41457637|NCT04776005|OTHER|Data collection|Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.
41457638|NCT02840162|DRUG|Celecoxib|Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
41457639|NCT02840162|DRUG|Placebo|
41457640|NCT02305407|PROCEDURE|Surgical Revascularization|Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
40967182|NCT04851314|DEVICE|ICU certified ventilator|Examine anesthetic consumption rates
41457641|NCT02305407|OTHER|Conservative treatment|Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
40967183|NCT04851314|DEVICE|Non-ICU certified ventilator|Examine anesthetic consumption rates
40967184|NCT00784498|DRUG|Ketamine/Midazolam|Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
41137978|NCT04749329|DEVICE|Mesh Group|"All MG patients underwent the procedure with ante rectus positioned prophylactic mesh according to the following standardized technique. A BIO-A circular-shaped mesh measuring 8X10 cm in diameter is prepared with an internal 2 cm hole to let the bowel pass.~An at least 8x8 cm space is created between the anterior rectus sheath and the rectus abdominis muscle and, then, the mesh is positioned. The bowel is passed through the rectus muscle via the circular incision in the middle of the mesh. Single absorbable monofilament sutures anchored the mesh laterally in the ante rectus pocket, while medially the mesh is fixed with four stitches to the colon and to both the anterior rectal sheet. The stoma is attached to the skin similarly to CG patients."
41137979|NCT02194907|BEHAVIORAL|Brain activity training - anterior insula|training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain
41137980|NCT02194907|BEHAVIORAL|Brain activity training - medial prefrontal cortex|training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain
41137981|NCT05851014|DRUG|GB491 combined with Letrozole|Patients were randomized to receive GB491 150 mg orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
41457642|NCT01986725|BEHAVIORAL|standardized care (Intervention I)|During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
41457643|NCT01986725|BEHAVIORAL|Standardized care + WOMAN-PRO II program (Intervention II)|This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
40967185|NCT00784498|DRUG|Propofol|Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
40967186|NCT04812145|RADIATION|Chemoradiation|Hypofractionated radiotherapy with concurrent Gemcitabine
40967187|NCT03996252|DRUG|Calcipotriene 0.005% Foam|Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
41295760|NCT00279903|DRUG|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
41295761|NCT05941182|OTHER|online questionnaires|Before and after online questionnaires
41295762|NCT05782218|DIETARY_SUPPLEMENT|Almonds|Participants will receive 2.2 oz (62 g) of almonds to ingest within 15 minutes.
40768104|NCT06596525|OTHER|Shod Whole Body Vibration Training (WBVTs)|"Each WBVT session will consist of the following schedule: 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest. Thus a treatment session will last 15 minutes in total. The participants will wear everyday sports shoes. A specially designed walker will be used to provide support during WBVT for children who are unable to stand independently on the platform and. All exercises and WBVT sessions will be performed under the supervision of a physiotherapist and postural correction will be encouraged through visual feedback (the platform will be placed in front of a mirror) and verbal cueing. One set of WBVT along with the dynamic exercise program to be implemented on the platform is summarized below.~Stage 1: Semi-squat (knees flexed 10-45º) for 1 minute~Stage 2: Semi-squat +Calf raise for 1 minute~Stage 3: Triceps surae stretch for 1 minute"
41295763|NCT05782218|DIETARY_SUPPLEMENT|Coconut|Participants will receive 1 oz (30 g) of a coconut-chocolate bar and 1.4 oz (40 g) of 100% dried coconut chips to ingest within 15 minutes.
41295764|NCT01636869|DRUG|Bupivacaine|"20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.~Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block."
41295765|NCT03407391|OTHER|None - observational|No intervention - observational only
41295766|NCT00247390|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
41295767|NCT00247390|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
41295768|NCT00244205|PROCEDURE|Identifying genes methylated in urine|
40768105|NCT06596525|OTHER|Sham Whole Body Vibration Training (WBVTsh)|"During Sham WBVT; the same exercises that the intervention groups will receive on the vibration platform will be performed on the platform for the same duration (3 days per week for 15 minutes each session, over a period of 4 weeks) without the platform being activated."
40768106|NCT06007690|DRUG|Bel-sar|Bel-sar via suprachoroidal administration followed by laser application.
40768107|NCT06007690|DEVICE|Suprachoroidal Microinjector|Suprachoroidal injection device
40768108|NCT06007690|DEVICE|Infrared Laser|Laser application
40768109|NCT06007690|DEVICE|Sham Infrared Laser|Sham laser application
40967188|NCT03996252|DRUG|Efudex 5% Topical Cream|Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
40967189|NCT01484197|DRUG|75 µg indacaterol maleate (LB)|75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
40967190|NCT01484197|DRUG|75 µg indacaterol maleate (PoS)|75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
41295769|NCT03843658|OTHER|There is no intervention, but a diagnosis.|Cohorts will be determined by the primary rheumatology diagnosis.
40967191|NCT01484197|DRUG|37.5 µg indacaterol maleate (PoS)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
40967192|NCT01484197|DRUG|placebo to indacaterol (LB)|Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
40967193|NCT01484197|DRUG|placebo to indacaterol (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
40967194|NCT05458843|PROCEDURE|Fluid replacement|Participants will drink Gatorade Zero ad libitum, up to 1 cup every 15 minutes.
40768110|NCT06007690|DEVICE|Sham Microinjector|Sham injection device
40768111|NCT05907291|DRUG|CRN04894|CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
40768112|NCT05299424|DRUG|CM336_group 1|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40967195|NCT05458843|PROCEDURE|No fluid replacement|Participants will not be permitted to drink.
41295770|NCT00915811|DRUG|Fludarabine|Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
41295771|NCT00915811|DRUG|Busulphan|Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
41295772|NCT00915811|DRUG|Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme|Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
41295773|NCT00915811|PROCEDURE|Haematopoietic stem cell infusion|The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
41295774|NCT01780389|DRUG|Open-label flexibly dosed milnacipran|
41295775|NCT06498063|OTHER|Glucagon|Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.
41295776|NCT06498063|OTHER|Placebo|Placebo (0.9% NaCl).
41295777|NCT06498063|OTHER|Glucagon and exendin 9-39|Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).
41295778|NCT00005398|OTHER|There is no intervention|No applicable
41295779|NCT00619931|DRUG|APD791|APD791 or matching placebo in escalating doses
41295780|NCT03510143|DEVICE|Neoveil (Polyglycolic Acid Mesh)|Apply the Neoveil (Polyglycolic Acid Mesh) in the neck node dissection area in thyroid cancer surgery.
41295781|NCT01728272|DRUG|blood concentration of metoprolol|measure blood concentration of metoprolol
41295782|NCT05958303|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Total dosing of 1000 mg vitamin C, 600 IU vitamin E, and 600 mg of alpha lipoic acid.
41295783|NCT05958303|OTHER|Placebo|Placebo
41295784|NCT02389946|DEVICE|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
41295785|NCT02389946|DEVICE|Xience DES|
40768113|NCT05299424|DRUG|CM336_group 2a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768114|NCT05299424|DRUG|CM336_group 2b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768115|NCT05299424|DRUG|CM336_group 3a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768116|NCT05299424|DRUG|CM336_group 3b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768117|NCT05299424|DRUG|CM336_group 4a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768118|NCT05299424|DRUG|CM336_group 4b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768119|NCT05299424|DRUG|CM336_group 5|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768120|NCT05299424|DRUG|CM336_group 6a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768121|NCT05299424|DRUG|CM336_group 6b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768122|NCT05299424|DRUG|CM336_group 7|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768123|NCT05299424|DRUG|CM336_group 8a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768124|NCT05299424|DRUG|CM336_group 8b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40967196|NCT04451239|DRUG|topical steroids and cyclosporin-A|All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
41295786|NCT02575794|DRUG|Terameprocol|Given PO
41295787|NCT02575794|OTHER|Pharmacological Study|Correlative studies
41295788|NCT04021784|DEVICE|SDS|The patient is implanted with SDS.
41295789|NCT04021784|DEVICE|NEMOST|The patient is implanted with NEMOST.
41295790|NCT03230175|BIOLOGICAL|TTAX01|TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
41295791|NCT03230175|PROCEDURE|Surgical resection and debridement|"Perform surgical sharp debridement in the OR, to remove:~* infectious agents and biofilms (purulence),~* all debris, eschar, callus and macerated non-viable tissue from the wound base, and~* dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge.~Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate."
41295792|NCT03230175|DRUG|Systemic antibiotics|Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
41295793|NCT03230175|DEVICE|Off-loading|Provide off-loading device appropriate to the location of wound with full length boot or total contact cast
40967197|NCT01564381|DIETARY_SUPPLEMENT|ResA|90mg of resveratrol conjugated with arginine.
40967198|NCT01564381|DIETARY_SUPPLEMENT|Resveratrol|90mg of resveratrol.
40967199|NCT01564381|DIETARY_SUPPLEMENT|Placebo|Made up of cellulose.
40967200|NCT06177327|OTHER|Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.|Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome
40967201|NCT04091854|DRUG|HMS5552|To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
40967202|NCT02971397|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
41137982|NCT05851014|DRUG|Placebo combined with Letrozole|Patients were randomized to receive placebo orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
41137983|NCT03609450|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
40768125|NCT05299424|DRUG|CM336_group 9|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
40768126|NCT05299424|DRUG|CM336_RP2D|CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
40768127|NCT06612866|DIETARY_SUPPLEMENT|Keratin hydrolysate|The clinical study will be conducted in two phases. The first phase will aim at characterizing the metabolites present in human serum after consumption of the Kera-Diet® ingredient and at determining the overall absorption peak of the tested ingredient. The second phase will involve collecting sera enriched with metabolites at the absorption peak, following the ingestion of the ingredient. Subsequently, the final objective will be to characterize the influence of these sera enriched with metabolites of interest on the behavior of human skin cell and intestinal epithelial cell cultures.
40768128|NCT06600971|OTHER|acupressure application|The patients in the experimental group received acupressure application for a total of 8 sessions, 2 sessions per week.
40768129|NCT01514578|DRUG|TRV130A|Intravenous infusion of 1 hour duration
40768130|NCT01514578|DRUG|Dextrose in Water|Intravenous infusion of 1 hour duration
40967203|NCT02971397|DRUG|Cytarabine|Given IV
40967204|NCT02971397|DRUG|Daunorubicin Hydrochloride|Given IV
40967205|NCT02971397|OTHER|Laboratory Biomarker Analysis|Correlative studies
40967206|NCT01783301|DRUG|FSH|
40967207|NCT01009632|BEHAVIORAL|Resonant voice|4-hr of resonant voice exercise
40967208|NCT01009632|BEHAVIORAL|Voice rest|4-hr of complete refrain from any voice use
40768131|NCT01979185|DRUG|Simvastatin|
40967209|NCT01009632|BEHAVIORAL|Spontaneous speech|
41295794|NCT03225755|DRUG|Growth hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
40768132|NCT01979185|DRUG|SSP-004184SS|
40768133|NCT00844220|PROCEDURE|CT/MR|CT/MRI-directed clinical management strategy
40768134|NCT00844220|PROCEDURE|Catheterization|Standard clinical management directed by conventional coronary angiography
40768135|NCT03014414|BEHAVIORAL|Fun First|Learn key enjoyable maintenance skills before losing weight
40768136|NCT03014414|BEHAVIORAL|Weight Watchers|Focus on losing weight first via convenient meetings and personalized online tools
40768137|NCT06401044|DRUG|AMG 732|SC injection
40768138|NCT06401044|OTHER|Placebo|SC injection
40967210|NCT05846932|BEHAVIORAL|OTEE HORS|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided while participants are riding horses
40967211|NCT05846932|BEHAVIORAL|OT Clinic|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided in a traditional clinic
40967212|NCT02697032|DRUG|Bicalutamide|150mg
40967213|NCT02697032|PROCEDURE|FDHT PET|PET scan
40967214|NCT02277756|DEVICE|thermode|thermal stimulation with test thermode
40967215|NCT01983436|OTHER|Manual Lymphatic drainage|Manual lymphatic drainage of the face and the neck is a massage technique that aims to remove an edema of this anatomical region. The technique consists to stimulate the lymph nodes in order to accelerate the lymph flow and to achieve a specific massage to promote the entry of lymph nodes in the initial lymphatics. Massages follow anatomical pathways of vessels and of lymph nodes of the head and the neck. The technique should be smooth and painless.
40967216|NCT03129984|DEVICE|Mandibular movement tracking|Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
40967217|NCT05512572|DEVICE|IPL|intense pulsed light
40967218|NCT05512572|PROCEDURE|Conservative treatment or excision with curettage|conservative treatment or excision with curettage but without IPL-MGX treatment as a control
40967219|NCT04770662|OTHER|Questionnaires|"Administered Questionnaires:~* Dutch version of Children's Yale-Brown Obsessive Compulsive Scale (CYBOCS, Goodman W.K. e.a.)~* Dutch version of Eating Disorder Inventory-3 (EDI-3, David M. Garner)~* General Questionnaire: demografic , scholar and social information and child psychiatric history~* Dutch version of the Child Behavior Checklist (CBCL, T.M. Achenbach)~* Anorectic Behavior Observation Scale (ABOS, Vandereycken W., Universitair Centrum Kortenberg, 1992)"
40967220|NCT05103631|GENETIC|CATCH T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2~DL2: 1x10\^8/m2~DL3: 3x10\^8/m2~DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
40967221|NCT04316923|DIAGNOSTIC_TEST|ECG|ECG will be performed during each visit in the study group.
40967222|NCT04316923|DIAGNOSTIC_TEST|24-hour ECG monitoring|24-hour ECG monitoring will be performed during each visit in the study group.
40967223|NCT04316923|DIAGNOSTIC_TEST|Cardio-pulmonary exercise test (CPET)|CPET will be performed during the first and the last visit in the study group.
40967224|NCT04316923|DIAGNOSTIC_TEST|Cardiac biomarkers|Cardiac biomarkers will be assessed during each visit in the study group.
40967225|NCT05226715|OTHER|chiropractic manual therapy|high velocity low amplitude thrust into a human joint
41295795|NCT06138847|DIAGNOSTIC_TEST|electroencephalogram|Polygraphic derivations generally include an ECG channel, which is standard on EEG recordings, plus an optional EMG channel. Subsequently, the signal was recorded at 512 Hz and inspected using the standard bipolar and referential montages
41295796|NCT01948934|PROCEDURE|Amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
41457644|NCT03647917|BIOLOGICAL|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
41457645|NCT03647917|BIOLOGICAL|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
41457646|NCT01633307|OTHER|Education|Teaching program
41457647|NCT00213551|DRUG|Glutamine|
40768139|NCT06588400|DEVICE|AOSEPT Plus and AOCup lens case|Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.
40768140|NCT06588400|DEVICE|AOSEPT Plus with HydraGlyde and AOCup lens case|Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus with HydraGlyde) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.
40768141|NCT06588400|DEVICE|Habitual contact lenses|Daily wear, reusable, soft (including hydrogel and silicone hydrogel) or rigid gas permeable (RGP) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
40768142|NCT06433947|DRUG|OPN-6602|orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily
40768143|NCT06433947|DRUG|Dexamethasone|Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle
40967226|NCT01949558|BEHAVIORAL|Dietary Intervention|
40967227|NCT03975608|BEHAVIORAL|"Adaptation of CALM"|"The therapy is built up by 3-8 sessions (duration about 45-60 min) over a period of 6 months. All dimensions are explored with every patient, but the order and extent of each dimension are adapted to the individual needs of the patient.~The sessions address the 4 dimensions of the original program designed for palliative cancer patients:~1. Symptom management and communication with healthcare providers~2. Changes in self and relations with each others~3. Spirituality, sense of meaning, and purpose~4. Thinking of the future, hope, and mortality~As an adaptation, the investigators will especially focus on two other aspects which take into account the specific symptoms and challenges in patients with ALS: (i) communication skills and (ii) emotional expression and control."
40967228|NCT01839851|DRUG|Treatment with any inhaled corticosteroid|Use of any inhaled corticosteroid (daily frequency and dose will be registered)
41295797|NCT01053624|PROCEDURE|Tracheostomy|This protocol has been design to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. We hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications
41457648|NCT00213551|DRUG|Glucose|
41457649|NCT00213551|DRUG|glutamine-antioxidants containing solution|
41457650|NCT05183282|DEVICE|Tarsus Patch|The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
40967229|NCT01839851|DRUG|Treatment with any intranasal glucocorticoid|Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
40967230|NCT05502601|PROCEDURE|Non-surgical periodontal treatment|"SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
40967231|NCT01811654|DEVICE|Intra-Articular Hyaluronic Acid-Euflexxa|IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
40967232|NCT03958851|DIAGNOSTIC_TEST|Doppler ultrasonography of renal arteries|"Ultrasound evaluation will be performed for all patients as well as healthy individuals.in patients with lupus nephritis,the ultrasound evaluation will be performed the 24 h prior to the renal biopsy . In the maximum long-axis section images, the largest diameter and width of each kidney will be measured. The participants will be scanned in a supine or decubitus position to achieve an ultrasound beam as close to parallel to the blood flow direction in the intrarenal artery as possible. RRI is measured as :~RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the average of three measurements will be taken."
40967233|NCT03958851|DIAGNOSTIC_TEST|Renal biopsy|Renal biopsy is a medical procedure in which a small piece of kidney is removed from the body for examination, usually under a microscope. Microscopic examination of the tissue can provide information needed to diagnose, monitor or treat problems of the kidney.Renal biopsy will be taken according American college of Romatology guidelines 2012.The renal biopsy samples were evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. the actvity index and chronicity index will be calculated.
40967234|NCT03958851|DIAGNOSTIC_TEST|kidney function tests|blood sample will be taken to measure blood urea nitrogen (BUN) and serum creatinine(S Cr). estimated glomerular filtration rate (eGFR) will be measured using CKD-EPI Equation.These investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
40967235|NCT03958851|DIAGNOSTIC_TEST|The 24-hour urine protein test|The 24-hour urine protein test checks how much protein is being spilled into the urine.Urine samples are collected in one or more containers over a period of 24 hours. The containers are kept in a cool environment and then sent to a lab for analysis. Specialists then check the urine for protein.This investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
40967236|NCT03958851|DIAGNOSTIC_TEST|complete blood counting (CBC)|A complete blood count is a blood panel that gives information about the cells in a patient's blood, such as the cell count for each blood cell type and the concentrations of hemoglobin.
40967237|NCT04481932|DRUG|Trastuzumab combined with Pyrotinib and chemotherapy|"Pyrotinib is a small molecule, irreversible tyrosine kinase inhibitor with targets of epidermal growth factor receptor 1 (EGFR/HER1/ErbB1), human epidermal factor receptor 2 (HER2/ErbB2/Neu) and human epidermis Factor Receptor 4 (HER4/ErbB4).~As a new generation of anti-HER2 therapeutic targeted drugs, pirotinib covalently binds to the ATP binding sites of the kinase regions of EGFR, HER2 and HER4 in cells to prevent homogeneity and heterogeneity of EGFR, HER2 and HER4 in tumor cells Dimer formation, inhibiting its own phosphorylation, blocking the activation of downstream signaling pathways, thereby inhibiting tumor cell growth"
40967238|NCT04773860|OTHER|Muscle Energy Techniques|A 4 week intervention will be carried out consisting of Muscle Energy Techniques on the accessory muscle of respiration. That is, Pectoralis Minor, Sternocleidomastoid, Upper trapezius, Scalene muscles and Latissimus Dorsi
40967239|NCT02634671|OTHER|schizophrenia|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
41295798|NCT01459107|PROCEDURE|Deceased donor hand transplantation|Deceased donor hand is surgically attached to recipient arm's stump.
41295799|NCT01459107|DRUG|Bone marrow cell-based therapy & single-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
41295800|NCT00687154|PROCEDURE|Scatter Laser Photocoagulation in 1 Sitting|1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
41295801|NCT00687154|PROCEDURE|Scatter Laser Photocoagulation in 4 Sittings|4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
41295802|NCT02270398|BEHAVIORAL|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
40768144|NCT01911260|DIETARY_SUPPLEMENT|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
40967240|NCT02634671|OTHER|the 22q11 deletion syndrome|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
40967241|NCT02634671|OTHER|control group|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
40967242|NCT00603668|BIOLOGICAL|milatuzumab|two or three times a week dosing of hLL1 for a total of 4 weeks
40967243|NCT06083272|DEVICE|Vitalthings Guardian M10 fixed and M10 mobile|VitalThings Guardian M10 / M10 mobile (VitalThings, Norway), are the investigational devices. These are the same technical devices made in two versions: one wall-mounted (VitalThings Guardian M10 fixed) and one mounted on a trolley (VitalThings Guardian M10 mobile). The Nox T3s and Nonin will be used as comparator devices.
40967244|NCT03948698|OTHER|Innovative approached to pediatric TB care|Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers
40967245|NCT03539536|DRUG|Telisotuzumab vedotin|Intravenous (IV) infusion
40967246|NCT04426968|DRUG|Hepalatide 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
40967247|NCT04426968|DRUG|Hepalatide 4.2mg|4.2mg/day subcutaneously (s.c.) for 24 week
40967248|NCT04426968|DRUG|Hepalatide 6.3mg|6.3mg/day subcutaneously (s.c.) for 24 week
40967249|NCT04426968|DRUG|placebo 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
40967250|NCT04426968|DRUG|placebo 4.2mg|4.2 mg/day subcutaneously (s.c.) for 24 week
40967251|NCT04426968|DRUG|placebo 6.3mg|6.3 mg/day subcutaneously (s.c.) for 24 week
40967252|NCT04426968|DRUG|Pegylated Interferon|180 ug/week subcutaneously (s.c.) for 28 week
40967253|NCT01010490|PROCEDURE|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
40967254|NCT01010490|PROCEDURE|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
40967255|NCT01010490|PROCEDURE|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
40967256|NCT03637114|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
40967257|NCT03637114|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
40967258|NCT01257087|DRUG|Insulin|All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
40967259|NCT02800681|OTHER|Expert panel evaluation|"From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'."
40967260|NCT02800681|OTHER|Semi-structured psychopathological interviews|Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.
40967261|NCT02800681|OTHER|Self-administered rating scales|1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.
40967262|NCT02800681|OTHER|Other general interviewer ratings|1. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
40967263|NCT04742517|DRUG|ASP1128|Intravenous
40967264|NCT04742517|DRUG|Placebo|Intravenous
40967265|NCT02981121|BEHAVIORAL|Exercise and Diet remedies|
41295803|NCT02270398|BEHAVIORAL|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
40967266|NCT02981121|DRUG|Metformin|
40967267|NCT05136768|DRUG|Sintilimab|Sintilimab: 200mg, administered by intravenous infusion on the first day of each cycle, one cycle every 3 weeks (Q3W), with the maximum cycle of 17. Suspension of Sintilimab administration: patients's request, disease progression, researcher-evaluated SAE
40967268|NCT05136768|RADIATION|SBRT|"At least one metastatic lesion is suitable for SBRT. If applicable, all metastatic lesions were allowed to be irradiated.~Recommended dose: BED ≥ 80Gy. Dose fractionation is determined as per physician's discretion, generally depending on the location of irradiated lesion and the distance to surrounding OARs.~Timing of SBRT: After completing at least 2 platinum-containing chemotherapy plus sintilimab treatments, SBRT can be started after assessing that there is no AE ≥ G2."
40967269|NCT05136768|DRUG|Platinum based chemotherapy|Platinum based single or doublet chemotherapy, one cycle every 3 weeks (Q3W), 4-6 cycles.
41295804|NCT02270398|BEHAVIORAL|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
41295805|NCT01225263|DRUG|Simvastatin|simvastatin, 20 mg, twice daily for 6 months
41295806|NCT01225263|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3, 1000 IU, twice daily for 6 months
41295807|NCT01225263|OTHER|Placebo|Two placebo pills, taken twice daily for 6 months
41295808|NCT00005999|DRUG|arsenic trioxide|
41295809|NCT00469014|DRUG|Clofarabine|Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily
40768145|NCT01911260|OTHER|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
40967270|NCT00719420|DRUG|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
40967271|NCT00719420|DRUG|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
40967272|NCT01628575|PROCEDURE|PAO|all patients underwent periodontal surgery for bone decortication followed by orthodontic treatment
40967273|NCT06088732|OTHER|Exercise Session|30 min cycling on bicycle ergometer at 60% peak power output
40967274|NCT06088732|DRUG|Ibuprofen 800 mg|A single oral dose of Ibuprofen
40967275|NCT06088732|OTHER|Rest|Resting for 30 min in chair
40967276|NCT06088732|DRUG|Placebo|Matched placebo
40967277|NCT05827510|DEVICE|BTL-585F|BTL-585F device with BTL-585-4 applicator
40967278|NCT02626546|PROCEDURE|Major surgical procedure|observation of postoperative outcomes
40967279|NCT00828347|DRUG|1.0 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
40967280|NCT00828347|DRUG|0.25 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
40967281|NCT01356108|DEVICE|Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)|The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.
40967282|NCT05862480|OTHER|Spray with Hypochlorous Acid Group|For Each Patient included . A prescription of a nasal spray in each nostril/3 hours and two oral sprays/3 hours by a solution of hypochlorous acid (NEED DEFENDER) for 5 days
40967283|NCT05862480|OTHER|Spray with Placebo Group|For Each Patient included , A prescription of an identical to the intervention nasal spray in each nostril/3 hours and two oral sprays/3 hours by Placebo for 5 days.
40967284|NCT02771912|DRUG|Propofol|Propofol and excipients
40967285|NCT02771912|DRUG|Placebo|Qualitative composition of Propofol lipuro 2% excipients
40967286|NCT00686933|DRUG|ABT-089|Subjects will take up to 80 mg daily for 24 months
40768146|NCT01143441|BIOLOGICAL|DAC-HYP|
41295810|NCT00469014|DRUG|Busulfan|"Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7."
41295811|NCT00469014|DRUG|Fludarabine|Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily
41295812|NCT00469014|OTHER|Stem Cell Infusion|Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
41295813|NCT00469014|DRUG|Thymoglobulin (ATG)|Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
41295814|NCT00469014|DRUG|Filgrastim|Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
40768147|NCT04950764|DRUG|Seladelpar 10 mg|Seladelpar 10 mg single oral dose
40967287|NCT02115893|DIETARY_SUPPLEMENT|Sodium Nitrate|
40967288|NCT02115893|DIETARY_SUPPLEMENT|Sodium Chloride|
40967289|NCT03164252|RADIATION|Grupo I- Lower laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
41295815|NCT06338696|OTHER|No intervention|No intervention
41295816|NCT04634162|DRUG|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
40768148|NCT04950764|DRUG|Seladelpar 10 mg or less|Seladelpar 10 mg or less, once daily for 28 days
40967290|NCT03164252|RADIATION|Grupo II- Greater laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
40967291|NCT03164252|RADIATION|Grupo III- Laser sham|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
40967292|NCT01296620|DRUG|Ulimorelin Intravenously (IV)|160 µg/kg daily (QD)
40967293|NCT01296620|DRUG|Ulimorelin Invtravenously (IV)|480 µg/kg daily (QD)
40967294|NCT01296620|DRUG|5% dextrose in water|Placebo
40967295|NCT01784978|DRUG|Sunitinib|50 mg pd
40967296|NCT01784978|DRUG|Everolimus|10 mg pd
40967297|NCT05475132|OTHER|Exergaming|exercise games will be done for a total of 8 weeks ,100min of exergaming/week (5 days × 20 min).
40967298|NCT05475132|OTHER|Conventional Dexterity Exercises|Exercises traditionally used for dexterity will be done for 8 weeks, 100min of exercises/week (5days × 20 min)
40967299|NCT04254471|DRUG|AL3810|5mgQD, 7.5mgQD, 10mgQD
40967300|NCT04254471|DRUG|carboplatin + etoposide|Carboplatin and etoposide are background treatment.
40967301|NCT04254471|DRUG|Placebo|Placebo
40967302|NCT05280782|DRUG|Ga-68 Galmydar|Single intravenous injection of the PET radiotracer 68Ga-Galmydar.
40967303|NCT05743270|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
40967304|NCT05743270|OTHER|CCRT(concurrent chemoradiation therapy)|CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum
40768149|NCT04175184|OTHER|Mobilisation with Movement|"MWM is a pain-free manual therapy procedure that aims to restore full active pain-free range of motion. It consists of an accessory movement performed by the therapist followed by an active movement executed by the patient. The accessory glide might be produced by the therapist´s hands or by a belt. Minor changes in the amount of force or direction of the glide are common to produce better results.~The MWM procedures will be used pragmatically in this study. Therefore, several attempts might be needed to produce the outcome desired. In the case of the shoulder, they can be applied to the glenohumeral joint, scapulothoracic joint, acromioclavicular joint, cervical and thoracic spines and the rib cage. The decision making process in this study will be based on the outcome observed. The procedure that produced the greatest improvement in active pain-free range of motion will be the one used on that occasion."
40768150|NCT04175184|OTHER|Sham Mobilisation with Movement|Sham MWM is a comparator procedure used in this research to control for placebo related mechanisms of action. This procedure has already been used in previous research (Delgado-Gil et al 2015). Briefly, the therapist will stand opposite to the affected shoulder, he/she will place the thenar eminence of the anterior hand on the skin in front of the humeral head, while the posterior hand will rest on the scapula. Both hands will just lightly rest on the skin, no accessory glide will be performed to the humeral head. Then, the participant will move his/her shoulder in the direction previously selected. Shall the procedure elicit pain-free full range of motion, the participant will move their shoulder ten times. Otherwise, the movement should be performed up to the onset of symptoms.
40768151|NCT04476147|OTHER|Diagnostic Test: CHA2DS2-VASc, HAS-BLED and Fried Scale.|This is an observational study. All the patients evaluate with CHA2DS2-VASc, HAS-BLED and Fried Scale, and observe the incidence of thrombotic events and the influence of frailty on thrombotic events in elderly patients with NVAF.
40768152|NCT06594705|DEVICE|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
40768153|NCT05803772|DRUG|APHD-012|Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
40768154|NCT05803772|DRUG|APH-012P|Distal jejunal-release placebo beads
40768155|NCT03997383|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
40768156|NCT03997383|DRUG|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
40768157|NCT05581199|DRUG|Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
40768158|NCT05581199|DRUG|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
40768159|NCT05581199|DRUG|Placebo|Matching placebo SC
40768160|NCT06475300|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
40967305|NCT05743270|OTHER|carboplatin and paclitaxel|chemotherapeutic agents
40768161|NCT06475300|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks.
40768162|NCT05561374|DRUG|Low-dose OKN-007, BID|Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.
40768163|NCT05561374|DRUG|Low-dose OKN-007, TID|Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.
40768164|NCT05561374|DRUG|Mid-dose OKN-007, TID|Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.
40768165|NCT05561374|DRUG|High-dose OKN-007, TID|Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
40967306|NCT05743270|BIOLOGICAL|nivolumab|anti-PD1 monoclonal antibody
40967307|NCT00075010|DRUG|Decitabine|15 mg/m\^2 by vein over 1 hour times 10 days
40967308|NCT00075010|DRUG|Valproic acid|20 mg/kg given orally daily for 10 days
40967309|NCT03101683|RADIATION|Partial chest wall radiation therapy|A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
40967310|NCT03802669|OTHER|oral mutans streptococcus|quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern
40967311|NCT01500694|DRUG|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
40967312|NCT04814134|DEVICE|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
40967313|NCT04814134|OTHER|Standard of care|Available standard treatment
40967314|NCT04271969|DEVICE|SmartVest Airway Clearance System|Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)
40967315|NCT02312661|DRUG|Metformin|Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
40967316|NCT02312661|DRUG|Carboplatin|Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
40967317|NCT02312661|DRUG|Paclitaxel|Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
40967318|NCT06505421|BEHAVIORAL|Resistance training|Eccentric resistance training and tradional resistance training
40967319|NCT00382252|PROCEDURE|computed tomography|
40967320|NCT00382252|PROCEDURE|positron emission tomography|
40967321|NCT00382252|PROCEDURE|radiofrequency ablation|
40967322|NCT06280170|OTHER|Artificial Intelligence platform for case managers|Providers will have access to the Eleos Health mobile AI platform to document their case management encounters.
40967323|NCT02765295|DEVICE|medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).
40967324|NCT02765295|DEVICE|Medical molecular mesh oxygen generator|"medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.~This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation."
40967325|NCT03736616|DRUG|Carboplatin|Chemotherapy
40967326|NCT03736616|DRUG|Ifosfamide|Chemotherapy
40967327|NCT03736616|DRUG|Etoposide|Chemotherapy
40967328|NCT03736616|BIOLOGICAL|Rituximab|Anti-CD20 mAb
41137984|NCT03609450|BEHAVIORAL|Low-Dose Comparator|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, and discussion. They are also given a list of leading community, online, print, and smartphone mindfulness resources. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
41295817|NCT04634162|DRUG|Placebo|Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
40967329|NCT03736616|DRUG|Carmustine|Chemotherapy
40967330|NCT03736616|DRUG|Cytarabine|Chemotherapy
40967331|NCT03736616|DRUG|Melphalan|Chemotherapy
41137985|NCT02718339|BEHAVIORAL|Intensive counseling|
40967332|NCT03736616|OTHER|Autologous HSCT|Cellular Therapy
40967333|NCT03736616|DRUG|Acalabrutinib|Bruton's Tyrosine Kinase Inhibitor
40768170|NCT02185768|DRUG|idarubicin|
40967334|NCT02176499|DRUG|Telmisartan, low dose|
40967335|NCT02176499|DRUG|Telmisartan, high dose|
40967336|NCT02176499|DRUG|Placebo|
40967337|NCT05892471|DRUG|ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
40967338|NCT05892471|DRUG|Propofol injection|Patients in propofol group received 1.5 mg/kg propofol for induction of anesthesia
40967339|NCT01372462|DEVICE|NIOV - Room Air|Noninvasive ventilation with device powered by compressed room air.
40967340|NCT01372462|DEVICE|NIOV - Oxygen|Noninvasive ventilation with device powered by compressed medical (100%) oxygen.
40967341|NCT01372462|DEVICE|Nasal Cannula Oxygen|Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.
40967342|NCT00043914|DRUG|lamotrigine|
40967343|NCT02095574|DRUG|[14C]ABT-199 (GDC-0199)|\[14C\]ABT-199 will be administered as a single oral administration
40967344|NCT04856371|DRUG|CYH33|Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
40967345|NCT04856371|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
40967346|NCT04856371|DRUG|Letrozole|Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
40967347|NCT04856371|DRUG|Palbociclib|Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
40967348|NCT03328312|DRUG|Sugammadex|Time period from administration of the reversal agent to recovery of TOFR \>0.9
40967349|NCT03328312|DRUG|neostigmine+atropine|Number and time of bradycardic episodes (HR\<60 bpm) as well as that of tachycardic episodes (HR\>100 bpm) before tracheal extubation
40967350|NCT03328312|DRUG|neostigmine+atropine+sugammadex|4. Time of extubation
41295818|NCT06179212|DIAGNOSTIC_TEST|Exercise Tests|Patients will complete 4 different cardiopulmonary exercise tests in random order.
41295819|NCT04210336|DEVICE|PAPILOCARE|"Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa.~Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, β-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera."
41295820|NCT04210336|DEVICE|PLACEBO|The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.
40967351|NCT01180946|DIETARY_SUPPLEMENT|ergocalciferol|ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
40967352|NCT01180946|OTHER|placebo pill|placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
40967353|NCT02417831|DRUG|tamsulosin capsules|
40967354|NCT02417831|DRUG|tamsulosin HCl|
40967355|NCT04992676|DIAGNOSTIC_TEST|Polysomnograpy|Home polysomnography will be conducted using the scalable, modular Embletta system. Trained staff will instrument the participants in the evening and perform biocalibration to ensure optimal data quality
40967356|NCT04992676|DIAGNOSTIC_TEST|actigraphy|A water resistant accelerometer with light sensor and event marker will be worn on the nondominant wrist for approximately 7 days. Activity counts from the device will be analyzed by proprietary software algorithms for determination of the following: sleep onset, sleep offset, total sleep time, total wake time, and sleep efficiency.16 Daytime sleep periods will be also scored to determine frequency and duration of naps. Daily data will be averaged across the 7-day period, as well as separately for weekdays and weekend, to compute measures of habitual sleep patterns.
40967357|NCT06451978|OTHER|Nature-based intervention|The nature-based intervention is a manualised, caregiver-led intervention consisting of a physical manual comprising of 8 sessions of 8 different nature-based activities. It is designed for the person living with dementia or mild cognitive impairment and their caregiver to carry out the sessions together, either in their own home or out in a local area of nature.
40967358|NCT02205632|DEVICE|MPS II|
40967359|NCT06260085|OTHER|Relatives vioce record|In the study, it was emphasized that the messages to be played to the patient should be 3-5 minutes and simple terms should be used in a way that can be understood by individuals with low education level. Written informed consent was obtained from the patient and the patient's relatives before the application. In the message recorded by a patient's relative decided by the patient's family members, the patient's relative said what he/she wanted to say to the patient and recorded it using a voice recorder. The researcher had a preliminary interview with the patient's relative before the voice recording was taken about the use of the voice recorder and the content of the message (Table 1) in order to prevent the messages from negatively affecting the patient. The voice recording created by the patient's relative was played to the patient by the researcher using a music pillow. After the patient listened to the audio recording, it was erased under the witness of the patient's relative.
40967360|NCT03274128|RADIATION|Radon therapeutic baths and inhalations|The natural water with low mineralized content plays a major therapeutic role with the parameters of Rn 303,1-441,5 Bq/l. In the treatment rooms (inhalation, cabins with baths and swimming pool) measurement of alpha radiation was 184,4-450,0 MeV. The measurements were analyzed every 3 months at the Institute of Occupational Medicine in the Department of Radiation Protection in Lodz, Poland. Among the types of treatments used in the therapy there was: comprehensive radon bath - with the temperature of 37 °C, duration 15 min., the treatments were performed every 2nd day, whereas radon inhalations lasted 15 min. with the temp. 37 °C- treatments were performed every 2nd day from Monday to Friday. Baths and inhalations were performed interchangeably and the total number of radon treatments during one stay was 15.
40967361|NCT03274128|PROCEDURE|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min,
40967362|NCT05935293|DRUG|Dexmedetomidine|iv administration dexmedetomidine
40967363|NCT02154243|DRUG|Midodrine|10 mg, p.o., once, on day of surgery after first physical therapy session
40967364|NCT02154243|OTHER|Intravenous fluid bolus|15 cc/kg, once, on day of surgery after first physical therapy session
40967365|NCT05311618|DRUG|NGM438|NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
40967366|NCT05311618|DRUG|Pembrolizumab (KEYTRUDA ®)|Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
41137986|NCT00691691|RADIATION|Stereotactic Body Radiation Therapy|Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
41295821|NCT03714386|DEVICE|A synthetic high-flux dialyzer will be used for OL-HDF.|A synthetic high-flux dialyzer used for OL-HDF must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
41137987|NCT01082159|PROCEDURE|lumbar decompression|The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
41137988|NCT02771366|DRUG|Fermented Papaya Preparation|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
41137989|NCT02771366|OTHER|Granulated Sugar|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
41295822|NCT03714386|DEVICE|A medium cut-off dialyzer will be used for HDx.|A medium cut-off dialyzer used for HDx must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
40768171|NCT02185768|DEVICE|Dc- Beads 300-500µm|
40967367|NCT02025621|DRUG|Levosimendan|
40967368|NCT02025621|DRUG|Placebo|matching placebo
40967369|NCT04254705|PROCEDURE|Rectal Biopsy|Suction biopsy or forceps biopsy
40768172|NCT04416724|PROCEDURE|Phacoemulsification|Lens removal by Phacoemulsification
40967370|NCT00314912|DRUG|Tramiprosate (3APS)|
40967371|NCT02737293|OTHER|Control Diet|4-week intake of Control Diet 5 day rotating menu
40967372|NCT02737293|OTHER|Med Diet|4-week intake of Med Diet 5 day rotating menu
40967373|NCT02737293|OTHER|Med Diet + Whole Egg|4-week intake of Med Diet plus Whole Egg 5 day rotating menu
40967374|NCT03809052|DRUG|GB1211|Hard capsules for oral use
40967375|NCT03809052|DRUG|Placebo|Hard capsules for oral use
40967376|NCT02031354|DIETARY_SUPPLEMENT|Lysine Chloride|Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
40967377|NCT00751270|BIOLOGICAL|AdV-tk|Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
40967378|NCT00751270|DRUG|Valacyclovir|The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
40967379|NCT04288531|DIETARY_SUPPLEMENT|Iodine supplementation|Recommendation, issued by the National Health Authorities, on supplementing with iodine (200 ug/day) women during preconception, pregnancy and lactation.
40967380|NCT02952781|DEVICE|EKG Patch monitors (Zio and Carnation)|Each patient will be provided with both a Zio-XT Patch monitoring system and the CAM system and will be instructed to wear both simultaneously for 7 days.
40967381|NCT05553249|BEHAVIORAL|Written Exposure Therapy|Virtual, group-based Written Exposure Therapy
40967382|NCT06036212|DEVICE|Robotic System|Robotic assisted Unicompartmental Knee replacement (UKA)
40967383|NCT06036212|DEVICE|Conventional|Unicompartmental Knee Arthroplasty (UKA) with conventional approach and conventional manual instrumentation
41137990|NCT00688415|DRUG|VTX-2337|Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
40768173|NCT04416724|DEVICE|Selective Laser Trabeculoplasty|Laser application in trabecular meshwork
40768174|NCT01370551|DRUG|Estriol 0.03 mg, lyophylized lactobacillus|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
40967384|NCT00404937|DRUG|Tobradex (Antibiotic steroid combination)|
40967385|NCT03036696|OTHER|Pregnant Mothers Interview|"Pregnant mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection and preferences for methods related to non-invasive sample collection.~Data collection for pregnant mothers includes Clinical Health Update (3rd trimester) and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
40967386|NCT03036696|OTHER|Breastfeeding Mothers Interview|"Breastfeeding mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection, and preferences for methods related to non-invasive sample collection.~Data collection for breastfeeding mothers includes Clinical Health update (post-natal), Infant Feeding, and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
40967387|NCT02563444|DEVICE|Ultrasound fusion guiding system - TUS A-500 (Aplio 500)|
40967388|NCT06364943|OTHER|with/without dry eye syndrome|compare tear ferning structure between dry eye and non-dry eye patients
40967389|NCT00221585|BEHAVIORAL|Psychosocial treatment/Psychodynamic treatment|
40967390|NCT00858130|DEVICE|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
40967391|NCT00415805|DRUG|Multihance|0.5 Molar, single injection at 0.2 mL/kg
40967392|NCT00415805|DRUG|vasovist|0.25 molar single injection 0.03 ml/kg
40967393|NCT02427022|OTHER|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
40967394|NCT02433730|DRUG|Testosterone|intramuscular injection
40967395|NCT02433730|DRUG|placebo|intramuscular injection
40967396|NCT01411904|DEVICE|MagProbe (TM)|CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
40967397|NCT04466020|OTHER|Qualitative research interviews to be conducted|None. Qualitative research interviews to be conducted
41137991|NCT01111006|DEVICE|Bidet (electronic cleansing toilet system)|The volunteers underwent rectal examinations and baseline manometry at lateral decubitus position. Subjects were then placed on a toilet with Bidet attached and manometry catheter was inserted and fixed placing the channels of the catheter at the high pressure zone (HPZ) of the anal canal. Anorectal pressures were measured before and after using the Bidet under different water pressures (4, 8, 16, 20 gram force, gf), types of water stream (narrow vs. wide), and different temperatures (24oC vs. 38oC).
41137992|NCT02414594|DRUG|IONIS-APO(a)-LRx|Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
41137993|NCT02414594|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
41137994|NCT01353872|DIETARY_SUPPLEMENT|Nutrattente / Nutraperf / Nutrarecup|500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match
40967398|NCT00566371|DRUG|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
40967399|NCT00566371|DRUG|placebo|placebo
40967400|NCT04165447|BEHAVIORAL|Front-of-pack labeling strategy|We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
40967401|NCT04983654|DIAGNOSTIC_TEST|patients with limb ulcers|"For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis ( sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks,~* Analysis of cytokine and metalloproteases in the wound fluid,~* Assessment of healing according usual treatment"
40967402|NCT04983654|DIAGNOSTIC_TEST|For patients without limb ulcers|"For patients without limb ulcers : at inclusion visit only~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis (sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks"
40967403|NCT05501730|DIAGNOSTIC_TEST|Quantra QPlus System|Coagulation monitoring system
40967404|NCT01594762|DRUG|Topical pexiganan cream 0.8%|14 days of treatment
40967405|NCT01594762|DRUG|Topical placebo cream|14 days of treatment
40967406|NCT01594762|OTHER|Standard wound care|14 days of treatment
40967407|NCT00069056|PROCEDURE|Laser Treatment|
40967408|NCT05315128|DRUG|Methotrexate|A randomized comparative effectiveness clinical trial
40967409|NCT04603456|DRUG|Lacteol fort|Lacteol fort is a drug containing lactobacilli
40967410|NCT04603456|DRUG|Standardized Timothy Grass Pollen|SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .
40967411|NCT04603456|DRUG|Lacteol fort and Standardized Timothy Grass Pollen|Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
40967412|NCT04997382|DRUG|Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab|Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.
40967413|NCT04997382|DRUG|Chemotherapy alone or Chemotherapy with or without Bevacizumab|Bevacizumab, 15mg/kg，every 21 day
40967414|NCT02004210|PROCEDURE|transarterial radioembolization (TARE)|transarterial radioembolization
40967415|NCT02004210|PROCEDURE|transarterial chemoembolization (TACE)|transarterial chemoembolization
41137995|NCT01353872|DIETARY_SUPPLEMENT|Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo|500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
41137996|NCT03350620|DRUG|NVK-002 Concentration 1|Study medication will be administered, once daily (QD)
41137997|NCT03350620|DRUG|NVK-002 Concentration 2|Study medication will be administered, once daily (QD)
41137998|NCT03350620|DRUG|Placebo|Vehicle (placebo) will be administered, once daily (QD)
41137999|NCT04927468|PROCEDURE|supramaximal rectus recession|inferior rectus recession is 10mm，medial rectus recession is 9mm,superior rectus recession is 14mm for large-angle strabismus
41138000|NCT04927468|PROCEDURE|normal rectus recession|inferior rectus recession is 7mm，medial rectus recession is 7mm,superior rectus recession is 7mm for large-angle strabismus
40967416|NCT05018130|PROCEDURE|Calcaneus Osteotomy (Metallic)|Calcaneus Displacement Osteotomy using two metallic screws
40967417|NCT05018130|PROCEDURE|Calcaneus Osteotomy (Bio-integrative)|Calcaneus Displacement Osteotomy using two bio-integrative screws
40967418|NCT01808989|OTHER|Exercise oxymetry|
40967419|NCT02649998|DRUG|Furosemide|Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
40967420|NCT02649998|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
41138001|NCT02993926|DRUG|Enantone|Enantone suspension for injection
40967421|NCT05770687|DRUG|SGLT2 inhibitor|Patients started on SGLT2 inhibitors after PCI for AMI
40967422|NCT01257997|BIOLOGICAL|15N-Thymidine, 2H-Water|"Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).~Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot)."
40967423|NCT02052583|PROCEDURE|therapeutic hypothermia at 32 ° C|
40967424|NCT02052583|PROCEDURE|therapeutic hypothermia at 34 ° C|
40967425|NCT02408315|DRUG|misoprostol/placebo|buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
40967426|NCT01880840|DRUG|205.5 mcg of azelastine hydrochloride|nasal spray
40967427|NCT01880840|DRUG|137 mcg of azelastine hydrochloride|nasal spray
40967428|NCT04557878|DRUG|Hypertonic Dextrose Solution|Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.
40967429|NCT04557878|BIOLOGICAL|Liquid Phase Concentrated Growth Factor (LPCGFs)|Patients in this group will receive single intra-articular injection of LPCGF in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.
40967430|NCT03849898|PROCEDURE|Surgery|Surgical fracture treatment
40967431|NCT03849898|OTHER|Non-Surgical fracture treatment|Non-Surgical fracture treatment
41295823|NCT06504082|DRUG|Letrozole|Patients in the MTX + letrozole group received letrozole tablets (Femara 2.5 mg) once daily for ten days starting from the day of MTX administration.
40967432|NCT02223832|DRUG|ACT-128800|
41295824|NCT06504082|DRUG|Methotrexate|After confirming the diagnosis of tubal ectopic pregnancy, each patient will receive a single dose of intramuscular MTX (50 mg/m² MTX) on the same day
40967433|NCT00319865|DRUG|Velcade|
40967434|NCT00319865|DRUG|Thalidomide|
40967435|NCT00319865|DRUG|Adriamycin|
40967436|NCT00319865|DRUG|Dexamethasone|
40967437|NCT04211623|OTHER|Constraint induced movement therapy|"Constrained on more affected side for three hours. To minimize the learned non use in hemiplegic CIMT is applied and criteria of applying CIMT is;~* 10 degrees active wrist extension on the affected hand,~* 10 degrees active thumb abduction,~* 10 º active extension of any two digits on the side or hand which is limited due to damage.~In order to gain the maximum good results from CIMT technique following points should also be considered attentively. Affected arm should move to 45 degrees shoulder flexion and abduction, and 90 degrees of elbow flexion and extension.~Constrained with cotton sling. 3 to 5 upper limb functional activities like~* using fork or a spoon,~* combing hair~* brushing teeth~* writing~* dressing all activities are performed for 10 t0 15 minutes in period of three hours on alternate days in a week"
40967438|NCT04211623|OTHER|Bimanual activities|"Bimanual activities of both hands are performed like~Set of bimanual activities is used to assess the bimanual hand function. Five bimanual activities are performed such as~* carrying a tray,~* cutting a fruit with a knife,~* holding and cutting the paper with scissor,~* buttoning and~* Carrying heavy objects with both hands.~Every activity was performed for 10 t0 15 minutes on alternate days for a period of 6 weeks session."
40967439|NCT04767932|BEHAVIORAL|vibration machine|Experimental: vibration intervention the experimental group will perform 20mins/ section, three times weekly for 8 weeks vibration training
40967440|NCT03464305|DRUG|acetylsalicylic acid|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
40967441|NCT03464305|DRUG|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
40967442|NCT05578391|BIOLOGICAL|Convalescent plasma|Admistration of one unit of convalescent plasma
40967443|NCT00724022|DRUG|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
41138002|NCT02993926|DRUG|GnRH agonist|A non-Enantone GnRH agonist
41295825|NCT06521008|DRUG|anti muscarinic drugs|a selective anti muscarinic drugs (5-10mg) once per day for 12 weeks.
41457651|NCT02751424|DRUG|GSK3342830|A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.
40967444|NCT00724022|DRUG|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
40967445|NCT00724022|DRUG|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
40967446|NCT04718298|DEVICE|ProFlor laparoscopic technique|Inguinal hernia repair laparoscopic
40967447|NCT01876160|OTHER|Transcutaneous electrical nerve stimulation|
40967448|NCT06033105|DEVICE|ELISA|Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.
40967449|NCT00002098|DRUG|Lentinan|
40967450|NCT00002098|DRUG|Didanosine|
40967451|NCT00943059|DRUG|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
40967452|NCT00943059|DRUG|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
40967453|NCT03208244|DRUG|Clinically prescribed direct acting antiviral|HCV treatment for 12 weeks
41138003|NCT01806207|DEVICE|Durolane injection|
41138004|NCT01806207|OTHER|Saline injection|
41138005|NCT05631236|DEVICE|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a more intense therapeutic blue light.
41138006|NCT05631236|DEVICE|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a non-therapeutic blue light.
41138007|NCT05396001|BEHAVIORAL|LowSalt4Life Application|LowSalt4Life is a dietary sodium intervention mobile application that promotes lower sodium intake.
40967454|NCT01738360|DRUG|Arsenic trioxide|"The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~* Pre-inclusion between D-35 and D-15~* Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~* A telephone contact between D32 and D34~* A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180"
40967455|NCT02119481|BEHAVIORAL|Mindfulness-based stress reduction|
40967456|NCT02119481|BEHAVIORAL|Expressive writing condition|
40967457|NCT03032705|DEVICE|SonicFill™ 2|The intervention in arm 1 is SonicFill™ 2, a sonic-activated, bulk fill dental composite system for posterior restorations that requires no additional capping layer.
40967458|NCT03032705|DEVICE|Filtek™ Supreme|The intervention in arm 2 is Filtek™ Supreme Ultra, a Universal Nanocomposite dental restorative material that is visible-light activated and designed for use in anterior and posterior restorations of any class.
40967459|NCT02577510|DRUG|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament \[7\]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic \[7\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
40967460|NCT02577510|DRUG|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle \[6\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
40967461|NCT04039698|OTHER|Telemedicine|Telemedicine monitoring and teleconsultation by video calls
40967462|NCT04039698|DRUG|Velpatasvir/Sofosbuvir|Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
40967463|NCT03660540|DIETARY_SUPPLEMENT|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations.
40967464|NCT04800354|BEHAVIORAL|Nurse-led Mindfulness Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time they experience intense pain or take pain medication before and after surgery.
40967465|NCT04800354|BEHAVIORAL|Nurse-led Pain Psychoeducation|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
40967466|NCT03185767|OTHER|blood sampling|blood sampling
40967467|NCT03576989|DIETARY_SUPPLEMENT|EPA+DHA|EPA+DHA are the n-3 polyunsaturated fatty acids contained in fish oil
40967468|NCT03576989|OTHER|placebo|placebo contains mineral oil
40967469|NCT05685966|OTHER|no intervention|no intervention
40967470|NCT00471328|DRUG|Nilotinib|Nilotinib 400 mg twice daily (bid)
40967471|NCT00471328|OTHER|Best Supportive Care (BSC) +/- imatinib or sunitinib|Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
40967472|NCT03052725|DRUG|reslizumab|Reslizumab was provided in a pre-filled syringe.
40967473|NCT03839901|OTHER|Home exercise program|Home exercise programme with participants followed up at week 1, 4, 6 and 8.
40967474|NCT02846311|DEVICE|Flu Test|
40967475|NCT01244724|DRUG|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
40967476|NCT00497718|PROCEDURE|Chiropractic Manipulation|
40967477|NCT04072497|BIOLOGICAL|One shot of the zoster vaccine|One shot of the zoster vaccine (with live virus \>=4.3 LgPFU per dose)
41138008|NCT05396001|BEHAVIORAL|Just-In-time Adaptive Intervention (JITAI)|LowSalt4Life is a dietary sodium application with a just-in-time adaptive intervention (JITAI) component enabled.
41138009|NCT02113449|DRUG|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
41295826|NCT06521008|OTHER|Instructions including bladder training|The program teaches women skills and strategies to prevent incontinence, including bladder irritants like caffeine and discussing bowel habits to prevent constipation. It also teaches them how to respond adaptively to urgency, such as pause, sit down, relax, and contract pelvic muscles to diminish urgency and prevent urine loss. Once urgency subsides, they can proceed to the toilet at a normal pace. The program emphasizes the importance of educating patients about bladder irritants and bowel habits.
41457652|NCT02751424|DRUG|Placebo|A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
40967478|NCT04072497|BIOLOGICAL|One shot of the varicella vaccine|One shot of the varicella vaccine (with live virus \>=3.3 LgPFU per dose)
40967479|NCT04072497|BIOLOGICAL|one shot of placebo|one shot of placebo with no live virus
40967480|NCT04717609|PROCEDURE|Saphenous Nerve Block|Preoperative Saphenous Nerve Block for partial Meniscectomy
40967481|NCT04717609|DRUG|Ropivacaine injection|preoperatively the participant will receive an injection ar the surgical site of 5 milliliters (mL) of 0.5% ropivacaine
40967482|NCT02762357|DEVICE|Novosyn® Quick|Episiotomy closure
40967483|NCT02325960|DRUG|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
40967484|NCT02325960|DRUG|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
40967485|NCT05928169|DRUG|Topical and systemic drugs|Recruitment and follow-up will be independent on the type of treatment
40967486|NCT05052762|OTHER|Group A: Elastic resisted training for Gluteus Maximus strength|"Subjects attended physical therapy two times per week for a total of 10 visits. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) are added. Each exercise was performed for 10 repetitions. Elastic resistance was Added to the fire hydrant, hip extension in prone and deadlift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
40967487|NCT05052762|OTHER|Group B: Weight resisted training for Gluteus Maximus strength|Subjects attended p two times per week for a total of 10 visits. The participants performed PHEKF in 90° knee flexion with 30° hip abduction and 10° hip extension to increase the muscle activity of the gluteus maximus. In the prone position, the participant performed 10° hip extension until the posterior knee reached the horizontal bar. The participants maintained 90° knee flexion with 30° hip abduction and 10° hip extension in the prone position against the resistance. Sandbags (3 kg) will be used to provide resistance on the ankle through a rope and pulley. Each subject performed three sets with three repetitions of five seconds each. 1-minute break is allowed between each set.
40967488|NCT02927431|DRUG|Danirixin 15 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
40967489|NCT02927431|DRUG|Danirixin 50 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
41138010|NCT01967394|OTHER|Use of internet based social marketing intervention|"Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: 16 and pregnant, teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention."
41138011|NCT01967394|OTHER|No use of social media|No social media ads will be available in these counties.
41138012|NCT04336709|DRUG|Calcipex II|Water based intracanal medicament
41138013|NCT04336709|DRUG|Metapex|Oil based intracanal medicament
41138014|NCT06178380|OTHER|rehabilitation|"For the experimental group:~Isokinetic training Antigravity treadmill Posturography~For the control group:~Patients will receive a standard rehabilitation prescription comprising:~Physiotherapy , muscle stretching and strengthening , proprioceptive exercises, and self-programmed"
41138015|NCT02929758|BEHAVIORAL|Speed of processing training (SOPT)|This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
41138016|NCT05360537|DRUG|Insulin Degludec / Liraglutide Injectable Product|administration of Insulin Degludec/Liraglutide
40967490|NCT02927431|DRUG|Placebo|No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
41138017|NCT05360537|DRUG|Insulin Glargine|Administration of glargine insulin
41138018|NCT03305172|BEHAVIORAL|Financial Incentive|Giving different structures of long term (36 weeks) financial incentives to increase physical activity
41138019|NCT03799809|DRUG|Intrabronchial Voriconazole instillation|Efficacy of intrabronchial voriconazole instillation for inoperable pulmonary aspergilloma
41138020|NCT00020527|DRUG|caspofungin acetate|
41138021|NCT00009191|DRUG|Sertraline [Zoloft]|
41138022|NCT01762982|DRUG|0.13% Benzalkonium Chloride|Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution
40768175|NCT05374798|DEVICE|Heart Rate Variability-Biofeedback (HRV-B) via Smartwatch Device Intervention|"Participants will wear activity trackers equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed. HRV-B will guide participants in an evidence-based paced breathing technique (about 6 breaths per minutes) using visualization on thier mobile device of thier real-time respiratory and cardiac parameters.~During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed."
40768176|NCT02769104|DRUG|Letrozole (Aromatase Inhibitors)|Letrozole (Aromatase Inhibitors) for 5 years
41295827|NCT06521008|OTHER|pelvic floor muscle training (PFMT)|The training program teaches bladder control through contracting the striated skeletal pelvic floor muscles (PFM). The women are instructed to empty their bladder, lie in a lithotomy position, and tighten their pelvic floor muscles. The duration of contraction and repetitions is gradually increased, totaling 20-30 minutes. The program is 3 sessions per week under supervision for 12 weeks, and each woman is instructed to perform exercises at home until they can do 300 contractions per day.
41295828|NCT06521008|OTHER|abdominal exercise|Women will engage in transverse abdominis exercises, focusing on drawing the lower abdominal wall towards the spine and pressing the lumbar region downward, repeated for 15 minutes per session, three times per week.
41295829|NCT06521008|OTHER|Diaphragmatic Training|The therapist will instruct each woman to lie on her back with knees bent, place one hand on her upper chest and the other on her belly. They will breathe in slowly, tighten abdominal muscles, and exhale through pursed lips. Expiration should be relaxed and lightly controlled, and not forceful. Expiration should not be prolonged, and the woman should not initiate inspiration with accessory muscles or upper chest. The session will be repeated 3-4 times, lasting 5-10 minutes, and repeated three times per week for 12 weeks.
41295830|NCT01467739|DEVICE|Ambu ® aScope®|
40768177|NCT02769104|DRUG|AC*4-T*4|CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
40768178|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Neutral-Relaxing)|Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of neutral everyday objects (e.g., tools, dirt) and their use (construction, gardening).
41295831|NCT01467739|DEVICE|a conventional reusable fiberscope|
41295832|NCT03330691|BIOLOGICAL|Patient-derived CD19- and CD22 specific CAR|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
41295833|NCT02782455|DRUG|Flavonoids|Daflon is administered
41295834|NCT02782455|DRUG|CDobi|Calcium dobesylate is administered
40768179|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Drug)|Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of drug paraphernalia (e.g., syringe, tourniquet, heroin) and preparation.
40967491|NCT02927431|DRUG|Oseltamivir 75 mg|Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
41295835|NCT01959308|OTHER||
40967492|NCT03558698|OTHER|Good ventilation|Good ventilation with a low concentration of CO2
40967493|NCT03558698|OTHER|Ventilation CO2|CO2 High and Good ventilation
41295836|NCT05233267|OTHER|Blood sample|Dosage of neopterin
41295837|NCT01524211|DEVICE|Zenith® t-Branch|The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.
41295838|NCT01524211|DEVICE|Terumo Arch Branch|The Arch Branch endograft is a custom-made endograft based on the Relay thoracic stent graft platform. The device is intended to land proximally in the ascending aorta just distal to the sinotubular junction, and distally either in the native thoracic aorta for focal arch pathologies, or more extensive pathologies either extended with another commercially available thoracic endograft or mated to a pre-existing thoracic endograft, which would serve as a distal landing zone. It is constructed of polyester graft material (same as those used for the Terumo Relay Plus or Pro) sewn to self-expanding nitinol stents with suture. The graft is fully stented to provide stability and the expansile force necessary to open the lumen of the graft during deployment. Additionally, the stents provide the necessary attachment and seal of the graft to the aortic wall.
40967494|NCT03558698|OTHER|Poor Ventilation|Poor ventilation with high concentrations of CO2 and bio effluents
40967495|NCT03801486|OTHER|Experimental: Sprouted Chickpea Flour|255g of pasta with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
40967496|NCT03801486|OTHER|Control: Semolina Flour|255g of pasta with 100% semolina flour (SEM100) with butter.
40967497|NCT05169047|OTHER|Best Medical Treatment|For each patient who is randomized to BMT, an optimal individual treatment plan will be developed by the treating physician.
41295839|NCT06378658|DRUG|BAY2927088|Oral administration
41295840|NCT06378658|DRUG|Esomeprazole|Oral administration
41295841|NCT06378658|OTHER|Food|light low-fat meal or high fat, high calorie meal
41295842|NCT00931892|DIETARY_SUPPLEMENT|Gluten|3g
41295843|NCT00931892|DIETARY_SUPPLEMENT|Gluten|10g
40768180|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Non-Food)|Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping an everyday object (e.g., box of crayons) and taking out its contents.
40768181|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Food)|Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping a snack (e.g., chocolate bar, bag of chips) and taking out its contents.
40768182|NCT05095922|DRUG|Heart-Protecting Musk Pill|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
40768183|NCT05095922|DRUG|Valsartan Capsules|Valsartan Capsules(capsule, 80mg, once a day, 3 months）
40768184|NCT05095922|DRUG|Calcium Dobesilate Capsules|Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
40768185|NCT05641116|OTHER|physical activity program|24 face-to-face APA sessions at the sport and health center for 3 months at a rate of 2 sessions per week near his home and 9 therapeutic patient education workshops for 3 months at a rate of 3 workshops per month (telecare).
40768186|NCT05641116|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice in autonomy for 3 months).
40768187|NCT06097364|DRUG|Odronextamab|Administered by intravenous (IV) infusion
40768188|NCT06097364|DRUG|Rituximab|Administered by IV infusion, or subcutaneous (SC)
40967498|NCT05169047|OTHER|Subthreshold Spinal Cord Stimulation|SCS will be programmed at subthreshold stimulation.
41138023|NCT01762982|DRUG|SLS Solution|Finn Chamber filled with SLS (0.3% w/v) water solution
41138024|NCT01762982|DRUG|Normal Saline Water|Finn Chamber filled with Normal Saline water (0.9% w/v)
41295844|NCT05090150|OTHER|Home delivery of ART|Home ART refill and monitoring, adherence support
41295845|NCT05090150|OTHER|Smart Lockers (Pele boxes)|Decentralized ART refills and monitoring, adherence support
41295846|NCT05090150|OTHER|Best clinic practices + conditional lottery incentives|Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART
41295847|NCT05090150|OTHER|Best clinic practices|Continue with best clinic practices
41295848|NCT02288975|DEVICE|CytoSorb 300ml device (3804606CE01)|
41295849|NCT02615717|BEHAVIORAL|Attention Bias Modification|comparison of treatment versus control
41295850|NCT02660580|DRUG|MSB11022|Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.
41138025|NCT01762982|OTHER|Empty Finn Chamber|Empty Finn Chamber
41138026|NCT04741009|DEVICE|CI632 Slim Modiolar Electrode|Cochlear Ltd CI632 cochlear implant with Slim Modiolar Electrode
41295851|NCT02660580|DRUG|Humira®|Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.
41295852|NCT00016861|DRUG|irinotecan hydrochloride|
41295853|NCT02060708|DEVICE|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
41295854|NCT00692705|DRUG|Radioligand (11C)AZD2995|Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
41295855|NCT00692705|DRUG|Radioligand (11C)AZD2184|Single dose of i.v solution. Once for AD patients respective healthy volunteers.
41295856|NCT00814840|DEVICE|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
41295857|NCT00814840|DEVICE|Triple-site cardiac resynchronization|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
40768189|NCT06097364|DRUG|Cyclophosphamide|Administered by IV infusion
40768190|NCT06097364|DRUG|Doxorubicin|Administered by IV infusion
40768191|NCT06097364|DRUG|Vincristine|Administered by IV infusion
40768192|NCT06097364|DRUG|Prednisone/Prenisolone|Administered orally (PO)
40768193|NCT01356940|DRUG|dalfampridine ER|dalfampridine ER 10mg bid for 4 weeks
40768194|NCT01356940|DRUG|placebo|identical placebo tablet administered bid for four weeks
40967499|NCT03491371|DRUG|Methylsulfonic apatinib|Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.
40967500|NCT02123121|DRUG|Resveratrol 1000 mg/day|Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
40967501|NCT02123121|DRUG|Resveratrol 1500 mg/day|Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
40967502|NCT02123121|OTHER|Vegetable cellulose|Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
41138027|NCT01995981|DRUG|Pazopanib|
41138028|NCT01003366|DEVICE|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
41138029|NCT01003366|DEVICE|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
41138030|NCT00994851|DRUG|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
40768195|NCT06512259|OTHER|AlloMend® Acellular Dermal Matrix allograft|AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.
40768196|NCT06381791|DRUG|Epidiolex|150mg of Epidiolex
40768197|NCT06381791|DRUG|Placebo oral solution|150mg of Placebo oral solution
40768198|NCT03874559|DIAGNOSTIC_TEST|Blood Draw|Serum samples will be obtained from each patient enrolled
40768199|NCT06621277|OTHER|No intervention|No intervention
41138031|NCT00994851|DRUG|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
41138032|NCT03622580|DRUG|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
41295858|NCT00231985|BEHAVIORAL|Habit reversal therapy|Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.
41295859|NCT00231985|BEHAVIORAL|Supportive therapy|Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
40768200|NCT06621277|OTHER|Tailored counseling programs (Phase 2)|Optimized care services and tailored counseling programs for young patients with GI tumors at the Heidelberg University Hospital (Phase 2)
40768201|NCT06049160|DRUG|Misoprostol|All participants will be assigned for giving misoprostol rectally either preoperative or postoperative
40768202|NCT01512576|OTHER|acupuncture|one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
40768203|NCT01512576|BEHAVIORAL|relaxation|1 treatment session of 30 minutes
40768204|NCT04618276|OTHER|Photodynamic Therapy|PDT with two different photosensitizers
40768205|NCT03382457|DEVICE|Transcatheter Tricuspid Valve Repair|Repair of the tricuspid valve through a transcatheter approach
40768206|NCT03599713|DRUG|Retifanlimab|INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks
40768207|NCT05656040|BIOLOGICAL|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously
40768208|NCT05656040|DRUG|Placebo|Normal saline administered subcutaneously
40768209|NCT04015141|DRUG|Perampanel Oral Suspension|Perampanel oral suspension.
40768210|NCT04015141|DRUG|Perampanel Tablet|Perampanel tablet.
40768211|NCT01728896|OTHER|Patient-controlled oral refeeding|
40768212|NCT05605899|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
41138033|NCT03622580|DRUG|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
40768213|NCT05605899|DRUG|Cyclophosphamide|Administered intravenously
40768214|NCT05605899|DRUG|Fludarabine|Administered intravenously
41295860|NCT05313919|DIAGNOSTIC_TEST|Comprehensive functional diagnostics of coronary circulation|"Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~* echocardiography with assessment of diastolic function~* flow-mediated dilation of brachial artery~* coronary angiography~* functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~* provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~* laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~* serum level of inflammatory cytokines and chemokines"
40967503|NCT02123121|OTHER|All groups|All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
40967504|NCT04531943|DRUG|Estrogen|Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.
41295861|NCT05694819|DRUG|Darolutamide|Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
41295862|NCT05694819|DRUG|Goserelin|Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
41295863|NCT00515463|BIOLOGICAL|denosumab|60 mg denosumab in 1mL
41295864|NCT00515463|BIOLOGICAL|denosumab|60 mg denosumab in 1mL
40967505|NCT04531943|DRUG|Estrogen plus Progesterone|Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.
40967506|NCT03129100|DRUG|Ixekizumab|Administered SC
40967507|NCT03129100|DRUG|Placebo|Administered SC
41295865|NCT00898261|GENETIC|microarray analysis|
41295866|NCT00898261|GENETIC|reverse transcriptase-polymerase chain reaction|
41295867|NCT00898261|OTHER|flow cytometry|
40768215|NCT05605899|DRUG|Etoposide|Administered intravenously
40768216|NCT05605899|DRUG|Rituximab|Administered intravenously
40768217|NCT05605899|DRUG|Doxorubicin|Administered intravenously
40768218|NCT05605899|DRUG|Vincristine|Administered intravenously
40768219|NCT05605899|DRUG|Prednisone|Administered orally
40768220|NCT06023589|BIOLOGICAL|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab
40768221|NCT06023589|OTHER|Placebo|Participants will be receiving subcutaneous injection of matching placebo
40768222|NCT05848297|DEVICE|Transcranial Doppler ultrasonography (TCD)|Portable, bedside, non-invasive diagnostic tool used for real-time assessment of cerebral hemodynamics
40768223|NCT05487391|DRUG|QL1706 injection|QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
40768224|NCT05487391|DRUG|Vinorelbine Tartrate|Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
40768225|NCT05487391|DRUG|Paclitaxel|Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
40768226|NCT05487391|DRUG|Cisplatin|Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
40768227|NCT05487391|DRUG|Carboplatin|Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
40768228|NCT05487391|DRUG|Pemetrexed|Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
40768229|NCT05487391|DRUG|Placebo|Placebo
40768230|NCT04025957|DRUG|SHR-1501|Administered subcutaneously
40768231|NCT05547984|DEVICE|Dual Mobility Cup|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup
40768232|NCT05547984|DEVICE|Standard Acetabular component|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head
40768233|NCT00432965|DEVICE|Moist Wound Therapy|Moist Wound Therapy (Standard of Care)
40768234|NCT00432965|DEVICE|VAC Therapy|VAC Therapy
41295868|NCT05020938|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
41295869|NCT02596347|PROCEDURE|Blood draw|We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)
41138034|NCT03622580|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
41138035|NCT02506192|DRUG|Modified-Release Prednisone|Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
41138036|NCT02506192|DRUG|Placebo|Placebo oral tablets (2x5mg) daily for 8 weeks
41138037|NCT00364455|DRUG|Epoetin alfa|
41138038|NCT03313726|DRUG|GnRH antagonist|Administration of GnRh antagonist after baseline PSMA-PET at day 0 and then repeated PSMA-PET scans at day 7, day 14 and day 28 to define the timeframe of the SUV-max.
41138039|NCT03313726|DRUG|GnRH antagonist|Administration of GnRh-antagonist after baseline PSMA-PET at day 0 and then repeated scan at day in which SUV-max was observed in the Arm A (day 7, day 14 or day 28). Then robot assisted radical prostatectomy and lymphadenectomy are performed to verify the finding.
41138040|NCT05352737|DIAGNOSTIC_TEST|methylmalonic acid testing|
41138041|NCT06324097|DIAGNOSTIC_TEST|endocytoscopy|The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue.
41138042|NCT03918005|OTHER|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
41295870|NCT02596347|PROCEDURE|bronchoscopy|CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.
40768235|NCT02637687|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
40967508|NCT02557620|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
40967509|NCT02557620|DRUG|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
40967510|NCT00272467|DRUG|Rebamipide|"1. Brand name: Mucosta® Tab.~2. Generic name: Rebamipide.~3. Chemical name:~   (±)-2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinon-4-yl\]propionic acid.~4. Formulation: Tablet (White, film-coated tablet).~5. Strength: One tablet contains rebamipide 100mg.~6. Storage condition: 15℃\~25℃.~7. Manufacturer: Korea Otsuka Pharmaceuticals"
40967511|NCT00272467|DRUG|Omeprazole|"1. Brand name: Losec® Cap.~2. Generic name: Omeprazole.~3. Chemical name:~5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃\~25℃. 7) Manufacturer: AstraZenaca Korea."
40967512|NCT05453656|BEHAVIORAL|exercise|physical activity promotion and engagement following kidney transplantation
40967513|NCT00291577|DRUG|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
40967514|NCT00291577|DRUG|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
41138043|NCT02356874|BEHAVIORAL|Exercise|An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
41138044|NCT01319032|OTHER|Extraction of whole blood|Extraction of DNA from whole blood
40768236|NCT05421858|DRUG|Fosmanogepix|IV infusion
40768237|NCT05421858|DRUG|Fosmanogepix|Oral tablet
40768238|NCT05421858|DRUG|Caspofungin|IV infusion
40768239|NCT05421858|DRUG|Fluconazole|Fluconazole oral capsule
40768240|NCT05421858|DRUG|Placebo|Matching placebo for caspofungin (IV infusion)
40768241|NCT05421858|DRUG|Placebo|Matching placebo for fluconazole (oral capsule)
41295871|NCT03020810|DRUG|Dupilumab|The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
40768242|NCT05421858|DRUG|Placebo|Matching placebo for fosmanogepix (IV infusion)
40768243|NCT05421858|DRUG|Placebo|Matching placebo for fosmanogepix (oral tablet)
40768244|NCT00425555|DRUG|Panobinostat|
40768245|NCT06042491|BEHAVIORAL|Prehabilitation intervention|The intervention consists of exercise, nutritional support and breathing techniques. The exercise component consists of 1) strength training; 2) cardio and 3) stretching. Participants will be encouraged to complete self-directed and/or group sessions \>= 3 times per week. Each intervention participant will be provided a unique login to the virtual prehabilitation platform, which is the STRIVE Trial website. The nutrition component includes: 1) protein supplementation; 2) nutrition advice to support healthy eating. For the breathing component, participants will be encouraged to watch the video on Inspiratory Muscle Training (IMT) which involves diaphragmatic breathing and coughing/huffing. They will also be provided with an instruction booklet to take to hospital with them to support postoperative conduct of IMT during early recovery.
40768248|NCT00582296|BEHAVIORAL|questionnaires, telephone interview, optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
40768249|NCT00582296|BEHAVIORAL|questionnaires, telephone interview and optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
40768250|NCT06565000|OTHER|AHA Not Instrumented then AHA Instrumented|First, the participant will undergo a performance assessment using the Assisting Hand Assessment test, following the standard protocol in the occupational therapy room. Subsequently, they will proceed to the motion analysis laboratory located across the hall, where an engineer will outfit them with motion capture markers. These markers comprise ultra-reflective spheres affixed to specific anatomical landmarks on their upper limbs using hypoallergenic tape. Afterward, the participant's functional capacity will be evaluated using the Melbourne Assessment. Finally, a second round of assessment using the Assisting Hand Assessment will be conducted.
40967515|NCT05228288|PROCEDURE|Conventional direct laryngoscopy (CDL)|This procedure is considered the gold standard for endotracheal intubation and is routinely used in the peri-operative setting as well as in intensive care and emergency medicine.
41295872|NCT00791128|DEVICE|GI Liner|Medical device placed endoscopically in the duodenum, nutritional counseling
41295873|NCT00233220|BEHAVIORAL|Multicomponent, multi-level intervention targeted at physicians and patients|The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
41295874|NCT00233220|BEHAVIORAL|Usual Care|Patients will receive usual care.
40967516|NCT05228288|PROCEDURE|Video assisted laryngoscopy with Macintosh-shaped blade (M-VAL)|This device is implemented in most german hospitals and used when conventional direct laryngoscopy is not sufficient. By positioning the camera at the tip of the blade, the achievable field of view onto the glottic plane is improved.
40967517|NCT05228288|PROCEDURE|Video assisted laryngoscopy with hyper-angulated blade (H-VAL)|The hyper-angulated blades are often used as a backup instrument when a view of the glottic plane cannot be achieved with the Macintosh blade due to anatomic abnormalities, even with a video-assisted laryngoscope.
40967518|NCT06074367|DRUG|Vitamin C 500 MG Oral Capsule(High dose 2g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins \& vitamin C 500 mg (2 g-daily in 4 divided doses) started one day before operation till the end of hospital stay or development of post operative atrial fibrillation
40967519|NCT06074367|DRUG|Vitamin C 500 MG Oral Capsule(Low-dose 1g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins, vitamin C 500 mg (1 g-daily in 2 divided doses) and also received 2 capsules containing starch to be completely equivalent in frequency to the other groups. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
41295875|NCT03799315|DRUG|Nicotine Replacement Therapy|All participants randomized to the JUST group will receive training on proper use of nicotine lozenges to aid in smoking cessation. Upon release from jail, participants will receive 2mg nicotine lozenges.
41295876|NCT03799315|BEHAVIORAL|Counseling|All participants randomized to the JUST group will receive one hour of in-person, individual, guideline-based smoking cessation counseling during their jail stay. Upon release from jail, they will receive four 30-minute counseling phone calls over 3 weeks. These phone calls will take place at 24 hours, day 7, day 14, and day 20.
41295877|NCT01051388|DRUG|Low-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
41295878|NCT01051388|DRUG|High-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
40768251|NCT06565000|OTHER|AHA Instrumented then AHA Not Instrumented|"First, the participant will proceed to the motion analysis laboratory located across the hall, where an engineer will outfit them with motion capture markers. These markers comprise ultra-reflective spheres affixed to specific anatomical landmarks on their upper limbs using hypoallergenic tape. Afterward, the participant's functional capacity will be evaluated using the Melbourne Assessment. Then, will undergo a performance assessment using the Assisting Hand Assessment test.~Finally, they will go to the occupational therapy room where a second round of assessment using the Assisting Hand Assessment without markers will be conducted."
40768252|NCT05270863|DRUG|BRIMOCHOL™ PF|A single drop in each eye at a visit.
40768253|NCT05270863|DRUG|Carbachol PF|A single drop in each eye at a visit.
40768254|NCT05270863|DRUG|Brimonidine tartrate|A single drop in each eye at a visit.
40768255|NCT03563001|DRUG|Budesonide(160ug) and Formoterol(4.5ug) bid|For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
40768256|NCT06590610|DEVICE|Radial pressure wave (RPW) - Intelect RPW2 Chattanooga|RPW treatment on one leg at the Gastrocnemius and NMES electrostimulation on the opposite leg. RPW or NMES treatment on each leg will be randomized prior to application with each device having an equal chance of being placed on the either leg (dominant and non-dominant).
40768257|NCT06596005|DRUG|TJ0113|200 mg or 400 mg Capsule, Once Daily
40768258|NCT06596005|DRUG|Placebo|Capsule, Once Daily
40768259|NCT04925284|DRUG|XB002|IV administration of XB002
40768260|NCT04925284|DRUG|Nivolumab|IV administration of Nivolumab
40967520|NCT06074367|DRUG|placebo capsules|A sixty CABG Patients commenced on maximum tolerated dose of b-blocker, statins and placebo capsules containing starch mimic vitamin C capsules was taken every 6 hrs. The placebo capsules were prepared in the same shape and size as the original ones manufactured by the same pharmaceutical company. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
40967521|NCT02974517|DEVICE|EmbryoScope®|The intervention is EmbryoScope® versus conventional incubators.
40768261|NCT05039307|BEHAVIORAL|Educational and motivational strategy|The intervention will focus on the following topics A) Healthy diet: food pyramid, a healthy plate distribution, type of carbohydrates and fats, healthy cooking techniques and healthy oils. B) Physical activity: definition, types of physical activity, advantages and benefits, examples, active physical activity sessions. C) Weight control: strategies, benefits and healthy weight gain during pregnancy. D) Knowledge and awareness of T2DM and GDM: definition, prevention, management and complications. These topics will be delivered through individualized education, group sessions and focus groups. Participants will be provided with printed material at baseline and also during the individual education sessions at the household containing a brief summary of the topics covered. The motivational components of goal setting and the use of a pedometer will be incorporated explained during the individual education sessions. The intervention will be primarily delivered by trained peer educators.
40768262|NCT06570395|PROCEDURE|Osteopathic Manipulative Treatment|"Osteopathic Manipulative Therapy (OMT) is a hands-on approach to treating conditions that affect all areas of the body. Physicians trained in OMT (Doctors of Osteopathic Medicine or DO) use OMT to correct structural imbalances in the body, relieve pain, and improve circulation. It is not only used as a treatment modality, but also to diagnose and prevent disease and improve overall functioning. There are over 40 OMT techniques that all involve gentle manipulation of the muscles, soft tissues, and joints in several ways to optimize alignment, improve blood flow, restore balance, and improve range of motion (Osteopathic Manipulative Therapy \& OMT. Cleveland Clinic)."
40967522|NCT01102504|DRUG|Placebo|Placebo
40967523|NCT01102504|DIETARY_SUPPLEMENT|Ateronon|Tomato extract containing 28 mg lycopene/ day
40967524|NCT04483141|DIAGNOSTIC_TEST|Abbey Pain Scale|Hetero-assessment of pain
40967525|NCT06499311|OTHER|Foot Reflexology|Foot Reflexology is an alternative medical practice involving the application of pressure to specific points on the feet. It has been reported as a non-invasive complementary therapy that was addressed as an effective technique that is reported to reduce premenstrual symptoms.
40967526|NCT06499311|OTHER|Acupressure|Acupressure is a sort of massage therapy, was addressed as an effective technique that is reported to reduce premenstrual symptoms. Acupressure is a well-known form of Traditional Chinese Medicine that is a component of alternative treatments.
40967527|NCT00601458|DRUG|pregabalin|Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
41138045|NCT04847180|PROCEDURE|Biopsy|The biopsy will be performed at the level of the capsular fold located just above the area devoid of cartilage in the postero-superior region of the humeral head, near the area where Hill Sachs notches occur.
41138046|NCT03541525|OTHER|Biological sampling|Biological samples including blood, surgical remainder, urine,...
41138047|NCT02516085|DRUG|Metformin|
41138048|NCT02516085|DRUG|L-Arginine|
41138049|NCT00476294|OTHER|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
41295879|NCT01051388|DRUG|Non-PPI (Gefarnate)|The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
40768263|NCT06571916|BEHAVIORAL|Brief-SfSL|"Brief-SfSL is a single 90-minute intervention that that:~1. helps clients understand their suicide narrative, which explores the origin and meaning of their suicidal thoughts~2. builds specific skills to keep oneself safe from suicide even if suicidal thoughts are present~3. includes enhanced safety planning by identifying the barriers to enacting a safety plan and solutions to overcome them"
40768264|NCT03543423|OTHER|Oral glucose tolerance test|Oral glucose tolerance test will be carried out with a glucose solution made up of 75g glucose dissolved in 300mL. To the glucose solution will be added 5g 3-OMG and 1g paracetamol 5g 3-OMG
40768265|NCT03543423|OTHER|Liquid mixed meal test|A standardised liquid mixed meal test will be carried out using a standard liquid mixed meal (fresubin drink supplemented with 1g paracetamol).
40768266|NCT06089317|DRUG|TCM ultrasonic atomization treatment with herbal Compound Decoction (CD)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the CD group is TCM compound decoction.~The prescription of atomization solution in the CD group contains Honeysuckle flower (金銀花) 5g, Chrysanthemum flower (菊花) 5g, Pale betterflybush flower (密蒙花) 5g, Mild mint herb (薄荷) 5g, Barbary wolfberry fruit (枸杞子) 10g, and Ophiopogon japonicus (麥冬) 5g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
40768267|NCT06089317|DRUG|TCM ultrasonic atomization treatment with Dendrobii Caulis (DC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the DC group is Dendrobii Caulis extracts.~The prescription of the DC group contains Dendrobium (石斛) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
40768268|NCT06089317|DRUG|TCM ultrasonic atomization treatment with Houttuynia Cordata (HC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the HC group is Heartleaf Houttuynia Herb extracts.~The prescription of the HC group contains Heartleaf Houttuynia Herb(魚腥草) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
40768269|NCT06089317|DRUG|Placebo TCM ultrasonic atomization treatment (PA)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the PA group is low-concentration compound decoction (5%) same with the CD group.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
40768270|NCT06089317|DRUG|Artificial Tears (AT)|The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.
40967528|NCT00601458|DRUG|naproxen sodium|Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
40967529|NCT00601458|DRUG|Comparator: Placebo|Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
41138050|NCT02367248|DRUG|deferoxamine|Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
41295880|NCT01193790|PROCEDURE|Coblation channeling|"The combination of the energy and the fluid creates a plasma field containing highly ionized particles (coblation). The ionized particles have sufficient energy to break organic molecular bonds that can remove tissue selectively without excessive heat production and subsequent damage to the surrounding tissue. Treatment of the tonsillar crypts and tissue by coblation may decrease antigen and immune system interaction and inflammation."
41295881|NCT05653726|OTHER|Telemonitoring follow-up using medical devices and telematic consultations|Home telemonitoring of blood pressure, heart rate and peripheral oxygen saturation on a daily basis during 12 months
41295882|NCT01264133|DRUG|Clevudine, Adefovir|Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
41295883|NCT01947673|OTHER|Mindfulness Meditation|
41295884|NCT01947673|OTHER|Health Education|
41295885|NCT02100657|DRUG|Plitidepsin|
41295886|NCT02100657|DRUG|Bortezomib|
41295887|NCT02100657|DRUG|Dexamethasone|
41295888|NCT05725369|BEHAVIORAL|Combined Lifestyle Intervention (CLI)|In the Netherlands, the combined lifestyle intervention (CLI, in Dutch: gecombineerde leefstijlinterventie (GLI)) is available for all Dutch citizens with a BMI ≥ 30 mg/kg2 or a BMI between 25 and 30 mg/kg2 and an increased risk of diabetes or cardiovascular disease. The CLI aims to realize health benefits for people with a moderate weight-related health risk and consists of a two-year program with advice and counseling to improve health-related behavior such as physical activity and diet.
41295889|NCT01485679|OTHER|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
40768271|NCT06347315|DIETARY_SUPPLEMENT|BrainXpert|sachet/stickpack of 25 g, has no preservatives, no flavors, no sweeteners, and no colorants.
40768272|NCT06347315|OTHER|Placebo|high-oleic acid sunflower oil as a calorie-equivalent, non-ketogenic vegetable oil, non added vitamin product will also be provided in a powder format in a sachet/stickpack of 25 g.
40768273|NCT05685602|PROCEDURE|Biopsy|Undergo a tumor biopsy
40768274|NCT05685602|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40768275|NCT05685602|PROCEDURE|Computed Tomography|Undergo a CT scan
40768276|NCT05685602|BIOLOGICAL|Emavusertib|Given PO
40768277|NCT05685602|DRUG|Gemcitabine Hydrochloride|Given IV
40967530|NCT03803397|BIOLOGICAL|PV-001-DC|Patient-specific cellular therapeutic for cancer immunotherapy
40967531|NCT06014814|PROCEDURE|Catheter ablation|Catheter ablation of atrial fibrillation
40967532|NCT04706091|DRUG|Suvorexant|10-mg or 20-mg suvorexant capsules
40967533|NCT04706091|OTHER|Placebo|Matching placebo capsules
40967534|NCT06133205|OTHER|Catgut Embedding at acupoints|Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.
41138051|NCT02367248|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
41138052|NCT02367248|DRUG|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
41295890|NCT00337298|DRUG|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
41295891|NCT00337298|DRUG|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
40768278|NCT05685602|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40768279|NCT05685602|DRUG|Nab-paclitaxel|Given IV
40967535|NCT00268593|DRUG|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
41295892|NCT04445077|OTHER|Dementia Competence Education for care home setting|The intervention is a competency-based education program for care home staff who provide dementia care in Mainland China.
41295893|NCT04445077|OTHER|Printed educational materials|The educational materials will be delivered to the participants in the control group for their self-study.
41295894|NCT00592358|DRUG|paliperidone|tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
41295895|NCT03428191|DRUG|Remifentanyl+Dexmedetomidine|In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method.
41295896|NCT05392192|DRUG|ADX-629|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
41295897|NCT05392192|DRUG|Placebo|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
41295898|NCT03292627|DEVICE|Portable Noninvasive Hemodynamic Monitor|A non-invasive monitor for estimating patient's heart contractility and cardiac output by the change of thoracic electrical bioimpedance.
41295899|NCT02004405|OTHER|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
40768280|NCT05685602|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
40967536|NCT00268593|DRUG|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
40967537|NCT00268593|DRUG|prednisone|5 mg twice a day orally
40967538|NCT01816282|DRUG|Evicel|Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
40967539|NCT03098550|BIOLOGICAL|Nivolumab|Specified dose on specified days
40967540|NCT03098550|BIOLOGICAL|Daratumumab|Specified dose on specified days
40967541|NCT05771376|OTHER|Qigong exercise program|"The intervention group will perform a qigong exercise program online (via Zoom video conference) for 12 weeks under the supervision of two physiotherapists. The qigong exercise program had previously been videotaped by the researchers.~qigong exercise program includes: Preparation posture Prop up the sky by two improve trijiao Draw a bow on both sides like shooting a vulture Raise single arm up to regulate spleen Look back to treat five strains and seven impairments Shake the head and wag to expel Heart (Xin)-fire Pull toes with both hands to reinforce the kidney Clench one's fist and glare to increase strength Rise and fall on tiptoe sevan times to treat all diseases Ending posture. Qigong exercises will be performed 45 minutes twice in a week for 12 weeks."
40967542|NCT05771376|OTHER|Home exercise program|"The home exercise program will include stretching for cervical, thoracic and lumbar flexibility, shoulder girdle, hamstring and erector spinal muscles, and strengthening exercises for abdominal, back, and proximal muscles.~Home exercises will be performed 45 minutes twice in a week for 12 weeks."
40967543|NCT00215332|DEVICE|CHARITE|Lumbar Total Disc Replacement
40967544|NCT05777577|DIETARY_SUPPLEMENT|probiotic therapy|probiotic including bifidobacterium
40967545|NCT05168527|DRUG|Fruquintinib,Albumin Paclitaxel,Gemcitabine|The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
41295900|NCT02004405|OTHER|flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
41295901|NCT05407298|OTHER|Non applicable|Non Applicable
41295902|NCT04376268|DRUG|Chlorhexidine mouthwash|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
40768281|NCT05685602|PROCEDURE|X-Ray Imaging|Undergo an x-ray
41295903|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (0.1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
41295904|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (0.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
41457653|NCT04313296|DEVICE|Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)|The historic echocardiograms from patients who meet the study inclusion criteria will be uploaded into this software, which was newly acquired by the PBMC Cardiology Department. MaineHealth Information Services are currently working with study staff to assure appropriate security compliance within the network. LA GLS has not been routinely collected previously from echocardiograms performed at PBMC because of a lack of such technology.
41457654|NCT05527639|BEHAVIORAL|strength training program|12-weeks of strength training consisting of warm ups, dead-lifts, squats and cool down exercises
40967546|NCT02417597|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
40967547|NCT01912365|PROCEDURE|Above Elbow Cast|
41457655|NCT01731028|DRUG|Somatropin|Somatropin powder and solvent for solution for injection
41457656|NCT04138251|DRUG|Empagliflozin|oral administration of Empagliflozin
41457657|NCT05485155|DRUG|Alpha-proteinase inhibitor|Intravenous infusion at 120 mg/kg body weight dose/week for 12 weeks for a total of 12 infusions.
40967548|NCT01912365|PROCEDURE|Long Arm Splint|
41457658|NCT00002936|DRUG|altretamine|
41457659|NCT00002936|DRUG|etoposide|
41457660|NCT05748938|BIOLOGICAL|RD14-01|ROR1 Targeted CAR-T cells
41457661|NCT06256562|DRUG|GZR18|Titrated to dose 1, dose 2, dose 3 or dose 4
41457662|NCT06256562|OTHER|Placebo|Administered the same volume as GZR18
40967549|NCT04289402|OTHER|Personalized tDCS|The participant will receive 10, 20-minutes sessions of personalized tDCS Monday-Friday, at approximately the same time of day, over two consecutive weeks.
41138053|NCT04121741|OTHER|Singing with Music Therapist|Music therapy sessions will begin with vocal and breathing warm-up exercises for about 10 minutes. The Music Therapist will play the songs (chosen from a list by the subject) to sing along to and will alter the characteristics of the music (volume, tempo, level of support) to ensure a successful experience for subjects and motivate them to put forth more effort into singing the song. The music therapist will continue to coach throughout the 30-minute session, reminding subjects of strategies practiced and how to implement those strategies while singing. Music therapy sessions will be led by Erica Flores, MT-BC, WMTR, Owner of Healing Harmonies Music Therapy, or a member of her team. Erica and her team of MTs were trained in Neurological Music Therapy.
41457663|NCT02342509|DRUG|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
41457664|NCT02342509|DRUG|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
41457665|NCT02342509|DRUG|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
41457666|NCT06435325|BEHAVIORAL|Precision diet|After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
41457667|NCT06435325|BEHAVIORAL|Control diet|After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
40967550|NCT04289402|OTHER|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation Monday-Friday, at approximately the same time of day, over two consecutive weeks.
40967551|NCT02932670|OTHER|costoclavicular nerve block|ultrasound-guided costoclavicular nerve block
40967552|NCT02968901|DRUG|macitentan|used in open label
40967553|NCT02968901|DRUG|tadalafil|used in open label
40967554|NCT01114425|DRUG|raltegravir (Isentress)|raltegravir (Isentress) 400 mg bid
40967555|NCT01114425|DRUG|Truvada®|
40967556|NCT01488929|DRUG|TC-5619|
40967557|NCT01488929|DRUG|Placebo|
40967558|NCT00289445|DRUG|Mitomycin C|
40967559|NCT00289445|DRUG|5-FU|
41457668|NCT04846686|BIOLOGICAL|Placenta pathological examination|a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
41457669|NCT01087567|DRUG|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
41457670|NCT01087567|DRUG|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
41457671|NCT02757703|DRUG|Somatostatin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
40967560|NCT00289445|DRUG|Folinic acid|
40967561|NCT03894553|DEVICE|ExAblate Neuro|Unilateral stereotactic focused ultrasound lesioning of the contralateral mesencephalon
40967562|NCT02352402|DRUG|Ticagrelor|
40967563|NCT02352402|DRUG|Placebo|
40768282|NCT06109324|OTHER|Robotic Rehabilitation of the upper limb|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
40768283|NCT06109324|OTHER|Conventional Rehabilitation of the upper limb|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
40768284|NCT05826626|DEVICE|MindLenses Professional|MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
40768285|NCT05826626|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
40967564|NCT03570021|PROCEDURE|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection|"total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association \[American Thyroid Association Surgery Working Group, Thyroid 2009\]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery \[French Society of Otolaryngology Head and Neck Sugery\].~- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection \[Hartl DM, Ann Surg 2012\], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons \[Hartl DM, World J Surg 2012\]."
41295905|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
41295906|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (1.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
41295907|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
41457672|NCT02757703|DRUG|Terlipressin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
41457673|NCT02757703|DRUG|Pantoprazole|Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
41457674|NCT02757703|DEVICE|Endoscopic variceal ligation|Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
41457675|NCT02386358|DRUG|Benznidazole|Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
41457676|NCT02386358|DRUG|Placebo|Placebo at a dose 5 m/Kg/day until 60 days
41457677|NCT02323555|OTHER|Paramedic telephone consultation|
40768286|NCT06641037|DRUG|LY3866288|Administered orally
40768287|NCT06623526|DRUG|YHR2402|Test Drug: YHR2402
40768288|NCT06623526|DRUG|YHR2402+YHR2403|Test Drug: YHR2402+YHR2403
40768289|NCT05838248|OTHER|antibiotic duration|Duration of antibiotic treatment post appendectomy
40768290|NCT00939185|DRUG|Azithromycin|Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
40768291|NCT06303310|OTHER|Gaze Stability Exercises|Group A ( Gaze Stability Exercise+ Routine Physical Therapy) Group A will receive gaze stability exercises consist of 5 structured components for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.(16)
40768292|NCT06303310|OTHER|Optokinetic Exercises|Group B (Optokinetic Exercises+Routine Physical Therapy) Group B will receive optokinetic exercises for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks
40768293|NCT06303310|OTHER|Routine Physical Therapy|Routine Physical Therapy
40768294|NCT06408233|OTHER|Performance Coaching|Performance coaching will consist of working with clinic staff to understand and guide current quality measurement practices as well as improving quality measurement and implementing new measures and management practices.
40768295|NCT04404153|DEVICE|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.|At-home remotely supervised tDCS delivered over the dorsolateral prefrontal cortex with the anode on the left, cathode on the right, at an intensity of 2 mA, delivered for 30 minutes five times per week (Monday-Friday) for 26 weeks (6 months).
40768296|NCT04404153|DEVICE|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.|Sham treatment will consist of the current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining time of the 30-minute application period five times per week (Monday-Friday) for 26 weeks (6 months).
40768297|NCT03483701|BEHAVIORAL|Cognitive Remediation Therapy|The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
40768298|NCT02586194|DRUG|ASP015K|Oral
40768299|NCT03301506|DRUG|Seladelpar 5 mg Capsule|Subjects will be assigned to a treatment group if tolerability issues noted in the previous study.
40768300|NCT03301506|DRUG|Seladelpar 10 mg Capsule|Subjects will be assigned to a treatment group unless there are tolerability issues.
40768301|NCT02447692|OTHER|PSV ventilation strategy|An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
40768302|NCT02447692|OTHER|PAV+ ventilation strategy|An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
40768303|NCT03503331|DRUG|[C-11]PiB-PET/MRI|All study participants will undergo brain imaging with \[C-11\]PiB-PET/MRI. \[C-11\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
40967565|NCT03570021|PROCEDURE|total thyroidectomy alone without neck dissection|This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
40967566|NCT02490332|DEVICE|Ventilation tube treatment|Tympanostomy
40967567|NCT02164825|DRUG|Ropivacaine perineural injection|Ultrasound guided single-shot femoral nerve block
40967568|NCT02164825|DRUG|morphine and ropivacaine|Continuous epidural analgesic perfusion Epidural perfusion with morphine and ropivacaine.
41138054|NCT04121741|OTHER|Singing with Guided Video|The videos will include a vocal warm-up (10 minutes long). The subject will then have the option to select and sing two songs (10 minutes each), with offerings in four music genres including Folk, Pop, Country, and a Hymn. Each piece will vary in tempo, melodic contour, and rhythm. The total duration of singing via this format will be 30 minutes.
40768304|NCT06616610|BEHAVIORAL|Intervention with the Mobility Platform|The experimental arm receives the Intervention with Mobility Platform that is a focus of the study. It aims to analyze the impact of a single-button-operated mobility platform on reaction times and keypress patterns in children with severe disabilities.
40967569|NCT04386252|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
40967570|NCT06077591|OTHER|Patient-Derived Tumor Organoids|Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
40967571|NCT01927224|DRUG|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
40967572|NCT01927224|DRUG|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
41138055|NCT04121741|OTHER|Control Arm|30 minute rest period, no singing will take place during this arm. During this rest period a member of the study team will assist the subject in a hearing test using headphones, a tablet, and a trumpet app. This is done to asses the current hearing level of the subject.
41457678|NCT04050943|OTHER|observational cohort|Recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.
40967573|NCT01927224|DRUG|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
41457679|NCT01897441|DRUG|Cyclophosphamide|Given IV
41457680|NCT01897441|OTHER|Cytology Specimen Collection Procedure|Correlative studies
41457681|NCT01897441|DRUG|Doxorubicin Hydrochloride|Given IV
41457682|NCT01897441|OTHER|Laboratory Biomarker Analysis|Correlative studies
41457683|NCT01897441|DRUG|Paclitaxel|Given IV
41457684|NCT01897441|BIOLOGICAL|Trastuzumab|Given IV
40967574|NCT02082275|OTHER|OB Nest|"* Reduction in the number of clinic office visits~* Assignment to a specific nursing care team~* Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.~* Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.~* Augmentation of in-person visits between care providers and patients with video conversations.~* Maternal outcomes will be monitored through surveys and questionnaires."
40967575|NCT00232024|DRUG|Tegaserod|
40967576|NCT05317832|BEHAVIORAL|WI program|This 14-week web-based physical activity intervention (WI) program was developed by the National Center on Health, Physical Activity and Disability. The WI program was developed with guidance from literature and practice in health behavior change and internet-based health promotion programming. The content and features of the WI program include motivational resource, updated weekly resources, and customizable features.
40967577|NCT05317832|BEHAVIORAL|WI Program Reminder|Participants will be provided with reminders to use the WI program
40967578|NCT05317832|BEHAVIORAL|JITAI Goal Setting|Participants will be provided with standard, tailored, or no goal for the day. The goal will focus on recommending minutes of moderate-intensity (or higher) physical activity and a reminder to perform strength exercises.
40967579|NCT05317832|BEHAVIORAL|JITAI physical activity message|Participants will be provided with minutes of moderate-intensity (or higher) physical activity achieved, minutes of physical activity remaining, or no message.
40967580|NCT05317832|OTHER|Notification EMA|Participants will be inquired through an ecological momentary assessment (EMA) if they received a JITAI physical activity message.
41138056|NCT05781932|PROCEDURE|Dermal barb suture combined with medical glue|In the experimental group, after tension reduction and suture were completed, the wound and surrounding skin were wiped clean with normal saline and clean gauze, and the blood accumulated in the wound was squeezed out. Histoacryl medical tissue glue (specification:0.5 ml/piece, main components: n-butyl 2-cyanoacrylate (embutate), pigment (1-hydroxy-4\[(toluene)amino\]-9,10-anthraquinone), and stabilizers (p-diphenol, sulfur dioxide, phosphoric acid)) were evenly spread on the surgical incision and kept in the butt state for 4 to 6 seconds. After it got solidify and dry, a sterile gauze covered the surgical incision. There was no need to disinfect and change the dressings after the operation. Patients can shower normally on the day after the operation by just avoiding rubbing the incision covered with glue. Patients can move normally 1-2 days after the operation, and the glue film falls off on its own within 5-10 days.
41138057|NCT05870761|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41138058|NCT05870761|PROCEDURE|Computed Tomography|Undergo MRI/CT
41138059|NCT05870761|BIOLOGICAL|Dostarlimab|Given IV
41138060|NCT05870761|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/CT
41138061|NCT05870761|DRUG|Niraparib|Given PO
41138062|NCT01966679|DRUG|AZD7325|
41138063|NCT01966679|DRUG|Placebo|
41138064|NCT03112005|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
41295908|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (2.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
40967581|NCT05317832|OTHER|End of day EMA|Participants will be inquired, through an ecological momentary assessment (EMA), if they performed aerobic and/or strength exercises for the day.
40967582|NCT05317832|OTHER|Wake up time EMA|Participants will be inquired, through an ecological momentary assessment (EMA), about the time they plan to wake up next day. This information will be used to provide a goal setting message for next day.
40967583|NCT05317832|OTHER|Weekly PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the last 7 days.
40967584|NCT05317832|OTHER|Daily PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the day.
40967585|NCT03355040|OTHER|induction of labour|induction of labour
40967586|NCT02299830|PROCEDURE|cryotherapy|use cryotherapy to delete soft neoplasm tissue in the airway
40967587|NCT02299830|PROCEDURE|argon plasma coagulation|use argon plasma coagulation to delete hard neoplasm tissue in the airway
40967588|NCT02299830|PROCEDURE|stent placement|use stent placement to open the airway compressed by out neoplasm
40967589|NCT02299830|PROCEDURE|deletion tumor tissue by snare|use snare to delete polypoid neoplasm tissue in the airway
40967590|NCT01202812|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)|Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
40967591|NCT01202812|OTHER|Placebo Capsules|Placebo capsules given by mouth daily for 6 months.
41138065|NCT03112005|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
41138066|NCT05300594|DIETARY_SUPPLEMENT|Plant extracts, vitamins and mineral|"Day tablet every day during 3 months : Magnesium (75 mg), Ginkgo Biloba extract (40 mg), hawthorn extract (37,5 mg), L-Theanin (50 mg) , Niacin (16mg), Quercetin (25mg), B12 Vitamin (2,5 µg), B6 Vitamin (1,4 mg), Thiamin (1,1 mg)~Night tablet every evening during 3 months : Magnesium (37,5 mg), Ginkgo Biloba extract (40 mg), Eschscholzia californica extract (40 mg), Zinc (10 mg), Melatonin (1mg), Lemon balm extract (80 mg), Tryptocetyn (65 mg)"
41138067|NCT05300594|DIETARY_SUPPLEMENT|Placebo|Day tablet every morning during 3 months : Excipients; Night tablet every evening during 3 months : Excipients
41138068|NCT01812330|DRUG|Clopidogrel|After 600mg loading dose, 75mg or 150mg Qd
41138069|NCT01812330|DRUG|Ticagrelor|90mg Bid
41138070|NCT01853384|BIOLOGICAL|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
41295909|NCT04376268|PROCEDURE|Boric acid mouthwash (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
40768305|NCT06616610|BEHAVIORAL|Intervention with Traditional Therapy|The traditional cause-effect therapies use an animated cartoon video that frequently pauses so that the children have to press an adapted button to continue watching it.
40967592|NCT01548651|DRUG|Saxagliptin|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and C Reactive Protein (CRP), Intracellular Adhesion Molecule (ICAM), vascular cell adhesion molecule (VCAM), plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
41138071|NCT01853384|OTHER|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
41138072|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|Administered as an injection into an anterior juxtascleral depot
41295910|NCT00615706|OTHER|No intervention|no intervention
41295911|NCT02448823|OTHER|Mass media and Stylish Events|"1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.~2. Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMLEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses."
41295912|NCT02448823|OTHER|Mass Media|1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
41295913|NCT03671083|DEVICE|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
41295914|NCT04397068|PROCEDURE|phaco-vitrectomy|phaco-vitrectomy. No other involvement drug or device. Standard of care procedure
41295915|NCT05566197|DIETARY_SUPPLEMENT|Diet Nusantara|Diet Nusantara consists of 1700 kilocalories (or 500 kilocalories lower than basal energy expenditure) on first month and subsequent reduction for the following months (200 kilocalories). The participants should also limit the sodium intake not more than 2300 mg daily
41295916|NCT05566197|BEHAVIORAL|Nutrition Counseling|Nutrition counseling consists of the definition of balancing food, metabolic syndrome, exercise, and related health parameters.
41295917|NCT04582500|DRUG|Iohexol|Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.
41295918|NCT04638127|BEHAVIORAL|PREEMIE PROGRESS|PREEMIE PROGRESS is a video-based training program for parents of preterm infants hospitalized in the neonatal intensive care unit (NICU).
41295919|NCT04638127|BEHAVIORAL|Attention Control|usual care and welcome videos
41295920|NCT06286280|DEVICE|cytokine adsorber (CytoSorb®)|binding of cytokines to the sorbent polystyrene of the adsorber during cardiac surgery with extracorporeal circulation
41138073|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 3.75 mg/mL|Administered as an injection into an anterior juxtascleral depot
41295921|NCT06030895|DRUG|Sorafenib Tablets|Sorafenib Tablets (200 -400 mg) twice daily
41295922|NCT01250067|PROCEDURE|Motor-related cortical potential (Procedure)|
41295923|NCT02769572|OTHER|real moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
41295924|NCT02769572|DRUG|placebo gel|4 grams per knee, 4 times per day, for 4 weeks
41457685|NCT00818220|PROCEDURE|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
40768306|NCT06414031|DRUG|Tranexamic Acid|Intravenous administration
40768307|NCT06414031|DRUG|Placebo|Intravenous administration
40768308|NCT05653206|PROCEDURE|Nonsurgical treatment|Cervical collar, Halo ring, Halo vest, cervical braces, skeletal skull traction, MAP, steroids, observation or bedrest
41138074|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 96 mg/mL|Administered as an injection into an anterior juxtascleral depot
41138075|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/ML|Administered as an injection into an anterior juxtascleral depot
41138076|NCT00788541|OTHER|Anecortave Acetate Vehicle|Administered as an injection into an anterior juxtascleral depot
41138077|NCT03012490|OTHER|CRT-P or CRT-D standard remote monitoring|standard for the control group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system
40768309|NCT05653206|PROCEDURE|Surgical treatment|Anterior discectomy and instrumented fusion (single level), Anterior discectomy and instrumented fusion (multi-level), Posterior decompression-laminectomy, Posterior decompression-laminoplasty, Posterior decompression and instrumented fusion, Combined anterior and posterior decompression and instrumented fusion
40768310|NCT06541197|OTHER|Robotic rehabilitation combined with Functional Electrical Stimulation (FES) bicycle ergometry group|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks. For FES bicycle ergometry, a current-controlled six-channel stimulator (RT 300-SLSA; Restorative Therapies, Baltimore, MD, USA) will be used. The quadriceps, hamstring and tibialis anterior muscles will be stimulated bilaterally with six channels through 3 × 4 cm2 adhesive surface electrodes. Stimulation intensity will be adjusted according to palpable muscle contraction and sensory discomfort felt by patients with incomplete SCI. The pedaling cadence range will be set to 40-50 rotations per minute. FES bicycle ergometry will be performed in 30-minute sessions for 4 weeks for a total of 20 sessions before robotic rehabilitation.
40768311|NCT06541197|OTHER|Robotic rehabilitation|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks.
40967593|NCT01548651|DRUG|Placebo|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
40967594|NCT04404296|DEVICE|25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomy|Pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
40967595|NCT06229197|PROCEDURE|Billroth II reconstruction|Billroth II reconstruction, in which a loop of jejunum is mobilized and anastomosed to the gastric remnant
40967596|NCT06229197|PROCEDURE|Braun Anastomosis|This is an additional surgical connection (anastomosis) created between two parts of the small intestine, specifically between the afferent (incoming) and efferent (outgoing) limbs of the jejunum near the gastrojejunostomy (the new connection between the stomach and small intestine created during a Billroth II procedure).
40967597|NCT00052689|DRUG|bortezomib|Given IV
40768312|NCT01648933|RADIATION|Rubidium PET|Myocardial Perfusion Imaging
40967598|NCT00052689|DRUG|gemcitabine hydrochloride|Given IV
40967599|NCT04433221|BIOLOGICAL|Multiple sarcoma-specific CAR-T cells and sarcoma vaccines|1 infusion, CART 1x10\^6\~1x10\^7 cells/kg via IV and vaccines 1-5x10\^6 irradiated cells via subcutaneous injection
40967600|NCT01604174|OTHER|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
40967601|NCT01604174|OTHER|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
40967602|NCT02418702|DRUG|0.2 mg/kg ketamine|20 patients will randomly be assigned 0.2 mg/kg of Ketamine
41138078|NCT03012490|OTHER|CRT-P or CRT-D full remote monitoring|Full follow-up for the Active group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system + supraventricular rhythm disorders, parameters related to heart failure, including symptoms and clinical signs of the patient
41138079|NCT03012490|OTHER|Symptoms and signs remote monitoring|symptoms and clinical signs of the patient
41138080|NCT05034432|PROCEDURE|Intra-Op Prophylactic VT ablation|For surgical intra-operative ablation, efforts will be made to identify scarred myocardium based on methods such as cardiac magnetic resonance imaging, nuclear scans, and/or echocardiogram. Electrophysiological mapping may be obtained either pre-surgery or intra-operation. Mapping and ablation will be performed with the currently approved and updated mapping and ablation systems available at each center. Voltage mapping of the ventricle(s) to delineate scars will be carried out through electroanatomic mapping
41138081|NCT05034432|OTHER|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
40967603|NCT02418702|OTHER|placebo|20 patients will randomly be assigned a placebo
41138082|NCT06272188|OTHER|web-based online preconceptional counselling|web-based online preconceptional counselling
41138083|NCT04853654|OTHER|exercise|exercise training for 8 weeks
41138084|NCT01542983|BEHAVIORAL|Brief behavioral treatment for insomnia and bright light|daily bright light exposure; 2 sessions for insomnia
40967604|NCT00520936|DRUG|pemetrexed|1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles
40967605|NCT03910062|PROCEDURE|Lower limb angiography via the reperfusion cannula and NIRS monitoring|Data collection only (lower limb angiography, lower limbs NIRS values).
40967606|NCT01410786|PROCEDURE|Conventional Instrumentation|Standard Oxford surgical instruments
40967607|NCT01410786|PROCEDURE|Signature Custom Guides|Signature Custom Guides used with Instruments in surgical technique
40967608|NCT06342414|DIAGNOSTIC_TEST|ELUCIDATE|ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)
41138085|NCT01542983|BEHAVIORAL|treatment as usual|Standard treatment for fatigue and insomnia
41138086|NCT02198898|DEVICE|GUARDIX-SG|
41138087|NCT01607320|DRUG|Raloxifene|Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
41138088|NCT01607320|DRUG|Clomiphene|Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
41138089|NCT00251199|DRUG|VX-950|
41138090|NCT00251199|DRUG|peginterferon|
40967609|NCT05590013|DRUG|Pectointercostal and ESP block|Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
40967610|NCT03200405|DEVICE|DynaMeshVisible|The umbilical hernias will be fixed with a mesh. In this group a MRI-visible mesh will be used.
40967611|NCT03200405|DEVICE|DynaMeshCICAT|The umbilical hernias will be fixed with a mesh. In this group a non-visible mesh will be used.
40967612|NCT00621985|DRUG|dexamethasone|Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
40967613|NCT00621985|DRUG|Hydrocortisone|Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
40967614|NCT03466008|BEHAVIORAL|Whole-Body Cryotherapy|10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
40967615|NCT00959764|DRUG|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
40967616|NCT00959764|DRUG|Intranasal Calcitonin|Intranasal Calcitonin Spray
40967617|NCT00959764|DRUG|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
40967618|NCT01699204|DIETARY_SUPPLEMENT|N-acetylcysteine|N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
40967619|NCT01699204|OTHER|Diesel exhaust|A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
40967620|NCT01699204|OTHER|Filtered air|A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
40967621|NCT04047394|DRUG|PEGylated recombinant candida urate oxidase|PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
40967622|NCT06238583|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The recommended dose of copanlisib is 60 mg administered as a 1 hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on and 1 week off), OR at a lower dose if dose reduction has occurred on prior treatment. Patients currently included on study protocols may continue their treatment regimen at the discretion of their healthcare provider.
40967623|NCT00056316|BEHAVIORAL|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
41295925|NCT02769572|DRUG|diclofenac sodium gel|4 grams per knee, 4 times per day, for 4 weeks
41295926|NCT02769572|OTHER|sham moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
41295927|NCT04195451|OTHER|Live-Video-Supervised Exercise Intervention|The live-video-supervised exercise intervention includes exercise sessions x3/week for 3 months, and then maintenance regimen for 6 months. Maintenance includes live-video-supervised exercise sessions, only x1/week, and self-exercise x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
41457686|NCT00818220|OTHER|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
40967624|NCT00056316|BEHAVIORAL|Behavioral Skills Training: Experimental|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
40967625|NCT01841983|OTHER|Be Well Work Well|"The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.~Overall intervention objectives:~1. Motivate individual staff members to engage in targeted health and safety behavior changes;~2. build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;~3. facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and~4. promote co-worker and supervisor support for targeted health and safety behaviors."
40967626|NCT00838578|BIOLOGICAL|KRN330|KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
40967627|NCT00838578|DRUG|Irinotecan|Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
40967628|NCT00702611|DEVICE|Granulocyte Monocyte Apheresis (GMA-Apheresis)|GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
40967629|NCT06440096|DIAGNOSTIC_TEST|hemogram|hemogram
41138091|NCT03136159|DEVICE|Silver-impregnated antimicrobial dressing|All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
41138092|NCT05076032|DRUG|OXO-001|OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.
41295928|NCT04195451|OTHER|Usual Care then Live-Video Supervised Exercise Intervention|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the live-video-supervised exercise intervention that includes exercise sessions x3/week for 3 months.
41457687|NCT04947150|BEHAVIORAL|Location-triggered notification|"If participants are randomized to have this component ON, the app will send the notification when the participant's smartphone is within a 50-meter geofence around designated grocery stores. No more than one notification will be sent per week. Mindfulness of program goals in the moment of decision making is expected to facilitate program-consistent food purchasing behaviors. Participants assigned to have location-triggered message delivery OFF will receive their weekly recommendations and reminders messages at standard times throughout the week. The content of the messages will not differ according to whether this component is ON vs. OFF."
41295929|NCT01499238|DEVICE|Nasal SIMV|rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
41295930|NCT01499238|DEVICE|nasal CPAP|PEEP: 4-6 mmHg, FİO2: 40%
40967630|NCT02268344|DEVICE|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
40768313|NCT02683993|DEVICE|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
40768314|NCT00525863|DRUG|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to \~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
40768315|NCT05994352|OTHER|virtual reality simulation|The effect of virtual reality simulation on therapeutic communication skill levels
40967631|NCT04012983|DIAGNOSTIC_TEST|gingival crevicular fluid level|gingival crevicular fluid collection
40967632|NCT02742610|BEHAVIORAL|Mindfulness with Contingency Management|
40967633|NCT02742610|BEHAVIORAL|Active Control|
40967634|NCT04176757|DRUG|ZN-c5|ZN-c5 study drug to be administered orally daily
40967635|NCT02414997|PROCEDURE|RIPC|Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
40967636|NCT02414997|PROCEDURE|Sham RIPC|Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
40967637|NCT03570073|OTHER|Manual vitrification|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
41138093|NCT05076032|DRUG|Placebo|Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
41138094|NCT03340922|DEVICE|Automatic annotation of LAT (WF-method)|Automatic annotation of LAT during PVC activation mapping. Acquisition of points will be automatically performed using the Wavefront (WF) annotation tool integrated into CARTO navigation system.
41138095|NCT03340922|DEVICE|Manual annotation of LAT (M-method)|Conventional, manual annotation of LAT during PVC activation mapping. Acquisition of points will be performed using the CARTO navigation system by an expert electrophysiologist.
41138096|NCT01873898|DEVICE|Rex Medical Closer™ Vascular Closure System|The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
41138097|NCT03477032|BIOLOGICAL|Faecal Microbiota Transplantation|Faeces acquired from a healthy donor
41138098|NCT05521256|DRUG|NNC0113-6856|Participants will receive NN0113-6856 orally or intravenously.
41138099|NCT05521256|DRUG|Placebo|Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.
41138100|NCT02814409|DRUG|Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase|IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion
41138101|NCT02814409|DRUG|Intravenous Tenecteplase|IV Tenecteplase 0.25mg/kg (max 25mg) single bolus
40768316|NCT03030755|OTHER|Optical coherence tomography|
40768317|NCT02987738|DRUG|Dapagliflozin|two administrations in the evening and 12 hours later
40768318|NCT02987738|DRUG|Placebo Oral Tablet|two administrations in the evening and 12 hours later
40768319|NCT06610903|DRUG|Hemay005|In the first cycle, 15mg (1 tablet/person) was given on an empty stomach for Hemay005-T1 or Hemay005-T2, and the second cycle was crossed over
40768320|NCT05576012|BIOLOGICAL|SOL-116|Participants will receive SC injection in a double-blind manner
40768321|NCT05576012|BIOLOGICAL|Placebo|Participants will receive SC injection in a double-blind manner
40768322|NCT00203606|DRUG|pegylated interferon alfa-2a ( Roche) and ribavirin|pegylated interferon alfa-2a ( Roche) and ribavirin
40967638|NCT03570073|OTHER|Vitrification with GaviTM system|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
40967639|NCT01433991|DRUG|Golvatinib|Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.
40967640|NCT01433991|DRUG|Lenvatinib|Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
40967641|NCT01433991|DRUG|Lenvatinib|Participants will receive lenvatinib 24 mg (1\*4 mg capsule + 2\*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
40768323|NCT02831049|BEHAVIORAL|Retrieval-extinction|Retrieval-extinction
40768324|NCT02831049|BEHAVIORAL|Extinction|extinction
40768325|NCT02831049|BEHAVIORAL|Retrieval|Retrieval
40967642|NCT06312605|PROCEDURE|Injectable applied vitamin C|Surgical gingival depigmentation is done for all participants, after then they receive injectable vitamin C
40967643|NCT06312605|PROCEDURE|Topical applied Vitamin C|Surgical gingival depigmentation is done for all participants, after then they are instructed to apply topical vitamin C
40967644|NCT06312605|PROCEDURE|Surgical depigmentation only|Surgical gingival depigmentation only without any drug
40967645|NCT02658929|BIOLOGICAL|bb2121|bb2121
40967646|NCT04335461|PROCEDURE|Cephalomedullary nailing of extracapsular hip fracture|All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.
40967647|NCT04335461|DEVICE|cephalomedullary nail|Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.
40967648|NCT04335461|DRUG|Regional Anesthetics|Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.
40967649|NCT05742100|DRUG|Darvadstrocel|expanded allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas
40967650|NCT06158126|DRUG|Initiating daily oral PrEP during pregnancy|Group 1a, will include pregnant women who initiate oral PrEP at enrollment into the study.
40967651|NCT06158126|DRUG|Already using daily oral PrEP at the time of pregnancy diagnosis|Group 1b will include women already using daily oral PrEP at the time of pregnancy diagnosis and enrollment in the study.
40967652|NCT06158126|DRUG|Initiating injectable PrEP during pregnancy|Group 2a will include pregnant women who initiate injectable PrEP (CAB-LA) at enrollment into the study.
40967653|NCT06158126|DRUG|Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis|Group 2b will include women using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis.
40967654|NCT04734015|BEHAVIORAL|Together Overcoming Diabetes (TOD)|Curriculum approaches health through a holistic lens of spiritual, mental, physical and emotional wellness. American Indian Family Health Coaches conduct motivational interviewing to help participant dyads (adult caregivers with Type 2 diabetes and their youth) set attainable goals and work through obstacles to reach those goals.
40967655|NCT05930977|PROCEDURE|total thyroidectomy followed by thyroid auto transplantation|"All studied cases received general endotracheal anaesthesia, and all underwent total thyroidectomy.~Frozen section will be done intraoperative to exclude malignancy and obtain piece of healthy tissue part .~Most healthy-looking part of gland was selected after complete excision. Thyroid tissue to be transplanted weighed between two and five grammes. This section was finely split into ten-fifteen fragments with scalpel. Small pocket was created in sternomastoid muscle, into which these minor fragments were implanted, and this pocket was closed with absorbable sutures to prevent displacement of implanted fragments and was marked with metallic stables, as well as good hemostasis of thyroid bed and skin was closed with subcuticular sutures using absorbable three-zero Vicryl sutures."
40967656|NCT05979701|OTHER|Simulation training|The intervention will consist of training participants through simulation in addition to theoretical training. The simulation will cover 3 themes, including diagnosis of haemorrhage, communication between healthcare providers, management of post-partum haemorrhage and transfusion monitoring.
40967657|NCT04962204|BEHAVIORAL|Virtual meeting between patients/physicians and caregiver|Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
40967658|NCT01798511|PROCEDURE|Nasogastric Tube Feeding|A nasogastric tube will be placed into the stomach of patients.
40967659|NCT01798511|OTHER|Conventional Nutritonal Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
40967660|NCT05009615|DIETARY_SUPPLEMENT|Green coffee extract|150 mg polyphenols from green coffee, twice daily
40967661|NCT05009615|DIETARY_SUPPLEMENT|Beta glucan|2.5 g BG twice daily
40967662|NCT05009615|DIETARY_SUPPLEMENT|Green coffee + beta-glucan|150 mg polyphenols from green coffee + 2.5 g BG, twice daily
40967663|NCT02704117|DEVICE|Transcranial Magentic Stimulation|This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
41138102|NCT06332326|DEVICE|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation: patients will receive non-invasive vagus nerve stimulation.
40967664|NCT01622504|DRUG|MVP005|2 mg single dose administered intranasally
41138103|NCT06332326|BEHAVIORAL|vestibular rehabilitation|vestibular rehabilitation: Patients will be given specially structured vestibular rehabilitation exercises.
41295931|NCT00011193|BEHAVIORAL|Exercise|Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
41295932|NCT04927988|OTHER|Ringer's Lactated|Using of Ringer's Lactated In Autologous Blood Cell Transfusion
41295933|NCT03827148|OTHER|Pharmaceutical Care|Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
41295934|NCT00897520|BIOLOGICAL|recombinant interferon alfa|
40967665|NCT01622504|DRUG|MVP005|4 mg single dose administered intranasally
40967666|NCT01622504|DRUG|Naloxone hydrochloride solution for injection with mucosal atomization device|2 mg single dose administered intranasally
40967667|NCT05199662|DRUG|Intravenous tenecteplase|Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).
40967668|NCT05199662|DRUG|Placebo|Placebo matching IV TNK
40967669|NCT00607009|BEHAVIORAL|ALIVE|ALIVE email-based behavioral program based on the participants selected intervention - physical activity, fats/sugars or fruits/vegetabls
41295935|NCT00897520|GENETIC|proteomic profiling|
41295936|NCT00897520|OTHER|immunoenzyme technique|
41295937|NCT00897520|OTHER|laboratory biomarker analysis|
41295938|NCT04260022|DRUG|Ascentage Pharma HQP1351 bioavailable inhibitor|HQP1351 taken by mouth every other day
41295939|NCT04260022|DRUG|Blinatumomab|Administered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7).
40967670|NCT03033394|DRUG|Beta-lactam antibiotic|Routine clinical dosing
40967671|NCT03346915|BEHAVIORAL|WoW and BNI|The Text/web based health information technology system, WoW, will provide educational resources for participants and their families to learn more about HPV vaccination and cervical cancer screening. WoW will be tailored to the participant and will be based on the participant's cancer screening and HPV vaccine health needs; It will then send custom text messages based their concerns and will remind them to schedule and attend their doctor's appointment. The brief negotiated interview will encourage and empower participants to have positive behavioral changes in regards to their health.
41295940|NCT02771808|OTHER|biomarker samples|biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)
40768326|NCT05488795|BEHAVIORAL|Team-Based Home Blood Pressure Monitoring|Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention
40967672|NCT06120998|PROCEDURE|Arthroscopic rotator cuff repair|All patients were placed in a semi-sitting position. Initially, a posterior portal was established to explore the inside of the joint, a lateral portal was created for the removal of subacromial bursa, and an additional anterior portal was created for repairing the tendons. Measurements were taken to determine the extent of rotator cuff damage, including its anterior-posterior and medial-lateral dimensions. In cases where complete repair was possible, a single-row or double-row repair technique was used depending on the degree of tendon damage. For situations where complete repair was not feasible, partial repair was performed. If the tendon could be stretched after relaxation, it was repaired to an anatomical position near the bone bed with the assistance of acellular dermal reinforcement. However, if the tendon lacked elasticity and was fully retracted upon relaxation, acellular dermis was used to bridge the tendon back to the anatomical position.
40967673|NCT03478020|DRUG|AQX-1125|Investigational Drug
40967674|NCT03478020|DRUG|Combined Oral Contraceptive|COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
40967675|NCT05346471|DEVICE|Multimodal neuromonitoring|Multimodal neuromonitoring accounts for intraparenchymatous ICP probe, brain tissue oxygen probe and/or cerebral microdialysis device
40768327|NCT04518748|DRUG|Yttrium-90|Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)
40967676|NCT02516345|DEVICE|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
40768328|NCT04518748|DEVICE|Selective Internal Radiation Therapy|SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres
40768329|NCT04518748|RADIATION|Stereotactic Body Radiation Therapy|3-5 fractions over 1-2 weeks, after Y-90 SIRT
40967677|NCT02516345|BEHAVIORAL|Incentives|Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
40967678|NCT05251090|DRUG|ADVATE|50 international units (IU)/kg, a single dose.
40967679|NCT05251090|DRUG|FRSW107|50 IU/kg, a single dose.
40967680|NCT02531906|DRUG|Gabapentin|Given PO
40967681|NCT02531906|DRUG|Methadone Hydrochloride|Given PO
40967682|NCT02531906|DRUG|Oxycodone Hydrochloride|Given PO
40967683|NCT02531906|OTHER|Quality-of-Life Assessment|Ancillary studies
40967684|NCT02531906|OTHER|Questionnaire Administration|Ancillary studies
40967685|NCT00500669|DRUG|Betadine|Topically
40967686|NCT05081154|OTHER|Product A|P1012915, a nicotine pouch with 8 mg nicotine
40967687|NCT05081154|OTHER|Product B|P1013018, a nicotine pouch with 10 mg nicotine
41295941|NCT04375631|DRUG|Cladribine|Given IV
40967688|NCT05081154|OTHER|Product C|P1013015, a nicotine pouch with 8 mg nicotine
40967689|NCT05081154|OTHER|Product D|P1012815, a nicotine pouch with 8 mg nicotine
40967690|NCT05081154|OTHER|Product E|P1013315, a nicotine pouch with 8 mg nicotine
40768330|NCT04518748|DIAGNOSTIC_TEST|PET/CT|Within 3 hours of completing Y-90 SIRT
40768331|NCT04518748|DEVICE|Therasphere|Glass microspheres containing Y-90, administered at day 0 by SIRT
40768332|NCT06424288|DRUG|BI 690517|BI 690517
40768333|NCT06424288|DRUG|Empagliflozin|Empagliflozin
40768334|NCT06424288|DRUG|Placebo|Placebo matching BI 690517
40768335|NCT06636006|BEHAVIORAL|Aerobic Exercise|50 continuous minutes, at moderate intensity (Identified by the Borg Subjective Perception of Exertion Scale, scores from 12 to 13)
40768336|NCT06636006|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I includes some therapies, including sleep restriction therapy, stimulus control therapy, sleep hygiene education, relaxation and cognitive therapy\[19\]. Traditionally, CBT-I is applied in person (individually or in a group) by a trained psychologist or psychiatrist. However, several studies show similar effects when CBT-I is performed remotely, and online (digital)
40967691|NCT05081154|OTHER|Product F|P1013115, a nicotine pouch with 8 mg nicotine
40967692|NCT05081154|OTHER|Product G|P1013215, a nicotine pouch with 8 mg nicotine
40967693|NCT04147130|OTHER|MultiPAP Plus|Complex intervention incorporating previous MultiPAP intervention (based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient-centered clinical interview) And it adds a clinical-decision support system to help structured treatment-plan review.
40967694|NCT04147130|OTHER|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
40967695|NCT03778762|PROCEDURE|Blind tracheal intubation through AirQ|underwent blind intubation with correction manoeuvres
40967696|NCT03778762|PROCEDURE|Fiberscopic tracheal intubation through AirQ|: underwent fibreoptic guided intubation
40967697|NCT00768157|DRUG|antiviral treatment (lamivudine or entecavir)|antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
41295942|NCT04375631|DRUG|Cyclophosphamide|Given IV
41295943|NCT04375631|DRUG|Cyclosporine|Given IV then PO
41295944|NCT04375631|DRUG|Cytarabine|Given IV
41295945|NCT04375631|BIOLOGICAL|Filgrastim|Given SC
41295946|NCT04375631|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
41295947|NCT04375631|DRUG|Mitoxantrone|Given IV
40967698|NCT00768157|PROCEDURE|radical resection of HBV-related HCC|Procedure/Surgery - radical resection of HBV-related HCC
40967699|NCT05184218|DRUG|IGM-6268|Active Comparator
40967700|NCT05184218|DRUG|Placebo|Placebo Comparator
40967701|NCT01959074|DRUG|Naftopidil|Naftopidil 75mg 1T qd hs
40967702|NCT01959074|DRUG|Placebo for Naftopidil|Placebo 1T qd hs
40967703|NCT01959074|DRUG|Standard treatment|aceclofenac 100mg on demand
40967704|NCT05806645|OTHER|Risk-guided transition of care intervention delivered through an integrated digital health strategy|The proposed experimental intervention will incorporate our risk prediction model which will be used to guide the hospital to home transition of care for medium and high-risk groups of patients. Patients will receive transition of care plans that are tailored to their risk and embedded within standardized discharge pathways within the electronic health record
40967705|NCT03205332|BEHAVIORAL|Concreteness Training|
40967706|NCT04053114|OTHER|DNA and RNA extraction from FFPE or frozen tissue sample|Next generation sequencing (NGS)
40967707|NCT02495168|DRUG|Generic Budesonide/Formoterol Fumarate Dihydrate|Oral inhalation, generic formulation of the brand-name product.
40967708|NCT02495168|DRUG|Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)|Oral inhalation, brand-name product.
40967709|NCT02495168|DRUG|Placebo|Oral inhalation, no active ingredient.
40967710|NCT00394147|DRUG|pemetrexed|pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
40967711|NCT00394147|DRUG|gemcitabine|gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
40967712|NCT06507813|DRUG|ADC189 tablets|Patients weigh between 20 to 80 kilograms, given 45 mg ADC189 tablets once; patients weigh over 80 kilograms, given 90 mg ADC189 tablets once.
40967713|NCT06507813|DRUG|Baloxavir Marboxil tablets|Patients weigh between 20 to 80 kilograms, given 40 mg Baloxavir marboxil tablets once. Patients weigh over 80 kilograms, given 80 mg Baloxavir marboxil tablets once.
40967714|NCT06507813|DRUG|Placebo of ADC189 tablets|Patients weigh between 20 to 80 kilograms, given 1 tablet of placebo once; patients weigh over 80 kilograms, given 2 tablets of placebo once.
40967715|NCT06507813|DRUG|Placebo of Baloxavir Marboxil tablets|Patients weigh between 20 to 80 kilograms, given 2 tablets of placebo once; patients weigh over 80 kilograms, given 4 tablets of placebo once.
40967716|NCT06507813|DRUG|ADC189 granules|"For patient 5-11 years old, patients weigh between 20 to 80 kilograms, given 45 mg ADC189 granules once; patients weigh over 80 kilograms, given 90 mg ADC189 granules once.~For patient 2-4 years old, patients \<10kg, given 15mg ADC189 granules once. 10kg \~ \<15kg, given 25mg ADC189 granules once. 15kg \~\<20 kg, given 35mg ADC189 granules once. 20kg \~ \<80kg, given 45mg ADC189 granules once."
40967717|NCT06507813|DRUG|Placebo of ADC189 granules|Placebo. Given once only.
41138104|NCT01632085|DEVICE|The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.|"Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.~Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R."
40967718|NCT06507813|DRUG|Placebo of Oseltamivir granules|For patients 2-4 years old. Placebo. Given 10 times (5 days, BID).
40967719|NCT06507813|DRUG|Oseltamivir granules|For patients 2-4 years old. Patients \<15kg, given 30mg×10 times (5 days, BID) Oseltamivir granules. 15kg \~ \<23kg, given 45mg×10 times (5 days, BID) Oseltamivir granules. 23kg \~ \<40kg, given 60mg×10 times (5 days, BID) Oseltamivir granules. ≥40kg, given 75mg×10 times (5 days, BID) Oseltamivir granules.
41138105|NCT01061580|DEVICE|Harvest SmartPReP2 BMAC System|Injection of 10, 15, or 20 cc of BMAC
41138106|NCT01349998|DRUG|Product 33525|Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
40967720|NCT05805904|DRUG|BMS-986278|Specified dose on specified days.
40967721|NCT05805904|DRUG|Placebo|Specified dose on specified days
40967722|NCT01455259|BIOLOGICAL|AdCD40L|Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
40967723|NCT01050712|DRUG|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
40967724|NCT01050712|DRUG|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
40967725|NCT02007694|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
40967726|NCT01572558|PROCEDURE|Appendectomy|Standard surgical treatment, normally laparoscopic appendectomy
40967727|NCT01572558|DRUG|Conservative, non-surgical treatment|Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
41138107|NCT03410420|DRUG|Pimonidazole hydrochloride|administration of pimonidazole-HCl
41138108|NCT05925335|DEVICE|Transseptal Transcatheter Mitral valve-in-valve Replacement|Transcatheter transfemoral mitral valve-in-valve replacement is an alternative surgery in patients with severe dysfunction of a degenerated mitral bioprosthesis and high surgical risk for repeat operation. The procedure is performed via femoral vein access. All procedures were carried out using intra-procedural TEE guidance to aid in transseptal puncture. After balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle and expanded in the mitral position during rapid ventricle pacing.
41138109|NCT03055598|DRUG|Ferric Citrate|Doses can be adjusted as needed by 1 to 2 tablets up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
41138110|NCT01327014|DRUG|XueZhiKang (XZK), a botanic product with multiple components|4 capsules of study drug twice a day for 12 weeks.
41138111|NCT01327014|DRUG|Placebo|4 capsules twice a day for 12 weeks.
41138112|NCT00201825|DRUG|Capecitabine|1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
41295948|NCT04375631|DRUG|Mycophenolate Mofetil|Given IV or PO
40967728|NCT06071130|BEHAVIORAL|Fit and Strong|Procedure: During Years 3-5, participants will be recruited in waves through our standard recruitment practices to participate in Experiments 4A at the City of Chicago park sites. We will first prescreen them via telephone to verify that potential participants meet the inclusion criteria. F\&S! classes will be offered at two pre-determined Chicago park sites. Each of the two sites will host the 8-week-long program once in the spring and once in the fall for two years for a total of four F\&S! cycles at each center (totaling 8 F\&S! cohorts). Upon consenting to be in E4A, participants will be enrolled in F\&S! at the site closest to their home or the wait-list control. In the pre-intervention phase, participants both in F\&S! and on the waitlist will come to the lab at DePaul to complete the pre-intervention measurement batter. Within one week after baseline measurements, participants will attend F\&S! for 3 sessions a week for 8 weeks.
40967729|NCT00653575|BEHAVIORAL|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
40967730|NCT00653575|BEHAVIORAL|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
41138113|NCT00201825|DRUG|Docetaxel|36 mg/m2 IV weekly for 3 weeks every 4 weeks.
41138114|NCT03733951|DRUG|KN046|"Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia."
41138115|NCT05334433|PROCEDURE|Local anesthesia injection|Local anesthesia administration
41457688|NCT04947150|BEHAVIORAL|Reflections on benefits of change|Participants will reflect on anticipated benefits of purchasing healthy foods, consistent with motivational interviewing and self-determination theory. Message content will be personalized as follows: During the initial workshop, all participants will complete an exercise identifying benefits of healthy eating that are important to them. Message content will then be programmed to be personalized according to anticipated rewards important to that participant. Participants assigned to have this intervention component OFF will not have content about anticipated benefits of change added to any messages.
41138116|NCT03279367|DIAGNOSTIC_TEST|Objective speech response detection|Changes in brain activity when a speech stimulus is presented will be measured using electro-encephalography (EEG)
41138117|NCT05351788|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
40768342|NCT05322850|BIOLOGICAL|Orca-Q|All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
41138118|NCT05351788|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
41138119|NCT05351788|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
41138120|NCT05351788|DRUG|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
41138121|NCT05729126|OTHER|Questionnare|A questionnaire form is emailed to radiologists to get their response of their practice with hemodialysis and chronic kidney disease patients
41138122|NCT03542747|DEVICE|Time to ventilation with the iLTS|Time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
41138123|NCT03542747|DEVICE|Time to ventilation with the Fastrach|Time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
41138124|NCT06401590|DIAGNOSTIC_TEST|FROZEN SENTINEL LYMPH NODE BIOPSY|FROZEN SENTINEL LYMPH NODE BIOPSY
41295949|NCT04375631|DRUG|Mycophenolate Sodium|Given PO
41295950|NCT04375631|RADIATION|Total-Body Irradiation|Undergo TBI
41295951|NCT04375631|DRUG|Idarubicin|Given IV
41295952|NCT04375631|DRUG|Fludarabine|Given IV
41295953|NCT04375631|DRUG|Cytarabine|Given IV
41295954|NCT04375631|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41295955|NCT04375631|PROCEDURE|Echocardiography|Undergo ECHO
41295956|NCT04375631|PROCEDURE|X-Ray Imaging|Undergo x-ray
41295957|NCT04375631|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
41295958|NCT04375631|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
41295959|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
41295960|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
40768343|NCT05094609|BIOLOGICAL|Ad5-triCoV/Mac|Ad5-triCoV/Mac is a recombinant type 5 human adenovirus vector which has been engineered to express our trivalent SARS-CoV-2 transgene cassette under the control of an MCMV promoter, and is followed by an SV40 polyA signal. The adenovirus construct is E1 and E3 deleted.This trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
40768344|NCT05094609|BIOLOGICAL|ChAd-triCoV/Mac|ChAd-triCoV/Mac is an E1 and E3 deleted chimpanzee adenovirus serotype 68 where the trivalent SARS-CoV-2 transgene cassette is under the control of an HCMV promoter and is followed by an SV40 polyA signal. The trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
41295961|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
41295962|NCT05163561|BIOLOGICAL|Sii Licensed IPV|Poliomyelitis Vaccine (Inactivated), produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Poliomyelitis Vaccine (Inactivated) is a highly purified, inactivated poliovirus vaccine.
40967731|NCT02376361|DEVICE|Transonic|"Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).~1. Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines~2. Recirculation, access flow will be performed according to HD03 Manual.~3. Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist."
41457689|NCT04947150|BEHAVIORAL|Coach monitoring|Coaches will monitor participant food purchases via a dashboard for viewing purchase data, and send messages designed to provide feedback and enhance supportive accountability for program goals. The messages will provide reinforcement for purchases consistent with program goals and express concern for areas in which adherence is low. Participants assigned to have this component OFF will not receive these extra messages or phone calls, and their food purchases will only be viewed by research staff for research outcome assessment purposes.
40967732|NCT03513328|DRUG|Thiotepa--single daily dose|Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
40768345|NCT05051228|DEVICE|CardioFlux|Magnetocardiography (MCG) is a noninvasive method that measure the magnetic field that arises from the electrical activity of the heart cycle.
40768346|NCT06144684|DRUG|GUB014295|GUB014295 is a long-acting amylin analogue in development, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
40768347|NCT06144684|DRUG|GUB014295-PLACEBO|GUB014295-PLACEBO is matching GUB014295 in appearance, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
40768348|NCT04822883|DRUG|RL-007|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
40967733|NCT03513328|DRUG|Thiotepa--escalated dose|Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
40967734|NCT05115903|DRUG|Tapered doses of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing dose intervals as specified
40768349|NCT04822883|DRUG|RL-007 Matching Placebo|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
40768350|NCT06247683|DEVICE|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
40768351|NCT02337556|OTHER|Peptamen Bariatric|Commercially available enteral diet
40768352|NCT02337556|OTHER|Replete|Commercially available enteral diet
40768353|NCT05845749|DRUG|Vosoritide Injection [Voxzogo]|Vosoritide will be given via a once daily subcutaneous injection at a dose of 15 ug/kg/day, at approximately the same time each day when feasible. Vosoritide will be supplied to the subject as 0.4 mg vial, 0.56 mg vial or 1.2 mg vials to be reconstituted with sterile water up to 0.8 mg/mL or 2 mg/mL concentrations for injection. The volume to be administered (injection volume) will be based on the subject's body weight and the concentration of vosoritide. All supplies will be provided to the subject for home based administration after training at the study site.
40768354|NCT06606847|DRUG|Oleclumab|Oleclumab IV (intravenous infusion)
40768355|NCT06606847|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
40967735|NCT05115903|DRUG|Standard dose of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab)
40967736|NCT00216632|DRUG|risperidone|
40967737|NCT05012488|OTHER|Comparison of gait and foot pressure|The spatio temporal gait parameters of the patients will be evaluated with Zebris (Zebris Medical Limited , Germany) FDM (Force Distribution Measurement ) treadmill system. The system has production of 3D motion analysis and force measurement technologies for biomechanics. When the treadmill is in static and dynamic condition, strong pressure distribution measurement will be taken.
40967738|NCT02272595|OTHER|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
40967739|NCT02272595|OTHER|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
41295963|NCT01868373|BIOLOGICAL|Microbiota Transplantation (FMT)|Active therapy
41295964|NCT05914311|DEVICE|Suture|secures SCS trial leads with a suture
40768356|NCT05600751|PROCEDURE|Radiosurgery of ganglion stellatum|Patients will undergo radiosurgery of ganglion stellatum (left one or both)
40967740|NCT01162512|BEHAVIORAL|physical activity|physical activity counseling sessions will occur by telephone weekly for 2 months
40967741|NCT05010421|DRUG|Clobetasol 0.05% Emollient Top Cream|Topical corticosteroid treatment of affected vulvar skin areas.
40967742|NCT05010421|DEVICE|Non-ablative CO2 Laser|Superficial non-ablative laser treatment of affected vulvar skin areas.
40967743|NCT00960778|DRUG|nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
40967744|NCT00960778|OTHER|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
40967745|NCT06141187|PROCEDURE|Vertebroplasty|PVP
40967746|NCT06141187|PROCEDURE|Sham Vertebroplasty|Sham PVP
40967747|NCT06341868|DEVICE|KneeStim|Participant will be randomized to either be in control or experimental group
40967748|NCT02098967|DRUG|RO6839921|Non-escalating IV doses given on Days 1-5 of Cycle 1.
40967749|NCT02098967|DRUG|RO6839921|Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
40967750|NCT02098967|DRUG|RO6839921|Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose \</= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
40768357|NCT05087342|DRUG|Semaglutide 2.4mg|The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
40768358|NCT05087342|DRUG|Placebo|A placebo will be given to the control group per the schedule outlined in the armed description.
40768359|NCT05918354|DEVICE|Skin Prick Automated Test|Detection of sensitisation to specific allergens via the skin prick automated test.
40768360|NCT06201234|DRUG|Olaparib + Elacestrant|Olaparib 600 mg orally daily and elacestrant 400 mg orally daily
40967751|NCT04051008|BEHAVIORAL|Online - use of online grocery shopping platform|The Online intervention will utilize online grocery shopping (shopping at a local grocery store via online platform).
40967752|NCT04051008|BEHAVIORAL|Default - use of online grocery shopping platform with default shopping carts|The Defaults intervention, will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make the recipes from provided recipe cards, and that they may modify their cart as they like.
41295965|NCT05914311|DEVICE|Dermabond|secures SCS trial leads with dermabond
40768361|NCT06201234|DRUG|Olaparib|Olaparib 600 mg orally daily
40768362|NCT04388475|DRUG|OKN-007|Drug: OKN-007 (400 mg OKN-007/mL in a phosphate buffer) Administered via IV infusion, at a dose level of 60 mg/kg, given three times a week for 12 weeks, two times a week for a further 12 weeks and once per week until disease progression or up to two years.
40768363|NCT04388475|DRUG|Temozolomide (TMZ)|Administered via oral, at a dose level of 150 mg/m2, once daily on Days 1-5 of each 28 day cycle in Cycle 1. If this dose level is tolerated, then in Cycle 2 (and subsequent cycles), at a dose level of 200 mg/m2, once daily on Days 1-5 of each 28 day cycle.
40768364|NCT06563102|COMBINATION_PRODUCT|Albuterol/Budesonide|Oral Inhalation. Rescue medication. Unit dose strength of 80 μg budesonide and 90 μg albuterol per actuation
40768365|NCT06563102|COMBINATION_PRODUCT|Albuterol|Oral Inhalation. Rescue medication. Unit dose strength of 90μg albuterol per actuation.
40768366|NCT06107699|OTHER|Patient Navigation|Assigned a Patient Navigator to provide information on transitional care and community resources.
40967753|NCT05089942|DRUG|Recombinant Human Insulin Patch ZJSRM2021|health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）
40967754|NCT05089942|DRUG|Placebo|health subjects receive placebo patch
40967755|NCT01634724|DRUG|a drug withdrawal during the long protocol|GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
40967756|NCT04945005|PROCEDURE|Transesophageal guidance of lead implantation|In patients undergoing lead implantation including transesophageal echocardiography for clinical reasons (e.g. intraprocedural cardioversion), echocardiography was also used for guidance of lead implantation to reduce lead-leaflet interactions
40967757|NCT00258401|DIETARY_SUPPLEMENT|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
40967758|NCT00258401|PROCEDURE|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
40967759|NCT00258401|PROCEDURE|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
40967760|NCT02254486|DRUG|NER1006|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
41295966|NCT04142476|OTHER|interview|interviews with patient's pharmacist to motivate in the hormonotherapy's compliance.
41295967|NCT01856634|DRUG|100 mg Delamanid|100 mg Delamanid BID for 10 days
41295968|NCT01856634|DRUG|50 mg Delamanid|50 mg Delamanid BID for 10 days
41295969|NCT01856634|DRUG|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 10 days
40967761|NCT02254486|DRUG|Trisulfate solution|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
41295970|NCT01856634|DRUG|10 mg Delamanid Pediatric Formulation|Patients \> 10 kg will receive DPF 10 mg BID for 10 days
41295971|NCT01856634|DRUG|5 mg Delamanid Pediatric Formulation|"Patients \> 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days~Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days"
41295972|NCT01856634|DRUG|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
41295973|NCT05791825|BEHAVIORAL|Cultivating Healthy Intentional Mindful Educators|The 8-week, manualized, CHIME intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Each CHIME session focuses on a specific mindfulness technique, such as mindful breathing, mindful listening and bringing attention to current states and surroundings to support optimal responsiveness, emotion regulation, and compassion. Social emotional learning is promoted by focusing on five broad competencies: self-awareness, social awareness, responsible decision-making, self-management, and relationship skills and these competencies are practiced and developed through small group discussions, storytelling, journal reflections, modeling, and guided awareness (e.g., meditations), and implementation activities (e.g., gratitude necklace).
40967762|NCT00257478|DRUG|YM155|
41295974|NCT02188121|DRUG|Simvastatin|3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
41295975|NCT02188121|DRUG|Losartan|Angiotensin II receptor antagonist
41295976|NCT04695730|OTHER|Active physical therapy (including both pain education and home exercises)|"One session (60 minutes). In this session, a physical therapist will explain and demonstrate the exercises to perform individually at home. Exercises will be performed daily. In addition, an education session will be provided, concerning pain mechanisms and management. To support patients during the treatment, a booklet will be created.~One booster session (30minutes) will be planned after 4 weeks. Patients will follow the active treatment for 8 weeks."
40967763|NCT03955744|OTHER|3D translabial ultrasound|All patients will undergo 3D translabial ultrasound with vaginal manometry
41295977|NCT04695730|OTHER|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
41295978|NCT03196297|DRUG|Concizumab|0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
41295979|NCT03196297|DRUG|Turoctocog alfa|Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
41295980|NCT04554030|BEHAVIORAL|Evaluate sperm count before and after immunotherapy|Evaluate sperm count before and after immunotherapy
41295981|NCT02956174|DEVICE|Co-Cr single crown|
41295982|NCT02956174|OTHER|Periodontal parameters|
41295983|NCT05463679|DRUG|Enzastaurin|500 mg QD orally in the form of four 125 mg tablets with background standard of care
40967764|NCT03444961|DEVICE|CAREN system training|CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
41295984|NCT05463679|DRUG|Placebo|Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
41295985|NCT01581112|BIOLOGICAL|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
41295986|NCT03658330|DRUG|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
40967765|NCT02364739|OTHER|Written information|Brochure
40967766|NCT02364739|OTHER|Written and oral information|Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
40967767|NCT00317356|DRUG|OPC-6535(Tetomilast)|
40967768|NCT01511198|DRUG|liraglutide|Injected subcutaneously once daily
40967769|NCT01511198|DRUG|metformin|1000 mg twice daily, administered orally
40967770|NCT03009578|DRUG|Iron Sucrose Injection|iron Intramuscular injections
40967771|NCT03009578|DRUG|Ferrous Bisglycinate|oral iron tablets
40967772|NCT02967835|BEHAVIORAL|Tele-psychiatry consult|tele-psychiatry consult for evaluation and treatment recommendations
40967773|NCT00456560|DRUG|AV650|
40967774|NCT00456560|DRUG|Fluvoxamine|
40967775|NCT00456560|DRUG|Paroxetine|
41295987|NCT02333240|OTHER|Self-management of postnatal anti-hypertensive treatment|Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
41295988|NCT00075751|DRUG|gemcitabine hydrochloride|Given IV
41295989|NCT00075751|DRUG|carboplatin|Given IV
41295990|NCT00075751|DRUG|bortezomib|Given IV
41295991|NCT03280732|DEVICE|Lung Ultrasound|A Mindray-DC-T6 ultrasound machine equipped with a linear probe with frequencies ranging from 7.5 to 12 MHz will be use. LUS examination will consist of both longitudinal and transversal sections according to the methodology described by Copetti and colleagues.
41295992|NCT00382889|DRUG|beclomethasone/salbutamol combination|
40967776|NCT01182987|BEHAVIORAL|Dementia Care Management|"The SCAN Memory Program is a care management program for cognitively-impaired SCAN members and for their informal/family caregivers. The program includes collaboration between SCAN Health Plan, partnering medical groups, and community organizations.~Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution."
40967777|NCT00736684|DEVICE|Proximal Femoral Nail AntirotationTM (PFNA)|intramedullary nailing
40967778|NCT00736684|DEVICE|Gamma Nail 3TM (Gamma3)|intramedullary nailing
40967779|NCT01830478|DRUG|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
40967780|NCT01830478|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
40967781|NCT01397084|DRUG|esomeprazole 20 mg|esomeprazole 20 mg once daily for 8 weeks
40967782|NCT04952493|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
40967783|NCT04952493|DRUG|Sodium Iodide I 131|RAI treatment may shrink the tumor
40967784|NCT04952493|DRUG|Penpulimab|Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
40967785|NCT02289339|DEVICE|aortic valve prostheses|balloon-expandable and self-expandable aortic valve prostheses
40967786|NCT05338593|OTHER|Outcome|Mortality rate of prolonged therapy.
40967787|NCT05000463|DRUG|Ozone|The participants will lay flat and the area of injection will be prepared with antiseptic. Maintenance of ultrasonography probe sterility was also guaranteed using a sterile barrier. Under sonographic guidance, superficial peroneal nerve, deep peroneal, sural , asphenous, and tibila nerves will be injected An ozone/oxygen mixture ( 25μg/ml) will be injected in each nerev
40967788|NCT05000463|DRUG|Convtrol group|The medical treatment included optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin.
40967789|NCT02256189|DRUG|Sitagliptin|Sitagliptin 100 mg daily
40967790|NCT02256189|DRUG|Placebo|Placebo one tablet daily
40967791|NCT03732157|PROCEDURE|outpatient management of parathyroidectomy|The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)
40967792|NCT03732157|PROCEDURE|conventional management of parathyroidectomy|The patient stays overnight in hospital after intervention
40967793|NCT05965154|DRUG|Carrilizumab, bevacizumab,capecitabine|"1. Carrilizumab: 200mg/ cycle, three weeks as a treatment cycle, the first day of each cycle, intravenous drip;~2. Bevacizumab: 7.5mg/kg, intravenous infusion on the first day of each cycle, every 3 weeks for 1 cycle (Q3W);~3. Capecitabine: 1250mg/m2, three weeks as a treatment cycle, oral twice a day (once in the morning and once in the evening; Stop the drug for 1 week after 2 weeks of treatment."
40967794|NCT05975944|DRUG|Selinexor，Olaparib|Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID.
40967795|NCT00378820|BEHAVIORAL|Whey without milk minerals|
40967796|NCT00378820|BEHAVIORAL|Whey with milk minerals|
40967797|NCT00378820|BEHAVIORAL|Casein without milk minerals|
40967798|NCT00378820|BEHAVIORAL|Casein with milk minerals|
40967799|NCT01101984|DRUG|diquafosol ophthalmic solution|DE-089 topical ocular application, 6 times daily for 4 weeks.
40967800|NCT01101984|DRUG|0.1% sodium hyaluronate ophthalmic solution.|0.1% HA topical ocular application, 6 times daily for 4 weeks.
40967801|NCT02080234|DRUG|GELOX|gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
40967802|NCT02080234|RADIATION|IFRT|IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
40967803|NCT05658146|DRUG|Mavacamten Capsule 1|Specified dose on specified days
40967804|NCT05658146|DRUG|Mavacamten Capsule 2|Specified dose on specified days
40967805|NCT05658146|DRUG|Mavacamten Capsule 3|Specified dose on specified days
40967806|NCT03585257|BIOLOGICAL|25% IV albumin|"Intravenous 25% albumin infusion 1.0 g/kg body weight (maximum 100gm) once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
41295993|NCT00382889|DRUG|beclomethasone|
40967807|NCT03585257|OTHER|Placebo|"Normal saline infusion 1.0g/kg body weight once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
40967808|NCT01175252|OTHER|Database analysis|Review and collect data from database
40967809|NCT06498011|OTHER|Home Graded Repetitive Arm Supplementary Program (GRASP)|The home-based exercise programme will be based on the Home Graded Repetitive Arm Supplementary Program focusing on stretching, arm strengthening, hand strengthening, coordination and hand skills. The Home Graded Repetitive Arm Supplementary Program will be delivered 2 hours/session, 3 times/week, for 6 weeks.
41295994|NCT00382889|DRUG|salbutamol|
41295995|NCT02440178|DRUG|Micafungin|
41295996|NCT06108323|BEHAVIORAL|Theapeutic exercise plus action observation training|Participants make an observation of actions related to the training they are going to perform. Subsequently, they perform the therapeutic exercise session.
41295997|NCT06108323|BEHAVIORAL|Therapeutic exercise plus sham observation training|Participants make a sham observation. Subsequently, they perform the therapeutic exercise session.
41295998|NCT00199264|DRUG|Albaconazole oral solution|
40768367|NCT01790191|BEHAVIORAL|Repeated consumption of basic artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
40768368|NCT01790191|BEHAVIORAL|Repeated consumption of sweet artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
40967810|NCT06498011|OTHER|integrated Somatosensory-MOtor training using a COgnitive approach(iCOSMO)|The first training approach of iCOSMO will focus on integrated somatosensory-motor variables during reaching and object manipulation (60 minutes). The second training approach will focus on proprioceptive, motor and cognitive tasks using the Kinarm robotic exoskeleton (60 minutes). iCOSMO will be delivered 3 times per week (2 hours per session) for 6 weeks (Total: 36 hours of treatment).
40967811|NCT02027896|OTHER|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
40967812|NCT00664872|OTHER|proactive psychosocial intervention by care managers|A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
40967813|NCT00664872|BEHAVIORAL|case management|
40967814|NCT02466178|DEVICE|Serene RF System|The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
40967815|NCT02568800|DRUG|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
40967816|NCT02568800|DRUG|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
40967817|NCT01056653|BEHAVIORAL|Standard Dose|Two intevention home visits
40967818|NCT01056653|BEHAVIORAL|High Dose|Four intervention home visits
40967819|NCT01056653|BEHAVIORAL|Comparison Group|One home visit, information only
40967820|NCT02085317|DRUG|acetylcholine Iontophoresis|Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
40967821|NCT02085317|DRUG|sodium nitroprusside Iontophoresis|After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
40967822|NCT00897104|DRUG|rizatriptan benzoate (MK0462)|single dose 5 mg rizatriptan p.o.
40967823|NCT00897104|DRUG|Comparator: sumatriptan|single dose 50 mg sumatriptan p.o.
40967824|NCT00897104|DRUG|Comparator: Placebo|Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
40967825|NCT04294576|DRUG|BJ-001|BJ-001 dosed via SC injection as single agent. One cycle is 6 weeks.
40967826|NCT04294576|DRUG|Pembrolizumab|"BJ-001 dosed via SC injection in combination with Pembrolizumab~One cycle is 6 weeks."
40967827|NCT03218904|DIETARY_SUPPLEMENT|Glucose intake|Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose
40967828|NCT03218904|DIETARY_SUPPLEMENT|Carbohydrates intake|Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2- single oral dose of Glycosade®
40967829|NCT04195087|DEVICE|Masimo Radical-7® Pulse CO-Oximeter®|The perfusion index and Pleth variability index will be recorded from the device monitor.
41295999|NCT01975935|DRUG|Amlexanox|25 mg amlexanox tablets blinded by encapsulation
41296000|NCT01975935|DRUG|Placebo|placebo sham blinded by encapsulation in the same capsules as the study drug arm
41296001|NCT06252610|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~* 6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded;~* The catheter will be flushed with 0.9% saline solution;~* The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
40768369|NCT01790191|BEHAVIORAL|Repeated exposure to fat artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
40768370|NCT01282398|DRUG|Simvastatin|The experimental group will take 40 mg each 24 hours for at least two years.
40768371|NCT01282398|DRUG|placebo|the control group wiil take placebo pills for at least two years.
41296002|NCT06252610|DRUG|Contrast Media, Magnetic Resonance|"The same intravenous catheter used to inject the radiotracer will be used to inject the hepatospecific gadolinium contrast agent Eovist (Bayer, Whippany, NJ);~* After being positioned on the PET/MRI table, the nuclear medicine technologist will connect the patient to the MRI-safe power injector;~* The catheter will be flushed before and after injection with 0.9% saline solution;~* About halfway through the imaging session, the study staff will inform the patient that they are going to be administering the contrast agent and what sensations they should and should not expect;~* The contrast will then be injected."
41296003|NCT06252610|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired When necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
41296004|NCT00387387|DRUG|Pazopanib|Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases
41296005|NCT00387387|DRUG|FOLFOX 6|FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter\^2\[mg/m\^2\]), and folinic acid (400 mg/m\^2), IV 5-fluorouracil bolus (400 mg/m\^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m\^2) infusion over 48 hours on Day 1 of every 14-day cycle.
41296006|NCT00387387|DRUG|CapeOx|CapeOx treatment consists of IV oxaliplatin (130 mg/m\^2) on Day 1 plus oral capecitabine (1000 mg/m\^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m\^2 twice daily.
41296007|NCT02674581|DRUG|Oral BMS-663068 (pro-drug)|Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
41296008|NCT01930734|DRUG|Dobutamine|Dobutamine infusion up to 5mcg/Kg/min
41296009|NCT01930734|DRUG|Normal Saline|Normal Saline solution 0.9% Placebo Arm
40967830|NCT06106178|OTHER|Simulator for Basic Ultrasound Skills|Basic course of a traditional ultrasound simulator focusing on hand-eye coordination
40967831|NCT06106178|OTHER|Serious Video Game|"The serious video game Underwater uses a 3D-printed ultrasound probe for maneuvering. During gameplay, coins must be collected in an underwater world using the aforementioned simulated ultrasound probe. The main focus of this game is to improve hand-eye coordination while using an ultrasound probe."
40967832|NCT04971408|OTHER|passive heat stress|as above
41296010|NCT02083250|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
41296011|NCT02083250|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
40967833|NCT04971408|OTHER|control|participant engage in activity as usual
40967834|NCT02161731|DRUG|Evacetrapib|Oral administration
40967835|NCT02161731|DRUG|Warfarin|Oral administration
40967836|NCT06135350|DRUG|Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day|"Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:~* 2400 mg/day (4 tablets twice a day) for the first 2 days and;~* 1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
40967837|NCT06135350|OTHER|Placebo|"Placebo arm patients will receive placebo:~* 4 tablets twice a day for the first 2 days and;~* 3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
40967838|NCT02809404|DRUG|Everolimus|
41296012|NCT02083250|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
41296013|NCT02083250|DRUG|Busulfan|Given IV
41296014|NCT02083250|DRUG|Clofarabine|Given IV
41296015|NCT02083250|DRUG|Fludarabine Phosphate|Given IV
41296016|NCT02083250|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
41296017|NCT02083250|OTHER|Pharmacological Study|Correlative studies
41296018|NCT02083250|DRUG|Vorinostat|Given PO
41296019|NCT05378789|PROCEDURE|Nap|"ICU nurses can take a 20-mn nap between 2 and 5 am according to a rotation of personal.~Naps will be carried out with the help of a Nap and Up ® cocoon deckchair."
41296020|NCT04409795|DRUG|Metformin Extended Release Oral Tablet|Initial oral hypoglycemic agent added to existing insulin treatment
41296021|NCT04409795|DRUG|Sitagliptin|Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
40967839|NCT01761890|BEHAVIORAL|Dasatinib discontinuation|Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
40967840|NCT05144321|OTHER|Impact of environment upon obstetrical|Impact of environment upon obstetrical
40967841|NCT05144321|OTHER|neonatal and maternal adverse outcome|neonatal and maternal adverse outcome
40967842|NCT01437072|OTHER|No treatment given|The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
40967843|NCT02528929|DIETARY_SUPPLEMENT|Gluten-free diet|Patients with IBS-D will commence a gluten-free diet for 6 weeks following dietetic input. They will be informed they do not have coeliac disease. They will however be blinded to whether or not they have any markers of at-risk serology. They will self-complete validated questionnaires over 6 weeks. Any subjects who opt to continue with a gluten-free diet thereafter of their own volition will be kept under observation as per routine clinical care.
41296022|NCT00149331|BEHAVIORAL|Structured education program|
41296023|NCT06351215|DRUG|Methadone group|5mg PO methadone for participants \&lt;50kg or 10mg PO methadone for participants \&gt;50kg
40967844|NCT05096897|OTHER|Self-administrated questionnaires|GOHAI, IBD-Q, IBD-disk
41296024|NCT06351215|DRUG|Placebo|sugar pill that is identical look-alike to study drug
41296025|NCT00210561|DRUG|tramadol hydrochloride , acetaminophen|
40768372|NCT04788693|OTHER|Physical rehabilitation of gait with motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. In this intervention, in addition to physical exercise to correct gait, mental exercises will be included in which the patient visualizes himself performing the exercises that he will then develop with the body.
40967845|NCT04670848|DEVICE|Sleepiz One+ vs. polysomnography|Simultaneous sleep recording with polysomnography and Sleepiz One+ device
41296026|NCT02909296|PROCEDURE|Endoscopic drainage|
40967846|NCT01443260|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.
40967847|NCT02777801|DRUG|Entecavir|anti-HBV
41296027|NCT01769404|BIOLOGICAL|LY2605541|
41296028|NCT01769404|BIOLOGICAL|Insulin Glargine|
41296029|NCT01943123|DIETARY_SUPPLEMENT|probiotic drink|comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
41296030|NCT01943123|DIETARY_SUPPLEMENT|Placebo Comparator: plain, unsweetend, unflavored pasturised milk|comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
41296031|NCT06361277|DRUG|Reference Drug or Test Drug|Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration
41296032|NCT04534426|DRUG|: Arnica montana|In Arnica group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
41296033|NCT04534426|DRUG|Mucopolysaccharide polysulfate|In Arnica group and MPSP group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
41296034|NCT04534426|OTHER|Control group|In Control group, only standard therapy was performed after surgery
41296035|NCT00193674|DRUG|Dydrogesterone|20 mg/day, oral
41296036|NCT00193674|DRUG|Placebo|Placebo
41296037|NCT01369719|DRUG|osveral|receive 20 mg/kg daily orally
41296038|NCT01369719|DRUG|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
41296039|NCT05746351|DRUG|Dexmedetomidine|a group will receive epidural Bupivacaine with Dexmedetomidine in normal labor
41296040|NCT05746351|DRUG|fentanyl|a group will receive epidural Bupivacaine with fentanyl in normal labor
40967848|NCT01206660|DRUG|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
40967849|NCT01206660|DRUG|placebo|Placebo administered to affected area twice a day for 28 days
40967850|NCT04115839|DRUG|Filgotinib|Tablets will be administered orally once daily with or without food.
40967851|NCT04115839|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food.
40967852|NCT06368544|OTHER|lower-body positive-pressure|By increasing the chamber in the lower body around Pressure acts as a counterweight to gravity
41296041|NCT05746351|DRUG|Nalbuphine|a group will receive epidural Bupivacaine with Nalbuphine in normal labor
41296042|NCT01299597|DRUG|Atorvastatin|20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.
41296043|NCT01299597|DRUG|Simvastatin|10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
41296044|NCT01299597|DRUG|SB649868|20mg daily given for 14 days.
41296045|NCT05041192|DIETARY_SUPPLEMENT|Synaquell|7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
40967853|NCT03930797|BEHAVIORAL|Intimacy Enhancement|The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.
40967854|NCT03930797|BEHAVIORAL|Living Healthy Together|The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
40967855|NCT04873505|DIETARY_SUPPLEMENT|troches|Take one troche after each meal.
40967856|NCT01939743|DRUG|Diclofenac suppository plus lidocaine gel|
40967857|NCT01939743|DRUG|Lidocaine gel only|
40967858|NCT04614064|OTHER|Exposure to London Underground ambient particulate matter|Exposure to particulate matter on the London Underground
40967859|NCT04614064|OTHER|Exposure to London air ambient particulate matter|Exposure to ambient particulate matter on the London Overground (as a proxy as a proxy for a clean air London area while maintaining other aspects of a train journey)
40967860|NCT03148132|DRUG|Bevacizumab Injection|0.5mg/0.02 mL
41296046|NCT05041192|DIETARY_SUPPLEMENT|Placebo|7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
40967861|NCT03148132|DRUG|Ranibizumab Ophthalmic|0.25mg/0.025 mL
40967862|NCT02491203|OTHER|Telerehabilitation system|Usual care plus home-based virtual reality telerehabilitation system.
41296047|NCT03735693|DIAGNOSTIC_TEST|Ulstrasound|measurement of right femoral cross-section
41296048|NCT04802356|DRUG|Belantamab mafodotin|"Dose of 2.5 mg/kg/every 8 weeks on day 1, intravenously, Induction: three induction cycles with belantamab mafodotin in combination with VRd.~Consolidation: one cycle after 90 days of transplantation with belantamab mafodotin in combination with VRd.~Maintenance: belantamab mafodotin in combination with lenalidomide until disease progression, patients withdrawal, death or up to two years, whichever occurs first"
41296049|NCT04802356|DRUG|Bortezomib|Dose of 1.3 mg/m2, on days: 1, 4, 8 and 11 of every 28-day cycle. Subcutaneous administration Induction: 6 cycles Consolidation: 2 cycles
41296050|NCT04802356|DRUG|Lenalidomide|Dose of 25 mg/day on days 1-21 of every 28-day cycle. Oral administration. Induction: 6 cycles Consolidation: 2 cycles Maintenance: 10 mg/day on days 1-21 continuously (may increase up to 15 mg/day) until disease progression, patients withdrawal, death, whichever occurs first
41296051|NCT04802356|DRUG|Dexamethasone|Dose of 20 mg on days: 1, 2, 4, 5, 8, 9, 11 and 12 of every 28-day cycle. Oral administration Induction: 6 cycles Consolidation: 2 cycles
41296052|NCT04802356|PROCEDURE|Autologous stem cell transplant (ASCT)|High-dose melphalan (200 mg/m2) and ASCT will be performed as per routine practice
41296053|NCT02426242|OTHER|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
41296054|NCT06554457|DRUG|Multimodal analgesia with oral strong opioids|Physician's choice of post-surgical multimodal analgesia with an oral strong opioid as the backbone analgesics
41296055|NCT04284436|BEHAVIORAL|Treadmill walking|Treadmill walking 4 days per week for 30 minutes in the target heart rate
41296056|NCT01949064|DEVICE|Grindcare|
41296057|NCT01949064|DEVICE|Michigan-type occlusal splint|
41296058|NCT01430429|DRUG|NI-0801|
41296059|NCT06272383|DRUG|0.15 mg/kg dexamethasone|25% less than the standard practice of dexamethasone at 0.6mg/kg
40768373|NCT04788693|OTHER|Physical rehabilitation of gait without motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. Motor imagery exercises are not included in this program.
40967863|NCT01594281|DRUG|Ranibizumab 0.5 mg|Pre-filled syringe for intravitreal injection
41296060|NCT03717324|OTHER|Procedure created in co-creation group|Interventions will be those obtained from the co-creation workshop with patients
41296061|NCT04463160|OTHER|"prevention program for prediabetes Say No to Diabetes"|10 therapeutic education sessions
41296062|NCT05118139|OTHER|P1211216|Flavor variant P1211216 of a 1.5% nicotine ENDS product
41296063|NCT05118139|OTHER|P1213416|Flavor variant P1213416 of a 1.5% nicotine ENDS product
41296064|NCT05118139|OTHER|P1213716|Flavor variant P1213716 of a 1.5% nicotine ENDS product
41296065|NCT05118139|OTHER|P1213616|Flavor variant P1213616 of a 1.5% nicotine ENDS product
41296066|NCT05118139|OTHER|P1213816|Flavor variant P1213816 of a 1.5% nicotine ENDS product
41296067|NCT05118139|OTHER|P1211916|Flavor variant P1211916 of a 1.5% nicotine ENDS product
41296068|NCT05118139|OTHER|P1210016|Flavor variant P1210016 of a 1.5% nicotine ENDS product
41296069|NCT05118139|OTHER|P1211217|Flavor variant P1211217 of a 2.4% nicotine ENDS product
41296070|NCT05118139|OTHER|P1213417|Flavor variant P1213417 of a 2.4% nicotine ENDS product
41296071|NCT05118139|OTHER|P1211222|Flavor variant P1211222 of a 5% nicotine ENDS product
41296072|NCT05118139|OTHER|P1213422|Flavor variant P1213422 of a 5% nicotine ENDS product
41296073|NCT05118139|OTHER|P1213722|Flavor variant P1213722 of a 5% nicotine ENDS product
41296074|NCT05118139|OTHER|P1213622|Flavor variant P1213622 of a 5% nicotine ENDS product
41296075|NCT05118139|OTHER|P1213822|Flavor variant P1213822 of a 5% nicotine ENDS product
41296076|NCT05118139|OTHER|P1211922|Flavor variant P1211922 of a 5% nicotine ENDS product
41296077|NCT05118139|OTHER|P1210022|Flavor variant P1210022 of a 5% nicotine ENDS product
40967864|NCT01594281|PROCEDURE|Panretinal laser photocoagulation|PRP treatment following DRS guidelines
41138125|NCT01596465|OTHER|Self-Study using MP3 Player|"Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training."
41296078|NCT05174689|DIAGNOSTIC_TEST|Exercise challenge in the cold chamber (ECC)|Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.
41296079|NCT05174689|DIAGNOSTIC_TEST|mRNA profile|Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.
41138126|NCT01596465|OTHER|Multimedia Lecture|Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
41138127|NCT01697826|DRUG|ClinSupV3 -soft gelatin capsule|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
41138128|NCT01697826|DRUG|ClinSupV3ER- Extended release tablet|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
41138129|NCT00673088|DRUG|Ropinirole Hydrochloride|Restless Leg Syndrome
41138130|NCT00454194|DRUG|pemetrexed disodium|given IV
41296080|NCT05174689|DIAGNOSTIC_TEST|standard diagnostic|bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
41296081|NCT00002826|DRUG|paclitaxel|
41296082|NCT00002826|DRUG|valspodar|
41296083|NCT03444363|DEVICE|Laser group|Laser application in addition to SRP
41296084|NCT03444363|DEVICE|Control group|Placebo laser application in addition to SRP
41296085|NCT02773758|OTHER|Stannous Fluoride Dentifrice|Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
41296086|NCT02773758|OTHER|Sodium monofluorophosphate Dentifrice|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
41296087|NCT05331664|PROCEDURE|Pars plana vitrectomy|Standard of care surgery
41296088|NCT05331664|DRUG|Triamcinolone Acetonide 40mg/mL|Sub-tenon injection of triamcinolone acetonide (40mg/mL) at the time of surgery
41296089|NCT05331664|DRUG|Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin|Antibiotic eye drop 4 times per day for 1 week after surgery
41296090|NCT05331664|DRUG|Prednisolone 1%|Steroid eye drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper) after surgery
41296091|NCT05331664|DRUG|Atropine 1%|Eye drop daily for 1 week after surgery
40967865|NCT02462460|DEVICE|MRI|
41138131|NCT00454194|DRUG|sorafenib tosylate|given orally
41138132|NCT00944359|DIETARY_SUPPLEMENT|Daily preventive Zn; placebo treatment|7 mg zinc / day and placebo supplement during diarrhea episodes
41138133|NCT00944359|DIETARY_SUPPLEMENT|Therapeutic Zn; daily placebo|20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement
41138134|NCT00944359|DIETARY_SUPPLEMENT|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes
41138135|NCT00944359|OTHER|Surveillance control group|Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
41296092|NCT02096393|DEVICE|Zimmer Patient specific instruments|A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
41296093|NCT02096393|DEVICE|Standard instrumentation|Standard instrumentation will be used during total knee replacement surgery.
41296094|NCT00312780|DRUG|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
41296095|NCT05117710|DRUG|Ebselen|Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).
41296096|NCT05117710|DRUG|Placebo|Matched placebo capsules
41296097|NCT00355004|OTHER|counseling intervention|
41296098|NCT00355004|PROCEDURE|fecal occult blood test|
41296099|NCT00355004|PROCEDURE|screening colonoscopy|
40768374|NCT06629961|PROCEDURE|abutment placement|Placement of a subcrestal implant at more than 35 N and placement of a trans-epithelial abutment at 30 N
40967866|NCT02462460|BEHAVIORAL|Optional Screening Questionnaire|
40967867|NCT04933994|DEVICE|computed Tomography|All cases were detected with computed Tomography
41138136|NCT00455715|DRUG|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
41138137|NCT03052998|DRUG|Ivermectin|Effect of Ivermectin on frequency of seizures
41296100|NCT06020859|DEVICE|undergo NaviEC-2000Pro Gastro Scan mode|Patients undergo NaviEC-2000Pro Gastro Scan mode.
41296101|NCT06020859|DEVICE|NaviEC-2000Pro Routine gastric examination|Patients undergo NaviEC-2000Pro Routine gastric examination mode.
41296102|NCT06020859|DEVICE|NaviEC-1000 Routine gastric examination|Patients undergo NaviEC-1000 Routine gastric examination mode.
40967868|NCT01619982|DRUG|Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is \> 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is \> 8 hours in duration.
41457690|NCT04947150|BEHAVIORAL|Household support|If participants are assigned to have household support ON, one adult in the household will receive weekly text messages designed to elicit support for changing food purchases. In addition, the index participant and household member will be invited to participate in one extra workshop session and three brief coaching calls focused on household support. If participants are assigned to have this OFF, household members will have no program involvement.
41457691|NCT05590676|DRUG|Metformin Hydrochloride|"Infants will receive 14 consecutive doses, once daily, of metformin, with two dose cohorts.~Arm 1: Five infants with HIE will be enrolled on the first dose cohort of 20 mg/kg. Once complete, another five infants will be enrolled on the second dose cohort of 25 mg/kg.~Arm 2: Five preterm infants will be enrolled on the first dose cohort of 15 mg/kg. Once complete, another five preterm infants will be enrolled on the second dose cohort of 20 mg/kg."
40967869|NCT01619982|DRUG|Cefazolin 30 mg/kg body weight|"Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery."
40967870|NCT05789810|OTHER|Manuel pressure|10-second manual pressure was applied on the insulin injection area.
40967871|NCT05789810|OTHER|ShotBlocker|ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.
40967872|NCT05789810|OTHER|Control|No intervention was performed to reduce pain and fear.
40967873|NCT03476330|DRUG|Quercetin (dietary supplement)|Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
40967874|NCT02251184|DRUG|Aggrenox|
40967875|NCT02251184|DRUG|Dipyridamole|
40967876|NCT02251184|DRUG|Aspirin|
41138138|NCT01279694|DRUG|Carfilzomib|There are 9 cycle of 20mg/m²,Intravenous for J1, J2, J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the first cohort; or 20mg/m²,Intravenous for J1, J2, and 27 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the second cohort for the last, third cohort 20mg/m²,Intravenous for J1, J2, and 36 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle)and the fourth cohort 20mg/m²,Intravenous for J1, J2, and 45 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle). .
41138139|NCT01279694|DRUG|Melphalan|from 9 cycle: 9 mg/m²/day PO from day 1-4
41296103|NCT05254522|OTHER|not aplicable since it is a Registry|not aplicable since it is a registry
41296104|NCT06439719|PROCEDURE|Blood sample collection|Collection of blood sample
41457692|NCT03087435|DEVICE|Well-Being questionnaire|Development and validation of a tool to access residents well-being.
41457693|NCT01471951|OTHER|Single embryo transfer in women at risk of multiple pregnancies|Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
41457694|NCT01420614|PROCEDURE|Femoral approach|diagnostic and interventional procedures by femoral artery access
40967877|NCT02251184|DRUG|Lansoprazole|
40967878|NCT00065403|DEVICE|Acupuncture|
40967879|NCT02496611|DRUG|Weight loss with pharmacotherapy|Participants randomized to the drug intervention group will receive Exenatide extended-release.
40967880|NCT02496611|DRUG|Weight loss without pharmacotherapy|Participants randomized to the placebo group will receive a placebo.
41138140|NCT01279694|DRUG|Prednisone|from 9 cycle: 60 mg/m²/day PO from day 1-4
41138141|NCT04213807|BIOLOGICAL|MAA868 Cohort 1|Subcutaneous injection: low dose
41138142|NCT04213807|BIOLOGICAL|MAA868 Cohort 2|Subcutaneous injection: high dose
41138143|NCT04213807|BIOLOGICAL|MAA868 Cohort 3|Subcutaneous injection: Dose to be determined.
41296105|NCT06254469|DRUG|[F-18]Flornaptitril|All participants will receive a single dose of F-18 FNT during an imaging visit.
41296106|NCT02372903|DRUG|Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin|Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
41296107|NCT00788658|BEHAVIORAL|Diet modifications|Diet consultation
41457695|NCT01420614|PROCEDURE|Radial approach|diagnostic and interventional procedures by radial artery access
41457696|NCT01876745|DRUG|eptacog alfa (activated)|Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
41457697|NCT05125276|DRUG|No aspirin|No aspirin
41457698|NCT05125276|DRUG|Aspirin|75-100 mg once daily
40768375|NCT06629961|PROCEDURE|Ti-base placement|Placement of a subcrestal implant at more than 35 N and placement of a Tibase placement at 30 N
40967881|NCT06259721|DRUG|Anti-PD1 antibody, nimotuzumab and capecitabine|"Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab (200mg), tislelizumab (200mg) or others; Intravenous infusion, every 3 weeks .~Nimotuzumab:: In the first 6 cycles, 200 mg, intravenous infusion, every 1 week, and 400 mg is administered for the first time.~Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks~Maintenance phase:~Anti-PD1 monoclonal antibody: anti-PD-1 monoclonal antibody drugs, Intravenous infusion, every 3 weeks.~Nimotuzumab treatment: 400 mg, intravenous infusion, every 3 weeks. Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks；~The duration of treatment is 1 year or until intolerable toxic reactions occur, or disease progresses, or the patient withdraws consent, or the investigator determines that the patient needs to withdraw from treatment."
40967882|NCT02430012|BEHAVIORAL|Quality improvement strategies|Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
40768376|NCT06235216|DRUG|Sacituzumab govitecan|Dose of 10 mg/kg intravenously
40967883|NCT00873574|BIOLOGICAL|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
40967884|NCT06197750|OTHER|Vestibular stimulation|Vestibular stimulation by swing
40967885|NCT06197750|OTHER|General strengthening exercises|General strengthening exercises
40967886|NCT01520012|DRUG|YH4808 100 mg|Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
40967887|NCT01520012|DRUG|YH4808 100 mg|Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
40967888|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
40967889|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
40967890|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
40967891|NCT00442078|DEVICE|I-STOP TOMS male sling|Bulbus urethral compression with polypropylene mesh
40967892|NCT05902780|DRUG|Caudal Bupivacaine injection|- Group B (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.
41138144|NCT04213807|OTHER|Placebo|Subcutaneous injection: Placebo
41146847|NCT01694147|DEVICE|PiCCO monitoring system|The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
41296108|NCT00788658|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
41296109|NCT00006386|DRUG|carmustine|
41457699|NCT04204096|BIOLOGICAL|Vi-DT (Multi-dose formulation)|"* Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years~* Storage Conditions: +2 to +8°C"
40768377|NCT05925400|DEVICE|Virtual Reality during Embryo Transfer|Patients randomized to the study group, will be provided with the VR headset. The VR exposure will take place 10-15 minutes before the Embryo Transfer (ET) and a 10 min immersion after the ET
40768378|NCT06230198|PROCEDURE|retrograde autologous priming (RAP)|sites follow an institutional policy of routine use of retrograde autologous priming (RAP) during cardiac surgery
40967893|NCT05902780|DRUG|Caudal Dexmedetomidine Injection|- Group D (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
40967894|NCT04388709|DRUG|Peginterferon Lambda-1A|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
40967895|NCT02131194|DIETARY_SUPPLEMENT|Lenstatin|Dietary Supplement Lenstatin
40768379|NCT06230198|PROCEDURE|Crystalloid priming|sites implement crystalloid priming use during cardiac surgery
40768380|NCT05457725|BEHAVIORAL|Contingent rtfMRI neurofeedback training|Contingent rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about real-time brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
40967896|NCT02131194|DRUG|Placebo|Placebo sugar pill manufactured to mimic Lenstatin
40967897|NCT02563405|DRUG|Doxazosin|Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.
40967898|NCT02563405|DRUG|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
40967899|NCT04494074|OTHER|External Cooling|External Cooling
40967900|NCT00695487|DRUG|THC 9-d-tetra hydro cannabinol|0.125mg/kg iv one time
40967901|NCT02066805|DRUG|Database assessment of off-label XGEVA use|No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
41457700|NCT04204096|BIOLOGICAL|Vi-DT (Single dose formulation)|"* Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years~* Storage Conditions: +2 to +8°C"
41457701|NCT04204096|BIOLOGICAL|Control Vaccine|"* For participant ≥ 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered~* For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject."
40967902|NCT05174377|DIAGNOSTIC_TEST|CT-scan algorithm|CADx model was developed with a Support Vector Machine (SVM) algorithm and trained using five-fold cross-validation
40967903|NCT02780310|DRUG|Lenvatinib|
40967904|NCT02300688|DRUG|Treatment A|administration of 1 time administration of the test drug (Treatment A)
40967905|NCT02300688|DRUG|Treatment B|administration of 1 time administration of the reference drug (Treatment B)
40967906|NCT05200091|OTHER|Combined explosive strength and specific balance training group|"Training will consist to perform one hour of combined ankle explosive strength training and specific balance training using randomized perturbations.~Explosive strength training: Participants will perform only 2 sets of 3 min (12 contractions for each set) for both lower limbs and both ankle plantar- and dorsiflexion movements.~Balance specific training: Participants will be standing, secured by an adjusted harness, which do not support the weight but is strictly there to prevent a fall. They will have online visual feedback of their CoP via an avatar on the screen in front of them. Each training session will consist of 10 sequences of 3 min, including the 5 different conditions:~* Forward tilt of base of support;~* Backward tilt of base of support;~* Translation forward;~* Translation backward;~* Without moving their feet, participants will have to move their avatar to reach different targets placed around them on the screen, at different distance from the center."
40967907|NCT02091934|PROCEDURE|Wavefront-guided PRK|Wavefront-guided PRK
41457702|NCT01337427|DRUG|BIIB017|BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
40967908|NCT02091934|PROCEDURE|Wavefront-optimized PRK|Wavefront-optimized PRK
41138145|NCT05213182|BEHAVIORAL|Young Women of Today|Adolescent mothers engaged in the development and implementation of the intervention which also involved key community stakeholders to address stigma related to mental illness and adolescent motherhood. Community health workers and peer educators in the intervention arm were recruited and trained on co-facilitating peer support groups. The intervention arm (n=104 adolescent mothers) participated in the peer support groups and completed sociodemographic, base-, mid-, and end-line surveys. The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys. Peer support groups (12 groups with 6-12 participants in each group) met in-person twice a month and completed 12 peer-group sessions from May-August 2019 addressing participant identified topics such as depression. WhatsApp Messenger was used for training and implementation support. Key community stakeholders met to discuss project progress and recommendations to improve adolescent mothers' health.
41138146|NCT01303744|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 12 weeks
41138147|NCT01303744|DRUG|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
41138148|NCT01303744|DRUG|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
41138149|NCT01303744|DRUG|Placebo|oral tablet, once a day in the morning for 12 weeks
41138150|NCT02137785|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
41138151|NCT02137785|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
41138152|NCT02137785|DEVICE|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
41138153|NCT01039610|DRUG|GSK945237|Dose detailed in Arm description
41138154|NCT01039610|DRUG|Placebo|matching placebo tablet
41138155|NCT01039610|DRUG|Linezolid|600 mg BID, 14 Days
41138156|NCT01039610|DRUG|Moxifloxacin|40 mg single dose
41138157|NCT00886548|PROCEDURE|Ultrasound performed|Nurse-driven ultrasound performed
41138158|NCT06199115|PROCEDURE|Photobiomodulation|"In oncology, photobiomodulation is used to help heal damaged tissues, improve immune response, reduce inflammation, and prevent or treat certain side effects of treatments such as chemotherapy. Photobiomodulation is also the subject of recent clinical studies to expand its indications (peripheral neuropathies induced by certain chemotherapies.~Patients in the experimental group will receive 3 photobiomodulation sessions per week during their oxaliplatin treatments (6 months), for a total of 72 sessions. Exposition to laser light is 30 minutes for each session."
41138159|NCT03944889|DRUG|Capsaicin|Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.
41138160|NCT03944889|DEVICE|Delsys Trigno Galileo System|This device is a wireless surface EMG device.
41138161|NCT03944889|DEVICE|Cadwell Sierra Wave|Intramuscular EMG recording machinery
41138162|NCT03944889|DEVICE|Sonosite Ultrasound Machine|Ultrasound System
41138163|NCT03944889|DEVICE|Goniometer|A device to measure angular position
41296110|NCT00006386|RADIATION|radiation therapy|
41457703|NCT01790308|DRUG|CSII|continuous subcutaneous insulin infusion for 2\~4 weeks
41457704|NCT01790308|DRUG|Liraglutide|CSII for 2\~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
41457705|NCT04556123|OTHER|Measurement of the hydration state and decongestive treatment according to bioimpedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes."
40967909|NCT04173468|OTHER|Moblization with Movement|patients with group 1 will receive two techniques pertaining to MWM intervention (straight leg raised with traction and tibial Gliding) Repeat it 10 times,3 sets and 1 mint interval. .For Tibial Gliding we will asks the patient to perform 10 repetitive active knee extensions. Practice will be performed by doing 10 reps for 3 sets with 1 min interval. After this home exercises will b guided stretching of hamstrings 8 to 10 reps 20 sec hold, strengthening of Quadriceps and VMO with 10 reps and 3 sets
40967910|NCT04173468|OTHER|Mulligan knee taping|patient with group 2 will receive Mulligan taping technique. Tape will be applied for two days then we will change it. After this home based exercise will be guided which is stretching of hamstrings 8 to 10 reps 20 sec hold , strengthening of Quadriceps and VMO with 10 reps and 3 sets.
40967911|NCT04234191|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
40967912|NCT04234191|DRUG|Hydromorphone|Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
40967913|NCT06141109|DRUG|Sintilimab 200mg+MB07133 600mg|"1. Adopting the classic 3+3 scheme design, 3 dose groups, with a cycle of 21 days. On the first day of each cycle, a single infusion of Sintilimab is given, and MB07133 is given for 7 consecutive days after a 2-hour interval between infusion initiation.~2. Sintilimab 200mg+MB07133 1800mg, recruiting 30 subjects，the administration method is as 1."
40967914|NCT01130012|BEHAVIORAL|Lifestyle: diet and exercise|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
40967915|NCT01130012|BEHAVIORAL|Close follow-up: reporting diaries of food and exercise|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
40967916|NCT00385983|DEVICE|Harmonic Scalpel|
40967917|NCT00796198|DRUG|Xalatan+Cosopt|Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
40967918|NCT00796198|DRUG|Xalatan|Xalatan ophthalmic solution one drop at 10pm
40967919|NCT02771002|DEVICE|Peripheral Perfusion index by Carescape Patientenmonitor|Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
40967920|NCT04293120|OTHER|Training with weighted ball|Participants will stop or catch a weighted ball
40967921|NCT00738595|DRUG|EVT 302|EVT 302 5 mg once daily
40967922|NCT00738595|DRUG|Placebo|Placebo to match EVT 302, 5 mg
40967923|NCT00738595|DRUG|EVT 302 plus open label Nicotine replacement|Double-blind EVT 302 plus open label nicotine replacement
40967924|NCT00738595|DRUG|Placebo plus open label Nicotine Replacement|Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
40967925|NCT05157230|BEHAVIORAL|exercise|volunteers in the exercise arm instructed to do three basic deltoid muscle exercises 3 times daily at least 20 repetitions for each exercise for five days. exercises were side lateral shoulder raises, front shoulder raises with hyperextension and mid range arm circles.
40967926|NCT06009705|DRUG|toripalimab|JS001, the active ingredient of toripalimab injection, independently developed by Shanghai Junshi Biomedical Technology Co., Ltd, is an independently developed novel recombinant humanised (degree of 97%) anti-PD-1 monoclonal antibody (Chinese Patent License No. CN104250302B, PCT Patent Publication No. WO2014/206107A1), belonging to the human IgG4/Kappa subtype, and introducing a point mutation at the Serine to Proline (S228P) protein site 228 in the hinge region of the IgG4 heavy chain.
40967927|NCT02699645|DRUG|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg|1 pill taken orally once daily for average of 72 months
40967928|NCT02699645|DRUG|Placebo|1 pill taken orally once daily for average of 72 months
40967929|NCT05868200|DRUG|Capitano zenzero toothpaste|"Filming toothpate formulation, enriched with 3%ginger as active ingredient and Zinc coco sulfate as surfactant, cleansing and emulsifying agent.~Subjectswill then be given the test intervention, Capitano zenzero toothpaste, and will be asked to brush with it for two minute twice per day and will be instructed torefrain from eating and drinking for 30 min after brushing. participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months ."
41296111|NCT00006386|RADIATION|stereotactic radiosurgery|
40967930|NCT05868200|DRUG|Colgate total toothpaste|Subjects will then be given Colgate total toothpaste, as an active comparator, and will be asked to brush with it for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles . participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
41457706|NCT04556123|OTHER|Measurement of the hydration state and decongestive treatment according to clinical judgement alone|Clinical judgement will be performed in each center by a reference physician or nurse
41457707|NCT02600676|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS) - active|TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
41296112|NCT05385718|OTHER|Magnetic Resonance Imaging|Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.
41296113|NCT01712438|BIOLOGICAL|Human cl rhFVIII|
41296114|NCT03628469|BEHAVIORAL|Proactive Health Support|Active listening, coaching and counselling
41296115|NCT00001933|DRUG|Nefiracetam|
41296116|NCT00000579|PROCEDURE|Low Tidal Volume Ventilation|
41296117|NCT00000579|PROCEDURE|Positive End-Expiratory Pressure|
41296118|NCT00000579|DRUG|Lysofylline|
40967931|NCT04067544|DEVICE|Acupuncture|"The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion."
40967932|NCT05273918|OTHER|cognitivo-comportmental therapy|15 workshops once a week during 90 minutes
40967933|NCT05273918|OTHER|body mediation|15 workshops once a week during 90 minutes
40967934|NCT01288066|PROCEDURE|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
40967935|NCT01288066|PROCEDURE|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
40967936|NCT01461603|DIETARY_SUPPLEMENT|Vamin (Fresenius Kabi)|Vamin 18gN 1ml/min infusion in 6 hours
40967937|NCT01461603|DIETARY_SUPPLEMENT|3hydroxybutyrate|Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
40967938|NCT01525810|DRUG|Peginterferon Lambda-1a (BMS-914143)|Observational study - No Intervention \[subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)\]
40967939|NCT05320120|DRUG|56mg esketamine (2x Spravato® 28 mg nasal spray)|56mg esketamine (2x Spravato® 28 mg nasal spray)
40967940|NCT05320120|DRUG|0.9% saline solution nasal spray|0.9% saline solution nasal spray
40967941|NCT04107610|DEVICE|I-PAS|I-PAS is a portable, head-mounted display goggle system with integrated eye tracking technology. I-PAS records eye movements in response to visual and auditory stimuli.
40967942|NCT04059978|DRUG|CBD|1600mg cannabidiol, single oral dose (8 ml oily solution)
40967943|NCT04059978|DRUG|Placebo|Placebo p.o, single oral dose (8 ml oily solution)
40967944|NCT04059978|DRUG|Remifentanil|Remifentanil 0.1 µg/kg/min i.v. for 30 min
40967945|NCT05832385|RADIATION|IMRT|anal cancer: chemoradiotherapy, radiation dose\>50Gy; rectal cancer: chemoradiotheray, radiation dose=50Gy
40967946|NCT05502757|OTHER|Fruit and vegetable provision|Fresh fruits and vegetables are provided to families at no cost
40967947|NCT00370032|DRUG|alosetron|
40967948|NCT04970797|DRUG|Xinglouchengqi decoction|the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
40967949|NCT01658462|DRUG|Docetaxel|75 mg/m2 IV Day 1 / 3 weeks
40967950|NCT01658462|DRUG|Nintedanib|"200 mg x 2 per os daily from D2\*~\*No Nintedanib on days when docetaxel is administered"
40967951|NCT01658462|DRUG|Docetaxel: increase of the dose|Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
40967952|NCT01947582|DEVICE|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
40967953|NCT05950958|OTHER|Multimodal therapy for prevention of delirium|Multimodal therapy for prevention of delirium
41296119|NCT00000579|DRUG|Methylprednisolone|
40967954|NCT01193868|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
40967955|NCT01193868|OTHER|laboratory biomarker analysis|Correlative studies
40967956|NCT01193868|OTHER|pharmacological study|Correlative studies
40967957|NCT05776589|DEVICE|The mechanical ventilation mode|Changing the mechanical ventilation mode
40967958|NCT02640014|DIETARY_SUPPLEMENT|Milk|Milk Oral immunotherapy
40967959|NCT02759328|BEHAVIORAL|Xbox Kinect™ training|Xbox Kinect™ (Xbox 360, Microsoft, United States) game console which is one of the commercial interactive game consoles was used. It was comprised of 3 components; Kinect™ sensor, Xbox 360™ game console and 42 inch Liquid crystal display (LCD) television.
40967960|NCT02759328|BEHAVIORAL|Conventional rehabilitation|The conventional rehabilitation program consisted of passive and active range of motion exercises, therapeutic stretching, muscle strengthening, neurophysiologic exercises, sitting, standing, balance and gait exercises, occupational therapy and activities of daily living training such as eating, grooming, dressing, toileting and transfer.
40967961|NCT06446011|PROCEDURE|root canal treatment in Ckd patients|root canal treatment in teeth with apical periodontitis to observe periapical healing , and change in eGFR ,blood urea and creatinine and HSCRP
40967962|NCT06446011|PROCEDURE|root canal treatment in healthy patients|root canal treatment in teeth with apical periodontitis to observe periapical healing and change in HSCRP
41296120|NCT00000579|DRUG|Ketoconazole|
40967963|NCT00130936|DRUG|Epirubicin|
40967964|NCT00130936|DRUG|Carboplatin|
41296121|NCT00000579|PROCEDURE|Fluid Management|
41296122|NCT00000579|PROCEDURE|Pulmonary Artery Catheter|
40967965|NCT00130936|DRUG|Capecitabine|
40967966|NCT01806298|DRUG|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
41296123|NCT01437631|PROCEDURE|prophylactic clip application|prophylactic clip application after colonoscopic polypectomy
41296124|NCT02834403|DRUG|L-NMMA|Nitric oxide synthase inhibitor
41296125|NCT02834403|DRUG|Docetaxel|Mitotic inhibitor, cytotoxic
41296126|NCT02834403|DRUG|Amlodipine|Long-acting calcium channel blocker
41296127|NCT02834403|DRUG|Pegfilgrastim|Colony-stimulating factor
41296128|NCT02834403|DRUG|Enteric-coated aspirin|non-steroidal anti-inflammatory drug
41296129|NCT05844527|DRUG|MRG-001|MRG-001 is a novel fixed-dose drug combination administered subcutaneously to mobilize stem cells and immunomodulatory cells to the wound to accelerate healing.
40967967|NCT03808532|OTHER|Cura+ Moisturizing Cream|Parents of at-risk infants in the intervention arm will be instructed to apply moisturizer to the infant's entire body once daily for six months.
40967968|NCT05249374|DRUG|Recombinant Human Serum Albumin|10 g/bottle (20%, 50 mL)
40967969|NCT05249374|DRUG|Human serum albumin|10 g/bottle (20%, 50 mL)
40967970|NCT02155062|OTHER|Whole grain rye|
40967971|NCT02155062|OTHER|Whole grain wheat|
40967972|NCT02155062|OTHER|Refined cereal|
40967973|NCT05059600|DRUG|ZULRESSO®|Intravenous infusion of ZULRESSO®.
40967974|NCT05223244|DRUG|bupivacaine, triamcinolone, and heparin (BTH)|30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
40967975|NCT05223244|DRUG|dimethyl sulfoxide (DMSO)|50mL of DMSO and 1mL of triamcinolone (10mg/mL)
40967976|NCT06383221|COMBINATION_PRODUCT|"Mental Fitness Boot Camp - Advanced Counseling Step-by-Step Care"|Simple and scientific advice
40967977|NCT02252783|DRUG|BFPET|Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
40967978|NCT01103648|DRUG|Simvastatin|Tablets of simvastatin 20 mg administered once a day for 12 weeks
41138164|NCT03353285|PROCEDURE|intracytoplasmic sperm injection (ICSI)|All eggs will be fertilized by ICSI
41138165|NCT00614614|BIOLOGICAL|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
41138166|NCT00614614|BIOLOGICAL|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
41138167|NCT00614614|BIOLOGICAL|Infanrix®|One dose as intramuscular injection
41138168|NCT00614614|BIOLOGICAL|ActHIB®|Three doses in the priming phase as intramuscular injection
41138169|NCT00614614|BIOLOGICAL|Pediarix®|Three doses in the priming phase as intramuscular injection
41138170|NCT02858115|OTHER|Fluid challenge|100 ml of crystalloid was infused over 1-min
41138171|NCT02858115|OTHER|Trans-oesophageal echography|an echocardiographic assessment at 1-min,
41138172|NCT04327089|DRUG|Setanaxib|Nox 1/4 inhibitor
41457708|NCT02600676|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS) - placebo|
40967979|NCT01103648|DRUG|Ezetimibe|Tablets of ezetimibe 10 mg administered once a day for 12 weeks
40967980|NCT01103648|DRUG|Combination Simvastatin plus Ezetimibe|"Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study."
40967981|NCT05792722|PROCEDURE|Prostate capsule-sparing radical cystectomy|Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
40967982|NCT05792722|PROCEDURE|Nerve sparing radical cystectomy|Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
40967983|NCT02429544|BEHAVIORAL|Residential Program|Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
40967984|NCT02429544|BEHAVIORAL|Questionnaires|Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
40967985|NCT02429544|DEVICE|Electroencephalogram (EEG)|EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
41138173|NCT00396487|DRUG|Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat|
41138174|NCT03711279|DRUG|SHR-1210 plus Apatinib|SHR-1210 200 mg q3w+ Apatinib 500 mg qd
41138175|NCT03711279|DRUG|ADM plus IFO or IFO alone|ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.
41138176|NCT00000532|BEHAVIORAL|diet, fat-restricted|
41457709|NCT02961205|DIETARY_SUPPLEMENT|Oral Nutritional Supplementation|"Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge."
41457710|NCT02760433|DRUG|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
40967986|NCT02429544|OTHER|Saliva Testing|Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
41138177|NCT03388957|DRUG|Propranolol|This drug will be given before the extraction procedure
41138178|NCT03388957|DRUG|Midazolam|This drug will be given before the extraction procedure
41146848|NCT05742646|BEHAVIORAL|MATADORS|Youth will have access to the MATADORS app to include basic information and expanded educational features. They will be asked to log into the app daily for one month and they will be asked to report within the app how they are feeling each day and their medications taken.
41146849|NCT05742646|BEHAVIORAL|MATADORS Control|Youth will have access to the MATADORS app basic information. They will be asked to log into the app daily for one month and they will be asked to report within the app their medications taken.
40967987|NCT02429544|BEHAVIORAL|Study Diary plus Actigraph|For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
40967988|NCT05864872|PROCEDURE|axillary brachial plexus block|conventional group, 3 to 6 mL of bupivacaine was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior ultrasound group:1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.
40967989|NCT00428311|DRUG|Metformin|
40967990|NCT00428311|DRUG|Ethynyl-estradiol plus cyproterone acetate|
40967991|NCT03922503|PROCEDURE|Advanced- platelets rich fibrin (A-PRF) with Demineralized freeze-dried bone allograft (DFDBA)|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier.The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
40967992|NCT03922503|PROCEDURE|Collagen membrane with Demineralized freeze-dried bone allograft (DFDBA)|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
40967993|NCT01305902|BEHAVIORAL|contingency management|Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
40967994|NCT01812174|DEVICE|17mm aortic valve (On-X )|Heart aortic valve replacement surgery: 17mm Aortic
40967995|NCT01812174|DEVICE|23mm mitral valve (On-X)|Heart mitral valve replacement surgery: 23mm Mitral
40967996|NCT04670198|BEHAVIORAL|Youth Empowerment Skills|The Youth Empowerment Skills (YES) programme is a novel psychoeducational intervention with simulation-based experiential learning tailored to the needs of young people. It is based on a social-cognitive learning model, and comprises attendance at 3 all-day YES sessions in non-healthcare settings (groups of 10); and then post-programme networking through social media and follow-up events facilitated by the youth worker. Sessions are led by a peer-educator and a health professional
40967997|NCT04670198|BEHAVIORAL|Waiting-list control|Usual care for 6 months, followed by the YES programme.
40967998|NCT00630396|DRUG|Minocycline|"Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses"
40967999|NCT00002136|DRUG|Tecogalan sodium|
40968000|NCT05845151|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET|Activation of renal fibroblast is quantified using 68Ga-FAPI-04 PET in patients with LN.
40968001|NCT01559597|BIOLOGICAL|Tetanus toxoid vaccine|Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
40968002|NCT02872207|DRUG|BAY 987516 (Y65-122)|5 µL in one eye
40968003|NCT02872207|DRUG|BAY 987516 (Y65-118)|5 µL in one eye
40968004|NCT02872207|DRUG|Control|5 uL in other eye
40968005|NCT06501833|OTHER|FIFA 11+ KIDS PROGRAM|The experimental group will perform eight weeks of FIFA 11+ kids program (3/week).
40968006|NCT06501833|OTHER|REGULAR TRAINING|The control group will be continuing their regular training
40968007|NCT05661799|BEHAVIORAL|Intervention Group|The programme is a PA programme consisting of one weekly session for 12 weeks. The one hour of PA is supplemented by two 15-minute periods. At the end of each session, a PA challenge and a positive reinforcement exercise are proposed for the coming week. At the beginning of the next session, the facilitator has a dedicated time to give feedback on these challenges (successes and difficulties encountered). At the end of each session, the facilitator explains the theme of the next challenge and exercise. For the challenge, three options are proposed. Each participant chooses the option he/she prefers. Positive reinforcement exercises are also offered in the same way. They aim to strengthen motivation, hope and the sense of self-efficacy (SEP). In addition to these two 15-minute sessions, participants are offered a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different themes.
40968008|NCT05661799|BEHAVIORAL|Control Group|The programme is a PA programme consisting of one weekly session for 12 weeks.
40968009|NCT03001531|DEVICE|HydroSun|a skin area of the lower limb will be treated three times with ultraviolet light emitted by a halogen lamp
40968010|NCT03001531|DEVICE|Hilotherm|a skin area of the lower limb will be treated three times with heat applied by a sleeve
41296130|NCT05844527|DRUG|Saline|Sterile saline will serve as placebo treatment.
41457711|NCT02760433|DRUG|Placebo|sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
40968011|NCT06113744|BIOLOGICAL|Placebo|saline
40968012|NCT06113744|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
40968013|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg|Low-dose
40968014|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg|Mid-dose
40968015|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg|High-dose
40968016|NCT01906502|DEVICE|Sensimed Triggerfish|
40968017|NCT03303924|DRUG|ETX2514 and sulbactam|Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
40968018|NCT02789202|OTHER|Silver diamine fluoride|Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.
41146850|NCT00001895|DRUG|FDG|
41146851|NCT00001895|DRUG|NH(3)|
41457712|NCT03680144|PROCEDURE|Dynamic Susceptibility Contrast-MRI (DSC-MRI)|Undergo DSC-MRI
41457713|NCT03680144|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo diagnostic MRI
40968019|NCT02789202|OTHER|Fluoride Varnish|Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
40968020|NCT02551965|OTHER|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
40968021|NCT05916014|DIAGNOSTIC_TEST|Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the Kimura-Takemoto classification independently when the patients is eligible.
40968022|NCT04384211|OTHER|Computer Assisted Detection Software For Vertebral Fractures|A device named Smart Bone that is using CT image retrospectively acquired to entails a second review of CT images with Vertebral Compression Fractures through an interactive AI program developed by Quanta Computer Inc. was applied to the CT images. The device is a computer-aided detection (CADe) software application and is designed to assist radiologists to analyze Spine CT images. The device uses deep learning methods to perform vertebrae detection and classification of images.
40968023|NCT05528354|DRUG|VEN and DEC based conditioning regimen|"Patients with age\<50 years and HCT-CI\<3:~Haploidentical transplantation: AraC 2g/m2 d-10\~d-9, BU 0.8mg/kg q6h d-8\~-6, CTX 1.8g/m2 d-5\~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5\~-2, VEN 400mg/d d-15\~-9, DEC 20mg/m2 d-15\~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7\~-4, CTX 60mg/kg d-3\~d-2, Meccnu 250mg/m2 d-1, VEN d-12\~-8, DEC 20mg/m2 d-12\~-6, and ATG for the unrelated donor type.~Patients with age\>50 years or HCT-CI≥3:~Flu 30mg/m2 d-10\~-5, BU 0.8mg/kg q6h d-7\~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4\~-1, VEN d-15\~-9, DEC 20mg/m2 d-15\~-11.~Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days."
40968024|NCT05528354|DRUG|DEC|"In the time window of 60-120 days after transplantation: DEC 5mg/m2/d for 5 consecutive days every 6 to 8 weeks with a total of 4 to 6 courses if there is no severe aGVHD (grade 3 or higher) and the donor chimerism rate of bone marrow blood (STR)\>95%.~If the MRD turns positive, DLI can be performed."
40968025|NCT00598832|DRUG|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
40968026|NCT00598832|DRUG|Adapalene Lotion Vehicle|Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
41296131|NCT02229149|DRUG|Trastuzumab|"Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving."
41296132|NCT02229149|DRUG|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
40968027|NCT00714649|DRUG|cetuximab|Cetuximab 250mg/m²/week IV before surgery till surgery
40968028|NCT00003211|BIOLOGICAL|filgrastim|
40968029|NCT00003211|DRUG|amifostine trihydrate|
40968030|NCT00003211|DRUG|cisplatin|
40968031|NCT00003211|DRUG|cyclophosphamide|
40968032|NCT00003211|DRUG|vincristine sulfate|
40968033|NCT00003211|PROCEDURE|peripheral blood stem cell transplantation|
40968034|NCT00003211|RADIATION|radiation therapy|
41138179|NCT04907617|OTHER|FAW|After the induction of anaesthesia, for patients assigned to groups 1 and 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.
41138180|NCT04907617|OTHER|Warmed fluids|In patients assigned to groups 2 and 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
40968035|NCT03564314|OTHER|SUPPORT AKI Clinical Decision Support|Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.
41146852|NCT04271813|DRUG|Anlotinib plus Sintilimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w
41296133|NCT02229149|DRUG|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|"physician's choice of chemotherapy:~* Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~* Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~* Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~* Docetaxel 75 mg/m2 IV every 3 weeks; OR~* Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off."
41296134|NCT01753115|BIOLOGICAL|BioThrax|route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule
41296135|NCT01753115|DRUG|Ciprofloxacin|500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
41296136|NCT00800033|BEHAVIORAL|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
41457714|NCT02645487|RADIATION|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Size \<= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy \>1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy \>2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy
41457715|NCT02212457|BIOLOGICAL|Bexsero|Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.
40968036|NCT00071474|PROCEDURE|shamanic healing|
40968037|NCT04976751|DRUG|Percutaneous electrical nerve stimulation treatment|Using the percutaneous electrical nerve stimulation instrument to different points of the body
40968038|NCT05119205|DIAGNOSTIC_TEST|Bone marrow biopsy and compete blood count|Bone marrow biopsy and compete blood count will be done for follow up in patients with multiple myeloma
40968039|NCT04988178|OTHER|Data extraction from medical files|Data extraction from medical files
40968040|NCT05061771|DRUG|nomacopan (rVA576)|Nomacopan an inhibitor of complement C5 and LTB4
40968041|NCT05061771|OTHER|Placebo|Placebo
40968042|NCT03465306|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.
40968043|NCT03465306|DEVICE|Self-guided|Self-guided refers to any contact between the participants and a therapist or coach.
40968044|NCT00217295|DRUG|Avonex and Topamax|
40968045|NCT01161862|DEVICE|Bi-hormonal (insulin and glucagon) artificial pancreas|Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
40968046|NCT00530309|DRUG|GSK716155 for injection|GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
40968047|NCT00530309|DRUG|Placebo|Subjects will also receive placebo.
40968048|NCT01417442|GENETIC|BRAF V600E POSITIVITY|BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
40968049|NCT04730284|OTHER|Health supplements|tailor-made Synbiotics, 4g per day for 28 days
40968050|NCT03435861|DRUG|VX-745|active drug capsules
40968051|NCT03435861|DRUG|placebo|placebo capsules
40968052|NCT04160195|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells|Dose-escalation trial starting dose: 0.66 x10\^6 CAR+ T cells/kg (weight-based dosing one time) (up to a maximum dose of 10x10\^6 CAR+ T cells/kg based on cohort) infuse on day 0
40968053|NCT04160195|DRUG|Cyclophosphamide|500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
41138181|NCT04907617|OTHER|Combination|"After the induction of anaesthesia, for patients assigned to groups 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.~In patients assigned to groups 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet."
41138182|NCT04907617|OTHER|Control|The patients assigned to group 4 will only receive 'routine care'. They will not be given intraoperative forced-air warming or heated IV and irrigation fluids.
41138183|NCT05051072|PROCEDURE|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"
41138184|NCT00641537|DRUG|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
41146853|NCT02845557|OTHER|OGTT and IVGTT tests|
41146854|NCT02033915|OTHER|Interactive discussion group|The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
40968054|NCT04160195|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
40968055|NCT01816204|BEHAVIORAL|Therapist assisted online treatment|7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
40968056|NCT01816204|BEHAVIORAL|face-to-face individual therapy|weekly individual counseling as usual.
40968057|NCT05682898|PROCEDURE|Timing of colorectal cancer surgery|The timing of colorectal cancer surgery is different according patients' different conditions which is difined as more than 7 weeks or less than 7 weeks.
40968058|NCT06460220|BEHAVIORAL|Safe Alternatives for Teens and Youth - Parent (SAFETY-P)|The parent component of SAFETY focuses on enhancing parents' skills in supporting youth safety and managing parental distress during a suicidal crisis, ideal content to adapt for web-based delivery for parents. Specifically, parent information includes psychoeducation about suicide risk and protective factors, lethal means restriction, development of a parent distress tolerance plan (i.e., Parent Safety Plan), parent self-care and sources of support, strengthening the youth/parent relationship, and focus on care linkage for the youth. The SAFETY-P asynchronous parent intervention module will include text, interactive handouts, vignettes, and short video examples. The SAFETY-P module will allow for parents to access information and skills training on their own time, with the opportunity and encouragement to ask informed questions of their child's clinician; this will provide clinicians the opportunity to utilize their check-ins with parents more effectively to address youth safety.
40968059|NCT06460220|BEHAVIORAL|Treatment As Usual (TAU)|TAU will consist of treatment and case management as usual in the NCH Critical Assessment and Treatment (CATC) program. This may include individual and group therapy sessions for the youth, family therapy, medication management, and case management/discharge planning. Frequency of these services varies by availability and care linkage to ongoing outpatient care. We will track the number, type and length of all treatment and case management services provided as part of TAU in CATC to control for time spent in by parents and youth in TAU across study conditions. Additionally, the Child and Adolescent Services Assessment (CASA), a services use measure, will be utilized to capture any additional treatments and parents' involvement in those treatments.
40968060|NCT01362205|DRUG|Dexmedetomidine|
40968061|NCT01362205|DRUG|Placebos|Inactive placebo (normal saline)
40968062|NCT03143439|BEHAVIORAL|Fathers Advancing Communities Together (FACT) program|The FACT program offers fathers and their families responsible parenting, healthy relationship, and economic stability services and activities.
40968063|NCT03304548|OTHER|Telephone concept elicitation interview|All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
40968064|NCT04736836|DRUG|Rifaximin|locally absorbed antibiotic
40968065|NCT04584645|OTHER|Targeted digital intervention|Messages that provide informational content on the influenza vaccine (sourced from the Centers for Disease Control and Prevention and the American Heart Association), specific information about influenza and cardiovascular disorders, and behavioral prompts (e.g., reminders) surrounding influenza vaccination behaviors.
40968066|NCT05292443|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
40968067|NCT00681005|DRUG|rabeprazole|20 mg bid for 14 days
41457716|NCT02212457|OTHER|Saline Placebo|One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.
40968068|NCT00681005|DRUG|pantoprazole|pantoprazole 40 mg bid
40968069|NCT01496807|DRUG|Sylatron|Sylatron - Once per week for 12 weeks, given as an injection under the skin.
40968070|NCT01496807|DRUG|Yervoy|Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).
40968071|NCT06373107|BEHAVIORAL|High intensity gait training|Participants will practice walking that is vigorous enough to keep their heart rate over a certain level during their physical therapy sessions. During the sessions, participants will walk and step vigorously enough to keep the heart rate between 60-80% of their maximum heart rate. Maintaining this heart rate during exercise helps to improve heart health and walking, which can affect people after a stroke.
40968072|NCT03723941|DRUG|Cisplatin plus Etoposide|"Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl."
40968073|NCT03723941|OTHER|Observation or Mitotane|Observation or mitotane alone according to the investigator's preference
40968074|NCT02452489|DEVICE|acupuncture|Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
40968075|NCT02452489|DEVICE|acupuncture|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
41138185|NCT00641537|DRUG|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
41138186|NCT00641537|DRUG|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
41138187|NCT00641537|DRUG|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
40968076|NCT02452489|DEVICE|acupuncture|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
40968077|NCT03785808|BEHAVIORAL|Special Diet Therapy (low-carb)|Receive dietary guidelines and recipes and consume a low-carbohydrate diet
40968078|NCT03785808|BEHAVIORAL|Special Diet Therapy (low-fat)|Receive dietary guidelines and recipes and consume a low-fat diet
40968079|NCT03785808|BEHAVIORAL|Special Diet Therapy (USDA control)|Receive dietary guidelines and recipes and consume USDA control diet
40968080|NCT00147446|BEHAVIORAL|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
40968081|NCT00147446|OTHER|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
40968082|NCT00897260|DRUG|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|"To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~* Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~* Fludarabine dose adjustment:~  70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion"
40968083|NCT00897260|RADIATION|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
40968084|NCT00897260|PROCEDURE|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
40968085|NCT06125028|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PTF i.v. injection
40968086|NCT06125028|DRUG|[18F]Fluorodeoxyglucose|\[18F\]FDG i.v. injection.
40968087|NCT00980057|DEVICE|Adaptive CRT (aCRT)|Adaptive CRT (aCRT) is an algorithm, which provides ambulatory adjustment of pacing configuration (LV-only or BiV) and AV and VV delays based on periodic automatic evaluation of electrical conduction to optimize cardiac function
40968088|NCT00980057|DEVICE|Echo|Standard BiV pacing with settings optimized using a standardized echocardiographic protocol
40968089|NCT02065115|OTHER|Cryotherapy (ice pack)|
40968090|NCT00855569|DEVICE|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
40968091|NCT04984720|BEHAVIORAL|Smartphone based digital application|Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
40968092|NCT02966028|DRUG|SNF472|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
40968093|NCT02966028|DRUG|Placebo|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
40968094|NCT00706823|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
41138188|NCT00641537|DRUG|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
41457717|NCT02212457|BIOLOGICAL|Havrix|Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
41457718|NCT02212457|BIOLOGICAL|MenABCWY|Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
40968095|NCT00706823|DEVICE|Laryngeal Mask Airway-Unique|supra-glottic airway device
40968096|NCT06058676|PROCEDURE|carotid artery stenting|The procedures will be performed for patients with general or local anesthesia. Implantation of stents at the site of carotid artery stenosis for the treatment of carotid severe stenosis. A suitable balloon will be selected based on the internal carotid arterial（ICA）diameter, as shown on the digital subtraction angiography（DSA）image. The use of a balloon for predilatation or postdilatation depends on the degree of stenosis. The type of stent will be selected according to several factors, such as the length and configuration of the lesion, vascular morphology, vessel diameter, plaque characteristics, stent characteristics, and surgeon experience.
40968097|NCT02713347|BEHAVIORAL|ADAPT Intervention|"The intervention includes 3 components:~1. nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~2. social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~3. collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone."
40968098|NCT00757887|BIOLOGICAL|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
40968099|NCT05130320|OTHER|Not Interventional their treatments are their routine NHS care|Not Interventional their treatments are their routine NHS care
41138189|NCT04490694|DRUG|Lenvatinib|Intervention Description：lenvatinib will be administered daily (for patients \<60kg, lenvatinib 8mg bid po for patients ≥60kg, lenvatinib 12mg bid po) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
41457719|NCT01282736|BEHAVIORAL|Integrative Response Therapy|A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.
41457720|NCT01282736|BEHAVIORAL|Cognitive Behavioral Therapy|A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
41457721|NCT01614184|DRUG|Fluorescein|Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
41457722|NCT04346680|PROCEDURE|ADSC administration|The treated nerve will be identified and released. Scar tissue will be removed, and nerve fibers will be exposed. Prepared solutions of ADSC will be administered via microinjection with a 30-G needle along the released nerve fascicles, above and below the reconstructed area and around the adjacent tissue, which stayed in contact with the nerves.
41457723|NCT01073631|DRUG|voriconazole tablet|200 mg PO bid (orally, twice a day)
41457724|NCT02101073|BIOLOGICAL|ALX-0061|single dose, intravenous
41457725|NCT02101073|BIOLOGICAL|ALX-0061|single dose, subcutaneous
41457726|NCT03457402|BEHAVIORAL|Shaping Delay Tolerance|Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
41457727|NCT00089427|DRUG|IL13-PE38QQR|
41457728|NCT00089427|PROCEDURE|Surgery for placement|
40968100|NCT00864383|DRUG|Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin|"Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
40968101|NCT04177797|DRUG|Toripalimab|Two cycles of Toripalimab(240 mg administered as an intravenous infusion over 30 minutes per 3 weeks), concurrently paclitaxel(135 mg/m2) and carboplatin(AUC 5) administered as an intravenous infusion per 3 weeks.
40968102|NCT06425666|PROCEDURE|Intervention group /arm 1 (Cataract surgery alone)|Cataract surgery (experimental intervention / arm 1) is performed using a small incision technique. The main incision will be localized between 11 and 12 o'clock and will have a width of 2.4 to 2.8 mm. A tunnel suture will only be placed if there is leakage from the incisions. A thin dispersive viscoelastic is applied to the endothelium for protection before phacoemulsification. A hydrophobic acrylic monofocal IOL will be implanted into the bag.
40968103|NCT06425666|PROCEDURE|Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK)|After cataract surgery DMEK is continued using the surgeon's standard technique for graft implantation and unfolding in triple-DMEK. In all cases the graft will be implanted using the same main incision as for IOL implantation. Once the DMEK graft is unrolled and attached to the posterior corneal stroma the complete anterior chamber will be filled with SF6 20%.
40968104|NCT03304743|DIAGNOSTIC_TEST|Dental panoramic radiograph|"If not performed within the previous 12 months at the Centre of Dentistry, an OPG will be performed during enrolment visit.~OPGs are routine low-dose x-rays that are often performed during dental check-ups, follow-ups or before dental treatments (e.g. extractions, implant placement, etc.), as they allow the evaluation of both bone and dental structures of both jaws, the sinus and temporo-mandibular joints."
40968105|NCT02314416|BIOLOGICAL|Amniotic Stem Cells and Collagen Matrix|Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
40968106|NCT00907777|BIOLOGICAL|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
40968107|NCT00907777|BIOLOGICAL|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
40968108|NCT05349916|OTHER|Control|300 g rice porridge + 150 ml drinking water
40968109|NCT05349916|OTHER|Isomaltodextrin Low Dose|300 g rice porridge + (5 g IMD in 150 ml drinking water)
40968110|NCT05349916|OTHER|Isomaltodextrin High Dose|300 g rice porridge + (10 g IMD in 150 ml drinking water)
40968111|NCT05349916|OTHER|GPC partially digestible maltodextrin|300 g rice porridge + (15 g GPC fiber in 150 ml drinking water)
40968112|NCT05349916|OTHER|Resistant Starch Type 4|300 g rice porridge + (15 g RS4 starch in 150 ml drinking water)
40968113|NCT04822454|OTHER|Night shift shadowing program|Our population, made up of 70 students, was divided into two randomly randomized groups: 31 (44.3%) had five night shift shadowing duty prior to their first official night shifts, and 39 (55.7%) did not participate in the shadowing program.
40968114|NCT03240302|DEVICE|ICSI petri dish|Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.
40968115|NCT03240302|DEVICE|PICSI petri dish|Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
41457729|NCT00089427|PROCEDURE|Radiation therapy|
41457730|NCT00089427|DRUG|Temozolomide with radiation therapy|
40968116|NCT03487068|DEVICE|The FibroScan device|The Fibroscan device (Echosens) works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe. The probe also has a transducer on the end that can measure the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed in kilopascals. Essentially, the technology measures the velocity of the sound wave passing through the liver and then converts that measurement into a liver stiffness measurement; the entire process is often referred to as liver ultrasonographic elastography.
40968117|NCT01523353|BEHAVIORAL|Exercise Intervention|4 week personalised exercise program on a static cycle. Supervised in a hospital environment
40968118|NCT05384574|DIETARY_SUPPLEMENT|cholecalciferol|daily supplementation of cholecalciferol, 10 000 IU, during 14 days
40968119|NCT02173327|DEVICE|Continuously helm CPAP|6 hours
40968120|NCT02173327|DEVICE|Intermittent Mask CPAP|10min every 2 hour for 18 hours
41457731|NCT05768087|RADIATION|Escalated proton therapy|According to allocated dose level: level 1-8, 69-90 Gy in 30 fractions of 2.3-3.0 Gy, to a subvolume of the radiation target
41457732|NCT02015832|DEVICE|Coronary stent|
41457733|NCT02015832|RADIATION|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
41457734|NCT02015832|DEVICE|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
41457735|NCT02015832|DEVICE|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
41457736|NCT02015832|DEVICE|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
41457737|NCT00221520|DRUG|midazolam with 2 different levels of sedation scores|
41457738|NCT00490503|PROCEDURE|Magnetic Resonance Imaging (MRI)|3 Scans performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
40968121|NCT01676844|DRUG|Oral thin film therapy (Potassium acid phosphate oral thin films)|"Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve."
40968122|NCT01676844|DRUG|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
40968123|NCT03460860|DIETARY_SUPPLEMENT|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|The intervention is to be taken once daily, for 12 weeks.
40968124|NCT03460860|DIETARY_SUPPLEMENT|Placebo|The intervention is to be taken once daily, for 12 weeks.
40968125|NCT01425281|DEVICE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|XIENCE implantation in the treatment of coronary artery disease.
40968126|NCT01425281|DEVICE|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System|ABSORB BVS implantation in the treatment of coronary artery disease.
40968127|NCT04449575|OTHER|eSwabs|from skin
40968128|NCT02591069|DEVICE|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
40968129|NCT02088281|DRUG|Indigo naturalis extract in oil ointment|Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
40968130|NCT02427893|DRUG|Cobimetinib|A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
40968131|NCT02427893|DRUG|Vemurafenib|A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
40968132|NCT01200602|DRUG|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
40968133|NCT01200602|OTHER|clinical observation|No treatment is given.
41457739|NCT00490503|PROCEDURE|Magnetic Resonance Spectroscopy (MRS)|3 MRI Scans with MRS performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
41457740|NCT00061776|DRUG|Capsaicin Dermal Patch|
40968134|NCT04942444|OTHER|Dry needling|One-hour weekly session of DN in the 18th tender points during 6 weeks in the DNG, apart from continuing their medical treatment. The CG continue with the habitual medical treatment.
41457741|NCT01362192|DEVICE|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|"The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~* Spot Size: 5 mm~* Fluence: 13-15 J/cm2~* Pulse Duration: 40 ms~* Epidermal contact-cooling: 5° Celsius"
40968135|NCT02753868|BEHAVIORAL|exercise|Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
40968136|NCT02753868|PROCEDURE|Hemodialysis treatment|Participants will receive a standard hemodialysis treatment during the study period
40968137|NCT04813198|BEHAVIORAL|TIPSTART|TIPSTART is a multimodal, cognitive behavior-based therapy integrating peer-sharing, technology, aerobic and resistance training.
40968138|NCT05277324|OTHER|Protective facial mask|Participants, students of health related professions, who wear protective facial mask daily during their internship/practice in health institutions.
40968139|NCT04743739|DRUG|Rituximab|Rituximab 1000mg, I.V. on Days 1 and 181, and will be retreated or not at Days 15 and 195 according to the CD19+ B cell count.
40968140|NCT04743739|DRUG|cyclosporine|cyclosporine (CsA) will be started at a dose of 3mg/kg/d and adjusted according to the blood levels of the CsA. CsA will be tapered after 6 months and discontinued over a three month period.
40968141|NCT00870792|BEHAVIORAL|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
40968142|NCT00318630|DRUG|Rosiglitazone|Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
40968143|NCT00318630|DRUG|Placebo|Subjects will also receive placebo oral tablet.
40968144|NCT03856892|OTHER|High Dose Yoga|"Participants engage in an intensive full yoga practice of hatha breath-based practices and inner meditative techniques along with body-based asana. Intensive level uses breath, management of abdomen, inner focus in all practices. The high dose of yoga is an interpretation of the Translational Model of Yoga (TMY) and Yoga Process formula, both developed in this study's cultural research: a systematized psycho-physical yoga method of Hatha Zone (HZ) focus (below-navel, exhale, inner focus), incorporating key components of practice-focus-surrender (PFS) approach and repeat-engage-trust (RET) elements."
40968145|NCT03856892|OTHER|Medium Dose Yoga|"The medium dose of yoga is a regular practice of primarily body-posture training with minimal reference to the breath, but with a longer period of time duration in training prior to intervention commencement. Participants have 5 months of pre-training before initiating the intervention."
40968146|NCT00612040|DRUG|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
40968147|NCT00612040|DRUG|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
40968148|NCT00612040|DRUG|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
40968149|NCT00612040|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
40968150|NCT01134276|PROCEDURE|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
41146855|NCT01280721|DRUG|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
41457742|NCT04883450|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit
40768381|NCT05457725|BEHAVIORAL|Non-contingent/sham rtfMRI neurofeedback training|Non-contingent/sham rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about non-contingent/sham brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
40768382|NCT05246566|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
40768383|NCT03794947|PROCEDURE|Remote Ischaemic Conditioning|Induced ischaemia to a limb by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg).
40768384|NCT03794947|PROCEDURE|Sham Intervention|The sham intervention will inflate pressure cuffs to much lower levels for the same number of cycles.
41457743|NCT01899053|DRUG|TAK-228|TAK-228 Capsules
40968151|NCT02877381|PROCEDURE|Revision Total Knee Arthroplasty (TKA)|Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
40968152|NCT02877381|PROCEDURE|Revision Total Hip Arthroplasty (THA)|Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
41296137|NCT00800033|DIETARY_SUPPLEMENT|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
41296138|NCT02402192|DRUG|Corifollitropin alfa|
41457744|NCT01899053|DRUG|TAK-117|TAK-117 Capsules
40768385|NCT05905302|OTHER|Forced and Voluntary Exercise|Participants will complete a forced exercise (FE) and voluntary exercise (VE) session. Forced exercise is a mode of high intensity exercise in which voluntary exercise rate is augmented, but not replaced. Voluntary exercise is standard stationary cycling. FE and VE exercise sessions will be Off antiparkinsonian medication. The order in which exercise session is conducted first will be randomized. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre, during FE or VE and post-exercise).
41457745|NCT06228196|DEVICE|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
41457746|NCT03379636|DEVICE|kinesiotape|Application of an elastic beige 5-cm width Leukotape®K (BSN medical, Germany). The first strip, a Y-strip, was applied with 10% to 15% of tension over the deltoid muscle, from origin to insertion with the first tail along the anterior deltoid while the arm was externally rotated and horizontally abducted. The second tail was applied along the posterior deltoid with the arm horizontally adducted and internally rotated. A second strip, an I-strip, was applied for mechanical correction, transversally in the sagittal plane over the acromioclavicular joint with a downward pressure applied to the KT, the arm being at trunk side
41457747|NCT03379636|DEVICE|sham tape|a rigid Leukotape®Classic (BSN medical, Germany) was used. A 5-cm strip was applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area.
41457748|NCT05721469|BEHAVIORAL|Art therapy|Determining the mothers of children with eating disorders with the data obtained from the questionnaires and scales and separating them into randomized experimental and control groups, 8-12 sessions of 90 minutes of music, painting, ceramics, etc. were given to the mothers participating in the experimental group. Art Therapy Studies
40768386|NCT00000884|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
40768387|NCT00000884|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
40768388|NCT00000884|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
40768389|NCT06217302|DRUG|Sotagliflozin|Oral sotagliflozin (200 mg per day)
40768390|NCT06217302|DRUG|Placebo|Inactive tablets identical to sotagliflozin tablets
40768391|NCT05198830|DRUG|Carboplatin|Given IV
41457749|NCT03326167|OTHER|Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)|Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
41457750|NCT02250651|DRUG|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
40768392|NCT05198830|DRUG|Cisplatin|Given IV
40768393|NCT05198830|PROCEDURE|Computed Tomography|Undergo CT and FDG-PET/CT
41296139|NCT01011881|OTHER|pleural level of procalcitonin|no intervention
41296140|NCT02823262|OTHER|Breast Cancer Treatment Decision Aid for women 70+|We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.
41296141|NCT02823262|OTHER|Usual Care|
41296142|NCT01772225|OTHER|Data collection|Medical record abstraction form and patient survey questionnaire.
40968153|NCT04302298|DEVICE|Virtual Reality|A machine which immerses the participant in a simulated environment where they can perform a procedure.
41138190|NCT04490694|PROCEDURE|TACE|Patients will be treated with TACE 2-4 weeks after randomization: the blood supply of the tumor will be evaluated by transradial / femoral artery approach, microcatheter will be inserted into the tumor feeding artery, and lipiodol plus epirubicin emulsifier will be injected (40mg epirubicin will be added to each 10ml lipiodol, the total amount should less than 20ml, epirubicin 40-60mg). Gelatin sponge particles / microspheres are used to strengthen embolization. Blood biochemical examination will be performed within 1 week before TACE, 3 days after operation and 1 month after operation.
40768394|NCT05198830|BIOLOGICAL|Durvalumab|Given IV
40768395|NCT05198830|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
40768396|NCT05198830|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40768397|NCT05198830|DRUG|Methoxyamine|Given PO
40768398|NCT05198830|DRUG|Pemetrexed|Given IV
40768399|NCT05198830|RADIATION|Radiation Therapy|Undergo thoracic radiation
40768400|NCT06625372|DIETARY_SUPPLEMENT|SMOF lipid|The SMOF lipid is given to the patient as a fat component of total parenteral nutrition.
40768401|NCT06625372|DIETARY_SUPPLEMENT|INTRALIPIDS|The Intralipid will be given to the patient as fat component of total parenteral nutrition.
40968155|NCT03539081|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry Scan|Body composition analysis will be obtained by DEXA scan.
40968156|NCT03539081|OTHER|Laboratory Measurements|The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).
40968157|NCT03539081|OTHER|Blood Flow Measurement|The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.
40968158|NCT03539081|OTHER|Continuous Blood Pressure|Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
40968159|NCT03539081|OTHER|Partial pressure of oxygen|Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.
40768402|NCT06541951|OTHER|Services as usual|During this phase of the stepped wedge design, agencies offering prenatal and postnatal care will follow their standard procedures
40768403|NCT06541951|OTHER|Scale-up implementation approach|An implementation approach for scaling up bundled equity-focused maternal health safety guidelines in community care settings county-wide, co-developed with partners. It may involve implementation approaches such as training, facilitation, learning collaboratives, coalitions, and other activities.
40768404|NCT06361173|OTHER|BMT4me|Caregivers will pilot test a Spanish version of the BMT4me app at a single time point.
41138191|NCT05819268|BEHAVIORAL|ReACT|ReACT includes 12 sessions with a therapist that will discuss a plan for managing FS.
40768405|NCT06058832|DEVICE|Low-intensity Shockwave Therapy|patients will receive 6 sessions, once per week of low-intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level plus Sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.
40768406|NCT06058832|OTHER|Kegel Exercises|"* The patient was asked to perform short (1 second) and long-lasting (6-10 seconds) contractions of the target muscles. Later, the exercises will do with the patient sitting or standing.~* Patient asked to repeat the contractions daily. Each patient performed 15 short and 15 long-lasting contractions in a prone, sitting, or standing position. Patients asked to do 30 contractions in the morning 30 contractions in the evening"
40768407|NCT00738660|DRUG|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
40768408|NCT01893086|PROCEDURE|LH alone|LH, laparoscopic hysterectomy
40768409|NCT01893086|PROCEDURE|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
40768410|NCT04649099|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
40768411|NCT05987813|DEVICE|TENS Unit|Usage of the Transcutaneous Electrical Nerve Stimulation device for 2 hours a day.
40768412|NCT06333678|DRUG|Durvalumab|10 mg/kg IV every 2 weeks or 1500 mg/kg IV every 4 weeks for up to 12 months.
40768413|NCT06333678|DRUG|Sotorasib|960 mg, Patients who do not tolerate sotorasib at 960 mg can be dose reduced to 120 mg.
40768414|NCT06557850|DRUG|Lu AG22515|Solution for infusion
40968160|NCT03539081|OTHER|Microneurography|The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.
40968161|NCT03539081|OTHER|Anthropometric Measurements|Height and weight will be obtained.
41138192|NCT05819268|BEHAVIORAL|CATCH-IT|CATCH-IT involves the parent and child completing CBT modules on the web-based CATCH-IT platform, and they will meet with a CATCH-IT coach 12 times to discuss the modules and plan how to apply this to their life and their FS.
41138193|NCT06509230|OTHER||The fibrosis grades were grouped without drug intervention
41138194|NCT00035048|DRUG|aprepitant|
41138195|NCT00035048|DRUG|Comparator: placebo (unspecified)|
40768415|NCT06486064|DIETARY_SUPPLEMENT|heat-treated Limosilactobacillus fermentum|one capsule daily for 8 weeks
40768416|NCT06486064|DIETARY_SUPPLEMENT|Placebo|one capsule daily for 8 weeks
40768417|NCT05548296|DRUG|ACR-368|ACR-368 is an experimental drug
40768418|NCT05548296|DRUG|Gemcitabine|Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368
40768419|NCT05548296|DIAGNOSTIC_TEST|OncoSignature|Biomarker profile based on prediction of drug sensitivity performed on biopsy tissue
40768420|NCT04614337|DRUG|LUM-201|Administered orally once daily
41138196|NCT01695044|DRUG|PSMA ADC|PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
41296143|NCT03591029|OTHER|blood samples|blood samples will be obtained from the superior vena cava (via centra venous catheter), from the pulmonary artery (via Swan Ganz catheter), and from a radial or femoral artery catheter
41296144|NCT01004146|PROCEDURE|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
40968162|NCT03539081|BEHAVIORAL|John Hopkins Restless Legs Severity Scale|Subjects will be administered questionnaires to evaluate RLS symptoms using John Hopkins Restless Legs Severity Scale.
41296145|NCT01084499|DRUG|Femara (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
40768421|NCT04614337|DRUG|rhGH Norditropin® pen (34 µg/kg)|Administered subcutaneously (s.c., under the skin) once daily.
40768422|NCT06206720|DRUG|Deuremidevir Hydrobromide for Suspension|"15 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg TID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension 3 times every day, total 15 times."
40968163|NCT03539081|BEHAVIORAL|Continuous Blood Pressure Diary|Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.
40968164|NCT01220375|DRUG|Vinorelbine, G-CSF, & Plerixafor|Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
40968165|NCT01220375|DRUG|Vinorelbine and Plerixafor|Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
40968166|NCT01220375|DRUG|G-CSF and Plerixafor|Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
40968167|NCT01220375|DRUG|Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood|Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
40968168|NCT03947320|DRUG|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
40968169|NCT05886829|COMBINATION_PRODUCT|Chlorpheniramine Maleate 0.4% Nasal Spray|Chlorpheniramine Maleate 0.4% Nasal Spray
40968170|NCT05886829|COMBINATION_PRODUCT|Placebo|Placebo nasal spray
40968171|NCT00139698|DRUG|olmesartan alone or in combination with hydrochlorothiazide|
40968172|NCT01925105|OTHER|Experimental: Optimization of treatment|Optimization of treatment of diseases and symptoms
40968173|NCT03500354|DIETARY_SUPPLEMENT|Nutrient drink|High calorie drink with therapeutic supplements
40968174|NCT05457764|DEVICE|Virtual reality headset|"The VR headset was a Pico G2, Pico Interactive, San Fransisco, USA, offering a choice from 60 erotic videos each of 10-30 minutes duration. The men were allowed to watch any and as many of these video clips as they wished. The No VR arm, donors used the computer monitor available in the donation rooms."
40968175|NCT00245115|BIOLOGICAL|filgrastim|
40968176|NCT00245115|DRUG|busulfan|
40968177|NCT00245115|DRUG|cyclophosphamide|
40968178|NCT00245115|PROCEDURE|in vitro-treated bone marrow transplantation|
41296146|NCT01084499|DRUG|Peratra (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
41296147|NCT01084499|DRUG|Femara (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
40968179|NCT00245115|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
40968180|NCT02532491|DRUG|Aripiprazole|Initial dose: 10 mg.
40968181|NCT02532491|DRUG|Risperidone|Initial dose: 2 mg.
40968182|NCT01260636|DRUG|Gadobenate Dimeglumine|0.1 mmol/kg, single dose
40768423|NCT06206720|DRUG|Placebo|"15 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg TID group: 5 subjects will receive placebo 3 times every day, total 15 times."
40768424|NCT03619980|OTHER|No intervention|Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
40768425|NCT04100018|BIOLOGICAL|Nivolumab|Specified dose on specified days
40768426|NCT04100018|DRUG|Prednisone|Specified dose on specified days
40768427|NCT04100018|DRUG|Docetaxel|Specified dose on specified days
40768428|NCT04100018|OTHER|Placebo|Specified dose on specified days
40768429|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 25 mg
40768430|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 50 mg
40768431|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 75 mg
40968183|NCT01260636|DRUG|Gadopentetate Dimeglumine|Double dose of 0.2 mmol/kg
40968184|NCT00387023|DRUG|Rituximab|250 mg/m\^2 IV over 4-6 hours for 2 weeks.
40968185|NCT00387023|DRUG|Zevalin|5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
40968186|NCT00596375|PROCEDURE|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
41296148|NCT01084499|DRUG|Peratra (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
41296149|NCT03985072|DRUG|Andes-1537 for Injection|Andes-1537 administered subcutaneously five days per week.
41296150|NCT04743037|BEHAVIORAL|iSMART|This patient-centered and participation-focused self-management intervention will help individuals develop strategies to manage chronic conditions and support their full participation in meaningful life activities.
41296151|NCT05807022|PROCEDURE|Percutaneous or transbronchial argon-helium cryoablation|The participants would undergo Percutaneous or transbronchial argon-helium cryoablation.
41296152|NCT01558089|DRUG|etanercept|according to SmPC and clinical practice
41296153|NCT01558089|DRUG|methotrexate|according to SmPC and clinical practice
40768432|NCT05944692|DEVICE|Tripolar electroencephalography|We will record physiological signals with the tripolar electroencephalography
40768433|NCT06272578|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
40968187|NCT00596375|DRUG|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
40968188|NCT00607971|DRUG|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
40768436|NCT05987449|DRUG|NXT007|Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
40768437|NCT01400412|DRUG|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
40768438|NCT01400412|DRUG|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
40968189|NCT00717132|BEHAVIORAL|Individual Behavior Modification|Individual behavioral treatment for obesity. Children and parents meeting individually for 15 total behavioral modification intervention sessions.
40968190|NCT00717132|BEHAVIORAL|Family-based behavior modification|Family-base behavior treatment for obesity. Children and parents meeting together for 15 total behavioral modification intervention sessions.
40968191|NCT01310101|DRUG|ofatumumab plus dexamethasone|"Dose and schedule~Cycle 1:~Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18~Cycles 2 to 6 (cycles every 28 days):~Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18"
40968192|NCT05830591|OTHER|Characterization of the microbiome in oral and fecal samples|The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.
40968193|NCT05701527|DRUG|EBC-129|EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
40968194|NCT05701527|DRUG|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.
40968195|NCT01826604|DEVICE|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used.
40968196|NCT01826604|OTHER|Control- Conventional retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
40968197|NCT05708183|DIETARY_SUPPLEMENT|Multiple micronutrient supplementation (MMS)|Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.
40968198|NCT05708183|DIETARY_SUPPLEMENT|Iron folate supplementation (IFA)|IFA delivered as part of routine antenatal care, according to current policy
41138197|NCT02467985|PROCEDURE|FIGARO|flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
41138198|NCT02944981|DRUG|Gabapentin|Single oral dose
41138199|NCT02944981|DRUG|Placebo|Single oral dose
40768439|NCT01400412|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
40768440|NCT01400412|DRUG|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
40768441|NCT01400412|DRUG|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
40768442|NCT01400412|DRUG|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
40768443|NCT01400412|DRUG|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
40968199|NCT05541770|OTHER|Survey|Healthcare workers/Physicians involved in cancer diagnosis \& management in the Arab countries should respond to a survey
41138200|NCT05414825|OTHER|focus group interview|Group interview gathering words, views, symptoms and its repercussions, and main issues of the subjects regarding severe dysmenorrhea
41296154|NCT01955174|DRUG|Esophageal endoscopic injection of botulinum toxin|Endoscopic injection of botulinum toxin in the esophageal muscle : one hundred units of type A botulinum toxin (Botox®, Allergan) diluted in 10 mL of normal saline and injected at the lower third of the esophageal wall in 10 sites between 2 and 10 cm above the Z-line.
41296155|NCT01955174|OTHER|No injection of botulinum toxin|Upper gastro-intestinal endoscopy without any injection
41296156|NCT04973111|DRUG|CT-868 as SC Injection|CT-868
41296157|NCT04973111|DRUG|Placebo as SC Injection|Placebo
41296158|NCT04973111|DRUG|Active Comparator as SC Injection|Active Comparator
41296159|NCT05923905|DRUG|FB1006|30mg/day
41296160|NCT05923905|DRUG|Placebo|30mg/day
41296161|NCT04742153|DRUG|MRG002|Administrated intravenously
41457751|NCT02250651|OTHER|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
41457752|NCT02250651|DRUG|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
40968200|NCT04344392|DIAGNOSTIC_TEST|Ultrasonographic study|Thyroid hyoid approximation and hyoid anterior replacement during swallowing. Tongue thickness in rest.
40968201|NCT04344392|DIAGNOSTIC_TEST|Videofluoroscopic study temporal parameters|Glossopalatine junction opening and closing time, velopharyngeal junction opening and closing time, laryngeal vestibule opening and closing time, upper esophageal sphincter opening and closing time in seconds.
40968202|NCT04344392|DIAGNOSTIC_TEST|Videofluoroscopic study distance parameters|Hyoid bone horizontal and vertical replacement, thyroid-hyoid approximation (THA) in millimeters.
40968203|NCT06501638|DRUG|Memantine Hydrochloride 10 MG|Take Memantine Hydrochloride for intervention First week, 5mg(half the tablet), p.o.，bid. Second to Sixth week, 10mg(one tablet), p.o., bid
40968204|NCT06501638|DRUG|Placebo|Take placebo for intervention First week, half the tablet, p.o., bid. Second to Sixth week, one tablet, p.o., bid
40968205|NCT05621785|DEVICE|Lung Ultrasonografi|All babies under 32 weeks of gestation will be included in the study. All data of postnatal corticosteroid users will be recorded using lung USG
41296162|NCT03545152|BEHAVIORAL|Exercise|"Prescription exercise: frequency, intensity, type, time, and progression (FITT-PRO).~150 min/week (the intensity will be moderate). exercise routine: warming up, resistance training and aerobic exercise training(range of motion and flexibility exercises)"
40968206|NCT03602183|DEVICE|Macintosh laryngoscope|intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope
40968207|NCT03602183|DEVICE|Miller laryngoscope|intubation will be performed using Miller laryngoscope
40968208|NCT03602183|DEVICE|McGrath MAC EMS|intubation will be performed using McGrath MAC EMS video - laryngoscope
40968209|NCT03602183|DEVICE|GlideScope|intubation will be performed using GlideScope video - laryngoscope
40968210|NCT02137174|OTHER|Home and school visits|Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
40968211|NCT03765905|DIAGNOSTIC_TEST|study|Scube-1 scube-2 scube-3
40968212|NCT04229394|DRUG|2ccPA|"Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1"
41296163|NCT03545152|BEHAVIORAL|Cognitive training|Cognitive training intervention consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
41296164|NCT03545152|BEHAVIORAL|New life-style|Combination of exercise and cognitive interventions
41457753|NCT02250651|DRUG|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
40968213|NCT04229394|DRUG|placebo|"A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1"
40968214|NCT04356950|OTHER|Thrombin generation test assay|lag time, initial velocity, time-to-peak, thrombin peak, total thrombin generation time, extrinsic thrombin potential (ETP). Crude quantitative values and relative values (%, by reference to the one obtained with an invariant reference plasma). Both without the addition of purified thrombomodulin (TM-) and with the addition of purified thrombomodulin (TM+). The ability of TM to inhibit thrombin generation will be calculated as follows: \[ETP (%)(TM+) / ETP (%)(TM-)\].
41296165|NCT03313505|BIOLOGICAL|S100B protein dosage|S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient
41296166|NCT03313505|OTHER|Brain CT scan|No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient
40968215|NCT04356950|OTHER|Fibrin generation markers assays|D-dimers (coagulation plus fibrinolysis), soluble fibrin monomers (coagulation only)
40968216|NCT01292616|DRUG|therapy with disease-modifying anti rheumatic drugs (DMARD)|DMARD drug and dosage is chosen by the treating physician without restriction by the study
40968217|NCT05511909|DRUG|Buspirone|Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
40968218|NCT05511909|DRUG|Lofexidine|Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
41296167|NCT03710785|BEHAVIORAL|cervical spine extension exercise|cervical spine extension exercise for 4 weeks
40768444|NCT06474013|DEVICE|ExAblate 4000 Type 2.1|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.1 system, and this will be performed 3 times every 2 months.
40968219|NCT05511909|DRUG|Placebo|Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
40968220|NCT01775085|BEHAVIORAL|manualized group intervention|MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts \& Sources of Meaning; 2) Identity, Cancer Survivorship, \& Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present \& Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity \& Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, \& Humor; and 8) Transitions: Reflections \& Hopes for the Future.
40968221|NCT01775085|BEHAVIORAL|standardized, manualized group intervention|DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
41296168|NCT04919486|BEHAVIORAL|visual feedback with non-weight bearing exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
40968222|NCT06465394|PROCEDURE|Exercise|Neck exercises in a cross over design that the participants will do both types of interventions with a washout period inbetween.
40968223|NCT00089154|BIOLOGICAL|apolizumab|Given IV
40968224|NCT00089154|OTHER|laboratory biomarker analysis|Correlative studies
41296169|NCT04919486|BEHAVIORAL|elastic band exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
41296170|NCT00038259|DRUG|Aldesleukin|
41296171|NCT04813146|OTHER|SLP|Synchronization of dietary intake with circadian rhythm of the body
41296172|NCT04813146|OTHER|SLP along with Physiotherapy|Synchronization of dietary intake along with Physiotherapy (aerobic, flexibility, resistance and balance exercises)
41296173|NCT04813146|OTHER|Physiotherapy|Physiotherapy given only (aerobic, flexibility, resistance and balance exercises)
41296174|NCT00886132|DRUG|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
40768445|NCT06617455|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40768446|NCT06617455|DRUG|Fezolinetant|Given PO
40768447|NCT06617455|DRUG|Placebo Administration|Given PO
40768448|NCT06617455|OTHER|Quality-of-Life Assessment|Ancillary studies
40968225|NCT00089154|OTHER|pharmacological study|Correlative studies
40968226|NCT06376279|GENETIC|IEM-EP|Data from IEM-inborn error of metabolism cohort of individuals
40968227|NCT01251601|OTHER|Pharmacokinetics|Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
40968228|NCT00889460|BIOLOGICAL|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
40968229|NCT00889460|BIOLOGICAL|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
41296175|NCT02145910|DRUG|Vemurafenib|Given PO
41296176|NCT02145910|RADIATION|Whole-brain radiation therapy (WBRT)|Undergo WBRT
41296177|NCT02145910|RADIATION|Radiosurgery (SRS)|Undergo SRS
41296178|NCT00973830|OTHER|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
41296179|NCT01729598|DRUG|Valproic Acid|generic valproic acid tablets packaged in placebo-matched capsules.
41296180|NCT01729598|DRUG|Placebo|Placebo capsule without active study medication in identical capsules as experimental medicine.
41296181|NCT00089180|DRUG|liposomal T4N5 lotion|Given topically
41296182|NCT00089180|OTHER|placebo|Given topically
41296183|NCT00089180|OTHER|laboratory biomarker analysis|Correlative studies
41457754|NCT03750695|BEHAVIORAL|Resistance exercise|One acute exercise session of resistance exercise (40 minutes including 3 sets of 8-10 repetitions at the participant's 10 repetition maximum load of upper and lower extremity exercise
41457755|NCT03750695|BEHAVIORAL|Aerobic Exercise|One acute session of aerobic exercise (40 minutes of cycle ergometry exercise at 70% of VO2peak)
41457756|NCT03750695|BEHAVIORAL|Rest|40 minutes of quiet rest in semi-recumbent position
41457757|NCT00128219|BIOLOGICAL|GBS III-TT|50 mcg GBS Type III capsular polysaccharide conjugated to 32 mcg of tetanus toxoid. A single dose of vaccine administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml.
41457758|NCT00128219|BIOLOGICAL|Tetanus and diptheria toxoids vaccine|Td vaccine is a sterile solution of alum-precipitated toxoids in isotonic sodium chloride solution. A single dose of vaccine will be administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml. Each 0.5 ml dose is formulated to contain 5 Lf (flocculation units) of tetanus toxoid and 2 Lf of diphtheria toxoid.
41457759|NCT02146690|OTHER|osteopathic manipulative treatment|
41457760|NCT02146690|OTHER|sham therapy|
41457761|NCT02146690|OTHER|usual care|
41457762|NCT00211562|DRUG|Olanzapine, Omega 3, Vitamin E+C|No adverse event nor SAE noted.
40968230|NCT04388618|OTHER|NHANES smell and taste tests|participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected
40968231|NCT02152033|BEHAVIORAL|Home-based Continuing Care|All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.
41296184|NCT04324827|DEVICE|Graston Technique|FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.
41296185|NCT04324827|OTHER|Dynamic stretch exercise|Dynamic stretch includes controlled movements in the active ROM for a joint. This type of exercise is actually the basis of sports movements used in training or competition.
41296186|NCT02209597|DRUG|Bupropion XL 300|"Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
41296187|NCT00282165|DRUG|naratriptan|four weeks double blind experimental treatment using oral naratriptan
41457763|NCT02190318|DRUG|Losartan|
41296188|NCT00282165|DRUG|placebo|four weeks double blind placebo treatment
41296189|NCT01383044|PROCEDURE|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
41296190|NCT01383044|DRUG|carvedilol|carvedilol 6.25mg-12.5 mg per day
41457764|NCT02190318|DRUG|spirolactone|
41457765|NCT02190318|OTHER|blank control|
41457766|NCT06388733|DRUG|Niraparib|Participants will receive niraparib 200 mg orally once daily starting on Day 1 of RT. Following completion of RT, participants will continue niraparib adjuvant therapy orally once daily on Days 1 to 28 of each 28-day cycle until progression by BICR
40768449|NCT06617455|OTHER|Questionnaire Administration|Ancillary studies
41457767|NCT06388733|DRUG|Temozolomide|Participants randomized to the comparator arm (Arm B) will receive SOC TMZ 75 mg/m2 orally once daily with RT starting on Day 1 of RT. Following completion of RT, participants will complete a 4-week rest period, and then receive adjuvant TMZ 150 to 200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle until progression by BICR or for a maximum of 6 cycles.
41457768|NCT01866124|OTHER|Cash transfer|Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
41457769|NCT01580046|DRUG|iodixanol|"1. coronary angiography, 32gI/100ml, 40～60 ml once injection~2. left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection"
41457770|NCT01580046|DRUG|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
41457771|NCT00646984|DRUG|Standard continuous antiretroviral therapy|
41457772|NCT00646984|DRUG|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
40968232|NCT02152033|BEHAVIORAL|Services as Usual|Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
40968233|NCT01408485|DEVICE|Therapy™ Cool Flex™ Irrigated Ablation System|"The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~* Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~* IBI 1500T9 V1.43 RF Generator"
40768450|NCT03631511|PROCEDURE|direct pulp capping with RetroMTA|The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
40768451|NCT04663308|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
40968234|NCT02407353|DRUG|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
40968235|NCT02407353|DRUG|Placebo|Placebo which will be dosed as oral suspension, single doses to match PF-06648671
40968236|NCT01734863|RADIATION|External Beam Radiotherapy|
40968237|NCT03613545|PROCEDURE|fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
40968238|NCT03613545|PROCEDURE|Infusion of sham|Infusion of sham
40968239|NCT03613545|DRUG|probiotics, antibiotics or antidepressants|Drugs such as probiotics, antibiotics, antidepressants
41138201|NCT05211596|BEHAVIORAL|Deaf Weight Wise intervention|The DWW intervention consists of groups of 5 subjects who meet together for 16 weeks, 2 hours each week. Group meetings will be held virtually on Zoom. A trained, deaf, ASL-fluent counselor will lead the sessions. Each session includes group sharing, problem solving, discussion of a weight management topic, and goal setting and action planning for the next week. A key principle of DWW is motivational interviewing, in which the counselor acts as a facilitator to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The maintenance phase starts immediately after the 16-week intervention, and consists of two meetings of the original group via Zoom; one at month 3 and one at month 6 of the maintenance period. Counselors also email participants bi-weekly to check in and provide additional support.
41138202|NCT00704340|DEVICE|DuraSeal Dural Sealant System|The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
41138203|NCT00704340|OTHER|Standard of Care|Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
41138204|NCT01009645|BEHAVIORAL|Fact Only Education Message|Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
41138205|NCT01009645|BEHAVIORAL|Fact and Myth Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.
41138206|NCT01009645|BEHAVIORAL|Fact, Myth, Why Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.
41138207|NCT01009645|BEHAVIORAL|Control Educational Message|Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
41138208|NCT00157794|DEVICE|Search AV+ algorithm|
41138209|NCT04325737|DRUG|SEP-363856|Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
40768452|NCT04663308|DRUG|Placebo|Capsules matched to study drug minus active substance
40768453|NCT05327647|DRUG|Bicalutamide|Induction intravesical BCG with bicalutamide 150 mg for 90 days
40768454|NCT05327647|BIOLOGICAL|Control Arm|Induction BCG
40768455|NCT06066333|RADIATION|Ablative Radiotherapy|All participants will first undergo ablative RT
40768456|NCT06066333|DRUG|Pembrolizumab|After completion of ablative RT, all subjects may begin pembrolizumab treatment
40768457|NCT06625437|BEHAVIORAL|Acceptance and commitment therapy|Acceptance and commitment therapy is a psychotherapy focused at increasing psychological flexibility and an individual\&#39;s engagement in valued activities rather than focusing solely or primarily on reducing psychiatric symptoms
40768458|NCT05214573|DRUG|Glucagon like peptide 1 receptor agonist|Patients in the data who filled a glucagon-like peptide-1 receptor agonist medication
41296191|NCT03061968|BEHAVIORAL|acupressure|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
40968240|NCT03604380|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
40768459|NCT05214573|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients in the data who filled a sodium-glucose cotransporter 2 inhibitor
40968241|NCT03604380|OTHER|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
40968242|NCT05027100|DRUG|Anlotinib Tislelizumab Irinotecan|Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
40968243|NCT01927237|OTHER|HLR|
40968244|NCT01927237|OTHER|EHR|
40968245|NCT00790985|DIETARY_SUPPLEMENT|flavocoxid|medical food
40968246|NCT00790985|DRUG|Naproxen|antiinflammatory drug
40968247|NCT02535988|RADIATION|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
40968248|NCT02535988|DRUG|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
40968249|NCT03192111|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
40968250|NCT01120002|DRUG|Tamibarotene|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
41138210|NCT04325737|DRUG|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
41138211|NCT01768585|DRUG|Ivabradine|Please see description of Intervention Arm
41138212|NCT01768585|DRUG|Placebo|
41138213|NCT03130946|DEVICE|Cryo-assisted core needle biopsy|Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.
41138214|NCT03130946|DEVICE|FNA|FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
41138215|NCT06177821|DEVICE|Rezum®|Rezum® Water vaporization device
41138216|NCT01867307|DRUG|Empagliflozin|
41138217|NCT01867307|DRUG|BI 10773|open label
41138218|NCT03876886|DRUG|Epirubicin|Epirubicin 90mg/m2 iv d1 or divide into two days
41457773|NCT00646984|DRUG|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
41457774|NCT05447416|DEVICE|Hyperbaric Oxygen Therapy - HBOT|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
40768460|NCT05214573|DRUG|Dipeptidyl Peptidase 4 Inhibitor|Patients in the data who filled a dipeptidyl peptidase-4 inhibitor
40768461|NCT05214573|DRUG|Sulfonylurea|Patients in the data who filled a sulfonylurea
40768462|NCT06500130|DEVICE|Body Surface Gastric Mapping|All study participants will be in this group and will have a total of three body surface gastric mapping tests conducted, pre, during and post liraglutide.
40968251|NCT01120002|DRUG|Placebo|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
41138219|NCT03876886|DRUG|Cyclophosphamide|cyclophosphamide600mg/m2 iv d1,q14d\*4cycles;with G-CSF support: 3ug/kg ih
41138220|NCT03876886|DRUG|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d\*4cycles
41138221|NCT03876886|DRUG|Carboplatin|carboplatin AUC=3 iv d2, q14d\*8cycles;with G-CSF support: 3ug/kg ih
41138222|NCT03876886|DRUG|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d\*8cycles
41138223|NCT00120107|DRUG|Black Tea|
41138224|NCT04249440|PROCEDURE|Preoperative systemic treatment|neoadjuvant chemotherapy combined with trastuzumab as preoperative systemic treatment
40968252|NCT01343498|DRUG|BEZ235|BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
40968253|NCT01468012|DRUG|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily
40968254|NCT01468012|DRUG|Placebo|matched placebo for LCE condition dosed twice daily
40968255|NCT04964310|GENETIC|genetic polymorphism|Observe the genetic polymorphism frequency difference between case and control groups
40968256|NCT00413127|DRUG|lidocaine|administration of lidocaine intravenously or epidural or administration of placebo
40968257|NCT00413127|DRUG|NaCl 0,9%|Administration of placebo i.v.
40968258|NCT01611649|DIETARY_SUPPLEMENT|Formula containing dairy lipids and plant oils|4 months consumption
41138225|NCT03133572|DEVICE|Supraglottic airway|Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
41138226|NCT03133572|DEVICE|Face-mask|In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
41138227|NCT04928937|PROCEDURE|Roux-en-Y gastric bypass, sleeve gastrectomy|bariatric surgery with the goal loosing weight
41138228|NCT03226600|DEVICE|OrACELL|OrACELL is human dermis that undergoes the MATRACELL process. MATRACELL is a patented and validated process that renders allograft tissue acellular, without compromising the biomechanical or desired biochemical properties of an allograft bio-implant for its intended surgical application.
40968259|NCT01611649|DIETARY_SUPPLEMENT|Formula containing plant oils|4 months consumption
40768463|NCT06014983|DIETARY_SUPPLEMENT|Ferrous fumarate|Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.
40768464|NCT06014983|DIETARY_SUPPLEMENT|Ferrous bisglycinate|Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.
40968260|NCT01611649|DIETARY_SUPPLEMENT|Formula containing dairy lipids and plant oils, DHA+ARA|4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
40968261|NCT03753529|OTHER|Deep friction massage|Submitted to three session weekly 30-minute sessions of therapy will performed by the administration of sliding and kneading maneuvers of the masseter and temporalis muscles, bilaterally,lateral pterygoid and digastric over four consecutive weeks (total:12 sessions) Sliding consisted of a unidirectional movement in which part of the therapist's hand (mainly the fingertips) will used, moving from the proximal to the distal portion of the face with constant, progressive pressure compatible with the status of each tissue. The degree of pressure varied depending on the level of pain, sensitivity and tension in each individual. Kneading consisted of a gripping maneuver of a muscle group or portion of a muscle.Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
40968262|NCT03753529|OTHER|Pressure release|First, using a pincer grasp moved throughout the fibers of the pterygoid, masseter, digastric and temporalis muscles to palpate the muscle aiming to locate a trigger point . A common location is detected according to Simon and Travell book. Once located on the trigger point, apply an IC by gradually applying pressure to the trigger point with your thumb. Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points were treated. Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
40968263|NCT03753529|OTHER|control group|Stretching and transcutaneous electrical nerve stimulation
40968264|NCT05850546|DRUG|Rituximab|Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy
40968265|NCT05850546|DRUG|Corticosteroid|guideline-recommended corticosteroid therapy
40968266|NCT05647655|DEVICE|Ultrasonography|Bedside thoracic ultrasound for patients complaining of acute dyspnea.
41138229|NCT03226600|DEVICE|Connective Tissue Graft|A measured layer of dermis is surgically removed from the palate for use as a graft to cover gingival recession
41146856|NCT01249378|OTHER|All subjects receive three sequences of a standard breakfast|"All subjects receive three sequences of a standard breakfast containing :~* 10 g non emulsified~* or 40 g non emulsified~* or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions"
41457775|NCT05447416|DEVICE|Intermittent Hypoxic Training - IHT|Each session lasts 60 minutes of 15.2% oxygen at 1.0 ATA. Subjects will be training according to individualized training protocol.
40768465|NCT02103179|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
41457776|NCT02144844|BEHAVIORAL|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
40768466|NCT06213831|DRUG|Ruxolitinib Cream 1.5%|Ruxolitinib Cream 1.5%
40768467|NCT05580042|DRUG|AC-1101|For each patient, once daily (QD)
40768468|NCT03574363|DRUG|KBP-5074 0.25 mg tablet|Oral administration, QD, 84 days
40768469|NCT03574363|DRUG|KBP-5074 0.5 mg tablet|Oral administration, QD, 84 days
40768470|NCT04683848|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
40768471|NCT04683848|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
40968267|NCT06347835|DIETARY_SUPPLEMENT|symbiotic|The intervention is made up of multiple probiotics and prebiotics (20g/d) and dietary pattern modification.
40968268|NCT06347835|DIETARY_SUPPLEMENT|whey protein|The intervention is made up of whey protein supplements (20g/d) and dietary pattern modification.
40968269|NCT06347835|DIETARY_SUPPLEMENT|symbiotic placebo|The intervention is made up of maltodextrin (20g/d) and dietary pattern modification.
40968270|NCT06347835|DIETARY_SUPPLEMENT|whey protein placebo|The intervention is made up of maltodextrin (20g/d) and dietary pattern modification.
40968271|NCT04316065|DRUG|YHP1906|YHP1906 Tab. 5 mg
40968272|NCT04316065|DRUG|YHR1902|Comparator. YHR1902 Tab. 5 mg
40968273|NCT03547583|DRUG|Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
40968274|NCT03547583|DRUG|Placebo|Placebo and sham up-titration at weeks 2, 4, and 6
40968275|NCT01145443|OTHER|Alternative Intensivist staffing models.|During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
41457777|NCT03820258|DRUG|SOF/VEL/VOX|Administered once daily with food.
41457778|NCT05712564|OTHER|Questionnaire|Questionnaire for fatigue assessment
40768472|NCT05761756|BEHAVIORAL|Sleep Deprivation|24 hours sleep deprivation
40768473|NCT05761756|DRUG|Caffeine|Oral administration of caffeine
40768474|NCT05761756|DRUG|Methylphenidate|Oral administration of methylphenidate
40768475|NCT05761756|DRUG|Carbon Dioxide|Oral administration of sodium bicarbonate to simulate carbon dioxide exposure
40768476|NCT05983133|DRUG|SGN-EGFRd2|Given into the vein (IV; intravenously)
41457779|NCT04848688|DRUG|Moxidectin 2 mg|Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.
41457780|NCT04848688|DRUG|Ivermectin 3 mg|Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.
40768477|NCT05883709|DRUG|Tafasitamab Injection|The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients
40968276|NCT04070430|OTHER|2 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
40968277|NCT04070430|OTHER|4 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
40968278|NCT00412659|PROCEDURE|Surgery for pilonidal disease, midline excision|A midline excision is made for the treatment of pilonidal sinus disease.
40968279|NCT00412659|PROCEDURE|Surgery for pilonidal disease, Karydakis operation|A Karydakis operation is done for the treatment of pilonidal sinus disease.
40968280|NCT04101877|DRUG|Bevacizumab Injection|25 mg/ml
40968281|NCT04101877|DRUG|Aflibercept Injection|40 mg/ml
40968282|NCT05119452|OTHER|Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)|The biological/targeted synthetic disease modifying anti-rheumatic drug will be discontinued in both arms at baseline
40968283|NCT03066804|DRUG|sacubitril/valsartan|Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
41457781|NCT04848688|DRUG|Placebo|Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
41457782|NCT03264092|PROCEDURE|Endoscopic ultrasound guided fine needle biopsy|Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
41457783|NCT03256227|BEHAVIORAL|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
40768478|NCT00656695|DRUG|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
40768479|NCT00656695|DRUG|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
40768480|NCT03331354|BEHAVIORAL|Distant vocational learning|use of hybrid distance learning to facilitate successful employment outcomes
40768481|NCT03331354|OTHER|Basic vocational services|self-help manual
40768482|NCT03287492|OTHER|Informational Intervention|Receive QPS
40768483|NCT03287492|OTHER|Informational Intervention|Receive GIS
41457784|NCT03256227|BEHAVIORAL|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
41457785|NCT04929730|OTHER|Nephrology care bundle|Nephrology care bundle
41457786|NCT00193323|DRUG|Docetaxel|
41457787|NCT00193323|DRUG|Gemcitabine|
41457788|NCT02946424|DRUG|Placebo Oral Capsule|12 month course of daily placebo
40768484|NCT03287492|OTHER|Questionnaire Administration|Ancillary studies
40768485|NCT04309682|PROCEDURE|crestal sinus approach technique|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm.
40768486|NCT04309682|PROCEDURE|Lateral sinus approach|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place
40768487|NCT06116175|PROCEDURE|60 degree thermal radiofequency of tennis elbow|under strict aseptic technique ultrasound guided TRF of lateral epicondylitis advanced for 5 mm active tip canula
40968284|NCT03066804|DRUG|Enalapril|Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
41457789|NCT02946424|DRUG|Simvastatin|12 month course of daily simvastatin
41457790|NCT05259852|BEHAVIORAL|Food Assistance and Cessation Resources Navigation Plus Economic Assistance|The intervention arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period. In addition, the intervention arm involves providing participants with economic assistance for food in the form of a reloadable debit card ($83 every 4 weeks for 12 weeks, for a maximum amount of $250).
40968285|NCT03066804|DRUG|Valsartan|Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
40968286|NCT03066804|DRUG|Placebo to match sacubitril/valsartan|Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
40968287|NCT03066804|DRUG|Placebo to match enalapril|Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
40968288|NCT03066804|DRUG|Placebo to match valsartan|Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
40968289|NCT00908713|DRUG|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
41457791|NCT05259852|BEHAVIORAL|Food Assistance and Cessation Resources Navigation|The comparison arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period.
40968290|NCT00908713|DRUG|Placebo|Sodium chloride 0.9% 10 mL every 12 h for 5 days
40968291|NCT02664844|BEHAVIORAL|Physical activity|
40968292|NCT03821155|OTHER|Vestibular rehabilitation|Specialized physical therapy aimed at restoring balance
40968293|NCT03821155|DRUG|Corticosteroid|Prednisolone
41457792|NCT01728480|DRUG|entolimod|Given SC
41457793|NCT01728480|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
41457794|NCT01728480|DRUG|cisplatin|Given IV
40768488|NCT03632044|DRUG|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia
40768489|NCT03632044|OTHER|Sham Comparator|The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.
40768490|NCT02538809|OTHER|measurement of tumor mRNA concentration in urine|bed-side test of tumor mRNA concentration in urine
41457795|NCT01728480|OTHER|pharmacological study|Correlative studies
40768491|NCT03557931|DRUG|ASP4345|oral administration
40968294|NCT00795106|DRUG|Capsaicin|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
40968295|NCT00795106|DRUG|Placebo|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
40968296|NCT02672878|DEVICE|Bioresorbable vascular scaffold|
40968297|NCT03414814|DRUG|Osimertinib 80 MG [Tagrisso]|Osimertinib 80mg once daily until disease progression
40968298|NCT03607162|DIAGNOSTIC_TEST|DIAFEVER algorithm|PCT rapid test-based predictive algorithm
40968299|NCT01874132|BEHAVIORAL|Exercise training|Both training programs were of moderate-to-vigorous intensity, three days per week for nine months.
41138230|NCT04050514|DEVICE|H-MAD with a hinge system according to Herbst|"The randomized grouping into blocks at a ratio of 1: 1 takes place over sealed envelopes containing the allocation key for the respective MAD. The assignment is stratified according to gender because gender is a strong predictor of sleep disorders and also temporomandibular dysfunctions Integration of the MAD (start of treatment) The laboratory-made MAD (F-MAD / H-MAD) is integrated and checked for a comfortable fit. The patient is instructed to always wear the splint during sleep.~All patients receive an extended guide to jaw gymnastics with the instruction to do it in the morning after waking up and in the evening before falling asleep.~Four weeks after incorporation, the titration phase begins, the slow adjustment of mandibular advancement to optimize sleep medical parameters while minimizing unwanted side effects.~Control appointments take place after four weeks, six months, one year and two years after insertion of the MAD"
41138231|NCT06369532|DEVICE|Active tDCS|During the whole therapy period, active tDCS group will receive active tDCS after CBT. They also receive active home-based tDCS.
40968300|NCT06402110|OTHER|Femoral Triangle Block|Patients will receive femoral triangle block (FTB) at the end of surgery. The probe will be positioned at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle, a block needle advanced in an in-plane technique into femoral triangle. After negative aspiration, 2ml of saline will be injected to confirm the needle tip position close to the femoral artery then injection of 15ml of bupivacaine 0.25% will be performed.
41296192|NCT04016883|OTHER|Problem Solving Therapy offered through a web platform|Problem Solving Therapy offered through a web platform. There will be four sessions, during the first four weeks of treatment, and subsequent sessions are dedicated to refining problem-solving skills. Participants set treatment goals; different ways to reach goals are discussed and evaluated; action plans are created, and its effectiveness is evaluated to achieve the objectives. Participants are expected to implement plans and apply the problem-solving model to additional problems between sessions. In the last two sessions, participants create a relapse prevention plan using the problem-solving therapy model.
41138232|NCT06369532|DEVICE|Sham tDCS|The sham tDCS group will receive sham tDCS after CBT. They also receive sham home-based tDCS.
41138233|NCT04237857|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
41138234|NCT00841711|BEHAVIORAL|Intensive Case Management|Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
41138235|NCT04186377|OTHER|Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers|Optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing
41138236|NCT04186377|DRUG|S26E|Daily application of S26E extract on wound site
41138237|NCT01354080|OTHER|massage based on the tensegrity rule|The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
41138238|NCT01354080|OTHER|massage - classical abdominal|The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
41138239|NCT04377542|PROCEDURE|LIFT|Ligation of the fistula tract in the intersphincteric plane
41138240|NCT04377542|PROCEDURE|Parks|Modified Parks fistulotomy with complete internal anal sphincterotomy
41138241|NCT04377542|PROCEDURE|Seton|Excision of the superficial part of fistula tract and tying loose seton around the remaining part and anal sphincter muscles
41138242|NCT02222506|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
40768492|NCT03557931|DRUG|placebo|oral administration
40768493|NCT03557931|DRUG|risperidone|oral or depot administration
41138243|NCT01536093|OTHER|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
41138244|NCT01536093|OTHER|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
41138245|NCT01213940|BEHAVIORAL|pre-bariatric weight loss program|standard 6 month physician directed pre-bariatric weight loss program
41138246|NCT01213940|PROCEDURE|bariatric surgery|bariatric surgery for weight loss
41138247|NCT05815459|DEVICE|OCOsense|Volunteers wear OCOsense glasses continuously during testing to monitor biobehavioural responses to tasks
41138248|NCT01154504|OTHER|clinical treatment|The clinical treatment will be optimized to gold standard international heart failure treatment
41138249|NCT01154504|PROCEDURE|ultrafiltration|The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.
41138250|NCT01154504|PROCEDURE|isovolumetric hemofiltration|The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
41138251|NCT00920985|DRUG|Gestodene/EE (FC Patch Low, BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
41138252|NCT00920985|DRUG|Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
41138253|NCT01662193|DIETARY_SUPPLEMENT|vitamin D3 supplement|
41138254|NCT01662193|DIETARY_SUPPLEMENT|calcium supplement|
41138255|NCT01662193|DIETARY_SUPPLEMENT|vitamin D3 and calcium supplement|
41138256|NCT01662193|DIETARY_SUPPLEMENT|placebo|
41138257|NCT02562521|BEHAVIORAL|Contingency management|Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
41138258|NCT02562521|DRUG|Nicotine replacement therapy|Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
41138259|NCT02562521|DRUG|Varenicline|Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
41138260|NCT02562521|BEHAVIORAL|Additional behavioral support|Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
41138261|NCT03072706|DEVICE|Corin OPS™|The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.
41138262|NCT03072706|OTHER|2D X-ray templating technology|Standard care where hip replacement is planned using 2D X-ray templating software
41138263|NCT00336882|DRUG|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
40768494|NCT03557931|DRUG|quetiapine|oral administration
41138264|NCT00336882|DRUG|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
41138265|NCT00985088|BIOLOGICAL|GSK2340274A|one or two intramuscular injections
41138266|NCT00985088|BIOLOGICAL|GSK2340273A|one or two intramuscular injections
41138267|NCT00985088|BIOLOGICAL|Saline placebo|One injection
41138268|NCT00523900|DIETARY_SUPPLEMENT|Quaker Complete Nutrition Supplements|3-6 250ml cans of Quaker Complete Nutrition Supplements per day
41138269|NCT02336802|BEHAVIORAL|Avoidance experiment|Participants complete an avoidance task
41138270|NCT04768556|OTHER|EEG experimental sessions 1|An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.
41138271|NCT04768556|OTHER|EEG experimental sessions 2|An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action
41138272|NCT05695599|DEVICE|Whole body vibration training|3 times per week of 20 to 30 minute sessions during 16 weeks of training
41138273|NCT03692871|BIOLOGICAL|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
41138274|NCT03692871|BIOLOGICAL|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 ml dose
41138275|NCT06448637|DEVICE|Drug Coated Balloon (DCB)|Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI)
41138276|NCT06448637|DEVICE|Drug Eluting Stent (DES)|Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI)
41138277|NCT04119024|PROCEDURE|Biopsy|Undergo biopsy
40768495|NCT03557931|DRUG|olanzapine|Oral or depot administration
40768496|NCT03557931|DRUG|ziprasidone|Oral or depot administration
40768497|NCT03557931|DRUG|aripiprazole|Oral or depot administration
41457796|NCT01728480|OTHER|laboratory biomarker analysis|Correlative studies
41457797|NCT02995187|DRUG|Apatinib Mesylate tablet|Apatinib 500 mg in tablet once daily
40968301|NCT06402110|OTHER|Adductor Canal Block|Patients will receive adductor canal block (ACB) at the end of surgery. The probe will be positioned at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the Sartorius muscle and a block needle advanced in an in-plane technique toward the target nerve after negative aspiration, 2ml of saline will be injected into adductor canal to confirm the block needle tip within it, the block needle will be advanced with the guidance of ultrasound in an in-plane technique and 15ml bupivacaine 0.25% will be injected.
40968302|NCT02601469|DRUG|DSXS|twice daily for 28 days
40768498|NCT03557931|DRUG|brexpiprazole|Oral administration
40968303|NCT03267706|OTHER|Palliative Care Comprehensive Tool|Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
40968304|NCT03956732|DIETARY_SUPPLEMENT|Milk Protein (high)|High protein yoghurt which contains approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
40968305|NCT03956732|DIETARY_SUPPLEMENT|Vitamin D|One daily tablet containing 20 μg of vitamin D3, cholecalciferol.
40968306|NCT03956732|DIETARY_SUPPLEMENT|Milk Protein (medium)|Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
40968307|NCT05393258|RADIATION|temporally-modulated pulsed radiotherapy (TMPRT)|Intensity modulated RT (IMRT) using single or two arc therapy will be used for RT delivery.
40968308|NCT03673332|DRUG|immune-checkpoint inhibitors therapies|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
40968309|NCT03213522|PROCEDURE|Pelvic Floor Physical Therapy|Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
40968310|NCT03213522|PROCEDURE|Craniosacral Therapy|Modified Upledger Institute 10-step protocol.
40968311|NCT03308877|BEHAVIORAL|BMI|Four 45-minute, brief motivational sessions for substance use
40968312|NCT03308877|BEHAVIORAL|Stadard Care (SC)|Standard procedures at pretrial program + assessement
40968313|NCT06063824|OTHER|Single-Session Method of Levels Intervention|This is a single session of method of levels psychotherapy delivered to patients of GP surgeries in primary care.
40968314|NCT04678271|BEHAVIORAL|AFIX-OB Quality Improvement Package|Practices randomized to the intervention arm will be provided with a package of core and supplemental quality improvement interventions to choose from so that the most effective combination for their practice is implemented. Each practice will be required to implement a tablet-based educational app for patients, and evidence based online educational module for providers, standing order protocol, and a reminder/recall protocol. They can then choose to also use flyers and posters in their waiting rooms, standardized talking points for maternal immunization for the providers, educational content for the practice website, and laminated and highlighted CDC Vaccine Information Sheets. The recruited patients and providers at the practice will be given a baseline and follow-up survey to assess their knowledge, attitudes, and beliefs towards maternal immunization.
41138278|NCT04119024|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41138279|NCT04119024|PROCEDURE|Computed Tomography|Undergo CT scan
41138280|NCT04119024|DRUG|Cyclophosphamide|Given IV
41138281|NCT04119024|DRUG|Fludarabine Phosphate|Given IV
41138282|NCT04119024|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
41138283|NCT04119024|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given IV
41138284|NCT04119024|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41138285|NCT04119024|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40768499|NCT03557931|DRUG|paliperidone|Oral or depot administration
40768500|NCT03557931|DRUG|lurasidone|Oral administration
40768501|NCT06446648|DRUG|ICG|Administer an IV ICG injection intraoperatively, using the optimal dosage and timing defined in the second phase of the study. Utilize the newly developed 3D vascular map for visualization of the arteries before and after prostate resection.
41138286|NCT03775252|DIETARY_SUPPLEMENT|Ketogenic diet|Diet rich in fats and poor in carbohydrate, to induce metabolic ketosis
41138287|NCT05056376|BEHAVIORAL|Digital Diabetes Prevention Program (dDPP)|"The Sweetch app is a hyper-personalized mobile digital coach that provides users with tailored recommendations to promote healthy lifestyle behaviors (150 minutes per week of physical activity, weight reduction, and healthy eating habits) to reduce the risk of type 2 diabetes.~The Sweetch app uses self-tracking and multiple evidence-based persuasive eCoaching strategies. The Sweetch artificial intelligence algorithm delivers just-in-time support and/or adapt recommendations based on the user's response. For example, push notifications will be sent when the algorithm detects that the user is potentially available and able to act upon the recommendation, based on various parameters including location, previous response, calendar availability, and weather, etc."
41146857|NCT01245699|BEHAVIORAL|scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing|scenario-based training for CPR, real-time audiovisual CPR feedback using R Series monitor-defibrillator during treatment, and post-event debriefing
41146858|NCT00648466|DRUG|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
41146859|NCT00648466|DRUG|Imitrex® Tablets 100 mg|100mg, single dose fasting
41457798|NCT03118063|DIAGNOSTIC_TEST|Evaluation of pain by algometry|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
41457799|NCT03195387|DRUG|MMV390048|Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
41457800|NCT00007787|BIOLOGICAL|Cyclosporine|
40968315|NCT03174834|OTHER|Bladder Stimulation technique|The bladder stimulation technique is performed following genital cleaning with a 2% castile soap towelette, which is part of the sterile clean catch urine collection cup kit. For the technique, infants will be held under their armpits by a parent over the bed, with legs dangling in males and hips flexed in females. The nurse or technician will then alternate between bladder stimulation maneuvers: gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. These two stimulation maneuvers will be repeated until micturition begins, or for a maximum of 300 seconds.
40968316|NCT03797599|BEHAVIORAL|20 minutes of mindfulness practice|A 20 minute audio guided mindfulness of breathing practice per session, for four sessions.
41296193|NCT04016883|OTHER|Conventional web platform|The conventional web platform, which will contain the general content on stress coping techniques.
41296194|NCT04784299|DEVICE|YVOIRE volume plus|Hyaluronic acid dermal filler
41296195|NCT04784299|DEVICE|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
41296196|NCT03561285|DIAGNOSTIC_TEST|antiphospholipid Abs|Laboratory test
41296197|NCT03143582|OTHER|Running|A 13-week running program where youth run for 30 minutes twice weekly.
41296198|NCT04708964|DRUG|Flurbiprofen|Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
41296199|NCT04708964|DRUG|saline solution|Saline solution will be administered, through the subglottic intake door of the endotracheal tube.
41296200|NCT01819220|DRUG|amlodipine/valsartan|"This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
40968317|NCT03797599|BEHAVIORAL|5 minutes of mindfulness practice|A 5 minute audio guided mindfulness of breathing practice per session, for four sessions.
40968318|NCT03797599|OTHER|5 minute audio book|5 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything') per session, for four sessions.
40968319|NCT03797599|OTHER|20 minute audio book|20 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
40968320|NCT03797599|OTHER|25 minute audio book|25 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
40968321|NCT00125294|DRUG|Methadone|
41296201|NCT01819220|DRUG|hydrochlorothiazide/telmisartan|"When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
41296202|NCT04095988|PROCEDURE|Allogeneic microbiota reconstitution|gastroscopic microbiota Infusion (Verum)
41457801|NCT00007787|BIOLOGICAL|Anti-human thymocyte globulin (rabbit)|Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.
40968322|NCT02023567|DRUG|SSRIs|fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
40968323|NCT02627105|BEHAVIORAL|Beef group|Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.
40968324|NCT02627105|BEHAVIORAL|Non-beef group|Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
40968325|NCT03915821|DEVICE|ECT|"Electroconvulsive therapy was administered by using bidirectional constant current, brief-pulse devices. During the procedure, the patients were sedated using propofol or thiopenthal. Succinylcholine (1 mg/kg) was used as muscle relaxant, and glycopyrrolate (0.2 mg) or atropine was used as an anticholinergic agent when necessary. The mean charges were 351 (SD, 143) mC for the unilateral electrode placement group, 417 (SD, 192) mC for the bitemporal electrode placement group and 260 (SD, 76) mC for the bifrontal electrode placement group, (Brus, Ole MSc, 2017).~The average course of treatment for depression is 6 to 12 treatments, but some patients may require as many as 20 treatments,"
41146860|NCT04468659|DRUG|Lecanemab|IV infusion.
41146861|NCT04468659|DRUG|Placebo|IV infusion.
41457802|NCT00007787|DRUG|Tacrolimus|
41457803|NCT02015351|DRUG|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
41457804|NCT05320237|OTHER|Immersive Virtual Reality Intervention|Eight week intervention with two sessions a week. Each session will be 30 minutes in duration and will involve participants partaking in VR and such games include targeting individual finger movement (playing piano); grasp and release and one game (catching falling stars) includes holding a controller for elbow flexion and extension (Whack-a-mole).
40768502|NCT02722785|BEHAVIORAL|Aerobic and Resistance Exercise Training|Supervised aerobic and resistance exercise program consisting of 2 weekly sessions of approximately 60 minutes. Patients will perform a test of maximum cardio-respiratory (Watt-max test) and muscle strength (1 repetition maximum \[1-RM\] test) capacity. Using the patient's individual capacity score (Watt-max and 1RM), a personalized exercise program will be prescribed. After a light warm-up, patients will perform 20-30 min of aerobic interval training of stationary bicycle. Resistance training comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
40768503|NCT06569719|OTHER|Complex decongestive therapy|Includes manual lymphatic drainage (MLD), compression therapy (which consists of compression bandages, compression sleeves, or other types of compression garments), skin care, and lymph-reducing exercises
41138288|NCT05056376|BEHAVIORAL|Human Coach-based Diabetes Prevention Program (hDPP)|The Human Coach-Based Diabetes Prevention Program will consist of a CDC recognized lifestyle change program. Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
41138289|NCT01929161|DRUG|Oxytocin|24 International Units
41138290|NCT01929161|DRUG|Placebo (for oxytocin)|intranasal spray manufactured to mimic oxytocin nasal spray
41138291|NCT01929161|BEHAVIORAL|Lovingkindness Meditation|
41138292|NCT01929161|BEHAVIORAL|Mindfulness Meditation|
41138293|NCT00946972|DRUG|JNJ-38431055; Placebo|
41138294|NCT02496559|PROCEDURE|Pre-consultation CRP|Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
41138295|NCT02671266|DRUG|Oxytocin|Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
41138296|NCT02671266|DRUG|Placebo|Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
41138297|NCT05143125|BIOLOGICAL|Decitabine combined with NK cell infusion|Decitabine combined with NK cell infusion
41138298|NCT03019289|DRUG|pridopidine (90 mg)|single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
41138299|NCT04269694|DRUG|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
41138300|NCT04269694|DEVICE|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
41138301|NCT02442557|BIOLOGICAL|recombinant human alpha B-crystallin|intravenous injection
41138302|NCT02442557|OTHER|placebo comparator|intravenous injection
41138303|NCT01916109|DRUG|Gemcitabine|
41138304|NCT01916109|DRUG|Carboplatin|
41138305|NCT01916109|DRUG|Panitumumab|
41138306|NCT01916109|PROCEDURE|radical cystectomy|
40768504|NCT06039761|PROCEDURE|Digestive or gynecological surgery by laparoscopy|Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia
40768505|NCT05529602|OTHER|conventional physical therapy|"core stability exercises~A total of 3 sessions per week were given for 15-20 minutes"
41457805|NCT01659073|PROCEDURE|Caloric Vestibular Stimulation|
40768506|NCT05529602|OTHER|relaxation exercise|"the experimental group was given Post-isometric relaxation exercise along with core stability~A total of 3 sessions per week were given for 15-20 minutes"
40768507|NCT00112385|DRUG|Etanercept|Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks
40768508|NCT00112385|DRUG|Placebo|Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
40768509|NCT04932577|BIOLOGICAL|Faecal microbiota transplantation|All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
40768510|NCT04932577|BIOLOGICAL|Placebo|Placebo
40768511|NCT02087852|OTHER|salvia for germline DNA|
40768512|NCT02087852|BEHAVIORAL|the Kidney Cancer Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
41457806|NCT03332264|DEVICE|SeQuent Please OTW|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter
41457807|NCT03332264|DEVICE|Eluvia Vascular Stent System|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent
41457808|NCT03332264|DEVICE|Nitinol stent|Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent
41457809|NCT00020358|BIOLOGICAL|aldesleukin|
41457810|NCT00020358|BIOLOGICAL|gp100 antigen|
40768513|NCT02087852|BEHAVIORAL|Family History Questionnaire (when applicable)|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
40768514|NCT02087852|OTHER|Blood draw|
40768515|NCT02087852|BEHAVIORAL|Epidemiologic Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
40768516|NCT05317481|BEHAVIORAL|BE-SMART-DR|Therapy that provides self-directed strategies to regularize sleep and other DRs to reduce short-term suicide risk that can be used lifelong to potentially also reduce long-term suicide risk
40768517|NCT05317481|BEHAVIORAL|psychoeducational control comparator condition (CC)|Structured sessions, matched for BE-SMART-DR session number and time, that will emphasize established strategies to manage health and well being
41138307|NCT05537532|BEHAVIORAL|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
41457811|NCT00020358|BIOLOGICAL|incomplete Freund's adjuvant|
40968326|NCT02048605|BEHAVIORAL|Psycho-social CBT based training|Number of Sessions: 9x Content: cognitive behavioral group-training-program to reduce stress and augment quality of life.
40968327|NCT02048605|BEHAVIORAL|Unspecific group training|Number of sessions: 9x Content: Music or Art Therapy Nutrition Education around Food Functional Movement Physical Activity Group discussion
40968328|NCT03187106|DRUG|Cephalexin|Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
40968329|NCT03187106|DRUG|Placebo|Placebo representing standard of care
40968330|NCT03187106|DRUG|Metronidazole|Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
40968331|NCT05831020|OTHER|VAC and bolster dressing|"Bolster dressing- Moist bulky cotton gauze dressing and wrapped with cotton bandage.~Vacuum assisted closure (VAC) dressing- A fenestrated tube placed between two sheets of sterilized foam secured to the surrounding skin using adhesive dressing (OPSITE)."
40968332|NCT05725967|PROCEDURE|Primary Obesity Endoscopic Procedures|Any primary endoscopic procedure for treatment of obesity including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGB), Aspiration therapy, pylorus sparing antral myotomy (PSAM), primary obesity surgery endoluminal (POSE), gastroplasty with endoscopic myotomy (GEM).
40968333|NCT05725967|PROCEDURE|Endoscopic Revision of Bariatric Surgical Procedures|Any endoscopic revision procedure in a post-bariatric surgical patient, including transoral outlet reduction (TORe), restorative obesity surgery endoluminal (ROSE), argon plasma coagulation of the outlet (APC), endoscopic suturing.
40968334|NCT05725967|PROCEDURE|Bariatric Surgery Procedures|Any bariatric surgical procedure including Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastroplasty (LSG), laparoscopic adjustable gastric banding (LAGB)
41138308|NCT05537532|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
41457812|NCT00020358|BIOLOGICAL|tyrosinase peptide|
41457813|NCT04733456|BEHAVIORAL|Quality of life questionnaires|Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, \*EQ5D-5L, \*GAD-774, \*PHQ-975, \*PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, \*Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy
41457814|NCT04733456|DEVICE|NIRS|A TechEn NIRSOptix continuous-wave fNIRS system will be used to record changes in cerebral oxygenation, at a sampling rate of 25 Hz
41457815|NCT04733456|OTHER|Stool Collection|For assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome
41457816|NCT04733456|OTHER|Blood and urine collection|for inflammatory markers and metabolomic \[IMC\] analysis
41457817|NCT01610050|DRUG|LFA102|
41457818|NCT02228486|DEVICE|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
41296203|NCT04095988|PROCEDURE|Placebo-Allogeneic microbiota reconstitution|gastroscopic saline Infusion (placebo)
41296204|NCT03259542|DRUG|Mifepristone 300 MG|mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days
41296205|NCT03259542|DRUG|Itraconazole 100 MG|itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing
41296206|NCT03159754|PROCEDURE|Early Appendectomy|Removal of the appendix within 24 hours of admission
41296207|NCT03159754|PROCEDURE|Interval Appendectomy|Removal of the appendix after initial antibiotic treatment and at least 6 weeks of recovery.
41296208|NCT03159754|DRUG|Antibiotics|Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
41296209|NCT03218852|DRUG|prednisone and cyclophosphamide|Prednisone and cyclophosphamide are both administered to participants in this group.
41296210|NCT03218852|DRUG|prednisone alone|Prednisone is administered to participants in this group.
41296211|NCT06237842|DIAGNOSTIC_TEST|Diagnostic Test: EEG headband+Ring oximeter (RO)+Actigraphy (ACT)|Combination of ACT+RO+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
41296212|NCT03974828|DEVICE|Anesthesia Control Tower Notification|Real-time data will be monitored through the AlertWatch system as well as the electronic health record. Risk forecasts of adverse events (30 day mortality, acute kidney injury, postoperative delirium, respiratory failure), PACU length of stay, and hospital length of stay will be generated by a machine learning algorithm. Additional outputs identifying the most important predictors and their effects will be combined with risk forecasts to form a report card.
41296213|NCT02967120|OTHER|no intervention|
41457819|NCT02228486|BEHAVIORAL|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
41296214|NCT05737693|DRUG|Ketamine|Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy
41457820|NCT04665817|DIAGNOSTIC_TEST|CT-QFR|CT-QFR is a novel method for evaluating the functional significance of coronary stenosis. It is calculated by coronary computed tomographic angiography images.
41457821|NCT04665817|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two. angiographic projections.
41457822|NCT04665817|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire is the gold standard for evaluating the functional significance of coronary stenosis.
41457823|NCT03534531|PROCEDURE|Intra-articular cervical zygapophyseal joint injection|Fluoroscopically-guided intra-articular cervical zygapophyseal steroid injection
41457824|NCT00283842|DRUG|DVS SR|
41457825|NCT00283842|DRUG|Placebo|
41457826|NCT01596127|DRUG|Intrathecal Rituximab|"Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I."
41457827|NCT01467362|DRUG|V0034CR01B|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
41457828|NCT01467362|DRUG|Vehicle cream|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
41457829|NCT01467362|DRUG|desonide 0.1% cream|cream, once a day (in the evening) during flares
40968335|NCT05725967|DEVICE|Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction|Any endoscopic procedure using an endoscopic suturing device for primary obesity treatment or revision of post bariatric complications.
41296215|NCT05737693|DRUG|Midazolam|Week-long exposure therapy with midazolam infusion on day 2 and 4 of the psychotherapy
41296216|NCT00957346|DRUG|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
41296217|NCT00957346|DRUG|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
41457830|NCT01467362|OTHER|Foaming gel|for the washing and cleaning
41457831|NCT03165669|DEVICE|"Viscospring PostuRite - medium model"|Cervical pillow use, 30-minutes instruction session supported by a brochure
41457832|NCT03165669|OTHER|Education|30-minutes educational session delivered by a physical therapist and supported by an informative brochure.
41457833|NCT01628887|OTHER|Educational Intervention|Undergo Bilingual Breast Cancer Educational Intervention
41138309|NCT05537532|BEHAVIORAL|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
41138310|NCT00490789|DRUG|sirolimus|daily oral sirolimus with dosage individualised by trough blood levels
41296218|NCT01197378|DRUG|Cysteamine Bitartrate Delayed-release Capsules|"Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose."
41296219|NCT00404781|DRUG|cilostazol in addition to aspirin and clopidogrel|
41296220|NCT05165576|BEHAVIORAL|Child-centered communication|The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
41296221|NCT01420640|BEHAVIORAL|Lower frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 1x/week
41457834|NCT00686868|OTHER|placebo|placebo
41457835|NCT00686868|DRUG|ofatumumab|fully human anti-CD20 monoclonal antibody
41457836|NCT04220606|DRUG|Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)|
40968336|NCT05725967|DEVICE|Intragastric Balloon|An endoscopic bariatric procedure involving the placement of an intragastric balloon.
40968337|NCT05725967|DEVICE|Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal|Any endoscopic procedure using an endoscopic plicating device for primary obesity treatment or revision of post bariatric complications.
40768518|NCT06291857|BIOLOGICAL|CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant|CIC will contain SARs-CoV-2 antigen (35 μg), tNIV antigens (2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains; 60 μg/strain
40768519|NCT06291857|BIOLOGICAL|Novavax COVID-19 Vaccine|Each 0.5 mL dose comprises 5 µg SARS-CoV-2 S protein and 50 µg Matrix-M adjuvant
40768520|NCT06291857|BIOLOGICAL|tNIV Vaccine|2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains (60 μg/strain), and Matrix-M adjuvant (75 μg)
40768521|NCT06291857|BIOLOGICAL|Fluzone High Dose|Fluzone High-Dose is supplied as a suspension for IM injection 0.5 mL with 60 µg per strain
40768522|NCT05411900|DRUG|BoNT-A|"A vial of 500 units of BoNT-A will be reconstituted with 2 mL of saline solution (0.9%) and 1 mL of lidocaine solution (2%) to obtain a final concentration of BoNT-A of 166.6 units/mL.~Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection of 16.6 units of BoNT-A.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
40768523|NCT05411900|DRUG|Placebo|"Placebo will consist of equal volume of saline solution (0.9%). Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
40768524|NCT05669027|DEVICE|Neurofeedback|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state.
40768525|NCT05669027|DEVICE|Sham (Placebo Control)|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo).
40968338|NCT05725967|DEVICE|Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy|Electrosurgical interventions for obesity. Use of electrosurgical devices, such as electrocautery for the primary treatment of obesity or obesity related complications.
40968339|NCT05725967|DEVICE|Aspiration Therapy|Placement of an aspiration therapy device for the treatment of obesity.
41138311|NCT01542255|DRUG|vinblastine|1 mg/m2 vinblastine given three times per week administered intravenously.
41138312|NCT01542255|DRUG|Cyclophosphamide|60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest
41138313|NCT01542255|DRUG|dacarbazine|15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
41138314|NCT05912049|DRUG|9MW3811 Injection|Single dose intravenously infused on day 1
41138315|NCT05912049|DRUG|Placebo|Single dose of matching placebo intravenously infused on day 1
41138316|NCT00724737|PROCEDURE|Presurgical MRI|"People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
41138317|NCT00724737|PROCEDURE|functional MRI (fMRI) of the brain|"Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
41146862|NCT00753896|DRUG|exenatide|subcutaneous injection, 2.0mcg, once weekly
40768526|NCT06209619|PROCEDURE|Biopsy|Undergo biopsy
40968340|NCT04019574|DRUG|CR845 0.5 mcg/kg IV|0.5 mcg/kg IV CR845
40968341|NCT04019574|DRUG|CR845 3 mcg/kg IV|3 mcg/kg IV CR845
40968342|NCT04019574|DRUG|Moxifloxacin 400 mg Oral Tablet|400 mg Oral Moxifloxacin
40968343|NCT04019574|OTHER|Placebo|IV Placebo as a bolus injection
40968344|NCT02487602|DEVICE|Gelesis100|Gelesis100 capsules
40968345|NCT02487602|OTHER|Placebo|Sucrose (sugar) capsules
41146863|NCT05058547|DEVICE|SWEPPE|In the smartphone application SWEPPE the individual can create an action plan, perform daily registrations of health aspects, self-monitoring of health aspects and goals, have access to a library with evidence-based facts and a coach, and possibility to share information with the employer.
41146864|NCT01625494|DRUG|Irbesartan/Amlodipine (150/5mg)|Pharmaceutical form: tablet Route of administration: oral
41146865|NCT01625494|DRUG|Irbesartan/Amlodipine (150/10mg)|Pharmaceutical form: tablet Route of administration: oral
40768527|NCT06209619|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41296222|NCT01420640|BEHAVIORAL|Higher frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 2x/week
41296223|NCT01420640|BEHAVIORAL|Shorter frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 1x/week
41296224|NCT01420640|BEHAVIORAL|Higher frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 2x/week
41296225|NCT01420640|BEHAVIORAL|Aerobic Exercise Training|24 weeks of supervised aerobic exercise training, 2x/week
41296226|NCT06300970|DRUG|Amodiaquine-artesunate (ASAQ)|Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
41296227|NCT06300970|DRUG|Artemether+Lumefantrine (AL)|Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
41296228|NCT05932628|OTHER|This study will observe participants who receive a supported self management approach for thumb base osteoarthritis but it is not an interventional study.|Participants will receive an occupational or physiotherapist led supported self-management programme, which equates to normal NHS care, having been adopted by the sites involved. This involves education, progressive exercises and hand splints if required. The educational materials used, and a minimum number of appointments will be consistent across the study sites. Additional treatments for coexisting conditions will be provided, additional stepped care for thumb base osteoarthritis will also be recorded.
41296229|NCT03247907|DEVICE|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
41296230|NCT03247907|DEVICE|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
41296231|NCT03247907|DEVICE|Condition C: CPAP with Cold Passover|CPAP with Cold Passover with mouth leak
41296232|NCT03247907|DEVICE|Condition D: CPAP with Modified humidifier|CPAP with Modified humidifier with mouth leak
41296233|NCT03247907|DEVICE|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
41296234|NCT03247907|DEVICE|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
40768528|NCT06209619|PROCEDURE|Computed Tomography|Undergo PET/CT
40768529|NCT06209619|DRUG|Golcadomide|Given PO
40968346|NCT04313218|DRUG|Carbetocin|iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
41146866|NCT01625494|DRUG|Irbesartan/Amlodipine (300/5mg)|Pharmaceutical form: tablet Route of administration: oral
41146867|NCT01625494|DRUG|Irbesartan/Amlodipine (300/10mg)|Pharmaceutical form:tablet Route of administration: oral
41296235|NCT03247907|DEVICE|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
41296236|NCT03247907|DEVICE|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
41296237|NCT06387901|DRUG|Paclitaxel Chemotherapy|Participants will receive paclitaxel, a taxane chemotherapeutic agent used in the treatment of breast cancer. The administration involves an intravenous infusion of paclitaxel at a dosage of 80 mg/m². The treatment is scheduled once a week, continuing for a total duration of 12 weeks. This regimen is part of a (neo-)adjuvant therapy for female patients diagnosed with stage II or III breast cancer. The intervention aims to assess the pharmacokinetics of paclitaxel in relation to patient body composition and physical activity, evaluating its impact on dose-limiting toxicities and overall treatment efficacy.
41296238|NCT02228278|BEHAVIORAL|Group A|"Phase 1: Group A will receive the typical clinic visits plus daily text messages for 12 weeks.~Phase 2: Group A will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider and for those prescribed medication for a chronic condition, medication counseling by a healthcare provide) plus daily text messages in between visits for 3 months to support their health goals."
40768530|NCT06209619|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40768531|NCT06209619|BIOLOGICAL|Rituximab|Given IV
40768532|NCT06305390|DIAGNOSTIC_TEST|PET/MRI|18F-PSMA PET/MRI
40768533|NCT05492045|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
40768534|NCT05492045|DRUG|Other|Standard treatment of NSCLC.
40968347|NCT00217620|DRUG|sorafenib|800 mg per day, daily until progression
40968348|NCT01191333|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
40968349|NCT01191333|DEVICE|Sham Device|Placebo Device that simulates active rTMS treatment
40968350|NCT01929798|DEVICE|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
40968351|NCT05174897|BEHAVIORAL|emotional liberation technique|experimental group; The child, to whom an intravenous catheter will be applied, is placed on a stretcher. pain ve score fear will be evaluated before the procedure. Then, the emotional liberation technique (EFT) will be applied for 10 minutes and an intravenous catheter will be applied to evaluate the pain and fear scores during and after the procedure.
40968352|NCT01267760|DEVICE|Multipass hemodialysis|8-hour dialysis using a recycled dialysis bath of 25-30 l
40968353|NCT06321315|BEHAVIORAL|Case-based instruction|"Case-based instruction will be applied to the students in the intervention group. Student Information Form, Critical Thinking Motivation Scale, Academic Motivation Scale and Knowledge Assessment Form will be . All students will receive classical in-class theoretical education about such as hemorrhages, hyperemesis gravidarum, oligohydramnios and urinary system diseases. In the intervention group, after the theoretical teaching of each subject within the scope of the Risky Pregnancy and Care course, cases prepared on the basis of the subject taught to the students will be applied. Student Information Form (13th and 14th questions), Critical Thinking Motivation Scale, Academic Motivation Scale, Knowledge Assessment Form and Visual Comparison Scale will be applied to all students as post-test data after case-based teaching of four topics."
40968354|NCT04023604|OTHER|Controlled diet with beef raised without antibiotics|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised without antibiotics.
40968355|NCT04023604|OTHER|Controlled diet with beef produced in conventional systems|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised with antibiotics.
40968356|NCT04946006|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
40968357|NCT04521153|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
40968358|NCT04521153|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
40968359|NCT04521153|PROCEDURE|TACE treatment|TACE treatment
40968360|NCT04521153|PROCEDURE|Radical surgery|Radical surgery
40968361|NCT01479517|DRUG|Kovacaine Mist 0.1 mL x 4 sprays|Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
40968362|NCT01479517|DRUG|Kovacaine Mist 0.2 mL x 2 sprays|Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
40968363|NCT01479517|DRUG|Kovacaine Mist 0.2 mL x 1 spray|Dose = 1 intranasal spray of study drug
40968364|NCT01824641|DEVICE|Eliminate aspiration catheter|Eliminate aspiration catheter
40968365|NCT01824641|PROCEDURE|Conventional primary angioplasty|Primary angioplasty without thrombus aspiration
40968366|NCT03087669|DEVICE|LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®|Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
40768535|NCT04593277|OTHER|Internet Mobile Technology|Use INSPIRE mobile application
40968367|NCT03087669|DRUG|MAP intervention using Noradrenalin|At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
40768536|NCT04593277|OTHER|Internet-Based Intervention|Access to a study-specific control website
40768537|NCT04593277|OTHER|Questionnaire Administration|Ancillary studies
40768538|NCT04593277|PROCEDURE|Supportive Care|Receive telehealth stepped care
40768539|NCT04593277|OTHER|Informational Intervention|Receive printed SCP materials
40768540|NCT05442047|DRUG|NNC6019-0001|Participants will receive i.v infusionof NNC6019-0001.
40968368|NCT03439553|BEHAVIORAL|Ads display with target websites|Ads are shown, but users are referred to control websites.
40968369|NCT03439553|BEHAVIORAL|Ads display with control websites|Ads are shown, but users are referred to control websites.
40968370|NCT00101595|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
40968371|NCT01084369|DRUG|Testosterone|"NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable."
40968372|NCT04400591|BIOLOGICAL|Nonconforming Lisocabtagene Maraleucel|Nonconforming lisocabtagene maraleucel is lisocabtagene maraleucel that does not meet the commercial release specifications, however is deemed acceptable to administer as an investigational product in the Expanded Access Protocol setting.
41296239|NCT02228278|OTHER|Group B|"Phase 1: Group B will receive current standard care - clinic visits every three months anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.~Phase 2: Group B will initially act as the control and will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider, and for those prescribed medication for a chronic condition, medication counseling by a healthcare provider) with typically with no patient-provider communication between visits. After a 6-month delay, Group B will then receive the intervention which includes the typical clinic visits as stated previously plus daily text messages in between visits for 3 months to support their health goals."
41296240|NCT02123017|DRUG|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses
41296241|NCT02123017|DRUG|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses
41296242|NCT02123017|DRUG|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses
41296243|NCT03287297|DIAGNOSTIC_TEST|OGTT & HBA1c|oral glucose tolerance test \& HBA1c: by measuring glycated hemoglobin
41296244|NCT04379804|PROCEDURE|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery (ITA).
40968373|NCT03002766|PROCEDURE|Breast conservative surgery|
40968374|NCT02505204|OTHER|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
41296245|NCT04379804|PROCEDURE|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN was identified at the point of entry both visually and with hand held stimulation probe
41296246|NCT04739124|OTHER|Follow-up questionnaires|"The patient normally follows the education program as usual but research specific data is collected:~* Biological sampling at the start and end of the education program (glycated hemoglobin).~* Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~* Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)"
41296247|NCT04739124|OTHER|Interviews|Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.
41296248|NCT03692910|DRUG|SAGE-217|SAGE-217 capsule
40968375|NCT02505204|OTHER|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
40968376|NCT01974804|PROCEDURE|MRI|
40968377|NCT01709513|DRUG|Atorvastatin|Atorvastatin over-encapsulated tablets.
40968378|NCT01709513|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablet.
40968379|NCT01709513|DRUG|Alirocumab|Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
40968380|NCT01709513|DRUG|Placebo|Placebo for alirocumab, ezitimibe and atorvastatin.
40768541|NCT05442047|DRUG|Placebo (NNC6019-0001)|Participants will receive i.v. infusion of placebo (NNC6019-0001).
40968381|NCT04985864|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
40968382|NCT04985864|DEVICE|Treadmill gait training|Lokomat robot training was applied to stroke patients.
41296249|NCT03692910|DRUG|Placebo|SAGE-217 matching placebo capsule
40968383|NCT04938232|DRUG|Nivolumab|Intravenous infusion
40968384|NCT04938232|DRUG|Ipilimumab|Intravenous infusion
40968385|NCT05609006|DIETARY_SUPPLEMENT|High-Energy, Low-Volume ONS|2 bottles/day of a High-Energy, Low-Volume ONS
40968386|NCT05609006|DIETARY_SUPPLEMENT|High-Energy Standard ONS|2 bottles/day of a High-Energy Standard ONS
40968387|NCT05641324|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
40968388|NCT05641324|DRUG|Lenalidomide with low-dose dexamethasone|Lenalidomide and dexamethasone administered orally
41457837|NCT04249765|OTHER|Assessing grasping force, pinch force,|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer.~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned. The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer on the table."
41457838|NCT02174185|BEHAVIORAL|validated health-related quality of life questionnaires|All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
40968389|NCT05641324|DRUG|Daratumumab|Daratumumab administered by subcutaneous injection
40968390|NCT00878423|DRUG|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
40768545|NCT06122909|DRUG|Group VTI|Group VTI will receive resuscitation guided by LVOT-VTI variation after PLR test.
40768546|NCT06122909|DRUG|Group IVC|Group IVC will receive resuscitation guided by IVC diameter variation after PLR test.
40768547|NCT06494059|OTHER|Intermittent theta burst stimulation (iTBS)|iTBS is a magnetic stimulation applied using a magnetic coil that is placed on top of the participants head to activate the brain. It consists of three very rapid bursts of electrical pulses at a frequency of 50 Hz (per burst) delivered at a rate of 5 per second for 2 seconds (10 bursts). The burst of pulses will be repeated every 10 seconds for a total duration of about 3 minutes. The stimulation will be applied to activate the brain regions that control upper limb, lower limb or trunk muscles. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
40768548|NCT06494059|OTHER|Functional electrical stimulation (FES)|FES is applied using electrodes that stick to the skin over the muscles or nerves. It will will be applied using an electrical stimulator to produce movements of the hand, leg or the trunk. The stimulation intensity will be determined by gradually increasing strength from 20-100 hertz (hz) until the right amount of movement is obtained. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
41457839|NCT04572854|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
40968391|NCT00878423|DRUG|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
40968392|NCT00002876|DRUG|cisplatin|
40968393|NCT00002876|DRUG|etoposide|
40968394|NCT00247975|DRUG|L-carnitine|Patients will be randomized to L-carnitine therapy or placebo. Patients in the treatment group will receive oral L-carnitine (3 grams daily) for 3 days prior to chemotherapy, 1 gram of intravenous L-carnitine (5 cc over 5 minutes, prior to chemotherapy) on the day of chemotherapy and oral L-carnitine (3 grams daily) for 3 days after chemotherapy.
40968395|NCT04221009|BEHAVIORAL|MI and CBT 4-session manualized intervention|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
40968396|NCT03275454|DRUG|BIVV009 6.5 grams|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
40968397|NCT03275454|DRUG|BIVV009 7.5 grams|Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
40968398|NCT03329573|DRUG|Paroxetine IR tablets A|Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
40968399|NCT03329573|DRUG|Paroxetine IR tablets B|Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
40968400|NCT03961581|BEHAVIORAL|Using electric car|Child will use little electric cars to go to the reception of operating theatre to operating room.
40968401|NCT04011761|OTHER|expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
40968402|NCT02650674|OTHER|Product A: NP-0148|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
40968403|NCT02650674|OTHER|Glucose solution|Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times
40968404|NCT02650674|OTHER|Product B: NP-0149|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
40968405|NCT02650674|OTHER|Product C: NP-0150|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
40968406|NCT02650674|OTHER|Product D: NP-0151|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
40968407|NCT02650674|OTHER|Product E: NP-0152|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
40968408|NCT05904197|OTHER|Gamified Cards about Nephrotic Syndrome|"* The study intervention Spin to Win - Nephro Cards will include the following items with simple Arabic language and graphic designation appropriate to children's developmental levels including; nephrotic syndrome, hygiene practices, weight control, fluids, blood pressure control, diet, medication...etc.~* A spin wheel with numbers and images similar to the educational gamified cards will be designed. Children will request to spin the wheel. After the spin, the educational gamified Nephro Cards will reveal and discuss with the child."
40968409|NCT00164775|DRUG|Imipramine|25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
40968410|NCT00164775|DRUG|Placebo|One tab nocte for first 2 weeks then 2 tabs for 10 weeks
40968411|NCT06201702|DIETARY_SUPPLEMENT|pomegranate extract|Drink 2 mL of pomegranate extract three times a day for 10 days during the 3 menstrual cycles (from 7 days before to 3 days after the estimated onset of menstruation).
40968412|NCT04869644|BEHAVIORAL|Goal setting|Goal setting: set or agree on a goal defined in terms of behavior to be achieved.
40968413|NCT04869644|BEHAVIORAL|Action Planning|Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity.
40968414|NCT04869644|BEHAVIORAL|Self-monitoring of behavior|Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit.
40968415|NCT04869644|BEHAVIORAL|Behavioral Practice/Rehearsal|Behavioral rehearsal: prompt practice or rehearsal of walking one or more times in a context when the performance may not be necessary, in order to increase habit and skill.
40968416|NCT04869644|BEHAVIORAL|Habit Formation|Prompt rehearsal \& repetition of walking 2,000 steps or more in the same context repeatedly so that the context elicits the behavior.
40968417|NCT00880828|OTHER|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
40968418|NCT00880828|OTHER|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
40968419|NCT00880828|DRUG|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
40968420|NCT01831050|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
40968421|NCT01831050|BIOLOGICAL|Trivalent Oral Polio Vaccine (tOPV)|Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
41296250|NCT02379741|BIOLOGICAL|ADC-1013|Agonistic human monoclonal IgG1 anti-CD40 antibody
40768549|NCT06494059|OTHER|Transcutaneous spinal cord stimulation (TSCS)|TSCS is applied using electrodes that stick to the skin over the spinal cord to activate spinal cord. Mild electrical stimulation will be applied to make sure the nerves on the back are activated (switched on). Different stimulation intensities (strength) will be tested at different frequencies (pulses per second) to determine the best setting for activating the nerves on the back. The stimulus current strength will be adjusted between 0-250 milliamperes (mA) and will remain within the self-reported tolerance limit of each participant. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
40768550|NCT06494059|OTHER|Sham Intermittent theta burst stimulation (iTBS)|Subjects will be fitted with a magnetic coil that is placed on top of the head that does not deliver any stimulation to the brain. Each subject is expected to participate longitudinally at least 9 times over 2 months.Each visit will take approximately 2-3 hours.
40968422|NCT01831050|BIOLOGICAL|Monovalent Oral Polio Vaccine Type 2 (mOPV2)|Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
40968423|NCT01831050|BIOLOGICAL|Sanofi-Pasteur IPV (Sanofi IPV)|Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
40968424|NCT01831050|BIOLOGICAL|Glaxo SmithKline IPV (GSK IPV)|Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
40968425|NCT01831050|BIOLOGICAL|Serum Institute of India IPV (SII IPV)|Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India \[SII\]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
40968426|NCT03719885|DEVICE|TrueTear Intranasal Tear Neurostimulator|This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
40968427|NCT05559138|OTHER|no intervention|no intervention
40968428|NCT01979445|DRUG|Cangrelor|Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.
40968429|NCT01979445|DRUG|Clopidogrel|Clopidogrel 600 mg single oral dose
40968430|NCT01979445|DRUG|Prasugrel|Prasugrel 60 mg single oral dose
40968431|NCT03273595|DRUG|Lapatinib|
40968432|NCT03273595|BIOLOGICAL|Trastuzumab|
40968433|NCT03273595|DRUG|Paclitaxel|
40968434|NCT03273595|DRUG|Epirubicin|
40968435|NCT03273595|DRUG|Cyclophosphamide|
40968436|NCT04229563|DEVICE|AURYON™ System|"The AURYON™ System consists of two sub-units: 1) a single use catheter (AURYON™ catheter); and 2) a laser system."
40968437|NCT02393508|OTHER|Fresh Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
40968438|NCT02393508|OTHER|Aged Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
40968439|NCT01977794|DRUG|Bisoprolol/Amlodipine (Bisoprolol failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
40968440|NCT01977794|DRUG|Bisoprolol/Amlodipine (Amlodipine failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
40968441|NCT00709930|DEVICE|Magnetic field generator|dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
40968442|NCT00709930|DEVICE|Placebo magnetic field generator|Placebo device with no magnetic fields
40968443|NCT00165776|DRUG|BOTULINUM TOXIN TYPE B|
40968444|NCT06019819|OTHER|strengthening exercise|Perform general physical training activities conducted in schools including upper limb forward elevation, lateral elevation, touching toes in standing and cervical range of motion, strengthening exercise will be performed for 3days a week for 4 weeks.
41146868|NCT05537935|DRUG|Low Dose Naltrexone|Subjects will be started with 3mg LDN orally administered daily for one week with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided a 4 week supply of study medication. The most common side effects are difficulty sleeping and vivid dreams, which is seen more frequently with nighttime dosing, so LDN will be given as a daytime dose.
41146869|NCT01077284|DRUG|Febuxostat|Febuxostat capsules
41146870|NCT01077284|DRUG|Allopurinol|Allopurinol capsules
41146871|NCT01077284|DRUG|Placebo|Placebo-matching capsules
41296251|NCT04936451|DEVICE|TENS (transcutaneous electrical nerve stimulation)|"Patients will benefit from screening for refractory pain, neuropathic or not, with myofascial syndrome, between 3 and 12 months after surgery.~The healthcare professional will determine 4 trigger points. TENS is applied twice 45 min every day for 2 months. Pain treatment will be done by using the P6 program in alternative mode: 2hz / 100Hz.~The time between 2 electrostimulations will be a minimum of 4 hours and a maximum of 15 hours."
40768551|NCT01752179|PROCEDURE|kinesio Tape : Width 5cm ,Length 35cm Y shape|"In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.~Taping method include :~1. stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.~2. puts the base of tape over the contralateral of sacrum with no tension.~3. attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.~4. attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.~This is an origin to insertion application."
41296252|NCT04936451|DEVICE|TENS (transcutaneous electrical nerve stimulation) ECOMODYN|"TENS ECOMODYN® is applied to 4 treatment points, 5 minutes per point 2 times a day for 2 months.~A minimum rest period of 4 hours between 2 sessions on the same point must be respected Stimulation is performed directly with the bipolar probe of the TENS ECOMODYN® device on the painful area by fixed stimulation of 4 active pain points in 77Hz mode."
41296253|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #1|Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
41296254|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #2|Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
41296255|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #3|"Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable."
41296256|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #4|Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
41296257|NCT02412644|DRUG|apremilast|
40768552|NCT02729519|PROCEDURE|TAVI|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
40768553|NCT05377723|DEVICE|Neodyne Device|See Arm Description: Neodyne Device
41296258|NCT03395340|DRUG|Ruxolitinib 1.5% cream|Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
41296259|NCT03395340|DRUG|vehicle cream|Matching vehicle cream applied as a thin film
40768554|NCT05329766|DRUG|Domvanalimab|Administered as specified in the treatment arm
40768555|NCT05329766|DRUG|Quemliclustat|Administered as specified in the treatment arm
41296260|NCT03536312|PROCEDURE|Thoracic Aortic Surgery|Thoracic aortic surgery to treat thoracic aortic aneurysm
41296261|NCT00002191|DRUG|Albendazole|
41296262|NCT00502905|DRUG|Busulfan|130 mg/m\^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.
41296263|NCT00502905|DRUG|Fludarabine|40 mg/m\^2 through a central venous catheter over one hour, once a day, for four days.
40768556|NCT05329766|DRUG|Zimberelimab|Administered as specified in the treatment arm
41138318|NCT04748341|OTHER|Pedagogical Framework (Learn, See, Practice, Prove, Do, and Maintain)|"The Learn, See, Practice, Prove, Do, and Maintain (LSPPDM) pedagogy is acting as a guiding path for educators in teaching and learning procedural skills. It is synthesized after intensely reviewing the literature comprises steps. In the 1st step, learners learn through didactic lectures, further proceeding to see procedural videos. The 3rd step, Practice expose learners to perform the skill on a simulator. In the 4th step Prove the learner proves the skill. The 5th step Do comprise real-life exposure through the clinical rotation. Then, finally the 6th stepMaintain the learner maintains skill supplemented with simulation as needed."
41457840|NCT00469885|DRUG|Nicotine replacement|For reduction
41296264|NCT03824977|DIAGNOSTIC_TEST|Six minutes stepper test (6MST)|"The 6MST is done using a stepper (Stepper essential, Decathlon(TM), France), with a walking height of 20 cm, placed in front of a wall or parallel bars, so patients can hold on if necessary.~Patients are instructed to make the maximum number of steps possible in 6 minutes, and are given a time check at one minute intervals."
41296265|NCT03824977|DIAGNOSTIC_TEST|Sit to stand test (STST)|The STST is done using a chair measuring 47 cm in height. The patient are instructed to sit in the chair and then to do the maximum number of lifts possible from the chair, in 1 minute, with arms folded and without leaning against the chair.
41296266|NCT01312428|DEVICE|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
41296267|NCT01312428|DEVICE|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
41296268|NCT02028338|COMBINATION_PRODUCT|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
41296269|NCT02028338|COMBINATION_PRODUCT|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
41296270|NCT01452776|DRUG|TAK-438|TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
41296271|NCT01452776|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
41296272|NCT03663608|PROCEDURE|WALANT Technique|pure local anaesthesia and without use of a tourniquet (WALANT Technique) for trigger finger release surger
41457841|NCT00469885|BEHAVIORAL|Motivational counseling|No drugs
41296273|NCT05555446|DIETARY_SUPPLEMENT|Bovine colostrum|Subject will receive bovine colostrum with gluten.
41296274|NCT05555446|DIETARY_SUPPLEMENT|Placebo|Subject will receive a placebo with gluten.
41296275|NCT03567499|DRUG|GSK3039294|GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.
41296276|NCT03567499|DRUG|Placebo|Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
41296277|NCT00679159|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
41296278|NCT00679159|BIOLOGICAL|Prevenar|Streptococcus pneumoniae vaccine
41296279|NCT06127225|DRUG|Proliverenol|1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily
41457842|NCT04589364|DRUG|Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)|injection of toxin on facial muscle
40768557|NCT05329766|DRUG|Fluorouracil|Administered as specified in the treatment arm
40768558|NCT05329766|DRUG|Leucovorin|Administered as specified in the treatment arm
40768559|NCT05329766|DRUG|Oxaliplatin|Administered as specified in the treatment arm
41296280|NCT06127225|DRUG|Placebo caplets of Proliverenol|2 caplets of Proliverenol Placebo daily
41296281|NCT02629081|OTHER|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
41296282|NCT01733316|DRUG|RP103|
41296283|NCT01733316|DRUG|Cystagon®|
41457843|NCT01116791|PROCEDURE|Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)|"* CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)~* HIPC is administered immediately after CRS"
41457844|NCT00268762|DRUG|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
41457845|NCT03252457|DRUG|Decitabine|given intravenously at a dose of 3.5mg/m2/d for 4 consecutive days as a cycle and repeated every 2 weeks for 3cycles
41457846|NCT03252457|DRUG|Dexamethasone|given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.
41457847|NCT04133116|DRUG|LY3471851|Administered SC
41457848|NCT04133116|DRUG|Placebo|Administered SC
40968445|NCT06019819|OTHER|Postural correction exercises|Chin Tuck, Strengthening shoulder retractors, Stretching sternocleidomastoiD, Pectorals stretch For strengthening exercises 3 sets of 10 repetitions were performed with 6 seconds rest period between each set and a hold of 6 seconds. Stretching exercises will be performed in 3 sets of 10 repetitions ,30 seconds hold and 30 seconds rest period between each exercise. The exercises were performed 3days a week for 4 weeks.
40968446|NCT04187014|DRUG|Aminocaproic Acid 1000Mg Tab|Oral administration of a total 6 g of aminocaproic acid to reduce blood loss
40968447|NCT04187014|DRUG|Tranexamic acid tablets|Oral administration of 3.9 g of tranexamic acid to reduce blood loss
40968448|NCT03155568|PROCEDURE|sciatic nerve block|sciatic nerve block at popliteal fossa
40968449|NCT03155568|PROCEDURE|ankle block|block of major nerves supplying the foot at the level of the ankle
40968450|NCT03155568|DRUG|Bupivacaine|blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
40968451|NCT04450368|DEVICE|Sylvee|The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
40968452|NCT01785693|DRUG|levobupivacaine, clonidine|
40968453|NCT04910802|BIOLOGICAL|Gardasil9|Concomitant vaccination and HPV screening. Gardasil9 will be administered using standard dosage. 1 dose at recruitment and the 2nd dose 3 years later.
40968454|NCT05611398|PROCEDURE|Orthopedic Surgery|A complete retrospective chart review was performed for all the patients' records and included all patients aged 18 years or higher who presented to Arrowhead Regional Medical Center with long bone fractures with Injury Severity Score \<16 and their repair and lactate levels at the time of surgery
40968455|NCT02706691|DRUG|BGJ398|Given by mouth (oral)
40968456|NCT02785432|DEVICE|Sham low level laser|Sham laser will be administered using the same time and contact exposure as delivered for the active group, but without any energy delivered.
40968457|NCT02785432|DEVICE|Active low level laser|Active treatment will be delivered using the time, contact, and energy exposures described in the arm description.
40968458|NCT02512588|DRUG|BTD-001|
40968459|NCT02512588|DRUG|Placebo|
40968460|NCT01560364|OTHER|renal replacement therapy|Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
40968461|NCT06342466|DRUG|Bortezomib|Bortezomib 1.3mg/m2 sc weekly
40968462|NCT06342466|DRUG|Pomalidomide|4mg per day taken orally on 1-21 of repeated 28-day cycles
40968463|NCT06342466|DRUG|Dexamethasone|Dexamethasone 20mg-40mg weekly
40968464|NCT00289991|DRUG|Itraconazole|Prophylaxis
40968465|NCT00289991|DRUG|Vfend - voriconazole|Prophylaxis
40968466|NCT00717691|DEVICE|Metatarsophalangeal Extension Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
40968467|NCT00717691|OTHER|Standard of Care|The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
40968468|NCT00933972|DRUG|RO4998452|20mg po single dose
40968469|NCT01324843|DRUG|EMLA Cream|
40968470|NCT01324843|DRUG|Aveeno Daily Moist|
40968471|NCT01324843|DEVICE|Derma Vax|
41138319|NCT04748341|OTHER|Traditional Method|"The traditional method group learns through 2-step method.~1. didactic lectures on neonatal resuscitation were delivered.~2. Practice skill on mannequins"
41457849|NCT01611506|BIOLOGICAL|Cetuximab|"Induction chemotherapy:~Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter~Followed by:~Cetuximab 250mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~3 cycles of Cetuximab 250mg/m2 weekly on day 1"
40968472|NCT01324843|PROCEDURE|Intradermal Electroporation|
40968473|NCT01324843|PROCEDURE|Visual Analogue Scale|
40968474|NCT01324843|PROCEDURE|Present Pain Intensity|
40968475|NCT01324843|PROCEDURE|McGill Pain Questionnaire|
40968476|NCT01324843|PROCEDURE|Skin Assessment|
40968477|NCT01007812|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
40968478|NCT01007812|DEVICE|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
40968479|NCT02662296|DRUG|Ibrutinib|Given PO
40968480|NCT02662296|DRUG|Idelalisib|Given PO
40968481|NCT01673867|BIOLOGICAL|Nivolumab|
40968482|NCT01673867|DRUG|Docetaxel|
40968483|NCT03972332|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
40968484|NCT01966159|DEVICE|SYNERGY Investigational Device|percutaneous coronary intervention
41457850|NCT01611506|DRUG|Capecitabine|"Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle"
41296284|NCT02725073|PROCEDURE|Photodynamic therapy|Photolon (Belmedpreparaty, Minsk, Republic of Belarus), was administered intravenously at a dose of 2.5 mg/kg at 3 hours before illumination. After advancing a catheter (7 F inner sheath of a plastic stent delivery catheter \[MAJ-1419; Olympus America, Center Valley, Pa., USA\]) across the biliary stricture using a 0.035-in guidewire, the cylindrical diffuser is inserted into a catheter at the level of the stricture to be treated. Photoactivation (660 nm with a light dose of 100-150J/cm2, and fluence of 0.8-1W/cm2; UPL- FDT; LEMT Research \& Development Private Unitary Enterprise, Minsk, Republic of Belarus) is performed
41296285|NCT04841629|OTHER|PreBioGyn Gel|Cellulose-based prebiotic gel developed to optimize vaginal health and reduce the risk of cervical cancer in women.
41296286|NCT04841629|OTHER|Trimosan Gel|Carbomer-based gel
40768560|NCT03988218|BEHAVIORAL|perceptive tests|many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
40768561|NCT05826054|DIETARY_SUPPLEMENT|Montbretin A|The investigational product is 95% pure montbretin A (MbA), a glycosylated acyl-flavonol isolated from the corms (bulbs) of the Crocosmia plant through hot water extraction. It is a potent and specific inhibitor of human pancreatic amylase (HPA).
40768562|NCT06547632|DEVICE|ClearPetra Ureteral access sheath|Patients will be randomly assigned (1:1) to vacuum-assisted (ClearPetra) or traditional approach group for retrograde intrarenal surgery according to standard of care.
40968485|NCT01966159|DEVICE|PE Plus Investigational Device|percutaneous coronary intervention
40968486|NCT03792581|DEVICE|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
41138320|NCT06154161|DIETARY_SUPPLEMENT|Whey protein supplement|A monthly supply of 35 g of whey protein isolate will be provided to participants in individual sachet packets with instructions of preparation. Every month, participants will come to the center to provide the standard monthly blood sample. At this time, the PI will have participants complete the quality-of-life instrument, ask if there have been any changes in their dietary habits, and collect weights for up to 6-months. Additionally, participants will indicate if they had consumed the protein daily and/or bring back their empty/full satchel packets. As this is a feasibility trial, it is necessary to determine the compliancy of consuming protein daily and the amount. Furthermore, understanding how protein markers may be affected by consumption of the protein daily vs less frequently throughout the week is important to establish improved recommendations for consumption of protein supplements.
41138321|NCT03608111|OTHER|single task balance training|single task balance training
41138322|NCT03608111|OTHER|dual task balance training|dual task balance training
41138323|NCT05126537|OTHER|no intervention|prospective and observational study with no intervention
41296287|NCT04841629|OTHER|RepHresh Gel|Carbomer-based gel
41457851|NCT01611506|DRUG|Cisplatin|"Induction chemotherapy:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle~Followed by:~Cisplatin 30mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle"
41457852|NCT03957096|DRUG|SGN-CD47M|SGN-CD47M administered intravenously
40768563|NCT03384966|DRUG|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.
40768564|NCT03384966|DRUG|Placebo|Matching placebo for subcutaneous administration.
40768565|NCT03384966|DRUG|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
40968487|NCT00262574|DRUG|Nesiritide,|PCI
40968488|NCT04007081|PROCEDURE|Bone Marrow Aspiration|collection of approximately 40 mL of bone marrow aspirate
40968489|NCT04007081|DIAGNOSTIC_TEST|Ultrasound Imaging of Salivary Glands|Salivary gland size will be measured by ultrasound.
40968490|NCT04007081|OTHER|Salivary Assay|Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions
40968491|NCT04007081|OTHER|Quality of Life Instruments|Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.
40968492|NCT02034669|DEVICE|Laminectomy|surgical laminectomy with glial scar resection
41138324|NCT05397509|OTHER|Olive leaf tea|250 mL of Olive leaf tea and a high-glycemic breakfast
41138325|NCT05397509|OTHER|Placebo tea|250 mL of placebo tea and a high-glycemic breakfast
41296288|NCT00002466|DRUG|cyclophosphamide|
41296289|NCT00002466|DRUG|doxorubicin hydrochloride|
41296290|NCT00002466|DRUG|etoposide|
41296291|NCT00002466|DRUG|ifosfamide|
41296292|NCT00002466|DRUG|vincristine sulfate|
41296293|NCT00002466|PROCEDURE|conventional surgery|
41296294|NCT00002466|RADIATION|radiation therapy|
40968493|NCT02034669|DEVICE|Intradural space|ADSCs injection into Intradural space at damage site
40968494|NCT02034669|DEVICE|Intrathecal|ADSCs Intrathecal into lumbar puncture
40968495|NCT02034669|DEVICE|Intravenous|ADSCs intravenous
40968496|NCT03947372|PROCEDURE|Appendectomy|removal of acutely inflamed appendix
40968497|NCT06234111|COMBINATION_PRODUCT|Semaglutide 2.4 mg, total diet replacement, behavioural intervention|Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.
40968498|NCT02984709|BEHAVIORAL|Positive Psychology Intervention|Health Behavior Contract - Baseline visit Education Packet - Baseline visit Positive psychology training for teen and parents - baseline visit Parent praise reminder (text message) - one time per week (over 8 week intervention period) Teen gratitude message (text message) - every Monday (over 8 week intervention period) Teen positive value message (text message) - every Wednesday (over 8 week intervention period) Teen mood booster (text message) - every Thursday and Saturday and alternative Sundays (over 8 week intervention period) Small gift ($5 gift card code sent every 2 weeks for 8 weeks)
40968499|NCT02984709|BEHAVIORAL|Education|Health Behavior Contract - Baseline visit Education Packet - Baseline visit
41138326|NCT06459544|DIAGNOSTIC_TEST|Bobath Technique with core stability|exercise to improve balance motor learning stretegy is basically used. Bobath in which we assess patient's posture, inhibit the abnormal muscle tone and facilitate normal patterns and posture through handling and posture. we also use sensory inputs like propioception to promote normal pattern. we take some exercise based on bobath technique with core stability like Bridging with core stability, quadroped with core stability, sitting and standing with core stablity, single leg standing , dynamic balance with core stability.treatment plan based on 45 minutes per day, 6 days a week for 4 week.
41138327|NCT06459544|OTHER|Conventional treatment for balance|like stretching, strenthening the Lower extremity muscles , PROMS, AAROMS,AROMS, RROMS,some balance exercise like sitting and standing
41138328|NCT05120752|OTHER|FODMAP diet|all participants need to follow a low FODMAP diet, the information will be given by a trained dietitian
41138329|NCT06368388|OTHER|Prospective data collection|Prospective data collection prior to, during and after phage treatment.
41138330|NCT06368388|OTHER|Prospective data collection|Prospective data collection prior to, during and after standard infection treatment.
41138331|NCT01775657|DEVICE|Thopaz (Digital drainage)|
41138332|NCT01775657|DEVICE|Pleur Evac (Analogue drainage)|
41138333|NCT04083209|BEHAVIORAL|Opioid counseling|The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
40768566|NCT05761301|DRUG|ALN-KHK|ALN-KHK will be administered by subcutaneous (SC) injection.
40968500|NCT00635167|DRUG|Contrast Enhanced-Transrectal Ultrasound|Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline \[Visit 2\]); week 5 (middle of treatment \[Visit 3\]); week 10 (end of treatment \[Visit 4\]); week 18 (2 months after end of EBRT \[Visit 5\]); week 26 (4 months after end of EBRT \[Visit 6\]); and week 36 (6 months after end of EBRT \[Visit 7\]).
40968501|NCT00541931|DRUG|Dietary Supplement: LifePak Nano|Daily use
40968502|NCT05499312|DRUG|HKIIM-KU formula|Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
40968503|NCT05499312|DRUG|Placebo|Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
41138334|NCT04180943|DRUG|interscalene nerve block|intra and post-operative analgesia
41138335|NCT02829398|PROCEDURE|CerebroSpinal fluid and plasma samples|CerebroSpinal fluid and plasma samples for biological markers
41138336|NCT02364856|DEVICE|Analgesia Nociception Index|"The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.~ANI is calculated from heart rate recording."
40768567|NCT05761301|DRUG|Placebo|Placebo will be administered by subcutaneous (SC) injection.
40768568|NCT00131885|DIETARY_SUPPLEMENT|Placebo Control (Placebo Herb)|Placebo herb three times daily (ground cellulose) for 4-6 weeks
40768569|NCT00131885|DIETARY_SUPPLEMENT|St. John's Wort|St. John's Wort (Hypericum perforatum) orally or 4-6 weeks
40968504|NCT04826432|DRUG|Pasireotide 0.9 MG/ML|0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
40968505|NCT04826432|OTHER|Saline water|0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
40968506|NCT02031068|BEHAVIORAL|Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~1. Sub-maximal aerobic training for up to 15 minutes~2. Light coordination and sport-specific exercises for up to 10 minutes~3. Visualization and imagery techniques~4. Home program~A physiotherapist will supervise the rehabilitation."
40968507|NCT02031068|BEHAVIORAL|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
40968508|NCT01155271|OTHER|Rehabilitation|"12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)~1 technical visit and 1 nursing visit every two months at home for the CPAP"
40968509|NCT03103568|DRUG|Nitisinone in Arm A|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
40968510|NCT03103568|DRUG|Tolbutamide|A 500 mg tablet is given as single oral dose 2 weeks apart.
40968511|NCT03103568|DRUG|Metoprolol|A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
40968512|NCT03103568|DRUG|Chlorzoxazone|A 250 mg tablet is given as single oral dose 2 weeks apart.
40968513|NCT03103568|DRUG|Furosemide|A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
40968514|NCT03103568|DRUG|Nitisinone in Arm B|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
40968515|NCT00679315|DRUG|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
40968516|NCT00679315|DRUG|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
41138337|NCT05918185|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40968517|NCT02533739|BEHAVIORAL|Cognitive and neuropsychological assesment|
41138338|NCT05918185|OTHER|Comprehensive Geriatric Assessment|Undergo cGA
41138339|NCT05918185|OTHER|Electronic Health Record Review|Medical records are reviewed
41138340|NCT05918185|OTHER|Survey Administration|Complete surveys
41138341|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
40968518|NCT01335984|PROCEDURE|Telemonitoring|"The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.~The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center."
40968519|NCT01335984|PROCEDURE|Telemonitoring & Telemedicine|"The subjects who are assigned in the Telemonitoring \& Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.~Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions."
41138342|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
41138343|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
41138344|NCT04803045|OTHER|Follow up email|Patients received an email 3 months after an initial consult asking why they had not returned to care. Patients were provided with 4 options and a space to write in comments. The email asked if the patient had any questions and offered support.
40968520|NCT01335984|OTHER|control group|"- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).~The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks)."
40968521|NCT04841460|DIETARY_SUPPLEMENT|Low-fat ground beef|5% fat ground beef
40968522|NCT04841460|DIETARY_SUPPLEMENT|High-fat ground beef|25% fat ground beef
40968523|NCT00583609|DRUG|PEG3350|PEG3350
40968524|NCT04525417|DIAGNOSTIC_TEST|AAZ Covid-19 rapid test|To assess the immune status
40968525|NCT00465374|PROCEDURE|Change ventilatory parameters with stress index monitoring|
40968526|NCT00790023|DRUG|80 mcg Ciclesonide|80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
40968527|NCT00790023|DRUG|160 mcg Ciclesonide|160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
40968528|NCT00790023|DRUG|Placebo|Placebo HFA Inhaler once daily (one actuation per nostril)
40968529|NCT05202652|DIETARY_SUPPLEMENT|HealthSpan|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the oral capsule containing the active ingredients, for three consecutive months.
40968530|NCT05202652|DIETARY_SUPPLEMENT|Placebo|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the placebo, for three consecutive months.
40968531|NCT05416398|OTHER|Aerobic Exercise, High Intensity Interval Training|Aerobic exercise is a form of exercise done by consuming oxygen in order to give energy to the body. High Intensity Interval Training consists of low-intensity periods of active rest combined with short periods of intense exercise.
40968532|NCT05165901|DEVICE|Scrambler Therapy|LG Medipain is a type of non-invasive neuromodulation.
40968533|NCT01716767|OTHER|Menthol|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
40768570|NCT00131885|DRUG|Levonorgestrel|Levonorgestrel in a single oral dose
40768571|NCT01585025|DRUG|Obeticholic acid|Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
40968534|NCT01716767|OTHER|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
41146872|NCT02168153|OTHER|Chiropractic Manipulative Therapy|Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.
40768572|NCT06192550|DEVICE|Profound Matrix™ System|Study subjects will be treated with the Profound Matrix System
40968535|NCT01728064|DRUG|Placebo|Placebo capsules
40968536|NCT01728064|DRUG|EPI-743 400 mg|
40968537|NCT01728064|DRUG|EPI-743 200 mg|
40968538|NCT05045014|OTHER|Balance assessment|Romberg test and one-leg standing test will be used.
40968539|NCT05045014|OTHER|Unterberger test|During 50 steps, he will count in place with 45 degrees of hip flexion, and after 50 steps, the angle of rotation between the first position and the final position of the right foot will be measured with the help of a goniometer and the displacement distance.
40968540|NCT05045014|OTHER|Corsi Block Tapping (mobıl app)|Spatial memory will be evaluated.
40968541|NCT05045014|OTHER|Navigation performance|Two triangles (one equilateral, one oblique triangle, at 30°, 60° and 90° angles respectively) with route segment lengths between 150 and 300 cm will be marked on the floor and the participants will be asked to complete the task with their eyes closed. The final deviation amount will be recorded.
40968542|NCT05045014|OTHER|Cobb angle measurement|It will be evaluated with the help of X-ray.
41457853|NCT00905008|PROCEDURE|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis \<30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
41457854|NCT00905008|DEVICE|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
40968543|NCT05045014|OTHER|Scolio Detector (mobıl app)|The degree of rotation will be measured with the mobile application called Scolio Detector.
40968544|NCT01609374|DEVICE|M6-C Artificial Cervical Disc|Total disc replacement
40968545|NCT01609374|DEVICE|Anterior plate system with corticocancellous allograft bone|Cervical fusion
41457855|NCT01236495|DRUG|spinal morphine 0.3 mg|spinal morphine 0.3 mg
40968546|NCT02144012|DRUG|Trastuzumab|For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
40968547|NCT02144012|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
40968548|NCT02144012|DRUG|Docetaxel|Docetaxel was administered IV at either 75 milligrams/square meter (mg/m\^2) or 100 mg/m\^2 Q3W.
40968549|NCT00786149|OTHER|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
40968550|NCT00786149|OTHER|Varenicline without counseling|Brief advice, one time during initial session
40968551|NCT00270868|PROCEDURE|Double guide wire technique|
40968552|NCT00270868|PROCEDURE|Standard bile duct cannulation|
40968553|NCT03181334|BEHAVIORAL|Branch I|FIT kits and a Standard (control) invitation letter to complete CRC screening is mailed to the homes of eligible patients.
40968554|NCT03181334|BEHAVIORAL|Branch II|"FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch II: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week."
40968555|NCT03181334|BEHAVIORAL|Branch III|"FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch III: Invitation letter to participate in free CRC screening, requesting they return the kit within 3-weeks."
41457856|NCT01236495|DRUG|spinal morphine 0.2 mg|spinal morphine 0.2 mg
41457857|NCT00484991|DRUG|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
40968556|NCT03181334|BEHAVIORAL|Branch IV|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch IV: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher incentive or within 3-weeks for a lower (half of the higher) incentive."
40968557|NCT03181334|BEHAVIORAL|Branch V|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch V: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as lower Branch IV) or within 3-weeks for a lower (half of lower Branch IV) incentive."
40968558|NCT03992001|BIOLOGICAL|Blood component A|PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs
40968559|NCT03992001|BIOLOGICAL|Blood component B|PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs
40968560|NCT03871712|BEHAVIORAL|Motivational interview|The participants will be called twice with 2-4 weeks interval after the randomisation. This will be after 8 weeks of sick leave.
40968561|NCT03871712|BEHAVIORAL|Stratified vocational advice|The participants will be called after the randomisation. The amount of calls/meetings will be decided after each call, but with a maximum of 4 for the high risk group. This may include physical meetings.
40968562|NCT05642208|DRUG|Dupilumab step-down|step down dupilumab injections
40768573|NCT06626516|DRUG|Tebentafusp-Tebn|Dosing: All patients enrolled in this study will receive treatment with tebentafusp-tebn based on the approved step-up dosing regimen of 20 mcg on C1D1, 30 mcg on C1D8, then 68 mcg weekly beginning on C1D15 and thereafter. This escalated dose administered at C1D15 will be the dose used for the remainder of the treatment period unless dose reduction is implemented for toxicity. Beginning with C1D8, tebentafusp-tebn will be administered on the scheduled day (± 2 days), and consecutive infusions of tebentafusp-tebn must be administered at least 5 days apart.
40768574|NCT06626516|DRUG|GM-CSF (Sargramostim)|Recombinant human GM-CSF (Sargramostim, Leukine®, Sanofi US) 1,500mg will be mixed with ethiodized oil (Ethiodol®). The GM-CSF/ethiodized oil mixture will be injected selectively into one of the hepatic lobes, followed by infusion of gelatin sponge particles to achieve the stasis of blood flow. This will repeat every 4 weeks.
40768575|NCT06626516|DRUG|BCNU|Patients will be treated with hepatic artery infusion of 300mg BCNU (1,3-bis \[2-chloroethyl\]-1-nitrosourea, Carmustine) dissolved in ethiodized oil followed by embolization with gelatin sponge particles \[TACE with BCNU 300mg\]; every 4 weeks +/- 7 days in the case of either bilobar or unilobar metastasis
40768576|NCT04756453|DEVICE|clip-traction|A endoscopic clip with a loop of tied dental floss will be attached to the lesion. The loop will then be caught by another endoscopic clip and attached to adjacent bowel wall, thus creating tension in the tissue, making dissection easier.
40768577|NCT04906512|DEVICE|3M™ Tegaderm™ CHG I.V. Securement Dressing|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
40768578|NCT04906512|DEVICE|3M™ Tegaderm™ Transparent Film Dressing 1626W|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
40768579|NCT01649869|OTHER|Placebo|Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
40768580|NCT01649869|DRUG|Valganciclovir|Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
40768581|NCT02843425|OTHER|Regular Diet|Participants follow their normal diet (not including beans for 8 weeks)
40768582|NCT02843425|OTHER|Navy Beans (Canned)|Participants add 1/2 cup of canned beans per day to their diets for the first 2 weeks. This is increased to 1 cup per day for the following 6 weeks of the study.
41146873|NCT02168153|OTHER|Wait-list|Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
40968563|NCT05948020|BIOLOGICAL|CBT102-A capsule|"Orally CBT102-A will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with 1.25×10\^11 live cell. The shelf life is 6 months.~Subjects receive oral dose of 1 capsule CBT102-A (1.25 x 10\^11 live cell) before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule CBT102-A (2.5 x 10\^11 live cell) before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule CBT102-A (5 x 10\^11 live cell) before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule CBT102-A (1 x 10\^12 live cell) before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21\~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
40968564|NCT05948020|OTHER|Placebo capsule|"Orally placebo will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with Lactose powder filler. The shelf life is 6 months. The color, condition, smell and other appearances are exactly the same as CBT102-A.~Subjects receive oral dose of 1 capsule placebo before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule placebo before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule placebo before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule placebo before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21\~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
40968565|NCT05450952|DIETARY_SUPPLEMENT|Theanine Formulation|Theanine Formulation Tablet
40968566|NCT05450952|DIETARY_SUPPLEMENT|Placebo|Placebo Tablet
40968567|NCT02322398|DRUG|rFSH plus rLH|150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
40968568|NCT02322398|DRUG|hMG|150-300 IU/d hMG
40968569|NCT05767645|DEVICE|Mistral Procedure|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
40968570|NCT02215187|BEHAVIORAL|Problem-Solving Training (PST)|Training in problem-solving skills to be applied to military caregiver problems.
40968571|NCT02215187|BEHAVIORAL|Attention Control|Social contact control (health education/no skill training)
40968572|NCT03046004|OTHER|Decision aid for breast cancer screening|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
40968573|NCT03046004|OTHER|Standard leaflet|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
40968574|NCT05374434|OTHER|Conventional irrigation|The participant will be treated by manual irrigation with sodium hypochlorite NaOCl.
40968575|NCT05374434|DEVICE|Inertial cavitation|The participant will be treated by inertial cavitation-generating device, that generates hydraulic cavitation to clean root canals deeper and more effectively than other existing systems.
40968576|NCT01332500|DRUG|Sumatriptan/Naproxen combination|Sumatriptan and Naproxen Sodium
40968577|NCT01332500|DRUG|other oral triptans|almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
40968578|NCT03485547|DRUG|Venetoclax|VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
40968579|NCT06229340|DRUG|Leflunomide|100 mg daily for 3 days at the loading dose, then 20 mg daily at the standard dose.
41138345|NCT04103164|DEVICE|Cutera excel V™ Laser|The Cutera® excel V laser is manufactured by Cutera, Inc. This laser with 532 nm KTP and 1064 nm Nd:YAG wavelengths has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the device for use in surgical and aesthetic applications requiring selective photothermolysis of target chromophores in soft tissue 510(k) number 022226. The 532 nm wavelength is indicated for the coagulation and hemostasis of benign vascular and cutaneous lesions in dermatology including, but not limited to, benign vascular lesions like angiomas, hemangiomas, port wine stains, venous anomalies and telangiectasia; benign pigmented lesions like nevi, lentigines, chloasma, café-au-lait; verrucae; skin tags; keratoses; plaques. The Cutera® excel V laser has also obtained the European CE Mark. The system was tested to ensure compliance with federal laser performance standards as applicable.
40968580|NCT06229340|DRUG|The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab|"Use of one of the possible MEK-inhibitor options:~Trametinib 2 mg once daily orally; Cobimetinib 60 mg on days 1-21, break 7 days, cycle 28 days orally; Binimetinib 45 mg 2 times a day daily orally. + Hydroxychloroquine 600 mg 2 times a day daily orally.~± Bevacizumab 7.5 mg/m² every 3 weeks intravenously."
41138346|NCT04094207|DRUG|Placebo oral tablet|Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
41138347|NCT04094207|DRUG|Pentoxifylline|Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day
40968581|NCT00456014|DRUG|Escitalopram|Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
40968582|NCT00456014|DRUG|Desipramine|Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
40968583|NCT04937673|DRUG|Camrelizumab+Albumin bound paclitaxel+Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Albumin bound paclitaxel: 130 mg / m2, intravenous drip for 30 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
41146874|NCT00878904|DRUG|epirubicin hydrochloride|
41146875|NCT00878904|DRUG|panobinostat|
40768583|NCT06468553|BEHAVIORAL|Prediabetes Care Program|Patients are cared for by the medical, nutritionist and psychology team, in a total of 14 individual and group visits, during 12 months of care. The intervention has an initial stage lasting 6 months in which 12 visits will be scheduled and a transition stage lasting 6 more months in which 2 more visits will be scheduled. Patients will be evaluated at 6 months, 12 months and 24 months
40968584|NCT04937673|DRUG|Camrelizumab+ Paclitaxel+ Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Paclitaxel: 80 mg / m2, intravenous drip for 180 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
40968585|NCT04200664|DIAGNOSTIC_TEST|Hearing assessment|All study participants will undergo hearing tests, including hearing-specific questionnaires
40968586|NCT04200664|DIAGNOSTIC_TEST|Vestibular/balance assessment|Siderosis group participants will undergo vestibular/balance tests, including gait assessment and balance-specific questionnaires
40968587|NCT04200664|OTHER|Quality of life assessment|All study participants will be asked to complete a set of quality of life questionnaires
40968588|NCT04200664|DIAGNOSTIC_TEST|Olfactory (smell) function testing|Siderosis group participants will undergo a formal smell identification testing by means of self-administered smell chart to identify the revealed scents
40968589|NCT04200664|GENETIC|DNA bio-banking|Siderosis group participants will be asked to provide a saliva sample for DNA bio-banking
40968590|NCT01881360|OTHER|Gluten-free diet|A diet that is free of the gluten component
40968591|NCT01881360|OTHER|Hypocaloric diet|A standard hypocaloric diet with a daily 1500 caloric intake.
40968592|NCT05351125|PROCEDURE|cardiac catheterization|catheterization in critical congenital heart disease requiring atrial septostomy or balloon valvuloplastyor PDA stenting
40968593|NCT05938972|BIOLOGICAL|Mepolizumab|Monoclonal antibodies
40968594|NCT03970278|OTHER|No intervention|No intervention
40968595|NCT05368571|OTHER|CHOICES-TEEN|This is a four-session hybrid in-person and Telehealth counseling intervention that is designed to reduce the risk of HIV/STI and alcohol- and marijuana-exposed pregnancy for young women who are involved in the juvenile justice system between the ages of 14-19.
41138348|NCT04640584|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
41138349|NCT04288869|OTHER|Continuous monitoring of arterial blood pressure|For all patients, mean arterial pressure (unit mmHg) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.
41138350|NCT04288869|OTHER|Transcranial Doppler|"Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography.~For all patients, CFV (unit cm/s) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
41138351|NCT04288869|OTHER|Bispectral Index (BIS)|"Continuous measurement of burst suppression (BS; %) with use of Bispectral Index (BIS).~For all patients, BS will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation"
41138352|NCT04288869|OTHER|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
41138353|NCT06233149|DRUG|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
41138354|NCT06233149|DRUG|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
40768584|NCT06534008|BEHAVIORAL|12-week home-based exercise intervention|All participants will be given the same 12-week distance-based exercise intervention.
40768585|NCT06609096|BEHAVIORAL|Sexual counseling based on the PLISSIT model|Four sessions of sexual counseling based on the PLISSIT model will be provided. The intervention consisted of four consecutive sessions, with one session per week. Each session is 30 minutes on average.
40768586|NCT06609096|BEHAVIORAL|Sexual counseling based on the BETTER model|A total of four sessions of sexual counseling based on the BETTER model will be provided. The intervention consists of four consecutive sessions, one session per week. Each session is 30 minutes on average.
40768587|NCT06062485|DRUG|Surufatinib+Toripalimab+AG|"This is a single-arm, prospective, exploratory clinical study of unresectable or relapsing metastatic ampullary tumors who were not systematically treated with surufatinib in combination with PD-1 antibody and AG regimen.Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.The AG regimen does not exceed 8 cycles, and maintenance therapy with surufatinib combined with toripalimab can be continued if the patient has not progressed after 8 cycles. The treatment period was 21 days; Tumor treatment and survival status were recorded until disease progression (RECIST 1.1) or death (during patient treatment).~Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；AG（Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W）Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W）"
40968596|NCT05368571|OTHER|Health and Life Skills Education|This is a four-session psychoeducational intervention that is designed to provide information on time management, sleep, nutrition and exercise, and financial management.
40968597|NCT03648541|DRUG|Spesolimab|Solution
40968598|NCT05530421|DRUG|Selinexor|Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
40968599|NCT05530421|DRUG|Venetoclax|Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
40968600|NCT05530421|DRUG|Dexamethasone|Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
40768588|NCT05345158|PROCEDURE|Robotic Retroperitoneal Lymph Node Dissection (RPLND)|Robotic RPLND performed using the DaVinci robotic surgical system.
40768589|NCT05227326|DRUG|PCNA Inhibitor AOH1996|Given PO
41296295|NCT01869894|PROCEDURE|metallic biliary stent insertion (double bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
40768590|NCT04104789|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
40768591|NCT04104789|DRUG|Articaine Injection|Local anesthetic
40968601|NCT05421624|DEVICE|Digital music therapeutic|The digital music therapeutic is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.
40768592|NCT04046744|PROCEDURE|Axillary brachial plexus block with a long-acting local anesthetic|axillary block with 15-30 ml Ropivacaine 0,5%.
40768593|NCT04046744|PROCEDURE|Axillary brachial plexus block with a short-acting local anesthetic + Analgesic block at the elbow with a long-acting local anesthetic|axillary block with 15-30 ml Lidocaine 1,5% + radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%.
40768594|NCT04046744|DRUG|Ropivacaine|axillary block with 15-30 ml Ropivacaine 0,5%
40768595|NCT04046744|DRUG|Ropivacaine|radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%
40768596|NCT04046744|DRUG|Lidocaine|axillary block with 15-30 ml Lidocaine 1,5%
40768597|NCT05997953|OTHER|Edinburgh Postnatal Depression Scale|Edinburgh Postnatal Depression Scale used as screening tool for postpartum depression
40768598|NCT01422382|DRUG|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
40768599|NCT01422382|DRUG|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
40768600|NCT04278781|DRUG|AG-120|AG-120 500 mg orally once daily days 1-28 of a 28-day cycle
40768601|NCT05142293|OTHER|Ambulatory procedure|In the same-day hospitalization group, some patients will be hospitalized on an ambulatory process
41296296|NCT01869894|PROCEDURE|metallic biliary stent insertion (single bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
41296297|NCT01869894|PROCEDURE|metallic biliary stent insertion (single bare - Taewoong Medical.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
40768602|NCT03836079|DEVICE|preCARDIA system|Intermittent occlusion of the SVC
40768603|NCT03510689|DIAGNOSTIC_TEST|echocardiography|Resting echocardiograms (Vivid E9 or E95, GE Healthcare) with conventional measures of systolic and diastolic function, in conjunction with posthoc quantitation of novel measures of strain and strain rate will be obtained at each study time point.
40768604|NCT03510689|OTHER|Cardiopulmonary Exercise Testing|A cardiopulmonary exercise test (CPET, also called V02 test) will be completed at each study time point utilizing a standard clinical protocol, on either a stationary bike or treadmill. The purpose of this test is to estimate maximal oxygen consumption (V02 max) as in index of cardiopulmonary fitness. Resting ECG, heart rate, and BP will be obtained prior to beginning the test, during each stage of the test and for 5 minutes after the test is stopped.
40768605|NCT03510689|OTHER|Blood Collection|We will obtain blood samples (approximately 16mL) at baseline and (approximately 12mL) at each follow-up visit. Typically these will be drawn via peripheral venipuncture, however if patients have a port-a-cath in place, blood may be drawn from the port instead.
40968602|NCT05421624|BEHAVIORAL|Active-Control|The Active-Control intervention will implement a similarly structured community-based walking program as Amped-PD, with the only exception the digital music therapeutic.
40968603|NCT05780385|DEVICE|nasotracheal intubation|patients requiring tracheal intubation receive nasotracheal intubation
40768606|NCT02881554|PROCEDURE|Computed Tomography|Undergo SC SPECT/CT
40768607|NCT02881554|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SC SPECT/CT
40768608|NCT02881554|DRUG|Technetium Tc-99m Sulfur Colloid|Given IV
40768609|NCT01761149|DRUG|Remifentanil|The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
40768610|NCT06399094|OTHER|Lung sound recordings|The lung sound recordings will be made during a consultation scheduled as part of the patient's usual follow-up, after obtaining the patient's non-opposition.
41296298|NCT03744169|DIAGNOSTIC_TEST|Lung ultrasound|A point-of-care lung ultrasound exam will be performed on admission (no later than 14 hours following admission, allowing for participant stabilization and care) to the PICU and within 6 hours of any escalation in mechanical ventilatory support without interrupting clinical care, by study investigators blinded to participant history, physical examination, and diagnostic testing/imaging and who are not involved in the clinical management of the participant. Investigators will use a six-zone standardized scanning protocol with pattern analysis to form a diagnosis for the cause of the participant's respiratory failure. Images will be acquired by pediatric critical care trainees and saved online; accuracy of diagnoses based on the ultrasound exam will be evaluated by a expert sonographer offline.
41296299|NCT03744169|DIAGNOSTIC_TEST|Clinical exam|Following morning ICU rounds, the PICU fellow or attending physician caring for the participant will be asked for his/her interpretation of the most recent chest radiograph and his/her diagnosis concerning the etiology of the participant's acute respiratory failure. This clinical diagnosis will be compared to ultrasound findings.
40768611|NCT03032029|DEVICE|Adaptive Servo-Ventilation|Adaptive Bi-Level positive airway pressure with a targeted minute ventilation and auto-adjusting expiratory pressure level.
40768612|NCT05303233|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anaesthetics around the nerve.
40768613|NCT05303233|PROCEDURE|IPACK|The IPACK will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where twenty mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anaesthetics will be observed above the posterior capsule.
41296300|NCT03744169|DIAGNOSTIC_TEST|Chest x-ray|Results of chest x-ray will be collected for comparison with ultrasound findings.
41296301|NCT01912872|DRUG|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
41296302|NCT01912872|DRUG|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
41296303|NCT01912872|DRUG|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
41296304|NCT01912872|DRUG|Budesonide|Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
40768614|NCT06317844|BEHAVIORAL|Behavioral Writing Intervention|This behavioral intervention will require participants to write about certain aspects of their lives.
40768615|NCT01809769|BIOLOGICAL|Mesenchymal stem cells low-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
40768616|NCT01809769|BIOLOGICAL|Mesenchymal stem cells mid-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
41296305|NCT01912872|DRUG|Formoterol|Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
40768617|NCT01809769|BIOLOGICAL|Mesenchymal stem cells high-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
41296306|NCT03344328|DRUG|Bortezomib|The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.
41296307|NCT00013598|DRUG|Pioglitazone|
41296308|NCT06156111|DEVICE|Transepithelial abutment group|Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments on the implants randomized to this group will be put at the torque the manufacturer recommends (30 Ncm typically), according to the appropriate gingival height and then the fixed implant-supported monolithic zirconia will be placed at the torque of 15 Ncm
40968604|NCT05780385|DEVICE|orotracheal intubation|patients requiring tracheal intubation receive orotracheal intubation
40968605|NCT03987217|DIETARY_SUPPLEMENT|Creatine Monohydrate|Given orally
40968606|NCT03987217|BEHAVIORAL|Exercise Intervention|Complete POWER resistance training program
40968607|NCT03987217|OTHER|Questionnaire Administration|Ancillary studies
40968608|NCT03313791|DIETARY_SUPPLEMENT|Whey protein concentrate|see arm description
40968609|NCT03313791|DIETARY_SUPPLEMENT|Yoghurt|see arm description
41138355|NCT00456339|DRUG|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
41138356|NCT00724009|DRUG|Clofarabine|Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
41138357|NCT02646098|PROCEDURE|CD34+ cell selection|CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
40968610|NCT03313791|DIETARY_SUPPLEMENT|50%whey-50% casein (Standard)|see arm description
40968611|NCT03313791|DIETARY_SUPPLEMENT|50%whey-50% casein (Alternative)|see arm description
40968612|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate- WPH|see arm description
41146876|NCT00878904|GENETIC|gene expression analysis|
41296309|NCT06156111|DEVICE|Direct to implant group|It will be registered the essential clinical data registration to produce an individual patient-oriented prosthesis, and then the fixed implant-supported monolithic zirconia will be placed at the torque of 30 Ncm.
41296310|NCT03015350|DRUG|Sevoflurane|Measurement of blood desflurane level during one lung ventilation
41296311|NCT03015350|DRUG|Desflurane|Measurement of blood desflurane level during one lung ventilation
41296312|NCT05470036|BEHAVIORAL|Educational intervention.|Educational intervention with trained educator on overview, rationale, implications, and risks and benefits of germline testing in prostate cancer.
41296313|NCT04578717|PROCEDURE|Air-abrasion|A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm
41296314|NCT04578717|PROCEDURE|Adhesive application - Etch&rinse|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .
41296315|NCT04578717|BIOLOGICAL|Adhesive application - Self-etch|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
41296316|NCT00406315|DRUG|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
41296317|NCT03566537|PROCEDURE|Thyroidectomy|Thyroidectomy
41296318|NCT03640091|PROCEDURE|Post-extractive inter-radicular implant bed preparation|Implant placement in mandibular molars
41296319|NCT01704781|DRUG|Lenalidomide|In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
41296320|NCT01704781|DRUG|Lenalidomide placebo|Capsules are identical to the active Lenalidomide capsules used.
41296321|NCT01704781|DRUG|Vacc-4X|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
41296322|NCT01704781|DRUG|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
41296323|NCT03702205|DIETARY_SUPPLEMENT|Betaine supplementation|Group taking oral betaine supplementation
41296324|NCT03702205|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (starch) in a similar capsule form.
40768618|NCT03593759|DRUG|Prednisone or Prednisolone|Oral prednisone/prednisolone tablet
40768619|NCT03593759|DRUG|Methotrexate|Oral, subcutaneous, or intramuscular methotrexate
40768620|NCT06344416|DEVICE|Use of ReX to dispense and monitor solid oral medication therapy.|ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).
40768621|NCT05280054|DRUG|AV-101|360 mg capsules
40768622|NCT05280054|DRUG|Probenecid|1000 mg oral
40768623|NCT06320782|BEHAVIORAL|Calorie restriction and balanced distribution of macronutrients|Progressive reduction of 500 to 1000 calories from the usual food intake or the recommendation of 20 calories/kg of current weight/day and distribution of macronutrients: 5% of carbohydrates, 2% of proteins and 3% of fats
40768624|NCT06320782|BEHAVIORAL|Calorie restriction and low-carbohydrate diet|Reduction in carbohydrate consumption and an increase in fat and protein intake, with the following proportions: 45% fat, 20% protein and 35% carbohydrate
40768625|NCT06320782|BEHAVIORAL|Calorie restriction and low-fat diet|Restriction of fat consumption and an increase in carbohydrate consumption, with the following proportions: 20% fat, 15% protein and 65% carbohydrate
41138358|NCT04277156|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063|7 drops contain Lactobacillus rhamnosus GG 5x10\^9 CFU; and Lactobacillus reuteri 1x10\^8 CFU.
41138359|NCT04277156|DIETARY_SUPPLEMENT|L rhamnosus ATCC 53103|5 drops contain Lactobacillus rhamnosus 5x10\^9 CFU.
40968613|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate - Na-caseinate|see arm description
40968614|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate|see arm description
41138360|NCT00630357|DRUG|Levetiracetam (Keppra)|
41138361|NCT00089609|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.
41138362|NCT00089609|DRUG|Thalidomide|Thalidomide 200 mg by mouth daily throughout the cycle.
40968615|NCT03313791|DIETARY_SUPPLEMENT|UHT milk|see arm description
40968616|NCT03313791|DIETARY_SUPPLEMENT|Recombined milk|see arm description
40968617|NCT03313791|DIETARY_SUPPLEMENT|Recombined 50%whey milk|see arm description
40968618|NCT03313791|DIETARY_SUPPLEMENT|Ca-caseinate|see arm description
41138363|NCT00089609|DRUG|Prednisone|Prednisone 10 mg by mouth daily throughout the cycle.
41138364|NCT00089609|BIOLOGICAL|bevacizumab|Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
41138365|NCT00089609|GENETIC|polymorphism analysis|Two buffy coat tubes (two 7mL blue tiger top tubes) will be obtained and wrapped in foil when the patient enters onto the study. DNA (deoxyribonucleic acid) will be isolated only for the purpose of genotype analysis of enzymes with putative relevance for docetaxel or thalidomide disposition.
40968619|NCT03313791|DIETARY_SUPPLEMENT|Milk protein isolate|see arm description
41138366|NCT00089609|OTHER|immunoenzyme technique|The PBMC (peripheral blood mononuclear cells) of patients will be analyzed pre-treatment and post cycle 2 for any changes in the function of regulatory T cells. The following analysis will be performed: flow cytometry analysis, CD4 CD25 T cell enrichment, and immunosuppression assay.
41138367|NCT00089609|OTHER|laboratory biomarker analysis|Serum and urine samples will be collected at baseline and monthly to measure VEGF (vascular endothelial growth factor) levels.
40968620|NCT03462303|COMBINATION_PRODUCT|Sham tDCS and tyrosine depleted drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.
41138368|NCT00089609|OTHER|pharmacological study|Plasma concentrations of docetaxel and thalidomide will be determined to assess interactions between docetaxel (and thalidomide) and the concomitant therapy.The analysis will be performed using a validated method based on liquid chromotography with mass-spectrometric detection.
41138369|NCT00598234|DRUG|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
41138370|NCT03315338|DRUG|CORT118335, 25 mg|CORT118335 is supplied as capsules for oral dosing
41138371|NCT03315338|DRUG|Prednisone Oral Tablet|"Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered."
41138372|NCT03315338|DRUG|Glucose|75 g in 300 mL solution, orally administered
41138373|NCT03315338|DRUG|Placebo oral suspension|"Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered."
41138374|NCT03315338|DRUG|CORT118335, 75mg|CORT118335 is supplied as capsules for oral dosing
41138375|NCT03315338|DRUG|CORT118335, 225mg|CORT118335 is supplied as capsules for oral dosing
41138376|NCT03315338|DRUG|CORT118335, 675mg|CORT118335 is supplied as capsules for oral dosing
41138377|NCT03315338|DRUG|CORT118335, 600mg|CORT118335 is supplied as capsules for oral dosing
41138378|NCT03315338|DRUG|CORT118335, 630mg|CORT118335 is supplied as capsules for oral dosing
41138379|NCT03315338|DRUG|CORT118335, 375mg|CORT118335 is supplied as capsules for oral dosing
41138380|NCT03315338|DRUG|CORT118335, 100mg|CORT118335 is supplied as a suspension for oral dosing
41138381|NCT03315338|DRUG|CORT118335, 300mg|CORT118335 is supplied as a suspension for oral dosing
41138382|NCT03315338|DRUG|CORT118335, 900mg|CORT118335 is supplied as a suspension for oral dosing
41138383|NCT03315338|DRUG|CORT118335, 150mg|CORT118335 is supplied as a suspension for oral dosing
41138384|NCT03315338|DRUG|CORT118335, 1500mg|CORT118335 is supplied as a suspension for oral dosing
41138385|NCT03315338|DRUG|Placebo oral capsule|Placebo capsules, orally administered
41138386|NCT03315338|DRUG|CORT118335, dose to be determined|CORT118335 is supplied as suspension for oral dosing
41138387|NCT04705389|OTHER|Samples|blood samples
41138388|NCT05445557|DRUG|RZL-012|small synthetic molecule for submental fat reduction
41138389|NCT05445557|DRUG|Placebo|Placebo
41138390|NCT02027584|OTHER|collection of remnant of clinically indicated blood sample|collection of remnant of clinically indicated blood sample
40768626|NCT06320782|BEHAVIORAL|Collective nutritional guidance|Recommendations of the Food Guide for the Brazilian Population: limitation of the intake of foods with high energy density from fats and simple carbohydrates; substitution of saturated fats for unsaturated fats; exclusion of trans fat from the diet; increasing fruit and vegetable consumption to a daily minimum of 400g; increased consumption of high-fibre foods and limiting the consumption of sugars and salt.
40768627|NCT03232567|BIOLOGICAL|NasoVAX|Single ascending dose study
40968621|NCT03462303|COMBINATION_PRODUCT|Anodal tDCS and tyrosine depleted drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.
41138391|NCT01271894|DRUG|Efavirenz|600 mg once daily; given as 3 x 200 mg once
41138392|NCT01271894|DRUG|Efavirenz|400 mg once daily; given as 2 x 200 mg + 1 x placebo
41138393|NCT03230448|OTHER|questionnaire|after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
41138394|NCT03698383|DRUG|Trastuzumab biosimilars(Herzuma), Gedatolisib|"* Trastuzumab biosimilar: Intravenously administered on Day 1 of every 21 day cycle at a dose of 6mg/kg (loading dose 8mg/kg at 1C)~* Gedatolisib: Intravenously administered on Day 1, 8 and 15 of every 21 day cycle at a dose of 180mg"
41146877|NCT00878904|GENETIC|protein expression analysis|
40968622|NCT03462303|COMBINATION_PRODUCT|Sham tDCS and balanced drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
40968623|NCT03462303|COMBINATION_PRODUCT|Anodal tDCS and balanced drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
41296325|NCT03611309|OTHER|Surgeon-palliative care team co management|Surgeon-palliative care team co management includes surgeon alone care and palliative care specialist team
41296326|NCT03611309|OTHER|Surgeon team alone management|The surgeon and surgical team will manage
41296327|NCT00198159|DRUG|ZD1839 Iressa|
41296328|NCT05402501|BEHAVIORAL|"Lifestyle intervention program Leef! met MS"|The lifestyle program consists of a three-months intensive program, followed by a 21-months 'inspiration' program with occasional meetings.
41296329|NCT01972477|DRUG|DLBS1449|Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
40968624|NCT06501066|BIOLOGICAL|umbilical cord mesenchymal stem cells|Patients assigned to UC-MSC administration groups will receive one administrations
40968625|NCT01919723|DRUG|Ticagrelor|Ticagrelor loading dose
40968626|NCT01919723|DRUG|Eptifibatide|i.v. infusion
41296330|NCT01972477|OTHER|Placebo|Placebo will be given every day for 8 weeks.
40968627|NCT02505997|DRUG|Midazolam|Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
40968628|NCT02505997|DRUG|Delafloxacin|Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
40968629|NCT04010487|GENETIC|whole exome sequencing and RNA-sequencing|The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
40968630|NCT01207791|BEHAVIORAL|screening|Brief screening to assess eligibility and collect minimal baseline data
40968631|NCT01207791|BEHAVIORAL|assessment|comprehensive substance use assessment
40968632|NCT01207791|BEHAVIORAL|referral|referral to treatment if indicated or requested
40968633|NCT01207791|BEHAVIORAL|Brief intervention|30-minute brief intervention session in ED
41296331|NCT03070418|PROCEDURE|Mini Incision Dynamic Hip Screw Technique|This technique is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision over the guide wire that is inserted parallel to the anteversion wire by using the 135° guide fixed on the T-handle; (step 2-2), and continuing AO technique steps, until step 3-4, for the plate assembling we remove the guide wire, and insert the plate sliding it through the skin cut over the femur shaft under the muscles using the plate for dissection the soft tissue above the bone surface non using any tool as periosteal elevator but the plate itself by holding it from its DHS screw canal and in 180 degree rotation position in axial aspect (transvers aspect) using the plate end for soft tissue gentle dissection over the bone, then turning the plate 180 degree over the bone shaft to the right position and sliding the DHS screw plat canal over the DHS screw using the measuring bar. Two skin stitches are enough.
41296332|NCT02241746|OTHER|no intervention|
41296333|NCT02028689|DRUG|Lesinurad 400 mg|
41296334|NCT02028689|DRUG|Metformin 850 mg|
41296335|NCT02028689|DRUG|Furosemide 40 mg|
41296336|NCT02793167|DEVICE|AKI alert|
41296337|NCT00282490|DEVICE|Nerve stimulator|
40968634|NCT01207791|BEHAVIORAL|booster sessions|two 15-minute booster counseling sessions conducted by telephone
40968635|NCT00496821|DRUG|ALN-RSV01|
40968636|NCT04348773|PROCEDURE|Dehydration|Dehydration of the natural tooth by tooth isolation
40968637|NCT04348773|PROCEDURE|Rehydration|Rehydration
40968638|NCT01844518|BIOLOGICAL|Abatacept|
40968639|NCT00116467|BIOLOGICAL|GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)|
40968640|NCT02697825|PROCEDURE|Schiotz tonometer for Intraocular Pressure|Both Values will be corelated
40968641|NCT02665520|PROCEDURE|liposuction for retrieval of own stem cells from fat cells|
40968642|NCT01314573|BEHAVIORAL|Sprint interval exercise|3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
40968643|NCT01314573|BEHAVIORAL|Maximal continuous exercise|3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
40968644|NCT04849598|OTHER|Oxygen therapy|Oxygen therapy during ESWTs and Stair Walking Test: one test using the prescribed constant oxygen flow and one using an automatic oxygen titration system. SpO2 target range: 90 - 94%
40968645|NCT00855920|DRUG|Rilonacept|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
40968646|NCT00855920|DRUG|Indomethacin|Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
40968647|NCT00855920|OTHER|Placebo (for Indomethacin)|Placebo (for Indomethacin) orally TID for 12 days.
40968648|NCT00855920|OTHER|Placebo (for Rilonacept)|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
40968649|NCT00612781|PROCEDURE|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
40968650|NCT00612781|PROCEDURE|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
40968651|NCT06358365|DEVICE|The AquaPass System|The system is a non-invasive, renal-independent, single-patient, multiple-use device intended for use at the hospital, outpatient clinic, or home. The system administers warm, dry air around the patient's body to create an environmental condition that activates the eccrine glands to produce sweat, in return it removes fluids from the interstitial compartment, where fluids accumulate in fluid overload.
40968652|NCT04495348|DRUG|Doravirine|Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.
40968653|NCT02102906|PROCEDURE|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
40968654|NCT01004627|PROCEDURE|Arterial and venous duplex ultrasound examination|Ultrasound mapping of all blood vessels in the upper limb of interest
40968655|NCT02209389|DEVICE|MRI|For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
40968656|NCT04648553|BEHAVIORAL|Task-Based Grounding|Three 50 minutes sessions with an interventionist that includes 6 non-punitive components of treatment common in Behavioral Parent Trainings: Education on behavior change, positive one-on-one time between parents and their children, differential attending to positive and negative behaviors, effective praise, giving effective instructions, and using a point and reward system to encourage prosocial behaviors. These components are distilled into 5 skill modules and paired with Task-Based Grounding, which involves a brief restriction of privileges and provides children with the opportunity to end the restriction by completing a prosocial task.
40968657|NCT04648553|BEHAVIORAL|Connected Care (Enhanced Treatment as usual)|Two sessions with a facilitator. The facilitator does NOT provide any guidance to the parent on managing their child's behavior, but provides empathy and problem solving to help them find a resource that best fits their needs. It is particularly geared towards helping parents connect with Behavioral Parent Trainings to address the needs of children with oppositional, defiant, or aggressive behaviors.
40968658|NCT03164902|DEVICE|Digital Medicine|The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose velpatasvir and sofosbuvir; fixed-dose ledipasvir and sofosbuvir; or fixed-dose glecaprevir and pibrentasvir; or fixed-dose sofosbuvir, velpatasvir, and voxilaprevir). The subject's prescribed HCV medication will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
40968659|NCT04644081|BEHAVIORAL|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postpartum mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
40968660|NCT04644081|BEHAVIORAL|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
40968661|NCT04644081|DRUG|TAU|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of mental health care).
40968662|NCT05803005|OTHER|inflammatory marker in autism spectrum disorder|Evaluate some Inflammatory markers \[IL-6, IL-8, TNF_alpha\] in children with autism spectrum disorder
40968663|NCT01163175|OTHER|Ruminant trans fats|"Consumption of the 4 experimental diets:~1. a diet rich in ruminant TFA (8 g/day);~2. a diet moderately rich in ruminant TFA (4 g/day);~3. a diet rich in industrial TFA (8 g/d);~4. a control diet (minimal dietary TFA of industrial and ruminant sources)."
40968664|NCT05013593|DIETARY_SUPPLEMENT|Red Clover Extract (RCE)|Red clover extract containing isoflavones Formononetin and biochanin A together with a heterogenous culture of probiotic lactic acid bacteria, and a natural sugar free raspberry/orange flavor. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening together with a meal)
40968665|NCT05013593|OTHER|Placebo (PL)|Placebo containing water, brown coloring, and natural sugar free raspberry/orange flavor.
40968666|NCT05199012|DIETARY_SUPPLEMENT|Black pepper extract|Subjects will be randomized to receive either the placebo or active (black pepper extract) in a 1:1
41296338|NCT00176566|DRUG|Lozenge Intake|of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
41296339|NCT00486226|DEVICE|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
41296340|NCT03009656|OTHER|No study specific interventions|
41296341|NCT03153111|DRUG|Macitentan|macitentan 10 mg; film-coated tablet; oral use
41296342|NCT03153111|DRUG|Placebo|film-coated tablet (identical to the macitentan tablet); oral use
40968667|NCT04592601|PROCEDURE|S.L.I.M.M.S. Procedure|Combined Gastric Bypass with Vertical Sleeve Gastrectomy
40968668|NCT06204146|BEHAVIORAL|massage|stressn level and preterm growth
40968669|NCT00160693|BIOLOGICAL|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
40968670|NCT03888456|OTHER|osteopathic treatment|the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified
41296343|NCT01287234|OTHER|Echocardiogram/SonR|All patients will have an echocardiograph and SonR sensor readings
41296344|NCT05556239|BEHAVIORAL|Resistance Exercise Training|Supervised resistance training program planned as 3 sessions per week of approximately 60 minutes. The resistance training program comprises 6 exercises for the major muscle groups, starting at 2 sets of 15 repetitions maximum progressing to 4 sets of 8 repetitions maximum. Each session will be supervised by physiotherapist to ensure proper technique, and progression in training load. The participants will choose an exercise ambassador from their network, who during the period will be encouraged to, on a weekly basis, to be in contact with the participant.
41296345|NCT00590083|BIOLOGICAL|CTL administration|"Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2."
40768628|NCT05504434|DEVICE|Single-use gastroscope|Adults patients are treated with a single use gastroscope instead of a reusable gastroscope
40768629|NCT02964078|DRUG|Pembrolizumab|Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
41296346|NCT00113802|DRUG|Epratuzumab (hLL2- anti-CD22 humanized antibody)|
40968671|NCT03888456|OTHER|sham|the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique
40968672|NCT05823961|DEVICE|Cross-linked hyaluronic acid eye drops|Cross-linked hyaluronic acid (CLHA)-based eyedrops
40968673|NCT02216591|DEVICE|Active Cognitive Training (ACT)|
40968674|NCT02216591|DEVICE|Control (CON)|
40968675|NCT04629352|DEVICE|Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)|In verum transcranial direct current stimulation (tDCS), patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
40968676|NCT04629352|DEVICE|Sham Accelerated Transcranial Direct Current Stimulation (acctDCS)|In sham transcranial direct current stimulation (tDCS), each SCZ patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. However, no current will be delivered beyond initial ramp-up time though the tDCS device display will indicate that 2mA current is being applied.
40968677|NCT05753423|DIAGNOSTIC_TEST|Interview-based questionnaires & Clinical examination|Interview-based questionnaires will be conducted among Egyptian mothers attending Pediatric Dentistry and Dental Public Health outpatient clinic at Faculty of Dentistry, Ain Shams University by the principal investigator. Clinical examination of the oral health status of their preschool children aged 3-5 years will be conducted by the principal investigator.
40968678|NCT00971594|BEHAVIORAL|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of \~0.2-0.4 kg/wk
40968679|NCT00971594|BEHAVIORAL|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
40968680|NCT05798091|BEHAVIORAL|Supportive-expressive group therapy|The intervention is based on the evidence-based supportive-expressive (SEGT) approach and was designed by an interprofessional team from psychiatry, social work, physiatry and occupational therapy, along with patient advisors. The SEGT approach fosters mutual support, promotes openness and emotional expression. It has been shown to yield improvements in anxiety, psychosocial functioning, health literacy, and social support in breast cancer survivors. This SEGT approach has been modified, in both content and process, to specifically address the needs of limb loss inpatients.
41296347|NCT04154267|PROCEDURE|Percutaneous renal biopsy.|The biopsy will be performed with a 16 Gauge semi-automatic needle gun for renal biopsy under real-time ultrasound control. After the procedure will be done ultrasound control
41296348|NCT05602597|DRUG|Itraconazole 200 mg|Study participants will be administered 200 mg itraconazole by mouth twice daily after the pharmacokinetic blood draw on Day 3 and once daily on Days 4 to 10, inclusive.
40968681|NCT05798091|OTHER|Treatment as usual|All patients may be referred to social work and/or a psychiatrist to address their mental health needs. As well, members of the interprofessional team provide psycho-social supports where needed. The types of psycho-social supports provided to patients in the TAU condition will be documented (e.g., referral to psychiatrist, social worker, etc.).
40968684|NCT04212650|DRUG|Losartan|Losartan will be administered to improve the quality of hip cartilage repair following arthroscopic microfracture. Losartan is a known anti-fibrotic agent via blocking of TGF-B1.
40968685|NCT04212650|OTHER|Placebo|Appearance-matched microcrystalline cellulose placebo
40968686|NCT04748120|PROCEDURE|Operative management|Patients will undergo surgical removal of the affected organ. The initial approach will be in a minimally invasive, laparoscopic fashion. If necessary, conversion to an open operation may be performed. These patients will be treated preoperatively and postoperatively with similar antibiotic regimens, however the duration of antibiotic therapies will be dependent on factors such as intraoperative findings, resolution of laboratory abnormalities, and tolerance of oral medications.
40990731|NCT06325007|DIETARY_SUPPLEMENT|Induction of labor|The study group only will drink a mixture of 60 ml of castor oil mixed with 140 ml of orange juice. Thirty minutes later, in both groups, an extraamniotic single balloon catheter will be inserted above the internal cervical os and filled with 60 mL of normal saline. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
40968687|NCT04748120|PROCEDURE|Non-operative management|"Patients will be treated with 3 days of intravenous antibiotics followed by 7 days of oral antibiotics, as described below:~Non-penicillin allergic patients~* piperacillin/tazobactam 3.375g IV every 6 hours for 3 days~* amoxicillin/clavulanate 875/125mg by mouth every 12 hours for 7 days~Penicillin allergic patients~* ertapenem 1g IV every 24 hours for 3 days~* ciprofloxacin 500mg every 12 hours AND metronidazole 500mg every 8 hours for 7 days~Patients may be considered to have failed non-operative management (e.g. treatment failure) if they experience absence of clinical improvement, worsening abdominal pain and/or localized/diffuse peritonitis in the judgment of the treating surgeon at any point within the study window. If this occurs, then surgeons may proceed with rescue appendectomy or percutaneous drainage in the setting of appendicitis, or with placement of a percutaneous cholecystostomy tube in the setting of acute cholecystitis."
40968688|NCT02475746|DRUG|PF-06372865|single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
40968689|NCT02475746|DRUG|itraconazole|Interacting drug which will be given 200 mg QD for 8 days in period 2
41138395|NCT03000725|BEHAVIORAL|Using Practice and Learning to Increase Favorable Thoughts|"Description of the UPLIFT program: Participants who choose to participate in UPLIFT will complete 8 weekly group sessions via telephone.~Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping \& Relaxing Session 4: Attention \& Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure \& the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks"
40768630|NCT02964078|DRUG|Interleukin-2|Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
40768631|NCT06376916|DRUG|Magnesium Sulfate 2 G|Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
40968690|NCT04913402|OTHER|Sufentanil administered by paramedics after the phone call consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
40968691|NCT04913402|OTHER|Sufentanil administered by paramedics based on their competency, without consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics with competency to administer sufentanil without medical doctor consultation.
40968692|NCT04964375|DRUG|ABSK043 oral capsule|ABSK043 is a novel, oral small molecule inhibitor of PD-L1
40968693|NCT03202498|DEVICE|4g Yaq-001|Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
40968694|NCT03202498|OTHER|4g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
40968695|NCT03202498|DEVICE|8g Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
41138396|NCT03000725|BEHAVIORAL|Usual Care|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
41138397|NCT00105170|DRUG|hCBE-11|
41138398|NCT06195345|DIAGNOSTIC_TEST|MR Imaging|MR imaging pertaining to the patient and project (ICHOR 1)
40768632|NCT06376916|DRUG|Magnesium Sulfate 4 G|Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
40768633|NCT06376916|DRUG|Saline|The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
40768634|NCT06201845|OTHER|Exercise awareness training|Group exercise training will consist of aerobic exercises including warm-up and cool-down exercises accompanied by music, and trunk strengthening training consisting of core exercises.
40768635|NCT06201845|OTHER|physical activity awareness training|In the physical activity awareness training, the benefits of exercises on systemic, psychological effects and general body health will be explained and they will be informed about different exercise practice.
40990732|NCT02446236|DRUG|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
40990733|NCT02446236|DRUG|Ibrutinib|560 mg PO daily
40990734|NCT02446236|DRUG|Rituximab|375 mg/m2 IV Day 1
41138399|NCT01005602|OTHER|Digoxin Dosing per Nomogram|Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).
41138400|NCT01005602|DRUG|Digoxin|All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
41146878|NCT00878904|GENETIC|western blotting|
41146879|NCT00878904|OTHER|immunologic technique|
40768636|NCT04889989|DEVICE|Microwave Ablation|Percutaneous microwave ablation using the NeuWave Microwave Ablation System for non-small cell lung cancer or oligometastatic lung tumors
40768637|NCT03374306|DRUG|Atropine (0.01%)|tropical application
40768638|NCT03374306|DRUG|Artificial tear|tropical application
41296349|NCT05602597|DRUG|Fluconazole 400 mg|Study participants will be administered 400 mg fluconazole by mouth daily on Day 3 after the pharmacokinetic blood draw, and 200 mg fluconazole by mouth daily on Days 4 to 10, inclusive.
41296350|NCT05602597|DRUG|Rifampin 600 mg|Study participants will be administered 600 mg rifampin by mouth daily starting on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 11, inclusive.
41296351|NCT05602597|DRUG|Rabeprazole 40 mg|Study participants will be administered 40 mg rabeprazole by mouth daily on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 9, inclusive.
41296352|NCT02183025|DRUG|Meloxicam 7.5 mg|
40768639|NCT06387953|DEVICE|Bridge Therapy|After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Bridge therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
40768640|NCT06387953|DEVICE|Sham Therapy|After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Sham therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
41138401|NCT04179565|BEHAVIORAL|Healthy Children Healthy Families|The Healthy Children, Healthy Families: Parents Making a Difference! intervention was developed by the investigators for low-income parents and caregivers focusing on the behaviors most likely to help children avoid unhealthy weight gain.
41138402|NCT00004939|DRUG|,4-diaminopyridine|
41296353|NCT02183025|DRUG|Meloxicam 15 mg|
41296354|NCT02183025|DRUG|Mefenamic acid 500 mg|
41296355|NCT02183025|DRUG|Placebo matching 7.5 mg meloxicam|
41296356|NCT02183025|DRUG|Placebo matching 15 mg meloxicam|
41296357|NCT02183025|DRUG|Placebo matching 500 mg mefenamic acid|
41296358|NCT03869138|BEHAVIORAL|Virtual-reality based dance training|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
41296359|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~1 mg/kg CDP6038 IV"
41296360|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~0.1mg/kg CDP6038 IV"
41296361|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~1.0mg/kg CDP6038 SC"
41296362|NCT01009242|OTHER|Placebo IV|"Single dose:~Placebo IV"
41296363|NCT01009242|OTHER|Placebo SC|"Single dose:~Placebo SC"
41296364|NCT01009242|DRUG|CDP 6038 SC|Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
40768641|NCT05595668|BEHAVIORAL|Prism Adaptation - 15-degree prism goggles|Patients in the experimental condition will wear prism goggles while completing an iPad-administered aiming task. The prisms will shift the patients' vision 15 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out for ten sessions for 15 minutes a day, over the span of two weeks.
40768642|NCT05595668|OTHER|Prism Adaptation - 5-degree prism goggles|5-degree goggles are worn instead of the 15-degree prism goggles, while completing the same tasks as those assigned to the 15-degree condition.
40768643|NCT03904134|OTHER|Donor Search Prognosis Score|Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.
41138403|NCT02613052|DRUG|normal saline|10 mL of normal saline agitated prior to IV administration
41138404|NCT02613052|DRUG|human albumin|10 mL of 5% albumin agitated prior to IV administration
41296365|NCT01009242|DRUG|Methotrexate|Individual stable doses of methotrexate.
41296366|NCT03351322|DRUG|ENERGI-F701|ENERGI-F701 are applied for treatment of hair loss.
41296367|NCT03351322|DRUG|Regaine|Regaine are applied for treatment of hair loss.
41296368|NCT06276972|OTHER|no intervention|there's no intervention. it's a cross sectional study correlation study
41296369|NCT03403491|OTHER|patientMpower application|electronic health journal for patient to record weight, blood pressure, medication adherence and symptoms
41296370|NCT03403491|OTHER|sham application|dummy application which does not allow recording of weight, blood pressure, medication adherence and symptoms
41296371|NCT05452161|OTHER|Control group|All patients follow only the standard care of the department, which includes a preoperative group session of 1h30, with 15 to 30 participants, 6 to 8 weeks before the operation The objectives of these sessions are to inform the patients in a general way about the operation, its preparation and the postoperative process in order to standardize the information received. The content includes general information from the surgeon, explanations related to the course and management of patients by the various professionals (nurse, surgeon, anesthesist, physiotherapist, ergotherapist and liaison-nurse).
40768644|NCT03636022|OTHER|VR System|Use of virtual reality to deliver exposure therapy
40768645|NCT03636022|OTHER|Control|Use of conventional delivery of exposure therapy
40968696|NCT03202498|OTHER|8g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
40768646|NCT02354573|DRUG|Ivabradine|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
40768647|NCT06493526|DRUG|Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.|Mycophenolate mofetil dose will be optimized to an AUC12 of 60 h.mg/L, thereafter the calcineurin inhibitor will be withdrawn.
40768648|NCT05982678|DRUG|Trastuzumab deruxtecan|T-DXd 5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.
40968697|NCT00467571|DRUG|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
40968698|NCT04388800|OTHER|Confront and Navigate Depression Online (CANDO)|This study adopts a blended mode of service delivery, which included both online and offline intervention. The online intervention includes 8 weekly online model, animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, reminder, online assessment, session review and online booking system. The offline intervention includes two face-to-face sessions and two telephone follow-ups.
40968699|NCT02948972|PROCEDURE|complete surgery|complete surgery of colorectal deep infiltrating endometriosis
41138405|NCT02613052|DRUG|human albumin and propofol|7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
41138406|NCT03187548|DRUG|Casein Phosphopeptide-Amorphous Calcium Phosphate Dental Paste|Application of CPP-ACP on one premolar once every 2 weeks for 3 months.
41138407|NCT04931966|PROCEDURE|block|Adductor canal block
41138408|NCT04931966|PROCEDURE|adductor canal block|adductor canal block bupivacain
40768649|NCT03926247|BEHAVIORAL|Immigrant Well-Being Project|The IWP intervention emphasizes a sustainable and replicable partnership model between community-based organizations and universities that involves Mexican immigrants and undergraduate advocates working together to: a) increase immigrants' abilities to navigate their communities; b) improve immigrants' access to community resources; c) enhance meaningful social roles by valuing immigrants' culture, experiences, and knowledge; d) reduce immigrants' social isolation; and e) increase communities' responsiveness to immigrants through changes in policy and practice. The IWP is administered by university students enrolled in a service learning course, and has two elements: 1) Learning Circles, which involve cultural exchange and one-on-one learning opportunities, and; 2) Advocacy, which involves collaborative efforts to mobilize community resources related to health, housing, employment, education, and legal issues.
40768650|NCT06300684|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|This intervention involves structured sessions aimed at addressing maladaptive sleep behaviors and promoting healthy sleep habits. Participants in this group will engage in cognitive restructuring, relaxation techniques, and sleep hygiene education to improve sleep quality and duration. The goal of CBTi is to modify behaviors and thoughts that contribute to insomnia, leading to more restful and consolidated sleep patterns.
40968700|NCT02948972|PROCEDURE|In vitro fertilization without surgery|IVF without endometriosis surgery
40968701|NCT00492583|DRUG|Bifidobacterium lactis (BB-12)|The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
40968702|NCT00492583|DRUG|Placebo|The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
40968703|NCT01331447|DRUG|exemestane|25 mg tablet
40968704|NCT01606436|DRUG|LY2140023|Administered orally.
40968705|NCT01606436|DRUG|Placebo|Administered orally.
41138409|NCT04931966|PROCEDURE|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using bupivacaine
41138410|NCT04931966|PROCEDURE|adductor Canal Block plus PAI Block|Adductor Canal Block plus PAI Block using bupivacaine
41146880|NCT00878904|OTHER|laboratory biomarker analysis|
40768651|NCT06550388|BEHAVIORAL|Nutritional Education|In addition to the traditional course of CBT-I, the PI will provide education and materials regarding the Mediterranean Diet. Patient will be provided with the Mayo Clinic booklet on Mediterranean Diet and asked to increase their daily intake in two categories assessed by the Mini-EAT.
40768652|NCT06550388|BEHAVIORAL|Physical Activity|In addition to the traditional course of CBT-I, the PI will recommend patient to increase physical activity minutes per week. The increase in physical activity will be based on patient's current level of physical activity.
40768653|NCT03802396|DRUG|CN-105|"Three doses of CN-105 will be used in three successive cohorts of 50 patients each.~0.1 mg/kg (cohort 1), 0.5 mg/kg (cohort 2), 1 mg/kg (cohort 3)~The study drug will be administered by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses."
40768654|NCT03802396|DRUG|Placebo|Patients will receive placebo intravenously every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses, identical to those receiving the study drug.
40768655|NCT04556006|OTHER|Patient education|"The data collection process of the study was carried out in two stages using data collection tools.~First stage: Personal Information Form and Compliance Questionnaire were applied to all patients in both groups. After anthropometric measurements, Framingham Risk Score was determined. The data collection forms were filled with the patients using face-to-face interview technique. The data collection process lasted for approximately 10-15 minutes. After the data collection, the patients in the intervention group were trained. No training was given to the patients in the control group but they received a Coronary Artery Disease Management Guide.~Second stage: 12 weeks after the first interview, the patients were interviewed again face-to-face interview technique and the forms and measurements applied initially were repeated."
40768656|NCT06500156|OTHER|Fluid challenge|Rapid infusion (\< 15 minutes) of a fluid bolus of crystalloids (200 to 500cc)
40768657|NCT01088906|DRUG|Pemetrexed/Cisplatin|Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
40768658|NCT04898179|OTHER|Telecare Group|"Home-based telehealth program: telenursing and specialist teleconsultation~Telemonitoring with a new pulse oximeter and specific App~E-health platform~Videoconference"
40968706|NCT01606436|DRUG|Moxifloxacin|Administered orally.
40968707|NCT00000208|DRUG|Buprenorphine|
40968708|NCT06012825|BEHAVIORAL|Physical Activity|"The program will consist of 2 consecutive rounds of 12-week programming, 2x/week for 60 minutes on a Health Insurance Portability and Accountability Act (HIPAA)-compliant Zoom account. The PA program will be structured to ensure equivalent PA doses are provided. This will be done by allocating time to a warm-up (5 min), an introduction and demonstration of the activity (5 min), the PA (30 min), cool down and stretching (5 min). Time will also be devoted for interaction to develop rapport, transition to the next activity, and to handle internet connectivity issues (15 min)."
40968709|NCT04412369|DIAGNOSTIC_TEST|Non-invasive cardiac imaging|Cardiac MRI ± CT coronary angiography ± Cardiac PET/MRI (68Ga-DOTATATE or 18F-FDG)
40968710|NCT00496054|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 \& P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
40968711|NCT05778097|DRUG|Apalutamide 60mg Tab|Apalutamide 60Mg Tab (4 x 60 mg) once daily on days 1-28 of a 28-day cycle
40768659|NCT04898179|OTHER|Control group|Usual care
40968712|NCT05778097|DRUG|Androgen deprivation therapy(ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
40968713|NCT00589251|OTHER|penicillin skin test|"Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique."
40968714|NCT03394326|BEHAVIORAL|family-based obesity prevention lifestyle intervention|A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
41138411|NCT01211509|DRUG|Montelukast|After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
40768661|NCT06535373|OTHER|Blood flow restriction|Both groups will undergo a 6-week training intervention with training 2x a week, after which grip strength and other relevant outcomes will be measured and compared. Exercise sessions will be at least 48 hours apart. Participants will be allowed to continue with their normal exercise routine outside of the study.
40768662|NCT05386472|DRUG|nirmatrelvir|Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)
40768663|NCT05386472|DRUG|ritonavir|Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)
40968715|NCT05740397|OTHER|Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm|"The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect"
41296372|NCT05452161|OTHER|Intervention group A|The day of the preparatory surgical consultation (CPC), the patient has a 30 minute patient-centered education session by a physiotherapist and a 30 minute patient-centered education session by a nurse. The physiotherapist's session addresses the technical skills to be mastered postoperatively (crutching, stairs, exercises), the course of postoperative rehabilitation, the patient's role in the rehabilitation process, the questions still remaining on this subject and the patient's perspective concerning the rehabilitation (degree and sources of anxiety, expectations of follow-up and results, degree of self-efficacy). The nursing intervention addresses the postoperative pain management, the patient's role in pain management, the care pathway, the organization of the return home and the postoperative follow-up.
40768664|NCT06643429|DIAGNOSTIC_TEST|colorectal cancer|Patients diagnosed with colorectal cancer by pathological biopsy.
40968716|NCT01020227|BEHAVIORAL|Integrative Therapies Intervention|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
40968717|NCT05693558|BIOLOGICAL|NVD-003, an autologous 3D scaffold free osteogenic graft|Bone correction and grafting surgery
40968718|NCT01725178|BEHAVIORAL|Cognitive and Physical training|"Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management."
40968719|NCT00687323|DRUG|temozolomide|
40968720|NCT00160485|DRUG|Glyburide|dosage required to obtain adequate glucose control
40968721|NCT00160485|DRUG|Insulin|variable dosage to obtain glucose control
40968722|NCT04026308|OTHER|Safety Net App|The Safety Net app is an electronic version of a safety plan and it is available for download in Apple's App Store. A preview of the app is available at: https://apps.apple.com/us/app/stanley-brown-safety-plan/id695122998. This app is owned by Two Penguins Studios, LLC. It was developed in partnership with the New York State Office of Mental Health. Unlike the paper version, the Safety Net app allows participants to email a copy of their safety plan to whomever they wish. It also allows patients to dial 911 or the National Suicide Prevention Lifeline from the app.
41138412|NCT00088166|DRUG|hCRF|hCRF ; open-label dexamethasone that the patient is currently taking
41138413|NCT00088166|DRUG|placebo hCRF|placebo hCRF 2mg/day and open-label dexamethasone that they are taking
41138414|NCT01199315|DRUG|AZD1446|oral capsule, Moderate Release
41138415|NCT01199315|DRUG|Placebo|oral capsule
41138416|NCT01636726|DRUG|Inhaled LABA use|LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
41138417|NCT03265132|BIOLOGICAL|anakinra|sub cutaneous injection
41138418|NCT03265132|DRUG|Placebo|sub cutaneous injection
41138419|NCT02393976|DIETARY_SUPPLEMENT|IMMUNONUTRITION|IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
40768665|NCT06643429|DIAGNOSTIC_TEST|colorectal neoplasm|Patients diagnosed with colorectal adenoma confirmed by colonoscopy.
40968723|NCT01755013|PROCEDURE|Photodynamic Therapy|Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
40968724|NCT02947997|DEVICE|OFDI capsule|Imaging of esophagus using OFDI capsule and system
40968725|NCT00657527|DRUG|Rosuvastatin|
40968726|NCT00657527|BEHAVIORAL|Cholesterol lowering diet|
40968727|NCT01949506|RADIATION|SBRT|Stereotactic Body Radiation Therapy
40968728|NCT03293589|PROCEDURE|open revascularization|surgical revascularization (i.e. Bypass surgery)
40968729|NCT03293589|PROCEDURE|endovascular revascularization|endovascular revascularization (stent, ballon angioplasty)
40990735|NCT02064166|DRUG|Intranasal Insulin|"1. treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~2. placebo arm: normal saline, daily, intranasally, for 4 weeks."
41138420|NCT02393976|DIETARY_SUPPLEMENT|STANDART NUTRITION|STANDART NUTRITION PERIOPERATIVE
41138421|NCT01564498|OTHER|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
41296373|NCT05452161|OTHER|Intervention group B|"In addition to intervention A, patients receive a interdisciplinary intervention of three 10-15 minute phone or video conferences between the patient, a physiotherapist and a nurse.~The aim of these interviews is to identify the patient's difficulties in the living environment, to detect possible postoperative complications and to provide advice on practical aspects (e.g. ability to perform activities), therapeutic aspects (e.g. exercises to be performed, medication), pain management, interpretation of symptoms and subjective needs (e.g. need for support). Advice on rehabilitation and care is individualized according to the results of the questionnaires administered on the day of the pre-surgical consultation and those administered at discharge, as well as the needs of the moment discussed with the patient. Any suspected complication is reported to the operating physician for appropriate management."
41296374|NCT00161824|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
40768667|NCT06640478|OTHER|Active Comparator: Intervention Group|Weekly distribution of healthy foods + intensive nutrition counseling based on anti-inflammatory nutrients for 12 weeks
40768668|NCT05713110|DRUG|tazemetostat|"Dose Escalation Phase (Phase IIa):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days;~Dose Expansion Phase (Phase IIb):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days"
40968730|NCT02737098|OTHER|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
40968731|NCT02737098|OTHER|Standard Implementation Strategy|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
40968732|NCT06389123|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
40968733|NCT03059602|OTHER|No specific treatment based intervention-health measurement instrument|Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
40968734|NCT01388764|DRUG|L-arginine|Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
40968735|NCT01325298|DEVICE|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
41138422|NCT05454943|BEHAVIORAL|Standardized TRE Protocol|A standardized 16:8 TRE protocol with an 11 am to 7 pm eating window.
41138423|NCT05454943|BEHAVIORAL|Personalized TRE Protocol|A personalized TRE protocol following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week.
41138424|NCT05454943|BEHAVIORAL|External Support for TRE|External support (from study staff) that includes consultation with a registered dietitian and ongoing tailored feedback via support calls at weeks 1, 3, 6, and 12.
41138425|NCT05454943|BEHAVIORAL|Peer Support for TRE|Matched pairs will meet by phone/video at weeks 1, 3, 6, and 12.
41296375|NCT03803761|DRUG|Copanlisib|Given IV
41296376|NCT03803761|DRUG|Fulvestrant|Given IM
41296377|NCT02381756|DEVICE|Ultrasound|Cardiac echocardiography to determin the left ventricular ejection fraction by the biplane modified Simpson rule and by the calculation of the Strain Longitudinal Global by 2-D speckle tracking strain echocardiography
40768669|NCT05713110|DRUG|HMPL-689|"Dose Escalation Phase (Phase IIa):~HMPL-689:20 mg and 30 mg, QD orally in a therapeutic cycle of 28 days.~Dose Expansion Phase (Phase IIb):~HMPL-689 (RP2D) in a therapeutic cycle of 28 days"
40968736|NCT01325298|DRUG|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
40968737|NCT01325298|DEVICE|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
40968738|NCT01325298|DRUG|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
40968739|NCT03490097|DRUG|Simvastatin 10mg|tablets
40968740|NCT03490097|DRUG|sofosbuvir plus daclatasvir|sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.
40990736|NCT03525210|BIOLOGICAL|9-valent HPV vaccine|Vaccination
41138426|NCT04921709|OTHER|Medical tests|Blood tests
41138427|NCT03788811|DEVICE|ERG assessment (RSPA)|Processing and analysis of retinal signals
41138428|NCT00410748|DRUG|OROS hydromorphone HCI CR|
41296378|NCT03321292|DRUG|L-arginine 1000 mg and Acetylesalicylic acid75mg|l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
41296379|NCT03321292|DRUG|acetylsalicylic acid 75 mg|acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
41138429|NCT02332824|DRUG|TAK-272|TAK-272 tablets
41138430|NCT02332824|DRUG|TAK-272 Placebo|TAK-272 placebo-matching tablets
41138431|NCT02332824|DRUG|Candesartan cilexetil|Candesartan cilexetil tablets
40968741|NCT04383405|OTHER|Aquatic Training|Aquatic Training training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises follow a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e. catching a ball thrown by the therapist). Subjects performed three sessions a week for four weeks and each session lasting 45 minutes. The training was carried out by a physiotherapist who had at least 5 years of experience in aquatic neurorehabilitation.
40968742|NCT04383405|OTHER|Conventional Training|Conventional land-based therapy consists of customized exercises focused on static and dynamic postural stability improvement. The exercises included the active-assisted mobilization, the muscle stretching the postural transition, the balance and the gait training. The control approach was carried out three times a week for four weeks and each session lasted 45 minutes.
40968743|NCT03725280|PROCEDURE|IVF|None interventional study (Collection of ovarian follicular fluid during IVF treatment)
40968744|NCT00000383|BEHAVIORAL|Trauma-Focused CBT|Structured skills, exposure, trauma-specific interventions
40968745|NCT00000383|BEHAVIORAL|Child-Centered Therapy|Client-directed supportive interventions
40968746|NCT00279591|DEVICE|Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device|Continuous blood pressure monitoring of patients during med flight to hospital
40968747|NCT00279591|DEVICE|Standard of care blood pressure monitoring|Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
40968748|NCT04208789|DIAGNOSTIC_TEST|Rapid Molecular Drug-Resistant Tuberculosis Test|"GeneXpert MTB/RIF assay is a nucleic acid amplification (NAA) test which simultaneously detects DNA of Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) (i.e. mutation of the rpoB gene) in less than two hours. This system integrates and automates sample processing, nucleic acid amplification, and detection of the target sequences. The primers in the XpertMTB/RIF assay amplify a portion of the rpoB gene containing the 81 base pair core region. The probes are able to differentiate between the conserved wild-type sequence and mutations in the core region that is associated with rifampicin resistance. The output of this procedure is detected, undetected, or indeterminate."
41296381|NCT02944799|DRUG|Placebo|Discontinuation of alendronate treatment
41296382|NCT02944799|DRUG|Alendronate|
41296383|NCT02944799|DRUG|Calcium|Daily dietary supplement of 800mg calcium
41296384|NCT02944799|DRUG|Vitamin D|Daily dietary supplement of 38 micrograms vitamin D
41296385|NCT01220310|BEHAVIORAL|Online diabetes workshop observation and learning sessions|We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.
40968749|NCT04208789|OTHER|Artificial Intelligent Model|The artificial intelligent model is a model that developed from several associated factors with machine learning and deep learning method in order to classify the possibility of drug-resistant tuberculosis. The Artificial neural network will be built using deep learning software.
40968750|NCT04208789|DIAGNOSTIC_TEST|Drug Susceptibility Test|This procedure uses Löwenstein-Jensen (LJ) medium to determine whether the isolates of M. tuberculosis are susceptible to anti-TB agents. Media containing the critical concentration of the anti-TB agent is inoculated with a dilution of a culture suspension (usually a 10-2 dilution of a MacFarland 1 suspension) and control media without the anti-TB agent is inoculated with usually a 10-4 dilution of a MacFarland 1 suspension. Growth (i.e. a number of colonies) on the agent-containing media is compared to the growth on the agent-free control media. The ratio of the number of colonies on the medium containing the anti-TB agent to the number of colonies (corrected for the dilution factor) on the medium without the anti-TB agent is calculated, and the proportion is expressed as a percentage. Provisional results for susceptible isolates may be read after 3-4 weeks of incubation; definitive results may be read after 6 weeks of incubation. Resistance may be reported within 3-4 weeks.
41296386|NCT00807547|BIOLOGICAL|Allergy vaccination (Alutard SQ)|Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
41296387|NCT02558881|PROCEDURE|Virtual colonoscopy|
41296388|NCT02558881|PROCEDURE|Colon capsule|
41296389|NCT01883128|DEVICE|Whole Body MRI|Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
41296390|NCT01883128|PROCEDURE|Focal Salvage Therapy|Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
41296391|NCT01883128|PROCEDURE|MRI Targeted biopsies|Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
40968751|NCT04488068|PROCEDURE|Sham Magnetic stimulation|Sham Magnetic stimulation for comparison.
41296392|NCT02460588|DRUG|Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
40768670|NCT03763370|DRUG|Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)|"Drug: Belantamab mafodotin~•Belantamab mafodotin 2.5 milligram per kilogram (mg/kg) intravenous (IV) will be administered at every cycle, once every 3 Weeks, on Day 1 of every cycle, until completion of treatment.~Drug: Bortezomib •Bortezomib will be administered based on the full prescribing information, for the first 8 Cycles~Drug: Dexamethasone~•Dexamethasone will be administered based on the full prescribing information, for the first 8 Cycles"
40768671|NCT03763370|DRUG|Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)|"Drug: Belantamab mafodotin:~* Cycle 1: Belantamab mafodotin 2.5 mg/kg IV administered once~* Cycle 2 onward: Belantamab mafodotin 1.9 mg/kg IV administered once every 4 weeks until completion of treatment~Drug: Pomalidomide •Pomalidomide will be administered at every cycle, based on the full prescribing information~Drug: Dexamethasone~•Dexamethasone will be administered at every cycle, based on the full prescribing information"
40968752|NCT04762784|DRUG|Tocilizumab|Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month for 3 months.
40968753|NCT04762784|DRUG|Glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
40968754|NCT00148018|DRUG|Bortezomib|
40968755|NCT00148018|DRUG|Dexamethasone|
40968756|NCT05382624|PROCEDURE|Abdominal circumference was measured at the umbilical level in the standing position at the end of a normal expiration.|The operation time (the time from the beginning of the surgical incision until the end of surgery), anesthetic complications, such as nausea or vomiting, the number of patients requiring ephedrine and atropine, the total amount of intravenous fluid used, and the total amount of ephedrine used during surgery were recorded.
40968757|NCT04056910|DRUG|ivosidenib and nivolumab|"Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events.~Nivolumab will be administered at 480 mg IV every 28 days."
40968758|NCT01756547|DRUG|Potassium Citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
40968759|NCT01756547|DRUG|Placebo|
40968760|NCT03761160|OTHER|Mobile Health App|mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit
40968761|NCT03761160|OTHER|Usual care|Usual care per hospital guidelines
40968762|NCT02223897|DRUG|huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
40968763|NCT02223897|DRUG|Placebo|Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
40968764|NCT05914298|DIAGNOSTIC_TEST|blood and buccal swab genetic test|blood samples and buccal swabs will be obtained from patients with HME in order to analyze the genotype (EXT1 or EXT2 mutations) and correlate the genotypic pattern with the phenotypic presentation
41296393|NCT02460588|DRUG|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
40768672|NCT03979001|OTHER|complete ophthalmological examination|"collection:~* ophthalmological history and current treatments~* occular tension measurement~* measurement of visual acuity (Snellen chart)~* Axial length measurement~* Photograph of the posterior segment of the eye~* 3x3 and 6x6 macular and papillary OCT angiography"
41138432|NCT02332824|DRUG|Candesartan cilexetil Placebo|Candesartan cilexetil placebo-matching tablets
40968765|NCT05914298|DIAGNOSTIC_TEST|PUL|measurement of ulnar length with anthropometer and patient's height
40968766|NCT05914298|DIAGNOSTIC_TEST|Range of motion|measurement of range of motion of elbow, forearm and wrist
40968767|NCT04813445|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
40968768|NCT05060302|OTHER|transthoracic echocardiography (TTE)|the included patients have a TTE preoperatively in order to evaluate the RV systolic function. TTE will also be done at day 2 and day-15 during the follow-up surgical consultation.
41138433|NCT03139526|OTHER|observational study so no intervention|observational study, so no intervention
41146881|NCT00878904|OTHER|pharmacological study|
41296394|NCT02460588|DRUG|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
40768674|NCT00492050|DRUG|Bortezomib|1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22.
40768675|NCT00492050|DRUG|Rituximab|375 mg/m\^2 IV on Day 8 and 22.
40768676|NCT00492050|DRUG|Valacyclovir|500 mg orally daily (or acyclovir 200 mg orally twice daily)
41296395|NCT00611793|DRUG|PTK787/ZK222584 and Bevacizumab|PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
41296396|NCT01100307|DRUG|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
40990737|NCT03761381|DEVICE|Optical Coherence Tomography Angiography (OCTA) Imaging|Optical coherence tomography is a non-invasive imaging technology that provides cross-sectional images of tissues in micron-scale resolution. The angiography component of this device allows for evaluation of blood vessel and blood flow changes in the eye. The Solix device with AngioVue software will be used to detect these blood vessel and flow changes as well as protein deposits in the retinal layers.
40990738|NCT03761381|DEVICE|Noninvasive Retinal Amyloid Imaging (NRAI)|The Spectralis will be used for NRAI. This system uses a special light source and optical filters to detect fluorescence of amyloid proteins in the eye.
40990739|NCT00453921|DRUG|Methylphenidate|Dosage dependent on weight
41138434|NCT05908656|PROCEDURE|Investigational procedure|Subjects that consent will have a single blood draw either via a finger stick or via venous blood draw (blood will be placed on a 5 spot blood card) used to determine whether they have Gaucher Disease or ASMD
41138435|NCT01567787|RADIATION|Proton Radiation for MPNST|30 CGE at 6 CGE/Fx
41138436|NCT01567787|RADIATION|Proton Radiation for neurofibromas|25 CGE at 5 CGE/Fx
41138437|NCT02997410|DEVICE|Ozone|
41138438|NCT02997410|DEVICE|Placebo (for Ozone)|
41138439|NCT02997410|DEVICE|Dental treatment with occlusal splint|
41138440|NCT00540111|DIETARY_SUPPLEMENT|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
41138441|NCT00004085|BIOLOGICAL|filgrastim|as prescribed by physician
41138442|NCT00004085|PROCEDURE|autologous bone marrow transplantation|1-2 weeks prior to treatment
41138443|NCT00004085|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
41138444|NCT00004085|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
41296397|NCT01100307|OTHER|sham injection|sham injection every 6 weeks
40768685|NCT01771354|BIOLOGICAL|Engerix B Vaccine|
40768686|NCT01771354|BIOLOGICAL|Placebo|
40768687|NCT05704803|DIAGNOSTIC_TEST|Diagnostic Test: IN Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
40768688|NCT02221726|DRUG|JNJ-35684-AAA-023: Size 1; small patch|Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm\^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
40768689|NCT02221726|DRUG|JNJ-35684-AAA-023: Size 2; large patch|Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 44 cm\^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
40768690|NCT05530733|PROCEDURE|Pacifier|Pacifiers produced for premature babies will be used in the study. Pacifiers will be made of silicone material suitable for premature baby health and will not contain any harmful substances. A separate pacifier will be used for each baby, and pacifiers will be sterilized before use.
40768691|NCT05530733|PROCEDURE|Breast milk|For babies assigned to the pacifier with breast milk group, their own breast milk will be applied by dripping 1 ml into the pacifier.
40768692|NCT00219414|DEVICE|Adacolumn Apheresis System|
40768693|NCT03671226|OTHER|Questionnaire Administration|Given questionnaire
40768694|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
40768695|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
40768696|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
40768697|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
40768698|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
40768699|NCT03318627|DEVICE|Sterile Spring Scale|Measuring intraoperative tension of tendon of rotator cuff tear
40768700|NCT02645799|DRUG|LABR-312|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
41138445|NCT01217736|DRUG|aliskiren|single dose, tablet
41138446|NCT01217736|DRUG|placebo|single dose, tablet
41138447|NCT01217736|DRUG|VTP-27999|single dose, tablet
40968769|NCT01983813|OTHER|PHCVRS Intervention|"A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:~1. Contact via email, phone or text every 2-4 weeks~2. Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.~3. Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.~Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk."
40968770|NCT01983813|OTHER|Personal Health Record|Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
41138448|NCT03936166|DRUG|CRN01941 Oral Solution|Investigational drug
41296398|NCT00863928|DRUG|belladonna 16.2 mg and opium 60 mg suppository|belladonna 16.2 mg and opium 60 mg suppository
41296399|NCT02954835|DEVICE|Prevena|Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.
41296400|NCT02954835|DEVICE|Traditional Dressing|Sterile gauze dressing secured by tape.
40768701|NCT02645799|DRUG|Saline (placebo)|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
40768702|NCT05985239|PROCEDURE|VI|Laparoscopic or robotic surgery with virtual ileostomy
40768703|NCT05985239|PROCEDURE|DI|Laparoscopic or robotic surgery with virtual ileostomy
40768704|NCT04540471|OTHER|music|MT group receives additional music therapy
40768705|NCT04540471|OTHER|comprehensive in-patient education program|comprehensive in-patient education program
40768706|NCT01442610|DRUG|Rasagiline|Rasagiline tablets 1mg once daily for 8 weeks
40768707|NCT01442610|DRUG|Placebo|Placebo 1tablet once daily for 8 weeks
40768708|NCT06398197|BEHAVIORAL|Nourish Intervention then No Intervention|Participants will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking. After 8 weeks, participants crossover into the No Intervention group.
40768709|NCT06398197|BEHAVIORAL|No Intervention then Nourish Intervention|Participants will receive no intervention for 8 weeks. After 8 weeks, they crossover into the Nourish Intervention group where they will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking.
40768710|NCT01923038|PROCEDURE|First arm: patients ventilated with zero end expiratory pressure|
40768711|NCT01923038|PROCEDURE|Patients ventilated with Positive End Expiratory Pressure|
40768712|NCT01923038|PROCEDURE|Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver|
40768713|NCT01052779|DRUG|Ferumoxytol|IV Ferumoxytol
41296401|NCT06555965|OTHER|Non-interventional study|There is no planned intervention in this study
40768714|NCT01052779|DRUG|Iron Sucrose|IV Iron Sucrose
40968771|NCT05229601|DRUG|HFB301001|"Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively.~Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation."
40968772|NCT02840097|DRUG|Tranexamic Acid|Active drug is provided to participants as described based on the TXA arm they are randomized to.
40968773|NCT02840097|DRUG|Placebo|Normal saline is provided to participants if randomized to this treatment arm.
40968774|NCT03647397|DEVICE|Photo Electrochemical Oxidation (PECO) for Air Purification|PECO air purifiers from Molekule will be placed in every patient room. Health metrics will be tracked for patients whose diagnosis is respiratory distress.
40968775|NCT05315154|PROCEDURE|No axillary surgery|In the study arm will be omitted surgery in axilla
40968776|NCT05315154|PROCEDURE|SLNB|in the control arm will be realized SLNB
40968777|NCT03767530|DEVICE|Mibo Thermoflo|Thermal therapy with Mibo Thermoflo for 11 minutes per eye, during each session.
41138449|NCT03936166|DRUG|CRN01941 Oral Capsule|Investigational drug
41138450|NCT03936166|DRUG|Placebo Oral Solution|Placebo
41138451|NCT03936166|DRUG|Placebo Oral Capsule|Placebo
41146882|NCT04085614|DEVICE|Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap|Standard of care Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap
40968778|NCT03767530|OTHER|Warm compresses and eyelid massage|Warm compresses plus eyelid massage 2 times per day 11 minutes per eye.
40768715|NCT06116123|DEVICE|Massage mattress with cube/block system|Patients with an odd number were assigned to group I, while those with an even number were allocated to group II. Patients in group I were provided with a pressure sore prevention bed featuring a support surface with vibration (massage) capabilities, a cube/block system creating a low-pressure area, and a ventilation system, routinely utilized in the unit. For group II patients, a viscoelastic pressure sore prevention mattress with an orthopedic support surface, routinely employed in the unit, was used.Within the first six hours after admission, patients in both groups underwent initial assessments using the Braden Scale to determine their pressure sore risk. Both groups were monitored for a maximum of four weeks, with daily pressure ulcer assessments conducted using the Pressure Ulcer Observation Form. Pressure sore area in both groups was calculated in square centimeters (cm2) using the Wound Measurement Ruler.
40768716|NCT01955551|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
40768717|NCT01955551|BEHAVIORAL|Anticipatory Guidance on Child Development|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
40768718|NCT02248233|DRUG|Nimodipine|Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
40768719|NCT02248233|DRUG|Saline + citicoline|physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
40768720|NCT06564831|OTHER|SLAM + SOC|Weekly Treatment visits for 12 weeks begin at day 0. SLAM applications with SOC until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
40768721|NCT06564831|OTHER|SOC|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
40768722|NCT00811837|DRUG|Midazolam|Intravenous infusion
40768723|NCT00811837|DRUG|Remifentanil|Intravenous infusion
40768724|NCT00086515|DRUG|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
40768725|NCT00086515|DRUG|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
40768726|NCT00086515|DRUG|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
40768727|NCT00086515|DRUG|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)
40768728|NCT06423664|BEHAVIORAL|Play and Learn Strategies (PALS) Program|Monthly modules and personalized coaching sessions designed to strengthen maternal responsiveness and sensitivity which, in turn, improves infant social-emotional behavior and development outcomes.
40968779|NCT03940404|DRUG|Anlotinib Hydrochloride|Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
40968780|NCT04144205|OTHER|Change of the fraction of inspired oxygen|"After the stabilization of cardiopulmonary bypass, in the first half of patients, fraction of inspired oxygen would be set at 0.5 and maintained for 5 minutes (T0), then it would be changed to 1.0 and maintained for 5 minutes (T1). Again, fraction of inspired oxygen would be resumed to be 0.5 and maintained for 5 minutes (T2).~In the other half of patients, the direction of change in fraction of inspired oxygen will be reversed as follows. It will be set at 1.0 and maintained for 5 minutes (T0), then changed to 0.5 and maintained for 5 minutes (T1), and finally to 1.0 and maintained for 5 minutes (T2)."
40968781|NCT03159767|DEVICE|ViMove Spinal Sensor|Sensors will be used to measure spinal movement
40968782|NCT04206501|DEVICE|Medtronic ICD with Opti Vol-Monitor|Physiologic and functional data from Cardiac Implantable Electronic Devices (CIEDs), including information on heart rate, activity, and fluid status derived from the OptiVol monitor, together with a concurrent patient engagement strategy through remote interactions, can be used to optimize the medical management of HF patients implanted with an ICD.
40968783|NCT06498401|DIETARY_SUPPLEMENT|gut microbiota-targeted dietary intervention|The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
40968784|NCT01259908|PROCEDURE|Laparoscopic vs open Ygraft|Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
40968785|NCT02139228|BIOLOGICAL|Hib-CRM197|No vaccine administered in V37_07E2 study
40968786|NCT02139228|BIOLOGICAL|Hib-TT|No vaccine administered in V37_07E2 study
40968787|NCT01513161|DRUG|nalfurafine hydrochloride (TRK-820)|Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
40768729|NCT05604703|DIAGNOSTIC_TEST|Periodontal classification|300 patients will be classified according to 1999 armitage and 2018 new periodontal classification and compared.
40768730|NCT06322901|PROCEDURE|Flap|Different flap designs for implant placement
40768731|NCT06569914|BEHAVIORAL|Humanized care|(1) Humanized environmental care；(2) Humanized medical guidance；(3)Humanized psychological nursing；(4) Humanized and standardized management of IVGTT treatment process
40768732|NCT01783808|OTHER|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
40968788|NCT01513161|DRUG|Placebo|
40968789|NCT00737282|DRUG|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
40968790|NCT00737282|DRUG|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
40968791|NCT00000443|DRUG|ondansetron (Zofran)|
40968792|NCT01595997|DRUG|DLX105|intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
40968793|NCT02222974|DRUG|BIIR 561 CL|
40968794|NCT02222974|DRUG|Placebo|
40968795|NCT01991210|DRUG|DNIB0600A|DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
40968796|NCT01991210|DRUG|PLD|PLD will be administered at a dose of 40 mg/m\^2 IV every 4 weeks.
40968797|NCT01819831|RADIATION|proton radiation|proton radiation: 2 GyE/Day to isocenter, one treatment per day, 5 days per week for 25 treatments (=50 GyE to isocenter/25 fractions)
40968798|NCT01819831|PROCEDURE|surgery (wide local excision; limb preservation surgery)|In areas with ample soft tissue that can be removed without compromising future function or wound closure, wide margins is the goal of treatment; associated rates of local failure are low in such instances. Margins will be determined by the surgeon; the goal is to achieve at least a 2 mm negative margin resection. However, smaller margins can be acceptable if it allows for limb-sparing surgery with conserved functional outcomes. Every effort will be made to have limb preservation surgery unless there is documented evidence of tumor progression during or after the course of radiation that would require amputation for an appropriate margin resection.
40968799|NCT03644212|DRUG|Vitamin D3|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
40968800|NCT03623815|OTHER|transcranial direct current stimulation|"Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered."
40968801|NCT00574132|DRUG|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
40968802|NCT00574132|DRUG|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
40968803|NCT00574132|DRUG|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions
40968804|NCT04758169|OTHER|Enhanced Homestead Food Production|Enhanced Homestead Food Production program will provide increased production and consumption of nutrient rich foods, increased income of the households through the sale of surplus produce, and increased self-efficacy and decision making by adolescents due to increased knowledge and skills- resulting increased food security and nutrition and ultimately delay of child marriage.
40968805|NCT04758169|OTHER|Control|Control group will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings.
41296402|NCT04707144|DEVICE|MRI 1.5 tesla|"* standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), o 3D STIR sequence.~* 3D PSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35 minutes)"
41296403|NCT02712684|PROCEDURE|multiparametric MRI. Multi-parametric ultrasound|The investigators aim to test the hypothesis that multiparametric ultrasound is able to detect clinically significant prostate cancer with an accuracy that is similar to multiparametric MRI. Multi-parametric ultrasound uses different types of ultrasound images to visualise different aspects of the tissue. In other words, the standard grey-scale images shows the gross anatomy, Power Doppler and Contrast enhanced Ultrasound image blood supply (cancers have more blood supply), and Real-Time Elastography images the density of tissue (cancers are more dense).
41296404|NCT03242096|COMBINATION_PRODUCT|Sirolimus coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)
41296405|NCT03242096|COMBINATION_PRODUCT|Paclitaxel coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)
41296406|NCT05646641|OTHER|Strength exercise|The protocol consists of 8 weeks of training, consisting of 16 sessions of 50 minutes, twice a week on alternate days.
41296407|NCT04548947|PROCEDURE|Cold snare polypectomy in conjunction with a submucosal injection|The cold snare polypectomy in conjunction with a submucosal injection is a procedure during which the endoscopist resects the colorectal polyps during a colonoscopy, without any electrocautery.
41296408|NCT05348850|DEVICE|Tensiomayography (TMG)|Quadriceps muscle contractile properties will be assessed using tensiomayography
41146883|NCT04085614|DEVICE|Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap|Standard of care Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
40968806|NCT00825591|DIETARY_SUPPLEMENT|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
40968807|NCT00825591|DIETARY_SUPPLEMENT|Placebo Comparator|Oral administration before bed. 6 week duration.
40990740|NCT00453921|BEHAVIORAL|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
40990741|NCT00453921|OTHER|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
41146884|NCT01870895|DRUG|YM060|oral
41146885|NCT01870895|DRUG|Placebo|oral
40968808|NCT02207244|DRUG|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
40968809|NCT02207244|DRUG|Placebo for guselkumab|Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
40968810|NCT02207244|DRUG|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
40968811|NCT02207244|DRUG|Placebo for adalimumab|Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
40968812|NCT01411202|DRUG|Doxycycline|One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
40968813|NCT01411202|OTHER|normal saline|One time injection of normal saline (placebo) into Pleurx catheter
40968814|NCT04830774|DEVICE|ILR, PMK, ICD|"* Patients receive a newly implanted ILR, PMK, or ICD during COVID-19 hospitalization or within 30 days after hospital discharge and are followed by daily automated remote transmissions.~* Patients have a previously implanted ILR, PMK, or ICD and are followed by daily automated remote transmissions"
41138452|NCT05492513|BEHAVIORAL|Grade 1 CI Therapy +Sensory Components|All participants will receive Grade 1 CI Therapy + Sensory Components over a two-week period of time. The treatment intervention will include all CI Therapy treatment strategies including: 1) supervised motor training in the form of shaping with repeated trials and task practice for 1.5 hours per day for 5 weekdays for 2 weeks 2) a behavioral Transfer Package (TP) will be employed to aid carry-over of skills gained by the participant in the laboratory to the life situation 3) each participant will wear a mitt on the less-affected hand for most of their waking hours to encourage use of the more-affected hand 4) participants will be given home assignments to be carried out for at least 30 minutes each day. Sensory component strategies will be added to stimulate sensory input through the more-affected arm and hand as well as to train sensory discrimination skills.
41138453|NCT05469516|DEVICE|Ulthera System [Ulthera, Inc.]|"The Ulthera System is indicated for: - Use for noninvasive dermatological sculpting and lifting of the dermis: Upper Face, Lower Face, Neck, Décolletage.~- Non-invasive treatment of Axillary Hyperhidrosis"
41138454|NCT05469516|DEVICE|Merz Radiesse Injectable Implant|Radiesse injectable implant is an opaque, sterile, non-pyrogenic, semi-solid, cohesive implant. The principal component is synthetic CaHA suspended in a gel carrier that consists primarily of water (sterile water for injection, United States pharmacopeia (USP)), glycerin (USP), and sodium carboxymethylcellulose (USP). Radiesse injectable implant (1.5mL syringe unit) has a CaHA particle size range of 25-45 microns and should be injected sub-dermally with a 27 gauge needle.
41138455|NCT01784107|DRUG|Belotecan and Ifosfamide|
41296409|NCT05057949|DRUG|Larotinib|Larotinib Capsules
41457858|NCT01158053|DEVICE|FFR and VH-IVUS|"* Stable Angina(SA), Unstable Angina(UA),Non ST-segment Elevation Myocardial Infarction(NSTEMI) or ST-segment Elevation Myocardial Infarction(STEMI) \>48hrs scheduled for cardiac catheterization ± PCI. All patient level inclusion and no exclusion criteria are met Signed Informed Consent~* No PCI or successful and uncomplicated PCI of all non study lesions. One or more study lesions identified.~All lesion level inclusion criteria and no exclusion criteria are met.~* FFR followed by VH-IVUS of study lesion(s)~* Any additional PCI based on routine clinical practice and FFR/IVUS data?~* If Yes: Final IVUS with VH imaging, Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years~* If No: Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years"
41457859|NCT01158053|DEVICE|IVUS and FFR|
41457860|NCT05413512|OTHER|Acute psychological stress|Participants will undergo an acute psychological stress task that has been shown to elicit neural, cardiovascular, and psychological (feelings of stressfulness) responses.
41138456|NCT00515892|DRUG|Immunotoxin therapy|
40768735|NCT05613127|BIOLOGICAL|Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL|Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
41138457|NCT00515892|DRUG|CAT-8015 Immunotoxin|
41138458|NCT00515892|PROCEDURE|Biological therapy|
41138459|NCT00515892|PROCEDURE|Antibody Therapy|
41138460|NCT00515892|PROCEDURE|Monoclonal Antibody Therapy|
41146886|NCT01331278|PROCEDURE|Total Knee Arthroplasty with Custom Cutting Blocks|Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant
41146887|NCT01331278|PROCEDURE|Total Knee Arthroplasty via Computer Assisted Surgery|Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
41146888|NCT03905928|OTHER|Nicotine Containing ECIG with tobacco flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor."
41296410|NCT05057949|DRUG|Rifampin|Rifampin Capsules
41296411|NCT05057949|DRUG|Itraconazole|Itraconazole Capsules
41296412|NCT01809262|DRUG|single dose of 5 mcg|solution for inhalation
41296413|NCT01809262|DRUG|single dose of placebo|solution for inhalation
41296414|NCT01809262|DRUG|single dose of 40 mcg|solution for inhalation
41296415|NCT01809262|DRUG|single dose of 20 mcg|solution for inhalation
41296416|NCT01809262|DRUG|single dose of 2 mcg|solution for inhalation
41296417|NCT01809262|DRUG|single dose of 10 mcg|solution for inhalation
41296418|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
41457861|NCT04058977|OTHER|Power training|Progressive exercise protocol with focus on velocity of movement
40768736|NCT05613127|BIOLOGICAL|HAVRIX 720 Junior 0.5 mL|Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
41296419|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
41296420|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
41296421|NCT05527704|DRUG|Salbutamol|Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
41296422|NCT05527704|DRUG|0,9% Chloride Sodium|3 mL nebulized 0.9% NaCl administered for 30 min.
40768737|NCT01751880|BEHAVIORAL|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
40768738|NCT03459222|BIOLOGICAL|Relatlimab|Specified dose on specified days
40768739|NCT03459222|BIOLOGICAL|Nivolumab|Specified dose on specified days
40768740|NCT03459222|DRUG|BMS-986205|Specified dose on specified days
40768741|NCT03459222|BIOLOGICAL|Ipilimumab|Specified dose on specified days
40968815|NCT05496062|DEVICE|F&P Toffee Nasal and Toffee Nasal Pillows Masks|F\&P Toffee Nasal and Toffee Nasal Pillows Masks are intended to be used within the traditional PAP therapy system and are designed to facilitate equivalent PAP therapeutic efficacy as defined by standard practice.
40968816|NCT05090059|DEVICE|Lower limb myofascial trigger points f-ESWT|3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
40968817|NCT06170723|DRUG|BMS-986368|Specified dose on specified days
41296423|NCT01673048|PROCEDURE|3-Nail-ESIN in femoral shaft fractures|
41296424|NCT05537324|OTHER|Brazil nut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 50g Brazil nuts
41296425|NCT05537324|OTHER|Coconut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 46g coconut flakes
41296426|NCT03391440|DRUG|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
41296427|NCT02028364|DRUG|Everolimus|10mg orally daily
41457862|NCT03651973|OTHER|Standard follow-up|Patients enrolled into standard group will be followed in a standard way without any additional procedure except randomization that allocates to the standard group
41457863|NCT03651973|OTHER|Learning workshops|Patients enrolled into experimental arm will participate to educative workshops before and after surgery for breast cancer. The aim of these workshop is to educate patient to self massages and self stretching.
40968818|NCT06170723|DRUG|Itraconazole|Specified dose on specified days
40968819|NCT06170723|DRUG|Famotidine|Specified dose on specified days
40968820|NCT04402931|PROCEDURE|Transcatheter Valve-in-Valve Intervention|Transcatheter mitral valve-in-valve implantation with SAPIEN 3
40968821|NCT04402931|PROCEDURE|Redo Mitral valve surgery|Transcatheter Valve-in-Valve Intervention
40968822|NCT04593225|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL SFCAMINA|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with SFC.
40968823|NCT04593225|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
40968824|NCT05380804|DIAGNOSTIC_TEST|cutaneous silent period (CSP) measurement|CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.
41138461|NCT06294145|BEHAVIORAL|Savoring Intervention|The savoring intervention is the first module of the Positive Affect Treatment (PAT) developed by Michelle Craske and colleagues to treat anhedonia, or loss of interest or pleasure in usual activities. The investigators focus here on the behavioral activation and savoring components of the intervention, which are administered first and are considered the basis for other components. Of note, a variety of other positive psychology interventions include a savoring component, but PAT is unique in its inclusion of six sessions devoted to savoring. These sessions involve pleasant events scheduling in which participants: 1) plan activities that generate anticipation of reward, 2) engage in activities that generate reward and 3) practice therapist-guided-in-the-moment recounting of positive emotions, sensations, and thoughts generated by these activities. The investigators will additionally include an introductory psychoeducation session before the savoring module, as PAT does.
41138462|NCT04798378|DEVICE|Neurosleeve|Myoelectric devices for restoration of independent arm function
41138463|NCT01835652|OTHER|Active Exercise|
41457864|NCT02783287|BEHAVIORAL|Text message reminder for medication adherence|Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
41457865|NCT02783287|BEHAVIORAL|Text message reminder for exercise regimen|Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
40968825|NCT02387060|DRUG|H-Bupivacaine|Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
40968826|NCT02387060|DRUG|Fentanyl|Intrathecal administration of fentanyl 25 mcg
40968827|NCT05968703|DEVICE|Combined STN+NBM DBS|This intervention is a 4-lead deep brain stimulation approach targeting the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM)
40968828|NCT06320002|BEHAVIORAL|Communication Intervention for fecal ostomy surgery|This is a educational video-based supportive intervention to address practical skills and adaptation to life with a fecal ostomy
40968829|NCT02643381|DRUG|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
40968830|NCT02643381|DRUG|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
40968831|NCT02643381|PROCEDURE|Emergency Endotracheal Intubation|Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
40968832|NCT02643381|DEVICE|Mechanical Ventilation|Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
41457866|NCT02011451|DRUG|95% Pure ECGC capsules 200mg|Theaphenon 95% 95% Pure EGCG
41457867|NCT02011451|DRUG|Placebo Comparator:|
41296428|NCT02028364|DRUG|Exemestane|25mg orally daily
41457868|NCT05306600|DIAGNOSTIC_TEST|whole exome and whole genome sequencing analysis|"Somatic and germline whole exome sequencing will be analyzed for prostate and HER2-positive breast cancer~Somatic whole exome and germline whole genome sequencing will be analyzed for triple-negative breast cancer"
41457869|NCT03572582|DRUG|Nivolumab|Nivolumab therapy combined with standard TACE treatment
41457870|NCT03572582|DRUG|TACE|TACE is performed by using drug eluting beads
40768742|NCT04868357|BEHAVIORAL|Hypnosis|Two 45-minute group sessions in which patients experience hypnosis and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. First session is introductory. Second session addresses concerns that patients may have identified after using self-hypnosis. Both sessions include group hypnosis exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, eye closure, relaxation, nodding). Patients are asked to concentrate in nature-themed metaphors and hypnotic suggestions of pure air entering their lungs. Both sessions end with a round of questions, instructions and motivation to use self-hypnosis throughout the duration of the PRP and beyond.
41457871|NCT02582944|DEVICE|Olympus BF-180 bronchoscope (standard adult)|-Standard of care
41457872|NCT02582944|DEVICE|Veran Spinview Thoracic Navigation System|-Electromagnetic navigation
41457873|NCT02582944|DEVICE|Olympus UM-S20-17S|-Endobronchial ultrasound mini-probe
41457874|NCT02582944|PROCEDURE|Biopsy|
41138464|NCT01835652|OTHER|Passive Exercise|
41296429|NCT05998993|RADIATION|Stereotactic Body Radiation Therapy SBRT|This is a non-randomized Phase II study in which all patients receive the experimental treatment with Stereotactic Ablative Radiotherapy (SABR) to residual tumor lesions (up to 5 residual metastatic lesions in a maximum of 2 organs) following 12 weeks of systemic treatment with Osimertinib. The study aims to enroll 35 patients diagnosed and treated at CTIC Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo.
41296430|NCT00038545|DRUG|Filgrastim SD/01|
41296431|NCT00038545|DRUG|Paclitaxel|
41296432|NCT00038545|DRUG|Topotecan|
41457875|NCT06438562|DIETARY_SUPPLEMENT|Unfortified bouillon plus vitamin A in oil|Participants consume unfortified bouillon with vitamin A oil
41296433|NCT05758441|BEHAVIORAL|Mentoring to be Active plus Family|Ten, structured peer mentoring sessions (once a week) covering new content each week and guided skill-building and practice. The MPBA sessions target increasing daily physical activity and replacing sugary drinks with water for hydration. Mentoring sessions are conducted virtually. A 6-month family reinforcement program follows with a reinforcement packet sent to child participants' homes once a month.
41296434|NCT05758441|BEHAVIORAL|Tracking Health and Fitness|10 self-guided, self-paced modules mailed to child participants home.
41296435|NCT04116632|DRUG|BMS-963272|Single dose with varying frequency among groups
41457876|NCT06438562|DIETARY_SUPPLEMENT|Bouillon fortified with vitamin A #1 plus unfortified oil|Participants consume vitamin A #1 fortified bouillon plus unfortified oil
41457877|NCT06438562|DIETARY_SUPPLEMENT|Bouillon fortified with vitamin A #2 plus unfortified oil|Participants consume vitamin A #2 fortified bouillon plus unfortified oil
41457878|NCT02469480|DRUG|FerInject|FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
40968833|NCT06313229|PROCEDURE|implant placement 6 months after ridge augmentation|the deficient ridge was grafted first followed by implant placement after 6-monthes
41296436|NCT04116632|DRUG|Placebo|Specified dose on specified days
41296437|NCT05255562|PROCEDURE|Combined Serratus Anterior Plane Block|Combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
41296438|NCT05255562|DRUG|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
41296439|NCT03880227|DEVICE|Active anodal tDCS|active anodal tDCS with behavioral tasks to assess visual attention
41296440|NCT03880227|DEVICE|Sham tDCS|sham tDCS with behavioral tasks to assess visual attention
41296441|NCT05413473|DEVICE|MR guided radiotherapy|MR guided radiotherapy using the Alberta linac-MR P3 system
41296442|NCT03688646|DIETARY_SUPPLEMENT|Intensive Nutrition Intervention|
41457879|NCT02469480|DRUG|Ferro sanol|200 mg ferro sanol per day over 12 weeks
41457880|NCT01907048|BEHAVIORAL|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
41457881|NCT01907048|BEHAVIORAL|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure patient awareness and understanding of the key messages in the patient card.
41296443|NCT05180305|DIAGNOSTIC_TEST|Mitomic Prostate Test|Mitomic Prostate Test
41296444|NCT04160156|DEVICE|Long term sensor|Observational study including subjects using long term sensor according to local guidelines and patients preferences
41296445|NCT04983940|DRUG|Jatenzo|237 mg soft gel capsule taken twice a day by mouth with food.
41296446|NCT01185535|PROCEDURE|times of topical anesthesia for glottis|topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
41296447|NCT06150105|OTHER|Exercise training|Intense endurance training
41296448|NCT02090114|DRUG|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
41296449|NCT02090114|DRUG|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
41296450|NCT02090114|DRUG|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
41457882|NCT05901116|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
40968834|NCT06313229|PROCEDURE|implant placement Simultaneously with ridge augmentation|the deficient ridge was grafted and followed by implant placement simultaneously
41296451|NCT02090114|DRUG|Enzalutamide|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
41296452|NCT05573594|OTHER|Muscle Energy Technique|"The Janda method (Post isometric relaxation PIR Technique), one of the Muscle Energy Techniques, was used on m.piriformis, m.quadratus lumborum, m.hamstring, m.psoas major muscles in the study group. First, the dysfunctional muscle was stretched passively by the physiotherapist up to the movement barrier, and 5-7 seconds of isometric muscle contraction in the opposite direction was requested from the patient at the barrier. This practice was continued until muscle tension or joint dysfunction disappeared.~All participants performed standard home exercises consisting of stretching and strengthening. These exercises were taught to the participants by the physiotherapist in the first treatment session, and when they came to each treatment session, it was questioned whether they did it or not, and a control chart was created for exercise follow-up."
41457883|NCT01125527|BIOLOGICAL|Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
41457884|NCT01125527|BIOLOGICAL|Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
40968835|NCT04688853|BIOLOGICAL|TEG002|TEG002 cells are autologous T cells transduced with a specific γδTCR
40968836|NCT05145530|PROCEDURE|selective anterior cervical discectomy and fusion (ACDF)|selective anterior cervical discectomy and fusion (ACDF)
41457885|NCT05646238|OTHER|psychoeducation|Students assigned to the experimental group will be divided into groups of 6-9. 3 psychoeducation sessions will be held with each group once a week for a total of 3 weeks. Group sessions are estimated to last between 60-75 minutes. Psychoeducational content based on Leventhal's Self-Regulation Model was prepared. In the first stage, cognitive bases of dysmenorrhea, in the second stage, strategies to cope with dysmenorrhea, and in the third stage, the effectiveness of coping strategies in dysmenorrhea will be discussed. In the second stage, the participants will be taught the progressive muscle relaxation exercise, which is among the strategies to cope with dysmenorrhea. Sessions will be held online.
40968837|NCT05145530|PROCEDURE|SNRB+ selective anterior cervical discectomy and fusion (ACDF)|US-guided selective nerve root block (SNRB) + selective anterior cervical discectomy and fusion (ACDF)
41296453|NCT05573594|OTHER|conventional physical therapy and rehabilitation|In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes.
41296454|NCT02168946|DRUG|Vabomere|Vabomere for IV injection, administered as a 2 g/2 g dose
41296455|NCT02168946|DRUG|Best Available Therapy|Antibiotic(s) chosen by Investigator
41296456|NCT03028025|DEVICE|StatSeal|Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
41296457|NCT03028025|DEVICE|TR Band|Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
40968838|NCT06058481|DEVICE|Blockbuster|The investigator inserted the BlockBuster in Group A patients.
41296458|NCT00886821|BIOLOGICAL|CVX-096|Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
41296459|NCT01025245|DRUG|remifentanil, MgSO4|Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ \& Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
41296460|NCT01361529|DRUG|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
41296461|NCT02169635|PROCEDURE|macular buckle|macular buckle with a three-armed silicone capsule
40968839|NCT06058481|DEVICE|Proseal-LMA|The investigator inserted the Proseal-LMA in Group B patients.
41296462|NCT04811677|OTHER|radiology|image analysis
41296463|NCT05504330|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|First of all, ICAS patients were given health education to exhort them to reduce the risk factors of exposure to stroke and get rid of their unhealthy lifestyles. Secondly, for patients in need, standardize their dosage and course of treatment, mainly including antiplatelet drugs and statins. In addition, patients with diabetes and hypertension urge rational medication to control blood pressure and blood glucose level.
41296464|NCT05090410|DRUG|filgotinib 200mg/day|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
40968840|NCT02627144|DRUG|Bevacizumab|Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
40968841|NCT02627144|DRUG|Interferon alpha-2a|Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
40968842|NCT00660023|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
40968843|NCT04947449|DEVICE|fractional CO2 laser|Standard of care laser treatment of burn-related injuries will be performed. This protocol assesses the effects of those treatments on skin blood flow and sweating responses.
40968844|NCT02817100|DRUG|BAY1817080|Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food \[Continental breakfast\])
41138465|NCT00950456|BIOLOGICAL|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
41138466|NCT03592797|OTHER|Laser acupuncture therapy|Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.
41138467|NCT03592797|OTHER|Sham laser acupuncture therapy|Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
41296465|NCT05090410|DRUG|subcutaneous tocilizumab 162mg/biweekly|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
41296466|NCT00783705|OTHER|placebo|Given orally
41296467|NCT00783705|DRUG|inositol|Given orally
41296468|NCT03585374|COMBINATION_PRODUCT|Methoxyflurane and Penthrox inhaler|3ml of methoxyflurane vaporized through an inhaler (Penthrox). Inhalation, by regular breathing, last about 25 minutes.
41296469|NCT03585374|DRUG|Morphine|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a dose of 0.10 mg/Kg body weight. The time of infusion should be not longer than 10 minutes.
41296470|NCT03585374|DRUG|Paracetamol|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 1 g dose The time of infusion should be not longer than 10 minutes.
41296471|NCT03585374|DRUG|Ketoprofen|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
41296472|NCT05346224|DRUG|HLX11|Neoadjuvant(q3w/cycle，total 4cycle): HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
41296473|NCT05346224|DRUG|EU-Perjeta®|Neoadjuvant(q3w/cycle，total 4cycle): Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11 or Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
41296474|NCT02292199|DEVICE|TENS High Frequency|TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
41296475|NCT02292199|DEVICE|TENS Low Frequency|TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
41296476|NCT02292199|DEVICE|TENS Placebo|TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
41296477|NCT02014532|DRUG|Montelukast|Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
41296478|NCT02014532|DRUG|Placebo|Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
41296479|NCT01893840|DEVICE|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
40968845|NCT02817100|DRUG|Placebo|Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food \[Continental breakfast\])
40968846|NCT02817100|DRUG|Itraconazole|Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
40968847|NCT00477243|BEHAVIORAL|Questionnaire|8 questionnaires will take about 40 minutes to complete.
41138468|NCT03758248|GENETIC|CYP2C19|The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19\*17 carriers) or higher (CYP2C19\*2 carriers) risk of major adverse cardiovascular events.
41138469|NCT01130870|DEVICE|Sensory Threshold|Sacral nerve stimulation with amplitude (sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
40968848|NCT05299281|DEVICE|Micropulse transscleral cyclophotocoagulation (MP-TSCPC)|"patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively."
40968849|NCT00883805|BIOLOGICAL|Blood draw|Subjects will give blood for analysis of metal ion concentrations
40968850|NCT00883805|RADIATION|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
40968851|NCT01307397|DRUG|Vemurafenib|Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
40968852|NCT02379871|OTHER|Experimental Group|Supine mid-thoracic spinal manipulation to the T4/5 region
40968853|NCT02379871|OTHER|Sham Group|Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
40968854|NCT04234178|DRUG|Epidural|2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
40968855|NCT04234178|DRUG|Intrathecal+Epidural|10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
40968856|NCT04905485|BEHAVIORAL|VIOME Precision Nutrition Program|Precision diet and supplement recommendations based on participants' microbiome results.
40968857|NCT04370938|BEHAVIORAL|Coping strategies video|No additional description
40968858|NCT02904330|DRUG|K1-70 intramuscular or K1-70 intravenous|Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
40968859|NCT00818818|DRUG|Meglumine antimoniate|5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
40968860|NCT00030121|DRUG|recombinant human atrial natriuretic polypeptide|
40968861|NCT05170841|DRUG|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 MG|Administered as one single tablet to be taken every 8 hours
40968862|NCT05170841|DRUG|Tramadol Hydrochloride 100 MG|Administered as two capsules with 50 mg each to be taken every 8 hours
40968863|NCT05170841|DRUG|Placebo|Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 MG or two capsules if matching Tramadol Hydrochloride 100 MG
40968864|NCT00232232|DRUG|Fish oil|
40968865|NCT02517567|DEVICE|Delefilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
40968866|NCT02517567|DEVICE|Narafilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
40968867|NCT02517567|DEVICE|Somofilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
40968868|NCT02223091|BEHAVIORAL|Consultation by a trained physician|
40968869|NCT02223091|BEHAVIORAL|Consultation by an untrained physician|
40968870|NCT02567916|DRUG|Fresofol|
40968871|NCT02567916|DRUG|Propofol|
40968872|NCT02385513|BIOLOGICAL|10-valent pneumococcal conjugate vaccine|
40968873|NCT04753060|PROCEDURE|Waxing|Donor sites of patients skin grafts are waxed prior to surgery for donor harvesting.
40968874|NCT02073552|DRUG|Polyethylene glycol 4000|- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
40968875|NCT02073552|DRUG|Macrogol 3350 plus ascorbic acid|- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
40968876|NCT02853110|RADIATION|Hypo-FLAME study|SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (\~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.
40968877|NCT04981769|DIAGNOSTIC_TEST|Covid-19 test|PCR Covid-19 test
40968878|NCT05968391|RADIATION|PET scan metabolic day|11C-Acetate and 11C-Acetoacetate PET scans
40968879|NCT00571545|BEHAVIORAL|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
40968880|NCT00571545|BEHAVIORAL|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
40968881|NCT05566912|OTHER|filling out a survey|This research is a descriptive study
41138470|NCT01130870|DEVICE|75% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (75% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
40968882|NCT03851705|DRUG|Inclisiran Sodium for injection|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
40968883|NCT03851705|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection)
40968884|NCT03851705|DRUG|Placebos|Sterile normal saline (0.9% sodium chloride in water for injection)
40968885|NCT02866552|DRUG|Stromal Vascular fraction|
40968886|NCT02866552|DRUG|Ringer lactate|
40968887|NCT00634530|BEHAVIORAL|Dietary Advice|The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
40968888|NCT05955937|OTHER|Enhanced HF Clinical Care (Core-HF)|All clinical care providers involved in HF care at participating RRHs will be trained in a HF service bundle including a care protocol (treatment algorithm based on global guidelines), self-care training for patients and providers, and medication stock management to ensure supply of HF medications to patients in need.
40968889|NCT05955937|OTHER|Digital health intervention (Medly Uganda) plus enhanced HF clinical care (Core-HF)|A patient-facing mobile health application designed to improve self-care will be provided to the study participant, which will operate on all mobile devices. This will be introduced after the Core-HF intervention has been delivered.
40968890|NCT00217594|DRUG|Alemtuzumab (Campath)|
40968891|NCT05413850|DRUG|177Lu-rhPSMA-10.1 injection|Therapeutic cycles of 177Lu-rhPSMA-10.1
40968892|NCT05413850|DIAGNOSTIC_TEST|18F-rhPSMA-7.3 injection|18F-rhPSMA-7.3 at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.
40968893|NCT03848117|OTHER|Cyriax approach i.e. DTF massage and Mill's manipulation|Each patient in group I i.e. Cyriax group was given 20-minute session. Each session started in sitting position and initially deep transverse friction massage was done at lateral compartment of the elbow joint and immediately after that mill's manipulation at elbow joint with flexion at wrist joint in pronated arm position. This session was repeated three times a week for one month (Total 12 sessions/ one month).
40968894|NCT03848117|OTHER|Mulligan approach i.e. Taping and MWM|Each patient in group II i.e. Mulligan group was given 30 to 45-minute session. Each session started in sitting position and it included mobilization with movement which was given in such a way that initially lateral glide at elbow joint was performed and after holding it, I asked the patient to make a fist and open the fist. In this way, I repeated this procedure 36 times and after 12 repetitions, a short rest period was given. Taping was applied after mobilization around the elbow joint over extensor carpi radialis muscles. This session was repeated three times a week for one month (Total 12 sessions/ one month).
40968895|NCT05409456|OTHER|mild aerobic exercise|mild aerobic exercise given to group A on treadmill
40968896|NCT05409456|OTHER|moderate aerobic exercise|moderate aerobic exercise given to group B on treadmill
41296480|NCT00222729|DRUG|Pemetrexed|500 mg/m2 day 1 q 21 days
41457886|NCT05646238|OTHER|training|The control group will be given a online training of 30-45 minutes covering dysmenorrhea and coping in a single session. From the first menstrual cycle after the training session is completed, measurements will be made in 3 consecutive menstrual cycles
40968897|NCT02704871|OTHER|SeptiCyte Lab molecular diagnostic test (non-interventional)|This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response.
40968898|NCT00618072|DRUG|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
41457887|NCT06316336|DRUG|Alfuzosin Hydrochloride 10 mg|Alfuzosin Hydrochloride 10 mg (test durg)
40968899|NCT01006096|DRUG|erlotinib|100mg tablet, once daily for 16 weeks
40968900|NCT01006096|OTHER|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
40968901|NCT05979090|BEHAVIORAL|Mastery learning in communication skills|Participants will undergo simulation-based mastery learning curriculum in difficult conversations.
40968902|NCT03000140|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
40968903|NCT03000140|BEHAVIORAL|Control group|Moderade Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
40968904|NCT00950105|DRUG|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
40968905|NCT05576870|OTHER|Plant based toddler nutrition|Plant based toddler nutrition fed daily ad libitum
40968906|NCT05576870|DIETARY_SUPPLEMENT|Dairy based toddler nutrition|Commercially available toddler nutrition fed daily ad libitum
40968907|NCT00480298|DRUG|Administration of oral methylprednisolone|
41296481|NCT00222729|DRUG|Bevacizumab|15 mg/kg IV q 21 days following pemetrexed
41296482|NCT00026468|DRUG|exisulind|
41296483|NCT04151381|DRUG|Aminophylline|"the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol."
41457888|NCT06316336|DRUG|Xatral® XL 10 mg|Xatral® XL 10 mg (reference drug)
41457889|NCT03504020|DEVICE|ECG Belt Research System|The ECG Belt Research System is used to identify the best vector and programming parameters.
41457890|NCT04129554|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.
40968908|NCT01823185|DRUG|clopidogrel|Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
40768743|NCT04868357|BEHAVIORAL|Relaxation|Two 45-minute group sessions in which patients experience dynamic relaxation and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. Both sessions include group relaxation exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, stretching, breathing exercises, nodding). Both sessions end with a round of questions, instructions and motivation to use relaxation throughout the duration of the PRP and beyond.
40968909|NCT01823185|DRUG|Ticagrelor or prasugrel|ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
40968910|NCT00940225|DRUG|Cabozantinib|
40968911|NCT00940225|DRUG|Placebo|
40968912|NCT00787891|DRUG|rabeprazole|0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
40968913|NCT00787891|DRUG|rabeprazole|1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
40968914|NCT04645875|OTHER|Sit regimen|See Sit regimen arm description
40968915|NCT04645875|OTHER|SitLess regimen|See SitLess regimen arm description
40968916|NCT03949504|PROCEDURE|New Find-risk questionnaire software|FINDrisk: software with 12 questions to define the risk of diabetes in the general population MyStar Connect: software to guide the diagnosis and the management of diabetes and its complications
40968917|NCT05083962|BEHAVIORAL|Healthy Lifestyle Program|An intensive behavior change curriculum designed to help create and sustain healthy habits
40968918|NCT02639143|DRUG|ticagrelor|
40968919|NCT02639143|DRUG|Clopidogrel|
40968920|NCT00674544|BEHAVIORAL|Lifestyle intervention|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
40968921|NCT04080414|BEHAVIORAL|Home-based high-intensity interval training|Participants will be instructed to complete four, high-intensity interval training workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
40968922|NCT04080414|BEHAVIORAL|Home-based moderate-intensity continuous exercise|Participants will be instructed to complete five, moderate-intensity continuous exercise workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
40968923|NCT02148198|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
40968924|NCT02148198|DIETARY_SUPPLEMENT|Placebo|A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
40968925|NCT03714867|DRUG|Pregabalin 150mg|150 mg concealed pregabalin capsule
40968926|NCT03714867|OTHER|Placebo|Concealed placebo capsule
41138471|NCT01130870|DEVICE|50% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (50% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
41138472|NCT02177825|DRUG|Imatinib Mesylate|oral administration
41138473|NCT02203656|DRUG|Placebo|placebo supplement
41138474|NCT02203656|DIETARY_SUPPLEMENT|Nutritional Supplement|protein supplement
40968927|NCT02346630|DRUG|Placebo|Placebo capsules daily for 3 weeks.
41138475|NCT02203656|BEHAVIORAL|In-home exercise|In-home exercise program
41138476|NCT02203656|DRUG|Testosterone|Testosterone injection
41138477|NCT05732727|DRUG|Antihypertensive algorithm|Antihypertensive algorithm based on diuretics agents
41457891|NCT04129554|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
41457892|NCT04129554|DRUG|Placebo for JNJ-73763989|Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.
40968928|NCT02346630|DRUG|Levodopa / Carbidopa|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
40968929|NCT02346630|DEVICE|Armeo|Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
41138478|NCT05732727|DRUG|Standard of care|standard of care management for antihypertensive therapy intensification
41138479|NCT02346357|PROCEDURE|Obturator Nerve Block|Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
41138480|NCT02346357|DRUG|Ropivacaine|
41138481|NCT02346357|DRUG|Placebo Saline|
41146889|NCT03905928|OTHER|Nicotine Containing ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor."
40968930|NCT03020160|DRUG|Emicizumab|Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.
40968931|NCT02010775|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
40968932|NCT02010775|DRUG|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
40968933|NCT03971058|BIOLOGICAL|IXIARO®- Japanese Encephalitis vaccine|Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
40968934|NCT02421432|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
40968935|NCT01720121|OTHER|Printed, digital video disc|The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
40968936|NCT01605877|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
40968937|NCT02660502|DRUG|Biochaperone insulin lispro 0.1 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
40968938|NCT02660502|DRUG|Biochaperone insulin lispro 0.2 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
40968939|NCT02660502|DRUG|Biochaperone insulin lispro 0.4 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
40968940|NCT02660502|DRUG|Humalog®|Injection of a single dose of Humalog® at the dose of 0.2 U/kg
40968941|NCT06293495|DEVICE|Gamma 3 Nail (Stryker)|Open reduction an internal fixation of proximal femoral fracture with a Gamma 3 nail (single cephalic screw system)
40968942|NCT06293495|DEVICE|Chimaera Nail (Orthofix)|Open reduction an internal fixation of proximal femoral fracture with a Chimaera nail (system with double cephalic screw)
40968943|NCT03170401|DIETARY_SUPPLEMENT|Protein supplementation|enteral protein supplementation
40968944|NCT03170401|OTHER|Standard enteral nutrition|Standard enteral nutrition.
40968945|NCT05693896|BEHAVIORAL|Centering Appetite|A digital treatment of Appetite Awareness Treatment (AAT) and behavioral weight loss treatment (BWL) over 6 months, delivered remotely using Zoom. The goal of AAT is to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants diagnosed with Binge Eating Disorder (BED) and bulimia nervosa reduce binge eating, overeating, urges to eat in response to non-appetite stimuli, and prevent weight gain.
40968946|NCT03167840|BEHAVIORAL|Physical and Cognitive Training|Physical Exercise and Cognitive Training
40968947|NCT03167840|BEHAVIORAL|Physical Training|Physical training alone
40968948|NCT03167840|BEHAVIORAL|Cognitive training|Cognitive training alone
40968949|NCT03798496|PROCEDURE|Open reduction and internal fixation|Open reduction of the Galeazzi fracture dislocation with a plate.
40968950|NCT02741024|DRUG|Amodiaquine-Artesunate (ASAQ)|Treatment on site with Amodiaquine-Artesunate according to the manufacturer's dose and instruction and follow-up for a period of 42 days. Drugs will be given under direct supervision, either at the clinic or at home
40968951|NCT02741024|DRUG|Artemether-Lumefantrine (AL)|Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
40968952|NCT02531204|DRUG|ASP1585|oral
40968953|NCT00597181|PROCEDURE|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
40968954|NCT00597181|PROCEDURE|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
40968955|NCT06068790|PROCEDURE|HoLEP Surgery|HoLEP will be performed per standard clinical care with the instruments assigned at randomization - 22Fr or 28Fr.
40968956|NCT02887885|DRUG|Gynoflor|1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
40968957|NCT00949520|OTHER|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
40968958|NCT00949520|OTHER|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
40968959|NCT01245660|DRUG|LAPATINIB|Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
40968960|NCT04397107|DRUG|IL-2|Patients were received low dose recombinant human Interleukin-2
40968961|NCT03558178|PROCEDURE|Doin with acupuncture|Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated. Doin sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
40968962|NCT03558178|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
40968963|NCT05536986|OTHER|Stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
41457893|NCT04129554|DRUG|Placebo for JNJ-56136379|Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
41457894|NCT04129554|DRUG|Entecavir (ETV) monohydrate|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
41457895|NCT04129554|DRUG|Tenofovir disoproxil fumarate (TDF)|TDF will be administered orally once daily up to 48 weeks as NA treatment.
40768744|NCT06631729|BEHAVIORAL|HRV-bio|participants will complete a HRV biofeedback task via the Elite HRV app. In this intervention, participants will learn how to use their HRV data that they will see in real-time via the Elite HRV app to improve their HRV by engaging in an app-guided diaphragmatic breathing exercise. They will complete this exercise twice daily (morning, night).
41457896|NCT04129554|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
41457897|NCT06316180|DRUG|drospirenone/estetrol 3mg/14.2mg|Hysteroscopic polipectomy after starting 14-day treatment with oral drospirenone/estetrol 3mg/14.2mg at any time of the menstrual cycle.
41457898|NCT03795441|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection on Day 1.
41457899|NCT03646162|DRUG|Veru-944|Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT
41457900|NCT03646162|DRUG|Placebo|Placebo
41457901|NCT02656316|DEVICE|Active tDCS|In this group subjects will receive 20 min of treatment.
40968964|NCT05669495|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a wireless remote monitoring system consisting of two flexible, soft, and skin-mounted electronic devices for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings. The ANNE Vital Sign System integrates simultaneous synchronized ambulatory measurement of electrocardiography, photoplethysmography with derived pulse oximetry, pulse arrival time with derived beat-to-beat blood pressure, triaxial accelerometry, respiratory rate, and temperature, which would enable accurate measurement of sleep apnea. Indeed, in compelling in-laboratory preliminary data, we show the capacity for the ANNE Vital Sign System to detect and characterize sleep apnea in older patients. The ANNE Vital Sign System is non-invasive, flexible, easy to use, comfortable, and skin safe.
40968965|NCT04954703|OTHER|Muscle energy technique of gluteus maximus and tensor fascia lata|it is used for lengthening of hypertonic muscles for relief of pain and range of motion.Position of patient is supine lying and therapist is at side of table .The patient leg is fully adducted to stretch IT band and then patient attempts to abduct the leg against resistance contracting the muscles being stretched at approximately 25% of maximum effort for 10 seconds. They then relax and the therapist lengthen it.
40968966|NCT04954703|OTHER|Myofascial release of iliotibial band syndrome|Myofascial release of IT band Syndrome. Therapist fingers track up and down your ITB with fingertips to find the most tender spots and use a tennis ball to apply small, circular, light release in those places.
40968967|NCT04006574|OTHER|Exercises|Core stabilization
40968968|NCT00302835|DRUG|non-phenacetin containing analgesics|
40968969|NCT02503735|DRUG|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
40968970|NCT02195440|DRUG|PRI-724|10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
40968971|NCT00158158|DRUG|Usual Care|If unable to quit at quit date, offered usual care to set another quit date.
40968972|NCT00158158|OTHER|Smoking Reduction|If unable to quit smoking, reduce smoking rate prior to quit date.
40968973|NCT04101461|DRUG|Iron|PharaFerro27; Devart Lab Company, Egypt
40968974|NCT04101461|DIAGNOSTIC_TEST|Complete blood count|to assess the anemia
41457902|NCT02656316|DEVICE|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
40968975|NCT04101461|DIAGNOSTIC_TEST|Serum ferritin|to assess the anemia
41138482|NCT05404997|DEVICE|Shockwave Therapy|"Subjects in Group A will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes. After the conventional therapy, this group will be given shockwave therapy treatment twice a week for four weeks.~After exposing and cleaning the treated area with alcohol, adequate amount of gel will be placed on the lower back region, and the machine will be adjusted at (2000 shock per session, 8 sessions 2 per week for 4 weeks, energy flux density 0,18mJ per mm square, 2 bars of pressure, frequency 10hz), with using 20mm D-Actor head."
41138483|NCT05404997|OTHER|Maitland's lumbar mobilizations|"Subjects in Group B will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes.~After the conventional treatment, Group B will be given Maitland's lumbar postero-anterior glide mobilizations initiating from Grade 1, with 3-4 sets of oscillations of 40 counts in each set, 2 sets of oscillations will be given below and above the affected joint level.This whole mobilization treatment will also be given twice a week for 10 minutes."
41138484|NCT06092307|DIAGNOSTIC_TEST|Bioelectrical impedance|Resistance, reactance, phase angle,free-fat mass, body cell mass, body cell mass index and total body will be recorded
40968976|NCT04101461|DIAGNOSTIC_TEST|Serum hepcidin|to assess the iron abosrption
40968977|NCT04101461|DIAGNOSTIC_TEST|Serum Iron|to assess the anemia
40968978|NCT04101461|DIAGNOSTIC_TEST|Serum total iron binding capacity|to assess the anemia
40968979|NCT01008592|DRUG|levocetirizine or placebo|oral administration, single tablet, 5 mg.
41138485|NCT06092307|DIAGNOSTIC_TEST|Handgrip strength test|Handgrip strength test using a hydraulic hand dynamometer and sit-to-stand test will be performed.
41457903|NCT05553496|DRUG|Rituximab|Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)
41457904|NCT05553496|DRUG|Dexamethasone|Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)
41457905|NCT01532908|BIOLOGICAL|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
41457906|NCT01532908|DRUG|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
41457907|NCT01532908|DRUG|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
40968980|NCT02088047|DEVICE|ProFoveate|ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.
40968981|NCT03281577|DRUG|TAK-954|TAK-954 IV infusion.
40968982|NCT03281577|DRUG|Placebo|TAK-954 placebo-matching IV infusion.
40968983|NCT01535547|DRUG|isavuconazole|oral
40968984|NCT01535547|DRUG|tacrolimus|oral
40968985|NCT05286281|DRUG|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
40968986|NCT01661621|DRUG|Detrusitol 4 mg QD|Group 1
40968987|NCT01661621|DRUG|Doxazosin 4 mg QD|Group 2
40968988|NCT01460888|DRUG|Olaparib|25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
40968989|NCT01460888|RADIATION|Radical external beam radiotherapy, 50Gy in 25 fractions|Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
40968990|NCT02644733|PROCEDURE|head of bed elevation 30 degree|the intraabdominal pressure will be measured by nasogastric tube when the head of bed elevated to 30 degree
40968991|NCT02644733|PROCEDURE|urinary catheter|the intraabdominal pressure will be measured by urinary catheter when the patient in supine position
40968992|NCT01055171|DRUG|Propranolol|40 mg; Single Administration.
40968993|NCT01055171|DRUG|Placebo|40 mg; Single Dose.
40968994|NCT04113005|DRUG|Desmopressin|To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
40968995|NCT00496808|DRUG|Herceptin (Trastuzumab)|8 mg/kg IV Over 90 Minutes
40968996|NCT01842074|DRUG|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
40968997|NCT00134238|DRUG|torcetrapib/atorvastatin|
40968998|NCT00134238|DRUG|atorvastatin|
40968999|NCT03609632|OTHER|Dietary Supplement: Glucose|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
41296484|NCT00328198|BIOLOGICAL|Alemtuzumab|"Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study."
41457908|NCT04517526|DRUG|pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles after informed consent, followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of what the investigator considers to be treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites.
40969000|NCT05079529|DRUG|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
40969001|NCT05079529|DRUG|Placebo Group|Takes placebo capsule 3 times daily for 90 days
40969002|NCT04694417|OTHER|Compression stocking|Please see the description of the intervention in another section
40969003|NCT04694417|DIETARY_SUPPLEMENT|Magnesium tablet|Please see the description of the intervention in another section
40969004|NCT04694417|OTHER|Placebo tablet|Please see the description of the intervention in another section
40969005|NCT06229990|DRUG|Furosemide Injection|After taking furosemide at 1.5 mg/kg intravenously, if the urine output exceeds 200 mL within 2 hours, the patients are going to withhold CRRT. But if there is no response, the titration of furosemide to 2.5 mg/kg and 3.5 mg/kg every 6 hours is scheduled according to the urine output \>200 mL in 2 hours (not exceeding 250 mg).
40969006|NCT04655391|DRUG|Bosutinib Monohydrate|Given PO
40969007|NCT04655391|DRUG|Decitabine|Given IV
40969008|NCT04655391|DRUG|Enasidenib Mesylate|Given IV
40969009|NCT04655391|DRUG|Gilteritinib Fumarate|Given PO
40969010|NCT04655391|DRUG|Glasdegib Maleate|Given PO
40969011|NCT04655391|DRUG|Ivosidenib|Given PO
40969012|NCT04655391|DRUG|Venetoclax|Given PO
40969013|NCT01015898|RADIATION|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
40969014|NCT02888886|OTHER|Questionnaires about food habits and tobacco|
40969015|NCT02888886|OTHER|Spirometry|
40969016|NCT02888886|OTHER|Carotid echography|
40969017|NCT02888886|OTHER|Blood sample|for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
41457909|NCT03031795|DRUG|Ketorolac|Oral Tablet
41457910|NCT03031795|DRUG|Placebo|Oral Tablet
40969018|NCT05871645|PROCEDURE|Jakarta Surgical Uterine Conservation (JSICA) Technique|a. Identifying the placenta accrete site; b. Meticulous dissection to create a bladder flap; c. Incision 1 cm above the placenta accrete; d. Fetal delivery; e. Bottom incision to resect the placenta; f. Placental delivery; g. Uterus without placenta; h. The resection area is approximated using interrupted horizontal mattress suture; i. The continuous suture used to close all incision areas; j. Evaluation of uterine contraction
40969019|NCT05871645|PROCEDURE|Standard Hysterectomy|The main types of hysterectomy are abdominal, vaginal, and laparoscopic hysterectomy
41296485|NCT00328198|BIOLOGICAL|Alemtuzumab|"Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration."
41457911|NCT03930849|BEHAVIORAL|AIMS|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
41457912|NCT03930849|BEHAVIORAL|AIMS plus|Participants randomized to the AIMS Plus arm will receive a weekly phone call in addition to being enrolled in VA's Annie text messaging program/study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
41457913|NCT02207582|DEVICE|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
40969020|NCT05581420|DRUG|Ferrous fumarate|Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.
40969021|NCT05581420|DRUG|MonoFer|Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.
41296486|NCT02458612|OTHER|control group|We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
40969022|NCT02648776|DRUG|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
40969023|NCT06040125|BEHAVIORAL|Supervised Circuit Training|16-week, multicomponent exercise intervention comprised of sessions supervised by certified exercise oncology trainer and home-based, self-directed aerobic exercises. Stationary bike and accelerometer (activity/heart rate monitor) will be provided.
40969024|NCT00653055|DRUG|Cabergoline|Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
40969025|NCT00653055|DRUG|Dostinex|Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
40969026|NCT05638568|DIAGNOSTIC_TEST|LS test|If the LS test indicated surfactant deficiency based on the cut off ratio early surfactant treatment will be done for patients in the intervention group If the LS test indicated no surfactant deficiency routine surfactant treatment will be done as per European RDS guidelines based on oxygen requirement (FiO2 \> 0.30)
40969027|NCT05174260|DEVICE|perfusion index, pleth variable index|a clip will be attached to the patient's finger and the perfusion index and pvi will be measured
40969028|NCT05813015|DRUG|Docetaxel|Docetaxel 40mg/m2，every 21 days，6 cycles.
40969029|NCT05813015|DRUG|Tegafur-Gimeracil-Oteracil|S-1 40-60mg/m2，p.o, BID, day 1-14, till 1 year postoperation.
40969030|NCT05722483|OTHER|Virtual Intensive Outpatient Program|Components of the intervention include a cognitive behavioral therapy for alcohol use disorder group (12 sessions), a DBT skills group (12 sessions), a Health and Wellness group (8 sessions), weekly individual therapy, weekly medication management appointments, and abstinence monitoring multiple times per day using breathalyzers equipped with facial recognition and internet connectivity.
40969031|NCT02949037|OTHER|Mobile Health Care Environment (MHCE)|An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
40969032|NCT04512404|DRUG|HMG-CoA Reductase Inhibitor|
40969033|NCT05211882|OTHER|Immediate ENABLE nurse coaching, on top of usual care|Participants in the intervention arm will start on the ENABLE program at point of randomization
40969034|NCT05211882|OTHER|Usual Care|Participants on wait-list will continue on usual care and only start ENABLE 6 months after randomization.
40969035|NCT03378232|DIETARY_SUPPLEMENT|Placebo Olive Oil|Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.
40969036|NCT03378232|DIETARY_SUPPLEMENT|High EPA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
40969037|NCT03378232|DIETARY_SUPPLEMENT|High DHA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
40969038|NCT02373215|DRUG|Nalbuphine HCL ER|Nalbuphine HCL extended release tablet
40969039|NCT04525378|OTHER|Mesenchymal stromal cell-based therapy|Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)
40969040|NCT01179568|DRUG|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
40969041|NCT01179568|BEHAVIORAL|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
40969042|NCT01179568|OTHER|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
40969043|NCT06218641|DEVICE|CP - conventional protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner."
40969044|NCT06218641|DEVICE|DP - delayed protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner."
40969045|NCT01652612|OTHER|PEEP|8 cmH2O PEEP throughout the period of OLV and 2nd TLV
40969046|NCT02809937|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
41138486|NCT06092307|DIAGNOSTIC_TEST|muscle ultrasound.|The following ultrasound parameters will be evaluated: radial, ulnar, rectus femoris, rectus abdominis and medial gastrocnemius muscle thickness and echo intensity with gray-scale-index; rectus femoris muscle cross sectional area; gastrocnemius muscle fiber length and pennation angle.
41138487|NCT06287671|PROCEDURE|Colorectal resection or stoma closure|Elective open or minimally invasive resection for colorectal cancer, IBD or other benign colorectal disorder, or stoma closure
41138488|NCT01698918|DRUG|Everolimus|Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
41138489|NCT01698918|DRUG|Letrozole|1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued
41138490|NCT01698918|DRUG|Exemestane|2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued
41138491|NCT01698918|DRUG|Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)|Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).
41138492|NCT01698918|DRUG|Standard of care to treat stomatitis (Stomatitis sub-study)|Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
41138493|NCT03104530|OTHER|Brown crabmeat|Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
41138494|NCT01874366|DRUG|P11187|"* Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~* Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~* Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval."
41138495|NCT01874366|DRUG|Placebo|"Placebo capsules will be matching in appearance with the active drug capsules of P11187.~* In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~* In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo"
41138496|NCT01357902|DRUG|Lamotrigine|Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
41138497|NCT02763657|OTHER|fMRI scanning|All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
41138498|NCT03080350|DRUG|Fentanyl sublingual|Fentanyl sublingual
41138499|NCT03080350|DRUG|Fentanyl ev|Fentanyl ev
41138500|NCT03080350|DRUG|Placebo sublingual|Placebo sublingual
41138501|NCT03080350|DRUG|Placebo ev|Placebo - NaCL 0,9% ev
41138502|NCT03734978|DIAGNOSTIC_TEST|Diagnosis|biochemistry
41138503|NCT04569188|BIOLOGICAL|Convalescent plasma|COVID-19 elderly patients treated with convalescent plasma
41138504|NCT05914532|OTHER|lab testing|Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.
41138505|NCT02833948|DRUG|Acetylsalicylic acid|"Drug: Acetylsalicylic acid:~75 - 100 mg OD (for first 90 days only in arm 1)"
41138506|NCT02833948|DRUG|Clopidogrel|Drug: Clopidogrel 75 mg OD for first 90 days
41296487|NCT02458612|OTHER|intervention group|"Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
41296488|NCT04764123|DIAGNOSTIC_TEST|AVNRT mapping|AV annuli mapping during AVNRT
40969047|NCT02809937|DRUG|placebo|normal saline infusion
40969048|NCT01904591|DIETARY_SUPPLEMENT|Selenium|"Selenium 50 micrograms daily per oral~1 year of treatment"
41296489|NCT03119376|OTHER|COBPEER|At the end of the online training, they can participate in the study and so peer review 1 manuscript randomly selected from our sample with our tool (COBPeer).
41296490|NCT01877330|PROCEDURE|Interscalene block for shoulder arthroscopy|
41296491|NCT01974674|PROCEDURE|Allogeneic transplantation of intrahepatic islet|
41457914|NCT02207582|DEVICE|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
41457915|NCT02407496|OTHER|Behavioral assessment and NAT EEG tests|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
40969049|NCT01904591|DIETARY_SUPPLEMENT|Vitamin E|"Vitamin E 400 international units daily per oral~1 year of treatment"
40969050|NCT00003746|DRUG|2-chlorodeoxyadenosine (CDA) daily|Daily administration
41138507|NCT02833948|DRUG|Rivaroxaban|"Drug: Rivaroxaban (Xarelto):~10 mg OD (once-daily)"
41138508|NCT03871075|DEVICE|intermittent pneumatic compression|Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
41138509|NCT03871075|BEHAVIORAL|exercise|Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.
40969051|NCT00003746|DRUG|2-chlorodeoxyadenosine weekly|Weekly administration
40969052|NCT02978430|DEVICE|Computer-assisted GDFT|Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
40969053|NCT02978430|OTHER|Standard of care|Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
41138510|NCT03871075|DEVICE|Sham device|The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
41138511|NCT03871075|BEHAVIORAL|Health Education|Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information.
41138512|NCT05889494|OTHER|Autologous Whole Blood Management|Intraoperative high volume autologous whole blood withdrawal with re-transfusion following weaning from CPB.
41296492|NCT01345786|DRUG|Commercial NOMAC-E2|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
41296493|NCT01345786|DRUG|"Phase 3 NOMAC-E2 Batch A"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods"
40969054|NCT05385731|OTHER|Nordic Walking (NWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
40969055|NCT05385731|OTHER|Free Walking (FWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
41457916|NCT01881737|DRUG|Pregnenolone|"With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs."
40969056|NCT05385731|OTHER|Health Education (HEG)|"The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months."
40969057|NCT00886899|DEVICE|Recanalization of a coronary chronic total occlusion|Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement
41457917|NCT04404725|DEVICE|comfilcon A|Subjects will be randomized to wear comfilcon A for one month.
41457918|NCT04404725|DEVICE|Samfilcon A|Subjects will be randomized to wear samfilcon A for one month.
41457919|NCT02582190|DRUG|Colchicine group|antiarrhythmic therapy plus colchicine \& antiarrhythmic therapy alone.
41457920|NCT04814628|PROCEDURE|scenario 1 : pre-oxygenation with a face mask held by the anaesthetist|"the face mask is held by the anaesthetist (reference technique) to obtain effective pre-oxygenation for Oxygen Reserve Index (ORI) which has reached a plateau value for more than 10 seconds. All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
40969058|NCT04997811|DRUG|Sodium Valproate, Bezafibrate, Medroxyprogesterone|Sodium valproate tablet 1 x 500mg bd, (starting 1 x 200mg bd) Bezafibrate standard release tablet 2 x 200mg tds, (starting 1 x 200mg tds) Medroxyprogesterone acetate tablet 1 x 400mg bd (starting 1 x 400mg od)
40969059|NCT04997811|DRUG|Danazol|Danazol 1 x 200mg capsules tds, (starting 1 x 200mg od)
40969060|NCT02650362|OTHER|fMRI|
40969061|NCT01155232|DRUG|Teriparatide|Forteo (teriparatide)pen daily for 24 months
40969062|NCT00844389|DEVICE|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
40969063|NCT00844389|DEVICE|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
40969064|NCT04447352|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
40969065|NCT04447352|DRUG|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
40969066|NCT04447352|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
40969067|NCT04447352|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
40969068|NCT04447352|DRUG|Cisplatin|intraoperative: 75mg/m² intraabdominal solution over 1 hour and 30 minutes
40969069|NCT01412359|DRUG|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
40969070|NCT04374721|DIAGNOSTIC_TEST|circadian gene expression evaluation|patients and controls will undergo circadian gene expression (CLOCK, ARNTL) evaluation at baseline and after 1, 3 and 6 months
40969071|NCT05069649|DRUG|Ergoferon|Tablet for oral use.
40969072|NCT05069649|DRUG|Placebo|Tablet for oral use.
40969073|NCT00373152|PROCEDURE|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
40969074|NCT00373152|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
40969075|NCT00373152|PROCEDURE|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
40969076|NCT00373152|RADIATION|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
40969077|NCT06382792|PROCEDURE|proximal humeral resection for tumor and allograft prosthetic composite reconstruction|allograft prosthetic composite
40969078|NCT01207869|BIOLOGICAL|ucMSCs|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
41296494|NCT01345786|DRUG|"Phase 3 NOMAC-E2 Batch B"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch B) orally in the morning on Day 1 for all periods"
41296495|NCT00477529|DRUG|ABI-008|nab-docetaxel
40969079|NCT01207869|OTHER|Normal saline|the same amount of ucMSCs suspension will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
40969080|NCT04785976|PROCEDURE|Surgical clipping and endovascular coiling|Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
41296496|NCT05774912|OTHER|Ultrasound evaluation|Fetal ultrasound evaluation will be collected longitudinally during the prenatal period from the weeks 14 every 4-5 weeks, for a total of maximum 6 ultrasound scans
41457921|NCT04814628|PROCEDURE|scenario 2: one anaesthetist in charge, face mask held by the patient for pre-oxygenation|"one anaesthetist is in charge of the simulated patient (volunteer), face mask held by the volunteer for pre-oxygenation for ORI which has reached a plateau value for more than 10 seconds All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Face mask held by the patient for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
40969081|NCT01619696|PROCEDURE|Pelvic MRI and F MISO TEP|Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
40969082|NCT04077827|DRUG|Propofol|Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
40969083|NCT04771039|OTHER|reason for consultation|search in medical files for reasons for ophthalmology consultation, functional signs, clinical signs, treatment, characteristics of IBD
40969084|NCT06508632|BEHAVIORAL|Mandala group|Individual mandala activity will be carried out in all sample groups after admission to the clinic where they come to receive outpatient chemotherapy and when they start taking medication. Children will color (paint).
40969085|NCT05139589|OTHER|None, observational|Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery
40969086|NCT01731990|DRUG|Canakinumab (ACZ885)|Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
40969087|NCT01731990|DRUG|Placebo|Matching placebo of Canakinumab
40969088|NCT05973500|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet for 42 Days
40969089|NCT02537197|DRUG|Naltrexone|Regular opioid antagonist dosing of disordered gamblers
40969090|NCT04165785|DEVICE|OPT IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
40969091|NCT04165785|DEVICE|Sham OPT IPL|Sham Optimal pulsed technology intense pulsed light IPL will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
40969092|NCT04165785|PROCEDURE|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.
40969093|NCT03645369|DEVICE|ShotBlocker|ShotBlocker is a drug-free tool with no side effects and does not require preparation. It is a flexible, plastic, C-shaped device with a number of short (2 mm) blunt contact points on its back.
40969094|NCT03645369|DEVICE|Ice pack|Ice pack containing gel
40969095|NCT05142943|OTHER|Visual illusion|the patient will be seated in a chair with a table in front of it. The front part of the trunk will be covered with a black blanket that will be attached to the table. On the table, you will see arms and hands projected performing different types of functional manual activities that will include mobility and strength tasks. The projected arms will be adapted to the dimensions of each subject so that the patient can recognize the projected arms as theirs. This program will last 10 minutes.
40969096|NCT05142943|OTHER|Physical exercise|"* General mobility and warm-up: flexion-extension joint movements, rotations, deviations, abduction-adduction, etc.~* Gross mobility and coordination: ball games.~* Fine mobility and coordination: writing tasks, puzzles, abacus ...~* Strength exercises: shoulder, elbow, wrist, fingers.~* Stretching."
40969097|NCT05142943|OTHER|Sham Visual illusion|only the placebo visual illusion
40969098|NCT02901314|OTHER|on-demand audio messages of heart failure education themes|
41296497|NCT02467452|DRUG|BDP/FF/GB|
41296498|NCT02467452|DRUG|FlF/VI + Tiotropium|
41296499|NCT02992470|DIETARY_SUPPLEMENT|Hydrolyzed oyster extract|1 tablet of oyster extract t.i.d. for 8 weeks
40969099|NCT01942330|PROCEDURE|Laparoscopic-Assisted Natural Orifice Surgery|Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
41296500|NCT02992470|DIETARY_SUPPLEMENT|Placebo|1 tablet of maltodextrin t.i.d. for 8 weeks
41296501|NCT04355117|DRUG|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
41296502|NCT05592470|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).|Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
41296503|NCT05251935|OTHER|Foot Muscle Exercise Protocol|Foot Muscle Exercise was given for 3 days per week for 40 minutes for the period of 6 months including home program
41296504|NCT05251935|COMBINATION_PRODUCT|Arch Support Insole and One Leg Balance Activities|Arch Support Insoles were provided that the child had to wear for 5 hours per day thrice weekly for 6 months plus performed one leg balance activities
40969100|NCT03618498|PROCEDURE|ILM flaps insertion techniques or free ILM flaps.|The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
41296505|NCT05032053|DRUG|Antithrombotic drugs|The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.
40969101|NCT06441994|DRUG|PSW-1025|PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)
40969102|NCT06498999|BEHAVIORAL|4-STEP-Training Program for Social Media Addiction (4-STEP-TPS)|"4 Modules with 1 Module being delivered in 1 weekly session of approximately 90 minutes. The details of each module/step is described as follows:~Step 1 (Module 1): S = Screening, Assessment and Psychoeducation: Involves screening and assessment of the problem, interpretation of the results, feedback and psychoeducation, identifying and breaking the resistance, motivation, and conceptualization.~Step 2 (Module 2): T = Treatment Conceptualization and Planning: Involves pattern identification, distortion identification, as well as pattern and distortions modifications.~Step 3 (Module 3): E = Effective Management Strategies: Involves management strategies to treat the earlier identified patterns as well as the implementation and confirmation of activities via a Pattern Schedule Chart.~Step 4 (Module 4): P = Prevention (Lapse-Relapse): Involves self-reflection and support building, monitoring and dependency check and slip plans and support additions"
41138513|NCT05889494|OTHER|Standard Care involving allogenic and/or derivative transfusion.|Therapeutic treatment of CPB-induced coagulopathy using donated allogenic blood products including plasma, platelets, and cryoprecipitate and/or derivative administration using prothrombin complex and fibrinogen concentrates.
41138514|NCT00003041|DRUG|pyrazoloacridine|
41138515|NCT01404000|DRUG|Iodinated Active Charcoal (IodoCarb)|3 g will be given as an oral suspension once daily for 56 days
41138516|NCT02941744|DRUG|nivolumab|low fixed dose ipilimumab in combination with nivolumab
41138517|NCT02941744|DRUG|ipilimumab|low fixed dose ipilimumab in combination with nivolumab
41138518|NCT01411137|DRUG|IPX066|"Subjects were converted from their current treatment to IPX066 over a 6-week period.~Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules"
41138519|NCT05214521|DEVICE|"digital interactive technology Smart glove SensoRehab"|"Participants will receive rehabilitation program including sessions on the Smart glove SensoRehab (SGSR) system. The program for IS patients includes 10 sessions with the SGSR: 15-30 minutes once a day for the affected hand, 2 weeks."
41138520|NCT01696500|DRUG|Intravenous immunoglobulin|
41138521|NCT04386538|BEHAVIORAL|Low Starch Diet (LSD)|6-week balanced diet program, adapted to individual energetic needs, with significant reduction of high content starchy food, naturally present in plant cells, roots, tubers, seeds, beans, legumes, fruits, and highly present in most farinaceous grains, especially in potatoes, corn, rice, pasta, bread, cookies and cakes.
41138522|NCT04386538|BEHAVIORAL|General healthy eating|6-week balanced healthy eating counseling program, according to the World Health Organization recommendations.
41138523|NCT01552083|OTHER|screening of sleep apnea|2 validated screening questionnaires (Berlin questionnaire, Epworth scale)
41138524|NCT03658603|PROCEDURE|thoracodorsal artery perforator flap|fascio-cutaneous flap used in cases of trauma or burns
41138525|NCT03658603|PROCEDURE|latissimus dorsi flap|musculo-cutaneous flap used in cases of trauma or burns
41138526|NCT00620139|BIOLOGICAL|the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,|patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
41138527|NCT03938207|DIAGNOSTIC_TEST|Whole-genome genotyping|Using Whole-genome genotyping from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
41138528|NCT03938207|DIAGNOSTIC_TEST|Whole-genome sequencing|Using whole-genome sequencing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
41138529|NCT03938207|DIAGNOSTIC_TEST|TCM pattern|We want to use TCM pattern to investigate the difference among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
41138530|NCT03938207|DIAGNOSTIC_TEST|DNA Exome sequencing|The DNA of dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease will take to do the DNA Exome sequencing.
41138531|NCT03938207|DIAGNOSTIC_TEST|Physical examination indicators, blood, urine and biochemical function test|To investigate the difference of Physical examination indicators, blood, urine and biochemical function test among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
41296506|NCT00787332|DRUG|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
41296507|NCT01544114|DRUG|VIMOVO 250/20|250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
41296508|NCT01544114|DRUG|VIMOVO 375/20|375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
41296509|NCT01544114|DRUG|VIMOVO 500/20|500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
41296510|NCT03558321|PROCEDURE|Hysteroscopic guided fractional curretage|Under general anaesthesia , evaluation of the endometrial cavity was done followed by biopsy of the whole endometrial tissue
40969103|NCT06066944|OTHER|Self-Thai Foot Massage|It is a specific technique and pressure to the feet and lower legs to promote relaxation, improve circulation, and enhance overall well-being. It is a traditional therapeutic practice originating from Thailand and is often performed by trained practitioners. Self-Thai foot massage is often based on traditional Thai massage techniques but adapted for self-application.
40969104|NCT00673465|DRUG|SCH 497079|SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
40969105|NCT00673465|DRUG|Placebo|Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
40969106|NCT00673465|DRUG|Metformin|Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)
40969107|NCT06163729|DRUG|Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy|Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Oxaliplatin, 100mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks
41296511|NCT03558321|PROCEDURE|total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection|Through abdominal incision , removal of the whole uterus , both tubes and ovaries and in some cases pelvic lymph nodes removal was done
41296512|NCT00299533|DRUG|Fish oil (Super Omega-3, 4 caps/d) vs. placebo|
41296513|NCT04444700|DRUG|Therapeutic anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
41296514|NCT02475707|BIOLOGICAL|MultiTAA-specific T cells|"The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart."
41296515|NCT00440128|DRUG|Docetaxel|Docetaxel
40969108|NCT01931124|BEHAVIORAL|High Intensity Training|
40969109|NCT01931124|BEHAVIORAL|Moderate Intensity Training|
40969110|NCT02792725|DRUG|Abemaciclib|Administered orally
40969111|NCT04013334|DRUG|MTG201|MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
41296516|NCT00440128|DRUG|Casopitant/Docetaxel|Casopitant/Docetaxel
41296517|NCT04196036|PROCEDURE|Day of vitrification|Supernumerary embryos after fresh transfer on Day 3 after oocyte aspiration are either vitrified on Day 3 or are kept in culture until Day 5 and vitrified on Day 5
41296518|NCT00733512|DEVICE|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
40969112|NCT04013334|DRUG|Nivolumab Injection [Opdivo]|Nivolumab 480 mg by IV infusion every 4 weeks
40969113|NCT02619552|DRUG|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
40969114|NCT02619552|DRUG|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
41138532|NCT03938207|DIAGNOSTIC_TEST|Demographics, personal health behavior, living environment, dietary status, family history|To investigate the difference among the demographics, personal health behavior, living environment, dietary status, family history of among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
41296519|NCT00963521|BIOLOGICAL|therapeutic autologous dendritic cells|
41296520|NCT04550546|DRUG|Nystatin|600,000 U/mL of nystatin in a rinse suspension
40768745|NCT06631729|BEHAVIORAL|ED-JITAI|"participants will be prompted to complete focused, guided body scan tasks that will be sent to them via the MindLogger app. These guided tasks will be sent to them in the form of 1 of 3 brief (3-5 minute) videos via the MindLogger app. The body scans will be designed to promote participants' connection with, vs.~distancing/distraction from, feared ED sensations (e.g., hunger, satiety, bloating).~Participants will receive prompts to complete the body scans at times when they report via EMA that they are experiencing worse interoception than usual. Worse interoception than usual will be defined as participants' EMA-reported interoception scores during the intervention period that fall 1 SD or more above their baseline EMA-reported interoception levels."
40969115|NCT02619552|DRUG|Steroids|All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
40969116|NCT03689478|OTHER|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
40969117|NCT04248452|DRUG|Capecitabine|Given PO
40969118|NCT04248452|DRUG|Fluorouracil|Given IV
40969119|NCT04248452|DRUG|Leucovorin|Given IV
40969120|NCT04248452|DRUG|Leucovorin Calcium|Given IV
40969121|NCT04248452|DRUG|Oxaliplatin|Given IV
40969122|NCT04248452|RADIATION|Radiation Therapy|Undergo radiation therapy
41138533|NCT03938207|DIAGNOSTIC_TEST|HLA typing|Using HLA typing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
41296521|NCT02222987|DRUG|Terbogrel|
41296522|NCT02222987|DRUG|Clopidogrel|
40969123|NCT00877253|DRUG|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
40969124|NCT00877253|DRUG|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
40969125|NCT00877253|DRUG|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
40969126|NCT03890172|OTHER|20-100 ml venous blood will be drawn the from patient into sterilized centrifuge tube ,following centrifuge to separate PRP and at the bed side and tricked onto the ulcer twice weekly|topical application of platelets rich plasma after Centrifugation at diabetic foot ulcer to study group ,history taking . Ankle brachial index (ABI) measuring and laboratory testes including hemoglobin A1c ( HgA1)c,cbc and prothrombin time( pt) and prothrombin concentration ( pc)
40969127|NCT03890172|OTHER|standard treatment|Subjects in the control group will receive Standard Wound Care treatment for chronic ulcers according to accepted medical practices.
40969128|NCT04489680|OTHER|Educational|Teaching session
40768746|NCT05247398|OTHER|Dynamic Stability Exercise Program|The thumb CMC DS intervention involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults.
40969129|NCT02172924|BIOLOGICAL|Early Decidual stromal cell therapy|Intervention given within 7 days after corticosteroids.
40969130|NCT02172924|BIOLOGICAL|Late Decidual stromal cell therapy|Intervention given after 7 days after corticosteroids.
40969131|NCT05385393|PROCEDURE|Arthroscopic posterior capsulotomy of the knee|"The arthroscopic posterior capsulotomy of the knee is performed according to the predefined surgical technique, which was described in detail in the following publication:~Malinowski K, Góralczyk A, Hermanowicz K, LaPrade RF, Więcek R, Domżalski ME. Arthroscopic Complete Posterior Capsulotomy for Knee Flexion Contracture. Arthrosc Tech. 2018 Oct 15;7(11):e1135-e1139. doi: 10.1016/j.eats.2018.07.008. PMID: 30533360; PMCID: PMC6262078."
40969132|NCT02495285|DRUG|Gelofusine 4%|
40969133|NCT02495285|DRUG|Gelaspan 4%|
40969134|NCT04418453|OTHER|Integration of telemedicine for MOUD in primary care|Patients with opioid use disorder in rural primary care settings may be referred to receive telemedicine for medication treatment for opioid use disorder
40969135|NCT06504849|BEHAVIORAL|Receiving LSM messages.|"* LSM messages via instant messaging applications~* Chat-type support messages via instant messaging applications"
40969136|NCT06504849|BEHAVIORAL|Receiving brief pre-HTN messages.|"* A flyer with brief pre-HTN information which is distributed during the recruitment phase~* Brief pre-HTN messages via instant messaging applications"
40969137|NCT01365910|DRUG|linifanib|Given PO
41296523|NCT00123526|BEHAVIORAL|Diet|Participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. Participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.
40768747|NCT03898011|DRUG|Lamotrigine|Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus
40768748|NCT03898011|DRUG|Lamictal|Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia
40969138|NCT06410612|DRUG|regional anesthesia and PAI|this is the block portion of the study
41296524|NCT00123526|BEHAVIORAL|Physical Activity|The intervention will promote active living, in which physical activity is incorporated into each participants' daily routine.
40768749|NCT01234376|DEVICE|Confocal laser endomicroscopy|Confocal laser endomicroscopy
40768750|NCT06560892|DRUG|Bupivacaine injection|patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline.
40768751|NCT06560892|DRUG|Dexmedetomidine injection|Patients were given intraperitoneal bupivacaine 50 ml 0.25% + dexmedetomidine 1 μg/kg with normal saline 5 ml.
40768752|NCT06609304|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel at 2.0×10\^6/Kg
40768753|NCT00581919|DRUG|Bort, Dex, and Dox with ALCAR|Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
40768754|NCT04323046|BIOLOGICAL|Nivolumab|Given IV
40969139|NCT06410612|DRUG|PAI|this is the no block portion of the study
40969140|NCT04677374|OTHER|Standard of care|Standard of care referral approach which is a brief health talk conducted once every morning by a VMMC mobilizer.
41296525|NCT00014573|BIOLOGICAL|aldesleukin|
41296526|NCT00014573|BIOLOGICAL|autologous tumor cell vaccine|
41296527|NCT00014573|BIOLOGICAL|filgrastim|
41296528|NCT00014573|BIOLOGICAL|sargramostim|
41296529|NCT00014573|BIOLOGICAL|therapeutic autologous lymphocytes|
41296530|NCT00014573|DRUG|carmustine|
41296531|NCT00014573|DRUG|cisplatin|
41296532|NCT00014573|DRUG|cyclophosphamide|
41296533|NCT00014573|DRUG|paclitaxel|
41138534|NCT03938207|DIAGNOSTIC_TEST|Full-length 16S Amplicon Sequencing|Using Full-length 16S Amplicon Sequencing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
41138535|NCT03938207|DIAGNOSTIC_TEST|Epigenomic|Using Epigenomic from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
41138536|NCT03938207|DIAGNOSTIC_TEST|Metabolomics|Using Metabolomics from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
41138537|NCT03938207|DIAGNOSTIC_TEST|Environmental Toxic|Using Environmental Toxic from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
41138538|NCT03938207|DIAGNOSTIC_TEST|Medical Image|Using Medical Image from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
41138539|NCT00359203|DEVICE|Dual chamber pacemeker|
41138540|NCT04994093|OTHER|Collection of blood (PBMC), biopsy (FFPE) and stool samples.|Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).
41138541|NCT05145348|BIOLOGICAL|Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)|The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, \<2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.
41138542|NCT00033748|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
41138543|NCT00033748|BIOLOGICAL|monoclonal antibody 3H1 Alu Gel|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
41138544|NCT01939288|DEVICE|Neuromuscular stimulation, followed by intermittent pneumatic compression|
41296534|NCT00014573|PROCEDURE|autologous bone marrow transplantation|
40768755|NCT04323046|OTHER|Quality-of-Life Assessment|Ancillary studies, given in person or online
40768756|NCT04323046|OTHER|Questionnaire Administration|Ancillary studies, given in person or online
40969141|NCT04677374|BEHAVIORAL|Intensified Health Education|More detailed health talk conducted during each group health talk session by the VMMC mobilizer and champions describing VMMC, its benefits and how to access the service and testimonies from men who have successfully undergone VMMC
40969142|NCT04677374|BEHAVIORAL|SMS/telephonic Tracing|SMS tracing to remind participants of VMMC appointments
40969143|NCT04677374|BEHAVIORAL|Transportation Reimbursement|Transportation reimbursement to offset the cost of transportation for VMMC appointments
40969144|NCT00975650|DRUG|Nasobol®|Intra-nasal Testosterone (2 syringes), b.i.d.
40768757|NCT06443632|OTHER|Sleep Adjustment|(1) Establishing a sleep schedule with early bedtime and wake-up times; (2) Establishing a consistent bedtime routine based on the child's preferences, such as wearing a sleep sack, providing soothing touch before sleep, offering a pacifier, using white noise, or playing sleep-inducing music; (3) Setting a fixed afternoon radiotherapy time each day and familiarizing the child with the radiotherapy environment beforehand; (4) Engaging the child in stimulating activities like watching videos, playing with toys, snacking, or outdoor activities to keep them awake from morning until 2 PM before radiotherapy; (5) Ensuring the child reaches deep sleep; (6) Completing the radiotherapy plan.
40969145|NCT00975650|DRUG|Androderm® (Positive Control)|QD administration
40969146|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
40969147|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
40969148|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
40768758|NCT05374603|DRUG|Savolitinib|Savolitinib combine with Durvalumab
40969149|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
40969150|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
40969151|NCT00631995|DIETARY_SUPPLEMENT|Meningococcal polysaccharide group C conjugated|0.5 mL, Intramuscular
40969152|NCT03078660|BEHAVIORAL|Smartphone Application|The smartphone Application generates a shopping list for participants, based on a low caloric diet (energy requirements minus 500 kcals), taking into consideration the Dietary Guidelines for Americans' recommendations and also considering the available budget for each shopping event and the weekly discounts from major supermarkets.
41296535|NCT00014573|PROCEDURE|conventional surgery|
41296536|NCT00014573|PROCEDURE|peripheral blood stem cell transplantation|
40969153|NCT03078660|BEHAVIORAL|Traditional Nutritional Counseling|Participants will have a face-to-face counseling session with a registered dietitian, who will provide recommendations for a low caloric diet (energy requirements minus 500 kcals) using the food group sheets from the Dietary Guidelines for Americans.
41138545|NCT01939288|DEVICE|Intermittent pneumatic compression, followed by neuromuscular stimulation|
41138546|NCT01542502|DRUG|Anakinra|Anakinra 100 mg daily subcutaneous injection
41296537|NCT02508727|OTHER|MRI|
41138547|NCT01542502|DRUG|Placebo|Placebo daily subcutaneous injection
41138548|NCT00659373|DRUG|Tamoxifen|
41296538|NCT02508727|OTHER|3D cardiac ultrasound|
41296539|NCT03260335|BEHAVIORAL|Anxiety management strategy|Anxiety management strategy as per standard care plan
41296540|NCT00916604|DRUG|AZD1656|Three increasing dose-steps with oral suspension, 8 days treatment
41296541|NCT00916604|DRUG|Placebo|Placebo oral suspension, 8 days treatment
41296542|NCT02406781|DRUG|Combination of MK3475 with Metronomic CP|"Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
41138549|NCT00659373|DRUG|triptorelin|
41296543|NCT02406781|DRUG|Combination of MK3475 with Metronomic CP and G100|"Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
41296544|NCT02793908|DRUG|Pleyris|Luteal phase will be supplemented starting by the ovulation day for 14 days
41296545|NCT02793908|DRUG|Crinone8|Luteal phase will be supplemented starting by the ovulation day for 14 days
41296546|NCT05419154|PROCEDURE|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
40969154|NCT03088982|OTHER|Questionnaire|"FPs who had agreed to participate worked according to the following plan: first, the multimorbid patient was asked to give his/her consent to participate in the study once the terms had been explained to him/her. After that, FPs completed a questionnaire about their patient.~The purpose of this questionnaire was to explore potential decompensation risk factors within the themes and subthemes of multimorbidity."
40969155|NCT04079101|DRUG|BIIB104|Administered as specified in the treatment arm.
41296547|NCT00985881|DEVICE|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
41296548|NCT00985881|DEVICE|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
40969156|NCT04079101|DRUG|Placebo|Administered as specified in the treatment arm.
40969157|NCT03594721|OTHER|Marvel AM|Study staff will perform each application of approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back at each of ten sequential visits.
40969158|NCT04774328|DRUG|CA-008 (vocacapsaicin)|Single administration of CA-008 (vocacapsaicin) versus placebo
41296549|NCT00802165|DEVICE|Electroacupuncture|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
41296550|NCT00802165|DEVICE|Sham electroacupuncture|Sham electroacupuncture treatment gives comparison to the experimental group
40768759|NCT05374603|DRUG|Durvalumab|savolitinib plus durvalumab
40969159|NCT04774328|DRUG|Placebo|Single administration of CA-008 (vocacapsaicin) versus placebo
40969160|NCT00712127|OTHER|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
40969161|NCT00712127|OTHER|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
40969162|NCT05221528|DIAGNOSTIC_TEST|Measurement of lipid profiles|Measured: total cholesterol, high-density lipoprotein cholesterol, and triglyceride Calculated: low-density lipoprotein
40969163|NCT05607277|PROCEDURE|Endovascular Repair of abdominal aortic aneurysms|Femoral artery access
40969164|NCT03346785|BEHAVIORAL|Food Photography|Participants will engage in food photography on their smart phones while eating
41296551|NCT01734993|DRUG|Tocilizumab|Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
40768760|NCT05788991|DRUG|Dequalinium Chloride|Fluomizin vaginal tablets (10 mg dequalinium chloride) used once a day for 6 days
40768761|NCT05788991|DRUG|Metronidazole Oral|Metronidazole oral tablets (500 mg) taken twice a day for 7 days
40768762|NCT00420537|DRUG|cyclosporine|cyclosporine trough levels between 100 and 150
40969165|NCT03346785|BEHAVIORAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
40969166|NCT03346785|BEHAVIORAL|No Phone Use|Participants will not use their smart phones while eating
41138550|NCT00659373|DRUG|Exemestane|
41138551|NCT01425398|DRUG|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
41138552|NCT01425398|DRUG|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
40969167|NCT05633823|OTHER|Mobile Application Game Training|"Mobile application game training can be used interactively with smartphones and tablets.~* A user account will be created after the application is downloaded to the mobile phone/tablet.~* After logging into the application, the map of the game will be displayed.~* The game will start with the first level of the game consisting of 5 levels.~* At each level, first of all, educational videos prepared in the form of short (1-2 minutes) animations will be watched. The number of videos varies between 1 and 3.~* After watching the videos, interactive games will be played.~* Children are required to complete each stage in the game, and each stage is planned to take approximately 7-10 minutes.~* After passing the first level, children will be able to move on to the next level of games and will not be able to move on to the next level until the previous level is finished."
40969168|NCT02581514|OTHER|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
40969169|NCT00002581|DRUG|cyclophosphamide|
40969170|NCT00002581|DRUG|fluorouracil|
41296552|NCT01516450|DRUG|GSK1550188 IV|Single IV dose of belimumab 200 mg
41296553|NCT01516450|DRUG|GSK1550188 SC|Single SC dose of belimumab 200mg
40969171|NCT00002581|DRUG|methotrexate|
41296554|NCT03949582|OTHER|Test food containing different types of dietary protein|"The test foods will be (in six study visits):~Soy mince/soup Chicken mince/soup Quorn mince/soup Soy mince/soup with guar gum Chicken mince/soup with guar gum Quorn mince/soup with guar gum"
41296555|NCT06097195|DEVICE|BioEP|When a consenting participant has their first electroencephalogram (EEG), they will be assigned with a unique participant study identifier before being uploaded. The centre will convert the EEG to European Data Format (EDF) format (or upload the total file) and upload this to the Neuronostics platform. The EEG will be stored on the Neuronostics database management system, within which the computational and mathematical analysis will be carried out. This study involves data analysis and mathematical modelling of the EEG recordings of each patient individually to generate a computational analysis score (BioEP).
41296556|NCT00204633|DRUG|Darbepoetin alfa|
41296557|NCT05716607|DRUG|OD dual-release Hydrocortisone|Treatment with once-daily dual-release hydrocortisone
41296558|NCT05716607|DRUG|TID Hydrocortisone|Treatment with thrice-daily conventional immediate-release hydrocortisone
41296559|NCT03911544|DEVICE|BIS monitor|Participants allocated to the intervention group will receive TIVA anesthesia adjusted by the BIS monitoring in addition to clinical signs of poor anesthesia.
41296560|NCT01903239|PROCEDURE|Low-Risk BCC Excisional Margins|After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
41296561|NCT01818622|DEVICE|Blue-blocking goggles/screens|Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
41296562|NCT01818622|DEVICE|Clear-lensed goggles|Clear lensed safety eyewear. Patients may choose model for best comfort.
41296563|NCT05598996|BEHAVIORAL|COT-Based Intervention|The COT-based approach uses a controller that runs case-by-case dynamical systems simulations modeling based on answers to daily questions rooted in social cognitive theory to produce ambitious but achievable daily adaptive step goal recommendations. The process for the COT-based approach is as follows: Phase 1) 2-week measurement only; Phase 2) open-loop system identification experiment (meant to create individualized dynamical models for each participant); Phase 3) closed-loop experiment to optimize for PA initiation, and Phase 4) closed-loop experiment to optimize for PA maintenance.
40768763|NCT00420537|DRUG|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
40969172|NCT00002581|DRUG|tamoxifen citrate|
40969173|NCT00002581|PROCEDURE|conventional surgery|
40969174|NCT00002581|RADIATION|radiation therapy|
40969175|NCT05011565|OTHER|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function
40969176|NCT02906059|DRUG|AZD1775|
40969177|NCT02906059|DRUG|Irinotecan|
40969178|NCT01948947|DEVICE|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
41296564|NCT06212895|OTHER|Survey|"A survey is handled out at the patient registration. Patients can fill it out during waiting for their appointment. The physician, who treats the patients is not aware aout the filling status or content. The Survy will not influence the treatment.~The Survey consists of 3 parts: patients attidude and expectations, and questionnaire about their usual physical activity and the validated Expectation Treatment Score."
41296565|NCT04412603|OTHER|Conventional Mirror Therapy|The Conventional Mirror Therapy was carried out with a mirror box and the Mirror Therapy Virtual Reality was carried out with virtual reality glasses and mobile application: Mirror Therapy VR.
41296566|NCT01052597|DRUG|curcumin|Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
41296567|NCT06328075|OTHER|non interventional study|non interventional study
41296568|NCT04475185|DEVICE|MakAir|MakAir artificial ventilator
41457922|NCT04814628|PROCEDURE|scenario 3: one anaesthetist in charge, THRIVE used for pre-oxygenation|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. THRIVE for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
41296569|NCT00161304|DRUG|Testosterone Enanthate|Testosterone Enanthate
41296570|NCT00161304|OTHER|Placebo|placebo
41296571|NCT03404414|DRUG|18F-FDG|"Single-dose 18F-FDG were injected into the patients before the PET/MR or PET/CT scans.~patients before the PET/CT scans"
41296572|NCT03135028|DRUG|Entospletinib|400 mg (2 × 200 mg tablets) orally twice daily
41296573|NCT03135028|DRUG|Daunorubicin|60 mg/m\^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle
41296574|NCT03135028|DRUG|Cytarabine|"100 mg/m\^2 intravenous administration twice daily on Days 1 to 7 of each 28-day induction cycle~Hi-DAC: 3 g/m\^2 IV administration twice daily on days 1, 3, and 5 (≤ 60 years of age) or 1 g/m\^2 IV administration once daily on Days 1 to 5 (\> 60 years of age) of each 28-day post-remission cycle"
41296575|NCT03785197|OTHER|Prolonged modified fasting|The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths
41296576|NCT06312618|DRUG|Propofol|"After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive propofol~1mg/kg over 10 minutes (group 1) ."
40969179|NCT01948947|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
41296577|NCT06312618|DRUG|Dexmedetomidine|After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive dexmedetomidine 0.2 mcg/kg over 10 minutes (group 2).
41457923|NCT04814628|PROCEDURE|scenario 4: one anaesthetist and one nurse anaesthetist in charge, the face mask is held by the anaesthetist or the nurse anaesthetist|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist or nurse anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
41457924|NCT01937767|DRUG|Remimazolam|
41138553|NCT05953025|BEHAVIORAL|Questionnaire|No intervention on care- questionnaire to see effect of standard care treatment on symptoms
41457925|NCT01937767|DRUG|Propofol|
41457926|NCT01937767|DRUG|Sevoflurane|
41457927|NCT01937767|DRUG|Remifentanil|
41457928|NCT01937767|DRUG|Fentanyl|
41457929|NCT01937767|DRUG|Rocuronium|
41457930|NCT04721145|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
41457931|NCT04173923|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
40768764|NCT00420537|DRUG|Mycophenolate mofetil|mycophenolate with low doses
41457932|NCT04173923|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
40768765|NCT00420537|DRUG|Everolimus|
40768766|NCT06607770|DRUG|Karelizumab+Apatinib|Karelizumab 200mg, q3w, and Apatinib 250mg, qd. every 3 weeks as a treatment cycle.
40969180|NCT04197934|PROCEDURE|Biospecimen Collection - blood samples|Undergo collection of blood samples
40969181|NCT04197934|PROCEDURE|Biospecimen Collection - CSF samples|Undergo collection of CSF samples
40969182|NCT04197934|PROCEDURE|Computed Tomography|Undergo CT
40969183|NCT04197934|DRUG|EGFR/EGFRvIII Inhibitor WSD0922-FU|Given PO
40969184|NCT04197934|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40969185|NCT04197934|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
40969186|NCT01581814|DRUG|Metformin|500 mg of Metformin per 3/die
40969187|NCT01581814|DRUG|Yasmin;|1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
40969188|NCT01581814|DRUG|Metformin plus Yasmin|0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
41296578|NCT05430334|COMBINATION_PRODUCT|e-liquid 1|30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated
41296579|NCT05430334|COMBINATION_PRODUCT|e-liquid 2|30/70 PG/VG ratio with nicotine concentration 10mg/ml protonated
41296580|NCT05430334|COMBINATION_PRODUCT|e-liquid 3|30/70 PG/VG ratio with nicotine concentration 4mg/ml free base
40969189|NCT01654536|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
40969190|NCT01654536|DRUG|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
41296581|NCT05430334|COMBINATION_PRODUCT|e-liquid 4|30/70 PG/VG ratio with nicotine concentration 10mg/ml freebase
41296582|NCT05430334|COMBINATION_PRODUCT|e-liquid 5|30/70 PG/VG ratio with nicotine concentration 0mg/ml (placebo)
41296583|NCT03847337|OTHER|Telehealth-Screening Tool for Autism in Toddlers (STAT)|Structured autism screening tool
41296584|NCT03847337|OTHER|Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)|Semi-structured autism screening tool
41296585|NCT04961801|DRUG|Acalabrutinib, tacrolimus, methotrexate|For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
40969191|NCT04597788|OTHER|Protein supplemented very low calorie diet program|"Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement.~Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss."
40969192|NCT04597788|OTHER|Conventional low calorie diet program|Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.
40969193|NCT02479178|DRUG|BIND-014 (docetaxel nanoparticles for injectable suspension)|docetaxel nanoparticles for injectable suspension
40969194|NCT04932278|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment (OMT) is hands-on care provided by an osteopathic physician (D.O.). During osteopathic manipulative treatment, an osteopathic physician may move participants' muscles and joints using osteopathic techniques including stretching, gentle pressure and resistance, as well as thrust techniques that apply a quick, therapeutic force of brief duration that travels a short distance.
40969195|NCT04932278|PROCEDURE|Usual care|Routine concussion management with healthcare professionals.
40969196|NCT01270776|DRUG|2% aqueous chlorhexidine|A single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
40969197|NCT01270776|DRUG|2% Chlorhexidine 70% isopropyl alcohol|single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
40969198|NCT03385005|DEVICE|Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.|The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.
40969199|NCT00553644|DRUG|Bortezomib|Given IV
40969200|NCT00553644|OTHER|Laboratory Biomarker Analysis|Correlative studies
40969201|NCT00553644|DRUG|Lenalidomide|Given PO
40969202|NCT01504035|DEVICE|Orthostat-L|Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
40969203|NCT01504035|DEVICE|Orthostat|Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
40969204|NCT05410561|BEHAVIORAL|Enhanced Usual Care (EUC)|EUC will comprise one session of brief psychoeducation and referral information to alcohol use disorder (AUD) treatment.
41457933|NCT04173923|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
40969205|NCT05410561|BEHAVIORAL|TeleTx intervention|TeleTx will consist of an initial session and then 8 \~counseling sessions.
40969206|NCT03905603|DRUG|ACTH|ACTH (Cosyntropin) 250 mcg will be given once during the study.
40969207|NCT03905603|DRUG|rhCG|rhCG (Ovidrel) 250 mcg will be given once during the study.
41138554|NCT01941576|DRUG|recombinant human brain natriuretic peptide (rhBNP)|Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
41138555|NCT01941576|DRUG|Placebo (0.9% sodium chloride)|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
41138556|NCT02798653|DRUG|Choriomon® injection|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
41457934|NCT04173923|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41296586|NCT03018782|OTHER|Brief Pain Inventory Short Form|Brief Pain Inventory Short Form
41457935|NCT04173923|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
40969208|NCT02845505|OTHER|Intravascular Ultrasound, coronary computed tomography angiography|
40969209|NCT02611219|OTHER|General Health Module-Baseline Adolescent-Self Report (13-18 years)|"* 38 question questionnaire~* Answers range from 1=all of the time to 5=none of the time"
40969210|NCT02611219|OTHER|General Health Module-Follow Up Adolescent-Self Report (13-18 years)|"* 38 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
40969211|NCT02611219|OTHER|General Health Module-Baseline Parent Report-Adolescent (13-18 years)|"* 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
40969212|NCT02611219|OTHER|General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|"* 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
40969213|NCT02611219|OTHER|General Health Module-Baseline Parent Report-School Age (5-12 years)|"* 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
40969214|NCT02611219|OTHER|General Health Module-Follow Up Parent Report-School Age (5-12 years)|"* 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
40969215|NCT02611219|OTHER|Demographic Data Form|-16 questions about demographics such as household income, race, and gender
40969216|NCT02611219|OTHER|SCT Daily Activity Log|"* Uses Fitbit Flex~* Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed"
40969217|NCT02611219|OTHER|The Functional Independence Measure for Children|"* 18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards~* Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category."
40969218|NCT02611219|OTHER|Manual Muscle Testing|"-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade."
40969219|NCT02611219|OTHER|3-Minute Step Test|"* Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after~* Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance"
40969220|NCT02611219|OTHER|HSCT Module-Follow Up Adolescent-Self Report (13-18 years)|"* 7 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
40969221|NCT02611219|OTHER|HSCT Module-Follow Child-Self Report (5-12 years)|"* 10 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
40969222|NCT02611219|OTHER|HSCT Module-Follow Up Parent Report-adolescent (13-18 years)|"* 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time"
40969223|NCT02611219|OTHER|HSCT Module-Follow Up Parent Report-School Age (5-12 years)|"* 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time"
40969224|NCT05415839|DEVICE|Laser|Laser
40969225|NCT04143321|DRUG|Empagliflozin 25 MG|after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
40969226|NCT05328193|BEHAVIORAL|Healthier Families, COVID Edition|Families randomized to this arm with receive12-weekly health coaching calls virtually with their family with topics such as nutrition, physical activity, sleep, and media use.
41457936|NCT04173923|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
40969227|NCT05328193|BEHAVIORAL|Teaching Kitchen Outreach|Families receiving this intervention will recipe 11-weekly video recipes and groceries delivered to their door.
40969228|NCT05772832|DRUG|Dexmedetomidine|Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery
40969229|NCT05772832|DRUG|Remifentanyl|Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery
40969230|NCT05961085|PROCEDURE|Adductor Canal Catheter|Ultrasound guided Adductor Canal Catheter for total knee arthroplasty analgesia
40969231|NCT04932551|OTHER|Questionnaire|physicians will participate in the questionnaire via WeChat. The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal.
41457937|NCT04173923|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
40969232|NCT04579757|DRUG|Surufatinib and Tislelizumab _ Part 1|Part 1 (all cohorts): oral surufatinib at a dose based on cohort level and intravenous tislelizumab at a 200-mg dose
40969233|NCT04579757|DRUG|Surufatinib and Tislelizumab _ Part 2|Part 2 (all cohorts): oral surufatinib at the RP2D dose selected in Part 1 and intravenous tislelizumab at a 200-mg dose
41138557|NCT02798653|DRUG|Choriomon® injection+Endometrin ®|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
41138558|NCT02798653|DRUG|Endometrin ® vaginal tablets|Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
41138559|NCT05647759|BEHAVIORAL|HEART Camp Connect|Once eligible and enrolled, participants will aim to complete 150 minutes of moderate-intensity exercise a week with the help of a virtual exercise coach
41138560|NCT01963598|DRUG|REGN1033 (SAR391786)|
41457938|NCT01506349|DIETARY_SUPPLEMENT|gluten|4 grams of gluten.
41457939|NCT01506349|DIETARY_SUPPLEMENT|Placebo|
41457940|NCT01529554|DRUG|Everolimus|(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
41296587|NCT01214616|DRUG|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
41296588|NCT01214616|DRUG|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
41296589|NCT01214616|DRUG|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
40969234|NCT01523990|DRUG|TG-2349|Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
41138561|NCT01963598|DRUG|placebo|
41138562|NCT04288388|BEHAVIORAL|massage group|In recent years, in the literature, it is known that many non-pharmacological techniques are applied to reduce the pain of birth in addition to local anesthesia. One of these nonpharmacological methods is the application of pressure to LI4 point on hand with ice.
41457941|NCT01529554|DRUG|Placebo|matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
41138563|NCT00329914|DRUG|Progesterone|Vaginal pessaries, 200 mg/day
41138564|NCT00329914|DRUG|Placebo|Placebo pessaries containing peanut oil
41138565|NCT02232997|OTHER|Standard Hydration|Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \< 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
41138566|NCT02232997|OTHER|Simplified Hydration|Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \<35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
41138567|NCT01083706|DRUG|azacitidine|Given SC or IV
41296590|NCT05082571|DRUG|vadadustat|Vadadustat tablet orally once a day for 52 weeks
41296591|NCT06523530|DRUG|Goserelin Acetate 3.6 mg inj, implant|3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)
41296592|NCT04954469|BIOLOGICAL|CoVAC-1|Peptide vaccination should be started as soon as possible after the screening visit.
40969235|NCT01523990|DRUG|placebo|Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
40969236|NCT04819568|DRUG|Terlipressin|Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid
41457942|NCT02860325|DEVICE|NIV-NAVA|Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
41457943|NCT02860325|DEVICE|Conventional|Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
41457944|NCT04753541|OTHER|no intervention|this is not an interventional study
41457945|NCT00141258|DRUG|pregabalin|
40969237|NCT04819568|OTHER|Standard of Care|Standard of Care
40969238|NCT04959344|BIOLOGICAL|Kleb4V target dose|Two doses of the non-adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
40969239|NCT04959344|BIOLOGICAL|Kleb4V target dose + AS03|Two doses of the adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
40969240|NCT04959344|BIOLOGICAL|Kleb4V low dose|Two doses of the non-adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
40969241|NCT04959344|BIOLOGICAL|Kleb4V low dose + AS03|Two doses of the adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
40969242|NCT04959344|BIOLOGICAL|Placebo|Two doses of the Placebo will be administered intramuscularly 2 months apart
40969243|NCT06183424|PROCEDURE|Transcranial Direct Stimulation|2 mA, 20 min, 5 days
40969244|NCT00094744|DEVICE|Eye patch|adhesive eye patch used to cover the sound eye
40969245|NCT03473977|BIOLOGICAL|Benralizumab|Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.
40969246|NCT03473977|BIOLOGICAL|Placebo|Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.
40969247|NCT04425694|DEVICE|e-EWS system|The e-EWS system is connected to a physiological monitor, which takes various physiological measurements. The system has an auto-charting module, which automatically captures patients' physiological measurements in an electronic chart (e-chart) and calculates their EWS. All the information in the auto-charting module is then wirelessly transferred to a central display in the ward's nurses station. The central display shows patients' status in terms of EWS and issues alerts when any EWS has exceeded a set threshold. The e-EWS system is not only capable of auto-charting but also provides an alert mechanism to help nurses detect early deterioration.
40969248|NCT02098759|DEVICE|epilepsy early diagnosis protocol|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
40969249|NCT04528381|PROCEDURE|Laparoscopy|Laparoscopic orchiopexy
40969250|NCT01856413|DRUG|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
40969251|NCT04749108|DRUG|Induction chemotherapy - modified FOLFIRINOX regimen|An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).
40969252|NCT04749108|OTHER|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
40969253|NCT04749108|RADIATION|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or Intensity-Modulated RadioTherapy (IMRT) (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of radiotherapy treatment (2 daily intake).
40969254|NCT04749108|PROCEDURE|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
40969255|NCT01996293|DRUG|lamotrigine|Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
40969256|NCT05230550|DRUG|Somapacitan|Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
40969257|NCT01603355|DRUG|Tocilizumab|"Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks"
40969258|NCT03950115|DEVICE|Intense Pulsed Light (IPL)|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
40969259|NCT05571540|BIOLOGICAL|U-CAR-T Cells (LstCAR019)|"LstCAR019 will be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one: 1×10\^6 cells/kg;Dose level two: 2×10\^6 cells/kg;Dose level three: 5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of LstCAR019 at the best dose verified in the first portion."
41138568|NCT01083706|OTHER|laboratory biomarker analysis|Correlative studies
41138569|NCT02486107|PROCEDURE|surgical procedure|
41138570|NCT02958553|DEVICE|emPOWER Ankle|The device is 510k cleared and is intended to replace a missing foot and ankle. The emPOWER Ankle is to be used exclusively for fittings of lower-extremity amputations as prescribed by a healthcare professional.
41138571|NCT02958553|DEVICE|Subject's own passive prosthesis|Devices will vary. Data gathered will form a baseline.
41138572|NCT05836844|DEVICE|The Anchorsure System®|Sacrospinous ligament fixation performed with the Anchorsure Device
41138573|NCT03603691|DIAGNOSTIC_TEST|Modified Manual Muscle Test|Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance
41457946|NCT04800926|DEVICE|Xavier wheelchair controller|Controlling a wheelchair using the Xavier surface EMG system
41457947|NCT03025776|BEHAVIORAL|Reaching|sitting reaching under various task conditions (size, speed, location)
41457948|NCT03025776|BEHAVIORAL|Kinematic collection while reaching|sitting reaching under various task conditions (size, speed, location), told how many \& which hand to use, kinematic data collected
40969260|NCT04239144|PROCEDURE|Bilateral sympathectomy|Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.
41457949|NCT04275349|DRUG|Xingnaojing injection within 24 hours of symptom onset|intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
40969261|NCT04239144|PROCEDURE|Catheter ablation|Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
40969262|NCT00107471|BIOLOGICAL|filgrastim|Given PO
40969263|NCT00107471|DRUG|topotecan hydrochloride|Given IV
40969264|NCT00107471|RADIATION|radiation therapy|
40969265|NCT00871260|DRUG|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
40969266|NCT03130257|DIAGNOSTIC_TEST|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure once within the subsequent three weeks.
41138574|NCT03603691|DIAGNOSTIC_TEST|BMRC manual muscle test|muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle
41138575|NCT03603691|DIAGNOSTIC_TEST|MicroFET2 handhold dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups
40969267|NCT03130257|DIAGNOSTIC_TEST|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to two measurements in the morning and two in the evening for at least 5 days over three weeks.
40969268|NCT03130257|DIAGNOSTIC_TEST|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
41138576|NCT03603691|DIAGNOSTIC_TEST|Modified Tardieu Scale|Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement
41138577|NCT03603691|DIAGNOSTIC_TEST|Fatigue Scale for Motor and Cognitive Functions|Measures cognitive and motor fatigue for people with MS
41138578|NCT03603691|DIAGNOSTIC_TEST|numeric rating scale Fatigue|visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)
41138579|NCT02500433|OTHER|Device: Kinect-Xbox 360TM|Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
41138580|NCT02500433|OTHER|Conventional therapy|
41138581|NCT00551421|BIOLOGICAL|pertuzumab|Given IV
41138582|NCT00551421|BIOLOGICAL|cetuximab|Given IV
41138583|NCT00551421|DRUG|irinotecan hydrochloride|Given IV
41457950|NCT03116776|PROCEDURE|Walnut Shell Glasses Moxibustion|Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
41457951|NCT03116776|DRUG|Sodium hyaluronate eye drops|One drop for each eye, four times per day for over 4 weeks.
40969269|NCT03130257|DIAGNOSTIC_TEST|24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)|Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.
40969270|NCT00670683|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40969271|NCT04766398|DRUG|KHK7791|oral administration
40969272|NCT04766398|DRUG|Placebo|oral administration
40969273|NCT02558140|BIOLOGICAL|RO6874813|RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
40969274|NCT02558140|BIOLOGICAL|RO6874813|RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
40969275|NCT01336764|BEHAVIORAL|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
40969276|NCT01336764|BEHAVIORAL|Control|Unguided listening to radio/music.
40969277|NCT03928600|COMBINATION_PRODUCT|Cervical Foley combined with Misoprostol|Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
40969278|NCT03928600|DRUG|Dinoprostone 10mg insert OR|Application for 24h of Dinoprostone 10mg insert
40969279|NCT03928600|DRUG|Misoprostol|Application of vaginal misoprostol 25ug 4/4h until 150ug
40969280|NCT02950532|OTHER|Retrospective radiological evaluation|Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
40969281|NCT05416502|PROCEDURE|Ultrasound|Enrolled patients underwent ultrasound scan of kidneys, ureters, and the bladder.
40969282|NCT04343547|DRUG|DWP16001|Tablets, Oral, once daily single dose
40969283|NCT04343547|DRUG|DWC202001+DWC202002|Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
41457952|NCT05036005|DRUG|Ontruzant|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
41138584|NCT00551421|OTHER|immunohistochemistry staining method|Correlative study
41138585|NCT00551421|OTHER|fluorescence in situ hybridization|Correlative study
41138586|NCT00551421|OTHER|gene expression analysis|Correlative study
40969284|NCT04343547|DRUG|DWP16001+DWC202001+DWC202002|Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
40969285|NCT06498154|RADIATION|Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy|Neoadjuvant radiotherapy: whole-breast irradiation ( 50 Gy in 25 fractions) plus a mandatory boost (14 Gy in seven fractions, which began on the day following completion of whole-breast irradiation) TCb (HP) \* : Triple negative patients will receive TCb regimens with or without immunotherapy and HER2 positive patients will receive TCb(HP) regimens.
40969286|NCT00038220|DRUG|Lopinavir/ritonavir|
40969287|NCT00038220|DRUG|Efavirenz|
40969288|NCT00038220|DRUG|Lamivudine|
40969289|NCT00038220|DRUG|Tenofovir DF|
40969290|NCT04240769|DEVICE|Total or Partial Knee Arthroplasty|Reconstruction of part or all of the native articulation at the knee joint via implant.
40969291|NCT04083053|PROCEDURE|Perianal Exam|Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
40969292|NCT04083053|PROCEDURE|high-resolution anoscopy (HRA) with biopsy|The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
40969293|NCT01306396|BEHAVIORAL|dietary intervention mainly focusing on fructose reduction|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
40969294|NCT00096070|RADIATION|radiation therapy|Undergo radiation therapy
40969295|NCT00096070|DRUG|oxaliplatin|Given IV
40969296|NCT00096070|DRUG|fluorouracil|Given IV
40969297|NCT00096070|DRUG|gemcitabine hydrochloride|Given IV
40969298|NCT01587820|DRUG|Intra-arterial cisplatin|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
40969299|NCT01587820|DRUG|Intravenous cisplatin|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
40768767|NCT05488522|BIOLOGICAL|SBRT + atezolizumab and bevacizumab|"Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT.~Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC. It is administered as a flat-dose 1200 mg intravenous infusion every three weeks.~Bevacizumab is an FDA-approved anti-VEGF monoclonal antibody that is used in the treatment of advanced HCC in combination with atezolizumab. It is administered as a weight-based dose of 15 mg/kg intravenous infusion every 3 weeks."
40969300|NCT02480439|DRUG|TAK-648 Tablet|Tak-648 tablet
40969301|NCT02480439|DRUG|TAK-648 Oral Solution|TAK-648 oral solution
40969302|NCT01129960|DRUG|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
40969303|NCT01129960|DRUG|Placebo|Tablets will be used.
40969304|NCT05324553|PROCEDURE|Tissue Collection|Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
40969305|NCT05324553|DIAGNOSTIC_TEST|Blood Collection|Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional
40969306|NCT05324553|DIAGNOSTIC_TEST|Buccal Swab|Buccal swab may be requested, if necessary, to generate germline data.
41457953|NCT05036005|DRUG|Chemotherapy|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator
40768768|NCT06402487|DIETARY_SUPPLEMENT|Propionic acid 1000 mg capsule|Patients will be assigned to propionic acid or placebo as add on MS treatment.
40969307|NCT02414984|BIOLOGICAL|Golimumab|This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
40969308|NCT02331914|PROCEDURE|Vena puncture for blood collection|GIST patients will be asked to provide 40ml blood that will be collected in four Na-EDTA 10ml blood collection tubes at every routine outpatient visit.
40969309|NCT02331914|PROCEDURE|Tumor biopsy|Tumor biopsy after disease progression
40969310|NCT06433869|DRUG|serplulimab|Additional intraperitoneal injection of bevacizumab or rmhTNF-NC is added to the PD-1 inhibitor.
40969311|NCT06433869|DRUG|Bevacizumab|Intraperitoneal injection of bevacizumab is added to PD-1 inhibitor or rmhTNF-NC.
40969312|NCT06433869|DRUG|rmhTNF-NC|Intraperitoneal injection of rmhTNF-NC is added to PD-1 inhibitor or bevacizumab.
40969313|NCT03261973|DEVICE|DV8|DV8 esophageal deviation tool
40969314|NCT02299700|OTHER|No Intervention|The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
40969315|NCT06451094|DEVICE|US therapy|3 MHz probe with a BTL brand device at a dose of 1.5 watts/cm2 for 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions.
40969316|NCT06451094|DEVICE|TECAR|Transfer Energy Capacitative and Resistive Therapy
40969317|NCT04604223|DRUG|Pioglitazone 45 mg|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
40969318|NCT02075710|OTHER|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
40969319|NCT02075710|OTHER|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
40969320|NCT02075710|OTHER|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
40969321|NCT02075710|OTHER|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
40969322|NCT02075710|OTHER|High sugar/ 3 meals a day|Weight-maintaining diet relatively high in sugar fed as 3 meals daily
40969323|NCT02075710|OTHER|High fat/ 3 meals a day|Weight-maintaining diet relatively high in fat fed as 3 meals daily
40969324|NCT05422196|PROCEDURE|Platelet-rich fibrin|Addition of platelet-rich fibrin into the cleft site.
40969325|NCT01993147|BEHAVIORAL|Dual task paradigm pilot|
41296593|NCT00720239|OTHER|Taliderm wound healing dressing|"Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase."
41296594|NCT02004340|DEVICE|ear vagus nerve stimulator|
41296595|NCT06238999|DEVICE|Restoration of non-carious cervical lesions|Non-carious cervical lesions will be treated with the experimental TM Flow or the well-established Tetric EvoFlow. The treatment workflow is very similar to other flowable composites.
41296596|NCT01761955|OTHER|High Dairy|Consuming 4 or more servings of dairy products per day for a period of 6 months
40969326|NCT01357733|OTHER|Early interim FDG PET/CT after 1 cycle of R-CHOP|FDG PET/CT imaging study obtained after 1 cycle of R-CHOP and before the second cycle of R-CHOP
40969327|NCT01308554|DRUG|Placebo: sterile normal saline|Bilateral TAP block using 20 ml of normal sterile saline per block.
41296597|NCT01848821|DEVICE|OASIS Ultra|Porcine derived intestinal submucosa
41296598|NCT01848821|DEVICE|Wound VAC Standard Therapy|Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
40969328|NCT01308554|DRUG|Marcaine|Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
41138587|NCT00551421|OTHER|mutation analysis|Correlative study
41138588|NCT00551421|OTHER|polymerase chain reaction|Correlative study
40969329|NCT02505867|DEVICE|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
40768769|NCT06402487|DIETARY_SUPPLEMENT|Placebo|Patients will be assigned to propionic acid or placebo as add on MS treatment.
40969330|NCT04857905|PROCEDURE|Microsurgical resection|Depending on the patient's choice, the microsurgical resection of the brain metastases will be performed.
40969331|NCT04857905|PROCEDURE|Gamma Knife radiosurgery|Depending on the patient's choice, the radiosurgical treatment of the brain metastases will be performed.
40969332|NCT00114036|BEHAVIORAL|Quality improvement strategies|
40969333|NCT01583491|PROCEDURE|autologous platlet rich fibrin|one dose immediate after surgery
40969334|NCT01583491|PROCEDURE|one side in control group|control group insert any things after surgery
41138589|NCT00551421|OTHER|laboratory biomarker analysis|Correlative study
41138590|NCT01763307|DRUG|RECONVAL CREAM|
41138591|NCT01763307|DRUG|PLACEBO|
40969335|NCT03631472|DEVICE|RheOx|RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
40969336|NCT04020965|BEHAVIORAL|Water Treatment|"Hardware: Chlorine dispensers provided for free at communal water sources, available to households in intervention arm who were and who were not enrolled in the WASH Benefits Kenya study.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the treatment of drinking water for all children living in the household. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits. After the completion of the WASH Benefits Kenya study, the NGO Evidence Action conducted educational campaigns to promote the use of dispensers."
41138592|NCT04263688|OTHER|Non-Intervention|Non-Intervention
41457954|NCT05036005|DRUG|Pertuzumab|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
41457955|NCT00310297|DRUG|Insulin Glulisine|
41138593|NCT02309892|DRUG|L-DOS47|A treatment cycle will be 21 days, with patients receiving L-DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
41138594|NCT01381198|PROCEDURE|Distal rectus femoris transfer|Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
41138595|NCT00443274|OTHER|NBIR - US National Breast Implant Registry|NBIR is intended to be a surveillance tool to track patient safety and real-world outcomes associated with breast implants used for aesthetic or reconstructive purposes..
40768770|NCT01280669|DRUG|Intravitreal injection 440mcg|Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
40768771|NCT01280669|DRUG|Intravitreal injection of sirolimus 880mcg|Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
41138596|NCT00443274|DEVICE|410 Arm|Anatomically shaped silicone gel-filled breast implants.
41138597|NCT00443274|DEVICE|BIFs - Breast Implant Follow-Up Study|Round silicone gel-filled breast implants and saline-filled breast implants
41296599|NCT06184919|OTHER|Process Mapping: Observations|Direct observations of the POSH clinic visit.
41296600|NCT06184919|OTHER|Process Mapping: Interviews|Semi-structured interviews of patients and providers involved in the POSH clinic.
41296601|NCT06184919|OTHER|Process Mapping: Focus Group|Focus group of providers and staff who conduct the POSH clinic.
41296602|NCT06184919|OTHER|Participatory Design|"Participatory design, also called co-design is a systems engineering approach where the researchers and participants work together in designing the workflow of an intervention. There will be two groups (design teams) of patients/caregivers and healthcare professionals per location, for a total of four groups."
41296603|NCT05025072|DRUG|Hydroxycarbamide dispersible tablets|Hydroxycarbamide dispersible tablets (20 x 50 mg)
41296604|NCT05025072|DRUG|Hydroxycarbamide film-coated tablet|Hydroxycarbamide film-coated tablet (1000 mg)
41296605|NCT02883465|PROCEDURE|Diaphragmatic ultrasound|"All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~* a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~* a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side"
41296606|NCT02033980|DEVICE|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
41296607|NCT03472482|DIAGNOSTIC_TEST|non-invasive retinal imaging|
41296608|NCT03290638|PROCEDURE|Guided Bone Regeneration (GBR)|Teeth Extraction With Bone Grafting and Membrane
41296609|NCT04676139|DRUG|Fluoxetine|Fluoxetine 10 mg capsules once daily for 12 months
41296610|NCT04676139|DRUG|Placebo|placebo for 12 months
41296611|NCT01452074|OTHER|Exercise Training|During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, \~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
41296612|NCT01452074|OTHER|Weight Loss with continued Exercise Training|After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
41296613|NCT02897193|DEVICE|ICE dental implant 4.2 mm|ICE dental implant 4.2 mm diameter
41296614|NCT02897193|DEVICE|NICE dental implant 3.2 mm|NICE dental implant 4.2 mm diameter
41296615|NCT02897193|DEVICE|Alpha Bio's Graft Bovine bone|Alpha Bio's Graft Bovine Bone
41296616|NCT02897193|DEVICE|Alpha Bio's Graft resorbable membrane|Alpha Bio's Graft resorbable collagen membrane
41296617|NCT02405039|DRUG|EBI-005|EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
41296618|NCT02405039|DRUG|Placebo|Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
41296619|NCT00450372|BIOLOGICAL|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
41296620|NCT00450372|OTHER|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
41296621|NCT04221451|DRUG|venglustat GZ402671|"Pharmaceutical form: tablet~Route of administration: oral"
41296622|NCT04221451|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
41296623|NCT01856946|DIETARY_SUPPLEMENT|4,000 IU vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
41296624|NCT04462848|BIOLOGICAL|anti-SARS-CoV-2 human convalescent plasma|Single transfusion. The total volume (mL) to be transfused will be based on participant weight (kg) and will be calculated as 5 mL/kg. The maximum volume to be transfused will be 500 mL.
41296625|NCT02691247|BIOLOGICAL|CLBS03 Low Dose|
41296626|NCT02691247|BIOLOGICAL|CLBS03 High Dose|
41296627|NCT02691247|BIOLOGICAL|Placebo|
41296628|NCT02688114|PROCEDURE|Baseline surveillance endoscopy|All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
41296629|NCT02688114|PROCEDURE|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
41296630|NCT02688114|PROCEDURE|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
41296631|NCT02688114|PROCEDURE|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
41296632|NCT02688114|PROCEDURE|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
41296633|NCT06403384|DEVICE|Vibration|Local vibration was applied
41296634|NCT05724667|OTHER|Flippin' Pain Seminar Series|A chronic pain education campaign
41296635|NCT02284334|OTHER|test meal|low- or high-glycemic index test meal, administered during mixed meal tolerance test
41296636|NCT05938088|DRUG|Arm I (mirogabalin group)|Take two capsules of Mirogabalin 5 mg within 30 minutes before going to the operating room. Patients take 5 mg of mirogabalin twice daily at 12-hour intervals until POD 7 days.
41296637|NCT05938088|DRUG|Arm II (placebo group)|It is performed in the same way as Arm l.
41296638|NCT02160977|PROCEDURE|total knee arthroplasty|
41296639|NCT01685294|BEHAVIORAL|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
41296640|NCT06554626|DRUG|Dexamethasone|Glucocorticoids
41296641|NCT06554626|DRUG|Blinatumomab|Bi-specific anti CD19/CD3 antibody
41296642|NCT06554626|DRUG|Venetoclax|BCL-2 inhibotor
40969337|NCT04020965|BEHAVIORAL|Sanitation|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each household enrolled in the WASH Benefits Kenya study. Upgrades included structural improvements, plastic slabs, and superstructure improvements. Households in intervention villages not enrolled in the original trial did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on handwashing with soap at critical times around food preparation, defecation, and contact with feces. Compounds in intervention villages that were not enrolled in the original trial did not receive such visits."
40969338|NCT04020965|BEHAVIORAL|Handwashing|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water, for each compound. Handwashing stations were stocked with soap for the duration of the WASH Benefits Kenya study. Compounds in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the use of latrines for defecation and the removal of human and animal feces from the compound. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
40969339|NCT04020965|DIETARY_SUPPLEMENT|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months, among children enrolled in the WASH Benefits Kenya study and for the duration of that study. Children in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any supplements.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver the following behavior change messages: (1) practice exclusive breastfeeding from birth to 6 months of age; (2) continue breast feeding with the introduction of LNS; (3) provide your child micronutrient-rich foods and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
40969340|NCT01752127|PROCEDURE|percutaneous coronary intervention using drug eluting stent|"1. Intracoronary stenting~1. The procedure could be conducted via brachial, radial or femoral approaches.~2. There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~3. When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~4. Direct stenting or bifurcation stenting is allowed.~5. Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator."
40969341|NCT03819101|DRUG|Acetylsalicylic acid|100mg
40969342|NCT03819101|DRUG|Atorvastatin|80 mg
40969343|NCT04720898|DEVICE|LUNA-EMG|The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot provides optimized range of motion's movements and a visual feedback on the patient's performance. In addition, it may enhance neuroplasticity due to the increased number of movements repetitions which could influence motor learning.
40969344|NCT04585386|OTHER|Visual analog scale|to measure the lumbar and radicular pain felt by the patient.
40969345|NCT04585386|OTHER|Mac Gill Pain Questionnaire|self-questionnaire that allows a qualitative assessment of chronic pain
40969346|NCT04585386|OTHER|Roland and Morris Disability Questionnaire|functional disability scale for assessing low back pain
40969347|NCT04585386|OTHER|Quebec questionnaire|To access the patient's perception of incapacity
40969348|NCT00673803|PROCEDURE|cataract surgery|cataract surgery with implantation of an IOL
41138598|NCT05477407|DRUG|Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine|Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)
41138599|NCT03345407|DRUG|Placebo ELLIPTA|Placebo will be administered via oral inhalation route once daily in the morning.
41138600|NCT03345407|DRUG|Nemiralisib ELLIPTA 50 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
41457956|NCT02262741|BIOLOGICAL|MEDI4736|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
41296643|NCT06554626|DRUG|Inotuzumab ozogamicin|a humanized monoclonal antibody-drug conjugate targeting CD22
41296644|NCT06554626|DRUG|Methotrexate|antifolate antineoplastic drug
41296645|NCT06554626|DRUG|Pegaspargase|antitumor drug
41296646|NCT06554626|DRUG|Cytarabine|Pyrimidine, antimetabolites
41457957|NCT02262741|BIOLOGICAL|tremelimumab|Tremelimumab will be administered by IV infusion in combination with MEDI4736.
41457958|NCT00065949|DRUG|magnesium sulfate|
41457959|NCT00904280|DRUG|Oxymorphone ER|Open label
41457960|NCT01510509|DEVICE|Titanium bare metal stent (Titan2®)|Titan2®, Hexacath, Paris, France
41457961|NCT01510509|DEVICE|Everolimus Drug Eluting Stent (Xience-V®)|Xience-V®, Abbott Vascular, Santa Clara, California, USA
41457962|NCT04898816|PROCEDURE|closure of wound using n- butyl 2-octyl cyanoacrylate tissue adhesive|Application of cyanoacrylate tissue adhesives over the surgical wound
41457963|NCT04898816|PROCEDURE|closure of wound using braided silk suture|suturing the surgical wound using braided black silk
41457964|NCT03721887|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
41296647|NCT04673409|DIAGNOSTIC_TEST|Novel Cardiac MRI sequences|Novel CMR sequences that allow accurate multiparametric evaluation of the whole myocardium with 3D high spatial resolution and in a patient-friendly free-breathing approach in a predictable amount of scanning time (3D T2 mapping and 3D anatomical and LGE imaging). This will be compared to the data acquired with conventional/2D sequences.
41296648|NCT05796167|DRUG|Pimavanserin|Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks
41296649|NCT01391312|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
41296650|NCT01391312|DRUG|normal saline (placebo)|Normal saline (placebo) injected into the glabellar region on Day 0.
40969349|NCT00003499|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
40969350|NCT04009343|DRUG|Artemether-lumefantrine|Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to \<15 kg: 1 tablet, 15 to \<25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.
40969351|NCT04009343|DRUG|Dihydroartemisinin-piperaquine|Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to \<8 kg: 1/2 tablet, 8 to \<11 kg: 3/4 tablet, 11 to \<17 kg: 1 tablet, 17 to \<25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.
40969352|NCT04338698|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)
40969353|NCT04338698|DRUG|Oseltamivir|Oseltamivir (75 mg orally twice a day for 5 days)
40969354|NCT04338698|DRUG|Azithromycin|Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)
40969355|NCT04673162|DRUG|Methylprednisolone, Placebo|iv administration
40969356|NCT01850771|PROCEDURE|Regenexx PL-Disc|Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
40969357|NCT01850771|PROCEDURE|Steroid Epidural|Injection into the epidural space under image guidance of 3 mg of betamethasone.
41296651|NCT03907722|OTHER|Long pentraxin 3|Primary PCI
41296652|NCT02324530|DEVICE|Continuous positive airway pressure (CPAP)|CT simulation with and without CPAP
40969358|NCT01699282|BEHAVIORAL|VKA (antivitamin K) education|Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
40969359|NCT01699282|BEHAVIORAL|conventional hospital education|Group thorough VKA education V.S. control group (conventional hospital education)
40969360|NCT03665805|OTHER|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of the TOFscan neuromuscular transmission monitor (iDMed, Marseille, France).
40969361|NCT00506480|PROCEDURE|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
40969362|NCT00920283|DEVICE|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
41296653|NCT06191276|BEHAVIORAL|STEP@Home Intervention|STEP@Home is a multi-component exercise program designed for prefrail older adults that incorporates active strategies to promote long-term engagement. The optimal level of training is 45-60 minutes of exercise three times per week for at least 20 weeks. For prefrailty management, emphasis is placed on balancing and resistance training (around 15-20 min each) to improve muscle strength and gross mobility and prevent falls. Aerobic and flexibility exercises (10 min each) are also included to improve fitness and walking pace. Sixteen training tasks, including but not limited to those recommended by Vivifrail, for each exercise component (namely, resistance, balance, flexibility and aerobic training) will be adopted. A training manual with step-by-step illustrations of each task in pictures and text will be provided to the subjects, together with a set of simple, easy-to-access equipment (water bottle, elastic band and weight-bearing belt) to support task fulfilment.
41296654|NCT06191276|BEHAVIORAL|Usual care|Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training.
41296655|NCT04051567|DRUG|Aspirin 100mg|In LDA group, patients were asked for taking 100mg aspirin per night;
41296656|NCT01563627|OTHER|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
41296657|NCT01563627|DEVICE|Magnetic Resonance Imaging|
41296658|NCT05700344|DRUG|Avelumab|Single Group Assignment
40969363|NCT00920283|DEVICE|Driver Cobalt Alloy Coronary Stent|
41296659|NCT02796404|DEVICE|Homebased cardiac rehabilitation program|homebased cardiac rehabilitation program with monitoring vest Nuubo
40969364|NCT01804465|DRUG|SipT Treatment|"All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion."
40969365|NCT01804465|DRUG|Ipilimumab|Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
40969366|NCT03340532|OTHER|THE INFORMATION + APPEARANCE VIDEO|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
40969367|NCT03340532|OTHER|Information SunSmart video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
40969368|NCT03340532|OTHER|Sleep hygiene video|Contain information on better sleep hygiene
40969369|NCT04232384|PROCEDURE|Standard Paracentesis|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography guided (in cases the ascites is not clinically detectable).
40969370|NCT04232384|PROCEDURE|Roll Over Paracentesis|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
41457965|NCT05554887|OTHER|Thrust manipulation|Participants will be positioned prone and the clinician will perform a high-speed, low-amplitude thrust into the most symptomatic segment of the thoracic spine. TM type, thrust direction, and number of thrusts will be at the clinician's discretion and will be based on the individualized assessment of the patient.
40969371|NCT03967652|DIAGNOSTIC_TEST|Nanomaterial-based sensors|Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.
40969372|NCT05123261|BEHAVIORAL|the mindfulness-based elder care (MBEC) therapy|According to the mindfulness-based elder care (MBEC) therapy developed by McBee (2008), the experimental group was offered eight 50-minute courses once a week.
40969373|NCT04359654|DRUG|Dornase Alfa Inhalation Solution [Pulmozyme]|Nebulised Dornase alfa 2.5mg bd for 7 days
40969374|NCT05512845|PROCEDURE|Double Factor technique|"The double factor computer assisted surgery technique, involves the combination of the static and dynamic computer assisted surgery protocols to place dental implants in the same surgery."
41296660|NCT02796404|OTHER|Traditional cardiac rehabilitation program|multidisciplinary intervention in cardiac rehabilitation gym
41296661|NCT00445055|DRUG|Droperidol|Intravenous injection
41457966|NCT05554887|OTHER|Sham thrust manipulation|The same protocol will be applied as the push thoracic manipulation application, but no push will be applied.
41457967|NCT04189120|PROCEDURE|Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block|neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks
41296662|NCT03340077|OTHER|Medicines Optimisation Review toolkit|The Review tool consist of two items. 'My Clinic companion' and 'MOR consultation form'. 'My clinic companion' (see appendix 1) is a patient-orientated questionnaire that promotes self-review of medications and adherence and will facilitate the pharmacist consultation. The 'MOR consultation form' (see appendix 2), is designed to aid a structured patient consultation using available information from local databases, GP medication histories as well as that obtained directly from the patient. The form also identifies key care providers involved in the patient case, including prior consent to contact with information if required.
41296663|NCT03340077|OTHER|Standard of Care|Pharmacist review of ART medications
41296664|NCT00002089|DRUG|Azithromycin|
41296665|NCT00325442|DRUG|Oral treprostinil (UT-15C) sustained release tablets|UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
41296666|NCT00325442|DRUG|Placebo|Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
41296667|NCT05436938|COMBINATION_PRODUCT|Jing Si herbal tea liquid packets use|with or without Jing Si herbal tea liquid packets use
41296668|NCT05837312|BEHAVIORAL|Reconnecting to Internal Sensations and Experiences|Reconnecting to Internal Sensations and Experiences (RISE) is a novel, self-guided interoceptive intervention designed to be accessible and convenient. RISE is hosted on Qualtrics and accessed on any internet-enabled device. RISE consists of four interactive 30-minute modules: (1) Progressive Muscle Relaxation and Body Functionality, (2) Understanding, Noticing and Managing Emotions, (3) Self-care and Communication, and (4) Body Sensations. The training consists of a mix of audio clips, psychoeducation, self-guided reading, and interactive writing prompts. Intervention materials are separated by multiple free-response prompts so that participants can relate the materials to their own lives, practice the introduced skills, and problem-solve difficulties implementing the skills.
41457968|NCT03700398|DEVICE|first OE|optical enhancement(OE)，a kind of electron straining endoscopy
41457969|NCT03700398|DEVICE|first WLI|the routine in the clinical practice
41457970|NCT02698345|DEVICE|drug-eluting balloon (In.PACT Admiral, Medtronic)|
40969375|NCT00572702|PROCEDURE|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
41457971|NCT05912335|DRUG|Topical anesthetic|The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
40969376|NCT00572702|PROCEDURE|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
41296669|NCT06203496|DIAGNOSTIC_TEST|Blood sample|Blood sample
41296670|NCT04207853|OTHER|whole body vibration em DM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
41296671|NCT04207853|OTHER|"Vibration sham em DM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
41457972|NCT04394130|DRUG|ropivacaine 0.2%|continuous peripheral nerve local anesthetic infusion (ropivacaïne 0.2 %) for 48 hours postoperative.
41457973|NCT00071539|DRUG|TP-38|Recombinant chimeric protein
41457974|NCT00071539|DRUG|TP38|recombinant chimeric protein
41457975|NCT02566096|DRUG|transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine|compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
41457976|NCT03095950|OTHER|News items with spin|Interpretation of news items with spin
41457977|NCT03095950|OTHER|News items without spin|Interpretation of news items without spin
40969377|NCT02454296|DRUG|Paracervical Block with lidocaine|Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
40969378|NCT02454296|DRUG|Sham paracervical block|A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
40969379|NCT02314611|DEVICE|PROFEMUR® Gladiator HA Coated Modular Femoral Stem|Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem
40969380|NCT00580684|BIOLOGICAL|pneumococcus conjugate vaccine 7 valent to reduce carriage|plain polisacaride vaccine 23 valent to reduce carriage
40969381|NCT00739674|DRUG|losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|"Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~* Losartan 50 mg~* Losartan 100 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~* Losartan 50 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~* Losartan 100 mg/HCTZ 25 mg + increasing CCB"
41457978|NCT06405815|OTHER|tumor and peritumor radiomic feature|extracted the tumor and peritumor radiomic feature from the preoperative enhanced chest CT
40969382|NCT00739674|BEHAVIORAL|Low Salt Diet|"Low-salt intake diet (Dietary Approaches to Stop Hypertension \[DASH\]) including:~* Healthy diet~* Reduction in sodium intake to less than 2300 mmol/day~* Low alcohol consumption (less than 2 standard drinks/day)"
40969383|NCT03771677|DRUG|Nucleotide Analog|such as Entecavir,entecavir 0.5mg per day
40969384|NCT03771677|DRUG|Interferon Alfa-2A|Peginterferon alfa-2a 180ug per week
40969385|NCT02539121|DEVICE|Acupuncture|Acupuncture needles
40969386|NCT02706340|OTHER|No intervention - observational study only|
40969387|NCT02325375|PROCEDURE|lumbar puncture for spinal fluid and blood sample|lumbar puncture for spinal fluid and blood sample
40969388|NCT04015336|BIOLOGICAL|E7 T-Cell Receptor (TCR)|The dose of E7 T-Cell Receptor (TCR) T cells will be 3 x 10\^10 TCR+ T cells (unless fewer cells are generated) administered once.
40969389|NCT05261256|DIAGNOSTIC_TEST|Exercise stress echocardiography|Study participants perform an exercise stress echocardiography on a semi-supine bicycle ergometer using using a continuous incremental bicycle protocol with a work rate increment every 3 minutes according to gender and weight.
40969390|NCT06046391|BIOLOGICAL|LP-003 dose 1|Liquid in vial
40969391|NCT06046391|BIOLOGICAL|LP-003 dose 2|Liquid in vial
40969392|NCT06046391|BIOLOGICAL|Placebo|Liquid in vial
40969393|NCT01603004|OTHER|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
40969394|NCT02943278|BEHAVIORAL|Intensive Sleep Retraining|Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
40969395|NCT02943278|BEHAVIORAL|Sleep Hygiene|Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
40969396|NCT03459547|DEVICE|dental implant|Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
40969397|NCT05329974|OTHER|Computer guided buccal cortical plate separation|Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
40969398|NCT00905073|DRUG|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
40969399|NCT03416530|DRUG|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
40969400|NCT00036452|DRUG|lopinavir/ritonavir|
41146890|NCT03905928|OTHER|Placebo ECIG with Tobacco Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor."
40969401|NCT00036452|DRUG|emtricitabine|
40969402|NCT00036452|DRUG|stavudine|
40969403|NCT00036452|DRUG|tenofovir DF|
40969404|NCT06045897|DEVICE|EEG 64 channels|64-channel EEG in wake and resting conditions for 1h30, with oculogram, electromyogram and electromyogram and electrocardiogram. Five minutes of eyes closed will be used for microstate analysis. 1h30 will be used for the sensorimotor task.
40969405|NCT06045897|DEVICE|Polysomnography 19 electrodes|Overnight polysomnography with 19 EEG channels and ventilatory polygraphy.
40969406|NCT06045897|BEHAVIORAL|Light hypnosis|Healthy controls will undergo a 5 min light hypnosis exercise that will be focused on proprioception.
40969407|NCT06045897|BIOLOGICAL|Biological sampling|Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.
41296672|NCT04207853|OTHER|whole body vibration em NDM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
41296673|NCT04207853|OTHER|"Vibration sham em NDM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
41296674|NCT01263535|DEVICE|SENSIMED Triggerfish|Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
41296675|NCT01721369|DIAGNOSTIC_TEST|Transient Loss of Consciousness (T-LOC)|
41296676|NCT06442917|BEHAVIORAL|Breathing Exercise|"32 the Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth was completed before the pregnancy intervention and the VAS was measured. Breathing exercise training and application were carried out during the latent phase process. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made.~During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed every 30 minutes from the beginning of contraction until the end of contraction. During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 15 minutes from the beginning of contraction to the end of contraction."
41457979|NCT05412121|DEVICE|Acupressure|"The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.~In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention."
41146891|NCT03905928|OTHER|Placebo ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor."
41146892|NCT00087724|DRUG|FK962|
41146893|NCT01597999|RADIATION|MRI|magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
41146894|NCT01739972|DRUG|Levothyroxine|Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
41146895|NCT01739972|DRUG|Desiccated thyroid extract|Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
41146896|NCT06153589|OTHER|Musicotherapy|"Musicotherapy will be offered to patients who meet the eligibility criteria, and have been randomized to the experimental arm.~Patients will only be seen once during the study. Patients are placed in individual rooms. Hifi audio headphones (equipped with hygienic earcups) and a tablet equipped with the Music Care application will be offered to patients in the experimental group and the investigators will help them choose the style of music, which respects the U-shaped sequence.~The Music Care application has proven that the use of headphones allows the patient to be isolated and therefore to obtain less parasitic care. He will be told at the start of the session that he can ask to interrupt it if he wishes to communicate with the team, particularly regarding possible pain.~The musicotherapy session begins before the act of debridement (10 minutes before), lasts during the act (40 minutes maximum), and continues for 10 minutes after the end of the debridement."
41146897|NCT03989609|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,
41146898|NCT03989609|DRUG|Midazolam|midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
41146899|NCT05941156|BIOLOGICAL|Anti-CD56 CAR T|CAR T cells were pretreated at -5 days before retransfusion (FC regimen: fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day). Anti CD56-CAR T cells were transfused back to the patient 2 days after the end of chemotherapy. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.
40969408|NCT06045897|BEHAVIORAL|Virtual reality|Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.
40969409|NCT06045897|DEVICE|Voice recording|A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.
41457980|NCT05958056|OTHER|Resistance exercise|The training session included leg curl and leg extension exercises with 4 sets each. Participants started with leg extension exercise for 4 sets with a 30-second rest periods between the sets. Then, participants took a rest for 60 seconds. Afterward, participants performed leg curl exercise for 4 sets with a 30-second rest periods between the sets. Exercises in each set were performed continuously (uninterrupted) with a speed of 2 seconds for each repetition and a medium exercise performance speed.
40969410|NCT02014597|DEVICE|HOCD|feasibility of HOCD and comparison of HOCD results between subjects with and without glaucoma
40969411|NCT04943315|PROCEDURE|Monolithic zirconia|posterior crowns
40969412|NCT04943315|PROCEDURE|Metal-ceramic|posterior crowns
41138601|NCT03345407|DRUG|Nemiralisib ELLIPTA 100 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
41138602|NCT03345407|DRUG|Nemiralisib ELLIPTA 250 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
41146900|NCT04151888|DEVICE|Foley catheter|Thin sterile tube will be inserted in choana
41457981|NCT02287220|DEVICE|Non-Contact Oximetry|Video Record subject when subjected to small amounts of near infrared light
40969413|NCT01022632|DIETARY_SUPPLEMENT|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
40969414|NCT01022632|DRUG|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
40969415|NCT01022632|DIETARY_SUPPLEMENT|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
40969416|NCT02364479|DRUG|50mg Yisaipu|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
40969417|NCT02364479|DRUG|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
40969418|NCT02364479|DRUG|Placebo|The injection method and frequency of placebo is the same as the other arms.
41296677|NCT06442917|BEHAVIORAL|Affirmation Method|"32 pregnant women who were admitted to the hospital for childbirth and were in the latent phase (0-3 cm) filled out the pre-intervention Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth, and the VAS was measured. During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained. During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and the affirmation phrases were repeated and used by the researcher every 30 minutes from the beginning of the contraction until the end of the contraction.~During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and affirmation sentences and support sentences were said every 15 minutes from the beginning of the contraction to the end of the contraction."
41296678|NCT06442917|BEHAVIORAL|Breathing Exercise and Affirmation Method|During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained and the application was made with breathing exercise training. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made. During the active phase process (4-7 cm), the Congenital Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 30 minutes from the beginning of contraction to the end of contraction, and the affirmation phrases were repeated and used by the researcher
41457982|NCT04580615|DEVICE|CardiacSense1 and capnograph Respiratory rate measurement|Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.
41457983|NCT03799224|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11
41457984|NCT03799224|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
41457985|NCT03799224|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3
41457986|NCT02973269|BIOLOGICAL|daxibotulinumtoxin type A|Intramuscular injection
41457987|NCT02973269|BIOLOGICAL|Placebo|Intramuscular injection
41457988|NCT06043375|DIETARY_SUPPLEMENT|Licorice Root Powder Capsule|Fresh licorice root will be obtained from local market of Lahore. The root will be washed and dried at room temperature. Then it will be converted into powder using grinder. After sieving the ground powder, it will be filled in capsules. One capsule will contain 1000mg of powder. Participants in experimental group will be instructed to consume one capsule per day.
40969419|NCT00718835|BEHAVIORAL|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
41457989|NCT03318133|PROCEDURE|anesthesia|in this study, we plan to make a prospective, multicenter, randomized controlled clinical trial to compare the effects of general anesthesia with endotracheal intubation and ultrasound-guided combined lumbar plexus and sacral plexus block with sedative anesthesia on the prognosis of elderly patients with hip fracture to clarify the clinical value of combined lumbar plexus and sacral plexus block with sedative anesthesia in elderly patients with hip fracture.
40969420|NCT02698839|DEVICE|BuMA Supreme|Stent platform: cobalt-chromium alloy
40969421|NCT02698839|DEVICE|BuMA™|Stent platform: stainless steel
40969422|NCT05538702|DEVICE|IQOS 3.0 DOU with bland taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
40969423|NCT05538702|DEVICE|IQOS 3.0 DUO with menthol taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
40969424|NCT05538702|DEVICE|Marlboro Gold (Conventional cigarette)|Conventional cigarette
40969425|NCT05538702|DEVICE|IQOS 3.0 DUO turned off with a bland taste unit|Placebo device
41296679|NCT01264991|PROCEDURE|Arthroscopic partial meniscectomy|The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
41296680|NCT01264991|PROCEDURE|Sham procedure|The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
41296681|NCT03193151|PROCEDURE|liver biopsy|5 mm fragment of liver transplant biopsy taken for clinical indication
41296682|NCT06007430|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
41296683|NCT06007430|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
41296684|NCT00581711|OTHER|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
41296685|NCT00581711|OTHER|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
41296686|NCT00581711|OTHER|1-part intervention|Provision of feedback on otitis media quality indicators
41296687|NCT00637273|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
41296688|NCT00637273|DRUG|sitagliptin|oral tablet, 100mg, once a day
40969426|NCT04775875|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory wave form confirmation of cerebral arteries, and optical tracking technology (eg, AntNeuro Visor2 system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
40969427|NCT01119885|DRUG|fentanyl matrix|Knee osteoarthritis, starting with 12mcg/h (flexible dose)
41296689|NCT00637273|DRUG|pioglitazone|oral tablet, 45mg, once a day
41296690|NCT00637273|DRUG|placebo tablet|oral tablet, once a day
41296691|NCT00637273|DRUG|placebo once weekly|subcutaneous injection, once a week
40969428|NCT01119885|DRUG|fentanyl matrix|Hip osteoarthritis, starting with 12mcg/h (flexible dose)
40969429|NCT04557397|DRUG|Fruquintinib|oral VEGFR inhibitor
40969430|NCT04557397|DRUG|Itraconazole|a synthetic triazole antifungal agent
40969431|NCT04557397|DRUG|Rifampin|a semisynthetic antibiotic derivative of rifamycin SV
40969432|NCT00107445|DRUG|EF5|Given IV
41146901|NCT05319756|DRUG|gabapentin 600 mg|Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl
41146902|NCT05319756|DRUG|gabapentin 1200 mg|Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl
41146903|NCT05319756|DRUG|gabapentin 600 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg
41146904|NCT05319756|DRUG|gabapentin 1200 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg
41146905|NCT05319756|DRUG|oxycodone HCl 20 mg|Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin
41146906|NCT05319756|DRUG|placebo|Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl
41146907|NCT03853941|BEHAVIORAL|Intervention|Theory-based communication training programme delivered to healthcare professionals
41146908|NCT04343274|DRUG|Tozuleristide|
41146909|NCT00505986|PROCEDURE|endometrial biopsy|
41146910|NCT02765204|DRUG|Dapagliflozin|
41146911|NCT02765204|DRUG|Saxagliptin|
41146912|NCT02765204|DRUG|Glucose|
41146913|NCT04180072|DRUG|Atezolizumab|Atezolizumab 1200 mg IV on day 1 every 3 weeks
41146914|NCT04180072|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV on day 1 every 3 weeks
41146915|NCT02213094|DRUG|Nicotinamide 500 mg|Nicotinamide 500 mg taken by mouth each morning
41146916|NCT02213094|DRUG|Nicotinamide 1000 mg|Nicotinamide 1000 mg taken by mouth each morning
41146917|NCT03627156|BEHAVIORAL|guided counseling|Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
41296692|NCT02438436|DIETARY_SUPPLEMENT|simo decoction|
41296693|NCT02438436|OTHER|gum chewing|
41296694|NCT03492450|OTHER|Treadmill training|Tailored treatment comprising of: 1) aerobic exercises with the aim of increasing fitness 2) task-oriented balance exercises on the treadmill to improve balance and 3) cognitive behavioral interventions to improve balance and gait during dual task activities.In accordance with the literature (Langeskov-Christensen, 2015, Latimer-Cheung, 2013) the treadmill training will be carried out without body weight support, but the participants will be allowed to use the handrails for balance support if needed. The training consists of three different walking sessions, each lasting for 10 minutes: 1) preferred walking speed at an increased slope; 2) walking doing dynamic balance exercises (for example walking with feet in tandem) 3) fast gait speed defined as a 10% increase in walking speed relative to preferred speed with dual task exercises. During the 8-week intervention, walking speed in session 3 will be gradually increased with 10% to 40% of preferred speed.
41296695|NCT00596518|DRUG|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
41296696|NCT06475222|OTHER|Study 1: Facial serum with alpha albutin|Applying with facial serum with 2% alpha albutin as active comparator daily for 12 weeks.
41296697|NCT06475222|OTHER|Study 1: Facial serum with Tubtim Chumpae rice extract|Applying with facial serum with Tubtim Chumpae rice extract as experimental intervention daily for 12 weeks.
41296698|NCT06475222|OTHER|Study 2: Facial mask with Hom Pathum rice extract|Applying with facial mask with Hom Pathum rice extract as experimental intervention for 30 min/day, 2 days/week for 12 weeks.
41296699|NCT06475222|OTHER|Study 3: Control jelly|Consumption with control jelly as active comparator at 3.5 g/kg body weight.
41296700|NCT06475222|OTHER|Study 3: Jelly with Tubtim Chumpae rice|Consumption with jelly with Tubtim Chumpae rice as experimental intervention at 3.5 g/kg body weight.
41296701|NCT06475222|OTHER|Study 3: Jelly with Hom Pathum rice|Consumption with jelly with Hom Pathum rice as experimental intervention at 3.5 g/kg body weight.
41296702|NCT00688493|DRUG|Dapagliflozin|3 x 50 mg tablets, single oral dose
41296703|NCT00688493|DRUG|Dapagliflozin|2 x 10 mg capsules, single oral dose
41296704|NCT00688493|DRUG|Moxifloxacin|Overencapsulated 400 mg capsule, single oral dose
41296705|NCT00688493|DRUG|Placebo to match moxifloxacin and dapagliflozin|Overencapsulated 400 mg capsule, single oral dose
41296706|NCT04289103|BIOLOGICAL|Inolimomab (Leukotac)|"* Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~* Treatment phase - Leukotac will be given up to D28~* Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion."
41296707|NCT04559906|OTHER|Spray and Stretch technique (Ethyl chloride)|"Group A receive spray and stretch technique (Ethyl chloride) with conventional treatment.~The upper trapezius muscle stretches on the basis of the Technique originally described by Simons. The subject is seated in a relaxed position on their homolateral hand for anchoring the distal end of the studied muscle. Initially, 3 to 5 parallel sweeps of ethyl chloride spray is applied covering the Upper trapezius muscle. Then, the muscle are positioned in a maximal but tolerable stretch and lengthened until the Physical Therapist felt the muscle tension barrier. This procedure repeated 2 or 3 times."
41296708|NCT04559906|OTHER|Sustain pressure release|"Group B receive sustain pressure release with conventional treatment. Progressive pressure release are considered in two stages. The initial step is to recognize and find the trigger in upper fiber of trapezius, utilizing trigger point palpation. Trigger point felt as firm and restricted hyperirritable knots with in gut of the muscle.~The second step is to applying pressure release ranging from eight to twelve second for each pressure, then it increases gradually for maximum of twenty seconds. The total duration of pressure is five minutes or more until the discharge is felt by the fingers."
41296709|NCT00404404|BIOLOGICAL|bevacizumab|
41296710|NCT00404404|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
40969433|NCT05118503|BEHAVIORAL|Customized education|Half of subjects will receive access to a customized app that will include brief educational videos that have been selected for each patient based on their medical history. These videos will address stroke etiology, underlying risk factors, and stroke prevention medications.
40969434|NCT05118503|BEHAVIORAL|Standard of care discharge education|Half of subjects will be randomized to receive typical discharge education, per the institutional guidelines for standard of care education for stroke patients.
40969435|NCT00005794|DRUG|perifosine|
40969436|NCT05739097|DIAGNOSTIC_TEST|iron deficiency, coagulation abnormalities|avoid transfusions, where possible
40969437|NCT04360915|DRUG|ASK120067|Take ASK120067 tablets orally in first day at 160 mg in fast condition.
40969438|NCT04360915|DIETARY_SUPPLEMENT|ASK120067 in fed condition|Take ASK120067 tablets orally in first day at 160 mg in fed condition.
40969439|NCT02589184|OTHER|Hypergravity|the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing
40969440|NCT02589184|OTHER|isometric load|at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load
41296711|NCT01757704|PROCEDURE|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
41296712|NCT01757704|PROCEDURE|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
40969441|NCT02589184|OTHER|normal gravity|the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
41296713|NCT00256828|DRUG|didanosine + lamivudine + efavirenz|
41296714|NCT05148208|DEVICE|Creatine supplementation to dialysate|Creatine supplementation to dialysate
41296715|NCT01105403|DRUG|POL6326|IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
41296716|NCT00110383|BEHAVIORAL|School-Based Supervised Asthma Therapy|Child's inhaled steroid use supervised daily at school
41296717|NCT03747172|DIETARY_SUPPLEMENT|complementary and alternative therapy|complementary and alternative therapies were grouped into five main categories: (1) biologically based therapies , (2) mind/body therapies, (3) manipulative and body-based therapies, (4) Energy therapies and (5) alternative medical systems.
41296718|NCT02560701|OTHER|Patient Interview|Investigators will conduct in-depth interviews with approximately 40 commercially insured individuals with bipolar disorder or their family caregivers to explore how they navigate deductibles, copayments, and other complex insurance features. Investigators will also determine the health care services that patients most value and assess how they prioritize difficult health care cost tradeoffs.
41296719|NCT02532868|DRUG|MK-0457|
41296720|NCT01531491|PROCEDURE|Rebreathing tube|750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
41296721|NCT01531491|PROCEDURE|No rebreathing tube (Nothing)|750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
41296722|NCT02209233|OTHER|Massage Therapy|
41296723|NCT02706093|OTHER|High Intensity Interval Training #1|(HIIT#1) 10 x 1 min. at \~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .
41296724|NCT02706093|OTHER|Moderate intensity continuous training|Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.
41296725|NCT02706093|OTHER|High Intensity Interval Training #2|(HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax \[25min; \~150kcals; 4d/wk\]
41296726|NCT02706093|OTHER|High Intensity Interval Training #3|(HIIT #3) 5 x 1 min at 90%HRmax \[15min; \~90kcals; 4d/wk\]
41296727|NCT05916196|DRUG|18F-Fluoroestradiol|18F-FES PET/CT
41296728|NCT01444521|DRUG|irinotecan and cisplatin|"irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
41296729|NCT00575822|DEVICE|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
40969442|NCT04134013|DIETARY_SUPPLEMENT|Combination: Nutrition AND Chiropractic Adjustment|LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
40969443|NCT04134013|OTHER|Chiropractic Adjustment: Spinal Manipulation Therapy|LBP chiropractic adjustment per protocol
40969444|NCT00730132|DRUG|Ezetimibe|Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
40969445|NCT00730132|DRUG|Statin|Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
40969446|NCT03951402|DRUG|100 mg CG5503 (tapentadol hydrochloride) PR tablet|100 mg CG5503 (tapentadol hydrochloride) PR tablet.
40969447|NCT03951402|DRUG|Placebo matching CG5503 PR tablet|Matching placebo tablet to CG5503 PR tablet.
40969448|NCT03951402|DRUG|Placebo matching moxifloxacin capsule|Matching placebo capsule to moxifloxacin capsule.
40969449|NCT03951402|DRUG|400 mg Moxifloxacin tablet (overencapsulated)|Overencapsulated 400 mg Moxifloxacin tablet.
41296730|NCT00575822|DEVICE|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
41296731|NCT02518620|BIOLOGICAL|ALX-0061|Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
41296732|NCT00931957|DRUG|Etanercept, Methotrexate, Prednisolone|"In: Arm A, Etanercept-MTX-Prednisolone:~Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.~In Arm B:~Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses."
41296733|NCT04470752|DRUG|Capsaicin 1% oral solution|Capsaicin 1.0 micrograms/ml
41296734|NCT04470752|DRUG|InOrpha Solution|glycerol based suspension vehicle
41296735|NCT02896426|BEHAVIORAL|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
41296736|NCT02896426|BEHAVIORAL|Positive Solutions For Families|Positive Solutions for Families groups provide information for families on how to promote children's social and emotional skills, understand their problem behavior, and use positive approaches to help children learn appropriate behavior.
41296737|NCT02857023|BEHAVIORAL|Cogmed RM|Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
41296738|NCT03558932|DIAGNOSTIC_TEST|pleural biopsy|diagnostic sampling
41296739|NCT00004033|DRUG|liposomal NDDP|
41296740|NCT00004033|PROCEDURE|therapeutic thoracoscopy|
41296741|NCT00069095|DRUG|Oxaliplatin 130 mg/m^2|Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
40969450|NCT04235478|DRUG|Combination Product: triamcinolone and saline|a mixture of 3 mL 0.09%saline and 2 mL 80 mg triamcinolone (kenacort-a)
41296742|NCT00069095|DRUG|Capecitabine 1000 mg/m^2|Capecitabine was taken within 30 min after the end of breakfast and dinner.
41296743|NCT00069095|DRUG|Bevacizumab 7.5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
41457990|NCT02515487|OTHER|Brain Fitness Program (BFP)|The program is designed to improve processing speed of auditory information and attention. The BFP is comprised of six computerized subtests that continuously adjust in the level of difficulty to maintain an 85% correct response rate. The subtest exercises include discrimination of confusable syllables, recognition of sequences of syllables, matching pairs of confusable syllables, reconstruction of sequences of verbal instructions and identification of details in a verbally presented story. Participants will participate in 40 one-hour training sessions over a 12 week period to complete all cognitive remediation training sessions. Since this intervention is presented both visually and verbally, noise cancelling headphones will be provided to the participants.
41457991|NCT06205316|DRUG|Antiandrogen Therapy|Receive ADT
40969451|NCT03040102|OTHER|Hospice Video Educational Tool|it's a 6 minute video regarding hospice care
41296744|NCT00069095|DRUG|Placebo for bevacizumab 7.5 mg/kg|Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
41296745|NCT00069095|DRUG|Oxaliplatin 85 mg/m^2|Oxaliplatin 85 mg/m\^2 was administered simultaneously with leucovorin in a 2 h infusion.
41457992|NCT06205316|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41457993|NCT06205316|PROCEDURE|Bone Scan|Undergo bone scan
40969452|NCT03040102|OTHER|Standard of Care|Standard of Care practice is used
40969453|NCT01224860|DRUG|Telmisartan|One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
41457994|NCT06205316|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
41457995|NCT06205316|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40969454|NCT01224860|DRUG|Losartan|One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
40969455|NCT01221571|DRUG|AFM 13|Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
41296746|NCT00069095|DRUG|Leucovorin 200 mg/m^2|Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.
41296747|NCT00069095|DRUG|Fluorouracil 400 mg/m^2|
41457996|NCT06205316|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40969456|NCT02289898|DRUG|Demcizumab|administered intravenously
40969457|NCT02289898|DRUG|Abraxane®|administered intravenously
40969458|NCT02289898|DRUG|gemcitabine|administered intravenously
41296748|NCT00069095|DRUG|Bevacizumab 5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
41296749|NCT00069095|DRUG|Placebo for bevacizumab 5 mg/kg|Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
41296750|NCT01147315|PROCEDURE|Hybrid bone substitution|The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
41296751|NCT04485169|PROCEDURE|Therapeutic Plasma Exchange|a. 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
41457997|NCT06205316|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41457998|NCT06205316|OTHER|Survey Administration|Ancillary study
41457999|NCT04381741|BIOLOGICAL|CD19-7×19 CAR-T plus PD1 monoclonal antibody|Three different doses of CD19-7×19 CAR-T (1×106/kg、2×106/kg、3×106/kg) plus 200mg Tislelizumab every 3 weeks for 6 times
41458000|NCT05745636|DIETARY_SUPPLEMENT|Broccoli, mustard, vitamin C|2 capsules per day for 4 weeks
41296752|NCT05639920|COMBINATION_PRODUCT|Scoreing|Validation of Emergency surgery score in predicting mortality and mortality in Egyptian patients undergoing Emergency laparotomy
41296753|NCT04604730|PROCEDURE|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
41296754|NCT04604730|PROCEDURE|Anastomosis with protective stoma|Anastomosis with protective stoma
41296755|NCT03805295|OTHER|BOKS Program|12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.
41296756|NCT03115489|DRUG|Traditional Treatment (Group T)|Patients will receive traditional drug infusions
41458001|NCT05745636|DIETARY_SUPPLEMENT|Placebo|2 capsules per day for 4 weeks.
41458002|NCT04970498|DIAGNOSTIC_TEST|MRI|MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed
41458003|NCT04970498|DIAGNOSTIC_TEST|blood routine test|The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.
41458004|NCT01919827|BIOLOGICAL|Endobronchial infusion of adult mesenchymal stem cells|
41458005|NCT01919827|BIOLOGICAL|Autologous mesenchymal stem cells derived from bone marrow|
41296757|NCT03115489|DRUG|Ketamine Infusion (Group K)|Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
41296758|NCT04061798|DRUG|ACT guided heparinization|"If the ACT is \<180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is \>200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is \>200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 2500 IU of protamine should be administered. If \>250 sec., 5000 IU protamine. If 180-200 sec., 1000 IU protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again."
41296759|NCT04061798|DRUG|5 000 IU of heparin|"A single dose of 5 000 IU of heparin is given 3-5 min before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.~If the ACT at closure is between 200 and 250 s, 2500 IU protamine should be administered. If the ACT is higher than 250 s, 5000 IU protamine should be administered. If the ACT is between 180 and 200 s, 1000 IU protamine should be administered. Five minutes after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 s. If the ACT is still more than 200 s, protamine should be administered again."
41458006|NCT01448434|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
41458007|NCT01448434|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
41458008|NCT02135991|BEHAVIORAL|Getting To Outcomes|These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
41458009|NCT02135991|BEHAVIORAL|Project CHOICE|Sites will receive standard training for Project CHOICE.
41458010|NCT03920449|DRUG|Botulinum Toxins|In group I (BT injection), 21 U will be injected in 3 divided doses through the internal anal sphincter at 3,9, and 12 o'clock. In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial; Ipsen Biopharm Ltd, Wrexham, UK). In case of Dysport it should be remembered that dosing is on a ratio of approximately 1 to 3, meaning that 50 IU of Botox have the same effect as 150 IU of Dysport.
41296760|NCT02101606|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
41296761|NCT00002263|DRUG|Zidovudine|
41296762|NCT00002263|DRUG|Sargramostim|
41296763|NCT02175563|DEVICE|Audiovisual feedback from smartphone based app|
41296764|NCT00247910|DRUG|Hydrochlorothiazide|Not recorded in detailed description.
41458011|NCT03920449|PROCEDURE|Posterolateral internal sphincterotomy|In group II (PIAS), A 1.5 to 2-cm circumferential skin incision will be placed at 5 o'clock position outside the anal verge using an electrocautery device. Dissection will be proceeded through the intersphincteric groove to separate both IAS and external anal sphincter (EAS). Then, the IAS will be identified by its characteristic white fibers, separated from the anal mucosa, and assessed under direct vision. Subsequently, about 50 % of the IAS will be divided at 5 o'clock position and any skin tags or hypertrophied anal papillae will be removed leaving the skin incision open to allow drainage.
41458012|NCT05317858|DEVICE|Blood Brain Barrier Disruption - Oncology|BBB opening via Exablate Type 2 system with microbubble resonators on the day of pembrolizumab infusion to treat brain metastases
41458013|NCT05317858|DRUG|Pembrolizumab|Pembrolizumab infusion
41458014|NCT03170739|DRUG|Dexmedetomidine|Dexmedetomidine given during surgery.
40969459|NCT02289898|DRUG|Placebo|
40969460|NCT05473767|BEHAVIORAL|Family Check Up Heart|Family Check-Up Heart consists of the Family Check up with an added heart health component. The Family Check-Up Heart assessment will include evaluations of maternal cardiovascular health; specifically, measurement of maternal blood pressure, body mass index, diet quality, exercise, and smoking, which will be included in the feedback session. After the Feedback Session participants will also receive information about healthy eating and weight loss, stress management, and smoking and to monitor weight and blood pressure.
41458015|NCT03170739|DRUG|Dopamine|Dopamine given during surgery.
41458016|NCT05706415|DIAGNOSTIC_TEST|Clinicians will review the suggestions of a hypothetical AI|There is no intervention. Clinicians will review the suggestions of a hypothetical AI
41458017|NCT01931449|PROCEDURE|Modified method of digestive tract reconstruction|
41458018|NCT01931449|PROCEDURE|Routine digestive tract reconstruction|
41458019|NCT00721955|DRUG|Inhaled Placebo|Inhaled loxapine Placebo, may repeat after 2 hours x 2
40969461|NCT05473767|BEHAVIORAL|Family Check-Up|"The Family Check-Up typically takes place over the course of 3-5 sessions, each about an hour long. First, a trained Family Check-Up family coach will conduct an Initial Interview. Second is an assessment of that includes questionnaires and videotaped interaction tasks. Third, during the Feedback Session, the family coach discusses with the participant strengths and challenges for their child and family as a whole. They then set goals for their family to support and maintain strengths, and to address any areas of concern. After the Feedback Session families have the option to continue meeting with their family coach to support the child's development and improve parental well-being."
40969462|NCT00542854|DEVICE|MP3|4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
40969463|NCT03740711|PROCEDURE|Left atrial venting|The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.
41296765|NCT03574467|BEHAVIORAL|Bobath Neurodevelopmental Treatment Approach|The Bobath Neurodevelopmental Treatment (NDT) rehabilitation approach is effective in increasing the functional capacity and acquiring independence in patients with stroke and brain tumor.
41296766|NCT05441150|DRUG|Low dose ketamine infusion|Administering low-dose ketamine infusion to the patient under general anesthesia for Ketamine Group.
41296767|NCT05441150|DRUG|0.9% NaCl infusion|Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
41296768|NCT02772497|DRUG|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
41296769|NCT02796690|OTHER|nasal swabs will be collected|After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
41296770|NCT01518582|DEVICE|Cervical arthroplasty surgery with Granvia-C|Discectomy and Cervical arthroplasty according to standard practice of the surgeon
41296771|NCT02353078|DRUG|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
41296772|NCT02353078|PROCEDURE|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
41296773|NCT02353078|DEVICE|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
41458020|NCT00721955|DRUG|Inhaled loxapine 5 mg|Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
41458021|NCT00721955|DRUG|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
41458022|NCT02856776|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D provided in capsule form
41458023|NCT04340843|DRUG|Belinostat|Given IV
41458024|NCT04340843|PROCEDURE|Biopsy|Undergo biopsy
41458025|NCT04340843|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41458026|NCT04340843|PROCEDURE|Computed Tomography|Undergo CT
41458027|NCT04340843|DRUG|Decitabine and Cedazuridine|Given PO
41458028|NCT04340843|DRUG|Guadecitabine|Given SC
41296774|NCT00661752|DEVICE|quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
41296775|NCT00661752|DEVICE|quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
41458029|NCT04340843|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40969464|NCT04554979|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
41296776|NCT06201195|PROCEDURE|Adductor canal blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
41296777|NCT06201195|PROCEDURE|Distal adductor canala blockade and anterior cutaneus nerve blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
41296778|NCT04115631|DRUG|Acalabrutinib|Given PO
40969465|NCT05490641|BEHAVIORAL|Glucose-based biofeedback|Participants will wear a Fitbit activity tracker and receive personalized text messages over a 12-week period. During the first 4 weeks of the study period, participants will also wear a continuous glucose monitor to check their glucose levels in real-time and receive text messages based on their activity and glucose data.
41296779|NCT04115631|DRUG|Bendamustine|Given IV
41296780|NCT04115631|DRUG|Bendamustine Hydrochloride|Given IV
41296781|NCT04115631|DRUG|Cytarabine|Given IV
41296782|NCT04115631|BIOLOGICAL|Rituximab|Given IV
41296783|NCT03851393|OTHER|Induction of cough with inhaled citric acid|perform artificially induced cough by inhalation of citric acid at various strengths
41458030|NCT02357927|BEHAVIORAL|Mini-AFTERc|20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
41458031|NCT02357927|BEHAVIORAL|telephone call|this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
40969466|NCT05490641|BEHAVIORAL|Standard feedback|Participants will wear a Fitbit activity tracker and receive non-personalized text messages over a 12-week period.
41296784|NCT03851393|PROCEDURE|Peptest™ analysis of saliva pepsin|collect patient saliva for analysis of pepsin levels
41296785|NCT03851393|DIAGNOSTIC_TEST|Peptest™|The Peptest™ lateral flow device
41458032|NCT06289296|OTHER|Fatty acid intake in lean and obese males|Acute and chronic intake of MCT and LCT
41458033|NCT06377007|DEVICE|IOLMaster 700 (Carl Zeiss Meditec AG)|Subjects will undergo measurements with the IOLMaster 700 device.
41458034|NCT06377007|DEVICE|Argos (Alcon Laboratories, Inc.)|Subjects will undergo measurements with the Argos device.
40969467|NCT03647033|DEVICE|iStent implantation|The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.
40969468|NCT05704361|DRUG|RO7121932 IV - SAD|Part 1: Participants will receive a single dose of RO7121932 administered as IV infusion.
40969469|NCT05704361|DRUG|RO7121932 SC - SAD|Part 2: Participants will receive a single dose of RO7121932 administered as SC injection.
40969470|NCT05704361|DRUG|RO7121932 - MAD|Part 3: Participants will receive multiple doses of RO7121932 administered as SC injections.
40969471|NCT01866696|DEVICE|oral implants|"For all cases, the following surgical and prosthetic protocol was followed.:~* Clinical examination~* Radiological examination~* Guided oral implants insertion~* Immediate Prosthetic loading~* Follow-up"
40969472|NCT01378949|DRUG|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
40969473|NCT01378949|DRUG|Morphine|Morphine 1 mg/cc
40969474|NCT02164760|DEVICE|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
40969475|NCT01083368|DRUG|temsirolimus|Given IV
40969476|NCT01083368|BIOLOGICAL|bevacizumab|Given IV
40969477|NCT01083368|GENETIC|polymorphism analysis|Correlative studies
40969478|NCT01083368|OTHER|laboratory biomarker analysis|Correlative studies
40969479|NCT06056037|BEHAVIORAL|Experimental: Making ART Work|A culturally tailored, theoretically grounded provider-facilitated group-based social support intervention (4 sessions) that emphasizes a collective approach to ART adherence and includes establishing a common understanding of ART, identifying potential barriers to ART adherence with a focus on social and structural barriers (e.g., stigma, relationship influences, family support, economic stressors), developing practical strategies to increase self-esteem and self-efficacy to enhance ART adherence, and generating and maintaining peer norms and support for ART adherence within one's social group. These sessions will include SGM youth-specific video vignettes that address the social/contextual realities faced by SGM YLWH in Brazil. Lastly, the intervention includes daily SMS text messaging that serve as both reminders and cognitive cues to take medication as prescribed.
41138603|NCT03345407|DRUG|Nemiralisib ELLIPTA 500 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
41458035|NCT00000516|DRUG|enalapril|
41458036|NCT06326424|DEVICE|Empatica EmbracePlus|wear a biosensor watch to passively collect biosensor data over 48 hours. The EmbracePlus will collect heart rate variability, accelerometry, and electrodermal activity.
41458037|NCT05475717|DRUG|Alprostadil liposome injection|Alprostadil liposome injection, iv drip, QD×4 days (1 to 3 hours before surgery and 3 days after surgery)
41458038|NCT01118234|DRUG|Rituximab|Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
41458039|NCT00725764|DRUG|GSK1363089 (foretinib)|Multitargeted tyrosine kinase inhibitor
40969480|NCT06056037|BEHAVIORAL|Standard of Care|Prior to randomization, all participants will meet briefly with a counselor to assess current needs for standard HIV primary care and referrals to social and/or health (including mental health) services. If participants do not have a primary HIV care provider, they will be linked to a provider at INI-Fiocruz or their preferred clinic, where they can access free HIV care through the no-cost universal access program of the Brazilian Public Health System. Additionally, the counselor will provide necessary referrals as needed, e.g., for social, general health and/or mental health services. Additionally, in order to provide a baseline level of standardized adherence information, all participants will receive a brief adherence educational session, which consists of a review of medications and recommended dosing, adherence expectations, toxicity expectations, and medication misperceptions.
40969481|NCT02206334|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
40969482|NCT05989984|DIETARY_SUPPLEMENT|ODF Iron Supplement|ODF iron supplement will be admistered daily for 8 weeks.
40969483|NCT05989984|DIETARY_SUPPLEMENT|Iron Supplement in Capsules|Iron supplement in capsule will be admistered daily for 8 weeks.
41296786|NCT06064695|DEVICE|Whole-body Electrical Muscle Stimulation Exercise|This is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs using an iPad App. The stimulation suit (fitted shorts/shirt, vest, leg straps, arm straps) will be donned with the assistance of trained research personnel. Muscle groups stimulated include biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings. The stimulation level of each individual muscle group can be tailored to participant responses and tolerance (i.e. stimulation of the quadriceps and biceps can occur at different settings). While the participant is following along with the video, a qualified health care professional will be monitoring and adjusting the stimulation levels based on participant responses; rate of perceived exertion will also be monitored to ensure safe moderate intensity levels are maintained.
41458040|NCT00968916|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
41458041|NCT01581892|PROCEDURE|Osteosynthesis|To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
41458042|NCT02587143|DRUG|Ethyl chloride|Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
41458043|NCT02587143|DRUG|Alcohol|Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
41458044|NCT02552082|DEVICE|Scorpio NRG posterior stabilized (PS)|
41458045|NCT04491734|DIETARY_SUPPLEMENT|maltosyl-isomalto-oligosaccharides (MIMO)|Digestion-resistant carbohydrate, ISOT-101, a specific formulation of maltosyl-isomalto-oligosaccharides (MIMO), that serves as a prebiotic, feeding selected bacteria that commonly inhabit the human GI tract.
41458046|NCT00591071|OTHER|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
40969484|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 10 mg administered once daily in the morning
40969485|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 15 mg administered once daily in the morning
40969486|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 20 mg administered once daily in the morning
40969487|NCT05246761|DEVICE|Balloon catheter|In the two groups, if their bishop score \<6, they will receive the cervical riening by the balloon catheter, and then the oxytocin if necessary.
40969488|NCT01925677|DEVICE|da Vinci® Single-Site™|Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
40969489|NCT02067169|BIOLOGICAL|CMV Infection|Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.
40969490|NCT03143894|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
40969491|NCT03143894|OTHER|Sham tDCS|Sham Transcranial direct current stimulation (tDCS)..
40969492|NCT01929460|DRUG|Ciprofloxacin|ciprofloxacin oral capsule (one capsule twice a day for 3 days)
40969493|NCT01929460|OTHER|Placebo (for ciprofloxacin)|oral placebo capsule (one capsule twice a day for 3 days)
41296787|NCT04955743|DRUG|Pembrolizumab|200 mg intravenous (IV) is administered every 3 weeks
41296788|NCT04955743|DRUG|Lenvatinib|20 mg orally (PO) is administered daily
41296789|NCT00151411|DRUG|Metformin|Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
41296790|NCT00151411|DRUG|Placebo|Placebo
41296791|NCT00151411|BEHAVIORAL|Lifestyle Intervention|A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
41296792|NCT05299827|OTHER|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,
41296793|NCT05682807|DRUG|Caffeine|5-10 mg/kg/day IV maintenance dose given after 24 h for 2 months.
41458047|NCT00591071|OTHER|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
41458048|NCT00274625|DEVICE|Surgisis Gold Graft|Surgisis Gold Graft is placed as an underlay following open bariatric surgery.
41458049|NCT00274625|PROCEDURE|Control|Incision is closed without the placement of a graft material (standard of care control)
41458050|NCT04148287|DRUG|APX001|Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.
41458051|NCT02328040|DRUG|Placebo and Insulin monotherapy via CL|In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)
41458052|NCT02328040|DRUG|Sitagliptin and insulin/novolog via CL|In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog (Sitagliptin and insulin/novolog via CL), Part B
41296794|NCT05682807|DRUG|Probiotic Formula|probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement after two months.
41296795|NCT01707212|BEHAVIORAL|Pain management education|Education about pain management during infant immunization
41296796|NCT01707212|BEHAVIORAL|No pain management education|Control - no education about pain management during infant immunization
41296797|NCT02815397|DRUG|Metformin|given in addition to standard of care treatment
41296798|NCT03634605|PROCEDURE|Chemical pleurodesis|
41296799|NCT03634605|DRUG|Tetracycline Topical Ointment|
41296800|NCT03634605|DRUG|Normal saline|
41458053|NCT01945580|PROCEDURE|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
41296801|NCT03634605|DRUG|Lidocaine 2% Injectable Solution|
41296802|NCT01359826|DRUG|Milnacipran|After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
41296803|NCT00163553|DRUG|Pethidine|
41296804|NCT00163553|DRUG|Placebo|
41296805|NCT06512363|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
40969494|NCT04995991|BEHAVIORAL|RRT rhythm only|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the RRT activities comprise only a rhythm accompaniment and no visual cue.
41296806|NCT06512363|DRUG|Ramelteon placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
41296807|NCT06247540|PROCEDURE|Biopsy|Undergo tissue biopsy
41138604|NCT03345407|DRUG|Nemiralisib ELLIPTA 750 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
41138605|NCT03345407|DRUG|Albuterol (Salbutamol) MDI or nebules|Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
41296808|NCT06247540|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41296809|NCT06247540|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41296810|NCT06247540|PROCEDURE|Computed Tomography|Undergo PET/CT, CT
41138606|NCT03345407|DRUG|Standard of care therapy|SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
41296811|NCT06247540|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41296812|NCT06247540|BIOLOGICAL|Nivolumab|Receive IV
41296813|NCT06247540|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41296814|NCT06247540|BIOLOGICAL|Rituximab|Receive IV
41296815|NCT06247540|DRUG|Venetoclax|Receive PO
41296816|NCT05732155|DRUG|methylenedioxymethamphetamine|The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of MDMA HCl, in participants with PTSD and moral injury, in individual and group treatment settings
41296817|NCT00778999|DRUG|Marvelon|oral contraceptive 1 tablet daily for 14 to 21 days
41296818|NCT03239808|PROCEDURE|Incremental haemodialysis|It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
41296819|NCT03239808|PROCEDURE|Conventional haemodialysis|It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
41296820|NCT03137394|OTHER|Observation|Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury; control group data will be collected at baseline and at the 1-year follow-up.
41296821|NCT01289392|DEVICE|Continuous Positive Airway Pressure (CPAP)|Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
41296822|NCT01289392|DEVICE|Oral Appliance (OA)|Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
41296823|NCT01289392|BEHAVIORAL|Physical Exercise|aerobic and resistance Physical exercise, three times a week, for four months
41296824|NCT02807454|DRUG|Daratumumab|
41296825|NCT02807454|DRUG|Durvalumab|
41296826|NCT02807454|DRUG|Pomalidomide|
41296827|NCT02807454|DRUG|Dexamethasone|
41296828|NCT04863287|BIOLOGICAL|2217LS|Fully Human Monoclonal Antibody
41138607|NCT04425837|BIOLOGICAL|SARS-CoV-2 convalescent plasma treatment|Plasma transfusion of convalescent patients from COVID-19 with negative RT-PCR, and antibody titers of 1:160 or greater at a dose of 400ml distributed in two doses administered on the same day intravenous administration
41296829|NCT04863287|OTHER|0.9% Sodium Chloride (NaCl)|Subcutaneous injection
41296830|NCT02082067|PROCEDURE|Adductor canal|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.
41296831|NCT02082067|PROCEDURE|Femoral|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.
41296832|NCT02082067|PROCEDURE|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
41138608|NCT04425837|OTHER|Standard care|Standard care according to guidelines and national regulations
41138609|NCT01724905|DIETARY_SUPPLEMENT|Modified Stop Light Diet (SLDm)|SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week
41296833|NCT02082067|PROCEDURE|Local anesthetic infusion|Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
41296834|NCT02082067|PROCEDURE|Intravenous analgesia|Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
41296835|NCT02082067|DRUG|Ropivacaine 0,75%|
41296836|NCT02082067|DRUG|Levobupivacaine 0,5%|
41296837|NCT02082067|DRUG|Levobupivacaine 0,125%|
41296838|NCT02082067|DRUG|Ketorolac 30mg|
41296839|NCT02082067|DRUG|Morphine|
41296840|NCT02082067|DEVICE|stimulong sono, Pajunk, Germany|
41296841|NCT01674543|OTHER|Resistance Training|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
40768772|NCT04571502|OTHER|My PATI ( Person Assisted Touchscreen Interface)|My PATI was designed to support communication between PWD and their caregiver, and healthcare provide; promotes person centered care by giving the PWD their voice and specifically by supporting the PWD in expressing their experiences , needs, preferences in care activities (e.g., food choices, clothing), and entertainment ( personalized pictures, videos , and music). My PATI has multiple features including allowing the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the healthcare provider. The clinical trial evaluates the impact of the My PATI interface that relies on touchscreen technology ( two interfaces one for PWD that can be used independently or with assistance, and a 2nd caregiver interface for customization ). The comparison group will receive usual care.
40969495|NCT04995991|BEHAVIORAL|RRT rhythm + visual cue|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the rhythmic accompaniment is synchronize with a visual cue (the verbal stimuli are highlighted using a red font in synchrony with the rhythm).
40969496|NCT04446546|PROCEDURE|Vascular access by pass using a cold stored venous allograft|Creation or surgical repair of a vascular access for hemodialysis using a cold venous allograft
40969497|NCT05290415|DIAGNOSTIC_TEST|DNA methylation testing|DNA CDO1 and CELF4 methylation testing
40969498|NCT02176330|OTHER|ePAQ-PF followed by a telephone consultation.|All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
40969499|NCT02176330|OTHER|ePAQ-PF followed by a face to face consultation|All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
40969500|NCT00616395|DEVICE|No intervention|
40969501|NCT03547180|BEHAVIORAL|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
40969502|NCT03547180|BEHAVIORAL|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
40969503|NCT03547180|BEHAVIORAL|In-vivo exposure|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
41138610|NCT01724905|DIETARY_SUPPLEMENT|Recommended Care Diet|RC diet includes traditional meal plans and 35 fruits and vegetables per week
41138611|NCT01466556|OTHER|Routine laboratory tests|Laboratory tests to determine metabolic syndrome
41138612|NCT02135315|DRUG|Isosorbide Dinitrate|administration of continuous intravenous isosorbide dinitrate to obtain a SBP between 110 and 120 mmHg. After 2 hours from the start of treatment and if the blood pressure goal is not achieved, labetalol is used
40768773|NCT05383482|DRUG|Afuresertib|Afuresertib 125 mg PO on days 1-5, 8-12, 15-19 or Afuresertib 125 mg QD
40768774|NCT05383482|DRUG|Nab paclitaxel|Nab-paclitaxel 80 mg/M2 IV D1,8, Q3W or 100 mg/M2 IV D1,8, Q3W
40969504|NCT03150615|OTHER|Early enteral nutrition|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament. Standard enteral diet, administered through a nasojejunal tube, is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.~After PD, enteral nutrition liquid regimen will be used step by step from postoperative day 1 to postoperative day 7.Patients are targeted to receive calories for 25 kcal/kg/day. Meanwhile, oral food intake was not restricted."
40969505|NCT03150615|OTHER|Saline|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament.~After PPPD,Only Normal Saline were given through nasojejunal tube. Entral nutrition was not administrated. Patients intake food orally at will."
40969506|NCT03150615|DEVICE|nasojejunal tube insertion|
40969507|NCT03150615|OTHER|Oral intake|Patients was encouraged to drink water on postoperative day 1, to eat liquid diet on postoperative day 2, to eat semi-solid on postoperative day 3, to eat solid food on postoperative day 4.
40969508|NCT03067168|DRUG|Bupivacaine|5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.
40969509|NCT03067168|DRUG|normal saline 0.9%|5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
40969510|NCT03358121|DIAGNOSTIC_TEST|Clamp study|Clamp study to achieve high, normal, and lower glucose levels to study the dynamics of Asprosin.
41296842|NCT01674543|OTHER|Concurrent Training|"The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
41296843|NCT01674543|OTHER|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
41296844|NCT00449748|DRUG|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
41296845|NCT01372878|DEVICE|PillCam® COLON 2 procedure|Subjects will undergo a PillCam® COLON 2 procedure which includes ingestion of the PillCam® COLON 2 capsule. PillCam® COLON 2 is a disposable, ingestible capsule that takes video images throughout the digestive system.
41296846|NCT01372878|PROCEDURE|Colonoscopy|"Subjects will undergo standard Colonoscopy procedure 4-6 weeks after PillCam® COLON 2 procedure.~Standard colonoscopy involves placement of a standard endoscope (a thin, flexible plastic tube) into the anus and into the colon, a tiny camera in the endoscope allows the study doctor to see the surface of the colon."
41296847|NCT03255525|OTHER|Deep friction massage P50|Deep friction massage as described by Dr. James Cyriax, applied with the mean pressure (P50)
40768775|NCT05383482|DRUG|Docetaxel|Docetaxel 50 mg/M2 IV D1 Q3W or Docetaxel 60 mg/M2 IV D1 Q3W
40969511|NCT04690491|OTHER|follicular cyclus|Days of cyclus 6-12
40969512|NCT04690491|OTHER|luteal cyclus|Days of cyclus 20-24
40969513|NCT03612505|BEHAVIORAL|Mother groups using principles of UNICEF/World Health Organization's Care for Child Development|"The intervention is expected to occur every two weeks for a total of ten sessions. On the study day, the child- caregiver dyads randomised to intervention group will be shown to the study room. Each intervention session will be estimated to last 90 minutes allocated as follows: 6~* Introduction (10 minutes)~* Lesson on \*Early Childhood Development\* topic (20 minutes)~* Discussions on strengthens in caregiving around this topic and areas for improvement (30 minutes)~* Observe caretakers one-on-one in play role with the child (25 minutes)~* Wrap up/Re-cap (5 minutes) Early Childhood development topics that will be covered include per session are: i) Importance of early childhood development ii) Showing love and building trust iii) Awareness of child's well-being iv) Consistency and daily routines v) Discipline and correction vi) consistency and daily routines vii) Nutrition and cleanliness Viii) Importance of play iX) Dealing with life stresses X) Planning for the future"
40969514|NCT02151591|DRUG|Varenicline|"12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day"
40969515|NCT00887978|DRUG|UT-15C SR|treprostinil diolamine sustained release tablets
40969516|NCT00887978|DRUG|Placebo|
40969517|NCT05801276|DIAGNOSTIC_TEST|Methylation assay|Methylation assay of CDO1 and HOXA9 genes in plasma circulating tumor DNA
40969518|NCT00573534|DRUG|Vyvanse|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
40969519|NCT05077722|DEVICE|Garmin|A smartwatch device that measures subjects level of activity, heartrate, respirations and quality of your sleep at night. Artificial intelligence will be applied to analyze all the data over the course of 12 weeks to monitor and attempt to predict the onset of tantrums or disruptive behavior. Subjects are required to wear the watch at least 70% of the day and night each day for 70% of days during 12 weeks of treatment.
40969520|NCT00552916|DEVICE|Compex Motion Stimulator|'True' Functional Electrical Stimulation Assisted Walking
40969521|NCT00552916|DEVICE|Compex Motion Stimulator|'False' FES
40969522|NCT01402492|DRUG|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
40969523|NCT01402492|DRUG|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
40969524|NCT04717791|DEVICE|Vivaer® ARC Stylus|The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions
40969525|NCT00054145|DRUG|perifosine|
40969526|NCT06040060|DRUG|Ketamine|The intervention was prepared by the research team (anesthesia resident) in the form of ketamine which had been diluted to a dosage of 10 mg/cc, taken according to the required dose based on actual body weight then diluted with 0.9% NaCl to 10 cc. Then the two solutions were given to researchers without knowing the contents of the drugs that had been prepared by the resident who assisted in this research.
40969527|NCT06040060|OTHER|Placebo|While the 0.9% NaCl solution was used as placebo was prepared in a 10 cc syringe
40969528|NCT06219512|BEHAVIORAL|CPET exercise prescription|Exercise mode: walk Frequency: 5 times/week
40969529|NCT06219512|BEHAVIORAL|6MWT exercise prescription|Exercise mode: walk Frequency: 5 times/week
40969530|NCT06219512|BEHAVIORAL|Regular exercise|Regular exercise
40969531|NCT02912910|OTHER|Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
40969532|NCT02912910|OTHER|Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
40969533|NCT03724760|OTHER|personalized repeated feedback approach|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
40969534|NCT05554094|DRUG|Psilocybin|Participants will receive 15 mg of oral psilocybin in the first session and 25 mg in the second session.
40969535|NCT01911078|PROCEDURE|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
40969536|NCT01911078|DEVICE|EnligHTN™ Renal Denervation System.|
40969537|NCT01937728|DRUG|A: Peg-interferon alpha-2a & Ribavirin|Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA \< 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
40969538|NCT01937728|DRUG|B: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks."
40969539|NCT01937728|DRUG|C: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
40969540|NCT01937728|DRUG|D: Peg-interferon alpha-2a & Ribavirin|Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
40969541|NCT01937728|DRUG|E: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
41296848|NCT03255525|OTHER|Deep friction massage P25|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 25 of the mean pressure (P25)
41296849|NCT03255525|OTHER|Deep friction massage P75|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 75 of the mean pressure (P75)
41296850|NCT05360615|DRUG|Empagliflozin 10 MG|SGLT2 inhibitors
41296851|NCT05360615|DRUG|Placebo|Placebo
40768776|NCT05383482|DRUG|Sintilimab|Sintilimab 200 mg Q3W
40768777|NCT05301127|DEVICE|spinal-epidural device|received combined spinal-epidural-general anesthesia.
40768778|NCT06218537|DIAGNOSTIC_TEST|Test group|Contains protease from KREON capsules, activated by adding sodium bicarbonate.
40969542|NCT01937728|DRUG|F: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks."
40969543|NCT03890081|OTHER|Questionnaire|Translate and culturally adapt the original English version of the Coping Strategies Questionnaire into Turkish
40969544|NCT03715010|DIETARY_SUPPLEMENT|BCAA|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa
40969545|NCT04963777|DIETARY_SUPPLEMENT|Prebiotic|Chicory root derived inulin-type fructan (13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ages ≥14 years)
41296852|NCT04818450|DRUG|Gabapentin|Gabapentin 100-300 mg is given to the intervention group
41296853|NCT04209868|DRUG|Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection|As per arm description
41296854|NCT04209868|DRUG|0.9% Sodium Chloride 20mL Injection|As per arm description
40969546|NCT04963777|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (isocaloric; 13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ≥14 years)
40969547|NCT04346602|OTHER|all treatment about COVID-2019|All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.
41296855|NCT02461732|BEHAVIORAL|Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings"
41296856|NCT02461732|BEHAVIORAL|Cognitive-Behavioral Therapy for Substance Dependence|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities"
41296857|NCT01187797|OTHER|Emotional stimulation|Increase of the physical correlates of an emotion
41296858|NCT01605071|DRUG|Estradiol|"1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo"
41296859|NCT06260176|BEHAVIORAL|exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
41296860|NCT06260176|BEHAVIORAL|exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
41296861|NCT06260176|BEHAVIORAL|exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
41296862|NCT06260176|BEHAVIORAL|exposure to sweetened beverage tax messaging|Message reminding consumers to make healthier choices
41138613|NCT04084262|DEVICE|Intramedullary Nail|Subjects undergo a Lapidus Arthrodesis procedure combined with a supinating reduction technique to create a multi-plane correction of hallux valgus
41138614|NCT06440915|OTHER|Theraputic drug monitoring|High Performance Liquid Chromatography (HPLC) is used to determine the plasma concentrations of isavuconazole
41296863|NCT03898583|DRUG|Microarray patch A|Microarray patch
41296864|NCT03898583|DRUG|Microarray patch B|Microarray patch
41296865|NCT03898583|DRUG|Placebo|Microarray patch vehicle
40969548|NCT05912621|DRUG|Tirzepatide|Tirzepatide dose is titrated up by 2.5 mg every four weeks as per below, starting with 2.5 mg weekly and maxing out at 15 mg.
41296866|NCT03898583|DRUG|Daivobet|Daivobet Gel
41296867|NCT03750110|OTHER|Intervention|"In addition to usual care, personalised feedback from the participants screening appointment will be provided;~* For participants with emphysema, an image of their own emphysematous lung compared to a library image of normal lung, or a section of their own non-emphysematous lung. Where emphysema is not present, library pictures showing normal and emphysematous lung will be used.~* For participants with coronary artery calcification, a cross sectional segment from their chest scan (either horizontal or vertical) showing the calcium compared to a library image of coronary arteries without calcification and/or a healthy section of the participant's own heart scan. Where coronary artery calcification is not present, library pictures showing normal and calcified coronary arteries will be provided."
41296868|NCT03750110|OTHER|Usual Care|Smoking cessation support in line with NICE PH48 guidelines
41138615|NCT06440915|DRUG|Isavuconazole|Isavuconazole
41296869|NCT00279500|DEVICE|Argus 16 Retinal Stimulation System|The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
41296870|NCT00317941|DRUG|Betaferon/Betaseron|250ug administrated with Betaject
41296871|NCT00317941|DRUG|Rebif|44ug administered with Rebiject II
41296872|NCT00317941|DRUG|Betaferon/Betaseron|250ug administrated with Betaject light
41296873|NCT05366907|OTHER|No intervention is done|It is a descriptive cross-sectional study so no groups like case/controls are present. All the cases are included in the study.
41296874|NCT05521685|PROCEDURE|Endoscopic Ultrasound (EUS) administration of cyanoacrylate tissue adhesive to control bleeding gastric varices|Subjects will have undergone treatment and been enrolled into the existing registry.
41296875|NCT03132246|DIAGNOSTIC_TEST|Blood draws|The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
41458054|NCT05634941|DEVICE|Active ON-tDCS|DC was transmitted via a saline-soaked pair of surface sponges and delivered by specially developed, battery-driven, constant current stimulator with a maximum output of 2 mA. For each participant receiving ON-tDCS, the anodal electrode placed over the left C2 nerve dermatome, and cathodal electrode placed over the right C2 dermatome. A constant current of 1.5 mA was applied for 20 min.
41458055|NCT05634941|DEVICE|Sham ON-tDCS|For sham group, placement of the electrodes was identical to that of active ON-tDCS. ON-tDCS was first switched on in a ramp-up fashion over 5 s. Current intensity (ramp down) was gradually reduced (over 5 s) as soon as ON-tDCS reached a current flow of 1.5 mA. Hence, sham ON-tDCS only lasted 10 s (as opposed to 20 min in the active group).
41458056|NCT04908540|PROCEDURE|Mini-screw Assissted Rapid Palatal Expansion|Mini-screw assissted RPE will be the main intervention in the two comparative groups. In the control (group A) will be used with its conventional activation protocol. While in experimental (group B) will be used with ALT-RAMEC protocol.
41458057|NCT04785911|DRUG|Antiemetic Combinations|Evaluation of response to treatment of hyperemisis gravidarum (antiemetics and other methods ) by PUQE score
40969549|NCT05283421|DIAGNOSTIC_TEST|Estrogen|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
40969550|NCT05283421|DIAGNOSTIC_TEST|Placebo|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
40969551|NCT02709733|BEHAVIORAL|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
40969552|NCT05279937|DRUG|Dextrose 50% Intravenous Solution|5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
41296876|NCT02429427|DRUG|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
41296877|NCT02429427|OTHER|Placebo|Two capsules once daily with food
41296878|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|1200 mg per os, once a day, 8 weeks
41458058|NCT04011098|DRUG|Epidural Fentanyl Bolus|Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
40969553|NCT05279937|DRUG|Lidocaine 1% Injectable Solution|10mL of 1% Lidocaine (Control)
40969554|NCT03676257|OTHER|Endocrine therapies|No intervention
41296879|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|600 mg per os, twice a day, 8 weeks
41296880|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|0 mg per os, daily, 8 weeks
41296881|NCT04532463|DRUG|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week|To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
41296882|NCT02146989|OTHER|reproducibility of upper extremity strength measurements|inter-rater reliability and test-retest reliability
41296883|NCT01883583|DEVICE|Contrast-enhanced Ultrasound And Sonoelastography|Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
41296884|NCT02847936|PROCEDURE|vicryl plus suture|episiotomy with triclosan-coated sutures
41296885|NCT02847936|PROCEDURE|vicryl suture|episiotomy with non antibacterial coated suture
41296886|NCT00895232|DRUG|Cohort I|
40969555|NCT04982809|DRUG|Betamethasone, Dexamethasone, Prednisolone|Corticosteroids
40969556|NCT00438984|DRUG|cyclophosphamide|Given IV
41296887|NCT00895232|DRUG|Cohort II|
41296888|NCT00895232|DRUG|Cohort III|
41296889|NCT01294254|DRUG|Oleogel-S10|Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
41296890|NCT01294254|PROCEDURE|Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site|wound is covered conventionally by applying one half of the Mepilex cut
41296891|NCT05910736|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
41296892|NCT04457726|BIOLOGICAL|SARS-CoV-2 Specific T Cells|Eligible patients will receive a single infusion of SARS-CoV-2 specific T cells intravenously.
41296893|NCT00087204|DRUG|becatecarin|Given IV
41296894|NCT00087204|OTHER|laboratory biomarker analysis|Correlative studies
41296895|NCT05933291|DRUG|steroid|Moderate- or high-dose steroids
41296896|NCT04988516|DEVICE|Virtual reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
41296897|NCT04988516|OTHER|Standard protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. The research nurse will be able to complete any information should they find it incomplete or substandard.
41296898|NCT05329688|PROCEDURE|novel nutrition program|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
41296899|NCT00734422|BEHAVIORAL|Virtual Reality Exposure Therapy|Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
41296900|NCT05840289|OTHER|fractionated first dose rituximab|Patients at high-risk to develop tumor lysis syndrome received a initial fractionated dose of rituximab over 2 or 3 days
41296901|NCT02310958|PROCEDURE|Laparoscopic surgical hernia repair|Laparoscopic surgical hernia repair in children
41296902|NCT01695980|PROCEDURE|ETT with non modified retractor|adenotonsillectomy
41296903|NCT01695980|OTHER|LMA with modified retractor|LMA with modified retractor
41296904|NCT05666011|DEVICE|M22 IPL|IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.
40969557|NCT00438984|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
40969558|NCT00438984|BIOLOGICAL|aldesleukin|Given IV or SC
40969559|NCT00438984|OTHER|immunohistochemistry staining method|Correlative studies
41138616|NCT00053300|DRUG|thalidomide|oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
41138617|NCT00053300|PROCEDURE|adjuvant therapy|Patients receive oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
41138618|NCT06306222|DEVICE|Laser lithotripsy|Ureteroscopic laser lithotripsy
41138619|NCT02072330|DRUG|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
41138620|NCT02072330|DRUG|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
41296905|NCT02257814|BEHAVIORAL|Incredible Years Teacher Training|
41296906|NCT02257814|BEHAVIORAL|Preschool PATHS|
41296907|NCT02257814|BEHAVIORAL|Tools of the Mind|
41296908|NCT03471091|DEVICE|NIV with the integrated tele-monitoring management program|Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.
41296909|NCT05321797|OTHER|Aerobic Training|This group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 12-week period
41458059|NCT04011098|DRUG|Standard Epidural Group|The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
40969560|NCT00438984|PROCEDURE|biopsy|Optional correlative studies
40969561|NCT00438984|OTHER|laboratory biomarker analysis|Correlative studies
40969562|NCT00438984|OTHER|immunologic technique|Correlative studies
40969563|NCT00438984|GENETIC|polymerase chain reaction|Correlative studies
40969564|NCT05565872|BEHAVIORAL|Urban training|A community-based exercise intervention (Urban Training) by using public spaces and urban walkable trails, adapted to each patient needs and capabilities
40969565|NCT03566316|DRUG|Telmisartan/Amlodipine|
40969566|NCT03566316|DRUG|Rosuvastatin|
40969567|NCT03566316|DRUG|Telmisartan|
40969568|NCT06327347|DEVICE|intraocular lens implantation in cataract surgery|Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
40969569|NCT01307007|DRUG|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
40969570|NCT01307007|DRUG|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
40969571|NCT04096963|DEVICE|The WATCHMAN FLX Delivery System|WATCHMAN FLX Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium
40969572|NCT05037708|PROCEDURE|Manual lymphatic drainage|"Subjects are randomly assigned to group 1. Group 1 receives treatment A\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B\*\* was applied to group 1 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment"
40969573|NCT05037708|PROCEDURE|Manual lymphatic drainage|"Subjects are randomly assigned to group 2. Group 2 receives treatment B\*\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A\* was applied to group 2 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment"
40969574|NCT04572932|DRUG|lactobacillus delbruekii|Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl
40969575|NCT03415191|DRUG|Ketamine|A bolus dose of ketamine 1 mg/kg intravenously five minutes before surgical incision
40969576|NCT03415191|DRUG|Normal Saline|A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
40969577|NCT01835587|DRUG|CC-486|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
40969578|NCT00577681|DRUG|Antiretroviral Therapy (ART)|Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
40969579|NCT03064451|PROCEDURE|cartofinder guided ablation followed by PVI|cartofinder guided ablation followed by PVI
40969580|NCT05350111|BEHAVIORAL|lifestyle education|education on healthy lifestyle through group sessions and telemedicine tools
40969581|NCT03598556|DIETARY_SUPPLEMENT|Vitamin D3|180,000IU Vitamin D3 oral emulsion
40969582|NCT03598556|OTHER|Placebo|Placebo
41138621|NCT02072330|DRUG|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
41138622|NCT02072330|DRUG|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
41138623|NCT02072330|DRUG|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
41138624|NCT06312592|BEHAVIORAL|Entrepreneurship School with Gender Lens|"The Entrepreneurship School with Gender Lens (ESGL) is an approach that targets gender based violence survivors and women at-risk to help them develop business ideas, access needed support for the prevention of and response to GBV, exploitation and trafficking, and improve participants' overall self-reliance. Participants will go through a general business curriculum, work on business plans and learn gender issues and ways to mitigate GBV risks. Upon training completion, participants are eligible to pitch their business idea to a panel of experts and receive $800 of seed capital. They will also receive follow-up business advisory support for at least six months, focusing on access to markets and finance and building support networks, in order to continue building self-reliance.~The ESGL will also include a mental health and psychosocial support module."
41296910|NCT05321797|OTHER|Conventional Physiotherapy|This group will be administered with Conventional Physiotherapy that includes 5 minutes of stretching exercises for quadriceps, hamstrings and gastrocnemius, 5 minutes of trunk control training, 5 minutes walking in the hall with and without the therapist assistance, walker or crutches, and finally 5 minutes of breathing exercises for Relaxation
40768779|NCT06218537|DIAGNOSTIC_TEST|Control group|Contains only sodium bicarbonate.
40768780|NCT05642338|DIAGNOSTIC_TEST|WATS3D|the WATS3D brush samples the esophagus by abresing the tissue. the brush is directed through the workingchanel of endoscope into the oesophagus
40969583|NCT00449020|DRUG|Carboplatin|CARBOPLATIN (AUC=2) IV in 250 cc NS over 30 minutes, weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
40969584|NCT00449020|DRUG|Docetaxel|DOCETAXEL 75 mg/m2 IV over one hour every three weeks for 3 cycles.
40969585|NCT00449020|DRUG|irinotecan hydrochloride|IRINOTECAN 30 mg/m2 IV over 90 minutes weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
41296911|NCT04710589|RADIATION|CTV|According to the clinical conditions of the patients, they will be assigned to two groups based on the doctor's recommendations and their own wishes
40969586|NCT00449020|RADIATION|radiation therapy|Radiotherapy will start on the first day of scheduled chemotherapy. The daily administered dose will be 1.8 Gy, 5 days a week for 4.4 weeks, 22 fractions, ( 39.6 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV). After 39.6 Gy, the same targets will be treated by oblique fields at 1.8 GY for 3 fxs to a toal dose of 45 GY. Thereafter, the primary tumor and involved nodal metastasis (secondary planning target volume SPTV) will be boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose will be 63 Gy in 35 fractions over seven weeks.
40969587|NCT05104229|DRUG|Aspirin 81Mg Ec Tab|Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
40969588|NCT05104229|DRUG|Standard of Care|Standard of Care VTE prophylaxis
41138625|NCT00051753|DRUG|levofloxacin; amoxicillin/clavulanate|
41138626|NCT00311545|BIOLOGICAL|CNTO 328|Anti-IL-6 chimeric monoclonal antibody
41138627|NCT00861874|DRUG|Decitabine|20 mg/m2 IV, Days 1-5
41138628|NCT00861874|DRUG|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
40969589|NCT04318795|PROCEDURE|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
40969590|NCT04318795|PROCEDURE|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
40969591|NCT03229278|DRUG|Enzyme Inhibitor Therapy|Given trigriluzole PO
40969592|NCT03229278|OTHER|Laboratory Biomarker Analysis|Correlative studies
40969593|NCT03229278|BIOLOGICAL|Nivolumab|Given IV
41458060|NCT05223608|OTHER|ImmuCCo Cohort|Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.
40969594|NCT03229278|BIOLOGICAL|Pembrolizumab|Given IV
40969595|NCT04316715|BEHAVIORAL|Lifesteps for PrEP|Four weekly nurse delivered counseling sessions plus two optional booster sessions. Sessions last approximately 40-50 minutes each. Sessions employ cognitive behavioral (CBT) techniques, motivational interviewing (MI), and psychoeducation.
40969596|NCT04316715|BEHAVIORAL|Daily text message reminders|Participants get daily text messages on their cell phone reminding them to take their PrEP medication.
40969597|NCT03553667|DEVICE|Standard group|Use radial arterial line to monitor mean arterial pressure
41296912|NCT03095534|BEHAVIORAL|3-Step Workout for Life|a 10-week moderate exercise program
40969598|NCT03553667|DEVICE|ClearSight|Use Edwards EV1000 Clinical Platform NI with ClearSight finger sleeve to monitor SV(stroke volume)
40969599|NCT00957775|BEHAVIORAL|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.
41296913|NCT04481425|OTHER|SMS intervention|SMS intervention
40969600|NCT00957775|BEHAVIORAL|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
40969601|NCT06041867|BIOLOGICAL|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
40969602|NCT06041867|DIETARY_SUPPLEMENT|Agaricus bisporus capsules|Participants have to consume 10 capsules per day containing 500 mg Agaricus bisporus powder each, corresponding to a total Agariicus bisporus powder intake of 5 g daily
40969603|NCT06041867|DIETARY_SUPPLEMENT|Control capsules|Participants have to consume 10 capsules per day containing 500 mg maltodextrin each, corresponding to a total maltodextrin intake of 5 g daily
41458061|NCT02577133|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
41458062|NCT02577133|DIETARY_SUPPLEMENT|Placebo|The placebo consisted of an identical bottle with distilled water
41458063|NCT02054754|DRUG|Dexanabinol Dose Level 1|Oral formulation of dexanabinol
40969604|NCT05070299|BEHAVIORAL|Psychosexual Educational Partner Program (PEPP)|A communication and intimacy promotion kit consisting of three modules devoted to information sharing, partner communication and activities for building intimacy.
40969605|NCT01738321|OTHER|Cuff pressure|Measuring endotracheal tube (ETT) cuff pressure
40969606|NCT00019097|DRUG|autologous tumor cell vaccine|
40969607|NCT00019097|DRUG|keyhole limpet hemocyanin|
40969608|NCT00019097|DRUG|melphalan|
40969609|NCT00019097|DRUG|sargramostim|
41138629|NCT02134782|BEHAVIORAL|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
41296914|NCT01306058|DRUG|TRC 105|15 mg/kg intravenous (IV) every 2 weeks
41296915|NCT01306058|DRUG|Sorafenib|400 mg twice a day (bid) continuously in a 28 days cycle
41296916|NCT01356602|DRUG|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
41296917|NCT01356602|DRUG|Canakinumab lyophilized powder|Canakinumab lyophilized powder
41296918|NCT01356602|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide
41458064|NCT02054754|DRUG|Dexanabinol Dose Level 2|Oral formulation of dexanabinol
41458065|NCT02054754|DRUG|Dexanabinol Dose Level 3|Oral formulation of dexanabinol
40969610|NCT06311201|OTHER|Abdominal belt|This was used for all women in both groups (A and B) for 8 weeks starting from the 7th days after delivery. The women was asked to wear the abdominal belt throughout the day except when bathing, eating and sleeping. The binder was worn over the skin directly or on a thin layer of clothing. The side of the abdominal binder without the straps was pulled over by the woman's stomach with one hand. The side of the binder with straps was stretched across the stomach and pulled to the center of the abdomen. The straps then was fitted into the buckles. Women were instructed not to wear the binder too tight or too loose as it might irritate the skin and produce difficulty in breathing creating discomfort. They were asked to inspect their skin regularly for any signs of sensitivity.
40969611|NCT06311201|OTHER|Pilates exercises|"The Pilates exercise program for the study group (B) consisted of a 10-minute warm-up with low-intensity exercises, followed by a 40-minute central part with floor exercises like leg circles, kicks, and stretches. It included the classic hundred exercise, performed with proper form. Each exercise had two sets of 10 repetitions. The session ended with a 10-minute cool-down of stretching exercises, supervised by a physical therapist. The program was conducted three times per week, one hour per session, for eight weeks, starting from the 7th day after delivery."
40969612|NCT05006911|DRUG|Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound|To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
40969613|NCT01433614|DRUG|Epirubicin|75 mg/m2 i.v. every 3 weeks, both study arms
40969614|NCT01433614|DRUG|Paclitaxel|175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
40969615|NCT01433614|DRUG|Capecitabine|1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
40969616|NCT00510120|BEHAVIORAL|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
40969617|NCT00510120|BEHAVIORAL|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
40969618|NCT00510120|BEHAVIORAL|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
40969619|NCT05024591|DEVICE|Lunit INSIGHT MMG CADe/x for medical imaging|• A software that detects areas suspected of breast cancer using mammographic images, marks areas suspected of malignant lesions, and displays the probability of malignant lesions to assist with the interpreting physician's diagnosis
41296919|NCT01356602|DRUG|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
41296920|NCT00271440|PROCEDURE|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
40768781|NCT05145010|DRUG|Infigratinib|Infigratinib minitablets or sprinkle capsules to be administered by mouth. In subjects that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
41138630|NCT02134782|OTHER|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
41296921|NCT02684240|DRUG|Nitazoxanide|nitazoxanide 1000 mg orally twice daily with food for 14 days
41296922|NCT02684240|OTHER|Control|The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
41458066|NCT02054754|DRUG|Dexanabinol Dose Level 4|Oral formulation of dexanabinol
40768782|NCT05145010|DRUG|Infigratinib|Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the subjects naïve to Infigratinib will be 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
40969620|NCT01308775|BEHAVIORAL|SIS.NET, Routine Follow-up|"* SIS.NET - One or two oncology related clinic visits per year (as recommended by the American Society of Clinical Oncology breast cancer follow up guidelines (18)), with additional access to oncology care driven by ongoing review of patient's self reported symptoms through web-based questionnaires.~* Routine follow up care with appointment frequency determined by the treating medical oncologist or oncology/breast surgeon. Patients complete the same web-based symptom questionnaires within 30 days of a scheduled clinic visit but the results are not reviewed until their clinic visit."
40969621|NCT03207854|PROCEDURE|Biospecimen Collection|Undergo collection of peripheral blood, bone marrow, and tissue
40969622|NCT03207854|OTHER|Laboratory Biomarker Analysis|Correlative studies
40969623|NCT03207854|OTHER|Questionnaire Administration|Ancillary studies
40969624|NCT02321644|DRUG|CC-90001|CC-90001 Active-ingredient-in-capsule and formulated tablet
40969625|NCT01346228|BEHAVIORAL|Panic Control Treatment (PCT)|2 Day treatment for Panic Disorder
40969626|NCT06506201|DEVICE|Velys hip navigation|Computer assisted surgery
40969627|NCT06506201|PROCEDURE|Standard of care|surgery without navigation
40969628|NCT05479084|OTHER|Kinesiotaping|Kinesio taping will be applied on the lower part of the trapezius.
41458067|NCT02054754|DRUG|Dexanabinol Dose Level 5|Oral formulation of dexanabinol
41458068|NCT02054754|DRUG|Placebo|
40969629|NCT02807532|OTHER|atrial fibrillation|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
40969630|NCT02807532|OTHER|non-atrial fibrillation|In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
41458069|NCT01647997|OTHER|bacterial endotoxin challenge|iv administration of 2ng/kg bacterial endotoxin
40969631|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
41138631|NCT01456156|RADIATION|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
40969632|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
40969633|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
40969634|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
40969635|NCT01385566|BIOLOGICAL|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
40969636|NCT01385566|BIOLOGICAL|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
40969637|NCT06281600|DIETARY_SUPPLEMENT|Human milk oligosaccharide|5g daily dose of HMOs.
40969638|NCT06281600|DIETARY_SUPPLEMENT|Maltodextrin placebo|5g daily dose of maltodextrin.
41138632|NCT00391066|DRUG|FCR + Lumiliximab|Dose, schedule, and duration specified in the protocol
40969639|NCT02685085|DRUG|Misoprostol ( Prostaglandin E2)|
40969640|NCT02685085|DEVICE|Foley's catheter|
40969641|NCT02292277|DRUG|Ticagrelor|Oral loading dose of 180 mg ticagrelor.
40969642|NCT04432896|OTHER|Dietary protocol|Dietary protocol to manage symptoms related to Systemic Nickel Allergy Syndrome.
40969643|NCT01680705|OTHER|High Volume Saline Irrigation|High volume saline irrigation (240 ml)
41458070|NCT01144845|PROCEDURE|Thoracic surgery|Thoracoscopy or anterior thoracotomy
41458071|NCT01435928|DRUG|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
41458072|NCT01435928|DRUG|Matching Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
41458073|NCT03786770|BIOLOGICAL|DaxibotulinumtoxinA for injection|Intramuscular injection
41458074|NCT02489864|DRUG|Terlipressin|
40969644|NCT05808972|DRUG|Sodium chloride 0.9% (SC)|This trial looks specifically at the type of hydratation liquid. The patients included will receive SC. The volume, frequency of fluid administration and other severe DKA therapies, such as insulin therapy and electrolytes, are prescribed similarly. The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
40969645|NCT05808972|DRUG|Ringer lactate (RL)|The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
41138633|NCT00391066|DRUG|FCR|Dose, schedule, and duration specified in protocol
41296923|NCT03637868|DRUG|Eribulin|Patients will receive eribulin 1.4 mg/m² administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
41458075|NCT06534164|DEVICE|Full/High Tech Telerehabilitation decision support system|"The TeleRehaB DSS intervention includes HOLOBalance balance rehabilitation programme delivered via an augmented reality hologram of a virtual physiotherapist. The system delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. It includes different multisensory balance and gait exercises, physical activity and memory training and exergames (video games which are also exercises) to improve balance function in older adults. The system can thus assess and remotely monitor how users are performing the exercises.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme."
41296924|NCT05670847|DRUG|Exogenous ketone ester|500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
41296925|NCT06343207|DEVICE|Percussive massage gun therapy|Between pre and post-test, there was a one and half minute period during which each participant were in a prone position on a medical examination bed. The experimental PT groups received a 30-second triceps surae massage on each limb, while the control group maintained the same prone position without massage. The massage gun was set to 2100bpm and 1 bar of surface pressure was indicated by the device. The massage gun movement was performed according to the manufactu'er's instructions.
41296926|NCT04330508|OTHER|Depression and Cognitive Tests|Health Related Quality of Life, neurocognitive tests, PHES
41296927|NCT03321240|PROCEDURE|visual and quantitative SEEG signal analysis|signal SEEG analysis
41296928|NCT03321240|PROCEDURE|Resective epilepsy surgery procedure|Surgical removal of the epileptogenic brain area
41458076|NCT06534164|DEVICE|Basic/Low Tech Telerehabilitation decision support system|"The basic system does not inlcude exergames, a smartwatch, or a mobile phone for activity tracking.~It includes different multisensory balance and gait exercise, cognitive training and real-time feedback from motion sensors.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme."
41458077|NCT06534164|PROCEDURE|OTAGO Home exercise program|balance rehabilitation program
40969646|NCT04250870|DIAGNOSTIC_TEST|Senior Fitness Test|"Chair stand test:The number of full stands performed on a seated position that can be completed within 30 seconds was recorded.~Arm curl test: The participants were asked to lift weights starting with a full elbow extension and then full flexion.~2-minute step test: The participant was asked to begin stepping as quickly as possible to reach the marked height for two minutes.~Chair sit-and-reach test:The participant could extend right or left knee to a full extension, heel on the floor and ankle in a neutral position of 90 degrees. Then, the participant was asked to reach to the toes.~Back-scratch test:The participant was asked to stand up and place his/her preferred hand over the same shoulder, palm down and fingers extended, and reach down the middle of the back as far as possible.~8-foot up and go test:The participant was asked to get up from a chair without any arm support and walk a distance of 2.44 meters; then turn around a cone and come back to sit down on the chair."
40969647|NCT04030611|DIAGNOSTIC_TEST|tongue diagnosis system|This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.
40969648|NCT01576263|DRUG|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
40969649|NCT01576263|DRUG|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
40969650|NCT05830721|DEVICE|MY01 + Standard of Care|In addition to standard of care, the MY01 device will be inserted by an orthopedic surgeon into the leg on the same side as the ECMO tubing. This will occur within 6 hours of the start of ECMO. Insertion of the device involves a needle, which is removed once the device is inserted. Monitoring of the device will occur as described by the device manufacturer, which includes a mobile application. If at any time the compartment pressures suggest that there may be ACS, an orthopedic surgeon will be called to perform a physical exam. If the physical exam supports the diagnosis of ACS, then an additional pressure measurement with a needle may be also taken to confirm the measurement. If the diagnosis of ACS is made, the decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team. Monitoring of with the device will be done for 24 hours. The device will be removed after 24 hours or if the diagnosis of ACS is made.
40969651|NCT05830721|DEVICE|14-Gauge Slit Catheter + Standard of Care|For the 14-gauge slit catheter group, the exact same protocol will be followed as the MY01 group. The 14-gauge slit catheter consists of tubing that is 14-gauge in size, which is inserted into the leg with a needle. The needle will be removed once the tubing is inserted. The tubing is then connected to a monitor, which will display the pressure in the leg. Just like the MY01 group, the leg will be numbed and cleaned before the tube is inserted in the leg. Instead of the data being recorded on a mobile device, a nurse or nurse technician will document pressure readings every 4 hours for a total of 24 hours. Once monitoring is finished, the 14-gauge slit catheter will be removed from the leg.
40969652|NCT05830721|OTHER|Standard of Care|If assigned to standard of care, the participant will undergo monitoring within 1 hour of the start of ECMO. For standard of care group, this will involve monitoring the leg with the ECMO tubing with physical exam every 4 hours for the first 24 hours. This will be performed by a trained nurse. If at any time there is suspicion for ACS, the physical exam will be verified by an orthopedic surgeon. The orthopedic surgeon will decide if pressure measurements will be necessary. If so, then a single pressure measurement from each compartment will be taken with a needle device. If the ACS diagnosis is made, any further monitoring of that leg is stopped. The decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team, which includes surgeons and medical doctors. This is currently the standard of care at the Johns Hopkins Hospital.
40969653|NCT05614830|OTHER|Dry needling ,|The intervention group will receive sessions of dry needling to relief myofacial pain on trapezius
40969654|NCT05614830|OTHER|usual physical therapy program|Therapeutic exercise
40969655|NCT01129479|DRUG|Galantamine|Galantamine XL 8 mg for 4 weeks, followed by Galantamine XL 16 mg for subsequent 12 weeks. Taken in the morning with food for total of 12 weeks.
40969656|NCT01129479|DRUG|Placebo pill|Placebo pill each morning with food for 12 weeks.
40969657|NCT00948701|BEHAVIORAL|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
40969658|NCT03098953|DRUG|Loteprednol Etabonate|one drop per eye for each eye
40969659|NCT02784808|DRUG|Biological DMARDs|Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
41138634|NCT01386372|DRUG|Tolvaptan|Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
41138635|NCT01386372|OTHER|Standard therapy|Fluid restriction, normal or hypertonic saline, furosemide.
41138636|NCT01705366|PROCEDURE|Non-MAKO® Robot Assisted Total Knee Arthroplasty|Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
41138637|NCT01705366|PROCEDURE|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
41296929|NCT00976768|DRUG|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
41296930|NCT01784510|PROCEDURE|distance of dissection of gastrocolic ligament from pylorus|
41458078|NCT06534164|PROCEDURE|Vestibular rehabilitation program|vestibular rehabilitation and dizziness program
41138638|NCT01705366|PROCEDURE|MAKO® Robot Assisted Medial and PF Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
41458079|NCT00672217|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
41296931|NCT02546856|OTHER|Heart Failure (HF) nurse up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines with cardiologist prescription and support."
40969660|NCT02784808|DRUG|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
40969661|NCT03216889|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.
40969662|NCT03216889|BEHAVIORAL|Control|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
40969663|NCT02285803|DEVICE|transcranial direct current stimulation (tDCS)|
41458080|NCT00672217|BEHAVIORAL|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
40768788|NCT06028412|PROCEDURE|Sublobar|"The minimize unit is the subsegment, the subloar group includes wedge resection, subsegmentectomy, segmentectomy.~It is recommended to perform intraoperative lymph node pathology (not mandatory). If lymph node metastasis is positive, we must switch to lobectomy+system lymph node dissection. lymph node sampling, selective lymph node dissection or systematic lymph node dissection are allowed in this group."
40768789|NCT06028412|PROCEDURE|Lobectomy|lobectomy+system lymph node dissection
40768790|NCT06094296|DRUG|BMS-986315|Specified dose on specified days
40969664|NCT03858114|OTHER|Mild-to-moderate physical activity|"According to ACSM guidelines, mild-to-moderate Physical Activity (PA) will be established as ≤ 60% of the Heart Rate Reserve (HRR). Baseline HR will be registered for all participants for three days, and the mean data will be utilized. PA intervention will consist of three phases:~1. warm up (10 minutes), up to 40% of HRR, with slow, dynamic movements and stretching for principal muscular groups;~2. Active phase (45 minutes), from \>40% to 60% HRR, with static and dynamic exercises for postural control and spine mobility, and balance exercises, with activation of core muscles;~3. cool down (10 minutes), \< 40% of HRR, with cardiorespiratory cool-down exercises followed by relaxation, and post-stretch exercises to return muscles to a pre-exercises length."
40969665|NCT03858114|OTHER|Cultural group program|A cultural group program with 12-weeks thematic meetings on places of historical and artistic interest in the city of Cagliari, Sardinia, with one visit/week to the same sites. The participants will be accompanied by expert tour guides to museums, monuments, city parks and archeological sites.
40969666|NCT03715764|OTHER|Physical therapy assessment|Primary assessment, diagnose and treatment by a physical therapist for patients with knee pain in primary care.
40969667|NCT03715764|OTHER|Physician assessment|Primary assessment, diagnose and treatment by a physician for patients with knee pain in primary care.
41296932|NCT02546856|OTHER|Heart Failure (HF) cardiologist up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines. Drugs are prescribed and titrated by the cardiologist."
41296933|NCT05182502|DEVICE|Tixel|Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage
41296934|NCT06300619|BEHAVIORAL|Pilates+4|12 weeks of seated Pilates twice weekly. In weeks 1-3, participants receive training on hip and shoulder cuff activation. This occurs through active isometric pressure on the stabilizing limb (not the moving limb during a Pilates movement) for 3 seconds at 30% strength using the participants' own hand (e.g., pressure on the outside of the knee with knee pressing against hand) prior to engaging in each exercise. Following the first 3 weeks, participants in the Pilates+4 group engage in the same Pilates protocol as the comparator group, however, they receive 4-quadrant cues for hip and shoulder cuff activation as they learned in weeks 1-3.
41296935|NCT06300619|BEHAVIORAL|Pilates|12 weeks of seated Pilates twice weekly. 18 exercises standard in Pilates instruction will be provided with standard Pilates cues (i.e., core activation, cuing the moving limb, breathing synchronization).
40768791|NCT06094296|DRUG|Nivolumab|Specified dose on specified days
40969668|NCT00867568|DRUG|TPI 287|Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
40969669|NCT00335868|DRUG|danusertib|
40969670|NCT00335868|OTHER|laboratory biomarker analysis|
41296936|NCT03387124|OTHER|Breastfed infants|Breastmilk
41296937|NCT01856491|DEVICE|RELIANCE 4-FRONT™ Passive Fixation lead implantation|Implantation of transvenous defibrillation lead with passive fixation mechanism.
41296938|NCT01175070|DRUG|Intravitreal injection of pegaptanib sodium|Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen \[TM\]) 0.3mg every 6 weeks over a 30 week period.
41296939|NCT02205567|DIETARY_SUPPLEMENT|Bergamot-derived product|Group 1: 500mg/day Group 2: 1000mg/day
40969671|NCT00335868|OTHER|pharmacological study|
41458081|NCT01342991|PROCEDURE|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
40969672|NCT03177694|DEVICE|Wireless bed sensor|Remote data collection
40969673|NCT00138203|DRUG|vorinostat|Given PO
40969674|NCT00138203|OTHER|laboratory biomarker analysis|Correlative studies
40969675|NCT00885430|DRUG|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
40969676|NCT00390468|DRUG|Tandutinib|500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
40969677|NCT05551039|OTHER|Retrospective patient chart review|Retrospective patient chart review to be completed by mCRC-treating physicians. Data is collected through an online case report form (CRF); physicians provide case histories of mCRC patients who initiated regorafenib treatment in most recent 3 years (2019-2021).
40969678|NCT02032121|PROCEDURE|Blood specimen|
40969679|NCT02032121|PROCEDURE|Echocardiography|
40969680|NCT01578460|DEVICE|Continuous Glucose Monitoring|Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
40969681|NCT01578460|DEVICE|Glucose Meter|Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
40969682|NCT03931538|DIAGNOSTIC_TEST|Guidance 4.0 PCR test|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
40969683|NCT03931538|DIAGNOSTIC_TEST|Urine Culture|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
40969684|NCT03428360|DRUG|Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category|The subjects in this study administered DBF themselves or with the help of a caregiver, (trained by the study site staff in study drug administration and documentation) in the same setting as they typically used the diazepam rectal gel or other rescue medication, without the presence of study staff.
40969685|NCT05650216|DRUG|Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)|"1. Neoadjuvant treatment period:~   Radiotherapy: Primary lesions and adjacent lymph nodes: The mode of involved field irradiation (IFI) is adopted, no preventive radiation is given. The total dose is 41.4Gy, 1.8Gy/23f. Distal lymph nodes ≥ 5cm away from the primary lesion: low-dose radiotherapy with a total dose of 4Gy, 0.5Gy/8f, Day1 to Day4, Day22 to Day25.~   Chemotherapy: Carboplatin(AUC=2), Nab-paclitaxel(80mg/m2), Day1/8/15/22/29. Immunotherapy: Camrelizumab(200mg, Day5, Day26).~2. Perioperative period:~   Undergo surgery within 4-6 weeks after neoadjuvant therapy~3. Adjuvant treatment period:~Camrelizumab: (200mg, Q3W)，continued for up to 1 years，until PD or intolerable toxicity."
40969686|NCT01929096|DRUG|Compound Edaravone Injection|
40969687|NCT01929096|DRUG|Edaravone Injection|
40768792|NCT06094296|DRUG|Pemetrexed|Specified dose on specified days
40768793|NCT06094296|DRUG|Cisplatin|Specified dose on specified days
40969688|NCT03383198|DRUG|Liposomal bupivacaine right injection|Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
40969689|NCT03383198|DRUG|Liposomal bupivacaine left injection|Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
40969690|NCT06486376|BEHAVIORAL|Water, Sanitation and Hygiene Education Against Diarrhoea, Undernutrition and Pneumonia|Intervention components include teacher training, stepdown training of teachers to children and distribution of IEC materials.
40969691|NCT03499704|DRUG|Pioglitazone + Alogliptin|Pioglitazone and Alogliptin FDC tablets
40969692|NCT03499704|DRUG|Alogliptin|Alogliptin tablets.
40969693|NCT03499704|DRUG|Metformin|Metformin tablets.
41296940|NCT00769704|BIOLOGICAL|Talimogene laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
40768794|NCT06094296|DRUG|Carboplatin|Specified dose on specified days
40768795|NCT06094296|DRUG|Paclitaxel|Specified dose on specified days
40969694|NCT03499704|DRUG|Dapagliflozin|Dapagliflozin tablets.
40768796|NCT03592264|DRUG|OBI-3424|liquid formulation for Intravenous infusion
40768797|NCT06608303|DRUG|Topical Human Granulocyte Macrophage Stimulating Factor Gel|Human granulocyte macrophage colony-stimulating factor (rhGM-CSF), as a multifunctional haematopoietic factor, stimulates the proliferation and differentiation of haematopoietic precursor cells to granulocyte macrophages and promotes their peripheral translocation, as well as enhances phagocytosis and secretion of granulocytes and macrophages \[11\]. Since macrophages are key players in regulating the inflammatory response of wounds and promoting wound repair, rhGM-CSF is thought to potentially play a positive role in the treatment of acute and chronic wounds.
40768798|NCT06608303|DRUG|Saline (NaCl 0,9 %) (placebo)|placebo
40768799|NCT05046730|DEVICE|Ileostomy Reversal using Self Forming Magnets (SFM)|The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
40969695|NCT01121237|DRUG|Recombinant human erythropoietin alfa (biosimilar)|Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
40969696|NCT04249583|BIOLOGICAL|botulinum toxin|neuromodulator to be injected in the GL region
40969697|NCT04249583|BIOLOGICAL|Placebo|Placebo to be injected in the GL area
40969698|NCT04805424|PROCEDURE|Lipo-abdominoplasty|Abdominoplasty plus liposuction
40969699|NCT04805424|PROCEDURE|Abdominoplasty|Abdominoplasty
40969700|NCT03844646|DEVICE|CGM|Intermittent use of a continuous glucose monitor (CGM)
40969701|NCT03844646|OTHER|Dietitian|Monthly meetings with a dietitian
40969702|NCT00844714|DRUG|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
40969703|NCT04264091|OTHER|Observational|Observational
41296941|NCT00769704|BIOLOGICAL|GM-CSF|125 µg/m² subcutaneous injection
41296942|NCT03501706|BEHAVIORAL|Sequenced Recall of Digits--Auditory|Auditory digit sequence AT memory component.
41296943|NCT03501706|BEHAVIORAL|Sequenced Reverse Recall of Digits--Auditory|Reversed auditory digit sequence AT memory component.
41296944|NCT03501706|BEHAVIORAL|Sequenced Recall of Words--Visual|Visual word sequence AT memory component
41296945|NCT03501706|BEHAVIORAL|Verbal Memory--Visual|word recognition AT memory component
41296946|NCT04166045|DEVICE|Sham Treatment Location|The device applies transcutaneous electrical nerve stimulation to the bicep
40969704|NCT00461162|BEHAVIORAL|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
40969705|NCT00461162|BEHAVIORAL|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
40969706|NCT00461162|BEHAVIORAL|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
40969707|NCT06158373|OTHER|infant massage practice|infant massage practice
40969708|NCT06158373|OTHER|Safe Swaddling|Safe Swaddling
40969709|NCT06158373|OTHER|Control|Control
40969710|NCT03119584|DRUG|linaclotide or placebo|
40969711|NCT05924620|DRUG|finerenone|Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).
40969712|NCT01190774|BEHAVIORAL|Information to health provider without patient knowledge|The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient
40969713|NCT01190774|BEHAVIORAL|dentist behaviour and patient expectancy|patient give information about their dental anxiety to the dentist
40969714|NCT04314336|DRUG|Public procurement|Cost minimisation study through public procurement
40969715|NCT04314336|DRUG|Drug and Therapeutics Committee|Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement
40969716|NCT00904644|DRUG|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
41138639|NCT01705366|DEVICE|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
41138640|NCT01705366|DEVICE|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
40969719|NCT04010149|DEVICE|Active tDCS|For the first two weeks of the study, participants will receive 20 min of brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
40969720|NCT04010149|DEVICE|SHAM tDCS|For the first two weeks of the study, participants will receive 20 min of SHAM brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
40969721|NCT02550106|DRUG|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
40969722|NCT05065632|DIAGNOSTIC_TEST|Wantai kit Elisa|to mesure antibodies against SARSCov-2 recombinant antigen
40969723|NCT05349175|DEVICE|Augmented Infant Resuscitator (AIR)|Real-time visual feedback from the AIR device regarding quality of bag-mask ventilation
41296947|NCT04166045|DEVICE|Verum Treatment Location|The device applies transcutaneous electrical nerve stimulation to the hand
41296948|NCT03212547|BEHAVIORAL|Verbal Intervention|"Promotion of verbal interventions:~1. Detecting whether the infant has social withdrawal.~2. The physician will verbally intervene.~3. Positive response (+) from the infant, the evaluator will point out this to the parents.~4. Negative response (-) from the infant, the evaluator will include the parents in the interaction.~5. If he infant establishes positive contact (+) with the parents, he/she will point out this response to them.~6. If the infant does not establish positive contact (-)with the parents, repeat step 2.~7. If the infant offers a positive response (+) to the second attempt of verbal intervention, the evaluator will point out this response to the parents.~8. At the end of each medical check-up, give and explain the ADBB Intervention Sheet."
41296949|NCT02260193|DRUG|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
41458082|NCT01342991|PROCEDURE|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
40969724|NCT03908697|DEVICE|Mira monitor comparison to ClearBlue monitor|Testing first morning urine with hormone test sticks at home
40969725|NCT01700777|OTHER|"HABIT-ILE"|"90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards)."
40969726|NCT03267758|DIETARY_SUPPLEMENT|Goodbelly first|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This is followed by 6 weeks of placebo.
40969727|NCT03267758|DIETARY_SUPPLEMENT|Placebo first|Consumption of 1 serving of probiotic placebo daily for 6 weeks. of 1 serving of Goodbelly probiotic daily for 6 weeks.
40969728|NCT02481232|BIOLOGICAL|freeze-dried group ACYW135 MCV|Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
40969729|NCT02455232|PROCEDURE|upper limb muscle block|
40969730|NCT02455232|DRUG|4cc of lidocaïne®|
40969731|NCT04397224|DIAGNOSTIC_TEST|Device interrogation|Ventriculo-ventricular conduction time measurement using device analyzer
40969732|NCT02058667|RADIATION|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
40969733|NCT03918720|BEHAVIORAL|Trekkers Family Health Empowerment Programme|Health Assessment, Health Enablement and Health Literacy provided to empower participants awareness towards a healthier life style
40969734|NCT03434275|DRUG|N1539|Once Daily
40969735|NCT03434275|DRUG|Placebo|Once Daily
40969736|NCT01377883|OTHER|standard|"Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.~Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure."
40969737|NCT01377883|BEHAVIORAL|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
40969738|NCT00490360|DRUG|Gemcitabine / Cisplatin|
40969739|NCT04177160|BEHAVIORAL|Music|Subjects sit still and listen to preferred music for 5 minutes.
40969740|NCT04177160|BEHAVIORAL|White noise|Subjects sit still and listen to white noise for 5 minutes.
40969741|NCT02771093|DRUG|Trelagliptin|Trelagliptin 100 mg tablet
40969742|NCT02771093|DRUG|Alogliptin|Alogliptin 25 mg tablet
40969743|NCT00018837|BEHAVIORAL|Community Re-Entry Program: What is Schizophrenia|
40969744|NCT00002169|DRUG|Nelfinavir mesylate|
40969745|NCT02628652|DIETARY_SUPPLEMENT|GOS|
40969746|NCT02628652|DIETARY_SUPPLEMENT|GLOS|
41296950|NCT02260193|DRUG|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
41458083|NCT02284139|DRUG|Arm EGF ointment 1ppm|EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day
41458084|NCT02284139|DRUG|Arm EGF ointment 20 ppm|EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day
40969747|NCT02628652|DIETARY_SUPPLEMENT|FOS|
40969748|NCT01920321|PROCEDURE|Endoscopic lung volume reduction|Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
40969749|NCT03672747|DEVICE|transcranial direct-current stimulation (tDCS)|20 minutes duration using high-definition system with center-surround configuration
40969750|NCT01815515|DRUG|18F-DCFBC|"18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push."
40969751|NCT02744014|BEHAVIORAL|Add-on Therapy for Axial Spondyloarthritis|
40969752|NCT01415284|DRUG|Hydroxyethylstarch 130/0.4|first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
40969753|NCT05867745|OTHER|Interview|As previously specified
41138641|NCT01705366|DEVICE|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
40969754|NCT05867745|OTHER|Survey|As previously specified
41296951|NCT02260193|DRUG|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
40969755|NCT05867745|OTHER|Letter to a friend (autoethnography)|As previously specified
40969756|NCT02893514|OTHER|Screening Only (SO) condition|Patient and PCP are not presented with screening results. The PCP does not receive clinical decision support, or clinical reminders.
40969757|NCT02893514|OTHER|SUSIT Condition|Following completion of substance use screening, the tablet computer presents screening results (including level of risk) to the patient for each substance used, asks them to identify their drug of most concern (DOMC), and assesses readiness and confidence to change behavior. Results are delivered to the PCP at the point of care, paired with clinical decision support tailored to the patient's screening results. This information is delivered on the tablet computer, which is handed to the PCP by a Medical Assistant. CDS guides the PCP through a brief intervention specific to the DOMC, recommends clinical actions pertaining to the substance and risk level, and generates a printed summary for the patient. At each scheduled follow-up medical visit, the PCP receives a clinical reminder containing a summary of the patient's substance use and level of risk, paired with CDS that guides them through a follow-up brief intervention.
40969758|NCT02183194|DEVICE|Lutonix Paclitaxel Drug Coated Balloon|
40969759|NCT02835924|DRUG|Regorafenib|
41458085|NCT02284139|DRUG|Arm Placebos|EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
41458086|NCT03774199|DEVICE|NightOwl|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
40969760|NCT05339737|DEVICE|Nociception Level (NOL) Index|The NOL integrates multiple physiologic parameters that are captured through a finger probe with disposable sensor. These parameters include heart rate, heart rate variability, photoplethysmography pulse wave amplitude, skin conductance and temperature, and their time derivatives. All these parameters are analyzed simultaneously to provide the NOL index which can range from 0 to 100. Values \>25 were found to be indicative of nociception and related-pain in the field of anesthesia. The investigators will use the Pain Monitoring Device-200 (PMD-200)TM, which offers the multi-parametric NOL index (0-100) (Medasense Biometrics Ltd., Ramat Gan, Israel), and was approved by Health Canada for clinical use in September 2017.
40969761|NCT06281106|DRUG|Deucravacitinib|Daily drug intake for 4 weeks.
41296952|NCT05657288|OTHER|Breathing mixtures of O2 and N2 and monitoring SpO2 on finger and left wrist|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
41296953|NCT05451121|DRUG|Propofol|patient sedation with a propofol (sedative agent) after cardiac surgery
41296954|NCT05451121|DRUG|Dexmedetomidine|patient sedation with dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) after cardiac surgery
41296955|NCT05451121|DRUG|Propofol and dexmedetomidine|Patients sedation with a drug combination: propofol and dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist)
41296956|NCT01653366|BEHAVIORAL|Physical Activity Goal Setting|"Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them."
41296957|NCT03334578|DRUG|Gastrografin|Gastrografin group
41296958|NCT03275883|PROCEDURE|Aortohepatic Conduit|Placement of an interposition graft between hepatic artery and aorta during liver transplantation
41296959|NCT00863785|DRUG|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
41296960|NCT00002706|PROCEDURE|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
41296961|NCT00002706|OTHER|Quality-of-Life Assessment|Ancillary studies
41296962|NCT00002706|PROCEDURE|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
41296963|NCT02868749|DEVICE|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
41296964|NCT02868749|DEVICE|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
41296965|NCT00914199|PROCEDURE|Percutaneous coronary intervention (PCI)|Implantation of coronary stent in bifurcation lesion.
41296966|NCT03175393|DEVICE|coronary angiography|per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score
41458087|NCT04039230|DRUG|Talazoparib|Talazoparib belongs to a group of drugs called PARP inhibitors. PARP is a protein that is involved with repairing damaged DNA (the genetic material of cells). Talazoparib is believed to work by inhibiting (stopping) the PARP proteins from working in the cancer cells so that the cancer cannot fix its damaged DNA.
41458088|NCT04039230|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the cancer cells from growing/spreading.
40969762|NCT06417294|OTHER|3D health education model|explanation combined with 3D printed health education model
40969763|NCT06417294|OTHER|traditional education|Regular education
40969764|NCT02554487|DEVICE|AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)|Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI \> 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI \< 5) following stroke serve as a control group
40969765|NCT06504901|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
41296967|NCT01168804|DRUG|bendamustine plus bortezomib plus dexamethasone|Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
41296968|NCT01792986|BEHAVIORAL|water-only 24-hour fasting once per week for 6 weeks|
41296969|NCT01003028|DRUG|Remifentanil (Limited) - Target Controlled Infusion system|Limit max plasma concentration to 9.8 ng/ml
41296970|NCT01003028|DRUG|Remifentanil (Control) - Target Controlled Infusion system|Use 20 ng/ml as max plasma concentration
41296971|NCT02659345|BEHAVIORAL|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
41458089|NCT01092169|OTHER|No intervention|
41458090|NCT02575456|BIOLOGICAL|Ebola Vaccine|
41458091|NCT02575456|BIOLOGICAL|Placebo|control
41458092|NCT00967395|OTHER|Healing|"Healing in our study is given be a healer no-touch, who just has to be present in the room."
41458093|NCT00967395|OTHER|Sham healing|"Sham Healing in our study is given be a student no-touch, who just has to be present in the room."
41458094|NCT03368027|BEHAVIORAL|A cognitive-behavioral intervention program|In this program, participants receive a training of assertive skills, social skills, acceptance, among other psychological aspects.
41458095|NCT03368027|OTHER|Standard intervention|Participants receive different activities conducted by a psychologist in the association where the attend.
41458096|NCT05981716|OTHER|No intervention|This is an observational study. There is no intervention.
40969766|NCT06504901|DRUG|Interleukin-2|Interleukin 2 100IU HD,QOD d1-d14
40969767|NCT06504901|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-d14
40969768|NCT06504901|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 ivd, d1
40969769|NCT06504901|DRUG|Neupogen|rhG-CSF 5mcg/kg HD, QD d1-d14
40969770|NCT01412320|OTHER|Cocoa|dissolved in water twice daily
40969771|NCT01412320|OTHER|Cocoa|dissolved in water twice daily
40969772|NCT03836937|DRUG|Obeticholic acid|Farnesoid X receptor ligand which is a semi synthetic bile acid analogue
40969773|NCT00982878|DRUG|Maraviroc|150mg twice daily
40969774|NCT03775811|OTHER|AUTOMATED POLYP CLASSIFICATION|COLONIC POLYP HISTOLOGY PREDICTION IN WHITE LIGHT IMAGES COMBINING ARTIFICIAL INTELLIGENCE AND CLINICAL INFORMATION
40969775|NCT02130570|OTHER|Multi-Model Intensive Discharge Intervention|"1. Inpatient medication safety interventions~2. Inpatient discharge advocate~3. Structured visiting nurse (VNA) appointments~4. Post-discharge phone call by primary care personnel within 2 business days of discharge~5. Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~6. Improved communication between inpatient and primary care teams~7. High-risk patients will receive additional interventions as needed:~   1. Home pharmacist visit~  2. Enrollment in the Partners integrated Care Management Program (iCMP)~  3. Enrollment in telemedicine programs for patients with CHF~  4. Palliative care consultation regarding goals of care~8. Novel health information technology to facilitate communication and transfer of clinical information"
40969776|NCT02373852|DEVICE|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
40969777|NCT04997161|DRUG|Sodium Zirconium Cyclosilicate (SZC)|Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
40969778|NCT04997161|OTHER|Enhanced dietary advice|Participants will receive enhanced dietary advice in addition to taking SZC. This will include advice from dietitians to consume fruit and vegetables. Participants will be encouraged to consume up to 70 mmol K+ per day.
40969779|NCT04997161|OTHER|Standard dietary advice including K+ restriction.|Participants randomised to the SoC arm of the Diet Comparison Phase will receive standard dietary advice including K+ restriction.
40969780|NCT02233647|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
40969781|NCT02233647|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
40969782|NCT00447460|PROCEDURE|Mesenchymal stem cell (MSC)|
40969783|NCT01822431|RADIATION|metaiodobenzylguanidine scintigraphy|
40969784|NCT00963196|DIETARY_SUPPLEMENT|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
41138642|NCT01110096|BEHAVIORAL|Parent Management Training - Oregon (PMTO)|Method to help parents and caregivers manage the behavior of the children they are responsible for.
40969785|NCT00963196|DRUG|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
40969786|NCT00888368|PROCEDURE|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
40969787|NCT00888368|PROCEDURE|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
41458097|NCT06062615|PROCEDURE|Total knee replacement using Omnibot Knee System|total knee replacement with robotic assistance
40969788|NCT06155604|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily
40969789|NCT06155604|DRUG|Standard maintenance therapy|Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)
41138643|NCT01110096|BEHAVIORAL|Motivational interviewing|Communication method to facilitate behavioral change and empower the parents.
40969790|NCT06231160|PROCEDURE|Systematic Therapy Combined With Microwave Ablation|Patients with unresectable pancreatic cancer were included for laboratory examination, and quality of life and pain scores were recorded. The experimental group underwent microwave ablation first, followed by chemotherapy according to the guidelines; The control group received the same chemotherapy. Record the use of chemotherapy drugs and the occurrence of adverse events. Follow up will be conducted at 30 days, 90 days, and 180 days after chemotherapy to evaluate pancreatic function and quality of life.
40969791|NCT02559193|OTHER|Observational study, data collection only trial.|Data collection only trial design.
40969792|NCT04448288|OTHER|Static stretching|Static stretchings were performed by subjects that involved varied repetitions of 30-s static-stretches and 20-s relax period.
40969793|NCT04218825|DRUG|chlormethine gel|Gel to be applied to all skin areas affected by MF-CTCL
40969794|NCT06365398|DRUG|Heparin|As soon as the sheath was inserted, three different doses of heparin were administered according to the patients group assignment. In the conventional systemic heparinization (Regular-dose) group (The drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 83 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
40969795|NCT06365398|DRUG|Heparin Sodium Injection|In the micro-dose systemic heparinization (Micro-dose) group (the drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 42 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
40969796|NCT06365398|OTHER|No heparinization|No additional heparin was administered via the sheath or arterial route in the no heparinization group.
40969797|NCT04502589|DRUG|Perampanel Tablet|Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
40969798|NCT04502589|DRUG|Disulfiram|Disulfiram will be kept at 250mg daily
41138644|NCT01110096|BEHAVIORAL|Dynamic group therapy|Focuses on individual experiences within families and/or parents/children, and that the participants are their own experts.
41138645|NCT00362284|BEHAVIORAL|NYUCI-AC|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
41138646|NCT00987272|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
41138647|NCT00987272|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%|
41138648|NCT00987272|DRUG|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
41138649|NCT00987272|DRUG|Olopatadine 0.1% Vehicle|Inactive ingredients used as placebo comparator
41138650|NCT03006718|OTHER|PROMIS for Pain Management App|At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
41138651|NCT02501369|BEHAVIORAL|Self-directed Teen Triple P|Manualised parenting programme that parents will complete at home. This involves reading weekly modules of the manual and completing small exercises to practice the skills taught. These include strategies to help build positive relationships between parent and child, helping parents to effectively manage challenging childhood behaviours, and providing parents with the skills to support their child's independence and independent management of their cystic fibrosis.
41458098|NCT06062615|PROCEDURE|Conventional Total knee replacement|Conventional total knee replacement without robotic assistance
41138652|NCT00263900|DEVICE|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
41138653|NCT05255744|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
41458099|NCT06062615|DEVICE|Omnibot Robotic Knee System|utilizes an active motorized knee spacer to measure ligament tension and gap balance after the tibia has been cut during surgery
41458100|NCT04664751|OTHER|Nil-per-Oral|NPO details
40969802|NCT01111097|DRUG|Dichloroacetate|Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
40969803|NCT03012438|DEVICE|NIRF imaging in thyroid surgery|a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
40969804|NCT00688753|DRUG|RAD001|
40969805|NCT01213745|OTHER|Intervention|
40969806|NCT01213745|OTHER|Attention|
40969807|NCT01213745|OTHER|Control|
40969808|NCT05000476|OTHER|eye mask and earplugs|Materials similar to those offered on long commercial flights
40969809|NCT05000476|OTHER|Nurse Education and Environmental Regulation|providing orientation to the patient (frequent orientation of the patient to the place, time and person), cognitive stimulation (objects such as clocks and calendars in the patient's field of view), reducing noise and light (minimizing monitors and fluid infusion pump alarms at night), providing early mobilization ( passive-active joint movements, sitting and walking in bed), reducing social deprivation (receiving visitors, telephone calls)
40969810|NCT02338440|DRUG|lipoprostaglandin E1|Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
40969811|NCT00198939|BEHAVIORAL|Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
40969812|NCT00198939|OTHER|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
40969813|NCT05009121|DIAGNOSTIC_TEST|Box and Block Test|"At first, each person will be asked basic questions about present feelings according to their condition using a questionnaire. Than he/she will be tested by the Box and Block Test according to the Czech version of extended manual for this test in only one session. Audio recording of verbal instructions will be used.~The results will be used only for establishing of the variability and inter-rater reliability of the Box and Block Test, not for patients' other interventions."
41458101|NCT02664350|GENETIC|CYP2D6|Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
40969814|NCT05096767|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed
40969815|NCT04614740|DRUG|VC004|25 mg capsules,50 mg capsules,100 mg capsules.
40969816|NCT01989078|DRUG|Losartan|"Adults and Children \>50 kg:~* Those with systolic blood pressure (SBP) ≥ 100 mm Hg at entry will start with 50 mg of oral losartan once daily. At the week 2 visit, losartan will be increased to 100 mg daily.~* Those with SBP \<100 mm Hg at entry will start with 25 mg of oral losartan once daily. Participants will return after 1 week for titration to 50 mg daily, if tolerated (i.e. SBP not lower than pre-losartan measurement by 10 mm Hg or more), and after 2 weeks to monitor blood pressure.~Children \<50 kg weight:~* Treatment will start with 25 mg oral Losartan once daily given as a morning dose. At the 2 week visit, Losartan will be increased to 50 mg daily. The dose will be increased to 100 mg once a body weight of 50 kg is achieved."
41138654|NCT03345706|PROCEDURE|Selective cerebral hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Cooling will be initiated and targeted to reach ipsilateral nasal temperature of 27±2°C for 12 hours, followed by controlled rewarming.
41138655|NCT03345706|PROCEDURE|Regular hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Subjects will receive systemic hypothermia via ECMO at 33.5±0.5°C (33-34°C) for 48 hours at the same time.
41138656|NCT05888740|DEVICE|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf
41138657|NCT05200624|DEVICE|2RT subthreshold nanosecond laser|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
41138658|NCT04313699|DRUG|Antiretroviral treatment|The cohort will recruit HIV infected participants who are on antiretroviral treatment
41138659|NCT00624377|DRUG|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
41138660|NCT02632188|PROCEDURE|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
41458102|NCT02664350|BEHAVIORAL|Brief Pain Inventory-Short Form (BPI-SF)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
41458103|NCT02664350|BEHAVIORAL|M.D. Anderson Symptom Inventory (MDASI)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
41458104|NCT02664350|GENETIC|OPRM1|Genetic testing of the OPRM1 will be performed after week 8.
40969817|NCT00594438|DEVICE|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
40969818|NCT00594438|DEVICE|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
41138661|NCT02632188|BIOLOGICAL|DC-PMAT treatment|Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
41138662|NCT00514670|OTHER|Alcohol-based hand sanitizer & quaternary ammonium wipes|
41138663|NCT04313985|DEVICE|Tennant Biomodulator-Pro™ Device|Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.
41138664|NCT01562964|BEHAVIORAL|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
41138665|NCT01562964|BEHAVIORAL|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
41138666|NCT01502839|OTHER|No Intervention|This retrospective data analysis will rely on data obtained from chart review.
41138667|NCT03730727|BEHAVIORAL|Physical activity|Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
41138668|NCT03730727|DIETARY_SUPPLEMENT|Meal|Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
41138669|NCT04594876|OTHER|Flouroscopic guidance cervical epidural versus cervical facet injection|The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.
41138670|NCT02458274|OTHER|Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)|
41138671|NCT00193102|DRUG|Thalidomide|Thalidomide
41138672|NCT00193102|DRUG|Capecitabine|Capecitabine
41138673|NCT06510985|DEVICE|transcutaneous vagus nerve stimulation|The study employs a CE-certified tVNS® E device, ensuring European safety standards (EU regulation 2017/745 on medical devices). This device features a stimulation cycle of 28 seconds on and 32 seconds off, with a 25 Hz impulse frequency. For the high-intensity group, the stimulation intensity will be individually adjusted in the session before starting the high-intensity tVNS stimulation at home. Recommended daily usage is max. 4 hours, after which it automatically shuts off.
41138674|NCT06510985|BEHAVIORAL|Monitoring|Participants are monitored over 12 weeks using a combination of questionnaires and ecological momentary assessment. This approach allows for a comprehensive assessment of the patient's health and well-being.
41138675|NCT06510985|DEVICE|cardiowatch bracelet|The study employs the medically certified cardiowatch bracelet from Corsano (CE-MDR medical certification, FDA 510 (k) cleared) for continuous monitoring of vital signals, such as heart rate, heart rate variability, breathing rate, SpO2, physical activity and sleep.
41138676|NCT01933945|PROCEDURE|TACE (transarterial chemoembolization)|First treatment for all patients included in the study
41138677|NCT01933945|DRUG|Sorafenib (Nexavar, BAY43-9006)|
41138678|NCT06404983|OTHER|Opioid Free Anaesthesia (OFA)|Patients are allocated to receive non-opioid anaesthesia intraoperatively. Patients will receive a mixture of dexmedetomidine, ketamine and lidocaine for intraoperative analgesia.
40969819|NCT03799731|DRUG|GM102|GM102 7 mg/kg weekly
40969820|NCT03799731|DRUG|Trifluridine/Tipiracil|Lonsurf 35 mg/m² twice daily during 10 days per cycle
41138679|NCT06404983|OTHER|Conventional General Anaesthesia (CGA)|Patients are allocated to receive conventional general anaesthesia intraoperatively with the use of fentanyl and morphine for intraoperative analgesia.
40969821|NCT03799731|DRUG|GM102 expansion|GM102 7 mg/kg weekly after a loading dose of 10 mg/kg q1w during 28-day cycle 1
40969822|NCT04829396|OTHER|placebo|Powder consisting of 13 g of digestible carbohydrates with similar appearance as the investigational fibre mixture.
40969823|NCT04829396|DIETARY_SUPPLEMENT|Fibre mixture|The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day.
41138680|NCT00936819|BIOLOGICAL|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
41138681|NCT00936819|BIOLOGICAL|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
41138682|NCT00936819|BIOLOGICAL|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
41296972|NCT02659345|BEHAVIORAL|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
41296973|NCT01938820|DRUG|entecavir|anti-viral therapy
41296974|NCT01938820|DRUG|Thymosin-α|antiviral and antifibrosis therapy
41296975|NCT00003667|DRUG|cyclophosphamide|
41296976|NCT00003667|DRUG|dexrazoxane hydrochloride|
41296977|NCT00003667|DRUG|disaccharide tripeptide glycerol dipalmitoyl|
41296978|NCT00003667|DRUG|doxorubicin hydrochloride|
41296979|NCT00003667|DRUG|vincristine sulfate|
41138683|NCT00519935|BEHAVIORAL|Multisystemic Therapy|MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
41296980|NCT00003667|PROCEDURE|surgical procedure|
41296981|NCT00003667|RADIATION|radiation therapy|
41296982|NCT00909285|DEVICE|TMS stimulation|TMS stimulation and cognitive training
41296983|NCT00909285|DEVICE|Sham comparator|Sham comparator
41296984|NCT00909285|BEHAVIORAL|Cognitive training|TMS stimulation and cognitive training
41296985|NCT04191278|DRUG|Varenicline|All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84
41296986|NCT04191278|DEVICE|Mobile phone application|Participants randomized to 2 of the 3 study groups will receive a mobile phone application designed to improve adherence to medication. The app has a number of functions, including: a) reminders to take medication; b) information about coping strategies for dealing with side effects and withdrawal symptoms; c) provision of a personalized graphical display of treatment progress (e.g., adherence, side effects); d) camera-based verification of having taken medication.
41296987|NCT04191278|BEHAVIORAL|Contingency management|Participants randomized to 1 of the 3 study groups will receive monetary reinforcement contingent upon verified medication adherence behaviors. Participants in the other 2 groups will be yoked to a participant in the CM group so that they also have a chance of earning monetary reinforcers, though not contingent upon their own behaviors.
41296988|NCT05447130|PROCEDURE|phacoemulsification|phacoemulsification with corneal endothelial evaluation by specular microscopy
41296989|NCT05040178|DRUG|Carglumic Acid|Current or previous treatment with Carbaglu, the dose of Carbaglu® prescribed will be determined by the investigator for each individual patient.
41138684|NCT02962024|DRUG|Morphine Sulfate|
41138685|NCT02962024|DRUG|Bupivacaine Hydrochloride|
41296990|NCT01565629|BEHAVIORAL|Computer assisted cognitive behavioral therapy.|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
41296991|NCT06511869|DRUG|AZD4205|AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.
41296992|NCT05022004|DRUG|Brinzolamide ophthalmic suspension|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
41296993|NCT05022004|DRUG|Azopt®|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
41296994|NCT00189007|DRUG|Allopurinol sodium|Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
41296995|NCT00189007|DRUG|Mannitol|Mannitol 500 mg/50 mL water for injection, intravenously, single dose
40969824|NCT00376727|BIOLOGICAL|cetuximab|Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
40969825|NCT00376727|GENETIC|molecular diagnostic method|Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
40969826|NCT00376727|OTHER|immunologic technique|Peripheral Blood Mononuclear Cells (PBMC)
40969827|NCT00376727|OTHER|laboratory biomarker analysis|Cetuximab Pharmacodynamics
40969828|NCT00732017|DEVICE|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
40969829|NCT00732017|DEVICE|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
40990742|NCT00762242|PROCEDURE|blood sampling and brachial artery ultrasound|"Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation."
41296996|NCT03348657|OTHER|Music Session|Three to four times a week, volunteer musicians came to the geriatric assessment unit and would provide music sessions (duration of about 60 minutes) to the patients who volunteered to attend.
41458105|NCT02786784|OTHER|6 week exercise treatment|This six-week exercise programme was developed based on the current recommendations, consisting of four exercises to strengthen gluteus medius and maximus muscle, as well as the quadriceps muscle. In addition, two exercises to stretch the hamstrings muscles and to increase the ankle dorsi range of motion were included.
41458106|NCT01131091|DRUG|SK-0403|SK-0403 400 mg
41458107|NCT03151824|OTHER|quality of life|Quality of life which was measured by the Korean version of the 36-item short-form health survey (SF-36)
41458108|NCT02970188|BEHAVIORAL|Time Restricted Feeding|consuming all daily calories within an 8 hour feeding window
41296997|NCT02850575|DEVICE|Mpact Double Mobility cup|
41458109|NCT03103711|BEHAVIORAL|Virtual Reality Intervention|"Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments."
41458110|NCT00151255|DRUG|Cytarabine|100mg/m² kont. i.v. day 1-5 (induction therapy); 1000 mg/m² 2x/die i.v. day 1-3 (first consolidation cycle)
41458111|NCT00151255|DRUG|Idarubicin|12mg/m² i.v. day 1+3 (induction therapy); 12mg/m² i.v. Tag 1+3 (second consolidation cycle)
41458112|NCT00151255|DRUG|All-trans retinoic acid|45mg/m² p.o. day 4-6, 15mg/m² p.o. day 7-28 (induction therapy); 15mg/m² p.o. day 4-28 (consolidation therapy)
41458113|NCT00151255|DRUG|Mitoxantrone|10mg/m² i.v. day 2-3 (first consolidation cycle)
41296998|NCT05186558|DRUG|penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin|"Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~* Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~* lenalidomide: 10 mg, po, for 18 months."
41296999|NCT01809990|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
41297000|NCT05196997|OTHER|Mobility and Functional Assessments|"The first evaluation was made on the day the patient was discharged from the intensive care unit. DEMMI, Bartel Index, Katz Activities of Daily Living Rating Scale and MRC Muscle Strength Test were performed to the patient, respectively.~De-Morton Mobility assessment for test-retest reliability was performed again on the 1st day of the patient's service."
41297001|NCT01421849|PROCEDURE|Denture implantation|"In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months."
41297002|NCT00250471|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
41458114|NCT00151255|DRUG|Etoposid|100mg/m² i.v. Tag 1-5 (second consolidation cycle)
40969830|NCT00732017|OTHER|standard physical therapy treatment|"* Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~* Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~* Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions."
40969831|NCT02426437|OTHER|Pulmonary Rehabilitation (PR)|Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
40969832|NCT02426437|OTHER|Usual Care|Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
40969833|NCT03952104|OTHER|Strength training|Strength training
40969834|NCT04847362|BEHAVIORAL|Experimental|education group
40969835|NCT01830972|DRUG|SA-ER 500 mg|oral tablets
40969836|NCT01830972|DRUG|SA-IR 500 mg|oral capsules
40969837|NCT05949008|DRUG|Metformin Extended Release (ER) Oral Tablet|Metformin ER will be provided as 1000 mg capsules by Qingdao Baheal Pharmaceutical Co., Ltd. In addition to the active ingredient metformin HCl,each tablet contains the following inactive ingredients: Povidone, Sodium Lauryl Sulfate, Magnesium Stearate, Cellulose Acetate, Polyethylene Glycol (PEG 400, PEG 8000), Triacetin, Hypromellose, Titanium Dioxide, Polysorbate 80, Ferrosoferric Oxide, Shellac.
40969838|NCT05949008|DRUG|Placebo|Matching placebo will be provided as 1000 mg capsules
40969839|NCT03405129|BEHAVIORAL|Phoenix|Phoenix cessation app
40969840|NCT03405129|BEHAVIORAL|NRT order button|Ability to order NRT through smartphone app
40969841|NCT03405129|BEHAVIORAL|Factoid|Factoid app
40969842|NCT03733002|DRUG|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.
40969843|NCT03733002|DRUG|Placebo of AngongNiuhuang pill|This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.
40969844|NCT03733002|OTHER|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke.
40969845|NCT02241174|DRUG|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
40969846|NCT06334783|BIOLOGICAL|Autologous tumor-infiltrating lymphocyte cells|On day 0, all patients will receive autologous tumor-infiltrating lymphocyte cells administered.
40969847|NCT05227404|DIAGNOSTIC_TEST|LumiraDX|Point-of-care test for SARS-CoV-2
40969848|NCT05227404|DIAGNOSTIC_TEST|RightSign|Point-of-care test for SARS-CoV-2
40969849|NCT05227404|DIAGNOSTIC_TEST|Case Control|Genscript assay performed on the plasma sample
40969850|NCT01625702|DEVICE|CellSearch® CTC kit|"Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
40969851|NCT01101087|DEVICE|Taurolock|
40969852|NCT01101087|OTHER|Placebo|Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
40969853|NCT01220843|DRUG|Placebo|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
40969854|NCT01220843|DRUG|Sevelamer carbonate|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
40969855|NCT00297830|DRUG|Zoledronic acid|Drug is administered through 5 mg intravenous infusion over 20 minutes
40969856|NCT00297830|DRUG|Alendronate|Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal
40969857|NCT00297830|OTHER|Placebo Zoledronic Acid|Infusion of placebo zoledronic acid during the first 5 weeks after transplantation
40969858|NCT00297830|OTHER|Placebo Alendronate|Placebo alendronate 70 mg once weekly
40969859|NCT01442675|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
40969860|NCT04985097|PROCEDURE|Implantation of trifocal diffractive intraocular lenses|Postsurgical monocular and binocular assessment of corrected and uncorrected near, intermediate and distance visual acuity and near and distance mesopic contrast sensitivity before and after the assigned vision training
40969861|NCT02601690|OTHER|Blood Sampling|
40969862|NCT04366102|OTHER|Multisensory stimulation with soft tissue therapy|Multisensory stimulation with soft tissue therapy will be given. Multisensory stimulation consists of Auditory, vestibular, tactile, olfactive, oromotor, Visual, and Kinesthetic stimulation. Soft tissue therapy consists of stroking, effleurage, fingertip kneading, tapping, and skin rolling will be given. Total intervention will be given for 30 min. 5 times per week
40969863|NCT04366102|OTHER|Routine hospital care|Routine hospital care will be given to the preterm neonates
40969864|NCT02793934|OTHER|Scales|"For stroke patients there are used scales:~Modified Rankin Scale, NIH Stroke Scale , Glasgow Coma Scale, Dysphagia Severity, Rating Scale Speech or Language Impairment Severity Rating Scale, Modified Rivermead Mobility Index, Berg Balance Scale, Modified Ashworth Scale, Medical Research Council Scale, Frenchay Arm Test, Montreal Cognitive Assessment Scale, Spielberger Scale, Beck's Depression Inventory, Visual Analogue Scale, Functional Independence Measure For patients after AMI: Rankin scale, GRACE scale, MoCA, VAS, Hospital scale of anxiety and depression, Canadian classification if stenocardia~For patients after THR:~The pain of the operated joint on VAS scores The Harris scale (the total amount), Scale Lequesne (total), Hospital scale of anxiety"
40969865|NCT02793934|OTHER|New model of rehabilitation|
40969866|NCT02793934|OTHER|Old model of rehabilitation|
40969867|NCT02793934|OTHER|ICF reader|
40969868|NCT03608501|DRUG|Ixazomib|Ixazomib capsules.
40969869|NCT03608501|DRUG|Thalidomide|Thalidomide capsules.
40969870|NCT03608501|DRUG|Dexamethasone|Dexamethasone tablets.
40969871|NCT04966715|PROCEDURE|Epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of colorectal carcinomatosis by this way
40969872|NCT06304376|PROCEDURE|Alveolar ridge grafting|Alveolar ridge grafting was carried out using anterior iliac crest bone graft. Khoury shell technique was the method of ridge reconstruction via a cortical bone shell was fixed away from alveolar ridge using two micro-screws and the gap created was filled by cancellous bone
40969873|NCT04040114|DEVICE|Molemap Skin Cancer Triage Artificial Intelligence Device|This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.
40969874|NCT03700775|OTHER|Remote Telemonitoring|Using the telemedicine kit, participants will record a daily health session including 2 BP measurements obtained one minute apart. Participants are encouraged to record a health session every day, with a minimum of 5 days per week. Participants are also encouraged to equally divide health session recordings between the mornings and evenings. Every 2 weeks BP measurements will be assessed. If less than 75% of measurements are at goal \<130/80 mmHg, the central Telehealth pharmacist will designate drug-therapy intensification according to an evidence-based treatment algorithm that is physician approved. Regardless of BP control, participants will be contacted by their nurse coordinator every 2 weeks. During all telephone visits nurse coordinators emphasize healthy lifestyle habits. Safety protocols are in place for dangerously high or low BP recordings.
40969875|NCT00713050|BEHAVIORAL|Imitate Therapy|Imitation-based computer therapy
40969876|NCT01158300|DRUG|VEGF inhibitor PTC299|This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)
40969877|NCT04743297|DRUG|Prostaglandin E2 (Propess)|Propess - The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour or at the occurrence of hyperstimulation.
40969878|NCT04743297|DRUG|Prostaglandin E2 (Prostin)|Prostin - 3 mg vaginal tablet is placed in the posterior vaginal fornix. Dose can be repeated every 8 hours till onset of active labour or the occurrence of hyper-stimulation.
40969879|NCT02646072|DRUG|Ketorolac tromethamine ophthalmic solution 0.45%|Indicated for the treatment of pain and inflammation following cataract surgery.
40969880|NCT01422317|DRUG|EPA / DHA / Alpha-Tocopherol|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
40969881|NCT01422317|DRUG|Corn Oil / Alpha-Tocopherol (4 mg)|Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
40969882|NCT00895167|DIETARY_SUPPLEMENT|curcumin|one oral dose of 12 caplets = 12 g curcumin
40969883|NCT03571815|DRUG|5% sodium fluoride varnish|application of sodium fluoride varnish on teeth
40969884|NCT03571815|OTHER|WATER ON TEETH|control group
40969885|NCT01183156|BEHAVIORAL|Re-invitation letter|Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
40969886|NCT01183156|BEHAVIORAL|Invitation to educational meeting|Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
41138686|NCT05732909|DIETARY_SUPPLEMENT|D-β-hydroxybutyrate/D 1,3 butanediol monoester|Ketone monoester
41138687|NCT03262714|OTHER|Dance|Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics. The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).
40969887|NCT06218693|BEHAVIORAL|VIA Family|A family-based, multi-component, individual-tailored intervention based on case-management.
40969888|NCT06218693|BEHAVIORAL|Treatment As Usual (TAU)|care as usual
40969889|NCT05450731|OTHER|12-week supervised exercise based cardiac rehabilitation program|12-week exercise-based cardiac rehabilitation intervention on the recurrence of atrial fibrillation (AF) in patients at six- and twelve-months post-ablation procedure.
40969890|NCT02881437|DRUG|IgHy10|Sub Cutaneous IgHy10 administration
40969891|NCT00144053|DRUG|Cisplatin+Vindesine+MMC/ concurrent radiation|
41138688|NCT03262714|OTHER|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).
40969892|NCT00144053|DRUG|Irinotecan+Carboplatin/concurrent radiation|
40969893|NCT00144053|DRUG|Paclitaxel+Carboplatin/concurrent radiation|
40969894|NCT06406283|BEHAVIORAL|High-Intensity Functional Training (HIFT)|"This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The training protocol will be designed based on Cross-Training workouts, emphasizing high-intensity interval training combined with functional resistance-training movements."
40969895|NCT06406283|BEHAVIORAL|Mindfulness-Based Stress Reduction Program (MBSR)|This intervention follows the official MBSR program designed by Jon Kabat-Zinn with some adaptations, as we did in Bermudo-Gallaguet, et al. (2022). The intervention will occur three days a week, including one 120-minute online synchronous session and two 20-40 min individual practices. The intensity of physical exercise will be adjusted to personal baseline characteristics.
40990743|NCT03060447|DRUG|Vesatolimod|Tablets Administered orally
40990744|NCT03060447|DRUG|Placebo|Tablets Administered orally
41138689|NCT03262714|OTHER|Stretching|Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks. Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s. There will be no music playing during the session.
40969896|NCT06406283|BEHAVIORAL|Qigong|"This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The program includes the Baduanjin sequence, considered one of the most ancient and beneficial forms for physical and mental health within the Qigong tradition."
40969897|NCT05086406|OTHER|Combination of Video and Virtual Pre-operative Counseling|Intervention will be a pre-operative counseling video followed by a virtual visit with a gynecologic surgery provider, using standard and secure communications.
40969898|NCT03395743|BIOLOGICAL|AB-PA01|AB-PA01 is an investigational bacteriophage therapeutic for treatment of Pseudomonas aeruginosa infections
40969899|NCT04429139|DRUG|photodynamic therapy|PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
40969900|NCT06201377|OTHER|Periodontal Access Surgery+ Suture with chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture coated with chlorhexidine (Novosyn Chlorhexidine). Standardized post-surgical recommendations will be followed.
40969901|NCT06201377|OTHER|Periodontal Access Surgery+ Suture without chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture (Novosyn). Standardized post-surgical recommendations will be followed.
40969902|NCT03068481|DRUG|KDT-3594|Oral administration
40969903|NCT03068481|DRUG|Placebo|Oral administration
40969904|NCT01660698|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin powder
40969905|NCT01660698|DIETARY_SUPPLEMENT|Probiotic|probiotic blended in maltodextrin powder
40969906|NCT00300391|DRUG|haloperidol|Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.
40768800|NCT05301764|COMBINATION_PRODUCT|LVGN6051 and Anlotinib|"LVGN6051: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits. Anlotinib: Rout of administration is oral. The initial dose of anlotinib was 12 mg for subjects with body surface area ≥ 1.5m2 and 10 mg for subjects with body surface area \< 1.5m2. If the subjects in the combined treatment group were not tolerated, the dose of anlotinib was reduced to 10 mg for subjects with body surface area ≥ 1.5m2 and 8 mg for subjects with body surface area \< 1.5m2.~One cycle is 3 weeks, including oral for 2 weeks and withdrawal for 1 week."
40768801|NCT03369223|BIOLOGICAL|BMS-986249|Specified dose on specified days
40768802|NCT03369223|BIOLOGICAL|Nivolumab|Specified dose on specified days
40969907|NCT00300391|OTHER|Saline placebo|control arem
40969908|NCT02220205|OTHER|PelvicSim|
40969909|NCT02220205|DEVICE|Manufacturer model|
40969910|NCT05540353|DEVICE|Transvaginal photobiomodulation|Low light laser therapy applied transvaginally using a small vaginal wand with sterile disposable wand covers. The intervention last 3-5 minutes based on a surface area calculation performed at the beginning of the intervention, and involves a gentle in and out motion of the wand to deliver light energy to the muscles of the pelvic floor.
40768803|NCT03369223|BIOLOGICAL|Ipilimumab|Specified dose on specified days
40969911|NCT05540353|DEVICE|Sham therapy|Use of the same vaginal wand as active arm, but without activation of the machine. The intervention last 3-5 minutes, and involves a gentle in and out motion of the wand to massage the muscles of the pelvic floor, without delivery of light therapy.
40969912|NCT04657120|PROCEDURE|YEARS algorithm|Patients randomized to the YEARS algorithm will be evaluated according to the YEARS algorithm consisting of three items of the original Wells rule (clinical signs of DVT, haemoptysis and 'PE most likely diagnosis') and a D-dimer test. In patients without any of the three items and a D-dimer level \<1.0 μg/mL (\<1000ng/mL), and in patients with ≥1 items and a D-dimer level \<0.5 μg/mL (\<500 ng/mL) a PE is excluded without CTPA. In the other patients a standard contrast enhanced CTPA will be performed according to local practice. PE is defined as at least one filling defect in the pulmonary artery tree on CTPA.
40969913|NCT04657120|PROCEDURE|CTPA|Patients randomized to the CTPA management group will undergo a contrast enhanced CTPA to rule out PE according to standard local practice.
40969914|NCT02302820|OTHER|Advance Care Planning Intervention|"ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids."
40969915|NCT05677724|DIAGNOSTIC_TEST|HBV DNA Sequencing|"Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed."
40969916|NCT01250275|OTHER|traditional canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from traditional canola oil.
40969917|NCT01250275|OTHER|high oleic canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high oleic canola oil.
40969918|NCT01250275|OTHER|soybean oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from soybean oil.
40969919|NCT01250275|OTHER|high linoleic safflower oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high linoleic safflower oil.
40969920|NCT01250275|OTHER|coconut oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from coconut oil.
40969921|NCT01250275|OTHER|traditional canola oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of food items prepared with traditional canola oil for eight weeks.
40969922|NCT01250275|OTHER|safflower oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of foods prepared with an oil mixture representing the typical western diet
40969923|NCT02798575|DEVICE|Astral 150 ventilator|Patients indicative for invasive ventilation will receive the Astral 150 ventilator at the weaning station of the hospital. The ventilator will be set by the physician. Afterwards patients will be transferred into home care.
40969924|NCT00939497|DRUG|Risperidone|
40969925|NCT02590614|DIETARY_SUPPLEMENT|800 IU Vitamin D|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
40969926|NCT02590614|DIETARY_SUPPLEMENT|Placebo|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
40969927|NCT00294437|DRUG|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
40969928|NCT00899054|DRUG|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
40969929|NCT00899054|RADIATION|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
40969930|NCT04548570|PROCEDURE|approximation of both rectus muscles|closure of both rectus muscle before closure of rectus sheeth
40969931|NCT04767373|BIOLOGICAL|Clesrovimab|Clesrovimab solution
40969932|NCT04767373|DRUG|Placebo|Placebo (0.9% sodium chloride \[NaCL\]) solution
40969933|NCT04443270|DRUG|Chloroquine phosphate|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
40969934|NCT05606497|DRUG|Corticosteroid|Antenatal corticosteroids are administered to pregnancies at risk for preterm birth in order to reduce risks of neonatal morbidity and mortality following preterm birth.
40969935|NCT00721500|DEVICE|etafilcon A|contact lens
40969936|NCT00721500|DEVICE|narafilcon A|contact lens
40969937|NCT03217175|DEVICE|Bihormonal Bionic Pancreas|The glucagon pump will be filled with glucagon during the exercise visit
40969938|NCT03217175|DEVICE|Insulin Only Bionic Pancreas|The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
40969939|NCT03217175|DRUG|Glucagon|Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
40969940|NCT03217175|DRUG|Placebo|Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
40969941|NCT00645060|OTHER|high performance liquid chromatography|Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
40969942|NCT00645060|OTHER|pharmacological study|Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
40969943|NCT00645060|PROCEDURE|radionuclide imaging|1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
40969944|NCT00645060|PROCEDURE|single photon emission computed tomography|2 days and 3-5 days post antibody infusion
40969945|NCT00645060|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
40969946|NCT01537393|BIOLOGICAL|Cornea tissue transplant|Cornea tissue preserved 0 to 7 days
40969947|NCT01537393|BIOLOGICAL|Cornea tissue transplant|Cornea tissue preserved 8 to 14 days.
41297003|NCT05517759|OTHER|Educational program|The sessions were delivered in form of face to face, group disscussion, brainstorming and smart cards. The educational package covered all aspect of knowledge regarding VAP such as definitions, risk factors m cause, manifestation, diagnostic criteria, and nursing care to prevent VAP. A PowerPoint and information pamphlet were used to display the material.
41297004|NCT00878072|DRUG|Famciclovir|Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
41297005|NCT01347918|DEVICE|19F capsule|Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
40969948|NCT01882491|DRUG|Placebo|Solution for subcutaneous injection
40969949|NCT01882491|DRUG|gevokizumab|Solution for subcutaneous injection
41297006|NCT01347918|DIETARY_SUPPLEMENT|sterculia|7g of sterculia will be ingested over one week together with the normal breakfast.
41297007|NCT01315015|OTHER|Contrast enhanced breast MRI|Gadolinium contrast is administered as a bolus with a standard dose of 0.1 mL/kg followed by a saline flush of 30 mL.
41297008|NCT02874794|DRUG|LCZ696 (sacubitril/valsartan)|24/26mg, 49/51mg and 97/103mg oral, tablets.
40969950|NCT02837783|DRUG|Linaclotide|Oral, once daily
40969951|NCT02837783|DRUG|Placebo|Oral, one daily
40969952|NCT02925494|DRUG|Estradiol/Norethindrone Acetate|capsules
40969953|NCT02925494|DRUG|Elagolix|film-coated tablets
40969954|NCT02319889|RADIATION|Stereotactic Body Radiotherapy|Undergo SBRT
40969955|NCT02319889|DRUG|Carboplatin|Given IV
40969956|NCT02319889|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
40969957|NCT01384760|BEHAVIORAL|Lifestyle modification|During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.
40969958|NCT01384760|BEHAVIORAL|Simple lifestyle advice|Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
40969959|NCT03793738|PROCEDURE|Anterior component separation|
40969960|NCT03793738|PROCEDURE|Posterior component separation|
40969961|NCT00495339|DRUG|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
40969962|NCT00453297|DRUG|MF101|
40969963|NCT05449795|DEVICE|Device: Contour Next and Contour Plus Elite BGMS testing of arterial blood|The purpose of the study is to extend the intended use of two BGMSs to include testing of arterial blood by Health Care Professionals (HCP) in a clinical setting.
40969964|NCT06411678|DRUG|68GA-DOTA-dPNE|Patients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection
41297009|NCT02874794|DRUG|Enalapril|2.5mg, 5mg, and 10mg, oral, tablets
41297010|NCT02874794|DRUG|Placebo of Enalapril|matching placebo (2.5mg, 5mg and 10mg) oral, tablets
41297011|NCT02874794|DRUG|Placebo of LCZ696|matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
41297012|NCT03568006|OTHER|Specific passive mobilization|Specific passive mobilizations for the shoulder
40969965|NCT00851500|DRUG|K-604|K-604 is given for 26 weeks
40969966|NCT00851500|OTHER|Placebo|placebo tablets are given for 26 weeks
40969967|NCT02980601|DEVICE|Integra plus STSG|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
40969968|NCT02980601|PROCEDURE|STSG|0.012mm STSG
40969969|NCT03667261|DEVICE|Sealing Socket Abutment|Sealing Socket Abutment (SSA) serves as a mechanical barrier to isolate the grafted area, stabilize the clot and contain the graft material, and seal the socket from foreign contaminants and also minimizing the risk of premature loading of the implant during healing. By preparing an SSA fabricated to follow the transmucosal contours of the natural tooth, the grafted area can be sealed and separated from the growth of soft tissue without the use of a membrane or releasing incisions
40969970|NCT03667261|DEVICE|cover screw|immediate implant placement in mandibular molar area will be covered with conventional cover screw
40969971|NCT04004715|DIETARY_SUPPLEMENT|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
40969972|NCT04004715|DIETARY_SUPPLEMENT|Whey Protein|commercially available whey protein isolate
40969973|NCT04004715|DIETARY_SUPPLEMENT|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
40969974|NCT04391647|OTHER|First-void urine collection|"* One time collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.~* IF HPV positive and the woman gave consent to be contacted again: Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) each day during 14 days (n = 14)"
40969975|NCT04391647|OTHER|Blood draw|- One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
40969976|NCT00655044|DRUG|insulin detemir|Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
40969977|NCT02966262|DEVICE|Optical coherence tomography|Intracoronary imaging device which can precisely observe intracoronary structures
40969978|NCT06340373|DEVICE|DCB Angioplasty|Drug-coated balloons (DCB) are designed to deliver drugs (antiproliferative drugs: Paclitaxel, Sirolimus etc.) to the target lesion/vessel wall without leaving nothing behind unlike stent strut or drug delivery system. Drug coated balloons (DCB) allow the homogenous transfer of an anti-proliferative drug to reduce neo-intimal hyperplasia whilst maintaining normal vessel anatomy and function
40969979|NCT06136793|BEHAVIORAL|HomeStyles-China|2-arm \~10 week educational intervention
40969980|NCT04971122|OTHER|Trendeleburg -5 degree,-10 degree,-15 degree|Use a -5 or -10 or -15 degree trendelenburg position
40969981|NCT02469753|DRUG|NSAIDs|continuous daily
40969982|NCT02469753|DRUG|NSAIDs|on demand
40969983|NCT02469753|DRUG|anti-TNF|
40969984|NCT01004705|DRUG|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
41297013|NCT03568006|OTHER|Standardized treatment (standard protocol)|Infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene
40969985|NCT01004705|DRUG|Simvastatin|A once daily oral dose of simvastatin for 12 weeks.
40969986|NCT00522197|DIETARY_SUPPLEMENT|multi-herbal agent ACAPHA|
40969987|NCT00522197|DIETARY_SUPPLEMENT|Sugar Pill|
40969988|NCT02478996|OTHER|Internet-based exercise program|Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
41297014|NCT01509586|DRUG|Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product|The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
40969989|NCT05412745|DEVICE|Kaloidon Plus|topical application; twice daily
40969990|NCT05412745|DEVICE|silicone gel|topical application; twice daily
41297015|NCT05636085|DEVICE|Mainz Biomed Colorectal Cancer Screening Test|There is no intervention.
40969991|NCT05333978|DEVICE|MSOT Device|The MSOT Device will be used to take images of the areas of inflammation in patients with inflammatory diseases such as GVHD, Colitis, and IBD, prior to, and after 4 weeks of treatment.
40969992|NCT05333978|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after each instance of MSOT imaging.
40969993|NCT05340023|BIOLOGICAL|blood sample|to realize proteomic analysis.
40969994|NCT00333814|DRUG|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
40969995|NCT00333814|DRUG|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
40969996|NCT00333814|DRUG|Sham injection|Sham injection at Day 0
40969997|NCT06504095|OTHER|intervention group (Flipped Teaching Method Group)|"Patient safety training will be provided to students using the flipped classroom teaching method, consisting of both out-of-class and in-class activities.~Out-of-Class Activity: For the Flipped Teaching method, a Learning Management System-Web-Based Distance Education System will be established. Lecture videos for each lesson will be uploaded to the system 7 days before the class day. Students will have the flexibility to watch the instructional videos as many times as they wish until the class day.~In-Class Activity: The researcher will come prepared for in-class activities such as question-answer sessions, discussions, brainstorming. No lecturing will be done by the researcher. The researcher will solely guide the students."
40969998|NCT02529345|DEVICE|RoadSaver stent|lesion treated with RoadSaver stent of Terumo
40969999|NCT01540240|DRUG|Zidovudine|Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
40970000|NCT01540240|DRUG|Zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
40970001|NCT01025791|DRUG|MK-8266 0.1 mg|Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
40970002|NCT01025791|DRUG|MK-8266 1.0 mg|MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
40970003|NCT01025791|DRUG|Placebo|Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
40970004|NCT00304993|DRUG|fenofibrate|
40768804|NCT05769036|DEVICE|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation of the left ventricular pacing lead will be performed by cannulating one of the tributaries of the coronary sinus using delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed for biventricular pacing.
40970005|NCT00304993|DRUG|niacin|
40970006|NCT00304993|DRUG|rosiglitazone|
40970007|NCT01186510|PROCEDURE|lung perfusion|see literature of proceeding
40970008|NCT01186510|PROCEDURE|no lung perfusion|see literature of proceeding
40970009|NCT04124276|DIETARY_SUPPLEMENT|Lycium barbarum polysaccharide|Experimental groups take Lycium barbarum polysaccharide (LBP) (300mg/day) for 6 weeks
40970010|NCT04124276|DIETARY_SUPPLEMENT|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks.
40970011|NCT02260700|DRUG|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
40970012|NCT02260700|DRUG|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
40970013|NCT02260700|DRUG|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
40970014|NCT01115101|DRUG|Oral Oxycodon|Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
40970015|NCT01115101|DRUG|Piritramid|"Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes~Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded."
41138690|NCT01345708|DRUG|prednisone, low dose rituximab|"Patients with warm AIHA will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28), and prednisone 1 mg/kg/die p.o. days from day +1 to day +30, followed by tapering (10 mg/week until 0.5/mg/kg/die, then 5 mg/week until stop)~Patients with CHD will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28)"
41138691|NCT05671549|PROCEDURE|Arthrocentesis of the temporomandibular joint|Arthrocentesis of the temporomandibular joint is a minimally invasive method performed under local anesthesia to irrigate the upper temporomandibular joint cavity with biocompatible substances. The procedure aims to wash out intra-articular inflammatory substances, reduce pain and restore the function of the related joint.
40970016|NCT03116971|DRUG|M3814|Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
40970017|NCT03116971|DRUG|Cisplatin|Cisplatin 75 milligram per square meter (mg/m\^2) was administered over a 60-minute intravenous infusion on Day 1.
40970018|NCT03116971|DRUG|Etoposide|Etoposide 100 mg/m\^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).
40970019|NCT01192854|DRUG|Clevudine|Clevudine flexible dosages of 30 mg/day
40970020|NCT01192854|DRUG|Adefovir|Adefovir flexible dosages of 10 mg/day
40970021|NCT04711044|OTHER|Papain|Papain will be applied using cowhage spicules inactivated by heat
40970022|NCT04711044|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied
40970023|NCT04711044|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
40970024|NCT04711044|OTHER|L-menthol|A 1 mL aliquot is dispensed onto a 2,5 × 2,5 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape.
40970025|NCT04170816|DEVICE|Dry needling|DN and KT therapy will be applied 3 sessions in 1-week intervals
40970026|NCT02248103|PROCEDURE|Periosteal pedicle graft|Autogenous pedicle graft harvested from the periosteum
40970027|NCT02248103|BIOLOGICAL|Bioresorbable collagen membrane|Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
40970028|NCT06505434|PROCEDURE|Cataract surgery|Phaco + IOL Implantation
40970029|NCT02574468|DRUG|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
40970030|NCT02574468|PROCEDURE|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
40970031|NCT02681562|DRUG|olaparib|
40970032|NCT04422470|OTHER|Non-interventional study|Non-interventional study
40970033|NCT03504475|DRUG|Paroxetine Hydrochloride Tablet 20 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
40970034|NCT03504475|DRUG|Paxil® 20 mg|Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
40970035|NCT05925660|DIAGNOSTIC_TEST|Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)|Mucorales PCR screening twice weekly during hospitalisation
40970036|NCT06485167|DEVICE|HIFEM- chair|The intervention consists of pelvic floor training combined with high-intensity electromagnetic energy treatment (HIFEM®). This includes six HIFEM® treatments (each lasting 28 minutes) with one session per week over six weeks. The woman completes a voiding diary before treatment and one week (±7 days) after treatment. She sits fully clothed on the HIFEM chair.
40970037|NCT01354977|DRUG|Resveratrol|1,000mg twice daily for 28 days
40970038|NCT05503394|BEHAVIORAL|Peer support WeChat platform intervention|Primary caregivers of children with biliary atresia are selected as the study population and divided into intervention and control groups in chronological order at a children's hospital in Shanghai. Primary caregivers who visit the hospital between August 2022 and October 2022 are assigned to the control group and primary caregivers who visit the hospital between January 2023 and March 2023 are assigned to the intervention group. The intervention group will receive a peer support WeChat platform intervention from the day of surgery to one month postoperatively. The level of negative emotions and caregiver burden will be compared between the two groups after the intervention. The intervention group receives the same routine care as the control group.
40970039|NCT05503394|BEHAVIORAL|Routine nursing care group|Provide routine inpatient education and post-discharge follow-up to primary caregivers of biliary atresia.
40970040|NCT02353104|DIETARY_SUPPLEMENT|Onion-Pumpkin Extract|
40970041|NCT05948696|BEHAVIORAL|Horticultural group therapy.|Estimated 10 persons with schizophrenia who attend to a 12-week horticultural group therapy will be assessed for their experience about the program.
40970042|NCT01131754|OTHER|heparin 100U/L flushes|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
40970043|NCT00020904|DRUG|ixabepilone|
40970044|NCT03086889|OTHER|immersion virtual reality (VR)-based rehabilitation|Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
40970045|NCT03086889|OTHER|traditional rehabilitation training|The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
40970046|NCT05348005|DEVICE|Ovira Transcutaneous Electrical Nerve Stimulation Unit|TENS units have a wide application from treatment of chronic back pain, chronic abdominal pain, cancer pain, perioperative pain, and labor pain.19-24 TENS units have been shown to be well-tolerated with minimal side effects and have been successful in reducing pain as well as pain medication use in patients with primary dysmenorrhea, which excludes pathology such as endometriosis. 11-18 Certain TENS units have also been FDA approved for the general indication of pelvic pain.
40970047|NCT04658498|OTHER|Procedure: Usual Care (UC)|Intermittent spontaneous breathing periods
40970048|NCT04658498|OTHER|Procedure: UC + HI-IMT|UC + Supervised daily sessions of training including 4 sets of 6-10 full vital capacity breaths against an external load using a tapered flow resistive device (POWERbreathe KH2, HaB International, UK). The maximum tolerable resistance allowing patients to inhale at least 70% of their inspiratory vital capacity will be chosen and progressively increased throughout the training period.
40970049|NCT04658498|OTHER|Procedure: UC + LI-IMT (sham IMT)|UC + superrvised daily sessions of training including 4 sets of 6-10 breaths at the lowest external imposable load with the tapered flow resistive device (POWERbreathe KH2, HaB International, UK) (i.e. 3 cmH2O).
40970050|NCT04804878|PROCEDURE|Collection of blood, tissue, and other biological samples.|Behavioral health assessments, including quality of life.
40970051|NCT04804878|OTHER|Medical Chart Review|Health data abstracted directly from patient's health records
40970052|NCT04803370|OTHER|Convalescent Plasma with antibody against SARS-CoV-2.|"Convalescent plasma plus standard treatment for COVID-19. The convalescent plasma is from patients recovered from COVID-19 and negative viremia in the test detection COVID-19.~The infusions will be given on days 1 and 2, of the study, after the positive result for COVID-19 of the recipient patient."
40970053|NCT04803370|OTHER|Standard treatment for COVID-19|The patients will receive the standard treatment for COVID-19, according to guidelines for COVID-19 (retrovirals drugs, interferon-α / β, anti-Interleukin-6 monoclonal antibody, oxygen therapy, etc..)
40970054|NCT00491075|DRUG|Pemetrexed|500 mg/m\^2 IV Over 10 Minutes on Day 1.
40970055|NCT00491075|DRUG|Gemcitabine|1500 mg/m\^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
40970056|NCT02469922|DEVICE|Positron emission tomography|
40970057|NCT02469922|RADIATION|radiochemotherapy|Every patients will be treated with radiochemotherapy as a standard of care
40970058|NCT01780818|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
40970059|NCT01780818|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
40970060|NCT01780818|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
40970061|NCT01391559|DRUG|arformoterol|15 mcg administered via nebulizer
40970062|NCT01391559|DRUG|salmeterol|50 mcg delivered vis Diskus
40970063|NCT02596308|BIOLOGICAL|Plague vaccine|Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
40970064|NCT02079545|DRUG|Sirukumab (IV infusion)|Participants will receive a single IV infusion of 100 mg sirukumab.
40970065|NCT02079545|DRUG|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
40970066|NCT02079545|DRUG|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.
40970067|NCT02079545|DRUG|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.
40970068|NCT02079545|DRUG|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
40970069|NCT06436872|OTHER|informing patients with using a booklet|The intervention group was informed before discharge and was given an information booklet. A phone number was given so that the researcher could contact the nurse. In the 4th week, 8th week and 12th week, information was given according to the information needs of the patient and caregiver.
40970070|NCT01031355|DRUG|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
40970071|NCT01031355|DRUG|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
40970072|NCT01031355|DRUG|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
40970073|NCT05251974|DIAGNOSTIC_TEST|Quest beta blocker assay|Blood assay to detect presence of beta blocker medications
40970074|NCT04032860|DRUG|Tenofovir Disoproxil|patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery
40970075|NCT04032860|DRUG|Entecavir|patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery
40970076|NCT03712072|DEVICE|Magnetoencephalography (MEG)|The purpose of the device is to measure magnetic fields produced by an individual's brain and provide information on the location of the source of the fields. Participants between the ages of 0-3 years of old whose head can fit in the MEG helmet will be the patient population used for the BabyMEG. The device will be used in this study to learn more about the somatosensory and motor networks of children who have cerebral palsy and compare their brain signals to healthy children.
40970077|NCT03712072|DEVICE|Electroencephalography (EEG)|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp.
40970078|NCT03712072|DEVICE|Transcranial Magnetic Stimulation (TMS)|The device will be used for motor mapping. Motor threshold is operationally defined as minimum machine output necessary to elicit a response from the abductor pollicis brevis right (APB), contralateral to the stimulated hemisphere, of 50 microvolts, on \>50% of trials. Upper limb motor mapping is conducted at 110% abductor pollicis brevis motor threshold in each hemisphere, or at 100% machine output (MO). Lower limb motor mapping is conducted at a fixed machine output corresponding to the magnitude sufficient to elicit reliable tibialis anterior (TA) motor evoked potentials (MEPs). Single pulse TMS is performed while motor evoked potentials are recorded bilaterally from the APB, deltoid, and TA using surface electromyography (EMG).
41297016|NCT04319289|OTHER|aerobic interval training and Vitamin D supplementation,|"The participants in both groups A will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age .~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting HR~* Frequency: 3 days/week., for 12 weeks~Also all participants in this group are taking gne capsule containing (cholecalciferol 400 IU) every day ."
41297017|NCT04319289|DRUG|Vitamin D supplementation only|One capsule containing (cholecalciferol 400 IU) was taken every day .
41458115|NCT04428645|DEVICE|DailyDose Decision Support|DailyDose provides on-demand, real-time dosing recommendations for insulin meal boluses and basal insulin doses as well as the option to receive recommendations for meals and exercise. DailyDose is an information system comprised of (1) a smart phone app that both collects continuous glucose measurement (CGM) data, insulin data, and fitness data and presents suggestions back to the user, (2) a cloud based information system that stores the raw data and relays suggestions to the user, (3) a glucoregulatory model, automatically personalized for each user, that resides on a cloud server and is fit with the user's individual glucose data, and (4) an adaptive agent that provides insulin dosing options and suggestions as well as meal and exercise recommendations to the user based on the subject's own outcomes and simulations done on the glucoregulatory model.
40970079|NCT02310568|DRUG|PF-06372865.|Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
40970080|NCT00059982|DRUG|perifosine|
40970081|NCT01294631|DRUG|Canagliflozin 300 mg once daily and HCTZ 25 mg once daily|"Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35.."
40970082|NCT04404361|DRUG|Pacritinib|100 mg capsules
40970083|NCT04404361|DRUG|Placebo|Placebo capsules matching pacritinib 100 mg capsules
40970084|NCT05243836|DEVICE|S.T.O.P® F2|Ocufilcon D, 55% water
40970085|NCT05243836|DEVICE|S.T.O.P® DT|Ocufilcon D, 55% water
40970086|NCT05243836|DEVICE|MiSight®|Omafilcon A (60% water)
40970087|NCT03537105|PROCEDURE|Skin biopsies|Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
41297018|NCT04319289|OTHER|aerobic interval training only|"The participants in group C will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age (Gellish ,2007).~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting heart rate (Broderick et al.,2014).~* Frequency: 3 days/week. The whole training lasting for 12 weeks"
41297019|NCT00734409|DEVICE|Bispectral Index (BIS) Monitor|BIS monitoring in addition to RASS assessments
41297020|NCT00620620|DRUG|Inhaled placebo|Inhaled Staccato Placebo
41297021|NCT00620620|DRUG|Inhaled Zaleplon 0.5 mg|Inhaled Staccato Zaleplon 0.5 mg
40970088|NCT03214965|BEHAVIORAL|Facebook group|A closed facebook group used to deliver multimedia content specifically produced to inform the participants about chronic kidney disease, kidney transplantation and related topics. This group is also used to share doubts and life experiences among participants and the interdisciplinary team.
41297022|NCT00620620|DRUG|Inhaled Zaleplon 1 mg|Inhaled Staccato Zaleplon 1 mg
41297023|NCT00620620|DRUG|Inhaled Zaleplon 2 mg|Inhaled Staccato Zaleplon 2 mg
40970089|NCT01664533|DRUG|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
40970090|NCT03475537|DEVICE|transcranial direct current stimulation|the treatment of transcranial direct current stimulation
40970091|NCT00179114|DRUG|Botulinum Toxin Type A|
41297024|NCT00620620|DRUG|Inhaled Zaleplon 4 mg|Inhaled Staccato Zaleplon 4 mg
41297025|NCT02218151|OTHER|Patient-Centered Medical Home (PCMH)|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home. Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
41297026|NCT02218151|OTHER|Standard Care|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient. Advanced practice providers (APPs) will perform histories and physical exams. Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
41458116|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
41458117|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
40970092|NCT00179114|DRUG|Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)|
40970093|NCT00667069|DRUG|triptorelin|
41458118|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
40970094|NCT00667069|PROCEDURE|adjuvant therapy|
40970095|NCT00667069|RADIATION|3-dimensional conformal radiation therapy|
40970096|NCT02204878|DRUG|Parecoxib Sodium|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
41138692|NCT05175794|DIAGNOSTIC_TEST|Xpert® MTB/XDR|The Xpert MTB/XDR Assay, performed on the GeneXpert Instrument Systems, is a nested real-time polymerase chain reaction(PCR) in vitro diagnostic test for the detection of extensively drug resistant (XDR) Mycobacterium tuberculosis (MTB) complex DNA in unprocessed sputum samples or concentrated sediments prepared from sputum. In specimens where MTB is detected, the Xpert MTB/XDR Assay can also detect isoniazid (INH) resistance associated mutations in the katG and fabG1 genes, oxyRahpC intergenic region and inhA promoter; ethionamide (ETH) resistance associated with inhA promoter mutations only; fluoroquinolone (FLQ) resistance associated mutations in the gyrA and gyrB quinolone resistance determining regions (QRDR); and second line injectable drug (SLID) associated mutations in the rrs gene and the eis promoter region.
41297027|NCT05670119|OTHER|Structured Training|Structured catheter-related infection control training was prepared by using evidence-based information and receiving 10 expert opinions. This training will be given to the participants with a face-to-face PowerPoint presentation by the infection control nurse (researcher) and will also be presented as written material.
41297028|NCT04436510|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily"
41297029|NCT04436510|DRUG|Verdiperstat|"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"
41297030|NCT00003859|DRUG|carboplatin|
41297031|NCT00003859|DRUG|cyclophosphamide|
41297032|NCT00003859|DRUG|etoposide|
41297033|NCT00003859|DRUG|vincristine sulfate|
41297034|NCT00003859|PROCEDURE|surgical procedure|
41138693|NCT00221065|DEVICE|Nasal Continuous positive airway pressure - Tyco 420G|CPAP at determined pressure nightly for 1 month
40970097|NCT05667545|DRUG|Peptide|it is about synthetic protein acting on tooth structure help information apatite crystals
40970098|NCT03129698|DRUG|Apatinib|Apatinib 250mg daily
40970099|NCT01658878|BIOLOGICAL|Nivolumab|
40970100|NCT01658878|DRUG|Sorafenib|
40970101|NCT01658878|DRUG|Ipilimumab|
40970102|NCT01658878|DRUG|Cabozantinib|
41297035|NCT00003859|RADIATION|radiation therapy|
40970103|NCT05890846|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
41297036|NCT04255186|DEVICE|Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
41297037|NCT04255186|DEVICE|Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
41297038|NCT04255186|DEVICE|Sham stimulation|a simulated stimulation protocol so that the device does not emit current
41297039|NCT01074411|DRUG|Bortezomib|Given IP
41297040|NCT01074411|DRUG|Carboplatin|Given IP
41297041|NCT01074411|OTHER|Laboratory Biomarker Analysis|Correlative studies
41297042|NCT01074411|OTHER|Pharmacological Study|Correlative studies
41297043|NCT04877782|DEVICE|Transcutaneous vagus verne stimulation|Non-invasive and short electrical stimulation by placing the stimulating electrode at the cymba conchae of the left ear. The reference electrode is placed near the left cymba conchae. It provides a light tingling, massaging feeling in the ear.
40970104|NCT05890846|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
40970105|NCT05890846|BEHAVIORAL|traditional 1on1 course|Between every two iTBS sessions, the participant will receive a personalized 30-minutes one-on-one behavioral course, 2 courses per day, 5 days per week for 12 weeks.
40970106|NCT02205112|DRUG|Nemonoxacin|
40970107|NCT02205112|DRUG|Levofloxacin|
41297044|NCT06111846|DRUG|human Bone Marrow Mesenchymal Stem Cell (hBMMSC)|Group 1: 1.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 2: 2.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 3: 2.0×10\^6 cells/kg (participant's body weight) administered twice (n=4)
40970108|NCT01230905|RADIATION|PET scan and ultrasound|Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound
40990745|NCT03060447|DRUG|ART|ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.
40990746|NCT05350319|RADIATION|A low-dose CT scan of the shoulder|Briefly, a conventional CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both).
41297045|NCT00149825|DRUG|Escitalopram|5 to 20 mg for 12 weeks
40990747|NCT02989350|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 vs Placebo
41297046|NCT00149825|BEHAVIORAL|CBTI|Cognitive Behavioral Treatment for Insomnia
41297047|NCT00149825|BEHAVIORAL|CTRL|Control Therapy consists of Pseudo-desensitization Therapy for Insomnia
40970109|NCT03498027|DEVICE|TaqMan Bacillus anthracis Detection Kit|The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
40970110|NCT01473836|DRUG|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
41297048|NCT02677701|DRUG|azithromycin|500mg tablet over-encapsulated to match placebo
41297049|NCT02677701|DRUG|placebo (for azithromycin)|
41297050|NCT02677701|DRUG|inhaled tobramycin|clinically prescribed inhaled tobramycin used by subjects participating in the study
41297051|NCT02383719|DEVICE|Oro-nasal Mask|
41297052|NCT05506332|DRUG|Venetoclax|Venetoclax and 6-mercaptopurine
41297053|NCT05506332|DRUG|6-mercaptopurine|Venetoclax and 6-mercaptopurine
41297054|NCT01784562|DRUG|Adempas (Riociguat, BAY63-2521)|Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
41297055|NCT00495664|DEVICE|Titan stent and Taxus-Liberte stent|
41297056|NCT00023985|BIOLOGICAL|autologous tumor cell vaccine|
41297057|NCT00023985|BIOLOGICAL|therapeutic autologous dendritic cells|
41297058|NCT00023985|PROCEDURE|conventional surgery|
40970111|NCT01473836|DRUG|Ceftriaxone sodium|Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
40970112|NCT01414010|DIETARY_SUPPLEMENT|Trametes versicolor extract|1,200 mg, 3 times daily on an empty stomach for 14 days
41297059|NCT02599766|OTHER|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
41297060|NCT02599766|OTHER|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
41297061|NCT00887692|BEHAVIORAL|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
41297062|NCT06553781|DRUG|Temozolomide、Fruquintinib、Cadonilimab|"Combination treatment period:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; Temozolomide: 150\~200mg/m2, poqd, d1-5, q4W; The combined treatment lasted 6 cycles.~Maintenance treatment:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; The maximum duration of maintenance treatment is not more than 2 years."
41297063|NCT00144105|DRUG|TPV500mg/RTV200mgBID|
41297064|NCT00144105|DRUG|TPV500mg/RTV100mgBID|
41297065|NCT00144105|DRUG|LPV400mg/RTV100mgBID|
41297066|NCT05265845|BEHAVIORAL|Intervention|The intervention aims to support infant feeding decisions and teach responsive feeding strategies.
41297067|NCT05265845|BEHAVIORAL|Text4Baby|Free health and wellness text messages timed to due date through pregnancy and up until the baby's first birthday.
41297068|NCT02389413|DRUG|PQ912 oral|
41297069|NCT02389413|OTHER|Placebo|
41458119|NCT02246296|DIETARY_SUPPLEMENT|Standard F75 Milk|This is the standard F75 milk used worldwide (Control group)
41458120|NCT02246296|DIETARY_SUPPLEMENT|Modified F75 Milk|This is the experimental group
41297070|NCT03216551|DIAGNOSTIC_TEST|Intra-operative frozen section|Tumor histologic subtypes (whether it is lepidic predominant adenocarcinoma), N1 nodes metastasis (lymph nodes adjacent to the tumor will be sent to frozen section) and visceral pleural invasion will be determined by the intra-operative frozen section.
40970113|NCT01414010|DIETARY_SUPPLEMENT|Saccharomyces boulardii|250 mg, 3 times daily on an empty stomach for 14 days
41458121|NCT05841693|DRUG|Carbohydrate|The experimental group of patients will consume the carbohydrate rich fluid 2 hours before the elective CD.
40970114|NCT01414010|DRUG|Amoxicillin|250 mg 3 times daily at least 1 hour before meals for 7 days
40970115|NCT00430690|PROCEDURE|acoustic startle testing|acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
41458122|NCT05841693|DRUG|Placebo|The control group will be offered same amount of placebo fluid.
41458123|NCT03523650|DRUG|Propranolol Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.
41458124|NCT03523650|DRUG|Placebo Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
41458125|NCT00964054|OTHER|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
41458126|NCT00964054|OTHER|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
40970116|NCT06318195|BEHAVIORAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
41297071|NCT05942898|OTHER|The present study does not contain any intervention|The present study does not contain any intervention
41297072|NCT00003068|DRUG|amifostine trihydrate|
41297073|NCT00003068|DRUG|cyclophosphamide|
41297074|NCT00003068|DRUG|mitoxantrone hydrochloride|
40970117|NCT01530997|RADIATION|Intensity Modulated Radiotherapy (IMRT)|All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).
40970118|NCT01530997|DRUG|Cisplatin|Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
40970119|NCT01530997|PROCEDURE|Limited surgical evaluation|4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
40970120|NCT00352560|DRUG|Irbesartan|Tablets, Oral, 300 mg, once daily, 30 days.
40970121|NCT00352560|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 30 days.
40990748|NCT02989350|DIETARY_SUPPLEMENT|Placebo|Lactobacillus reuteri DSM 17938 vs Placebo
41297075|NCT00003068|DRUG|thiotepa|
41297076|NCT00003068|PROCEDURE|peripheral blood stem cell transplantation|
41458127|NCT04381481|BEHAVIORAL|Experimental Drink: Nutrition claim on fruit drinks|Fruit drink contains a nutrition claim (task 1)
41458128|NCT04381481|BEHAVIORAL|Control Drink: No nutrition claim|Fruit drinks does not contain a nutrition claim (task 1)
41458129|NCT04381481|BEHAVIORAL|Experimental snack: Text warning|The snack contains a text warning (task 2)
41458130|NCT04381481|BEHAVIORAL|Experimental snack: Graphic warning|The snack contains a graphic warning (task 2)
41458131|NCT04381481|BEHAVIORAL|Control snack: barcode label|The snack contains a neutral barcode label (task 2)
41458132|NCT02171988|DRUG|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
41458133|NCT02171988|DRUG|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
41458134|NCT02171988|DRUG|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
41458135|NCT02171988|DRUG|Bisoprolol+pyridostgmine|Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
41138694|NCT03662698|BEHAVIORAL|Guided Imagery|GI is a relaxation technique involving the visualization of images and is considered an adjuvant cancer therapy.The GI intervention will include two hour-long meetings between the participant and a trained interventionist. The sessions will include direct, written, and audio delivery of one of three GI vignettes. The patient will be able to choose one of the three vignettes. The approximately twelve minute long vignettes included in the study will be: Taking a Walk, Healthy Cell Alliance for Treatment, and Daily Intention (32). Patients will also be given access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
41138695|NCT03662698|OTHER|Treatment as Usual|This will include a tour of the treatment room and education about RT. Patients will also receive educational materials about RT including the process of RT and CT simulation, treatment side effects, pain management, and swallowing exercises. Participants in this condition will also have access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
41297077|NCT03249896|BEHAVIORAL|Habits-GDM mobile app|The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina or Aina Mini device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
41297078|NCT02433210|DEVICE|ELISIO-15H|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
41297079|NCT02433210|DEVICE|Revaclear|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
41297080|NCT02433210|DEVICE|Optiflux|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
41297081|NCT01171547|DRUG|Daptomycin|once daily over 5 days
41297082|NCT01950481|DRUG|LDK378|Oral LDK378 750 mg once
41458136|NCT02225015|BEHAVIORAL|Follow-up Telephone Genetic Counselling|Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
41297083|NCT06080113|RADIATION|Focal Brachytherapy|Targeted focal brachytherapy is an image-guided technique, where the radioactive source is placed only, and directly into the cancerous area of the prostate. The aim is to preserve the normal surrounding prostate gland tissue to limit treatment-related side effects to the adjacent anatomical structures. A multiparametric prostate MRI is used to identify, localize, and delineate the intraprostatic PCa tumour lesion and plan treatment. A specialized MRI-ultrasound image-fusion software combines the MRI-images with dynamic ultrasound performed in the operating room and is used to focally guide the placement of the radioactive source in the prostate cancer (PCa) tumour focus based on focal dosimetry calculations. A safety margin around the tumour is applied where it is possible to account for MRI tumour volume underestimation, microscopic spread, and treatment uncertainties.
41297084|NCT01985685|DRUG|Thiamine|200 mg IV thiamine
41297085|NCT02205970|DEVICE|TENS|In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.
41297086|NCT02205970|DEVICE|TENS (sham)|In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
41297087|NCT00907478|BIOLOGICAL|romiplostim|Romiplostim administered by subcutaneous injection
41297088|NCT02612077|OTHER|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
41297089|NCT02612077|DRUG|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
41297090|NCT04343885|DRUG|177Lu-PSMA-617|Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
41297091|NCT04343885|DRUG|Docetaxel|Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
41297092|NCT01072279|OTHER|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
41297093|NCT01072279|OTHER|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
41297094|NCT06021652|DEVICE|MindCotine Virtual reality|Virtual reality platform
41297095|NCT03819244|DEVICE|940 nm Gallium Aluminum Arsenide Diode Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with diode laser for placing the healing abutment.
41297096|NCT03819244|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
41458137|NCT03472196|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
40970122|NCT03640845|OTHER|tele-expertise|"Tele-expertise consists of the remote realization of a multi-professional medication review (clinical pharmacist and doctor / geriatrician), ie a complete and systematic analysis of sociodemographic, clinical, biological and pharmaceutical data transmitted in such a way standardized at the EHMP and aimed at optimizing the therapeutics of the resident patient of the EHPAD requesting tele-expertise.~Tele-expertise is realized in three stages, that are~* the transmission, the collection and the organization of the data,~* the analysis of the data and their confrontation with the referential and recommendations~* the writing of a Personalized Pharmaceutical Plan"
40970123|NCT03565744|BEHAVIORAL|B'N Fit POWER|Participants will undergo a medical assessment and using an Electronic Medical Record (EMR) template, providers will screen for a healthy weight and the 7 target behaviors. Participants will set goals with the provider to attain one of the target behaviors and will receive an EMR-generated treatment plan summarizing healthy weight and target behavior goals. At 20-minute follow-up visits during the school day, the provider will review weight and target behavior attainment and monitor co-morbidities and barriers to participation. Group 1 participants will also have access to daily MMCC afterschool programming from 3-6pm from September through May each year with tailored programming including weekly core nutrition, behavior, and cooking classes and at least five hours of physical activity.
40970124|NCT00543504|DRUG|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
40970125|NCT00543504|DRUG|Sorafenib|200 mg By Mouth Daily for 28 Days
40970126|NCT00543504|DRUG|Erlotinib|50 mg By Mouth Daily for 28 Days.
40970127|NCT00543504|DRUG|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
40970128|NCT00543504|DRUG|Lapatinib|250 mg By Mouth Daily for 21 Days.
40970129|NCT00543504|DRUG|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
41458138|NCT04486716|DRUG|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)
41458139|NCT02313662|DEVICE|NBI and PDD|
40970130|NCT00543504|DRUG|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
40970131|NCT05534945|DRUG|Programmed intermittent epidural bolus 5 ml|patients in this group will receive a programmed epidural intermittent bolus of 5 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
41138696|NCT06306937|DIAGNOSTIC_TEST|Evalution of serum levels of vitamin D and IL8|"Group 1 (Periodontitis Group): The intervention involves observing and analyzing individuals diagnosed with periodontitis based on established clinical criteria. The focus is on assessing vitamin D and IL8 levels in the serum and correlating these levels with the severity of periodontitis, determined by clinical indices such as probing depth, clinical attachment loss, and bleeding on probing.~Group 2 (Control Group): The intervention involves observing and analyzing individuals without any signs or history of periodontal disease. The focus is on assessing vitamin D and IL8 levels in the serum for comparison with the periodontitis group. This group serves as the healthy control for the study."
41138697|NCT04788407|DRUG|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID for 7 days
41297097|NCT01037374|OTHER|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
41458140|NCT02506205|BEHAVIORAL|Lee Silverman Voice Treatment (SVLT) LOUD|
41138698|NCT04788407|DRUG|Placebo|Subjects will receive placebo TID for 7 days
41458141|NCT03278041|PROCEDURE|Submental flap for palatal reconstruction|"Under General Anesthesia the tumor in the maxilla will be resected (partial maxillectomy) with a safety margin, then the defect will be reconstructed immediately by :~Submental artery flap : from submental area with 1 cm distance from inferior mandibular border in paddle shape.~* 1st step will be identify the facial artery and vein,~* 2nd step dissection and extend toward midline in subplatsmal plane. The flap contains submental artery and vein.~* 3rd step creating submucous tunnel between vestibular border of post maxillectomy defect and to extraoral incision .~The flap will be through the oral cavity and will be anchored to the intact remaining hard plate with bone sutures by 2-0 vicryl® suture."
41458142|NCT03278041|DEVICE|maxillary obturator|immediate surgical obturator
41458143|NCT00253838|PROCEDURE|Restoration HA stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
40970132|NCT05534945|DRUG|Programmed intermittent epidural bolus 6 ml|patients in this group will receive a programmed epidural intermittent bolus of 6 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
41458144|NCT00253838|PROCEDURE|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
40970133|NCT05534945|DRUG|Programmed intermittent epidural bolus 7 ml|patients in this group will receive a programmed epidural intermittent bolus of 7 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
40990749|NCT00780325|DRUG|CG100649 (2 mg)|CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
41138699|NCT04482413|DRUG|AstroStem|Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36.
41138700|NCT04482413|DRUG|Placebo|Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
41138701|NCT00378898|DEVICE|BRAVO capsule|
41138702|NCT00378898|PROCEDURE|Fluoroscopy|"one time xray to determine evacuation of bravo"
41138703|NCT00378898|OTHER|sham BRAVO capsule placement|
40970134|NCT05534945|DRUG|Programmed intermittent epidural bolus 8 ml|patients in this group will receive a programmed epidural intermittent bolus of 8 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
40970135|NCT05534945|DRUG|Programmed intermittent epidural bolus 9 ml|patients in this group will receive a programmed epidural intermittent bolus of 9 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
41138704|NCT01189552|BEHAVIORAL|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.
41138705|NCT01189552|BEHAVIORAL|Nondirective Therapy (NDT)|The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet over the course of 4 weeks.
40970136|NCT05534945|DRUG|Programmed intermittent epidural bolus 10 ml|patients in this group will receive a programmed epidural intermittent bolus of 10 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
40970137|NCT06177587|OTHER|Assesment of biomarkers in acute coronary syndromes|Collection of 20ml of blood from peripheral vein.
41138706|NCT02446015|DRUG|SYSTANE® ULTRA Lubricant Eye Drops|
40970138|NCT03995121|RADIATION|[11C]APP311|It has been shown that \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
41138707|NCT03052517|DRUG|QAW039 150 mg|One tablet of QAW039 150 mg once daily
41458145|NCT02583191|DRUG|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
41138708|NCT03052517|DRUG|QAW039 450 mg|One tablet of QAW039 450 mg once daily
41138709|NCT03052517|DRUG|Placebo|One tablet of Placebo once daily
40970139|NCT01308060|DRUG|Botulinum Toxin Type A|During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
41297098|NCT06482645|PROCEDURE|Perilesional/regional systematic biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra). The location of these nine cores depended on the shape and location of the suspicious lesion.
41458146|NCT02583191|DRUG|low-molecular heparine|"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~* Enoxaparin 1 mg/kg BW twice daily~* Tinzaparin 175 I.E./kg BW once daily~* Dalteparin 200 I.E./kg BW once daily"
41458147|NCT05863845|DRUG|Venetoclax|100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO
41458148|NCT05863845|DRUG|Carmustine|300mg/m2 day -7, Given IV
41458149|NCT05863845|DRUG|Cytarabine|100mg/m2/d, day -6 to day -3, Given IV
40970140|NCT01308060|OTHER|Placebo|
40970141|NCT05083572|DRUG|Colonic lavage with polyethylene glycol|The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
40970142|NCT05083572|DIETARY_SUPPLEMENT|Probiotic|The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
40970143|NCT05083572|DRUG|Antibiotic|"The subjects will undergo pre-treatment to cleanse the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course."
40970144|NCT03825315|BIOLOGICAL|DAXI 80 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)
40970145|NCT03825315|BIOLOGICAL|DAXI 120 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) 120 U (High Dose Group)
41458150|NCT05863845|DRUG|Etoposide|200mg/m2/d, day -6 to day -3, Given IV
40970146|NCT03825315|OTHER|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
40970147|NCT04951999|OTHER|Blood sampling|For 10 visits (out of the 12 of the protocol), \~40 ml of blood is sampled for research purposes in addition to care sampling.
40970148|NCT00112320|PROCEDURE|PVR plus RV remodeling|PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume
40970149|NCT00112320|PROCEDURE|Standard PVR|PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
41297099|NCT06482645|PROCEDURE|Combination of systematic biopsy and targeted biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core biopsy.
40970150|NCT06361485|BIOLOGICAL|Lumbar Injections with 10cc's of Wharton's Jelly Allograft|Low Back Injections with Minimal Manipulation Umbilical Cord Tissue
40970151|NCT05209958|DIAGNOSTIC_TEST|Neutrophil Lynphosite ratio|The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).
40970152|NCT05369637|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
40970153|NCT05369637|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
40970154|NCT05369637|BEHAVIORAL|Behavioral: Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
40990750|NCT00780325|DRUG|Celecoxib|Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
41297100|NCT03252639|PROCEDURE|EVT for RAS & PBV acquisition protocol for target kidneys|
41297101|NCT05002192|DRUG|Eucalyptol, Limonene and Pinene Enteric Soft Capsule|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
41458151|NCT05863845|DRUG|Melphalan|140mg/m2, day -2, Given IV
41458152|NCT05863845|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
40970155|NCT05369637|BEHAVIORAL|Psychoeducation|This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.
40970156|NCT05369637|OTHER|Diagnosis and correction of hearing impairment|This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.
40970157|NCT03025477|DRUG|CC0 - Carboplatin (IV) - Paclitaxel (IV)|(6 cycles)
40970158|NCT03025477|DRUG|CC0 - Cisplatin (IP) - Epirubicin (IV)|(6 cycles)
40970159|NCT03025477|DRUG|CC>0 - Carboplatin (IV)- Paclitaxel (IV)|"* carboplatin (IV) - paclitaxel (IV) (3 cycles)~* Interval surgery~* Carboplatin (IV) - paclitaxel (IV) (3 cycles)"
40970160|NCT03025477|DRUG|CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)|"* Cisplatin (IV) - Epirubicin (IV) (3 cycles)~* Interval surgery :~  * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~ * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)"
40970161|NCT00350909|BEHAVIORAL|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
40970162|NCT03667924|BEHAVIORAL|PorchLight Project|Senior Companions (or other LSS-MN volunteers providing senior companionship services) who deliver the PorchLight Project will complete online CARES® Dementia Care Specialist training modules, additional trainings delivered by the research team (1. overview of the PorchLight Project, 2. review of the National Consensus Guidelines on Palliative Care, 3. review of the list of guided questions, and 4. review of journaling approach and LTSS resources), and participate in unstructured monthly check-ins (discussions and case review as applicable) with the research team.
40970163|NCT00563381|DRUG|Tiotropium bromide|18 mcg/daily
40970164|NCT00563381|DRUG|Salmeterol|100 mcg/daily
40970165|NCT00563381|DRUG|Placebo Salmeterol|Placebo identical to Salmeterol device
40970166|NCT00563381|DRUG|Placebo Tiotropium|Placebo identical to Tiotropium device
40970167|NCT04440202|BEHAVIORAL|Conventional sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional sea bream fillets and will be asked to consume them twice weekly for 1 month. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
40970168|NCT04440202|BEHAVIORAL|Enriched sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 enriched sea bream fillets and will be asked to consume them twice weekly for 1 month. Enriched sea bream fillets will be produced by a fish farming company from fish bread with a diet enriched with a fraction of bioactive polar lipids extracted from olive oil by-products. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
41458153|NCT01627639|DRUG|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
40970169|NCT05114798|BEHAVIORAL|Time restricted eating|daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
41458154|NCT01627639|DRUG|Placebo|Placebo
41458155|NCT02132624|BIOLOGICAL|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
41458156|NCT04010227|BEHAVIORAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
41138710|NCT03845881|DRUG|Oxycodone|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
41138711|NCT03845881|DRUG|Placebo Oral Tablet|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
40970170|NCT05114798|BEHAVIORAL|Calorie Restriction|daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
41458157|NCT04010227|BEHAVIORAL|Education/Support|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
41458158|NCT03924154|DRUG|RVT-1201|RVT-1201 600 mg immediate-release tablet
40990751|NCT00780325|DRUG|Placebo capsules|Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
41138712|NCT01386632|DRUG|DCA (dichloroacetate)|DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m\^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
41458159|NCT03924154|DRUG|Placebo|Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
41138713|NCT01386632|DRUG|Placebo|Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
41458160|NCT03651336|DEVICE|ARGOS-IO Sensor Pressure System|The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
41458161|NCT03104231|OTHER|three-dimensional (3D) movie|Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
41458162|NCT03515044|DRUG|40 mg Rifaximin SSD once daily|SSD once daily (QD)
41458163|NCT03515044|DRUG|40 mg Rifaximin SSD twice daily|SSD twice daily (BID)
40990752|NCT00780325|DRUG|Naproxen|Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
40990753|NCT00780325|DRUG|Acetazolamide|Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
41458164|NCT03515044|DRUG|80 mg Rifaximin SSD once daily|SSD once daily (QD)
40970171|NCT05221515|BEHAVIORAL|Anger can go!|"The intervention Anger Can Go! was designed to treat anger regulation problems in autistic children aged 8 to 13 years old. The intervention consists of nine sessions of 60 minutes and is divided in four phases. Phase 1: psycho-education, affect-education and measuring anger with an anger-thermometer. This is a self-report scale presented as the drawing of a thermometer, that allows the child to indicate his level of anger, as linked to specific bodily and behavioral representations on a scale from 0 to 3. Phase 2: making a functional behavior assessment (FBA) and taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts. Phase 3: taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts, shifting attention away from aversive stimuli, to cope with the stress of the anger provoking situation. Phase 4: creating solutions to cope with an anger provoking situation."
41297102|NCT05002192|DRUG|Ambroxol injection|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort
41297103|NCT05002192|DRUG|Other oral mucolytic drugs|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
41297104|NCT03406949|BIOLOGICAL|obrindatamab|B7-H3 x CD3 DART protein
41297105|NCT03406949|BIOLOGICAL|retifanlimab|anti-PD-1 antibody
41297106|NCT01152450|DRUG|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
41297107|NCT01152450|DRUG|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
41297108|NCT01152450|DRUG|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
41458165|NCT03515044|DRUG|80 mg Rifaximin SSD twice daily|SSD twice daily (BID)
41297109|NCT03013491|DRUG|CX-072|
41297110|NCT03013491|DRUG|ipilimumab|
41297111|NCT03013491|DRUG|vemurafenib|
41297112|NCT01099410|PROCEDURE|Fiberoptic bronchoscopy|"which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed (lavaged) with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours."
41458166|NCT03515044|DRUG|Placebo|Administered twice daily (BID)
41458167|NCT04947761|DRUG|modified Tian Wang Bu Xin Dan hydrogel patch|modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
41458168|NCT04947761|OTHER|placebo patch|placebo patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
40970172|NCT05221515|BEHAVIORAL|Parent psycho-education|Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
40970173|NCT04649060|DRUG|Melflufen|Powder for solution for i.v. infusion
41138714|NCT04226118|DEVICE|Vein Illumintion System device|Spotting veins of a patient by use of a Vein Illumintion System device
41297113|NCT01099410|PROCEDURE|blood draw|Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.
41297114|NCT01099410|PROCEDURE|intravenous catheter|An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
40970174|NCT04649060|DRUG|Dexamethasone|Oral tablets
40970175|NCT04649060|DRUG|Daratumumab|Solution for s.c. injection
40970176|NCT01876797|DRUG|ticagrelor/prasugrel|
40970177|NCT05755048|BIOLOGICAL|Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)|Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
40970178|NCT05755048|BIOLOGICAL|Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)|Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
40970179|NCT04456660|DIAGNOSTIC_TEST|Markers of ultrasound|CRL, HR, and other ultrasound measurements.
40970180|NCT04456660|DIAGNOSTIC_TEST|Immunologic factors|Measurement of NK cells subpopulations types in the maternal serum
40970181|NCT04456660|DIAGNOSTIC_TEST|Serum factors|Measuring the maternal serum concentration of sFlt-1, PLGF, glycodelin-A, and other substances.
41138715|NCT06301048|PROCEDURE|Stent Placement in Pancreatic and Bile Ducts|Post-resection, endoscopic retrograde cholangiopancreatography (ERCP) was performed for stent placement in pancreatic or bile ducts as needed, with X-ray confirmation of stent positioning.
41138716|NCT06371950|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis|5 billion colony forming units (CFU) per day for 9 weeks (3 weeks before surgery to six weeks after surgery)
41138717|NCT06371950|OTHER|Placebo|Placebo
41297115|NCT01328288|DRUG|standard ART according to the Thai Ministry of Public Health national guidelines|Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
41458169|NCT04174053|DEVICE|Enteric capsule|Enteric capsule to measure body temperature will be ingested every 24 hours during aplasia. the temperature measured with this technique will be compared with auricular temperature measurement (in current practice nurse measure temperature every 4 hours during aplasia).
41458170|NCT04883333|DRUG|LEO 153339|LEO 153339
40970182|NCT06124560|DRUG|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
41458171|NCT04883333|DRUG|Placebo|Placebo
41458172|NCT04712734|DRUG|Iloperidone|oral tablet, long-acting injection
41458173|NCT00625157|DRUG|ASF 1096 0.5 % cream|
41458174|NCT00625157|DRUG|ASF 1096 placebo cream|
41458175|NCT02804724|OTHER|No intervention|
41458176|NCT02107196|DRUG|Ibodutant 10 mg|Oral tablet, to be given once daily.
41458177|NCT02107196|DRUG|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
41458178|NCT00139594|DRUG|licarbazepine|
41458179|NCT00844974|OTHER|Prevalence|Mood and cognitive assessments
41458180|NCT00379353|DRUG|Thalidomide|100 mg capsules orally, once a day for 14 days.
41458181|NCT00379353|DRUG|Placebo|Two placebo capsules orally, once a day for 14 days.
41458182|NCT06315660|BEHAVIORAL|Cognitive Miljeu Therapy|TAU is an integrated voluntary inpatient treatment based on the principles of CBT, lasting between 12-20 weeks. This treatment includes exercise, close medical monitoring, group-based CBT for SUD, planning with social services, and is called Cognitive Milieu Therapy.
41458183|NCT06315660|BEHAVIORAL|Virtual Reality based CBT for Anxiety|The experimental intervention is a manualized add-on to TAU and comprises eight sessions of 60 minutes over a period of four weeks. Of these eight sessions, six will include 30 minutes of VR-based behavioral experiments targeting agoraphobic and social fear.
40970183|NCT00388778|DRUG|Doxycycline|
41458184|NCT02285491|DRUG|10ml of bupivacaine 0.5%|This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs
40970184|NCT00078637|DRUG|E7820|
40970185|NCT01962805|DRUG|Proellex Formulation A|
40970186|NCT01962805|DRUG|Proellex Formulation B|
40970187|NCT01293357|DRUG|LEO 90105|Ointment
40970188|NCT04162639|BIOLOGICAL|Skin allograft|Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.
41458185|NCT02285491|DRUG|Placebo|10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
41458186|NCT03324217|OTHER|Mental Practise|They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
41458187|NCT02183376|DRUG|BI 1356|
41458188|NCT00560326|DRUG|Tacrolimus Ointment 0.03%|Once or twice daily topical application
41458189|NCT00469898|DRUG|Carboplatin|"Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~\*up to 6 cycles at physician's discretion"
40970189|NCT03182088|DRUG|norepinephrine infusion (0.025 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)
40970190|NCT03182088|DRUG|norepinephrine infusion (0.050 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)
41458190|NCT00469898|DRUG|irinotecan hydrochloride|"50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes."
41458191|NCT03371524|OTHER|Cardiac Echography|While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.
40970191|NCT03182088|DRUG|norepinephrine infusion (0.075 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).
40970192|NCT03182088|DRUG|Bupivacaine|The patient will receive spinal anesthesia using Bupivacaine (10 mg).
40970193|NCT05779098|PROCEDURE|Extensive hepatectomy|Extensive hepatectomy
40970194|NCT01936103|DRUG|standard group|standard statin treatment:Atorvastatin statins 20mg / night .
40970195|NCT01936103|DRUG|intensive group|intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
41458192|NCT02151149|DRUG|nab-paclitaxel|
41458193|NCT02151149|DRUG|Carboplatin|
41458194|NCT04986254|OTHER|Blood sampling|During a single dosing interval, each participant will have 1 - 8 blood samples taken for each antibiotic. Blood samples (3 mL each) will be drawn from an existing arterial line or central venous catheter. Blood samples will be collected on 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
41458195|NCT04986254|OTHER|Epithelial lining fluid sampling|Epithelial lining fluid will be sampled using either a bronchoalveolar lavage (BAL) or mini-BAL technique, in accordance with the preferred procedure in participating sites. 3 BAL or mini-BAL samples will be collected over 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
41458196|NCT04986254|OTHER|Urine sampling|The total urine volume over the duration of the dosing interval will be collected on the two sampling occasions for a calculated urinary creatinine clearance measurement.
41458197|NCT04986254|DRUG|Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam|Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.
41458198|NCT04006873|DRUG|Tezacaftor/Ivacaftor + Ivacaftor|As per description in arms.
40970196|NCT02389348|DRUG|DSM265|Single oral doses of DSM265
40970197|NCT02389348|DRUG|OZ439|Single oral doses of OZ439
40970198|NCT02129998|OTHER|IVF/ICSI treatment|
40970199|NCT01663532|DRUG|Aripiprazole IM Depot|
40970200|NCT01663532|DRUG|Placebo|Matching Placebo
40970201|NCT05059210|BEHAVIORAL|Coach McLungs Intervention|Practices have received implementation of Coach McLungs
40990754|NCT00780325|DRUG|CG100649 (8 mg)|CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
41458199|NCT04006873|DRUG|Placebo oral tablet|As per description in arms
41458200|NCT00245986|PROCEDURE|Blood draw|
41297116|NCT02755740|OTHER|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
40970202|NCT01788332|DRUG|Olaparib|Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
41138718|NCT06325852|OTHER|DBS programing|The physician will utilize the Boston Scientific Chronos Clinician Programmer (software) to make adjustments to the Deep Brain Stimulation (DBS) settings for the patients.
41297117|NCT02401555|DEVICE|Geenius HIV1/2 Supplemental Assay|The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
41297118|NCT00984464|BIOLOGICAL|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
41297119|NCT00984464|DRUG|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
41297120|NCT00984464|DRUG|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
41297121|NCT05346601|DRUG|Chiauranib|50mg po only once
41297122|NCT05552378|DEVICE|Multi-Gyn FloraFem|Vaginal gel packed in 5 single use plastic tubes.
41297123|NCT04614545|DRUG|Phentermine 37.5 Mg|Patients will receive 37.5 mg of phentermine daily for a 12 week duration
41297124|NCT04614545|BEHAVIORAL|Dietary program|Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician
41297125|NCT04614545|BEHAVIORAL|Exercise program|Patients will be provided with a personalized exercise program
41297126|NCT02203253|DRUG|Thalidomide|100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1
41297127|NCT02203253|DRUG|Placebo for thalidomide|Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1
41297128|NCT02203253|DRUG|Palonosetron and Dexamethasone|Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
41138719|NCT01623011|PROCEDURE|Arthroscopic Sub-acromial Decompression Surgery|The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
41138720|NCT01623011|PROCEDURE|Shoulder Arthroscopy|This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
41138721|NCT01623011|OTHER|Active Monitoring with Specialist Reassessment|Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
41297129|NCT06247696|OTHER|Herbal Pillows|Pillows containing herbs
41297130|NCT00653796|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
41297131|NCT00653796|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
41297132|NCT04479501|OTHER|Asthma exacerbation related hospitalization|Evaluate the difference between patients with single and multiple hospitalizations for asthma exacerbation
41297133|NCT01182129|DRUG|Nicotine|Nicotine pouch, 2.2 mg, single dose, 30 minutes
41297134|NCT01182129|DRUG|Nicotine|Chewing Gum, 4 mg, single dose, 30 minutes
41297135|NCT00275405|DRUG|Garlic Oil Macerate|
41297136|NCT00585299|OTHER|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
41297137|NCT00585299|OTHER|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
41297138|NCT01892254|DRUG|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
41297139|NCT01892254|DRUG|Placebo|Placebo (to metformin)
41297140|NCT01797783|DEVICE|Nelfilcon A multifocal contact lens with comfort additive|
41297141|NCT01797783|DEVICE|Nelfilcon A multifocal contact lens|
41297142|NCT01712386|DIETARY_SUPPLEMENT|Beetroot|
41297143|NCT01712386|DIETARY_SUPPLEMENT|Beetroot placebo|
41297144|NCT01454401|DEVICE|LeucoPatch treatment|weekly
41297145|NCT00282958|DRUG|Botulinum Toxin type a (Botox)|
41297146|NCT01780558|OTHER|natural cycles|the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
41297147|NCT01780558|DRUG|estradiol and progesterone|oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
41297148|NCT00293072|DRUG|Rituximab|
40970203|NCT01788332|OTHER|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water
40970204|NCT03445104|OTHER|Huperzine A|During one of the two experimental sessions, participants will be given huperzine A.
40970205|NCT03445104|OTHER|Placebo|During one of the two experimental sessions, participants will be given a placebo.
40970206|NCT01997632|BIOLOGICAL|a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)|a single dose m-IPV2 HD (study vaccine), 0,5ml
40970207|NCT01997632|BIOLOGICAL|a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).|a single 0.5 ml dose Imovax Polio (control vaccine)
40970208|NCT03870698|PROCEDURE|Laparoscopic group|The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
40970209|NCT03048968|PROCEDURE|Gait, sit-to-stand movement, stair climbing and treadmill gait|Spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system, surface electromyography (sEMG) and F-Scan Mobile system during 10m walking test. Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during stair climbing. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
40970210|NCT03048968|PROCEDURE|Sit-to-stand movement and treadmill gait|Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
41138722|NCT04432415|DEVICE|Silver Diamine Fluoride|Annual application od Silver Diamine Fluoride
41297149|NCT04353622|DEVICE|Exoskeleton robot for upper extremity|"Robot-assisted Treatment Program:~* 10 minutes elbow flexion/extension~* 10 minutes forearm supination/pronation~* 10 minutes wrist flexion/extension~* 10 minutes ulnar/radial deviation~Frequency: 2/week Duration: 12 sessions (6 weeks)"
41297150|NCT04353622|OTHER|Conventional physiotherapy|Ferquency: 2/week Duration: 12 sessions (6weeks) Each session: 50 minutes
41297151|NCT06326840|DRUG|Metformin|All participants were administered 1500 mg/day of metformin for eight weeks. The trial design is single-group with no masking.
41297152|NCT00541892|OTHER|Medium with no human serum albumine added|See above
40970211|NCT03048968|DEVICE|gait enhancing mechatronic system (GEMS)|"Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS in elderly adults.~Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients."
41297153|NCT00541892|OTHER|Conventional medium|See above
41297154|NCT00392002|DRUG|Esomeprazole|
41297155|NCT02615106|DRUG|Endostar|7.5 mg/m2/day, day 1-14
41297156|NCT02615106|RADIATION|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
40970212|NCT03048968|DEVICE|treadmill|Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
40970213|NCT04758780|DRUG|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
40970214|NCT00023504|BIOLOGICAL|Pneumovax|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
40970215|NCT00023504|BIOLOGICAL|Rabavert|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
41297157|NCT00872716|DRUG|Quetiapine XR|100 mg single-dose Quetiapine XR
41297158|NCT00872716|OTHER|Placebo|Placebo
41297159|NCT00227279|BIOLOGICAL|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
41297160|NCT00392444|DRUG|sunitinib malate|Given orally
40970216|NCT00023504|BIOLOGICAL|Prevnar|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
41297161|NCT01401088|DEVICE|Artificial drainage implant|Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
41297162|NCT00606762|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
40970217|NCT00023504|BIOLOGICAL|Tetanus diphtheria toxoid|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
40970218|NCT06248632|OTHER|Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R)|Expression of inflammatory markers obtained from circulating monocytic cells of XLH
41458201|NCT04000191|PROCEDURE|MAC|Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
40970219|NCT01854710|DRUG|ADASUVE 10 mg 2 doses 2 hours apart|Inhaled loxapine 10 mg 2 doses 2 hours apart
40970220|NCT01854710|DRUG|Inhaled Placebo|Staccato placebo via inhalation x 2 at 2 hours apart
40970221|NCT01854710|DRUG|Oral moxifloxacin 400 mg|Oral moxifloxacin 400 mg single dose
40970222|NCT01854710|DRUG|Oral placebo|Oral capsule identical in appearance to moxifloxacin
40970223|NCT05152589|DIAGNOSTIC_TEST|hearing test|Auditory Brainstem Response (ABR) Test
40970224|NCT00453882|DEVICE|flostat (TM) System|
41458202|NCT04000191|OTHER|Perianal ice application|Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
40970225|NCT01713686|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
40970226|NCT06006468|GENETIC|High genetic risk for type 1 diabetes|in individuals without diabetes comparison of prevalence of islet auto antibodies between individuals at high genetic risk of type 1 diabetes versus controls
40970227|NCT06006468|GENETIC|High gentic risk for Coeliac disease|in individuals without Coeliac disease comparison of prevalence of anti tissue transglutaminase antibodies between individuals at high genetic risk of coeliac disease versus controls
40970228|NCT00840450|DRUG|Gleevec/Paclitaxel|"One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m\^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression."
40970229|NCT05540405|DIETARY_SUPPLEMENT|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
41138723|NCT04432415|DEVICE|Soduim Fluoride Varnish|biannual apllication of Sodium Fluoride Varnish
40970230|NCT05540405|DIETARY_SUPPLEMENT|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
40970231|NCT05540405|DIETARY_SUPPLEMENT|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
40970232|NCT03342105|PROCEDURE|Cettum|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Moxibustion will be provided at 11 standard acupuncture points: EX-HN3, and both EX-HN8, LI20, LI4, GB2, ST36. A specifically designed device, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea), will be used to treat patients in this group. The expected total time of each treatment session will be 15 min.
40990755|NCT03492216|BEHAVIORAL|Incentives for negative EtG test|Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.
41297163|NCT03767205|DEVICE|Ankle Assist Robot|"1. overground walking in three conditions (with robot-torque on/with robot-torque off/without robot). During overground walking, gait function was measured using motion analysis, sEMG, and force plate~2. treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot). During treadmill walking, the metabolic energy expenditure was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy)."
41297164|NCT00339014|DRUG|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
40970233|NCT03342105|PROCEDURE|Acupuncture|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Acupuncture will be provided at same points in the Cettum group. Sterile stainless steel disposable acupuncture needles (0.25X30mm, DongBang Acupuncture Inc, Korea) will be used to treat patients in this group. The needles will be kept in place for 15 min.
40970234|NCT03158376|DRUG|Gabapentin|
40970235|NCT03158376|DRUG|Placebo|
40970236|NCT04203238|OTHER|Reduced Meat High Potato Diet|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes.
40970237|NCT04203238|OTHER|Reduced Meat High Pulses Diet|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses.
40970238|NCT04517812|OTHER|Exercise-based games via the VirtualRehab platform|A 12-week exercise-based home rehabilitation intervention delivered via the VirtualRehab platform. A personalised exercise-based rehabilitation plan will be created for each participant.
40970239|NCT01277263|DEVICE|Diffuse Optical Spectroscopy Imaging|Monitoring Breast Cancer during chemo therapy
40970240|NCT05662228|DRUG|Lorazepam|Lorazepam will be administered as an oral pill over the first 15 days of study in a daily titration, starting at 0.5 mg BID and increasing to up to 2 mg three times daily, as tolerated. Dosing will continue at the maximum tolerated dose through the 12-week endpoint. Participants will be titrated off lorazepam over at least four weeks after completing the endpoint visit. Taper will be tailored to individuals for safety reasons with a goal of decreasing dosage by 25% weekly. Phone check ins will be conducted every three days to monitor patient.
40970241|NCT05662228|DRUG|Intravenous immunoglobulin (IVIG)|IVIG will be administered as a series of four intravenous infusions at a dose of 1 mg/kg with pre-infusion medications of 1 mg/kg diphenhydramine and 15 mg/kg acetaminophen. The first two infusions occur at baseline and one day after (induction dosing), followed by one infusion at 4 weeks and one infusion at 8 weeks.
40970242|NCT05662228|DRUG|Tofacitinib|Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.
40970243|NCT00050934|DRUG|oxcarbazepine|
40970244|NCT01487551|DRUG|paquinimod|Hard gelatine capsules 3.0 mg/day for 8 weeks
41138724|NCT04432415|DEVICE|Placebo|biannual application of artificial saliva
41138725|NCT05602272|PROCEDURE|General anesthesia for per-oral endoscopic myotomy|Intra-abdominal pressure measurement
41138726|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
41138727|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)|One dose of rMenB concomitantly with the routinely administered infant vaccines
41138728|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)|One dose of rMenB concomitantly with the routinely administered infant vaccines
41138729|NCT00657709|BIOLOGICAL|Infanrix Hexa|Routine vaccination
41138730|NCT00657709|BIOLOGICAL|Menjugate|One dose of the routinely administered infant vaccines + MenC vaccine
41297165|NCT00339014|OTHER|Placebo|Identical placebo
41297166|NCT02665442|DEVICE|Esophageal Stylet - EsoSure|The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
41297167|NCT02994589|OTHER|Tegaderm™(Absorbant, 3M)|3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.
41297168|NCT02994589|DEVICE|OASIS® wound matrix|OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).
41297169|NCT02994589|OTHER|Xeroform™|Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
40970245|NCT03223597|DRUG|Radium-223 dichloride|Registry of patients who receive Radium-223.
41138731|NCT00657709|BIOLOGICAL|Prevenar|Routine vaccination
41138732|NCT05396885|BIOLOGICAL|anitocabtagene-autoleucel|Anitocabtagene-autoleucel-directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-domain
41297170|NCT03890887|DRUG|BI 1291583|Tablet
41297171|NCT03890887|DRUG|Itraconazole|Oral solution
41297172|NCT01215734|BIOLOGICAL|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
41138733|NCT04166084|OTHER|Active ROM Exercises|Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.
41138734|NCT04166084|OTHER|Trunk Stabilization Exercises Training|Trunk stabilization exercises training will be given under the supervision of a physiotherapist. This training exercises will include diphragmatic exrecises, posterior pelvic tilt exercises, abdominal streghtening exercises,
41138735|NCT05763732|BEHAVIORAL|Rhythmic Auditory Stimulation (RAS)|"Rhythmic auditory stimulus (RAS) is a Neurologic Music Therapy (NMT) technique that utilizes an auditory rhythmic cue to entrain gait to a specific rhythm.~RAS, as an anticipatory time cue, can be used as both an immediate entrainment stimulus, providing rhythmic cues during movement, and as a facilitating stimulus for planning and executing a movement to achieve more functional gait patterns. Cadence, gait velocity, and stride length are the commonly used parameters to monitor changes in a patient's gait."
40990756|NCT03492216|BEHAVIORAL|Incentives for positive IsoScreen test|Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
40990757|NCT01216579|OTHER|mannitol (an airway challenge agent)|
40990758|NCT00239707|DRUG|GIP|One-time 20 ng/kg/min infusion over 3 hours
40768805|NCT05769036|DEVICE|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation to the left bundle branch will be performed by using special delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed left bundle branch pacing.
40768806|NCT05287373|DEVICE|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
41297173|NCT01215734|BIOLOGICAL|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
40768807|NCT05287373|OTHER|conventional medical management|Conventional medical management
40768808|NCT04114955|BEHAVIORAL|Manas por Manas|Manas for Manas works at both the group- and individual-levels to increase self-care and reduce the negative health impacts of stigma, including: 1) a group-level, peer-led intervention, which first demonstrated efficacy with trans women in the US as 'Sheroes' and has been successfully adapted for Brazil, and 2) an individual-level peer navigation program.
40990759|NCT00239707|DRUG|Modified GIP|One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
40990760|NCT00239707|DRUG|Normal Saline|one-time infusion over 3 hours
40990761|NCT01627821|DEVICE|Jarvik 2000 VAS|Jarvik 2000 LVAD
40970246|NCT02923934|DRUG|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
40970247|NCT02923934|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
40970248|NCT01526798|DEVICE|Theralite (high cut-off hemodialysis)|Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
40970249|NCT01526798|DEVICE|Conventional high-flux dialyzer|
40970250|NCT03132220|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive therapy is a 16 in-person hours intervention. The intervention in this population is designed to reduce symptoms of PTSD and BOS and increase resiliency scores.
40970251|NCT03132220|BEHAVIORAL|Book Club Active Control Intervention|Participants randomized to the book club active control intervention will meet for 16 in-person hours that are broken into sessions. Books will be assigned to read during homework time and discussions regarding the books will occur during the sessions. The time involved will be similar to the MBCT intervention.
41138736|NCT04038190|BEHAVIORAL|behavioral activation|Behavioral activation (BA) is an intervention that indirectly addresses psychopathy by guiding individuals to identify goals in their lives, and encouraging individuals to engage in reinforcing activities that align with their goals (Lejuez et al, 2001). While initially used to treat depression, BA has been efficaciously applied to substance use because BA acts on the same reinforcement system common to many disorders (Daughters et al., 2018).
41297174|NCT03029403|DRUG|Pembrolizumab|Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.
40970252|NCT01889004|DRUG|Dexmedetomidine|Escalating concentrations until loss of responsiveness
40970253|NCT01889004|DRUG|Propofol|Escalating concentrations until loss of responsiveness
40970254|NCT04736420|DRUG|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure group
40970255|NCT04736420|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
40970256|NCT05416593|BEHAVIORAL|General exercise prescription (FITT)|The (1) control group (FITT) will receive a preexercise evaluation and 3 individualized training sessions based on the ACSM and FITT principles (ACSM, 2021). These are the procedures commonly used for apparently healthy individuals that start to exercise in health clubs.
40990762|NCT01627821|DEVICE|HeartMate II|HeartMate II LVAD
40990763|NCT00641407|DRUG|NPL insulin|Starting dose 10 IU bedtime and then titration
40990764|NCT00641407|DRUG|Insulin glargine|10 IU bedtime and then titration
40990765|NCT00988754|BEHAVIORAL|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
40990766|NCT03691896|DIETARY_SUPPLEMENT|Cholecalciferol 400|dose 400 UNT/day for 12 months
40970257|NCT05416593|BEHAVIORAL|Affective regulation (AFFECT)|As for the (2) experimental group (AFFECT), the focus will be given to exercise intensity assessment and manipulation. The same preexercise evaluation, number of individualized sessions, and methodological approach (i.e., FITT) will be made. However, individual preferences and experiences regarding exercise intensity will be assessed in the preexercise evaluation. These will be used to select the exercise sessions' initial intensity. Moreover, intensity self-selection guidance and affective response assessments will be made throughout the session for continuous intensity adjustments (aiming for pleasurable feelings).
40768809|NCT05650866|DEVICE|Activation of pro-erectile nerves within the pelvic plexus|The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.
40768810|NCT06507618|DRUG|Tamoxifen, Letrozole, Anastrozole, or Exemestane|Choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist.
40970258|NCT01218568|DRUG|Rifaximin plus lactulose|Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
40970259|NCT01218568|DRUG|Lactulose|Lactulose 30-60 ml in two or three divided doses.
40970260|NCT02264197|DRUG|BIBX 245 CL - fed|
40970261|NCT02264197|DRUG|BIBX 245 CL- fasted|
40970262|NCT00728871|PROCEDURE|peripheral blood isolation|To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
41138737|NCT02301507|BEHAVIORAL|cell phone SMS text messaging|This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
41458203|NCT03582423|OTHER|electro-acupuncture|Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
41458204|NCT01177657|PROCEDURE|Stool sampling|Stool samples collected and checked for the presence of rotavirus
40768811|NCT04437745|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
40970263|NCT02945683|DIETARY_SUPPLEMENT|Reuterin D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
40970264|NCT02945683|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
40970265|NCT04669600|DRUG|SAR445088 (BIVV020)|Pharmaceutical form:solution for injection
40970266|NCT01165437|DEVICE|Blood Pressure Measurement|Systolic blood pressures will be obtained from each limb using Doppler, oscillometric, and photoplethysmographic (PPG) modalities.
41458205|NCT04020445|OTHER|de-escalation of complex insulin regimens|complex insulin regimens are switched to fix ratio combinations consisting of of a basal insulin and a GLP-1 (glucagon-like peptide-1) receptor agonist
40768812|NCT06395935|OTHER|Wecare (website)|support feedback of qutionaire \& supply educational contents
40768813|NCT06586255|RADIATION|Concurrent Immunotherapy and Radiation Therapy|Radiation therapy will begin between 12 to 18 weeks from the start of adjuvant nivolumab. Patients will receive radiation therapy for about 6 weeks.
40768814|NCT06519981|DRUG|HRS-9231or matching placebo|HRS-9231 injection or matching placebo will be administered through IV injection.
40768815|NCT03067636|BEHAVIORAL|Physical Exercise|Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.
40970267|NCT03959358|DRUG|Lenalidomide|Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
40970268|NCT03959358|DRUG|Pomalidomide|Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
40990767|NCT03691896|DIETARY_SUPPLEMENT|Cholecalciferol 800|dose 800 UNT/day for 12 months
40970269|NCT06110611|DEVICE|Astra Tech Osseospeed EV® dental implant|Prospective study of a group of 50 patients which were treated 5 years ago with a dental implant and a screw-retained implant-supported zirconia restoration because of a missing tooth in the posterior region.
40970270|NCT01104506|PROCEDURE|fMRI|
40970271|NCT01104506|PROCEDURE|mTMS|
40970272|NCT02891759|OTHER|Alloderm RTU|-Most commonly used acellular dermal matrices
40970273|NCT02891759|OTHER|Cortiva 1mm Allograft Dermis|-Tutoplast processed dermis
40970274|NCT02891759|PROCEDURE|Skin or nipple-sparing mastectomy|-Standard of care
40970275|NCT02891759|OTHER|Breast Q|"* 15 questions~* 10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time~* Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time"
40970276|NCT02891759|PROCEDURE|Surgery|"* To address the tissue expander~* Standard of care"
40970277|NCT04152161|BIOLOGICAL|BCG vaccine SSI|Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.
40970278|NCT04152161|BIOLOGICAL|Placebo|Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.
40970279|NCT06284174|DRUG|Povidone-iodine solution; chlorhexidine gluconate|Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
40970280|NCT06102759|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
40970281|NCT04849143|OTHER|Stingless bee honey ( Kelulut honey)|"The honey will be acquired from Brainey Sdn Bhd, a company that provides stingless bee honey certified with Good Manufacturing Practice (GMP), ISO 22000, and Halal.~As the honey used is not medical-grade honey, sterilization with 25kGy gamma-ray irradiation will be done for safety purposes to eradicate any potential life-threatening infection such as spores from Clostridium botulinum."
40970282|NCT04849143|OTHER|Gel dressing|Smith-Nephew's Intrasite gel
40970283|NCT03102372|DIETARY_SUPPLEMENT|Whey protein supplementation|
40768816|NCT03067636|BEHAVIORAL|Stress management training A|Stress management training A: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
40970284|NCT03102372|OTHER|walking program|
40970285|NCT03102372|OTHER|Very Low Calorie Diet|
40970286|NCT04469036|OTHER|Virtual Pediatric Trauma Center|Telehealth
40970287|NCT05613595|BEHAVIORAL|Positive Psychotherapy|"Positive Psychotherapy is an effective treatment for many mental disorders and depression is primary empirical target. Its primary goal is to build positive emotion, engagement, and meaning in life that will alleviate depression and other mental health disorders. Thus PPT may offer a new way to treat and prevent mental health issues.~Interventions sessions included, Session Records Session One: Positive Introduction and Gratitude Journal Session Two: Character Strengths and Signature Strengths Session Three: Practical Wisdom , Session Four: A Better Version of Me , Session Five: Open and Closed Memories, Session Six: Forgiveness Session Seven: Maximizing versus Satisficing, Session Eight: Gratitude ,Session Nine: Hope and Optimism, Session Ten: Posttraumatic Growth, Session Eleven: Slowness and Savoring, Session Twelve: Positive Relationships, Session Thirteen: Positive Communication, Session Fourteen: Altruism , Session Fifteen: Meaning and Purpose"
40970288|NCT05613595|BEHAVIORAL|Counseling Group|Caregivers in control group only regular counseling will be provided (psychoeducation). it will be based upon the insight of cerebral palsy and training based on Adaptive skill functioning of the CP child of the caregivers
40970289|NCT00346112|PROCEDURE|psycho-educational|
41138738|NCT02400749|DRUG|Apremilast|"Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."
41138739|NCT02400749|DRUG|Placebo|Placebo tablets will be provided to sites in blister cards.
41138740|NCT06464666|PROCEDURE|Renal interlobar artery US|By using convex US transducer, first find interlobar artery. Then get a pulsed wave doppler at renal interlobar artery for similar 3 to 5 waveforms. Measure peak systolic and minimum diastolic velocity and calculate RRI value.
41138741|NCT06464666|PROCEDURE|Renal inter-lobular artery US|By using convex US transducer, first find interlobar artery. Then get a pulsed wave doppler at renal interlobar artery for similar 3 to 5 waveforms. Measure peak systolic and minimum diastolic velocity and calculate RRI value.
41138742|NCT01477866|DIETARY_SUPPLEMENT|citogenex|CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).
41138743|NCT01477866|OTHER|conventional therapy|conventional therapy for colon-rectal cancer
40768817|NCT03067636|BEHAVIORAL|Stress management training B|Stress management training B: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
40768818|NCT06633393|OTHER|Feedback on Predicted High Myopia Risk at Age 18 Using the Myopia Prediction System|At baseline and six months, participants will be provided with the results of their predicted risk of high myopia at age 18 based on the myopia prediction system.
40768819|NCT06633393|OTHER|Feedback on Ophthalmic Examinations|At baseline and six months, participants will be provided with the results of their ophthalmic examinations.
40768820|NCT03189719|BIOLOGICAL|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
40990768|NCT03691896|DRUG|Cholecalciferol 1200|dose 1200 UNT/day for 12 months
41138744|NCT05635409|BIOLOGICAL|STEM-PD|STEM-PD is a cryopreserved cell product, consisting of ventral midbrain dopaminergic progenitor cells derived from the clinical-grade hESC line RC17. STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.
41138745|NCT03995394|OTHER|Positive Reinforcement Text Message|"A text message comprising the words, Great job! We're so proud of you! Keep up the good work!"
40768821|NCT03189719|DRUG|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
41297175|NCT03029403|BIOLOGICAL|DPX-Survivac|Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.
40970290|NCT02732119|DRUG|Ribociclib|supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle
40970291|NCT02732119|DRUG|Everolimus|supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
40970292|NCT02732119|DRUG|Exemestane|supplied in 25 mg tablets taken orally, daily for 28 day cycle
40970293|NCT01029626|PROCEDURE|Endoscopy|Realization of an upper GI endoscopy
41297176|NCT03029403|DRUG|Cyclophosphamide|Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.
41297177|NCT00674336|PROCEDURE|High Hydrostatic Pressure Processing|High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
41297178|NCT03636503|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatmen
41297179|NCT03636503|DRUG|Utomilumab|Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
41297180|NCT03636503|DRUG|Avelumab|Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
41458206|NCT00658034|PROCEDURE|Acupuncture|Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.
40970294|NCT04689633|PROCEDURE|nerve block|bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest
40970295|NCT01002027|BEHAVIORAL|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
40970296|NCT06505369|DRUG|Daratumumab|Daratumumab will be administered by SC injection
40970297|NCT06505369|DRUG|Bortezomib|Bortezomib will be administered by SC injection
40970298|NCT06505369|DRUG|Lenalidomide|Lenalidomide will be administered by oral route
41138746|NCT00498797|DRUG|Zactima (vandetanib)|
41138747|NCT00498797|DRUG|Docetaxel|
41138748|NCT00498797|DRUG|Prednisolone|
41138749|NCT03792178|OTHER|Bulk fill composite|Composite resin dental material
41138750|NCT03792178|OTHER|Nano resin composite|Dental composite material
40970299|NCT06505369|DRUG|Dexamethasone|Dexamethasone will be administered by oral route
40970300|NCT06505369|DRUG|Talquetamab|Talquetamab will be administered by SC injection
40970301|NCT06505369|DRUG|Teclistamab|Teclistamab will be administered by SC injection
41138751|NCT00454922|BEHAVIORAL|standard of care|no intervention
41297181|NCT03636503|DRUG|PF04518600|In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
41297182|NCT05553548|PROCEDURE|biologically oriented alveolar ridge preservation|xenogenic bone graft placed in coronal part of the non molar socket ,, collagen plug placed in appical part of socket and as socket seal
41297183|NCT05553548|PROCEDURE|xenogenic bone graft in entire (apico-coronal) extension|xenogenic bone graft placed in the entire apico coronal extension and sealed with collagen plug
41297184|NCT03142997|DIAGNOSTIC_TEST|Lung ultrasound|we will perform lung ultrasound for both groups to calculate lung score.
40970302|NCT03478267|DIAGNOSTIC_TEST|AChE levels|AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.
41138752|NCT00454922|OTHER|education|meet with trained glaucoma educator 6 times over life of study
41138753|NCT06452121|OTHER|triglyceride glucose index|"The TyG index was calculated using the following equation: Ln \[TG (mg/dL)×FPG (mg/dL) / 2\].~CAD was referred to as at least one major coronary artery with≥50% stenosis evaluated by CAG"
41458207|NCT00658034|PROCEDURE|Placebo Acupuncture|"Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.~Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture."
41138754|NCT04707599|OTHER|Reminder plus (telephone call from therapist)|Reminder plus (telephone call from therapist)
41138755|NCT00236535|DRUG|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
41138756|NCT01864590|DEVICE|Vacuum Pack|Vacuum Pack Technique described by Barker et al.
41138757|NCT01864590|DEVICE|Double Sylo Bag - Mesh Protocol|"double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.~At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure"
40970303|NCT01152710|DRUG|Capecitabine|Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
40970304|NCT03519932|DEVICE|comfilcon A toric lens|Contact lens
40970305|NCT03519932|DEVICE|samfilcon A toric lens|Contact lens
40970306|NCT01754623|DRUG|Capecitabine|Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
40970307|NCT01754623|DRUG|Gemcitabine|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
40970308|NCT01754623|DRUG|Docetaxel|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
40970309|NCT01754623|RADIATION|Stereotactic body radiation therapy (SBRT)|30/40 Gy to pancreatic tumor/area of borderline resectability
40970310|NCT01754623|OTHER|Restaging review after radiation|After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
40970311|NCT01754623|PROCEDURE|Surgery|Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
40970312|NCT01754623|DRUG|5-Fluorouracil|Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
40970313|NCT03251300|DRUG|daytime dosing of mirabegron|All OAB female patients will receive daytime dosing (08:00 AM) of mirabegron
40970314|NCT03251300|DRUG|nighttime dosing of mirabegron|All OAB female patients will receive nighttime dosing (08:00 PM) of mirabegron
40970315|NCT04051723|DRUG|The dexamethasone plus ropivacaine|The local infiltration solution containing 0.25mg Dexamethasone and 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
40970316|NCT04051723|DRUG|The ropivacaine|The local infiltration solution containing 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
40970317|NCT05993260|BEHAVIORAL|Behavioural science-informed text messages|Behaviourally-informed content in vaccination eligibility reminder text messages
40970318|NCT05993260|BEHAVIORAL|Control|Control vaccination eligibility reminder text message
40970319|NCT04357678|OTHER|Qi Gong Programme|"Warm-up: In warm up session joint activities were performed along with light stretching. Patients performed these activities with instructor's commands for 5 minutes.~Liu Zi Jue exercise: patients performed intact Liu Zi Jue exercise (form of Qigong).~This includes six healing sounds, Xu, He, Hu, Si, Chui, Xi and the Harmonized actions along with the instructor for 20 minutes. Cooling-down: After completion of Qigong, patient done gentle stretching to adjust back their breathing and this cool down session lasted for 5 minutes. Subjects received supervised training session for 30 min twice a week."
40970320|NCT04357678|OTHER|Short Form Sun Style Tai Chi|"Commencing Movement, Opening and closing hand, Single whip, Waving hands in the cloud, Opening and closing hands, Brush knee, Playing lute, Perry and Punch, Block and close, Pushing the mountain, Closing movement.~Participants attended two supervised 30min sessions twice a week. Participants learnt 3 to 4 forms per week and at the completion of study (which is the six week of training), they completed all 21 forms. In each training session, participants revised previous SSTC forms that they learnt earlier up to that session."
40970321|NCT01452828|DRUG|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
40970322|NCT01452828|DRUG|TR-701 FA|Two separate infusions of 200 mg
40970323|NCT01452828|DRUG|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
40970324|NCT01150864|DEVICE|Airway Conditioning|Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
41458208|NCT01956162|DEVICE|Orthèse Diabète|The device ensures the discharge of the wound by the excavation of the orthopedic insole facing the wound and the load distribution in the healthy areas.
40970325|NCT00821353|PROCEDURE|RF catheter ablation|RF catheter ablation
40970326|NCT00821353|DRUG|Antiarrhythmic drugs|One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
40970327|NCT05731778|DRUG|Stannous Fluoride Toothpaste|0.454% stannous fluoride toothpaste
40970328|NCT05731778|DRUG|Colgate fluoride toothpaste|0.76 % Sodium MonoFluorophosphate (MFP)
40970329|NCT03393637|BEHAVIORAL|Mentors Offering Maternal Support (M-O-M-S)|10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
40970330|NCT03817788|DRUG|polyethylene glycol|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For polyethylene glycol group (group P): the day before colonoscopy, 750 mL (1 box) of polyethylene glycol solution should be drunk 2 hours after dinner; the other 1500 ml (2 boxes) of polyethylene glycol solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same juniar clinician, and related indicators were recorded.
41458209|NCT01956162|DEVICE|"Conventional Device"|Standard (e.g.: CHUT, BAROUK, Tera-Diab, Sanital, Teraheel, Aircast boots, Walker Stabil D, etc.), or customized (orthopedic insole, Ransart boot, D.T.A.C.P., etc.) removable off-loading systems
41458210|NCT02725515|BIOLOGICAL|XmAb5871|
41458211|NCT02725515|BIOLOGICAL|Placebo to match XmAb5871|
41458212|NCT05339191|BEHAVIORAL|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
41458213|NCT04541173|OTHER|Y-90 TARE|"This plan will involve treating the predominant liver lesions with segment Y-90 TARE using predetermined dosimetry, while keeping FLR equal or greater than 40% (FLR is estimated by excluding the liver volume of Y-90 infused distribution).~The maximal amount of Y-90 TARE treatment will be limited to only one lobe of the liver if segmental Y-90 TARE is not possible to treat the predominant lesion. Since segmental Y-90 TARE may result in less long term liver damage compared to lobal Y-90 TARE, segmental Y-90 TARE treatment is preferred to lobar Y-90 TARE if segmental Y-90 TARE treatment is able to treat all blood supply to the predominant lesion or lesion with vascular invasion to preserve liver function. For segmental treatment, a minimum tumor dose of 190 Gy should be used for glass microspheres and 120 Gy for resin microspheres. For lobar treatment, a minimum dose of 100 Gy should be used for resin microspheres."
41458214|NCT04541173|DRUG|Atezolizumab|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks). The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 minutes.
41458215|NCT04541173|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle.The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 minutes
41458216|NCT04711317|DEVICE|Nasal high flow oxygen|Pregnant women scheduled for cesarian section in general anaesthesia will be preoxygenated using nasal high flow oxygen
41458217|NCT02579577|OTHER|Observation|Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
41458218|NCT02579577|OTHER|Interviews|Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
41458219|NCT02579577|OTHER|Medical notes review|The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
41458220|NCT03733587|DRUG|GX-I7|GX-I7 25mg/ml/vial
41458221|NCT03733587|DRUG|Cyclophosphamide|Cyclophosphamide 500mg/vial
40970331|NCT03817788|DRUG|sodium phosphate|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For sodium phosphate group (group S), 750 mL (1 box) of sodium phosphate solution should be drunk 2 hours after dinner; and the other 750 mL (1 box) of sodium phosphate solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same clinician, and related indicators were recorded.
40990769|NCT05799807|PROCEDURE|Conservative treatment|Patients with negativ weight-bearing CT will be treated conservative
40990770|NCT05799807|PROCEDURE|Minimally invasive stabilization|Patients with positive weight-bearing CT will be operated by minimally invasive stabilization (eg, isolated homerun screw)
40990771|NCT03930888|DIETARY_SUPPLEMENT|Dietary supplement|Patients with preoperative nutritional support with special nutritional supplements vs. patients without special nutritional support.
40990772|NCT05782751|PROCEDURE|GROUPI|10 sites treated with Free connective tissue graft (FCTG) + growth factors enhanced matrix 21 s GEM 21S + coronally advanced flap (CAF)
40990773|NCT05782751|PROCEDURE|GROUP II|10 sites treated withCollagen membrane + GEM 21S + coronally advanced flap (CAF)
41458222|NCT04664881|DEVICE|SmartHeart Device|A body-worn device that allows an individual to immediately transmit a 12-lead ECG from anywhere and anytime, using a smartphone application to a physician's office, hospital or monitoring center where designated on-call staff interpret the ECG and make recommendations.
41458223|NCT06468904|PROCEDURE|cervical stabilization exercises and integrated neuromuscular technique.|"Patients received cervical stabilization exercises and integrated neuromuscular inhibition technique. Cervical stabilization protocol included strengthening exercises of deep cervical flexors muscles which included chin tucks, isometric holds, ball squeeze, as well as deep cervical extensors muscles which included cranio-cervical flexion from neutral, upper cervical rotation and extension of cervical spine.~integrated technique includes ischemic compression, muscle energy technique and strain counter strain."
40768822|NCT03189719|DRUG|Cisplatin|80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
41458224|NCT03201341|OTHER|Electrooculogram (EOG)|The acquisition of the surface EOG activity will be carried out by means of 3 surface electrodes, one of which, referred to as a reference, is placed on a bone zone (the glabella, above the nasion) and two others placed on The temples, coupled to an EOG amplifier.
40768823|NCT03189719|DRUG|5-FU|800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
40768824|NCT04894864|DRUG|Opioid-Based Anesthesia-Analgesia Strategy|A perioperative Opioid-Based multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Based arm of the study.
40768825|NCT04894864|DRUG|Opioid-free Anesthesia-Analgesia Strategy|A perioperative Opioid-Free multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Free arm of the study.
40990774|NCT00866411|PROCEDURE|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
40990775|NCT00866411|PROCEDURE|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
40990776|NCT05277844|RADIATION|Local Consolidative Radiation Therapy|Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI
40990777|NCT05277844|DRUG|TKI|TKI
40970332|NCT06145061|DEVICE|all patients and healthy people will receive at least 3 infrared thermal imaging examinations of acupoints and pain threshold examinations of acupoints.|Infrared thermal imaging detection scheme of acupoints:Detection equipment NEC R550 infrared thermal imager.Records the corresponding acupoints coordinates,and starts to collect the infrared thermal image.and 6 images will be taken continuously for each detected part.The infrared thermograms were stored and extract the temperature values of the corresponding coordinates of the acupoints.The average temperature values of the acupoints in the six infrared thermograms were calculated as their temperatures.Pain threshold detection scheme of acupoints:The instrument and equipment use the FDX25 hand-held pain threshold test instrument to explore the acupoints.Place the probe of the pain measuring instrument vertically on the pain measuring acupoint, slowly and steadily press downward at a constant speed, and stop pressing immediately when the subject begins to feel pain. At this point, the reading on the display is the subject's pain threshold. All acupoints shall be measured once in total.
40970333|NCT03918590|DRUG|nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)|NSAID
40970334|NCT03918590|DRUG|Theratears tear drop, (Akron, Ann 111 Arbor, MI)|preservative-free Artificial Tears
40970335|NCT03918590|OTHER|patching|no drug/ patching
40970336|NCT01634971|PROCEDURE|Internal Drainage of Pancreatic Duct after pancreatomy|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
40970337|NCT05028894|OTHER|No intervention|No intervention
40970338|NCT02008201|DIETARY_SUPPLEMENT|vitamin D|
40970339|NCT04367636|BEHAVIORAL|Behavioral: OCAT-sham|Placebo version of the online contingent attention training preceded by psycho-education movieclip.
40970340|NCT04367636|BEHAVIORAL|Behavioral: OCAT|Online contingent attention training preceded by psycho-education movieclip.
40970341|NCT04367636|OTHER|psycho-education video|Both groups get to see a psycho-education video before the smartphone training starts.
40970342|NCT00118001|BEHAVIORAL|Worry exposure|
40970343|NCT00118001|BEHAVIORAL|Applied relaxation|
40970344|NCT01725334|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
40970345|NCT03606733|PROCEDURE|Custom suorachoroidal needle|Custom made Supra Choroidal Space needle
40970346|NCT00231075|DRUG|Paraplatin|
40970347|NCT00231075|DRUG|Paclitaxel|
40970348|NCT05826652|OTHER|Single injection subcostal transversus abdominis plane block|Single injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 20 ml between tranvers and rectus abdominis muscle immediately next to the linea semilunaris.
40970349|NCT05826652|OTHER|Multiple injection subcostal transversus abdominis plane block|Multiple injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 5 ml between transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volume lateral to this point near the subcostal margin.
40970350|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .
40970351|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
40970352|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment S HR20031 FDC 5/50/750 mg\*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state.
40970353|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fast state.
40970354|NCT03041597|PROCEDURE|placement of implants|surgical procedure and placement of implants
40970355|NCT03041597|PROCEDURE|immediate loading|cone-anchored implant supported removable dental prostheses placement
40970356|NCT03041597|PROCEDURE|conventional loading|cone-anchored implant supported removable dental prostheses placement in 3mo
40970357|NCT03041597|DEVICE|Ankylos implant|
40970358|NCT01965275|DRUG|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
40970359|NCT06076642|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
40970360|NCT06076642|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
40970361|NCT05386069|DRUG|NOMO Protocol|Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications
40990778|NCT03176992|DRUG|SURGICEL®|insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
40990779|NCT05992597|DRUG|ZR2 RDHAP|ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.
40970362|NCT02309502|DEVICE|Green Pascal|"Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session~Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%~Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
40970363|NCT02309502|DEVICE|Yellow Pascal|": Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
40970364|NCT06349031|DRUG|Administration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants|As per treatment allocation, PEG 4000 will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
40970365|NCT06349031|DRUG|Administration of Polyethylene Glycol (PEG) 3350 + Electrolyte as per treatment allocation to participants|As per treatment allocation, PEG 3350 + Electrolytes will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
40970366|NCT05985577|OTHER|Without any intervention|There were no special interventions for the two groups.
40970367|NCT01053416|PROCEDURE|Yag laser iridotomy|the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
40970368|NCT00000752|DRUG|Pseudoephedrine hydrochloride|
40970369|NCT00000752|DRUG|Guaifenesin|
40970370|NCT00000752|DRUG|Cefuroxime axetil|
40970371|NCT00000752|DRUG|Beclomethasone dipropionate|
40970372|NCT06158594|BEHAVIORAL|Summer day camp|The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
40970373|NCT00646009|DRUG|budesonide/formoterol|
40970374|NCT00646009|DRUG|fluticasone/salmeterol|
40970375|NCT00646009|DRUG|albuterol|
40970376|NCT04490538|DIAGNOSTIC_TEST|Transthoracic echocardiography|Conventional transthoracic echocardiographic examination at the intensive care unit.
40970377|NCT05238441|BIOLOGICAL|SCTV01E|D0; intramuscular injection
40970378|NCT05238441|BIOLOGICAL|Comirnaty|D0; intramuscular injection
40970379|NCT05238441|BIOLOGICAL|SCTV01E|D180; intramuscular injection
40970380|NCT05238441|BIOLOGICAL|Comirnaty|D180; intramuscular injection
40970381|NCT02600572|OTHER|Isometric exercises|Subjects will perform one session of isometric exercises at the end of Day 1
40970382|NCT02600572|OTHER|Eccentric exercises|Subjects will perform one session of eccentric exercises at the end of Day 2
40970383|NCT04974385|DRUG|Liposomal bupivacaine|Validate the analgesic efficacy of admixed LB + bupivacaine compared with plain bupivacaine when injected for ISNB for total shoulder arthroplasty.
41458225|NCT03201341|OTHER|Surface Electromyography (EMG)|In behavioral or transcranial stimulation protocols, surface EMG activity may be recorded for further analysis. No protocol included in this project will involve the recording of intramuscular electromyographic activity, which is invasive and involves the implantation of needle electrodes into the muscles.
40970384|NCT04974385|DRUG|Bupivacaine|Active comparator as standard of care.
40970385|NCT00286403|DRUG|Fenoldopam Mesylate and/or MESNA|
40970386|NCT02449655|DRUG|AZD5363|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
40970387|NCT02449655|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
40970388|NCT02449655|DRUG|AZD2014|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
41458226|NCT03201341|OTHER|Electrodermal response|The electrodermal response is a useful, simple and reproducible method for recording sweat gland activity that reflects autonomic nervous activity. Recordings will be made using traditional devices, including an amplifier (Delsys or BrainAMP or equivalent) as well as disposable electrodes.
40970389|NCT02449655|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
40970390|NCT03636932|DRUG|N-acetylcysteine (NAC)|Intravenous injection of 2 gram of N-acetylcysteine (NAC) during 4 weeks, 3 times per week during the first three hours of dialysis.
40970391|NCT03636932|DRUG|Placebo|Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.
40970392|NCT03636932|BIOLOGICAL|Blood sample|Circulating tissue factor assay
40970393|NCT03636932|BIOLOGICAL|Blood sample|The test of pro-coagulant activity of the tissue factor
40970394|NCT00122668|DRUG|non-nucleoside reverse transcriptase inhibitors|
40970395|NCT00122668|DRUG|nucleoside reverse transcriptase inhibitors|
40970396|NCT00122668|DRUG|protease inhibitor|
40970397|NCT05391698|BEHAVIORAL|Behavioral Parent Training (BPT)|The parent training consists of 8 weekly group sessions where parents are trained on behavior modification techniques, optimal parental practices as well as techniques for the enhancement of their children's cognitive deficits.
40970398|NCT05391698|COMBINATION_PRODUCT|Child Training (iVR + CBT)|The child training program is comprised of 16 individualized weekly sessions. It utilizes the potentials of immersive virtual reality (iVR) technology for the training of focused and sustained attention and combines practices based on cognitive-behavioral approach for children's training on behavioral and emotional self-regulation skills.
40970399|NCT02269241|DRUG|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
40970400|NCT06293404|DRUG|Bupivacain|7.5 mg Bupivacaine hydrochloride (0.5% heavy Marcaine) will be used on spinal anesthesia. (each group)
40970401|NCT02073760|OTHER|There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.|The investigators will conduct tape recorded interviews with hospital staff about infection prevention.
40970402|NCT04167644|DIAGNOSTIC_TEST|Modified Rankin Scale (mRS)|Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to six
40970403|NCT00831168|BEHAVIORAL|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
40970404|NCT01282892|PROCEDURE|excess of visceral fat|excess of visceral fat
40970405|NCT01282892|PROCEDURE|patients with NAFLD|patients with NAFLD
40970406|NCT03911804|PROCEDURE|bolus group and infusion group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.
40970407|NCT02959931|OTHER|High Potassium Meal|Breakfast meal that provides \~2400 mg of dietary potassium. Meals are isocaloric.
40970408|NCT02959931|OTHER|Low Potassium Meal|Breakfast meal that provides \~540 mg of potassium. Meals are isocaloric.
40970409|NCT04278638|RADIATION|IORT|IORT in surgery of laryngocarcinoma
40970410|NCT04278638|PROCEDURE|surgery|total laryngectomy or hemilaryngectomy
40970411|NCT04278638|RADIATION|External radiotherapy|External radiotherapy
40970412|NCT05427695|DRUG|Lactobacillus sakei proBio65|Lanto Sinus probiotic Lactobacillus sakei is a currently available over the counter supplement from the common source kimchi and produced in South Korea. Patients will be instructed to mix 1 packet with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
40970413|NCT05427695|OTHER|Isotonic Saline Solution|Saline sinus irrigations (SAL group): NeilMed® Isotonic Sinus Rinse™ is marketed as a saline sinus irrigation formula. Subjects will be given instructions to mix one unlabeled packet (containing NeilMed® premixed buffered salt powder) with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
40970414|NCT01126476|OTHER|Proton Radiotherapy|
41138758|NCT05202444|PROCEDURE|Osteotomy using piezoelectrical device|"osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla."
41458227|NCT03201341|OTHER|Changes in skin temperature|The skin temperature will therefore be recorded during behavioral protocols using techniques for manipulating the representation of the body (perceptual illusion, prismatic deviation, etc.) using a specific measuring device.
41458228|NCT03201341|OTHER|MRI|Whatever the protocol, a diffusion tensor MRI (DTI) acquisition sequence as well as an image of the entire brain and high spatial resolution (T1 weight, 1x1x1 mm, nasion markers and pre-atrial points) will be acquired (Total duration: 20 minutes).
41458229|NCT03201341|OTHER|MEG|During the examination, the subject will have to perform tasks comparable to those described for the fMRI procedure, but with the additional possibility, offered by the MEG environment, of performing pointing or seizing of objects, provided that the Trunk and the subject's head be held in place by a suitable restraint system.
41458230|NCT03201341|OTHER|Transcranial magnetic stimulation (TMS)|TMS is a non-invasive technique that uses very short (\~ 100μs) magnetic pulses applied to the scalp to transiently and focally disrupt or improve the functioning of neuronal populations in the underlying superficial cortical regions.
40970415|NCT03269864|PROCEDURE|perforator flaps|40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
40970416|NCT03259776|OTHER|Qualitative interviews and questionnaire survey|Qualitative interviews and questionnaire survey
40970417|NCT00660998|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
40970418|NCT00660998|DRUG|Placebo|Matching placebo
40970419|NCT04303832|OTHER|eye exercises|Eye exercises for correcting eye deviation
40970420|NCT04303832|DEVICE|eye glasses|Eye glasses for correcting eye deviation
40970421|NCT03469375|DRUG|modified-FOLFIRINOX|LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention
40970422|NCT02888444|DRUG|Varenicline|Two 0.5mg tablets taken twice daily
40970423|NCT02888444|BEHAVIORAL|Behavioural support|Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.
40970424|NCT02888444|DRUG|Placebo|Two 0.5mg tablets taken twice daily
40970425|NCT01340898|BIOLOGICAL|Meningococcal vaccine GSK 134612|Intramuscular injection
40970426|NCT01340898|BIOLOGICAL|SynflorixTM|Intramuscular injection
40970427|NCT01340898|BIOLOGICAL|Infanrix-IPV/HiberixTM|Intramuscular injection
40970428|NCT01315678|DRUG|Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
40970429|NCT01315678|DRUG|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~* Nebulization time is approximately 20 minutes for each administration.~* Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
40970430|NCT05723237|OTHER|Breast Cancer Education|The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers.
40970431|NCT00560859|PROCEDURE|Adenotonsillectomy (AT) - removal of adenoids and tonsils|Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils
40970432|NCT00560859|OTHER|Watchful Waiting|Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
40970433|NCT04806724|BEHAVIORAL|Opening the Conversation|The intervention includes 5 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on reproductive and sexual health distress.
40970434|NCT04806724|BEHAVIORAL|Side by Side|The intervention includes 4 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on general cancer-related distress.
40970435|NCT01206608|DRUG|SKY0402 + bupivacaine HCl|Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
40970436|NCT01206608|DRUG|Mid-dose SKY0402 + bupivacaine HCl|Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
40970437|NCT06173921|PROCEDURE|robotic system|Implant placement will be navigated by robotic system based on a digital plan
40970438|NCT06173921|PROCEDURE|Static navigation system|Implant placement will be navigated by static navigation system based on a digital plan
40970439|NCT02551978|OTHER|The serious game KOP|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
40970440|NCT02056314|OTHER|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
40970441|NCT02056314|OTHER|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
41458231|NCT03201341|OTHER|Transcranial electrical stimulation in direct current (tDCS)|The tDCS consists in passing a current of low intensity (generally ≤ 1mA to stimulate the cerebral cortex) between an anode and a cathode placed on the scalp, a part of this current crossing the tissues, and in particular the cortical regions situated between these two Electrodes. Generally, if the cathode is placed on the region of interest, it will be inhibited, while it will be energized if the anode is positioned thereon.
40970442|NCT04334031|GENETIC|Biobanking with genetic analysis|Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
40970443|NCT04334031|OTHER|SF-12 questionnaire|Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.
40970444|NCT02857543|OTHER|Plant-Based Diet|
40970445|NCT02857543|OTHER|American Heart Association Diet|
40970446|NCT02857543|OTHER|Mediterranean Diet|
40970447|NCT06190691|DRUG|Pirtobrutinib|Administered orally
40970448|NCT01375647|BIOLOGICAL|IPV|Administered per protocol
40970449|NCT01375647|BIOLOGICAL|Rotarix|Administered per protocol
40970450|NCT03798405|BEHAVIORAL|Proactive Analgesic Inpatient Narcotic-Sparing|Medications suggested to the physician with enhanced ease of ordering.
40970451|NCT00819611|BEHAVIORAL|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
40970452|NCT00819611|BEHAVIORAL|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
40970453|NCT01405248|DRUG|Butylphthalide|20 mg/time per os three times a day. 180days
40970454|NCT01405248|DRUG|Placebo|20 mg/time per os three times a day. 180days
40970455|NCT05348070|PROCEDURE|Laparoscopy/Laparotomy|All patients included in the study were operated patients.
40970456|NCT01068132|DRUG|Cetuximab|cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
40970457|NCT01068132|DRUG|FOLFIRI|irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
40970458|NCT03854305|DRUG|PRV-6527|Treatment
40970459|NCT03854305|DRUG|Placebo|Comparator
40970460|NCT00000105|BIOLOGICAL|Intracel KLH Vaccine|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
40970461|NCT00000105|BIOLOGICAL|Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
40970462|NCT00000105|DRUG|Montanide ISA51|Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
40970463|NCT00000105|BIOLOGICAL|Tetanus toxoid|Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
40970464|NCT03356990|DIETARY_SUPPLEMENT|Resistant Starch|"Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose (one bag) in the evening."
40970465|NCT01846416|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
40970466|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
40970467|NCT03478358|DRUG|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
40970468|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
40970469|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
40970470|NCT03478358|DRUG|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).
40970471|NCT03478358|DRUG|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
40970472|NCT00004915|DRUG|raloxifene|
40970473|NCT06348602|DRUG|Cyclosporine ophthalmic solution 0.1%|Ophthalmic prophylaxis begins once engraftment is documented, with a dose of 1 drop in each eye every 12 hours, continued for a duration of 12 continuous months
40970474|NCT06348602|DRUG|Tacrolimus ophthalmic ointment 0.03%|Ophthalmic prophylaxis begins once engraftment is documented, with a dose of approximately 1 cm or the necessary amount to cover the lower fornix, every 12 hours, continued for a duration of 12 continuous months
40970475|NCT06020378|DRUG|Hydroxychloroquine|Hydroxychloroquine was administered during pregnancy
41458232|NCT02360007|DRUG|Interim Buprenorphine Treatment (IBT)|"The Interim Buprenorphine Treatment (IBT) includes:~1. Buprenorphine (BUP)~2. Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~3. Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~4. Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~5. HIV+Hepatitis Education delivered via iPad"
41458233|NCT02093377|DEVICE|Adaptive servo-ventilation|Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)
40768826|NCT04707209|DRUG|Sirolimus|"An intravitreal injection of 20 µL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.~Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.~The interval between injections is roughly suggested to be between 3 to 8 weeks based on the drug deposit present in the eye. A total of 3-12 injections will be given per eye, over 6-24 months."
40970476|NCT05695898|DRUG|XmAb22841|Given intravenously (IV)
40768828|NCT02956564|PROCEDURE|intrauterine intervention|choose different surgeries according to different causes
40768829|NCT03167060|DEVICE|Active RhinoChill|"Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
40768830|NCT03167060|DEVICE|Control Rhinochill|"Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
40768831|NCT01598155|PROCEDURE|Group 1 - Supragingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient."
40970477|NCT05695898|DRUG|XmAb23104|Given intravenously (IV)
40970478|NCT00663169|BIOLOGICAL|canakinumab|10 mg/kg intravenous infusion 250 mL over 2 hours.
40970479|NCT00663169|DRUG|dexamethasone|12 mg intravenous infusion 50 mL over 30 minutes.
40970480|NCT00663169|OTHER|placebo matching canakinumab|5% glucose in water intravenous infusion.
40970481|NCT00663169|OTHER|placebo matching dexamethasone|Placebo intravenous infusion.
40970482|NCT01661296|OTHER|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
40970483|NCT01661296|DRUG|Sodium stibogluconate|Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
40970484|NCT00646776|DRUG|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
40970485|NCT00646776|DRUG|Rifabutin + Atazanavir + Ritonavir|"Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)"
40970486|NCT01384253|OTHER|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
40970487|NCT01384253|BIOLOGICAL|trastuzumab|4 mg/kg.
41458234|NCT04804839|OTHER|First research arm|Patients in this group were given 8-week PFMT (including knack maneuver) and lifestyle recommendations for the treatment of urinary incontinence symptoms.
41458235|NCT04804839|OTHER|Second research arm|Patients in this group were given only 8-week PFMT (including knack maneuver) for the treatment of urinary incontinence symptoms.
40970488|NCT03579732|DRUG|Aspirin (Acetylsalicylic Acid, BAYE4465)|Low dose of aspirin, i.e. \< 150 mg daily
40970489|NCT03579732|OTHER|No drug|Non-consumers
40970490|NCT03470441|DRUG|FDY-5301|FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
41458236|NCT04804839|OTHER|Third research arm|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
40768832|NCT01598155|PROCEDURE|Group 2 - Supra- and subgingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing of coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;~* Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged."
40768833|NCT05972772|DRUG|Doxycyclin|100-mg film-coated tablets; Pfizer
40768834|NCT05972772|DRUG|Azithromycin|250-mg capsules; Pfizer
40970491|NCT03470441|OTHER|Placebo|Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
40970492|NCT06373627|OTHER|Hypnosis|"A hypnosis session takes place in 3 stages:~* An induction stage, where we move from an ordinary state of consciousness to a modified state of consciousness through dissociation.~* A work phase to deepen the hypnotic trance. This phase is fueled by the construction of suggestions and metaphors, analogous to those of the patient in pain.~* Finally, a return to the ordinary state of consciousness through re-association with the patient."
40970493|NCT06373627|DRUG|Conventional medications used for sedation-analgesia|MEOPA + intravenous ketamine (0.5 mg/kg) + intraveinous midazolam (50µg/kg)
40970494|NCT06373627|DRUG|Medications used in addition to hypnosis|MEOPA + intravenous ketamine (0.3 mg/kg)
40970495|NCT04014712|DRUG|Tetrahydrobiopterin|Oral, Single dose
40970496|NCT04014712|DRUG|Placebo oral tablet|Single dose
40970497|NCT06409572|DIAGNOSTIC_TEST|GeneXpert MTB/RIF|Rapid and accurate method for detection of tuberculosis.
40970498|NCT03772691|PROCEDURE|lateral suspension|• The vesico-vaginal space was found between the bladder and the anterior vaginal wall in the fascia plane. A polypropylene mesh (25 , 25 cm, Ethicon, Inc., Somerville, NJ) was cut to obtain two long arms (15-20 mm wide) and a rectangular piece (4-7 cm wide).
41138759|NCT05904652|DEVICE|"Fisher and Paykel HealthCare Airvo™ 3 high flow system"|High Flow Nasal Oxygen Delivery Device
41138760|NCT05904652|DEVICE|Conventional Oxygen Therapy|Low flow oxygen delivery device (Flow rate between 2 litres per minute and 15 litres per minute)
41458237|NCT04109209|BEHAVIORAL|Psychosocial Intervention Group|The intervention will consist of six one-on-one sessions (45 minutes each). Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks
41458238|NCT04109209|BEHAVIORAL|Usual Care Group|"Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~•Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
40970499|NCT03772691|PROCEDURE|sacropexy|• The mesh is fixed on the anterior longitudinal ligament of sacrum with separated number 1 prolene sutures. The other end of the mesh is passed through the peritoneal tunnel and fixed to the cervix using prolene 1 and vicryl o sutures.
40970500|NCT03761524|PROCEDURE|Customized V plate fixation|(CT) scan is taken for the patients and a customized V pattern plate will be designed .Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position guided by the CAD/CAM plate. MMF will be done.Fracture fragments will be fixed using CAD/CAM plate .
40970501|NCT03761524|PROCEDURE|Conventional miniplates fixation|Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position. MMF will be done.Fracture fragments will be fixed using conventional miniplates fixation of angle fracture.
40970502|NCT00323921|DEVICE|dermatological infrared laser|
40970503|NCT01327105|DEVICE|TVU|Use of transvaginal ultrasound to determine location of micro-insert
40970504|NCT03677531|OTHER|Quality-of-Life Assessment|Ancillary studies
40970505|NCT03677531|OTHER|Questionnaire Administration|Ancillary studies
40970506|NCT03677531|RADIATION|Radiation Therapy|Undergo RT
40970507|NCT03677531|OTHER|Video|Watch video of choice during RT
40970508|NCT00371137|DRUG|Xyrem®|two doses
40970509|NCT00371137|DRUG|Placebo|Oral Solution
40970510|NCT06281990|BEHAVIORAL|Education|"1. Patients who were planned to undergo sleeve gastrectomy surgery were informed about the perioperative period when they came to the outpatient clinic2-4weeks before surgery and were educated about the exercises to be performed before and after surgery. The content of this education included pain management, breathing exercises,foot rotation, and leg exercises. In addition, the education book prepared by the researchers was given to the patients to make the education and information permanent until the day of surgery.~2. When the patient was hospitalized, anxiety level with the Trait Anxiety scale and pain level with VAS were determined one day before surgery.~3. Postoperatively, the patient's pain level before analgesics every 4-6hours for 2days, the patient's anxiety level with the State Anxiety Scale one day after surgery, the development of complications in the postoperative period, vital signs were evaluated, and the duration of hospitalization was recorded."
40970511|NCT04984083|DIETARY_SUPPLEMENT|vitamin k|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
40970512|NCT00002210|DRUG|Delavirdine mesylate|
40970513|NCT06139432|DEVICE|Active tDCS|"* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* The stimulation level is 2mA for 20 minutes.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
40970514|NCT06139432|DEVICE|Sham tDCS|"* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
40970515|NCT04763304|OTHER|Gown personal protective equipment (PPE-G) suit|Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
40970516|NCT04763304|OTHER|Coverall personal protective equipment (PPE-C) suit|Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
40970517|NCT00981734|OTHER|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
40970518|NCT02490228|PROCEDURE|TAURFUC|female patients with urethral caruncle will receive transurethral resection combine with extension tube.
41458239|NCT04054258|DEVICE|App support Programme (ASP) group|All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
41458240|NCT04971512|DRUG|EDP-721|Oral administration (Part 1)
41458241|NCT04971512|DRUG|Placebo (Part 1)|Placebo to match EDP-721, oral administration (Part 1)
40768835|NCT05166811|DRUG|Magnesium Sulfate, Heptahydrate|A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.
40768836|NCT05166811|DRUG|0.9% saline|A single dose of intravenous 0.9% sodium chloride given over 20 minutes through a peripheral intravenous line as the placebo arm of the study.
40970519|NCT01322178|DRUG|Cetuximab; mFOLFOX6|"Cetuximab (Erbitux): 500 mg/m2 iv gtt, D1~Oxaliplatin: 85 mg/m2 iv gtt over 2 hours, D1; leucovorin: 400 mg/m2 iv gtt , D1; 5-FU: 400 mg/m2 iv, 2400 mg/m2 civ46h~repeated every two weeks for 4.5 months(9 cycles)"
40970520|NCT04258397|DRUG|Pirfenidone|Pirfenidone vs. matching placebo
40970521|NCT04258397|DRUG|matching placebo|matching placebo
41458242|NCT04971512|DRUG|EDP-721 (Part 2)|Oral administration (Part 2)
41458243|NCT04971512|DRUG|Placebo (Part 2)|Placebo to match EDP-721 (Part 2)
41458244|NCT04971512|DRUG|EDP-514|Oral administration
41458245|NCT04971512|DRUG|Placebo (Part 2)|Placebo to match EDP-514
40970522|NCT03965962|BIOLOGICAL|VRVg-2|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
40970523|NCT03965962|BIOLOGICAL|Purified Inactivated Rabies Vaccine|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
40970524|NCT03965962|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV)|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
40970525|NCT03965962|BIOLOGICAL|Rabies immune globulin (human)|"Pharmaceutical form: Solution for injection;~Route of administration: IM"
40970526|NCT01379040|OTHER|Cystic Fibrosis patients|
40970527|NCT04244331|DIAGNOSTIC_TEST|CCO|Determination of COO in tumor biopsies from patients with GBDD using the Lymph2Cx assay using NanoString tectology
40970528|NCT04381598|DRUG|stevia rebaudiana bertoni|Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
40970529|NCT04381598|OTHER|placebo|A placebo without the active drug will be placed in the control sites.
40970530|NCT02054091|DIETARY_SUPPLEMENT|Bovine colostrum|The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
40970531|NCT02781493|DRUG|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
40970532|NCT02781493|DRUG|2 mg Placebo plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
40970533|NCT05699499|OTHER|KeryFlex|KeryFlex is a painless, in-office cosmetic application of artificial nails which improves the appearance of nails damaged by various nail disorders. The composite resin creates a flexible, nonporous nail that allows the remaining natural nail to grow. KeryFlex is a three-step procedure that takes 10 to 15 minutes for a typical nail. At least 15% of the existing nail must be present for the resin application. The material used in KeryFlex is approved as a cosmetic by the FDA.
40970534|NCT01950650|BEHAVIORAL|No treatment given|Survey conducted through computer-assisted telephone interviewing.
40970535|NCT01950650|BEHAVIORAL|survey|Survey conducted via the Internet.
41458246|NCT03333863|OTHER|descriptive study which reviewed the data of patients hospitalized with positive bacterial cultures|A retrospective, descriptive study was conducted at shengjing hospital of China Medical University between 2015- 2017. Data regarding bacterial culture isolates, antimicrobial susceptibility spectrum, and the general data of patients with fever or suspicion of sepsis were collected.
40970536|NCT05838105|DRUG|GnRH agonist|125 mcg once at the day mentioned
40970537|NCT05838105|DRUG|hCG|dose as mentioned
40970538|NCT05838105|DRUG|Progesterone 100Mg Vag Tab|dose as mentioned
40970539|NCT05574699|OTHER|Social Risk Score and CDS Tool|A social risk score, which helps to identify patients with high social needs based on the risk score in the CDS tool and a closed loop referral, which helps to refer the patients to CBOs, if needed.
40970540|NCT05574699|OTHER|Standard of Care|Currently available process for screening, assessment, and addressing social needs in the clinic setting, which may include providing a sheet of various educational resources, or a list of organizations that can address the identified social need.
40970541|NCT03205033|DRUG|Melatonin 20 MG Oral Capsule|1 capsule/day 1 hour before go to bed
41458247|NCT06170034|BEHAVIORAL|Satisfaction questionnaire|Satisfaction questionnaire to assess how TIA patients feels about their medical care.
40970542|NCT03205033|DRUG|Placebo oral capsule|1 capsule/day 1 hour before go to bed
40970543|NCT05510804|COMBINATION_PRODUCT|ALISA|assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance
40970544|NCT05177978|DIETARY_SUPPLEMENT|Phosphatidylserine|Phosphatidylserine containing supplement (2 x chewable gummies/day; Total daily dose of 100 mg elemental phosphatidylserine)
40970545|NCT05177978|DIETARY_SUPPLEMENT|Placebo|Placebo comparator (2 x chewable gummies/day, matched to shape and color without active ingredient)
40970546|NCT05526820|BIOLOGICAL|The live attenuated varicella vaccine and the inactivated hepatitis A vaccine|"The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd,the inactivated hepatitis A vaccine was manufactured by Sinovac Biotech Co., Ltd.~The live attenuated varicella vaccine:live varicella-zoster virus in 0.5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection.~The inactivated hepatitis A vaccine:250 U inactivated virus in 0.5mL of aluminium hydroxide solution per injection.~All subjects received hepatitis A vaccine in the upper left arm and varicella vaccine in the upper right arm."
40970547|NCT01740193|PROCEDURE|TAP Block|While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
40970548|NCT01740193|PROCEDURE|Ilioinguinal/iliohypogastric blockade|Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
40970549|NCT03023475|DEVICE|LigaSure endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the LigaSure system.
41458248|NCT06170034|OTHER|Medical care questionnaire|Recording appointments and results of examinations and consultations in TIA management
41458249|NCT04381013|DEVICE|Emergency Ventilator Splitter|Device to enable oxygen delivery to two patients independently from a single ventilator.
40970550|NCT03023475|DEVICE|TLS2 endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the TLS2 system.
40970551|NCT00733408|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
40970552|NCT00733408|BIOLOGICAL|bevacizumab|Given IV
40970553|NCT00733408|DRUG|erlotinib hydrochloride|Given PO
40970554|NCT04352504|OTHER|Almond|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
40970555|NCT04352504|OTHER|Pretzel|Consume 2 oz. serving of pretzels (216 calories) daily for 12 weeks
40970556|NCT04441021|OTHER|Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
40970557|NCT03074591|DRUG|Ferric Carboxymaltose 50Mg/Ml Inj 15Ml|After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
40970558|NCT03074591|DRUG|Saline Solution for Injection|In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
40970559|NCT03296241|DEVICE|laser|
40970560|NCT03296241|DEVICE|sham control|
40970561|NCT06431490|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
40970562|NCT05015465|DIAGNOSTIC_TEST|Anterior Segment OCT|AS-OCT for juvenile SLE patients and compare them with normal subjects
40970563|NCT01437722|DRUG|1% SPL7013 Gel|vaginal gel
40970564|NCT01437722|DRUG|3% SPL7013 Gel|vaginal gel
40970565|NCT01437722|DRUG|placebo gel|vaginal gel
41458250|NCT06062160|OTHER|Therapeutic Touch|Experimental group received deep Therapeutic Touch two time at 10th and 40nd hours after cesarean section.
40970566|NCT04286321|OTHER|Zero hard-boiled egg|No eggs will be consumed on test day
41146918|NCT01342718|DIETARY_SUPPLEMENT|Herbal extract granule and probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)"
41458251|NCT00493883|DEVICE|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
40970567|NCT04286321|OTHER|Two egg whites|Two egg whites will be consumed on test day
40970568|NCT04286321|OTHER|Two hard-boiled eggs|Two eggs will be consumed on test day
40970569|NCT04286321|OTHER|Vegetable oil|Vegetable oil will be consumed on test day
40970570|NCT02534870|DRUG|ABT-450/r/ABT-267|Tablet
40970571|NCT02534870|DRUG|ABT-333|Tablet
40970572|NCT04036344|BEHAVIORAL|Peer Mentorship Program|Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
40970573|NCT01717261|RADIATION|Single Pre-Operative Radiation Therapy|Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
40970574|NCT05044390|PROCEDURE|Lung transplantation (single, lobar or bilateral lung transplantation)|Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis
40970575|NCT01996501|DRUG|Olanzapine Orally Disintegrating 5mg Tablets|
40970576|NCT03423381|OTHER|Cereal product 1|Cereal products based on rye, barley, wheat, oat, and corn
40970577|NCT03423381|OTHER|Cereal product 2|Cereal products based on rye, barley, wheat, oat, and corn
40970578|NCT03423381|OTHER|Cereal product 3|Cereal products based on rye, barley, wheat, oat, and corn
40970579|NCT03423381|OTHER|Cereal product 4|Cereal products based on rye, barley, wheat, oat, and corn
40970580|NCT03423381|OTHER|Cereal product 5|Cereal products based on rye, barley, wheat, oat, and corn
40970581|NCT03423381|OTHER|Control product|A cereal based product with low concentrations of df
40970582|NCT01450436|OTHER|Peapod assessment|"EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.~After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old)."
40970583|NCT05228262|OTHER|Cohort follow-up|"* Inclusion medical consultation,~* Inclusion clinical examination,~* Collection of biological samples (bone biomarkers, epigenetic biomarkers (microRNA)) and analysis of microbiota and genotyping,~* Calculation of the Kauppila score on profile spine radiographs by the rheumatologist,~* Cardiovascular investigations (FMD, Flow-Mediated Dilation); measurement of digital volume increase (RHI, Reactive hyperhemia index); measurement of microcirculatory perfusion of the skin at the hand (FLD, Flow Laser Doppler) ; measurement of the stiffness of the main arteries (aorta) by the Pulse Wave Velocity (PWV),~* Exploration of sarcopenia: questionnaires and tests: SARC-F, SPPB, muscle strength,~* Quality of life component questionnaires Pittsburgh Sleep (PSQI), Numerical Scale (NS), Brief Pain Inventory (BPI), Hospital Anxiety and Depression scale (HADs), and 36-Item Short Form Survey (SF-36) Quality of Life Questionnaire."
40970584|NCT05679232|DEVICE|Hydrogel coating|hydrogel coating applied to implant's surfaces during cementless hip revision arthroplasty
40970585|NCT05679232|PROCEDURE|Control|standard cementless hip revision arthroplasty
41458252|NCT03206749|DRUG|VX-150|Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.
40970586|NCT05272020|DIAGNOSTIC_TEST|CPET, 6MWT, QOL assessment|Preoperative and postoperative (6 months + 18 months) assessment
40970587|NCT04010357|DRUG|Abemaciclib,|Abemaciclib (CDK4/6 inhibitors) is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells. Some cancer cells develop because their cells overrun the molecular brakes that normally permit cell to divide only when they are needed to replace old ones. These brakes are regulated by a group of enzymes known as cyclin-dependent kinases (CDKs). Alterations causing over-activity of two of these enzymes, CDK4 andCDK6, are found in a variety of cancers, including small cell lung cancer with retinoblastoma (Rb) protein.The drugs work by selectively turning off the overactive CDK4 and CDK6. As a result, the cancer cells' division cycle is halted, preventing them from proliferating.
40970588|NCT01516437|PROCEDURE|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
40970589|NCT01516437|PROCEDURE|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
40970590|NCT01516437|PROCEDURE|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
40970591|NCT01414283|DRUG|PSMA ADC|PSMA ADC administered IV
40970592|NCT00313378|DRUG|Hypothetica|
40970593|NCT04566991|DRUG|Deferoxamine|"There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.~Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine."
40970594|NCT04566991|DRUG|Placebo|There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr. The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.
40970595|NCT04107194|DRUG|Pantoprazole 40mg|Proton pump inhibitor
40970596|NCT04107194|DRUG|Amoxicillin 1000 MG|Antibiotic
40970597|NCT04107194|DRUG|Clarithromycin 500mg|Antibiotic
40970598|NCT04107194|DRUG|Metronidazole|Antibiotic
40970599|NCT04107194|DRUG|Tetracycline 125 MG|Antibiotic
40970600|NCT04107194|DRUG|Bismuth Subcitrate|Antibiotic adjuvant
40970601|NCT04107194|DRUG|Rifabutin 150 MG|Antibiotic
40970602|NCT04107194|DRUG|Levofloxacin 500mg|Antibiotic
41146919|NCT01342718|DIETARY_SUPPLEMENT|Herbal extract granule and placebo probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
41297185|NCT04174885|PROCEDURE|epicardial ablation|"In general anesthesia and left lung ventilation, authors will access the right thorax by three working ports. However, a rigid video thoracoscopic camera with a direct optics will be used. Pericardium will be widely opened anterior to a phrenic nerve and transverse and oblique sinuses were dissected. An insertion of the ablation catheter will be a tricky part of the surgery with the first MW catheter, while no special introducer will be provided. Later RF devices will be equipped with a special flexible introducers, lately also with a magnetic tip and the positioning of the catheter around PVs became much safer and easier.~The correct position of catheter will be visualized by trans esophageal echocardiography before the ablation."
41297186|NCT03732768|DRUG|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.
40768837|NCT06638411|BEHAVIORAL|ADHD information workshop|ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms. To control for the duration of the nocebo module (see the condition below), participants will also learn about sleep and its relevance for maintenance of good cognitive health. At the end, the workshop will involve a writing reflection activity about personal experiences with ADHD symptoms.
40970603|NCT00138996|DEVICE|automated direct feedback on CPR from defibrillator|
40970604|NCT05182138|OTHER|Unfortified potato plus placebo|Volunteers will be given 300g of zinc unfortified cooked potato as well as a placebo every day.
40970605|NCT05182138|OTHER|Zinc Biofortified potato plus placebo|Volunteers will be given 300g of cooked potato biofortified with zinc and a placebo every day.
40970606|NCT05182138|OTHER|Unfortified potato plus zinc supplement|Volunteers will be given 300g of zinc unfortified cooked potato and a zinc supplement containing 18mg of zinc, every day.
40970607|NCT01211002|RADIATION|radiotherapy combined with EP|Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
40970608|NCT01211002|DRUG|radiotherapy / EP combined with recombinant human endostatin|Anti-vascular targeting therapy The number of courses is 3 \~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
40970609|NCT03775655|DRUG|Dexmedetomidine|10μg dexmedetomidine will be added to the injectate to be injected intrathecally
40970610|NCT00366288|DRUG|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
40970611|NCT00205582|DEVICE|Positron Emission Tomography|
40970612|NCT05954013|BEHAVIORAL|PD_Pal intervention|The PD_Pal intervention will be delivered by a nurse that is specifically trained to deliver the PD_Pal intervention, i.e. the PD_Pal nurse. In the PD_Pal intervention, the patient, family caregiver and PD_Pal nurse complete four steps wherein they discuss and compose a: 1) Individual care plan; 2) Proactive care plan; 3) Quality of life and end-of-life plan and; 4) Coordination and revision plan. Together these steps lead to the Parkinson Support Plan. To facilitate patients in taking these steps, all patients receive a Parkinson Support Plan workbook. This workbook consists of information and questions aligned with the four steps. Patients can utilize this workbook before, during, or after the conversations with the PD_Pal nurse.
41458253|NCT03206749|DRUG|HB/APAP|Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.
41458254|NCT03206749|DRUG|Placebo|Participants received placebo matched to VX-150 and HB/APAP for 2 days.
41458255|NCT05568849|DIAGNOSTIC_TEST|OCTA measurements|OCTA images will be obtained from the retina at 1-3 time points around the time of children's heart surgery
40970613|NCT02338141|DEVICE|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
40970614|NCT02338141|DEVICE|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
40970615|NCT02848651|DRUG|Atezolizumab|Atezolizumab 1200 mg was administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
41297187|NCT04686734|OTHER|No active intervention (observational only)|No active intervention (observational only)
41297188|NCT00627640|DRUG|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
40768838|NCT06638411|BEHAVIORAL|ADHD information workshop with nocebo education|ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms, together with a module on nocebo effects and their potential role in worsening symptoms. The nocebo module will describe the current understanding of the role of expectations in creating side effects and elaborate on how this applies to the field of mental health through a series of examples. It will also involve a writing reflection activity about personal experiences with ADHD symptoms, potential for nocebo effect when talking about ADHD symptoms, and ability to apply this information to personal experiences.
40768839|NCT06638411|BEHAVIORAL|Sleep workshop|An information workshop about sleep and dream experiences that will be delivered by a clinical psychologist in one 30-minute session to a group of participants. It will be matched on duration, type of content, and engagingness with the experimental sessions.
40768840|NCT06588582|OTHER|Water Temperature Variation - WW|Participants are assigned to warm water temperature.
40768841|NCT06588582|OTHER|Water Temperature Variation - CW|Participants are assigned to cold water temperature and are video recorded.
40768842|NCT06473675|PROCEDURE|Hysterectomy with adnexal surgery|Robotic-assisted and laparoscopic hysterectomy with adnexal surgery for benign disease.
40768843|NCT06596135|DRUG|Setmelanotide|Open-label daily injections of setmelanotide
40768844|NCT04466358|PROCEDURE|Modified CLOSE protocol|Modified CLOSE protocol guided isolation of pulmonary veins.
41458256|NCT03816449|OTHER|exercises|"Aerobic exercise will be conducted as a dose walk, 3-5 km / h, lasting 50 minutes per day, least five days per week, for 12 weeks. The intensity of the training will be around 70% of the maximal heart rate.~Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased on weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions and load straps. Progression and maintenance load tapes will be carried out depending on the capacity of individualized persons. Frequency of training will be 3 times a week,will last 70 minutes per day for 12 weeks."
41458257|NCT01884844|DRUG|Vitamin D3, Cholecalciferol|
41458258|NCT01884844|DRUG|Placebo|
41458259|NCT06283888|DRUG|CYP2C19 Genotype Guided DAPT|Patients with \*2 or \*3 carrier will be received ticagrelor 60mg or 45mg bid (if \<50 kg, ≥75 years) + aspirin 100 mg qd; Patients with \*2 or \*3 non-carrier will be received clopidogrel 75mg qd + aspirin 100 mg qd
40970616|NCT00793598|DRUG|Placebo|
40970617|NCT00793598|DRUG|Brincidofovir|
40970618|NCT05109156|OTHER|This is an observational study|This is an observational study
40970619|NCT02521610|DRUG|Placebo|Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
40970620|NCT02521610|DRUG|RG7625|Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
40970621|NCT02637284|DRUG|Bepecin|"Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.~Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics."
40970622|NCT02637284|DRUG|Placebo|"Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group."
40970623|NCT04644627|DRUG|Gentamicin Sulfate|Topical gentamicin ointment on wounds once daily for 6 weeks
40970624|NCT06341400|DRUG|DisitamabVedotinForIicction Toripalimab|Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles.
40970625|NCT04936256|DEVICE|Clareon|Clareon monofocal intraocular lens (IOL)
40970626|NCT01652703|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
40970627|NCT01652703|OTHER|Placebo|Administered by subcutaneous injection
40970628|NCT01990404|DRUG|Premixed 50% nitrous oxide and oxygen|Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
41297189|NCT00627640|DRUG|Matching Placebo|Matching Placebo
40970629|NCT01990404|DRUG|Medical Air|Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
40970630|NCT05746871|DEVICE|Agilik|The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.
40970631|NCT05746871|OTHER|standard care|Subjects will continue with their standard care for 5 weeks
40970632|NCT04869332|DEVICE|three cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Three screws for internal fixation in the three-screw group, and three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
40970633|NCT04869332|DEVICE|four cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Four screws for internal fixation in the four-screw group, and the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
40970634|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% THC concentration \<1% CBD concentration) will be smoked.
40970635|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% THC concentration \<1% CBD concentration) will be vaporized.
40970636|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% CBD concentration \<1% THC concentration) will be smoked.
40970637|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% CBD concentration \<1% THC concentration) will be vaporized.
40970638|NCT00009698|BIOLOGICAL|aldesleukin|Given SQ and IV
40970639|NCT05784350|DRUG|fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone|"group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia."
41297190|NCT00084422|DRUG|lestaurtinib|Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
41297191|NCT01609959|DRUG|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
41297192|NCT01609959|DRUG|Valsartan|Valsartan 160 mg per day
41297193|NCT00950690|DRUG|Xalatan 0.005% eye drops|ophthalmic solution dosed once daily for 3 months
41458260|NCT06283888|DRUG|Conventional DAPT|Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd
41458261|NCT04082741|DRUG|BMS-986318|Specified dose on specified days
41458262|NCT04082741|OTHER|Placebo|Placebo Matching BMS-986318
40970640|NCT05377385|BEHAVIORAL|Questionnaire|Questionnaire about usability of the Omnipod DASH insulin administration system
41458263|NCT00088608|DRUG|SOM230 s.c.|
41458264|NCT04771767|DRUG|Ketamine|Patients will receive 6 sub-anesthetic IV ketamine infusions over 8 weeks, each one lasting 40 minutes.
41458265|NCT04771767|BEHAVIORAL|Online Trauma-Focused Cognitive Behavioural Therapy|Participants will enrol in a 12-week online CBT program mirroring in-person trauma-focused CBT.
41458266|NCT03062787|DEVICE|Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)|Intra-articular injection
41458267|NCT03062787|DEVICE|Monovisc® (Sodium hyaluronate)|Intra-articular injection
41458268|NCT05303948|DEVICE|Videolaryngoscopy / Direct Laryngoscopy|First pass success analysis
41458269|NCT00869115|DRUG|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
40970641|NCT00349440|DRUG|Cyclosporine, Refresh Plus|"Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily."
40970642|NCT04243967|OTHER|Music therapy|"On the surgery day, the patient is accompanied by music-therapist all the way from her room to the operating theatre in order to monitor and adapt music-therapy intervention.~The patient, prior to the anesthetic, take faces 3 phases of music therapy intervention (1 hour):~* 1° Phase Active Music therapy: the patient takes part in a session of live improvisational music therapy, with the therapist, to elaborate pre-operative stress.~* 2° Phase Relaxation with Receptive Live Music: music therapist play live to relax patients with autogenic training and tunnings breathing.~* 3° Phase playlist listening based on the patient's needs. Patients listen to music with an mp3 player with earphones within the ear canal (H\&H CE mp3/Usb; Headphones on Air in-ear with volume control) with a maximum volume of 60 dB (previously set with a sound level meter)."
40970643|NCT04243967|OTHER|Control|Standard perioperative management including perioperative care (without the use of music / music therapy)
40970644|NCT01801891|DEVICE|VASGARD stimulator|The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
40970645|NCT01801891|OTHER|Compression bandaging|Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
41138761|NCT04848740|DEVICE|ReLex-smile|Using VisuMax femtosecond laser we created the stromal pocket with diameter of 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness set to 130 μm from corneal surface and 4 mm superior incision. Hinge position flap was set at 90° angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values We noticed during intervention that implantation of fresh lenticule depends from corneal thickness, for example if c.th.is 300-400 μm we implanted 1/2 stroma, if c.th.is 400 μm or more we implanted 1/3 stroma Example: if corneal thickness is 300 μm we implanted 150 μm (becoming 450 μm) we added more stroma due to more live keratocytes and stromal steam cells, aiming to overcome dead and non-functional keratocytes
41138762|NCT02107976|DIETARY_SUPPLEMENT|Vitamin E|400 IU per day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
41458270|NCT00869115|DRUG|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
41458271|NCT00869115|DRUG|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
41458272|NCT00869115|DRUG|Istaroxime|Placebo continuous i.v. infusion for 24 hours
41458273|NCT05333653|OTHER|Continouse supportive care|"Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.~Participants in the control group, on the other hand, received routine care given in the hospital by other midwives in the clinic."
41458274|NCT05333653|OTHER|routine care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
41458275|NCT05823922|BEHAVIORAL|Clinician Delivered CBT|Clinicians teach cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety and depression. Participants will attend weekly sessions with their clinician for 6 weeks.
40970646|NCT04010708|DIAGNOSTIC_TEST|Urinary Iodine Concentration Measurement|UIC
40970647|NCT02077244|BEHAVIORAL|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
40970648|NCT05710536|OTHER|Formulation X|This formulation containing stem cell secretome and liquorice root extract
40970649|NCT03262818|DEVICE|Transvaginal ultrasound|-Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson
40970650|NCT03262818|DEVICE|Ultrasound/Photoacoustic imaging|-The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
40970651|NCT00763672|OTHER|Transmission of sFlt-1 results to the investigator|Transmission of sFlt-1 results by the laboratory to the investigator
40970652|NCT00763672|OTHER|No transmission of the sFlt-1 results to the investigator|The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
40970653|NCT03982628|DIAGNOSTIC_TEST|Abdominal CT imaging|Routine abdominal CT imaging
40970654|NCT02076698|PROCEDURE|AN-DBS|Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
41138763|NCT02107976|DIETARY_SUPPLEMENT|Vitamin C|500mg twice a day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
41297194|NCT03921281|OTHER|scalp acupuncture treatment|"The parameters for scalp acupuncture are set as follows:~1. Scalp acupoint selection: The Motor Area of Jiao's Scalp acupuncture and Si shencong (EX-HN1).~2. Acupuncture manipulation: Disposable stainless steel needles will be manually inserted in at an approximately 15-degree angle to a depth of 1.5-2.0 cm respectively along the upper point and middle point of the motor area on the scalp. The acupuncture direction of Si shencong (EX-HN1) acupoint is toward the Baihui (GV20) acupoint. the needles will be rotated for at least 200 revolutions per minute for 1 minute every 20 minutes for a total of 60 minutes.~3. Treatment course: three times a week, 12 weeks in total."
41458276|NCT05823922|BEHAVIORAL|Supplemental MAYA App|"The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.~Participants will attend weekly sessions with their clinician as well as using the MAYA application for at least 20 minutes twice a week"
41458277|NCT02040961|DEVICE|ETView Double-Lumen Tube|Tracheal intubation is performed using a ETView Double-Lumen Tube
40970655|NCT02076698|DRUG|Usual treatment|usual treatment of epilepsy Vagus nerve stimulation: maintained
40970656|NCT04630171|DEVICE|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
40970657|NCT04630171|DEVICE|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
40970658|NCT04630171|OTHER|Group #3: Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
40970659|NCT04630171|DEVICE|Group #4: VerTouch utilized for identification of site for lumbar puncture procedure|Group #4: VerTouch utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
40970660|NCT04630171|DEVICE|Group #5: Ultrasound (US) utilized for identification of site for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
40970661|NCT04630171|OTHER|Group #6: Control group, palpation utilized for identification of site for lumbar puncture procedure|Group #6: Control group, palpation utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
40970662|NCT01446900|DRUG|Rituximab|375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
41138764|NCT00224835|BEHAVIORAL|Mindfulness Based Stress Reduction Class|Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
41138765|NCT00224835|BEHAVIORAL|Cardiac Education Class|"Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format."
41458278|NCT00051805|BEHAVIORAL|Promotion of adherence to ARV medications|
41458279|NCT06103383|DRUG|Controlled ovarian stimuation|3 days stimullation protocol using hMG-HP
41458280|NCT06103383|PROCEDURE|Oocyte pick up|Surgical oocyte pick up without triggering
40970663|NCT01446900|DRUG|Cladribine|0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
40970664|NCT00039832|DRUG|Abciximab (ReoPro) and Reteplase (Retavase)|
40970665|NCT06112262|DRUG|Heparin|Comparison between heparin and hirudin
40970666|NCT02513953|PROCEDURE|Laparoscopic|Four Port Laparoscopic cystectomy
40970667|NCT00203125|DRUG|rasagiline mesylate|0.5 or 1 mg oral, once-daily
40970668|NCT00203125|OTHER|tyramine|50 mg once daily
40970669|NCT01438424|DRUG|Entecavir|Tablets, Oral, 1.0 mg, once daily
41458281|NCT06103383|PROCEDURE|Oocyte in vitro maturation|In vitro maturation procedure
40970670|NCT01438424|DRUG|Lamivudine|Oral, 100 mg, daily
40970671|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
40970672|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
40970673|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
40970674|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
41138766|NCT03369483|OTHER|Abdominal pressure assessment|We will perform measurements of the abdominal pressure an urinary catheter connected with an intra-abdominal pressure device (Uno-Meter ® - Unomedical) in all patients undergoing on open-surgical procedures after mechanical ventilation withdrawal and extubation, 30 minutes and 4 hours after the application of CPAP.
41138767|NCT06380959|OTHER|Art Based Activity|"Art Based Activity Module consists of 3 art-based activities under the titles My Life Journey, The Power Within Me and Letter to the Future. Each activity consists of three stages. In the first stage, the participants were made to practice breathing exercises. At this stage, the participant was expected to become aware of himself and his ideas. In the second stage, art activity was carried out. In the final stage, the revealed art object was concretized by the participants with a verbal expression. The materials used in the activities (dry paint, pastel paint, watercolor) are dermatologically tested and consist of anti-allergen products."
41138768|NCT02900937|DEVICE|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
41297195|NCT03921281|OTHER|Rehabilitation Treatment|The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
41297196|NCT03345836|DRUG|Matching Placebo for Upadacitinib|Matching placebo tablets
41297197|NCT03345836|DRUG|Upadacitinib|Upadacitinib tablets
41458282|NCT06103383|PROCEDURE|Oocyte in vitro activation|In vitro oocyte activation procedure
40970675|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
40970676|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
40970677|NCT00599924|DRUG|sunitinib + FOLFOX|25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
40970678|NCT00003594|DRUG|irinotecan|
40970679|NCT00003594|DRUG|fluorouracil|
40970680|NCT00003594|DRUG|leucovorin calcium|
40970681|NCT00003594|DRUG|oxaliplatin|
40970682|NCT03781596|DIAGNOSTIC_TEST|Retrospective evaluation of endoscopy prior to study drug|Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.
40970683|NCT03781596|OTHER|Symptom Survey|Patient will complete symptom survey prior to starting the study drugs.
40970684|NCT03781596|OTHER|Medication Compliance Phone Call|The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.
40970685|NCT03781596|DIAGNOSTIC_TEST|Endoscopy while on study drug|Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.
40970686|NCT03781596|OTHER|Symptom Survey|The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.
40970687|NCT03781596|DRUG|Fluticasone|Participants in the experimental and placebo arms will be given swallowed fluticasone for an 8 week course. Doses determined by age and weight.
40970688|NCT03781596|DRUG|Omeprazole|The participants in the experimental arm will be given oral omprazole capsules for an 8 week period (along with the swallowed fluticasone). Doses determined by age and weight.
40970689|NCT03781596|DRUG|Placebo oral capsule|The participants in the placebo arm will be given placebo capsules for an 8 week period (along with the swallowed fluticasone). Number of pills determined by age and weight (to match omeprazole dosing).
40970690|NCT01110434|DRUG|Topiramate|Topiramate (200 mg daily)
40970691|NCT01110434|DRUG|Placebo|Placebo (daily)
40970692|NCT02197715|BEHAVIORAL|Computer-adaptive SAFE|
40970693|NCT02197715|BEHAVIORAL|Face-to-face SAFE|
40970694|NCT02197715|BEHAVIORAL|Usual Care|
40970695|NCT01695265|OTHER|Exercie oronasal breathing (ONB)|10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)
40970696|NCT01695265|DEVICE|Exercie nasal breathing through the FB|Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
41297198|NCT00024297|DRUG|warfarin|
41297199|NCT05873413|BEHAVIORAL|Motivate-the-Bystander|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for increased bystander behaviors.
41458283|NCT03965065|DEVICE|Sutureless aortic bioprosthesis|Patients will receive a sutureless aortic bioprosthesis
41458284|NCT03965065|DEVICE|Conventional stented sutured aortic prosthesis|Patients will receive a stented sutured aortic prosthesis
41458285|NCT03734458|OTHER|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.
40970697|NCT00873223|DRUG|liraglutide|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
40970698|NCT00873223|DRUG|insulin detemir|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
40970699|NCT05655962|OTHER|STARS|STARS is a structured framework for assessment of rehabilitation and sicklisting, applied by primarily the rehabilitation coordinators working at the primary health care centers.
40970700|NCT04550390|DIAGNOSTIC_TEST|Saliva collection|2 saliva samples are self-collected by participants
40970701|NCT05412511|BEHAVIORAL|MB-TB|Training exercises with throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
40970702|NCT05412511|BEHAVIORAL|MB-NTB|Training exercises without throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
40970703|NCT00001723|DRUG|Orlistat|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
40970704|NCT00001723|DRUG|Placebo|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
40970705|NCT01738373|DRUG|Plerixafor|Plerixafor will be prescribed independently by the physician, according to usual practice.
40970706|NCT06432920|DEVICE|ResWave|Prototype wearable in-phase chest wall vibration device
40970707|NCT03120416|BEHAVIORAL|Resistance exercise training|12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
40970708|NCT01411774|BEHAVIORAL|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
40970709|NCT01411774|DRUG|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (\~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (\~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
40970710|NCT01411774|DRUG|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
41297200|NCT05873413|BEHAVIORAL|Motivate-the-Bystander+Alcohol|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for reduced alcohol use and increased bystander behaviors.
41297201|NCT05873413|BEHAVIORAL|Attention-only Control|A Zoom-based stress reduction program in which progressive muscle relaxation and other techniques are introduced and practiced.
41297202|NCT00004747|DRUG|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
41297203|NCT05174052|DRUG|Dapagliflozin 10Mg Tab|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.
41297204|NCT05174052|DRUG|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
41458286|NCT03734458|OTHER|Group B - PRF only with a CAF|Group B - PRF only with a CAF will be used surgically to cover the exposed roots.
41458287|NCT03734458|OTHER|Group C - CTG with a CAF|Group C - CTG with a CAF will be used surgically to cover the exposed roots.
41297205|NCT02887105|OTHER|Standard neuropsychological assessment|
40970711|NCT03433768|GENETIC|Real time PCR|We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.
41297206|NCT02887105|OTHER|Brain MRI|
41297207|NCT02811484|DRUG|Exenatide-LAR plus Dapagliflozin placebo|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
41297208|NCT02811484|DRUG|Exenatide-LAR plus Dapagliflozin|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
41297209|NCT02811484|DRUG|Insulin Titration|Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%
41297210|NCT02811484|BEHAVIORAL|Behavioral Therapy|Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
41297211|NCT05221450|PROCEDURE|primary endodontic treatment|
41297212|NCT00059436|BEHAVIORAL|Mental effort in muscle strengthening|
41297213|NCT03519308|DRUG|Nivolumab|Before Surgery Wks 1 \&3, After Surgery Wks 1 \&3
41297214|NCT03519308|DRUG|Nab-Paclitaxel|Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
41297215|NCT03519308|DRUG|Gemcitabine|Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
41297216|NCT03519308|DRUG|Paricalcitol|Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery
41458288|NCT05503992|OTHER|Intervention package|The intervention package will include a mobile device configured with OpenSRP configured to facilitate clinical/service provision and stock management. The intervention also incorporates a training component on OpenSRP with accompanying follow-up supervisory visits for a limited period. Per the theory of changes, these activities will improve CHWs' knowledge and ability to use the platform for clinical care, dispensing, and workflow management, leading to an improved stock of commodities to meet preferred FP needs among last mile women.
41458289|NCT06471725|OTHER|combination of pilates exercises, Low-level laser therapy, and low-intensity ultrasound|The core and hip muscles will be targeted through a customized workout program consisting of exercises such as Breathing, Planks, Side- Planks, Weighted lunges, Glute Bridge, Clamshell, Half-Kneeling Hip Flexor Stretch, Swan dive, Roll down, Ab curls, and Shoulder bridge, Low-intensity Ultrasound , and low level laser therapy
41458290|NCT03282539|DEVICE|LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents
41458291|NCT03282539|DEVICE|LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
41458292|NCT03224767|DRUG|Vemurafenib|Given PO
41458293|NCT03224767|DRUG|Cobimetinib|Given PO
41458294|NCT03224767|OTHER|Laboratory Biomarker Analysis|Correlative studies
40768845|NCT04466358|PROCEDURE|High density mapping guided pulmonary vein isolation|Modified CLOSE protocol guided isolation of pulmonary veins with additional ablations at sites of gaps or dormant conduction as evidenced by high density mapping of pulmonary vein antra.
40970712|NCT00615758|DRUG|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression
40970714|NCT03592199|DRUG|Sunitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
40970715|NCT02501473|DRUG|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
40970716|NCT02501473|DRUG|Pembrolizumab|PD-1 Inhibitor
41297217|NCT04857398|DRUG|insulin icodec|"Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin.~The study will last for 15 to 22 weeks."
40970717|NCT02501473|DRUG|Rituximab|Rituximab (anti-CD20 antibody)
40970718|NCT04314778|BEHAVIORAL|social incentive-based gamification|At the beginning of each week, starting from postoperative day 3, the participant receives 70 points (10 points for each day that week). If the participant does not meet their daily step goal, they lose 10 points from their balance. This leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. At the end of each week if the participant has at least 40 points, they will move up a level (levels from lowest to highest: blue, bronze, silver, gold, platinum). If not, the participant will drop a level. All participants begin at the silver level. Each week, participants get a fresh set of 70 points. Participants will receive daily feedback for the step counts, and weekly feedback for their levels. Participants in the intervention arm will be asked to identify a family member or friend to be their support sponsor. A weekly report will be sent to this person with the participant's performance (points and level).
41458295|NCT03224767|OTHER|Quality-of-Life Assessment|Ancillary studies
40970719|NCT05466526|PROCEDURE|High frequency deep sclerotomy (HFDS)|The surgery was performed using the abee® glaucoma tip of Oertli phacoemulsiﬁcation machine (Cata-rhex3, Switzerland) and goniolens. During the procedures, nasal six pockets penetrating 1mm deep from the trabecular meshwork to Schlemm's canal will be formed to promote the aqueous humor outflow.
40970720|NCT00859404|DRUG|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
40970721|NCT04556695|OTHER|Questionnaire survey|Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)
41458296|NCT03028155|DRUG|Oxaliplatin: BSA-based HIPEC|oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
40970722|NCT04556695|DEVICE|Accelerometer study|Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.
41297218|NCT02136823|DRUG|sugar pill|
41297219|NCT02136823|DRUG|Riluzole|
41297220|NCT02136823|DRUG|Isradipine|
41297221|NCT02136823|DRUG|Memantine|
41297222|NCT02136823|PROCEDURE|Therapeutic muscle stretching|
41297223|NCT04185324|BEHAVIORAL|Standard zippering vest|Standard zippering vest used to teach zippering
41458297|NCT03028155|DRUG|Oxaliplatin: Concentration-based HIPEC|oxaliplatin: 230 mg/L
41458298|NCT02134639|PROCEDURE|68Ga-DOTATOC PET-CT Imaging|
41458299|NCT01664169|OTHER|laboratory biomarker analysis|
40768846|NCT05756322|DRUG|LBS-007|Open Label.
41458300|NCT03660787|DRUG|Seroguard|Seroguard 0.41 g/L solution
40768847|NCT03884101|DRUG|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
41458301|NCT03660787|DRUG|Placebo|Saline
41458302|NCT00327847|DRUG|Oral Vitamin D Supplementation|
41458303|NCT01301937|DRUG|Meglumine antimoniate|"Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:~1. High continuous dose: 20 mg/kg/day for 30 continuous days.~2. Low continuous dose 5 mg/kg/day for up to 120 continuous days.~There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat~Arms: High continuous dose, Low continuous dose"
40970723|NCT04556695|OTHER|Semi-structured interview study|Semi-structured interviews will take place via telephone or webcam. Participants will be given feedback regarding their accelerometer data relating to their levels of physical activity and sedentary behaviour. Questions will examine participants' thoughts and opinions regarding sedentary behaviour and physical activity in the General Practice setting. Further questions will explore participants' experiences of wearing accelerometers, their knowledge of and attitudes towards physical activity and sedentary behaviour and their thoughts or suggestions on interventions to reduce sedentary behaviour among GPs and GPSTs.
40970724|NCT06244732|PROCEDURE|Postoperative pain control|Postoperative analgesia after OR-AAA
40970725|NCT05579821|DIAGNOSTIC_TEST|Typhoid DPP assay|The index test used in this study diagnose typhoid fever by detecting IgA antibodies against LPS and HlyE antigen in patient's serum.
40970726|NCT06051227|DRUG|Fentanyl Citrate|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
40970727|NCT06051227|DRUG|Esketamine|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
40970728|NCT03759847|OTHER|Fluid intake app|Use of fluid app to monitor intake of fluids
40970729|NCT03759847|OTHER|Survey|A survey will be used to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of pre-selected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review) as well as to collect recommendations for changes to the app itself.
40970730|NCT02720991|DRUG|Mifepristone|200 mg of oral mifepristone
40970731|NCT02720991|DRUG|Sublingual misoprostol|400 ug of misoprostol sublingually following mifepristone
40970732|NCT00309387|DIETARY_SUPPLEMENT|Centrum|Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
40970733|NCT00309387|OTHER|Placebo|placebo tablets manufactured to mimic Centrum tablets.
40970734|NCT04016285|DEVICE|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
40970735|NCT04016285|DEVICE|Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
40970736|NCT01033266|DIAGNOSTIC_TEST|CPET|CPET will be done on patients with overlap syndrome before and after clinical CPAP treatment.
40970737|NCT00844831|DRUG|Lubiprostone|24 mcg bid for 28 days
40970738|NCT03432754|BEHAVIORAL|Mindfulness-Based Attention Training|The mindfulness-based attention training is closely modeled after the traditional mindfulness-based stress reduction (MBSR) protocol, it incorporates formal MBSR practices such as breath exercises, body scans and long sitting meditations. Specifically, MBAT is an abbreviated version of MBSR with a focus on the cognitive components.
40970739|NCT03432754|BEHAVIORAL|Lifestyle Education|"The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning and mind wandering in older adults, will comprise of scientific health and lifestyle information. Lectures will be focused on concepts presented in the book The Culprit and the Cure: Why lifestyle is the culprit behind America's poor health and how transforming that lifestyle can be the cure. Meetings will cover how to begin and maintain a more nutritious diet, classifying healthy choices across food groups, completing stretching/toning exercises, and reviewing homework."
40970740|NCT06093698|BIOLOGICAL|Recombinant Anti-EpCAM-CD3 Antibody Injection|Intravenous Infusion
40970741|NCT01194180|BIOLOGICAL|BCG: 100 microlitres ~ 2-8 x 105 pfu|BCG vaccination at day C (challenge day) then punch biopsy at day C+14
41458304|NCT04758390|BEHAVIORAL|IMARA (intervention group)|The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
41458305|NCT04758390|BEHAVIORAL|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
41458306|NCT03380325|DRUG|Iloprost infusion|Iloprost is a stable prostacyclin analogue
40970742|NCT01194180|BIOLOGICAL|MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu|MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14
41458307|NCT01044134|BEHAVIORAL|Dietary counseling|Participants will receive personalized dietary counseling to promote behavior change
40970743|NCT04478955|DIAGNOSTIC_TEST|Schirmer test|Tear tests Meibomian gland grading test
40768848|NCT03884101|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
40768849|NCT03884101|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
40768850|NCT03884101|DRUG|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
40970744|NCT02820753|BEHAVIORAL|EHR + (Text or Portal)|"Per protocol analysis:~Patients who received the initial 6 weeks of SMS messaging continuously, or logged on to the patient portal and completed at least one survey."
40970745|NCT00436683|DRUG|Fermagate|Film coated tablet 500mg
40970746|NCT00436683|DRUG|Sevelamer HCl|tablet 800mg
40970747|NCT02236195|DRUG|Mocetinostat|
40970748|NCT00003993|BIOLOGICAL|aldesleukin|
40970749|NCT00003993|DRUG|bryostatin 1|
41458308|NCT05327322|BEHAVIORAL|Glycemic load|Participants will be provided food to meet GL prescription for the duration of the trial.
40970750|NCT03748797|OTHER|Moderate intensity exercise training under supervision|Upper and lower limbs cycling, treadmill walking, multi-gym strengthening, stepper exercise, dumb bell and squatting exercise
40970751|NCT06171763|OTHER|Telemedicine|The telehomecare solution involves an early discharge with continued home monitoring through the use of telemedicine utilizing an user-friendly mobile. Additionally, there were a clinical reassessment in person 72 hours after discharge to evaluate the outcomes and results of the intervention.
40970752|NCT03682445|OTHER|exercise|Aerobic tyep of exercise will be made at different intensities in 2 groups.
40970753|NCT03879707|DRUG|Melatonin 5 mg|Melatonin is known to induce sleep
40970754|NCT03879707|DRUG|Placebo Oral Tablet|Placebo
40970755|NCT03879707|DRUG|Magnesium 500Mg Oral Tablet|Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep
40970756|NCT02591589|OTHER|Normoxic oxygenation|FiO2 set at 0.35 to maintain PaO2 \> 70 mmHg or oxygen saturation greater than or equal to 92%.
40970757|NCT02591589|OTHER|Hyperoxic oxygenation|FiO2 set at 1.0 throughout the procedure
40970758|NCT03468153|BIOLOGICAL|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patient-derived dual specificity CD19 and CD22 CAR-T Cells
40970759|NCT06227845|OTHER|Fecal microbiota transplant|0.1-0.3 ml liquid containing 3.5 mg/ml of maternal fecal content, (0.35mg/kg)
40970760|NCT02165774|DEVICE|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
40970761|NCT02165774|DEVICE|Turning ON the neuromodulator|
41138769|NCT06354725|OTHER|Plyometric|Players were randomly assigned to a two-times-a-week (2PLYO, n = 15) or four-times-a-week (4PLYO, n = 15) PT group. Both groups performed the same weekly total volume of jumps during PT in addition to regular basketball training and competition. After the eight-week intervention, all players underwent a one-week detraining period with no PT training while basketball training and competitions continued. Testing was performed at baseline (pre-test), after intervention (post-test), and after the detraining period. Players were assessed for lower body power using jump tests (countermovement jump \[CMJ\], drop-jump \[DJ\] from a 20-cm box, and horizontal jump \[HJ\]; change of direction ability using a planned agility test; and speed using a 20-m sprint and a 5-m split.
41138770|NCT05815420|DEVICE|Non invasive ventilation|Treatment by non invasive ventilation
41138771|NCT04720209|OTHER|CARE|CARE is a 16-week, supervised, periodized AE and RE program performed in a circuit fashion 3 days/week on-site
41138772|NCT04720209|OTHER|TARE|TARE is a 16- week, supervised AE and RE program consisting of three sessions per week on-site
41297224|NCT04185324|BEHAVIORAL|Modified zippering vest|Modified zippering vest used to teach zippering, along with related story
41297225|NCT02713581|BIOLOGICAL|Blood sampling|Venous blood will be sampled for laboratory analyses (see outcomes).
41297226|NCT06488573|BEHAVIORAL|Nutritional intervention|7 individual sessions + 8 small group sessions
41297227|NCT04547244|OTHER|echocardiographic optimization of CRTd|the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.
41297228|NCT02222129|DRUG|Bupivacaine|
41297229|NCT02222129|DRUG|liposomal bupivacaine|
41297230|NCT00472342|BEHAVIORAL|exercise prescription|
41297231|NCT01062646|BEHAVIORAL|Multimodal music therapy|
41297232|NCT01062646|BEHAVIORAL|Community treatment as usual|
41297233|NCT00921856|OTHER|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
41297234|NCT01097616|DRUG|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
41458309|NCT05327322|BEHAVIORAL|Calorie restriction|Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).
41458310|NCT05327322|BEHAVIORAL|Behavioral support|All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.
40970762|NCT05765604|BIOLOGICAL|Recombinant COVID-19 variant vaccine(Sf9 cell)|IM
40970763|NCT05765604|BIOLOGICAL|Recombinant COVID-19 vaccine(CHO cell)|IM
40970764|NCT04106960|OTHER|No Intevention Used|N/A as in the study does not have intervention in place. It is exploring the relationships between the social and physical features of the environment and participation through using standardized outcome measures.
40970765|NCT01126450|DRUG|lenalidomide|Given orally
40970766|NCT01126450|BIOLOGICAL|cetuximab|Given IV
40970767|NCT01126450|OTHER|mutation analysis|Correlative studies
40970768|NCT01126450|OTHER|polymerase chain reaction|Correlative studies
40970769|NCT01126450|GENETIC|polymorphism analysis|Correlative studies
40970770|NCT02868320|OTHER|SMS messages|"Daily educational messages addressing the following categories: diet, exercise, complications, medications, foot care, blood sugar testing, and hypo- and hyperglycemia.~Weekly reminder messages of blood glucose testing."
40970771|NCT02868320|OTHER|Instruction booklet|General detailed instructions addressing the same SMS categories.
40970772|NCT00686192|DIETARY_SUPPLEMENT|Calcium Carbonate|1500 mg per day
40970773|NCT02460614|PROCEDURE|Rhinopharyngeal clearance|At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
40970774|NCT02460614|PROCEDURE|Aspiration|A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
40970775|NCT02460614|OTHER|0.9% saline|0.9% saline consists of physiological solution and was instilled in both experimental groups.
40970776|NCT01524692|DRUG|Dovitinib (TKI258)|500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
40970777|NCT02315716|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Randomisation to melphalan conditioned autologous stem cell transplant
40970778|NCT02315716|DRUG|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
40970779|NCT02028065|DRUG|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
40970780|NCT02028065|DRUG|Placebo|Placebo administered as a single IV bolus over 10 seconds
41458311|NCT04400292|OTHER|Injection of indocyanine green (ICG)dye|Patients will receive a perilesional injection of indocyanine green (ICG) before the laparoscopic phase of the esophagectomy.
40970781|NCT02310061|PROCEDURE|Extra-vascular lung water measurements by ultrasound (LW-US)|It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
40970782|NCT02310061|OTHER|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
40970783|NCT05373368|BEHAVIORAL|multi purpose activities|
40970784|NCT01201382|BEHAVIORAL|IPT-AST|A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions
40970785|NCT01201382|BEHAVIORAL|Group Counseling|Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
40970786|NCT06410287|OTHER|ArtSpective|ArtSpective is an interactive, educational program that uses art and museum-based pedagogy. The intervention is delivered asynchronously using a web-based platform. Participants engage with artwork, watch short educational videos, and read short clinical vignettes. After completing the program, participants receive a certificate of completion.
40970787|NCT00119626|DRUG|NXY-059|
40970788|NCT01344005|OTHER|caregiver-related intervention or procedure|
40970789|NCT01344005|OTHER|questionnaire administration|
40970790|NCT01344005|PROCEDURE|quality-of-life assessment|
40970791|NCT01344005|PROCEDURE|radiography|
40970792|NCT00002418|DRUG|Emivirine|
40970793|NCT00002418|DRUG|Hydroxyurea|
40970794|NCT00002418|DRUG|Nevirapine|
40970795|NCT00002418|DRUG|Stavudine|
41458312|NCT04400292|DEVICE|Near-Infrared Image-Guided|Real-time near-infrared (NIR) fluorescence imaging will be performed by use of the Novadaq PINPOINT minimally invasive system with a laparoscopic camera.
40768851|NCT06634784|OTHER|Bone Conduction Implant (BCI)|Improvement in hearing using BCI.
40970796|NCT00002418|DRUG|Didanosine|
40970797|NCT02066246|DEVICE|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
40970798|NCT02066246|DEVICE|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
40970799|NCT00465205|DRUG|Valacyclovir|500mg oral twice daily
40970800|NCT00465205|DRUG|Matching Placebo|500 mg oral twice daily
40970801|NCT05529303|BEHAVIORAL|Such as art therapy, play therapy, breathing techniques|The Cognitive Behavioral Therapy (CBT) model suggests that the individual's dysfunctional thoughts about self, the world, and/or others are based on irrational or illogical assumptions. An individual's self and his/her view of the world are central to the determination of his/her feelings and behaviors and thus can be changed through changing the individual's thoughts, feelings, and behaviors. CBT techniques are in line with the use of expressive art techniques. The common goal in both CBT and expressive arts is to achieve behavior change in the individual. An intervention program has been prepared by the researcher in line with this literature information.
40970802|NCT00801632|PROCEDURE|Kidney Transplantation|Surgical transplantation of donor kidney
40970803|NCT00801632|PROCEDURE|Bone marrow transplantation|During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
40970804|NCT00801632|BIOLOGICAL|MEDI-507|0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
40970805|NCT00801632|DRUG|cyclophosphamide|60 mg/kg infusion on days -5, -4
40970806|NCT00801632|BIOLOGICAL|rituximab|375 mg/m\^2 infusion on days -7, -2, 5, and 12
40970807|NCT00801632|DRUG|Tacrolimus|0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
40970808|NCT00801632|DRUG|corticosteroids|2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
40970809|NCT00801632|RADIATION|thymic irradiation|700 cGy of thymic irradiation administered in a single dose on day -1
40970810|NCT04112056|DIETARY_SUPPLEMENT|Drink the study formula (NAN Comfort producted by Nestle Deutschland AG)|It is same as that stated in arm description.
40970811|NCT00121745|GENETIC|Rexin-G Dose 1|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
40970812|NCT00121745|GENETIC|Rexin-G Dose 2|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
40970813|NCT00121745|GENETIC|Rexin-G Dose 3|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml"
40970814|NCT00121745|GENETIC|Rexin-G Dose 4|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml"
40970815|NCT03903705|DRUG|Fruquintinib in Combination with Sintilimab|"Fruquintinib plus Sintilimab:~Cohort A: Fruquintinib 3 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2weeks on/1 weeks off + Sintilimab 200mg Q3W, intravenous dosing~Cohort E: Fruquintinib 3 mg QD, continuous, oral dosing, + Sintilimab 200mg Q3W, intravenous dosing~Fruquintinib monotherapy arm:~Fruquintinib 5 mg QD, oral dosing, 3 weeks on/1 weeks off~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
40970816|NCT05505682|BIOLOGICAL|Biological (Male Wolbachia-infected Aedes aegypti)|Releases of male Wolbachia-infected Aedes aegypti mosquitoes
40970817|NCT06508216|DRUG|Dato-DXd|Patients in module 1 \& 2 will receive Datopotamab Deruxtecan (Dato-DXd) 6mg/kg every 21 days
40970818|NCT06508216|DRUG|Durvalumab|Patients in module 2 only will receive Durvalumab 1120mg every 21 days
40970819|NCT02789709|PROCEDURE|Surgery|Segmental resection for colon cancer and anterior resection in patients with rectal cancer
40970820|NCT00317005|DRUG|folate treatment|
40970821|NCT04430543|BEHAVIORAL|Cognitive Bias Modification|"CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%)."
40970822|NCT04430543|BEHAVIORAL|Sham Training|"Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)"
40970823|NCT02637752|BEHAVIORAL|Lifestyle counseling or nutrition/physical counselling|A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
40970824|NCT04983264|DRUG|GBT021601|Tablets and capsules which contain GBT021601 drug substance
40970825|NCT00833885|DEVICE|Masks|Wearing of surgical masks
40970826|NCT00833885|DEVICE|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
40970827|NCT00833885|OTHER|Control|General information about virus transmission in households and basic means to prevent it
40970828|NCT06057662|OTHER|personalized comprehensive diabetes support|personalized comprehensive diabetes support
40970829|NCT02532972|DEVICE|Med-el MAESTRO Cochlear Implant with Flex 28 electrode array|Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
40970830|NCT01765088|DRUG|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
40970831|NCT01765088|DRUG|α-IFN|3mIU (3million) D1，3，5
40970832|NCT04653129|PROCEDURE|Autologous Fat Grafting|"* The fat grafts will be harvested from the abdomen or lateral thighs in a closed sterile system, then prepared according to Coleman guidelines. The blood and oil layers are then separated from the adipose tissue.~* The lipoaspirate will be injected based on a technique described by Vaienti et al, by 17-gaug cannula which will be inserted through the skin around the main incision at the nerve repair site, and the fat graft will be injected after closure of the skin."
40970833|NCT04653129|PROCEDURE|Primary Nerve Repair|Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
40970834|NCT06081257|DIETARY_SUPPLEMENT|"KB-120 small molecular nutrient and vitamin E"|"The experimental group was given oral KB-120 small molecular nutrients, once a day, once a bag (30ml), and vitamin E100mg orally twice a day for a total of 3 menstrual cycles"
40970835|NCT06081257|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles
41458313|NCT04400292|PROCEDURE|Sentinel Lymph Node (SLN) mapping|Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy.
40970836|NCT01772108|DEVICE|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
40970837|NCT00275769|DEVICE|Pacemaker|
40990780|NCT04902456|PROCEDURE|Power chain and Crimpable hook fro En-masse Retraction|"Retraction will start on a 0.017x0.025 stainless steel wire using elastomeric chain ( for applied will be 212 g per side ) extending between the cripmable hooks and the miniscrew"
41458314|NCT01688882|DRUG|QGE031|QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
41458315|NCT01688882|DRUG|Placebo|Placebo will be used to control for normal variability in disease severity.
40970838|NCT04569266|OTHER|Specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
40970839|NCT04569266|OTHER|No specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
40970840|NCT00812578|DRUG|Cholecalciferol|8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
40970841|NCT01348503|DRUG|Lenalidomide|Escalating doses starting at 15 mg by mouth per day.
40970842|NCT01348503|DRUG|Sorafenib|Fixed dose of 400 mg by mouth twice a day.
40970843|NCT02704715|PROCEDURE|general anesthesia,orbital operation|to evaluate the pain under general anesthesia
40970844|NCT00230607|DRUG|agalsidase beta|Pharmaceutical form: powder for reconstitution Route of administration: intravenous
40970845|NCT04980040|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets
40970846|NCT06325020|OTHER|The assessment of patients with possible angina using the ORACLE pathway|"Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms.~Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured.~The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events."
40970847|NCT05013073|OTHER|ASTHMAXcel ED Application|A mobile application designed to assist patients in asthma symptom recognition, treatment best practices, and trigger identification.
40970848|NCT02204397|DRUG|INGAP Peptide, Ustekinumab|
40970849|NCT00267384|DRUG|Oral N-Acetylcysteine|
40970850|NCT02122250|BEHAVIORAL|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
40970851|NCT02122250|BEHAVIORAL|Static web-based materials|Static web-based materials
40970852|NCT04388189|DRUG|Duloxetine|FDA approved antidepressant
40970853|NCT04388189|DRUG|Bupropion|FDA approved antidepressant
40970854|NCT03097094|DIAGNOSTIC_TEST|Male dog|Male dog extract
40970855|NCT03097094|DIAGNOSTIC_TEST|Female dog|Female dog extract
40970856|NCT03497208|PROCEDURE|Microneedling|The technique is about applying a dermaroller equipped with 0.25 mm needles over the vitiligo area.
40970857|NCT03497208|PROCEDURE|Cell suspension|The technique involves preparation of a cell suspension (keratinocyte/melanocyte) prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermarollerequipped with 0.25 mm needles.
40970858|NCT03497208|RADIATION|Phototherapy|The patient will receive phototherapy UVB-NB in the lesions of vitiligo after 15 days of the surgical procedure.
40970859|NCT01970046|DRUG|Placebo/Metformin|"* Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~* Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~* Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks"
40970860|NCT01970046|DRUG|SP2086 50 mg b.i.d/Metformin|"* Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~* Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks"
40970861|NCT01970046|DRUG|SP2086 50 mg q.d./Metformin|"* Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~* Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks"
41458316|NCT02336308|DRUG|Ketamine|
40970862|NCT01300598|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL
40970863|NCT00189982|DRUG|Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care."
40970864|NCT03777878|DRUG|Carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
41458317|NCT02336308|DRUG|Placebo, Normal Saline|
41458318|NCT00333450|BIOLOGICAL|Pneumococcal vaccine|
41458319|NCT03367780|DEVICE|PSMA PET/CT-scan|PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.
41458320|NCT02287636|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
41458321|NCT02287636|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
40768852|NCT05552339|DRUG|Finerenone (Kerendia, BAY94-8862)|Following the physicians' decision.
41297235|NCT01097616|DRUG|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
41297236|NCT01097616|DRUG|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
40970865|NCT03777878|DRUG|oxytocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
40970866|NCT03777878|DRUG|TA|2 ampoules of TA in 100 ml saline by slow infusion
40970867|NCT03777878|DRUG|placebo to carbetocin|placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
40970868|NCT03777878|DRUG|placebo to TA|2 placebo ampoules to TA in 100 ml saline by slow infusion
40970869|NCT03777878|DRUG|placebo to oxytocin|two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
40970870|NCT05812456|OTHER|Estimation of Shear Bond Strength|"Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure."
40970871|NCT01413529|BEHAVIORAL|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
40970872|NCT01413529|BEHAVIORAL|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
40970873|NCT00275184|DRUG|Senna|
40970874|NCT00275184|DRUG|Citramag powder|
40970875|NCT00275184|DRUG|Metoclopramide|
40970876|NCT04284410|BEHAVIORAL|CLASP-PE arm|Participants will complete 8-16 weekly or twice weekly individual therapy sessions (with total session number determined by clinical need, as is typical in clinical trials of PE for PTSD), 1 therapy session (session 3) with a supportive significant other (SO), consistent with the CLASP protocol, and 11 brief (30 minute) phone calls as possible, with calls occurring every week in between therapy sessions and on a less frequent basis following treatment termination up to 3 months after the final in-person therapy session. In addition, the supportive SOs will complete 11 brief (30 minute) phone calls with the therapist at the same frequency as participants. Participants will sign a release of information prior to involving the supportive significant other in treatment.
40970877|NCT03974945|DEVICE|Passive-elastic prosthetic foot|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using their own passive-elastic prosthesis with and without visual feedback of peak propulsive force targets.
40970878|NCT03974945|DEVICE|Powered ankle-foot prosthesis|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using a battery-powered ankle-foot prosthesis with and without visual feedback of peak propulsive force targets.
40970879|NCT01918085|OTHER|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
40970880|NCT01918085|OTHER|Strata strip|An adhesive strip made of the Strata adhesive
40970881|NCT03055793|OTHER|budesonide formoterol fixed combination|Asthmatic patients who will be on budesonide formoterol fixed combination treatment administered by Elpenhaler device.
40970882|NCT01261689|DRUG|Ropivacaine/ Sufentanil according to local hospital protocol|according to local hospital protocol
40970883|NCT01261689|OTHER|Care-as usual pain treatment|Pain treatment only on request of the women in labour. Treatment is given according to local hospital protocol.
41458322|NCT02287636|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
40970884|NCT04740788|DEVICE|Monofocal IOL|Patients are already implanted with a monofocal lens
41458323|NCT02287636|PROCEDURE|positron emission tomography|Undergo PET/MRI
40970885|NCT01402414|RADIATION|NB-UVB|The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
40970886|NCT01402414|RADIATION|Bath-PUVA|Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.
40990781|NCT04902456|PROCEDURE|T-loop|closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine.
40768853|NCT05552339|DRUG|Type 2 DM drugs|Following the physicians' decision
40970887|NCT01402414|RADIATION|NB-UVB plus salt water baths|First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
40970888|NCT03752294|DRUG|Dabigatran|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.
40970889|NCT03752294|DRUG|Placebo - Cap|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
40970890|NCT02786797|BEHAVIORAL|MBSR(BC) 6 Week Program|The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.
40970891|NCT02786797|BEHAVIORAL|BCES 6 Week Program|"The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention."
40970892|NCT05627960|DRUG|AG-01 Compound|"Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D."
40970893|NCT03275012|DRUG|Gabapentin + Morphine|"Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and \>15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period."
40970894|NCT03275012|DRUG|Placebo + Morphine|Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
40970895|NCT04659304|DRUG|Allocetra-OTS|Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
40970896|NCT06408051|PROCEDURE|Injection of onabotulinumtoxinA into the bladder wall|BTX was injected into the detrusor muscles at 20 sites
40970897|NCT00977899|BIOLOGICAL|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine|
40990782|NCT01983527|PROCEDURE|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
40990783|NCT01983527|DRUG|Intra-articular corticosteroid Depo Medrol|Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
41138773|NCT04720209|OTHER|Home-Based Stretching|This group will perform a home-based program of the same stretches utilized in the CARE and TARE groups.
41138774|NCT01762839|DRUG|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
41138775|NCT01762839|DRUG|Placebo|Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
41138776|NCT01762839|DRUG|Moxifloxacin|Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.
41138777|NCT04582994|BEHAVIORAL|Beta tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)
41138778|NCT04582994|BEHAVIORAL|Alfa tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)
41138779|NCT04582994|BEHAVIORAL|Sham|participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered
41458324|NCT02287636|PROCEDURE|magnetic resonance imaging|Undergo PET/MRI
40768854|NCT05963984|DRUG|Samuraciclib|Samuraciclib tablet by mouth once a day
40970898|NCT00935597|BIOLOGICAL|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
40970899|NCT05495906|BIOLOGICAL|Nonavalent HPV vaccine|Routine dosing form and dosage
40970900|NCT04250883|OTHER|Low intra-abdominal pressure|8 mmHg
40970901|NCT04250883|OTHER|Deep neuromuscular blockade (NMB)|Deep NMB (PTC1-2)
40970902|NCT04250883|OTHER|Standard intra-abdominal pressure|14 mmHg
40970903|NCT04250883|OTHER|Moderate neuromuscular blockade (NMB)|Moderate NMB (TOF 1-2)
40970904|NCT01464099|DRUG|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
40970905|NCT01464099|DRUG|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
40970906|NCT00543556|DRUG|MK0767|
40970907|NCT00404677|OTHER|deep inhalation|deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
40970908|NCT04555291|DRUG|Ropivacaine injection|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
40970909|NCT04555291|OTHER|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
40970910|NCT04579705|OTHER|Using a brush|Surgical hand scrubbing will be performed in 1 minute and 2 minutes using a disposable nail brush.
40970911|NCT00440219|DRUG|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
40970912|NCT00440219|DRUG|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
40970913|NCT06146452|OTHER|Not|Not
40970914|NCT00471068|DRUG|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
40970915|NCT00471068|DRUG|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
40970916|NCT00471068|DRUG|Placebo (Timolol Vehicle)|Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
40970917|NCT05205005|DRUG|Endocalyx|3,712mg (six capsules) of DSGP for eight weeks.
40970918|NCT05205005|DRUG|Placebo|Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg
41458325|NCT04318249|BEHAVIORAL|Assisted Relaxation Therapy|This intervention includes using a smartphone application that helps with breathing techniques and sleep.
40970919|NCT04359550|BIOLOGICAL|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
40970920|NCT04359550|OTHER|placebo|placebo
40970921|NCT02790528|DRUG|Atorvastatin|20mg QD
40970922|NCT02790528|DRUG|Placebo|Placebo drug will be administered.
40970923|NCT00427843|BEHAVIORAL|home exercise program for the hip abductor muscles|"All patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. Patients will be instructed in the following program: contraction of the gluteus medius muscle during functional activities (gait, stepping sideways up on a step and standing on one leg); and side lying isotonic hip abduction exercises using graded resistance elastic bands positioned around the distal thighs.~The program will be performed 3 times per week for 8 weeks and subjects will record exercise frequency and level of resistance on exercise calendars. Follow-up visits will occur at the end of week 1 and week 4 for review and progression of exercises. A telephone follow-up call will occur for support and participants will be encouraged to call with any questions or concerns."
40970924|NCT02860013|DEVICE|Telemedicine|
40970925|NCT06150313|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T)|"This is a 36-hour group training involving 4 theoretical + 11 practice online sessions using video-feedback, the core component of MISC original trainings.~Session 1: MISC presentation; Session 2: Bases of the interaction and MISC culture-context components; Session 3: The emotions in the interaction and MISC emotional components; Session 4: MISC cognitive components and implications for learning; Session 5: Practice with you-tube examples of interaction; Session 6: Practice with trainer's examples of video-feedback. Sessions 7 to 14: Practice with participants' video-recordings. Session 15: End of the intervention, last video-feedback training and preparing for post-assessment."
40970926|NCT06150313|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 36-hour individual training involving 25-weekly online, individual, self-administered 50' sessions (21h) + 4 online 1.5-hour group meetings with a supervisor (6h) and 9h of between sessions work (readings, video-recordings for later video-feedback, reflection exercises). Session 1 (Supervisor): Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC: Session 9 (Supervisor): Summary, online group exercises and keys for forward recordings; Sessions 10-11 (Christmas Homework): Recording daily life interactions; Sessions 12-17 (SA): guided reflection with video-feedback; Session 18 (Supervisor): Control session for doubts and video-feedback group training. Sessions 19-28 (SA): guided reflection with video-feedback. Session 29 (Supervisor): Final online video-feedback group training.
40990784|NCT03826862|RADIATION|CT three-dimensional reconstruction|All patients will receive CT three dimensional reconstruction before surgery
40990785|NCT01620710|RADIATION|hypofractionated helical IMRT|hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
41458326|NCT04318249|BEHAVIORAL|Modified Assisted Relaxation Therapy|This intervention includes using a smartphone application that is modified to help with breathing techniques and additional sleep instructions.
41458327|NCT00388063|DRUG|Atiprimod|oral, 14 days on / 14 days off; 30mg capsules
41458328|NCT05402046|OTHER|"Mobile phone application ProRodinki"|"Patient were underwent photography using mobile phone and tested application ProRodinkijust before preplanned excisional or incisional biopsy.~Application AI result than will be compared with pathology report by independent investigator"
41297237|NCT03742960|BEHAVIORAL|Behavioral Sleep Restriction|Participants will be instructed to go to bed 30 minutes later than their usual bedtime. On the other hand, wake up time will be unchanged resulting a nightly sleep restriction of 30 minutes. This protocol will be followed for two weeks.
41458329|NCT04258709|BEHAVIORAL|AME|Participants receive education on AME and feedback on technique with a remotely-based IBCLC via live streaming video.
40970927|NCT06150313|OTHER|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|This is an equivalent 36-hour online self-administered training involving 27 x 45' individual online sessions (20.25h), mostly based on reflection exercises around brief readings, animated shorts, or pills, but not video-feedback. This is complemented with 2 x 1.5h online group face-to-face sessions with a supervisor (3h) and 13h of between-sessions work based on looking for new information, adult-child activities (but not for video-feedback) or out-of-line guided reflective exercises. Session 1 (Supervisor): group meeting for program presentation; Sessions 2-28 (Self-Administered): Online self-administered sessions doing readings or watching pills; Session 29 (Supervisor): Final doubts session to close de course.
40970928|NCT06372002|BEHAVIORAL|Cognitive Stimulation Therapy (CST)|"The intervention will consist of the Spanish adapted version of Cognitive Stimulation Therapy (CST) followed by the Maintenance CST program.~CST is a cognitive intervention for treating mild to moderate dementia consisting of fourteen 45-minute group sessions that take place twice a week for 7 weeks. Each session follows a main topic (reminiscing about the person's life, current events, word games...) and is led by two group facilitators. The same structure is followed in every CST session: 1. Introduction (5 minutes). 2. Main Activity (25 minutes). 3. Closing (5 minutes).~The Maintenance CST program follows the principles and structure of the original CST program and consists of 24 sessions, one per week, that will be administered after the original program.~The topic, activities, and materials required for each session are specified in the CST-ES manuals, which also provide the key principles that should guide the intervention and other information necessary for its implementation."
40970929|NCT03779724|OTHER|exercises|
40970930|NCT02164812|DRUG|Moxifloxacin|
40970931|NCT02164812|DRUG|Placebo|
40970932|NCT02164812|DRUG|Efavirenz|
40970933|NCT05489198|PROCEDURE|cataract surgery with Centurion phacoemulsification system|Cataract surgery performed with the Centurion phacoemulsification system
40970934|NCT05489198|PROCEDURE|cataract surgery with Quatera 700 phacoemulsification system|Cataract surgery performed with the Quatera 700 phacoemulsification system
40970935|NCT06201559|DRUG|Albendazole IP 400 mg|Albendazole IP 400 mg tablets will be administered under fed conditions
40970936|NCT06201559|DRUG|Albendazole 400 mg|Albendazole 400 mg tablets will be administered under fed conditions
40970937|NCT00027898|DRUG|bortezomib|Given IV
40970938|NCT00027898|DRUG|carboplatin|Given IV
40970939|NCT00027898|DRUG|etoposide|Given IV
40970940|NCT00027898|OTHER|laboratory biomarker analysis|Correlative studies
40970941|NCT00027898|OTHER|pharmacological study|Correlative studies
40970942|NCT01563302|DRUG|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
40970943|NCT04121377|OTHER|Resistance training|"Weekly sessions introducing resistance exercises and monitoring the patients acceptability. The exercises are isometric contractions, seated heel-rise and elastic band. The patient register the amount of exercise in a home exercise journal. To protect the tendon while doing range of motion of the foot, dorsiflexion is restricted beyond neutral (0 degrees of dorsiflexion). The load on the strength exercises will progress from isometric contraction without external load to strengthening exercises with 10-20 RM (RM: Repetition Maximum). Each strength exercise can progress with added weight or stronger elastic band. The Borg scale is used to guide the patient to progress or regress the load in each exercise. The recommended level being easy to hard (2-5/10). It is emphasised that the exercises must not cause sudden or severe pain in the tendon, but muscle soreness is to be expected."
40970944|NCT02146898|OTHER|Position|
40970945|NCT05360381|DRUG|HLX35|A Recombinant Human Anti-EGFR and Anti-4-1BB Bispecific Antibody, HLX35 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
41458330|NCT04258709|BEHAVIORAL|Video-based infant care education|Participants view a standard set of web-based streamed videos addressing evidence-based infant care, unrelated to feeding/breastfeeding.
41458331|NCT05589636|DIETARY_SUPPLEMENT|Bergamot Juice|Bergamot Juice (35% in water)
41458332|NCT00147693|BEHAVIORAL|Diagnosis of caregivers' problems|
41458333|NCT00147693|BEHAVIORAL|Professional service: treatment of problems by counseling or practical support|
41458334|NCT05330780|OTHER|Breathing Room|8 total group classes performed twice a week over the course of 4 weeks, with IMTs utilized during the classes as well as 3 days outside of the class days at 5 sets of 5 breaths completed 5 times a day
41458335|NCT04302935|OTHER|Global pain-assessment|Global pain-assessment, based on the ICF framework
41458336|NCT01098539|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
41458337|NCT01098539|DRUG|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
41458338|NCT06024148|OTHER|phone survey|patients complete a 10-minute telephone questionnaire on their osteoporosis management
41458339|NCT03347019|OTHER|Accelerated rehabilitation|advances in arthroscopic surgery have resulted in biomechanically stronger repairs that might allow for accelerated rehabilitation protocols and hence faster return to daily living activities and scapular control
41458340|NCT03347019|OTHER|Delayed rehabilitation|Patients were not allowed to start rehabilitation programme first three weeks after surgery.
41458341|NCT00307541|BIOLOGICAL|Pneumococcal (vaccine)|
40970946|NCT00795314|DRUG|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
40970947|NCT00795314|DRUG|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
40970948|NCT05773508|DEVICE|Video regulation and emergency kit|Video regulation and emergency kit
40970949|NCT02695498|OTHER|Mindfulness Based Stress Reduction|"MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class \[9 total classes.\] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief."
40970950|NCT02695498|OTHER|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
40970951|NCT00765050|BIOLOGICAL|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
40970952|NCT03274505|OTHER|Questionnaires|"* Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~* Clinical evaluation~* Routine neuropsychological evaluation (for stroke patients)~* Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) \> 10)"
40970953|NCT01246700|OTHER|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks."
40970954|NCT01246700|OTHER|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks."
40768855|NCT05963984|DRUG|Fulvestrant|Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15
40970955|NCT06446700|OTHER|neck disability index and visual functional questionnaire|participants complete the 2 questionnaire by an online form and paper
40970956|NCT03910023|OTHER|Usual care comporting a home-exercise program (UCHE)|"The UCHE intervention will correspond to current practice (including the continuation of previous treatments, if applicable) as decided by the attending physician. The patient will also be provided with a practical guide on how to manage back pain (the back book), including a recommended home exercise program."
40970957|NCT03910023|OTHER|Spa therapy|the spa-therapy intervention consists of 18 consecutive days of spa-therapy (excepting Sundays), that must occur with 60 days of randomisation. The latter will combine mineral water with physical and hydrotherapeutic treatments, including massages, heat and water exercises.
40970958|NCT00254904|DRUG|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
40970959|NCT00254904|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
40970960|NCT00254904|DRUG|PF-3512676|PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
40970961|NCT00254904|DRUG|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
40970962|NCT00254904|DRUG|Gemcitabine + Cisplatin|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
40970963|NCT00869154|BEHAVIORAL|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
40970964|NCT00869154|BEHAVIORAL|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
40970965|NCT01164982|DEVICE|Mepitel One|Each subject will be followed once a week for 3 weeks or until healing if that occurs earlier
40970966|NCT04698460|PROCEDURE|Hybrid coronary revascularization|A staged procedure with a minimally invasive direct coronary artery bypass grafting of left anterior descending artery by left internal mammary artery (LIMA-LAD MIDCAB) at first stage, and percutaneous stenting of iFR-significant lesions in non-LAD arteries at the second stage
40970967|NCT04698460|PROCEDURE|Coronary artery bypass grafting|A conventional procedure of median thoracotomy with on-pump bypass grafting of left anterior descending artery by left internal mammary artery and saphenous vein grafting of circumflex and/or right coronary artery
40970968|NCT01828281|DEVICE|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
40970969|NCT02289040|PROCEDURE|cardiac surgery|cardiac surgery with extracorporeal circulation for congenital heart disease
40970970|NCT02562053|DRUG|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
40970971|NCT02562053|DRUG|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
40970972|NCT02562053|DRUG|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
40970973|NCT02562053|DRUG|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
40970974|NCT00922181|DEVICE|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
40970975|NCT00922181|DEVICE|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
40970976|NCT04186520|BIOLOGICAL|8/12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
40970977|NCT04186520|BIOLOGICAL|8/12-Day Production of Cryopreserved Car-T Cells|A fixed cryopreserved dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
41138780|NCT01577875|DEVICE|NBI with magnification|After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
41138781|NCT00027014|DRUG|St. John's Wort|
40970978|NCT04186520|BIOLOGICAL|12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
41138782|NCT00027014|DRUG|oxycodone|
40970979|NCT00301665|BIOLOGICAL|Botulinum toxin type A|
40970980|NCT03547869|DEVICE|Active tDCS|Active tDCS will be adminestered
40970981|NCT03547869|DEVICE|Sham tDCS|Sham tDCS will be administered
40970982|NCT02635945|DRUG|PBF-680|
40970983|NCT02635945|DRUG|Placebo|
40970984|NCT04066673|DIAGNOSTIC_TEST|Stanford-Binet Intelligence Scale, 5th Edition|The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores
40970985|NCT03254836|OTHER|Standard of care|Elective radical surgery for adenocarcinoma.
40970986|NCT05033860|OTHER|Read leaflets containing knowledge of COVID-19 and vaccination.|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and participants are asked to read the leaflets.
40970987|NCT05531084|DEVICE|Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)|Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components.
40970988|NCT05473702|DEVICE|Nanowear SimpleSense Wearable monitoring device|The Nanowear SimpleSense is a non-invasive, wearable and portable medical device for evaluation and monitoring of cardiopulmonary condition. It utilizes physiologic and biometric sensors, SAU, and software system with a suite of algorithms to monitor patient. The parameters include: two vectors of ECG, two vectors of impedance cardiography, thoracic impedance, respiration, heart sounds, and actigraphy and postures. The device is comprised of a wearable device made of an elastomeric harness comprising of active and passive Nanosensors, heart sound sensor, connector to electrically connect the sensors to SAU, it comprises of Inertial Measurement Unit, analog front end, processing unit, storage unit, power supply, and a wireless module, and a software system equipped with the suite of algorithms to monitor heart. The signals are recorded by SAU, transferred to the iPhone over Bluetooth, which later transfers the data to a secure website over an internet connection Wi-fi or mobile network.
40970989|NCT01837615|DEVICE|Photopill treatment|
40970990|NCT03598985|DIAGNOSTIC_TEST|"Smartphone MyAnkle balance application"|"Balance will be assessed simultaneously using MyAnkle application and the Biodex balance system. The smartphone will be fixed to the middle of the shin with an armband. Participants will assume a single leg stance on each side under two conditions: eyes opened and closed. Testing will be done at three levels of difficulty; least difficult (level 8), moderate (level 6) and severe difficult (level 4). A conditioning trial for each level will be given for 30 seconds. Further, a 2-minute rest between tests will be given. During the testing, participants should not touch the ground or stance limb by other limb nor to grasp the handrail. Participants will repeat the same testing in two separate sessions, with one-week interval in between."
40970991|NCT05217147|OTHER|Obtaining blood samples|Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.
40970992|NCT03940612|DIETARY_SUPPLEMENT|STP4 (product with probiotics)|STP4 contains Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, Lactobacillus delbrueckii subsp. lactis, LDL114. Administration at 10 log CFU/day for 8-weeks.
41458342|NCT03736460|BEHAVIORAL|Mindfulness|The mindfulness-based intervention adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of four 3h group sessions spread over 8 weeks. Each session consists of guided experiential mindfulness exercises (e.g. focus on the breath, body scan, breathing space, mindful movement, sitting meditation), sharing of experiences of these exercises, reflection in small groups, psycho-education (e.g. stress, depression, fear of cancer recurrence, self-care) and review of home practices.
41458343|NCT03736460|BEHAVIORAL|Physical training|This intervention is based on the recommended levels of physical activity for adults aged 18 - 64 year from the World Health Organization. These recommendations are the same for women after a breast cancer treatment (Schmitz et al., 2010). Just as the mindfulness intervention this will consist of four 2h group sessions spread over 8 weeks. Each session will consist of psycho-education (e.g. basics of movement, advantages of physical activity, training-principles), endurance and resistance training, stretching, balance and relaxation exercises, sharing of experiences of these exercises and review of home practices.
41458344|NCT04554186|PROCEDURE|Serratus anterior plane block|Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound
40970993|NCT03940612|DIETARY_SUPPLEMENT|Placebo (product without probiotics)|Capsules are similar to STP4 except the presence of probiotics. Administration daily for 8-weeks.
41458345|NCT04554186|PROCEDURE|Thoracic Paravertebral block|Injection of bupivacaine in the thoracic Paravertebral space using ultrasound
40970994|NCT04616378|OTHER|Phase 2 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
40970995|NCT04616378|OTHER|Phase 2 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
40970996|NCT04616378|OTHER|Phase 3 No Prosthesis|No prosthetic device is attached.
40970997|NCT04616378|OTHER|Phase 3 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
40970998|NCT04616378|OTHER|Phase 3 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
41297238|NCT06092372|BEHAVIORAL|Diet intervention program|"Participants will get 5 meals/day based on their calorie needs minus 500 kcal/day less than their daily calorie expenditure. All meals will be tracked via a mobile application, including any meals outside the recommended food plan. The calories will be calculated based on the information provided.~To calculate the calories burned from any activities, all participants in the diet intervention arm will get an activity tracking device. The first calorie level is calculated based on the information in the registration form: age, height, weight, gender, and personal view of the daily activity. After that, and once the activity tracker is synced to the program, the calorie level is calculated based on the 7-day average calories burned.~The external diet intervention provider will be blinded to whether the study participants belong to the top or bottom 5% of the polygenic score for BMI."
41297239|NCT01194557|DEVICE|Rapid diagnostic test|Diagnosis of malaria using rapid diagnostic test
41297240|NCT01194557|DRUG|Lumartem|Presumptive treatment of malaria/fever
41297241|NCT02305251|OTHER|Survey|Standard Gamble Survey
41297242|NCT05762744|DRUG|Exenatide Injection|Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.
41297243|NCT05762744|DRUG|Saline injection|Nurses administered saline (0.2 mL) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.
41297244|NCT05394272|OTHER|Energy Therapy - Pranic Healing|Energy therapy - Non invasive non touch and non pharmacological - 100% natural complementary therapy
41297245|NCT06106022|DRUG|Vonoprazan|Administered orally
41297246|NCT01479790|DEVICE|EyeGiene|The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
41297247|NCT03769740|DEVICE|Cerebral Oximetry|Non invasive, near infrared spectroscopy cerebral oximetry
41297248|NCT03662152|DEVICE|Foam roller|Foam roller massage after DOMS
41297249|NCT03662152|DEVICE|Vibration foam roller|Foam roller massage with vibration after DOMS
41297250|NCT00058578|DRUG|Cyclophosphamide|
41297251|NCT00058578|DRUG|Mesna|
41297252|NCT00058578|DRUG|G-CSF|
41297253|NCT00058578|PROCEDURE|Leukopheresis|
41297254|NCT00058578|PROCEDURE|Total Body Irradiation|
40970999|NCT03527277|OTHER|Naturally-sweetened orange juice|Commercially-available ready-to-serve refrigerated orange juice
41138783|NCT00027014|DRUG|fentanyl|
41138784|NCT02129751|DRUG|bupropion hydrobromide|study drug
41138785|NCT02129751|DRUG|Placebo|placebo arm
41138786|NCT02382172|BEHAVIORAL|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
41297255|NCT02573441|BEHAVIORAL|Jump Math|Jump Math is a workbook based program aimed at improving math skills
41297256|NCT02573441|BEHAVIORAL|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
41297257|NCT02573441|BEHAVIORAL|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
41297258|NCT01000064|DRUG|Vyvanse|30 mg - 70 mg capsules taken every morning for 6 weeks.
40971000|NCT03527277|OTHER|Sugar-sweetened beverage|Sugar-sweetened water flavored with Kool-Aid (TM)
41297259|NCT01000064|PROCEDURE|fMRI|Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
41297260|NCT01000064|DRUG|Placebo|Placebo capsules taken every morning for 6 weeks.
41297261|NCT02416908|DRUG|Selinexor|
41297262|NCT02416908|DRUG|Cladribine|
41297263|NCT02416908|DRUG|G-CSF|
41297264|NCT02416908|DRUG|Cytarabine|
41297265|NCT02416908|PROCEDURE|Bone marrow biopsy|
41297266|NCT04831216|BEHAVIORAL|Type 2 Diabetes Appropriate Food Boxes + Diabetes Education|All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
41297267|NCT01613469|DRUG|5FU/Leucovorin|450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
41297268|NCT04788199|OTHER|Closure of mesenteric defects using glue|Cyano-acrylate glue is a glue known to be used in surgery as tissue adhesive.
41297269|NCT05332067|DRUG|Omalizumab|"Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe"
41297270|NCT05332067|DRUG|Placebo|Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
41297271|NCT00206115|DRUG|Seroquel Sustained Release (SR)|
41297272|NCT00206115|DRUG|Seroquel Immediate Release (IR)|
41297273|NCT00206115|DRUG|Placebo|
41297274|NCT01818791|BEHAVIORAL|Making Proud Choices|Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
41458346|NCT04554186|PROCEDURE|Control|Place a fentanyl patch 50 microgram
41458347|NCT04684511|DRUG|TRM-201 (Rofecoxib)|Eligible patients will be randomized to receive TRM-201 or placebo
40990786|NCT01620710|RADIATION|hypofractionated helical IMRT|helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
41138787|NCT02382172|OTHER|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
41138788|NCT03481985|OTHER|Fenestration status|The exposure variable will be status of the Fontan fenestration
41138789|NCT02102802|DRUG|Midomafetamine|125 mg MDMA
41138790|NCT00304642|DRUG|dapivirine (TMC120) vaginal gel|
41138791|NCT02064335|BEHAVIORAL|Physical activity coaching|Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
41138792|NCT06499116|DRUG|Topiramate|Treatment will be prescribed for GPs and they will decide the specific dosage 25-100 mg/12h.
41138793|NCT06499116|DRUG|Flunarizine|Treatment will be prescribed for GPs and they will decide the specific dosage 2,5-10 mg mg/24h.
41138794|NCT06499116|DRUG|Amitriptyline|Treatment will be prescribed for GPs and they will decide the specific dosage 10-75 mg/24h.
41138795|NCT06499116|DRUG|Propranolol|Treatment will be prescribed for GPs and they will decide the specific dosage 20-120 mg/12h.
41138796|NCT04693637|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion
41138797|NCT03033667|DIETARY_SUPPLEMENT|G group|patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L
41138798|NCT03033667|DIETARY_SUPPLEMENT|group L|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour
41138799|NCT03033667|DIETARY_SUPPLEMENT|Group C|Over night fasting with no supplementation
41138800|NCT03434106|DRUG|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
41138801|NCT03434106|DRUG|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
41138802|NCT05469607|DEVICE|Vagus Nerve Stimulator|The device consists of implantable (inside the body) and external (outside the body) components. Implantable components consist of a stimulating/recording electrode assembly that is placed around the vagus nerve in the abdomen, between the diaphragm and the stomach, a cable connecting the electrode assembly to an implantable pulse generator (IPG) that generates the stimulus and records nerve responses. The external components include a Clinical Control/Review Tool (used by the study team after implantation to adjust and periodically review the stimulation settings) and a Patient Control Unit and Charger (to turn on/off the system and perform limited adjustment of the stimulation strategy).
41138803|NCT00230906|PROCEDURE|Haemodialysis with either low or high flux membranes|
41138804|NCT01747538|DRUG|Placebo|Solution for subcutaneous injection
41138805|NCT01747538|DRUG|Dose 1 gevokizumab|Solution for subcutaneous injection
41138806|NCT01747538|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
41138807|NCT06113393|PROCEDURE|GRV thresholds|Hold enteral feeding when GRV reaches 200 mL(current standard)
41138808|NCT03438565|DEVICE|Asahi Chikai Black 18 neurovascular guidewire|"The Asahi Chikai Black 18 microguidewire employs a reverse tapered shaft with 0.018 tip and 0.014 proximal shaft, which provides additional support and tactile feedback."
41138809|NCT00244452|DRUG|Cetrorelix|
41138810|NCT00446095|DRUG|fostamatinib|200 mg PO BID
41138811|NCT02007070|BIOLOGICAL|Pembrolizumab|Intravenous infusion
41138812|NCT02738398|RADIATION|FDG PET/CT|
41138813|NCT00390845|DRUG|SB681323|15 milligrams (mg)/day
41138814|NCT00390845|DRUG|Placebo|
41138815|NCT05158426|DRUG|Propofol|anesthesia induction is initiated with intravenous infusion propofol at 1.5µg/ml, and increased 0.5µg/ml every 3min until OAA/S score 0.
41138816|NCT06100354|OTHER|Answering preference|Patients will answer a questionnaire with two possible choices describing several scenario of used of customized and connected prosthesis
41138817|NCT00868894|DRUG|DE-104 medium concentration|Topical ocular application
41138818|NCT00868894|DRUG|DE-104 high concentration|Topical ocular application
41138819|NCT00868894|DRUG|Placebo|Topical ocular application
41138820|NCT00868894|DRUG|0.005% latanoprost|Topical ocular application
41138821|NCT04680598|DRUG|ICI|Patients received ICI, including PD-1 inhibitor (pembrolizumab, toripalimab, nivolumab, sintilimab, camrelizumab) or PD-L1 inhibitor (atezolizumab)
41138822|NCT04680598|DRUG|Antiviral Prophylaxis|Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir
41138823|NCT04181385|DRUG|Olanzapine 10 milligram|Oral olanzapine capsule
41138824|NCT04181385|DRUG|Bromocriptine 5 milligram|Oral bromocriptine capsule
41138825|NCT04181385|DRUG|Placebo oral tablet|oral placebo capsules
41138826|NCT04446949|OTHER|Register follow-up|Number of adverse pregnancy outcomes
41138827|NCT00048932|DRUG|Double-blind Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Day 1, 15, and 29.
41138828|NCT00048932|DRUG|Double-blind Placebo|Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
41138829|NCT00048932|DRUG|Open-label Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Every 28 days.
41458348|NCT04684511|DRUG|Placebo|Matching Placebo
41458349|NCT00935623|BIOLOGICAL|Malaria Challenge|Malaria challenge
41458350|NCT01086969|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
41458351|NCT01947738|DRUG|VBY-891|Cathepsin S inhibitor
41458352|NCT01947738|DRUG|Placebo|
41458353|NCT05727579|OTHER|Salt-Diet and/or Ertugliflozin|The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo
40971001|NCT04540601|OTHER|Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)|"We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure.~We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday."
40971002|NCT04249674|DIAGNOSTIC_TEST|Dextrometorphan|Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)
40971003|NCT04249674|GENETIC|Genotyping by single nulcetoide polymorphism.|Single nucleotide polymorphism determination
40971004|NCT00327678|DRUG|Rituximab|
40971005|NCT00327678|DRUG|Imatinib Mesylate|
40971006|NCT00563979|DIETARY_SUPPLEMENT|VitaluxPlus®|1 tablet daily
40971007|NCT00563979|DIETARY_SUPPLEMENT|Omega 3|1 tablet daily
40971008|NCT00791245|BIOLOGICAL|Particulated Juvenile Cartilage Allograft|Particulated Juvenile Cartilage Allograft
40971009|NCT00127660|BEHAVIORAL|Menu: calories=yes, value pricing=no|
40971010|NCT00127660|BEHAVIORAL|Menu: calories=yes, value pricing = yes|
40971011|NCT00127660|BEHAVIORAL|Menu: calories=no, value pricing = no|
40971012|NCT05316142|PROCEDURE|AGV implantation|This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world
40971013|NCT04350489|OTHER|Non-surgical periodontal treatment|Conventional non-surgical periodontal treatment were performed
40971014|NCT02402127|DEVICE|Narafilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
40971015|NCT02402127|DEVICE|Stenfilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
40971016|NCT02402127|DEVICE|Somofilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
40971017|NCT03006497|OTHER|Exercise program based on motor learning principles|The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
40971018|NCT01073891|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single oral dose of moxifloxacin (Avelox, BAY12-8039) IR (immediate release) tablet 400 mg under fasting conditions
40971019|NCT01073891|DRUG|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fasting conditions
40971020|NCT01073891|DRUG|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fed conditions
40971021|NCT05641753|DRUG|Evolocumab Cartridge|Injectable PCSK9 inhibitor.
40971022|NCT05641753|DRUG|Atorvastatin Calcium Tablets|HMG-CoA reductase inhibitor for oral use.
40971023|NCT05641753|DRUG|Ezetimibe Tablets|Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.
40971024|NCT05641753|DRUG|18F-FDG|Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.
40971025|NCT05641753|DEVICE|Angiocatheter 20IV|Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.
40971026|NCT05641753|DEVICE|J-Wire|Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.
40971027|NCT05641753|DEVICE|GlycoCheck Glycocalyx Measurement Software|Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.
40971028|NCT02380677|DRUG|CRLX301|
40971029|NCT05858762|DIAGNOSTIC_TEST|Breast digital tomosynthesis|Introduction of an almost three-dimensional imaging technique called breast digital tomosynthesis
40971030|NCT05601817|BEHAVIORAL|Vita|Vita is developed by this study team based on Attention Restoration Theory. The Vita intervention involves viewing 360 degree nature pictures on a virtual reality headset.
40971031|NCT05601817|BEHAVIORAL|Com|Com intervention uses BrainHQ from PositScience that was developed based on the brain neuroplasticity. The com intervention involves doing game-like training on a iPad.
40971032|NCT05601817|BEHAVIORAL|Vita+Com|Vita+Com intervention is a combination of both Vita and Com interventions. Participants will be asked to complete Vita first and then Com intervention.
40971033|NCT05079139|PROCEDURE|surgical technique of Musset|"The one-stage rectovaginal fistula cure according to Musset is an intervention indicated in the treatment of simple post-obstetrical or simple post-surgical rectovaginal fistulas.~The procedure consists in performing a perineal section to the perineal section to the fistula pathway in order to perform local excision followed by a repair plane by plane with rectal and anal closure, then of the external sphincter of the anus, and interposition of the deep and superficial transverse elevator and perineal muscles before closing the vagina and perineum."
40971034|NCT01490229|DRUG|Ezetimibe|os, 10 mg, once daily, 1 year
40971035|NCT01490229|DRUG|Nutraceuticals|os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
40971036|NCT03281486|DEVICE|HA formulation Oral Spray|It is an HA formulation of FDA listed ingredients
40971037|NCT03281486|DEVICE|Placebo|Placebo formulation without the active ingredients
40971038|NCT00929318|PROCEDURE|blood sampling|
40971039|NCT00929318|PROCEDURE|blood sampling|
40971040|NCT02003820|BEHAVIORAL|video modeled social story|Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
41297275|NCT01818791|BEHAVIORAL|Making Proud Choices AND Getting To Outcomes|"In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality-i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors."
40971041|NCT03293290|DRUG|PrEP|Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
40971042|NCT05426902|BEHAVIORAL|SLE@Duke|SLE@Duke is a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 \& 2 SLE.
40971043|NCT03872167|DEVICE|BIPAP, Intelligent automatic mode defined by assured volume with pressure support|Correction of night ventilation through an automatic mode of ventilation with assured volume with pressure support
40971044|NCT03872167|DEVICE|BIPAP, manual tritration.|Correction of night ventilation through a manual titration of non-invasive mechanical ventilation using polysomnography.
40971045|NCT02715674|DEVICE|Plasti-med TRIFLO|
40971046|NCT02715674|DEVICE|BIPAP VISION|
40971047|NCT02715674|DEVICE|Plasti-med oxygen therapy mask|
40971048|NCT04188327|PROCEDURE|Stellate ganglion block|"While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
40971049|NCT04188327|PROCEDURE|Sham Stellate ganglion block|"The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day for 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
40971050|NCT01635946|DRUG|Isavuconazole|oral
40971051|NCT01635946|DRUG|atorvastatin|oral
41297276|NCT03421288|DRUG|Atezolizumab|Day 1 q2w: 840 mg IV over 1 hour (4 cycles perioperative with FLOT) + Day 1 q3w: 1200 mg IV over 1 hour (8 additional cycles monotherapy)
41297277|NCT03421288|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
41297278|NCT03421288|DRUG|Calciumfolinat|Day 1 q2w: 200 mg/m² IV over 1 hour
41297279|NCT03421288|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
41297280|NCT03421288|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
40971052|NCT03627624|OTHER|Pulmonary rehabilitation|Stable COPD inpatients undergoing 30-STST and 6-minute walk test (6MWT) before and after PR were included. Responsiveness to PR was determined by pre-to-post PR (Δ) evaluation of 30-STST.
40971053|NCT03662490|DEVICE|High resolution oesophageal manometry|High resolution oesophageal manometry (HRM) is the gold standard for the diagnosis of oesophageal motility disorder.
40971054|NCT05935852|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses
40971055|NCT05577390|OTHER|Intraneural Facilitation Therapy Treatment|Intraneural Facilitation Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
40971056|NCT05577390|OTHER|Standard Physical Therapy Treatment|The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.
40971057|NCT03036046|DRUG|F901318 with fluconazole low dose|adverse events
40971058|NCT03036046|DRUG|F901318 with fluconazole high dose|adverse events
40971059|NCT03036046|DRUG|F901318 with posaconazole|adverse events
40971060|NCT03716089|PROCEDURE|Laparoscopic resection|Laparoscopic surgery under general anesthesia
40971061|NCT03320954|BEHAVIORAL|Anomia treatment|Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
40971062|NCT02906618|DRUG|LY3039478|Administered orally
40971063|NCT02906618|DRUG|3C 15N 2H-LY3039478 IV|Administered IV
40990787|NCT02469428|OTHER|Clean air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
41458354|NCT04791345|DRUG|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally in a single dose.
41458355|NCT04791345|DRUG|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally every 24 hours during 3 days.
41458356|NCT04791345|DRUG|Deflazacort|30 mg of deflazacort (1 pill) administered orally in a single dose.
41458357|NCT04791345|DRUG|Dexamethasone|4 mg of dexamethasone (1 pill) administered orally in a single dose.
41458358|NCT04791345|DRUG|Dexamethasone|2 mg of dexamethasone (1/2 pill) administered orally every 12 hours during 5 days.
41138830|NCT05600439|BEHAVIORAL|CareME|"CareME program was planned to integrate 12 group session (90 minutes), implemented fortnightly during a 6-month period, and facilitated by two psychologists and expert researchers on attachment framework. Components included psychoeducation (description of core concepts such as attachment, secure base, safe haven, emotion regulation, mentalization, trauma, and discussion of research on professional caregiving in YRC); experiential and relational exercises (roleplay; cases discussion, film script discussion).~The program has 7 moduli: (i) adolescents' pain-based behaviors and attachment theoretical lens; (ii) adolescence and main developmental challenges (iii) setting rules and limits; (iv) trust \& secure base (figures and environment); (v) professionals' stories of attachment \& caregiving (vi) personal and structural characteristics that prevent a secure caregiving environment and (vii) professional impairment and strategies promoting healthy secure base provision."
41458359|NCT02340962|DRUG|TG-2349|TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
40971064|NCT06304194|OTHER|Analysis of biological samples|"The collected biological sample will be isolated and the specific nucleic acid (DNA/RNA/cfDNA) extracted for molecular analysis for understanding the reproducibility of the analysis and thus the feasibility of centralization:~* hot spot on DNa (ddPCR/Sanger)~* fusion genes on RNA (target resequencing)~* Known mutation analysis by liquid biopsy (cfDNA) for somatic mutations with a mutation frequency of less than 10%~* Tumor type-associated gene sequence analysis by Sanger sequencing and NGS"
40971065|NCT00487773|DRUG|budesonide|budesonide
40971066|NCT00487773|DRUG|D3 vitamin|D3 vitamin
40971067|NCT00487773|DRUG|montelukast sodium|montelukast sodium
40971068|NCT00487773|DRUG|salbutamol|salbutamol
41138831|NCT02198105|DEVICE|Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA|"Interventional procedure:~1. PTA with Cutting-Balloon (60-120 seconds).~2. PTA with DC-Balloon (60 seconds).~Technical success is defined as~1. no recoil \>30%~2. no dissection \>Type B~3. no stenting \>30% of lesion length."
41138832|NCT01620788|DRUG|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
41138833|NCT01620788|DRUG|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
41297281|NCT04122768|BEHAVIORAL|Multi-component physical activity tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
41297282|NCT04122768|BEHAVIORAL|Light coaching intervention|"A. Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity.~B.A step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period)."
41297283|NCT05262595|DRUG|NNC0471-0119 A|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
41297284|NCT05262595|DRUG|NNC0471-0119 B|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
41297285|NCT05262595|DRUG|NNC0471-0119 D|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
41297286|NCT05262595|DRUG|Faster aspart|"Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
41297287|NCT02300077|DRUG|methadone|Escalating dose of methadone up to .3mg/kg.
41297288|NCT02300077|DRUG|Control (Intra-operative administration of opioids, other than methadone)|Intra-operative administration of opioids, other than methadone
40971069|NCT05563233|OTHER|Helfer skin tap technique|Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.
40971070|NCT05563233|DEVICE|Shot Blocker|Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.
40971071|NCT03458273|PROCEDURE|Zero fluoroscopy ablation|Catheter ablation for the treatment of atrial and ventricular arrhythmia - no fluoroscopy guidance
40971072|NCT03458273|PROCEDURE|Conventional ablation without 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance only. 3D system (Every Ensite/Carto) is not allowed
40971073|NCT03458273|PROCEDURE|Conventional ablation with 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance + 3D system support (Ensite/Carto)
40971074|NCT00068471|DRUG|anidulafungin|
40971075|NCT04648631|DEVICE|antibiofilm surfactant wound gel (ABWG)|ABWG is a hydro-gel applied topically using a tongue depressor
40971076|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3"
40971077|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3"
40971078|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6"
40971079|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6"
40971080|NCT02459353|DRUG|Dapagliflozin|
40971081|NCT02459353|DRUG|Placebo|
40971082|NCT01393704|DRUG|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
41138834|NCT01620788|DRUG|Hyzaar®|1 tablet of Hyzaar®, oral, a day
40971083|NCT05834660|BEHAVIORAL|Safe Alternatives for Teens and Youth-Acute for Schools (SAFETY-A for Schools)|SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts by phone at 1, 2, and 4 weeks after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
41297289|NCT02482363|RADIATION|UVA radiation|20 minutes of low dose UVA from a phototherapy unit
40971084|NCT03785002|OTHER|Strength training|24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week
40971085|NCT03785002|OTHER|Protein intake|Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
40971086|NCT01033968|PROCEDURE|retina photocoagulation|Each patient had one eye treated with infrared laser (diode, 810nm wavelength) and the other eye treated with green laser (frequency-doubled solid state laser, diode-pumped, with 532-nm wavelength
40971087|NCT04943094|OTHER|Urodynamic examination|A urodynamic examination is performed in all patients four to six weeks following TURBT and repeated six months later in order to obtain bladder function and possible changes.
40971088|NCT01177917|OTHER|Infant Formula|
40971089|NCT06485882|BEHAVIORAL|Self-Care Training|Animation films are watched children about self-care and social competence
40990788|NCT02469428|OTHER|Ozone|Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
40990789|NCT06361823|DRUG|Semaglutide|Giving Semaglutide via subcutaneous injections on a weekly basis for a duration of 3 months. The dosage is 0.25 mg for the initial month, then upped to 0.5 mg for patients who could handle it in the second month, and eventually escalated to 1.0 mg for patients who continued to tolerate it in the third month.
41138835|NCT01620788|DRUG|Hyzaar®|1 tablet of Hyzaar®, oral, a day
41297290|NCT02482363|RADIATION|Sham Control|20 minutes of sham control exposure
41297291|NCT02914743|BEHAVIORAL|Motivational Interviewing|This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.
40971090|NCT03750604|DIAGNOSTIC_TEST|visceral fat obesity (surface area and function)|"WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein"
40768856|NCT06213480|DIETARY_SUPPLEMENT|Synbiotic Group|"WBF-038: Noninfectious and nonhazardous lyophilized commensal bacteria (probiotics). Contains no genetically modified organisms (GMOs) and contains no animal ingredients or by-products, and were originally isolated from human sources. The (probiotic) strains are grown in a FDA registered food facility, adhering to Good Manufacturing Practice (GMP) conditions.~Probiotic Ingredients:~Clostridium butyricum WBSTR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WBSTR-0001, and Bifidobacterium infantis~The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"
40971091|NCT03660267|OTHER|caffeine coffee|"drank 3 cups of caffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
41297292|NCT02914743|PROCEDURE|Dental cleaning|This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
40971092|NCT03660267|OTHER|decaffiene coffee|"drank 3 cups of decaffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
40971093|NCT03660267|OTHER|still water|"drank 3 cups of still water daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
40971094|NCT05870540|DRUG|BPL-003|A single dose administered intranasally
40971095|NCT06279962|OTHER|Survey questionnaire|The intervention is being assigned to one of the 8 different versions of the survey vignette.
40971096|NCT01154764|DRUG|CG100649|I period: CG 100649 II period: Ketoconalzole + CG100649 at the same time
40971097|NCT01154764|DRUG|Ketoconazole|I period: ketoconazole + CG100649 II period: CG 100649
40971098|NCT01654029|BEHAVIORAL|Patient-Centred Communication Intervention|The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
41297293|NCT05219721|DRUG|CAR-T (CAR-GPRC5D)|CAR-GPRC5D is an individualized, gene-modified autologous T cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. CAR specifically recognizes GPRC5D with a hypoimmunogenic human single-chain variable fragment (ScFv) that promotes car-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain. The amplification and persistence of CAR T are enhanced by 4-1BB costimulation signal.
40971099|NCT03370601|DRUG|Infliximab|Infliximab 10mg/kg every 8 weeks
40971100|NCT03370601|DRUG|Mercaptopurine|6-mercaptopurine 1 à 1,5 mg/kg
41297294|NCT05680129|DRUG|Ecnoglutide high dosage|Administered subcutaneously
41297295|NCT05680129|DRUG|Ecnoglutide low dosage|Administered subcutaneously
41297296|NCT05680129|DRUG|Dulaglutide|Administered subcutaneously
41297297|NCT05680129|DRUG|Metformin|Administered orally
40971101|NCT03370601|DRUG|Azathioprine|Azathioprine 2 à 2.5mg/kg/j
40971102|NCT03370601|DRUG|Infliximab|Infliximab 5mg/kg every 8 weeks
41297298|NCT05153733|DEVICE|RIFRAM implant|Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.
41297299|NCT05358639|DRUG|Olaparib tablet|Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.
40768857|NCT06213480|OTHER|Placebo Group|Ingredients: Chicory inulin and oligofructose (prebiotic fiber, hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation).
40971103|NCT03344250|DRUG|EGFR BATs with TMZ following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
41297300|NCT05358639|DRUG|Navitoclax|For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
41297301|NCT03919890|DRUG|ONO-7684|Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
40768858|NCT04966169|DEVICE|GentleWave System|The GentleWave hydrodynamic cavitation system is a 510k FDA-approved multisonic energy system that is used in complex root canal procedures.
40971104|NCT03344250|DRUG|Weekly EGFR BATs following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ
40971105|NCT00719134|DRUG|Maxalt|anti-migraine drug
40971106|NCT00719134|DRUG|placebo pill|placebo pills
40971107|NCT00719134|DRUG|placebo pills|placebo pills
40971108|NCT01299792|OTHER|sonographic measurement of bladder wall thickness|measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
40971109|NCT00488436|DRUG|Antithymocyte globulin|
40971110|NCT00488436|DRUG|Cyclosporine|
40971111|NCT06275698|DIETARY_SUPPLEMENT|Manuka honey MGO 1000|Natural Manuka honey, produced in New Zealand. With MGO content ≥ 1000.
40990790|NCT06361823|DIETARY_SUPPLEMENT|Low calorie diet|Low calorie diet (max 1200 kcal/day)
41297302|NCT03919890|DRUG|ONO-7684 Placebo|Placebo comparator
41297303|NCT00288470|DEVICE|Hylaform, Hylaform Plus (hylan B gel)|
41297304|NCT01332435|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
41138836|NCT04062578|BEHAVIORAL|Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature|The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
41297305|NCT03515603|PROCEDURE|Endoscopic resection|Transsphenoidal endoscopic resection of pituitary adenoma
41138837|NCT05514678|BEHAVIORAL|Cognitive Stimulation Therapy|CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and 10 min. 45 minutes in total, including the ending. in progress.
41138838|NCT01228565|OTHER|Radiotherapy + Erbitux® + placebo|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy
40971112|NCT06275698|DIETARY_SUPPLEMENT|Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring|"Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring, 15ml, three times a day, for 14 days.~To be kept on the tongue for at least 10 seconds prior to swallowing."
40971113|NCT03440021|DRUG|ORM-12741|Novel selective alpha2c adrenoceptor antagonist
40971114|NCT03440021|DRUG|Placebo|Identical in appearance to experimental drug, not psycho-active
40971115|NCT01525537|DRUG|administration of sufentanil|10 microgram sufentanil were given when SPI above 50 for more then 20 sec
40971116|NCT01525537|DRUG|sufentanil|sufentanil was given at standard practise
40971117|NCT05138497|OTHER|HILIT|A total of 92 men and women 65 years old, distributed in an experimental group that will receive a 12-week of HILIT program (n = 46); and a control group (n = 46) that will only receive general recommendations on the benefits of physical exercise. The variables will be measured for both groups with the same validated tools and the same researcher to avoid information biases and differential incorrect classification.
41297306|NCT03515603|PROCEDURE|Microsurgical resection|Transsphenoidal microsurgical resection of pituitary adenoma
41297307|NCT03375658|OTHER|PDWS Intervension|Patients admitted to the emergency department in the intervention period will have their vital values presented on the PDWS in addition to existing patient monitoring systems
40990791|NCT03190655|DEVICE|Aluminaid|Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium
41138839|NCT01228565|OTHER|Radiotherapy+Erbitux+OTD70DERM|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
41138840|NCT02398955|DEVICE|percutaneous coronary intervention|percutaneous coronary angioplasty with implantation of at least one Biomime stent
41138841|NCT01890278|RADIATION|Whole Brain IMRT|
41138842|NCT01890278|RADIATION|Conventional Whole Brain RT|
41297308|NCT01807507|DEVICE|VeinViewer|VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
41297309|NCT01421290|PROCEDURE|Surgery|Knee surgery
41297310|NCT01421290|OTHER|Conservative comparator|Kinesitherapy, intra-articular injection, wearing a brace, thermotherapy, intake of supplements.
41297311|NCT05436808|RADIATION|Partial Chest Wall Radiation Therapy|Patients will receive radiation therapy (30 Gray in 5 fractions) to the affected chest wall, delivered on consecutive days or every other day
40990792|NCT03190655|DEVICE|Hydrogel|Hydrogel based wound dressing
41138843|NCT02430909|BIOLOGICAL|Bimekizumab|"* Pharmaceutical form: Solution for infusion~* Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose~* Route of administration: iv infustion"
41138844|NCT02430909|BIOLOGICAL|Certolizumab Pegol|"* Pharmaceutical form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection"
41297312|NCT00400933|BEHAVIORAL|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
41297313|NCT01945931|OTHER|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
41297314|NCT00973908|DRUG|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
41297315|NCT00973908|DRUG|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
41297316|NCT02844582|DRUG|Cabazitaxel|Given IV
41297317|NCT02844582|DRUG|Prednisone|Given PO
41297318|NCT01382589|DRUG|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
41458360|NCT02340962|DRUG|Ribavirin|RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
40971118|NCT01177592|DEVICE|VerifyNow, Verigene|Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19\*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
40971119|NCT01264497|DRUG|TH9507|1 and 2 mg, sc daily for 12 weeks
40971120|NCT00177398|DRUG|Glargine insulin vs regular insulin|
40971121|NCT04253184|DRUG|Micra AV Transcatheter Pacing System|The Micra AV Transcatheter Pacing System (TPS) is a miniaturized single chamber pacemaker that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart to provide bipolar sensing and pacing. The Micra AV system provides a form of VDD pacing that is based on mechanical atrial sensing utilizing a 3-axis accelerometer.
40971122|NCT01877265|DRUG|LY2605541|
41138845|NCT02430909|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Concentration: 0.9% saline~* Route of administration: Intravenous infusion"
41297319|NCT01382589|DEVICE|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
41297320|NCT02662686|OTHER|Transfer according to morphological criteria|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).
41297321|NCT02662686|OTHER|Transfer according to the MitoScore results|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
41458361|NCT02340962|DRUG|Interferon Alfa-2a|"IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5."
41458362|NCT04792580|DRUG|Lifitegrast 5% Ophthalmic Solution|Used twice a day in both eyes for 4 weeks after a 2 week washout.
40971123|NCT03321123|DRUG|MB-CART19.1|Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
41458363|NCT04792580|DRUG|Placebo|Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
41458364|NCT01745887|DRUG|EBI-005-2|The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
40971124|NCT02298959|PROCEDURE|Biopsy|Undergo tumor biopsy
40971125|NCT02298959|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40971126|NCT02298959|PROCEDURE|Computed Tomography|Undergo CT scan
40971127|NCT02298959|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
40971128|NCT02298959|BIOLOGICAL|Pembrolizumab|Given IV
40971129|NCT02298959|BIOLOGICAL|Ziv-Aflibercept|Given IV
40971130|NCT00140595|DRUG|rituximab|
40971131|NCT00140595|DRUG|doxorubicin|
40971132|NCT00140595|DRUG|cyclophosphamide|
41138846|NCT03838575|DRUG|2% alcoholic chlorhexidine skin prep (SKIN PREP)|This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
41138847|NCT03838575|DEVICE|Iodophor Antimicrobial Incise Drapes (DRAPE)|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~This intervention describes the application of a single Iodophor Antimicrobial Incise Drape to be applied topically onto the prepared and draped surgical field by sterile, gloved members of the surgical team before the surgical incision is performed. Only after the skin preparation solution has dried completely can the incise drape be applied."
41138848|NCT03838575|DEVICE|Gentamicin-impregnated implants/ sponges (SPONGE)|This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.
41138849|NCT03838575|OTHER|NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
41138850|NCT01529866|DEVICE|New Abutment Connection implant|New abutment connection implant
41138851|NCT01529866|DEVICE|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
41138852|NCT05841342|OTHER|No intervention|No intervention
41138853|NCT06067295|OTHER|Non-Interventional Study|Non-interventional study
41138854|NCT03305185|COMBINATION_PRODUCT|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
41138855|NCT03305185|DEVICE|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
41138856|NCT03400007|DEVICE|Dynamic floor magnetic resonance imaging|Dynamic floor magnetic resonance imaging (MRI)
41138857|NCT03400007|DEVICE|Colpocystodefecography|Colpocystodefecography (CCD)
41138858|NCT05116098|COMBINATION_PRODUCT|zinc 50 mg + Epigallocatechin gallate|ZINC 50 MG and EGCG 200mg oral daily for 1 month
41138859|NCT05924373|DRUG|Human Dental Fulp Stem Cells|Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection
41138860|NCT04907383|OTHER|quality of life|QoL assessment
41138861|NCT04383392|DEVICE|Rate adaptive pacing|Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
41138862|NCT03996798|OTHER|Disability Case Manager|The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
41138863|NCT00039884|DRUG|NESP - Novel Erythropoiesis Stimulating Protein|
41138864|NCT04202822|OTHER|Oral soft tissues biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) will be harvested by the examiner at the time of the surgery (immediately before to start the surgical procedure -T0) and 24 hours after surgery (T24) at the level of the vertical released incisions (VRIs) with a biopsy punch with plunger of 2.0 mm diameter.
41138865|NCT02333565|DRUG|Everolimus|
41138866|NCT02333565|DRUG|Octreotide|
41138867|NCT04493411|PROCEDURE|WBMRI|"WBMRI will be performed either at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
40971133|NCT03391180|DRUG|ICON Remineralization|A material used for the Remineralization of white spot lesions.
40971134|NCT03391180|DRUG|CPP-ACPF|Casein phosphopeptide-Amorphous calcium phosphate fluoride used for the remineralization of white spot lesions.
41458365|NCT01535911|OTHER|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
40971135|NCT04970888|OTHER|Cognitive training|"The cognitive training will involve attention control training and memory training, with thrice-weekly 30-min sessions.~Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general."
40971136|NCT04970888|OTHER|Exercise training|Participants will follow a 20-week physical training program, with 60-min thrice-weekly trainings. The training sessions will start with a 5-min warm-up, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with a 10-min cool-down. Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test. For home-training sessions, participants will have access to a complete exercise training program. A certified kinesiologist will supervise trainings. With the Heart rate sensor Polar H10, all the characteristics of the activities will be recorded (type of the activity, intensity, heart rate, duration). A kinesiologist will call participants every week to ensure the smooth running of the exercises training sessions and individualize the care according to the patient's level.
40971137|NCT04970888|OTHER|Usual care|All patients will receive usual care and be treated according to evidence-based treatments. This will include optimal medical therapy, systematic information regarding dietary and fluid management, and a recommendation for regular physical activity consistent with the latest update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Moreover, patients who benefit from a prescription for a cardiovascular rehabilitation program will be able to follow it, but they will not receive other forms of intervention for the duration of the study.
40971138|NCT01572220|OTHER|UCA stress echocardiography or myocardial SPECT|Comparative Effectiveness of cardiac stress imaging modalities
40971139|NCT05307419|PROCEDURE|Rectal suction biopsy.|Suction biopsy performed
40971140|NCT05307419|PROCEDURE|Full-thickness rectal biopsy.|Full-thickness biopsy performed
40971141|NCT02905552|OTHER|No intervention|
40971142|NCT02556814|DRUG|Caffeic acid tablets|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
40971143|NCT02556814|DRUG|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
40971144|NCT02556814|DRUG|placebo|Oral administration of placebo tablets 0.3g three times per day for 3 months
40971145|NCT02197845|BEHAVIORAL|Patient Navigator|A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
40971146|NCT02197845|BEHAVIORAL|Recruitment into Specialty Care|A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
40971147|NCT00088517|DRUG|[11C]NNC-112|
40971148|NCT03489824|PROCEDURE|modified- WIM colonoscopy|Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
40971149|NCT05084521|DRUG|Famotidine 400 mg/50 mL|Administration of a suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.
40971150|NCT00869453|OTHER|test meal|Mixed meal containing bread, butter, beef
40971151|NCT00869453|OTHER|glucose|administration of a glucose meal
40971152|NCT00869453|OTHER|fat|administration of a lipid meal
40971153|NCT00869453|OTHER|protein|administration of a protein meal
40971154|NCT00869453|OTHER|control|no meal
41297322|NCT06073002|OTHER|home-based concurrent exercise|3 weekly sessions of home-based concurrent exercise on non-consecutive days. Resistance exercise is comprised of lunges, hip thrusts, pushups, resistance band rows, core and performed for 3 sets with 15-20 repetitions at an RPE of 14-18 (6-20 BORG scale). Endurance exercise can be done by the mode of choice and is monitored by heartrate zones. Sessions are of low to moderate intensity (below VT2) and the duration will be slowly increased for 20-40min.
41458366|NCT00225329|PROCEDURE|Labour assessment and support|
41458367|NCT04142996|DEVICE|Theta burst stimulation|Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
41458368|NCT01531790|DRUG|Carboplatin|d1, AUC 5, i.v.
41458369|NCT01531790|DRUG|Pemetrexed|d1, 500 mg/m2, i.v.
40971155|NCT04613063|OTHER|Diagnostic laparoscopy|A diagnostic laparoscopy was performed where a dilated jejunum was encountered with impaction of fecal content. Surgery was converted to open surgery, where a longitudinal enterotomy of 5 cm after the transition zone was created, evacuating manually the fecal material with mucous secretion.
40971156|NCT04084665|DRUG|Guselkumab|Guselkumab
41458370|NCT01531790|DRUG|Endostar|d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
41458371|NCT01531790|DRUG|Centrum|1 tablet/day
41458372|NCT03001934|OTHER|No intervention|Registration of all NS patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
41458373|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
41458374|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
41297323|NCT03490669|BIOLOGICAL|MSC-1|humanized monoclonal antibody for intravenous administration
41297324|NCT05433103|OTHER|Low-Load Exercise with Blood Flow Restriction|Participants in the BFR group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training with at least 60% blood flow occlusion. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
41458375|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
41458376|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
41458377|NCT05799235|DEVICE|Telerehabilitation TAR program using a mobile application|Participants in this study arm will use a mobile application which allows participants to perform their home exercises with real-time feedback given, allowing for proper execution of exercises, on top of standard care.
41458378|NCT05799235|OTHER|Standard rehabilitation sessions|Participants in this control group will attend standard in person rehabilitation sessions with home exercise program given as per standard care.
41458379|NCT04918992|DIAGNOSTIC_TEST|Artificial Intelligence|investigators utilize a Artificial Intelligence (AI) supportive system to predict radiation proctitis for patients with pelvic cancers underwent radiotherapy
41458380|NCT03792139|DRUG|LY3200882|Administered orally.
41458381|NCT03792139|DRUG|Itraconazole|Administered orally.
41458382|NCT01820962|PROCEDURE|heparin|when not in use CVCs are locked with heparin
41458383|NCT01820962|PROCEDURE|concentrated citrate|when not in use the CVC is locked with concentrated citrate
40971157|NCT04763798|OTHER|Straight-leg-raise (SLR)|The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the SLR, the knee was kept in full extension and then, hip flexion was performed until a marked resistance. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.The stretch lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes
40971158|NCT04763798|OTHER|Passive Knee extension test (PKE)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the PKE, the hip was kept in 90º flexion and then, knee extension was performed. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
40971159|NCT04763798|OTHER|Maximum hip flexion (MHF)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For MHF, a maximal hip flexion was performed and then, knee extension was applied. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
40971160|NCT03116893|DRUG|BI 685509 After Standardised Breakfast|High-fat high calorie breakfast
40971161|NCT03116893|DRUG|Itraconazole|Administration of itraconazole together with BI 685509
40971162|NCT03116893|DRUG|Rifampin|Administration of rifampicin together with BI 685509
40971163|NCT03116893|DRUG|BI 685509 Fasted Conditions|BI 685509, given alone
40971164|NCT00050518|BIOLOGICAL|Aventis Pasteur Smallpox Vaccine|
40971165|NCT00494182|DRUG|Carboplatin|Given IV
40971166|NCT00494182|DRUG|Paclitaxel|Given IV
40971167|NCT00494182|DRUG|Sorafenib|Given PO
40971168|NCT05518539|DEVICE|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
40971169|NCT05466682|BEHAVIORAL|Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)|Relaxation technique delivered via RELAXaHEAD app.
40971170|NCT05466682|BEHAVIORAL|Monitored Usual Care (MUC)|Standard of care plus daily symptom reporting using the RELAXaHEAD app electronic diary.
40971171|NCT05950009|OTHER|No intervention (observational studies)|No intervention (observational studies)
40971172|NCT03326765|OTHER|Questionnaires|"* Epworth sleepiness scale~* Pittsburgh sleep quality Index (PSQI)~* EQ-5D Adults~* Pediatric Daytime Sleepiness scale (PDSS)~* Sleep disturbance Scale for Children (SDSC~* EQ-5D Children~* Sleaping diary"
40971173|NCT03326765|PROCEDURE|electroencephalogram (EEG)|is an electrophysiological monitoring method to record electrical activity of the brain
40971174|NCT03326765|PROCEDURE|polysomnography|type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
40971175|NCT03326765|PROCEDURE|Actigraphy|type of sleep study based on bracelet around the wrist
40971176|NCT02603094|PROCEDURE|clear fluid ingestion|drinking of clear fluid in preoperative period
40971177|NCT03089450|DEVICE|CGBio stent|Percutaneous Coronary Intervention
40971178|NCT03089450|DEVICE|Biomatrix flex|Percutaneous Coronary Intervention
40971179|NCT00583778|DRUG|ipratropium|0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
41297325|NCT05433103|OTHER|Low-Load Exercise Control Group|Participants in the Control group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
41297326|NCT05216211|DRUG|Bupivacaine Hydrochloride|1 ml / kg, % 0.25 bupivacaine
40971180|NCT06069284|OTHER|No intervention|No intervention
40971181|NCT03516994|BEHAVIORAL|Respecting Choices First Steps|Advance Care Planning Approach
40971182|NCT03516994|BEHAVIORAL|Five Wishes Form|Advance Care Planning Approach
40971183|NCT05825820|BEHAVIORAL|Enhanced Outreach Intervention (EOI) plus Care as Usual|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~A phone call (or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if you have suicidal thoughts, and (c) discuss participants' plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals give for individuals who present to the ED with suicidal thoughts."
40971184|NCT01655615|BEHAVIORAL|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
41297327|NCT02037919|OTHER|Immediate Nexplanon Insertion|Patient will have a Nexplanon inserted within 15 minutes of her abortion
41297328|NCT02037919|OTHER|Post-op Nexplanon Insertion|Place Nexplanon at post operative visit rather than at surgery
41297329|NCT03549273|DIETARY_SUPPLEMENT|Glizigen® + Ocoxin-Viusid®|"* Glizigen® spray, topical use, 2 times a day for 6 months with an interruption for 2 months at the end of the third month.~* Ocoxin®-Viusid® 60 ml daily (1 vial every 12 hours) by oral route for 8 months, preferably administered after breakfast and lunch, without interruption."
41297330|NCT00211770|BEHAVIORAL|Behavioral Assessment|functional behavioral assessments are conducted at two separate visits for each subject.
41297331|NCT05185882|OTHER|Single leg squat|Single leg squat exercise in different circumstances
40971185|NCT05342545|OTHER|Alert-based computerized decision support|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
40971186|NCT03628560|DEVICE|RespirAct Step-Wise Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
40971187|NCT03628560|DEVICE|RespirAct Slope Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
40971188|NCT03628560|DEVICE|RespirAct Step-Wise Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
40971189|NCT03628560|DEVICE|RespirAct Slope Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
40971190|NCT03628560|DEVICE|ROBD Step-Wise desaturation sequence|Blood carbon dioxide is controlled at normal or lower value by subject's own breathing rate.
40971191|NCT05965505|DRUG|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
40971192|NCT03972553|PROCEDURE|Sugarbaker technique for repairing parastomal hernia|The bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
40971193|NCT03972553|PROCEDURE|Keyhole technique for repairing parastomal hernia|The bowel will be brought through defects in the posterior rectus sheath or contiguous peritoneum, mesh, and anterior fascia.
40971194|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given one dose of PF-06817024 intravenously
40971195|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 intravenously
40971196|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given one dose of PF-06817024 subcutaneously
40971197|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 subcutaneously
40971198|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
40971199|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
40971200|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given 2 doses intravenously
40971201|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given 2 doses intravenously
40971202|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given doses of PF-06817024 intravenously
40971203|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given doses of Placebo intravenously
40971204|NCT00533195|DRUG|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
40971205|NCT00533195|DEVICE|UVA1 phototherapy|"Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients."
41297332|NCT02538237|DRUG|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
41297333|NCT02538237|DRUG|Ibuprofen 2% mouthwash|
41297334|NCT04424433|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
40971206|NCT05531760|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK-operated eyes
40971207|NCT00723983|DRUG|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
40971208|NCT00723983|DRUG|NP101 Study Patch|NP101 study patch 4 hour application
40971209|NCT03169556|DEVICE|Video-laryngoscope guided lightwand|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.
40971210|NCT03169556|DEVICE|lightwand alone|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
41297335|NCT00207376|DEVICE|Solysafe Septal Occluder|
41297336|NCT06467760|DEVICE|InDx CMC Implant|The InDx CMC Implant is a hemiarthroplasty device for the CMC joint which consists of a unified assembly of three components: metacarpal stem, polyethylene liner, and articulating head. Because the device functions as a hemiarthroplasty, it does not link or constrain the CMC joint
40971211|NCT04851834|DRUG|NTX-301|Oral hypomethylating agent
40971212|NCT04851834|DRUG|Platinum-based Chemotherapy|Standard of care for ovarian and bladder cancer
40971213|NCT04851834|DRUG|Temozolomide|Standard of care for high-grade glioma
40971214|NCT01594879|DEVICE|MIrena(LNG-IUS), oral MPA|"1. General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.~2. General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate"
40971215|NCT00754260|BEHAVIORAL|Caffeine reduction|patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
40971216|NCT02554357|DRUG|Exparel block in arthroscopic shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
41297337|NCT00938327|BIOLOGICAL|Rotarix™|Two doses of oral vaccine.
41297338|NCT01109901|PROCEDURE|anterior subcutaneous transposition|transposition of ulnar nerve into subcutaneous bed
40971217|NCT02554357|DRUG|Bupivacaine block in shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
40971218|NCT03021408|OTHER|MIRT + Treadmill|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
40971219|NCT03021408|OTHER|MIRT + Treadmill Plus|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
40971220|NCT03021408|OTHER|MIRT + Virtual Reality|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
40971221|NCT00325728|DRUG|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
40971222|NCT00325728|DRUG|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
40971223|NCT01745172|PROCEDURE|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
40971224|NCT05230771|COMBINATION_PRODUCT|Palliative surgery after translational therapy|"A total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy .~location."
40971225|NCT05230771|DRUG|Chemotheraoy along|Patients receive only the prescribed chemotherapy.
40971226|NCT02024815|RADIATION|External Beam radiotherapy|External Beam radiotherapy
40971227|NCT04347044|OTHER|Pulmonary Rehabilitation|Exercise training+ Optimal medication and clinical follow-up
40971228|NCT04347044|OTHER|Standart care|Optimal medication and clinical follow-up
40971229|NCT04258722|OTHER|Resuscitation Personnel|Type of resuscitation team
40971230|NCT02352350|OTHER|Blood Lactate Levels|Blood lactate levels will be performed on all participants.
40971231|NCT02352350|OTHER|Neurological Outcomes|Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
40971232|NCT05601284|BEHAVIORAL|Acceptance and commitment therapy|ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
40971233|NCT05601284|BEHAVIORAL|Progressive relaxation training|PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
40971234|NCT02301052|DRUG|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
40971235|NCT02301052|DRUG|placebo topical cream|placebo topical cream 2 cc twice daily for 3 weeks
40971236|NCT02301052|DRUG|Anti-hemorrhoid topical cream|Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
40971237|NCT06024356|DRUG|Thymalfasin|Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.
40971238|NCT06066554|DEVICE|Puva (psoralin and uva )|Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque
40971239|NCT05517044|OTHER|Nitrogen tent preacclimatization to high altitude|The participants assigned to the preacclimatization group spend a minimum of six hours during sleep, throughout the acclimatization period (four weeks preceding the expedition) in a nitrogen concentration tent (Hypoxico OHG, Traunstein, Germany) set to an environmental PO2 corresponding to an altitude of 2500 masl, with a progression to 5500 masl within 28 days in steps of 1000 m every seven days. Respiratory Polygraphy is used to detect periodic breathing, SpO2, and heart rate continuously during sleep and is performed before and after the designated preacclimatization period, and repetitively when increasing normobaric hypoxia in the group with nitrogen concentration tent preacclimatization.
40971240|NCT01596400|DRUG|granisetron transdermal system|patch
40971241|NCT01596400|DRUG|Granisetron IV|IV
40971242|NCT02329353|DRUG|Lactobacillus brevis CD2 Lozenges|Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
40971243|NCT01366209|DRUG|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
40971244|NCT01366209|DRUG|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
40971245|NCT06440395|BEHAVIORAL|Behavioural: Small Steps for Big Changes Diabetes Prevention Program|The 4-week behaviour change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 4-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the YMCA). The supervised session will include brief behavioural counselling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
40971246|NCT05832359|RADIATION|Panoramic rad.|In the study, digital panoramic x-rays of the patients will be evaluated and dental age estimation with Willems method and mandibular bone morphometric measurements will be made.
40971247|NCT01306591|DRUG|Bevacizumab 1|Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
40971248|NCT01306591|DRUG|Bevacizumab|Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
40971249|NCT05895747|DRUG|Low Dose 5-hydroxytryptophan|5-hydroxytryptophan 100mg PO BID
40971250|NCT05895747|DRUG|High Dose 5-hydroxytryptophan|5-hydroxytryptophan 200mg PO BID
40971251|NCT05895747|DRUG|Low Dose Creatine Monohydrate|Creatine monohydrate 5g PO qday
40971252|NCT05895747|DRUG|High Dose Creatine Monohydrate|Creatine monohydrate 10g PO qday
40971253|NCT05895747|DRUG|Placebo|Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
40971254|NCT04031937|OTHER|Psychomotor assessment|the intervention include a depression scale, an anxiety scale, a sensory profile scale, a body image questionnaire, a self-esteem questionnaire, a psychomotor retardation scale and a standardized assessment of : muscle tone (dangling and extensibility); gross motor skills (walks, jump, static balance, dynamic balance); manual performance; manual praxis; adaptation of rhythm; manual gnosis; executive function
40971255|NCT04873791|DIAGNOSTIC_TEST|Assessment of geriatric individuals living in home environment and nursing home.|Assessments explained in the arm section were made as described in one session in both group
40971256|NCT00557960|DRUG|Mixed salts of a single-entity amphetamine|
40971257|NCT00557960|DRUG|Atomoxetine hydrochloride|
40971258|NCT02835404|DRUG|Nedaplatin|Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
40971259|NCT02835404|RADIATION|Pelvic External Radiotherapy|patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
41458384|NCT06262503|DEVICE|Virtual Reality|Virtual Reality device is used for creating 3d avatar to engage the patient into a virtual world so he can overcome his pain
41297339|NCT01109901|PROCEDURE|Anterior submuscular transposition|transposition of ulnar nerve into muscular tissue
41297340|NCT02718794|PROCEDURE|Simulation training|spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios
41297341|NCT02718794|PROCEDURE|Problem-based learning|spend 3 hours for PBL steps with each of 10 nurse anesthetist students
41297342|NCT05270538|DEVICE|Mask Zero Seam Virus Bac-Off Lupo® 98% Polyamide and 2% Elastane|The 26 participants allocated as G2 had to perform the physical exercise using the Zero Sewing Virus Bac-Off Virus® 98% Polyamide and 2% Elastane, in order to totally seal the nose and mouth.
41458385|NCT06262503|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS stimulation plays on pain gate theory it sends stimulation to close C-fibers to relieve the pain and make the patient comfortable. The electrodes were put around the stump leg (residual limb) and the session lasts for 15 minutes, the parameters were Conventional TENS - high frequency (50-100 Hz), low intensity, short pulse width (50-200 μs). Pain relief by means of the pain gate mechanism involves activation (excitation) of the A beta (Aβ) sensory fibers, and by doing so, reduces the transmission of the noxious stimulus from the 'c' fibers, through the spinal cord and hence on to the higher centers.
41297343|NCT03939130|DIETARY_SUPPLEMENT|Fructose|Consumption of 1.0g / kg of body mass / day of fructose.
41458386|NCT06262503|DEVICE|Mirroring Therapy|"Mirroring Therapy :it tricks the brain. By placing a mirror between the healthy limb and the missing limb, patients see a reflection of the healthy limb, essentially replacing the phantom limb with a visual representation. This visual feedback is thought to reactivate brain areas responsible for the missing limb, potentially restoring its representation and reducing the discomfort of PLP. Essentially it aims to heal the brain's image of the body, which might in turn alleviate the pain associated with the missing limb."
41458387|NCT06262503|OTHER|Phantom Exercises|The study investigated phantom exercises (PE) for phantom limb pain (PLP) relief. Patients performed specific foot and leg movements 15 times, stopping if PLP disappeared early. Exercises were repeated daily or upon PLP recurrence. Patients imagined their phantom limb position and mimicked it with their remaining limb, performing ankle, foot, knee, and hip movements until relaxation and PLP subsided.
41458388|NCT00458822|DRUG|bortezomib|Given IV
41458389|NCT00458822|DRUG|dexamethasone|Given orally
40971260|NCT02835404|RADIATION|252-Cf Neutron Intracavitary Brachytherapy|total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
41297344|NCT03939130|DIETARY_SUPPLEMENT|Glucose|Consumption of 1.0g / kg of body mass / day of glucose.
41297345|NCT03939130|OTHER|Fructose and exercise|Consumption of 1.0g / kg of body mass / day of fructose + 3 weekly sessions of 60 minutes of aerobic exercise.
41297346|NCT00380484|DRUG|Budesonide|200µg daily
41297347|NCT00380484|DRUG|Montelukast|5 mg daily
41458390|NCT03458845|DIAGNOSTIC_TEST|Computed Tomography Scan|The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
41458391|NCT03414073|DEVICE|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
41458392|NCT03414073|DEVICE|Conventional flossing technique|"The subject will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
41458393|NCT03414073|DEVICE|Conventional Interdental Brushing|The subject will gently insert the interdental brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
40768863|NCT03702270|OTHER|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
40768864|NCT04774445|BEHAVIORAL|MyCancerGene|Interactive Health Communication Application
40971261|NCT02367183|DRUG|GED-0301|
40971262|NCT02367183|DRUG|Placebo|
41297348|NCT06162676|BEHAVIORAL|HPV game|A brief health game for parent-child dyads to promote child's HPV vaccination
41297349|NCT04613583|OTHER|SAFeR fetuses|NO active intervention performed.
41297350|NCT03640143|OTHER|venous blood lead|data about ve,nous blood lead
41297351|NCT05875623|OTHER|MALPIP criteria|In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients
41297352|NCT03288272|RADIATION|Whole Brain Radiotherapy|Radiotherapy of the whole brain
41297353|NCT03288272|OTHER|Best Supportive Care|Best Supportive Care including nutrition, pain medication, steroids as needed
40971263|NCT03379805|DIAGNOSTIC_TEST|Near Infrared Fluorescence Imaging|The functional state of lymphatics is investigated using near infrared fluorescence imaging, NIRF.
40971264|NCT03379805|DIAGNOSTIC_TEST|Non-contrast MRI|The anatomy is described using non-contrast MRI.
41297354|NCT01576861|DRUG|Somatotropin|Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
41297355|NCT01703819|DRUG|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
40971265|NCT03379805|DIAGNOSTIC_TEST|Strain Gauge Plethysmography|The capillary filtration rate is measured using plethysmography
40971266|NCT04374032|DRUG|metenkefalin + tridecactide|ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection
40971267|NCT04374032|DRUG|The standard of care|The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina
40971268|NCT00637481|DRUG|atorvastatin calcium|Given orally
40971269|NCT00637481|OTHER|laboratory biomarker analysis|Correlative studies
40971270|NCT05924204|RADIATION|Photobiomodulation|Application of photobiomodulation
40971271|NCT05924204|OTHER|Simulation of Photobiomodulation|Simulation of photobiomodulation
40971272|NCT02870296|BEHAVIORAL|Enhanced Assessment and Education|Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
40971273|NCT02324569|DRUG|SYR-472|SYR-472 tablets
40971274|NCT02324569|DRUG|Placebo|Placebo tablets
40971275|NCT00433095|DRUG|Navelbine|
41297356|NCT01703819|OTHER|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
41297357|NCT03953586|DIAGNOSTIC_TEST|Bubble suction test and tubal peristalsis|Efficacy of this test in cases of hydrosalpnix (group A) and normal tubes (group B)
41297358|NCT06056739|DEVICE|Alio platform|Remote monitoring platform
41297359|NCT00849693|DRUG|Placebo|Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
40971276|NCT00433095|DRUG|Herceptin|
40971277|NCT00433095|DRUG|Navelbine (oraly)|
40971278|NCT00847860|DRUG|Cilostazol|Cilostazol 100 mg bid for 12 months
40971279|NCT00847860|DRUG|Aspirin|Aspirin 100 mg qd for 12 months
40971280|NCT05770791|DIETARY_SUPPLEMENT|Black Seed ( Nigella Sativa)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
40971281|NCT05770791|DIETARY_SUPPLEMENT|Cumin Seed (Cuminum Cyminum)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
40971282|NCT00576927|DRUG|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
40971283|NCT00576927|DRUG|Placebo|
41297360|NCT00849693|DRUG|fluoxetine|20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
41297361|NCT00849693|DRUG|duloxetine|60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
41297362|NCT00849693|DRUG|duloxetine|30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
41458394|NCT04099680|PROCEDURE|Partial thickness recipient bed|Flap will be separated by sharp dissection and elevated toward apical direction, leaving the periosteum covering the bone, and the elevated pedicle flap will be incised and removed.
41458395|NCT04099680|PROCEDURE|Full thickness recipient bed|Full-thickness (mucoperiosteal) flap will be raised on the recipient bed to establish a denuded bone area. Two bone screws will be placed at the most apical border of the denuded bone.
41297363|NCT04742465|OTHER|Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
41297364|NCT06270797|PROCEDURE|intubation for general anesthesia|routine intubation for general anesthesia
41297365|NCT02605863|DRUG|Enzalutamide|160 mg by mouth daily for 12 months
41297366|NCT05258058|BEHAVIORAL|Memory and Adaptation Training-Geriatrics|MAAT-G is a cognitive behavioral therapy-based intervention comprised of 10 workshop sessions as well as a participant workbook. The workshop sessions are delivered one on one by a health professional via videoconferencing technology.
41297367|NCT05524272|OTHER|This study aims to evaluate the effects of colour by number mandala in decreasing the stress of children hospitalized due to their chronic disease.|Colour by number Mandala in different sizes includes pictures and numbers. The child has to find the colour specified in the number and colour it with the specified colour. Colourful pictures emerge as a result of colouring
41297368|NCT03556683|DEVICE|3% Hypertonic Saline|4 mL of 3% hypertonic saline
41297369|NCT03556683|DEVICE|7% Hypertonic Saline|4 mL of 7% hypertonic saline
41297370|NCT01583322|DRUG|vargatef|"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."
40971284|NCT02052674|DEVICE|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
40971285|NCT02052674|DEVICE|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
40971286|NCT00869674|PROCEDURE|GeneSearch™ Breast Lymph Node (BLN) Assay|"Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing."
41297371|NCT01583322|DRUG|placebo|"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years."
41297372|NCT04083040|PROCEDURE|transcatheter aortic valve implantation|"1. Tilt angle.~2. Depth of implantation of the valve.~3. Type of the valve.(Medtronic core valve self expandable valve ,Edwards sapient balloon expandable valve"
41297373|NCT03851744|OTHER|Sea Level|Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL
41297374|NCT03851744|OTHER|High Altitude|Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
41297375|NCT06024577|BEHAVIORAL|Walking|Prescribed 150 minutes per week of moderate to vigorous walking.
40971287|NCT00205738|DRUG|Risperidone, Olanzapine|
40971288|NCT00174278|DRUG|Somatropin|
40971289|NCT00878774|BIOLOGICAL|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
41297376|NCT06024577|BEHAVIORAL|Variety|Prescribed 150 minutes per week of moderate to vigorous variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training.
40971290|NCT00878774|BIOLOGICAL|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
40971291|NCT03932227|DEVICE|Cardioskin|Subjects will have a 24h recording with Cardioskin, next will be unequipped.
41297377|NCT06024577|BEHAVIORAL|Progressive|Prescribed 150 minutes per week of moderate to vigorous progressive variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training. Participants can choose which exercise they want to do, and can do as much or little as they want.
40768865|NCT05720104|DEVICE|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
40768866|NCT05720104|OTHER|Standard oral hygiene instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
40971292|NCT03932227|DEVICE|Holter|Subjects will have a 24h recording with Holter, next will be unequipped.
41138868|NCT04493411|PROCEDURE|Positron Emission Tomography/Computed Tomography (PET/CT)|"PET/CT will be performed at at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
41138869|NCT03133299|DRUG|Glucocorticoids|Oral prednisolone for four months
41138870|NCT03133299|DRUG|Vitamin D|Oral vitamin D for two months
41138871|NCT01177449|PROCEDURE|Prolotherapy|inject normal saline and 50% glugose water with 1:1 ratial in volumn
41138872|NCT02924051|BEHAVIORAL|Motivational Interviewing|"Baseline and monthly assessment of barriers/facilitators of dietary change, ambivalence to change and coaching to resolve barriers and ambivalence."
41138873|NCT02924051|BEHAVIORAL|Cooking skills and nutritional education|Participants in this group will develop an understanding of healthy food options and healthy food preparation.
41138874|NCT00005654|DRUG|clomiphene citrate|
41297378|NCT03238092|DRUG|Testosterone|testosterone gel daily during the late luteal phase.
41297379|NCT03238092|DRUG|Estradiol|oral estradiol during the late luteal phase.
41297380|NCT01733069|DEVICE|APTIMA COMBO 2 Assay (AC2 Assay)|APTIMA COMBO 2 Assay (AC2 Assay
41458396|NCT04099680|DEVICE|Bone screw (FDA approved bone screw)|Two bone screws placed at the most apical border of the denuded bone after osteotomy.
41458397|NCT04099680|PROCEDURE|Periosteal sutures|Interrupted periosteal sutures placed at the 4 corners of each graft, and mesial and distal surfaces to engage the graft at an equidistance from the graft corners.
41458398|NCT04099680|PROCEDURE|Sling sutures|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and the periosteum apically.
40971293|NCT05489510|COMBINATION_PRODUCT|Pulsed or continuous lighting|The cross-linking procedures will be performed on an outpatient basis using the PXL Platinum 330 System (UVA light source and riboflavin solution).
40971294|NCT02782975|DRUG|aducanumab|
41458399|NCT04099680|PROCEDURE|Sling sutures around screws|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and each is apically looped around the corresponding apically positioned screw.
40971295|NCT02547649|BIOLOGICAL|V114-A|Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
40971296|NCT02547649|BIOLOGICAL|V114-B|Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).
41138875|NCT00005654|DRUG|metformin|
41138876|NCT00247507|DRUG|acetylcysteine|
41297381|NCT03822403|DEVICE|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
41297382|NCT03822403|DEVICE|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
41297383|NCT00061308|DRUG|Topotecan|
41297384|NCT00061308|DRUG|Gemcitabine|
41297385|NCT05060510|DIAGNOSTIC_TEST|Take home saliva kit|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
41297386|NCT02445378|PROCEDURE|Aromatherapy and Essential Oils|Undergo aromatherapy and essential oils
41297387|NCT02445378|OTHER|Placebo|Undergo placebo intervention using rose water
41297388|NCT02445378|OTHER|Questionnaire Administration|Ancillary studies
41297389|NCT03532971|OTHER|Symptom index questionnaire|A survey administered to identify the symptoms of the patient
41297390|NCT03532971|DIAGNOSTIC_TEST|BK polyomavirus PCR|quantitative PCR testing
41297391|NCT03532971|OTHER|quality of life questionnaires|Standard questionnaires validated for HCT recipients
41297392|NCT03701165|DEVICE|DryMouth Shield|The DryMouth Shield provides an elastomeric, one-piece design with breath-actuated, one-way valves configured to create an air-tight seal between the teeth and lips, which effectively reduces oral venting and air leakage while also allowing air flow into the mouth by generating a high-volume, low resistance airflow during inhalation while sealing when the user exhales.
41297393|NCT00651118|DRUG|Placebo|placebo
41297394|NCT00651118|DRUG|azelastine Hcl|azelastine Hcl 548 mcg
40768867|NCT02381587|OTHER|Retrospective study|no interventional study - Retrospective study that valuate The effect of HCQ treatment in cardiovascular AVENTS IN patients with primary sjogren syndrome
40768868|NCT05406713|DRUG|Pembrolizumab|400 mg intravenously
40768869|NCT06454240|DRUG|lunsekimig|Pharmaceutical form:solution for injection-Route of administration:subcutaneous
40768870|NCT06454240|DRUG|placebo|Pharmaceutical form:solution for injection-Route of administration:subcutaneous
41297395|NCT00651118|DRUG|azelastineHcl / fluticasone propionate|azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
41297396|NCT00651118|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
41297397|NCT02974062|OTHER|Lumbar stabilization exercise|Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
41297398|NCT06259955|OTHER|Mindfulness|In the hybrid education process, the group that received their first year education online realized their first face-to-face clinical practice this year. In the fall semester, internal medicine nursing course and practice, and in the spring semester, surgical diseases nursing course and practice. These two practice areas, which have a high tendency to make medical errors, require clinical decision-making skills and increase stress levels, constitute the beginning of clinical practice. Studies show that the most stressful period for students is the second year of their education (Alzayyat \& Al- Gamal, 2014; White, 2011; Coram, 2015). This is because their professional knowledge and skills are not yet fully developed and they are not sufficiently prepared to meet the demands for higher level knowledge and skills (Alzayyat \& Al- Gamal, 2014; Coram, 2015). Based on the results of these studies, our study group consisted of second-year students.
41297399|NCT00003342|BIOLOGICAL|filgrastim|
41297400|NCT00003342|DRUG|carboplatin|
41297401|NCT00003342|DRUG|doxorubicin hydrochloride|
41297402|NCT00003342|DRUG|gemcitabine hydrochloride|
40768871|NCT05767086|DRUG|Gonadotropin releasing hormone antagonist (Cetrotide)|clinical pregnancy rates
40971297|NCT02547649|BIOLOGICAL|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
41138877|NCT05870163|DEVICE|RefluxStop implantation|Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use
41138878|NCT05870163|PROCEDURE|Nissen fundoplication|Standard of care Nissen fundoplication surgery
41138879|NCT05159271|DEVICE|Azeol spray nasal|Azeol Spray Nasal is a nasal spray intended to reduce the nasal congestion due to rhinitis, rhinosinusitis and colds which is marketed. The ID is conforming to the European Union (EU) legislation and is bearing the CE-mark. The ID is manufactured by PILEJE S.A.S (France).
41138880|NCT05159271|DEVICE|Placebo nasal spray|with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
41138881|NCT00217152|DRUG|CellCept|
41138882|NCT03784898|OTHER|Blood draw for future biomarker analysis|Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).
41138883|NCT02298998|OTHER|Intervention|Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
41138884|NCT02298998|OTHER|Control|Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
41297403|NCT00003342|DRUG|paclitaxel|
41297404|NCT00102505|DRUG|Motexafin Gadolinium Injection|
40768872|NCT05767086|DRUG|Medroxyprogesterone Acetate (Tarlusal)|clinical pregnancy rates
40768873|NCT05767086|DRUG|Dydrogesterone|clinical pregnancy rates
40768874|NCT03519945|DRUG|Mirikizumab|Administered SC.
40768875|NCT04614532|DIAGNOSTIC_TEST|cognitive assessment|"global cognitive assessment :~* Mini Mental State~* Evaluation of manual laterality~* Hospital Anxiety and Depression scale~* 5 words of Dubois~* Trail Making Test~* short battery of the praxies~* neuropathic pain scale (DN4 in french)~* Analog Visual Scale for pain~* Fast Front End Efficiency Battery"
40971298|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
40971299|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
40971300|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
41138885|NCT05662930|BEHAVIORAL|First arithmetic problem solving|"In a quiet environment, a white paper in A4 format was placed in front of the patient on the table, and the patients were asked to subtract the number 3 from 2907 for 100 seconds.~The researcher was standing in front of the patient and asks to make corrections by giving a warning whenever the patient made a mistake in the calculation."
41138886|NCT05662930|BEHAVIORAL|Second arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the first subtraction process, patients were asked to subtract 7 from 6828 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
41297405|NCT02399813|DRUG|Axalimogene filolisbac|
41297406|NCT00668343|DRUG|simvastatin|40 mg/ day
40971301|NCT00403234|DRUG|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
40971302|NCT03513562|DRUG|Ibrutinib|Given PO
40971303|NCT03513562|OTHER|Laboratory Biomarker Analysis|Correlative studies
41138887|NCT05662930|BEHAVIORAL|Third arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 13 from 9561 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
41138888|NCT05662930|BEHAVIORAL|Fourth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 8 from 5113 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
41297407|NCT00668343|DRUG|placebo|80 mg /day
41297408|NCT01214434|DEVICE|Promiseb Topical Cream|topical non steroidal cream, twice daily
41297409|NCT01214434|OTHER|Bland emollient|Eucerin cream twice daily
41297410|NCT03037320|PROCEDURE|comparison of coronally advanced flap and semilunar vestibular incision technique for root coverage in maxillary teeth|
41297411|NCT04473261|DRUG|Iodine Complex|Iodine Complex capsule (200mg) will be given three times a day
41297412|NCT04473261|DRUG|Iodine Complex|Iodine Complex syrup form (40ml) will be given three times a day
41458400|NCT05028855|DIAGNOSTIC_TEST|Cerebral autoregulation assessment|Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
41458401|NCT02016235|DRUG|Phosphorus Supplement|250 mg po qid
41458402|NCT02016235|OTHER|Observation|Baseline blood and urine measurements only
41458403|NCT06423196|OTHER|Experimental group|In the development of the exercises, the players will mobilise dumbbells of different weights that will be estimated according to the calculation of 30% of 1 RM. This workload with dumbbells is based on previous work where blood flow restriction was used in healthy athletes.
41458404|NCT00616993|DRUG|Difluprednate|Difluprednate
41138889|NCT05662930|BEHAVIORAL|Fifth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 14 from 8318 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
41297413|NCT04473261|DRUG|Placebo|Empty capsule will be given as placebo
41458405|NCT00616993|OTHER|Placebo|Vehicle
41458406|NCT03344120|OTHER|Administration of USSQ Symptoms questionnaire after stent positioning|Administration of USSQ Symptoms questionnaire to patients with two different type of stents after ureteroscopy
40971304|NCT03513562|DRUG|Venetoclax|Given PO
41458407|NCT00452218|DRUG|Sorafenib|200 mg daily and dose escalated to a maximum of 400 mg twice daily
41458408|NCT05544656|DRUG|Tolperisone Hydrochloride|Tolperisone Hydrochloride tablets of 150 mg, administered three times a day
41458409|NCT05544656|DRUG|Placebo|matching placebo administered three times a day
41458410|NCT01740934|OTHER|Anatabloc Cream|subject will apply active cream topically, twice per day according to instructions
41297414|NCT04473261|DRUG|Idoine Complex|Iodine Complex spray form 2 puffs will be given three times a day
41458411|NCT01740934|OTHER|Placebo Cream|subject will apply placebo cream topically, twice per day according to instructions
40971305|NCT03750799|DEVICE|Whole body vibration|Whole body vibration was applied on the right lower extremity in the experimental group.
40971306|NCT03750799|DEVICE|Sham vibration|Sham vibration was applied on the right lower extremity in the Control sham group
40971307|NCT05911516|DIETARY_SUPPLEMENT|Pennisetum purpureum|300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks
41458412|NCT01507207|PROCEDURE|Injection laryngoplasty|Patients will undergo a direct microlaryngoscopy in the operating room for diagnostic purposes. In patients in whom laryngeal cleft is diagnosed, injection laryngoplasty will be carried out using sodium carboxymethylcellulose aqueous gel (commercial name Radiesse) injection material.
40971308|NCT05911516|DIETARY_SUPPLEMENT|Placebo|Placebo
40971309|NCT01695902|DRUG|Levosert-20|
40971310|NCT01695902|DRUG|Mirena|
40971311|NCT01658072|PROCEDURE|Peri-Articular Injection|Use of a different analgesic protocol, based on a peri-articular injection
40971312|NCT01658072|PROCEDURE|Epidural Patient Controlled Analgesia (Epidural PCA)|Epidural analgesia pathway.
40971313|NCT01690208|OTHER|EMERALD|"Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.~These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule."
41297415|NCT00308542|DRUG|dexamethasone|
41297416|NCT00708994|DRUG|THC|"* Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~* Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~* Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
41458413|NCT00575601|DRUG|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
41138890|NCT05662930|BEHAVIORAL|Sixth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 17 from 9994 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
41138891|NCT00000284|DRUG|Cotinine fumarate|
41138892|NCT01992276|BIOLOGICAL|CR8020|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
41458414|NCT01213407|DRUG|Trivax, Temozolomide, Surgery, Radiotherapy|"Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32~Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.~Break: weeks 7, 8, 9, 10.~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31."
41138893|NCT01992276|BIOLOGICAL|CR6261|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
41138894|NCT01992276|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion on Day 1
41138895|NCT05206994|BEHAVIORAL|Close to Home|Close to Home (C2H), a community mobilization model developed in Boston and adapted for California, is specifically designed to prevent SV by strengthening community social connections and engaging whole communities in dialogue and action to transform social norms. The C2H model guides communities through four phases: 1) Assess, 2) Talk, 3) Build, and 4) Act. C2H mobilizes diverse groups of people residing in a shared geography and linked by social and political ties to engage in joint actions for SV prevention
41138896|NCT02253966|DRUG|Methylprednisoloneacetate|
41138897|NCT02253966|DRUG|Lidocaine|
41138898|NCT02253966|OTHER|sodium chloride|
41138899|NCT06026462|DIAGNOSTIC_TEST|Observation of clinical indicators related to asthma|Observe the severity of asthma, drug compliance, comorbidities, asthma control, pulmonary function, FeNO, and the number of acute episodes of asthma
40971314|NCT01690208|OTHER|Usual Care|Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment \& explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
40971315|NCT00112060|DRUG|PT-523 for Injection|
40971316|NCT05786391|OTHER|Flat position|Flat patient position during the cystoscopy
40971317|NCT05786391|OTHER|Trendelenburg position|Trendelenburg position (head down) during the cystoscopy
40971318|NCT05786391|DEVICE|Insufflation|Insufflation to 15 mm Hg
40971319|NCT02584673|DEVICE|Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
40971320|NCT00612690|BEHAVIORAL|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
40971321|NCT00612690|BEHAVIORAL|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
40971322|NCT02622321|DRUG|Emicizumab|Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
40971323|NCT02622321|DRUG|rFVIIa|Participants will continue to receive rFVIIa.
41138900|NCT05148052|DEVICE|Virtual reality exergames|Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
41138901|NCT05148052|BEHAVIORAL|Conventional occupational therapy|Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
41138902|NCT00351026|DRUG|Methadone|short-term methadone maintenance
41138903|NCT02142595|DRUG|dexmedetomidine|The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
40971324|NCT02622321|DRUG|aPCC|Participants will continue to receive aPCC.
40971325|NCT03198234|BIOLOGICAL|T-allo10|The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
40971326|NCT05196789|DIAGNOSTIC_TEST|whole genome and transcriptome sequencing|To perform whole genome/transcriptome analysis of patients in a cohort of up to 350 Australian patients with IBMFS-RD
41138904|NCT02142595|DRUG|Midazolam|The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
41138905|NCT05578807|PROCEDURE|without reverse ureteral catheter insertion|In contrast to conventional total tubeless percutaneous nephrolithotomy, there was no reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, no change in position, and no repeated disinfection.
41138906|NCT03560206|BEHAVIORAL|Family SWaP intervention|The Family Sodium Watcher Program (Family SWaP) proposed in this study incorporates the use of a unique electronic salt monitoring device that easily measures salt content in food-the major source of sodium. The intervention is designed to improve adherence to a sodium restricted diet by both patients and family caregivers through education and strategies for gradual taste adaptation to low salt foods. The Family SWaP intervention (6 weekly 45-minute sessions followed by 5 bi-weekly booster sessions) will be delivered remotely using a video-conferencing program on an iPad tablet.
41138907|NCT03560206|BEHAVIORAL|usual care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
41138908|NCT00907959|DRUG|BZL101|Oral BZL101 20 grams/day (10 grams BID).
41138909|NCT04635657|OTHER|Long-term Cognitive testing|These patients will undergo their standard of care cognitive testing at baseline, six weeks post-operatively and one year post-operatively.
41138910|NCT00748891|DRUG|Recentin (Cediranib)|30mg once daily, oral dose
41138911|NCT02573129|OTHER|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
41138912|NCT02573129|OTHER|Red Meat Rich|Mediterranean diet rich in red meat
41138913|NCT01228500|DEVICE|PriMatrix|Dermal Repair Scaffold
41138914|NCT02614157|PROCEDURE|LLND|advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
41138915|NCT02614157|DEVICE|labeled line|
41138916|NCT00466037|BIOLOGICAL|Influenza vaccine|
41138917|NCT00237809|DRUG|D-serine|D-serine (30 mg/kg)
41138918|NCT00237809|BEHAVIORAL|Cognitive Retraining (CRT)|Cognitive retraining therapy (CRT)
41138919|NCT00237809|DRUG|Placebo|Placebo D-serine Drug
40971327|NCT05459675|OTHER|Very low-calorie diet|Meal replacement (800 kcal/day, protein 90 g/day)
41138920|NCT00237809|BEHAVIORAL|Cognitive Retraining Placebo|Cognitive retraining therapy (CRT) control
41138921|NCT00911014|OTHER|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
41297417|NCT00708994|DRUG|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
41297418|NCT06182033|BEHAVIORAL|Peer-mediated pivotal response training|Teachers support children in the implementation of three strategies directed toward a target child identified as having language impairment and as isolated from the classroom social network.
41297419|NCT02974946|DEVICE|RenalGuard|
41297420|NCT03267095|BEHAVIORAL|music therapy sessions .|In this intervention songs compose by the therapist will be use for the study. The songs included the target word .The target words will be selecte from functional vocabularies that typically developing 3years old children can use effectively in everyday interactions.The general criteria for vocabulary words included: names of familiar objects and persons, functional action words such as words for social control , and emotional words . Inherent musical structures structures and organized musical patterns in the songs will be provide .The patients will reflect on the music therapy activity as singing the song together.
41297421|NCT02316093|OTHER|Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling|
41458415|NCT01213407|DRUG|Temozolomide, Surgery, Radiotherapy|"Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6~Break: weeks 7, 8, 9, 10~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31"
41458416|NCT03359941|PROCEDURE|acupuncture|Acupuncture points: Examples of acupuncture points to be used include BL23 (Sinsu, bilateral), BL24(Gihaesu, bilateral), BL25(Daejangsu, bilateral), BL40(Wijung, bilateral), BL60(Gollyun, bilateral), BL65(Sokgol, bilateral), LI11(Gokji, bilateral), LI4(Hapgok, bilateral), ST36(Joksamni, bilateral), GB41(Jogimeup, bilateral), LR3(Taechung, bilateral). Electrical stimulation with alternating frequency of 2-100 Hz will be applied to the selected points (e.g., BL 23-25, bilateral). Treatments will be provided by qualified Korean traditional medicine doctors with more than 2 years of clinical experience.
41458417|NCT04933357|RADIATION|Dose escalation|Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost
41458418|NCT04933357|RADIATION|Standard dose|Standard dose to good responders to achieve dose equivalent of 70 Gy.
41458419|NCT06440863|PROCEDURE|Total Knee Arthroplasty|Patients undergoing total knee arthroplasty
41458420|NCT06440863|PROCEDURE|Total Hip arthroplasty|Patients undergoing total hip arthroplasty
41297422|NCT02237053|DRUG|Glucagon|
41297423|NCT02237053|DRUG|Octreotide|
41297424|NCT02237053|BEHAVIORAL|Placebo|
41297425|NCT02237053|DRUG|Insulin|
41297426|NCT05640232|DRUG|CDE100 association|Experimental drug.
41297427|NCT05640232|DRUG|Buscopan® Composto association|Active comparator.
41297428|NCT05299203|DRUG|Sapropterin dihydrochloride tablets|dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.
41297429|NCT05960344|PROCEDURE|Spirometry|Supervised v unsupervised spirometry
41297430|NCT04137276|DRUG|vitamin C, vitamin B1|vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days
41297431|NCT04137276|DRUG|vitamin B1|thiamine 200 mg/12 hours for 3 days
41297432|NCT04756635|OTHER|Experimental Group|This 3-year project will include two groups of participants: 1) young men accustomed to resistance training (study #1) and 2) young men accustomed to endurance training (study #2). Inclusion will be limited to healthy participants (i.e. nonsmokers, normotensive with systolic and diastolic values \<135/85 mmHg, non-obese, non-medicated, and free of any known disease as assessed by medical history) (Pickering, Hall et al. 2005). Month 1-3 will focus on literature review and month 4 to 8 will address experimental settings preparation and selection of participants to include in each study. Testing and data collection will be scheduled for months 9-14 and 13-18 (study # 1 and 2 related testing, respectively). Data processing, analysis and presentation will occur from month 21 to 33. All participants will read and sign an informed consent document with the description of the testing procedures. The Faculty's ethical committee will be asked to approve this document before testing.
41297433|NCT02214199|OTHER|Manipulative Therapy Techniques|
41138922|NCT01453764|PROCEDURE|Harvesting and Implantation of SVF|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
41138923|NCT00458783|BIOLOGICAL|Prolonged RBC storage|Transfusion with oldest available matching RBCs
41138924|NCT00458783|BIOLOGICAL|Short RBC storage|Transfusion with youngest available matching RBCs
41138925|NCT03001635|DRUG|Oxytocin|26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
41138926|NCT03001635|DRUG|Placebos|26 patients will receive 0.9% normal saline infusion for 6h as placebo
41138927|NCT05396365|DIAGNOSTIC_TEST|Dynamometry|Hand grip dynamometer measure of strength and anthropometric measurements
41138928|NCT00799838|DRUG|Ketoprofen|"Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
41138929|NCT00799838|DRUG|Placebo (for Ketoprofen)|"Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
41297434|NCT02214199|OTHER|Home Exercises|
41297435|NCT02682888|BEHAVIORAL|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
41297436|NCT02682888|DRUG|Oxytocin|intranasal administration of oxytocin
41297437|NCT02682888|DRUG|Placebo|intranasal administration of placebo
41458421|NCT06248294|DIAGNOSTIC_TEST|CT follow-up|Computed tomography angiography assessment of BAV-related aorthopathy
41138930|NCT00799838|DRUG|Amoxicillin|"Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d"
41138931|NCT05208788|DIAGNOSTIC_TEST|Biomarker test|collection of 500µl to 1 ml of a spot urine sample
41138932|NCT01729793|DIETARY_SUPPLEMENT|Digestive Enzyme #2|Contains dietary supplement proteases, lipases and carbohydrases
41138933|NCT01729793|OTHER|Placebo|Capsule containing microcrystalline cellulose
41138934|NCT00482911|DRUG|cyclophosphamide|25-50 mg by mouth once daily on days 1-28.
41138935|NCT00482911|DRUG|lenalidomide|10 mg by mouth once daily on days 1-28.
41138936|NCT00482911|DRUG|sunitinib malate|12.5 - 25 mg by mouth once daily on days 1-28.
41138937|NCT00861991|BEHAVIORAL|Perspective taking instruction|Students were asked to take the perspective of their standardized patients during clinical skills examinations
41138938|NCT00234000|DRUG|arsenic trioxide|Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
41138939|NCT00234000|DRUG|azacitidine|Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
41138940|NCT01667159|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
41138941|NCT01667159|BEHAVIORAL|Standard Care|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
41297438|NCT01735110|PROCEDURE|transfemoral intervention (TFI)|
41297439|NCT01735110|PROCEDURE|Transradial intervention|
41297440|NCT01323673|DRUG|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
41297441|NCT01323673|DRUG|Vehicle / Placebo|2 times a day, 14 total days of study treatment
41458422|NCT00619853|BEHAVIORAL|treatment approach - CIMT|CIMT, 2 months, 2Hr per day
41458423|NCT00619853|BEHAVIORAL|treatment approach - HABIT|HABIT-2 months, 2Hr per day
41297442|NCT03771144|PROCEDURE|arthrolysis|Surgery is performed under general anesthesia. The usual duration of this surgery is on average 1h30. This surgery requires an anterior approach and a posterior approach. The patient is placed in lateral decubitus. The arthroscope of 2.7 is introduced by a posterior route. An anterior instrumental track is made from inside out through the rotator interval.
41458424|NCT03428945|DRUG|Hydroxychloroquine|Hydroxychloroquine for oral administration, dosed by weight
41458425|NCT03428945|DRUG|Placebo|Placebo tablet identical to active drug
41458426|NCT02451696|DRUG|Everolimus|This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
41297443|NCT02190435|DEVICE|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
41297444|NCT02190435|DEVICE|Conventional technique|Conventional Technique
41297445|NCT00647777|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fed
41297446|NCT00647777|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fed
41297447|NCT05834244|DRUG|Azacitidine|Given by IV (vein)
41297448|NCT05834244|DRUG|Venetoclax|Given by PO
41297449|NCT05834244|DRUG|NK Cells|Given by IV (vein)
41297450|NCT04488692|OTHER|Early intervention (Mobility functional training)|functional training focused on mobility (bed mobility, sitting balance, standing balance, and ambulation)
41297451|NCT04488692|OTHER|Sham intervention|friendly visit and education
41297452|NCT04770233|PROCEDURE|Early ACL reconstruction|ACL reconstruction followed by rehabilitation
41297453|NCT04770233|PROCEDURE|Active rehabilitation|Non-operative treatment with active rehabilitation led by a physiotherapist with optional delayed surgery if indicated.
41297454|NCT02886026|DEVICE|Bladder tumor resection using diathermia|Conventional bladder tumor resection using diathermia
41297455|NCT02886026|DEVICE|Diode laser (980 nm) tumor destruction|Laser mediated destruction of bladder tumors (LMD-BT)
41138942|NCT06278194|PROCEDURE|Gasserian Ganglion Radiofrequency Thermocoagulation|Gasserian ganglion radiofrequency thermocoagulation is performed in the operating room under fluoroscopy. In sterile condition, the foramen ovale is shown by the pain management specialist under fluoroscopy guidance. After this condition, the entry of the needle is marked and anaesthetised with local anaesthetic. After the entry of the gasserian ganglion with the radiofrequency needle, 10 cm long, the location is checked with sensory and motor stimulation. If the placement is correct, 70 degrees 70 seconds of radiofrequency thermocoagulation is applied.
41138943|NCT03430440|DEVICE|Apply CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button. Compared with the conventional mode in which only the basal infusion rate is set to be fixed, the CIPCA mode sets the basal infusion rate, the increase / decrease rate of basal rate, and the increment / decrement interval.
41297456|NCT04923412|PROCEDURE|Pulmonary branch of vagus nerve preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is made.
41297457|NCT04923412|PROCEDURE|Pulmonary branch of vagus nerve not preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is not made/ can be severed.
41297458|NCT00718861|DRUG|Placebo|
41297459|NCT00718861|DRUG|Zoledronic acid|
41297460|NCT02582749|DRUG|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
41297461|NCT02582749|DRUG|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
41297462|NCT02582749|RADIATION|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
41297463|NCT02974257|DRUG|Thiamine|Thiamine 500mg IV twice daily for 2 days
41297464|NCT02974257|OTHER|placebo|100mL normal saline IV every 12 hours for 2 days
41297465|NCT03661541|DRUG|Squaric Acid Dibutyl Ester|2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.
41297466|NCT06011005|OTHER|Ethyl Chloride spray (group A)|Cold test spray
41297467|NCT06011005|OTHER|Benzocaine gel 20% (group B)|Topical analgesia
41297468|NCT01225783|OTHER|Self measurement of limb volume +water displacement|Comparison will be made between self measurement is two types of tape measure compared with water displacement
41297469|NCT04039828|DRUG|Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)|Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for \> 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
41297470|NCT03789773|DEVICE|Millimeter-Wave Holographic Imaging|Undergo mm-wave holographic imaging
41297471|NCT01005394|DEVICE|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
41297472|NCT03303339|DRUG|Onvansertib|Onvansertib orally
41297473|NCT03303339|DRUG|Cytarabine|subcutaneously
41138944|NCT03430440|DEVICE|Conventional mode|PCA pumps typically set a fixed basal infusion rate to set the analgesic to enter at a constant rate every hour (conventional mode).
41297474|NCT03303339|DRUG|Decitabine|intravenously
41466506|NCT02408120|DRUG|Insulin glargine|"Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is \>180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
41138945|NCT03466983|DRUG|Iron Isomaltoside|administered IV
40971328|NCT05459675|PROCEDURE|Bariatric surgery|Bariatric surgery will be performed by single surgeon at Ramathibodi Hospital Mahidol University, Thailand. Postoperative diet progression according to the current guideline will be prescribed from early post-op period to 1 year after surgery
40971329|NCT01897402|BIOLOGICAL|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
40971330|NCT01897402|BIOLOGICAL|US Licensed Vaccine|Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
40971331|NCT04522362|OTHER|Control task and Trier Social Stress Task|Same as Arm
40971332|NCT04564729|OTHER|Shared Decision Making|The intervention group will receive a shared decision-making intervention including a decision aid and conversation with a study investigator. The intervention group will have the opportunity to choose the number of opioid pills they receive at discharge from hospital after total knee arthroplasty.
41297475|NCT03651999|OTHER|"participation in a workshop: dream workshop animated by a nurse anesthesist"|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; the nurse anesthetist will take care to explain to them the progress of the hospitalization and help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...) ; he can customize his mask and choose the blanket he wants to take; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
40971333|NCT01038050|DRUG|Ginkgo Biloba Extract (GBE)|Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
40971334|NCT05894928|DRUG|LOXO-783|Administered orally.
40971335|NCT05894928|DRUG|Cholestyramine|Administered orally.
40971336|NCT01648101|DRUG|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
40971337|NCT01648101|DRUG|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
40971338|NCT01648101|OTHER|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
40971339|NCT06505616|DEVICE|Compared the trombogenicity of the Solacea dialyzer with synthetic dialyzers after progressively decreasing heparin until discontinuing it|The duration of the study was four weeks, carried out in two phases. After screening, patients were randomized to be dialyzed with the Solacea™ hemodialyzer versus the usual hemodialyzer, which in all cases had to be a synthetic membrane. In both arms, heparin was progressively decreased until it was discontinued. Afterwards the patients were crossed over to the other arm.
40971340|NCT02918175|BEHAVIORAL|mHealth|Personalized step count feedback and medication teaching tool.
40971341|NCT00988611|OTHER|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
41138946|NCT03466983|DRUG|Ferric Carboxymaltose|administered IV
41138947|NCT04497415|OTHER|Video-Based intervention|Three minutes video of a nurse that shares her personal story
41297476|NCT00434850|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
41138948|NCT04081532|PROCEDURE|surgical removal of superficial peritoneal endometriosis|In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
41138949|NCT05005351|DEVICE|Digital ACT|Participants in Digital ACT arm complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual.
41138950|NCT05005351|DEVICE|Digital Symptom Tracker|Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual.
41297477|NCT00434850|DRUG|Deoxyspergualin|An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
41297478|NCT00434850|BIOLOGICAL|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
40971342|NCT05433792|DEVICE|Myolens CN (Central-Near) soft contact lens|Personal fitting of the Myolens-CN/CF.
41297479|NCT00434850|BIOLOGICAL|Daclizumab or basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
41297480|NCT00434850|DRUG|Sirolimus|Maintenance immunosuppressive therapy
41297481|NCT00434850|DRUG|Tacrolimus|Maintenance immunosuppressive therapy
41297482|NCT00434850|BIOLOGICAL|Etanercept|Blocks TNF-alpha which is toxic to islet cells
41297483|NCT03527056|BIOLOGICAL|Fecal Microbiota Transplantation|This is a parallel arm study. All participants in the experimental arm will receive a single fecal transplantation via oral capsules to determine effectiveness and safety in decolonizing gastrointestinal CRE.
41297484|NCT00178360|BEHAVIORAL|Music Therapy|"During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.~Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:~* Group singing~* Group drumming~* Music assisted relaxation~* Group song writing~* Lyric analysis~* Improvisation~* Music with art"
41297485|NCT06135597|OTHER|This is a blood test without regarding to intervention nor diagnostic tests|This is a blood test without regarding to intervention nor diagnostic tests
41297486|NCT00496873|DRUG|Cytoxan|600 mg/m\^2 on Day 1 of 21-day cycle.
41297487|NCT00496873|DRUG|Nipent|4 mg/m\^2 on Day 1 of 21 Day Cycle.
41297488|NCT00496873|DRUG|Rituxan|375 mg/m\^2 on Day 1 of 21 Day Cycle.
40971343|NCT05433792|DEVICE|MiSight® soft contact lens|Control arm device, FDA approved (P180035), and CE marked soft lenses for the management of Myopia in children aged 8-12.
41297489|NCT00012727|PROCEDURE|Matching Symptom Severity to Service Intensity|
41297490|NCT05108324|PROCEDURE|zygomatic implant|2 zygomatic implants and 2 anterior conventional implant
41297491|NCT05108324|PROCEDURE|conventional implant|patients will receive 4 conventional dental implant
40971344|NCT01749514|DRUG|Luspatercept|Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).
40971345|NCT03210818|DEVICE|Extra-corporeal membrane oxygenation life support|Adjustment of blood flow of extra-corporeal membrane oxygenation life support
40971346|NCT05037734|DEVICE|Persona Partial Knee System|Unicompartmental Knee Replacement
40971347|NCT04882540|DRUG|brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 100 mg tablets~* Route of administration: Oral use"
40971348|NCT05087212|DRUG|plerixafor + G-CSF|subcutaneous (SC) injection
40971349|NCT02984748|DEVICE|Cochlear implant|
40971350|NCT04464369|DRUG|itopride|itopride is a gastroprokinetic drug that has previously been evaluated in the treatment of functional dyspepsia and which is available in a number of countries worldwide
40768876|NCT04614532|OTHER|Cold Pressor Test|"consists of the complete immersion of the participant's arm in a basin of cold water maintained at a temperature.~The test will be divided into two conditions (pain, no pain). In the first, the container will be filled with cold water. In the second, the water in the container will be at room temperature. The investigators will test each arm. During the immersion of the arm, participants will have to remain silent and remove their arm when the ordeal becomes too painful for the painful condition.~For the non-painful condition, the immersion time will be determined according to the results of the pre test."
40768877|NCT04614532|OTHER|digital sensor of Nociception Level Index|placed on the contralateral index finger with the arm immersed in the tank to measure the variation of physiological parameters.
40768878|NCT05119582|DEVICE|TOOsonix System ONE-M|Selected neurofibromas will be treated by high intensity focused ultrasound. Untreated fibromas will be used for controls.
40768879|NCT04720001|DRUG|Florbetaben F18|A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
40768880|NCT04720001|DEVICE|PET|PET Scan for brain imaging
41138951|NCT02191540|DRUG|Abnoba Viscum F 20mg|intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
41138952|NCT06046807|OTHER|Phone call|This follow-up will be conducted over the phone and by mail (some questionnaire may be sent by patient, as per his/her preference)
41138953|NCT01971255|BIOLOGICAL|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
41138954|NCT00142246|DRUG|Intermittent preventive treatment (SP and amodiaquine)|Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
41138955|NCT00142246|OTHER|Placebo|Three doses given over three days (Day 1: placebo SP + placebo AQ; Days 2 and 3: placebo AQ). Dosage given according to age
41138956|NCT05379166|DRUG|Azacitidine|Given IV
41138957|NCT05379166|OTHER|Quality-of-Life Assessment|Ancillary studies
41138958|NCT05379166|OTHER|Questionnaire Administration|Ancillary studies
41138959|NCT05379166|DRUG|Venetoclax|Given PO
41138960|NCT05073822|DRUG|Tacrolimus|reduction of both standard Tacrolimus \& Mycophenolate mofetil does in one arm
41138961|NCT03803657|DEVICE|Monitoring of energy expenditure|Continuous monitoring of energy expenditure.
41138962|NCT01802619|OTHER|inhaled nitric oxide|Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
41138963|NCT01802619|OTHER|inhaled Nitrogen|Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
41138964|NCT01323244|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
41297492|NCT05431582|DRUG|ZN-c3|Given by PO 1 time a day with a glass (about 8 ounces) of water
40768881|NCT02310321|DRUG|Gilteritinib|Once-daily oral administration on 14 consecutive days in every cycle in each period.
40768882|NCT02310321|DRUG|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.
40768883|NCT02310321|DRUG|Cytarabine|"Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5."
40768884|NCT06285253|COMBINATION_PRODUCT|miroliverELAP treatment|Subject's blood will be perfused through a bioengineered liver graft via an extracorporeal blood circuit.
40768885|NCT06523166|PROCEDURE|Transesophageal echocardiography (TEE)|TEE will be performed using a 3D probe. TEE images will be acquired at the standard 0, 45, 90, and 135 degree views along with a 3D acquisition encompassing the entire LAA, device, left pulmonary vein and lateral mitral annular landmarks.
41138965|NCT01144533|PROCEDURE|isotonic saline injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* isotonic saline 4ml + telebrix(contrast media) 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
41138966|NCT01144533|PROCEDURE|steroid injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + isotonic saline 3ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
41138967|NCT01144533|PROCEDURE|sodium hyaluronate injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* sodium hyaluronate 2ml + isotonic saline 2ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
41138968|NCT01144533|PROCEDURE|steroid and hyaluronate injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + sodium hyaluronate 2ml + isotonic saline 1ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
41138969|NCT04997798|DRUG|Trastuzumab Pyrotinib Exemestane Dalpiciclib|Early triple positive breast cancer patients receive combination regimen of Dalpiciclib in Combination With Exemestane and Trastuzumab plus pyrotinib
41138970|NCT05376839|DRUG|Cedirogant|Capsule, Oral
41297493|NCT05431582|DRUG|Bevacizumab|Given by vein over about 30-60 minutes on Day 1 of each cycle
41297494|NCT05431582|DRUG|Pembrolizumab|Given by vein over 30-60 minutes on Day 1 of each cycle.
40768886|NCT06523166|PROCEDURE|Cardiac CTA|Cardiac CTA will be performed with ECG gating using systems with ≥ 64 detector rows and with temporal resolution that is at least 175 msec (rotation speed ≤ 350 msec for single source systems). Cardiac CTA images will be acquired for the entire cardiac cycle without ECG phase specific pulsing and with contrast appropriately timed for peak left atrial/arterial phase contrast enhancement. In addition, a targeted end systolic only delayed phase image set (45 seconds after the arterial phase scan and limited to the left atrium and appendage device) will be acquired.
40768887|NCT03141437|OTHER|Best Practice|Receive standard of care
41297495|NCT05688267|OTHER|Continuous Mobility Training|The continuous mobility training adopted 5 grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists.
40768888|NCT03141437|OTHER|Educational Intervention|Receive educational materials
40768889|NCT03141437|OTHER|Internet-Based Intervention|Use decision-making website
41297496|NCT05688267|OTHER|Usual Care|Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training.
41297497|NCT01247818|DRUG|PH-10 (0.002% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
41297498|NCT01247818|DRUG|PH-10 (0.005% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
40768890|NCT03141437|OTHER|Questionnaire Administration|Ancillary studies
40768891|NCT06611306|RADIATION|DE-iPTV|Dose-escalated VMAT-based radiotherapy, as previously described in our planning study
40768892|NCT00297791|PROCEDURE|surgery|randomized to open or laparoscopic technique
40768893|NCT05781685|DRUG|Testosterone|Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
40768894|NCT05781685|OTHER|Placebo Syrup|Oil-based sublingual product.
40971351|NCT04464369|DRUG|Placebo|placebo pills matching the look and weight of the itopride tablets
40971352|NCT04782427|OTHER|COVID-19 infection|Case of nosocomial infection within the long-term care facility
40971353|NCT00084721|DRUG|celecoxib|
40971354|NCT00084721|DRUG|irinotecan hydrochloride|
40971355|NCT03978520|DRUG|Elsubrutinib|Capsule; Oral
41297499|NCT01247818|DRUG|PH-10 (0.01% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
41297500|NCT01247818|DRUG|Vehicle|PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
40768895|NCT05914324|DEVICE|Phefumla device|The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.
40768896|NCT05914324|DEVICE|LB-01 device|The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.
40971356|NCT03978520|DRUG|Placebo for elsubrutinib|Capsule; Oral
40971357|NCT03978520|DRUG|Upadacitinib|Film-coated tablet; Oral
40971358|NCT03978520|DRUG|Placebo for upadacitinib|Film-coated tablet; Oral
41297501|NCT03465800|BEHAVIORAL|self-monitoring|self-monitoring of physical activity
41297502|NCT03465800|BEHAVIORAL|daily incentives|daily incentive payments for physical activity
41297503|NCT03465800|BEHAVIORAL|delayed lump sum incentives|delayed lump sum payments for physical activity
40768897|NCT04586751|OTHER|Pecs block|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed.
40768898|NCT04586751|OTHER|no Pecs block|no regional block will be performed in this arm
40990793|NCT04760366|OTHER|fascial- muscular lengthening therapy|"Patients in this group will receive interventional therapy~To perform this technique:~1. Have the patient in side lying position~2. Hip is maximally flexed to shorten the iliopsoas muscle.~3. Therapist fingers should be on to the targeted area.~4. Apply gentle pressure in upward direction.~5. While maintain the pressure, stretch the muscle by moving the hip in extension through full ROM.~6. Therapist will maintain the pressure in opposing direction. This is considered as one pass. This technique is performed bilaterally. Patients in this group will also receive the conventional therapy which will include:~   * Hot pack for 15 minutes.~  * Myofascial release of iliopsoas.~  * TENS for 15 minutes."
41297504|NCT02754778|BEHAVIORAL|conditional workout|6 month of regular conditional workout 1-3 times a weak
41297505|NCT00424580|DRUG|Montelukast (10mg) and Desloratadine (5mg)|
40768899|NCT04876456|DRUG|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
41138971|NCT05448222|DIAGNOSTIC_TEST|Diagnostic Test: gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
41138972|NCT04154891|GENETIC|Trio Whole Genome Sequencing|WGS trio analysis will be performed using the genome data of the index case in addition to the genome data of his parents. This analysis will follow a consensus protocol that contains 3 obligatory steps: first of all, de novo variants (SNV, CNV and others SV) will be examined in the whole genome data set; then, a SNV/CNV/other SV analysis will be performed under a AR or X linked Mendelian mode hypothesis in the whole genomic regions of a OMIM extended list (that contains all genes already involved in human genetic diseases). Finally, analysis will focus on inherited pathogenic variants under an AD mode hypothesis (analysis of variations already reported as pathogenic in clinVar or HGMD pro; CNV or truncating variation in OMIM genes, etc). When these 3 steps analysis is completed then variants of interest identified at each step will be recorded until examination by a specific multidisciplinary meeting.
41138973|NCT04154891|GENETIC|Simplex Whole Genome Sequencing|This analysis will be performed using only the index case following a similar strategy than the one used for the WGS trio
41138974|NCT04154891|GENETIC|Current French Reference strategy|Actual ANPGM recommendations defined by the following analysis: Fra-X + chromosomal microarray analysis + 44GPS
41297506|NCT01971476|DRUG|volasertib|intravenous administration on day 1of a treatment course
41297507|NCT00138099|DRUG|Fragmin (dalteparin sodium)|
41297508|NCT05971290|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure administered by face mask
41297509|NCT05971290|DEVICE|Ambient air|Air (fraction of inspired oxygen) at 14000 feet in elevation
41297510|NCT01543451|DRUG|Elsiglutide|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
40768900|NCT01160718|DRUG|fulvestrant|Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
40768901|NCT01160718|DRUG|selumetinib|AZD6244 75 mg p.o. bid
41297511|NCT01543451|DRUG|Placebo|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
41297512|NCT05272163|BEHAVIORAL|Stimulus Type|Targets can be specific or categorical
41297513|NCT05272163|BEHAVIORAL|Target Presence|There is or is not a target present on each trial
41297514|NCT05272163|BEHAVIORAL|Checklist|In fact, there is a checklist on every trial but these results will be compared to a non-checklist condition from another experiment
41297515|NCT04547296|DRUG|Sodium Bicarbonate Ringer's Solution|After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH \<7.2, 5% sodium bicarbonate injection was given to correct it.
41297516|NCT06224543|DEVICE|SubtleGAD|SubtleGAD is an image processing software developed to enhance MR images acquired with low dose gadobutrol.
40768902|NCT05520736|BEHAVIORAL|Appointment reminders, motivational interviewing and targeted vaccine drives|Automated and real time phone call reminders, motivational interviewing and targeted vaccine drives applied in sequence
40768903|NCT06640153|DIAGNOSTIC_TEST|mpMRI|Gastroesophageal junction or upper gastric adenocarcinoma patients undergo mpMRI at siewert classification, length of esophageal involvement, primary staging and restaging
40768904|NCT06442761|DRUG|Motixafortide|Given Subcutaneously (under the skin).
40768905|NCT06486467|OTHER|Fluid challenge (cristalloids) OR passive leg raising|"Patients in whom fluid administration is considered necessary, based on hypoperfusion criteria will be included in the trial.~One member of group A and one of group B will proceed independently to evaluate LVOT VTI, guided by the UltraSight AI software to obtain the best 5-chamber view. The measure of LVOT VTI will be calculated as the average of three consecutive cardiac cycles.~The order of acquisition between group A and B will be randomized. Each operator will be blinded to the values obtained by the other.~After baseline LVOT VTI measurement, a 250 mL fluid challenge of crystalloids or a passive leg raising test (non-pharmacological and reversible fluid challenge of roughly 250 mL), depending on the appreciation of the clinician will be performed. Measurements will be repeated immediately after the fluid challenge by the same operators, still blinded to each other, guided by the UltraSight AI software. The order of the 2nd acquisition will be the same as the 1st acquisition"
40768906|NCT06498557|OTHER|Peripheral nerve block methods|We apply different nerve blocks to patients for analgesic purposes after knee replacement surgery. These blocks are a combination of SFIP block and adductor channel block and iPACK block.
41138975|NCT03626376|DRUG|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily|Treatment used in standard of care
40768908|NCT05309291|DEVICE|Theranova 400 Dialyzer|Dialysis performed in HD mode.
40768909|NCT05309291|DEVICE|FX 800 Dialyzer|Dialysis performed in HDF mode.
40768910|NCT06558604|DRUG|Obinutuzumab|1000 mg/40mL
40768911|NCT06558604|DRUG|Glofitamab|10mg/mL
40768912|NCT06558604|DRUG|Venetoclax Oral Product|10mg, 50mg and 100mg tablets
40768913|NCT06558604|DRUG|Zanubrutinib Oral Capsule|80mg capsules
41138976|NCT03626376|DRUG|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops|Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
40768915|NCT06519526|DRUG|SHR-0302|SHR-0302 will be administered orally as tablets.
40768916|NCT06519526|DRUG|SHR-2554|SHR-2554 will be administered orally as tablets.
40768917|NCT03750019|BEHAVIORAL|Satisfying rehearsal task|Participants rehearsed satisfying aspects of the lunchtime meal they just ate.
40768918|NCT03750019|BEHAVIORAL|Dissatisfying rehearsal task|Participants rehearsed dissatisfying aspects of the lunchtime meal they just ate.
40768919|NCT03750019|BEHAVIORAL|Neutral rehearsal|Participants rehearsed their journey to campus that day.
41138977|NCT01307540|DEVICE|phototherapy|low level light therapy, broad band light wavelengths.
41138978|NCT05168280|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively.
41297517|NCT06224543|DRUG|Gadobutrol|Gadavist is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
40768920|NCT06618638|BEHAVIORAL|Shared decision making model|Shared decision making model for choosing pharmacotherapy in ADPKD patients. This newly developed shared decision making model follows the SHARE approach and includes patient education, identifying values and preferences, reaching a decision and evaluating.
40768921|NCT06618638|BEHAVIORAL|Usual Care|Usual care for ADPKD patients
40768922|NCT06029647|OTHER|Mango|The participants will consume the treatment for 16 weeks, followed by a 4-week washout period.
40768923|NCT06029647|OTHER|vanilla wafers|vanilla wafers
41138979|NCT05168280|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
41138980|NCT00990184|DRUG|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
41138981|NCT00990184|OTHER|placebo|tablet (s) orally given with evening meal
40768924|NCT04725513|DEVICE|Shockwave Therapy|Participants will receive shockwave therapy once a week for three weeks
41297518|NCT04328064|DRUG|Rosuvastatin calcium 40mg|Active drug -Rosuvastatin
41297519|NCT04328064|DRUG|Placebo oral tablet|40 mg placebo for 12 months
41297520|NCT03166358|BEHAVIORAL|Hatha yoga|8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
40768925|NCT04725513|DEVICE|Photobiomodulation Therapy|Participants will receive photobiomodulation therapy twice a week for three weeks
40768926|NCT04725513|OTHER|Physical Therapy|Participants will enroll in physical therapy and complete an at-home exercise protocol
40768927|NCT06562283|OTHER|Thumb test|Thumb adduction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
40768928|NCT06562283|OTHER|Grip test|Muscle contraction gripping test, consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
40768929|NCT06562283|OTHER|Quadriceps Intermittent Fatigue test (QIF test))|Quadriceps muscle contraction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
40768930|NCT06385938|DIAGNOSTIC_TEST|Ultrasound with quantitative vibro-acoustic assessment|Imaging with non-invasive bone assessment based on wide range of frequencies and free from soft tissue artifact of the wrists and the knees
40768931|NCT02918942|DEVICE|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure.
41297521|NCT03557398|DEVICE|Hydeal-D vaginal pessaries|One vaginal application of Hydeal-D vaginal pessaries every 3 days to a total of 12 consecutive weeks.
41297522|NCT02689336|BIOLOGICAL|Erlotinib|
40768932|NCT03131193|OTHER|Physician|Study primary health centers will be staffed with an additional physician
40768933|NCT03131193|OTHER|Mid-level provider|Study primary health centers will be staffed with an additional mid-level provider
40768934|NCT03131193|BEHAVIORAL|Conditional Cash Transfer|Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
40768935|NCT01353729|DRUG|600 mg zanamivir + moxifloxacin placebo|zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
40768936|NCT01353729|DRUG|1200 mg zanamivir + moxifloxacin placebo|zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
40971359|NCT05112432|DEVICE|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. Exercises continuously adjust difficulty level to user performance to maintain an approximately 80% current performance rate. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
41297523|NCT02689336|DRUG|Temozolomide|
41297524|NCT00844428|DRUG|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
41297525|NCT02528669|DEVICE|RX Navigait|The RX Navigait is an accelerometer that tracks the number to steps taken, duration of walking, and time of walking. In addition, this device sends messages to patients regarding daily walking goals and walking reminders.
41297526|NCT02107391|BIOLOGICAL|Dendritic Cells DCVAC/PCa|Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy
41297527|NCT02107391|DRUG|Leuprolide acetate|Standard of Care Hormone Therapy as an Active Comparator
41297528|NCT02107391|DRUG|Goserelin Acetate|Standard of Care Hormone Therapy as an Active Comparator
41297529|NCT05890638|DRUG|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
40768937|NCT01353729|DRUG|zanamivir placebo + moxifloxacin placebo|zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
40768938|NCT01353729|DRUG|zanamivir placebo + 400 mg moxifloxacin|moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
40768939|NCT05338736|DIAGNOSTIC_TEST|LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)|Kit to test the concentration of Immunoglobulin G anti-SARS-CoV-2 in the plasma of included patients
40768940|NCT05338736|DIAGNOSTIC_TEST|LIAISON SARS-CoV2-IgM (DiaSorin)|Kit to test the concentration of Immunoglobulin M anti-SARS-CoV-2 in the plasma of included patients
40768941|NCT05338736|DIAGNOSTIC_TEST|Human IFN-g ELISpot PLUS (ALP) (AUROGENE)|Kit to test the cellular immunity response by measuring the Interferon gamma released by mononuclear cells (PBMCs)
41297530|NCT05890638|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
41297531|NCT00897559|GENETIC|gene expression analysis|
41297532|NCT00897559|GENETIC|mutation analysis|
41297533|NCT00897559|GENETIC|polymorphism analysis|
41297534|NCT00897559|GENETIC|protein analysis|
41297535|NCT00897559|OTHER|flow cytometry|
41297536|NCT00897559|OTHER|laboratory biomarker analysis|
41297537|NCT04956692|BIOLOGICAL|Pembrolizumab SC|SC injection
41297538|NCT04956692|BIOLOGICAL|Pembrolizumab IV|IV injection
41297539|NCT04956692|DRUG|Paclitaxel|IV injection
41297540|NCT04956692|DRUG|Nab-Paclitaxel|IV infusion
41297541|NCT04956692|DRUG|Carboplatin|IV infusion
41297542|NCT04956692|DRUG|Cisplatin|IV infusion
41297543|NCT04956692|DRUG|Pemetrexed|IV infusion
41297544|NCT02963467|PROCEDURE|cigarette|smoking 4 conventional cigarettes
41297545|NCT02963467|PROCEDURE|"dummy cigarette"|"smoking a dummy cigarette"
40768942|NCT04740567|BEHAVIORAL|Cognitive Training|The cognitive training program regimen and its degree of difficulty will be tailored to the patient's current level of cognitive functioning and interests. Patients will be asked to work through progressively more challenging exercises pertaining to orientation, attention, problem-solving, and memory. These cognitive training exercises will be significantly difficult but when they can be completed easily (\>85% mastery), their difficulty will be increased, and this process will be repeated as appropriate. They will also perform puzzles, games, or cognitive tasks related to their hobbies.
40768943|NCT04740567|BEHAVIORAL|Goal Management Training|"Goal management training will (1) teach patients compensatory strategies such as stop techniques \[e.g., to stop and think about consequences of a decision before making it\]; (2) help them to take complex tasks and divide them into manageable subtasks to increase the likelihood of completing the task; and (3) enable them to learn to regain cognitive control when their behavior becomes incompatible with their intended goals. GMT is anchored in sustained and vigilant attention theory and it enables patients to actively attend to higher order goals critical to functioning. GMT is tailored to the individual needs of the patient. During the initial session, the Cognitive Intervention Specialist will meet with the subject and their family member or caregiver to identify these functional and cognitive deficiencies."
40768944|NCT00265499|PROCEDURE|Skeletonization of the internal thoracic artery|
40768945|NCT02473042|PROCEDURE|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
40768946|NCT02473042|DRUG|Zofran|4 mg by vein for 1 dose.
40768947|NCT02473042|DRUG|Dexamethasone|10 mg by vein for 1 dose.
41297546|NCT03598231|DEVICE|Sacral neuromodulation|"After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period."
41297547|NCT02002078|DRUG|methylprednisolon|
41297548|NCT05163990|OTHER|transcutaneous acupoint electrical stimulation|The corresponding transcutaneous acupoint electrical stimulation is given to different groups before spinal anesthesia, which last from 10 minutes before anesthesia to 30 minutes after subarachnoid administration.
41297549|NCT05433298|BIOLOGICAL|Mesenchymal stem cell|Administration of advanced cell product
41297550|NCT05433298|OTHER|Placebo|Ringer's lactate, albumin and heparin solution
41297551|NCT00611455|DRUG|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
41138982|NCT02932176|DEVICE|Non-invasive vascular testing|Results of clinically indicated non-invasive vascular testing will be used to develop a machine learning algorithm
41138983|NCT02932176|DEVICE|machine-learning algorithm|
41138984|NCT01579955|DRUG|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
41297552|NCT00611455|DRUG|Placebo|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
41297553|NCT03234868|DEVICE|Impression procedure|Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
41297554|NCT03234868|DEVICE|Crown manufacturing procedures|Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
41297555|NCT05336968|DRUG|Triamcinolone acetonide-Ketorolac-Ropivacaine|Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
41297556|NCT01790438|DRUG|LY2605541|
41297557|NCT01790438|DRUG|Human Insulin NPH|
40768948|NCT02473042|DRUG|Phenergan|6.25 mg by vein for 1 dose.
40768949|NCT02473042|DRUG|Pepcid|10 mg by vein for 1 dose.
40768950|NCT02473042|BEHAVIORAL|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
41138985|NCT03022825|DRUG|N-803 and BCG|BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
41138986|NCT03022825|DRUG|N-803|N-803 will be administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
40971360|NCT05112432|BEHAVIORAL|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
40971361|NCT05112432|OTHER|Early Psychosis Coordinated Specialty Care|Participants will continue to receive treatment as usual at their early psychosis coordinated specialty care clinics. These clinics may follow the NAVIGATE model, as an example.
40971362|NCT00811798|BIOLOGICAL|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
40971363|NCT05038189|DIAGNOSTIC_TEST|Gait parameters|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
40971364|NCT05038189|DIAGNOSTIC_TEST|Spine posture|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
40971365|NCT05038189|DIAGNOSTIC_TEST|Trunk position sense|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
40971366|NCT05284149|DIETARY_SUPPLEMENT|Hirsutella Sinensis Nutrient Supplements|"This randomized control study will be conducted in 2 years. We expect to recruit 50 participants with age ≥ 50 years old. Enrolled participants will be recruited into Hirsutella Sinensis nutrient supplement group (50 patients H.S. suppl.) . The medication will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving Hirsutella Sinensis nutrient supplement."
41138987|NCT02053298|DRUG|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
41138988|NCT05594732|BEHAVIORAL|Weak outdoor light|Stay and stare far on the balcony or under the tree
41138989|NCT05594732|BEHAVIORAL|Strong outdoor light|Stay and stare far in the sunlight
41297558|NCT01790438|DRUG|Oral Antihyperglycemic Medications (OAM)|
41138990|NCT04849091|DEVICE|iReadMore|Digital Alexia Therapy
41138991|NCT05859659|DIAGNOSTIC_TEST|This study does not intervene in this process.|This study does not intervene in this process.
41138992|NCT00442507|DRUG|Erlotinib|
41138993|NCT00442507|DRUG|Avastin|
41138994|NCT03441490|BEHAVIORAL|Guided-ICBT for adolescents with anxiety|Internet-based cognitive behavioural therapy with therapeutic guidance through mail, 8 weeks.
41138995|NCT03441490|BEHAVIORAL|Guided-ICBT with chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat, 8 weeks.
40971367|NCT05284149|DIETARY_SUPPLEMENT|Placebo|"We expect to recruit 50 placebo participants with age ≥ 50 years old. This randomized control study will be conducted in 2 years. The placebo will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving placebo."
41138996|NCT03441490|BEHAVIORAL|Guided-ICBT with learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail, 8 weeks.
41138997|NCT03441490|BEHAVIORAL|Guided-ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat, 8 weeks.
41138998|NCT05885620|DEVICE|drinking reminder and cognitive task (smartwatch-based application)|task A: prompt to drink some water task B: prompt to circle bells on a sheet
41138999|NCT05596006|DRUG|ASIMOMMY®|ASIMOMMY 500 mg
41139000|NCT05596006|DRUG|Domperidon|Domperidone capsule 10 mg
41139001|NCT05596006|DRUG|Placebo|Capsules of placebo 500mg.
41139002|NCT02105571|BEHAVIORAL|Intervention|
41139003|NCT05533905|DIAGNOSTIC_TEST|Lumbar puncture|A thin needle is inserted between the bones in the spine.
41139004|NCT05533905|DIAGNOSTIC_TEST|MRI|A scan of the head.
41139005|NCT01297595|DRUG|crizotinib|Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
41139006|NCT00410150|DRUG|Helium-oxygen-driven albuterol nebulizer|Subjects will be treated with continuous albuterol nebs with Heliox
41139007|NCT00410150|DRUG|Oxygen|Subjects will be treated with continuous albuterol nebs in oxygen
41297559|NCT00542685|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
41139008|NCT06176014|PROCEDURE|implant placement|5 implant were placed in intraforaminal area using surgical guide
41297560|NCT00542685|DRUG|Placebo|Capsules, oral, placebo BID, 8 weeks with 2 week taper.
41297561|NCT00542685|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
41297562|NCT00542685|DRUG|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
40768951|NCT06016244|OTHER|Oxygen saturation threshold|Oxygen saturation threshold on which supplemental oxygen is decided
40768952|NCT04953026|DIAGNOSTIC_TEST|Diagnositic test|The results of shoulder arthroscopy were taken as the gold standard, and MRI examination was taken as the research object.
40971368|NCT02442518|PROCEDURE|antenatal ultrasound|Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
40971369|NCT03937297|BEHAVIORAL|Six Arts|"The Six Arts intervention is a 24 session, twice a week intervention protocol. There will be four sessions per Art, with specific sequence designed to enhance group dynamic and create harmony. Each session starts with a 15 minutes warm-up exercise, followed by the Six Art theme activity. The program design emphasizes on integrated cognitive, physical, and social activities covering all domains of Six Arts."
40971370|NCT03937297|BEHAVIORAL|Cognitive Stimulation Therapy (CST)|The CST to be used involve 24 sessions of theme activities, twice a weekly intervention protocol. It is modified into CST-Hong Kong for activities that are not applicable in Hong Kong Chinese culture (e.g. word games involving alphabets)
40971371|NCT03937297|BEHAVIORAL|Usual Care|usual dementia care provided by participating center
40971372|NCT03669172|BIOLOGICAL|Donor IL-15 stimulated NK cells infusion|DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT
40971373|NCT02256852|BIOLOGICAL|QBKPN SSI|QBKPN SSI is administered subcutaneously for 12 weeks
40971374|NCT01987505|DRUG|Rituximab|1400 mg will be injected subcutaneously (SC).
41297563|NCT01670851|DEVICE|Strattice|Perineal reconstruction and stoma reinforcement with Strattice
41297564|NCT03236350|DEVICE|Active autoRIC® (CRIC Treatment)|The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.
41297565|NCT03236350|DEVICE|Sham Control autoRIC® (Sham Control)|The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
41297566|NCT04577859|DEVICE|ensoETM. Esophageal cooling during AF ablation|Esophageal cooling during AF ablation: The ensoETM probe is inserted via the orogastric route when the patient is under general anesthesia. The device is set to cool during ablation of the posterior aspect of the left atrium, to protect against transmitted thermal energy and so reduce or prevent esophageal thermal injury.
40971375|NCT05114720|DRUG|standard adjuvant chemotherapy plus moxifloxacin|docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days
40971376|NCT05114720|DRUG|standard adjuvant chemotherapy plus placebo|docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days
40971377|NCT04606082|DRUG|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
40768953|NCT05278715|DRUG|Carboplatin|Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
41297567|NCT04577859|DEVICE|Esophageal temperature monitoring probe|An esophageal temperature monitoring probe is a typical monitoring device used in standard of care AF ablations. This allows any temperature rise in the esophagus to be detected during ablation. If the temperature reaches \>38 degrees then it is widely recognized that ablation should be halted until the temperatures fall back to below 38 degrees. It therefore has the ability to detect esophageal temperature rise only.
41297568|NCT02092415|DEVICE|Application of a Junctional Tourniquet|All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.
41297569|NCT01241838|DEVICE|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
41297570|NCT03506698|OTHER|Kangaroo Mother Care (KMC)|Skin to skin contact of newborns with mothers or caregiver for a minimum of at least eight hours over a 24-hours period, along with exclusive breastfeeding or breast milk feeding via tube or spoon
41297571|NCT02152865|DRUG|Lupeol|Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.
41297572|NCT02152865|DRUG|Control vehicle|Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
41297573|NCT00722592|DRUG|Vintafolide|2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle
41297574|NCT00722592|DRUG|pegylated liposomal doxorubicin (PLD)|50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
41297575|NCT00722592|OTHER|EC20|During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
40768954|NCT05278715|DRUG|Vincristine|Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.
40768955|NCT05278715|DRUG|Recombinant human endostatin|Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
40768956|NCT05462262|DRUG|Intensive lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
40971378|NCT04606082|DRUG|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
40768957|NCT05462262|DRUG|Moderate-intensity lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
40768958|NCT06105632|DRUG|PF-07220060 CDK4 inhibitor|Experimental
40971379|NCT02528071|OTHER|Diaphragmatic endurance test|This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
40971380|NCT03624894|OTHER|impression|common polyvinylsiloxane oral impression
41297576|NCT02633072|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AMO® Tecnis® multifocal intraocular lenses with an addition of +2.75 D in the distance-dominant eye and +3.25 D in the fellow eye.
41139009|NCT05333666|OTHER|Data collection|This investigation aims to collect and analyze the data from a cohort. During the cohort development, all participants received venous puncturing for NOAC concentration measurement. However, the standard treatment protocol was not changed after study enrollment. In this retrospective cohort study, we only collect data from the cohort without further intervention to the participants.
41139010|NCT05325983|OTHER|lemonade ice cubes|Mixing 1 part lemon juice and 6 parts boiling water, make 10ml lemonade ice cubes. The experimental group was given a 10ml lemonade ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the lemonade ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The experimental group was given a brand new 10ml lemonade ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
40768959|NCT06105632|DRUG|Fulvestrant|Experimental and Active comparator
40768960|NCT06105632|DRUG|Everolimus|Active Comparator
41139011|NCT05325983|OTHER|water ice cubes|make 10ml water ice cubes. The control group was given a 10ml water ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the water ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The control group was given a brand new 10ml water ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
40768961|NCT06105632|DRUG|Exemestane|Active Comparator
40768962|NCT02888340|OTHER|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
40768963|NCT03238053|PROCEDURE|Vaginal laser treatment|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
40768964|NCT03238053|DEVICE|sham|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
40768965|NCT03238053|DEVICE|laser system|FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
40971381|NCT04908878|PROCEDURE|Pectoral nerve (PECS) block -transversus thoracic plane (TTP) block|Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
41139012|NCT02684656|PROCEDURE|Hemodialysis|Hemodialysis \>/=4h
41139013|NCT02684656|PROCEDURE|Hemodiafiltration|Hemodiafiltration \>/=4h, \> 20l convection
40971382|NCT04908878|PROCEDURE|Serratus anterior plane (SAP) block|Patients will receive US-guided SAP block after induction of general anesthesia.
40971383|NCT02474459|DEVICE|iPad-Based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.
40768966|NCT01374854|BIOLOGICAL|Umbilical mesenchymal stem cell (UC-MSCs) infusion|1×10\^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.
40971384|NCT02474459|OTHER|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
41297577|NCT04993027|DRUG|Vancomycin Powder|Vancomycin is a bactericidal aminoglycoside antibiotic which inhibits cell wall synthesis. It is effective against gram positive bacteria. Though most commonly administered intravenously, it can be delivered orally or directly into surgical incisions and wounds in certain indications.
41297578|NCT03716063|DRUG|Jianpi Huatan dispensing granule|once a day in the morning and evening, every month for a course of treatment, a total of three courses
40768967|NCT01374854|DRUG|traditional therapy|exogenous insulin injection daily
40768968|NCT01250327|DEVICE|Melody|insertion of a pulmonic valved stent
40768969|NCT01250327|DEVICE|bare stent|insertion of a bare metal stent
40768970|NCT01250327|PROCEDURE|Surgery|conventional surgery methode
40768971|NCT00997763|DEVICE|XIENCE V|everolimus-eluting stent
40768972|NCT00997763|DEVICE|CYPHER|sirolimus-eluting stent
40768973|NCT03246412|DIAGNOSTIC_TEST|Nevus doctor clinical decision support|The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
40768974|NCT01435356|BIOLOGICAL|recMAGE-A3 + AS15 ASCI|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
40768975|NCT01435356|BIOLOGICAL|Placebo|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
40971385|NCT01185132|RADIATION|accelerated partial breast irradiation - 3D-conformal planning|38.5 Gy, 10 fractions over 5 days
41297579|NCT04048967|BEHAVIORAL|Professional development|professional development of preschool staff
41297580|NCT04891250|DRUG|Ivermectin|Treatment of SARS Cov-2 patients with Ivermectin
41297581|NCT04891250|OTHER|Prophylaxis|Treatment of high risk population with Ivermectin as prophylaxis
41297582|NCT02515591|OTHER|Bronchoalveolar Lavage validation study|Bronchoalveolar lavage involved the washing out of the right middle lobe of the lung of a healthy volunteer with 200mls of warmed normal saline with or without sedation.
41297583|NCT06397872|DRUG|100 mg Resmetirom Tablet|Once daily oral dose for 6 days
41297584|NCT04341194|BEHAVIORAL|Parent-driven pain management with skin-to-skin contact|The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
40971386|NCT01185132|RADIATION|accelerated partial breast irradiation - IMRT planning|38.5 Gy, 10 fractions over 5 days
41297585|NCT04341194|BEHAVIORAL|Parent-driven pain management with skin-to-skin contact/breastfeeding/parental singing|Live parental infant-directed lullaby singing is an individually tailored, non-verbal, multisensory, multimodal and affective tool to regulate the infant before, during and after venipuncture. Direct breast-feeding has demonstrated efficacy that is equal to, or greater than, sweet taste interventions in reducing behavioral and physiological responses to pain in full-term infants undergoing venipuncture with no demonstrated adverse outcomes. Direct breast-feeding should be considered the preferred first-line analgesic intervention for painful procedures performed on full-term infants.
40971387|NCT05256953|PROCEDURE|Erector spina plane block + general anesthesia|"Bilateral-injection ultrasound-guided bilateral erector spinae plane block~Pre-operatively, with the patient in the sitting position, 20ml 0.25% bupivacaine will be administered between the T9 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane. The same procedure was applied bilaterally.~Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day)."
40768978|NCT05575466|DIAGNOSTIC_TEST|Blood samples|Hemostatic biomarkers
40768979|NCT05575466|DIAGNOSTIC_TEST|Questionnaires|Eating Disorder Inventory - third version (EDI-3) Eating Disorder Quality of Life Scale (EDQLS)
40768980|NCT04347109|DIAGNOSTIC_TEST|Non invasive epicardial mapping|Non invasive mapping using Cardio Insight system is performed in all included patients.
40971388|NCT05256953|PROCEDURE|Only general anesthesia|"Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day)."
40971389|NCT02314897|DEVICE|LV pacing|Left ventricular pacing lead implanted via the coronary sinus.
40971390|NCT02314897|DEVICE|RV pacing|Conventional right ventricular pacing.
40971391|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
40971392|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
40971393|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
40971394|NCT03217487|PROCEDURE|Corneal epithelial autograft|Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.
41139014|NCT01058018|DRUG|RVX000222|RVX000222 twice a day for 12 weeks
41139015|NCT01058018|DRUG|Placebo|Placebo twice a day for 12 weeks
40768981|NCT05986578|DEVICE|TMS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. For dmPFC, approximately 25% of the nasion-inion distance or Talairah coordinates X 0 Y+60 Z+60 will be measured. The first session will begin with the acquisition of the resting motor threshold (rMT) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last \~3 minutes. The stimulation will start at a lower percentage and ramp up over time to acclimate participant to the feeling of stimulation. The intensity will be lowered in participant cannot tolerate the stimulation. Each participant will receive 3 sessions per visit with a 15-20 minute interval between sessions to increase the likelihood of detecting acute effects.
40768982|NCT05986578|DEVICE|TMS to dlPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. For dlPFC, position F3 will be measured, using probabilistic EEG placement. The first session will begin with the acquisition of the resting motor threshold on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last 3 minutes. The stimulation will start at a lower percentage and ramp up over time to acclimate participant to the feeling of stimulation. The intensity will be lowered in participant cannot tolerate the stimulation. Each participant will receive 3 sessions per visit with a 15-20 minute interval between sessions to increase the likelihood of detecting acute effects.
40768983|NCT05986578|DEVICE|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 3 sessions with a 15-20 min interval between sessions.
40768984|NCT05360706|GENETIC|AAV5-hFIX|AAV5 containing a codon-optimized human factor IX gene
40768985|NCT03255395|DEVICE|Magnetic resonance-guided focused ultrasound|Ten amputees wil recieve a magnetic resonance-guided focused ultrasound treatment aimed at ablating neuromas, which are believe to contribute to their phantom / residual limb pain
41139016|NCT04828915|OTHER|Machine learning|Machine learning on vital parameters, clinical symptoms and underlying diseases
41139017|NCT04828915|OTHER|Machine based evaluation|Quantification of the prediction power and identification of the most relevant predictive parameters
40971395|NCT03217487|PROCEDURE|Limbal conjunctival autograft|A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.
40971396|NCT03217487|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
40971397|NCT03217487|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
40971398|NCT03925883|BEHAVIORAL|Patient navigation|Receive up to 6 live phone calls with a patient navigator for education, barrier assessment, and barrier resolution to follow up colonoscopy
40971399|NCT02101060|OTHER|exercise|16-week progressive aerobic and resistance exercise training
40971400|NCT02135302|DRUG|eravacycline|Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
40971401|NCT05665478|OTHER|Dose prediction using population pharmacokinetic models|Dose prediction using population pharmacokinetic models.
41139018|NCT00003152|BIOLOGICAL|filgrastim|
41139019|NCT00003152|BIOLOGICAL|recombinant interferon alfa|
41139020|NCT00003152|DRUG|cyclophosphamide|
41139021|NCT00003152|DRUG|prednisone|
41139022|NCT00003152|DRUG|vincristine sulfate|
41297586|NCT02371733|OTHER|Upper extremity aerobic exercise training|"Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.~Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
41139023|NCT00003152|PROCEDURE|autologous bone marrow transplantation|
41139024|NCT00003152|PROCEDURE|bone marrow ablation with stem cell support|
41139025|NCT00003152|PROCEDURE|peripheral blood stem cell transplantation|
41139026|NCT00003152|RADIATION|radiation therapy|
41139027|NCT04976946|OTHER|Comprehensive questionnaire|Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.
41139028|NCT01655082|DRUG|V0116 transdermal patch|One patch per day (during 24 hours) for 21 days
41139029|NCT01655082|DRUG|Nicotine transdermal patch|One patch per day (during 24 hours) for 21 days
41139030|NCT02899533|DRUG|[18F] FES|\[18F\] FES PET/CT scan, imaging tracer
41139031|NCT05804357|BEHAVIORAL|Manual Therapy|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion
41139032|NCT05804357|BEHAVIORAL|Exercise|It is an approach that is combined with diaphragmatic breathing, activating the passive-active musculoskeletal and neural systems. In this approach, transversus abdominis and multifudus muscles are activated as deep core muscles.
41139033|NCT06506409|DEVICE|Smart-Video Based Game Therapy|The Active Arcade program will be practiced 2 days a week for 8 weeks. Individuals in this group will be given a 1-minute rest break between games. Sessions will be approximately 30 minutes. Selected games focus on balance, coordination and weight transfer.
40768989|NCT04362644|DRUG|PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714|Study participants will undergo PET/CT with the glucose analogue \[F-18\]FDG and the translocator protein (TSPO) ligand \[F-18\]DPA-714 in two separate imaging sessions.
40768990|NCT02572648|OTHER|Brain Imaging (Neuroimaging)|"Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.~Total time in scanner will be approximately 53 minutes."
40768991|NCT02572648|OTHER|Cognitive Function Assessment|Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 \& 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
40768992|NCT00734032|DRUG|SB480848 40mg EC Tablet|1 tablet once a day
40768993|NCT00734032|DRUG|SB480848 80mg EC Tablet|1 tablet once a day
40768994|NCT00734032|DRUG|SB480848 160mg EC Tablet|1 tablet once a day
40768995|NCT00734032|DRUG|SB480848 Placebo Tablet|1 tablet once a day
40768996|NCT01208766|DRUG|Bortezomib, Melphalan, Prednisone (VMP)|"* Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11,22,25,29,32~* Melphalan _ 9 mg/m² _ p.o. _ days 1-4~* Prednisone _ 60 mg/m² _ p.o. _ days 1-4"
40768997|NCT01208766|DRUG|1 or 2 cycle(s) HDM (High Dose Melphalan)|"- Melphalan _ 100 mg/m² _ i.v. rapid infusion _ -3, -2\*~\*Patients with renal insufficiency 100 mg/m2 only at day -3~If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR."
40768998|NCT01208766|DRUG|2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)|"* Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11~* Lenalidomide _ 25 mg _ p.o. _ days 1-21~* Dexamethasone _ 20 mg _ p.o. _ days 1,2,4,5,8,9,11,12"
40768999|NCT03563079|OTHER|Instrument Assisted Soft Tissue Mobilization|Soft Tissue Mobilization
40769000|NCT03563079|OTHER|Manual Myofascial Release|Myofascial Release Technique
40769001|NCT05148338|OTHER|Comprehensive risk factor treatment|"1. Apnea screening with Home Sleep Apnea Test. Referral to sleep physician if apnea-hypopnea index (AHI) is greater than 5~2. Weight management counseling by dietician if body mass index (BMI) is above 27 kg/m2~3. Physical activity program under supervision of physiotherapist at a specialized cardiac rehabilitation centre if BMI is over 27 or if there are complaints during exercise~4. Smoking cessation at specialized outpatient clinic~5. Blood pressure control, lipid management, glycaemic control, alcohol intake reduction by specialized AF nurse~6. Motivation and education through a digital health platform"
40769002|NCT05148338|OTHER|Standard of care|Standard usual care: Treatment by cardiologist conform existing guidelines
40769003|NCT05703763|DIAGNOSTIC_TEST|Applanation tonometry|"Applanation tonometry will be used to measure arterial stiffness in these segments, bilaterally:~* Superficial temporal artery to frontal temporal artery~* Common carotid artery to frontal temporal artery"
40769004|NCT05703763|DIAGNOSTIC_TEST|Standardized GCA assessment|Clinical assessment, blood test review, high-resolution temporal artery ultrasound using a 24mHz probe.
40769005|NCT01080235|OTHER|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
40769006|NCT01080235|OTHER|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
40769007|NCT00583154|DRUG|BLI-801|Dose 1
41139034|NCT06506409|OTHER|Otago Based Structured Exercise|Exercises will be done 2 days a week for 8 weeks and last approximately 30 minutes. In general, if individuals can perform 2 sets of 10 repetitions at a difficulty level with quality, they can move on to a higher difficulty level. It consists of warm-up, balance and strengthening exercises. It was developed to increase balance.
41297587|NCT02371733|OTHER|Alternative upper extremity exercises|"Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
41297588|NCT00781781|DRUG|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
40769008|NCT00583154|DRUG|BLI-801|Dose 2
40769009|NCT00583154|DRUG|BLI-801|Dose 3
40769010|NCT00583154|DRUG|BLI-801|Dose 4
40769011|NCT04923672|BEHAVIORAL|Moderate continuous exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of continuous moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
40769012|NCT04923672|BEHAVIORAL|High intensity interval exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
41297589|NCT04962321|BEHAVIORAL|Wellness Education|Psychoeducation on relationships between mood, anxiety, eating, and exercise behaviors. One one-hour session each week for 8 weeks.
41297590|NCT04389476|OTHER|Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)|"Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors."
41297591|NCT01782183|DEVICE|Thermal camera by Flir -HM series.|The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
40769013|NCT05884528|BIOLOGICAL|CC BoNT/A|Complex-containing BotulinumtoxinA (BoNT/A) formulations
40769014|NCT05884528|BIOLOGICAL|CF BoNT/A|Complex-free BotulinumtoxinA (BoNT/A) formulation
40769015|NCT05884528|BIOLOGICAL|CF to CC BoNT/A|Switch from complex-free to complex-containing BoNT/A formulations
40769016|NCT05884528|BIOLOGICAL|CC to CF BoNT/A|Switch from complex-containing to complex-free BoNT/A formulations
40769017|NCT06522997|DRUG|BAY3283142|Tablet, intake orally once daily
40769018|NCT06522997|DRUG|Placebo|Matching with BAY3283142
40769019|NCT05668741|DRUG|VX-522 mRNA therapy|Oral inhalation using nebulizer.
40769020|NCT05668741|DRUG|IVA|Tablet for oral administration.
40769021|NCT01163942|DRUG|G-CSF|Yes/no addition of G-CSF
41297592|NCT03872583|OTHER|Understanding MRI in MS (website)|Access to an innovative, interactive and evidence-based online education tool about MRI in multiple sclerosis.
41297593|NCT03872583|OTHER|Control website|Access to a specifically designed control website containing information on MRI in MS freely available on the websites of major European MS self-help organizations.
41297594|NCT06332144|BEHAVIORAL|Structural vs. Random sequences of stimuli|Participants will see or listen to sequences of sounds and images either in a structured condition or a random condition.
41297595|NCT06332144|BEHAVIORAL|Intact vs. Degraded speech|"Participants will listen to an audiobook Alice in Wonderland in the MRI scanner. The speech is either intact or degraded."
41297596|NCT06332144|BEHAVIORAL|Repeating 5-syllable nonwords or 2-syllable nonwords|Participants will listen to nonwords (either 5-syllable or 2-syllable) and then repeat them as accurately as possible in the MRI scanner.
41297597|NCT06332144|BEHAVIORAL|Recall letter or syllable strings that either contain highly frequent bigram/trigram items or infrequent items according to English Corpus data.|Participants will read (orthographic serial recall) or listen to (phonological serial recall) strings.
40769022|NCT01163942|DRUG|Early retreatment with ATG|Yes/no early retreatment with ATG
40769023|NCT05002309|BEHAVIORAL|Cognitive-Behavioural Therapy|"20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly homework will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials."
40769024|NCT05002309|DRUG|Antidepressant medication|The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
40769025|NCT04905641|PROCEDURE|Bilateral intermediate cervical plexus block|Bilateral intermediate cervical plexus block was performed under ultrasound guidance.
40769026|NCT06570070|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
41297598|NCT05465733|DRUG|Envafolimab;Pemetrexed|single agent, 300mg Q3W IH until disease progressed,The duration of treatment with Envafolimab should not exceed 2 years.
41297599|NCT01442129|BIOLOGICAL|MPC Intramyocardial injection|Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
41297600|NCT01442129|BIOLOGICAL|Control Solution|Injection of control solution during the LVAD implantation.
40971402|NCT02834507|DRUG|Placebo|Matching placebo capsules
41297601|NCT04341844|DRUG|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
41297602|NCT04341844|DRUG|Placebo|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
41297603|NCT06309810|RADIATION|Radiotherapy|"The treatment will be administered with a TrueBeam™ (Varian Medical Systems, Palo Alto, CA, USA) linac, equipped with a Millenium 120-leaves MLC.~The target will be represented by 5 mm of the specific spinal nerve responsible for the spams. A lateral~1 mm margin will be added to the target to generate the corresponding planning treatment volume (PTV). The prescribed dose will be 45-60 Gy in a single fraction. The treatment dose will be chosen based on patients' general condition, and possibility to respect the dose limits (constraints) for the organs at risk (OARs)."
41297604|NCT05318625|DEVICE|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
40769027|NCT06570070|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
40769028|NCT06570070|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
40769029|NCT06570070|BEHAVIORAL|AI-powered chatbot support|Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
41297605|NCT04516486|OTHER|retrospective metagenomics on clinical samples collected during hospitalization|Massive sequencing of respiratory samples (restrospective)
41297606|NCT04806932|PROCEDURE|The modified approach|The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
41297607|NCT04806932|PROCEDURE|The conventional approach|The conventional approach
41466507|NCT02408120|DRUG|Insulin aspart|"Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is \>180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
40769030|NCT06570070|BEHAVIORAL|Counselor individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
41297608|NCT03792269|DRUG|Irinotecan|intraperitoneal
41297609|NCT03792269|DRUG|Oxaliplatin|intravenous
41297610|NCT03792269|DRUG|Capecitabine|
41297611|NCT03172546|GENETIC|PK-PD genetic polymorphisms|PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
40769031|NCT03508674|DEVICE|Levita Magnetic Surgical System|use of surgical tool
41297612|NCT01734187|DIETARY_SUPPLEMENT|Fermented Cinnamon Vine Powder|Fermented Cinnamon Vine Powder (30g/day)
41297613|NCT01734187|DIETARY_SUPPLEMENT|Placebo|Placebo (30g/day)
41297614|NCT05140876|BEHAVIORAL|START mHealth Intervention|The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.
40769032|NCT05548114|PROCEDURE|EUS-guided gastrojejunostomy|AXIOS lumen-apposing metal stent will be used to create a gastrojejunostomy under EUS guidance.
40971403|NCT02834507|DRUG|BIA 3-202|Capsules containing nebicapone 75 mg or 150 mg
41297615|NCT00962065|DRUG|LX4211 Low Dose|A low dose of LX4211; daily oral intake for 28 days
41297616|NCT00962065|DRUG|LX4211 High Dose|A high dose of LX4211; daily oral intake for 28 days
41297617|NCT00962065|DRUG|Placebo|Matching placebo dosing with daily oral intake for 28 days
41297618|NCT01441687|OTHER|laboratory biomarker analysis|Correlative studies
41297619|NCT01441687|PROCEDURE|transrectal prostate biopsy|Undergo prostate biopsy
41297620|NCT04684485|DRUG|Placebo|Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
41297621|NCT04684485|DRUG|SCD-044_Dose 1|SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
40971404|NCT02834507|DRUG|Comtan®|Capsules containing entacapone 200 mg
40971405|NCT02834507|DRUG|Sinemet®|levodopa/carbidopa (Sinemet®) dose patient used to take
40971406|NCT00171730|DRUG|Pasireotide|
40971407|NCT00727025|DEVICE|wound closure device (Steri-Strip™)|wound closure with steri-strip S
40971408|NCT00673569|DRUG|erlotinib hydrochloride|
40971409|NCT00673569|GENETIC|gene expression analysis|
40971410|NCT00673569|GENETIC|protein expression analysis|
41297622|NCT04684485|DRUG|SCD-044_Dose 2|SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
40769033|NCT05548114|PROCEDURE|Surgical gastrojejunostomy|A surgical gastrojejunostomy will be created via laparoscopic (preferred) or open technique, as clinically appropriate.
40769034|NCT05889091|OTHER|HRQOL instruments|These instruments include Face Q for Appearance, Eating \& drinking, Swallowing, and Saliva (patient-reported); the Neck Dissection Impairment Index (patient-reported); the Long-term ENT-Subjective/Objective/Management/Analysis (LENT-SOMA) for skin-subcutaneous tissue, muscle-soft tissue, mucosa - oral and pharyngeal, salivary gland, and mandible (patient- and clinician-reported); modified barium swallow study (8-point penetration aspiration scale).
40971411|NCT00673569|OTHER|immunoenzyme technique|
40971412|NCT00673569|OTHER|immunologic technique|
40971413|NCT00673569|OTHER|laboratory biomarker analysis|
40971414|NCT00673569|PROCEDURE|needle biopsy|
41139035|NCT06506409|OTHER|No intervention|A training presentation based on the guidelines and individuals' needs will be developed for participants in the control group. The presentation will include an infographic developed with the CANVA program, a test created with Google Forms, and a summary video developed with the Powtoon program. The created presentation will be presented online to individuals in the control group, and the participants will be followed by phone once a week for 8 weeks. The topics of the training will be: What is Osteoporosis, Osteoporosis Prevalence, Findings and Risk Factors, Diagnosis of Osteoporosis, Osteoporosis Prevention and Nutrition, Osteoporosis and Exercise, Preventing Falls.
41139036|NCT01198314|PROCEDURE|immunosuppression withdrawal|tapering off immunosuppressant
41139037|NCT01198314|PROCEDURE|continue of taking immunosuppressant|maintain immunosuppression
41139038|NCT06358599|DRUG|Cisplatin|Neoadjuvant cisplatin-containing combination chemotherapy was defined as the receipt of multiagent systemic chemotherapy initiated within 6 months prior to the date of radical cystectomy
41139039|NCT02514824|DRUG|MLN0128|Investigational mTOR kinase inhibitor
41139040|NCT05174026|OTHER|Fludeoxyglucose F-18|Given IV
41139041|NCT05174026|PROCEDURE|Magnetic Resonance Imaging|Undergo 18F-FDG PET-MRI
41297623|NCT04684485|DRUG|SCD-044_Dose 3|SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
41297624|NCT01278680|BEHAVIORAL|Incentives for walkstation usage|The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
41297625|NCT01818167|DRUG|10% Benzoyl Peroxide Topical Body Wash|
41297626|NCT01818167|DRUG|Provodine Topical Cream|
41297627|NCT02551367|DRUG|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
41139042|NCT05174026|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET-MRI
41297628|NCT02551367|DRUG|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
41297629|NCT02551367|DRUG|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
41297630|NCT03704792|DEVICE|FibroScan 530 Compact|The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
41139043|NCT03611556|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
41139044|NCT03611556|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
41139045|NCT03611556|DRUG|Gemcitabine|Participants will receive IV infusion of gemcitabine as stated in arm description.
41297631|NCT02936505|DRUG|Cyclosporine|"Cyclosporin A (Sandimmun Neoral® or similar):~* Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.~* Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; \>12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily."
41297632|NCT02936505|DRUG|Mycophenolate mofetil (MMF)|"MMF target dose: 2000 mg/day (1gx2):~o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly."
40769035|NCT05889091|OTHER|LENT SOMA instrument|LENT SOMA instrument will also be provided to summarize objective quality-of-life-related measures recorded at 12 months postoperatively, including interincisor distance (mm); neck range of motion measured in degrees of flexion, extension, lateral flexion, and rotation to both sides; and shoulder range of motion, measured in degrees of abduction.
40769036|NCT00141011|DRUG|Ancrod (Viprinex)|0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
40769037|NCT00141011|DRUG|Placebo|0.6 mL/kg/hr
40769038|NCT06293053|DRUG|Dupilumab|"Pharmaceutical form: Injection solution~Route of administration: Subcutaneous"
40769039|NCT06143839|DRUG|Vyxeos liposomal|Standard of care JZP351 administered intravenously over 90 minutes.
40769040|NCT06533059|DRUG|ALTA2618|Oral ALTA2618 tablets will be administered at protocol-defined dose
40971415|NCT01502098|PROCEDURE|Postoperative early passive motion|Shoulder exercises starting on the first postoperative day
40971416|NCT01502098|OTHER|Sling|Sling for 4 weeks
40769041|NCT06317597|DRUG|Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfate oral solution to 500ml and intake 12-14 hours before colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
40769042|NCT06317597|DRUG|Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfates oral solution to 500ml and intake 16-18 hours before the colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
40769043|NCT02887794|OTHER|Clinical and psychoacoustic measures|Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
40769044|NCT06625528|BIOLOGICAL|open flap debridement|does lyophilized platelet rich fibrin combined with open flap debridement or combination of open flap debridement, lyophilized platelet rich fibrin and nano-crystalline hydroxyapatite bone substitute can add benefits to open flap debridement alone or not
40769045|NCT05962489|OTHER|Clinically optimized deep brain stimulation|Participants will have DBS implanted as standard-of-care. We will be examining the effects of their regular clinical stimulation settings versus no stimulation.
40769046|NCT05287451|OTHER|RIsk-Reducing Salpingectomy (RRS)|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
40769047|NCT05287451|OTHER|Risk-Reducing Oophorectomy-RRO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
40769048|NCT05287451|OTHER|Risk-Reducing Salpingo-Oophorectomy-RRSO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
41297633|NCT02936505|DRUG|Rabbit Anti thymocyte globulin|Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).
41297634|NCT02936505|DRUG|Corticosteroids|"Corticosteroids:~* Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~* From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg \> 6 months."
41297635|NCT02936505|DRUG|Tacrolimus|"* Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.~* Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, \>12 months 6-8 ng/ml. Tacrolimus will be administered once daily."
41297636|NCT06058780|PROCEDURE|Implantable Collamer Lens (ICL)|Phakic intraocular lenses (pIOL) have proven to be a great alternative to corneal refractive surgery in certain situations. They offer several advantages over corneal techniques, such as being suitable for high myopes and causing relatively fewer higher-order aberrations
41297637|NCT06058780|PROCEDURE|Implantable Intraocular Lens (IPCL)|The IPCL offers a distinct economic advantage as the cost of the IPCL implant is only 2. times that of the ICL implant. Moreover, the IPCL can correct higher degrees of myopia, up to -30. D, compared to the maximum correction of -18. D provided by the ICL.
41297638|NCT02237495|DRUG|dexmedetomidine|dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
41297639|NCT02237495|DRUG|placebo|The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
41458427|NCT05244928|OTHER|"The team training program Team Strategies and Tools to Enhance Performance and Patient Safety®"|"Team Strategies and Tools to Enhance Performance and Patient Safety® is a team training program consisting of an evidence-based set of tools designed to develop teamwork skills with the goal of improving quality in healthcare services and providing safer patient care. In this study, selected tools from the Team Strategies and Tools to Enhance Performance and Patient Safety® curriculum have been chosen for implementation over a 4-month period together with a general emphasis on the key principles: communication, leadership, situation monitoring and mutual support. A full day introduction will be held to mark the start of the intervention and each successive month will have a focus on a single key principle with associated tools.~A stepped wedge cluster randomized controlled trial provides the framework for the intervention of the team training program in two clusters including seven ambulance stations, in total."
40769049|NCT03272321|DRUG|Oxytocin|Syntocinon nasal spray
40769050|NCT03272321|DRUG|Placebo|Placebo nasal spray
41139046|NCT03611556|DRUG|Nab-paclitaxel|Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
41139047|NCT03611556|DRUG|Oxaliplatin|Participants will receive IV infusion of oxaliplatin as stated in arm description.
41139048|NCT03611556|DRUG|Folinic acid|Participants will receive IV infusion of folinic acid as stated in arm description.
41139049|NCT03611556|DRUG|5-FU|Participants will receive IV infusion of 5-FU as stated in arm description.
40971417|NCT02397785|DEVICE|ApexM|Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.
40971418|NCT02397785|DEVICE|Sham Device|Identical to ApexM but will not deliver any electrical stimulation
40971419|NCT00102726|DRUG|SB497115|SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
41297640|NCT05638386|PROCEDURE|Bone plug|The investigational treatment is the use of a bone plug in the two drill-holes in the tibia, made by two pins for securing the tibial array to the bone. The pins that are used for this, are 4.0mm wide. The bone plug that is used to fill the drill-holes of tibia, is obtained from the bone that is removed during the operation to make place for the new prosthesis. A piece as wide as the drill-hole is cut off the recessed bone and put into this hole. After this, the wound is closed using surgical staples.
41297641|NCT05727566|OTHER|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
41297642|NCT00328263|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285 and Lactobacillus casei|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
41297643|NCT00328263|DIETARY_SUPPLEMENT|placebo|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
40971420|NCT00102726|OTHER|Placebo|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
41297644|NCT02481960|PROCEDURE|CM-BC2 Irinotecan drug-eluting bead|
41297645|NCT03484000|BEHAVIORAL|Online Mindfulness Based Cancer Recovery (MBCR)|MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement
41297646|NCT05092815|DRUG|HLX208|HLX208 450mg bid po
41297647|NCT02826044|DRUG|SP2086|The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
41297648|NCT01002625|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
41297649|NCT01002625|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
41297650|NCT04002440|COMBINATION_PRODUCT|AMIA with SHARESOURCE Connectivity Platform|The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.
41297651|NCT04002440|DEVICE|HomeChoice PRO|Usual care
41297652|NCT01746992|DRUG|Cyclophosphamide 750mg/m2|day 1 in both arms
41297653|NCT01746992|DRUG|Vincristine 1.4mg/m2|day 1
41297654|NCT01746992|DRUG|Doxorubicin 50mg/m2|day 1
41297655|NCT01746992|DRUG|prednisone 60mg/m2|day1-day5
41297656|NCT01746992|DRUG|ifosfamide 2000mg/m2|day 22-day 24
41297657|NCT01746992|DRUG|pirarubicin 50mg/m2|day 1
40971421|NCT02181413|DRUG|Ixazomib Citrate|Ixazomib citrate capsules
40971422|NCT02181413|DRUG|Placebo|Ixazomib citrate placebo-matching capsules
41297658|NCT01746992|DRUG|pirarubicin 25mg/m2|day 22
41297659|NCT01746992|DRUG|Etoposide phosphate 100mg/m2|day 22-day 24
41297660|NCT01746992|DRUG|methotrexate 1500mg/m2|day 43
41297661|NCT06115577|DIAGNOSTIC_TEST|endometrial tissue and peripheral blood mononuclear cells receptivity|Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.
41297662|NCT06121947|PROCEDURE|The DBS electrodes are implanted into MLR.|MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy,exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
41297663|NCT06121947|PROCEDURE|The electrodes are implanted into the patient's vagus nerve|A pre-surgery assessment was performed. Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
41297664|NCT04077203|BEHAVIORAL|Biofeedback / No biofeedback|Biofeedback / No biofeedback
41297665|NCT04742257|DEVICE|MyoRegulator® device|Trans-spinal DCS paired with peripheral DCS
41297666|NCT03891069|DEVICE|AHA Exergame System|The AHA Exergame System consists of a mobile computing platform running a set of parameterizable exergames purposely designed for elderly fitness training. The platform is equipped with a 1000 lumens video projector capable of creating a 2.05m by 1.16m floor projection display and a Kinect V2 sensor to serve as game controller. The AHA exercise-based computer games have been designed for and tested with elderly people and were adapted for the functional limitations of PD patients. The system includes five different games that aim to train patients motor ability, cardiorespiratory and muscular strength.
41297667|NCT01893723|PROCEDURE|ANI guided remifentanil|remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
41297668|NCT01893723|PROCEDURE|ANI blind arm|remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
40769051|NCT04277130|BEHAVIORAL|Intervention with active video games|Participants in intervention group were paired up by their teachers. Each participant had a classmate playing with him/her, and the waiting time is minimal because Xbox 360 Kinect allowed double play mode. The intervention group was provided with an AVG, the Xbox 360 Kinect technology (Kinect Sports Seasons I \& II, including bowling, soccer, boxing, track and field, table tennis, beach volleyball, golf, tennis). The AVG intervention consisted of two 30-min sessions per week, for a total of 12 weeks. Participants either played in PE classes and/or recess. They had no other specific routing of activities but straight played the AVG during the intervention. They could free to choose games they like in the Xbox 360. The AVGs of Xbox 360 chosen was of moderate to vigorous intensity (3-6 METs) and no matter what games they chose, their PA level would be between moderate and vigorous intensity.
40971423|NCT00111345|DRUG|Anthracyclines|3x12 mg/qm
41297669|NCT02797106|OTHER|Practice survey of health professionals|Survey of the practices and opinions of health care professionals to describe care pathways, assessment and treatment of drooling in children with cerebral palsy
41297670|NCT03855306|DRUG|Glibesyn|1 tablet contains 5 mg Glibenclamide
41297671|NCT03855306|DRUG|Daonil|1 tablet contains 5 mg Glibenclamide
40971424|NCT00111345|DRUG|liposomal daunorubicin|3x80 mg/qm
41297672|NCT05055661|OTHER|Pharmaceutical Teleconsultation|The pharmacist will apply the teleconsultation according to the elaborated workflows and will follow in seven steps: scheduling the teleconsultation; pre-consultation, in which the pharmacist will make a checklist of the adequacy of the teleconsultation environment; presentation of the professional and the objectives of the teleconsultation to the patient; search for information about the patient and their pharmacotherapy; identification of problems related to pharmacotherapy; elaboration of a care plan and appointment for the re-consultation.
41297673|NCT02605733|DEVICE|EEG|amplitude integrated electroencephalography
41297674|NCT02605733|DEVICE|NIRS|regional tissue oximetry
41297675|NCT01137331|DRUG|K301|Liquid- applied once daily prior to bed
41297676|NCT01137331|DRUG|Placebo|Liquid- applied once daily prior to bed
41297677|NCT02952066|PROCEDURE|Bronchial biopsy|Bronchial tissue taken during biopsy
41297678|NCT01492114|DIETARY_SUPPLEMENT|Resveratrol|"Subjects in the group resvetarol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
40971425|NCT00111345|DRUG|2-CDA|2x6 mg/qm
40971426|NCT00111345|DRUG|AI|AI
40971427|NCT00220870|BEHAVIORAL|Decision aid|
40971428|NCT04226001|OTHER|Quality of life questionnaire|Quality of life questionnaire
41297679|NCT01492114|DIETARY_SUPPLEMENT|resveratrol|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
41297680|NCT01800227|DRUG|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
41297681|NCT02089386|DRUG|Tamoxifen|
41297682|NCT02089386|PROCEDURE|Endoscopy|
40769052|NCT06047470|BEHAVIORAL|Kangaroo Care|Lactating parents will participate in kangaroo care (holding an infant upright, directly on the chest with skin-to-skin contact) prior to expressing a breast milk sample.
40769053|NCT06047470|BEHAVIORAL|No Kangaroo Care|Lactating parents will provide a breast milk sample after having no contact with their infant for at least 6 hours.
41297683|NCT01465737|OTHER|Histologic types|evaluate survival among different histologic types
41297684|NCT04053179|DEVICE|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
41297685|NCT06318546|DRUG|Dexmedetomidine Injection [Precedex],,,|patients will receive 0.5ml (10 µg) Dexmedetomidine as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
41458428|NCT03506087|BEHAVIORAL|Advance care planning coaching session.|A 60-minute in-person coaching session. The advance care planning coach, trained in motivational interviewing, will use a flexible script and checklist to assess the participant's readiness to engage in advance care planning and guide the participant forward in the process, proceeding at the participant's pace. Some participants may complete advance directives while others will not get that far. Some participants may receive a follow-up session 2-4 weeks later. Typically this 20 to 30-minute conversation will be by phone, but it may be conducted at the clinic as indicated for the participant.
41458429|NCT03506087|BEHAVIORAL|Printed advance care planning materials|Participants are provided with a folder containing an advance care planning guide developed by the Coalition for the Supportive Care of Kidney Patients for persons with Chronic Kidney Disease. The patient folder also contains the advance directive form used by the clinic that is appropriate to the state.
40769054|NCT06352970|OTHER|TB infection|Outcomes will be compared with regard to result of interferon-gamma release assay test for TB infection
40769055|NCT03622606|DIAGNOSTIC_TEST|Right Language screening test (R-LAST)|Validation of the Right Language screening test in acute and subacute phase of right stroke
41458430|NCT03784274|BEHAVIORAL|Stakeholder analysis|"• INCLUSION CRITERIA FOR NET MAPPING ACTIVITIES: Those respondents who are directly involved or knowledgeable about pneumonia related policy environment in the country/province.~* Respondents who consent to participate in the study.~* Respondents belonging to Sindh, Punjab, Baluchistan, KPK and Islamabad.~EXCLUSION CRITERIA:~• Respondents belonging to Gilgit-Baltistan (GB), Azad Jammu and Kashmir (AJK) and Federally Administered Tribal Area (FATA). Reasons of their exclusion are newly developed governance system (GB), separate governance (AJK) and security threat (FATA)."
41458431|NCT05540522|BIOLOGICAL|Quadrivalent influenza modRNA vaccine|Quadrivalent influenza modRNA vaccine (single dose)
41458432|NCT05540522|BIOLOGICAL|Quadrivalent influenza vaccine|Licensed quadrivalent influenza vaccine (single dose)
40769056|NCT05509777|DRUG|Mirikizumab|Administered IV or SC
40769057|NCT03985527|DEVICE|Transvenous nerve stimulation|Acute transvenous nerve stimulation during a commercial implant of remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator).
40769058|NCT06526429|PROCEDURE|rapid local ischemic postconditioning|Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
40769059|NCT05405608|DRUG|Ondansetron|hemodynamic stability in orthopedic surgeries
40769060|NCT06626126|OTHER|ApoB-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets
40769061|NCT06626126|OTHER|LDL-C-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.
40769062|NCT03376386|RADIATION|Adaptive dose-Escalated multi-modality image-guided radiotherapy|FDG-PET/CT-scan will be used twice during radiotherapy for a mild dose-escalation to the less-responding parts of the tumor. By adapting the radiotherapy plan, these areas will receive 74-78 Gy.
41139050|NCT00602732|BEHAVIORAL|The Reach Out for a Safe Environment (ROSE) program|Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.
41297686|NCT06318546|DRUG|Fentanyl|will be given 0.5 ml of one ampoule (2ml) of 100µg fentanyl (Fentanyl Hameln® 0.1mg/2ml - Sunny pharm) equivalent to 25 µg fentanyl as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
41297687|NCT04436822|DEVICE|Continuous Glucose Monitoring|CGM and frequent sample testing
40769063|NCT05172258|PROCEDURE|Biopsy|Undergo biopsy
40769064|NCT05172258|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40769065|NCT05172258|PROCEDURE|Computed Tomography|Undergo CT
40769066|NCT05172258|DRUG|Ipatasertib|Given PO
40769067|NCT05172258|BIOLOGICAL|Pembrolizumab|Given IV
40769068|NCT00271180|DEVICE|Device|
40769069|NCT06644768|DRUG|valemetostat tosylate|Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
40769070|NCT06644768|DRUG|pembrolizumab|One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
40769071|NCT00583583|DEVICE|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
40769072|NCT04892277|BIOLOGICAL|Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563|Given IV
40769073|NCT04892277|DRUG|Bendamustine|Given IV
40769074|NCT04892277|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
40971429|NCT04261348|OTHER|No intervention|There is no intervention
41297688|NCT05438485|OTHER|Registry|Observational (Registry)
41297689|NCT01612793|DEVICE|AlphaCore Device|multiple stimulation treatments per day for duration of hospitalization
41458433|NCT01710670|DRUG|Brivaracetam|"Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1."
41297690|NCT01256619|DRUG|Marvelon|The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest
41297691|NCT00515008|BEHAVIORAL|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
41297692|NCT00515008|BEHAVIORAL|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
40769075|NCT04892277|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40769076|NCT04892277|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41297693|NCT04631471|DRUG|Ibudilast|Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
41297694|NCT04631471|PROCEDURE|Cervical decompressive surgery|Surgical decompression of degenerate cervical myelopathy
41297695|NCT04631471|DRUG|Matching placebo|Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
41458434|NCT01710670|OTHER|Ethanol|"Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L."
40769077|NCT04892277|PROCEDURE|Computed Tomography|Undergo CT
40769078|NCT04892277|DRUG|Cyclophosphamide|Given IV
40769079|NCT04892277|DRUG|Fludarabine|Given IV
40769080|NCT04892277|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40769081|NCT04892277|PROCEDURE|Positron Emission Tomography|Undergo CT/PET
40769082|NCT06593522|DRUG|AMG 193|Film-coated tablet
40769083|NCT05849766|DRUG|Dapagliflozin Farxiga®|Dapagliflozin 10 mg once daily
40769084|NCT05849766|DRUG|Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®|Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily
40769085|NCT05634200|PROCEDURE|Bronchoscopy|During bronchoscopy endobronchial biopsy, transbronchial biopsy, transbronchial needle aspiration, bronchial washing, bronchoalveolar lavage, EBUS-TBNA and EUS-B-FNA may be performed
40769086|NCT02299999|DRUG|AZD2014|Target: m-TOR
40769087|NCT02299999|DRUG|AZD4547|Target: EGFR
40769088|NCT02299999|DRUG|AZD5363|Target: AKT
40769089|NCT02299999|DRUG|AZD8931|Target: HER2, EGFR
40769090|NCT02299999|DRUG|Selumetinib|Target: MEK
40769091|NCT02299999|DRUG|Vandetanib|Target: VEGF, EGFR
40769092|NCT02299999|DRUG|Bicalutamide|target: Androgen receptor
40769093|NCT02299999|DRUG|Olaparib|Target: PARP
40769094|NCT02299999|DRUG|Anthracyclines|DNA intercalation
40769095|NCT02299999|DRUG|Taxanes|Target: mitotic tubulin and microtubules
40769096|NCT02299999|DRUG|cyclophosphamide|Alkylating agents
40769097|NCT02299999|DRUG|DNA intercalators|DNA intercalators
40769098|NCT02299999|DRUG|Methotrexate|DNA intercalators
40769099|NCT02299999|DRUG|vinca alkaloids|Target: mitotic tubulin and microtubules
40769100|NCT02299999|DRUG|Platinum based chemotherapies|Platinum based chemotherapies
40769101|NCT02299999|DRUG|Bevacizumab|Target: VEGF
40769102|NCT02299999|DRUG|Mitomycin C|Alkylating agents
40769103|NCT02299999|DRUG|Eribulin|Microtubule modulator
40769104|NCT02299999|DRUG|MEDI4736|Target: PD-L1
40971430|NCT01804621|BEHAVIORAL|Health Newsletter|Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
40769109|NCT06445777|BEHAVIORAL|Mental Health Prevention and Promotion|The Inner Lion Programme is made up of 12 interactive workshops which are based on four key pillars: building confidence by identifying strengths and personal qualities; improving emotional intelligence and self-awareness; establishing adaptive coping strategies and channels of support; and boosting resilience. Professionally created by Child Psychologist Stijn de Leeuw together with an advisory team of psychologists from the Netherlands and South Africa, the programme follows a carefully structured and curated prevention and promotion mental health curriculum with games, crafting activities, psycho-educational stories, dance, movement, and breathing exercises. Workshops are led by local role models (a male-female duo) with lived experience trained to be mental health coaches.
40769110|NCT04945837|OTHER|self administered questionnaire|longitunidal descriptive study
40769111|NCT05697380|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted.
40971431|NCT05503615|OTHER|Observational|No application will be made to the control group.
40971432|NCT05503615|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
41139051|NCT00602732|BEHAVIORAL|Enhanced care as usual (ECU)|Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
41139052|NCT02994498|DRUG|DCB-BO1301|1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
41139053|NCT05054556|DIAGNOSTIC_TEST|Labaratory tests|"Estimation of serum levels of the following parameters:~galectin-3, proBNP, TNI, proGRP, CA15-3, CK, creatinine, urea, crp, pct, leucozytes"
41139054|NCT06412809|OTHER|Combined Land- and Water-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented both on land and in water. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~Land-based exercise:~1. Plank exercise~2. Russian twist~3. Push-up~4. Goblet squat~5. Kettle bell swing~Water-based exercise:~1. Flutter kicks~2. Isometric core crunches~3. Jump lunges~4. Kicks~5. Resisted knee flexion"
41139055|NCT06412809|OTHER|Land-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented on land. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~1. Plank exercise~2. Russian twist~3. Dead bug~4. Push-up~5. Goblet squat~6. Nordic hamstring curl~7. Lunges~8. Kettle bell swing~9. Calf raises~10. Bird dog"
41139056|NCT06412809|OTHER|Water-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented in the water. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~1. Core pulls~2. Flutter kicks~3. Water cycling~4. Isometric core crunches~5. Seated push-up~6. Jump squats~7. Jump lunges~8. Kicks~9. Ankle jumps~10. Resisted knee flexion"
41139057|NCT01052714|BEHAVIORAL|Lifestyle Balance|Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
41139058|NCT00879827|BIOLOGICAL|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
41139059|NCT00879827|BIOLOGICAL|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
41139060|NCT02489357|PROCEDURE|Cryosurgery|Undergo whole gland cryoablation
41139061|NCT02489357|DRUG|Degarelix|Given SC
41139062|NCT02489357|OTHER|Laboratory Biomarker Analysis|Correlative studies
41139063|NCT02489357|BIOLOGICAL|Pembrolizumab|Given IV
41139064|NCT01378884|DRUG|Domperidone|Patient to receive treatment with Domperidone
41139065|NCT04501744|DRUG|Cohort 1 of M701|Patients in Cohort 1 will receive 4 escalating doses (2, 5, 10 and 25 μg) of M701 on Days 1, 8, 15 and 22. The maintenance dose during extended treatment period is 25 μg.
41139066|NCT04501744|DRUG|Cohort 2 of M701|Patients in Cohort 2 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 25 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
41139067|NCT04501744|DRUG|Cohort 3 of M701|Patients in Cohort 3 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
41139068|NCT04501744|DRUG|Cohort 4 of M701|Patients in Cohort 4 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 200 μg.
41139069|NCT04501744|DRUG|Cohort 5 of M701|Patients in Cohort 5 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 150 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
41139070|NCT04501744|DRUG|Cohort 6 of M701|Patients in Cohort 6 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 200 μg, and the maintenance dose during core treatment period and extended treatment period is 400 μg.
41139071|NCT04501744|DRUG|Cohort 7 of M701|Patients in Cohort 7 will receive a starting doseon Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 250 μg, and the maintenance dose during core treatment period and extended treatment period is 500 μg.
40971433|NCT03633695|DEVICE|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye for use over the lifetime of the patient. The IC-8 IOL implanted in the second eye for use over the lifetime of the patient.
40971434|NCT03633695|DEVICE|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted for lifetime use of the patient.
40971435|NCT02350790|PROCEDURE|Robotic ablation|Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
41139072|NCT03142932|DEVICE|Individualized carbon monoxide (iCO) monitor|a personal monitor for a breath test for carbon monoxide (CO)
41139073|NCT03142932|OTHER|COach2Quit smartphone application|This smartphone application works in conjunction with the iCO monitor
41297696|NCT04215081|DEVICE|Gait training using ExoAtlet exoskeleton|Subjects will learn to use the ExoAtlet II exoskeleton, with the assistance of a trained medical professional, to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
41297697|NCT02818153|OTHER|Self questionnaire for allergic rhinitis control|
40971436|NCT02350790|PROCEDURE|Robotic excision|Robotic excision of endometriosis
40971437|NCT02418598|GENETIC|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10\^11 vg/subject.
40971438|NCT02418598|GENETIC|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10\^11 vg/subject.
40971439|NCT01456247|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
40971440|NCT01456247|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
40971441|NCT01456247|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
41297698|NCT04897503|DRUG|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.
41297699|NCT05633576|DRUG|steroid eye drops|Self-administration of steroid eye drops three times a day for four consecutive weeks.
41297700|NCT05633576|DRUG|Placebo|Self-administration of placebo eye drops three times a day for four consecutive weeks.
41297701|NCT05883267|DEVICE|Virtual reality glasses|"PICO model neo 2 VR glasses"
41458435|NCT01710670|OTHER|Brivaracetam Placebo|In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
41458436|NCT01710670|OTHER|Ethanol Placebo|In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
41139074|NCT03142932|BEHAVIORAL|Cessation counseling|The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
40971442|NCT01456247|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
40971443|NCT01456247|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
40971444|NCT01456247|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
40971445|NCT00002096|DRUG|Zidovudine|
40971446|NCT00002096|DRUG|Didanosine|
40971447|NCT00002096|DRUG|Ganciclovir|
40971448|NCT03308734|BEHAVIORAL|Reduced-Exertion High-Intensity Interval Training|The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
40971449|NCT00871702|GENETIC|CD34-TK75 transduced donor lymphocytes|
40971450|NCT00871702|RADIATION|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
41139075|NCT01480258|BIOLOGICAL|PR5I|DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis \[acellular, component\], hepatitis B \[recombinant DNA\], polio virus \[inactivated\], and Haemophilus influenza type b conjugate vaccine \[adsorbed\]) Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
41139076|NCT01480258|BIOLOGICAL|Rotavirus vaccine|Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
41297702|NCT05883267|DEVICE|Vocal-guided affective imagery|Audio via telephone
41297703|NCT03713723|DEVICE|NICaS bioimpedance system|NICaS is a bioimpedance system focusing on noninvasive assessment and monitoring of cardiovascular, respiratory, and fluid parameters.Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes
41297704|NCT04180436|DRUG|rivaroxaban 20 mg once daily 8 days|Blood samples for the measurement of rivaroxaban PK parameters
41297705|NCT02226510|DRUG|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
41297706|NCT02226510|DRUG|Placebo|Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
41297707|NCT06499545|OTHER|Pressure release|Release of pre-pressure at the latent trigger point of flexor digitorum brevis
41297708|NCT06499545|OTHER|Non emision Laser|Non emision laser in Flexor digitorum brevis latent trigger point
41297709|NCT06298773|OTHER|Spatial analysis of paraffin samples from solid tumors|The intervention involves the collection of tumour samples included in paraffin present in the pathological anatomy archive or requested to external archives for samples older than 2003 and the subsequent multiparametric spatial analysis of the main populations of the microenvironment tumor.
41297710|NCT01346137|DRUG|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
40971451|NCT02396485|OTHER|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
40971452|NCT03641924|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
41139077|NCT01480258|BIOLOGICAL|Prevenar 13™|Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
41297711|NCT01554878|PROCEDURE|knee surgery|Reparative, replacement or regenerative techniques, with or without associated osteotomy.
41297712|NCT04165343|RADIATION|Positron Emission Tomography (PET) on EXPLORER|"Positron Emission Tomography (PET): Your blood sugar level will be checked by a finger stick before the PET scan. A small amount of radioactive tracer (approximately 0.5 teaspoons) will be injected into a vein in your arm before the imaging test. You will be asked to lay on your back on the EXPLORER scanner platform with both of your arms over the head during the duration of the test. A small amount of blood (1 tablespoon) will be collected after the test. This test will last for up to one (1) hour. This is a research test. Although the results may be available it cannot be used for clinical care. If any incidental findings are noted, it will be reported to you."
41297713|NCT04165343|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI will be performed that can measure both the liver stiffness or fibrosis by a method called MR elastography (MRE) and the amount of fat deposited in the liver by MR proton density fat fraction (MR-PDFF). You will be asked to lay on your back on the scanner platform with both of your arms over the head during the duration of the test. MRE and MRI-PDFF are Food and Drugs Administration (FDA) approved tests and the results will be available to you. This test will last up to one (1) hour.
41297714|NCT04165343|DIAGNOSTIC_TEST|Echocardiogram and Electrocardiogram|You will have baseline echocardiogram images and electrocardiogram (ECG) taken and will be asked to walk on a treadmill, which will increase in elevation and speed every 3 minutes until you can go no longer. This usually takes 9 to 12 minutes. Immediately after exercise, echocardiogram images and ECG will be taken again. The total time you will be in the stress lab including prep time and recovery is about 60 minutes. Wear comfortable or exercise clothing and walking/running shoes. You will be asked to not eat or drink (except for water) for 4 hours prior to the time of your test. Please drink water the day of the test so you are not dehydrated. This is an FDA approved test and the results will be available to you.
41297715|NCT04165343|DIAGNOSTIC_TEST|Blood test|We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
41297716|NCT03454048|DRUG|Piperaquine (low dose)|subcurative regimen (480 mg)
41297717|NCT03454048|DRUG|Piperaquine (high dose)|Curative regimen (960mg)
41139078|NCT01480258|BIOLOGICAL|INFANRIX™ hexa|Combined Diphtheria-Tetanus-acellular Pertussis \[DTaP\], Hepatitis B \[HepB\], Poliovirus \[IPV\] and Haemophilus influenzae type b \[Hib\] Vaccine 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB). Prior to administration, the vaccine must be reconstituted by adding the liquid DTaP-HepB-IPV component to the vial containing the Hib pellet.
41139079|NCT01114685|DIETARY_SUPPLEMENT|AlgaeCal-1|Daily consumption of 7 capsules containing bone health ingredients
41139080|NCT01114685|DIETARY_SUPPLEMENT|AlgaeCal-2|Taking 7 capsules a day for six months
41139081|NCT00814749|PROCEDURE|midureteral sling|midureteral sling
41139082|NCT00814749|OTHER|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
41139083|NCT05813990|OTHER|recostructive ear surgery|recostructive ear surgery in pediatric population
41139084|NCT03275467|OTHER|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
41139085|NCT01818999|DRUG|IXABEPILONE|injection
41139086|NCT01818999|RADIATION|STEREOTACTIC BODY RADIATION THERAPY|SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
40971453|NCT04658277|DRUG|Clarithromycin|Patients in the intervention arm will take Clarithromycin 250mg daily.
40971454|NCT04658277|OTHER|Usual care|Patients will receive usual medical care
40971455|NCT05471778|BEHAVIORAL|Watching comedy movie|A 25-minute comedy film created by the researchers was watched.
41139087|NCT00709605|DRUG|VRC-HIVADV014-00-VP|
41139088|NCT00230269|PROCEDURE|PET-CT|
41139089|NCT00986505|DRUG|Lidocaine|Intravenous lidocaine once a week
41139090|NCT00798863|PROCEDURE|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
41139091|NCT03564106|DRUG|intraarticular radiofrequency + intraarticular methylprednisolone|intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)
41139092|NCT03564106|DRUG|intraarticular methylprednisolone|intraarticular methylprednisolone (30 mg)
41139093|NCT03492853|GENETIC|DNA extraction and sequencing|DNA extraction from peripheral blood and KASP sequencing
41297718|NCT03454048|DRUG|Sulfadoxine pyrimethamine|Curative regimen (1000mg/50mg)
41297719|NCT03454048|DRUG|Atovaquone Proguanil|Curative regimen (1000/400 mg, for 3 days)
40971456|NCT05471778|BEHAVIORAL|listening to music|25 minutes of music created by the researchers was played.
40769113|NCT04527432|OTHER|Survey|Survey at baseline, 6 and 12 months
40769114|NCT04527432|DIAGNOSTIC_TEST|SARS-CoV-2 antibody test|SARS-CoV-2 antibody test results and testing again at 6 and 12 months
40769115|NCT06592521|DEVICE|OPTI-FREE EXPRESS MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
40769116|NCT06592521|DEVICE|OPTI-FREE PureMoist MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
40971457|NCT02817191|DRUG|Hylo-Comod eye drop|The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
40971458|NCT02817191|DRUG|Tears Naturale Forte eye drop|The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
41297720|NCT03454048|OTHER|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
41297721|NCT03454048|OTHER|Blood stage malaria challenge infection, P. falciparum 3D7|P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.
41297722|NCT05329467|OTHER|Validation of Faces Thermomether Scale|Participants are introduced to all three painscales and are asked to rate their pain with each and one of them according to instructions for each scale
41297723|NCT03911674|OTHER|Oral manual stimulation of feeding in preterm infants|Manual stimulation of the cheeks (internal and external), lips, gums, tongue and palate by finger-strokin.
41458437|NCT01376596|BEHAVIORAL|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
41458438|NCT01376596|BEHAVIORAL|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
40769117|NCT06592521|DEVICE|OPTI-FREE REPLENISH MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
40769118|NCT06592521|DEVICE|Habitual contact lenses|Daily wear, reusable, soft (including hydrogel and silicone hydrogel) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
40769119|NCT04236154|OTHER|Pedometer|Participants will wear a pedometer for 4 days at baseline, and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
40769120|NCT04236154|OTHER|Actigraph|Participants will wear a Actigraph for 4 days at baseline and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
40971459|NCT05737303|DRUG|nab-paclitaxel combined with carboplatin|"Nab-Paclitaxel/carboplatin q3weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
40971460|NCT03817307|DIAGNOSTIC_TEST|USPIO-enhanced MRI|The USPIO contrast agent will be administered intravenously to the subjects. An MRI scan of the neck region is performed 24-36 hours later to detect lymph node metastases.
40971461|NCT06115213|BEHAVIORAL|Patient counselling|Patient counseling, lifestyle modifications, medication evaluation, and adherence
40971462|NCT00797472|DRUG|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
40971463|NCT00797472|DRUG|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
40971464|NCT03642405|DIAGNOSTIC_TEST|Electrocardiogram examination|12-lead ECG monitored by Holter
40971465|NCT03642405|DIAGNOSTIC_TEST|Echocardiography|Echocardiography in accordance to Danish Society of Cardiology
41297724|NCT03533478|DIETARY_SUPPLEMENT|Oral treatment Alzer y Diamel|"Alzer:~Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.~Diamel:~Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year."
41297725|NCT03533478|DIETARY_SUPPLEMENT|Placebo|Placebo treatment
41297726|NCT04644419|OTHER|none (observational study)|This is an observational study and does not include intervention delivery.
41297727|NCT01362712|RADIATION|[F18]CP-18 Injection|Normal volunteers dose will not exceed 20 mCi. For cancer subjects, the dose will be closer to 10 mCi.
41297728|NCT00690716|DRUG|Nasal CO2|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
41297729|NCT00690716|DRUG|Inactive Placebo|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
40769121|NCT04236154|OTHER|Perturbation Treadmill|Participants will walk on an instrumented treadmill while wearing a safety harness at baseline and 4-6 weeks later. The perturbation treadmill will assess an individual's risk for falling. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
40769122|NCT04770896|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
41297730|NCT06471140|OTHER|magnetic resonance imaging (MRI)|MRI performed three times during pregnancy and 6 months postpartum
40769123|NCT04770896|DRUG|Lenvatinib|Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of \< 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
40769124|NCT04770896|DRUG|Sorafenib|Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
40769125|NCT05607576|OTHER|Uncovered CGM during radiologic procedures|Dexcom G6 CGM will not be covered during radiologic procedures.
40769126|NCT05071326|BEHAVIORAL|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
40769127|NCT01597700|DRUG|10mg Ezetimibe|1 tablet taken by mouth
40769128|NCT01597700|DRUG|10 mg Ezetimibe - wash out period|1 tablet taken by mouth received after wash out period
41297731|NCT02020343|BEHAVIORAL|taste tests|"Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling."
41297732|NCT00945750|DRUG|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
41297733|NCT00945750|DRUG|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
41297734|NCT03242928|DRUG|AFQ056|50 mg and 100 mg tablets taken orally
41297735|NCT03242928|DRUG|Placebo|Matching placebo tablets taken orally BID
41297736|NCT04569305|PROCEDURE|Negative Pressure Wound Therapy|NPWT technique was applied to injured area of the foot and ankle after debridement and cleaning of the necrosed tissue and using Vacuum Assisted Closure (VAC) consisting of evacuation tube, vacuum pump, collecting canister and a multiporous polyurethane sponge. VAC dressings were changed every 72 hours.
41297737|NCT04569305|PROCEDURE|Conventional treatment|In conventional treatment moist gauze dressings were applied and change of dressings were done daily.
41297738|NCT02752867|DRUG|Jianpi Yishen Huatan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
41297739|NCT02752867|OTHER|the placebo|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
41297740|NCT02778867|OTHER|1 Food Elimination Diet Therapy|
41297741|NCT02778867|OTHER|6 Food Elimination Diet Therapy|
40769129|NCT04714177|DRUG|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
40769130|NCT04714177|DRUG|Placebo|Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
40769131|NCT04635280|DEVICE|any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-marking|A closed-loop automatic insulin delivery system includes a combination of an insulin pump, a continuous glucose monitoring system and an algorithm.
40971466|NCT03642405|PROCEDURE|Blood Samples|Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).
40971467|NCT03642405|BEHAVIORAL|Questionnaire|Questionnaire regarding patients quality of life
41297742|NCT02778867|OTHER|6 Food Elimination Diet (after 1FED failure)|
41297743|NCT02778867|DRUG|Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)|
41297744|NCT04027465|DIETARY_SUPPLEMENT|Egg allergy oral desensitization|Subjects in the treatment will begin treatment by undergoing an egg oral challenge. This will confirm that the subject is still allergic to egg and establish the dose of egg the subject can tolerate. The last dose of egg tolerated during the challenge will serve as the first desensitization dose Subjects will then come to the research center every two weeks to receive their dose increases until they reach the maintenance dose of 300 mg. Subjects will then enter the maintenance phase for one year. During this period they will undergo another oral food challenge one month after attaining the maintenance dose
41297745|NCT02393599|DRUG|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
41297746|NCT02393599|DRUG|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
41297747|NCT02393599|DRUG|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
41297748|NCT03191396|DRUG|Semaglutide|Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any
40769132|NCT06111027|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation is a non-invasive treatment option. As stimulators, we will apply a pair of light-weight encapsulated cylindrical vibrators to both sides of the larynx (voice box). The vibration frequency for VTS will set be to 100Hz and the participant may feel a mild tingling or vibrating sensation during VTS. The participants will be asked to apply for VTS at home over a period of 8 weeks. The participants will be asked to use this device for 3 days in the first week, 4 days in the second week, 5 days in the third week and 6 days in the fourth week. During the last 4 weeks, the participants will apply VTS on self-selected days as needed, not exceeding 6 times a week, to control and improve symptoms.
40769133|NCT05245175|OTHER|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
40769134|NCT05245175|OTHER|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
41297749|NCT03191396|DRUG|Liraglutide|Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any
41297750|NCT04598165|BEHAVIORAL|Interactive two-way SMS dialogue|We will utilize Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated theoretically grounded SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day for the remaining four weeks. Women who experience pregnancy or infant loss will be enrolled into an infant loss track where they will receive messages of support.
41297751|NCT02439281|DRUG|Clonidine|Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
41297752|NCT02439281|DRUG|Ropivacaine|One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
41297753|NCT03318107|DEVICE|Transvaginal probe using photoacoustic and ultrasound imaging|-Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
41297754|NCT03285009|OTHER|Training intervention|"Based on the baseline screening, which is part of the normal prevention routine within the school, all athletes are given individual advice with regard to points of attention within training. For example: those athletes with reduced balance, will get more balance training.~Intervention is individual as said and will be guided and supervised by the physical trainer and medical staff of the school."
41458439|NCT02465892|BEHAVIORAL|Pillars4Life|The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
40769135|NCT05245175|OTHER|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
40769136|NCT05245175|OTHER|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
40769137|NCT05245175|OTHER|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
41458440|NCT04117880|DRUG|Ataluren|Oral
41458441|NCT06403137|BEHAVIORAL|Resistance exercise|4 single-leg exercise sessions
41458442|NCT06403137|BEHAVIORAL|Standardized diet|Fully standardized provided energy-balanced diet providing recommended daily allowance for protein.
40769138|NCT03403179|OTHER|Functional Remediation|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
41139094|NCT02751957|BEHAVIORAL|Early Start Denver Model|The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
41458443|NCT06403137|DIETARY_SUPPLEMENT|Plant protein supplement|Dissolved in water with breakfast and prior to sleep.
41458444|NCT06403137|DIETARY_SUPPLEMENT|Maltodextrin supplement|Dissolved in water with breakfast and prior to sleep.
41458445|NCT06403137|DIETARY_SUPPLEMENT|Milk protein supplement|Dissolved in water with breakfast and prior to sleep.
41458446|NCT04859140|OTHER|Psychometric ratings (Likert-scale)|Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)
41458447|NCT04859140|BEHAVIORAL|Range of motion measures|Sit-and-reach and toe touch tests
41458448|NCT04859140|BEHAVIORAL|Mental calculation task|Iterated substractions (for 2 minutes)
41458449|NCT04859140|DEVICE|Resting-state electroencephalography|Alpha and beta oscillation power (4 minutes recordings)
40769139|NCT04557449|DRUG|PF-07220060|CDK4 inhibitor
40769140|NCT04557449|COMBINATION_PRODUCT|Letrozole|Endocrine Therapy
40769141|NCT04557449|COMBINATION_PRODUCT|Fulvestrant|Endocrine Therapy
40769142|NCT04557449|DRUG|Midazolam|Benzodiazepine used for DDI
40769143|NCT04557449|COMBINATION_PRODUCT|Enzalutamide|Androgen Receptor inhibitor
40769144|NCT05114174|OTHER|mami-educ|The intervention corresponds to sending 3 messages a week through Telegram, with nutritional information, for 12 consecutive weeks (a different nutritional topic each week). The messages address the three domains of learning, cognitive, affective, and psychomotor for each topic.
40971468|NCT04344925|DEVICE|Aerosol-reducing Mask|Patient will be put on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
41297755|NCT06392984|DIAGNOSTIC_TEST|Pectus deformity study form|Pectus deformity study form consisting of clinical and radiological measurements of participants aged 10-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.
41297756|NCT06392984|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders. Investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second) (Liter-L), FEV1 (%predicted), FVC (Forced Vital Capacity) (Liter-L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
41297757|NCT06392984|DIAGNOSTIC_TEST|Ultrasonographic Diaphragm Thickness Measurement|Diaphragm thickness (millimeter-mm) will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (millimeter-mm), end-inspiratory (Total Lung Capacity-TLC) (millimeter-mm)) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
41297758|NCT05242276|DEVICE|USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMY|The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. . It is inserted vaginally through the cervical canal into the endometrial cavity. The uterine manipulator facilitates the uterus mobilization during the surgery, generating tension on the main supporting elements of the uterus to improve surgical field exposure and provide a landmark for the colpotomy.
41297759|NCT03402867|PROCEDURE|Deep dry needling|Insertion of a filiform needle in the active trigger point of musculoskeletal muscle
41458450|NCT04859140|DEVICE|Resting-state galvanic skin resistance measures|Skin conductance during the resting state period
41458451|NCT00850551|OTHER|Early Intervention|Twice a week home spirometry and symptom assessment
40971469|NCT04344925|DEVICE|Standard Mask|Patient will be put on BIPAP using the standard mask
40971470|NCT02616055|DRUG|tesevatinib|
41139095|NCT02860702|OTHER|Human Milk Derived Fortifier|Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
41139096|NCT02860702|OTHER|Human/Bovine Milk|Bovine milk derived fortification
41139097|NCT01184105|DRUG|Intervention A|A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
40971471|NCT02589756|OTHER|The fatty fish group|At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (\~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
40971472|NCT02589756|OTHER|The nut group|At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (\~1400 kcal \~100 grams walnuts, \~50 grams hazelnuts and \~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
40971473|NCT02589756|OTHER|The control group|After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
41139098|NCT01184105|DRUG|Intervention B|A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
41297760|NCT05894278|OTHER|Prescription data collection|Prescription data collection
41297761|NCT04468958|BIOLOGICAL|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
41458452|NCT05427994|OTHER|National Eye Institute Visual Function Questionnaire|National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) measures the quality of life related to vision. This questionnaire has been validated for use on low vision patients.
41458453|NCT04628975|DEVICE|transillumination dispositif|infrared light
41458454|NCT05294016|DEVICE|BRA CONNECT device|skin thermal analysis for the detection of breast abnormalities
41458455|NCT03329924|OTHER|Activity level measurement by accelerometer|Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
41458456|NCT06428149|PROCEDURE|Midline interproximal soft-tissue incision|Firstly, the marginal tissue will be elevated around the periodontal defect, through the tunneling of the tissues, entering through the gingival sulcus and the periodontal pocket of the teeth involved in the defect periodontal. Once the marginal tissues have been disinserted to full thickness, the soft supra-alveolar component of the defect to be reconstructed will be stretched, in a buccal direction, with a blunt instrument, applying pressure on the lingual aspect. Visualizing the midpoint of the interproximal tissue, the papilla will be dissected at its midpoint, entering through the mesial aspect, with the scalpel blade perpendicular to the central axis of the teeth.
40971474|NCT05447715|DRUG|Fruquintinib|Fruquintinib sequential BEV+FOLFIRI vs. BEV+FOLFIRI sequential fruquintinib in the treatment of metastatic colorectal cancer that has failed previous fluorouracil/oxaliplatin therapy
41139099|NCT01829711|DRUG|Moxetumomab pasudotox|
41139100|NCT01829711|DRUG|IV Bag Protectant for Moxetumomab pasudotox|
41139101|NCT04097509|BIOLOGICAL|AFG application on palatinal wound healing|9 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. In the protocol, venous blood collected in the tube was centrifuged for 2 minutes at 2700 rpm (approximately 692 g) in a special centrifuge (Medifuge, Silfradent, Italy) to obtain two layers: the lower layer of red blood cells and the upper layer of AFG. The AFG at the top of the tube was collected by means of an injector and transferred to the metal godet. It was held for 15-20 minutes for polymerization. After polymerization occurred, the polymerized AFG in the metal gum was applied to the wound surface in the donor site . No suture or tissue glue was used. Adhesive properties of AFG were utilized.
41297762|NCT04468958|OTHER|Normal saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
41297763|NCT04451434|DRUG|Danicopan|Oral tablet
41297764|NCT02126904|DRUG|IVA group|
41297765|NCT01710228|DRUG|methylprednisolone|192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
40971475|NCT01853761|DEVICE|Exercise after|"Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
40971476|NCT01853761|DEVICE|Exercise at same time|"Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
40971477|NCT01853761|DEVICE|Transcutaneos|Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
40971478|NCT01853761|DEVICE|percutaneous microcurrent|Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
40971479|NCT01853761|DEVICE|25-10Hz|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
40971480|NCT01853761|DEVICE|25-50Hz microcurrent|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
40971481|NCT01421108|BEHAVIORAL|Framing (Gain-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
40971482|NCT01421108|BEHAVIORAL|Framing (Loss-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.~The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing."
40971483|NCT02174120|DRUG|propofol|
40971484|NCT02174120|DRUG|etomidate|
40971485|NCT03198117|DRUG|Huaier Granule|a Chinese traditional medicine
40971486|NCT03198117|OTHER|placebo|placebo
40971487|NCT00840346|DRUG|panobinostat|20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
40769145|NCT06421350|DEVICE|Spinal Cord Stimulation Device|The closed-loop spinal cord stimulation mechanism uses dynamic adjusting stimulation parameters based on real-time physiologic response and is uniquely positioned to mitigate the aberrant inflammatory and neurosensory processing and autonomic dysfunction driving CRPS and its progression between phases.
40971488|NCT00273871|DRUG|Cyclosporin or tacrolimus|
40971489|NCT00691418|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
40971490|NCT00691418|DIETARY_SUPPLEMENT|placebo|placebo once per day starting at 22-24 weeks gestation until delivery.
40971491|NCT00653744|DRUG|Rosuvastatin|
40971492|NCT00653744|DRUG|Atorvastatin|
40971493|NCT00767637|DRUG|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
40971494|NCT05593393|DEVICE|Endoscopic ultrasound|The EUS follow-up will be conducted at baseline and every 12 months thereafter. For patients with new WF or HRS in the evaluation, the follow-up physician and the patient can jointly decide whether to perform EUS evaluation in the 6 or 3 month intensive follow-up.
41139102|NCT04097509|BIOLOGICAL|i-PRF application on palatinal wound healing|10 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. Based on G force, collected venous blood were centrifuged at 2300 rpm (about 241 g) in a centrifuge (PC-O2, Process for PRF, Nice, France) for 3 minutes to obtain two layers: The two layers are the lower layer of red blood cells and the upper layer of i-PRF. The i-PRF at the top of the tube was collected with a syringe and transferred to the metal godet. It was held for 20-25 minutes for polymerization. After the polymerization, the polymerized i-PRF was applied to the wound surface in the donor site. No suture or tissue glue was used. Adhesive properties of AFG were utilized.
41139103|NCT04097509|OTHER|control|no application
41458457|NCT06428149|PROCEDURE|Marginal approach by palatal incision|First, an incision will be made in the palatal aspect of the interproximal papilla, at the base of the papilla, parallel to the axis of the tooth until touching the palatine alveolar crest, in order to detach and move the papilla from its base, attached to the vestibular flap. From the palatal incision the interproximal tissue will be elevated towards the buccal until the buccal bone crest is exposed.
41139104|NCT03108430|OTHER|Risk factors and incidence of IP after inhalation|Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.
40769146|NCT06643195|PROCEDURE|anti-leukemic treatment|2.Receive a second course of anti-leukemic treatment prior to allogeneic HSCT. The anti-leukemic treatment regimen will be determined based on the genetic mutation status. Patients without targetable mutations will receive a combination of BCL-2 inhibitors and demethylating agents as salvage chemotherapy. Patients with targetable mutations will receive appropriate targeted therapy (e.g., FLT3 inhibitors, IDH inhibitors).
40769147|NCT06643195|PROCEDURE|HSCT|1.patients proceeded to allogeneic HSCT as soon as possible..
40769148|NCT06567002|DRUG|MK-6552|Oral Administration
40971495|NCT06007885|OTHER|Pathways and Resources to Engagement and Participation (PREP)|Participants engage in an 8-week community-based activity of their choice (Goal#1). To engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home/community and use the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will work with the youth to search for the programs, identify and remove potential environmental barriers for participation (e.g., accessibility, equipment) and educate instructors regarding the youth's specific needs. This process, which includes up to 9 hours of OT support, will set the stage for enrolment of the youth in a community activity for a period of 8 weeks. The intervention will be repeated for a new goal (Goal#2). However, for Goal#2, youth will have the opportunity to select and pursue their new goal (#2) for 8 weeks without OT support first. Then, the OT will provide the PREP intervention for up to 6 weeks to achieve Goal #2.
40971496|NCT03907358|PROCEDURE|phacoemulsification|
40971497|NCT03795987|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
40971498|NCT04464889|DRUG|MDG1021 dose 1|3 patients to receive dose1: target dose of 0.3x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
40971499|NCT04464889|DRUG|MDG1021 dose 2|3 patients to receive dose 2: target dose of 1x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
40971500|NCT04464889|DRUG|MDG1021 dose 3|3 patients to receive dose 3: target dose of 3x10\^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL
40971501|NCT04464889|DRUG|MDG1021 optimal dose|20 patients to receive the selected optimal dose
40971502|NCT03916120|GENETIC|Genetic analysis|Collect 2ml intravenous blood from patients after anaesthesia.
40971503|NCT04781998|DRUG|liraglutide 3 mg (Saxenda®) once-daily|Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.
40971504|NCT03809143|DRUG|RBP-6000|All study participants are scheduled to receive monthly subcutaneous injections of depot BPN, RBP-6000. RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.
40971505|NCT03620240|BEHAVIORAL|Sleep Education|Assessing the effectiveness of a Sleep Education Program in improving sleep behaviors in secondary school students.
40971506|NCT00691015|BIOLOGICAL|rituximab|Given IV
40971507|NCT00691015|DRUG|busulfan|Given IV
40971508|NCT00691015|DRUG|carmustine|Given IV
40971509|NCT00691015|DRUG|cyclophosphamide|Given IV
41458458|NCT06428149|PROCEDURE|Minimally invasive surgical technique|The defect will be accessed through an incision at the base of the papilla on the vestibular aspect. Depending on the anatomy of the interproximal space, two types of incisions will be made: simplified papilla preservation flap (SPPF) when the width of the interproximal space is equal to or less than 2 mm, or modified papilla preservation technique (MPPT) when the width is greater than 2 millimeters. The interproximal incision will extend intrasulcular on the lingual and buccal aspect of the teeth adjacent to the defect, and mesio-distally it will extend as necessary to allow access to the defect and its debridement. The papilla will move from its base towards the palatine.
40769149|NCT03044054|DEVICE|ECHOPULSE|HIFU Under ultrasound guidance
41458459|NCT04049097|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
41458460|NCT00108030|PROCEDURE|Partial Body-weight supported Treadmill Training|
40769150|NCT02776735|DRUG|Sarilumab|Pharmaceutical form:Solution Route of administration: Subcutaneous
40971510|NCT00691015|DRUG|cytarabine|Given IV
40971511|NCT00691015|DRUG|etoposide|Given IV
40971512|NCT00691015|DRUG|fludarabine phosphate|Given IV
40971513|NCT00691015|DRUG|melphalan|Given IV
40971514|NCT00691015|RADIATION|total body irradiation (TBI)|Given once or twice daily
40769156|NCT04993196|DIAGNOSTIC_TEST|T1rho imaging|Magnetic Resonance Imaging using T1rho
40769157|NCT03779620|DEVICE|Ultrasound treatment of Calcified aortic valve|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement
40971515|NCT00691015|DRUG|anti-thymocyte globulin IV|Given IV
40971516|NCT00806390|DRUG|Metoprolol|Metroprolol tartrate titrated up
40971517|NCT03312270|BEHAVIORAL|Multimodality information comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
40971518|NCT01385215|DRUG|Fluzone|0.5 ml/15 micrograms
41458461|NCT00108030|PROCEDURE|PBWST + Power training|
40769158|NCT04625205|BIOLOGICAL|NEO-PTC-01|Administered via intravenous infusion.
40971519|NCT01385215|DRUG|Fluzone|0.5 ml/60 micrograms
40971520|NCT03031678|DEVICE|Electric-Acoustic Stimulation (EAS) Cochlear Implant System|Combination of a cochlear implant and a hearing aid
40971521|NCT01485237|OTHER|We will compare the resources used by both groups|The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
40971522|NCT03740945|DRUG|Placebo|Daily administration of one placebo vaginal ovule at bedtime
40971523|NCT03740945|DRUG|Prasterone (DHEA)|Daily administration of one prasterone vaginal ovule at bedtime
40971524|NCT00725569|DRUG|Bellis perennis and Staphysagria (C6)|homeopathic remedy
40971525|NCT00725569|DRUG|Bellis perennis and Staphysagria (C30)|Homeopathic Remedy
40971526|NCT00725569|DRUG|Placebo|Placebo remedy, identical in size, shape and taste to treatment remedies
40971527|NCT05015608|DRUG|Savolitinib + Osimertinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
40971528|NCT05015608|DRUG|Pemetrexed + Cisplatin /Carboplatin|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
40971529|NCT05322876|BEHAVIORAL|Healthy Hearts Family Program|Participants will participate in a baseline health and knowledge screening, followed by a 6-week once-weekly class series, and 3- and 6-month follow-up health and knowledge screenings.
40971530|NCT04810312|OTHER|Combined exercise and nutrition intervention|Back extensor strengthening exercise and nutritional supplementation for 12 weeks
40971531|NCT01082991|OTHER|Preemptive Rapid Response Team intervention|Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
40971532|NCT01864811|BEHAVIORAL|Baby-CIMT|Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.
40971533|NCT01864811|BEHAVIORAL|Baby-Massage|For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
40971534|NCT03253497|DRUG|Chlorobenzene Liquid|before induction will be used for oropharynx
41458462|NCT00108030|PROCEDURE|"Usual physiotherapy care"|
41458463|NCT02161549|DEVICE|Motus Gl CleanUp System|
40769159|NCT04625205|DRUG|IL-2|Administered via intravenous infusion.
40769160|NCT04625205|DRUG|αPD-1 therapy|Administered via intravenous infusion.
40769161|NCT04083378|PROCEDURE|Ablation Therapy|Undergo standard of care ablation
40769162|NCT04083378|PROCEDURE|Image-Guided Therapy|Undergo software-aided imaging (Morfeus)
40769163|NCT04083378|OTHER|Quality-of-Life Assessment|Ancillary studies
40769164|NCT04083378|OTHER|Questionnaire Administration|Ancillary studies
40971535|NCT02812160|DEVICE|Spatz3 Adjustable Balloon|An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
40971536|NCT00580190|DRUG|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
41297766|NCT03179098|OTHER|Modified Weeks protocol|The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
40769165|NCT05611775|DEVICE|Triaxial accelerometer|Monitors placed on the waist, thigh, and bilateral ankles. Accelerometry will measure patients' physical activities in the free-living environment for 4 consecutive days. The patients will wear the monitor during waking hours and remove it during sleeping, showering, and swimming time.
41297767|NCT03179098|OTHER|CIVM|Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
41297768|NCT03179098|OTHER|GC- Sustained Stretching|The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
40769166|NCT05042479|OTHER|Usual distraction and pain prevention techniques.|"For the first painful procedure, the child will benefit usual distraction and pain prevention techniques.Pain prevention and management techniques commonly used in the conduct of care:~* Application of a patch or anaesthetic cream 1 hour before the treatment~* Vigilant sedation using a premedication for lumbar punctures: Midazolam /Nalbuphine/Hydroxyzine/Morphine.~* Apart from care using VR, MEOPA can be given to the child for all assessed care on prescription.~* Apart from care using VR, the usual distraction techniques are left to the patient's choice (electronic tablet, smartphone, games, songs...)~* The presence of the parents"
40769167|NCT05042479|OTHER|Virtual reality|For the 2nd painful procedure, the child will use a VR (virtual reality) headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age.
40769168|NCT05042479|OTHER|Choice between usual distraction or virtual reality|"For the 3rd painful procedure, the child will choose his/her favorite technique between :~Usual distraction and pain prevention techniques or virtual reality"
40769169|NCT04066504|DRUG|sonidegib|Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
41297769|NCT02573805|DEVICE|Rigiscan test|Rigiscan tests are performed in enrolled subjects for consecutive two nights.
41458464|NCT01390051|DRUG|Innohep (Tinzaparin)|Dose: 4,500 IU daily in half of the study populationrandomised to treatment
41458465|NCT01390051|DRUG|tinzaparin|Dose 4,500 IE daily
40769170|NCT04010344|BEHAVIORAL|Enhanced Usual Care Group|"Medtronic® Labs' Akoma pa app, a culturally-tested and locally attuned mobile health platform, will be used in the intervention arm of the study to improve communication between the Community Health Officer (CHO) and the participant. This platform will be used to enhance shared decision making, clinical decision support, participatory communication, knowledge, treatment adherence (medication and lifestyle modification), and self-monitoring of hypertension. We will test the feasibility of the Akoma pa app in addressing patient-level and provider-level barriers to hypertension control.~The app will consist of the following components:~1. Reminders~2. Participant to CHO messaging~3. Home BP tracking~4. Educational materials on cardiovascular disease (CVD) and Stroke- Participants will have access to education modules on reducing the risk of CVD and stroke tailored to their knowledge level.~5. CHO provider portal- The provider portal will include decision support tools."
40769171|NCT04010344|OTHER|Usual Care Group|Regular/usual appointments or visits to patients' healthcare provider for management of study outcomes
40769172|NCT06520553|DRUG|BI 1569912 (C-14)|unlabelled BI 1569912 mixed with \[14C\]- labelled BI 1569912
40769173|NCT06520553|DRUG|BI 1569912 (C-13)|\[13C\]- labelled BI 1569912
40769174|NCT06631534|DRUG|Dexmedetomidine|Dexmedetomidine 1ug/kg bolus administered over 10 minutes followed by a continuous infusion of 0.5ug/kg/hr
40769175|NCT06631534|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline (placebo)
40769176|NCT06421311|DRUG|nivolumab|According to approved product label (France)
40769177|NCT05704647|DRUG|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV (vein)
40769178|NCT05704647|DRUG|Nivolumab|Given by IV (vein)
40769179|NCT05704647|DRUG|Relatlimab|Given by IV (vein)
40769180|NCT05172297|BEHAVIORAL|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
40769181|NCT05591365|OTHER|Structured In-Patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
40769182|NCT05591365|OTHER|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
40971537|NCT00580190|OTHER|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
41458466|NCT03702816|DRUG|GE180 PET Scan|GE180 PET Scan
40971538|NCT00580190|DRUG|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
40971539|NCT06506383|OTHER|No Intervention as this is an ecological study|No Intervention as this is an ecological study
41458467|NCT00474188|DRUG|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
41458468|NCT00474188|DRUG|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
41458469|NCT03184649|DRUG|Ibuprofen|It is a pre-analgesic will be taken before painful procedures.
40769183|NCT00622206|DRUG|ritonavir and saquinavir|saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
40769184|NCT05524246|DRUG|Pravastatin|Participants will receive pravastatin orally once daily through the first 35 days after bone marrow transplant.
40769185|NCT00406926|DRUG|Somatropin|
40769186|NCT05293717|DRUG|Ruxolitinib|1.5% Ruxolitinib cream
40769187|NCT06253767|PROCEDURE|Endodontic Treatment|Conventional endodontic treatment will be performed equally on all participants.
40769188|NCT06253767|DEVICE|Low Level Laser Therapy|Treatment Group (TG) will receive photobiomodulation for molars with 808nm application (AsGaAl), infrared, equipment with a power of 100 mW, and an exit beam area of 1 cm² perpendicular in contact with the mucosa at the level of the root apices at two vestibular points and one complementary palatal point, with 3J of energy per point (30s per point), totaling 9J of total delivered energy and 90 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 9J/cm² overall. To premolars the parameters will be 808nm application (AsGaAl), infrared, Laser Duo® equipment with a power of 100 mW and an exit beam area of 1cm² perpendicular in contact with the mucosa at the level of the root apices at one vestibular point and one complementary palatal point, with 3J of energy per point (30s per point), totaling 6J of total delivered energy and 60 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 6J/cm² overall
40971540|NCT03421119|DRUG|Liraglutide 6 MG/ML Pen Injector|Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.
40971541|NCT03421119|DRUG|Metformin|Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.
40971542|NCT03421119|DRUG|Sulfonylurea/non-sulfonylurea insulin secretagogues|Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
40971543|NCT02684760|DRUG|PF-06651600|PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
40971544|NCT03234686|DRUG|Deferiprone 600mg delayed release tablets|The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
40971545|NCT03234686|DRUG|Placebo Oral Tablet|The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
40971546|NCT04728074|OTHER|The Entering Employment and Sustaining Work Program|A structured, motivation and self-awareness based group intervention
40971547|NCT04728074|OTHER|vocational rehabilitation|An individual based, focused on desired job or occupation, face-to-face intervention
40971548|NCT01419678|OTHER|collection of blood samples for PK testing|PK samples collected around dosing of posaconazole
40971549|NCT01658891|DRUG|combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg|beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
40971550|NCT01658891|DRUG|free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
40971551|NCT04235114|DRUG|50 mg 89Zr-DFO-Nimotuzumab|A maximum of 2 mCi (range 1 - 2 mCi) 50 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
40971552|NCT04235114|DRUG|1 mg 89Zr-DFO-Nimotuzumab|A maximum of 2 mCi (range 1 - 2 mCi) 1 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
40990794|NCT04760366|OTHER|Stretching's of iliopsoas muscle|"Patients in this group will receive the interventional therapy which will include:~Stretching's of iliopsoas muscle which can be done in two positions:~1. modified lunge position.~2. The prone stretch.~Patients in this group will also receive the conventional therapy which will include:~* Hot pack for 15 minutes.~* Myofascial release of iliopsoas~* TENS for 15 minutes."
40990795|NCT04760366|OTHER|the conventional therapy|the conventional therapy
41458470|NCT03184649|DRUG|paracetamol|it is a pre-analgesic drug will be taken before painful procedure.
41458471|NCT03184649|DIETARY_SUPPLEMENT|A fruit-flavored orange color placebo solution|orange juice as a comparative group.
41458472|NCT04734704|PROCEDURE|skin swabs at lesional and non-lesional sites|It will be examined in patients skin swabs sampled at lesional and non-lesional sites
41458473|NCT04734704|PROCEDURE|skin swabs on skin|It will be examined in patients skin swabs sampled on skin
40769189|NCT06253767|DEVICE|Simulation Low Level Laser therapy|A simulation of low-level laser therapy was performed on the control group starting from patient preparation (placement of glasses) and the reproduction of device sounds without activation.
40769190|NCT01844596|BEHAVIORAL|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
40971553|NCT05099874|DEVICE|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
40769191|NCT01844596|BEHAVIORAL|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
40769192|NCT03043573|BEHAVIORAL|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
40971554|NCT05101005|DEVICE|Drug-Coated Balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions.
40971555|NCT05101005|DEVICE|Sirolimus-Eluting Stent|Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.
40971556|NCT03385902|OTHER|optimal start time|patients will start hemodialysis when their DIFE reach 35, and can not wait if the DIFE decline to 30.
41297770|NCT03505697|OTHER|inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement16, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
40971557|NCT03385902|OTHER|late start time|patients will start hemodialysis when their DIFE less than 30
40971558|NCT00989378|BEHAVIORAL|baseline study|normal bedtimes
40971559|NCT05588232|PROCEDURE|scheduled outpatient interventions in interventional cardiology|coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
40971560|NCT04047940|DRUG|LY900020|Administered orally
41297771|NCT03505697|OTHER|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
41297772|NCT01582724|PROCEDURE|Self-care acupressure at three predefined points|Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
40971561|NCT04047940|DRUG|Metformin XR|Administered orally
40971562|NCT04047940|DRUG|Atorvastatin|Administered orally
40971563|NCT04047940|DRUG|Valsartan|Administered orally
40971564|NCT00000938|DRUG|ceftriaxone|
41297773|NCT05507944|DIAGNOSTIC_TEST|FeNO measurement|Diurnal measurements before work and at 3 hours after work start.
40769193|NCT03043573|BEHAVIORAL|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
40971565|NCT00000938|DRUG|doxycycline|
40971566|NCT01126853|BIOLOGICAL|Twinrix|Up to three intramuscular doses of 1cc of Twinrix (combined hepatitis A/B vaccine) at 0, 1, and 6 months post-enrollment
40971567|NCT04454268|PROCEDURE|cyst extirpation|complete removal of the cyst without rupture
40971568|NCT00271583|DRUG|CDB-2914|
40971569|NCT00271583|DRUG|levonorgestrel|
40971570|NCT00461045|DRUG|MRZ 0.5 mg/m^2|NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
40971571|NCT01779401|DRUG|Clopidogrel 75mg|
40971572|NCT01779401|DRUG|Clopidogrel 150mg|
40971573|NCT01779401|DRUG|Aspirin 100mg|
40971574|NCT01779401|DRUG|Cilostazol 100mg|
40971575|NCT04654676|DRUG|Vildagliptin|Vildagliptin added on to stable doses of pre-mixed insulin with or without metformin
40971576|NCT02267512|DRUG|ATG-F|Intravenous (IV)
40971577|NCT00785668|DRUG|AER 001|10 mg dry powder administered using a handheld device
40971578|NCT06113809|DRUG|Palbociclib|"Palbociclib is a CDK4/6 inhibitor.~Palbociclib, 125 mg, (pediatric dose 75mg/m2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab"
40971579|NCT06113809|DRUG|Pembrolizumab|"Pembrolizumab is a PD-1 blocking antibody.~Given 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)"
40971580|NCT00808977|DRUG|Dersalazine sodium|Dersalazine sodium 2400 mg daily
40971581|NCT00808977|DRUG|Mesalazine|Mesalazine 2400 mg daily
40971582|NCT00808977|DRUG|Placebo|Placebo matching active and experimental treatments
40971583|NCT01900704|DRUG|SER120 750 ng|SER120 750 ng
40971584|NCT01900704|DRUG|SER120 1500 ng|SER120 1500 ng
40971585|NCT01900704|DRUG|Placebo|Placebo
40971586|NCT06418100|PROCEDURE|The recto intercostal fascial plane block|After ensuring aseptic conditions, the high-frequency linear ultrasound probe was used to detect the rectus abdominis muscle and the 6-7th costal cartilage as described by Tulgar et al. After rotating and shifting the transducer, 6-7th costal cartilages, the rectus abdominis muscle, and intercostal muscles between the cartilages were confirmed. The primary investigator (B.C.) directed the needle tip caudad in the cephalic direction in-plainly, and 20 ml 0,25% bupivacaine was injected bilaterally into the plane between the costal cartilage and the rectus abdominis muscle following negative aspiration.
40971587|NCT01441206|DRUG|rifampin|"Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)~Cohort 1:~Dosing will be as follows:~GA at birth \< 32 weeks - PNA \< 14 days: 10 mg/kg QD GA at birth \< 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA \< 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD"
40971588|NCT01293721|DEVICE|Low-magnitude high - frequency vibration treatment|stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
40971589|NCT04070989|DEVICE|THA|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem
40971590|NCT02662491|DIETARY_SUPPLEMENT|Vitamin D and calcium|
40971591|NCT02662491|DIETARY_SUPPLEMENT|Vitamin D|
40971592|NCT02662491|DIETARY_SUPPLEMENT|Calcium|
40971593|NCT02662491|DIETARY_SUPPLEMENT|Placebo|
40971594|NCT01554150|BEHAVIORAL|Method of Levels Cognitive Therapy|In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
40971595|NCT04535700|DRUG|Pioglitazone 30 mg|Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital
40971596|NCT04535700|OTHER|standard of care|Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.
40971597|NCT06352801|BEHAVIORAL|Self-Compassion Intervention|Children participants are expected to learn the concepts of self-compassion and strategies of applying self-compassion to their daily lives.
40971598|NCT04324073|DRUG|Sarilumab|(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1
41297774|NCT05815329|OTHER|cognitive training|After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered to half of the outpatients included in this research by means of technological devices (Neurotablet). A neuropsychologist will supervise the cognitive training offline (about 30 minutes per 5 days, 8 weeks) and through a face-to-face 1 hour-session each week per each outpatient.
41297775|NCT01671436|BEHAVIORAL|Central Meditation and Imagery Therapy|
40769194|NCT03974061|BEHAVIORAL|Brief Acceptance and Commitment Therapy|Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
40769195|NCT03974061|BEHAVIORAL|Brief Alcohol Intervention|The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
40971599|NCT03027778|OTHER|Exercise|Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
40971600|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
40971601|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
40971602|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
40971603|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
40971604|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
40971605|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
40971606|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
40971607|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
40971608|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
40971609|NCT00928681|BIOLOGICAL|Multiple dose-Group B|PF-00547659, multiple dose
40971610|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
40971611|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
40971612|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
40971613|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
40971614|NCT00928681|BIOLOGICAL|Multiple dose-Group B|PF-00547659, multiple dose
41297776|NCT00471367|DRUG|AZD4877|intravenous infusion administered twice a week for 2 weeks
41297777|NCT05606354|OTHER|Intervention group|Experimental
41458474|NCT05521919|BEHAVIORAL|Sympathetic Nervous System Activation|Participants will complete a task that increases sympathetic nervous system activation.
40769196|NCT05510167|BEHAVIORAL|Study arm|Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
41297778|NCT05632133|DRUG|Lacosamide 50 MG Oral Tablet|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
41297779|NCT05632133|DRUG|Ibuprofen 400 mg|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
41297780|NCT03095183|DEVICE|Grape flavored Puritan Junior tongue depressor|
41297781|NCT03095183|DEVICE|Traditional unflavored Puritan Regular Tongue Depressor|
41297782|NCT01486316|DEVICE|Reveal XT® Insertable Cardiac Monitor|If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).
41297783|NCT01486316|OTHER|Heart Failure Risk Status Diagnostic|"The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.~Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High."
41297784|NCT00228488|DRUG|Gefitinib|
40769197|NCT04281940|DEVICE|Transcatheter implantation of chordal repair system|Implantation of anchor via transcatheter delivery system to delivery chordal repair system tethering the mitral leaflets to the ventricle
40769198|NCT03266783|DRUG|Apixaban|Refer to Apixaban group
40769199|NCT03266783|DRUG|Rivaroxaban|Refer to Rivaroxaban group
40769200|NCT05399888|DRUG|BIIB080|Administered as specified in the treatment arm.
41297785|NCT05526170|DEVICE|Devices for long-term monitoring of objective and subjective parameters of the body|Patients will use a 1-lead Holter ECG (Bittium Faros) for heart rhythm and physical activity analysis, a wearable wrist-worn device with photoplethysmography and 6-lead ECG for heart rhythm analysis, a sleep tracking mat (Withings sleep analyser) for sleep analysis, a smartphone with triggers application for entering the subjective triggers (stress, coffee, alcohol intake and others), a 48-hour ambulatory blood pressure monitor for 2 days and a regular blood pressure monitor for up to 5 days. Patients will be monitored for up to 7 days with the described system of devices. In addition, patients will receive investigations of heart echocardiography, laboratory tests and surveys to evaluate the system and the use of acquired information.
41297786|NCT03887637|DRUG|DAAs|Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.
41297787|NCT05312905|OTHER|Mirror Therapy|Mirror Therapy applied alone
41297788|NCT05312905|OTHER|Mirror Therapy + Cognitive Therapy|Mirror Therapy supported with Cognitive Exercises
41297789|NCT01605396|DRUG|Ridaforolimus|Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, \& 22-26 of 28-day cycle.
41297790|NCT01605396|DRUG|Dalotuzumab|Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.
41297791|NCT01605396|DRUG|Exemestane|Exemestane 25 mg tablet administered PO QD.
40769201|NCT05399888|DRUG|BIIB080-matching placebo|Administered as specified in the treatment arm.
41297792|NCT05986344|DEVICE|Copper intrauterine contraceptive device|copper T-380 IUD
41297793|NCT05986344|DEVICE|LNG-IUS|Levonorgestrel Intrauterine System
40769202|NCT06393712|DRUG|Placebo|Placebo will be administered intrathecally
40769203|NCT06393712|DRUG|ALN-APP|ALN-APP will be administered intrathecally
40769204|NCT01356147|DRUG|Dornase alfa|2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
40769205|NCT01356147|DRUG|Placebo|No therapy will be given to placebo arm
40769206|NCT05388474|OTHER|No ibalizumab or Pre-ibalizumab treatment|Patient registry
40769207|NCT05388474|BIOLOGICAL|On ibalizumab treatment|Patient registry
40769208|NCT00213525|OTHER|Questionnary for environmental factors research|Questionnary for environmental factors research
40769209|NCT01748656|DEVICE|IVAPS|IVAPS mode (RESMED Stelar 150) during 1 night
40769210|NCT01748656|DEVICE|AVAPS|AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
41297794|NCT03774017|PROCEDURE|one-staged hybrid operation|An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
41297795|NCT03774017|PROCEDURE|Traditional microsurgical operation|The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
41458475|NCT05521919|BEHAVIORAL|No-stress|Participants will complete a task that will not affect their sympathetic nervous system activity.
40971615|NCT02837198|DRUG|FYU-981|
40971616|NCT02837198|DRUG|Topiroxostat|
41297796|NCT06486922|BEHAVIORAL|StEP OUT|The details of program structure and content will evolve as the study progresses based on feedback from participants, interventionists, and the community advisory board. Initially, we will plan to have 5 formal sessions structured as groups with multiple participants receiving the session simultaneously, primarily via remote videoconference, though sessions may occur individually, based on participant schedule and preference. All sessions are designed to be supportive, educational, and interactive, with opportunities to practice skills and discuss feeding and parenting concerns.
41297797|NCT03237832|DRUG|ARN-6039|Ascending doses per Cohort
41297798|NCT03237832|OTHER|Placebo|Placebo to match ARN-6039
41297799|NCT06532461|DEVICE|Mio Advanced infusions set|Insulin infusionsset fitting Medtronic 780 G insulin pump
41297800|NCT06532461|DRUG|Novorapid|Randomized to either Novorapid or Humalog
41297801|NCT06532461|DEVICE|Extended wear insulin infusion (EWIS)|Insulin infusionsset fitting Medtronic 780 G insulin pump
41297802|NCT06532461|DRUG|Humalog|Randomized to either Novorapid or Humalog
41297803|NCT03431675|DRUG|Ciprofloxacin|Single-dose oral ciprofloxacin
41297804|NCT01842061|BEHAVIORAL|Active Living Program|
41297805|NCT01842061|BEHAVIORAL|Education|
40769211|NCT05400564|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up app and telehealth coaching provided by trained mental health providers. Parents can contact their Coach as often as they like and a minimum of 3 coaching sessions will be scheduled.
40971617|NCT02132091|OTHER|Intermittent Fasting|The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
40769212|NCT00829465|DRUG|Licartin|Licartin
40769213|NCT00829465|PROCEDURE|Transcatheter arterial chemoembolization|TACE
40769214|NCT05417906|OTHER|Standard care|Oral prednisolone for 5 days
40769215|NCT05417906|OTHER|Eosinophil-directed care|Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10\^3/µL, or 3 days if eosinophil is \< 0.300 x 10\^3/µL
40769216|NCT03766191|BEHAVIORAL|Food Ads|Exposure to foods ads embedded in an age-appropriate TV program
40769217|NCT03766191|OTHER|Non-food Ads|Exposure to non-food ads embedded in an age-appropriate TV program
40971618|NCT02132091|DIETARY_SUPPLEMENT|400 IU Vitamin E|once each day in morning; oral pill form
40971619|NCT02132091|DIETARY_SUPPLEMENT|1000 mg Vitamin C|500mg twice each day; morning and evening; oral pill form
41297806|NCT03340493|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
41297807|NCT01452126|DRUG|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
41297808|NCT06266403|BEHAVIORAL|Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the ____ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success."
41297809|NCT06266403|BEHAVIORAL|Clear Speech|"PALS and age-matched speakers will read critical words consisting of target segments (e.g., hid, ship, net) in random order four times. These words will be embedded in the carrier phrase Click on the ___ this time. Participations will be instructed to overenunciate the critical words."
41297810|NCT06266403|BEHAVIORAL|Unstructured communicative interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set."
41297811|NCT06266403|BEHAVIORAL|Clear Speech Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the ____ this time, and the listener will click on it. The speaker will be instructed to overenunciate the critical words. After the listener has made their selection, both participants will receive feedback on trial success."
40971620|NCT02968953|DRUG|Triheptanoin|A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).
41139105|NCT06298747|OTHER|Selective cervical nerve root pulsed radiofrequency|A 5-12 MHz linear US probe was used during the procedure. C7 has a more prominent posterior tubercle and a rudimentary anterior tubercle. C5 and C6 have more prominent and smooth anterior and posterior tubercles, respectively. After visualizing the hypoechoic nerve root between the tubercles of the transverse process, the surrounding vascular structures were identified and RF canula is used. After approaching the hypoechoic nerve root, after sensory and motor stimulation, PRF was applied to each nerve root.
41139106|NCT06552351|DEVICE|Needle-Free Jet Injection of 1 % lidocaine|The needle-free jet injection device delivers 1% lidocaine through high-pressure fluid without the use of a needle. This method aims to reduce the pain associated with needle-based anesthesia during infant lumbar punctures.
41297812|NCT06401512|BEHAVIORAL|Guided self-determination (GSD) follow-up approach by primary care nurses.|The GSD counseling program consists of four scheduled consultations with a nurse and a digital platform with tools to help people better manage their health. The consultations will be facilitated by using reflection sheets to stimulate written reflection in the context of GSD.
41297813|NCT00849303|OTHER|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
41139107|NCT06552351|OTHER|traditional needle infiltration of 1% lidocaine|Traditional needle infiltration involves injecting 1% lidocaine with a needle to provide local anesthesia before an infant lumbar puncture. This method is the standard practice for pain management in such procedures.
41297814|NCT00849303|OTHER|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
41297815|NCT00013403|PROCEDURE|Blindness|
40971621|NCT04448574|OTHER|Chest Wall Deformities Questionaire|Questionaire about epidemiological data was sent to Patients and families
41297816|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
41297817|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
41297818|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
40769218|NCT05758688|RADIATION|Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)|The study intervention is Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) as part of the definitive treatment of gynecologic cancers in the post-hysterectomy, adjuvant setting. Patients will be treated with doses of 45 or 50.4 Gy in 1.8 Gy daily fractions. The volume treated will include the whole pelvis according to Radiation Therapy Oncology Group post-hysterectomy pelvis guidelines.
40769219|NCT03938740|DRUG|HDV-Insulin Lispro and Insulin Degludec (-40%)|HDV-Insulin Lispro and Insulin Degludec (-40%)
40769220|NCT03938740|DRUG|HDV-Insulin Lispro and Insulin Degludec (-10%)|HDV-Insulin Lispro and Insulin Degludec (-10%)
40971622|NCT04119882|DIAGNOSTIC_TEST|Blood collection|New biomarker test
40971623|NCT03761277|DEVICE|Medtronic SynchroMed™ II infusion system|Implanted infusion system consisting of a pump and catheter, as well as external components of a clinician programmer, refill and catheter access port kits, and the Personal Therapy Manager (myPTM™).
41297819|NCT00365716|BIOLOGICAL|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
41297820|NCT00365716|BIOLOGICAL|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
41297821|NCT05839990|PROCEDURE|Surgery|Replacement of the ascending aorta in case of anerysm and dilatation
41297822|NCT00830453|PROCEDURE|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
41297823|NCT02058355|BEHAVIORAL|Consequences List Feedback|
41458476|NCT01326351|PROCEDURE|Regenerative injection therapy|Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
40971624|NCT03761277|DRUG|Preservative-free morphine sulfate (PFMS)|The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).
40971625|NCT00191789|DRUG|gemcitabine|1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
41139108|NCT03706872|OTHER|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care
41139109|NCT06134232|DRUG|Sipuleucel-T Injection|Single Infusion
40769221|NCT00149357|OTHER|Thrombophilia Testing|TP testing in Group 1 and 3 only
40769222|NCT04124757|OTHER|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
40769223|NCT02343185|OTHER|manual therapy with diaphragmatic treatment|Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
40769224|NCT02343185|OTHER|Placebo treatment|Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
40769225|NCT04232553|DRUG|Mirikizumab|Administered IV
40769226|NCT04232553|DRUG|Mirikizumab|Administered SC
40769227|NCT06153693|DRUG|Placebo|Placebo once daily (QD) for 12 weeks
40769228|NCT06153693|DRUG|lorundrostat Dose 1|50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
40971626|NCT00191789|DRUG|doxorubicin|60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)
40971627|NCT00191789|DRUG|cisplatin|70 mg/m\^2, IV, every 21 days x 4 cycles (5-8)
41139110|NCT05843448|BIOLOGICAL|PD-L1/IDO Peptide Vaccine|Given SC
41139111|NCT05843448|BIOLOGICAL|Pembrolizumab|Given IV
41139112|NCT05660811|DRUG|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
41139113|NCT05660811|DRUG|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months
41297824|NCT02058355|BEHAVIORAL|Personalized Normative Feedback|
40769229|NCT06153693|DRUG|lorundrostat Dose 2|50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
40769230|NCT06635785|DRUG|AI-081|AI-081 is a humanized monoclonal antibody with a silenced Fc targeting PD-1 and VEGF.
40769231|NCT03743519|DIETARY_SUPPLEMENT|Cherry juice|30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.
40769232|NCT03743519|DIETARY_SUPPLEMENT|Placebo|Identical in taste and colour to the Cherry juice, but with no anthocyanin content
40769233|NCT05773469|OTHER|Exercise|Ski traverse of Greenland polar Icecap
40769234|NCT05773469|OTHER|Nutrition|Maximising energy intake by consuming over the theoretical 2.4 x RMR
40769235|NCT06645223|DRUG|No Interventions|no interventions
40769236|NCT00143845|PROCEDURE|Reduced intensity conditioning|Busulfan and Fludarabine regimen
40769237|NCT00143845|PROCEDURE|Rapid immunosuppressive taper|Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
40769238|NCT00143845|PROCEDURE|Prophylactic donor leukocyte infusions|If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.
40971628|NCT00191789|PROCEDURE|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
40971629|NCT00482612|DRUG|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
40971630|NCT00482612|DRUG|Placebo|Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
40971631|NCT03462082|OTHER|Asymmetric STN-DBS|Asymmetric deep brain stimulation
41139114|NCT05660811|DRUG|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
41139115|NCT05660811|DRUG|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
41139116|NCT00838448|BEHAVIORAL|Exercise|Exercise performed on a treadmill for 20-30 minutes
41297825|NCT00935220|DRUG|linagliptin QD (once daily) for 7 days|dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
41297826|NCT03611959|OTHER|Non Applicable|
41297827|NCT00442247|DEVICE|Pelvicol|
41297828|NCT06332053|DRUG|SY-5007|SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11
41297829|NCT06332053|DRUG|Itraconazole|Itraconazole 200 mg, Capsules, Day 8-Day 18
41297830|NCT06332053|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16
41297831|NCT06332053|DRUG|Rifampin|Rifampin 600 mg, Capsules, Day 8-Day 21
41297832|NCT01556945|BIOLOGICAL|FMP1/AS02|The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
41297833|NCT01556945|BIOLOGICAL|RTS,S/AS02|The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
41297834|NCT01556945|OTHER|AS02 adjuvant alone|AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
41297835|NCT01556945|OTHER|Malaria challenge|Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
41297836|NCT03819803|BIOLOGICAL|Fecal microbiota transplantation|200 ml of a tested stool suspension of a healthy donor is instilled into the patient´s caecum or terminal ileum
41139117|NCT04373772|OTHER|abdominal massage|the patients in the AM group were given a total of 30 minutes of AM by the nurses (HD, OM) everyday for 15 minutes in the morning and evening.In this study AM, which included effleurage, strokes, petrissage and vibration techniques, was applied to the patients for 15 minutes in each session at 9:00 am and 9:00 pm.
41139118|NCT01048385|DIETARY_SUPPLEMENT|Coenzyme Q10 concomitant treatment|Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
41139119|NCT01048385|DIETARY_SUPPLEMENT|Placebo|Treated with capsules containing the vehicle (Sesame oil).
41297837|NCT04459299|DEVICE|Robotic-PCI (CorPath GRX System)|Robotic-PCI for acute ST elevation myocardial infarction (STEMI).
41297838|NCT03481764|GENETIC|HRC-test|"Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used."
41297839|NCT03819946|DEVICE|esophageal cooling device (Attune Medical, Chicago, IL)|The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.
41458477|NCT01326351|PROCEDURE|Dry needle injection|Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
40769239|NCT06643923|OTHER|Exercise|"F (Frequency): 3 days per week, with a total of 24 sessions. I (Intensity): Low to moderate intensity exercises with progression, ensuring no fatigue is induced.~T (Time): Each session will last 30 minutes, over a total period of 8 weeks.~T (Type):~Warm-up exercises Core stabilization exercises: Aimed at improving core stability. Cool-down exercises E (Enjoyment): Gamified exercises, with sessions conducted to music. A (Adherence): A follow-up system will be implemented, including reminder notes and regular sending of session links to ensure compliance."
40769240|NCT06643923|BEHAVIORAL|Urotherapy|The urotherapy education program was developed by an expert physiotherapist and was piloted with the families of children with DMD (16 parents) prior to the study. Pre-test and post-test assessments demonstrated that the knowledge level of DMD families increased after the training. Additionally, results from the satisfaction survey indicated a high level of satisfaction among the families regarding the urotherapy education (Mean satisfaction score: 33.875/35.000, Minimum=28, Maximum=35). Therefore, it was deemed appropriate to deliver the same urotherapy presentation to the DMD families within the scope of this study. The training lasts approximately 1 hour and will be delivered to families via an online method. Each family will receive the education individually, and no group sessions will be conducted.
40769241|NCT05810480|DIAGNOSTIC_TEST|polyreactive immunoglobulin G|Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.
40769242|NCT06643572|DEVICE|Virtual reality simulator|This virtual reality simulator allows for the simulation of a lumbar transforaminal epidural steroid injection using the patient's 3D lumbar images.
41139120|NCT01617889|OTHER|Experimental powdered milk-based infant formula with an alternate fat blend|formula to be consumed ad lib
40769243|NCT02499237|DRUG|Denosumab|Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
40971632|NCT03506178|DRUG|Oxymetazoline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
40971633|NCT03506178|DRUG|Menthol Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
40971634|NCT03506178|DRUG|Normal saline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
41139121|NCT01617889|OTHER|A powdered milk-based infant formula, standard fat blend|formula to be consumed ad lib
41297840|NCT03819946|OTHER|Standard esophageal temperature probe|If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.
41297841|NCT05725798|DRUG|Sitagliptin|Group 1 who regularly takes Sitagliptin due to diabetes mellitus type 2 continues the treatment perioperatively. Group 2 and group 3 do not take Sitagliptin.
40769244|NCT02499237|DRUG|Zoledronic acid|Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
40769245|NCT04558736|DRUG|Anti-Thymocyte Globulin (Rabbit)|Given intravenously (IV)
40769246|NCT04558736|DRUG|Fludarabine|Given intravenously (IV)
40769247|NCT04558736|DRUG|Cyclophosphamide|Given intravenously (IV)
40769248|NCT04558736|DRUG|Mesna|Given intravenously (IV)
40769249|NCT04558736|DRUG|G-CSF|Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days, or as clinically indicated
40769250|NCT04558736|RADIATION|Total Lymphoid Irradiation (TLI)|TLI will be given at 800 cGy total dose in 4 fractions.
40769251|NCT04558736|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
40769252|NCT04558736|BIOLOGICAL|HPC, A Infusion|Given intravenously Day 0-HPC, A Infusion (TCR αβ+/CD19+-depleted graft)
40769253|NCT04558736|BIOLOGICAL|CD45RA-depleted DLI|CD45RA-depleted DLI will be given at least ONE week after engraftment
40769254|NCT06251973|BIOLOGICAL|AgenT-797|AgenT-797 is an investigational product, composed of allogeneic human unmodified iNKT cells, isolated from mononuclear cell aphaeresis units from healthy donors
40769255|NCT06251973|BIOLOGICAL|Botensilimab|Botensilimab is a novel, human, Fc-engineered IgG1 anti-CTLA-4 antibody
40769256|NCT06251973|DRUG|Balstilimab|Botensilimab is supplied as a sterile, single-use solution for IV administration
40769257|NCT06251973|DRUG|Ramucirumab|Ramucirumab is a fully human anti-VEGFR2 monoclonal IgG1 antibody (IgG1) that binds with high affinity to the extracellular domain of VEGFR2. Ramucirumab is a part of standard of care treatment for advanced gastric cancer or GEJ adenocarcinoma, after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
40769258|NCT06251973|DRUG|Paclitaxel|Paclitaxel is widely used across multiple cancer types and is a part of standard of care treatment for advanced EG adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
40769259|NCT06319248|DRUG|Midodrine|Subjects will receive standard of care for sepsis and 10 mg of Midodrine every 8 hours administered orally or enterally (via nasogastric tube)
40769260|NCT06319248|OTHER|Standard of Care|Subjects will receive standard of care for sepsis treatment.
40769261|NCT06258564|BIOLOGICAL|vaccination against human papillomavirus infection (HPV vaccination)|Women with or without HPV vaccination before or after excision
40971635|NCT03506178|DEVICE|Nasal mask with partly blocked|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
40971636|NCT05686850|PROCEDURE|High-Flow Oxygen|Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula
40769262|NCT06563830|OTHER|educational application|The content of the training to be applied to nurses will include: definition of MDRPI, etiology, prevalence and cost, staging, risk factors, nursing initiatives to be implemented to prevent MDRPI.
40769263|NCT03449576|OTHER|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
40769264|NCT03449576|OTHER|Exposure Therapy with Psychotherapy group|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
40769265|NCT05385978|DRUG|APHD-012|Distal jejunal-release dextrose beads (Aphaia technology, AT)
40971637|NCT05686850|PROCEDURE|Non invasive ventilation|NIV will be carried out in pressure-support mode with a minimal pressure-support level of 5 cmH2O targeting a tidal volume around 6 to 8 mL/kg of predicted bodyweight, a positive end-expiratory pressure (PEEP) level at least 8 cm H2O, and FiO2 adjusted to obtain adequate oxygenation
40971638|NCT05062382|BEHAVIORAL|Complementary feeding intervention|"The study promoted eggs.~GAIN provided training to egg farmers to increase their egg production and marketing, helped increase mother's access to eggs by making them more available in local kiosks and getting retailers to display promotional messages around eggs, conducted sensitization workshops with retailers to increase egg purchases, and employed a demand creation campaign."
40971639|NCT05077397|DEVICE|StO2|InSpectra Tissue Spectrometer Model 1615 probe (Hutchinson Technology Inc. Hutchinson, MN, USA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices and StO2 values in the devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
40971640|NCT05077397|DEVICE|O3|O3TM Regional Oximeter System (O3 System, Masimo Corporation, Irvine, CA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
40971641|NCT06056713|BEHAVIORAL|Hand Massage|The hand massage application lasted 10 minutes, 5 minutes on each hand, before each brachytherapy (3 times in total in the 1st, 2nd and 3rd sessions).
40971642|NCT01152242|DRUG|Isoglycemic Clamp|Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
40971643|NCT01152242|DRUG|Comparator: insulin glargine|Insulin glargine at 0.4 U/kg
40971644|NCT04127864|PROCEDURE|Colorectal cancer surgery|All participants will undergo surgery for colorectal cancer.
40971645|NCT05846945|OTHER|Threshold inspiratory muscle trainer device|The threshold inspiratory muscle trainer (IMT) device offers resistance to respiration through the spring-loaded valve.
40971646|NCT05846945|OTHER|Adjusting mechanical ventilator trigger sensitivity|modifying the mechanical ventilator trigger sensitivity so that patients can only initiate inspiratory flow by producing more negative intrathoracic pressure
40971647|NCT05846945|OTHER|Chest physiotherapy|Conventional chest physiotherapy
40971648|NCT03026010|PROCEDURE|central blood pressure|SphygmoCor XCEL will be used to measure both standard blood pressure in the arm and central pressure, the blood pressure at the heart.
40971649|NCT03695250|DRUG|IDO1 Inhibitor BMS-986205|Given PO
40971650|NCT03695250|BIOLOGICAL|Nivolumab|Given IV
40971651|NCT03930199|OTHER|Needs-based intervention (physical, psychological, or both)|Individuals identified as having physical issues (poor prosthesis fit, function, comfort or physical conditioning) will receive prosthetic care and physical therapy. This includes adjusting socket fit, component fit and repair, and in some instances replacement. Rehabilitation strategies include gait and prosthesis use retraining, balance fall-prevention, and range-of-motion training, strengthening, pain management, and activities of daily living training, based on participant-reported mobility goals. Individuals whose prosthesis use is reduced due to psychological issues will be provided with motivational interviewing and other related psychological interventions. During these interventions participant will be asked to set personal goals using a semi-structured interview that explores facilitators and barriers to wearing their prosthesis. If both physical and psychological issues are present, participant may receive both types of interventions simultaneously.
41139122|NCT04179526|BEHAVIORAL|Transdiagnostic Internet-delivered REBT|The protocol is based on Rational Emotive and Behavioral Therapy (REBT; Ellis, 1962, 1994). The program will consist of 8 modules, delivered online over six weeks.
41139123|NCT02873897|DIETARY_SUPPLEMENT|Session A: Experimental products (selected enriched products)|
41139124|NCT02873897|DIETARY_SUPPLEMENT|Experimental session: to select enriched products|
40971652|NCT02304172|DEVICE|Thunderbeat (Group A)|hemostatic device utilized intraoperatively
40971653|NCT02304172|DEVICE|Harmonic (Group B)|hemostatic device utilized intraoperatively
40971654|NCT02624908|DRUG|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
40971655|NCT02624908|DRUG|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
40971656|NCT04949477|DRUG|Dexmedetomidine|the patient will receive intranasal dexmedetomidine at a dose of 1 μg/kg to the patient 45 min. before the procedure.
40971657|NCT04949477|DRUG|paracetamol|the patient will receive paracetamol orally \[Rx paracetamol 250 mg/ml\] at a dose of 20 mg/kg given to the patient 45 min before the procedure by drinking.
41139125|NCT02873897|DIETARY_SUPPLEMENT|Session B: Control (standard products without enrichment)|
41139126|NCT02873897|DIETARY_SUPPLEMENT|Control session|
41139127|NCT00184743|DRUG|somatropin|
41139128|NCT00634998|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C capsules orally twice daily
41297842|NCT05580003|DRUG|PF-07817883|Oral suspension or solid oral formulation(s)
41297843|NCT05580003|DRUG|Placebo|Placebo suspension
41139129|NCT00634998|DIETARY_SUPPLEMENT|Placebo|1000mg Placebo capsules orally twice daily for 90 days
41139130|NCT04347005|DRUG|Cohort 1: AR882|Single dose of AR882 or matching placebo
41139131|NCT04347005|DRUG|Cohort 2: AR882|Single dose of AR882 or matching placebo
41139132|NCT04347005|DRUG|Cohort 3: AR882|Single dose of AR882 or matching placebo
41139133|NCT04347005|DRUG|Cohort 4: AR882|Single dose of AR882 or matching placebo
41139134|NCT04347005|DRUG|Cohort 5: AR882|Single dose of AR882 or matching placebo
41139135|NCT04347005|DRUG|Cohort 6: AR882 Food Effect|Single dose of AR882 or matching placebo in a fed state
41139136|NCT04347005|DRUG|Cohort 7: AR882 Solid Oral Formulation|Single dose of AR882 or matching placebo
41139137|NCT04347005|DRUG|Cohort 8: AR882 in combination with allopurinol|Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
41297844|NCT05580003|DRUG|Midazolam|midazolam oral solution
41297845|NCT05580003|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet
41458478|NCT01326351|BEHAVIORAL|Exercise|At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
41297846|NCT05360186|DEVICE|MateRegen® gel (BioRegen)|Modification of Hyaluronic acid structure to 3-dimensional self-cross-linked network structure enables all-dimensional coverage of tissue surface to enhance better healing process. Self-cross-linked HA hydrogels can maintain the biocompatibility and biodegradability that characterize the unmodified material. Moreover, high dynamic viscosity enables continuous indwelling in the uterine cavity. The gel could provide precise regulation, and degradation and absorption time prolonged to 7-14 days post operatively, which completely cover key postoperative healing period (5-7 days), at the highest time of intrauterine adhesion formation.
41297847|NCT03209544|BEHAVIORAL|Online self-help intervention|The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, \& Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).
41297848|NCT01629485|BEHAVIORAL|Online Video Curriculum|A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.
41297849|NCT01629485|BEHAVIORAL|Whole Task Mastery Training|Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.
41297850|NCT01629485|BEHAVIORAL|Part Task Mastery Training|Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.
41297851|NCT02976493|OTHER|No Intervention|No Intervention
41297852|NCT04041388|OTHER|Conebeam CT|medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
41297853|NCT01140542|DRUG|Roflumilast|500µg, once daily
41297854|NCT03394170|OTHER|Collection of specimens prior to and during surgery|Collection of specimens prior to and during surgery
41297855|NCT05173272|DRUG|Neoadjuvant Therapy|Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21+serplulimab 300mg d1 q21
41297856|NCT05173272|RADIATION|CCRT|weekly cisplatin for 4 or 5 weeks is administered concomitant with EBRT (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes.
41297857|NCT05173272|RADIATION|Brachytherapy|The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.
41458479|NCT06036927|DRUG|TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
41458480|NCT06036927|DRUG|TQC2731 matching placebo|It'a a placebo injection without active substances.
41297858|NCT05967234|BEHAVIORAL|Telehealth solution|Telehealth solution offered for breastfeeding education.
41297859|NCT01720511|DIETARY_SUPPLEMENT|Purple Rice|Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
41297860|NCT01720511|DIETARY_SUPPLEMENT|Brown Rice|Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
40971658|NCT05776420|BEHAVIORAL|Food voucher|A voucher of $65 (or $85 for people in larger households) that can be redeemed for food at grocery stores.
40971659|NCT04832360|BEHAVIORAL|Financial Incentives|Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)
40971660|NCT00208091|DRUG|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
40971661|NCT04821921|OTHER|No intervention|Care as usual
40971662|NCT01943890|DEVICE|Hypertonic saline|1 mmol/ml hypertonic saline given from (small children) 1,5 ml in 3 positions twice daily increasing to (children) 2 ml in 3 positions twice daily and up to (adults) 3 ml in 3 positions twice daily
40971663|NCT01943890|PROCEDURE|Physiotherapy|
40971664|NCT01148784|PROCEDURE|ACL reconstruction|Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.
40971665|NCT00969202|RADIATION|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
40971666|NCT06245135|BEHAVIORAL|TIME at Home|"Sessions involve a 15-minute pre-video safety check and social time; streaming a 1-hour pre-recorded exercise video; and a 15-minute post-video social time. Two trained facilitators run each class, with a maximum group size of 10 people.~The 1-hour exercise videos include a seated warm-up and cooldown, and 40 minutes of functional, self-paced exercises. In the video, 2 healthcare professionals demonstrate a lower and higher difficulty level of each exercise. The program starts with a level 1 video and switches to a level 2 video midway.~A registered healthcare professional, called the healthcare partner, visits select classes and serves as a resource to participants and facilitators."
40971667|NCT01108302|OTHER|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
40971668|NCT01640223|DEVICE|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
40971669|NCT01640223|DEVICE|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
40971670|NCT06102239|DIAGNOSTIC_TEST|Bilirubin level sodium level c reactive protein level|detect level of bilirubin,sodium \&c-reactive protein as indicator of complicated appendicitis
41139138|NCT04347005|DRUG|Cohort 9: AR882 in combination with febuxostat|Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
41139139|NCT01905566|DRUG|Clopidogrel|75mg once a day
41139140|NCT01905566|DRUG|Ticagrelor|90mg twice a day
41139141|NCT06220578|DEVICE|Oculus pentacam HR|Examination of corneal parameters by pentacam
41139142|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
41139143|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
41139144|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
41139145|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
41139146|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
41297861|NCT01461863|DIETARY_SUPPLEMENT|Porridge protein calorie supplement|250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
41297862|NCT01461863|DIETARY_SUPPLEMENT|multivitamin|Standard multivitamin
41297863|NCT02354170|DRUG|Mifepristone|
41297864|NCT02354170|DRUG|Placebo|
41297865|NCT00798967|DRUG|teduglutide|0.05 mg/kg/day sc injection for 24 weeks
40769266|NCT05385978|DRUG|APHD-012P|Distal jejunal-release placebo beads
40769267|NCT04215991|DRUG|Cefiderocol|Administered intravenously over 3 hours
41297866|NCT00798967|DRUG|placebo|Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
40769268|NCT04215991|DRUG|Standard of Care|Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
40971671|NCT05778916|PROCEDURE|5 year follow up on patients operated for hallux valgus deformity|Clinical and radiological control of patients operated for hallux valgus deformity between 2016-2018.
40971672|NCT01350414|DEVICE|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
41139147|NCT01208506|DRUG|placebo|A single dose of NNC0114-0000-0005 placebo.
41139148|NCT05263713|OTHER|Suture Closure of Linear Wounds|Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.
41297867|NCT00928473|BEHAVIORAL|A family-centered, multidisciplinary obesity treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
41297868|NCT02060396|DRUG|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
41458481|NCT03895151|DIETARY_SUPPLEMENT|Milk supplementation|Fresh milk from local farmer. No artificial sweetener and preservatives. Brandless.
41458482|NCT03895151|OTHER|Food Based Recommendation (FBR) nutrition education|Food Based Recommendation is result of OPTIFOOD WHO that analysed local food to optimize nutritional status according to problem nutrient.
40769269|NCT05614869|DEVICE|Prevena Plus Incision Management System with Prevena Dressings|Negative pressure pump and dressings
40769270|NCT01146821|DIETARY_SUPPLEMENT|0.20 gm/kg fish oil|Group 2: 7 patients will receive 0.20gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care
40769271|NCT01146821|DIETARY_SUPPLEMENT|0.50 gm/kg fish oil|Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care.
40769272|NCT05677347|DRUG|GSK3923868|GSK3923868 will be administered
40769273|NCT05677347|DRUG|Placebo|Placebo will be administered
40769274|NCT06594770|PROCEDURE|Atraumatic Restorative Treatment|"A sharp excavator will be used to remove soft demineralized carious tissue from the patient\&#39;s primary molar 2-The molar will then be restored with capsulated Glass Ionomer in accordance to ART procedure.~3-Each capsule will be mixed for ten seconds and used for restoring teeth isolated by cotton rolls.~4-After the cement is cured, excess material will be removed with an excavator and a carver.~5-The occlusion will be tested for interferences with carbon paper. A layer of varnish coat will be applied to the surface and light-cured for 20 seconds ."
40769275|NCT06594770|PROCEDURE|Hall technique|"The procedure involves assessing the occlusion, contact points, and tooth shape. If contact points are present, orthodontic separators will be placed between the primary molars to create space for crown fitting, with the child seated upright to maintain airway safety. After 3 to 5 days, the separators will be removed, and loose plaque and debris will be cleared.~The correct crown size will be selected, ensuring it doesn't impinge on adjacent teeth, and will be filled with glass ionomer cement. The child will be instructed to bite down for two minutes to ensure proper seating. Excess cement will be removed, and contacts will be flossed. Any initial occlusal discrepancies are expected to resolve within weeks."
40769276|NCT06352073|DRUG|Dupilumab|300mg weekly subcutaneous injection
40971673|NCT04711447|DEVICE|kinesio-tape|Twenty-one individuals with healthy shoulders completed 10 repetitions of an arm elevation task during three taping conditions (no-tape, experimental KT, sham KT) and 2 loading conditions (no-load and loaded).
40971674|NCT02747095|DEVICE|IQon Spectral CT|Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
40971675|NCT00080808|DRUG|Alprostadil (E1)|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
40971676|NCT00080808|DRUG|Papaverine|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
41139149|NCT05851157|DRUG|VX-548|Tablets for oral administration.
41297869|NCT04829318|DRUG|Esketamine|Esketamine will be self-administered as nasal spray.
41297870|NCT04829318|DRUG|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
41458483|NCT01407484|DRUG|Prednisone|0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
41458484|NCT01407484|DRUG|Placebo|Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
41458485|NCT00013364|BEHAVIORAL|Talker variability|
41458486|NCT05421195|DRUG|corticosteroids therapy|Oral corticosteroids
41458487|NCT05421195|OTHER|Olfactory training|repeat and deliberate sniffing of a set of odorants
41458488|NCT04129944|DRUG|UBX0101|Investigational drug intra-articular injection
41458489|NCT04129944|OTHER|Placebo|Placebo intra-articular injection
40971677|NCT00080808|DRUG|Phentolamine mesylate|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
40971678|NCT00080808|DRUG|Sildenafil citrate|Oral sildenafil as needed
40971679|NCT00080808|PROCEDURE|conventional surgery|Unilateral cavernous nerve sparing radical retropubic prostatectomy
40971680|NCT02021240|DRUG|Ketamine|
40971681|NCT02021240|DRUG|Dexamethasone|
40971682|NCT02021240|DRUG|Normal Saline|
40971683|NCT06304220|DRUG|Cerazet|Comparation of the utilization of two distinct progestogens for pituitary suppression
40971684|NCT02381288|DRUG|TAK-448|TAK-448 solution for subcutaneous injection
40971685|NCT02381288|DRUG|TAK-448 Placebo|TAK-448 placebo-matching solution for subcutaneous injection
40971686|NCT00002378|DRUG|Ritonavir|
40971687|NCT00002378|DRUG|Nelfinavir mesylate|
40971688|NCT00002378|DRUG|Saquinavir|
40971689|NCT00002378|DRUG|Delavirdine mesylate|
40971690|NCT00002378|DRUG|Lamivudine|
40971691|NCT00002378|DRUG|Stavudine|
40971692|NCT00002378|DRUG|Zidovudine|
40971693|NCT05782491|PROCEDURE|Interscalene Block|It is an ultrasound guided brachial plexus nerve block at roots/trunks used to anesthetize the shoulder and upper arm. Goal is to spread local anesthetic around superior and middle trunks of brachial plexus, between the anterior and middle scalene muscles.
40971694|NCT05782491|PROCEDURE|PECS II Block|PECS II block is comprised of two separate fascial plane blocks to anesthetize anterolateral chest wall using an ultrasound guided injection between the pectoralis major muscle and pectoralis minor muscle at third rib and a second ultrasound guided injection between pectoralis minor and serratus anterior. The goal is a high volume hydro dissection of the two fascial planes to anesthetize anterolateral chest wall and axilla.
40971695|NCT05782491|PROCEDURE|Superficial Cervical Plexus Block|This block is a superficial injection to the deep cervical fascia between the investing layer of the deep cervical fascia and the prevertebral fascia in the neck. This block provides anesthesia of the skin of the anterolateral neck and the ante-auricular and retro-auricular areas, as well as the skin overlying and immediately inferior to the clavicle on the chest wall. This is an ultrasound guided injection with the goal of placing the needle tip in the fascial layer underneath the SCM adjacent to the cervical plexus, which is contained within the tissue space between the Cervical fascia and posterior sheath of the SCM.
40971696|NCT05833854|OTHER|Virtual reality glasses group|It is suggested that the use of virtual reality glasses during the injection will positively affect the pain and fear levels in children who received penicillin injection in the pediatric emergency department where the study was conducted.
40971697|NCT05833854|OTHER|Manual pressure group|In the pediatric emergency department where the study was conducted, pressure will be applied to the area to be injected for 10 seconds before the injection procedure in children who received penicillin injection. Pressing with the thumb of the hand, which will be passive in the pressing application, will be understood by the whitening of the nail, and thus pressure will be applied to the skin. It is suggested that it can positively affect pain and fear levels.
40971698|NCT05798169|OTHER|Resistance training|Moderate resistance training by a innovative training robot 2 times a day during hospitalisation
40971699|NCT01829373|BIOLOGICAL|vaccine 1650-G|
40971700|NCT04166916|OTHER|Acoustic stimulation|Acoustic stimulation to modulate slow waves.
40971701|NCT04166916|OTHER|SHAM acoustic stimulation|This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
40971702|NCT04922008|DRUG|capecitabine and trastuzumab|In IRIS-C cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given capecitabine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
40971703|NCT04922008|DRUG|vinorelbine and trastuzumab|In IRIS-4 cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given vinorelbine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
41139150|NCT04346784|BEHAVIORAL|maintaining positive working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
40971704|NCT06091995|BEHAVIORAL|impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)|Evaluate the clinical impact of administering one dose of belatacept on eGFR at one-year post-transplant, patient and graft survival outcomes, graft rejection, and incidences of BK virus, EBV and CMV infections.
40971705|NCT03149198|OTHER|Mat Pilates exercises|The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.
40971706|NCT03149198|OTHER|Aquatic aerobic exercises|"The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.~The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator."
41139151|NCT04346784|BEHAVIORAL|repressing negative working memory training|Participants complete 10 sessions of repressing negative working memory training during a two-week period. Each session consists of 15 blocks.
41139152|NCT04346784|BEHAVIORAL|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
41139153|NCT04346784|BEHAVIORAL|Positive placebo ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes
41139154|NCT05432518|DRUG|Afatinib|Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
40971707|NCT03769454|DRUG|PP-001|PP-001 eye drops
41297871|NCT06332625|DIAGNOSTIC_TEST|Brain quantitative magnetic resonance imaging|Identification and predictability of early structural and metabolic markers from 3T and 7T quantitative magnetic resonance imaging (qMRI)
41297872|NCT03105154|OTHER|Prevena Dressing|Prevena dressing is applied on one groin
41297873|NCT03105154|OTHER|Conventional Dressing|Conventional dressing is applied on the contralateral groin
40971708|NCT03769454|OTHER|Placebo|Placebo eye drops
40971709|NCT01817998|OTHER|Physical Exercise|Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
40971710|NCT04173078|BEHAVIORAL|Computerized Distress Intolerance Intervention|
40971711|NCT04173078|BEHAVIORAL|Computerized Healthy Behaviors Intervention|
40769277|NCT06591728|DIETARY_SUPPLEMENT|Oral PCA|Administration of 1,000 mg BID of oral PCA in individuals with knee prosthetic joint infection prior to revision surgery
40769278|NCT03267849|OTHER|wearing swimming goggles or having laser suturelysis|Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the interventions
41297874|NCT01275261|BEHAVIORAL|Nursing protocol to avoid Foley catheter placement|A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
40769279|NCT03396861|DRUG|Aflibercept|Subconjunctival aflibercept
40769280|NCT02208167|BIOLOGICAL|HXTC infusion|
40769281|NCT03952598|DEVICE|3T MRI scanner|Research proton MRS (1H-MRS)followed by DW-MRI
40769282|NCT05294146|DRUG|Clofazimine|"All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.~Blood samples will be taken at Day 28 (+/- 2 days), Day 29 (Day 28 +1) and after 4 months of treatment to assess the pharmacokinetics of CFZ, both with the loading dose and the standard dose. In addition, the safety/tolerability of CFZ will monitored."
40971712|NCT00826215|DEVICE|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
40971713|NCT00826215|DEVICE|Sham laser acupuncture|Sham laser acupuncture
40971714|NCT05124964|OTHER|PedsQL 4.0 Scale|The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL. PedsQL 4.0 will be evaluated at baseline, yearly through 3 years post-enrollment.
40971715|NCT05124964|OTHER|Short Form-36|Altogether, 36 questions with standardized response choices were organized into eight scales, including physical functioning (PF), role limitations as a result of physical health problems (RP), body pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations as a result of emotional problems (RE), and general mental health (MH). Additionally, reported health transition (HT) was used to evaluate general health changes during the previous year. The raw scores were converted to a 0-100 scale according to the instructions, and higher scores indicated a better HRQOL. Physical component score (PCS) and mental component score (MCS) were also calculated. SF-36 will be evaluated at baseline, yearly through 3 years post-enrollment.
40971716|NCT05124964|OTHER|Chinese Wechsler Intelligence Scale for Children|The intelligence of the child was tested by the China-Wechsler Intelligence Scale for Children (C-WISC), which was revised by Gong and Cai at Hunan Medical University. The C-WISC consists of 11 individual tests that include six verbal tests \[Information (I), Comprehend (C), Sorting (S), Arithmetic (A), Vocabulary (V), and Digit symbol (D)\] and five performance tests \[Picture Completing (PC), Picture Arrangement (PA), Block Pattern (BP), Object Assembly (OA), and Coding (CD)\]. Based on individual testing, vocabulary scores (V), procedure scores (P), and full scores (F) were obtained. Furthermore, the VIQ, PIQ, and full intelligence quotient (FIQ) were calculated progressively . C-WISC will be evaluated at baseline, yearly through 3 years post-enrollment.
40971717|NCT05033353|DIAGNOSTIC_TEST|Monitoring of regional cerebral oxygenation|Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.
40971718|NCT04853511|DEVICE|OCT-FLIM (optical coherence tomography-fluorescence life time)|comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
40971719|NCT02936570|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)"
40971720|NCT06395636|DEVICE|Infection-Prediction Algorithm|This machine learning algorithm will be developed(Aim1a) and validated(Aim 1b) using the participant Fitbit data and survey results collected during Aim 1. In Aim 2 the algorithm will be used in real time to predict postoperative infection.
40971721|NCT00499577|BIOLOGICAL|CMV pp65 peptide|Given intramuscularly
40971722|NCT00499577|BIOLOGICAL|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
40971723|NCT00499577|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
40769283|NCT05127174|DRUG|Fedratinib Pill|Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
40769284|NCT06061185|DEVICE|Multimodal CT|Non-contrast computed tomography, computed tomography angiography and computed tomography perfusion
40769285|NCT03573089|DRUG|Liberal phosphate target|All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
40769286|NCT03573089|DRUG|Intensive phosphate target|This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
40769287|NCT04089358|OTHER|Educational Intervention|Receive educational materials
40769288|NCT04089358|DEVICE|FitBit|Wear a Fitbit
40971724|NCT00499577|BIOLOGICAL|survivin Sur1M2 peptide vaccine|Given subcutaneously
40971725|NCT06508424|OTHER|PulseOn|PulseOn - 1 week washout period between interventions 75g crackers
40971726|NCT06508424|OTHER|Wheat flour control|Control -1 week washout period between interventions 75g crackers
41139155|NCT05432518|DRUG|Dasatinib|Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
41139156|NCT05432518|DRUG|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
41139157|NCT05432518|DRUG|Everolimus|Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
40971727|NCT00763568|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
40971728|NCT00763568|BIOLOGICAL|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
40971729|NCT03762421|BEHAVIORAL|Psycho-social skills development workshops based on PM plus|5 weekly, psycho-social skills development workshops will be conducted for newly inducted civil servants in groups, based on the problem management plus intervention. These workshops will be integrated into routine induction sessions of trainee civil servants. Workshop 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, teaches the difference between technical and adaptive challenges, and trains participants in a basic stress management strategy. Workshop 2 addresses a participant-selected problem using problem-solving techniques and introduces behavioral activation. Workshops 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks whenever required. In Workshop 5, education about retaining intervention gains are provided and all learned strategies are reviewed.
40971730|NCT03762421|BEHAVIORAL|Routine training induction sessions|The control group will receive 5 routine training induction sessions. These orientation sessions include lectures introduction to governance, public sector management, basic information technology, economics and public finance and official rules of procedure of the government of Pakistan. These lectures are held in a friendly and supportive environment.
40971731|NCT01302093|DRUG|Racecadotril Film-Coated Tablet (FCT)|A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
40971732|NCT01302093|DRUG|Racecadotril Capsule|A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
40769289|NCT04089358|OTHER|Goal Setting|Set goals
40769290|NCT04089358|OTHER|Health Promotion and Education|Receive text message about goal setting
40769291|NCT04089358|OTHER|Media Intervention|Follow Instagram group
40769292|NCT04089358|BEHAVIORAL|Telephone-Based Intervention|Receive phone call about goal setting
40769293|NCT01189760|BIOLOGICAL|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
40971733|NCT03244215|DIAGNOSTIC_TEST|Corneal Confocal Imaging|Retinal imaging will be ordered for all subjects in the study group. Corneal
40971734|NCT03244215|DIAGNOSTIC_TEST|Magnetic resonance Imaging|MRI will be ordered for all study subjects at the completion of their participation at year 1. The MRI will assess the the progression or regression of the cerebrovascular health of the study subjects.
40971735|NCT03244215|OTHER|Blood sample|Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
40971736|NCT05799066|DIAGNOSTIC_TEST|Swinging Light test|The swinging light or pen light test with manual pupil measurements is the standard of care test for RAPD. This test consists of a light being shone in one eye for 3 to 4 seconds then shown in the other eye for 3 to 4 seconds, repeating 2 to 3 times. Pupils are measured manually immediately after the light test. Measurements are recorded in patient's medical record.
41139158|NCT05432518|DRUG|Olaparib|Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
41297875|NCT04652063|OTHER|Osteopathic Manipulative Medicine|Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
40769294|NCT01189760|BIOLOGICAL|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart
41139159|NCT03950726|PROCEDURE|ileocolic resection|Ileocolic resection through McBurney incision
41139160|NCT03979040|BEHAVIORAL|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
41139161|NCT03979040|BEHAVIORAL|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant's principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and Depression (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
41139162|NCT03166605|DRUG|Simethicone|Giving simethicone before and after capsule ingestion.
41139163|NCT00643409|DRUG|azithromycin SR (Zithromax; compound: CP-62,993)|Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
40769295|NCT01189760|DRUG|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
40971737|NCT05799066|DIAGNOSTIC_TEST|Virtual Reality Head-Mounted Display (VR HMD)|A light is shone from within the VR HMD, pupillary measurements are taken and recorded by the machine learning (ML) algorithm.
41139164|NCT00643409|OTHER|placebo|placebo
40769298|NCT06639997|DRUG|AZD5148|Participants will receive AZD5148 as IM injection or IV bolus
40769299|NCT06639997|DRUG|Placebo|Participants will receive matching doses of placebo as an IM injection or IV bolus
41139165|NCT00643409|DRUG|levofloxacin|levofloxacin 500 mg capsule by mouth qd x 10 days
41139166|NCT00643409|OTHER|placebo|placebo
41139167|NCT00246350|PROCEDURE|massage|8 light massage treatments and hot pack
41139168|NCT00246350|PROCEDURE|massage|16 light massage treatments and hot packs
41139169|NCT00246350|PROCEDURE|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
41139170|NCT00246350|PROCEDURE|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
41139171|NCT02065609|DRUG|89Zr-Trastuzumab Human Dosimetry and Safety|PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
41139172|NCT02065609|DRUG|HER2 Positive Lesion Detection and Safety|Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
41297876|NCT06323330|OTHER|Speech rehabilitation|Melodic Intonation Therapy- Indian Adaptation module which will be developed in the pilot phase
41297877|NCT03648996|OTHER|Low-fructose diet, isocaloric|6 month of consumption a low fructose diet
41297878|NCT03648996|DRUG|Allopurinol|6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
41297879|NCT03648996|DRUG|Placebo|6 months of placebo treatment
41297880|NCT03648996|OTHER|Low-fructose, hypocaloric|6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction
40971738|NCT00302250|DRUG|ALT-711 (alagebrium chloride)|
40971739|NCT04697524|BEHAVIORAL|Support Group Therapy|Virtual group meetings
40971740|NCT04697524|BEHAVIORAL|Symptom Management Service (SMS) Consultation|Virtual individual meetings with symptom management service (SMS) over 5 minutes
40971741|NCT04697524|OTHER|Quality of Life (QOL) Questionnaires|Administered at each study visit
40971742|NCT04697524|OTHER|Interview|Virtual exit interview at end of study
40971743|NCT00479076|DRUG|aflibercept (AVE0005)|intravenous infusion
40971744|NCT00479076|DRUG|S-1|oral administration
40971745|NCT03893799|DRUG|RBT-1|intravenous administration
40971746|NCT05292846|DRUG|Direct-acting oral anticoagulation|Apixaban Dabigatran Edoxaban Rivaroxaban
40971747|NCT06021730|BEHAVIORAL|Standardized After Visit Instructions Only|The intervention took a standardized approach to after visit instructions which included a customizable template that would review patients conditions, changes in any medications, and any future labs, imaging, or referrals.
40971748|NCT06021730|BEHAVIORAL|Standardized After Visit Instructions & Teach Back|This intervention included the Standardized After Visit Instructions and included teach back, a process by which patients restate in their own words their understanding of their condition, what was discussed in the visit, and what potential changes were made
40971749|NCT03519425|OTHER|Optimised HIV screening and linkage to care|As described in group descriptions
40971750|NCT03519425|OTHER|Optimised tuberculosis screening and linkage to care|As described in group descriptions
40971751|NCT01803373|DRUG|Treatment A (reference)|One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
41458490|NCT06175741|PROCEDURE|erector spinae plane block|The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in one level (between T3and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group
40971752|NCT01803373|DRUG|Treatment B|Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
40971753|NCT01803373|DRUG|Treatment C|5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
40971754|NCT01286298|PROCEDURE|Laser gingivectomy|Gingivectomy by diode laser
40971755|NCT01286298|PROCEDURE|Laser gingivectomy|Diode laser gingivectomy for gingival enlargement
40971756|NCT05447637|DIAGNOSTIC_TEST|Invitae multi-cancer gene panel|Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
40971757|NCT05564936|DEVICE|ME&MG mobile application|ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
40971758|NCT06280937|OTHER|Wearing a tie|Individuals in the study group will be asked to wear a tie during one office working day.
40971759|NCT03937310|DIAGNOSTIC_TEST|Next-generation sequencing of swabs collected during surgery|Traditional swabs for culturing as well as swabs for NGS testing will be collected
40971760|NCT01562418|BEHAVIORAL|Ergonomic intervention|Ergonomic intervention, how to sit and work, an d muscle re education with a SurfaceElrctromyograph Biofeedback (SEMG biofeedback)
40971761|NCT01562418|BEHAVIORAL|Standard ergonomic intervention|Standard ergonomic intervention , how to sit and work with computers
40971762|NCT01562418|BEHAVIORAL|control group|general instructions no intervention
41139173|NCT04588207|DRUG|Urea|"Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day."
41458491|NCT05726058|DEVICE|XyCAM with oxygen|After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.
41458492|NCT01547507|DEVICE|AirWay Medix Closed Suction System|AirWay Medix Closed Suction System
41458493|NCT05483608|OTHER|Vertical climbing ergometer exercise|Exercise using the CLMBR, a vertical climbing exercise ergometer.
41458494|NCT05483608|OTHER|Recumbent cycling|Exercise using a recumbent cycle ergometer
41458495|NCT00292760|DRUG|Alemtuzumab|
41458496|NCT00292760|DRUG|Methyprednisolone|
40971763|NCT04255602|DRUG|Ticagrelor 60mg|Ticagrelor 60mg plus Aspirin 100mg for experimental group
40971764|NCT04255602|DRUG|Ticagrelor 90mg|Ticagrelor 90mg plus Aspirin 100mg for active comparator group
40971765|NCT04847492|PROCEDURE|Traditional corticotomy|A full-thickness mucoperiosteal flap will be elevated including the interdental papilla, and extended from the distal side of the second premolar on the right side to the same position on the left side without performing any vertical releasing incisions. Then, one vertical incision between the roots of upper anterior teeth and two vertical incisions in the site of first premolar extraction will be made by the piezosurgery knife.
40971766|NCT04847492|PROCEDURE|Flapless corticotomy|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva by using a blade N.15. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
40971767|NCT03578861|OTHER|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
40971768|NCT01327898|BEHAVIORAL|empowerment theory-based small group discussion|four small group discussion sessions followed by one individual counseling session
40971769|NCT01327898|BEHAVIORAL|individual resilience counseling|one individual resilience counseling session
40971770|NCT03241251|OTHER|questionnaire|Questionnaire of psychosocial risk factors
40971771|NCT03928574|PROCEDURE|Ultrasound-Guided Plane Block|Ultrasound-Guided Plane Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
40971772|NCT03928574|PROCEDURE|Conventional Block|Conventional Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
40990796|NCT00818428|BEHAVIORAL|Speech Production Intervention|Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
41139174|NCT00408109|DRUG|VRC-AVIDNA036-00-VP|
41458497|NCT04022941|DRUG|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5 days.
41458498|NCT04022941|OTHER|Powdered table sugar as palcebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
41458499|NCT01444196|DRUG|Desloratadine|Every day,per mouth,in the evening, for 14 +- 2 days.
41139175|NCT04725552|BEHAVIORAL|'Change' - an e-health intervention|The aim of the e-health intervention is to support the patient's change process and facilitate the doctor's ability to help. We plan for a web-application instead of a native application. A web-application enables use from mobile devices and from computers and is thus not dependent on a specific mode or system. Before including patients (postponed to September 2020 because of the Corona-virus pandemic), about 30 members of the general public have tested the e-health intervention.
41139176|NCT03049332|BEHAVIORAL|self- and family-management intervention sessions|The self- and family management intervention will have six elements: (a) biofeedback for relaxation; (b) family support; (c) coping skills; (d) anxiety, stress, and depression management; (e) cognitive-behavioral management skills; and (f) psycho-educational classes.
41139177|NCT05673109|DRUG|AC176|AC176 will be given orally (PO) on a 28-day cycle.
41458500|NCT04233866|DRUG|Fluorouracil|Given IV
41458501|NCT04233866|DRUG|Gemcitabine|Given IV
41458502|NCT04233866|DRUG|Gemcitabine Hydrochloride|Given IV
41458503|NCT04233866|DRUG|Leucovorin|Given IV
41458504|NCT04233866|DRUG|Leucovorin Calcium|Given IV
41458505|NCT04233866|DRUG|Liposomal Irinotecan|Given IV
41458506|NCT04233866|DRUG|Nab-paclitaxel|Given IV
41458507|NCT04233866|OTHER|Quality-of-Life Assessment|Ancillary studies
40769300|NCT03286361|DEVICE|BeGraft Peripheral Plus Stent Graft System|Patients will be treated with the BeGraft Peripheral Plus Stent Graft System
41458508|NCT04233866|OTHER|Questionnaire Administration|Ancillary studies
40769301|NCT03399773|BIOLOGICAL|Dilanubicel|Given IV
41458509|NCT03019016|PROCEDURE|Right Colectomy|Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.
40769302|NCT03399773|DRUG|Cyclophosphamide|Given IV
40769303|NCT03399773|DRUG|Fludarabine|Given IV
41139178|NCT00054197|DRUG|gemcitabine hydrochloride|
41139179|NCT00054197|DRUG|paclitaxel poliglumex|
41458510|NCT03695354|DEVICE|whole body vibration plus conventional therapy|"Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise."
41458511|NCT03695354|PROCEDURE|conventional therapy|conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
41458512|NCT05590390|DIAGNOSTIC_TEST|DXA|bone densitometry at lumbar and femoral site+ morphometry (DXA),
41458513|NCT05590390|DIAGNOSTIC_TEST|serum sample|serum samples for bone biomarkers ( eg. P1NP, CTX, Dkk-1, etc)
40769304|NCT03399773|DRUG|Thiotepa|Given IV
40769305|NCT03399773|RADIATION|Total-Body Irradiation|Undergo TBI
41458514|NCT05590390|DIAGNOSTIC_TEST|PROs|questionnaires to investigate patients reported outcome on quality of life
40769306|NCT03399773|PROCEDURE|Umbilical Cord Blood Transplantation|Given IV
40769307|NCT03399773|OTHER|Laboratory Biomarker Analysis|Correlative studies
40769308|NCT03399773|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40769309|NCT03399773|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate and biopsy
41139180|NCT00054197|DRUG|vinorelbine tartrate|
41139181|NCT02782260|DRUG|Dipyridamole|
41139182|NCT02782260|DRUG|Placebo|
41139183|NCT00164996|PROCEDURE|Local pharyngeal anaesthesia|
41458515|NCT03747107|BEHAVIORAL|P-DQIP|The 'intervention' is a health board quality improvement programme to be implemented across all practices in one Scottish NHS health board and comprises the following components: (i) Case finding via the P-DQIP informatics tool to identify patients with drug therapy risks for review; (ii) Decision support via the P-DQIP informatics tool to facilitate medication reviews; (iii) Practice pharmacists will be trained on the use of the P-DQIP informatics tool and instructed to target patients at risk of bleeding and hypoglycaemia first (iv) Ongoing performance feedback. Practices and locality pharmacists will be able to access reports on review activity and targeted prescribing; (v) promotion of the P-DQIP tool and intervention among GP practices. The P-DQIP intervention will be evaluated in all NHS Tayside practices who agree to share their data for monitoring and evaluation purposes.
41458516|NCT00582244|BEHAVIORAL|CBT and relaxation|Group A: CBT and relaxation.
40769310|NCT03399773|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspirate and biopsy
40769311|NCT03399773|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40769312|NCT03399773|PROCEDURE|Electrocardiography|Undergo ECHO
40769313|NCT03399773|PROCEDURE|Computed Tomography|Undergo CT
41139184|NCT00164996|DEVICE|Ultrathin endoscope|
41139185|NCT00110032|DRUG|EF5|Given IV
41139186|NCT00110032|PROCEDURE|conventional surgery|Undergo surgery
41139187|NCT00110032|PROCEDURE|positron emission tomography|Undergo PET
41139188|NCT00110032|RADIATION|fluorine F 18 EF5|Given IV
41139189|NCT00110032|OTHER|pharmacological study|Correlative studies
41458517|NCT00582244|BEHAVIORAL|Physical activity|Group B: Physical exercise program.
41458518|NCT00582244|BEHAVIORAL|CBT and physical activity|Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
41458519|NCT00582244|OTHER|Control group|Waiting list control group
41458520|NCT04371224|DRUG|Irinotecan Liposomal Injection [Onivyde]|both arm
41458521|NCT04371224|DRUG|Capecitabine|NaliCap
41458522|NCT04371224|DRUG|5-fluorouracil|NAPOLI
41458523|NCT04371224|DRUG|Leucovorin|NAPOLI
41458524|NCT00414479|DRUG|praziquantl, iron, ACT|
40971773|NCT05466162|OTHER|Soft tissue mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
40971774|NCT05466162|OTHER|Joint and nerve mobilization|"Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
40971775|NCT02333877|OTHER|Skinlink|suture using Skinlink
40971776|NCT02333877|OTHER|Nylon|conventional suture using nylon
40971777|NCT05508581|PROCEDURE|microwaves ablation of varicose veins|"Microwave ablation is an endovenous treatment. This is a similar treatment approach as laser ablation and radiofrequency ablation. Endovenous means that the treatment device is inside the vein during treatment."
40971778|NCT01506128|OTHER|Collecting a Pad used at the first menstrual period after enrollment|Collecting a Pad used at the first menstrual period after enrollment
41139190|NCT03561870|DRUG|Olaparib 150 MG|Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity
41139191|NCT00828178|DRUG|Omega-3|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
41139192|NCT00828178|DEVICE|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
41458525|NCT04794179|DEVICE|Naida Link CROS|Individuals 65+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
41458526|NCT00356096|DRUG|pramipexole|
41458527|NCT02834962|PROCEDURE|single bundle ACL reconstruction|anterior cruciate ligament reconstruction using single bundle technique
41458528|NCT02834962|PROCEDURE|double bundle ACL reconstruction|anterior cruciate ligament reconstruction using double bundle technique
41458529|NCT01632423|DRUG|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
41458530|NCT06383949|DEVICE|Synergy Cervical Disc system|motion preservation disc
40971779|NCT00003128|BIOLOGICAL|filgrastim|
40971780|NCT00003128|DRUG|ifosfamide|
41139193|NCT00828178|OTHER|corn starch|3 capsules qd for 12weeks
41139194|NCT03979352|DRUG|empagliflozin|Treatment with empagliflozin 25mg orally once a day
41139195|NCT03979352|DEVICE|artificial pancreas|Insulin delivery via a closed loop single-hormone artificial pancreas system.
41139196|NCT03500406|DEVICE|RestoreX|Penile traction therapy in the straight position
41458531|NCT04638400|DRUG|Simvastatin 40mg|Simvastatin administered daily for 6 weeks
40971781|NCT00003128|DRUG|paclitaxel|
40971782|NCT00652405|DIETARY_SUPPLEMENT|alcohol|250 ml of white wine (13% vol; \~25 gram of alcohol per day)
40971783|NCT00652405|DIETARY_SUPPLEMENT|Placebo|250 ml of mineral water (Brand name: Vittel)
40971784|NCT02498184|OTHER|acupuncture|
40971785|NCT00902915|DRUG|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
41458532|NCT04638400|DRUG|Ezetimibe 10mg|Ezetimibe administered daily for 6 weeks
41458533|NCT00002592|BIOLOGICAL|c-myb antisense oligonucleotide G4460|
41458534|NCT00002592|BIOLOGICAL|filgrastim|
41139197|NCT03500406|OTHER|Control|No treatment
41139198|NCT03002194|DEVICE|Cutometer|Skin elasticity will be measured by a Cutometer prior to beginning treatment, week 7 and 3 months after completion of the treatment.
41139199|NCT03002194|OTHER|Photographs|Photographs will be taken prior to beginning treatment, week 7 and 3 months after completion of the treatment.
41139200|NCT03569241|RADIATION|whole pelvic radiotherapy|addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
41139201|NCT03569241|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
41139202|NCT03569241|PROCEDURE|salvage Lymph Node Dissection|metastasis-directed treatment
41139203|NCT03569241|DRUG|androgen deprivation therapy|LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
41139204|NCT02067689|DEVICE|Transcranial Direct Current Stimulation|Application of a weak electrical current to the scalp
41139205|NCT05765526|DEVICE|A novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 10 minutes on the participant's scalp until half bottle (200ml) of water is used. Their scalp will then be rinsed and gently dried with a towel.
41139206|NCT00105222|DRUG|Sodium Nitrite|
41139207|NCT03953079|DRUG|Drug: GB-102|Intravitreal injection of GB-102
41139208|NCT03953079|DRUG|Aflibercept|Intravitreal injection of aflibercept (2 mg dose)
41139209|NCT06307951|OTHER|No intervention|No intervention
41458535|NCT00002592|DRUG|busulfan|
41458536|NCT00002592|DRUG|cyclophosphamide|
41458537|NCT00002592|PROCEDURE|autologous bone marrow transplantation|
41458538|NCT00002592|PROCEDURE|in vitro-treated bone marrow transplantation|
41458539|NCT02845336|DRUG|Celecoxib|celecoxib 100mg PO twice per day for 3 months
41458540|NCT02845336|DRUG|artificial tears|Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.
40971786|NCT02823431|DRUG|lidocaine gel|
40971787|NCT02823431|OTHER|Plain aqueous gel|
40971788|NCT03203304|DRUG|Nivolumab|240mg every two weeks by IV infusion
40971789|NCT03203304|DRUG|Ipilimumab|1mg/kg every six weeks by IV infusion
40971790|NCT02519036|DRUG|ISIS 443139 10 mg|ISIS 443139, 10 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
40971791|NCT02519036|DRUG|ISIS 443139 30 mg|ISIS 443139, 30 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
40971792|NCT02519036|DRUG|ISIS 443139 60 mg|ISIS 443139, 60 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
40971793|NCT02519036|DRUG|ISIS 443139 90 mg|ISIS 443139, 90 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
40971794|NCT02519036|DRUG|ISIS 443139 120 mg|ISIS 443139, 120 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
41297881|NCT06133829|BEHAVIORAL|upREACH Home Visitation Program|upREACH is a brief perinatal home visitation program delivered by community health workers or similarly qualified personnel. The mission statement of the program is: Families are prepared to bring home their newborn to a safe, stable, and nurturing environment, and have access to tools, resources, and knowledge that promote family health and well-being. Through the program, families will receive a minimum of 2 home visits during pregnancy and/or postpartum from a home visitor (community health worker (CHW) or similarly qualified personnel). The home visitor will assess each family's strengths and needs so they may provide tailored support and brief education to promote maternal health and self-care, infant health and safety, and connection to and knowledge of resources (community orientation).
41297882|NCT04813237|OTHER|n a|the participants are not subjected to any type of intervention
41458541|NCT01507233|DRUG|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.
41458542|NCT01507233|DRUG|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
41458543|NCT05734716|DRUG|Erythropoietin|use of erythropoietin to stimulate red blood cell development prior to ascent to altitude
40971795|NCT02519036|OTHER|Placebo|Placebo was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
41139210|NCT01555307|OTHER|Typical range of motion and muscle strengthening exercises, and balance exercises|Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
41139211|NCT01555307|OTHER|Typical group|Seven typical exercises, 10 times each, 3 times a day
41297883|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (10 mg)|A low dose of 10 mg 2C-B will be administered.
41297884|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (20 mg)|A medium dose of 20 mg 2C-B will be administered.
41297885|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (30 mg)|A high dose of 30 mg 2C-B will be administered.
41297886|NCT05523401|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 125 mg MDMA will be administered.
41297887|NCT05523401|DRUG|Psilocybin|A moderate dose of 25 mg psilocybin will be administered.
41297888|NCT05523401|OTHER|Placebo|Placebo (Mannitol)
41297889|NCT05817773|DEVICE|breastfeeding cradle|Mothers with postop mobile cesarean section should be breastfed with a nursing cradle for 30 minutes every 2-3 hours, even if the baby does not cry, until after mobilization (for 6 hours after coming to the service) every time the baby cries.
41458544|NCT05734716|DRUG|Iron sucrose (Venofer)|use of iron sucrose to stimulate red blood cell development prior to ascent to altitude
40971796|NCT06379178|PROCEDURE|Oral colostrum application 2 hours|Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 2 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
40971797|NCT06379178|PROCEDURE|Oral colostrum application 4 hours|Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 4 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
40971798|NCT04693234|DRUG|Tislelizumab|Administered as specified in the treatment arm
40971799|NCT04693234|DRUG|Ociperlimab|Administered as specified in the treatment arm
40971800|NCT00314093|DRUG|RFT5pdgA|
40971801|NCT02536196|DEVICE|Embolic Protection Device|Embolic protection
40971802|NCT02536196|PROCEDURE|Transcatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
40990797|NCT00818428|BEHAVIORAL|Speech Perception Intervention|Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
41139212|NCT03274648|DIETARY_SUPPLEMENT|Oral butyrate|Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
41139213|NCT03274648|DIETARY_SUPPLEMENT|Vegetarian diet|Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
41139214|NCT03274648|DIETARY_SUPPLEMENT|Habitual diet|Patients follow the habitual diet
40971803|NCT03323931|BEHAVIORAL|(2) robot--enhanced intervention|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by the robotic agent (Softbank Robotics Nao robot). All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
40971804|NCT03323931|BEHAVIORAL|(1) discrete trial training / cognitive-behavior therapy|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by an interaction partner (human), under the supervision of the therapist. All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
40971805|NCT02161367|DRUG|Simethicone|"Pharmacological category: antiflatulent~160mg Simethicone orally, 4 times a day for the first five postoperative days"
40971806|NCT02161367|DRUG|Oral Suspending Vehicle|"ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days"
40971807|NCT05872841|DRUG|Recombinant human adenovirus type 5 + TACE|"1. Recombinant human adenovirus type 5 : Recombinant human adenovirus type 5 injection is administered intratumorally 48-72h prior to TACE treatment.Before administration, the recombinant human adenovirus type 5 injection was diluted to 30% of the total tumor volume with normal saline. H101 dose:~   ① The sum of the maximum diameters of the lesions was ≤10cm, and the total dose was 1. 0×1012vp (2 injections);~   ② The sum of the maximum diameters of the lesions was \>10cm, and the total dose was 1. 5×1012vp (3 injections);~2. TACE：The specific chemotherapeutic drugs were: oxaliplatin 85mg/m2, calcium folinic acid 400mg/m2, 5-fluorouracil 1200mg/m2, followed by superfluid iodinated oil bolus according to the intraoperative contrast tumor blood supply.~Recombinant human adenovirus type 5 was administered in combination with TACE in cycles of every 3 weeks for a total of 2-4 cycles."
40971808|NCT04236830|DRUG|Silver diamine fluoride/ potassium iodide|Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.
40971809|NCT04236830|DRUG|Silver diamine fluoride|Thirty six first permanent molars will receive 38% SDF as an indirect pulp capping material.
41458545|NCT05734716|DRUG|Sterile Sodium Chloride|sham treatment with sterile saline
40971810|NCT04236830|DRUG|Resin modified glass ionomer cement|Thirty six first permanent molars will receive RMGIC as an indirect pulp capping material.
40971811|NCT02669381|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
41139215|NCT04296734|BEHAVIORAL|Mothers and Babies|Mothers \& Babies (MB) is a program that promotes healthy mood management by teaching pregnant women and new moms how to effectively respond to stress in their lives through increasing the frequency of thoughts and behaviors that lead to positive mood states. Designed as a perinatal depression prevention, the Mothers \& Babies targets three specific risk factors: limited social support, lack of pleasant activities, and harmful thought patterns.
41139216|NCT04062383|BEHAVIORAL|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
41139217|NCT04364230|DRUG|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
41139218|NCT04364230|DRUG|NeoAg-mBRAF|BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
41139219|NCT04364230|DRUG|PolyICLC|polyICLC, local adjuvant
41139220|NCT04364230|DRUG|CDX-1140|CDX-1140, local adjuvant
41139221|NCT03259126|DEVICE|SCUT|Two different home made curtains were attached to the angiographic table
41139222|NCT03175406|DIAGNOSTIC_TEST|Manipal cervical scoring system|
41139223|NCT05894291|OTHER|Swimmer Prone Position|"Patients will be positioned with the head rotated. This rotation is followed by shoulder elevation/abduction, then 90° elbow flexion for the arm opposite to the head rotation. The hand is placed flat on the bed.~A 60° to 90° flexion is performed on the hip homolateral to head rotation, combined with knee flexion.~The position is changed to the mirror position every 4 hours."
41458546|NCT00530660|BIOLOGICAL|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
41458547|NCT04459754|DRUG|Fuzheng Yiliu Formulation|"The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption."
41458548|NCT04123366|DRUG|Olaparib|Oral tablet
41458549|NCT04123366|BIOLOGICAL|Pembrolizumab|Intravenous infusion
41297890|NCT03852888|BIOLOGICAL|Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level|Each patient will have to complete a total of 8 urine samples after treatment with methotrexate. The 8 samples will be taken over one week (just before taking, then 2 hours after taking treatment and then on D3, D4, D5, D6, D7, D8 before the new dose of methotrexate).
40971812|NCT03935204|BIOLOGICAL|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
40971813|NCT03935204|BIOLOGICAL|Placebo|Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
41297891|NCT06044753|DEVICE|Virtual Reality Headset|"Non immersive VR experience basically means providing a near reality environment for viewers, however, viewers won't be able to make any changes to it as they can only watch.~This Non-immersive Virtual reality experience will be applied unto the child by using a headset that incorporates a computerized dimensional environment which will be simulated to make the child feel near reality .The VR headset consist of a cover for handphone slot, screen display, two lenses with adjustable eye pieces to focus, foam padding and adjustable elastic head mount strap."
40971814|NCT04813406|DRUG|Anlotinib + Sintilimab|"Anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Sintilimab: 200 mg/time, intravenous injection, every 3 weeks is one cycle."
40971815|NCT01539850|DEVICE|OMS102|Subjects will receive implanted OMS102 System.
40971816|NCT01074112|DEVICE|EFAST exam|Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
40971817|NCT01074112|DEVICE|Pelvic Ultrasound|Ultrasound view of the pelvis. including the bladder and uterus
40971818|NCT01074112|PROCEDURE|Ultrasound Guided Vascular Access|Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
40971819|NCT01074112|DEVICE|Focused Ultrasound Scan|Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
40971820|NCT01074112|DEVICE|Cardiac Ultrasound|Ultrasound views of the heart
41458550|NCT02941939|OTHER|Hyperbaric chamber|
41458551|NCT02941939|OTHER|Ambient pressure|
41466508|NCT02408120|DRUG|Supplemental insulin aspart|"Insulin aspart will be administered following the supplemental insulin scale protocol.~For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:~* BG \>141-180 mg/dL; 2-4 units of insulin aspart~* BG between 181-220 mg/dL; 3-6 units of insulin aspart~* BG between 221-260 mg/dL; 4-8 units of insulin aspart~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart~For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart"
41139224|NCT05894291|OTHER|Prone position with arms alongside the body|"The head will be positioned either straight or rotated to one side, depending on ICU habits. The arms are positioned symmetrically along the body, palms up. The lower limbs are positioned symmetrically and parallel, knees extended or slightly flexed if a cushion is used on the front of the feet.~Head rotation, if applicable, is performed every 4 hours."
41139225|NCT06488742|OTHER|3% kanuka oil|To assess the efficacy in patients with mild atopic dermatitis, 3% kanuka oil will be applied twice a day for 28 days. 3% kanuka oil is a naturally occurring extract from the kanuka tree and is considered an over-the-counter agent.
41139226|NCT03701607|OTHER|PD-L1 group|PD-L1 expression is evaluated using immunohistochemical assay
40971821|NCT01575769|DRUG|RoActemra/Actemra (tocilizumab)|Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
40971822|NCT04441606|RADIATION|68Ga-FAPI-04 PET/CT|"* Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days.~* Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists.~* Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression."
40971823|NCT02412475|DRUG|Decitabine|Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
40971824|NCT02412475|DRUG|Vorinostat|180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5
40971825|NCT02412475|DRUG|Fludarabine|30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10
40971826|NCT02412475|DRUG|Cytarabine|2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
41139227|NCT03026920|PROCEDURE|less invasive method|The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
41139228|NCT03371316|BIOLOGICAL|ViaShield|Anti-adhesion scores using amnion patch
41139229|NCT03311880|BEHAVIORAL|Cognitive remediation|Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
40971827|NCT02412475|DRUG|Filgrastim|5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12
40971828|NCT02412475|DRUG|Cytarabine|"Patient Age (years) IT Cytarabine Dose \> 1 30 mg~* 2 and \< 3 50 mg~* 3 and ≤ 18 70 mg \> 18 100 mg~given IT on day 0 or -1"
40971829|NCT02412475|DRUG|Sorafenib|150 mg/m2/dose twice daily by mouth on days 11-28
40971830|NCT00001596|DRUG|Pirfenidone|Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
40971831|NCT00001596|DRUG|Placebo|Placebo (3 pills), three times daily.
40971832|NCT05933395|DRUG|Fulvestrant|Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.
40971833|NCT05933395|DRUG|Neratinib|Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
40971834|NCT05933395|DRUG|Alpelisib|Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
41458552|NCT04478526|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will begin either. If deemed unresponsive to either prior to study, commence medication they have not been previously unresponsive to. Unresponsive if GAD did not improve after treatment with maximum tolerated dose for 8-weeks. If deemed unresponsive to SSRI and SNRI/pregabalin, commence secondary medication arm (bupropion/mirtazepine, buspirone/imipramine) with both being described to patient and begin either. Switch protocol: If unresponsive after 4 or 6 weeks, switch to another class. If started in primary or secondary and not previously demonstrated non-response to second class of medications within arm, switch to second class within arm. If started in primary and previously deemed unresponsive to second class, begin secondary if non-response indicates switch necessary.
41458553|NCT04478526|BEHAVIORAL|Electronic Cognitive Behavioural Therapy|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session was designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
40971835|NCT05933395|DRUG|Everolimus|Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.
40971836|NCT05933395|DRUG|Abemaciclib|Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
40971837|NCT04305262|DEVICE|Wireless continuous vital parameter monitoring|The patients included in this study will have continuous, wireless monitoring of vital parameters during the first four days of acute admission
40971838|NCT03780283|DRUG|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity
41139230|NCT05479708|DEVICE|ctDNA-based MRD detection|Postoperative circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection for predicting relapse and survival benefit
41139231|NCT05253092|OTHER|Virtual mindfulness meditation|Subjects will participate in 30 minutes of a virtual mindfulness meditation session, totaling eight sessions.
41139232|NCT03535636|OTHER|Polysomnography|Sleep architecture will be assessed by polysomnography
41139233|NCT04864899|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging (CMR)|Imaging
41139234|NCT04864899|DIAGNOSTIC_TEST|Blood test|Blood investigation
41139235|NCT04864899|DIAGNOSTIC_TEST|6-minute walk test|Correlating the cardiac MRI parameters with functional capacity
40971839|NCT03103737|BEHAVIORAL|Virtual Reality (VR) and Reminiscence Intervention|First and third sessions are dedicated to remember positive and meaningful personal experiences. Second and fourth sessions are oriented to positive emotions by the use of VR. Participants can choose the virtual environment to work with.
41297892|NCT05815121|OTHER|Acupressing|Acupuncture with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.
40971840|NCT01506713|DRUG|Clopidogrel|Clopidogrel Tablets 75 mg
40971841|NCT03751111|DRUG|Naloxone|Naloxone at an sublingual dose of 40 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.
40971842|NCT03751111|DRUG|Placebo|Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
40971843|NCT00644995|BEHAVIORAL|Step Up Wellness Program|Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.
40971844|NCT00644995|BEHAVIORAL|Usual care|Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
40971845|NCT03290898|BEHAVIORAL|High Intensity Interval Training|Training (HIIT)
41139236|NCT02455427|DEVICE|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
41297893|NCT05815121|OTHER|Control|with stickers only on the points, and the points should not be massaged.
40971846|NCT06278467|DIAGNOSTIC_TEST|visual pain scale (VASpain/fatigue), Beck depression index (BDI),|VAS (0-10)
41139237|NCT02455427|OTHER|Physical Therapy|Physical therapy will be administered for 60 minutes
40971847|NCT06278467|DIAGNOSTIC_TEST|Pain catastrophizing scale, sleep quality with a single Likert type question in the Pittsburgh questionnaire|PCS (Pain catastrophizing scale); sleep quality with a single Likert type question in the Pittsburgh questionnaire (0-3)
40971848|NCT06278467|DIAGNOSTIC_TEST|Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36),|functional disability level with Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36)
40971849|NCT06278467|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Scale (MOCA); Standard Mini mental test (SMMT)|cognitive status was measured by Montreal Cognitive Assessment Scale (MOCA) and Standard Mini mental test (SMMT)
40971850|NCT01064713|DRUG|Tesetaxel|"Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days."
40971851|NCT03545165|DRUG|177Lu-PSMA-617|\[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)\]
40971852|NCT03545165|DRUG|177Lu-J591|\[1.35 GBq/m2 or 36.5 mCi/m2\]
40971853|NCT03545165|DRUG|68Ga-PSMA-HBED-CC|\[185 ±74MBq or 5 ±2 mCi\]
40971854|NCT00651794|BEHAVIORAL|Teamwork training|Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
40971855|NCT00651794|BEHAVIORAL|Standard NRP curriculum|The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
40971856|NCT00651794|BEHAVIORAL|Skills practice with low-fidelity mannequin|
40971857|NCT00651794|BEHAVIORAL|Skills practice with high-fidelity mannequin|SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
40971858|NCT04700709|DRUG|Sirolimus Tab.|Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/ml.
40971859|NCT04700709|DRUG|Mycophenolate Mofetil Cap./Tab.|Up to 1g BID(total 2g daily), PO
41297894|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group|"The study involved the fabrication of occlusal-coverage bonded type RME devices utilizing Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy). Each patient in Group 1 (classical RME method) was instructed to open Hyrax screw twice a day for a week. At the end of the respective periods (1 week), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
40971860|NCT02720471|DRUG|Locoregional anesthesia|classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
40971861|NCT02720471|DRUG|peroperative infiltration of local anesthetics|peroperative infiltration of local anesthetics
40971862|NCT06501014|OTHER|Action Observation Therapy-Experimental Group|Patients will be asked to watch the exercises before doing them.For each exercise, patients will first watch the relevant video and do the exercise after the video ends.
40971863|NCT06501014|OTHER|Conventional Exercises-Control Group|Patients will be asked to perform exercises that are described verbally and/or shown through pictures.
40971864|NCT03284944|DEVICE|Small-Volume|"Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes."
40971865|NCT03284944|DEVICE|Standard-Volume|Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
41139238|NCT02455427|DEVICE|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
41139239|NCT04981431|DRUG|Elinzanetant (BAY3427080)|Oral administration
41139240|NCT04981431|DRUG|Placebo|Oral administration
41139241|NCT05087407|PROCEDURE|Decomprssion and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
41139242|NCT05087407|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
41466509|NCT05950217|OTHER|Education|Nurse-led patient education
41466510|NCT02527330|OTHER|MR T2* imaging|Cardiac magnetic resonance imaging with T2\* imaging
41139243|NCT00690079|DRUG|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol\*h/L
40971866|NCT04812964|DIETARY_SUPPLEMENT|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
40971867|NCT04812964|DIETARY_SUPPLEMENT|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
40971868|NCT00120835|DRUG|valopicitabine|
40971869|NCT00120835|DRUG|pegylated interferon|
40971870|NCT00854477|DRUG|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
40971871|NCT03012802|PROCEDURE|Colorectal Surgery|Postoperative Audit
40971872|NCT04074460|DRUG|Propofol|General Anaesthesia
40971873|NCT04074460|DRUG|isoflurane, sevoflurane or desflurane|General Anaesthesia
41458554|NCT03249350|BEHAVIORAL|Standard Contingency Management (CM)|"CM utilizes behavior modification \& cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
40971874|NCT04413396|PROCEDURE|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
40971875|NCT02875756|PROCEDURE|10 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
40971876|NCT02875756|PROCEDURE|20 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
40971877|NCT02401438|OTHER|5D ultrasound|
40971878|NCT02401438|OTHER|2D ultrasound|
40971879|NCT00230230|DRUG|SCH 486757|
40971880|NCT03763214|DEVICE|Stenting with PTFE-coated stent (HILZO)|Placing a metal stent in the biliary tract by duodenoscopy
40971881|NCT02550249|DRUG|Nivolumab|Intravenous administration of nivolumab
40971882|NCT03920579|DRUG|CKD-386 formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
40971883|NCT03920579|DRUG|CKD-386 formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
40971884|NCT03920579|DRUG|D326, D337 and D013|A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
40971885|NCT06313814|DIETARY_SUPPLEMENT|Swanson ginger capsule|"Swanson Ginger Root? gingerols, shogaols, and paradols, and possesses multiple bioactivities, such as antioxidant, anti-inflammatory, and antimicrobial properties.~Ginger is most commonly associated as a culinary spice flavouring to oriental dishes and even the local bakery character biscuit, the gingerbread man. But since ancient times the spice has also been recognized for its health properties, most popular being to settle the stomach, alleviate indigestion and event prevent motion sickness. More recently research has confirmed Ginger's historical effectiveness on digestive health and beyond."
40971886|NCT02471430|DRUG|Panobinostat|Panobinostat will be administered orally.
40971887|NCT02471430|DRUG|Pegylated Interferon-alpha2a|Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
40971888|NCT02656784|BEHAVIORAL|Cognitive Therapy|Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.
40971889|NCT02656784|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
40971890|NCT00672867|DRUG|Clevudine|30mg
40971891|NCT00672867|DRUG|Adefovir dipivoxil|10mg
40971892|NCT05127434|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
40971893|NCT05127434|DRUG|mRNA-1345|Sterile liquid for injection
40971894|NCT02033616|BIOLOGICAL|AVOVA-1|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
40971895|NCT02033616|BIOLOGICAL|MC|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
40971896|NCT05399056|BEHAVIORAL|Telephonic Peer Coaching|Telephonic Peer Coaching from an individual with lived experience with COPD and Pulmonary Rehabilitation trained in motivational interviewing
40971897|NCT05399056|BEHAVIORAL|Storytelling|Video narratives of an individual with lived experience with COPD and Pulmonary Rehabilitation describing their journey through Pulmonary Rehabilitation
40971898|NCT01918930|BIOLOGICAL|MGA271|MGA271 anti-B7-H3 monoclonal antibody
40971899|NCT00530764|DRUG|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
41139244|NCT00690079|DRUG|Placebo|Oral admin. of doses at 11 days through a 12 days period.
41466511|NCT03016741|BIOLOGICAL|GnRH agonist/antagonist|Given GnRH agonist/antagonist therapy
41466512|NCT03016741|DRUG|Prednisone|Given by mouth
41466513|NCT03016741|DRUG|Abiraterone Acetate|Given by mouth
41466514|NCT03016741|DRUG|Enzalutamide|Given by mouth
40971900|NCT00530764|DRUG|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
40971901|NCT00530764|DRUG|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
40971902|NCT02468115|DRUG|VIS410|Single fixed IV dose of VIS410
40971903|NCT02468115|DRUG|Placebo|Single IV dose of placebo
41139245|NCT02223728|BEHAVIORAL|Lifestyle|
41139246|NCT02223728|BEHAVIORAL|Health Education|
41139247|NCT00157105|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
41139248|NCT01790542|OTHER|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
41139249|NCT01790542|OTHER|Iron fortified cereal with fruit|
40971904|NCT02617745|OTHER|Platelet level determination|evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
40971905|NCT06504043|DRUG|HST101|Biological: HST101
40971906|NCT01606930|BEHAVIORAL|Patient Primer Tool|"The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs."
40971907|NCT00006361|DRUG|semaxanib|
40971908|NCT04673864|DRUG|CKD-386|QD, PO
40971909|NCT04673864|DRUG|D012, D326, D337|QD, PO
40971910|NCT04097002|BIOLOGICAL|ORCA-010|The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.
40971911|NCT04443725|DRUG|Hydroxychloroquine , Sofosbuvir, daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol), Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days.
40971912|NCT04443725|DRUG|Standard of care treatment|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol),
40971913|NCT02498860|DRUG|Pemebit|500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
40971914|NCT02498860|DRUG|Cisplatin|75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
40971915|NCT02322034|OTHER|Interval Training|Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
40971916|NCT02254993|DRUG|C16G2|antimicrobial peptide
40971917|NCT02421523|PROCEDURE|Aim 2 Exercise group|The experimental group will participate in an isometric exercise strengthening intervention with a frequency of \~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
40971918|NCT02421523|PROCEDURE|Aim 1 Exercise Dosing|The maximal voluntary contraction (MVC) will be determined for each subject. The first four subjects will exercise at an intensity of \~30% of the subject's MVC. Subjects will be asked to perform \~4 sets of 6 reps of knee extension and knee flexion contractions. 48hs after the exercise is completed a safety assessment will be performed for muscle damage. If none has occurred, four additional subjects will perform the exercise at the next level of intensity (\~50% MVC). Similarly, if no damage has occurred at \~50% MVC, four more subjects exercise at \~70% MVC. All safety measures will be performed 48hrs after the exercise has been completed at each of the levels. These safety assessments include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels.
41458555|NCT03249350|BEHAVIORAL|Enhanced Contingency Management (CM+)|The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
41458556|NCT06533150|OTHER|multiomic profiling|2 aliquots of patients-derived bone tissue specimens (collected as surgical waste from routinely surgeries) will be collected and exploited from proteins and metabolites isolation according to standardized protocol. Then, samples will be digested using Filter-aided sample preparation digestion protocol and analysed by Liquid Chromatography Tandem Mass Spectrometry. Peptides will be loaded on the PepMap 100 C18 trap cartridge, and subsequently separated on an EASY Spray C18 analytical column. The mass spectrometer, equipped with a nanoESI spray source, operates in positive ion polarity and MS/MS mode. Also metabolites will be assessed by LC-MS/MS and will be separated by HPLC. Obtained results will be analyzed by integrated pathway analysis (IPA) to achieve the multiomic profiling of each patient thus identifying druggable targets to be exploited in drug design. The selected biomolecules will be then tested in patient cells using the developed bioink-nanoparticle complex.
41458557|NCT03428542|BEHAVIORAL|Yin yoga|Yin yoga 2 times per week for 5 weeks. Daily breathing assignments.
40971919|NCT02421523|PROCEDURE|Aim 2 Control group|This group will receive safety assessments at baseline, 1 week, 6 weeks, and 12 weeks including T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. They will also receive safety assessments at 3 weeks and 9 weeks that will include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
40971920|NCT04656691|DRUG|bamlanivimab|Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.
41297895|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 2. Each patient in Group 2 (3-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. At the end of the respective periods (3 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
41458558|NCT03428542|BEHAVIORAL|YOMI|"30 minutes of psychoeducation combined with mindfulness practice followed by 60 minutes of Yin yoga allowing the psychological theme to be further explored, aided by verbal instructions of the yoga teacher. 2 times per week for 5 weeks.~Daily breathing assignments."
41458559|NCT00757991|GENETIC|polymorphism analysis|
40971921|NCT06236178|DRUG|Corticosteroid|1 ml of 40 mg methylprednisolone acetate
41297896|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 3. Each patient in Group 3 (5-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. The aforementioned screw open-close procedure was implemented over a period of five weeks. At the end of the respective periods (5 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
41297897|NCT06075758|OTHER|ribociclib|"There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.~Treatment plan represents the prescription."
41297898|NCT04842721|DRUG|Hypertonic Saturated Saline Mouth Rinse Active Arm|Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
40971922|NCT06236178|DRUG|Autologous Blood|1 ml of autologous venous blood
41297899|NCT04842721|OTHER|Placebo Plain Water Mouth Rinse Arm|Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
41297900|NCT03102775|OTHER|Comprehensive follow-up program for low-income families|The main follow-up areas within the HOLF-program is to improve employment, housing, financial situation of the children. Beside manuals, family coordinators participate in five seminars with home-based tasks in between. Alo a comprehensive supervision structure is implemented that follow the train the trainer model. Coordinators ought to work directly with th families, but also with other actors important to the family, such as child-welfare and school. Coordinators should use specific tools improving the quality of the meetings, such as forms for preparation of meetings, being goal-focused and empowering.
41458560|NCT00757991|OTHER|laboratory biomarker analysis|
41458561|NCT00757991|OTHER|questionnaire administration|
41458562|NCT02824510|OTHER|Algorithmic changes in insulin therapy.|Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.
41458563|NCT02824510|OTHER|Treadmill exercises|25 min treadmill exercise at 60% of maximal heart rate estimated for age
41458564|NCT02824510|DRUG|Insulin aspart, glargine and detemir|
41458565|NCT03283982|DEVICE|Robotic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the da Vinci robotic platform
41458566|NCT03283982|DEVICE|Laparoscopic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the laparoscopic platform
41458567|NCT02661022|DRUG|SL-401 7 µg/kg/day|SL-401 7 µg/kg/day in combination with pom/dex
41458568|NCT02661022|DRUG|SL-401 9 µg/kg/day|SL-401 9 µg/kg/day in combination with pom/dex
41458569|NCT01710696|DRUG|17-beta estradiol|5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
40971923|NCT06236178|DRUG|Local Anesthetic|1 ml of 2% prilocaine HCl
40971924|NCT05288231|DIAGNOSTIC_TEST|Diagnostic of ECG|All participants who enrolled in the study will be performed ECG, cardiac enzyme and echocardiography
40971925|NCT03376022|OTHER|Attitudes, knowledge|To investigate attitudes and knowledge to oral Health and oral care
40971926|NCT00489541|DEVICE|Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent implantation
41139250|NCT01790542|OTHER|Meat|
41458570|NCT01710696|DRUG|17-beta estradiol|0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
41458571|NCT01041495|DRUG|cyclobenzaprine ER (AMRIX)|active drug
41458572|NCT01041495|DRUG|placebo|matching placebo for AMRIX
41297901|NCT03102775|OTHER|local family projects|The control group offices will develop local family projects, depending on local needs. they will also recruit and follow-up families.
41297902|NCT01783626|DEVICE|Evodial|
41458573|NCT02838953|BEHAVIORAL|Pulmonary Rehabilitation|Comprehensive intervention based on a thorough patient assessment followed by patient- tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.
41458574|NCT00033527|DRUG|INS316|
41297903|NCT01783626|DEVICE|Evodial+ Condition B1|
41458575|NCT00033527|OTHER|sputum cytology|
41458576|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
41458577|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
41458578|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
41458579|NCT04929821|DEVICE|Biliary Duct Stenting|UNITY-B Balloon-expandable Biodegradable Biliary Stent deployment in obstructed biliary ducts.
41458580|NCT02934334|OTHER|Observational|
41458581|NCT00260026|DRUG|Docetaxel|
41458582|NCT00260026|DRUG|Jin Fu Kang|
41458583|NCT04795245|DRUG|afatinib|afatinib
41458584|NCT01208194|DRUG|MGN1703|solution, 60 mg, twice a week, until progression
41297904|NCT01783626|DEVICE|Evodial+ Condition B2|
41458585|NCT01208194|DRUG|Placebo|solution, 60 mg, twice a week, until progression
41458586|NCT03212651|DRUG|Pembrolizumab|Pembrolizumab 200mg IV infusion
41458587|NCT05215054|DEVICE|Gana V®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
40990798|NCT00818428|BEHAVIORAL|Articulation Parent Group|Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
41297905|NCT01783626|DEVICE|Evodial+ Condition C|
41458588|NCT05215054|DEVICE|Sculptra®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
41458589|NCT05810636|DEVICE|Garmin Vivosmart wearable device|Wearing smartwatches to collect data
41458590|NCT00990574|DEVICE|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
41458591|NCT00990574|DEVICE|Spinal Anesthesia Group (SAG)|"The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position."
41458592|NCT00046839|DRUG|celecoxib|
41458593|NCT00046839|RADIATION|radiation therapy|
41297906|NCT00589472|DRUG|Bicalutamide|Given PO
41297907|NCT00589472|DRUG|Goserelin Acetate|Given SC
41297908|NCT00589472|OTHER|Laboratory Biomarker Analysis|Correlative studies
41297909|NCT00589472|DRUG|Leuprolide Acetate|Given IM
41297910|NCT00589472|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical prostatectomy
41297911|NCT00589472|DRUG|Vorinostat|Given PO
41297912|NCT03844633|DRUG|Depo-Provera Injectable Product|Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
41297913|NCT03844633|DRUG|Placebos|Placebos -- Shot administered within 48 hours of childbirth
41297914|NCT02222727|DRUG|Donepezil|Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
41297915|NCT02379923|DEVICE|Crossing of Coronary Artery CTO|"Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires"
41458594|NCT04919785|DEVICE|Deep brain stimulation|Stereotactic functional neurosurgery was first developed in 1947 and is today an established treatment for movement disorders. The surgical procedure is initiated by mounting a stereotactic frame on the head of the patient and a magnetic resonance image (MRI) is performed. Using a computerized navigational system the target structure is identified on the MRI and a trajectory chosen. In the operating theatre a burrhole is made on each side of the midline for the implantation of two electrodes. The electrodes are about 1.3 mm in diameter with several contacts at their distal end. An extension cable is tunneled under the skin, connecting the electrodes with a neuropacemaker placed below the clavicle in a subcutaneous pocket. The hospitalization time after surgery is dependent on the time needed for programming of the device, but the patients can usually return home within 3-5 days.
41458595|NCT03390244|DEVICE|Foldable Capsular Vitreous Body Implant|Vitrectomy augmented with the implantation of the FCVB implant
41458596|NCT06431776|DRUG|Molgramostim|Molgramostim nebulizer solution will be administered once daily using a proprietary nebulizer optimized for the delivery of high molecular weight biologic compounds.
41458597|NCT02911636|RADIATION|Pelvic SABR with intra-prostatic SABR|described elsewhere
41458598|NCT03039816|DEVICE|Nasaleze|Nasaleze cellulose powder
41458599|NCT03039816|DEVICE|Placebo|Lactose powder in the same plastic container as Nasaleze and with the same taste
41297916|NCT02566330|DEVICE|EndoBarrier|The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
41458600|NCT00073632|BEHAVIORAL|Acceptance Based Behavioral Therapy|
41458601|NCT01296841|DEVICE|Collaborative Imaging|Hardware and software communication tools to provide clinical care from a distance.
40769314|NCT05102448|DRUG|Tofacitinib|"1. Tofacitinib 5mg twice a day for 12 months;~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria."
40769315|NCT05102448|DRUG|Methotrexate|"1. Methotrexate (15mg each week) for 12 months~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria."
40769316|NCT05941429|DRUG|Nano-Silver Fluoride|NSF is a varnish which has been introduced as experimental formulation . the laboratory synthesis of NSF was carried out in a nano techonolgy center .
40769317|NCT05941429|DRUG|Silver diamine fluoride|38% silver diamine fluoride
40769318|NCT02321514|DEVICE|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system
40971927|NCT06334510|BIOLOGICAL|One dose of quadrivalent influenza virus split vaccine was administered|"Safety observation: All 4900 vaccine recipients participated in the safety observation after vaccination, and were followed up for adverse events (AE) within 30 minutes and 0-30 days after vaccination, and SAEs within 6 months after vaccination.~In addition to 1050 recipients aged 18-59 years who were included in the first layer test, 350 recipients aged 3-17 years and 350 recipients aged ≥60 years were randomly selected from each group. Blood samples were collected before and 30 days after vaccination for influenza virus HI antibody detection."
40971928|NCT06013670|PROCEDURE|Endoscopy+NSBBs|Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure\>90mmHg and heart rate\>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.
41139251|NCT05899348|BEHAVIORAL|iTEST|iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities.
41458602|NCT02331628|DEVICE|ESWT - Extracorporeal Shockwave Therapy|"Patients will receive:~* Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\\52 from baseline until and including week 14\\52, one dose every two weeks ± 3 days), administered by the principal investigator.~* Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~* The energy flux density (EFD) will be 'high level'~* All participants will be supplied with headphones to reduce the noise level emitted by the machine."
41458603|NCT05430815|BEHAVIORAL|Enhanced Postpartum Care System|The intervention consists of a comprehensive postpartum care system that integrates American College of Obstetrician and Gynecologist's (ACOG) postpartum care guidelines together with American College of Cardiology and American Heart Association (ACC/AHA) guidelines for the prevention of cardiovascular disease in women, as well as patient preferences for care coordination and communication. The system consists of: 1) a tailored postpartum care plan that is collaboratively developed with patient and provider input and addresses both social and medical needs; 2) an electronic medical record (EMR) based tool for documenting the plan and monitoring postpartum care; and 3) a postpartum follow-up phone call at 1 week postpartum.
41458604|NCT01371617|DRUG|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
41139252|NCT00108589|DRUG|S-adenosylmethionine|
41139253|NCT03294187|DEVICE|Wrist-worn wearables|See arm/group description.
41139254|NCT02594709|RADIATION|Multisession Radiosurgery|Patients will undergo multisession radiosurgery as clinical practice.
41458605|NCT02418754|DRUG|REGN2176-3|
41458606|NCT02418754|DRUG|Intravitreal Aflibercept Injection (IAI)|
41139255|NCT04247906|DRUG|Narsoplimab|
41139256|NCT03654326|DRUG|Gefapixant|Gefapixant tablet 45 mg taken orally
41139257|NCT03654326|DRUG|Placebo|Placebo matching gefapixant tablet taken orally
41139258|NCT03654326|DRUG|Naproxen|Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
41139259|NCT02731066|OTHER|Standard pro|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
41139260|NCT02731066|OTHER|High pro|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
41297917|NCT01641016|DRUG|efavirenz|May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
41297918|NCT04895059|DRUG|Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose|Form: Tablets Dosage: 20 mg Adminstration way: Oral
41297919|NCT04895059|DRUG|Rosuvastatin 20mg|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
41297920|NCT04895059|DRUG|Ezetimibe 10mg|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
41458607|NCT05560139|DEVICE|a-tDCS|Transcranial direct current stimulation
40769321|NCT04261985|BEHAVIORAL|healthy weight behaviors supported by web-based mobile phone application|Chorus is a mobile phone platform that provides texting, a web application, and an online community for mHealth interventions.Content is created using existing templates to insert text, images, pictures, audio, video clips, or any combination of these. Users interface with Chorus by clicking a hyperlink embedded in a text message sent to their phone to then access web-based interactions via prompts and clicks. Content was created in English and Spanish.
40971929|NCT06013670|PROCEDURE|Transjugular intrahepatic portosystemic shunt|TIPS group: All TIPS procedures are completed by a professional liver disease intervention treatment team.
40971930|NCT02418364|OTHER|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
40971931|NCT02418364|OTHER|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
40971932|NCT00005094|DRUG|celecoxib|Given orally
40769322|NCT06563804|DRUG|S227928|For administration via intravenous (IV) infusion
40769323|NCT06563804|DRUG|Venetoclax|For oral administration
40769324|NCT06567925|BEHAVIORAL|Customized Sleep Coaching|Demonstrate the feasibility of a gradual sleep extension strategy using customized sleep coaching.
40769325|NCT06567925|BEHAVIORAL|Sleep Hygiene Training|Sleep hygiene training aimed at increasing sleep efficiency in patients with heart failure with preserved ejection fraction on guideline-directed medical therapy
40769326|NCT04344912|OTHER|Data collection|Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies
40971933|NCT00005094|OTHER|placebo|Given orally
40971934|NCT01276353|DRUG|E2020|Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation
40971935|NCT01276353|DRUG|E2020|10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
40971936|NCT00424671|DRUG|Licarbazepine|
40971937|NCT03192254|BEHAVIORAL|self-monitoring|recording fruit and vegetable consumption
40971938|NCT03192254|BEHAVIORAL|daily monetary incentives|daily payments for consuming fruits and vegetables
40971939|NCT03192254|BEHAVIORAL|delayed lump sum monetary incentives|lump sum payments for consuming fruits and vegetables
40971940|NCT03379532|DEVICE|BCI-NMES|From the recorded brain activity (EEG) subject specific patterns will be extracted with machine learning techniques from recordings where the subject executes movements tasks. Whenever a subject-specific pattern can be identified and detected, this is used for triggering neuromuscular electrical stimulation.
40971941|NCT03379532|DEVICE|Sham-NMES|Neuromuscular electrical stimulation is triggered independently of the patient's movement intentions.
40971942|NCT04786015|OTHER|Active Surveillance Reporting System|A system to actively record change in symptoms older adult patients experience following a chiropractic visit.
40971943|NCT05104320|PROCEDURE|MICS-CABG|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
40971944|NCT05104320|PROCEDURE|sternotomy CABG|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
41466515|NCT05305131|DRUG|cisplatin and gemcitabine|Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
40769327|NCT05437419|DRUG|TCK-276|Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.
40769328|NCT05437419|DRUG|TCK-276 Placebo|Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.
41297921|NCT05844800|PROCEDURE|Nuss repair of Pectus Excavatum|The Nuss procedure is a minimally-invasive repair technique of PE (MIRPE), whereby one to three curved metal bars are inserted behind the sternum to correct the shape of the anterior chest wall. The bars are left in situ for three years and then removed.
40971945|NCT01929915|PROCEDURE|Epidural patient controlled analgesia|Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control
40971946|NCT01929915|DRUG|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
40971947|NCT01797653|OTHER|CPAP therapy withdrawal|CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
40769332|NCT04845347|DEVICE|Bright Light Therapy|Participants will be provided with active, unaltered Re-Timer glasses that will be worn in the morning daily for 60 minutes for 5 weeks on study.
40971948|NCT01797653|PROCEDURE|Continue CPAP treatment|Continue treatment with therapeutic continuous positive airway pressure device
40971949|NCT03863249|PROCEDURE|SCALE AND ROOT PLANING|"SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA)."
40971950|NCT03863249|DRUG|ADJUNTIVE ANTIBIOTICS|"The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN."
41297922|NCT05844800|DRUG|Epidural anesthesia|The Nuss procedure of pectus excavatum repair surgery is performed under general anesthesia. Epidural anesthesia, with a constant infusion of 0.25% bupivacaine, was routinely used and was maintained in the early postoperative period.
41297923|NCT04497246|OTHER|Questionnaire|Data collection by means of various questionnaires
40769333|NCT04845347|DEVICE|Dim Light Therapy|Participants on this arm will wear the placebo version of the Re-Timer fitted with neutral density filters. These will be worn in the morning daily for 60 minutes for 5 weeks on study.
41297924|NCT03679208|DEVICE|Investigational device coded KIO014|Innovative chitosan-based biomaterial intended for intraarticular injection.
40769334|NCT03755427|BIOLOGICAL|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
40971951|NCT03863249|DIAGNOSTIC_TEST|MICROBIAL SAMPLING|"1. Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~2. The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy."
40971952|NCT03038191|DEVICE|Neuroelectrics Enobio 8(R)|Monitoring
41297925|NCT03679208|DEVICE|Durolane(r) as control device|Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
41297926|NCT02848846|DEVICE|Robotic Hand|"The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.~During this phases the patient will perform different task requiring the use of the robotic hand."
41297927|NCT03474523|OTHER|Experimental group|"Cavitation: 70% intensity, 30 minutes apply plane electrode and 10 minutes focal electrode.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
41297928|NCT03474523|OTHER|Control group|"Diathermy-Radiofrecuency: 30 minutes at 70% intensity (40-43ºC) in manual resistive modality and 10 minutes in automatic capacitive modality.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
41297929|NCT00195559|DRUG|Levonorgestrel/Ethinyl Estradiol|
41297930|NCT02122861|BIOLOGICAL|ID-LV305|pembrolizumab
41297931|NCT03643432|BEHAVIORAL|Exercise adherence intervention|Before their physiotherapy appointment participants will be given four short questions to answer. Following this the participant will be assessed as normal. As part of the treatment they will be given an exercise programme as standard within physiotherapy. Following this participants will be asked to answer a further seven short questions; depending on the answers to both sets of questions, and on any discussion based on the answers, the physiotherapist will suggest one or more adherence approaches from a list of suggestions. These are; Review of exercise programme; Review of method of delivery; Cues or prompts; Discussion of barriers and problem solving; Motivational interviewing, Decision balance sheets; Behavioural contract; Goal setting review; Monitoring telephone call; Reminders.
41458608|NCT04380233|DRUG|Investigational drug for Functional Dyspepsia-Postprandial Distress Syndrome|The investigational drug is a new pure type of gastrointestinal function modulator traditional Chinese medicine, composed of 4 kinds of Chinese herbs: Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus, Radix Bupleuri and Fructus Crataegi. The preliminary clinical trial showed that it has a good therapeutic effect on FD patients, its Fructus Aurantii Immaturus promotes gastric emptying by stimulating the cells to release motilin, thereby significantly improving patients' symptoms of fullness, epigastric pain, eructation, and nausea and vomiting.
40769335|NCT03755427|BIOLOGICAL|Aluminum Hydroxide Adjuvant|The seasonal influenza vaccine was a inactivated, split virion preparation of the influenza virus, propagated in embryonated chicken eggs. The aluminum hydroxide adjuvant was 0.5ml aluminum hydroxide adjuvant.
40971953|NCT00573911|PROCEDURE|Endoscopy and pH study|endoscopy and PH study done one time
40971954|NCT00318110|PROCEDURE|NST using MUD for metastatic renal cell carcinoma|"Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11"
40971955|NCT05604118|DRUG|Aspirin|1 week of aspirin supplementation prior to sampling
41297932|NCT03643432|BEHAVIORAL|Usual Care|Participants in usual care will attend physiotherapy sessions as they would have had they not been in the trial.These sessions will include assessment and treatment approaches as given as part of routine care, without including the intervention described above for the 'exercise adherence intervention' arm
41297933|NCT03518229|DEVICE|Microsoft Band 2 + UV messaging|wearable device (wrist) and associated mobile application; UV sensor and messaging activated
41297934|NCT03518229|DEVICE|Microsoft Band 2|wearable device (wrist) and associated mobile application; UV messaging not activated
41297935|NCT03791983|OTHER|Scalp Acupuncture|Scalp acupuncture is a form of alternative medicine in which thin needles are inserted into the scalp. It is a key component of traditional Chinese medicine (TCM).
41458609|NCT04380233|DRUG|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
41458610|NCT01186562|DRUG|Sitagliptin|100 mg PO daily
41458611|NCT01186562|DRUG|Placebo|Placebo
40971956|NCT00166478|DRUG|Exisulind Therapy|
40971957|NCT06162936|DIAGNOSTIC_TEST|Phagoburst|The main objective is to perform oxidative burst activity in pediatric patients with a definitive diagnosis of IBD and compare them with healthy controls.
41297936|NCT03791983|OTHER|Body Acupenture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM).
41297937|NCT02945761|PROCEDURE|High concentration of sugar solution|
41297938|NCT02945761|PROCEDURE|conventional surgical dressing change|
41297939|NCT02986958|OTHER|Pre-visit patient-family agenda-setting checklist|Pre-visit patient-family agenda-setting checklist
41297940|NCT02986958|OTHER|Usual care|routine primary care
41297941|NCT05104151|DIETARY_SUPPLEMENT|Nutritional bar|Protein-based nutritional bar, providing 155 calories per bar
41297942|NCT05104151|BEHAVIORAL|Healthy Habits Intervention|The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.
41297943|NCT03736083|DEVICE|Freestyle Libre Blood Glucose Monitor|The intervention arm of this study will begin using the Freestyle Libre glucose monitor within 2 weeks of their diabetes diagnosis
41297944|NCT01373567|DRUG|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
41297945|NCT04065880|OTHER|TachoSil®|topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.
41297946|NCT04065880|OTHER|Neoveil®|bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.
41297947|NCT03288779|DEVICE|Theta Burst Stimulation|Transcranial magnetic stimulation with theta burst stimulation
41297948|NCT06444737|DRUG|Intravenous ondansetron|Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia
41297949|NCT06444737|DRUG|Intravenous normal saline|Intravenous normal saline 5 ml (control group) 5 min before spinal anesthesia
41297950|NCT00491114|DRUG|Gemcitabine|
41297951|NCT02294721|DEVICE|Standard BLS|Resuscitation without feedback devices, standard manual standard basic life support
41297952|NCT02294721|DEVICE|The CPREazy|feedback device-1
41297953|NCT02294721|DEVICE|TrueCPR|feedback device -2
41297954|NCT02294721|DEVICE|The CPR PRO APP|feedback device -3
41297955|NCT02294721|DEVICE|The CardioPump|feedback device- 4
41297956|NCT04263662|OTHER|Analgesia-Sedation algorithm|The analgesia-sedation algorithm is a suggested protocol for approach to providing analgesia and sedation to patients admitted to the pediatric ICU who are newly intubated. The approach focuses on using dexmedetomidine as the primary sedative, non-opioids as the primary analgesia, then stepwise approach to adding in adjunctives (e.g. opioids, non-benzodiazepines) with the intention of minimizing benzodiazepine exposure and utilizing minimal-dose effective analgesia/sedative dosing.
41297957|NCT02618850|PROCEDURE|PET/CT|PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
41297958|NCT02618850|DRUG|first-line chemotherapy|as prescribed by oncologist
41297959|NCT02237807|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
41297960|NCT02237807|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
41297961|NCT00589888|DRUG|Intralipid 20% @ 20cc/hour|In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
41297962|NCT00589888|DRUG|Intralipid 20%@ 40cc/hour|In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
40971958|NCT06162936|DIAGNOSTIC_TEST|Lymphocytes subsets|To determine lymphocytes subsets in patients with suspicion of IEI
40769336|NCT06529484|OTHER|Warm Water Foot Bath Intervention|Participants will take a warm water foot bath at 38-40ºC for 20 minutes nightly for 7 days.
40769337|NCT04427384|DEVICE|GammaTile|Surgically Targeted Radiation Therapy
40769338|NCT03722407|DRUG|Ruxolitinib|Ruxolitinib 5 mg tablets, 4 per dose
40971959|NCT06162936|DIAGNOSTIC_TEST|Genetic testing|Perform targeted genetic testing in those with reduced to absent oxidative activity in search of PIDs and susceptibility variants
41297963|NCT00589888|DRUG|Normal Saline|In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
41297964|NCT00589888|DIETARY_SUPPLEMENT|32-gram oral fat load|In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
41297965|NCT00589888|DIETARY_SUPPLEMENT|64-gram oral fat load|In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
41297966|NCT00187707|DRUG|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
41297967|NCT04222127|OTHER|EUS guided injection of gastric varices by CYA|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate \& lipidol using 19G EUS-FNA needle
41297968|NCT04222127|OTHER|Direct endoscopic injection of gastric varices by CYA|Direct endoscopic injection of gastric varix by CYA
41297969|NCT06555094|BEHAVIORAL|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
41297970|NCT06555094|BEHAVIORAL|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
41297971|NCT06555094|BEHAVIORAL|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
41297972|NCT03841149|OTHER|Ultrasound Imaging|3D volume calculation using on-line and off-line softwares
41297973|NCT06313281|PROCEDURE|Preoperative Antiseptic preparation prior to transnasal skull base surgery|The patient received one of three antiseptic preparation before transnasal skull base surgery
41297974|NCT05628467|DRUG|Antidepressive Agents|Compare the signal obtained from the pharmacovigilance database study between adults over 65 who fall on antidepressants versus those who fall on other drugs
41297975|NCT00151762|DRUG|Colesevelam hydrochloride|
41297976|NCT02927808|BEHAVIORAL|Motivational Interview|Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
41297977|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
41297978|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
41297979|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
41297980|NCT05380414|BIOLOGICAL|Tumor samples (archival FFPE) and blood samples|Molecular screening
41297981|NCT05669482|DRUG|avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel|The RP2D of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel determined in Part A will be used in Part B dose expansion.
41297982|NCT01477697|DIETARY_SUPPLEMENT|Omega-3|50 mg/kg per day of omega-3 fatty acids
40769339|NCT00814255|DRUG|Adalimumab|Adalimumab 24 mg/m\^2 (maximum dose 40 mg) sc q 14 days
40769340|NCT00814255|DRUG|Lisinopril, losartan, and atorvastatin|Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
40769341|NCT00814255|DRUG|galactose|galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
40769342|NCT05817786|DEVICE|electrical stimulation of the brachial plexus nerve roots|treated by chronic electrical stimulation of the brachial plexus nerve roots
41297983|NCT01477697|DIETARY_SUPPLEMENT|Placebo|50 mg/kg per day of placebo equivalent
41297984|NCT04822363|DRUG|Aspirin|Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B
41297985|NCT04822363|DRUG|Clopidogrel|Arms C and E
41297986|NCT00475280|PROCEDURE|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
41297987|NCT00475280|PROCEDURE|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
41297988|NCT04706507|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
41297989|NCT05069051|DRUG|Belimumab 200 MG/ML [Benlysta]|Patients obtain belimumab treatment in combination with rituximab and venetoclax
41297990|NCT05069051|DRUG|standard of care|Patients obtain the standard of care: combination rituximab and venetoclax
41297991|NCT02272621|PROCEDURE|Minimally invasive aortic valve replacement|
41297992|NCT02272621|PROCEDURE|Full sternotomy aortic valve replacement|
41297993|NCT04840654|PROCEDURE|Caudal Block|"A caudal block is a procedure that will help lessen a child's pain after an operation.~100 subjects will be randomized to this block procedure."
41297994|NCT04840654|PROCEDURE|Pudendal Block|"form of local anesthesia commonly used in the practice of obstetrics to relieve pain during the delivery of baby by forceps.~100 Subjects will be randomized to this block procedure."
41297995|NCT03690258|DEVICE|Variable load exercise|This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
40769343|NCT05817786|OTHER|sham stimulation|treated by sham stimulation
40769344|NCT04039464|DRUG|Mono-Therapy with Sildenafil|The subjects will be randomized to receive sildenafil alone and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
40971960|NCT02838303|OTHER|Organophosphate|Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous
40971961|NCT02838303|OTHER|Placebo|Multineem, WHO Class U: Unlikely to present acute hazard in normal use
40971962|NCT03268720|OTHER|FODMAP low diet|2 week FODMAP low diet
40971963|NCT03268720|OTHER|gluten-free diet|2 week gluten-free diet
40971964|NCT05786820|DIETARY_SUPPLEMENT|Pycnogenol|daily consumption of a pycnogenol-containing capsule
40971965|NCT05786820|DIETARY_SUPPLEMENT|Placebo|Daily consumption of a placebo capsule
40971966|NCT01538420|DRUG|GLPG0492|Oral solution
40971967|NCT01538420|DRUG|Placebo|Placebo oral solution
40971968|NCT05549570|DRUG|Sitagliptin/Metformin HCl 50/850 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
40971969|NCT04937998|PROCEDURE|Autologous PRP injection|Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis
40971970|NCT04937998|PROCEDURE|HA injection|Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis
40971971|NCT00071513|BEHAVIORAL|CAST-T/HSTS|Skills training small group.
41297996|NCT04020237|BEHAVIORAL|Education about particulate matter practice score|"For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~* 1) Start air purifier~* 2) Do not go out and make it to the minimum when absolutely necessary~* 3) It is recommended to wear a mask when going out.~* 4) The investigators recommend a lot of water, fresh fruit and vegetables.~* 5) Prepare an inhaler and use it when symptoms get worse."
41297997|NCT02894047|BIOLOGICAL|blood|measurement of CaSR expression levels on synovial fluid monocytes
41297998|NCT02951988|DRUG|Rapastinel|Rapastinel pre-filled syringes for IV injections.
40971972|NCT00071513|BEHAVIORAL|Brief Intervention|Assessment of needs and referral to services as needed.
40971973|NCT05891262|DRUG|BMS-986196|Specified dose on specified days
40971974|NCT05891262|DRUG|Loestrin|Specified dose on specified days
40971975|NCT00605111|DRUG|biphasic insulin aspart|
41297999|NCT02951988|DRUG|Placebo-matching Rapastinel|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
41298000|NCT02424955|DRUG|perflutren lipid microspheres|
41298001|NCT02424955|DIAGNOSTIC_TEST|3D ultrasound|
41298002|NCT03103269|BEHAVIORAL|Challenge! Small Group Intervention|The Challenge! Small Group intervention consists of curriculum related to health behavior goal setting, healthy eating, and staying active, working out with Health Educators, and receiving a year-long membership to the YMCA.
41298003|NCT03103269|OTHER|Challenge! Environmental Intervention|The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier.
41298004|NCT05514717|DRUG|XMT-2056|XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
41298005|NCT00064662|PROCEDURE|Burch Modified Tanagho|The Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.
41298006|NCT00064662|PROCEDURE|Autologous Fascia Sling|The fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
41298007|NCT03606083|DEVICE|Endovascular repair|Endovascular repair of aorto-iliac or iliac aneurysms using an iliac branch device (IBD)
40769345|NCT04039464|DRUG|Duo-Therapy with Sildenafil + Bosentan|The subjects will be randomized to receive combination up-front therapy sildenafil and bosentan and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
40971976|NCT03548103|DIETARY_SUPPLEMENT|Green tea extract|Green tea extract 500 mg tid for 16 weeks
40971977|NCT03548103|DIETARY_SUPPLEMENT|Placebo|Placebo tid for 16 weeks
40971978|NCT04446520|PROCEDURE|autogenic drainage|breathing control using expiratory airflow to mobilize secretions from smaller to larger airways. Secretions are cleared independently by adjusting the depth and speed of respiration in a sequence of controlled breathing techniques during exhalation in addition to traditional physiotherapy (deep breathing exercise, diaphragmatic breathing and splinted coughing)
40971979|NCT05586529|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol is vitamin D derivative and as our population already vit D deficient so post-operative hypocalcemia can be prevented.
40971980|NCT05188690|OTHER|Data collection from medical records|Data collection from medical records
40971981|NCT05159700|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
40971982|NCT01874613|DEVICE|FRC implant reconstruction|A cranioplasty with the FRC implant is performed.
40971983|NCT01874613|DEVICE|FRC implant reconstruction|The orbital floor fracture is reconstructed with the FRC implant.
40971984|NCT03623802|OTHER|Local Movement Therapy|Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.
40990799|NCT00818428|BEHAVIORAL|Dialogic Reading Parent Group|Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
40971985|NCT03623802|OTHER|Integral Movement Therapy|Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
41298008|NCT01340287|DIETARY_SUPPLEMENT|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
41458612|NCT01888107|DRUG|Risperidone Long-acting Injectable (LAI) 25 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
41458613|NCT01888107|DRUG|Risperidone LAI 37.5 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
41458614|NCT01888107|DRUG|Risperidone LAI 50 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
40971986|NCT04238598|PROCEDURE|Pulse Radiofrequency|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed Radiofrequency treatment will be administered.
40971987|NCT04238598|PROCEDURE|Standard of Care Intra- Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Intra-Articular treatment will be administered.
40971988|NCT04238598|PROCEDURE|Placebo Intra-Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Placebo Intra-Articular treatment will be administered.
40971989|NCT01655706|DRUG|escitalopram|Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
40971990|NCT01655706|DRUG|aripiprazole|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
40971991|NCT03178877|OTHER|No intervention|
40971992|NCT00694993|DRUG|GSK1004723|GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
40971993|NCT00694993|DRUG|Placebo|Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
40971994|NCT00752232|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
40971995|NCT00752232|OTHER|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
40971996|NCT00752232|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
40971997|NCT00752232|OTHER|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
40971998|NCT00752232|OTHER|PBS|IM injection, Day 1, month 3, 6, 9, 12
40971999|NCT04517474|BEHAVIORAL|CANreduce|"CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence. It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying no to foster refusal skills, Dealing with burdens, Preserving achievements). Participants can study all modules at their own pace and order, though a specific order will be advised."
40972000|NCT04517474|BEHAVIORAL|psychological support|psychological support
41298009|NCT01340287|DIETARY_SUPPLEMENT|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
41298010|NCT02337504|OTHER|community-based care|Will receive HIV care in the community and not in the clinic which is the normal standard of care
41458615|NCT03937791|BIOLOGICAL|E7 T Cell Receptor (TCR)|One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
41458616|NCT03540160|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
41458617|NCT02490800|DRUG|Lisavanbulin Phase 1 dose escalation portion|Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 35 mg/day
41458618|NCT02490800|DRUG|Lisavanbulin Phase 2a expansion portion|Recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
41458619|NCT03337893|DIAGNOSTIC_TEST|blood pressure|it will be done both right and left arms
41458620|NCT04810533|DRUG|[14C] SH-1028|Volunteer will receive a single oral dose of 200 mg/88 uCi \[14C\]SH-1028 as a solution on Day 1
41458621|NCT04848207|DEVICE|Digital impression technique|3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
41458622|NCT04848207|OTHER|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
41298011|NCT05809011|DRUG|Dexamethasone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
41298012|NCT05809011|DRUG|Prednisone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
41298013|NCT01517789|DEVICE|Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®|"Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.~Flash and steady state visual evoked potential are measured during the surgical procedure at different times."
41298014|NCT04421989|BEHAVIORAL|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
41298015|NCT04421989|OTHER|Support Group|Participants randomized to FBT + Support Group parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The support group will have a facilitator introduce each topic weekly and parents will discuss. The facilitator's role is to ensure the group remains on topic and on time. Weekly discussion topics include: co-morbid medical diagnoses, understanding levels of care in treatment, taking time off from work, and medications.
41298016|NCT01139723|DRUG|MINT1526A|Intravenous escalating dose
41298017|NCT01139723|DRUG|bevacizumab|Intravenous repeating dose
41298018|NCT00287833|OTHER|placebo|Given orally
41298019|NCT00287833|DRUG|Bowman-Birk inhibitor concentrate|Given orally
41458623|NCT02324335|DRUG|Brilacidin|Oral Rinse used 3 times daily for 7 weeks
41458624|NCT02324335|OTHER|Placebo|
41458625|NCT03467737|OTHER|Normal sorghum porridge, algal starch|Normal sorghum porridge with 13C-labeled algal starch was fed, breath tested, as the first arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
41458626|NCT03467737|OTHER|Normal sorghum porridge, algal dextrins|Normal sorghum porridge with 13C-labeled starch limit dextrins was fed, breath tested, as the second arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
41139261|NCT02731066|OTHER|carbo bev|During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing \~1.8 g carbohydrate/min.
41139262|NCT02731066|OTHER|placebo bev|During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
41458627|NCT03467737|OTHER|Normal sorghum porridge, labeled flour|Normal sorghum porridge with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
40972001|NCT01928394|BIOLOGICAL|Nivolumab|
40972002|NCT01928394|BIOLOGICAL|Ipilimumab|
40972003|NCT01928394|DRUG|Cobimetinib|
40990800|NCT01328821|DRUG|CTP-499|600 mg, 1200 mg, 1800 mg and 2400 mg
41139263|NCT00126958|PROCEDURE|urinary analysis|
41139264|NCT00911404|BEHAVIORAL|Low CHO|"Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat."
41139265|NCT00911404|DIETARY_SUPPLEMENT|High CHO diet|Diet with 55% total calories from carbohydrates.
41139266|NCT06048588|DRUG|YN001|In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg up to 15 days. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg up to 85 days.
41139267|NCT06048588|DRUG|Placebo for YN001|The injection solution to mimic the YN001
41139268|NCT06048588|DRUG|rosuvastatin calcium tablets|In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days
41139269|NCT03630653|PROCEDURE|Sentinel LN in breast cancer recurrence|Sentinel Lymph-Node (LN) procedure and Axillary LN dissection ; Mastectomy or breast conservative surgery
41139270|NCT00651326|DRUG|bicalutamide|
41139271|NCT00651326|DRUG|buserelin|
41139272|NCT00651326|DRUG|flutamide|
41139273|NCT00651326|DRUG|goserelin|
41139274|NCT00651326|DRUG|leuprolide acetate|
41139275|NCT00651326|PROCEDURE|neoadjuvant therapy|
41139276|NCT00651326|PROCEDURE|quality-of-life assessment|
41139277|NCT00651326|RADIATION|radiation therapy|"46 Gy in 23 fractions over \< 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over \< 3 weeks"
41139278|NCT00651326|DRUG|Docetaxel|
41139279|NCT00644306|DRUG|Thalidomide|100 mg/day continuously for 18 months
41139280|NCT00644306|DRUG|melphalan, prednisone|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
41139281|NCT00644306|DRUG|melphalan, prednisone, thalidomide|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
41458628|NCT03467737|OTHER|Modified sorghum porridge, labeled flour|Modified sorghum porridge with shear stirring to reduce viscosity with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
40972004|NCT02155608|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.
40972005|NCT02155608|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
40972006|NCT05963217|BIOLOGICAL|TBI-2001|"Phase-I portion:~cohort 1: 3×10\^5 cells/kg, cohort 2: 1×10\^6 cells/kg, cohort 3: 3×10\^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion."
40972007|NCT05963217|DRUG|Cyclophosphamide|IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
40972008|NCT05963217|DRUG|Fludarabine|IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
40972009|NCT04479423|PROCEDURE|Soda-water instead of pure water to observe gastric filling|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of 2L polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at hospital in the morning after an over night fast (\>8hours). Then they would be randomly assigned to controll group or soda group. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg simethicone. During the period, patients were asked to have a proper walk to wash out bubbles. An additional 900ml pure water or 400ml soda-water was drunk to obtain good vision before undergoing MCE examination.
40972010|NCT04891874|RADIATION|Stereotactic radiotherapy|Radiation using stereotactic radiotherapy device.
40972011|NCT05163600|OTHER|Blod flow restriction training|includes one strength and one endurance training
40972012|NCT01691001|DRUG|Dexmedetomidine|dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
40972013|NCT01691001|DRUG|normal saline|
40972014|NCT00725023|DEVICE|TDP© Lamp|TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals
41139282|NCT04901585|PROCEDURE|Totally intracorporeal distal gastrectomy|Minimally invasive distal gastrectomy with intracorporeal anastomosis and handsewn enterotomy closure
41139283|NCT04453488|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.
41139284|NCT04453488|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
41139285|NCT01419184|DRUG|Daptomycin|
41139286|NCT01419184|DRUG|Vancomycin|
41139287|NCT01388413|DRUG|Weekly Oral Cyclic Antibiotic programme|The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.
41139288|NCT04973306|PROCEDURE|Neoadjuvant Chemoradiotherapy|"Chemotherapy: carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. For each cycle, Carboplatin and paclitaxel were administered 30 minutes apart.~Radiotherapy: A total radiation dose of 41.4 Gy was given in 23 fractions of 1.8 Gy, 5 days per week (Radiotherapy was performed on the 2nd, 3rd, 4th, 5th, and 6th day in each cycle, and only 3 times in the 5th cycle)"
41139289|NCT04973306|DRUG|Tislelizumab|"Tislelizumab (200mg/time) was administered intravenously on the 1st and 22nd day.~The intravenous injection lasts about 30 minutes (micropump is recommended, intravenous bolus is prohibited, duration should be not less than 20 minutes and not more than 60 minutes);"
41139290|NCT04973306|PROCEDURE|Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)|After neoadjuvant therapy, patients in groups receive Ivor-Lewis or Mckeown Esophagectomy (Mckeown Esophagectomy recommended)
41298020|NCT02620332|DRUG|MultiPepT1De injection|A mix of peptides
41298021|NCT02620332|OTHER|Placebo|Water for injection
41458629|NCT03467737|OTHER|Thinned sorghum porridge, labeled flour|Thinned sorghum porridge treated with an alpha-amylase liquifying enzyme with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
41458630|NCT03467737|OTHER|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with shear stirring to reduce viscosity with addition of 13C-labeled octanoic acid was fed, breath tested, for gastric emptying assessment in healthy and moderately malnourished children.
41458631|NCT03867916|BEHAVIORAL|Patient Navigation Program|Use patient navigation program
40972015|NCT00725023|DEVICE|Dummy TDP© Lamp|The dummy TDP© heat lamp is an electrical device with the heating element removed.
40972016|NCT01356472|DRUG|Imipenem/cilastatin|the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
40972017|NCT00119054|BEHAVIORAL|In Home Health Messaging Device|
40972018|NCT02388204|PROCEDURE|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
40972019|NCT02388204|PROCEDURE|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
40972020|NCT01153347|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
40972021|NCT01153347|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
40972022|NCT03100032|BIOLOGICAL|NVD-001|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with NVD-001.
40972023|NCT03100032|PROCEDURE|Standard of Care|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with autologous locally cancellous bone (laminectomy)
40972024|NCT02039492|PROCEDURE|Sympathetic Renal Denervation|
40972025|NCT02039492|DRUG|Treatment with aldactone|
40972026|NCT03269383|DRUG|Bupivacaine|Patients will receive a stellate ganglion block using 10 ml of 0.5% bupivacaine
40972027|NCT03269383|OTHER|Saline|Patients will receive a stellate ganglion block using 10 ml of 0.9% saline
40972028|NCT00253045|BEHAVIORAL|Motivational groups|Motivational interviewing in group format
40769346|NCT05787249|BEHAVIORAL|Patient nudge|Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts
40769347|NCT05787249|BEHAVIORAL|Provider nudge|Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts
40972029|NCT03018171|DRUG|Clonidine|Intrathecal clonidine addiction
40769348|NCT06094803|BEHAVIORAL|Mindfulness-based Zentangle Program|"Session 1 focuses on Self-awareness and Self-kindness through the Zentangle method. It covers the introduction, basic techniques, and eight steps of Zentangle. Participants practice mindfulness and learn grid and round patterns. Drawing mindfully and interactive sharing are encouraged for engagement and reflection.~Session 2 emphasizes Acceptance and Non-judgmental Attitude. It builds on the previous session, exploring advanced techniques in the Zentangle method. Participants practice mindfulness, learn organic and texturing patterns, create their own artwork, and engage in interactive sharing for reflection."
40972030|NCT03018171|DRUG|Sufentanil|Intrathecal
40972031|NCT03026452|PROCEDURE|US-guided RFA|The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
41139291|NCT04478409|BIOLOGICAL|one additional blood sample during a planned blood test|The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients.
41139292|NCT04163432|DRUG|Durvalumab|Durvalumab is administered at a dose of 1500mg for patients who weigh \>30 kg. If weight falls to ≤ 30 kg, weight-based dosing at 20mg/kg will be a utilized
41139293|NCT04163432|DRUG|Pemetrexed|Pemetrexed dosing is adjusted for kidney function. Pemetrexed is dosed at 500mg/m2 for patients with a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula). If creatinine clearance is \< 45 mL/min, pemetrexed is dosed at 400 mg/m2.
41139294|NCT04163432|DRUG|Carboplatin|Carboplatin dosing is adjusted for kidney function.The total dose (in mg) of carboplatin will be calculated using the Calvert Formula utilizing a target AUC of 5 and a patient's GFR in mL/min.
41139295|NCT01247077|OTHER|selenium|200 ug selenium once daily
41139296|NCT01247077|OTHER|placebo|
41298022|NCT06098261|DRUG|Test (T) Bilastine|Specification: Bilastine 20mg. Produced and supplied by Shandong Hubble Kisen Biological Technology Co., Ltd.
41298023|NCT06098261|DRUG|Reference (R) Bilastine|Specification: Bilastine 20mg. Produced by Menarini International Operations Luxembourg S.A.
41458632|NCT03867916|OTHER|Quality-of-Life Assessment|Ancillary studies
41458633|NCT03867916|OTHER|Survey Administration|Ancillary studies
40769349|NCT00725855|DRUG|MEM 3454|1 mg dose
40769350|NCT00725855|DRUG|MEM 3454|5 mg dose
40769351|NCT00725855|DRUG|MEM 3454|15 mg dose
40769352|NCT00725855|DRUG|MEM 3454|50 mg dose
40769353|NCT00725855|DRUG|Placebo for MEM 3454|Placebo dose
40972032|NCT04008615|OTHER|2 times : 6-minute stepper test with cardiorespiratory parameters and gaz exchange monitoring (with a rest of 20min between each test).|"For the 6-minute stepper test, please refer to NCT02842463 and NCT04004689. Gaz exchange analyzer will be calibrate before every test. Data will be recorded breath by breath.~Heart rate will be monitored using a 12-lead electrocardiogram. Transcutaneous oxygen saturation will be assessed using a pulse oxymetry system at the earlobe."
40972033|NCT05577260|DRUG|magnesuim sulphate|magnesuim sulphate
40972034|NCT05577260|DRUG|Dexmedetomidine|Dexmedetomidine
40972035|NCT05577260|DRUG|isobaric bupivacaine|20ml isobaric bupivacaine 0.25%
40972036|NCT04448483|DEVICE|Paretic upper limb functional electric stimulation through RehaStim|"The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.~The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release."
40972037|NCT04448483|DEVICE|Non-invasive transcranial current stimulation through DC-Stimulator|Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.
40972038|NCT05908513|DRUG|N-acetylcysteine|Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.
40972039|NCT05908513|DRUG|Placebo|Similar chemical structure of NAC but without function
40972040|NCT02790398|BEHAVIORAL|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol for emotional disorders whose aims are to learn and practice adaptive ways to regulate emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention. These components are organized in twelve modules.
40972041|NCT02790398|BEHAVIORAL|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol for emotional disorders + PA regulation components has the purpose of learning and practicing adaptive ways to regulate emotions from a transdiagnostic perspective. This protocol includes the same components but it also includes 4 additional modules focused specifically on the regulation of positive affectivity.
41298024|NCT03042611|DRUG|Rivoceranib|Oral tablet
41298025|NCT03042611|DRUG|Placebo|Oral tablet
40972042|NCT00314392|BEHAVIORAL|Information (behavior)|
41458634|NCT01541215|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
40972043|NCT05184244|OTHER|Activity Limitation Assessment|The ACTIVLIM-CP scale evaluates the global activity performance and combined movements of the body.
40972044|NCT03749070|DIETARY_SUPPLEMENT|Silymarin|It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment will be collected at the beginning and end of the trial for comparison purposes.
40972045|NCT01753791|DRUG|80 mg PF-06473871|80 mg of PF-06473871 or placebo
40972046|NCT01753791|DRUG|160 mg PF-06473871|160 mg of PF-06473871 or placebo
40972047|NCT01753791|DRUG|320 mg PF-06473871|320 mg of PF-06473871 or placebo
40972048|NCT01753791|DRUG|480 mg PF-06473871|480 mg of PF-06473871 or placebo
40972049|NCT05950490|DRUG|Intravitreal injection of methotrexate|"Intravitreal injection of methotrexate:400ug/0.1mL，Once a week\*4 weeks → Once every two weeks\*4 weeks → once a month \*10 times(16 times a year)~Systemic therapy:~Induction period:（Zanubrutinib + Rituximab，ZR） (28 days/cycle) x 6 cycles:Rituximab iv375mg/m2 D1, Zanubrutinib 160mg bid D1-D21; Maintenance treatment:Zanubrutinib 160mg bid x 2 years"
40972050|NCT06217198|BEHAVIORAL|Deprexis|Deprexis is an internet-delivered treatment for depressive symptoms and related functional impairment. The intervention draws from various theoretical frameworks and consists of 12 modules: 10 core content modules and an introductory and summary module. Deprexis is designed to be interactive, includes answering questions and learning techniques and concepts through instruction and examples.
40972051|NCT02486432|DRUG|Levodopa/Carbidopa (Sinemet)|Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
40972052|NCT04366453|PROCEDURE|echocardiography|Four measurements in echocardiography performed in addition to standard care
40972053|NCT00489021|PROCEDURE|sub-acute hospitalization|
41139297|NCT06282926|DIAGNOSTIC_TEST|Echocardiography assessment|"Group 1 will have healthy adult volunteers recruited at the workplace following specific criteria to participate in the study. A research cardiac ultrasound protocol to assess the RV will be performed at two different visits, with a maximum interval of two weeks between them.~Group 2 will have ACHD patients with known moderate or severe pulmonary regurgitation after ToF repair, following specific criteria to participate in the study. This group of patients will be studied in two separate visits. The patients will be recruited during the first visit when attending to an existing hospital appointment for ACHD CMR. A research cardiac ultrasound protocol to assess the RV will be performed on the same day, either before or after the CMR. For all patients who will have a second follow-up visit at the ACHD outpatient clinic within a maximum interval of one year, the same research protocol will be performed, in addition to the usual cardiac ultrasound."
41139298|NCT04534738|BEHAVIORAL|Mediterranean Diet|The Mediterranean Diet is high in fruit, vegetables, legumes, nuts and seeds, whole grains, and olive oil; moderate in seafood, dairy products (e.g., cheese and yogurt but not whole milk or butter), eggs, poultry, and red wine with meals; and low consumption of sweet desserts, red meat, and highly processed foods.
41139299|NCT00525616|DRUG|Mabthera|Two IV perfusions of 1000mg at 15 days intervals
41139300|NCT03138720|DRUG|Paclitaxel Protein Bound (Abraxane)|Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
41139301|NCT00069706|DRUG|AL-12182 0.003% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
41139302|NCT00069706|OTHER|AL-12182 Ophthalmic Solution Vehicle|Placebo
41139303|NCT00069706|DRUG|Latanoprost 0.005% Ophthalmic Solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
41139304|NCT00069706|DRUG|AL-12182 0.01% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
41139305|NCT00069706|DRUG|AL-12182 0.03% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
41139306|NCT06093490|DEVICE|Eysz Hyperventilation Recorder|App used to guide and record hyperventilation
41139307|NCT04663256|OTHER|Cognitive stimulation group|Each week for 12 weeks, GE participants attend three 60-minute sessions of cognitive exercises.
41298026|NCT06554574|DRUG|LTG-305|Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts
41298027|NCT02166840|PROCEDURE|Plastic stent (7-10Fr)|
41298028|NCT02166840|PROCEDURE|Self Expanding Metal Stent|
40769354|NCT06312930|DEVICE|Transcranial pulse stimulation|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency)
40972054|NCT05666492|OTHER|Platelet rich plasma|Platelet-rich plasma will be placed on the olfactory epithelium topically.
40972055|NCT05666492|OTHER|Saline|Saline will be placed on the olfactory epithelium topically.
40972056|NCT04477902|OTHER|none - observational|online survey
41458635|NCT01541215|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
41458636|NCT01541215|DRUG|metformin|Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
41458637|NCT00400634|DRUG|CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])|CERE-120 5.4 x 10\^11 vg
40769355|NCT06569407|OTHER|Online Educational Intervention|An educational program for EBP based on the online learning model was planned to be developed based on the literature and expert opinions. In the program, in line with the literature, the introduction to the EBP, the importance of EBP, EBP steps, clinical research question design in line with PICO, and introduction of EBP databases. It is planned to include topics such as literature search strategies, types of research, use of scientific research and evidence evaluation tools, introduction of clinical decision support systems, reflection of EBP on patient care and clinical decision-making processes, and it is planned to determine the final version of the education content with expert opinions. The program will include recorded videos, slides and documents for each module. The content of the program will be integrated into the Koç University Online Programs Platform by the experts working at Koç University Educational Technologies Unit.
40972057|NCT05739955|OTHER|Sani24|24-hour continuously acting quaternary ammonium salt disinfectant
40972058|NCT05739955|OTHER|Standard EPA-registered disinfectant|Standard EPA-registered disinfectant
40972059|NCT05739955|OTHER|Routine Disinfection|Routine disinfection at the study hospital
40972060|NCT06054698|DRUG|HRS9531 injection|HRS9531 injection , QW，36 weeks
40972061|NCT06054698|DRUG|HRS9531 injection Placebo|HRS9531 injection Placebo，QW，36 weeks
40972062|NCT05311540|DRUG|Zinc Sulfate|
40972063|NCT06104670|DIETARY_SUPPLEMENT|Synaquell(TM)|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
40972064|NCT06104670|DIETARY_SUPPLEMENT|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
40972065|NCT02728076|RADIATION|Phase II - Preoperative Radiation followed by Lumpectomy.|Selected patients will undergo a radiation planning procedure utilizing magnetic resonance imaging (MRI). Once this is completed, patients will receive five radiation treatments given every other day. After 28 days (four weeks), patients will have another MRI scan to compare tumor response to the radiation therapy. Following the MRI scan, roughly five to eight weeks later, patients will have a lumpectomy and possibly a sentinel lymph node biopsy. After surgery, tests will be performed on the tumor tissue to determine if genes expressed in the sample have changed. Following surgery, patients will receive chemotherapy and/or antihormone therapy at the discretion of the patient and physician.
40972066|NCT06034470|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40972067|NCT06034470|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
40972068|NCT06034470|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40972069|NCT06034470|DRUG|Cytarabine|Given IV
40972070|NCT06034470|PROCEDURE|Echocardiography|Undergo ECHO
40972071|NCT06034470|DRUG|Fludarabine|Given IV
40972072|NCT06034470|DRUG|Granulocyte Colony-Stimulating Factor|Given SC
41458638|NCT00400634|PROCEDURE|Sham Surgery|Bilateral partial thickness burr holes placed, no intraparenchymal injections
40972073|NCT06034470|DRUG|Idarubicin|Given IV
40972074|NCT06034470|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
40972075|NCT06034470|DRUG|Pivekimab Sunirine|Given IV
40972076|NCT01530568|OTHER|Xpert|This arm receives the GeneXpert test
40972077|NCT01530568|OTHER|Smear|This arm receives smear microscopy
40972078|NCT06340815|DEVICE|Radiation: Proton Therapy System (ProBeam)|"All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.~And long-term follow-up report will be submitted for future post market evaluation when requested by NMPA."
40972079|NCT05276401|DRUG|5% Bisphosphocin Topical Gel|Topical Gel
40972080|NCT05276401|DRUG|Placebo Topical Gel|Topical Gel
40972081|NCT05276401|DRUG|10% Bisphosphocin Topical Gel|Topical Gel
40972082|NCT04592315|DRUG|Lipovirtide Injection|Single dosage of Lipovirtide Injection
40972083|NCT04849455|DRUG|0.2% ropivacaine local anesthetic continuous erector spinae plane block|Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)
40972084|NCT04849455|DRUG|0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block|Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
40972085|NCT04849455|DRUG|Spinal Morphine|200-300 mcg of spinal morphine
41466516|NCT05305131|DRUG|induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.|Day -7 (+/-1 day): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2+ IV pembrolizumab 200mg over 30 minutes Day 8: IV Gemcitabine 1000mg/m2 Day 15 (for cycles 1 and 2 only): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes
40972086|NCT06074068|BEHAVIORAL|Fathers for Change|18 week individual therapy focused on fathers' emotion regulation, reflective functioning and family communication.
40972087|NCT06074068|BEHAVIORAL|Duluth BIP|18 week individually delivered psychoeducation and CBT focused program focused on intimate partner violence
40972088|NCT05284214|BIOLOGICAL|Sargramostim|Sargramostim for injection
40972089|NCT05284214|BIOLOGICAL|Ipilimumab-containing therapy|Treatment for cancer containing ipilimumab at either 1 mg/kg or 3 mg/kg, intravenously..
40972090|NCT05931861|DEVICE|T2769|T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
40972091|NCT01250405|DRUG|Cinacalcet|One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
40972092|NCT01250405|DRUG|Placebo|One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
40990801|NCT01328821|DRUG|CTP-499|400 mg immediate release capsule
40972093|NCT01080534|DRUG|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
40972094|NCT00281255|DRUG|Allopurinol|
41298029|NCT05064345|DRUG|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
40972095|NCT00281255|DRUG|Dobutamine|
40972096|NCT00357968|DRUG|Prasugrel|Administered orally
40972097|NCT00357968|DRUG|Clopidogrel|Administered orally
40972098|NCT00357968|DRUG|Placebo for Prasugrel|Administered orally
40972099|NCT00357968|DRUG|Placebo for Clopidogrel|Administered orally
40972100|NCT00475358|DRUG|Duloxetine|
40972101|NCT00475358|DRUG|Placebo|
40972102|NCT01096901|BEHAVIORAL|Behavioral Weight loss|Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
40972103|NCT03582540|PROCEDURE|Double-guidewire cannulation technique|With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
40972104|NCT02275871|OTHER|MRI|High risk screening MRI will be performed as part of the patient's routine care.
40972105|NCT02275871|OTHER|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
40972106|NCT02733939|DEVICE|Home monitoring kit|"The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:~* leaves the home without notice, since this might occur in a moment of disorientation;~* leaves a water tap open;~* forgets something on the stove;~* gets out of bed during the night and doesn't come back within a certain time interval;~* never goes to the bathroom in 24 hours;~* never opens refrigerator door in 24 hours.~Depending on the personal choice of the study participants, the kit will also :~* automatically turn on a light to help avoid a fall during the night;~* alert the caregiver when the temperature in the house falls or rises excessively;~* act as burglar alarm in some areas of the home."
41139308|NCT05887609|DRUG|Mirvetuximab Soravtansine|is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
41298030|NCT05064345|DRUG|Placebo|Palcebo
41466517|NCT01854255|DRUG|doxorubicin and cisplatin|doxorubicin and cisplatin as intraperitoneal chemotherapy
40972107|NCT02546804|PROCEDURE|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
40972108|NCT02546804|PROCEDURE|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
40972109|NCT02546804|PROCEDURE|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
40972110|NCT03069547|OTHER|Quadriceps Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details can be requested rom the responsible party. In brief the QE-program consists of:~- A short warm-up and 3 specific exercises for the quadriceps muscle~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, free weights, etc."
40990802|NCT06457841|BEHAVIORAL|Direct Discrimination|Simulated racial discrimination that is received directly from a perpetrator, commonly experienced in everyday lives by African American individuals
40990803|NCT06457841|BEHAVIORAL|Vicarious Discrimination|Hearing or observing racial discrimination experienced by another person of the same racial background
41139309|NCT05887609|DRUG|Olaparib|Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
41298031|NCT06058494|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the anterior cruciate ligament by means of the three reported techniques, namely single-bundle, single-bundle with extraarticular tenodesis and anatomic double-bundle.
41298032|NCT05490628|OTHER|Cognitive Rehabilitation|Language, memory, attention and executive function exercises are performed for the participants' deficient cognitive functions.
41298033|NCT05490628|OTHER|Conventional Therapy|Strengthening, walking, balance and coordination exercises are performed according to the needs of the participants.
41298034|NCT02268565|DRUG|Aspirin|81mg aspirin daily at bedtime over a 2 week period
41298035|NCT02268565|DRUG|Placebo|pill that looks like aspirin without the effects of aspirin
41298036|NCT00298610|DRUG|Artesunate|Intravenous Artesunate (2.4 mg/kg) once a day for three days
41298037|NCT00298610|DRUG|Malarone|(proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
41298038|NCT01115946|DRUG|ASP1585|oral
41298039|NCT01115946|DRUG|enalapril|oral
41466518|NCT01322334|BEHAVIORAL|Singing exercises|A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
41298040|NCT02664636|PROCEDURE|Physiotherapy|"Physiotherapy regimen (days 0 to 60): orthopedic maintenance, work on trunk balance, sensorimotor techniques for restoration of motor skills, exercises for standing balance and walking. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. They occur as daily sessions during the first two weeks and then two sessions / day.~This is part of routine care."
40769356|NCT06569407|OTHER|Educational Booklet|An educational booklet for EBP was planned to be developed based on the literature and expert opinions. The learning objectives and content of the educational booklet to be developed will be created by considering Bloom\&#39;s taxonomy. In line with the literature, it is planned to include topics such as introduction to EBP, importance of EBP, evidence-based practice steps, clinical research question design in line with PICO, introduction of evidence-based databases, literature search strategies, research types, use of scientific research and evidence evaluation tools, introduction of clinical decision support systems, reflections of EBP on patient care and clinical decision-making processes, and finalization of the booklet topics with expert opinions.
40972111|NCT03069547|OTHER|Hip Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details be requested rom the responsible party. In brief the HE-program consists of:~- A short warm-up and 3 specific exercises for the hip abductor and extensor muscles~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, body weight etc."
40972112|NCT02769455|OTHER|Reference intakes|"FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.~The presentation of the products will always include the label affixed on it. Moreover, the product pages will include two pictures of the product: one with only the package (including the RI as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant. These elements ensure higher visibility, awareness and understanding of the label."
40972113|NCT02769455|OTHER|5-CNL|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format includes five categories, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the one corresponding to the product being enlarged.~The presentation of the products will always include the label affixed on it. Two pictures of the product will be included: one with only the package (including the 5-CNL as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant."
40972114|NCT00285805|DRUG|Rosiglitazone versus placebo|
41139310|NCT05162352|DRUG|Donafenib+sintilimab|"Part 1 (Safety Run-in): donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-days cycle.~Part 2: donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W.~Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity."
41298041|NCT02664636|PROCEDURE|Occupational therapy|"Occupational Therapy (days 0 to 60): Orthopaedic maintenance, exercises for sitting and standing balance, sensorimotor techniques for the restoration of motor skills, grip exercises. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. 1 session is performed per day.~This is part of routine care."
40769357|NCT05902754|DIETARY_SUPPLEMENT|Generally Recognized as Safe - Sulforaphane|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of Sulforaphane a day with a meal for 28 days.
40769358|NCT05902754|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of placebo a day with a meal for 28 days.
40769359|NCT06630156|BIOLOGICAL|Revascularization of Immature Young Permenant Teeth|"An access cavity was prepared under rubber dam, isolation, root canal system disinfection was done without mechanical instrumentation. Subsequently, triple antibiotic paste was placed into the apical portion of the canal and filled to just below the CEJ. The access cavity was temporarily restored with glass ionomer.~4 weeks later, after reopening of the access, the antibiotic paste was gently flushed out of the canal with sterile normal saline. The root canal system was irrigated. A sterile #35 K-file will be introduced into the canal beyond the apical foramen using a push and pull motion to provoke bleeding from the periapical tissue. After bleeding control and formation of fresh blood clot, 3 mm of Bio (MTA) will be placed in Group A, 3 mm of Total Fill biocearmic root repair material will be placed in Group B after a moist cotton pellet was placed over the capping material and the access cavity will be sealed with G C"
40769360|NCT06643143|DRUG|IkT-001Pro|IkT-001Pro
40769361|NCT06643143|DRUG|Placebo|Placebo
40769362|NCT05581511|OTHER|Evaluation of the natural history of cutaneous neurofibromas|Cutaneous neurofibromas (cNFs) are the most common tumors in people with neurofibromatosis type 1 (NF1). Despite their benign histology, they can significantly impact patients' quality of life (QoL). In this project, the natural history of cNFs will be prospectively and systematically studied. To accomplish this, the reproducibility and efficiency of using 3D whole-body photography was evaluated in a small cohort of patients. The study is enrolling patients of all ages with cNFs into groups by epochs of life to characterize the baseline tumor burden and the change in number and morphology of cNFs over five years. In addition, the study will perform next generation sequencing to describe the genetic variations in the NF1 gene and evaluate potential relations between genotype and phenotype. Lastly, the study will validate clinician- and patient-reported severity scales of cNFs developed for this patient population.
41298042|NCT02664636|PROCEDURE|Functional near-infrared spectroscopy|During the therapy protocol, cortical activation measures using the fNIRS method will be conducted every 15 days (at Day0, Day 15, Day 30, Day 45 and Day 60 for 5 sessions in total) at the technical platform of the Grau du Roi physical therapy centre, during the completion of a standardized motor task (maintaining a level of force) using the healthy upper limb and the paretic upper limb.
41298043|NCT03864263|OTHER||
41298044|NCT03360981|DRUG|Incretins|after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
41298045|NCT01889810|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
41298046|NCT01570985|DRUG|Triamcinolone Acetonide|Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.
41298047|NCT01570985|DRUG|Triamcinolone Acetonide|Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
41298048|NCT00128206|DRUG|Isoniazid|Isoniazid 900 mg twice weekly
41298049|NCT00128206|DRUG|Rifampin|Rifampin 600mg once per day
41298050|NCT01051375|BEHAVIORAL|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
41298051|NCT02352246|PROCEDURE|Physical activity programs steady-state exercise (SSE) program|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
41298052|NCT02352246|PROCEDURE|Physical activity programs high intensity intermittent exercise (HIIE)|
41298053|NCT06512805|BEHAVIORAL|Routine transport|"1. Before the transfer of the patient:~   ① The doctor determines the destination of the patient based on the patient's condition and issues transfer orders.~  * The responsible nurse assesses the patient's consciousness, circulation, respiration, etc., and fills out the Transfer Patient Handover Record in the transferring department section.~     * The responsible nurse prepares the equipment, medications, and patient's belongings required for the transfer.~2. During the transfer:~   Monitor the patient's vital signs.~3. Upon arrival at the receiving department:~   * Place the patient with the receiving department nurse. ② Verbally hand over the patient's condition to the receiving department nurse and hand over the patient's belongings and medications.~     * The responsible nurse of the receiving department completes the remaining part of the Transfer Patient Handover Record."
41298054|NCT06512805|BEHAVIORAL|Post-guideline transfer|"In the intervention group, nurses receive implementation strategies developed during the preparation phase. These strategies aim to modify the behavior of healthcare personnel through implementation, thereby conducting evidence-based (based on the guidelines) in-hospital transfer interventions for pediatric patients.The interventions received by pediatric patients are derived from the recommended practices evaluated for evidence availability in the guidelines. These include specific transfer procedures, the Transfer Risk Level Classification Criteria, Personnel Qualifications, Equipment, and Medications Allocation Based on Transfer Risk Level, Transfer Preparation Checklist, and Transfer Handover Checklist 2.0."
41298055|NCT02015598|DRUG|Carbocysteine|carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
41298056|NCT02015598|DEVICE|Continuous Positive Airway Pressure|Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
40972115|NCT00285805|DRUG|response (sodium excretion) to amiloride infusion|
40972116|NCT00285805|DRUG|response (sodium excretion) to furosemide infusion|
40972117|NCT06499259|OTHER|Mandala coloring|Mandala Pack and Application: The mandala pack is a pack consisting of 7 different patterns suitable for adults and 12 pencils. Mandala patterns will be photocopied by the researcher. Packages will be given to the mothers about mandala coloring and their questions will be answered. The choice of the color of the paint to be used in mandala coloring will be entirely up to the mother. No guidance will be given in this regard.
41139311|NCT03176407|DIAGNOSTIC_TEST|HemoPill acute|Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
41298057|NCT03321786|OTHER|The University of Pennsylvania Smell Identification Test (UPSIT)|"This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets."
40972118|NCT00543140|DEVICE|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
40972119|NCT03901833|BEHAVIORAL|Telemedicine Support|Telemedicine intervention
40972120|NCT03901833|OTHER|Standard of Care|Standard of Care
41139312|NCT04482556|DEVICE|Q-NRG+ Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
40972121|NCT01817621|BEHAVIORAL|Experimental Intervention|The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.
40972122|NCT01817621|BEHAVIORAL|TAU|Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
40972123|NCT05144360|DRUG|Atenas|ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day
40972124|NCT05144360|DRUG|Atenas placebo|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
40972125|NCT03158116|DRUG|Inhaled Aztreonam|Inhaled antibiotic with anti-pseudomonal properties
41298058|NCT01111981|DRUG|Clobetasol Propionate 0.05% Emollient Foam|Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
40972126|NCT03954925|PROCEDURE|Anatomic anterior cruciate ligament with short hamstring graft technique|ACL and short hamstring graft
40972127|NCT03954925|PROCEDURE|Anatomic anterior cruciate ligament with a standard hamstring graft technique|ACL with standard hamstring graft
40972128|NCT02236832|DEVICE|transcranial magnetic stimulation|
40972129|NCT02236832|OTHER|MRI imaging|
40972130|NCT02236832|OTHER|EEG recording|
40972131|NCT02236832|BEHAVIORAL|Neuropsychological examination|
41298059|NCT05563077|OTHER|Moderate-intensity interval training (MIIT)|MIIT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period (∼6-7 reps of 4 min at ∼4.2 METs, with 3 min of active recovery at ∼2.2 METs between each interval), and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs). We will select the same aerobic dose of training (i.e., kcal/kg of body weight per week) to match total energy expenditure in both exercise groups.
41298060|NCT05563077|OTHER|Moderate-intensity continuous training (MICT)|MICT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period at ∼3.2 METs, and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs).
41458639|NCT03612973|DIAGNOSTIC_TEST|lipid profile|Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)
40972132|NCT02188251|DIETARY_SUPPLEMENT|Activamp|
40972133|NCT02188251|OTHER|Placebo|
40972134|NCT02302001|DEVICE|Silicone Implant|
41458640|NCT03612973|DIAGNOSTIC_TEST|fasting insulin|serum samples used for doing the test by ELISA after fasting for 8 h
41458641|NCT03612973|DIAGNOSTIC_TEST|fibro scan|liver stiffness by fibro scan before and after treatment
41458642|NCT01774058|DRUG|Ilomedin|3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
41458643|NCT02401139|DRUG|Ketamine|
41458644|NCT02401139|DRUG|Placebo|
40972135|NCT00848705|BEHAVIORAL|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
40972136|NCT02438098|DRUG|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
40972137|NCT00798499|OTHER|Laboratory variables|1 visit
40972138|NCT06131034|OTHER|Music|Participant in the intervention group will receive music interventions perioperatively.
41458645|NCT01151449|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
41458646|NCT01151449|OTHER|laboratory biomarker analysis|Correlative studies
40972139|NCT04404374|PROCEDURE|A-PRF/EMD|Comparing healing effect of an autologous and a xenogenic product
40972140|NCT02847156|OTHER|Physical assessment|1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
40972141|NCT02982876|PROCEDURE|Dynamic Flexible Bronchoscopy|The bronchoscope will be introduced into the proximal trachea at the level of the cricoid. At that point, patients will be instructed to take a deep breath, hold it and then blow it out (forced expiratory maneuver). Maneuvers will be done at the following six sites: proximal trachea at the level of the cricoid; mid-trachea 5 cm proximal to the carina; distal trachea 2 cm proximal to the carina; right main stem bronchus at the right tracheobronchial angle; bronchus intermedius and left main bronchus at the left tracheobronchial angle
40972142|NCT02982876|PROCEDURE|Rigid Bronchoscopy|Under general anesthesia, a rigid bronchoscope (Bryan-Dumon Series II; Bryan Corporation; Woburn, MA) will be introduced, and respiration will be maintained through jet ventilation.
40972143|NCT02982876|DEVICE|Stent placement|Silicone Y stent or uncovered self-expanding metallic stent will be placed in the standard fashion and good fit will be confirmed visually.
40972144|NCT02302027|DEVICE|platinium IRC9LXO2AWQ|high flow concentrator delivering normobaric oxygen after extraction, 9 liter per minute dimensions: 46 \* 67 \* 36 cm
40990804|NCT06457841|BEHAVIORAL|Daily Hassles|Day-to-day stressors associated with school, work, finances
40990805|NCT01838642|DRUG|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
40972145|NCT03648268|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation"
40972146|NCT01871532|DRUG|Gonal-f®|
40972147|NCT06074315|DEVICE|Nail Genesis DLSO Product|Nail fungus is difficult to treat with topical drugs because of the thickness of the nails (Murdan, 2002). Nail Genesis DLSO Product does not contain a drug or antifungal agent and so is not designed to have a direct action on the microorganism, but instead will act by changing the conditions that allow growth of the fungus (i.e., keeping the nail plate and underlying nail bed dry and inhibiting secondary infection).
40972148|NCT06074315|DEVICE|Nail Genesis DLSO Product (vehicle only)|The Nail Genesis DLSO product poly-urethane vehicle
40972149|NCT01655472|DEVICE|imaging follow up: MRI scan|.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
40972150|NCT01655472|DEVICE|imaging follow up: Ultrasonographic examination|
40972151|NCT02259868|DRUG|BILR 355 BS /1B, current low dose formulation|
40972152|NCT02259868|DRUG|BILR 355 BS /1B, current high dose formulation|
40972153|NCT02259868|DRUG|BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation|
40972154|NCT02259868|DRUG|BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation|
40972155|NCT02259868|DRUG|BILR 355 BS - Suspension low dose|
40972156|NCT02259868|DRUG|BILR 355 BS - Suspension high dose|
40972157|NCT02259868|DRUG|Ritonavir|
40972158|NCT04073654|PROCEDURE|Placement of dental implants (surgical procedure)|The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
40972159|NCT04458974|DEVICE|Transcranial direct current stimulation|"The intervention consists in two-weeks treatment, 10 consecutive sessions of tDCS ( Monday to Friday) applied concurrently to neuropsychological rehabilitation.~The tDCS Multisite StratStim® 8-channel device (Neuroelectrics) will be used for tDCS stimulation. The duration of the stimulation will be 20 minutes at 2 mA. The tDCS will be applied with the cathode positioned in P3 (following the international 10/20 EEG system), and the return electrodes will be placed in C3, CP5, CP1, Pz, PO3, PO7, P7.~The sessions will last 1 hour."
40972160|NCT04458974|PROCEDURE|Neuropsychological rehabilitation|"The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session)."
41298061|NCT06510296|BEHAVIORAL|Digital Mind Body Intervention mobile application|A DMBI mobile application with psychoeducation and skill-building in illness perception, coping, mindfulness, and disease acceptance informed by needs/barriers of Black and Hispanic patients with IBD who have elevated psychological distress and GI professionals caring for IBD patients.
41298062|NCT04930640|DIETARY_SUPPLEMENT|SGF200 group|1 times a day, 1 capsule for 1 time, before breakfast meal, for 8 week
41298063|NCT04930640|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
41298064|NCT01704248|DEVICE|Eye Drop Guide technique|"1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.~5. Then place the upper lip down to cover the whole orbital rim area.~6. Tilt the head back if seated or standing.~7. Insert the bottle in the device all the way. Hold the bottle gently.~8. Look upward.~9. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~10. Close the eye 2-3 minutes.~For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward."
41298065|NCT01704248|BEHAVIORAL|Routine self-instillation technique|"1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Lie down or tilt the head back if seated or standing.~5. Using the other hand, pull the lower lid down.~6. Hold the bottle over the eye and look up.~7. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~8. Close the eye 2-3 minutes.~For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye."
40972161|NCT02454400|OTHER|Pre-surgery physiotherapy|"Physiotherapy guided intervention twice a week for nine weeks. The program includes:~1. Active physiotherapy according to a treatment based classification:~   1. Specific exercises and mobilization~  2. Motor control exercises~  3. Traction~2. Tailor-made general supervised exercise program~3. Behavioral approach to reduce fear avoidance and increase activity level.~4. Standardized information about:~   1. the surgery~  2. post-surgery rehabilitation~  3. to stay active"
41458647|NCT01181830|DRUG|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate
41458648|NCT01181830|DRUG|placebo|administration of 8.1 mmol bid of placebo
41458649|NCT03548155|DRUG|Berberine|Berberine 300mg（three times a day） plus any atypical antipsychotic drug
41458650|NCT03548155|DRUG|atypical antipsychotic|Any atypical antipsychotic drug as the basic treatment
41458651|NCT03548155|DRUG|placebo|The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles
40972162|NCT02454400|OTHER|Waiting-list|"Standardized information about:~1. the surgery~2. post-surgery rehabilitation~3. to stay active"
40972163|NCT05740644|DEVICE|CM-1600|Healthy subjects undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline will be connected to the CM-1600 device.
40972164|NCT01877434|PROCEDURE|Reversed shoulder arthroplasty|
40972165|NCT05526430|DRUG|Harmine Hydrochloride Capsules|capsules taken orally
40972166|NCT06270498|DIETARY_SUPPLEMENT|Sucrosomial iron|"Sucrosomial iron with the addition at a fixed dose of vitamin C to promote iron absorption (SiderAL® Forte) will be administered orally once a day for 12 weeks.~The dose regimen for all participants will be calculated according to the haemoglobin (Hb) levels at baseline evaluation and to patient's body weight as follows:~Hb 14-15 g/dL: 1 tablet once a day, corresponding to 30 mg/daily, for 12 weeks; Hb 10-13.9 g/dL: 2 tablets once a day, corresponding to 60 mg/daily, for 12 weeks"
41298066|NCT04539301|DIAGNOSTIC_TEST|Estimated anticoagulant level (conversion factor x anti-Xa activity)|Estimated anticoagulant level (conversion factor x anti-Xa activity)
40972167|NCT06270498|OTHER|Placebo|"Placebo pills will be identical in shape, form and color of SI pills; they will contain the same components of SiderAL Forte® except for sucrosomial iron and vitamin D.~Placebo will be administered orally once a day for 3 months according to the same dose scheme in the intervention arm."
40972168|NCT05035953|DRUG|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis
40972169|NCT05035953|DRUG|Placebo|Edaravone Dexborneol matching injection, addition to thrombolysis
40972170|NCT04610268|DEVICE|transcranial direct current stimulation|Depending on the location of sEEG electrode implanted in the patient's head, the tDCS electrode (5 cm×7 cm each) was placed on occipital-frontal lobe or bilateral temporal lobe. Current intensity: 2 mA and 4 mA, Stimulus time: 3 min (each stimulus session).
40972171|NCT01561365|BEHAVIORAL|Ottawa ankle rules|Ottawa ankle rules implementation
41139313|NCT04482556|DEVICE|V(max) Encore Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
41139314|NCT06461585|OTHER|Sprint interval training|Group A the Interventional group will receive SIT . Group A will perform SIT 3 times a week for 30-second sprints on a cycle ergometer with 4 minutes of rest between each sprint, complete session will be for 30 -40 minutes. Group B will receive the aerobic exercise. Group B will perform the aerobic exercise for 30-40 minutes of moderate-intensity continuous exercise on a treadmill and stationary cycle
41139315|NCT02084615|DRUG|Aspirin|Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
41139316|NCT02782000|OTHER|lessons,long-term supervision and message|
41139317|NCT02782000|OTHER|lessons,short-term supervision and message|
41139318|NCT02680145|DEVICE|Preoperative Pessary Use|Pessary use for 1-4 weeks prior to surgical prolapse repair
41139319|NCT02950961|BEHAVIORAL|Collaborative Care for Women Veterans|This is a collaborative care model that focuses on identifying need for depression and/or anxiety care. Patients with possible anxiety and/or depression are referred to a care manager in primary care-mental health integration. The care manager then conducts a thorough assessment, offers the patient a variety of appropriate treatment options, and works with the patient to determine a care plan. One of the key options the investigators offered in this study is the Calm Tools for Living (CALM) intervention, which is focused on anxiety and which is rooted in patient preferences. Patients can choose web-based cognitive behavioral therapy (CBT) and/or pharmacologic treatment. In this study the investigators trained appropriate MH providers in CALM and studied the ways in which the intervention needs to be tailored to women Veterans.
41139320|NCT04530370|BIOLOGICAL|recovered covid 19 patients plasma|we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
41139321|NCT02131454|OTHER|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
41139322|NCT00003599|DIETARY_SUPPLEMENT|Vitamin E (AT)|Orally daily
41466519|NCT04449224|DRUG|Adalimuab, Etanercept, Tocilizumab, or Abatacept|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
41466520|NCT04449224|DRUG|Tofacitinib or Baricitinib|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
40972172|NCT04554667|BEHAVIORAL|Exercise Intervention|Heavy Lifting Strength Training
40972173|NCT02417701|OTHER|Laboratory Biomarker Analysis|Correlative studies
40972174|NCT02417701|OTHER|Pharmacological Study|Correlative studies
40972175|NCT02417701|DRUG|Sapanisertib|Given PO
40972176|NCT06194565|DRUG|99mTc-ABH2|Each patient will receive an intravenous injection of 99mTc-ABH2, and undergo a SPECT/CT scan within specified time.
40972177|NCT03634462|OTHER|CDT with graded negative pressure|Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise. The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.
40972178|NCT04150913|DRUG|Anakinra|Subcutaneous, dosage per protocol. Day 0 through Day 6.
40972179|NCT04150913|DRUG|Axicabtagene Ciloleucel|Once, intravenous infusion, dosage per protocol
40990806|NCT00187460|BEHAVIORAL|Publicly released hospital cardiac report cards|Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
41139323|NCT00003599|DRUG|Isotretinoin|Orally daily
41139324|NCT00963924|DRUG|D-cycloserine|50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
41139325|NCT00963924|DRUG|Placebo|Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
41139326|NCT00963924|BEHAVIORAL|Cognitive Remediation|40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
40972180|NCT01236599|OTHER|Polyethylene for thermoregulation in the preterm infant|3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
40972181|NCT03768960|DRUG|Daratumumab|Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
41466521|NCT04573296|DEVICE|Vitadio|A 6-month digitally administered behavioral change program Vitadio focus on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and remote coaching.
40972182|NCT06033794|DEVICE|Fluorescence laparoscopic system|Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
40972183|NCT03933345|OTHER|Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.|At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.
40972184|NCT02090569|DEVICE|Functional micro-Doppler Sonography (fmDS)|"1. Craniotomy according to MRI images~2. Dura opening~3. Sulcal Localization using neuronavigation~4. Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.~5. Exeresis of the dysplasic tissue~6. Control using fmDS before wound closure"
40972185|NCT03606408|DRUG|osilodrostat|osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
40972186|NCT02023398|DEVICE|BTL-9000 HFT|Deep tissue heating with the BTL-9000 HFT for HFT group
40972187|NCT02023398|DEVICE|sham BTL-9000 HFT|sham deep tissue heating with BTL-9000 HFT in Placebo group
40972188|NCT01032005|OTHER|double fortified salt|Refined salt of particle size \< 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
40972189|NCT02788357|DRUG|Atomoxetine|Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
40972190|NCT02788357|DRUG|Placebo|Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
40972191|NCT02941978|BEHAVIORAL|Motivational interview|Patients assigned to the intervention group receive additional medical consultation aiming to boost optimal uptake of the anticoagulation regimen prescribed. Initially (i.e., at hospital discharge), this includes a physician-patient interactive session and provision of an educational leaflet. The leaflet is designed in a culturally and linguistically conceivable template in Greek language. It uses simple terms together with both written and pictorial materials. Patients in the intervention group will also undergo short telephonic sessions at 1 week, 2 months, 6 months and 12 months following hospital discharge
40972192|NCT02941978|BEHAVIORAL|Control|Patients assigned to the control group receive usual treatment, corresponding to standard practice and management of hospitalized patients with AF. For both patient-groups, the choice of OAC agent and any other background therapy is left to the discretion of the treating physician.
41139327|NCT01494766|DIETARY_SUPPLEMENT|L-Tyrosine|L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
41139328|NCT01753674|DIETARY_SUPPLEMENT|TA-65|TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
41139329|NCT01753674|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
41139330|NCT02108496|DEVICE|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
41139331|NCT02108496|DRUG|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
41139332|NCT02108496|DRUG|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
41139333|NCT02108496|DRUG|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
40972193|NCT02266225|OTHER|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
40972194|NCT04635943|DRUG|Ivermectin|One daily dose of NOXAL-Ivermectin Oral Solution (6 mg/mL) at 300mcg/kg for three (3) consecutive days. A weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).
40972195|NCT04635943|DRUG|Placebo|The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.
40972196|NCT02376088|DRUG|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
40972197|NCT02363517|DRUG|Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)|SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
40972198|NCT05339568|OTHER|Patients' whole process follow-up and management platform|Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.
40972199|NCT05181683|DRUG|Casirivimab+Imdevimab|Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
40972200|NCT00084565|DRUG|estramustine phosphate sodium|
40972201|NCT00084565|DRUG|paclitaxel|
40972202|NCT00084565|DRUG|topotecan hydrochloride|
40972203|NCT01246401|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
40972204|NCT00638768|OTHER|Physiotherapy|10 weekly individual sessions with the therapist each lasting approximately 45 minutes. Techniques included postural taping, massage, mobilisation, exercises. The patients also performed home exercises
40972205|NCT00905697|PROCEDURE|Living donor lung transplantation|Living donor lung transplantation
40972206|NCT05171595|DEVICE|Lifetouch single-lead ECG monitoring|The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.
40972207|NCT05171595|DIAGNOSTIC_TEST|high-sensitive TnT measurements|Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
40972208|NCT01689701|DIETARY_SUPPLEMENT|Hizikia Fusiformis extract|Hizikia Fusiformis extract(1.3g/d)
40972209|NCT01689701|DIETARY_SUPPLEMENT|Placebo|Placebo(1.3g/d)
40972210|NCT06229353|BIOLOGICAL|Gardasil 9|Prevent HPV-associated diseases and cancers
40972211|NCT04606914|DRUG|mirvetuximab soravtansine (MIRV; IMGN853)|Mirvetuximab soravtansine (also known as IMGN853 and MIRV) is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridin-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB) linker. FRα is a glycosyl-phosphatidylinositol (GPI)-linked protein, which shows limited normal tissue expression and high expression on the surface of solid tumors, particularly epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (referenced herein collectively as EOC), endometrial cancer, non-small cell lung cancer (NSCLC), and renal cell cancer.
41139334|NCT01729767|DRUG|Acyclovir|Patients who were randomly allocated to the Acyclovir group besides sticking with low salt diet will take the Acyclovir 400 mg pills for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and their tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
41458652|NCT05093686|BEHAVIORAL|RUBIES|RUBIES is an 8 module intervention that begins with foundational education on ASD (Session1), followed by introducing basic applied behavior analysis principles (Session 2). Instruction is then provided on strategies that can prevent problematic behaviors from occurring (Session 3 and 4). Reinforcement (Session 5) reviews the use of tangible and social reinforcers tools to promote new/desired behaviors while planned ignoring and functional communication training (Session 6) teaches that disruptive behavior can serve as a form of communication while ignoring disruptive communicative attempts. Sessions conclude with instruction on effective ways to deliver commands to promote compliance (Session 7) and targeting approaches to ensure positive behavior gains can maintain over time and strategies can be used across classrooms and staff (Session 8).
40972212|NCT03585998|DRUG|Durvalumab|Concurrent radiotherapy Maintenance therapy
40972213|NCT00954434|DIETARY_SUPPLEMENT|red wine|intake of red wine on a daily basis
40972214|NCT00275990|DEVICE|rheolytic thrombectomy with direct stenting|
40972215|NCT00275990|DEVICE|direct stenting|
40972216|NCT01917474|DIETARY_SUPPLEMENT|low lipid diet|Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
40972217|NCT01917474|DIETARY_SUPPLEMENT|normal lipid diet|Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
40972218|NCT01339429|DEVICE|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
40972219|NCT03019822|DRUG|LSD|100ug per os, single dose
40972220|NCT03019822|DRUG|MDMA|125mg per os, single dose
40972221|NCT03019822|DRUG|Amphetamine|40.3mg per os, single dose
40972222|NCT03019822|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs
40972223|NCT02810860|PROCEDURE|Laparoscopic cholecystectomy|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
40972224|NCT00086320|DRUG|Paliperidone ER|
40972225|NCT06240975|OTHER|Theragun Technique|Use the Theragun for a designated duration per session, such as 5-10 minutes for one session per week for 6 weeks
40972226|NCT06240975|OTHER|Dry Needling Technique|Dry needle deep (20 mm) TrP acupuncture of myofascial duration per session, such as 5-10 minutes for one session per week for 6 weeks
40972227|NCT06237660|PROCEDURE|Bronchoscopy, with bronchoalveolar lavage and endobronchial biopsy|These children who will be having a bronchoscopy (a long thin tube, with a camera at the end, which is put inside the lung to look at and collect samples) as part of their standard clinical management, determined by their own consultants or treating physicians. They will be having lung samples (washings from the lung and a tiny piece of tissue taken from the breathing tubes) taken as part of their usual medical management. The research team will ask for consent to use the leftover samples for the bronchoscopy, for the study
40972228|NCT06237660|DIAGNOSTIC_TEST|Skin prick test|To identify children with allergies. This test will not be done if the child has had allergy testing in the last 6 months
40972229|NCT06237660|DIAGNOSTIC_TEST|Finger prick blood test|Finger prick testing will be used for blood samples, and it is the same technique used by children with diabetes, to test their blood sugar levels, and therefore is regularly used in this age group successfully. The research team will be obtain the results within minutes, using a point-of-care device. A few more drops of blood, from the same finger prick sample, will be taken to look at how one of the blood cells work, in more detail, in the laboratory. There is no additional finger prick required for this lab test, and the drops of blood will be collected at the same time, from the same prick, as the point of care test.
40972230|NCT06237660|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|Breathing test will be performed using forced oscillation technique (FOT), to see how the child's lungs work and to detect airway inflammation. The test will be explained to the child and completed using our established protocols. This test will only require the child to breathe in and out normally, and therefore can be done in preschool aged children. The current test that is used to check lung function called spirometry cannot be used in preschool children, as it involves following complicated instructions. The aim is to assess how well this newer lung function test is tolerated, in children aged 1-5 years.
40769363|NCT03379870|DEVICE|Electric Acoustic Speech Processor: Electric-acoustic stimulation fitting|Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
40972231|NCT06237660|PROCEDURE|Sputum induction|Sputum induction is a test of obtaining phlegm after inhalation of salt water mist (saline nebuliser) and this will allow the research team to look for any relationships between infection in the lungs and the accuracy of the less invasive, nose and throat swabs. The research team will obtain phlegm samples, with a quick suction after patients have inhaled the salty mist (saline nebuliser) which will help loosen up their phlegm. If the child can cough it up, they will be encouraged to do it.
40972232|NCT06237660|DIAGNOSTIC_TEST|Oropharyngeal swab|Swabs from children's nose and throats (similar to swab tests that are done for Covid tests), that will be used to test for bacterial infection
40972233|NCT03900078|OTHER|Incisional negative pressure wound therapy|A negative pressure dressing is applied to the skin incision.
40972234|NCT03900078|OTHER|Wound dressing with adhesive tapes|Regular adhesive wound tapes are applied over the closed skin.
40972235|NCT01025752|BEHAVIORAL|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
40972236|NCT01025752|BEHAVIORAL|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
40972237|NCT00161083|DRUG|ursodeoxycholic acid|
40972238|NCT04934397|OTHER|Study Infant Formula|Powdered partially hydrolyzed whey (WPH) based infant formula with oligosaccharides
40972239|NCT04942691|OTHER|physical activity|training with trampoline. Each session lasted sixty minutes. Organization: a 5 minutes warm-up with breathing and mobility exercises from upper to lower body, central phase with jumping exercises involving the total body and 5 minutes of cool-down phase with total body active stretching exercise.
40972240|NCT06123845|BEHAVIORAL|static CPAP 8 cmH2O|Set static CPAP or PEEP pressure level at 8 cmH2O
40972241|NCT06123845|BEHAVIORAL|static CPAP 5 cmH2O|Set static CPAP or PEEP pressure level at 5 cmH2O
41298067|NCT04610242|DIAGNOSTIC_TEST|skin test|"For skin prick tests (SPT), rituximab solution of 1mg/ml was applied on the volar aspect of the forearm. For intradermal tests (IDT), 0.02 mL of a 1:100 dilution (0.1mg/ml) of full-strength solution (10mg/ml) was injected first. If the result was negative, a 1:10 dilution（1mg/ml）was then used.~As to the desensitization protocol, three solutions with different concentrations are delivered in 12 consecutive steps, each step increasing the rate of drug administration by 2- to 2.5-fold. Solution 1 is a 100-fold dilution (0.01mg/ml) of the final target concentration, solution 2 is a 10-fold dilution (0.1mg/ml) of the final target concentration, and the concentration of solution 3 is the target concentration (1mg/ml). Each step takes 15 minutes until the target rate of 200ml/h is reached, and the final step is prolonged to complete the target dose. The whole procedure takes about 5.5 hours."
40972242|NCT05623098|DIETARY_SUPPLEMENT|dietary fiber nutrients|Whether to add nutrients containing dietary fiber
41298068|NCT04076124|DEVICE|Active rTMS-DLPFC|Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
40972243|NCT00247091|BIOLOGICAL|standard-titer measles vaccine|
40972244|NCT00552721|OTHER|Physical therapy with strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
40972245|NCT00552721|OTHER|Physical therapy without strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
40972246|NCT06289998|DRUG|Tamibarotene|Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks.
40972247|NCT06289998|DRUG|Placebo|Subjects are administrated to placebo in daily for 52 weeks.
40972248|NCT05225766|OTHER|bupivacaine|used for peripheral block
41298069|NCT04076124|DEVICE|Active iTBS-DLPFC|Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
40972249|NCT03683108|DRUG|Resveratrol and Carbossimetyl Beta Glucan|Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.
40972250|NCT03683108|OTHER|Saline Solution|Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
40972251|NCT02507505|PROCEDURE|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
40972252|NCT02507505|PROCEDURE|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
40769364|NCT03379870|DEVICE|Electric Acoustic Speech Processor: Full-electric stimulation fitting|Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
40769365|NCT00600496|DRUG|AZD6244|twice daily oral dose
40769366|NCT00600496|DRUG|Dacarbazine|intravenous infusion
40972253|NCT02839070|OTHER|Sleep/Wake Schedule|Timing of sleep and wake
40972254|NCT00001830|DRUG|Th2 cells in allo HSCTT|
40972255|NCT00001830|DRUG|Th2 Cells|
40972256|NCT06301685|BEHAVIORAL|Routine therapy|The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
40972257|NCT06301685|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40972258|NCT06301685|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. once a day.
40972259|NCT00002916|BIOLOGICAL|human papillomavirus 16 E7 peptide|
40972260|NCT00002916|BIOLOGICAL|synthetic human papillomavirus 16 E6 peptide|
40972261|NCT00002916|PROCEDURE|adjuvant therapy|
40972262|NCT00002916|PROCEDURE|surgical procedure|
40972263|NCT00002916|RADIATION|radiation therapy|
40972264|NCT03697629|DRUG|Daratumumab|"Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6."
41298070|NCT04076124|DEVICE|Sham TBS-DLPFC or Sham rTMS-DLPFC|Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
41298071|NCT03938376|DIAGNOSTIC_TEST|Micro-Ultrasound guided biopsy|High-resolution imaging device
40972265|NCT05960266|BIOLOGICAL|Polvac Grass+Rye|Aqueous suspension of a co-precipitate of allergen extract and tyrosine
40972266|NCT03099421|PROCEDURE|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
40972267|NCT03938389|DRUG|Sacubitril-Valsartan Tab 97-103 MG|Participants will take Sacubitril-Valsartan for 26 weeks
41298072|NCT00096746|DRUG|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
41298073|NCT00096746|DRUG|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
40769367|NCT00600496|DRUG|Erlotinib|daily oral dose
40769368|NCT00600496|DRUG|Docetaxel|intravenous infusion
40769369|NCT00600496|DRUG|Temsirolimus|intravenous infusion
40972268|NCT03938389|DRUG|Valsartan 160mg|Participant will take Valsartan for 26 weeks
41298074|NCT01166659|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
41298075|NCT00319618|DRUG|Gefitinib|
41298076|NCT00319618|DRUG|Docetaxel|
41458653|NCT05093686|BEHAVIORAL|Usual Care Training|Usual Care Training is an 8 module psychoeducation program that will provide foundational information on autism spectrum disorders, including the diagnostic criteria, appropriate educational services, common interventions, and how to promote social skills in the classroom.
41458654|NCT04476563|DIAGNOSTIC_TEST|Obtaining biological samples|Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated
41458655|NCT02784262|DRUG|botox injection Multiguide|botox injection under CT/MR navigation and with the navigation tool MultiGuide
41458656|NCT01969864|BEHAVIORAL|HRSA Video Intervention|
40972269|NCT03938389|DRUG|Placebo Oral Tablet|Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
40972270|NCT04168385|DRUG|Maralixibat|"Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication.~\*equivalent to 1140 mcg/kg/day maralixibat"
40972271|NCT02799511|BIOLOGICAL|protein expression|Differential protein expression between the period of acute cerebral ischemia and the control period
40972272|NCT02860169|BEHAVIORAL|Participants self-administered questionnaire and assessment|Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
40972273|NCT00307294|DRUG|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
40972274|NCT00307294|DRUG|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
40972275|NCT04410211|DRUG|Sevoflurane|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator"
40972276|NCT04410211|DRUG|Midazolam injection|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator."
40972277|NCT03322878|DRUG|Magnesium SO4|The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
40972278|NCT06014034|OTHER|Programmed Weaning From Noninvasive Mechanical Ventilation|Programmed withdrawal unit: daily morning review arterial blood gas analysis (since the 2nd, daily morning stop non-invasive ventilation 1 hours, 2 hours, 3 hours, 4 hours after check arterial blood gas analysis), blood gas results suggest respiratory acidosis compensatory period (pH value greater than 7.35) can reduce daily noninvasive ventilation time, namely the noninvasive ventilation use time for 24 hours, 20 hours, the third day 16 hours, the fourth 12 hours, fifth day 8 hours. If ABG indicates still acid decompensation, continue the non-invasive ventilation regimen of the previous day. If noninvasive ventilation failed, invasive mechanical ventilation was performed.
40972279|NCT03793777|DIETARY_SUPPLEMENT|Aronia|daily supplementation
40972280|NCT03793777|DIETARY_SUPPLEMENT|Placebo|daily supplementation
40972281|NCT05252117|DRUG|Articaine Hydrochloride 40 MG/ML|Analysis of uterovaginal plexus block with articain for intrauterine device placement
40972282|NCT05252117|DRUG|Mepivacaine|Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement
40972283|NCT02764515|DRUG|Kunxian Capsule|Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
40972284|NCT02764515|DRUG|Methotrexate|the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
40972285|NCT04231357|DRUG|platelet rich plasma|platelet rich plasma prepared from peripheral blood using single spin centrifugation
41458657|NCT01969864|BEHAVIORAL|PI Video Intervention|
41298077|NCT04359823|DRUG|Lovastatin 2%, 2% Cholesterol Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
41298078|NCT04359823|DRUG|Lovastatin 2% Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
41298079|NCT00676481|BEHAVIORAL|HIV risk education|Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
41458658|NCT01969864|BEHAVIORAL|CDC Health Website Intervention|
41458659|NCT03492567|BIOLOGICAL|Blood test|Blood draw (max 15 ml)
41458660|NCT03508154|OTHER|Control Meal 1|carbohydrate test meal
41458661|NCT03508154|OTHER|Control Meal 2|carbohydrate test meal
41458662|NCT03508154|OTHER|Experimental Nutritional Product|ready to drink nutritional formulation
41458663|NCT04740424|DRUG|FS222|Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.
41458664|NCT00659815|DEVICE|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Daily care for contact lenses.
41458665|NCT00659815|DEVICE|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.|Daily care for contact lenses
41458666|NCT05756738|DIAGNOSTIC_TEST|Dried blood spot testing|To evaluate the efficacy defined as the rate of diagnostic tests against hepatitis C virus (HCV) performed with a dried blood spot test
41458667|NCT01495715|DRUG|Idebenone|
41458668|NCT01495715|DRUG|Placebo|
41298080|NCT02832804|DEVICE|transcranial Direct Current Stimulation|Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
41298081|NCT04497558|DIAGNOSTIC_TEST|Endometrium biopsy|In the experimental group, those patients undergo endometrial receptivity array. In the control group, those patients do not receive any treatment before next cycle of transfer. In the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. In the control group, no intervention will be performed.
41298082|NCT04841499|DRUG|BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)|take 2 capsules orally each day for 7 days
41298083|NCT05718791|DIAGNOSTIC_TEST|blood sample|blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant
41298084|NCT02298270|BEHAVIORAL|The Relaxation Response Resiliency Program (3RP) via Skype|8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
41298085|NCT05051735|DRUG|Paracetamol|Paracetamol 500 mg
41298086|NCT05051735|DRUG|Placebo|Placebo
41298087|NCT02474017|DRUG|MGR001|Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
41298088|NCT02474017|DEVICE|CRC749 inhaler|
41298089|NCT05029076|DRUG|Liraglutide injection|Human glucagon-like peptides-1 analogue
41298090|NCT05029076|DRUG|Victoza|Human glucagon-like peptides-1 analogue
41298091|NCT00775359|DRUG|Fenofibrate 160 mg tablets|
41298092|NCT03048240|DEVICE|"perPDT"|"The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes)."
41298093|NCT03048240|DRUG|GLIOLAN|patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
41298094|NCT00573326|DRUG|Imatinib|200 mg p.o. once a day for 6 months
41298095|NCT05000580|PROCEDURE|Surgical|Conservative vs surgical management
41298096|NCT05170139|DIETARY_SUPPLEMENT|Caffeine|Participants will ingest a drink with 3mg/kg of body weight mixed with carbohydrates
41298097|NCT05170139|DIETARY_SUPPLEMENT|Placebo drink|Participants will ingest the exact same drink without caffeine
41298098|NCT01223976|OTHER|Tuberculin skin test and Quantiferon -TB Gold test|"TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.~QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions."
41298099|NCT02575313|DIETARY_SUPPLEMENT|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
41298100|NCT02543398|PROCEDURE|Ridge preservation|Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
41298101|NCT03623984|DRUG|Gallium Dotatate|Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
41298102|NCT05005208|OTHER|rehabilitation program with the support of the technological platform SI-ROBOTICS|"A 16-treatment session will be conducted, divided into 2 training sessions per week, for 8 weeks. The therapy sessions last 60 minutes; each session will involve 2 patients at time. Cardiac and respiratory activity monitoring is planned during robotic treatments in order to detect the heart rate during physical activity. Individual participants must complete at least 80% of the sessions. Recovery of 2 sessions will be possible.~Each session involves the following activities:~* Breathing, relaxation and postural harmonization exercises;~* Active mobility and stretching exercises;~* Irish dance with the SI-ROBOTICS system;~* Relaxation exercises."
41298103|NCT01348282|DRUG|Lithium|lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
41298104|NCT01348282|DRUG|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
41298105|NCT03415724|PROCEDURE|Inferior alveolar nerve block|Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars
41298106|NCT02003651|DIETARY_SUPPLEMENT|Quick Defense|Echinacea product from Gaia Herbs.
41298107|NCT02003651|DIETARY_SUPPLEMENT|Placebo|Placebo
41298108|NCT03283163|BEHAVIORAL|Exercise Testing and Training|The study group will perform a baseline maximum load exercise test which will inform the individualized exercise prescription for the participant. Based on a progressive methodology, the participant will engage in 12 weeks of exercise of their choice (walking, running, cycling or swimming) with the goal of working towards a maximum heart rate range of 80% between weeks 6 and 12 of the study.
41298109|NCT02991820|DEVICE|Miller|Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope
41298110|NCT02991820|DEVICE|Macintosh|Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope
41298111|NCT02991820|DEVICE|C-MAC|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the C-MAC video laryngoscope
41298112|NCT02991820|DEVICE|GlideScope|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the GlideScope video laryngoscope
41298113|NCT04562064|DEVICE|corneal tomography scans|corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system
41298114|NCT01390701|DEVICE|transcutaneous electrical nerve stimulation|30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
41298115|NCT01390701|DRUG|felodipin|2,5mg of felodipin once daily. Duration: 28+-4 days.
41298116|NCT04841135|OTHER|Multiomics quantification|One time blood, stool and urine samples will be taken.
41298117|NCT04841135|OTHER|Polysomnography|Facultative polysomnography
41298118|NCT05573165|OTHER|3 hours of preoperative fasting for breast milk|3 hours of preoperative fasting for breast milk
41298119|NCT05573165|OTHER|4 hours of preoperative fasting for breast milk|4 hours of preoperative fasting for breast milk
41298120|NCT02952547|DRUG|Co-administration of DWC20155 and DWC20156|
41298121|NCT02952547|DRUG|DWJ1366 Tab.|
41298122|NCT03626753|DRUG|Nefopam 20 MG/ML|given by Oral route the dose of 20mg every 6 hours.
41298123|NCT03626753|DRUG|"Nefopam (Acupan) 20 MG/ML Injectable Solution"|given by intravenous route at the dose of 20mg every 6 hours.
41458669|NCT04163094|DRUG|W_ova1 Vaccine|Patients will be treated with a W_ova1 vaccine that includes 3 OC TAA RNA-LPX products.
40769370|NCT05713266|DEVICE|MouthLabTM|Aidar Health's MouthLab device is a non-invasive, hand-held, home monitoring tool that measures multiple clinically meaningful parameters such as temperature, blood pressure, heart rate, heart rate variability, pulse rate, SpO2, single-lead ECG, respiratory rate, breathing pattern, and basic lung functions in 60 seconds.
40972286|NCT04285879|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device following the Owens Recovery Science Protocol
41298124|NCT03626753|DRUG|"Acetaminophen, (paracetamol) 500Mg Tab"|"2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours."
41298125|NCT03626753|DRUG|"(Acetaminophen paracetamol) IV Soln 10 MG/ML"|Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
41298126|NCT03626753|DRUG|"(Piroxicam piroxan) 20 MG Oral Tablet"|"2 tablets of piroxicam (piroxan) administrated orally once per 24 hours."
41298127|NCT03626753|DRUG|"(Piroxicam piroxan) 20Mg/1mL Injection"|"2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours."
41298128|NCT01327339|DRUG|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
41298129|NCT01394029|DRUG|deferasirox|
41298130|NCT01920620|BEHAVIORAL|Inpatient weight loss counseling|Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
41298131|NCT01920620|BEHAVIORAL|Motivational interviewing and troubleshooting via phone|All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
41298132|NCT01954121|DRUG|Levetiracetam|"Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~* Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~* Down-titration Period (Week 30 up to Week 33)"
41298133|NCT01954121|DRUG|Carbamazepine|"Immediate release tablets at a strength of 200 mg.~* Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~* Down-titration Period (Week 30 up to Week 33)"
41298134|NCT05399706|DIAGNOSTIC_TEST|CTA Aorta|Computed Tomography Angiography - Aorta Whole
41298135|NCT03987412|BEHAVIORAL|Lifestyle intervention with APP|The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
41298136|NCT03974646|BEHAVIORAL|Nurse-led self-management Program|Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20-30 minutes each at week three, week five and week seven.
41298137|NCT03520023|OTHER|Palliative Care Consult|Consult of hospital palliative care service for those meeting study inclusion criteria
40972287|NCT03688165|DEVICE|Treadmill-based Robotic Gait Training|All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
40972288|NCT05090137|OTHER|Diuretics|As per group descriptions
40972289|NCT00808366|DRUG|Keratolytic/Antifungal|Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
41298138|NCT03026543|PROCEDURE|Pulmonary Recruitment Maneuver|
41298139|NCT03026543|PROCEDURE|Laparoscopic cholecystectomy|
41298140|NCT03026543|DEVICE|Ventilator|
41298141|NCT03241797|PROCEDURE|EUS-FNA|Once the lesion was evaluated by EUS, the echoendoscopist would select the shortest pathway, while avoiding blood vessels, to reach the lesion. Under real-time visualization, slow-pull technique and suction technique were used to punctured each lesions. The specimens were expelled onto glass slides, and then prepared for histological and cytological examinations.
41298142|NCT06109116|OTHER|Self myofascial release+ Conventional PT|The participant will be asked to sit on a chair and feet resting on the ground. A tennis ball is used on the sole of each foot behind the metatarsal heads to the heel Conventional PT including Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise concentrating on the medial arch for 2 minutes in sitting position,with as much pressure as they could, pushing into discomfort but not pain Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 35 mins Type: Self myofascial release to improve hamstring flexibility
41298143|NCT06109116|OTHER|Conventional PT|"Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise .~Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins"
41298144|NCT02473133|RADIATION|Personalized dose redistribution|Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy. An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.
41298145|NCT02473133|RADIATION|No personalized dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
41298146|NCT03732872|DIAGNOSTIC_TEST|Biopsy tissue analysis|biopsy samples for IHC staining and PCR
41298147|NCT03732872|DIAGNOSTIC_TEST|Saliva analysis|Saliva samples for miRNA 21 expression analysis
41298148|NCT05567068|DRUG|Atorvastatin 80mg|Atrovastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement and immunomodulation independent of its basic lipid-lowering properties
41298149|NCT05567068|DRUG|Mesalamine|Mesalamine
41298150|NCT06041672|BEHAVIORAL|Warm Water Hand Baths|"1. Patients in the experimental group receive warm water hand baths as an intervention on the evening before surgery.~2. The intervention is carried out in the patient's room, room temperature was adjusted to 26°C and the timing is determined based on the patient's preference.~3. The study utilizes a foldable water bucket with temperature maintenance capability.Patients in the experimental group have their hand immersed in warm water (40°C) for ten minutes in a comfortable lying position."
41298151|NCT00757562|DRUG|desloratadine|desloratadine syrup: 1.25 mg (2.5 mL) for subjects \>=2 to \<6 years, 2.5 mg (5 mL) for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
41298152|NCT00757562|DRUG|Placebo|placebo syrup: 2.5 mL for subjects \>=2 to \<6 years, 5 mL for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
40769371|NCT04977349|OTHER|Manual Therapy|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
40769372|NCT04977349|OTHER|Exercise program|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
41298153|NCT03550716|PROCEDURE|mTESE|mTESE is performed according to the initial description by Schlegel (4). General anesthesia is used. Midline incision of the scrotum is made and carried down to the level of the tunica vaginalis, which is opened to deliver the testis. Equatorial incision is made and the testis bivalved. The operating microscope is used to identify plump-appearing seminiferous tubules, and biopsies are taken from these areas. These samples are examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24G angiocatheter. The procedure is stopped if spermatozoa are found. If no plump tubules are found, random biopsies targeting every area of the testis are taken. If necessary the procedure is carried out on the contralateral testis. Hemostasis is obtained with careful bipolar cautery, and the tunica albuginea and the tunica vaginalis are closed with a running 4-0 Vicryl. Standard scrotal closure is performed and gentle pressure dressing is applied.
40972290|NCT00808366|DRUG|Keratolytic/Antifungal|Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
40972291|NCT04271137|COMBINATION_PRODUCT|3D printed PEEK onlay|3d computer-designed Orbital onlay
40972292|NCT04271137|COMBINATION_PRODUCT|Pre-bent orbital mesh|Pre-bent orbital mesh on 3d printed template
40972293|NCT06204744|OTHER|Home-based GRASP program|The home-based Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve the upper extremity function for people with stroke, including exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
40972294|NCT06204744|OTHER|Conventional occupational therapy home program|The conventional OT home program will be prescribed by the occupational therapists, customizing stroke rehabilitation exercises to individual patient goals, with a primary focus on improving upper extremity function.
40972295|NCT02287272|DRUG|CHF 5993 pMDI|4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
40972296|NCT02287272|DRUG|Cimetidine plus CHF5993 pMDI|Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
40972297|NCT04231864|BIOLOGICAL|Durvalumab|Given intravenously (IV)
41458670|NCT02417571|DEVICE|Ambulatory blood pressure monitoring (ABPM)|24-hour ambulatory BP monitoring using TM-2430 device (A\&D Company, Tokyo, Japan)
40972298|NCT04231864|DRUG|Epacadostat|Given orally (PO)
41458671|NCT04879927|OTHER|Resource Matching|Resource staff involved in the customized resource matching arm of the intervention will include staff from DFCI Patient Services and DFCI Financial Counseling. Financial counseling will support patients with financial resource needs. DFCI Patient Services will provide assistance for all other patient Social Determinants of Health needs.
41458672|NCT04879927|OTHER|Usual Care|Patients randomized to the control group will receive a pre-existing pamphlet detailing DFCI resources.
40769373|NCT06624345|PROCEDURE|Inspiratory muscle training|Patients in the IMT group received the intervention using a threshold loading device set at a pressure range of 5-39 cmH₂O. They were instructed to perform six sets of five breaths, totaling 30 breaths, twice daily for six weeks. Additionally, the aerobic exercise regimen included upper limb exercises (raising arms without resistance), a lower limb stepping warm-up, and a walking routine consisting of 5 minutes of slow walking, 2 minutes of brisk walking, and another 5 minutes of slow walking, for a total of 30 minutes per day.
41298154|NCT03550716|PROCEDURE|TESA|In general anesthesia an 18 gauge needle is introduced into each testis, and negative pressure applied with a 10 ml syringe. Multiple passes throughout the entire testis, numbering 50-100 passes, are made through a single percutaneous/tunical entry and continued until tissue is visible in the hub of the needle. This is removed by brisk extraction of the needle and pressure held to tamponade bleeding. The aspirated tissue is examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24 gauge angiocatheter.
40972299|NCT06471452|DEVICE|Interaktor|"In the app (Interaktor), the patients will report frequency and distress on common symptoms and concerns.~Free text comments will also be possible to make to cover the patients' other potential needs. Information about the concerns will be included in the app containing; a) general information about why they have the side effects and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents, web pages or YouTube videos.~Supportive Care delivered from a study-specific nurse. During the health dialogues with a nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and needs and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patient's journal."
40972300|NCT03421028|DEVICE|Electromyography Biofeedback|EMG-Biofeedback- assisted training is a method in which electrodes situated on the surface of the skin detect small voltage changes which arise from the working muscles (in this case masseter and temporalis muscles). The voltage is transformed into a visual or sound time-variable signal which gives the patient feedback as he willingly tries to change the muscle tension (in this case to lower the excessive masseter tension)
40972301|NCT03421028|OTHER|Classic treatment for myogenous TMD|Combination of physiotherapy (manual therapy), stabilization occlusal splint usage and counseling
40972302|NCT04931745|DEVICE|Virtual reality|VR headset will be used 5-10 minutes prior to and during port access
40972303|NCT04931745|DEVICE|Tables distraction|Tablet distraction will be used 5-10 minutes prior to and during port access
40972304|NCT04931745|OTHER|No or non-technologic distraction|This approach will be used 5-10 minutes prior to and during port access
41298155|NCT00102453|DRUG|Pentoxifylline|Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
41298156|NCT03527615|OTHER|Clinical Pharmacist Medication Review|Programmatic review of physician orders for direct anticoagulants by clinical pharmacists.
41458673|NCT03806491|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Study therapists will follow the 2014 CBT-I in Veterans manual developed by leading researchers in the behavioral sleep medicine field. Intervention components include (1) sleep hygiene: limiting naps; avoiding caffeine, tobacco, alcohol, and rich/heavy foods before bedtime; exercising; establishing a bedtime routine; and creating a comfortable sleep environment; (2) sleep restriction: limiting time in bed in order to improve sleep efficiency, or the percentage of time in bed that is actually spent sleeping; time in bed will be titrated each week based on sleep efficiency; (3) stimulus control: strengthening association between bedroom and sleep to decrease conditioned arousal; (4) relaxation: diaphragmatic breathing, progressive muscle relaxation, and visual imagery to reduce arousal; and (5) cognitive therapy: identifying and challenging thoughts that interfere with sleep.
41458674|NCT03806491|BEHAVIORAL|Sleep Hygiene|Study therapists will review a one-page handout on sleep hygiene with all participants. This is the only intervention that participants assigned to the sleep hygiene condition will receive. This is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
40769374|NCT06624345|PROCEDURE|Control Group|Subjects received routine care.
40972305|NCT01925053|OTHER|PAL meal|The effect of consuming the PAL meal on gastric retention will be assessed
40972306|NCT01925053|OTHER|REF meal|The effect of consuming the REF meal on gastric retention will be assessed
40972307|NCT01970449|BIOLOGICAL|DNA Nat-B env vaccine|The DNA Nat-B env vaccine will be administered as a 4-mg dose injection intramuscularly (IM) by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
41298157|NCT05868642|PROCEDURE|subarachnoid block|subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty
40972308|NCT01970449|BIOLOGICAL|NYVAC Nat-B env vaccine|NVYAC Nat-B env vaccine will be administered as a 3 × 10\^7 plaque forming units (pfu) dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
41458675|NCT03806491|BEHAVIORAL|Alcohol Use Disorder Treatment as Usual|CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.
41458676|NCT03062176|DRUG|Anakinra|Anakinra (Kineret)
41458677|NCT00351117|DRUG|St. John's Wort|SJW in capsule form 300 mg PO TID
41458678|NCT00351117|DRUG|Lactose|lactose in gelatin capsule that same as St. John's wort
41458679|NCT04498676|OTHER|CB-0002B|CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
41458680|NCT01572623|DRUG|Clopidogrel|Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
41458681|NCT01572623|DRUG|Atorvastatin|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
41458682|NCT05531136|OTHER|Foot strengthening training|a 12-weeks exercise program consisting of foot strengthening exercises prescribed for 5 daily sessions a week, of which 1 supervised, 20 minutes per session on top of the regular exercise therapy to prevent falling
41458683|NCT00690027|PROCEDURE|Emergency portacaval shunt|
41458684|NCT00690027|PROCEDURE|Emergency and long-term endoscopic sclerotherapy|
41458685|NCT06432140|GENETIC|VGN-R09b injection|Two levels of VGN-R09b will be injected into bilateral putamen in dose-escalating phase, and one dose level will be injected in dose confirming phase
40972309|NCT01970449|BIOLOGICAL|DNA CON-S env vaccine|The DNA CON-S env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
41298158|NCT05889130|OTHER|Resistant Exercise|"The exercises were planned to be performed in 3 sets, 10 repetitions in each set, with 3 minutes rest between sets. Before starting the main exercises, it was planned to do 1 set of the same exercises without weight as a warm-up and cool-down exercise.~Exercises were planned as lower extremity hip abduction, adduction, flexion and extension, straight leg raise, terminal knee extension, ankle flexion and bridge exercises. During the exercises, it was planned to be combined with breathing, paying attention to respiratory control."
41458686|NCT03475433|DEVICE|Actigraphy device|Both groups will receive an actigraphy device that will passively measure their movement data.
41458687|NCT05962164|BEHAVIORAL|Passive Heat Therapy|The intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
41458688|NCT05962164|BEHAVIORAL|Sham Immersion|The sham intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
41458689|NCT04244643|OTHER|data collection|"Data collected from patient records~* Demographic data: date of birth, sex, city of birth~* Contact lenses: laboratory, brand, model, wearing time before the exam, opening date of the blister, solution of contact lenses, material, renewal time~* Refraction~* Dry eye disease: Ocular Surface Disease Index (OSDI) score~* LACRYDIAG data: Non-Invasive Break-Up Time (NIBUT), interferometry and tears meniscus height"
41458690|NCT03670719|OTHER|Manual Therapy and Exercise|Combination of physiotherapy (manual therapy) techniques and exercises for the cervical spine
41458691|NCT03670719|OTHER|Exercise|Exercises for the cervical spine
41458692|NCT06324305|PROCEDURE|Pars plana vitrectomy (PPV) and drainage of subretinal fluid|Drainage of subretinal fluid during Pars Plana Vitrectomy in patients with rhegmatogenous retinal detachment (RRD)
41298159|NCT04655495|DIETARY_SUPPLEMENT|Low FODMAPs /balanced gluten free diet|Dietary Supplement: Balanced low FODMAPs /gluten free diet
41298160|NCT03344731|BEHAVIORAL|Cognitive evaluation|Cognitive task
41298161|NCT03344731|DEVICE|Non-invasive brain stimulation|Transcranial Magnetic Stimulation (TMS)
41458693|NCT00175669|DRUG|Botox injections|Data not known.
41458694|NCT06075849|DRUG|PB101|"Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator."
41458695|NCT00997477|DRUG|Foradil Combi (Formoterol-budesonide)|
41458696|NCT01503658|DRUG|Clopidogrel+Aspirin|Clopidogrel 75 mg, Aspirin 100 mg
40769375|NCT06161493|DRUG|ZEN003694|A bromodomain extra-terminal inhibitor (BETi) that blocks a group of proteins called bromodomain and extra-terminal (BET), which may counteract the effect of NSD3 on tumor growth.
40769376|NCT06161493|DRUG|Niraparib|An anti-cancer medication (PARP inhibitor) used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer .
40972310|NCT01970449|BIOLOGICAL|NYVAC CON-S env vaccine|NVYAC CON-S env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
40972311|NCT01970449|BIOLOGICAL|DNA Mosaic env vaccine|The DNA Mosaic env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
40972312|NCT01970449|BIOLOGICAL|NYVAC Mosaic env vaccine|NVYAC Mosaic env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
41298162|NCT01810146|OTHER|Digestive functions investigations|
41298163|NCT03888300|OTHER|Physiotherapy|Chest Physiotherapy, physical exercises
41298164|NCT02137434|OTHER|Dietary calcium|Dietary calcium from skimmed milk
41458697|NCT01406639|DRUG|Ranibizumab|Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
41458698|NCT03995849|DIAGNOSTIC_TEST|Cone Beam CT Scan|In this study, children will receive one CBCT scan before starting RT as part of standard approach. Then after RT, another CBCT scan will be used to measure movement between the beginning and end of RT.
40972313|NCT01970449|BIOLOGICAL|Placebo|Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.
41298165|NCT02137434|DIETARY_SUPPLEMENT|Supplementary calcium|Supplementary calcium from calcium carbonate
41298166|NCT03978494|DRUG|Advagraf®|Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
41298167|NCT03978494|DRUG|Generic tacrolimus|Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)
41298168|NCT02645305|BIOLOGICAL|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
41298169|NCT00229372|BEHAVIORAL|Prolonged Exposure (PE) therapy|
41298170|NCT03570229|OTHER|Hyperbaric oxygen treatment|"Participants in this study will receive hyperbaric oxygen treatment (HBOT) but the investigators do not assign this specific intervention to the study participants. Thus, the patients in this study will receive HBOT as part of routine medical care. Consequently, we regard this as an observational study because the patients will get HBOT independently of the study and they are NOT assigned prospectively to HBOT according to a protocol to evaluate the effects.~HBOT for pelvic radiation injury typically involves a treatment pressure of 2.4 ATA (Atmospheres Absolute) breathing oxygen for 90 minutes. The treatment is delivered as series treatment, usually daily treatment up to 30 dives."
41298171|NCT01191294|OTHER|Simulation teaching session|Simulation-based, mastery learning educational intervention in visual screening for melanoma
41298172|NCT02456116|DEVICE|acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
41298173|NCT02456116|DEVICE|sham acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
41298174|NCT02456116|OTHER|PCA/NSAID|standard boli of morphine by pressing a button of PCA
41298175|NCT02946710|BIOLOGICAL|cerebrospinal fluid|Biological analysis on cerebrospinal fluid
41298176|NCT04000672|PROCEDURE|3D printed patient specific metal jigs (PSI jig)|PSI jig is created based on the pre-operative CT image. Standard medial open wedge osteotomy described previously is performed. Incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Then the PSI jig is positioned onto the tibia. Due to the jig patient specific design (individually based on each patient's CT image), it can fit closely to the proximal tibia. The slot opening on the PSI jig corresponds to 4 cm below the medial joint line and the slot design allow the sawblade cut direction toward the safe zone of the lateral cortex under fluoroscopy. The PSI Jig is removed after the bone cut completed and would not retain in patient's body.
41298177|NCT04000672|PROCEDURE|HTO with navigation|In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
41298178|NCT03988777|DEVICE|Preoperative localisation technique|Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
41298179|NCT02142192|DRUG|natalizumab|Administered as specified in the treatment arm
41298180|NCT04624893|DRUG|Polatuzumab Vedotin-Piiq|Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
41298181|NCT01401426|PROCEDURE|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
41298182|NCT01401426|PROCEDURE|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy
41298183|NCT00858702|DRUG|olmesartan medoxomil and a CCB|olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks
41458699|NCT02896296|DRUG|RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
41458700|NCT05469958|OTHER|Hypothermia prevention bundle|pre-warming of the patient for 10 minutes with forced air blankets before the surgery starts, which will be maintained during surgery and during the immediate postoperative period, the intravenous perfusions will be warmed up to 38 Celsius degree (ºC) and the environmental temperature will be controlled at 21 Celsius degree (ºC) during surgery
41298184|NCT00858702|DRUG|olmesartan medoxomil and a diuretic|olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks
41298185|NCT06554223|BEHAVIORAL|SUSTAIN-DSD|"Participants randomized to SUSTAIN-DSD will be enrolled into an Adherence Club and will have 6 months of ART dispensed through a pre-packed dispensing service. Participants may choose to use the decentralized pick-up point solely for medication retrieval or may opt into the peer-support aspect of the Clubs by attending the group session of up to 30 PWH, who will meet once every 6 months in a safe space (e.g., clinic meeting room, church, or local library).~At 6 months, 12 months, and every 12 months thereafter, a visiting nurse will draw a blood specimen for viral load. Optional process uptake will be recorded. Participants with a raised viral load will be called and offered enhanced adherence counselling; then recalled for a repeat viral load in 3 months."
41458701|NCT05469958|OTHER|Conventional care|the patient will be attended with textile blankets on patient demand
41458702|NCT05491850|OTHER|Moderate Physical Activity for Peripheral Diabetic Neuropathy|Moderate physical activity can increase movement and heart rate are particularly important for people suffering with peripheral neuropathy. Physical activity can improve blood circulation, which strengthens nerve tissues by increasing the flow of oxygen.
41298186|NCT06554223|OTHER|Enhanced (guideline-driven) Standard of Care (E-SoC)|"As per current SA ART guidelines, all patients who are \>28 days late for a scheduled visit are offered enhanced adherence counselling (EAC) at reengagement and restarted on ART. Patients who are \>90 days late also have blood drawn for a CD4 count to test for advanced HIV disease. Individual clinic visits occur every 3 months, with 3-month ART dispensing. VL testing is repeated 3 months after restart, then at 12 months and annually there-after, if suppressed.~These visits will be managed by clinic staff (nurse or doctor). EAC is a single counselling session delivered by a lay counsellor.~The study team will ensure all SoC processes are complete as per the guidelines; and reported to the COCT team as appropriate."
41298187|NCT00001262|DRUG|Copper Histidine|
41298188|NCT02025738|DEVICE|MAGNET APPLICATION|
41298189|NCT02025738|DEVICE|REPROGRAMING|
41298190|NCT02025738|DEVICE|NO ACTION|
41298191|NCT06097936|DIAGNOSTIC_TEST|HPV-ASSOCIATED OROPHARYNGEAL CANCER|The study involves the coexistence of a retrospective part, in which a group of patients with HPV-associated OPC for whom follow-up data of at least 2 years after diagnosis are available, designed in order to evaluate the expression of HPV16-specific E5 transcript as well as that of pEGFR and HLA, and a multicenter prospective part, involving the enrollment of a control group, enrolled at the ENT outpatient clinic of the IRE and the outpatient clinics of the relevant LILT provincial committees, to better elucidate the role of HPV16-E5 in identifying potentially transforming infections due to the presence of HPV.
41458703|NCT01911429|DRUG|Lurasidone 40 mg|Lurasidone 40 mg once daily
40769377|NCT06431581|BEHAVIORAL|m-Health intervention (educational video, SMS and reminder phone call)|Pregnant women meeting the inclusion criteria and assigned to the intervention group will receive m-health intervention that includes a tailored educational video regarding perinatal care targeting positive birth outcomes and infant health, SMS messages, and reminder phone calls for follow-up
41298192|NCT01830452|PROCEDURE|Self-fixating Parietex Progrip Mesh|Lichtenstein hernioplasty using a self fixating Parietex Progrip mesh not needing any fixating devices
41298193|NCT03318640|BEHAVIORAL|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
41298194|NCT02154269|DRUG|Treatment with G-CSF (Granulocyte colony stimulating factor)|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
41298195|NCT02154269|DRUG|Placebo saline|Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
41298196|NCT01353833|DRUG|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
41298197|NCT02060201|DRUG|Saxagliptin|
41298198|NCT02060201|DRUG|Dapagliflozin|
41298199|NCT02060201|DRUG|Saxagliptin/Dapagliflozin FDC|
41458704|NCT01911429|DRUG|Lurasidone 80 mg|Lurasidone 80 mg once daily
41458705|NCT01911429|DRUG|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
41458706|NCT03530241|DIAGNOSTIC_TEST|Presence of bile duct stones|MRCP verified gall stones in the bile ducts
41458707|NCT03530241|DIAGNOSTIC_TEST|Non-presence of bile duct stones|MRCP without bile duct stones
41458708|NCT02305134|DRUG|Tipepidine Hibenzate|
41458709|NCT02305134|DRUG|Placebo|
41458710|NCT01754935|DRUG|VX-509|50 mg oral tablet
41458711|NCT01754935|DRUG|VX-509 matching placebo|0 mg oral tablet
41458712|NCT03483350|DRUG|Granisetron|Ampoule
41458713|NCT03483350|DRUG|Midazolam|Ampoule
40972314|NCT01970449|DEVICE|Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)|All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
40972315|NCT00000350|PROCEDURE|radioactive substance|
40972316|NCT03410550|DEVICE|Exoskeleton Training|Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).
40972317|NCT04232124|BEHAVIORAL|Hypertension Management Model|"1. Blood Pressure readings by barbers~2. Clinical Pharmacist evaluation and counseling~3. Blood pressure measurement~4. Point of care basic metabolic panel measurement"
41139335|NCT01729767|DRUG|Placebo|Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
41139336|NCT04009109|DRUG|Lenalidomide|Induction and Maintenance
41139337|NCT04009109|DRUG|Ixazomib|Induction and Only Maintenance Arm B
41298200|NCT03229759|DRUG|Octenidine Dihydrocloride in aqueous solution|application of investigational product
41458714|NCT00135187|DRUG|VELCADE|"VELCADE will be used biweekly at 1.3 mg/m2 during week 1 and 2 on (days~1, 4, 8, and 11) followed by a 1-week break."
41298201|NCT03229759|OTHER|Vehicle Control|application of vehicle control
41458715|NCT00135187|DRUG|Doxil|Doxil will be administered at 30 mg/m2 IV on day 4
40769378|NCT00693511|BEHAVIORAL|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
41298202|NCT03229759|OTHER|Saline Control|application of placebo
40769379|NCT00693511|BEHAVIORAL|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
40769380|NCT06592079|PROCEDURE|Immediate implant and connective tissue graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
40972318|NCT01754610|BEHAVIORAL|Strengthening Family Coping Resources (SFCR)|"Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.~Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based."
40972319|NCT01803919|DEVICE|Silver Alloy-Coated Urinary Catheters|
40972320|NCT01803919|DEVICE|Conventional Urinary Catheter|
40972321|NCT02332850|BIOLOGICAL|Isatuximab|Given IV
40972322|NCT02332850|DRUG|Carfilzomib|Given IV
40972323|NCT02332850|DRUG|Dexamethasone|Given IV or PO
40972324|NCT02239978|BEHAVIORAL|Postural perturbation|Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.
40972325|NCT01548521|DRUG|Oxytocin|2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
40972326|NCT03008681|DEVICE|Andresen functional removable orthodontic appliance|Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
40972327|NCT01995032|DRUG|750 mg metformin and 7.5 g L-citrulline daily p.o.|
40972328|NCT01995032|DRUG|Placebo|
40972329|NCT01877070|BEHAVIORAL|assessments|
40972330|NCT05858710|DRUG|DPPG2-TSL-DOX|DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.
40972331|NCT00395369|DRUG|intraoperative aprotinin administration|
40972332|NCT05022108|BIOLOGICAL|Alpha bisabolol gel|Using alpha bisabolol gel with a concentration of 0.5%, 2,5% or 5% to treat sensitized area with histamine.
40972333|NCT02015871|DRUG|Degarelix|
40972334|NCT00600483|DRUG|gentamicin-collagen sponge dipped in saline|100-cm2 sponge
41139338|NCT04009109|DRUG|Daratumumab Injection|Induction and Only Maintenance Arm B
41298203|NCT00398710|DRUG|Perifosine|150 mg daily (100 mg daily in case of dose reduction)
41298204|NCT00003771|BIOLOGICAL|therapeutic estradiol|
41298205|NCT00003771|DRUG|norethindrone acetate|
41298206|NCT02538666|BIOLOGICAL|Nivolumab|
41298207|NCT02538666|BIOLOGICAL|Ipilimumab|
41298208|NCT02538666|OTHER|Placebo|
41458716|NCT00135187|DRUG|Dexamethasone|Dexamethasone at 40 mg during the first cycle and 20 mg during cycles 2-6 po or IV daily on days of VELCADE and day after VELCADE (i.e. days 1, 2, 4, 5, 8, 9, 11, 12). The patient will be treated for six 3-week cycles followed by three 5-week maintenance cycles.
41458717|NCT02769741|OTHER|Cashews followed by Control|Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.
41458718|NCT02769741|OTHER|Control followed by Cashews|Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.
40972337|NCT01244425|DRUG|Fibrin Sealant (FS) VH S/D 500 s-apr|Dosage form: spray application; dosage frequency: single application
40972338|NCT01244425|OTHER|Manual compression|Dosage form: surgical gauze swab; dosage frequency: single application
40972339|NCT03647982|DRUG|Meditoxin|injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
40972340|NCT03647982|DRUG|Botox|injection of Botox into the intradermal of each contralateral upper back in equal doses
40972341|NCT03729505|PROCEDURE|Pyloric injection of magnesium sulfate and lidocaine mixture|100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus
40972342|NCT03729505|PROCEDURE|Pyloric injection of saline|5 ml of normal saline is injected in the pylorus
40972343|NCT03535844|OTHER|Wolfberry|Consumption of cooked dehydrated wolfberry as part of a mixed meal.
40972344|NCT03535844|OTHER|Healthy diet|Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.
40972345|NCT03731611|PROCEDURE|Umbilical Cord Milking|Umbilical cord milking (UCM) is typically performed by placing the infant below the level of the placenta. The cord is held at 20-25 cm distance from the baby and milked vigorously towards the umbilicus for 3 times at a speed of 10 cm/sec. After completion, the cord is clamped, and the neonate is handed to the resuscitation team.
40972346|NCT01622790|DRUG|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
41298209|NCT06499753|OTHER|high molecular weight HA-based artificial tears|use of high molecular weight HA-based artificial tears three times per day
41466522|NCT04573296|BEHAVIORAL|Conventional high-intensity lifestyle intervention program|A 6-month high-intensity lifestyle intervention program consisting of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator.
41466523|NCT01280227|BEHAVIORAL|SiSom|SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
40972347|NCT01622790|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
40972348|NCT01622790|DRUG|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
40972349|NCT00672412|DRUG|GPO-Vir Z30 tablet|Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
41466524|NCT03945799|DRUG|Anlotinib Hydrochloride|Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.
40972350|NCT00672412|DRUG|Lamivudine|Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
40972351|NCT00672412|DRUG|Nevirapine|Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
40972352|NCT00672412|DRUG|Zidovudine|Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
40972353|NCT02915198|DRUG|Metformin XR|The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.
40972354|NCT02915198|DRUG|Placebo|"For patients \< 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR \< 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo"
40972355|NCT03938168|DIAGNOSTIC_TEST|Biopsy, fecal sample|Preoperatively and at 12 months after surgery, patients will obtain a fecal stool sample for microbioma analysis. Adhesions that are cut and released to acquire access to the operative field are stored for molecular and histological analyses.
41139339|NCT04009109|DRUG|Dexamethasone|Induction and Only Maintenance Arm B
41139340|NCT00346398|BIOLOGICAL|Oral mucosal immunoprophylaxis (OMIP)|OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
41139341|NCT00346398|BIOLOGICAL|Placebo|The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
40972356|NCT02992106|OTHER|Parental questionnaires|"We will provide parents with questionnaires depending on the age of their children:~* Children aged 0-6 years old:~  1. Questionnaire on socio-demographic characteristics~ 2. Dutch Eating Behaviour Questionnaire~ 3. Food Frequency Questionnaire~ 4. Ages and Stages Questionnaire~ 5. Strengths and Difficulties Questionnaire~ 6. Questionnaire on developmental milestones~ 7. Questionnaire on behaviour~* Children older than 6 years:~  1. Questionnaire on socio-demographic characteristics~ 2. Dutch Eating Behaviour Questionnaire~ 3. Food Frequency Questionnaire~ 4. Pediatric Quality of Life Questionnaire~ 5. Children's Behaviour Questionnaire in Dutch~ 6. Questionnaire on developmental milestones~ 7. Developmental Coordination Disorder Questionnaire~ 8. Strengths and Difficulties Questionnaire"
40972357|NCT02992106|OTHER|Blood sample|We will determine the following biochemical parameters: glucose, insulin, total cholesterol, LDL, HDL, triglycerides, uric acid, IGF-1, adiponectin, leptin, hs-CRP, IL-6, TNF-α and ICAM-1.
41458719|NCT05756465|DEVICE|Smartphone-based virtual reality relaxation (SVR)|SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) that is attached to the head of a cancer patient undergoing chemotherapy, displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical instruments. SVR device is paired with smartphone using operating system either Android (minimum generation 11, Android 4.4 KitKat) or OS version 12, minimum screen size of 5.5-inch and maximum of 6.0-inch, screen resolution of at least 1080 x 1920 pixels, can connect to WIFI/ internet and provides a YouTube app to access 360-degree videos. SVR content uses original 360o videos produced by researchers using a video editor software for ± 10 minutes duration.
41458720|NCT06002386|DEVICE|Vsling|Implantable ventricular repair device
40769381|NCT06592079|PROCEDURE|Immediate implant with connective tissue graft and bone graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Xenograft will placed to fill the jumping gap.Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
40769382|NCT06295354|OTHER|No intervention, we just study 'aging'|No intervention, we just study 'aging'
40769383|NCT05199753|DRUG|LM-108|Administered intravenously
40769384|NCT05199753|DRUG|An Anti-PD-1 Antibody|Administered intravenously
40769385|NCT02170519|DRUG|Inhaled Iloprost|A 20 mcg dose of Iloprost will be given initially.
40769386|NCT03162627|DRUG|Selumetinib|"Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
40769387|NCT03162627|DRUG|Olaparib|"Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
40972358|NCT02992106|OTHER|Urine sample|We will take a urine sample to evaluate the albumin to creatinin ratio.
40972359|NCT02992106|OTHER|Anthropometric measurements|We will measure weight, Height, hip, waist and neck circumference, blood pressure, 4-site skinfold measurements and BIA.
40972360|NCT02992106|OTHER|Ultrasound|We will do an abdominal ultrasound to measure the abdominal fat accumulation
40972361|NCT02992106|OTHER|EndoPAT|We will use the EndoPAT device to measure endothelial function, which is a non-invasive and innovative technique (peripheral pulse wave amplitude measurement).
40990807|NCT04241497|BEHAVIORAL|Home-based rehabilitation|1 supervised exercise session at the hospital; 3 weeks of supervised home-based exercise training (3x/week); 9 weeks of unsupervised home-based exercise training (3x/week)
41458721|NCT03789630|DEVICE|Continuous physiology monitoring in ambulatory setting pre and post surgery|This study will recruit 55 patients aged 21 to 80 years who will be undergoing total knee replacement surgery. All study participants undergoing total knee replacement surgery will be monitored using the wearable biosensor to continuously monitor physiology biomarkers. Participants will be followed for an estimated total of 39 days, beginning four days before surgery, the entire period during in-patient recovery (four to five days), and 30-days post-discharge at-home.
40972362|NCT02992106|OTHER|Faces Pain Scale|After performing the measurements with the EndoPAT device, Harpender kalliper and ultrasound, the children will be asked to fill out a Faces Pain Scale, validated for children aged 4-16 years old and obtained for use from the International Association for the Study of Pain
40972363|NCT01512277|BIOLOGICAL|rSh28GST|subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
40972364|NCT02253251|GENETIC|KRAS-variant and microRNA binding site mutation testing|Participant in these studies will be tested for the KRAS-variant
40972365|NCT02876354|DRUG|Menaquinone|Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
40972366|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
40972367|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Zagreb post-exposure immunization schedule at day 0,7,21.
40972368|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
41298210|NCT01740622|OTHER|Injury Prevention Measures|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
41298211|NCT05823909|DEVICE|fabian Therapy evolution ventilators with PRICO (Predictive Intelligent Control of Oxygenation)|12 hours Automated PRICO FiO2 control
41298212|NCT05823909|DEVICE|fabian Therapy evolution ventilators with manual FiO2 control|12 hours Manual PRICO FiO2 control
41458722|NCT04763031|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
40769388|NCT06642415|PROCEDURE|Surgery under loupes|surgery performed under loupes
40972369|NCT00254449|DRUG|NGX-4010|
40972370|NCT02071121|DRUG|BIIB061|BIIB061 capsules for oral administration
40972371|NCT02071121|DRUG|Placebo|BIIB061 matching placebo capsules
40972372|NCT02071121|DRUG|14C-BIIB061|Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
40972373|NCT03735225|DRUG|Dasiglucagon|Dasiglucagon injection
40972374|NCT03735225|DRUG|Placebo|Placebo for Dasiglucagon injection
40972375|NCT05950932|DIETARY_SUPPLEMENT|Melissa phytosome|Melissa phytosome® is composed of dry extract of Berberis aristata root (550mg/cpr), complexed with phospholipids (soy lecithin), Pisum sativa proteins, and proanthocyanidin oligomers from Vitis vinifera. 2 tablets of 200 mg Melissa phytosome will be provided to participants, to be taken 30 minutes before bedtime for 14 days.
40972376|NCT05950932|OTHER|Placebo|2 tablets with an equivalent form, color, flavor, and coating as the experimental product, to take 30 minutes before bedtime.
40972377|NCT00650260|DEVICE|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
40972378|NCT00650260|DEVICE|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
40972379|NCT03962920|DRUG|Tigecycline 50 MG|Local instillation of drug directly to the tumour tissue
40972380|NCT03962920|OTHER|Placebo|Local instillation of sterile water directly to the tumour tissue
40990808|NCT02229136|DRUG|Miracle Mouthwash Plus Hydrocortisone|Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
40990809|NCT02229136|DRUG|Prednisolone|Prednisolone oral solution 15 mg/5 ml
40990810|NCT03320564|DIAGNOSTIC_TEST|F-18 FDG PET|Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.
41298213|NCT05200949|PROCEDURE|Kidney transplant|Transplant surgery of Kidney
40769389|NCT06642415|PROCEDURE|surgery performed under microscope|surgery performed under microscope
41298214|NCT03291197|DRUG|Suprascapular and median nerve blocks|Ultrasound guided injection of the median and suprascapular nerve of the affected side.
41298215|NCT00724035|DRUG|Midazolam|"Procedural sedation before the execution of the block.~* 0.03 mg/kg iv bolus"
41298216|NCT00724035|DRUG|Ropivacaine|0.75% (wt/vol) solution, 20 ml perineural injection
41298217|NCT00724035|DRUG|Fentanyl|50 µg iv bolus prn for pain during surgery, up to 150 µg
41298218|NCT00724035|PROCEDURE|General anesthesia|General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
41298219|NCT00724035|PROCEDURE|Axillary brachial plexus nerve block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.~A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose."
41458723|NCT04238195|DRUG|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo|Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.
41458724|NCT04238195|DRUG|Moxifloxacin 400mg|Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.
41458725|NCT04238195|OTHER|Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment C: Subjects receive TBPM-PI-HBr matching placebo.
40769390|NCT06454916|DEVICE|Small Bowel Anastomosis with Flexagon SFM Device with OTOLoc|This study will investigate one type of intervention: small bowel anastomosis creation in subjects undergoing laparoscopic small bowel surgery. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically into two different sections of small bowel that are intended to be anastomosed. An OTOLoc device will be deployed into the small bowel wall in one section of the small bowel to provide access for the deployment of a Flexagon SFM into that section of bowel. The process is repeated at the second section of bowel. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two sections of bowel until the anastomosis is fully formed.
40769391|NCT04017208|DRUG|ASP2713|Administered intravenously
40972381|NCT02243332|DEVICE|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
40972382|NCT06076616|BEHAVIORAL|Prehabilitation and rehabilitation|A personalized lifestyle counseling programme.
40972383|NCT04022902|OTHER|No intervention|This is an exploratory qualitative study to understand the needs of patients with pneumoconiosis, and the care-giving experience of their family caregivers.
40972384|NCT05325554|BEHAVIORAL|Multimodal rehabilitation|Multimodal rehabilitation
40972385|NCT02323113|DRUG|TAK-659|TAK-659 tablets.
40972386|NCT03352622|OTHER|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness.
40972387|NCT03352622|OTHER|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
41298220|NCT00724035|PROCEDURE|Infraclavicular brachial plexus block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.~The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks."
40972388|NCT05283668|BIOLOGICAL|i-PRF|"* Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~* The treatment was depigmentation by laser thin injection by I-PRF Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
41298221|NCT00278265|DRUG|MTX followed by fludarabine|MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
41298222|NCT03660371|PROCEDURE|PPV/MP|Internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
41298223|NCT03660371|PROCEDURE|PPV without MP|No internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
41298224|NCT04743635|DEVICE|Avéli device|Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.
40769392|NCT04017208|DRUG|placebo|Administered intravenously
40769393|NCT06160167|DRUG|IMiD treatment|Participants with MM treated with IMiDs
40769394|NCT06160167|DRUG|No IMiD treatment|Participants with MM not treated with IMiDs
40769395|NCT06160167|DRUG|Systemic therapy|Participants with MM treated with systemic therapy
40769396|NCT05039840|DRUG|SAR441344 IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
40990811|NCT03307720|DRUG|Gonadotropin Releasing Hormone Agonists (GNRH-A)|Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
40990812|NCT03307720|DRUG|Human chorionic gonadotropin|Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
41458726|NCT04238195|DRUG|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment B: Subjects receive TBPM-PI-HBr.
40972389|NCT05283668|PROCEDURE|Diode Laser|"Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
40972390|NCT01979016|DRUG|Dupilumab|
40972391|NCT01979016|DRUG|Placebo|Matching placebo
40972392|NCT01979016|OTHER|Background treatment|Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).
40972393|NCT03675698|OTHER|Nasotracheal Intubation|side of nostril and size of endotracheal tube estimation for nasotracheal intubation will be done based on radiological imaging ( CT/MRI head)
40972394|NCT01656473|OTHER|MI and DBT|One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
40972395|NCT01656473|OTHER|MI and DBT|Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
40972396|NCT01118221|BEHAVIORAL|pulmonary rehabilitation|structured exercise program
40972397|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
40769397|NCT05039840|DRUG|SAR441344 SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
41139342|NCT00552591|BEHAVIORAL|12-week risk reduction program, managed by a Heart Health Educator|The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.
41139343|NCT01363128|DRUG|Cyclophosphamide|Given IV
41458727|NCT01813864|BEHAVIORAL|CASPAR/Treatment Planning|All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
41458728|NCT01354301|DRUG|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
41458729|NCT01354301|DRUG|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
41458730|NCT01354301|DRUG|Basiliximabe|days 0 and 4, according to the package insert instructions.
40972398|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
40972399|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
40972400|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
40972401|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
40972402|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
40972403|NCT04771442|DRUG|Stromal vascular fraction|Single dose
40972404|NCT02775721|OTHER|Nursing Education related to Gastrostomy Tube Care|The research nurse will provide educational intervention at each study visit utilizing the nursing process.
40972405|NCT02775721|OTHER|Speech Therapy Education and Evaluation|Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
40972406|NCT02775721|OTHER|Nutritional Therapy Education and Evaluation|Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
40972407|NCT02775721|OTHER|Quality of Life Questionnaire C30 version 3|30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
40972408|NCT02775721|OTHER|Quality of Life Questionnaire EORTC QLO - H&N35|35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
40972409|NCT05495516|GENETIC|without Intervention|without Intervention
41458731|NCT01354301|DRUG|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
41458732|NCT01354301|DRUG|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
41458733|NCT01354301|DRUG|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
40769398|NCT05039840|DRUG|Placebo IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
41458734|NCT01354301|DRUG|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
41458735|NCT02966782|DRUG|venetoclax|Tablet
40972410|NCT02480023|RADIATION|calcaneal quantitative ultrasound assessment|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
40972411|NCT03454776|DEVICE|Unloader One brace|A knee brace used to unload affected compartments in osteoarthritic knees
40972412|NCT03454776|DEVICE|Placebo brace|A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
40972413|NCT01906008|DRUG|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
40972414|NCT01906008|DRUG|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
41298225|NCT02009137|DEVICE|EVERA|EVERA apply for 12 weeks
41298226|NCT02009137|DEVICE|ESTES|ESTES apply for 12 weeks
41298227|NCT06029816|DRUG|Neratinib tablets|Neratinib tablets
41298228|NCT05927246|DIAGNOSTIC_TEST|ECG|12 lead ecg for each participant
41298229|NCT01680224|BEHAVIORAL|Healthy Weight|
41298230|NCT01680224|BEHAVIORAL|Project Health|
41458736|NCT02966782|DRUG|azacitidine|Powder for injection, subcutaneously or intravenous
41458737|NCT04808908|BIOLOGICAL|N-803|N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)
41458738|NCT01608906|DRUG|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
40769399|NCT05039840|DRUG|Placebo SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
40972415|NCT01906008|BEHAVIORAL|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
40972416|NCT01906008|BEHAVIORAL|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
40972417|NCT02167893|DRUG|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
40972418|NCT00958152|DRUG|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
40972419|NCT00958152|DRUG|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
40972420|NCT00958152|DRUG|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
40972421|NCT00958152|DRUG|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
40972422|NCT01892293|DRUG|Treatment with NY-ESO-1c259-modified T cells|"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to \< 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
40972423|NCT04842266|DEVICE|IlluminOss pelvic implant for oncologic indication|Impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis
41139344|NCT01363128|DRUG|Cytarabine|Given IV
41139345|NCT01363128|DRUG|Dexamethasone|Given IV or PO
41139346|NCT01363128|DRUG|Doxorubicin Hydrochloride|Given IV
41139347|NCT01363128|OTHER|Laboratory Biomarker Analysis|Correlative studies
41139348|NCT01363128|DRUG|Methotrexate|Given IV
41139349|NCT01363128|BIOLOGICAL|Ofatumumab|Given IV
41139350|NCT01363128|DRUG|Vincristine Sulfate|Given IV
40769400|NCT03814044|DEVICE|PEEK Suture Anchors|"Subjects who have undergone hip joint repair using PEEK Suture Anchors:~BIORAPTOR™ Knotless Suture Anchor and SpeedLock Hip Suture Anchor"
41139351|NCT01995292|DEVICE|bronchoscope|
41139352|NCT01995292|DEVICE|Enk Fiberoptic Atomizer|
41139353|NCT00418119|DRUG|erythropoietin|
41139354|NCT05495711|BIOLOGICAL|human umbilical cord mesenchymal stem cell complex collagen|1 \* 10\^7 cells (2ml)
41139355|NCT05495711|PROCEDURE|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
41139356|NCT00248898|PROCEDURE|Cardiac Surgery|Coronary artery bypass graft surgery, aortic valve replacement, mitral valve replacement, aortic aneurysm repair
41298231|NCT01680224|BEHAVIORAL|Placebo Control|Participants will view a video on overweight and obesity
41298232|NCT03458000|DEVICE|PillCam UGI|An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.
41298233|NCT03458000|OTHER|Standard of Care|Patient was admitted to hospital for care and received in-patient EGD.
41298234|NCT01943864|DRUG|Trametinib (single tablet)|The drug substance is blended with inert
41298235|NCT01943864|DRUG|Trametinib (Multiple tablet)|The drug substance is blended with inert
41298236|NCT01279135|RADIATION|Conventional Radiation|Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks
41298237|NCT01279135|RADIATION|Tomotherapy based IGRT|Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
41298238|NCT03627455|OTHER|Percutaneous coronary intervention|Percutaneous coronary intervention
41298239|NCT01678807|BIOLOGICAL|MK-8237 6 DU|
41298240|NCT01678807|BIOLOGICAL|MK-8237 12 DU|
41298241|NCT01678807|BIOLOGICAL|Placebo|
41298242|NCT03762525|RADIATION|ECG gated CTA|"Routine care consists of a preoperative and several postoperative CTA scans. In A. The preoperative and first postoperative CTA will be replaced by ECG-gated CTA imaging and in B. the scheduled imaging will be replaced by an ECG-gated CTA.~General information: The protocol is based on the ECG gated cardiac protocol using abdominal parameter settings."
41298243|NCT01624129|DRUG|Fluticasone|Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
40769401|NCT05430438|OTHER|dialysis with low dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
40769402|NCT05430438|OTHER|dialysis with standard dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
40769403|NCT06636877|DRUG|BR1019|One tablet administered alone
41139357|NCT01691404|DIETARY_SUPPLEMENT|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
41139358|NCT01691404|DIETARY_SUPPLEMENT|Quercetin|Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
41298244|NCT02654327|DEVICE|VV-ECCO2R to enable lower tidal volume mechanical ventilation|In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
41139359|NCT01691404|DIETARY_SUPPLEMENT|Placebo|Subjects will be asked to consume capsules containing placebo (cellulose) daily
41139360|NCT02699099|DIETARY_SUPPLEMENT|Vitamin A|Oral administration of Vitamin A (1 dose)
41298245|NCT02494349|DRUG|JLP-1207|The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
41298246|NCT02494349|DRUG|Solifenacin 5mg+Tamsulosin 0.2mg|The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
41298247|NCT03123939|BIOLOGICAL|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10\^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg)
41298248|NCT04941378|DRUG|OTL38|One time infusion of OTL38
41298249|NCT04941378|DEVICE|intraoperative imaging camera system|intraoperative imaging camera system
41298250|NCT00002572|BIOLOGICAL|aldesleukin|
41298251|NCT00002572|BIOLOGICAL|muromonab-CD3|
40972424|NCT04842266|DEVICE|IlluminOss pelvic implant for geriatric trauma indication|Pelvic fragility fracture in a geriatric patients (age 65 or older)
40769404|NCT06636877|DRUG|BR1019-2|One tablet administered alone
40769405|NCT06636877|DRUG|BR1019-3|One tablet administered alone
40972425|NCT06472063|OTHER|pre- or perioperative treatment and D2 gastrectomy|pre- or perioperative treatment and D2 gastrectomy
40972426|NCT01931852|PROCEDURE|Cardiac MRI|Participants in the CMR-guided care group will receive a cardiac MRI.
41139361|NCT02699099|BIOLOGICAL|Candidate Plasmodium falciparum malaria vaccine|Intramuscular administration of SB257049 vaccine (4 doses)
41139362|NCT02699099|BIOLOGICAL|MR-Vac|Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
41139363|NCT02699099|BIOLOGICAL|Stamaril|Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
41139364|NCT03110809|DIETARY_SUPPLEMENT|Capsinoid|Capsinoids are nunpungent analogs of capsaicin that activate BAT by stimulating sensory neurons in the gastrointestinal tract. Chronic ingestion of capsinoids may stimulate the development or recruitment of new BAT from precursor stem cells within white adipose tissue depots.
41298252|NCT00002572|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
41298253|NCT00002572|PROCEDURE|conventional surgery|
41298254|NCT02423824|BIOLOGICAL|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
41298255|NCT02232516|DRUG|romidepsin|Given IV
41298256|NCT02232516|DRUG|lenalidomide|Given PO
41298257|NCT02232516|OTHER|laboratory biomarker analysis|Correlative studies
41298258|NCT04656964|DRUG|remimazolam tosilate group|Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).
41298259|NCT04656964|DRUG|Midazolam group|Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).
41298260|NCT01809561|PROCEDURE|tissue biopsy during surgical treatment|The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
41298261|NCT03949049|DRUG|Citicoline|Citacoline as neuroprotector
41298262|NCT03949049|OTHER|Placebo|placebo group
41298263|NCT00484250|DRUG|metronidazole,doxycycline|
41298264|NCT00147628|DRUG|sildenafil citrate|
41298265|NCT00147628|DRUG|placebo for sildenafil citrate|
41298266|NCT01905397|DEVICE|Conventional wound therapy|Sterile bandages and wound coverings
41298267|NCT01905397|DEVICE|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
41466525|NCT00076531|DRUG|Leuprolide Acetate for Injectable Suspension 22.5 mg|
41298268|NCT01926041|DRUG|Varenicline for tobacco smoking cessation|The 16-week varenicline course conforms to real-practice government regulations in Taiwan.
40972427|NCT01931852|OTHER|ACC/AHA Guideline adherent care|Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
40972428|NCT03764501|DEVICE|Image fusion system|Image fusion system for the 3D preoperative planning
40972429|NCT04561193|OTHER|Observational|Observational
41298269|NCT01926041|BEHAVIORAL|Individualized counseling about both smoking cessation and weight control techniques|The FIT2 program also offers behavior coaching in diet and physical activity to restrict post-cessation weight gain, which is not covered in conventional smoking cessation services.
41298270|NCT03588767|DRUG|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
41298271|NCT03588767|OTHER|No Vitamin D3 + anabolic substance|Retrospectively analyzed group of patients, no Vitamin D3 + anabolic substance administration
41298272|NCT06024330|DIAGNOSTIC_TEST|VAN assessment|An investigator assesses the VAN scale when a patient arrives at ED triage with a suspected stroke.
41298273|NCT06024330|DIAGNOSTIC_TEST|VES assessment|An investigator assesses the VES scale when a patient arrives at ED triage with a suspected stroke.
41298274|NCT06024330|DIAGNOSTIC_TEST|LARIO assessment|An investigator assesses the LARIO scale when a patient arrives at ED triage with a suspected stroke.
41298275|NCT01031758|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
41298276|NCT00085540|DRUG|depsipeptide|Given IV
41298277|NCT04316572|BEHAVIORAL|mental health specialist video consultation|"The consultations will be based on a psychodynamic understanding with a solution-oriented stance and will follow a manual:~Session 1: Getting familiar with the telemental health setting, building a working alliance and deepening diagnostics.~Session 2: Clarification of the task/objective, focus building, motivational interviewing if necessary.~Session 3-4: Focused brief interventions e.g. psychoeducation, promotion of social resources, activation of health-promoting lifestyles (sleep hygiene, eating diary, relaxation etc.), work on personal problems and, if necessary, initiation of further specialised treatment.~Session 5: Ending the intervention, stabilisation, subsequent treatment plan and communicating a case summary to the general practitioner"
41298278|NCT05611684|DRUG|Polyethylene Glycol Losenatide|Treatment 0.2mg QW for 12 weeks
41298279|NCT01127425|PROCEDURE|laparoscopic colonic resection|Conventional surgery compared to laparoscopic sigmoid resection
41298280|NCT01127425|PROCEDURE|laparoscopic sigmoid resection|sigmoid resection by laparoscopic surgery
41298281|NCT04389606|OTHER|Study Formula (SF)|New infant formula for term infants fed ad lib
41298282|NCT04389606|OTHER|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
41298283|NCT06517953|DRUG|Icotinib|An orally first-generation EGFR inhibitior.
40972430|NCT02740777|BIOLOGICAL|HPV-16/18 vaccine|HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
41298284|NCT06517953|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
41298285|NCT03282123|DRUG|Midomafetamine|80 to 120 mg MDMA
41298286|NCT03282123|BEHAVIORAL|Therapy|Non-directive therapy conducted during MDMA-assisted therapy session
40972431|NCT02090244|DRUG|Teriparatide|Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
40972432|NCT03147014|BIOLOGICAL|Maternal hyperoxygenation|approximately 10-15 minutes of maternal hyperoxygenation
40972433|NCT02669732|DRUG|DS-8500a|tablets
40972434|NCT02669732|DRUG|placebo|tablets
40990813|NCT02788981|DRUG|Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
40990814|NCT02788981|OTHER|Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
41139365|NCT03110809|DIETARY_SUPPLEMENT|Placebo|Placebo for capsinoid. Capsule contains no active ingredients.
41298287|NCT00832754|DEVICE|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
41298288|NCT00832754|OTHER|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
41298289|NCT00835094|DEVICE|Mometasone furoate|MF-DPI 400 mcg once daily in the morning for 12 weeks
41298290|NCT00835094|DEVICE|Mometasone furoate|MF-DPI 400 mcg once daily in the evening for 12 weeks
41298291|NCT06390982|RADIATION|Radiotherapy|45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
40769406|NCT06637111|PROCEDURE|Ultrasound guided office hysteroscopy group|"One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem. The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia.~Transabdominal ultrasound will be used to guide the access of the hysteroscope to the uterine cavity"
40769407|NCT06637111|PROCEDURE|Conventional office hysteroscopy group|"One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem . The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia."
41298292|NCT06390982|DRUG|Tislelizumab|200 mg IV on Day 1 of each 21-day cycle.
41298293|NCT06390982|DRUG|Capecitabine|Capecitabine 1000 mg/m2 orally twice daily (bid) on Day 1 to 14 of each 21-day cycle in CAPOX regimen
41298294|NCT06390982|DRUG|Oxaliplatin|130 mg/m2 IV on Day 1 of each 21-day cycle in CAPOX regimen
41298295|NCT06390982|DRUG|Capecitabine|825 mg/m2 orally twice daily (bid) 5 days/week during radiotherapy.
41298296|NCT05663723|DEVICE|Intervention group with the IV and V LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
41298297|NCT05663723|DEVICE|Intervention group with the IV, V and Violet LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
41298298|NCT05663723|DEVICE|Control group with LED board without emitting light|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
41298299|NCT00003753|DRUG|dexamethasone|
41298300|NCT00003753|DRUG|floxuridine|
41298301|NCT00003753|DRUG|irinotecan hydrochloride|
41298302|NCT00003753|PROCEDURE|adjuvant therapy|
41298303|NCT00003753|PROCEDURE|conventional surgery|
41298304|NCT01095952|DEVICE|AVNS ON|Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
41298305|NCT03342612|PROCEDURE|Brain Magnetic Resonance Imaging (MRI)|
41298306|NCT03502707|BIOLOGICAL|Placebo|Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
41298307|NCT03502707|BIOLOGICAL|RSV preF Protein 50 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
41298308|NCT03502707|BIOLOGICAL|RSV preF Protein 150 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.
41298309|NCT03502707|BIOLOGICAL|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1\*10\^11 vp.
41298310|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
41458739|NCT01608906|DRUG|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
40972435|NCT05038423|BEHAVIORAL|5R Shared Leadership Program|"The manualised 5RS program aims to develop the leadership qualities of peer leaders by teaching them how to create, embody, advance, and embed a collective sense of 'us' in their teams. More specifically, 5RS consists of two key components that involve (1) implementing a structure of shared leadership, and (2) strengthening the identity leadership skills of the appointed peer leaders (Fransen et al., 2020).~Fransen, K., Haslam, S. A., Steffens, N. K., Mallett, C. J., Peters, K., Mertens, N., \& Boen, F. (2020). All for us and us for all: Introducing the 5R Shared Leadership Program. Psychology of Sport and Exercise, 51, 101762. https://doi.org/10.1016/j.psychsport.2020.101762 Haslam, S. A., Steffens, N. K., Peters, K., Boyce, R. A., Mallett, C. J., \& Fransen, K. (2017). A social identity approach to leadership development: The 5R program. Journal of Personnel Psychology, 16(3), 113-124. https://doi.org/10.1027/1866-5888/a000176"
41458740|NCT02791958|DRUG|Cardiovascular Fixed Dose Combination Pill AAR|A once daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) for 4 weeks.
40972436|NCT05038423|BEHAVIORAL|12-week structured walking program|Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
40972437|NCT04669782|DIETARY_SUPPLEMENT|Vitamin K (MK7)|MK-7 will be administered at a dose of 375 microg / day
40972438|NCT04669782|DRUG|Teriparatide|Teriparatide will be administered as standard of care
40972439|NCT06408025|OTHER|Syrenity App|"Currently, the Syrenity App has two active interventions. One is an exposure-based intervention called Face your fears. Another is an intervention based on behavioral activation called Get better. The app also provides self-report questionnaires for tracking mood along with psychoeducation on a variety of topics relevant to mental health."
40972440|NCT05779995|DRUG|XW001|Inhalation solution
40972441|NCT05779995|DRUG|Placebo|Inhalation solution with matched volume
41139366|NCT06360224|DEVICE|MiraQ systems with Transit Time Flow Measurement (TTFM) and High Frequency Ultrasound (HFUS) probes|The objective of this study is to harvest a wide dataset of high quality to allow exploratory analysis and training of machine learning
41298311|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
41298312|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
41298313|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
41298314|NCT03502707|BIOLOGICAL|Selected Regimen|A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.
41298315|NCT03206034|BEHAVIORAL|Stylistic Memory Enhancement|
41298316|NCT02998008|BEHAVIORAL|high intensity interval training|
41458741|NCT02791958|DRUG|Atorvastatin 40 mg|A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks
41458742|NCT02791958|DRUG|Ramipril 10 mg|A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
41458743|NCT02835157|DRUG|Balanced crystalloid solution|Multiple electrolyte solution as boluses would be administered.
41458744|NCT02835157|DRUG|0.9%sodium chloride|saline as boluses would be administered
41458745|NCT01675739|BEHAVIORAL|Short message service of mobile phone (SMS)|In SMS group, patients took 1st dose polyethylene glycol (PEG) 2L at 6-8pm the day before colonoscopy and then start to take 2nd dose PEG 2L after receiving Short message service of mobile phone (SMS) 6hours before afternoon colonoscopy.
41458746|NCT01675739|DRUG|polyethylene glycol (PEG)|"No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.~SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS"
41458747|NCT02484508|DRUG|Guli capsule|Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
41458748|NCT02484508|DRUG|Kangguzengsheng capsule|Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
40972442|NCT03878628|DRUG|Adipose tissue-derived mesenchymal stem cells|CSCC_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
40972443|NCT03542474|BEHAVIORAL|High Intensity Endurance Exercise|Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
40972444|NCT01880398|OTHER|Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
40972445|NCT01191398|DRUG|Atropine (0.01mg/kg)|Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
40972446|NCT01191398|DRUG|Glycopyrrolate (0.01mg/kg)|Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
40972447|NCT01191398|DRUG|Normal saline 0.9%|Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
41458749|NCT03900234|OTHER|No intervention will be administered|No intervention will be studied. Clinical and ultrasound examinations will be used to find the prevalence of CVD.
41458750|NCT05623228|COMBINATION_PRODUCT|The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia|The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia.
41458751|NCT05997030|DEVICE|low intensity focused ultrasound (LIFU)|Subjects will undergo undergo a single LIFU of the target brain region
40972448|NCT03063567|DEVICE|CPAP interfaces|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
40972449|NCT03861351|DEVICE|Mini WELL Toric Ready intraocular lens|The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
40972450|NCT02254187|DRUG|Salmeterol capsule - low|
40972451|NCT02254187|DRUG|Salmeterol capsule - high|
40972452|NCT02254187|DRUG|Salmeterol via Serevent® Diskus®|
40972453|NCT02495441|OTHER|Use of Rapid Immunoassay Tests for the Detection of PROM|"After informed consent , both the ROM Plus®, ActimProm Amnioquick® Complete and AmniSure® bedside tests (without the use of a speculum) will be performed.~The patient will then undergo the standard clinical assessment, which includes a sterile speculum exam (SSE). If either 1) amniotic fluid is seen leaking from the cervical os, or 2) if at least two of the following three clinical signs are present: visual pooling of fluid in the posterior fornix, positive nitrazine test, and microscopic evidence of ferning, then the patient will be considered positive for ROM.~Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of IGFBP-1/AFP tests and Amnisure®."
40972454|NCT02638545|DRUG|Dexmedetomidine|Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
40972455|NCT02677467|BIOLOGICAL|Blood-pressure variability|Day to Night Blood pressure variability
40972456|NCT05637398|DRUG|Colchicine|The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator
40972457|NCT03107936|BEHAVIORAL|smokeSCREEN game|smokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
40972458|NCT04937621|DIAGNOSTIC_TEST|ECG data analysis|Baseline ECG as well as follow-up ECG are analysed
40972459|NCT04937621|DRUG|Treatment data collect|Baseline treatment data as well as follow-up treatment data are collected
40972460|NCT04937621|BIOLOGICAL|Biological check-up data collect|Baseline Biological check-up data as well as follow-up data are collected
40972461|NCT04937621|OTHER|Collection of clinical events of interest|Clinical events of interest at the baseline as well as follow-up clinical events are collected
40972462|NCT01954602|PROCEDURE|Guide-wire cannulation|Direct guide-wire hovering a few millimeters through the catheter or sphincterotome
40972463|NCT01954602|PROCEDURE|Sphincterotome assisted guide-wire cannulation|Sphincterotome is inserted initially a few millimeters through the papillary orifice
40972464|NCT05801250|BEHAVIORAL|AI Platform|AI platform can help patients evaluate the adequacy of bowel cleansing without the aid of caregivers.
40972465|NCT00153075|DEVICE|Berodual Respimat|
40972466|NCT00153075|DEVICE|Berodual HFA-MDI|
40972467|NCT04199611|PROCEDURE|Liposuction|This is a type of fat removal procedure used in plastic surgery.
41458752|NCT02517424|DRUG|High THC/Low CBD Cannabis|Dried cannabis
41458753|NCT02517424|DRUG|High THC/High CBD Cannabis|Dried cannabis
41458754|NCT02517424|DRUG|Low THC/Low CBD Cannabis|Dried cannabis
41458755|NCT03828435|DEVICE|rTMS|Magnetic stimulation will be given using a hand-held figure-of-eight coil with an median winding diameter of 70 mm or a cone coil (Magstim Co., Whitland, Dyfed, UK) connected to one Magstim Rapid2 Package (Magstim Co., UK). The figure-of-eight coil will be placed tangentially to the scalp with the handle pointing backwards, which is thought to preferentially activate the corticospinal cells trans-synaptically (Kaneko et al., 1996), while the cone coil will be placed along the anterioposterior axis to induce a posterior-to-anterior current in the cortex.
40972468|NCT04199611|BEHAVIORAL|Cognitive Behavioral Therapy|This is a psycho-social intervention that aims to improve mental health.
40972469|NCT02555072|BIOLOGICAL|yellow fever vaccine|yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
40972470|NCT06346964|OTHER|Health education|Health education prepared for chronic disease self-management aims to improve the health behaviors of older adults.
40972471|NCT03764865|PROCEDURE|day 3 uterine transfer|uterine transfer of embryo on day 3 after fertilization (cleavage stage)
40972472|NCT03764865|PROCEDURE|day 5 uterine transfer|uterine transfer of embryo on day 5 after fertilization (blastocyst stage)
41458756|NCT02409316|DRUG|[18F]FES|\[18F\]FES PET/CT scan
41458757|NCT02865824|DRUG|Continue thienopyridine|Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
41458758|NCT02865824|DRUG|Discontinue thienopyridine|Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
41466526|NCT04975347|DRUG|Naloxone|One bolus and one infusion of naloxone
40972473|NCT06350825|PROCEDURE|Cytoreductive prostatectomy or brachytherapy|local treatment+SOC for metastatic prostate cancer
40972474|NCT06350825|DRUG|ADT+second-generation antiandrogens ± chemotherapy|SOC(Triplet or doublet therapy) for mHSPC
40972475|NCT01230944|PROCEDURE|Laparoscopic Nissen fundoplication|
40972476|NCT01230944|PROCEDURE|Open Nissen fundoplication|
40972477|NCT03378362|PROCEDURE|Partial denervation of the wrist joint|Partial denervation of the wrist (posterior and anterior interosseous neurectomy) through a single dorsal approach.
40769408|NCT02758821|OTHER|No CRP will be measured onsite|No CRP will be measured onsite
40972478|NCT01743053|DEVICE|Standard Care plus ReCell|
40972479|NCT01743053|OTHER|Standard Care|
40972480|NCT04068090|OTHER|Patient Questionnaires|FACT-Ntx, EORTC-CIPN20
40972481|NCT04068090|OTHER|Blood Collection|biomarker analysis
40972482|NCT02760069|DRUG|Inhaled isopropyl alcohol|Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
41298317|NCT02698761|OTHER|Comprehensive Care Plan|"Care Plan~1. Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.~2. Other Medications. All medications will be given during daytime hours, if possible.~3. Pain Psychology.~4. Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.~5. Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.~6. Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).~7. Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily."
41298318|NCT04973228|DRUG|Roflumilast Foam|Roflumilast 0.3% foam for topical application
41298319|NCT04973228|DRUG|Vehicle Foam|Vehicle foam for topical application
40972483|NCT02760069|DRUG|Oral ondansetron|Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
40972484|NCT02760069|DRUG|Inhaled normal saline|Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.
40972485|NCT02760069|DRUG|Oral placebo|Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
40972486|NCT05735132|PROCEDURE|Conventional Line-blocking|Participants will receive a 2 cm subcutaneous 1% lidocaine local infiltration injection parallel to the arm at the puncture site.
40972487|NCT05735132|PROCEDURE|Bar-blocking|Participants will receive a bar-shaped subcutaneous 1% lidocaine local infiltration injection in the vertical arm, 2 cm away from the puncture site.
40972488|NCT05735132|PROCEDURE|V-blocking|Participants will receive a V-shaped subcutaneous 1% lidocaine local infiltration injection at a 90-degree angle 2 cm away from the puncture site.
40972489|NCT02108470|OTHER|Dental consultation using OHIP|The S-OHIP\[M\] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
40972490|NCT02587715|BIOLOGICAL|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
40972491|NCT02587715|OTHER|Liberation therapy|
40972492|NCT03534557|DIAGNOSTIC_TEST|FEV6 spirometry|During the same spirometry, to compare the relative value of FVC and FEV6
40972493|NCT01385202|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
40972494|NCT03183076|OTHER|modified adkins diet|Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
40972495|NCT03183076|DRUG|Pharmacotherapy without diet|Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
40972496|NCT01761331|OTHER|Acupuncture|"Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute."
40972497|NCT04802278|BIOLOGICAL|COVID-19 vaccine|Any COVID-19 vaccine
40972498|NCT04899921|DRUG|Ipilimumab|Intravenous injection
40972499|NCT04899921|DRUG|Nivolumab|Intravenously (IV) into the vein
40972500|NCT04899921|DRUG|Troriluzole|Taken orally
41458759|NCT04595669|BEHAVIORAL|Personalised advise|personalised dietary advice in combination with feedback on dietary behaviour and health status (i.e. waist circumference, blood pressure, cholesterol, glucose and triglycerides)
40972501|NCT04899921|DRUG|Placebo|Taken orally
40972502|NCT03445650|DRUG|ADX-102 1% Topical Dermal Cream (reproxalap)|ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
40972503|NCT03445650|DRUG|Vehicle of ADX-102 Topical Dermal Cream|Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
40972504|NCT00435292|DRUG|Naproxen|nonsteroidal anti-inflammatory drug
40972505|NCT00435292|DIETARY_SUPPLEMENT|flavocoxid 250 mg|flavonoid mixture
41458760|NCT02082834|OTHER|abdominal MDCT examination|
41458761|NCT03765190|COMBINATION_PRODUCT|Radiation: Proton Therapy+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
40769409|NCT02758821|OTHER|CRP cut-off of 20mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 20mg/L.
40972506|NCT00435292|DIETARY_SUPPLEMENT|flavocoxid 500 mg|flavonoid mixture
40972507|NCT01950507|DRUG|Budesonide|Entocort EC 3 mg given orally three times daily for at least 14 days
40972508|NCT01950507|DRUG|Fluconazole|400 mg orally once daily for CrCl greater than or equal to 50 ml/min
40972509|NCT01950507|DRUG|Voriconazole|Subjects in Cohort 1 who are not established on voriconazole will receive a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours
40972510|NCT01950507|DRUG|Micafungin|Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients
40972511|NCT01899300|DEVICE|Metal Stent (WallFlex™ Esophageal RX)|
40972512|NCT03142087|OTHER|exercises|exercise
40972513|NCT04779840|OTHER|anemia assessment|evaluation of anemia status
40972514|NCT03477877|BEHAVIORAL|Indashyikirwa Couples Training|A training curriculum for heterosexual couples in Rwanda comprising 20 3-hour modules (60 hours total) delivered to groups of 15 couples (30 people). Each module facilitated by male and 1 female facilitator. Curriculum topics include: types and uses of personal and interpersonal power (power within, power over, power with, power to), gender, gender based violence, triggers for intimate partner violence, conflict management, economic development, sexuality, alcohol, social norms and community change. Delivered by RWAMREC.
40972515|NCT03477877|BEHAVIORAL|Indashyikirwa Activist Training|This training is offered to a subset of individuals who complete the couples curriculum (randomly selected from among those who are are willing and eligible). These individuals are trained to serve as community activists, teach peers about the types of power (power within, power over, power with, power to), and advocate for community change to prevent intimate partner violence. Delivered by RWAMREC.
40972516|NCT03477877|BEHAVIORAL|Indashyikirwa Opinion Leader Training|"Training delivered to opinion leaders (political office holders, religious leaders, service providers), in intervention communities. Training comprised 8 x 3 hour sessions (24 hours) delivered for groups of up to 40 participants. Introduces Opinion Leaders to the concepts of power (power within, power over, power with, power to) and to essential concepts around women's legal rights. Delivered by Rwanda Women's Network."
40972517|NCT03477877|OTHER|Indashyikirwa Women's Spaces|"Establishment of 1 Women's Space per intervention sector -- a physical space with trained facilitators on duty from which support and referrals for women experiencing IPV could be offered and ad hoc programming responsive to community needs and interest can be run. Typical activities include once-off open trainings for community members on the concepts of power (power within, power over, power with, power to), essential concepts around women's legal rights, conflict management in families, etc. Delivered by Rwanda Women's Network."
40972518|NCT03477877|BEHAVIORAL|Village Savings and Loan Association (VSLA)|A standard Village Savings and Loan Association program as run nationwide by CARE Rwanda.
40972519|NCT05187715|DRUG|Simvastatin 40mg|Simvastatin 40mg OD
40972520|NCT05187715|OTHER|Placebo|Placebo
40972521|NCT05187715|OTHER|Standard medical Treatment|Standard medical Treatment eccluding pentoxiphylline
40972522|NCT00321945|PROCEDURE|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
40972523|NCT04957693|BEHAVIORAL|vegan diet and lifestyle changes|vegan diet and lifestyle changes
40972524|NCT03674996|OTHER|Same day discharge|Discharge of the patient 12 hours after the minimally invasive radical prostatectomy - experimental group
40972525|NCT03674996|OTHER|Next-day discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - experimental group
41298320|NCT05616065|OTHER|Blinding to academic performance of candidate|Each candidate applying to our program will be interviewed by three core faculty. One of them will be selected, a priori, to be asked not to view a candidate's academic performance (medical school transcripts, standardized test scores). This will not be randomized. Instead, it shall be set up so that each assessor has two blinded candidates to interview each day scheduled. Given that different faculty will be scheduled each day, it may end up that certain faculty will be blinded more than others.
40972526|NCT03674996|OTHER|2-days discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - control group
40972527|NCT02926365|BEHAVIORAL|ICBT|
40972528|NCT00197964|BEHAVIORAL|Enhance asthma knowledge, self-efficacy, social support|
40972529|NCT05990114|OTHER|The structured caregiver support program|It consists of 8 sessions in total. It is planned as once a week and 45 minutes.
40972530|NCT00203996|DEVICE|continuous positive airway pressure (CPAP)|CPAP is the most effective treatment available for sleep disordered breathing. CPAP provides a constant, controllable pressure to keep your upper airway open during sleep so that you can breathe normally. The pressure acts much in the same way as a splint and holds the airway open.
40972531|NCT00203996|DRUG|depot leuprolide plus estrogen/progestin replacement|Depot leuprolide is a long-acting, modified version of the natural brain hormone, gonadotropin releasing hormone (GnRH). This study drug will temporarily reduce the pituitary hormones that stimulate the ovaries to make both female (estrogen) and male (testosterone) hormones. The effect of this study drug will last approximately 12 weeks. During this time, your female hormone levels will be brought to normal by the use of a patch that contains estrogen and progesterone. This patch is placed on the skin and is changed twice a week. The subject will continue to wear this patch for 4 weeks after the end of the study, until the effects of the Lupron injection wear off.
41139367|NCT04942288|OTHER|The first group is acupressure and massage, the second group is massage|In the study, acupressure + massage will be applied to one group during 3 menstrual cycles and in the first 3 of the menstrual cycles, and only to the other group by the researcher in the experiment groups with dysmenorrhea.
41139368|NCT03069209|BIOLOGICAL|Stem Cells|Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
41298321|NCT05616065|OTHER|Usual Interview methodology|Each candidate applying to our program will be interviewed by three core faculty. Two of them will be selected, a priori, to be asked to interview their candidates as they see fit.
41298322|NCT01005472|DRUG|sunitinib malate|
41298323|NCT01005472|DRUG|temozolomide|
41298324|NCT02508168|DRUG|Alogliptin|Alogliptin 12.5 mg tablets
41298325|NCT02508168|DRUG|Metformin Hydrochloride|Metformin hydrochloride 1000 mg tablets
41298326|NCT02508168|DRUG|SYR-322MET|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
41298327|NCT03865017|BIOLOGICAL|Regulatory T cells|The trial will be carried out in Alzheimer's disease patients. The investigators will isolate CD4+CD25+ Tregs from these patients, expand and injection.
41298328|NCT03865017|OTHER|Saline|Saline+cell suspension solution infusion
41298329|NCT06361745|BIOLOGICAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
40972532|NCT00203996|DRUG|pioglitazone|Pioglitazone (Actos). Pioglitazone is an oral medication approved in the Unites States for the treatment of patients with type 2 diabetes (however it is not approved for studies in this protocol). This is one of a class of drugs known as thiazolidinediones. This class of drugs has been associated with potential beneficial changes in the metabolism (use of glucose by the body) as well as lipids (fats) in the blood.
40972533|NCT00203996|PROCEDURE|REM frag|Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
40972534|NCT00203996|PROCEDURE|SWS supp|SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
41139369|NCT03875729|BIOLOGICAL|teplizumab|Treatment
41139370|NCT03875729|BIOLOGICAL|Placebo|Control
41139371|NCT04749797|DRUG|Liposomal bupivacaine|Used as cranial block for craniotomy surgery
41139372|NCT04749797|DRUG|Bupivacaine Injection|Used as cranial block for craniotomy surgery
41298330|NCT01104818|BEHAVIORAL|Siblings in foster care curriculum, Parent Management Training|Each year, approximately 800,000 youth are cared for in foster homes across the nation. About 70% of these youth are known to suffer from mental health and educational disabilities and frequently transition to adulthood with lifelong deficits. The majority of youth in foster care have siblings in care. It is anticipated that the proposed intervention will significantly improve key outcomes for youth in the study and will provide much needed information on best practices to help youth in foster care.
40972535|NCT05695443|BEHAVIORAL|Motivational Interviewing|This study investigates the effects of an intervention based on Motivational Interviewing (MI) on oral hygiene, oral cleaning routines, and attitudes towards own oral health. The first step is for the dental staff to ask open questions to the prisoner about their oral health or oral health behavior. The next step is to confirm to the prisoner what he or she is doing. The third step is called reflection. At this stage, dental staff tries to provide reflections on what the prisoner have said, for example by repeating what the prisoner have said or say the same using synonyms (simple reflection), by extracting the underlying opinion or feeling (complex reflection), or by illuminate both negative and positive sides of the situation (double sided reflection). The final step is to summarize the conversation. In addition, the intervention includes a change plan, in which the prisoner and dental staff agrees on specific behavior that the prisoner should follow based on the MI conversation.
40972536|NCT06501482|DRUG|Postoperative reintroduction of FOLFIRI based chemotherapy|Postoperative reintroduction of FOLFIRI: irinotecan 180 mg/m2 + leucovorin 400 mg/m2 at day 1 then 5-FU 400 mg/m2 bolus followed by 2400 mg/m2 continuous infusion over 46 h biweekly. For a total of 12 cycles of perioperative chemotherapy including the preoperative chemotherapy
41298331|NCT01669369|DRUG|Lithium Carbonate|400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
41298332|NCT01669369|DRUG|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
41298333|NCT01637051|DEVICE|Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
40972537|NCT04757870|OTHER|frequency|Macro-scale risk factors for the frequency of and mortality of infection
40972538|NCT00160251|DRUG|Boceprevir (BOC)|100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
40972539|NCT00160251|BIOLOGICAL|PegIntron (PEG)|1.5 mcg/kg weekly subcutaneously
40972540|NCT00160251|DRUG|Ribavirin (RBV)|200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])
40972541|NCT06245330|DRUG|AST-001|liquid formulation for Intravenous infusion
41139373|NCT04749797|DRUG|Saline|Used as cranial block for craniotomy surgery
40972542|NCT02547454|DRUG|Methoxy polyethylene glycol-epoetin beta|
41139374|NCT03820024|BEHAVIORAL|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.
41139375|NCT02689011|PROCEDURE|Femoral Nerve Block|For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
41139376|NCT02689011|PROCEDURE|Epidural|Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
41139377|NCT03713476|OTHER|Motor task training|motor task specific training
41458762|NCT05727020|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.
40769410|NCT02758821|OTHER|CRP cut-off of 40mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 40mg/L.
40769411|NCT04524871|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
40972543|NCT06000098|OTHER|Restrictive fluid therapy|"0,5 ml/hour fluid administration during prostatic anastomosis.~After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down)."
40972544|NCT05255068|BEHAVIORAL|OPTIMAL|A person-centered mealtime care intervention
40972545|NCT04358120|DEVICE|Hyaluronic Acid Combined With Chondroitin Sulfate|"Subjects' participation in the study will last 26 weeks. The study includes 7 visits that consist of a Screening visit, three treatment visits and three follow-up visits.~Eligible subjects will undergo a Baseline visit (V1 at week 0) during which, after the confirmation of eligibility, assessments and ultrasound evaluation, the study subjects will be treated with the 1st injection of 2%Hyaluronic Acid and 2% chondroitin sulfate Subsequent treatments will be administered at weekly intervals during Visit 2 (V2 at week 1) and Visit 3 (Visit 3 at week 2) after the effectiveness assessments.~Study subjects will return for Follow-up visits 1 month (Visit 4 at week 6), 3 months (Visit 5 at week 14) and 6 months (Visit 6 at week 26) after the last injection"
40972546|NCT02902198|DIETARY_SUPPLEMENT|Placebo|Tap water 200ml
41139378|NCT03249805|DEVICE|Steenbeek Foot Abduction Brace (SFAB)|The FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor in order to avoid increased compliance due to the sensor. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
41139379|NCT03249805|DEVICE|MiracleFeet Foot Abduction Brace (mFAB)|Sensors in the mFAB will measure whether the shoe is on, the foot is in contact with the sole of the shoe and the shoes are clipped into the bar. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
41139380|NCT04986371|DRUG|Niraparib|Usage following drug insert is recommended
40769412|NCT04524871|DRUG|Bevacizumab 15 mg/kg|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
40769413|NCT04524871|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
40769414|NCT04524871|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
41139381|NCT03042767|BIOLOGICAL|IMM-124E|IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.
41139382|NCT03042767|OTHER|Placebo|Matched Placebo
41139383|NCT02640703|BIOLOGICAL|Infanrix + Prevenar 13|Different time of application
41458763|NCT05727020|DIAGNOSTIC_TEST|Collection of matched samples of breath, biofluids and pancreatic tissue|In accordance with routine clinical practices, patients will be fasted for a minimum of six hours prior to surgery. Exhaled breath, saliva, blood and urine will be collected immediately prior to surgery (before induction of general anaesthesia). Pancreatic tissue samples and duodenal aspirate which will be collected upon resection of the pancreatic specimen.
40769415|NCT04524871|DRUG|TPST-1120|TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
40769416|NCT04524871|DRUG|Tobemstomig 2100 mg|Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.
40769417|NCT04524871|DRUG|Bevacizumab 10 mg/kg|Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
40972547|NCT02902198|DIETARY_SUPPLEMENT|Glucose|25g Glucose in 200ml tap water
40972548|NCT02902198|DIETARY_SUPPLEMENT|Monosodium glutamate|1g monosodium glutamate in 200ml tap water
40972549|NCT02902198|DIETARY_SUPPLEMENT|Quinine|17mg quinine in 200ml tap water
40972550|NCT03053804|RADIATION|MR/PET|MR/PET with contrast media and FDG-18
40972551|NCT04160897|DRUG|Entecavir|entecavir naive for chronic hepatitis B patients
40972552|NCT04160897|DRUG|Tenofovir Disoproxil|tenofovir disopropyl naive for chronic hepatitis B patients
40972553|NCT00468689|DRUG|SB-751689 oral tablets (100 and 400 ng)|
41139384|NCT02170532|DRUG|levalbuterol|0.5 ml. levalbuterol
41139385|NCT02170532|DRUG|saline|0.5ml saline
41139386|NCT02170532|OTHER|levalbuterol MDI|
41139387|NCT02170532|DEVICE|breath actuated nebulizer|
41139388|NCT02170532|DEVICE|aerochamber max|
41298334|NCT01637051|DEVICE|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
40769418|NCT04524871|DRUG|Tobemstomig 600 mg|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
40769419|NCT04524871|DRUG|Tobemstomig 1200 mg|Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.
40769420|NCT04524871|DRUG|ADG126|ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).
40769421|NCT04524871|DRUG|IO-108 1800 mg|IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.
40769422|NCT04524871|DRUG|NKT2152|NKT2152 will be administered by mouth.
40972554|NCT00468689|DRUG|Ketoconazole (NIZORAL) oral tablets (200 mg)|
40972555|NCT02406482|BEHAVIORAL|Microfinance intervention (MF)|Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
40972556|NCT02406482|BEHAVIORAL|HIV risk reduction (HIVRR)|Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
41298335|NCT06338865|OTHER|Carbon dioxide|Gas used for insufflation pressure
40769423|NCT04524871|DRUG|IO-108 1200 mg|IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.
40769424|NCT00216190|DRUG|Dexmedetomidine HCL Injection|
41298336|NCT06338865|DRUG|Bupivacaine|Local subcutaneous infiltration of all port sites with 0.25% bupivacaine will be performed prior to each incision. Remaining local anesthetic will be administered into the incision sites prior to the conclusion of the case (30cc total).
41298337|NCT06338865|DRUG|Oxycodone|All patients will be prescribed a total of 10 pills of oxycodone 5mg, which is the standard amount that our practice prescribes for patients after laparoscopic surgery.
40769425|NCT00216190|DRUG|Midazolam Injection|
40972557|NCT01125683|DRUG|AZD1446|Capsule, oral single and multiple dose
40972558|NCT01125683|DRUG|Donepezil|Capsule, oral and single dose
40972559|NCT01125683|DRUG|Placebo|Capsule, oral and single dose
40972560|NCT04205071|DRUG|Lorcaserin|Given PO
40972561|NCT04205071|DRUG|Lorcaserin Hydrochloride|Given PO
40972562|NCT04205071|OTHER|Questionnaire Administration|Ancillary studies
40972563|NCT02250170|DRUG|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on \& 3 days-off (21 days=1cycle)
40972564|NCT01095445|DRUG|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
40972565|NCT05765240|DRUG|Hyaluronic Acid Topical Gels|Hyaluronic acid is a linear polysaccharide found naturally in different organs and tissues such as the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, and skin. The periodontal ligament is a key element found in periodontal tissues such as the gingiva, alveolar bone, and cementum. It plays a regulatory role in the inflammatory response, impedes the penetration of viruses and bacteria into the tissue, and is involved in inflammation, granulation tissue formation, epithelial formation, and tissue remodeling. There are no reported drug interactions or contraindications for the use of hyaluronic acid.
40972566|NCT05765240|PROCEDURE|Diode Laser Biostimulation|Laser therapy can amplify wound healing by increasing cell regeneration and modulating the immune response. In animal experiments with diode laser, it was observed that postoperative low-level laser application increased wound healing. Diode laser applied at frequencies of 20 mW and 670 nm and 200 mW and 820 nm accelerated clot organization and new vessel formation after tooth extraction.
41298338|NCT02574312|DEVICE|ATTUNE TKA with ATTUNE RUI|ATTUNE TKA with ATTUNE RUI
41298339|NCT02574312|DEVICE|ATTUNE TKA with ATTUNE SUI|ATTUNE TKA with ATTUNE SUI
40769426|NCT06290128|DRUG|Riliprubart|Pharmaceutical form:Solution-Route of administration:IV Infusion
40769427|NCT06290128|DRUG|Placebo|Pharmaceutical form:Solution-Route of administration:IV Infusion
40769428|NCT06290128|DRUG|Riliprubart|Pharmaceutical form:Solution-Route of administration:SC Injection
40769429|NCT06290128|DRUG|Placebo|Pharmaceutical form:Solution-Route of administration:SC Injection
40769430|NCT05961709|DRUG|Cemiplimab|Given by IV (vein)
40769431|NCT06483113|DEVICE|Delefilcon A spherical soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)
40972567|NCT03291054|DRUG|Pembrolizumab|Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.
40769432|NCT06483113|DEVICE|Delefilcon A toric soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
40972568|NCT03291054|DRUG|Epacadostat|Epacadostat will be dosed at 100 mg PO twice a day (BID) daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
40769433|NCT06483113|DEVICE|Delefilcon A multifocal soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with presbyopia
41139389|NCT02170532|DRUG|ipratroprium|
40769435|NCT03559556|OTHER|CT angiography|CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
40769436|NCT05445843|DRUG|JDQ443|JDQ443 orally administered
40769437|NCT01738412|DEVICE|Neurokeeper stroke detector|Monitoring stroke patients
40972569|NCT04973826|DRUG|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
40972570|NCT03517956|DRUG|Rogaratinib (BAY1163877)|"Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part."
40972571|NCT03517956|DRUG|Copanlisib (BAY80-6946)|"Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part."
40972572|NCT06259266|OTHER|Anti-reflux valve for dialysis catheter|
40972573|NCT00481000|BEHAVIORAL|Dialectical Cognitive Therapy|Dialectical Behavior Therapy in Combination with Traumafocused CBT
40972574|NCT05533281|DRUG|tropisetron|One tropisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.
40972575|NCT05533281|DRUG|metoclopramide|One dose of metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
40972576|NCT05533281|DRUG|dexamethasone|One dose of dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
41139390|NCT06360276|BEHAVIORAL|Seated Exercises|A quasi-experimental research was conducted in the main University Hospital, Alexandria, Egypt. women practiced seated exercises
41458764|NCT05820789|OTHER|Family support|Before the extubation procedure, the patient's relatives will be informed, and the patient will be allowed to enter the intensive care unit, and the patient will be able to express that he is with the patient by holding his hand and talking.
40769438|NCT05427929|DEVICE|NVR 4mm Edi catheter|Receive NAVA ventilation using the newly designed NVR 4 mm Edi catheter
41139391|NCT06360276|BEHAVIORAL|Psychoeducational Rehabilitation|Women received Psycho-educational Rehabilitation, including mindfulness breathing, problem-solving training, cognitive re-framing technique, and thought stopping.
41139392|NCT06360276|BEHAVIORAL|Routine Care|Women received routine health education in the unit, where nurses provided general instructions about the postoperative activities for women with breast cancer.
41298340|NCT03884348|DRUG|proton pump inhibitor, amoxicillin, clarithromycin|non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
40769439|NCT06251115|DRUG|QY-1-T|QY-1-T is a TCR-T drug targeting HBV-related HCC
40769440|NCT06569251|DRUG|Dexamethasone 12 mg QD|Administration of dexamethasone to the mother as an inducer of fetal lung maturity. shortened scheme
40769441|NCT06569251|DRUG|Dexamethasone 6 mg BID|Administration of dexamethasone to the mother as an inducer of fetal lung maturity. standard Scheme
40769442|NCT05849844|DEVICE|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure
40769444|NCT02020226|DRUG|TH-302|480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
40769445|NCT00572819|DRUG|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
40769446|NCT00572819|DRUG|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
40769447|NCT05642325|DRUG|Vamikibart|Participants will receive vamikibart IVT injection
40769448|NCT05642325|OTHER|Sham|Participants will receive a sham procedure that mimics an IVT injection.
41139393|NCT00001255|DRUG|ADA PBSC|
41139394|NCT00001255|DRUG|ADA Umbilical Cord Blood Cells|
41139395|NCT00001255|DRUG|Transduced Lymphocytes|
41139396|NCT02624830|DRUG|Sulfonylurea|See Arm description.
41139397|NCT00926107|DRUG|Temsirolimus|Temsirolimus 25mg weekly until clinical progression
41139398|NCT01487837|DRUG|Human fibrinogen concentrate|Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
41139399|NCT04659382|DRUG|Atezolizumab|Atezolizumab combined to standard chemotherapy (XELOX + bevacizumab) and targeted therapy in patients whose tumour has been made immunogenic by radiotherapy (Therasphere) and ICI (atezolizumab).
41139400|NCT04659382|DEVICE|Therasphere|Therasphere injected to patients to promote the release of neoantigens from their tumour and convert it into an immunogenic tumour.
41139401|NCT04659382|DRUG|XELOX|standard chemotherapy for first line treament of metastatic CRC (in pMMR and/or MSS patients)
41458765|NCT03291145|DRUG|Beta Blockers|With and without Beta Blockers
41458766|NCT03291145|DRUG|Spironolactone|Brisk Standing before and after seven days treatment with Spironolactone
40769449|NCT05351229|DRUG|Morphine Sulfate|5 mcg/kg intrathecal preservative free morphine sulfate
41298341|NCT03884348|DRUG|proton pump inhibitor, amoxicillin, metronidazole|clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
41298342|NCT01641315|BIOLOGICAL|rabies vaccine|"Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0."
41298343|NCT05921916|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
41298344|NCT05921916|DRUG|Placebo oral capsule|Placebo oral capsule solid microcrystalline cellulose
40769450|NCT05351229|OTHER|Placebo|Sterile saline, placebo
40972577|NCT05533281|OTHER|normal saline|Equal dose of normal saline was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
40972578|NCT04613960|DRUG|Magnesium sulfate|MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset
40972579|NCT04613960|DRUG|normal saline|Placebo treatment
40972580|NCT06499155|DEVICE|Use of periacryl in gingival recession closure procedures|Unlike the traditional procedure, periacryl tissue adhesive will be used in both the recipient and donor areas.
40972581|NCT06499155|PROCEDURE|Use of sutures in gingival recession closure procedures|Both recipient and donor areas will be closed with traditional suturing techniques.
40972582|NCT04475653|BEHAVIORAL|Physical Activity using an Activity Tracker|
40972583|NCT03090113|DRUG|Shuxuetong Injection|intravenous drip
41298345|NCT02112162|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/MRI
41298346|NCT02112162|DEVICE|positron emission tomography|Undergo FDG PET/MRI
41298347|NCT02112162|DEVICE|magnetic resonance imaging|Undergo FDG PET/MRI
40972584|NCT03090113|DRUG|Placebo Injection|intravenous drip
40972585|NCT02157467|DRUG|BMS-955176|
40972586|NCT02157467|DRUG|Ortho Cyclen|
41298348|NCT02112162|OTHER|laboratory biomarker analysis|Correlative studies
41298349|NCT02285764|OTHER|Nutritional Supplement|Modified carbohydrate
41298350|NCT02285764|OTHER|Standard of Care|As determined by the study site
41298351|NCT06474741|BEHAVIORAL|in-app notification|Parents will receive bi-weekly prompts in a baby monitor app to change infant's orientation within crib, allow for tummy time several times per day, alternate the side from which infants are fed, alternate the side the infant faces during carrying, and in general note any side preferences of the infant so that positioning can assist in symmetry.
40769451|NCT06028464|DRUG|BI 1810631|BI 1810631
40769452|NCT06028464|DRUG|Carbamazepine|Carbamazepine
40769453|NCT05953337|DEVICE|EYE90 Microspheres Treatment|Y90 glass microspheres
40769454|NCT05640427|DRUG|Dexmedetomidine|Groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine to 30min before the end of the operation.Groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine to 30min before the end of the operation.
40769455|NCT05640427|DRUG|normal saline|The same capacity of 0.9% normal saline was used in group C
40769456|NCT06280235|DRUG|BI 1569912|BI 1569912
40769457|NCT06280235|DRUG|Placebo|Placebo matching BI 1569912
40972587|NCT02396615|DIETARY_SUPPLEMENT|SATIN pineapple|Active juice with added fibre and ginseng
40972588|NCT02396615|DIETARY_SUPPLEMENT|SATIN pineapple control|Control products without active ingredients
40769458|NCT02209987|DRUG|GS-5745 SC|GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe
40769459|NCT02209987|DRUG|GS-5745 IV|GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
41298352|NCT04955145|DRUG|RUTA C 60|Rutin known as vitamin p or rotoside and C-retard is Ascorbic acid
40769460|NCT06017986|OTHER|Ultra-processed food - Picture Set Meal|A meal containing ultra-processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
40972589|NCT03145285|DRUG|Abiraterone Acetate|"Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision."
41298353|NCT06285916|DRUG|NORA520 Dose 1|Oral NORA520 tablets Dose 1 for 3 days
40972590|NCT03252834|DIAGNOSTIC_TEST|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
40972591|NCT04153240|DEVICE|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA)|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) has been developed for adult patients with positional OSA, and snorers. Worn on the back of the neck, it begins to vibrate when the patient starts to sleep in the supine position and increases in intensity until the patient changes.
41298354|NCT06285916|DRUG|NORA520 Dose 2|Oral NORA520 tablets Dose 2 for 3 days
41298355|NCT06285916|DRUG|Placebo|Oral Placebo tablets for 3 days
41298356|NCT01520324|DEVICE|oral delivery mucosal stain|200mg methylene blue MMX tablet taken prior to colonoscopy
41298357|NCT05209568|DIETARY_SUPPLEMENT|Gluten Powder|Single oral dose of gluten powder
41298358|NCT00136747|DRUG|Memantine|Two capsules of Memantine twice daily for 12 days.
41298359|NCT00136747|DRUG|bupropion|
41298360|NCT00136747|DRUG|placebo|
41298361|NCT05337267|DRUG|sintilimab (after the change)|0.3mg/kg，I.V.，single dose
40769461|NCT06017986|OTHER|Ultra-processed food - Additives Meal|A meal containing ultra-processed foods that very on degree of additives.
40972592|NCT03758352|PROCEDURE|remote ischemic preconditioning (rIC)|Short intermittent peripheral occlusions and reperfusions of the blood flow in the right lower extremity with the help of a tourniquet.
40972593|NCT03758352|OTHER|non remote ischemic preconditioning (non-rIC)|Retrospective group who have not undergone intervention.
41298362|NCT05337267|DRUG|sintilimab (before the change)|0.3mg/kg，I.V.，single dose
40769462|NCT06017986|OTHER|Ultra-processed food - Ingredients Meal|a meal containing ultra-processed foods that very on degree of processing but not ingredients.
40972594|NCT05092724|PROCEDURE|fetal blood transfusion|transfusion of fetal blood
40972595|NCT04766580|BEHAVIORAL|Placebo and nocebo effect|The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
40972596|NCT00909051|DRUG|Acarbose (Glucobay, BAYG5421)|Patients with diabetes type 2 newly treated with Glucobay
41298363|NCT02124187|DEVICE|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
40972597|NCT02573350|DRUG|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
41139402|NCT04659382|DRUG|Bevacizumab|standard targeted therapy associated with XELOX for first line treament of metastatic CRC (in pMMR and/or MSS patients)
41139403|NCT01179100|DRUG|Lidocaine|Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
41139404|NCT00893009|DRUG|Theophylline|100 mg twice a day
41139405|NCT00893009|DRUG|Placebo|Placebo
41139406|NCT00608699|DRUG|GSK256073A tablets + IR niacin tablets|single dosing for 4 to 5 sessions
41139407|NCT02602548|OTHER|Culture|Specimens will be obtained and sent to the lab for cultures.
41139408|NCT03593785|DRUG|AZD8233|Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
41298364|NCT02124187|DEVICE|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
41298365|NCT02124187|DEVICE|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
41298366|NCT05071781|DRUG|Corticotropin-release hormone|intravenous CRH (100 µg)
41298367|NCT05071781|DRUG|Corticotropin-release hormone|a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
41298368|NCT02078622|OTHER|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
41298369|NCT05464758|OTHER|Repeated cold exposure|8 consecutive days of exposure to 8°C air for 120 minutes each day
41298370|NCT00259259|BEHAVIORAL|SALATRIM|
41298371|NCT04205903|DRUG|Nilotinib|Given PO
41298372|NCT04205903|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO on cycle 1 Days 7, 14, 15 once a day 24 hours prior to the paclitaxel infusion and again 30 minutes prior to the paclitaxel infusion on days 8, 15.
41298373|NCT04205903|DRUG|Paclitaxel|Given IV weekly on days 1, 8, 15, of every 21 days, at a starting dose of 80mg/m2
41298374|NCT04205903|OTHER|Placebo|Given PO
41298375|NCT04205903|OTHER|Questionnaire Administration|Ancillary studies
40769463|NCT06017986|OTHER|Minimally Processed Food - Picture Set Meal|a meal containing minimally processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
41139409|NCT02327442|RADIATION|68Ga-NOTA-NFB|In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
41139410|NCT04707820|DIAGNOSTIC_TEST|ELISPOT|"The evolution of the number of gamma interferon (IFN) producing T lymphocytes in response to Spike glycoprotein (Spike glycoprotein) will be assessed by enumeration in ELISPOT method at 4 measurement times: D0 (confirmation of infection by PCR), D+7, D+14 or at hospital departure (D+Departure) and D+56±14 days.~The ELISPOT method consists in stimulating peripheral blood mononuclear cells (isolated by density gradient and containing a known CD3+ T lymphocyte count) over a short period of time (16 to 20 hours) with a pool of 15 amino acid peptides (overlapping on 11 amino acids) representative of the S protein."
41139411|NCT05884567|OTHER|Isometric exercises|These exercises are used to increase muscle endurance, power and ROM
41139412|NCT05884567|OTHER|Mobilization|These exercises are used to increase ROM and used for pain reduction
41298376|NCT01094340|DRUG|Thalidomide|fixed dose over 8 clinic visits
41139413|NCT03611985|DRUG|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
41298377|NCT03579875|DRUG|Total Body Irradiation (TBI) (Plan 1)|300 cGy with thymic shielding on day -6
41298378|NCT03579875|DRUG|Cyclophosphamide (CY) (Plan 1)|10 mg/kg IV daily on days -5, -4, -3, and -2
41298379|NCT03579875|DRUG|Fludarabine (FLU)|35 mg/m2 IV daily on days -5, -4, -3, and -2
40769464|NCT06017986|OTHER|Minimally Processed Food - Additives Meal|A meal containing minimally processed foods that very on degree of additives.
40769465|NCT06017986|OTHER|Minimally Processed Food - Ingredients Meal|A meal containing minimally processed foods that very on degree of processing but not ingredients.
40972598|NCT02573350|DRUG|OBR|Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
41298380|NCT03579875|DRUG|Methylprednisolone (MP)|1 mg/kg IV q12h on days -5, -4, -3, -2, and -1
41298381|NCT03579875|DEVICE|Donor mobilized PBSC infusion|T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0
41298382|NCT03579875|DRUG|G-CSF|Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \>2.5 x 10\^9/L for 3 consecutive days)
41298383|NCT03579875|DRUG|Cyclophosphamide (CY) (Plan 2)|5 mg/kg IV daily on days -5, -4, -3, and -2
40769466|NCT03531580|DEVICE|Magnetic Resonance Imaging|Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
40769467|NCT04980157|BEHAVIORAL|CARES-HCV|CARES-HCV is an educational intervention to promote both hepatitis c screening and colorectal cancer screening among diverse baby boomers in the area.
40769468|NCT06598306|DRUG|Tarlatamab|Administered by SC injection.
40769469|NCT03756961|DRUG|Dexmedetomidine|The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
40769470|NCT03756961|BEHAVIORAL|Person-centred care (PCC)|The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge. This will be part of patients in Phase 2
40769471|NCT03756961|DRUG|Esketamine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
40769472|NCT03756961|DRUG|Lidocaine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.
40769473|NCT03756961|DEVICE|Transcutaneous Nerve Stimulation (TENS)|The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.
40769474|NCT03756961|DRUG|Remifentanil|The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
40769475|NCT03756961|DRUG|Desflurane|The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia
41139414|NCT03611985|DRUG|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
41139415|NCT01303822|BEHAVIORAL|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
41139416|NCT05503407|PROCEDURE|Baseline V-RESOLVE score-guided PCI|"Jailed wire technique (JWT): Both main vessel (MV) and side branch (SB) are wired. The MV is stented with wire protection in SB. If suboptimal results exist, the SB would be rewired and a kissing balloon inflation (KBI) is undertaken.~Jailed balloon technique: A monorail balloon is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB.~Provisional two-stent strategy: Lesion preparation and MV stenting are consistent with JWT. Provisional SB stenting could be undertaken when suboptimal results occur after SB rewiring and a KBI is undertaken.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which usually stenting SB before MV stenting."
41139417|NCT05503407|PROCEDURE|Angiography-guided PCI|The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
41139418|NCT06377137|BEHAVIORAL|Small-sided soccer games groups (SSSG)|Physical exercise intervention
41139419|NCT06377137|BEHAVIORAL|Traditional soccer training groups (TSG)|Physical exercise intervention
41139420|NCT05518214|DIETARY_SUPPLEMENT|Beetroot|Participants receive a 12-week supply of beetroot juice.
40769476|NCT03756961|DRUG|Propofol|The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia
40769477|NCT03756961|DRUG|Oxycodone|The control group receives Oxycodone as the routine pain management drug post-operative.
40769478|NCT06230913|DEVICE|Kinesiotape|To perform taping of the chest, the patient was asked to stand upright with the affected shoulder rotated externally. Five straps of the fan shaped tape were extended to the chest toward the affected axilla with 15% to 20% tension, and the anchor was positioned without tension in the anterior axilla on the sound side.
40769479|NCT06230913|DEVICE|Pressure garment|The skin was washed and dried before applying the PG. The Premium Lymphedema Gradient Garment (Jobskin, Long Eaton, England) was used to apply PGs. This garment has a pressure gradient built into it, applying between 20 and 60 mm Hg for at least 15 to 18 hours each day for three weeks. The gradient counter pressure is applied using a gram tension.
40769480|NCT06602817|OTHER|Exposure: prone position|Exposure: surgery in prone position
40769481|NCT06602817|OTHER|Exposure: Supine position|Exposure: Surgery in supine position
40769482|NCT06585449|DRUG|ALN-HTT02|ALN-HTT02 will be administered intrathecally
40769483|NCT06585449|DRUG|Placebo|Placebo will be administered intrathecally
40769484|NCT06295471|DEVICE|DFG Laser|Laser treatment to the upper thigh
40769485|NCT06295471|DEVICE|CO2 Laser|Laser treatment to the upper thigh
40769486|NCT06295471|DEVICE|Optical coherence tomography (OCT)|Angiographic OCT imaging at areas of interest
40769487|NCT03470051|DIAGNOSTIC_TEST|QT Ultrasound|All subjects will be asked to agree to an ultrasound-guided breast needle biopsy by a qualified radiologist experienced in this procedure if not already completed prior to study entry.
40769488|NCT06644703|OTHER|Cryotherapy|The pulpotomy area was irrigated with 2 °C saline solution for 5 minutes in cryotherapy group.
41139421|NCT05518214|DIETARY_SUPPLEMENT|Placebo|Participants receive a 12-week supply of placebo beetroot juice.
41298384|NCT03579875|DRUG|Rituximab|200 mg/m2 IV once on day -1
40769489|NCT02798757|DRUG|Dapagliflozin|Urine samples will be collected for 1HNMR spectroscopies
40769490|NCT05712538|DRUG|ARCT-032|ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
40769491|NCT05712538|OTHER|Placebo|Normal saline
40769492|NCT02447406|DRUG|AZD6094|
40769493|NCT02447406|DRUG|docetaxel|
40769494|NCT02998866|PROCEDURE|Esophageal Temperature-Guided Ablation|Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI \[means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
40769495|NCT06122948|DRUG|The midazolam group|The midazolam group will receive intranasal midazolam (0.1 mg/kg)
41139422|NCT02626117|DEVICE|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
41298385|NCT03579875|DRUG|Busulfan|Busulfan 0.6 mg/kg if \> 4 years old and/or \>12 kg (0.8 mg/kg IV if ≤ 4 years old and/or ≤ 12 kg) is given IV over 2 hours every 12 hours for 2 days.
41298386|NCT03579875|DRUG|Alemtuzumab|Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)
40769496|NCT06122948|DRUG|The midazolam ketamine group|the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
40769497|NCT03899155|DRUG|Nivolumab|Specified dose on specified days
40769498|NCT03899155|DRUG|Ipilimumab|Specified dose on specified days
40769499|NCT03899155|DRUG|Cabozantinib|Specified dose on specified days
40769500|NCT03899155|DRUG|Trametinib|Specified dose on specified days
40769501|NCT03899155|DRUG|Relatlimab|Specified dose on specified days
40769502|NCT03899155|DRUG|Nivolumab + Relatlimab|Specified dose on specified days
40769503|NCT03899155|DRUG|Capecitabine|Specified dose on specified days
40769504|NCT03899155|DRUG|Bevacizumab|Specified dose on specified days
40769505|NCT03899155|DRUG|Temozolomide|Specified dose on specified days
40769506|NCT03899155|DRUG|Rucaparib|Specified dose on specified days
40972599|NCT04949048|DEVICE|Magneto PE Kit|All enrolled patients will be treated with Magneto PE Kit
40972600|NCT03817177|PROCEDURE|high flow nasal cannula oxygenation|high flow nasal cannula application in PACU
40972601|NCT03817177|PROCEDURE|nasal prong|conventional nasal prong application in PACU
40972602|NCT01975545|DRUG|Fluor varnish|Dental varnish will be applied to one anterior superior teeth in a random side.
40972603|NCT01975545|DRUG|Fluor varnish with nanoparticles|Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
41298387|NCT03579875|DRUG|Melphalan|If available, MEL dosing will be model-based using Bayesian methodology. If Bayesian methodology is unavailable, MEL dosing will be weight-based: MEL 70 mg/m2 for patients ≥10 kg (2.35 mg/kg for patients \<10 kg\^) IV for one dose over 30 minutes.
40972604|NCT04500002|DRUG|Isonicotinic Acid Hydrazide|total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
40972605|NCT04500002|DRUG|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
41298388|NCT04357093|OTHER|Grape seed extract mouthwash|Mouthwash 15% grape seed extract
41298389|NCT04357093|OTHER|Sodium fluoride mouthwash|Sodium fluoride mouthwash
41298390|NCT00164905|DEVICE|Doppler ultrasound probe|Applying to ulcer base to assess the blood flow underneath the ulcer
41298391|NCT03704597|OTHER|cryotherapy|Cooling of oral mucosa
41298392|NCT03591796|DEVICE|HFOV|Ventilated infants were randomized to HFOV
41298393|NCT03591796|DEVICE|CMV|Ventilated infants were randomized to CMV.
41298394|NCT01996345|PROCEDURE|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
41298395|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
40972606|NCT04459091|DIETARY_SUPPLEMENT|Amino Essential Acid|8 gr die in two administration
40972607|NCT04459091|DIETARY_SUPPLEMENT|placebo|8 gr die in two administration
40769507|NCT03899155|DRUG|Daratumumab|Specified dose on specified days
40769508|NCT03899155|DRUG|Regorafinib|Specified dose on specified days
40769509|NCT03899155|DRUG|Leucovorin|Specified dose on specified days
40769510|NCT03899155|DRUG|Fluorouracil|Specified dose on specified days
40769511|NCT03899155|DRUG|Oxaliplatin|Specified dose on specified days
40769512|NCT03899155|DRUG|Enzalutamide|Specified dose on specified days
40972608|NCT03752632|DEVICE|Veinplicity with tourniquet|Veinplicity will be used with a tourniquet
40972609|NCT03752632|DEVICE|Tourniquet|A tourniquet alone will be used.
40972610|NCT01417273|DIETARY_SUPPLEMENT|vitamin A|1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
40972611|NCT01417273|DRUG|Drug: placebo|1 cap placebo/day for 12 month
40990815|NCT02788981|DRUG|Nab-Paclitaxel|Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.
41298396|NCT00923091|DRUG|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
41298397|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
41298398|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
40769513|NCT03899155|DRUG|Sunitinib|Specified dose on specified days
40769514|NCT03899155|DRUG|Pemetrexed|Specified dose on specified days
40769515|NCT03899155|DRUG|Pembrolizumab|Specified dose on specified days
40769516|NCT06468826|DRUG|Avacopan|Oral capsules
40769517|NCT03599076|OTHER|HD Wear|Wearable sensor system for monitoring Huntington's chorea during activities of daily living
40769518|NCT06486844|DRUG|Vericiguat (Verquvo, BAY1021189)|Vericiguat was given following routine clinical practice.
40990816|NCT03905460|DIAGNOSTIC_TEST|Point-of-care ultrasound|Focused ultrasound of the heart, lungs and pleurae
41298399|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
40769519|NCT01450631|DEVICE|Prevena™ Incision Management System (PIMS)|PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.
40769520|NCT01450631|DEVICE|Standard-of-care Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
40769521|NCT04937166|BIOLOGICAL|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
40769522|NCT04937166|DRUG|Azacitidine|Azacitidine is an analog of the pyrimidine nucleoside cytidine.
40990817|NCT06022120|BEHAVIORAL|An integrated health literacy intervention|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish contexts among students at risk of poorer health outcomes compared to their peers with stronger literacy skills.
40990818|NCT03854656|OTHER|Time-restricted eating|"Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~1. The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~2. The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority."
41139423|NCT02626117|DEVICE|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
41139424|NCT04131855|OTHER|Pumice prophylaxis|Pumicing the teeth is the recommended prophylaxis to be used prior to the application of the self etch primer by the manufacturer - 3M Unitek Transbond Plus Self Etch Primer which will be used in the experiment.
41139425|NCT04131855|OTHER|No pumice prophylaxis|Pumice prophylaxis will not be used as per manufacturers instructions.
41139426|NCT04546555|DEVICE|Dual chamber pacemaker|Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.
41139427|NCT04546555|OTHER|Accelerated Physiologic Pacing|The lower rate limit will be programmed to an individualized heart rate.
41139428|NCT04546555|OTHER|Nocturnal Pacing|In addition to adjustment of the lower rate limit to an individualized heart rate, nocturnal pacing a moderate HR elevation of 110bpm will be implemented between 8pm and 6am.
41139429|NCT00930475|DRUG|RAD001 (Everolimus) in combination with carboplatin|phase I: dose levels: 2,5 mg, 5 mg, 7,5 mg and 10mg daily in combination with carboplatin AUC2 weekly until progress
41139430|NCT00930475|DRUG|RAD001 (Everolimus) in combination with carboplatin|phase 2: 10mg RAD001 in combination with carboplatin
41139431|NCT01593137|DRUG|Liraglutide + metformin|"Liraglutide 1.8 mg/day + metformin \>1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.~Patients will continue on metformin therapy as they were prescribed before enrolment."
41139432|NCT01593137|DRUG|Glimepiride + metformin|"Glimepiride 4 mg/day + metformin \>1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.~Patients will continue on metformin therapy as they were prescribed before enrolment."
41139433|NCT02054429|DRUG|Insulin|Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
41139434|NCT01455948|DEVICE|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
41139435|NCT01455948|PROCEDURE|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
40769523|NCT04937166|DRUG|Venetoclax|Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
40769524|NCT06115967|DRUG|AZD6912|AZD6912 will be administered as a single sub-cutaneous dose.
40769525|NCT06115967|DRUG|Placebo|Placebo will be administered as a single sub-cutaneous dose.
40769526|NCT06054542|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the DESQ
40769527|NCT06175832|DRUG|Elonva®|Single injection
40769528|NCT06175832|DRUG|Puregon®|Multiple injections
41139436|NCT02243800|OTHER|cholecalciferol versus placebo|
41298400|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
41298401|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
40769529|NCT06175832|DRUG|Orgalutran®|Multiple injections
40769530|NCT06175832|DRUG|Gonapeptyl®|Double injection
40769531|NCT06175832|DRUG|Cerazette®|Oral tablet
40769532|NCT06508021|DRUG|Andecaliximab|Dose level A or B
40769533|NCT06508021|DRUG|Placebo|Blinded
40769534|NCT06508021|DRUG|Andecaliximab|Dose level A or B (or age adjusted dose)
40769535|NCT04076709|PROCEDURE|goal directed anaesthesia|Deep neuromuscular blockade (PTC 1-2) Nociception level index (NOL) target 10-25
40769536|NCT02073201|OTHER|High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
40769537|NCT02073201|OTHER|Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
40769538|NCT02073201|OTHER|Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
40769539|NCT05368883|OTHER|Exercise- One-Legged|The exercise program consisted of a 5-minute warm-up, followed by 10 minutes of cycling for each leg during the first 2 weeks, increasing to 15 minutes for each leg in the subsequent weeks (with a 5-10 minute rest period between switching legs), and concluded with a 5-minute cool-down period. During the exercise, the inactive leg was kept stationary and in contact with the ground . In the one-legged cycling exercise training, whether patients started with the dominant or non-dominant leg was determined randomly
40769540|NCT05368883|OTHER|Exercise-Two-Legged|The exercise program consisted of a 5-minute warm-up, followed by 20 minutes of cycling during the first 2 weeks, increasing to 30 minutes in the subsequent weeks, and concluded with a 5-minute cool-down period.
40769541|NCT06637683|COMBINATION_PRODUCT|LiveSpo COLON|LiveSpo® COLON has a registration number: 10401/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
41298402|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
40769542|NCT06637683|OTHER|Routine treatment|The standard internal medicine treatment protocol of the hospital
40769543|NCT05493657|DRUG|Aspirin single antiplatelet therapy|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
40769544|NCT05493657|DRUG|Clopidogrel single antiplatelet therapy|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
40769545|NCT06327425|DEVICE|Magnetocardiography|Magnetocardiography
40769546|NCT04430010|BEHAVIORAL|BEST in CLASS|BEST in CLASS is a Tier-2 evidence based program (EBP) that has demonstrated effectiveness at reducing children's Disruptive Behavior Problems (DBPs) and risk for Emotional and Behavioral Disorders (EBDs)
40769547|NCT06506422|DRUG|Empagliflozin 10 MG|10mg Empagliflozin daily for 12 weeks
40769548|NCT06506422|DRUG|Placebo|10mg Placebo daily for 12 weeks
40972612|NCT02482506|BEHAVIORAL|MF-WLP|The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
41298403|NCT01746667|BEHAVIORAL|Exposure in vivo|
41298404|NCT01746667|BEHAVIORAL|Virtual Reality Exposure Therapy|
40769549|NCT00002759|DRUG|cyclosporine|
40769550|NCT00002759|DRUG|irinotecan hydrochloride|
40769551|NCT00002759|DRUG|phenobarbital|
40769552|NCT03079778|PROCEDURE|transarterial chemoembolization|Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
40769553|NCT03079778|RADIATION|TACE plus RT|radiobiologically guided radiation
40769554|NCT04950439|OTHER|Collect blood sample|A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
40769555|NCT04674969|DEVICE|Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.|Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
40990819|NCT01680718|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
41298405|NCT00653835|DRUG|Ezetimibe + Simvastatin|oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
41298406|NCT00653835|DRUG|Simvastatin|oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
41298407|NCT02143518|BIOLOGICAL|Na-GST-1/Alhydrogel®|The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
40972613|NCT02482506|BEHAVIORAL|SG-WLP|Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
40972614|NCT05471622|BEHAVIORAL|Nudge for PHPC Referral|The case manager and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for Penn Home Palliative Care (PHPC) upon hospital discharge will be asked to refer their patient for these home palliative care services.
40972615|NCT05937204|OTHER|Nursing Teaching|A nursing teaching scheme refers to a systematic and structured plan developed by nurses to provide teaching and instruction to patients. The components of a nursing teaching scheme typically include assessing learning needs, setting learning objectives, developing teaching materials, delivering information using various teaching methods, demonstrating skills, providing written instructions, assessing learning outcomes, and conducting follow-up
40972616|NCT04300127|DRUG|Pioglitazone 30 mg|Patients will received 30 mg of Pioglitazone once a day for 8 weeks
40972617|NCT06337188|DEVICE|Experimental AAC|Participant receives an AAC system comprising 2 wearable sensors for movement-mediated cursor control and muscle activity mediated cursor selection that is integrated with an adaptive and individualized keyboard to test communication performance.
40972618|NCT06337188|DEVICE|Generic AAC|Participant receives an AAC system that is similar to that used to satisfy their normal daily communication needs such as an eye-tracking device with a generic AAC keyboard to test communication.
41139437|NCT05793866|BEHAVIORAL|BUTEYKO RESPIRATORY TECHNIQUE|Buteyko Breathing Technique In recent years, breathing exercises have been used as one of the non-pharmacological, alternative and/or complementary approaches in the management of many chronic diseases and conditions. Buteyko Breathing Technique (BST), Russian Dr. It was developed by Konstantin Buteyko in the 1950s. Dr. Buteyko evaluates the normal respiration over carbon dioxide, the respiratory holding time used in the technique is defined as a control pause, and this value shows the body's oxygenation and carbon dioxide tolerance. BST is a technique performed only through the nose, which includes respiratory control and respiratory hold after inhalation.
41139438|NCT06056726|PROCEDURE|BIB positioning|BIB positioning in obese patients with rectal cancer elegible for neoadjuvant therapy
41298408|NCT02143518|BIOLOGICAL|CpG 10104|Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
41298409|NCT01461031|DRUG|nefopam|nefopam infusion for postoperative 24 hours
41298410|NCT01461031|DRUG|normal saline (control)|normal saline infusion for postoperative 24 hours
41298411|NCT00392171|DRUG|Temozolomide|Subjects will receive temozolomide 50 mg/m\^2 for cycles of 28 days for 12 months or until progression
41298412|NCT06503302|DIAGNOSTIC_TEST|ultrasound Doppler function detection|Doppler function detection is an ultrasound technique that measures and visualizes blood flow within an object, such as vessels and soft tissue. It can be used to check for the inflammation status of calcifications by detecting blood flow around the calcified areas before performing an ultrasound-guided injection.
41298413|NCT04708145|DRUG|Aflibercept Injection|Intravitreal 2mg aflibercept injection
41298414|NCT00814073|DRUG|Masitinib|Masitinib 6 mg/kg/day
41298415|NCT00814073|DRUG|Placebo|Matching placebo
41298416|NCT00814073|OTHER|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.
41298417|NCT00921505|DRUG|Ibuprofen|Tablet ibuprofen 400 mg oral single dose (1 tablet)
41298418|NCT00921505|DRUG|Ibuprofen|Tablets (2 x 600 mg) oral single dose (2 tablets)
41298419|NCT00921505|DRUG|Paracetamol (acetaminophen) 1000 mg|Tablets (2 x 500 mg) oral single dose (2 tablets)
41298420|NCT00921505|DRUG|Paracetamol + ibuprofen|Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
41298421|NCT00755352|DRUG|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
41298422|NCT00755352|DRUG|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
41466527|NCT05457634|OTHER|Combustible Cigarette|Subjects smoke their Usual Brand Combustible Cigarette, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
41466528|NCT05457634|OTHER|blu Disposable A|Subjects use the blu disposable e-cigarette with flavor A, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
40769556|NCT06569979|OTHER|Survey|"The survey was developed using the Google Forms platform. The first part of the questionnaire consisted of descriptive information such as age, gender, duration of academic experience. In addition to this informations, the questionnaire also included information related the status of use ICF in any fields.~In the other part of the questionnaire, a total of 59 questions (16 related to body functions, 3 related to body structures, 30 related to activity and participation, 10 related to environmental factors) were asked to the academicians whether these categories are present in the amputee rehabilitation course content. Academicians were asked to answer yes or no to each question."
40972619|NCT03547687|DEVICE|Electrical Stimulation Treatment|"An Intelect Neuromuscular Electrical Stimulator (NMES) (Chattanooga Group) device will be used to provide the stimulation. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 5 seconds on, 15 seconds off Ramp up and down time: 2 seconds each"
40769557|NCT06498479|DRUG|HS-20093|HS-20093 will be administered as an IV infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle.
40769558|NCT06498479|DRUG|Topotecan|Topotecan will be administered per drug label.
40972620|NCT03547687|DEVICE|Neuromuscular Electrical Stimulation Treatment|"If a muscle contraction is not produced with the Intelect NMES portable device, the Vectra Neo Clinical Therapy System (Chattanooga Group) device will be used instead. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 10 seconds on, 30 seconds off Ramp up and down time: 2 seconds each"
40972621|NCT01228760|DRUG|ASG-5ME|IV
40972622|NCT04740502|PROCEDURE|Parahtyroidectomy|Parathyroidectomy
40972623|NCT04925037|BEHAVIORAL|self-questionnaire to patients undergoing SpAax follow-up|On the occasion of a single visit in consultation or hospitalization, an anonymous self-questionnaire will be distributed to patients undergoing SpAax follow-up
40972624|NCT05135897|DEVICE|Electroconvulsive therapy|Treatment with Electroconvulsive therapy
40972625|NCT05135897|DEVICE|rTMS|repetitive Transcranial Magnetic Stimulation
40972626|NCT03742934|OTHER|Short peptide|Short peptide formula during bowel preparation
40972627|NCT03742934|OTHER|Liquid diet|Liquid diet during bowel preparation
40972628|NCT06136741|DRUG|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
40769559|NCT06557161|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
40769560|NCT06557161|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
40972629|NCT06136741|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
40972630|NCT00441883|DRUG|PF-03187207 and Latanoprost Vehicle|
40972631|NCT00441883|DRUG|Latanoprost 0.005% and PF-03187207 Vehicle|
41458767|NCT06217276|OTHER|Respiratory muscle fatigue protocol|It will be performed using a powerbreath device at 60% of the maximum inspiratory pressure (MIP) amount obtained by measuring mouth pressure. The protocol includes 7 sets consisting of 2 minutes of inspiratory effort and 1 minute of rest. To further confirm the occurrence of fatigue, the patient will score fatigue using the modified Borg scale, and the score will be 5 or above11. During the application, heart rate, blood pressure and peripheral oxygen saturation will be monitored. The measurement will be performed once for each case.
40769561|NCT06557161|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
40769562|NCT04172220|DRUG|Midazolam|1-2 mg of Midazolam as premedication.
40972632|NCT05306938|BEHAVIORAL|Adolescent Wellness Visit|Adolescent Wellness Visits (AWVs) are a new health service platform for reaching young adolescents with HTC and other evidence-based prevention services which are clinic-based and school-facilitated. The AWVs bundle the following health screenings, education, and counseling on: nutrition, vision, dental, mental health (depression), contraception, sexually transmitted infections, and optional HIV testing.
40972633|NCT05850572|DRUG|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
40990820|NCT01680718|DRUG|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
41139439|NCT06031714|OTHER|Saliva sampling|HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.
40769563|NCT04172220|PROCEDURE|PECS|"Loco-regional anesthesia: PEC I and serratus plane block with an echoguided technique.~For the PEC I: infiltration of 10 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of the pectoralis major muscle and the small pectoralis muscle at the height of the third rib on the anterior axillary line.~For the serratus plane block: identification of the fifth rib on the average axillary line and infusion of about 20 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of large dorsal muscle and of the anterior serratus muscle."
40769564|NCT04172220|PROCEDURE|Opioid-free general anesthesia|"Induction with Propofol 1.5-2 mg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in Target-Controlled Infusion (TCI) of 6 mcg/ml, subsequently modified to maintain a Bispectral Index (BIS) value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
40972634|NCT05850572|OTHER|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
40972635|NCT01488682|PROCEDURE|Neck dissection with Harmonic scalpel|The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
41298423|NCT00369434|DRUG|Desvenlafaxine succinate sustained-release (DVS SR)|
41298424|NCT00431860|PROCEDURE|Coronary computed tomographic angiography|
41298425|NCT01646008|OTHER|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
41298426|NCT01646008|OTHER|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
41298427|NCT03960710|OTHER|Anonymized CT examinations|The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.
40972636|NCT01488682|PROCEDURE|neck dissection with conventional hand-tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
41298428|NCT03960710|OTHER|Training (1)|"An initial training phase of the artificial intelligence network will be carried out :~- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals"
41298429|NCT03960710|OTHER|Training (2)|"An initial training phase of the artificial intelligence network will be carried out :~- Use of computer data to drive the artificial intelligence network."
41298430|NCT03960710|OTHER|Validation (1)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by an intern at the Lyon hospitals"
41298431|NCT03960710|OTHER|Validation (2)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by the neural network"
41298432|NCT03569111|DEVICE|Bronchoscopic ablation catheter|The Emprint™ Ablation Catheter Kit with Thermosphere™ Technology is deployed endoscopically and will be used to conduct bronchoscopic ablations in the lung using the superDimension™ navigation system.
41298433|NCT06263426|OTHER|HIV D+/R+|Receipt of kidney transplant from a deceased donor with HIV.
41298434|NCT06263426|OTHER|HIV D-/R+|Receipt of kidney transplant from a deceased donor without HIV.
40972637|NCT05403905|PROCEDURE|non surgical treatment|Conservative treatment is required to use a curved splint for 6 weeks to keep the feet on the ground, bathing and sleeping without loosening the utensils and taking no steroids during the period. Physical examination and magnetic resonance imaging were performed after 6 weeks. If laxity remained unsatisfactory, the outcome was recorded as failure and surgery was changed.
40972638|NCT05403905|PROCEDURE|surgical treatment|The patient underwent knee arthroscopic anterior cruciate ligament surgery at the Institute of Sports Medicine of the Third Hospital of Peking University. The surgical methods were all anatomical single-bundle.
40769565|NCT04172220|PROCEDURE|General anesthesia|"Induction with Propofol 1.5-2 mg/kg; Fentanyl 1μg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in TCI of 6 mcg/ml, subsequently modified to maintain a BIS value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
40972639|NCT02383277|OTHER|Stretching|Stretching of the rib cage muscles
40769566|NCT04172220|PROCEDURE|Postoperative analgesia|Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS\>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.
40972640|NCT02383277|OTHER|Control|Rest without stretching (sham)
40972641|NCT02383277|OTHER|Exercise|Constant load exercise on a bike
40769569|NCT04581577|OTHER|Semi-structured telephone questionnaire|Semi-structured telephone questionnaire
40769572|NCT06296225|DEVICE|Vibration|"Grip strenght measurement will always be done in the same way : for each series, 3 measurements of maximum strength will be taken for each side. Participants will receive verbal encouragement.~After initial both sides grip strength evaluation, all participant will first experiment the vibration situation using the device Vibramoov Physio (TechnoConcept, Manosque, France): the vibrations had a frequency of 100Hz, with an amplitude of 2mm, they will be applied to the anterior part of the forearm for 10 minutes, 3 times. At the end of each 10 minutes vibration session, handgrip strength will be assessed.~* Participants then have a one-hour rest period.~* Control situation: participants will have 4 series of grip strength measurements every 10 minutes.~At the end of the 2 hours, the patient will be discharged from the study protocol."
40972642|NCT02208557|PROCEDURE|Reinforcement with Absorbable Mesh|
40972643|NCT02208557|RADIATION|Control CT|"At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure."
40972644|NCT02208557|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
40769573|NCT06517043|BEHAVIORAL|Balance Training|Complex balance task involving static and dynamic weight shifting and coordinated stepping
40769574|NCT06517043|DEVICE|Spinal Active tsDCS|Active tsDCS over lumbar regions
40769575|NCT06517043|DEVICE|Spinal Sham tsDCS|Sham tsDCS over lumbar regions
40769576|NCT05821205|BEHAVIORAL|Narrative Persuasion|Narratives will use anonymous testimonials from our prior work combined with open-source pictures. The researchers will ask participants to rate the testimonial message as a measure of engagement.
40769577|NCT05821205|BEHAVIORAL|Reciprocity|Researchers will track clicking on the gift card as a measure of engagement
40769578|NCT05821205|BEHAVIORAL|Personalized Feedback|Researchers will track clicking on a link and/or opening to review visual data as a source of engagement.
40769579|NCT05821205|BEHAVIORAL|Commitment|Providers will receive a commitment message and be asked to reply as a measure of engagement.
40769580|NCT06088667|OTHER|Fascial mobilization group|In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments for 4 weeks.
40769581|NCT02730169|DRUG|BGS649|Capsules were taken weekly for a maximum of 24 weeks
40769582|NCT02730169|DRUG|Placebo|Capsules were taken weekly for a maximum of 24 weeks
40972645|NCT02870582|DRUG|Donafenib|treatment drug
40972646|NCT02870582|DRUG|Placebo|Best support treatment
40972647|NCT00076284|DRUG|GW873140|
40972648|NCT05660551|OTHER|Demostration|This group will be demonstrated on a model after the theoretical training. The maneuvers used in the management of shoulder dystocia will be shown to the students on the model, respectively.
40972649|NCT05660551|OTHER|Telesimulation|After the theoretical training for this group, telesimulation will be applied. A scenario will be created for the telesimulation experience and a video will be shot with this scenario. These videos will be watched by the students in groups of 4 on Microsoft Teams and a case discussion will be made through this scenario.
40972650|NCT05660551|OTHER|Kahoot Game|Kahoot, a game-based program, will be applied to this group one week after the theoretical training. The game will be organized according to the learning objectives and achievements related to shoulder dystocia.
40972651|NCT01938677|RADIATION|Initial Gamma knife radiosurgery|
40972652|NCT05989763|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
40972653|NCT05989763|DEVICE|Sham-TEA|Sham TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
40972654|NCT02134795|DEVICE|TNM (trade name), a form of brainstem Stimulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes. The stimulation is non-invasive and non-electrical. The form of stimulation acts on the brainstem.
40972655|NCT04988646|DRUG|Acyclovir 200 MG|Administered with 240 mL of water
40972656|NCT04988646|DRUG|Acyclovir 400 MG|Administered with 240 mL of water
40972657|NCT04988646|DRUG|Zovirax 200 MG Tablet|Administered with 240 mL of water
40972658|NCT04988646|DRUG|Zovirax 400 MG Tablet|Administered with 240 mL of water
40972659|NCT03902821|OTHER|XR-NTX and Certified Recovery Mentor|All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.
41298435|NCT01284322|DRUG|Fresolimumab|intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
41298436|NCT03517046|DRUG|CartiLife|Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.
41298437|NCT05764798|DRUG|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
41298438|NCT05764798|DRUG|Control group: Placebo combined with zolpidem|Placebo and zolpidem orally for 8 consecutive weeks
41298439|NCT00538382|DRUG|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
41298440|NCT05005559|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
40769583|NCT05013138|BEHAVIORAL|Training for ACEs and study procedures|"The providers will lead a resilience-based conversation discussion regarding the impact of caregiver ACEs, after receiving training for ACEs and study procedures.~The first training component will provide an overview of ACEs using the ACE Interface Training. The second training component will address the implementation of the caregiver ACEs screening in the clinic."
40972660|NCT01033591|BEHAVIORAL|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
40972661|NCT01033591|BEHAVIORAL|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
41298441|NCT05005559|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
40972662|NCT02820272|PROCEDURE|NPWT with cold water|Each of dressing change would be treated with NPWT and injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change
40972663|NCT02820272|PROCEDURE|NPWT with normal saline room temp|Each of dressing change would be treated with NPWT and injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change
41298442|NCT00633828|BEHAVIORAL|Increased physical education in primary school (daily)|Increased physical education in primary school, 40 minutes per day
41298443|NCT05949814|DIAGNOSTIC_TEST|acceptability of a PrEP program among HIV-negative MSM and TG|STI screening by rapid tests and self-sampling after contact on a geolocated community application or a community physical place of sociability
40972664|NCT02820272|PROCEDURE|NPWT without other intervention|Each of dressing change would be treated with NPWT without injection of any liquids into sponge before dressing change
40972665|NCT04348734|DIAGNOSTIC_TEST|pleural ultrasound|Patients will benefit from a daily pleural ultrasound for 96 hours, D1 being the day of hospitalization. The therapeutic course of action will depend on the presence or not, and on the type of pleural effusion according to a pre-established algorithm
41298444|NCT03160404|DRUG|Zolpidem|The ZOLPIDEM group will be treated with zolpidem 10mg/night
41298445|NCT03160404|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
41298446|NCT01823822|DIETARY_SUPPLEMENT|Oral protein supplement (Tested product)|Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
41298447|NCT01823822|DIETARY_SUPPLEMENT|Iso-caloric supplement (Control product)|Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
40972666|NCT02707510|OTHER|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
40972667|NCT01779102|BIOLOGICAL|C-Tb|C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
40769584|NCT05013138|BEHAVIORAL|Training on study procedures|Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination.
41298448|NCT01201369|DEVICE|Coronary Stent Cypher|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols.
41298449|NCT01201369|DEVICE|Coronary stent Xience|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols
41298450|NCT03670082|DRUG|Lu AF35700|20 mg Lu AF35700 single oral dose
40769585|NCT04470037|DRUG|DAAOI-P|DAAOI-P 250-1500mg
41298451|NCT03670082|DRUG|Lu AF35700 iv|100 μg \[14C\]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
41139440|NCT06031714|OTHER|Blood sampling|"Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,~The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out."
41298452|NCT04239235|BEHAVIORAL|CRAFT|CRAFT is an evidence-based and non-confrontational approach for teaching friends/family members strategies to help their loved one reduce/refrain from using substances. It focuses on improving the lives of both the friends/family members and the individual struggling with substance use.
41298453|NCT06554301|DRUG|empagliflozin in treatment pulmonary aerterial hypertension|On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.
41298454|NCT06554301|DRUG|placebo in treatment pulmonary aerterial hypertension|On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.
41139441|NCT06031714|OTHER|Interviews|V2 and/or V3
41298455|NCT05146232|OTHER|induction of anesthesia|induction of anesthesia during gastric sleeve surgery
41298456|NCT05146232|OTHER|maintainance of anesthesia|maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based
41298457|NCT05146232|OTHER|monitoring|electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.
41298458|NCT05146232|OTHER|First postoperative analgesia|IV acetaminophen will be administered every 6 h
41298459|NCT05146232|OTHER|Second postoperative analgesia|50 mg IV dexketoprofen every 8 h for the first 48 h.
41298460|NCT05480137|PROCEDURE|NSE scoring balloon and plain balloon angioplasty|Using NSE scoring balloon or plain balloon in BPA surgery.
41298461|NCT00235729|DRUG|Lofexidine|Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
41298462|NCT00235729|DRUG|Placebo|Placebo is an exact match of lofexidine, less the active ingredient.
41298463|NCT00834002|BIOLOGICAL|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
41298464|NCT00625066|OTHER|biologic sample preservation procedure|
41298465|NCT00625066|OTHER|cytology specimen collection procedure|
41298466|NCT00625066|OTHER|medical chart review|
41298467|NCT00625066|OTHER|questionnaire administration|
41298468|NCT00625066|OTHER|survey administration|
41298469|NCT00625066|PROCEDURE|biopsy|
41298470|NCT00625066|PROCEDURE|evaluation of cancer risk factors|
41298471|NCT00625066|PROCEDURE|screening colonoscopy|
41298472|NCT01901471|DRUG|Single bolus of Placebo of CicloMulsion® (Neurovive).|"The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
41139442|NCT06031714|OTHER|Clinical examination|V2 and/or V3
41298473|NCT01901471|DRUG|Single bolus of cyclosporine A (CicloMulsion®, Neurovive)|"The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).~Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.~CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.~CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
41298474|NCT00511589|OTHER|chagas disease diagnostic|
41298475|NCT02758886|BEHAVIORAL|Animal assisted activity|Allowed to interact (e.g. talking, petting, scratching, feeding treats, playing with) live animals
41298476|NCT02758886|BEHAVIORAL|Animal photos|A 10 minute, silent, PowerPoint slide show of a variety of dogs and cats
41298477|NCT02758886|BEHAVIORAL|Observing human-animal interaction|Participants watched others participate in petting dogs and cats, while they waited in line for 10 minutes. Participants did not physically touch any animals during this time.
41298478|NCT05898503|BEHAVIORAL|Walking exercise + resistance training|Walking exercise and resistance training for 12 weeks
41298479|NCT05898503|BEHAVIORAL|Resistance training|Resistance training for 12 weeks
41298480|NCT05898503|BEHAVIORAL|Walking exercise|Walking exercise for 12 weeks
41298481|NCT05898503|BEHAVIORAL|Health promotion|Health promotion for 12 weeks
41298482|NCT02971696|DRUG|Sorafenib|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
41298483|NCT02971696|DRUG|Best Supportive care|Liver Support, pain management
41298484|NCT00004697|DRUG|choline chloride|
41466529|NCT05457634|OTHER|blu Disposable B|Subjects use the blu disposable e-cigarette with flavor B, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
40769586|NCT04470037|DRUG|Placebo|starch pill
40769587|NCT06291987|DRUG|Ivosidenib|Ivosidenib will be given at assigned dose once daily.
40769588|NCT06291987|DRUG|Ruxolitinib|Ruxolitinib will be given at assigned dose twice daily.
40769589|NCT04733079|OTHER|Cleanweb electronic messaging ePro|Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
41139443|NCT02773082|DEVICE|Reclaim™ DBS Therapy|DBS is indicated for bilateral stimulation of the ventral anterior limb of the internal capsule as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.
41139444|NCT02954783|BEHAVIORAL|High Intensity Interval Training|"Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
40769590|NCT04733079|OTHER|Usual follow-up|Adaptation and follow-up of ULT according to referring physician's habits
40769591|NCT05338268|BEHAVIORAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth.
40769592|NCT05338268|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
40972668|NCT01779102|BIOLOGICAL|Tuberculin PPD RT 23 SSI|Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
40972669|NCT01779102|BIOLOGICAL|C-Tb / Tuberculin PPD RT 23 SSI|The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
41466530|NCT05457634|OTHER|blu Disposable C|Subjects use the blu disposable e-cigarette with flavor C, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
40769593|NCT06639178|OTHER|DECLARAN cream|Patients will apply 1 mL of DECLARAN cream, as a single pressure dispensing (1 for hands, 1 for feet), 2 times/day on hands and feet, starting 3 days before the beginning of treatment with capecitabine and for the first 24 consecutive weeks of treatment.
40769594|NCT05932914|PROCEDURE|Liver Biopsy|Standard transjugular liver biopsy under moderate sedation
40972670|NCT04086862|PROCEDURE|Therapeutic ultrasound|A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm\^2 and 100% duty cycle sequentially to each masseter muscle.
40972671|NCT03762824|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccination during antirheumatic treatment
40769597|NCT05789290|DEVICE|Hilotherm cryocompression device|An electronic device that is capable of circulating warm or cooled water at a user-selected temperature between 10-30℃. Water is circulated from a central unit, through a tube, to a cuff wrapped around the intended therapy area (the knee). A treatment lasts for 30-minutes, at which point the device is turned off and the cuff is removed from the limb of the user.
40769598|NCT05009069|RADIATION|Radiotherapy|Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
40769599|NCT05009069|DRUG|Capecitabine|Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.
40769600|NCT05009069|DRUG|Fluorouracil|Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
40972672|NCT03762824|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccination during antirheumatic treatment
41139445|NCT02954783|BEHAVIORAL|Usual Care Observational Control|The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
41139446|NCT02761499|DEVICE|U-Motion II+ Acetabular System|U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
41298485|NCT04509492|DIAGNOSTIC_TEST|Endoscopic ultrasound ( EUS )|"- EUS will be done to all patients. During EUS examination the liver will be examined thoroughly to detect hepatic focal lesions with possible EUS-FNA of any detected lesions.~All EUS examination will being done by EUS linear array Echoendoscope, Pentax EG-3870UTK attached to Hitachi Avius US machine under Propofol deep sedation"
40769601|NCT05009069|DRUG|Atezolizumab|Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
40769602|NCT05009069|DRUG|Tiragolumab|Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
40769603|NCT03048825|DRUG|Colchicine|Colchicine 0.5 mg once daily
40769604|NCT03048825|DRUG|Spironolactone|Spironolactone 25 mg once daily
40972673|NCT06065995|DEVICE|StoMakker|A mobile application that offers age dependent information, a peer support platform and a game
41298486|NCT06175312|OTHER|Stimulus properties: salience-defining feature|The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)
41298487|NCT06175312|OTHER|Stimulus properties: magnitude of salience|The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
41298488|NCT04536415|DRUG|Oseltamivir Phosphate 75 mg capsules|Capsules, 75 mg, single, oral dose
41298489|NCT04536415|DRUG|Tamiflu capsules 75 mg|Capsules, 75 mg, single, oral dose
40990821|NCT01680718|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
40769605|NCT03048825|DEVICE|SYNERGY Bioabsorbable Polymer Drug-Eluting Stent|Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
40769606|NCT03048825|DRUG|Colchicine-Placebo|Matching Colchicine-placebo once daily
41298490|NCT01744847|DEVICE|Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide|one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
41298491|NCT03053089|DRUG|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
41298492|NCT00504166|DRUG|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
40769607|NCT03048825|DRUG|Spironolactone-Placebo|Matching Spironolactone-Placebo once daily
40769608|NCT00001465|DEVICE|Toshibia Aquilion One CT|The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
40769609|NCT00285194|DRUG|Allogeneic Islets of Langerhans|
40769610|NCT00285194|DRUG|hOKT3γ1 (Ala-Ala)|
40769611|NCT05665452|PROCEDURE|Patellar mobilization, retinacula release, deep friction message, stretch and strength|"All exercises will be performed for 30 to 45 minutes per session, 3 times per week for 4 weeks (12 sessions). Group (1): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise).~Group (2): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise). manual therapy consists from iliotibial band release, deep friction message for lateral retinacula and medial patella mobilization."
40769612|NCT06373120|DEVICE|CorVad|The CorVad percutaneous ventricular assist system device is a microaxial rotary blood pump that expels blood from the left ventricle into the ascending aorta, thus unloading the left ventricle. The CorVad system device can be introduced through a femoral percutaneous approach (14Fr) and can deliver an output of up to 4-6 L/min.
40769613|NCT06373120|DEVICE|VA-ECMO|Veno-arterial extracorporeal Membrane Oxygenation (VA-ECMO) is a device originally created to replace heart and lung function. Venous deoxygenated blood is mechanically suctioned from a large central vein through a venous cannula by a centrifugal pump. It is then oxygenated, warmed, and restored into systemic circulation through an arterial cannula.
40769614|NCT06470048|DRUG|Placebo|Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol
40769615|NCT06470048|DRUG|Ianalumab|subcutaneous (s.c.) injection as defined in the protocol
40972674|NCT06331416|DEVICE|Telemonitoring|Patients will be asked to carry out one measurement (arterial pressure, oxygen saturation, body temperature, heart rate, spirometry) every 24 hours for 90 days. The system will be supplied by the company Vivisol. The telemonitoring data will be read once a day and the principal investigator will be alerted in case of alteration of any parameter. If vital parameters remain stable, a phone call will be performed every 5 days. In case of compromise of any parameter, the patient will be offered a phone call within the same day. In case of new occurrence of any respiratory or non-respiratory symptoms, the patient must contact the principal investigator and he will be offered a phone call or a video-assisted call within the same day. If the alterations or symptoms persist for 24 hours, or in any case upon decision of the investigator in charge, the patient will be offered an in-person evaluation in the same day. If deemed necessary according to usual care, the patient will be hospitalized.
40972675|NCT01328925|DRUG|Nitazoxanide|"Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days"
40972676|NCT05855252|OTHER|No intervention|No intervention
40972677|NCT04800705|OTHER|ultrasound assessment|Zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) measurements (µg/L,mean±SD)
40972678|NCT00468182|DRUG|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
40972679|NCT05708287|DEVICE|HFNC|The patients with mild hypoxemia, defined as the need for conventional oxygen therapy (COT) using nasal cannula at 4-5 liters per minute (LPM) to maintain O2 Saturation \>90%, were commenced on HFNC therapy
40972680|NCT06507319|DEVICE|Direct bone anchored pull distal slider|distalization from the palatal side only.
40769616|NCT06063876|PROCEDURE|Induction of experimental peri-implant mucositis|Patients will refrain from oral hygiene measures at the implant sites for 3 weeks to induce peri-implant mucositis, by using a stent in the included implant during oral hygiene.
40769617|NCT06063876|PROCEDURE|Resolution of experimental peri-implant mucositis|Patients will reinstitute oral hygiene measures, receive an oral prophylaxis and oral hygiene instructions and will be evaluated during 3 weeks.
40769618|NCT05044845|BEHAVIORAL|Interview|Semi structured interview will be conducted virtually using an online video-conferencing platform, phone or in person.
40769619|NCT06045078|OTHER|Elequil Lavender-peppermint Aromatabs|100% pure essential oils Lavender-peppermint aromatabs purchased through Beekley Medical
40769620|NCT06045078|OTHER|Elequil Almond-Oil Aromatabs|100% pure essential oils Almond-oil aromatabs purchased through Beekley Medical
40769621|NCT00427830|BIOLOGICAL|MVA85A|
40769622|NCT04863664|DEVICE|Defibrillation (RV Implant)|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
40769623|NCT04863664|DEVICE|Defibrillation (LBBAP Implant)|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
40972681|NCT06507319|DEVICE|Indirect bone anchored dual force distalizer.|distalization from the palatal and buccal sides.
40972682|NCT02362217|BIOLOGICAL|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
40972683|NCT02362217|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
41139447|NCT05479565|DIAGNOSTIC_TEST|venous blood sample for determining the value of highly sensitive C-reactive C protein from serum|The non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness. In a quiet room at room temperature, the subjects will lie relaxed for 15 minutes before the start of the measurement. After that, the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, will be measured with a gynecological compass, and the resulting value will be entered into the device.
41139448|NCT00022165|DIETARY_SUPPLEMENT|selenium|
41298493|NCT00504166|OTHER|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
40769624|NCT03610698|BEHAVIORAL|LEAF Positive Emotion Intervention|5-week online intervention teaching 8 positive emotions skills for caregivers
40769625|NCT03610698|OTHER|Emotion Reporting Control Condition|Daily reporting of emotions for participants assigned to the control condition.
40769626|NCT06637215|PROCEDURE|laparoscopic colorectal day surgery|laparoscopic colorectal day surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
40769627|NCT06637215|PROCEDURE|traditional laparoscopic colorectal surgery|traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
40769628|NCT05686122|BEHAVIORAL|PainPac|Patient-focused behavioral pain intervention delivered via mobile application.
40769629|NCT00179686|DRUG|CC-5013|
40769630|NCT06567392|DRUG|[14C] HRS-5965|Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.
40769631|NCT05900388|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain
40769632|NCT05900388|DRUG|Standard of care (SOC)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
40769633|NCT06616155|PROCEDURE|Biopsy|Undergo tissue biopsy
40769634|NCT06616155|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40769635|NCT06616155|PROCEDURE|Bone Scan|Undergo bone scan
40769636|NCT06616155|PROCEDURE|Computed Tomography|Undergo CT
40769637|NCT06616155|DRUG|Enzalutamide|Given PO
40769638|NCT06616155|DRUG|Ruxolitinib|Given PO
40769639|NCT01840072|OTHER|Active antihypertensive treatment|Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
40769640|NCT03549325|BIOLOGICAL|Neisseria lactamica|Colonisation by bacteria is an immunising event; we proved this in humans by inoculating university students intranasally with the harmless commensal N. lactamica and we observed both specific systemic and mucosal antibody responses by 4 weeks. Experimental challenge with defined bacteria could tease out the Th17-mediated response mechanisms, which include waning of immunity over time, the induction of an incorrectly polarised T cell response, lack of cross-reactivity between strains or active immune evasion mechanisms employed by bacteria to subvert host immune effector mechanisms.
40972684|NCT02362217|BIOLOGICAL|ChAdV63.HIVconsv|Genetic vaccine against HIV-1 infection
40972685|NCT02362217|BIOLOGICAL|MVA.HIVconsv|Genetic vaccine against HIV-1 infection
40972686|NCT04954274|DRUG|Cyclic peptide Fertiline|"Upon retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCC-M medium supplemented with the molecule.~After ICSI, the zygote will be incubated in CSCM-C medium supplemented with the peptide."
40972687|NCT06242951|DIAGNOSTIC_TEST|VO2 max assessment|Measurement of the maximum oxygen consumption (VO2max) by a cardiopulmonary exercise test (CPET)
40972688|NCT06379477|PROCEDURE|Refractive surgeries|after primary phacoemulsification surgery any resulting refractive error surprises will be corrected with different refractive surgery options
40972689|NCT05539352|BEHAVIORAL|Problem Solving Therapy (PST) plus EUC|"All caregivers are assigned to this condition and receive EUC and PST. EUC is delivered along with the treatment to ensure the safety of all caregivers enrolled in the study. In addition to EUC, caregivers receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by caregivers and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress."
41298494|NCT05886647|OTHER|Active non-invasive stimulation and inspiratory muscle training|Simultaneously with the current application, the patient will perform inspiratory muscle training (IMT) by KH2; PowerBreathe International Ltd. UK along with a feedback Breathelink, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI.
40769641|NCT05576337|OTHER|16 weeks of strength training protocol|16 weeks of strength training protocol
40769642|NCT05817110|OTHER|Participant Cohort|Patients coming to the facility for chest x-rays for any reason, will undergo x-rays as ordered by their treating clinician. In case of any nodule detection by qXR, it will be classified either as low-risk (Lung nodule malignancy score ) LNMS or high-risk LNMS confirmed by radiologist. Then if patient is eligible will be included in the study and a CT Scan will be requested upon enrolment of the patient.
40769643|NCT00159445|DRUG|gemcitabine, capecitabine|
40769644|NCT06583655|RADIATION|SLND(clinical low risk)|treated with whole breast irradiation(WBI)alone 50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx or no PMRT
40769645|NCT06583655|RADIATION|SLND(clinical high risk, genomic low risk)|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
40972690|NCT05376124|OTHER|original therapy|* Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
41298495|NCT05886647|OTHER|Sham compatorator and inspiratory muscle training|As for the patients allocated in the control group, they will receive the HD-tDCS sham for 20 minutes associated with IMT, following for the same training, duration and load increment used in the experimental group.
40972691|NCT05376124|OTHER|rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
41139449|NCT02530892|PROCEDURE|EmbryoHug|"An oocyte or embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the oocyte or embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity. The term micropipette aspiration refers to the pressure applied to the edge of the embryo -- this procedure is not invasive and does not involve any sort of puncture or removal of material from the oocyte or embryo."
41139450|NCT02148120|DRUG|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg|
41139451|NCT02148120|DRUG|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg|
41458768|NCT03161353|DRUG|Perjeta|All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.
41458769|NCT03161353|DRUG|Herceptin|All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.
41458770|NCT03161353|DRUG|Docetaxel|Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin
40972692|NCT06243263|DRUG|Bupivacain|At the end of the surgery, after wound closure, an inferior alveolar nerve block with 2ml bupivacaine 0,5 % will be realized.
41139452|NCT02148120|DRUG|Placebo|
41139453|NCT01407874|DRUG|Placebo|Oral dose administered daily for 84 days.
40769646|NCT06583655|RADIATION|SLND alone ,clinical high risk and genomic high risk group|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node Irradiation+ axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
41139454|NCT01407874|DRUG|Ulodesine (BCX4208) 5 mg|Oral dose administered daily for 84 days.
41139455|NCT01407874|DRUG|Ulodesine (BCX4208) 10 mg|Oral dose administered daily for 84 days.
41139456|NCT00687297|DRUG|vandetanib induction|100 mg daily by mouth
41139457|NCT00687297|DRUG|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
41139458|NCT00687297|DRUG|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
41298496|NCT00958568|DRUG|Olanzapine and Fluoxetine combination (OFC)|"Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.~Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.~Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks."
41458771|NCT03161353|DRUG|Carboplatin|Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.
41139459|NCT00687297|DRUG|Placebo|
41139460|NCT00687297|DRUG|Vandetanib maintenance|300 mg daily by mouth
40972693|NCT01785550|OTHER|Ultrasound of nerve and muscle|Ultrasound of 6 muscles and 2 nerves will be performed.
41139461|NCT00264888|DRUG|PTC124|
41139462|NCT00407888|DRUG|doxorubicin hydrochloride|Given IV
41139463|NCT00407888|DRUG|cyclophosphamide|Given orally
41139464|NCT00407888|BIOLOGICAL|filgrastim|Given SC
41139465|NCT00407888|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
41139466|NCT00407888|BIOLOGICAL|trastuzumab|Given IV
41139467|NCT00407888|OTHER|laboratory biomarker analysis|Correlative studies
41139468|NCT00407888|PROCEDURE|quality-of-life assessment|Ancillary studies
41139469|NCT01029704|DRUG|EGT0001442|"Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.~Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days."
41139470|NCT01029704|DRUG|Placebo capsules to match EGT0001442|"Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days."
41139471|NCT01047709|DEVICE|Positional therapy including the use of a special pillow|Avoidance of supine sleep via a special pillow and other measures.
41298497|NCT00958568|DRUG|Fluoxetine|25 or 50 mg/day fixed dosing for 27 weeks
41298498|NCT04715724|OTHER|Positioning and Attachment video-based simulation (telesimulation)|Participants will teach a standardized patient actor (SP) to position and attach the baby doll at the breast of the Lactation Simulation Model in a video-based simulation (telesimulation)
41298499|NCT03170336|DRUG|Amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
41298500|NCT03170336|DRUG|Hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
41298501|NCT03819283|DIAGNOSTIC_TEST|Hepatic evaluation|Evaluation of hepatic steatosis and fibrosis by non invasive tests, either serum markers (steatotest, Fibrotest) or imaging methods (CAP, FibroScan)
41298502|NCT00731445|DRUG|Z-208|Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
41139472|NCT03489811|OTHER|Test Essential Oil Blend|The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
41139473|NCT03489811|OTHER|Active Essential Oil Blend|The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
41139474|NCT03489811|OTHER|Control Blend|The control blend consists of inert vegetable oils which are produced from plant matter.
41139475|NCT02840045|DEVICE|high-density electroencephalography|Musical stimulation during electroencephalography recording
41298503|NCT05951153|COMBINATION_PRODUCT|Tributyrin|Tributyrin is a nutritional supplement prepared by esterification of glycerin with butyric acid that promotes delivery of free butyrate to distal portions of the gut.
41298504|NCT05365451|DRUG|MetFORMIN Oral Solution|liquid
41298505|NCT05365451|DRUG|Cimetidine 400 MG|tablet
41298506|NCT05365451|DRUG|Furosemide Oral Liquid Product|oral solution
41298507|NCT05365451|DRUG|Probenecid 500 MG|tablet
41298508|NCT01423240|DRUG|Lurasidone 20 mg|Lurasidone 20 mg once daily orally in the evening
41298509|NCT01423240|DRUG|Lurasidone 60 mg|Lurasidone 60 mg once daily orally in the evening
41298510|NCT01423240|DRUG|Placebo|Placebo once daily orally in the evening
41298511|NCT04982549|DRUG|Durvalumab|Durvalumab (intravenous infusion)
41298512|NCT04982549|DRUG|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
40769647|NCT06583655|RADIATION|Sentinel Lymph Node Dissection(SLND) + axillary lymph node dissection(ALND)|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
40972694|NCT03912155|OTHER|Multi-scale analysis of physiological brain networks|It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
40769648|NCT06081920|BIOLOGICAL|IBI363|IBI363 monotherapy
40972695|NCT01896544|DIETARY_SUPPLEMENT|Cholecalciferol|7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
40972696|NCT01896544|DIETARY_SUPPLEMENT|Placebo|7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
40972697|NCT00282594|DRUG|Novolin R (human recombinant Insulin)|
40972698|NCT06507891|DRUG|TQ-A3334 tablets|TQ-A3334 is a highly efficient and highly selective Toll-like receptor-7 (TLR-7) agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including interferon alpha (IFN-α), Interleukin 12 (IL-12), Tumor Necrosis Factor Alpha (TNF-α), and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
40972699|NCT06507891|DRUG|TQ-A3334 tablets + Anlotinib capsules|"TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
40972700|NCT02568085|DEVICE|Arista|Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
40972701|NCT05729659|DIETARY_SUPPLEMENT|Sideritis Scardica (SidTea+) extract supplementation|1500 mg of Sideritis Scardica (SidTea+) extract per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
41298513|NCT04982549|DRUG|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
40972702|NCT05729659|DIETARY_SUPPLEMENT|Placebo supplementation|1500 mg of placebo per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
40972703|NCT03502044|DEVICE|Inactive Kinetic Oscillation Stimulation (KOS)|10 minutes inactive KOS treatment in each nasal cavity.
40972704|NCT03502044|DEVICE|Active Kinetic Oscillation Stimulation (KOS)|10 minutes active KOS treatment in each nasal cavity.
40972705|NCT01118702|DRUG|Ritalin-SR|3-20mg tablets, once
40972706|NCT01118702|DRUG|Concerta|one 54mg tablet, once
40972707|NCT01118702|DRUG|Novo-Methylphenidate ER-C|one 54mg tablet, once
40972708|NCT02652520|PROCEDURE|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
40972709|NCT03508921|DRUG|Periprocedural Antibiotics|"One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection."
41298514|NCT04982549|DRUG|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
41298515|NCT04982549|RADIATION|Radiation|5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
40769649|NCT05375929|DRUG|Abrocitinib 100 mg|Orally administered, abrocitinib 100 mg tablets QD
40972710|NCT03508921|DRUG|Extended Antibiotics|"Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only."
40972711|NCT03508921|PROCEDURE|Injection of OnabotulinumtoxinA (BTX-A)|Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
41298516|NCT01465178|DIETARY_SUPPLEMENT|cholecalciferol|2000 IU cholecalciferol gelcaps by mouth daily
41298517|NCT01465178|DIETARY_SUPPLEMENT|Placebo|matching placebo
40769650|NCT05375929|DRUG|Abrocitinib 200 mg|Orally administered, abrocitinib 200 mg tablets QD.
41298518|NCT04446143|BEHAVIORAL|Mindfulness meditation|Mindfulness meditation
41298519|NCT01261728|DRUG|Gemcitabine and Cisplatin|Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
41298520|NCT00380354|DRUG|GSK256066|
41458772|NCT03161353|DRUG|Letrozole|Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
40769651|NCT02671292|BEHAVIORAL|Interpersonal Psychotherapy|IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.
40769652|NCT02671292|OTHER|Health Education|"The HE group is based upon the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex."
40769653|NCT02055339|DEVICE|Fisher & Paykel heated humidified high flow nasal cannula|
40769654|NCT02055339|DEVICE|InfantFlow/RAM nasal continuous positive airway pressure|
40769655|NCT04977986|DRUG|ZYN002 - transdermal gel|Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
40769656|NCT04977986|DRUG|Placebo|"Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)~Other Names:~Placebo Comparator Matching Placebo"
40769657|NCT02719509|PROCEDURE|Cardiac Ultrasound|
40769658|NCT00643656|DRUG|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
40769659|NCT00643656|DRUG|Mix of 50% oxygen and 50% nitrogen|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
40769660|NCT01334879|DRUG|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
40769661|NCT00750399|DRUG|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
40769662|NCT00750399|DRUG|ranibizumab|intravitreal ranibizumab 0.5 mg
40769663|NCT04839640|OTHER|Bredent denture teeth|composite resin denture teeth
40769664|NCT05942222|BIOLOGICAL|dupilumab|Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.
40769665|NCT05942222|BIOLOGICAL|mepolizumab|Subcutaneus injections in standard doses, i.e. 100 mg s.c. every 4 weeks.
40769666|NCT06303518|OTHER|High normal ETCO2: ETCO2 50 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'High Normal ETCO2' (50 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
40769667|NCT06303518|OTHER|Normal ETCO2: ETCO2 40 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'Normal ETCO2' (40 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
40769668|NCT06303518|OTHER|Low Normal ETCO2: ETCO2 30 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'Low Normal ETCO2' (30 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
41139476|NCT04393571|OTHER|Mobile application|telemedicine is used to overcome distance when patients must travel to receive specialized care. We depend on the available, widely used smartphones via a mobile application to conduct follow up data as regard to patient quality of life and comparing this to conventional follow up visits and whether it help to obtain a complete follow up data
41139479|NCT03096132|BEHAVIORAL|Family Based Behavioral Treatment|Treatment includes 20 90 minute visits over 6 months which include 60 min parent and child separate groups and 30 min behavioral coaching. FBT includes information regarding nutrition and physical activity, as well as behavior therapy skills, including parenting skills, self-monitoring, problem solving skills, motivation systems, emotional regulation, stress management, stimulus control, and relapse prevention.
41139480|NCT03096132|BEHAVIORAL|Guided Self-Help Fam. Based Bx Treatment|Treatment includes 14 20 minute visits over 6 months. gshFBT is delivered to parent/child dyads and includes the same content in the FBT groups but it is provided in a manual. The 20-minute visits focus on clarifying information in the manuals, collecting weight and self-monitoring logs, and problem solving any barriers to implementation.
41139481|NCT01061307|DIETARY_SUPPLEMENT|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
41139482|NCT00321672|DRUG|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
41139483|NCT00321672|DRUG|0.04% capsaicin patch|Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
41139484|NCT00321672|DRUG|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
40972712|NCT05944809|DRUG|rhTPO|"Standard treatment options:~Radiotherapy: 95% planning target volume （planning target volume，PTV） ≥45Gy(without simultaneous boost).~Concurrent chemotherapy:~Weekly regimen: paclitaxel 50mg/m2 d1, nedaplatin/cisplatin 25 mg/m2d1, a total of 5 cycles.~Three weeks regimen: paclitaxel 135-175mg/m2 d1, nedaplatin/cisplatin 80mg/m2, a total of 2 cycles.~The active bone marrow was determined by magnetic resonance（magnetic resonance，MR）, and the dose limits are: V5\<95%,V10\<85%,V20\<60%，V30\<40%；95%PTV\>45Gy.~rhTPO，15000U ih. qw(during the radiotherapy course)"
40972713|NCT05945524|OTHER|Bone marrow sampling|Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)
40972714|NCT00290914|DRUG|Vilazodone|
41298521|NCT05222347|DIETARY_SUPPLEMENT|Olive Leaf Tea|Olive-leaf tea (OLT) is widely used in the traditional medicine in the Mediterranean region. Due to the high concentration of phenolic compounds, of which most abundant is oleuropein, interest in olive leaf has increased recently \[22, 23\]. The components of the olive leaves are known for their immune-modulatory, anti-inflammatory, antioxidant, hypoglycemic, antihypertensive, antimicrobial, and anti-atherosclerotic effects \[24, 25\]. Although its antiviral mechanism of action is not fully known, many studies have been conducted on the antiviral effects of olive leaf extract .
40769669|NCT03653819|OTHER|First exercise session + compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
40972715|NCT01494194|OTHER|Air Structuring Protein|A novel food protein preparation
40972716|NCT01494194|OTHER|Placebo sorbet|Placebo sorbet for double blind placebo controlled food challenge
40972717|NCT00313391|DRUG|Risperdal Consta|
40769670|NCT03653819|OTHER|First exercise session - compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
40769671|NCT02249520|OTHER|PET-MR imaging on Biograph mMR scanner|Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
40769672|NCT02249520|OTHER|MR-only imaging on Biograph mMR scanner|Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
40769673|NCT02249520|OTHER|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo MR imaging to test the technical aspects of the MR protocol on the Vida MR scanner
40769674|NCT03519880|DEVICE|Custom Mask Interface|Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.
40769675|NCT04142723|BIOLOGICAL|blood withdraw|venous blood sampling
40769676|NCT03334955|PROCEDURE|Laparoscopic ovarian drilling|A specially designed monopolar electrocautery probe was used to penetrate the ovarian capsule at 4 points, with the aid of a short burst of monopolar diathermy. The probe (which has a distal stainless steel needle measuring 10 mm in length and 2 mm in diameter) was applied to the surface of the ovary at a right angle to avoid slippage and to minimize surface damage. A monopolar coagulating current at a 40 W power setting was used. The needle was pushed through the ovarian capsule for about 4 mm depth into the ovarian tissue and electricity was activated for 4 seconds.
40769677|NCT03464201|DRUG|Enzalutamide 40 MG|Enzalutamide 160 mg p.o. every day
40972718|NCT05227027|BEHAVIORAL|Game Module|Receive access to the the game module through the free, 'Smoke Free' smartphone application
40769678|NCT06325410|PROCEDURE|resection of colorectal cancer|resection of bowel segment and re-anastmosis or stoma formation
40972719|NCT05227027|BEHAVIORAL|Smoke Free smartphone application|Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
40769679|NCT00835549|DRUG|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
40769680|NCT00835549|DRUG|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
40769681|NCT04891198|DRUG|Envafolimab|Subcutaneous injection
40769682|NCT06564987|DRUG|4% Articaine with 1:200,000 epinephrine|Inferior Alveolar Nerve Block with 4% articaine
40769683|NCT06564987|DRUG|2% lidocaine with 1:100,000 epinephrine|Inferior Alveolar Nerve Block with 2% lidocaine
40769684|NCT02245659|DEVICE|CPAP|Continuous Positive Airway Pressure
40972720|NCT02380781|BEHAVIORAL|Information in the form of a video|see intervention description
41139485|NCT00321672|DRUG|0.04% capsaicin patch|Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
41139486|NCT00884026|DEVICE|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
41298522|NCT01741194|DRUG|AC-1204|AC-1204 taken once daily, by mouth
41298523|NCT01741194|DRUG|Placebo|Placebo taken once daily, by mouth
40769685|NCT02245659|OTHER|Nasal dilator strip|Nasal dilator strip to be worn nightly
40769686|NCT05198245|DRUG|Rimegepant|Rimegepant 75mg
40769687|NCT05198245|DRUG|Various|Various
40769688|NCT05198245|OTHER|No intervention|No intervention
40972721|NCT00937625|BIOLOGICAL|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
41298524|NCT00397969|OTHER|counseling intervention|
41298525|NCT00397969|PROCEDURE|screening colonoscopy|
40972722|NCT06142045|DEVICE|RespirACT RA-MR System|RespirAct RA-MR™ is a computer-controlled gas blender to implement precise control of blood gases for a consistent and repeatable stimulus.
40972723|NCT02480114|OTHER|Educational Intervention|Undergo oral care and pain management education session
41298526|NCT03819179|OTHER|Burt's Bees Serum|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol.
41298527|NCT03819179|OTHER|Burt's Bees Serum with Biulin|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, PreBIULIN FOS (GOVA).
40769689|NCT01404247|OTHER|Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
40769690|NCT01404247|PROCEDURE|OCT imaging.|All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
40769691|NCT03684980|DRUG|Methotrexate|(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2
40769692|NCT03684980|DRUG|Rituximab|Patients will be treated with rituximab 500 mg/m\^2.
40769693|NCT03684980|DRUG|leucovorin|Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
40769694|NCT03684980|DRUG|Glucarpidase|Glucarpidase 2000 units. Arm E 1000 units.
40769695|NCT05737680|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg daily
40769696|NCT05737680|DRUG|Colchicine|Colchicine continued
40769697|NCT03295786|DRUG|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
40769698|NCT03295786|DEVICE|Renishaw Drug Delivery System|Stereotactically implanted device
40769699|NCT03925246|DRUG|Nivolumab|"Nivolumab (Opdivo) is a potent human monoclonal antibody (mAb) of the IgG4 isotype designed to directly block the interaction between Programmed Cell Death 1 (PD-1) and its ligands, Programmed Death Ligand 1 (PD-L1) and PD-L2.~Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 (+/- 2 days) weeks for 8 cycles (4 months), followed by a dose of 480 mg administered by a 60 minutes intravenous infusion every 4 weeks (+/-3 days) (beginning at cycle 9) for a total therapy duration of 1 year (maximum 16 cycles of treatment) or until progression, death, unacceptable toxicity."
40972724|NCT02480114|DRUG|Gabapentin|Given PO
40972725|NCT02480114|OTHER|Pain Therapy|Receive usual oral health care
40972726|NCT02480114|OTHER|Quality-of-Life Assessment|Ancillary studies
41298528|NCT03819179|OTHER|Burt's Bees Serum with Bonicell|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, Bonicel (Ganaden).
40769700|NCT05497934|DRUG|Glycerol|In this study, 99.5% pure glycerol will be used as an optical clearing agent. The glycerol will be applied topically to the tympanic membrane.
41298529|NCT03819179|OTHER|Burt's Bees Serum with Berenew Complex|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, BeRenew CLR Complex (CLR).
40769701|NCT06205069|DEVICE|Tissue flossing|While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.
40769702|NCT02371187|DRUG|Dapagliflozin|Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
40769703|NCT02371187|DRUG|Placebo|Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
40769704|NCT01481103|PROCEDURE|Acupuncture|participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
40769705|NCT01577407|DRUG|Nefopam|Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
40769706|NCT01458457|OTHER|Individualized complementary medicine treatment|An individual treatment plan will be made for each patient that includes one to all of the following treatments: acupuncture, traditional Chinese herbal medicine, enzyme therapy, nutrition advise, Healing Touch, homoeopathy, hyperthermia treatment, infusions, laser therapy, lymphatic drainage, manual therapy, mistel therapy, neural therapy, orthomolecular therapy, osteopathy, phytotherapy, shiatsu
40769707|NCT01458457|OTHER|Individualized usual care|Patients get usual care from their general practitioners/specialized physicians
40972727|NCT02480114|OTHER|Questionnaire Administration|Ancillary studies
40972728|NCT02480114|DRUG|Oxycodone/Acetaminophen|Analgesia
40972729|NCT02480114|DRUG|Hydrocodone/Acetaminophen|Analgesia
40972730|NCT02480114|DRUG|Fentanyl|Transdermal Analgesia
40972731|NCT02480114|DRUG|Ibuprofen|NSAID Analgesia
40972732|NCT02480114|DRUG|Magic Mouthwash|Oral Solution to treat mucositis
40972733|NCT01029795|DRUG|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
40972734|NCT01029795|DRUG|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
40972735|NCT01029795|DRUG|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
40972736|NCT04815161|BEHAVIORAL|Adherence|Adherence to medication using an electronic pillbox
41458773|NCT03161353|DRUG|Tamoxifen|"Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.~Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy."
40769708|NCT04482920|DIAGNOSTIC_TEST|p-aminohippurate clearance study|To measure kidney blood flow, small doses of a substance called p-aminohippurate (PAH) are used.
41298530|NCT03819179|OTHER|Burt's Bees Serum with Ecoskin|This is a commercially available over-the-counter product. Ingredients: Caprylic/Capric Triglyceride, Dimer Dilinoleyl Dimer Dilionoleatem, Silica, Citronellyl Methylcrotonate, Tocopheryl Acetate, Xymenynic Acid, Alpha-glucan Oligosaccharide, Fragrance, Slareolide, Polymnia sonshifolia root juice, Helianthus annuus (sunflower) seed oil, Maltodextrin, Tocopherol, Beta-sitosterol, Lactobacillus, Squalene.
40769709|NCT04482920|DIAGNOSTIC_TEST|Iohexol infusion|To measure glomerular filtration rate (GFR)
40769710|NCT01139515|DRUG|Eletriptan commercial tablet|20 mg tablet, single dose
40769711|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, single dose of 1 X 40 mg
40769712|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, single dose of 2 X 40 mg
40769713|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
40769714|NCT06298708|BIOLOGICAL|Mevac-A vaccine|"Mevac-A: A freeze-dried live-attenuated hepatitis A vaccine.~Dose and administration: a freeze-dried live-attenuated vaccine, subcutaneous injection of 0.5 ml will be administered for 1 time."
40769715|NCT06298708|BIOLOGICAL|Havrix 720 Junior|"Havrix 720 Junior: An inactivated hepatitis A vaccine, 720 ELISA units per 0.5 ml of formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain).~Dose and administration: a pre-filled syringe, intramuscular injection of 0.5 ml will be administered for 2 times with 6-month interval."
40769716|NCT05517434|BIOLOGICAL|Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation|Participants will undergo a bone marrow aspiration. About 10 mL of BMA will be collected from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest using the Cervos Marrow Cellution™ kit. The BMA does not require processing using a centrifuge after collection. 9 mL (or less) of BMA is injected into the osteoarthritic knee joint after collection (Arm A, Study 1).
40769717|NCT05517434|OTHER|Saline (Placebo Comparator for BMA)|Participants will undergo a bone marrow aspiration to collect about 10 mL of BMA from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest. However, 0.9% sodium chloride (NaCl) Baxter or equivalent (9 mL) is injected into the osteoarthritic knee joint (Arm C, Study 1).
40972737|NCT00940420|DRUG|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
41298531|NCT00900133|OTHER|immunoenzyme technique|Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
41298532|NCT00900133|OTHER|laboratory biomarker analysis|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
41298533|NCT04476537|DEVICE|OncoTreat|OncoTreat is a computational pipeline that begins with a tumor expression profile and ends with a list of several candidate regimens.
41298534|NCT01219244|BEHAVIORAL|caloric restriction|6 months of caloric restriction (15 %)
41298535|NCT01219244|BEHAVIORAL|omega-3 supplementation|6 months of omega-3 supplementation
41458774|NCT05044962|DRUG|Cabotegravir/ Rilpivirine|"For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).~For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)~CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709"
40769718|NCT05517434|BIOLOGICAL|Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations|Participants will undergo a lipoaspiration. 40 mL of lipoaspirate (LA) will be collected from subcutaneous adipose tissue. LA will be processed using the Cervos LIPO-PRO™ kit and a centrifuge. Participants will also undergo a blood draw. About 30 mL of whole blood will be collected from the antecubital fossa. Whole blood will be processed using the Cervos KEYPRP kit and a centrifuge. After processing, 9 mL (or less) of LAM is injected first followed immediately by 2 mL (or less) of LP-PRP into the osteoarthritic knee joint (Arm B, Study 2).
40769719|NCT05517434|OTHER|Saline (Placebo Comparator for LAM + LP-PRP)|Participants will undergo a lipoaspiration to collect 40 mL of LA and a blood draw to collect about 30 mL of whole blood. However, 0.9% of sodium chloride (NaCl) Baxter or equivalent is injected twice (9 mL + 2 mL) into the osteoarthritic knee joint (Arm D, Study 2).
40769720|NCT03405350|PROCEDURE|Redon-sulfide baths|Encompassing whole body or isolated limbs - upper and/or lower limbs - temperature: 37-38 degrees Celsius, duration: 20 minutes.
40972738|NCT00940420|DRUG|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
40769721|NCT03405350|PROCEDURE|Partial Mud Baths|duration: 20 minutes, temperature 40-42 degrees Celsius
40972739|NCT00940420|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
40972740|NCT00940420|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
41139487|NCT00884026|DEVICE|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
41139488|NCT06118008|DRUG|HS-20094 5mg|Administrated by subcutaneous injection
41139489|NCT06118008|DRUG|HS-20094 10mg|Administrated by subcutaneous injection
41139490|NCT06118008|DRUG|HS-20094 15mg|Administrated by subcutaneous injection
41139491|NCT06118008|DRUG|HS-20094 20mg|Administrated by subcutaneous injection
41139492|NCT02855762|OTHER|High polyunsaturated fatty acid diet.|The investigators hypothesize the diet will improve gut health and psychiatric clinical outcomes.
41139493|NCT03630549|OTHER|Standard of Care|Clinic-based HIV care
41298536|NCT01219244|BEHAVIORAL|resveratrol supplementation|6 months of resveratrol supplementation
41298537|NCT01219244|BEHAVIORAL|Placebo|6 months of placebo intake
41298538|NCT01219244|BEHAVIORAL|2nd step: intervention + physical / cognitive training|most effective dietary intervention plus physical and cognitive training
41298539|NCT01219244|BEHAVIORAL|2nd step: intervention + control|most effective dietary intervention plus control
41458775|NCT05044962|DRUG|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm
41298540|NCT03568539|DRUG|IBI308|IBI308 200mg IV infusion, every 3 weeks.
41458776|NCT05044962|DRUG|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide
41458777|NCT05044962|DRUG|Levonorgestrel|Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm
40769722|NCT03405350|PROCEDURE|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min.
40769723|NCT03405350|PROCEDURE|Terrain Therapy|walking, outdoors physical activities,
41458778|NCT05044962|DRUG|NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens|ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
41458779|NCT02350257|BEHAVIORAL|Internet-based CBT|12 weeks of internet-based CBT
41466531|NCT05457634|OTHER|blu Disposable D|Subjects use the blu disposable e-cigarette with flavor D, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
40769724|NCT03405350|PROCEDURE|Dry Massage|Depending on the needs of each patient it involved cervical (CC), thoracic (TH), or lumbar spine (LS).
40972741|NCT02221193|OTHER|traditional mouth rinsing and site-specific mouth rinsing (crossover)|blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
40972742|NCT01694589|DRUG|LDE-225|LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
40972743|NCT03761914|BIOLOGICAL|galinpepimut-S|Galinpepimut-S will be administered as monotherapy, then galinpepimut-S will be co-administered with pembrolizumab. After that, there will be un-paired administration of pembrolizumab and galinpepimut-S according to the schedule described in the protocol and described in the arm/group descriptions on ClinicalTrials.gov.
41458780|NCT02285049|OTHER|Urticaria Control Test|"* The patients get the 1st UAS28 form and four-week appointment to follow up.~* Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)~* Then patients fill the 1st UCT and DLQI questionnaire by themselves.~* The patients get the 2nd UAS28 form and four-week appointment to follow up.~* At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves."
40769725|NCT03405350|PROCEDURE|Laser Therapy|treatment parameters: sweeping, continuous, wavelength 808 nm, power 12 J, 400mV, duration 30s,
40769726|NCT03405350|PROCEDURE|Low-frequency Magnetic Field|duration 20 minutes, impulse shape - rectangular, induction 5 mT, frequency 20-50Hz,
40769727|NCT03405350|PROCEDURE|Ultrasonotherapy|treatment parameters: 800kHz/6cm2 head, ultrasound impulse wave: 2ms - impulse, 9ms - break, dose 0.5-0.6 W/cm2 over 6 minutes,
40769728|NCT03405350|PROCEDURE|Cryotherapy|ventilator, treatment duration 2-3 minutes, temperature - 80 to - 110 degrees Celsius,
40769729|NCT03405350|PROCEDURE|Electrotherapy|Bernard's diadynamic currents - treatment parameters: DF1 CP4 LP4, Nemec interference currents (frequency range 0-100Hz), percutaneous electrostimulation (TENS) - rectangular impulse currents, impulse duration 0.2ms, frequency 40Hz, regulated current 0-100mA,
40769730|NCT03405350|PROCEDURE|Light Therapy|blue filter Sollux lamp, radiation distance 30-40 cm, duration 15 minutes, Bioptron lamp - radiation distance 10 cm, duration 5-10 minutes
40769731|NCT05320809|BIOLOGICAL|3D189|"3D189 (200 mcg per peptide x 4 WT1 peptides within the drug product; total weight: 800 mcg) is mixed (1:1 v/v) and emulsified with the adjuvant Montanide, which is then injected subcutaneously to the patient.~A maximum of 15 total injections of 3D189 will be administered as follows:~1. Initial immunization induction phase（the first series of 6 injections of 3D189): every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment.~2. Early immune booster phase（the second series of 6 injections of 3D189): every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment.~3. Late immune booster phase（the third series of 3 injections of 3D189): every 6 weeks (between Weeks 40 and 52)."
40769732|NCT04139408|DEVICE|Disposable Pulmonary Surgical Marker|The subjects will undergo Marker placement procedure, within 24h before VATS.
40769733|NCT05604586|DIETARY_SUPPLEMENT|N-acetylcysteine|100 women and men supplementing 1200 mg of N-acetylcysteine daily in three equal doses. Supplementation will last for 7 days.
40769734|NCT05604586|DIETARY_SUPPLEMENT|Placebo|100 women and men supplementing 1200 mg of placebo daily in three equal doses. Supplementation will last for 7 days.
40972744|NCT03761914|DRUG|Pembrolizumab|Galinpepimut-S will be administered as monotherapy, then galinpepimut-S will be co-administered with pembrolizumab. After that, there will be un-paired administration of pembrolizumab and galinpepimut-S according to the schedule described in the protocol and described in the arm/group descriptions on ClinicalTrials.gov.
40972745|NCT04647578|DEVICE|GT3X Actigraph accelerometer.|GT3X Actigraph accelerometer during 7 days
40972746|NCT05739305|OTHER|Risk factor|No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
41139494|NCT03630549|OTHER|Village-based ART refill|Option to get ART refill and care by the village health worker
40769735|NCT01190527|RADIATION|FDG-PET|This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
40769736|NCT05798520|DRUG|BIIB091|Administered as specified in the treatment arm.
40769737|NCT05798520|DRUG|DRF|Administered as specified in the treatment arm.
40769738|NCT05798520|DRUG|Placebo|Administered as specified in the treatment arm.
40769739|NCT06113328|BIOLOGICAL|MK-6194|MK-6194 administered subcutaneously (SC)
40769740|NCT06113328|DRUG|Placebo|Placebo comparator to MK-6194 administered SC
40769741|NCT01096251|BEHAVIORAL|CBT vs BST|The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
41139495|NCT06226116|PROCEDURE|socket preservation|After the tooth extraction the investigator will select two sockets, one will be assigned as the experimental side and we will preserve it with cold-processed autologous dentin. The second will be designated the control group and we will only stabilize the blood clot.
41458781|NCT04125134|DRUG|Preservative-free Refresh Optive Advanced Lubricant Eye Drops|over the counter artificial tear
41458782|NCT03152162|DEVICE|iTotal PS KRS|Total knee arthroplasty for treatment of osteoarthritis
40769742|NCT05855694|DEVICE|THOR LED Photobiomodulation Helmet - Therapeutic|"Photobiomodulation (PBM) is a non-invasive treatment option that uses nonionizing light sources such as laser diodes and light-emitting diodes in the visible and near-infrared spectrum.~Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'therapeutic setting' of 35mW/cm2 = 42J/cm2"
40769743|NCT05855694|DEVICE|THOR LED Photobiomodulation Helmet - Control|"Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'non-therapeutic setting' of 0mW/cm2 = 0J/cm2"
40769744|NCT05913687|DIAGNOSTIC_TEST|AIDP|Machine learning algorithm of imaging data
40769745|NCT02781558|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
40769746|NCT02781558|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
40769747|NCT02007460|BEHAVIORAL|Exercise|multidirectional unilateral hopping exercise
40769748|NCT00726583|DRUG|PX-866|Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
40769749|NCT05425121|PROCEDURE|Core stability exercises|The intervention in the control group will core stability exercises for different back muscles and strengthening exercises of Gluteal Muscles.
40769750|NCT05425121|DEVICE|Biofeedback training|EMG biofeedback training will be administered to the participants in combination with core stability exercise training.
40769751|NCT04612192|DEVICE|Active luminette|receive an active light using glasses of 1500 lux (an average of 180 photons/s/cm2, with a maximum wavelenght at 468 nm), 30-minute long light therapy in the morning, in a time period defined by sleep log and chronotype questionnaire, on a 4-week period
40769752|NCT04612192|DEVICE|Placebo luminette|receive a placebo light using glasses (an average of n photons/s/cm2, single- band spectrum with a narrow peak at 660 nm under 50 lux), with the same modality as the experimental group
40769753|NCT04501718|DRUG|Apatinib Combined With Temozolomide and Etoposide Capsules|"Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator."
40769754|NCT06174220|DRUG|Tideglusib|Tideglusib 1g po daily
40769755|NCT06174220|DRUG|Placebo|Matching placebo 1g po daily
40769756|NCT06115954|OTHER|Self-Management Supported Telerehabilitation|Supporting the exercises with an internet-based environment and self-management training for Children and Adolescents with Juvenile Idiopathic Arthritis
40769757|NCT03966547|PROCEDURE|Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.
40769758|NCT03966547|PROCEDURE|Ganglion sphenopalatine block with placebo administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
40769759|NCT05914129|OTHER|Diaphragm, Stomach and Liver techniques|"Diaphragm Stretching:~The participant is seating down and the researcher will be behind, placing their hands on the inferior costal border. Cephalic traction is performed during inhalation, remaining during exhalation. Procedure is repeated 2 times, for 10 respiratory cycles, with 1-minute intervals.~Inferior Mobilization of the Stomach:~The participant is seating down with slight flexion of the torso, while the investigator stands behind them, placing the thumbs on the epigastric region. The volunteer will extend their body while the researcher performs a caudal traction. This procedure lasts 5 minutes.~Liver Pump:~Participant is laying on their back, and the investigator is standing on the participants side. The researcher places one hand on the right side inferior costal border posteriorly and the other one bellow the costal border anteriorly. Researcher compresses during exhalation and releases their hands abruptly during inhalation. This procedure lasts 5 minutes."
40769760|NCT05914129|OTHER|Stomach and Liver techniques|In this group, techniques are the exact same as described previously but only liver and stomach ones will be performed.
40769761|NCT05914129|OTHER|Sham technique|In the sham group, manual contact without any therapeutic intention will be performed in the same regions as the experimental groups. This contact will be maintained during the same amount of time as for the experimental group A.
40769762|NCT05143411|OTHER|PRE-test|we are going to verify glucose levels before (pre) and after (post) the use of the mobile application.
40769763|NCT05861843|DIAGNOSTIC_TEST|Virtual Reality-based cue exposure paradigm|Virtual Reality (VR) cue exposure to alcohol-associated cues using head-mounted displays (HMD)
40769764|NCT03708315|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride
40769765|NCT03708315|DRUG|Placebos|Placebo
40769766|NCT06571799|OTHER|BENEV Exosome Regenerative Complex+|BENEV Exosome Regenerative Complex+® is an intensive dual-action complex formulated to absorb quickly into the skin and scalp delivering the concentrated power of stem cell derived lyophilized exosomes, potent growth factors, peptides, coenzymes, minerals, amino acids and vitamins.
40769767|NCT02926846|DRUG|Intravenous vancomycin & gentamicin with adjunctive lavage|"Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
41139496|NCT06226116|PROCEDURE|placement of experimental implants|After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.
41139497|NCT06226116|PROCEDURE|histological sample collection|"Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long."
41298541|NCT03366740|OTHER|GB mixed full strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the Green banana mixed full strength rice suji The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
40769768|NCT02926846|DRUG|Intraperitoneal vancomycin & gentamicin|"Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
41298542|NCT03366740|OTHER|Full strength rice suji Alone|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
40769769|NCT06570278|DIAGNOSTIC_TEST|WGS coupled with MCM|Whole genome will be screened and analysis will focus on pathogenic and likely pathogenic variants. The list of variants of interest will be recorded until examination and discussion during the MCM. MCM will edit a final synthesis concerning the pathogenicity of identified variants.
40769770|NCT06046378|OTHER|Digital Story Group Prepared With Digital Audio File (Podcast)|"The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to. At the end of the subject on the date planned according to the academic calendar, the students will be interviewed again and a questionnaire will be applied to evaluate the effectiveness of the digital stories prepared with the post-test and digital audio file (podcast). The retention test will be applied 21 days after the last test application."
40769771|NCT06046378|OTHER|Control Group|After the students in the control group are determined, a pre-test will be conducted before the subject receives education. The same knowledge test will be repeated as a post-test after the students receive the classical course education and after the end of the subject. Students will be given a retention test 21 days after the last test. After the retention test application, digital stories prepared with a digital audio file (podcast) will be sent to the students in the control group. In this way, all students participating in the study will have access to the training material used in addition.
40769772|NCT02116335|DRUG|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
40769773|NCT02116335|DRUG|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
40769774|NCT06625710|DRUG|GV1001|Lyophilized peptide from hTERT
40769775|NCT06625710|DRUG|Placebo|0.9 % Normal Saline
40972747|NCT03954236|DRUG|topical ruxolitinib 1.5% cream|Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
41458783|NCT01878513|DRUG|risperidone|3 levels of dosing dependent on which condition a patient is assigned to.
41458784|NCT01426334|DRUG|dasatinib|Given PO
40769776|NCT00087035|DRUG|docetaxel|Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
40769777|NCT00087035|DRUG|erlotinib hydrochloride|Will be taken at a starting daily dose of 150mg
40972748|NCT03954236|OTHER|Topical vehicle/moisturizer cream|Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
41458785|NCT01426334|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
40769778|NCT04584008|DRUG|FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.|According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.
41458786|NCT01426334|OTHER|pharmacological study|Correlative studies
41458787|NCT01426334|DRUG|cyclosporine|Given PO
41458788|NCT03519490|DEVICE|Hybrid Contact Lens|Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs
41458789|NCT04594434|OTHER|Scale SUD|Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
41458790|NCT04594434|OTHER|VOC scale|The VOC (Validity Of Cognition) scale is a scale of value given to cognition.
41458791|NCT04594434|OTHER|DES II scale|The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
40769779|NCT04584008|DRUG|Other Therapy|Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..
40769780|NCT03113344|DRUG|cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
40769781|NCT03982173|DRUG|Tremelimumab|tremelimumab 75mg
40769782|NCT03982173|DRUG|Durvalumab|Durvalumab 1500mg
40769783|NCT05207839|DIETARY_SUPPLEMENT|Milk powder|one sachet per day dissolved in 200 ml of water
40972749|NCT05229380|DRUG|Saccharin test|Saccharin is a nonnutritive sweetener. It has property of being inert to respiratory epithelium that is it does not hamper physiological mucus clearance of sino-nasal mucosa. Methylene blue is a chemical compound. It can be used to check patency of (ET). The dye, because of its liquid form, gravitates through the ET to the nasopharynx.
40972750|NCT02375113|DIETARY_SUPPLEMENT|soy supplementation|"Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone."
41458792|NCT06348979|PROCEDURE|Fiber flowable (SFRC) support below hybrid nanoceramic endocrowns|restoration of endodontically treated teeth by endocrowns
41139498|NCT04474171|BEHAVIORAL|SCI&U online health coaching program|Online secure videoconferencing health coaching platform with resource library to promote self-management. Maximum number of sessions is 14 over 6 months and covers health related topics to reduce secondary complications
40769784|NCT01117246|DEVICE|High Intensity Focused Ultrasound|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
40769785|NCT02184013|PROCEDURE|Catheter ablation|Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).
40769786|NCT03074669|BEHAVIORAL|ACT program|ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
40769787|NCT01312298|PROCEDURE|General anesthesia|Patients will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml
40769788|NCT01312298|PROCEDURE|Regional anesthesia|Patients will receive intrathecal anesthesia
41139499|NCT01840085|DRUG|0.03% DSC127 topical gel|
41139500|NCT02394912|DEVICE|vena cava filter implantation (LUMIFI with Crux VCF System)|
41298543|NCT03366740|OTHER|3/4th strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
41458793|NCT06348979|PROCEDURE|all ceramic Endocrowns (emax)|restoration of endodontically treated teeth by endocrowns
41458794|NCT02359864|RADIATION|5 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
41458795|NCT02359864|RADIATION|10 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
40769789|NCT05437250|DRUG|Non interventional study|CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection
40769790|NCT00583531|DRUG|AST-120|Oral, 2 grams TID in sachets for 4 weeks
40769791|NCT04957472|DEVICE|fabian HFO, fabian +nCPAP evolution and fabian Therapy evolution with PRICO function|24 hours of automated control of FiO2
40769792|NCT04957472|OTHER|Manual Control|24 hours of manual control of FiO2
40769793|NCT04729439|BEHAVIORAL|Homework Organization and Planning Skills (HOPS) Intervention|A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills
40769794|NCT04729439|DEVICE|Digital Health Application (Online Platform) for Encouraging Skills Practice|This online platform can be used on participants' personal devices including laptops, phones, tablets, or other computers and is designed to encourage adolescent's skills practice, monitor and reward treatment progress, and optimize motivation in treatment
40769795|NCT03712761|DIETARY_SUPPLEMENT|Enriched Protein®|This product contains high quality bovine milk proteins enriched with additional leucine.
41458796|NCT04196296|BEHAVIORAL|Psychoeducation|Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
41298544|NCT02844205|OTHER|quotation of the newborn behavioral observation scale|quotation of the newborn behavioral observation scale by 12 experimented nurses. Patient will be filmed during an usual care and nurses will quote the scale thanks to the video.
41298545|NCT00782925|OTHER|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
41298546|NCT00782925|OTHER|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
41298547|NCT00782925|OTHER|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
41298548|NCT06159361|BEHAVIORAL|Balance targeted exercises|6-week exercise program, 3 sessions per week (2 sessions in person, 1 session of home exercises. Participants will receive a booklet with information about the home exercises and will receive a text message reminder), each session will last 60 minutes.
41298549|NCT04648878|OTHER|Hybrid combination of physical therapy and powered exoskeleton|18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks
41298550|NCT04648878|OTHER|Powered Exoskeleton Only|18 visits of powered exoskelton only, three times a week for approximately 6 weeks
41298551|NCT04648878|OTHER|Physical Therapy only|18 visits of physical therapy only, three times a week for approximately 6 weeks
41298552|NCT01844700|DRUG|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
41298553|NCT01844700|DRUG|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
41298554|NCT06273241|OTHER|food intake|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics..
41298555|NCT04874909|OTHER|Blood sample|"Blood sample of 15ml max by subject (case, related individual, control) once time:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max"
41298556|NCT04874909|OTHER|Urine sample|Urine sample (500 ml) once time
41298557|NCT01280123|DRUG|Pioglitazone|"Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated."
40972751|NCT02198274|DRUG|BIBH 1|100 mg/week
40972752|NCT00214708|PROCEDURE|Screening for Tuberculosis|
41458797|NCT04196296|BEHAVIORAL|Motivation|Online exercises/activities regarding social anxiety (and treatment thereof) based in principles from Acceptance and Commitment Therapy (ACT) and Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET).
40972753|NCT06361030|DRUG|surufatinib combined with gemcitabine plus nab-paclitaxel|"Surufatinib capsules: oral, once daily. Combination treatment period: 200 mg each time, every 4 weeks for a treatment cycle(Q4W). If all the chemotherapy drugs were stopped during the maintenance treatment period, only surufatinib was left, the dose of Surufatinib could be increased to 300 mg per dose according to the patient\&#39;s condition.~Gemcitabine: iv, 1000 mg/m2, days 1, 8, and 15 of each treatment cycle, Q4W. Paclitaxel (albumin-bound), iv, 125mg/m2, on days 1, 8 and 15 of each treatment cycle, Q4W.~All they will be used until disease progression, death, intolerable toxicity, initiation of new antineoplastic therapy, withdrawal of consent, loss to follow-up, or any other protocol-specified event requiring treatment discontinuation or study closure, whichever occurred first.~But If surgical resection was performed, they will be only maintained for 6 months after surgery."
40972754|NCT05984160|OTHER|Paragastric neural block|A block method used to control patients' symptoms of pain, nausea and vomiting after surgery.
40972755|NCT00261664|DEVICE|telehomecare|
41458798|NCT03576053|DRUG|Lidocaine|Lidocaine intradermal injection
41298558|NCT01280123|DRUG|placebo|Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
41298559|NCT02829086|OTHER|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
41298560|NCT02829086|OTHER|Family Stress and Conflict Management|Family Stress and Conflict Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
41298561|NCT02829086|OTHER|Financial Management|Family Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
41298562|NCT03536429|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
41298563|NCT03536429|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
41298564|NCT00495560|DRUG|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
41298565|NCT02444897|DRUG|Epidural PCA Ropivacaine|"Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.~Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S"
41298566|NCT02444897|DRUG|IV PCA Fentanyl+nefopam+Ramosetron|Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
41298567|NCT00745264|DRUG|Diractin|100 mg Ketoprofen to 2 joints
41298568|NCT00745264|DRUG|Diractin|400 mg ketoprofen to 4 joints
41298569|NCT00745264|DRUG|Diractin|100 and 400 mg Ketoprofen used concomittant with heat
41298570|NCT00745264|DRUG|Diractin|100 and 400 mg Ketoprofen concomittant with moderate exercise
41458799|NCT03576053|OTHER|Histamine|Skin Prick Test with Histamine
41458800|NCT03576053|OTHER|Cowhage|Manually skin insertion of cowhage spicules
41458801|NCT03576053|OTHER|Heat stimulation|Short heat stimulation
41458802|NCT03576053|OTHER|Pre-heating|Mild skin pre-heating
41458803|NCT03576053|OTHER|Serotonin|Serotonin electrophoresis
41458804|NCT04323683|GENETIC|Microarray|High throughput technique for determining global gene expression of the condition of interest
41458805|NCT05915923|PROCEDURE|1 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 1Hz)
41458806|NCT05915923|PROCEDURE|10 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 10Hz)
41458807|NCT05915923|PROCEDURE|Sham Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received sham-rTMS once a day with the same parameters as the 10 Hz rTMS group, but the coil rotated 90° away from the scalp
41458808|NCT01361334|DRUG|Pazopanib|800 mg QD p.o.
41458809|NCT01546363|OTHER|Blood draw|phlebotomy
41298571|NCT04637659|PROCEDURE|Root Canal Treatment|Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.
40769799|NCT05468177|COMBINATION_PRODUCT|neoadjuvant chemotherapy|"Cetuximab: 500mg/m2,day1, every 2 weeks. mFOLFOX: oxaliplatin 85mg/m2, day 1;LV 400mg/m2, day 1;5-FU 400mg/m2, day 1, then 1200mg/ (m2•d) ×2days(total 2400mg/m2, infusion 46-48h) (every 2 weeks).~Anti-PD-1(Sintilimab Injection):200mg every 3 weeks. Surgery will be performed after 4 cycles for locally advanced or initially resectable metastatic right colon cancer.If the initial unresectable metastatic right colon cancer were converted into resectable metastases, and surgery will be performed. Patients who failed to convert after 6 cycles of treatment will be withdrawn from the study.Cetuximab +mFOLFOX was treat for 8 cycles, and Anti-PD-1 was treated for one year in the perioperation period unless disease progression, toxicity intolerance, initiation of new anti-tumor therapy."
41298572|NCT00164424|DRUG|Acyclovir|
41298573|NCT00348972|DRUG|Lantus® (insulin glargine)|
41298574|NCT03677089|BEHAVIORAL|12 ECHO Autism telehealth clinics|Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
41458810|NCT04933240|DRUG|Tamoxifen Citrate 10Mg Tab|nonsteroidal antiestrogen for oral administration in 10 mg tablets. Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.
41458811|NCT04933240|DRUG|Estradiol|estradiol tablets for oral administration contains 1 mg of micronized estradiol per tablet.
40769800|NCT01661543|DIETARY_SUPPLEMENT|Beans|120g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
40769801|NCT01661543|DIETARY_SUPPLEMENT|Control (rice)|110g (3/4 c) of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group. This amount of rice equates to a similar volume as 120g of cooked beans or peas.
41458812|NCT04933240|DRUG|Placebo|A sugar tablet that does not contain any active medicine
41458813|NCT02597049|DRUG|Dulaglutide|Administered SC
41458814|NCT02597049|DRUG|Placebo|Administered SC
41458815|NCT02597049|DRUG|SGLT2 inhibitor|Administered orally as standard of care for type 2 diabetes
41458816|NCT02597049|DRUG|Metformin|Administered orally as standard of care for type 2 diabetes
41458817|NCT05228717|DIAGNOSTIC_TEST|Point of Care Ultrasound|q48-72h point of care ultrasound of the lungs, heart, and IVC (inferior vena cava)
41458818|NCT00343720|DRUG|VELCADE|
41458819|NCT00343720|DRUG|Alimta|
41458820|NCT04439760|PROCEDURE|Superior Cervical Ganglion Block|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
41458821|NCT00002727|RADIATION|radiation therapy|
41458822|NCT00801515|DRUG|Maraviroc|150 mg twice per day
40769802|NCT01661543|DIETARY_SUPPLEMENT|Peas|120 grams of peas will be consumed 5 out of 7 days per week
41298575|NCT00401622|BEHAVIORAL|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
41298576|NCT00401622|BEHAVIORAL|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
41458823|NCT01211262|DRUG|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
41458824|NCT01124786|DRUG|CO-1.01|1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
41458825|NCT01124786|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
41458826|NCT02288923|PROCEDURE|Femoral nerve block|"Supine position~If using peripheral nerve stimulator for localisation of the femoral nerve:~50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine~If using ultrasound for localisation of the femoral nerve:~High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic"
41298577|NCT01837147|BEHAVIORAL|Technology-Based Physical Activity Promotion|Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
41298578|NCT01837147|BEHAVIORAL|Pedometer Intervention|Participants assigned to this group will receive a pedometer and be trained in its use.
41298579|NCT00818142|BEHAVIORAL|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
40769803|NCT06564558|OTHER|Spinal Strengthening Exercises|Individuals in the experimental group will carry out 3 sets of 10 repetitions or what is tolerated within a Borg scale intensity of 4-5 with 70-80% of perceived exertion with appropriately picked elastic bands. The exercises include: Shoulder horizontal abduction; Shoulder elevation; Back Extensions over a plinth; Shoulder extension exercises; One arm and opposite leg lifts from quadruped; and finally bilateral arm lifts with upper thoracic extension from prone (superman exercise).
41298580|NCT01526018|BEHAVIORAL|Podee bottle|Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
41298581|NCT02098317|DRUG|DHA plus Vitamin D|DHA 500 mg plus Vitamin D 800 IU
41298582|NCT02098317|DRUG|Placebo|Placebo pearls mimicking pearls with DHA and Vitamin D
41298583|NCT03695523|BEHAVIORAL|PLAY (PhysicaL ActivitY) Policy Intervention|An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
40769804|NCT06564558|OTHER|Thoracic Spine Stretching|Participants will be instructed to do two exercises: Firstly, to lay supine with and hinge the thoracic spine over a roller placed in a way that would ensure the patient is forward lying and not completely supine. The participant will be instructed to maintain hinging until a stretch or pressure feeling is felt in the midback and hold this position for 3 sets of 30 seconds. Secondly, the patient was asked to be in a seated position, clasp the hands together and behind the head while arching backward over the chair and looking up. This exercise will be done for 3 sets of 20-30 repetitions with a slight hold time at the end of the movement. All interventions will be carried out for 45 minute sessions 3 times per week.
40769805|NCT06564558|OTHER|Thoracic Spine Mobilization|The patient will be seated with both hands clasped at shoulder level. An experienced and blinded therapist standing homolateral to the patient supports the clasped hands with one arm while placing the other hand was placed at different thoracic regions until the thoracolumbar junction. Specifically, the dorsal aspect of the index finger and pad of the thumb were used to create a fixation point at the junction. Following that, gentle extension-directed glides (postero-anterior) will be done by the therapist for 3 sets of 10 repetitions or until tolerated by the patient.
41298584|NCT00962923|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10\^6 cells/kg body weight).
40769806|NCT06564558|OTHER|Sham Postural Correction|comprised an hour of social interaction with similar participants where a blinded therapist will provide educational tips for dealing with kyphosis along with educational reading material for each participant.
40769807|NCT06571617|PROCEDURE|Mini PCNL (mini percutaneous nephrolithotomy)|half of the cases will be treated using mini PCNL
41298585|NCT01893593|OTHER|Intervention|Guideline summary and data feedback from a baseline medical record review and a multifaceted intervention to improve clinical systems
41298586|NCT01893593|OTHER|Control|Guideline summary and data feedback from a baseline medical record review
41298587|NCT00260741|DRUG|Smoked Cannabis|
41298588|NCT01675921|OTHER|Facebook group|Facebook will be used to remind participants to take the ACT survey once every month for 12 months.
41298589|NCT01721408|DRUG|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
41298590|NCT01721408|DRUG|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
41298591|NCT02556645|OTHER|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
41458827|NCT02288923|PROCEDURE|Local Infiltration Analgesia|"Local infiltration analgesia to be administered by surgeon towards the end of operation:~40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve)."
41466532|NCT05457634|OTHER|blu Disposable E|Subjects use the blu disposable e-cigarette with flavor E, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
41298592|NCT02556645|OTHER|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
41298593|NCT04024683|PROCEDURE|Serratus block with ropivacaine 2mg/ml|The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
41298594|NCT05769803|DIAGNOSTIC_TEST|Nasal and mouth swab|"Whinin 7 days from diagnosis, the subjects will be requested to sample another two specimens i.e. nasal swab and mouth swab, that will be tested for the presence of SARS-CoV-2 RNA. Results, expressed as cycle threshold will be then compared to analyze viral loads from the two different sites.~Moreover, an aliquot will be retro-transcribed into cDNA and sequenced by Next Generation Sequencing (NGS) to obtain the virus entire genome sequence or evaluated by RT-PCR for variantdetermination."
41298595|NCT03466346|DRUG|Fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
40769808|NCT06571617|PROCEDURE|RIRS (retrograde intrarenal surgery/ flexible URS)|THE OTHER HALF WILL BE TRAETED USING Flexible URS
40769809|NCT03327129|PROCEDURE|fMRI|An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
40769810|NCT04463355|BEHAVIORAL|Video discharge instructions|Short video (2 minutes) including information about clinical features, management and follow up of pediatric patients with acute gastroenteritis
40769811|NCT02108808|DRUG|Ticagrelor|
40769812|NCT02108808|DRUG|Prasugrel or Clopidogrel|
40769813|NCT04588883|BEHAVIORAL|Kuja Pamoja - HIV|Information has been provided in the treatment arm description.
40972756|NCT03292588|BIOLOGICAL|Mepolizumab|"Mepolizumab administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
41298596|NCT03466346|BEHAVIORAL|Interpersonal Psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
41298597|NCT00524745|BIOLOGICAL|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
41298598|NCT02805218|DRUG|PEG-rhG-CSF|
41298599|NCT02979795|PROCEDURE|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy. 2.5 Gray/fraction (Total in 45-54 Gray)
40769814|NCT05143814|DEVICE|3D Printed Mask Adapter Designed from Facial 3D scans for Fit testing.|Given the high level of fit test failures, without the provision of improved fits of masks, patient care will be highly curtailed for frontline staff at risk of SARS-CoV-2. Therefore, a reusable bespoke mask adapter used with a soft FFP3 disposable mask might be an economical solution to address the passing of fit testing. Currently, this is a major challenge in delivery of healthcare and urgent action is needed.
40972757|NCT03292588|DRUG|Placebo|"Placebo administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
40972758|NCT02877420|OTHER|Non-Technical Skills Training Curriculum|
40972759|NCT02877420|OTHER|Conventional Simulation Training Group|
40972760|NCT05930912|DIAGNOSTIC_TEST|Psychoanalysis|Case-specific psychoanalysis is performed, including the participant's background during birth.
41458828|NCT02288923|PROCEDURE|Sub arachnoid analgesia|Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
40972761|NCT05930912|DRUG|sertraline 50mg|After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.
40972762|NCT05930912|DRUG|Duloxetine 20 MG|Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.
40972763|NCT05930912|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is tailored to the participant's current activities and life decisions.
41298600|NCT02650284|DEVICE|Stryker Triathlon Primary Total Knee System|Total Knee Replacement
41298601|NCT02650284|DEVICE|Restoris MCK Multicompartmental Knee System|Bicompartmental Knee Replacement
41458829|NCT02288923|PROCEDURE|Sedation or general anaesthesia|After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
40972764|NCT04947553|DRUG|AXS-05 (dextromethorphan-bupropion)|AXS-05 tablets, taken twice daily
40972765|NCT04947553|DRUG|Placebo|Placebo tablets, taken twice daily
40972766|NCT00109798|DRUG|temozolomide|Patient will take drug on day 1-5 of 28 day schedule
40972767|NCT00109798|DRUG|topotecan hydrochloride|Patient will have IV on days 2-6 on a 28-day schedule
40972768|NCT01975753|DRUG|Morphine|
41298602|NCT01201538|DRUG|Nilotinib|
41298603|NCT05780853|DIAGNOSTIC_TEST|Tablet Game-based Assessment - YARN assessment service|Tablet game-based assessment to assess neurodevelopmental profile.
41298604|NCT05780853|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System, Third Edition (ABAS-3)|A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.
40972769|NCT01975753|DRUG|Fentanyl|
40972770|NCT00823368|DRUG|STX209|
40972771|NCT04261751|OTHER|Clinician Questionnaire|Nurses will take the Clinician Questionnaire electronically
40972772|NCT03535116|DRUG|Ketorolac|Toradol is a type of brand name. We will be using the generic version.
40972773|NCT03535116|DRUG|Saline|injectable normal saline
40972774|NCT04868890|BIOLOGICAL|Ampion|Inhaled Ampion
40972775|NCT04868890|OTHER|Placebo|Inhaled Placebo
40972776|NCT00349284|DRUG|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
40972777|NCT03790488|DRUG|JTX-4014|Specified dose on specified days
40972778|NCT04497688|DRUG|PEG-rhG-CSF|Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
41298605|NCT05780853|OTHER|Demographic questionnaire|Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.
41298606|NCT03642015|BEHAVIORAL|Music listening|listening the music 15 min
41298607|NCT01936649|DRUG|AdreView (Iobenguane I 123 Injection)|AdreView 10 mCi as a single i.v administration
41298608|NCT02345642|DEVICE|ActiveCare+SFT Supine|
41298609|NCT02345642|DEVICE|VenaFlow Elite Supine|
40972779|NCT01684007|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
40769815|NCT06631833|BEHAVIORAL|Intervention measures based on the YPAP model.|The intervention group received an 8-week intervention program designed to gradually increase their physical activity levels. The intervention program included the following components: 1) Physical activity 3 times a week, each lasting 45 minutes, of moderate intensity. The content of these activities was provided by sports experts. 2) Health education lectures were held once a week, each lasting 60 minutes. 3) Family physical activity was arranged twice a week, each lasting 30 minutes, of low intensity. After the intervention period, measurements were taken using relevant questionnaires.
40769816|NCT04938427|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
40769817|NCT04938427|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
41139501|NCT01839032|DRUG|Vinorelbine cisplatin radiotherapy|"During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy)."
40769818|NCT06564402|BEHAVIORAL|Positive Mental Rehearsal|After exposure trial, participants are asked about the positive aspects of their exposure experience (e.g., thoughts, feelings), based on which an imagination script is formulated and recounted
40769819|NCT06564402|BEHAVIORAL|Mental Rehearsal|After exposure, participants are asked about what happened during the exposure experience and whether their central concerns/expected outcome actually occurred during exposure
40769820|NCT06564402|BEHAVIORAL|Exposure|All participants complete exposure exercises (i.e., talking on the phone and talking with a stranger) before positive mental rehearsal is executed
40769821|NCT04419987|GENETIC|draw blood|search for new genetic variations (when the diagnostic exploration will have been non informative) by sequencing exons.
40972780|NCT01684007|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
40972781|NCT02088255|PROCEDURE|Static surface|During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.
41139502|NCT03391700|DRUG|Rocuronium(deep)|In the group with deep relaxation during surgery, rocuronium is given by continuous infusion (0.6 mg/kg/h).
41139503|NCT03391700|DRUG|Rocuronium(moderate)|In the group with deep relaxation during surgery, rocuronium is given by bolus dose(0.15mg/kg) induced a train of four count of 1-2.
40769822|NCT06615050|DRUG|Tacrolimus (Tac)|Tablet or intravenously (IV)
40769823|NCT06615050|DRUG|Methotrexate (MTX)|Intravenously (IV)
40769824|NCT06615050|DRUG|Ruxolitinib (Rux)|Tablet
40769825|NCT06615050|DRUG|Cyclophosphamide|Intravenously (IV)
40972782|NCT02088255|PROCEDURE|Dynamic surface|During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
41298610|NCT02345642|DEVICE|ActiveCare+SFT Standing|
41298611|NCT02345642|DEVICE|VenaFlow Elite Standing|
41298612|NCT00544128|DRUG|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
41298613|NCT00544128|DRUG|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
41298614|NCT06376604|OTHER|Fasting Mimicking Diet|Subject will consume 6 cycles of 5-day fasting mimicking diet: 3 days prior to, the day of, and 1 day following chemotherapy treatments.
41298615|NCT06376604|DRUG|Chemotherapy|6 cycles of standard chemotherapy for the gynecologic malignancy.
41298616|NCT04365816|OTHER|Interview|A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
41298617|NCT00893594|DRUG|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
40769826|NCT06615050|DRUG|Mycophenolate mofetil (MMF)|Tablet or intravenously (IV)
40972783|NCT02016560|DRUG|florbetapir F 18|
40769827|NCT06211296|DEVICE|Shortcut|Splitting bioprosthetic aortic valve leaflets
40769828|NCT05711394|DRUG|Atogepant|Oral Tablet
40769829|NCT05711394|DRUG|Placebo-Matching Atogepant|Oral Tablet
40769830|NCT06564350|DEVICE|IMU (Inertial Measurement Unit) sensors|IMU sensors track an object's acceleration and angular velocity over time and do not emit any electromagnetic fields or radiation. They use tiny masses and springs to measure the acceleration, as well as Hall effect materials to measure the magnetic fields. The force sensor changes its electric resistor value based on the force applied to the sensor surface.
40769831|NCT02790736|DRUG|propranolol|active treatment
40769832|NCT02790736|DRUG|Placebo|inactive pill
40972784|NCT02016560|DRUG|Flortaucipir F18|
40972785|NCT02016560|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
40972786|NCT05219214|OTHER|Chinese medicine|There are no restrictions on TCM therapy, including Chinese herbal medicine, Chinese patent medicine, external treatment, acupuncture and moxibustion, etc
41139504|NCT00315848|DRUG|Buprenorphine transdermal delivery system|
41139505|NCT00585793|DRUG|NRTI/NNRTI/ Kaletra|Fixed dose and cild formulation Kaletra
41139506|NCT02596737|BEHAVIORAL|wittyFit concept|
41139507|NCT02978066|OTHER|Spinal anaesthesia|
41298618|NCT00893594|DRUG|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
41298619|NCT02110108|DEVICE|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
41298620|NCT03206944|DRUG|acetylsalicylic acid|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
41298621|NCT03206944|DRUG|Tomato Fruit Extract|Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
41298622|NCT00367497|DRUG|Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin|
41458830|NCT02288923|DRUG|Pre-medication|All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
40972787|NCT04435132|DEVICE|PCL under fluoroscopy with the aid of the robotic device|During the surgery, the robot was positioned over the estimated insertion point. It was aligned to be parallel to the fluoroscope imaging plane as much as possible. The needle is to be placed through the holder, and slightly penetrate the surface of the skin. An x-ray image is then taken to ensure that the whole device can be seen on the screen. Image calibration is then performed through the software GUI. After which, the clinician is also to perform needle tip selection. After which, needle alignment will then be performed. Once needle alignment is complete, the clinician will then advance the trocar needle into the patient's body, using the fluoroscopy to judge the penetration depth. Once the target has been reached, the needle style is to be extracted. The indication of leakage of fluid through the outer needle confirms the success of the procedure.
40972788|NCT03057431|DRUG|Placebo oral capsule|Once daily for 3 years
40972789|NCT03057431|DRUG|12.5 mg hydrochlorothiazide|Once daily for 3 years
40972790|NCT03057431|DRUG|25.0 mg hydrochlorothiazide|Once daily for 3 years
40972791|NCT03057431|DRUG|50.0 mg hydrochlorothiazide|Once daily for 3 years
40972792|NCT00002862|DRUG|perillyl alcohol|
41139508|NCT00512902|DRUG|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
40972793|NCT02141243|PROCEDURE|Lingual Frenotomy|For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.
41139509|NCT00512902|DRUG|Imatinib|Up to 600 mg QD PO for up to 1 year.
41139510|NCT05062070|DRUG|TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
40769833|NCT03596554|OTHER|Descriptive study|Description of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).
41139511|NCT05062070|DRUG|Vehicle Topical Gel|TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
41139512|NCT05344209|BIOLOGICAL|UV1|UV1 vaccine
41139513|NCT05344209|DRUG|Sagramostim|for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
40769835|NCT06564363|DIAGNOSTIC_TEST|IUrisure test|Postoperative patients are followed up every three months on average, and IUrisure test was performed at each follow-up visit.
41139514|NCT05344209|DRUG|Anti-PD-1/PD-L1 treatment|either pembrolizumab, atezolizumab or cemiplimab
41139515|NCT04604717|OTHER|Pulmonary rehabilitation|8 weeks of exercise training (twice weekly) of education and exercise
40972794|NCT02141243|PROCEDURE|Labial Frenotomy|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
40972795|NCT02141243|PROCEDURE|Sham Procedure|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
40972796|NCT02521636|OTHER|Antibiotic therapy randomization|
40972797|NCT02521636|OTHER|Serum PCT dosage|
40972798|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
40972799|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
40972800|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
40972801|NCT00864214|DRUG|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
40972802|NCT03694821|DRUG|Ketorolac Tromethamine Injection|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
40972803|NCT03694821|DRUG|Methylprednisolone Acetate Injection|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
40972804|NCT03694821|DRUG|Hylan G-F 20|One knee injection of Hylan G-F 20 (Synvisc-One)
40972805|NCT02055716|DRUG|Sulforadex|
40972806|NCT02055716|DRUG|alpha-cyclodextrin|
41139516|NCT04806659|DRUG|SH1573 Capsules|Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
41139517|NCT01921166|DRUG|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
41139518|NCT01921166|DRUG|Leuprolide flare|Leuprolide flare ovulation induction
40972807|NCT04061915|BEHAVIORAL|Infographic Intervention|The intervention consists of participants viewing an HIV self-testing infographic.
40972808|NCT04061915|BEHAVIORAL|Paper-based HIV self-testing information|The control arm will read paper-based HIV self-testing instructions.
40972809|NCT02654522|DRUG|Hylenex|1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
41139519|NCT00604461|DRUG|Carboplatin, Bevacizumab and Pemetrexed|Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
41139520|NCT02033174|OTHER|Oral fat diet plus water with sugar|All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.
40769836|NCT06571890|DEVICE|Narcotrend bispectral index anaesthesia monitor|A bispectral index anaesthesia monitor collects simplified EEG via forehead electrodes and displays an index of 0-100, where an index of 40-60 is considered optimal
40769837|NCT06571890|DEVICE|Mdoloris Anaesthesia Nociception Monitor|A heart rate variability-based nociception monitor collects ECG-signal from electrodes on the patient's chest and displays an index of 0-100 where an index below 50 is considered nociceptive.
40972810|NCT03608449|OTHER|questionnaires|questionnaire about mental health status during psychotherapy
40972811|NCT04240067|DIAGNOSTIC_TEST|READ-MA Multimarker Approach|The presence or absence of ALSHF (gold standard used in the READ study) : diagnosis by 2 experts (cardiologist and emergency physician) based on data collected in the ED and during hospitalization (clinical examination, history, usual treatment, haemodynamic parameters, ECG, chest X-ray, emergency treatment, clinical and paraclinical results during hospitalization), biological assays (except NT-proBNP) and echocardiography (Left Ventricular Ejection Fraction, segmental kinetic, potential valvulopathy, transmitral flow, tissue doppler E' velocity) performed by a cardiologist within 24 hours of admission.
40972812|NCT02066870|DRUG|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
41139521|NCT02033174|OTHER|Oral fat diet plus alcoholic beverages|Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.
41139522|NCT02138838|DRUG|Cinacalcet HCl|Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
40769838|NCT03558126|DEVICE|silicone tube|
40972813|NCT02066870|DRUG|Arsenic trioxide|"Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
40769839|NCT03592017|DEVICE|Long-wavelength autofluorescence imaging|Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
40769840|NCT01657188|DEVICE|Cheyne-Stokes respiration by adaptive servoventilation|
40972814|NCT00003325|PROCEDURE|Sentinel lymph node mapping|Sentinel lymph node mapping
40972815|NCT02315001|DRUG|Liraglutide|GLP-1 receptor agonist administered via subcutaneous injection
40972816|NCT02315001|OTHER|Placebo|Volume-matched normal saline placebo administered via subcutaneous injection
41139523|NCT02138838|DIETARY_SUPPLEMENT|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
41139524|NCT06245564|DRUG|Ketamine 0.5%|Ketamine cream 0.5% will be applied in a 4x4 area in the forearm of each participant.
41139525|NCT06245564|DRUG|Amitriptyline|Amitriptyline cream 1% will be applied in a 4x4 area in the forearm of each participant.
41139526|NCT06245564|DRUG|ketamine + amitriptyline|A cream containing ketamine 0.5%, amitriptyline 1%, will be applied in a 4x4 area in the forearm of each participant.
41139527|NCT06245564|OTHER|Vehicle|A vehicle cream will be applied in a 4x4 area in the forearm of each participant.
41139528|NCT06245564|OTHER|Histamine|After the cream removal, itch will be induced using histamine in the first session
41139529|NCT06245564|OTHER|Cowhage|After the cream removal, itch will be induced using cowhage in the second session
41139530|NCT02290548|DEVICE|high flow nasal cannula|High flow nasal cannula used in postextubation patients
41298623|NCT05438680|DIETARY_SUPPLEMENT|The bovine colostrum ( trade name : baby steps sachets, 300mg )|"The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.~Enteral route, either through nasogastric tube or orally."
41298624|NCT05438680|DIETARY_SUPPLEMENT|Placebo|distilled water with no bovine colostrum
41298625|NCT04760314|DRUG|Lebrikizumab|Administered SC
40972817|NCT03018704|DRUG|Topiramate|anticonvulsant medication. The medication was dosed twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
40972818|NCT03018704|DRUG|placebo|inactive medication. the doses of placebo were titrated the same as the active intervention.
40972819|NCT02038023|DRUG|Intravaneous iron(low molecular weight iron dextran)|1000 mg of Iron dextran administered over one hour
41139531|NCT01000207|BIOLOGICAL|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
41139532|NCT01355445|DRUG|Vincristine, Irinotecan|"* D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days"
41139533|NCT01355445|DRUG|Vincristine, Irinotecan, Temozolomide|"* D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience \> grade 3 toxicity of any kind)~* D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days"
41139534|NCT04555226|PROCEDURE|Lymph node dissection|Open/minimaly invasive pelvic and para-aortic lymph node dissection
41139535|NCT04555226|RADIATION|Standard chemoradiation|"1. A point/HCR-CTV D90 ≥80Gy（+20%）~2. Extended-field EBRT: image-positive common iliac lymph nodes with short diameter ≥10mm and/or image-positive para-aortic lymph node~3. Target doses for the image-positive nodes can range from 55 to 60Gy~4. Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~5. CCRT will be completed in 56 days~6. After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) will be performed."
41298626|NCT04760314|DRUG|Placebo|Administered SC
41298627|NCT04760314|DRUG|Topical Corticosteroid|Self-applied
41298628|NCT00020930|BIOLOGICAL|cetuximab|
41298629|NCT06316258|BEHAVIORAL|Compassion focused therapy group|6 session compassion focused therapy group for adults with ABI
41298630|NCT00198341|PROCEDURE|Radiological Arm|Clinical Visit + X-Ray Chest
41298631|NCT00198341|PROCEDURE|Scannographic arm|Clinical visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous cell)
41298632|NCT00746577|OTHER|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
41298633|NCT05241171|DEVICE|Fitbit|The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.
40769841|NCT05852431|DRUG|Pegozafermin|Subcutaneous injection
40769842|NCT05852431|DRUG|Placebo|Subcutaneous injection
40769843|NCT03887780|DRUG|Rivaroxaban (Xarelto,Bay 59-7939)|15 mg and 20 mg (OD)
40769844|NCT06000683|BEHAVIORAL|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
40769845|NCT06000683|BEHAVIORAL|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
40972820|NCT00439244|DRUG|Zoledronic acid|Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
40769846|NCT06000683|BEHAVIORAL|Patient Reminders|Within 2 weeks prior to primary care appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss the LCS with their provider.
40972821|NCT00439244|DRUG|Placebo|Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
40972822|NCT00439244|DRUG|Teriparatide|"Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days."
41139536|NCT04555226|RADIATION|Chemoradiation|"1. A point/HCR-CTV D90 ≥80Gy（+20%）~2. Extended-field EBRT: Pathlogical positive para-aortic lymph node~3. Target doese for pelvic and/or abdomal lymph nodes is usually 45Gy. After operation, the residual lymph node need to be labeled and the target doses for it ranges from 55-60Gy.~4. Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~5. CCRT will be completed in 56 days~6. After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) will be performed."
41139537|NCT05193175|BEHAVIORAL|Prolonged sitting|Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping
41139538|NCT04897347|DEVICE|Robotic Trunk-Support-Trainer (TruST)|"This will involve tailoring the level of postural assistance via force fields and systematically introduce postural task-progression across training sessions. Age-appropriate activities, including toys and games, will be used in training.~- Twelve 2hr training sessions (3 times per week for 4 weeks)"
41139539|NCT04897347|DEVICE|Static Trunk Support|"This will involve static support for the trunk via a trained therapist. Age-appropriate activities, including toys and games, will be used in training.~- Twelve 2hr training sessions (3 times per week for 4 weeks)"
41139540|NCT02765867|DRUG|RBP-6000|A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system
41139541|NCT04500665|DRUG|Colchicine|Colchicine
41139542|NCT04500665|DRUG|Placebo|Placebo
41139543|NCT01623609|DRUG|Naloxegol|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
40769847|NCT06000683|BEHAVIORAL|Provider Reminers|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for LCS.
40769848|NCT06409130|DRUG|NNC0194-0499|Administered subcutaneously.
40769849|NCT06409130|DRUG|Semaglutide|Administered subcutaneously.
40769850|NCT06409130|DRUG|NNC0194-0499 placebo|Administered subcutaneously.
41139544|NCT01623609|DRUG|Naloxegol|Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
41139545|NCT05983861|DIAGNOSTIC_TEST|Identification o Multi Drug Resistant Bacteria|Identification o Multi Drug Resistant Bacteria
41298634|NCT05940987|BEHAVIORAL|Phone-based smoking cessation intervention|Participants who allocate to the intervention group will receive regular phone-based smoking cessation intervention by professional team.
40769851|NCT06409130|DRUG|Semaglutide placebo (Group A)|Administered subcutaneously.
40769852|NCT06409130|DRUG|Cagrilintide + semaglutide|Administered subcutaneously.
40769853|NCT06409130|DRUG|Cagrilintide|Administered subcutaneously.
40769854|NCT06409130|DRUG|Cagrilintide placebo|Administered subcutaneously.
40769855|NCT06409130|DRUG|Semaglutide placebo (Group B)|Administered subcutaneously.
40769856|NCT02041273|DRUG|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under overnight fasting conditions
40769857|NCT02041273|DRUG|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under minimal fasting conditions (1 hr before palbociclib administration and 2 hrs post dose)
40972823|NCT01479673|DIETARY_SUPPLEMENT|Indirect Calorimetry measurement of Resting Energy Expenditure .|Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
40972824|NCT00965718|BIOLOGICAL|Activated T lymphocyte|Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.
40972825|NCT05619263|BEHAVIORAL|Disaster PrepWise-Caregiver|The Disaster PrepWise (DPW) intervention consists of five interactive modules and two supplemental sections (special topics and resources on various types of disasters). The five modules are: (1) Complete a Personal \& Household Assessment, (2) Develop a Personal Emergency Network, (3) Develop Emergency Information \& Gather Important Documents, (4) Keep a 3-5 Day Supply of Medications \& Medical Supplies, and (5) Build an Emergency Supply Kit. Through an initial visit (IV1) and a follow-up phone conversation 4 weeks later (IV2), the interventionist will develop a personalized disaster management plan and provide it to the participant for sharing with family and friends. Eight weeks after the initial session, the interventionist will make a final follow-up call (IV3) to provide any additional assistance caregivers may need.
40972826|NCT02268604|DRUG|BIIB 722 CL|
40972827|NCT02268604|DRUG|Placebo|
41466533|NCT04608201|DRUG|Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|"Treatment involves escalating doses to the target dose of 14 mg / day~1. / Dose escalation:~   * Level 1: 3.5 mg/day (1/2 patch) for 2 days (D1 and D2)~  * Level 2: 7 mg/day (1 patch) for 2 days (D3 and D4)~  * Level 3: 10.5 mg/day (1.5 patch) for 2 days (D5 and D6)~  * Level 4: target dose = 14 mg/day (from D7 to discharge from hospital + 1 week or maximum 5 weeks after the start of treatment)~2. / Decrease in dose (1 week after exit from hospital or maximum 5 weeks after the start of treatment): Decrease of 3.5 mg (1/2 patch) per week (over 3 weeks maximum)"
41466534|NCT04608201|DRUG|Placebo of NICOTINE Transdermal patch|Placebo of nicotine patch administered to the same administration schedule as in the experimental arm
40972828|NCT04258384|OTHER|survey application|Data collection tools used in the study; Demographic Data Form, Mcgill and Melzack Pain Questionnaire, Short Form-36 (SF-36), Vanderbilt Multidimensional Pain Coping Inventory (VMPCI), Pain Coping Inventory (PCI), Pain Coping Scale were used.
40972829|NCT05926102|GENETIC|Precision screening intervention|The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
40972830|NCT05926102|OTHER|Usual care|Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
40972831|NCT01327521|DEVICE|CyberKnife|Standard of Care
40972832|NCT01327521|PROCEDURE|TACE|Standard of Care
40972833|NCT01327521|DRUG|CT Contrast|Standard of Care
40972834|NCT01327521|DRUG|doxorubicin|Standard of Care
40972835|NCT01327521|DRUG|Epirubicin|Standard of Care
40972836|NCT01327521|DRUG|5-fluorouracil|Standard of Care
41298635|NCT02949765|DRUG|Iron sulfate 105 mg|Daily supplementation with iron sulfate 105 mg 1 pill/day
40972837|NCT01327521|DRUG|Mitomycin C|Standard of Care
40972838|NCT01327521|DRUG|Gemcitabine|Standard of Care
40972839|NCT01327521|DRUG|Cisplatin|Standard of Care
40972840|NCT01327521|DEVICE|SMANCS|Standard of Care
40972841|NCT01240447|BIOLOGICAL|racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
40972842|NCT01240447|OTHER|Best support treatment|Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
40769858|NCT02041273|DRUG|palbociclib commercial free base capsule|125 mg palbociclib commercial free base capsule under fed conditions ( moderate fat meal)
40972843|NCT03047694|OTHER|tablet therapy|stimulation of the lexico semantic system on a tactile tablet therapy for 3 months
40972844|NCT03047694|OTHER|usual care|speech therapy
40972845|NCT00775424|BIOLOGICAL|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
40972846|NCT00775424|BIOLOGICAL|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
40972847|NCT00775424|BIOLOGICAL|PLACEBO|PLACEBO
41139546|NCT00234676|DRUG|Premarin ®|Premarin ® 0.625 mg per day orally
41298636|NCT02949765|DIETARY_SUPPLEMENT|Iron-rich diet|
41298637|NCT05791318|DRUG|VYD222|Monoclonal antibody
41298638|NCT05791318|OTHER|Placebo|Matching Placebo
41298639|NCT05279794|OTHER|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
41298640|NCT05279794|OTHER|Myofascial Induction Group|Myofascial Induction technique on the lumbar fascia
41298641|NCT05279794|OTHER|Placebo Group|No pain positioning of participants
40769859|NCT05893732|DEVICE|High-Intensity Laser Therapy (HILT)|Participants will undergo HILT treatment using a diode laser device (wavelength: 1064 nm; power: 12 W; peak power: 50 W; energy density: 600 J/cm²; spot size: 1 cm²; pulse duration: 200 μs; pulse frequency: 10 Hz) applied in continuous mode. The laser probe will make contact with the skin over the LFCN entrapment site at three specific points: (a) the inguinal ligament, (b) the point of maximum tenderness along the nerve pathway, and (c) the mid-point between the ASIS and the lateral border of the patella. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
40972848|NCT00775424|BIOLOGICAL|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
41458831|NCT02288923|DRUG|Intra-operative medication|If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
40769860|NCT05893732|DEVICE|Sham High-Intensity Laser Therapy (Sham HILT)|Participants will undergo sham HILT treatment using an identical laser device with no active laser output, following the same treatment protocol as the HILT group. The laser probe will make contact with the skin over the LFCN entrapment site at the same three specific points as the HILT group. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
40769861|NCT05366751|DRUG|SAGE-324|SAGE-324 oral tablets
40972849|NCT00375076|DRUG|enoxaparin|
40972850|NCT04219943|PROCEDURE|Surgical Treatment for Impacted Femoral Neck Fracture|Surgical Treatment for Impacted Femoral Neck Fracture
40972851|NCT00134095|DRUG|irinotecan hydrochloride|
40972852|NCT00134095|DRUG|tegafur-gimeracil-oteracil potassium|
41298642|NCT05649514|PROCEDURE|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
41298643|NCT05649514|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
41298644|NCT05649514|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
41298645|NCT05649514|PROCEDURE|Actimetrics|Measurement of actimetrics for 14 days at inclusion and at 24 months
41298646|NCT05649514|OTHER|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
41298647|NCT06553313|DEVICE|Micro-Western Array|The subjects first took the energy measurement of the pulse sphygmograph and Ryodoraku, rested for 20 minutes, and then repeated the measurements again. In order to comply with the acupuncture treatment course was 5 weeks in the previous study, we have two blood draw point. Each subject's blood was drawn for the first time, and then for the second time in 5 weeks later. Each subject drew 10ml of blood each time. The blood samples are analyzed by Micro-Western Array (MWA) and Enzyme-linked immunosorbent assay (ELISA) to obtain the serum protein content value of healthy individuals.
41458832|NCT02288923|DRUG|Post-operative analgesia - morphine|Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight \>70kg 2 hourly.
41458833|NCT02288923|DRUG|Post-operative analgesia - ibuprofen and paracetamol|All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
40769862|NCT00890760|BIOLOGICAL|AdCh63 ME-TRAP|5 x 10\*10 vp IM
41298648|NCT00382096|DRUG|Vildagliptin|
41458834|NCT02288923|DRUG|Regular anti emetics|All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
40769863|NCT00890760|BIOLOGICAL|MVA ME-TRAP|2 x 10\*8 pfu ID
40972853|NCT00134095|PROCEDURE|adjuvant therapy|
41298649|NCT00382096|DRUG|Metformin|
41298650|NCT00382096|DRUG|Vildagliptin + Metformin|
41298651|NCT01072864|OTHER|Walnuts|Consumption of 5 g of walnuts.
41458835|NCT04835116|DRUG|Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.|Group A patients were administered per-operative peri tract local anesthesia infiltration with 0.25% bupivacaine augmented by post-operative oral analgesia with a combination of Paracetamol 650 mg and Orphenadrine 50mg 6 hourly.
40972854|NCT00134095|PROCEDURE|conventional surgery|
40972855|NCT00134095|PROCEDURE|neoadjuvant therapy|
40972856|NCT03809117|DIAGNOSTIC_TEST|Biofire Film Array Gastrointestinal Panel|The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.
40972857|NCT03369392|OTHER|Panda application|A smartphone-based postoperative pain management tool
41139547|NCT00240994|DRUG|Alemtuzumab|Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
41298652|NCT01072864|OTHER|Walnuts|Consumption of 20 g of walnuts.
41298653|NCT01072864|OTHER|Walnuts|Consumption of 30 g of walnuts.
40972858|NCT00005589|BIOLOGICAL|filgrastim|
40972859|NCT00005589|BIOLOGICAL|rituximab|
40972860|NCT00005589|DRUG|carmustine|
40972861|NCT00005589|DRUG|cyclophosphamide|
40972862|NCT00005589|DRUG|cytarabine|
40972863|NCT00005589|DRUG|etoposide|
40972864|NCT00005589|DRUG|melphalan|
41298654|NCT01072864|OTHER|Walnuts|Consumption of 40 g of walnuts.
41298655|NCT04328740|DRUG|TP-1454 monotherapy|Flat dose once or twice daily, alone
40972865|NCT00005589|PROCEDURE|bone marrow ablation with stem cell support|
40972866|NCT00005589|PROCEDURE|peripheral blood stem cell transplantation|
40972867|NCT06497933|PROCEDURE|Atrial fibrillation ablation|Pulmonary veins isolation potentially associated with other atrial lesions, performed with the pentaspline PFA catheter
40769864|NCT00890760|OTHER|Sporozoite challenge|Infected mosquito bite
40769865|NCT00890760|BIOLOGICAL|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10\*10 vp MVA ME-TRAP 2 x 10\*8 pfu
40769866|NCT05652569|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions
40769867|NCT03490240|BEHAVIORAL|BIPAMS|"The primary content of the website is delivered through interactive video courses. The interactive video courses are released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~Another key part of the website is the Tracker feature. This feature allows for tracking of daily step counts (via Yamax SW-200 pedometer) as well as setting goals and monitoring progress over the program.~The one-on-one video chats are conducted face to face through skype and are semi-scripted. The chats consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral change based on SCT and current website content. The chats occur seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention."
40769868|NCT03490240|BEHAVIORAL|WELLMS|The control condition focuses on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the NMSS, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. The participants in the control condition will not be offered the behavioral intervention for increasing physical activity after completion of the study procedures.
40972868|NCT00139009|DRUG|Cyclosporine A|
40972869|NCT05955027|DRUG|ZX-7101A|a drug to treat influenza, oral
41466535|NCT01177163|DRUG|Placebo|one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
40769869|NCT02697448|DRUG|propofol|Participant receives propofol as anesthetic for cardiac ablation.
40769870|NCT02697448|DRUG|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
40769871|NCT01833078|DRUG|ghrelin|ghrelin administration subcutaneously for 7 days
40972870|NCT05955027|DRUG|Placebo|placebo control, oral
40972871|NCT03679936|DIAGNOSTIC_TEST|PET/CT dynamic scan|This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.
40972872|NCT02671552|DRUG|Perflutren Protein-Type A Microspheres|Given IV
40972873|NCT02671552|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
40972874|NCT03808493|DRUG|TAK-438 OD|TAK-438 OD tablet
40972875|NCT03808493|DRUG|TAK-438|TAK-438 tablet
40972876|NCT05557799|RADIATION|Photobiomodulation|The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.
40972877|NCT05557799|RADIATION|Placebo Photobiomodulation|The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
40769872|NCT03921567|DRUG|Lidocaine Hydrochloride|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
40769873|NCT03921567|DRUG|Lidocaine Hydrochloride and Ketamine|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
40769874|NCT03921567|DRUG|Placebo|will be given opioids during surgery, and opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
40769875|NCT01044069|BIOLOGICAL|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed \& frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, \& transduced with the 19-28z chimeric receptor \& expanded. All relapsed (either MRD+ or morphologic) \& refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo \& highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
40769876|NCT05548283|DRUG|Beta-lactam antibiotic|Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
40769877|NCT05548283|DRUG|Aminoglycoside|Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
40769878|NCT03900650|BEHAVIORAL|High provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
40769879|NCT03900650|BEHAVIORAL|Low provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
40769880|NCT03900650|BEHAVIORAL|Alcoholic beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
40769881|NCT03900650|BEHAVIORAL|Non-alcoholic beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
40769882|NCT04023045|DEVICE|Assist-Knee|Assist-Knee is an experimental lower limb knee prosthesis.
40769883|NCT04023045|DEVICE|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
40769884|NCT04586660|DRUG|XGEVA®|Participants will receive XGEVA® 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15.
40769885|NCT04732468|BIOLOGICAL|hAd5-S-Fusion+N-ETSD (Suspension for injection)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
40769886|NCT04732468|DRUG|hAd5-SFusion+ N-ETSD (Oral capsule)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
40769887|NCT02615613|OTHER|Low Acceptability Meal|
40769888|NCT02615613|OTHER|High acceptability meal|
40769889|NCT04667572|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
40972878|NCT04953780|DRUG|Calaspargase pegol-mknl|Calaspargase pegol-mknl
41458836|NCT04835116|DRUG|paracetamol 1000mg. Tramadol 50mg. Dimenhydrinate 50mg.|Group B patients were only given post-operative intra-venous analgesia by Paracetamol 1gm intravenous 8 hourly augmented with a combination of Tramadol 50mg and Dimenhydrinate 50mg as and when required
40972879|NCT00671697|DRUG|Arsenic Trioxide|
40972880|NCT00671697|DRUG|Decitabine|
40972881|NCT04376710|OTHER|Completion of pre-pandemic survey|Surgeons will take a pre-pandemic survey to determine surgeon perceptions to telemedicine and barriers to implementation.
41139548|NCT00240994|DRUG|Tacrolimus|Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
41139549|NCT00240994|DRUG|Mycophenolate mofetil|Per recommendation
40972882|NCT04376710|OTHER|Completion of survey after peak of pandemic|Surgeons will take another survey after the peak of pandemic to determine surgeon perceptions to telemedicine and barriers to implementation.
40972883|NCT04376710|OTHER|Completion of post telemedicine encounter survey|Patients will take a post telemedicine encounter survey to determine patient perceptions to telemedicine and barriers to implementation.
40972884|NCT00380497|DRUG|PEG-Lyte®|
40972885|NCT00380497|DRUG|Pico-Salax®|
41139550|NCT00240994|DRUG|Sirolimus|Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
41139551|NCT04571944|DRUG|Suvorexant|Suvorexant administered at a dose of 15 mg QD via oral tablet
41139552|NCT04571944|DRUG|Placebo|Suvorexant-matching placebo administered QD via oral tablet
41139553|NCT00070421|PROCEDURE|complementary or alternative medicine procedure|
41139554|NCT00070421|PROCEDURE|management of therapy complications|
41139555|NCT00070421|PROCEDURE|psychosocial assessment and care|
41139556|NCT01276275|DRUG|Risk of selected safety events|First time users of ticagrelor, clopidogrel and prasugrel, respectively
41139557|NCT05885516|PROCEDURE|intrauterine insemination|Giving washed sperm concentrate into uterine cavity via a soft catheter
41139558|NCT01584167|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
41139559|NCT01584167|DEVICE|EMCOOLS Flex.Pads|Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
41458837|NCT00273130|PROCEDURE|transnasal endoscopy|
41458838|NCT00273130|PROCEDURE|transoral thin endoscopy|
41458839|NCT01574027|DRUG|Vitamin D3 (cholecalciferol)|One capsule per day for six months
40972886|NCT02525341|OTHER|Hatha yoga|A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.
40972887|NCT02525341|OTHER|Aerobic and strengthening exercises|A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.
41458840|NCT01574027|DRUG|Placebo|One capsule per day for six months
40972888|NCT02525341|OTHER|General education|One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
40972889|NCT05770856|DIAGNOSTIC_TEST|Metagenomic sequencing|Samples shall be submitted to high throughput sequencing using both illumine MiSeq and Oxford Nanopore Technologies.
40972890|NCT01024634|BEHAVIORAL|Endurance Exercise|8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
40972891|NCT00569478|OTHER|rehabilitation|Nursing consultations and physical training
40972892|NCT03406572|DEVICE|HFHO Group|"* Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~* Brand name: Airvo 2"
40972893|NCT03406572|DEVICE|Standard O2|Standard oxygen therapy
40972894|NCT02432014|BEHAVIORAL|PMTO-PTC Group clinic-based|
40972895|NCT02432014|BEHAVIORAL|PMTO Individual home-based|
41458841|NCT00926367|DRUG|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
41458842|NCT00926367|DRUG|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
40972896|NCT02432014|BEHAVIORAL|PMTO Individual clinic-based|
40972897|NCT02432014|BEHAVIORAL|Services as Usual|
40972898|NCT03598621|DRUG|Semaglutide, 0.5 mg/mL|A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
40972899|NCT03598621|DRUG|Semaglutide, 1.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
41139560|NCT05052398|DRUG|PSP NEURO SERUM|PSP NEURO SERUM is a topical product that contains a concentration of Paralytic Shellfish Toxins of 10 micrograms/mL of equivalent of Gonyautoxin 2/3. Each patient will apply 1 g of PSP NEURO SERUM in their hands, three times a day.
41298656|NCT00510588|OTHER|training|regular physical exercise training for 6 months
41139561|NCT05052398|DRUG|Placebo PSP NEURO SERUM|Placebo PSP NEURO SERUM is the same topical product as PSP NEURO SERUM without the active ingredient. Each patient will apply 1 g of Placebo PSP NEURO SERUM in their hands, three times a day.
41139562|NCT04413994|DIETARY_SUPPLEMENT|Humavant|"Premature infants are randomized to either:~1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR~2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.~After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included."
41298657|NCT00510588|OTHER|training + metformin|regular physical exercise training in combination with metformin for 6 months
41298658|NCT00510588|OTHER|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
41298659|NCT05892783|OTHER|manual treatment|soft tissue mobilization applied by the therapist on the plantar fascia of both legs and self massage and stretching using foam roller and self stretching.
41298660|NCT01221675|DRUG|Antibody TF2|preciblage with an antibody
41298661|NCT01221675|RADIATION|IMP-288-Lutetium|Internal Radiation
41458843|NCT01524016|DRUG|68Ga-DOTATATE|Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
40972900|NCT03598621|DRUG|Semaglutide, 1.34 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
40972901|NCT03598621|DRUG|Semaglutide, 2.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
40972902|NCT03598621|DEVICE|DV3372, 0.5 mg/mL|DV3372 device will be used for administration of semaglutide 0.5 mg/mL.
40972903|NCT03598621|DEVICE|DV3372, 1.0 mg/mL|DV3372 device will be used for administration of semaglutide 1.0 mg/mL.
40972904|NCT03598621|DEVICE|PDS290|PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.
41298662|NCT01221675|RADIATION|IMP-288-Indium|Imaging
41298663|NCT05859880|BEHAVIORAL|Expressive writing intervention|4 videoconference-delivered group-based expressive writing sessions
40972905|NCT03598621|DEVICE|NovoPen®4|NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
40972906|NCT05990972|PROCEDURE|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation (FMT) is a therapeutic method to transplant the microbiota from the feces of healthy people into the intestinal tract of patients. This treatment aims to improve a range of diseases associated with the gut microbiota by restoring the balance of the gut microbiota.
40972907|NCT03710538|DIETARY_SUPPLEMENT|Snack beverage|Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
40972908|NCT03710538|BEHAVIORAL|Exercise|3min walk at 60% VO2max every 30 minutes,(x5)
41458844|NCT04411654|GENETIC|LY3884961|Participants will receive a single dose of LY3884961 administered intracisternally.
41458845|NCT04411654|DRUG|Methylprednisolone|Single IV pulse administered as concomitant medication.
41458846|NCT04411654|DRUG|Sirolimus|Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.
41458847|NCT04411654|DRUG|Prednisone|Administered orally as concomitant medication, followed by dose tapering.
41458848|NCT01189656|BIOLOGICAL|HBV DNA Vaccine|HBV DNA Vaccine, 1mg/ml/syringe, formulation
41458849|NCT01783392|PROCEDURE|Transcutaneous Electrical Nerve Stimulation|
40769897|NCT06317987|BEHAVIORAL|Care Navigation|Care navigation is an intervention that seeks to help patients follow up on substance use treatment plans that are established by care coordinators in the health system by reducing barriers to accessing treatment. This includes advocating for patients to reduce disparities based on language, income or geographical barriers, and cultural preferences (i.e., linkage to available services); and using motivational enhancement techniques to help patients maintain their motivation to obtain substance use treatment while working through these barriers (i.e., motivational intervention). Thus, the care navigator's role is to take the care plan developed between the patient and the mental health care coordinator forward and connect the patient to available services and provide motivational enhancement techniques to help direct the patient toward completion of the care plan.
40769898|NCT03729609|DRUG|Brentuximab vedotin (Genetical Recombination)|Brentuximab vedotin Intravenous Infusion
40972909|NCT00526513|DRUG|Insulin Glulisine|subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
40972910|NCT00878085|DEVICE|Robot Therapy Device|3x a week for 4 weeks
40972911|NCT00878085|BEHAVIORAL|Occupational Therapy|3x a week for 4 weeks
40972912|NCT03081065|DIETARY_SUPPLEMENT|Mediterranean Diet|Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
40972913|NCT04691505|DRUG|Methotrexate|Methotrexate is used as the reference group.
40972914|NCT04691505|DRUG|Hydroxychloroquine|Hydroxychloroquine is used as the exposure group.
40972915|NCT05289180|OTHER|Questionnaires|A questionnaire will be administered post-procedure to assess for pain and anxiety. This questionnaire will be administered by study personnel delegated to administer questionnaires, namely the study coordinator or PI.
40972916|NCT02263989|DRUG|Telmisartan film coated tablet|
40972917|NCT02263989|DRUG|Telmisartan conventional tablet|
40972918|NCT02498314|OTHER|Grade I-II SZ mobilization|Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
40972919|NCT02498314|OTHER|Grade II TZ mobilization|Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
41139563|NCT05260944|DEVICE|Acapella device|patients will receive a two supervised sessions using acapella device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
41458850|NCT05848440|DRUG|AZD9550|Participants will be administered AZD9550 subcutaneously.
40769899|NCT05083481|DRUG|ASP1570|Oral tablet
40769900|NCT05083481|DRUG|pembrolizumab|Intravenous Infusion
40972920|NCT02498314|OTHER|Grade III mobilization|Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
41298664|NCT00387660|DRUG|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
40972921|NCT00628784|PROCEDURE|Endoscopic spray cryotherapy|A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
41139564|NCT05260944|DEVICE|Power lung device|Group B. patients will receive a two supervised sessions using power lung device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
40972922|NCT00628784|PROCEDURE|Endoscopic spray cryotherapy|After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
40972923|NCT03674749|OTHER|Meditation and Hyperbaric Oxygen Treament|Meditation sessions will be combined with hyperbaric oxygen treatment
40972924|NCT03640130|BEHAVIORAL|Gaze-contingent text enhancement|"In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight."
40972925|NCT02034279|DRUG|Albumin|Intravenous infusion of 20% albumin
40972926|NCT04625309|OTHER|Adaptive sports|This will be the number of hours per week the subjects actively partake in adaptive sports teams.
40972927|NCT03180723|DRUG|Rituximab|Intravenous injection
40972928|NCT03180723|DRUG|Cyclosporin|Oral tablets
40972929|NCT01423058|DRUG|Momelotinib|"In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles."
40972930|NCT05783778|DIAGNOSTIC_TEST|Free testosterone levels and toxoplasma igG|Free testosterone levels and toxoplasma igG in serum by ELISA
40972931|NCT00892853|PROCEDURE|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
41139565|NCT05260944|OTHER|routine Physical Therapy program|Group C. Thirty patients will receive only routine physical Therapy program
41139566|NCT00368394|DRUG|Insulin glulisine|
41139567|NCT03163472|PROCEDURE|Axillary brachial plexus block with 10 mL oof local anaesthetic|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
41139568|NCT03163472|PROCEDURE|Axillary brachial plexus block with 30 ml of local anaesthetic|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
41139569|NCT05377476|OTHER|Motor Imagery training|Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation.
41139570|NCT05377476|OTHER|Action Observation training|Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation.
41298665|NCT00387660|DRUG|irinotecan|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
41298666|NCT01340235|DRUG|Oral erythromycin|Severe Dowling Meara EBS patients from 6 months to 8 years old
41298667|NCT01914445|DRUG|Indigo Carmine|Oral administration of Indigo Carmine prior to colonoscopy
41458851|NCT05848440|DRUG|AZD9550|Participants will be administered AZD9550 intravenously.
40769901|NCT00740675|OTHER|Outpatient Medication Reconciliation|"The post-discharge medication reconciliation module has the following features:~1. Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~2. Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~3. Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists)."
40769902|NCT06249919|BIOLOGICAL|NS101|NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
40769903|NCT06249919|BIOLOGICAL|Placebo|Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
40769904|NCT06592001|DEVICE|Atala™ lead|Subjects will receive the Atala™ lead being evaluated in the study.
40972932|NCT02566655|BIOLOGICAL|Fucosylated MSC for Osteoporosis|"Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access."
40972933|NCT01311570|DRUG|Buprenorphine|"In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.~From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician."
40972934|NCT03229850|DRUG|Insulin lispro|Insulin lispro will be injected into the abdomen into an area of subclinical lipohypertrophy or an area with no subclinical lipohypertrophy
40972935|NCT03580694|DRUG|REGN4659|REGN4659 will be administered by intravenous (IV) infusion.
40972936|NCT03580694|DRUG|Cemiplimab|Cemiplimab will be administered by intravenous (IV) infusion.
41139571|NCT05377476|OTHER|standard rehabilitation|40 minutes of standard rehabilitation.
41139572|NCT01128322|DRUG|S-Amlodipine, Telmisartan|
41139573|NCT01128322|DRUG|S-Amlodipine|
41139574|NCT01128322|DRUG|Telmisartan|
41298668|NCT06503653|DIAGNOSTIC_TEST|syncope channel|"The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.~No additional procedures, invasive or non-invasive explorations or blood sampling not provided for as part of routine care will be offered or carried out as part of the study.~The only change in practice for patients included in the syncope pathway The only change in practice concerns the grouping of patients included in the syncope pathway into a single day at a day hospital within 10 days of their emergency consultation."
41298669|NCT06503653|DIAGNOSTIC_TEST|routine care|"The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.in routine care, medical examinations are carried out by specialists such as cardiologists who do not practice in hospitals"
41139575|NCT01128322|DRUG|Placebo|
40769905|NCT06139354|BEHAVIORAL|decision aid|"A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - I want to do everything I can to prevent HIV, privacy - I don't want others to know about the exposure, or cost - I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making."
40972937|NCT05745584|DRUG|Mirabegron (beta3-adrenoceptor agonist), Anticholinergics|Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
40972938|NCT00902408|DIETARY_SUPPLEMENT|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
40972939|NCT04745429|OTHER|breathing exercises, cold exposure and meditation|It is a combination of exercises that include breathing exercises, cold exposure and meditation
41139576|NCT04930445|DRUG|Oxbryta® (voxelotor) 500mg Tablets|Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
40769906|NCT02800785|DRUG|Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin|Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
40769907|NCT02800785|PROCEDURE|Appendectomy|Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference.
40769908|NCT01166646|DRUG|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
40769909|NCT01166646|DRUG|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
40769910|NCT03451851|DRUG|Guselkumab|Participants will receive a weight-based dose of guselkumab subcutaneously.
40769911|NCT03451851|DRUG|Placebo for guselkumab|Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
40769912|NCT03451851|DRUG|Etanercept|Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
40769913|NCT04794504|DRUG|Botox 100 UNT Injection|Botox will be injected intramuscularly into the masseter and temporalis muscles bilaterally to investigate if it can supplement postoperative analgesia in orthognathic surgery patients
41139577|NCT04101045|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
41458852|NCT05848440|DRUG|Placebo|Participants will be administered matching volumes of placebo subcutaneously or intravenously.
40769914|NCT04794504|OTHER|0.9% Saline Injection|As a placebo control to the 100 UNT Botox injection, 0.9% saline will be injected intramuscularly into the masseter and temporalis muscles bilaterally
40769915|NCT05432609|DIAGNOSTIC_TEST|Weight bearing CT|Weight bearing CT in loaded and unloaded positions
40769916|NCT05967169|DEVICE|Nasal Septal Strap implantation|Correction of NSD with Nasal Septal Strap implant
40769917|NCT00496119|RADIATION|Proton Beam Therapy|70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
40769918|NCT00496119|RADIATION|Photon Beam Therapy|Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
40769919|NCT06632873|DRUG|177Lu-TATE-RGD|accepted intravenous injection of 177Lu-TATE-RGD
40769920|NCT02845414|DRUG|CD133KDEL (dCD133KDEL)|Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
40769921|NCT06073132|DRUG|AC-203|The investigational product is formulated as 1% topical ointment
40769922|NCT06073132|DRUG|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
40769923|NCT06146062|DRUG|Mesenchymal Stromal Cells (MSC)|3 injections one week apart
40769924|NCT06146062|DRUG|placebo|3 injections one week apart
40972940|NCT00493324|DRUG|alefacept|Intramuscular
40972941|NCT00493324|DRUG|polyvalent pneumococcal vaccine|Injection
40972942|NCT00150449|DRUG|Pregabalin|
40972943|NCT01115725|DRUG|Gonal-f® (follitropin alfa)|Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
40972944|NCT04617509|DRUG|Formulation A GS-248|Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
40972945|NCT04617509|DRUG|Formulation B GS-248|Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
40769925|NCT06152224|DEVICE|The Leva Pelvic Health System|The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage.
40769926|NCT01051635|DRUG|LMP400|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
40769927|NCT01051635|DRUG|LMP776|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
40972946|NCT06112782|DEVICE|Keravive by Hydrafacial Treatments|Scalp hydradermabrasion
40972947|NCT01516554|DRUG|Testosterone undecanoate|40 mg twice daily
40972948|NCT01516554|DRUG|placebo|twice daily
40972949|NCT01169974|OTHER|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 \& 3 minutes
40972950|NCT00068497|DRUG|gefitinib|Given orally
40769928|NCT04981392|BEHAVIORAL|Primary care text message outreach to unvaccinated patients and resources to support PCPs|"Patients: Eligible patients will receive a series of text messages from their PCP or primary care clinic recommending a study website as a trusted source of information about the COVID-19 vaccines and information on how and where to schedule a vaccination.~Providers: PCPs will receive resources to support their conversations with patients about the COVID-19 vaccines (factsheets, prescription pads, electronic smartphrase)."
40972951|NCT05029440|OTHER|Pulsed Electromagnetic Field|PEMF was administered to the whole body for PEMF groups using a 1.8×0.6m mat 30 minutes/day, 3 times/week for 3 months.
40972952|NCT05029440|OTHER|Exercise Program|The exercise training program included treadmill and aerobic exercises for hip and upper limb and performed for 50 minutes.
40972953|NCT05029440|OTHER|Pulsed High Laser Therapy|High Laser was delivered with a total dose of energy of 3000 J was delivered in two treatment phases. The initial phase was performed with fast manual scanning at 510, 610, and 710 mJ/cm2 in three successive subphases and 500 J in each subphase for a total of 1500 J. The final phase was the same as the initial phase except that the scanning was slow. The average area for the upper thigh or lower back was 200 cm2 with an average fluency of 15 J/cm2 and the application time for each area was 18 min. HILT was applied using a HIRO 3 device (ASA, Arcugnano, Vicenza, Italy).
40972954|NCT00284271|DRUG|Cyclophosphamide|
41139578|NCT00444054|BEHAVIORAL|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
41139579|NCT02809755|DRUG|4% Lidocaine|
41139580|NCT02809755|OTHER|Saline|
41298670|NCT01344811|PROCEDURE|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
41298671|NCT01344811|OTHER|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
41298672|NCT02495649|OTHER|[18F]-DOPA|To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
41298673|NCT02495649|DEVICE|PET-CT|To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
41298674|NCT02791789|OTHER|Autism Spectrum Disorder|Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
41298675|NCT01254604|DRUG|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
41298676|NCT01254604|DRUG|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
41298677|NCT04068558|DEVICE|VNI-NAVA/sNIPPV|Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
41298678|NCT04068558|DEVICE|sNIPPV/VNI-NAVA|Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
41458853|NCT03650751|OTHER|Nursing observation indexes|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
40769929|NCT05516121|DRUG|VLT-015|100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days
40972955|NCT00284271|DRUG|Adramycin|
40972956|NCT00284271|DRUG|Procarbacine|
41139581|NCT01634802|OTHER|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
41139582|NCT01634802|OTHER|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
41298679|NCT05816239|PROCEDURE|Dual Energy CT|Patient will receive Dual Energy CT
41458854|NCT02018263|DRUG|Cocaine hydrochloride|
41458855|NCT02018263|BEHAVIORAL|Exercise|
41458856|NCT02018263|DRUG|Nicotine|
40769930|NCT05648812|DIAGNOSTIC_TEST|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
40769931|NCT05648812|DRUG|Sulfur Hexafluoride|To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
40769932|NCT04239703|DIAGNOSTIC_TEST|MMDx|Portion of kidney transplant indication biopsy
40769933|NCT04239703|DIAGNOSTIC_TEST|Prospera|Transplant patient blood sample
40769934|NCT04239703|DIAGNOSTIC_TEST|HLA antibody|Transplant patient blood sample
40972957|NCT00284271|DRUG|Prednisone|
40972958|NCT00284271|DRUG|Vincristine|
40972959|NCT00284271|DRUG|Bleomycin|
40972960|NCT00284271|DRUG|Erythropoietin beta|
40972961|NCT05123768|DIAGNOSTIC_TEST|NGS|A genetic panel of more than 100 genes, associated with CP spectrum disorders, will be assessed using NGS
41139583|NCT03125148|DEVICE|Enteral stenting|Enteral stent for malignant duodenal obstruction
41458857|NCT05696327|OTHER|Tyler Twist Exercises|Tyler twist exercises are the group of exercises which are used to strengthen wrist ex tensors.The protocol consists of several steps using colored twist-able bands and patients are guided to actively perform the steps for their grip strength development.
41458858|NCT05696327|OTHER|conventional physical therapy|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.)
40972962|NCT05288075|DRUG|Indacaterol/glycopyrronium|"In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration."
40972963|NCT00004978|DRUG|Recombinant interleukin-2 (rIL-2)|Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
40972964|NCT02670837|DEVICE|Cellutome Epidermal Harvesting System|
40972965|NCT02063022|DRUG|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
40972966|NCT02063022|DRUG|Intensified chemotherapy|"* Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks~* Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment~* Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)"
40972967|NCT05422703|DEVICE|Kinesio tape|Skin-colored Kinesiology Tape (ARES tape,5 cm×5 m) is waterproof tape is made of 100% cotton,applied in the shape of a fan strip, waterproof. The width is 5 cm and thickness of 0.5 mm (5 cm×5 m ).This tape is sticking with a small stretch (about 15%).
40972968|NCT05422703|OTHER|Gauze pack|Place gauze pack over surgical site for one hour after surgery.
40972969|NCT05422703|DEVICE|ice pack|Ice packs will be applied for 6 hours after surgery in all patients
40972970|NCT05422703|PROCEDURE|Manual therapy|passive and active range of motion, stretching exercises, resistive mouth exercises, mobilization exercises and coordination exercices.
40972971|NCT05422703|DRUG|Analgesic|NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
40972972|NCT05422703|DRUG|Proteolytic enzymes|1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
40972973|NCT05422703|DRUG|Mouth wash|use 0.12% chlorhexidine or povidone iodine mouthwash daily
40972974|NCT05422703|DIETARY_SUPPLEMENT|Soft cold diet|For the day of surgery
40972975|NCT05786885|PROCEDURE|Microneedling will be done with application of topical vitamin C paste for depigmentation|"A Dermapen device will be used to microneedle the gingival tissue (model M8) with 24 microneedles arranged in rows, which is adjusted with 1.5 mm depth at the 6th mode speed of 700 cycles/min.~It will be used in intermittent motion on the affected area for 30-40 seconds / tooth.~Once bleeding points are observed on all areas of the pigmented gingiva, it will be irrigated using saline solution and dried using sterile gauze.~Topical vitamin C powder (1000 mg/ml) will be mixed with saline, and the resultant slurry mix will then be applied to the gingiva for 10 minutes."
40972976|NCT05786885|PROCEDURE|Vitamin C injection|"1-1.5 ml Vitamin C will be injected into the gingiva, using an insulin syringe, once weekly, for 3 weeks.~All the injection procedures will be performed by the same operator. The treated area will be left without dressing in both groups."
40972978|NCT02673437|OTHER|This is a non-interventional study|This is a non-interventional study
40972979|NCT01985867|DIETARY_SUPPLEMENT|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10\^8 CFU, twice daily, orally for 4 weeks)
40972980|NCT01985867|DIETARY_SUPPLEMENT|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
41298680|NCT00918476|DRUG|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
41466536|NCT01177163|DRUG|JNJ 28431754 300 mg/placebo|one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
41466537|NCT01177163|DRUG|JNJ 28431754 100 mg/placebo|one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
41466538|NCT05389709|DRUG|Iberogast (STW5-II, BAY98-7410)|Survey without any intervention assigned in the study.
40972981|NCT06311968|RADIATION|Proton radiotherapy|Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
40972982|NCT06311968|OTHER|combined platinum based chemotherapy|combined platinum based chemotherapy
40972983|NCT02104713|BIOLOGICAL|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose~1. Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.~2. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.~3. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.~4. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.~Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
40972984|NCT02132130|DRUG|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
40972985|NCT04201860|DIAGNOSTIC_TEST|Arterial blood gas analyses and haemostasis measures|Under aseptic conditions, a puncture of radial artery was performed: three mL of the arterial blood sample were used for the haemostasis measure, while one mL was tested for the blood gases analysis.
40972986|NCT05464069|DEVICE|Nerivio|Nerivio is a Remote Electrical Neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
40972987|NCT03021122|DEVICE|PedAMINES™ / Conventional Method|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• PedAMINES™ (Period 1) and then Conventional Method (Period 2)"
40972988|NCT03021122|DEVICE|Conventional Method / PedAMINES™|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Conventional Method (Period 1) and then PedAMINES™ (Period 2)"
40972989|NCT05773963|DEVICE|Irilens; Iridina; Afomill Lubricating Eye Drops|"* Irilens (with 0.4% HA as key ingredient);~* Iridina (with 0.4% HA as key ingredient);~* Afomill Lubricating Eye Drops (with 0.2% HA as key ingredient and distilled water of Chamomile)."
40972990|NCT04078113|OTHER|Pupillometer|Measurements of pupillary dilatation with pupillometer to administer or not analgesia
40972991|NCT04244721|OTHER|Preschool Autism Communication Therapy (PACT)|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
40972992|NCT04244721|OTHER|Treatment As Usual (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
40972993|NCT02322918|GENETIC|Blood samples for whole genomic/transcriptomic sequencing|Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
40972994|NCT03577691|OTHER|Training for use of web based Decision Aid|Subjects will be guided during a 30 minutes training session to use the website
40972995|NCT03577691|OTHER|No training for use of web based Decision Aid|Subjects will not be guided during a 30 minutes training session to use the website
40972996|NCT03577691|OTHER|Pretest surveys and posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
40972997|NCT03577691|OTHER|Only posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
40972998|NCT05360576|DRUG|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|To prevent pregnancy
40972999|NCT05360576|DRUG|NuvaRing Vaginal Ring|To prevent pregnancy
40973000|NCT03073044|DIAGNOSTIC_TEST|BELASTUNGSFRAGEBOGEN PARKINSON KURZVERSION (BELA-P-K)|"we proposed the translation and validation of Bela-p-K, a questionnaire that evaluates the Quality of Life in parkinsonian patients.~we applied the method of translation and back-translation at dutch version of questionnaire. after, we evaluated 103 PD patients with Bela-p-K and PDQ39.~The internal consistency of questionnaire was analyzed calculating alpha-Chronbach. We also evaluated the construct validity correlating Bela-p-K and PDQ39"
40973001|NCT03806998|DIETARY_SUPPLEMENT|Ketoacids|Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks
41466539|NCT04330495|DRUG|Hidroxicloroquina|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
41466540|NCT04330495|DRUG|Control group|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
40769935|NCT06308315|OTHER|Rhythmic balance visual auditory exercise + Routine physical therapy|"5 minute warm-up activities.~Bal-A-Vis-X training includes:~1. Ball Rectangle; A and B hold one ball in each hand, simultaneously bounce right balls to patient left hand; while balls bounce, clap left balls on right hand; catch patient ball with left hand; continue pattern. Bounces must be simultaneous. (10 minutes)~2. Ball rectangle in which one hand has to toss a ball to a partner and the other hand catch an incoming bag from the partner and 2 ball drop/pass/catch, two-foot jumping forward, tandem walking on ground. (10 minutes)~Routine Physical therapy treatment includes:~Range of Motion exercises, Stretching, Strength, balance training for 15 minutes~5 minute cool-down activities."
40769936|NCT06308315|OTHER|Strength Training + Routine Physical Therapy|"The expert managed sessions based on:~5 minute warm-up activities. 5 minute cool-down activities. Strength training includes 5 tasks for 20 minutes~1. core strengthening,~2. upper and lower limbs strength in both static positions as well as with dynamic movements~3. standing long jump,~4. knee push-ups,~5. sit-ups~Routine Physical therapy treatment will be given for 15 minutes.~It includes:~Range of Motion exercises, Stretching, Strength, balance training."
41298681|NCT05938439|DEVICE|MAGUS placement|"An upper endoscopy will be performed with the use of fluoroscopy under general anaesthesia with orotracheal intubation. The delivery system will be placed over a guidewire, under fluoroscopy. The main steps are the following:~* Placement through the endoscope of a soft guidewire through the upper GI tract;~* Insertion of the MAGUS system on the guidewire;~* Advancement of the MAGUS system until proximal magnet reach the top of the septum;~* Release and placement of the proximal magnet at the bottom of the septum, pouch side;~* Meeting of the distal and proximal magnet on both sides of the septum, by pulling on the delivery system;~* Release of the distal magnet and activate the retractable wire;~* Insure that wire is not blocked and unblocked it if applicable.~Endoscopy and contrast injection will be performed before and after placement to ensure the correct positioning of the magnets."
41298682|NCT04292119|DRUG|Lorlatinib|"Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days."
40769937|NCT03984578|DRUG|CAPEOX|Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle, and IV Oxaliplatin: 130mg/m2 on Day 1
40769938|NCT03984578|DRUG|Pembrolizumab|IV infusion of 200mg on Day 1 and Day 22
41298683|NCT04292119|DRUG|Crizotinib|"Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days."
41298684|NCT04292119|DRUG|Binimetinib|Binimetinib will be taken orally twice daily for 28 days.
41298685|NCT04292119|DRUG|TNO155|TNO155 will be taken orally once daily for 14 days.
41298686|NCT05335070|DRUG|Temporo-masseteric Nerve Block|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
41298687|NCT06554613|DRUG|Olanzapine|Olanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.
41298688|NCT06554613|DRUG|Nivolumab|Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
41298689|NCT01591018|PROCEDURE|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
41298690|NCT01591018|PROCEDURE|cardiac surgery|coronary artery bypass graft (CABG) heart valve replacement
41458859|NCT04263233|OTHER|Analysis using descriptive statistics of patient clinical outcomes.|"Evaluation of the following:~* Laboratory values at admission, week 4, and day 90.~* Pre and post blood pressure at week one and week 4.~* Intradialytic hypotension at week one and week 4.~* Ultrafiltration rates at week one, week 4, day 90, day 180, and day 360.~* Target weight defined and achievement in week one and week 4 and changes between week one and week 4.~* Dialysis access type at week one and day 90.~* Hospitalization and mortality rates."
40769939|NCT03984578|DRUG|Capecitabine/ 5-FU|Capecitabine: Oral dose of 825mg/m2/day twice a day on radiation days with concurrent radiation median 50.4 Gy/ 28 fractions; or 5-FU: 225mg/m2/day concurrent with radiation
40769940|NCT03984578|DRUG|Pembrolizumab|IV infusion of 200mg on Day 1 of each cycle
40769941|NCT03984578|DRUG|CAPEOX/Pembrolizumab|"* Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle.~* IV Oxaliplatin: 130mg/m2 on Day 1 of a 3-week cycle.~* Pembrolizumab: IV infusion of 200mg on Day 1 of a 3-week cycle."
40769942|NCT03984578|DRUG|Pembrolizumab alone|IV infusion of 200mg 21 days from the last CAPEOX/Pembrolizumab combination dose.
40973002|NCT03806998|DIETARY_SUPPLEMENT|Placebo|Provision of placebo capsules similar to active supplement
40973003|NCT01170858|DRUG|Icodextrin PD solution|2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)
40769943|NCT03984578|PROCEDURE|Surgical resection|Performed after all medical intervention.
40769944|NCT04255433|DRUG|Tirzepatide|Administered SC
40769945|NCT04255433|DRUG|Dulaglutide|Administered SC
40973004|NCT01170858|DRUG|glucose solutions|
40973005|NCT05849389|DRUG|Vosoritide|Vosoritide administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.
40973006|NCT01428544|DRUG|Fondaparinux sodium|For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
41139584|NCT05488509|DRUG|Cannabis|Participants will inhale vapor from cannabis containing either 20mg THC or 40mg THC.
41139585|NCT05488509|DRUG|Placebo|Participants will inhale vapor from a placebo product.
41139586|NCT03765385|OTHER|High-intensity training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
41139587|NCT03765385|OTHER|Moderate-intensity continuous training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
41139588|NCT02325154|DEVICE|Cerebral Oximeter|Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
41139589|NCT03902626|OTHER|Physiotherapy students|
41139590|NCT03902626|OTHER|Medical students|
41139591|NCT00860457|DRUG|Rituximab|375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles
41139592|NCT00860457|DRUG|Fludarabine|25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles
40973007|NCT04938804|DEVICE|Low-dose computed tomography|The Low-dose computed tomography is conducted according to the guideline suggested by American College of Radiology.
40973008|NCT01103791|DRUG|Docetaxel-PNP|Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
40973009|NCT01811160|DRUG|Melatonin|A capsule of melatonin was administered nightly (20:00hrs).
40973010|NCT01811160|DRUG|Placebo|Placebo capsules were administered at 20:00hrs for eight weeks
41298691|NCT04114994|DIAGNOSTIC_TEST|Boston Cognitive Assessment (BoCA)|"The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.~BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.~After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts."
41298692|NCT03797950|BEHAVIORAL|Voice Reminder (Group A)|Woman with a recent delivery will be contacted via mobile phone by a central study staff member to encourage them to vaccinate their newborn with OPV0 and BCG, and information on where and when vaccines are available in this community will be provided. Community volunteers will receive small incentives for documenting births in the community.
40973011|NCT00023764|DRUG|bortezomib|Given IV
40973012|NCT04755127|PROCEDURE|Arthroscopic synovectomy of the wrist|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
40973013|NCT04755127|DRUG|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
40973014|NCT04342897|DRUG|LY3127804|Administered IV
41298693|NCT03797950|BEHAVIORAL|Cash Incentive (Group B)|Mobile phone based monetary incentives will be provided to community volunteers and to women with a recent delivery who vaccinate newborns with OPV0 and BCG on time. Community volunteers will receive small incentives for documenting births in the community.
40973015|NCT04342897|DRUG|Placebo|Administered IV
40973016|NCT02343627|DRUG|NVXT Solution|NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
40973017|NCT02343627|DRUG|Vehicle of test product|Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
40973018|NCT01980368|OTHER|Educational Intervention|Receive readings and attend book club
40973019|NCT01980368|BEHAVIORAL|Exercise Intervention|Receive Tai Chi Easy class, DVD, and exercise manual
40973020|NCT01980368|OTHER|Questionnaire Administration|Ancillary studies
41298694|NCT01555463|DRUG|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
40973021|NCT03340701|DRUG|vaginal progesterone suppository|200mg vaginal suppository micronized progesterone
40973022|NCT01189903|DRUG|Regorafenib|
40973023|NCT03729089|OTHER|Modified Biophysical Profile scan|Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
40973024|NCT01833520|DRUG|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."
40973025|NCT04605484|BIOLOGICAL|Posoleucel (formerly known as ALVR105) cells|Infusion
40973026|NCT04605484|BIOLOGICAL|Placebo (visually identical to Posoleucel)|Infusion
40973027|NCT06374160|BEHAVIORAL|Exercise intervention|Exercise
41458860|NCT04263233|OTHER|Surveys with participants using validated survey tools.|Surveys will assess participants' Symptom index, Quality of Life, Patient Activation as well as satisfaction with the program.
40973028|NCT03330769|DRUG|New course of treatment|Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
40973029|NCT03537898|OTHER|Lactated Ringer's|Lactated Ringer's will be used whenever an isotonic crystalloid is ordered
40973030|NCT03537898|OTHER|Normosol|Normosol-R pH 7.4 will be used whenever an isotonic crystalloid is ordered
41298695|NCT01555463|DRUG|Vehicle foam|twice daily topical application
41298696|NCT04012268|DEVICE|RIC|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
41466541|NCT03028623|PROCEDURE|Salpingectomy|Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.
40769946|NCT06051357|DRUG|HRS-5965 tablets|HRS-5965 tablets for 12 weeks
40973031|NCT06258356|DRUG|Remimazolam|novel ultra-short-acting benzodiazepine-like anesthetic.
40973032|NCT06258356|DRUG|placebo|normal saline (compared to Remimazolam)
40973033|NCT05918692|DRUG|BMF-500|Investigational Product
40973034|NCT00309569|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2
40973035|NCT00309569|DRUG|Methotrexate|Methotrexate 40mg/m2
40973036|NCT00309569|DRUG|Fluorouracil|Fluorouracil 600mg/m2
40973037|NCT00309569|DRUG|Epirubicin|Epirubucin 60mg/m2 (only node-positive patients)
40973038|NCT00309569|OTHER|Surgery|Surgery
40973039|NCT00680381|BEHAVIORAL|MTI, Minimal Transitional Intervention|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
40973040|NCT00680381|BEHAVIORAL|GTI, Group Transitional Intervention|Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
40973041|NCT00680381|BEHAVIORAL|STI, Systems Transitions Intervention|Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
40973042|NCT00954070|DEVICE|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
40769947|NCT05599165|OTHER|signal processing on consonant recognition|Consonant recognition will be measured in noise without any signal processing.
40769948|NCT03999476|DEVICE|ambu ascope|nasal route intubation by the device in fixed cancer tongue patients
40769949|NCT03999476|DEVICE|fibreroptic bronchoscope|nasal route intubation by the device in fixed cancer tongue patients
40769950|NCT01364831|BEHAVIORAL|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
40769951|NCT06127173|OTHER|Positive End Expiratory Pressure PEEP|children will receive different levels of PEEP during induction of anesthesia
40973043|NCT00656110|DRUG|equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml|Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks
40973044|NCT00656110|DRUG|Normal saline - 1ml|Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
40973045|NCT01259505|BIOLOGICAL|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
40973046|NCT01872988|DRUG|Tenofovir|Administer Tenofovir to HCC patients who are indicated for TACE after randomization
40973047|NCT01872988|DRUG|Placebo|Administer Placebo to HCC patients who are indicated for TACE after randomization
40973048|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter \[mg/mL\], i.e. 16 mL) under fasting conditions
40973049|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
40973050|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
40973051|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
41139593|NCT00860457|DRUG|Lenalidomide|5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
41139594|NCT04495153|BIOLOGICAL|Aglatimagene besadenovec|Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) of CAN-2409 injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
41139595|NCT01506700|DEVICE|Optical Coherence Tomography|Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
41139596|NCT01164176|DRUG|everolimus|
41458861|NCT04263233|OTHER|Evaluation of the program process including time, costs, referral rates, admission to the program and length of stay.|Data will be collected using tracking tools throughout the program.
40973052|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
40973053|NCT05504564|GENETIC|The experiment does not required any intervention|The experiment does not required any intervention
40973054|NCT05746312|BEHAVIORAL|healing attempt|The intervention consists of pre-composed and pre-recorded guided meditations, songs, and poems that total 25 minutes in duration. The elements of the intervention were set to background music tracks that were informed by Black diasporic music traditions and anxiety reduction principles from the music therapy literature.
40769952|NCT01520441|DRUG|BOTOX|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
40973055|NCT01080352|DRUG|Ascorbic Acid (Vitamin C)|60grams of ascorbate given intravenous infusion in 1000ml sterile water.
40769954|NCT01427478|DRUG|AFATINIB|AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
40769955|NCT01427478|DRUG|Placebo of AFATINIB|placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
40769956|NCT06603571|DRUG|LY3841136|Administered SC
40769957|NCT06603571|DRUG|Tirzepatide|Administered SC
40769958|NCT06603571|DRUG|Placebo|Administered SC
40769959|NCT04632862|DRUG|DWP16001|DWP16001 A mg
40769960|NCT05039281|BIOLOGICAL|Atezolizumab|Given IV
40769961|NCT05039281|DRUG|Cabozantinib|Given PO
40973056|NCT02233816|BIOLOGICAL|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
40973057|NCT02233816|BIOLOGICAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
40973058|NCT02233816|BIOLOGICAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
40973059|NCT02233816|BIOLOGICAL|Placebo|A single dose of placebo
40973060|NCT01234298|DRUG|SPD489 Low-Dose|SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
41139597|NCT01164176|OTHER|laboratory biomarker analysis|
41139598|NCT03396445|DRUG|Boserolimab|IV infusion
41139599|NCT03396445|BIOLOGICAL|Pembrolizumab|IV infusion
41139600|NCT03396445|DRUG|Pemetrexed|IV infusion
41139601|NCT03396445|DRUG|Carboplatin|IV infusion
41139602|NCT03396445|DRUG|Nab-paclitaxel|IV infusion
41139603|NCT02010866|BEHAVIORAL|counseling|in-person counseling through RFWP offered to distressed respondents on the ISP and others who seek counseling (due to other reasons for referral)
41139604|NCT03678688|DRUG|10 mg OPC-167832|Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.
41139605|NCT03678688|DRUG|30 mg OPC-167832|Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.
41139606|NCT03678688|DRUG|90 mg OPC-167832|Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.
41139607|NCT03678688|DRUG|3 mg OPC-167832|Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
41298697|NCT04012268|DRUG|Aspirin|patients will accept medication guided by neurologists
40973061|NCT01234298|DRUG|SPD489 High-Dose|SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
40973062|NCT01234298|DRUG|Placebo|Placebo capsule taken once-daily for up to 26 weeks
41298698|NCT05782101|DIAGNOSTIC_TEST|Integrated proteomic HPLC-ESI-MS analysis of salivary peptides|A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.
41298699|NCT04132752|OTHER|Motivation|Families were called via phone weekly and all questions were answered. Parents were motivated through phone.
40973063|NCT00692081|BEHAVIORAL|Social competence training|8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants
40973064|NCT00692081|BEHAVIORAL|Special vocational training|as provided in German special centres for vocational training
40973065|NCT06244472|DEVICE|Experiment 1: visual and auditory attention task|We will use the FYNA Research system on 20 healthy volunteers with a visual and auditory attention task to evaluate the system's performance in recording brain signals complex frequency content.
40973066|NCT06244472|DEVICE|Experiment 2: language production and rest tasks|We will use the FYNA Research system on 20 healthy healthy volunteers with a language production task to assess the system's functional mapping capabilities and a resting task to assess the system's ability to identify resting networks.
40973067|NCT06244472|DEVICE|Experiment 3: visuo-motor task|We will use the FYNA Research system in 20 healthy volunteers with a visuo-motor task to evaluate the system's performance in recording brain signals when the subject moves, inducing perturbations that affect the classical system (loss of spatial precision) and the FYNA Research system (low-frequency artifacts).
40973068|NCT06244472|DEVICE|Experiment 4: brain activity at rest|We will be using the FYNA Research system on 20 concussed male athletes volunteers to assess the system's ability to detect modulations in the frequency content of resting brain activity.
40973069|NCT02980445|BEHAVIORAL|Outdoor activity 1|40-minute outdoor activity
41298700|NCT01723501|DRUG|0.25% chlorhexidine|0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
41298701|NCT01723501|DRUG|sterile water|Sterile water wipes (placebo)
41458862|NCT05983627|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion. All subjects received experimental drugs and conventional treatment during the study period.
41458863|NCT05594225|BEHAVIORAL|Virtual Neuromuscular/Dual-Task Training|The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
41458864|NCT00000623|DRUG|Deferoxamine|
40973070|NCT02980445|BEHAVIORAL|Outdoor activity 2|Dose 1 plus an additional 40-minute outdoor activities during recesses
41458865|NCT00000623|DRUG|Deferiprone|
40973071|NCT04119492|BEHAVIORAL|CO-OP Treatment Group|"Cognitive Orientation to Occupational Performance (CO-OP) is a cognitive approach to solving functional motor problems (Polatajko et al., 2001). Therapists teach children a global problem-solving strategy (Goal-Plan-Do-Check) as means to develop specific strategies for overcoming motor problems; the strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists trained in CO-OP will see children for one hour, once weekly for 10 weeks. Parents or caregivers will be encouraged to attend treat¬ment sessions so therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select 3 functional motor goals to be addressed during treatment."
40973072|NCT01675414|OTHER|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
41298702|NCT02980835|DRUG|Normal Saline|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
40769962|NCT03578315|DEVICE|HGM|To Study the Efficacy and safety of QSRL and PSNYL in the Treatment of target: A nonrandomized, controlled, split-face comparative study
41298703|NCT02980835|DRUG|Ropivacaine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate A and C contain 9 and 24 mL of ropivacaine HCl 0.5%, respectively.
41298704|NCT02980835|DRUG|Epinephrine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
40973073|NCT00850668|BIOLOGICAL|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
40973074|NCT00642460|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (patients\>=30kg) or 12mg/kg (patients \<30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
40973075|NCT00642460|DRUG|Placebo|iv every 2 weeks for 12 weeks
40973076|NCT00642460|DRUG|Non-steroidal anti-inflammatory drugs (NSAIDs)|as prescribed
40973077|NCT00642460|DRUG|methotrexate|as prescribed
41458866|NCT00000623|DRUG|Arginine|
40973078|NCT00642460|DRUG|corticosteroids|orally, as prescribed
40973079|NCT01115634|BIOLOGICAL|Fibroblast|20 million cell in three injection
40973080|NCT01115634|BIOLOGICAL|fibroblast and gel|20 million cell in three injection plus filler
40973081|NCT00549965|DRUG|Risedronate Sodium|
41458867|NCT00000623|DRUG|Sildenafil|
41458868|NCT00000623|DRUG|Decitabine|
41458869|NCT00102349|BEHAVIORAL|Behavior Therapy|
41458870|NCT04372641|DRUG|p97 Inhibitor CB-5339 Tosylate|Given PO
41458871|NCT03324815|DRUG|Morphine|Pain Treatment
41458872|NCT03324815|DRUG|Methadone|Pain Treatment
40973082|NCT06378476|BEHAVIORAL|IMPaCT Community Health Worker Program|The IMPaCT intervention consists of three stages: goal-setting, tailored support, and connection with long-term support. CHWs first seek to understand the patient's individual circumstances, life histories, and priorities by using a semi-structured interview guide inquiring about social and behavioral determinants of health. CHWs will then partner with patients to create customized action plans based on patient needs.
40973083|NCT06378476|OTHER|Trauma-Informed Care Training|Primary care providers and staff at two General Internal Medicine clinics will receive training in providing supportive care to patients who have experienced trauma. The trainings are all action focused and include a review of racism in medicine, understanding intergenerational trauma and its impact on care, naming and mitigating barriers to health equity, and the basics of motivational interviewing
40973084|NCT05086991|OTHER|Follow up|like group descriptions
40973085|NCT05117320|DEVICE|AI support|Images were allocated to participants. In randomized allocation, one half of the images for each participant are viewed with AI support and the other half is viewed without AI support on the first trial day. On the second trial day the same images are viewed without versus with AI, respectively. This ensures that all images are read twice by the same participant both with and without AI support.
40973086|NCT03353493|BEHAVIORAL|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams \& Teasdale (2013).
40973087|NCT03353493|OTHER|TAU|Treatment as usual (TAU)
40973088|NCT00630981|BEHAVIORAL|Psychotherapy|Specific psychotherapy for dissociative disorders
40973089|NCT00630981|DRUG|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
40973090|NCT04300114|DRUG|Fluzoparib|Fluzoparib capsules po. 150 mg twice daily
40973091|NCT04300114|DRUG|Placebo|Placebo capsules po. twice daily
40973092|NCT00797030|DRUG|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
40973093|NCT00797030|DRUG|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
40973094|NCT03529851|OTHER|Weekly questionnaires|In case of alarming symptoms reported in the questionnaire, an alert is automatically sent to the hospital. The clinicians will contact the patient, confirm the symptoms and intervene according to standard practice.
40973095|NCT06386250|PROCEDURE|regional block|In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.
40973096|NCT06386250|PROCEDURE|Caudal block|In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.
40973097|NCT06386250|PROCEDURE|Epidural|In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.
40973098|NCT02824874|DRUG|Duvie Tab. 0.5mg|Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO
40973099|NCT02824874|DRUG|Duvie Tab. 0.5mg + Januvia Tab. 100mg|Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO
40973100|NCT04839523|DEVICE|Exufiber|A sterile nonwoven wound dressing made from highly absorbent PVA fibers.
40973101|NCT04839523|DEVICE|Exufiber Ag+|A sterile nonwoven wound dressing made from highly absorbent PVA fibers, and coated with silver sulphate.
40973102|NCT01958008|DRUG|Placebo to BI 113608 high dose b.i.d.|Film-coated tablet
40973103|NCT01958008|DRUG|Placebo to BI 113608 low dose b.i.d.|Film-coated tablet
40973104|NCT01958008|DRUG|BI 113608 high dose b.i.d.|Film-coated tablet
40973105|NCT01958008|DRUG|Placebo to BI 113608 medium dose b.i.d.|Film-coated tablet
40973106|NCT01958008|DRUG|BI 113608 low dose b.i.d.|Film-coated tablet
40973107|NCT01958008|DRUG|BI 113608 medium dose b.i.d.|Film-coated tablet
40973108|NCT04742010|DRUG|Zoledronic Acid|"* A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted)~* Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo)~* Administration: slow intravenous infusion with a duration of at least 15 minutes"
40973109|NCT04742010|DRUG|Placebo|as above
40973110|NCT02931968|DEVICE|Monolithic zirconia prosthesis|Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
40973111|NCT02300532|OTHER|No intervention|
40973112|NCT04383795|DRUG|Antithyroid Drug|Administration of antithyroid Drug for 6 months
41139608|NCT03678688|DRUG|RHEZ|"RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight:~* Participants weighing 30 to 37 kg received 2 tablets per day~* Participants weighing 38 to 54 kg received 3 tablets per day~* Participants weighing 55 to 70 kg received 4 tablets per day~* Participants weighing \> 70 kg received 5 tablets per day"
41139609|NCT03678688|DRUG|30 mg OPC-167832 + 300 mg delamanid|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.
41466542|NCT03028623|PROCEDURE|Tubal ligation|Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
40973113|NCT05647434|PROCEDURE|sustained inflations|Sustained inflation will be applied at a pressure of 30 cmH2O and will be held for a period of 30 secs. After each SI the standard ventilatory settings will be resumed with a PEEP setting of 8 cmH2O to prevent lung derecruitment. Lung recruitment will be stopped immediately if mean arterial pressure and/or heart rate change by at least 25% from baseline values.
40973114|NCT03810898|RADIATION|Radioligand [¹¹C]CHDI-00485180-R|Intravenous injection of radioligand in the arm with PET imaging of the brain.
40973115|NCT03810898|RADIATION|Radioligand [¹¹C]CHDI-00485626|Intravenous injection of radioligand in the arm with PET imaging of the brain.
40973116|NCT04952402|BIOLOGICAL|Study-provided Moderna mRNA-1273 COVID-19 vaccine|Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).
40973117|NCT04952402|BIOLOGICAL|Community-provided Moderna mRNA-1273 COVID-19 Vaccine|Participants received a two-dose series.
40973118|NCT04952402|BIOLOGICAL|Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine|Participants received a two-dose series.
40973119|NCT00035334|DRUG|NC-503 (Anti-amyloidotic (AA) Agent)|
40973120|NCT02010554|BEHAVIORAL|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
40973121|NCT02010554|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
40973122|NCT03939884|DRUG|MuscleCare Topical Product|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
40769963|NCT02599831|DEVICE|Electrical pudendal nerve stimulation|Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
40769964|NCT02599831|DEVICE|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
40973123|NCT03939884|DRUG|Voltaren Topical|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
40973124|NCT03939884|DRUG|Nivea, Topical Cream|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
40973125|NCT01448811|DEVICE|AEP monitor|In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI\>40, titrate up propofol dosage, AAI\<25, titrated down propofol dosage.
40973126|NCT01448811|PROCEDURE|Ramsay Sedation Scale|During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
40973127|NCT03725098|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
40973128|NCT03725098|DEVICE|FLOSEAL|The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
40973129|NCT02450903|DRUG|LDK378|Oral LDK378 750mg once daily
40973130|NCT00018200|DRUG|Desipramine|Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
40973131|NCT00018200|DRUG|Fluoxetine|Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
40973132|NCT00018200|DRUG|Benztropine|Daily dose 0.125 to 0.5mg
40973133|NCT02419053|OTHER|Surgical Safety Checklist|An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
40973134|NCT00959309|BEHAVIORAL|Strategies to decrease screen time in children|"15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.~Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')"
40973135|NCT00959309|BEHAVIORAL|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
40973136|NCT04846621|DRUG|Potassium Channel Opener|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
40973137|NCT04846621|DRUG|Calcium channel blocker|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
40973138|NCT03268902|DRUG|Azithromycin Oral Liquid Product|Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
40973139|NCT03268902|DRUG|Nitazoxanide Oral Suspension|Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
40973140|NCT03268902|DIETARY_SUPPLEMENT|Nicotinamide|"Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age"
40973141|NCT03268902|DRUG|Placebos|"Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age"
41139610|NCT03678688|DRUG|30 mg OPC-167832 + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
40769965|NCT02599831|DEVICE|Transanal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
40769966|NCT00280488|BEHAVIORAL|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
40769967|NCT00280488|BEHAVIORAL|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
40769968|NCT00280488|BEHAVIORAL|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
40973142|NCT01342302|BEHAVIORAL|Psychosocial Intervention for Couples|Intervention delivered on line
40973143|NCT01053221|DRUG|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
40973144|NCT01053221|DRUG|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
40973145|NCT02465216|OTHER|Placebo|Placebo
40973146|NCT02465216|BIOLOGICAL|ID93 + GLA-SE|ID93 + GLA-SE
40973147|NCT00718224|DRUG|Semuloparin sodium|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
40973148|NCT00718224|DRUG|Enoxaparin|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
40973149|NCT00718224|DRUG|Placebo|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
40973150|NCT00186030|BEHAVIORAL|HIV Skills-based Prevention|
40973151|NCT00048555|DRUG|IDEC-114|Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions
40973152|NCT04964531|OTHER|speckle tracking echocardiography|before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views
40973153|NCT06035510|DIETARY_SUPPLEMENT|whey protein supplement|Participants are given Isolated whey protein supplement in evening before surgery and first day of post operation to compare with standard operative care on postoperative outcomes after gynecological cancer surgery
40973154|NCT00783003|DRUG|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
40973155|NCT00783003|DRUG|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
40973156|NCT00783003|DRUG|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
41139611|NCT03678688|DRUG|30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
41139612|NCT01500070|DEVICE|Everolimus-Eluting Stent (PROMUS ELEMENT)|PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
41139613|NCT03150589|DRUG|SB11 (Proposed ranibizumab biosimilar)|SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
40769969|NCT06077357|OTHER|MMSE Test|Mini Mental State Examination (MMSE), is a brief mental test used to assess individuals' cognitive functions. This test evaluates basic cognitive abilities such as memory, attention, calculation, language, orientation, and problem-solving. MMSE is commonly used for monitoring and assessing mild cognitive impairments, dementia, and other neurological conditions. This test is typically scored out of 30, with higher scores indicating better cognitive function.
40973157|NCT00783003|DRUG|Placebo|Matching placebo.
40973158|NCT05809401|BEHAVIORAL|Pragmatic Rehabilitation|A series of behavioral activities to improve specific pragmatic abilities in patients
40973159|NCT05809401|BEHAVIORAL|Neuropsychological Rehabilitation|A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
40973160|NCT05496257|OTHER|direct pulp capping in primary molars|caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.
40973161|NCT01958320|OTHER|pharmacologic treatment of the PDA|Following randomization, infants will be treated with medications used to produce PDA closure.
41139614|NCT03150589|DRUG|Lucentis (ranibizumab)|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
41139615|NCT01754389|DRUG|Tacrolimus|
41139616|NCT01754389|DRUG|Methotrexate|
41139617|NCT01754389|DRUG|Bortezomib|
41298705|NCT02980835|DRUG|Dexamethasone|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectates A and C both contain 1 mL of dexamethasone 4mg/mL preparation.
41298706|NCT00370786|DRUG|bevacizumab|
41298707|NCT02811133|DRUG|Inositol|Subjects will receive inositol
41298708|NCT03186404|DRUG|Atorvastatin|Atorvastatin 40mg OD
41298709|NCT03186404|DRUG|Placebo oral tablet|Placebo
40973162|NCT01958320|OTHER|no pharmacologic treatment of the PDA|Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).
40973163|NCT01958320|DRUG|NSAID|Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment
40973164|NCT06507982|DEVICE|EWL|the working length determination with EAL method
40973165|NCT06507982|DEVICE|SWL|In this method, an endodontic motor with a built-in EAL that provides continuous feedback during root canal instrumentation and allows clinicians to make real-time adjustments to the WL. Thus, it provides continuous feedback, allowing the clinician to make real-time adjustments. The motor of devices using this method has automatic apical reverse and automatic apical stop operation. In this way, when the tip of the file reaches the apical foramen, the file safely reverses and stops rotating.
40973166|NCT06507982|DEVICE|RWL|Radiographic method was used for determining the working length
40973167|NCT03880071|BEHAVIORAL|DBT+ACT|- The experimental group (DBT+ ACT) will have: 25 therapy group sessions (1 sessions of 2 hours once a week) 25 individual interview sessions (1 sessions of 1 hour once a week) will receive 25 group sessions and 25 individual ones during 6 months.
41139618|NCT01754389|DRUG|Sirolimus|
41139619|NCT03338166|OTHER|LDH serum level|Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
40973168|NCT03880071|BEHAVIORAL|DBT|"The control group (DBT) will have:~50 therapy group sessions (1 session of 2h30 once a week) 50 individual interview sessions (1 sessions of 1 hour once a week)"
40973169|NCT04921371|OTHER|Colgate® Cavity Protection Toothpaste|Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
40973170|NCT04921371|OTHER|Listerine® Cool Mint®|Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.
40973171|NCT04921371|OTHER|Concept Curve Winter Series Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
40973172|NCT04921371|OTHER|5% Hydroalcohol Mouthrinse|Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.
40973173|NCT04921371|OTHER|Mouthrinse Prototype 1|Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.
40973174|NCT04921371|OTHER|Mouthrinse Prototype 2|Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
40973175|NCT06095453|OTHER|Pain control regimens|Narcotics in cholecystectomy and hernia repairs
40973176|NCT00277836|DRUG|MST-997|
40973177|NCT04118166|DRUG|Ipilimumab|Ipilimumab 1 mg/kg, injection
40973178|NCT04118166|PROCEDURE|Cryoablation|Cryoablation of the tumors occur between investigational agent treatment Cycles 1 and 2, and will be performed according to standard procedures
40973179|NCT04118166|DRUG|Nivolumab|Nivolumab 3 mg/kg, injection
40973180|NCT00929799|DRUG|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
40973181|NCT04632108|DRUG|ASKB589 Injection|ASKB589 Injection with dose escalation stage of 0.3mg/kg up to10mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.
40973182|NCT00494078|DEVICE|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
41139620|NCT00603798|DRUG|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
41458873|NCT04715906|BEHAVIORAL|UP-Caregiver|The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
40973183|NCT00494078|DRUG|intensive insulin therapy|intensive insulin therapy according to an algorithm
40973184|NCT05089760|OTHER|No intervention|This is a prospective observational cohort study. The purpose of the study was to compare the incidence of mortality, complications, and other outcomes between infants with multi-resistant bacteria sepsis and infants with sepsis caused by non-multi-resistant bacteria, and compare the incidence of complications and other outcomes between infants with sepsis-related death and infants who survive.
40973185|NCT01747798|DRUG|auranofin|Given PO
40973186|NCT01747798|OTHER|laboratory biomarker analysis|Correlative studies
40973187|NCT02813564|BEHAVIORAL|Cognitive Assessment & Video-game INtervention Solutions (CAVINS)|"This is a computerized video-game like intervention. The participants will exercise/strengthen the cognitive (mental) deficits that may be responsible for symptom profiles such as socialization impairments, academic disabilities, and repetitive behaviour for several weeks. This program will stimulate communication between brain regions that make up an information processing neural network in order to promote proper network development."
40973188|NCT04804475|OTHER|Exercise Trainig|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
41139621|NCT00603798|DRUG|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
41458874|NCT01406249|DRUG|SP|"Drug: S-1:~S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle."
40973189|NCT01144286|DRUG|arasertaconazole nitrate|Arasertaconazole nitrate pessary, placebo pessary
40973190|NCT01144286|DRUG|placebo|placebo, single dose
40973191|NCT00805103|RADIATION|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
40973192|NCT04856774|DRUG|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion~Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined."
41139622|NCT00603798|DRUG|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
41139623|NCT06372899|OTHER|E-cigarettes|Participants randomized to ECIGS are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. They will be provided with an e-cigarette device and nicotine pods.
40973193|NCT05798650|BEHAVIORAL|facial dissatisfaction|"Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs."
40973194|NCT02438202|DEVICE|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
40973195|NCT06037395|BIOLOGICAL|CT-P41|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
40973196|NCT06037395|BIOLOGICAL|US-licensed Prolia|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
40973197|NCT04829708|OTHER|MRI Surveillance|Receive MRI surveillance
40973198|NCT04829708|RADIATION|Prophylactic Cranial Irradiation|Receive PCI
40973199|NCT00420927|BIOLOGICAL|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
40973200|NCT00420927|DRUG|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
40973201|NCT00420927|BIOLOGICAL|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
40973202|NCT06062511|DIETARY_SUPPLEMENT|ESIT12 D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 D contains 400 mg of ESIT12
40973203|NCT06062511|DIETARY_SUPPLEMENT|ESIT12 4D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 4D contains 1600 mg of ESIT12
40973204|NCT06062511|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of the carriers of ESIT12 : arabic gum, sucrose and silicon dioxide mix
40973205|NCT00677612|BIOLOGICAL|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
40973206|NCT05494333|OTHER|no intervention|NO intervention
40973207|NCT01101932|DRUG|PF-04308515|PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
40769970|NCT06077357|OTHER|PASE Test|"The PASE test stands for Physical Activity Scale for the Elderly. This scale is used to assess the physical activities undertaken by elderly individuals in their daily lives. The PASE test allows for the evaluation of both daily activities such as walking, climbing stairs, and household chores, as well as exercise routines. It is used to determine the level of physical activity in elderly individuals and support the process of healthy aging."
40973208|NCT01101932|DRUG|Placebo|Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
40973209|NCT01101932|DRUG|PF-04308515 Tablet|Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
40973210|NCT04073589|BIOLOGICAL|ARGX-113 with rHuPH20|subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)
40973211|NCT00193154|DRUG|OSI-774|150mg PO, days 1-28, cycle repeated every 28 days
40973212|NCT00193154|DRUG|Bevacizumab|10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
40973213|NCT00790855|DRUG|Bendamustine|Starting dose of 50 mg/m\^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
40973214|NCT05268900|DEVICE|Volume control ventilation group|Volume control ventilation mode
41298710|NCT03023644|BEHAVIORAL|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
40769971|NCT06077357|OTHER|The PRISMA-7 Frailty Scale|The PRISMA-7 Frailty Scale is a tool used to assess the level of frailty in elderly individuals. This scale evaluates signs of frailty such as physical activity, fatigue, weight loss, and difficulties with vision and hearing. PRISMA-7 is employed in determining the risk of frailty in the elderly and aids in identifying appropriate treatment and support methods.
40973215|NCT05268900|DEVICE|Pressure control ventilation-volume guaranteed group|Pressure control ventilation-volume guaranteed mode
40973216|NCT05657834|DRUG|[14C]-TVB-2640|50 mg of TVB-2640 oral administration
40973217|NCT00136617|DRUG|chlordiazepoxide|
41139624|NCT06372899|OTHER|Oral nicotine pouches|Participants randomized to ONPS are instructed to switch from smoking combustible cigarettes to using nicotine pouches for 6 weeks. They will be provided with nicotine pouches.
40973218|NCT03462264|DEVICE|Scoliogold App|The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.
40973219|NCT03462264|OTHER|Pre-Formatted Diary|The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
41139625|NCT05687214|OTHER|Osteopathic manipulative treatment|"Each participant in the experimental group will receive eight osteopathic manipulative treatments. Each treatment will include the following manipulations:~* Pompage Cv4;~* Occipital-sternal technique;~* Relaxining manipulation of the diaphragmatic domes;~* Pelvic and abdominal diaphragm synchronization;~* Dynamogenic technique;~* Mesenteric traction;~* Release of colic angles;~* Manipulation and mobilization of the sacrum."
40769972|NCT06077357|OTHER|TAMPA Test|"The TAMPA test, abbreviated from Tampa Scale for Kinesiophobia, is a scale used to assess fears related to pain. This scale is employed to evaluate the fear of pain and avoidance behaviors associated with it. By measuring individuals' attitudes and fears towards pain, the TAMPA test helps identify their emotional and behavioral responses in this area."
40973220|NCT03743389|DEVICE|12G pigtail catheter|12G pigtail catheter would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with the traditional 16F chest tube.
40973221|NCT03743389|DEVICE|16F chest tube|16F chest tube would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with 12G pigtail catheter.
40973222|NCT01310621|DRUG|Bovine surfactant|"* Dose of diluted surfactant : 20ml/kg~* Type :Bovine surfactant~* Phospholipid concentration: 5 mg/ml~* Number of lavages to be given: 2 (10ml/kg each)"
40973223|NCT06502717|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
40973224|NCT00569569|DRUG|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
40973225|NCT05973331|OTHER|Pancreatic Cancer Risk Model (PRISM)|A neural network model (PrismNN) and a logistic regression model (PrismLR) that use routinely collected EHR data to stratify individuals from the general population into PDAC risk groups
40973226|NCT02674152|DRUG|BI 836880|
40973227|NCT01516697|PROCEDURE|experimental|Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
40973228|NCT01516697|PROCEDURE|Control|Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
40973229|NCT03719521|OTHER|Community-based package of integrated HIV, SRH and general health services|HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive
40973230|NCT06241872|OTHER|Dry needling group|Dry needling will be performed using a 27-gauge, 5 cm long dental needle, guided by ultrasound, on predetermined trigger points in patients.
40973231|NCT01427504|DRUG|boceprevir; etravirine|boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
40973232|NCT01028144|BEHAVIORAL|Physical Activity Program|A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
40973233|NCT01028144|BEHAVIORAL|General Health Program|A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
40973234|NCT05201560|DRUG|Butorphanol Tartrate Injection|Patients of this group will receive Butorphanol Tartrate Injection
41139626|NCT02684994|BEHAVIORAL|Cognitive Processing Therapy|Cognitive-processing therapy is a well-supported treatment for reactions following traumatic events. It includes 12 individual psychotherapy sessions and consists of 4 components: education about trauma responses, experiencing emotions related to the assault, development of skills for examining the truth of thoughts, and examination of beliefs in areas commonly influenced by the trauma.
41298711|NCT04005443|OTHER|radiopharmaceutical|his study will consist of a monthly intra-ocular injection of antiangiogenic and a follow-up ophthalmological consultation with OCT and visual acuity score
41298712|NCT03604692|DRUG|SNDX-6352|SNDX-6352 is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
41298713|NCT05094154|DRUG|anti-pseudomonal cephalosporin|Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
40769973|NCT06077357|OTHER|(JAMAR) Muscle Test|The JAMAR Muscle Test is a widely used clinical assessment tool for evaluating hand grip strength. It involves using a device called a dynamometer to measure the force exerted by a person's hand when squeezing the instrument. This test provides valuable information about an individual's upper body strength, which can be important in various medical and rehabilitative contexts. The JAMAR Muscle Test is often utilized in physical therapy, sports medicine, and other healthcare fields.
40973235|NCT05201560|DRUG|Fentanyl|Patients of this group will receive Fentanyl
41298714|NCT05094154|DRUG|anti-pseudomonal penicillin|Providers will be prompted to order anti-pseudomonal penicillin, such as piperacillin-tazobactam with a dose range of 3.375 g or 4.5 g and frequency every 6, 8, or 12 hours based on provider discretion.
40973236|NCT03004027|OTHER|Self help leaflet|Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
40973237|NCT03954756|DRUG|Apatinib and PD1|"1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal~2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks."
40973238|NCT02840370|DEVICE|transcranial direct current stimulation|In tDCS, the prefrontal cortex is stimulated during 20minutes through a weak constant electric current (1-2 mA) through two electrodes in a non-invasive and painless manner.
40973239|NCT02840370|DEVICE|Sham tDCS|S-tDCS refers to a control condition in which the subject will receive a brief current in the beginning in order to induce a similar sensation on the scalp as in tDCS, and then the stimulator remains off for the rest of the stimulation time.
40973240|NCT04069091|BEHAVIORAL|'Enjoy your Bump' (iloodottaa.fi) online self-help intervention|"The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention has been adapted to the Finnish culture and healthcare setting (ilodottaa.fi)."
40973241|NCT04885361|BIOLOGICAL|CoVepiT (OSE13E)|Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.
40973242|NCT01777100|DRUG|Sufentanil|Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
40973246|NCT05427253|DRUG|C106 solution|selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
40973247|NCT05427253|DRUG|Placebo|Placebo for C106 solution
40973248|NCT05065177|BIOLOGICAL|Investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
40973249|NCT05065177|BIOLOGICAL|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
40973250|NCT00524784|BIOLOGICAL|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
40769974|NCT06077357|OTHER|Fatigue Severity Scale|The Fatigue Severity Scale (FSS) is a self-report questionnaire used to assess the severity of fatigue in individuals. It consists of nine items that measure the impact of fatigue on various aspects of daily life, such as physical functioning, motivation, and mental clarity. The FSS is commonly used in clinical settings and research studies to quantify the level of fatigue experienced by individuals with various medical conditions, including chronic illnesses, neurological disorders, and mental health conditions. It provides valuable information for healthcare professionals in understanding and managing fatigue-related symptoms.
40769975|NCT04695366|OTHER|No intervention|No intervention
40769976|NCT02720458|OTHER|Standardized gradual hypnotic taper|The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
40973251|NCT00894660|DRUG|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
40973252|NCT00894660|DRUG|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
40973253|NCT01474057|BEHAVIORAL|DESTRESS-PC|"An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician."
40973254|NCT01474057|OTHER|Optimized Usual Primary Care PTSD treatment|Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
40973255|NCT00211809|BEHAVIORAL|Cognitive Behavioral Therapy|standard psychiatric evaluation
40973256|NCT00211809|DRUG|Venlafaxine|start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.
40973257|NCT03982368|DRUG|rhNGF 20 μg/ml|one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
40973258|NCT03982368|DRUG|rhNGF 20 μg/ml + vehicle|"one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon."
41458875|NCT01406249|DRUG|XP|"Drug: Capecitabine:~Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
40973259|NCT03982368|OTHER|Vehicle|one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)
40973260|NCT02063360|DRUG|BMS-663068|BMS-663068
40973261|NCT02063360|DRUG|Darunavir (DRV)|Darunavir (DRV)
40973262|NCT02063360|DRUG|Ritonavir (RTV)|Ritonavir (RTV)
40973263|NCT02063360|DRUG|Etravirine (ETR)|Etravirine (ETR)
40973264|NCT04256798|DRUG|Chlorhexidine mouthwash|0.2% Chlorhexidine digluconate
40973265|NCT04256798|DRUG|Oxygen|Oxygen 80-100%
40973266|NCT04256798|DRUG|Oxygen|Oxygen 21-30 %
41458876|NCT01661517|BEHAVIORAL|Motivational interviewing and referral to treatment|
40973267|NCT02049281|DRUG|Vintafolide|Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
40973268|NCT04299490|BEHAVIORAL|Sleep Fragmentation|Subjects are provided an 8-hour sleep opportunity. Two speakers are placed 12 inches from the head of the bed and four remote-activated mechanical vibrators are placed underneath the mattress. EEG microarousals (\>3 s), as defined according to standard criteria, are elicited at a frequency of 30 or more events per hour.
41139627|NCT01475110|DRUG|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
41458877|NCT03601845|OTHER|Stimuli|Visual stimulation while using additional sequencing
41458878|NCT03601845|OTHER|No stimuli|Additional sequencing only
41458879|NCT05562011|DEVICE|Caretaker Device placement|a continuous non-invasive blood pressure and vital signs monitor that is worn on the wrist
40973269|NCT04299490|DRUG|Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)|On the third day of the in-patient visit participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter pain medications, or placebo (saline).
40973270|NCT04299490|BEHAVIORAL|Sleep Continuity Disruption|An 8-hour sleep opportunity period starting from lights out is divided into eight, one-hour intervals. One of the intervals is randomly determined to be a 60 minute forced awakening, during which no sleep is permitted. Each of the remaining seven, 60-minute intervals are subdivided into tertiles (20 min. blocks). A 20-min forced awakening (FA) is randomly scheduled to occur in either the 1st, 2nd, or 3rd tertile of each hour. During FAs, staff keep subjects awake, either by voice or gentle shaking.
40973271|NCT04299490|BEHAVIORAL|Undisturbed Sleep|Subjects sleep normally for an 8 hour period.
40973272|NCT01092611|PROCEDURE|Blood collection|Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
40973273|NCT01092611|BIOLOGICAL|GSK HIV vaccine 732462|No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
40973274|NCT03498300|BIOLOGICAL|Tdap vaccine|A single dose of Tdap vaccine at GA 27 - 36 weeks
40973275|NCT02048787|DRUG|Buparlisib|Subjects will receive a single dose of 50 mg buparlisib.
40973276|NCT00748501|DRUG|SB-509|Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
41298715|NCT03969901|DRUG|IMI/REL|"Age-based dosing:~* 12 to \<18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~* 2 to \<12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 3 months to \<2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* Birth to \<3 month, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention."
41298716|NCT03969901|DRUG|Active Control|"All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents."
40973277|NCT01694030|OTHER|Attachment security priming|
40973278|NCT02139332|BEHAVIORAL|PFR Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
41298717|NCT03569423|PROCEDURE|Transepithelial photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
41298718|NCT03569423|PROCEDURE|Alcohol assisted photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
41298719|NCT04747574|DRUG|EXO-CD24|The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device, QD for 5 days.
40769977|NCT02720458|BEHAVIORAL|Short-term simple self-help program|"The short-term simple self-help program consists in:~* Restriction of time in bed~* Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program."
40769978|NCT05949957|BEHAVIORAL|LvL UP App|LvL UP App: A Smartphone-based conversational agent-delivered holistic lifestyle intervention. The intervention group will receive several digital coaching sessions focus on 3 pillars: diet, physical activity, and mental well-being to promote health literacy and promote healthy lifestyles. The app includes practical exercises per pillar (e.g., journaling, slow-breathing exercises, lifehacks).
40769979|NCT05949957|BEHAVIORAL|HAPPY App|HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.
40769980|NCT05949957|BEHAVIORAL|Oura Ring And Oura App|Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App
40769981|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Active Treatment questionnaire|Electronic questionnaire to be administered to patients in active treatment.
40769982|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Survivors questionnaire|Electronic questionnaire to be administered to cancer survivors.
40769983|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Palliative Care questionnaire|Electronic questionnaire to be administered to patients in palliative care.
40769984|NCT00860769|BEHAVIORAL|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
41298720|NCT00027040|DRUG|Selegiline hydrochloride|
41298721|NCT00003386|BIOLOGICAL|BCG vaccine|
41298722|NCT00003386|BIOLOGICAL|autologous tumor cell vaccine|
41298723|NCT00003386|DRUG|carboplatin|
41298724|NCT00003386|DRUG|cisplatin|
41298725|NCT00003386|DRUG|cyclophosphamide|
41298726|NCT00003386|DRUG|paclitaxel|
41139628|NCT05210309|PROCEDURE|Stem Cell Therapy|Application of Darvadstrocel locally, after fistula tract curettage and internal opening closure.
41298727|NCT00003386|OTHER|dinitrophenyl|
40769985|NCT00860769|BEHAVIORAL|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
40769986|NCT05660642|DRUG|BPL-003|Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
40769987|NCT01379690|OTHER|HBA1C|Used level of HBA1C as a reflection of glycaemic control of the cases and controls
40769988|NCT06126315|DRUG|Acetyl-l-carnitine|Acetyl-l-carnitine
40769989|NCT06126315|DRUG|Placebo|placebo
40769990|NCT05085847|OTHER|Mindfulness meditation training|Mindfulness-based intervention encompasses different practices which intend to exercise awareness by using mindfulness meditation training moment by moment. Thus, practices such as mindful breathing, compassionate communication, loving-kindness, self-compassion, mindful listening, dealing with difficulties, the 3 step meditation, walking meditation, body scan with progressive relaxation, thoughts, emotions, gratitude, and sounds and breathing will be teaching to participants. Mindfulness training will be conduct by two instructors with more than 30 years' experience in meditation practices (Zen and Tibetan Buddhist approach to mind-training) and extensive mindfulness teaching and practices (\> 5 years each) experiences.
40769991|NCT05085847|OTHER|Active control|Participants will receive lectures that provide cognitive and sensorial stimulus which does not specifically involve awareness training (meditation). Lesson topics include science.
41139629|NCT02581904|DEVICE|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
41139630|NCT02581904|DEVICE|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
41139631|NCT01248715|DRUG|oseltamivir|These patients will receive early (within 8-12 hours of admission, no later than 24 hours after admission) oseltamivir plus current, standard empiric antibacterial therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP (2). Anti-influenza therapy will be given using oseltamivir at a dose of 75 mg twice daily. The oseltamivir dose will be adjusted in patients with renal insufficiency according to the package insert. Duration of antiviral therapy will be for a minimum of 5 days for patients with evidence of early clinical improvement and prolonged depending on clinical stability
41146920|NCT01342718|DIETARY_SUPPLEMENT|Placebo herbal extract granule and probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)"
41298728|NCT00003386|PROCEDURE|surgical procedure|
41298729|NCT03551145|OTHER|Acellular collagen matrix|3D collagen matrix consists of the collagen porcine type I and III
40769992|NCT05616026|BEHAVIORAL|Intervention|6 months of diabetes management support via SMS texts including reminders for medication adherence, appointments, and diabetes self-care activities as well as education, and support
41298730|NCT03551145|OTHER|Autogenous free gingival graft|Autogenous graft harvested from the posterior palate
41298731|NCT05556382|RADIATION|radiation of brain tissue specimen and dna damage analysis|increasing doses of radiation on brain tissue specimen and analysis of related dna damage.
41298732|NCT00624130|DRUG|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
41298733|NCT00624130|DRUG|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
41298734|NCT02592304|DEVICE|Dual energy computed tomography|one extra scanning with a dual energy ct.
40973279|NCT02139332|BEHAVIORAL|Resource & Referral Group|The Resource \& Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc...), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
40769993|NCT05616026|BEHAVIORAL|Attention Control|6 months of texts for general health promotion
40973280|NCT00869349|BEHAVIORAL|IFS|"The program will begin with a half day orientation to meet the trained professional coaches and other patients enrolled in the program. Following the orientation there will be group meetings of 8-10 RA patients every other week for twelve weeks with one of the trained coaches. In the weeks patients do not meet with the group, patients will have individual coaching sessions. The group meetings will last approximately 90 minutes and the individual meetings will last 50 minutes. A maintenance program will follow with bimonthly coaching sessions and a group meeting once a month over the next six months.~Three, six and nine months after the beginning of the program, patients will return to the hospital to complete the same research questionnaire and physical examination they received at baseline."
40973281|NCT00869349|OTHER|Education|The intervention for the controls includes an initial meeting with a health professional. Once a month for 9 months, patients will received educational material and a follow-up phone call to ask if the patient received the information and to answer any questions about the material.
40973282|NCT06049940|BIOLOGICAL|Investigational tetanus vaccine, adsorbed|The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.
40973283|NCT06049940|BIOLOGICAL|Control tetanus vaccine, adsorbed|The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.
40973284|NCT04580667|OTHER|Collection of plasma samples|Collection of plasma samples - Plasma samples are collected at different times during the study for the RadTox test.
40973285|NCT00123396|BEHAVIORAL|BioCASES and BioTESTS|
40973286|NCT02908555|OTHER|No intervention|This is a descriptive study with no intervention
40973287|NCT06093295|DEVICE|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation)|"The repetitive transcranial magnetic stimulation device will generate successive magnetic pulses to the left dorsolateral prefrontal cortex (experimental condition) and the vertex (control condition).~The theta burst stimulation protocol is as follows:~* Total stimulation time \~190 seconds~* Intensity: 80% of active motor threshold~* 2 seconds train, repeated every 10 seconds~* In every 2-second train, 3 pulses of stimulation are delivered at 50 Hz, repeated every 200 milliseconds (i.e., 5 Hz) for a total of 600 pulses"
40973288|NCT06373991|BIOLOGICAL|ATHENA CAR-T|Phase 1 dose escalation (3+3): dose 1 and dose 2.
40973289|NCT06373991|DRUG|Fludarabine|Intravenous injection of fludarabine.
40973290|NCT06373991|DRUG|Cyclophosphamide|Intravenous injection of cyclophosphamide.
40973291|NCT00635960|DRUG|Growth Hormone (Somatropin)|The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.
40973292|NCT00635960|DRUG|Placebo|Same as for Growth hormone group
40973293|NCT06422130|OTHER|Pregnant women and their offspring without intervention|Pregnant women and their offspring with those exposures of interest determined in specific research based on the database
40973294|NCT01850524|DRUG|Ixazomib|IXAZOMIB capsules.
40973295|NCT01850524|DRUG|Placebo|IXAZOMIB matching-placebo capsules.
40769994|NCT04039347|DRUG|Liposomal Cyclosporine A 5 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
40973296|NCT01850524|DRUG|Dexamethasone|Dexamethasone tablets.
40973297|NCT01850524|DRUG|Lenalidomide|Lenalidomide capsules.
40973298|NCT02267811|OTHER|Orthodontic Treatment|Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
40973299|NCT02267811|DEVICE|OrthoPulse™|Participants carry out daily OrthoPulse™ treatments at home.
40973300|NCT06051929|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
41146921|NCT01342718|DIETARY_SUPPLEMENT|Placebo herbal extract granule and placebo probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
41458880|NCT05998291|OTHER|Assessment of prognosis of refractory dermatitis herpetiformis. No intervention|Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
40973301|NCT05076903|DRUG|OFA|Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
40973302|NCT05076903|DRUG|Control|Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
40973303|NCT04234581|DIETARY_SUPPLEMENT|Lysulin|Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.
40973304|NCT01876030|DEVICE|FES|
40973305|NCT03744611|DIETARY_SUPPLEMENT|CE|550mg capsule (Eucommia ulmoides Oliver extract)
40973306|NCT03744611|DIETARY_SUPPLEMENT|Placebo|550mg capsule (Placebo)
40973307|NCT04750148|DIAGNOSTIC_TEST|6-minute walking test|The subject walks as far as possible for 6 minutes along a 30m long corridor.
40973308|NCT04750148|DIAGNOSTIC_TEST|2-minute walking test|The subject walks as far as possible for 2 minutes along a 30m long corridor.
40973309|NCT04750148|DIAGNOSTIC_TEST|10-meter walk test|The natural and fast walking speeds of the subject are measured over 10m. This speed is measured by the examiner as well as by the subject (self-tested version).
40973310|NCT04750148|DIAGNOSTIC_TEST|One leg stance test|The time held in unipodal equilibrium is measured by the examiner.
40973311|NCT03751488|DRUG|LY03010|Single Dose of LY03010 at 351 mg or 156 mg or 117mg
41139632|NCT04794244|BEHAVIORAL|ASGE-FABES Program|In the control group study, pretest-posttest and experimental design with repeated measurements were used in randomized groups. An overweight and obese adolescent constituted the sample of 250 (125-experiment, 125-control) of the study. Research data Socio-Demographic Features Information Form, Adolescent Nutrition Information Scale, Adolescent Physical Activity Information Scale, Adolescent Lifestyle Scale, Healthy Lifestyle Choice Scale for Adolescents, Beck Anxiety Scale, Daily Food Consumption Form, Beverage Consumption Form, collected using. Data are saved before and after application. ASGEFABES PROGRAM was applied to the experimental group for 10 weeks. Measurements after the training program were collected in four measurements: 1st week, 6th and 12th months.
41139633|NCT05484297|BEHAVIORAL|Crisis Caring Contacts post cards|A series of post cards with Crisis Caring Contacts content sent over 10 months
41139634|NCT05484297|BEHAVIORAL|Control post cards|"A series of post cards intended to control for attention received but not including elements thought to be active ingredients in the intervention"
41139635|NCT04704440|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
41139636|NCT04704440|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
41139637|NCT04704440|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
41139638|NCT04704440|OTHER|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
41139639|NCT00658632|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
41139640|NCT00658632|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
41139641|NCT06444087|OTHER|secukinumab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
41139642|NCT05786378|BIOLOGICAL|Platelet Rich Plasma|"Sample of patient's blood drawn at time of Treatment; the blood drawing occurs with addition of anticoagulant such as citrate dextrose A to prevent platelet activation prior to its use.~Obtain whole blood by venipuncture in acid citrate dextrose (ACD) tubes. Centrifuge the blood using a 'soft' spin. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~PRP activation prior to injection. PRP can be activated exogenously by calcium chloride."
41146922|NCT00801606|DRUG|Zinc|Zinc 20 mg/day
41146923|NCT00801606|DRUG|Micronutrient without zinc|Multimineral 2 RDA
40973312|NCT03751488|DRUG|Invega Sustenna 156 MG in 1 ML Prefilled Syringe|Single Dose at 156mg
40973313|NCT00812864|DRUG|Capecitabine|"Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day"
40973314|NCT02193867|DRUG|Sebelipase Alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
40973315|NCT06410820|DEVICE|Procedure/Surgery: Ultrasound method group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
40973316|NCT06410820|DEVICE|Landmark method group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
40973317|NCT02152696|DRUG|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
40973318|NCT02152696|PROCEDURE|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
40973319|NCT02152696|OTHER|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
40973320|NCT01574131|DRUG|Fenofibrate|Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months
40973321|NCT01574131|DRUG|Sugar Pill|pill every day for 6 months
40973322|NCT02697812|PROCEDURE|slow sternal retraction|the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
40973323|NCT02255604|DRUG|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
40973324|NCT02255604|DRUG|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
40973325|NCT02255604|DRUG|0.1 ml Isoton saline|4 injection into a lymphnode
40973326|NCT00888862|DRUG|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
40973327|NCT02075229|DEVICE|Cochlear implant|A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
40973328|NCT00783250|DRUG|Salbutamol + Tiotropium|Salbutamol 400 micrograms + Tiotropium 18 micrograms
40973329|NCT00783250|DRUG|Placebo + Tiotropium|Placebo via MDI + Tiotropium 18 micrograms
40973330|NCT03909256|OTHER|NUTRI-HAB|"The rehabilitation program is a coordinated multidisciplinary effort involving several specialists e.g. clinical dietitians, nurses, physiotherapists, occupational therapists (responsible for dysphagia management in Denmark), psychologists and social workers.~The program includes group sessions with patient education on how to handle the different aspects of living with eating problems and other late effects. Practical kitchen exercises, physical activity sessions and instruction in swallowing training are included. Individual counseling sessions with clinical dietitians and other health professionals (e.g. physicians) are offered depending on participants' needs.~Participants stay at the premises and all meals throughout the day are served in the dining room or in the café. Foods of different textures and flavors are served to inspire participants and to allow them to experiment.~Between the initial stay and follow-up participants are contacted twice by a clinical dietitian."
40973331|NCT03984097|DRUG|TAK-079|TAK-079 subcutaneously.
40973332|NCT03984097|DRUG|Lenalidomide|Lenalidomide orally.
40973333|NCT03984097|DRUG|Dexamethasone|Dexamethasone orally.
40973334|NCT03984097|DRUG|Bortezomib|Bortezomib subcutaneously.
40973335|NCT03984097|DRUG|Pomalidomide|Pomalidomide orally.
40973336|NCT02048891|DRUG|GnRH agonist trigger|
40973337|NCT02048891|DRUG|hCG trigger|
40973338|NCT02034110|DRUG|Dabrafenib|A 150 mg twice daily capsule administered orally on a continuous basis.
40973339|NCT02034110|DRUG|Trametinib|A 2 mg once daily tablet administered orally on a continuous basis.
40973340|NCT00118963|DRUG|Metformin|Tablets of 500 mg; 1000 mg two times daily.
40973341|NCT00118963|DRUG|Insulin BIAsp30 (Novolog 70/30)|Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
41139643|NCT05786378|DRUG|local anesthesia in external auditory canal|local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
41139644|NCT05786378|PROCEDURE|Intratympanic Injection|0.5-1 ml of PRP will be injected in middle ear cavity in round window niche Using microscope or endoscope.
40973342|NCT00118963|DRUG|Repaglinide|Tablets of 1 mg; Dosage: 2 mg three times daily.
40973343|NCT00118963|DRUG|Placebo-Metformin|Tablets corresponding to 500 mg; two tablets two times daily.
40973344|NCT00118963|DRUG|Placebo-Repaglinide|Tablet corresponding to 1 mg; two tablets three times daily.
40973345|NCT00355693|DEVICE|Pump for propofol delivery|
40973346|NCT01681225|OTHER|Esophageal-pressure guided mechanical ventilation|
40973347|NCT01681225|OTHER|High PEEP mechanical ventilation|
40973348|NCT03907553|DIAGNOSTIC_TEST|targeted genome sequencing|
40973349|NCT04150393|DRUG|MaaT033 capsule|Oral capsule
40973350|NCT04579185|DEVICE|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
40973351|NCT00545194|DRUG|Prostaglandin E2|
41139645|NCT06222437|DRUG|Semaglutide|effectiveness of semaglutide in PCOS
41139646|NCT02751294|DRUG|Tafenoquine Control|It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine
41139647|NCT02751294|DRUG|Tafenoquine dissolution profile X|"It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine and will be intermediate aged TQ Product."
41139648|NCT02751294|DRUG|Tafenoquine SIL|It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.
41139649|NCT00990314|DRUG|Beraprost Sodium Modified Release|
41139650|NCT06317610|OTHER|growth prediction of ovarian cancer organoids in the frame of bright field image by leveraging AI|biopsy or puncture: Patients received biopsy or puncture to obtain tumor tissues or Malignant effusion for organoids establishment
41139651|NCT02183909|OTHER|Testing and linkage to care for Y/MSM|Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
41298735|NCT01519570|OTHER|An informational packet regarding shingles and the HZV was sent to patients identified by the EMR|The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
41298736|NCT00493116|DRUG|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
41298737|NCT00493116|DRUG|methylprednisolone|dosage and frequency as per Biogen Idec protocol
41466543|NCT02785653|DRUG|Sevoflurane|Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen
40769995|NCT04039347|DRUG|Liposomal Cyclosporine A 10 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
40769996|NCT06238973|OTHER|Group Low|In order to maintain arterial blood pressure within the range of 50-57 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
40769997|NCT06238973|OTHER|Group Middle|In order to maintain arterial blood pressure within the range of 58-65 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
40769998|NCT03127930|BEHAVIORAL|Intervention|Participants receive 5 individualized contacts (home visits and phone calls) with either a social worker or a nurse to develop problem solving skills as applied to medication management.
40769999|NCT05261126|DRUG|Enlicitide Decanoate|Enlicitide Decanoate administered orally
40770000|NCT05261126|DRUG|Placebo|Placebo matching enlicitide decanoate administered orally
40770001|NCT00928772|DEVICE|CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM|APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION
40770002|NCT00928772|DRUG|MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY|CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION
40770003|NCT00928772|OTHER|NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED|NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
40770004|NCT00839501|DIETARY_SUPPLEMENT|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
40770005|NCT00839501|DRUG|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
40770006|NCT06048029|PROCEDURE|laparscopic Cholecystectomy in children|Evaluate preoperative and operative risk factors for conversion of laparoscopic cholecystectomy to open cholecystectomy
40770007|NCT02955290|OTHER|Laboratory Biomarker Analysis|Correlative studies
40770008|NCT02955290|BIOLOGICAL|Nivolumab|Given IV
40770009|NCT02955290|BIOLOGICAL|Pembrolizumab|Given IV
41298738|NCT02391623|DRUG|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
41298739|NCT02391623|DRUG|Placebo|Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
41298740|NCT02391623|DRUG|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
40770010|NCT02955290|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given CIMAvax IM
40770011|NCT05405270|DRUG|Imiquimod|Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.
40770012|NCT05405270|DIAGNOSTIC_TEST|3x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.
40770013|NCT05405270|OTHER|Expectative management|Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
40770014|NCT05405270|DIAGNOSTIC_TEST|2x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
40770015|NCT02446509|BEHAVIORAL|Psychoeducation|Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
41466544|NCT02785653|DRUG|Rocuronium|rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
40770016|NCT02446509|BEHAVIORAL|Psychoeducation - Delayed|The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
40770017|NCT03421353|DRUG|AZD9150|"AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
41146924|NCT00801606|DRUG|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
41146925|NCT00801606|DRUG|Placebo|Placebo
41466545|NCT06233539|OTHER|Observational research without intervention|Observational research without intervention
41466546|NCT02483936|DRUG|Olmesartan medoxomil 40mg + chlorthalidone 12,5mg|1 tablet a day
40973352|NCT01612936|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage|"On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent."
40973353|NCT01612936|PROCEDURE|PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)|Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
40973354|NCT03804047|OTHER|kinesio tape|kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
40973355|NCT04482881|DRUG|Isosorbide Mononitrate 40 MG|giving women isosorbide mononitrate 40 MG
40973356|NCT04482881|DRUG|Isosorbide Mononitrate 60 MG|giving women isosorbide mononitrate 60MG
40973357|NCT04482881|DRUG|Misoprostol|Giving women misoprostol
40973358|NCT04147208|DRUG|GLS4|Administered GLS4 120 mg orally three times daily in fed state
40973359|NCT04147208|DRUG|RTV|Administered RTV 100 mg orally three times daily in fed state
40973360|NCT04147208|DRUG|ETV|Administered orally ETV 0.5 mg once daily in fasted state
40770018|NCT03421353|DRUG|Durvalumab|"Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
40770019|NCT03421353|DRUG|Cisplatin|Cisplatin will be infused over 30-60 minutes on Day 1.
40770020|NCT03421353|DRUG|5-Flourouracil|5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
40770021|NCT03421353|DRUG|Carboplatin|Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
40770022|NCT03421353|DRUG|Gemcitabine|Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
40973361|NCT00240162|DRUG|PTK787/ZK 222584|
40973362|NCT04498013|DRUG|Cyclodynon|Cyclodynon 1 tablet a day during 6 menthes period.
40973363|NCT04498013|BEHAVIORAL|Lifestyl modification|Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.
41298741|NCT02391623|DRUG|Placebo|Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
40770023|NCT03421353|DRUG|Nab-paclitaxel|Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
40973364|NCT02692703|DRUG|glecaprevir/pibrentasvir|Tablet; glecaprevir coformulated with pibrentasvir
40973365|NCT04140591|DRUG|Proton-pump inhibitor|PPI: Pariet EC 20mg/QDAC
40973366|NCT04140591|DRUG|Propranolol+Proton-pump inhibitor|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure \>90mmHg) PPI: Pariet EC 20mg/QDAC
40973367|NCT00546637|DRUG|Fesoterodine|Fesoterodine 4mg or 8mg
40973368|NCT00546637|DRUG|Placebo|Placebo
41139652|NCT02183909|BEHAVIORAL|Engagement and retention for HIV-positive Y/MSM in care|Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
40770024|NCT03407950|BEHAVIORAL|IPT+|Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
40770025|NCT03407950|BEHAVIORAL|Treatment as usual|no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
40770026|NCT03287986|OTHER|MRI|Structural and functional sequences
40770027|NCT05656664|DIETARY_SUPPLEMENT|Folic Acid|Folic acid supplementation to assess for increased arsenic metabolite excretion
40770028|NCT05656664|OTHER|Placebo|Placebo group to assess arsenic metabolite excretion
40973369|NCT01923493|OTHER|tuina|Patients in the tuina group will receive a tuina therapy (also known as Chinese massage). A Chinese massage lasts about 20 to 30 minutes. A series of 6 sessions with 2 treatments per week is applied.
40973370|NCT01923493|OTHER|no intervention|Patients in the no intervention waiting list group will not receive a study intervention. They will continue their respective pre-study therapy during the study period.
40973371|NCT00030810|RADIATION|Hyperfractionated|Hyperfractionated radiotherapy
40973372|NCT00030810|DRUG|Taxotere/Cisplatin|Taxotere/Cisplatin
40973373|NCT00030810|PROCEDURE|conventional surgery|conventional surgery
41466547|NCT02483936|DRUG|Olmesartan medoxomil 40mg + chlorthalidone 25mg|1 tablet a day
41466548|NCT02483936|DRUG|Olmesartan 40mg + Hydrochlorothiazide 12,5mg|1 tablet a day
40973374|NCT05732688|DIAGNOSTIC_TEST|Image-based ex-vivo drug screening platform (pharmacoscopy)|"Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds. A drug score is calculated for each compound (defined as 1 - (% target cells in drug treated conditions / % target cells under control condition)). If a drug kills all target cells specifically, the best possible score is 1. If the drug is killing all non-target cells, the score goes to negative infinite. If a drug kills both target and non-target cell populations equally, or does nothing, the score is 0."
40973375|NCT04062175|DRUG|cephalosporin|72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision
40973376|NCT04062175|DRUG|Azithromycin Tablets|72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
40973377|NCT00380757|PROCEDURE|bystander CPR using 30:2 ratio vs 15:2 ratio|Participants will use 2 CPR techniques with different chest compression to ventilation ratios
40973378|NCT04057391|DIAGNOSTIC_TEST|QT Scanner|Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.
40973379|NCT01216306|BEHAVIORAL|Television reduction curriculum|Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
40973380|NCT00121602|DRUG|Darbepoetin Alfa|Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
40973381|NCT02664753|DRUG|56 days of weight-adjusted L-Carnitine treatment|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.~Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes~For the next 46 days, patients will take oral doses of L-Carnitine as follows:~\< à 60kg : 2g/day \> 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization"
40973382|NCT02664753|DRUG|10 days of intravenous placebo (isotonic saline)|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening."
40973383|NCT04355845|DRUG|Sumatriptan|25 milligrams (mg) single dose tablet
40973384|NCT04355845|DRUG|PF-06651600|PF-06651600 400 mg single dose
40973385|NCT03141476|DRUG|Cefuroxime 1,5g|Patients with BMI of \<30kg/m\*m: 1,5 g Cefuroxime
40973386|NCT03141476|DRUG|Cefuroxime 3g|Patients with BMI of 30-50kg/m\*m: 3g Cefuroxime
41139653|NCT02183909|OTHER|Engagement and retention for HIV-negative Y/MSM in sexual health services|Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
41458881|NCT06047626|OTHER|Fatigue Reduction Diet|Sessions will be \~15 minutes for 8 sessions. The FRD maintains participants on a diet with their typical caloric intake as assessed at baseline, and replaces some of their calories with the following foods on a daily basis: at least 50% of servings grains to be whole grains (these would replace non-whole grain foods); 5 servings of vegetables (1 leafy green, 1 tomato, and 1 yellow/orange); 2 servings of fruit (1 high in vitamin C), both fruit and vegetables would replace some of the carbohydrates from non-fruit and vegetable sources; 1 serving of fatty fish and or 1 serving of nuts and/or seeds (2 servings of nuts and/or seeds for vegetarians), both the fish, the nuts, and seeds will replace existing sources of fats and proteins in the diet.
41458882|NCT06047626|OTHER|General Health Curriculum|These sessions will be matched counseling method, time spent (\~15 minutes per session), for 8 sessions. Registered Dietitians will discuss general health topics with the participant, excluding topics of diet and food.
41458883|NCT05564845|DIAGNOSTIC_TEST|MR scan of the brain|Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.
40973387|NCT03141476|DRUG|Cefuroxime 4,5g|Patients with BMI of \>50kg/m\*m: 4,5 g Cefuroxime
40973388|NCT02139111|DRUG|Placebo|Oral placebo capsule
40973389|NCT02139111|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
40973390|NCT02139111|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
40973391|NCT02139111|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
40973392|NCT02139111|DRUG|PRC-063 85 mg|Oral 85 mg capsule - active
40973393|NCT04809688|DIETARY_SUPPLEMENT|Saskatoon berry|Freeze dried Saskatoon berry (30 g) will be orally administrated daily for 10 weeks.
40973394|NCT05519410|DRUG|Sintilimab and Lenvatinib|Tislelizumab, 200mg, ivd,q3w; Lenvatinib,8mg/kg,po,qd.
40973395|NCT05519410|DRUG|HAIC-FOLFOX|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
40973396|NCT06008457|DEVICE|Labcorp COVID-19+Flu+RSV Test Home Collection Kit|The self-collected Labcorp COVID-19+Flu+RSV Test Home Collection Kit results as generated by the commercially available Labcorp Seasonal Respiratory Virus RT-PCR Test will be compared to the HCP-collected results as generated by Labcorp R\&D using the comparator assays.
40973397|NCT06129071|PROCEDURE|US guided block of maxillary nerve|Extraoral ultrasound-guided block of the maxillary nerve will be performed in the examined group using an ultrasound device and local anesthetic levobupivacaine (0,5%, 2 mL) combined with triamcinolonacetonid (2mL).
40973398|NCT03032146|PROCEDURE|Cardiac Rehabilitation|Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
40973399|NCT05246501|OTHER|Simulation|A case scenario with a diagnosis of dementia was used in the study. The scenario consisted of preliminary preparation, implementation and evaluation parts. Psychiatric nursing laboratory practice was applied to the students in the scenario study group. An elderly female standard patient who was diagnosed with dementia took part in the scenario. During this simulation, students were expected to perform mental state examination of the patient, use therapeutic communication techniques and ensure environmental safety.
40973400|NCT05246501|OTHER|No simulation|The students in the control group did not receive simulation training.
40973401|NCT02170051|BEHAVIORAL|CBSST-CCT|
41139654|NCT02183909|DRUG|Stribild PEP Substudy|A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
41139655|NCT04266626|OTHER|kinesiotaping therapy|Kinesiotaping is a new therapeutic technique that gives support to the lip and tongue base muscles without restricting range of motion or blood flow.
41139656|NCT04266626|OTHER|oral motor manipulation therapy|Manipulation therapy include tapping and massage of oral motor muscles including orbicularis oris and base of tongue.
41139657|NCT03155022|DEVICE|Remote ischemic conditioning and intracoronary ischemic conditioning|"RIC: Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.~ICIC: Four cycles of \[1 min balloon inflation followed by 1 min balloon deflation\] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization."
41139658|NCT03155022|DEVICE|Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning|Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
41139659|NCT00997750|DRUG|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
41139660|NCT06241300|BEHAVIORAL|Chicago Parent Program|Chicago Parent Program is an evidence-based group parenting intervention designed to reduce disruptive behavior in young children (2-8 years old).
41139661|NCT03653897|DEVICE|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
41139662|NCT03653897|DEVICE|Wearable Sensor|Subjects will wear an ID-Reader
41139663|NCT03527888|DRUG|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
41139664|NCT00278928|DRUG|Liposyn III 20% (lipid infusion)|
41139665|NCT00278928|DRUG|Intralipid 20% (lipid infusion)|
41139666|NCT04453930|DRUG|Camrelizumab，an engineered anti-PD-1 antibody|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6) and maintenance phase (Cycle onward).
41139667|NCT04453930|DRUG|Platinum|"Carboplatin： Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6).~Cisplatin： Cisplatin intravenous infusion was administered at a dose of 30 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6)."
41139668|NCT04453930|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 65 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).
41139669|NCT04453930|DRUG|Apatinib|Apatinib was administered at a dose of 250 mg during the maintenance phase.
41139670|NCT04518306|DRUG|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg|Oral tablets
41139671|NCT04518306|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Oral tablets
41139672|NCT04518306|DRUG|Placebo|Placebo
41139673|NCT02341222|DEVICE|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
41139674|NCT02341222|DEVICE|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
41146926|NCT03202056|OTHER|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments.
41146927|NCT03202056|OTHER|Sham Dry needling|Sham Dry needling use a non-penetrating acupuncture needle
41458884|NCT05564845|DIAGNOSTIC_TEST|Blood work|Lab work for current lab values and biobanking
40973402|NCT02170051|BEHAVIORAL|Goal focused supportive contact|
40973403|NCT01675271|OTHER|individual exercise|individual exercise and dietary prescription
40973404|NCT01675271|OTHER|general exercise|general exercise counselling
40973405|NCT04967443|DRUG|Prazosin HCl 2mg|Prazosin HCL 1 X 2 mg capsule.
40973406|NCT04967443|DRUG|Prazosin HCl 1 mg|Prazosin HCl 2 X 1 mg capsule.
40973407|NCT04967443|DRUG|Prazosin HCl 5 mg|Prazosin HCL 1 X 5 mg capsule.
40973408|NCT00891254|DEVICE|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
40973409|NCT03240614|DEVICE|Non-rebreather oxygen mask|This intervention will be preoxygenation using a Non-rebreather that will be placed upon the participant for preoxygenation. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After 3 minutes, an ABG will be taken and labeled as Intervention A.
40973410|NCT03240614|DEVICE|Bag-valve-mask|This intervention will be preoxygenation using a BVM apparatus for preoxygenation for 3 minutes. At the end of 3 minutes an ABG will be obtained.
40973411|NCT03240614|DEVICE|High Flow Nasal Cannulae|This intervention will be preoxygenation using High Flow Nasal Cannulaes at an FiO2 of 100%. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After the 3 minutes, an ABG will be taken and labeled as Intervention C.
40973412|NCT04782024|DIETARY_SUPPLEMENT|7-Keto 50mg|
40973413|NCT04782024|DIETARY_SUPPLEMENT|7-Keto 25mg|
40973414|NCT04782024|DIETARY_SUPPLEMENT|Placebo|
40973415|NCT01914198|OTHER|Sleep apnea symptom survey|Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
40973416|NCT02990910|DRUG|Individualized opioid analgesia|(a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
40973417|NCT02990910|DEVICE|conventional opioid analgesia|(b) all received 25μg/kg morphine
40973418|NCT04819646|DIETARY_SUPPLEMENT|Marine Lipid Oil Concentrate Formulation|Marine Lipid Oil Concentrate softgels
40973419|NCT04819646|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement capsules
40973420|NCT04620993|OTHER|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position."
40973421|NCT04620993|OTHER|Evaluation of navıcular drop|The amount of navicular drop of both feet will be measured
40973422|NCT04620993|OTHER|Evaluation of plantar pressure distrubution|The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.
41139675|NCT01959009|OTHER|HFOV combined with sigh breaths|"We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
41139676|NCT00500604|DRUG|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
40973423|NCT02122562|DRUG|Ketamine|Treatment
41139677|NCT00500604|DRUG|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
41139678|NCT00500604|DRUG|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
41139679|NCT00674037|OTHER|monetary incentive|75 euros for each patient included
41298742|NCT06059378|DEVICE|Artificial intelligence-assisted classification (CADx)|CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.
41298743|NCT03328130|BIOLOGICAL|AAV2/5-hPDE6B|Subretinal administration in one eye
40973424|NCT03305653|DEVICE|Esophageal String Test (EST)|The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
40973425|NCT01480050|DRUG|temozolomide|standard of care drug
41139680|NCT00024245|DRUG|pralatrexate|
41139681|NCT00024245|DRUG|probenecid|
41139682|NCT01120457|DRUG|BMS-936564 (Anti-CXCR4)|
41298744|NCT00833235|OTHER|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
40973426|NCT01480050|OTHER|3'-deoxy-3'-[18F]fluorothymidine|tracer used for FLT PET CT
40973427|NCT01480050|OTHER|pharmacological study|
40973428|NCT01480050|DRUG|Mibefradil|
40973429|NCT01426373|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
40973430|NCT06352281|BIOLOGICAL|CAR-T cells|CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.
40973431|NCT05506085|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of Globus Pallidus interna
40973432|NCT02246660|DRUG|Resveratrol|"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."
40973433|NCT02246660|DRUG|Placebo|Placebo will be taken orally for 6 months.
41139683|NCT03507699|RADIATION|Liver radiation therapy|21 Gy in three fractions to one liver metastasis
41298745|NCT00899743|GENETIC|polyacrylamide gel electrophoresis|polyacrylamide gel electrophoresis
41458885|NCT05564845|DIAGNOSTIC_TEST|Neurological examination|Classical neurological examination
40973434|NCT03347877|PROCEDURE|autologous osteo-periosteal cylinder graft transplantation|Autologous osteo-periosteal cylinder graft transplantation is a novel treatment for Hepple V osteochondral lesions of the talus.
40973435|NCT03347877|PROCEDURE|autologous osteochondral graft transplantation|Autologous osteochondral graft transplantation is the most common treatment for Hepple V osteochondral lesions of the talus.
40973436|NCT03347877|DEVICE|autologous osteo-periosteal cylinder graft|Autologous osteo-periosteal cylinder graft is taken from ilium.
40973437|NCT03382145|OTHER|No intervention|No intervention
40973438|NCT04419584|DRUG|Modified Qing-Ying Decoction|Herbal granules
40973439|NCT04419584|DRUG|Identical looking placebo|Placebo granules
40973440|NCT01465997|DRUG|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
40973441|NCT01465997|DRUG|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years)
40973442|NCT01584102|BEHAVIORAL|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
40973443|NCT01584102|BEHAVIORAL|group fitness classes only|15 weeks biweekly group fitness
40973444|NCT00056524|DRUG|AVP-923|
40973445|NCT06372223|DRUG|SPH5030|SPH5030 tablets：400mg,orally, Dosing in the fasted state followed by fed dosing.
40973446|NCT06372223|DRUG|SPH5030|SPH5030 tablets：400mg, orally, Dosing in the fed state followed by fasted dosing.
40973447|NCT03916198|DRUG|Polydeoxyribonucleotides|Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
40973448|NCT03916198|DRUG|Normal saline|Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
41139684|NCT03507699|DRUG|Nivolumab Injection [Opdivo]|administered IV at a dose of 3mg/kg every 2 weeks
41298746|NCT00899743|GENETIC|western blotting|western blotting
41298747|NCT00899743|OTHER|immunologic technique|immunologic technique
41298748|NCT00899743|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
41466549|NCT02483936|DRUG|Olmesartan 40mg + Hydrochlorothiazide 25mg|1 tablet a day
41466550|NCT03992339|DRUG|ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
40973449|NCT00382577|DRUG|Itopride|
40973450|NCT00382577|DRUG|Placebo|
40973451|NCT01812824|BEHAVIORAL|Intervention (Virtual Patient Advocate)|"Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week."
40973452|NCT01636804|DEVICE|Quicksite|St. Jude Medical produced lead called Quicksite
40973453|NCT01636804|DEVICE|Quickflex|St. Jude Medical produced lead called Quickflex
40973454|NCT02974166|OTHER|Conventional Group|Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
40973455|NCT02974166|OTHER|Osteopathic Group|Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
40973456|NCT02974166|DRUG|Ibuprofen|The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
40973457|NCT02974166|DRUG|Cyclobenzaprine Hydrochloride|The medication was prescribed by the dentist as muscle relaxer if necessary.
40973458|NCT03659812|OTHER|MACS technique|MACS is a technique that allow us to tag and detect apoptotic spermatozoa. These apoptotic spermatozoa have phosphatidylserine in their membranes, so we add magnetic beads with Annexin V, which binds specifically to phosphatidylserine. The spermatozoa are then tagged and can be retained in a magnetic field, allowing us to collect just the non-apoptotic spermatozoa.
40973459|NCT01927367|OTHER|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
40973460|NCT05130398|BIOLOGICAL|rVSVΔG-ZEBOV-GP, V920|The experimental vaccine is the rVSVΔG-ZEBOV-GP, an Ebola vaccine.
40973461|NCT05130398|DIETARY_SUPPLEMENT|Fibre and equilibrate breakfast and lunch|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days.
41139685|NCT03507699|DRUG|Ipilimumab Injection [Yervoy]|administered IV at a dose of 1mg/kg every 6 weeks
41139686|NCT03507699|DRUG|CMP-001|A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.
41298749|NCT06194435|OTHER|Remote Monitoring of Participant Progress and Well-being via Video Calls|Participants with Rotator Cuff Syndrome undergo remote evaluations via video calls with a physician. On the same day, they receive an asynchronous exercise brochure containing instructions for performing home exercises three times a day. They are also provided with an exercise diary to track their daily exercise sessions. Follow-up assessments and discussions about their condition take place remotely on video calls with the physician on the 7th and 15th days. During the final video call on the 15th day, participants are asked to submit their exercise diaries via WhatsApp for assessment of exercise adherence.
41466551|NCT00630578|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
41466552|NCT05507528|DEVICE|reborn treatment|Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure
41466553|NCT03876028|BIOLOGICAL|Tisagenlecleucel|Infusion
40973462|NCT05130398|DIAGNOSTIC_TEST|Active detection and treatment of pathogens|Monthly diagnostic and treatment of childhood infections Active detection and treatment of pathogens.
40973463|NCT05130398|COMBINATION_PRODUCT|Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days and diagnostic and treatment of childhood infections Active detection and treatment of pathogens every month for 12 months
40973464|NCT05130398|BIOLOGICAL|Chikenpox or Varicella vaccine (VARILRIX)|The active comparator vaccine, a Varicella vaccine (VARILRIX®)
40973465|NCT05130398|OTHER|Placebo|About 30 children do not receive diet, nor active pathogen detection
40973466|NCT04432194|DIETARY_SUPPLEMENT|Nutritional supplementation and Pulmonary Rehabilitation|Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
40973467|NCT06217055|DRUG|remimazolam based MAC|The surgery will be performed under monitored anesthesia care by maintaining spontaneous breathing using remimazolam.
40973468|NCT06217055|DRUG|general anesthesia with sevoflurane|The surgery will be performed under mechanical ventilation with inhalation general anesthesia
40973469|NCT04717115|GENETIC|Genetic diagnosis|No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
40973470|NCT02509247|DEVICE|Telemonitoring|Wireless telemonitoring
41466554|NCT03876028|DRUG|Ibrutinib|Oral (tablets or capsules)
40973471|NCT01089062|DRUG|MAP0004|1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
41466555|NCT05965102|DRUG|Tirelizumab；Chemotherapy monotherapy|Tirelizumab combined with chemotherapy in first-line treatment of relapsed/metastatic non-small cell lung cancer with ECOG PS score of 2
40973472|NCT01089062|DRUG|IV Placebo (Saline)|IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
40973473|NCT01089062|DRUG|Placebo Inhaler|Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
40973474|NCT01089062|DRUG|IV Dihydroergotamine Mesylate (DHE)|IV DHE administered in Treatment A as per protocol
40973475|NCT02954237|DEVICE|AMPLATZER™ Cardiac Plug|The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
40973476|NCT00004196|BIOLOGICAL|recombinant interferon alfa|
40973477|NCT00004196|PROCEDURE|lymphangiography|
40973478|NCT00004196|DRUG|Observation|
40973479|NCT03985631|OTHER|Rehabilitation intervention|Rehabilitation sessions based on Tai Chi through telerehabilitation
40973480|NCT01847222|BIOLOGICAL|SANGUINATE™|PEG-bHb-CO
40770029|NCT05706740|OTHER|Physician survey on antithrombotic medication during end-of-life care in cancer patients|"Participating healthcare professionals will be asked to complete the survey electronically within seven days. The survey will consist of general questions (i.e., Have you ever considered deprescribing antithrombotic medicine?), a discrete choice experiment (DCE), and questions involving actual decision-making in patients.~For the DCE, participants will be presented a sequence of choice sets with (hypothetical) scenarios that vary along several characteristics (attributes; e.g., bleeding risk, thrombotic risk). Attributes will be further specified by varying choice levels (attribute levels; e.g., low or high bleeding risk). Participants will be asked to select the healthcare intervention with the highest benefit for the patient according to their opinion.~Finally, participants will be asked to describe actual decisions they made in max. three consecutive patients with active cancer, who were considered to receive end-of-life care."
40973481|NCT01847222|DRUG|Normal Saline Solution|Placebo
40973482|NCT01163045|PROCEDURE|thyroidectomy|total thyroidectomy and lobectomy
40973483|NCT05043506|DRUG|Palbociclib + aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
40973484|NCT05043506|DRUG|Aromatase inhibitor|Aromatase inhibitor monotherapy
40973485|NCT03446469|OTHER|Fascial Manipulation|Myofascial release of densified centers of coordination
40973486|NCT03331003|DEVICE|low level light therapy|iRestore low-level light therapy on androgenetic alopecia
40973487|NCT03331003|DEVICE|non-LLLT wavelength group|A LED light device is non-curative for the patients.
40973488|NCT00743340|DRUG|Emtricitabine|6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
40973489|NCT00187486|DRUG|Tarceva|Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
40973490|NCT00187486|DRUG|Temodar|Temodar 200 mg/m\^2/day x 5 days every 28 days
40973491|NCT00187486|PROCEDURE|Radiation Therapy|Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
40973492|NCT02503553|BEHAVIORAL|Option grid for cerebral aneurysm treatment|Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.
40973493|NCT02503553|BEHAVIORAL|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
40973494|NCT03296930|DRUG|Sofosbuvir 400 MG Oral Tablet,|Interferon free direct acting antiviral drugs used for treatment of HCV.
40973495|NCT03296930|DRUG|Ombitasvir/paritaprevir/ritonavir|Interferon free direct acting antiviral drugs used for treatment of HCV.
40973496|NCT02045134|DIETARY_SUPPLEMENT|Placebo|Soluble corn flour not rich in anthocyanins
40973497|NCT02045134|DIETARY_SUPPLEMENT|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
40973498|NCT04397653|DRUG|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
41139687|NCT02099409|DEVICE|FLORENCED2|FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
41139688|NCT02234999|DRUG|CC-122|3mg \[14C\]-CC-122 will be administered as a single dose
41139689|NCT04680988|DRUG|SHR-1210|SHR-1210 intravenously every 3 weeks
41139690|NCT04680988|DRUG|SHR-1020|SHR-1020 Orally once daily
41139691|NCT04680988|DRUG|Physician's choice chemotherapy|Investigators will declare one of the following regimens:Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection
41139692|NCT00249405|DRUG|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
41139693|NCT00249405|BEHAVIORAL|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
41139694|NCT01494467|DRUG|CD5024|CD5024 1% Cream, once daily
40973499|NCT04397653|DRUG|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
40973500|NCT04397653|DRUG|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
40973501|NCT04369521|OTHER|low free sugar diet|low free sugar diet with nutrition and exercise recommendation
40973502|NCT03151837|DIETARY_SUPPLEMENT|Greenyn Momordica charantia extracts|Extracts from Momordica charantia containing Momordica charantia insulin receptor binding protein (mcIRBP)
40973503|NCT03151837|DIETARY_SUPPLEMENT|Placebo control|Starch
40973504|NCT03851068|DEVICE|Foldax Tria Aortic Valve|Aortic Valve Replacement
41466556|NCT03008837|DEVICE|Military Field Stimulator|The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
41466557|NCT03008837|OTHER|Standard Therapy|Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
40770030|NCT06463366|DEVICE|3D-MRE,MRI-PDFF|3D-MRE(storage modulus, ., loss modulus and damping ratio \[DR\] for liver inflammation and fibrosis) MRI-PDFF(liver fat content)
40770031|NCT06506461|DRUG|Plerixafor|Given Subcutaneous (under the skin)
40770032|NCT06506461|DRUG|Busulfan|Given Intravenous (IV)
40770033|NCT06506461|DRUG|Gene-modified CD34+ cells|Given Intravenous (IV)
40770034|NCT05356715|PROCEDURE|Ultrasound guided bilateral ESBP|Patients in group A will be positioned in the lateral position , ESPB will be done under complete aseptic conditions , using , linear ultrasound probe(Philips HD11XE Ultrasound System) , to locate the ESP at the level of the fifth dorsal vertebrae , 22 G spinal needle will be used to inject 20 ml of 0.25% of bupivacaine in the ESP bilaterally, block will done by an expert anesthesiologist , who will not be included in the data collection
40770035|NCT03725592|OTHER|Standard Treatment|Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
40770036|NCT03725592|BEHAVIORAL|Intensive Education|Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
40770037|NCT06011733|OTHER|Placebo|Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.
40770038|NCT06011733|DRUG|Bimekizumab|Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.
40770039|NCT04531579|DRUG|Valproic Acid Solution|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
40770040|NCT04531579|DRUG|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
40973505|NCT05837819|DEVICE|Active Lighting Intervention|Lighting intervention using high light levels designed to effect the circadian system
40973506|NCT05837819|DEVICE|Control Lighting Intervention|Lighting intervention using low light levels designed to not effect the circadian system
40973507|NCT01167894|DRUG|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
40973508|NCT00386945|BEHAVIORAL|Brief counseling (Ask, Advise, Arrange)|Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
40973509|NCT00248989|DRUG|Dehydroepiandrosterone|3.0 ml of 0.3% DHEA cream applied on the skin twice daily.
40973510|NCT00248989|DRUG|Placebos|3.0 ml of placebo cream applied on the skin twice daily.
40973511|NCT04897308|PROCEDURE|Local injection of shoulder joint|Under ultrasound guidance , local shoulder joint injection will be done
40973512|NCT05000060|OTHER|Timing/1 week|Time of restart of antiplatelet therapy is one week after injury
40973513|NCT05000060|OTHER|Timing/3 weeks|Time of restart of antiplatelet therapy is left to treating clinician discretion
40973514|NCT02270957|BIOLOGICAL|Abatacept|
40973515|NCT02270957|OTHER|Placebo|
40973516|NCT01332474|DRUG|BOTOX|BOTOX
40973517|NCT04298112|DIAGNOSTIC_TEST|PSMA PET/CT|Whole-body PET/CT (contrast enhanced CT or low-dose CT); from vertex to thighs.
40973518|NCT04298112|DIAGNOSTIC_TEST|PSMA PET/MR|Pelvic PET/MR in addition to targeted PET/MR according to other findings from the PET/CT (e.g. columna)
40973519|NCT02240238|DRUG|NC-6004|NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
40973520|NCT02240238|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
40973521|NCT04522960|DIAGNOSTIC_TEST|MEG+hdEEG+MRI|"We will perform several tests:~* Neuropsychological testing to evaluate evolution of cognition during our study.~* Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.~* MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls"
40973522|NCT00197132|DRUG|Avandia|
40973523|NCT03651921|BEHAVIORAL|CTS-BC-CH|"CTS-BC-CH is a standardized program with 7 weekly group sessions (2.5. to 3 hours). The CTS-BC-CH focuses on building skills, sharing experiences, and support among the participants.~Program elements are: Brainstorming, action plan formulation, action plan feedback, problem solving, and decision making."
40973524|NCT04825418|DEVICE|Artic Sun|"1. Induction phase A. Temperature using by esophageal or bladder thermometer. B. Application of a surface cooling device (Arctic Sun) C. Target temperature: 35 ± 0.5 °C D. Induction should be initiated as soon as possible after surgery (less than 6 hours)~2. Maintain phase A. Maintain duration : at least 72 hours and duration can be prolonged according to patient's clinical status B. Use the bedside shivering assessment scale (BSAS) and anti-shivering protocol C. Neuromuscular blocker can be used according to the discretion of the attending physician D. Lung-protective ventilation strategies including low-tidal volume are recommended E. Prophylactic antibiotics can be used to prevent pneumonia during hypothermia~3. Rewarming phase A. Rewarming rate: 0.05 - 0.1 ℃/hr (about 20 - 40 hours) to 37 ℃"
40973525|NCT00320411|DRUG|lapatinib|Lapatinib 1500mg QD
40973526|NCT01497691|DEVICE|NIPPV (PALMtop PTV)|PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
40973527|NCT01497691|DEVICE|Volumetric CO2 (NM3)|The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
40973528|NCT01497691|DEVICE|USCOM|The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
40973529|NCT04676282|OTHER|Hypothetical Scenario|Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
40973530|NCT06359470|OTHER|Positioning technique|"First time of testing: Firstly, the patients were scanned in the conventional neutral supine position and a 3D-CT scan was taken.~Second time of testing: after 10 minutes, the patients were scanned in the modified reversed contralateral rotation (side-lying on a hard pillow with side bending to the non-affected side and rotation to non affected side). This is achieved through instructing the participant to first lie on the side lying on a wedge pillow (that is flexible with dimensions of 30 cm in height and 75 cm in length) to achieve trunk side bending to non-affected side this pillow is the same for all patients, then the patient/participant rotated to the affected side (pelvis on the trunk rotation), and 3D-CT scan.~Third time of testing: after 48 hours, the patients were scanned in the modified reversed contralateral rotation."
40973531|NCT04403971|DRUG|0.12% Chlorhexidine Oral Liquid Product|The intervention group 1 received 10ml 0.12% chlorhexidine solution for oral rinse twice a day.
40973532|NCT04403971|DRUG|Listerine Oral Liquid Product|The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.
40973533|NCT04403971|OTHER|Normal Saline Product|The control group received 10ml normal saline for oral rinse twice a day.
40973534|NCT00025766|DEVICE|PCI with stenting|PCI with stenting of the occluded culprit infarct-related artery
40973535|NCT00025766|BEHAVIORAL|Optimal Medical Therapy|Participants will receive optimal medical therapy.
40973536|NCT00707824|DRUG|nalbuphine|nalbuphine 5 mg epidural
40973537|NCT00707824|DRUG|nalbuphine|nalbuphine 10 mg epidural
40770042|NCT05888922|DRUG|Minoxidil Tablets|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
41466558|NCT02440035|BIOLOGICAL|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 in Group 3.
40973538|NCT00707824|OTHER|NSS|NSS
40973539|NCT03059823|DRUG|retifanlimab|Anti-PD-1 monoclonal antibody
40973540|NCT02273024|BEHAVIORAL|Exercise|
40973541|NCT03007576|BIOLOGICAL|RegStem|RegStem, 1.5 ml, one injection
40973542|NCT00070174|DRUG|asparaginase|
40973543|NCT00070174|DRUG|busulfan|
40973544|NCT00070174|DRUG|cyclophosphamide|
40973545|NCT00070174|DRUG|cyclosporine|
40973546|NCT00070174|DRUG|cytarabine|
40973547|NCT00070174|DRUG|daunorubicin hydrochloride|
40973548|NCT00070174|DRUG|etoposide|
40973549|NCT00070174|DRUG|gemtuzumab ozogamicin|
40973550|NCT00070174|DRUG|methotrexate|
40973551|NCT00070174|DRUG|mitoxantrone hydrochloride|
40973552|NCT00070174|PROCEDURE|allogeneic bone marrow transplantation|
40973553|NCT03283592|OTHER|Rank-Heat Plot|provides a visual presentation of treatment hierarchy across multiple outcomes
40973554|NCT03283592|OTHER|SUCRA Plot|provides a visual presentation of treatment ranking for a single outcome.
40973555|NCT05699395|DIAGNOSTIC_TEST|Non interventional|No intervention
40973556|NCT00794131|BIOLOGICAL|GL-ONC1|a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )
40973557|NCT03740061|DIAGNOSTIC_TEST|Ultrasonographic assessment of muscle|Ultrasonographic assessment of quadriceps muscle
40973558|NCT02418026|OTHER|hypnosis|Conversational hypnotic induction and therapeutic suggestions
40973559|NCT04793685|DRUG|Prazosin|Prazosin (16mg/day) versus Placebo comparator, with a 2 week titration period, 9 weeks at full dose and a 5-day taper in week 12.
40973560|NCT04793685|BEHAVIORAL|12-Step Facilitation with Relapse Prevention and Contingency Management|12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.
40973561|NCT01119612|DIETARY_SUPPLEMENT|Iron|Daily oral dose of 60 mg from enrollment until delivery
40973562|NCT01119612|OTHER|Placebo|Daily oral dose from enrollment until delivery
40973563|NCT00002054|DRUG|Pentamidine isethionate|
40973564|NCT03983291|BEHAVIORAL|FaReWell Depression|Facial massage and force exercise
40973565|NCT06198868|PROCEDURE|Operable|Enrolled patients capable of surgical treatment
40973566|NCT02020330|DRUG|Artemether-lumefantrine 3 days|One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
40973567|NCT02020330|DRUG|Artemether-lumefantrine 5 days|One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
40770043|NCT05888922|DRUG|Minoxidil Topical|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
40973568|NCT02863029|PROCEDURE|Flexible Sigmoidoscopy|A sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon, using a flexible endoscope.
40973569|NCT03466697|OTHER|Glucose injection/Normal saline injection|Before each PET scan, subject will be injected either glucose or normal saline.
40973570|NCT00691821|OTHER|Standard Dressings|Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
40973571|NCT00691821|DEVICE|Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])|Participants will receive negative pressure wound therapy.
40973572|NCT02981498|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
40973573|NCT02981498|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
40973574|NCT01324765|BEHAVIORAL|TARGET|12-session group therapy twice weekly 6 weeks
40973575|NCT01324765|BEHAVIORAL|SGT|12 sessions supportive group therapy twice weekly 6 weeks
40973576|NCT01119391|BEHAVIORAL|There was no intervention; this was a survey only study|There was no intervention; this was a survey only study
40973577|NCT05237154|OTHER|Intervention with intermittent fasting.|Intervention with fasting protocol of alternate days 2 days a week and the other days with ad libitum consumption. Restricted food in 25% of the total daily needs on the days of the intermittent fasting protocol, with 18 hours of fasting and 6 hours of restricted feeding (18:6).
40973578|NCT05237154|OTHER|Intervention with high-intensity interval training.|Intervention with high-intensity interval training, 3x per week, with intensity maintained between 70-85% of maximum heart rate.
40973579|NCT04085809|OTHER|AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days. AmLactin is an over-the-counter cosmetic.
40973580|NCT04982198|PROCEDURE|ROSA assisted TKA|Robotic assisted total knee arthroplasty
40973581|NCT05967156|DRUG|Empagliflozin10Mg Tab|10 mg daily
40973582|NCT03793933|PROCEDURE|Liver resection|Surgery for the liver
40973583|NCT06003127|DEVICE|Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation and measurement of related evoked potentials in the EEG.
40973584|NCT06140927|DRUG|Ketamine|Patients will be administered ketamine at increasing doses followed by measurements of motor-evoked potentials.
40973585|NCT02291198|DEVICE|NK Vue: NK cell activity in stimulated whole blood|One mL of blood is collected from each subject, on the day of colonoscopy, using NK Vue Promoca Tubes blood collection tubes containing a proprietary stimulating cytokine. After incubation, NK cell activity is measured in the collected plasma using an ELISA.
40973586|NCT02187185|OTHER|Sonicare/Elite-Flexcare Toothbrush|Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
40973587|NCT02187185|OTHER|Manual Toothbrush|traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
40973588|NCT01439191|DRUG|humanized anti-HER2 antibody|Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
40973589|NCT01439191|DRUG|Vinorelbine|Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
40973590|NCT02970422|OTHER|Patient Survey|Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
40770044|NCT05888922|DRUG|Placebo oral tablet|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
40973591|NCT03767816|DRUG|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml around umbilicus
40973592|NCT03767816|DRUG|Ultrasound erector spinae plane block|Ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml at T7 level
40973593|NCT05604092|DIAGNOSTIC_TEST|VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)|VolBrain, a fully automated platform that uses anonymized compressed NIFTI files to generate the volumetric data. Volbrain is increasingly recognized and compared to other volumetric tools. LesionBrain is a pipeline to automatically segment WM-L from T1 and FLAIR data. Number of lesions, absolute total lesion volume (in cubic cm), normalized lesion volume (percentage of total lesion volume to whole brain volume), lesion burden (percentage of total WM lesion volume to WM volume), and location (Periventricular, Juxtacortical, and Infratentorial) were obtained.
40973594|NCT05604092|OTHER|Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|It includes the Symbol Digit Modalities Test (SDMT) for evaluating the information processing speed, the California Verbal Learning Test (CVLT-II) for evaluating verbal learning and memory, and the Brief Visual Memory Test (BVMT) for evaluating visual learning and memory. Cut off values were calculated as 1.5 SD below mean according to a group of healthy individuals who are matched in age, sex and education as following: 22 for SDMT, 38 for CVLT, and 10 for BVMTR
40973595|NCT06436482|DEVICE|Optical Coherence Tomography|Placing the probe of OCT in RB10c through the working channel of bronchoscope for real time dynamic scanning and collecting OCT parameters from participants in different groups.
40973596|NCT04085068|OTHER|cranioscaral treatment|dural release
40973597|NCT05184140|PROCEDURE|Sentinel node detection|"Injection of the radiotracer to infundibulo-pelvic and utero-ovarian ligament in patients with high suspicion of malignancy adnexal mass. Injection of green indocyanine r to infundibulo-pelvic and utero-ovarian stumps only in case of malignancy after the adnexectomy.~Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer diagnosis."
40973598|NCT04346537|DEVICE|INGEVITY+™ Pace/Sense Lead|The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.
40973599|NCT01717560|OTHER|Collaborative, multidisciplinary, integrated care|"Collaborative, multidisciplinary, integrated care for hepatitis C~multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management."
40973600|NCT01711970|DRUG|Paclitaxel|
40770045|NCT05888922|DRUG|Vehicle solution|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
40770046|NCT02496000|DRUG|ORMD-0801|Oral Insulin
40973601|NCT00320892|DRUG|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
40973602|NCT05078008|PROCEDURE|Physiotherapy modalities|parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan
40973603|NCT05078008|PROCEDURE|Balneotherapy modalities|Immersion in a thermal pool with 15 minutes of automatic hydromassage and 15 minutes of spine flexibility exercises; thermal steam treatment to spinal column; hydromassage bath with Vichy thermal water
40973604|NCT01447602|BEHAVIORAL|IPT-A|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
40973605|NCT02332278|PROCEDURE|Early feeding|Fluid diet four hours after cesarean section
40973606|NCT02332278|PROCEDURE|Late feeding|Fluid diet 12 hours after cesarean section
40973607|NCT00150982|DRUG|Mechanism of action of alefacept|
40973608|NCT05558514|OTHER|Place-based cochlear implant mapping|Pre-operative, 3D CT scans of the temporal bone will be uploaded into a deep learning-based tool which automatically resamples, crops, segments, analyzes, and measures the patient's specific cochlear anatomy. These measurements will be input into an individualized pitch mapping function to determine a patient-specific tonotopic distribution of frequencies (place-based map). At device activation (approximately 1 month post-surgery) CIs will be programmed according to the place-based map.
40973609|NCT05558514|OTHER|Default cochlear implant mapping|At device activation (approximately 1 month post-surgery) CIs will be programmed according to the clinical default program.
40973610|NCT06293755|DEVICE|Microneedle patch|with 20 units botulinum toxin
40973611|NCT06293755|DEVICE|Intradermal injection|with 20 units botulinum toxin
40973612|NCT04021940|PROCEDURE|ULOD|ULOD
40973613|NCT03898154|DRUG|Dexamethasone|Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone
41139695|NCT01494467|DRUG|Azelaic acid 15% Gel|Topical Gel applied twice daily
40770047|NCT02496000|DRUG|Placebo Comparator|Placebo
40770048|NCT06489028|DRUG|allo-APZ2-CVU|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
40770049|NCT06489028|DRUG|Placebo|Placebo
40770050|NCT05527769|PROCEDURE|mastectomy + immediate breast reconstruction|pre- or retro pectoral prosthesis
40973614|NCT03898154|DRUG|Methylprednisolone|Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6
40973615|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (text only)|The uterine fibroid Option Grid patient decision aid facilitates choice awareness and deliberation about treatment options when clinicians and patients discuss the management of uterine fibroids. The content is organized in a tabular format and is based on patients' frequently asked questions.
40770051|NCT03248752|BEHAVIORAL|Fitbit use and reports|Participants will receive a Fitbit device to be used for the duration of the study. Participants will engage with the Fitbit and application and receive Weekly Progress Reports from Fitbit.
40770052|NCT03248752|BEHAVIORAL|Partner engagement|Participants will be connected with their partner in the Fitbit app and therefore have the ability to access their partner's progress. Participants' Weekly Progress Reports will be automatically forwarded to their partner. Participants will engage in a weekly discussion on the topic of their Weekly Progress Reports.
40770053|NCT06301113|DIETARY_SUPPLEMENT|CBD infused candy|300 Nano mg CBD Candy cherry flavor
40770054|NCT06301113|DIETARY_SUPPLEMENT|Sugar free Candy|Raspberry flavored sugar free candy
40973616|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)|The Picture Option Grid uses the same evidence as the text version while integrating images and simpler text, thus utilizing pictorial superiority to help patients better understand and remember information more easily compared to just using words.
40973617|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (online)|Clinicians can click a link in the electronic health record that will lead them to the EBSCO Health website where they can click the treatment options relevant to the patient and generate a decision aid.
40973618|NCT03247855|PROCEDURE|minimal invasive coronary artery bypass graft surgery|coronary artery bypass grafting surgery by using a minimal invasive technique
40973619|NCT04900220|DRUG|Betamethasone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of betamethasone (6 mg)
40973620|NCT04900220|DRUG|Methylprednisolone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)
40973621|NCT02196558|DRUG|E6011|
40973622|NCT03682666|DEVICE|Kinesiotaping|Kinesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
40973623|NCT03682666|BEHAVIORAL|modified Constraint Induced Movement Training|A 2-hour time period would be arranged to constraint patient's unaffected hand by using a bandage by a therapist. During this two hours, patients would not be allowed to use this unaffected to do any activity, so that they will need to use the affected hand. The caregivers would also be educated to provide less help if it is not necessary. This intervention would be executed two hours a day for five days per week, for three weeks.
40973624|NCT03682666|DEVICE|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
40973625|NCT00642577|DRUG|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
40973626|NCT00642577|DRUG|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
40973627|NCT00642577|DRUG|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
40973628|NCT00642577|DRUG|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
41139696|NCT02009332|DRUG|ABI-009|ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.
41139697|NCT02009332|DRUG|Gemcitabine|Gemcitabine is administered after ABI-009 in the Phase 2 study.
40770055|NCT02734004|DRUG|Olaparib|Olaparib
40770056|NCT02734004|DRUG|MEDI4736|MEDI4736
40770057|NCT02734004|DRUG|Bevacizumab|Bevacizumab
40973629|NCT00081484|DRUG|epoetin alfa or beta|iv or sc, as prescribed
40973630|NCT00081484|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
40973631|NCT04381403|OTHER|Bio-descaling D-Tart toothpaste|Patients received Bio-descaling D-Tart toothpaste, which is a new dentifrice (Visionaturolab Inc., QC) that contains a natural bio-descaler powder of cuttlefish bone
41139698|NCT02011360|OTHER|Low Carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein
41139699|NCT02011360|OTHER|Low Fat diet|Low Fat diet: 65%carb; 15%fat; 20% protein
41139700|NCT04270032|DIAGNOSTIC_TEST|ABUS and HHUS|Using deep learning method to analyze and extract the features of automated breast ultrasound and hand-held ultrasound images
40973632|NCT04381403|OTHER|Crest® toothpaste|Patients received Crest toothpaste; Anti-tartar toothpaste
40973633|NCT04276792|BEHAVIORAL|TCU Opioid-Treatment Linkage Model (O-TLM)|The O-TLM is focused on best practices for improving screening, identifying and linking to MOUD providers, reducing stigma, and addressing other important factors that impact justice-involved individuals returning to their communities.
40973634|NCT03501316|DEVICE|Hand Instrumentation Treatment|Provision of treatment for periodontal disease using hand instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
40973635|NCT03501316|DEVICE|Ultrasonic Instrumentation Treatment|Provision of treatment for periodontal disease using ultrasonic instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
40973636|NCT03957304|DRUG|Dexmedetomidine|Intranasal dexmedetomidine
41139701|NCT06143124|DRUG|Bismuth Subcitrate|shorter duration of therapy (7 instead of classical 14 days) with four dugs instead of three (adding Bismuth subcitrate).
41139702|NCT01030315|DRUG|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
40770058|NCT02050399|OTHER|Isometric exercise|The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
40973637|NCT06366620|BEHAVIORAL|FAST-B PEERS|FAST-B PEERS consists of trained Peer Support providing weekly check-in calls with families going through FAST-B behavioral parent training program. Peer Support are parents who have previously participated in a behavioral parent training program who have undergone 6-8 hours of additional dedicated training.
40973638|NCT06366620|BEHAVIORAL|FAST-B (First Approach Skills Training - Behavior)|5-week parent behavioral management training program
40973639|NCT03867981|BEHAVIORAL|Internet-based weight loss program|12-month, Internet-based weight loss/maintenance program.
40973640|NCT03867981|BEHAVIORAL|Brief phone coaching|Some individuals will receive 3 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
40973641|NCT03867981|BEHAVIORAL|Extended phone coaching|Some individuals will receive 12 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
40973642|NCT04094363|OTHER|Product A|Usual Brand, filtered combustible cigarette
40973643|NCT04094363|OTHER|Product B|CSD1902-11, an electronic nicotine delivery system
40973644|NCT04094363|OTHER|Product C|CSD1902-21, an electronic nicotine delivery system
40973645|NCT04094363|OTHER|Product D|4mg Nicotine gum
40973646|NCT03453710|PROCEDURE|Bankart Repair plus Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
40973647|NCT03453710|PROCEDURE|Latarjet coracoid transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
40973648|NCT00080977|BIOLOGICAL|aldesleukin|
40973649|NCT01012960|DRUG|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
40973650|NCT06334471|OTHER|no intervention needed|no intervention needed
40973651|NCT04029948|PROCEDURE|Laser En Bloc Resection Of bladder Tumor|Using laser beam starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
40973652|NCT04029948|PROCEDURE|Electro-surgical En Bloc Resection Of bladder Tumor|Using electro-surgical loop starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
40973653|NCT06507592|DIAGNOSTIC_TEST|Saliva samples collection|The first sample of saliva was be taken before the start of the treatment and considered as the control sample (T0); the second sample was be taken one month after the start of the treatment (T1) and the third one after three months (T2).
40973654|NCT00816985|PROCEDURE|Liposuction|Liposuction is a procedure that involves the removal of fat from deposits beneath the skin using a hollow stainless steel tube with the assistance of a powerful vacuum. Liposuction can be accomplished either with the use of local or general anesthesia.
40973655|NCT00816985|OTHER|Quality of Life Questionnaires|Ratings of 0 to 4, with 0 being Not at ll and 4 being Very Much, regarding how true each statement has been. Statements are in the following categories: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns.
40973656|NCT01867424|DRUG|Eovist|0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
41139703|NCT01117402|RADIATION|Radiotherapy|"Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.~Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions."
41146928|NCT03771261|BEHAVIORAL|Weight Loss|Participants will be prescribed hypo-caloric diet by a registered dietitian and attend weekly social support/nutrition education meetings.
41466559|NCT02440035|BIOLOGICAL|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 4.
41466560|NCT02440035|DRUG|Placebo|Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
40973657|NCT02554669|BEHAVIORAL|postprandial and postabsorptive physical activity on treadmill|
40973658|NCT03186560|DEVICE|gekoTM|The geko™ W devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
40973659|NCT04056689|DRUG|DNL151|Oral repeating dose
40973660|NCT04056689|DRUG|Placebo|Oral repeating dose
41146929|NCT03771261|DIETARY_SUPPLEMENT|Egg Protein|Participants will be provided pre-packaged hard-boiled eggs (3/day, medium) and egg white protein powder.
40973661|NCT00001105|DRUG|F105 Monoclonal Antibody (Human)|
40973662|NCT02050529|DRUG|Labetalol|Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
41146930|NCT00265252|DRUG|Alendronate|
40973663|NCT02050529|DRUG|Hydralazine|Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
41139704|NCT03477799|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry
41139705|NCT03132909|OTHER|Feelings Determination|Determine the feelings of doctors caring for their colleagues
41466561|NCT01315028|OTHER|Cognitive Interpersonal Therapy|Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley \& Schwannauer, 2006).
40770059|NCT02069847|DRUG|Budesonide|"Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.~The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.~Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide."
40770060|NCT00375232|DRUG|Administration of montelukast or placebo|
40770061|NCT00860496|DRUG|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
40770062|NCT00860496|DRUG|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
40770063|NCT05414045|PROCEDURE|Autologous testicular tissue transplantation of prepubertal frozen testicular tissue|"Freezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells (SSCs).~If patient has a childwish on adult age and in case no spermatozoa are found in the ejaculate or after performing a testicular biopsy (TESE), we will perform autologous testicular tissue transplantation with the primary objective being to restore spermatogenesis and fertility."
40770064|NCT04169763|DRUG|Cisplatin|Given IV
40770065|NCT04169763|RADIATION|External Beam Radiation Therapy|Undergo EBRT
40770066|NCT04169763|DRUG|Nelfinavir|Given PO
40770067|NCT00723632|BIOLOGICAL|peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
40770068|NCT00723632|DRUG|ribavirin|Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants \<65 kg, 1000 mg/day for participants \>65 to \<85 kg, and 1200 mg/day for participants \>=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
40770069|NCT05023018|DRUG|NEO100|NEO100 is a purified form of perillyl alcohol.
40770070|NCT06570616|DEVICE|CPAP (fixed mode)|Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
40770071|NCT06570616|DEVICE|APAP (automatic mode)|Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
40770072|NCT06400082|DRUG|Insulin|Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
41466562|NCT01315028|OTHER|Treatment As Usual|The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
40770073|NCT06400082|DRUG|Povidone-Iodine|Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
40770074|NCT00374179|DRUG|CT-322|IV solution, weekly or bi-weekly
40770075|NCT04630769|DRUG|IP FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation
40770076|NCT04630769|DRUG|Enoblituzumab|Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 which is highly expressed on ovarian cancer. Enoblituzumab at 15 mg/kg IV, one day before lymphodepleting chemotherapy
40973664|NCT00136656|DRUG|antibiotic|cephalosporine by oral route : cefixime
40973665|NCT00136656|DRUG|antibiotics|cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
40973666|NCT00118365|OTHER|placebo|Given orally
40973667|NCT00118365|DRUG|eflornithine|Given orally
40973668|NCT00118365|DRUG|sulindac|Given orally
40973669|NCT00118365|OTHER|laboratory biomarker analysis|Correlative studies
40973670|NCT06042452|GENETIC|Genetic|A saliva sample test will be undertaken by all participants in order to analyze their DNA for personalizing their recommendations. The Global Screening Array (GSA) will be used.
40973671|NCT03447132|DRUG|Fulvestrant 500mg|All patients in all arms will receive Fulvestrant 500mg
40973672|NCT03447132|DRUG|Palbociclib 125mg|Dose reduction to 100 mg and 75 mg
40973673|NCT03447132|DRUG|Goserelin 3.6 MG|Only for pre or peri menopausal patient
40973674|NCT03447132|DRUG|Placebos|Placebo
40973675|NCT00133614|PROCEDURE|Prone Positioning|
40973676|NCT02882009|DRUG|Gantenerumab|Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
40973677|NCT02882009|DRUG|Placebo|Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
40973678|NCT04109794|PROCEDURE|E-CTG|Envelope connective tissue graft
40973679|NCT02856503|DRUG|Vitamin D3|Weekly oral dose of Vitamin D3 per protocol.
40973680|NCT01654341|BEHAVIORAL|Exercise, dietary and educational program|
40973681|NCT02922556|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
40973682|NCT02922556|OTHER|Commercially available computerized training|
40770077|NCT04630769|DRUG|IL-2|IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
40973683|NCT01827397|BIOLOGICAL|EN41-UGR7C HIV vaccine|
40973684|NCT01827397|BIOLOGICAL|NaCl|
40973685|NCT04712305|OTHER|No intervention required|No intervention required
40973686|NCT03111901|DRUG|Pembrolizumab|Pembrolizumab solution
40973687|NCT03111901|DRUG|Interleukin-2|Interleukin-2 solution
40973688|NCT02483728|OTHER|Patch Test|Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
40973689|NCT01396720|DRUG|fluvoxamine|Fluvoxamine 100mg daily, 7 days
40973690|NCT01396720|DRUG|citalopharm|Citalopharm 20mg daily, 7 days
40973691|NCT02445092|OTHER|washing the insemination catheter with sperm washing media|"Intervention: pre-washing of the IUI catheter~Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:~* Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.~* Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..~* Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.~Labeling:~Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter."
40973692|NCT02566434|DIETARY_SUPPLEMENT|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
40973693|NCT06121687|PROCEDURE|Shaeer-I|Ligation of the internal pudendal vein under the Gluteus Maximus muscle as it courses above the scar-spinous ligament.
40973694|NCT06121687|PROCEDURE|PPI|Penile prosthesis implantation (PPI) will be performed
40973695|NCT00002602|RADIATION|3D-CRT|3 dimensional conformal radiation therapy
40973696|NCT01275391|BEHAVIORAL|Computer Screening, Brief Intervention, Referral toTreatment|A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
40973697|NCT01829191|DEVICE|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
40973698|NCT01829191|DEVICE|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
40973699|NCT02966990|DEVICE|Hand Orthotic Devices|Orthotic device made to provide the patient with better hand function
40973700|NCT00830596|OTHER|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
40770078|NCT01678742|DIETARY_SUPPLEMENT|High-protein diet|"The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.~A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea."
40770079|NCT01678742|DIETARY_SUPPLEMENT|Standard diet|The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
40973701|NCT00830596|OTHER|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
40973702|NCT00830596|OTHER|Sham Intervention|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
40973703|NCT06503523|OTHER|Hypertonic Saline|A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.1 mL
40973704|NCT06503523|OTHER|Histamine|A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
40973705|NCT06503523|OTHER|Cowhage|This insertion is conducted by forceps using a stereomicroscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
40973706|NCT06503523|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMSevoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
40973707|NCT05845684|OTHER|Physiotherapy application|massage, oral and intraoral tactile stimuli and non-nutritive sucking will be performed to stimulate sucking, and massage applications and neurodevelopmental therapy for motor development.
40973708|NCT05845684|OTHER|Control Group|standard daily applications will be performed on patients
40973709|NCT04047498|DEVICE|Alternating DBS|Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
40973710|NCT00251550|DRUG|Pemetrexed|
40973711|NCT00251550|DRUG|Cisplatin|
40973712|NCT02272920|PROCEDURE|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
40770080|NCT05229744|DEVICE|sequence MRI 3D FLAIR|"Participation in this research entails the addition of an MRI sequence and an injection of contrast product (Gadovist®):~- 3D FLAIR MRI sequence dedicated to the exploration of the inner ear, lasting 6min30s, performed 4 hours after the initial injection of contrast product"
40973713|NCT03552263|DRUG|T89 capsule|T89 capsules (75mg), orally, twice daily.
40973714|NCT03552263|DRUG|Placebo capsule|Placebo capsules (0mg), orally, twice daily.
40973715|NCT05241496|DIAGNOSTIC_TEST|The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration|Lidocaine in spray form is a simple and convenient local anaesthetic with minimal adverse effects and is often used in dentistry for oral mucosal anaesthesia during minor surgical interventions. The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration. Lidocaine acts by stabilization of the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action (Hüseyin Aksoy et al. ,2016 ) .
40973716|NCT03721601|DEVICE|Heart rate monitor chest strap|Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.
40973717|NCT03721601|DEVICE|Wrist band photoplethysmography|Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
40770081|NCT01313676|DRUG|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
41139706|NCT03719547|PROCEDURE|Abdominal radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
40770082|NCT01313676|DRUG|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
40770083|NCT01313676|DRUG|vilanterol|25mcg given once daily via novel dry powder inhaler
40770084|NCT01313676|OTHER|Placebo|placebo comparator once daily via novel dry powder inhaler
40770085|NCT06419504|OTHER|SAP block group|US-guided SAP block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
40770086|NCT06419504|OTHER|PECS II block group|US-guided PECS II block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
40770087|NCT06419504|OTHER|ESP block group|US-guided ESP block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
40770088|NCT06419504|OTHER|Control group|No intervention
40770089|NCT00443014|DEVICE|Cognitive, physical and social stimulation|Sessions of 30 minutes daily five days a week for one year
40770090|NCT03395093|DRUG|Fentanyl|Five minutes before the patients is done the flexible bronchoscopy, fentanyl will be intravenous injected.
40770091|NCT03395093|DRUG|Midazolam|Five minutes before the patients is done the flexible bronchoscopy, midazolam will be intravenous injected.
40770092|NCT03395093|DRUG|Propofol|Propofol will be intravenous injected as soon as the flexible bronchoscopy begins.
40770093|NCT03395093|DEVICE|Bispectral Index monitoring|Bispectral Index monitoring will be used in the process of the flexible bronchoscopy.
40973718|NCT01087190|DRUG|Isoniazid treatment|isoniazid 300 mg po qd for 9 months
40973719|NCT05454592|BEHAVIORAL|Stress and Coping Online Outreach Program|3 videos and a resource library disseminated over the course of 9 weeks.
40973720|NCT06088706|PROCEDURE|Intra-articular injection of ozone|the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 and 40 micrograms ozone are used under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.
41139707|NCT03719547|PROCEDURE|Robot-assisted radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
41139708|NCT03719547|DIAGNOSTIC_TEST|Sentinel lymph node biopsy|Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)
40973721|NCT04762433|DEVICE|Kegel Exercise Pregnancy Training - app|"KEPT-app is designed to educate pregnant women on PFMT via the step-by-step training with the capability element to improve their confidence and skills (beginner, intermediate and advance skills). Pregnant women are encouraged to continue adopt the PFMT throughout pregnancy until postpartum period.~The details of the mHealth app content was developed based on the need assessment gathered from the cross-sectional study (Jaffar et al., 2020). It was conducted to identify the need of PFMT by looking at the prevalence of the UI among pregnant women and to understand their knowledge, attitude, and practices towards PFMT."
40973722|NCT00235898|DRUG|CoFactor|
40973723|NCT00235898|DRUG|5-FU|
40973724|NCT00235898|DRUG|Leucovorin|
40973725|NCT04342364|OTHER|Vitrification via slush nitrogen|oocytes will be vitrified using slush nitrogen
40973726|NCT04342364|OTHER|Vitrification via liquid nitrogen|oocytes will be vitrified using liquid nitrogen which is currently routine practice
40973727|NCT01832987|DRUG|co-trimoxazole|On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
40973728|NCT04770350|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
40973729|NCT03081260|OTHER|Patellar resurfacing|The resurfacing of the patella is generally done at the end of the surgery, after having ejected the patella. A frontal bone cut is made using a dedicated ancillary to remove the entire cartilage. Orifices are then made in the patella so that the polyethylene implant can be accommodated with studs which will be cemented on the joint face of the ball joint.
40973730|NCT03081260|OTHER|Patellar non-resurfacing|Non-resurfacing of the patella does not involve any additional surgical action
40973731|NCT03935100|PROCEDURE|Endoscopic clipping|Endoscopic clips fired to close mucosa over diverticular defects.
40973732|NCT03935100|OTHER|Placebo - colonoscopy without clipping|Colonoscopy performed, no clipping of diverticula
40973733|NCT05659095|OTHER|autologous hair follicle derived mesenchymal stem cell suspension|Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point. The follow-up duration was 9 months.
40973734|NCT03776383|OTHER|Antibiotic use feedback letter|Mailed letters indicating that the physician prescribes more antibiotics than 75% of their peers
40973735|NCT04043260|DEVICE|Advisor Pro|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
40973736|NCT02487693|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
40973737|NCT02487693|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
40973738|NCT04953377|BEHAVIORAL|PFMT educational intervention|an educational intervention to learn about the pelvic floor and how to train it
40973739|NCT05893173|BEHAVIORAL|Sleep Deprivation|Ten individuals (aged 18-85) with a DSM-V diagnosis of MDD will undergo baseline GluCEST imaging prior to and following approximately 30 hours of total sleep deprivation.
40973740|NCT05109689|BEHAVIORAL|ACT-P|ACT-P consists of five modules. The Big Picture sessions are interwoven throughout the 24 sessions to introduce the main concepts of the curriculum, such as values identification and awareness of criminal behaviors. The Emotion Regulation and Cognitive Skills modules focus on awareness of internal experiences; learning new ways to respond to internal experiences; identifying and stepping back from problematic/criminal thoughts and beliefs; awareness of behaviors in service of values versus behaviors in service of control/avoidance; and identifying steps for behavior change. The Behavioral Skills module focuses on practicing prosocial behaviors, such as speaking and listening effectively and conflict resolution. Finally, the Barriers to Change module addresses environmental or life circumstances that can hinder successful behavior change (e.g., toxic masculinity, substance use, and parenting difficulties).
40973741|NCT05109689|BEHAVIORAL|T4C|T4C is an integrated cognitive behavioral change program authored by Drs. Jack Bush, Barry Glick, and Juliana Taymans under a cooperative agreement with the National Institute of Corrections (NIC). The program is based on the principle that thinking controls how people act, and that to change the way people act, they have to control their thinking. T4C systematically presents the concept that thoughts cause one's behavior, and offenders learn to identify their own thought patterns that lead to risky behavior, and then to replace those maladaptive thoughts with new ones. T4C incorporates research from cognitive restructuring theory, social skills development, and the learning and use of problem solving skills.
40973742|NCT05186064|DIAGNOSTIC_TEST|whole genome sequencing|whole genome sequencing will be performed on tumor material after re-resection per standard of care
41139709|NCT04317430|DRUG|Niclosamide|Niclosamide tablets 1 gram once daily
41139710|NCT04317430|DRUG|Placebo oral tablet|lactose tablets
41139711|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|5 mg Vardenafil orally 1 hour prior to sexual intercourse
40973743|NCT04884854|DEVICE|Efferon LPS|Efferon LPS is a single-use therapeutic device for extracorporeal blood purification using direct hemoperfusion. Detoxification is carried out by selective adsorption of lipopolysaccharides (bacterial endotoxins) and non-selective removal of cytokines by internal porous structure. It is a cylindrical polycarbonate casing filled with spherical granules of LPS-selective polymeric adsorbent mesoporous beads and isotonic sodium chloride solution. The device is registered in Russia as a medical device RZN 2019/8886.
40973744|NCT00720434|DRUG|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
40973745|NCT00720434|DRUG|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
40973746|NCT00720434|DRUG|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
40973747|NCT00720434|DRUG|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
40973748|NCT05448053|PROCEDURE|Ilizarov|Ilizarov fixation in open type III pediatric and adolescent tibial shaft fractures
40973749|NCT00226161|PROCEDURE|Inguinal herniorrhaphy|
40973750|NCT00666627|DRUG|Ibandronate|once monthly
40973751|NCT00666627|DRUG|Risedronate|Risedronate 35mg once weekly
40973752|NCT00666627|DRUG|Alendronate|Alendronate 70mg once weekly
40973753|NCT05593120|DIAGNOSTIC_TEST|CT-FFR|"In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis 30%-90% data in at least one major epicardial vessel will be referred for CT-FFR. In patients in whom CT-FFR analysis is performed, FFR will be derived for all vessels. CT-FFR will be evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour. The data derived from this test will determine their management strategy."
40973754|NCT05593120|DIAGNOSTIC_TEST|Routine care|All patients in the routine care group will be assessed according to their current conventional pathways that are based upon routine practice in Wuhan Asia Heart Hospital. The trial will encourage the routine and standard assessment and management of all patients (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance).
40973755|NCT01525368|BEHAVIORAL|cognitive intervention|Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
40973756|NCT05028478|DRUG|CN202|Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
40973757|NCT02732704|DEVICE|JenaValve Pericardial TAVR System|TAVR with JenaValve Pericardial Valve and Delivery System
40973758|NCT02898337|DEVICE|AliveCor handheld mobile ECG|"Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center."
40973759|NCT00379574|DRUG|Bortezomib|"Bortezomib:~For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.~For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks."
40973760|NCT00379574|DRUG|Cyclophosphamide|cyclophosphamide 750mg/m2 day 1, every 2 weeks
41139712|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil orally 1 hour prior to sexual intercourse
41139713|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|20 mg Vardenafil orally 1 hour prior to sexual intercourse
41139714|NCT00668057|DRUG|Placebo|5 mg matching placebo
41458886|NCT05564845|DIAGNOSTIC_TEST|Neuropsychological assessment|"Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults~* Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA)~* A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II)~  * Narrative memory~ * Word fluency~ * Route finding NEPSY-II~* World Fluency~* Additional Questionnaires (6-18 years):~  * Child Behavior Checklist (CBCL)~ * Teacher Report Form (TRF)~ * Youth Self Report (YSR)~ * Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report)~ * Conners-3® • Additional Questionnaires (18+ years):~ * Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ\<70)~ * Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ\<70)~ * Conners' Adult ADHD Rating Scales (CAARS)~Emma toolbox"
41458887|NCT02176616|PROCEDURE|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
41458888|NCT02176616|PROCEDURE|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
40973761|NCT00379574|DRUG|Doxorubicin|doxorubicin 50 mg/m2 day 1, every 2 weeks
40973762|NCT00379574|DRUG|Vincristine|vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks
40973763|NCT00379574|DRUG|Prednisolone|prednisolone 100 mg days 1-5, every 2 weeks
40973764|NCT00379574|DRUG|Lenograstim|Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
40973765|NCT00477282|DRUG|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
40973766|NCT00477282|DRUG|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
40973767|NCT03210168|OTHER|BioFe Medical Food|BioFe is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
40973768|NCT03766633|DIAGNOSTIC_TEST|Liver volumetry of the graft on CT|Preoperative liver volumetry using the CT images of the potential living liver donors.
41139715|NCT00668057|DRUG|Placebo|10 mg matching placebo
41139716|NCT00668057|DRUG|Placebo|20 mg matching placebo
40770094|NCT05910346|BEHAVIORAL|education and counseling based on maternal role theory|Pregnant women in the experimental group will be given training and counseling based on the maternal role theory, starting at 32 weeks of gestation (1 week in total, 2 days a week, 3 sessions every day, 6 sessions in total, 8 hours in total). After the training and counseling program given to the pregnant women in the experimental group according to the motherhood role theory is completed, a training booklet will be prepared so that they can repeat the information they have learned until birth (for improving the motherhood role). It is planned to give the training booklet at the end of the training in order to ensure continuity in the program.
41458889|NCT01939106|DEVICE|One Piece Drainable Pouch|
41458890|NCT02379624|DRUG|pectin|Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
41458891|NCT03300687|DRUG|FX-322|intratympanic injection
41139717|NCT00508144|DRUG|Alimta|500 mg/m\^2 by vein Once Over 10 Minutes Every 3 Weeks
40770095|NCT04974528|BIOLOGICAL|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
40770096|NCT04974528|BIOLOGICAL|Rapid-acting Insulin Analog|"Pharmaceutical form: clear and colorless solution for injection~Route of administration: subcutaneous"
40770097|NCT04974528|BIOLOGICAL|Basal Insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40770098|NCT06221449|PROCEDURE|Positive end expiratory pressure|"The patients will be divided into three groups:~Control group:(31 patients); Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate10-14 RR/min) II) Group (II) Sustained inflation group (SI): (31 patients); Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 cmH2O, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate 10-14 RR/min) III) Group (III) Stepwise PEEP increasing: (31 patients); Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in PEEP 2 cmH2O every 5 respiratory cycle with maximum 10-12 cmH2O guided by hemodynamics \& airway pressure not exceeding 40 cmH2O."
40770099|NCT05765474|BEHAVIORAL|Practice Variable|This group receives the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
40770100|NCT05765474|BEHAVIORAL|No Practice Variable|This group does not receive the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
40770101|NCT02852837|DRUG|Daratumumab|Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
40770102|NCT02154230|DIETARY_SUPPLEMENT|"Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)"|"During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
40770103|NCT02154230|DIETARY_SUPPLEMENT|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
40770104|NCT00853853|DEVICE|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
41139718|NCT00388726|DRUG|E7389|1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
41458892|NCT03300687|DRUG|Placebo|intratympanic injection
40770105|NCT00853853|PROCEDURE|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
40973769|NCT03476694|PROCEDURE|ultra sound guided supraclavicular brachial plexus block|ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.
41139719|NCT00388726|DRUG|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
41139720|NCT04697615|DEVICE|Algometry|The evaluation with the algometer was carried out in the same way by the two examiners, who held the instrument with the dominant hand, in order to adjust and coordinate the movements, while the non-dominant hand was used to stabilize the participant's skin, providing more security, avoiding thus small deviations. The pressure was applied at an angle of 90 ° (between the tool surface and the evaluated point), the rate of pressure increase was approximately 2 kg / cm² / s (kilogram per centimeter squared per second), up to the level that the participant reported a change in the sensation of pressure to a sensation of discomfort and immediately the examiner removed the device from the positioned location.
41458893|NCT01964872|DRUG|JNJ-38877618: Part 1a|Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
41458894|NCT01964872|DRUG|JNJ-38877618: Part 1b|Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
41458895|NCT01964872|DRUG|JNJ-38877618: Part 1c (optional)|Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
40973770|NCT04435860|OTHER|Truncal flexion-extension muscle power|Patient performs a maximum truncal flexion laying supine on the bed with cap of muscle tester placed on sternum,
40770106|NCT06069570|BIOLOGICAL|KB-GDT-01|KB-GDT-01 is an allogeneic, gamma delta T-cell suspension product manufactured from the isolation of healthy donor peripheral blood mononuclear cells (PBMC). The KB-GDT-01 cells are cryopreserved in vapor phase liquid nitrogen (LN2) in 50 mL CryoMACS® cryobags for a total of 200 × 106 viable cells/bag. The KB-GDT-01 cryopreserved product is thawed and administered intravenously (IV) until the entire bag is infused by gravity. Low dose radiotherapy (LDRT) will be administered to selected tumor sites (maximum of 5 isocenters) at 1.0 Gy/fraction on Days 1 and 2, followed by the KB-GDT-01 IV infusion on Day 3. LDRT will be repeated on Days 8 and 9, and the 2nd KB-GDT-01 IV infusion on Day 10.
40973771|NCT04435860|OTHER|Truncal extension muscle power|Patient performs a maximum truncal extension laying prone on the bed while the cap of manual muscle tester placed on vertebrae at the level of midline between superior angles of scapulae.
40973772|NCT04435860|OTHER|Cervical flexion muscle power|Patient performs a maximum cervical flexion sitting while the cap of manual muscle tester placed on the middle of the forehead.
40973773|NCT04435860|OTHER|Cervical extension muscle power|Patient performs a maximum cervical extension sitting while the cap of manual muscle tester placed on protuberantia occipitalis.
40770107|NCT05630456|OTHER|Receving feedback|Receving regular feedback from a health provider
40770108|NCT05630456|OTHER|No regular feedback|No regular feedback from a health provider
40973774|NCT04435860|OTHER|Cervical lateral flexion muscle powers|Patient performs a maximum cervical lateral flexions on right and left sitting while the cap of manual muscle tester placed on relevant pterion.
40770109|NCT02578251|DRUG|Paracetamol|
40770110|NCT02578251|DRUG|Pethidine|
40770111|NCT01952977|DIETARY_SUPPLEMENT|Test breakfast|
40770112|NCT06571682|DEVICE|Target Controlled Infusion|TCI (Target Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
40973775|NCT04435860|OTHER|Shoulder flexion muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior aspect of acromion and anterior elbow.
40973776|NCT04435860|OTHER|Shoulder extension muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior aspect of acromion and posterior elbow.
40973777|NCT04435860|OTHER|Shoulder internal rotation muscle power|Patient performs a maximum shoulder internal rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior elbow and wrist.
40973778|NCT04435860|OTHER|Shoulder external rotation muscle power|Patient performs a maximum shoulder external rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior elbow and wrist.
40973779|NCT04435860|OTHER|Shoulder abduction muscle power|Patient performs a maximum shoulder abduction of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line lateral aspect of acromion and lateral epicondyle.
40973780|NCT04435860|OTHER|Hip flexion muscle power|Patient performs a maximum hip flexion laying supine on the bed while the cap of manual muscle tester placed on middle of the anterior thigh.
40770113|NCT06571682|DRUG|Inhalation anesthetic|In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
41139721|NCT01487954|DIETARY_SUPPLEMENT|alkaline water|Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
41139722|NCT01487954|DIETARY_SUPPLEMENT|distilled water|Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
41139723|NCT01487954|RADIATION|external beam radiation therapy (EBRT)|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
41458896|NCT01964872|DRUG|JNJ-38877618: Part 2|Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
40770119|NCT03404180|PROCEDURE|Peripheral nerve block|All enrollees will have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator and lateral femoral cutaneous nerve blocks will also be performed.
40770120|NCT03404180|DRUG|Intravenous Sedatives|Intravenous sedation using propofol or dexmedetomidine will be administered.
40770121|NCT03404180|PROCEDURE|Lateral femoral cutaneous nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
40770122|NCT03404180|PROCEDURE|Obturator nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
40770123|NCT00693147|PROCEDURE|Total Thyroidectomy|Late postoperative course of patients with mini Video Assisted Thyroidectomy (miVAT) versus classic Thyroidectomy (T)
40770124|NCT05490446|DRUG|Tebapivat|Tebapivat Tablet
40973781|NCT04435860|OTHER|Hip extension muscle power|Patient performs a maximum hip extension laying prone on the bed while the cap of manual muscle tester placed on middle of the posterior thigh.
40973782|NCT04435860|OTHER|Hip abduction muscle power|Patient performs a maximum hip abduction laying supine on the bed while the cap of manual muscle tester placed on middle of the lateral thigh.
40973783|NCT04435860|OTHER|Hip internal rotation muscle power|Patient performs a maximum hip internal rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between lateral condyle of femur and lateral malleolus.
40973784|NCT04435860|OTHER|Hip external rotation muscle power|Patient performs a maximum hip external rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between medial condyle of femur and medial malleolus.
41298750|NCT06194435|OTHER|Face-to-Face Clinic-based Monitoring of Participant Progress and Well-being|Participants with Rotator Cuff Syndrome undergo in-clinic evaluations by a physician, during which they receive an exercise brochure with instructions for performing home exercises three times a day. They are also given an exercise diary to track their daily exercise sessions. On the 7th and 15th days, participants return for follow-up assessments and discussions about their condition. During the final clinic visit, participants are requested to submit their exercise diaries for assessment of exercise adherence.
41298751|NCT05856799|DEVICE|Leadless Micra AV Transcatheter Pacing System|Patients are implanted with a leadless Micra AV TPS
41298752|NCT05856799|DEVICE|Transvenous Azure XT DR dual chamber pacemaker|Patients are implanted with a transvenous Azure XT DR pacemaker
41298753|NCT01300780|DRUG|Etoricoxib|Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
41458897|NCT01964872|DRUG|JNJ-38877618: Part 3|Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
41458898|NCT01964872|DRUG|JNJ-38877618: Part 4 (optional)|Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
40770125|NCT01568879|OTHER|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
40973785|NCT04435860|OTHER|Bath Ankylosing Spondylitis Functional Index (BASFI)|"This questionnaire evaluates the functionality in patients with AS. The ten questions that comprise the BASFI were chosen with input from patients with AS. The first 8 questions evaluate activities related to functional anatomical limitations due to the course of this inflammatory disease. The final 2 questions evaluate the patients' ability to cope with everyday life. A visual analogue scale (with 0 being easy and 10 impossible) is used to answer the questions on the test. The final score varies between 0 and 10."
40973786|NCT04435860|OTHER|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|This questionnaire evaluates the disease activity level in patients with AS. The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS. The final score varies between 0 and 10.
40973787|NCT04435860|OTHER|The Health assessment questionnaire (HAQ)|The Health assessment questionnaire (HAQ) is a questionnaire for the assessment of disability in an individual. The patients report the amount of difficulty they have in performing eight daily living activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). The final score varies between 0 and 3.
40973788|NCT04435860|OTHER|Bath Ankylosing Spondylitis Metrology Index (BASMI)|Bath Ankylosing Spondylitis Metrology Index, a combined index to assess the spinal mobility. It evaluates the patients regarding cervical rotation, tragus-to-wall distance, lumbar flexion, lumbar lateral flexion and intermalleolar distance. The total score varies between 5 to 15 in patients with ankylosing spondylitis
40973789|NCT03210597|OTHER|Exercise|The subjects performed training in aquatic environment
40973790|NCT01907815|DRUG|Akt Inhibitor GSK2141795|Given PO
40973791|NCT01907815|OTHER|Laboratory Biomarker Analysis|Correlative studies
40973792|NCT01907815|DRUG|Trametinib|Given PO
40973793|NCT02852408|PROCEDURE|Laparoscopic cholecystectomy|
40973794|NCT00090974|PROCEDURE|quality-of-life assessment|
40973795|NCT01713972|DRUG|dabrafenib|Given PO
40973796|NCT01713972|DRUG|pazopanib hydrochloride|Given PO
40973797|NCT01713972|OTHER|Correlative studies|"Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
40973798|NCT02385552|BEHAVIORAL|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
40973799|NCT05388214|BEHAVIORAL|E-Co|The E-Co intervention will integrate active components of a mobile health exercise intervention (GO-EXCAP) into a cognitive rehabilitation intervention (MAAT-G).
40973800|NCT02516683|OTHER|Shigella sonnei infection|A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
40973801|NCT01154855|PROCEDURE|Prophylaxis ; Gross debridement for diseased patients|1 per patient at 2nd visit lasting approximately 1 hour.
40973802|NCT03295578|OTHER|Personalized feedback|"The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.~Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake."
40973803|NCT03295578|OTHER|Generic feedback|The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
41298754|NCT01300780|OTHER|Placebo|Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
41298755|NCT02645448|OTHER|Resistance Exercise|"Control Session~Resistance exercise at different intensities (40%1RM or 80%1RM)~Duration of effect"
41458899|NCT01964872|DRUG|Placebo: Parts 1a, 2, 3, and 4 (optional)|Administered orally matched to study drug
41458900|NCT05174754|BEHAVIORAL|Physician-prescribed Exercise Programme|A 20-week structured exercise programme derived and supervised by a Sports Medicine Physician following the FITT Principles
41458901|NCT05174754|DRUG|Best Medical Therapy|Best medical therapy with biologic agent or small-molecule therapy
41458902|NCT05510141|OTHER|Virtual reality gaming|Instead of nitrous oxide, which is the standard procedure, virtual reality gaming is applied to reach pain reduction in minor surgery procedures
40973804|NCT03295578|DEVICE|Continuous glucose monitoring device|This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
40770126|NCT01568879|OTHER|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
40770127|NCT06268249|DRUG|Ulinastatin|Ulinastatin was pumped continuously during the operation
40973805|NCT03266094|DEVICE|BiZact™: A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
40973806|NCT02283697|BEHAVIORAL|Dietary Counseling|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
40973807|NCT02283697|OTHER|Control: Standard Care|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
40770128|NCT01554904|DEVICE|Facial-Flex|Oral exercise device
40770129|NCT00934180|DRUG|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
40973808|NCT05506891|BEHAVIORAL|Physical therapy group|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
40973809|NCT05506891|DRUG|Astragalus|After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.
40770130|NCT00934180|DRUG|Zofran®|1 x 8 mg ODT
40770131|NCT04578041|DEVICE|TRPMS (Transcranial Rotating Permanent Magnet Stimulation)|"TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~* Modality: Excitatory stimulation~* Frequency: 5 Hz~* Interval between stimulus: 100 ms~* Duration of each stimulus: 25 ms~* Duration of stimulation: 40 minutes~* Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2"
40973810|NCT05796297|DEVICE|Transcutaneous Capnography|Transcutaneous Capnography will be realized at patient home to monitoring nocturnal concentration of carbon dioxide during nocturnal sleeping ventilation
40973811|NCT04053205|DRUG|Gentuximab|Administered intravenously (IV)
40973812|NCT04053205|DRUG|Paclitaxel|Administered intravenously (IV)
40973813|NCT01598012|DRUG|Ayurved Siriraj Prasaplai with or without mefenamic acid|Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
40973814|NCT01598012|DRUG|Placebo with or without mefenamic acid|Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
40973815|NCT03833115|OTHER|vaginal gel containing or not sodium lauryl sulfate|Prevention
40973816|NCT01728701|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
40973817|NCT01728701|BIOLOGICAL|Normal Saline (NS)|Normal saline
41298756|NCT00389896|DRUG|MK0733 / Duration of Treatment: 18 Weeks|
41298757|NCT00389896|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|
41298758|NCT06555055|OTHER|CT trochlear thickness change|"Preoperative and postoperative CT scan measuring trochlear thickness of PFJ was defined as distance from deepest part of trochlea and line tangential to the anterior aspect of the femoral cortex. It was assessed on the sagittal cuts.~CT images will be viewed using Sante DICOM viewer version 5.4.2 and image fusion will be done using Overlay multiple image software.~Two observers will measure the angles and the intraobserver and interobserver reliabilities will be assessed for consistency by the intraclass correlation coefficient (ICC) and reliability coefficient using the SPSS software"
40770132|NCT04578041|OTHER|Aerobic Exercise Program|Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.
40973818|NCT05167214|DEVICE|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain
41458903|NCT05510141|DRUG|Nitrous oxide|Standard procedure
41458904|NCT02482558|OTHER|High/Low Glycaemic index test breakfast|High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
41458905|NCT04410653|DRUG|Afatinib 40 MG|single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events
41458906|NCT03214523|BEHAVIORAL|Sleep Education|The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
40973819|NCT04885972|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
40973820|NCT04885972|DRUG|Zilretta|Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.
40973821|NCT04885972|DRUG|Placebo|Vehicle solution
40990822|NCT02117999|DEVICE|Cross-linking with iontophoresis|The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.
41298759|NCT03344601|BEHAVIORAL|physical activity|The program will consist of 18 face-to-face coaching sessions (\~1 hour) over 12 months. The timing of these sessions will be decided between participant and coach. A coaching manual will be used to provide a structured approach to coaching sessions, focussing on physical activity engagement (specifically aerobic and strengthening exercise) and adherence to exercise. The intervention will take place in the participant's home or in a rehabilitation facility at the research site. Each participant will be provided with a choice of exercise equipment options (e.g. exercise bike, weights, therabands), gym membership or use of online exercise resources. Participants will develop physical activity goals that will be monitored and adjusted throughout the program. Physical activity diaries will be completed to record the amount and type of physical activity involvement. Wearable activity monitors will also be used to facilitate/monitor physical activity and sedentary behaviours.
41298760|NCT05368428|OTHER|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
41298761|NCT03336398|DRUG|Ketamine Hydrochloride in saline|0.5 mg/kg IV of ketamine hydrochloride in saline will be administered with one of the MRS Scan
40973822|NCT00774618|DEVICE|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
41298762|NCT03336398|DRUG|Saline|Saline will be administered with the other MRS scan
41458907|NCT01712451|DRUG|salmeterol xinafoate, fluticasone propionate|LIPO-102
41458908|NCT01712451|DRUG|Placebo|Placebo
40770133|NCT04578041|OTHER|Computerized CT (Cognitive Training)|"Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training.~The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session."
40770134|NCT06507540|OTHER|No intervention (observational study)|Retrospective description of diagnostics and treatements of dental emergencies
40770135|NCT02758730|BIOLOGICAL|AFFITOPE® PD01A + Adjuvant|s.c. injection
40770136|NCT02758730|BIOLOGICAL|Adjuvant without active component|s.c. injection
40770137|NCT05770973|OTHER|Compression dressing (build by Kompressen, gauze swabs, Nobamed Paul Danz AG, Wetter, Germany and NOBALUMENAL® - steril, eye pad, Nobamed Paul Danz AG, Wetter, Germany|Compression dressing after ptosis surgery
40770138|NCT01964261|DEVICE|Neural Prosthetic System 2 (NPS2)|The NPS2 comprises 3 NeuroPort Arrays (SIROF). The tip of the electrodes are sputtered iridium oxide film (SIROF). Each array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
40770139|NCT06288828|BEHAVIORAL|Aerobic exercise|"Participants in the intervention group will engage in 150 minutes of moderate aerobic exercise weekly for 16 weeks, primarily brisk walking or jogging. They will follow a personalized nutritional plan: 1.2 grams of protein per kilogram of ideal body weight daily and 35 kilocalories per kilogram of ideal body weight daily.~For the initial four weeks, they will visit the hospital weekly for guidance. Healthcare professionals will help adjust exercise intensity based on heart rate (60-80% of max) and perceived exertion (RPE 12-15), monitoring vital signs and adverse events.~After, they will transition to a home exercise program for eight weeks, recording exercise details in a logbook. Weekly follow-up calls will ensure adherence and monitor adverse events."
40973823|NCT00539136|DRUG|GSK561679 tablet or solution|
40973824|NCT01818921|DRUG|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
40973825|NCT01818921|DRUG|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
40973826|NCT01818921|DRUG|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
40973827|NCT05717374|DRUG|caudal block using dexamethasone|patient will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) through the sacral hiatus
40973828|NCT05717374|DRUG|caudal block using methylprednisolone|patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
40973829|NCT04664062|BEHAVIORAL|Medication Assisted Treatment|All subjects will undergo MAT induction with buprenorphine. Participants will be randomized to the behavioral aspects of induction, specifically comparing office induction vs home vs synchronous telehealth induction.
40973830|NCT02523898|DRUG|metformine|1500 mg metformine 8week plus 100 mg clomiphene for 5 days
41146931|NCT04264156|COMBINATION_PRODUCT|Lucinactant for Inhalation|A drug-device combination product that delivers aerosolized SRT to preterm neonates with RDS who are being supported with nasal continuous positive airway pressure (nCPAP).
41458909|NCT01712451|DRUG|salmeterol xinafoate|Salmeterol
41458910|NCT02039635|DIETARY_SUPPLEMENT|Korean Red Ginseng|Given Orally
40973831|NCT02523898|DRUG|placebo|placebo 8 weeks plus 100 mg clomiphene for 5 days
40973832|NCT02523898|DRUG|clomiphene citrate|100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
40973833|NCT04167202|PROCEDURE|Hydrogen-rich water|Hydrogen-rich water (one hydrotherapy every 4 hours)
40973834|NCT04167202|PROCEDURE|RICE|RICE protocol
40973835|NCT02851758|OTHER|autologous mitochondria transplantation|Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium
40973836|NCT04086147|DRUG|Low dose tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
41146932|NCT04264156|OTHER|nCPAP Only|Nasal continuous positive airway pressure (nCPAP) alone
41458911|NCT02039635|DIETARY_SUPPLEMENT|Placebo|Given Orally
40973837|NCT04086147|DRUG|High dose tenecteplase|Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)
40973838|NCT04072302|DRUG|KAF156|100 mg tablet, 20 mg tablet, 50 mg tablet
40973839|NCT04072302|DRUG|Placebo|100 mg tablet, 20 mg tablet, 50 mg tablet
40973840|NCT02744235|DEVICE|Polysomnography Data|
40973841|NCT02744235|DEVICE|Jawbone UP®|
40973842|NCT02744235|DEVICE|Fitbit Charge ®|
40973843|NCT01101646|DRUG|rabeprazole sodium|four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
40973844|NCT01101646|DRUG|rabeprazole sodium|two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
40973845|NCT01101646|DRUG|rabeprazole sodium|four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
40973846|NCT02852785|BEHAVIORAL|PNF D2 for flexion; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
40973847|NCT02852785|BEHAVIORAL|PNF D2 for flexion; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
41139724|NCT05232357|DRUG|Sodium thiosulfate and Methylene blue solution|Take a methylene blue injection (2ml:20mg), add 18ml distilled water and mix well. Add NaS2O3.5H2O800mg to the methylene blue solution 10ml, add 4 drops of dilute hydrochloric acid, heat the water bath until the dark blue fades, the solution is milky and turbid, adjust the PH to about 3.5. Put the prepared solution into a glass bottle with a rubber stopper, which is wrapped in tin foil, sealed and protected from light, and stored in a refrigerator at-20 ℃. It can be used after high-pressure sterilization before operation. Sodium thiosulfate-Methylene blue (DMB) staining solution was used as nerve staining agent. During gastroenteroscopy, DMB staining solution was locally sprayed on the surface of gastrointestinal lesion mucosa or injected into the lesion mucosa.
41139725|NCT05670561|DRUG|Esketamine|PCIA formula#100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min.The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
41146933|NCT02429973|DRUG|Gemcitabine plus rapamycin|Gemcitabine and rapamycin given in combination
41146934|NCT00047684|BEHAVIORAL|Brief Integrative Therapy|
41146935|NCT00188747|PROCEDURE|Thromboelastograph, Point of Care|
41458912|NCT06088095|OTHER|Mobility group|Patients will be mobilized in accordance with the gradual mobilization procedure 12 hours after the angiography procedure.
40770140|NCT06288828|BEHAVIORAL|Nutrition consultant|"Participants will be provided with a personalized nutritional plan by a nutritionist, which will involve consuming 1.2 grams of protein per kilogram of ideal body weight daily, while also maintaining a calorie intake of 35 kilocalories per kilogram of ideal body weight per day. To assess adherence and make necessary adjustments, participants will complete a 3-day food record at the beginning of the study, at week 8, and at the end of the study at week 16.~If participants encounter difficulty in adhering to the recommended nutritional intake, the nutritionist will offer additional guidance to help them meet the requirements. The primary objective of this nutritional plan is to ensure that participants receive adequate nutrition to support their exercise regimen and maintain their body weight throughout the study period."
40770141|NCT05917145|DRUG|WSD0628|A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
40770142|NCT00798408|DIETARY_SUPPLEMENT|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
40770143|NCT00798408|DIETARY_SUPPLEMENT|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
40973848|NCT02852785|BEHAVIORAL|PNF D2 for extension; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
40973849|NCT02852785|BEHAVIORAL|PNF D2 for extension; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
40973850|NCT00452010|DEVICE|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
40973851|NCT00452010|DEVICE|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
40973852|NCT01214629|DRUG|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
40973853|NCT01214629|DRUG|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
40973854|NCT01214629|DRUG|pegfilgrastim|6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
40973855|NCT03866005|DIETARY_SUPPLEMENT|Diabetes Visual Function Study (DiVFuSS) softgels|The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).
40973856|NCT03866005|OTHER|canola oil placebo softgels, 2 per day|Placebo containing canola oil, 2 softgels per day
40973857|NCT04956497|DEVICE|extracorporeal membrane oxygenation (ECMO)|ECMO under ongoing cardiopulmonary resuscitation (eCPR) in patients with refractory cardiac arrest
40973858|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo strength training classes
40973859|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo tai chi classes
40973860|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo stretching and relaxation classes
40973861|NCT01635413|OTHER|Questionnaire Administration|Ancillary studies
41298763|NCT05348265|OTHER|Low Intensity steady state training|Intervention will be provided for a period of 8 weeks. For the first 4 weeks the intervention will consist of 35-40 minutes of supervised slow paced treadmill walk, five days a week. From week 5 till 8 the intervention will consist of 50-60 minutes of supervised slow paced treadmill walk, five days a week.
40973862|NCT01634360|DRUG|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
40973863|NCT04944953|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
40973864|NCT04944953|DRUG|Botulinum toxin type A injection [HG-102]|Single administration, Day 0, 20 units
40973865|NCT06274489|DRUG|Setanaxib|Setanaxib (formerly GKT137831) is a first-in-class inhibitor of the human protein NADPH NOX1/4. It is a low molecular weight organic molecule and a member of the pyrazolopyridine dione chemical class.
40973866|NCT06274489|DRUG|Placebo|Matching film-coated placebo tablets, containing only excipients
40973867|NCT00081068|BIOLOGICAL|alemtuzumab|
40973868|NCT04461678|DIAGNOSTIC_TEST|HPV Genotyping Nucleic Acid Assay Kit|The total sample size of screening population is approximately 12,000 cases (all females ≥ 21 years of age). Two cervical cytology samples will be collected from each subject with a tube of SurePath sample followed by a tube of PreservCyt sample. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks.
40973869|NCT06355154|OTHER|Nutritional intervention|The intervention will contain a diet with a reduced amount of carbohydrates compared to the standard treatment today but without caloric restriction.
40973870|NCT05387031|DRUG|Ustekinumab|The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.
40973871|NCT04565860|OTHER|Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)|"Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations)."
40973872|NCT02365090|OTHER|patching|covering the sound eye with a patch to force use of the amblyopic eye
40973873|NCT02365090|OTHER|binocular games|playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
40973874|NCT05738668|OTHER|Description of clinical characteristic|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
40973875|NCT01672697|BEHAVIORAL|Physical Therapy (PT) and Behavioral Therapy (BT)|"1. Physical Therapy (PT) Protocol states that each participant in the treatment arm only will undergo a total of four 45-minute sessions with a certified pelvic floor (PF) physical therapist over the course of the 12 weeks. Routine monitoring of patient progress will be performed. Each session includes using the body core muscles and internal pelvic floor muscles, focusing on PF protection techniques, PF exercises, Core exercises, progression to full ADLs(activities of daily living), and an exercise routine.~2. Behavioral Therapy (BT) Instructions are given only to participants in the treatment arm after randomization at week-2 visit; handout provides specific instructions about appropriate diet, hygiene and level of activity during the 12 weeks of enrollment."
40973876|NCT06094569|PROCEDURE|Endovascular Therapy|Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging. Endovascular therapy includes any one or more of the following: Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices
40973877|NCT00439842|BEHAVIORAL|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
41458913|NCT04598958|OTHER|IMPROVE|Health system interventions that include: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees
40973878|NCT02600702|OTHER|Siriraj knee exercise|Siriraj knee exercise, 12 position of exercise protocol
40973879|NCT02600702|OTHER|Physical modalities|
40973880|NCT03874247|DRUG|pelubiprofen 45mg|bid for 3 days after meal
41458914|NCT03201276|DRUG|Glucosamine Sulfate|Patients taking glucosamine sulfate 1500mg every day for at least four days.
40973881|NCT03874247|DRUG|pelubiprofen placebo|bid for 3 days after meal
41458915|NCT02346149|OTHER|glucose 20%|Intravenous infusion (0.75 ml / kg) over 1 min
41458916|NCT01617096|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
40973882|NCT03528993|OTHER|exercise by hippotherapy device|Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.
40973883|NCT03528993|OTHER|conventional rehabilitation|Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
40973884|NCT03528993|OTHER|postural control exercises|perturbation on four directions, weight bearing exercises on standing positions
40973885|NCT00036738|DRUG|Cyclosporine|Given IV or PO
40973886|NCT00036738|DRUG|Dasatinib|Given PO
40973887|NCT00036738|DRUG|Fludarabine Phosphate|Given IV
40973888|NCT00036738|DRUG|Imatinib Mesylate|Given PO
40973889|NCT00036738|DRUG|Mycophenolate Mofetil|Given PO
40973890|NCT00036738|DRUG|Nilotinib|Given PO
40973891|NCT00036738|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
40973892|NCT00036738|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
40973893|NCT00036738|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
40973894|NCT00036738|RADIATION|Total-Body Irradiation|Undergo TBI
40973895|NCT02326025|DRUG|Olaratumab|Administered IV
40973896|NCT02326025|DRUG|Doxorubicin|Administered IV
40973897|NCT03658655|BIOLOGICAL|Stem Cells From Human Exfoliated Teeth|"Basic treatment:~The original treatment regimen will be maintained during the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped, but patients still had frequent hypoglycemia).~Stem cell therapy:~Usage: drip slowly, 50ml normal saline first, then Stem Cells From Human Exfoliated Teeth (during 60 min), then 50ml normal saline."
40973898|NCT00867009|DRUG|Pemetrexed|Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation
40973899|NCT00867009|DRUG|Cisplatin|Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
40973900|NCT00867009|DRUG|Cetuximab|"Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles~Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation"
40973901|NCT01903187|DEVICE|EnligHTN Renal Denervation|Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
40973902|NCT01903187|PROCEDURE|Sham|Renal artery angiogram
40973903|NCT00696696|DRUG|Gemcitabine|1000 mg/m\^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
40973904|NCT00696696|DRUG|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
40973905|NCT00696696|DRUG|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
40973906|NCT05213650|OTHER|non-abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Non-abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
40973907|NCT05213650|OTHER|abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
40973908|NCT05213650|OTHER|Efferdent|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water.The Efferdent tablet will be used once a week as an intervention to aligner cleaning during invisalign treatment.
40973909|NCT05213650|OTHER|Cleaning Crystals|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Invisalign Cleaning Crystals will be used once a week as an intervention to aligner cleaning during invisalign treatment.
40990823|NCT02117999|DEVICE|Standard corneal cross-linking|In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.
40770144|NCT02500108|DRUG|Domperidone|"Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.~Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).~Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date)."
40770145|NCT00843960|BEHAVIORAL|behavioral adaptation and symptom management|behavioral adaptation and symptom management
40770146|NCT06459778|DEVICE|Piezo-ICSI|Participants had their oocytes cohort divided, where half were injected using conventional ICSI and the other half were injected using Piezo-ICSI.
40770147|NCT06268847|DIETARY_SUPPLEMENT|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~2 capsules per day for 90 days of placebo."
40770148|NCT06268847|DIETARY_SUPPLEMENT|ACT01|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
40770149|NCT06268847|DIETARY_SUPPLEMENT|ACT02|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
40770150|NCT00005980|DRUG|pegylated liposomal doxorubicin hydrochloride|
40770151|NCT00137449|DRUG|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
40770152|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given
40770153|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given
40770154|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given
40770155|NCT01085903|DRUG|Modafinil|200 mg once daily with morning meal for three days administered only to stroke patients
40770156|NCT01085903|DRUG|Placebo|Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
40770157|NCT01085903|BEHAVIORAL|Baseline|Observations made at baseline before any intervention
40770158|NCT01085903|BEHAVIORAL|CPS|Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
40770159|NCT01085903|BEHAVIORAL|Post CPS|20 minutes following the CPS condition.
40770160|NCT01085903|BEHAVIORAL|Follow up|Follow up testing occurred at 3 months
40770161|NCT03132987|OTHER|Progressive strengthening program|The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
40770162|NCT06497673|OTHER|sample collection|New collected samples, as well as surplus surgical and diagnostic samples.
40770163|NCT02705963|DRUG|Trametinib|Each tablet is 2mg trametinib to be taken orally once daily.
40770164|NCT02705963|DRUG|Trametinib|Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
40770165|NCT02705963|DRUG|Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)|Combined oral contraceptive to be taken orally once daily.
40770166|NCT03336606|DRUG|MEDI0562|Surgical resection of tumor
40770167|NCT03506360|DRUG|Dexamethasone|Given PO
40770168|NCT03506360|DRUG|Ixazomib Citrate|Given PO
40770169|NCT03506360|OTHER|Laboratory Biomarker Analysis|Correlative studies
40770170|NCT03506360|BIOLOGICAL|Pembrolizumab|Given IV
40770171|NCT05611164|DEVICE|Software assisted selection of individual spermatozoa for intracytoplasmic sperm injection|Half of the oocytes will be injected with a sperm selected with SiD's assistance
40770172|NCT00480727|PROCEDURE|Halo pin re-tensioning|Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch
40770173|NCT00480727|PROCEDURE|Placebo Re-tensioning|Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
40770174|NCT04046991|DEVICE|high-definition transcranial direct current stimulation|High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
40770175|NCT04046991|BEHAVIORAL|modified constraint-induced language therapy|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
40973910|NCT05349994|OTHER|Extended physiotherapy|At admission to the surgical ward after ICU care, participants received an individual rehabilitation plan developed in collaboration with the participants and the ward-based physiotherapist. The rehabilitation plan included specified exercises for 1- 2 sessions of approximately 30 minutes a day. For example breathing exercises, practicing transfer in and out of bed and from sitting to standing, stairclimbing, and walking with or without walking aids.
40973911|NCT04508244|DRUG|Placebo|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
41458917|NCT01617096|COMBINATION_PRODUCT|Placebo Ring|Vaginal ring containing no drug substance
41458918|NCT05430464|DEVICE|1726nm Laser System|Subjects will receive 1726nm laser treatments on one side of the face
40973912|NCT04508244|DRUG|Propranolol|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
40973913|NCT05231395|OTHER|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
40973914|NCT05231395|OTHER|Control Group|"Control group will be given breathing exercises 120 times/day, 7days/week, for 8 weeks as home program.~Control group will be followed-up by telephone once a week"
40973915|NCT04089384|OTHER|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
40973916|NCT04089384|OTHER|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
40973917|NCT04089384|OTHER|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment).
41458919|NCT05430464|DEVICE|Sham Laser System|Subjects will receive sham laser treatments on the other side of the face.
40770176|NCT05573672|COMBINATION_PRODUCT|Dietary Counselling combined with Omega-3 Supplementation|"Dietary Counselling: Seven, bi-weekly counselling sessions over 12-weeks conducted by a licensed Naturopathic Doctor. Each session will be 45-60 minutes in length. The recommendations will be based on the Mediterranean diet and the results of a recent scoping review which summarized the research related to diet and anxiety. The intervention will include motivational interviewing, mindful eating techniques, goal setting and action planning. A range of resources related to meal planning, recipes, cooking education, shopping lists and tracking sheets will be provided in an individualized manner.~Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of Eicosapentaenoic acid (EPA), 532mg of docosahexaenoic acid (DHA), and 800IU of Vitamin D), with a meal."
40973918|NCT06112015|OTHER|Bulgarian split squat exercise variations|The participants performed 4 different sessions of Bulgarian split squat exercises-Bulgarian split squat with trunk flexion (BSS flexion), Bulgarian Split squat with trunk neutral (BSS neutral), suspension based Bulgarian split squat with trunk flexion (SBSS flexion), suspension based Bulgarian split squat with trunk neutral (SBSS neutral)-with EMG recordings being taken from the dominant extremity throughout each session. For each exercise, participants were instructed to perform three successful repetitions. Between each repetition, there was a 30-second break, and there was at least 10 minutes in between each of the 4 exercises. The movement was standardized by a metronome. The modified Borg scale was used to ensure that fatigue did not occur before each exercise since it was believed that fatigue could affect exercise performance. When scores reported using the modified Borg scale were 1 or lower, exercise recording was started.
40973919|NCT04772911|DEVICE|Optical Coherence Tomography (OCT)|OCT will be performed at baseline and prior to each standard of care laser treatment to characterize the mean diameter and depth of blood vessels.
40973920|NCT04920370|DRUG|ALXN1720 SC|ALXN1720 will be administered via SC route.
40973921|NCT04920370|DRUG|ALXN1720 IV|ALXN1720 will be administered via IV route.
40973922|NCT04920370|DRUG|rHuPH20|rHuPH20 will be administered via SC route.
41139726|NCT05670561|DRUG|Sufentanil|PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously.No obvious adverse reactions were observed for 10min. The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
41139727|NCT06205836|DRUG|Cemiplimab|Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
41139728|NCT06205836|DRUG|Fianlimab|Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
41139729|NCT06073587|DIAGNOSTIC_TEST|Scintigraphy scan|Scans will be performed as specified in the arm description.
41139730|NCT01062438|GENETIC|DNA analysis|
41139731|NCT01062438|GENETIC|RNA analysis|
41139732|NCT01062438|GENETIC|gene expression analysis|
41139733|NCT01062438|GENETIC|gene rearrangement analysis|
41139734|NCT01062438|GENETIC|mutation analysis|
41139735|NCT01062438|OTHER|laboratory biomarker analysis|
41139736|NCT06243588|OTHER|clinical records review|review the medical records, radiological imaging, and histological data of these patients
41139737|NCT00635635|BEHAVIORAL|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
41458920|NCT03993080|DEVICE|Virtual reality relaxation|1-3.5 minute 360° videos
41458921|NCT00112437|DRUG|Odanacatib|Odanacatib 3 mg, once weekly for 24 months
41458922|NCT00112437|DRUG|Odanacatib|Odanacatib 10 mg, once weekly for 24 months
41458923|NCT00112437|DRUG|Odanacatib|Odanacatib 25 mg, once weekly for 24 months
41458924|NCT00112437|DRUG|Odanacatib|Odanacatib 50 mg, once weekly for 24 months
41458925|NCT00112437|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 2800 IU weekly throughout the study
41458926|NCT00112437|DIETARY_SUPPLEMENT|Calcium Carbonate|Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
41458927|NCT00112437|DRUG|Placebo|Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
41458928|NCT01246687|BEHAVIORAL|e-Intervention|Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
40973923|NCT04920370|DRUG|Placebo SC|Placebo will be administered via SC route.
40770177|NCT06154590|DRUG|Method(s)1 Attribution|"Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use the Adverse Event Dose Units- Indicate the dosing units (e.g., mg) administered to the patient. TAC, Reporting Group: Participants with Disease, Description: Presence of Disease as Defined by positive reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
40770178|NCT06154590|DRUG|Method(s)2 Attribution,|"Intervention(s): -Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use Adverse Events. Dose Units- Indicate the dosing units (e.g., mg) administered to the patient TAC. Reporting Group: Participant without Disease, Description: Absence of Disease as defined by negative reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
40770179|NCT04987814|OTHER|HD-sEMG|high definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair lifts, depending on the patient's functional state.
40973924|NCT04920370|DRUG|Placebo IV|Placebo will be administered via IV route.
40770180|NCT04987814|OTHER|- Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed.
40770181|NCT04987814|OTHER|IPAQ Physical Activity Questionnaire.|physical activity assessment questionnaire/adapted version for seniors
40770182|NCT02033408|DRUG|AB (antibiotics)|"1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug."
40770183|NCT02033408|DRUG|CS (corticosteroids) Only|"1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks"
40770184|NCT01137084|DRUG|solu medrol|total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
40770185|NCT01137084|DRUG|a steroid-free immunosuppression protocol|receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
40770186|NCT05507333|DEVICE|Gedea pessary|Daily administration of the Gedea pessary during 6 days
40770187|NCT03790189|BIOLOGICAL|Subchondral and intra-articular injection of BMC|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
40770188|NCT04057157|DEVICE|Biodesign Dural or Duraplasty Repair Grafts|Patients will receive the Biodesign Dural or Duraplasty Repair Grafts according to the Instruction for Use.
40973925|NCT04351321|PROCEDURE|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
40973926|NCT04351321|PROCEDURE|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-Assisted Total Gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
41139738|NCT00635635|BEHAVIORAL|Music Audio|Music only audio to be listened to 5x per week
41298764|NCT05348265|OTHER|High intensity interval training|"Intervention will be provided for a period of 8 weeks, thrice a week. Intervention will start with a 5 minutes warm up period of jogging in place. For the first 4 weeks, 3 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches.~Intervention will start with a 5 minutes warm up period of jogging in place. For weeks 5 to 8, 4 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches."
41298765|NCT04960345|DEVICE|Brainlab Knee 3|Brainlab knee 3 navigation system is a kind of imageless computer-assisted navigation system.
41298766|NCT00692900|DRUG|intravenous docetaxel with intraperitoneal oxaliplatin|IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
41298767|NCT00692900|DRUG|intravenous oxaliplatin with intraperitoneal docetaxel|IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
41298768|NCT00428506|DRUG|albumin 4 gr/L ascites removed|albumin 4 gr/L ascites removed
41298769|NCT00428506|DRUG|albumin 8 gr/L ascites removed|albumin 8 gr/L ascites removed
40770189|NCT02714751|BEHAVIORAL|Daily asynchronies information|
40770190|NCT01596023|DEVICE|Breathe NIOV Ventilator|Portable, non invasive open ventilation system
40770191|NCT06421649|RADIATION|Proton Beam Therapy|All patients will be offered radical adjuvant proton beam therapy to a dose of 60-66 Gray (Gy) in 30-33 fractions delivered Monday to Friday over 6-6.5 weeks.
40973927|NCT01324336|DRUG|6-Mercaptopurine|75 mg/m2/dose/day
40973928|NCT03649750|DRUG|Mucinex®|Mucinex® 600 mg ER bi-layer tablets
40770192|NCT03934294|OTHER|Specific acupuncture group|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G."
40770193|NCT03934294|DRUG|Metoclopramide 10mg|Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.
40770194|NCT03934294|OTHER|Non-specific acupuncture group|Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related conditions, and are not reported to improve digestive function.
40770195|NCT06548828|BEHAVIORAL|NNS Restriction Intervention|"Discuss current scientific literature surrounding NNS consumption, obesity, and chronic disease and the emerging evidence that consumption in pregnancy/lactation may have unfavorable effects on infants' adiposity and health.~Provide detailed handouts, which will include a list of specific foods and beverages containing NNS to avoid during the study and summarize current scientific evidence on the metabolic and health effects of NNS.~Emphasize that sugar is not the best alternative to NNS, and that the participant should drink still water, sparkling water, flavored waters with no added sweeteners, or unsweetened tea instead.~Bi-weekly shipments of unsweetened beverages of participant's choice to replace usual consumption of NNS containing beverages.~Automated text messages will also be sent to mothers once per week with reminders that they should avoid NNS"
40770196|NCT06548828|BEHAVIORAL|Control Intervention|"Counsel about best practices for home safety and babyproofing.~Provide a detailed booklet to take home, which will provide information about home safety and baby proofing.~Educate about common causes of accidental infant and young child injuries or death.~Automated text messages will also be sent to mothers once per week with reminders about home safety, infant safety, and baby proofing."
40770197|NCT00567580|RADIATION|PBRT|1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.
40770198|NCT00567580|RADIATION|PLNRT|1.8 Gy per fraction once daily, 5 days a week, totaling 45 Gy. 3D-CRT or IMRT required.
40770199|NCT00567580|DRUG|AA|Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.
40770200|NCT00567580|DRUG|LHRH agonist|Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
40973929|NCT02052284|OTHER|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
40973930|NCT02050776|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
40973931|NCT06062953|DRUG|Melatonin|3-9 mg flexible dosing before bed time
40973932|NCT06062953|DRUG|Quetiapine|50-150 mg flexible dosing before bed time
40973933|NCT06062953|DRUG|Placebo|1-3 capsules flexible dosing before bed time
40973934|NCT02281461|DEVICE|Male circumcision using a non-surgical device|Male Circumcision
40973935|NCT02563223|OTHER|Parabolic flight|
40973936|NCT02563223|DEVICE|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
40973937|NCT05261360|DRUG|SF-MSC-EX|Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
40973938|NCT05261360|DRUG|SF-MSC|Intra-articular administration of synovial fluid-derived mesenchymal stem cells
40973939|NCT04829903|DRUG|Dulaglutide|Dulaglutide injections
40973940|NCT04829903|DRUG|Liraglutide|Liraglutide injections
40973941|NCT00885105|BIOLOGICAL|Influenza Virus Vaccine|0.25 mL, Intramuscular
40973942|NCT00885105|BIOLOGICAL|Influenza Virus Vaccine|0.25 mL, Intramuscular
40973943|NCT00382278|PROCEDURE|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
40973944|NCT04631081|PROCEDURE|coverage of the fingertips with bipedicled palmar island flap|The initial step is wound debridement. To design the flap, a longitudinal line is drawn at the junction of the volar and dorsal parts of the finger, starting from the distal part of the proximal interphalangeal joint flexion crease. It will be harvested from distal to proximal dissecting the digital canal plane. By releasing the Cleland and Grayson ligaments, the neurovascular bundle will be dissected. On the intermediate phalange, the dorsal branch of the neurovascular bundle must be preserved to maintain blood flow to the dorsal skin. Dissection is completed at the junction between the palmo-dorsal arteries and the collateral neurovascular bundles on both sides of the finger. A triangle may be resected at the distal edge of the flap to reshape of the pulp. Bone may be resected if needed to allow tension-free closure of the distal part of the flap. No Immobilization will be necessary.
41139739|NCT05441293|PROCEDURE|flap reconstruction|received flap reconstruction over sacrum, back, trochanter, ischium, elbow, and lower extremities
41139740|NCT02584257|OTHER|methacholine chloride|
41139741|NCT02584257|DRUG|placebo ProAir HFA|
41139742|NCT02584257|DRUG|ProAir HFA|
41139743|NCT02584257|DRUG|Lupin albuterol HFA MDI|
41139744|NCT02584257|DRUG|placebo Lupin albuterol HFA MDI|
40973945|NCT04631081|OTHER|occlusive dressing|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing. Skin proximal to the injury will be degreased to increase adherence of the dressing. Distally, the film leaves a pocket to collect wound exudate. During treatment, the foul-smelling liquid produced by the wound and clots collected in the occlusive dressing will not be removed. A gauze covers the occlusive dressing to protect the liquid pocket and cover potential smell.
41139745|NCT03782285|PROCEDURE|sacrospinous Ligament Fixation|sacrospinous ligament suspension (SSLF) as a typical native tissue repair procedure is one of the most widely used vaginal procedures for correcting apical prolapse. Ischial spinous fascia fixation (ISFF) will be the replacement procedure if SSLF will not be accomplished by conventional surgical instruments due to unsatisfactory exposure of spinous fascia.
41298770|NCT02761993|BIOLOGICAL|ST266|1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
41298771|NCT02761993|DRUG|Saline (0.9% NaCl)|Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
41458929|NCT00709137|DRUG|spironolactone|tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
41458930|NCT00709137|DRUG|amiloride|amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
41139746|NCT05549466|DRUG|Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W."
40770201|NCT03682965|BIOLOGICAL|Intra-lymphatic allergenic extract|Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.
40770202|NCT03682965|BIOLOGICAL|Intra-lymphatic placebo|The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.
40990824|NCT03527199|DIAGNOSTIC_TEST|Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)|Standard of care-Pelvic CT or MRI and MDP bone scan + or - 18F-NaF PET/CT
41139747|NCT05549466|DRUG|Apatinib, Camrelizumab|Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
41139748|NCT05549466|DRUG|Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Camrelizumab, iv, 200mg, D1, Q3W."
41298772|NCT02058199|DRUG|rivaroxaban|Single dose pharmacodynamic study
41298773|NCT00305851|PROCEDURE|Music Therapy|Undergo therapeutic music video therapy
41298774|NCT00305851|PROCEDURE|Psychosocial Assessment and Care|Undergo books on tape therapy
41298775|NCT00305851|OTHER|Quality-of-Life Assessment|Ancillary studies
41298776|NCT00203645|BEHAVIORAL|Self-help treatment|"Workbook Becoming a Winner,"
41298777|NCT05819632|OTHER|curcumin gel 2%|curcumin gel 2%
41458931|NCT05913115|DRUG|FPA144|FPA144 will be administered intravenously Q2W.
40770203|NCT03615638|OTHER|Fall prevention program|12-week fall prevention program (including warm-up, cool-down, education, Tai Chi, and lower limb strengthening)
40770204|NCT04928547|DIAGNOSTIC_TEST|Test|Different test
40973946|NCT00187876|PROCEDURE|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
40973947|NCT00187876|PROCEDURE|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
41458932|NCT03221205|DEVICE|Sham CPAP|CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (measured at the nasal mask) via a resistance to assure the lack of distal pressure.
41458933|NCT03221205|DEVICE|Therapeutic CPAP|Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
40973948|NCT05993468|OTHER|TMC Treatment Approach|The TMC approach consists of 16 weekly group sessions, each lasting 2 hours. The first 10 sessions focus mainly on building mindfulness capacities, and the last 6 sessions on developing compassion toward self and others. Between sessions, participants are encouraged to do exercises with the support of audio files. The approach was developed with a transdiagnostic perspective, including clients with a variety of trauma-related symptoms.
40973949|NCT02205814|DRUG|Fasitibant- low dose|Single intra-articular injection of low dose of fasitibant
40973950|NCT02205814|DRUG|Fasitibant- intermediate dose|Single intra-articular injection of intermediate dose of fasitibant
40973951|NCT02205814|DRUG|Fasitibant- high dose|Single intra-articular injection of high dose of fasitibant
40973952|NCT02205814|DRUG|Placebo comparator|Single intra-articular injection of placebo
40973953|NCT00784992|PROCEDURE|Endonasal dacryocystorhinostomy|"The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted."
40973954|NCT04366440|BEHAVIORAL|Order set review and modification with facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
40973955|NCT04366440|OTHER|Order set review and modification|The antimicrobial stewardship program will work to eliminate unnecessary post-operative antibiotics by reviewing and changing order sets of clean or clean-contaminated procedures.
40973956|NCT06076057|DIAGNOSTIC_TEST|vital signs monitoring|Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors
40973957|NCT06001476|PROCEDURE|Cold snare polypectomy|For eligible patients, use cold snare polypectomy to resect 5-9mm short-pedicled, broad-pedicled or sessile small bowel polyps
40973958|NCT01382823|PROCEDURE|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
40973959|NCT03402386|DRUG|MT-6548|Oral tablet
40973960|NCT01401270|BEHAVIORAL|prize contingency management|Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
40973961|NCT02552199|OTHER|gravimetric|
40973962|NCT02461303|OTHER|Counseling|Subjects will be counseled on the impact of KS on the reduced fertility potential, and about providing a semen sample for semen analysis. Semen analysis is the gold standard for fertility preservation in adult patients, but is only rarely considered by post-pubertal adolescent and young adult patients and their families. Only the semen analysis parameters will be used by the study for the comparison with physical and endocrine measures to assess whether spermatogenesis in these patients coincides with pubertal development. All potential frozen samples will be stored for the patient's future use, and samples will not be used for research experiments.
41139749|NCT05549466|DRUG|Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.
41139750|NCT05556304|OTHER|assessment in the 8th month of pregnancy and during delivery|"* Day 0: presentation of the study~* During pregnancy between Day 0 and 36-38SA: inclusion~* During pregnancy: collection of pelvic MRI data if performed during pregnancy for maternal or fetal reasons~* Between 36 and 38 WG: collection of demographic, obstetrical, fetal ultrasound and clinical data / Perineal elastographic recording / Recording of the perineal deformation by stereovision camera~* In the delivery room, at the beginning of labor and before pushing: collection of clinical data / Collection of obstetrical ultrasound data / Perineal elastographic recordings / Recording of the perineal deformation by stereovision camera~* In the delivery room, during expulsion : recording of the perineal deformation by stereovision camera~* In the delivery room, after childbirth: collection of obstetrical, clinical and neonatal data / Perineal elastographic recordings / Cephalic and shoulder measurements of the newborn with a tape measure"
41139751|NCT05514184|DIETARY_SUPPLEMENT|PLAFOND diet|PLAFOND is a pragmatic patient-centered dietary intervention supported by dietitians who provide education and counseling in the form of Medical Nutrition Therapy (MNT) consisting of 0.6-0.8 g/kg/day dietary protein with \>2/3% of the protein from plant-proteins.
41139752|NCT02106325|DRUG|Ketamine|IV of Ketamine (.25mg/kg)
40973963|NCT05001386|BIOLOGICAL|Blood collection for the evaluation of the anti-drugs sensitivity|The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.
41458934|NCT05263505|DRUG|Baricitinib 2 MG [Olumiant]|Two tabs daily
41458935|NCT05263505|DRUG|Methotrexate|Target dose: 20mg weekly
40770205|NCT01495013|DRUG|1mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
40770206|NCT01495013|DRUG|2mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
40770207|NCT01495013|DRUG|3mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
40973964|NCT04811989|BEHAVIORAL|Instructive video on diabetic foot care|In the video, the diabetic foot care is presented verbally and appropriately captioned, as well as exemplified by real patients and health professionals from the hospital
40973965|NCT04811989|BEHAVIORAL|Informative leaflet with real-time guided reading|The leaflet has information about diabetic foot care. Researcher will guide its reading with patients.
40973966|NCT04811989|BEHAVIORAL|Informative leaflet to read at home|Patients receive a leaflet about diabetic foot care to read at home.
40973967|NCT04811989|BEHAVIORAL|Face-to-face teaching|Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
40973968|NCT01953120|DRUG|Belatacept|Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
40973969|NCT05573789|GENETIC|Tumor molecular profiling|Tumor molecular profiling was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic
40973970|NCT03341949|BIOLOGICAL|Recurring blood sample|An additional tube will be collected for the assay of CD146s as part of the research
40973971|NCT05885204|PROCEDURE|Robot-assisted radical cystectomy|Robot-assisted laparoscopic radical cystectomy
40973972|NCT05885204|PROCEDURE|Conventional laparoscopic radical cystectomy|Conventional laparoscopic radical cystectomy
40973973|NCT04876625|DEVICE|myTAP oral appliance plus mouth shield|myTAP anti-snoring oral appliance worn with mouth shield for all 8-weeks; the mouth shield is a comfort accessory that fits over the oral appliance itself and extends into the oral vestibule.
40770208|NCT01495013|DRUG|4mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
40770209|NCT01495013|DRUG|1mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
40770210|NCT01495013|DRUG|2mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
40770211|NCT01495013|DRUG|3mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
40770212|NCT01495013|DRUG|4mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
40770213|NCT01495013|DRUG|1mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
40770214|NCT01495013|DRUG|2mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
40770215|NCT01495013|DRUG|3mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
40973974|NCT04876625|DEVICE|myTAP oral appliance alone for first 4 weeks|myTAP anti-snoring oral appliance worn alone for first 4 weeks followed by wearing it for 4 weeks with the mouth shield
40973975|NCT01813578|OTHER|Exercise|Intensive aerobic and muscle endurance exercise
41139753|NCT02106325|DRUG|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
41458936|NCT05263505|DRUG|Azathioprine|Target dose: 2mg/kg daily
40770216|NCT01495013|DRUG|4mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
40770217|NCT01495013|DRUG|10mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
40973976|NCT01929278|DRUG|CT Gel (clindamycin 1% and tretinoin 0.025%)|Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
40990825|NCT03161028|DRUG|Lipoic acid|1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.
40990826|NCT03161028|DRUG|Placebo|The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
41139754|NCT01906905|DEVICE|Transcranial Magnetic Stimulation|
41298778|NCT04877015|DEVICE|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
41458937|NCT05263505|DRUG|Mycophenolate|Target Dose: 1g twice daily
40770218|NCT01495013|DRUG|20mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
40770219|NCT03181984|DRUG|Hemoporfin|Hemoporfin mediated photodynamic therapy
40770220|NCT01497730|DEVICE|Total Knee Replacement|"Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices."
40770221|NCT02177162|OTHER|Education to physiotherapists|
40770222|NCT05385822|BEHAVIORAL|Pelvic Floor Muscle Training|"* Isolated, quite light tension in the pelvic floor 10 times, where the tension is released immediately~* Constant tension for 30 seconds twice, with a 30-second pause~* Total relaxation for 1 minute They must perform these exercises once a day during the trial period of 3 months"
40770223|NCT00835354|DRUG|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
40770224|NCT00835354|DRUG|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
40770225|NCT04709523|PROCEDURE|bovine-derived xenograft with i-PRF|Bovine-derived xenograft was mixed with i-PRF and was placed in the augmentation site.
41139755|NCT03847727|DRUG|BR as Maintenance|Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
41139756|NCT02268851|DRUG|TGR-1202|Capsules taken whole daily with water and with food
41139757|NCT02268851|DRUG|Ibrutinib|Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
41139758|NCT00017355|BIOLOGICAL|filgrastim|
41139759|NCT00017355|BIOLOGICAL|therapeutic autologous dendritic cells|
41458938|NCT01707316|DRUG|Treatment A: Canagliflozin 100 mg|Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
41458939|NCT01707316|DRUG|Treatment B: Canagliflozin 300 mg|Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
41458940|NCT01707316|OTHER|Treatment C: Placebo|Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
40973977|NCT01929278|OTHER|Vehicle gel patch|Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
40973978|NCT01929278|OTHER|Blank patch|Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril \[approximately 2 cm x 2 cm\]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
40770226|NCT04709523|PROCEDURE|bovine-derived xenograft alone|Bovine-derived xenograft was placed in the augmentation site.
40770227|NCT02966548|DRUG|Relatlimab|Specified dose on specified days
40770228|NCT02966548|DRUG|Nivolumab|Specified dose on specified days
41458941|NCT02957760|DRUG|Hydroxycarbamid|20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).
41458942|NCT03757468|DEVICE|orthodontic - maxillary expansion|After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
41458943|NCT05522634|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
40770229|NCT00712283|DRUG|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
41458944|NCT00804973|DRUG|LY2590443|200 milligrams (mg) as four 50-mg capsules, oral, once
41458945|NCT00804973|DRUG|Placebo injection|saline solution, injection, once
41458946|NCT00804973|DRUG|Sumatriptan|6 milligrams (mg) injection (0.5 milliliter \[mL\] of 12 mg/mL solution), once
40770230|NCT03942081|DEVICE|Ulcer Measurement Software|Photos being taken of foot ulcers. Software estimation of foot ulcer being compared to actual measured size.
40770231|NCT03908047|OTHER|magnetic resonance imaging|functional magnetic resonance imaging and diffusion tensor imaging after tibialis nerve stimulation
40770232|NCT03815344|DRUG|Standard|20 units diluted in 100mL of Normal Saline injected laparoscopic needle
40770233|NCT03815344|DRUG|Standard-vaginal misoprostol|20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
40770234|NCT04992130|BEHAVIORAL|Pre-season supplementary neurologic training program|A two-month standardized, pre-season, supplementary multi-modal training program will be prescribed to 200 athletes (intervention cohort) by a team of experienced sport science and medicine professionals targeting the specific intrinsic risk factors of interest identified in the current concussion and ACL prevention literature.
40770235|NCT03758846|BEHAVIORAL|Cognitive-motor exergaming|Participants undergo 6 weeks of cognitive-motor exergaming using Wii-fit Nintendo. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
40770236|NCT03758846|BEHAVIORAL|Conventional balance Training|Participants undergo 6 weeks of conventional exercise training. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
40770237|NCT03758846|BEHAVIORAL|Dance Therapy for Stroke|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
40770238|NCT03758846|BEHAVIORAL|Dance Therapy for Older adults|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two therapists."
40770239|NCT03758846|BEHAVIORAL|Home education for Older adults|Participants will receive a one-hour education on conventional physical exercises.
40973979|NCT00217386|BIOLOGICAL|anti-thymocyte globulin|
40973980|NCT00217386|BIOLOGICAL|etanercept|
40770242|NCT02772302|DEVICE|mindBEAGLE EEG-based brain-computer interface|
40770243|NCT04600089|DRUG|Saline|Saline infusion
40770244|NCT04600089|DRUG|Ketamine|Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
40770245|NCT06595290|OTHER|High intensity care|This arm follows a structured algorithm for initiating and uptitrating all four pillars of HFrEF oral medications post-randomization (pre-discharge) and during at least 4 visits over 6 weeks post-discharge.
40973981|NCT06166160|OTHER|Bulk fill flowable composite SDR Dentsply sirona|caries removal in class II cavities of primary molars and application of experminted restorations
40973982|NCT01411111|DRUG|Rosuvastatin 10 mg|days 1-14
40973983|NCT01411111|DRUG|GSK2190915 30mg|1x30mg tablet, days 8-14
40973984|NCT01411111|DRUG|GSK2190915 100mg|1x100mg tablet, days 8-14
40973985|NCT03591471|DRUG|Glycosides Of Tripterygium Wilfordii Hook(GTW)|"For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time"
40973986|NCT03591471|DRUG|Sulfotanshinone Sodium Injection|Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
41458947|NCT00804973|DRUG|Placebo capsule|4 capsules, once
41458948|NCT00938782|DEVICE|Sedline|
41458949|NCT04828616|DRUG|DP303c injection|DP303c injection, every 3 weeks (Q3W)
41458950|NCT03201003|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
41458951|NCT03201003|OTHER|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
41458952|NCT06204367|DIAGNOSTIC_TEST|Lung Ultrasonografisi|It is aimed to compare the agreement between lung ultrasonography and clinical score in the diagnosis and follow-up of newborn babies who are followed up in the neonatal intensive care unit due to bronchiolitis caused by frequently encountered RSV and other viral factors.
40973987|NCT03591471|DRUG|Chinese herbs based on syndrome differentiation|"For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome."
40973988|NCT03591471|DRUG|Prednisone Acetate Tablets|Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
40973989|NCT03591471|DRUG|Benazepril Hydrochloride Tablets|In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
40973990|NCT03591471|DRUG|Low Molecular Weight Heparin Calcium Injection|In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
40973991|NCT03591471|DRUG|Dipyridamole Tab 25 MG|In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
40973992|NCT03591471|DRUG|Chinese medicine placebo|In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
40770246|NCT06595290|OTHER|Usual care|Patients will be managed by their cardiologist according to their usual practice. Follow-up appointments will be scheduled as per the cardiologist\&#39;s instructions. Participants will return to the recruiting study site for clinical outcome assessment by study investigators at 90 and 180 days post-discharge.
40770247|NCT06100120|PROCEDURE|Implant placement|Placement of osteointegrated implants
40770248|NCT06517290|OTHER|Non applicable|Non applicable
40973993|NCT03796429|DRUG|GS+Toripalimab|"Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid\*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years)."
40973994|NCT00188149|DRUG|Combined chemotherapy (ABVD, BACOPP-D)|
40973995|NCT00188149|PROCEDURE|Radiation therapy|
40973996|NCT02892071|DRUG|22% TCA peel|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
40973997|NCT02892071|DEVICE|CO2 laser|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
41139760|NCT03822897|RADIATION|Radiation|"35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy"
41139761|NCT03822897|DRUG|Cisplatin|100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
41139762|NCT05230433|DIETARY_SUPPLEMENT|High-fat Challenge|The shake will be composed of a mixture of BOOST Glucose Control(R) (Nestlé Products) supplemented with palm oil. Each participant will consume a volume of liquid equivalent to 25% of their estimated daily caloric needs, calculated by the USDA Dietary Reference Intakes using a moderate activity factor.
41139763|NCT05557695|DRUG|Acalabrutinib|Acalabrutinib
41139764|NCT02858206|RADIATION|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
41139765|NCT02858206|DRUG|Nimotuzumab|nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
41139766|NCT02858206|DRUG|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
41139767|NCT02858206|DRUG|Nedaplatin|Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
41139768|NCT02858206|PROCEDURE|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
41139769|NCT01579071|PROCEDURE|CO2 or room air insufflation during ESD for gastric tumor|CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
41139770|NCT05923788|DIAGNOSTIC_TEST|T1 mapping measurement|T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
41139771|NCT02945085|OTHER|Home Based Care Team|Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
41139772|NCT02945085|OTHER|Telephone Based Care Team|Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
41139773|NCT01084772|OTHER|VISIONAIRE Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation, depending on randomization assignment.
41139774|NCT01084772|OTHER|Standard Total Knee Arthroplasty|TKA will be performed with standard instrumentation, depending on randomization assignment.
41139775|NCT04499898|DRUG|Carvedilol|Carvedilol
41458953|NCT04477863|OTHER|Follow-up Interview|Non Applicable
40770249|NCT01380665|DEVICE|Prevena Incisional Management System|All evaluable patients will utilize the Prevena Incisional Management System
41139776|NCT04499898|PROCEDURE|Endoscopic band ligation|Endoscopic band ligation
41139777|NCT02404298|DRUG|IVIg|
41139778|NCT01525459|PROCEDURE|Glioma resection|Patients will be treated with the standard surgical therapy - glioma resection.
40973998|NCT02892071|DEVICE|Qs-NdYag laser|Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
40973999|NCT05848960|DIETARY_SUPPLEMENT|Hypercaloric, hyperproteic oral supplement|2 supplements per day
40974000|NCT05848960|OTHER|Mediterranean diet|Mediterranean diet
40974001|NCT03902574|DRUG|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
40974002|NCT03902574|DRUG|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
40974003|NCT03902574|DRUG|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
40974004|NCT05985889|OTHER|Robot|You have to walk with a robot mounted on your lower limb. To move, to change direction.
40974005|NCT05985889|OTHER|Fizio|Patients do state-funded physical therapy.
40974006|NCT05985889|OTHER|EXE1|Patients undergo intensive virtual reality therapy once a day.
40974007|NCT05985889|OTHER|EXE2|Patients undergo intensive virtual reality therapy twice a day.
40974008|NCT05985889|OTHER|EXE+ROB|The patients intensively performed 1 virtual reality therapy and 1 robotic therapy every day.
40974009|NCT02707874|DRUG|CI 0.2% ropivacaine|Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
40974010|NCT02707874|DRUG|PIB 0.2% ropivacaine|Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
40974011|NCT02460302|DRUG|Vaginal progesterone|Micronized vaginal progesterone 100mg inserted vaginally
40974012|NCT02460302|DRUG|Placebo|Placebo suppository inserted vaginally
40974013|NCT05885789|PROCEDURE|Intubation in Bed-Up-Head-Elevated (BUHE) position|Comparing laryngoscopic view in paediatric patients during sniffing position and BUHE position
40974014|NCT05397821|PROCEDURE|UNC technique|In general, UNC techniques can be divided in being either intravesical or extravesical and refluxing or non-refluxing
40974015|NCT05173402|DEVICE|dentoalveolar compensation method|orthopedic treatment was performed using the dentoalveolar compensation method with permanent apparatus with a palatal expanding screw
40974016|NCT05173402|DEVICE|face mask|orthopedic treatment was performed using a face mask.
40974017|NCT05333146|PROCEDURE|Cardiac Surgery|Cardiac surgery (e.g. coronary bypass surgery, cardiac valve surgery, ascending aortic surgery)
40974018|NCT01490476|DRUG|RAD001|10 mg per os / day or 05mg per os / day with 12 month
40974019|NCT05814978|OTHER|Experimental Scapular Therapeutic Exercise Group|"All subjects will perform a program of scapular therapeutic exercises including: neuromuscular control/strength - scapular therapeutic exercises that leads to, at least, moderate muscular activity levels; and stretching exercises.~The intervention period will be of 8 weeks, considering in-person and/or home sessions."
40974020|NCT01485770|DRUG|ADX-N05|150 mg once a day for seven days followed by 300 mg once a day for seven days
40974021|NCT01485770|DRUG|Placebo|Placebo to match ADX-N05 once a day for 2 consecutive weeks
41139779|NCT01525459|OTHER|Blood sampling|Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
41458954|NCT04358367|DRUG|Dexmedetomidine Injectable Product|Spinal anesthesia and intravenous dexmedetomidine (1μg/kg). The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
40974022|NCT00928603|PROCEDURE|Focal Cryoablation|Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
40974023|NCT04541550|DRUG|AMP-001 Low Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
40974024|NCT04541550|DRUG|AMP-001 Medium Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
40974025|NCT04541550|DRUG|AMP-001 High Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
40974026|NCT01849380|DRUG|S-1|S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
40770250|NCT06337448|DEVICE|Blue LED|The patient will remain naked, in a closed room, in the lithotomy position on a gynecological table, and he LED will be positioned in the direction of the patient's genitalia, keeping the internal and external vulvar lips open, so the LED can reach the largest possible region for therapeutic action.
41458955|NCT04358367|DRUG|Saline|Spinal anesthesia and intravenous saline. The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
40974027|NCT01849380|DRUG|5-FU|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
40974028|NCT05841394|DRUG|Esomeprazole 40mg|40 mg i.v. twice daily (q12h)
41458956|NCT01513941|DRUG|Telaprevir|Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
41458957|NCT01513941|DRUG|Ribavirin|Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
41458958|NCT01513941|DRUG|Pegylated-Interferon-alfa-2a|Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
41458959|NCT00844870|BEHAVIORAL|stabilization training|training of arm function with the trunk stabilized
41458960|NCT00844870|BEHAVIORAL|auditory training group|response to an auditory signal
41458961|NCT00569660|DRUG|Azacitidine|75 mg/m\^2 subcutaneous daily for 7 days (every 4 week cycle)
41458962|NCT05139394|PROCEDURE|emergency pancreaticoduodenectomy|Emergency pancreaticoduodenectomy (EPD) is a complex surgical procedure, that can be performed for complex pancreaticoduodenal injuries, that cannot be controlled through less invasive procedures. EPD can be performed either as a classical Whipple procedure, or as a pylorus-preserving procedure. A one stage procedure implies the reconstruction step being done in the same surgical intervention, while a two step procedure implies the reconstruction being done in a later stage, through a second surgical intervention.
40770251|NCT04782375|DRUG|Stop group|discontinue antiviral treatment
40770252|NCT05049863|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil is commercially available.
40974029|NCT05841394|DRUG|Ilaprazole Sodium|10 mg i.v. once daily, 20 mg i.v. in the first day.
40974030|NCT05841394|DRUG|Placebo 1|Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.
40974031|NCT05841394|DRUG|Placebo 2|Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
40974032|NCT05557604|DRUG|Decapeptyl|STAD androgen deprivation
41458963|NCT01363817|DRUG|BMS-906024|
41458964|NCT01363817|DRUG|Dexamethasone|
40770253|NCT05049863|DRUG|Allopurinol|Allopurinol is commercially available.
40770254|NCT05049863|DRUG|Irinotecan|Irinotecan is commercially available.
40770255|NCT04695990|DRUG|Wenyang Huoxue Decoction|Wenyang Huoxue granules
40770256|NCT04695990|DRUG|Wenyang Huoxue placebo|Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
40974033|NCT00573469|DRUG|D9421-C, 9mg|D9421-C 9 mg was given once daily for 8 weeks.
40974034|NCT00573469|DRUG|D9421-C, 15mg|D9421-C 15 mg was given once daily for 8 weeks.
40974035|NCT00573469|DRUG|Placebo|D9421-C matching placebo was given once daily for 8 weeks.
40974036|NCT02917304|BIOLOGICAL|GC3110A vaccine|0.5mL, Intramuscular
40974037|NCT00837811|BIOLOGICAL|LY2127399|60 milligrams \[(mg) with potential for dose escalation to 120 mg\] subcutaneously every 4 weeks for 48 weeks
40974038|NCT04930016|BEHAVIORAL|Quality of life diagnosis and therapy during the completed RCT DIQOL|Quality of life measurement, diagnosis, and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
41139780|NCT04876430|DRUG|Meropenem|Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR \< 50mL/min.
41458965|NCT01677650|DRUG|Methadone|Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
41458966|NCT01954030|DRUG|CTO and Bevacizumab|
41458967|NCT01954030|DRUG|CTO alone|
41458968|NCT00510419|DRUG|"InvestigationalAuto-injector (sumatriptan succinate)"|
40974039|NCT01008007|DIETARY_SUPPLEMENT|Viusid|One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
40974040|NCT01008007|DRUG|Conventional treatment|Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
41458969|NCT03318757|DRUG|Bupivacaine Extended Release Liposome Injection|Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
40974041|NCT05592964|DIETARY_SUPPLEMENT|Fasting|Standard fasting
40974042|NCT05592964|DIETARY_SUPPLEMENT|Water|In Group S, water was given 1 hour before the operation.
41298779|NCT04877015|DEVICE|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
41458970|NCT03318757|DRUG|Bupivacaine HCl|10ml of Bupivacaine HCl 0.5% will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
41298780|NCT03025048|BEHAVIORAL|A holistic dietary intervention for persons with spinal cord injury|A lifestyle program over 9 weeks combining individual consultations with a dieatitian and interdiciplinary group sessions
41298781|NCT00992446|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
41298782|NCT00992446|DRUG|Bortezomib|Given IV
41298783|NCT00992446|DRUG|Carmustine|Given IV
41458971|NCT04657315|DRUG|MSC11FCD|"Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.~Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day~Directions:~Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.~Route of administration: Oral administration"
41458972|NCT00207662|DRUG|infliximab or placebo|
41458973|NCT04273295|OTHER|Abdominal massage|The patients lying in comfortable relaxed supine position and physiotherapist performed slow circular clockwise movements on the abdomen, throw tangential pushing, with digital pulp, slow and gradual pressure, with fingers inclination 45 degree. The pressure applied to the abdomen on each point for 1 min, beginning with the ascending colon, transverse colon, descending colon and sigmoid; this sequence was repeated approximately 15 min. The therapist teaches the parents this technique and asked them to apply at home 3 times / day for 15 min.
41458974|NCT04551183|OTHER|Surgeons CT scan analysis|Surgeons extract diameter by hand (Gold Standard method) then realised a semi-manual segmentation of the images to extract volumes and diameters of the aorta (espacially AAA)
41298784|NCT00992446|DRUG|Cytarabine|Given IV
41458975|NCT04551183|DEVICE|PRAEVAorta CT scan analysis|CT scans are analysed by the software under investigation : PRAEVAorta. It will extract volumes and diameters of the aorta (AAA espacially)
41298785|NCT00992446|DRUG|Etoposide|Given IV
41298786|NCT00992446|DRUG|Melphalan|Given IV
40770257|NCT06189573|PROCEDURE|Anterior cruciate ligament Reconstruction with autologous quadriceps tendon graft|Surgical reconstruction of anterior cruciate ligament with autologous quadriceps tendon graft
40770258|NCT06189573|PROCEDURE|Anterior cruciate ligament Reconstruction with autologous bone patellar tendon bone graft|Surgical reconstruction of anterior cruciate ligament with autologous bone patellar tendon bone graft
40974043|NCT05592964|DIETARY_SUPPLEMENT|Carbohydrate fluid|In Group K, carbohydrate fluid was given 1 hour before the operation.
40974044|NCT01443988|DEVICE|iStent|Implantation of two iStent devices
40974045|NCT01443988|DRUG|Travoprost|Travoprost drops
40974046|NCT01786044|BEHAVIORAL|MasterMed|An online interactive educational program
40974047|NCT01786044|BEHAVIORAL|Usual Care|
40974048|NCT05841251|DRUG|Topical Phenylephrine Solution|phenylephrine-soaked pack using the whole 5 ml of the solution provided with.5% phenylephrine will be applied after induction of surgery and intubation, 15 minutes before surgery. 100 ml of normal saline will be given.
41298787|NCT00992446|DRUG|Rituximab|Given IV
41298788|NCT00992446|DRUG|Vorinostat|Given PO
41298789|NCT00728507|DRUG|Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Rifapentine:150mg tablets, dose = 300mg for subjects \<= 45kg and 450mg for those \>45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
41298790|NCT00728507|DRUG|Isoniazid, Rifampin, Pyrazinamide, Ethambutol|Administered per standard of care for TB treatment
41298791|NCT02467907|DRUG|Bevacizumab|Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
41298792|NCT02467907|DRUG|Carboplatin|Administration of carboplatin at 5 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 every 3 weeks for at least 6 cycles
41298793|NCT02467907|DRUG|Paclitaxel|Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m\^2) on Day 1 every 3 weeks for at least 6 cycles
41298794|NCT01915849|DRUG|LIK066|LIK066 15 mg, 50 mg and 150 mg
41298795|NCT01915849|DRUG|Placebo|
40974049|NCT05841251|DRUG|intravenous tranexamic acid|patients will receive intravenous Single dose of tranexamic acid 15 mg/kg in 100 mL normal saline over 10 minutes. Saline-soaked pack will be applied.
41458976|NCT05768334|DRUG|Lubiprostone 24Mcg Oral twice daily|"The patients will be randomized (closed envelopes) into one of two groups:~1. Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~2. Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks."
41458977|NCT06204939|PROCEDURE|Randomizing for EPGB procedure|"Classic gastric bypass with 2 anastomoses but with an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
41298796|NCT05121727|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
41458978|NCT06204939|PROCEDURE|Randomizing for OAGB procedure|"Gastric bypass with 1 anastomosis and an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
41458979|NCT01439620|DEVICE|MGH Optical Frequency Domain Imaging (OFDI)|Imaging of biliary tract with OFDI system using MGH Optical Frequency Domain Imaging (OFDI) System
41458980|NCT04791007|DRUG|OB-002|vaginal or rectal administration
41298797|NCT05121727|PROCEDURE|Deep and Superficial Serratus Anterior Plane Block|Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
41298798|NCT05547438|DRUG|NTS-104 TRIS|Subjects will receive a single IV infusion of either 0.8, 4, 8, or 16 mg/mL NTS-104 depending on the Cohort number
41298799|NCT05547438|DRUG|Placebo|Subjects will be administered an IV infusion of placebo and the same duration and volume as the subjects administered NTS-104 TRIS in the cohort
41298800|NCT04498429|OTHER|Integrated Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. In addition to verbal cueing, the manual cueing group will receive hands-on tactile facilitation from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
41298801|NCT04498429|OTHER|Verbal Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. The verbal cueing protocol consists of verbal cueing from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
41298802|NCT00234104|DRUG|OPC-41061(Tolvaptan)|
41298803|NCT03340792|DEVICE|Ambulation training utilizing an exoskeleton robot|Participants undergo 40 hours of ambulation training utilizing an exosksleton robot within 3 months.
41458981|NCT04791007|DRUG|Placebo|vaginal or rectal administration
41458982|NCT04309162|OTHER|Soft tissue therapy|Soft tissue therapy consists of various soft tissue manipulating techniques which includes the stroking, percussive and tapping manipulations. The treatment techniques are divided according to the body parts. under this techniques are tapping, flat finger kneading, Stroking, skin rolling etc.
41458983|NCT00000124|PROCEDURE|Brachytherapy|
41458984|NCT00000124|PROCEDURE|Eye Removal|
41458985|NCT03511976|BEHAVIORAL|Tier 1 Classroom Management|The primary teacher for each participating student will receive consultation related to implementing Tier I management strategies at a classroom level for all students including the target child (see Appendix C). Consultation will be provided by trained study personnel and the strategies will be implemented by the general education teacher (i.e., the end user of the intervention)
40770259|NCT04958603|PROCEDURE|"L type release surgery"|Lateral release of the lateral support belt
40974050|NCT06163313|OTHER|Observation of patients suffering from kidney stones who undergo endoscopic surgery|Clinical data will therefore be acquired through a collection of medical history, physical examination, blood chemistry and instrumental test reports;
40974051|NCT05673278|DIAGNOSTIC_TEST|Bowel Ultrasound Scan|"Ultrasound scans will attempt to measure predefined criteria implemented in other research work using bowel ultrasound.~I - Bowel wall thickness II - Colour Doppler signal III - Loss of wall layer stratification IV - Loss of haustration V - Fatty wrapping VI - Motility in terminal ileum (TI) VII - Lymphadenopathy VIII - Abscess IX - Stricture~+ Image quality"
40974052|NCT01785732|PROCEDURE|Renal Denervation|Sympathetic renal denervation via renal arteries
41458986|NCT03511976|BEHAVIORAL|Daily Report Card (DRC)|Students in the RTI DRC condition will receive Tier II strategies, namely an individualized DRC. Behavioral consultants will meet with teachers to identify appropriate behavioral targets and establish a DRC according to established protocol (see our website for an example http://ccf.fiu.edu/for-families/resources-for-parents/printable- information/). Consultants will also meet with parents to develop a plan for reinforcing the DRC at home using a hierarchical menu of rewards/privileges that will be provided contingent on meeting daily goals.
41458987|NCT03511976|BEHAVIORAL|Enhanced DRC (DRC-E)|"In this condition, students who did not show sufficient response to the Phase 1 DRC will receive additional and more intensive Tier II supports.~Following student assignment to RTI-E, the teacher will have meet with one of the consultants to complete a functional behavior analysis (FBA) to identify remaining target behaviors and ascertain their function. The consultant and teacher will then use the completed FBA to develop a treatment plan for an enhanced DRC (DRC-E).~Tier II enhancements will be chosen to directly map on to the functions of the target behaviors as outlined in the FBA."
41298804|NCT00634543|DRUG|Tramadol hydrochloride/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
41458988|NCT03511976|DRUG|Stimulant|Students will receive either a long-acting methylphenidate preparation or a long-acting mixed amphetamine salts preparation based on parent consultation with the study physician. The prescribed medication will be taken daily.
41458989|NCT00858403|DRUG|Dasatinib|Take tablets of Dasatinib by mouth once a day.
41298805|NCT00634543|DRUG|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
41298806|NCT04618692|OTHER|Surgical Loupes|Biliary reconstruction will be performed using surgical loupe
40770260|NCT02244398|OTHER|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
41298807|NCT04618692|OTHER|Microscope|Biliary reconstruction will be performed using microscope
41298808|NCT01414816|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|EOD, dosage frequency and duration will be decide by physicians.
40974053|NCT04928040|DIAGNOSTIC_TEST|Measurement of optic nerve sheath diameter|The fluid challenge effects of optic nerve sheath diameter
40974054|NCT02499302|BEHAVIORAL|Mental training|
41298809|NCT03511261|DRUG|10% Curcumin mucoadhesive gel|Group 1 10%of mucoadhesive gel for topical application two times per day.
41298810|NCT03511261|DRUG|Curcumin capsules 500mg|Group 2 curcumin 500 mg capsules for oral intake two times per day
41298811|NCT03511261|DRUG|5% curcumin mucoadhesive gel + Curcumin capsules 250 mg|Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day
41298812|NCT03511261|DRUG|Placebo capsule|Group 4 placebo capsules for oral intake two times per day
40770261|NCT02244398|OTHER|FP services|VHTs in the control arm only provide family planning services
40770262|NCT03514576|DRUG|Pasireotide 0.3 MG/ML|See arm description
40770263|NCT03514576|DIAGNOSTIC_TEST|Meal tolerance test (MTT)|Subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
40770264|NCT06565676|DIETARY_SUPPLEMENT|Bread with whey protein powder added|Volunteer participants will consume bread with and without whey powder added and its effect on blood sugar will be examined.
40974055|NCT05390281|DIAGNOSTIC_TEST|increase in serum creatinine|any of the following: increase in serum creatinine by ≥ 0.3 mg/dl within 48 h of surgery or increase in serum creatinin
40974056|NCT04320446|BEHAVIORAL|Test in the morning|The exercise test was performed between 8 a.m and 11 a.m
41458990|NCT02672761|BEHAVIORAL|MBSR meditation|"Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head."
41298813|NCT01489787|PROCEDURE|HIFU|"The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:~* One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.~* One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient."
41298814|NCT01489787|PROCEDURE|HIFU|The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
41298815|NCT01489787|PROCEDURE|HIFU|"Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.~Several metastases can be treated in the same patient"
41298816|NCT00982306|BEHAVIORAL|Brief intervention|20 minute one to one counseling session
40770265|NCT06232616|PROCEDURE|vitrectomy combined with intravitreal dexamethasone implant|The dexamethasone implant will be injected into the vitreous cavity at the end of the surgery.
40770266|NCT05812690|OTHER|This is a non intervention - observation only study|This is non intervention study
40770267|NCT00804232|BEHAVIORAL|childhood diabetes|the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
40770268|NCT04635774|DRUG|Insulin|40 IU via four activations of an intranasal spray
40770269|NCT04635774|DRUG|Saline|Four activations of an intranasal spray containing placebo (normal saline).
40770270|NCT05118308|PROCEDURE|Transjugular hepatic venous pressure gradient measurement with liver biopsy|This procedure will be performed by an experienced interventional radiologist who will be supported by a radiology technician and nurse. Transjugular hepatic venous pressure gradient measurement will be performed using standard procedure. Following this, a transjugular liver biopsy will be obtained using an 18-gauge transjugular liver biopsy needle.
40974057|NCT04320446|BEHAVIORAL|Test in the afternoon|The exercise test was performed between 5 p.m. and 8 p.m.a
41298817|NCT02572830|BEHAVIORAL|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
41298818|NCT02572830|BEHAVIORAL|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
41298819|NCT05691244|DRUG|Drug: Normal Saline|Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
41298820|NCT05691244|DRUG|Sovateltide|Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
41298821|NCT02016417|DRUG|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
40974058|NCT02940145|OTHER|Resistance Training|The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
41298822|NCT02016417|DRUG|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
41298823|NCT05690412|PROCEDURE|Endoscopic Papillectomy|Endoscopic resection of ampullary neoplasm
41298824|NCT05782413|OTHER|mechanical vestibular stimulation|Device produces mechanical vestibular stimulation. The child was placed in a sitting position on the swing and his hands grasping the ropes at the sides then the therapist stood behind him and begin pushing the platform in fast and jerky movements in back and front, side to side, and in spinning directions with the child trying to maintain his balance in all different directions.
41298825|NCT05782413|OTHER|The design exercise program|"A selected therapeutic exercises program was based on the principles of NDTBobath neurodevelopmental therapy, which is effective in controlling spasticity in children with cerebral palsy and improving motor function.~i. Preparation of structures and mobilizations of the scapula, shoulder joint, and chest according to the NDT-Bobath concept ii. Exercises to increase shoulder mobility and elbow joint extension. iii. Fine motor skill exercises, wrist, and hand"
41298826|NCT00110656|OTHER|Observations|This is a non-interventional study- only observational.
41298827|NCT04250298|DIETARY_SUPPLEMENT|sucrosomal iron|oral intake of iron as sachets or capsules
41298828|NCT00005051|DRUG|carboplatin|
41298829|NCT00005051|DRUG|cisplatin|
41298830|NCT00005051|DRUG|paclitaxel|
41298831|NCT00005051|DRUG|topotecan hydrochloride|
41298832|NCT02316470|BIOLOGICAL|VLA84|a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
41298833|NCT02316470|BIOLOGICAL|Placebo|phosphate buffered saline (PBS) solution
40770271|NCT05118308|PROCEDURE|Endoscopic ultrasound portal pressure gradient measurement with liver biopsy|A linear echoendoscope is inserted with the patient under conscious sedation. Using a through the scope 25-gauge needle connected to a digital manometer, portal and hepatic veins will be punctured under EUS guidance from a trans-gastric/hepatic approach. Following this, EUS-Liver biopsy is then performed immediately following EUS-PPG using a 19-gauge fine needle biopsy (FNB).
41298834|NCT00983450|OTHER|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
41298835|NCT00983450|OTHER|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity \[Celnik et al., 2008\]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
41298836|NCT03299517|DRUG|Antiarrythmic Drugs|Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
41298837|NCT03299517|DRUG|Antiarrhythmic drugs|Patient will be randomly randomized 1: 1 for the the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
41298838|NCT04220528|DRUG|Capecitabine/Tiggio|"Drug: Capecitabine/Tiggio~Radical chemoradiotherapy：Induction chemotherapy plus Concurrent chemoradiotherapy~Induction chemotherapy：Gemcitabine (1000mg/m2) D1 D8+ nida platinum (80mg/m2) D2 q3w ×3cycle~Concurrent chemoradiotherapy：IMRT was used for radiotherapy, during which D1 and D22 were given two cycles of single drug concurrent chemotherapy with nidapatin (100mg/m2)."
41298839|NCT06298370|DRUG|Pericapsular nerve group block plus intrathecal bupivacaine|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Subsequently, intrathecal bupivacaine will be administered at the L3-L4 intervertebral level with 10-15 mg bupivacaine while the patient is in a sitting position.The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
41298840|NCT06298370|DRUG|Intrathecal bupivacaine and morphine|Patients will receive intrathecal bupivacaine and morphine without Pericapsular Nerve Group block. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
41458991|NCT02672761|BEHAVIORAL|MBT training|"A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.)."
40974059|NCT05036551|DIAGNOSTIC_TEST|Kellgren Lawrence classification|The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)
40974060|NCT05562128|BEHAVIORAL|Active forest therapy|Participants take part in a two-hour active clinical forest therapy in Berlin-Wannsee on two days (with a break day in between). In this setting, a trained clinical forest therapist teaches exercises on the perception of nature and the connection between nature and health.
41139781|NCT04717687|PROCEDURE|Irreversible electroporation|Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
40770272|NCT06568575|BEHAVIORAL|experiment of music|Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by exercise program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes.
41298841|NCT06298370|DRUG|Pericapsular nerve group block plus intrathecal bupivacaine and morphine|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal drugs. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a S22 Gauche 80 mm block needle. Subarachnoid block will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
40974061|NCT05562128|BEHAVIORAL|Passive forest therapy|Participants take part in a two-hour passive clinical forest therapy in Berlin-Wannsee over two days (with a break day in between). In this setting, a trained clinical forest therapist will guide participants to various locations in the forest where participants can stay and let nature have its effect on them.
41298842|NCT04864535|DIAGNOSTIC_TEST|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
40974062|NCT01366521|BIOLOGICAL|Mepolizumab|Monoclonal antibody
40974063|NCT04182360|DRUG|Carbetocin|Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.
41458992|NCT02672761|BEHAVIORAL|Wellness|"The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session."
40974064|NCT00850824|BEHAVIORAL|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
41298843|NCT02157272|DRUG|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
41298844|NCT03408080|DRUG|BHV-4157|BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.
41298845|NCT06520072|BEHAVIORAL|Children Eating Well (CHEW) mobile app|"The target users of the CHEW app are parents/guardians of preschool aged children. The purpose of the CHEW app is to provide parents/guardians with easy, practical ways to improve nutrition and wellness among their preschool-aged children. The app provides guided goal setting and tracking tools. Parents/guardians set goals related to their preschool-aged children focused on nutrition, physical activity, sleep behaviors and parenting styles. The parents/guardians can also to set goals for themselves for behaviors related to nutrition, physical activity, sleep, and stress. The app does not have features that target children as users.~The CHEW app was developed by the study team and can be downloaded for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). After downloading the CHEW app, enrolled participants must enter the Access Code provided by the study team in order to unlock the app and use it."
41298846|NCT06520072|BEHAVIORAL|Beanstalk mobile app|"Beanstack is free commercially-available mobile app that provides goal setting and tracking tools similar to the CHEW app, but focused on a different topic, specifically encouraging parents/guardians to read to their preschool children more frequently. In the case that a parent/guardian is not able to successfully download Beanstack to their mobile device, as a backup alternative they will be asked to use a similar free commercially-available mobile application called Bookroo.~Beanstack is available to the public for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). Bookroo is a web-based application that users access via the mobile device's web browser and looks and functions like a regular mobile application. It should work on any mobile device with a browser and data/wifi access,"
40974065|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
41298847|NCT02934776|DEVICE|MRI machine|The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
41298848|NCT01518699|DRUG|Ha44|Abametapir Lotion 0.74%
41298849|NCT01518699|DRUG|Ha44 Placebo|Ha44 Vehicle Gel without Abametapir
41298850|NCT01518699|DRUG|Moxifloxacin Placebo|Moxifloxacin Placebo
41298851|NCT01518699|DRUG|Moxifloxacin|Moxifloxacin 400mg
41298852|NCT02290639|BEHAVIORAL|Brief Cognitive Behavioral Treatment|Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
41458993|NCT02672761|BEHAVIORAL|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
41458994|NCT04025398|BEHAVIORAL|Cognitive remediation program|Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)
41458995|NCT04025398|BEHAVIORAL|Control group|"Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)"
40974066|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
40974067|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
40974068|NCT01291173|DRUG|Placebo|Placebo capsule taken once daily for up to 11 weeks
40974069|NCT05699798|OTHER|Conservative Treatment (CT)|Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
41139782|NCT03340662|DRUG|CC-122|CC-122
41139783|NCT03340662|DRUG|Itraconazole|CYP3A Inhibitor
41139784|NCT03340662|DRUG|Fluvoxamine|CYP1A2 Inhibitor
41139785|NCT03340662|DRUG|Rifampin|CYP3A Inducer
41139786|NCT03137446|OTHER|Intravenous Fluid Cap|Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
41139787|NCT00734682|DRUG|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m\^2 (wild type) or 60 mg/m\^2 IV q3 weeks.
41139788|NCT05663502|PROCEDURE|Biospecimen Collection|Undergo blood and/or tumor tissue sample collection
41139789|NCT01037868|OTHER|Supportive SMS text messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
41139790|NCT01984216|PROCEDURE|Roux-en-Y for the gastrojejunostomy reconstruction|
40974070|NCT05699798|OTHER|Instrument-assisted Soft Tissue Mobilization (IASTM)|"IASTM was performed only on the neck and upper back muscles on the aching side using the sweep technique on the origo and insertion lines. A total of 6 sessions were applied, two sessions per week for 3 weeks.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
41139791|NCT01984216|PROCEDURE|Billroth II for the gastrojejunostomy reconstruction|
41139792|NCT05570227|OTHER|[U-13C]Glucose Infusion|Peri-operative infusion of \[U-13C\]glucose
41139793|NCT05363397|DRUG|TBO-309|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.
41139794|NCT02034188|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
41139795|NCT01497184|PROCEDURE|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
41139796|NCT01497184|GENETIC|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10\^6/m\^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
41139797|NCT02730091|DRUG|Letrozole|Letrozole 2.5 mg daily
41139798|NCT02730091|DRUG|Anastrozole|anastrozole 1 mg daily
41139799|NCT02730091|DRUG|Vinorelbine|50 mg three times a week (Monday Wednesday and Friday)
41139800|NCT04388748|BEHAVIORAL|Stress Management and Resiliency Training for Depression (SMART-D) Therapy|6 SMART-D group therapy sessions over 8 weeks
41139801|NCT01444404|DRUG|AMG 820|AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
41139802|NCT05450718|DRUG|buprenorphine-naloxone|Low-dose initiation of buprenorphine-naloxone protocol
41139803|NCT05450718|DRUG|buprenorphine-naloxone|Standard clinical guidelines for a two-day buprenorphine-naloxone initiation
41139804|NCT06365905|OTHER|Non-Interventional Study|Non-Interventional Study
41139805|NCT02053506|DIETARY_SUPPLEMENT|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
41139806|NCT02053506|DIETARY_SUPPLEMENT|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
41139807|NCT02053506|DIETARY_SUPPLEMENT|Placebo (for nutritional beverage and probiotic)|Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
41139808|NCT00506025|DIETARY_SUPPLEMENT|Cranberry Juice|Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
41139809|NCT00506025|DIETARY_SUPPLEMENT|De-Activated Cranberry juice|De-Activated Cranberry juice in the am, then placebo (P) in the pm
41139810|NCT06434584|OTHER|without AI assistance|provide insulin dosage and confidence score without AI assistance
41139811|NCT06434584|OTHER|with AI dosage assistance|provide insulin dosage and confidence score with AI dosage assistance
41139812|NCT06434584|OTHER|with explainable AI assistance|provide insulin dosage and confidence score with explainable AI assistance
41139813|NCT06434584|OTHER|with faulty explainable AI assistance|provide insulin dosage and confidence score with faulty explainable AI assistance
41139814|NCT00799409|DRUG|Placebo/ CONCERTA (methylphenidate HCl)|Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
41139815|NCT00799409|DRUG|CONCERTA (methylphenidate HCl) / Placebo|Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
41139816|NCT06357455|DEVICE|Cell Salvage Autotransfusion: SAME™ device|"* Intervention studied: processing of salvaged blood using the SAME™ autotransfusion device~* Population studied: 20 patients planned to undergo high-risk liver transplantation.~* Treatment group.~All perioperative measures will be performed according to international, national and in-house standards."
41139817|NCT06357455|DEVICE|Cell Salvage Autotransfusion: Autolog™ device|"* Intervention studied: processing of salvaged blood using the Autolog™ (Medtronic) autotransfusion device (in-house standard device).~* Population studied: 20 patients planned to undergo high-risk liver transplantation.~* Control group~All perioperative measures will be performed according to international, national and in-house standards."
41139818|NCT02807285|DRUG|Ocrelizumab|Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.
41139819|NCT01745666|OTHER|exercise test|Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
41139820|NCT01745666|OTHER|Epinephrine test|Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
40974071|NCT05699798|OTHER|Extracorporeal Shock Wave Therapy (ESWT)|"ESWT therapy was applied on the muscle with active trigger point, at 1.5-2.0 bar pressure, at 10 Hz frequency, 2000 beats in each session, twice a week, in total 6 sessions.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
40974072|NCT04794972|DRUG|GNC-039|Administration by intravenous infusion.
40974073|NCT02374801|DEVICE|"SonR automatic optimization feature turned ON (AV+VV)."|
40974074|NCT01000389|DEVICE|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
40974075|NCT05777876|DEVICE|non-invasive transcranial deep brain stimulation|A new non-invasive transcranial deep brain stimulation, Temporal Interference Stimulation (TIS), can focus the stimulation region specifically on the deep brain region without affecting the upper level of the target region. At present, the safety of this method has been preliminarily verified in animals and healthy people, but the brain target of TRD treatment is not clear.
40974076|NCT05777876|DEVICE|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 30 seconds of electrical current will be delivered to the brain (compared to 30 minutes in the experimental intervention arm), therefore it is expected to elicit no changes in neural activity.
40974077|NCT05777876|DEVICE|Motor cortex stimulation|Receive stimulation in the motor cortex stimulation instead of deep brain.
40974078|NCT05777876|DEVICE|non-invasive transcranial deep brain stimulation with closed-loop|Non-invasive transcranial deep brain stimulation devices based on closed-loop regulation of EEG can improve the accuracy of treatment.
40974079|NCT00987220|DRUG|Placebo|Oral
40974080|NCT00987220|DRUG|donepezil (Aricept)|5mg oral
40974081|NCT01279278|OTHER|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
40974082|NCT01279278|OTHER|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
40974083|NCT05843123|OTHER|Respiratory support a|Invasive mechanical ventilation mode
40974084|NCT05843123|OTHER|Respiratory support b|Invasive mechanical ventilation mode
40974085|NCT06204913|OTHER|Menu label|Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
40974086|NCT01954550|BEHAVIORAL|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
40974087|NCT01954550|BEHAVIORAL|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
40974088|NCT01402791|OTHER|Questionnaires|All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
40974089|NCT01113983|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation via transapical and transfemoral approach
40974090|NCT01410032|PROCEDURE|Plate fixation|Reconstruction plate
40974091|NCT01410032|PROCEDURE|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
40974092|NCT02976428|PROCEDURE|Sensor Guided Soft Tissue Balancing|Primary TKR with soft tissue balancing with a sensor guided device.
40974093|NCT02976428|PROCEDURE|Standard Soft Tissue Balancing|Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
40974094|NCT03053076|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for safety and effect evaluation
41139821|NCT05919732|DRUG|Bupivacaine, Dexmedetomidine, Caffeine, Tylenol|bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg). Dexmedetomidine 0.5mcg/kg, Caffeine 15mg/kg, rectal Tylenol 30mg/kg
40974095|NCT03053076|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
40974096|NCT03846011|OTHER|24-h urine collection|Collecting 24-h urine prior and after stone removal surgery
40974097|NCT00772343|BIOLOGICAL|0.9% Normal Saline|0.5 mL, intramuscular on Days 0, 7, and 28
40974098|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
40974099|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine with adjuvant|0.5 mL, intramuscular on Days 0, 7, and 28
40974100|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
40974101|NCT03846596|BIOLOGICAL|Additional blood tube|Additional blood tube during care
40974102|NCT01828957|BIOLOGICAL|Pneumostem®|
40974103|NCT01828957|OTHER|Normal Saline|
40974104|NCT01532414|DRUG|Androxal|oral, capsules, taken one time daily, for 3 months
40974105|NCT01532414|DRUG|Placebo|Oral capsule taken one time daily for 3 months
40974106|NCT04506554|DRUG|AMVAC + Nivolumab|Nivolumab 240mg will be administered intravenously for 3 doses - on days 1, 15 and 29. AMVAC will be dosed intravenously every 2 weeks for 3 doses on days 1, 15 and 29 with Neulasta or equivalent. Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.
40974107|NCT06508073|OTHER|Neural Therapy|The injection was prepared using a solution of lidocaine 2% and saline 0.9%. A 0.4% lidocaine solution was prepared by diluting 1 cc of lidocaine with 4 cc of saline.
40770273|NCT06568575|BEHAVIORAL|experiment of exercise|Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by music program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes. The music experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time, and a total experiment time of 1420 minutes. Examples of songs：Everytime We Touch- Cascada (115 bpm), Beat It - Michael Jackson (120 bpm), Viva La
40770274|NCT02251041|DRUG|Antithrombin-III|
40974108|NCT05295511|OTHER|Recreational Team Handball programme|All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
40974109|NCT02056340|DRUG|Atorvastatin|
40974110|NCT02056340|DRUG|Placebo|
40974111|NCT01138553|DRUG|Mifepristone|200mg capsules daily for 5-28 days
40974112|NCT01482884|DRUG|tralokinumab|2 sc injections of every 2 weeks for 12 weeks.
40974113|NCT01482884|DRUG|placebo|2 sc injections of every 2 weeks for 12 weeks.
40974114|NCT04321525|BEHAVIORAL|Cognitive-behavioral therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
40974115|NCT04321525|BEHAVIORAL|Personal Construct Therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
40974116|NCT04321525|BEHAVIORAL|Personal Construct Therapy with virtual reality|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
40974117|NCT00684593|DRUG|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
40974118|NCT00684593|OTHER|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
40770275|NCT02251041|DRUG|Infliximab|
40770276|NCT02251041|DRUG|Apotransferrin|
40770277|NCT02251041|DRUG|Human recombinant erythropoietin|
40770278|NCT02251041|DRUG|C1-Inhibitor|
40974119|NCT01444118|BIOLOGICAL|Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
40974120|NCT01679860|PROCEDURE|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|"Clin A:~* CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~* HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~* Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation."
41139822|NCT05919732|DRUG|Propofol, rocuronium, caffeine, Tylenol, bupivacaine|"propofol 3mg/kg and rocuronium 0.6mg/kg. Caffeine 15mg/kg and rectal Tylenol 30mg/kg.~single shot caudal with bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg)"
40770279|NCT02251041|DRUG|Glutathione|
40770280|NCT02251041|DRUG|Alfa-tocopherol|
40770281|NCT02251041|DRUG|Melatonin|
40770282|NCT02251041|DRUG|Epoprostenol|
40770283|NCT02251041|DRUG|Sodium chloride solution|
40770284|NCT02247128|DRUG|Aspirin + clopidogrel|
40770285|NCT02247128|DRUG|Aspirin monotherapy|
40770286|NCT02247128|DRUG|OAC + clopicogrel|
40770287|NCT02247128|DRUG|OAC monotherapy|
40770288|NCT06616415|DRUG|Belumosudil|Pharmaceutical form: Tablet Route of administration: Oral
40770289|NCT05259098|DRUG|Sufentanil Sublingual Tablet System|Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
40770290|NCT05259098|DRUG|Intravenous Patient-Controlled Analgesia with morfine|Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
40770291|NCT05231915|GENETIC|HOXB13 c.853delT mutation|Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
40770292|NCT06037811|DRUG|Adalimumab|Participants will be randomized 1:1 (non-blinded) to receive either adalimumab (40 mg subcutaneous every 2 weeks for 12 weeks) and prednisone vs prednisone alone. Addition of methotrexate (MTX) and/or hydroxychloroquine (HCQ) is permitted, as needed, at the discretion of the treating rheumatologist. No additional conventional synthetic, targeted synthetic or biologic DMARDs are permitted during the trial.
40770293|NCT06037811|DRUG|Prednisone|Prednisone as per standard of care.
40770294|NCT00291837|DRUG|CT-2106|
40770295|NCT04855890|PROCEDURE|Ablation|The ablation procedure will be performed during deep sedation using midazolam, fentanyl and a continuous infusion of propofol. Vital parameters will be monitored. For catheter access three 8F sheaths will be inserted into the femoral veins. A multipolar diagnostic catheter will be placed in the coronary sinus. Single transseptal puncture and insertion of a 8.5 F transseptal sheath or 12F Cryo-Sheath (FlexCath AdvanceTM, Medtronic, Minneapolis, MN, USA) will be followed by PV angiographies. Before or shortly after transseptal puncture unfractionated heparin will be repeatedly administered to maintain an activated clotting time between 250 and 400s.
40770296|NCT03340779|DRUG|Norepinephrine|After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
40770297|NCT05937802|DIETARY_SUPPLEMENT|Osmotin|Oral administration for 6 months of 7 capsules per day (4 in the morning and 3 in the evening) for a daily dosage of 5 grams.
40770298|NCT03899415|BIOLOGICAL|TCR redirected T cells|HBV antigen specific TCR redirected T cell Infusions. Subjects will receive 1x10\^4 - 5x10\^6 TCR redirected T cells by IV infusion.
40974121|NCT01679860|DRUG|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|"Clin B:~* CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course."
40974122|NCT02313181|OTHER|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
40974123|NCT02313181|OTHER|Standard Care|Continue exclusive breastfeeding unless otherwise directed by a health care provider
40770299|NCT04555759|OTHER|2-minute walk test|The patients will do a 2-minute walk test, using their walking aids or braces
40770300|NCT04347967|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
40974124|NCT02468414|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
40974125|NCT02468414|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
40974126|NCT00031863|DRUG|rofecoxib|
40770301|NCT05903235|BEHAVIORAL|Virtual Reality-based Mirror Therapy (VR+MT)|In this VR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb simultaneously while observing the animated hand as mirroring reflection of the affected hand within the immersive environment, which presented on the goggle via the VR+MT system.
40770302|NCT05903235|BEHAVIORAL|Mixed Reality-based Mirror Therapy (MR+MT)|In the MR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb concurrently meanwhile watching the real-time mirroring image reflection of the non-affected upper limb's movements of the patients captured, transformed, and superimposed on the affected upper limb, which projected to the screen from the front side via the MR+MT system.
40770303|NCT05903235|BEHAVIORAL|Traditional Mirror Therapy (MT)|In the traditional MT group, patients will be instructed to perform the unilateral movements of the non-affected upper limb at the same time while watching the mirror of a mirror box placed in front of the patient's midsagittal plane, in which the illusory reflection of the non-affected upper limb appears as if it were the another affected upper limb.
40770304|NCT00205322|DRUG|chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)|
40770305|NCT06004037|DRUG|Delpazolid|"Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks.~After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total."
40974127|NCT00031863|PROCEDURE|adjuvant therapy|
40770306|NCT06572072|DEVICE|Negative Pressure Ventilation|Substitution of positive pressure ventilation by negative pressure ventilation
40770307|NCT06172023|DRUG|Silver Nanoparticles Irrigant|Nanosilver irrigant solution
40770308|NCT06172023|DRUG|Chitosan Nanoparticles Irrigant|Chitosan nanoparticles irrigant solution
40770309|NCT01533987|DIETARY_SUPPLEMENT|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
40770310|NCT02322840|DEVICE|Twelve TMVR Implant|Implantation of the Twelve TMVR System -Apical
40770311|NCT02322840|DEVICE|Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System|Implant of Intrepid valve -Transfemoral
41458996|NCT01396655|DRUG|docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
41458997|NCT03112031|DRUG|Tamoxifen|Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
41458998|NCT03112031|DRUG|Amphotericin B|Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
40974128|NCT02554266|DEVICE|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
40974129|NCT05343351|OTHER|Technique of injection method|"In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel.~In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel."
40770312|NCT02276040|DRUG|periarticular bupivicaine and liposomal bupivicaine|Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
41139823|NCT06236204|PROCEDURE|Arthroscopic Scapholunate Ligament Reconstruction|reconstruction of the SL ligament with palmaris tendon graft tunneled through the scaphoid and lunate as described by Corella et al.
41139824|NCT01847456|DRUG|human insulin as nasal spray|
41139825|NCT01847456|DRUG|Placebo|
41139826|NCT02042092|DEVICE|Ultrasound|
41458999|NCT03112031|DRUG|Fluconazole|Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
41459000|NCT04203433|DRUG|DLX105-DMP|1mg applied to target lesion
41459001|NCT01625403|DRUG|rhBNP|intravenous administration of rhBNP 0.01 µg/kg/min
41459002|NCT01625403|DRUG|standard of care|standard of care for heart failure
41459003|NCT01775722|DEVICE|Pulsed Dye Laser|port wine stain
41459004|NCT01775722|DEVICE|Combined Bipolar Radiofrequency&Pulsed Dye Laser|Combined Bipolar Radiofrequency\&Pulsed Dye Laser Treatment
40770313|NCT04219020|OTHER|Co-created intervention|
40770314|NCT03795142|BIOLOGICAL|BGB149|Single Ascending Dose
40770315|NCT03795142|BIOLOGICAL|Placebo|Matching placebo
41139827|NCT02042092|DEVICE|MRA|
41139828|NCT03942107|PROCEDURE|Group 1: single-visit RCT|both root canal treatment and post and core restoration of the coronal part of the tooth is completed in single visit prior to postoperative pain evaluation at 24, 48 and 72-h and 7-day follow-up time
41139829|NCT03942107|PROCEDURE|Group 2: two-visit RCT|after root canal treatment is completed, postoperative pain evaluation will be conducted in this group at 24, 48 and 72-h and 7-day follow-up time. post-core application will be completed at the seventh day after postoperative pain evaluation.
41139830|NCT00667953|DRUG|Gleevec|Gleevec (600 mg) daily.
41139831|NCT00667953|DRUG|Temodar|Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.
40770316|NCT01993732|PROCEDURE|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
40770317|NCT03282916|DRUG|Valacyclovir|Valacyclovir hydrochloride 500mg caplet
40770318|NCT03282916|DRUG|Placebo|Placebo sugar pill 500mg caplet
40770319|NCT06373679|BEHAVIORAL|Switching to E-Cigarette|Participants will receive eleven weeks of e-cigarette products with instructions to switch completely at switch date
40770320|NCT06373679|BEHAVIORAL|Switching using Medication|Participants will receive eleven weeks of FDA approved medication, either varenicline or combination NRT, with instructions to quit smoking cigarettes at quit date
40770321|NCT01146197|DRUG|TREATMENT|Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
40770322|NCT03562156|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
40770323|NCT03562156|DRUG|Placebo|matching placebo capsule
40770324|NCT01661673|DRUG|EVP-0962|Arms: 1,2,3,4
40770325|NCT01661673|DRUG|Placebo|Arm 5
40770326|NCT03810807|DRUG|Dacomitinib|Dose level 1 Dacomitinib, Dose level 2 Dacomitinib, Dose level 3 Dacomitinib. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
40770327|NCT03810807|DRUG|Osimertinib|Dose level 1, 2 and 3 Osimertinib 40mg daily. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
40770328|NCT05408780|DRUG|AC-OLE-01-VA|formulation of tricaprilin or matching placebo
40974130|NCT02414750|DRUG|Vemurafenib plus cobimetinib|Molecular targeted therapy for BRAF mutated advanced melanoma patients
40974131|NCT02414750|DEVICE|Positron Emission Tomography|Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression
41139832|NCT02851134|GENETIC|genetic analysis|genetic (Whole Exome Sequencing )
41459005|NCT03461341|OTHER|High intensity postoperative oncologic surveillance|High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).
41459006|NCT03264716|DEVICE|HepaSphere TACE (transarterial chemoembolization)|100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
41459007|NCT05356169|DRUG|with or without venetoclax|Bcl-2 inhibitor
41459008|NCT04402892|OTHER|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
41459009|NCT04402892|OTHER|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
40770329|NCT02341274|DRUG|Tacrolimus|Bioequivalence study
40770330|NCT02315950|OTHER|Botulinum toxin and cineMRI-UDS|The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.
40770331|NCT05328648|BEHAVIORAL|Community Score Card|In Community Score Card intervention, all communities associated with the targeted facilities will assess the primary barriers to quality family planning service delivery and develop indicators. The communities will then each complete the score card and generate ideas for quality improvement. Family planning providers in the target facilities will meet and determine the barriers to high quality family planning service delivery. Providers will decide on priority areas and make suggestions for improving service delivery. Study facilitators will bring these two groups together to share their respective score cards and jointly develop an action. Within the action plan, agreed upon responsibilities will be assigned and a timeline will be communicated.
40770332|NCT05328648|BEHAVIORAL|Citizen Report Card|Citizen Report Card (CRC): The data from the CRC questionnaire will be analyzed and translated into a report card. Extensive dissemination activities will ensure the CRC is widely shared with members of the community. The goal is to create a public record of service quality.
40770333|NCT01481610|DRUG|Lumiracoxib|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
40974132|NCT02414750|PROCEDURE|Tissue sampling|Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion
40974133|NCT02414750|PROCEDURE|Blood sampling|Before and during treatment and at time of progression patients will undergo blood sampling
40974134|NCT06070298|DIAGNOSTIC_TEST|Computer algorithms|Collection of lightweight computer algorithms called ausculto™ that is designed to perform real-time heart sound analysis to detect heart murmur.
40974135|NCT00088478|DRUG|Intramuscular Olanzapine Depot|
40974136|NCT00088478|DRUG|Placebo|
40974137|NCT00228059|DRUG|Licarbazepine|
41139833|NCT02851134|BIOLOGICAL|blood and stools samples|biological collection
41459010|NCT00471094|DRUG|Ilaprazole|Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
41459011|NCT00471094|DRUG|Ilaprazole|Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
41459012|NCT00471094|DRUG|Ilaprazole|Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
40770334|NCT01481610|DRUG|Diclofenac|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
41459013|NCT00471094|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
41459014|NCT05418790|DEVICE|TASSO device|During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
41459015|NCT00999115|DRUG|Expanded allogenic adipose-derived adult stem cells|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
41459016|NCT05613426|DRUG|Rosuvastatin 20 mg|Very early use of Rosuvastatin before primary PCI in anterior STEMI
41139834|NCT03564184|BEHAVIORAL|MT during NICU|Music therapy (MT) by trained music therapist, 3 times/week for 30-40 minutes/session during NICU hospitalization. Involves primary caregiver and infant in musical communication matched to infant post-menstrual age, family/cultural preferences, and infant readiness for stimulation. Music therapist assesses infant´s needs and behavior state, supports caregiver in using basic touch (e.g., hand lightly and statically on infant´s chest or back to perceive breathing pattern) and caregiver´s hummed/sung voice matched to infant behavioral responses, to promote infant state regulation and bonding. Music includes input from music therapist as needed, and multimodal aspects such as gentle dynamic touch when infant demonstrates readiness. MT may occur while infant is held in a static manner by caregiver or is resting in his/her isolette or basinet. MT may occur during skin-to-skin care, if such care is part of standard care.
41298853|NCT02290639|BEHAVIORAL|Minimal Contact|Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
41298854|NCT02864745|DEVICE|functional electrical stimulation-assisted cycle ergometry|Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
41298855|NCT02864745|OTHER|standard rehabilitation|This group will receive standard rehabilitation, which will be monitored, but not protocolised.
41298856|NCT05517525|DRUG|Brensocatib|Oral tablet.
41298857|NCT03121742|BEHAVIORAL|Ecological Momentary Intervention|Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.
41298858|NCT03121742|BEHAVIORAL|Treatment as Usual|Standard care as part of inpatient hospitalization.
41298859|NCT01530399|DRUG|MDCO 1|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
41298860|NCT01530399|DRUG|MDCO 2|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
41298861|NCT01530399|DRUG|MDCO 3|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
41298862|NCT01530399|DRUG|MDCO 4|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
41459017|NCT05613426|DRUG|Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]|Very early use of Evolocumab before primary PCI in anterior STEMI
41459018|NCT02888743|BIOLOGICAL|Durvalumab|Given IV
41459019|NCT02888743|RADIATION|Radiation Therapy|Undergo radiation therapy
41459020|NCT02888743|BIOLOGICAL|Tremelimumab|Given IV
41459021|NCT03669731|OTHER|food diary|This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.
41459022|NCT05667597|DIAGNOSTIC_TEST|Humoral immunity|determine binding and neutralizing antibody levels against the epidemiologically predominant SARS- CoV-2 variants of concern (VOC) and the wild type SARS-CoV-2 (Wuhan strain).
41459023|NCT06282562|OTHER|High-Intensity Interval Training (HIIT)|Individualized High-Intensity Interval Training (HIIT) program with two exercise sessions per week for 12 weeks. The exercise sessions will be conducted on a stationary bike, with intensity tailored to each participant's maximum exercise capacity.
40770335|NCT00951639|DIETARY_SUPPLEMENT|Cassia cinnamon|5g encapsulated ground bark administered once in experimental session
40770336|NCT00951639|PROCEDURE|50 minutes exercise|50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)
40974138|NCT03287661|BEHAVIORAL|Acceptance-based Behavioural Therapy|The treatment program is an eight module (8-week) ABBT for chronic pain. The online treatment material is administered via the WebCAPSI Therapy program. This online program allows participants to progress through the treatment modules at their own pace. Each module is designed to cover a specific component of ABBT and will facilitate understanding of the components through audio files, veteran, military and RCMP-specific vignettes, text-based material, and homework exercises/assignments. Each module is designed to be completed in 60 minutes or less. On the completion of each module, and facilitated through the WebCAPSI Therapy program, the participants are asked to complete a homework exercise to which they answer questions previously encountered throughout the module. The principle therapist responds to each homework exercise within 24-hours of its online submission.
40770337|NCT00951639|DIETARY_SUPPLEMENT|Cellulose Powder|5g encapsulated powder administered during placebo experimental session
40770338|NCT05870631|BIOLOGICAL|vaccinate with DTaP|vaccinate with DTaP
40770339|NCT05870631|BIOLOGICAL|vaccinate with DT|vaccinate with DT
40770340|NCT06570850|DRUG|Colistin Sodium Methanesulfonate|Intravenous colistin (colistinmethate soidum) 5 mg/kg/day intravenous (dosage will be adjusted according to creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
40770341|NCT06570850|DRUG|Colistin Sodium Methanesulfonate plus Fosfomycin|Intravenous colistin(dosage is same as colistin group) plus intravenous fosfomycin(dosage will be adjusted according to MIC and creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
40770342|NCT01950494|OTHER|fiteBac Hand Sanitizer|Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
40974139|NCT06159530|PROCEDURE|dental implants|4 dental implants placed in the mandible according to all-on 4 concept
40974140|NCT06159530|PROCEDURE|peek framework|peek framework screwed to multi-unit abutments of 4-implants
41298863|NCT01530399|DRUG|Tranexamic Acid|Tranexamic acid will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with tranexamic acid. The flow rates will be the same as for MDCO-2010.
40770343|NCT05734196|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
40770344|NCT04379830|DIETARY_SUPPLEMENT|Very Low Energy Diet|Optifast 900 is an FDA approved commercial nutritionally complete meal replacement product manufactured and marketed in the United States. Optifast 900 will be employed as part of the VLED in the present study in the following manner: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
40770345|NCT05388487|DRUG|HF1K16 /Arm 45 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
40770346|NCT05388487|DRUG|HF1K16 /Arm 90 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
40974141|NCT06159530|PROCEDURE|visio-lign nano composite|peek framework veneered with nano composite (visio-lign) as an occlusal material
40770347|NCT05388487|DRUG|HF1K16 /Arm 120 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
40974142|NCT06159530|PROCEDURE|zirconia crowns|peek framework covered with zirconia crowns as an occlusal material
40974143|NCT02683161|DRUG|Varenicline|Varenicline will be administered as clinically indicated and will begin approximately 4-6 weeks prior to surgery. All participants will receive a 1-week dose induction period before transitioning to a full maintenance dose.
40974144|NCT02683161|BEHAVIORAL|Contingency Management|Contingency Management payments will begin on the target quit date (week 2) and will be in place for 5 weeks or until surgery (whichever is sooner). Participants will receive monetary incentives for biochemical evidence of smoking abstinence.
40974145|NCT02683161|BEHAVIORAL|Behavioral Counseling|All participants will complete a 3-session behavioral counseling intervention with a trained member of our study staff during 3 of the pre-surgical study visits. This brief counseling intervention provides participants with information about the experience of quitting smoking, including a benefits/disadvantage analysis, functional analysis of craving/risk periods, and skills-building exercises to prevent lapse and relapse.
40974146|NCT03459248|OTHER|Dual therapy|combination of 10 mg metoclopramide with 4 mg ondansetron
40974147|NCT03459248|OTHER|Monotherapy|10 mg metoclopramide
41298864|NCT01530399|DRUG|Saline|A loading dose of saline will be followed by a continuous infusion of saline until sternal closure. In addition, the CPB reservoir will be primed with saline. The flow rates will be the same as for MDCO-2010.
41459024|NCT02041013|OTHER|Taking Card|Recordable greeting card-style discharge instruction card
41459025|NCT06037564|DRUG|DOR/DTG/3TC|Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.
40770348|NCT05388487|DRUG|HF1K16 /Arm 160 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
40770349|NCT05388487|DRUG|HF1K16 /Arm 120 mg or 180 mg|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
40770350|NCT06456671|OTHER|All nicotine/ tobacco products at market price|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
40974148|NCT03459248|OTHER|General anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation.
40770351|NCT06456671|OTHER|Nicotine vaping products at 1/2 market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
40974149|NCT00585819|PROCEDURE|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
40770352|NCT06456671|OTHER|Heated tobacco products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
40770353|NCT06456671|OTHER|Nicotine pouch products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
40770354|NCT05401799|DEVICE|BURT|Use of Barrett Upper extremity Robot (BURT) to improve strength and mobility of hemiplegic upper extremity.
40770355|NCT05401799|PROCEDURE|Other Occupational Therapy|Standard occupational therapy sessions will be 60-90 minutes a day and are UE neuroeducation sessions are typically focused on improving strength and mobility of the hemipelagic arm.
40770356|NCT06571058|OTHER|Assistance|Assist patient with walking approximately 90 feet
40770357|NCT06571058|OTHER|Educational Intervention|Receive a short instructional session
40770358|NCT06571058|DEVICE|Medical Device Usage and Evaluation|Wear the B3 Buddy device
40770359|NCT06571058|OTHER|Medical Device Usage and Evaluation|Secure the urinary drainage bag to the patient using the B3 Buddy device
40770360|NCT06571058|OTHER|Questionnaire Administration|Ancillary studies
40974150|NCT00585819|PROCEDURE|Freebreathing in Body fix mold|Freebreathing in Body fix mold
40974151|NCT00578812|DEVICE|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
40974152|NCT00578812|DEVICE|PCM Cervical Disc|PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
40974153|NCT03558776|DIETARY_SUPPLEMENT|linseed oil|linseed oil and defined background diet
40974154|NCT05833191|DEVICE|Auricular vagus stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
40974155|NCT05833191|DEVICE|Tibial Nerve Stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
40974156|NCT02554448|OTHER|ISET system|Use ISET system to test the number of CTCs from patients before and during treatment.
40974157|NCT04633694|DIETARY_SUPPLEMENT|insect, pea or whey protein|The protein powder is dissolved in 400 mL water and given relative to lean body mass, 0.25 g protein pr kg lean body mass.
40974158|NCT04255524|DEVICE|Optic coherence tomography angiography (OCTA)|Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map
40974159|NCT03998189|OTHER|Breath Collection|Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing
40770361|NCT06571058|PROCEDURE|Remove|Remove the device and return urinary drainage bag to the standard position
40974160|NCT03998189|OTHER|Saliva Collection|Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes
40974161|NCT03998189|OTHER|Blood Collection|Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube
40974162|NCT03998189|OTHER|Urine Collection|Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers
40974163|NCT03998189|OTHER|Tumor Collection|During surgical tumor removal, a tumor tissue sample will be collected
40974164|NCT03998189|OTHER|Medical History Data Collection|Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
40974165|NCT05538221|DIAGNOSTIC_TEST|SILEMA|SILEMA consists of a webcam connected to a laptop, a LED reflector, and a software. To carry out gait analysis with SILEMA, an Evaluator must place six yellow auto-adhesive markers over certain anatomical landmarks in the lower limbs, namely, greater trochanter, external femoral condyle, head of the fibula, lateral malleolus and base and head of the fifth metatarsal. The patient is asked to walk barefoot through an eight meter walkway at a self-selected speed, while a webcam connected to a laptop records a video. Then, an Operator, making use of the software, processes the video, obtaining spatio-temporal and joint kinematic parameters.
40770362|NCT06571058|OTHER|Walking|Walk approximately 90 feet
40770363|NCT05089916|DRUG|Osimertinib|Osimertinib: according to its marketing authorization, i.e. at daily doses of 80 mg, for a maximum of 12 months within the study.
40770364|NCT05089916|RADIATION|Radiotherapy|"Radiotherapy: according to standard of care~The target population will comprise 3 parallel cohorts, for cohort 1 and 3 a minimum of 10 subjects is planned to be enrolled:~1. Irradiation of bone, solid organ (non-lung, non-brain) or soft-tissue metastases~2. Irradiation of brain metastases (initial lesion size \< 3 cm)~3. Irradiation of lung lesions (primary tumor or metastases, lesion size \< 5 cm)"
40974166|NCT04870593|BEHAVIORAL|Information|Elder informed about vaccination.
40974167|NCT04870593|BEHAVIORAL|Buddy|"Elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated."
41459026|NCT02352233|PROCEDURE|RETROVIEW colonoscope|withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
41459027|NCT04573309|DRUG|ALXN1840|Administered orally as tablets.
40770365|NCT04641832|OTHER|Soccer heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
41298865|NCT00672542|BIOLOGICAL|Proteasome siRNA and tumor antigen RNA-transfected dendritic cells|The safety and toxicity of vaccination with tumor antigen RNA-transfected dendritic cells (DC), derived from either untransfected or siRNA-transfected monocytes, will be evaluated in subjects with metastatic melanoma. Subjects will undergo leukapheresis and monocytes will be isolated. These monocytes will then be left untreated (Study Arm A) or transfected with either control siRNA (Study Arm B) or siRNA targeting immunoproteasome subunits LMP2, LMP7, and MECL1 (Study Arm C), then differentiated into DC in vitro . After the induction of maturation, these DC will be transfected with RNA encoding defined melanoma antigens MART, MAGE-3, tyrosinase, and gp100. These RNA-transfected autologous DC will be cryopreserved, then used to vaccinate subjects with metastatic melanoma, each of whom will receive a total of six intradermal (ID) injections using 1x10e7 DC at each cycle, administered weekly.
41298866|NCT04527224|DRUG|AstroStem-V|Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
41298867|NCT00384540|PROCEDURE|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
41298868|NCT01142323|DRUG|fenofibrate|160 mg po daily
40770366|NCT06545552|DIETARY_SUPPLEMENT|An oral formulation of green tea extract, bamboo shoot extract and selenium-enriched yeast|Hard shell capsule containing 280mg of the oral formulation
40770367|NCT06545552|DIETARY_SUPPLEMENT|Placebo|Hard shell capsule containing maltodextrine
40770368|NCT06198400|DIAGNOSTIC_TEST|Perioperative assessment of the perfusion of post-resection pancreatic remnant using indocyanine green-VerDye|The adequacy of the vascular supply of the post resection pancreatic remnant after pancreatic neck division will be evaluated using ICG detector. Indocyanine green fluorescence product -Verdye™ will be intravenously applied. The application of the substance will be performed according to the current consensus statement and recommendation
40770369|NCT01771497|DEVICE|Koning Breast CT|Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
40770370|NCT00233246|PROCEDURE|FFP Infusion|
40770371|NCT05613946|DRUG|Lumason|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
40770372|NCT05613946|DRUG|Optison|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
40770373|NCT05613946|DRUG|Definity|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
40770374|NCT04647357|DRUG|SHR-1316|Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks
41298869|NCT03559244|OTHER|Dynamic compression brace|custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax
41298870|NCT03559244|OTHER|Exercises|posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
41459028|NCT05964049|DEVICE|active rTMS treatment|Participants will receive 5 sessions per day of 1800 pulses per session, lasting for 15 days. Individualized targets will be generated using the pBFS method.
40770375|NCT00283166|BEHAVIORAL|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
40770376|NCT03683433|DRUG|Azacitidine|Given SC or IV
40770377|NCT03683433|DRUG|Enasidenib Mesylate|Given PO
40770378|NCT04523025|DIAGNOSTIC_TEST|NLR-ratio|The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation
40770379|NCT06365502|DEVICE|Drug-coated balloon|Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed.
40770380|NCT06365502|DRUG|Guideline-directed medical treatment|All individuals will receive guideline-directed medical treatment.
40770381|NCT05713292|DRUG|Pirfenidone Oral Product|Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
40770382|NCT05713292|DRUG|Pirfenidone placebo|Pirfenidone placebo
40770383|NCT04316143|DRUG|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat
40770384|NCT05438121|DEVICE|SeQuent Please Neo|DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
40770385|NCT05826665|OTHER|Persistent AF ablation assisted with the STAR Apollo Mapping System|This exploratory hypothesis generating data set will be collected during standard AF ablation procedures using FDA cleared technologies as described in their Instructions for Use (IFU). No randomization or experimental protocols will be used during this study, and all follow up will be performed as per the center's standard of care(SOC).
40770386|NCT05709327|OTHER|Integrating Smart Ring Wearable Technology in Pregnancy Health Monitoring (I-SMART)|Single-arm observational study where all participants in the study will be given a smart ring (Oura Ring) to wear throughout the duration of the study.
40770387|NCT03204812|BIOLOGICAL|Durvalumab|Given IV
40770388|NCT03204812|BIOLOGICAL|Tremelimumab|Given IV
40770389|NCT06172088|OTHER|Fasting|Sieben days of online supervised prolonged therapeutic fasting (max. 350 kcal/d).
40770390|NCT05021848|OTHER|partnered multicomponent exercises program|aerobic,strength, flexibility and balance exercises and game
40770391|NCT06482034|DRUG|N-acetyl cysteine|N-acetyl cysteine sachets
40770392|NCT06482034|DRUG|Zinc sulfate|zinc sulfate capsules
40770393|NCT06482034|DRUG|saline mouth wash|saline mouth wash
40770394|NCT06571864|DRUG|Anti-CD38 Monoclonal Antibody|Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)
40770395|NCT02304185|BIOLOGICAL|gp140, 50 mcg|Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.
40770396|NCT02304185|BIOLOGICAL|gp140, 50 mcg + Adjuvant|The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
40770397|NCT02304185|BIOLOGICAL|gp140, 250 mcg|The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.
40770398|NCT02304185|BIOLOGICAL|gp140, 250 mcg + Adjuvant|The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
40770399|NCT02304185|DRUG|Placebo|Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
41298871|NCT05687994|BEHAVIORAL|Audiovisual Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, auditory, and visual cues for speaking
41298872|NCT05687994|BEHAVIORAL|Auditory Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, and auditory cues for speaking
41298873|NCT02868125|RADIATION|X ray radiography|All studied patients will undergo an x-ray radiography of the operated hip. This protocol is a part of the investigators' common practice policy regardless of the study.
40770400|NCT01969929|PROCEDURE|20G Vitrectomy|
40974168|NCT04870593|BEHAVIORAL|Gossip intervention|"Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders. If buddy intervention assigned in community, gossips also asked to encourage their communities to use the buddy system to get elders vaccinated."
41298874|NCT00758927|DRUG|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
41298875|NCT00758927|DRUG|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
41298876|NCT02142179|BEHAVIORAL|Knowledge about Asthma and Respiratory Education (KARE)|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
41298877|NCT02031380|DEVICE|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
41298878|NCT05831059|RADIATION|Pulsed radio frequency therapy|Pulse Radio Frequency mode is a high voltage and low temperature Radio Frequency mode formed by discontinuous and pulsed current around nerve tissue
40770401|NCT01969929|PROCEDURE|23G vitrectomy|
40770402|NCT05537376|BEHAVIORAL|SUicide Prevention by Peers Offering Recovery Tactics|Following the completion of a comprehensive mental health evaluation by a licensed VA provider, which includes a suicide safety plan, if a Veteran is having active thoughts of suicide or made a suicide attempt in past three months, they may be eligible for SUPPORT. In SUPPORT, the Peer Specialist and Veteran co-create a personalized suicide-focused recovery plan (SUPPORT Plan) in flexible, 50-minute weekly encounters. The SUPPORT Plan includes modules that focus on valuing recovery, building a hope kit and daily plan, setting recovery goals, and looking ahead to enhance the Veteran's safety plan. Learning strategies are incorporated into each module to promote salience and recall of intervention material. The Peer Specialist works closely with the Veteran's treatment team and uses the most recent safety plan in the Veteran's chart to help complete the SUPPORT Plan as well as reinforce the usage of the Veteran's safety plan.
40770403|NCT06135064|DEVICE|Diadem|The device delivers low-intensity ultrasonic waves into specified brain targets.
40974169|NCT04870593|BEHAVIORAL|Information assigned in community|Information intervention assigned for other elders in community.
40974170|NCT04870593|BEHAVIORAL|Buddy assigned in community|Buddy intervention assigned for other elders in community.
40974171|NCT01797601|DRUG|Human Insulin|160 U of insulin
40974172|NCT01797601|DRUG|Placebo|Insulin dilution medium without insulin
41298879|NCT05831059|OTHER|sham operation|The means to achieve double-blind treatment had no practical effect on the subjects
41459029|NCT05964049|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
41459030|NCT02382822|OTHER|No intervention.|
40770404|NCT05463341|BEHAVIORAL|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at Project DAWN sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
40770405|NCT03405740|DEVICE|Remote Patient Management|"1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic.~2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years.~3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit)~4. VIRTUES access"
40770406|NCT03405740|DEVICE|Standard of Care|No intervention
40770407|NCT05852327|OTHER|Observation only|Observation only
40770408|NCT01504360|GENETIC|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
40770409|NCT01504360|GENETIC|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
40770410|NCT05646082|DRUG|Dostarlimab in Combination Antiretroviral Therapy|Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.
40770411|NCT00163293|DRUG|Ciclesonide|Ciclesonide metered-dose inhaler
40770412|NCT00163293|DRUG|Placebo|Ciclesonide placebo-matching metered-dose inhaler
40770413|NCT06160245|OTHER|exercise therapy|core stabilization exercises
41298880|NCT05344079|DEVICE|18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey)|Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal®, 2% 100 mg/5 mL amp., Biosel, Turkey) + 1/2000000 adrenaline test dose.
41298881|NCT05344079|DEVICE|20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump|spinal anesthesia was maintained with 10-15 mg of hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceutical Industry and Trade Ltd.) after free cerebrospinal fluid flow was observed by entering the subarachnoid space with a 22 G spinal needle (Egemen Quincke Sharpened Spinal Anesthesia Needle; İzmir) from the L4-L5 or L5-S1 vertebral space. At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line. Pain pump and the catheter was withdrawn at the end of the postoperative 24th hour.
41298882|NCT03903029|DRUG|Low-dose (10mg) rosuvastatin|Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
41459031|NCT02350036|OTHER|ultrasound monitoring|Uterine artery Doppler assessment
41459032|NCT05601596|DIAGNOSTIC_TEST|Analysis of menstrual blood to predict endometriosis|Menstrual blood from controls and symptomatic cases will be analyzed using single cell RNA-sequencing to develop a panel of biomarkers that can be developed into a screening test or diagnostic test for endometriosis.
41459033|NCT04262739|DRUG|NYH817G|Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
41459034|NCT04262739|DRUG|NYH100P|Subject will orally administer NYH100P (100 mg) during the cycles(21 days)
41459035|NCT04262739|DRUG|NYH817G and NYH100P|Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
41459036|NCT01446445|DRUG|Ganciclovir/ Valganciclovir according to SPC|Doses according to Summaries of Product Characteristics (SPC)
41459037|NCT01446445|DRUG|Ganciclovir/ Valganciclovir according to PK model|Doses according to population pharmacokinetic model
41459038|NCT03522649|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours.
40770414|NCT04827914|BEHAVIORAL|Enhanced Care|Smokers in the enhanced care group will receive live counseling (either in person or telehealth consult) while hospitalized combined with post-hospital discharge automated calls using interactive voice recognition (IVR) technology.
40770415|NCT04827914|BEHAVIORAL|Basic Care|Smokers assigned to the basic care group will only receive the post-discharge IVR phone calls.
40770416|NCT00370084|DRUG|Itopride|oral, three times daily
41459039|NCT03522649|DRUG|Fluorouracil|Fluorouracil 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion.
40770417|NCT00370084|OTHER|Placebo|oral, three times daily
40770418|NCT01924819|DRUG|Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel|"Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)"
40770419|NCT01924819|RADIATION|Preoperative chemoradiotherapy|"Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
40770420|NCT01924819|PROCEDURE|Gastric resection|The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers \[Siewert Type II and Siewert Type III\] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
40770421|NCT01600651|OTHER|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
40770422|NCT01600651|OTHER|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
40770423|NCT05209035|DRUG|Trazodone|Trazodone 50mg daily
40770424|NCT05209035|OTHER|Placebo|Starch 50mg
40770425|NCT05731245|DRUG|Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
40770426|NCT00005038|BIOLOGICAL|aldesleukin|
40770427|NCT00005038|DRUG|histamine dihydrochloride|
40770428|NCT05194332|DEVICE|LIFUP sonication to the amygdala|LIFUP sonication to amygdala will be performed.
40770429|NCT01108874|DRUG|Metaraminol|Patients will be given metaraminol every time SBP falls below baseline value.
40770430|NCT03826472|OTHER|Almond Butter|Natural almond butter
40770431|NCT04174586|BIOLOGICAL|microtransplantation|HLA mismatched donor cord blood infusion
40770432|NCT06140225|BEHAVIORAL|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
40770433|NCT06140225|BEHAVIORAL|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
40770434|NCT06140225|BEHAVIORAL|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
40770435|NCT06140225|BEHAVIORAL|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
40770436|NCT06140225|BEHAVIORAL|"JEFIT APPLICATION"|It is an app whose goal is to be a support in training of strength-resistance training. Setting a specific goal, with a full databaseover of exercises to perform.
41298883|NCT06497647|DRUG|Sulbutiamine|"sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group B and combined with imipramine in group C"
41298884|NCT06497647|DRUG|Imipramine|"imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group A and combined with sulbutiamine in group C"
41298885|NCT03550326|PROCEDURE|airway management|patients will be intubated or will be placed an airway device
40770437|NCT06140225|BEHAVIORAL|"FITBIT-FLEX APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
40770438|NCT06140225|BEHAVIORAL|"MEIZU BONG 2S APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
40770439|NCT05044481|PROCEDURE|third molar surgical removal|ambulatory surgical intervention of the maxilla and / or mandible for third molar removal
40770440|NCT05314387|DEVICE|SMR TT Hybrid Glenoid without Cementless Finned Short Stem|The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.
40770441|NCT05314387|DEVICE|SMR TT Hybrid Glenoid with Cementless Finned Short Stem|"The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.~The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation."
40770442|NCT04701242|DRUG|Ezetimibe 10mg|comparing upfront use of Ezetimibe (added to high intensity statins) after acute myocardial infarction versus selective Ezetimibe initiation to those failing to achieve LDL-C targets when assessed in follow up visit.
40770443|NCT00526799|DRUG|Sorafenib|"Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid"
40770444|NCT00526799|DRUG|Topotecan|3.5mg/m2 weekly, 3 weeks on and one week off.
40770445|NCT05231980|DIETARY_SUPPLEMENT|Alpha lipoic acid (ALA)|ALA is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect.
40770446|NCT05231980|DRUG|Pentoxifylline (PTX)|Pentoxifylline is a methylxanthine derivative which acts as a vasodilator by increasing blood flow to tissues, inhibits inflammatory responses, and reduces blood viscosity by impeding platelet aggregation
40974173|NCT03971097|BEHAVIORAL|Six Step Model of Self-Forgiveness|"The six-step model includes a workbook that applies Worthington's (2013) conceptualization of self-forgiveness and guides the practitioner and participant through the self-forgiveness process. Each step provides a framework for techniques and includes psychoeducation, interventions, and homework to be completed in between sessions. The individual sessions will not conflict with the timing or content of the unit's regular treatment schedule, thus, participation in the study will not affect a patient's ability to participate in TAU. All interventions will be done individually to ensure that participant confidentiality is respected throughout the therapeutic process."
40770447|NCT05231980|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
40770448|NCT01445275|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
40770449|NCT01445275|OTHER|Medical Chart Review|Ancillary study
40770450|NCT01445275|OTHER|Study of Socioeconomic and Demographic Variables|Ancillary studies
40770451|NCT06071221|BEHAVIORAL|Living Healthy educational program + peer coaching|The Living Healthy intervention is an 8-session health education program with cognitive behavioral training (CBT) techniques. For those in the interventional arm, the Living Healthy intervention program will be delivered by trained peer coaches by telephone or Zoom over 3 months. In this study, trained peer coaches are trained home health aides themselves. Informed by social cognitive theory (SCT), peer coaches train participants on cognitive behavior techniques and empower participants to adopt positive health behaviors through personalized goal setting, motivational interviewing, and peer modeling. Each content-based session incorporates principles of CBT, teaching participants to recognize and modify negative thinking and modifying outcome expectations through self-monitoring, reflection, and practice.
40770452|NCT06071221|BEHAVIORAL|Living Healthy educational program|Participants assigned to receive health education alone will be asked to read health education (online; covering aspects of the Living Healthy program) which corresponds to a weekly topic about health. They will be called by a research assistant each week to prompt them to do this and answer any questions they might have about the materials.
40770453|NCT02695836|OTHER|Initial face-to-face dissemination workshop|Managers and directors of care will receive a printed report (tailored to their facility) on their facility's performance and performance of each unit (microsystem) within that facility. The workshop will include a presentation of the feedback reports with a particular focus on the core set of actionable context targets (Formal Interactions, Evaluation, Social Capital, Organizational Slack (OS) - Time) in the face-to-face workshops. Following the presentation, participants will discuss their reports in facilitated, round-table group discussions to a) help with interpretation of the results overall, b) draw attention to elements of context that are modifiable, c) encourage microsystem teams to work on improving the more modifiable areas
40770454|NCT02695836|OTHER|Face-to-face goal setting workshop|Sessions will build on the dissemination workshops and will be held three months after. Feedback reports on Formal Interactions, Evaluation, Social Capital, and Organizational Slack (OS) - Time will be discussed. Small group activities will take place including: a) reflecting on context data, b) performance goal setting using the 'tell and sell' method, which capitalizes on the workshop leaders' perceived expertise about what goals are achievable, c) establishing a series of proximal learning goals that will provide teams with explicit strategies for attaining performance goals set in (b). An action plan and instructions for reporting back at the Virtual Support Workshop will be provided.
40770455|NCT02695836|OTHER|Virtual support workshops|On virtual support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges.
41459040|NCT03522649|DRUG|Leucovorin|Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
41459041|NCT03522649|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
41459042|NCT03074799|OTHER|Symptom -based Screening(Child Contacts)|"Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.~Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).~Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy."
41298886|NCT00257192|DRUG|placebo|Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
41298887|NCT00257192|DRUG|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
41298888|NCT01096082|DRUG|Lithium Carbonate|300 mg tablets, starting dose 300 mg/day
41298889|NCT01096082|DRUG|Placebo|Similar shape, color and taste and the same number of tablets from the experimental group
41298890|NCT03042013|DRUG|ASP8273|Oral
41298891|NCT03032068|OTHER|At-Home Monitoring|Patient reported outcomes, functional measures such as the maximum attainable range of motion (AROM) and the number of steps taken will be tracked using sensors worn by the patient. The AROM sensor values will be verified with range of motion measurements taken using a goniometer during therapy and MD visits.
41298892|NCT00086840|DRUG|temsirolimus|Given IV
41298893|NCT00086840|OTHER|laboratory biomarker analysis|Correlative studies
41298894|NCT03201198|BEHAVIORAL|Active Life|The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
41298895|NCT03201198|BEHAVIORAL|Chair exercises|Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
40770456|NCT02695836|OTHER|Face-to-face support workshops|On face-to-face support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges. Workshops will be attended by all participating teams from a region, to maximize opportunities for teams to learn from one another and trouble-shoot together with the support of workshop leaders.
41298896|NCT00126542|BIOLOGICAL|bevacizumab|Given IV
41298897|NCT00126542|DRUG|erlotinib hydrochloride|Given orally
41298898|NCT00126542|OTHER|laboratory biomarker analysis|Correlative studies
41298899|NCT02229968|DRUG|Amicar (ε-aminocaproic acid)|
41298900|NCT02229968|DRUG|normal saline|
41298901|NCT01302041|DRUG|Enzalutamide|Oral
41298902|NCT03566693|DEVICE|Dexcom G6 CGM System|continuous glucose monitor
41298903|NCT03566693|DEVICE|Blood glucose meter|Blue-tooth enabled blood glucose meter
41298904|NCT01232972|PROCEDURE|vitrification of oocytes|eggs will be preserved via vitrification the day they are retrieved from the participant
41298905|NCT00216606|DRUG|topiramate|
41298906|NCT05880368|OTHER|Patient partnership tools|The intervention consists of two patient partnership tools: (1) a one-page 'visit prep guide' given to relevant patients by clinic staff before seeing the primary care provider, with the intention to improve communication and shared decision-making; and (2) a series of short educational videos that clinic staff can encourage patients to watch. The interventions will be included in the workflow of the clinics during the intervention periods (i.e., clinics either do not use the intervention or use them for all relevant patients depending on study period).
41298907|NCT04364074|DIETARY_SUPPLEMENT|Goodbelly|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This will be followed by an observation period for 6 weeks during which the subjects will not consume Goodbelly.
41298908|NCT04364074|DIETARY_SUPPLEMENT|Placebo|To prepare the placebo, the dietitian will first heat a water bath to 80 degrees Celsius. This removes the lactobacillus plantarum 299v from the probiotic drink
41298909|NCT01879618|DRUG|Fragmin|variable dosing regimen
41298910|NCT04141345|DIAGNOSTIC_TEST|cardiopulmonary exercise test|Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.
40770457|NCT02695836|OTHER|On-demand email and telephone support|Participants can contact the research team if needed with requests for support in defining or implementing improvement strategies or dealing with barriers towards improvement.
40770458|NCT06277284|DRUG|MG-K10 humanized monoclonal antibody injection (prefilled syringe)|MG-K10 Humanized Monoclonal Antibody Injection
40770459|NCT06277284|DRUG|MG-K10 humanized monoclonal antibody injection（Penicillin bottle）|MG-K10 humanized monoclonal antibody injection (single injection)
41298911|NCT06114953|DRUG|Mizoribine|Mizoribine+glucocorticoid+tacrolimus after kidney transplantation
41298912|NCT06114953|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil+glucocorticoid+tacrolimus after kidney transplantation
41298913|NCT00598533|DEVICE|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
40770460|NCT02913846|OTHER|Nutritional evaluation|A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.
40770461|NCT02913846|OTHER|Muscular assessment|An assessment of muscular force will be performed once a week.
40770462|NCT02913846|OTHER|Pre-albumine dosage|Dosage performed once a month.
40770463|NCT06090552|BEHAVIORAL|Letter, AD, PREPARE|Letter, AD, PREPARE
40770464|NCT06090552|BEHAVIORAL|Letter, AD, PREPARE, reminders|Letter, AD, PREPARE, reminders
41298914|NCT00598533|DEVICE|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
40770465|NCT06090552|BEHAVIORAL|Letter, AD, PREPARE, reminders, healthcare navigator|Letter, AD, PREPARE, reminders, healthcare navigator
40770466|NCT02860403|PROCEDURE|motor imagery|Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
41298915|NCT00540436|DRUG|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
41298916|NCT02260167|OTHER|A mix of natural treatments and medications|
41298917|NCT01783522|DRUG|glutamine|Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
41298918|NCT01783522|OTHER|quality-of-life assessment|Ancillary studies
41298919|NCT01783522|OTHER|placebo|Given PO
41298920|NCT00779090|PROCEDURE|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
41298921|NCT02610088|DRUG|Dapagliflozin|Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.
41298922|NCT02610088|DRUG|Gliclazide|Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.
41298923|NCT06405841|OTHER|Survey|All patients will be asked to complete a survey at 1, 2, 4, 12 and 24 weeks from the trauma to assess their quality of life
41298924|NCT06405841|OTHER|Pain management|All patients will be asked about their pain management at 1, 2, 4, 12 and 24 weeks from the trauma to assess if they are under medication and what kind of medication are they taking
40770467|NCT02215473|DRUG|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
40770468|NCT02215473|PROCEDURE|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
40770469|NCT02898688|BEHAVIORAL|Control Site|Control sites will continue with their standard practice regarding discussing vaccines with their patients.
40974174|NCT03971097|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
41298925|NCT00695084|BEHAVIORAL|Constraint-Induced Movement Therapy|Intensive practice with the hemiparetic arm for 30 contact hours
41459043|NCT03074799|OTHER|Clinical based Decisions|the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
40770470|NCT02898688|BEHAVIORAL|Intervention Site|Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits. AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level. A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines. Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
40770471|NCT02898688|BEHAVIORAL|Patient-level Control Group|"Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app. The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questionnaire includes questions requiring a yes or no response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions."
40974175|NCT00696722|DRUG|placebo + atazanavir|"Placebo treatment first, atazanavir treatment second~4 day treatment"
40974176|NCT00696722|DRUG|atazanavir + placebo|"Atazanavir treatment first, placebo treatment second~4 day treatment"
40974177|NCT02151253|DRUG|Armodafinil|Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
41139835|NCT03564184|BEHAVIORAL|MT after NICU|Music therapy offered by trained music therapist, 7 times for approximately 45 minutes/session across first 6 months following discharge from initial NICU hospitalization. Sessions include infant and caregiver, and siblings, if desired, and occur at home or in municipal settings. MT after NICU consists of a consult-to-parent model with each session including a brief verbal check-in regarding infant´s progress, musical interactions with music therapist modelling musical engagement, discussion of current challenges and strategies for using musical interactions to address needs in areas such as infant self-regulation, parent/infant interaction, and challenges with bonding. Caregivers will demonstrate techniques discussed during session, and form a brief plan for use of musical interaction in the interim before next session. Sessions will be adapted to infant developmental level and ongoing needs.
41139836|NCT03564184|OTHER|Standard care|Includes necessary medical care and standard supportive interventions offered as part of care during hospitalization, and standard follow-up procedures post-hospitalization.
41139837|NCT05649891|OTHER|Emergency Manual|Collection of crisis checklists and fact sheets
41139838|NCT01727167|DRUG|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
41139839|NCT01727167|OTHER|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
41139840|NCT06419257|DEVICE|VRDS|VRDS is an augmented virtual reality driving simulator.
41139841|NCT01163929|DRUG|paclitaxel|"Paclitaxel:~80mg/m2 IV TRO 3 hours every 28 days for 4 cycles~Trastuzumab:~4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks~Everolimus: 10mg PO daily 16-18 weeks"
41139842|NCT05392972|BEHAVIORAL|Assessment of stress, resilience and associated factors in anesthesia professionals|Assessment of stress, resilience and associated factors in anesthesia professionals
41139843|NCT05015842|OTHER|Conventional Physical Therapy|This is a combine protocol of different therapeutic exercises and heat therapy.
41139844|NCT05015842|OTHER|Kinesio Tapping|Kinesio Tapping is an adhesive and elastic fiber used for different outcomes like pain and swelling reduction among physical therapists.
41139845|NCT06309355|DRUG|YR001 ointment|The intervention is YR001 ointment on a range of body surface area for multiple topical administration
41139846|NCT06309355|OTHER|Placebo|The intervention is Placebo on a range of body surface area for multiple topical administration
41139847|NCT01308684|DRUG|RO5323441 + bevacizumab [Avastin]|Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks
41139848|NCT01308684|DRUG|bevacizumab [Avastin]|Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
41139849|NCT03919851|DRUG|Antibiotics|Administration of antibiotics
41139850|NCT02068157|OTHER|Laboratory Biomarker Analysis|Correlative studies
41139851|NCT02068157|DRUG|Photodynamic Therapy|Undergo image-guided I-PDT
41139852|NCT02068157|DRUG|Porfimer Sodium|Given IV
41139853|NCT04119947|DRUG|SY-009|The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
40974178|NCT02151253|DRUG|Placebo|Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
40974179|NCT04352647|BEHAVIORAL|female athletes|The type of incontinence is assessed, whether there are risk factors and quality of life and psychological performance
41139854|NCT01220999|DRUG|CS-1008|CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).
41139855|NCT02016365|DRUG|Doxycycline|200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
41139856|NCT02016365|DRUG|Ursodeoxycholic acid|750 mg/day (500 mg +250mg orally) continuously
41298926|NCT02426983|DEVICE|Direct Current Stimulation|"Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).~Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks."
41139861|NCT01170936|DRUG|canakinumab|Single dose of canakinumab 300mg s.c. injection
41139862|NCT02822703|DEVICE|rTMS Active 20Hz|Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
41139863|NCT02822703|DEVICE|rTMS Sham|The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
41139864|NCT00004496|DRUG|alpha-melanocyte stimulating hormone|
41139865|NCT03490006|PROCEDURE|Erector Spinae Plane Block|A relatively recent alternative to the paravertebral block is the thoracic erector spinae plane block, which involves the ultrasound-guided injection of local anesthetic into the interfascial plane deep to the erector spinae muscle at the level of the transverse process. It results in a loss of somatic sensory sensation across multiple unilateral dermatomes due to local anesthetic mediated blockade of the dorsal and ventral rami of the spinal nerve roots. It is increasingly being used due to ease of placing the block and a perception of greater safety. It has been shown to provide pain relief from rib fractures, thoracotomy, and chronic neuropathic pain of the chest wall. However, to date, erector spinae plane block has not been compared with paravertebral block in regards to analgesia with mastectomy surgery, which has been extensively studied.
41139866|NCT03490006|PROCEDURE|Paravertebral Block|Paravertebral block is a classic regional anesthesia technique that has been in use for over 100 years. It is performed by the injection of local anesthetic into the space between the costotransverse ligament and parietal pleura resulting in blockade of ipsilateral intercostal nerves. It results in a loss of somatic sensation over multiple unilateral dermatomes.
41146936|NCT06255132|DEVICE|Automated pupillometer NPi-200|"Pupillary variables in both eyes are recorded and measured with NPi-200 every 30 minutes from the induction of anesthesia. At the end of the surgery, the patient is transferred to the intensive care unit (ICU), and the pupillary variables are recorded until the patient regains consciousness (Richmond agitation sedation scale, RASS\>-3). Specific hemodynamic, respiratory, surgical, and EBP data are also recorded as well as NIRS variables.~As soon as the patient had regained consciousness (RASS \> 3), they were assessed for delirium for a total period of five days. Nursing and/or medical staff administered the CAM-ICU score to patients twice a day (morning and afternoon)."
40974180|NCT00045123|DRUG|tarenflurbil|
40974181|NCT00045123|PROCEDURE|adjuvant therapy|
41459044|NCT05894031|BEHAVIORAL|Wim Hof Method|The intervention followed the guidelines provided by Wim Hof. The intervention comprised three components: cold water exposure, breathing exercise, and meditation.The participants were instructed to perform the WHM daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
41459045|NCT03033030|DIAGNOSTIC_TEST|Ultrasound|Ultrasound examination
41459046|NCT04563260|DRUG|Normal saline injection|Normal saline 2 mL, intravenous injection
40770472|NCT02898688|BEHAVIORAL|Patient-level Intervention Group|"Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines. The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questions require yes or no responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses. After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants."
40770473|NCT06354049|OTHER|Reiki|Reiki, originating in Japan, is a biofield therapy where a skilled practitioner places their hands on or above the body of the recipient or themselves to induce relaxation and promote healing.
40770474|NCT06264310|DRUG|Placebo|Matching placebo SC injection
40770475|NCT06264310|DRUG|R2R01|Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
40770476|NCT00265798|DRUG|Sorafenib Tosylate|
40770477|NCT03174067|DRUG|Buprenorphine|The participant receives buprenorphine
40770478|NCT03174067|DRUG|Clonidine|The participant receives clonidine
40770479|NCT02290912|BEHAVIORAL|Health education program|"The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes cafeteria style (i.e. based on their individual preferences)."
40770480|NCT05128903|DRUG|[18F]DPA714|"Intravenous injection~* Before or within 2 weeks of starting radiation therapy~* Before starting chemotherapy~* 1 year after the start of radiation therapy Timing cont.~* 1.5 to 2 years after the start of radiation therapy"
40770481|NCT06464991|DRUG|Equecabtagene Autoleucel Injection|dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
40770482|NCT06464991|DRUG|Daratumumab|"dosage form: Injection dose level:16mg/kg frequency: 28days/cycle for DPd regimen~* Cycle1-2：D1, D8, D15, D22；~* Cycle3-6：D1, D15；~* above Cycle7：D1"
40770483|NCT06464991|DRUG|Pomalidomide|dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.
41298927|NCT02426983|DRUG|Dextromethorphan|Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
40770484|NCT06464991|DRUG|Bortezomib|dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11； above cycle 9: D1, D8.
40770485|NCT06464991|DRUG|Dexamethasone|dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23； for PVd: Cycle1-8：D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.
41298928|NCT01318083|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
40770486|NCT06610890|DRUG|Hemay005|One 15mg tablet, four tablets at a time
40770487|NCT06610890|DRUG|Midazolam maleate|One 15mg tablet, one tablet at a time
40770488|NCT03520114|DEVICE|RP sling placement|A 1.5 cm incision will be made at the mid-urethra through a separate vaginal incision with lateral dissection with Metzembaum scissors. After placement of both trocars, cystoscopy with a 70-degree scope will be performed to assess for bladder and urethral injury. Surgeons will set the tension of the tension-free vaginal tape (TVT) slings so that a spacer can be placed between the sling and the urethra. Sling tensioning will be performed after anterior and apical prolapse is corrected.
41298929|NCT01318083|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
41298930|NCT01318083|DRUG|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
41459047|NCT04563260|DRUG|Palonosetron Injection [Aloxi]|Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
41298931|NCT05094102|DEVICE|OnLume Imaging System|for fluorescence-guided surgery with ICG dye
41298932|NCT05094102|DRUG|Indocyanine green|Indocyanine green is a cyanine dye used in medical diagnostics
40770489|NCT03520114|DEVICE|SIS placement|The sling is introduced through a single anterior vaginal incision of 1.5 cm at the mid-urethra. The sling/needle assembly is advanced behind the ischiopubic rami in a transobturator trajectory toward the obturator space bilaterally. The needle is then removed by simply sliding the fixating tip back out. The other side is then completed in an identical fashion. After the fixation of the two anchors at the 2 and 10 o'clock positions, the patient's bladder is filled with 250 mL of Sodium Chloride (NaCl). Afterward, an intraoperative crede maneuver is performed and the tension adjustment suture is pulled, when necessary, to achieve the desired continence. The mesh will lie in direct apposition to the urethra. The adjustment thread is then cut short and the vaginal incision is closed with an absorbable suture.
40770490|NCT02878473|PROCEDURE|Deceased donor Liver Transplantation|Deceased donor orthotopic liver transplantation
41298933|NCT02674737|DRUG|dexmedetomidine, tramadol and flurbiprofen|
40770492|NCT06129903|OTHER|referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences.|The primary intervention in this study is referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences. This study will not dictate specific psychiatry interventions beyond providing the referral.
41298934|NCT02674737|DRUG|tramadol and flurbiprofen|
41459048|NCT04631133|DEVICE|Lumbar Implant for Stiffness Augmentation (LISA)|The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).
41459049|NCT00006262|DRUG|becatecarin|
41459050|NCT01525680|OTHER|Hydrocortisone augmented Prolonged Exposure Therapy|11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
41459051|NCT01525680|OTHER|Prolonged exposure therapy with placebo administration|11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
40770493|NCT06533553|DRUG|Dexpramipexole Dihydrochloride|Administration of dexpramipexole tablet
40770494|NCT05851963|DEVICE|Sonicare Diamond Clean 9000|Brush teeth with the electric toothbrush 1 daily during the orthodontic treatment
40770495|NCT05851963|DEVICE|HydroSonic Pro|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
40770496|NCT05851963|DEVICE|Oral-B 123|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
40770497|NCT05851963|DEVICE|Curaprox CS 5460|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
40770498|NCT01661595|DRUG|Sildenafil|50 mg/day for 4 weeks
40770499|NCT01661595|DRUG|tadalafil|10 mg/day for 4 weeks.
41459052|NCT02906917|DRUG|Insulin degludec/insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
41459053|NCT02906917|DRUG|Insulin glargine|Administered subcutaneously (s.c. under the skin) once daily.
40770500|NCT01661595|DRUG|Placebo|Placebo 1 capsule per day for four weeks.
40770501|NCT01006395|DRUG|Zoledronic acid|yearly infusion
40770502|NCT01006395|DRUG|Placebo|yearly infusion
40770503|NCT06298734|BEHAVIORAL|Exercise Program|A high-intensity interval training, aerobic exercise program virtually supervised, home-based, and appointment-based program under direct one-on-one supervision by a trained oncology exercise specialist. Sessions will be conducted via the Zoom platform. Participants will be provided with home stationary bike, heart rate monitor, blood pressure monitor. For participants who do not have a smart device, a Wi-Fi enabled tablet will be provided.
40770504|NCT06298734|BEHAVIORAL|Diet Program|A virtual dietary consultation program supervised by trained research staff. Appointments will be conducted via the Zoom platform. Participants will receive an education handout at the baseline visit.
40770505|NCT03886857|DEVICE|transcutaneous spinal cord stimulation|noninvasive electrical stimulation of the human lumbar spinal cord
40770506|NCT06516198|OTHER|Auricular Acupressure|Seeds will be placed during the clinic visit by the acupuncturist or the research associate according to the group the patient was assigned to. The care partner will observe the placement. A photograph of the seed placement will be taken and given to the care partner and to the patient after the relevant points are labeled by number or letter. The method of pressing is demonstrated for 1 one of the seeds, the care partner practices pressing on 2 other seeds, and the patient practices pressing on the remaining 2 seeds. Pressing consists of applying pressure, gradually increasing the pressure until the patient expresses discomfort, and maintaining that pressure until 2 minutes have passed. After pressing has been performed for each seed, the seeds are removed in clinic prior to clinic discharge.
41298935|NCT04417088|DRUG|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
41298936|NCT04417088|DEVICE|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system with microbubble resonators.
41298937|NCT03165357|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|
41298938|NCT03165357|DIETARY_SUPPLEMENT|Placebo treatment|
41298939|NCT03229746|DRUG|Hydroxychloroquine|200mg twice daily orally for at least 12 weeks
41298940|NCT03229746|DRUG|vincristine|1mg intravenous weekly for 4 weeks
41298941|NCT03229746|DRUG|azathioprine|dose 100mg daily for at least 3 weeks
40974182|NCT03571152|OTHER|Educational videos|The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.
40974183|NCT04943185|DEVICE|XEN gel microstent implantation|"Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention"
41298942|NCT00373971|BEHAVIORAL|Involving the patients in their own nutritional care|
41298943|NCT00158652|PROCEDURE|Conventional radiotherapy 70 Gy in 7 weeks|2 gy per fraction, 1 fraction per day, 5 fractions per week
41459054|NCT02906917|DRUG|Insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
40974184|NCT03767504|DIETARY_SUPPLEMENT|Thymol|Musclin - a dietary supplement: 2 capsules (20 mg thymol per capsule) BID with a meal for 30 days increased to 4 capsules for an additional 30 days.
41139867|NCT06352307|OTHER|Diagnosis of ACM|Definite ACM diagnosis is based on the consensus-based 2010 Task Force Criteria, which include major and minor criteria in six categories (depolarization and repolarization abnormalities, arrhythmia, imaging, histology, and family history/genetics). Among these, repolarization abnormalities (T-wave inversion in the precordial leads) constitute the most commonly observed, followed by frequent premature ventricular complex. With regards to imaging techniques, both the presence of wall motion abnormalities and an abnormal ventricular volume or function are required for fulfilment. Definite ACM consists of two major criteria or one major and two minor criteria or four minor criteria from different categories. Borderline ACM consists of one major and one minor criterion or three minor criteria from different categories.
41139868|NCT00413283|BIOLOGICAL|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
41139869|NCT00413283|DRUG|Placebo|Placebo subcutaneous injection.
41139870|NCT00413283|DRUG|Gemcitabine|Intravenous infusion
41139871|NCT00413283|DRUG|Carboplatin|Intravenous infusion
41139872|NCT00413283|DRUG|Cisplatin|Intravenous infusion
41139873|NCT05796141|BEHAVIORAL|Core Behavioral Weight Loss (BWL) intervention|Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)
41139874|NCT05796141|BEHAVIORAL|Dyadic Action Planning|Participants will develop dyadic action plans together.
41298944|NCT00158652|PROCEDURE|middle accelerated radiotherapy 70 Gy in 6 weeks|5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks
41298945|NCT00158652|PROCEDURE|very accelerated radiotherapy 64.8 Gy in 3.5 weeks|2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks
40770507|NCT03815552|DEVICE|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with diabetes for the operating life of the sensor.The System comprises a sensor and a transmitter. The small sensor will be subcutaneously inserted in the arm.The transmitter reads glucose data from the subcutaneous sensor.
40974185|NCT00948129|OTHER|Laboratory Biomarker Analysis|Correlative studies
40974186|NCT00948129|BEHAVIORAL|Smoking Cessation Intervention|Undergo standard of care smoking cessation intervention
40974187|NCT00948129|BEHAVIORAL|Telephone-Based Intervention|Undergo telephone based smoking cessation intervention
41139875|NCT05796141|BEHAVIORAL|Joint Feedback|Participants will see data on their partner's progress, in addition to their own weight and behavioral data.
41139876|NCT05796141|BEHAVIORAL|Autonomy Support Training|Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.
41139877|NCT05796141|BEHAVIORAL|Home Environment Modifications|Participants will be trained in how to structure their home environment to support health behavior.
41139878|NCT05283876|DEVICE|Excimer light|Excimer light sessions
41139879|NCT03034863|BEHAVIORAL|Safe Actions for Families to Encourage Recovery|A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
41139880|NCT03034863|BEHAVIORAL|Individual Safety Planning Intervention|The comparison condition will be an assessment-only enhanced treatment-as-usual intervention called the Individual Safety Planning Intervention (I-SPI).
41139881|NCT00886834|DRUG|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
41298946|NCT00158652|DRUG|5FU, Paraplatin|5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
41298947|NCT01666444|DRUG|pegylated liposomal doxorubicin (PLD)|
41298948|NCT01666444|DRUG|VTX-2337|TLR8 Agonist
41298949|NCT01666444|DRUG|Placebo|
40770508|NCT03761706|BEHAVIORAL|Engagement in Physical Activity|Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits. Participants will also complete a daily exercise log to record the total number of minutes walked and the total number of steps from the FitBit.
40770509|NCT03761706|OTHER|Questionnaires|Study participants will complete the following questionnaires: Health Behavior Questionnaire (HBQ), Short Physical Performance Battery (SPPB), Functional Assessment of Cancer Therapy-General (FACT-G), 4.4.5 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS Cognitive Function (Short Form 8a), Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Version 4, Nutrition Survey, Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM),
40770510|NCT05395338|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
41298950|NCT04695847|DRUG|M1231|M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
40770511|NCT05204485|PROCEDURE|Fibular intramedullary nail|The standard manufacturers approved technique will be performed including the use of 2 distal interlocking screws and the use of a minimum of 1 fibula pro tibia fixation screw depending on the patients' anatomical characteristics.
40770512|NCT05204485|PROCEDURE|Open reduction and internal fixation|An open approach (direct lateral or posterolateral incision) will be carried out. The reduction will be performed using standard techniques of clamping and traction. Fixation will be performed after reduction of the fracture with a plate and screw construct. The surgeon will then proceed to perform surgical fixation of other associated fractures or ligament injuries as indicated. This will most often include open reduction and internal fixation of the medial malleolus with screws through a separate medial incision.
40770513|NCT06267846|DRUG|NBI-1070770|Suspension for oral administration
40770514|NCT06267846|DRUG|Placebo|Suspension for oral administration
40770515|NCT06565312|DIETARY_SUPPLEMENT|Flora Power Probiotic Vaginal Suppository|The suppository contains Microcrystalline Cellulose, Ascorbic Acid, Vitamin C, Gelatin Capsule, Vaginal Probiotic Blend (Lactobacillus fermentum LF61, Lactobacillus acidophilus LA85, Lactobacillus plantarum Lp90), Magnesium Stearate, and Silicon Dioxide.
40770516|NCT00265122|DRUG|Ustekinumab 90 mg|one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
40770517|NCT00265122|DRUG|Ustekinumab 4.5 mg/kg|one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
40770518|NCT00265122|DRUG|Placebo SC|one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
40770519|NCT00265122|DRUG|Placebo IV|one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
40770520|NCT04743011|DRUG|Heparin sodium|Nebulized inhalation of 5 mL of a solution containing high molecular weight heparin - enriched heparin - 2.5mg/mL and 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
40770521|NCT04743011|DRUG|Placebo|Nebulized inhalation of 5 mL of 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
40770522|NCT04809805|DRUG|BAY2666605|One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
40770523|NCT00809588|BIOLOGICAL|Autologous, lethally irradiated melanoma cells|Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
40770524|NCT02502552|OTHER|blood specimen|blood specimen
40770525|NCT05105620|DIAGNOSTIC_TEST|Fluorescein Angiography|Fluorescein Angiography for pateints with diabetes using fundus camera (TRC-NW8F retinal camera; Topcon Corporation, Tokyo, Japan).
40770526|NCT05105620|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography for pateints with diabetes using • Topcon DRI OCT Triton device (ver.10.13; Topcon Corporation, Tokyo, Japan).
41298951|NCT04695847|DRUG|M1231|M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
40770527|NCT06112379|DRUG|Dato-DXd|Experimental drug IV infusion
40770528|NCT06112379|DRUG|Durvalumab|Experimental drug IV Infusion
40770529|NCT06112379|DRUG|Pembrolizumab|IV Infusion Active comparator
40770530|NCT06112379|DRUG|Doxorubicin|IV infusion Experimental/Active Comparator
40770531|NCT06112379|DRUG|Epirubicin|IV Infusion Experimental/Active Comparator
41139882|NCT00886834|DRUG|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
40770532|NCT06112379|DRUG|Cyclophosphamide|IV infusion Experimental/Active Comparator
40770533|NCT06112379|DRUG|Paclitaxel|IV infusion Experimental/Active Comparator
40770534|NCT06112379|DRUG|Carboplatin|IV infusion Experimental/Active Comparator
40770535|NCT06112379|DRUG|Capecitabine|Tablet Oral route of administration Experimental/Active Comparator
40770536|NCT06112379|DRUG|Olaparib|Tablet Oral route of administration Experimental/Active Comparator
40770537|NCT04722354|OTHER|Hyperinsulemic euglycemic clamp|Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.
40770538|NCT04722354|PROCEDURE|Muscle Biopsy|One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.
40974188|NCT00948129|OTHER|Tobacco Cessation Counseling|Undergo smoking cessation counseling
41298952|NCT02457338|DIETARY_SUPPLEMENT|Bifidobacterium|
41298953|NCT00909987|DRUG|Capecitabine|PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
41298954|NCT00909987|DRUG|Oxaliplatin|IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)
41298955|NCT00909987|DRUG|Bevacizumab|IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)
41298956|NCT00909987|RADIATION|Radiotherapy|Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).
41298957|NCT00909987|DRUG|Capecitabine during all Radiotherapy period|825 mg/m2 bid
41298958|NCT00909987|PROCEDURE|Total Mesorectal Excision (TME)|4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
41298959|NCT01568190|BIOLOGICAL|AVANZ MITE|Immunotherapy Dermatophagoides mix
41298960|NCT02749487|OTHER|Neutrophil Lymphocyte Ratio|Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.
41298961|NCT03715569|DIAGNOSTIC_TEST|Vestibular function|Vhit, Caloric test
41298962|NCT03715569|DIAGNOSTIC_TEST|OAE/WBT|Oto acoustic emissions Wide Band Tympanometry
41298963|NCT03715569|DIAGNOSTIC_TEST|Biomarker|Biomarker examination
41298964|NCT03715569|DIAGNOSTIC_TEST|MOCA, eGOS|Cognitive tests
41298965|NCT03715569|DIAGNOSTIC_TEST|Audiometry|Hearing test
41298966|NCT04337138|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin (Mylotarg) administered in any form or combination
41459055|NCT01348958|DEVICE|iDXA knee software|"Following surgery, subjects who have undergone knee arthroplasty will have the knee that has undergone arthroplasty (post-operative) scanned at least 8 weeks after surgery.~During one visit, each subject will have the post-operative knee scanned 1 time using Lunar orthopedic application, and 3 times with the subject repositioned between scans using the Lunar orthopedic knee application (total of 4 scans). Lunar iDXA measurement procedures will be done"
41459056|NCT02406287|DRUG|Netarsudil (AR-13324) Ophthalmic Solution|Topical ophthalmic solution
41459057|NCT02406287|DRUG|Netarsudil (AR-13324) Ophthalmic Solution Placebo|Ophthalmic solution once a day
41298967|NCT06350539|OTHER|Biological Sample Collection|Excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
41298968|NCT04200170|DEVICE|Rose|Rose is a patient-centric, mobile mental health platform designed for in-between clinical mental health monitoring in form of mood tracking, clinical surveys and daily journaling. Rose is used as a participant-facing mobile app and clinician-facing dashboard. Each day, they complete mood and anxiety scales and update their journals. Biweekly, they are also asked to complete the PHQ-9 and GAD-7 assessments as well. The Rose mobile app sends timely self-help articles and notifications for users. The curated insights are selected based on participant responses to the daily mood and anxiety surveys, as well as a built-in sentiment analysis of the journaling. The clinical dashboard is a secure, web-based portal that has a unique login for each provider. Providers have access to only their patients through the system and are able to see all the health metrics collected with the Rose mobile app and the summarized metrics produced by our models.
41298969|NCT03333785|BEHAVIORAL|eOncoNote|"* Diagnosis phase: The patient's nurse navigator will initiate an eOncoNote to the patient's PCP, inviting them to send any questions related to the patient's diagnostic process. The nurse navigator will initiate case closure after the diagnostic process has been completed (case will be open up to 4 months).~* Treatment phase: The patient's medical or radiation oncologist will initiate an eOncoNote to the patient's PCP inviting them to ask questions related to the patient's cancer treatment and/or request information related to the patient's co-morbidities. The oncologist will initiate case closure after the treatment has been completed.~* Survivorship phase: The patient's registered nurse within the Wellness Beyond Cancer Program will send an eOncoNote invitation to the patient's PCP inviting them to ask any questions as the patient transitions back to their care. The nurse will initiate case closure after one year."
41298970|NCT00175006|OTHER|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
41298971|NCT00602316|DRUG|gadolinium-chelate|
41298972|NCT00602316|PROCEDURE|conventional surgery|
41459058|NCT00293878|DRUG|Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)|
41298973|NCT00602316|PROCEDURE|magnetic resonance imaging|
41298974|NCT00602316|PROCEDURE|magnetic resonance spectroscopic imaging|
41298975|NCT04990544|BIOLOGICAL|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
40770539|NCT04722354|DIETARY_SUPPLEMENT|Oral abscisic acid (ABA)|Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)
40770540|NCT04722354|OTHER|Placebo|Those in this group will receive placebo (300 mg cornstarch)
40770541|NCT01550510|DRUG|Ascorbic Acid|3x a week for 9 weeks
40770542|NCT01550510|DRUG|Irinotecan|350mg/m2 once a week every 3 weeks
40770543|NCT03457662|COMBINATION_PRODUCT|OMC and pseudo-SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
40974189|NCT05163444|DEVICE|Gait analysis with rolling cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
40974190|NCT05163444|DEVICE|Gait analysis with quadripod cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
40974191|NCT04703335|DRUG|Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution). Following a 14-day restriction period, subjects will be sampled for baseline, 10-minutes, 6-hours, and 24-hours microbial reduction evaluations post-product application. Subjects will not be sequestered for the 6-hour or 24-hour evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and inguen: ≥ 5.0 log10 CFU/cm2.
40974192|NCT04817865|DIAGNOSTIC_TEST|Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)|M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance.
40974193|NCT04817865|DIAGNOSTIC_TEST|Urine Culture|A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods.
40974194|NCT01448278|PROCEDURE|"All-inside"|"The All-inside technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation."
40974195|NCT01448278|PROCEDURE|Classical technique|The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
40974196|NCT03942627|BEHAVIORAL|Mindfulness Program|The intervention consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of mindfulness practices delivered via audio recordings to assist mothers in managing stress during the NICU stay and another series for the transition home.
41146937|NCT05118867|BEHAVIORAL|iPREPARED|iPREPARED is a mobile health technology that can be accessed via the web, tablet, or phone. It contains a preparatory video that outlines what to expect during the hospitalization. Instructional videos and examples are provided for the patient and their recovery partner to use to do their own reorientation, distraction techniques, physical activity, and sleep hygiene.
41298976|NCT04990544|BIOLOGICAL|202-CoV low antigen dose|low dose of 202-CoV with CpG / alum adjuvant
41298977|NCT04990544|BIOLOGICAL|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
41146938|NCT02066389|DRUG|Placebo|Tablets for oral administration
41146939|NCT02066389|DRUG|Upadacitinib|Tablets for oral administration
41298978|NCT04990544|BIOLOGICAL|Placebo|Normal saline solution
41298979|NCT05881551|DEVICE|eEgg|In the eEgg-Arm, patients are given the eEgg immediately before the intervention to familiarize themselves with this method. Here, the patient is asked to press the device with maximum force for five seconds, which would correspond to an NRS value of 10, and to press the eEgg only with half force, which corresponds to an NRS value of 5. Following the instruction, the current pain score present is recorded and documented using the NRS and the eEgg. The same procedure takes place at the end of the 24h observation interval when the eEgg is returned. Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
41298980|NCT05881551|OTHER|NRS|Patients record their pain on the numeric rating scale (NRS) within the 24-hour interval. An interval from 0 to 10 is given (0 = no pain, 10 = most pain imaginable).
41298981|NCT00205504|DRUG|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
41298982|NCT01940757|BIOLOGICAL|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
41298983|NCT03638089|BEHAVIORAL|Fall-recovery training|Participants practice recovering from simulated, treadmill-induced slips and trips.
41298984|NCT01190657|DRUG|Selbex|50mg/day, 3 times/day, for 14 days
41298985|NCT01190657|DRUG|Selbex|50mg/day, 3 times/day, for 56 days
41298986|NCT02027298|DRUG|Abatacept|by SC injection of 125 mg weekly for 6 months
41298987|NCT05157672|DIETARY_SUPPLEMENT|Cinnamon (2 g)|oral capsules, 2 g
41298988|NCT05157672|DRUG|Nicotine gum (2.5 mg)|gum, 2.5 mg
41298989|NCT05157672|DRUG|Letrozole (2.5 mg)|tablet, 2.5 mg
40770544|NCT03457662|COMBINATION_PRODUCT|OMC and SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
40770545|NCT06363708|DRUG|Tislelizumab|Tislelizumab 200mg D1 ,Q3W
40770546|NCT06363708|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 ) D1,Q3W
40770547|NCT06363708|DRUG|Carboplatin|Carboplatin(AUC=5) D1,Q3W
40770548|NCT02788292|DRUG|Acetylcysteine|See arm description
40770549|NCT01836757|DRUG|MethylSulfonylMethane (MSM)|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
40770550|NCT01836757|DRUG|Placebo|
40770551|NCT01817400|OTHER|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
40770552|NCT01817400|DIETARY_SUPPLEMENT|Vascepa - Fish Oil|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
40770553|NCT01817400|DRUG|Aspirin|
40974197|NCT03942627|BEHAVIORAL|Infant Health Education Program|The active control condition consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of audio recordings providing information on infant health and development for mothers to use during the NICU stay and another series for the transition home.
41298990|NCT00763685|DRUG|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
40974198|NCT05241106|DRUG|HYML-122|each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
40974199|NCT02602496|OTHER|Fruits and Vegetables|5 servings of fruits or vegetables
40770554|NCT01817400|DRUG|Pioglitazone|e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
40974200|NCT02602496|OTHER|Whole Grain|3 servings of whole grain
40974201|NCT02602496|OTHER|Control|3 servings of refined grain
41298991|NCT04229446|BEHAVIORAL|Music based caregiving|The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement.
40974202|NCT02893878|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
40974203|NCT03111602|OTHER|restrict polyphenol-rich foods|dietary orientation to restrict polyphenol-rich foods
40974204|NCT02632474|DRUG|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)|The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
40974205|NCT03713970|PROCEDURE|celtra duo press|celtra duo press ingot
40974206|NCT03713970|PROCEDURE|IPS e.max press|IPS e.max press ingot
40974207|NCT05392010|OTHER|no intervention|no intervention
40974208|NCT01109043|DRUG|Bisoprolol or bisoprolol + HCTZ|Film-coated tablets containing 5 mg or 10 mg of bisoprolol hemifumarate or film-coated tablets containing 5 mg of bisoprolol fumarate (2:1) and 12.5 mg of HCTZ were given
40974209|NCT05169749|PROCEDURE|Control-Service Nurse Group|"Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery."
40974210|NCT05169749|PROCEDURE|Nursing Visiting Group|"Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery."
40974211|NCT00000534|DRUG|calcium|
40974212|NCT00000534|BEHAVIORAL|dietary supplements|
41298992|NCT02420964|OTHER|video instruction|Patient Directed Video Instruction
41298993|NCT02420964|OTHER|Nurse instruction|Nurse directed instruction
41298994|NCT04466683|RADIATION|Low dose radiation 35 cGy|A dose of 35 cGy of whole thorax irradiation will be delivered at a single timepoint
41298995|NCT04466683|RADIATION|High dose radiation 100 cGy|A dose of 100 cGy of whole thorax irradiation will be delivered at a single timepoint
41298996|NCT06191354|GENETIC|SKG0201 Injection|SKG0201 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
40974213|NCT04953468|DIAGNOSTIC_TEST|expression level of ANXA2 protein|The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry
40974214|NCT03467191|DRUG|Alcohol|target BAC .08%
40974215|NCT03467191|OTHER|Placebo|placebo beverage
40974216|NCT01929434|OTHER|rehabilitation|Patients only receive rehabilitation of physical therapy and occupational therapy.
40974217|NCT01929434|BIOLOGICAL|stem cell injection|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
40974218|NCT01847794|DEVICE|Cell Search® CTC epithelial kit|"Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
40974219|NCT00462267|BEHAVIORAL|Enriched lifestyle intervention|Multi-component lifestyle intervention
40974220|NCT03053544|DRUG|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1-2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
40974221|NCT01186354|BEHAVIORAL|Receiving results via genetic counselor|participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
40974222|NCT05764759|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
40974223|NCT05764759|BEHAVIORAL|Treatment as usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
40974224|NCT04532164|DRUG|Butenafine HCl 1% (BAY1896425) - Induction Phase|To each of two test sites, approximately 20 μl/cm\^2 of the Butenafine HCl 1% was applied directly to the skin and covered with a 25 mm Hilltop chamber with a Webril pad (2 cm in diameter, within an area of approximately 3 cm\^2), and tape was applied over the chamber to secure the occlusive patch to the skin. On the next day, the chambers were removed and both test sites were lightly wiped. Approximately 2 μl/cm\^2 of Butenafine HCl 1% was reapplied directly to the skin and lightly spread over the treated irradiated test site. The treated non-irradiated test site did not receive a similar reapplication. Between 5 and 15 minutes after application, the treated irradiated test site was irradiated with two times the subject's Minimal Erythema Dose (MED). Evaluation of the test sites occurred two days after the irradiation. This procedure was repeated two times per week for three consecutive weeks for a total of 6 induction exposures per test site.
40974225|NCT04532164|DRUG|Butenafine HCl 1% (BAY1896425) - Challenge Phase|5 μl/cm\^2 of the Butenafine HCl 1% was applied directly to each of the two virgin sites (treated sites) adjacent to the induction patch sites and covered with Hilltop chambers with Webril pad and tape was applied over the chambers to secure the occlusive patches to the skin. Two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Sites were at least 2.5 cm apart. The patches were removed 24 hours later and the sites were lightly wiped. Test sites were evaluated. Butenafine HCl 1% (2 μl/cm\^2) was applied to the treated irradiated site. After 15 minutes, the treated irradiated site and the untreated irradiated site were irradiated with 0.5 MED of UVA/UVB irradiation followed by 10 Joules/cm\^2 of UVA from a xenon arc solar simulator equipped with a Schott WG345 to eliminate UVB radiation. The remaining sites served as the treated non-irradiated site and untreated non-irradiated site.
40974226|NCT05192681|DRUG|Tislelizumab|Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
40974227|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
41459059|NCT05965986|OTHER|Experimental: PREPS only|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative."
40770555|NCT05276856|DRUG|Levothyroxine|"Step 1:~* Reduce the dose of T4 therapy by 50% and recheck serum T4 after 2 weeks.~* If serum T4 is normal, go to step 2.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 2:~* Discontinue T4 therapy altogether and recheck serum TSH and T4 after 2 weeks.~* If serum T4 is normal, go to step 3.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 3:~* Recheck serum TSH and T4 after 8 weeks.~* If serum TSH and T4 levels are normal, these patients will be regarded as having successful T4 withdrawal.~* If T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure)."
40974228|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
40974229|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
40770556|NCT03073512|OTHER|Ultrasound examination|Participants will undergo ultrasound examination at 32 weeks gestation
40770557|NCT04002479|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
40770558|NCT03092518|PROCEDURE|Surgery|Heated Intraperitonial Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitomycin C and sodium thiosulfate
40770559|NCT03092518|DRUG|Cisplatin|Cisplatin (90 mg/m2) will be administered via circuit to the peritoneal cavity
40770560|NCT03092518|DRUG|Mitomycin C|Mitomycin C 10 mg/m2 will be administered via circuit to the peritoneal cavity
40770561|NCT03092518|DRUG|Sodium Thiosulfate|Sodium thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
40770562|NCT05495126|DIAGNOSTIC_TEST|Standard Limbic Access pathway|Relevant information for clinical referral (e.g. demographics) and basic clinical information (e.g. PHQ-9 \& Gad-7 scores) are collected during the self-referral process which is then attached to the referral notes in order to facilitate the clinical assessment conducted by the clinician.
40770563|NCT05495126|DIAGNOSTIC_TEST|Limbic Access with AI pathway|"The same information as in the Limbic Access pathway is collected. However, additional information (i.e. disorder specific questionnaires) are collected for the most likely problem descriptors based on the ML-model predictions.~All information is attached to the referral in order to facilitate the clinical assessment conducted by the clinician."
40770564|NCT03332056|DRUG|Belladonna and Opium|
40974230|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
40770565|NCT03332056|OTHER|Placebo suppository|
40770566|NCT04970966|DEVICE|PuraSinus|A randomized ethmoid cavity in the patient will have PuraSinus applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
40770567|NCT04970966|DEVICE|Bioresorbable Nasal Dressing|PosiSep X will be applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
40770568|NCT02551185|DRUG|ACY-241|
41298997|NCT05784909|DEVICE|rezum|"Technique With the patient in a lithotomy position, after cystoscopy, an RF current is applied to. Water vapour is delivered through a retractable vapor needle via emitter holes in the transurethral device. This is done in 9-second bursts to the transition zone of the prostate, where, via convection, it diffuses evenly throughout the target tissue. The depth of the needle penetrating is approximately 10 mm.~Upon contact with body-temperature tissue, the water vapour then condenses. This phase shift to a liquid state dispenses concentrated energy onto the cell membranes of the target tissue, triggering instant cell necrosis. Overlapping injection sites can be established with repeated applications in order to fully target areas of hypertrophy. Saline flush irrigation is used to both cool the urethra and to promote visualization.~At the end of the procedure Urethral catheter is fixed for 1-3 days."
41298998|NCT04713020|OTHER|Intervention:APP educational programs|Use mobile device education programs to improve disease knowledge and self-efficacy of stroke patients, and reduce depression
41298999|NCT04713020|OTHER|No Intervention:general care|general care
41299000|NCT04160468|DRUG|Exebacase|Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
41299001|NCT04160468|DRUG|Placebo|Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
41299002|NCT06177834|DEVICE|Alisklamp|Alisklamp
41299003|NCT06177834|OTHER|Dorsal slit circumcision technique|In this group, included the patients who will operated with dorsal slit circumcision technique
41299004|NCT04103645|DRUG|Vactosertib|This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
41299005|NCT04604249|DIAGNOSTIC_TEST|SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)|Presence of specific SARS-CoV-2 antibodies (IgM or IgG).
41299006|NCT05847270|PROCEDURE|Anterior and posterior treatment strategy|Before surgery, a large weight traction of 1/6 body weight was used to determine the reversibility of atlantoaxial dislocation. After determining that it is difficult to restore the dislocation, a technique of anterior oral release and posterior fixation fusion was used for reduction, with sequential release of the longus colli and longus capitis, the anterior longitudinal ligament, the blitateral lateral mass joints, the contracted soft-tissue mass between the odotiod and the anterior C1 tubercle, and the peri-odontoid ligaments (i.e., the alar ligaments and the apical ligament), followed by posterior internal fixation and bone grafting was used between C1 and C2 lamina.
40770569|NCT02898038|DIETARY_SUPPLEMENT|AYMES PARIS|AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
41299007|NCT05847270|PROCEDURE|Simple posterior approach treatment strategy|Preceding the surgical procedure, an assessment was conducted utilizing 1/6 weight traction to ascertain the reducibility of atlantoaxial dislocation. Upon confirmation of IAAD, the chosen approach involved the utilization of a specially designed spreader, tailored to the patient's atlanto-axial joint morphology. Upon entering the joint space, the spreaders were skillfully maneuvered to gently open the joint through rotational and prying actions. Subsequently, two cages, pre-filled with autogenous bone grafts, and designed with the appropriate angle and height, were meticulously placed between the Atlanto-axial joints via a posterior approach. This procedure facilitated direct distraction and reduction of the dislocated joint. In the final step of the surgical process, stabilization was achieved by securing the atlas and axis with screws and rods. This surgical approach was selected to address the unique challenges posed by IAAD, with the aim of achieving optimal patient outcomes.
41459060|NCT05965986|OTHER|Experimental: PREPS and therapy|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative. In addition, participants will have a therapist call on week 2 and 4 of the program and then one week after surgery to check in and ensure the patient is meeting all milestones and answer any questions."
41459061|NCT02826395|DRUG|Carbon-11 Sodium Acetate|PET/CT Scans will be performed with or without oral and IV contrast. All investigational scans will be read by at least one board-certified nuclear medicine physician with established expertise in PET/CT of at least 5 years' experience. Fifteen minutes after injection of 11C-Sodium Acetate, we will acquire a scan Emission images will be acquired for 3-5min/bed position. Intravenous and oral contrast will be given for the CT portion of the study.
40770570|NCT05946044|BEHAVIORAL|Diet and Exercise|Group and individual weight loss and weight maintenance sessions combined with exercise throughout the 48 months.
40770571|NCT01565759|DRUG|Lithium Carbonate|"The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.~Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg."
40770572|NCT00922857|PROCEDURE|Respiratory rehabilitation|The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
40974231|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
41459062|NCT02364258|DRUG|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
41459063|NCT02364258|DRUG|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
41299008|NCT05874219|DRUG|Local antibiotic spray Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU|The intervention Sprayed 1 to 3 times /day
41299009|NCT05874219|DRUG|Mupirocin 2% ointment|10 mm of mupirocin ointment squeezed directly on to their exit sites from a 15 g tube with an outlet diameter of 5 mm
40974232|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
40974233|NCT03876444|DRUG|Intravenous Methylprednisolone|Intravenous Methylprednisolone will be used in the intervention group
41459064|NCT02763696|OTHER|Composition of Viginal flora of Child-Bearing women|Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis
40770573|NCT06044571|OTHER|Prescriptive|Prescriptive A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals, Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs), will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs)will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapist: 40 min).
40974234|NCT03876444|DRUG|Oral Pednisolone|Oral Prednisolone will be used in the Control Group
40974235|NCT05806788|BEHAVIORAL|Binge Eating Syndrome Treatment (BESTOW)|The BESTOW program involves discussions as well as written and behavioral activities. Participants will also be asked to complete activities, or 'homework,' in between sessions that will help to stop binge eating and to improve eating habits.
40974236|NCT04783480|OTHER|Birthly|Women will receive a code to sign up for 3 free interactive childbirth education classes through the Birthly platform. They will be enrolled in 3 courses: Prenatal Education, Childcare and Breastfeeding. They will be encouraged to complete all courses prior to 36 weeks gestational age.
40974237|NCT04783480|OTHER|Standard of care|Subjects will participate in childbirth education at their own discretion.
40974238|NCT03957720|DRUG|DMPS|Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
40974239|NCT03957720|DRUG|Penicillamine|Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;
40974240|NCT03957720|DRUG|DMSA|Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
41459065|NCT04411017|PROCEDURE|Endoscopy|Colonoscopy
41299010|NCT04420871|DRUG|150 mg of Xeloda®|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period. 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.The subjects randomly received single oral administration of 150 mg of Xeloda®.
41299011|NCT04420871|DRUG|150 mg of capecitabine|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
41299012|NCT02238028|BEHAVIORAL|Wear respirator|Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
41299013|NCT05154773|BEHAVIORAL|Kidney donation and transplant information made easy|Same as arm description
41299014|NCT05629533|DEVICE|SimpleSense|The study is observational only. No interventions will be triggered by the SimpleSense device
41299015|NCT02030561|DRUG|Trastuzumab + NK cells|
41459066|NCT00000562|PROCEDURE|extracorporeal membrane oxygenation|
41459067|NCT00048139|DRUG|Irinotecan|250mg/m2 iv on day 1 of each 3 week cycle
41459068|NCT00048139|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
41459069|NCT00944190|BEHAVIORAL|Self-management intervention|Brief counseling technique, self-management,
41459070|NCT00944190|BEHAVIORAL|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
41459071|NCT04152356|DRUG|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
41459072|NCT04152356|DRUG|Sorafenib|Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
41299016|NCT04805021|OTHER|no intervention|no intervention
41299017|NCT01655264|BEHAVIORAL|Home-based self training exercises for weak upper extremity|Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
41299018|NCT01655264|BEHAVIORAL|Tele-rehabilitation exercises for weak upper extremity|The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
41299019|NCT04405804|DRUG|Ivabradine 5Mg Tab|"Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 2.5 mg/day in patients between 3-18 years with weight \> 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 15 mg/day in patients between 3-18 years, weight \> 40 kg"
41299020|NCT01221233|OTHER|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) to the low back muscles (i.e. spinal extensors) will be applied at the parameters previously used in the knee muscles at the maximal tolerable intensity, which results in a full, sustained isometric contraction of the back muscles. Pad placement will be just below the waist line, with 2, 2X2 inch pads, on either side of the spine. Participants will be positioned on their belly with 2 pillows under their stomach to level the spine and secured to a table using a belt that crosses the buttock.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
41299021|NCT01221233|OTHER|Moist Heat|"For participants who do not receive NMES, moist heat will be applied for 15 minutes in a position of comfort for the participant.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
41299022|NCT02384499|BIOLOGICAL|ALLO-ASC injection|Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence
40770574|NCT06044571|BEHAVIORAL|Behavioral|Behavioral Health coaches have a bachelor's degree and take a 6-8-week certification program. Behavioral Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.
40974241|NCT03957720|DRUG|Zinc gluconate|Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;
41299023|NCT02384499|DRUG|Placebo|0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
41299024|NCT06302933|BIOLOGICAL|Blood sampling|Blood samples collected from children followed in the Pediacam III ANRS12225 cohort
41299025|NCT02461914|DRUG|PEX168|200µg,injected subcutaneously,once a week.
41299026|NCT02461914|DRUG|Warfarin|5mg,oral,two times.
40770575|NCT03070665|DRUG|Norepinephrine|Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
40974242|NCT01009125|OTHER|$2 cash|$2 cash incentive will be included in the mailed survey
40974243|NCT01009125|OTHER|$5 cash|$5 cash incentive will be included in the mailed survey
41299027|NCT00615940|DRUG|WX-671|capsules taken per os once daily until progression or toxicity
41299028|NCT00615940|DRUG|placebo|capsule taken per os once daily until progression or toxicity
41459073|NCT03084263|PROCEDURE|Arthroscopic Assisted Open Reduction Internal Fixation|Surgical fixation of ankle fractures with use of arthroscopy.
41459074|NCT03084263|PROCEDURE|Open Reduction Internal Fixation|Surgical fixation of ankle fractures.
41459075|NCT05540171|OTHER|Oral health education and instructions/training for self-oral care|Education intervention
40770576|NCT06168344|OTHER|Web-Based Education Program|This study was assessed the impact of a web-based education program provided to mothers of infants with congenital heart diseases on their quality of life and self-efficacy levels
40770577|NCT01150357|DRUG|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
40770578|NCT01150357|DRUG|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
40770579|NCT01150357|DRUG|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
40770580|NCT03868696|PROCEDURE|MUA with sham ultrasound|Standard MUA with sham ultrasound
40770581|NCT03868696|PROCEDURE|MUA with active ultrasound|Standard MUA guided by ultrasound
40974244|NCT05239923|BIOLOGICAL|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
41139883|NCT03030651|BEHAVIORAL|Breastfeeding Education and Support|Women Development Army (WDA) leaders will function as peers for mothers in intervention group. There will be two visits during pregnancy and 8 visits postnatally. During pregnancy, WDA leaders will cover in detail the importance of EBF, feeding colostrum first, and discouraging prelacteal foods and encourage the mother to deliver at the nearby health center. During Postnatal visits, mothers will be observed positioning, attaching, and feeding the new-born, with appropriate feedback provided, solving any BF problems, encourage the mothers to continue exclusive breastfeeding for 6 months, emphasize nutrition for sufficient breast milk to breastfeed successfully and hands-on guidance only when necessary.
41139884|NCT02002689|DRUG|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
41139885|NCT01000649|DRUG|FE 202158 1.25|FE 202158 at dose 1.25 ng/kg/min infused.
41459076|NCT00053339|DRUG|tamoxifen|
41459077|NCT00053339|DRUG|trastuzumab|
41459078|NCT04231292|DRUG|RD01|RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin
41459079|NCT04231292|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
41139886|NCT01000649|DRUG|FE 202158 2.5|FE 202158 at dose 2.5 ng/kg/min infused.
41299029|NCT05221294|DRUG|Modified Del Nido Versus Custodiol Cardioplegia|Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery
41299030|NCT06334393|BIOLOGICAL|VLA1601|0.45mL (milliliter), Day 1 and 29
41299031|NCT06334393|BIOLOGICAL|CpG 1018®|CpG 1018® will be investigated in combination with VLA1601 Low dose
41299032|NCT06334393|BIOLOGICAL|3M-052-AF|3M-052-AF will be investigated in combination with VLA1601 Low dose
41299033|NCT01403740|DRUG|rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin|According to local clinical standards
41299034|NCT05115500|DRUG|ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|RC48-ADC combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2
41459080|NCT04231292|DRUG|placebo|placebo
41459081|NCT01878435|OTHER|SMS reminder|
41459082|NCT01878435|OTHER|Travel subsidy|
41459083|NCT01878435|OTHER|Travel subsidy 2|
41459084|NCT00599105|PROCEDURE|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
41459085|NCT03900013|PROCEDURE|Injectable platelet rich fibrin combined with DFDBA|The i-PRF will be mixed with bone graft then will be placed into the intraosseous defect
41459086|NCT03900013|PROCEDURE|Demineralized Freeze Dried Bone Allograft|Demineralized Freeze Dried Bone Allograft alone will be placed into the intraosseous defect
41459087|NCT00352807|DRUG|Brimonidine Purite|
41459088|NCT00491738|DRUG|bevacizumab|Intravenous repeating dose
41459089|NCT00491738|DRUG|sunitinib|Oral repeating dose
41459090|NCT00491738|DRUG|placebo|Intravenous repeating dose
40770582|NCT06471010|OTHER|Blended Dynamic Interpersonal Therapy (B-DIT)|The B-DIT intervention, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp (http://www.onlinepsyhulp.be), integrates FTF therapy and online modules into a cohesive treatment program for clients with personality pathology. Both FTF and online treatment components are anchored in the Dynamic Interpersonal Therapy (DIT) framework (Lemma et al., 2011).The program spans three phases: an individual phase lasting approximately two months, followed by a five-month group phase, concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases. Both verbal psychotherapy and art therapy are offered as treatment modalities in the face-to-face treatment sessions. The program is implemented by a multidisciplinary team.
40770583|NCT02525198|DIETARY_SUPPLEMENT|fatty acid/flavonoid blend|see arm description
40770584|NCT02525198|DIETARY_SUPPLEMENT|Placebo|see arm description
40770585|NCT06571097|DRUG|Levoﬂoxacin|0.5g/day for 2 weeks
40770586|NCT05341843|DRUG|sertraline|sertraline at the intended dose of 50 mg twice daily for 8 weeks.
40770587|NCT05341843|DRUG|placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
40770588|NCT03802019|OTHER|LNC Cigarettes + Colored Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.
40770589|NCT03802019|OTHER|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive their own preferred brand of cigarette (i.e., control).
40770590|NCT05576649|OTHER|Task difficulty adaptation according to Arvaneh et al. (2019)|The task difficulty in the P300 speller training will be adapted according to Arvaneh et al. (2019).
40770591|NCT05576649|OTHER|Random task difficulty|The task difficulty in the P300 speller training is chosen randomly.
40770592|NCT05576649|OTHER|Task difficulty adaptation according to iterative learning controller|The task difficulty in the P300 speller is determined by an iterative learning controller.
40770593|NCT06323421|BEHAVIORAL|Mindfulness|Participants attend seven 60-90 min group mindfulness sessions each week and a 1/2 day retreat, with three sessions in-person and six sessions remote, led by a mindfulness interventionist. Additionally, participants will be encouraged to engage for at least 30 minutes per week in asynchronous mindfulness activities through a web-based program to increase exposure to mindfulness practices beyond group sessions.
40770594|NCT05454514|DEVICE|HiDO medication adherence platform|The HiDO medication adherence platform will be shipped directly to the home of record of each participant. The Primary Endpoint is medication adherence as assessed by remote observation through the HiDO device at 90 days.
40770595|NCT05454514|DEVICE|Automated Medication Platform with Video Observation|There is no drug intervention. The device elicits increases adherence of medications.
40770596|NCT05454514|OTHER|Time on Task|"Other Endpoints include Time on Task for initial registration, first click testing, facial recognition setup, medication administration, number and type of critical and non-critical errors and error-free rate, System Usability Scale (SUS), and Net Promoter Score."
40770597|NCT05399433|OTHER|Biopsy and venous blood|"A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.~Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis"
40770598|NCT05482295|BIOLOGICAL|Hepatitis B vaccine lot 1|3 doses of Hepatitis B vaccine lot 1
40770599|NCT05482295|BIOLOGICAL|Hepatitis B vaccine lot 2|3 doses of Hepatitis B vaccine lot 2
40770600|NCT05482295|BIOLOGICAL|Hepatitis B vaccine lot 3|3 doses of Hepatitis B vaccine lot 3
40770601|NCT05482295|BIOLOGICAL|Hepatitis B vaccine (registered)|3 doses of Hepatitis B vaccine (registered)
41139887|NCT01000649|DRUG|FE 202158 3.75|FE 202158 at dose 3.75 ng/kg/min infused.
41139888|NCT01000649|OTHER|Placebo|Isotonic saline infused.
40770604|NCT06152926|OTHER|Physical Activity and Exercise in Cancer Immunotherapy Treatment - Exploratory study of experiences and perceptions|"People diagnosed with a urological cancer receiving Immune checkpoint inhibitor treatment at a single centre trust will be invited to either face to face or online video-conference individual interviews (Microsoft teams) according to participant preference.~Consenting participants will be interviewed via semi-structured interview methods round a topic guide and audio-recorded. Inductive thematic analysis will be conducted to explore participant experiences and perceptions of physical activity and exercise."
40770605|NCT05856448|DRUG|GLPG3667|Capsule
40770606|NCT05856448|DRUG|Placebo|Capsule
40770607|NCT01254214|BEHAVIORAL|tMBSR|MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
41299035|NCT01257646|OTHER|Gait analysis|A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
40770608|NCT01254214|BEHAVIORAL|Support group|The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
40770609|NCT04132297|BEHAVIORAL|Asthma Academy|The Asthma Academy is a one hour virtual training that includes providing information about asthma, asthma medications, communicating with healthcare providers and navigating healthcare resources.
40770610|NCT04132297|BEHAVIORAL|Telehealth Visit|The telehealth Visit will be conduct by a trained Doctor of Nurse Practice (DNP) student via a scheduled meeting through zoom on the participant's smart phone or computer. The visit will last about one hour wherein participant will be asked about their asthma knowledge and will be given information about asthma.
41139889|NCT01714908|OTHER|Erlotinib w Concurrent Radiotherapy|
40974245|NCT01650623|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
40974246|NCT01650623|BEHAVIORAL|Gait training alone|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
40974247|NCT04812691|BIOLOGICAL|JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10\^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.
40974248|NCT04887051|OTHER|pulmonory based home exercises|web based telerehablitation
40974249|NCT02435784|OTHER|The Two-Way Communication Checklist|The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.
41299036|NCT01176396|OTHER|Caries prevention active intervention|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) 2x daily Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk In addition to the treatment above the intervention group receives OTC fluoride rinse as well as xylitol candies or gums.~High Caries Risk The high caries risk level subjects will receive a prescription 5,000 ppm F toothpaste, will rinse 1 day for one week per months with a Chlorhexidine rinse to reduce the bacteria level, and receive a fluoride varnish in the dental office."
41139890|NCT01714908|OTHER|etoposide/cis-platin (EP) w Concurrent Radiotherapy|Etoposide / Cis-platin w Concurrent Radiotherapy
41139891|NCT02320097|OTHER|Foot pressure measurement|"Description of the foot pressure measurement:~The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
41139892|NCT01492127|BIOLOGICAL|Blood test|Blood test
41299037|NCT01176396|OTHER|control treatment|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis (if prescribed) Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) as currently used by patient Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk Control group receives regular dental care (placebo rinse and gums without active ingredients allow blinding).~High Caries Risk The control treatment group receives regular dental care (regular 1,100 ppm F toothpaste, a placebo rinse without antibacterial ingredients and placebo varnish to allow blinding)."
41299038|NCT01840176|PROCEDURE|McCall culdoplasty|The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
41299039|NCT05836818|OTHER|Question (Q)|Flu vaccine acceptance question: a question asked of participants about their willingness to accept a flu vaccine
41459091|NCT00919516|PROCEDURE|Bone marrow mononuclear cell implantation|Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
41459092|NCT05421039|BEHAVIORAL|Exposure to unintended injuries|"After taking a verbal consent , an explanation of the study will be given to the caregivers~, those who fulfill the inclusion criteria will be enrolled in the study. Personal interviews by the researcher will be made with individuals or groups (2-4 persons) , participants will be chosen by means of systematic random sampling among visitors ؛ every 3rd or 5th child according to density and flow of attendance .~the investigator will fill the questionnaire through personal interview with the caregivers"
40770611|NCT04434729|DEVICE|Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils|The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix.
40770614|NCT06192420|DRUG|Traumeel®|3g of gel three times daily for 7days (+1 day visit window)
41459093|NCT05219435|DRUG|Nivolumab|Nivolumab at 1 mg/kg by intravenous (IV) infusion on D1 of each cycle. Nivolumab at a fixed dose of 480 mg by intravenous (IV) infusion on D1 of each cycle. The maximum duration of treatment with nivolumab will be 2 years, and patients will discontinue treatment at any time in case of unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
40770615|NCT06192420|DRUG|Diclofenac sodium gel 1%|3g of gel three times daily for 7days (+1 day visit window)
40770616|NCT06192420|DRUG|Placebo|3g of gel three times daily for 7days (+1 day visit window)
40974250|NCT02435784|OTHER|Treatment as usual|Patients will attend a psychiatric consultation as usual.
41299040|NCT05836818|OTHER|Messaging (M)|Flu vaccine educational materials -videos and flyers containing flu vaccine educational information
41299041|NCT02824380|DRUG|DA-4001 H|5% minoxidil / high dose of finasteride
40770617|NCT06309628|DIAGNOSTIC_TEST|Breathe sample|Patients will provide two breathe sample into the Breathe device to see if their VOC patterns can be used to diagnose lung transplant rejection.
40770618|NCT00511199|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year)."
40770619|NCT00511199|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
40770620|NCT05323344|OTHER|Neuro-physiotherapy|Neuro-Physiotherapy will be done in Intervention group I
40770621|NCT05323344|OTHER|Combination of metacognitive behavioral therapy and Neuro-physiotherapy|Combination of metacognitive behavioral therapy and Neuro-physiotherapy will be done in intervention group II
40974251|NCT05806814|BIOLOGICAL|Sipuleucel-T|Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.
40770622|NCT04709393|OTHER|FRAX+SARC-F questionnaire pre-screening|Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
41139893|NCT05051826|OTHER|Resistance training that combines water and land|"Device: Swimmers in the experimental group received resistance training in water for 12 weeks, and the resistance training in the experimental group was divided into 3 categories:Resistance palm and resistance umbrella, resistance suit.~Device: The swimmers in the experimental group underwent core strength training on land for 12 weeks, and the resistance training in the experimental group was divided into 4 types of resistance zones: Swiss ball, medicine ball and drive zone.The combination of two resistance training methods can improve teenagers' swimming performance."
41299042|NCT02824380|DRUG|DA-4001 L|5% minoxidil / low dose of finasteride
41299043|NCT00403117|DRUG|Placebo + Inactive Marijuana (0% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
41299044|NCT00403117|DRUG|Placebo + Active Marijuana (3.27% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.
41299045|NCT00403117|DRUG|Naltrexone 12 Mg+ Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
41299046|NCT00403117|DRUG|Naltrexone 25 Mg + Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
41299047|NCT00403117|DRUG|Naltrexone 50 Mg+ Active Marijuana (3.27% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
41459094|NCT05219435|DRUG|Ipilimumab|Ipilimumab at 3 mg/kg by intravenous (IV) infusion on D1 of each cycle.
40770623|NCT05996120|PROCEDURE|Hypothermic Cardiopulmonary Bypass|Mild hypothermia (between 32 - 35 °C) during cardiopulmonary bypass
40770624|NCT05996120|PROCEDURE|Normothermic Cardiopulmonary Bypass|Normothermia (active maintenance of temperature between 36.5 °C to 37.5°C; no active cooling below 36.5 °C) during cardiopulmonary bypass
40770625|NCT06340269|DEVICE|MEX-CD1 Dialysis|"MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in Slow low-volume continuous veno-venous hemodialysis. One treatment will last 3 hours and 20 minutes.~Patients enrolled are hospitalized in Intensive Care Unit."
40770626|NCT02749916|OTHER|Methods of carotid wall imaging|
40770627|NCT06500585|OTHER|Mill's Manipulation|"Mill's Manipulation: The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5 min.~Stretching of Wrist Extensors: 15 sec hold, 10 stretches/session/day. Wrist extensors Isometric: resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks."
40974252|NCT00327249|DRUG|imexon|
40974253|NCT04472195|OTHER|Simulation Airway Coaching|Airway coaching on laryngoscopy technique for intubation of neonates/infants within 1 hour of case utilizing RCDP simulation technique.
40974254|NCT01224431|DRUG|Buffered Lidocaine J-tip|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
40770628|NCT06500585|OTHER|Mill's Manipulation and Muscle Energy Technique|"Mill's Manipulation:The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Muscle Energy Technique: Extensor carpi radialis stretch for 30 sec repeated 5 times during a single treatment session. Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5min.~Stretching of Wrist Extensors, 15 sec hold, 10 stretches/session/day. Wrist Extensors Isometric, resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks."
40974255|NCT02257944|BEHAVIORAL|Motivational Interviewing|Brief hospital-based intervention, rooted in motivational interviewing
40974256|NCT02257944|OTHER|Treatment as Usual|treatment as usual
40974257|NCT04922437|PROCEDURE|Native bladder implantation|Continent catheterizable channel implanted in the detrusor of the native bladder
41299048|NCT00403117|DRUG|Naltrexone 100 Mg+ Active Marijuana (3.27% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
41299049|NCT00403117|DRUG|Naltrexone 12 Mg + Inactive Marijuana (0% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
41299050|NCT00403117|DRUG|Naltrexone 25 Mg + Inactive Marijuana (0% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
41299051|NCT00403117|DRUG|Naltrexone 50 Mg + Inactive Marijuana (0% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
41459095|NCT02156453|PROCEDURE|Total knee arthroplasty|All patients will undergo total knee replacement using midvastus approach by single surgeon.
40770629|NCT00934921|DRUG|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
40770630|NCT00934921|DRUG|Zofran®|1 x 8 mg ODT
40770631|NCT01161966|DRUG|Zonisamide|Zonisamide capsules 100 mg
40770632|NCT01161966|DRUG|Zonegran|Zonegran Capsules 100 mg of EISAI INC
40974258|NCT04922437|PROCEDURE|Enterocystoplasty implantation|Continent catheterizable channel implanted by seromuscular plicature on the front wall of the bladder augmentation
40974259|NCT00292266|DRUG|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
40974260|NCT00292266|DRUG|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
40974261|NCT01682057|DEVICE|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
41139894|NCT00540566|DEVICE|Optical Biopsy imaging|Optical Biopsy imaging
41139895|NCT02364648|DIETARY_SUPPLEMENT|MitoQ|Mitochondria targeted antioxidant
41139896|NCT02364648|DIETARY_SUPPLEMENT|Placebo|Placebo
41139897|NCT05291403|OTHER|Medical thoracoscopic cryotherapy combined with standard first-line therapy for advanced non-cell lung cancer|"Medical thoracoscopic cryotherapy: medical thoracoscopy biopsy hole insert bendable freezing probes, place the frozen probe placed in the center of the tumor at the top will be frozen carbon dioxide gas source pressure adjustment to the bar of 50-60 bar, tread down switch, foot pedal to start the probe, after about 30 s at the top of the probe to form a ice hockey, local tissue after frozen white, sometimes a small amount of bleeding; Fix the probe, loosen the pedal, and wait 30 seconds for automatic melting and rewarming (bleeding probability is low after full rewarming). Freeze 5 to 10 at a time.~In addition, all patients were treated with standard first-line regimens according to guidelines of non small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) scores."
41139898|NCT05291403|OTHER|Sequential intrathoracic injection of cisplatin/erythromycin combined with standard first-line therapy for advanced non-cell lung cancer|"The pleural effusion was fully drained and cisplatin 40mg/m2 was given, dissolved in 100mL 0.9% sodium chloride (NaCl) solution 100 mL, then injected into the pleural cavity and retained for 24 hours. Erythromycin was sequentially injected into the thorax to seal the pleural cavity.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
41139899|NCT05291403|OTHER|Standard first-line therapy for advanced non-cell lung cancer without intrathoracic treatment|"Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
41139900|NCT04699578|DIAGNOSTIC_TEST|Covid-19 positive|All pregnant women at any stage of pregnancy afferent to obstetrics services who tested positive in confirmation tests by nasopharyngeal swab for viral RNA detection through real-time reverse transcriptase - polymerase chain reaction (rRT-PCR) will be included.
41139901|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2.5 grams
41139902|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
41139903|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
41299052|NCT00403117|DRUG|Naltrexone 100 Mg + Inactive Marijuana (0% THC)|One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
40770633|NCT04408612|DIAGNOSTIC_TEST|Scales for assessment of symptoms|"Medical Research Council Dyspnea scale, the visual analogue scale of dyspnea, Borg scale, modified dictionary of dyspnea, G. Rose questionnaire, Seattle Angina Questionnaire, Framingham criteria for chronic heart failure, the SHOCK scale."
40974262|NCT01682057|DEVICE|ROX Anastomotic Coupler System (ACS)|
40974263|NCT03092609|BEHAVIORAL|Attention Bias Modification|Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
40770634|NCT04196621|DEVICE|High viscous artificial tears|Instillation of one drop high viscous artificial tears
40770635|NCT04196621|DEVICE|Low viscous artificial tears|Instillation of one drop low viscous artificial tears
40770636|NCT05085366|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline)
41299053|NCT02413398|DRUG|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
41299054|NCT02413398|DRUG|Matching Placebo for Dapagliflozin|Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
40770637|NCT05085366|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
40770638|NCT04805593|DEVICE|WaveLight EX500 excimer laser system|FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the Wavefront Optimized (WFO) Ablation profile of the WaveLight EX500 excimer laser system will be used for bilateral LASIK treatment of hyperopia with and without astigmatism.
40770639|NCT04805593|PROCEDURE|LASIK|Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system.
40770640|NCT04748237|DIAGNOSTIC_TEST|Coronary computed tomopraphic angiography|CCTA as soon as possible, preferably within 24 hours, but not later than within 21 days.
41459096|NCT03680261|RADIATION|chemoradiotherapy|CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
40770641|NCT04477512|DRUG|Cabozantinib|Supplied by Exelixis
40770642|NCT04477512|DRUG|Nivolumab|Supplied by Bristol-Myers Squibb
41459097|NCT03680261|DRUG|chemotherapy|CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
40770643|NCT04477512|DRUG|Abiraterone acetate|Commercially available
40770644|NCT04477512|DRUG|Prednisone|Commercially available
41139904|NCT06050850|BEHAVIORAL|NOURISH-ALL|Our NOURISH-ALL intervention will build on this existing NOURISH-T family based behavioral intervention with families of cancer survivors. The intervention, NOURISH-ALL, will adapt these family-based health promotion strategies to the early ALL treatment context.
41139905|NCT00000617|DRUG|azithromycin|
40770645|NCT04477512|PROCEDURE|Peripheral blood collection|Prior to start of treatment, after 8 weeks of combination therapy, with every subsequent imaging (every 12 weeks), end of treatment
40770646|NCT06460376|OTHER|Wurn Technique|"Treatment:~Site-specific pressures for 30 seconds across the restrictive bands of adhered tissues and structures, working progressively deeper from the most superficial tissues Traction: focusing on these adhered areas, engage the uterine fundus and sidewalls and traction them to the left.~To assist and improve the mobility of the soft tissues, release the traction tension either suddenly or gradually, depending on the desired effect to decrease spasms and adhesions between the uterus and the bladder. The baseline treatment was moist heat.~Each therapy session was 30 minutes for 6 weeks and 2 sessions per week. 10 minutes for baseline treatment."
40770647|NCT06460376|OTHER|Mercier Therapy|"Treatment:~The patient lay face up on a massage or exam table. Feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles.~Manual poking, pressing, and massage actions do three things:~Reveals visceral adhesions. Find tender spots. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that make up fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely.~Abdominal massage with pressing, deep strokes, and friction. The baseline treatment was moist heat. Each therapy session was 25 minutes for 6 weeks and 1 session per week. 10 minutes for baseline treatment"
40770648|NCT06307457|DRUG|Palbociclib in combination with AI|Patients with HR+/HER2- locally advanced or metastatic breast cancer treated with palbociclib in combination with AI as first-line treatment, in Denmark.
41299055|NCT04280601|DIETARY_SUPPLEMENT|vitamin D|Patients with insufficient and/or deficient vitamin D status (\<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months
41299056|NCT01414088|OTHER|isotonic saline 0,9 mg/ml|infusion, 23 ml/kg, during 50 minutes
41299057|NCT01414088|OTHER|hypertonic saline 2,9 mg/ml|infusion, 7 ml/kg, during 50 minutes
40770649|NCT05426083|OTHER|Physiological Assessment|Observational only
40770650|NCT01798225|DRUG|Placebo|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
40770651|NCT01798225|DRUG|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
40770652|NCT03440411|DRUG|Pomalidomide|4 mg/daily as oral administration (PO) on days 1-21.
41299058|NCT01414088|OTHER|glucose 5%|infusion, 23 ml/kg, during 50 minutes
41299059|NCT01123278|DRUG|Testosterone|Testosterone transdermal gel 50 mg/day (5 gr)
41459098|NCT00246792|BEHAVIORAL|Group treatment|
41299060|NCT01123278|DRUG|Placebo|Placebo transdermal gel (5 gr)
41299061|NCT03711552|OTHER|ObsQoR-11|Quality of recovery questionnaire
40974264|NCT03092609|BEHAVIORAL|Attention Control|Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
40974265|NCT02279901|BEHAVIORAL|Telemedicine Education|"Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:~1. OSA program~2. CPAP program~Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor."
40974266|NCT02279901|BEHAVIORAL|IVR|"Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.~Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform."
40974267|NCT02612324|BEHAVIORAL|Pono Choices|Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
41299062|NCT03711552|OTHER|QoR-15|Quality of recovery questionnaire
41299063|NCT05547763|PROCEDURE|surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates|under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.
41299064|NCT06112340|DRUG|linsitinib|Study medication taken twice daily by mouth
41299065|NCT05239286|PROCEDURE|General anaesthesia|"All patients in supine position will receive breathing 100% oxygen, induction of anaesthesia will be achieved using propofol (2 mg/Kg), 1-2 mcg/kg of fentanyl and atracurium (0.5 mg/Kg). Endotracheal tube will be inserted after 3 minutes of mask ventilation. Patients who will experience prolonged airway instrumentation due to a difficult intubation will be excluded from further data analysis because of excessive stimulation. Then mechanical ventilation will be performed using a tidal volume of 6-8 mL/kg of ideal body weight at an inspiratory to expiratory ratio of 1:2 without positive end-expiratory pressure. The ventilatory frequency will be adjusted to maintain an end-tidal carbon dioxide tension of 35-40 mmHg.~Anaesthesia will be maintained by isoflurane (1-1.5%), atracurium 10 mg intravenous increments every 20 minutes and morphine 0.1 mg/kg intravenous will be given as a long acting analgesia."
41299066|NCT05239286|DRUG|Conventional fluid managment|Ringer solution at the dose of 5 ml/kg/h infused throughout the surgical procedure by taking the parameters such as Heart rate (HR), mean arterial pressure (MAP) and urine output, Hypotension was defined as a condition in which the MAP was below 30% of the baseline MAP of the patient. In this case, bolus of 250 ml crystalloids (0.9% NaCl) was given and in case of hypotension persistence, 5 mg I.V. ephedrine administered and repeated every 5 min till the MAP increased over 70% of baseline.
40974268|NCT02612324|BEHAVIORAL|Business as Usual|Teen pregnancy and STI prevention education left to the discretion of the school.
40974269|NCT00499876|DRUG|mefloquine|250mg weekly PO for 6 months
41299067|NCT05239286|DRUG|PVI dependant goal directed fluid therapy|"After the induction of anesthesia, Ringer solution infused at the dose of 2 ml/kg/h started as a basal rate of infusion. If the PVI was higher than 13% for more than 5 min, a 250-ml bolus of crystalloids administrated. If the PVI was still higher than 13% after the bolus, it was repeated every 5 min until the PVI was less than 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~In the cases where PVI was less than \< 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~Then the patient was turned to prone position and the same steps according to Massimo readings were repeated."
40974270|NCT00499876|OTHER|placebo|1 tablet weekly PO for 6 months
40974271|NCT00959621|DRUG|Aspirin|ASA 100 mg once daily per os
40974272|NCT00959621|DRUG|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
40974273|NCT00959621|DRUG|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
41459099|NCT03005834|OTHER|incidence of cancers|With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.
41459100|NCT00569777|DEVICE|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
40974274|NCT00298051|PROCEDURE|Delayed umbilical cord clamping|
40974275|NCT04323787|OTHER|observational|No Intervention
41459101|NCT00569777|DEVICE|Placebo Lens|contact lens without drug
40770653|NCT03440411|DRUG|Cyclophosphamide|50 mg every other day as oral administration (PO) on days 1-28
41459102|NCT04985838|BEHAVIORAL|HEADS: UP (Helping Ease Anxiety and Depression)|A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered online using a video communication platform. An introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course. Course materials include a manual (provided after the introductory session), weekly pre/post-session emails with instructions and information about joining the sessions and engaging in personal practice, including links to audio files to complement class-based sessions.
40770654|NCT03440411|DRUG|Dexamethasone|40 mg as oral administration (PO) on days 1, 8, 15, 22.
40770655|NCT02558868|DRUG|Irinotecan|
40770656|NCT02558868|DRUG|Oxaliplatin|
40770657|NCT02956473|DEVICE|Supine MRI|
40770658|NCT02956473|OTHER|Neoadjuvant Therapy (NAT)|
41139906|NCT04958265|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing =\> 40 to \<100 kg) or 1500 mg IV (for participants weighing \>=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing =\> 40 to \<100 kg) or 1020 mg SC (for participants weighing \>=100 kg). Enrollment of participants weighing \<40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing \>=20 kg to \<40 kg, followed by Group 2 participants weighing \>=5 kg to \<20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.
41139907|NCT03234010|OTHER|FT21092|An electronic cigarette
41139908|NCT03234010|OTHER|FT21093|An electronic cigarette
41139909|NCT03234010|OTHER|FT21096|An electronic cigarette
41139910|NCT03234010|OTHER|FT21097|An electronic cigarette
41139911|NCT01726998|OTHER|Robot-assisted gait therapy|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
41139912|NCT01726998|OTHER|conventional gait training|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
41139913|NCT02442622|OTHER|Occupational therapy|Occupational therapy for de Quervain's Tenosynovitis
41139914|NCT02442622|DEVICE|Occupational therapy with ASTYM|Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
41139915|NCT02412540|BEHAVIORAL|Comprehensive Lifestyle Intervention|Dietary, behavioral and activity interventions designed to reduce weight.
40770659|NCT02956473|DEVICE|Ultrasound|
40770660|NCT02956473|DEVICE|Mammography|
40770661|NCT02956473|PROCEDURE|Standard of Care|
40770662|NCT02956473|DEVICE|Standard MRI|
40770663|NCT05997901|OTHER|Varenicline healthbot|The intervention is a healthbot that will provide information, reminders, answers to questions, and support to participants using varenicline for smoking cessation.
40770664|NCT05648214|DRUG|ALN-PNP - Part A|Administered by subcutaneous (SC) single ascending dose (SAD)
40770665|NCT05648214|DRUG|ALN-PNP - Part B|Administered by SC parallel single dose
40974276|NCT01429753|OTHER|Advanced Imaging Guided LV lead placement|Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
40974277|NCT01429753|DEVICE|Standard LV lead placement|Standard LV lead placement not guided by advanced imaging
40974278|NCT01543698|DRUG|LGX818|
40974279|NCT01543698|DRUG|MEK162|
40974280|NCT01543698|DRUG|LEE011|
40974281|NCT05420077|BIOLOGICAL|RVM-V001 10 µg|Low Dose
40974282|NCT05420077|BIOLOGICAL|RVM-V001 30 µg|Mid Dose
40974283|NCT05420077|BIOLOGICAL|RVM-V001 60 µg|High Dose
40974284|NCT01874054|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
40974285|NCT01874054|DRUG|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
40974286|NCT06013865|DRUG|Empagliflozin|SGLT2 Inhibitor
40974287|NCT02272491|DEVICE|ZrO2 (Straumann CARES)|"1. Straumann CARES Variobase Abutment RN~2. Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
40974288|NCT02272491|DEVICE|PFM crown (Straumann Gold)|Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
40974289|NCT02671396|BEHAVIORAL|Virtual reality based intervention|Virtual reality based balance training
40974290|NCT02671396|BEHAVIORAL|Conventional intervention|Conventional balance training
40974291|NCT04860453|GENETIC|WES via Illumina NextSeq 550 sequencing system|Sequencing will be performed on an Illumina sequencing system
40974292|NCT04860453|DIAGNOSTIC_TEST|Blood Draw|Blood draw will be via any University Hospitals Laboratory site and sent at room temperature via courier to the Center for Human Genetics (CHG) Laboratory
40974293|NCT04860453|DIAGNOSTIC_TEST|Skin biopsy|Skin samples obtained via 3mm punch biopsy will be suspended in cell culture media prepared per CHG routine and sent via courier to the Center for Human Genetics Laboratory
40974294|NCT04860453|DIAGNOSTIC_TEST|Saliva Sample|Participant will provide a saliva sample which be shipped to University Hospitals Laborator site at room temperature
40974295|NCT01786798|DEVICE|Transvaginal sonography|"Transvaginal sonography will be performed to:~* measure the endometrial thickness~* detect the endometrial pattern"
40974296|NCT04186039|DIAGNOSTIC_TEST|Functional magnetic resonance imaging - Blood Oxygenation Level Dependent|"First Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence under ambient air.~Oxygenation of 5 minutes at a rate of 12 l / min. Second Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence."
40974297|NCT02279420|DEVICE|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
40974298|NCT00952679|DEVICE|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
40974299|NCT05833789|DEVICE|Magnetic Flexible Endoscope (MFE)|After colonoscopy has been completed with the legacy colonoscope, the MFE will be introduced into the colon and traverse from the rectum to the cecum.
40974300|NCT04937491|DEVICE|New medical device (ReBalans)|Body worn, battery powered bioimpedance measuring patch device.
40974301|NCT05812612|DRUG|ursodeoxycholic acid|To study the incidence of COVID-19 infection and COVID-19 pneumonia in patients with autoimmune liver disease treated by UDCA, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
40974302|NCT00540826|DRUG|Atomoxetine|in-label use
40974303|NCT00540826|DRUG|stimulants (any approved ADHD medication)|in-label use
40974304|NCT02940977|OTHER|Blood draws|Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
40974305|NCT01947205|DRUG|paracetamol|
40974306|NCT01947205|DRUG|dexketoprofen trometamol|
40974307|NCT01947205|DRUG|suction curettage|
40974308|NCT01947205|DRUG|suction curettage|
40974309|NCT01947205|OTHER|without drug|
40974310|NCT06300060|DIETARY_SUPPLEMENT|Synbiotic|Combination of a probiotic and prebiotic. Daily administration in a single dose in powder form.
40974311|NCT06300060|DIETARY_SUPPLEMENT|Placebo|Placebo. Daily administration in a single dose in powder form.
41299068|NCT04413240|DEVICE|Telerehabilitation|"* VRRS is a medical device to perform cognitive telerehabilitation and home speech therapy in online or offline mode.~* K-Wand is an additional device to VRRS for motor telerehabilitation of the upper limb and trunk. It works with a set of motion sensors through light recognition technology.~* Khymu is a set of sensors added to the VRRS used to carry out motor telerehabilitation activities of the lower limb. The use in combination with the K-Wand is able to allow full-body motor telerehabilitation.~Patients will have at their home a special workstation connected to the internet. The same equipment will also be present in the reference structure. Only the online telerehabilitation mode will be used, including an audio and video teleconference. The rehabilitator will be able to remotely control the patient's system. The patient, will see on his screen the exercises to be performed, their realization and the results achieved."
41459103|NCT02109458|DEVICE|Navigation guided bronchoscopy|Navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB); guidance system is by Veran Medical Technologies, Inc.
40974312|NCT03576924|BEHAVIORAL|MICT|Individuals randomized to MICT will be asked to engage in only MICT 5 times/week for 30 min/session at 60-70% of heart rate max, consistent with physical activity guidelines of 150 min/week of moderate activity. Individuals are asked to engage in only MICT exercise during the 4-week supervised and unsupervised exercise sessions. During the supervised exercise the intensity will be based on the heart rate (HR) monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
40974313|NCT03576924|BEHAVIORAL|HIIT|Individuals randomized to HIIT will be asked to engage in only HIIT 5 times/week for 4 weeks. HIIT consists of 5 repeated vigorous intervals of 1-min duration at 80-90% of heart rate max interspersed with 1-min recovery periods. A 3-min warm-up and 2-min cool-down are also included, for a total session duration of 15 minutes. This matches the guidelines of 75 min of vigorous exercise per week. During the supervised exercise sessions, intensity will be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
41299069|NCT04413240|OTHER|Conventional rehabilitation|It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated.
41299070|NCT03952546|DEVICE|Saline-coupled Bipolar Sealer|The Aquamantys® System is a commercially available device used routinely used in the operating room for a wide variety of surgical cases. It allows for temperatures to stay at approximately 100°C, nearly 200°C less than conventional devices, which produces a tissue effect without the charring associated with other methods. The temperature is sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels, resulting in the reduction in bleeding from both soft tissue and bone. The device can be used to spot coagulate vessels that are actively bleeding or to broadly paint tissue surfaces to prevent bleeding or treat active oozing.
41299071|NCT03952546|DEVICE|Unipolar electrocautery|The Coviden ForceTriad™ energy platform is a full-featured electrosurgical system that provides electrosurgical cutting and coagulation, bipolar functionality, and vessel sealing in a single generator.
41299072|NCT02876224|DRUG|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
41299073|NCT02876224|DRUG|Bevacizumab|Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
41459104|NCT04566549|COMBINATION_PRODUCT|Test group Probiotic Shampoo|Probiotic Shampoo
41459105|NCT04566549|COMBINATION_PRODUCT|Placebo group|Shampoo base
41459106|NCT04823533|DIETARY_SUPPLEMENT|Probiotic-placebo supplement|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
41459107|NCT03915977|BEHAVIORAL|Post ICU recovery program|Standardized follow up program
41459108|NCT03910049|DRUG|Indocyanine Green|Indocyanine green will be administered intravenously to patients enrolled in this study after the completion of total thyroidectomy in order to assess the visibility of parathyroid glands and to assess the possible correlation of ICG score with post-operative parathormone levels in order to predict post-thyroidectomy hypoparathyroidism.
41459109|NCT03350191|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
41459110|NCT03350191|DRUG|[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
41459111|NCT03350191|DRUG|[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
41459112|NCT00001239|DRUG|FLAC with GM-CSF|
41459113|NCT03045822|DRUG|Bioimpedance analysis|
41459114|NCT00268164|DRUG|lactobacilus acidophilus & bifidobacterium animalis/lactis|
41459115|NCT04055233|DRUG|Polihexanide; Serasept|"Experimental arm: irrigation of subcutaneous tissue after fascia closure with polihexanide (ten minutes).~A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
40974314|NCT03576924|BEHAVIORAL|CHOICE|Participants will first be familiarized with HIIT and MICT in a randomized, counter-balanced order during supervised sessions 1 and 2, and will subsequently self-select the exercise type for the supervised and unsupervised exercise sessions. The HIIT and MICT protocols will match to the parallel imposed conditions. During the supervised exercise, intensity will also be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
40974315|NCT02612974|BIOLOGICAL|Hirudinaria granulosa, qurse mafasil|compare the efficacy of both groups
40974316|NCT03233503|DIAGNOSTIC_TEST|Basic taste, fat sensation and texture perception|"This is an observational Sensory study methodologically similar to Astringency and bitterness perception clinicalTrials.gov identifier NCT03171402 Participants are first involved in sensory training sessions that train how they recognise between different basic tastes and differentiate perceived intensity in solutions and foods. After 6 months of training, the trained participants are involved in tasting a wide array of commonly consumed foods. At this study phase, participants will rate for the foods' taste, fat sensation perception and texture"
40974317|NCT01116011|DRUG|AZD7268|Capsule, Oral, BID
40974318|NCT01116011|DRUG|Placebo|Capsule, Oral, BID
40974319|NCT03867292|OTHER|Myofascial|"The aim of the application of the crossed hands technique is to produce a deep fascial release, placing the subject in prone position, while the standing physiotherapist will contact with one hand on the spine at the level of the thoracolumbar hinge and with the other hand on the sacrum, so that the hands are crisscrossed. The crossed hands technique will be performed between 90 seconds and 5 minutes.~The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally."
40974320|NCT03867292|OTHER|Electrotherapy|The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally.
40974321|NCT04560296|BEHAVIORAL|Community-based E-Health Program|Community-based E-Health Program will be developed to engage and empower older adults to manage the chronic conditions effectively.
40974322|NCT04560296|BEHAVIORAL|usual self-management and follow up with doctors/nurse|usual self-management and follow up with doctors/nurse as planned in the community nurse post.
40974323|NCT01760707|BEHAVIORAL|exercise training|
40974324|NCT01760707|BEHAVIORAL|usual care|
40974325|NCT03254004|DRUG|Pembrolizumab|pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
40974326|NCT05712928|BEHAVIORAL|Dance/movement therapy (eMove)|Ten weekly 60-minute individual dance/movement therapy telehealth sessions (eMove) delivered by a board-certified dance/movement therapist. eMove treatment protocol integrates movement techniques, creative embodiment, the non-verbal aspects of self-awareness and interpersonal communication in treatment. eMove sessions focus on helping the participant to increase physical activity level, increasing participants' energy levels and motivation to stay active and better cope with everyday activities, improving overall functioning; reducing severity of negative symptoms of schizophrenia; and providing participants with a sense of connection and social support by connecting with a therapist. In addition, sessions are individualized to the participant's presenting needs.
40974327|NCT06287411|DIAGNOSTIC_TEST|FAPI PET/MR combined with gadoxetate disodium|Patients with clinical suspected hepatic malignancies will receive the FAPI PET/MR.
40974328|NCT04120545|DEVICE|Microcurrents|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7, L3 or S1.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
41466563|NCT02672969|DEVICE|RapidVac Smoke Evacuator|"The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).~Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas)."
40770666|NCT05648214|DRUG|Placebo (PB)|Administered by SC injection
40770667|NCT04138355|OTHER|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
40770668|NCT00938574|DRUG|Atu027|
40770669|NCT06194838|DEVICE|Ossur Power Knee|Newest version of the commercially-available powered knee developed by Ossur.
40770670|NCT06194838|DEVICE|Reboocon Intuy Knee|Commercially-available powered knee developed by Reboocon.
40974329|NCT04120545|DEVICE|Placebo Microcurrents|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
41299074|NCT02876224|DRUG|Cobimetinib|Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
41299075|NCT03757481|OTHER|no intervention|SF-36 questionnaire , PembQoL, Villalta score ,PembQoL
41299076|NCT00505700|DRUG|velcade|
40974330|NCT06131177|DIETARY_SUPPLEMENT|Nutritional supplement|Protein supplement
41299077|NCT00505700|DRUG|Idarubicin|
41299078|NCT00505700|DRUG|Cytarabine|
41299079|NCT04712578|DIETARY_SUPPLEMENT|Caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse caffeinated pre-workout supplement (Legion Athletics, Inc.).
41299080|NCT04712578|DIETARY_SUPPLEMENT|Non-caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse non-caffeinated pre-workout supplement (Legion Athletics, Inc.).
41299081|NCT04712578|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of consuming a standardized meal followed by a placebo beverage.
41299082|NCT02148458|OTHER|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
41299083|NCT02148458|OTHER|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
41299084|NCT01543464|DRUG|Chemotherapy: Temozolomide|Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
40974331|NCT04567225|DRUG|Early Glargine|A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion
40974332|NCT04567225|DRUG|Late Glargine|A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.
40974333|NCT04567225|OTHER|IV insulin infusion|Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol
40974334|NCT04567225|OTHER|IV fluid and electrolytes replacement|The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
40974335|NCT04445545|DEVICE|High intensity laser therapy (HILT)|Laser application with powers greater than 500 milliwatts (mW) in the myofascial trigger point and muscle belly of the upper trapezius. Laser therapy will be applied to the upper trapezius muscle with a total energy delivery of 1,060J divided into 3 phases will be achieved (phase 1, 500J; phase 2, 60J; phase 3, 500J). It will work with an average power of 3W and an energy density of 50J/cm2. For the application of laser therapy, the 12W BTL-6000 equipment that emits infrared wavelengths of 1064nm will be used.
40974336|NCT04445545|DEVICE|Therapeutic Ultrasound (US)|Application of ultrasound therapy in the myofascial trigger point of the upper trapezius muscle. The ultrasound application will be performed with the person in a seated position. The ultrasound parameters will consist of a frequency of 1MHz, the intensity of 1.5 W/cm2, a Duty cycle of 100%, an ERA of 5cm2, and a treatment time of 6 minutes.
40974337|NCT04445545|PROCEDURE|Stretching exercise|t the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series
40974338|NCT03853265|BEHAVIORAL|Simulated dental office visit|An immersive first-person point of view (POV) video simulation of the dental office in the three-dimensional environment (using a virtual reality headset) which allows participant to look around the room as they move down the hallways which is to be watched/experienced by the participant as often as possible between the initial visit and the follow up visit
41299085|NCT04618393|BIOLOGICAL|EMB-02|EMB-02 is a FIT-Ig® bispecific antibody against PD-1 and LAG-3.
41299086|NCT00887718|BIOLOGICAL|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
41299087|NCT06041698|OTHER|Planned Notification|Receive text notification
41299088|NCT06041698|OTHER|Survey Administration|Complete surveys
41299089|NCT06041698|BEHAVIORAL|Behavioral Intervention|Participate in TXT-Chatbot
41299090|NCT06041698|OTHER|Electronic Health Record Review|Ancillary studies
41299091|NCT06041698|OTHER|Interview|Ancillary studies
41299092|NCT06041698|OTHER|Survey Administration|Complete surveys
41299093|NCT06041698|OTHER|Planned Notification|Receive email notification
41299094|NCT06041698|BEHAVIORAL|Behavioral Intervention|Participate in MyChart/Patient Portal
41299095|NCT06041698|OTHER|Electronic Health Record Review|Ancillary studies
41299096|NCT06041698|OTHER|Interview|Ancillary studies
41299097|NCT00628511|DEVICE|ARES (Apnea Risk Evaluation System)|application of portable monitoring device with PSG
41299098|NCT03930212|DRUG|Progesterone|received rectal progesterone suppositories 400 mg once daily
41299099|NCT03930212|DRUG|Placebos|received placebo suppositories rectally once daily.
41299100|NCT03415919|OTHER|no intervention will be given to patients.|samples are collected at the time of a scheduled procedure that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
41299101|NCT01467908|DEVICE|Navigated transcranial magnetic brain stimulation|Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
41299102|NCT02520804|DRUG|sterofundin|sterofundin for shock patients in the first 72 hours
41299103|NCT02520804|DRUG|normal saline|Normal saline for shock patients in the first 72 hours
41466564|NCT01488240|PROCEDURE|pulsed dye laser|laser energy
41466565|NCT01970917|DEVICE|Olixia pure eye drops|
41466566|NCT01970917|DEVICE|Placebo|0.9% physiological saline solution
41299104|NCT03586843|DRUG|JNJ-64565111|JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
41299105|NCT04687202|OTHER|follow up and record|None additional intervention was applied to the subjects.
40974339|NCT04077645|BEHAVIORAL|Sun salutations|This group will be asked to participate in 25 minutes of low-to-moderate intensity Yoga. This acute session will include engaging in sun salutations, breathing exercises and relaxation. Sun salutations involves performing 10 postures in a particular sequence, and then repeating that sequence. Some of the positions include bending over and touching one's toes, and lying belly-down on the ground and pushing up from ground while arching backwards. The activity will begin as a low intensity activity for the first 5 minutes, and the intensity will be gradually increased. Participants' heart rate will be measured before and after the intervention. The intervention will be delivered by a video displayed on a tablet device. An orientation session in the beginning will familiarize participants with the activity.
41299106|NCT00114205|DRUG|docetaxel|
41299107|NCT00114205|PROCEDURE|therapeutic thoracoscopy|
41299108|NCT03140254|DRUG|Chlorhexidine gluconate|
41299109|NCT03140254|DRUG|N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride|
41299110|NCT03140254|DRUG|Placebo|
41299111|NCT01082913|DEVICE|SSE|Use of SSE or not use of SSE
41299112|NCT03510663|DRUG|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
41299113|NCT03510663|DRUG|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
41299114|NCT03510663|DRUG|Moxifloxacin|400mg tablet will be administrated once a week.
41299115|NCT03510663|DRUG|Placebos|Placebo will be intravenously administered once a week.
41299116|NCT02255851|DEVICE|SENTINEL (Cerebral Protection System)|
41299117|NCT02929095|DRUG|dexmedetomidine|
41299118|NCT02929095|DRUG|midazolam|
41299119|NCT02929095|DRUG|remifentanil|- remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
41299120|NCT00675974|DEVICE|Jobst Pressure Garment|Pressure garment therapy for 18 months post burn injury. May be Jobst pressure garment or Medical Z pressure garment.
41299121|NCT00675974|DEVICE|Medical Z pressure garment|Pressure garment to be worn for 18 months post burn. May be Jobst pressure garment or Medical Z pressure garment.
41299122|NCT00606697|DRUG|GR205171|10 milligrams (mg)
41299123|NCT00606697|DRUG|GW597599|15 mg
41299124|NCT02657252|DRUG|Glucose|Sclerotherapy of telangiectasis in one lower limb.
41299125|NCT02657252|DRUG|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
41299126|NCT00096096|DRUG|mycophenolate mofetil|
41299127|NCT00096096|DRUG|tacrolimus|
41299128|NCT03774693|OTHER|General anesthesia with fentanyl boluses|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1
41299129|NCT03774693|PROCEDURE|Regional block|Patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block.
41299130|NCT03575091|OTHER|Non-individualized|Comparing two experimental interventions with standard care
41299131|NCT03575091|OTHER|Individualized|Comparing two experimental interventions with standard care
41299132|NCT02639117|DRUG|Vismodegib|Vismodegib 150 mgs po qd for 3 months
41299133|NCT05158595|OTHER|Exergaming low intensity group|wobble board-based Exergame balance training, the game intensity will be low for this group (Size of goal will be kept small for 3 times a week, 30 minutes per day for 8 weeks.
41299134|NCT05158595|OTHER|Exergaming moderate intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept medium).for 3 times a week, 30 minutes per day for 8 weeks.
41299135|NCT05158595|OTHER|Exergaming high intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept high).for 3 times a week, 30 minutes per day for 8 weeks.
41299136|NCT05158595|OTHER|control group exergaming|Exer games training with soccer heading and penguin slide games(Wii Fitt balance games) for 3 times a week, 30 minutes per day for 8 weeks.
41299137|NCT00112151|DRUG|LowT|Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
41299138|NCT00112151|BEHAVIORAL|Resistance Training|Weight training 45-60 minutes 3 times per week
41299139|NCT00112151|DRUG|Placebo|2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
41299140|NCT00112151|DRUG|HighT|High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
41299141|NCT04755543|DRUG|LP002|600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
41299142|NCT04755543|DRUG|Cisplatin|50mg/m2 IV on Day 1, Q2W
41299143|NCT04755543|DRUG|Fluorouracil|2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
41299144|NCT04755543|BIOLOGICAL|OH2 oncolytic virus|106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
41299145|NCT05942339|DEVICE|Procedure/Surgery|The intervention involves the replacement of parts of the current implanted system with components of the ARC-IM Lumbar system.
41299146|NCT04429503|DRUG|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
41299147|NCT04429503|DRUG|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
41299148|NCT02738827|PROCEDURE|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
41299149|NCT03047993|DRUG|Azacitidine|Given IV or SC
41299150|NCT03047993|DRUG|Glutaminase Inhibitor CB-839|Given PO
41299151|NCT00005022|DRUG|cisplatin|
41299152|NCT00005022|DRUG|etoposide|
41299153|NCT00005022|RADIATION|radiation therapy|
41299154|NCT04357379|BEHAVIORAL|IQOS|Participants will try an IQOS product and then take home the IQOS to sample for one week.
41299155|NCT02519244|DEVICE|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
41299156|NCT03900559|BEHAVIORAL|NO-FEAR Airlines|"NO-FEAR Airlines is an Internet-based self-applied treatment program that allows people with Flying Phobia the exposure to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines contains 6 scenarios related to the flight process: (1) flight preparation, (2) airport, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway, and landing, (6) sequences with images and auditory stimuli related to plane crashes."
41299157|NCT00353847|DEVICE|Acupuncture|
41299158|NCT03047577|BEHAVIORAL|Brief intervention|A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
41299159|NCT03072719|DRUG|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
41299160|NCT03072719|DRUG|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
41299161|NCT05331612|BEHAVIORAL|Blended intervention condition|Participants receive the online protocol treatment and face-to-face sessions during 13 weeks.
41299162|NCT03641989|OTHER|Plaque disclosing toothpaste|Plaque identifying toothpaste with a FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
41299163|NCT03641989|OTHER|Non-plaque disclosing toothpaste|Toothpaste that does not contain the FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
40770671|NCT01532739|BEHAVIORAL|Cognitive training|The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
40770672|NCT04304248|DRUG|Albumin-bound paclitaxel, Carboplatin, Toripalimab|Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment
40770673|NCT05014282|DRUG|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
40770674|NCT05014282|BEHAVIORAL|Counseling|Phone counseling with the state tobacco quitline.
40770675|NCT05014282|DRUG|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
40770676|NCT05014282|BEHAVIORAL|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
40770677|NCT05446207|OTHER|Routine Physiotherapy and Task-oriented Training|The routine physiotherapy treatment will include TENS and Hot pack. The task oriented training for lower extremity will include walking training on the ground, equal weight bearing sit-to-stand exercises, resistance exercises e.g. leg press, leg extension, and leg curl and reaching tasks for improving balance. There will be a rest period of 5 minutes between each set of training.
40770678|NCT05446207|OTHER|Music Therapy and Task oriented Training with Routine Physiotherapy|Relaxing Music will be provided through headphones having voice cancellation property for 15 minutes.
40770679|NCT04723719|BEHAVIORAL|SIESTA|SIESTA is a CBT sleep training for adolescents with ADHD with a focus on sleep hygiene, motivational interviewing and planning and organization.
40770680|NCT04723719|OTHER|Treatment as usual for ADHD|Participants continue their treatment as usual for ADHD.
40770681|NCT04662450|BEHAVIORAL|ABM affective pain stimuli|Patients undergo ABM training to shift attention away from affective pain stimuli
40770682|NCT04662450|BEHAVIORAL|ABM sensory pain stimuli|Patients undergo ABM training to shift attention away from sensory pain stimuli
40770683|NCT04662450|BEHAVIORAL|Placebo|Patients undergo ABM training to receive affective/neutral and sensory/neutral word pairs
41299164|NCT05275153|OTHER|Home based cognitive rehabilitation program|The home based cognitive rehabilitation program intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
41299165|NCT03094936|PROCEDURE|APC|Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
41299166|NCT03094936|DEVICE|Endoscopic Suture Technique (OverStitch TM)|OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
41299167|NCT02991053|DRUG|ketamine|
41299168|NCT02920684|OTHER|Passive legs mobilisation|A physiotherapist performs a passive leg movement
41299169|NCT02920684|OTHER|Passive cycloergometer|A motorised cycloergometer performs a passive cycling
41299170|NCT02920684|OTHER|Muscular electrical stimulation|A neuromuscular electrical stimulation device performs a quadriceps located stimulation
41299171|NCT02920684|OTHER|FES cycling|A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
41299172|NCT06463769|BEHAVIORAL|8 week predominantly plant-based New Nordic LPF-diet program|An 8-week patient-centered dietary intervention program will be implemented to maintain a predominantly plant-based New Nordic LPF-Diet.
40974340|NCT04077645|BEHAVIORAL|Aerobic exercise|This group will be asked to walk on the treadmill for the same amount of time (i.e. 25 minutes) at a moderate intensity (50-70% of their maximum heart rate). Participants will receive an initial 5-minute orientation and then begin at a self-selected speed for the first 5 minutes. Heart rate will be measured and monitored by an undergraduate research assistant. Speed will be increased after 5 minutes if participants have not reached the moderate zone. If participants still have not reached the target heart rate zone by the 10-min mark, the incline of the treadmill will be increased by a 5% grade until the zone is reached.
40974341|NCT04077645|BEHAVIORAL|Seated rest|This group will be watching educational videos for the same amount of time as the intervention groups. An orientation session of 5 minutes will be held in the beginning. Participants will be watching videos on general health related topics, such as healthy eating, while being seated in a quiet room, free of distractions.
40974342|NCT04194034|BIOLOGICAL|TG6002|"Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D).~Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment.~A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient."
41299173|NCT06463769|BEHAVIORAL|maintenance of the predominantly plant-based New Nordic LPF-diet|Follow-up of long-term adherence to the diet at one and six months after completion of the intervention program.
41299174|NCT06368921|BIOLOGICAL|VRT106|intratumoral injection
41299175|NCT02322320|DRUG|Lenalidomide|In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
40974343|NCT04194034|DRUG|Flucytosine (5-FC)|"Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination.~A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between."
40974344|NCT02356224|DRUG|SHR3824|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
40974345|NCT02356224|DRUG|Placebo|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
40974346|NCT02095587|DRUG|IPI-145|25 mg single oral capsule
40974347|NCT02599129|DRUG|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
40974348|NCT02599129|DRUG|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
41299176|NCT03747016|DIETARY_SUPPLEMENT|high-energy digestible food E2|The women undergoing Cesarean section are given high energy digestible food 300ml before surgery
41299177|NCT03747016|DIETARY_SUPPLEMENT|glucose injection G2|The women undergoing Cesarean section are given glucose injection 300ml before surgery
41299178|NCT03747016|DIETARY_SUPPLEMENT|normal saline N2|The women undergoing Cesarean section are given normal saline 300ml before surgery
41299179|NCT03747016|DIETARY_SUPPLEMENT|high-energy digestible food E1|The women in delivery room are given high energy digestible food 300ml.
41299180|NCT03747016|DIETARY_SUPPLEMENT|glucose injection G1|The women in delivery room are given glucose injection 300ml.
41299181|NCT03747016|DIETARY_SUPPLEMENT|normal saline N1|The women in delivery room are given normal saline 300ml.
41299182|NCT02134314|DRUG|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
41299183|NCT02134314|DRUG|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
41299184|NCT03126136|DEVICE|Nicom (TM)|Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
41299185|NCT01097330|PROCEDURE|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization
41299186|NCT01097330|DRUG|Amiodarone|Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
41299187|NCT03782740|DRUG|Melatonin 10 mg|Melatonin capsule
41299188|NCT03782740|DRUG|Placebo|Sugar pill manufactured to mimic Melatonin capsule
41299189|NCT03782740|DRUG|Melatonin 20 mg|Melatonin capsule
41299190|NCT05288985|DEVICE|Erector spinae plane catheter group in addition to Systemic Analgesia|Erector spinae plane catheter is placed in the post-interventional surveillance room in the operating theatre by an anaesthetist-intensive care physician or in the MIR department by the intensive care physician in charge of the patient within 2 hours after randomisation. The local anaesthetic injected into the catheter is Ropivacaine, prescribed according to a protocol of continuous flow, bolus and refractory period. The catheter is repositioned if a secondary displacement occurs.
41299191|NCT05288985|DRUG|Systemic Analgesia Only Group|Systemic analgesia alone consists only of the 3 levels of analgesic treatment
41299192|NCT03666000|BIOLOGICAL|Azer-cel|Infusion of Allogeneic Anti-CD19 CAR T cells
41299193|NCT03666000|DRUG|Fludarabine|Specified dose on specified days
41299194|NCT03666000|DRUG|Cyclophosphamide|Specified dose on specified days
41299195|NCT03666000|DRUG|IL-2|Specified dose on specified days
41299196|NCT03666000|DRUG|Bendamustine|Specified dose on specified days
41299197|NCT02552355|DRUG|Metformin|Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
41299198|NCT02552355|DRUG|Placebo|Daily administration of matching placebo during a 12 week exercise training program.
41299199|NCT02552355|DIETARY_SUPPLEMENT|Carbohydrate Beverage|Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
40770684|NCT04391751|PROCEDURE|Carpal tunnel release and basal joint arthroplasty through single incision|Group I: experimental - single incision The surgical technique chosen for thumb basal join was trapeziectomy with ligamentous reconstruction and tendon interposition (LRTI), using flexor carpi radialis (FCR). Through a dorsal approach over trapeziometacarpal joint, the entire trapezium was excised. Volar traction of FCR allowed us to longitudinally incise the deep leaflet of FCR tendon until flexor pollicis longus (FPL) tendon was clearly visualized. Then, ulnar half of FCR tendon was harvested proximally through a second transverse incision in middle third of the forearm and split all the way to its insertion on the index metacarpal. A hole was placed in the base of the first metacarpal and FCR tendon was routed through the bone canal and then fixed with non-reabsorbable sutures. Finally, the tendon remanent was rolled up and placed into the trapezial void to act as a spacer.
40770685|NCT04391751|PROCEDURE|Carpal tunnel release and basal joint arthroplasty through double incision|Group II: active comparator - double incision Trapezial excision and ligament reconstruction were performed in the same way as in group I, except that FCR deep leaflet was not incised. After radial incision wound closure, carpal tunnel release was performed through a second separate longitudinal palmar incision.
41299200|NCT02552355|DIETARY_SUPPLEMENT|Protein Beverage|Supervised aerobic exercise 3 days per week followed by a protein drink
41299201|NCT02887534|DRUG|SPARC1401-low dose|SPARC1401- low dose
41299202|NCT02887534|DRUG|SPARC1401-mid dose|SPARC1401- mid dose
41299203|NCT02887534|DRUG|SPARC1401-high dose|SPARC1401-high dose
41299204|NCT02887534|DRUG|Reference1401 (Tizanidine)|Reference1401 (Tizanidine) three times a day
41299205|NCT02887534|DRUG|Placebo1401|Placebo
41299206|NCT06039254|DRUG|HRS-1780|Single dose in each arm
40770686|NCT04070703|BEHAVIORAL|The Go for Exercise & Healthy Aging Project|Exercise and Cognition
41299207|NCT03596177|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
41459116|NCT04055233|DRUG|NaCl; saline|"Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
41459117|NCT04334837|DIAGNOSTIC_TEST|Copper Cu 64 Dotatate|The drug product contains Copper Cu 64 Dotatate filled in a glass vial, closed with butyl rubber stopper secured with an aluminum crimp seal. The drug product will be delivered by Curium to the clinical site. The EAP drug will be administered as an intravenous bolus injection. The dose will be administered according to the schedule detailed in the protocol.
41299208|NCT03596177|DRUG|Placebo|Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
41299209|NCT02446730|DEVICE|BES (biodegradable polymer biolimus-eluting stent)|BES implantation
41299210|NCT02446730|DRUG|Prasugel|
41299211|NCT02446730|DRUG|Clopidogrel|
41299212|NCT02361203|BEHAVIORAL|Exercise|30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
41299213|NCT00850460|DRUG|Statins|Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.
41299214|NCT00850460|DRUG|Placebo|Placebo pills will consist of lactose and will be given one capsule once daily
41299215|NCT03693287|DRUG|Standardized-parenteral nutrition (S-PN)|NUMETA G13%E 300 mL is a triple-chamber (lipid emulsion, amino acids solution with electrolytes, and glucose solution), ready-to-use parenteral nutrition product available to treat preterm infants (less than 37 weeks gestational age).
41299216|NCT03693287|DRUG|Personalized-parenteral nutrition (P-PN)|"Intravenous glucose will be dextrose 50%, amino acids (AA) will be Primene® and lipids (FAT) will be Clinoleic®.~Parenteral nutrition bags will be prepared by the hospital pharmacy according to the prescription of the attending neonatologist."
40974349|NCT05954806|DRUG|Antivenom Snakes|No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
40770687|NCT00672035|BIOLOGICAL|Biological: heat-labile enterotoxin of E. coli (LT)|LT patch applied on either the deltoid or the lower back.
41299217|NCT02740569|OTHER|No intervention|Observational study. Intervention according to the clinical routines (not included in this part)
41459118|NCT02058160|DRUG|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg."
41459119|NCT02058160|DRUG|Insulin glargine (HOE901)|"Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L)."
40770688|NCT04416711|BEHAVIORAL|Personalized Feedback|The personalized feedback consists of four components: normative feedback, risk/protective feedback, decisional balance/goal setting, and protective strategy review. Personalized feedback targets include readiness to change, perceptions of risk, and misperceptions of peer attitudes/behaviors.
41459120|NCT02058160|DRUG|Metformin (Background Drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration
40974350|NCT03617445|DRUG|FMT oral capsule|FMT oral capsules, single dose of 5 capsules
40974351|NCT03617445|DRUG|Oral Vancomycin|Oral Vancomycin 125 mg capsules every 6 hours for 14 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days
40974352|NCT03617445|DRUG|FMT oral placebo|Placebo oral capsules, single dose of 5 capsules
40974353|NCT03617445|DRUG|Oral Vancomycin placebo|Placebo oral vancomycin capsules every 6 hours for 14 days, followed by 125 mg oral vancomycin every 12 hours for 7 days, followed by 125 mg oral vancomycin once daily for 7 days, followed by 125 mg oral vancomycin every 3 days for 14 days.
40974354|NCT02324062|OTHER|Questionnaires|These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.
40974355|NCT02324062|OTHER|Blood Draw and Baseline Questionnaire|Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
40974356|NCT05351762|DRUG|Nimotuzumab Combined With Neoadjuvant Chemotherapy|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
40974357|NCT04356664|DRUG|GnRH agonist|One or two intramuscular injections of Decapeptyl 3 mg
41459121|NCT00757705|DRUG|Paliperidone ER|Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
40974358|NCT05602181|BEHAVIORAL|ALL Phonics Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech.
40974359|NCT05602181|BEHAVIORAL|ALL Sight Word Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech. This group will only use the sight word lessons, as well as the library for sight word books. No phonics instruction will be provided through the app.
40974360|NCT01184794|DRUG|levobupivacaine|40 ml over 48 hours
41299218|NCT03293095|PROCEDURE|Standard Care|The guidelines for the management according to the musculoskeletal disorder in primary care will be the treatment guidelines for the Standard Care.
41299219|NCT04338945|BEHAVIORAL|COVID-surgRES questionaire|The questionaire gives a multidimensional assessment of residents' impression with regard to impact of COVID emergency on Italian specialist training programs
40974361|NCT03369405|OTHER|NO intervention, patient records review only|There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
40974362|NCT01073553|DRUG|Cephalexin capsules (Optocef, BAYO5448 )|Single dose of 500 mg (One 500 mg capsule)
41299220|NCT02530320|DRUG|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
41459122|NCT05011656|DEVICE|Seraph-100 + State of the Art Care|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.
40974363|NCT01073553|DRUG|Cephalexin capsules (Keflex)|Single dose of 500 mg (Two 250 mg capsules)
40974364|NCT02687945|PROCEDURE|Outpatient physiotherapy|
41299221|NCT05427825|OTHER|ERAS anesthetic care|The ERAS anesthetic care includes EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
41299222|NCT05427825|OTHER|Standard anesthetic care|The standard anesthetic care includes bispectral index guided general anesthesia and arterial line monitored hemodynamic care.
41459123|NCT05011656|DEVICE|State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
41459124|NCT03332433|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device，the flow is up to 60L/min
41459125|NCT03334045|RADIATION|PET/MR scans|Observations of glucose metabolism and dopamine binding potential
41459126|NCT05000138|DIAGNOSTIC_TEST|FDG PET/CT|Patients with suspected giant cell arteritis, of which FDG PET/CT is indicated for diagnosis of large vessel involvement, will have the small cranial arteries analyzed for involvement.
41459127|NCT04320576|DEVICE|Bulk-fill|Bulk-fill resin composite (bulk technique)
41459128|NCT04320576|DEVICE|Nano-fill|Nano-fill resin composite (layering technique)
41459129|NCT04667390|OTHER|total knee arthroplasty|total knee arthroplasty
40974365|NCT02687945|PROCEDURE|Self-guided physiotherapy|
41459130|NCT06035211|OTHER|3D model pré-operative education|Before surgery, during a preoperative therapeutic education consultation, 3D models will be presented to the patients according to the allocated study group
40974366|NCT03275376|DRUG|Atorvastatin 10mg|Atorvastatin or placebo will be administered according to randomized allocations.
40974367|NCT03275376|DRUG|Placebo Oral Tablet|Atorvastatin or placebo will be administered according to randomized allocations.
41459131|NCT02749305|OTHER|Collection of patient-reported outcome measures|Preoperative and postoperative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
40974368|NCT01369797|OTHER|specific intervention|"Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed."
40974369|NCT04049396|OTHER|Berberine|24 Patient consumed 6,25 g/day Berberine for 6 weeks
41299223|NCT03037957|DEVICE|ARIES Group A Strep Assay|
41299224|NCT02372825|PROCEDURE|Reconstructive surgery|Reconstructive surgery with the free iliac crest flap
41299225|NCT05256277|DRUG|CT101a|cytokine-induced memory-like NK cells
41299226|NCT04346628|DRUG|Favipiravir|Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).
41299227|NCT04346628|DRUG|Placebo|Placebo to match favipiravir administered orally through day 10.
41299228|NCT04346628|OTHER|Standard of care treatment|Standard of care treatment for COVID-19 infection
41299229|NCT01439529|OTHER|Device programming: nominal|CRT device is programmed to nominal values
41299230|NCT01439529|OTHER|Programming optimization by QRS|CRT device is programmed by QRS optimization
41299231|NCT01831973|DRUG|Lipotecan|
40974370|NCT03576976|BEHAVIORAL|Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
40974371|NCT02740764|OTHER|Optimization of drug prescribing|The patients included in this group will have the intervention. The optimization of drug prescribing consists to a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital and sent to the referring physicians of patients, who can accept or not the recommendations.
41299232|NCT05813210|DIAGNOSTIC_TEST|Exercise in combination with biomarkers and pharmacological stress CMR test|A bicycle ergometry combined with pharmacoligical stress test is performed. High sensitive Troponin is taken before and after the stress test.
41299233|NCT01253681|DRUG|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
41299234|NCT05628233|DRUG|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) B.I.D. up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy.
41299235|NCT04032743|OTHER|ICU treatment|any treatment available by ICU
41299236|NCT03650348|DRUG|PRS-343 in Combination with Atezolizumab|HER2/4-1BB Bispecific
41299237|NCT04133779|PROCEDURE|neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
41299238|NCT04133779|PROCEDURE|neurological evaluation, ecocolor-Doppler|For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
41299239|NCT04133779|PROCEDURE|medical history, vital signs, ecocolor-Doppler|For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
41299240|NCT04510922|DRUG|Droxidopa 100 MG [Northera]|droxidopa taken three times a day titrated up to a maximum of 600 mg.
40974372|NCT01780636|DRUG|botulinum toxin|
40974373|NCT05760833|PROCEDURE|Ablation|Ablation of either the pulmonary veins or the atrioventricular node
40974374|NCT02370160|BIOLOGICAL|DT2219ARL|DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
40974375|NCT05404295|OTHER|Umbilical cord blood platelel lysate gel|For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
41299241|NCT03909763|DRUG|Berberine plus danazol|Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks
40974376|NCT00850564|DRUG|Growth Hormone Releasing Hormone (Tesamorelin)|Tesamorelin 2mg subcutaneous daily x 2 weeks
40974377|NCT04889456|PROCEDURE|Implementation standardised laparoscopic right hemicolectomy with proctoring|Implementation standardised laparoscopic right hemicolectomy with proctoring
41299242|NCT04247022|OTHER|Health care product (intimate gel)|heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days
41459132|NCT05289557|DRUG|Bonjesta|Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
40974378|NCT04889456|PROCEDURE|Implementation standardised laparoscopic right hemicolectomy without proctoring|Implementation standardised laparoscopic right hemicolectomy without proctoring
40974379|NCT04000490|OTHER|SCARE Score|Predictive Score of acute coronary syndrome during the medical assessment of chest pain
40974380|NCT00822991|DEVICE|CE-US (Sonazoid™)|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
40974381|NCT00822991|DEVICE|B-mode US|screening by conventional B-mode US every 3-5 months
40974382|NCT04412408|DRUG|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
40974383|NCT03555955|DRUG|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
40974384|NCT03555955|DRUG|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
40770689|NCT04416711|BEHAVIORAL|Cognitive Skills Training|We will address three cognitive targets: focus on affective cues, focus on non-affective cues, and over-perception of sexual interest. The first module targets enhanced focus on women's affective cues and reduced over-perception of sexual interest. We will introduce the role of men's sexual-perception skills in satisfying social and sexual interactions with women, as well as problematic sexual behavior including RSB and SAB. Next, we will instruct participants that affective information is the best-available nonverbal information about how a woman is feeling about a specific man. This instruction will focus on distinguishing four primary dating relevant cues: sexual-interest, friendliness, sadness, and rejection. More detailed focus on each cue will emphasize the increased difficulty of reading these cues with a new partner and under the influence of alcohol and sexual arousal, as well as the importance of checking verbally on assumptions about a woman's current sexual interest.
40770690|NCT04416711|OTHER|Services As Usual|These participants will receive services as usual
40974385|NCT00458198|BEHAVIORAL|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
40974386|NCT04810845|DEVICE|Application of Class II A device SmartCardia|Application of SmartCardia monitor patch 30 minutes before coronary angiography (2/3 devices per-patients would be applied). Non invasive recording of single-lead ECG, respiratory rate, pulse transit time, heart rate would occur pre, during and post (30 minutes) primary angioplasty procedure
41299243|NCT00959296|DEVICE|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
41299244|NCT04854265|OTHER|Mindfulness Meditation|Mindfulness meditation will include mindfulness based stress reduction program, Qigong, Tai Chi exercise, Yoga, and Pranayama breathing exercise.
41299245|NCT06463158|DEVICE|Family Room App|The Family Room is a dynamic, point of care tool. It guides families on how best to contribute to patient care by providing real time education, a sense of connection, emotional support, and resources that enable meaningful caregiving. Importantly, family caregivers receive virtual training on comfort-focused care activities that can be done at the bedside, as well as a mechanism within the electronic health record (EHR) to measure and record the effectiveness of the care they provide.
41299246|NCT00252902|BEHAVIORAL|Behavior change counseling|
40974387|NCT01338792|DRUG|oxaliplatin|Given IV
41459133|NCT05289557|DRUG|Placebo|Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
40974388|NCT01338792|DRUG|pemetrexed disodium|Given IV
40974389|NCT01338792|OTHER|questionnaire administration|Ancillary studies
41299247|NCT02786355|OTHER|Frova bougie|Squeezing an Ambu bag and delivering air through a Frova bougie. Measuring mean volumes of air delivered and peak pressures generated.
41299248|NCT05922267|OTHER|ACTIVE CYCLE OF BREATHING TECHNIQUES|"The participants in group A will be given ACBT with conventional chest physiotherapy .~Instruction for patient~* Try to keep your chest~* Take a long, slow and deep breath in, through your nose if you can.~* At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing~* Breathe out gently and relaxed, like a sigh. Don't force the air out.~* Repeat 3 - 5 times.~* If the patient feels light-headed then it is important that they revert back to the breathing control phase of the cycle~* Huffing"
41299249|NCT05922267|OTHER|SLOW EXPIRATION WITH OPEN GLOTTIS IN LATERAL POSITION|The participants in group B will be given slow expiration with open glottis in lateral posture and conventional chest physiotherapy .In this technique, a patient adopts a lateral posture or a lateral decubitus posture. The affected lung is in the dependent position. A patient commences breathing normally, at tidal volumes. They are then instructed to perform a series of slow expirations with an open glottis. Expiration from functional residual capacity to the end of the expiratory reserve volume are encouraged to achieve maximum inflation . To assist in maintaining an open glottis, a mouthpiece may be used, to decrease the degree of airway compression A series of three ELTGOL may be performed, with each series composed of approximately 10 slow and deep expirations. In between each series of maneuvers, a rest period (around 1-2 minutes) is provided, with the patient staying in the same position. A typical treatment lasts for around 20 minutes
41299250|NCT03813563|DRUG|RL|lactated Ringer's
41299251|NCT03813563|DRUG|PLA|PlasmaLyte
41459134|NCT04008680|OTHER|EQ-5D-5L survey internal consistency|To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.
41459135|NCT06465654|OTHER|Automated variable dose oxygen treatment|The participant will receive closed loop oxygen titration during a walking test based on oxygen saturation measurements every second measured by a pulse oximeter connected to the O2matic. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
41459136|NCT06465654|OTHER|Fixed dose oxygen treatment|The participant will receive a fixed oxygen dose during a walking test. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
41459137|NCT05625269|OTHER|Education|The first session of the individual training will be held for the patients in the intervention group on the first day of the service hospitalization, covering the issues related to the procedure and the hospital process. Afterwards, the second session of individual education will be held the day before discharge on issues related to the patient's home care, such as treatment site care, nutrition, exercise, medication and symptom management. In addition to the patients, their families will also participate in the training sessions. The training will be given face-to-face in a quiet environment to increase intelligibility in patients' rooms. The patients will be given a booklet and magnet prepared by the researcher in addition to the oral explanation.
41459138|NCT00225641|PROCEDURE|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
41459139|NCT00225641|PROCEDURE|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
41459140|NCT01653704|BEHAVIORAL|observational role|observational role in crisis scenario
41459141|NCT01653704|BEHAVIORAL|active role|active role in managing crisis scenario
41459142|NCT01049282|BIOLOGICAL|Antigen (Ag85B-ESAT-6)|Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
41459143|NCT01049282|BIOLOGICAL|Antigen (Ag85B-ESAT-6) with adjuvant (IC31)|Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
41459144|NCT04988737|OTHER|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
41459145|NCT01581164|BIOLOGICAL|Influenza vaccine|Influenza vaccine: Injection, post transplant
41459146|NCT01581164|BIOLOGICAL|Varicella vaccine|Varicella vaccine: Injection, post transplant
41459147|NCT04423003|PROCEDURE|Endoscopic intervention|All endoscopic interventions in COVID-19 positive tested patients were included
40770691|NCT06570005|OTHER|Water Quality Assurance Fund|"* At the water system level: Written legal agreements between water systems, centralized laboratories, and the organization facilitating the Assurance Fund will provide water systems with regular water quality testing and provide laboratories a guarantee of payments if water systems fail to pay for testing services on time (for up to three concurrent unpaid invoices). Regular debrief meetings will be held with water operators and local government authorities to discuss test results and water treatment options, and to encourage water systems to share water quality information with their consumers. Technical guidance to improve water treatment will be provided, if requested by water system operators or local government authorities.~* At the community level: Community engagement, primarily at the onset, to inform the community about the water quality testing program and answer questions."
40974390|NCT01338792|OTHER|laboratory biomarker analysis|Correlative studies
40974391|NCT01338792|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
40974392|NCT01338792|GENETIC|polymorphism analysis|Correlative studies
40974393|NCT00276744|BIOLOGICAL|cetuximab|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
40974394|NCT00276744|DRUG|capecitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
40974395|NCT00276744|DRUG|docetaxel|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
40974396|NCT00276744|DRUG|Erlotinib|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
40974397|NCT00276744|DRUG|Gemcitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
40974398|NCT00276744|DRUG|Irinotecan|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
40770692|NCT04012450|PROCEDURE|Epidural anesthesia|Performing an epidural anesthesia
40770693|NCT04012450|PROCEDURE|spina-epidural anesthesia|Performing a spina-epidural anesthesia
40770694|NCT03096431|BEHAVIORAL|Physical Activity|"* Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~* One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching."
40770695|NCT03096431|BEHAVIORAL|Cognitive rehabilitation|One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
40770696|NCT05525390|BEHAVIORAL|Extended Reality-Enhanced Behavioral Activation|"Participants will choose at least four activities to complete in Oculus extended reality over the course of the week. These activities are chosen from the Oculus and may include video 360, social interactions, gaming, etc."
40770697|NCT05525390|BEHAVIORAL|Traditional Behavioral Activation|Participants will choose at least four pleasurable and/or mastery activities to complete over the course of the week in real life.
40974399|NCT00276744|DRUG|mitomycin C|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
41139916|NCT05615337|BEHAVIORAL|MBSR|"The MBSR is an eight-week group-based psychoeducational program. It is performed in weekly group sessions with the duration of 2.5 hours and a half-day retreat of 4 hours.~The program involves focused attention, consisting of body scan, yoga, and meditation. This program trains participants to be attentive to their thoughts, emotions, and sensations. There are also discussions on relevant topics related to the physiology of stress and strategies of coping. Materials for home practice are provided."
40770698|NCT06536426|BEHAVIORAL|Knee Isometric Program (KIP)|"The KIP physical therapy protocol follows the schedule outlined below:~* Session 1 (Completed 4-5 days/week including HEP): Double Leg wall sit 3x30 seconds, Double Leg glute bridge hold 3x30 seconds, Single Leg Stance hold 3x1 minutes, Lunge hold 3x1 minutes~* Session 2 (Completed 4-5 days/week including HEP): Single Leg wall sit 3x20 seconds, Single Leg glute bridge hold 3x20 seconds, Single Leg stance hold 2x1.5 minutes, Lunge hold 2x1.5 minutes~* Session 3 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes~* Session 4 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes"
40770699|NCT05851547|RADIATION|Prostate SBRT with Focal Boost|Prostate stereotactic body radiotherapy delivered to 27 Gy in 3 fractions on alternating days to uninvolved regions with up to 39 Gy in 3 fractions delivered to mpMRI-defined intraprostatic lesions
40770700|NCT05851547|DRUG|Triptorelin Injection|Six months of androgen deprivation therapy for intermediate-risk localized prostate cancer and 24 months for high-risk localized prostate cancer
40770701|NCT05443321|OTHER|Health Information Exchange (HIE) platform|An improved health information exchange (HIE) platform will be developed at the start of the study with key stakeholder input. This platform will be implemented for use after baseline data collection, and will allow for improved data exchange between transferring and accepting hospital. We will allow for a 6-month wash-in period prior to intervention data collection.
40770702|NCT06587659|DEVICE|Transcranial Magnetic Stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
40974400|NCT00276744|DRUG|rapamycin|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
40974401|NCT00276744|PROCEDURE|conventional surgery|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
41299252|NCT04054778|BEHAVIORAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
41299253|NCT04054778|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
41299254|NCT00875017|DRUG|Lanthanum Carbonate|1 x 1000mg tablet
41299255|NCT00875017|DRUG|Sevelamer|3 x 800mg tablets
40770703|NCT06587659|DEVICE|Robotic Arm|This robotic system is based on a commercially available collaborative robot. The robot is mounted on a cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
40974402|NCT01595698|OTHER|Physical Exercise|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
41299256|NCT00366834|DRUG|Casopitant (GW679769) oral tablets|
41299257|NCT00366834|DRUG|Casopitant (GW679769) intravenous|
41299258|NCT00366834|DRUG|Dexamethasone intravenous|
41299259|NCT00366834|DRUG|Ondansetron oral tablets|
41299260|NCT00366834|DRUG|placebo|casopitant placebo
41299261|NCT02244450|BIOLOGICAL|SCID screening|
41299262|NCT05828823|DEVICE|Hemodialysis twice weekly|Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)
41299263|NCT05828823|OTHER|Hemodialysis thrice weekly|Conventional hemodialysis regimen
41299264|NCT06397391|DEVICE|TREM-AB|Wearing medical device on site during 1 hour
41299265|NCT02989636|OTHER|Laboratory Biomarker Analysis|Correlative studies
41299266|NCT02989636|BIOLOGICAL|Nivolumab|Given IV
41299267|NCT02989636|RADIATION|Stereotactic Radiosurgery|Undergo SRS
40974403|NCT01595698|OTHER|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
40974404|NCT02590848|DIETARY_SUPPLEMENT|Walnut intake|Nutritional intervention: 30g walnut kernels per day
40974405|NCT05996198|DEVICE|Oculus Rift headset|The Oculus Rift is a commercially-available virtual reality (VR) headset. It is used to present the visual environment in which participants perform the reaching task.
40974406|NCT05996198|DEVICE|Exoskeleton Device|The exoskeleton was designed and constructed to provide either gravity assistance or gravity resistance. It applies a torque to both shoulders. Torque values do not exceed 50% of the torque due to gravity. The device is mounted to a testing chair and attached to the participant using Velcro straps.
40770704|NCT03746210|DIAGNOSTIC_TEST|Standard diagnostic procedures|B-Mode ultrasound, Duplex sonography, contrast-enhanced ultrasound, elastography, CT, MRI, anthropometrics
40770705|NCT02306252|OTHER|Occupational and Physical Therapy|OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
40974407|NCT01104350|OTHER|external radiation therapy with gemcitabine|"All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.~* Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)~* Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)~* Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)"
40974408|NCT04245332|DIETARY_SUPPLEMENT|Fish oil|Fish oil-derived omega-3 polyunsaturated fatty acids (4g fish oil concentrate: 2g EPA+ 1g DHA)
41299268|NCT02226094|DEVICE|DWT device dose A|Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments.
41299269|NCT02226094|DEVICE|Ellex Tango SLT machine|Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage.
41299270|NCT02226094|DEVICE|DWT device dose B|Same as DWT device dose A except 20 second spot treatments.
40974409|NCT04245332|DIETARY_SUPPLEMENT|Coconut oil|Coconut oil (4g/d)
41299271|NCT02226094|DEVICE|DWT sham|Same as DWT device dose A except device not applied to ocular surface.
41299272|NCT02426658|OTHER|Laboratory Biomarker Analysis|Correlative studies
41299273|NCT02426658|DRUG|Pemetrexed Disodium|Given IV
40974410|NCT02822768|PROCEDURE|Packing|The patient will receive packing as part of their wound care
40974411|NCT02822768|OTHER|No packing|The patient will not receive packing as part of their wound care
40974412|NCT01129609|DEVICE|Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System|All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
41299274|NCT02426658|OTHER|Quality-of-Life Assessment|QOL studies
41299275|NCT00909142|DRUG|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
41299276|NCT01629342|BEHAVIORAL|Standardized activities|"All patients do each of the following standardized activities over a course of 2 days:~* treadmill walking (5 minutes, 1 and 2km/h)~* staircase walking (1 floor, normal pace)~* cycling with fixed load (5 minutes)~* standing up from sitting position and sitting down again (x5)~* standing up from supine position~* turning from left to right and back while lying in bed~* raising outstretched arm 90° (x5, standing position)~* eating (5 minutes, sitting position)~* drinking a glass of water~* sleeping (6 hours)"
41299277|NCT03452150|DRUG|D-0316|If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
41299278|NCT05249543|BEHAVIORAL|Unified protocol|Transdiagnostic cognitive-behavioral therapy
40974413|NCT02239757|PROCEDURE|Left radial approach|Primary PCI performed through left radial approach.
40974414|NCT02239757|PROCEDURE|Right radial approach|Primary PCI performed through right radial approach.
40974415|NCT00789139|DEVICE|ICM Implantation|Sub cutaneous implantation of the ICM
40974416|NCT02278198|DRUG|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
41299279|NCT05249543|BEHAVIORAL|Diagnosis-specific cognitive-behavioral therapy|Diagnosis-specific cognitive-behavioral therapy
41299280|NCT03481881|DRUG|Standard of care drug|This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.
41299281|NCT05943977|DRUG|MB-102 DMID|130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
41299282|NCT05943977|DRUG|MB-102 OMID|130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
41299283|NCT05943977|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR sensor placed on their chests, and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements terminated by the system when a low signal-to-noise threshold is reached.
41299284|NCT04315649|OTHER|3D movie viewing|3D movie viewing
41299285|NCT02005653|DRUG|Diethylcarbamazine|Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
41299286|NCT02005653|DRUG|Albendazole|Experimental
41299287|NCT02005653|DRUG|Doxycycline|Experimental
41299288|NCT04009174|OTHER|Imaging Panel|"Initial Protocol (REB approval date 08-Sept-2011)~Pre-operative Imaging Panel~* \[18F\]-FCH PET + Dynamic CT~* MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)~* 3D-Transrectal ultrasound~* Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)~* Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)~Protocol Amendment #3, REB approval date 20-Oct-2015:~Pre-operative Imaging Panel~* \[18-F\]-DCFPyL PET+Dynamic CT~* PET/MRI with endorectal coil~* 3D-Transrectal Ultrasound~* Optional Sodium (23Na) MRI"
41299289|NCT05427851|PROCEDURE|pulpotomy|coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material
40770706|NCT02247921|OTHER|Rehabilitation|Patients recruited into the intervention arm will have their family-nominated caregivers trained by a trained nurse and guided by a culturally appropriate and easy-to-understand rehabilitation manual to be given to caregivers at the last session, shortly before hospital discharge to reduce contamination. The training sessions will take at least 90 minutes per day for 2 or 3 days.The nurse will call the patients and caregivers at 2, 4, and 8 weeks after hospital discharge to monitor progress and offer guidance on rehabilitation.Duration of the standardized yet individualized intervention by nurses will be 8 weeks; however, trained caregivers are expected to deliver the rehabilitation services to patients as long as they are needed.
40974417|NCT04834076|DIAGNOSTIC_TEST|ELISA|ELISA is is a test that detects and measures toxoplasma IgG and IgM antibodies in blood.
40974418|NCT04834076|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction (PCR) is a method widely used to rapidly make millions to billions of copies of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail.
40974419|NCT04834076|DIAGNOSTIC_TEST|Sequencing|DNA sequencing is a laboratory technique used to determine the exact sequence of bases (A, C, G, and T) in a DNA molecule. The DNA base sequence carries the information a cell needs to assemble protein and RNA molecules. DNA sequence information is important to scientists investigating the functions of genes.
40974420|NCT02737189|PROCEDURE|Mechanical embolectomy|Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
40974421|NCT02737189|DRUG|Medical Treatment|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
40974422|NCT02268084|DEVICE|Magnetic EEG/ECG-guided Resonance Therapy|A coil delivers a pulsed magnetic field to the cortex of the brain
40974423|NCT02268084|DEVICE|Sham|Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
40974424|NCT05408949|BEHAVIORAL|Single exercise into pain (SEP) program|"* Baseline assessment \& commencement of treatment: Resisted isometric shoulder abduction into pain (or lateral rotation or flexion into pain) against a wall, or Resisted shoulder abduction from 0 to 30° using moderate resistance from Theraband ( Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Initial follow-up \& progression: Resisted shoulder abduction into pain from 80 to 120° using light weight (Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Second follow-up \& progression: eccentric shoulder abduction into pain from 80 to 120° with progressively increasing repetition and weight, e.g. heavy Theraband or dumbbell.~* Final assessment to identify any non-resolved functional limitations and progress eccentric exercises into pain as required~* Functional rehabilitation program"
40974425|NCT05408949|BEHAVIORAL|Shoulder Symptom Modification Procedure (SSMP)|\[1\] Finger on the sternum,\[2A\] Scapula modification \[3\] 'Humeral head' modification \[4\] Isometric (most painful movement) Heavy slow resistance (HSR): start from the mid-range and pain-free
41299290|NCT05427851|DEVICE|Diode laser - fonalaser|diode laser beam application
41299291|NCT02519075|OTHER|No intervention|Observational study
41299292|NCT03161769|PROCEDURE|Neurovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms using flow diverting stents
41299293|NCT03161769|DEVICE|AneurysmFlow image processing software|Software to process and display images of intracranial aneurysm treatment using flow diverting stents.
41299294|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 1|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar among all three arms.
41299295|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 2|Patients will undergo imaging on a modern 128 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
40770707|NCT03454347|DIETARY_SUPPLEMENT|Profile Perform|The dietary supplement includes 1.5 grams of fat, 19 grams of carbohydrate, and 25 grams of protein per serving. Participants in the experimental group will consume 3 servings per day.
40770708|NCT03454347|OTHER|Lower Limb Suspension|This group will complete two weeks of lower limb suspension.
40770709|NCT03888105|DRUG|Odronextamab|Administered by intravenous (IV) infusion
40770710|NCT06570369|DRUG|SP-624|Oral dose, once daily for 2 weeks
40770711|NCT06570369|DRUG|Placebo|Oral dose, once daily for 2 weeks
40770712|NCT04557423|BEHAVIORAL|Community-Based Education|A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.
40770713|NCT04557423|BEHAVIORAL|Navigation to Screening|Community health educators provide navigation assistance to access clinic-based cervical cancer screening.
40770714|NCT04557423|BEHAVIORAL|HPV Self-Sampling|An HPV self-sampling kit will be provided for home-based collection of cervical samples. Samples will be sent for analysis of HPV subtypes.
40770715|NCT06236646|OTHER|Thai dance with twenty-five squares (TDT)|The participants received a Thai dance with twenty-five squares (TDT) program 3 days/week, 12 weeks. This training comprises 10 minutes of warm up, following by 40 minutes of exercise at 40-50% of heart rate reserve at week 1-4, 50-60% of heart rate reserve at week 5-8, and 60-70% of heart rate reserve at week 9-12, 5 minutes of cool down.
40770716|NCT06236646|OTHER|Control (CON)|The CON group did not have any intervention but usual care.
40770717|NCT06571526|BEHAVIORAL|External focus|The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to focus on a random series of digits ranging from 0 to 9 displayed on monitors placed at the immediate and future destinations of the walkway. Each number was displayed for at least 2 seconds to allow participants to have sufficient time to read them.
40770718|NCT06571526|BEHAVIORAL|Control|The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to walk to the end of the walkway at your natural pace.
40770719|NCT06168773|DRUG|Haloperidol Injection|to evaluate the efficacy and safety of short-term intravenous combination of low-dose haloperidol and magnesium for delirium prevention in critically ill elderly patients after elective major surgery.
40770720|NCT04964700|DRUG|Natalizumab|Monthly Infusions
40770721|NCT05364502|DEVICE|Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter|The Embrace Hydrogel Embolic System (HES) is indicated for embolization of peripheral arterial bleeds in vessels ≤6mm
40770722|NCT05299580|DRUG|dabrafenib|Dabrafenib 150 mg bid
40770723|NCT05299580|DRUG|Trametinib|Trametinib 2mg qd
40770724|NCT06630767|PROCEDURE|ERAS|Enhanced recovery after surgery (ERAS) programs are a combination of evidenced-based perioperative care approaches that work synergistically to improve recovery after surgery. The core elements of ERAS protocols are preoperative advice, optimization of diet, systematic analgesic and anesthetic regimes, and early mobilization.
40770725|NCT06630767|PROCEDURE|Conventional|Conventional care for patients subjected for laparoscopic common bile duct exploration
40770726|NCT03301584|OTHER|Enhanced collaboration to promote patient participation|"Enhanced OT and PT collaboration: to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
40770727|NCT03301584|OTHER|Usual Care treatment|The control group received standard rehabilitation from occupational therapists and physiotherapists (Monday to Friday), planned individually and gradually progressed for each patient. Mobilisation was initiated within 24 hours after surgery, 7 days a week. Patients were provided with a booklet with information about the fracture, operation method, exercise regime and assistive walking and ADL aid available.
40770728|NCT06058793|DRUG|Brigimadlin|Brigimadlin
40770729|NCT04925427|BEHAVIORAL|Case Management and Peer Recovery|A blend between a Critical Time Intervention (CTI) case management model and a peer recovery coaching approach. CORI will employ peer-based case management/recovery coaching and other transitional services (e.g., peer navigation) to provide support and service linkages to medication-assisted treatment (MAT) and harm reduction interventions to reduce subsequent opioid use and related harms.
40770730|NCT04925427|BEHAVIORAL|Naloxone-Only|Participants will be trained on naloxone administration, and upon re-entry, they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
40770731|NCT05586776|DRUG|4% Chlorhexidine Gluconate|Used for daily showering/bathing for 30 days after hospital discharge.
40770732|NCT05586776|DRUG|2% Mupirocin|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
40770733|NCT05586776|DRUG|Soap Without Antiseptic Properties (Placebo)|Used for daily showering/bathing for 30 days after hospital discharge.
40770734|NCT05586776|DRUG|Placebo Nasal Ointment|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
40770735|NCT06570161|DEVICE|SEEUS95 Transparent mask|SEEUS95 developed transparent filtering mask
40770736|NCT06570161|DEVICE|CrystalGuard Mask|CrystalGuard transparent mask
40770737|NCT06570161|DEVICE|N95 face mask|Standard N95 style face mask
40770738|NCT03170986|BEHAVIORAL|Multisectoral agriculture and Microfinance Intervention|
40770739|NCT05812859|DEVICE|Vaginal Orthosis (COSM Medical)|A vaginal orthosis will be 3-D printed by COSM Medical and provided for patients to use from week 2 through week 12 post-operatively. Device will be placed in morning and removed before bed daily.
40770740|NCT06564129|DEVICE|electroencephalography|Fifty-nine EEG electrodes conforming to international standard points were placed using a saline electrode EEG cap (Gelfree, Prysmian, China), and an accompanying portable multimodal EEG acquisition system (Neurohub, Prysmian, China) was used. EEG data were collected using collect software (Brycon, China).
41299296|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 3|Patients will undergo imaging on a modern 20 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
40770741|NCT06455462|DRUG|Tezepelumab|tezepelumab treatment initiated as part of the tezepelumab patient access programme (TPAP) between 1st January 2023 and 19th July 2023
40770742|NCT04876248|BIOLOGICAL|Belantamab Mafodotin|Given IV
40770743|NCT04876248|DRUG|Lenalidomide|Given PO
40770744|NCT03787615|DEVICE|sipIT tools|Just in time drinking detection tools to promote increase fluid consumption
40770745|NCT06530459|DRUG|Menopausal hormone therapy|Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily Ingest Micronized Progesterone 200mg daily for 12 days each month
40770746|NCT06530459|BEHAVIORAL|Exercise training|Exercises would focus on upper and lower body strength generally. It is anticipated that the participants ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week.
40770747|NCT06530459|COMBINATION_PRODUCT|Menopausal hormone therapy + exercise training|"1. Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily and Ingest Micronized Progesterone 200mg daily for 12 days each month~2. Exercises would focus on upper and lower body strength generally. It is anticipated that patients ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week."
40770748|NCT04900298|DEVICE|SafeHaven Automated Hand Hygiene Device|Anesthesia providers in the intervention arm will be given a personal hand hygiene device, containing 64% ethyl alcohol, which provides actionable real-time performance feedback. The personalized device will be affixed to the provider's waist and will remain there for use throughout the perioperative period. Performance feedback is given to the anesthesia provider in real time with the number of personal hand hygiene events and an hourly hand hygiene rate, which is displayed on the device. Devices will be handed out to participating providers in the preoperative bay and retrieved in the post-anesthesia care unit upon case completion.
40770749|NCT02295865|DRUG|JNJ-38518168 60 mg|Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
40770750|NCT02295865|DRUG|JNJ-38518168 30 mg|One tablet of JNJ-38518168, 30 mg, orally, once daily.
40974426|NCT05408949|BEHAVIORAL|Functional Rehabilitation Program|Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability\[18\] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units \[18\]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
40974427|NCT05408949|BEHAVIORAL|EPTL|In EPTL it involves eccentric training in Full range (with dumbbells 15-10 RM) of Internal and external rotation at scapular plane elevation (0-45) degree and Flexion, Abduction, in full range (5 repetitions with a 45 second hold at slow speed) to target the series elastic component of the muscle .
40770751|NCT02295865|DRUG|JNJ-38518168 3 mg|One tablet of JNJ-38518168, 3 mg, orally, once daily.
40770752|NCT02295865|DRUG|Placebo|Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
40770753|NCT04860466|DRUG|CC-96673|IV Infusion
40974428|NCT05408949|BEHAVIORAL|HSR|In HSR it involves eccentric training in mid-range of motion (with dumbbells 15-10 RM) targeting the contractile component of the muscles and improving mechanical strength. Additionally, when there is 90% pain reduction on NPRS functional rehabilitation program start and they follow the same program as Group A.
40974429|NCT00572585|DRUG|AEB071|
40974430|NCT00572585|DRUG|Placebo|
41139917|NCT05615337|BEHAVIORAL|HPP|The HPP has the same structure of MBSR, including different components such as music, nutrition, cognitive enhancement, risk factors for dementia, and physical activity. During the half-day retreat participants are involved in watercolor painting activities. Materials for home practice are also provided.
41299297|NCT03430245|DEVICE|VelaShape III|The VelaShape III device combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with vacuum.
40770754|NCT05167708|PROCEDURE|Micro-osteoperforation|flapless small punctures in the bone at direction of tooth movement to accelerate the movement.
40974431|NCT05040321|DRUG|MIB-626|Participants will be randomized to either receive MIB-626 or matching placebo. The proposed intervention - targets multiple contributors to the pathology of AD; MIB-626 improves mitochondrial function, bioenergetics, and insulin sensitivity, inhibits A beta accumulation by reducing its synthesis and increasing its clearance, reduces neuroinflammation, exerts neuronal protective effects, and promotes neuronal regeneration and connectivity in preclinical models.
40974432|NCT05040321|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 500mg MIB-626 twice daily orally.
40974433|NCT06323278|BEHAVIORAL|Cognitive training|The training, provided by normal clinical practice, will consist of two cycles of cognitive stimulation (8 sessions each) structured and aimed at maintaining and learning compensatory strategies that take advantage of the integrated cognitive skills.
41299298|NCT03430245|DEVICE|UltraShape Power|The UltraShape Power device uses focused ultrasound energy for lipolysis (breakdown of fat) via a non-thermal mechanism of action.
41299299|NCT02567344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
41299300|NCT02567344|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
41299301|NCT05512130|DRUG|Empagliflozin 25 mg|Participants will take empagliflozin daily for 2 weeks.
41299302|NCT05512130|DRUG|Placebo|Participants will take a placebo daily for 2 weeks. The placebo will be identical to empagliflozin in appearance.
41299303|NCT00409630|DRUG|fluticasone|
41299304|NCT03464708|DIETARY_SUPPLEMENT|HMB|Powder form
41299305|NCT03464708|OTHER|Lactose (placebo)|Powder form
41299306|NCT05774457|BEHAVIORAL|Voice training|Traditional vs. virtual reality
41299307|NCT00075348|GENETIC|mutation analysis|
40974434|NCT02329730|BIOLOGICAL|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
40974435|NCT02329730|BIOLOGICAL|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
40974436|NCT02329730|BIOLOGICAL|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
41139918|NCT00433706|PROCEDURE|Control position by 3DOBI before the fraction|
41299308|NCT00843297|DEVICE|Coolgard|invasive Cooling via femoral ICY-catheter
41299309|NCT00843297|DEVICE|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
41299310|NCT00843297|OTHER|Conventional treatment|Intensive care-treatment without cooling
41299311|NCT01736202|BIOLOGICAL|fat orally|Oral ingestion of palm oil or canola oil or water at timepoint zero
41299312|NCT03000816|RADIATION|SBRT|Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
41459148|NCT04039360|COMBINATION_PRODUCT|self-expanding metallic stent placement followed by neoadjuvant chemotherapy|Neoadjuvant chemotherapy was administered 1 week after successful SEMS placement and decompression for patient with obstructing left-sided colonic cancer. Patients received either three cycles of mFOLFOX6 repeated every 2 weeks or two cycles of CAPOX repeated every 3 weeks. Elective surgery was performed 2 weeks after completion of chemotherapy by experienced colorectal surgeons.
41139919|NCT00433706|PROCEDURE|Standard imaging|
41139920|NCT04675268|DIAGNOSTIC_TEST|oximetry|A CE medical approved polygraphy device (Dreamscan 2 - Medatec) will be used to obtain oximetry (and PPG) data
41139921|NCT01817491|OTHER|American Heart Association Diet|
41139922|NCT01817491|OTHER|Reduced Fat Vegan Diet|
41139923|NCT02125292|DRUG|Mesalamine|
41139924|NCT05862402|DRUG|Dose-adjustment by PKPD|Dose-adjustment by pharmacokinetic and pharmacodynamic using Monte Carlo simulation
41139925|NCT03996577|DRUG|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
41139926|NCT03996577|DRUG|placebo|the control group will be given the same volume of saline.
41139927|NCT00321971|BEHAVIORAL|PST-MCI/AD Caregiving|The PST-based intervention will train participants to effectively use problem-solving skills with the aim of strengthening their ability to cope and preventing the onset or worsening of depressive and anxiety disorders. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
41299313|NCT03089177|BEHAVIORAL|Community Garden Intervention|"The investigators will recruit prospective adult gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. Individuals randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The Wait List Control group will remain on the community gardening wait lists and will not receive these resources.~Duration of the intervention is 1 year."
41299314|NCT00402974|DRUG|menaquinone 7|
41299315|NCT02183545|DRUG|BI 1060469|single rising doses given as tablet
41299316|NCT02183545|DRUG|Placebo|given as tablet (matching placebo of BI 1060469)
41299317|NCT00466999|DRUG|misoprostol|single dose of 400 mcg misoprostol administered sublingually
41459149|NCT01206439|DRUG|nebivolol|nebivolol 5 or 10 mg oral, daily
40974437|NCT02329730|BIOLOGICAL|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
41299318|NCT00466999|PROCEDURE|surgery|standard surgical treatment (dilation and curettage or manual vacuum aspiration)
41299319|NCT02995343|PROCEDURE|Hypogastric and/or uterine artery ligation|
41299320|NCT00868959|DRUG|lurasidone|Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
41299321|NCT04045249|DIETARY_SUPPLEMENT|Home based food|Home based food is compare able to RUTF
41299322|NCT02560688|DRUG|DS-1040b|20 mg single 12-hour intravenous infusion
41299323|NCT02560688|DRUG|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
41459150|NCT02179151|DRUG|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
41459151|NCT02179151|DRUG|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
41459152|NCT05436626|PROCEDURE|Early BDI reconstruction without abdominal sepsis control|BDI reconstruction within 6 weeks after the injury without abdominal sepsis control
41459153|NCT05436626|PROCEDURE|Early BDI reconstruction with abdominal sepsis control|BDI reconstruction within 6 weeks after the injury with abdominal sepsis control
41459154|NCT05436626|PROCEDURE|Delayed reconstruction|BDI reconstruction after 6 weeks after the injury
41299324|NCT03332108|OTHER|EpxBreastfeeding|"We developed an algorithm using the Epharmix platform, an automated toll-free phone and text message-based system that can programmatically query patients via their personal phones and subsequently collect response data, allowing clinically-relevant responses to trigger alerts to designated healthcare providers. The intervention for breastfeeding, hereafter referred to as EpxBreastfeeding, was built using significant clinical and patient input to only ask the most clinically-relevant questions for breastfeeding in a multiple-choice manner, such as In the past \[x\] days, have you fed your baby 1) breast milk only, 2) breast milk and formula or 3) formula only?. These communications elicit patient-reports of breastfeeding at intervals of interest for the provider, which is, on average, every 2 days in the first three weeks postpartum and every 5 days subsequently. All data is filtered by clinician-designed algorithms to stratify patients into categories."
41299325|NCT03332108|OTHER|Baby book survey|"We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe"
41299326|NCT00916955|OTHER|Observation|Observe development of syndrome over time
41299327|NCT05636579|BIOLOGICAL|EO2002|Intracameral injection of magnetic human corneal endothelial cells (EO2002)
41299328|NCT05636579|DRUG|Ripasudil|Daily use of Ripasudil drops
41299329|NCT05828186|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) catheter|Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of Shockwave IVL catheter treatment by their physicians.
41299330|NCT00003546|DRUG|gemcitabine hydrochloride|given IV
41299331|NCT00003546|RADIATION|radiation therapy|1.8 Gy to tumor bed
40770755|NCT05444387|OTHER|Upper limb loading|1 lb. external weight will be wrapped around both wrists during partial body weight support treadmill training. The partial body weight support treadmill training will be given for a maximum of 30 minutes and will finish earlier if the child asked to stop, or if the child stopped stepping. Body weight support will be systematically reduced, walking speed will be progressively increased over the training period, upright standing posture will be emphasized and normal kinematic components of the gait cycle will be facilitated during the training session. The training protocol for the current study will consist of 2 training sessions per weeks with at least one day in between and will last for 6 weeks.
41139928|NCT00321971|BEHAVIORAL|NT-MCI/AD Caregiving|The nutritional education program will be based on the new USSDA dietary recommendations. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
41299332|NCT01554956|BIOLOGICAL|Human Plasminogen|Eye Drops
40770756|NCT02959463|OTHER|Laboratory Biomarker Analysis|Correlative studies
40770757|NCT02959463|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
40770758|NCT02959463|BIOLOGICAL|Pembrolizumab|Given IV
41139929|NCT02134626|DRUG|Simvastatin|40mg / pill, one pill orally once a day for three months
41139930|NCT02134626|DRUG|Placebo pill|
41139931|NCT06012409|DEVICE|Hall Technique Prefabricated Metal Crown|The Hall Technique is a type of minimally invasive dental treatment. Hall Technique involves sealing the carious lesion under a Prefabricated Metal Crown to stop its progression preventing pain and/or infection.This makes the technique less invasive and it can be more acceptable to children than a traditional filling involving injections and drilling.
41299333|NCT03968861|DRUG|Xenon|Inhaled xenon gas given via purposely designed ventilator
41299334|NCT01044173|DEVICE|MR scan|axial and coronal free breathing HASTE sequences 3D T1 weighted gradient echo breathhold
41299335|NCT02972723|DRUG|Metformin|Oral Metformin 1g bd. (total = 2g per day) for 14 days
41299336|NCT05038163|OTHER|Nutrition Facts|The nutritional information label for each beverage is enlarged.
41299337|NCT05038163|OTHER|Text Warning|The health risks of sugary beverages are communicated to subjects using words/text and simple images.
41299338|NCT05038163|OTHER|Graphic Warning|The health risks of sugary beverages are communicated to subjects using a combination of words/text and graphic images/photographs.
41299339|NCT04158908|BEHAVIORAL|Oncolo-GIST|"Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~1. Principles of introducing prognosis in the setting of worsened scan results~2. Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months... with emphasizing that the oncology team will always provide care for you)~3. Addressing informational needs and psychological reactions~4. Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
41299340|NCT06181396|DRUG|Oxytocin|Native oxytocin analog
41299341|NCT01515982|BEHAVIORAL|Aerobic Exercise|The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
41299342|NCT01515982|BEHAVIORAL|Control Group|All participants were asked not to commence any new exercise regimen.
41299343|NCT00953550|DRUG|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
41299344|NCT00953550|DRUG|Succinylcholine|1 mg/kg
41299345|NCT04151017|OTHER|Autologous fibrin glue|Conjunctival graft fixation with autologous fibrin glue
40770759|NCT02959463|RADIATION|Radiation Therapy|Undergo hemithoracic radiation therapy
40974438|NCT02329730|BIOLOGICAL|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
40974439|NCT02329730|BIOLOGICAL|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
41299346|NCT04151017|OTHER|Suture|Graft fixation using 10.0 mononylon
41299347|NCT01596075|DRUG|Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade\>2). Cannabidiol will be given up to 90 days.
41299348|NCT04950881|PROCEDURE|Ultrasound guided vagus nerve block|Before the operation starts, patients received the ultrasound guided vagus nerve block. A 50mm Braun nerve stimulation needle is guided by the ultrasonic beam to insert into the carotid sheath and 10ml of lidocaine or ropivacaine is injected.
41299349|NCT04950881|DRUG|Bradycardia Treatment|If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
41299350|NCT04933305|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic surgical procedure
41299351|NCT00108849|DRUG|estradiol, 10 mcg|
41299352|NCT00848692|DRUG|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
41299353|NCT00848692|DRUG|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
41299354|NCT06126705|DRUG|Radiation: 18F-AlF-FAPi-04|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
41299355|NCT06126705|DRUG|Radiation: 18F-FDG|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
41299356|NCT00277316|DRUG|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
41299357|NCT01066078|OTHER|Echocardiography and SonR recording|
41299358|NCT00995735|PROCEDURE|Cholecystectomy|Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
41299359|NCT00995735|PROCEDURE|Appendectomy|Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
41299360|NCT00088634|DRUG|Lurasidone|80 mg AM dosing once daily
40770760|NCT05569317|OTHER|primary nursing|The primary responsibility of one nurse for the planning, evaluation, and care of a patient throughout the course of illness, convalescence, and recovery.
40770761|NCT06564714|DRUG|Early baclofen Intervention|"Baclofen is initiated as soon as any sign of acute spasticity.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response, i.e. when spasticity is no longer problematic."
40770762|NCT06564714|DRUG|Usual routine care|"Baclofen is initiated only when acute spasticity is deemed problematic.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response."
40770763|NCT02333448|BIOLOGICAL|Blood sample taken on the day the treatment is initiated|
40770764|NCT02333448|BIOLOGICAL|Blood sample taken on day 3 after initiation of treatment|
41299361|NCT00088634|DRUG|Placebo|Matching Placebo to 40mg lurasidone tablets
41299362|NCT01196169|DRUG|Daptomycin|One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
41299363|NCT01196169|DRUG|Vancomycin|Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if \> one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of \< 50 ml/min. Patients with creatinine clearance of \< 50 ml/min will only receive one dose.
41299364|NCT05872425|DRUG|DingKunDan(GuangYuYuan)|"The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment."
40974440|NCT02329730|BIOLOGICAL|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
40974441|NCT02329730|BIOLOGICAL|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
40974442|NCT05659797|DEVICE|BPET/DBT imaging|Imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of \[18F\]-Fluoroestradiol (FES).
40974443|NCT05659797|DRUG|18F-FES|Radiolabelled fluoroestradiol for PET imaging
40974444|NCT02775162|DEVICE|Normothermic Machine Perfusion (NMP)|
40974445|NCT02775162|OTHER|Standard of Care (Ice)|
40974446|NCT04398498|DIAGNOSTIC_TEST|Diagnostic Test: TruGraf® Testing|5 mL collection PAXgene blood sample
40974447|NCT02986399|OTHER|Fast track patient pathway|Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
40974448|NCT00296374|DRUG|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
40974449|NCT00296374|DRUG|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
40974450|NCT00296374|DRUG|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
40974451|NCT02345681|DRUG|Furosemide|
40974452|NCT00774644|DRUG|Clarithromycin 500mg|
40974453|NCT03807466|BEHAVIORAL|Dynamic/Interactive vs. Static/Paginated Report|Evaluate whether a stand-alone interactive audit-and-feedback report highlighting antibiotic prescribing can lead to greater reductions in antibiotic use, than a report embedded in a broader static feedback system
40974454|NCT03807466|BEHAVIORAL|LTC Physicians Enrolled vs. Not Enrolled in Reports|Evaluate whether being provided an audit-and-feedback report (regardless of dynamic or static) can lead to greater reductions in antibiotic use, than those who do not receive either report
40974455|NCT02316808|DIETARY_SUPPLEMENT|Plant stanol ester|Smoothie that contains plant stanol ester
40974456|NCT02316808|DIETARY_SUPPLEMENT|placebo|Smoothie that contains placebo
41299365|NCT05872425|DRUG|Drospirenone and Ethinylestradiol Tablets (Ⅱ)|The experimental group and the control group would be given oral Drospirenone and Ethinylestradiol Tablets (Ⅱ). According to the packaging instructions, on the first day of menstruation, according to the packaging instructions, the subjects should take the tablet, then take the rest sequential at the same time every day for 28 consecutive days, menstruation would happen after drug withdrawal (or after 7 days of drug withdrawal), and the next medication cycle begin on the first day of menstruation.
41299366|NCT01741272|PROCEDURE|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
41299367|NCT01741272|PROCEDURE|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
41299368|NCT00000849|DRUG|Aldesleukin|
41459155|NCT03056144|DEVICE|whole body vibration therapy|"The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~1. st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~2. nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~3. th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~4. th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min \>5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant."
40974457|NCT00870571|DRUG|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
40974458|NCT00870571|DRUG|NorvasC® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
40974459|NCT00688974|PROCEDURE|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
40974460|NCT00688974|PROCEDURE|Adjustable gastric band|Laparoscopic adjustable gastric band
40974461|NCT00804791|OTHER|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
40974462|NCT00804791|OTHER|Unisol 4 Saline Solution|saline solution for irrigating the cornea
40974463|NCT01122836|OTHER|Massage|Therapeutic Massage
40974464|NCT03178864|DRUG|Rivaroxaban|Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)
40974465|NCT03178864|DRUG|Standard of care|Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
40974466|NCT02483520|BEHAVIORAL|FamTechCare|Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
41459156|NCT02986256|BEHAVIORAL|Taking pictures|Photograph of foot ulcer with transmission to referring nurse 1 time per week
40974467|NCT05115734|DIAGNOSTIC_TEST|Serum acylcarnitine profiling|"Blood samples are collected through a central or peripheral venous line placed for clinical use, or through venous punction. Blood will be drawn into a serum gel tube (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), before being centrifuged (3500 rpm, 15 min, 4°C). Supernatant will be frozen at -20°C and stored for later analysis.~Serum ACs concentrations (free carnitine (C0), C2-, C3-, C3DC-, C4-, C4-OH-, C4-DC-, C5-, C5:1-, C5-OH-, C5DC-, C6-, C6-OH-, C6-DC-, C8-, C8:1-, C10-, C10:1-, C10:2-, C12-, C12:1-, C14-, C14:1-, C14:2-, C14-OH-, C16-, C16:1-, C16-OH-, C16-1-OH-, C17-, C18- ,C18:1-, C18:2-, C18-OH-, C18:1-OH-, C18:2-OH-carnitine) will be determined on a TQ5500 tandem mass spectrometer (Sciex, Framingham, MA, USA)."
41299369|NCT03175380|BIOLOGICAL|bacillus Calmette-Guérin|BCG injection for prevention of tuberculosis
41459157|NCT02986256|BEHAVIORAL|Visit at home|Home visit by the referring nurse every 15 days
40974468|NCT05490329|BEHAVIORAL|Tough Talks COVID|Intervention participants will download the TT-C app from the iOS or Google Play store and complete the intervention within one month.
40974469|NCT05486676|BEHAVIORAL|VR-Moodboost; a Virtual Reality intervention for depression to enhance positive affect and reduce depressive symptoms.|All participants receive the same VR-Moodboost treatment, they only differ in the length of the baseline; 3 or 5 weeks.
41299370|NCT03037658|OTHER|Offering a financial incentive to increase walking|"After a baseline week of walking while wearing a pedometer, participants will be randomly assigned to one of the five conditions. In each of these conditions, participants will have the chance to earn .02/step for each additional step per day (on average across the week, above baseline levels). After a week of incentivized walking, participants will again be asked to wear the pedometer for one final week (with no incentive).~Because the investigators need a week of walking before the incentive week, it is important that participants do not know the specific incentive aspect at the beginning of the study. Therefore, the investigators will not disclose the incentive structure at the beginning of the study. The investigators will debrief participants at the end of the study, and they will be fully informed of the purposes of the study at that time."
41299371|NCT06555692|BIOLOGICAL|Transplant acellular dermal matrix(ADM)|The principle of surgery is the pectoral muscle preservation (prepectoral) method and the subpectoral method (Breast Reconstruction using implants). After wrapping the implant with acellular dermal matrix(ADM), it is inserted into the breast and fixed to the underlying muscle or surrounding tissue depending on the situation.
41299372|NCT01473251|DRUG|Avastin|1.25 mg monthly for 4 months
41299373|NCT01473251|DRUG|Avastin|1.25 mg monthly for 4 months
41299374|NCT01473251|DRUG|Lucentis|0.5 mg monthly for 4 months
41299375|NCT03491163|DIAGNOSTIC_TEST|Syndecan-1 concentration evaluation|Blood sample will be taken and analysed using ELISA method.
41299376|NCT04072354|DRUG|SEP-363856 50mg|SEP-363856 50mg tablet dosed once daily
41299377|NCT04072354|DRUG|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
41299378|NCT04072354|DRUG|Placebo|Placebo tablet dosed once daily
40974470|NCT04416594|OTHER|Data collection|Only data collection
40974471|NCT03331419|BEHAVIORAL|Exercise test|30 sec of knee squats followed by a six minute walk test repeated on consecutive days.
41299379|NCT03117049|DRUG|ONO-4538|360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
41299380|NCT03117049|DRUG|Carboplatin|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
41299381|NCT03117049|DRUG|Paclitaxel|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
40974472|NCT02634229|GENETIC|blood sample|
41299382|NCT03117049|DRUG|Bevacizumab|Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
41299383|NCT03117049|DRUG|Placebo|Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
41299384|NCT05160545|DRUG|GNC-035|Administration by intravenous infusion
41299385|NCT04825093|DIETARY_SUPPLEMENT|Vitamin D supplementation in pregnant women|Intervention group will be administered 1,000 UI of vitamin D and a control group will be administered 400 UI of vitamin D. Participants will take the supplementation from the enrollment to delivery.
41299386|NCT00320385|DRUG|Lapatinib|oral lapatinib once daily
41299387|NCT00320385|BIOLOGICAL|Trastuzumab|IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose
41299388|NCT06404125|DIAGNOSTIC_TEST|Range of Motion of Shoulde Joint|Goniometric measurements will be made for both upper extremities. Flexion, extension, abduction, adduction, internal and external rotation angles of the shoulder complex will be evaluated in the measurement.
41299389|NCT06404125|DIAGNOSTIC_TEST|Hand Grip Test|The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 10 seconds. The test will be repeated for both upper extremities separately.
41299390|NCT06404125|DIAGNOSTIC_TEST|Numeric Rating Scale|Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
41299391|NCT06404125|DIAGNOSTIC_TEST|Pain-Pressure Threshold Measurement With an Algometer|"The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral shoulder region and left forearm as control region and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~1. Bilateral supraspinatus muscle: 1 cm cranial to the midpoint of the spina scapulae~2. Bilateral infraspinatus muscle: Medial edge of the scapula, intersection of the spina scapula and the inferior scapular angle~3. Bilateral upper trapezius muscle: MidN point of the line joining the acromion and C7 spinous process~4. Left forearm volar face center as control point"
40770765|NCT02333448|BIOLOGICAL|Blood sample taken on day 5 after initiation of|
40974473|NCT04497805|BIOLOGICAL|ALLO-ASC-SHEET|Hydrogel sheet containing Allogenic Mesenchymal Stem Cells
40974474|NCT03196934|DRUG|Cannabidiol oral solution|Cannabidiol; Pharmacological class of drug
40974475|NCT01633333|OTHER|Water exchange colonoscopy|Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
40974476|NCT01633333|OTHER|Carbon dioxide insufflation|Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
40974477|NCT02185833|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
40974478|NCT02185833|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
41299392|NCT06404125|DIAGNOSTIC_TEST|Quick DASH|The arm, shoulder and hand problems rapid questionnaire is a shortened version of a questionnaire designed to detect symptoms and loss of function secondary to musculoskeletal problems of the upper extremity. The questionnaire will be used to assess quality of life related to upper extremity function.
41299393|NCT06404125|DIAGNOSTIC_TEST|SF-36|The scale was developed by Ware in 1987 and consists of 36 questions in which 8 sub-parameters related to the health status of the person are questioned. These parameters are physical function, pain, limitation due to physical and emotional problems, emotional well-being, social function, fatigue and general health perception. The Turkish validity and reliability of the scale was performed by Pınar et al. It is one of the leading methods used in the evaluation of quality of life in our country as well as all over the world.
40974479|NCT05236010|DEVICE|rTMS|Transcranial magnetic stimulation is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. During an rTMS session, an electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain being targeted.
40974480|NCT05236010|DEVICE|HD-tDCS|Transcranial direct current stimulation (tDCS), is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain. A constant, low intensity current is passed through two electrodes placed over the head which modulates neuronal activity.
40974481|NCT05236010|OTHER|Attention Process Training|Attention Process Training (APT) is a multi-session exercise designed to help improve the ability to focus on relevant material while ignoring irrelevant distractions. Further, it helps improve the speed of processing information.
41299394|NCT06404125|DIAGNOSTIC_TEST|Central Sensitization Scale|The central sensitization scale was developed primarily to detect central sensitization findings in patients with chronic pain and consists of two parts, A and B. In part A, 25 somatic and psychosocial symptoms frequently found in patients with central sensitization are questioned. In part B, the presence of diseases with a well-defined relationship with central sensitization is questioned without participating in the scoring. Patients who score 40 points or more out of a total of 100 points are considered to have central sensitization. Düzce et al. stated that the Central Sensitization Scale can be used as a valid method in the Turkish population to screen the presence of central sensitization in patients presenting with chronic pain.
41299395|NCT06404125|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|This scale was developed by Zigmond and Snaith in 1983 to screen anxiety and depression in individuals with physical illness. The scale consists of fourteen questions, seven for anxiety and seven for depression, to be answered on a four-point Likert scale. The Turkish validity and reliability of the scale has been demonstrated and a score above ten for anxiety and seven for depression is considered significant.
41299396|NCT04483739|DRUG|Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
41459158|NCT00640341|DEVICE|PureVision Contact Lens|contact lens for daily wear
40770766|NCT02333448|BIOLOGICAL|Blood sample taken on day 7 after initiation of treatment|
41459159|NCT00640341|DEVICE|Acuvue Oasys Contact Lens|contact lens for daily wear
40770767|NCT02333448|BIOLOGICAL|Blood sample taken on day 10 after initiation of treatment|
41459160|NCT00640341|DEVICE|O2Optix Contact lens|contact lens for daily wear
41459161|NCT00991692|OTHER|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
41459162|NCT02823327|GENETIC|Laboratory Biomarker Analysis|Correlative studies
41459163|NCT02823327|OTHER|Medical Chart Review|Medical chart review is performed
41459164|NCT00796328|DRUG|Phenylephrine infusion|Up-down, biased coin design
40974482|NCT02324894|PROCEDURE|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
40974483|NCT01656785|DRUG|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
40974484|NCT01911871|BIOLOGICAL|Blood sample|a blood sample was taken on the day of inclusion
40974485|NCT02106091|DRUG|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
40974486|NCT01831193|DRUG|Curcumin|
40974487|NCT02256904|PROCEDURE|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
40974488|NCT02256904|PROCEDURE|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
40974489|NCT01652560|DRUG|bevacizumab|The patients will be treated with Avastin combined neoadjuvant chemotherapy
40974490|NCT00331682|DRUG|alvocidib|Given IV
40974491|NCT00331682|DRUG|docetaxel|Given IV
40974492|NCT02075450|DEVICE|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
40974493|NCT02075450|OTHER|Just in Time Video|CPR Just in Time training video administered before the simulation case
40974494|NCT01220323|DEVICE|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
40974495|NCT01220323|DEVICE|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
40974496|NCT02059486|BEHAVIORAL|Teen Choice|The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
40974497|NCT00459953|DRUG|Extended treatment|All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
40974498|NCT00221273|PROCEDURE|ACL surgery|
40974499|NCT06476262|BEHAVIORAL|This research has only one arm. The intervention focuses on occupational issue|During the post-stroke consultation, each participant is invited to complete questionnaires on occupational gaps, mood disorders, fatigue, cognition, and quality of life.
40974500|NCT01074450|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
40974501|NCT01074450|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
40974502|NCT04506021|DRUG|Bicarbonate Ringer's solution|According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution. no Intervention.
40974503|NCT04506021|DRUG|Other Crystalloid|According to the choices of the patients' immediate family members, patients will be divided into other clinical used crystalloid. no Intervention.
40974504|NCT00256893|DRUG|ropinirole|
40974505|NCT00294268|BEHAVIORAL|cognitive behavioural therapy|20 weekly sessions of CBT integrated with motivational enhancement strategies
40974506|NCT01847417|DRUG|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
40974507|NCT01847417|DRUG|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
40974508|NCT01847417|DRUG|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
40974509|NCT01847417|DRUG|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
40974510|NCT03718585|OTHER|whole exome sequencing analysis|Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing
40974511|NCT00321802|DRUG|Simvastatin|Patients take 40 mg of simvastatin per day for 6 months.
40974512|NCT00321802|DRUG|Placebo|Placebo
40974513|NCT04481581|OTHER|Electronic Alerts|When FiO2 remains =\>0.4 and SpO2 =\>94% for more than 45 minutes, an electronic health record based alert will be sent to respiratory therapists to titrate oxygen per decision support tool.
40974514|NCT01539694|DEVICE|LD118033 contact lens|Multifocal contact lens worn on a daily wear basis for 1 week
40974515|NCT01539694|DEVICE|PureVision multifocal contact lens|PureVision multifocal contact lens worn on a daily wear basis for 1 week.
40974516|NCT05825521|OTHER|MRI|During management, patients with hydrocephalus will be subjected to flow MRI and diffusion MRI. Flow parameters and diffusion parameters will be measured and compared to those found in control subjects receiving the same type of imaging
40974517|NCT00279240|DRUG|Metformin|
40974518|NCT04242303|PROCEDURE|Total knee replacement|"Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts."
40974519|NCT01134783|BEHAVIORAL|CHOICES Intervention|Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
40974520|NCT03247530|DRUG|Placebo|Placebo was administered once daily
40974521|NCT03247530|DRUG|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
41459165|NCT00006516|BEHAVIORAL|Infant stimulation|
41299397|NCT04483739|DRUG|Isatuximab Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
40974522|NCT03247530|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
41299398|NCT03464058|DRUG|BOS172767 tablets|Oral tablets
41299399|NCT03464058|DRUG|BOS172767 liquid capsules|Oral capsules
41299400|NCT03464058|DRUG|BOS172767 micronized capsules|Oral capsules
41299401|NCT03464058|DRUG|BOS172767 immediate release capsules|Oral capsules
41299402|NCT03464058|DRUG|BOS172767 matching placebo capsules|Oral capsules
41459166|NCT04712903|DRUG|Durvalumab|Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.
40974523|NCT02989194|DRUG|VIS410 low dose|Single intravenous fixed low dose of VIS410
40974524|NCT02989194|DRUG|VIS410 high dose|Single intravenous fixed high dose of VIS410
40974525|NCT02989194|DRUG|Placebo|Single intravenous infusion of placebo
40974526|NCT06195163|DRUG|Transdermal Gel in Sachet Dosage Form|Transdermal testosterone gel application prior to ovarian stimulation in the study group.
40974527|NCT06195163|DRUG|No pretreatment|No pretreatment prior to the ovarian stimulation in the control group.
40974528|NCT03181581|BIOLOGICAL|acoustic coupling fluid|ultrasound images obtained with both ACF and Ringer's acetate
40974529|NCT03181581|BIOLOGICAL|Ringer's acetate|ultrasound images obtained with Ringer's acetate only
40974530|NCT03900351|PROCEDURE|Wii fit protocol of virtual reality games|the Wii fit session by standing on the Wii fit board with bare feet, hands on hips and both eyes open. Pretest on Wii fit was done to make the subject familiar with the board and tasks of weight shift .
40974531|NCT03900351|PROCEDURE|Regular exercise rehabilitation protocol|It will be according to the criterion of Adams et al. (2012).
40974532|NCT04337749|DRUG|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
40974533|NCT04337749|DEVICE|ZnO-NPs socks|ZnO-NPs socks were given to patients for 2 weeks
40974534|NCT04337749|COMBINATION_PRODUCT|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks were given to patients for 2 weeks
40974535|NCT04337749|DEVICE|Placebo socks|Placebo socks were given to patients for 2 weeks
40974536|NCT00352144|DRUG|Eszopiclone|Eszopiclone 3 mg
40974537|NCT00352144|DRUG|Placebo|Placebo tablet
40974538|NCT06463210|DEVICE|Virtual reality as a distraction technique|A 360º relaxing video with music was displayed through a VR headset
40974539|NCT00664391|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
40974540|NCT02733068|BIOLOGICAL|HPV-16/18 vaccine|0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
40974541|NCT02733068|BIOLOGICAL|HPV-16/18 placebo|0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
40974542|NCT05300620|DEVICE|Custom Foot Orthotics EVA|these are custom foot orthotics made out of Ethyl Vinyl Acetate material
40974543|NCT05300620|DEVICE|Original Liner|these are original shoe liners
40974544|NCT05300620|DEVICE|Custom Foot Orthotics PU|these are custom foot orthotics made out of Expanded Poly Urethane Material
40974545|NCT05300620|DEVICE|Custom Hybrid Foot Orthotics|these are custom foot orthotics made out of a combination of Ethyl Vinyl Acetate and Expanded Poly Urethane Material
40974546|NCT04023851|DEVICE|Mobile application Brain4U|Brain4U application provides participants to record seizures, medications, side effects, and combined psychiatric problems. It also reminds participants when to take antiepileptic drugs.
41459167|NCT04712903|DRUG|Cisplatin|Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.
40974547|NCT01084746|BEHAVIORAL|PC-based tailored intervention|Patients will receive a tailored interactive PC-based intervention at a freestanding kiosk.
40974548|NCT01084746|BEHAVIORAL|Printed educational materials|Patients will receive generic printed educational materials about CRCS in the PEC when they arrive at the Main Campus for their appointment.
40974549|NCT00666029|DRUG|atorvastatin|40 m.g. o.d. tablets for 6 months
40974550|NCT00666029|DRUG|placebo|Placebo
40974551|NCT00735956|BEHAVIORAL|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
40974552|NCT05021991|DRUG|100 mg PRAX-944|Once daily oral treatment with titration
41299403|NCT03464058|DRUG|BOS172767 matching placebo tablets|Oral tablets
41299404|NCT03464058|DRUG|Rabeprazole|Oral tablets
41459168|NCT04712903|DRUG|Etoposide|Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.
41459169|NCT04712903|DRUG|Carboplatin|Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.
41459170|NCT03387462|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
41459171|NCT03387462|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
41459172|NCT03860441|OTHER|Computerized cognitive training|Intervention used CogniFit platform with Personalized brain training sub-option
41139932|NCT05495633|OTHER|Collection and evaluation of clinical (CROMs) and patient-reported outcomes (PROMs)|"The study uses a web-based German-language registry database called heartbeat ONE by heartbeat medical solutions GmbH (Berlin, Germany) that provides both clinical reported outcome measures (CROMs) and patient-reported outcome measures (PROMs). PROMs are investigated by validated questionnaires: IPSS/QoL, ICIQ-MLUTS, MSHQ, ICIQ-MLUTSsex, QoR-15GE, PROMIS Global Health 10, ICIQ-S, NRS, and by home urine flow measurement (iUFlow) as well as by self-designed questionnaires to assess patients´ preferences and expectations for Rezum and for surgical therapy of the prostate, satisfaction with the Rezum therapy, side effects of the Rezum therapy, (re)medication to treat BPO and LUTS, and reoperations after Rezum therapy."
41139933|NCT05495633|OTHER|Analysis of uroflowmetry data by Kesem Health iUFlow medical uroflowmetry device|If patients have a smartphone with app function (Android or Apple), they will be provided with a certified and approved home uroflowmetry medical device (iUFlow from Kesem Health) at study entry. This should enable patients to measure their urine flow conveniently from home and thus be independent of the medical consultation (automated home bladder monitoring solution). iUFlowTM is marketed by Kesem Health Pty Ltd, 5A Hartnett Cl, Mulgrave VIC 3170, Australia. The Device is FDA and CE approved and is approved to be used in the EU and Switzerland. Every time a patient is using the device urine flow measurement data and additional voluntary parameters entered by the patient (micturition protocol, drinking protocol) will be sent to the study database.
41139934|NCT04131556|DRUG|Maribavir|Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.
41139935|NCT02664870|PROCEDURE|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
40974553|NCT05021991|DRUG|60 mg PRAX-944|Once daily oral treatment with titration
41139936|NCT02664870|PROCEDURE|Arthroplasty|Total hip, shoulder, or knee arthroplasty
41139937|NCT03511781|RADIATION|Hypofractionated Radiotherapy|Palliative Hypofractionated radiotherapy 35 GY in 10 fractions over 2 weeks in advanced incurable Breast Cancer
41139938|NCT03648749|BEHAVIORAL|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
41139939|NCT01615614|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
41139940|NCT01615614|DRUG|Rifabutin|Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
41139941|NCT03031782|DRUG|secukinumab|secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
41139942|NCT03031782|OTHER|placebo|Matched placebo to AIN457 for use in the double blind Treatment Period 2
41139943|NCT03547206|DRUG|RPh201 Cohort A|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
40974554|NCT05021991|DRUG|Placebo|Once daily oral treatment
40974555|NCT05021991|DRUG|Flexibly dosed 20 mg to 100 mg PRAX-944|Once daily oral treatment
40974556|NCT00700960|DRUG|insulin detemir|initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
40974557|NCT03471650|DRUG|18F-DCFPyL Injection|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
40974558|NCT03923855|DEVICE|BTL-899|BTL-899 therapy
40974559|NCT04775459|DRUG|Surfactant administration until 2020|Surfactant is administrated if Fi02 \>30% among the Guidelines of 2019
40974560|NCT04775459|DRUG|Surfactant administration since 2021|Surfactant is administrated if Fi02 \>30% OR if score LUS \>8/18 among the literature
40974561|NCT06428669|DRUG|Nitro-Bid 2 % Topical Ointment|Intervention group will get 30mg of Nitro-Bid topical ointment applied over the chest (15mg/ 1 packet on each side) one time intra-operatively
40974562|NCT05004610|DRUG|Sodium Lactate Solution|continuous intravenous infusion of half-molar sodium lactate
40974563|NCT03171415|DRUG|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
41139944|NCT03547206|OTHER|Placebo Cohort A|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
41139945|NCT03547206|DRUG|RPh201 Cohort B|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
41139946|NCT03547206|OTHER|Placebo Cohort B|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
41139947|NCT01404338|DRUG|Halobetasol 0.05% ointment|
41139948|NCT01404338|DRUG|Placebo Ointment|
41139949|NCT00264576|BIOLOGICAL|Influenza Virus Vaccine|
41459173|NCT05762653|DIAGNOSTIC_TEST|Endoscopic ultrasound|Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.
40974564|NCT03171415|DRUG|Placebo|Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
40974565|NCT01706081|PROCEDURE|Acupuncture|Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.
40974566|NCT01706081|PROCEDURE|Wait-list|For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
40974567|NCT01235247|BEHAVIORAL|reminders vs. no reminders|Intervention providers will receive clinical reminders as part of patient care, and control group providers will not receive the reminders
40974568|NCT01303107|DRUG|Bupivacaine|single dose of 15 mg by a slow injection rate of 1 mL/s
40974569|NCT05436392|BEHAVIORAL|Peer Comparison Feedback|USAP anesthesia providers will receive monthly alerts via USAP's smartphone-based practice management application, text message, or email presenting individual-level data on their benzodiazepine administration patterns versus other USAP providers, using data from the USAP clinical and quality data warehouse.
40770768|NCT02921867|OTHER|Simulation-based training|The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
40770769|NCT05409794|BIOLOGICAL|Blood sample|Blood sample for the determination of plasma lithium levels
41139950|NCT05431322|DRUG|Dexmedetomidine|Initially give loading dose with 0.5 mcg/kg for 10 min and then keep maintenance dose with 0.5 mcg/kg/h until two-lung ventilation.
41139951|NCT00449254|DRUG|oleoyl-estrone (MP-101)|
41139952|NCT02192632|DRUG|Epiduo once daily with detailed instruction for how to apply it|
40770770|NCT00867139|DRUG|TCAD|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
40770771|NCT00867139|DRUG|Zanamivir or Oseltamivir|Zanamivir or Oseltamivir
40770772|NCT00867139|OTHER|Open label treatment with TCAD|TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
40770773|NCT05326295|DIAGNOSTIC_TEST|CTC detection|CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.
40770774|NCT03468998|DEVICE|Socket Grafting with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket
40770775|NCT03468998|DEVICE|Socket Grafting with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket
40770776|NCT03468998|DEVICE|Lateral ridge augmentation with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
40974570|NCT05436392|BEHAVIORAL|Patient Informational Letter|Breif informational letters will be distributed to eligible patients within the 2 weeks prior to surgery. Letters will be produced on USAP letterhead and signed by the USAP Chief Quality Officer. Letter text will state USAP's commitment to brain health and avoiding potentially unnecessary medications for patients undergoing surgery. It will also include a statement encouraging patients to discuss anesthesia plans with their clinicians at the time of surgery to aid tailoring of care to individual needs. Letters will be distributed directly to patients via text link, email, or hard copy as a component of standard pre-operative instructional communications and other educational and patient outreach materials related to clinical care.
40974571|NCT05981417|OTHER|Therapeutic exercise|Therapeutic exercise sessions will be guided by a physiotherapist.
40974572|NCT05981417|OTHER|Therapeutic exercise|Therapeutic exercise sessions will be performed at home.
41139953|NCT02192632|DRUG|Epiduo- once daily, simple instruction for application|
40770777|NCT03468998|DEVICE|Lateral ridge augmentation with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
40770778|NCT06015516|DRUG|Minoxidil Tablets|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
40770779|NCT06015516|DRUG|Minoxidil topical solution 20 mg/ml|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
40770780|NCT00448513|DIETARY_SUPPLEMENT|catechin extracts|comparison with placebo
41139954|NCT02192632|DRUG|BPO once daily|
41139955|NCT06506175|DRUG|HRS9531 tablets|HRS9531 tablets
40770781|NCT00778401|DRUG|Gabapentin tablets 800 mg|
40770782|NCT06482983|PROCEDURE|Mechanical Ventilation Mode|after intubation different ventilation mode (VC,PC,PC-VG)
40770783|NCT00140686|BIOLOGICAL|Rotavirus (vaccine)|
40770784|NCT02712203|BIOLOGICAL|MMR vaccine / MMRV vaccine|Subcutaneous injection, two doses
41139956|NCT03453645|PROCEDURE|ventricular tachycardia ablation|The usual organization of hospitalization of the patients addressed for ventricular tachycardia ablation and his follow-up are not modified by the protocol. .
41139957|NCT00195819|BIOLOGICAL|adalimumab (D2E7)|Adalimumab 40 mg every other week (eow)
41139958|NCT00195819|BIOLOGICAL|placebo|Placebo every other week (eow)
41139959|NCT04620265|OTHER|Antigravity treadmill training 100% weight bearing|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
41139960|NCT04620265|OTHER|Antigravity treadmill training 75% weight bearing|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
41139961|NCT04620265|OTHER|Antigravity treadmill training 50% weight bearing|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
41299405|NCT05904405|OTHER|quationaire|"Data will be collected through a semi-structured interview administered questionnaire which includes:~1. Socio-demographic characteristics of women~2. Family planning practice: This will include number of living children, current use of FP method and its type, and suggested causes of discontinuation of FP, previous contraceptive use, and reason for the visit 3-Facility factors such as gender of providers, qualification of providers, type of the health facility.~4-Quality of contraceptive counseling (QCC) scale: it is a 22-item scale which measures the quality of care received by women during family planning visits. It includes : 1) information exchange, 2) interpersonal relations, and 3) disrespect and abuse in contraceptive counseling. The information exchange subscale consists of ten items, the interpersonal relationship subscale consists of seven items, and the disrespect and abuse subscale consists of five items."
41299406|NCT03000309|DRUG|Apremilast|
41299407|NCT06554314|DIETARY_SUPPLEMENT|probiotics|Eat a capsule for once, and once a day
41299408|NCT04323397|DEVICE|Non-invasive ventilation|Intervention nasal high frequency oscillatory ventilation (nHFOV) and nasal synchronized intermittent positive pressure ventilation (nSIPPV) were generated by neonatal ventilators (SLE6000 infant ventilators, United Kingdom) using bi-nasal prongs (RAM cannula, NEOTECH®, USA) or the nasal mask of the same type for both ventilation modes. The size of the prongs was determined by the infant's weight. The largest possible prongs were used, with a snug fit to avoid leakage. Pacifier for preterm and term neonate (Jollypop™, USA) was taken to avoid leakage from the mouth. The disposable ventilator circuit (Fisher \& Paykel RT268™, Evaqua Dual Limb Infant Breathing Circuit Kit with Evaqua 2 Technology and Pressure Line, Flow \> 4L/min, New Zealand) was used. The initial NIV setting was (7) described in arm description. (above)
41299409|NCT03384290|DRUG|PRS-060|Drug
41299410|NCT03384290|DRUG|Placebo|PRS-060 Matching Placebo
41299411|NCT01411293|OTHER|Low-Fat Milk|Participants will ingest 2 cups of low-fat milk on 1 occasion.
40770785|NCT05137158|DEVICE|Intermittent theta burst stimulation|Intermittent theta burst stimulation(iTBS) on the left DLPFC, the left DLPFC will be targeted utilizing the localite neuronavigation system. The stimulation intensity is set at 80% of resting motor threshold(RMT), and the other parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 600 pulses per session, total duration of 3 minutes and 20 seconds.
41139962|NCT04620265|OTHER|Antigravity treadmill training 25% weight bearing|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
41139963|NCT04620265|OTHER|The conventional exercise program|This group received the conventional exercise program only.
41139964|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
41139965|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
41139966|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
41139967|NCT00696241|DRUG|Olmesartan|Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
41139968|NCT00696241|DRUG|Placebo|Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
41139969|NCT05799534|OTHER|Physical Therapy Rehabilitation|Physical Therapy Rehabilitation program to to establish a novel physiotherapeutic plan to determine the effects on post-COVID-19 patients' psychoemotional condition, lung capacity, cardiorespiratory condition, and muscle strength.
41299412|NCT01411293|OTHER|Rice Milk|Participants will ingest 2 cups of rice milk on 1 occasion.
40770786|NCT05137158|DEVICE|Sham stimulation|The same procedure will be performed in sham group including the RMT assessment and the neuronavigation system for target localization, but the sham coil will vertical to the brain surface and deliver a very slight magnetic field, which have the same appearance and sound, and provide the same tactile sensations as the active coils.
40770787|NCT05984290|DEVICE|orthokeratology lens|Each subject will wear the study lenses in both eyes overnight for approximately 3 months.
40770788|NCT02530255|DIETARY_SUPPLEMENT|cycloastragenol|Oral telomerase activator - cycloastragenol.
41139970|NCT03377049|DRUG|Acetazolamide|1 g acetazolamide through a peripheral IV line
41139971|NCT01523184|DRUG|Placebo Capsule|This is the placebo capsule
41139972|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 10 mg under investigation
41139973|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 20 mg under investigation
40770789|NCT02530255|DIETARY_SUPPLEMENT|placebo (for cycloastragenol)|placebo comparator, placebo for cycloastragenol.
40770790|NCT00409656|DRUG|Basiliximab|
40770791|NCT00004419|DRUG|insulin-like growth factor I|
40974573|NCT02226055|DEVICE|Arterial Stiffness Assessment|"The following will be measured: brachial systolic and diastolic bp, heart rate, mean arterial bp, pulse pressure, brachial augmentation index (difference between the amplitudes of the late (backward) systolic wave (P2) and the early (forward) systolic wave (P1) over the pulse pressure x 100), central augmentation, ejection duration of the left ventricle, return time (time of the pulse wave travelling from aortic root to the bifurcation and back), aortic pulse wave velocity ( velocity of the pulse wave in the aorta), central systolic bp, central pulse pressure and diastolic reflection area (provides information about the quality of diastolic filling in the coronary arteries).~We will perform an arterial age assessment. Patients are given a feedback form with their results to give to their general. Those with increased arterial stiffness will be tested for serum calcium and phosphate levels, and audited to ensure that a statin is commenced if not contraindicated."
41139974|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 30 mg under investigation
40770792|NCT04787809|BEHAVIORAL|Living Well|Living Well is a single session digital intervention that aims to decrease experiential avoidance and increase engagement in values-consistent behavior.
40770793|NCT01916473|OTHER|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
41139975|NCT06041438|DRUG|BI 1584862|BI 1584862
41139976|NCT06041438|DRUG|itraconazole|itraconazole
41139977|NCT01049490|BIOLOGICAL|S-OIV H1N1 vaccine|Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
41459174|NCT06343727|DIETARY_SUPPLEMENT|Egg white protein pudding|Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks
41459175|NCT06343727|DIETARY_SUPPLEMENT|: Ensure Plus|Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks
40770794|NCT01916473|OTHER|Continuous wound infusion|Continuous wound infusion via catheter
40770795|NCT05196620|OTHER|Endoanal Ultrasound (EAUS)|Endoanal Ultrasound pre- and postpartum
40974574|NCT01937559|BIOLOGICAL|Tranexamic acid (TXA)|1.5g of TXA in 100ml normal saline solution
40974575|NCT01937559|DRUG|Normal saline|
40974576|NCT01634815|PROCEDURE|The Edge|measuring blood lactate
40974577|NCT05409573|OTHER|double monitoring of EtO2|"A double monitoring of EtO2 will be performed during the procedure of intubation (from the beginning of the preoxygenation to the success of intubation):~* In the pharynx (via a nasopharyngeal catheter) for the needs of the study~* On the facemask (as the practice in the OR)"
40974578|NCT02707991|BEHAVIORAL|Nurse Case Management|Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
40974579|NCT00031057|DRUG|Thiamine hydrochloride|
40974580|NCT00031057|DRUG|Riboflavin|
40974581|NCT00413452|DRUG|Etanercept|50 mg once weekly
40974582|NCT03737721|COMBINATION_PRODUCT|Avelumab and Radical radiotherapy|A single-arm, interventional study combining Avelumab with radical radiotherapy. Avelumab will be delivered on a 14-day cycle, with the first cycle administered 14 days in advance of the radiation therapy start date; 63-66 Gy radiation will be delivered over 30 daily fractions concurrent with an additional 4 cycles of Avelumab
40974583|NCT04095845|DEVICE|CO THA|Replacement of arthritic hip with artificial implant using CT-based navigation and conventional technique
40974584|NCT04095845|DEVICE|Mako THA|Replacement of arthritic hip with artificial implant using mako robotic-arm assist
40974585|NCT02192931|DRUG|Creatine monohydrate|
40974586|NCT00002714|BIOLOGICAL|bleomycin sulfate|
40974587|NCT00002714|DRUG|Stanford V regimen|
40974588|NCT00002714|DRUG|doxorubicin hydrochloride|
41139978|NCT03224988|DEVICE|TMS|A multimodal approach consisting of single pulse TMS, dual-coil TMS, and EEG will be used to examine whether synchronous hemispheric interactions associated with TMS will be present in weighted phase-lag coherence (WPLI), if these measures will be enhanced by in-phase TMS and reduced by counter-phase TMS, and if WPLI will be greater for normal controls than MCI-ADs.
41459176|NCT01072162|DRUG|Eltrombopag|25 mg tablet
41459177|NCT01072162|DRUG|Eltrombopag|25 mg powder for oral suspension
40770796|NCT02987140|BEHAVIORAL|Clinical evaluations|Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
41299413|NCT04667195|OTHER|Clinical assessment|"Within 4 hours of admission to the emergency department, clinical assessment will include:~* Demographics,~* comorbidity,~* symptoms,~* objective findings,~* triage at admission,~* blood test results,~* urine test results"
41299414|NCT03527446|BEHAVIORAL|Sprint Interval Training|The 4-week sprint interval intervention will consist of a work-rest ratio of four 30-s intervals of exercise at maximal capacity and 4-min of passive recovery at 50% of maximal capacity between intervals. There will be three sessions per week.
41299415|NCT00235846|PROCEDURE|vein harvest|Conventional open vein harvest or endoscopic vein harvest
41299416|NCT02407951|BEHAVIORAL|CBIT group|"Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians."
41299417|NCT02407951|BEHAVIORAL|Psycho-Educational group|"Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.~During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.~Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.~All group meetings will be executed and managed by two trained clinicians."
41299418|NCT04215354|DEVICE|Magnetic field|Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA). Mattress which is flexible, 6 flat coil was used for whole body therapy.
40770797|NCT06048042|BIOLOGICAL|Autogenous Demineralized Dentin Graft|The participant's own freshly extracted tooth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present) and have their crown decapitated, using a high- speed fine finishing stone and saline irrigation. The pulp chamber and root pulp will be cleaned by split opening the root and cleaning it out using a high-speed diamond bur. Subsequently, teeth will be ground, and demineralized using a hand bone mill. Then the particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid5 for 30 min then washed twice in saline and dried with sterile gauze. Then it will be used as a graft for the intra-bony defect after modified minimally invasive surgical technique.
40770798|NCT06048042|BIOLOGICAL|Autogenous Bone Graft|Modified minimally invasive surgical technique (M-MIST) will be performed in the intra-bony defects, with autogenous bone graft placement. The graft will be harvested from the retromolar area using automatic chip maker (ACM) bur and a hand bone mill will be used to grind the chips into particles, then it will be placed in the defect.
40974589|NCT00002714|DRUG|etoposide|
41139979|NCT02319707|DRUG|Oxytocin|"The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor."
41139980|NCT02319707|DRUG|Oxytocin in 100 ml NaCl 0.9%|"The control group:~pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department)."
41139981|NCT00430586|DRUG|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
41139982|NCT00430586|DRUG|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
41139983|NCT02817386|OTHER|interview|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The interview included the Confusion Assessment Method (CAM) and MDAS. CAM is a diagnostic algorithm used to determine the presence or absence of delirium.
41139984|NCT03419754|DIETARY_SUPPLEMENT|Glucose|Glucose
41139985|NCT03419754|BEHAVIORAL|Fidgetting|low intensity physical activity (fidgetting)
41299419|NCT04215354|DEVICE|Virtual reality|Wii Fit plus machine which required balance board . It is a video game console designed by Nintendo 2009
41299420|NCT01655823|DRUG|Placebo|Sham treatment acting as control arm
41299421|NCT01655823|DRUG|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
41299422|NCT01562015|DRUG|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
41299423|NCT00000748|DRUG|Sulfamethoxazole-Trimethoprim|
41139986|NCT04776122|DEVICE|Therapy|Device-assisted breathing for relaxation
41139987|NCT04776122|OTHER|No device|Breathing platform without device
41139988|NCT02006641|DRUG|Placebo|Once daily, matching placebo capsules, orally
41139989|NCT02006641|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
41299424|NCT03414840|DRUG|Atorvastatin|Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
41299425|NCT04150640|DRUG|Nal-IRI|chemotherapy drug
41299426|NCT04150640|DRUG|Oxaliplatin|chemotherapy drug
41299427|NCT04150640|DRUG|5-FU|chemotherapy drug
41299428|NCT04150640|DRUG|Trastuzumab|immunotherapy
41299429|NCT04150640|DRUG|Pembrolizumab|immunotherapy
41459178|NCT03550196|OTHER|Provisional stenting with rePOT technique|"All revascularizations have to be performed with complete rePOT technique: initial POT + side branch inflation + final POT. Compliant or semi compliant balloon have to be preferred to inflations. The POT balloon positioning have to be precise as obtain the loose of the parallelism just at the carina cut plan. The rest of the medication or procedure characteristics stay at the discretion of the operator.~The follow-up will be clinic every years."
41459179|NCT00107016|DRUG|RAD001, Letrozole 2.5mg|
40974590|NCT00002714|DRUG|mechlorethamine hydrochloride|
40974591|NCT00002714|DRUG|prednisone|
41299430|NCT04150640|DRUG|Nivolumab|immunotherapy
41299431|NCT02022683|DEVICE|ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves|
41459180|NCT00107016|DRUG|Letrozole 2.5mg|
41459181|NCT04385511|DEVICE|supraglottic jet ventilation|patients who were randomized into supraglottic jet ventilation group would be placed Wei Nasal Jet Tube after conducted. Then they will get the supraglottic jet ventilation to make sure their pulse oximetry is over 95%. After 3 minutes, endotracheal intubation was performed via mouth approach.
40974592|NCT00002714|DRUG|vinblastine sulfate|
40974593|NCT00002714|DRUG|vincristine sulfate|
40974594|NCT00002714|RADIATION|radiation therapy|
40974595|NCT02030392|BEHAVIORAL|Intervention group|Cognitive-behavioral intervention
40974596|NCT02030392|BEHAVIORAL|Active control group|Education and information
40974597|NCT04488484|OTHER|Serology test follow-up|"The enrolled participants will be invited to visit ESS. They will then meet the occupational physician, who wil obtain their free, informed and written consent. The information and consent will be recorded in the personal medical follow-up file.The staff will then complete the self-questionnaire and the ESS physician will provide a prescription for the blood samples to be taken.~In case of positive answers to one or more of the questions in this self-questionnaire, the enrolled participant will be contacted in order to schedule another post-COVID-19 consultation with additional examinations if needed (new COVID PCR, scanner, etc.)."
40974598|NCT03063372|DIETARY_SUPPLEMENT|Pomella pomegranate extract|Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.
41299432|NCT02287792|PROCEDURE|18-FDG PET/CT scan|Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
41299433|NCT03152136|DEVICE|Cala ONE device|The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.
41299434|NCT01107977|BEHAVIORAL|Iyengar yoga|Iyengar yoga twice/week for 6 weeks
41299435|NCT02781467|BIOLOGICAL|PNK-007|
40974599|NCT03063372|OTHER|Placebo|Participants will take a gelatin placebo twice daily for 28 days.
40974600|NCT01528488|OTHER|EVOZAC Calming Skin Spray|EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
40974601|NCT01528488|OTHER|Physiological saline|Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
40974602|NCT06335914|DIAGNOSTIC_TEST|Ga 68 PSMA-11 PET|Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer
40974603|NCT06335914|DIAGNOSTIC_TEST|18F-DCFPyL PET|Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.
40974604|NCT06335914|DIAGNOSTIC_TEST|FDG PET|Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.
40974605|NCT02978261|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
41139990|NCT03346590|BEHAVIORAL|Energy metabolism of patients suffering from RA|Energy metabolism of patients suffering from RA
41139991|NCT05719909|BEHAVIORAL|Cognitive Training|8 sessions of web-based cognitive training
40974608|NCT02064868|DRUG|Serelaxin|30 µg/kg/day IV infusion
40974609|NCT02064868|DRUG|Standard of Care|This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
40974610|NCT02885753|DRUG|Oxaliplatin intravenous|85 mg/m² in intravenous. 1 cycle each 15 days
40974611|NCT02885753|DRUG|5 FU bolus|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
40974612|NCT02885753|DRUG|Folinic acid|400 mg/m² in intravenous
41139992|NCT05719909|BEHAVIORAL|Sham Training|8 sessions of web-based sham training
41139993|NCT05950594|RADIATION|Radiotherapy|Standard of care pre-operative radiotherapy
41139994|NCT05950594|OTHER|Surgery|Standard of care definitive surgery
41139995|NCT04555057|PROCEDURE|Music therapy|Music selected according to the patient's individual preferences.
41139996|NCT05259605|OTHER|Observational|The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
41139997|NCT00511316|DRUG|Montelukast/ Singulair|20 mg daily for six months
41139998|NCT00511316|DRUG|Placebo|Placebo 20 mg daily for 6 months
41139999|NCT01045057|DEVICE|Puncture Set and Flexible Protector|The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
41140000|NCT05652907|DRUG|FSD201|Tablets for oral administration.
41299436|NCT02781467|DRUG|Cyclophosphamide|
41299437|NCT02781467|DRUG|Fludarabine|
40974613|NCT02885753|DRUG|Oxaliplatin intra-arteriel|85 mg/m² in intra-arterial. 1 cycle each 15 days
41299438|NCT02781467|DRUG|Human recombinant Interleukin-2 (rhIL-2)|
41299439|NCT04906239|PROCEDURE|Erector Spinae Plane Block|A high-frequency ultrasound linear probe, covered with a sterile sheath, will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After showing the T 4-5 transverse process and the erector spinae muscle on top of it, a 22-gauge, 80 mm insulated quincke type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal, using the in-plane technique. When the transverse process is touched, the needle will be pulled out and after a negative aspiration test with 0.5 mL of normal saline and after the demonstration of a hypo-echogenic image and hydro dissection, a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.
41299440|NCT01766830|DEVICE|rk28 ICT|rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
41299441|NCT01766830|DEVICE|IT LEISH (rK39)|IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
41299442|NCT01766830|DEVICE|Immunochromatographic HAT test|This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
41299443|NCT01766830|DEVICE|HAT Serostrip|The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
40974614|NCT02885753|DRUG|Panitumumab|Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous
41299444|NCT01766830|DEVICE|Card Agglutination Trypanosoma Test (CATT)-10|The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
40770799|NCT03942744|DEVICE|on-line hemodiafiltration|on-line postdilutional hemodiafiltration with high convective transport above 21 liters
40974615|NCT02885753|DRUG|Bevacizumab|5 mg/kg at each cycle in intravenous
40974616|NCT02885753|DRUG|5 FU continuous|2400 mg/m² intravenously over 46 hours
40974617|NCT02885753|DRUG|Irinotecan|150 mg/m² intravenous
40974618|NCT01223001|DRUG|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
41140001|NCT05652907|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
41140002|NCT06084988|BIOLOGICAL|Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given via ultrasound-guided intra-articular injection
41140003|NCT00201656|PROCEDURE|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
41140004|NCT00201656|PROCEDURE|Removal of Cerclage|Immediate removal of Cerclage following randomization
41140005|NCT00201656|PROCEDURE|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
41140006|NCT04159545|OTHER|Qualitative and quantitative interviews|Qualitative semi-structured interviews and quantitative questionnaires
41140007|NCT03173625|DRUG|AC-076 for s.c. administration|Lyophilized AC-076A to be reconstituted with 1 mL of water for injection
41140008|NCT03173625|DRUG|Placebo|Sterile 0.9% w/v sodium chloride solution
41140009|NCT00439686|DRUG|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
41140010|NCT00973414|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
40770800|NCT05856396|BIOLOGICAL|Triaxis® (Pertussis-containing vaccine)|"Triaxis® (Pertussis-containing vaccine) will be administered:~* in non-pregnant women presenting to the Travel and Vaccine clinic for pertussis immunization only or hospital member staff requiring Tetanus Toxoid (TT)-booster immunisation~* in Pregnant women between 16 and 29 weeks of gestation."
40770801|NCT05856396|BIOLOGICAL|Vaxelis® (Pertussis-containing vaccine)|Vaxelis® (Hexavalent vaccine) will be proposed in infants at 8, 12 and 16 weeks of life.
40974619|NCT01223001|DRUG|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
41140011|NCT00973414|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
40974620|NCT01325636|OTHER|Cell therapy|"Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.~A second injection could be made at day 21"
40974621|NCT00241813|BEHAVIORAL|Mindfulness Meditation (MM) Program|Participants will take part in a mindfulness meditation (MM) program.
40974622|NCT00241813|BEHAVIORAL|Health Education Control Program (CTL)|Participants will take part in a health education control program (CTL)
40974623|NCT00241813|BEHAVIORAL|Lifeskills Program (LP)|Participants will take part in a lifeskills program (LP).
40974624|NCT04371991|DIAGNOSTIC_TEST|blood test|blood test (serum samples) for biochemical examination
41140012|NCT06121765|OTHER|Tyrosine kinase inhibitor|Follow up base metabolic index,lipid profile, HbA1c, thyroid function in CML patients treated with TKI
41140013|NCT04131036|OTHER|assessment of joint health and bone density|We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
41140014|NCT02162394|DEVICE|Observational ambulatory ECG monitoring|
41140015|NCT00420368|DIETARY_SUPPLEMENT|No food supplement|
41140016|NCT00420368|DIETARY_SUPPLEMENT|Food supplement: fortified spread|
41140017|NCT00420368|DIETARY_SUPPLEMENT|Food supplement: maize-soy flour|
41140018|NCT01230970|DRUG|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
40770802|NCT02943473|DRUG|Ibrutinib|"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."
40770803|NCT04815174|OTHER|Standard of Care|(i) advanced clinical and biological monitoring system (ii) symptomatic treatment adapted to the patient's needs, such as antibiotic therapy, oxygen therapy and blood transfusion; (iii) dialysis or mechanical ventilation.
40770804|NCT05585294|BEHAVIORAL|Exercises|Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.
40974625|NCT01803204|OTHER|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
41140019|NCT02754375|PROCEDURE|rTMS|
41140020|NCT00884676|DRUG|Ixabepilone|"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~* Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~* Schedule B: Day 1 of each 3-week cycle."
41140021|NCT00884676|DRUG|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
41140022|NCT00851513|DRUG|Lidocaine|local anesthetics
41140023|NCT00851513|DRUG|Depmedrol|local steroids
41140024|NCT00851513|OTHER|physiological serum|important volumes of physiological serum
41140025|NCT05688891|OTHER|Virtual reality|"5 minutes before the burn dressing procedure, virtual reality glasses were put on the patient's head by the researcher and a 360° VR video with submarine and nature content pre-loaded on the glasses was opened.~Audio and video settings were made and started to be watched. Video monitoring with Virtual Reality continued throughout the entire dressing. This procedure was performed during 2 consecutive dressing changes. A 1-week period was given between 2 dressings."
41140026|NCT05688891|OTHER|Music|"5 minutes before the burn dressing procedure, the patient was asked about the type of music he preferred in the introductory patient information form. Then, the patient was started to listen after putting on headphones and adjusting the volume. The patient was asked to keep his eyes closed while listening to music. Music listening was continued throughout the entire dressing.~After the process was finished, the music was turned off and the headphones were removed.~This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings."
41140027|NCT00909909|RADIATION|External beam boost|3-dimensional conformal radiation therapy and intensity modulated radiation therapy
41140028|NCT00909909|RADIATION|whole breast irradiation|accelerated, hypofractionated whole breast irradiation
41140029|NCT05935839|DEVICE|Multispectral optoacoustic tomography|Molecular Imaging of tissue changes using MSOT in macroangiopathy in diabetes. Dual imaging before and after physical stress.
41140030|NCT05935839|DIAGNOSTIC_TEST|Ankle Brachial Index|Dual measurement of ABI index before and after physical exercise.
41140031|NCT05935839|DIAGNOSTIC_TEST|Neuropathy Disability Score|Single measurement of the NSS
41140032|NCT02579109|OTHER|memory test|
41140033|NCT00780793|DRUG|progressive spacing of TNF-blocker injections|"Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~* if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~* if DAS28 \> 2.6 and DAS28 change ≤ 0.6: continue at step N~* if DAS28 \> 2.6 and DAS28 change \> 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~* Adalimumab 40 mg / 14 days~* Etanercept 50 mg / 7 days~Step 1 :~* Adalimumab 40 mg / 21 days~* Etanercept 50 mg / 10 days~Step 2 :~* Adalimumab 40 mg / 28 days~* Etanercept 50 mg / 14 days~Step 3 :~* Adalimumab 40 mg / 42 days~* Etanercept 50 mg / 21 days~Step 4 :~* TNF-blocker stop"
41140034|NCT00780793|DRUG|DMARD maintenance|DMARD maintenance
41140035|NCT02283086|BEHAVIORAL|Physician Feedback Reporting|The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
41140036|NCT03293043|DEVICE|NPV-EVLP|Lungs deemed marginal based on standard lung donor criteria that meet study eligibility will be physiologically assessed during ex-vivo perfusion. NPV-EVLP of these lungs will be performed with the addition of numerous pre-determined additives. With respect to the decision of lung utilization post-EVLP, eligibility criteria listed in the Post-NPV-EVLP section of the trial will need to be met. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
41140037|NCT04271865|OTHER|Nutritional Education|Provision of weekly awareness and educational sessions for 6 months. Sessions were conducted at the community based associations within the cases respective villages. Cases were subjected to 24 sessions for improving the patients' own nutrition situation through nutritional education about food rich in iron and counselling. The sessions focused on basic knowledge on iron deficiency anaemia, the most common presenting symptoms, iron rich dietary sources, factors that enhance and inhibit iron absorption, effects of anaemia on health and how to prevent it, Role of dates fruit in preventing and treating anaemia. Th e sessions also focused on the provision of a diverse range of local iron rich food. Special focus was on increasing patients' awareness for self-management of their status
41140038|NCT04271865|OTHER|model nutrition kitchen|Implementing model nutrition kitchen; once every month for six months with six sessions for each village (6 sessions/village) with cooking sessions was done to promote eating healthy and provide innovative ideas for feeding anaemic cases. 117 patients were reached by the nutritional kitchen activities with 6 sessions until the end of the project. Special focus was done on skills like sharing cooking, meal planning, and label reading that help support healthy eating patterns. Suggesting ways that individuals can model healthy eating behaviors for friends and family members that is based on Dates fruit was encouraged.
41299445|NCT01766830|DEVICE|Typhidot M|The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
41459182|NCT04598633|DIETARY_SUPPLEMENT|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
41459183|NCT04598633|DIETARY_SUPPLEMENT|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia) 2 times per day for 12 weeks
41459184|NCT00841620|PROCEDURE|Haemorrhoidectomy a.m. Milligan|Surgery
41459185|NCT00841620|PROCEDURE|Stapled anopexy|Surgery
40974626|NCT03605459|DEVICE|Comfort Plug™|
40974627|NCT02803489|DEVICE|medical device intervention|
40974628|NCT00022308|DRUG|cisplatin|
40974629|NCT00022308|DRUG|irinotecan hydrochloride|
40974630|NCT00022308|RADIATION|radiation therapy|
40974631|NCT01894191|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
40974632|NCT01894191|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
40974633|NCT01894191|PROCEDURE|Water exchange|Water will infused and removed during insertion phase of colonoscopy
40974634|NCT01045720|DRUG|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
40974635|NCT01045720|DRUG|Placebo|Placebo (starch)
40974636|NCT03275662|BEHAVIORAL|Dietary Fiber|
41140039|NCT04271865|OTHER|recipe book|3) Development of recipe book that is based on the local food in the market to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
40974637|NCT03275662|BEHAVIORAL|Fermented Foods|
40974638|NCT01513473|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
40974639|NCT01513473|DRUG|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
40974640|NCT01513473|DRUG|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
40974641|NCT03303534|DIETARY_SUPPLEMENT|ScandiShake|weight gain supplement low in protein
40974642|NCT02407821|DRUG|Escitalopram|Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
40974643|NCT02407821|DRUG|Placebo|The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
40974644|NCT06502535|DIETARY_SUPPLEMENT|Inulin|15 g inulin once daily for 4 weeks.
40974645|NCT06502535|DIETARY_SUPPLEMENT|Potassium nitrate and inulin|1300 mg potassium nitrate once daily for 4 weeks and 15 g inulin once daily for 4 weeks.
40974646|NCT01674270|DRUG|Degarelix|
40974647|NCT01674270|DRUG|Casodex|
40974648|NCT01674270|DRUG|LHRH Agonist|
40974649|NCT00002904|DRUG|trabectedin|
41299446|NCT01766830|DEVICE|S. typhi IgM/IgG|The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
41299447|NCT01766830|DEVICE|Test-it Typhoid IgM|Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
40974651|NCT05612789|BEHAVIORAL|Exercise Program (Cohort A Prehab)|Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
40974652|NCT05612789|BEHAVIORAL|Exercise Program (Cohort B Rehab)|All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
40974653|NCT01516931|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
40974654|NCT01516931|BEHAVIORAL|counseling|Placebo monthly by general counseling for 12 months.
40974655|NCT03932721|DRUG|Evolocumab 140 MG/ML|Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
40974656|NCT02336711|RADIATION|dose escalation|molecular imaging based radiotherapy dose escalation
40974657|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 8 Gy|
40974658|NCT02811250|RADIATION|Stereotactic radiotherapy 5 x 8 Gy|
40974659|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 10 Gy|
40974660|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 12 Gy|
40974661|NCT05381116|DEVICE|Avation System|Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.
40974662|NCT05381116|DEVICE|Sham Avation System|Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.
40974663|NCT00358124|DRUG|insulin glargine|
40974664|NCT00358124|DRUG|rosiglitazone|
40974665|NCT00358124|DRUG|metformin|
40770805|NCT05470686|BIOLOGICAL|blood gas via arterial catheter|Patients will have a blood sample plus a lung ultrasound before and after the physical therapy session combined with non invasive ventilation the morning after the heart surgery
41299448|NCT01766830|DEVICE|Test-it Leptospirosis IgM|The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
40770806|NCT05360784|DRUG|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
41299449|NCT01766830|DEVICE|Leptospira IgG/IgM|This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
40770807|NCT05360784|DRUG|Lumify® (brimonidine tartrate ophthalmic solution 0.025%)|Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
41299450|NCT02775864|DRUG|Antipsychotic|New initiation of any antipsychotic medication
41299451|NCT02775864|DRUG|Antidepressant|New initiation of any antidepressant medications
41459186|NCT00494013|DRUG|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
41459187|NCT00494013|DRUG|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
41459188|NCT01868243|DRUG|Dabigatran|Group 1 - Dabigatran 110 mg (50 patients)
41459189|NCT01868243|DRUG|Warfarin|Warfarin adjusted-dose
41459190|NCT01617551|DRUG|NG-monomethyl-L-arginine (L-NMMA)|Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
40770808|NCT05538728|DEVICE|poly-l-lactic acid (Sculptra)|Sculptra
40770809|NCT04890509|DRUG|Bemcentinib|Bemcentinib capsules will be administered orally.
40770810|NCT04890509|OTHER|SoC|The SoC will be administered based on local guidelines.
40770811|NCT04841148|DRUG|HCQ|600 mg tablets twice daily D1-28 of each 28-day cycle
40770812|NCT04841148|DRUG|Avelumab|10 mg/kg, IV, D1 and D15 of each 28-day cycle
41299452|NCT02775864|DRUG|Benzodiazepine|New initiation of any benzodiazepine
41299453|NCT02775864|DRUG|Mood stabilizer|New initiation of lithium or any mood stabilizing anti-epileptic drug
41299454|NCT03102736|DRUG|Placebos|Placebo saline
41299455|NCT03102736|DRUG|Ketamine|0.5 mg/kg ketamine
40770813|NCT04841148|DRUG|Palbociclib|125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.
40974666|NCT00089245|DRUG|Iodine I 131 MOAB 8H9|Patients will be injected, intrathecally, with 2 mCi 131I-Omburtamab during week 1 of a 5 week cycle.
41299456|NCT03102736|DRUG|Nitroprusside|0.5 mcg/kg nitroprusside
41299457|NCT03619148|DEVICE|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen
41299458|NCT02191787|DRUG|Seresis®|
41299459|NCT02191787|DRUG|Placebo|
41299460|NCT03240211|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV
41299461|NCT03240211|DRUG|Pralatrexate|Pralatrexate 20 or 30 mg/m2 IV push
41299462|NCT03240211|DRUG|Decitabine|Decitabine 10 mg/m2
41299463|NCT00230386|DEVICE|MRI|
41299464|NCT04209504|DIAGNOSTIC_TEST|Ultrasound|Ultrasound guided evaluation of diaphragm ipsilateral to the block side.
41299465|NCT04209504|DRUG|Ropivacaine|Local anesthetic (numbing drug)
41299466|NCT04209504|DRUG|Bupivacaine|Local anesthetic (numbing drug)
41299467|NCT04209504|DEVICE|MediPines AGM100 Advanced Respiratory Monitoring System|Non-invasive respiratory monitor to measure oxygenation and ventilation parameters
41299468|NCT05493865|BEHAVIORAL|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|This study will be a three-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents by comparing to a C-SMILE intervention group and a no-intervention waitlist control group.
41299469|NCT04867655|OTHER|Orange Juice|Approximately 500 ml of orange juice will be consumed and then blood and urine samples will be collected for 24 hours
41299470|NCT04867655|OTHER|Orange juice with either 6g or 3 g of β-Glucan|Approximately 500 ml of orange juice mixed with either 6g or 3 g of β-Glucan will be consumed and then blood and urine samples will be collected for 24 hours
41299471|NCT00536978|DRUG|ARA-C|100 mg/m\^2 IV Daily Over 1 Hour for 4 Days
41299472|NCT00536978|DRUG|BCNU|300 mg/m\^2 IV Over 1 Hour for 1 Day
41459191|NCT01710358|DRUG|Adalimumab|Administered SC
41459192|NCT01710358|DRUG|Baricitinib|Administered orally
41459193|NCT01710358|DRUG|Methotrexate|Administered orally
41459194|NCT01710358|DRUG|Adalimumab Placebo|Adalimumab placebo administered SC.
41459195|NCT01710358|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally.
41459196|NCT05575245|DEVICE|Drug-eluting Stent|Drug-eluting Stent angioplasty
41459197|NCT05575245|DEVICE|Excimer Laser Ablation Combined Drug-coated Balloon|Excimer Laser Ablation Combined Drug-coated Balloon angioplasty
41299473|NCT00536978|DRUG|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
40974667|NCT00089245|DRUG|Iodine I 131 MOAB 8H9|The dose used in this study is 50 mCi 131IOmburtamab, (averaging 5 mCi/mg Omburtamab at 50 mCi dose) which will be administered to each patient during week 2 of a 5 week cycle.
40770814|NCT04306926|DRUG|TQB2450|TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.
41140040|NCT04271865|OTHER|Provision of Dates|"Dates fruit intake for all the anaemic patients was provided for 16 weeks (four months):~• Diagnosed anemic patients were given five to seven pieces of Dates (dependent on its weight) on daily basis for 16 weeks (each date fruits is about 10 -20 gm). Dates was taken as breakfast on daily base.~The Dates fruit that was used during the proposed trial is Saudi's Dates extract know as Barni which is organic Dates. The fruit is mentioned more than 20 times in the Quran, This Barni is known for its very high nutritive value (vitamins, minerals and antioxidants) compared with other Dates types. The nutritive value of Barni is shown in the below table, calculated per every 100 gram (range 5- 10 pieces) of dry weight (DW) :~The nutritive value of Barni calculated per every 100 gram (average 7-10 pieces) of dry weight (DW) of which iron constitutes 6.78 mg that represent 67.8 % of the recommended dietary allowance (RDA) of the males and 45.20 % of the RDA of the females"
40770815|NCT04306926|RADIATION|SBRT|Give according to the location of the lesion and clinical condition.
40770816|NCT03076151|DRUG|Tacrolimus monohydrate (ADOPORT®)|Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
40770817|NCT02753972|BEHAVIORAL|Mindful Eating and Living|8 week mindfulness skills intervention
40770818|NCT02753972|BEHAVIORAL|Active Weight Loss Control|8 week active weight loss control group
40770819|NCT05534646|DRUG|Apalutamide|Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle
40974668|NCT03503955|OTHER|Leap-Motion virtual reality games|Games that Fizyosoft has prepared on Leap Motion equipment to improve hand and grip activities will be played individually and will focus on running hand, wrist and grip movements
40974669|NCT03503955|OTHER|fine motor skills activities|activities that stimulate finger movements such as holding, reaching, catching, writing, and strengthening muscles
40974670|NCT03967964|DRUG|Dehydroepiandrosterone 2.2 g|Vaginal ring with 2.2 grams DHEA.
41140041|NCT05954247|DRUG|DWJ1543|DWJ1543
41140042|NCT05954247|DRUG|DWC202216|DWC202216
41299474|NCT00536978|DRUG|Cyclophosphamide|1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days
41299475|NCT00536978|DRUG|Etoposide|100 mg/m\^2 IV Daily Over 3 Hours for 4 Days
41299476|NCT00536978|DRUG|Fludarabine|30 mg/m\^2 IV Daily Over 1 Hour for 3 Days
41299477|NCT00536978|DRUG|Melphalan|100 mg/m\^2 IV Over 30 Minutes for 1 Day.
41299478|NCT00536978|DRUG|Rituximab|375 mg/m\^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m\^2 IV Over 5-7 Hours Weekly for 3 Weeks.
40974671|NCT03967964|DRUG|Dehydroepiandrosterone 1.5 g/Testosterone 25 mg|Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
41299479|NCT00536978|OTHER|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
41299480|NCT00536978|RADIATION|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
41299481|NCT00536978|DRUG|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
40974672|NCT03967964|DRUG|Testosterone|Vaginal ring with 35 mg testosterone.
40974673|NCT03967964|DRUG|Testosterone Topical Gel|Gel containing 1% testosterone.
40974674|NCT03967964|DRUG|Dehydroepiandrosterone Oral Capsule|Capsule containing 25 mg DHEA
40974675|NCT00721552|DRUG|Sitagliptin 100 mg|28 days administration of 100 mg daily
40974676|NCT00721552|DRUG|Prednisolone 30 mg|14 days administration of 30 mg daily
40974677|NCT00721552|DRUG|Sitagliptin-placebo|28 days administration once daily
40974678|NCT00721552|DRUG|Prednisolone-placebo|14 days administration once daily
40974679|NCT01152086|OTHER|Mountain hiking in the Austrian and Bavarian Alps|"Regularly supervised physical exercise training program.~Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;~Program:~* Endurance training (performed within 70-85% of the maximum heart rate)~* Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)~* Stretching after hiking (ca. 5 min)~* Short break at half-time (ca. 15 min)"
40974680|NCT06364449|OTHER|No intervention|No intervention
41140043|NCT05197452|BEHAVIORAL|COVID-19 Testing|"For in-person PCR testing, a nasal swab will be inserted shallowly into the participant's nose and rotated in each nostril. The swab will be broken off into a designated test tube and placed into a specimen bag along with a label. All specimens will be stored in a cooler until they are transported the Rush Laboratory for COVID-19 analysis.~For at home antigen testing, participants will download an app to their mobile phone and watch an informational video. The test will be self-administered by inserting a nasal swab into the nostril until a cap containing the swab touches the nose; rubbing the swab tip around the nose cavity 3 times; removing the swab and repeating in the other nostril. The nasal swab, a dropper, processing fluid, and a blue tooth connected analyzer are provided with the testing kit to analyze the sample for COVID-19. COVID-19 home test results are displayed on the participants smart phone after 15 minutes."
41140044|NCT06003244|OTHER|6-minute walk distance (6MWD) test|6-minute walk distance (6MWD) test will be performed according to clinical standards
41140045|NCT06003244|OTHER|6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (3l/min, nasal)
41140046|NCT03470597|OTHER|dietary iodine restriction on subjects with iodine overload|In this case registry study (observational study),all intervention will be performed not for research purposes, but only part of routine treatment, which will be recorded in database of the registry study.
41140047|NCT04111991|BEHAVIORAL|Usual Care|Usual care in the NCH in the Complex Concussion Clinic involves assessment and treatment with a neurologist for medical management of concussion, weekly sessions with an athletic trainer for exercise therapy, and physical therapy sessions depending on need
41140048|NCT04111991|BEHAVIORAL|C-STEP (Cognitive Behavioral Therapy)|The C-STEP intervention involves 4 primary components: psychoeducation, activity management, sleep hygiene, and relaxation training
41140049|NCT01503450|DRUG|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
41140050|NCT00539084|DEVICE|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
41140051|NCT02544191|DRUG|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
41140052|NCT04329585|DRUG|flumazenil|EEG is observed in both groups to compare the difference between two groups.
41140053|NCT04329585|DRUG|Placebos|Placebo is the normal saline, which is given in the controlled group.
41140054|NCT03456856|DRUG|Ivabradine|Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.
41299482|NCT00536978|DRUG|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
41459198|NCT03209115|DRUG|combination of calcium hydroxide and chlorhexidine|placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
40974681|NCT01085591|DRUG|CB-183,315|
40974682|NCT01085591|DRUG|Placebo|
40974683|NCT01085591|DRUG|Vancomycin|
40974684|NCT02354989|DEVICE|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
40974685|NCT02354989|DEVICE|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
40974686|NCT00005970|DRUG|Aromatase Inhibition Therapy|Given orally
40974687|NCT00005970|DRUG|Cyclophosphamide|Given IV
40974688|NCT00005970|DRUG|Doxorubicin Hydrochloride|Given IV
40974689|NCT00005970|OTHER|Laboratory Biomarker Analysis|Correlative studies
40974690|NCT00005970|DRUG|Paclitaxel|Given IV
40974691|NCT00005970|DRUG|Tamoxifen Citrate|Given orally
40974692|NCT00005970|BIOLOGICAL|Trastuzumab|Given IV
40974693|NCT01962207|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
41140055|NCT00097409|DRUG|Ispinesib|
41140056|NCT02233998|OTHER|Mouth Rinse 1|
41140057|NCT02233998|OTHER|Mouth Rinse 2|
41140058|NCT02233998|OTHER|Mouth Rinse 3|
40974694|NCT04368767|BEHAVIORAL|Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, usually in the afternoon. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. After pre-intervention measures of axillary temperature, heart rate, respiratory rate, and oxygen saturation by pulse oximetry (SPO2) are obtained; cotton balls placed in the diaper for urine collection will be removed and stored in an appropriate container. Salivary oxytocin and cortisol will be collected per protocol below. Mothers will be requested to sit in reclining chairs with a front opened blouse or hospital gown. Infants will be removed from the incubator and placed naked except for a diaper and hat directly onto the skin between the mother's breasts and covered with a blanket. All infants will be monitored. After the two hours of SSC is completed, the infant will be returned to the incubator.
40770820|NCT05534646|DRUG|Carotuximab|"Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose."
41299483|NCT00536978|PROCEDURE|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
40770821|NCT02852330|DEVICE|SA16 research software|Software for measurement of voltage tomography intraoperatively.
40770822|NCT02852330|DEVICE|CS19 (1.6.2)|Software for measurement of voltage tomography post-operatively.
40974695|NCT03283852|GENETIC|blood sample|search for genetic mutations
40974696|NCT03003936|BEHAVIORAL|Dinner timing|Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
40974697|NCT04103853|DRUG|Proxalutamide|Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
40974698|NCT03789318|DRUG|CA-008 5 mg|5 mg CA-008 reconstituted in saline.
40974699|NCT03789318|DRUG|Placebo|Each cohort will use placebo reconstituted in saline.
40770823|NCT00003680|DRUG|CMF regimen|
40974700|NCT03789318|DRUG|Bupivacaine Hydrochloride|0.25% administered pre-surgery
40974701|NCT03789318|DRUG|Hydromorphone|0.02 mg/kg IV administered intraoperatively
40974702|NCT03789318|DRUG|Fentanyl|100 mcg IV administered intraoperatively
40974703|NCT03789318|DRUG|Acetaminophen|1000 mg IV administered intraoperatively
40974704|NCT03789318|DRUG|Oxycodone|5-10 mg PO administered post-surgery
40974705|NCT03789318|DRUG|CA-008 10 mg|10 mg CA-008 reconstituted in saline.
40974706|NCT03789318|DRUG|CA-008 15 mg|15 mg CA-008 reconstituted in saline.
40974707|NCT04073498|DRUG|SerpinPC|Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
41299484|NCT01064453|DRUG|E2/DRSP (Angeliq, BAY86-4891)|Take one tablet daily, continuously
40770824|NCT00003680|DRUG|cyclophosphamide|
40974708|NCT04073498|DRUG|Placebo|Matching placebo administered by SC injection according to cohort dosing instructions.
40974709|NCT00277290|DRUG|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
40974710|NCT01133483|DRUG|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
40974711|NCT01338766|PROCEDURE|Decompression using the iO-Flex® system|Decompression using the iO-Flex® system
40974712|NCT06076265|PROCEDURE|Radical Gastric Cancer Surgery|Laparoscopic (robotic) radical surgery for gastric cancer
40974713|NCT04773483|DIETARY_SUPPLEMENT|Quorn Foods products|180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)
40974714|NCT04773483|DIETARY_SUPPLEMENT|Meat/fish products|Standard meat/fish products matched to Quorn group for protein intake
40974715|NCT04101357|DRUG|BNT411|intravenous
40974716|NCT04101357|DRUG|Atezolizumab|intravenous
40974717|NCT04101357|DRUG|Carboplatin|intravenous
40974718|NCT04101357|DRUG|Etoposide|intravenous
41140059|NCT00191542|DRUG|Atomoxetine|
40770825|NCT00003680|DRUG|fluorouracil|
40770826|NCT00003680|DRUG|methotrexate|
40770827|NCT00003680|DRUG|tamoxifen citrate|
40770828|NCT00003680|DRUG|thiotepa|
40770829|NCT00003680|PROCEDURE|peripheral blood stem cell transplantation|
40770830|NCT00003680|RADIATION|radiation therapy|
40770831|NCT05269173|DRUG|Flos gossypii flavonoids tablet|The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
40770832|NCT06217263|DEVICE|Vibration device|Vibracool vibration device from Pain Care Labs will be used.
40770833|NCT06217263|OTHER|Vibration device&Cold application pack|Pain Care Labs' Vibracool vibration device and cold gel pack will be used.
40770834|NCT03728335|DRUG|Enasidenib Mesylate|Given PO
40770835|NCT06558578|DIAGNOSTIC_TEST|Helicobacter pylori antigen in stool|"H pylori antigen in stool: for all patients suffering from migraine and control group.~Upper GIT endoscopy: for children with positive H Pylori antigen in stool."
40770836|NCT04868422|DEVICE|Telemonitoring via wireless internet-based system|
40770837|NCT06511349|DRUG|YOLT-203|The IP is administered intravenously at the predetermined dose.
40770838|NCT01516476|DRUG|Placebo|Placebo for 12 weeks
41140060|NCT00191542|DRUG|Placebo|
41140061|NCT04839809|DRUG|CC-92480|Oral
41140062|NCT04839809|OTHER|Placebo|Oral
41140063|NCT01482325|DEVICE|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
41140064|NCT01765855|DRUG|Betrixaban single oral dose|
40770839|NCT01516476|DRUG|RO6807952|multiple doses for 12 weeks
40770840|NCT01516476|DRUG|RO6807952|multiple doses for 12 weeks
40770841|NCT01516476|DRUG|liraglutide|liraglutide for 12 weeks
40770842|NCT00461890|DRUG|Injectable Naltrexone|
40770843|NCT00190957|DRUG|Atomoxetine|
40974719|NCT00679302|DRUG|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
40974720|NCT00679302|DRUG|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
40974721|NCT06384040|PROCEDURE|platelet-rich plasma knee injection|platelet-rich plasma knee injection and observation for 12 months for definition of responder and non responder
40974722|NCT05730751|PROCEDURE|spinal anesthesia|spinal anesthesia
40974723|NCT05730751|PROCEDURE|caesarean section|LSCS
40974724|NCT06152978|DRUG|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
40974725|NCT06152978|DRUG|Chemotherapy|Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
40974726|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
40974727|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
40974728|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|"Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.~Phase B: All patients will receive 500µg s.c.every other day (open-label)."
41140065|NCT05702788|DRUG|Jaktinib hydrochloride tablets|75mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
41140066|NCT05702788|DRUG|Jaktinib hydrochloride tablets|100mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
41140067|NCT05702788|OTHER|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
41140068|NCT03450642|OTHER|Observational|Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
41140069|NCT03065400|DRUG|Pembrolizumab|200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
41140070|NCT06464302|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
41140071|NCT06464302|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation
41140072|NCT00424502|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
41299485|NCT04738045|DRUG|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.
41140073|NCT00424502|DRUG|Methotrexate|10-25mg po/week
41459199|NCT03209115|DRUG|Calcium Hydroxide|placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
41459200|NCT05103644|DRUG|Atorvastatin 80mg|patients received statin experimental group
41459201|NCT05103644|OTHER|placebo|patients received placebo control group
40770844|NCT00190957|DRUG|placebo|
40770845|NCT03528733|DEVICE|Multi-Energy Digital Radiography Detector System|A Multi-energy digital flat panel detector for Single Exposure Dual-Energy Subtraction radiography is developed to capture x-ray images with improved tissue differentiation. Tissue-selective images can be produced at various tissue levels such as bone and soft tissue to visualize obscured anomalies that are not apparent to General Radiography.
40770846|NCT05883787|OTHER|Exploration of a database|extraction of data
40770847|NCT04168125|DEVICE|Tilapia skin|Application tilapia skin as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
40770848|NCT04168125|DEVICE|Surgical Wound Dressing|Application surgical wound dressing as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
40974729|NCT02299297|DRUG|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
40974730|NCT00429104|DRUG|Herceptin|4 mg/kg IV Over 90 Minutes
40974731|NCT00429104|DRUG|GM-CSF|250 mcg/m\^2 Subcutaneously
40974732|NCT03053323|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
40974733|NCT04488900|DRUG|CKD-508 Capsule|Investigational drug
40770849|NCT02958345|BIOLOGICAL|Zostavax|Vaccination with one dose of Zostavax per Zostavax package insert
40770850|NCT02958345|OTHER|Placebo|Injection of 0.65 mL of sterile normal saline
40770851|NCT06540885|DRUG|Palonosetron (Group P)|Group P will be receiving palonosetron 1.5mcg/kg before the commencement of general anaesthesia
40770852|NCT06540885|DRUG|Granisetron (Group G)|Group G participants will receive IV Granisetron 1mg at the start of wound closure
40974734|NCT04488900|DRUG|Placebo Capsule|Placebo
40974735|NCT04488900|DRUG|CKD-508 Tablet|Investigational drug
40974736|NCT04488900|DRUG|Placebo Tablet|Placebo
40770853|NCT06565325|BEHAVIORAL|Exercise + Audible Cues|Combined Terminal Knee Extension Exercise with Audible Cues
40770854|NCT06565325|BEHAVIORAL|Exercise|Terminal Knee Extension Exercise
40770855|NCT04211948|PROCEDURE|robotic surgery|Pancreatectomy with robotic assisted system
40770856|NCT04211948|PROCEDURE|open surgery|Traditional open pancreatectomy
40770857|NCT05391555|DRUG|Remifentanil Hydrochloride|Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes. Pupillary measurements will be taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.
40770858|NCT05391555|DEVICE|Pupillometry measurement|The pupil will be examined with the pupillometer at regular intervals, before during and after the opioid infusion
40770859|NCT04160832|GENETIC|Multi-Cancer Cancer Panel|Eligible patients will receive genetic testing to determine germline cancer predisposition.
40770860|NCT02923167|DEVICE|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
40770861|NCT06524973|OTHER|Telemedicine|Attend telehealth self-management coaching sessions
40770862|NCT06524973|OTHER|Counseling|Attend telehealth self-management coaching sessions
40770863|NCT06524973|OTHER|Best Practice|Receive standard of care
41140074|NCT00831948|GENETIC|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
41140075|NCT02709044|DRUG|Ringer lactate|
40770864|NCT06524973|OTHER|Questionnaire Administration|Ancillary studies
40770865|NCT06524973|OTHER|Inrweview|Ancillary studies
40974737|NCT01916213|PROCEDURE|PICSI|If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
40974738|NCT02231541|DEVICE|Very Low Frequency Magnetic Fields|The device is set to an analgesic program lasting about 30 minutes.
41140076|NCT06342128|OTHER|No intervention|No intervention
41140077|NCT06146634|BEHAVIORAL|Hazard Perception Training|The hazard perception training is comprised of three modules. Each module is comprised of four scenarios. Each hazard perception scenario has two activities. The entire training is expected to take approximately an hour to complete.
41140078|NCT06146634|BEHAVIORAL|Vehicle Maintenance Training|For participants randomized into the placebo group, they will receive a brief training on vehicle maintenance using a series of short videos. These videos describe regular checks that drivers should do, such as checking windshield wiper fluid levels, and how to change engine oil. Altogether the videos will last approximately 1 hour.
40974739|NCT02231541|DEVICE|Very Low Frequency Magnetic Fields|The device is turned off.
40770866|NCT02474498|DRUG|EMD|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
41140079|NCT06146634|BEHAVIORAL|Attention Maintenance Training|The attention maintenance training is comprised of three modules. Each module is comprised of four scenarios, with each scenario corresponding to one activity. The entire training is expected to take approximately an hour to complete.
41140080|NCT02714777|DEVICE|Autonomic nervous system activity|Autonomic nervous system activity (parasympathetic activity) will be measured by electrocardiogram (holter) during 24 hours postoperative
40974740|NCT02058576|DRUG|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
40974741|NCT02058576|DRUG|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
40974742|NCT05358951|BEHAVIORAL|STEP-YA with Coaching|Online instruction on behavioral changes to improve sleep with 2 additional individually coached session
40974743|NCT05358951|BEHAVIORAL|STEP-YA without Coaching|Online instruction on behavioral changes to improve sleep without additional individually coached session
40974744|NCT02421315|BEHAVIORAL|CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment|CBT treatment consisted of 12-16 hour-long sessions. For exceptional cases not showing clinical improvement after six CBT treatment sessions, complementary pharmacological treatment (SSRI) was offered as part of our treatment protocol. CBT for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
40770867|NCT02474498|DEVICE|βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
40974745|NCT03403660|OTHER|non White coat|Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
40974746|NCT05292040|DRUG|LY3857210|Administered orally.
40974747|NCT01342796|BIOLOGICAL|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
40974748|NCT01342796|BIOLOGICAL|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
40974749|NCT04658953|OTHER|Ultrasound guided infiltration|In the patient in prone position, an infiltration guided by ultrasound will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
40974750|NCT04658953|OTHER|Fluoroscopy guided infiltration|In the patient in prone position, an infiltration guided by fluoroscopy will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
40974751|NCT06254586|PROCEDURE|Aerobic exercises|This group received a single session of low-intensity cycling for 20 minutes. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
40974752|NCT06254586|PROCEDURE|Resisted exercises|This group received four sets of 15 repetitions of knee extension, hamstring curls, and standing calf raises (20-40% 1RM) with 30 sec to 1 minute rest period between sets. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
40974753|NCT01045512|DRUG|fluvastatin|40-80mg once daily
40974754|NCT02117648|DRUG|Abemaciclib|Administered orally
40974755|NCT02117648|DRUG|Clarithromycin|Administered orally
40974756|NCT01868685|DRUG|BYM338|BYM338
40974757|NCT01868685|DRUG|Placebo|Placebo
40974758|NCT00408356|DRUG|Zinc|
41140081|NCT01374152|OTHER|cognitive sensory motor training therapy|training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
40770868|NCT02474498|PROCEDURE|Flap access surgery|In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
40770869|NCT06539481|DRUG|fluocinolone acetonide 190 micrograms|ILUVIEN®, is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye. ILUVIEN® delivers corticosteroid directly to the intended site of action for up to 36 months.
41140082|NCT02174978|BIOLOGICAL|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
41140083|NCT02174978|OTHER|P falciparum Controlled Human Malaria Infection (CHMI)|
41459202|NCT03328390|OTHER|Quadratus lumborum block|15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
40974759|NCT01414855|DRUG|obinutuzumab|1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
41140084|NCT01444365|DRUG|ABT-652 NSAID|ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
40974760|NCT01414855|DRUG|cyclophosphamide|750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
40974761|NCT01414855|DRUG|doxorubicin|50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.
40974762|NCT01414855|DRUG|prednisone|100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
40974763|NCT01414855|DRUG|vincristine|1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.
41140085|NCT01444365|DRUG|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID- as prescribed
41140086|NCT04874142|DRUG|YYC506-T|single administration
41140087|NCT04874142|DRUG|YYC506-A|single administration
41140088|NCT04874142|DRUG|YYC506-T + YYC506-A|concomotant administration
41140089|NCT04874142|DRUG|YYC506-A + YYC506-T|concomotant administration
41140090|NCT04890457|DEVICE|Vagus nerve stimulation via tragus|The device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
41140091|NCT04890457|DEVICE|Sham stimulation via earlobe|The device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
41140092|NCT04738214|OTHER|Neoadjuvant CCRT+operation +/- adjuvant treatment|Patients receive neoadjuvant CCRT and operation. Adjuvant treatment after operation is performed depending on pathologic response. The patients showing pathologic complete response after neoadjuvant CCRT are not treated with any adjuvant treatment.
41140093|NCT00995683|DRUG|half molar sodium lactate|intravenous infusion of 0.5 ml/kg during 48 hours
41140094|NCT00995683|DRUG|isotonic sodium chloride|intravenous infusion of 0.5 ml/kg during 48 hours
40770870|NCT05019079|OTHER|electroacupuncture|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation will be stopped 30min later.
40770871|NCT05840250|OTHER|Continuous Glucose Monitoring and Education Support|Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
40770872|NCT06265415|DRUG|Labetalol|it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent
40770873|NCT06265415|DRUG|Nitroglycerine|a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses
40770874|NCT06265415|DRUG|Nifedipine|dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive
40770875|NCT00319761|DRUG|Calcitriol|
40770876|NCT03420820|BIOLOGICAL|Bacterial Culture Swab|Culture swabs will be obtained before application of PI and after injection.
40770877|NCT02892370|DRUG|SHR0302|SHR0302 tablets (10 mg)
41299486|NCT04738045|DRUG|Lopinavir/ Ritonavir and Remdesivir combination|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
40770878|NCT04198012|DEVICE|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
40770879|NCT00553254|DRUG|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
40770880|NCT04746755|DEVICE|Orthotic Insole: Lower Back|This Insole is a full-length shaped orthotic insole, with a heel cup and an arch support. The insole can cover several shoe sizes and can be cut to the correct size to fit in the shoe.
40770881|NCT04746755|DEVICE|Orthotic Insole: Heel|This Insole is a horseshoe shaped flexible heel cup with a softer area where the heel would be expected.
40770882|NCT04746755|DEVICE|Orthotic Insole: Knee to Heel|This Insole is a ¾ length rigid orthotic insole with a softer area where the heel would be expected. Each insole will cover several shoe sizes.
41140095|NCT05907070|OTHER|Mandala group|Mandala group will participate in 2 sessions of individual mandala drawing art activity with the theme of 'Emotions' accompanied by classical or instrumental music. In each session, a mandala will be created.
41140096|NCT05907070|OTHER|Value clarification group|Value clarification groups will participate in the value clarification activity by writing 2 sessions individually with the theme of 'Emotions' accompanied by classical or instrumental music.
41299487|NCT00041717|DRUG|Fampridine-SR|25mg bid (twice daily)
41299488|NCT00041717|OTHER|Placebo|Placebo
41299489|NCT03653611|OTHER|On-site Practice Assessment|The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
41299490|NCT03653611|OTHER|Clinical Staff Questionnaires|"Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff."
41299491|NCT03653611|OTHER|Patient Opinion Surveys|200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.
41459203|NCT03328390|OTHER|Transversus abdominis plane block|15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
40770883|NCT04746755|DEVICE|Orthotic Insole: Arch|"This Insole is a ¾ length shaped medical device with a softer area incorporated into the ball of foot and heel area and an external arch.~support and 6-8 mm metatarsal dome. The slim fit insole runs from the heel along under the arch of the foot and reaches to just behind the toes to prevent squashing the toes in tight fitting shoes."
41140097|NCT02790788|DRUG|Methylprednisolone; hydrocortisone|Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
41140098|NCT02790788|DRUG|Saline Placebo|Saline placebo during resuscitation and during the postresuscitation phase.
41140099|NCT06434636|DRUG|Transamine 10% IV/IM Solution for Injection|10 mg/kg tranexamic acid (Transamine 10% IV/IM Injectable Solution) will be placed into 100 cc physiological saline through the appropriate vascular access and injected within 15 minutes.
40770884|NCT05432167|DRUG|CIN-107|Patients will take CIN-107 tablets by mouth once daily.
41140100|NCT06434636|DRUG|%0.9 Saline|100 cc %0.9 Normal Saline will be injected through the appropriate vascular access within 15 minutes
40770885|NCT05432167|DRUG|Placebo|Patients will take placebo tablets by mouth once daily.
40770886|NCT05438329|DRUG|DB-1305/BNT325|Administered Injection of Vein (I.V.)
40770887|NCT05438329|COMBINATION_PRODUCT|Pembrolizumab|Administered I.V.
40770888|NCT05438329|DRUG|BNT327|Administered I.V.
41140101|NCT04998552|RADIATION|Cyberknife|5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
41140102|NCT05944094|DEVICE|Clorhexidine|Antiseptic treatment aimed at reducing potential bacterial overgrowth consisted of 10 days (1 box) of vaginal ovules of CLX (CumLaude CLX ® , CLX digluconate 0.2%) always starting between 10+0 and 16+0 weeks.
41140103|NCT04265235|OTHER|Home-based exercise program|see 'arm' section
41140104|NCT06432257|DEVICE|head mounted magnifying glass assistance|When performing thyroid surgery for patients in the experimental group, the surgeon uses a head mounted magnifying glass for assistance
41140105|NCT06428656|DIETARY_SUPPLEMENT|Postbiotics supplementation|The participants will consume one capsule of postbiotics supplement per day
41140106|NCT06428656|DIETARY_SUPPLEMENT|Placebo supplementation|The participants will consume one capsule of placebo per day
41140107|NCT02504762|PROCEDURE|Treatment|Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
41140108|NCT02504762|PROCEDURE|Control|Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
41140109|NCT02832128|DRUG|AUT00063|4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
41140110|NCT02832128|DRUG|Placebo|4 capsules of placebo, to take orally with food for 4 weeks
41140111|NCT04169802|DIAGNOSTIC_TEST|Retinal Health Monitoring System Visual Acuity Module|Assessment of corrected near visual acuity
41140112|NCT04169802|DIAGNOSTIC_TEST|Sloan letter, logarithmic near visual acuity chart (Reference Chart)|Assessment of corrected near visual acuity
41140113|NCT03711058|DRUG|Copanlisib|"Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV"
41140114|NCT03711058|DRUG|Nivolumab|"Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV"
41140115|NCT00753259|OTHER|AF Clinic|Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
41140116|NCT00753259|OTHER|Care as Usual|Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.
41140117|NCT01735214|DRUG|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
41140118|NCT05678725|DEVICE|tACS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as the stimulation electrode, while the return electrode placed on the right shoulder . The dose was at 2mA, 20Hz for 20 minutes.
41140119|NCT05678725|DEVICE|tDCS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 2mA for 20 minutes.
41140120|NCT05678725|DEVICE|sham|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The stimulation lasted for 20 minutes and included a 10-second ramp-up and 10-second ramp-down.
41140121|NCT02176694|BEHAVIORAL|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
41140122|NCT06275841|DRUG|vepdegestrant|experimental
41140123|NCT06275841|DRUG|esomeprazole|Experimental treatment to assess an endpoint
41140124|NCT05647642|DRUG|Precedex and dormicum|Premedication
41140125|NCT05625230|BEHAVIORAL|Behavioral Activation plus Dynamic Mental Imagery|This intervention consists of an 8-session behavioural activation treatment with an added dynamic imagery exercise after each session. The dynamic imagery exercise is structured as follows: (1) the therapist explains the intervention; (2) the therapist models dynamic simulation skill (dynamic imagery) and repeats with the participant while giving appropriate feedback; (3) the participant completes a 10-minute Kinect training; (4) the participant completes a short Actfulness exercise that involves focusing on the feelings of movements of breathing and hands and dynamic imagery of one planned activity. From the second session, participants memorize daily activities forming a short dynamic memory of the activity focusing on feelings of movements.
41140126|NCT05625230|BEHAVIORAL|Behavioral activation|"The BA intervention is a short 8 session behavioural intervention. Participants learn to monitor the activities, plan anti-depressant activities for the next week and find support for the implementation of the activity."
41140127|NCT03432871|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.
41140128|NCT04121234|OTHER|"Exposure:  being admitted to HDU with a red code to OEWS"|High Dependency Unit, a set of predefined variables was assessed at hospital admission, HDU admission and at discharge from HDU with the aim to investigate epidemiology, clinical outcomes and risk factors for mortality in critically-ill parturients admitted to an obstetric HDU in a high volume, urban resource-limited maternity hospital
40974764|NCT03075540|BEHAVIORAL|Genetic Counseling and Testing YouTube Video|Participants (n=40) will watch a 15-minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a telenovela style format. Participants will complete pre- and post-assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to the patient navigator at their respective sites, who will navigate participants to identified no cost or low cost services
40974765|NCT01266512|DRUG|DOCETAXEL|Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
40974766|NCT01266512|RADIATION|Intensity Modulated Radiotherapy (IMRT)|2 Gy per fraction
40974767|NCT01266512|DRUG|CISPLATIN|Pharmaceutical form: solution for infusion Route of administration: intravenous
40974768|NCT01965496|DRUG|PEX168|A injection administered subcutaneously
40974769|NCT01265290|DEVICE|repeated 24 hours ECG Holter monitoring|repeated 24 hours ECG Holter monitoring
40974770|NCT01265290|DEVICE|Telemetric ECG monitoring|Telemetric ECG full disclosure monitoring with GSM technology
40974771|NCT05545696|DEVICE|AI on algorithm|The mandibles of the participants were scanned with ''AI on'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
41299492|NCT03653611|OTHER|Modular online COPD Education|Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).
40770889|NCT05136495|OTHER|caffeinated coffee - decaffeinated coffee|Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
40770890|NCT06228937|OTHER|analysis of a sample of stool|typing of the gut microbiota from a stool sample
40974772|NCT05545696|DEVICE|AI off algorithm|The mandibles of the participants were scanned with ''AI off'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
41140129|NCT03683849|OTHER|Training|One hour of training, twice a week, for six months.
41140130|NCT02675322|DRUG|Danlou Tablets|Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
41140131|NCT02675322|OTHER|Placebo|Placebo with no chemical effects.
41140132|NCT05298540|BEHAVIORAL|Home-based computerised cognitive training with BrainHQ|Participants will be registered for individual accounts to an online CCT program created by BrainHQ (Posit Science, San Francisco), that can be administered using their own computer or tablet. BrainHQ has been associated with improvements in memory, attention, and processing speed. The program will be customised to target domains thought to be deficient in the postoperative period and will include training in memory, attention, and processing speed. Specifically, the following six games have been selected: hear, hear (auditory memory and attention), to-do list training (working memory), divided attention (attention), target tracker (attention), double decision (useful field of view and visual processing speed), and eye for detail (visual processing speed and visual working memory). The exercises are adaptive, adjusting the application difficulty to the participants performance.
41140133|NCT01849523|BEHAVIORAL|Web-based information and support|
41299493|NCT03653611|OTHER|COPD in Primary Care/CAPTURE Introduction Focus Groups|Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
41299494|NCT03962998|DRUG|Lactulose/Rhamnose solution|Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine
41299495|NCT03962998|DRUG|MB-102|MB-102 solution administered orally followed by measurement of excreted MB-102 in urine
41140134|NCT04834830|DIAGNOSTIC_TEST|Pleural effusion will be examined for various cytokines and PD1-lymphocytes.|Examination of pleural effusion
41299496|NCT03268746|DEVICE|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision intended for long-term use over the lifetime of the cataract subject
40770891|NCT02209675|OTHER|liver biopsy|C4d assessment by immunohistchemistry in liver biopsy
40770892|NCT05423613|PROCEDURE|Microneedling|A 5% lidocaine anesthetic cream will be applied to the scar to be treated and will be wrapped with an occlusive dressing (saran wrap) for 30 minutes prior to the procedure. The same scar will be subjected to the ACS-Pen treatment at a depth of 1.5 mm or less depending on the results of the thickness measurement performed prior to treatment. Within 5 minutes after the microneedling treatment, a thin layer of triamcinolone acetonide and 2% xylocaine (1:3 ratio) suspension will be spread over the scar. The physician will then gently massage the product into the microneedling columns. The same amount will be used for each subsequent treatment. The patient will also be given a small amount of hydrocortisone 2.5% (low potency corticosteroid) to be applied to the treated site at 12 hours and 24 hours post-treatment.
40974773|NCT01104493|BIOLOGICAL|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
40974774|NCT01104493|OTHER|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
40974775|NCT02823301|BEHAVIORAL|VAMOS Program|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
40974776|NCT00936585|OTHER|Immunologic Monitoring|blood draws and colonoscopy before and after receiving study drug
40974777|NCT01288495|DIETARY_SUPPLEMENT|supplemental L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
40974778|NCT01288495|DIETARY_SUPPLEMENT|Metamucil|Subjects will consume the placebo prior to eating fructose-containing foods.
40770893|NCT01772654|DEVICE|Arterial Spin Labeled (ASL) MRI sequence|"The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence."
40770894|NCT05336695|DIAGNOSTIC_TEST|PET/MR Imaging|PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol
40770895|NCT05336695|DRUG|64Cu-FBP8|Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center
40770896|NCT04431063|PROCEDURE|Distal Stump Suturing|in ACL Reconstruction case , Group A consist of subject with operation procedure suturing the distal stump peroneus longus against the peroneus brevis in ACL reconstruction using the peroneus longus autograft.
40770897|NCT04752826|DRUG|BI-1808|BI-1808, a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets TNFR2 administered at different dose \[Phase I, Part A\] and at Recommended Dose for Part B \[Phase I, Part B and Phase IIa\] by intravenous (IV) infusions every 3 weeks.
40770898|NCT04752826|DRUG|Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection|Pembrolizumab a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
40974779|NCT04734080|DRUG|Dronabinol 5mg Cap|Dronabinol is a synthetic tetrahydrocannabinol (THC) agent approved for nausea and vomiting with chemotherapy and as an appetite stimulant in AIDS patients.
41140135|NCT00299676|DRUG|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
41140136|NCT03266432|OTHER|blood samples|three blood samples : first one pre intervention and the other two blood samples post-intervention
41140137|NCT03849937|BEHAVIORAL|Changing Talk Online (CHATO)|Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
40770899|NCT01596270|DRUG|SAR245409|Pharmaceutical form: tablet Route of administration: oral
40974780|NCT04734080|OTHER|Placebo oral tablet|Non-active placebo
40974781|NCT02520076|DRUG|Alpha-1 Antitrypsin|"Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~* Pre-transplant Day -1~* Post-transplant Day 3~* Post-transplant Day 7~* Post-transplant Day 14"
40974782|NCT00617773|BIOLOGICAL|hu3S193|20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
40974783|NCT06319508|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
41140138|NCT03927794|OTHER|Self-Assembling Peptide P11-4|Self-Assembling Peptide P11-4 promotes subsurface biomimetic remineralization of enamel. It is a small peptide comprising 11 amino acids that when applied to an initial carious lesion diffuses into the body of the lesion, re-assembles itself into fibrils forming larger fibers and hence a 3-dimensional (3-D) matrix is formed. Natural remineralization driven by saliva is promoted through the surface of the P11-4 by increasing the surface area for calcium phosphate deposition. As a result, mineralization of the subsurface lesion occurs possibly due to the formation of de novo hydroxyapatite crystals on the surface of the P11-4 fibers.
41140139|NCT05370378|OTHER|Hold Relax with Agonist Contraction|"1. Participant will be in prone lying and heating pad will be applied on gluteal region for 10 to 15 minutes.~2. Passive sustained stretch to piriformis will be applied for 10 seconds.~3. The participant will be asked to actively contract the muscle for about 10 seconds (isometric contraction) and then relax.~4. Immediately after that participant is ask to again actively contract the muscle against therapist resistance for 6-10 seconds.~5. Ask the participant to relax while therapist will apply stretch the muscle to its new tissue tension barrier position and this position will be maintained for 30 seconds.~6. This maneuver is repeated for 3 to 4 repetitions, each starting from where the previous finished."
41140140|NCT05370378|OTHER|Active Release Therapy|"1. Specific muscle will be warmed up by applying heating pad for 10 to 15 minutes.~2. Patient will be positioned prone lying and the therapist will be standing at the side of affected limb.~3. Therapist will apply deep pressure at the area of tenderness while patient will actively move the limb from internal to external rotation repeatedly.~4. This maneuver will take about 15 minutes to complete in one session and will be applied alternatively 3 days a week for two weeks.~5. After this, cold pack is applied and general ROMs and strengthening exercises are performed to prevent soreness"
41140141|NCT04389788|DEVICE|carboxy therapy|6 sessions of carboxy therapy every 2 weeks
41459204|NCT05575557|PROCEDURE|Right heart catheterization|All groups were detected with SW catheter by the internal jugular vein before the procedure. After the measurement, the catheter was indwelled, and the pacemaker implantation procedure was started. After ventricular pacing for 5 minutes, the SW catheter measurement was performed again. After the measurement, the SW catheter was withdrawn.
41459205|NCT03090282|PROCEDURE|mechanical treatment(mainly scaling and root planing), periodontal surgery(if indicated), implant placement.|The investigators shall follow the regular procedure to these patients.
41459206|NCT04418167|DRUG|JSI-1187|JSI-1187 capsules for oral administration
40974784|NCT06319508|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40770900|NCT06569862|PROCEDURE|Postoperative day 1 dressing|The patient's dressing will be removed on the first day after surgery, leaving the incision exposed to air, with daily cleaning.
40770901|NCT06569862|PROCEDURE|Postoperative day 6+/-1 dressing|The patient will have a daily dressing change according to the usual nursing procedures, including saline serum washing, until the sixth day (+/- 1 day) after surgery. This will be done while the patient is in hospital, or at home if discharged before the sixth day.
40770902|NCT04031508|COMBINATION_PRODUCT|lipid injectable emulsion with Fish oil|TPN will start at 1.5-2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 3.0 g/kg/d for at least 7 days.
40770903|NCT00002673|PROCEDURE|infection prophylaxis and management|
40770904|NCT06271915|OTHER|SNAGs - eccentric exercise|intervention done 2 times per week, 45 minutes each session for 4 weeks
40770905|NCT05512338|OTHER|Treatment|ACT-informed interventions combined with standard physiotherapy methods.
40770906|NCT05512338|OTHER|Active control group|Standard physiotherapy methods.
40770907|NCT04639791|OTHER|No intervention|Observation only, no intervention
40770908|NCT05951959|DRUG|Acalabrutinib|Investigational Product
40974785|NCT06319508|DRUG|Lidocaine hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Once a day.
40770909|NCT05951959|DRUG|Venetoclax|Investigator Product
40770910|NCT05951959|DRUG|Rituximab|Investigator Product
40974786|NCT06319508|PROCEDURE|Placebo injection|The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. 1 milliliter of normal saline will be used for injection.
40974787|NCT00756860|DRUG|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
40974788|NCT00756860|DRUG|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
40974789|NCT02759432|OTHER|High-intensity interval exercise training|
40974790|NCT01166113|DRUG|Pomalidomide, Cyclophosphamide, Prednisone|"Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d"
40974791|NCT03541720|DRUG|18F-DA|18F-DA is an investigational PET radiotracer
40974792|NCT02688140|DRUG|Arsenic trioxide|
40770911|NCT04429763|BIOLOGICAL|Umbilical cord derived mesenchymal stem cells|One dosis of 1\*10\^6 cells/Kg
40770912|NCT04429763|BIOLOGICAL|Placebo|Placebo
40974793|NCT02688140|DRUG|Idarubicin|
40974794|NCT02688140|DRUG|Cytarabine|
40770913|NCT06509815|DEVICE|MIRA|The study device is a Multi-Sensory Stimulation Device named MIRA, which uses commercially available hardware and builds off the SOLUNA software created by Studio Elsewhere. The device produces audio and visual stimuli of immersive experiences. Participants in the intervention group will either have periodic or scheduled intervention sessions. The study team member will roll the MIRA device into the patient participant's room before the session and roll it out after. The intervention requires the participant to be in bed. The study team member will set up the device and start the intervention session which can last between 15-60 minutes. During the session, data will be collected by the study team member.
40770914|NCT02556047|DEVICE|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N\&S
40770915|NCT04759287|DEVICE|C-MAC VS|The first group (VS group) will include patients undergoing awake intubation using the C-MAC VS
40770916|NCT04759287|DEVICE|flexible fibreoptic bronchoscope|The second control group (FOB group) will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
40770917|NCT00246103|DRUG|Valproic acid|Beginning Dose, Level 1: 15 mg/kg/day.
40770918|NCT00246103|DRUG|Epirubicin|Beginning Dose, Level 1: 75 mg/m\^2.
40974795|NCT02688140|DRUG|Tretinoin|
40974796|NCT02688140|DRUG|Mitoxantrone|
40974797|NCT02688140|DRUG|Mercaptopurine|
40974798|NCT02688140|DRUG|Methotrexate|
40770919|NCT00246103|DRUG|5-fluorouracil|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m\^2.
40974799|NCT01035515|DRUG|Placebo|Single dose oral capsule placebo comparator
40974800|NCT01035515|DRUG|BIIB014 50mg|Single dose oral capsule 50mg BIIB014
40770920|NCT00246103|DRUG|Cyclophosphamide.|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m\^2.
40770921|NCT05601882|DRUG|Upadacitinib|Oral Tablets
40770922|NCT05601882|DRUG|Dupilumab|Subcutaneous Injection
40770923|NCT01829451|OTHER|Hyaluronic acid gel|"Hyaluronic acid gel is placed into the uterus after endometrial ablation~--------------------------------------------------------------------------------"
40770924|NCT06424743|OTHER|exercise|exercise programs with different volumes
40770925|NCT06477770|PROCEDURE|Clorhexidine soap|surgical wound will be washed with saline solution and 10 ml of chlorhexidine soap
40770926|NCT06477770|OTHER|Sucrose|75 g of sucrose will be administered to the surgical wound at 8:00 am every day, once a day, and then it will be covered with sterile gauze.
40974801|NCT01035515|DRUG|BIIB014 100mg|Single dose oral capsule 100mg BIIB014
40974802|NCT06501768|DRUG|Genistein|Escalation genistein dosing, followed by wash-out period
40974803|NCT03211416|OTHER|Laboratory Biomarker Analysis|Correlative studies
40974804|NCT03211416|BIOLOGICAL|Pembrolizumab|Given IV
40974805|NCT03211416|DRUG|Sorafenib Tosylate|Given PO
40974806|NCT03861975|OTHER|Breast Cancer-Related Lymphedema Measurements|All patients will receive bilateral arm measurements using the LymphaTech Scanner and the Perometer.
40974807|NCT02301494|DRUG|3.75% Imiquimod Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
41140142|NCT04389788|DEVICE|Dermapen with topical glutathione|6 sessions of Dermapen microneedling with topical glutathione every 2 weeks
41140143|NCT04816305|DEVICE|rTMSc|In all rTMS protocols the patient will remain seated in a comfortable chair with adjustable arms and head rests. Before the start of the conventional rTMS (rTMSc), the resting motor threshold (RMT) of the first dorsal interosseous muscle contralateral to the lesioned hemisphere will be determined. The RMT will be defined as the lowest RMT intensity necessary to produce a motor evoked potential amplitude greater than or equal to 50 µV in at least 5 out of 10 attempts.
41140144|NCT04816305|BEHAVIORAL|Neurofunctional physiotherapy|All patients will be submitted to a protocol of exercise with different levels according to motor learning, neuroplasticity principles and motor impairment. All physiotherapists will be trained prior to the study.
41140145|NCT04816305|DEVICE|rTMS sham|During the rTMS sham sessions the same procedures will be used as the rTMSc protocols, however, the magnetic stimulator and its coil will be turned off.
41140146|NCT02845921|OTHER|leg elevation|A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
41140147|NCT02845921|OTHER|leg wrapping|Esmarch bandage is used to wrap each lower limb
41140148|NCT02845921|OTHER|control|no intervention has been done
41140149|NCT05966272|DRUG|HRS9531 injection|single dose
41140150|NCT05966272|DRUG|HRS9531 injection Placebo|single dose
41140151|NCT00188812|DRUG|donepezil hcl|
41140152|NCT02106884|DRUG|Nab-paclitaxel|
41140153|NCT02106884|DRUG|Gemcitabine|
41140154|NCT06474039|DRUG|Trelegy or Anoro|Both drugs delivered via Ellipta device and blinded package appearance
41140155|NCT01439854|DRUG|Dapagliflozin|Treatment arm, 10 mg per day for 2 weeks
41140156|NCT01439854|DRUG|Placebo|Patients are treated with placebo
41140157|NCT02695004|DRUG|DKF-310|
41140158|NCT02695004|DRUG|Placebo|
41140159|NCT00519207|DRUG|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
41140160|NCT00519207|DRUG|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
41140161|NCT03152214|OTHER|Vigorous Intensity Aerobic Exercise and Community Engagement|"Each veteran will be provided with an Apple watch for the duration of the study. Research staff will use the resultant data to monitor the veteran's activity level. Veterans will be asked to complete three 25-minute sessions of vigorous intensity aerobic exercise per week (either running, cycling, rowing, or elliptical workouts). Data collected will include the number of minutes exercised and the heartrate level (77-85% maximum heart rate). Any exercise session of 25 minutes at \> 76% of maximum heart rate will be characterized as 1 completed session of vigorous-intensity exercise. Veterans will enter the activity, minutes exercised, average heartrate, and perceived exertion into REDCap.~Community engagement will involve attending at least one Team RWB event per week through the Austin or Killeen chapters. This could be a weekly running group, hike, or community service project-among other activities. Veterans will enter whether or not they attended a Team RWB event on REDCap."
41140162|NCT03152214|OTHER|Community Engagement|Veterans in the study will receive a monthly calendar of Team RWB events upon assignment. Veterans will be able to participate in any Team RWB event located in Austin or Killeen. Veterans will be asked to attend at least one Team RWB event. This could be a weekly running group, hike, or community service project- among other activities. Veterans will enter whether or not they attended a Team RWB event on the REDCap exercise adherence surveys.
41140163|NCT03386500|DRUG|BMX-001|BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.
41140164|NCT03442777|DEVICE|Allevyn® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith\&Nephew (Allevyn® brand).
41140165|NCT03442777|DEVICE|Mepilex® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
41140166|NCT03617575|DIETARY_SUPPLEMENT|apo-Lactoferrin|1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf \[total of 1.5 mg iron\]) in a maize porridge (extrinsically labeled)
41140167|NCT03617575|DIETARY_SUPPLEMENT|holo-Lactoferrin|1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge
41140168|NCT03617575|DIETARY_SUPPLEMENT|FeSO4|1.5 mg FeSO4 as 54Fe in a maize porridge
41140169|NCT03617575|DIETARY_SUPPLEMENT|1. FeSO4|10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge
41140170|NCT03617575|DIETARY_SUPPLEMENT|FeSO4 after 1 day break|10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period
40974808|NCT02301494|DRUG|0.1% Fluocinonide Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
40974809|NCT04505267|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or intranodally
40974810|NCT04505267|RADIATION|Radiation Therapy|Undergo RT
41140171|NCT03617575|DIETARY_SUPPLEMENT|FeSO4 after 2 day break|10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period
41140172|NCT02597166|DRUG|Ledipasvir/Sofosbuvir|Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
41459207|NCT04418167|DRUG|Dabrafenib|Dabrafenib capsules for oral administration
41140173|NCT02757911|GENETIC|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene. The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector. These transduced cells will be cryopreserved until safety testing and infusion into the patient.
41299497|NCT04561843|DIAGNOSTIC_TEST|pelvic floor ultrasound|2D and 3D trans-perineum ultrasound examinations will be performed by single examiner who was blind to clinical data, using a GE Voluson 730 machine (GE Medical System Kretz Technik, Zipf, Austria) with a RAB 4-8 MHz curved array volume transducer. In the supine position, with flexed and slightly abducted hips after urine voiding. The transducer was placed on the perineum, in the mid sagittal plane with minimal pressure being applied after covering it with an un-powdered glove or thin plastic wrap for hygienic reasons
41140174|NCT01255800|DRUG|IPI-926 and Cetuximab|"* Patients will receive Cetuximab IV every week.~* Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day."
41299498|NCT04249141|OTHER|Survey and concept mapping|ICU providers who participoated in SCCM ICU Liberation Collaborative will be invited to participate in surveys and a concept mapping excercise
41299499|NCT03555279|BEHAVIORAL|PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm|HIV Prevention Behavioral Health Intervention delivered by Probation Staff
41299500|NCT03555279|BEHAVIORAL|PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm|HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
41299501|NCT01276067|DRUG|Donepezil|10 mg Tablet
41299502|NCT01333267|DRUG|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
41299503|NCT01333267|DRUG|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
41299504|NCT01333267|DRUG|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
41299505|NCT00518453|BIOLOGICAL|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
41299506|NCT00539630|DRUG|Docetaxel|
41459208|NCT05705791|DEVICE|QuiremSpheres|166Holmium selective internal intra-arterial radiation therapy at C1D15 of the Atezolizumab and Bevacizumab therapy
40770927|NCT05589025|PROCEDURE|pulpotomy technique with formocresol|The pulpotomy procedure performed was a modification of that described by Pinkham et al; 2005 where pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. After the completion of the access cavity, coronal pulp was extirpated using a sharp excavator. Any residual coronal pulpal tissue was removed using a sterile round bur in a slow-speed handpiece to a depth of few millimeters below the free gingival margin. Hemostasis was achieved with a water-dampened cotton pellet. If hemostasis was not achieved after the initial application of the cotton pellet, the case was eliminated from the study. Following hemostasis, a cotton pellet, moistened with formocresol was applied for 3 minutes and removed. A zinc- oxide and eugenol base was placed over the amputation site. Thereafter, a glass ionomer base was applied.
40770928|NCT05589025|PROCEDURE|pulpectomy technique with zinc oxide and eugenol|The pulpectomy procedure used herein was a modification of that described by Payne et al;1993 Pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. An initial endodontic K-file fitting snugly in the canal was introduced inside it. In most cases, the pulp tissue was removed completely on the first attempt. If the first attempt was unsuccessful, the procedure was repeated and canals were generally enlarged three sizes past the initial file to eliminate the organic remnants. Copious irrigation with a light flow of sterile 0.9% NaCl-solution was used throughout the procedure. At the end, the canals were dried and filled with zinc-oxide \& eugenol.
41140175|NCT00878189|DRUG|PF-03084014|10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
41140176|NCT00547456|DRUG|Oxygen|Oxygen 2-3L Nasal cannula
41140177|NCT02353507|DEVICE|Opticell Ag+|
41140178|NCT02353507|DEVICE|Aquacel Ag+|
41140179|NCT02133625|DRUG|carboplatin|
41140180|NCT02133625|DRUG|pioglitazone|
41140181|NCT05020067|RADIATION|superficial parotid lobe-sparing intensity-modulated radiotherapy|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.
41140182|NCT03661398|DEVICE|Transcatheter Mitral Valve Replacement|All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.
41140183|NCT00893698|PROCEDURE|bilateral allotransplantation|bilateral allotransplantation of upper limbs
41140184|NCT01214070|OTHER|Vision Restoration Therapy|Therapy that enhances the neuronal plasticity of the visual system
41140185|NCT01214070|BEHAVIORAL|NVT Eye Scanning Therapy|Therapy that trains eye and head scanning into the blind hemianoptic visual field
41140186|NCT01214070|BEHAVIORAL|Eccentric Viewing Training|Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
41459209|NCT01228552|DRUG|Topical, intra-oral ketoprofen gel|Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
41459210|NCT01228552|OTHER|Placebo gel|Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
41299507|NCT05609747|PROCEDURE|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
41299508|NCT04105543|DRUG|CLR 131|CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
40770929|NCT04861701|BEHAVIORAL|Static stretching exercise|The intervention of this study is home-based stretching exercise. The experimental group will receive 6 stretching exercises which stretch 60 seconds for each side (left or right) of each movement, and relax for 10-20 seconds between the movements. It will take 10-15 minutes every day for continuous 4 weeks. The 6 stretching exercises include : (1) pectoral muscles + calf muscles ; (2) quadriceps ; (3) levator scapulae ; (4) gluteal muscles ; (5) hamstrings ; (6) trunk side-flexors.
40770930|NCT00184392|PROCEDURE|debridement or saline irrigation|debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
40770931|NCT01697644|DRUG|somatropin|3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
40770932|NCT01697644|DRUG|somatropin|3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
40974811|NCT01456468|DRUG|Oral all-trans retinoic acid (ATRA)|"The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m\^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process."
40974812|NCT02512237|DRUG|ARX788|ARX788, an antibody drug conjugate
41140187|NCT01214070|BEHAVIORAL|Sham|Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
41140188|NCT05308589|DEVICE|CPPF|Continuous Postoperative Pericardial Flush
41140189|NCT01380145|BIOLOGICAL|recMAGE-A3 Protein + AS15 Adjuvant|recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
41140190|NCT05309057|DIETARY_SUPPLEMENT|Intermittent Fasting|Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
41140191|NCT01564472|OTHER|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
41140192|NCT02577939|BEHAVIORAL|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
41140193|NCT05149963|OTHER|Cognitive Behavioural Therapy (CBT) for Chronic Loneliness|Participants will receive an average of 12 50-minute sessions of Cognitive Behavioural Therapy (CBT) aiming to reduce their feelings of loneliness
41299509|NCT06338553|DRUG|Placebo|placebo capsule or tablet once before the pre-TZIELD® MMTT and once before one of the post-TZIELD® MMTTs.
41299510|NCT06338553|DRUG|Semaglutide (Rybelsus®)|7 mg single dose of Rybelsus® by mouth once before one of the post-TZIELD® MMTTs
40770933|NCT01464606|DRUG|Vincristine|≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
40770934|NCT01464606|DRUG|Dactinomycin|≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
40770935|NCT01464606|DRUG|Cyclophosphamide|≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
41299511|NCT00928616|DIETARY_SUPPLEMENT|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
41299512|NCT00928616|DIETARY_SUPPLEMENT|margarine (placebo)|non-sterol ester supplemented margarine
40974813|NCT02998593|DRUG|Bahman capsules|Oral Use of Bahman capsules for 3 months by patients.
40974814|NCT02998593|DRUG|Placebo|Oral use of placebo capsules by patients for 3 months.
40770936|NCT01464606|DRUG|Ifosfamide|≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
40770937|NCT01464606|DRUG|Doxorubicin|≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
40974815|NCT02915497|BEHAVIORAL|Abbreviated Early Prolonged Exposure Therapy|Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
40974816|NCT00062374|DRUG|Cisplatin|Given IV
40974817|NCT00062374|PROCEDURE|Computed Tomography|Undergo FDG and FLT PET/CT
40974818|NCT00062374|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
41299513|NCT06498739|DRUG|Erector spinae plane block(15 ml bupivacaine 0.5%)|Patients will preoperatively receive high concentration-low volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% }, for each patient).
41299514|NCT06498739|DRUG|Erector spinae plane block (15 ml bupivacaine 0.5% and 15ml normal saline)|Patients will preoperatively receive low concentration-high volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline}, for each patient.
41299515|NCT03537820|OTHER|questionnaire|questionnaire EVAN-G
40974819|NCT00062374|OTHER|Fluorothymidine F-18|Undergo FLT-PET/CT
40974820|NCT00062374|DRUG|Irinotecan Hydrochloride|Given IV
41140194|NCT05038202|DRUG|Bencycloquidium Bromide Nasal Spray|"The content of this product is a colorless and clear liquid, press the sprayer, the liquid will be sprayed out in mist.~This product is suitable for improving the symptoms of runny nose, nasal congestion, nasal itching and sneezing caused by allergic rhinitis."
41299516|NCT02859545|BEHAVIORAL|Emotional Validation Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.
41299517|NCT02859545|BEHAVIORAL|Chronic Pain Education Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
41299518|NCT04478682|OTHER|Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application|Breastfeeding support provided to mothers through WhatsApp messaging application will be maintained for the first 6 months after birth. In the first 1 month, standard information sharing will be made through whatsApp. Also, for the first 6 months, solutions generating shares will be made according to the problems and questions of the mother regarding breastfeeding.
41299519|NCT03993691|DEVICE|Tomo-E scan|High-resolution limited-angle tomography positioning and examination will vary depending on injury.
41299520|NCT03993691|DEVICE|Radiograph|Standard of Care radiographic imaging of wrist.
41299521|NCT01267097|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
41299522|NCT01267097|BEHAVIORAL|Psycho-Education Program (PEP)|PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
41299523|NCT04969016|PROCEDURE|LSA (liquid skin adhesive)|surgical wound closure with liquid skin adhesive (LiquiBand®)
41299524|NCT04969016|PROCEDURE|stapler|surgical wound closure with stapler
41299525|NCT03466320|BIOLOGICAL|NKR-2|This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
40974821|NCT00062374|PROCEDURE|Positron Emission Tomography|Undergo FDG and FLT PET/CT
41299526|NCT05478044|DRUG|Ascorbic acid|Ascorbic acid IV ampoules (20%).
41140195|NCT05038202|DRUG|Mometasone Furoate Aqueous Nasal Spray|"Mometasone furoate nasal spray is a quantitative hand-press spray device, and the content is a white to off-white suspension.~This product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children from 3 to 11 years old. For patients who have had moderate to severe seasonal allergic rhinitis symptoms, it is recommended to use this product 2-4 weeks before the start of the pollen season Preventive treatment."
41140196|NCT01275859|DRUG|Letrozole, Lapatinib|Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks
41140197|NCT03556852|DRUG|Carbetocin|1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby
41140198|NCT03556852|DRUG|Misoprostol|2 rectal misoprostol tablets (800 μg) after the delivery of the baby.
41140199|NCT00916110|DRUG|ATN-103|1.5 mg solution, single subcutaneous injection
41299527|NCT05478044|OTHER|saline|saline (0.9%)
41140200|NCT00916110|DRUG|ATN-103|4 mg solution, single subcutaneous injection
41140201|NCT00916110|DRUG|ATN-103|10 mg solution, single subcutaneous injection
40974822|NCT00062374|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical subtotal or total gastrectomy with lymph node dissection
40974823|NCT02670083|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
40974824|NCT02670083|DRUG|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
40974825|NCT01922128|DRUG|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
41140202|NCT00916110|DRUG|ATN-103|25 mg solution, single subcutaneous injection
41140203|NCT00916110|DRUG|ATN-103|25 mg solution, single intravenous injection
41299528|NCT01244334|DRUG|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
41299529|NCT01244334|DRUG|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
41299530|NCT06234735|BEHAVIORAL|Physical activity in the community|Supervised and guided PA sessions in the community setting using public resources such as parks, sports facilities, etc.
41299531|NCT06234735|BEHAVIORAL|Conventional intervention|Conventional protocol for lung cancer and PA recommendations.
41299532|NCT02124720|BEHAVIORAL|iSTIM|Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
41299533|NCT00004106|DRUG|temozolomide|Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks
41299534|NCT05183581|DEVICE|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and outer thigh of the test subject to measure skin temperature during erection.
40974826|NCT03633682|BEHAVIORAL|Headspace - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
40974827|NCT03633682|BEHAVIORAL|Stop, Breathe, & Think - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, \& Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
41299535|NCT01765764|DRUG|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
41299536|NCT01765764|DRUG|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
41299537|NCT00084682|DRUG|romidepsin|Given IV
41299538|NCT03649958|DEVICE|HIRREM-SOP or Cereset|HIRREM-SOP for ten 90 minute sessions
41299539|NCT03649958|DEVICE|Cereset 2x|Cereset 2x for five 90 minute sessions
40974828|NCT01533025|PROCEDURE|anterior cruciate ligament reconstruction|single bundle anterior cruciate ligament reconstruction with Achilles allograft
40974829|NCT02466360|BEHAVIORAL|Back Belief questionnaire|
40974830|NCT02466360|BEHAVIORAL|QUEBEC scale|
41299540|NCT00371033|DRUG|Pregabalin|dosage
41299541|NCT00371033|DRUG|Placebo|dosage
40974831|NCT02466360|BEHAVIORAL|Fear Avoidance beliefs questionnaire|
40974832|NCT02466360|BEHAVIORAL|Visual analog scale|
40974833|NCT02466360|BEHAVIORAL|individual interviews|
40974834|NCT02466360|BEHAVIORAL|Focus groups|
40974835|NCT02755558|BEHAVIORAL|Low energy density|Low energy density milk served
40974836|NCT02755558|BEHAVIORAL|High energy density|High energy density milk served
40974837|NCT02755558|BEHAVIORAL|Small portion|Small portion of milk served
40974838|NCT02755558|BEHAVIORAL|Large portion|Large portion of milk served
40974839|NCT01767155|DRUG|AEZS-108 / zoptarelin doxorubicin|267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
40974840|NCT01767155|DRUG|doxorubicin|60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
40974841|NCT01078012|BEHAVIORAL|Trained counselling|
40974842|NCT03176251|OTHER|Gamified-Integrated Curriculum|The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
41299542|NCT03958617|DEVICE|Bilateral Deep brain stimulation of the thalamus, Medtronic Device|
41299543|NCT02644083|DRUG|Dimethyl fumarate|
41299544|NCT03108755|DRUG|ASP7713|oral
41299545|NCT03108755|DRUG|Placebo|oral
41299546|NCT06516796|OTHER|No intervention|Patients were retrospectively screened.
41299547|NCT06552520|DRUG|TQH2722 injection|Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody
41299548|NCT06552520|DRUG|Placebo of TQH2722 injection|Placebo without drug substance
41299549|NCT04177654|DRUG|Benzimidazoles|A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.
41299550|NCT03604471|DRUG|Atorvastatin|Blood sampling for atorvastatin quantification and pharmacogenetic analysis.
41299551|NCT06282757|OTHER|Video placebo communication|The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.
41299552|NCT06282757|OTHER|Video nocebo communication|The nocebo communication video comprises of an educational VR video containing nocebo stimulating verbal language.
41299553|NCT04649528|BEHAVIORAL|Effective endurance 4x4 training - Supervised|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
41299554|NCT04649528|DEVICE|Effective endurance 4x4 training - APP|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
41299555|NCT05480787|DRUG|Remimazolam 0.1mg/kg/h|Remimazolam Tosilate for Injection(36mg)
41299556|NCT05480787|DRUG|Remimazolam 0.3mg/kg/h|Remimazolam Tosilate for Injection(36mg)
41299557|NCT05480787|DRUG|Remimazolam 0.5mg/kg/h|Remimazolam Tosilate for Injection(36mg)
40974843|NCT01417234|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
40974844|NCT02412423|DRUG|post-transplantation cyclophosphamide|
41140204|NCT00916110|DRUG|ATN-103|50 mg solution, single subcutaneous injection
41140205|NCT00916110|DRUG|ATN-103|100 mg solution, single subcutaneous injection
41140206|NCT00916110|DRUG|ATN-103|200 mg solution, single subcutaneous injection
41140207|NCT00916110|DRUG|ATN-103|200 mg solution, single intravenous injection
41140208|NCT05763823|DRUG|Letermovir|Letermovir 240 mg or 480 mg oral tablets or IV once daily dose
41140209|NCT00286039|PROCEDURE|Blood sampling|Blood sampling is used.
41140210|NCT00816205|DRUG|Coated Nifedipine Suppositories|"Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:~The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.~The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine."
41140211|NCT04919369|BIOLOGICAL|Atezolizumab|Given IV
41140212|NCT04919369|DRUG|Tretinoin|Given PO
41140213|NCT02102698|DRUG|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1 receptor family.
41140214|NCT03690466|DEVICE|Study device treatment|The ultrasound portable device comprises a tabletop control unit and a transducer connected to the control unit by a cord.
41140215|NCT03690466|DEVICE|Sham device treatment|A similar device as used for the study device treatment will be used, except that no energy will be delivered to the spleen.
41140216|NCT00516399|DRUG|povidone-iodine 1.25% ophthalmic solution|
41140217|NCT00516399|DRUG|natamycin ophthalmic suspension, USP 5%|
41140218|NCT01799603|DRUG|TMC435|TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
41140219|NCT06330116|DEVICE|IQoro|Please refer to arm/group description for information
41140220|NCT06330116|DEVICE|eXciteosa|Please refer to arm/group description for information
41140221|NCT06330116|BEHAVIORAL|Grouptraining|Please refer to arm/group description for information
41140222|NCT05646407|DEVICE|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
41140223|NCT04472715|PROCEDURE|follicular unit extarcation and platelet rich plasma|hair transplantation procedure
41140224|NCT01061658|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Higher dosage of vaccine
41140225|NCT01061658|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Lower dosage of vaccine
41140226|NCT01061658|OTHER|Placebo|Placebo
41140227|NCT00392652|DRUG|oral microencapsulated diindolylmethane|Given PO
41299558|NCT06451237|DRUG|Isotretinoin capsules|A one year follow up for patients on three maintenance regimens after acne clearance, including weekend isotretinoin and adapalene gel.
41299559|NCT04290650|BEHAVIORAL|Modified CBT for insomnia|Nurses who are working closely with the patients around the clock will perform an adjusted and modified version of CBT for sleep disturbances, in addition to standard evidence based treatment for psychosis and affective disorders as per today.
41299560|NCT04290650|BEHAVIORAL|Treatment as usual|All patients on the two other psychosis wards will receive standard evidence based treatment for psychosis and affective disorders as per today.
41299561|NCT03462446|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
41299562|NCT03462446|DRUG|Vitamin K antagonists (VKAs)|As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
41299563|NCT01044277|DRUG|Glutathione supplementation|500 mg, two times daily
41299564|NCT01044277|DRUG|Gluthathione peroxidases|125 mg, two times daily
41299565|NCT01044277|OTHER|Placebo|2 times daily
41299566|NCT03719560|DRUG|Methotrexate|Systemic methotrexate
41299567|NCT03719560|DRUG|Cytarabine|Systemic cytarabine
41299568|NCT05354284|OTHER|online questionnaire|Questionnaire at three timepoints
41140228|NCT04017104|DIAGNOSTIC_TEST|18F-FDG PET/CT|"For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
40770938|NCT03257657|BEHAVIORAL|Observation Group participants|Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
40974845|NCT04334720|OTHER|Comprehensive treatment of tumor|According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
41140229|NCT04017104|DIAGNOSTIC_TEST|68Ga-DOTATOC PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
41140230|NCT04017104|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
41140231|NCT04353856|OTHER|quality of life assessment|quality of life assessment using the EQ5D questionnaire once a month
40974846|NCT04221841|OTHER|descriptive|correlation
40770939|NCT03257657|BEHAVIORAL|Lifestyle group participants|Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
40974847|NCT05582746|BEHAVIORAL|Tri-City COVID Attitudes Study|We propose a two-year study to rapidly assess (Aim 1), build and push (Aim 2), evaluate and disseminate (Aim 3) an mHealth intervention to boost COVID-19 testing and vaccine literacy, access, and uptake among women with CLSI in three cities
40974848|NCT06232811|BEHAVIORAL|Assessment|Sensory processing skills of children in the preterm and term groups will be evaluated. Additionally, the attachment between mother and baby will be evaluated.
40974849|NCT00516438|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
40974850|NCT00516438|DRUG|Topotecan|intravenous infusion
40974851|NCT04939402|DIAGNOSTIC_TEST|Serological testing|Antibody testing for Sars-CoV-2 specific antibodies in blood + T cell immunity
40974852|NCT01053884|DRUG|Anidulafungin|"standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC \> 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture."
40974853|NCT04341389|BIOLOGICAL|Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Intramuscular injection
40974854|NCT04341389|OTHER|Placebo|Intramuscular injection
40974855|NCT02573311|DRUG|tamsulosin hydrochloride|
40974856|NCT04214054|OTHER|Moldable self-hardening biphasic calcium phosphate graft|Incision was performed in the canine area then a full thickness mucoperiosteal flap was elevated and exposure of the lateral aspect of the maxillary sinus. Osteotomy of the buccal window was performed using the piezosurgery device followed by meticulous dissection of the sinus membrane. Drilling the site were implants were to be placed, guided by the preformed surgical stent. Implants of appropriate size were torqued to engage the apical aspect of the implant recipient site. The sinus was augmented with moldable self-hardening biphasic calcium phosphate. Repositioning and suturing of the flap using 3-0 black silk suture material.
41140232|NCT00729547|BEHAVIORAL|Neurofeedback|enhance relative activity level of left frontal activity
41140233|NCT00729547|BEHAVIORAL|Psychotherapy placebo|These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
41140234|NCT00147615|DRUG|Eplerenone|
41140235|NCT06300294|OTHER|acupressure|After the CAG procedure, acupressure will be applied to individuals whose vital signs are within the normal range.
41140236|NCT05364515|DRUG|PRGF|"Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)"
41140237|NCT05364515|DRUG|Clobetasol Propionate|0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
41140238|NCT00540956|DRUG|cytarabine|
41140239|NCT00540956|OTHER|laboratory biomarker analysis|
41140240|NCT04899557|PROCEDURE|Single Port Robotic Splenectomy|Pediatric patient with splenomegaly underwent a single port robotic splenectomy.
41140241|NCT02741557|DRUG|DTG|DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
41140242|NCT02741557|DRUG|RPV|RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
41140243|NCT02741557|DRUG|DTG/RPV FDC|DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
41140244|NCT02073214|OTHER|Probiotic|Standard treatment plus probiotic
41140245|NCT02073214|OTHER|Placebo|Standard treatment plus placebo
41140246|NCT03686839|BEHAVIORAL|SMR neurofeedback training to MCI|SMR neurofeedback training consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta ratio training was recorded at channel Cz according to the International 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed. A 32 channels system (EEGDigitrack Biofeedback plus module, Inc Elmiko Medical) was used for SMR/theta neurofeedback training.
41140247|NCT03822806|OTHER|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise for the first 30 minutes of those 2 hours using the video game
41140248|NCT06369844|OTHER|Pressure injury education|Pressure injury education will be provided to participants in the intervention group in three separate sessions covering the topics of Pressure Injury Definition and Classification, Risk Assessment, Prevention, and Care.
41147123|NCT05345041|BEHAVIORAL|Keep it Movin'|Individual participants in churches randomized to the intervention arm will participate in the Keep it Movin' multi-component PA education program, as well as be encouraged by their church and study interventionist to participate in the church-wide walking program. Individuals enrolled in Keep It Movin' will attend weekly 90-minute sessions for 24 weeks. All sessions will include the structured physical activity component from the LIFE study intervention, with the following components, which were added to address needs of the target community: functional education, social support and problem-solving. To increase the functional gains seen in the LIFE pilot study and add content addressing self-management and PA with multiple chronic conditions (MCCs), the number of sessions in the proposed trial has been increased from 16 to 24 weeks.
41299569|NCT03975868|OTHER|Analysis of associated factors for cut-out in internal fixation of extracapsular proximal femoral fracture.|Identification of factors for mechanical failure of internal fixation of extracapsular proximal femoral fracture in over 75 year olds
41299570|NCT01614769|DRUG|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
41299571|NCT01614769|DRUG|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
41299572|NCT01614769|DRUG|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
41299573|NCT01614769|PROCEDURE|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
40974857|NCT04214054|PROCEDURE|No graft material placed - Blood Clot only|A pyramidal full thickness mucoperiosteal flap was performed distal to the canine area with a crestal incision located palatally in the edentulous area and vertical extension of the incision to the buccal vestibule using Bard Parker blade number 15. The flap was reflected exposing the alveolar bone. Lateral window was performed and the sinus membrane was elevated using piezo surgery. Drilling at the sites where implants were to be placed was done using Neobiotech implant drilling Kit. Implants. Implants were placed in a self-tapping fashion using a torque wrench. Flaps were replaced back and sutured using 3-0 black silk suture material.
40974858|NCT03068130|DRUG|Bardoxolone methyl|Capsules of Bardoxolone methyl
40974859|NCT05982392|DRUG|Tramadol|Tramadol 100mg will be given 60 minutes before start of procedure.
40974860|NCT05982392|DRUG|Naproxen Sodium|Naproxen sodium 550mg will be given 60 minutes before start of procedure.
41140249|NCT06416540|OTHER|Theraband Exercises plus Conventional Physiotherapy and Rehabilitation Program|"Upper extremity, shoulder flexion, abduction, elbow flexion and wrist extension movements will be applied to the study group by the physiotherapist in combination with the breathing pattern. The program will start with yellow therabant and the difficulty level will be increased according to the patient's condition. Exercise training will be applied in a total of 3 sets, 30-60 min/session, 5 days/week, 8-10 repetitions/set, depending on the condition of each patient, during the patients' stay in the intensive care unit.~Conventional Physiotherapy and Rehabilitation Program Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient."
41140250|NCT06416540|OTHER|Conventional Physiotherapy and Rehabilitation Program|Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient.
41140251|NCT06397989|DIETARY_SUPPLEMENT|Ready-to-use school food|80 grams of peanut paste-based food containing skim milk powder, cowpea, peanuts, vegetable oil, and multiple micronutrients
41140252|NCT06397989|DIETARY_SUPPLEMENT|Standard meal|300ml of porridge made with rice/millet flour
41140253|NCT06346652|OTHER|Routine Physical Therapy|Routine physical therapy involving muscle strengthening exercises, range of motion exercises and stretching exercises up to patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks.
41140254|NCT06346652|OTHER|Routine Physical Therapy+ PNF and Core Stregthening|Routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in lower extremity in D1 flexion pattern and D1 extension pattern up to patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks.
41140255|NCT01199185|BEHAVIORAL|Smoking Cessation|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
41140256|NCT01199185|BEHAVIORAL|Smoking Cessation plus Weight Loss|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
41140257|NCT02721407|DRUG|Retroviral vector-transduced autologous T cells to express CD22-specific CARs|
41140258|NCT05585398|DRUG|IncobotulinumtoxinA|Intradermal injections using different delivery methods (conventional needle and microneedles)
41140259|NCT03600207|OTHER|Complex training|The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.
41140260|NCT03600207|OTHER|Diaphragm training|The training program contains strengthening exercises on the diaphragm muscle.
41140261|NCT02027350|DEVICE|CD Leycom/Millar Instruments conductance catheter|Conductance catheter-Pressure volume relationship
41140262|NCT01661972|DRUG|Capecitabine and aflibercept|"Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle."
41299574|NCT02558738|DEVICE|ear spray|
40974861|NCT05982392|DRUG|Placebo|Placebo will be given 60 minutes before start of procedure.
40974862|NCT02902419|OTHER|Wound dressing removal.|
40974863|NCT04024020|OTHER|lumbar puncture|Subjects will have a lumbar puncture to collect cerebrospinal fluid collection
40974864|NCT02786446|DRUG|Lidocaine gel,|2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
40974865|NCT02786446|DRUG|Naproxen Sodium|Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
41140263|NCT04235894|DRUG|Propofol|Intravenous anesthesia with propofol started with 0.5 mg kg-1, and was titrated until a patient was unresponsive to painful stimuli \& maintaining spontaneous breathing during gastrointestinal endoscopy
41299575|NCT05203133|DIETARY_SUPPLEMENT|Energy Balance|Energy balance phase to elicit weight-maintenance
40974866|NCT02786446|DRUG|Lidocaine gel and Naproxen Sodium|Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
40974867|NCT00426907|PROCEDURE|Unlimited postoperative weightbearing|Unlimited postoperative weightbearing
40974868|NCT00587639|DEVICE|rTMS Treatment|Active rTMS treatment.
40974869|NCT03235076|DRUG|BAY1101042|Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
40974870|NCT03142568|DRUG|Sildenafil|Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.
40974871|NCT03142568|OTHER|Placebo|Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
40974872|NCT01401283|DEVICE|measurement of cardiac output and pulse pressure variation|hemodynamic optimization according to cardiac index and pulse pressure variation
40974873|NCT04473924|DRUG|Mycophenolate Mofetil|Body surface area-based dosing of mycophenolate
40974874|NCT04473924|DRUG|Mycophenolate Mofetil|Standard (fixed) dosing of mycophenolate
40974875|NCT04792164|PROCEDURE|Ultra sound guided nerve block|Ultra sound guided nerve block by lidocaine before open inguinal hernia repair.
40974876|NCT04792164|PROCEDURE|Usual infiltration|Usual infiltration by lidocaine before open inguinal hernia repair.
40974877|NCT02551276|DRUG|Salbutamol|
40974878|NCT02551276|DRUG|Placebo|
40974879|NCT02551276|OTHER|Resistance training|
40974880|NCT00603889|BIOLOGICAL|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
40974881|NCT03487276|DRUG|IFX-1|Single IV infusions of IFX-1 diluted in sodium chloride.
40974882|NCT03487276|DRUG|Placebo|Placebo
40974883|NCT00964860|DEVICE|Glide dental floss|Glide waxed dental floss
40974884|NCT04719754|DIAGNOSTIC_TEST|Vaginal swab|The other vaginal swab will be cultured on blood agar, chocolate agar, MacConkey agar and Sabourauds dextrose agar. The cultures will be incubated at 37ºC for 24-96 h or until the colonies appear.
40974885|NCT03015389|PROCEDURE|Diagnostic Test|WATS3D brush biopsy
40974886|NCT04172506|DRUG|AK105|Anti-PD-1 antibody
40974887|NCT05758051|PROCEDURE|subtrochanteric valgus osteotomy|subtrochanteric valgus osteotomy
40974888|NCT06036771|DEVICE|Voice-activated Intelligent Personal Assistant (VIPA)|Apple HomePod mini is selected as the intervention medium of this study as it is the only available smart speaker that supports Cantonese
40974889|NCT01044862|DRUG|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
40974890|NCT01044862|DRUG|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
40974891|NCT01044862|DRUG|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
40974892|NCT04201002|PROCEDURE|Resection plus intraoperative radiotherapy|En-bloc resection plus intraoperative radiotherapy
40974893|NCT00638378|DRUG|Ruxolitinib|Ruxolitinib 25 mg tablets taken with water twice a day.
40974894|NCT05871294|DEVICE|Acoustic stimulation|The sound used for treatment is selected based on the patient's tinnitus frequency and loudness. Patients receive 90 minutes of acoustic stimulation therapy every day (at least 5 days per week). The entire treatment period is 3 months.
40974895|NCT05871294|DEVICE|Repetitive transcranial magnetic stimulation|The course of repeated transcranial magnetic stimulation therapy is 4 weeks, with 5, 5, 4, and 3 treatments per week, each lasting 90 minutes (including rest time)
40974896|NCT03730246|PROCEDURE|cesarean sectio|consecutive parturients due for cesarean sectio
41299576|NCT05203133|DIETARY_SUPPLEMENT|Energy Deficit|Energy deficit phase to elicit weight-loss
41299577|NCT05203133|DIETARY_SUPPLEMENT|Baseline Assessment|Free-living assessment of energy status
41299578|NCT02086565|BEHAVIORAL|Portal training and home visits|patient portal training and home visits by CHW to coordinate care
41299579|NCT02086565|BEHAVIORAL|Portal training|training in use of patient portal
41299580|NCT03312777|DRUG|Omnitram|Omnitram tablets overencapsulated
40974897|NCT04412720|OTHER|Aerobic and Breathing Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, Buteyko Breathing Technique also will be performed during 20 minutes each exercise, in the same treatment session. During the first two weeks, the patient will learn the technique supervised by a physical therapist. In addition, the patients will receive a breathing exercise booklet for in-home training. Before and after each session, patients will be evaluated in relation to blood pressure, heart rate, oxygen saturation and asthma symptoms.
40770940|NCT03909061|BEHAVIORAL|Wheelchair Maintenance Training|Wheelchair Maintenance Training Program: WMTP training consists of three parts. It starts with an overview of basic wheelchair maintenance items, continues with the second section discussing how to inspect the parts of a wheelchair and finishes with the third section discussing how to perform wheelchair maintenance on a wheelchair. Throughout the course, there are videos and pictures demonstrating the activities discussed in the training program. Participants will also be informed when a repair requires professional assistance and where such assistance may be found.
40974898|NCT04412720|OTHER|Aerobic and Stretching Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, stretching exercises will be performing for major muscle groups, during 30 seconds each one. The patients will receive a stretching exercise booklet for in-home training.
40974899|NCT02753023|OTHER|no intervention|No intervention related
40974900|NCT02858193|DRUG|1.35 g SCMC- lys powder|1.35 g SCMC- lys powder for oral solution
40974901|NCT02858193|DRUG|Fluifort® syrup|SCMC-lys Syrup 90 mg/ml
40974902|NCT06221293|DIAGNOSTIC_TEST|immunoenzyme analysis|immunoenzyme analysis with EVOLIS system
40974903|NCT05846191|DIAGNOSTIC_TEST|serum pentraxin 3 and high sensitive CRP|serum pentraxin 3 and high sensitive CRP
40974904|NCT05484739|OTHER|Water Spray|Participants will receive water spraying on their body throughout the climate chamber exposure.
40974905|NCT05484739|OTHER|Fan|Participants will be exposed to a fan throughout the climate chamber exposure.
40974906|NCT05484739|OTHER|Water Spray and Fan|Participants will receive both water spraying and a fan throughout the climate chamber exposure.
41140264|NCT04701645|COMBINATION_PRODUCT|Microdevice|"Placement of 1 to 6 implantable microdevices with multiple miniature drug reservoirs into a tumor mass 24 +/- 8 hours prior to surgery. Drugs will be released over 24 (+/- 8) hours while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice will harbor up to 20 drugs and drug combinations relevant to the treatment of ovarian cancer.~* Each drug or drug combination will be released from a single, separate reservoir. At least two reservoirs will harbor a drug vehicle only.~* Drugs will include all or a subset of the following: Cisplatin, Carboplatin, Paclitaxel, Doxorubicin or pegylated liposomal doxorubicin (PLD), Cyclophosphamide, Etoposide, Gemcitabine, Ifosfamide, Pemetrexed, Topotecan, Vinorelbine, Olaparib, Niraparib, Rucaparib, Carboplatin + paclitaxel (combination), Carboplatin + doxorubicin (combination),Carboplatin + gemcitabine (combination)"
41140265|NCT02266927|DRUG|Flovent HFA|
41140266|NCT02266927|DRUG|OPTINOSE™ FLUTICASONE|
40770941|NCT03964090|DRUG|TEDD-R|Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
40770942|NCT03964090|DRUG|TEDDI-R|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
40770943|NCT03964090|DRUG|Ibrutinib|For Arm 1:Ibrutinib given on days -14 to day -1 prior to cycle 1;then given every 21 days for cycles 1-4 For Arm 2: Ibrutinib given on days -14 to day -1 prior to cycle 1; then on days 1-10 for cycles 1-4
40770944|NCT03964090|DRUG|Cytarabine|Cytarabine on days 1 and day 5 of cycles 2-5 (all arms), as applicable
40770945|NCT03964090|DRUG|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy unless ibrutinib discontinued permanently
40974907|NCT05484739|OTHER|Control|Participants will NOT receive either water spray or a fan exposure.
40974908|NCT06384768|OTHER|Video training|A 4 week support program consist of videos for fear of childbirth
40974909|NCT03766308|DIETARY_SUPPLEMENT|Highland Barley Diet|Highland Barley Diet
40974910|NCT03766308|DIETARY_SUPPLEMENT|ADA diet|ADA diet
41140267|NCT06216002|DIAGNOSTIC_TEST|Train of four nerve stimulator|Patient receive nerve stimulation by TOF-scan equipment at recovery room after surgery.
40770946|NCT03964090|DRUG|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
41140268|NCT03675282|DRUG|(11C)PE2I|Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
40974911|NCT04464356|DEVICE|mechanical circulatory support|mechanical circulatory support: cardiopulmonary bypass, extracorporeal membrane oxygenation(ECMO), left ventricular assist device
40974912|NCT03352830|BEHAVIORAL|RANAS Behavior Change Intervention|The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.
41299581|NCT03312777|DRUG|Tramadol|Tramadol tablet overencapsulated
41299582|NCT03312777|DRUG|Placebo|Microcrystalline powder overencapsulated
41299583|NCT05009823|DIETARY_SUPPLEMENT|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml.
41299584|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 With CMV|Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.
41299585|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 Without CMV|Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.
41299586|NCT05009823|DIETARY_SUPPLEMENT|F100|100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
41299587|NCT05009823|DIETARY_SUPPLEMENT|Standard F75 + RUTF|Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive
41299588|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 with CMV + RUTF|Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase
41299589|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 without CMV + RUTF|Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase
41299590|NCT02111824|DEVICE|MIMIG System|Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
41299591|NCT02111824|DRUG|Indocyanine Green (ICG)|Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
41299592|NCT00493948|DEVICE|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
40974913|NCT03352830|OTHER|Infrastructural Intervention - Direct Delivery|Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.
40974914|NCT00039364|DRUG|imatinib mesylate|
41299593|NCT04542798|DEVICE|Radiofrequency COSMAN|Radiofrequency ablation and neuromodulation
41299594|NCT06155266|DIAGNOSTIC_TEST|2 additional whole blood samples of 6mL each will be taken|"As part of the initial blood work-up, 2 additional samples of 6mL each of whole blood will be taken, to which 1mL of Cytodelics® Stabiliser will be added. The tubes will be mixed by inverting 10 to 15 times, incubated at +20°C for 10 minutes, then transported within 1 to 2 hours at 4°C by courier to the CRB at Pitié-Salpêtrière for aliquoting and freezing at -80°C . The expression level of cell surface markers will then be measured in series on an Aurora spectral cytometer, after frozen samples (1 to 2 aliquots) have been sent from the CRB-PSL to CIMI (INSERM U1135) at -80°C approximately once a month.~Any remaining samples sent to CIMI will be destroyed once the analyses have been completed."
41299595|NCT00540176|DRUG|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
41299596|NCT05590234|DRUG|Dexmedetomidine injection|1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%
40770947|NCT06597656|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
40770948|NCT06597656|PROCEDURE|Plasmapheresis|Therapeutic plasma exchange procedure
40974915|NCT05253170|RADIATION|Hypofractionation|Radiation regimen of 2.5-3.0Gy x 13-17 fractions +/- sequential boost 0-7 fractions
40974916|NCT05253170|RADIATION|Conventional Fractionation|Radiation regimen of 1.8-2.0Gy x 23-28 fractions +/- sequential boost 0-5 fractions
41140269|NCT03675282|DRUG|Ioflupane|Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
41140270|NCT03441256|DEVICE|LION procedure|Laparoscopic implantation of an impulse generator and four leads for electrical stimulation of femoral and sciatic nerves.
41140271|NCT03441256|DEVICE|NMES|Conventional neuromuscular electrical stimulation via surface electrodes.
41299597|NCT05590234|DRUG|Bupivacaine 0.25% Injectable Solution|20 ml of bupivacaine 0.25%,
41299598|NCT05590234|DRUG|normal saline|20 ml of normal saline 0.9%.
41299599|NCT04367701|DIAGNOSTIC_TEST|Hemolysis|Authors measured free plasma hemoglobin concentration in gram
41299600|NCT05406297|PROCEDURE|pressure-temperature sensor guidewire-based measurement|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire was first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
41299601|NCT03977727|DRUG|Fiasp®|Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
41299602|NCT03977727|DRUG|Novolog®|Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
41299603|NCT03977727|DEVICE|670G hybrid closed loop continuous subcutaneous insulin infusion system|CSII
41299604|NCT00647842|DRUG|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
41299605|NCT00647842|DRUG|Fentanyl Transdermal System 25 mcg/h|single application
41299606|NCT04975607|BEHAVIORAL|Music Therapy|The three live music therapy sessions will be provided after lung transplant. All three music therapy sessions will employ a variety of data-based interventions to address pain, anxiety, and improve relaxation. Music therapy interventions may include patient preferred live music, active music listening, singing or other active music-making, and guided breathing and relaxation.
41299607|NCT02607969|OTHER|Home program|Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
41299608|NCT06290830|BEHAVIORAL|Abdominal massage group|abdominal massage creates reflex and mechanical movement of the intestines by applying pressure to the rectum and changing intra-abdominal pressure.
41299609|NCT06290830|BEHAVIORAL|Kegel Exercises group|Kegel exercises (also called pelvic floor exercises) have a functional connection with other core muscles and contribute to the synergistic effect of the abdominal and pelvic floor muscles
40770949|NCT04656912|PROCEDURE|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min. Moreover, if necessary, patients were treated with HBO2, even after 24 h, until all symptoms resolved.
40770950|NCT02331303|OTHER|Radium-223 dichloride (Xofigo, BAY88-8223)|Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
41299610|NCT06290830|BEHAVIORAL|Both abdominal massage and kegel exercises to gether|with both exercises are performed to accelerate the peristalsis movement by mechanical movements
41299611|NCT04341597|OTHER|cervical ultrasound|All volunteer patients for whom a cervical ultrasound is indicated will have with a first operator the performing the usual technic, and with a second operator performing the trans perineal technic without being aware of the first measurement.
41299612|NCT03601338|DRUG|Bemiparin|second generation low molecular weight Heparin
41299613|NCT03601338|OTHER|multivitamins and routine antenatal follow up|multivitamins and routine antenatal follow up
40770951|NCT00236041|DRUG|ACTIQ®|
40770952|NCT05020808|DIETARY_SUPPLEMENT|NEAA|Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
40770953|NCT05020808|DIETARY_SUPPLEMENT|PPI|Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
40770954|NCT05847166|RADIATION|[99mTc]Tc-PSMA-T4|\[99mTc\]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The \[99mTc\]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product \[99mTc\]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.
41299614|NCT05029544|OTHER|Dynamic taping|The intervention of this experimental study was therapeutic taping (dynamic tape) on the symptomatic shoulders of the participants.
40770955|NCT06399224|DEVICE|Local Plantar vibrator|A vibrating device that applies 80 hz vibration waves applied on the sole of the foot
40770956|NCT06399224|OTHER|Otago exercise|Warm up Front Knee strength Back knee strength Side hip strength Calf raising Toe raising Sit to stand Heel walk Toe walk One leg standing Side way walk Cool down
41299615|NCT05029544|OTHER|Kinesio taping|The intervention of this experimental study was therapeutic taping (kinesio tape) on the symptomatic shoulders of the participants.
41299616|NCT05029544|OTHER|Physiotherapy and Rehabilitation|exercise, manuel therapy, mobilization, massage, sensorimotor control
40974917|NCT02768012|BEHAVIORAL|mindfulness-based cognitive therapy|Six two-hour small group sessions (6-9 participants) will be administered over 8 weeks focusing on MBCT. The intervention follows a written protocol to ensure fidelity of delivery. Participants will receive detailed manuals summarizing session content and home assignments (HAs), including mindfulness practices, audio versions of which will be available on an internet link.
40974918|NCT03024450|DRUG|H+CT|All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
40974919|NCT05062798|PROCEDURE|Standart bottle|"1. After the surgery, standard bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
40974920|NCT05062798|PROCEDURE|Squeezable bottle|"1. After the surgery, squeezable bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
41299617|NCT02060617|BEHAVIORAL|Patient Education|All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.
41299618|NCT02060617|PROCEDURE|Manual therapy of the thoracolumbosacral spine and hips|Thrust and/or non-thrust manipulation and soft tissue mobilization as determined by mobility impairments identified on clinical examination.
41299619|NCT02060617|PROCEDURE|Motor control exercises|Motor control exercises as determined by motor control impairments identified on clinical examination.
40974921|NCT00303277|DRUG|simvastatin|simvastatin 40 mg tablets once per day for 12 weeks
40974922|NCT00303277|DRUG|pravastatin|pravastatin 80 mg tablets once per day for 12 weeks
40974923|NCT01382953|DEVICE|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
40974924|NCT06286904|DEVICE|Skiin Garment system|Individuals will be asked to wear a Skiin Garment system for the duration of their hospitalization (minimum one day).The system will collect accelerometer, ECG, temperature, heart rate, steps and sleep metrics data if enable. Then, they will be asked to answer a questionnaire about their experiences with the device and the study.
40974925|NCT00192205|BIOLOGICAL|CAIV-T or TIV|
40974926|NCT02384889|DRUG|Difluoromethylornithine|Active Therapy with DFMO
40974927|NCT02384889|DRUG|Placebo|Placebo Comparitor
41140272|NCT01303471|DRUG|opioid (remifentanyl)|Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
41140273|NCT03770897|PROCEDURE|3D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 3D laparoscopic procedure
41140274|NCT03770897|PROCEDURE|2D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 2D laparoscopic procedure
41140275|NCT06318377|DIETARY_SUPPLEMENT|Peanut group|These are commercially available peanuts that are high in antioxidants and are believed to be beneficial for physiological health
41140276|NCT03837093|DRUG|ILT101|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
41140277|NCT03837093|DRUG|Placebo|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
41140278|NCT05190172|RADIATION|Radiation therapy|Radiation therapy either with protons or photons
41140279|NCT00458185|DRUG|etanercept|
41140280|NCT02602691|OTHER|AlloMap®|
41140281|NCT02602691|PROCEDURE|Endomyocardial biopsies|
41140282|NCT01960972|OTHER|Salt substitute|A salt substitute using 25% of potassium chloride and 75% of sodium chloride will be implemented in each of the villages.
40770961|NCT02748798|DRUG|HP 3He|3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
40770962|NCT02748798|DRUG|HP 129Xe|129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
40770963|NCT02748798|DRUG|PFP|Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
40770964|NCT02748798|DRUG|SF6|Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
40770965|NCT02748798|DEVICE|129Xe Small and Large Human Lung Coil|The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
40770966|NCT02748798|DEVICE|3He Human Lung Coil|The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
40770967|NCT02748798|DEVICE|PFP and SF6 Human Lung Coil|The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
41140283|NCT06415825|BEHAVIORAL|Standard advice and Preliminary muscle contraction|The maneuver groups will receive standard advice and an additional one - preliminary contraction of the muscles in the corresponding kinesiology segment. This advice will be embedded in all motor activities of daily living involving the relevant area.
41140284|NCT06415825|BEHAVIORAL|Standard advice|Standard advice includes avoiding heavy physical activity, sudden and unexpected loads, repetitive and prolonged overloads, and long periods of hypomobility.
41140285|NCT03020433|DEVICE|rTMS Contralesional M1|1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT
40770968|NCT02485184|PROCEDURE|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
40770969|NCT02485184|DRUG|Non-selective beta blockers|Non-selective beta blockers are the drugs for reducing the portal pressure.
40770970|NCT02485184|PROCEDURE|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation
40770971|NCT02485184|DRUG|Anticoagulation|Anticoagulation therapy includes heparin and warfarin.
40974928|NCT01233440|BIOLOGICAL|Recombinant Coagulation Factor IX Albumin Fusion Protein|Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion
40974929|NCT01233440|BIOLOGICAL|Plasma derived FIX [pdFIX]|Single dose of 50 IU/kg of reference product, given as intravenous infusion
40974930|NCT00157534|DRUG|Celgosivir|
40974931|NCT03555591|DRUG|Trelagliptin|Trelagliptin tablets
40974932|NCT00948987|DRUG|Aspirin|325 mg enteric coated single dose p.o.
40974933|NCT02231723|DRUG|BBI608|Administered continuously twice daily with doses separated by 12 hours
40974934|NCT02231723|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
40974935|NCT02231723|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
40974936|NCT02231723|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
40974937|NCT02231723|DRUG|Leucovorin|Arm C, D: Leucovorin 400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
40770972|NCT00561379|DRUG|CHOP+RITUXIMAB|CHOP-14- Rituximab x 8 courses
41299620|NCT02060617|PROCEDURE|Treatment-Based Classification intervention|Lumbopelvic manipulation and range of motion exercise, spinal stabilization exercises, direction specific exercises, and/or traction will be applied as determined by the Treatment-Based Classification (TBC) Algorithm.
41299621|NCT05320458|OTHER|Pulmonary Rehabilitation|1-Pulmonary Rehabilitation: Pulmonary rehabilitation program was applied at 40-60% of submaximal heart rate, 3 days a week for a total of 8 weeks. Diaphragmatic breathing, pursed lip breathing and segmental breathing exercises were practiced with the patients in the company of a physiotherapist. Walking and aerobic exercise training was given.
40974938|NCT02231723|DRUG|Irinotecan|Arm B: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
40974939|NCT02231723|DRUG|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
40974940|NCT02231723|DRUG|MM-398|MM-398 70 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
40974941|NCT02127879|DEVICE|Transcranial Magnetic Stimulation|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
40974942|NCT02127879|DEVICE|Transcranial Magnetic Stimulation with sham coil|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
40974943|NCT01735682|DEVICE|Whole body vibration|The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
40974944|NCT01735682|BEHAVIORAL|Conventional exercise|The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
40974945|NCT01735682|BEHAVIORAL|Control|The control treatment involves exercises of the upper limbs.
40974946|NCT03552315|DIETARY_SUPPLEMENT|Carbonated water with amino acids and chromium|The active carbonated water containing amino acids and chromium picolinate is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
40974947|NCT03552315|DIETARY_SUPPLEMENT|Placebo Carbonated Water|The placebo carbonated water is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
40974948|NCT06506734|OTHER|Questionnaires|"*  Psychosocial Impact of Dental Aesthetics Questionnaire  PMID 24280547~*  Orofacial Esthetic Scale  PMID 30856637~*  Orofacial Esthetic Scale  PMID 34231057~* A photograph of the patient's smile will be sent to 2 dentists who will also assess the presence or absence of dental dyschromia."
41299622|NCT04471103|OTHER|Participation in a Delphi survey|Participants will be asked to participate in an online Delphi survey (using one of two randomly allocated methods) to rate the importance of outcomes that should be measured to determine the effect of treatment for neonatal encephalopathy. Outcomes will be prioritised on their importance in a consensus-driven manner.
41299623|NCT04207567|BEHAVIORAL|Bodyweight exercises (push-ups, angled-rows, bodyweight squats) on weekdays|Participants will be instructed to perform one set each of push-ups, angled-rows, and bodyweight squats every weekday. They will be given the equipment and training necessary to properly perform the exercises. They will also be trained in the Tiny Habits® Method and receive digital coaching.
40974949|NCT00602953|OTHER|No intervention planned.|This is a cross-sectional observational study, no intervention is planned.
40770973|NCT00561379|DRUG|CEEP-RITUXIMAB|High dose chemotherapy with rituximab including autologous stem cell support.
40974950|NCT04287244|DEVICE|Transcutaneous Spinal Direct Current Stimulation|tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
40974951|NCT00022139|DRUG|carboplatin|
41299624|NCT00369668|BEHAVIORAL|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
41299625|NCT00369668|BEHAVIORAL|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
41299626|NCT00369668|BEHAVIORAL|Bilateral movements and sham electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
41299627|NCT04503486|DIAGNOSTIC_TEST|handgrip strength|measure of handgrip strength using Jamar Dynamometer and a standardized protocol, strength expressed in kg
41299628|NCT04503486|DIAGNOSTIC_TEST|quadriceps strength|maximal isometric quadriceps strength measured using a handheld dynamometer and a standardized protocol, strength expressed in Newton
41299629|NCT01651182|DRUG|No tranexamic acid|Control
41299630|NCT01651182|DRUG|Tranexamic Acid|
41299631|NCT05676489|DRUG|[F-18]MeFAMP PET|Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
41299632|NCT05984381|DRUG|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) orally
41299633|NCT05984381|DRUG|Dapsone|Dapsone 100 mg/day
41299634|NCT05984381|DRUG|Methotrexate|Methotrexate 15 mg weekly
41299635|NCT03736837|DRUG|Anlotinib Plus Icotinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
41299636|NCT01300468|DRUG|PHA-848125AC|
41299637|NCT03175744|DEVICE|Stellarex DCB|Intervention with the Stellarex DCB
41299638|NCT03175744|DEVICE|PTA Catheter|Intervention with an uncoated Standard PTA
41299639|NCT01383200|DRUG|Tetracaine drop|0.5% Tetracaine Right eye / 2% Lidocaine Left eye
41299640|NCT01383200|DRUG|Lidocaine gel|0.5% Tetracaine Left eye / 2% Lidocaine Right eye
41299641|NCT02621268|DRUG|Indocyanine Green|Infusion of ICG 24 hours prior to surgery
41299642|NCT06285474|DEVICE|Low Intensity Focused Ultrasound Pulsation (LIFUP)|All participants will undergo 3 identical LIFUP sessions. All sessions must occur at least 1 day apart, and no more than 3 days apart, such that sessions may occur at minimum on days 1, 3, 5 and at maximum may occur on days 1, 5, 9.
41299643|NCT02734602|DRUG|Ketamine|Ketamine will be administered after the initial PET scan for subjects participating in the ketamine aim.
41299644|NCT03718494|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|Performed on a single 3T system and sequences will be acquired in a single sitting with an exam time under 45 minutes.
41299645|NCT03718494|DIAGNOSTIC_TEST|F-18 Florbetapir Positron Emission Tomography (PET) Imaging|After a 50-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless. Injection of 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq) given. A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 20-minute PET acquisition consisting of four 5-minute dynamic frames.
41299646|NCT03718494|DIAGNOSTIC_TEST|F-18 AV-1451 Positron Emission Tomography (PET) Imaging|Intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451 (approved under IND 124449). PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 50-60 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame. Serial frames will allow for adjustment in the case of patient motion.
41299647|NCT03718494|OTHER|Neuropsychological Testing|A comprehensive battery of standardized neuropsychological tests administered by trained personnel.
40974952|NCT00022139|DRUG|fluorouracil|
40974953|NCT00022139|DRUG|paclitaxel|
40974954|NCT00022139|PROCEDURE|conventional surgery|
40974955|NCT00022139|RADIATION|radiation therapy|
41299648|NCT04371172|OTHER|cognitive research battery, MRI, laboratory values|cognitive research battery, MRI, laboratory values
41299649|NCT00039273|BIOLOGICAL|panitumumab|
40770974|NCT05696119|BEHAVIORAL|I-PROTECT|I-PROTECT is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes end-user-targeted information and injury prevention physical and psychological training, specifically tailored for youth handball. The intervention is delivered through a mobile application (I-PROTECT GO) specifically developed for the I-PROTECT project, including coach, player, club administrator, and caregiver modules. Tailored support to implement I-PROTECT is specifically developed for Swedish community youth handball.
40770975|NCT05696119|BEHAVIORAL|Control|"Coaches of youth teams in the control group clubs will be offered currently available injury prevention training (i.e., Redo för Handboll, English: Ready for Handball), accessible online through the Swedish Handball Federation's coach education material."
40770976|NCT05016271|BEHAVIORAL|Air purifier and fresh air ventilation systems with high-efficiency particulate air (HEPA) filters|This group will receive an intervention of true air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems with HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers with HEPA filters) operate during the home time in the intervention period (4 months anticipated).
41299650|NCT06090253|BEHAVIORAL|Gerotechnology enhanced multi-component exercise|Intervention courses will be divided into 3 categories: Musculoskeletal training course, Neuromuscular and fall prevention training course, and cardiometabolic training course. The courses will be enabled by wearable technology, digital platform and visual display. Each of the courses will be 8 weeks in length (1 session per week), and 60 minutes per session.
41299651|NCT06090253|BEHAVIORAL|Home-based exercise|The proposed elderly home gym training services will be conducted by professional fitness instructors and tailor-made for the participants. 4 personal training sessions will be assigned (once per week, 45 to 60 minutes per session).
41299652|NCT06090253|BEHAVIORAL|Walking exercise|Two interventions will be provided: A) Walk-focused intervention, B) Disease-related walk intervention for participants with chronic diseases.
41299653|NCT06090253|BEHAVIORAL|Slow sports and exercise|Participants will receive 10 training sessions (once or twice per week, 2 hours per session) conducted by professional fitness instructors. The training programs can be selected according to the participants' preference, including water exercises, stretching/fitness/gymnastics, slow walking/jogging, sports massage, Tai Chi, Yoga, etc.
41299654|NCT06090253|BEHAVIORAL|Football|The Football Training Programme will be arranged (10 training sessions+1 game day per stage, 4 stages per season). held on artificial turf football pitch or indoor sport facilities in 5 regions
41299655|NCT05085548|DRUG|ProAgio Dose Levels (DL) 1,2,3|ProAgio is administered to study participants by intravenous injections once every 14 days.
41299656|NCT05085548|DRUG|ProAgio Dose Levels (DL) 4,5,6|ProAgio is administered to study participants by intravenous injections once every 7 days.
41299657|NCT05085548|DRUG|ProAgio Dose Levels 4a,5a,6a|ProAgio is administered to study participants by intravenous injections once every 7 days with a drug holiday after every 5 administrations. Optional co-administration of gemcitabine (Gem) during dose expansion beginning with Cycle 2.
41299658|NCT01792622|OTHER|Interview|Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
41299659|NCT01792622|OTHER|Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
41299660|NCT03218293|DEVICE|RIPC device (IPC-906X)|Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.
41299661|NCT04717843|OTHER|4D Flow MRI|Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.
41299662|NCT04717843|OTHER|Medical consultation with 12 leads ECG|Collection of medical history, treatment, physical examination and realization of a 12 leads ECG.
41299663|NCT04717843|OTHER|Holter ECG|48 hours ECG recording
41299664|NCT04717843|OTHER|Trans thoracic echocardiography|Trans thoracic echocardiography with standard measures performes in the core lab.
41299665|NCT04717843|BIOLOGICAL|Blood sample|Blood sample in a peripheral vein, send to medical laboratory to dosage of NT pro BNP and troponin serum level.
41299666|NCT04717843|OTHER|Standard MRI|Acquisitions of MR imagining
41299667|NCT04439630|DIETARY_SUPPLEMENT|Nopal fractions|Nopal flour were divided in two fractions and mixed in two different test breads
41299668|NCT04439630|DIETARY_SUPPLEMENT|Test product without the active components|Test product without the active components
41299669|NCT00705224|BIOLOGICAL|Pegylated Interferon|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous~injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
41299670|NCT00705224|DRUG|Ribavirin|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
40770977|NCT05016271|BEHAVIORAL|Air purifier and fresh air ventilation systems without high-efficiency particulate air (HEPA) filters|This group will receive an intervention of sham air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems without HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers without HEPA filters) operate during the home time in the intervention period (4 months anticipated).
41140286|NCT03020433|DEVICE|rTMS Contralesional PMC|5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
41299671|NCT06511713|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
41299672|NCT00177541|BEHAVIORAL|Biofeedback, pelvic floor muscle training, fMRI|Biofeedback, pelvic floor muscle training, fMRI
41299673|NCT00245193|BEHAVIORAL|Motivationally-Enhanced Interpersonal Psychotherapy|
41299674|NCT06346028|DEVICE|Brainsway H4 deep rTMS coil and Brainsway stimulator system|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a PowerPoint presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member from the NDC."
41299675|NCT03686254|COMBINATION_PRODUCT|RFA, bevacizumab and second-line chemotherapy|Navigated by CT-ultrasound merged images, RFA is taken in the experimental arm at the first day of the first cycle during the second-line therapy. Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
41299676|NCT03686254|DRUG|Bevacizumab and second-line chemotherapy|Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
41299677|NCT02638805|DRUG|ITCA 650 Osmotic Mini Pump 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
41299678|NCT02638805|DRUG|ITCA 650 Osmotic Mini Pump 60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
41299679|NCT02638805|DRUG|Metformin|Stable dose for at least 3 months (at least 1000 mg/day)
41299680|NCT02638805|DRUG|Liraglutide|Stable dose for at least 3 months (at least 1.2 mg/day)
41299681|NCT05952219|DRUG|CKD-379|2 tablet administration under fed condition
41299682|NCT05952219|DRUG|D759+D745+D029+D150|4 tablet co-administration under fed condition
41299683|NCT00005655|BIOLOGICAL|rh IL-12|rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
41299684|NCT00005655|BIOLOGICAL|rh IL-2|rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
40770978|NCT05024162|DIAGNOSTIC_TEST|MRT Accuracy|Predicted Grade Group (GG) by the MRI-based Radiomics Tool (MRT) at each Magnetic Resonance Imaging of the Prostate (MRI-P)
41140287|NCT03020433|DEVICE|rTMS Ipsilesional PMC|5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
40770979|NCT05024162|DIAGNOSTIC_TEST|MRT Stability|MRT's predicted GG at second MRI-P.
40770980|NCT06211907|DEVICE|Postoperative intraocular tamponade|Flushing the eye cavity with a tamponade at the end of surgery
40770981|NCT05588843|DRUG|SAR443122|oral capsule
40770982|NCT05588843|DRUG|Placebo|oral capsule
40770983|NCT06132789|BIOLOGICAL|Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried|This vaccine（1.0ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive the Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried vaccinated by intramuscular injection.
40770984|NCT01928056|DRUG|Torrent's Montelukast Sodium Tablets 10 mg|
41140288|NCT03020433|DEVICE|rTMS sham at Ipsilesional M1|1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
41140289|NCT05606185|PROCEDURE|retraction method|Three dimensional evaluation of root resorption using cone beam computed tomography
41140290|NCT05391867|DRUG|Lenvatinib|Tyrosine kinase inhibitor
41140291|NCT00996242|DRUG|L-lysine|6 g/day for four weeks
41299685|NCT05015400|OTHER|Plain Water|To increase water fluid intake, an additional 1.89 L, during phase 1 of the menstrual cycle (days 1-5).
41299686|NCT04893330|DIETARY_SUPPLEMENT|pepticate syneo|follow up of pepticate syneo for one month
41299687|NCT05990764|DIETARY_SUPPLEMENT|Probiotic, Prebiotic, Polyphenol-rich Extracts|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry extract~Once a day"
41299688|NCT05990764|DIETARY_SUPPLEMENT|Probiotic, Prebiotic|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum)~Once a day"
41299689|NCT05990764|OTHER|Placebo|"placebo~Once a day"
41299690|NCT02140918|DRUG|Fludrocortisone 100 μg|Fludrocortisone 100 μg/day
41299691|NCT02140918|DRUG|Fludrocortisone 200 μg|Fludrocortisone 200 μg/day
41299692|NCT02140918|DRUG|Fludrocortisone 400 μg|Fludrocortisone 400 μg/day
41299693|NCT02140918|DRUG|Placebo|
41299694|NCT01990599|OTHER|Nasopharyngeal Tube|
41299695|NCT05110898|DRUG|fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg|Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.
41299696|NCT05110898|DRUG|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.
40770985|NCT01716000|OTHER|vaginal gel imaging|Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
40974956|NCT05496387|OTHER|Sciatic nerve neuromobilization techniques|Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.
41299697|NCT00591227|DRUG|insulin aspart|"insulin aspart: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
41299698|NCT00591227|DRUG|insulin detemir|"insulin detemir: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
41299699|NCT05387395|OTHER|NO intervention|no intervention
41299700|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 25 mg tablet
41299701|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 50 mg tablet
41299702|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 100 mg tablet
41299703|NCT01803763|DRUG|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
41299704|NCT01803763|DRUG|Placebo|Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
41299705|NCT02178618|DEVICE|Deployment of Partially covered biliary self expandable metal stent|
41299706|NCT02178618|DEVICE|Deployment of uncovered biliary self expandable metal stent|
40770986|NCT01716000|BEHAVIORAL|computer aided self interview|Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
41299707|NCT03666260|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block with echography
41299708|NCT03666260|PROCEDURE|femoral block|femoral block with echography
41299709|NCT02535949|DRUG|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
41299710|NCT02535949|OTHER|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
41459211|NCT03599921|BEHAVIORAL|Family-based treatment|"Family-based treatment, or FBT, is the leading evidenced based therapy for children and adolescents with an eating disorder.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore the patient's weight, then hand control of eating back to the patient as is age appropriate. Toward the end of treatment, it is concerned with developmental issues that may have been impacted by the illness."
40770987|NCT05745844|OTHER|activity sessions|77 activity sessions ; muscle strengthening, testing or unloading
40770988|NCT04175015|OTHER|Smartie© sweet/candy|one chocolate sweet/ chocolate candy
40770989|NCT05108428|DRUG|Capecitabine|Capecitabine 825 mg/m\^2 twice daily orally 5 days per week on days of planned radiation therapy.
40770990|NCT05108428|RADIATION|Radiation Therapy|Participants will receive varying doses of radiotherapy based on MRI guidance, beginning at 28-33 fractions (1.8 Gray units) .
40770991|NCT05108428|DRUG|FOLFOX regimen|Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m\^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m\^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus\* (optional) 400 mg/m\^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours day 1 each cycle.
40974957|NCT03764189|PROCEDURE|microosteoperforation|small holes made using large round bur
40974958|NCT00040664|DRUG|ritonavir|ritonavir oral capsules or oral solution
40770992|NCT06343623|PROCEDURE|myomucosal resection and direct closure|myomucosal resection and direct closure
40770993|NCT06343623|PROCEDURE|superiorly based flap|superiorly based pharyngeal flap
40770994|NCT05935085|DRUG|ANB032|BTLA agonist antibody
40770995|NCT05935085|DRUG|Placebo|Placebo
40770996|NCT03477812|DEVICE|Polysomnography (Full sleep registration)|For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.
40770997|NCT02330003|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
40770998|NCT02330003|BIOLOGICAL|Fluarix Prefilled Syringe|Fluarix Prefilled Syringe 0.5mL
40770999|NCT05472870|DEVICE|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
40771000|NCT04110132|PROCEDURE|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative."
40771001|NCT04110132|PROCEDURE|Ganglion impar block with normal saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
40771002|NCT00748774|BEHAVIORAL|Questionnaire|Two questionnaires taking about 10 minutes to complete.
40771003|NCT03058952|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
40771004|NCT03058952|BEHAVIORAL|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
40771005|NCT06564753|DRUG|Drug: Placebo daily and orally|• Placebo comparator
40771006|NCT06564753|DRUG|NA-931, dose 1, daily and orally|"Drug: NA-931 dose 1, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
40771007|NCT06564753|DRUG|NA-931, dose2, daily and orally|"Drug: NA-931 dose 2, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
40771008|NCT06564753|DRUG|NA-931 dose 3, daily and orally|"Drug: NA-931 dose 3, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
40771009|NCT06564753|DRUG|NA-931 dose 4, daily and orally|"Drug: NA-931 dose 4, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
40771010|NCT04205786|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12, orally, 2500 mcg, daily, for 90 days
41140292|NCT04454112|DEVICE|24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).|24-hour esophageal pH monitoring application
40771011|NCT04205786|OTHER|Blood collection|"Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~1. Serum B12 levels~2. CRP~3. Homocysteine level~4. MMA"
40974959|NCT00040664|DRUG|fosamprenavir|fosamprenavir oral suspension or tablet
41140293|NCT02868983|OTHER|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
41140294|NCT01711788|PROCEDURE|Intrabone infusion of umbilical cord blood stem cells|
41140295|NCT05488990|DRUG|AKVANO-Calcipotriol formulation 1|Novel lipid based formulation (AKVANO) type 1 containing Calcipotriol (50 μg/g)
41140296|NCT05488990|DRUG|AKVANO-Calcipotriol formulation 2|Novel lipid based formulation (AKVANO) type 2 containing Calcipotriol (50 μg/g)
41140297|NCT05488990|DRUG|AKVANO vehicle formulation 1|Novel lipid based formulation (AKVANO) vehicle 1
41140298|NCT05488990|DRUG|AKVANO vehicle formulation 2|Novel lipid based formulation (AKVANO) vehicle 2
41140299|NCT05488990|DRUG|Daivonex solution|Daivonex solution containing Calcipotriol (50 μg/g)
41140300|NCT05488990|DRUG|Daivonex cream|Daivonex cream containing Calcipotriol (50 μg/g)
41140301|NCT03210298|COMBINATION_PRODUCT|PIPAC|A chemotherapeutic solution is aerosolized into the expanded abdominal cavity during laparoscopy, under pressure. This allows a relatively homogeneous repartition of the drug and an effective tissue penetration.
41140302|NCT01074034|DEVICE|AV Therapy Assessment-B301 investigational device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
41140303|NCT02260973|DIETARY_SUPPLEMENT|Omega-3 (Triglyceride form)|
41140304|NCT03070548|DRUG|Talazoparib|1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
40771012|NCT04205786|OTHER|Brief Pain Inventory - Short Form survey|Brief Pain Inventory - Short Form survey
40771013|NCT04205786|OTHER|FACT-ES Trial Outcome Index (Version 4)|FACT-ES Trial Outcome Index (Version 4)
40771014|NCT04205786|OTHER|Questionnaire to Assess Adherence to Aromatase Inhibitors|Questionnaire to Assess Adherence to Aromatase Inhibitors
40771015|NCT04205786|OTHER|Demographics Questionnaire|Demographics Questionnaire
40771016|NCT03194347|DIAGNOSTIC_TEST|molecular genetic analyses|molecular genetic analyses
40771017|NCT00415636|DRUG|IC83/LY2603618|40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2.
40771018|NCT00415636|DRUG|IC83/LY2603618|70 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
40974960|NCT00650624|DRUG|valdecoxib|valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
40974961|NCT00650624|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
40771019|NCT00415636|DRUG|IC83/LY2603618|105 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
40771020|NCT00415636|DRUG|IC83/LY2603618|150 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
40771021|NCT00415636|DRUG|IC83/LY2603618|195 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
40771022|NCT00415636|DRUG|pemetrexed|pemetrexed 500 mg/m\^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
40771023|NCT00415636|DRUG|pemetrexed|pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
40974962|NCT00650624|DRUG|valdecoxib|valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
40974963|NCT00650624|DRUG|placebo|placebo tablet by mouth once daily in the morning for 6 weeks
40974964|NCT01402544|DRUG|ranibizumab|0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
41140305|NCT06504719|DRUG|Antibody-Drug Conjugates|Patients with advanced breast cancer treated with ADCs
41140306|NCT05008003|DRUG|Standard of care|Standard of care treatment as per the hospital guidelines
41299711|NCT01495897|DEVICE|Tracking eye movement|Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
40974965|NCT04579731|DRUG|Lactitol Monohydrate|Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
40974966|NCT02899988|DRUG|Mirikizumab|Administered SC
40974967|NCT02899988|DRUG|Placebo|Administered SC
41140307|NCT05008003|DIETARY_SUPPLEMENT|Vitamin D3|A daily dose of 5000 IU vitamin D3 for 7 days.
41299712|NCT01495897|DEVICE|Tracking eye movement under deep brain stimulation|Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
41299713|NCT03950102|RADIATION|SBRT|Radiation dose of 27.5-50Gy in 5 fractions over 5-14 days with a radical dose as high as achievable based on mean liver dose (MLD), while fulfilling the dose constraints of OARs
41299714|NCT02236546|DIAGNOSTIC_TEST|[18F]fluorodeoxyglucose|FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
40771024|NCT02339051|BEHAVIORAL|Jumping on one leg|
40771025|NCT05705167|DRUG|Plitidepsin|IV infusion over 60-minutes
40771026|NCT02475356|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|The treatment of Mirena should comply with the local product information.
40974968|NCT03746873|BEHAVIORAL|COPD Web|"The COPD Web will be introduced to the participant randomized to intervention by a letter containing a code to get access to the web site and how to create an account and login. At the web site there will be an instruction movie showing/ discussing specific content on the COPD Web. The web site will be self-managed. To secure that there is no technical or user problems participants will be contacted by a researcher the first week of intervention.~Participants will receive push notifications (email) with targeted information containing links to the COPD Web and reminder to register the number of steps walked during that week. The push notifications will come every week (week 1-12), every other week (week 12 to 24) and every fourth week (week 24-52)."
40974969|NCT01880385|BIOLOGICAL|Bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
40771027|NCT00027599|BIOLOGICAL|bevacizumab|
40771028|NCT00027599|BIOLOGICAL|prostatic acid phosphatase-sargramostim fusion protein|
40771029|NCT00027599|BIOLOGICAL|sipuleucel-T|
40771030|NCT00027599|BIOLOGICAL|therapeutic autologous dendritic cells|
40771031|NCT00027599|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
40974970|NCT01880385|DRUG|Cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
40974971|NCT01880385|DRUG|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
40771032|NCT02979990|OTHER|Instructional Video|The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
40771033|NCT02979990|OTHER|Control Video|The control group will have access to a video about the IVF process
40771034|NCT02686775|BEHAVIORAL|Patient coach|
40771035|NCT02686775|BEHAVIORAL|Standard care|
40974972|NCT01880385|DRUG|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
40974973|NCT01880385|DRUG|Docetaxel|Adjuvant: 100 mg/m2 q3w, 4 cycles
40974974|NCT01880385|BIOLOGICAL|Trastuzumab|Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
41140308|NCT03686345|DRUG|Midostaurin|Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
41140309|NCT02627794|DEVICE|Restora™ Steroid eluting spacer|The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
40974975|NCT01631578|PROCEDURE|Injection of an autologous mitochondria to the oocyte.|In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
40974976|NCT01050972|BEHAVIORAL|Behavioral: Cognitive, Relaxation, Exercise Therapy|Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
40974977|NCT03130361|DEVICE|Non-Invasive Ventilation|
40974978|NCT06401395|DEVICE|DIGIPARK MONITOR|remote monitoring application (containing a questionnaire to assess the patient's symptoms, adapted from the clinical examination using the MDS-UPDRS scale). This questionnaire will be completed weekly for 12 months via the DIGIPARK MONITOR application by the patient or caregiver.
40974979|NCT04940351|PROCEDURE|GROUP - A: PIEZOCISION GROUP|This group will receive piezocisions after placement of initial arch wire, in between the roots of mandibular anteriors (in a vertical line) i.e., between mandibular canine and lateral incisors bilaterally, lateral incisors and central incisors bilaterally and between two cental incisors with the help of piezotome. These piezocisions will be performed on the labial cortical bone only, 4mm below the interdental papilla under 2% lidocaine with 1:100,000 epinephrine and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle. A piezosurgical microsaw with piezosurgical drill will be placed over that incision with irrigation. Then, vertical 5- to 8-mm and 3mm deep corticotomies will be perform using periapical radiographs as a guide to avoid penetrating into the adjacent roots. No subsequent sutures required.
40974980|NCT04940351|PROCEDURE|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive MOPs after initial arch wire placement. These MOPs will be performed under local anesthesia with standard asepsis, using a self drilling 1.6mm x 8mm orthodontic mini-implants and mini-implant screw driver and no flap will be raised. MOP's will be placed on five sites i.e., interproximally between mandibular canine and lateral incisors bilaterally, central incisor and lateral incisor bilaterally and between two central incisors. Each site will receive two MOP's, first 2mm apical to alveolar crest and second 2mm below the first in a vertical line and 2mm deep into the bone. Then the mini-implant will be removed by rotating the screw driver anticlockwise and pressure will be applied to achieve hemostasis.
40974981|NCT00310791|DRUG|Hormone replacement therapy (estrogen/progestin)|Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
40974982|NCT00310791|OTHER|Placebo (Sugar Pill)|Placebo (sugar pill)
40974983|NCT00310791|DRUG|Dehydroepiandrosterone (DHEA)|50 mg tablet, 1 daily
40974984|NCT06026761|DEVICE|Skiin garment and pods|"Participants will be asked to wear two pieces of equipment to record physiological data:~1. A Skiin garment that contains IMU and ECG sensors~2. A Cosmed K5 metabolic cart that will record breathing rate data~Participants will then be asked to perform various tasks of daily living (e.g. watching TV, sweeping the floor), general strength exercises (e.g. squats, triceps dips, lunges), and aerobic exercises (e.g. walking, running) as instructed by researchers"
40974985|NCT01135199|DRUG|pomalidomide (CC-4047|
40974986|NCT00590720|BIOLOGICAL|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
41459212|NCT03599921|BEHAVIORAL|Enhanced Cognitive behavioral therapy|"Enhanced Cognitive behavioral therapy, or CBT-E, is a leading evidence based treatment for adolescents and adults with an eating disorder.~The treatment is a one-to-one talking type of treatment that primarily focuses on what is keeping the eating problem going. It is therefore mainly concerned with the present and the future. It addresses the origins of the problem as needed."
41459213|NCT03599921|BEHAVIORAL|Family-based treatment modified for ARFID|"Family-based treatment modified for individuals with an ARFID diagnosis is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore patient's weight and variety in eating, as needed."
40974987|NCT00590720|OTHER|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
40974988|NCT04380168|PROCEDURE|Modified pec11 trunk block|Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles
40974989|NCT01057342|DRUG|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
40974990|NCT01057342|DRUG|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
40974991|NCT01057342|DRUG|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
40974992|NCT03580655|DRUG|Avapritinib|Avapritinib tablet
40974993|NCT04229017|PROCEDURE|Anterior Cervical Discectomy and Fusion|Anterior Cervical Decompression and Fusion (ACDF) is a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate.
40974994|NCT04229017|DEVICE|Posterior Cervical Stabilization System (PCSS)|Posterior Cervical Stabilization System (PCSS) is non-segmental instrumentation with integrated screw fixation intended to provide immobilization and stabilization of spinal segments. PCSS achieves bilateral facet fixation by spanning the interspace at each level with points of fixation at each end of the construct.
40974995|NCT01888679|PROCEDURE|Head movement|Head movement in extension, flexion, right and left rotation
40974996|NCT04090450|RADIATION|chemo-radiotherapy|The study will not have a direct intervention. It will recruit patients who have had chemo-radiation as part of their standard of care treatment for rectal cancer.
40974997|NCT05205044|DIAGNOSTIC_TEST|Apelin-13, Apelin-36|Serum levels of Apelin-13 and Apelin-36
40974998|NCT03364023|DEVICE|Neurothrombectomy|Medtronic Market-Released Neurothrombectomy Device
40974999|NCT02234960|DRUG|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
40975000|NCT05916495|OTHER|Hybrid care arm|Patients will be evaluated at 3 months via a remote review. This will review the patients-recorded spirometry and a questionnaire developed for this study which asses the patients' symptom burden and medication adherence. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
40975001|NCT05916495|OTHER|Standard of care arm|Patients will be reviewed in clinic at 3 months per the standard of care. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
41140310|NCT02627794|DEVICE|Silastic Silicone Spacer|The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
41299715|NCT02236546|OTHER|Molecular assays on biopsied tissue|Correlative studies
41299716|NCT02236546|DEVICE|positron emission tomography|Undergo FDG-PET/CT
41299717|NCT02236546|DEVICE|computed tomography|CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
41299718|NCT01433627|OTHER|trans-radial and short-term bivalirudin|trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
41299719|NCT01433627|OTHER|trans-radial and long-term bivalirudin infusion|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
41299720|NCT01433627|OTHER|trans-radial and standard of care pharmacology|Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
41299721|NCT01433627|OTHER|Trans-femoral and Short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
41299722|NCT01433627|OTHER|trans-femoral and long-term bivalirudin infusion|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
41459214|NCT03599921|BEHAVIORAL|FBT + UP for ARFID|"Family-based treatment combined with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and begins with focus on psychoeducation, family engagement, and weight gain as needed. The Unified Protocol is then added to build skills that empower the patient to cope with difficult emotions, address avoidance, and increase tolerance of emotions or disgust responses."
41459215|NCT02798406|BIOLOGICAL|DNX-2401|On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
40975002|NCT01294657|BEHAVIORAL|Health Education|Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.
41140311|NCT02369328|DEVICE|MULTIMODAL MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
41140312|NCT04917315|DRUG|JLP-2002 A mg|administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
41140313|NCT04917315|DRUG|Placebo|administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
41140314|NCT00161122|BIOLOGICAL|trivalent inactivated influenza vaccine|
40975003|NCT01294657|BEHAVIORAL|MAPS|12 counseling phone calls over 1 year, lasting about 20-30 minutes.
40975004|NCT01471236|DEVICE|Agili-C Bi-phasic Implant|"The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).~The implant will be inserted gently in a pressed fit manner."
41140315|NCT00161122|BIOLOGICAL|combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine|
41140316|NCT05017909|BEHAVIORAL|Face to face education|Face to face education techniques on the acquisition of the mothering Role
41140317|NCT05017909|BEHAVIORAL|Web based education|web based education techniques on the acquisition of the mothering Role
41140318|NCT05017909|BEHAVIORAL|No education|Control group will not be educated
41140319|NCT01403285|DRUG|Cyclophosphamide|One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
41140320|NCT01403285|BIOLOGICAL|IMA950 plus GM-CSF|Six vaccinations with IMA950 plus GM-CSF as adjuvant on 8 pre-defined days from Day 1 to Day 78
41140321|NCT01403285|BIOLOGICAL|IMA950|After Day 78, vaccinations with IMA950 (no GM-CSF) will be given on a monthly basis for up to one year from start of vaccination or until disease progression
41140322|NCT01403285|DRUG|Imiquimod|Imiquimod will be topically applied 10-20 minutes after each vaccination. After the third vaccination onward patients will apply additional imiquimod 24 hours after each vaccination at home on their own
41459216|NCT02798406|BIOLOGICAL|pembrolizumab|Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
40771036|NCT05549102|BEHAVIORAL|Cognitive Behavioural Therapy|In the Cognitive Behavioural Therapy group (N=87), patients will undergo CBT as part of their routine care in Step 3 of the IAPT programme. This will be administered by suitably trained clinicians. The specification of CBT is as recommended by the National Institute for Health and Care Excellence (NICE) guidelines (CG113 - Generalised anxiety disorder and panic disorder in adults: management). In these guidelines, patients are offered on average, 12-15 hourly, weekly sessions of CBT with a trained and competent practitioners. Therapy sessions involve discussions that identify patterns in thinking or behaviours which may be problematic, and therapists and patients work to set goals to reduce these using cognitive techniques. The principle is to teach the patient how to use CBT techniques in their day-to-day life to promote a lasting effect on mental health. We will test patients before (T1) and after (T2) a course of treatment.
40771037|NCT05549102|OTHER|Waiting List|In the control group (N=87), we will test patients who are currently seeking (but not undergoing) treatment before (T1) and after a wait (T2) of equivalent time (i.e. waiting list controls)
40771038|NCT02014467|DRUG|Denosumab|Injection
40771039|NCT02014467|DRUG|Placebo|Injection
40771040|NCT02014467|DIETARY_SUPPLEMENT|Elemental Calcium|Oral, at least 600 mg
40771041|NCT02014467|DIETARY_SUPPLEMENT|Vitamin D|Oral, at least 400 IU
41140323|NCT05917158|DRUG|RC48-ADC and JS001|Patients in group will receive 6 x 2 week cycles of JS001 (Toripalimab) 3mg/kg in combination with RC48-ADC (Disitamab Vedotin) 2mg/kg intravenously.
41140324|NCT02502136|PROCEDURE|carbon dioxide insufflation during endoscopy|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
41140325|NCT02502136|PROCEDURE|Room air insufflation during endoscopy (Placebo)|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
41140326|NCT01584999|BIOLOGICAL|Blood transfusion|RBCs have been transfused in septic patient admitted in ICU
41140327|NCT00212459|BEHAVIORAL|Counseling|Patients are contacted every two weeks after initial counseling to discuss the completion of bleeding records.
41140328|NCT00212459|BEHAVIORAL|Control|No more contacts are made with control patients after the initial counseling session.
41140329|NCT00837044|DRUG|Treximet|Treximet
41140330|NCT00837044|DRUG|Migraine rescue medication of choice|Migraine rescue medication of choice
41140331|NCT00053118|BIOLOGICAL|filgrastim|IV
41140332|NCT00053118|DRUG|carboplatin|IV
41140333|NCT00053118|DRUG|etoposide|IV
41140334|NCT00053118|PROCEDURE|bone marrow ablation with stem cell support|IV
41140335|NCT00053118|PROCEDURE|peripheral blood stem cell transplantation|IV
41140336|NCT01186809|BIOLOGICAL|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
41140337|NCT01586416|BEHAVIORAL|Behavioral Intervention|Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
41140338|NCT03683641|DEVICE|Extracorporeal Shock Wave Therapy|Use ESWT on chronic insertional Achilles tendinopathy
41140339|NCT03683641|DEVICE|Sham Control group|Use sham ESWT on chronic insertional Achilles tendinopathy
41140340|NCT06100900|DRUG|BCX10013|Four dose levels may be tested in this study.
41140341|NCT02226237|PROCEDURE|group of pelvic floor exercises|contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
41140342|NCT02226237|PROCEDURE|anal electrostimulation group|The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
41140343|NCT01648114|OTHER|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
41140344|NCT01779245|DIETARY_SUPPLEMENT|Calcium|Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
41140345|NCT01779245|DIETARY_SUPPLEMENT|Placebo|
41140346|NCT01772199|DRUG|GSK239512|White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
41140347|NCT01772199|DRUG|Placebo|White to almost white, round tablets. Once daily orally.
41459217|NCT03329209|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
41140348|NCT03674788|DEVICE|Transcatheter valve intervention|
41459218|NCT01058122|PROCEDURE|Collection of adverse drug events|
41459219|NCT02090231|DEVICE|rTMS, Magstim Rapid2|5 Hz rTMS
41459220|NCT02463019|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate
41299723|NCT01433627|OTHER|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
41299724|NCT06472895|DRUG|AK112 monotherapy|A novel PD-1/VEGF bispecific antibody; RP2D intravenously (IV)，Q3W
41299725|NCT05170893|DIETARY_SUPPLEMENT|Coenzyme Q10|Oral capsules
41299726|NCT05170893|OTHER|Placebo|Oral capsules
41299727|NCT01873742|OTHER|STIC feedback system|This condition includes the use of the STIC feedback system.
41299728|NCT04875819|DRUG|Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine|One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.
41299729|NCT04875819|DRUG|13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine|One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
41459221|NCT03757520|DIAGNOSTIC_TEST|Pain Pressure Threshold|The pain pressure thresholds (PPTs) will be measured using an pressure algometer commander over potential trigger points (TrPs) on the body for upper fiber of trapezius, and sternocleidomastoid muscle.
40771042|NCT05215145|BEHAVIORAL|Baby Navigator Bundle|The Baby Navigator Bundle includes 1) Baby Navigator, an online collection of resources: videos, growth charts, milestones, short articles, checklists, tools, and tips to help families promote early learning. Tools are customized to the child's age (in months). Baby Navigator can be found at https://babynavigator.com. 2) Social Communication (SoCo) Growth Charts is a self-guided app for parents of babies from birth to 24 months. Parents can watch video clips of early milestones and chart their child's social communication development. 3) Baby Navigator Webinars are held twice a month. Parents can learn how to support their child's growth from birth to 24 months. Content and videos focus on social communication milestones. Expert-led sessions cover a range of topics: gestures and sounds babies need to learn to talk, everyday activities that encourage learning, getting ahead of the Terrible Twos, and how Baby Navigator can help families.
40771043|NCT05215145|BEHAVIORAL|Baby Navigator Bundle + Individual-ESI|Continued Baby Navigator Bundle. Addition of ESI mobile coaching. ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that session's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are also invited to and guided through the Autism Navigator How-To Guide for Families online course.
40771044|NCT05974176|BEHAVIORAL|Trauma Focused CBT (TF-CBT)|TF-CBT is an evidence-based treatment for children and adolescents impacted by trauma and their parents or caregivers. It is a components-based treatment model that incorporates trauma-sensitive interventions with cognitive behavioral, family, and humanistic principles and techniques.
41299730|NCT04922125|COMBINATION_PRODUCT|Pulse flour|Traditionally processed pulse flour in vitro digestion conditions were related to potentially influence appetite sensations.
41299731|NCT04922125|COMBINATION_PRODUCT|Pre-processed pulse flour|Pre-processing of pulse flour was related to altered in vitro digestion conditions and thus suggested to potentially influence appetite sensations.
41299732|NCT01094964|BIOLOGICAL|BCG solution|
41299733|NCT01094964|BIOLOGICAL|recombinant interferon alfa|
41299734|NCT01094964|DRUG|epirubicin hydrochloride|
41299735|NCT01094964|DRUG|mitomycin C|
41299736|NCT01094964|OTHER|laboratory biomarker analysis|
41299737|NCT01094964|PROCEDURE|hyperthermia treatment|
41299738|NCT01094964|PROCEDURE|quality-of-life assessment|
41299739|NCT04987983|OTHER|Experimental SLP-R|SLP-R will be given to the infant during bottle-feeding.
41299740|NCT04987983|OTHER|Experimental SLP-L|SLP-L will be given to the infant during bottle-feeding.
41459222|NCT03757520|DIAGNOSTIC_TEST|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation The test will be performed twice, and the higher value between the two measurements will be selected."
40771045|NCT05974176|BEHAVIORAL|Trauma Systems therapy (TST)|Trauma Systems Therapy (TST) is focused on the factors that contribute to children and adolescents who experience traumatic stress through the lens of the social context, vulnerabilities, and strengths of the person undergoing treatment.
40771046|NCT00522379|DRUG|Rotigotine|2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
40771047|NCT00522379|DRUG|Rotigotine|4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
40771048|NCT00522379|OTHER|Placebo|Placebo transdermal patch applied daily
40771049|NCT00522379|DRUG|Rotigotine|6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
40771050|NCT00522379|DRUG|Rotigotine|8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
40771051|NCT03960177|DRUG|Glucarpidase|Given IV
41140349|NCT04970732|PROCEDURE|Gum chewing|The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
41140350|NCT04240197|DEVICE|CompuFlo|The occurrence of epidural pulse waves with CompuFlo and with standard pressure trnsducer
41140351|NCT02936544|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code:Z09-054)
41140352|NCT01019135|BEHAVIORAL|Cardiac Rehabilitation|comparison of multiple cardiac rehabilitation program models
41140353|NCT02378376|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|
41140354|NCT02378376|DIETARY_SUPPLEMENT|Dietary fiber enriched bran|
41140355|NCT06179485|DRUG|Ketamine|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
41299741|NCT01165801|PROCEDURE|Cataract Surgery|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
41459223|NCT05361408|DRUG|Zoledronic acid, once|Intravenous infusion of 5mg zoledronic acid, once
40771052|NCT03960177|OTHER|Quality-of-Life Assessment|Ancillary studies
40771053|NCT03773419|BEHAVIORAL|Texting Intervention (T-WRITE)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using a cellular phone
40771054|NCT03773419|BEHAVIORAL|HandWriting Intervention (ORLA+WTG)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using pen and paper
40771055|NCT03910075|BEHAVIORAL|I-ACQUIRE - High Dosage|Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
40771056|NCT03910075|BEHAVIORAL|I-ACQUIRE - Moderate Dosage|Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
41459224|NCT05361408|DRUG|Zoledronic acid, twice|Intravenous infusion of 5mg zoledronic acid for 6month interval, twice
41140356|NCT06179485|DRUG|Etomidate|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
41140357|NCT03180476|DRUG|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
41140358|NCT01633359|DRUG|Intensive statin|the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
41140359|NCT01633359|DRUG|Routine statin|the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
40771057|NCT03910075|BEHAVIORAL|Usual & Customary Treatment (U&CT)|Children in this group will receive the same U\&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
40771058|NCT03416894|DEVICE|Deep Brain Stimulation|DBS offers the opportunity to insert electrodes into deep brain structures and electrically stimulate them in a titratable and ultimately reversible manner
41140360|NCT01078051|PROCEDURE|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
40771059|NCT03225404|OTHER|Epte group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
40771060|NCT03225404|OTHER|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
40771061|NCT05814159|DRUG|Anakinra|sub cutaneous daily injection
40771062|NCT05814159|DRUG|Placebo|sub cutaneous daily injection
41140361|NCT01078051|DRUG|optimal medical therapy|optimal medical therapy
41140362|NCT02064283|PROCEDURE|Diffusion MRI|
40771063|NCT04089696|DEVICE|ExSprion|The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
40771064|NCT01323374|DRUG|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
40771065|NCT01323374|DRUG|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
40771066|NCT01323374|DRUG|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
40771067|NCT01323374|DRUG|Placebo|Oral, placebo TID
40771068|NCT00718432|BEHAVIORAL|Exercise and nutritional integrated care|Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.
40975005|NCT01471236|PROCEDURE|mini-arthrotomy|"The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator's final decision. Related treatments during the procedure should be recorded.~Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded."
40975006|NCT03146715|OTHER|Feeding trial|Children were asked to eat the designated portion of the assigned food once a day for six weeks.
40975007|NCT01082120|DRUG|AZD1656|Tablets orally, twice daily for 10 days
41140363|NCT03332316|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone injection
41140364|NCT03332316|DRUG|Ropivacaine Hydrochloride Inj 2 mg/ml|Ropivacaine injection
41140365|NCT03332316|DRUG|Sodium Chloride 9mg/mL|Sodium Chloride injection
41140366|NCT03660527|OTHER|Not refered|No intervention was refered.
41140367|NCT04867044|OTHER|STUDY|One Hundred Fifty woman patients diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
41140368|NCT04867044|OTHER|Control|healthy woman volunteers
41140369|NCT02584426|DEVICE|Ultrasonic Distribution of Cefazolin|
41140370|NCT00244556|DRUG|Methotrexate plus ENBREL or ENBREL alone|
41459225|NCT01304979|PROCEDURE|Acupuncture therapies|Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.
41459226|NCT01304979|PROCEDURE|Control|Indirect therapies that mimic direct therapy intervention
41140371|NCT03911297|OTHER|Women with polycystic ovary syndrome|Prospective cohort study in women with polycystic ovary syndrome to identify the risk of developing metabolic disease
41140372|NCT04794439|DRUG|Dentifrices|Dentifrice on plaque
41140373|NCT03804866|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
41140374|NCT03804866|DRUG|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
41140375|NCT03804866|DRUG|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
41140376|NCT01504984|DRUG|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
41140377|NCT01504984|DRUG|Glivec film coated tab 4T(400mg)|Imatinib 100mg/tablet, PO, 4 tablets once daily for period I\&II D1(crossover)
41140378|NCT00448344|BEHAVIORAL|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
40975008|NCT01082120|DRUG|Pioglitazone|Tablet oral single dose for 10 days
40975009|NCT01224067|DRUG|Quetiapine|Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.
40975010|NCT02916108|OTHER|Reading EEG|EEG recording for 5 minutes (not an intervention)
40975011|NCT03284827|DRUG|NOAC|edoxaban (60 mg once daily \[OD\]) for at least 6 months
40975012|NCT03284827|DRUG|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
40975013|NCT04675645|OTHER|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
40975014|NCT05145452|DIETARY_SUPPLEMENT|Fish-oil derived n-3 polyunsaturated fatty acids|4.2 g/d (7 pills with 600 mg each)
40975015|NCT01514929|DRUG|ACHN-490 Injection|20mg/kg IV 30 minute infusion given once
40975016|NCT01514929|DRUG|ACHN-490 Injection|15mg/kg IV 30 minute infusion given once
41299742|NCT03486535|DRUG|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Diabetic patients.
41299743|NCT03486535|DRUG|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Nondiabetic patients.
41299744|NCT05032443|OTHER|Awareness survey|The 33-item questionnaire will sent to pediatric endoscopy nurses in our country. Questionnaires will be delivered to nurses through hospital visits or electronic media.
41299745|NCT03881917|DIAGNOSTIC_TEST|Cystatin c and beta 2 microglobulin kits|Kits for measurement concentration
41299746|NCT03883048|OTHER|Observation of bronchiectasis with pulmonary hypertension|
41299747|NCT00368134|DRUG|Vildagliptin|
41299748|NCT03285880|BEHAVIORAL|Napping|Children nap during the nap opportunity
41299749|NCT02551133|DRUG|dexamethasone|1 hour before surgery
41299750|NCT03083158|DRUG|Hepatitis B vaccine|1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
40975017|NCT01514929|DRUG|Moxifloxacin|400mg oral pill given once
40975018|NCT01514929|DRUG|Placebo|Placebo oral pill given once
40975019|NCT04756791|PROCEDURE|SAPB|local anesthetic is injected between the serratus anterior and latissimus dorsi muscles.
40975020|NCT04756791|PROCEDURE|Local Injection Anesthesia|Anesthesia is injected directly into the tissue that is will be numbing.
40975021|NCT05792891|OTHER|Collecting biological material from frail patients, with or without COVID-19|The study planned to collect demographic information, disease history, COVID-19 symptomatology, COVID-19 molecular test details, COVID-19 serological test results, and biobanking of biological specimens (PBMCs, sera, plasma). In addition, clinical analyses, anamnestic data, and pharmacological treatment pieces of information were collected.
40975022|NCT00002416|DRUG|Emtricitabine|
40975023|NCT00002416|DRUG|Lamivudine|
40975024|NCT03780855|DEVICE|nerve scaffold|It is a new kind of nerve scaffold with the microstructure of longitudinally oriented microchannels. It's made of collagen as the main raw material.
40975025|NCT00604539|DRUG|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
41299751|NCT04070378|DRUG|Daratumumab Injection|Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion
41299752|NCT04458038|OTHER|driving simulator|For this study a driving simulator is being used which is an internationally approved method. Besides the driving simulator following tests are done: COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), a clock drawing test and a continuous reaction time test (CRT). A CardioRespiratory Monitor (CRM), NOX T3TM, is used to measure if the patients have moderate to severe OSA. Furthermore, following tests are done: Epworth Sleepiness Scale (ESS).
40975026|NCT00604539|DRUG|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
40975027|NCT00360789|BEHAVIORAL|Conventional UK physical therapy|
40975028|NCT00360789|BEHAVIORAL|Increased intensity of UK conventional physical therapy (PT)|
40975029|NCT00360789|BEHAVIORAL|UK conventional PT plus functional strength training|
40975030|NCT06249191|PROCEDURE|Biopsy|Undergo tumor biopsy
40975031|NCT06249191|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40975032|NCT06249191|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
40975033|NCT06249191|PROCEDURE|Computed Tomography|Undergo CT scan
40975034|NCT06249191|DRUG|Cyclophosphamide|Given IV
40975035|NCT06249191|DRUG|Doxorubicin|Given IV
40975036|NCT06249191|PROCEDURE|Echocardiography|Undergo echocardiography
40975037|NCT06249191|DRUG|Etoposide|Given IV
40975038|NCT06249191|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40975039|NCT06249191|BIOLOGICAL|Mosunetuzumab|Given IV
40975040|NCT06249191|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40975041|NCT06249191|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40975042|NCT06249191|DRUG|Prednisone|Given PO
40975043|NCT06249191|DRUG|Vincristine|Given IV
41299753|NCT03574896|OTHER|Computer model predictions of acute kidney injury|Comparison of the performances of AKIpredictor and physicians in predicting AKI stage 2 or 3 in the 7 days following ICU admission
41299754|NCT06042699|DIETARY_SUPPLEMENT|Oral ferrous sulfate|Oral ferrous sulfate 325mg is used as a dietary supplement providing 65mg elemental iron.
41299755|NCT06042699|DIETARY_SUPPLEMENT|Oral placebo tablet|Oral placebo tablet provided as placebo comparator.
41299756|NCT00918528|PROCEDURE|Internal urethrotomy|
41299757|NCT00918528|DRUG|Mitomycin C - local injection|
41299758|NCT03312140|DRUG|Choline Chloride|
41299759|NCT02512263|PROCEDURE|Home-based training program|A home-based training program of 8 exercises to do 5 times a week during 9 weeks
41299760|NCT06034704|OTHER|Plantar fascia self massage with a magnetic fascia ball|Participants were asked to roll the magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
41299761|NCT06034704|OTHER|Plantar fascia self massage with a non-magnetic fascia ball|Participants were asked to roll the non-magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
41299762|NCT04713917|DEVICE|Hyaluronique Acid Gel|Vaginal gel based on HA with liposomal structure applicated 2 times a week
41299763|NCT04713917|DEVICE|Laser CO2|The laser energy delivered along the vaginal wall heats the tissue without damaging it.
40771069|NCT00718432|BEHAVIORAL|Usual care with education|The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.
40771070|NCT00718432|BEHAVIORAL|Problem solving therapy (PST) integrated care|Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
40771071|NCT04785638|COMBINATION_PRODUCT|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
40771072|NCT06283212|DRUG|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A)
40771073|NCT00296712|DRUG|escitalopram + bupropion|same dosing as for monotherapy arms
40975044|NCT02573298|DEVICE|ice|local ice application for 30 minutes
40771074|NCT06565091|DEVICE|Measurements of physiological parameters of the anterior chamber|Acquisition by the investigational device
40771075|NCT06565091|DEVICE|Measurements of the Axial biometry|Acquisition by the investigational device
40771076|NCT05329831|BEHAVIORAL|Structured training using telehealth|The intervention is based on self-care activities. Self-care states that people have an innate ability to take care of themselves.
40975045|NCT02573298|DEVICE|cold gas|local cold gas application for 2 minutes
40771078|NCT03772119|PROCEDURE|Surgical resection|Surgical resection of hemivertebra
40975046|NCT01784640|DRUG|Hsp90 inhibitor AUY922|Given IV
40975047|NCT01784640|DRUG|pemetrexed disodium|Given IV
40975048|NCT01784640|OTHER|pharmacological study|Correlative studies
40975049|NCT01784640|OTHER|laboratory biomarker analysis|Correlative studies
40975050|NCT00368355|DRUG|Ara-C|"day-8 through day-5~3 g/m2 q 12 hours"
41299764|NCT04713917|DEVICE|Hyaluronique Acid Injection|HA injection performed under the mucosae (2-3mm in depth) following one injection point every 5mm on the 3 first cm of the vagina and on the posterior part of the introitus.
41299765|NCT04611126|DRUG|Ipilimumab|Ipilimumab 3 mg/kg is administered 2-6 weeks before surgical removement of the tumor. The medicine is administered i.v. over 30 minutes.
41299766|NCT04611126|DRUG|Cyclophosphamid|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
41299767|NCT04611126|DRUG|Fludarabine Phosphate|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
41299768|NCT04611126|BIOLOGICAL|Tumor Infiltrating Lymphocytes infusion|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
41299769|NCT04611126|DRUG|Nivolumab|Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.
41299770|NCT04611126|DRUG|Relatlimab|Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
41299771|NCT06113354|DEVICE|Transcatheter mitral valve repair (MRace Implant and Delivery System)|"The MRace Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture~Other Names:~TMVr"
41299772|NCT04076722|BEHAVIORAL|Stress reactivity stimuli|An evaluated speech task delivered to participants after baseline testing.
41459227|NCT03099590|DIETARY_SUPPLEMENT|kudzu extract, puerarin|Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
41459228|NCT03099590|DIETARY_SUPPLEMENT|Placebo control|Matched sugar beet placebo capsules will serve as placebo.
40975051|NCT00368355|DRUG|Cyclophosphamide|"day-7 and day-6~45 mg/kg"
40975052|NCT00368355|BIOLOGICAL|Campath-1H|"day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~\>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS"
40975053|NCT00368355|RADIATION|Total Body Irradiation|"day-4 through day-1~175 cGy x 2 at 24 cGy/min"
40975054|NCT00368355|PROCEDURE|Stem Cell Infusion|Stem cells are infused on day 0
40975055|NCT05512611|DIAGNOSTIC_TEST|Finger photoplethysmography|Finger photoplethysmography in tested hand, noninvasive blood pressure and heart rate during blood donation.
40771079|NCT06040398|BEHAVIORAL|JUMPSTART exercise program|The intervention is an early mobilization protocol (JUMPSTART). Four interactive exercise videos, at different intensity levels, include a variety of stretches and exercises designed to improve the full body mobilization of post-TAVR patients. Videos have been developed in consultation with a physiotherapist and cardiac rehabilitation specialist and have been piloted for initial acceptability by patients at the Hamilton General Hospital. The videos will be freely accessible to all eligible patients and their caregivers (regardless of participation in the research study) online (www.hhscebi.ca/projects/jumpstart). A written version of the exercise program, with photographs and detailed instructions, will also be made available. Additional exercise videos will be developed based on patients' needs and feedback received.
40771080|NCT04237584|DRUG|Enzalutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in ARB (enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
40771081|NCT04237584|DRUG|Lead-in Enzalutamide followed by Radium-223/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
40771082|NCT04237584|DRUG|Lead-in Enzalutamide followed by Placebo/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
40771083|NCT04237584|DRUG|Darolutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in darolutamide that will continue after double-blind randomization to radium-223 or placebo.
40771084|NCT04237584|DRUG|Lead-in Darolutamide followed by Radium-223/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
40771085|NCT04237584|DRUG|Lead-in Darolutamide followed by Placebo/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
40771086|NCT06570304|PROCEDURE|iCount Device|"Designed as single use. Intended purpose - To be used to count swabs and tampons after surgery in an objective manner. This is intended to be used in patients during and just after surgery.~This is a device accessory."
40771087|NCT02399228|DRUG|0.25% EISO mouth rinse|A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
40771088|NCT06112275|DRUG|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A).
40771089|NCT05378802|OTHER|different modes of mechanical ventilation|Four different ventilation modes were performed one by one and respiratory parameters were recorded.
40771090|NCT00386581|DRUG|atomoxetine|
40771091|NCT00386581|DRUG|placebo|
40771092|NCT02085863|DRUG|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
40771093|NCT02085863|DRUG|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
40771094|NCT02756585|RADIATION|ct perfusion|computed tomography perfusion of the head
40771095|NCT04518228|DRUG|Bictegravir (BIC)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
40771096|NCT04518228|DRUG|Tenofovir alafenamide (TAF)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
40771097|NCT04518228|DRUG|Cabotegravir (CAB)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
40975056|NCT02883153|DRUG|Zirconium-89 girentuximab PET/CT|Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
40771098|NCT04518228|DRUG|Dolutegravir (DTG)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
40771099|NCT04518228|DRUG|Atazanavir/ritonavir (ATV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
40771100|NCT04518228|DRUG|Darunavir/ritonavir (DRV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
40771101|NCT04518228|DRUG|Lopinavir/ritonavir (LPV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
40771102|NCT04518228|DRUG|Cobicistat|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
40771103|NCT04518228|DRUG|Ritonavir|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
40771104|NCT04518228|DRUG|First-Line TB Treatment|"Participants will be receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), or moxifloxacin (MFX).~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
40771105|NCT04518228|DRUG|Second-Line TB Treatment|"Participants will be receiving second-line TB treatment with at least one of the following second-line TB treatment drugs:~* Levofloxacin (LFX) 750mg - 1000mg q.d.~* Clofazimine (CFZ) 100mg q.d.~* Linezolid (LZD) 300mg - 600mg q.d.~* Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~* Delamanid (DLM) 100mg b.i.d.~* Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
40771106|NCT04518228|DRUG|Doravirine (DOR)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
40975057|NCT04851249|PROCEDURE|Hallux Valgus - chevron osteotomy, lapidus procedure|The purpose is to compare the preoperative clinical features (previous medical history, age, BMI, occupational status etc), PROMs (Manchester-Oxford Foot and ankle questionnaire, SF-36, VAS activity scale) and radiological parameters (both two and three dimensional) with the postoperative PROMs (+ likert scale) and the postoperative radiological parameters.
40975058|NCT04575922|DRUG|Nivolumab|Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.
40771107|NCT06216288|OTHER|Repeated back extension exercise (McKenzie)|repetitive back extension exercises in prone position with 1 minute hold on maximal back extension. 3 sets of 10 repetitions with 1 minute break between sets. The intervention was done 3 times per week for 6 weeks.
40975059|NCT04575922|DRUG|Ipilimumab|Administered into vein by intravenous infusion day 1 of each 6 week study cycle.
40975060|NCT04575922|RADIATION|Radiation Therapy|3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.
40975061|NCT04736888|OTHER|extended-reality CPR training|extended-reality technologies based CPR training module
40975062|NCT04736888|OTHER|conventional CPR training|conventional CPR training with video
40975063|NCT02339272|OTHER|non interventional|
40975064|NCT01092559|DRUG|Nitric Oxide generated by the GeNO nitrosyl delivery system|single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
40975065|NCT02584335|DRUG|"Lidocaine solution (A)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
41140379|NCT00448344|BEHAVIORAL|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
41140380|NCT01596985|PROCEDURE|Ablation using the PlasmaJet system|Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
41140381|NCT01596985|PROCEDURE|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
41140382|NCT03531242|BIOLOGICAL|0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1|"administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (\< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
41140383|NCT06390345|OTHER|FOCuSEd Integrated Intervention|"Participants randomized to the intervention will receive an integrated telehealth-delivered, remote lifestyle intervention that promotes healthy eating and 150 minutes per week of moderate-intensity physical exercise. This intervention will include a core curriculum during the first 3 months that includes: 1) a 12-session video based program; 2) goal setting and self-monitoring using a Fitbit tracker and MyFitnessPal; 3) lifestyle coaching; and 4) three tele-pulmonary rehab sessions and an additional 60-75 minutes of gradually increasing self-directed exercise per week. At the end of 3 months, we will offer to enter a recommendation for weight loss medications to intervention participants with a BMI of ≥ 27 kg/m2. In the post-core period (months 4-12), participants will continue to have as-needed access to the lifestyle coach."
41140384|NCT06390345|OTHER|Enhanced Usual Care|"Participants in the enhanced usual care group will be referred to MOVE! (VA's weight loss management program) and pulmonary rehabilitation in coordination with their primary care provider."
41140385|NCT06509295|OTHER|Calcium Hypochlorite as Root Canal Irrigant|Calcium Hypochlorite used as root canal irrigant during chemo-mechanical preparation
41140386|NCT01474356|OTHER|hyperthermia|45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
41140387|NCT06100406|OTHER|Biofield tuning|Biofield Tuning is a non-invasive, non-medical therapeutic practice in which a resonating tuning fork is used to identify and re-balance off-the-body sites at which perturbations in the tuning fork sound are detected.
41140388|NCT05735379|DRUG|Deprescribing anticholinergic and sedative mediications|Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
41140389|NCT01383785|OTHER|Intracoronary direct injection|"Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory."
41140390|NCT01383785|OTHER|Intracoronary and distal injection by aspiration device|"Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C."
41140391|NCT01383785|OTHER|Intracoronary distal injection by aspiration catheter device|"Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter."
41140392|NCT05645445|DEVICE|virtual reality|patients who include intervention gruop during the ESWL process, patients will be shown videos with virtual reality glasses, which include nature and landscapes, giving people a feeling of comfort and peace, and making them feel like they are inside.
41140393|NCT01031056|PROCEDURE|Blood Draw|
41140394|NCT01031056|PROCEDURE|Frozen Tumor Specimens|
41140395|NCT00964171|DRUG|efavirenz|
41459229|NCT01430286|BEHAVIORAL|psycho-social intervention based on a web-based psycho-educational program, called Diapason.|This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
41459230|NCT01430286|BEHAVIORAL|Consultation in memory clinic|This group will receive treatment as usual (consultation in memory clinic every 6 months)
41459231|NCT06226259|DIETARY_SUPPLEMENT|GABA supplement|Oral administration of GABA supplement once daily before sleep for 14 days.
41459232|NCT06226259|DIETARY_SUPPLEMENT|placebo|Oral administration of placebo once daily before sleep for 14 days.
41459233|NCT04882254|PROCEDURE|Normothermic machine perfusion|Additional 2h of normothermic machine perfusion of the donor kidney with a red cell based perfusate.
41459234|NCT04031560|BEHAVIORAL|Integrative treatment|The experimental group (62 patients) will take part on the integrative group program consisting of 12-sessions, 90 minutes each, once a week (4 focused on psychoeducation, 1 directed to the family relatives, 3 on mindfulness and 4 on functional remediation)
40771108|NCT06216288|DEVICE|Mechanical traction|The traction was applied using a 3D ActiveTrac table. This motorized split table applied static traction to the lumbar spine with the participant in a prone position. The intensity of the force of traction was 40% to 60% of the participant's body weight applied for 15 minutes. The intervention was done 3 times per week for 6 weeks.
40975066|NCT02584335|DRUG|"Saline solution (B)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
40975067|NCT03608592|BIOLOGICAL|umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.
40975068|NCT03608592|BIOLOGICAL|normal saline|A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
40975069|NCT00290888|PROCEDURE|Acromioplasty|
40975070|NCT02292602|BEHAVIORAL|Family-Based Weight Control|Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
40975071|NCT01408004|DRUG|Pazopanib|Tablet 800mg qd til progression
40975072|NCT01408004|DRUG|Everolimus|tablet 10 mg qd til progression
40975073|NCT01408004|DRUG|Pazopanib|tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
40975074|NCT01408004|DRUG|Everolimus|tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
41140396|NCT00964171|PROCEDURE|quality-of-life assessment|
41140397|NCT00442559|DRUG|montelukast sodium|Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
41140398|NCT00442559|DRUG|inhaled corticosteroid|Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
41140399|NCT03204773|DIAGNOSTIC_TEST|EuroQol five dimensions questionaire (EQ-5D)|Testing quality of life.
41459235|NCT02392689|OTHER|Procalcitonin|Procalcitonin guided antibiotic therapy
41459236|NCT04273386|OTHER|Evaluation|The study will be carried out with the method of filling the evaluation form which is printed on paper with ballpoint pen.
40975075|NCT01408004|DRUG|Everolimus|Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
40975076|NCT01408004|DRUG|Pazopanib|Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
41140400|NCT03204773|DIAGNOSTIC_TEST|Modified Fatigue Impact Scale (MFI)|Screening for fatigue
41140401|NCT03204773|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI)|Testing for pain
41140402|NCT03204773|DIAGNOSTIC_TEST|Becks Depression Inventory (BDI)|Screening for depression
41140403|NCT03204773|DIAGNOSTIC_TEST|Restless-leg Questionaire (RLS diagnostic criteria)|Testing for restless-legs
41140404|NCT04926259|DRUG|18F-T807|Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.
41140405|NCT04269044|DIAGNOSTIC_TEST|non-contact EKG|ultra-sensitive, non-contact EKG pad will be placed beneath the infant
41140406|NCT03147586|DRUG|Bio-tech and omega-3 plus|immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
41140407|NCT03147586|DRUG|placebo|placebo
41140408|NCT00082667|DRUG|gefitinib|
41140409|NCT00082667|PROCEDURE|Surgery|
40975077|NCT06063772|DRUG|Clevidipine|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90 seconds to a maximum rate 32 mg/hr for clevidipine or the volume equivalent of placebo.
40975078|NCT06063772|DRUG|Lactated Ringers, Intravenous|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90s to a maximum rate 32mg/hr for clevidipine or the volume equivalent of placebo.
40975079|NCT05260788|PROCEDURE|Cystoscopy|Standard of care cystoscopy procedure
41299773|NCT06203548|BEHAVIORAL|Lifestyle modification programme|All patients will attend sessions weekly in the first 2 months and monthly in the remaining 4 months. The programme focuses on reducing caloric intake and increasing energy expenditure. At the first visit, the dietitian will perform a complete behavioural assessment including the patient's eating and lifestyle patterns, specific eating-related behaviours, knowledge, concerns and feelings. A target body weight will be set. During follow-up visits, the dietitian will review the patient's dietary pattern and provide recommendations. Each patient will be given an individualised meal plan. The dietary component and portion size are based on recommendations by the American Dietetic. The patients will be taught techniques to cope with at-risk situations such as parties and festival celebrations. In addition, the patients will be encouraged to have a combination of aerobic exercise and resistance training with intensity and frequency following the Physical Activity Guidelines.
41299774|NCT02929563|DRUG|Pantoprazole|
41299775|NCT02929563|DRUG|Placebo (for pantoprazole)|
41299776|NCT01205191|BEHAVIORAL|Cell-phone supported CBT|Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications
41299777|NCT01205191|BEHAVIORAL|CBT with digital audio player support|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.
41299778|NCT01205191|BEHAVIORAL|CBT|CBT for anxiety disorders
41299779|NCT02937103|BIOLOGICAL|Anti-CD123-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
41299780|NCT03441191|DEVICE|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study
41299781|NCT03568149|PROCEDURE|assessment of pain symptoms at first medical examination|First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.
41299782|NCT03568149|PROCEDURE|assessment of pelvic vascular insufficiency signs|"Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~* Ovarian vein diameter \<4mm~* Slow ovarian blood flow (\<3cm/sec)~* Retrograde blood flow~* Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~* Standard 2D study, to measure vessels diameter~* Vascular doppler study, to evaluate flow direction and blood speed~* 3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree."
41459237|NCT04540068|DRUG|Transforaminal Epidural Injection|Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
41459238|NCT01749085|DRUG|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
41459239|NCT01749085|DRUG|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
40975080|NCT02630498|PROCEDURE|Brachial plexus block|Patients receiving brachial plexus block for hand/arm surgery
41459240|NCT01496118|DRUG|panobinostat|Specified dose on specified days
41459241|NCT01496118|DRUG|carfilzomib|Specified dose on specified days
41459242|NCT02650973|DRUG|CHS-1701|
40771109|NCT00517790|DRUG|ABT-869 .25 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
40975081|NCT06034236|OTHER|Resistance training|"Task oriented resistance training will be performed, there will be 10 workstations:~1. Sitting at a table and reaching in different directions for objects located beyond arm's length.~2. Sit to stand from various chair heights~3. Stepping forward, backward and sideways onto blocks of various heights.~4. Heel lifts in standing~5. Standing with narrow base of support, feet in parallel and tandem stance and reaching for objects, including down to the floor.~6. Reciprocal leg flexion and extension.~7. Sit ups~8. Standing up from chair, walking a short distance and returning to the chair.~9. Walking races between participants~10. Walking over various surfaces and obstacles"
41140410|NCT02871245|PROCEDURE|Laparoscopic Surgery|
41140411|NCT02871245|DEVICE|Acupuncture treatment|
41140412|NCT02296307|OTHER|Blood test: CA-125 biomarker|"* CA-125 biomarker blood test at visit 1, day 1.~* CA-125 biomarker blood test at visit 2, week 6."
41140413|NCT02296307|OTHER|Second Test: Transvaginal Ultrasound|-Transvaginal Ultrasound at visit 1, day 1.
40771110|NCT00517790|DRUG|ABT-869 0.10 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
40771111|NCT02871440|DRUG|Omega 3|
40975082|NCT06034236|OTHER|Otago Exercises|"It has total 17 exercises, out of which 12 exercises are performed to improve balance and 5 are performed to improve strength.~1. First component of intervention starts with head movements followed by neck movements, back extension, trunk movements and ankle movements.~2. Second component is muscle strengthening exercises, it includes: i. Front knee strengthening exercise ii. Back knee strengthening exercise iii. Side hip strengthening exercise iv. Calf raises (with support and without support) v. Toe raise (with support and without support). 3. Third component is balance exercises, it includes: i. Knee bends ii. Backward walking iii. Heel toe standing iv. Heel toe walking v. One leg stand vi. Heel walking vii. Sideways walk viii. Toe walking ix. Heel toe walking backwards x. Walk and turn around (figure of 8) xi. Sit to stand xii. Stair walks"
40975083|NCT06040372|DRUG|LB64640|The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.
40975084|NCT06040372|DRUG|Placebo|Placebo is provided as a matching placebo
40975085|NCT04280133|BEHAVIORAL|Educational Video Tool|The video educational tool was written by the investigators in collaboration with a panel of experts on CAR T-cell therapy, medical ethicists, palliative care clinicians, and oncologists.
40975086|NCT04571138|BIOLOGICAL|SCRI-CAR22v2|Single infusion of SCRI-CAR22v2
41299783|NCT06261138|DRUG|Transarterial chemoembolization|A 5-French RH catheter was then introduced to the celiac artery, superior mesenteric and artery common hepatic artery for angiography to determine tumor location, quantity, size, and vascularity. After confirmation by C-arm cone-beam computed tomography (CBCT), chemoembolization was administered by superselective catheterization of the branches of the tumor-feeding arteries using a 2.8-French coaxial microcatheter. For cTACE, oxaliplatin, raltitrexed and an emulsion containing idarubicin and ethiodized oil were infused for over 20 minutes, followed by combined embolization with blank embolic microspheres. For DEB-TACE, DC/LC Beads® (Biocompatibles, Farnham, Surrey, UK), as drug carriers and embolic materials, were loaded with doxorubicin hydrochloride and mixed with nonionic contrast medium. Real-time assessment of embolization was performed with the assistance of CBCT.
41299784|NCT06261138|OTHER|Systemic treatment|"sorafenib (Bayer HealthCare, Berlin, Germany), lenvatinib (Eisai, Tokyo, Japan), apatinib (Hengrui Pharmaceuticals, Lianyungang, China) and donafenib (Zelgen Biopharmaceuticals, Suzhou, China), while a minority of patients received bevacizumab (Innovent Biologics, Suzhou, China).~sintilimab (Innovent Biologics, Suzhou, China), toripalimab (Junshi Biosciences, Suzhou, China), camrelizumab (Hengrui Pharmaceuticals, Lianyungang, China), tislelizumab (BeiGene, Shanghai, China), pembrolizumab (Merck Sharp \& Dohme, NewJersey, USA), nivolumab (Bristol Myers Squibb, New York, USA), atezolizumab (Roche, Basel, Switzerland) and envafolimab (Alphamab Biopharmaceuticals, Suzhou, China)."
41299785|NCT02851680|BIOLOGICAL|blood samples|
41299786|NCT01168713|DRUG|Levofloxacin|"Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5"
41299787|NCT01168713|DRUG|CEM-101|"CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5"
41299788|NCT00549237|DIETARY_SUPPLEMENT|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
41299789|NCT00549237|OTHER|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
41299790|NCT06554496|DEVICE|CPAP Treatment|Continuous Positive Airway Pressure (CPAP) therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
41299791|NCT04805567|DEVICE|endocuff|The Endocuff is a device that can be mounted on the tip of an endoscope and may assist to inspect a greater surface of the colonic mucosa by pulling backwards, flattening, and stretching the colonic folds as the endoscope is gradually withdrawn.
41299792|NCT04618497|DRUG|Methoxyflurane|Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.
41299793|NCT04618497|DRUG|Ketorolac|Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
41299794|NCT01829789|BEHAVIORAL|Group Community Reinforcement Training for Parents|
41459243|NCT02650973|DRUG|Pegfilgrastim|
40975087|NCT05741320|OTHER|questionnaire|27 questions will be asked to public to find out what is the role of anesthetists after the covıd pandemic
40975088|NCT00284050|DRUG|Ranibizumab 0.3 mg|6 mg/ml ranibizumab solution for intravitreal injection
40975089|NCT00284050|DRUG|Ranibizumab 0.5 mg|10 mg/ml ranibizumab solution for intravitreal injection
40975090|NCT00284050|DRUG|Sham injection|Non-treatment control for sham intravitreal injection.
40975091|NCT02886520|DEVICE|PVDF transobturator tape|
40975092|NCT02886520|DEVICE|Polypropylene transobturator tape|
40771112|NCT02871440|DRUG|Optive Advanced|
40771113|NCT02871440|DRUG|Optive|
40771114|NCT00476645|DRUG|Fulvestrant|Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly
40975093|NCT00935753|DRUG|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
40975094|NCT03030508|OTHER|No intervention|
40975095|NCT02229747|DRUG|Meloxicam|
40975096|NCT02229747|DRUG|Diclofenac|
40975097|NCT02229747|DRUG|Nimesulide|
40975098|NCT04216771|DRUG|Idarubicin|Idarubicin 10mg/m²/day, D1 (IV)
40975099|NCT04216771|DRUG|ID cytarabine|Cytarabine 1.5g/m² /12h, D1-D3 (IV)
40975100|NCT00479609|DRUG|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
40975101|NCT00479609|DRUG|Placebo|Placebo gel
40975102|NCT03208855|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
40975103|NCT00939250|BEHAVIORAL|Diabetes and depression intervention|Disease self management for diabetes and depression
41299795|NCT01829789|BEHAVIORAL|Individual Community Reinforcement Training for Parents|
40771115|NCT04720807|DRUG|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
40771116|NCT00189475|DRUG|Montelukast|
40771117|NCT00189475|DRUG|Placebo|
40771118|NCT01392157|DEVICE|copper-releasing intrauterine device|100 women received a 380 mm2 of copper releasing intrauterine device
40771119|NCT01392157|DEVICE|ENG-releasing implant|60 mcg/day releasing etonogestrel implant
40771120|NCT01392157|DEVICE|LNG-releasing intrauterine system|a LNG-IUS releasing 20 mcd/day of LNG
40975104|NCT00939250|BEHAVIORAL|Diabetes intervention|Disease self management for diabetes
40975105|NCT01550302|PROCEDURE|Superficial Cervical Plexus Block|"At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site."
40975106|NCT01550302|DRUG|Bupivacaine|Single dose of 37.5 mg of bupivacaine subcutaneously
40975107|NCT01776333|BEHAVIORAL|video decision aid|
40975108|NCT02425657|BEHAVIORAL|Training of junior doctors|Training program
40975109|NCT00280631|DRUG|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
40975110|NCT03125343|PROCEDURE|endoscopy|"Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.~They will be followed ever third month for the first two years as follows:~* PET-CT is optional, but can be performed at inclusion~* Pelvic MRI including diffusion weighted imaging according to appendix C.~* Clinical examination~* Endoscopy (flexible sigmoidoskopy) with photodocumentation~* CEA~After two years the patients will be followed every six month with:~* Pelvic MRI including diffusion weighted imaging according to appendix as at baseline~* Clinical examination~* Endoscopy with photodocumentation~* CEA"
40771121|NCT01392157|DEVICE|LNG-IUS|100 women will receive an LNG-IUS
40975111|NCT03125343|PROCEDURE|Surgery|Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
40975112|NCT03125343|DEVICE|MRI|
40771122|NCT03290521|PROCEDURE|intraperitoneal washing with saline solution|intraperitoneal washing at the end of surgery
40771123|NCT03290521|PROCEDURE|No washing|no washing
40975113|NCT01593215|DRUG|Yohimbine|Yohimbine capsule
40975114|NCT03012256|OTHER|Cardio-respiratory management model|Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
40975115|NCT02696473|DIETARY_SUPPLEMENT|Carrot|
40975116|NCT02384408|PROCEDURE|Endometrial Biopsy|Histological assessment
40975117|NCT02384408|DEVICE|Transvaginal Ultrasound|Endometrial Thickness made by ultrasound
40975118|NCT02384408|PROCEDURE|Endometrial Immunohistochemical|Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
41140414|NCT02296307|OTHER|Follow-up phone call|Phone call 6 months after last visit to verify continued health.
41299796|NCT04838691|BEHAVIORAL|interpersonal counseling|In the intervention group, it will be administered for 40 minutes for 8 weeks to people with symptoms of premenstrual syndrome.
40771124|NCT04182334|OTHER|Slow Tempo Music|For up to seven days, enrolled subjects will receive one-hour slow tempo music listening sessions twice daily through noise-cancelling headphones.
40771125|NCT04182334|OTHER|Attention Control|Subjects will receive a noise cancellation headphone-applied condition identical to the music intervention experimental treatment in twice daily one hour-sessions for up to seven days.
40771126|NCT02894398|DRUG|Palbociclib|"Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"
40771127|NCT02894398|DRUG|Letrozole|Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
40771128|NCT02894398|DRUG|Anastrozole|Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
40771129|NCT02894398|DRUG|Exemestane|Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
41299797|NCT00138125|DRUG|Faslodex|Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.
41299798|NCT00138125|BIOLOGICAL|Herceptin|Given at 4 mg/kg IV on day 1 (cycle 1) then 2mg/kg IV weekly
41299799|NCT03564171|COMBINATION_PRODUCT|Prehabilitation|stress counseling, exercise, nutritional counseling, smoking cessation counseling
40771130|NCT02894398|DRUG|Fulvestrant|Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
40771131|NCT01422577|DEVICE|Bright Narrow Band Imaging|It is a High Definition system with narrow band imaging option in th endoscope.
40771132|NCT01422577|DEVICE|White light Endoscopy|White light Endoscopy
40771133|NCT06114745|DRUG|SHR-1707 injection|Drug: SHR-1707 SHR-1707 will be administered through IV infusion. Drug: Placebo Placebo will be administered through IV infusion
40771134|NCT06114745|DRUG|Placebo|Placebo will be administered through IV infusion
40771135|NCT06010979|PROCEDURE|conventional intrumentation assisted knee arthroplasty|conventional intrumentation assisted knee arthroplasty
40771136|NCT06010979|PROCEDURE|computer navigation assisted knee arthroplasty|computer navigation assisted knee arthroplasty
40771137|NCT06010979|PROCEDURE|robotic system assisted knee arthroplasty|robotic system assisted knee arthroplasty
40771138|NCT06010979|PROCEDURE|patient-spercific assisted knee arthroplasty|patient-spercific assisted knee arthroplasty
40771139|NCT04543786|DEVICE|Transcutaneous spinal cord stimulation|Neuromodulation with transcutaneous spinal cord stimulation applied on lower back adjacent to spine for 30-60 minutes for 5 consecutive days.
40771140|NCT06439524|DRUG|40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate|if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis
40771141|NCT02314195|DRUG|Selective serotonin re-uptake inhibitor|A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.
41299800|NCT05474040|DRUG|Morphine versus multimodal analgesia for post elective craniotomy pain|To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain
41299801|NCT01449019|DRUG|exendin(9-39)amide|intravenous infusion of exendin(9-39)
41299802|NCT01449019|DRUG|saline|intravenous infusion of saline
41299803|NCT01449019|OTHER|duodenal meal|duodenal perfusion of a meal
41299804|NCT01449019|OTHER|duodenal saline|duodenal perfusion of saline
41299805|NCT04221074|PROCEDURE|PECS II versus ESP|compare between :ultrasound guided Pectoralis nerve(pecs) II block or erector spinae plane (ESP) block in surgical treatment for gynecomastia patients under general anaesthesia.
40771142|NCT02314195|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
40771143|NCT02314195|OTHER|Music therapy|12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
40771144|NCT05664178|BEHAVIORAL|Tele-Resistance Training|Tele-Resistance training sessions will be supervised and guided by a certified exercise trainer via smartphone, tablet or laptop. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously. Participants will engage in brief warm up exercises lasting 2-3 minutes prior to each RT session and will rest at least 1 minute between sets of the same exercise to aid muscle recovery. Participants will perform at least 2 sets of 12 repetitions for each of 6 exercises. Including warm up, training sets, and rest, sessions will last approximately 30 minutes. RT will include six target exercises focusing on major muscle groups of the upper body, lower body, and core.
40771145|NCT03731429|DRUG|Lidocaine|prior to extubation
40771146|NCT03731429|DRUG|Saline Solution|Prior to extubation
40771147|NCT03659825|DIETARY_SUPPLEMENT|Ketone Ester|Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
41140415|NCT02718885|DIETARY_SUPPLEMENT|Inulin|Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
41140416|NCT02718885|DIETARY_SUPPLEMENT|Maltodextrin|Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
41299806|NCT00253617|DRUG|porfimer sodium|
41299807|NCT00253617|PROCEDURE|adjuvant therapy|
40771148|NCT03659825|DIETARY_SUPPLEMENT|Taste Matched Placebo|Placebo that tastes similar to active intervention
41140417|NCT04514978|PROCEDURE|Blood donation and blood transfusion|24 subjects (12 female, 12 male) is phlebotomized and four weeks later \~130 mL packed red blood cells are re-infused in the same subjects.
41299808|NCT00253617|PROCEDURE|laser therapy|
41299809|NCT00253617|PROCEDURE|photodynamic therapy|
41299810|NCT00253617|PROCEDURE|phototherapy|
41299811|NCT02065869|BIOLOGICAL|BPX-501 T cells|1x10E6 cells/kg infused on Day 0
40771149|NCT03659825|OTHER|Hypoxic exposure|Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
41299812|NCT02065869|DRUG|Rimiducid|0.4mg/kg administered IV to treat GVHD
41299813|NCT04729452|OTHER|blood test|blood test to test immune response to SARS-CoV-2
41299814|NCT00677027|OTHER|lentinan|Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
41299815|NCT00677027|OTHER|placebo|Placebo
41299816|NCT06442709|DRUG|Tocilizumab Asprin|"Tocilizumab alone, Asprin alone, Tocilizumab combined with Asprin. Tocilizumab, an IL6R inhibitor, injected once a month at a dose of 4mg/kg in advanced NPC patients.~Asprin，an anticoagulant, taken orally once daily at a dose of 100mg in advanced NPC patients."
41299817|NCT06442709|OTHER|Placebo|Placebo replaces tocilizumab and asprin in advanced NPC patients.
41299818|NCT04081844|DRUG|HCP1306|Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
41299819|NCT04081844|DRUG|HGP0904|Amlodipine 5mg(Norvasc)
41299820|NCT04081844|DRUG|HGP0608|Losartan 100mg(Cozaar)
41459244|NCT05006833|BEHAVIORAL|Brief Provider Training - Bundled Approach|At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).
40771150|NCT04956016|DEVICE|classic rTMS using the 8-shaped coil|20 rTMS sessions are planned (5 sessions per week)
40771151|NCT04956016|DEVICE|deep rTMS using the H1-shaped coil|20 rTMS sessions are planned (5 sessions per week)
41299821|NCT04399967|BEHAVIORAL|Chat-based support|Participants will receive three months of chat-based support through IM apps (e.g. WhatsApp, WeChat). The regular messages and instant messaging on psychosocial support aim to provide hygienic advice to reduce the risk of exposure to SARS-cov2, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
41299822|NCT04399967|BEHAVIORAL|AWARD plus COVID-specific advice|Ask about smoking history, Warn about the risks associated with the COVID-19 and smoking (with a COVID-related health warning leaflet), Advise to quit as soon as possible during the COVID-19 pandemic, Refer smokers to SC services (with a referral card, see below for information), and Do it again: to repeat the intervention
41299823|NCT04399967|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
41299824|NCT04399967|BEHAVIORAL|COVID-19 related health warning leaflet|The 2-sided color printed A4 leaflet, which covers the risk of COVID-19 and smoking and the most important messages to motivate smoking cessation
41299825|NCT04399967|BEHAVIORAL|Health warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation.
41459245|NCT05006833|BEHAVIORAL|Brief Provider Training - Benefits Approach|At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.
41459246|NCT05006833|BEHAVIORAL|Parent Interactive Text Message - Bundled Approach|Text messages sent to parents will focus on receiving all three adolescent vaccines.
41140418|NCT04171011|DEVICE|Stimulator device|The stimulator device will be used to electrically stimulate the NVB
41459247|NCT05006833|BEHAVIORAL|Parent Interactive Text Message - Benefits Approach|Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.
41459248|NCT00006942|DRUG|bryostatin 1|Given IV
41459249|NCT00006942|DRUG|cisplatin|Given IV
40771152|NCT02174237|DRUG|LNP1892|Tablets of two strengths (5 and 25 mg)
40771153|NCT02174237|DRUG|Placebo|Matching placebo
41459250|NCT00006942|OTHER|laboratory biomarker analysis|Correlative studies
41459251|NCT05255549|PROCEDURE|ESWT + Stretching|"3 weeks intervention:~* 3 sessions of ESWT, once a week~* 6 sessions of passive stretching, twice a week"
41459252|NCT05255549|PROCEDURE|ESWT and SHAM + Stretching|"3 weeks intervention:~* 1 sessions of ESWT + 2 sessions of Sham, once a week~* 6 sessions of passive stretching, twice a week"
41459253|NCT06441695|DIETARY_SUPPLEMENT|xumXR extended release caffeine|proprietary capsule for extended release of caffeine
40771154|NCT05213221|DRUG|Envafolimab|300mg, subcutaneous injection, q3w
40771155|NCT05213221|PROCEDURE|TACE|The first TACE will be started on d1, and the subsequent TACE will be performed on demand.
40771156|NCT05213221|DRUG|Lenvatinib|8mg,QD (body weight \<60kg); 12mg, QD (body weight ≥ 60kg)
40771157|NCT05562388|DEVICE|Somnodent Classic|The efficacy of the device will be evaluated in regards to the response of nocturia. Once patients report an average of voiding per night of less than 2 in the preceding 2 weeks of the follow up they will be classified as responders in term of nocturia and will be evaluated with a second sleep study. Efficacy of MAD will be assessed by comparing the apnea hypopnea index (AHI) values of pre and post sleep study with MAD, and they will be classified as responders if they have 50% improvement in AHI.
40771158|NCT06501196|DRUG|BH-30236|BH-30236 will be provided as either a 5 or 30 mg tablet. Patients will take BH-30236 orally depending on their dose level assignment.
40771159|NCT03777605|DRUG|Nitroglycerin 0.4 MG|"The study evaluate absorption rate of nitroglycerine 0.4 milligrams as tablets or a quickly absorbable capsuel NTG1523 determined by T-max and area under the response curve in the blood of NTG as well as from clinical effects.~Data is entered on data sheet in anonymous form and processed. The results are presented in anonymous form by publication and lecture. Experts are given the supplement: The applicant's rights in a biomedical research project"
41140419|NCT02604693|OTHER|Nothing|No interventions will be administered.
41140420|NCT00187356|PROCEDURE|Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories|Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
41140421|NCT04624906|DRUG|Acalabrutinib|100 mg oral capsules twice daily for 1 year
41140422|NCT04624906|DRUG|Bendamustine|90 mg/m2 on days 1 and 2 of each cycle.
41299826|NCT04399967|BEHAVIORAL|SMS-based support|Participants will receive regular SMS with similar frequency to Intervention group but with generic information on smoking cessation.
41299827|NCT04399967|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
41299828|NCT04399967|BEHAVIORAL|COSH Self-help smoking cessation booklet|A general smoking cessation self-help booklet
41299829|NCT03153215|OTHER|treatment|We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.
41299830|NCT03153215|OTHER|Placebo|Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.
41459254|NCT06441695|DIETARY_SUPPLEMENT|immediate release caffeine|immediate release caffeine capsule
40771160|NCT03277599|DRUG|IV patient-controlled analgesia (PCA) tramadol|Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
40771161|NCT03277599|DRUG|ultrasound guided superficial cervical plexus block|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
40771162|NCT03277599|DRUG|ultrasound guided Great Auricular nerve block|ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
40771163|NCT02026167|BEHAVIORAL|Collaborative Care|Addition of a Health Care Assistant to treatment team, case review by expert panel of supervisors, non-medical interventions
41299831|NCT02471248|DEVICE|Ankle Robot with Power Assistance|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.~They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded."
40771164|NCT02729415|PROCEDURE|Stromal Vascular Fraction Cells (SVF Cells) Injection|The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.
41299832|NCT02471248|DEVICE|Sham|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.~They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion."
41299833|NCT05355090|DIETARY_SUPPLEMENT|PP|Protein Pacing three times per day
41299834|NCT04090281|GENETIC|CYP2C19 genotyping|Upon hospital discharge, patients will undergo CYP2C19 genotyping to guide initial P2Y12 inhibitor selection. At 14 days, post discharge, patients will undergo on treatment platelet reactivity phenotyping to further guide deescalation of P2Y12 inhibitor therapy
41299835|NCT05388435|DRUG|SKL27969|SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
41299836|NCT06190210|DIAGNOSTIC_TEST|electroencephalography|Pre-, per- and postoperative electroencephalography
41299837|NCT06190210|DIAGNOSTIC_TEST|Near-Infrared Spectroscopy|Pre-, Per- and Postoperative near-infrared spectroscopy returning regional cerebral oxygen saturation
41299838|NCT06190210|DIAGNOSTIC_TEST|neuronal cell-free DNA|CfDNA which is characterized based on methylation patterns to determine the tissue of origin
40975119|NCT05443789|BEHAVIORAL|Proton pump inhibitor education|A 15 minutes (preferable) one-on-one educational visit about deprescription of proton pump inhibitor
40975120|NCT05443789|BEHAVIORAL|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
41299839|NCT02514512|DEVICE|MLC Tracking|Treat patient with Non FDA approved MLC Tracking
41299840|NCT01312350|DRUG|neoadjuvant docetaxel/cisplatin/fluorouracil|2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
41299841|NCT01312350|DRUG|No treatment before definitive CCRT|concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
41299842|NCT02860468|OTHER|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
41299843|NCT02860468|OTHER|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
41299844|NCT03629626|PROCEDURE|ERAS protocol|"preoperative management Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling~intraoperative management Multimodal prevention of prophylaxis against nausea and vomiting (PONV) (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.~postoperative management Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV.~It is proposed to chew gum three times daily , fluid therapy, early mobilization, early feeding within 2 hours postoperative for at least 15 minutes and eventually to promote a faster bowel function."
41459255|NCT01279109|BEHAVIORAL|Social network building intervention|Group support and 12 weekly health education/skills building sessions during pregnancy
41459256|NCT01279109|BEHAVIORAL|Home visit|Three home visits during pregnancy focused on providing education on infant injury prevention
41459257|NCT00158925|DEVICE|EASYTRAK EPI lead|EASYTRAK EPI lead
41459258|NCT00326326|DRUG|CP-778,875|
41459259|NCT01245491|OTHER|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
40771165|NCT02729415|PROCEDURE|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).
40771166|NCT02729415|OTHER|Hair Measurements|Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
40771167|NCT06122597|OTHER|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
40771168|NCT04789941|DRUG|Cis Platinum + Irinotecan|Studying the efficacy and safety of neoadjuvant cisplatin and irinotecan use in treatment of locally advanced cancer cervix.
40771169|NCT04233892|DRUG|CBD-bFGF|CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound
40771170|NCT04233892|DRUG|Collagen/BMMNCs|A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound
40771171|NCT04233892|DRUG|Estrogen|Patients will receive regular estrogen therapy
40975121|NCT05048940|BIOLOGICAL|Janssen vaccine|0.5 ml millilitre(s) Intramuscular use
40771172|NCT03482232|DRUG|Benzodiazepines|Benzodiazepines for insomnia, agitation or delirium in people older than 65
40771173|NCT03482232|DRUG|Non-steroidal anti-inflammatory drugs|Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
40771174|NCT03482232|DRUG|paracetamol|paracetamol 1g for more than 3 days
41299845|NCT05534555|DIAGNOSTIC_TEST|FebriDx|Testing of finger-prick blood sample using FebriDx
41299846|NCT01639859|OTHER|Elastography|The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
41299847|NCT03814317|DRUG|Inhaled Treprostinil|"Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
41299848|NCT03416582|BEHAVIORAL|Symptom Management Education and Nurse Coaching|"The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home. The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management. The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the Cancer Treatment Symptom Management Education Toolkit geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration."
41299849|NCT03416582|BEHAVIORAL|Drinks Diary|The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.
41299850|NCT01025778|DRUG|Clofarabine for remission induction|
41299851|NCT01025778|DRUG|Etoposide for remission induction|
41299852|NCT01025778|DRUG|Cyclophosphamide for remission induction|
41299853|NCT01025778|DRUG|Clofarabine in conditioning before transplantation|
41299854|NCT01025778|DRUG|Thiotepa in conditioning before transplantation|
41299855|NCT01025778|DRUG|Melfalan in conditioning before transplantation|
41299856|NCT01025778|PROCEDURE|Haploidentical transplantation of T-cell depleted graft|
41299857|NCT01025778|PROCEDURE|Donor lymphocyte infusion|
41299858|NCT02196194|DRUG|Tiotropium|
41299859|NCT05605327|DEVICE|EUS-guided gastroenterostomy|EUS-guided gastroenterostomy using the Hot-Axios and the WEST approach.
41459260|NCT00597428|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
41459261|NCT00597428|DRUG|Placebo|0 mcg capsules twice daily (BID)
41459262|NCT01120899|DRUG|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
41459263|NCT04019054|DEVICE|Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC)|iTBS delivered to vmPFC for active treatment of spider phobia.
40771175|NCT03482232|DRUG|Antimicrobial agent|antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
40771176|NCT03482232|DRUG|Lipid-lowering drug|Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
40771177|NCT03482232|DIAGNOSTIC_TEST|Prostate cancer|Screening for prostate cancer in asymptomatic patients
40771178|NCT03482232|RADIATION|Lumbago|image tests in non-specific lumbago
40771179|NCT03482232|DRUG|Antimicrobial agent|antibiotics for pharyngitis (infants)
40771180|NCT03482232|DRUG|Mucolytic|mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
41299860|NCT05605327|OTHER|Laparoscopic gastroenterostomy|Laparoscopic gastroenterostomy
41299861|NCT02084134|DRUG|hydrocortisone|100mg at the time of surgery
41299862|NCT02084134|DRUG|dexamethasone|0.5mg every 6 hours for a total of four doses
41299863|NCT04040712|OTHER|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
41299864|NCT04040712|OTHER|Sham FMT|Sham fecal microbiota transplantation
41459264|NCT04019054|DEVICE|Intermittent Theta Burst Stimulation (iTBS), vertex|iTBS delivered to vertex for placebo treatment of spider phobia.
41299865|NCT06421428|OTHER|LEI Interview|"In accordance with the IPA (Interpretative phenomenological analysis) methodology, a semi-structured interview outline will be defined, aimed at understanding the lived experiences of women (lived experience) during their coexistence with urinary incontinence and during the treatment process.~The screwdriver questions were formulated starting from the reference literature and will be discussed in a focus group composed of a uro-gynecologist, two midwives, a nurse, an expert in qualitative methodology. The final screwdriver questions resulting from the focus group will be tested on a small group of women."
41459265|NCT02907073|DRUG|BF4|Single IV dose of 9-11 millicurie (mCi) sodium \[Fluorine-18\] radiolabeled B4\^F
41459266|NCT00892749|DRUG|ASP1585|oral
41459267|NCT01670643|BEHAVIORAL|Video camera magnifier|reading with video camera magnifier
41459268|NCT05319574|RADIATION|SBRT|Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy
41459269|NCT05319574|DRUG|Tislelizumab|200mg q3w for two cycles administrated concurrently with chemotherapy
40975122|NCT05048940|BIOLOGICAL|Spikevax (Moderna) vaccine|0.5 ml millilitre(s) Intramuscular use
40975123|NCT03258021|DEVICE|TTFields|Tumor treating fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
40975124|NCT05017766|OTHER|analysis of antimicrobial resistance|"In samples from patients infected with one of the focus pathogens (E. coli, Klebsiella species, S. aureus, P. aeruginosa) will be:~(i) isolated and pathogenic bacteria characterized; (ii) pathogen in-situ properties at single-cell and bulk average determined; (iii) human metabolites, proteins and cells determined (iv) antibiotic concentration determined (v) bacterial growth monitored~Deducted from the data will be:~1. relevant human components and pathogen properties that are common to most patients with similar indication~2. underlying regulatory networks and triggers in pathogen cells and human tissues.~Clinical outcomes (survival/mortality) and treatment response (response or failure) will be correlated to the in vitro retrieved host and bacterial data."
40975125|NCT05591274|DEVICE|SmileyScope Virtual Reality Headset|The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.
40975126|NCT02399501|PROCEDURE|hysteroscopy|Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
40975127|NCT02399501|DEVICE|two dimensional ultrasound|Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
40975128|NCT02399501|DEVICE|saline sonohysterography|sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
40975129|NCT02399501|DEVICE|three dimensional ultrasound|The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
40975130|NCT01295502|DRUG|Carboplatin|Given IV
40975131|NCT01295502|DRUG|Cisplatin|Given IV
40975132|NCT01295502|RADIATION|External Beam Radiation Therapy|Undergo EBRT
40975133|NCT01295502|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
40975134|NCT01295502|DRUG|Paclitaxel|Given IV
41459270|NCT01913054|DRUG|Fentanyl Injection|
41459271|NCT01913054|DRUG|Etomidate Fat Emulsion Injection|
41459272|NCT01913054|DRUG|Propofol Injection|
40975135|NCT01499745|BEHAVIORAL|Pulmonary Rehabilitation|"Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation"
40975136|NCT05714813|BEHAVIORAL|High-Speed Circuit Resistance Training|Performance of 24 weeks of high-speed concentric and low-speed eccentric lift across three circuits on eleven pneumatic machines. Each training session will be in person and will last between 45 minutes and one hour.
40975137|NCT05714813|BEHAVIORAL|Lecture on Diet, Exercise and Cognition|Lectures on diet, exercise, and cognition. Lectures will be provided in person or online and will last approximately one hour.
41459273|NCT04739423|DRUG|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
41459274|NCT01452035|OTHER|Exercise|single session of exercise
41459275|NCT01083797|DRUG|Dexmedetomidine|1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1
41459276|NCT01083797|DRUG|Chloral Hydrate|Initial dose=50 mg/kg
41459277|NCT05069974|DRUG|Linezolid 600 mg|After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days or 1 tablet of of Linezolid every 24hours during 5 days.
41459278|NCT05069974|DRUG|Benzathine Penicilllin G|After randomized to the control arm, the patient will receive a single dose of intramuscular BPG.
41459279|NCT04417439|OTHER|universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)|The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.
41459280|NCT00002367|DRUG|Saquinavir|
41459281|NCT00002367|DRUG|Lamivudine|
41459282|NCT00002367|DRUG|Zidovudine|
41459283|NCT00683592|DRUG|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
41459284|NCT00683592|DRUG|placebo|placebo
40975138|NCT03556150|OTHER|Manual Therapy protocol|"This protocol consists of:~* Six minutes of joint's mobilisation (two minutes of each technique).~* Nine minutes of ischemic pressure . Three minutes per muscle in this order: temporal muscle, masseter muscle and lateral pterygoid. Choosing the two most painful trigger points.~* Three minutes of trigemino's nerve stretching."
40975139|NCT03556150|OTHER|Effleurage|"The protocol consists of:~* Five minutes in temporal muscle.~* Ten minutes superficial massage in the neck and cheek of the most painful joint.~* Five minutes of effleurage in the cheek, with the index finger inside the mouth and the thumb outside."
40975140|NCT03530904|OTHER|mobilization|Early mobilization after CIED implantation
41299866|NCT06421428|OTHER|LEI Survey|Some sociodemographic data identified from the reference literature will be collected in paper form immediately at the end of each interview, for the description of the sample. The data will concern: age, nationality, marital status, level of education, number of children, menopause, social relationships, level of information, period of onset of symptoms, type of symptomatology, frequency of episodes of urinary incontinence, quantity of urinary leakage, uro-gynecological pathological history.
41299867|NCT06430749|DEVICE|Microtaze|Targeted Microwave Tissue Coagulation
41459285|NCT03391622|DEVICE|Calibrated Automated Thrombogram|blood samples will be collected . Thrombin generation in platelet-poor plasma will be measured by means of the Calibrated Automated Thrombogram (CAT).
40975141|NCT00824512|DRUG|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
40975142|NCT00824512|DRUG|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
40975143|NCT05614128|OTHER|IVIg|Patients will be treated with IVIg as recommended by expert guidelines for treatment of CIDP under care of their primary neurologist. This will not be provided by the study.
40975144|NCT01773785|DRUG|SPI-1620|SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
40975145|NCT01773785|DRUG|Docetaxel|Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
40975146|NCT02035878|OTHER|Probiotics|probiotic intervention: 400mg of probiotic capsule
40975147|NCT02035878|DRUG|Placebo|placebo comparator
40975148|NCT05552560|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection before the first consultation with the centre's psychologist.~This questionnaire includes questions on the socio-demographic characteristics, the motivations, as well as the procreative history of the patients."
40975149|NCT01502059|OTHER|Pilates|Pilates training - twice a week (one hour per class) during 90 days
40975150|NCT01148823|OTHER|Incisions covered for 1 day|Dressing was removed on the first postoperative day.
41299868|NCT00174746|DRUG|AVE2635A|
40975151|NCT01148823|OTHER|Incisions covered for 6 days|Dressing was removed on the 6th postoperative day.
40975152|NCT00029614|DRUG|Atomoxetine|
41299869|NCT06302205|OTHER|Physical activity|The home-based training intervention consists of two phases of each three months in duration. It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.
41459286|NCT00016653|DRUG|Creatine Monohydrate|
40771181|NCT03482232|DRUG|Ibuprofen and paracetamol|treatment with ibuprofen and paracetamol (infants)
40771182|NCT03804255|OTHER|Survey Administration|Complete surveys
40975153|NCT05258175|OTHER|KT|Kinesio tapping will be applied in three session and it will be changed on every fifth day in total 15 days.
40975154|NCT05258175|OTHER|Standardized physiotherapy protocol|3 sets with five repetitions per day for total of 15 days.
40975155|NCT03733795|OTHER|TCD|Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.
40975156|NCT02193568|PROCEDURE|Arm I (light sedation)|If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
40975157|NCT02193568|PROCEDURE|Arm II (intubated general anesthesia)|Receive intubated general anesthesia
40975158|NCT02193568|PROCEDURE|Arm II (intubated general anesthesia)|Undergo craniotomy
40975159|NCT02193568|OTHER|Arm II (intubated general anesthesia)|Ancillary studies
40975160|NCT02193568|PROCEDURE|Arm I (light sedation)|Undergo craniotomy
41140423|NCT04624906|DRUG|Rituximab|day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
41140424|NCT02894086|OTHER|database.|database
41299870|NCT06302205|OTHER|Sham intervention|2 times a week, flexibility and balance training
41299871|NCT00000348|DRUG|Dihydrexidine|
41299872|NCT05399758|DEVICE|NOL monitor|NOL monitor data will be acquired, as well as clinical assessment of pain and fentanyl dosage.
41459287|NCT00016653|DRUG|Glutamine|
41459288|NCT05079230|DRUG|Magrolimab|Administered intravenously (IV)
41459289|NCT05079230|DRUG|Venetoclax|Tablets administered orally
40771183|NCT00759395|DRUG|AZD2327|Tablet, Oral, Daily
40771184|NCT00759395|DRUG|Placebo|Tablet, Oral, Daily
40771185|NCT04461886|DRUG|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
40771186|NCT01218321|BIOLOGICAL|antiepileptic treatment|White blood cells from peripheral blood samples
40771187|NCT06196905|DRUG|MT-2990|i.v. infusion
40771188|NCT00037882|DRUG|PEG-Intron|Once weekly injection.
40975161|NCT02193568|OTHER|Arm I (light sedation)|Ancillary studies
41140425|NCT02095145|OTHER|Laboratory Biomarker Analysis|Correlative studies
41140426|NCT02095145|OTHER|Pharmacological Study|Correlative studies
41140427|NCT02095145|OTHER|Placebo|Given PO
41140428|NCT02095145|DRUG|Pomegranate-Extract Pill|Given PO
41459290|NCT05079230|DRUG|Azacitidine|Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
41459291|NCT05079230|DRUG|Magrolimab Placebo|Administered intravenously (IV)
41299873|NCT05557890|BEHAVIORAL|System Constellation VR-Seminar|individual-centered intervention in a group VR-setting, duration 2 to 3 days
41299874|NCT03330743|BEHAVIORAL|Parent Mentor with Standard Education|Parent mentors will provide coaching based on the current guidelines around diet and physical activity
41459292|NCT03261817|BEHAVIORAL|Physical activity (APA)|"2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition"
41299875|NCT03330743|BEHAVIORAL|Parent Mentor with Positive Deviance|Parent mentors will provide coaching based on findings from the positive deviance study
41459293|NCT03261817|BEHAVIORAL|Health Education program (HE)|2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
41459294|NCT03417427|DRUG|Decitabine and Ara-C|Decitabine in combination with high-dose of Ara-C is used to improve the effect of consolidation chemotherapy. It is expected to make minimal residual disease (MRD) become negative in more patients with intermediate-risk AML.
41459295|NCT03417427|DRUG|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
41459296|NCT00516087|BIOLOGICAL|Genetically modified CTLs|"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x10\^8 cells/m2"
41299876|NCT02811458|BEHAVIORAL|Transdiagnostic Cognitive-Behavioral Therapy|Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.
41299877|NCT00483288|OTHER|educational intervention|
41299878|NCT00483288|OTHER|questionnaire administration|
41299879|NCT00483288|OTHER|study of socioeconomic and demographic variables|
41299880|NCT00483288|OTHER|survey administration|
41299881|NCT05511753|DEVICE|electroacupuncture|Insert stainless steel needles into the above acupoints and twist the needles to get qi. In addition, electroacupuncture stimulation (intensity 1mA, frequency 2Hz) was applied to connect the ipsilateral Yifeng and Wangu, and the ipsilateral Zhongzhu and Quchi.
41299882|NCT04961840|OTHER|No Intervention|This is a non-interventional study.
41459297|NCT06273709|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|(Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
41459298|NCT01242124|PROCEDURE|side-to-side stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive side-to-side stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
41459299|NCT01242124|PROCEDURE|circular-stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive circular-stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
41459300|NCT03266276|OTHER|PSOPC pathway approach|"The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.~Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral."
41459301|NCT05001009|BEHAVIORAL|Clinician Implementation Strategy Stage 1: low intensity clinician training|"A booster of the established LSTDI implementation strategy. Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study. Online training options and when and how to complete goals of care conversations and documentation will be highlighted."
40771189|NCT04322279|DIAGNOSTIC_TEST|Serology|SARS-CoV-2 serology
40771190|NCT04322279|GENETIC|Sequencing|Whole exome sequencing
41299883|NCT05916833|OTHER|hypopressive breathing|Hot pack for 10min.Hypopressive breathing in sitting, lying and standing position. Hypopressive breathing 2 times/weekly, 5sec hold, 2-3reps, 1-2sets for 12 weeks. Session will be weekly progress.
40771191|NCT00706173|DRUG|Hydrocortisone|Hydrocortisone 10-20 mg PO daily for 4 weeks.
40771192|NCT00706173|DRUG|Placebo|"Placebo 10-20 mg PO daily for 4 weeks."
40771193|NCT05918770|DIAGNOSTIC_TEST|systematic screening and early treatment|in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition
40771194|NCT04619602|DRUG|GSNO|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
41299884|NCT05916833|OTHER|noble technique|Hot pack for 10min. Noble technique in relaxed supine position 2time/weekly, 3-5sec hold, 10-15reps, 2-3sets for 12 weeks. Session will be weekly progress.
41299885|NCT05057585|BEHAVIORAL|Turning in bed, arm and leg exercises|Exercises (arm and leg exercises, turning in bed) were applied only to the experimental group. It was applied for 15 minutes 12-24 hours before the operation.
41299886|NCT05714306|BIOLOGICAL|PEP-DC1|PEP-DC1 vaccine comprises autologous dendritic cells pulsed with personalized peptides detected or predicted a priori (using our current integrated antigen identification methodologies).
41299887|NCT05714306|BIOLOGICAL|OC-DC|OC-DC vaccine is an autologous dendritic cell vaccine loaded with autologous oxidized tumor lysate.
41299888|NCT05714306|BIOLOGICAL|PEP-DC2|PEP-DC2 comprises autologous dendritic cells pulsed with the peptides detected or predicted after vaccination with OC-DC.
41299889|NCT05714306|DRUG|Low dose cyclophosphamide|Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)
41459302|NCT05001009|BEHAVIORAL|Clinician Implementation Strategy Stage 2: high intensity clinician training|"This includes two components:~1. Team facilitation to help the primary care team (advance practice provider, nurse, social worker) work together to create roles and responsibilities for accomplishing goals of care conversations with patients~2. A patient list trigger of patients potentially eligible for goals of care conversations (the patient study population) will be sent to the primary care clinicians."
41459303|NCT05001009|BEHAVIORAL|Low patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website.
41459304|NCT05001009|BEHAVIORAL|High patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website. Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.
41459305|NCT03506841|DRUG|Cerebrolysin|Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
41459306|NCT01566851|OTHER|Cardiovascular check-up|Cardiovascular check-up once a year in patients with rheumatoid arthritis
41459307|NCT06147258|BEHAVIORAL|expressive writing|A typical session will begin with the teaching artist (i.e., writing coach) introducing a new writing theme. Participants will have at least 20 minutes to write, and each session will include post-writing reflections and sharing, an undirected supportive interaction among participants.
41459308|NCT06060522|DIAGNOSTIC_TEST|CT, CBCT|"Under general anesthesia, a lingual envelope incision is performed to access and remove the displaced third molar tooth or root, and a mucoperiosteal flap is released from the retromolar trigone to the medial surface of the mandibular first premolar. By carefully retracting the lingual soft tissue, an envelope flap is raised on the lingual side from the second premolar to the anterior boundary of the ramus. This protected the lingual nerve from injury. With great caution, the lingual flap is reflected up to the submandibular area so that the tooth or root fragment will be identified. An extra-oral finger is used as support.Through blunt dissection, the loose tooth or root is located, grabbed using a pair of artery forceps, and extracted.~The flaps are sutured using 3-0 Vicryl sutures after the wound is irrigated with normal saline."
40771195|NCT00864279|DRUG|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
40771196|NCT00864279|DRUG|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
40771197|NCT06540976|BEHAVIORAL|Cognitive testing|Cognitive tasks testing executive and episodic based decisions, and the switching between these processes.
40771198|NCT05651490|BEHAVIORAL|Problem Solving Treatment for Diabetes|"In the introductory session, the structure of and rationale behind PST-D will be explained. The specialist will work with the participant to develop a problem list related to diabetes self-management and smoking cessation, if applicable.~During the weekly sessions, the participant will be taught and guided through the seven steps of problem solving:~1. Clarifying and defining the problem~2. Setting a realistic goal~3. Brainstorming multiple solutions~4. Generating pros and cons for each solution~5. Evaluating and choosing a preferred solution~6. Developing a specific action plan to implement the solution~7. Evaluating outcomes from the previous session.~Participants will also plan to engage in at least 1 enjoyable activity daily during the week.~The number of sessions will differ based on the specialist's assessment of the participant's problem-solving skills.~Maintenance sessions will be delivered monthly across 3 months in order to follow-up with participants."
40771199|NCT05651490|BEHAVIORAL|Attention Control Group|During the sessions, the healthcare practitioners will provide general information and recommendations on general health topics such as oral health, hearing loss, sleep, dementia, adult vaccination, influenza, and dengue fever. Participants will also be given handouts adapted from government agencies and/or public bodies, such as HealthHub, National Health Service, National Addictions Management Service, and National Environmental Agency, on these topics. The healthcare practitioners will avoid discussing topics related to diabetes, diet, physical activity, and medication.
40771200|NCT05728242|DIAGNOSTIC_TEST|Gastric ultrasound|Preoperative gastric antrum examination to detect gastric content (empty, liquid, or solid) and measure gastric volume
40771201|NCT03553836|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
40771202|NCT03553836|OTHER|Placebo|Administered as an IV infusion every 3 weeks (Q3W)
40771203|NCT05879029|DRUG|Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.|Participants in the experimental group were given Jinsang Liyan Capsule + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
40771204|NCT05879029|DRUG|Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets.|Participants in the control group were given Jinsang Liyan Capsule placebo + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
40771205|NCT06563167|DIAGNOSTIC_TEST|CXR|CXRs will be performed at 3 different time points - (i) within 1 hour after TTLB, (ii) at 4 hours (± 1 hour) after TTLB and (iii) at 18 hours (± 2 hours) after TTLB.
40771206|NCT02144532|DEVICE|short-sleeved vest CICATREX SED®)|Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
40771207|NCT01204957|DIETARY_SUPPLEMENT|Seaweed and Soy Protein|5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk
40771208|NCT01204957|DIETARY_SUPPLEMENT|Placebo and Soy Protein|5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
40771209|NCT03796104|OTHER|Delta-haemolysin|comparison of groups having infection with S. aureus with and without delta-haemolysin Production
40771210|NCT03604744|DRUG|LSD|LSD 0.1 mg per os, single dose
40771211|NCT03604744|DRUG|LSD|LSD 0.2 mg per os, single dose
40771212|NCT03604744|DRUG|Psilocybin|Psilocybin 15 mg per os, single dose
40771213|NCT03604744|DRUG|Psilocybin|Psilocybin 30 mg per os, single dose
40771214|NCT01322152|DRUG|irinotecan, capecitabine|Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
40771215|NCT06571877|OTHER|Dietary intervention with manipulation of the energy density|Dietary intervention with manipulation of the energy density either during breakfast or during lunch
40771216|NCT01640080|DRUG|Esketamine|Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
40771217|NCT01640080|DRUG|Esketamine|Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
41140429|NCT05034588|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance, including functional and structural parameter
41140430|NCT04419571|PROCEDURE|Emergency Laparotomy|All adult patients undergoing emergency laparotomy
41140431|NCT02322645|DRUG|Eszopiclone Tablets 3 mg|
41140432|NCT04775732|BIOLOGICAL|infliximab therapeutic drug monitoring|dose optimization of infliximab based on a predefined dosing algorithm
41140433|NCT05873296|BEHAVIORAL|Health Education|The intervention will last for 12 weeks, a health education program (face-to-face meetings and information in social networks).
41140434|NCT01731210|DEVICE|implantation of the new LV lead: NANO system.|
41140435|NCT06034977|DRUG|ADI-PEG20|Lenvatinib + ADI-PEG20 combination treatment.
41140436|NCT01865695|DRUG|Creon|Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (\<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
41140437|NCT01865695|OTHER|Placebo|
41140438|NCT04709185|DRUG|Dexamethasone 1 MG Oral Tablet|oral 1 mg dexamethasone at 23:00-24:00 the night before AVS
41140439|NCT04709185|DRUG|Placebo|oral placebo at 23:00-24:00 the night before AVS
41140440|NCT01597856|BEHAVIORAL|SBIRT|"SBIRT Therapy overview-~1. Therapist explains purpose of the therapy.~2. Inquiry about Compensation examination-ask if Veteran has questions about determination process and address concerns.~3. Discuss relationship between PTSD and substance use- long-term substance use is a form of avoidance and barrier to recovery.~4. Discuss treatment needs, administer screening, provide feedback."
41140441|NCT02050815|DRUG|MEK162|
41140442|NCT03422705|DEVICE|Optimised programming|Optimised programming to avoid RV pacing when possible.
41140443|NCT03422705|DRUG|Lisinopril|Uptitration of lisinopril
41140444|NCT03422705|OTHER|Standard care|No pacemaker adjustment or medical therapy
41140445|NCT05606796|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
41140446|NCT01092325|DRUG|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
41140447|NCT01092325|DRUG|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
41140448|NCT01092325|DRUG|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
40771218|NCT01640080|DRUG|Placebo|Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
40771219|NCT05234216|OTHER|Informed consent|the investigator will verify the inclusion criteria, the patient's understanding of the protocol and will obtain oral informed consent
40771220|NCT05234216|PROCEDURE|Surgery|The patient will undergo surgery in accordance with standard care
41140449|NCT01092325|DRUG|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
41140450|NCT01092325|DRUG|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
41140451|NCT01092325|DRUG|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
41140452|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
41140453|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
41140454|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
41140455|NCT05642702|OTHER|1% w/v Sodium Lauryl Sulphate (SLS) solution|1g of Sodium Lauryl Sulphate will be dissolved in distilled water and made up to 100 mL solution using distilled water. A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
41140456|NCT05642702|OTHER|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v|A 0.04 mL of 0.9% w/v solution of Isotonic Saline Solution will be dispensed on the center of an appropriately sized filter paper, which will be further placed in the designated IQ/Finn chambers prefixed to a micropore tape.
41140457|NCT04237792|DRUG|dexmedetomidine|dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
41140458|NCT04237792|DRUG|propofol|propofol IV administration will be given if needed to maintain sedation
41299890|NCT05351086|DRUG|PUR3100|PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
41299891|NCT05351086|DRUG|Dihydroergotamine (D.H.E 45)|D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.
41299892|NCT05351086|OTHER|Matching Placebo for PUR3100|Each capsule of matching placebo is filled with iSPERSE powder comprised of mannitol, leucine, and sodium chloride. The PUR3100 inhalation powder is administered using the supplied RS01 inhalation device (RS01 UHR2, Plastiape S.p.A.).
41299893|NCT05351086|OTHER|Matching Placebo for D.H.E 45|The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
41299894|NCT06184269|DRUG|BR1017-1|One tablet administered alone
41299895|NCT06184269|DRUG|BR1017-1A|One tablet administered alone
41299896|NCT06184269|DRUG|BR1017-1B|One tablet administered alone
41299897|NCT03411746|OTHER|Subarachnoid haemorrhage|Data on the type of patients enrolled have been described already in other sections.
41299898|NCT05615597|PROCEDURE|Para-discal injection of corticoid|In this pilot study, all patients underwent the same procedure: a corticosteroid infiltration via a para-discal approach. The infiltrations were performed under CT or scopy.
41299899|NCT00747890|PROCEDURE|Modified tonsillectomy|"* Tonsillectomy~* Uvulectomy~* Soft palatal resection~* Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance"
41299900|NCT00747890|OTHER|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
41299901|NCT05325138|OTHER|Interview|Parents of girls aged 9-14yearsold will undergo an interview to determine their knowledge, attitudes and beliefs concerning HPV vaccination
41299902|NCT01911182|OTHER|Inhalation of low concentration of CO2|Inhalation of 1% CO2 through nasal prongs
41299903|NCT05443958|OTHER||
40975162|NCT03879226|DEVICE|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for the applications during the training and/or detraining periods will be 30 Joules (J) per site (510 J per lower limb). PBMT will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
41299904|NCT04278118|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
41299905|NCT04278118|RADIATION|Photon Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
40771221|NCT05234216|BEHAVIORAL|Comfort scale|The patient will be evaluated, in the post-operative care unit, with a comfort scale
40771222|NCT05234216|BEHAVIORAL|Pain|The patient will be evaluated, in the post-operative care unit, with a pain scale
41299906|NCT04278118|RADIATION|Proton Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
41299907|NCT04278118|OTHER|Quality-of-Life Assessment|Ancillary studies
41299908|NCT04278118|OTHER|Questionnaire Administration|Ancillary studies
41299909|NCT02731508|DEVICE|Bihemispheric transcranial direct current stimulation|5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
41299910|NCT03207022|PROCEDURE|axillary brachial plexus block|ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
41299911|NCT01539837|DRUG|Deferiprone 20mg|20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
41299912|NCT01539837|DRUG|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
40771223|NCT05234216|OTHER|Questionnaires|Evaluation of the Experience of Local/General Anesthesia
40771224|NCT04480866|DEVICE|Colli-Pee® (FV5000 and Small Volumes)|"Colli-Pee® device (Novosanis, Belgium) attached to collector tubes prefilled with a non-toxic nucleic acid preservative (including an internal process control). The collector tubes differ in size to collect a total sample volume of 4, 10, and 20 mL.~Each participant will collect three urine samples using the Colli-Pee Small Volumes 4 and 10 mL, and the Colli-Pee FV5000 (20 mL) device, in a random order."
40771225|NCT05338073|DIAGNOSTIC_TEST|Known 3Dx Test|Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test
41299913|NCT01539837|DRUG|Deferiprone 30mg|30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
41299914|NCT05493787|BEHAVIORAL|Reminder|Patient portal, SMS, email, and/or another modality
41299915|NCT01579539|DRUG|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
41299916|NCT01579539|DRUG|Esomeprazole|40mg i.v. infusion once a week for 12 weeks
41299917|NCT00073333|BEHAVIORAL|Social Skills Training|Social skills training once per week
41299918|NCT00073333|BEHAVIORAL|Exposure Treatment|Exposure once per week
41299919|NCT00073333|BEHAVIORAL|Placebo|Placebo
41299920|NCT03755531|DRUG|Carbetocin|"Heat stable Carbetocin, a clear colourless solution. Oxytocic activity: approximately 50 IU of oxytocin/vial. One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection, slowly over 1 minute after labor of the baby at once. It was used once and no further doses were given.~Drug was kept in cold storage (2 to 8°C)."
40771226|NCT05136560|DRUG|Dexamethasone|Intervention drugs would be administered for 1 or 2 days.
41299921|NCT03755531|DRUG|Oxytocin|"Oxytocin, a clear colourless solution. One ml of oxytocin (10 IU), was given as a bolus intravenous injection over 1 minute, after labor of the baby at once. Further doses can be given accordingly.~Drug was kept in cold storage (2 to 8°C)."
41299922|NCT02429596|DRUG|Experimental|Switch from brand to generic
40975163|NCT03879226|DEVICE|Placebo|Placebo will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
40975164|NCT05809622|BEHAVIORAL|Elbow focused rehabilitation|"* Patient education~* Activity modification~* 2 days/week, 8 weeks in total~* Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)"
40975165|NCT05809622|BEHAVIORAL|Scapular and rotator cuff muscles strengthening|"* Patient education~* Activity modification~* 2 days/week, 8 weeks in total~* Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)~* Scapular stabilizer muscle + rotator cuff (RM) strengthening"
40975166|NCT02615366|DRUG|Tranexamic Acid|
40975167|NCT02615366|DRUG|Placebo|
40975168|NCT02608710|DRUG|RDEA3170 4.5 mg|
40975169|NCT02608710|DRUG|RDEA3170 6 mg|
40975170|NCT02608710|DRUG|RDEA3170 12 mg|
40975171|NCT02345694|DEVICE|Effective CPAP|Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks
40975172|NCT02345694|DEVICE|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
40975173|NCT03994965|DRUG|Pimavanserin 34 milligrams (MG) [Nuplazid]|Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
41299923|NCT01861340|DRUG|Lenalidomide, Dexamethasone, and MEDI-551|Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
41299924|NCT01595750|DRUG|Roflumilast 500|Roflumilast 500 mcg , 12 weeks of treatment
41299925|NCT01595750|DRUG|Placebo|Placebo 500 mcg , 12 weeks of treatment
40771227|NCT04280380|DIAGNOSTIC_TEST|Real time PCR|At inclusion, serum samples will be collected to determine CMV serological status. Plasma samples will be collected weekly for CMV PCR analysis. Antibodies for CMV will be assessed using a commercial enzyme immunoassay kit for detection of total antibodies to CMV (LIAISON CMV IgG assay, DiaSorin S.p.A). DNA will be extracted in 200 μL of plasma eluted in 60 μL of elution buffer using a NucliSENS easyMAG system (bioMérieux, Boxtel, The Netherlands). Samples will be amplified using Affigene CMV Trender diagnostic assay (Cepheid AB, Bromma, Sweden), according to the manufacturer instructions. Amplification will be performed on a MX3000P instrument (Stratagene Instruments Systems, La Jolla, CA, USA). Samples with \>500 copies/mL of plasma will be considered positive.
40771228|NCT05745922|BEHAVIORAL|Moderate intensity exercise|Treadmill walking/running with moderate intensity
40771229|NCT05745922|BEHAVIORAL|High intensity exercise|Treadmill walking/running with high intensity
40771230|NCT04978415|PROCEDURE|peribulbar block versus subtenon's block|"Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery."
40975174|NCT04386421|OTHER|Video on oral hygeine instructions|A 3 minute video will be shown providing information regarding the care of the dentition during Fixed appliance treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions.
40975175|NCT04386421|DRUG|Plaque disclosing tablets|"Plaque disclosing tablets:~Product: 2-Tone Disclosing Tablets Young Dental Manufacturing 13705 Shoreline Court East Earth City, MO 63045 Composition: Flavor, SD Tutti Fruiti 1 %, D and C Red 1 % and FD and C Blue 1 %"
40975176|NCT01262053|OTHER|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
41299926|NCT01850849|DRUG|LEO 39652 cream|
41299927|NCT01850849|DRUG|cream vehicle|
41299928|NCT05420519|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
41299929|NCT02354391|DRUG|Ingenol mebutate Picato® and MAL PDT day 1, day 5|Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
41299930|NCT02354391|DRUG|Ingenol mebutate Picato® day 2, 3, 4|Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
41299931|NCT02354391|PROCEDURE|MAL PDT day 5|Methyl aminolevulate combined with Photodynamic therapy at day 5
41299932|NCT03940651|DRUG|Spinal Anesthesia|Patients will be randomized to type of anesthesia
41299933|NCT03940651|DRUG|General Anesthetics|Patients will be randomized to type of anesthesia
41299934|NCT06532019|OTHER|Targeted intervention based on risk factors|Correct hypoalbuminemia, anemia or hyponatremia, and try to enhance medication to lower NT-proBNP, CRP, NYHA Classification, to add diuretics for patients with higher RADs, multidiscipline intervention for patients complicating COPD, and actively reperfusion for ischemic HFpEF patients.
41459309|NCT03788876|OTHER|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge.
41299935|NCT04914637|PROCEDURE|Cervical interlaminar epidural steroid injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 cc 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the rest room after the procedure and followed up for any complications.
40771231|NCT03681678|DEVICE|fCO2 Laser Therapy Group|Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
40771232|NCT04666610|DRUG|Brivaracetam|"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered."
41299936|NCT04914637|PROCEDURE|Dry needling|Dry needling will be applied to the active trigger points for the patients in this group. After cleaning the area of interest with an antiseptic solution, dry needling will be applied with the fast-in/fast-out technique for the active trigger point. During needle maneuvers, local contractions (local twitch response-LTR) are obtained and rapid needle movements are continued until the contractions end. Afterwards, the needle is removed and compression is applied to ensure hemostasis in the relevant area.
40975177|NCT01262053|OTHER|Active Intervention|"The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type dd76m to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function."
40975178|NCT01262053|OTHER|Control|Parallel control with no intervention
41299937|NCT04914637|PROCEDURE|Sham dry needling|Although the method of intervention is like dry needling, the only difference is that the blunt end of the needle is used and it does not penetrate the skin.
41299938|NCT05085392|BEHAVIORAL|Trauma-Informed Yoga|6 weeks of twice weekly trauma-informed yoga for 45 minutes per session
41299939|NCT01993329|DRUG|Gefapixant 50 mg|Gefapixant 50 mg tablet administered orally
41299940|NCT01993329|DRUG|Gefapixant 300 mg|Gefapixant 300 mg tablet administered orally
41459310|NCT03788876|OTHER|Conventional care|Physiotherapy protocol will be performed by HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.
40771233|NCT04666610|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding.
40771234|NCT03282994|DEVICE|Dermal Cooling System|Cryotherapy
40771235|NCT06316765|PROCEDURE|Intubation with stylet|The cohort of premature infants was intubated with stylet.
40771236|NCT04118764|DEVICE|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
41299941|NCT01993329|DRUG|Placebo to mimic 50 mg tablets|Sugar pill manufactured to mimic gefapixant 50 mg tablets
41299942|NCT01993329|DRUG|Placebo to mimic 300 mg tablets|Sugar pill manufactured to mimic gefapixant 300 mg tablets
41299943|NCT03912922|OTHER|Activity regime|Activity regime of 4 days followed by a test day.
41299944|NCT01259492|DRUG|Placebo|Placebo Comparator: Placebo
41299945|NCT01259492|DRUG|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
41299946|NCT01259492|DRUG|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
41459311|NCT00325182|DRUG|Levetiracetam|
40975179|NCT02051608|DRUG|Placebo|Participants received Placebo SC injection Q4W.
40975180|NCT02051608|DRUG|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
40975181|NCT03716024|DRUG|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
40975182|NCT03716024|DRUG|Linezolid|Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
40975183|NCT01730391|OTHER|Data collection|Collection of demographic data and vaccination history
40975184|NCT01730391|OTHER|CSF samples testing|CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
40975185|NCT05821114|OTHER|Head elevation_H|High flow_Head-elevation
41459312|NCT00325182|OTHER|Historical controls|
41459313|NCT01876758|BEHAVIORAL|Cognitive Intervention: Memory Training|Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
40975186|NCT05821114|OTHER|Supine_H|High flow_Supine
40975187|NCT05821114|OTHER|Head elevation_L|Low flow_head elevation
40975188|NCT05821114|OTHER|Supine_L|Low flow_supine
41299947|NCT03125746|DRUG|LXI-15029|The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
40771237|NCT04118764|DRUG|Definity|Definity microbubbles (10 μl/kg) will be used in conjunction with the ultrasound transducer to temporarily open the blood brain barrier.
40771238|NCT04118764|OTHER|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|MRI scans will be completed at baseline and immediately after the focused ultrasound treatment to confirm BBB opening and safety. A follow-up MRI will be performed three days after treatment to confirm BBB closure, only in the case of successful BBB opening.
41459314|NCT01876758|BEHAVIORAL|Comparable general mental stimulation|Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
40771239|NCT04118764|OTHER|Positron Emission Tomography (PET)|A follow-up PET scan will be performed three days after treatment to determine amyloid plaque load.
41459315|NCT00176943|DRUG|Aldara Cream 5%|
41299948|NCT03125746|DRUG|LXI-15029+Exemestane|The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
41299949|NCT06472258|DRUG|IV Artesunate|IV artesunate with a weight-appropriate dosage at 0, 12, 24, and 48 hours and continued 12-hourly for a maximum duration of seven days, with each dose diluted in normal saline and given as an infusion.
41459316|NCT01459757|OTHER|non-interventional|Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
41459317|NCT05005637|DRUG|Anti Tuberculosis Drug|ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 4RH (4 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.
41459318|NCT05005637|DRUG|Prednisone tablet|Oral prednisone will be given at the dose of 1 mg/kgBW/day (max 60 mg/day) until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
41459319|NCT03241186|DRUG|Ipilimumab|1mg/kg
41459320|NCT03241186|DRUG|Nivolumab|3mg/kg
41459321|NCT03241186|DRUG|Nivolumab|480mg
41459322|NCT06343688|OTHER|"Assessment of Balance and Lower Extremity Gross Motor Function with and without DAFO"|"Measurements will be conducted with the child's custom-made DAFO (Dynamic Ankle-Foot Orthosis) and barefoot."
40975189|NCT01384968|DIETARY_SUPPLEMENT|beetroot juice|170 mL beetroot juice (Beet It, James White drinks Ltd).
40975190|NCT03578159|OTHER|Chhatralaya|Chhatralaya, home for children provide living resources along with spiritual practices.
41299950|NCT06472258|DRUG|IV Quinine Hydrochloride|IV Quinine hydrochloride in accordance to weight with loading dose 20mg salt/kg in 10% dextrose infusion followed by 10mg salt/kg infusion 8 hourly for 2 days and for 12 hourly onwards for a maximum of 7 days.
41299951|NCT03555539|DRUG|Danicopan|Oral tablet.
41299952|NCT02804802|OTHER|questionnaire|dietary habits and physical activity questionnaire
41459323|NCT02573285|PROCEDURE|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
41459324|NCT02573285|PROCEDURE|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
41459325|NCT00967148|DRUG|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
41459326|NCT03335241|DRUG|Fludarabine and Pegylated liposomal doxorubicin|"Fludarabine 25mg/m2 iv on days d1-d3 of each 4-week cycle~Pegylated liposomal doxorubicin 30mg/m2 iv every 4 weeks"
41459327|NCT03335241|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 iv every 4 weeks
40771240|NCT04118764|OTHER|Amyvid|To be used during the PET scan to determine uptake of Amyvid within the treated area.
40771241|NCT05466383|BEHAVIORAL|Exercise|Exercise rehabilitation with Schroth method
40771242|NCT05466383|DEVICE|Brace|Wear an orthopedic brace
40975191|NCT02385045|DEVICE|i-scan|i-scan function is located on the head of the Pentax endoscopes
40975192|NCT02385045|DEVICE|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
40975193|NCT05678894|OTHER|Scanner and EOS imaging|Cross-sectional imaging and 3D reconstruction to measure and compare acetabular anteversion in 4 functional pelvic positions.
40975194|NCT01050426|OTHER|UFT, Leucovorin|UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
40975195|NCT01050426|OTHER|UFT/ Leucovorin + Cetuximab + Radiotherapy|UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
40975196|NCT03157778|OTHER|Obese men|Biological measures before, just before, and after lunch, in obese men
41459328|NCT05937724|OTHER|Family Caregiving|Family caregiving and sibling inclusive
41459329|NCT02310841|DEVICE|ANGELAA|Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
41459330|NCT01728987|DRUG|cholecalciferol|as in arm description
41459331|NCT01728987|DRUG|placebo|capsule looking identical to the cholecalciferol capsule
41459332|NCT03634735|DRUG|Thiamine|Vitamine B1
41299953|NCT05937854|DRUG|Tadalafil|one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
40771243|NCT04838288|DRUG|Change from Prograf to Envarsus XR|Change from Tacrolimus taken twice a day to Envarsus XR taken once a day
41299954|NCT05937854|DRUG|Placebo|one or two encapsulated tablets of placebo po QD
41299955|NCT02601885|DRUG|ABT-555|Intravenous Infusion
41299956|NCT02601885|OTHER|Placebo|Intravenous Infusion
41299957|NCT00540969|PROCEDURE|cryosurgery|Patients undergo cryosurgery using guidance from CT scan or ultrasound
41299958|NCT00540969|RADIATION|radiation therapy|Patients undergo radiotherapy for 1 week
41299959|NCT01060735|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
41299960|NCT03580577|DEVICE|thromboelastography|thromboelastography will assess all coagulation abnormalities including platelets function in cirrhotic group with venous thromboembolism , and guide us about is there increased thrombosis risk or not, for that a fresh blood sample will be withdrawn from each patient before starting any treatment
41299961|NCT01629667|BIOLOGICAL|Tralokinumab|Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
41299962|NCT01629667|BIOLOGICAL|Tralokinumab|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
41299963|NCT01629667|OTHER|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
41299964|NCT06300762|DEVICE|Superabsorbent dressing application|Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate
41299965|NCT04498533|OTHER|forearm strap (counterforce brace)|
41299966|NCT04498533|OTHER|Kinesio tape application|
41299967|NCT02120651|PROCEDURE|Fibrin monomer|Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
41299968|NCT02120651|PROCEDURE|Hemostatic sponge|Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
41299969|NCT02065947|PROCEDURE|paravertebral block|catheter with 3-level-injection
41140459|NCT03925909|DIETARY_SUPPLEMENT|Eriocitrin|The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
41299970|NCT02065947|DRUG|fentanyl, propofol, atracurium|endotracheal intubation
41459333|NCT03634735|OTHER|Placebo|Placebo tablets
41459334|NCT00002116|DRUG|Cidofovir|
40771244|NCT06447103|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40771245|NCT06447103|PROCEDURE|Bone Scan|Undergo bone scan
40771246|NCT06447103|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, and CT of the brain
40771247|NCT06447103|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI of the brain
40771248|NCT06447103|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40771249|NCT06447103|OTHER|Questionnaire Administration|Ancillary studies
40771250|NCT06447103|DRUG|Zirconium Zr 89 Girentuximab|Given IV
40771251|NCT05587127|BEHAVIORAL|Cognitive Behavioral Therapy|Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.
40771252|NCT04466007|DRUG|High dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
41140460|NCT03720249|DIETARY_SUPPLEMENT|supplementation of compound nutrients|Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc per day orally for 12 weeks.
41140461|NCT03720249|DIETARY_SUPPLEMENT|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of supplement.
41140462|NCT06012786|DIAGNOSTIC_TEST|Diagnostic Criteria of Myofascial Pain Syndrome|"Major criteria:~1. The patient's complaint of regional pain~2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point~3. Presence of palpable taut band~4. Presence of palpable and tender points along the length of the taut band~5. Restriction of ROM in the area of the affected muscle~Minor criteria:~1. Pain/sensory change with pressure palpation of the trigger point~2. Local twitch response with palpation/injection of the trigger point in the taut band~3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis"
41299971|NCT02065947|DRUG|lidocaine , adrenaline, ketamine bolus, midazolam|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
41299972|NCT02065947|DEVICE|catheter with 3-level-injection|
41299973|NCT02065947|DRUG|sevoflurane and 50% oxygen in air|
41299974|NCT00266110|BIOLOGICAL|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
41299975|NCT00266110|BIOLOGICAL|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
41459335|NCT01157598|DEVICE|bispectral index monitoring|parameter monitoring of bispectral index
41459336|NCT00881426|DRUG|Cefprozil 500 mg Tablets (Sandoz GmbH)|
41459337|NCT00881426|DRUG|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
41459338|NCT00003725|DRUG|valrubicin|
41459339|NCT00003725|PROCEDURE|conventional surgery|
41459340|NCT01954901|DEVICE|Hyperbaric oxygen therapy|
41459341|NCT01954901|DEVICE|Hyperbaric room air|
40771253|NCT04466007|DRUG|Low dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
40771254|NCT04466007|DRUG|Placebos|0,9% physiological saline
41299976|NCT00266110|BIOLOGICAL|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
41299977|NCT00266110|DRUG|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
41459342|NCT01415245|DEVICE|Fluent (VGS Fluent external support device)|Fluent external support device applied to saphenous vein graft
41459343|NCT03671343|BEHAVIORAL|Physical rehabilitation|It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.
40771255|NCT05600517|OTHER|Fluoride|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
40771256|NCT02866747|RADIATION|Hypofractionated stereotactic radiation therapy|
40771257|NCT02866747|DRUG|Durvalumab|
41299978|NCT02743403|DEVICE|Neurodyn Portable activeTENS, IBRAMED®|Randomization and secret Allocation active TENS (GI / n = 27)
41299979|NCT02743403|DEVICE|Neurodyn Portable placeboTENS, IBRAMED®|Randomization and secret Allocation placebo TENS (GII / n = 27)
40771258|NCT02444247|OTHER|High Dose Exercise (300 kcal)|Subjects will participate in 3 physical activity sessions per week expending 300 kcal per session and rate their liking of exercise.
40771259|NCT02444247|OTHER|Low Dose Exercise (150 kcal)|Subjects will participate in 3 physical activity sessions per week expending 150 kcal per session and rate their liking of exercise.
40771260|NCT02444247|OTHER|No Exercise (0 kcal)|Subjects will participate in 3 sessions per week expending 0 kcal per session and rate their liking of exercise.
40771261|NCT02444247|OTHER|Sedentary Option|Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.
40771262|NCT00835367|DRUG|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
40975197|NCT03157778|OTHER|Normal-weight men|Biological measures before, just before, and after lunch, in normal-weight men.
40975198|NCT00715078|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
40975199|NCT03763591|BEHAVIORAL|Trauma Systems Therapy for Refugees Group Intervention|Psychological skills group for youth of refugee and immigrant backgrounds.
41299980|NCT02743403|DEVICE|Carboxyderm S20-1C|Randomization and secret Allocation control group (CG / n = 27).
41299981|NCT01481571|DEVICE|Vitrification medium oocyte, warming medium oocyte and Rapid-i|Media and device for vitrification of human oocytes
41299982|NCT00252486|DRUG|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
41299983|NCT00461266|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
41459344|NCT01663467|DRUG|Ginkgo biloba|Ginexin-F 80mg tablet will be given twice a day for 6 months.
41459345|NCT01663467|BEHAVIORAL|modified TRT|"modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
41459346|NCT00427154|DRUG|rosiglitazone|Tablets, 4 mg once or twice daily.
41459347|NCT00427154|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
41459348|NCT00427154|DRUG|metformin|Tablets, 2000 mg/day.
40771263|NCT00835367|DRUG|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
40771264|NCT01220583|DRUG|cisplatin|Given IV
40975200|NCT04325581|DRUG|Liraglutide 6 MG/ML|Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily
41299984|NCT00461266|DRUG|Antiretroviral therapy|As prescribed
41299985|NCT01032512|DIETARY_SUPPLEMENT|SUPPORTAN + GLUTAMINE PLUS|600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
41299986|NCT01032512|DIETARY_SUPPLEMENT|NO PREOPERATIVE NUTRITION SUPPORT|Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
41299987|NCT00744146|BIOLOGICAL|Protexia|Single 50 mg IM dose
41299988|NCT00744146|BIOLOGICAL|Protexia|Single 100 mg dose
41459349|NCT00427154|DRUG|glimepiride|Tablets, 8 mg/day.
41459350|NCT01792453|OTHER|Spring water|
40771265|NCT01220583|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
40771266|NCT01220583|RADIATION|intensity-modulated radiation therapy|Undergo radiotherapy
40771267|NCT04682847|DRUG|Ferumoxytol injection|This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
40771268|NCT05583955|DRUG|NOE-105|Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained
40771269|NCT05583955|DRUG|Placebo|Escalating dose levels of matching Placebo will be given
40975201|NCT04325581|DRUG|Placebos|Normal Saline SC daily
40975202|NCT06347614|PROCEDURE|Two-step Radical Prostatectomy|The first step was the enucleation of the hyperplastic adenoma, followed by the anterograde radical prostatectomy of residual tissue
41459351|NCT00897676|DRUG|Exendin-(9-39)|100-500pmol/kg/min
41459352|NCT00897676|DRUG|placebo|placebo (0.9% NaCl)
40975203|NCT00779467|DRUG|Neostigmine|utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
41459353|NCT04850027|PROCEDURE|TME+Lateral lymph node dissection.|TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.
40975204|NCT00779467|DRUG|Bupivacaine|
40975205|NCT00779467|DRUG|fentanyl|fentanyl 2 mcg/ml
40975206|NCT06072170|DRUG|Kratom|Single administration thirty minutes after the start of a high-fat breakfast
40975207|NCT06072170|DRUG|Placebo|Single administration thirty minutes after the start of a high-fat breakfast
40975208|NCT06048445|DEVICE|intraoperative plancement of Biliary Drainage Stent|plancement of Biliary Drainage Stent in liver transplantation of pediatric patients
40975209|NCT04353076|OTHER|Simulated heatwave exposure|Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.
40975210|NCT04353076|OTHER|Simulated heatwave exposure with mid-day cooling|Older adults (cooling) are exposed to a 9-hour simulated exposure with mid-day ambient cooling.
40975211|NCT05196165|OTHER|No Intervention|No investigational product (IP) will be administered in this study
40975212|NCT00001598|DRUG|Dehydroepiandrosterone|
40975213|NCT05157984|PROCEDURE|ZPOEM|Zenker's diverticulum management by Per oral endoscopic myotomy (POEM)
40975214|NCT03374878|OTHER|no oral contraceptive and training|10 weeks of training in a group of oral contraceptive users
40975215|NCT03374878|OTHER|oral contraceptive and training|10 weeks of training in a group of users of oral contraceptives
40975216|NCT05877781|DIETARY_SUPPLEMENT|Palmitoylethanolamide|8-week treatment 3x400 mg per day
40975217|NCT02421276|OTHER|Phlebotomy|White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
40975218|NCT04542772|OTHER|Mirror Therapy|Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.
40975219|NCT04542772|OTHER|Regular Rehabilitation|Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
40975220|NCT05798429|OTHER|compassion education|6 weeks of compassion training
40975221|NCT04797793|DRUG|Adapalene Gel 0.1%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
41140463|NCT06012786|DIAGNOSTIC_TEST|The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer|Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
41140464|NCT06012786|DIAGNOSTIC_TEST|Hand Grip Test|The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately.
41140465|NCT06012786|DIAGNOSTIC_TEST|VAS|Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
41140466|NCT06012786|DIAGNOSTIC_TEST|Quick DASH|The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
41140467|NCT06012786|DIAGNOSTIC_TEST|Lymqol-Arm|Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.
41140468|NCT06012786|DIAGNOSTIC_TEST|Range of Motion of Shoulde Joint|Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
41299989|NCT00744146|BIOLOGICAL|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
41299990|NCT00744146|BIOLOGICAL|Protexia|Single 500 mg dose, IM
40975222|NCT04797793|DRUG|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
41299991|NCT00744146|BIOLOGICAL|Protexia|Single 750 mg dose, IM
41299992|NCT01950936|OTHER|Discontinuation of Antibiotcs|Discontinuation of Antibiotcs against lower respiratory tract infections
41299993|NCT04229550|BEHAVIORAL|Festival participation|One week's participation in Roskilde Festival 2016 or living a normal daily life.
41459354|NCT01278641|BEHAVIORAL|Graded strength resistance training program|Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
41459355|NCT01278641|BEHAVIORAL|Temperate pool exercise program|Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
40975223|NCT04797793|DRUG|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
40975224|NCT06367790|OTHER|Experimental group|"The athletes included in the experimental group will undergo an intervention using a plyometric exercise protocol, 2 days a week, and dry needling of the gastrocnemius muscles will be applied in a weekly session.~To perform the dry needling intervention, 0.3x50mm disposable steel needles will be used, applying the quick in-and-out technique. To do this, first of all, the intervention area will be cleaned with alcohol and sterile gloves will be used to perform the manoeuvre in complete safety. The active or latent trigger point is then located within the taut band by inserting the needle deeper and deeper, and then moving the needle up and down in search of a local contraction response. A maximum of 8 insertions or up to the athlete's tolerance limit will be applied."
40975225|NCT06367790|OTHER|Control group|The athletes included in the control group will perform an intervention using a plyometric exercise protocol, 2 days a week, under the same conditions as the experimental group.
40975226|NCT02829515|PROCEDURE|tonsil surgery with or without concomitant adenoidectomy|tonsillectomy, tonsillectomy with adenoidectomy, tonsillotomy, tonsillectomy with adenoidectomy
40975227|NCT03684811|DRUG|FT-2102|FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
41140469|NCT00332852|DRUG|Letrozole|2.5 mg/day - oraly
41140470|NCT05852197|DRUG|anticoagulant or antiplatelet drugs|combination of anticoagulant or antiplatelet drugs
41140471|NCT02407899|DRUG|Saxagliptin|Take saxagliptin tablet 5mg p.o. qd. for 104 weeks after randomization.
41140472|NCT02407899|DRUG|Vitamin D3|Take vitamin D drops 2000 IU p.o. qd. for 104 weeks after randomization.
41140473|NCT02407899|DRUG|Insulin|For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
41140474|NCT02407899|DRUG|Metformin|Take Metformin tablet 1.5g p.o. per day for 104 weeks (adjust the dose between 1-1.7g per day according to subject's specific situation) before or after randomization.
41140475|NCT03277456|BIOLOGICAL|MVA-NP+M1|Intramuscular injection of novel vaccine
41140476|NCT05304676|OTHER|Experimental: KTT group|This group will receive neurodevelopmental treatment along with kinesotape and neuromuscular electrical stimulation
41140477|NCT05304676|OTHER|Active Comparator: conventional treatment|Group B will receive neurodevelopment treatment along with neuromuscular electrical stimulation.
41140478|NCT02315014|OTHER|whey protein|whey protein.
41140479|NCT02315014|OTHER|placebo|placebo.
41140480|NCT01702103|DRUG|Mometasone furoate|
41140481|NCT04859062|DRUG|lidocaine gel 2%|assessing its efficacy in decreasing muscle traction pain,In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In the experimental group, we applied lidocaine gel 2% abundantly below both eyelids of the surgical eye for at least 3 minutes before the surgical incision, while nothing was applied to patients in the control group.
41140482|NCT04859062|OTHER|control group|In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In control group, we didn't apply lidocaine gel 2% to the operative eye .
41140483|NCT03326037|GENETIC|Genotyping of the NPHS2 variant rs61747728|Genotyping of the NPHS2 variant rs61747728 will be performed by Real-time TaqMan Allelic Discrimination Assay (Life technologies, CA, USA) according to standard manufacturer protocols. Allelic discrimination analysis will be performed and analyzed using ABI 7500 Fast Real-time PCR system SDS software (Life technologies, CA, USA)
41140484|NCT02875730|PROCEDURE|Pulse Sequence|Cylindrical Navigator Preparatory Pulse Sequence
41140485|NCT02875730|PROCEDURE|CMRI|Cardiac Magnetic Resonance Imaging
41140486|NCT05185089|DRUG|Orvepitant Maleate|Orvepitant tablets 30mg or 10mg
41140487|NCT05185089|DRUG|Placebo|Placebo tablets to match orvepitant 30mg and 10mg tablets
41140488|NCT05983939|DRUG|PIPE-791|Single and multiple ascending oral doses of PIPE-791 tablets.
41140489|NCT05983939|DRUG|Placebo|Single and multiple ascending oral doses of matching placebo tablets.
41140490|NCT05672485|DIAGNOSTIC_TEST|SPECT/CT imaging with 99mTc-P137 nuclide probe|inject the tracer 99mTc-P137 to subjects and perform SPECT/CT scans
41140491|NCT00505024|BEHAVIORAL|Interactive Voice Response System|Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.
41140492|NCT00505024|OTHER|Symptoms Report|A report of severe symptoms will be sent to your doctor or nurse.
41140493|NCT06223698|DRUG|Letrozole|Letrozole 2.5 mg daily
41140494|NCT06223698|DRUG|Anastrozole|Anastrozole 1 mg daily
41140495|NCT06223698|DRUG|Exemestane|Exemestane 25 mg daily
41140496|NCT06223698|DRUG|Tamoxifen|Tamoxifen 20 mg daily
41140497|NCT03368274|DRUG|T 614|Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.
41299995|NCT04478292|DRUG|Sodium Thiosulfate Injection|Weight ≥ 10 kg: 20 g/m2/dose STS or Weight 5-10 kg: 15 g/m2/dose STS or Weight \< 5 kg: 10 g/m2/dose STS will be administered by IV over 2 hours beginning 6 hours after the completion of each cisplatin infusion.
41299996|NCT04478292|PROCEDURE|Primary surgery resection|Resection of the primary tumor up-front
40771270|NCT04109300|GENETIC|HLADQA1*05A>G screening|DNA will be extracted from whole blood collected from subjects in both arms using the MagNA Pure Compact instrument (Roche, Laval, Quebec, Canada). A custom TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) will be used to determine the presence of wild-type and/or variant alleles in the class II HLA gene region at rs2097432 mapped to the HLA-DQA1\*05 region in infliximab-exposed IBD subjects. Genetic data will be used to determine whether or not one of methotrexate or azathioprine should be applied to the patient in the experimental arm.
41299997|NCT04478292|DRUG|mono CDDP-Group A2|Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).
40771271|NCT04109300|OTHER|Standard of Care|The treating physician will use clinical judgement to determine need for the addition of one of methotrexate or azathioprine to infliximab therapy.
41299998|NCT04478292|DRUG|Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C|All the patients in Group C (2 arms) will receive 6 cycles chemotherapy in total. Cisplatin 100 mg/m2/dose Day 1; 5-Fluorouracil 600 mg/m2/dose Day 1; Vincristine 1.5 mg/m2/dose Day 1,8 and 15; Doxorubicin 30 mg/m2/dose Day 1 and 2; (Dexrazoxane : 300 mg/m2/dose Day 1 and 2, where is available)
41299999|NCT04478292|PROCEDURE|Biopsy|Tumors are deemed unresectable at diagnosis.
41300000|NCT04478292|PROCEDURE|Resection or transplant|Ideal timing to resect of the primary tumors or transplant if if excellent response achieved at 1st or 2nd evaluation timepoint. But surgery timing is not mandated. Irrespective of the timing of surgery, patients should complete all planned protocol cycles of chemotherapy (including post transplantation). If surgical resection of the primary tumor is delayed until the end of therapy, no further post-operative chemotherapy should be given.
41300001|NCT04478292|PROCEDURE|Resection of pulmonary nodules|Resection of pulmonary nodules should be considered in Group D2, patients at any cycle if continuing to respond to consolidation therapy.
41300002|NCT04478292|DRUG|mono CDDP- Group B|Cisplatin 80 mg/m2/dose Day 1. All patients in Group B (2 arms) will receive 6 cycles of mono cisplatin chemotherapy. Each cycle lasts 2 weeks (14 days).
40771272|NCT04696029|DRUG|Difluoromethylornithine|"DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C)."
40771273|NCT06563076|OTHER|Vestibular Rehabilitation|supervised vestibular rehabilitation program
40771274|NCT06563076|OTHER|Vestibular Electrical Stimulation|80 Hz high frequency transcutaneous vestibular electrical stimulation (VES)
40771275|NCT02711098|BIOLOGICAL|"Inflammatory biomarkers dosage Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
40771276|NCT02711098|BIOLOGICAL|"Inflammatory biomarkers dosage Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
41459356|NCT06167850|PROCEDURE|Copenhagen plank|Performing Copenhagen adduction as prevention for adductor injury.
40771277|NCT06145646|DEVICE|Muscle warm-up|Passive heating of the vastus lateralis of the right quadriceps will be performed using a microwave device. The device will be set at a power of 150 W and a distance of 10-15 cm from the skin surface for 20 minutes with the purpose of increasing local muscle temperature to 40 ºC.
41140498|NCT02636114|PROCEDURE|scaling and root planing|Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
41459357|NCT01923311|DRUG|EVG|Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
41459358|NCT01923311|DRUG|Background regimen|Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
40771278|NCT05465304|DRUG|Azithromycin|The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
40771279|NCT01731145|DEVICE|SNUMAP|Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
40975228|NCT03684811|DRUG|Azacitidine|Azacitidine will be administered per the site's standard of care.
41140499|NCT01294644|DRUG|Deoxycholic acid injection|
41140500|NCT01294644|DRUG|Placebo|Phosphate buffered saline placebo for injection
41140501|NCT01868061|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
41140502|NCT01868061|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
41140503|NCT00864188|DIETARY_SUPPLEMENT|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
40975229|NCT03684811|BIOLOGICAL|Nivolumab|Nivolumab will be administered per the site's standard of care.
40975230|NCT03684811|DRUG|Gemcitabine and Cisplatin|Gemcitabine and cisplatin will be administered per the site's standard of care.
40975231|NCT04141878|BEHAVIORAL|Aerobic Exercise|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise may vary, but will primarily focus on walking tutorials.
40975232|NCT04141878|BEHAVIORAL|Diet Skills|Participants will attend weekly classes focused on incorporating heart healthy foods into their existing diets. Calories will be restricted, and portion control will be taught with the goal of losing body weight. Hands-on skills will be taught for preparing healthy home-cooked meals by professional chefs.
40975233|NCT03915496|DRUG|PF-04965842 200 mg|PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
41300003|NCT04478292|DRUG|Block 1 to 3 (Cisplatin, Doxorubicin) Group D|Block 1 and 2: Cisplatin 70 mg/m2/dose Day1, 8 and 15; Doxorubicin 30 mg/m2/dose, Day 8 and 9; (Dexrazoxane: 300 mg/m2/dose Day 1 and 2, where is available); Block 3: Cisplatin 70 mg/m2/dose Day1and 8; Doxorubicin 30 mg/m2/dose Day 8 and 9; (Dexrazoxane BSA ≥ 0.6 m2/dose: 300 mg/m2/dose Day 8 and 9, where is available) All patients in Group D will receive 3 blocks in induction, followed by consolidation therapy. Block 1 and 2 last 28 days. Block 3 is 21 cycles.
41300004|NCT04478292|DRUG|Consolidation (Carboplatin, Doxorubicin) -Group D1|Following Block 1-3 of induction therapy, Group D1 patients will receive 3 cycles of Carboplatin + Doxorubicin consolidation therapy. Each cycle lasts 3 weeks (21 days). Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).
41300005|NCT04478292|DRUG|Consolidation (Carboplatin +Doxorubicin/Vincristine + Irinotecan)-Group D2|"Following Block 1-3 of induction therapy, patients in Group D2, will receive 6 cycles of consolidation chemotherapy with Carboplatin + Doxorubicin in Cycles 1, 3, and 5 alternating with Vincristine + irinotecan in Cycles 2, 4, and 6. One cycle of therapy lasts 3 weeks (21 days). Cycle 1, 3 and 5: Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).~Cycle 2, 4 and 6: Vincristine 1.5 mg/m2/dose, Day 1 and 8; Irinotecan 50 mg/m2/dose, Day 1 to 5;"
41300006|NCT05495074|OTHER|ATP III dietary intervention|The dietary intervention will consist of an approximate decrease of 500 kcal from the calories participants habitually consume, with the following macronutrient distribution 15-20% protein, 50-60% carbohydrates, 25-35% fat. Participants will receive recipes with menus for two weeks.
41300007|NCT00011765|DRUG|Fluoxetine|
41300008|NCT02021500|DRUG|ABI-007|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
41300009|NCT02145299|DEVICE|TruePath CTO Device|"The TruePath CTO Device is composed of a 0.018 guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions."
41300010|NCT02145299|DEVICE|CROSSER CTO Device|
41300011|NCT05925816|BEHAVIORAL|Video|Video uses BA techniques for approximately 5 minutes
41300012|NCT05925816|BEHAVIORAL|Active game|Game provides positive feedback in response to decisions made by participants
41140504|NCT00864188|DIETARY_SUPPLEMENT|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
40975234|NCT03915496|DRUG|PF-04965842 100 mg|PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
40975235|NCT03915496|DRUG|Placebo|Placebo administered as two tablets to be taken orally once daily for 12 weeks
40975236|NCT01606514|BEHAVIORAL|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
41140505|NCT00864188|DIETARY_SUPPLEMENT|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
41140506|NCT00864188|DIETARY_SUPPLEMENT|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
41300013|NCT05925816|BEHAVIORAL|Neutral game|Game without feedback
41300014|NCT01492647|DRUG|JNJ 10229570-AAA 1.2%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
41459359|NCT01169038|DRUG|levaquin; ethambutol; rifampin and azithromycin.|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~\*\*Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. \*\*We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
41140507|NCT03064256|BEHAVIORAL|Physical training program|Physical training program consisted of three weekly sessions lasting up to one hour over a period of twelve weeks. and will be carried out respecting the traditional training principles: biological individuality, Specificity, overload, adaptation and reversibility
41459360|NCT01967901|BEHAVIORAL|Self-care management program|The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
41459361|NCT05687448|DRUG|Apixaban 5 MG Oral Tablet|Patients treated with apixaban 5 mg twice daily (BID)
41459362|NCT05687448|DRUG|warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)|Patients treated with warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)
41459363|NCT03898908|DRUG|encorafenib|"Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.~If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death."
41459364|NCT03898908|DRUG|binimetinib|Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.
41459365|NCT03898908|RADIATION|Whole brain radiation therapy|"The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.~Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks."
41459366|NCT03898908|RADIATION|Radiosurgery/stereotactic radiosurgery|"Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.~Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.~For GTV \> 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week."
41459367|NCT06533215|OTHER|antimicrobial efficacy of nano based intracanal medications on Enterococcus faecalis count reduction in secondary endodontic infection cases.|"The paper points of three samples (S1, S2, and S3) will be placed each in a sterile falcon tube containing 1ml of brain heart infusion and labeled according to the type of intracanal medication used. Samples will be homogenized by the vortex and and one micron of each sample will be cultured on Bile Esculin Agar for E. faecalis.~The plate will be labeled as the tube of the same sample and incubated at 37οC for 24-48 h and then after incubation, the total numbers of E.faecalis will be counted and calculated to get the colony forming units (CFU/ml)."
41459368|NCT00377156|RADIATION|radiation therapy|Patients undergo radiation therapy 5 days a week for 2.5 weeks
41459369|NCT00377156|RADIATION|stereotactic radiosurgery|
40771280|NCT06149182|BEHAVIORAL|Life stress interview according to EAET|This interview has the aim to jointly explore potential emotional factors contributing to patients functional somatic symptoms. While exploring this, it has the aim to not only describe such potential patterns but also emotionally process them.
41140508|NCT03064256|BEHAVIORAL|Physical training program|All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise.
41140509|NCT03542604|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I involves identifying and replacing thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. There will be 6 intervention sessions over an 8-week period. The first two sessions are consecutive weekly in-person sessions followed by a rest week. The third session is conducted remotely by phone, followed by another rest week. The three remaining sessions are weekly and conducted remotely.
41459370|NCT00499473|DRUG|sunitinib malate|Given orally
41459371|NCT00499473|OTHER|pharmacological study|Correlative studies
41459372|NCT05419505|DRUG|CCH-aaes|Administered by subcutaneous injection.
41459373|NCT05419505|DRUG|Antifibrinolytic Agent|Self-administered by participants enrolled in Cohort 7.
40771281|NCT06149182|BEHAVIORAL|"Psychiatric interview according to region stockholm - basutredning"|This interview has the aim to gain enough information to diagnose some of the main psychiatric disorders
41459374|NCT00165516|DRUG|Cisplatin|Heated and given as an one-hour lavage of the chest and abdomen during surgery
41459375|NCT00165516|DRUG|Sodium Thiosulfate|After the one-hour lavage, sodium thiosulfate is given intravenously
41459376|NCT01457196|DIAGNOSTIC_TEST|Tumor Genetic Sequencing|This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
41459377|NCT05619822|BEHAVIORAL|TAU + A comprehensive third-generation intervention|This is a individual intervention with with a total of 12 sessions: Session 1. Constructing the Therapy Experience. Session 2. Life history and immediate reactions to trauma. Session 3. Preparing to deal with trauma. Session 4. Regulating emotions. Session 5-9. Focusing on retelling and processing the traumatic event (EMDR PHASES_PHASE 3: Evaluation of the traumatic memory. EMDR PHASE 4: Desensitization. EMDR PHASE 5: Positive Belief Installation. PHASE 6: Body Scan). Session 9. Re-evaluating traumatic memory and self-care through positive emotions. Session 10. Cultivating self-kindness. Session 11. Developing a healthy identity. Session 12. Building a better future
41459378|NCT05619822|BEHAVIORAL|TAU|Treatment as usual
41459379|NCT01552330|DRUG|Primaquine and Pyronaridine-artesunate|"Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets"
41459380|NCT01552330|DRUG|Primaquine and Pyronaridine-Artesunate|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets"
41459381|NCT02195544|DRUG|Synvisc®|
41459382|NCT00508898|DRUG|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
40771282|NCT05462704|DRUG|Ferric derisomaltose|Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.
41459383|NCT00508898|DRUG|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
41459384|NCT03022890|BEHAVIORAL|hatha yoga|12 weeks of hour-long gentle hatha yoga classes
41459385|NCT03022890|BEHAVIORAL|health education|12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
41459386|NCT04085744|DRUG|Lidocaine 10% Spray|lidocaine will be apply on the cuff
40771283|NCT05462704|DRUG|Ferrous sulfate|325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.
40771284|NCT06015009|OTHER|Symptom management mobile health application with personalised support|"Other: Symptom management mobile health application with personalised support Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
40771285|NCT06223152|OTHER|parental support|parental support
40771286|NCT05166902|DEVICE|Lens A (comfilcon A lens)|1 month
40771287|NCT05166902|DEVICE|Lens B (lehfilcon A lens)|1 month
40771288|NCT05645380|DRUG|Carboplatin|AUC=6, IV
40771289|NCT05645380|DRUG|Docetaxel|75 mg/m2, IV
41140510|NCT03542604|BEHAVIORAL|Sleep Education|EDU involves learning behavioral treatment information about sleep that is widely available to patients and practitioners. The program will parallel the CBT-I intervention in schedule, number, and length of sessions.
41140511|NCT00392197|DRUG|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
41140512|NCT00824850|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
41140513|NCT00824850|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
41140514|NCT05466786|OTHER|Standard Management|Standard Management
40771290|NCT05645380|DRUG|Doxorubicin|60 mg/m2, IV
40771291|NCT05645380|DRUG|Cyclophosphamide|600 mg/m2, IV
40771292|NCT05645380|DRUG|Pembrolizumab|200 mg, IV
41140515|NCT03455140|DRUG|PEG- BCT-100|PEGylated recombinant human arginase 1
41459387|NCT04085744|DRUG|Mometasone nasal spray|mometasone spray will be applied on the cuff
41459388|NCT00925873|DRUG|Active comparator (no fludarabine)|"1. Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).~2. The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm~3. Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)"
41459389|NCT00925873|DRUG|Experimental (fludarabine)|"The same regimen with addition of fludarabine in every treatment sequence~1. Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~2. Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~3. Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2."
41459390|NCT04386213|DEVICE|coronary artery in-stent restenosis|treat the petients with coronary artery in-stent restenosis
41459391|NCT01256060|DRUG|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
41459392|NCT01773239|BEHAVIORAL|TARA computer-based exercises|
41459393|NCT06334016|PROCEDURE|Biospecimen Collection|Undergo blood collection
41459394|NCT06334016|DRUG|Cannabis sativa Extract|Vape THC
41459395|NCT06334016|DRUG|Nicotine|Vape active nicotine
41459396|NCT06334016|DRUG|Placebo Administration|Vape placebo nicotine
41459397|NCT06334016|OTHER|Questionnaire Administration|Ancillary studies
41459398|NCT06263114|DIAGNOSTIC_TEST|TruGraf® Liver gene expression panel (GEP)|Test done on blood sample collected during for cause or routine liver biopsy
41459399|NCT02404558|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
41459400|NCT02404558|DRUG|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
41459401|NCT00108550|DRUG|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
41459402|NCT00108550|DRUG|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
41459403|NCT05546398|DRUG|Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab|No study drug was administered during this study.
41459404|NCT05546398|OTHER|No study drug|No study drug was administered during this study.
41459405|NCT02107469|DRUG|Sida cordifolia roots|Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
41459406|NCT02107469|DRUG|Phyllanthus niruri|Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
41459407|NCT02107469|DRUG|Sida cordifolia roots extract|gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
41459408|NCT02107469|DRUG|Phyllanthus niruri extract|gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
41459409|NCT02107469|OTHER|Sida cordifolia placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals
40771293|NCT00839930|DRUG|Cilostazol 50 mg Tablets|1 x 50 mg, single-dose fasting
40771294|NCT00839930|DRUG|Pletal®|1 x 50 mg, single-dose tablet
40771295|NCT00789711|DRUG|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
40771296|NCT00789711|DRUG|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
40771297|NCT06571539|DEVICE|AR-assisted EVD placement|Cfr. arm description
40975237|NCT04624568|DEVICE|PAPILOCARE|"Papilocare® is a self-administered vaginal gel. Its single-dose cannula contains hyaluronic acid and pre-biotics (Coriolus Versicolor) that would improve the re-epithelialization of the uterin cervix. By creating a protective film on the cervix, this gel could induce a favorable environment for regression of the cervical intraepithelial lesions 1 and for clearance of Human Papillomavirus.~The specific approach related to our study would be to apply Papilocare® vaginal gel for 6 months for the treated group.~Smear and HPV test will be perform by all patients at 6 and 12 months."
40975238|NCT05243862|DRUG|PolyPEPI1018|PolyPEPI1018 vaccine contains 6 synthetic peptides emulsified with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 tumor-specific antigens, which are the most frequently expressed antigens in colorectal cancer.
40975239|NCT05243862|DRUG|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
40975240|NCT00099853|DRUG|Vildagliptin|Vildagliptin 50 mg tablets
40975241|NCT00099853|DRUG|pioglitazone|pioglitazone 45 mg qd
40975242|NCT00099853|DRUG|Placebo|Vildagliptin matching placebo
40975243|NCT05236569|DRUG|Tranexamic acid injection|The tranexamic acid injection was given intradermally to the facial skin
40975244|NCT05236569|DRUG|Injection Water|The 0.9% normal saline injection was given intradermally to the facial skin
40975245|NCT03421392|OTHER|non interventional study|non interventional study
41459410|NCT02107469|OTHER|Phyllanthus niruri placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
41459411|NCT02505035|BEHAVIORAL|Default ordering of palliative consult|
41459412|NCT06361654|OTHER|The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer|"The measurements will be taken during different climbing sessions, after the warm-up.~The study will include measurements on different climbers. Informed consent and personal data will be collected from the climbers before the measurements are taken. The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer."
41459413|NCT03110380|DRUG|B/F/TAF|50/200/25 mg FDC tablet(s) administered orally once daily
41459414|NCT03110380|DRUG|F/TAF|200/25 mg FDC tablet(s) administered orally once daily
41459415|NCT03110380|DRUG|DTG|50 mg tablet(s) administered orally once daily
41459416|NCT03110380|DRUG|DTG Placebo|Tablet(s) administered orally once daily
40771298|NCT06571539|PROCEDURE|Freehand EVD placement|External ventricular drain (EVD) placement using the conventional freehand technique. This intervention covers the matched, non-concurrent control group, retrospectively obtained without active enrollment to receive study treatment.
40771299|NCT03018873|OTHER|remote ischemic preconditioning （RIPC）|once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
41140516|NCT02820506|PROCEDURE|SLN mapping and removal of PET-positive lymph nodes|Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes
41300015|NCT01492647|DRUG|JNJ 10229570-AAA 3.6%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
41300016|NCT01492647|DRUG|Color-matched vehicle containing 0 mg of JNJ 10229570-AAA|One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
41300017|NCT03251014|OTHER|YSS|Intervention providing steamed whole YSS (\~265 g/day, 3 days/week) for eight weeks
41300018|NCT03251014|OTHER|Salmon|Intervention providing steamed salmon fillet (\~246 g/day, 3 days/week) for eight weeks
41300019|NCT02545296|OTHER|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
41300020|NCT01266798|BEHAVIORAL|Portal|"The portal was tailored to improve the lay public's' healthy skepticism, or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.~1. A checklist for critical assessment of health information~2. Access to research databases for health information and an introduction to research methods and principles of science~3. A checklist to the consultation"
41300021|NCT04445467|DRUG|Favipiravir|Favipiravir
41300022|NCT00390364|DRUG|everolimus|
41300023|NCT00390364|PROCEDURE|antiangiogenesis therapy|
41300024|NCT00390364|PROCEDURE|biopsy|
41300025|NCT00390364|PROCEDURE|diagnostic procedure|
41300026|NCT00390364|PROCEDURE|gene expression analysis|
41300027|NCT00390364|PROCEDURE|immunohistochemistry staining method|
41140517|NCT05891002|DEVICE|Cirq® Robotic Alignment Module Cranial|Robotic navigation for cranial biopsy procedure
41300028|NCT00390364|PROCEDURE|laboratory biomarker analysis|
41300029|NCT00390364|PROCEDURE|mutation analysis|
41300030|NCT00390364|PROCEDURE|protein tyrosine kinase inhibitor therapy|
41300031|NCT00390364|PROCEDURE|reverse transcriptase-polymerase chain reaction|
41300032|NCT03274336|BEHAVIORAL|questionnaire|questionnaire post preanesthetic interview
41300033|NCT03274336|BEHAVIORAL|face-to-face interview|Group A = face-to-face interview
41300034|NCT03274336|BEHAVIORAL|brochure|after reading a brochure a face to face interview will take place
41300035|NCT03274336|BEHAVIORAL|movie|after seeing a film about the procedure a face-to-face interview will take place
40771300|NCT03682367|DRUG|Gabapentin|Use of Gabapentin peri- and post-operatively.
40771301|NCT03682367|DRUG|Placebo - Concentrate|Use of sugar-free Placebo peri- and post-operatively.
41300036|NCT01913210|DIETARY_SUPPLEMENT|Ginseng|
41300037|NCT03222479|BEHAVIORAL|Stress guide|smartphone-based application that can evaluate stress level and teach how to manage their stress
41300038|NCT04030052|DRUG|Nuwiq (low dose protocol)|After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
41300039|NCT04030052|DRUG|HEMLIBRA|Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
41300040|NCT04030052|DRUG|Nuwiq (Atlanta protocol)|After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
41300041|NCT00017316|DRUG|semaxanib|
41300042|NCT00017316|DRUG|thalidomide|
41300043|NCT04030481|OTHER|inhalation anesthesia|sevoflurane was used to maintain anesthesia
41300044|NCT04030481|OTHER|Total intravenous anesthesia|propofol was used to maintain anesthesia
41300045|NCT02261870|DEVICE|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
40771302|NCT00003053|DRUG|cisplatin|
41140518|NCT02439892|BEHAVIORAL|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
41300046|NCT05714020|OTHER|Real rTMS|Repetitive transcranial magnetic stimulation (rTMS) is applied to the primary motor cortex. The protocol consists of 15 minutes of 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses.
41300047|NCT05714020|OTHER|Sham rTMS|A sham coil is also used to mimic the clicking sound of the transcranial magnetic coil and skin stimulation.
41300048|NCT02519751|DIETARY_SUPPLEMENT|D3 Creatine|One dose of D3 Creatine (60mg capsule) given orally on Day 1
41300049|NCT02519751|DIETARY_SUPPLEMENT|Creatine|Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
41300050|NCT00243230|DRUG|Vicriviroc 30 mg|Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).
41300051|NCT00243230|DRUG|Vicriviroc 20 mg|Two tablets of vicriviroc 10 mg once daily for 48 weeks.
41300052|NCT00243230|DRUG|Placebo|Three tablets of placebo once daily for 48 weeks.
41300053|NCT00243230|DRUG|Placebo|Two tablets of placebo once daily for 48 weeks.
41300054|NCT00243230|DRUG|Background ART Regimen|"An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir."
41300055|NCT01879605|DRUG|Docusate natrium and sorbitol|
41300056|NCT01879605|DRUG|Bisacodyl|
41300057|NCT00073593|DRUG|Bivalirudin|250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of surgery with the option to increase or decrease the infusion in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT) \>300 seconds (s).
41300058|NCT00073593|DRUG|Heparin|: Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of \>300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
41300059|NCT00073593|DRUG|Protamine|Per institutional practice. Batches from hospital stock.
41300060|NCT03011840|OTHER|Information leaflet|Patient information leaflet with instructions to be carried out before procedure under general anesthesia
41300061|NCT05228912|DRUG|COVID-19 Vaccines|Each group will receive a complete scheme of the vaccine according to local government assignation
41300062|NCT05405296|DEVICE|Truenat™ MTB Plus/COVID-19|Truenat™ MTB Plus/COVID-19is a disposable, room temperature stable, chip-based Real Time duplex PCR test, along with freeze dried PCR reagents provided in microtube for performing Real Time PCR for infectious disease and runs on the Truelab® Real Time micro-PCR Analyzer.
41300063|NCT04710901|BEHAVIORAL|uTECH + YMHP|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention. In addition, participants in this arm will also receive the YMHP intervention, which provides a four-session, evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in the study."
41300064|NCT04710901|BEHAVIORAL|YMHP|YMHP intervention provides a four-session evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in this study. Months 3-12 are inactive.
41300065|NCT04710901|BEHAVIORAL|uTECH|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention."
41300066|NCT04484519|OTHER|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging
41300067|NCT05545813|DIETARY_SUPPLEMENT|Probiotic|Participants will be asked to take 1 capsule (3 billion CFU) daily for 8 weeks in the morning with their first meal.
41459417|NCT03110380|DRUG|F/TAF Placebo|Tablet(s) administered orally once daily
41459418|NCT03110380|DRUG|B/F/TAF Placebo|Tablet(s) administered orally once daily
40771303|NCT00003053|DRUG|etoposide|
41300068|NCT05545813|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take 1 capsule daily for 8 weeks in the morning with their first meal.
41459419|NCT05650151|DIETARY_SUPPLEMENT|Vitamin D|576 000 IU D 5-7 days prior to the surgery and 144 000 IU daily on post-operative day 1-2
41459420|NCT05650151|DIETARY_SUPPLEMENT|Placebo|An equal volume of medium chain triglyceride (MCT, as placebo) to vitamin D 5-7 days prior to the surgery and on the post-operative day 1-2.
41459421|NCT03271996|PROCEDURE|Primary closure|Asymmetric skin incision and total excision of the lesion with monopolar scalpel. Accurate hemostasis, creation of a cutaneous-subcutaneous flap, primary closure with non-absorbable sutures, optional aspiration drainage.
41459422|NCT03271996|PROCEDURE|Fistulectomy|Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
41459423|NCT01928615|DRUG|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
41459424|NCT01928615|DRUG|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
41459425|NCT01928615|DRUG|Chemotherapy|Standard chemotherapy for early breast cancer.
41459426|NCT00504634|DRUG|Bortezomib|1 mg/m\^2 IV On Days 1, 4, 8, and 11.
41459427|NCT02296957|PROCEDURE|Hypnosedative discontinuation|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
41459428|NCT03624777|BEHAVIORAL|Outdoor Fall prevention brochure|Participants in the wait list control group will initially receive written information only about preventing outdoor falls
41459429|NCT03624777|BEHAVIORAL|Stroll Safe outdoor fall prevention program|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/ problem solving, practice in strategy use, and action planning for safe community mobility.
41459430|NCT00645944|DRUG|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
40771304|NCT00003053|PROCEDURE|adjuvant therapy|
40771305|NCT04408885|OTHER|Rehabilitation|Non-surgical interventions to patients with an Anterior cruciate ligament injury. Rehabilitation regime is the regime provided by the physician at the rehabilitation clinic.
41300069|NCT05122663|BEHAVIORAL|Vestibular Rehabilitation|Vestibular Rehabilitation refers to the specific interventions that physical therapists provide to patients with dizziness and vertigo symptoms. These interventions can involve repositioning maneuvers, habituation exercises, gaze stabilization, and/or balance training exercises, depending on the specific etiology of dizziness and vertigo per an established clinical protocol utilizing a patient's history and exam findings. Physical therapists instruct patients in how to perform these exercises at home and provide instructions and referral for patients to follow-up with an outpatient physical therapist for further care.
40771306|NCT04252079|PROCEDURE|Endovascular Repair of Juxtarenal Aortic Aneurysm|"1. History taking and clinical examination.~2. Preoperative Imaging~   CTA is the cross-sectional imaging modality of choice.~3. Preoperative evaluation~   a-Renal evaluation~   b_ cardiac evaluation C-Pulmonary evaluation~4. Surgical techniques~   1. Anesthesia The use of general anesthesia due to the duration of the procedures and the necessity to control patient breathing to allow precise imaging and accurate device deployment.~  2. Intra operative imaging A hybrid operating room with high-quality fixed imaging is needed for the performance of FEVAR.~C-Device delivery and deployment all FEVAR procedures begin with access of the femoral arteries by either open or percutaneous technique."
41459431|NCT00645944|DRUG|Placebo|"Placebo or inactive substance (sugar pill)taken each night for all weeks of the study"
41459432|NCT02297087|GENETIC|Standard of care based on target(s) identified via GWS.|
40771307|NCT00863304|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
40771308|NCT00863304|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
40771309|NCT00863304|DRUG|naproxen|naproxen 1000 mg daily for 16 weeks
40771310|NCT00863304|OTHER|placebo|placebo to match tanezumab and naproxen dosing
40771311|NCT04164901|DRUG|Vorasidenib|Vorasidenib oral film-coated tablets
40771312|NCT04164901|DRUG|Matching Placebo|Matching Placebo oral tablets
41459433|NCT01104181|DEVICE|HC2 collection kit with a swab or brush|We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
40771313|NCT06565182|OTHER|Exercise|The intervention consists of two different types of moderate intensity exercise: Continuous aerobic and resistance exercise.
40771314|NCT03781479|DRUG|Amifampridine Phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
40771315|NCT03781479|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
40771316|NCT06378840|RADIATION|Nab-paclitaxel/Platinum, Sintilimab|Sintilimab Combined With Concurrent Nab-paclitaxel/Platinum-based Chemoradiotherapy
40771317|NCT04432623|DRUG|Benserazide Only Product|Investigational drug
41300070|NCT05122663|OTHER|Usual Care|Usual Care refers to any combination of diagnostic testing, medications, and patient education or counseling provided by a patient's treating ED physician.
41300071|NCT04795804|DIETARY_SUPPLEMENT|Human Milk Oligossaccharide|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
41300072|NCT04795804|DIETARY_SUPPLEMENT|Maltodextrin|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
41300073|NCT04795804|DIETARY_SUPPLEMENT|Human Milk Oligossaccharide and resistant starch|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
41300074|NCT00641043|DRUG|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
41300075|NCT00641043|DRUG|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
41300076|NCT04082767|DRUG|Precedex|Precedex, dexmedetomidine hydrochloride, IV, 4mcg/mL, infusion duration determined by the clinical care team
41300077|NCT04082767|DRUG|Midazolam|Midazolam, IV, 5mg/mL (for patients more than 10kg), 1mg/mL (for patients 2-10kg), infusion duration determined by the clinical care team
41300078|NCT00935857|DEVICE|Single Balloon Colonoscopy|Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
41300079|NCT00935857|DEVICE|Standard Colonoscopy|Use of the standard adult colonoscope to complete colonoscopy.
41300080|NCT05152160|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell Therapy|Umbilical Cord Mesenchymal Stem Cell Therapy
41300081|NCT02329795|RADIATION|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
41300082|NCT02329795|DRUG|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
40975246|NCT04606173|OTHER|Team Education for Adopting Changes in Healthcare (TEACH)|TEACH, an educational strategy which includes evidence-based strategies to improve task-specific teamwork will occur across 4 brief (20-30 minutes) team meetings over a 12-week period.
40975247|NCT01005745|PROCEDURE|Surgery|Surgery to remove a tumor for growth of TIL
40975248|NCT01005745|DRUG|Administration of Lymphodepletion|Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo
40975249|NCT01005745|OTHER|Adoptive Cell Transfer|T-cell infusion
40975250|NCT01005745|DRUG|High Dose IL-2|Beginning approximately 12 - 16 hours after cell infusion.
40975251|NCT05884723|DIETARY_SUPPLEMENT|Ketogenic Diet|4-week preoperative well-formulated very low carbohydrate isocaloric diet consisting of 50g net daily carbohydrates and 1.5g/kg protein with the remaining energy needs consisting of primarily mono- and polyunsaturated fats
40975252|NCT05485038|PROCEDURE|Tumor resection in awake patient|Surgeon performs critical steps of tumor removal in awake patient and controls his/her motor functions by brain mapping and assessing of voluntary movements
40771318|NCT00581100|DRUG|etanercept|"Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period."
40975253|NCT05485038|PROCEDURE|Tumor resection in asleep patient|Surgeon removes tumor in asleep patient and controls his/her motor functions by brain mapping
40975254|NCT00555321|DRUG|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])
40975255|NCT00555321|DRUG|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
40975256|NCT00555321|DRUG|Belatacept More Intensive (MI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])"
40975257|NCT00555321|DRUG|Belatacept Less Intensive (LI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)"
41140519|NCT02439892|BEHAVIORAL|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
41300083|NCT02075255|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
41459434|NCT05134571|DRUG|Laronidase|Solution for injection; Intravenous
41459435|NCT01468688|DRUG|STI571|
40975258|NCT00555321|DRUG|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])
40975259|NCT01426880|DRUG|Carboplatin|Carboplatin, AUC, 2 min/mL weekly, infusion
40975260|NCT01426880|DRUG|background treatment|"background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients)."
40975261|NCT03935529|BEHAVIORAL|Behavioural Activation|"Participants will receive five sessions of Behavioural Activation. Behavioural Activation uses strategies such as activity scheduling, mastery and pleasure ratings, and graded task assignments to change a participant's perception of specific situations.~Behavioural Activation is based on the behavioural model of depression (Lewinsohn \& Shaffer, 1971). Specifically, that depression is a result of reduced positive reinforcement, particularly in social relationships. Behavioural Activation aims to reduce depressive symptoms by implementing a schedule of positive reinforcement by altering a participant's behaviour and/or their environment. As, in certain environmental contexts, behaviours that reduce depression will continue to occur through reinforcement and those that increase depression will decrease over time (Roane, Fisher, \& Carr, 2016).~Behavioural Activation has been shown to be an effective intervention for the reduction of depressed mood."
40975262|NCT03562481|DRUG|1% Buffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
40975263|NCT03562481|DRUG|2% Unbuffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
41300084|NCT02075255|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 24 inclusive.
41300085|NCT02075255|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
41300086|NCT03744780|BEHAVIORAL|ACT Workshop for Emotional Eating|"This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
41300087|NCT05379361|BEHAVIORAL|Emotional Intelligence Development Program|It is a training program that was developed in line with the literature and preliminary research results and includes the bar-on emotional intelligence sub-dimensions.
41300088|NCT05379361|BEHAVIORAL|Plasebo Training Group|It is a training program that was developed in line with the literature and includes the environmental awareness skills education.
41300089|NCT00363805|DIETARY_SUPPLEMENT|green tea|Given orally
40975264|NCT05725109|OTHER|Hepatitis C Treatment Alerts in CHORUS™|Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based healthcare analytics and reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients with certain conditions who have a scheduled appointment in the coming week and may require close attention. CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. In the after period of this study, the alert will identify patients with active hepatitis C infection.
40975265|NCT05725109|OTHER|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients with active hepatitis C infection will be disseminated.
40975266|NCT05759676|DEVICE|Cre8™/Cre8™ EVO drug-eluting stent|Patient with CAD who undergoing PCI with Cre8™/Cre8™ EVO drug-eluting stent
40975267|NCT00629681|DRUG|Pregabalin|Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
41300090|NCT00363805|DRUG|Polyphenon E|Given orally
41459436|NCT01468688|DRUG|BKM120|BKM120 combination therapy
41459437|NCT03755596|DRUG|Z. officinale extract|Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
41459438|NCT01680367|PROCEDURE|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
41459439|NCT01680367|PROCEDURE|wound care management|Receive native collagen wound dressing
41459440|NCT01680367|OTHER|questionnaire administration|Ancillary studies
41459441|NCT05758623|DEVICE|Device|The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.
41459442|NCT01355328|PROCEDURE|laser and radiofrequency|different laser and radiofrequency with different fluences
41459443|NCT04629170|DRUG|SYNB8802|SYNB8802 is formulated as a nonsterile solution intended for oral administration
41459444|NCT04629170|DRUG|Placebo|In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
41459445|NCT05080140|DRUG|Ezetimibe 10mg|Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites
41459446|NCT06257979|OTHER|This study is with minimal risk and minimal constraints due to the addition of questionnaires|"In this study, the specific procedures compared to routine care are :~* Considering the addition of questionnaires, this study will be prospective. Due to the use of bacteriological samples, it is considered as a minimal-risk research.~* The research procedure involves a bacteriological analysis of operative elements (sutures placed during the first intervention, the product of tendon debridement, and the subacromial bursa (cleaning product)) used during the re-intervention. These usually discarded operative samples are collected for bacteriological analysis.~* Antibiotic treatment cannot be prescribed immediately after the surgery and during the first month following this re-intervention (time for biofilm formation). As per the protocol, even a positive sample should not lead to the initiation of systematic antibiotic therapy. In the case of identification of a pathogenic microorganism, antibiotic therapy will be prescribed, leading to discontinuation of the study."
41459447|NCT00530348|BIOLOGICAL|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
41459448|NCT00530348|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
41459449|NCT05747560|DIETARY_SUPPLEMENT|Buckwheat|Take buckwheat at a dose of 500 mg twice a day for 6 months.
41459450|NCT05747560|DIETARY_SUPPLEMENT|Astragalus extract|Take astragalus extract at a dose of 450 mg twice a day for 6 months.
40975268|NCT02648178|DEVICE|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
40975269|NCT01676389|OTHER|Sham OMM|Sham Osteopathic Manual Medicine (OMM).
40975270|NCT01676389|OTHER|Osteopathic Manual Medicine (Body Therapy)|OMM techniques include the following - paraspinal soft tissue myofascial release, rib raising, cervical spine soft tissue myofascial release, suboccipital inhibition, thoracic balanced ligamentous tension technique, thoracic lymphatic pump and pedal lymphatic pump.
40975271|NCT02206568|DRUG|URAL|
40975272|NCT03119194|DRUG|[14C]-BIA 9-1067|1 × 100 mg capsule, Oral
40975273|NCT01658670|BEHAVIORAL|Enhanced Usual Care Group|The EUC group is provided access to the exercise facility and regular facility staff for the 18 month study period.
41147124|NCT05345041|BEHAVIORAL|Go 4 Life Self Guided Education|Individual participants in churches randomized to the comparator arm will receive the church-wide walking program and the Go4Life Your Everyday Guide to Exercise and Physical Activity which was developed by the National Institutes of Health National Institute on Aging to promote physical activity in older adults. This includes an evidence-based exercise guide and motivational tips to help older adults start and sustain an exercise program. The Go4Life guide will add individual level education and encouragement to the interpersonal and community levels of intervention provided by the church-wide walking program.
41300091|NCT00363805|OTHER|placebo|Given orally
41300092|NCT04087655|BEHAVIORAL|Exercise|Eight weeks of interval exercise training
41300093|NCT02235753|BEHAVIORAL|High-intensity aerobic interval training, short interval|The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
41459451|NCT05747560|DIETARY_SUPPLEMENT|Wolfiporia extract|Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.
40975274|NCT01658670|BEHAVIORAL|HEART Camp (HC) Intervention Group|The HC intervention group will be provided access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
41459452|NCT01385423|DRUG|Preparative Regimen|Fludarabine 25 mg/m\^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (\*if \< 4 months from prior transplant, omit day -4 dose)
41459453|NCT01385423|BIOLOGICAL|Intravenous Recombinant Human IL-15 (rhIL-15)|IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
40771319|NCT01573429|OTHER|deuterated-Bisphenol A (d-BPA)|The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
40771320|NCT01782274|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
40771321|NCT01782274|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
40771322|NCT00323622|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|IM injection in the deltoid muscle
40771323|NCT00323622|BIOLOGICAL|Engerix™-B|IM injection in the deltoid muscle
40771324|NCT00323622|BIOLOGICAL|Hiberix®|IM injection in the deltoid muscle
40771325|NCT00323622|BIOLOGICAL|Prevnar™|IM injection in the deltoid muscle
40975275|NCT01326416|DIETARY_SUPPLEMENT|L-Leucine and L-arginine|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
41147125|NCT02962076|DRUG|[C-11] Meta-hydroxyephedrine radioactive tracer (MHED)|this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
41147126|NCT04657718|DEVICE|KODEX-EPD system|Cardiac pacing leads implantation for PM, ICD, CRT, HBP and LBBP
41147127|NCT01133600|DRUG|Cubicin|dosed at 6 mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if CrCl is \<30ml/min.
41459454|NCT04162197|DEVICE|GEO|Robot-Assisted Gait Training (RAGT) The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
41459455|NCT04162197|DEVICE|GEO and HUNOVA|Robot-Assisted Gait Training (RAGT) and Balance Training. The Balance Group (GHG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland) and a Balance training using a robotic proprioceptive platform (Hunova - Movendo Technology, Italy).
41459456|NCT02196467|BIOLOGICAL|Myoblast transplantation|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
41459457|NCT02196467|PROCEDURE|Saline injection|A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
41459458|NCT04167696|BIOLOGICAL|CYAD-02|CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.
41459459|NCT04167696|DRUG|ENDOXAN|administered as preconditioning chemotherapy
40771326|NCT00323622|DRUG|sulfadoxine-pyrimethamine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
40771327|NCT00323622|DRUG|amodiaquine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
40771328|NCT03371212|DEVICE|Dual mobility cohort|Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell.
41459460|NCT04167696|DRUG|Fludara|administered as preconditioning chemotherapy
41459461|NCT04561713|PROCEDURE|Virtual reality task|Virtual reality application in an immersive room (CAVE) in three dimensions to assess child's sustained attention in a dynamic environment that is as close as possible to everyday situations.
41459462|NCT05995379|DIAGNOSTIC_TEST|Donor-derived cell-free DNA|"Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection.~One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed."
41459463|NCT04554264|OTHER|questionnaire|Inventory of Complicate Grief (ICG) score in relative from patients who died in ICU after SARS-Cov2 infection. This is the most commonly used assessment tool for complicated grief which focuses on different symptoms than depression or anxiety. A score \> 25 indicate complicated grief.
40771329|NCT03371212|DEVICE|Conventional cohort|Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell
40771330|NCT02593630|DEVICE|Unicirc circumcision|Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
40771331|NCT04190472|DIAGNOSTIC_TEST|IOP HPV test|Immediately after the LEEP, a cervical sample was taken for the IOP-HPV test
40975276|NCT01326416|OTHER|Physical Reconditioning by a trainer|Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
40975277|NCT00905398|DRUG|Nilotinib|400mg, Oral, Bid, Daily for three years
40975278|NCT01955733|DRUG|BI 695500|
40975279|NCT06226753|PROCEDURE|Type of anaesthesia used|Spinal anaesthesia will be used for closure of loop ileostomy
40975280|NCT04225611|DRUG|Dexamethasone|The investigators have developed a topically-applied corticosteroid-delivery system that has the potential to treat recurrent cystoid macular edema with fewer risks to patient, and more dose control. The system is comprised of a drug-polymer film that is completely encapsulated within the periphery of a hydrogel that is commonly used to make contact lenses.
41459464|NCT03947905|PROCEDURE|Virtual visit|Type of visit
41147128|NCT01133600|DRUG|Vancomycin|dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
41147129|NCT01779492|DRUG|GL2907|once a day
41147130|NCT01779492|DRUG|Oxycontine CR 10mg|twice a day
41459465|NCT05995873|DEVICE|unilateral transcranial photobiomodulation|An 810nM LED at 240mW/cm2 is placed at either F3 or F4 for 4 minutes.
41459466|NCT01711567|DRUG|tenofovir|tenofovir 300 mg qd
41459467|NCT01711567|DRUG|entecavir|entecavir 0.5 mg qd
41459468|NCT02686762|DRUG|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
40975281|NCT03584711|COMBINATION_PRODUCT|FOLFOX + panitumumab|"FOLFOX + panitumumab according to a stop and go strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment"
40975282|NCT02965547|DEVICE|Remote ischemic conditioning equipment|The RIPC consisted of 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm and other side thigh. This intervention was undertaken one time in total.
40975283|NCT02965547|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 6ml twice(at baseline and 1h after RIPC).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
40975284|NCT02965547|PROCEDURE|dCA measurement|Serial measurements of dCA were performed at 7 time points, baseline, 1h, 3h, 6h, 9h, 12h, 24h after RIPC.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
40975285|NCT00883116|DRUG|Ixabepilone|
41300094|NCT02235753|BEHAVIORAL|High-intensity aerobic interval training, long interval|The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
41300095|NCT02606045|DRUG|recombinant von Willebrand factor|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
41300096|NCT02606045|DRUG|tranexamic acid|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
41300097|NCT03919253|COMBINATION_PRODUCT|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
41300098|NCT04644575|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form:Solution for Injection Route of administration: Intravenous
41300099|NCT01199263|OTHER|Laboratory Biomarker Analysis|Correlative studies
41300100|NCT01199263|DRUG|Paclitaxel|Given IV
41459469|NCT02686762|DRUG|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
40975286|NCT00883116|DRUG|Doxorubicin|
40975287|NCT00883116|DRUG|Paclitaxel|
41147131|NCT00304278|DRUG|Erlotinib (Tarceva)|150 mg daily X 7 weeks
41147132|NCT00304278|DRUG|Intra-arterial Cisplatin (PLAT)|1 dose (150 mg/sq) per week X 4 weeks
41300101|NCT01199263|BIOLOGICAL|Pelareorep|Given IV
41459470|NCT02686762|DRUG|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
41459471|NCT02931630|OTHER|Whey protein powder|60 g of whey protein powder
41459472|NCT02931630|OTHER|Maltodextrin powder|60 g of Maltodextrin powder
41459473|NCT02931630|OTHER|High fiber bread|Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
41147133|NCT00304278|RADIATION|Radiation Therapy (RAD)|5 days per week X 7 weeks
41459474|NCT02931630|OTHER|Low fiber bread|Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
41459475|NCT05349240|DEVICE|C2 CryoBalloonTM Ablation System.|Cryoablation is used to ablate the tissue under the cryogenic condition. The device is mainly used to destroy the unhealthy tissues.
41147134|NCT01855672|DEVICE|Stimulation of the Occipital Nerves|Electrical stimulation of the occipital nerves.
41147135|NCT03044834|OTHER|PPB|Global current care
41147136|NCT00035256|DRUG|teriparatide|
41147137|NCT00035256|DRUG|raloxifene HCl|
41147138|NCT00035256|DRUG|placebo|
41147139|NCT03572907|OTHER|Rhinoplasty questionnaire|Each patient will complete a validated rhinoplasty questionnaire (Rhinoplasty Outcome Evaluation) before and after the intervention
40975288|NCT05025761|OTHER|Personal protection package|The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.
40975289|NCT02108353|DRUG|Melatonin 2mg|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
40975290|NCT02108353|DRUG|Placebo|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
40975291|NCT06214104|BEHAVIORAL|Acupressur|Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.
40975292|NCT01901497|DEVICE|Nebulizer|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
40975293|NCT01580618|DRUG|normal saline|Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
40975294|NCT01580618|DRUG|TNK (Tenecteplase)|Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
40975295|NCT05002010|DEVICE|Echo|Measure the Left ventricle (LV): IVS (interventricular septum), LVEDD(left ventricle end diastolic dimension ),LVESD((left ventricle end systolic dimension ), PWD(posterior wall dimension), LV systolic dysfunction and LV diastolic dysfunction.
40975296|NCT05285605|DRUG|Ulipristal Acetate|Ulipristal acetate 30mg x 1 dose as needed for unprotected intercourse
40975297|NCT00164554|BEHAVIORAL|Parent-child Interaction Therapy (PCIT)|
41459476|NCT01970592|BEHAVIORAL|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be \~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
41459477|NCT00502658|BEHAVIORAL|Dietary supplement containing vitamins, minerals, and herbs|
41459478|NCT00502658|BEHAVIORAL|Shakes with nutrients and herbs|
41459479|NCT00502658|BEHAVIORAL|Control dietary supplement|
40975298|NCT00923598|DRUG|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
40975299|NCT04978740|OTHER|Ophthalmological examination|"Eye examination :~Ocular tonometry to determine intraocular pressure Refraction assessment Retina examination Slit lamp examination Visual acuity Schirmer's test Corneal topography Funduscopic examination Optical coherence tomography"
40975300|NCT01357187|OTHER|Scheduled removal of posterior instrumentation with AmnioFix|
40975301|NCT01357187|OTHER|Scheduled removal of posterior instrumentation without AmnioFix|
40975302|NCT04489823|DEVICE|AVP III|Transcatheter closure of a paravalvular leak using AVP III
40975303|NCT03855280|DRUG|APVO101|Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for a total of 50 ED. The starting prophylaxis dose will be based on APVO101 recovery from PK Phase assessments (only pre-infusion and 15-30 minute post-infusion samples).
40975304|NCT01250834|DRUG|Atorvastatin|Administered orally.
40975305|NCT01250834|BIOLOGICAL|LY2189265|Administered subcutaneously.
40975306|NCT04931862|DRUG|WVE-004|WVE-004 is a stereopure antisense oligonucleotide (ASO)
40975307|NCT04931862|DRUG|Placebo|Artificial cerebrospinal fluid (aCSF)
40975308|NCT04984798|DRUG|Vitamin E|Twice daily oral supplementation with Vitamin E for 6-9 weeks.
40975309|NCT01971411|DRUG|Calcium 500mg with 200 IU Vitamin D - 2 tablets daily|
40975310|NCT01971411|PROCEDURE|Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH|
40975311|NCT01971411|BEHAVIORAL|Usual sun exposure documentation|
40975312|NCT01971411|BEHAVIORAL|Dietary intake of calcium, vitamin D, magnesium|
40975313|NCT03501069|DRUG|TAK-418|TAK-418 capsules.
40975314|NCT03501069|DRUG|TAK-418 Matching Placebo|TAK-418 matching placebo capsules.
40975315|NCT03457129|DRUG|Perampanel Oral Tablet|Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
41459480|NCT00502658|BEHAVIORAL|Isocaloric, isonitrogenous control shakes without herbs|
41459481|NCT00502658|BEHAVIORAL|Personal energy tracking tool|
41459482|NCT00131092|BEHAVIORAL|The Stanford Active Choices program|
40975316|NCT06066658|DEVICE|cranial electrotherapy stimulation (Alpha-Stim AID)|Alpha-Stim AID
40975317|NCT05153668|DRUG|Everolimus Oral Tablet|Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.
40975318|NCT00821977|DRUG|Vildagliptin|
40975319|NCT00821977|DRUG|Vildagliptin|
40975320|NCT00821977|DRUG|Placebo|
40975321|NCT02216188|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
40975322|NCT02216188|OTHER|Control|Untreated control group
40975323|NCT00376662|DRUG|Hormone Replacement Therapy and Etidronate|
41147140|NCT01491100|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
41459483|NCT00131092|BEHAVIORAL|The TLC system|
41459484|NCT01567319|BIOLOGICAL|Skin Prick Test|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
40771332|NCT03236545|OTHER|No to Low Endogenous Estrogen|Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration (Oberye, Mannaerts, Huisman \& Timmer, 1999; Oberye, Mannaerts, Kleijn, \& Timmer, 1999).
41300102|NCT01103349|DRUG|BI 671800|Double blind randomised parallel group study to assess efficacy and tolerability of BI 617800 in patients with symptomatic asthma
40771333|NCT03236545|OTHER|Estradiol|Short term estradiol administration elicits changes in vascular function in women, and 0.1mg/day patch is the upper recommended limit for hormone therapy in women (Wenner, Taylor, \& Stachenfeld, 2011; Moreau, Hildreth, Meditz, Deane \& Kohrt, 2012).
41300103|NCT01103349|DRUG|Placebo|Patients receive placebo capsules and/or encapsulated tablets
41300104|NCT01103349|DRUG|Montelukast|Double blind randomised parallel group study to assess efficacy and tolerability of BI 671800 in patients with symptomatic asthma
40771334|NCT00433186|DRUG|Mycophenolate Mofetil|Mycophenolate 3000 mg each day
40771335|NCT03255473|DRUG|Dexamethasone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
40771336|NCT03255473|DRUG|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
40771337|NCT04922216|BEHAVIORAL|Core|Behavioral weight loss core includes behavioral lessons, activity tracker, daily self-weighing, weekly tailored feedback summary.
40771338|NCT04922216|BEHAVIORAL|Standard Diet Monitoring|Standard monitoring using smartphone tracking of all calorie intake.
40771339|NCT04922216|BEHAVIORAL|Simplified Diet Monitoring|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
40771340|NCT04922216|BEHAVIORAL|Adaptive Activity Goals (Daily)|Physical activity goals that adapt once each day using the participants' data derived from activity tracker.
40771341|NCT04922216|BEHAVIORAL|Adaptive Activity Goals (Weekly)|Physical activity goals that adapt once each week using the participants' data derived from activity tracker.
40771342|NCT04922216|BEHAVIORAL|Message Decision Points (Fixed)|Message timing is fixed and evaluated at specific times each day to determine message eligibility.
40771343|NCT04922216|BEHAVIORAL|Message Decision Points (Adaptive)|Message timing is adaptive and derived from individual user data to determine message eligibility.
40771344|NCT04922216|BEHAVIORAL|Message Decision Rules (Standard)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors.
40771345|NCT04922216|BEHAVIORAL|Message Decision Rules (Adaptive)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors and overall progress.
40771346|NCT04922216|BEHAVIORAL|Message Choice (No)|Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision
40771347|NCT04922216|BEHAVIORAL|Message Choice (Yes)|Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.
40771348|NCT03556891|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
41147141|NCT04489914|DEVICE|High-Flow Oxygen Therapy|high-flow oxygen therapy after percutaneous transfemoral aortic valve replacement
41147142|NCT05925751|DIAGNOSTIC_TEST|CT/PET/WSI-based Deep Learning Signature|CT/PET/WSI-based Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
41147143|NCT01803945|DRUG|AVE8112|
41147144|NCT01803945|DRUG|Placebo|
41147145|NCT02261675|DRUG|dexmedetomidine|children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
41300105|NCT00569920|DRUG|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
41300106|NCT00569920|DRUG|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
41459485|NCT01567319|BIOLOGICAL|Skin Prick Test - Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
41300107|NCT00569920|DRUG|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
41300108|NCT06019780|OTHER|blood flow restriction trainin|"Following exercise will be performed~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption İndividual in the group will be having two session per week, 16 session of exercise training for 8 weeks.50% of arterial occlusion pressure (60 to 80 mmHg) will be applied for total duration of 15mins. Occlusion pressure will be calculated according to formula for each patient \[Pressure=0.4x(systolic BP)+2.7x(shoulder circumference)+62\].4 sets with one set of 30 repetition and three sets of 15 repetition. After each set subject will have 30 seconds of rest with cuff inflated."
41300109|NCT06019780|OTHER|exercise|"Following exercises will be performed without application of pneumatic cuff~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption Conventional treatment will include: Hot pack 5 mins Maitland grade 3 and 4 mobilization: inferior glide (10reps x3sets), posterior glide (10reps x 3sets), anterior glide (10 reps x 3sets) Home plan: wand exercise, pendulum exercise, wall walking exercise (10reps x 2sets each)"
41300110|NCT04626219|OTHER|Imaging|Imaging - Magnetic Resonance Imaging (MRI) scan of their heads
41300111|NCT04626219|BEHAVIORAL|fast|hungry state - refrain from eating after lunch at 12 noon until 9 a.m. the next morning
41300112|NCT04626219|BEHAVIORAL|regulated meals|standardized diet from noon until 9 a.m. the next day
41300113|NCT01173627|DRUG|Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
41300114|NCT01173627|DRUG|Actiq 400 mcg|Actiq 400 mcg administered as a single dose under fasted conditions
41300115|NCT06480513|BEHAVIORAL|live yoga|following live yoga classes twice a week and using yoga video's at home once a week
40975324|NCT05713747|OTHER|Life Skills Boot Camp|"The boot camp is designed to be taken by undergraduate students across all disciplines with no pre-requisite coursework and students who participated in the Life skills 101 course and have selected to participate in a boot camp training as part of their Individual Self Development Plan. The boot camp will consist of 3 training programs with 4 sessions (1.5 hour per session) each, including an introductory and a closing part.~Content The boot camp was designed by a team of academics having several years of experience in clinical psychology, educational psychology, and health psychology. The focus of the bootcamp is to teach students practical skills in three different domains of soft skills: a) Interpersonal Skills, b) Resilience and Flexibility and c) Emotion Regulation."
41300116|NCT06480513|BEHAVIORAL|live remote yoga|The control group will be offered live remote yoga classes after the intervention period
41300117|NCT05926986|OTHER|Exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise. Additionally, pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
41300118|NCT05926986|OTHER|control|No additional treatment will be practiced to the control group.
41459486|NCT01567319|BIOLOGICAL|Skin Prick Test - No Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
41300119|NCT00993603|BEHAVIORAL|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
41300120|NCT02342561|DEVICE|Ioban 2 incision drape, 3M|The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
41300121|NCT01374815|OTHER|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
41300122|NCT01374815|OTHER|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
41300123|NCT01371838|DRUG|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
41300124|NCT01371838|DRUG|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
41300125|NCT00000650|DRUG|Ditiocarb sodium|
41300126|NCT01025180|OTHER|Procalcitonin level|"The duration of antibiotic treatment is based on PCT level:~* \< 0.25 ng/ml: antibiotic should be stopped~* 0.25 \< PCT \<0.5: antibiotic prescription is not recommended~* \> 0.5 ng/ml: antibiotic should be used"
41300127|NCT04893226|BEHAVIORAL|Time-Restricted Feeding (TRF)|Subjects will be educated about the health benefits of time-restricted feeding (TRF). Each subject in the TRF group will self-select a 10 hour (10h +/- 1hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily meals for the duration of the study.
41300128|NCT05075096|OTHER|No intervention.|No intervention observational study.
41300129|NCT02415296|OTHER|stage 1|The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
41459487|NCT02678780|DRUG|Lenvatinib|
40975325|NCT05281939|DIAGNOSTIC_TEST|Artificial intelligence diagnosis|Participants were divided into the intervention group and the control group using a random number table. The intervention group participants' cervical colposcopic image data and non-image data as follow：age, the infection of high-risk human papillomavirus (HR-HPV),the type of HR-HPV infection,the duration of HR-HPV infection, cervical cytology (TCT) results, HIV/sexually transmitted infection history, marriage and childbearing history,first sexual life history, sexual partner history, smoking history,oral contraceptives history,the use of immune drug and possible clinical symptoms of cervical lesions such as postcoital bleeding, abnormal vaginal secretions, vaginal bleeding symptoms, etc.
40975326|NCT06499077|DIAGNOSTIC_TEST|Sampling of exhaled breath|Exhaled breath of all participants is collected following our standardized procedure
40975327|NCT01890356|DEVICE|Transcranial electrical stimulation|
40975328|NCT02656121|DRUG|Vitamin D|6000 IU of vitamin D3
40975329|NCT02656121|DRUG|Ovulatory Agent|only Clomophine Citrate
40975330|NCT00144092|PROCEDURE|stem cell source|
40975331|NCT04372030|OTHER|Online questionnaire|this is an online questionnaire collecting retrospective data on health care use and non-use
40975332|NCT03049280|DEVICE|Transoral robotic surgery|Transoral robotic surgery for T1 \& T2 oropharyngeal cancers
40975333|NCT00020475|DRUG|gp100 antigen|
40975334|NCT00020475|DRUG|interleukin-2|
41300130|NCT02415296|OTHER|stage 2|The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
41459488|NCT03531450|BEHAVIORAL|Cognitive Behavioral Therapy|Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
40975335|NCT00020475|DRUG|MART-1 antigen|
40975336|NCT00020475|DRUG|Montanide ISA-51|
40975337|NCT00881582|DRUG|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 \& 4: 48 weeks; genotypes 2 \& 3: 24 weeks)
41300131|NCT02415296|OTHER|stage 3|The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
41300132|NCT03067766|PROCEDURE|Art Therapy|Participate in a comic art creation workshop
41300133|NCT03067766|OTHER|Interview|Undergo qualitative interviews
41300134|NCT03067766|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
41300135|NCT03067766|OTHER|Questionnaire Administration|Ancillary studies
41300136|NCT05338294|PROCEDURE|Laparoscopic splenectomy and azygoportal disconnection|Laparoscopic splenectomy and azygoportal disconnection is performed by the same surgical team.
41459489|NCT04077125|DRUG|Rifaximin|to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
41459490|NCT02311517|DRUG|Ropivacaine|90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.
40975338|NCT01705639|DRUG|Melatonin|All subjects receive the same dose of melatonin
40975339|NCT03242057|OTHER|NAVA|Infant will be extubated to NAVA, settings based per protocol
40975340|NCT03242057|OTHER|NIPPV|Infant will be extubated to NIPPV, settings detailed in protocol
40975341|NCT02742324|DRUG|Ruxolotinib|Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
40975342|NCT02742324|DRUG|peg-IFN alpha -2a|Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
40975343|NCT01935271|DIETARY_SUPPLEMENT|Muscle Armor Supplement|
40975344|NCT01935271|DIETARY_SUPPLEMENT|Placebo|
40975345|NCT01613404|OTHER|No intervention|Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
41300137|NCT01066416|PROCEDURE|Endoscopic Sinus Surgery|
41300138|NCT01066416|OTHER|medical therapy|Subjects will undergo surgery 6 months after randomization
41300139|NCT03998462|BEHAVIORAL|Mindfulness Based Stress Reduction|MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
40975346|NCT02390895|PROCEDURE|endoscopic repair of myelomeningocele before 26 SA|prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
41300140|NCT03998462|BEHAVIORAL|Creative Education Care|Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
41300141|NCT00159744|DRUG|Asenapine|Asenapine, 3 weeks
41300142|NCT00159744|DRUG|Olanzapine|Olanzapine, 3 weeks
41300143|NCT00159744|DRUG|Placebo|placebo, 3 weeks
41300144|NCT02835638|DEVICE|Adaptative Servo Ventilation|the ASV treatment will be observed during this study on the patients included
41300145|NCT01477190|DRUG|Spinal analgesia|isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged \> 75 years.
41300146|NCT01477190|DRUG|Patient Control Analgesia (PCA) Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
41300147|NCT04181567|OTHER|electroconvulsive therapy|electroconvulsive therapy 2 times weekly
41300148|NCT04181567|DRUG|agomelatine|agomelatine
41300149|NCT04181567|DRUG|Placebo|placebo
41300150|NCT05955859|PROCEDURE|Samplings from patient's affected paranasal sinus|Samplings from patient's affected paranasal sinus during endoscopic surgery.
41459491|NCT02311517|DRUG|Normal Saline|
41459492|NCT00275639|DRUG|Cozaar|
41459493|NCT04315779|PROCEDURE|Salpingectomy|Patients will undergo removal of the affected tube
41459494|NCT03965130|BIOLOGICAL|Glucagon|PINTA study with or without glucagon
41300151|NCT01180140|DEVICE|Seamguard|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
41459495|NCT01859936|DEVICE|MRI|The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
41459496|NCT05396950|DEVICE|CPAP|CPAP in conjunction with radiotherapy
41459497|NCT03174938|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
40975347|NCT01885143|RADIATION|Digital Breast Tomosynthesis|
40975348|NCT03232047|DEVICE|Combined executive function and memory training|Computerized combined executive function and memory training
41300152|NCT03321552|PROCEDURE|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
41300153|NCT03321552|DEVICE|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
41300154|NCT00004865|BIOLOGICAL|cetuximab|
41300155|NCT00004865|DRUG|cisplatin|
41300156|NCT00004865|DRUG|fluorouracil|
41300157|NCT00004865|DRUG|paclitaxel|
41300158|NCT06459531|BEHAVIORAL|Virtual Reality (VR) Therapy|"Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
41300159|NCT06459531|OTHER|Conservative Treatment|"Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
41459498|NCT03174938|DIAGNOSTIC_TEST|[18F]-RO6958948|PET imaging of Tau aggregates
41459499|NCT03174938|DIAGNOSTIC_TEST|Elecsys (Roche) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
41459500|NCT03174938|DIAGNOSTIC_TEST|Lumipulse (Fujirebio) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
41459501|NCT00858416|DEVICE|"Kineticure System followed by sham"|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
41459502|NCT00858416|DEVICE|"sham followed by Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
41459503|NCT02230176|DRUG|Sunitinib|
41459504|NCT02230176|DRUG|177Lu-DOTA0-Tyr3-Octreotate|
41459505|NCT06374108|BEHAVIORAL|Progressive resistance training|The RT exercise regime will focus on lower extremity exercises (60-90% of 1 repetition maximum) as well as incorporating functional exercises.
41459506|NCT00213005|DRUG|Carraguard (PC-515)|
41459507|NCT02940652|RADIATION|Magnetic resonance imaging|No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
41300160|NCT05853562|OTHER|structured vestibular rehabilitation program|The structured Vestibular rehabilitation protocol consisted of a structured vestibular rehabilitation program that included vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises, and posture exercises.
41300161|NCT05006807|DEVICE|Mechanomyograph Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
41300162|NCT05006807|DEVICE|Stimpod Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
41300163|NCT05006807|DEVICE|TetraGraph Twitch Monitor|Measurement of train-of-four count and ratio and post titanic count
41300164|NCT05006807|DEVICE|TwitchView Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
41300165|NCT05006807|DEVICE|Nihon Kohden Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
41300166|NCT05006807|OTHER|Palpation of twitch count|The train-of-four count is determined by manual palpation of the evoked twitch response
41300167|NCT03823937|OTHER|Sniffin' Sticks test and Taste strips|"Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth."
41300168|NCT00797459|DEVICE|Restylane and Restylane-L|This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
41300169|NCT04975256|DRUG|MRTX849|KRAS G12C inhibitor
41300170|NCT04975256|DRUG|BI 1701963|SOS1 Inhibitor
41300171|NCT00092586|DRUG|MK0653, ezetimibe|
41300172|NCT00092586|DRUG|Comparator: statins|
41300173|NCT03711071|OTHER|"Workshop ICE training"|The workshop includes training in communication skills in relation to evidence based medicine.
41300174|NCT02276157|DEVICE|Direct peroral cholangioscopy|"The multibending (MB) or conventional ultra-slim endoscope was inserted through the mouth. After facing the papillary orifice, the endoscope was inserted directly, without any accessories, into the distal bile duct. The second bending of the MB ultra-slim endoscope was kept in an upward angled position to achieve a more acute angle of the endoscope tip for entering the distal CBD. Then, the endoscope was pushed by steering the first bend into an upward angle (α shape) or the endoscope was pulled by steering the first bend into an upward angle and torqueing it counter-clockwise (u shape) for insertion into the distal CBD. If the distal bile duct was visualized on an endoscopic view, carbon dioxide insufflation was stopped. The endoscope was advanced into the hilum or the obstructed segment of the extrahepatic bile duct under fluoroscopic and endoscopic control. Then, the diagnostic and therapeutic interventions were performed during direct POC as necessary."
41300175|NCT05828264|BEHAVIORAL|Quantum touch|this group by the nurse who is included in the study and who has a practice certificate before vascular access is established. In this process, the treatment process of the patient will continue and will not create an obstacle. While the child is in a comfortable position (lying or sitting position) during the application, the child's back/shoulder/head will be touched by the practitioner and guantum touch energy will be applied. Then, vascular access will be performed by the nurse included in the study. The child will be asked to rate the level of pain during the procedure with 'FPS-R', the level of fear with 'CDS', and the level of anxiety with 'ÇAS-D'.
41300176|NCT01814800|BIOLOGICAL|RI-002|Immune Globulin Intravenous (IGIV)
41147146|NCT01002209|PROCEDURE|Hyperbaric Oxygen treatment (HBO)|"HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).~HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital."
41147147|NCT01002209|PROCEDURE|Sham HBO|"HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.~For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included."
41147148|NCT00476957|DEVICE|Stent|Stent implantation
41147149|NCT00476957|DEVICE|Stent|Stent implantation
41147150|NCT03635242|OTHER|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
41147151|NCT03635242|OTHER|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
41147152|NCT02167191|BEHAVIORAL|HIT|12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
41147153|NCT06202547|BIOLOGICAL|Intra-ovarian injection of bone marrow mesenchymal stromal cells-derived extracellular vesicles|he patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
40771349|NCT05717439|DIAGNOSTIC_TEST|CAPS-5-R|A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.
40771350|NCT05717439|DIAGNOSTIC_TEST|Senseye DT|Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
40771351|NCT06336564|OTHER|Pelvic floor muscle training|"Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform The Knack, which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days."
41459508|NCT00998595|OTHER|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
40975349|NCT02054221|PROCEDURE|myoectomy|The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
40975350|NCT02054221|PROCEDURE|Mitral valve surgery|41 patients will be performed mitral valve replacement with complete excision of the subvalvular apparatus.
41459509|NCT06536049|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41459510|NCT06536049|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
41459511|NCT06536049|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
40975351|NCT02054221|PROCEDURE|Mitral valve surgery|41 patients will be performed mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
41147154|NCT06416605|PROCEDURE|Maxillary Alveolar Ridge Augmentation|using tooth graft or bone graft to increase alveolar ridge width to be able to insert dental implant
41459512|NCT06536049|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
41459513|NCT06536049|BIOLOGICAL|Epcoritamab|Given SC
41459514|NCT06536049|DRUG|Ibrutinib|Given PO
41459515|NCT06536049|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41459516|NCT00769587|DRUG|thalidomide|
41459517|NCT06361550|OTHER|VENREDI group|Practical seminars aimed at improving the Mediterranean diet, guided by researchers.
41459518|NCT06361550|OTHER|Health education|Health education on Mediterranean diet
41459519|NCT02802462|BEHAVIORAL|HIT|3-minute intervals at 40% and 80%VO 2max
41459520|NCT02802462|BEHAVIORAL|MCT|sustained 60%VO 2max
40771352|NCT06336564|DEVICE|Microablative Radiofrequency|Patients will be placed in the lithotomy position and through speculum examination and under direct vision or guided by colposcope, sequential application of radiofrequency will be carried out on the vaginal walls and introitus. The Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic energy fractionation circuit, connected to a vaginal pen with 64 microneedles, 200μm in diameter and 1 mm in length, mounted on a Teflon body and divided into a matrix of eight columns with eight needles each. In the vestibule and vaginal opening, 10% lidocaine spray will be applied three minutes before the procedure. Three applications will be carried out in the vagina/vaginal introitus, with an interval of 30 to 40 days.
41459521|NCT01182792|DIETARY_SUPPLEMENT|Vitamin C and E|1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)
41459522|NCT01182792|DIETARY_SUPPLEMENT|Placebo|1 month Placebo
41459523|NCT03182751|DRUG|Tranexamic Acid (TXA)|Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours
41459524|NCT03182751|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
41459525|NCT00006467|DRUG|ISIS 2503|
41459526|NCT00006467|DRUG|gemcitabine hydrochloride|
41459527|NCT04547179|DRUG|Fremanezumab-Vfrm|Patients will receive three injections of Ajovy® if in the corresponding arm of the study.
41459528|NCT04547179|DEVICE|BLAfit®|Usage of the BLAfit device, a fixed orthotic appliance that allows users to tone facial muscles with one minute usage per day
41459529|NCT04547179|OTHER|Saline|Patients will receive three injections of saline if in the corresponding arm of the study. This is a placebo meant to simulate the Ajovy® injection.
41459530|NCT03121079|DRUG|Interferon-alpha|patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
41459531|NCT03278509|DRUG|Metoprolol Succinate|Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
41459532|NCT03278509|DRUG|Bisoprolol|Please see the section above.
41459533|NCT06127745|DEVICE|Discure System|All subjects enrolled into the study will be implanted with the Discure System in a minimally invasive procedure.
41300177|NCT06373081|BIOLOGICAL|Anti-CD19-CD3E-CAR-T cells|The injection of anti-CD19-CD3E chimeric antigen receptor T (CAR-T) cells, referred to as anti-CD19-CD3E-CAR-T cells. The anti-CD19-CD3E-CAR protein is composed of a murine-derived CD19 single-chain variable fragment (scFv) FMC63, CD28 hinge and transmembrane regions, the intracellular domain of CD3E, the intracellular domain of CD28, and the intracellular domain of CD3ζ, all linked in sequence.
41300178|NCT05585411|PROCEDURE|Left bundle branch area pacing|"LBBAP success is defined if ventricular lead is successfully placed at interventricular septum and RBB configuration observed during unipolar tip pacing.~LBB capture is defined if fulfilling criterion 1 and at least one in criteria 2.~1. RBBB configuration observed during unipolar tip pacing~2. One of the following should be met:~   1. Abrupt shortening of Stim-LVAT (stimulus to peak of the R wave in V6 \[LV activation time\]) of \>10ms during increasing output~  2. Short and constant stim-LVAT and the shortest stim-LVAT \<75ms in non-LBBB and \<85ms in LBBB~  3. Programmed stimulation by pacing lead changes QRS morphology from nonselective LBB to LV septal capture~  4. LBB potential (LBB-V interval of 15 to 35ms)~  5. Transition from nonselective LBB capture to selective LBB capture at near threshold outputs~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be deep septal pacing (DSP)."
41300179|NCT05585411|PROCEDURE|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. Implantation of a RV pacing lead (apex or septum of right ventricle) will be attempted using the standard-of-care technique first
41300180|NCT01648608|DRUG|Exemestane|Exemestane for neoadjuvant chemotherapy
41300181|NCT05320770|PROCEDURE|US guided TMJ intra articular injection|therapeutic TMJ intra articulatr injection of blood under sonography guidance to reduce joint hyper mobility
41300182|NCT03934593|BEHAVIORAL|Faith-Based (FB, BHT DSMS)|BHT DSMS Intervention components include Health Sermon and a 6-session Health Bible Study with cooking demonstrations, followed by the Stanford DSMP and a Diabetes Resource Seminar. All intervention activities are implemented by trained church lay leaders.
41300183|NCT03934593|OTHER|Faith-Placed (FP, Stanford DSMP)|Standard Stanford DSMP delivered by health professional
41459534|NCT04960761|OTHER|İntervention Group|"In the experimental group, pre-operative anxiety and quality of life scales will be applied to the child and their parents before and after the operation with audio and picture books, the preoperative quality of life scale will be made, the postoperative anxiety and quality of life scale will be repeated and the early mobilization scale will be made.~The control group will be routinely informed before the operation, an anxiety scale will be given to the child and their parents before the operation, a quality of life scale will be given to the child, the postoperative anxiety and quality of life scale will be repeated, and early mobilization form will be applied."
41300184|NCT05387720|PROCEDURE|Manual diaphragmatic facilitation (PNF) technique|"Diaphragmatic PNF is a facilitator technique used to improve chest expansion, increase epigastric excursion, promote breathing frequency and depth, by applying external proprioceptive tactile stimuli over diaphragm. The therapist places the thumbs toward the xiphoid process and the fingers along the costal margins of the lower ribs and pushing deep to stimulate the diaphragm During inspiration, the patient will be instructed take a deep breath breathe in and the therapist assists the movement to promote the subject's respiratory pattern in downward movement. At the maximum inspiration, therapist will say hold your breath for 5 seconds. The therapist gives mild resistance to the inferior movement of the contracting diaphragm during inspiration while pushing diaphragm superiorly. During expiration, therapist says breathe out and pushed under lower ribs on both sides upward to assist the discharge of air remaining in the lungs."
41459535|NCT01120691|DRUG|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
41459536|NCT01120691|DRUG|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
41459537|NCT01120691|DRUG|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
41459538|NCT01120691|DRUG|Salbutamol/albuterol|As needed throughout the study
41459539|NCT01310361|DRUG|Amoxicillin|
41140520|NCT04947709|BEHAVIORAL|Physical Activity|The main structure of the physical activity program will focus on increasing physical activity. Physical activity will initially start at a duration of 15-30 minute bouts, and at rate of perceived exertion levels of 5-6 (somewhat hard). Over the course of the intervention, goals will be set to progress to 60 minutes of continuous physical activity, at a rate of perceived exertion level of 5-6 (somewhat hard). Participants will be instructed on the use of the ratings of the perceived exertion scale (Borg's RPE 1-10 scale). Participants will be instructed to walk, or engage in other forms of leisure-time physical activity to achieve these goals (cycling, running, swimming, etc). As the adolescent and young adults' health and fitness status improve, frequency, intensity, and session duration will be modified accordingly during weekly support calls. Moreover, goals will be responsive to the most recent week's achieved minutes and rate of perceived exertion.
41300185|NCT05387720|PROCEDURE|Trigger sensitivity adjustment on mechanical ventilation|The pressure trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training by decreasing trigger sensitivity towards negative pressure. In the first session, inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reaches 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing negative pressure of the trigger sensitivity by 10% of the initial MIP. The maximal acceptable intensity is 40% of MIP, Patients who can't tolerate IMT with 20% of MIP for 5 min will be trained with 10% of MIP
41300186|NCT05387720|PROCEDURE|concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique|Diaphragmatic PNF technique will be applied synchronously in the same time, on each breath with trigger sensitivity adjustment on mechanical ventilation in same manner as discussed before
41459540|NCT01310361|DRUG|Intramuscular Benzathin Penicillin G|It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
41459541|NCT03043898|OTHER|Lung sound transmission measurement|Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.
41459542|NCT03043898|OTHER|Lung sound recording|Lung sounds are recorded using a sensor array.
41300187|NCT03999567|OTHER|Pen and Paper Digit Symbol Substitution Test (DSST)|The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
41300188|NCT03999567|OTHER|Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)|Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
41300189|NCT04951336|DIETARY_SUPPLEMENT|FoTv|Fomitopsis Officinalis and Trametes Versicolor
41459543|NCT06252675|BIOLOGICAL|Obinutuzumab|Given intravenously (IV)
41459544|NCT06252675|BIOLOGICAL|Glofitamab|Given IV
41459545|NCT06252675|DRUG|Pirtobrutinib|Given Orally (PO)
41459546|NCT06252675|PROCEDURE|Tumor Imaging|Undergo regular care imaging/scans
41459547|NCT06252675|PROCEDURE|Biospecimen Collection|Blood and tissue samples
41459548|NCT06252675|DEVICE|ClonoSeq Assay|ClonoSEQ is an FDA-cleared, Clinical Laboratory Improvement Amendments of 1988 (CLIA)-validated measure used to determine minimal residual disease (MRD). This helps uncover how much, if any, cancer remains in your body during and after treatment.
41459549|NCT06252675|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration.
41459550|NCT05338853|OTHER|Gongs mobilization|to deal adhesive capsulitis
41459551|NCT05338853|OTHER|scapular mobilization|scapular mobilization
41459552|NCT05158660|DEVICE|transcranial duplex sonography|it is an imaging device that will measure the intracerebral hematoma expansion
40771353|NCT04951193|BEHAVIORAL|Behavioral Activation Therapy app|Goal2QuitVaping focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
41459553|NCT03196817|DRUG|betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%|6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%
40771354|NCT04951193|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about quitting vaping nicotine with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
41459554|NCT03196817|DEVICE|Wrist splinting|Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
40771355|NCT06355297|BEHAVIORAL|Education about pelvic floor|The three educational sessions will last 60 minutes, as follows: session1, anatomy of pelvic floor; session2, function and dysfunction of pelvic floor; session3, risk factor for pelvic floor dysfunctions.
40771356|NCT04535297|OTHER|exposure|Exposure to social distancing due to COVID-19
40771357|NCT00200746|DRUG|Arginine|Amino Acid Arginine
41300190|NCT03955107|DEVICE|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) every 4 weeks since diagnosed with GDM，and the control grouponly once receive CGMS during the last month and have management adjusted based on the CGMS readings Other Name: iPro, Medtronic
40771358|NCT02956148|RADIATION|Radioligand [18F]MNI-659|The effective radiation dose for the injection of \[18F\]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
41300191|NCT02244359|BEHAVIORAL|Training|
40771359|NCT03955978|DRUG|TSR-042|-TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion
41300192|NCT02244359|BEHAVIORAL|Usual care|
40771360|NCT03955978|RADIATION|Brachytherapy|-This trial will include image-guided brachytherapy with three-dimensional (3-D) treatment planning and in cases where pelvic radiation is deemed appropriate by the treating radiation oncologist, external beam radiation therapy (EBRT) using intensity modulated radiation therapy (IMRT) technique.
40771361|NCT03955978|PROCEDURE|Endometrial biopsy|-Prior to the start of treatment with TSR-042. If this biopsy yields insufficient tumor tissue, an archival sample may be requested, with Fraction 1 of brachytherapy, with Fraction 4 of brachytherapy
40771362|NCT03955978|PROCEDURE|Blood draw for immune response|-Prior to the start of any treatment, at the time of brachytherapy fractions 1 and 4 (corresponding to endometrial biopsy), prior to fourth dose of TSR-042, 6 weeks after the completion of all protocol related therapy
40771363|NCT06500507|DRUG|QLS4131 Injection|Participants confirming to the eligibility criteria will be assigned to 1 of the 9 dose groups (0.06/0.3/1 \~ 600 ug/kg, respectively) based on the sequence of inclusion.
40771364|NCT04357470|OTHER|Hand Therapy|The patients were admitted to 12-weeks rehabilitation program and were called up once a week for follow-up appointments. Hand therapy continued as home program between 12th week and 6th month.
40771365|NCT00589524|DEVICE|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
40771366|NCT05121350|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.
40771367|NCT05121350|DRUG|Epirubicin|Epirubicin can inhibit the synthesis of DNA and RNA.
41300193|NCT00003369|DRUG|cisplatin|75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle
41300194|NCT00003369|DRUG|tirapazamine|260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
41459555|NCT04943887|BEHAVIORAL|eSupport Health Weekly Group Sessions for PwMS|A formal semi-structured program of psychoeducational support delivered in an online weekly small group format by health coaches (licensed therapists) who specialize in MS.
40771368|NCT05121350|DRUG|Arotinib hydrochloride capsule placebo|Placebo of Anlotinib hydrochloride capsule
40771369|NCT02568319|DRUG|LIPO-202|
40771370|NCT02568319|DRUG|Placebo|
40771371|NCT05179577|DRUG|Arbaclofen|Arbaclofen Extended Release Tablets
40771372|NCT05179577|DRUG|Placebo|Placebo tablets
40771373|NCT05827341|OTHER|No intervention|No intervention needed
41140521|NCT03909074|BIOLOGICAL|36-71 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
41140522|NCT03909074|BIOLOGICAL|36-71 months old children-control EV71 vaccine.|Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.
41459556|NCT01023061|DRUG|abiraterone acetate|Given PO
41459557|NCT01023061|DRUG|prednisone|Given PO
41459558|NCT01023061|DRUG|leuprolide acetate|Given via injection
41140523|NCT03909074|BIOLOGICAL|6-35 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
41140524|NCT03213587|DRUG|Apatinib|500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
41140525|NCT02958722|PROCEDURE|diagnostic hysteroscopy|Endoscopic procedure to visualize uterine cavity
41140526|NCT02958722|DRUG|physiological solution|
41459559|NCT01023061|OTHER|laboratory biomarker analysis|Correlative study
41459560|NCT01023061|RADIATION|external beam radiation therapy|Undergo radiotherapy
40771374|NCT06549348|RADIATION|Measure average procedure fluoroscopy time using LumiGuide and conventional fluoroscopy guidance|Fenestrated Endovascular Aortic Repair (FEVAR) procedure done with either LumiGuide or conventional fluoroscopy guidance
41300195|NCT03661073|BEHAVIORAL|Assessment of motor imagery ability|The intervention will last 3 hours ± 45 minutes, the assessment will be spread over 3 sessions of 1 hour ± 15 minutes on one week. The time between two sessions will depend on patient fatigability and availability. The VMIQ-2 and the KVIQ-20 will be realized during the first session. In the second session, patients will perform the hand laterality judgment task and the MIQ-RS. During the last session the Timed up and go and the box and block test will be realized.
41300196|NCT03661073|BEHAVIORAL|Assessment of motor imagery ability of healthy subject|The intervention will last 2 hours ± 15 minutes. All the tests will be spread over 1 session. Assessment order will be VMIQ-2, KVIQ-20, the hand laterality judgment task, the after a break MIQ-RS, iTUG and iBBT.
41300197|NCT03092258|OTHER|Questionnaire|Questionnaire to be completed by staff
41300198|NCT01180374|DRUG|Cannabidiol|Active Cannabidiol 5mg.
41459561|NCT01023061|DRUG|goserelin acetate|Given via injection
41459562|NCT02581917|OTHER|Cytology Specimen Collection Procedure|Undergo collection of PBMC samples
40771375|NCT03199079|OTHER|Measurement|Measurement of cervix elasticity and length measurements is not an intervention
41459563|NCT02581917|OTHER|Laboratory Biomarker Analysis|Undergo metabolic analysis
41459564|NCT02497235|DRUG|TAK-935|TAK-935 oral solution.
41459565|NCT02497235|DRUG|[18F]MNI-792 (tracer)|\[18F\]MNI-792 injection.
40771376|NCT05399212|DRUG|FPT-20|FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(\>6 to 12 months) until the therapeutic purpose is achieved.
40771377|NCT05380700|DEVICE|Virtual Reality Stimulation|Participants in the intervention group will be provided with up to 30 minutes of relaxing, 360-degree virtual reality (VR) stimulation and corresponding sounds, twice in 24 hours during their stay on the intermediate care unit.
40771378|NCT00391716|DRUG|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
40771379|NCT00391716|BEHAVIORAL|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
40771380|NCT00391716|DRUG|placebo|lactose capsule compounded to mimic gabapentin capsules
40771381|NCT00391716|DRUG|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
41140527|NCT02958722|DRUG|carbon dioxide|
41140528|NCT04299009|DEVICE|Bright light therapy glasses|Bright light therapy delivered through glasses
41140529|NCT06500546|PROCEDURE|Treatment of cervical lesions|"Four non-carious cervical lesions from patients will be separated into four groups according to according to the adhesion trategies described below:~1. adhesive material will be applied in total-etch mode,~2. adhesive material will be applied in self-etch,~3. universal adhesive material will be applied for 10 sec. in total-etch mode, which includes rubbing,~4. universal adhesive material will be applied for 10 sec. in self-etch mode, which includes rubbing,"
41140530|NCT00286832|PROCEDURE|PET scan|One extra PET scan after 1 cycle of treatment.
41140531|NCT05934175|BEHAVIORAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
41140532|NCT05934175|BEHAVIORAL|Weekly delivered prolonged exposure|Weekly delivered prolonged exposure sessions for 15 weeks
41140533|NCT02713594|BEHAVIORAL|Counseling from WTQL|Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
40771382|NCT04952714|DEVICE|Oxiris|Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device, at a dose of 25 mL / Kg of PrismaSate dialysis solutio and the removal filter oXiris® cytokines (Baxter) vs. the standard filter.
40771383|NCT05031962|DEVICE|CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in breast reconstruction
40771384|NCT02835105|DRUG|Surotomycin|A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
41140534|NCT02713594|OTHER|Financial incentive to participate|Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
40771385|NCT02835105|DRUG|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
41459566|NCT01256996|PROCEDURE|Air abrasion of the implant surface with a low abrasive powder|Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
40771386|NCT06558773|DRUG|Eliglustat+Immune checkpoint inhibitor+Regorafenib|"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."
40771387|NCT06558773|DRUG|Eliglustat+Immune checkpoint inhibitor|"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) ."
40771388|NCT06558773|DRUG|Regorafenib+Immune checkpoint inhibitor|"Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."
40771389|NCT00977444|DRUG|kondrium|intraarticular injections once month
40771390|NCT00977444|DRUG|kondrium f|intraarticular injections once month
41300199|NCT01180374|DRUG|Delta-9-THC|"Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint."
41300200|NCT01180374|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
40771391|NCT00977444|DRUG|methyl prednisolone (corticosteroid)|intraarticular injections once month
40771392|NCT06006286|DRUG|Atezolizumab|Given by IV (vein)
40771393|NCT06006286|DRUG|Bevacizumab|Given by IV (vein)
40771394|NCT06006286|DRUG|ADI-PEG 20|Given by Injection (inj)
40771395|NCT04474847|DRUG|Abatacept|Participants randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
40771396|NCT04474847|DRUG|Placebo|Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
40771397|NCT03231553|OTHER|MiQuit text message support programme|MiQuit is an automated, responsive text message support programme lasting 12 weeks which sends texts containing self-help smoking cessation support and advice to participants mobile phones.
40771398|NCT04354623|OTHER|A 6-minute walk test|Each subject will perform a 6-minute walk test during which gait assessment will be obtained from the APDM system (Portland, OR). In addition there will be four video cameras (on the front, back and sides) that will measure raw video data for our gait analysis. The camera does not record any facial data (in fact, 'deepfake' software in the system deletes all facial details) and the patient's movements are converted to a 'stick figure' prior to being saved in the system.
41140536|NCT01190436|DRUG|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
41140537|NCT02613767|OTHER|Protein meal|Ingestion of protein
41140538|NCT02613767|OTHER|L-[ring 13C6]Phenylalanine infusion|experimental method for determining protein synthesis rates
41140539|NCT05389202|OTHER|Perfusion CT scanning|Abdominopelvic CT scan with perfusion and spectral analysis performed 7 days (± 5 days) before prostate embolization.
41300201|NCT01180374|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
41300202|NCT04048122|BEHAVIORAL|MultiContext for PD Strategy Training|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
41140540|NCT03543982|DIETARY_SUPPLEMENT|Oral probiotic product|Once per day (QD), 28 days
41459567|NCT04832776|DRUG|Cetuximab|one group plus cetuximab
41459568|NCT04832776|DRUG|Bevacizumab|one group plus bevacizumab
41459569|NCT04832776|DRUG|FOLFOXIRI|FOLFOXIRI
41459570|NCT01724762|OTHER|Nursing Orientation|"* Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information~* Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath"
41459571|NCT05232773|PROCEDURE|Assessment|Evaluation of clinical and kinematic parameters
41140541|NCT05351697|DRUG|BR105 injection|0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively
41140542|NCT06034145|OTHER|No intervention|No intervention
41459572|NCT05114668|DRUG|EVT801|"Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study."
41459573|NCT03430635|PROCEDURE|Hepatectomy|Surgery of the liver: removal of a given part of the liver affected by hepatocellular carcinoma
41140543|NCT04812977|DRUG|Group A|Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)
41300203|NCT04048122|BEHAVIORAL|Standard of Care|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
41300204|NCT02897635|BEHAVIORAL|Individualized Integrative Medicine Intervention|
41300205|NCT04752579|OTHER|Pilates exercise program|"The program will be individually supervised and will be conducted twice a week at the physiotherapy center.~• Slow execution of 7-10 repetitions of the following Pilates exercises: Pelvic Curl, Pilates Single Legs Lifts \& Leg Change, Twist Supine Pilates exercise, Chest Lifts Pilates Exercise, Chest Lift with Rotation Pilates exercise, 100's Prep Pilates Exercise, Single Leg Stretch Pilates Exercise, Front Support Pilates Exercise and Basic Back Extension Pilates Exercise. After the 6th week, while the person will be familiar with the basic exercises of the Pilates method the following exercises will be added: Leg Pull Front, Side Bend Pilates Exercise, Sphinx - Abdominal Lift Pilates Exercise, Shoulder Bridge Prep Pilates and Shoulder Bridge Pilates Exercise. Each session will be completed with breathing exercises and stretching exercises of the torso and lower limbs for 5 minutes."
41300206|NCT02094586|BIOLOGICAL|PXVX0200 Lot A|Lot P700-1CA03
41300207|NCT02094586|BIOLOGICAL|PXVX0200 Lot B|Lot P700-3CA03
41300208|NCT02094586|BIOLOGICAL|PXVX0200 Lot C|Lot P700-6BA03
41300209|NCT02094586|BIOLOGICAL|Placebo|Placebo
41300210|NCT05049512|OTHER|Multi-nut OIT|Finely ground pure peanut, almond, cashew, hazelnut, and walnut.
41300211|NCT01290081|OTHER|Case management approach in referral to health care services|Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
41300212|NCT00540722|DRUG|R-(-)-gossypol acetic acid|Given PO
41300213|NCT00540722|OTHER|laboratory biomarker analysis|Correlative studies
41300214|NCT04015947|DEVICE|CelluTome® Epidermal Harvesting System|split-thickness skin grafts from a matched bone marrow donor using the CelluTome® Epidermal Harvesting System
41459574|NCT01292837|DRUG|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
41459575|NCT00195754|DRUG|divalproex sodium|
41459576|NCT01372930|DRUG|Etanercept|Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
41459577|NCT01372930|DRUG|saline|saline 1ml(subcutaneous injection) at 2h and 72h after PCI
41459578|NCT00770952|DRUG|Pioglitazone and Glimepiride|"Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks."
41140544|NCT01249144|DEVICE|Intraocular Lens (IOL)|Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
41300215|NCT06171880|DRUG|JLP-1901|administration of JLP-1901
41300216|NCT06171880|DRUG|JC-001(active comparator)|administration of JC-001(tenofovir)
41300217|NCT01825044|DRUG|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
41300218|NCT01825044|DRUG|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
41300219|NCT01217658|BEHAVIORAL|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
41300220|NCT01217658|BEHAVIORAL|AAP Infant Colic counseling|Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
41300221|NCT02680847|DRUG|ALO-02|Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
41300222|NCT03242278|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
41300223|NCT06549296|DRUG|RD06-04 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
41300224|NCT00717418|DRUG|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
41300225|NCT04376346|BEHAVIORAL|Native WYSE CHOICES|Native WYSE (Women, Young, Strong, and Empowered) CHOICES (Changing High-risk alcohOl use and Increasing Contraception Effectiveness Study) is an alcohol-exposed pregnancy prevention program that translates CHOICES, an evidence-based targeted intervention, into an mHealth universal intervention for young urban American Indian/Alaska Native (AI/AN) women ages 16-20.
41459579|NCT00770952|DRUG|Glimepiride|"Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks."
40975352|NCT02994979|OTHER|Delirium-prevention|"Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients."
40975353|NCT02994979|OTHER|Sham comparator|Usual care plus sham visits by CNA
40975354|NCT01511315|DRUG|Ustekinumab|Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
40975355|NCT04958005|DIAGNOSTIC_TEST|ELISA|Enzim linked immunoabsorbant assay
40975356|NCT06140784|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
40975357|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
40975358|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
40975359|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
40975360|NCT05983276|DRUG|Decitabine|Decitabine is classified as hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
40975361|NCT05983276|DRUG|Carboplatin|Carboplatin is classified as an alkylating agent that is used to treat ovarian cancer.
40975362|NCT05983276|DRUG|Paclitaxel|"Paclitaxel is classified as a plant alkaloid, a taxane and an antimicrotubule agent."
40975363|NCT05983276|DRUG|Selinexor|Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by killing cancer cells.
40975364|NCT00846430|DRUG|Peg-Interferon alpha-2b|age and weight dependant
40975365|NCT00846430|DRUG|Celecoxib (Celebrex)|age and weight dependant
40975366|NCT00846430|DRUG|Temozolomide (temodar)|age and weight dependant
41300226|NCT02612662|DRUG|AZD4076|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
41459580|NCT04657458|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
41459581|NCT04789733|OTHER|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management)
41459582|NCT04789733|OTHER|Routine pressure management|Routine intraoperative blood pressure management and immediate restart of antihypertensive medications.
41459583|NCT06359275|DRUG|PD-1|Toripalimab，240 mg/time，D1， Q3W
41459584|NCT06359275|DRUG|Nab-paclitaxel|Nab-paclitaxel, 125mg/m2，IV，D1，8, Q3W
41300227|NCT02612662|DRUG|Placebo|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
41300228|NCT03714113|DIAGNOSTIC_TEST|Anti-HLA donor-specific antibodies monitoring|Monitoring anti-HLA donor-specific antibodies in the patients serum at the time of kidney transplantation and 3, 12 and 24 months after the procedure. Blood samples from patients will be collected.
41300229|NCT05703802|DIAGNOSTIC_TEST|Procalcitonin-variants ELISA-Assay|Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.
41300230|NCT02210871|DRUG|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
41459585|NCT06359275|DRUG|Gemcitabine|Gemcitabine，1000mg/m2，IV，D1，8，Q3W
41459586|NCT06359275|RADIATION|PULSAR|5-10 Gy per session, a total of 5 times.
40975367|NCT00846430|DRUG|Vincristine Sulfate (Oncovin)|age and weight dependant
40975368|NCT03062683|OTHER|Lactate, prolactin and creatine kinase conc.|Lactate, prolactin and creatine kinase conc. in blood samples were measured
40975369|NCT04655274|DIAGNOSTIC_TEST|The Quality of Vision questionnaire|The Quality of Vision questionnaire rates glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception conditions.
40975370|NCT00166114|DRUG|Escitalopram|10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
40975371|NCT00166114|DRUG|Desipramine|25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
40975372|NCT00019578|PROCEDURE|Sterotactic radiosurgery|
41459587|NCT06375915|RADIATION|radioembolization with Y-90|Radioembolization with Y-90 will be performed in nominal day 0
41459588|NCT06375915|DRUG|Durvalumab|Following radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle
41459589|NCT06375915|DRUG|Cisplatin|Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
40975373|NCT05984732|BEHAVIORAL|Reminiscence with digital storytelling|The older and young adult participants will be randomly assigned into the intervention (reminiscence) or control (social wellness) groups and then be randomly matched as dyads within each group. Older adults in the intervention group will receive 10 sessions of life-review with the trained young adult volunteers (1-1.5 hours each week for 10 weeks). During weeks 1-6, a life history interview will be carried out with different themes in each week: major turning points in life (W1), family history (W2), life/career accomplishments (W3), history of loves and hates (W4), stress experiences (W5), and meaning and purpose of life (W6). During weeks 7-10, the dyads will develop the DST together using tablets already owned by the UTA School of Social Work. The contents of sessions 7-10 will be structured as: outline/script, plan and storyboard (W7), film and record (W8), evaluate, integrate and finalize (W9), and publish/share (W10).
40771399|NCT05923723|OTHER|FIBNUTRITION|"The dietary product selected for the study is commercially known as FIBNUTRITION, marketed in Colombia by Bio-Nutrition S.A.S with sanitary registration number NSA-001942-2016.~Ingredients of the product:~Flaxseed, Chia seeds, Psyllium, Polydextrose, Oat flour, Apple, Orange, Artificial flavor (Orange), Pineapple, Nopal, Xanthan gum (thickener), Silicon dioxide, Stevia (Natural sweetener), Lactobacillus Acidophilus Bifidus Casei (Prebiotics), Sodium Benzoate (Preservative), and Turmeric (Natural colorant)."
40771400|NCT05923723|OTHER|Placebo|The placebo is a dietary product composed of maltodextrin, cornstarch, orange flavoring, and stevia.
40975374|NCT05984732|BEHAVIORAL|Social wellness with scrapbook or journal|Older adults in the control group will have general social wellness discussion with the young adult volunteers, instead of structured reminiscence guidelines. The topics are: diet and health (week 1); exercise/activity and health (week 2); emotions and health (week 3); religious/spiritual practices and health (week 4); family/friend relationships and health (week 5); and social activities/engagement and health (week 6). For weeks 7-10, instead of DST, the young adult volunteer will work with the older adult to create an unstructured, non-digital record of the social visit related to wellness in later life (e.g. wellness scrapbook/journal).
40975375|NCT03414034|DRUG|Onvansertib|Onvansertib orally
40975376|NCT03414034|DRUG|Abiraterone|Abiraterone orally
40975377|NCT03414034|DRUG|Prednisone|Prednisone orally
40771401|NCT05627037|DEVICE|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will be randomly allocated to receive Temporary restoration after 30 days and definitive restoration after 90 days
40771402|NCT05627037|DEVICE|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will receive definitive restoration after 90 days
40771403|NCT03524157|DRUG|PRO-087|The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.
40771404|NCT03524157|DRUG|Systane Ultra|The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.
40771405|NCT03524157|DRUG|Xyel Ofteno|The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.
40771406|NCT03286868|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
40771407|NCT03286868|DEVICE|Total Knee Arthroplasty with Verasense sensor|Total Knee Arthroplasty with Verasense sensor
40975378|NCT06292065|DIAGNOSTIC_TEST|Point-of-care gastric ultrasound|Using ultrasound to visualise the gastric antrum in supine position and right lateral decubitus.
40975379|NCT03555201|OTHER|Manual therapy|protocol of soft tissues techniques
41459590|NCT06375915|DRUG|Gemcitabine|Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
41459591|NCT05419817|DRUG|pembrolizumab|Pembrolizumab is an immunotherapy (monoclonal antibodies) that will be given at a dosage of 200 mg IV, on Day 1 of each 21 day treatment cycle
40975380|NCT03555201|OTHER|Regular treatment control.|Regular treatment control.
40975381|NCT05861921|OTHER|Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture|Lithium Di-silicate as final restorative material for resin bonded Fixed Partial Denture replacing missing upper anterior tooth.
41459592|NCT05419817|DRUG|Sitravatinib|A small molecule inhibitor of multiple tyrosine kinases that will be taken at a dosage of 100 mg orally, every day
40975382|NCT03194321|DRUG|Tacrolimus Extended-Release Oral Capsule|Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
40975383|NCT04022044|BEHAVIORAL|Observational group|
41300231|NCT04449068|OTHER|Neurological and neuropsychological Follow-up after deep brain stimulation|Investigation of tic severity, psychiatric co-morbidities, quality of life, and neuropsychologcial measures until the 5-year after deep brain stimulation (DBS)
40771408|NCT03817580|DRUG|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
40771409|NCT03817580|DRUG|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
41300232|NCT03849040|PROCEDURE|Endobronchial Ultrasound|All patients will undergo EBUS-TBNA as per routine care, except for the one difference where the procedures will be video-recorded so that they can be used for computer analysis at a later time. Static images will be obtained from EBUS videos in order to perform segmentation. Segmentation will be conducted by both an experienced endoscopist and NeuralSeg.
41300233|NCT00398619|DRUG|INCB13739|
41300234|NCT03959540|DRUG|Opicapone|Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.
41300235|NCT03959540|DRUG|Levodopa (L-DOPA) + Standard care|Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
41300236|NCT05736588|BEHAVIORAL|Elimisha HPV|Elimisha HPV is a multi-level stigma-responsive cervical cancer prevention service delivery model that incorporates stigma-responsive education, peer navigation and a patient-centered delivery strategy, addressing drivers while mitigating harms from stigma.
41459593|NCT00238563|DRUG|Triamcinolone injection, sub-tenon|
41459594|NCT06377449|DIAGNOSTIC_TEST|Ultrasound examination of the lungs|Experimental: Standard ultrasound examination of the lungs based on modified BLUE protocol Active Comparator: Standard ultrasound examination of the lungs based on modified BLUE protocol
41459595|NCT02178891|DEVICE|extra short implant|
41459596|NCT04211480|BIOLOGICAL|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression
40771410|NCT03817580|DRUG|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
40771411|NCT05229666|OTHER|Cognitive Challenge|Cognitive challenge delivered via computer.
40771412|NCT05495568|BIOLOGICAL|CT-P17|CT-P17 40mg will be subcutaneous administered
40771413|NCT05495568|BIOLOGICAL|EU-approved Humira|subcutaneous administration
40771414|NCT05514288|PROCEDURE|Endobariatric procedure|Endoscopic sleeve gastroplasty or transoral outlet reduction
40975384|NCT05544357|OTHER|Short set configuration resistance training|Resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
40975385|NCT05544357|OTHER|Long set configuration resistance training|Resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
40975386|NCT01092104|DRUG|TBR-652|TBR-652 25 mg
40975387|NCT01092104|DRUG|TBR-652 Matching Placebo|Matching Placebo
40975388|NCT01092104|DRUG|TBR-652 50 mg|TBR-652 50 mg QD for 10 days
40975389|NCT01092104|DRUG|TBR-652 75 mg|TBR-652 75 mg QD for 10 days
40975390|NCT01092104|DRUG|TBR-652 100 mg|TBR-652 100 mg QD for 10 days
40975391|NCT01092104|DRUG|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
40771415|NCT04705766|OTHER|Urine Collection|A urine collection kit will be mailed to subjects' residence at 3 different timepoints over the course of 1 year to be returned to study team, upon which KIT score and other biomarkers will be assessed as outlined in the study design.
40771416|NCT06549231|DRUG|Rituximab|one course of IV rituximab consisting of an infusion of 1000 mg rituximab (diluted in 500 mL of saline 0.9 % sodium chloride) will be given at day 1, day 15 and an infusion of 500 mg rituximab (in 500 mL of saline 0.9 % sodium chloride) at week 24;
41300237|NCT00876980|DEVICE|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
41300238|NCT04208867|BEHAVIORAL|QI Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH services
40975392|NCT02968407|OTHER|Peer- and self-rating|Participants will be given a print and a e-mail of the modified OSATS global rating scale and will be introduced to how the rating scale is used to rate technical performance. The participant will receive a USB stick each allowing the participant to see a video of his/her own performance and two videos from previous post-test performances from participants enrolled in the course. One video is a video of a participant who performed poorly,the other is from a participant who performed well. The participants will be asked to watch and rate the videos of their peers' performance first and afterwards watch and rate the participants own video performance. The investigators choose to let the participants rate their peers' performances before their own, so the participants will have the best opportunities to self-rate. Participants will be asked to email the results of their ratings to the principal investigator within 3 days. And expert in surgery will also rate the videos using OSATS.
40975393|NCT02689388|PROCEDURE|Femoral Nerve Block|Use of femoral nerve block as part of general anesthesia
40975394|NCT05030038|BIOLOGICAL|Fecal swab collection|Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab
40975395|NCT05030038|BIOLOGICAL|Blood samples|Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.
40975396|NCT00286169|DRUG|Amrubicin Hydrochloride|
40975397|NCT02260921|DEVICE|iovera°|
40975398|NCT02260921|DEVICE|Sham Comparator|
40975399|NCT06211478|DRUG|Vitamin E|Vitamin E will be taken for 6 months for gaucher disease patients who have oxidative stress and vitamin E defecient
40975400|NCT05822713|DRUG|Amisulpride|5mg/2ml
40975401|NCT05822713|DRUG|Amisulpride Placebo|2ml
40975402|NCT06381882|PROCEDURE|Pancreatic resection|Any kind of pancreatic resection will be included
40975403|NCT01087398|DRUG|Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|"For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2"
40975404|NCT01087398|PROCEDURE|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical"
40975405|NCT01087398|DRUG|Cyclosporin, Methotrexate (GVHD prophylaxis)|"* Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)"
40975406|NCT05134012|DRUG|[O-15]-Water PET Myocardial Perfusion Imaging (MPI)|\[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
40771417|NCT06549231|DRUG|Placebo|one course of intravenous placebo of rituximab consisting of an infusion of 500 mL of saline (0.9% sodium chloride) infusion will be given at day 1, day 15 and week 24;
40771418|NCT06561243|DRUG|BTK inhibitor (Ibrutinib or Acalabrutinib)|Adult patients with a chronic B-cell malignancy included in this study will be separate into 2 groups according to the BTK inhibitor (ibrutinib and acalabrutinib)
41300239|NCT06255561|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
41300240|NCT05564598|BIOLOGICAL|CMV Cytotoxic T-Lymphocytes|Patients will receive maternal CMV CTLs on day 0. Additional doses of CMV CTLs may be re-infused at a minimum of every two weeks for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg) only in patients not achieving a CR and no prior dose limiting toxicity of any prior dose.
41300241|NCT05564598|DRUG|Anti-viral Therapy|"All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~* Reduce dose by 50% for ANC less than 500 cells/mm3~* Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~* Treatment will continue for 6 months"
41300242|NCT04523285|DRUG|TQB3728|TQB3728 tablets is a small molecule oral drug.
41300243|NCT01795469|DEVICE|Zoex compression garment|5-strap compression of abdomen, thighs and legs
41459597|NCT06220526|DEVICE|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Transbronchial biopsy with Menghini-type or Franseen type Needle
41459598|NCT02118987|DRUG|Omalizumab|
40975407|NCT05303636|DRUG|LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet|LF111 (drospirenone 4 mg tablet orally daily on days 1-24, followed by placebo tablet orally daily on days 25-28) or drospirenone (DRSP) 3.5 mg chewable tablet chewed daily on days 1-24, followed by placebo tablet chewed daily on days 25-28) (USA only). Subjects in the USA who choose to use the hormonal contraceptive method may choose between LF111 and DRSP 3.5 mg chewable tablets. The DRSP 3.5 mg chewable tablets are not available to subjects in Europe. Subjects in Europe who choose to use the hormonal contraceptive method will only receive LF111.
40975408|NCT00246727|DRUG|Selected Vegetable and Herb Mix|The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
41140545|NCT02399111|DEVICE|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
41300244|NCT04180059|COMBINATION_PRODUCT|CTL 19|Patients candidate for allogeneic transplantation who are both HLA-DPB1\*04:01 and with a HLA-DPB1\*04:01-expressing hematological malignancy (almost 100% of cases) with a donor HLA-DPB1\*04:01 negative, will be proposed to receive one single infusion of the T cell clone at 4-5 months post-transplantation, once the immunosuppression by cyclosporine and/or mycophenolate mofetil has been discontinued.
41300245|NCT05684978|DRUG|Perampanel|The purpose of this study is to determine the efficacy of Perampanel, an approved antiseizure medication, in the treatment of refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
41300246|NCT03220048|DRUG|PrEP-001|
41140546|NCT03008785|OTHER|exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
41300247|NCT03220048|OTHER|Placebo Comparator|
41300248|NCT00385567|DRUG|PEHRG214|
41300249|NCT01958034|DIETARY_SUPPLEMENT|Bilberry extract|
41300250|NCT00830037|DRUG|IV Iron|IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
41300251|NCT00830037|DRUG|Ferrous Sulfate|Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
41300252|NCT03914820|PROCEDURE|HIPEC CO2 surgery|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
41459599|NCT01489930|BEHAVIORAL|Endurance exercise|Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
41459600|NCT01489930|BEHAVIORAL|Resistance exercise|Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for \~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
41459601|NCT01489930|BEHAVIORAL|Control/Combined training|Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
41140547|NCT03008785|OTHER|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
41300253|NCT03914820|PROCEDURE|Standard surgery|Standard surgery without HIPEC CO2
41300254|NCT03914820|DRUG|Mitomycin|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
41300255|NCT01048229|DRUG|Rasagiline|1 mg rasagiline once daily (plus placebo twice daily)
41300256|NCT01048229|DRUG|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
41300257|NCT05994794|DIETARY_SUPPLEMENT|Alpha-GPC, Creatine and Ashwagandha (Sensoril®)|Other Ingredients: Microcrystalline Cellulose, Rice Fiber, Maltodextrin, Silica, Vegetable Stearate
41300258|NCT05994794|OTHER|Placebo|Microcrystalline Cellulose
41300259|NCT04080154|DRUG|Anlotinib|12mg orally (p.o.) every day (qd) for 2 weeks of every 3 week cycle (i.e. 2 weeks on, 1 week off)
41300260|NCT06034834|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
41300261|NCT01073696|DRUG|granisetron IV|IV
41300262|NCT01073696|DRUG|granisetron patch|patch
41300263|NCT02510235|DEVICE|Lubricin|Lubricin 150 µg/ml eye drops
41300264|NCT02510235|DEVICE|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
41459602|NCT03990233|DRUG|BI 765063|mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor
41459603|NCT03990233|DRUG|BI 754091|mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor
41459604|NCT01974362|DEVICE|Dental Implant|Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications
41459605|NCT01974362|DEVICE|Monolithic Zirconia (MZ)|rehabilitation with monolithic zirconia implant-prosthesis with bucal feldspathic veneer
41459606|NCT01974362|DEVICE|Zirconia-Feldspathic (PVZ)|restore dental implants with a zirconia suprastructure and feldspathic veneers
41459607|NCT01974362|DEVICE|Monolithic Zirconia (FCMZ)|Full contour full arch zirconia rehabilitation
40975409|NCT05612984|COMBINATION_PRODUCT|Calcium aspirin multiple micronutrients|Women randomized to CAMMS will receive weekly blister cards containing all 3 components: 1 81 mg aspirin tablet, 1 UNIMMAP MMS, and 1 500-mg elemental calcium tablets. Blister packages will be labeled with times of day and days of week when tablets are to be taken. 4 weekly blister cards will be packaged in one unit box.
40975410|NCT05612984|DIETARY_SUPPLEMENT|Iron-folic Acid|Women randomized to IFA will receive monthly (28-day) blister cards containing containing 1 combined IFA tablet to be taken each day. 1 4-weekly blister card will be packaged in one unit box.
40975411|NCT03546192|BIOLOGICAL|Fluzone Quadrivalent Influenza Vaccine|0.5-mL, Intramuscular, SH 2015 formulation
40975412|NCT05407402|BEHAVIORAL|laughter yoga practice|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
40975413|NCT05407402|BEHAVIORAL|watching funny videos|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
40975414|NCT02382393|OTHER|Brain Performance Test (BPT, Lumos Labs, Inc)|A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.
40975415|NCT02382393|OTHER|Computerized Assessment|a validated, computerized cognitive assessment tool
40975416|NCT01896440|DRUG|Ondansetron|There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
40975417|NCT06166303|DIAGNOSTIC_TEST|sFlt-1/PGIF|Index of sFlt-1/PGIF
40975418|NCT06254404|DRUG|Low dose protamine|Administration of 70% of the normal dose of protamine
40975419|NCT06378463|OTHER|Cognitive remediation + active tDCS|"The cognitive remediation program Computerised Interactive Remediation of Cognition - a Training for Schizophrenia (CIRCuiTS) improves cognitive and metacognitive skills and strategies and is specifically aimed at the generalization of newly learnt skills to daily life. This method also offers the possibility to personalize the training program based on individual goals and cognitive functioning of the service user.~Transcranial Direct Current Stimulation is used to promote neural plasticity, which applies a small electrical current over the cortex. This can alter the excitability of neurons, such that it increases or decreases spontaneous network activity. When applied to fronto-parietal neural networks simultaneously with their engagement in cognitive tasks of CIRCuiTS, it is expected that plasticity of these networks will be modulated, resulting in improvements in cognitive functioning.~In this condition, participants will receive active brain stimulation."
40975420|NCT06378463|OTHER|Cognitive remediation + sham tDCS|"The cognitive remediation program Computerised Interactive Remediation of Cognition - a Training for Schizophrenia (CIRCuiTS) improves cognitive and metacognitive skills and strategies and is specifically aimed at the generalization of newly learnt skills to daily life. This method also offers the possibility to personalize the training program based on individual goals and cognitive functioning of the service user.~Transcranial Direct Current Stimulation is used to promote neural plasticity, which applies a small electrical current over the cortex. This can alter the excitability of neurons, such that it increases or decreases spontaneous network activity. When applied to fronto-parietal neural networks simultaneously with their engagement in cognitive tasks of CIRCuiTS, it is expected that plasticity of these networks will be modulated, resulting in improvements in cognitive functioning.~In this condition, participants will receive sham brain stimulation."
40975421|NCT02028624|BEHAVIORAL|Nutrition counseling|Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
40975422|NCT03529916|OTHER|isolation of endothelial cells precursors in blood|Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.
40975423|NCT00438113|DRUG|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
40975424|NCT02118389|DIETARY_SUPPLEMENT|Glucerna|Glucerna 52g meal replacement
40975425|NCT02214524|DEVICE|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
41459608|NCT03944057|DRUG|ATG-010|"ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).~Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)"
40975426|NCT04691453|PROCEDURE|QM-C Hysterectomy|This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.
40975427|NCT04691453|PROCEDURE|QM-B Hysterectomy|Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.
40975428|NCT02766725|DRUG|preparation F12 sildenafil in situ gel|in situ vaginal gel
40975429|NCT02766725|DRUG|preparation F2 sildenafil in situ gel|in situ vaginal gel
40975430|NCT02766725|DRUG|placebo gel|vaginal gel
40975431|NCT03704207|OTHER|nNO testing|Collection of already performed clinical data and nNO testing
41300265|NCT04349254|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The change of modulus produces a change of corneal stiffness and shape that modifies the distribution of light onto the retina. Light rays are redirected from dysfunctional areas of the retina that have been damaged by age-related macular degeneration (AMD) to functional areas of the retina, thereby improving patient vision.
41140548|NCT03008785|OTHER|Placebo|Daily supplementation in 1 capsule per day containing starch of corn.
41140549|NCT02225288|DRUG|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
40771419|NCT06158152|DIETARY_SUPPLEMENT|AM3 + Probiotic|Two capsules daily in the morning during 12 weeks. The capsule contains the mixture of AM3 Technology and probiotic SynBalance Metsyn.
40771420|NCT06158152|DIETARY_SUPPLEMENT|Placebo|Two capsules daily in the morning during 12 weeks. The capsule contains starch.
40771421|NCT06158152|DIETARY_SUPPLEMENT|AM3|Two capsules daily in the morning during 12 weeks. The capsule contains AM3 Technology.
40771422|NCT05803785|DRUG|BBC1501|BBC1501 solution for Intravitreal injection
41140550|NCT01324648|BEHAVIORAL|Telephone-supported self-help and GP treatment as usual|"Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing."
41140551|NCT01324648|BEHAVIORAL|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
41140552|NCT01324648|OTHER|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
41140553|NCT03662841|PROCEDURE|Ablative chemoembolization (ACE)|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
41140554|NCT01472796|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
41140555|NCT01472796|DRUG|Tekturna(Aliskiren) plus placebo|Aliskiren 300 mg per day supplemented with placebo
41140556|NCT05057637|DEVICE|Optical coherence tomography measurements|Optical coherence tomography measurements in femoropopliteal tract
41140557|NCT00220805|DRUG|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
41140558|NCT00220805|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
40771423|NCT00656370|DRUG|recombinant human hyaluronidase|150 Units in 1mL
40771424|NCT06197724|DEVICE|Magnetocardiography|Magnetocardiography
40771425|NCT05032352|DRUG|Adjuvant|Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.
40771426|NCT05032352|OTHER|Observation|All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
40771427|NCT05671666|DIAGNOSTIC_TEST|Urea cycle flux study|Quantification of ureagenesis
40771428|NCT05574270|DEVICE|IC-8 Intraocular Lens (IOL)|A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
40771429|NCT06467188|OTHER|Validity and reliability|"In order to evaluate the content validity of the Turkish version of the scale, 12 expert researchers in the field of gynecology and obstetrics were consulted. The experts were asked to evaluate the items as 1-Not Appropriate, 2-Somewhat Appropriate, 3-Reasonably Appropriate, and 4-Very Appropriate. Experts were asked to suggest items not evaluated as very appropriate. In the Davis technique, the content validity index which is calculated by dividing the number of experts who marked the options a (The item is appropriate) and b (The item needs minor revision) for each item by the total number of experts providing opinions is expected to be over 0.80 \[30\]. Based on expert opinions, the content validity index (CVI) value of the scale was calculated to be 96%, meaning that content validity was ensured. The items were reorganized by considering the experts' suggestions. The scale was administered to 252 women over 18 who were included in the study sample after scoring."
40975432|NCT04184869|DRUG|Belinostat|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A \& B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
40975433|NCT04184869|DRUG|Atazanavir|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir) Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
41140559|NCT02795741|DEVICE|Cooling Bolero|a vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
41140560|NCT00680134|DRUG|AN2690|AN2690 1% Solution, once daily for 180 days
41140561|NCT00680134|DRUG|AN2690|AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
41140562|NCT03874949|DEVICE|SEALITE Regular|Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
41140563|NCT03874949|DEVICE|SEALITE Ultra|"Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).~The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control."
41140564|NCT04710576|DRUG|Axatilimab|Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.
41140565|NCT02359929|BIOLOGICAL|Autologous mesenchymal stromal cells (MSCs)|Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
41140566|NCT01613599|DRUG|Rituximab|Participants received rituximab at the discretion of their treating physicians.
41140567|NCT04257916|OTHER|Experimental|Myofascial technique intervention of the subastragalar joint, kinesiotape and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
41140568|NCT04257916|OTHER|Manual therapy group|Myofascial technique of the subastragalar joint and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
41140569|NCT01640288|DRUG|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
41140570|NCT01640288|OTHER|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
41300266|NCT02422953|DIETARY_SUPPLEMENT|Wheat Soya Blend (WSB)|A monthly ration of 5 Kg of Wheat Soya Blend (WSB) will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth
41300267|NCT02422953|DIETARY_SUPPLEMENT|Wawa Mum|Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period
41300268|NCT02422953|DIETARY_SUPPLEMENT|Micronutrient Powders (MNP)|Children 24-59 months of age will receive a sachet of Micronutrient Powders (MNP) in alternate days
41300269|NCT02422953|BEHAVIORAL|Behavior change and preventive health massages|Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
40771430|NCT03161873|DEVICE|Ava|Ava is a fertility monitoring bracelet that collects various physiological parameters
40771431|NCT01437189|DRUG|Sertraline|Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
40771432|NCT01405664|OTHER|Weight-Bearing as Tolerated|WBAT immediately after surgery
40771433|NCT05147142|DEVICE|Low Intensity Focused Ultrasound|Brainsonix BX Pulsar 1002
40975434|NCT04907721|DIAGNOSTIC_TEST|Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon|"The test consists of two experimental study days:~Day 1: intravenous bolus-injection of glucagon (0.2 mg at time 0 minutes) evaluating the effect of exogenous glucagon on amino acid disappearance. Blood samples will be obtained from time -10 to 120 minutes.~Day 2: 45-minute intravenous infusion of mixed amino acids (331 mg/min/kg body weight from time 0-45 minutes) to evaluate the effect of endogenous glucagon on amino acid metabolism. Blood samples will be obtained from time -10 to 180 minutes.~All participants will be subjected to a magnetic resonance imaging scan to assess whole-liver steatosis, and a bioelectrical impedance analysis to assess body composition.~Following study inclusion and the magnetic resonance imaging scan, participants will be stratified into groups based on hepatic steatosis. Individuals with \<5.6 % hepatic steatosis will be classified as controls and individuals with ≥5.6 % hepatic steatosis will be classified as MASLD."
40975435|NCT03924973|BEHAVIORAL|ESDM followed by treatment as usual|"The intervention was ESDM, delivered by professionals, one therapist per child, 12 hours per week during 2 years.~Then, they will receive the treatment as usual during 3 years in this current follow-up study.~Precise description of the 2 years ESDM treatment can be found in the published protocol of IDEA.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community.~All the interventions received by the children will be monitored in IDEA-2. All different treatment approaches will be quantified (type, frequency, intensity and duration)."
41140571|NCT04829188|BEHAVIORAL|Structured Telephone Support (STS)|Structured telephone support (STS) consists of post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care within seven days post-discharge.
41140572|NCT04829188|BEHAVIORAL|Low-intensity Remote Patient Monitoring (RPM-Low)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
41300270|NCT03807999|DRUG|Nab-paclitaxel|
41140573|NCT04829188|BEHAVIORAL|High-intensity Remote Patient Monitoring (RPM-High)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
41140574|NCT04829188|BEHAVIORAL|Standard Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' PCP or specialist to coordinate care and ensure timely follow-up.
41300271|NCT03807999|DRUG|Gemcitabine|
41300272|NCT00210015|DRUG|INS37217 Nasal Spray|
41300273|NCT03587558|DRUG|Carvedilol|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
41300274|NCT03587558|DRUG|Flecainide|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
41300275|NCT06554353|DEVICE|Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
41300276|NCT01158534|DRUG|celecoxib|Given orally
41300277|NCT01158534|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously
41300278|NCT01158534|OTHER|polymerase chain reaction|Correlative studies
41300279|NCT01158534|OTHER|laboratory biomarker analysis|Correlative studies
41300280|NCT01158534|OTHER|reverse transcriptase-polymerase chain reaction|Correlative studies
41300281|NCT01158534|OTHER|immunologic technique|Correlative studies
41300282|NCT01158534|OTHER|immunohistochemistry staining method|Correlative studies
40771434|NCT01809431|BEHAVIORAL|Intervention|Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy.
40975436|NCT05208255|OTHER|Exercise|"NEP is a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercises are progressed from simple to complex tasks. Varied equipment (such as different sized balls, rackets, tulles, exercises balls, eye bands, ropes etc.) is used during different exercises containing cross-limb movements, throwing, jumping, walking, and cognitive tasks. Although the stages of the NEP and exercise selection are the same for each participant, the use of materials or cognitive tasks selection may differ according to the age and skill of the participant. The cognitive tasks were performed by using different visual (colored cards, numbered cards etc.) or auditory cues.~Motor Imagery Program: Motor imagery (MI) is a dynamic mental state during which the representation of a given motor movement is rehearsed in working memory without overt motor output. MI training will be performed in the form of imagined NEP exercises in the last 15 minutes of the session."
40975437|NCT04742296|DEVICE|low level laser therapy|We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.
40975438|NCT00945048|DEVICE|electrical velocimetry|determination of cardiac output by electrical velocimetry
40975439|NCT00945048|DEVICE|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
40771435|NCT05312658|PROCEDURE|External aortic compression|External aortic compression by assistant in cesarean section.
40771436|NCT00875446|DRUG|PLACEBO|Placebo
40771437|NCT00875446|DRUG|GSK1223249|I.V Infusion
40771438|NCT04133415|RADIATION|Lattice stereotactic body radiation therapy|-As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed
40771439|NCT04133415|PROCEDURE|Peripheral blood|-Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy
41140575|NCT04829188|BEHAVIORAL|Enhanced Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives.
41140576|NCT04019925|DEVICE|ADM/MDM hip|Dual Mobility Hip prosthesis manufactured by Stryker Orthopaedics: ADM/MDM
41140577|NCT04347148|PROCEDURE|SNAGs Treatment|a sustained passive accessory movement (glide), i.e. SNAGs, will be applied by the physiotherapist while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing his symptoms.
41140578|NCT04347148|PROCEDURE|Sham Laser Treatment|A Laser YAG 3 Chronic (Winform Medical Engineering s.r.l., San Donà di Piave (VE), Italy), will be detuned and applied in the region of cervical spine in order to have a sham treatment
41140579|NCT04570488|OTHER|EPIC risk score display|Display of risk score/ colored flag in Epic patient list column
41300283|NCT01158534|OTHER|flow cytometry|Correlative studies
41300284|NCT06440590|PROCEDURE|suprapectineal quadrilateral buttress plating|15 cases will undergo anatomical supra-pectineal quadrilateral plate
40771440|NCT04846998|DRUG|BR9003|"Treatment group B:~Once-daily oral administration of one BR9003 2mg tablet in the fasting state.~Treatment group C:~Once-daily oral administration of one BR9003 2mg tablet after a meal(high-fat meal) 30 minutes before the scheduled time of administration and finishing it."
40771441|NCT04846998|DRUG|BR9003A|"Treatment group A:~Twice-daily oral administration of one BR9003A 1mg tablet in the fasting state"
40771442|NCT00663078|BEHAVIORAL|Brief CBT Group therapy|CBT based therapy also expert patient programme
40975440|NCT00945048|DEVICE|spirometry|spirometry for testing the ventilatory function
41300285|NCT06440590|PROCEDURE|Infra-pectineal plating|15 cases will undergo conventional manually contoured infra-pectineal plate
40975441|NCT00945048|DEVICE|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
40975442|NCT04224311|BIOLOGICAL|Menactra|0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.
40975443|NCT04016753|DRUG|BMS-986256|30 mg(6ml)
40975444|NCT04016753|DRUG|Loestrin|1.5 mg Norethindrone and 30ug ethinyl estradiol
41140580|NCT00289952|DRUG|Valproic Acid|Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.
41300286|NCT01419366|DRUG|Torrent's Donepezil Hydrochloride Tablets 10mg|
40975445|NCT03886350|OTHER|blood and sputum samples|Blood and sputum samples for research purpose collected during routine tests performed at steady state and acute exacerbation
41140581|NCT00289952|DRUG|HAART|As per standard of care.
41140582|NCT05230394|DIAGNOSTIC_TEST|Attended Polysomnography in the Lab|Using standard Level 1 polysomnography
41459609|NCT04349696|DRUG|Mitiglinide|"Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)"
41459610|NCT05956717|DEVICE|Orthokeratology|The experimental group wore orthokeratology lenses
40771443|NCT05337566|DRUG|Azithromycin Pill + Cefuroxime|Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
40771444|NCT05337566|DRUG|Placebo + Cefuroxime|Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
41140583|NCT05230394|DIAGNOSTIC_TEST|Unattended Polysomnography in the Home|Using Cerebra's Prodigy system
40771445|NCT06207942|DEVICE|Feed back controlled temperature device|If core temperature exceeds 37.7 degrees celsius a feedback controlled-device will be used at set to 37.5 degrees celsius
40771446|NCT06207942|OTHER|High MAP|A mean arterial blood pressure (MAP) of \>85mmHg will be used. Vasopressors will be titrated to this target during 36 hours
40771447|NCT06207942|OTHER|Deep sedation|Deep sedation for at least 36 hours
41459611|NCT01436448|DRUG|Probiotics Lactobacillus Rhamnosus|Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
40771448|NCT06207942|OTHER|Fever control without a device|Management of fever in the intensive care unit without a device
40771449|NCT06207942|OTHER|Low MAP|A mean arterial blood pressure (MAP) of \>65mmHG will be used. Vasopressors will be titrated to this target during 36 hours
40771450|NCT06207942|OTHER|Minimal sedation|A strategy of minimal sedation in the intensive care unit, used only as needed to facilitate transport, imaging and invasive procedures
41459612|NCT01273480|DRUG|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
40771451|NCT04218981|DRUG|Antipsychotic drugs|Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group
40771452|NCT04218981|DRUG|Mood stabilizer|Choose lithium or valproate for bipolar disorder group
40771453|NCT04218981|DRUG|Paroxetine|Patients with major depressive disorder are treated with paroxetine
40771454|NCT03308357|DIAGNOSTIC_TEST|Drug assays to measure infliximab|See protocol
40771455|NCT02649309|PROCEDURE|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
40771456|NCT02649309|PROCEDURE|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
40771457|NCT02649309|PROCEDURE|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
40771458|NCT02649309|PROCEDURE|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
40771459|NCT02929732|OTHER|Sympathetic nervous activity measurement|Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement
40771460|NCT01855984|DIETARY_SUPPLEMENT|Oral mixed tocotrienols|200mg per day
40771461|NCT01855984|DIETARY_SUPPLEMENT|Placebo|Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
40771462|NCT01702298|DRUG|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
40771463|NCT01702298|DRUG|Metformin|Participants will continue pre-study dose of metformin tablet(s) \>=1000 per day
40771464|NCT05617079|OTHER|Survey|an electronic survey will be conducted
40771465|NCT00925574|DRUG|CNTO 1959; Placebo|
40771466|NCT00936650|DRUG|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
41300287|NCT06207500|PROCEDURE|Pharmacist-led Medication Reconciliation|The best possible medication history (BPMH) at hospital admission was obtained from medical and pharmacy records and by interviewing the patient or carers. The BPMH - an accurate and complete (or as close as possible) list of medications the patient is currently taking - was documented in the medication information system. At hospital admission the BPMH was compared with the therapy in hospital to identify discrepancies. All discrepancies were discussed with the treating physician, unintentional discrepancies were reconciled. Intentional discrepancies were documented in the medical records. Prior to discharge from hospital, the BPMH and the medications planned in the discharge therapy were compared again to ensure that all unintentional discrepancies were corrected. Intentional discrepancies were explained in the discharge letter. Individual patient counselling on discharge medications and pharmacotherapy changes was conducted and coupled with written instructions in lay language.
41459613|NCT01273480|DRUG|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
41459614|NCT01273480|DRUG|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
40771467|NCT00936650|DRUG|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
40771468|NCT06244823|DRUG|Fremanezumab Prefilled Syringe|MRI will be scanned prior to the first administration of Fremanezumab, within 0-14 days, prior to Fremanezumab injection. The second MRI will be acquired at 12 ± 1 weeks after the first Fremanezumab injection.Images will be acquired during interictal periods, defined as at least 24 hours from last migraine attack. All the scans will be acquired during the same session, starting with the T1-weighted scan, followed by the diffusion-weighted scan and ending with the rs-fMRI scan. Total acquisition time for a single subject is approximately 28 minutes, divided in the following periods of time: six minutes for the T1-weighted scan, 12 minutes for the diffusion-weighted scan and 10 minutes for the rs-fMRI scan. If we consider patient preparation, obtainment of documents and informed consent form, the whole process will take about 50-70 minutes.
40771469|NCT05014152|DEVICE|Q-temp-w1|Q-temp-w1 is a contact type body temperature patch developed by Quanta Computer Co., Ltd. It is mainly used to measure the body temperature of the human body. It can be used for general body temperature measurement, home temperature measurement records and medical tracking.
41459615|NCT01273480|DRUG|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
40975446|NCT03028714|BEHAVIORAL|Technology-based nutrition education|All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
40771470|NCT05014152|DEVICE|Omron thermometer(MC-171W)|Omron thermometer(MC-171W) is mainly used to measure the body temperature of the human body. The reference temperature patch used in this study is the OMRON thermometer, model: MC-171W.
40771471|NCT06274957|OTHER|CONTROL|Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education
40975447|NCT02395380|OTHER|C-reactive protein dosage|
40975448|NCT01798004|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
41300288|NCT01752569|DRUG|Selumetinib|"The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib."
41459616|NCT03929328|PROCEDURE|High flow oxygen therapy in spontaneous breathing trial|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
41459617|NCT00972231|OTHER|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
41459618|NCT05842720|PROCEDURE|un-sedated colonoscopies|un-sedated colonoscopies in high risk patients with ASA\>=3
41459619|NCT02712294|OTHER|Neuromuscular Electrical Stimulation|
41459620|NCT00190450|BIOLOGICAL|graft intracerebral of foetal neurons|graft intracerebral of foetal neurons
41459621|NCT04293354|PROCEDURE|Serratus Plane Block|Serratus Plane Block was performed
41459622|NCT04293354|PROCEDURE|Control|No block was performed
41459623|NCT02971787|DIETARY_SUPPLEMENT|Probiotics|Day 1-21: 2 capsules per day
40771472|NCT06274957|DEVICE|PEP DEVICE|"Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~PEP training was applied using the Acapella device.~In addition, participants were subjected to two sessions of 10 minutes each with the Acapella device. In the study, the Acapella device, capable of sustaining expiratory flow of at least 15 L/min for 3 seconds, was activated by taking a deep breath, holding the breath for 2-3 seconds, and then exhaling into the device."
40771473|NCT06274957|DEVICE|HFCWO DEVICE|"Patients were provided with conventional exercises including Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~In addition, participants will receive High-Frequency Chest Wall Oscillation (HFCWO) therapy twice a day for 10 minutes each.~HFCWO training was applıed using the WEST device"
41459624|NCT02971787|DIETARY_SUPPLEMENT|Salt|Day 8-21: 10 tablets à 600 mg per day
41459625|NCT05194709|BIOLOGICAL|Anti-CAR-NK Cells|The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10\^9 cells.
41459626|NCT00594503|DRUG|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
41459627|NCT02753465|PROCEDURE|left colic artery|Laparoscopic D3 Lymph Node Dissection with preservation of left colic artery
41459628|NCT02753465|PROCEDURE|High ligation|Laparoscopic D3 Lymph Node Dissection with ligation above the left colic artery
40975449|NCT01798004|DRUG|Busulfan|Given IV
40975450|NCT01798004|DRUG|Cisplatin|Given IV
40975451|NCT01798004|DRUG|Cyclophosphamide|Given IV
40975452|NCT01798004|DRUG|Doxorubicin Hydrochloride|Given IV
40975453|NCT01798004|DRUG|Etoposide|Given IV
40975454|NCT01798004|RADIATION|External Beam Radiation Therapy|Undergo EBRT
40975455|NCT01798004|BIOLOGICAL|Filgrastim|Given SC or IV
40975456|NCT01798004|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
40975457|NCT01798004|DRUG|Melphalan|Given IV
40975458|NCT01798004|DRUG|Mesna|Given IV
40975459|NCT01798004|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
40975460|NCT01798004|OTHER|Pharmacological Study|Correlative studies
40975461|NCT01798004|DRUG|Topotecan Hydrochloride|Given IV
40975462|NCT01798004|DRUG|Vincristine Sulfate|Given IV
40975463|NCT04470674|DRUG|Durvalumab|Durvalumab 1500 mg
40975464|NCT04470674|DRUG|Carboplatin|carboplatin AUC 5
40975465|NCT04470674|DRUG|Pemetrexed|pemetrexed 500 mg/m2
40771474|NCT03923088|BEHAVIORAL|jacobson's progressive muscle relaxation technique|This involves tensing specific muscle groups for 5-7 seconds, followed by 20 seconds of relaxation. The method can be demonstrated chairside, and should be practiced and rehearsed by the patient at home. Four major muscle groups are commonly tensed and relaxed. These are: 1) feet, calves, thighs, and buttocks; 2) hands, forearms, and biceps; 3) chest, stomach, and lower back; and 4) head, face, throat, and shoulders
40771475|NCT03923088|BEHAVIORAL|audio-visual distraction technique|audiovisual distraction not only leads to full involvement of scenes (visual and auditory), but it also induces a positive emotional reaction resulting in a relaxed experience.
40771476|NCT00679614|DRUG|tramacet, naloxone|Group A: oral tramacet 2 tablets preoperatively, then 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. A naloxone infusion will started preop at 0.25ug/kg/hr and will continue during patient's stay in hospital (an equivalent of 400ug over 24 hours in a 70 kg man). Infusion discontinued 1 hour before patient discharge. All the patients in groups A and B will be provided Morphine PCA for the duration of their hospital stay. Use of morphine PCA will be noted.Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice.
40975466|NCT04488198|OTHER|Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with acupuncture needles.
40975467|NCT04488198|OTHER|Placebo-Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with placebo-needles.
40975468|NCT00159471|DRUG|capecitabine, gemcitabine, docetaxel|
40975469|NCT04108533|BEHAVIORAL|Text-Based Support|Text-based breastfeeding support as described in arm/group descriptions
41459629|NCT03043040|BEHAVIORAL|Telephone follow up|Already described in previous page
40975470|NCT04785014|PROCEDURE|interventional|In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.
41459630|NCT03043040|BEHAVIORAL|Treatment as usual|Already described in previous page
40975471|NCT06089928|PROCEDURE|vertical augmentation|sandwich osteotomy with an Interpositional inlay graft
40975472|NCT04294472|DRUG|MAU868|MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
40975473|NCT04294472|OTHER|Placebo|250 mL D5W placebo IV to be labeled to match that of MAU868
40975474|NCT04590365|DEVICE|Carrageenan nasal and throat spray|Iota-carrageenan nasal and throat spray (verum Coldamaris plus i.e. Iota-Carrageenan 0.12% plus 0.04% Kappa-Carrageenan in 0.5% saline)
40975475|NCT04590365|DEVICE|Saline nasal and throat spray|Saline nasal and throat spray (placebo Coldamaris sine i.e. 0.5% saline)
40975476|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
41300289|NCT02222012|DEVICE|"single channel Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
40975477|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
40975478|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
41459631|NCT05998980|PROCEDURE|Componeer prefabricated veneers|Individual Randomized Clinical Trial
41459632|NCT05998980|PROCEDURE|Essentia resin composite veneers|Individual Randomized Clinical Trial
41459633|NCT02117141|DRUG|HC-ER 20 mg capsule (fasted)|Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
41459634|NCT02117141|DRUG|HC-ER 20 mg capsule (fed)|Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
40975479|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
40975480|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
40975481|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
40975482|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
40975483|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
40975484|NCT01678677|DRUG|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
40975485|NCT00617123|DRUG|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
40975486|NCT00617123|DRUG|Placebo|matching placebo oral tablet
41459635|NCT03637127|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
41459636|NCT03637127|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
41459637|NCT02126657|DRUG|70% glycolic acid|
41459638|NCT03409315|PROCEDURE|Centralized Therapeutic Drug Monitoring|Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.
41459639|NCT04619862|DRUG|Gabapentin|See arm descriptions
41459640|NCT04619862|DRUG|Placebo|See arm descriptions
41459641|NCT00235560|DRUG|rapamycin|sirolimus
41459642|NCT03366194|DEVICE|SkinStylus Sterilock System|Microneedling device will be used to treat ventral hypertrophic scars.
41459643|NCT05595720|DEVICE|hight intenisty laser|7W(LAZR-207)/15W(LAZR-215\&115)HIGH POWER LASER THERAPYUNIT WITH 2 WAVELENGTHMODES,COMBINATION(810+980 NM) AND SINGLE(1064 NM)
40975487|NCT02252094|DEVICE|Prismalung|Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
40975488|NCT02252094|OTHER|Ultra-protective ventilation|Ventilation with \</= 3ml/kg predicted body weight
40975489|NCT02252094|OTHER|Conventional Lung Protective Ventilation|Ventilation with 6ml/kg predicted body weight
40975490|NCT06504602|DEVICE|Active Virtual Reality|Active virtual reality group will play a game through a virtual environment.
40975491|NCT06504602|DEVICE|Passive Virtual Reality|Passive virtual reality group will watch a movie through a virtual environment.
40975492|NCT05516602|OTHER|Peer Support|"Peer-led support groups over the weekend will include the following activities:~* Peer leader counselling on oral PrEP and HIV risk reduction~* Peer leader discussion to dispel myths and misconceptions around oral PrEP~* Peer leader sharing of experiences of daily pill taking~* Participants sharing experiences of influencers and barriers to oral PrEP uptake and adherence followed by a discussion by group members.~* 1-2 role plays per support group session."
40975493|NCT06243991|DEVICE|in vivo Corneal Confocal Microscopy|CCM was performed using the Heidelberg Retinal Tomograph 3 with the Rostock Cornea Module (HRT3-RCM, Heidelberg Engineering GmbH, Germany) under topical anesthesia. A viscous gel (Viscotears, Novartis Pharmaceuticals UK) served as a coupling agent between the cornea and the applanation cap. The subjects were instructed to focus on the fixation light with the unexamined eye to ensure proper positioning. Five high-quality images of the SNP were selected and analyzed using the automated tracing of nerve fibers program (ACCMetrics, M.A. Dabbah, Imaging Science and Biomedical Engineering, Manchester, England).
41140584|NCT04402125|BEHAVIORAL|TargEted MAnageMent Intervention (TEAM)|"TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows:~1. A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning.~2. Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED.~3. Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers."
41140585|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Materials Only|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment."
41140586|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Direct Training|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers."
41459644|NCT04481451|PROCEDURE|Erector spinae block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
41459645|NCT04481451|PROCEDURE|Quadratus lumborum block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
41459646|NCT04481451|DRUG|Ropivacaine|ropivacaine 0.2% nerve block injection
41459647|NCT00752076|OTHER|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
41459648|NCT02955004|PROCEDURE|Electrical cardioversion|Transthoracic direct current electrical cardioversion
41459649|NCT01251393|DRUG|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
41459650|NCT01251393|DRUG|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
41459651|NCT04656938|BEHAVIORAL|Pre-frail intervention|Pre-frail partiipants will undergo 4 month intervention consisted of group-based physical exercise and nutritional classes.
41459652|NCT04305730|BEHAVIORAL|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
41459653|NCT04305730|BEHAVIORAL|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
41459654|NCT06176885|DRUG|Camrelizumab|Combination therapy with Camrelizumab monoclonal antibody will be administered after the initial two cycles of induction therapy.
41459655|NCT02223169|DIETARY_SUPPLEMENT|Egg albumin-derived peptide|Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
41459656|NCT04432077|BEHAVIORAL|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR)|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR) - a parent-mediated cognitive-behavioral treatment modified for young children with ASD
41459657|NCT05086913|OTHER|Lifestyle medicine smartphone booklets|Participants will receive a pocket size 6-page booklet weekly over 8 weeks that covers 8 lifestyle medicine, mental health and CBT themes including stress, relaxation, diet, exercise, sleep hygiene, worry management, mindfulness, and positive psychology, and guides participants to set and meet short term and long-term goals.
41459658|NCT05086913|OTHER|Lifestyle medicine smartphone app|The lifestyle medicine app offers 8 modules with identical content as the wellness booklets, in addition to videos, relaxation, exercise and cooking demonstrations, daily challenges, record of goals, and ecological momentary assessments of diet, physical activity, sleep, stress and mood.
41459659|NCT05086913|OTHER|Waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
41459660|NCT05926245|DIETARY_SUPPLEMENT|Glutaryl Solution|Glutathione, ascorbic acid, cyclodextrin, potassium sorbate and radish root extracts
41459661|NCT05926245|DIETARY_SUPPLEMENT|Placebo Solution|Empty nanoparticles
41459662|NCT02369458|DRUG|Mitomycin-C|
41459663|NCT02369458|DRUG|Pegfilgrastim|
40975494|NCT06243991|DIAGNOSTIC_TEST|Corneal Sensitivity|Corneal sensitivity was evaluated using a Cochet-Bonnet esthesiometer (Luneau Ophtalmologue, Chartres, France), comprising a nylon filament measuring 60 mm in length and 0.12 mm in diameter. Participants were instructed to maintain a forward gaze while the esthesiometer gently made perpendicular contact. The procedure involved gradually decreasing the filament length in 5 mm increments, starting from 60 mm, until the initial response from the subject was detected.
40975495|NCT06243991|DEVICE|Non invasive tear break up time|Noninvasive tear break-up time (NI-TBUT) was assessed using a Sirius Scheimpflug camera (CSO, Florence, Italy) and the device automatically provided the average NI-TBUT value
40975496|NCT06243991|DIAGNOSTIC_TEST|Ocular Surface Disease Index Qestionnaire|The Ocular surface disease index (OSDI) questionnaire consists of a total of 12 questions categorized into three subscales as follows: ocular symptoms, vision-related function, and environmental triggers. Each patient is asked to rate the symptoms on a 5-point scale ranging from never (0 score) to always (4 score) for every question in the questionnaire. The fourth and fifth questions in the first section, concerning blurred vision and reduced vision symptoms, were excluded from the questionnaire as these symptoms may already be present in patients with keratoconus disease. The total OSDI score was calculated according to the formula: OSDI = \[(sum of scores for all questions answered) × 100\] / \[(total number of questions answered) × 4\].
40975497|NCT06243991|DEVICE|Corneal tomography|Scheimpflug-tomography device (Pentacam, OCULUS, Wetzlar, Germany) was used for measurement of keratometric values.
40975498|NCT04784949|PROCEDURE|portland cement|pulpotomy with PRF and white Portland cement
40975499|NCT04784949|PROCEDURE|Mineral trioxide aggregate|pulpotomy with PRF and white Mineral trioxide aggregate
40975500|NCT04784949|PROCEDURE|Biodentine|pulpotomy with PRF and Biodentine
40975501|NCT03968484|BIOLOGICAL|platelet transfusion|Transfusion of platelets
40975502|NCT04883190|OTHER|Fulfilling Questionaires|Fulfilling Questionaires PHQ-D (brief) and FSMC
40975503|NCT02234089|DRUG|Degarelix|According to medical practice
40975504|NCT02234089|DRUG|LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)|According to medical practice
40975505|NCT02825992|DEVICE|AcQMap System|3D imaging and mapping system for cardiac chambers
40975506|NCT00719121|DRUG|Talarozole|Topical Application (20 mg)
40975507|NCT00719121|DRUG|Differin™, 0.1% adapalene gel|Topical Application (20 mg)
40975508|NCT04906213|DRUG|Empagliflozin10Mg Tab|Empagliflozin10 Mg daily or placebo daily for 18 months
40975509|NCT04906213|DRUG|Placebo|10Mg Placebo Tab
40975510|NCT01161147|DRUG|Meloxicam|Meloxicam Tablets 15 mg
40975511|NCT04981743|DIETARY_SUPPLEMENT|Nigella Sativa capsule twice daily|investigate the safety and efficacy of Nigella Sativa versus Vitamin D3 versus Nigella Sativa / vitamin D3 combination as supplement for management of COVID-19 .
41140587|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Local Supervision|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers. This arm will also receive one year of ongoing (at least monthly) supervision in LGBTQ-affirmative CBT from an expert supervisor at your center."
41140588|NCT00072670|DRUG|Trabectedin|Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m\^2) weekly as 3-hour infusion or 1.5 mg/m\^2 or 1.2 mg/m\^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
40975512|NCT03176329|OTHER|Nursing 1 : INTELLIVENT-ASV|
40975513|NCT03176329|OTHER|Nursing 2 : INTELLIVENT-ASV|
40975514|NCT03176329|OTHER|Nursing 1 : Conventional mode|
40975515|NCT03176329|OTHER|Nursing 2 : Conventional mode|
40975516|NCT04908176|DRUG|Avapritinib|avapritinib tablets
40975517|NCT04908176|DRUG|midazolam|midazolam syrup
40975518|NCT01113281|BIOLOGICAL|VPM1002 live vaccine|
40975519|NCT01113281|BIOLOGICAL|commercially available live vaccine BCG|
40975520|NCT03025503|OTHER|nipple stimulation|
40975521|NCT00616200|OTHER|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
40975522|NCT04378751|BEHAVIORAL|Decision aid video|Decision aid video
40975523|NCT04378751|BEHAVIORAL|Genetic counseling informational brochure|Genetic counseling informational brochure
40975524|NCT03957707|PROCEDURE|stereotactic surgery plus thrombolysis|stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
40975525|NCT04478474|DRUG|Ganciclovir|Type of allogeneic transplant, HLA match, graft manipulation, use of ATG and/or Campath, CMV status (donor and recipient), maximal acute GVHD stage and grade, CMV viremia/disease through day +100, days received ganciclovir prophylaxis, adverse events related directly or secondary to ganciclovir prophylaxis.
40975526|NCT02057406|DRUG|2:1 EPA/DHA|400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
40975527|NCT02057406|DRUG|High EPA|
40975528|NCT02057406|OTHER|Placebo|
41140589|NCT00753337|DEVICE|Assurant® Cobalt Iliac Stent System|Iliac Stenting
41140590|NCT02973932|BEHAVIORAL|Cognitive-bahavioral psychotherapy|
41140591|NCT00630409|DRUG|Gemcitabine|800 mg IV day 1 and 8
41140592|NCT00630409|DRUG|Doxil|24 mg/m2 every 21 days IV
41140593|NCT01333709|DRUG|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
41459664|NCT05731687|OTHER|Hybrid DEB approach with drug-eluting balloon|If a patient is randomized to the hybrid DEB approach, lesion preparation of the SB with non-compliant balloon (NC) is mandatory before DEB application. The application of DEB can be performed if acceptable result of the lesion preparation is obtained (at least TIMI III flow and no flow limiting dissection). The drug- eluting balloon used in this study is the CE- marked Magic Touch Sirolimus Coated Balloon Catheter (Concept Medical, Gujarat, India). The size of the DEB is measured on a ratio 1:1 on reference diameter of the SB. The DEB balloon is inflated for 60 seconds, or two times more than 30 seconds if long duration inflations are not possible. Finally low pressure kissing inflation with the same DEB in place, and Proximal Optimization Therapy (POT) are performed. In case of SB occlusion, or flow limiting dissections in non-Left Main (LM) bifurcations and \< TIMI 3 flow or 70-99% residual stenosis in LM bifurcations, cross- over to two-stent technique is performed.
41459665|NCT05731687|OTHER|Two-stent strategy|When randomized to the conventional two-stent strategy, TAP/T or Culotte stenting is performed. First lesion preparation of the SB is mandatory. The drug-eluting stent (Supraflex stent) can be placed in the SB if acceptable result of the lesion preparation is obtained and is measured on a 1:1 ratio on reference diameter of the SB. Finally, kissing inflation and POT are mandatory.
40771477|NCT00679614|DRUG|tramacet|Group B: oral tramacet 2 tablets preop,then 2 tablets every 6 hours for five days(or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). Group also receives saline infusion at 4-6mls/hour during hospital stay.All patients in groups A and B will have Morphine PCA during hospital stay. Use of morphine PCA will be noted. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraopby the surgeon as per our standard practice.
40771478|NCT00679614|DRUG|Acetaminophen|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
40771479|NCT02706392|OTHER|Laboratory Biomarker Analysis|Correlative studies
40771480|NCT02706392|BIOLOGICAL|ROR1 CAR-specific Autologous T-Lymphocytes|Given IV
40771481|NCT04155632|DRUG|N-acetylcysteine|N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease. It has a long-established safety record in adults and children, with FDA approval since 1963. The side effects most commonly noted in people who take NAC by mouth include diarrhea, nausea, vomiting, and headache. These side effects are usually mild and go away even with continued use of NAC by mouth. There is also a risk of a skin reaction, such as flushing, itching, or rash. A meta-analysis of studies evaluating long-term oral treatment with NAC for prevention of chronic bronchitis found that NAC was well tolerated, with generally mild, most commonly gastrointestinal adverse effects that did not require treatment interruption.
40771482|NCT04155632|DEVICE|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
40771483|NCT04876287|DRUG|Radioiodine|cancer therapy
40771484|NCT03686657|DRUG|Metformin|1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks
41140594|NCT01333709|OTHER|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
41459666|NCT03981705|RADIATION|Standard Trimodality Breast Imaging|Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).
40771485|NCT03686657|DRUG|Val, Cel and Met XR Low|500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.
40771486|NCT03686657|DRUG|Val, Cel and Met XR High|1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
40771487|NCT02636010|DRUG|Pembrolizumab|
40771488|NCT00767780|DEVICE|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
40771489|NCT00867035|DRUG|Chlorine dioxide and scraper|20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
41459667|NCT04162327|DRUG|IBI315|Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.
40975529|NCT06166355|BEHAVIORAL|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
40975530|NCT06166355|BEHAVIORAL|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
40975531|NCT06166355|BEHAVIORAL|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
40975532|NCT01502449|BEHAVIORAL|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
40975533|NCT01502449|OTHER|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
40975534|NCT00090480|BIOLOGICAL|HyperAcute - Breast cancer vaccine|Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
40975535|NCT02356068|OTHER|ROTEM analysis|3 blood samples for ROTEM analysis
40975536|NCT01523860|DRUG|Rituximab, Mitoxantrone, Bendamustine|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
40975537|NCT03729960|OTHER|LENA recorder|The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
41459668|NCT04162327|DRUG|IBI315|Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.
40975538|NCT01002703|DRUG|Lenalidomide, Bendamustine, Prednisone|During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
40975539|NCT05480085|BEHAVIORAL|School-based extracurricular intervention focusing on screen media use and time spent with friends|"The intervention includes the following components:~1. Within each class parents will engage in two meetings combining education and parent-to-parent communication about 1) the children's leisure time activities, and 2) family and class screen time culture. Parents will engage in a short exercise focusing on screen media dilemmas conducted by the teacher in the beginning of 4th grade.~2. Children will engage in school hour workshops focusing on the class culture related to screen media use and leisure time activities.~3. Afterschool club personal will engage in mini actions learning program consisting of three workshops aimed to increase participation rate in the afterschool club.~4. Local stakeholders, e.g., parents, school- and afterschool club personal and others relevant to children's leisure time (e.g., sports clubs) will engage in workshops to adjust the predetermined intervention components (1-3 above) to fit their local context and to develop a local action plan."
40975540|NCT05000177|OTHER|30-minute computer typing task|The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.
40975541|NCT05000177|OTHER|30-minute rest|Rest for 30 minutes
40975542|NCT02285790|DEVICE|Reflectance confocal microscopy|
40975543|NCT02285790|PROCEDURE|Punch biopsy|
40975544|NCT02285790|PROCEDURE|Surgical excision|Excision of the suspected basal cell carcinoma lesion under local anesthetics
40975545|NCT02033694|DEVICE|NIRS-IVUS Imaging (TVC Imaging System)|Diagnostic Imaging Catheter
41140595|NCT01333709|RADIATION|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
41140596|NCT01333709|RADIATION|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
41140597|NCT01333709|PROCEDURE|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
41140598|NCT00142532|PROCEDURE|Acupuncture and Questionnaires|"Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (\~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (\~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.~Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.~Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
40975546|NCT00367094|DRUG|Benazepril plus hydrochlorothiazide|
40975547|NCT04113304|BEHAVIORAL|Parenting Young Children Check-up (PYCC)|The PYCC intends to motivate parents to learn behavioral parenting strategies to reduce child disruptive behavior.
41459669|NCT00751023|DRUG|Modafinil|400 mg daily for four weeks
41459670|NCT00751023|DRUG|Placebo|Placebo 2 tablets daily for 4 weeks
41459671|NCT05457868|DRUG|Salbutamol|Salbutamol claim is used as the exposure group.
40975548|NCT02837016|DEVICE|Wearable biofeedback|
40975549|NCT02837016|BEHAVIORAL|Relaxation Treatment|group-based relaxation treatment based on mindfulness meditation principles
41300290|NCT02222012|DEVICE|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|"During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)."
40771490|NCT00867035|DRUG|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
40975550|NCT06158789|PROCEDURE|MR guided low intensity focused ultrasound|Low intensity focused ultrasound opens the blood brain barrier
40975551|NCT04967833|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
40975552|NCT02268864|DRUG|Simeprevir|Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
41140599|NCT00142532|PROCEDURE|Placebo Acupuncture, Questionnaires|"The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (\~1.25cm) from the spine. The leg studs will be placed at 2 cun (\~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (\~ 5cm) proximal and 3 cun (\~ 5cm) medial to the midpoint of the antecubital crease.~Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked no pain at one end and worst pain at the other."
41140600|NCT06321094|DRUG|Vericiguat|Investigators divide our participants into two groups ;one group is required to take vericiguat,and the other isnot required to take vericiguat.Expect this,no intervention is used in the research.
41140601|NCT04603898|DIETARY_SUPPLEMENT|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days
41140602|NCT04603898|DIETARY_SUPPLEMENT|Carbon-13 Ascorbic Acid Oral Load|Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.
41140603|NCT00234585|DEVICE|Renal Artery Stent with Protective Device/Drug|
41140604|NCT01334606|DEVICE|4 mm x 32G pen needle (Nano)|The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
41140605|NCT01334606|DEVICE|8mm x 31G pen needle (Short)|The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
41140606|NCT02733731|DRUG|Chinese Herbal Compound Ointment|
41140607|NCT02733731|DRUG|Estriol|
41140608|NCT04439591|OTHER|Computerised cognitive training|A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres
41140609|NCT04805008|OTHER|Lactation cookies|1 serving of 2 OZ of cookies per day for 30 consecutive days. These cookies will contain ingredients thought to increase breast milk production.
41140610|NCT04805008|OTHER|Control cookies|"1 serving of 2 OZ of cookies per day for 30 consecutive days.~The cookies will not contain ingredients thought to increase breast milk production."
41140611|NCT06231667|OTHER|Education|four training sessions were applied to the intervention group
41140612|NCT05329402|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
41140613|NCT05329402|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
41140614|NCT04540926|DRUG|Cyclosporin A|COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
41140615|NCT01428583|DRUG|oxycodone HCl and naltrexone HCl extended-release capsules|Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
41300291|NCT03198169|DEVICE|Atteris Antimicrobial Skin and Wound Cleanser|Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
41300292|NCT03198169|DEVICE|Atteris Antimicrobial Barrier Film Dressing|Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
40771491|NCT06138418|PROCEDURE|Neurotomy|Surgical treatment of spastic foot
40975553|NCT02268864|DRUG|Daclatasvir|Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
40975554|NCT04563793|DEVICE|Superion™ IDS|All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.
40975555|NCT00776958|OTHER|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
40975556|NCT01463540|DEVICE|A 20 Fr gastrostomy tube, placed using push/pull techniques.|In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.
40771492|NCT04337970|DRUG|Talazoparib|"Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined."
40771493|NCT04337970|DRUG|Axitinib|5 mg PO BID
40975557|NCT01463540|DEVICE|A 20 Fr balloon type tube, placed after gastropexy.|In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
41300293|NCT04181203|DRUG|Apalutamide|"240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months."
40975558|NCT02292979|DRUG|Doxorubicin|25mg/m2
41300294|NCT04181203|RADIATION|Salvage radiotherapy (SRT)|"The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images."
41300295|NCT04181203|DRUG|Luteinising Hormone Releasing Hormone agonist (LHRHa)|Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
41459672|NCT05457868|DRUG|LAMA|Long-acting muscarinic antagonists (LAMA) - umeclidinium, aclidinium, tiotropium, glycopyrolate, glycopyrronium - claim is used as the reference group.
40771494|NCT03514134|BEHAVIORAL|Virtual Reality Job Interview Training|Students will engage in didactic training related to strategies to perform well during a job interview as well as repeated practice with a virtual hiring manager. Throughout and after completion of the virtual interviews, participants will receive feedback on their performance.
40975559|NCT02292979|DRUG|Bleomycin|10mg/m2
40975560|NCT02292979|DRUG|Vinblastine|6mg/m2
40975561|NCT02292979|DRUG|Dacarbazine|375mg/m2
40975562|NCT02292979|DRUG|Brentuximab Vedotin|1.2 mg/kg
40975563|NCT02122393|DRUG|Sertraline|
40975564|NCT02122393|BEHAVIORAL|Cognitive Behavioural Therapy|
40975565|NCT05146401|OTHER|Plasma fatty acid concentration|Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.
40975566|NCT06298110|BIOLOGICAL|Platelets Rich plasma of the same patient|on the morning of surgery, 30 mL of venous blood will be drawn from the patient in anticoagulant-containing PRP tube for preparation of PRP solution. The drawn blood will be centrifuged at 1,200 rpm for 12 minutes to be separated into three layers: an upper layer that contains platelets and white blood cells, an intermediate thin layer (the buffy coat) that is rich in white blood cells, and a bottom layer that contains red blood cells. The upper and intermediate buffy layers will be transferred to an empty sterile tube. The plasma will be centrifuged again at 3,300 rpm for 7 minutes to help with the formation of soft pellets (erythrocytes and platelets) at the bottom of the tube. Pellets are homogenized in the lower third (5 mL) of the plasma to create the PRP. The prepared PRP solution will be transferred within sterile single use syringe (3cm) from the laboratory to the operation room, then applied and spread over the subcutaneous space before skin closure
40975567|NCT01441505|DRUG|Ketamine|Ketamine IV, IM, or SC will be administered in Phase I and II
40975568|NCT01441505|DRUG|Saline or Midazolam (active placebo)|Saline, or midazolam 0.01mg/kg will be administered in Phase I
40975569|NCT05966181|BEHAVIORAL|experimental group|"Experimental Group-Repetitive Simulation~* First simulation application; It will be done in groups of four with a total of 5 groups (n=20). In each scenario, one student in the group will participate in the role of nurse and three other students will participate as audience. Four students in each group will take part in a standard patient simulation consisting of four different scenarios.~* Second simulation application; It will be carried out with the students in the experimental group about 3-4 weeks after the first simulation. Each student will use one new scenario alone in the second simulation."
41140616|NCT01051648|DRUG|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly \& completely as possible after finishing anterior vitrectomy
41140617|NCT04108104|DRUG|Cyproheptadine|3-month treatment
41140618|NCT04108104|DRUG|Alpress LP|3-month treatment
41300296|NCT00376402|BIOLOGICAL|H5N1 Pandemic Influenza Vaccine|
41300297|NCT01108809|DRUG|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
41300298|NCT02739334|BEHAVIORAL|ENRICH|The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
41300299|NCT02739334|BEHAVIORAL|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
40975570|NCT03938532|DEVICE|Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
41300300|NCT02659683|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
41459673|NCT06389227|OTHER|dynamic ecological approach (DEA)|The DEA completed 18 ninety-minute sessions (3 per week) for six weeks oriented to soccer training using the dynamic ecological approach
40771495|NCT03514134|BEHAVIORAL|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
40975571|NCT03938532|DEVICE|Tidal Volume Measurement using the Philips Respironics NM3 monitor|Tidal Volume Measurement using the Philips Respironics NM3 monitor
40975572|NCT06382584|PROCEDURE|Femoral fracture surgery|Hip fracture surgery
40975573|NCT01218230|DRUG|Intravitreal Pegaptanib|Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
40975574|NCT05909098|COMBINATION_PRODUCT|autologous NK cell|autologous NK cell
40975575|NCT01818908|DRUG|DA-EPOCH|DA-EPOCH regimen
40975576|NCT04267367|BEHAVIORAL|Dietitian-led dietary approach to management of diabetes|In the intervention phase, the educational and diet plan package will be developed. All the intervention packages will be approved by a multi-disciplinary expert team comprising an endocrinologist and dietitian prior to the intervention. Patients in the usual care arm will receive routine care as to how he/she is practicing in their daily life. Routine care includes general knowledge on diabetes disease process, blood glucose monitoring, a healthy lifestyle, preventing treating diabetes complications and developing personalized strategies for the decision-making process\[27\]. The intervention package will include mainly two-phase, nutritional counseling emphasis on lifestyle modification of diabetes patients and individual basis diet plan for each T2DM patients for intervention arm. The nutrition education and counseling and individual diet plan will be applied by trained dietitians.
40975577|NCT06454383|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40975578|NCT06454383|DRUG|Cholestyramine|Given PO
40975579|NCT06454383|PROCEDURE|Computed Tomography|Undergo CT
40975580|NCT06454383|PROCEDURE|Diagnostic Imaging|Undergo imaging scans
40975581|NCT06454383|DRUG|Gemcitabine|Given IV
40975582|NCT06454383|DRUG|Leflunomide|Given PO
40975583|NCT06454383|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40975584|NCT04492202|OTHER|Survey|The survey will be sent to health professionals via online link.
40975585|NCT02670564|GENETIC|Pharmacogenomics|"Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).~For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples."
40975586|NCT02670564|OTHER|Busulfan plasma level measurements|"Bu PK analysis after the first dose of IV Bu (+potential subsequent ones).~Blood sampling:~-\>For Bu 4 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 15 min (Time 2), 30 min (Time 3), 1 hour (Time 4) and 4 hour (Time 5) after the end of infusion~-\>For Bu 1 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 1 hour (Time 2), 3 hour (Time 3), 5 hour (Time 4), 7 hour (Time 5) and 11 hour (Time 6) after the end of infusion.~For centers not performing BU TDM, perform Dried Blood Sampling (DBS) analysis:~-\> 0.5ml blood sample should be collected and 5µl spotted onto DBS cards in duplicate. Dry them max 5 hours and then keep in a sealed envelope and store at -80°C, as below"
40975587|NCT05445986|PROCEDURE|flap elevation and guided bone regeneration|to rebuild the alveolar ridge convexity
40975588|NCT05445986|PROCEDURE|gap filling|to use biomaterials to fill the jumping gap
40975589|NCT05445986|PROCEDURE|connective tissue graft|to change the soft tissue phenotype by connective tissue graft
40975590|NCT01602146|OTHER|ultramarathon running|"* blood samples before and after ultramarathon~* urinary samples before and after ultramarathon~* voluntary ant electrically muscular forces measuring before and after ultramarathon~* Broadband ultrasound Attenuation before and after ultramarathon"
41300301|NCT02659683|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
41300302|NCT00700752|DEVICE|senofilcon A|silicone hydrogel contact lens
40771496|NCT06563817|DRUG|Rapamycin|All enrolled patients receive treatment with sirolimus (rapamycin)#The prescribed regimen involved a daily oral dosage of 1.5 mg for a duration of four weeks.
40771497|NCT05750784|PROCEDURE|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
40975591|NCT05255172|OTHER|Supervised Exercise|12 weeks of supervised aerobic exercise individually adapted to exercise capacity according to a VO2 peak test
40975592|NCT03656328|DIETARY_SUPPLEMENT|Lactobacillus Reuteri 4659|supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy
40975593|NCT03656328|DIETARY_SUPPLEMENT|Placebo|supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
40975594|NCT02619955|OTHER|samples with DNA|
40975595|NCT04716569|DRUG|intranasal ivermectin spray|usage of ivermectin as intranasal spray for treating early covid patiens
41300303|NCT00700752|DEVICE|balafilcon A|silicone hydrogel contact lens
41300304|NCT02495077|BIOLOGICAL|Infliximab|A single dose, of 3mg/kg infusion
41300305|NCT02495077|DRUG|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
41300306|NCT02495077|DRUG|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
41300307|NCT02495077|DRUG|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
41300308|NCT02495077|BIOLOGICAL|Thymoglobulin®|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
40771498|NCT03388827|DEVICE|Laminaria tent|Laminaria tent was inserted for 12 hours before Hysteroscopy
41140619|NCT01509183|DEVICE|Propeller Health System (formerly Asthmapolis System)|The Propeller (formerly Asthmapolis) system works through the provision of information to patients and their providers. With the Propeller (formerly Asthmapolis) device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Propeller (formerly Asthmapolis) where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
41140620|NCT00297297|OTHER|No intervention. Applying gene profiling on needle aspirates|
41140621|NCT03655366|OTHER|Questionnaire for Dog owners|Questionnaire directed to epileptic patients, parents of epileptic children and legal representatives of epileptic patients with intellectual disabilities. It includes questions about demographics, epilepsy diagnosis, seizures, the behavior of their dogs around the time they have a seizure and a validates scale to measure dog personality traits.
41300309|NCT02495077|DRUG|Acetaminophen|"30 to 60 minutes prior to the start of the infusion~* Tylenol, 600 to 1000mg by mouth or~* Suppository form"
41300310|NCT02495077|DRUG|Loratadine|"30 to 60 minutes prior to the start of the infusion~* Claritin (Loratadine) 10mg by mouth or~* Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
41300311|NCT02495077|BIOLOGICAL|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
41300312|NCT02495077|DRUG|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
41300313|NCT02495077|DRUG|Diphenhydramine|"30 to 60 minutes prior to the start of the infusion~* Claritin (Loratadine) 10mg by mouth or~* Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
41300314|NCT05775692|DRUG|fluconazole|According to the models of population pharmacokinetics,the investigators and want to correlate use of fluconazole with treatment effectiveness and safety in newborns
41300315|NCT06148233|RADIATION|[18F]CSF-23|Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[18F\]CSF-23 in a single dose.
41300316|NCT01455428|DRUG|Lyrica (pregabalin)|Capsule, 300 mg/d, BID, 8 weeks treatment
40771499|NCT03388827|DRUG|Laminaria plus Misoprostol|Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
40771500|NCT03487133|DRUG|bortezomib/dexamethasone|"Induction therapy -\>1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy -\>1cycle=28 days~1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none"
41300317|NCT01455428|DRUG|Placebo|Capsule, 300 mg/d, BID, 8 weeks treatment
41300318|NCT05528497|OTHER|VR+|Use of a virtual reality helmet during ovocyte retrieval
41300319|NCT02574780|OTHER|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
41300320|NCT02574780|OTHER|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
41300321|NCT04066556|OTHER|Brain CT imaging|"The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~* Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~* Cut-off values in areas of irreversible changes according to non-contrast CT images~* Cut-off values in occlusion sites and collateral scores according to CT angiographies~* Cut-off values of consolidated CT imaging index including clot, core, and collateral score~* Cut-off values of comorbidity index~* Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments."
41140622|NCT03655366|OTHER|Questionnaire for Dog trainers|Questionnaire for seizure response and seizure alert dog trainers including information on number of active working dogs, dog demographic information and selection criteria, the type of patient inclusion criteria they use, training methods used.
41140623|NCT05547724|OTHER|Virtual reality|Virtual reality visit of the birth room, cesarean and pediatric hospitalization department: neonatology and neonatal intensive care
41300324|NCT04592380|DRUG|Stage 1: Clevidipine (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
40975596|NCT05209438|DEVICE|Cereset Research|Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
41140624|NCT00520663|DRUG|14C-SB649868|SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
41300325|NCT04592380|DRUG|Stage 1: Placebo (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
41300326|NCT04592380|DRUG|Stage 2: Clevidipine (open-label)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
41300327|NCT04592380|DRUG|Stage 2: Standard of Care (open-label)|Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
41300328|NCT00079612|DRUG|Sorafenib (Nexavar, BAY43-9006)|800mg daily (2x 400mg tabs)
41300329|NCT00079612|DRUG|Placebo|2x 400mg tabs daily
41300330|NCT05144295|DRUG|Lubiprostone Pill|Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.
41300331|NCT05144295|DRUG|Lactulose Oral Liquid Product|"Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)"
41300332|NCT05144295|DRUG|Bisacodyl 5 MG|Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for \< 12 years or 3 tab/day for \> 12 years
41300333|NCT05144295|DRUG|Sodium Picosulfate|Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day
41300334|NCT00989430|BEHAVIORAL|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
41300335|NCT00083239|DRUG|talabostat (PT-100) tablets|
41300336|NCT03067896|DRUG|Bupivacaine|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
41300337|NCT03067896|DRUG|Dexmedetomidine|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline
41300338|NCT03067896|DRUG|Magnesium Sulfate|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml magnesium sulfate 50 mg in 0.5 ml normal saline
40771501|NCT06478524|BEHAVIORAL|Live music|Patients will have baseline data collection in the first week, followed by live music sessions and data collection during dialysis in the second week. The live music will be played for 45 minutes to one hour per dialysis session, and will be played during each of patients' three dialysis sessions in week 2 of this arm of the study.
41140625|NCT01196286|BEHAVIORAL|Multifamily Group Psychoeducation (MFG)|Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
41140626|NCT01196286|BEHAVIORAL|Cognitive Remediation (CR)|Computer exercises designed to improve cognitive functioning (3hr/wk).
41140627|NCT02270502|DEVICE|Ultrasound Philips CX50|The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.
41140628|NCT02270502|OTHER|Frailty Index Questionnaire|Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
41140629|NCT02270502|OTHER|Muscle strength tests|MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
41140630|NCT01260883|DRUG|Ketorolac Tromethamine 1 mg/kg|Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
41140631|NCT01260883|DRUG|Ketorolac Tromethamine 0.5 mg/kg|Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
41140632|NCT01260883|DRUG|Placebo|Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
41140633|NCT03878407|OTHER|Monitoring of ARCH variants|Blood samples will be tested for mutations, before patients are given Standard of Care chemotherapy/radiation or after given Standard of Care chemotherapy/radiation. Another testing is done after 3 months and after 1 year if positive for ARCH.
41140634|NCT04971902|OTHER|Pharmacogenetic Test|Cheek swab sample with PGx results lab analysis
41140635|NCT06505928|DRUG|hepalatide|hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks
40771502|NCT06478524|BEHAVIORAL|Pre-recorded music|Patients will have baseline data collection in the first week, followed by pre-recorded music sessions and data collection during dialysis in the second week. The pre-recorded music will be played for 45 minutes to one hour per dialysis session, and will be played during each of patients' three dialysis sessions in week 2 of this arm of the study.
40975597|NCT00671892|BIOLOGICAL|Lipopolysaccharide endotoxin|"Delivered in nebulized form expressed in activity units(endotoxin units -EU).~Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:~Challenge One first saline then 5000 EU 10,000 EU 20,000 EU~Challenge 1 and 2 must be at least 2 weeks apart.~Challenge 2 Saline 40,000 EU 80,000 EU"
40975598|NCT02669433|DRUG|RVT-101 35 mg|once daily, oral, 35-mg tablets
41459674|NCT06389227|OTHER|traditional training group|The TTG followed a traditional soccer training program for the same period and number of sessions without any intervention attributable to the dynamic ecological approach
40771503|NCT01955863|PROCEDURE|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
40975599|NCT02669433|DRUG|RVT-101 70 mg|once daily, oral, 35-mg tablets
40975600|NCT02669433|DRUG|Placebo|once daily, oral, matching tablets
40975601|NCT01824394|DEVICE|nMARQ Navigation Catheters|
40975602|NCT01824394|DEVICE|NaviStar ThermoCool Catheters|
40975603|NCT00545168|DRUG|Spinosad|10 minute topical application of product, followed by a complete rinse off.
40975604|NCT00545168|DRUG|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
40975605|NCT00545168|DRUG|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
40975606|NCT03903848|OTHER|Exercise|Single session of treadmill walking and resistance exercise
41300339|NCT00500045|DRUG|nicotinic acid|niacin 1500 mg po qd
41300340|NCT05866822|OTHER|APA|24 APA sessions
41300341|NCT05866822|OTHER|PAE|8 individuals sessions of PAE
40771504|NCT01955863|PROCEDURE|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
40771505|NCT01955863|PROCEDURE|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
40975607|NCT03970798|DRUG|Midazolam|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
40771506|NCT05788926|DRUG|TG6050|Oncolytic Vaccinia virus containing genes encoding the human interleukin 12 (IL-12) and an anti-CTLA4 antibody administered at different dose.
40771507|NCT02786329|DRUG|TIVA+lidocaine|Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
40771508|NCT02786329|DRUG|Sevoflurane+lidocaine|Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
40975608|NCT03970798|DRUG|Caffeine|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
40975609|NCT03970798|DRUG|Rosuvastatin|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
40975610|NCT03970798|DRUG|KW-6356|In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.
40975611|NCT02617628|DRUG|extended release naltrexone|Extended Release Naltrexone is currently marketed in the US for use in adults with alcohol dependence. It will be administered in this study at the currently marketed dose of 380 mgs. Subjects will be randomized to receive one injection of 380 mg of extended release naltrexone, at baseline, before they leave the prison, or either 380 mg of extended release naltrexone after they are released from prison. Both groups will receive three additional monthly doses of 380 mgs while enrolled in intensive outpatient treatment for six months. Subjects will also receive weekly psychosocial counseling.
40975612|NCT00296478|DRUG|Endometrin|Endometrin 100mg BID x 10weeks
40975613|NCT00296478|DRUG|Endometrin|Endometrin 100mg TID x 10weeks
40975614|NCT00296478|DRUG|Crinone|Crinone QD x 10weeks
40975615|NCT00848081|DRUG|Tadalafil|5 mg taken by mouth once daily for 12 weeks
40975616|NCT00848081|DRUG|Placebo|By mouth once daily for 12 weeks
40975617|NCT00004860|DRUG|leucovorin calcium|
40975618|NCT00004860|DRUG|tegafur-uracil|
40975619|NCT04818398|DRUG|DS-6016a|DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
41300342|NCT06000722|OTHER|eDelphi method|This is a Delphi technique-based study using a purposive sample of convenience. Consensus development methods will be used to generate clinical guidelines, endorsed by key clinical groups, on the use of SGLT2i's in patients with diabetic foot ulcer disease, including acknowledgement of specific scenarios or patient characteristics that may influence these guidelines.
40975620|NCT04818398|DRUG|Placebo|Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
40975621|NCT05810142|DRUG|furquimatinib and sintilimab|furquimatinib and sintilimab
40975622|NCT04650360|BEHAVIORAL|Postoperative Intervention Educational Program|The health educational program consisted of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics were addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls. The educational session was implemented during the postoperative hospital stay, with an approximate duration of 30-45 min. The session ended with a summary of the content and comments from the patient and relative in order to ensure understanding of the program. Written information was provided on the aspects addressed in the session (brochures). These patients were treated according to routine protocols. All patients were monitored during admission, at 1 month, at 6 months, and at 1 year after the intervention
40975623|NCT01240720|DRUG|131I-F16SIP Radioimmunotherapy (RIT)|"* Dosimetric evaluation with 131I-F16SIP or 124I-F16SIP will be performed to assess eligibility for Radioimmunotherapy.~* Patients eligible for Radioimmunotherapy will receive 55.5 mCi/m2 as established in the Phase I part of the study. A single dose of 5 to 10 mg of 131I-F16SIP will be administered intravenously (I.V)."
40975624|NCT01953198|OTHER|Hypobaric hypoxia|Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
41459675|NCT04247841|OTHER|Visual Aid|The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual discription stating the anticipated risk. For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS.
40975625|NCT06289491|PROCEDURE|Hydrus Microstent|Patients will have a Hydrus Microstent inserted into the canal of Schlemm at the time of cataract surgery
40975626|NCT06289491|PROCEDURE|Incisional goniotomy|Patients will have incisional goniotomy to open the trabecular meshwork with a Sinskey hook at the time of cataract surgery
40975627|NCT06289491|PROCEDURE|Excisional goniotomy|Patients will have excisional goniotomy to remove the trabecular meshwork with a Kahook Dual Blade at the time of cataract surgery
40771509|NCT02786329|DRUG|TIVA+placebo|Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
40975628|NCT03048565|BEHAVIORAL|MBSR|Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
40975629|NCT01458652|DRUG|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
40975630|NCT05234151|OTHER|NEWS|Newborn Early Warning Score
40975631|NCT05965310|BEHAVIORAL|Virtual Psychological Intervention: Cognitive Behavioral Therapy|An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.
41300343|NCT02963727|BIOLOGICAL|Wharton Jelly derived mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
41300344|NCT01013948|OTHER|Non-Interventional|Non-Investigational Product (Survey Study)
40771510|NCT02786329|DRUG|Sevoflurane+placebo|Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
40771511|NCT05966714|DEVICE|NIRS|cerebral oxygenation and electrical activity monitoring
41300345|NCT00697047|BEHAVIORAL|Automated Mailing|Usual Care plus Automated mailing
41300346|NCT00697047|BEHAVIORAL|Automated Mailing Plus Assisted|If not screened after automated mailing, MA assists with screening.
41459676|NCT04247841|OTHER|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
40771512|NCT05966714|DEVICE|aEEG|amplitude-integrated electroencephalography
40771513|NCT05410223|DRUG|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
40771514|NCT05410223|DRUG|IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
41300347|NCT00697047|BEHAVIORAL|Auto Plus Assisted Plus Navigation|If not screened after automated mailing and assistance by MA, RN begins navigation.
41300348|NCT05146973|BIOLOGICAL|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)
40771515|NCT05410223|DRUG|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline|"Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd."
40771516|NCT05410223|DRUG|IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
40771517|NCT04980209|DEVICE|ultrasound evaluation|According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.
41300349|NCT05727163|DRUG|Dexamethasone|25mg via HAI (Pre-chemotherapy)
41300350|NCT05727163|DRUG|Anisodamine|10 mg via HAI (Pre-chemotherapy)
41300351|NCT05727163|DRUG|Oxaliplatin|85 mg/m2 via HAI over 3 hours
41300352|NCT05727163|DRUG|Leucovorin|200 mg/m2 via HAI
41459677|NCT00185120|DRUG|Olmesartan medoxomil|
40771518|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
40771519|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
40771520|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
40771521|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16
40771522|NCT02676180|OTHER|Group|
40771523|NCT02160431|BEHAVIORAL|CBT for pediatric OCD|Participants complete standard CBT for OCD as delivered in the POTS study .
40771524|NCT06570252|DEVICE|activated Light Source (aPDT)|"Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~Activation of SW4000 Light Source (Class 1 Laser Device) that generates red light consisting of 2 channels of 700 mW, 664 nm light (continuous wave) used to activate the disinfecting formulation.~Duration of illumination 2 minutes"
41300353|NCT05727163|DRUG|Fluorouracil|400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours
41300354|NCT05727163|DRUG|Irinotecan|150 mg/m2 intravenously
41300355|NCT05727163|DRUG|Bevacizumab|5 mg/kg intravenously
41300356|NCT05727163|DRUG|Oxaliplatin|85 mg/m2 intravenously over 3 hours
41300357|NCT05727163|DRUG|Leucovorin|200 mg/m2 intravenously
41300358|NCT05727163|DRUG|Fluorouracil|400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours
41300359|NCT06466720|BEHAVIORAL|Neurocognitive testing|The MoCA is a brief tool developed to screen mild cognitive impairment and has been validated in patients aged 55-85 years old. It has been tested and validated in patients with brain metastases, and its acceptability has been tested in the general brain tumour population. The paper version of the MoCA is available in nearly 100 languages. The online version is available currently in 5 languages.
41300360|NCT06466720|BEHAVIORAL|Quality of Life questionnaire|The EORTC-QLQ-C30 is a quality-of-life questionnaire that was developed by the European Organisation for Research and Treatment of Cancer (EORTC) for use in clinical trials. It is a 30-item questionnaire that incorporates the following five scales: physical, role, cognitive, emotional and social. It has also been validated and is available in more than 100 languages. The EORTC-QLQ-BN20 is a questionnaire that was developed for use specifically with patients that have brain cancer. The BN20 is a 20-item questionnaire and addresses four different scales (multi-item): future uncertainty, visual disorder, motor dysfunction and communication deficit. There are seven items that assess physical symptoms: headaches, seizures, drowsiness, hair loss, itchy skin, weakness of legs and bladder control. The questionnaire has been validated in over 15 languages. The two questionnaires are meant to complement each other when used in patients with brain cancer.
41300361|NCT06466720|RADIATION|Stereotactic radiosurgery|This is a Standard of Care treatment for all the patients that will be recruited in both cohorts. Stereotactic radiosurgery will be delivered to one or more sites and in the prospective cohort can be delivered more than once.
41459678|NCT00185120|DRUG|Hydroclorothiazide|
41459679|NCT00185120|DRUG|Benazepril|
41459680|NCT00185120|DRUG|Amlodipine|
41300362|NCT00932139|PROCEDURE|Electro-acupuncture control|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
41300363|NCT00932139|PROCEDURE|Electro-acupuncture test|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
41300364|NCT04241237|PROCEDURE|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
41300365|NCT03363828|DRUG|Estrofem|Patients will be asked to obtain self-collected vaginal swabs from the mid-vagina from the beginning of their Estrofem® treatment
41300366|NCT05641376|DRUG|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. Treatment will be stopped when the nebulizer began to sputter. At end of nebulizer administration, they will be observed for 30 min before induction of general anaesthesia. then the children will be transferred to the operation room and will receive intravenous (IV) normal saline 0.9% in 10 ml volume over 10 minutes after anesthesia induction.
41300367|NCT05641376|DRUG|Intravenous Dexmedetomidine|Children will receive nebulized 3 ml of 0.9% normal saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. then the children will be transferred to the operation room and will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
41300368|NCT01180413|DRUG|Amlodipine|5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
40975632|NCT01804296|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
41300369|NCT01180413|DRUG|Ramipril|5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.
41459681|NCT05040139|PROCEDURE|Malone Procedure|Surgical procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, the procedure is performed under general anesthesia. The surgeon bring the end of the appendix (or a tubulized segment of the ileum) out through the abdominal wall. The appendix is opened and sutured to the abdominal skin.
41459682|NCT05040139|PROCEDURE|Percutaneous endoscopic caecostomy|Endoscopic procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, a coloscopy is performed to reach the caecum. The cutaneous location of the caecostomy is determined by transillumination of the caecum. A caecopexy is performed with 3 anchors at the chosen location. A specific pig-tail catheter (Chait catheter) is placed percutaneously into the caecum in the center of the 3 anchors.
41459683|NCT05655429|PROCEDURE|physical therapy|The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 day per week.
41140636|NCT06445140|BEHAVIORAL|Collecting the variables and Implementation of a behavioural intervention|"The observational phase (during 15 days)~* Two measurements per day for motivational variables and physical activity and nutrition~* Two measurements per day for nutrition~* Three measurements per day for fatigue~* Continuous PA measurement by accelerometer~The interventional phase :~Part A (during 7 days)~* measuring physical activity (PA)~* complete questionnaires and numerical scales :~  * Motivational factors~ * Self-evaluation of nutrition~ * Self-assessment of fatigue~Part B: BEHAVIORAL INTERVENTION (10 weeks),the APA teacher will call a patient once a week for follow-up.~Answer questionnaires and scales on the digital platform will be done :~* Motivational factors~* Self-evaluation of nutrition~* Self-assessment of fatigue~Part C : End of interventional phase(during 7 days)~* measuring physical activity~* complete questionnaires and numerical scales :~  * Motivational factors~ * Self-evaluation of nutrition~ * Self-assessment of fatigue"
41459684|NCT05655429|PROCEDURE|arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy surgery procedure
41140637|NCT04740541|OTHER|Dietary Intakes (Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies)|Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies to meet nutritional requirements, 5 levels of threonine intakes
41140638|NCT05636345|OTHER|pain science education|A full day of pain science education
41140639|NCT03954106|DRUG|Defibrotide|"* Part 1: Defibrotide 2.5 mg/kg/dose or 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7).~* Part 2 Recommended Phase 2 Dose: Defibrotide 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7)."
41140640|NCT05260437|BIOLOGICAL|CV2CoV (2 µg)|Study vaccine was administered as a single intramuscular injection.
41300370|NCT01180413|DRUG|Lercanidipine|Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
41300371|NCT01180413|DRUG|Losartan|Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
41300372|NCT01519427|DRUG|Akt inhibitor MK2206|Given PO
41300373|NCT01519427|DRUG|selumetinib|Given PO
41300374|NCT01519427|OTHER|laboratory biomarker analysis|Correlative studies
41459685|NCT04865341|BEHAVIORAL|IMB|Intervention content will be focused on the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
41459686|NCT01691612|BIOLOGICAL|installation of D. pteronyssinus allergens|We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
41459687|NCT02783326|OTHER|Rehabilitation|Pulmonary rehabilitation, exercise in COPD individuals and health individuals
41459688|NCT05717985|PROCEDURE|modified combined approach|A thin layer of epithelium will be excised from the harvested graft. This epithelium will be replaced at the donor site and sutured.
41459689|NCT05717985|PROCEDURE|de-epithelized gingival graft|Only dressing material will be placed at the donor site after graft harvesting
41459690|NCT03395015|OTHER|VAS scale (from 1 to 10) esthetic assessment of facial 3-D images|The rating process is biphasic: firstly a 3-D model is showed to the raters, who can orientate the vultus, familiarize with the 3-D technology and have a first glance evaluation. Secondly, the judges are asked to rate each of the following patient views: right profile, left profile, frontal, neck hyperextension and hyperflexion views Two weeks after the first assessment, the same judges assessed the same number of pictures, once again in random order.
41300375|NCT05300867|OTHER|Neurorehabilitation|Neurorehabilitation with soft exsoskeleton robotic 3-week-long
41459691|NCT03486938|DRUG|Placebo Oral Tablet|Placebo oral tablet
40975633|NCT04044235|BEHAVIORAL|PrEP Cohort|AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.
41300376|NCT05300867|OTHER|Physiotherapy|Physiotherapy 3-week-long
41300377|NCT06243757|OTHER|MDASI-GI|"The MDASI-GI assesses 5 symptoms specific to gastrointestinal cancer:~constipation diarrhea or watery stools difficulty swallowing change in taste feeling bloated~Using this questionnaire, participants score the severity of their symptoms over the previous 24 hours on a scale of 0 (not present) to 10 (as bad as you can imagine)."
41300378|NCT04201769|DRUG|Netupitant/Palonosetron|NEPA is adiministered 60 minutes before chemotherapy, on day 1
41300379|NCT04201769|DRUG|Dexamethasone|"Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm"
41300380|NCT00850759|DEVICE|virtual pedestrian environment|a computer-driven virtual pedestrian environment
41300381|NCT00850759|DEVICE|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
41300382|NCT00850759|BEHAVIORAL|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
41300383|NCT02372292|DRUG|intravenous furosemide|Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
41300384|NCT06297460|BEHAVIORAL|Systems Training for Emotional Predictability & Problem Solving (STEPPS)|STEPPS is based on a cognitive-behavioral and skills training approach divided into three major components. The first component (sessions: 1-2) teaches participants to replace misconceptions about the presented issues with greater awareness of thoughts, feelings, and behaviors that characterize them. It also helps them identify their own thought patterns driving their behaviors. The second (sessions 3-12) teaches skills to more effectively manage the cognitive and emotional effects of the issues, such as distancing, communication, challenging, distraction, and problem-solving. The third component (sessions 13-19) teaches behavioral skills where participants are encouraged to master habits of healthy eating, sleep hygiene, regular exercise, leisure activities, health monitoring, self-harm prevention, and interpersonal effectiveness. The therapeutic objectives of the three blocks are awareness of illness (1), emotional regulation (2), and behavioral regulation (3).
41459692|NCT03486938|DRUG|AGB101 220 mg tablet|220 mg AGB101 active compound
41459693|NCT01062334|PROCEDURE|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
41459694|NCT00566657|BIOLOGICAL|riferminogene pecaplasmid|"Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid~Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated"
41459695|NCT00566657|BIOLOGICAL|Placebo (for riferminogene pecaplasmid)|"Formulation: 5 ml glass vials containing 2,5 ml placebo~Route: IM injection of 2.5 mL in the ischemic leg to be treated"
41459696|NCT00654641|PROCEDURE|Negative pressure wound closure|Applying negative pressure to primary wound closure
41459697|NCT00654641|PROCEDURE|Standard wound closure|Standard wound closure
40975634|NCT06136754|DRUG|Varnishes, Fluoride|Fluoride varnish containing 5.0% NaF
41300385|NCT00227383|DEVICE|Electroacupuncture (device)|
41300386|NCT04018963|PROCEDURE|Single nostril approach endoscopic transsphenoidal pituitary surgery|Single nostril approach endoscopic transsphenoidal pituitary surgery
41300387|NCT04018963|PROCEDURE|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
41300388|NCT02557971|DRUG|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
41300389|NCT03156556|BEHAVIORAL|Mood Mechanic Course|French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
41459698|NCT03214237|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
41459699|NCT01112891|DRUG|Vitamin D|10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
40975635|NCT03124875|DEVICE|LimFlow System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia.
40975636|NCT03249727|DIAGNOSTIC_TEST|IVDD for NK cell activity in whole blood|Once subject has been scheduled for a colonoscopy by the institution (up to 4 weeks prior to procedure), the subject will perform a FIT at home and an NK Vue test (one sample of one mL of blood) at the institution, prior to the day of colonoscopy.
40975637|NCT01995825|DRUG|Brand lamotrigine|Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
40975638|NCT01995825|DRUG|Generic lamotrigine|Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
40975639|NCT01030939|DRUG|SB-649868|In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
41459700|NCT01112891|DRUG|Vitamin D3|25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
41459701|NCT01112891|DRUG|Vitamin D|50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
41459702|NCT02502331|BIOLOGICAL|Test Oral Cholera Vaccine|Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
41459703|NCT02502331|BIOLOGICAL|Euvichol®|Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
41459704|NCT00570128|DRUG|Donepezil HCl|Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day \[mL/day\]) orally for participants with body weight (BW) 20 and less than (\<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to \<50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (\>=) 50 kg liquid formulation (1 milligram per 1 milliliter \[1 mg/1 mL\]) (titrated to 0.1 to 0.2 milligram per kilogram per day \[mg/kg/day\] based on BW).
40771525|NCT06570252|DEVICE|non activated Light Source (Control)|"Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~No activation of SW4000 Light Source~Waiting for 2 minutes"
40771526|NCT05557721|PROCEDURE|Topical lidocaine|Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage.
40771527|NCT05557721|PROCEDURE|MP-TLT|"Micro pulse transscleral laser treatment will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations.~In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning."
40771528|NCT00480532|DRUG|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
40771529|NCT00480532|DRUG|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
40771530|NCT00480532|DRUG|Oracea|40-mg tablet daily for 84 days
40771531|NCT00480532|DRUG|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
40771532|NCT00480532|DRUG|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
40771533|NCT00480532|DRUG|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
40771534|NCT00480532|DRUG|placebo daily|Placebo daily for the first 84 days of the study
40771535|NCT02102945|PROCEDURE|Computed tomography perfusion|Computed tomography perfusion of the head
40771536|NCT05193708|DEVICE|Windowed Bonding|A 3D printed tray/guide with open window for the orthodontic brackets
40975640|NCT03140553|DRUG|TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)|TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
40975641|NCT05568472|OTHER|Best Practice|Standard of care hormone therapy and standard visit with clinician
40975642|NCT05568472|PROCEDURE|Biospecimen Collection|Undergo correlative studies
41300390|NCT04137133|DIAGNOSTIC_TEST|collection|bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
41300391|NCT01819922|DRUG|PF-05175157|600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
41459705|NCT00570128|DRUG|Placebo|Liquid formulation matched to active treatment for oral administration.
40771537|NCT05193708|DEVICE|Digital Indirect bonding tray|Vacuum formed on a 3d printer cast with brackets
40771538|NCT04528186|DIAGNOSTIC_TEST|Maternal thyroid volume|Maternal thyroid volume measurement
40975643|NCT05568472|PROCEDURE|Endocrine Drug Therapy|Undergo endocrine therapy
40975644|NCT05568472|BEHAVIORAL|Health Education|Receive list of websites
40975645|NCT05568472|OTHER|Questionnaire Administration|Ancillary studies
40975646|NCT05568472|OTHER|Symptom Specific Assessment Tool|Receive a weblink via email or text message and asked 6 brief questions about symptoms
40975647|NCT01705184|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
41300392|NCT01819922|DRUG|Placebo|Placebo powder in capsule, one dose within 5 minutes prior to AM meal
41459706|NCT05619796|PROCEDURE|pulpectomy procedure|single visit pulpectomy was performed under strict aseptic conditions by a single operator. Peri-operative evaluation was done using intraoral digital senso. The teeth were anesthetized with 2% mepivacaine with 1:20,000 levonordefrin \& isolated using rubber dam. caries was removed using no. 330 round carbide burs in high-speed contra angle headpiece. Access opening was gained \& the roof of the pulp chamber was removed. Working length was determined by apex locator, then confirmed by periapical radiograph. Working length will be determined 1 mm shorter than apex. mechanical preparation was done using the tested files according to each group. Then, canals were irrigated with 1% sodium hypochlorite between each file followed by irrigation with normal saline. The root canals were dried using paper points \& root canals were filled with Metapex. Intermediate restorative material was placed, and the tooth was restored with a preformed stainless-steel crown in the same appointment.
41459707|NCT05619796|RADIATION|Post-operative Cone Beam Computed Tomography|"post-operative CBCT image was taken after completing the procedure with fixed exposure parameters (120 Kv, 5mA and 0.125mm voxel size) using smallest field of view (8D, 8Hcm) to improve spatial resolution. The CBCT images were obtained by using 3D module of On Demand Dental software (version 1.0 (build 1.0.10.7462),× 64 Edition, copyright 2004-2017 Cybermed, Korea and license key 670094709).~The Immediate post-operative CBCT was taken to evaluate the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique ."
41300393|NCT04964830|DEVICE|Orthodontic treatment with functional appliance (MAD)|Expansion plate and z-activator (MAD)
41300394|NCT05920187|OTHER|Mediterranean diet and Anti-inflammatory diet|"Cases will be randomly allocated to two groups: Mediterranean diet group (following dietary intervention based on MD), and Anti_inflammatory diet group(following dietary intervention based on IBD-AIF). Patients of the control group will not be instructed to follow a specific dietary intervention.~Evaluation of adherence of cases to dietary intervention will be at two points of time: after four weeks and after 12 weeks by using Mediterranean Diet Serving Score (MDSS) for MD adherence and Anti- Inflammatory Diet Serving Score for IBD- AID adherence. The AID Serving Score (AIDSS) is based on the latest update of the Anti-Inflammatory Diet Pyramid, using the recommended consumption frequency of foods and food group."
40975648|NCT01705184|DRUG|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
40975649|NCT01705184|DRUG|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
40975650|NCT03157258|BEHAVIORAL|Social Network Training|Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.
40975651|NCT03157258|BEHAVIORAL|Single Care-Related Counseling Session and Referral to Care|Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
40975652|NCT00703079|DRUG|Octreotide-LAR or lanreotide|Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
40975653|NCT00703079|PROCEDURE|Transsphenoidal adenomectomy|Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
40975654|NCT00237198|DRUG|Letrozole|
41300395|NCT01283581|DRUG|Delafloxacin|300mg IV every 12 hours for 5-14 days
41300396|NCT01283581|DRUG|Linezolid|600mg IV every 12 hours for 5-14 days
40975655|NCT01733771|OTHER|CAM treatments|CAM treatments last 10-30 minutes
40975656|NCT03653650|COMBINATION_PRODUCT|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
41300397|NCT01283581|DRUG|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
41300398|NCT03972592|DRUG|Topical 0.1% Sirolimus|The formulation is 0.03 g rapamycin, 1.5 g Transcutol, Quantum Satis (QS) 30g Excipial® hydrocream, corresponding to a concentration at 0.1%. The cream will be packaged in 30 ml aluminium tubes.
40975657|NCT03653650|COMBINATION_PRODUCT|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
40975658|NCT03653650|COMBINATION_PRODUCT|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
40975659|NCT00468325|PROCEDURE|Multi-slice computed tomography|Patient receives a CT scan (multi-slice computed tomography) of the heart.
40975660|NCT00468325|PROCEDURE|Rest-stress Nuclear Myocardial Perfusion Imaging|Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.
41300399|NCT03972592|DRUG|Topical Vehicle|The same vehicle than the one used in the topical 0.1% sirolimus preparation will be used for the other half area of CMLM, i.e. Excipial® hydrocream. It will be packaged to maintain the double blind way of this trial and will be undistinguishable from the sirolimus cream.
40975661|NCT00468325|PROCEDURE|Multi-slice Computed Tomography|Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
41140641|NCT05260437|BIOLOGICAL|CV2CoV (4 µg)|Study vaccine was administered as a single intramuscular injection.
41140642|NCT05260437|BIOLOGICAL|CV2CoV (8 µg)|Study vaccine was administered as a single intramuscular injection.
41140643|NCT05260437|BIOLOGICAL|CV2CoV (12 µg)|Study vaccine was administered as a single intramuscular injection.
41140644|NCT05260437|BIOLOGICAL|CV2CoV (16 µg)|Study vaccine was administered as a single intramuscular injection.
41140645|NCT05260437|BIOLOGICAL|CV2CoV (20 µg)|Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it.
41140646|NCT05792852|BEHAVIORAL|ENGAGE|ENGAGE is a group intervention designed to improve social participation within the context of the COVID-19 pandemic.
41459708|NCT05619796|OTHER|Post-operative pain assessment|The parents of the children were given a questionnaire to record the intensity of postoperative pain at six, twelve, twenty-four and forty-eight hours after the pulpectomy procedure. A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain. The four-point pain intensity scale was used to record postoperative pain (figure 5). This scale categorizes pain as follows: (1) no pain; (2) slight pain; (3) moderate pain; and (4) severe pain. To ensure standardization, the same parent was asked to record the child's pain intensity at all time intervals. To reduce the possibility of the parents failing to record the pain at a given time, the investigator also recorded findings via telephonic conversation with the parents. The children returned to the department two days after the pulpectomy procedure with their completed questionnaire form.
41459709|NCT05328700|OTHER|Kinesiotaping|Perform a neuromuscular bandage with kinesiotape in patients with plantar fasciitis
41459710|NCT05328700|OTHER|Tape|Perform a neuromuscular bandage with tape (Hipofix(R)) in patients with plantar fasciitis
41459711|NCT02316457|BIOLOGICAL|IVAC_W_bre1_uID|vaccination
41459712|NCT02316457|BIOLOGICAL|IVAC_W_bre1_uID/IVAC_M_uID|vaccination
41459713|NCT03863041|OTHER|Additional sequence performed during MRI scan|An additional sequence will be performed during the MRI scan.
41459714|NCT01898598|DRUG|Placebo|Participants will receive matching placebo to vismodegib for 12 weeks.
40771539|NCT03235804|DIETARY_SUPPLEMENT|Soy protein, honey and yogurt.|Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
40771540|NCT05054101|OTHER|Real-time assessment using the VieCovid2020 smartphone application|a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention
40975662|NCT01974349|DRUG|selumetinib (oral)|Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
41300400|NCT01386099|DRUG|PSN821|Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
41459715|NCT01898598|DRUG|Vismodegib|Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
40771541|NCT02852707|BEHAVIORAL|Chronic exposure to unilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports)."
40771542|NCT02852707|BEHAVIORAL|Chronic exposure to bilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports)."
40975663|NCT01648205|DRUG|Placebo|Matching Placebo will be given for first month.
40975664|NCT01648205|DRUG|Ranolazine|Patients will receive ranolazine 1000mg bid for subsequent 5 months.
41459716|NCT03927495|DRUG|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
41459717|NCT03927495|RADIATION|palliative radiotherapy|3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.
40975665|NCT03763253|COMBINATION_PRODUCT|Standard of Care|Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).
41459718|NCT03927495|DRUG|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
41459719|NCT03699254|DRUG|Valganciclovir|"Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
40975666|NCT03763253|PROCEDURE|Minimally Invasive Ablative Therapy (MIAT)|"MIAT includes High intensity focused ultrasound (HIFU) or Cryotherapy to the prostate.~Metastatic Directed Therapy available for use."
41140647|NCT00502684|DRUG|Propranolol, etodolac|propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
41140648|NCT01217697|DRUG|Abiraterone Acetate|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets once daily.
41140649|NCT01217697|DRUG|Prednisone\Prednisolone|Participants will receive prednisone 5 mg twice daily as oral tablet OR prednisolone 5 mg (if prednisone is not available).
41140650|NCT04105907|DEVICE|GentleWave|Subject teeth will receive a partial root canal treatment with the Sonendo GentleWave system followed by extraction of the tooth and histological evaluation of the tooth
41140651|NCT00184444|BEHAVIORAL|Hypoxic interval training|4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max
41140652|NCT00184444|BEHAVIORAL|Normoxic interval training|4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
41140653|NCT02704156|DEVICE|Cyberknife plus Pembrolizumab and Trametinib|Radiation therapy plus drug
41140654|NCT02704156|DEVICE|Cyberknife plus Gemcitabine|Radiation therapy plus drug
41140655|NCT04128956|DRUG|Aspirin 100mg|Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
41459720|NCT03699254|DRUG|Ganciclovir|"Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
40975667|NCT03763253|PROCEDURE|Radical Therapy (Prostatectomy or Radiotherapy)|"Radical therapy includes: Prostatectomy (any surgical approach) or External beam radiotherapy (High dose).~Metastatic Directed Therapy available for use."
40975668|NCT03398967|BIOLOGICAL|Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells|"1. Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells~2. Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose~3. Other: Laboratory Biomarker Analysis"
40975669|NCT06169748|DEVICE|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
40771543|NCT02852707|BEHAVIORAL|Not exposed|People not engaged in regular sports competition/exercise training.
40975670|NCT06169748|DEVICE|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
40975671|NCT06169748|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
40975672|NCT01090960|DRUG|GDC-0068|Oral repeating dose
40975673|NCT01036841|DRUG|desmopressin tablet|Administration of desmopressine tablet
40975674|NCT01036841|DRUG|desmopressin MELT formulation|Administration of desmopressine MELT formulation
40975675|NCT06469983|DEVICE|ErigoBasic or ErigoPro®|Static bed with integrated robotic stepper (ErigoBasic) and optionally integrated with Functional Electrical Stimulation (FES ErigoPro®). The Erigo is a robot designed to be used for early functional mobilisation of patients with neurological manifestations or who are bedridden, even in intensive care. It is a tilt table equipped with an integrated passive stepper controlled by microprocessors that generate physiological leg movements: the patient's thighs are secured by straps to the movement mechanisms and the feet are secured to plates equipped with shock absorbers, while the upper body is held in place by a sling integrated into the table. Erigo provides active functions: gradual elevation in orthostatism up to 90°, controlled and independent mobilisation of the lower limbs, and functional stimulation.
40975676|NCT06469983|BEHAVIORAL|Traditional Verticalization|gradual verticalization (from supine position up to maximum 90°, in 3 steps), depending on the patient's vital signs compliance, using a traditional standing device (i.e., non-robotic traditional tilt table)
40975677|NCT06179797|DEVICE|remote ischemic conditioning|suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.
40975678|NCT03944460|DRUG|Contraloid|Oral administration of capsules, drug substance or placebo without any excipients.
40975679|NCT00477971|BIOLOGICAL|filgrastim|No administration information given
40975680|NCT00477971|DRUG|dexamethasone|Given orally
40975681|NCT00477971|DRUG|melphalan|Given IV or orally
40975682|NCT00477971|PROCEDURE|autologous hematopoietic stem cell transplantation|Given on day 0
40975683|NCT03628703|DEVICE|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area
40975684|NCT06141395|DIAGNOSTIC_TEST|NGS-based assay for bacterial identification|A total volume of 26ml of whole blood will be sampled from each enrolled patient for three consecutive days. This will be used for Standard-of-Care (SoC) culture and Next Generation Sequencing (NGS), for identification of circulating microorganisms.
41300401|NCT01386099|DRUG|Placebo|Placebo twice a day for 12 weeks.
41300402|NCT02241850|OTHER|High intensity training|9 weeks of supervised high intensity training
40975685|NCT01735513|DEVICE|Intra-aortic embolic protection management system; Embol-X|"The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream."
41300403|NCT03990766|DRUG|Theophylline|Theophylline delivered via high-volume, low-pressure nasal saline irrigation
41300404|NCT03990766|DRUG|Saline Nasal|Lactose delivered via high-volume, low-pressure nasal saline irrigation
41300405|NCT03865407|DRUG|Allopurinol|Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
41300406|NCT04095286|DRUG|AMB new formulation (1 mg)|AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
41300407|NCT04095286|DRUG|Reference AMB (5 mg)|AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
41300408|NCT03476018|DRUG|Z-100|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
41300409|NCT03476018|DRUG|Placebos|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
41300410|NCT03532945|DEVICE|Bioactive Glass-Ceramic Spacer|
41300411|NCT03532945|DEVICE|Titanium cage|
41300412|NCT04013737|DEVICE|EPIC IMPOC|Clinical Decision Support System for antibiotic prescribing.
41459721|NCT05580887|DRUG|mFOLFIRINOX|every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1 Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
41459722|NCT05580887|DRUG|Doxorubicin|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
41459723|NCT05580887|DRUG|Cyclophosphamid|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
41459724|NCT05580887|DRUG|Paclitaxel|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
41459725|NCT05580887|DRUG|Carboplatin|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
41140656|NCT02254902|BEHAVIORAL|Physical Activity intervention|The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
41459726|NCT00114322|DEVICE|light exposure from LED source at narrow 468 nm or broader 400-700 nm wavelength|
41459727|NCT01630616|DRUG|Odanacatib|single oral dose, tablets, 10 or 50 mg
41459728|NCT01630616|DRUG|Placebo|single oral dose, tablets
41459729|NCT04483895|PROCEDURE|Endotracheal tube insertion|ETT was inserted and the depth was estimated by either OHL method or 7-8-9 method
41140657|NCT00000111|PROCEDURE|Oral mucosal graft|
41300413|NCT03002116|OTHER|Tissue thermometry using non-invasive microwave radiometry device|In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
41300414|NCT05826197|OTHER|Radiomics|PET Radiomics
41300415|NCT00166010|DRUG|Nesiritide|Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
41459730|NCT01781234|DRUG|Intranasal Insulin|
41459731|NCT01781234|DRUG|Placebo|
41147155|NCT03046888|PROCEDURE|Robot assisted pyelolithotomy|A 12-mm camera port is placed at the level of the umbilicus and lateral; this port is moved farther laterally in morbidly obese patients to allow for the instruments to reach the target organs. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. For right-sided stones, an additional 5-mm port is placed in the midline just below the xiphoid process for liver retraction. Placement of the trocars can be changed according to surgeon preference. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
41300416|NCT00683358|BIOLOGICAL|VEGFR1-A24-1084 (SYGVLLWEI)|HLA-A\*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.
41300417|NCT02498080|PROCEDURE|DEB PTA|paclitaxel drug eluting balloon PTA
41300418|NCT02498080|PROCEDURE|Standard PTA|Standard PTA
41459732|NCT04678063|OTHER|Exposure to Placebo|Patients are exposed to placebo in the EEC
41459733|NCT04678063|OTHER|Exposure to dose A and dose B of cat allergen|Patients are exposed to dose A and B for successive exposures in the EEC
41459734|NCT04678063|OTHER|Exposure to a single dose of cat allergen|Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)
41459735|NCT04265287|OTHER|Data collection|Demographic, clinical, microbiological, critical care support and management data will be collected.
41459736|NCT05740215|DRUG|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)
41459737|NCT05740215|DRUG|Lenvatinib|Lenvatinib capsules
41459738|NCT00828828|BIOLOGICAL|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
41459739|NCT04660032|BEHAVIORAL|Nudge|An electronic prompt (nudge) will be sent to the participant's obstetric care provider. The provider will receive a staff message in Epic (Penn Chart) that his/her patient has an upcoming postpartum visit. The message will be sent 1 week before the scheduled visit. The message will have patient-specific information including hypertensive diagnosis, blood pressure medication(s), gestational diabetes diagnosis, and primary care provider as listed in the Epic banner. The message will also have dot phrases for recommended counseling and contact information for UPHS primary care and cardiology providers. There will be example text recommending follow-up with primary care or cardiology; counseling on risk of future CVD; and recommending aspirin in a future pregnancy.
41459740|NCT00367536|DRUG|bazedoxifene/conjugated estrogens combination tablet|
41459741|NCT03547830|DRUG|Plerixafor|Plerixafor for Conditioning before HSCT.
40771544|NCT06564883|DEVICE|0.20% sodium hyaluronate gel|Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
40771545|NCT04450953|DRUG|Eplerenone 50mg/day (cross over design)|Eplerenone 50mg/day for 6 months followed
41300419|NCT06324487|OTHER|Progressive Exercises|Electrotherapy, stretching of the capsules, strengthening, ROM exercises, proprioceptive exercises
41300420|NCT06324487|OTHER|Blood Flow Restriction Therapy|Strengthening exercises performed by using cuff surrounding proximal part of the arm.
41300421|NCT05224622|DIAGNOSTIC_TEST|VOX|Breath exhalation into the mouthpiece of the VOX breath diagnostic device.
41300422|NCT04520113|BEHAVIORAL|Household contact tracing|Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.
41300423|NCT01313026|PROCEDURE|Percutaneous nerve evaluation|Implantation of a nerve stimulator to stimulate the sacral nerve plexus
41459742|NCT03547830|DRUG|Gcsf|GCSF for Conditioning before HSCT.
41459743|NCT05438927|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
41459744|NCT05438927|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth
40771546|NCT04450953|OTHER|Period without eplerenone (cross over design)|6-month period without eplerenone
41459745|NCT05438927|BEHAVIORAL|Fact G Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
41459746|NCT05438927|BEHAVIORAL|General Anxiety Disorder (GAD)-7|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.
41459747|NCT05438927|BEHAVIORAL|Patient Health Questionnaire (PHQ)-9|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.
40771547|NCT00000720|DRUG|Globulin, Immune|
40771548|NCT00000720|DRUG|Zidovudine|
41147156|NCT05903820|DRUG|Estradiol patch|Transdermal patch of estradiol
41147157|NCT05903820|DRUG|Progesterone|Oral progesterone capsules 100mg/day
41147158|NCT04552444|DRUG|Biapenem|In the course of CRKP treatment, double dose biapenem was selected.
41147159|NCT03562702|OTHER|Standard IV Rehydration Therapy|IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)
41147160|NCT03562702|OTHER|Oral Rehydration Therapy (ORT)|Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge
41147161|NCT01692652|DRUG|topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage|
41147162|NCT01692652|OTHER|warm compress only group|
41147163|NCT04178876|PROCEDURE|ethanol sclerotherapy|Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol
41147164|NCT04178876|PROCEDURE|stripping technique|Endometrioma laparoscopic cystectomy
41147165|NCT00913445|PROCEDURE|appendicectomy|Wound healing after absorbable and nonabsorbable stitches are compared
41147166|NCT01861509|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
41147167|NCT06292247|BEHAVIORAL|Cognitive behavioral therapy|CBT aims to treat anxiety by restructuring unfavorable beliefs and controlling negative thoughts so as to reduce dental anxiety.
41147168|NCT06292247|BEHAVIORAL|Auricular plaster therapy|APT involves the application of plaster with seeds on specific points of the outer ear, known as auricular points (acupoints). This process is believed to restore balance and harmony within the body's system and achieve a therapeutic effect (e.g. reduce anxiety)
41300424|NCT06291103|DRUG|Conversion to Belatacep|CNI will be tapered within 3 months: 75 % of initial dose on the first month, 50 % on the second month, 25 % on the third month, and stopped and a conversion to Belatacept will be performed. It will be administered (6mg/kg) every 2W for the first 2 months and then every month until kidney graft survival.
41300425|NCT06291103|DRUG|Standard of care treatment (SOC regimen) with Tacrolimus|Tacrolimus will be continued until kidney graft survival with objective of whole blood through levels between 6 and 8 ng/mL
40975686|NCT04171778|OTHER|whole food, plant-based diet|The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
40975687|NCT06382298|OTHER|COTTONSEED OIL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as cottonseed oil for 28 days.
41300426|NCT03544671|DIETARY_SUPPLEMENT|Vitamin D|
41300427|NCT01884454|BEHAVIORAL|Sleep deprivation|Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
41300428|NCT00255684|BIOLOGICAL|graft-versus-tumor induction therapy|
40771549|NCT03462602|PROCEDURE|NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was retained until the return of bowel function (passage of flatus or passage of stool) in the patients assigned to the NGT group.
40975688|NCT06382298|OTHER|MATCHED PUFA DIET|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs from oils with similar fatty acid composition as CSO for 28 days.
40975689|NCT06382298|OTHER|CONTROL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
40975690|NCT04274842|OTHER|observation by D-OCT|observation by D-OCT before, after, 1-3 days after, and 1 month after IPL treatment
40975691|NCT05953220|OTHER|Exclusive tobacco smoking|No intervention, participants own tobacco products
40975692|NCT05953220|OTHER|Exclusive e-cigarette use|No intervention, participants own e-cigarette products
40975693|NCT05953220|OTHER|Dual use of e-cigarettes and tobacco smoking|No intervention, participants own tobacco and e-cigarette products
41300429|NCT00255684|DRUG|cyclophosphamide|
41300430|NCT00255684|DRUG|cyclosporine|
41300431|NCT00255684|DRUG|fludarabine phosphate|
41300432|NCT00255684|DRUG|mycophenolate mofetil|
41300433|NCT00255684|PROCEDURE|umbilical cord blood transplantation|
41300434|NCT00255684|RADIATION|radiation therapy|
41459748|NCT04703751|DEVICE|Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter|Investigated device - the CIRCULATE Catheter will be introduced, using a standard radial or femoral access and a typical guiding catheter and typical coronary wire, first into the right coronary artery. After that the one dose of NTG (200µg) will be administered followed by a typical angiographic recording to visualize the vasodilatatory effect of the medication. Then CardioCell in doses of 10mln cells each (6.7mL) will be administered transcoronary to each of the coronary arteries (right coronary artery (RCA), LAD, left circumflex (Cx)). Angiography will be performed routinely before and after each product administration.
41459749|NCT03100019|DIETARY_SUPPLEMENT|Resveratrol|
41459750|NCT03100019|DRUG|Placebo|
41459751|NCT02413008|DRUG|estriol|0.005% estriol vaginal gel
41459752|NCT02413008|DRUG|Placebo|placebo vaginal gel
41459753|NCT04204590|OTHER|Deprescribing algorithm|For this study an implicit, evidence-supported and patient-centred algorithm has been developed. The outcome of the algorithm is an advice to the doctor to deprescribe or not deprescribe the statin and/or PPI.
41459754|NCT00748566|DRUG|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
41300435|NCT00399269|DRUG|Recombinant Human Erythropoietin alpha|
41459755|NCT01523236|DRUG|Mometasone furoate|50 mcg/actuation Nasal Spray
41459756|NCT01523236|DRUG|Nasonex®|50 mcg/actuation Nasal Spray
41459757|NCT01523236|DRUG|Placebo|Nasal Spray
41459758|NCT05609695|DRUG|Immune checkpoint inhibitor|After signing the written informed consent form, patients begin to receive single or combined therapy with immune checkpoint inhibitor. The use of immune checkpoint inhibitors takes 3 weeks as a cycle, and the treatment dose for each cycle is carried out in accordance with the latest international authoritative guidelines.
40975694|NCT05953220|OTHER|No use of e-cigarettes or tobacco smoking|No intervention
40975695|NCT03172455|DRUG|Glassia|Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 - day 15)
40975696|NCT02151760|DRUG|18F-DCFPyL|
41459759|NCT02593019|DRUG|AZD1775|"AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.~Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date)."
41459760|NCT05337644|DRUG|Indocyanine green solution|"5 ml of ICG were then injected intravenously to identify the stomach, carefully assessing the angle of His (preoperative written informed consent was obtained from the patient).~Adequate perfusion was defined as the direct and clear visualization of the fluorescence around the gastric tube, after an estimated time of 150-180 s followingi.v. administration."
41459761|NCT05771935|PROCEDURE|ultrasound guided radial versus ulnar artery cannulation|"Ultrasound examination will be performed using a hockey stick, high frequency (5-10 MHz) ultrasound probe (S-NerveTM; SonoSite Inc., Bothell, WA, USA).~. Arterial cannulation will be performed using the long axis view (in-plane) technique with a 24 or 22-gauge canulae according to the operator preference. Cannulation will be considered complete when the arterial waveform is confirmed on the monitor. If cannulation is unsuccessful within the third attempt or within 10 min, the case will be considered a failure at the chosen artery. After the failure, an alternative site will be used for cannulation and the case will be excluded from the study."
40975697|NCT03950648|BEHAVIORAL|Spatial Cognitive Training|map reading and route-learning skills
41300436|NCT03649100|PROCEDURE|Implant placement|Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
41300437|NCT00520676|DRUG|pemetrexed|500 mg/m\^2, IV, q 21 days x 6 cycles maximum
41300438|NCT00520676|DRUG|docetaxel|75 mg/m\^2, IV, q 21 days x 6 cycles maximum
41300439|NCT00520676|DRUG|carboplatin|AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum
40975698|NCT00289471|OTHER|No intervention delivered.|No intervention delivered.
40975699|NCT02950025|DEVICE|Online, adaptive MR-guided SBRT|Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
40975700|NCT02950025|DEVICE|Online, non-adaptive MR-guided SBRT|Patients will not have online-adaptive treatment planning
41300440|NCT03963245|BEHAVIORAL|Meaningful Activities and Recovery|"MA\&R is a new rehabilitation program for people with psychiatric disabilities. MA\&R aims to enable participation in everyday activities that are meaningful to the individual.~MA\&R is based on occupational science, and the underlying premise that there is a connection between mental health, recovery and meaningful everyday activities. The goal of MA\&R is that participants through the course become better at connecting daily activities with values, interests, plans and goals. When this connection is strengthened, it supports the experience of meaningfulness in everyday life.~MA\&R is led by two mentors where one mentor is an occupational therapist (or similar) and the other has lived experiences of mental vulnerability and recovery."
41300441|NCT03963245|BEHAVIORAL|Standard Care and Treatment|"For community mental health centres: medicine, psychoeducation, relational support, peer-support, psychotherapy, social counselling, care manager~For psychiatric rehabilitation services in Copenhagen, Odense and Svendborg: drop in centres, relational support, skills training, peer-support"
41300442|NCT01221467|DEVICE|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
41300443|NCT04328623|PROCEDURE|Hypnosis|"conversational hypnosis technique call the magic glove"
41300444|NCT04328623|PROCEDURE|Infiltration|Ultrasound-guided hand infiltration
41300445|NCT03471676|OTHER|Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording
41300446|NCT04670653|DRUG|MAGNÓLIA NASAL GEL|Magnólia nasal gel spray
41300447|NCT04670653|DRUG|MOMETASONE FUROATE|Mometasone furoate nasal spray
41300448|NCT01038284|BEHAVIORAL|Patient education|Pharmaceutical care of patients with PAH
41300449|NCT01038284|OTHER|Data collection|Clinical and biological data, treatment, medication errors and ADEs
41300450|NCT02242071|BIOLOGICAL|Stem Cell|intrathecal autologous bone marrow mononuclear cell transplantation
41300451|NCT05317663|BEHAVIORAL|Test Health Warning Label (HWL)|Effect of Health Warning Label (HWL)
41300452|NCT05317663|BEHAVIORAL|Test without Health Warning Label (no-HWL)|Effect of no Health Warning Label (no-HWL)
41300453|NCT03641469|DEVICE|Green Sun Dynamic Brace|Change from standard-of-care TLSO to GSM brace
41300454|NCT01496573|OTHER|laboratory biomarker analysis|Correlative studies
41300455|NCT00049959|DRUG|verteporfin PDT|
41300456|NCT01676480|BEHAVIORAL|Endurance training|12 weeks of endurance training 3 times per week
41300457|NCT06438913|DRUG|Tezepelumab|Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine suggested to be important in the initiation and continuation of airway inflammation.
40975701|NCT02950025|OTHER|European Organization for Research and Treatment of Cancer (EORTC) QLQ-30|"* 30 questions~* 28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~* 1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~* 1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent"
40975702|NCT01125865|DEVICE|SEMS insertion|Self-expandable metallic stent will be inserted for malignant hilar obstruction.
40975703|NCT01125865|DEVICE|DLS insertion|DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
41300458|NCT00006708|BIOLOGICAL|filgrastim|5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
41300459|NCT00006708|BIOLOGICAL|rituximab|
40975704|NCT04525664|DRUG|Clarithromycin 500mg|500 mg per os twice daily for 14 consecutive days.
40975705|NCT04525664|DRUG|Amoxicillin 1000 MG|1000 mg per os twice daily for 14 consecutive days.
40975706|NCT04525664|DRUG|Omeprazole 40 MG|40 mg per os twice daily for 14 consecutive days.
40975707|NCT04525664|DRUG|Omeprazole 20 MG Oral Tablet|20 mg per os daily for 1 month; only for patients with chronic dyspepsia and who are negative for Helicobacter pylori.
40975708|NCT02588807|DRUG|Spirit1|Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants
40975709|NCT05744154|BEHAVIORAL|Audit & feedback with educational outreach and facilitation|As in arm descriptions
40975710|NCT05744154|BEHAVIORAL|Simple audit & feedback (usual practice)|As in arm descriptions
40975711|NCT00189254|DRUG|Imiquimod|No defined treatments were given during this study.
40975712|NCT02091544|OTHER|Lifestyle intervention|
40975713|NCT04358380|OTHER|Liver injury|LFTs elevation or liver decompensation
41300460|NCT00006708|DRUG|carboplatin|
41300461|NCT00006708|DRUG|etoposide|
41300462|NCT00006708|DRUG|ifosfamide|
41300463|NCT03132792|GENETIC|Autologous genetically modified AFPᶜ³³²T cells|Infusion of autologous genetically modified AFPᶜ³³²T cells
41300464|NCT06429683|OTHER|Sexually transmitted diseases training for young adolescents aged 17-21|Education
41300465|NCT05927389|OTHER|Adapted Physical Activity program|The Adaptated Physical Activity program consists of a Personalized Training Program adapted to each patient's condition and capacities
41300466|NCT03166436|PROCEDURE|Radiofrequency ablation|radiofrequency ablation
41300467|NCT03166436|PROCEDURE|Biliary stenting|biliary stenting
41300468|NCT06517615|BEHAVIORAL|Home Visit Supported Nursing Training Program|Individualized Nurse Education Program with Home Visit Support (• Walking and exercise programs, Disease self-management training for those with chronic diseases, techniques and practices that facilitate medication compliance, vital sign monitoring, • • • Nutrition charts and follow-ups, food characteristics information and weight tracking, cooking activities in the kitchen,• Helping to create family and friend systems, creating neighbor communication mechanisms
40975714|NCT03253250|DRUG|ETV；TDF；ADV|NAs
40975715|NCT03253250|DRUG|Peginterferon Alfa-2a|peginterferon
40975716|NCT02728050|DRUG|Cladribine|Given IV
41300469|NCT03968367|PROCEDURE|Magnetic activated sperm sorting|MACS is a technique which allows the spermatozoa with the best characteristics to be selected for use in assisted reproduction treatments. This technique removes apoptotic spermatozoa - those which will die without achieving fertilisation - and selects the healthy ones, thus increasing the possibility of pregnancy.
41300470|NCT03501355|DEVICE|Inspiratory muscle strength training|"Treatment group will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 50% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 50% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
41300471|NCT03501355|DEVICE|Inspiratory muscle endurance training|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
41300472|NCT05816616|DIAGNOSTIC_TEST|Functional imaging of the lungs using MagniXene (hyperpolarized xenon-129) MRI|Patients for this observational study will be selected on a voluntarily basis from the ongoing Airflow-3 interventional clinical trial at Temple University Hospital. For this observational sub-study, patients will have their lung function measured using hyperpolarized xenon-129 MRI prior to TLD treatment, and 90 days post-treatment for a better understanding of treatment effects. This sub-study does not influence in any way the patient treatment or the outcomes for the main Airflow-3 TLD clinical trial.
40771550|NCT03462602|PROCEDURE|non-NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was removed in the operation room immediately after the surgery in those assigned to the non-NGT group.
40771551|NCT01174563|DRUG|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
40771552|NCT06344091|DRUG|Bupivacaine Liposome Injection|Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)
40771553|NCT01890031|OTHER|Interactive Cholesterol Advisory Tool|using the virtual clinician computer program for cholesterol information and education.
40771554|NCT01890031|OTHER|Study physician visits|In-person individual visits with a study physician to give information on cholesterol
40771555|NCT06101420|DRUG|Vonoprazan|Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily
40975717|NCT02728050|DRUG|Cytarabine|Given IV
40975718|NCT02728050|BIOLOGICAL|Filgrastim|Given SC
40975719|NCT02728050|OTHER|Laboratory Biomarker Analysis|Correlative studies
40975720|NCT02728050|OTHER|Quality-of-Life Assessment|Ancillary studies
40975721|NCT02728050|DRUG|Mitoxantrone|Given IV
40771556|NCT00023335|DRUG|Rifapentine|
40771557|NCT00023335|DRUG|Isoniazid|
40771558|NCT04541927|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
40975722|NCT02728050|DRUG|Sorafenib|Given PO
40975723|NCT03627533|PROCEDURE|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
40975724|NCT04412824|DRUG|Intravenous blood draw|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
40975725|NCT03055260|DEVICE|Blood flow restriction cuff|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
40975726|NCT03055260|DEVICE|Blood Flow restriction Cuff-Placebo|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
40975727|NCT05154006|BEHAVIORAL|Information about benefits of the behavior|The women will be informed that the safe carrying behaviors can reduce pelvic strain. She is informed about the benefits reducing pelvic strain may imply \[5.1; 5.3.,5.6 Information about health; environmental; social; and emotional consequences, (Michie et al., 2013)\]
40975728|NCT05154006|BEHAVIORAL|Instruction on how to perform a behavior|"For the target behavior reduce carried weight information on recommended weight limits will be given. The women will be encouraged, that even if these limits may not be feasible for them, any reduction of weight can still reduce the strain on the pelvic floor.~For the target behavior safe lifting techniques, instructions to learn the correct behavior (how to perform safe lifting techniques?) based on leaflets developed and validated by Caagbay et al., (2017, 2020) \[4.1 Instruction on how to perform a behavior (Michie et al., 2013)\]"
40975729|NCT05154006|BEHAVIORAL|Self-efficacy|Self-efficacy will be promoted by the four sources of self-efficacy (Bandura, 1977): 1) Mastery Experiences (experience that one is able to successfully apply the behavior), vicarious experience (observing successful others performing the safe carrying behavior), verbal persuasion (receiving positive feedback when performing the behavior and encouraging messages to do so) and emotional state (e.g. being in a positive emotional state when performing the behavior). \[6.1 Demonstration of the behavior; 8.1 Behavioral practice/rehearsal; 15.1 Verbal persuasion about capability; 15.2 Mental rehearsal of successful performance; 15.3 Focus on past success;15.4 Self-talk; 5.4 Monitoring of emotional consequences (Michie et al., 2013)\]
41300473|NCT01600131|BEHAVIORAL|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
40975730|NCT05154006|BEHAVIORAL|Social Support|A self-selected social partner from the same or neighboring household (e.g. husband, mother-in-law) will be involved in the learning process (observational learning, feedback). The partner will participate in the intervention activities and will be instructed to provide emotional social support and practical informational support. \[3.2 practical support, 3.3 emotional support; 6.3 Information about others' approval (Michie et al., 2013).\]
40975731|NCT02674529|DRUG|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
41300474|NCT01600131|OTHER|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
41459762|NCT02990078|DRUG|Sildenafil citrate|Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
40975732|NCT02674529|DRUG|Placebo|Placebo
40975733|NCT02674529|BEHAVIORAL|Real-time Neurofeedback fMRI task pre- and post-RCT|Placebo experiment during an fMRI scanning session
40975734|NCT01032642|DEVICE|device for hysterosalpingography|a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
40975735|NCT04465539|DRUG|Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]|Hydroxyethyl starch dose is 500 cc in 6 hours
40975736|NCT04465539|DRUG|Hydrocortisone|Hydrocortisone dose is 200-300 mg /day intravenously
40975737|NCT04465539|DRUG|Placebo|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
40975738|NCT01648946|BIOLOGICAL|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
41140658|NCT05207397|OTHER|Lactate infusion|The unlabeled lactate infusion cocktail (30% L(+)-lactic acid solution (Sigma) with 2N NaOH, pH4.8) and stable isotope infusions will be made by the O'Brien Pharmacy (Mission, Kansas) and tested to be sterile and pyrogen free.. Upon arriving to the KU Clinical and Translational Science Unit, a catheter will be placed in the subject's hand, which will be placed into a heated hand box for collection of arterialized blood. A second catheter will be placed in the opposing forearm vein for the infusion of lactate isotope solution and unlabeled lactate infusion cocktail. After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. We will then administer priming doses of 57.5 mg \[3-13C\]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of \[3-13C\]lactate at 10 mg/min and D2-glucose at 2 mg/min \[53\]. Along with the continuous isotope infusion we will begin infusion of the Na-lact
41140659|NCT05689684|DIETARY_SUPPLEMENT|AG+XOS+AXOS|4-month parallel randomized controlled study
41140660|NCT05689684|DIETARY_SUPPLEMENT|Placebo Maltodextrin|4-month parallel randomized controlled study
41459763|NCT02990078|DEVICE|Functional Near Infared Spectroscopy|Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity. are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
41459764|NCT02990078|OTHER|Hypercapnia Challenge|The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange. It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired. For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject. The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
41140661|NCT01368484|DIETARY_SUPPLEMENT|Sunflower oil|1500 mg sunflower/day for 10 weeks
41140662|NCT01368484|DIETARY_SUPPLEMENT|Docosahexanoic acid|1500mg/day for 10 weeks
41140663|NCT06305910|DRUG|Treatment with CD200AR-L|Treatment with CD200AR-L (up to 3 dose levels of CD200AR-L with a Dose Level -1 in the event of toxicity) with fixed doses of GBM6-AD vaccine. Each patient will also be given topical imiquimod and a single dose of 300cGy re-irradiation.
41140664|NCT03337022|DRUG|CC-90006|CC-90006
41140665|NCT03337022|OTHER|Placebo|Placebo
41140666|NCT00453440|PROCEDURE|Cheek swab & blood test|Cheek swab \& blood test
41300475|NCT00321984|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
41300476|NCT00321984|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
41300477|NCT00321984|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
41300478|NCT02053389|BEHAVIORAL|DVD Decision Aid|"The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation."
41300479|NCT02053389|BEHAVIORAL|Written decision aid|"A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer."
40975739|NCT01648946|BIOLOGICAL|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
40975740|NCT04934384|DIAGNOSTIC_TEST|prehospital extended focused assessment sonography for trauma|Sonographic procedure performed in the prehospital environment aiming at evaluating peritoneal free fluid in trauma patients
41300480|NCT02882399|OTHER|Shortystrap|
41300481|NCT05874063|DRUG|Thromboprophylaxis|Thromboprophylaxis in addition of the standard chemotherapy
41300482|NCT00565695|DEVICE|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
40975741|NCT03757897|DRUG|Dexmedetomidine|The standard dosing of 1mcg/kg will be implemented over 10 minutes followed by a maintenance infusion of 0.2-1.0 titrated to a the target BIS (60-70) during the 20 minutes prior to MRI.
40975742|NCT02128178|DRUG|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
40975743|NCT02128178|DRUG|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
40975744|NCT00088985|BIOLOGICAL|therapeutic autologous dendritic cells|10 μg/kg subcutaneously (sc) each day for four days or g-CSF at 5 μg/kg sc each day for four days with GM-CSF 250 μg/m2 sc each day for four days. G-CSF and/or GM- CSF will be self-administered. On the fifth day patients will have two intravenous lines placed in the apheresis area of the Blood Bank and then undergo a 15 litre apheresis collection
40975745|NCT00088985|BIOLOGICAL|trastuzumab|4 mg/kg intravenously, every 14 days
40975746|NCT00088985|DRUG|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
40975747|NCT04867538|OTHER|no intervention|No intervention
41300483|NCT00150371|DRUG|atorvastatin|
41459765|NCT04366284|OTHER|No Facilitation Support|Clinicians will have full use of the NOCTEM platform. They will not have scheduled and/or structured contacts with the facilitation teams, however can reach out to the NOCTEM team or their local point of contact and coordinator with questions or technical issues that may arise.
41459766|NCT04366284|OTHER|External Facilitation Support|Clinicians will have full use of the NOCTEM platform and the NOCTEM team will provide external facilitation via bi-weekly consult or supervision teleconference, or via telephone. The NOCTEM team will also be available by email and text messaging on an as needed basis.
40771559|NCT04017312|DEVICE|High Frequency Chest Wall Oscillation|High frequency chest wall oscillation (HFCWO) therapy (also known as high-frequency chest-wall compression or HFCWC) is commonly prescribed to provide routine airway clearance in patients with bronchiectasis as well as other patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow. This airflow is thought to mobilize secretions by the sheer force created, effecting changes in rheology and moving mucus in a cephalad direction during the oscillation. The Vest® Airway Clearance System, a commonly used device, generates HFCWO using an air pulse generator and an inflatable garment that delivers pressure pulses to the thorax. These pressure pulses within the garment create HFCWO.
40975748|NCT05195970|OTHER|Walnuts|Participants consume 2 ounces of walnuts daily for 21 days
40975749|NCT00937612|RADIATION|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
40975750|NCT02104700|DRUG|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
40975751|NCT01023230|DRUG|DV-601|Six injections of DV-601 administered over a period of 12 weeks.
40975752|NCT01023230|DRUG|Entecavir|Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
41300484|NCT01571037|DRUG|Inhaled, nebulized, Milrinone|1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
40975753|NCT05058443|DRUG|Denosumab 60 mg/ml [Prolia]|denosumab subcutaneously every 6 months (Q6M)
40975754|NCT05058443|DRUG|Placebo|placebo subcutaneously every 6 months (Q6M)
40975755|NCT03236974|DRUG|Standard Arm - Fulvestrant|500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
40975756|NCT03236974|DRUG|AZD9496|Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
40975757|NCT01613729|DRUG|Rosuvastatin 5 mg|Rosuvastatin 5 mg
40975758|NCT01613729|DRUG|Rosuvastatin 10 mg|
40975759|NCT01635972|DRUG|Isavuconazole|oral
40975760|NCT01635972|DRUG|bupropion hydrochloride|oral
40975761|NCT04140851|DIETARY_SUPPLEMENT|Dietary fiber intervention|Dietary intervention
40975762|NCT04140851|DIETARY_SUPPLEMENT|Normal diet|Normal diet
40975763|NCT02734940|DRUG|Lidocaine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
40975764|NCT02734940|DRUG|Unrestricted Fentanyl|No changes to current practices, using unlimited narcotic medications intraoperatively.
40975765|NCT02734940|DRUG|Ketamine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
40975766|NCT02734940|DRUG|Precedex|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
41300485|NCT01571037|DRUG|inhaled nebulized milrinone|0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
41300486|NCT04217902|OTHER|Description of patients' experiences of diabetes care delivery and planning|Semi-directed interviews will be conducted with people living with type 1 or type 2 diabetes in person or by phone to assess and describe the care delivery pathway they have been through. Information on 3 domains will be assessed: clinical (information they consider essential for health care professionals to systematically have access to during consultations and other health-related interventions such as therapeutic education sessions), technological (what kind of digital services and technologies they use or are willing to use), and behavioural (the decision-making process and the key interactions that build the care delivery pathway).
41300487|NCT04217902|OTHER|Description of health care professionals needs and experiences in diabetes care delivery and planning|Semi-directed interviews will be conducted with health care professionals working in diabetes care in person or by phone to assess and describe their needs and experiences in diabetes care. Information on 3 domains will be assessed: clinical (the information they consider to be essential to inform decisions in diabetes care, where and if they currently find that information and problems they might encounter), technological (which software they currently use and how data is input into clinical information systems), and behavioural (how care coordination is currently managed, how interactions with patients and other professionals are undertaken).
41300488|NCT05520996|BEHAVIORAL|Cyberball|Social exclusion or ostracism can be measured by the Cyberball 5 task. The principle of Cyberball is based on the creation of a situation of exclusion through a computerized task. During this task, the participant passes a ball to 2 other players controlled by Artificial Intelligence (AI). The ball-passing method of AI-controlled players is determined in advance in the computer program code. A series of ball passing is carried out with initially an equal passing between the three participants and then an exclusive passing between the players controlled by an artificial intelligence
40975767|NCT02734940|DRUG|Duramorph|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
40975768|NCT03998033|BIOLOGICAL|ET140202 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140202 expression construct
40975769|NCT00147199|DRUG|Inhaled treprostinil|Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
40975770|NCT00147199|DRUG|Placebo inhalation solution|Doses are titrated to 9 breaths four times daily.
40975771|NCT00064194|DIETARY_SUPPLEMENT|selenium|
41300489|NCT00301067|DIETARY_SUPPLEMENT|Calcitriol|The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle
41300490|NCT00301067|DRUG|Temozolomide|The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
41300491|NCT05951764|DIAGNOSTIC_TEST|Non-invasive measurement of arterial stiffness by Pulse Wave Velocity (PWV)|For all patients PWV in (cm/s) will be collected from D-30 to D-1 before the procedure and at D3 postoperatively.
41300492|NCT06324747|PROCEDURE|Vestibular socket therapy|Vestibular socket therapy will be used for the intervention.
41300493|NCT06324747|PROCEDURE|conventional full thickness flap|reflecting the mucoperiosteum to access the extraction socket
40975772|NCT00064194|DIETARY_SUPPLEMENT|soy protein isolate|
40771560|NCT04017312|DEVICE|Oscillating Positive Expiratory Pressure (OPEP)|Oscillating PEP is an airway clearance technique, where the person blows all the way out many times through a device. These types of oscillating PEP devices work in two ways. Firstly, they use resistance to make it more difficult during the breath out, like non-oscillating PEP devices. Oscillating PEP devices also create vibrations when breathing out. The vibrations move mucus from the surface of the airways. After blowing through the device several times, the person will huff and cough to clear the mucus from the lungs.
40771561|NCT00663156|PROCEDURE|breast implants|patients will have breast augmentation using implants
40771562|NCT00663156|PROCEDURE|Liposuction, fat grafting|Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
40771563|NCT04697823|OTHER|use of hyaluronan-enriched transfer medium|In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium
40771564|NCT01498809|DRUG|Midodrine|Single 10 mg dose
40771565|NCT05164172|DRUG|Eptinezumab|Concentrate for solution for infusion
40975773|NCT00064194|DIETARY_SUPPLEMENT|vitamin E|
40975774|NCT01316107|DRUG|ipragliflozin|oral
40975775|NCT01316107|DRUG|nateglinide|oral
40975776|NCT01202474|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day
41459767|NCT04366284|OTHER|External and Internal Facilitation Support|Clinicians will have full use of the NOCTEM platform and external facilitation support. In addition to external facilitation by the NOCTEM team a local point of contact and coordinator will serve as a more proximal facilitator.
41459768|NCT00958724|DRUG|Neratinib|
41459769|NCT00958724|DRUG|Vinorelbine|
41459770|NCT00919711|DRUG|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
41459771|NCT00919711|DRUG|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
41459772|NCT04011449|DEVICE|Medtronic RC+S DBS system|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
40975777|NCT01202474|DRUG|INSULIN GLARGINE|Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values
41140667|NCT04150965|DRUG|Elotuzumab, pomalidomide, dexamethasone|Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.
41140668|NCT04150965|DRUG|Anti-LAG-3|"Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long."
41140669|NCT04150965|DRUG|Anti-LAG-3 + Pomalidimide + Dexamethasone|Patients with Relapsed \& Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
41459773|NCT00845130|BIOLOGICAL|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
41459774|NCT04353986|DRUG|Sofosbuvir and Ledipasvir|fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir
40771566|NCT05911165|OTHER|No surgical coaching|During the twelve-month study period, all participants will have access to an instructional video related to laparoscopic vaginal cuff suturing and the laparoscopic vaginal cuff trainer in order to practice laparoscopic suturing as desired. All participants will keep a log of voluntary practice time on the vaginal cuff trainer. These resources will constitute the control arm of the study
41459775|NCT05061992|DRUG|Lactulose|"Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.~In addition, outcome measurements will be completed at baseline and day 28."
41459776|NCT01873339|DRUG|Darapladib|The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
41459777|NCT01873339|DRUG|Midazolam|The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
41140670|NCT04150965|DRUG|Anti-TIGIT|"Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~Each cycle is 28 days."
41300494|NCT03066817|DRUG|Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]|50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
41300495|NCT03066817|DRUG|Propylene Glycol|50cc of propylene glycole will be given to participants as one-time dose, used as placebo
41300496|NCT05239949|OTHER|Hypopressive exercises|For hypopressive exercises, the patient will be instructed to inhale, then breathe to expand the ribcage, and then exhale completely. Hold the breath out before relaxing core and ribcage.
40771567|NCT05911165|OTHER|Surgical coaching|Surgical coaching sessions will include 30-60 minute meetings in which the coach-coachee pair reviews recorded laparoscopic suturing practice sessions to examine different aspects of surgical performance.
41300497|NCT05239949|OTHER|Pelvic floor exercises|For pelvic floor exercises, the patient is instructed to hold each contraction for 6 seconds.
41300498|NCT00112099|PROCEDURE|Surgery: Splenectomy|Procedure/Surgery: Surgery: Splenectomy
40771568|NCT05626712|BIOLOGICAL|CELZ-201 Administration|Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10\^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.
41300499|NCT00112099|PROCEDURE|Surgery: Spleen-preservation|Procedure/Surgery: Surgery: Spleen-preservation
41300500|NCT02273154|DRUG|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
40771569|NCT05626712|OTHER|Control Group|Enhanced standard of care for Type 1 Diabetes treatment only.
40771570|NCT00780598|DRUG|Tosedostat|"In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~* 120 mg for 6 months once daily, OR~* 240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A."
41140671|NCT04150965|DRUG|Anti-TIGIT + Pomalidimide + Dexamethasone|Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
41140672|NCT01685476|DEVICE|Echodia® hand-held equipment|
41140673|NCT02560961|OTHER|Kinesio Taping (Kinesio Tex Gold®; color: black)|Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
41140674|NCT02560961|OTHER|Placebo Taping|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
41140675|NCT00397098|DRUG|SR58611A|
41459778|NCT06325124|OTHER|Muscle energy technique|"They would be receiving treatment as follow:~Muscle energy technique of hamstring and gastro-soleus. Frequency: 10 reps 3 times/week for 4 consecutive weeks Intensity starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings."
40771571|NCT04166747|OTHER|Virtual Reality experience|Participants will receive virtual reality based experience and will be assessed for its influence on happiness, functional fitness components and quality of life of older age groups.
40771572|NCT02534922|BIOLOGICAL|Prolanta, a human prolactin receptor antagonist|Daily subcutaneous dosing
40771573|NCT06564844|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
40771574|NCT06564844|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
41300501|NCT02273154|DRUG|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
41300502|NCT03868228|PROCEDURE|Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)|Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
41300503|NCT05397613|BEHAVIORAL|STAIR|Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials. STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
41300504|NCT01358500|DRUG|Fentanyl|Intravenous infusion using STANPUMP
41459779|NCT06325124|OTHER|Conventional PT|"They would be receiving treatment as follow:~Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings."
40771575|NCT06564844|DRUG|Carboplatin|Carboplatin IV (intravenous), Active Comparator
40771576|NCT06564844|DRUG|Cisplatin|Cisplatin IV (intravenous), Active Comparator
40771577|NCT06564844|DRUG|Etoposide|Etoposide IV (intravenous), Active Comparator
40771578|NCT06564844|DRUG|Pemetrexed|Pemetrexed IV (intravenous), Active Comparator
40771579|NCT06564844|DRUG|Vinorelbine|Vinorelbine IV (intravenous), Active Comparator
40771580|NCT06564844|DRUG|UFT|UFT Oral route of administration, Active Comparator
40771581|NCT03841279|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) produces detailed images of the body's internal structures without relying on radiation. It is used to diagnose and also gauge efficacy of treatment.
41147169|NCT06292247|BEHAVIORAL|Tell Show Do|TSD is composed of 3 phases. The Tell phase involves an age-appropriate explanation of the procedure. The Show phase is used to demonstrate a procedure up to the point where the instrument is performed. The Do phase is then initiated, and the treatment is performed.
40975778|NCT00390858|DRUG|Deferasirox|Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
41140676|NCT06225323|DRUG|Lidocaine|"Patients will receive Lidocaine infusion for 6 hours. After cord clamping and according to ideal body calculate the bolus dose 1.5 mg/kg of lidocaine 1% and complete the dose by normal saline to 20 ml total volume will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of lidocaine 1% for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours."
41140677|NCT06225323|OTHER|Saline|"Patients will receive normal saline infusion for 6 hours. After cord clamping 20 ml total volume normal saline will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of normal saline for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours."
41140678|NCT05949788|OTHER|No intervention|Retrospect study, no direct intervention
41140679|NCT06519448|DRUG|Empagliflozin 10 miligrams (mg)|Use of empagliflozin 10 mg daily for 12 months.
41140680|NCT06361212|DRUG|Ethoximod|Ethoximod is a S1P1 modulator.
41140681|NCT06099444|DEVICE|Conventional High Intensity Gait Training|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity. The participants will complete 18 training sessions.
41140682|NCT06099444|DEVICE|Standard FES to the Tibialis Anterior (TA)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while wearing a FES stimulator on the tibialis anterior muscle of their more affected leg. Stimulation will be triggered prior to swing phase to combat drop foot. The participants will complete 18 training sessions.
41140683|NCT06099444|DEVICE|Synergy-Based Multichannel FES (MFES)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while FES is applied to multiple muscles of the leg throughout the gait cycle based on the healthy muscle synergies. The goal will be to have the FES applied for at least 20 minutes of each gait training session. The participants will complete 18 training sessions.
41140684|NCT06099444|DEVICE|Muscle Synergy Visual Biofeedback|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while receiving visual feedback of the similarity of their muscle synergies to healthy muscle synergies. They will be instructed to try to optimize the similarity score. The participants will complete 18 training sessions.
40975779|NCT00186381|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
40975780|NCT05718128|PROCEDURE|Endocardiomyocardial biopsy|Endocardiomyocardial biopsy
40975781|NCT03117101|DRUG|Lucitanib|
41459780|NCT01309854|DRUG|fostamatinib|oral tablets, 100mg (2 X 50mg) twice daily for 8 days
40975782|NCT03554746|OTHER|GC group|"1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps~3. Additional gluteal muscle control training: hold 10 s/reps, 20 reps/times 1st to 2nd:~   1. clam ex. without resistance~  2. single leg bridge with maintain bil. ASIS even level 3rd to 4th: maintain 1st to 2nd ex. with resistance 5th:~   <!-- -->~   1. maintain 3rd to 4th ex.~  2. single leg standing on rock board to maintain balance 6th:~   <!-- -->~   1. maintain 5th ex.~  2. lunge ex. without hip internal rotation"
41140685|NCT03741985|BEHAVIORAL|The handgrip exercise|The control group was given routine dialysis treatment and daily handgrip exercise .Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
41140686|NCT03741985|BEHAVIORAL|The dumbbell exercise|The experimental group was given routine dialysis treatment and daily dumbbell exercise .Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
41140687|NCT06058130|DRUG|Anticoagulant Oral|Anticoagulation alone
40771587|NCT02971163|BEHAVIORAL|SynDA|SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
40771588|NCT01673919|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
40771589|NCT06570564|DEVICE|The arm crank ergometer|Before starting the program, patients will perform an adaptation session for familiarization with the ergometer and also to identify the training load. For this, patients will perform 10 bouts of two minutes of exercising with a minimum load and two minute passive intervals between bouts. Patients will be instructed to maintain 50 revolutions per minute (RPM) during the exercise. Subsequently, to determine the training load for each session, patients will perform a progressive test where the load will be increased by 10 watts every minute of the test, following the protocol of two minutes of exercise with two minutes of interval
40771590|NCT06570564|DEVICE|bicycle ergometer|bicycle ergometer program will consist of a bicycling exercise 3 days per week. Exercise intensity was set at 70% of maximal load with 30 minutes per session. The exercise protocol also incorporated warm-up and cool-down sessions that involved stretches of the major lower limb muscle groups (total exercise time, 40-60 minutes)
40771591|NCT06570564|DEVICE|treadmill|Supervised treadmill exercise as routine physiotherapy program
40771592|NCT03110562|DRUG|Selinexor|oral 100 mg dose
40771593|NCT03110562|DRUG|Bortezomib|subcutaneous dose of 1.3 mg/m2
40771594|NCT03110562|DRUG|Dexamethasone|oral dose of 20mg
40771595|NCT06473688|PROCEDURE|Cholecystectomy|Robotic-assisted and laparoscopic cholecystectomy
40771596|NCT02458235|DRUG|azacitidine|40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
40771597|NCT02458235|BIOLOGICAL|donor lymphocyte infusion|For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
40771598|NCT00751231|DRUG|clopidogrel|Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg
40771599|NCT00751231|DRUG|PRT060128|80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
40771600|NCT02467270|DRUG|Ponatinib|Tablet, taken orally once daily.
41140688|NCT06058130|DRUG|Anticoagulation combined with antiplatelet therapy|Anticoagulation combined with antiplatelet therapy
41140689|NCT00882856|DRUG|Bisoprolol|"Bisoprolol Vitabalnas 10 mg once daily"
40771601|NCT02494492|OTHER|intravitreous administration of regulator T-cells|The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
40771602|NCT02772692|BEHAVIORAL|Squatting pan|Using squatting pans to replace standard-sized toilets in one group of the included constipation patients
40771603|NCT00839579|OTHER|1x4 min interval|Aerobic interval training
41140690|NCT00882856|DRUG|Placebo|placebo
40771604|NCT05044468|DRUG|Lidocaine|Given via injection
40771605|NCT05044468|DRUG|Liposomal Bupivacaine|Given via injection
41140691|NCT03006393|DRUG|Infliximab|One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.
41140692|NCT03006393|OTHER|Placebo|One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
41140693|NCT03903978|BEHAVIORAL|Cognitive Behavioral Therapy|"The training protocol consists of 6 weekly modules:~0.Welcome:Introduction module to the program, with an explanation about the tools and the way to use CORE~1. Psychoeducation: Explanation of psychological wellbeing and the concept of resilience~2. Autonomy, building my way: Enhancement of autonomy~3. Mindfulness and self-compassion:Training in mindfulness, savoring, and an attitude of self-compassion~4. Overcoming obstacles: Development of coping strategies to deal with daily difficulties in life~5. Connecting to others:Acknowledge the relevance of relationships and how they can be helpful in the construction of well-being~6. Purpose in life and personal growth:Approach the future with a positive attitude, planning goals for the future."
40771606|NCT05044468|OTHER|Questionnaire Administration|Ancillary studies
40771607|NCT00088946|DIETARY_SUPPLEMENT|Polyphenon E|4-200mg capsules PO daily for 12 months
40771608|NCT00088946|DRUG|erlotinib hydrochloride|100 mg PO daily for 12 months
40771609|NCT00088946|OTHER|Erlotinib placebo|identical to Erlotinib in look and appearance of dosing.
40771610|NCT00088946|OTHER|Polyphenon E|identical to Polyphenon E in look and appearance of dosing.
40771611|NCT04255381|DEVICE|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)
40771612|NCT04705233|OTHER|sputum colour chart|5-point Sputum Colour Chart plus best standard care
40771613|NCT06560021|OTHER|Biopsy strategy|Number of random biopsies, in addition to targeted biopsies, taken during colonoscopies where at least one indication for the colonoscopy is surveillance for dysplasia
40771614|NCT00356187|DRUG|Propranolol|
40975783|NCT03554746|OTHER|CG group|"1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps"
40975784|NCT03107325|OTHER|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
40975785|NCT03107325|DRUG|F-18 Fluorodeoxyglucose|Participants will be asked to be imaged at an additional time point during an FDG PET study
40975786|NCT00179634|BEHAVIORAL|Visualization relaxation|
40975787|NCT00179634|BEHAVIORAL|Visual Milieu Enhancement (Fine art photograph)|
40975788|NCT02290561|PROCEDURE|SmartTarget Therapy|MRI to Ultrasound fusion directed HIFU
40975789|NCT02290561|DEVICE|MRI|
40975790|NCT02290561|DEVICE|high intensity focused ultrasound (HIFU)|
40975791|NCT03107754|DRUG|Lidocaine|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
40771615|NCT05580705|OTHER|Routine Physical Therapy|The Routine Physiotherapy treatment will include Transcutaneous Electrical Nerve Stimulation, Hot pack, Range of Motion (ROM) Exercises and Muscle Strengthening Exercises
40771616|NCT05580705|OTHER|Vibration Therapy|Vibration Therapy will include a vibration device of brand Manipol, model number RK-001. It has 360 degree off-centered axis with a frequency of 2500 times per minute. It will be applied on sole of the foot for about 15 mins.
40771617|NCT05848570|OTHER|Keeping it LITE|observational cohort only
40771618|NCT03009292|DRUG|lenvatinib|once daily continuous dosing
40771619|NCT02048540|BIOLOGICAL|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
40771620|NCT02048540|DRUG|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
40771621|NCT02048540|PROCEDURE|Gastrectomy|
40771622|NCT05598788|OTHER|Measurement of drug concentrations|Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample
40771623|NCT06237855|OTHER|Self-drain removal|Subjects will be trained to self-remove drain at home following ventral hernia repair.
40771624|NCT06166433|BEHAVIORAL|Smoke-free homes intervention|Theory-based intervention involving 3 mailed sets of educational materials and a brief coaching call using motivational interviewing, delivered over a 6-week period.
40771625|NCT06443814|BEHAVIORAL|Health Education|This was a didactic classroom-based control which educates the patient on adapting a healthier lifestyle through proper diet, exercise, and moderating substance usage according to current AHA guidelines. This intervention does not include a stress management component.
40771626|NCT06443814|BEHAVIORAL|Transcendental Meditation|TM was taught in a standardized and validated format as a simple, natural mental technique practiced for 20 minutes twice a day (morning and evening) to give rest and relaxation to mind and body. TM was taught by a certified instructor and a 7-step process taking place over 4 consecutive days after which the meditator can practice at home twice a day.
40771627|NCT04148209|DRUG|PF-07081532|Participants will receive single ascending doses PF-07081532
40771628|NCT04148209|DRUG|Placebo|Participants will receive placebo
40771629|NCT04110145|DRUG|Linaclotide|Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.
40771630|NCT04110145|DRUG|Placebo|Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
40771631|NCT06077279|BEHAVIORAL|Horticultural Therapy Program|Horticultural Therapy Program Is selected plant therapy
40771632|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging with physical grid using conventional processing|X-ray imaging with physical grid using conventional processing
40771633|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging without physical grid using conventional processing|X-ray imaging without physical grid using conventional processing
40771634|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging without physical grid using experimental SimGrid offline processing|X-ray imaging without physical grid using experimental SimGrid offline processing
40771635|NCT05006248|DEVICE|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session.
40771636|NCT05006248|DEVICE|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
40771637|NCT05006248|DEVICE|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
40771638|NCT04991948|DRUG|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
40771639|NCT04991948|DRUG|FOLFOX|5-FU, leucovorin and oxaliplatin
40771640|NCT04991948|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
40975792|NCT03107754|DRUG|Lidocaine-Sodium Bicarbonate|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
40975793|NCT04082312|OTHER|No intervention|No intervention
40771641|NCT00249626|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
40771642|NCT06195007|BEHAVIORAL|Motivational Interview|"The motivational interview (MI) is a 10-15 minute patient-centered conversation which will focus on tobacco use. Multiple communication strategies can be employed during the MI, including open-ended questions, affirmative statements, reflective listening, use of a 'confidence ruler', and summarizing. The 'confidence ruler' technique in this patient population involves asking the patient On a scale of zero to ten, how confident are you that you can stop using tobacco?, and then requesting further information about why they selected a certain number. These communication strategies and techniques are designed to uncover and foster a patient's own internal motivations to change the target behavior."
40771643|NCT05727501|OTHER|Post isometric relaxation|post isometric relaxation in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
40771644|NCT05727501|OTHER|Post facilitation stretching|post facilitation stretching in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
40771645|NCT04659343|OTHER|Measurement of concentration of active metabolite in cancer treatment.|Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib, ipilimumab and nivolumab.
40975794|NCT04847505|DIAGNOSTIC_TEST|68Ga-DOTA-TATE|The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.
40975795|NCT05218460|DEVICE|MRI examination|All subjects (healthy and pathological subjects) will have an MRI examination with a component of the MRI system under development.
40771646|NCT06176586|OTHER|Mat Pilates Exercises|The intervention will consist of mat Pilates exercises performed twice a week over a duration of 12 weeks, as an adjunct to the routine medical treatment for the patients, under the guidance of a qualified physiotherapist. Each exercise session will last for approximately 60 minutes. The treatment protocol will encompass targeted mobility exercises for the thoracic and lumbar regions, along with strengthening exercises focusing on core activation. The exercise program will be progressed in every four weeks.
40771647|NCT01172392|DRUG|Pegylated interferon-alpha-2a|180 mcg / wk / SC from D0 to W48
40975796|NCT01347008|DRUG|Sildenafil citrate|Oral sildenafil citratre, 50mg b.i.d., 8 weeks
40975797|NCT01347008|DRUG|Placebo (Sugar pill)|Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
40975798|NCT00218465|DRUG|GW468816|Pharmacotherapies for Relapse Prevention
40975799|NCT00218465|DRUG|Placebo Comparator: Placebo|
40771648|NCT01172392|DRUG|Nucleotidic or Nucleosidic Treatment|Analog treatment according to investigators practice
40975800|NCT03905187|BEHAVIORAL|Modified CR|Stress management involved modified cardiac rehabilitation
40975801|NCT03905187|BEHAVIORAL|Traditional CR|Traditional cardiac rehabilitation
41459781|NCT01309854|DRUG|pioglitazone|oral tablets, 30mg single dose per period
40771649|NCT05368519|DEVICE|Brijjit®|Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.
41140694|NCT03903978|BEHAVIORAL|Healthy lifestyle|"1. Beginning of a lifestyle change The patient will learn to identify healthy and risky behaviors and recognize obstacles that prevent them from adopting a healthy lifestyle.~2. Physical activity The importance of moving on and activating behavior will be taught through regular exercise information to improve mood.~3. Diet This module is dedicated to teaching the importance of diet for good physical and mental health. The Mediterranean diet will be taken as an example for a balanced and balanced diet, because it does not differ from the habits of other countries.~4. Sleep The importance of good sleep will be addressed with information and strategies for understanding the relationship between sleep and overall health."
40771651|NCT05507047|DRUG|Enamel Matrix Protein|Enamel matrix derivated is used with transcrestal sinus lifting treatment
40975802|NCT03905187|BEHAVIORAL|Education|Education
40975803|NCT00667368|DRUG|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
40975804|NCT04682015|OTHER|WeChat platform group|Participants in the intervention group will receive educational messages related to hypertension, such as impact of hypertension on cardiovascular system, lifestyle adjustment and side effects of antihypertensive drugs. Participants will be reminded to take their blood pressure regularly and enter the blood pressure readings into the WeChat platform. If participants enter extremely high or low readings, they will be asked to seek medical help from doctors. Participants can also consult doctors online via WeChat platform by text and voice messages, or voice calls.
41300505|NCT02463266|BEHAVIORAL|SUSTAIN Monitoring and Care Management|Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
41300506|NCT03091062|DEVICE|Vest® Airway Clearance System|High frequency chest wall oscillation (HFCWO) therapy is commonly prescribed to provide routine airway clearance in patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow that is thought to mobilize secretions by the sheer force created.
41459782|NCT04139460|DEVICE|CRT-D|After randomization, devices will be implanted as soon as possible (within 2 weeks). The ICD will be programmed with anti-tachycardia pacing and shock therapy as per common praxis.
41459783|NCT04139460|DEVICE|CRT-P|After randomization, devices will be implanted as soon as possible (within 2 weeks).
41459784|NCT05822674|DRUG|Sitagliptin/metformin ( 50/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
40975805|NCT03818828|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
40771652|NCT03923335|OTHER|DNA methylation detection|detecting the methylation status of colorectal cancer specimen
40975806|NCT03818828|OTHER|Profore Compression Therapy|Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits
40975807|NCT03818828|OTHER|Cadexomer Iodine dressing|During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
40975808|NCT02993068|OTHER|Educational Intervention|Watch genetic testing online educational video
40975809|NCT02993068|OTHER|Genetic Counseling|Receive post-telephone genetic counseling
40975810|NCT02993068|OTHER|Genetic Counseling|Receive pre-telephone genetic counseling
40975811|NCT02993068|OTHER|Laboratory Biomarker Analysis|Correlative studies
40975812|NCT02993068|OTHER|Questionnaire Administration|Ancillary studies
40975813|NCT01782495|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
40975814|NCT01782495|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
40975815|NCT01782495|DRUG|ribavirin|tablet
40975816|NCT02663323|DEVICE|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
41140695|NCT02670161|DRUG|Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)|brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
40771653|NCT03247101|DRUG|Miyarisan-BM (Clostridium Butyricum Miyairi)|40mg po tid x 6months
40975817|NCT05955729|BEHAVIORAL|On-duty Nap|For 12 weeks, an opportunity for a 30-minute nap during the night shift, between 1 a.m. and 4 a.m., in a quiet room with facilities for lying down.
40975818|NCT05955729|BEHAVIORAL|Control condition (30-min rest)|For 12 weeks, an opportunity for a 30-minute rest during the night shift, between 1 a.m. and 4 a.m., in a quiet room without facilities for lying down or napping.
40975819|NCT05955729|DEVICE|EndoPAT|"The EndoPAT device® measures vascular reactivity after a 5-minute occlusion on one arm.~This device measures changes in vascular tone induced by the endothelium at fingertip level using a pair of plethysmographic sensors. The measurement consists of performing a reference recording for 5 minutes on the 2 arms, then a test arm is chosen to perform an occlusion for 5 minutes while continuing the recording."
40975820|NCT05955729|DEVICE|Popmeter®|The tool is connected to the caregiver's finger and toe via photodiode sensors. Its simple operation enables reproducible measurement of the propagation speed of the pulse wave in 14 seconds.
40975821|NCT05955729|DEVICE|Panasonic EW3109|Diastolic and systolic blood pressure measured 3 times in succession using an automatic blood pressure monitor (Panasonic EW3109) in the sitting position on the left arm.
40975822|NCT05955729|DEVICE|ECG Holter|The Holter takes an ECG during the subject's daily activities at home.
40975823|NCT05955729|BIOLOGICAL|Fasting blood sample|15 ml blood sample (venous sampling) will be taken to measure inflammatory biomarkers (hsCRP, IL-6 TNF-α, IL-1β) and blood markers of endothelial function (NO, CRP, SOD, IL-18).
40975824|NCT05955729|OTHER|Pichot fatigue scale|The Pichot fatigue scale is an 8-item questionnaire, with a score above 22 indicating excessive fatigue.
40975825|NCT05955729|OTHER|French version of the Recovery Needs Scale (BRD)|BRD questionnaire consists of 11 items coded 0 or 1. A score is calculated for each participant, multiplied by 10 to give a score ranging from 0 to 100. The greater the need for recovery, the higher the score.
40975826|NCT05955729|OTHER|The Short-Form 36 (SF-36)|The SF-36 questionnaire is used to assess quality of life. It comprises 8 sub-scores ranging from 0 (minimum quality of life) to 100 (maximum well-being).
40975827|NCT05955729|OTHER|Pittsburgh Sleep Quality Index (PSQI)|24-question sleep quality assessment scale, a score \> 5 indicates poor sleep quality
40975828|NCT05955729|OTHER|Epworth questionnaire|8-question sleepiness assessment scale, a score above 10 indicates excessive sleepiness
40975829|NCT05955729|OTHER|The Karolinska Sleepiness Scale|The Karolinska Sleepiness Scale measures daytime sleepiness on a 9-point scale, based on 5 states and 4 intermediate states that are not verbally indicated.
41300507|NCT03091062|DEVICE|Monarch™ System|Generates airflow at frequencies similar to those provided by HFCWO and also provides direct percussive therapy.
41459785|NCT05822674|DRUG|Empagliflozin/metformin(10/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
40975830|NCT05955729|DEVICE|Actimeter|An actimeter will be worn on the non-dominant wrist, uninterrupted day and night, for 7 consecutive days.
40975831|NCT05627154|DRUG|Citalopram|Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.
40975832|NCT05627154|BEHAVIORAL|Behavioural Activation|A NICE recommended psychological intervention for mild to moderate depression. In behavioural activation, the person with depression and the therapist work together to identify the relationships between the activities the person undertakes and their mood. It encourages people to become less mood-dependent when planning activities and doing constructive things that they would usually avoid doing.
40975833|NCT05627154|DRUG|Placebo|A lactose-based tablet.
40975834|NCT04309188|DEVICE|Senaptec Strobe Glasses|The glasses use liquid crystal technology that causes a flicker from clear to opaque to enhance vision.
41300508|NCT04470310|DRUG|Glimepiride|
40771654|NCT03247101|DRUG|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
40771655|NCT03247101|DRUG|Biotase group|Biotase 1# \[Biodiastase 30mg + lipase 65mg + newlase 10mg\]/tab po tid x 6 months
40771656|NCT02137343|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
40771657|NCT02137343|DRUG|Placebo|Placebo
40771658|NCT02137343|DRUG|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
40975835|NCT04309188|OTHER|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
41140696|NCT04151030|PROCEDURE|PEG placement|Push PEG placement
41140697|NCT02174146|PROCEDURE|non-surgical periodontal therapy|supra and subgingival debridement
41140698|NCT05964309|OTHER|supine group|after pre-oxygenation in supine position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
41140699|NCT05964309|OTHER|sitting group|after pre-oxygenation in sitting position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
41140700|NCT03477084|BIOLOGICAL|ESBL-producing enterobacteriaceae carriage|Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
41140701|NCT02003885|DRUG|increment of desflurane|"After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.~After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.~Reduction of BP is managed by the increment of phenylephrine infusion"
41140702|NCT06241183|DRUG|Intravenous Famotidine|Patients in this group will receive 20mg IV Famotidine.
41140703|NCT06241183|DRUG|Oral Maalox/ Mylanta|Patients in this group will receive 30 ml Maalox/ Mylanta.
41140704|NCT06398015|PROCEDURE|Surgical reconstruction of hip abductor tendon tear|"If the patient is allocated to surgical reconstruction, the incision from the sham surgery is continued into the iliotibial band (ITB) and down to the hip abductor tendon complex/greater trochanter. A standardized reconstruction of the HAT with bone anchors is then performed.~This standardized procedure has been used by the surgeons for the last 6 years. The ITB is then closed with looped suture, the subcutaneous tissue sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing is applied."
41140705|NCT06398015|PROCEDURE|Sham surgery of hip abductor tendon tear|If the patient is allocated to sham surgery, the incision will only include the skin and subcutaneous tissue. Subsequently, the subcutaneous tissue will be sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing applied. The patient will be kept in general anesthesia for 10 minutes after the procedure is finalized to mimic a true intervention (to hinder staff or relatives to comment on the duration of the procedure). The normal standard procedure takes approximately 40 minutes.
41140706|NCT00308308|DRUG|Technosphere Insulin|Inhalation, 15U/30U
41140707|NCT00308308|DRUG|Active comparator|sc injectable insulin
41140708|NCT05188378|BIOLOGICAL|CT-P47|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
41140709|NCT05188378|BIOLOGICAL|EU-approved RoActemra,|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
41140710|NCT02694107|OTHER|Proprioceptive exercises|
41140711|NCT02694107|OTHER|Control|
41140712|NCT03794388|DRUG|Capsaicin|Application of capsaicin patches at 8% on painful area
41140713|NCT03794388|DRUG|Pregabalin|Taking Pregabalin tablets
41140714|NCT03471884|PROCEDURE|Nonintubated thoracoscopic lobectomy|Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.
40771659|NCT02137343|DRUG|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
40771660|NCT00834197|DRUG|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose non-fasting
40771661|NCT00834197|DRUG|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose non-fasting
41140715|NCT03471884|PROCEDURE|Intubated thoracoscopic lobectomy|Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.
41147170|NCT02955225|DEVICE|Active Moticon OpenGO insole|A Moticon OpenGO insole measures shoe pressure and connects/sends data to a ANT+ enabled smartphone.
41147171|NCT02955225|DEVICE|Passive shoe insole|A deactivated insole measures shoe pressure only.
41300509|NCT04470310|DRUG|Alogliptin 25Mg Tab|
40771662|NCT05131256|BEHAVIORAL|Neurofunctional characterization of emotional regulation (fMRI)|Investigation of neurofunctional characterization of emotional regulation and its links with the eating behaviours of patients suffering from obesity using a comprehensive, clinical, and cognitive assessment and task-based MRI exams.
40975836|NCT02097576|OTHER|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
40975837|NCT02097576|OTHER|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
41147172|NCT03763409|DRUG|Losartan Potassium|active drug
41147173|NCT03763409|OTHER|placebo|placebo
41147174|NCT00275418|DRUG|beta carotene from Dunaliella algae|
41147175|NCT05811000|DRUG|PM012|PM012 650 mg tablet drug
41147176|NCT05811000|DRUG|PM012 Placebo|PM012 tablet placebo
41147177|NCT05811000|DRUG|Donepezil|Aricept 5 mg (donepezil hydrochloride) drug
40771663|NCT01399853|BIOLOGICAL|160U /0.5ml EV71 Vaccine|inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
40771664|NCT01399853|BIOLOGICAL|320U /0.5ml EV71 vaccine|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
40771665|NCT01399853|BIOLOGICAL|640U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
40771666|NCT01399853|BIOLOGICAL|(without adjuvant) 640U /0.5ml|inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
40771667|NCT01399853|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
40771668|NCT06368206|DEVICE|Investigational device Aktiia G2C|Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia G2C.
40771669|NCT06368206|DEVICE|Marketed device used as reference for blood pressure monitoring: double auscultation cuff|Study subjects are asked to stay seated and relaxed while successive measurements are taken with cuff for double auscultation.
40771670|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2|Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia Bracelet G2.
40771671|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric upper-arm cuff|Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric upper-arm cuff.
40771672|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric wrist cuff|Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric wrist cuff.
40771673|NCT06368206|DEVICE|Marketed device used as reference for pulse rate monitoring: pulse finger oximeter|Study subjects are asked to stay seated and relaxed while successive measurements are taken with pulse finger oximeter.
40771674|NCT00741728|OTHER|Spider flash EKG, echocardiography tracking, step test|cardiac rhythm recorded during health check up, echocardiography tracking of the right common carotid, step test during 2 minutes
40771675|NCT00899301|OTHER|biologic sample preservation procedure|Tissue, urine and blood collection.
40771676|NCT05617196|BEHAVIORAL|Virtual PREHAB|The Virtual PREHAB program begins with a virtual health care team assessment. The physiotherapist will support patients in identifying ways to safely engage in home-based physical activities and in their neighborhoods. Additional weekly 30-minute telephone consultations with the physiotherapist, nurse, and dietitian are provided as well as three 30-minute online consultations are provided; telephone calls will replace these online consults if the patient does not have internet access. Telephone and/or online consults with participants will monitor the progression of the individual through the program, review patient materials, review medication changes, as well as provide recommendations to adopting a physically active lifestyle, diet, well-being, smoking, or other supports available to the patient. Medication changes are monitored by a nurse and any necessary medication recommendations involve the program's medical director, the patient's family physician, and TAVI team.
40771677|NCT05617196|BEHAVIORAL|Standard care|In Nova Scotia, patients are referred to the TAVI program. The TAVI health care team, consisting of a cardiac surgeon, cardiologist, nurse, and geriatric team conduct patient assessments and provide guidance and resources on self management.Once patient assessments are completed, patients are discussed at a multidisciplinary team meeting. When a patient is accepted for TAVI, they are placed on a waiting list which lasts for 3-6 months depending on urgency.
40771678|NCT06095011|DEVICE|UpRight Go|The UpRight Go posture trainer is a commercially available biofeedback sensor that externally attaches to the wearer via a necklace or silicon adhesive. It vibrates when it senses that the wearer is slouching and connects to a smartphone application which sets daily goals, tracks usage, and provides assistance and support. It complies with International Electrotechnical Commission (IEC) standards.
40771679|NCT05817357|DEVICE|Rensair Compact air purifier unit|Installation of Rensair Compact air purifier (Rensair Ltd.) in the homes of children/young people participating in this study
40771680|NCT02263547|DRUG|teriflunomide|
40771681|NCT02263547|DRUG|Colestipol|
40771682|NCT04087642|DIAGNOSTIC_TEST|Intraoperative Crede manoeuver|In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
40771683|NCT04087642|DIAGNOSTIC_TEST|Preoperative prolapse reduction cough stress test|In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
40771684|NCT00461318|PROCEDURE|Individual placement and support (vocational rehabilitation)|
40771685|NCT06564662|DEVICE|Rapid Response EEG|The Ceribell(R) Rapid Response EEG is a relatively new device that is becoming standard of care in the adult critical care. In this pediatric study the device will be placed by trained ICU physicians
40771686|NCT02683447|OTHER|CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
40771687|NCT02443857|DEVICE|ChARMin|The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.
40975838|NCT00603993|BIOLOGICAL|Adalimumab|40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
41147178|NCT05811000|DRUG|Donepezil placebo|Aricept 5 mg (donepezil hydrochloride) placebo
41147179|NCT02717780|DRUG|Fentanyl and sevoflurane|
41147180|NCT02717780|DRUG|Remifentanil and desflurane|
41147181|NCT00002094|DRUG|Atevirdine mesylate|
41147182|NCT00257309|DRUG|Tenecteplase + UFH (+ clopidogrel, since 01/97)|
40771688|NCT02443857|DEVICE|ChARMin|The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.
41140716|NCT06174948|DEVICE|CUE1 non-invasive device|This is a 9-week feasibility study which will involve wearing the CUE1 device on a daily basis at participants' homes while they continue their usual activities of daily living (ADL). The CUE1 is a non-invasive medical device which delivers low frequency metronomes like tactile cueing and high frequency focused vibrotactile stimulation. All participants will be using the same pre-programmed settings for the CUE1 device which are: vibration strength delivered at 80%, pulse length 800 milliseconds (ms), and rest length 800ms as set at baseline and will not change. The CUE1 device is attached to the skin via an adhesive patch which has been dermatologically tested and approved. Participants will be provided with the adhesive patches and shown how to use them and the CUE1 device by the research team.
41300510|NCT04470310|DRUG|Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet|
40975839|NCT01661439|DRUG|low molecular weight heparin (enoxeparine)|1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
40975840|NCT03032315|DRUG|TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
40975841|NCT03032315|DRUG|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
40975842|NCT03032315|DRUG|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
40975843|NCT05532839|OTHER|High intensity interval training|The therapy lasted 6 weeks, and HIIT comprised of two 12-24 × 30 second high-intensity runs separated by thirty seconds of relaxation.
40975844|NCT05532839|OTHER|Moderate intensity continuous training|The MICT ran continuously for 24-48 minutes. From the day of the six weeks intervention strategies, the mentioned assays were conducted: Yo-Yo Intermittent Recovery Test level 1, repeated sprint ability , sprint test, alter of way test which is t drill, and physical activity enjoyment scale and shuttle run. Through these trainings, individuals in both groups must follow the old their balanced meal.
40975845|NCT01737788|PROCEDURE|Cervical occlusion|Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
40975846|NCT00812890|DEVICE|semi-quantitative pregnancy test|
41140717|NCT03738592|OTHER|behavioral exploration of spatial hearing performances|"Normal hearing children and cochlear implant children will have to localize a sound source in three dimensional space by using a virtual reality system (Neuro immersion platform). The experiment will last thirty minutes.~For normal hearing children, this experience will be performed at the inclusion visit.~For cochlear implant children, this experience will be performed 28 days (+/- 2 days) after inclusion."
41140718|NCT03738592|OTHER|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for cochlear implant children and their parents)|"For cochlear implant children and their parents, a SSQ questionnaire will be given and completed during the first visit (at the inclusion).~This questionnaire offers a version for parents of children with hearing loss (SSQ Parents CI) and a version for the children themselves (SSQ Children CI)."
41140719|NCT03738592|OTHER|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for parents of CI children)|"The SSQ questionnaire for Parents of CI children is composed of three distinct sections (A, B and C).~Each section will be filled separately by parents of CI children with one of the study collaborators during 3 telephone calls spaced 1 week apart. Thus, section A will be completed 7 days (+/- 2 days) after inclusion , section B 14 days (+/- 2 days) after inclusion, and section C 21 days (+/- 2 days) after inclusion."
41300511|NCT04011436|OTHER|Strengthening program|"Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises"
41300512|NCT03961919|DRUG|Fludarabine|Fludarabine i.v. 30 mg/m²/d day -6 to -2
41300513|NCT03961919|DRUG|ARA-C|Cytarabine i.v. 2 g/m²/d day -6 to -2
41300514|NCT03961919|DRUG|Treosulfan|Treosulfan i.v. 10 g/m²/d day -6 to -4
41300515|NCT03961919|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3"
41300516|NCT06038097|PROCEDURE|Radiofrequency Pallidotomy|Radiofrequency bilateral simultaneous pallidotomy
41300517|NCT04120792|BEHAVIORAL|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
41300518|NCT04120792|BEHAVIORAL|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
40771689|NCT02443857|DEVICE|ChARMin|The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.
40771690|NCT02443857|DEVICE|ChARMin|The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
40975847|NCT01065623|DRUG|BAY79-4620|1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
40975848|NCT03140644|OTHER|Patients with thoracic sarcoidosis|Ultra-low dose CT scan and MRI with UTE
40975849|NCT04757064|OTHER|standard rehabilitation protocol|they will receive knee flexion exercises and increase the extensor strength
41140720|NCT06213545|DIAGNOSTIC_TEST|In-clinic interpretation|Reading patch test result at clinic
41147183|NCT00257309|PROCEDURE|Primary angioplasty|
40771691|NCT02443857|DEVICE|ChARMin|The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.
40975850|NCT05763550|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
40975851|NCT05763550|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.
40975852|NCT05763550|DRUG|Pregabalin 150mg|pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week；300 mg (150 mg twice daily) daily for 3 week
40975853|NCT04648956|OTHER|Standard treatment|Participants shall fill the ICOAP-Ar questionnaire three times within one month in addition to other questionnaires including the KOOS/HOOS, and the Global Rating of Change Scale (GRoC). The first two times will be within a time frame of 48-72 hours. The third time will be after one month.
40975854|NCT01867268|DRUG|Acetazolamide|Acetazolamide administration for 10 days adjust dosage with weight of the patient
40975855|NCT01867268|OTHER|prone positioning|prone positioning the patient for 10 days following the surgery
40771692|NCT02443857|DEVICE|ChARMin|The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
40975856|NCT01867268|OTHER|Acetazolamide+ prone positioning|administration of acetazolamide and position the patient for 10 days following the surgery
40975857|NCT01359397|DRUG|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
40975858|NCT01359397|DRUG|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
40975859|NCT01539057|DRUG|Fibrinogen|"The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts"
40975860|NCT01539057|DRUG|Saline|the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
40975861|NCT03348033|BIOLOGICAL|Chronic Myeloid Leukemia + NK cell|Patients with chronic phase chronic myeloid leukemia who lost response to the second line of treatment with tyrosine kinase inhibitor with indication of bone marrow transplantation or refractory. Infusion of autologous natural killer cells, expanded in the laboratory, after chemotherapeutic conditioning.
40975862|NCT03158064|DRUG|Durvalumab|1500 mg by IV
40975863|NCT03158064|DRUG|Tremelimumab|"75 mg by IV~\*300mg"
40975864|NCT03673553|OTHER|Multimodal treatment of patients with FM|The intervention group took part in 2.5-hour sessions of MRT once a week for 10 weeks. This intervention combined physical exercise with stretching. Health education was geared towards pain management, the pathology itself, healthy habits, insomnia, postural correction and ergonomics. The psychological approaches used in the MRT were problem-solving therapy, cognitive behavioural therapy and sophrology. Given the diversity of the sessions, they were directed by a rheumatologist, a nurse, a psychologist, and a physiotherapist. If the patient needed their pharmacological treatment to be altered, they were offered an appointment with the rheumatologist.
40975865|NCT03673553|OTHER|Association of people with fibromyalgia|The control group attended the activities organised by the association of people with FMS. These consisted of a weekly 1-hour session of group psychology and a weekly 2-hour session of handicrafts for 10 weeks.
40975866|NCT00804830|DRUG|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
40975867|NCT05787561|DRUG|Avutometinib (VS-6766)|3.2 mg PO, twice weekly
40975868|NCT05787561|DRUG|Defactinib|200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
41300519|NCT04120792|BEHAVIORAL|Cognitive Training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
40975869|NCT01574040|BEHAVIORAL|Promotion of stair climbing|"Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories."
40975870|NCT01574040|BEHAVIORAL|Promotion of a low-salt soup alternative for the 'soup of the day'|"Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure."
40975871|NCT01574040|BEHAVIORAL|Promotion of a low-fat alternative for the butter croissants|"Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids."
40975872|NCT01574040|BEHAVIORAL|Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations|Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
40771693|NCT04537650|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VFSS)|A standardized dynamic radiographic examination of oropharyngeal swallowing
40975873|NCT03383172|BEHAVIORAL|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
40975874|NCT05122520|OTHER|Questionnaire|The HMBT-Q is a 26-item questionnaire, split into four main sections: food related symptoms; general digestive symptoms; extra-intestinal symptoms and co-morbidities and Medication and onset.
41300520|NCT04120792|BEHAVIORAL|Neutral video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
40975875|NCT06163170|DRUG|Nivolumab +/- ipilimumab|Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma
40975876|NCT06163170|DRUG|Nivolumab|Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma
40975877|NCT01571427|BEHAVIORAL|Active social engagement group|Engage in 30 minutes conversation daily using internet/webcam, 5 days per week for 6 weeks, tracking of daily conversational amount outside of the trial by using a digital recording device, lasting effects will be assessed at the 3rd and 6th month after completion of the intervention
41300521|NCT05988541|DIAGNOSTIC_TEST|Ultrasonography imaging|Ultrasonography: rotator cuff tendons (supraspinatus, infraspinatus, subscapularis) integrity, long head of the biceps tendon integrity and location, SASD (subacromial-subdeltoid) bursitis, synovitis and muscle atrophy.
41459786|NCT00152516|DRUG|levetiracetam (LEV)|Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
40771694|NCT05884125|DEVICE|Checkpoint BEST System|Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair
40771695|NCT02510924|DEVICE|Tracheal intubation|tracheal intubation with Airtraq sp vs Airtraq mobile
40975878|NCT01571427|BEHAVIORAL|Control group|No active intervention, weekly phone calls by interviewer to complete health/social engagement monitoring survey, tracking of daily conversational amount by using a digital recording device. Participants will be reassessed at the 3rd and 6th month after completion of the intervention.
41459787|NCT03493919|BIOLOGICAL|rMenB+OMV NZ vaccine|Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.
40771696|NCT04904913|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
40771697|NCT04904913|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
40771698|NCT03970031|DRUG|MSDC-0602K|MSDC-0602K tablet
40771699|NCT03970031|DRUG|Placebo|Matching tablet
40771700|NCT00224549|DRUG|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
40771701|NCT05236023|BEHAVIORAL|Zero separation and couplet care|"The essence of the intervention is that treatment-requiring mother-infant dyads are admitted together and receives couplet care provided by neonatal nurses.~The nurses will be educated for the intervention by participating in a two-day course about postpartum observations, treatment and care; and participate in education about family-centred care and family-focused nursing."
40771702|NCT03358082|DRUG|Tacrolimus 0.03% Ointment|topical tacrolimus 0.03% twice daily for 6 months
40771703|NCT03358082|DRUG|Hydrocortisone Acetate 1% Ointment|hydrocortisone acetate 1% ointment twice daily for 6 months
40975879|NCT01748032|BEHAVIORAL|Cognitive training|20 minutes/day for 5 sequential working days
40975880|NCT06415292|DRUG|Winlevi (clascoterone) 1% cream|Split face. Blinded study treatment product to be applied to the randomized half face
40975881|NCT00002079|DRUG|Butyldeoxynojirimycin|
40975882|NCT00002079|DRUG|Zidovudine|
41459788|NCT03493919|BIOLOGICAL|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|One dose of MenACWY vaccine were administered intramuscularly at Day 1.
41459789|NCT02411149|DRUG|Adductor Canal Block|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
41459790|NCT02411149|DRUG|Adductor Canal Block with Morphine|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
40975883|NCT04091022|DRUG|Solaraze and Vaniqa|Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months
40975884|NCT05747781|BEHAVIORAL|Pilot Phase: standardized behavioral task|"Pilot Phase:~* Mobility under variable light conditions (scotopic, photopic, glare, dark adaptation), performed in a virtual environment.~* Visual search for objects in real life scenes (office, kitchen, living room) performed in a virtual environment.~* Ability to drive (UFOV and DVFAT psychophysical tests)."
41459791|NCT02411149|DRUG|Local Infiltration|30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
41459792|NCT04716829|DEVICE|LUNA-EMG|The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot allows the adaptation of movements during rehabilitation sessions according to the individually generated strength.
40771704|NCT01969409|DRUG|Rituximab|i.v. rituximab given on two occasions 14 days apart.
40771705|NCT01969409|DRUG|Placebo|Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
40771706|NCT02656056|OTHER|Food: (Q-Can Plus fermented soybean beverage)|Fermented soybean beverage. Dose is 8 oz, twice daily.
40771707|NCT05949593|DRUG|Tinlarebant|5 mg tablet taken orally once a day
40771708|NCT05949593|DRUG|Placebo|Placebo tablets for tinlarebant 5 mg prepared similarly.
40771709|NCT01587560|DEVICE|PyroTITAN, Ascension Orthopedics, Inc.|All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.
40771710|NCT01587560|DEVICE|TITAN, Ascension Orthopedics, Inc.|
40975885|NCT05747781|BEHAVIORAL|Validation Phase: standardized behavioral task|"Validation Phase:~* Mobility in variable light conditions (photopic and scotopic), performed in real and virtual environments.~* Visual search for objects in real scenes (office, kitchen, bedroom, living room) performed in a virtual environment.~* Driving ability (two psychophysical tests UFOV and DVFAT, one supervised road test)."
40975886|NCT05799729|DRUG|Ketamine|CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.
41140721|NCT06213545|DIAGNOSTIC_TEST|Photo interpretation|Reading patch test result by sending photo to clinic
41459793|NCT00379158|DRUG|Micronutrient supplements|
40771711|NCT06402305|DIAGNOSTIC_TEST|Lipid profile|Abdominal ultrasound and lipid profile will be done
41459794|NCT04795869|DRUG|Brentuximab Vedotin|Given IV
41459795|NCT04795869|BIOLOGICAL|Pembrolizumab|Given IV
40771712|NCT02552264|BEHAVIORAL|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
40771713|NCT01859013|DRUG|Topiramate|Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.
40771714|NCT01859013|OTHER|Placebo|Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.
40771715|NCT05866640|DEVICE|F2 filter and delivery system|Placement of F2 device in aorta to cover great cerebral vessels
40771716|NCT03804424|DRUG|64Cu-LLP2A|-64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
40771717|NCT03804424|DEVICE|PET/MR|-All PET imaging will be performed as PET/MR or PET/CT
40771718|NCT03804424|PROCEDURE|Blood samples for serum stability|-3 venous samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (2 mL each) will be obtained at the following time points: Cohort 1: prior to injection, at completion of dynamic scanning in those who undergo dynamic imaging and at completion of one of the body imaging time points. In those who do not undergo dynamic imaging, prior to injection, and after completing body imaging at 2 of the 3 time points. Cohort 2: subjects will have samples drawn prior to injection, at completion of dynamic scanning, and at completion of body imaging.
40975887|NCT02099357|DIETARY_SUPPLEMENT|Creatine|Daily supplementation with 3g of monohydrate creatine during 8 weeks
40975888|NCT02099357|DIETARY_SUPPLEMENT|Placebo|
40975889|NCT02099357|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D supplementation with 25000 IU each two weeks during eight weeks
40975890|NCT01993654|PROCEDURE|HRT III with Non-Contact Cornea Rostock Module|Confocal imaging of the conjunctival lesion
41140722|NCT00728013|DRUG|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
41140723|NCT00728013|DRUG|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
41140724|NCT01811459|DRUG|Quetiapine|PO
41140725|NCT01811459|DRUG|Haloperidol|IV
41140726|NCT01811459|DRUG|Placebo|PO or IV
41140727|NCT01491815|DRUG|Non-biological DMARD's|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
41459796|NCT05453708|OTHER|Survey|One 15-20-minute survey
41459797|NCT05846256|OTHER|Sperm DNA Fragmentation|Sperm DNA Fragmentation analysis.
41459798|NCT00897923|PROCEDURE|radionuclide imaging|
41459799|NCT00897923|RADIATION|indium In 111-labeled autologous peripheral blood mononuclear cells|
41459800|NCT00897923|RADIATION|indium In 111-labeled autologous polymorphonuclear leukocytes|
41459801|NCT06269861|DEVICE|patient transfer scale|patient transfer scale is a device to measure actual weight for critically ill patient who are unable to stand
41459802|NCT01500005|DRUG|Baby D3 drops|2000-4000 iu per day
40975891|NCT05360511|DRUG|particulate xenograft + erythropoietin gel.|"1. Surgical sites will be anaesthetized using local anaesthesia.~2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~   * In Group A (test group):~Particulate xenograft will be mixed with EPO gel and applied to fill the whole defect."
40975892|NCT05360511|COMBINATION_PRODUCT|particulate xenograft|"* All surgeries will be performed by the same operator as follows:~  1. Surgical sites will be anaesthetized using local anaesthesia.~ 2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~ 3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~ 4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~ 5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~* In Group B (control group):~Particulate xenograft will be applied to fill the whole defect."
40975893|NCT00005937|DRUG|Antithymocyte globulin|Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
40975894|NCT00005937|DRUG|Cyclosporine|Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
40975895|NCT01247740|DRUG|NuTRIflex Lipid peri|parenteral nutrition
40771719|NCT03804424|PROCEDURE|Blood samples for metabolite analysis|-Typically, 2 blood samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (preferably 1 within the first 5 min and 1 at the completion of the first hour of imaging) will be obtained.
40771720|NCT03804424|PROCEDURE|Urine sample|-Cohort 1 only
40975896|NCT01247740|DRUG|compounded monobag|parenteral nutrition
40975897|NCT02415660|PROCEDURE|Thoracic spinal manipulation|All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
40975898|NCT02415660|PROCEDURE|Trigger point dry needling|The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the deep cervical extensor muscles and/or the upper trapezius muscles using FDA approved (FDA regulation # 880.5580) disposable 0.2-0.3 x 40-50 mm stainless steel Seirin J-type needles (Seirin, Japan). Those subjects randomized to TDN will undergo this treatment.
40975899|NCT02415660|BEHAVIORAL|Cervical range of motion exercises|The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
40771721|NCT03804424|PROCEDURE|Tumor biopsy|-Cohort 2 only and only if there hasn't been a recent biopsy of disease
40771722|NCT03804424|PROCEDURE|Electrocardiogram|-A standard 12-lead ECG will be obtained on all subjects at baseline (within 30 mins prior to injection of 64Cu-LLP2A), and at least 60 minutes post injection or prior to study discharge
40771723|NCT03804424|DEVICE|PET/CT|-All PET imaging will be performed as PET/MR or PET/CT
40771724|NCT02415114|DIETARY_SUPPLEMENT|Omega Q Plus Resveratrol (with 50mg CoQ10)|Omega Q Plus Resveratrol (with 50mg CoQ10)
40975900|NCT02415660|BEHAVIORAL|Posterior neck muscle activation exercise|The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
40975901|NCT02415660|PROCEDURE|Trigger point dry needling sham|The sham group will receive a simulated TDN. Using a toothpick in a needle guide-tube, the investigator will tap, rest, and twist the toothpick for approximately 30 seconds in the same 2 muscles, 2 sites in each muscle. The sham treatment will not penetrate the skin.
40975902|NCT02415660|DEVICE|Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm|A trained investigator will insert the needle through the participants skin into the deep cervical extensors and/or the upper trapezius muscles. Needles are FDA approved (#880.5580)
40771725|NCT04033640|DIAGNOSTIC_TEST|SD Biosensor STANDARD G6PD Test|"The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency.~The test is currently not licensed for use in Brazil and is considered an investigational product."
40771726|NCT04033640|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
41140728|NCT01491815|BIOLOGICAL|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
41140729|NCT01491815|BIOLOGICAL|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
41140730|NCT01491815|BIOLOGICAL|RoActemra|"Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.~Methotrexate: 25mg/week"
41140731|NCT00870168|DRUG|chemotherapy|
41140732|NCT00870168|GENETIC|gene expression analysis|
41140733|NCT00870168|OTHER|laboratory biomarker analysis|
41140734|NCT00870168|PROCEDURE|breast biopsy|
41147184|NCT04044885|BEHAVIORAL|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
41459803|NCT03827005|DIETARY_SUPPLEMENT|L-arginine|NOW Foods, Bloomingdale, IL
40771727|NCT04033640|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
40975903|NCT01573572|DRUG|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
40975904|NCT00742534|DRUG|Intravenous L-Citrulline|This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
40975905|NCT01596868|DRUG|gemcitabine and cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
40975906|NCT01596868|DRUG|docetaxel and cisplatin|Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
40975907|NCT01554553|PROCEDURE|Posterior crural repair|All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
40975908|NCT00609492|BIOLOGICAL|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
40975909|NCT00609492|BIOLOGICAL|Infanrix™-IPV/Hib|Single dose, intramuscular injection
40975910|NCT03520374|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography use for the evaluation of gastric contents
40975911|NCT06155409|DEVICE|Anterior cervical interbody fusion|Anterior cervical interbody fusion indicates a surgical approach in the cervical spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height.
40975912|NCT04207970|OTHER|Adapted Structured Clinical Management|Adapted form of a previous Evidence Based Treatment- adapted to local context, in light of input from service-users and commissioners.
40975913|NCT05071989|BEHAVIORAL|Sleep Education|A single-blind school- based randomized controlled design
41140735|NCT05870995|DRUG|CALGE-VEN- RIC-conditioning|Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation
41140736|NCT00655213|DEVICE|Symphony D 2450|
41140737|NCT00655213|DEVICE|Symphony DR 2550|
41459804|NCT03827005|DIETARY_SUPPLEMENT|Placebo|InHealth Specialty Pharmacy, Fargo, ND
40771728|NCT04033640|DIAGNOSTIC_TEST|Complete blood count (CBC)|In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).
40771729|NCT04167735|DEVICE|Hearing Aid without Reverberation Canceller (RevC).|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is without Reverberation Canceller principle enabled.
40771730|NCT04167735|DEVICE|Hearing Aid Reverberation Canceller enabled (RevC_1)|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The experimental condition applies the Reverberation Canceller and is predicted to provide a benefit in reverberant room simulations.
40771731|NCT03639935|DRUG|Rucaparib|Rucaparib 600 mg PO BID days 1-28
40771732|NCT03639935|DRUG|Nivolumab|Nivolumab 240 mg IV days 1 and 15
40771733|NCT05102370|DRUG|Enasidenib|Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.
41140738|NCT00309673|DRUG|lidocaine / Prilocaine|
41140739|NCT02839850|DEVICE|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)
41147185|NCT00623844|BEHAVIORAL|physical activity|activity program at kindergarten 5 \* 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
41459805|NCT00564096|DEVICE|DEEP TMS H1 coil|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
41459806|NCT00564096|DEVICE|Deep H1 coil TMS|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
40771734|NCT03184545|DEVICE|EMS|The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.
40771735|NCT03184545|OTHER|Physical therapy|Standard physical therapy exercises
40975914|NCT00894569|DRUG|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
40975915|NCT00894569|DRUG|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
41459807|NCT01479062|BEHAVIORAL|Alive-PD|Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
40975916|NCT04848545|OTHER|Observational|Prenatal maternal exposure to endocrine disrupting chemicals
40975917|NCT04355572|DRUG|Vitamin D 4000IU daily|Randomized to receive vitamin D 4000IU daily
40975918|NCT04355572|DRUG|Placebo|Randomized to placebo daily
40975919|NCT05331274|OTHER|exercise group|"1 stage~* In a sitting position, pull the leg up and extend the knee forward~* Standing, bending forward and bending the knee~* Supine, tucked legs~* Maintaining spinal smoothness in crawling~* Prone heel pull to buttock~Stage 2~* Prone on forearms-hands~* Extending the supine hands to the knees~* Rounding and hollowing the waist in crawling~* Progressive sit-stand~* Standing up from sitting and putting on and taking off socks~* Reaching up while standing and maintaining the straightness of the spine~* Squatting~* Climbing and descending stairs~Stage 3~* Maintaining standing, arms forward~* Slipping hands on the bed while standing~* Initiating the standing throw and maintaining the position until the final interval~* Putting on and taking off socks while standing~* Taking weight towards the ground from a certain height~* Picking up different weights from the ground~* Push-pull items~* Crossing obstacles of certain height~* Walking a certain distance"
40975920|NCT05331274|OTHER|pain training group|"The training provides participants with the opportunity to explain the central sensitization mechanism and also integrates the behavioral, psychological and environmental aspects that contribute to the persistence of pain. It is intended to teach that education reduces pain and improves endogenous pain inhibition, mental health, physical function, vitality and self-rated disability in patients with chronic pain, and reduces passive coping, kinesiophobia, and catastrophizing.~The same exercises will be applied as the exercise group."
40975921|NCT00933309|DRUG|Exemestane|25 mg tablets orally once a day
40975922|NCT00933309|DRUG|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
40975923|NCT00639054|PROCEDURE|Bone marrow examination|7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.
40975924|NCT00639054|PROCEDURE|Blood samples|24 ml of cubital vein blood drawn in addition to diagnostic samples.
40975925|NCT05168488|BEHAVIORAL|Fasted morning resistance exercise|On three separate occasions, participants will perform a standardized resistance exercise protocol in the morning while fasting.
40975926|NCT05168488|BEHAVIORAL|Afternoon resistance exercise|On three separate occasions participants will perform a standardized resistance exercise protocol in the afternoon after eating their regular lunch
41140740|NCT04572165|DRUG|Ozempic®|Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
41140741|NCT04572165|DRUG|Active Comparator|Patients have been treated with commercially available active comparators according to local label and to routine clinical practice at the discretion of the treating physician. Active comparators will include the following antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin. The decision to initiate treatment with commercially available active comparators had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
41140742|NCT04572165|DRUG|Rybelsus®|Patients have been treated with commercially available Rybelsus® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Rybelsus® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
41140743|NCT00237926|BEHAVIORAL|Exercise|aerobic or resistance training
40975927|NCT00759031|DRUG|Sodium Monofluorophosphate|Brush teeth and evaluate plaque score after one use of the study toothpaste
40975928|NCT00759031|DRUG|Triclosan/Fluoride/Copolymer|Brush teeth and evaluate plaque score after one use of the study toothpaste
40975929|NCT00425451|DRUG|PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip|
40975930|NCT04017585|DIETARY_SUPPLEMENT|diet containing gluten|gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days
40975931|NCT04017585|DIETARY_SUPPLEMENT|Diet containing placebo|Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days
40975932|NCT02116907|DRUG|E2007|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
40975933|NCT01112241|DRUG|albuterol plus tiotropium|Four separate doses of 100 μg of albuterol and 18 μg of tiotropium bromide. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber and tiotropium by a dry-powder device.
41140744|NCT05534230|DRUG|Dexmedetomidine Injectable Solution|Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
41140745|NCT05534230|DRUG|Saline|Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
41140746|NCT06014671|BEHAVIORAL|Interpersonal Psychotherapy|Intervention Group were took interpersonal psychotherapy
41140747|NCT00162409|DRUG|Folic acid|
41140748|NCT05504135|DIAGNOSTIC_TEST|Pharmacogenomics Testing|To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.
40771736|NCT05786326|DEVICE|group 1|Insertion of fully covered self-expanding metallic stents with multi-holes (FCSEMS- MH) Biliary stent HANAROSTENT® CCC (M.I.Tech Co., Ltd, pyeongtaek, Korea) in a biliary tree through endoscopic retrograde cholangiopancreatography (ERCP) under general anesthesia by expertise in patients with malignant biliary obstruction
40771737|NCT05786326|DEVICE|group 2|Insertion of partially covered self-expanding metallic stents HANAROSTENT® Biliary (NCN) in the biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
40771738|NCT05786326|DEVICE|group 3|Insertion of uncovered self-expanding metallic stents (Biliary stent HANAROSTENT® NNN) (M.I.Tech Co., Ltd. Pyeongtaek, Korea) in a biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
40771739|NCT02038036|DRUG|Best Available Therapy|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
40771740|NCT02038036|DRUG|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
40771741|NCT00172367|DRUG|Lycopene|
40771742|NCT00398814|DRUG|Perifosine|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
40771743|NCT00398814|DRUG|Sorafenib|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
40771744|NCT03102086|PROCEDURE|Scaling|Scaling of dental calculus
40771745|NCT00834574|DRUG|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
40771746|NCT00834574|DRUG|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
40771747|NCT01758120|DRUG|prednisone plus cyclophosphamide|"1. prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day\*6 months) plus cyclophosphamide(1g intravenous use,per 1 month\*6months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
40771748|NCT01758120|DRUG|Prednisone alone|"1. prednisone alone: prednisone(0.5mg/kg/day\*6 months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
40771749|NCT00358878|DRUG|Satavaptan|oral administration once daily
40771750|NCT00358878|DRUG|placebo|oral administration once daily
40771751|NCT00836706|DRUG|clarithromycin|500 mg Tablet
40771752|NCT00836706|DRUG|BIAXIN®|500 mg Tablet
40975934|NCT04982887|OTHER|Exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
40975935|NCT00803725|DRUG|Mepivacaine without fentanyl|45 mg 1.5% mepivacaine injection for spinal anesthesia
41140749|NCT00638456|DRUG|Budesonide plus Prevacid|Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
40771753|NCT01942369|DRUG|Triptorelin Acetate 3.75mg intramuscular injection|"Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks."
40771754|NCT06456892|DRUG|Pucotenlimab|Pucotenlimab Combined with Standard Chemotherapy Regimen
40771755|NCT06035887|DIAGNOSTIC_TEST|Hand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated)|RETEval Complete hand-held electroretinogram
40771756|NCT06035887|DIAGNOSTIC_TEST|Trolley-Mounted Multifocal Skin-Electrode Electroretinography (Device to be evaluated)|UTAS multifocal electroretinogram
40771757|NCT06035887|DIAGNOSTIC_TEST|Spectral-Domain Optical Coherence Tomography (Standard of Care test)|Heidelberg Engineering Spectralis Spectral-Domain Optical Coherence Tomography (macular structural scan)
40771758|NCT06035887|DIAGNOSTIC_TEST|Macular Autofluorescence (Standard of Care test)|Heidelberg Engineering Spectralis Autofluorescence imaging (macular structural image)
40771759|NCT00113373|DRUG|lapatinib ditosylate|Given orally
40771760|NCT00113373|OTHER|laboratory biomarker analysis|Correlative studies
40771761|NCT03896633|DRUG|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
40771762|NCT03896633|DRUG|Azopt 1%|Azopt 1%, RLD
40771763|NCT06563609|BEHAVIORAL|Intensive physical Therapy, individualised Nutritional Support|An Intensive physical Therapy and individualised Nutritional Support intervention
40771764|NCT06563609|DIETARY_SUPPLEMENT|Probiotic treatment|Administration of probiotic yeast Saccharomyces boulardii twice daily
40771765|NCT01078532|OTHER|SMART PHR|Patient receives an active PHR
40771766|NCT01078532|OTHER|usual care|Usual passive PHR
40771767|NCT05077423|DRUG|CD33*CD3 BsAb|CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
40771768|NCT06387342|DRUG|Namodenoson 25mg|oral capsule
40975936|NCT00803725|DRUG|Mepivacaine with Fentanyl|10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
40975937|NCT02853591|PROCEDURE|Pneumoinsufflator mode and setting|Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
40975938|NCT06044285|OTHER|Low UP (meals provided)|"This study incorporates within- and between-subject comparisons. All participants complete a series of three in-lab visits with remote data collection:~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Food is provided by the study team for 7 days in accordance with a low UP diet.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
41140750|NCT00638456|DRUG|placebo plus Prevacid|Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
41300522|NCT05988541|DIAGNOSTIC_TEST|American Shoulder and Elbow Surgeons (ASES) Score|"The patient self-assessment (pASES) includes 6 pain items and 10 functional items that are shoulder specific (Angst, 2008).~The pASES form has 3 sections: pain, instability, ADLs (Goldhahn, 2008).~1. Pain section: 4 questions with yes/no responses, 1 question covering number of pain tablets per day, and a VAS (visual analogue scale) from 0 (no pain) to 10 (worst pain).~2. Instability section: 2 questions (1. Response yes/no about feelings of instability, 2. Quantify instability from 0 (stable) to 10 (very unstable)).~3. Activities of daily living (ADLs): Each shoulder is included (affected/non affected), 10 items, with a 4 point ordinal scale, range: 0 (unable to perform activity) to 3 (no difficulty in doing activity) (Goldhahn 2008)."
41300523|NCT05988541|DIAGNOSTIC_TEST|The Constant-Murley score (CMS)|The test is divided into four subscales: pain (15 points), activities of daily living (ADL) (20 points), strength (25 points) and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder (40 points).
41300524|NCT05988541|DIAGNOSTIC_TEST|The Disabilities of the Arm, Shoulder and Hand (DASH)|"30-item self-report questionnaire designed to assess symptoms and function of the entire upper extremity.~Total scores range from 0 (minimum) to (100) maximum."
41300525|NCT02674997|BIOLOGICAL|Factor VIII|Licensed Factor VIII products. Study is brand agnostic
41300526|NCT02669927|OTHER|Observational|
41300527|NCT02226042|BEHAVIORAL|Mindfulness-based Cognitive Therapy|MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
41300528|NCT00780468|BEHAVIORAL|Existing diet plan|
41300529|NCT00780468|BEHAVIORAL|New diet plan|
41300530|NCT02915861|OTHER|Non-invasive eschar samples + blood|EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).
41300531|NCT02915861|OTHER|Non-invasive eschar samples+eschar biopsy+blood|EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).
41300532|NCT02915861|OTHER|Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood|EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).
41300533|NCT02915861|OTHER|Blood+Skin sample|Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
41300534|NCT00444886|DRUG|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
41300535|NCT00444886|DRUG|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
41300536|NCT03139955|DEVICE|Bodytrak|Bodytrak is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone with an over-the-ear hook. Bodytrak is currently in a prototype stage. For further information please visit http://www.bodytrak.co
41300537|NCT02041715|DRUG|TKM-100802 for Injection|IV infusion
41140751|NCT05981209|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41140752|NCT05981209|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
41140753|NCT05981209|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
41140754|NCT05981209|PROCEDURE|Computed Tomography|Undergo CT
41140755|NCT05981209|DRUG|Dexamethasone|Given IV or PO
41300538|NCT02041715|DRUG|Placebo|IV infusion
41300539|NCT01752842|DRUG|Fenofibrate|
41300540|NCT01752842|DRUG|Placebo for fenofibrate|
41300541|NCT00813553|DIETARY_SUPPLEMENT|placebo|daily
41300542|NCT00813553|DIETARY_SUPPLEMENT|beta-alanine|daily
41300543|NCT00813553|DIETARY_SUPPLEMENT|beta-alanine|daily
41300544|NCT04830995|DIETARY_SUPPLEMENT|moderate restricted diet (1800-2000 kcal/day) for four weeks|high intensity interval training 3 sessions for four weeks
41140756|NCT05981209|PROCEDURE|Echocardiography|Undergo ECHO
41300545|NCT01959867|DEVICE|SurgiMend® PRS|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
41140757|NCT05981209|BIOLOGICAL|Elotuzumab|Given IV
41140758|NCT05981209|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41140759|NCT05981209|BIOLOGICAL|Mezigdomide|Given PO
41140760|NCT05981209|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
41140761|NCT00937807|DRUG|xenon|Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
41140762|NCT00937807|DRUG|sévoflurane|Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
41140763|NCT02070640|DRUG|Injection of indocyanine green (ICG)|2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
41140764|NCT02070640|DEVICE|Near Infrared Cholangiography Fluorescence (NIRF-C)|These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
41140765|NCT06505863|PROCEDURE|Transanal total mesorectal excision|Transanal approach in surgical treatment of rectal cancer along the anatomical and embryological planes, called total mesorectal excision, as described in 1988 by Heald et al.
41140766|NCT02142569|DRUG|Sugar Pill|Sugar Pills/Placebo 4 capsules/day for 12 weeks.
41140767|NCT02142569|DRUG|Chinese Red Yeast Rice (CRYR)|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + placebo (2 capsules) for 12 weeks.
40771769|NCT01215331|DRUG|Insulin|Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
40975939|NCT06044285|OTHER|Low UP (self-guided)|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat a low UP diet according to study provided nutritional guidance.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
40975940|NCT06044285|OTHER|Active Control|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat as they normally do.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
40975941|NCT06000514|DRUG|Sm29 Protein, Schistosoma Mansoni|Sm29 cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
40975942|NCT06000514|DRUG|Pentavalent antimony (Sbv)|Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
40975943|NCT01493570|DRUG|BI 409306|Film-coated tablet
40975944|NCT01493570|DRUG|Placebo|Film-coated tablet
41140768|NCT02142569|DRUG|CRYR + TRF|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
41140769|NCT02142569|DEVICE|Tocotrienol-enriched Fraction of Palm Oil (TRF)|TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
41140770|NCT03788226|DRUG|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
41140771|NCT03788226|DRUG|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
41140772|NCT00489554|BIOLOGICAL|Synflorix|Intramuscular injection, 3 doses.
41140773|NCT00489554|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses.
41140774|NCT00489554|BIOLOGICAL|Rotarix|Oral, 2 doses.
41140775|NCT01335061|BIOLOGICAL|Nonacog alfa|Period 1: During on-demand period, dosing at the discretion of investigator.
41140776|NCT01335061|BIOLOGICAL|Nonacog alfa|Period 2: During the prophylaxis period, 100 IU/kg once weekly
41140777|NCT00799331|DRUG|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
41140778|NCT00799331|DRUG|placebo|Oral suspension.
41140779|NCT02079259|PROCEDURE|Ultrafiltration|
41140780|NCT01273298|DRUG|Bisoprolol|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
41140781|NCT01273298|DRUG|Placebo|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
41140782|NCT04417309|BEHAVIORAL|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
41140783|NCT04417309|BEHAVIORAL|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for 30 minutes.
41140784|NCT04323800|BIOLOGICAL|Anti- SARS-CoV-2 Plasma|SARS-CoV-2 convalescent plasma (1 unit; \~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320
41459808|NCT01479062|BEHAVIORAL|Usual Care|Placebo Control
41459809|NCT05892731|OTHER|with depression|age-related hearing loss with depression
41459810|NCT05892731|OTHER|without depression|age-related hearing loss without depression
41459811|NCT00595140|DRUG|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
40975945|NCT02006745|DRUG|Ribavirin|24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR
40975946|NCT02006745|DRUG|Telaprevir|12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA \>25 but \<1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA \>1000 iU/mL at week 4).
41140785|NCT04323800|BIOLOGICAL|SARS-CoV-2 non-immune Plasma|Normal human plasma collected prior to December 2019
41140786|NCT02377544|DIETARY_SUPPLEMENT|Probiotic|
41459812|NCT00595140|DRUG|combination with somatostatin analogue octreotide|s.c., 100µg, one time
41459813|NCT00595140|DRUG|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
41459814|NCT02048696|OTHER|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
41459815|NCT05008120|OTHER|No intervention|No intervention
41459816|NCT00067327|DRUG|Inosine|
40975947|NCT04104945|RADIATION|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
40975948|NCT05085652|PROCEDURE|spinal anesthesia induced hypotension in SARS-CoV-2 patients.|SARS-CoV-2 infection prognosis remains unclear during pregnancy. according to ESA, ASRA and WHO regional anesthesia was recommended to use for caesarian section procedures. But at the beginning of the pandemic Chen et al shared their retrospective analyses about regional anesthesia for caesarian section and they showed high spinal anesthesia induced hypotension in 14 patients of the 17 and also again Chen and Zahng et al made another study and this time they found 57,4% hypotension incidence. In our study we aimed to find if the spinal anesthesia safe procedure in the 249 patients and one center hospital.
41140787|NCT02377544|OTHER|Placebo|
40975949|NCT05945043|OTHER|Surface parasternal eletromyogram|The surface parasternal EMG of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
40975950|NCT05945043|OTHER|Surface diaphragm electromyogram|The ipsilateral and contralateral surface diaphragm EMG of participants will be measured pre and immediately post pleural fluid removal
40975951|NCT05945043|OTHER|Parasternal muscle ultrasound|The thickness of the parasternal intercostal muscle of participants will be measured using thoracic ultrasound pre and immediately post pleural fluid removal
40975952|NCT05945043|OTHER|Breathlessness assessment|The VAS breathlessness score and Dyspnoea-12 questionnaire of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
40975953|NCT00507962|DRUG|Cisplatin|100 mg/m\^2 Intraarterial On Day 1 Every 4 Weeks
40975954|NCT00507962|DRUG|Liposomal Doxorubicin|Starting dose 20 mg/m\^2 IV On Day 1 Every 4 Weeks
40975955|NCT01887873|DEVICE|Hyaluronan Thiomer i.o. implant|
40975956|NCT05044598|OTHER|RAFT-OS|RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) is an artificial tissue, populated with limbal epithelial cells and stromal cells.
41140788|NCT05656456|OTHER|Y-BOCS or FAS online survey, interview|Y-BOCS or FAS and online survey will be administered interview will be conducted
41140789|NCT02232737|OTHER|Very low nicotine content cigarettes|
41140790|NCT01643122|OTHER|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
41140791|NCT01643122|OTHER|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
41459817|NCT04688515|BEHAVIORAL|Nutrition program developed using positive deviance approach|It is a 3-month nutrition program including nutrition education session and rehabilitation session. The education session consists of half hour education lesson and one and half hours peer-led cooking session. The cooking demonstration will be led by volunteers from PD family. Participating mothers will need to bring along their children during this session, prepare meal according to pre-planned menu and feed their children with the prepared meal after cooking as snack or additional meal. The rehabilitation session will be the rest of the days following each education session until the next education session. Growth monitoring session will also be conducted in each session, whereby mothers will be taught and trained to weigh their children.
41459818|NCT05642949|DRUG|MHB036C|MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).
41459819|NCT01460030|DRUG|Cinacalcet HCl|Oral administration
41459820|NCT02941523|DRUG|NOX66|NOX66 administration
41459821|NCT02941523|DRUG|Carboplatin|Carboplatin administration
41140792|NCT04750902|DRUG|0.24% Sodium Fluoride Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
41140793|NCT04750902|DRUG|1.5% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
41459822|NCT02976051|RADIATION|HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
41459823|NCT00387608|DRUG|veliparib|
41459824|NCT00387608|OTHER|pharmacological study|
41459825|NCT00387608|PROCEDURE|biopsy|
40975957|NCT06103357|OTHER|blood sample collection|Before and after angioplasty, blood samples upstream and downstream of the coronary lesion will be taken, arterial sampling at the aortic root level will be performed, and peripheral venous blood will be collected.
40975958|NCT01840501|DRUG|JNJ-42721458 (single dose)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
40975959|NCT01840501|DRUG|JNJ-42721458 (multiple doses)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
40975960|NCT01840501|DRUG|Placebo (single dose)|Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
40975961|NCT01840501|DRUG|Placebo (multiple doses)|Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
40975962|NCT03117712|DIAGNOSTIC_TEST|Delirium Scores|"* Confusion Assessment method for the ICU (CAM-ICU) and~* The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~1. Postoperative day (POD) 1~2. POD 2~3. POD 5"
41140794|NCT04750902|DRUG|4.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
41459826|NCT03448276|OTHER|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
41459827|NCT03448276|OTHER|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
41459828|NCT03501420|OTHER|Interview|A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment
40975963|NCT03117712|DIAGNOSTIC_TEST|Carotis duplex sonography|"Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~1. Before induction of anaesthesia~2. Before going on cardiopulmonary bypass (CBP)~3. During CPB, 5 min after aortic cross clamping~4. After CPB~5. 24 hours after CPB"
40975964|NCT03117712|DIAGNOSTIC_TEST|TCD for detection of HITS|"Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~1. During cannulation of the ascending aorta~2. After aortic cross-clamp~3. After opening of the aortic cross-clamp~4. During decannulation"
40975965|NCT04042337|BEHAVIORAL|Pivotal Response Treatment|PRT will target functional communication abilities
40975966|NCT00911820|DRUG|Bevacizumab|
40975967|NCT00911820|DRUG|Cisplatin|
40975968|NCT00911820|DRUG|Irinotecan|
40975969|NCT00911820|DEVICE|Docetaxel|
40975970|NCT00751829|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
40975971|NCT00751829|DRUG|nitrendipine + hydrochlorothiazide, if necessary|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
41140795|NCT04750902|DRUG|8.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
40975972|NCT00483223|DRUG|Cisplatin|Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
41140796|NCT00774826|DRUG|R-CVP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
41140797|NCT00774826|DRUG|R-CHOP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
40975973|NCT00483223|DRUG|carboplatin|Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
40975974|NCT01066533|OTHER|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
41140798|NCT00774826|DRUG|R-FM|Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
41140799|NCT00824057|DRUG|AZD6280|oral
41140800|NCT00824057|DRUG|Midazolam|oral
41140801|NCT00824057|DRUG|Caffeine|oral
41300546|NCT01959867|OTHER|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
41300547|NCT01652248|PROCEDURE|Cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
41459829|NCT03501420|OTHER|PSC questionnaire|All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.
41459830|NCT03501420|OTHER|PRFs|PRFs will be completed by the physicians for seven of their consulting pSS subjects.
41459831|NCT01889797|BIOLOGICAL|Arm A: Rituximab|Rituximab 375 mg/m² IV x 4 weekly doses.
41459832|NCT01889797|BIOLOGICAL|Arm B: GA101|GA101 1,000 mg (flat dose) IV x 4 weekly doses.
41459833|NCT01219140|DIETARY_SUPPLEMENT|2 POMx Capsules|2 POMx Capsules daily
41459834|NCT01219140|DIETARY_SUPPLEMENT|2 placebo Capsules|2 placebo Capsules daily
41459835|NCT03079427|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks
41459836|NCT03079427|DRUG|Capecitabine|Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
40771770|NCT01215331|DRUG|Metformin, glyburide and insulin|"Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.~Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.~Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents."
41300548|NCT00210080|DRUG|Uridine 5'-Triphosphate (UTP) Solution for Inhalation|
41300549|NCT06421415|DRUG|Allergen Immunotherapy Extract|Patients will be treated as usual. The study is an observation of the long term effect of the treatment
41459837|NCT02480608|DRUG|Imatinib|
41459838|NCT02480608|DRUG|Hydroxyurea|
41459839|NCT06331650|DRUG|cadonilimab|Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
41459840|NCT01426087|DRUG|Somatostatin|giving stilamin 250ug/h after endoscopic therapy for 5 days
41459841|NCT01426087|PROCEDURE|endoscopic therapy|gastroscope plus EIS/EVL/HI
41459842|NCT06117241|BEHAVIORAL|IMAGINE HEALTHY|An anti-inflammatory nutrition program including cooking classes, physical activity, and stress reduction.
41459843|NCT01475487|PROCEDURE|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
41459844|NCT05967936|DRUG|Bupivacaine Injection|evaluation of pain by using two different types of local anesthesia
41459845|NCT03530306|DEVICE|PS1-PS4|Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
41459846|NCT03530306|DEVICE|PS6-PS10|Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
40771771|NCT06070376|DEVICE|Fully Covered Esophageal Prosthesis (FC-SEMS)|The placement of the Fully Covered Esophageal Prosthesis (FC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
40771772|NCT06070376|DEVICE|Partially Covered Esophageal Prosthesis (PC-SEMS)|The placement of the Partially Covered Esophageal Prosthesis (PC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
40771773|NCT02878785|DRUG|Decitabine|DNA methyltransferase inhibitor
40975975|NCT01066533|OTHER|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
41459847|NCT03530306|DEVICE|PS7-PS4|Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
41459848|NCT03530306|DEVICE|PS9-PS6|Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
40975976|NCT04219553|BEHAVIORAL|Antimicrobial stewardship|The multifaceted AMS intervention includes pharmacist education, a clinical decision support tool, a parent/guardian questionnaire, and individualized monthly audit and feedback with each pharmacist.
40975977|NCT04219553|OTHER|Comparator (no intervention)|No active intervention
40975978|NCT05778825|DRUG|Oral Minoxidil|minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day
40975979|NCT05778825|OTHER|Placebo|placebo for 4 months
40975980|NCT01285674|DRUG|Intra-tympanic Cisplatinum|Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
40975981|NCT01627522|PROCEDURE|TURP|Transurthral resection of prostate
40771774|NCT02878785|DRUG|talazoparib|poly ADP ribose polymerase (PARP) inhibitor
40975982|NCT05240053|OTHER|enhanced recovery programe|Early postoperative analgesia , early oral intake , early mobilization , early removal of nasogastric tube \& drains if any. The patients in this group started clear fluid once they awaked from anesthesia , a full liquid diet on first postoperative day , normal diet on second day provided that there was no vomiting or abdominal distension. The patients in this group were instructed for early ambulation \& encouraged to stay out of the bed for 4 hours on first day postoperative , 6 hours in following day , 8 hours on subsequent days. Also they were encouraged to walk the length of 3 meters once on first day postoperative , twice on day 2 \& three times on subsequent days. Regarding analgesia in this group postoperatively , they were received fentanyl via an epidural catheter.
40975983|NCT04887714|OTHER|Mask|Mask wearing
40975984|NCT02597075|OTHER|standard therapy + physical activity program|
40975985|NCT02597075|OTHER|standard therapy|
40975986|NCT04068662|BEHAVIORAL|Pregnant Moms' Empowerment Program|The Pregnant Moms' Empowerment Program is a five session group therapy program designed for pregnant women with a recent history of exposure to intimate partner violence. One session is administered each week with a duration of 2 hours each, for a total of ten contact hours across the course of the intervention. Intervention topics includes safety planning, social support, resilience, psychoeducation about intimate partner violence, cognitive and behavioral strategies for remediating distress, infant sleep and breastfeeding, responsive parenting, and co-parenting.
40975987|NCT04068662|BEHAVIORAL|Nondirective Support Group|Participants in the non-directive support group condition participate in groups of the same size and with the same total contact time as women in Intervention 1. In contrast to the structured, manualized content delivered as a part of the Pregnant Moms' Empowerment Program, however, group leaders in this condition facilitate open conversation on topics that women identify together as a group.
40771775|NCT06569550|DEVICE|Real Repetitive Transcranial Magnetic Stimulation|"Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The active side is an actively cooled figure-of-eight coil with an outer diameter of 65mm.~Intensity is 80% of resting motor threshold. It is kept the same across all 5 sessions.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France )."
40771776|NCT06569550|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|"Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The sham side does not deliver a magnetic pulse to the participant.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France )."
40975988|NCT01581931|DRUG|Linagliptin/metformin|FDC
40975989|NCT01581931|DRUG|Metformin|single tablet Metformin
40975990|NCT01581931|DRUG|Linagliptin|single tablet Linagliptin
41140802|NCT05856409|DIAGNOSTIC_TEST|68Ga-FAPI|\[68Ga\]-FAPI is tumor imaging agent for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF)
41140803|NCT00786344|BEHAVIORAL|Lifestyle Redesign|"For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects."
41140804|NCT06015659|DRUG|Zentalis|Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.
41140805|NCT06015659|DRUG|Gemzar|Nucleoside metabolic inhibitor, per standard care via intravenous infusion.
41140806|NCT02322489|DEVICE|Microcurrent Therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
41140807|NCT02322489|DEVICE|Sham microcurrent therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
41140808|NCT06297603|DRUG|Retatrutide|Administered SC
41140809|NCT06297603|DRUG|Placebo|Administered SC
41140810|NCT05968885|PROCEDURE|Intradetrusor Botox® (onabotulinumtoxinA) injection|The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.
41140811|NCT05968885|DRUG|Combine Mirabegron and Solifenacin.|Combination pharmacotherapy
41140812|NCT00785499|BEHAVIORAL|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
41140813|NCT00917098|BEHAVIORAL|Behavior Therapy|Eight weekly sessions during Phase 1 and four sessions every other week during Phase 2; participants will work on implementing habit reversal techniques with psychoeducation, cognitive restructuring, and relaxation, if necessary
41140814|NCT00917098|BEHAVIORAL|Supportive Counseling|Eight weekly sessions during Phase 1 of psychoeducation, support, and emotion management related to trichotillomania and other stressors
41140815|NCT03229291|DRUG|SM04755|SM04755 is a small molecule inhibitor of the Wnt pathway.
41140816|NCT03229291|DRUG|Vehicle|Same formulation as topical SM04755 solution, without SM04755 included.
41140817|NCT02160496|BEHAVIORAL|Weight loss interventional study with 20% protein-diet|
41140818|NCT02160496|BEHAVIORAL|Weight loss interventional study with 27% protein-diet|
41140819|NCT02160496|BEHAVIORAL|Weight loss interventional study with 35% protein-diet|
41147186|NCT04047355|DRUG|Propranolol|Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.
41147187|NCT04828668|DIETARY_SUPPLEMENT|Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)|Hemp seed oil
40975991|NCT06239376|PROCEDURE|GnRHa+AI - AC|"Pre-treatment includes two doses of 3.75 mg GnRH agonist (Diphereline®, Ipsen, France) on days 2-4 of the menstrual cycle and 28 days later, along with daily 2.5 mg Letrozole (Femara®, Novartis, Switzerland) starting from the first agonist injection.~Endometrial preparation in an artificial cycle begins 28 days after the second agonist injection. Patients take 6 mg/day of oral estradiol valerate (Valiera; Abbott) at least 9 days before progesterone. Endometrial thickness is monitored starting on the 10th day. When it reaches ≥7 mm, 400 mg twice times a day of vaginal progesterone (Cyclogest®, Actavis, UK) is initiated. Embryo transfer aligns with progesterone initiation, taking the embryo's stage into account. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA."
40975992|NCT06239376|PROCEDURE|Artificial cycle|The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises estradiol 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
40771777|NCT04512690|DEVICE|Epidural electrical stimulation (EES) of the cervical spinal cord|All participants enrolled in this group will undergo a surgical procedure to implant a system which provides epidural electrical stimulation (EES) of the cervical spinal cord. Researchers will quantify the ability of EES to recruit arm and hand muscles and produce distinct kinematic movements. The implant will be removed after less than 30 days.
40771778|NCT03320005|OTHER|Resistance training group|Resistive exercises for legs and arms
40771779|NCT04907955|PROCEDURE|phacoemulsification with implantation of presbyopia correcting IOL|cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL
40771780|NCT05640557|OTHER|Physical Exercises|An original, noninvasive exercise program
40771781|NCT02919618|RADIATION|stereotactic body radiotherapy (SBRT)|(Cardiac ablative radiotherapy)
40771782|NCT04139291|OTHER|Complex decongestive therapy phase 1|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
40771783|NCT02825667|OTHER|Physiotherapy sessions|Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
40975993|NCT06452654|DRUG|Comirnaty Injectable Product|Vaccination
40975994|NCT06452654|DRUG|Sodium Chloride 0.9% Inj|Vaccination
40975995|NCT05673512|COMBINATION_PRODUCT|Injection of IAH0968 + CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
40975996|NCT05673512|COMBINATION_PRODUCT|PLACEBO+CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
40975997|NCT00230997|DRUG|Galantamine|
40975998|NCT05113472|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Patients who were administered any dose of the Pfizer-BioNTech COVID-19 vaccine.
41459849|NCT04254809|BEHAVIORAL|Re-Evaluating Suicidal Thoughts|Re-Evaluating Suicidal Thoughts (REST) is a is a computerized intervention designed to mitigate the experiential avoidance of suicidal thoughts. Over the course of approximately 30 minutes, individuals are provided with psychoeducation regarding the incidence rate, origin, conceptualization, and misconceptions of suicidal thoughts. Empirical evidence is presented to provide a scientific understanding of suicidal thoughts, and is aided through the use of metaphors to make concepts more accessible to viewers. REST draws from therapeutic strategies rooted in cognitive behavioral therapy (CBT) and Acceptance and Commitment Therapy (ACT) to further suggest tips for accepting (cp. approving of) the occurrence of suicidal thoughts, and introduces mindfulness and acceptance strategies for coping with them.
40975999|NCT01995240|DRUG|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
40976000|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
40976001|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
40976002|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
40976003|NCT01331798|DEVICE|Cohera TissuGlu Surgical Adhesive|TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.
40976004|NCT01331798|PROCEDURE|Control- Standard of care|Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
40976005|NCT04508478|BEHAVIORAL|Aerobic training|Aerobic training
40771784|NCT06529627|PROCEDURE|Long Gn-RH agonist protocol - Intracytoplasmic Sperm Injection|pituitary downregulation with GnRH agonist - ovarian stimulation with exogenous gonadotropin - hCG adminstration as trigger of oocyte maturation Oocyte retriveal via transvaginal ultrasound guided aspiration embryo transfer progesterone as luteal phase support
40771785|NCT03131479|DRUG|LIK066|LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
40771786|NCT01538199|DEVICE|Near-infrared radiation via Transcranial LED Therapy|"The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject."
40771787|NCT01538199|DEVICE|Sham device|The sham device does not emit near-infrared radiation.
40771788|NCT05456087|DRUG|incobotulinumtoxin A|Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area
41300550|NCT05687201|DIAGNOSTIC_TEST|Non-enhanced CT scan、Nuclear Magnetic Resonance (MRI)|Non-surgical patients were followed up by CT on days 1 and 5-7 after ICH, and by CT or MRI on day 5-7. Surgical patients were followed up by CT before surgery and then transferred to the operating room. The first postoperative follow-up CT scan was performed on the second day after surgery, and the second postoperative CT scan was performed on the third day after surgery. Some patients need a third or even a fourth CT follow-up after surgery. The CT scan can be repeated at any time if the patient has neurologic deterioration.
41300551|NCT05794152|OTHER|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
41300552|NCT05794152|OTHER|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
41300553|NCT05794152|OTHER|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
40771789|NCT03132467|BIOLOGICAL|Durvalumab|Given IV
40771790|NCT03132467|BIOLOGICAL|Tremelimumab|Given IV
40771791|NCT05031832|DIAGNOSTIC_TEST|HIV test|HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status
41300554|NCT02039336|DRUG|Dacomitinib|
41300555|NCT02039336|DRUG|PD-0325901|
41300556|NCT02039336|DRUG|Docetaxel|
40771792|NCT00668642|DRUG|Dutasteride|0.5 mg capsule given orally on daily basis
41300557|NCT01883882|BEHAVIORAL|opioid taper support|Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
41300558|NCT04352634|OTHER|Exposure to the SARS-CoV-2 and its consequences|This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences
41300559|NCT01370278|OTHER|Normal Saline|Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
41300560|NCT01370278|OTHER|Sodium Bicarbonate|4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
41300561|NCT03907735|OTHER|Myometrial tissue sample collection|Myometrial tissue samples by core needle biopsy under ultrasound guidance
41300562|NCT00633139|BIOLOGICAL|Recombinant human Arylsulfatase A (rhASA)|intravenous infusion, every other week for 26 weeks
41300563|NCT03245671|DRUG|Kenalog Injectable Product|80 mg of Kenalog will be used.
40771793|NCT00668642|DRUG|Placebo|Identical placebo
40771794|NCT03323255|DEVICE|repeated transcranial magnetic stimulation continuous theta-burst stimulation|cTBS
40771795|NCT03323255|DEVICE|SHAM repeated transcranial magnetic stimulation|SHAM stimulation
40771796|NCT01828060|DIETARY_SUPPLEMENT|Jobelyn™|Sorghum bicolor leaf sheath extract
40771797|NCT01828060|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
40771798|NCT02314923|BIOLOGICAL|V920 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.
40771799|NCT02314923|OTHER|Placebo|0.9% Saline
40771800|NCT05507242|BIOLOGICAL|Tezepelumab|Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously
40771801|NCT05507242|OTHER|Placebo|Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)
41300564|NCT03245671|DRUG|Decadron Phosphate, Injectable|15 mg of Decadron will be used.
41300565|NCT03245671|PROCEDURE|Epidural Steroid Injection|Patient will receive epidural steroid injections of either Kenalog or Decadron.
41300566|NCT05702684|OTHER|electronic Holistic Needs Assessment (eHNA)|eHNA to be completed within 31 days of diagnosis (standard care). ARC clinic previously offered 6-24 months post-diagnosis.
40771802|NCT03919162|DRUG|PQ912|PQ912 150 mg tablets
40771803|NCT03919162|OTHER|Placebo|Placebo tablets to mimic PQ912 150 mg tablets
40771804|NCT04830085|PROCEDURE|Hysterectomy|Hysterectomy (abdominal, vaginal or laparoscopic)
40976006|NCT04508478|BEHAVIORAL|Resistance training|Resistance training
40976007|NCT04508478|BEHAVIORAL|Control physical exercise|Control physical exercise
41459850|NCT04254809|BEHAVIORAL|Healthy Social Living|To control for potential effects of time and presentation of educational material on study outcome variables, participants randomized to the control intervention will complete a computerized psychoeducation program regarding the benefits of social support networks. Across approximately 20 minutes of audiovisual slides, participants are informed of the ways in which social connections buffer against loneliness and facilitate social learning, provided tips for expanding and maintaining their social network, and administered a brief quiz to assess for comprehension.
41459851|NCT00907205|DRUG|SF1126|Dose Escalating with 3+ patients in each cohort
40976008|NCT00925912|PROCEDURE|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
40976009|NCT00925912|PROCEDURE|Perianal block|0.25% bupivacaine injected at perianal region
41459852|NCT05311150|DEVICE|Narrow band imaging bronchoscopy guided endobronchial biopsy|Examination of the airways will be performed with the narrow band imaging mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
40976010|NCT03500627|DRUG|OP-101|Intravenous Injection of OP-101 in healthy volunteers.
41300567|NCT03554538|BEHAVIORAL|Web app exercises program|Exercise on an evidence based program for shoulder pain with web app animations to improve performance and adherence
41300568|NCT03554538|BEHAVIORAL|Exercise program|Exercise on an evidence based program for shoulder pain
41459853|NCT05311150|DEVICE|White light bronchscopy guided endobronchial biopsy|Examination of the airways will be performed with the white light bronchoscopy mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
40976011|NCT01948622|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
40976012|NCT01948622|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
41140820|NCT05434507|DEVICE|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
41140821|NCT01799005|DIETARY_SUPPLEMENT|Flavanol (410 mg)|
41140822|NCT01799005|DIETARY_SUPPLEMENT|Control (no flavanols)|
41459854|NCT04194151|DRUG|Propofol Injection|1, 1.5 or 2 mg/kg of propofol according to the subgroup
40976013|NCT02835820|DIETARY_SUPPLEMENT|Ketogenic Diet|12 week delivery of all meals/snacks (eucaloric) prepared by a registered dietician.
40976014|NCT04541940|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
40976015|NCT04541940|OTHER|In-person Rehabilitation Therapy|Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
40976016|NCT04019002|DRUG|Hyperpolarized 13C Pyruvate|Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
40976017|NCT00447161|DRUG|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10\^9 of Bacillus clausii spores, orally suspension in water
40976018|NCT00447161|DRUG|Placebo|Matched placebo
40976019|NCT01014650|DRUG|GLYX-13|single IV or SC dose
40976020|NCT01014650|DRUG|IV normal saline|Single IV dose of normal saline
40976021|NCT02240251|OTHER|Prospective Chart Review|The laser assisted IVC filter removal procedure itself is not part of this study. This is a prospective chart review for patients undergoing this procedure.
41140823|NCT06500195|PROCEDURE|implantation of the hybrid instrumentation system|Surgery corrections were performed using the hybrid instrumentation system (screws and bands).
41140824|NCT06252454|DRUG|Furosemide 40 mg|Furosemide will be used to block C fibers in the lungs, thus lowering intensity of sensation of dyspnea.
41140825|NCT06252454|DRUG|Levodropropizine|Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation
41140826|NCT06252454|OTHER|Placebo - saline|Placebo will be used as a comparator
41140827|NCT05813522|DRUG|Furmonertinib Mesilate Tablets|160mg of Furmonertinib mesilate tablets (given as four 40mg tablets) administered orally once daily
41300569|NCT04674852|DEVICE|Research Marker|The research marker is a cylindrical-shaped marker made of an FDA-approved material that can be seen by ultrasound.
41300570|NCT06141213|DIAGNOSTIC_TEST|Ultrasound screening|Ultrasound screening for fetal membrane thickness at 18-24 weeks of pregnancy.
41300571|NCT05156203|DRUG|T-1301 Capsules|T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
41300572|NCT01830153|DRUG|RAD001|
40976022|NCT01454622|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
40976023|NCT01454622|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
41140828|NCT05383586|OTHER|Creative Music Therapy|Creative Music Therapy is provided during kangaroo-care. It is an individualized, family- centered approach offering infant-directed humming and singing accompanied with the monochord.
41300573|NCT05183958|RADIATION|Radiotherapy group|Stereotactic body radiotherapy (SBRT, 8Gy/time, 3 -5 times, if other segmentation schemes are used, recommend BED10 \>60Gy) or conventional fractional radiotherapy (parts that are not suitable for SBRT, the total dose is more than 30Gy); the primary lesion should be treated with conventional fractional radiotherapy with a dose of 4000cGy or more;
41300574|NCT05183958|DRUG|Camrelizumab|4 cycles for combined therapy. Camrelizumab maintenance.
41300575|NCT05183958|DRUG|Chemotherapy|4 cycles for combined therapy.
41300576|NCT01585129|DRUG|Postpartum Antibiotics|Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
41300577|NCT01585129|DRUG|No postpartum antibiotics|Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
40976024|NCT00760578|DRUG|Placebo|Once daily, oral
40976025|NCT00760578|DRUG|Pioglitazone|Once daily, oral
40976026|NCT00760578|DRUG|MSDC-0160 90 mg|Once daily, oral
40976027|NCT00760578|DRUG|MSDC-0160 220 mg|Once daily, oral
40976028|NCT03066089|DRUG|Fenfuro|
40976029|NCT01860651|BEHAVIORAL|Web-monitoring|During the E-health intervention, symptoms and FC are monitored closely through the web-program and treatment will be initiated by symptoms and elevated FC.
40976030|NCT00911053|DRUG|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
40976031|NCT00911053|BEHAVIORAL|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
40976032|NCT00911053|BEHAVIORAL|Light|Subjects will be exposed to light.
40771810|NCT01927913|DRUG|SPD602|32, 50 or 75 mg/kg/day BID, capsule
40771811|NCT01927913|DRUG|Deferasirox|Per approved country specific label
40771812|NCT04986150|OTHER|Resistance exercise|Acute leg-based resistance exercise bout performed at 80% 1RM (4 sets to volitional failure on leg extension and leg curl machines)
40771813|NCT05115773|PROCEDURE|Intraligamentary anaesthesia|one tooth anaesthesia by 2 or 4 points intraligamentary injection
40771814|NCT05115773|PROCEDURE|Mandibular anaesthesia|Inferior alveolar nerve block by direct standart method
40771815|NCT01394185|DRUG|Dronabinol 120mg/day|Participants receive 40mg dronabinol 3 times daily
41300578|NCT04615689|OTHER|The collection of feces|When the infants will be diagnosed with urinary tract infection, feces will be collected. Feces will be collected from healthy infants with informed consent.
40771816|NCT01394185|DRUG|Placebo|Participants receive placebo
40771817|NCT01394185|DRUG|Dronabinol 240mg/day|Participants receive 80mg dronabinol 3 times daily
40771818|NCT05374616|GENETIC|Observation|Retrospective and prospective Natural History Study
40771819|NCT06407011|OTHER|Control|The CON group did not have any intervention but usual care.
40771820|NCT06407011|OTHER|Swedish massage prior circuit breathing training group (SBT)|Participants Swedish massage prior circuit breathing training 3 days/week, 12 weeks. They perform Swedish massage using techniques such as stroking, kneading, and tapping the upper muscle area of the body for 20 minutes per day. Then, they do circuit breathing exercises for about 30 minutes per day, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
40771821|NCT06407011|OTHER|Circuit breathing training group (CBT)|Participants perform circuit breathing exercises for about 30 minutes per day, 3 days/week, 12 weeks, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
40771822|NCT02754297|DRUG|177Lu-Octreotate|"* The induction course will consist in 4 cycles at 8-10 weeks intervals.~* Concomitant amino acids will be administered for renal protection.~* Intra-arterial LuTate administration will be allowed in suitable cases.~* Dosimetry will be based on quantitative SPECT/CT imaging.~* In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles."
40976033|NCT04465331|OTHER|Questionnaires|completion of Exercise Adherence Rating Scale (EARS)
41300579|NCT04446793|DRUG|Onvansertib|15 mg/m\^2 will be administered orally on Day 1 to Day 5 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
41300580|NCT04446793|BIOLOGICAL|Bevacizumab|5 mg/kg will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
41300581|NCT04446793|DRUG|FOLFIRI|FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
40771823|NCT03828604|BEHAVIORAL|Stress; Trier Social Stress Task|Standardized acute psychosocial stressor
40771824|NCT03828604|BEHAVIORAL|Placebo Trier Social Stress Task|Active control version of the TSST
40771825|NCT02302287|DIETARY_SUPPLEMENT|Ketoacids diet|Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
40771826|NCT02302287|OTHER|Mediterranean diet|Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
40771827|NCT02302287|OTHER|Free diet|Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
40771828|NCT02553733|DRUG|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
40771829|NCT02553733|DRUG|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
40771830|NCT03463655|DIAGNOSTIC_TEST|cirrhotic albumin|Ascites puncture
40771831|NCT03463655|DIAGNOSTIC_TEST|serum albumin|blood punctures
40976034|NCT04019665|OTHER|MMSE (mini mental state examination)|mini mental state examination takes place during the consultation. The consultation is a general or post-emergency geriatric consultation.
40976035|NCT04019665|OTHER|SAGE (Self-Administered Gerocognitive Exam)|SAGE test contains a series of questions that assess the cognitive functioning. Sage was developed by the Ohio State University Wexner Medical Center. it's an online, at-home, self-screening dementia tool that has been scientifically evaluated, and it's demonstrated good results in accurately identifying cognitive deficits.
40976036|NCT03684395|DRUG|DOACs: Rivaroxaban, Dabigatran, Apixaban|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
40771832|NCT05921786|DEVICE|Electrophysiological system|Electrophysiological system is used for examining voltage variation in biological samples. And multiphoton microscopy is a common type of nonlinear optical microscope.
40771833|NCT05921786|DEVICE|Multiphoton microscope|Multiphoton microscope acquires high-resolution image based on nonlinear optics and can be used for detect biological specimens.
40771834|NCT05961527|DRUG|MDMA|Initial dose of 120 mg MDMA HCL and optional supplemental dose of 60 mg MDMA HCL at 1.5 to 2 hours after first dose
40771835|NCT05961527|BEHAVIORAL|Group Therapy|Standardized group psychotherapy performed by therapist team in combination with non-directive MDMA therapy
40771836|NCT01712373|DRUG|Ginseng|it is kind of drug
40976037|NCT03684395|DRUG|Standard of care (Warfarin)|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
40976038|NCT01588808|BEHAVIORAL|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
40976039|NCT01793649|DRUG|GS-5737|A single dose of GS-5737 in 2.8% saline
40976040|NCT01125384|OTHER|additional swabbing|physician swabs patient's throat according to standard rules before referral of the patient to throat swabbing by nurse.
40976041|NCT01813591|DRUG|H.P. Acthar Gel|Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
40976042|NCT04648072|PROCEDURE|Adductor Canal Block|As previously described.
40976043|NCT04648072|PROCEDURE|Periarticular Injection|As previously described.
40976044|NCT00007657|PROCEDURE|Intensive medical therapy|
40976045|NCT00007657|PROCEDURE|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy|
40976046|NCT02248155|DRUG|Pramipexole|
40976047|NCT01255657|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
40976048|NCT05860803|DEVICE|LungTrainers|A training device that provides a variable resistance against which users breathe out. Users breathe through a plastic mouthpiece that is connected to an acrylic cylinder via rubber tubing. The mouthpiece has several small holes of various diameters and up to three stainless steel weights (half-weight increments) can be inserted into the acrylic tube. With each breath-out, the user exhales against the resistance provided by the weight inserts, and each inspiration (i.e., breath-in) is unresisted. During each resisted exhalation, the weight inserts are 'lifted' within the acrylic tube depending on the level of expiratory pressure generated by the participant.
40976049|NCT05860803|BEHAVIORAL|LungTrainers Pulmonary Rehabilitation regime|Series of different exercises using the LungTrainers device 3-5 days per week for approximately 10 weeks. Exercises complete in one long session (20-30 minutes) or be broken down into multiple shorter sessions (e.g., 3 x 10 minutes). A health coach will be assigned to guide participants through the LT-PR program.
40976050|NCT04233645|OTHER|5-minute educational video|The 5-minute educational video depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
40976051|NCT04233645|OTHER|Usual Care|The groups will be given a standard scripted verbal and identical written instructions as per usual care.
40976052|NCT03687489|DEVICE|Abdominal Aortic Aneurysm Stent Graft System|Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.
41140829|NCT03005106|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
41140830|NCT03005106|PROCEDURE|Autograft|The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
40976053|NCT03920033|RADIATION|Salvage radiation therapy|Salvage radiation therapy for biochemical recurrence
40976054|NCT02464462|DIETARY_SUPPLEMENT|vitamin D3 and calcium|1800 IU vitamin D3 plus 720 mg Calcium
40976055|NCT02464462|OTHER|Placebo|Rice powder pills
40976056|NCT00398060|BEHAVIORAL|Cognitive-behavioral life-style counseling|
41140831|NCT05493488|BIOLOGICAL|DBI-001 Gel|Topical application of DBI-001 gel on foot/feet affected with tinea pedis
41300582|NCT02041351|DRUG|Docetaxel|evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
40771837|NCT01712373|DRUG|Placebo|it is placebo
40771838|NCT06570980|DRUG|sulfonylurease with metformin, DPP4 inhibitors with Metformin|Oral hypoglycemic agents
40976057|NCT02079181|RADIATION|fluorine F 18 d-FMAU|Given IV
40976058|NCT02079181|PROCEDURE|positron emission tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
40976059|NCT02079181|PROCEDURE|computed tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
40976060|NCT01708681|DIETARY_SUPPLEMENT|Lean seafood|
40976061|NCT01708681|DIETARY_SUPPLEMENT|Meat, egg, milk|
40976062|NCT00938639|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
40976063|NCT00938639|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
40976064|NCT00349804|OTHER|cool dry air|cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
40976065|NCT05815940|BEHAVIORAL|Mobile Application|a mobile application was developed that can be used by children with urinary incontinence and their parents.
40976066|NCT03495362|DIETARY_SUPPLEMENT|Yeast Beta-glucan|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
40976067|NCT03495362|OTHER|Placebo|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
41140832|NCT05493488|BIOLOGICAL|DBI-002 Gel|Topical application of DBI-002 gel on foot/feet affected with tinea pedis
41140833|NCT05493488|BIOLOGICAL|Aqueous Gel|Topical application of Aqueous gel on foot/feet affected with tinea pedis
41140834|NCT02793557|DRUG|FOL-005|Intradermal injection of 50 μl solution
41140835|NCT02793557|OTHER|Placebo|
41147188|NCT01131325|DRUG|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
40976068|NCT01723592|DIETARY_SUPPLEMENT|Probiotics|Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)
40976069|NCT01723592|DIETARY_SUPPLEMENT|Oral lactose placebo|Placebo
40976070|NCT00295841|DRUG|clofarabine|
40976071|NCT00295841|DRUG|cytarabine|
40976072|NCT03728660|DEVICE|Virtual bioptic magnification with large field of view|The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).
40976073|NCT03728660|DEVICE|Full field magnification with small field of view|Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification
40976074|NCT00262808|BIOLOGICAL|sargramostim|
40976075|NCT00262808|DRUG|fluorouracil|
40976076|NCT00262808|DRUG|leucovorin calcium|
40976077|NCT00262808|DRUG|oxaliplatin|
40976078|NCT00262808|PROCEDURE|adjuvant therapy|
40976079|NCT00262808|PROCEDURE|conventional surgery|
40976080|NCT00262808|PROCEDURE|neoadjuvant therapy|
40976081|NCT04557371|OTHER|Serum|Participants will topically apply the serum to the face as per normal home use application in place of their current facial serum product.
40976082|NCT04557371|OTHER|Lotion|Participants will topically apply lotion to the face as per normal home use application in place of their current facial lotion product.
40976083|NCT04557371|OTHER|Cream|Participants will topically apply cream to the face as per normal home use application in place of their current facial cream product.
41300583|NCT03389126|DRUG|Avelumab|Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity
40976084|NCT04138654|DIETARY_SUPPLEMENT|Processed meat product|300 grams per day during 2 weeks
40976085|NCT04138654|DIETARY_SUPPLEMENT|White meat wash-out|300 grams per day during 2 weeks
40976086|NCT04138654|DIETARY_SUPPLEMENT|Processed meat products enriched with natural compounds|300 grams per day during 2 weeks
40976087|NCT04138654|DIETARY_SUPPLEMENT|Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds|3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week
40976088|NCT02407704|DRUG|Venlafaxine XR|
40976089|NCT02407704|OTHER|Aerobic Exercise|
40976090|NCT02407704|DRUG|Lorazepam|Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
41147189|NCT03785756|DRUG|Ibuprofen 300 mg Oral Tablet|2 × 300 mg tablets at Hours 0 and 12
41300584|NCT03479879|DRUG|Estradiol|Estradiol
41300585|NCT03479879|DRUG|Placebo Oral Tablet|Placebo
40976091|NCT00553514|DRUG|AS900672-Enriched 10 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 10 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
41300586|NCT03479879|DRUG|Misoprostol|Misoprostol
41459855|NCT06381687|BEHAVIORAL|A multi-component, multi-level programme (MoviMusi)|"The MoviMusi program will be designed and implemented in each city by the 12 ECEC centres in the intervention group. In addition, the intervention programme will aim to address the main barriers and facilitators identified during the first year (baseline assessment) in relation to movement and music curricular practices. The programme will have three axes:~(1) Training. Educators and families will actively participate in a series of seminars and training workshops on the promotion of PA as a healthy behaviour and the use of music as a didactic resource to strengthen holistic education both inside and outside ECEC. (2) Participation. Each ECEC institution will be supported as they design a movement and music programme to offer children better opportunities to learn about the body, its possibilities of action, and musical skills.(3) Implementation. The specific actions of the MoviMusi Programme will be put into practice in each ECEC institution."
41459856|NCT02416934|DRUG|Treatment 1; Dexamethasone|Dexamethasone IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
40976092|NCT00553514|DRUG|AS900672-Enriched 20 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 20 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
40976093|NCT00553514|DRUG|AS900672-Enriched 30 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 30 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
40976094|NCT00553514|DRUG|AS900672-Enriched 40 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 40 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
40976095|NCT00553514|DRUG|Follitropin alfa 75 international unit (IU)|Follitropin alfa (Gonal-f®) 75 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 14 (S14) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 10, 20, 30 and 40 mcg will also receive daily dose of follitropin alfa 75 IU subcutaneously from Stimulation Day 7 (S7) up to S14. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
40976096|NCT00553514|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to \[=\<\] 3 follicles with a mean diameter of greater than or equal to \[\>=\] 14 millimeter \[mm\], and one or two of these follicles with a diameter of \>= 17 mm).
40976097|NCT03013478|BEHAVIORAL|Standard Treatment As Usual (TAU)|Treatment normally offered at this primary care clinic
40976098|NCT03013478|BEHAVIORAL|CBT4CBT program|
40976099|NCT02071251|PROCEDURE|Prospective wound complication protocol|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
40976100|NCT03590106|BEHAVIORAL|Peer Recovery Support Program|See above
41140836|NCT03054766|PROCEDURE|Ranibizumab combined macular laser|subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
41140837|NCT03054766|DRUG|Ranibizumab|all subjections received 3+PRN ranibizumab injections by BCVA stabilization
41140838|NCT06153784|DRUG|Hydroxyurea and Thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
41140839|NCT01739738|DEVICE|Ureteral Stent|patients who need to receive stent as per standard of care
41140840|NCT01124045|DRUG|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
41140841|NCT01124045|DRUG|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
41140842|NCT02327806|DEVICE|pulsed electromagnetic field therapy|
40976101|NCT00836290|BEHAVIORAL|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
41140843|NCT02239991|PROCEDURE|Thromboelastometry|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
41140844|NCT04522661|PROCEDURE|Vitrectomy|Vitrectomy within 48 hours of randomisation
41140845|NCT04522661|PROCEDURE|Intravitreal antibiotics|Intravitreal Antibiotics at 48 hours
41140846|NCT02418286|OTHER|expose to any drugs or procedures based on traditional Korean medicine theory|There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
41140847|NCT01602302|DRUG|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
41140848|NCT03014726|COMBINATION_PRODUCT|Urotronic Drug Coated Balloon (DCB)|Urotronic Drug Coated Balloon (DCB) is a catheter with a tapered atraumatic tip. The distal end of the catheter has a semi-compliant inflatable balloon coated with a proprietary coating containing the drug and carriers.
41140849|NCT00115167|DRUG|Placebo|Q4W
41140850|NCT00115167|DRUG|Darbepoetin alfa|Q4W
41140851|NCT02619825|DEVICE|Echography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
41140852|NCT02619825|DEVICE|Elastography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
41140853|NCT00848094|RADIATION|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
40771839|NCT03713450|DEVICE|Control with imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
40771840|NCT03713450|DEVICE|Control without imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure not using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
40976102|NCT00836290|BEHAVIORAL|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
41300587|NCT05756621|DRUG|Ketamine|"Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight \> 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight \< 50 kg), followed by gradual reduction according to clinical evolution."
40976103|NCT05585697|OTHER|None - crossectional|None - crossectional
40976104|NCT02657174|DEVICE|low level laser in auricular acupuncture points|40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.
40976105|NCT02657174|DEVICE|low level laser device off in auricular acupuncture points|40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
40976106|NCT02891083|DRUG|Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
40976107|NCT02891083|RADIATION|Adjuvant radiotherapy|"Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)~Dose: 50Gy~Technology: strong tone~Segmentation: conventional segmentation 2Gy/d"
41300588|NCT05756621|DRUG|Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel|Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
40771841|NCT01626742|OTHER|Ready to Drink Flavored Beverage|2 servings a day
40771842|NCT01626742|OTHER|Ready to drink flavored beverage w/ AN 777|2 servings a day
40771843|NCT06283966|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension
40771844|NCT06283966|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium and formoterol fumarate pressurized inhalation suspension
40976108|NCT02891083|OTHER|Control group (Surgery alone)|
41140854|NCT00848094|RADIATION|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
41140855|NCT03218085|DRUG|Tenofovir|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
41300589|NCT04706182|PROCEDURE|Platelet-rich fibrin (PRF)|Platelet rich fibrin (PRF) serves as a structural reservoir of cytokines such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), platelet factor 4 (PF4) and vascular endothelial growth factor (VEGF) which aids in healing and preventing infection. PRF will be prepared as recommended by the manufacturer (Intra-Lock International) by centrifuging 20 mL of the subject's venous blood for 12 minutes at 2700 rpm, followed by compression. The fibrin clot will then be applied to the SSO site prior to fixation. The blood draw for the PRF will be performed approximately 15 minutes prior to fixation of the mandible. 20 mL will be drawn for each PRF side treated. The blood venous draw will be from the subject's arm or from an existing intra-venous line.
41459857|NCT02416934|DRUG|Treatment 0; Saline placebo|Saline (placebo) IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
41459858|NCT02036749|PROCEDURE|nerve block|quadratus lumborum block
41459859|NCT03076645|BEHAVIORAL|Facilitator support and education|Group engaged with facilitator support and education
41459860|NCT02171897|PROCEDURE|Osteosynthesis|
40771845|NCT00195780|DRUG|Divalproex Sodium (Depakote ER)|
40771846|NCT02663362|OTHER|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|Outside standard MR instrumentation there will be no interventions.
41459861|NCT02171897|PROCEDURE|Total hip replacement|
41459862|NCT03658434|RADIATION|Palliative radiotherapy|Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
40771847|NCT04576455|DRUG|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day cycle.
40976109|NCT04894903|OTHER|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring \& preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
40976110|NCT00602706|BIOLOGICAL|sargramostim|
40976111|NCT00602706|DRUG|melphalan|
40976112|NCT00602706|PROCEDURE|autologous hematopoietic stem cell transplantation|
40976113|NCT00602706|PROCEDURE|peripheral blood stem cell transplantation|
40976114|NCT00602706|RADIATION|samarium Sm 153 lexidronam pentasodium|
40771848|NCT04576455|DRUG|Fulvestrant or an Aromatase Inhibitor (Physician Choice)|Physician choice of endocrine monotherapy (fulvestrant or an aromatase inhibitor) is taken in accordance with the local prescribing information for the respective product.
40771849|NCT04576455|DRUG|LHRH Agonist|Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
40771850|NCT04949087|PROCEDURE|Glenohumeral Injection|Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.
40976115|NCT05130177|DRUG|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.
40771851|NCT02410187|RADIATION|SBRT|10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
40976116|NCT05130177|DRUG|Domvanalimab|Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
41140856|NCT03218085|DRUG|Emtricitabine|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
41459863|NCT00001873|DEVICE|Isolex 300i plus MoAbs|
41459864|NCT01056926|BEHAVIORAL|Quit smoking|Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
41459865|NCT01056926|DRUG|Nicotine patch|Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
41459866|NCT01056926|DRUG|Placebo Patch|Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
41459867|NCT02545530|DRUG|transdermal clonidine|2.5mg/patch per week
40976117|NCT00972569|DRUG|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
40976118|NCT00972569|DRUG|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
40976119|NCT01320085|DRUG|MEK162|
41459868|NCT02383706|DEVICE|ApneaLink Air|Overnight, home polysomnography device
41459869|NCT02383706|BEHAVIORAL|Berlin Quesionnaire|OSA screening questionnaire
41459870|NCT02383706|BEHAVIORAL|Epworth Sleepiness Scale|OSA screening questionnaire
41459871|NCT02383706|BEHAVIORAL|STOP-BANG questionnaire|OSA screening questionnaire
41459872|NCT02383706|OTHER|Physical exam|Physical exam of neck, mouth and upper airway
41459873|NCT05472896|PROCEDURE|cTACE|transcatheter arterial chemoembolization with
41300590|NCT04706182|PROCEDURE|Proximal segment grooving (PSG)|Proximal segment grooving is a mechanical method to create additional space within the inferior alveolar canal to allow the IAN to rest without compression or trauma. The surgeon uses a round or acrylic bur to cautiously remove any bony spicules, and remove cancellous bone in the proximal mandibular segment. PSG will be done by using an acrylic round bur on a surgical handpiece to remove 3 to 4 mm of cancellous bone where the IAN will passively rest into prior to fixation.
41300591|NCT03581773|DRUG|Folic Acid|5 mg pr day for 12 weeks
41300592|NCT03581773|DRUG|Placebo Oral Tablet|1 placebo pill pr day for 12 weeks
40976120|NCT05209984|DRUG|ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg|Participant will receive for two (2) weeks one (01) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsule once daily + one (01) sibutramine placebo capsule 10mg; after that 2 weeks, participants will receive one (01) placebo capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) 10mg sibutramine placebo capsule; after this period, they will receive two (02) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 10mg of sibutramine and 50mg of topiramate) + a placebo capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once a day + one (one) 10mg sibutramine placebo capsule, taken once daily, for two (02) additional weeks, on the titration scheme. On the treatment period, will receive one (01) ADF Sibutramine IR/Topiramate XR 15mg/75mg capsule + one (01) Sibutramine IR 15mg placebo capsule (Sibus®) + one (01) Topiramate XR 100mg placebo capsule, once daily, for 52 weeks.
40976121|NCT05209984|DRUG|ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg|Participant will receive for two (02) weeks one (01) capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once daily + one (01) capsule of placebo sibutramine 10mg; after this initial period of 2 weeks, participants will receive (02) ADF sibutramine IR/topiramate XR 5mg/25mg capsules (totaling 10mg of sibutramine and 50mg of topiramate) + one (01) 10mg sibutramine placebo capsule, taken once daily, for two (02) weeks; after this period, they will receive three (03) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 15mg of sibutramine and 75mg of topiramate) + one (01) capsule of 10mg sibutramine placebo, taken once daily, for two ( 02) additional weeks, on titration scheme. On the treatment period, will receive one (01) Sibutramine IR 15mg capsule (Sibus®) + one (01) Topiramate XR 100mg capsule + one (01) ADF placebo capsule sibutramine IR/topiramate XR 15mg/75mg, taken once daily, taken once daily, for 52 weeks.
40976122|NCT05209984|DRUG|SIB Group Sibus (Sibutramine) 15mg|Participant will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) 5mg/25mg sibutramine ADF placebo capsule IR/topiramate XR; after this initial period, they will receive for two (02) weeks one (01) 10mg sibutramine capsule + two (02) placebo capsules of ADF sibutramine IR/topiramate XR 5mg/25mg; after this 4-week period, participants will receive one (01) 10mg sibutramine capsule and three (03) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) additional weeks. This corresponds to the titration scheme.On the treatment period, patient will receive one (01) Sibutramine 15mg capsule + one (01) Sibutramine IR/topiramate XR 15mg/75mg placebo capsule + one (01) placebo capsule of Topiramate XR 100mg, taken once daily, for 52 weeks.
40976123|NCT05209984|DRUG|Placebo Group|participants randomized to the Placebo Group will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) sibutramine IR/ topiramate XR 5mg/25mg placebo capsule; after this initial period, they will receive one (01) sibutramine 10mg placebo capsule + two (02) sibutramine IR/ topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) weeks; after this 4-week period, participants will receive one (01) 10mg sibutramine placebo capsule + three (03) ADF placebo capsules, taken once daily, for two (02) weeks.On the treatment period, patient will receive one (01) Sibutramine 15mg placebo capsule + one (01) ADF sibutramine IR/Topiramate XR 15mg/75mg placebo capsule + one (01) Topiramate XR 100mg placebo capsule, in once daily intake for 52 weeks.
40976124|NCT05951062|BEHAVIORAL|behavior management for anti-hypertensive medication|five sessions of educational interview and home visiting to improve medication-related self-management skills
40976125|NCT05951062|OTHER|placebo group|treatment as usual
40976126|NCT05699239|DRUG|TS-172 10mg bid|oral administration of TS-172 10 mg bid
40976127|NCT05699239|DRUG|TS-172 30mg bid|oral administration of TS-172 30 mg bid
40976128|NCT05699239|DRUG|TS-172 60mg bid|oral administration of TS-172 60 mg bid
40976129|NCT05699239|DRUG|TS-172 20mg tid|oral administration of TS-172 20 mg tid
40976130|NCT05699239|DRUG|Placebo|oral administration of placebo
40976131|NCT06087276|DRUG|60 mg ulixacaltamide|Once daily oral treatment with titration
40976132|NCT06087276|DRUG|Placebo|Once daily oral treatment
40976133|NCT03180151|PROCEDURE|piezotome assisted orthodontic tooth movement|"Surgical procedure~1. After local anesthesia, vertical interproximal incisions will be done under the interdental papilla, on the labial aspect of upper arch using a blade No. 15.~2. The incisions will be kept minimal.~3. The incisions go though the periosteum, which permit the blade to reach to the alveolar bone.~4. A Piezo surgical knife will be used to make the cortical alveolar incision through the gingival incisions to a depth of approximately 3mm.~5. As we will not use bone graft so we don't need use suturing after cortication.~6. We give patient antibiotic and analgesic cover."
40976134|NCT05693779|BEHAVIORAL|Home exercise training|"Participants will complete an Exercise Treadmill Test at baseline. The 12 weeks exercise program that will be assigned to each patient will be based on these results. The exercise will be three 20-minute exercise sessions per week for 6 weeks. This will increase to four 60-minute exercise sessions per week at increased intensity progressively over the course of the exercise program. The exercise program will involve walking/jogging, elliptical training, or biking 3-4 times per week for up to an hour each session. If participants don't have access to a bike or elliptical, they will be asked to exercise by walking/jogging.~Participants will also a phone call or video chat that takes about 15 minutes per week to discuss the exercise program and take 2 short surveys weekly on the MyDataHelps application and filling out a logbook recording exercise sessions. In addition, participants activity will be measured by using a smartwatch during the study."
40976135|NCT03806140|BEHAVIORAL|text messages|receive about one health-related text message a day for 16 weeks
40771852|NCT02410187|DRUG|systemic therapy (chemotherapy, hormon therapy, target therapy etc)|"Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT."
41459874|NCT05472896|DRUG|Dicycloplatin (TP21)|the dosage of dicycloplatin was based on the body surface area (550 mg/m2) according to previous research. The volume ratio of lipiodol to dicycloplatin aqueous solution was 1:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
41459875|NCT05472896|DRUG|Epirubicin|the dosage of epirubicin was determined according to the tumor size, and the maximum dose was limited to 40 mg. The volume ratio of lipiodol to epirubicin aqueous solution was 2:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
41459876|NCT03349632|DEVICE|verofilcon A contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
41459877|NCT03349632|DEVICE|senofilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
41459878|NCT03349632|DEVICE|stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
40771853|NCT02410187|RADIATION|palliative RT|fraction size of RT = \< 3 Gy
40771854|NCT05500534|DEVICE|Laser lithotripsy with stone recognition|Application of Revolix HTL+ which features automatic real-time stone recognition
40771855|NCT05500534|OTHER|Laser lithortripsy|Standard laser lithotripsy
41300593|NCT03613090|DRUG|Collagen-hydroxyapatite scaffold (Syn-Oss)|The aim of this study is to add to the existing body of regenerative endodontics research by providing human radiographic evidence for the healing process which occurs after the placement of a FDA-approved collagen-hydroxyapatite scaffold, in the use of a blood clot
40771856|NCT00901914|BIOLOGICAL|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
40771857|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
40771858|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
40771859|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
40771860|NCT06559319|DIAGNOSTIC_TEST|blood sampling|Venous blood is collected, and sIgE and BAT will be detected using whole blood and serum, respectively.
40771861|NCT04984200|PROCEDURE|Retinal imaging|Subjects will undergo retinal imaging before and/or after administration of mydriatic agent
40771862|NCT04984200|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
40771863|NCT02495883|OTHER|Ethanol|50ml of 40% Ethanol
41147190|NCT03785756|DRUG|Ibuprofen 200 mg Oral Tablet|2 × 200 mg tablets at Hours 0, 8, and 16
40771864|NCT02495883|DRUG|Propranolol|Beta blocker
40771865|NCT00654602|DRUG|Rosuvastatin|
40771866|NCT00654602|BEHAVIORAL|Maintenance of specific diet|
40771867|NCT04957589|DIETARY_SUPPLEMENT|Very Low Calorie Diet|"A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day."
41147191|NCT03785756|DRUG|Placebo of PR tablet|2 tablets up to four times in 24 hours
41300594|NCT03613090|DRUG|Collagen Scaffold (Colla-Plug)|Traditionally, endodontic therapy consisted of removing the infected dental pulp from the canal spaces and replacing it with an artificial substitute called gutta percha. Regenerative endodontic research efforts were originally concentrated upon treatment of the immature necrotic tooth whereby stem cells from the bone near the root end were stimulated to grow onto a blood clot scaffold created within the debrided and disinfected canal space. The hope is that the stem cells would differentiate into cells which could potentially replace the lost pulpal tissues, restoring what was lost due to infection.
41300595|NCT02362711|DRUG|NPC-16 Standard Dosing Regimen Group|
41300596|NCT02362711|DRUG|NPC-16 Continuous Dosing Regimen Group|
41300597|NCT02362711|DRUG|Placebo Group|
41300598|NCT05323786|PROCEDURE|The combined topical anesthesia induction group|Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.
41300599|NCT05323786|PROCEDURE|The routine induction group|Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.
41300600|NCT04005092|DEVICE|hCPAP versus HFNC|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
41300601|NCT01748396|DRUG|Calcitriol|
41300602|NCT01748396|DRUG|Calcium Carbonate|
41300603|NCT03127202|DEVICE|Cardiac Resynchronization Therapy -Defibrillator (range PARADYM, LivaNova, Clamart, France)|Patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator (model PARADYM RF SONR CRT-D 9770 or PARADYM RF CRT-D 9750, Sorin) having 3 left ventricular polarities. The choice of the right atrial, right ventricular and bipolar left ventricular leads was left to investigators' discretion.
41300604|NCT01745627|DEVICE|755nm Alex laser|
41300605|NCT05399628|DEVICE|Surfactant administration with less invasive surfactant administration (LISA) marked tip catheter|Participants will be assigned to perform the procedure with LISA catheter with a marked tip
41300606|NCT05399628|DEVICE|Surfactant administration with less invasive surfactant administration (LISA) unmarked tip catheter|Participants will be assigned to perform the procedure with LISA catheter with an unmarked tip
41300607|NCT01140516|DRUG|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
41300608|NCT01140516|OTHER|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
41300609|NCT00629694|PROCEDURE|adenoidectomy, myringotomy, tubes insertion|adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
41300610|NCT00629694|PROCEDURE|A-M|adenoidectomy and myringotomy alone
41300611|NCT03825601|DIAGNOSTIC_TEST|PET with [11C]Flumazenil|7T MRI sequences : TSE, T2w FLAIR GRE-T2\* and DIR 3T MRI sequences: T1, T2, T1 with gadolinium, magnetization transfer, diffusion weighted, resting state fMRI.
40771868|NCT04957589|OTHER|High Intensity Interval Training|The HIIT training will consist of a five-exercise approach across three movements (star jumps, standing squats, on-the-spot-sprinting, standing squats and star jumps), which are collectively described as a cycle in this context. Each exercise is performed for 60 seconds with a 90 seconds recovery period. Each training session will begin with a two minute warm-up and cooldown (on-the-spot-jogging) followed by five minutes of static stretching. Volunteers would aim to exceed the initial number of star jumps and standing squats in the subsequent attempt per cycle. A total of three training sessions per week are to be completed, preferably non-consecutive but may be consecutive on no more than two training sessions per week. Progression is through a gradual increase in volume (repetitions of star jumps and standing squats) on a per-session basis.
40771869|NCT00267176|DRUG|lumiracoxib|
41140857|NCT05766566|PROCEDURE|Perianal fistula surgery|surgical treatment of the perianal fistula through curettage, closure with suture thread (vicryl 2/0) of the internal orifice and lipofilling of the passage with microfragmented autologous adipose tissue processed with the Lipogems® system.
41140858|NCT00149409|DIETARY_SUPPLEMENT|Omacor|
41300612|NCT03388983|OTHER|6-week prehabilitation|Participants will be trained at 3 sessions/week for 6 weeks before the surgery to enhance the overall muscle strength, endurance and spinal stability. A physiotherapist/physical trainer in the participating hospital will supervise the preoperative training. The 45-minute exercise regime will include warm-up and cool-down exercises, and a cardiovascular training on a stationary bicycle, stabilization exercises with emphasis on co-contraction of abdominal and back muscles, and hip raise and hip abduction exercises. The number of repetitions and sets of each exercise will be determined based on individual's ability. Each exercise will be slightly modified based on individual progress. The exercise intensity and complexity will be increased over time.
41300613|NCT01507584|DEVICE|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
41300614|NCT03165591|BIOLOGICAL|V3-P|one tablet of V3-P given once daily for 2 months
41300615|NCT02930655|DRUG|Lucerastat|Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
41300616|NCT02930655|DRUG|Enzyme replacement therapy (ERT)|All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
41300617|NCT02474940|BEHAVIORAL|Intervention #1|Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.
41300618|NCT02474940|BEHAVIORAL|Intervention #2|Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.
41459879|NCT03349632|DEVICE|etafilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
41459880|NCT04427033|DEVICE|Bone Conduction Implant|Bonebridge system BCI 602
41459881|NCT06453837|OTHER|Mentha Suaveolens extract incorporated into a food supplement|Each subject of this group takes 1 capsule of the food supplement per day, with lunch, for 84 consecutive days.
41459882|NCT06453837|OTHER|Placebo product|Each subject of this group takes 1 capsule of comparator product per day, with lunch, for 84 consecutive days.
41459883|NCT01866644|DRUG|N-acetylcysteine|Bath transplanted liver with N-acetylcysteine
40976136|NCT02032810|DRUG|Panobinostat|Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.
41140859|NCT02749253|OTHER|Sudarshan Kriya Yoga Tauma Relief Program (SKY).|Sudarshan Kriya Yoga Trauma Relief Program (SKY) participants will undergo a 12-week training course in SKY conducted by certified instructors from the Art of Living Foundation
41140860|NCT04553809|PROCEDURE|ENB|ENB for biopsy sampling of peripheral lung lesion
41140861|NCT04553809|PROCEDURE|ENB in combination with rEBUS|The combination of ENB and rEBUS for biopsy sampling of peripheral lung lesions
41140862|NCT01204502|BIOLOGICAL|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~* dose 1 5x104 cells/kg~* dose 2 5x105 cells/kg"
41459884|NCT01866644|DRUG|Saline|Bath saline transplanted liver
41459885|NCT02247037|OTHER|Chemotherapy|Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.
41459886|NCT01909115|DRUG|1000 IU of Vitamin D3|1000 IU of Vitamin D will be administered in capsule form, once daily.
41459887|NCT01909115|DRUG|4000 IU of Vitamin D3|4000 IU of Vitamin D will be administered in capsule form, once daily.
41459888|NCT01936012|DRUG|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
41459889|NCT01936012|DRUG|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
41459890|NCT04501536|BEHAVIORAL|Word Learning Intervention|The word learning intervention uses the 10 commercially available children's books and 6 target vocabulary words from each book that meet common criteria for appropriate vocabulary targets. Children will receive 1-on-1 treatment sessions with a trained, speech-language research assistant. Each week, 2 of 10 storybooks chosen for the study will be read with 3 of 6 targeted vocabulary words targeted from each book. The book and words targeted will be consistent between random assignment conditions. For each book reading, speech-language interns will implement word learning strategies during pre reading, during reading, and post reading. Strategies include providing a definition, a synonym, and a contextual sentence. The number of strategies used will vary on which word is being targeted; all words will be randomly assigned to a particular dose, ranging from 0 (no strategies) to 20 (all of the strategies at each reading).
41459891|NCT02847416|DEVICE|BreatheMAX breathing device|
40771870|NCT01688804|BEHAVIORAL|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
41459892|NCT02509286|DRUG|5-Fluorouracil|2600 mg/m² (24 hours), d1 every two weeks;
41459893|NCT02509286|DRUG|Leucovorin|200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
40771871|NCT00514189|BIOLOGICAL|Autologous Dendritic Cells|The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
40771872|NCT04743232|OTHER|Decision tool for clinicians|Clinical decision aid, using a structured approach to advanced care directives and a comprehensive view of available risk scores.
40771873|NCT01519479|OTHER|Palliative Care Consultation|Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
40771874|NCT01519479|OTHER|Control|The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
40771875|NCT05379530|DIAGNOSTIC_TEST|Thromboelastography (TEG)|Thromboelastography (TEG) is a type of Viscoelastic testing (ROTEM is another example) and is a validated point of care method of dynamically assessing intraoperative coagulopathy via functional assay.
40771876|NCT05379530|OTHER|Anesthesia Provider Survey|Pre-operative and post-operative provider surveys will be distributed to anesthesiologists caring for study subjects to assess knowledge, practice, and attitudes about TEG.
40771877|NCT04217317|DRUG|CPI 613|CPI-613 is to be given as 2-hr IV infusion via a central venous catheter. The starting dose of CPI-613 will be 2500 mg/m2 which was determined to be the MTD in the previous phase I clinical trial.
40771878|NCT04217317|DRUG|Bendamustine|Bendamustine at 90 mg/m2 is infused by IV over 10 minutes on Days 1 and 2 of each treatment cycle. Bendamustine is given immediately after CPI-613 administration.
40771879|NCT03359161|COMBINATION_PRODUCT|sc2Wear Furosemide Infusor|Subcutaneous furosemide for the treatment of fluid overload
41300619|NCT02474940|BEHAVIORAL|Intervention #3|Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
41459894|NCT02509286|DRUG|Oxaliplatin|85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;
41459895|NCT02509286|DRUG|Docetaxel|50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
41459896|NCT02509286|DRUG|Carboplatin|Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
41459897|NCT02509286|DRUG|Paclitaxel|50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
41459898|NCT02509286|RADIATION|Neoadjuvant radiation|41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
41459899|NCT04906876|DRUG|Gemcitabine|Gemcitabine as a 90-minute IV infusion
41459900|NCT04906876|DRUG|Docetaxel|Docetaxel as a 60-minute IV infusion
40976137|NCT02032810|DRUG|Ipilimumab|Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
41300620|NCT02929992|OTHER|ART initiation in the home|Participants initiate ART use in the home without visiting a clinic
41300621|NCT02929992|OTHER|Mobile Van Refill and Monitoring|Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
41459901|NCT04906876|DRUG|9-ING-41|9-ING-41 as an IV infusion over 1-4 hours twice weekly
41300622|NCT02929992|OTHER|Clinic ART Initiation|Participants are referred to the clinic to initiate ART use
41300623|NCT02929992|OTHER|Clinic ART Refill and Monitoring|Participants will return to the clinic for ART refill and clinical monitoring.
40771880|NCT05536115|DEVICE|Alveogyl|"The patients will be treated by Alveogyl. Global treatment protocol (curettage, cleaning, local anaesthesia etc.) of the dry socket is at the discretion of the Investigator.~Alveogyl is used as an alveolar dressing. Placement of Alveogyl (about 0.2 g of paste) into the dental socket is done according to its instruction for use by a dental professional only."
41300624|NCT04014153|PROCEDURE|Iodinated contrast media|Percutaneous coronary intervention with iodinated contest media
41300625|NCT05179369|BEHAVIORAL|Standard Care with Well-Mama Intervention|The intervention involves: (1) a Well-Mama checklist on 5 topic areas aligned with leading causes of MM and SMM: (a) mental health/depression; (b) cardiovascular symptoms; (c) safety (e.g., guns at home and intimate partner violence); (d) opioid/substance abuse; and (e) social support, self-agency, and well-being; and (2) Community Doula Navigators (CDNs) who will: (a) conduct biweekly check-ins with pregnant and postpartum women using the Well-Mama List and make appropriate referrals to providers and other resources following check-ins; (b) attend select patient visits; (c) lead virtual pregnancy \& postpartum support groups; and (d) provide labor support.
41300626|NCT02597842|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|Electric stimulation was given through electrode attached to specific acupoints
41300627|NCT02711670|DRUG|chlorthalidone|
41300628|NCT02711670|DRUG|Hydrochlorothiazide|
41300629|NCT00833248|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
41300630|NCT00833248|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
41300631|NCT00833248|DRUG|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
41300632|NCT05055635|RADIATION|Pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day
40771881|NCT06000787|RADIATION|External beam radiotherapy|Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B receive standard-of-care external beam radiotherapy to the brain tumor.
40771882|NCT06000787|RADIATION|131I-Metaiodobenzylguanidine (MIBG)|Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B receive the radiopharmaceutical 131I-Metaiodobenzylguanidine (MIBG) 15 mCi/kg via either a central or a peripheral IV catheter over 1.5 to 2 hours at a maximum rate of 500 mCi/hour.
41300633|NCT06387719|DIAGNOSTIC_TEST|Magnetic resonance imaging|"* Basic sequence for ethical consideration: evaluation of casual findings.~* Structural MRI.~* Functional MRI (fMRI) in the Resting-state~* fMRI- task based. Presented in a computer screen on a magnetically compatible googles."
41300634|NCT04632784|DEVICE|Artiflex Presbyopic implantation|Implantation of iris-fixated multifocal Artiflex Presbyopic IOL
41300635|NCT05704543|DRUG|Buprenorphine Extended-Release Injection|Administered as a subcutaneous injection.
41300636|NCT06397729|BEHAVIORAL|Wait-List Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
41459902|NCT00032227|PROCEDURE|Early Carpal Tunnel Release for Mild or Moderate CTS|Either open or endoscopic surgery
41459903|NCT00032227|OTHER|MR Nerve Imaging for CTS|New diagnostic test for CTS to directly image the median nerve
41459904|NCT03234309|DRUG|Ferumoxytol|Given IV
41459905|NCT03234309|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41459906|NCT01223027|DRUG|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
40771883|NCT04993261|PROCEDURE|Dual-Energy Computed Tomography|Undergo dual energy CT scan
40771884|NCT05901207|DIAGNOSTIC_TEST|blood test|blood test
40771885|NCT03272932|OTHER|No intervention|No intervention
41147192|NCT03785756|DRUG|Placebo of IR tablet|2 tablets up to four times in 24 hours
41147193|NCT03596775|DRUG|Dexmedetomidine|Children in Dexmedetomidine group receive intravenous dexmedetomidine 0.5 ug/kg over 10 minutes after induction of anesthesia.
41147194|NCT03596775|DRUG|saline|Children in Control Comparator group receive intravenous saline 10ml over 10 minutes after induction of anesthesia.
41459907|NCT01223027|DRUG|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
40976138|NCT00967798|DRUG|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
40976139|NCT04542785|OTHER|Rate control|Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
41140863|NCT02751125|DRUG|BCP with autologous mesenchymal stem cells (MSC).|Augmentation of narrow alveolar ridge with BCP and MSC
41459908|NCT03670758|DIAGNOSTIC_TEST|Protein S activity|Intravenous blood sample
41459909|NCT00003850|DRUG|thalidomide|
41459910|NCT03594617|BEHAVIORAL|Interaction Competencies with Children - for Caregiver|"Interaction Competencies with Children - for Caregiver (ICC-C) aims to reduce maltreatment and to improve care quality in institutional care facilities. Following the idea of a train-the-trainer approach, ICC-C is designed to be delivered by trained local facilitators. ICC-C is based on attachment, behavioral and social learning theories.~The key principles are its feasibility in low-resource contexts, participatory approach, and practical orientation. ICC-C includes sessions on (a) caregiver-child interaction, (b) maltreatment prevention, (c) effective non-violent caregiving strategies, and (d) identifying and supporting burdened children."
40976140|NCT04581161|DEVICE|Life2000® Ventilator|"POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded."
41140864|NCT02424305|DRUG|LEO 43204 gel 0.018%|
41140865|NCT02424305|DRUG|LEO 43204 gel 0.1%|
41140866|NCT02424305|DRUG|LEO 43204 gel 0.037%|
41140867|NCT06275802|BEHAVIORAL|Nutrition Education|Nutrition interventions consisting of 8 modules (powerpoint supported classroom lesson, video demonstration, role-play, healthy plate model game, poster preparation, bookmarks, refrigerator magnets, etc. preparation of reminder messages, competitions such as slogan-painting contest, activities such as sports and nutrition festival).
41300637|NCT06397729|BEHAVIORAL|PREVENT Tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help the care team link patients to resources in their community. PREVENT follows up with patients electronically and communicates progress on behavior change to the care team.
41140868|NCT06275802|BEHAVIORAL|nutritional status, eating habits|At the beginning of the study (June 2022), an introductory form (sociodemographic characteristics, body image (Stunkart scale), dietary habits, knowledge about weight status) was applied to all students. Adolescent Nutrition Literacy Scale (ANLS), Instrument of Nutrition Literacy, Mediterranean Diet Quality Index (KID-MED), Eating Attitudes Test 26 (EAT-26), International Physical Activity Questionnaire Short Form (IPAQ) were applied, anthropometric measurements and three-day food consumption records were taken
41300638|NCT01445743|BIOLOGICAL|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
40771886|NCT04790500|OTHER|mobilization technique|Mobilization of sacroiliac joint which will increase the range of motion and reduction in pain and improvement in functional limitation.
40771887|NCT04790500|OTHER|muscle energy technique|Muscle energy technique it is known as active muscular relaxation technique. It helps in lengthening the shorten muscle and increasing range of restricted muscles
40771888|NCT03132142|DRUG|Capsaicin|4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
40771889|NCT03132142|DRUG|Trans-cinnamaldehyde|1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
40771890|NCT03132142|DRUG|L-Menthol|1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
40771891|NCT03132142|DRUG|Vehicle patch|Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
40771892|NCT00100425|PROCEDURE|Viceral Perception Testing|
40771893|NCT05005416|BEHAVIORAL|GOALS Intervention|Weekly treatment sessions are comprised of a graded activity program focused on goal setting in 4 treatment domains: therapeutic exercise, aerobic activity, functional activity, and pain coping skills. Instruction in cognitive behavioral coping skills for pain include: explaining pain (pain neuroscience education), pacing, soliciting positive social support, cognitive restructuring, present mindedness, and symptom self-management planning.
40771894|NCT05005416|BEHAVIORAL|Usual Care Physical Therapy|Usual care will be characterized by extracting the following variables from participants' electronic health record: date of physician referral to physical therapy for neck or low back pain diagnosis (index referral), attendance of at least one PT visit (adherence), dates of first and last PT visits for index referral (duration of care), number of PT visits attended across an 8-week episode of care for the index referral (number of visits), clinic where PT services were provided (service location), and CPT billing codes issued during the episode of care for the index referral (type and frequency of treatments provided).
40771895|NCT01344356|RADIATION|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
40771896|NCT01344356|RADIATION|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
41140869|NCT05185973|DIETARY_SUPPLEMENT|"For Baby supplements provided as powder"|One sachet daily
41140870|NCT05185973|DIETARY_SUPPLEMENT|Micronutrient powder provided as powder|One sachet daily
40771899|NCT03801590|DEVICE|Crosslinking with Riboflavin and UV-A|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.
40771900|NCT00925275|DRUG|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
40771901|NCT02531256|DEVICE|LMA Protector|Insertion of airway device for airway management during gynaecological procedure
40771902|NCT01644331|DRUG|Tolvaptan|IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)
40771903|NCT01644331|DRUG|Placebo|IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
40771904|NCT06564090|OTHER|robot assisted gait training|Morning Walk® is a new end-effector type robot developed by Hyundai Heavy Industries and Taeha Mechatronics for lower limb rehabilitation in the patients with gait disturbance.The RAGT group received RAGT with robot training for 30 minutes and conventional physiotherapy for 30 minutes per session.
40771905|NCT06564090|OTHER|conventional gait training|The control group received conventional physiotherapy for 60 minutes per session. Conventional physiotherapy consisted of 30 minutes of therapist-assisted gait and balance training and 30 minutes of strengthening exercises. The both group patients received five training sessions per week for 8 weeks (a total of 40 sessions).
40771906|NCT03312114|DRUG|Avelumab|Avelumab\* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)
40771907|NCT06560190|OTHER|Orthopaedic Manual Physical Therapy|Individualized Treatment
41300639|NCT04702555|DRUG|VTS-K|An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
41300640|NCT00200278|BEHAVIORAL|PROJECT STRIDE|
40771908|NCT06003504|OTHER|First aid training with blended learning approach|"The content of the first aid blended learning training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of 2 consecutive parts:~1. First aid theory is learned independently in a mobile application followed by an online test to ob-tain an admission ticket for the subsequent in-class training;~2. First aid skills are practiced during a 1-day in-class training facilitated by a certified first aid instructor of the Rwanda Red Cross.~Participants get at least 10 days to learn in the mobile application and obtain the admission ticket."
41140871|NCT01950689|DRUG|Nimorazole|
40771909|NCT06003504|OTHER|First aid training with face-to-face approach|"The content of the first aid face-to-face training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of a 3-days in-class training with lectures and practical exercises on first aid the-ory and skills, facilitated by a certified first aid instructor of the Rwanda Red Cross."
40771910|NCT00995787|DRUG|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
41300641|NCT02584634|DRUG|Avelumab|Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
41300642|NCT02584634|DRUG|PF-06463922|Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
41300643|NCT02584634|DRUG|Crizotinib|Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
41459911|NCT03685409|DRUG|Metformin Hydrochloride 500 MG|Metformin hydrochloride tablets 500 mg given orally once daily.
41459912|NCT03685409|DRUG|Placebo Oral Tablet|Starch Placebo oral tablets will be given once daily to the control group
40771911|NCT00995787|DRUG|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
40771912|NCT04641351|DRUG|Zilretta Injectable Product or Placebo|The purpose of this intervention is to determine the use of extended release steroid knee injection (Zilretta) at the end of the surgery and its effects on your knee pain.In this study Zilretta will be injected intra-operatively for your arthroscopic partial meniscectomy (APM) surgery.Participants will have MRIs x-rays, and provide a sample of the synovial fluid from both knees at the beginning of surgery. This fluid is drained at the beginning of surgery and then usually discarded. Three samples each of blood and urine will be collected over the study period from each participant and sample of joint (synovial tissue) taken. Participants will be asked to answer questions about knee pain.
41459913|NCT03854409|DRUG|Aripiprazole|Injection.
41459914|NCT02642809|DRUG|Pembrolizumab|
41459915|NCT02642809|RADIATION|Brachytherapy|
41459916|NCT02642809|PROCEDURE|Endoscopic biopsy|
41459917|NCT02642809|PROCEDURE|Computed tomography-guided biopsy|
41459918|NCT02642809|PROCEDURE|Peripheral blood collection|
41459919|NCT00588783|DEVICE|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
41459920|NCT00588783|DEVICE|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
41459921|NCT01499160|DRUG|letrozole|Drug is are to be taken orally. 2.5 mg once daily
41459922|NCT01499160|DRUG|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
41459923|NCT01499160|DRUG|everolimus|Drug is to be taken orally. 5 mg once daily.
41140872|NCT01950689|RADIATION|Radiotherapy|
41140873|NCT03945084|DRUG|Niraparib|"Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily \<77 kg or \<150,000 µL: 200 mg (2 X 100 mg capsules) daily\*~\* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy"
41140874|NCT03945084|OTHER|Best supportive care|"In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment."
40771913|NCT04227587|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
40771914|NCT04227587|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
40771915|NCT00824954|PROCEDURE|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
40771916|NCT02507726|DEVICE|Flexima Active soft convexe|The Investigational Device will be used during 14 +- 3 days.
40771917|NCT04380142|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
40771918|NCT04380142|DRUG|Placebo for Levodopa/Carbidopa (LD/CD)|Oral capsule
40771919|NCT04380142|DRUG|Levodopa/Carbidopa (LD/CD)|Oral encapsulated tablet
40771920|NCT04380142|DRUG|Placebo for ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
40771921|NCT02035657|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
40976141|NCT03096210|OTHER|Titanium-Prepared Platelet Rich Fibrin|Blood samples were collected from the each participant's arm in the test group by 20 ml syringe and then was transferred into 10ml grade IV titanium tube without anticoagulant. After centrifugation of blood samples (2800 rpm, 12 minutes) at room temperature, the T-PRF clot was removed from the tubes with sterile tweezers. 6 blood tubes were collected for a sinus floor elevation/lifting operation and 6 T-PRFs were prepared for each participant.
41140875|NCT05756569|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40771922|NCT05005533|OTHER|Observational|Chronic Obstructive Pulmonary Disease Severity of Individuals by Chronic Obstructive Pulmonary Disease Assessment Test, shortness of breath Modified Medical Research Council scale, cough related quality of life Leicester Cough Questionnaire, respiratory muscle strength with Maximum Inspiratory and Expiratory Pressure, Posture with Spinal Mouse device, pain with Visual Analog Scale, severity of fatigue Fatigue Physical performance of the lower extremities will be evaluated with the Short Physical Performance Test, functional mobility will be evaluated with the Time Up and Go Test, and balance will be evaluated with the Biodex Balance System
40771923|NCT02578082|DRUG|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
40771924|NCT01192074|DEVICE|Ultrasound|Preprocedure ultrasound examination of the spine
40771925|NCT04194827|DIAGNOSTIC_TEST|Adalimumab serum trough concentration|Dose reduction based on adalimumab serum trough concentration
40771926|NCT04194827|DIAGNOSTIC_TEST|Disease activity|Dose reduction based on adalimumab diseas activity
40771927|NCT04194827|DRUG|Adalimumab|Adalimumab
40771928|NCT06420700|PROCEDURE|Combined gastric mucosal ablation with endoscopic sleeve gastroplasty|Combined gastric mucosal ablation with endoscopic sleeve gastroplasty in the treatment of adults with obesity
40771929|NCT03648892|DRUG|[c11] raclopride|The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
40771930|NCT03648892|DRUG|[18F]fallypride|The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
40771931|NCT02326584|DRUG|Standard dose cytarabine for induction|100 mg/m2/day Days 1-7
40771932|NCT02326584|DRUG|SGN-CD33A|Given intravenously Day 1 or Days 1 and 4 of each cycle
40771933|NCT02326584|DRUG|Daunorubicin|60 mg/m2/day Days 1-3
41140876|NCT05756569|PROCEDURE|Computed Tomography|Undergo CT
41140877|NCT05756569|DRUG|Enfortumab Vedotin|Given IV
41459924|NCT02952924|DRUG|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
41459925|NCT02952924|OTHER|Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
40771934|NCT02326584|DRUG|High dose cytarabine for consolidation|3g/m2 on Days 1, 3, and 5 of each cycle
40771935|NCT03336229|BEHAVIORAL|Exercise intervention|Graduated walking programme, strengthening exercises and respiratory muscle training.
40771936|NCT03473587|BEHAVIORAL|Motivational interview|A lay health advisor will engage the subject in a motivational interview to promote the importance of colorectal cancer screening
40771937|NCT03473587|BEHAVIORAL|Standard of care|A lay health advisor will provide the subject with a brochure promoting the importance of colorectal cancer screening
40771938|NCT00518180|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
40771939|NCT00518180|BIOLOGICAL|Tdap Vaccine|One dose of vaccine administered intramuscularly
40771940|NCT00518180|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
40771941|NCT00376103|DRUG|temozolomide|75 mg/m2/day
40771942|NCT00376103|PROCEDURE|Brachytherapy|60 Gy to 1 cm
40771943|NCT00376103|PROCEDURE|External Beam Radiation Therapy|60 Gy
40771944|NCT03325231|OTHER|Reconstructive surgery following bladder removal.|Investigating patient experience of bladder reconstructions.
41140878|NCT05756569|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41140879|NCT05756569|BIOLOGICAL|Pembrolizumab|Given IV
41140880|NCT05756569|OTHER|Questionnaire Administration|Ancillary studies
40771945|NCT03670472|OTHER|smear of nasal fossae|1 smear of nasal fossae during a usual or scheduled visit
40771946|NCT00468091|DRUG|exendin(9-39)amide|
40771947|NCT00468091|DRUG|atropine|
40771948|NCT05348122|DRUG|TG103,Q2W|TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
40771949|NCT05348122|DRUG|TG103,QW|TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
40771950|NCT05348122|DRUG|Placebo,Q2W|Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
40771951|NCT05348122|DRUG|Placebo,QW|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
40771952|NCT05348122|DRUG|Dulaglutide,QW|Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
40771953|NCT02458014|BIOLOGICAL|Blinatumomab|Given IV
40771954|NCT02458014|OTHER|Laboratory Biomarker Analysis|Correlative studies
40771955|NCT01350076|DRUG|conventional liberal fluid regimen|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
40771956|NCT01350076|DRUG|restricted fluid regimen|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
40771957|NCT06565052|BEHAVIORAL|Prehabilitation Program|A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed.
40771958|NCT04077502|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
40771959|NCT05545059|DRUG|Sacubitril/valsartan|In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
40771960|NCT05545059|DRUG|valsartan|In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
40771961|NCT05685303|DEVICE|Alleviant ALV1 System|Creation of interatrial shunt
40976142|NCT03096210|OTHER|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
40771962|NCT05685303|OTHER|Sham-Control|Cardiac imaging
40976143|NCT05433714|OTHER|Assesment|The figure of walk test, Berg Balance scale, Timed 25-Foot Walk, Timed up and go test, Foursquare walk test
41459926|NCT02952924|DRUG|RO7049389|RO7049389 will be administered as per schedule described in individual arm.
41459927|NCT03605641|OTHER|JUUL|JUUL Virginia Tobacco
41459928|NCT03605641|OTHER|VUSE Solo|VUSE SOLO Original
41459929|NCT03605641|OTHER|Conventional Cigarette|Subject preferred conventional cigarette
40771963|NCT01332916|PROCEDURE|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
40771964|NCT01332916|PROCEDURE|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
40771965|NCT04883463|DEVICE|Epidural stimulation|Epidural electrical stimulation implant weekly sessions for 21 months.
40771966|NCT06563869|DRUG|PEG-rhG-GSF|Polyethylene glycolylated recombinant human granulocyte stimulating factor （6mg）will be given 24 hours after the end of chemotherapy.
40771967|NCT02003313|BIOLOGICAL|Group T|0.5ml, Intramuscular
40976144|NCT03041545|DEVICE|Fitbit|Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
40976145|NCT06207994|DEVICE|Narrow TR|The width of the PRICO SpO2 TR is set to 3% SpO2.
40976146|NCT06207994|DEVICE|Shifted TR|The lower and the upper limits of the PRICO SpO2 TR are increased by 1% SpO2.
40976147|NCT01018186|DRUG|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
40976148|NCT01018186|DRUG|Fluticasone propionate|Inhaled corticosteroid
40976149|NCT01386554|DRUG|Repository Corticotropin Injection|Acthar given SC for 6 months
40771968|NCT02003313|BIOLOGICAL|Group C|0.5ml, Intramuscular
40771969|NCT00287560|DRUG|propofol (drug)|
40771970|NCT00862940|DRUG|Memantine|10 mg tablets twice daily
40771971|NCT00862940|DRUG|Placebo|Tablets twice daily
40771972|NCT01259011|BEHAVIORAL|the SPIRIT intervention|the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
40771973|NCT06537687|OTHER|Control|A standardized handout on HPV and vaccine education will be given
40771974|NCT06537687|OTHER|Intervention|A video about HPV and vaccines on a tablet provided by a research assistant
40771975|NCT04581395|OTHER|non-pretreated Succinylcholine|no pretreatment
41300644|NCT02717871|DEVICE|PACK-CXL|"Local anesthesia~- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times~Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer~Corneal scrape~Hypo-osmolaric riboflavin solution~- Apply one drop every 2 minutes for 20 minutes~UV-A irradiation~* 3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)~* Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.~Additional postoperative treatment~* Homatropin or Scopolamin, if anterior chamber reaction~* Systemic NSAID/NSAR, if substantial pain~* Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching"
41300645|NCT02717871|DRUG|Cefazolin in combination with either tobramycin or gentamicin|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml)."
41300646|NCT02717871|DRUG|Cycloplegic agents (cyclopentolate 1% eye drops)|Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
41300647|NCT02717871|DRUG|Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
41300648|NCT02717871|DRUG|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
41300649|NCT05155787|DEVICE|Neurofeedback|Neurofeedback training as a method is going to let the brain producing the alpha signal (8-13 Hz).
41300650|NCT05155787|DEVICE|Shame neurofeedback|shame neurofeedback
41459930|NCT01151618|DEVICE|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
41459931|NCT01599689|OTHER|Mirrors Intervention|"Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.~To be administered at set times and in a standardised way by ICU nursing and physical therapy teams."
40771976|NCT04581395|DRUG|succinylcholine 1 minute after rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 1 min +/- 10 sec after pretreatment
40771977|NCT04581395|DRUG|succinylcholine 2 minutes following rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 2 min +/- 10 sec after pretreatment.
40771978|NCT03446690|DRUG|MI Varnish|MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
40771979|NCT03446690|OTHER|Control group|Participants received routine treatment and oral hygiene regimes. No intervention for this group.
41140881|NCT06049407|BEHAVIORAL|Participation in a socio-emotional competence program through a technological platform (EMOWELL)|(1) Participants who meet the inclusion criteria will be contacted. (2) Participants will answer the questionnaire battery (T1) (3) Participants will participate in the intervention by remotely playing the EMOWELL desktop serious game and the EMOWELL app. (4) They will answer the T2 questionnaires. (5) They will answer the follow-up (T3) questionnaires.
41459932|NCT05048862|DIAGNOSTIC_TEST|Neuromuscular ultrasound|Ultrasound will be performed with the Affiniti 70 (Philips Medical Instruments, Bothell, WA). all patients following standardized methods of our hospital. All the patient would be checked the skin surface temperature before the ultrasound examination. The image would be exported from the echo machine as DICOM format.
41140882|NCT02374372|DEVICE|conventional hemodialysis|
40771980|NCT00817609|DRUG|Angongniuhuang Pill|7 days of Angongniuhuang Pill
40771981|NCT00817609|DRUG|placebo|7 days of placebo
41140883|NCT02374372|DEVICE|hemodiafiltration On-line|
41140884|NCT03693989|DRUG|Difluprednate 0.05%|Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
41459933|NCT05048862|DIAGNOSTIC_TEST|Muscle MRI|Muscle MRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject will lie in a supine position comfortably, supplied with ear plugs. A high resolution T1 weighted scan and Short-T1 Inversion Recovery series (STIR) of the four limbs muscle were obtained in axial and coronal plane. MR spectroscopy in interested muscle was also sampled to evaluate the composition of fat, water, lactate, and other studied molecules.
41140885|NCT03693989|DRUG|Prednefrin|"1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~- Route of administration: topical ophthalmic"
41140886|NCT02815345|DEVICE|Rhinometry|An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
41300651|NCT02238405|OTHER|Intensive anti-smoking counseling|Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
41300652|NCT03020901|DRUG|Teicoplanin for Injection|Use Teicoplanin for Injection
41300653|NCT00365976|DRUG|Eszopiclone|Eszopiclone 3 mg po nightly for duration of study blind phase.
41300654|NCT00365976|DRUG|Placebo|Placebo nightly over duration of double blind study phase
41459934|NCT05048862|DIAGNOSTIC_TEST|Nerve conduction studies and autonomic function tests|Nerve conduction study will be performed with a Nicolet Viking IV Electromyographer (Madison, WI) in all patients following standardized methods recommended by the Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. Studied nerves include sural, peroneal, tibial, median and ulnar (motor and sensory) nerves.Autonomic functions will be assessed by the SSR and RRIV with established protocol by using Nicolet Viking IV Electromyographer (Madison, WI).
41140887|NCT04766996|BEHAVIORAL|Guided mindfulness exercises|Guided Meditation twice daily
41300655|NCT03273738|DIAGNOSTIC_TEST|folate level measurement|the level of folate measured in plasma with homocysteine
41300656|NCT03273738|DIAGNOSTIC_TEST|B12|B12 measurement in blood
41140888|NCT04766996|OTHER|Self-administered aromatherapy|Self-administered aromatherapy every 6 hours and at bedtime
41140889|NCT04766996|DRUG|Baby aspirin|Baby aspirin 81mg: Twice daily for 6 weeks after surgery
41300657|NCT06035432|OTHER|Bluesky software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Bluesky software.
41300658|NCT06035432|OTHER|3D slicer software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by 3D slicer software.
41300659|NCT06035432|OTHER|OnDemand software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by OnDemand software.
40976150|NCT01386554|DRUG|Placebo|"Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week)."
40976151|NCT02964351|BIOLOGICAL|High PSA levels|
40976152|NCT05711953|OTHER|Egyfil Pain Lotion|"Egyfil is a cosmetic product to be applied to intact skin, useful to attenuate muscolar pain and stiffness, with a novel topical formulation containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1.~The presence of sodium hyaluronate and peptides mixture promotes the pain alleviating activity and soothing properties of the product."
41140890|NCT04766996|DRUG|Tylenol/Acetaminophen|Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery
41140891|NCT04766996|DRUG|Pregabalin|"Pregabalin 25mg:~Twice a day for two weeks before surgery; Pre-operative 25-100 mg; Twice a day for two weeks after surgery"
41140892|NCT04766996|DRUG|Prednisone|Prednisone 5mg: Daily for three weeks after surgery
40771982|NCT05429411|OTHER|Silicone gel|At the selected treatment sites the participants will wear the gels for 4 hours for the first 2 days, 8 hours for the second 2 days with a gradual increase of at least 2 hours/day until they reach \>21 hours/day. Once the graduate progression has been completed the gel sheet will be applied daily by the subjects for as close to 21+ hours as possible. The gel will be removed for exercise and treatment interventions as well as personal hygiene
41140893|NCT04766996|DRUG|Meloxicam|"Meloxicam 7.5mg:~Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery"
41140894|NCT04766996|DRUG|Prilosec|"Prilosec 20mg:~Daily for two weeks before surgery; Daily for for two weeks after surgery"
41140895|NCT04766996|DRUG|Tramadol|Rescue pain medicine Tramadol 50mg up to three times a day as needed will be provided for rescue pain
41459935|NCT05048862|DIAGNOSTIC_TEST|Quantitative sensory test|Quantative sensory test will be performed with a Thermal Sensory Analyzer and Vibratory Sensory Analyzer (Medoc Advanced Medical System, Minneapolis, MN). The procedure is the same as previously described 25. Briefly, the machine delivers to the patient a stimulus of constant intensity which is pre-set by the algorithm. By adjusting the intensity of stimulus (increase or decrease the intensity by a fixed ratio) according to the response of the subject (i.e. whether the subject perceives the stimulus or not), sensory thresholds of the warm, cold and vibratory modalities will be measured.
40771983|NCT04766567|PROCEDURE|Cesarean section with cesarean myomectomy (serosal)|Serosal or endometrial myomectomy performed during cesarean section
40771984|NCT04766567|PROCEDURE|Cesarean section without myomectomy|Cesarean delivery without performing myoemctomy
40771985|NCT02997085|DEVICE|Live-Action 360° Video Virtual Reality|360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
40976153|NCT05156853|DIETARY_SUPPLEMENT|Insect menus|The insect menus will consist of 6 different products: flatbread, spice-mix, paste, minced meat, sausage and falafels. The products are based on either crickets, mealworms or buffaloworm larvae.
40976154|NCT05156853|DIETARY_SUPPLEMENT|Plant menus|The plant menus will be based on products which can be purchased in normal supermarkets and chosen to be as equal to the insect-based products as possible.
41140896|NCT04766996|DRUG|Voltaren|Voltaren 1% topical arthritis gel up to 4 times daily pre-operative only
41140897|NCT04766996|DRUG|Zofran|Zofran 4 mg pre-operative
41140898|NCT04766996|DRUG|Pepcid|Pepcid 20 mg pre-operative
41140899|NCT04766996|DRUG|Reglan|Reglan 10 mg pre-operative
41140900|NCT04766996|DRUG|Versed|Versed 2 mg pre-operative
41140901|NCT04766996|DRUG|Lidocaine|Lidocaine (preservative free) height based dosing for subarachnoid block intraoperatively
41140902|NCT04766996|DRUG|Propofol|Propofol 10-125 mcg/kg/min intraoperative
41140903|NCT04766996|DRUG|Ancef|Ancef 2-3 gm weight-based dosing intraoperative
41140904|NCT04766996|DRUG|Tranexamic Acid (TXA)|Tranexamic Acid (TXA) 2 gm intraoperative
41140905|NCT04766996|DRUG|Decadron|Decadron 10 mg intraoperative
40976155|NCT01260285|DRUG|Vardenafil|10 mg PO once
40976156|NCT03886376|OTHER|Deep Massage|The deep massage group received 12 minutes of massage on the legs, arms and the back with three different sliding pressures.
40976157|NCT03886376|OTHER|Superficial Massage|The superficial massage group received 12 minutes of only one sliding pressure performed on the legs, arms and the back.
40976158|NCT03187197|DRUG|Pradaxa®|Dabigatran etexilate
40976159|NCT00382460|DRUG|PRAVASTATIN SODIUM|
41140906|NCT04766996|DRUG|Bupivacaine hydrochloride|Local anaesthetic 0.5% bupivacaine hydrochloride intraoperative
41140907|NCT04766996|DRUG|Toradol|Toradol nonsteroidal anti-inflammatory drug max 30 mg intraoperative
41140908|NCT06405386|BEHAVIORAL|ReCharge|ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
41300660|NCT06035432|OTHER|Mimics software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Mimics software.
41300661|NCT05027646|DRUG|Sancuso - Part 1|Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
41300662|NCT05027646|DRUG|Sancuso - Part 2|Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
41300663|NCT04761094|DEVICE|Insulin pump|Treatment with continuous subcutaneous insulin infusion
41300664|NCT01820689|OTHER|Tympanometry measurement|The tympanometry measurement will be verify and compared with the time of palatoplasty.
41459936|NCT05048862|DIAGNOSTIC_TEST|Skin biopsy|A skin specimen of 3 mm in diameter will be taken with a biopsy punch from the lateral side of the distal leg under 2% lidocaine local anaesthesia 26. No suturing is required, and the wounds are covered with a piece of gauze. Wound healing takes 7\~10 days, similar to a typical abrasion wound. Informed consent will be obtained from each patient before the skin biopsy. The intraepidermal nerve fiber density and sweat gland nerve innervation will be examined.
40771986|NCT02997085|DEVICE|CGI 360° Video Virtual Reality|Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
40771987|NCT00175500|DEVICE|Large Diameter Femoral Head|
40771988|NCT06125405|DRUG|Telitacicept|The study duration was 52 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 52 weeks.
40771989|NCT03624075|OTHER|application of kinesio taping|application of kinesio taping in the rectus femoris muscle and in the medial and lateral region of the knee
40771990|NCT03014089|BIOLOGICAL|mRNA-1325|Escalating dose levels
40771991|NCT03014089|OTHER|Placebo|
40771992|NCT05586373|DRUG|medication 1|Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days
40771993|NCT05586373|DRUG|medication 2|Dipyrone pills, identical to the intervention (ibuprofen pills), will be administered every 6 hour for a maximum of five days
40771994|NCT02758028|BEHAVIORAL|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
40771995|NCT03859011|OTHER|Acupuncture|"Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion."
40771996|NCT03859011|OTHER|Usual Care|Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
40771997|NCT04869098|DIETARY_SUPPLEMENT|whey protein|Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
40771998|NCT04869098|DIETARY_SUPPLEMENT|Placebo|Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
40771999|NCT04349969|DRUG|AK117|All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
40772000|NCT04349969|DRUG|AK117+AK104|All Subjects will receive 3 weekly infusions of AK117 (Days 1, 8, and 15) and 1 infusion of AK104 (on Day 1) as combination therapy in each 21-day treatment cycle until unacceptable toxicity, documentation of confirmed PD, or subject withdrawal.
40772001|NCT03014635|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
40976160|NCT01923701|BEHAVIORAL|Cognitive Behavioral Therapy|GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
40976161|NCT03752580|DEVICE|User Instructions of novel nasal mask|User Unstructions interpretation of novel nasal mask for the treatment of obstructive sleep apnea (OSA).
40976162|NCT01810354|DRUG|Cefazolin|
40976163|NCT04101825|DEVICE|Auralya|Hyaluronic Acid-Dermal Filler
41300665|NCT01355068|DRUG|Epanutin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
41300666|NCT01355068|DRUG|Dilantin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
41300667|NCT00657761|DRUG|Enfuvirtide|90 mg/12h sc for 7 days
40772002|NCT03014635|BIOLOGICAL|Placebos|Intramuscular injection
40772003|NCT02710032|BEHAVIORAL|Social Network-Based Adherence Intervention|Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
41300668|NCT00657761|DRUG|Placebo|0.9% saline solution/12h sc for 7 days
41300669|NCT02137772|DRUG|Letermovir|Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
41300670|NCT02137772|DRUG|Placebo|Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
41300671|NCT00592397|OTHER|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
41300672|NCT02058927|DRUG|Measles vaccine|measles revaccination administered at 12 months from start of ART
41300673|NCT01623817|DRUG|Vancomycin HCL|"Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours.~Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day."
41300674|NCT04772183|DEVICE|SpO2 and SaO2 comparison|"Several pulse oximeter will be place on patient find few minutes before arterial blood gases.~During an arterial blood sample, all SpO2 will be recorded"
41300675|NCT01476176|DRUG|Experimental paracetamol|experimental paracetamol with caffeine
40772004|NCT02710032|BEHAVIORAL|Social Media Platform|ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.
40976164|NCT02789150|DRUG|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 65-70
40976165|NCT02789150|DRUG|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 85 or greater
40976166|NCT05712616|DRUG|Strontium Ranelate|Dual mode of action, anabolic and anti-resorptive
40976167|NCT05712616|DRUG|Lacto-N-Hexaose|Placebo look alike drug
40976168|NCT00003170|DIETARY_SUPPLEMENT|glutamine|
40976169|NCT00003170|OTHER|placebo|
40976170|NCT02061267|DIETARY_SUPPLEMENT|Niacin|The subjects will receive a vitamin B3 supplement (2 g)
40976171|NCT02061267|DIETARY_SUPPLEMENT|Saturated meal|Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
40772005|NCT00421564|DRUG|DBT-Danggui Buxue Tang|
40772006|NCT02801578|DRUG|Ibrutinib|Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).
40976172|NCT02061267|DIETARY_SUPPLEMENT|Monounsaturated meal|Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
40976173|NCT02061267|DIETARY_SUPPLEMENT|Polyunsaturated meal|Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
40976174|NCT03812094|DEVICE|Enurad 400|Alarm treatment
40976175|NCT03812094|BEHAVIORAL|Basic Bladder advice|Pre-specified Basic bladder advice
40976176|NCT05377983|OTHER|Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes|During the hospitalization period after CABG surgery, 2% lavender oil (Lavandula angustifolia) inhalation will be applied to the intervention group three times a day.
40976177|NCT02042378|DRUG|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
40976178|NCT02305056|DRUG|C13 N15 Valine|C13 N15 Valine administration
40976179|NCT03222050|OTHER|Distraction technique|
40976180|NCT03552198|BEHAVIORAL|Alternative health advice|These messages targeted specific beliefs about air pollution and protective actions aimed at reducing exposure to air pollution. In addition, message specificity was targeted, which means that compared to the usual messages, the alternative messages reported more detailed health recommendations.
40976181|NCT00560976|DRUG|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
40976182|NCT04356131|OTHER|progressive relaxation exercises and massage|Progressive relaxation exercises included 30 minute rhythmic breathing and muscle relaxation exercises were demonstrated in the second part of the CD with river sounds and verbal instructions. Massage techniques were performed on the site between upper symphysis pubis and umbilicus with 15 minute effleurage demonstrated in the third part of the CD with nature sound.
40976183|NCT01080521|PROCEDURE|Cognitive Assessment|Ancillary studies
40976184|NCT01080521|OTHER|Quality-of-Life Assessment|Ancillary studies
41300676|NCT01476176|DRUG|Paracetamol marketed formulation|marketed formulation containing caffeine
40772007|NCT05951907|PROCEDURE|Maxillary extraction without palatal injection|Extraction of maxillary premolars by only buccal injection without palatal by using articaine 4% HCL with epinephrine (1:100,000)
40976185|NCT02839707|DRUG|Atezolizumab|Given IV
40976186|NCT02839707|BIOLOGICAL|Bevacizumab|Given IV
40976187|NCT02839707|PROCEDURE|Computed Tomography|Undergo CT
40976188|NCT02839707|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
40976189|NCT02839707|OTHER|Quality-of-Life Assessment|Ancillary studies
40976190|NCT02061982|DIETARY_SUPPLEMENT|Coffee consumption|Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
40976191|NCT02694510|OTHER|Light-protection of TPN solutions|TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
40976192|NCT06175091|DEVICE|alarm management left to the discretion of the nurse|alarm management left to the discretion of the nurse in charge of the patient
40976193|NCT06175091|DEVICE|restrictive alarm use strategy|more restrictive protocol for the use of alarms
41300677|NCT03796156|DRUG|Aspirin|75mg low dose non enteric coated or dispersible
40976194|NCT05732454|DRUG|etrasimod|PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks
40772008|NCT05951907|PROCEDURE|Maxillary extraction with buccal and palatal injection|Extraction of maxillary premolars by only buccal and palatal injection by using lidocaine 2 % HCL with epinephrine (1:80,000)
40772009|NCT01813383|OTHER|There is not any intervention|
40772010|NCT04458766|BEHAVIORAL|Monetary incentives|This intervention will assess the efficacy of subjects using the Wellth mobile phone application to provide reminders to take their statin medication, and receiving monetary incentives for taking their medication as prescribed.
40772011|NCT05734885|OTHER|Back and Sacral massage massage application|Massage will be applied to the pregnant woman in the position preferred by the pregnant woman. Circular movements are applied to the sacrum with the thumb. Pressure is applied to both sides of the spinal cord with the thumb. The thumb is moved towards the hip of the pregnant woman at 1.5 cm intervals, starting from the lower part of the pelvis and the sacrum. The palm is placed in direct contact with the mother's sacrum and pressure is applıed. The massage is completed by making a bunch of flowers from the sacrum upwards, towards the shoulder and around it.
40772012|NCT05729087|BEHAVIORAL|Blended intervention group|"Face-to-face workshops will be delivered in the neighborhood elderly center every week. Each workshop will consist of two sections (a) a 60-minute PA session, including a Health talk (20 minutes), and a physical exercise training (40 minutes); and (b) a 60-minute healthy diet promotion, including group discussion and sharing (30 minutes), and knowledge of diet and nutrition (30 minutes).~In addition, a 15-minute online psychological session will be implemented following the PA and diet session."
40772013|NCT06026098|BEHAVIORAL|Artificial Intelligence|Participants will use the Artificial Intelligence assistance tool for case reports.
40772014|NCT06228378|OTHER|Raman microspectroscopy|Raman microspectroscopy is a non-destructive method for observing and characterising the molecular composition and external structure of a biological sample based on the phenomenon of inelastic light scattering (Raman effect).
40772015|NCT00397540|PROCEDURE|PEIT|Percutaneous Ethanol Injection Therapy
40772016|NCT00397540|PROCEDURE|RFTA|Radiofrequency Thermal Ablation
40772017|NCT03275337|DEVICE|Transcranial Direct Current Stimulation|tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
40772018|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination A|Combined influenza and Pfizer-BioNTech COVID-19 Vaccine
40772019|NCT06178991|BIOLOGICAL|Licensed influenza vaccine|Licensed influenza vaccine
40772020|NCT06178991|BIOLOGICAL|COVID-19 Vaccine|Pfizer-BioNTech COVID-19 vaccine
40772021|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination B|Combined influenza and Pfizer-BioNTech COVID-19 vaccine
40772022|NCT06178991|BIOLOGICAL|Placebo|Saline Solution
40772023|NCT06178991|BIOLOGICAL|Investigational influenza vaccine|Investigational influenza vaccine
40772024|NCT05629871|PROCEDURE|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
40772025|NCT05629871|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
40772026|NCT05629871|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
40772027|NCT05629871|PROCEDURE|Actimetry|Measurement of actimetrics for 14 days at inclusion and at 24 months
40976195|NCT05732454|DRUG|Placebo|PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
40976196|NCT04770012|DRUG|Placebo|patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment
41300678|NCT01984346|DEVICE|AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax|Convergent Epicardial Endocardial Ablation Procedure
40772028|NCT05629871|DIAGNOSTIC_TEST|Fractional diuresis|Split diuresis from 7pm-7am, 7am-12am and 12pm-19pm during polysomnography at inclusion inclusion and 24 months to measure melatonin concentration
40772029|NCT05629871|PROCEDURE|Internal temperature measurement|eCelsius capsule to measure internal temperature at inclusion and 24 months
40772030|NCT05629871|OTHER|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
40772031|NCT04881565|OTHER|Reactive balance training|During each one-hour session, participants will experience 40-50 perturbations (i.e. approximately one perturbation per training minute) during standing and/or walking activities. The perturbations will be applied in any direction (e.g. forwards, sideways, backwards, etc.) To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness at waist level. The perturbation will be sufficient in magnitude to elicit a stepping response from the participant. Throughout the session, participants will complete challenging balance tasks, customized to their ability level. Balance tasks will be organized into five categories: stable, quasi-mobile, mobile, unpredictable and participant-selected.
40772032|NCT03931551|DRUG|Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]|Participants will receive olaparib (300 mg tablets, orally twice daily during 21-day cycles) in combination with herceptin (intravenous dose of 4 mg/kg body weight with subsequent weekly doses of 2 mg/kg or subcutaneous dose of 600 mg every 3 weeks) until progression or unacceptable toxicity.
40772033|NCT04826302|OTHER|Myofascial treatment|"40 minutes of myofascial intervention: 10 min in each of the following regions with the patient face up:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area"
40976197|NCT04770012|DRUG|aspirin|patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment
41300679|NCT01984346|DEVICE|Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering|Endocardial Catheter Ablation Procedure
40772034|NCT04826302|OTHER|Sham myofascial treatment|"40 minutes of sham myofascial intervention: 10 min in each of the following regions with the patient face up and with the contact of the physiotherapist through a towel and without any intention:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area"
40772035|NCT04153487|DRUG|Ascorbic Acid Injectable Product|Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours
40772036|NCT04153487|DRUG|Placebo|Placebo saline / 6 hours for 96 hours
40772037|NCT03910595|OTHER|Mepitel Film|Mepitel film is a barrier film that may help in reducing radiation dermatitis by limiting friction.
40772038|NCT04667949|DRUG|Fingolimod 0.5mg|Subjects will receive fingolimod 0.5mg capsule QD up to month 24
40976198|NCT04770012|DRUG|Clopidogrel|patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment
40976199|NCT04661540|DRUG|CM4620-IE (Injectable Emulsion)|Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion
40976200|NCT04661540|DRUG|Placebo|Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
40976201|NCT02692716|DRUG|semaglutide|For oral use once daily.
40976202|NCT02692716|DRUG|placebo|For oral use once daily.
40976203|NCT02708160|DRUG|Fluoride Free toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
40976204|NCT02708160|DRUG|1.1% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
40976205|NCT02708160|DRUG|0.243% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
40976206|NCT01129648|DRUG|Placebo|Administered daily for 21 days
40976207|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
40772039|NCT04611243|BIOLOGICAL|third dose vaccination with CoronaVac vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine
40976208|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
40976209|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
40976210|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
40772040|NCT04611243|BIOLOGICAL|third dose vaccination with BionTech vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine
40772041|NCT04611243|BIOLOGICAL|Vaccination with Coronavac vaccine|Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart
40976211|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
40976212|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
41140909|NCT06405386|BEHAVIORAL|TakeCharge|TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
41140910|NCT05558748|PROCEDURE|USG-guided Caudal block|USG-guided Caudal block after general anesthesia
41140911|NCT05558748|PROCEDURE|USG-guided Ilioinguinal/Iliohypogastric block|USG-guided Ilioinguinal/Iliohypogastric block after general anesthesia
41140912|NCT06399939|BEHAVIORAL|Nap|Naps are common but promoted by soothing, lying the infant down, and/or rocking and massaging
41140913|NCT06399939|BEHAVIORAL|Wake|Wake is encouraged by keeping the infant upright, providing stimulation (e.g., reading books, handing toys)
40772042|NCT04611243|BIOLOGICAL|Vaccination with BionTech Vaccine|Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart
40772043|NCT05210543|OTHER|not applicable, observational study|Patients do not receive intervention; observational study
40976213|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
40976214|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
40976215|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
40976216|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
40976217|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
40976218|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
40976219|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
40976220|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
41300680|NCT05782920|DEVICE|Platelet rich plasma|PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.
40772044|NCT00780585|DRUG|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
40772045|NCT06438731|OTHER|BREAST MILK|The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
40772046|NCT06438731|OTHER|KNITTED OCTOPUS|The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
40772047|NCT03430999|DRUG|Calmangafodipir|Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg
40772048|NCT03430999|DRUG|Placebo|Placebo
40976221|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
40976222|NCT01129648|DRUG|BCX4208|Adminstered daily for 21 days
40976223|NCT00642876|DEVICE|Allograft Fusion and ATLANTIS™ Cervical Plate System|The patients that received the control treatment underwent a single level anterior cervical fusion procedure involving allograft bone and the ATLANTIS™ Cervical Plate System.
40976224|NCT00642876|DEVICE|PRESTIGE® Cervical Disc|The PRESTIGE® Cervical Disc is a stainless steel device that was inserted into the intervertebral disc space. The device is composed of two metal plates that interface via a ball and socket mechanism permitting segmental spinal motion.
40976225|NCT02136524|DRUG|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
40976226|NCT02136524|DRUG|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
41300681|NCT05782920|DEVICE|non cross-linked hyaluronic acid|HA filling is a known modality for rejuvenation
40976227|NCT05194592|DRUG|Dapagliflozin|The patients assigned to the Dapagliflozin group will take Farxiga Pill 10mg for 6 months.
40976228|NCT05194592|DRUG|Gemigliptin|The patients assigned to the Gemigliptin group will take Zemiglo Pill 50mg for 6 months.
41300682|NCT05782920|DEVICE|topical HA gel|the standard treatment of vaginal atrophy and dryness
41300683|NCT05725057|DRUG|AX-158|Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.
41300684|NCT05725057|DRUG|Placebo|Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.
40976229|NCT03619486|DEVICE|Low energy shock wave|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 4 weeks
40976230|NCT03619486|DEVICE|Placebo|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second but no energy once a week for 4 weeks
40976231|NCT03639298|DEVICE|Intendu|intensive training with Motion Based Cognitive Video Games Software
40976232|NCT01121822|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
41300685|NCT04126070|DRUG|Androgen Deprivation Therapy|Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
41300686|NCT04126070|DRUG|Nivolumab|Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.
41300687|NCT04126070|DRUG|Docetaxel|Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
41300688|NCT01958606|OTHER|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
41300689|NCT01958606|OTHER|Traditional Aerobic Training|Moderate intensity continuous aerobic exercise on a treadmill
41300690|NCT01253421|DRUG|amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
41300691|NCT01253421|DRUG|placebo|single-dose placebo capsule
41300692|NCT04318743|DRUG|Glepaglutide|GLP-2
41300693|NCT04044391|DIAGNOSTIC_TEST|CardioFlux Magnetocardiograph|CardioFlux is a noninvasive diagnostic modality which can measure and image the heart's intrinsic magnetic field created by ion transit across cardiac cell membranes.
41300694|NCT05907967|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
41300695|NCT05314166|OTHER|meditation practice|Description: meditation practice
41300696|NCT01142986|BEHAVIORAL|Low intensity care|During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
40976233|NCT01121822|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
40976234|NCT03102255|PROCEDURE|Sniffing position|All procedure is done under sniffing position.
40976235|NCT03102255|PROCEDURE|Nasal tip lifting|Before inserting the endotracheal tube to patient's nose, the researcher lift up the nose tip.
40976236|NCT02317068|DEVICE|HBR|
40976237|NCT02317068|DEVICE|DD|
40976238|NCT03992859|PROCEDURE|Continuous serratus plane block|Peripheral nerve catheter placed by the surgeon at the end of surgery
40976239|NCT01945957|DRUG|Oxytocin|"For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin."
40976240|NCT02228629|DEVICE|CrocsRx Medical Silver cloud clogs|
40772049|NCT04882865|DEVICE|assist|A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients
40772050|NCT06040255|DRUG|methylprednisolone, prednisolone, prednisone|Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
41300697|NCT01142986|BEHAVIORAL|Voucher reinforcement|Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
41459937|NCT05048862|DIAGNOSTIC_TEST|Muscle and nerve biopsy|Two muscle specimens with 5 x 5 x 5 mm were collected in an open muscle biopsy or needle biopsy at studied muscles under 2% lidocaine local anaesthesia. The wound was about 2-3 cm long, and suture was required. Would healing usually takes 10-14 days. First specimen was undergoing snap freezing fixation in a longitudinal axis perpendicular to the cork with the liquid nitrogen and isopentane. The second specimen was divided into two equiponderous tissues, and one was freezed in liquid nitrogen for DNA and protein analysis. The another one was treated with RNAlater solution in 4°C overnight for RNA analysis. Sural nerve biopsies or superficial peroneal nerve were obtained from a standard site posterior to the lateral malleolus under local anesthesia. The nerves were then fixed in 5% glutaraldehyde in 0.1 M phosphate buffer (PB) at 4 °C overnight. All samples were stored in the -80°C refrigerator for further analysis.
41459938|NCT05048862|DIAGNOSTIC_TEST|Genomics, transcriptome, and proteomics|The DNA, RNA, and protein of the tissues (blood, muscle, nerve and skin) were retrieved and stored in the -80°C refrigerator. The next generation sequencing (whole exon sequencing or whole genome sequencing) and RNA-seq would be performed by NGS \& Microarray Core lab in National Taiwan University or another professional team. The protein analysis would be performed by the Proteomics \& Protein Function Core Lab in National Taiwan University.
41459939|NCT05048862|DIAGNOSTIC_TEST|Laboratory of blood chemical substances, metals and endocrine profiles|The methods of the measurement will follow the standards set by Department of Laboratory Medicine of National Taiwan University Hospital.
40772051|NCT06396559|BEHAVIORAL|pre test-post test|The mobile application will be installed on the mobile devices of student nurses and its effectiveness will be tested.
40772052|NCT01772940|DRUG|nevirapine|Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
40976241|NCT04975685|BEHAVIORAL|SMART|SMART (Strengthening Mental Abilities Through Relational Training) is a web-based cognitive training program that directly trains 'relational skills' - skills necessary to understand how concepts relate to one another, which underpin complex cognition.
40976242|NCT04975685|BEHAVIORAL|Sham brain training (Sudoku)|Sudoku was selected to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials.
41140914|NCT00265902|PROCEDURE|diagnostic imaging|
40772053|NCT01772940|DRUG|ritonavir-boosted Lopinavir|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
40772054|NCT01772940|DRUG|Tenofovir/emtricitabine|tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
40772055|NCT01772940|DRUG|Zidovudine/lamivudine|zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
41300698|NCT05264090|OTHER|Ambulatory blood pressure monitoring|The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
41300699|NCT05264090|OTHER|Combined aerobic-resistance exercise|Combined aerobic-resistance exercise (group 2) was scheduled twice weekly in the form of 60-minute workouts with a load intensity at the level of sub-maximum heart frequency (75-85% SFmax). The minimum time span between the workouts was 24 hours. The workout consisted of a 10-minute warm-up, 25 minutes of aerobic exercise (spinning bicycle or bicycle ergometer), 15 minutes of resistance exercise on gym machines (bench press, leg extension and pull down) with 40-50% 1-RM (one repetition maximum) intensity (3 series of 10 exercises), and a 10-minute cool-down (stretching of the main muscle groups).
41300700|NCT05264090|OTHER|The cardiovascular exercise|The cardiovascular exercise (group 4) took the form of sixty-minute workouts scheduled two to three times weekly. The nature of the workouts was similar, combined aerobic-resistance exercise (a 10-minute warm-up, aerobic endurance on bicycle ergo meter for 25 minutes, resistance exercise on multifunctional gym machines for 15 minutes, and a 10-minute cool-down). The workout intensity was set at the level of the first ventilation threshold (VAT-1), corresponding to the following workout parameters: load (W) and heart rate (HR).19,20 The resistance exercise intensity was specified by the 1-RM (one repetition maximum) method. The maximum load lifted across the full range of motion for every exercise was used as the benchmark for the workload intensity specification, corresponding to 30 - 60% 1-RM.
41300701|NCT03521167|DRUG|Ketamine|"Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction.~Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg."
41300702|NCT03521167|DRUG|Lidocaine|Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
41300703|NCT03521167|DRUG|Dexmedetomidine|Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
41300704|NCT03521167|DRUG|Gabapentin|Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for \>65y or if patient having significant sedation/dizziness
41300705|NCT03521167|DRUG|Tylenol|Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if \<70kg
41300706|NCT03521167|DRUG|Gabapentin Pill|Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients \>65y or with GFR \< 50 Consider dose reduction in patients with sleep apnea
41300707|NCT03521167|DRUG|Tylenol Pill|Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
41300708|NCT03177135|DEVICE|AmnioSense|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis.
41300709|NCT03097328|DRUG|TAK-228|TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth
41300710|NCT03468192|OTHER|Non-precaution group|Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed
41459940|NCT05048862|DIAGNOSTIC_TEST|Contact heat evoked potentials|A contact heat evoked potential stimulator (Medoc, Ramat Yishai, Israel) will be used for delivering heat stimulation. Stimuli will be delivered repeatedly to the same stimulation site and the inter-stimulus interval will be randomly set to around 18\~22 s. CHEP will be recorded using a Nicolet Bravo evoked potential system (Nicolet Biomedical, Madison, WI). The recording electrode was placed at the Cz and P3 of international 10-20 system. The impendence of all recording electrodes was kept below 3 kΩ. The evoked potentials were filtered with a bandpass filter at 0.1\~30 Hz. Recording was triggered by the onset of each stimulus, and the sweep time was 1500 ms.
41459941|NCT05048862|DIAGNOSTIC_TEST|Nerve excitability study|Nerve excitability studies will be undertaken on the median, tibial, peroneal and sural nerves as per previously detailed protocols. Skin temperature will be monitored at the site of stimulation and was maintained at \>32°C. Stimulation and recording will be controlled by automated computerized system (QTRAC; Institute of Neurology, London, U.K.) and the stimulus current will be administered using an isolated linear bipolar constant-current stimulator (DS5; Digitimer, Welwyn Garden City, U.K.). Responses will be amplified (ICP511 AC amplifier, Grass Technologies, West Warwick, USA) with electronic noise removed (Hum Bug 50/60 Hz Noise Eliminator, Quest Scientific Instruments, North Vancouver, Canada).
40772056|NCT00159016|DRUG|Glivec|
40772057|NCT06268106|BEHAVIORAL|Graphic novel visualization|Patients in interventional group do receive and visualize graphic novel, which is more informative than standard informed consent.
40976243|NCT03873233|DEVICE|Aisys Carestation ventilator and normal endotracheal tube|Fraction of Inspired Oxygen (FIO2) 0.3 End Expiratory Pressure (EEP) at +5 cm H2O Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 Tidal Volume: 6 mL/kg Zero inspiratory pause Respiratory frequency will be adapted to produce an End-Tidal CO2 35-40 mmHg
40772058|NCT05321602|DRUG|LY03010 156 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
40772059|NCT05321602|DRUG|LY03010 156 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
40772060|NCT05321602|DRUG|LY03010 351 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
40772061|NCT05321602|DRUG|LY03010 351 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
40772062|NCT05744479|DRUG|Metformin|Metformin oral, 2000mg/day, for 24 weeks.
40772063|NCT05744479|DRUG|Placebo|Oral placebo for 24 weeks
40772064|NCT05744479|BEHAVIORAL|Lifestyle Intervention|Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.
40772065|NCT06184802|BEHAVIORAL|TAU+Multisensory room|Multisensory room session included exercises in different interaction areas that allow to make up a multisensory experience where the patient can freely perform in different directions experimenting combinations of play
40772066|NCT06184802|BEHAVIORAL|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
40772067|NCT05687344|DRUG|Nifedipine ER|Postpartum BP treatment to \<140/90 mmHg
40772068|NCT04586257|PROCEDURE|Erector spinae plane block|While patients in the prone position, 1.4-5.1 MHz low-frequency probe (C5-1s convex transducer) will be first placed in a longitudinal orientation in the midline to identify the spinous process of at the appropriate lumbar level, then it will be scanned laterally about 2-3 cm until visualization of the paraspinal muscles and the transverse process at the same time. After standard sterilization, a 21-G short bevel nerve block needle will be advanced in a cephalad-to-caudal direction, in-plane under real- time ultrasound guidance, through skin, subcutaneous tissue, and erector spinae muscles until reaching the transverse process. After negative aspiration of blood or cerebral spinal fluid, a small volume of local anesthetic was injected to confirm the position of the needle tip between the erector spinae muscles and the transverse process. A total of 20 ml of 0.0.25% plain bupivacaine will be incrementally injected with intermittent negative aspiration on each side.
40976244|NCT03873233|DEVICE|Evone ventilator and Tritube|Fraction of Inspired Oxygen (FIO2) 0.3 Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 End Expiratory Pressure (EEP) at +5 cm H2O Flow: start with 10 L/min and adjusted along with the peak inspiratory pressure to produce a tidal volume of 6 mL/kg and End-Tidal CO2 35-40 mmHg
40976245|NCT02927522|DRUG|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
40976246|NCT02927522|DRUG|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
41140915|NCT03878394|OTHER|aerobic exercise and balance exercises|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
41140916|NCT03878394|OTHER|aerobic exercise and balance exercises with cognitive exercises|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
41140917|NCT00754325|DRUG|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
41140918|NCT00754325|DRUG|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
40976247|NCT03007160|DRUG|Potassium Citrate Extended-release Tablets|Daily 3.24g, Po ,Tid, each 1.08g/tablets
40976248|NCT01432080|DRUG|Prednisone|Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
40976249|NCT01432080|DRUG|Azithromycin|Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
40976250|NCT01432080|DRUG|Montelukast|Montelukast 10 mg PO qhs for 3 months
40976251|NCT01432080|DRUG|Symbicort|Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
40976252|NCT00038857|PROCEDURE|Megadose of CD34 Selected Progenitor Cells|Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.
40976253|NCT00038857|DRUG|Melphalan|140 mg/m\^2 on day -8
40976254|NCT00038857|DRUG|Thiotepa|10 mg/kg on day -7
40772069|NCT04586257|PROCEDURE|Throacolumbar interfacial plane block|USG-guided TLIP block will be performed using a high-frequency linear probe while the patient in prone position. The probe will be covered with sterile sheath positioned transversally in a midline position at approximately the level of the 3rd lumbar vertebra (L3). The corresponding spinous process and interspinal muscles will be identified, and the probe will be slid laterally to identify the multifidus (MF) muscle and longissimus (LG) muscle. Sliding the probe from midline to laterally helps in the correct identification of various muscles. After identifying the muscles, TLIP block will be performed aseptically on both sides of L3 vertebra. Under ultrasound guidance, an insulated echogenic needle will be inserted in-plane in a lateral to medial orientation in-plane USG guided through the belly of LG toward the MF. When needle reach deep to middle of MF/LG interface, 20 ml 0.25% bupivacaine will be injected after negative aspiration. The block will be administered bilaterally.
40772070|NCT00002035|DRUG|Zidovudine|
40976255|NCT00038857|DRUG|Fludarabine|160 mg/m\^2 over 4 days on days -6, -5, -4, -3
40976256|NCT00038857|DRUG|Rabbit ATG|1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
41459942|NCT05048862|DIAGNOSTIC_TEST|Transcranial magnetic stimulation (TMS)|In simple rTMS protocols, individual stimuli are spaced apart by identical interstimulus intervals (ISI). The stimulation protocol was in accordance with published safety recommendations. The patterned rTMS protocols included (1) Theta burst stimulation, (2) Repetitive paired-pulse TMS. All the above stimulation protocols or paradigms will follow the international guideline of the use of TMS in clinical practice and research (Rossi et al., 2009; Fitzgerald and Daskalakis, 2012; Groppa et al., 2012; Steeves et al., 2012).
40772071|NCT00002035|DRUG|Didanosine|
40976257|NCT02611557|PROCEDURE|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
40976258|NCT00936910|DRUG|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome \[2 mg/ml\]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
40976259|NCT00903695|DRUG|Memory XL|An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, \& acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
40976260|NCT00903695|DRUG|placebo|placebo comparator
40976261|NCT01773382|BEHAVIORAL|weight reduction|"1. Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)~2. Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.~3. Daily body weight measurement.~4. Record food diary"
40976262|NCT04540224|DIAGNOSTIC_TEST|Flow-Cytometric analysis|Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33
41300711|NCT03474133|DRUG|Brentuximab Vedotin|brentuximab vedotin 1,8 mg/kg, intravenous infusion every 21 days, up to 16 infusions per patient during study period
40976263|NCT00861276|DRUG|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
40976264|NCT00861276|DRUG|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
41300712|NCT03885726|DEVICE|Precision Flow Plus|High velocity nasal insufflation
40976265|NCT02018328|DIETARY_SUPPLEMENT|Curcumin|
40976266|NCT03403595|DRUG|177Lu-EB-PSMA-617|accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
40976267|NCT03697408|DRUG|Itacitinib|A JAK 1 selective small molecule inhibitor
40976268|NCT03697408|DRUG|Everolimus|A mammalian target of rapamycin (mTOR) inhibitor
40976269|NCT00033215|DRUG|S-3304|
40976270|NCT04128176|DRUG|Rituximab combined with Omalizumab|Rituximab 1000 mg will be administered by IV infusion 6 months after the patient's initial cycle of rituximab (received in the screening period).Omalizumab (300 mg) will be administered subcutaneously every 2 weeks starting on Day 1 until week 24 (primary endpoint) and again until week 52 (secondary endpoint).
40976271|NCT05160220|DRUG|Psilocybin|0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.
40976272|NCT05160220|DRUG|Placebo|0.5 g dried edible non-psychoactive mushroom material.
41140919|NCT05281588|PROCEDURE|Micro-osteoperforations|All micro-osteoperforations were performed only one time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations were performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations was controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations were aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation was performed between the two central incisors. The first perforation was performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
41140920|NCT03924362|PROCEDURE|PCNL|Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.
41140921|NCT03122548|BIOLOGICAL|CRS-207|Administered by IV infusion over 1 hour.
41140922|NCT03122548|BIOLOGICAL|Pembrolizumab|Administered by IV infusion over 30 minutes.
41140923|NCT00942266|DRUG|fluorouracil|Given IV
41300713|NCT03885726|DEVICE|Treatment as Usual|Conventional therapy per institution
41300714|NCT02928393|DRUG|Basmisanil|Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
41300715|NCT02928393|DRUG|Placebo|Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
41140924|NCT00942266|DRUG|leucovorin calcium|Given IV
41140925|NCT00942266|DRUG|vorinostat|Given orally
41300716|NCT04992832|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group.
41459943|NCT05048862|DIAGNOSTIC_TEST|fMRI acquisition and image analysis|fMRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject's head will be positioned comfortably inside a receive-only 8-channel birdcage head coil, supplied with ear plugs, heavily padded and secured with a strap across the forehead in order to minimize head motion. All data will be processed using SPM2 (Wellcome Department of Cognitive Neurology, London UK) 36 implemented on MATLAB (Mathworks Inc. Sherborn, MA).
41459944|NCT01816789|DRUG|rFSH|
41459945|NCT01816789|DRUG|buserelin|
40976273|NCT05371743|DIAGNOSTIC_TEST|Plasma RNA isolation, qPCR analysis of micro RNA|qPCR will be performed using Taqman microRNA assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Total RNAs going to be used to make cDNAs using TaqMan microRNA RT Kit. Diluted cDNAs were mixed with TaqMan Universal PCR Master Mix (No AmpErase UNG). Taqman miRNA assay will run in the 7500 Real-Time PCR System (Applied Biosystems). miR-39 also will be used as an exogenous control. All assays will be done in triplicates. The expression levels will be evaluated using the comparative cycle threshold (∆∆_Ct) method
40976274|NCT05371743|DIAGNOSTIC_TEST|estimation of serum level of IL2|"2ml of patient serum will be used to measure IL 2 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
40976275|NCT05371743|DIAGNOSTIC_TEST|estimation of serum level of IL17|"2ml of patient serum will be used to measure IL17 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
40976276|NCT06474585|DEVICE|Plantar orthosis|Plantar orthosis taken in sitting position Plantar orthosis taken in standing position
40976277|NCT03339960|OTHER|Ergonomic measurement|Ergonomic measurement of the surgeon and assistant
40976278|NCT04684498|DRUG|Oseltamivir phosphate capsules|Treatment group vs. Control group
40976279|NCT05657314|DIETARY_SUPPLEMENT|Active Comparator|Consists of 15 grams of pea protein
40976280|NCT03779802|OTHER|Device programming of ABBOTT CRT pacemaker or defibrillator|Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session.
40976281|NCT01535053|BIOLOGICAL|Dactinomycin|Given IV
40976282|NCT01535053|DRUG|Leucovorin Calcium|Given PO
40976283|NCT01535053|DRUG|Methotrexate|Given IV and IM
40976284|NCT01535053|OTHER|Quality-of-Life Assessment|Ancillary studies
41140926|NCT00942266|OTHER|pharmacological study|Correlative study
41300717|NCT04992832|OTHER|human serum albumin|Saline solution containing 1 percent human serum albumin will be infused to the control group.
41459946|NCT02754492|DEVICE|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
41459947|NCT02627001|DEVICE|NuMask Intraoral Airway Device|NuMask Intraoral Airway Device
41459948|NCT02627001|DEVICE|Bag Valve Mask|Conventional bag valve mask
41459949|NCT04962139|DRUG|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
41459950|NCT04962139|OTHER|Vehicle Cream|ON101 Cream Placebo
40976285|NCT02747589|PROCEDURE|Surgical device implant in brain|Neuropace RNS implant ove visual cortex
40976286|NCT04998474|BIOLOGICAL|FRAME-001 personalized vaccine|Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs.
40976287|NCT01957553|DEVICE|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
41140927|NCT00607607|DRUG|MKC-1|capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
41140928|NCT00663429|DRUG|Atiprimod|Oral, 14 days on / 14 days off; 30mg capsules
41140929|NCT02869230|PROCEDURE|ROLL|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
41300718|NCT00216359|DRUG|Fuzeon (Enfuvirtide)|
41300719|NCT00216359|PROCEDURE|Laboratory diagnostic (CD4-cells)|
41300720|NCT00216359|PROCEDURE|Laboratory diagnostics (HIV-1 viral load)|
41459951|NCT00105040|DRUG|Levetiracetam|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
41459952|NCT00105040|OTHER|Placebo (PB)|Oral tablets and oral solution
41459953|NCT02663856|OTHER|observational|Self assessment of ageing transition using a frailty index through MySAwH app
41459954|NCT02431624|DRUG|BTDS|
41459955|NCT01746654|DRUG|P128-0.1 mg|P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
40976288|NCT01957553|DEVICE|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
40976289|NCT03687853|DEVICE|Intrahepatic Arterial Infusion|Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.
40976290|NCT02551757|DEVICE|Auto-titrating CPAP|Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
40976291|NCT02551757|DEVICE|Sham-CPAP|Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
40976292|NCT04386980|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
40976293|NCT04386980|DRUG|Placebo|Diluent in normal saline
40976294|NCT03132376|DIETARY_SUPPLEMENT|Water Preload Drink|Participants were given 275 ml (0 kcal) water to consume in the morning following an overnight fast. This served as the control drink.
40976295|NCT03132376|DIETARY_SUPPLEMENT|Whey Protein Isolate Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g whey protein to consume in the morning following an overnight fast.
40976296|NCT03132376|DIETARY_SUPPLEMENT|Micellar Casein Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g micellar casein to consume in the morning following an overnight fast.
40976297|NCT03132376|DIETARY_SUPPLEMENT|Egg White Isolate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white isolate protein to consume in the morning following an overnight fast.
40976298|NCT03132376|DIETARY_SUPPLEMENT|Egg White Concentrate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white concentrate protein to consume in the morning following an overnight fast.
40976299|NCT06391723|DEVICE|Active rTMS|rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session)
40976300|NCT06391723|DEVICE|Sham rTMS|Sham rTMS will be administered over the left dorsolateral prefrontal cortex
40976301|NCT05545215|DEVICE|Dexyane Med|Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
40976302|NCT05784064|BEHAVIORAL|Survey|This is a nationalwide survey developed in order to know the management of patients diagnosed of acute uncomplicated diverticulitis.
40976303|NCT05691452|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
40976304|NCT03291808|BEHAVIORAL|Weight loss intervention|"This 6-month intervention will include restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate changes in dietary habits and activity patterns will be introduced, promoted and reinforced throughout the program. Weekly group meetings in a synchronous chat (i.e., in real time) led by a facilitator will be the venue for the group process. Extensive web-based resources to support behavior changes will be offered. Group chat sessions will meet online weekly for 6 months."
40976305|NCT01586676|BEHAVIORAL|SAU|Supervision-as-usual
40976306|NCT01586676|BEHAVIORAL|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
40976307|NCT03629132|PROCEDURE|Platelet-rich plasma|Platelet-rich plasma intrauterine injection
40976308|NCT03629132|PROCEDURE|gel|Self-crosslinking sodium hyaluronate gel intrauterine injection
40976309|NCT04610840|PROCEDURE|Puncture of the caliceal system|Puncture of the caliceal system under ultrasound/Xray control
40976310|NCT04756492|DRUG|sandimmun|follow up for treatment response
40976311|NCT04840615|BIOLOGICAL|LMB-100|LMB-100 administered into lesion on days 1 and 4 during cycle 1.
40976312|NCT04840615|DRUG|ipilimumab|Administered intravenously once per cycle up to three 21-day cycles. Administration will occur during cycles 2,3,4.
40976313|NCT04840615|DRUG|Diphenhydramine|Infusion related reactions precaution: All participants will be premedicated with 25-50 mg Diphenhydramine by mouth (PO) or intravenous (IV) (or alternative antihistamine at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
41140930|NCT02869230|PROCEDURE|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
41300721|NCT00216359|DRUG|antiretroviral co-medication beside Fuzeon|
41459956|NCT01746654|DRUG|P128-0.3 mg|P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
41459957|NCT01746654|DRUG|P128-1.0 mg|P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
41459958|NCT01746654|DRUG|Placebo|Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
40976314|NCT04840615|DRUG|Famotidine|Infusion related reactions precaution: All participants will be premedicated with 20 mg Famotidine by mouth (PO) or intravenous (IV) (or alternative histamine H2- receptor antagonists (H2) blocker at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
41300722|NCT03428412|DRUG|TCM and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
41300723|NCT03428412|DRUG|TCM placebo and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
41300724|NCT06552585|OTHER|12-weeks weight prevention program|Twice a week, over 12-weeks, the weight program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with two weights Domyos with 1, 2, 3, 4, or 5 kg.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
41300725|NCT06552585|OTHER|12-weeks elastic band prevention program|Twice a week, over 12-weeks, the elastic band program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with an elastic band Bodytone Power Band with 10, 15, 20, 25, or 30 kg weights Domyos.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
41300726|NCT06552585|OTHER|sham intervention|The control group performed a sham intervention, twice a week, for 12-weeks. This intervention consisted of 2 sets of 10 repetitions of 5 shoulder mobility exercises, without preventive aim, normally carried out in warm-up before training: shoulder maximum flexion and extension, horizontal abduction and adduction starting from 90º of shoulder abduction, maximum internal/external rotation starting from 90º of shoulder abduction, circumduction of the shoulder in a clockwise direction and circumduction of the shoulder in a counterclockwise direction. There was no progression after 6-weeks of this sham intervention. The coach of the respective team checked the execution of the exercises, but there was no individualized monitoring with a regular exercise technique correction by a physiotherapist.
41300727|NCT00003943|BIOLOGICAL|filgrastim|5 ug/kg
41300728|NCT00003943|DRUG|carboplatin|AUC 5
41300729|NCT00003943|DRUG|cyclophosphamide|3 gm/m2
41459959|NCT02546661|DRUG|AZD4547|AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
41459960|NCT02546661|DRUG|MEDI4736|MEDI4736
41459961|NCT02546661|DRUG|Olaparib|MEDI4736 (durvalumab) + Olaparib
41459962|NCT02546661|DRUG|AZD1775|MEDI4736 (durvalumab) + AZD1775
41459963|NCT02546661|DRUG|Vistusertib|MEDI4736 (durvalumab) + Vistusertib
41459964|NCT02546661|DRUG|AZD9150|MEDI4736 (durvalumab) + AZD9150
41459965|NCT02546661|DRUG|Selumetinib|MEDI4736 (durvalumab) + Selumetinib
41459966|NCT05404451|DIAGNOSTIC_TEST|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
41459967|NCT05404451|DIAGNOSTIC_TEST|Mckenzie Exercises|Using Mckenzie Exercises
41459968|NCT01386034|DRUG|Citrulline and placebo|After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-\[1-13C\]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
41459969|NCT04600739|PROCEDURE|TAVI|Replacement of the aortic valve using a biological prosthesis that is inserted via a catheter.
41459970|NCT04197154|BEHAVIORAL|Threat manipulation (control, no threat)|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
40976315|NCT04840615|DRUG|Acetaminophen|Infusion related reactions precaution: All participants will be premedicated with 650 mg Acetaminophen by mouth (PO) or intravenous (IV) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
40976316|NCT04840615|DRUG|Dexamethasone|Additional infusion precaution at infusions of LMB-100 after Cycle 1 Day 1 (as appropriate): Dexamethasone 20 mg by mouth (PO), 6-12 hours prior to LMB-100 administration OR 10mg, intravenous (IV), 30-60 minutes prior to LMB-100 administration OR equivalent dose of another corticosteroid as clinically indicated.
41300730|NCT00003943|DRUG|paclitaxel|250 mg/m2
41300731|NCT00003943|DRUG|topotecan hydrochloride|10 mg/m2
41300732|NCT00003943|PROCEDURE|peripheral blood stem cell transplantation|harvest via apheresis
40976317|NCT04840615|PROCEDURE|Biopsy|As feasible at screening, Cycle 1 Day 1 and 5, Cycle 2, 3, \& 4 Day 1, and Cycle 4 Day 21 (±7 days).
40976318|NCT04840615|DIAGNOSTIC_TEST|FDG-PET|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
40976319|NCT04840615|DIAGNOSTIC_TEST|CT CAP|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
40976320|NCT04840615|DIAGNOSTIC_TEST|MRI|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
40976321|NCT04840615|DIAGNOSTIC_TEST|ECG|At screening, Cycle 1 Day 1, Cycles 2, 3, \& 4 Day 1 and Follow-Up Visit (4-6 weeks after end of treatment).
40976322|NCT04840615|DIAGNOSTIC_TEST|Echocardiogram|At screening.
40976323|NCT05711849|BIOLOGICAL|Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.|Bone marrow will be harvested from the posterior superior iliac crest under local anaesthetic, and mononuclear cells will be separated using a Ficoll technique in a certified laboratory. Later that same day, the participant will undergo an intracoronary cell infusion of the mononuclear cells. Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the bone marrow aspiration and cell infusion).
41300733|NCT00540449|DRUG|TMC278|25 mg tablet once daily for 96 weeks
41300734|NCT00540449|DRUG|Efavirenz|600mg once daily for 96 weeks
41300735|NCT01651130|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
41300736|NCT05217979|DEVICE|Transcutaneous pulsed radiofrequency|single treatment with transcutaneous pulsed radiofrequency, for a duration of 15 minutes, at a strength of 800 mA.
41300737|NCT05217979|DEVICE|Sham|Sham treatment by turning on the device in demo mode. No treatment delivered, but indistinguishable by sound or visual signals or sensations felt by the study participant
41459971|NCT04197154|BEHAVIORAL|Threat manipulation|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin is very sensitive and their nerve fibers are very responsive and they may have adverse reactions to the heat-pain application. A skin-sensitivity reading shows participants a scale that is in the red (higher danger) zone.
40976324|NCT05711849|PROCEDURE|Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).|These participants will have a sham bone marrow aspiration (a 3mm incision in the skin under local anaesthetic) and a sham intracoronary infusion procedure (the insertion of radial or femoral sheath under local anaesthetic). Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the sham bone marrow aspiration and sham cell infusion).
40976325|NCT03585608|PROCEDURE|Neck extension|The neck extension is routine posture during palatoplasty. We will evaluate the change in optic nerve sheath diameters before and after neck extension.
40976326|NCT00399776|RADIATION|Bone Density Test|Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
40976327|NCT01442493|OTHER|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
40976328|NCT01442493|OTHER|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
40976329|NCT05916391|GENETIC|FT-003|Administration via intraocular injection
40976330|NCT02123498|DRUG|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
40976331|NCT02123498|DRUG|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
40976332|NCT02123498|DRUG|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
40976333|NCT02123498|PROCEDURE|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
40976334|NCT02123498|PROCEDURE|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
40976335|NCT02403154|PROCEDURE|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
40976336|NCT02403154|PROCEDURE|External fixator|External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
41140931|NCT04413175|OTHER|music therapy|"Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.~A portable MP3 player connected to double earphones was used in the present study. After patients took the lithotomy position for cystoscopy, their headphones were inserted and music began to be played. Music was played to the individuals for 20 minutes before and during the procedure. Headphones were removed immediately after the procedure was completed and the double earphones were cleaned with antiseptic solution after each application."
40976337|NCT02344485|PROCEDURE|OMM treatment|OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
40976338|NCT01174303|DRUG|insulin degludec/insulin aspart|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
40976339|NCT01174303|DRUG|biphasic insulin aspart 30|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
40976340|NCT03095014|PROCEDURE|Cesarean Myomectomy|Myomectomy was done during Cesarean section
40976341|NCT03095014|PROCEDURE|Cesarean section|Cesarean delivery
40976342|NCT00602342|DRUG|Terbinafine|
40976343|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level|50g added sugar
41140932|NCT03478072|DEVICE|trichoscopy|hair and scalp dermoscopy) is a non-invasive technique in which either a handheld dermoscope or a digital videodermoscope can be used to visualize hair and scalp structures
41140933|NCT01645241|DRUG|gonadotropins plus GnRH antagonists|
41300738|NCT02075502|BEHAVIORAL|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
40976344|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + one serving sugar sweetened beverage|90 grams added sugar
40976345|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + two servings sugar sweetened beverage|130 grams added sugar
40976346|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + three serving sugar sweetened beverage|170 grams added sugar
40976347|NCT01643655|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
41140934|NCT01645241|DRUG|ganirelix|
41140935|NCT00523458|DRUG|efavirenz or nevirapine|"Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin."
41140936|NCT00595764|BEHAVIORAL|Manual-guided Physician Management (PM)|Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.
41140937|NCT00595764|BEHAVIORAL|Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)|CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
40772076|NCT00189137|DRUG|ifosfamide and doxorubicin vs gemcitabine and docetaxel|"Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection."
40772077|NCT06266546|DRUG|Tranexamic acid|Prophylactic tranexamic acid will be instilled via endobronchial route in all patients undergoing transbronchial cryobiopsy. The medication will be administered through the bronchoscope one minute prior to the cryobiopsy. 500 mg of TXA diluted in 10 ml of saline and the procedure would be carried out as usual.
40772078|NCT04769869|DRUG|AZD4604 for inhalation via DPI|Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
40772079|NCT04769869|DRUG|Placebo for AZD4604 for inhalation via DPI|"Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI.~Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7.~Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10."
40772080|NCT04769869|DRUG|AZD4604 for IV administration|Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
40772081|NCT04769869|DRUG|AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
40772082|NCT04769869|DRUG|AZD4604 for inhalation via DPI|Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
40772083|NCT04442269|DRUG|dupilumab|Single-use prefilled glass syringe administered by subcutaneous (SC) injection.
40772084|NCT04442269|DRUG|Placebo|Matching placebo
40772085|NCT06261255|PROCEDURE|ATT + EMD|All surgical treatments will be performed by the same experienced periodontist (IP) after the administration of local anesthesia. Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the remaining fragments will be extracted as minimally invasively as possible. A tooth-supported surgical guide will be used to prepare the recipient site following the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the CARP model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if osteotomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, EMD will be applied to the root surface of the donor tooth
40976348|NCT06234657|BEHAVIORAL|Telerehabilitation for stroke patient|The subjects of the study were intervened by telerehabilitation through video instructions and online group training via Online meeting software. The content of the intervention program included upper limb exercises, transfer, and ambulation functions. This training program was designed based on the clinical practice guidelines for post-stroke physiotherapy management from the United States Department of Veterans Affairs and the guidelines for the diagnosis, and treatment of rehabilitation stroke patients of the Vietnam Ministry of Health. The training results of the subjects will be evaluated by the Barthel Index
40976349|NCT05577481|COMBINATION_PRODUCT|sham iTBS combined with antidepressants|Two sessions of sham prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
40976350|NCT05577481|COMBINATION_PRODUCT|iTBS combined with antidepressants|Two sessions of prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
41140938|NCT05836402|DIETARY_SUPPLEMENT|Low carbohydrate diet intervention|"Patients will receive a study kit. The kit will contain the following:~* Instruction sheet containing medical food instructions and food journal and a web link to the weekly online journal~* A 30-day supply of the medical food, KetoCitra, developed by Santa Barbara Nutrients, Inc. KetoCitra® is a ready-to-mix powder to be dissolved in water and taken twice per day with meals. KetoCitra® contains BHB, citrate, and a blend of minerals (potassium, calcium, magnesium) and is flavored with natural lemon flavor and stevia natural sweetener. KetoCitra® is sugar- and sodium-free and is intended to support the metabolic switch aimed for with the low-carbohydrate diet by providing exogenous BHB (Package insert)"
41140939|NCT05989178|OTHER|Data Registry|Follow-up questionnaires sent every year for the 5 years following the patient's initial visit.
41140940|NCT06032156|DIETARY_SUPPLEMENT|Low Dose β-OHB|Ingestion of a low dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.3 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
41140941|NCT06032156|DIETARY_SUPPLEMENT|High Dose β-OHB|Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
41140942|NCT06032156|OTHER|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
41140943|NCT02135666|PROCEDURE|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
41300739|NCT02075502|PROCEDURE|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
41300740|NCT02075502|PROCEDURE|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
40772086|NCT06548048|DIETARY_SUPPLEMENT|Dietary supplement containing plant derived phenolics|Dietary supplement containing plant derived phenolics
40772087|NCT06548048|DIETARY_SUPPLEMENT|Microcrystaline cellulose|Microcrystaline cellulose (MCC)
40772088|NCT05712681|DRUG|JP-1366 20mg tablet|T : JP-1366 20mg tablet after the meal
41300741|NCT04617613|DRUG|Omeprazole, Amoxicillin, Metronidazole and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
40772089|NCT05712681|DRUG|JP-1366 20mg tablet|R : JP-1366 20mg tablet under fasting condition
40772090|NCT05755269|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40772091|NCT05755269|PROCEDURE|Genotyping|Undergo genotyping
40772092|NCT05755269|OTHER|Survey Administration|Complete surveys
40772093|NCT00823797|DRUG|Bendamustine Hydrochloride|Given IV
40772094|NCT00823797|OTHER|Quality-of-Life Assessment|Ancillary studies
41300742|NCT04617613|DRUG|Omeprazole, Amoxicillin and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
41300743|NCT02945449|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
41300744|NCT03254017|PROCEDURE|Bilateral surgical implantation of DBS system to Habeluna|The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.
40772095|NCT00005978|BIOLOGICAL|filgrastim|
40976351|NCT03465202|DRUG|Capecitabine|
40976352|NCT03611764|BEHAVIORAL|Body Scan|-All efforts will be made to normalize their experience: for example, the desire to open their eyes, thinking about other things, wanting to move around - these are all normal and participants will be encouraged to become interested in and curious about, and to allow these natural tendencies
40976353|NCT03611764|OTHER|Rotterdam Symptom Checklist|"* 39 Likert-scale items, including physical and psychological symptoms (30 questions), daily function (8 questions), and overall valuation of life (one question)~* For the 30 questions pertaining to symptoms, the four-item Likert scale ranges from 'not at all=1' to 'very much=4'; the higher the total score, the greater the score, the higher the level of distress. The single question pertaining to overall valuation of life asks participants to circle one of the seven items, ranked from extremely poor to excellent"
40976354|NCT03611764|OTHER|Practice Logs|-Describe frequency of the Zen Den
40976355|NCT01476371|BEHAVIORAL|Mindfulness-based group treatment|An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here \& Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
40976356|NCT00369993|DRUG|fluticasone propionate/salmeterol|
40976357|NCT00147810|PROCEDURE|Telephone outreach to enhance asthma care|
40772096|NCT00005978|DRUG|carboplatin|
40772097|NCT00005978|DRUG|etoposide|
40772098|NCT00005978|DRUG|melphalan|
40772099|NCT00005978|PROCEDURE|autologous bone marrow transplantation|
40772100|NCT00005978|PROCEDURE|peripheral blood stem cell transplantation|
40772101|NCT00005978|RADIATION|iobenguane I 131|
40772102|NCT00005978|RADIATION|radiation therapy|
40772103|NCT03651206|DRUG|Niraparib|PARP Inhibitor
40976358|NCT01011634|DRUG|Intravenous moderate sedation versus oral medication|Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
40976359|NCT06190639|DRUG|sintilimab|200 mg once on day 1, every 21 days
40772104|NCT03651206|COMBINATION_PRODUCT|Niraparib + TSR-042 (Dostarlimab)|Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1
40772105|NCT03651206|DRUG|Chemotherapy Drugs|Chemotherapies given in standard of care
40772106|NCT00559039|OTHER|questionnaire administration|
40772107|NCT00559039|PROCEDURE|evaluation of cancer risk factors|
40772108|NCT01296165|BEHAVIORAL|Analysing the behaviours of travellers while visiting India|For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value \<0.05 will be deemed to represent statistical significance.
40976360|NCT03085420|DIAGNOSTIC_TEST|Echocardiogram|A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
41300745|NCT03254017|OTHER|Follow-up Period|The researchers will remotely program the DBS biweekly after opening the stimulator and face to face test the patients' cognitive function every half year. Montgomery-Asberg Depression Rating Scale will be tested biweekly until the Programmed parameter has stable therapeutic efficacy and then tested after 3 months, 6 months, 9 months and 12 months.The other neuropsychological scales will be test on 3 months, 6 months, 9 months and 12 months.
41300746|NCT01468727|DIETARY_SUPPLEMENT|xylitol wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
41300747|NCT01468727|DIETARY_SUPPLEMENT|placebo wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
40976361|NCT05654753|DRUG|active FMT|MaaT033®, a lyophilized full-ecosystem intestinal microbiota delayed release oral capsule containing native, donor-derived (pooled from 4-6 donors) microbiome product manufactured by MaaT Pharma® will be delivered orally. Patients will receive 20 Maat033 capsules, each containing approximatively 0.42 g of microbiome product at once at day 0, then 3 capsules/day from day 1 through day 20.
40976362|NCT05654753|DRUG|Placebo|Patients will receive 20 capsules placebo, each containing placebo at once at day 0, then 3 capsules/day from day 1 through day 20.
41459972|NCT04197154|BEHAVIORAL|Conditioning of moderate pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to 'baseline' pain of lower intensity."
41300748|NCT01850563|DEVICE|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
41300749|NCT02341170|RADIATION|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
41300750|NCT03430882|DRUG|Carboplatin|Given IV
41300751|NCT03430882|DRUG|Paclitaxel|Given IV
41300752|NCT03430882|DRUG|Sapanisertib|Given PO
41300753|NCT03817593|OTHER|Transcendental Meditation (TM)|Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
41300754|NCT00479804|DEVICE|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
41300755|NCT00479804|DEVICE|spirometry|spirometry for testing the ventilatory function
41300756|NCT00479804|DEVICE|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
41300757|NCT04152525|OTHER|Psychoeducation|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
40772109|NCT05603676|OTHER|Intermittent hypoxia-hyperoxia conditioning|The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.
41300758|NCT03204838|GENETIC|IDH mutation test performed at diagnosis|Observation of the test result
41300759|NCT03393013|DRUG|KZR-616|Subcutaneous Injection of KZR-616
40772110|NCT05603676|OTHER|Placebo intervention|Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
41300760|NCT03828838|DRUG|Lu-177 PSMA-617|Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)
41300761|NCT01863264|OTHER|Cold Thin Liquid Barium|Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
41300762|NCT03223220|DRUG|Ketamine|IV infusion
41459973|NCT04197154|BEHAVIORAL|Conditioning of high pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned high-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to pain of lower intensity."
41459974|NCT04197154|BEHAVIORAL|Extinction|"During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages ON and OFF) to pain stimuli of only lower intensity."
41459975|NCT02825316|BEHAVIORAL|Mediterranean diet|Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).
41459976|NCT02825316|BEHAVIORAL|Low residue diet|Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
41459977|NCT01833754|DRUG|Romosozumab|Administered as three 70 mg/mL prefilled syringe injections
41459978|NCT03563560|DRUG|Alvocidib|ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3
41459979|NCT03563560|DRUG|Cytarabine|300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
41459980|NCT03563560|DRUG|Mitoxantrone|14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)
41459981|NCT03563560|DRUG|Cytarabine|100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
41459982|NCT03563560|DRUG|Daunorubicine|60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
41459983|NCT06018064|DEVICE|Prone Positioner|An innovative device to allow for infants to be supported while in the prone position
41459984|NCT06532968|DEVICE|Sham|Sham
41459985|NCT06532968|DEVICE|ORION spinal lamina cover|an artificial lamina coverage of the ORION spinal system
41459986|NCT06427044|DRUG|Anterior serratus block group|Bupivacaine lipid 20mL (20mL 266mg bupivacaine liposomes) was ultrasound-guided for a single anterior serranus plane block
41459987|NCT05816655|DRUG|Fulvestrant plus AI plus ribociclib|Fulvestrant + AI + ribociclib +/- GnRH agonist
41459988|NCT05816655|DRUG|AI plus ribociclib|AI + ribociclib +/- GnRH agonist
41459989|NCT00595673|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
41459990|NCT05696509|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor.
41459991|NCT05696509|DRUG|Isoflurane|Isoflurane was used as an anaesthetic in a dose of - 1.1-1.2 MAC
41459992|NCT05696509|DRUG|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
41459993|NCT00510003|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
40772111|NCT06415240|OTHER|Facilitated Tucking|Facilitated Tucking is a position to be adopted for pain relief in neonates.
40772112|NCT06415240|OTHER|Gentle Human Touch|while gentle human touch is caressing on head for pain relief.
41300763|NCT03223220|OTHER|Normal Saline|IV infusion
41459994|NCT05454085|DIETARY_SUPPLEMENT|Bisphenol-A|measurement of BPA levels in maternal blood and amniotic fluid
41459995|NCT01566994|BEHAVIORAL|TTM Tailored|This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages
41459996|NCT01566994|BEHAVIORAL|Motivational Enhancement Therapy|This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.
40772113|NCT04921267|BEHAVIORAL|training|training with filtered speech
40772114|NCT00646230|DRUG|fenretinide|
40772115|NCT00646230|OTHER|high performance liquid chromatography|
40772116|NCT00646230|OTHER|pharmacological study|
41300764|NCT03223220|DRUG|Midazolam injection|Injection
41459997|NCT01566994|BEHAVIORAL|Integrated Treatment|This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
41459998|NCT02377349|BIOLOGICAL|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
41459999|NCT02377349|DRUG|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
41300765|NCT01123239|BEHAVIORAL|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches, who themselves have diabetes, and have been trained to meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making. Using a decision tree algorithm, they help patients identify relevant questions about symptoms, barriers to self-management and treatment options to discuss with doctor. They encourage mutual decision-making about tailoring the patient's medication regimen, diet and physical activities and work with the patients to overcome barriers to communication with their doctor. After the medical visit, the coach and patient review any treatment decisions and goals for self-care."
41300766|NCT01123239|BEHAVIORAL|Standard Diabetes Education|Patients randomized to the control group will receive 20 minutes of standardized diabetes education delivered by staff research assistants. Education materials have been adapted from materials developed by the American Diabetes Association. The content of these materials includes information about the causes and complications of diabetes, as well as ways to reduce complication risks. Patients in the control arm will receive 20 minutes of standardized diabetes education before each visit
41300767|NCT06551077|PROCEDURE|POSTERIOR RECTUS SHEATH HIATAL AUGMENTATION (PORSHA)|Use of a novel permanent autologous vascularized biologic fascial flap to reconstruct the diaphragmatic hiatus following standard hiatal hernia repair in selected patients. This technique is called a posterior rectus sheath flap hiatal augmentation or PoRSHA.
41300768|NCT03380117|BEHAVIORAL|eBridge Online Counseling|In eBridge, students take an online screen and receive personalized feedback about their self-reported depression, alcohol/substance use, and level of functioning. Students are randomly assigned to either the eBridge or control condition. In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students' communications with eBridge counselors will occur via online dialogues, in which students and counselors exchange messages using a secure website. In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
41300769|NCT06368739|BEHAVIORAL|Nurture program|"1. Nurture Monthly Packages: Sent every four weeks until the member reaches the end of pregnancy (delivery or other reasons, e.g., miscarriage), with a maximum of eight packages. Each package includes:~   * A US$40 gift card (2 x $20 each) to a grocery store.~  * A healthy eating information sheet selected from Brighter Bites project (https://brighterbites.org/).~  * A set of three recipes.~  * Nutrition-related Frequently Asked Questions (included in four out of the eight packages).~2. Two 30-Minute Nutritional Consultations over the phone: Designed by a Registered Dietitian Nutritionist (RDN) who trained a bilingual nutrition specialist to deliver the consultations. Topics revolved around healthy eating during pregnancy, such as food choices, portion sizes, budget-friendly shopping, food safety, and food preparation. No nutrition therapy advice to manage diseases was provided."
41300770|NCT06368739|OTHER|Regular benefits|Includes regular healthcare services offered as part of the health plan coverage with Medicaid/CHIP.
41300771|NCT03341897|PROCEDURE|endovasculer embolization of varicocele|"Step 1: Vascular Access~Access can be achieved via the internal jugular or femoral veins. Step 2: Left Renal Vein Injection Step 3: Left Spermatic Vein Catheterization Step 4: Spermatic Vein Occlusion Step 5: Right Spermatic Venography POSTPROCEDURE CARE~The patient is kept in bed for 1 hour postprocedure. The patient is advised to take anti-inflammatory agents as needed and to avoid any activity involving the Valsalva maneuver, such as lifting, vigorous, or hitting type sports for 3 full days beginning the day after the proce¬dure. Most patients report a minor dull ache in the back or groin lasting \< 2 to 5 days. Fewer than 5% of patients will develop more severe pain lasting up to 14 days, requiring oral analgesics and anti-inflammatory agents and avoidance of vigorous exercise."
41300772|NCT01505491|DRUG|adalimumab|40mg adalimumab single s.c. injection
41300773|NCT01505491|DRUG|BI695501|BI 695501 single s.c injection
41300774|NCT01505491|DRUG|adalimumab|40mg adalimumab single s.c. injection
41300775|NCT06370702|OTHER|Handgrip Exercises|Participants will firmly grip and squeeze the ball for 10 seconds, relax for 10 seconds and repeat for 10 minutes. They will be instructed to do this 3 times per day.
41460000|NCT05704491|DIAGNOSTIC_TEST|artificial intelligence (AI) algorithm of the MONA DR model|A 45-degree fundus image is taken for each eye and patient using the Crystalvue NFC 600. The fundus photographs are then analyzed using the MONA DR model and classified for presence of diabetic retinopathy.
41460001|NCT04546412|DEVICE|Vitrification and thawing|Vitrification using the Cryotop® - Open System followed by thawing
41460002|NCT01318161|DRUG|Ropivacaine + opioid epidurally|Epidural analgesia with local anesthetic + opioid
41460003|NCT01318161|DRUG|Morphine|Morphine via PCA pump
41460004|NCT04742608|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
41460005|NCT04742608|OTHER|Electronic Health Record Review|Medical charts are reviewed
41460006|NCT04417348|DRUG|Retinoic acid|To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
41460007|NCT00002976|DRUG|conjugated estrogens|
40772117|NCT06385028|BEHAVIORAL|Physical activity promotion|The intervention will be delivered through a phone application: each week, the participant will define a new daily step goal for the following week. Then he/she will receive daily notifications (except Sundays) about physical activity, sedentary behavior and their consequences on general health and osteoarthritis specifically. These notifications are designed to promote physical activity in this specific population.
41460008|NCT01705002|DRUG|Promitil|2 mg/kg dose IV
41460009|NCT01705002|DRUG|Capecitabine|1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
41460010|NCT01705002|DRUG|Bevacizumab|for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
41460011|NCT03794245|BEHAVIORAL|Men-Centered HIV Testing|The intervention involves bringing mobile HIV testing to venues where men congregate, talking to them as a group about HIV testing, and then providing testing at that venue.
40772118|NCT01524744|DRUG|Pimecrolimus ointment|Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
40976363|NCT06171633|BEHAVIORAL|E-STOP online educational program (treatment condition)|Participants access online video modules through an online learning platform. Program includes modules on civility and upstander interventions and education about sexual harassment, microaggressions, and implicit bias.
40976364|NCT06171633|BEHAVIORAL|E-STOP online educational program (control condition)|Participants access online video modules through an online learning platform. Program includes authorship ethics only.
40976365|NCT04518150|DEVICE|Bakri balloon|the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
40976366|NCT04518150|PROCEDURE|Bilateral Uterine Artery Ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
40976367|NCT01264588|OTHER|Topical calcium glycerophosphate lotion|2g once daily for 6 weeks (post-op day 3 thru 42)
41140944|NCT06341504|BEHAVIORAL|Prevention pop-up messages|"Messages are shown full screen on the EGM's play screen on a fixed presentation schedule. Clock of the gambling session starts the first time the participant puts money in the EGM. From this event, messages are shown at those timepoints: \[1\] +10 minutes; \[2\] +40 minutes; \[3\] +70 minutes; \[4\] +100 minutes. Messages block the screen for 15 seconds before automatically closing. Up to 4 different messages are presented during the gambling session. Order is determined by sortition without replacement.~Messages have a warning heading Caution!. Content is, from top to bottom: (a) time spent gambling from beginning; (b) warning that gambling could lead to serious monetary loss; (c) 1 of 4 self-appraisal phrases about current gambling behaviour; (d) advice to the participant that a break could help choose what is best for them; (e) countdown before the message closes itself; (f) Health department logo is shown in the lower right corner as a more neutral endorsement of the messages."
41300776|NCT04723108|OTHER|Destek V4 Virtual Reality Headset|The DESTEK V4 is a smartphone VR headset made by DESTEK, a manufacturer based in the US. This mobile virtual reality headset is compatible with most iOS and Android smartphones, as long as their screen size is between 4.5 and 6.
41300777|NCT03072017|BEHAVIORAL|MBAT|Breathing-based intervention
41300778|NCT00331786|DRUG|nitric oxide-releasing acetylsalicylic acid derivative|
41300779|NCT00331786|OTHER|laboratory biomarker analysis|
41300780|NCT00331786|PROCEDURE|biopsy|
41300781|NCT02725892|OTHER|NIS observational stud|NIS observational study : Epidemiologic registry
41300782|NCT04017533|PROCEDURE|GMK Sphere TKR|Se earlier
41300783|NCT03336138|OTHER|AMA (Assistance for ambulatory patients)|telephone follow-up modality
41300784|NCT03739944|PROCEDURE|Laparotomic radical hysterectomy|Laparotomic radical hysterectomy for patients without fertility requirement
41300785|NCT03739944|PROCEDURE|Laparotomic radical trachelectomy|Laparotomic radical hysterectomy for patients with fertility requirement
41300786|NCT03739944|PROCEDURE|Laparoscopic radical hysterectomy|Laparoscopic radical hysterectomy for patients without fertility requirement
41300787|NCT03739944|PROCEDURE|Laparoscopic radical trachelectomy|Laparoscopic radical hysterectomy for patients with fertility requirement
41300788|NCT03003416|DRUG|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
41460012|NCT03794245|BEHAVIORAL|Linkage to Care for HIV+ Men|Men diagnosed with HIV are accompanied to the clinic and registered there with the help of a community health worker.
40772119|NCT01524744|DRUG|Adcortyl|triamcinolone acetonide 0.1% in orabase
40772120|NCT01714674|DIETARY_SUPPLEMENT|Dietary nitrate beverage|ingestion of single dose NaNO3 beverage two hours prior to exercise bout
41460013|NCT03794245|BEHAVIORAL|Clinic-based HIV Testing|Individuals present to a clinic and request HIV counseling and testing
40772121|NCT01714674|DIETARY_SUPPLEMENT|NaCl beverage|ingestion of single dose NaCl beverage two hours prior to exercise bout
40772122|NCT02880319|DRUG|Stereotactic Body Radiation Therapy (SBRT)|
40772123|NCT02880319|DEVICE|Stereotactic Linear Accelerator|
40772124|NCT01514357|DRUG|Nesiritide (BNP)|NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.
40772125|NCT01514357|DRUG|Placebo|Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
40772126|NCT02704884|DIETARY_SUPPLEMENT|probiotic soy milk|
40772127|NCT01300637|DRUG|Metformin|metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
40772128|NCT01300637|DRUG|placebo|identical-appearing pill of placebo
40976368|NCT03551028|DEVICE|HPV self collection|The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
40976369|NCT02678260|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
40976370|NCT02049957|DRUG|Sapanisertib|Sapnisertib capsules
40976371|NCT02049957|DRUG|Fulvestrant|Fulvestrant IM injection.
40976372|NCT02049957|DRUG|Exemestane|Exemestane tablets.
40772129|NCT03884673|DRUG|DTG+ 3TC|It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
40772130|NCT05703295|PROCEDURE|Biopsy|Sentinel lymph node biopsy
40772131|NCT02124408|BEHAVIORAL|Personalized Behavioral Intervention|
40772132|NCT05486507|DIETARY_SUPPLEMENT|Montmorency tart cherry|US grown Montmorency tart cherry 60ml per day for 6 weeks.
40772133|NCT05486507|DIETARY_SUPPLEMENT|Placebo|Taste matched placebo.
40772134|NCT05338307|DIETARY_SUPPLEMENT|R-1,3-Butanediol|Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol.
40772135|NCT01978301|DRUG|Triamcinolone acetonide|Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
40772136|NCT01978301|DRUG|Placebo|Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
40772137|NCT04363892|OTHER|Optical and infrared imaging|Acquiring images (photographs) of the skin
40976373|NCT04806854|DRUG|LUM-201|Administered orally once daily
40976374|NCT03053284|DRUG|Pasireotide 0.6Mg Solution for Injection|Pasireotide 0.6Mg Solution for Injection will be given once per study visit
40976375|NCT03053284|DRUG|Saline Solution|Saline Solution injection will be given once per study visit
40976376|NCT02399826|DEVICE|Offloading|"Provision of an offloading cam walker or cast boot, may also convert to total contact cast and add felt or foam to supplement"
40772138|NCT05280860|PROCEDURE|ultrasound-guided bilateral rectus sheath block|Bilateral RSB was guided by ultrasound before surgery after the completion of general anesthesia, First, the probe is placed transversely and perpendicular to reveal the anterior, hypoechoic, and posterior rectus sheath of the hyperechoic rectus abdominis. Moving the probe outward to reveal the sound images of the lateral margin of the rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles. After the scanning, the needle was inserted from any segment of the probe under the guidance of real-time ultrasound; the tip reached between the rectus abdominis muscle and the posterior sheath of the rectus abdominis muscle. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct, If the needle tip was correctly positioned, 0.5 % ropivacaine 10 mL of local anesthetic was injected on each side. The same anesthesiologist was performed bilateral RSB under ultrasound guidance.
40772139|NCT00661856|DIETARY_SUPPLEMENT|Soy protein|25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
40772140|NCT04171960|DIAGNOSTIC_TEST|Blood draw|Venous whole blood collection within 12 hours and 12-24 hours following injury.
40772141|NCT04171960|OTHER|Outcome assessments|Administered at baseline.
40772142|NCT03452345|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
40772143|NCT03452345|DRUG|Placebo|Placebo (Normal saline)
40976377|NCT02399826|PROCEDURE|Dressing Application|Application of a non adherent dressing, and a multi-layer compression dressing
40976378|NCT03186222|DIAGNOSTIC_TEST|blood sample|"Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.~The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method."
40772144|NCT02311504|DEVICE|OCT examination|
40772145|NCT01483560|DRUG|Metformin|3 years treatment duration
40772146|NCT01483560|DRUG|Placebo|3 years duration
40976379|NCT04077983|DRUG|combined therapy using nab-paclitaxel and gemcitabine chemotherapy|"1. Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~2. Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~3. Three weeks is a course of treatment with a total of 4 courses."
40976380|NCT02431234|OTHER|serum RANKL|
41460014|NCT03794245|BEHAVIORAL|Clinic Referral for HIV+ Men|Individuals diagnosed with HIV are referred to the nearest clinic for treatment of HIV
40772147|NCT02133079|BIOLOGICAL|autologous gp96 vaccination|vaccination of autologous gp96 derived from tumor tissue + basal treatment
40772148|NCT03058887|OTHER|Exercise intervention - Cycling|The patients that will be randomly allocated to the exercise group - cycling will be requested to perform an exercise session on a cycle ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
40772149|NCT03058887|OTHER|Exercise intervention - arm cranking|The patients that will be randomly allocated to the exercise group - arm cranking will be requested to perform an exercise session on an arm crank ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
40772150|NCT05905146|OTHER|personalized pharmaceutical plan|multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
40772151|NCT01480830|DEVICE|Magnetic Endoscopic Imaging (MEI) colonoscopy|Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
40772152|NCT04029779|BIOLOGICAL|I-PRF|Local anaesthesia was administered and mucoperiosteal flap was reflected. Atraumatic tooth extraction was performed. Socket was curetted to remove the granulation tissue present in the socket with the help of curettes. The socket was well irrigated with saline. Implant osteotomies wasl performed with sequential drilling with standardized drills.I-PRF was freshly prepared 600rpm for 7 min(50g). 1ml of the i-PRF was applied in to the osteotomy site and the implant surface will be thoroughly coated followed by placing of the implant. The surgical site was thoroughly irrigated and debrided. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
40772153|NCT06424067|DRUG|Fingolimod 0.5 milligram (mg) [Gilenya]|Oral fingolimod will be administered at a dose of 0.5 mg once a day.
40976381|NCT00667004|DRUG|ecabet ophthalmic solution|sterile ophthalmic solution
40976382|NCT00667004|DRUG|placebo|sterile ophthalmic solution
40976383|NCT00004760|BEHAVIORAL|Exercise|
41460015|NCT01721772|BIOLOGICAL|BMS-936558 (Nivolumab)|
41460016|NCT01721772|BIOLOGICAL|Placebo matching BMS-936558 (Nivolumab)|
41460017|NCT01721772|DRUG|Dacarbazine|
40976384|NCT04993092|OTHER|muscle energy technique|Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
40772154|NCT05577741|BEHAVIORAL|Multisensory virtual reality pod (SENSIKS©)|Six sessions of 20 minutes of mindfulness.
40976385|NCT04993092|OTHER|mulligan mobilization technique|Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
41140945|NCT06341504|BEHAVIORAL|Mandatory time limit|Activated either when (a) the previous time limit is up; or (b) the player bank meter reaches $0. When the previous time limit is up, a pop-up takes up the upper third of the play screen and requires the player to set a new time limit using one of five choice buttons (four firsts buttons: 15, 30, 45 or 60 minutes; fifth button: cash out, which prints a receipt and ends the gambling session). As the EGM cannot track who is playing, there are no limits on consecutive gambling sessions. When the player's bank meter reaches $0, the the pop-up described above appears as soon as new money is inserted in the EGM, no matter if the previous time limit is up or not.
40772155|NCT05577741|BEHAVIORAL|Cognitive bike (Vélo-cognitif®)|Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).
40772156|NCT05577741|OTHER|Standard treatment|Standard of care treatment
40772157|NCT03350945|PROCEDURE|Device: tumor localization|At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
40772158|NCT06059898|DEVICE|GBR surgery including membrane placement|After the application of local anesthesia, an incision of the mucosa will be performed and the flap will be elevated. The flap closure line should not be directly over the defect, but away from the defect site to prevent wound dehiscence. The bony defect will be thoroughly cleaned and, in some cases, activated by drilling small holes in the cortical bone to increase blood flow into the bone graft. Bone substitute will be inserted, the membrane will be adapted and fixed, and the flap will be sutured
40772159|NCT06059898|PROCEDURE|Biopsy|After a healing period of 6 months, at the implantation site, a biopsy is taken from the site of dental implant insertion for further analysis of bone regeneration
40772160|NCT02116023|OTHER|Orange flavored beverage|
40772161|NCT04055012|DRUG|Metformin|500mg tabs of Metformin Extended Release
40772162|NCT04055012|DRUG|Placebo|Placebo Tabs
40976386|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation
40976387|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Standard treatment
40976388|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Intensified treatment
40976389|NCT05605314|OTHER|Cyclosporine|eye drop
41140946|NCT06341504|BEHAVIORAL|Responsible gambling information|Located in a submenu accessed through a button on the main touch screen. This open a window which contains basic information on randomness and responsible gambling advice. The information is presented in small white font on a black background.
41300789|NCT05103319|OTHER|Data collection for statistical analysis to identify patterns of treatment response/ non-response|All data are restricted from the patient physical and electronic record of the Pain Management-Unit of the University Hospital Basel. No external data sources will be used. Records will be screened from 2012- May 2021. Variables collected are e.g. demography, medical diagnosis, psychological diagnosis, infusion therapy, medication, pain.
41300790|NCT05415956|BEHAVIORAL|Walking exercise therapy|Moderate-to-high intensity walking exercise therapy (7 weeks, 14 session) with progression in duration and intensity.
41300791|NCT02624401|DRUG|Dexmedetomidine|Intravenous infusion
41300792|NCT02624401|DRUG|Propofol|Intravenous infusion
41300793|NCT02624401|DRUG|S-ketamine|Intravenous infusion
40772163|NCT00541424|PROCEDURE|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
40772164|NCT06485310|OTHER|Teleconsultation for psychological support|Teleconsultation with a nurse for psychological support, after the diagnosis has been announced, before hospitalization for the first treatment (chemotherapy, surgery, radiotherapy) in addition to the standard practice
40772165|NCT04501822|DIAGNOSTIC_TEST|Evaluation of clinical, instrumental and laboratory diagnostics tests|During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests
40772166|NCT03370315|OTHER|Dance Program|The dance program consists of dance classes inspired by the rhythm of Forró and Samba. The sessions are divided into four stages: 1) stretching and sensitization of the body, with the support of chairs; 2) balance and rhythm exercises, with the support of the bar; 3) dance inspired by the genres worked - Forró and Samba; 4) Fun activities that stimulate socialization or with visual clues, working displacements, motor coordination, rhythm, improvisation and creativity. 24 sessions, twice a week, which session take 60 min.
40976390|NCT00748683|OTHER|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
40976391|NCT00504933|DRUG|bilastine|20 mg (encapsulated) tablets QD/14days
41460018|NCT01721772|DRUG|Placebo matching Dacarbazine|
40772167|NCT03370315|OTHER|Walking Program|The walking program consists of 3 moments: 1) a brief warm-up of free walking for 3 minutes in the comfortable velocity; 2) then walking according to the training cycle, the intensity will be between 60 and 80% of the reserve heart rate; 3) a relaxation. 24 sessions, twice a week, which session take 60 min.
40976392|NCT00504933|DRUG|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
40976393|NCT00504933|DRUG|Placebo|(encapsulated) Tablets QD/14 days
40976394|NCT06243809|DRUG|Linagliptin 5 mg Oral Tablet|Linagliptin 5 mg Oral Tablet
40976395|NCT06243809|DRUG|Trajenta 5 MG Oral Tablet|Linagliptin 5 mg Oral Tablet (Trajenta )
40976396|NCT00241280|DEVICE|etafilcon A|
40976397|NCT00241280|DEVICE|galyfilcon A|
40976398|NCT00464087|DRUG|Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin|
40976399|NCT03847233|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
40976400|NCT01635101|DRUG|IV Acetaminophen|IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours
40976401|NCT01635101|DRUG|IV Control|IV Control q6h; 4 doses, in 24 hours
40976402|NCT06231615|OTHER|Fascia exercises|Fascia exercises are slow and calm movements similar to yoga performed by the person herself/himself.
41140947|NCT06341504|DEVICE|Electronic gambling machine (model IGT GL20)|"EGM model currently in use in Quebec, Canada, the location where this study is conducted. The EGMs used in this study are fully functional and unaltered except for the presentation of prevention pop-up messages in the experimental arm of this study. These machines are equipped with basics responsible gambling features, the two main ones described in this section (i.e. Mandatory time limit; Responsible gambling information). Wins/losses sequence is fully randomized and not determined beforehand."
40772168|NCT01537328|OTHER|Total knee replacement rehabilitation|After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
40772169|NCT01623947|DIETARY_SUPPLEMENT|Placebo Beverage|1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
40772170|NCT01623947|DIETARY_SUPPLEMENT|2.8 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
40772171|NCT01623947|DIETARY_SUPPLEMENT|19.6 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
40772172|NCT01616147|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
40772173|NCT01616147|BEHAVIORAL|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
40772174|NCT01352455|PROCEDURE|Hemodialysis|5 days per week hemodialysis
40772175|NCT05044767|DEVICE|total hip arthroplasty|hip replacement surgery
40772176|NCT05501899|DRUG|Levocarnitine|Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients \< 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)
40772177|NCT03575598|DRUG|Sitravatinib|Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
40772178|NCT03575598|BIOLOGICAL|Nivolumab|Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
40772179|NCT04392622|DRUG|D-Limonene Gelcaps|Administered orally at 2 to 8 grams daily
40772180|NCT04392622|RADIATION|Intensity modulated radiotherapy (IMRT)|Standard of Care -All patients will receive standard radiation treatment of 66 to 70 Gy given in 33 to 35 fractions (2 to 2.12 Gy/fractions) over 6.5 to 7 weeks.
40772181|NCT04392622|DRUG|Cisplatin|Standard of Care -Cisplatin as 100 mg/m2 IV
40772182|NCT04392622|OTHER|Xerostomia questionnaire|Xerostomia questionnaire consists of 4 items on dryness while eating/speaking and 4 on dryness at rest. Patients rate each symptom on an 11 point ordinal Likert scale from 0 to 10, with higher scores indicating greater xerostomia
40772183|NCT02951481|BEHAVIORAL|Systematic evaluation by an ID expert.|"Specific bundle of measures:~1. Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy (antimicrobial stewardship).~2. To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course."
40772184|NCT00732888|DRUG|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
41460019|NCT03552367|OTHER|Personalized structured exercise program|The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters. Patients are monitored using a heart rate monitor to evaluate treatment adherence and compliance
40772185|NCT00732888|DIETARY_SUPPLEMENT|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
40772186|NCT03025035|DRUG|Pembrolizumab|Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
40976403|NCT06231615|OTHER|Conventional physiotherapy and breathing exercises|Head and neck exercises and breathing exercises
40976404|NCT01652898|DRUG|LDLA202|Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
40976405|NCT01652898|DRUG|ONO LDL50|Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
41300794|NCT02624401|DRUG|Sevoflurane|Inhalation
41300795|NCT02624401|DRUG|Placebo|Intravenous infusion of saline (Ringer's Acetate)
41460020|NCT03552367|OTHER|Non personalized non-structured exercise program|The type of exercise is non-structured and patients' heart rate is not monitored. Patients receive exercise recommendations without any personalization according to their fitness parameters
41460021|NCT03438643|DIAGNOSTIC_TEST|Blood samples|Blood samples (42mL) will be taken before and during treatment.
41300796|NCT06504550|OTHER|Schroth Exercises|The patients in the Schroth exercise group will start their exercise program under physiotherapist supervision.Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.These exercises include spinal elongation, de-rotation, de-flexion, stretching, strengthening exercises to maintain vertebral alignment.The participants will be asked to combine these exercises with their daily living activities (ADLs).During the Schroth exercises, rice bags, foam blocks, a stool, and long sticks will be used to adjust the posture and give passive support.Exercises are progressed from lying, sitting, or standing positions and from most to least passive support per a review of the quality of the performance.Decreasing the amount or degree of passive support, changing the patient's position, and adjusting the sets and repetitions of exercises will depend on the patient's improvement in exercise performance
40772187|NCT03025035|DRUG|Olaparib|Olaparib administered orally twice a day
40976406|NCT01652898|DRUG|Esmolol hydrochloride|Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
40976407|NCT00248014|DEVICE|Mandibular Advancement Via A Functional Appliance|Functional appliance
40772188|NCT05919563|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
40976408|NCT03123653|DRUG|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks
40772189|NCT05727332|BEHAVIORAL|Single-Sprint Training|A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks
41140948|NCT06341504|DEVICE|Square terminal|This terminal allows for buying non-alcoholic beverages (soft drinks or coffee) and chips during the experimentation. This is done to enhance the realism of the bar setting. It also allows for real cash withdrawal from bank account during gambling session. Quebec's code of conduct for EGMs commercialization prohibits retailers from having an ATM near their EGMs, and prohibits them from lending money to consumers or withdrawing cash for them to gamble. However, this rule is not always followed in practice. For this study, participants will be allowed to withdraw from their bank account, at the bar counter, if they ask for it. However, this will not be offered to them upfront.
41300797|NCT06504550|OTHER|Klapp Exercises|The patients in the Klapp exercise group will be treated with supervised klapp exercises. Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.In each session, a sequence of 8 postures of Klapp Exercises will be carried out. Each posture will be maintained for 4-5 minutes with rest breaks when needed.Positions that will be held are: 1) Lateral crawl, 2) Horizontal sliding, 3) Crawl posture near the ground, 4) Bunny hopping, 5) Arm turn, 6) Big arch, 7) Lateral crawl near the ground, 8) Big curve
41300798|NCT03785717|PROCEDURE|ROG|Bone width augmentation using bone grafting and membrane non cross linking.
41300799|NCT03785717|PROCEDURE|ROG & ESWT|Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
41300800|NCT02088684|DRUG|LEE011|LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
41300801|NCT02088684|DRUG|BYL719|BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
41300802|NCT02088684|DRUG|fulvestrant|Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
40772190|NCT03716596|RADIATION|SBRT|SBRT radiation dose is 40-50 Gy in total.
41140949|NCT03507998|DRUG|CGX1321|CGX1321 capsules for oral administration
40976409|NCT02401815|DRUG|PLX9486|PLX9486 will be administered per dose and schedule specified in the arm.
40976410|NCT02401815|DRUG|Pexidartinib|Pexidartinib capsules will be administered per dose and schedule specified in the arm.
41140950|NCT04769921|DEVICE|dental implants and abutments from Nobel Biocare|The implants will be inserted in an All-on-4 configuration; Abutments will be connected to the implants and serve as support for a full-arch implant-supported restoration.
40772191|NCT03716596|DRUG|anti-PD-1 antibody|Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
40772192|NCT01172782|DRUG|Hydromorphone|2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
41140951|NCT04653285|BEHAVIORAL|motor skill practice|Motor learning task on a stability platform (stabilometer). Participants try to keep the tiltable platform in a horizontal position in trials of 30s.
40772193|NCT05098821|OTHER|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
40772194|NCT02970565|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
40772195|NCT02970565|BEHAVIORAL|Nutrition and Play Intervention|Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
40772196|NCT05790876|PROCEDURE|SSO2 therapy|SSO2 therapy consists of overoxygenating the patient's blood and delivering it to the origin of the LAD for 60 min. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images
40976411|NCT02401815|DRUG|Sunitinib|Sunitinib will be administered per dose and schedule specified in the arm.
40976412|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: exposure in vivo|Behavioral, chronic pain rehabilitation therapy
40976413|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: graded activity|Behavioral, chronic pain rehabilitation therapy
40976414|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: acceptance and commitment therapy|Behavioral, chronic pain rehabilitation therapy
41140952|NCT04653285|BEHAVIORAL|aerobic exercise|A bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice.
41140953|NCT04653285|BEHAVIORAL|rest|Seated rest following motor skill practice.
41140954|NCT00002086|DRUG|Zidovudine|
41140955|NCT00002086|DRUG|Zalcitabine|
41140956|NCT00002086|DRUG|Interferon alfa-n1|
40772197|NCT06564064|DEVICE|abdominal binder|study group will be abdominal binders and control group will be control group , 12 hrs and one week later VAS and QOR 40 will assess patient,s wellbeing
40772198|NCT02875418|DEVICE|EUM|"STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
40772199|NCT02875418|DEVICE|Tocodynamometry|"STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
40772200|NCT03926013|DRUG|JNJ-63898081|JNJ-63898081 will be administered.
40772201|NCT03367104|DEVICE|ECG Belt|Assess electrical dyssynchrony with an anterior-posterior body surface mapping system.
40772202|NCT06042816|PROCEDURE|Free-opioid anesthesia|Free opioid anesthesia (FOA) has been used in many countries around the world, making use of multimodal analgesia therapy which includes hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics and anti-inflammatory agents and sympathetic block in surgery. This method was demonstrated to contribute to enhanced recovery after surgery (ERAS). The use of long-acting local anesthetics also enhances postoperative pain relief. As a result, the concept of balanced anesthesia now has a change in three basic components: hypnotics, muscle relaxants and sympathomimetic inhibitors
40772203|NCT06042816|PROCEDURE|opioid anesthesia|Opioids have been used as one of three basic components of balanced anesthesia, including anesthetic drugs, pain relievers, and neuromuscular blockade agents (opioid anesthesia). Opioids not only facilitate deep anesthesia but also create the most favorable conditions for surgeries. Fentanyl is a potent opioid used to control pain, reduce the dose of sympathomimetic inhibitors and maintain hemodynamic stability. However, several common side effects of fentanyl are well known: nausea and vomiting, constipation, urinary retention, headache, pruritus, rash, histamine release, biliary spasm and respiratory depression, the most severe adverse effect
40772204|NCT02766855|DRUG|Cysteamine|Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
41140957|NCT03420040|DEVICE|QS-M Needle Free Injector|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
41140958|NCT03420040|DEVICE|Glargine pen|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
41140959|NCT02819609|PROCEDURE|myomectomy|Myomectomy as part of routine clinical care
41460022|NCT03438643|DIAGNOSTIC_TEST|skin biopsy|skin biopsy will be taken before and during treatment.
41140960|NCT02819609|PROCEDURE|endometrial ablation|Endometrial ablation as part of routine clinical care
40772205|NCT05847153|BEHAVIORAL|MASC|"The intervention arm will be comprised of:~1. Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~2. At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
40772206|NCT01542892|OTHER|Exercise Intervention|Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
40772207|NCT01542892|DIETARY_SUPPLEMENT|Supplement Intervention|Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
40772208|NCT00270556|DRUG|tenofovir disoproxil fumarate|
40772209|NCT00270556|DRUG|Abacavir|
40772210|NCT04824911|DRUG|Clopidogrel|300mg loading and 75mg/day from day 2
40772211|NCT04824911|DRUG|Aspirin|Aspirin(100-300mg/day)
41140961|NCT02819609|PROCEDURE|uterine artery embolization|Uterine artery embolization as part of routine clinical care
41140962|NCT02819609|PROCEDURE|MRI-guided focused ultrasound ablation|MRI-guided focused ultrasound ablation as part of routine clinical care
41140963|NCT00681226|DRUG|Ramipril or matching placebo|10 mg Ramipril or matching placebo once daily for 6 months
41140964|NCT02197702|DIETARY_SUPPLEMENT|vitamin D|Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter
41460023|NCT01489605|DEVICE|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
41460024|NCT01489605|DEVICE|Control: Standard GlideScope|Patients will be intubated using the standard GlideScope. (Verathon)
40976415|NCT05433805|OTHER|Fasting-mimicking diet (FMD) and physiotherapy|"FMD is a diet held monthly during five days with the restriction of calories to less than 1000 kcal, glucose and proteins.~Physiotherapy will be organized as home-based exercises explained by the physiotherapeutist at the beginning of the study."
41140965|NCT02197702|DIETARY_SUPPLEMENT|placebo|Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
41300803|NCT02088684|DRUG|BKM120|BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
41300804|NCT02364193|DEVICE|MRI|"Cardiac MRI for LVEF and segmentation.~* Phase-contrast MRI for CO in aorta and each pulmonary vein.~* DCE-MRI for bolus kinetic parameter analysis."
41300805|NCT02364193|DRUG|Gd-CA|Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
41300806|NCT02364193|DEVICE|BIS ImpediMed™ SFB7|"BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).~Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.~Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds."
41300807|NCT02364193|DEVICE|Autotransfusion Lympamat Digital Gradient system|Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
41300808|NCT03886181|DEVICE|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
41300809|NCT00303108|DRUG|Pegylated liposomal doxorubicin|30 mg/m2 IV on Day 1 of each 28 day cycle
41300810|NCT00303108|DRUG|Carboplatin|AUC=5 on Day 1 of each 28 day cycle
41300811|NCT00303108|DRUG|trastuzumab|4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
41300812|NCT03169738|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
41300813|NCT03169738|BIOLOGICAL|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
41300814|NCT03169738|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
41300815|NCT03169738|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
41300816|NCT03169738|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
41300817|NCT03169738|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
41300818|NCT03169738|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
41300819|NCT03169738|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
41300820|NCT03169738|DRUG|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
41140966|NCT02735005|OTHER|SMAF assessment|"After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)"
41300821|NCT03169738|BIOLOGICAL|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
41140967|NCT04210830|DIAGNOSTIC_TEST|Quantra-Device|Point of Care Coagulation Monitoring System
41300822|NCT03169738|DRUG|Lovaza|Omega-3-acid ethyl esters
41300823|NCT03169738|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
41300824|NCT03169738|RADIATION|Stereotactic Body Radiation Therapy|(SRBT)
41300825|NCT03169738|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL15N72D:IL-15RαSu/IgG1 Fc complex\]
41300826|NCT03169738|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
41300827|NCT03169738|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
41300828|NCT03169738|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
41300829|NCT03169738|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
41300830|NCT03169738|BIOLOGICAL|GI-4000|Ras yeast vaccine
40976416|NCT01214811|DEVICE|Mepilex Border Ag|Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
40976417|NCT02177305|DRUG|0.02 mcg tiotropium solution|
41300831|NCT03169738|BIOLOGICAL|GI-6207|CEA yeast vaccine
41300832|NCT03169738|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
41300833|NCT03169738|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
41300834|NCT00854529|DRUG|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
41300835|NCT06134167|DEVICE|Transdermal Compress Device|Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participants will be followed through the end of the study as they complete rehabilitation.
41300836|NCT04437017|DRUG|Olanzapine+NK-1 RA+5-HT3 RA|On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
41300837|NCT04437017|DRUG|Dexamethasone+NK-1 RA+5-HT3 RA|On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.
41300838|NCT04850040|DRUG|Apatinib Mesylate|250 mg, oral every other day. Approximately half an hour after a meal (the daily dose should be taken at the same time as possible) with warm boiled water.
41300839|NCT04850040|DRUG|Camrelizumab|200 mg, 30 minutes intravenous drip (overall dosing time no shorter than 20 minutes and no longer than 60 minutes, including tube flush time) once every 2 weeks, with the first dose administered concurrently with Apatinib Mesylate Tablets.
41300840|NCT04850040|DRUG|Oxaliplatin|85 mg/m2, once every 2 weeks, to be administered half an hour after Camrelizumab injection.
41300841|NCT03691610|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
40772212|NCT04824911|DRUG|Atorvastatin|Atorvastatin 40-80mg/day
40772213|NCT04824911|DRUG|Rosuvastatin|Rosuvastatin 20 mg/day.
40772214|NCT05388578|DEVICE|Blood pressure monitor|Participants will receive the Withings BPM connect monitor and do weekly self-measurements of blood pressure.
40772215|NCT05388578|DEVICE|Weighting scale|Participants will receive the Withings Body scale and do weekly self-measurements of their body weight and BMI.
40772216|NCT05388578|DEVICE|Activity tracker|Participants will receive the Withings Move to automatically keep track of their number of steps and activity type.
41300842|NCT03691610|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
40772217|NCT05388578|DEVICE|ECG device|Participants will receive the Withings Move ECG to make daily measurements of heart rhythm, an algorithm will detect abnormalities in heart rhythm such as atrial fibrillation.
40772218|NCT06001255|DRUG|HS-20093|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
40772219|NCT03419819|DIETARY_SUPPLEMENT|PKU Sphere|PKU Sphere is a glycomacropeptide based alternative to amino-acid based products for the dietary management of phenylketonuria.
41300843|NCT03691610|BIOLOGICAL|Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
41300844|NCT03691610|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
40772220|NCT02373657|BEHAVIORAL|instruction in soap-making and hygiene education|
40772221|NCT03663023|PROCEDURE|Intestinal obstruction|
40772222|NCT05534126|PROCEDURE|Stellate Ganglion Block Treatment|Stellate ganglion block procedure is a treatment that involves injection of local anesthetic around the stellate ganglion (located at the base of the neck) to block its transmission of pain signals.
41300845|NCT03691610|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
40772223|NCT05534126|PROCEDURE|Placebo|Sham
40772224|NCT03227549|PROCEDURE|Direct Superior Approach|Total hip arthroplasty using direct superior approach
40772225|NCT03227549|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using direct superior or posterior approach
40772226|NCT03227549|PROCEDURE|Posterior Approach|Total Hip Arthroplasty using posterior approach
41300846|NCT03691610|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
41300847|NCT03691610|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
41300848|NCT03691610|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:Oral solution Route of administration: Oral, 2 mL
41300849|NCT03691610|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
41300850|NCT03691610|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL
41300851|NCT03691610|BIOLOGICAL|Varicella Virus Vaccine Live|Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL
40976418|NCT02177305|DRUG|0.04 mcg tiotropium solution|
40976419|NCT02177305|DRUG|0.08 mcg tiotropium solution|
41300852|NCT02648048|DRUG|Pirfenidone|Pirfenidone will be administered as per the dosage schedule mentioned in arm description.
40772227|NCT03562637|BIOLOGICAL|adagloxad simolenin combined with OBI-821|In the neoadjuvant and adjuvant phases of the study for a total of 100 weeks; subcutaneously injections.
40772228|NCT03562637|DEVICE|Globo H IHC Assay|The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.
40772229|NCT03562637|OTHER|Standard of care treatment|Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.
40772230|NCT06564766|OTHER|Debriefing|"In the experimental group, an expert instructor conducted a structured debriefing lasting about 10-15 minutes for each clinical scenario, while in the control group, no additional intervention was provided.~The debriefing used in this study has the following characteristics: brief (≤ 15 minutes), educator present, educator experienced in debriefing, focused on healthcare management or decision-making, and used the Plus-Delta method, where participants are asked to reflect on the simulation event and assess their performance by identifying what went well and areas for improvement."
40976420|NCT02177305|DRUG|0.16 mcg tiotropium solution|
40976421|NCT02177305|DRUG|0.28 mcg tiotropium solution|
40976422|NCT02177305|DRUG|0.40 mcg tiotropium solution|
40976423|NCT02177305|DRUG|Placebo solution|
40976424|NCT03362398|DRUG|Omarigliptin 25 mg|Once weekly new anti-diabetic drug approved only in Japan
40976425|NCT03362398|DRUG|Trelagliptin 100 mg|Once weekly new anti-diabetic drug approved only in Japan
41300853|NCT02648048|DRUG|Vismodegib|Vismodegib will be administered as per the dosage schedule mentioned in arm description.
41300854|NCT05067790|DRUG|Nusinersen|Administered as specified in the treatment arm
41300855|NCT03952897|OTHER|balneotherapy|10 days of balneotherapy with immersion techniques using Fitero spa water.
40772231|NCT05163639|PROCEDURE|Non-invasive pairing of cortical and spinal stimulation|Transcranial magnetic stimulation (TMS) threshold, Transcutaneous spinal cord stimulation (TSCS) threshold, and peripheral and central motor conduction times will be determined. In the active intervention, two TMS pulse intensities will be tested: 90% and 120% of motor threshold. Two conditioning TSCS pulse intensities will be tested: 50% and 90% of response threshold. Single TSCS pulses will be delivered timed to arrive in the cervical spinal cord at a range of intervals from 30ms before to 30ms after the TMS pulse. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
40976426|NCT06310720|OTHER|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
40976427|NCT04720820|OTHER|Early Supported discharge with home based Rehabilitation|Treatment by Physiotherapist and occupational therapist at least 30 minutes each, per week provided at home.
40976428|NCT04720820|OTHER|Conventional rehabilitation|Treatment will be provided according to current hospital's stroke rehabilitation program.
40976429|NCT03423095|BEHAVIORAL|Active Jaw Exercise with Relaxation|This is the control group that will complete exercises unrelated to the primary outcome measures.
40976430|NCT03423095|BEHAVIORAL|Active Tongue Exercise|This is the active comparator group that will complete exercises already shown to increase tongue strength measures.
40976431|NCT03423095|BEHAVIORAL|Active Tongue Exercise + Mental Practice|This is an experimental group that will complete active tongue and mental tongue exercises to assess effect on tongue strength measures.
40976432|NCT03423095|BEHAVIORAL|Mental Practice Tongue Exercise|This is an experimental group that will complete mental tongue exercises only to assess effect on tongue strength measures.
40976433|NCT00205790|DEVICE|Vascular graft|
40976434|NCT00786682|DRUG|docetaxel|
41140968|NCT04996654|BEHAVIORAL|Exergame|According to the training concept, each participant is instructed to train 5x/week for 21 min per session resulting in a weekly exercise volume of 105 min. All training sessions are planned to take place at participant's homes using the exergame training system Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification).
41140969|NCT04996654|BEHAVIORAL|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
41140970|NCT06144723|DRUG|HS-20105|Administered intravenously every 21 days.
41140971|NCT04896567|DIAGNOSTIC_TEST|Cell isolation|Tissue from kidney biopsy will be used to isolate Cluster Differentiation 34+ cells.
41140972|NCT02706483|DRUG|Plecanatide|
41140973|NCT00065611|DRUG|Oral dexamethasone|"Stage I: Dexamethasone 25 mg/m2, 2 doses every 2 weeks over 48 weeks or dexamethasone 25 mg/m2, 4 doses every 4 weeks over 48 weeks.~Stage II: 1.) Dexamethasone 50 mg/m2, 2 daily doses every 12 weeks, followed by 25 mg/m2, 2 daily doses every 2 weeks over 36 weeks, or 2.) Dexamethasone 50 mg/m2, 4 daily doses every 4 weeks over 12 weeks, followed by 25 mg/m2, 4 daily doses every 4 weeks over 36 weeks.~over 36 weeks."
41140974|NCT00060502|DRUG|Infliximab; Gemcitabine|
41140975|NCT01942525|OTHER|aEEG|The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)
41140976|NCT05459584|DEVICE|Technological Rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
41140977|NCT03824340|DRUG|Doxycycline before ICSI|Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
41300856|NCT03567291|DRUG|TEV-50717|6, 9, and 12 mg oral tablets
41300857|NCT03567291|DRUG|Placebo|Placebo comparator
41300858|NCT02253667|DEVICE|HFONC|
40976435|NCT00786682|DRUG|hydroxychloroquine|
40976436|NCT06314542|OTHER|relaxing eligibility criteria|Quantitative evaluation of the impact of relaxing eligibility criteria on the risk-benefit profile of drugs for lung cancer based on real-world data
41140978|NCT01319344|DRUG|Eplerenone|25 mg o.d. per os
41140979|NCT01997866|OTHER|STOP-BANG Scoring Model|Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
41140980|NCT01997866|OTHER|Polysomnogram Sleep Study|Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
41140981|NCT03170440|OTHER|Transcutaneous nerve stimulation location 1|Non-invasive stimulation by transcutaneous electrical nerve stimulation device in test location
41300859|NCT02253667|DEVICE|Conventional oxygen therapy|
41300860|NCT03534258|DEVICE|Ceribell Rapid Response EEG, Survey|This trial will qualitatively examine how information from rapid response and conventional EEG data changes physicians' diagnostic suspicion or their treatment decisions and confidence levels. In addition, the results will examine the mean time to EEG lead placement, and ease of use.
41300861|NCT06189677|OTHER|Observation of biological characteristics of fertile men|Sampling in outpatient settings, after biopsy or after surgery and collection of biological samples in fertile subjects
41300862|NCT01675219|PROCEDURE|white light TUR-BT|traditional transurethral bladder tumor resection
41300863|NCT01675219|PROCEDURE|blue light TUR-BT|photodynamic transurethral bladder tumor resection
41300864|NCT01675219|DRUG|optimized MMC|six weekly optimized mitomycin-C instillations
41300865|NCT01675219|DRUG|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
41460025|NCT03023137|BEHAVIORAL|Walking & dietary modification|"1. Daily walking at a moderate pace (4 km/h) \> 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding \>12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.~2. At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention"
40772232|NCT05163639|PROCEDURE|Intraoperative pairing of cortical and spinal stimulation|The surgeon will position spinal cord electrodes on the epidural surface one level rostral (typically C4/C5) to the site of myelopathy. Spinal and cortical thresholds will be determined. Investigator will then test the immediate effects of paired stimulation by stimulating the cortex at 120% of threshold and the spinal cord at 90% of threshold at various latencies relative to the time of synchronous convergence. The control intervention will include cortical only (120%) spinal only (90%) and non-convergent latency pairing stimulation.
40976437|NCT02814851|DEVICE|Transesophageal echocardiogram|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann. A transesophageal echocardiogram (TEE) will be performed and the TEE probe will stay continuously during the entire procedure, to allow all necessary measurements.
40976438|NCT02814851|DEVICE|Thermistor-tipped catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a thermistor-tipped catheter (model 93A-131-7F, Edwards, Santa Ana, CA) will be inserted into the pulmonary artery to measure right atrial pressure (Pra), pulmonary arterial pressure (Ppa), Ppao and thermodilution cardiac output. Ringer's lactate will be infused to maintain an occluded pulmonary arterial pressure (Ppao) of 8-10 mmHg.
40976439|NCT02814851|DEVICE|Pressure/volume catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a pressure/volume catheter (CD Leicom, Zoetermeer, Netherland) will be placed in the left ventricle through a left superior pulmonary vein purse string, in order to measure alternatively LV pressure/volume loops and LA pressure.
40976440|NCT02814851|DEVICE|Transthoracic echocardiography|"A complete transthoracic echocardiography will be performed the day before the surgical procedure. It will establish the presence of the inclusion and exclusion criteria, as stipulated above. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).~During the surgical procedure, a transesophageal echocardiogram will be performed, using an Acuson Sequoia system (Siemens AG, Germany)."
40976441|NCT05148754|DRUG|Elsulfavirine|Elsulfavirin 200 mg tablets.
41140982|NCT03170440|OTHER|Transcutaneous nerve stimulation location 2|Stimulation will be performed using electrodes placed in alternate location.
41140983|NCT02452567|OTHER|Moderate (8-10%) diet-induced weight loss|MAL participants will meet with the study dietitian to lose \~8-10% of their body weight through diet-intervention.
41140984|NCT05637684|DEVICE|low intensity pulsed ultrasound|mechanical sound waves
41140985|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
41140986|NCT00070642|DRUG|dacarbazine|dacarbazine 850mg/m2 in three-week cycles until disease progression
41140987|NCT00070642|DRUG|Chemotherapy|"Chemotherapy in three-week cycles until disease progression:~dacarbazine 850mg/m2"
41140988|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
41140989|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
41140990|NCT03165825|DRUG|Transforaminal Epidural Steroid Injection with Dexamethasone|Transforaminal Epidural Steroid Injection with Dexamethasone
41140991|NCT03165825|DRUG|Interlaminar Epidural Steroid Injection with Betamethasone|Interlaminar Epidural Steroid Injection with Betamethasone
41140992|NCT05198219|DEVICE|Ambu® aScope™ 4 Rhinolaryngo|Patient indication following a rhinolaryngoscopy
41140993|NCT05198219|DEVICE|Conventional reusable rhinolaryngoscope|Patient indication following a rhinolaryngoscopy
41140994|NCT01653106|PROCEDURE|cryotherapy|Receive shaved ice
41140995|NCT01653106|OTHER|questionnaire administration|Participate in PROMS
41140996|NCT01653106|OTHER|pharmacological study|Correlative studies
41300866|NCT03542071|OTHER|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
41300867|NCT03542071|OTHER|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 55 E%; fat 25 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
41300868|NCT04032496|BEHAVIORAL|Contemplative-Based Intervention for People Living with SLE|Intervention sessions will follow a 6-week format consisting of weekly in-person sessions as well as guided homework to encourage practice at home. Some mindfulness practices that will be included are meditation, group exercise (yoga), group discussions, and deep breathing. Both participants diagnosed with SLE as well as caregivers will participate in the intervention sessions. 5 sessions will be approximately 2 hours long, while the final session will be approximately 4 hours long. Each intervention group will include approximately 4 participants with SLE and 4 caregivers.
41300869|NCT04032496|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP was designed to create an active control for mindfulness-based stress reduction (MBSR) interventions. The structure of this intervention will mirror that of the other arm of this study, but will lack the mindfulness component. The HEP includes topics such as physical activity, functional movement, music therapy, and nutrition education.
41300870|NCT03339648|BEHAVIORAL|Professional Development Enhancement|Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
41300871|NCT03613415|OTHER|Expansion|non invasive technique to increase thickness of thin ridge
41300872|NCT01148056|RADIATION|Intensity Modulated Radiation Therapy|Radiation therapy once a day for 5 days
41300873|NCT05762185|DEVICE|nursing consultation|nursing consultation
41300874|NCT02330627|BEHAVIORAL|Positive Valence System Treatment|Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
41300875|NCT05145504|DIAGNOSTIC_TEST|Evaluation of IL-6 biomarkers in synovial fluid|Evaluation of IL-6 biomarkers in synovial fluid in obese and normal weight patients with gonarthrosis
41300876|NCT03074162|DRUG|Diclofenac Sodium|twice daily
41300877|NCT03074162|DRUG|Diclofenac & Capsaicin|twice daily
41300878|NCT03074162|DRUG|Diclofenac Sodium Topical Gel|twice daily
41300879|NCT01335568|PROCEDURE|Hepatocyte Matrix Implant|Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
41300880|NCT02697955|DRUG|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
41300881|NCT02697955|OTHER|Placebo|9 mg sodium chloride pr. ml (0,9 %)
41460026|NCT01704534|DRUG|Ustekinumab|subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
41460027|NCT00296270|BEHAVIORAL|Memory for truth|
40976442|NCT03194022|OTHER|Blood sample|measurement of electrolytes and blood count
41300882|NCT02870452|BEHAVIORAL|Hypnosis|4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
40976443|NCT04718051|DRUG|Shen Pu Yang Gan Wan|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.
40976444|NCT04718051|DRUG|Placebo|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.
40976445|NCT00126568|DRUG|sorafenib tosylate|Given orally
40976446|NCT02933125|BEHAVIORAL|Group psychotherapy|"Motivational enhancement psychotherapy (MEP) for Youths:~The participating youths have to attend one session a week for 10 weeks of a group program for relapse prevention based on motivational enhancement ideas and led by two experienced psychologists from the hospital.~Parenting skill training (PST) for Caregivers:~The PST program for the youths' caregivers also consist of 10 weekly, 120-minute sessions that were led by a senior consulting psychologist."
40976447|NCT02933125|BEHAVIORAL|Standard supervision|The standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court provide the adolescents with moral education, as well as counseling in their work or studies.
41140997|NCT03690557|BEHAVIORAL|IncentaHealth|IncentaHealth is a comprehensive, behavioral weight management program designed to help individuals initiate and maintain weight loss. Individuals participate in the IncentaHealth program from their homes, receive program information electronically through daily emails and through a smartphone app for the duration of the study, and have the option to receive text messages and speak with health coaches over the telephone. Participants in this study will be enrolled in the IncentaHealth program for 12 months, and will engage with health coaching, tracking of body weight, and are provided a number of resources for healthy living throughout the 12 months.
41140998|NCT02050555|DIETARY_SUPPLEMENT|Placebo|
40976448|NCT03680573|DRUG|Control: Lacated Ringers|This site will serve as the control site
40976449|NCT03680573|DRUG|Apocynin|This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.
40976450|NCT03680573|DRUG|Allopurinol|This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.
40976451|NCT03680573|DRUG|BH4|This site will be use to locally supplement BH4.
40976452|NCT03680573|DRUG|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
40976453|NCT03680573|DRUG|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
41140999|NCT02050555|DIETARY_SUPPLEMENT|Koji-extracted beverage fermented with Pediococcus pentosaceus LP28|
41141000|NCT03437655|PROCEDURE|Carie removal|Carie removal with a low speed handpiece
41141001|NCT03437655|PROCEDURE|Relative isolation|Relative isolation with cotton and gauze.
41141002|NCT03437655|PROCEDURE|Manipulation of the temporary material based on Zinc Oxide and Eugenol|Manipulation of the temporary material based on Zinc Oxide and Eugenol according to the manufacturer's recommendations
41141003|NCT03437655|PROCEDURE|Manipulation of the temporary material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations
40976454|NCT03680573|DRUG|Acetyl-ß-methylcholine chloride|Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
40976455|NCT02144051|DRUG|AZD5312|AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
40976456|NCT00674700|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
41141004|NCT03437655|PROCEDURE|Material insertion on the cavity|Material insertion on the cavity according to the manufacturer's recommendations
41141005|NCT03437655|PROCEDURE|Finishing the temporary direct restoration|Excess cement removal; Occlusal Adjustment; Finishing and polishing.
41141006|NCT03077256|DEVICE|BioBurst Fluid, Burst Allograft|BioBurst Fluid, Burst Allograft in Foot and Ankle Surgery
41141007|NCT00484198|DRUG|Pioglitazone|45 mg over-encapsulated tablet administered orally, once daily
41141008|NCT00484198|DRUG|Placebo|Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
41141009|NCT00484198|DRUG|Rivoglitazone|1.0 mg tablet administered orally, once daily
41141010|NCT00484198|DRUG|Rivoglitazone|1.5 mg tablet administered orally, once daily
41141011|NCT03187704|OTHER|HEPA air filtration|Air filters were placed in participant homes
41141012|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po
41141013|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
41141014|NCT00768755|DRUG|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
41141015|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
41141016|NCT00768755|DRUG|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
41300883|NCT02870452|BEHAVIORAL|Cognitive-Behavioral Therapy|4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
41300884|NCT01896037|DIETARY_SUPPLEMENT|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
41300885|NCT04506827|PROCEDURE|Maxillary Sinus Augmentation|Biomaterial Graft into the Maxillary Sinus
41300886|NCT04506827|DEVICE|Maxillary Sinus Graft with ABBM|The maxillary sinuses in the control group are grafted with ABBM
41300887|NCT04506827|DEVICE|Maxillary Sinus Graft with TCP|The maxillary sinuses in the test1 group are grafted with TCP
40976457|NCT00674700|DRUG|500 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
41460028|NCT03385954|OTHER|Intervention|The distance eduacation group course has a workload of 8 hours and will be developed over 2 weeks. It is suggested that students have a minimum of 1 hour of study per day. The course will consist of work tips, clarifications and procedures for the prevention of RIS/WRMD physical training tips to improve cardiovascular condition and, of strength and flexibility, available literature and theoretical evidence that should be answered through the knowledge acquired in the EAD course of prevention of LERDORT from the HCPA's Physiatrics and Rehabilitation Service. This Course will be available through moodle.
40772233|NCT05163639|PROCEDURE|Non-invasive repeated pairing of cortical and spinal stimulation (SCAP)|Thresholds will be determined as above. Immediately prior to repetitive pairing, a set of 12 TMS pulses will be delivered at 120% threshold to measure the baseline cortical MEP. Likewise, a set of 12 TSCS pulses will be delivered at 120% of threshold to establish the baseline spinal MEP. For each session, baseline maximal pinch dynamometry will be determined. Immediately after the SCAP protocol is completed, response to TMS, TSCS, and maximal pinch dynamometry will be measured again every 10 minutes over the subsequent hour. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
40772234|NCT05163639|PROCEDURE|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)|Intraoperative: Spinal and cortical thresholds will be determined. Immediately prior to repetitive pairing, a set of 12 baseline cortical pulses and 12 baseline spinal pulses will be delivered at 120% threshold. SCAP protocol will be applied, both of which have been successful at inducing lasting effects in the rat. After pairing, cortical stimulation at 120% of threshold and spinal cord stimulation at 120% threshold will be repeated every 10 minutes for the duration of surgery. In a subset of patients repeated pairing will be conducted with a latency that investigator does not expect will induce SCAP, or with electrodes placed over the ventral epidural surface. The control intervention will include repeated pairing at a non-convergent latency, as well as pairing of cortical stimulation with ventral epidural stimulation.
40772235|NCT05163639|PROCEDURE|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region|As per the intervention 'Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)' targeted at or below myelopathic region.
40772236|NCT02609594|OTHER|Weekly application of Amnioband|Weekly application of Amnioband.
40772237|NCT02609594|OTHER|Biweekly application of Amnioband|Biweekly application (every two weeks) of Amnioband.
40976458|NCT00674700|DRUG|Placebo tablet|One sublingual tablet daily for one year
40976459|NCT02297074|OTHER|Ordinary white bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
41141017|NCT03196622|DEVICE|Handgrip test|Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
41141018|NCT00924833|DRUG|placebo|placebo tablet BID
41141019|NCT00924833|DRUG|Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
41141020|NCT00924833|DRUG|Nebivolol|nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
41141021|NCT05080348|PROCEDURE|Ropivacaine iPACK Injection|Injection of 20mL of 0.25% Ropivacaine with 1:400,000 Epinephrine between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
41141022|NCT05080348|PROCEDURE|Normal Saline iPACK Injection|Injection of 20mL of 0.9% Normal Saline between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
41141023|NCT02312544|DRUG|OTX-TP|OTX-TP and placebo drops
41141024|NCT02312544|DRUG|Timolol|Timolol drops and placebo punctum plug
41141025|NCT06220123|DRUG|SHR-2004|Investigational product arm: SHR-2004
41300888|NCT04506827|DEVICE|Maxillary Sinus Graft with TCP + HA|The maxillary sinuses in the test1 group are grafted with TCP + HA
41300889|NCT01143597|OTHER|Arm and hand training|Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.
41460029|NCT03385954|OTHER|Control|will receive a lecture of 30 minutes.
41460030|NCT03519438|OTHER|Mepitel|Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis
41460031|NCT05771051|DEVICE|Headpulse measurements|Placement of headset on subject
41141026|NCT06220123|DRUG|Enoxaparin Sodium Injection; Rivaroxaban Tablets|Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets
41141027|NCT04795999|BEHAVIORAL|Project With|There are 12 lessons in Project With, typically delivered in six weekly sessions, with each session having two one-hour long lessons and a meal with facilitators in between the two lessons. Each lesson includes a discussion of selected literary works, including poetry, short stories, and excerpts from films and other videos. The curriculum is intended to be delivered to groups of 8-12 youth. In ideal program delivery, participants also share a meal with each other and with the Youth Advocate. Shared mealtimes create group cohesion and allow Youth Advocates to connect with participants on a personal level, building trust. At the end of the Project With curriculum, youth will partake in an offsite day excursion to Camp Eaton, a wooded camp outside of Los Angeles. At Camp Eaton, Youth Advocates will lead a Project With session, lunch, bonding activities and games, and an opportunity to engage in an outdoor activity.
41141028|NCT02211872|DRUG|BI 2536 BS, intravenous|
41300890|NCT04065022|DEVICE|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
41300891|NCT01660841|DRUG|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
41300892|NCT05135130|DRUG|ON101 Cream|Not applicable in this retrospective study
41300893|NCT03804346|DIAGNOSTIC_TEST|Acceleromyography|At the End of Surgery, shortly before Extubation, the TOF-Ratio is measured by an independent investigator using Acceleromyography.
41460032|NCT03687619|OTHER|CO-OP|Interventions (from top to down) related to the development of fine-motor skills
41460033|NCT03687619|OTHER|Conductive Education|Interventions (from down to top) related to the development of fine-motor skills
41460034|NCT01954212|OTHER|Enhanced complex oral health care|"Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:~1. Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.~2. Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.~3. Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available."
41460035|NCT02587806|BIOLOGICAL|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
41460036|NCT02587806|OTHER|Liberation therapy|
40772238|NCT02609594|OTHER|Standard of Care|Standard of care for this study is weekly multi-layer compression bandaging.
40772239|NCT01283984|DRUG|AZD2115|Single dose, oral inhalation (nebuliser solution)
40976460|NCT02297074|OTHER|Precooked-Frozen White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
40976461|NCT02297074|OTHER|Candeal-flour White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
40976462|NCT02297074|OTHER|Alfacar White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
41141029|NCT05371002|BEHAVIORAL|Online group nonviolent communication (NVC) interventions|"The primary purpose of NVC as defined by Dr. Marshall Rosenberg is to resolve interpersonal conflict using empathic communication skills. Nonviolence does not refer to the mere absence of physical harm. It is a way of life that helps us to transform old patterns of defensiveness and aggressiveness into compassion and empathy and to improve the quality of all types of relationships. The basic model of NVC consists of four key principles: the separation of observation from evaluation (observation), exploring and expressing the feelings that emerge from observations (feeling), taking responsibility for one's feelings (need), and telling others the need to enrich lives (request). A book on NVC specifically targets parents to improve communication and connection with their children. The NVC model emphasizes the importance of observation and has similarities with the concept of mindful parenting, which refers to a non-judgmental and open parenting style."
40976463|NCT02297074|OTHER|Wholemeal Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
40976464|NCT02297074|OTHER|Glucose|50 g of glucose were administered as a reference
41141030|NCT05371002|OTHER|Waitlist control group|Waitlist control, but included a short active intervention during the 2nd and 3rd assessments.
41141031|NCT05328817|DRUG|Antibiotics|In the absence of labor, broad-spectrum antibiotics (often called latency antibiotics) are recommended for women with PPROM less than 34 weeks to reduce chorioamnionitis, prolong latency, and decrease neonatal sepsis (12,13).
41300894|NCT05811494|DEVICE|Lexo|Lexo is a Robot-Assited Gait device based on an end-effector system that supports the weight of the patient and help him to recover the walking function.
41300895|NCT05811494|DEVICE|Lokomat|Lokomat is a Robot-Assited Gait device based on a fixed exoskeleton that supports the weight of the patient and help him to recover the walking function guiding the hips, knees and feet of the patient while walking.
41300896|NCT05811494|DEVICE|C-Mill|C- Mill is a body weight support treadmill which includes virtual reality. I can provide feedback to the patient, assisting or hindering the gait task.
41300897|NCT05811494|DEVICE|Body-weight support treadmill|Body-weight support treadmill group will receive the same time and intensity of training like the robotic groups but using the treadmill
41460037|NCT03292263|DRUG|Melphalan|iv infusion 70-100 mg/m2 on day -3, -2
41460038|NCT03292263|DRUG|Nivolumab|iv infusion 100 mg on day -3, +17
41460039|NCT03292263|PROCEDURE|Autologous Stem Cell Transplantation|peripheral blood stem cell transfusion at day 0
41460040|NCT03450629|DRUG|Brimonidine Tartrate Ophthalmic Suspension|PDP-716
41460041|NCT03450629|DRUG|Brimonidine Tartrate Ophthalmic Solution|Three Times Brimonidine Tartrate Ophthalmic Solution
41460042|NCT03694938|DEVICE|Magnetic resonance imaging|Annually magnetic resonance imaging
41460043|NCT05449080|DIAGNOSTIC_TEST|Karyotype|Patients were subjected to karyotype to determine their genotype
41460044|NCT04677686|BEHAVIORAL|Bundle of Care|Hair removal with Clipper Glucose Control Preoperative antibiotics Repeat antibiotics after 4 Hours Optimize Body temperature Instrument change for colorectal anastomosis Use of wound protectors Experienced surgeon Preoperative showering
41460045|NCT00082160|BEHAVIORAL|Meditation|
41141032|NCT04641715|PROCEDURE|OAGB-MGB|One Anastomosis Gastric Bypass - Mini Gastric Bypass as both restrictive and malabsorptive bariatric procedure
41300898|NCT03743558|BEHAVIORAL|smartphone homemade video|value of a video recording of the child sleep on smartphone made by the parents
41300899|NCT05112458|OTHER|Cope 360 mobile health application|Cope 360 is a mHealth (mobile health) app designed to support caregivers of children with cancer with symptom tracking, medication management, and emergency preparedness. We will evaluate Cope 360 via a pilot, randomized control trial in which some caregivers will receive the app and some will not. The purpose of this study is to assess: 1) feasibility of caregiver use over extended period of time, 2) acceptability of the mHealth tool by caregivers in a real-world setting, 3) impact of the mHealth tool on caregiver self-efficacy, mastery of caregiving skills/knowledge, and caregiver stress, and 4) effect on healthcare utilization of the child with cancer (i.e. preliminary data about sick visits and ED encounters).
41300900|NCT05112458|OTHER|Usual care|Caregivers of children with cancer will receive the usual clinical care provided to our patient population.
41300901|NCT03014219|DRUG|Only 1 arm: treatment with MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
41460046|NCT00082160|PROCEDURE|Functional Magnetic Resonance Imaging|
41460047|NCT03316157|DIETARY_SUPPLEMENT|ProSure|Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition
41460048|NCT03316157|BEHAVIORAL|Physical Exercise|Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
41460049|NCT05568758|OTHER|Thoracic lymphatic pump technique|The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.
40772240|NCT01283984|DRUG|Placebo|Single dose, oral inhalation (nebuliser solution)
40772241|NCT03508583|OTHER|Participation|"The mpoc 56 and mpoc 20 will be field-tested with a sample of 300 parents of children with disabilities residing in the Turkey.~Professionals working with children with disabilities will be assessed with MPOC SP questionnaires"
40772242|NCT04041193|BEHAVIORAL|SIDERA^B|The group will receive a kit home-based (a tablet home, access to a daily individualized training program). Five sessions for a week (3 components: monitoring, motor rehabilitation acitivities, motivational support)
40772243|NCT04041193|BEHAVIORAL|Usual Care Program|Usual Care program activities (paper and pencil at home)
40976465|NCT02389933|DRUG|LCZ696|immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
40976466|NCT01709162|BIOLOGICAL|Ipilimumab|
41460050|NCT05568758|OTHER|Exercises (stretching and strenghtening )|"stretching exercises include: Hamstring stretching exercises~Lower back stretching exercises :~strenghtening exercises include:~Abdominal curl up exercises :~Supine bridging exercises. Trunk extension exercises"
41460051|NCT04346654|DRUG|Eltrombopag|Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.
41460052|NCT04346654|DRUG|Dexamethasone|Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
41460053|NCT00691756|PROCEDURE|Cold blood renal perfusion|Both kidneys receive intermitent perfusion with cold (4 degrees C) autologous blood during thoracoabdominal aortic aneurysm repair.
40976467|NCT01709162|DRUG|Chemotherapy|
40976468|NCT04744142|DRUG|Ketone supplementation|Subjects receive either placebo or ketone ester supplementation
40976469|NCT04744142|DIETARY_SUPPLEMENT|Increased protein intake|Subjects receive either normal or increased protein intake
40976470|NCT00381095|DRUG|Pregabalin|Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
40976471|NCT00381095|DRUG|Placebo|Placebo
40976472|NCT03988985|OTHER|Patient-targeted feedback|The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
40976473|NCT03988985|OTHER|GP-targeted feedback|The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
40976474|NCT02245308|DRUG|Nicotine Patches|Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
40976475|NCT02245308|BEHAVIORAL|mobile contingency management (mCM)|Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
40772244|NCT05712109|OTHER|Follow-up after Anterior cruciate ligament reconstruction|The patients were referred to the sport medicine department for the post ACL-R follow-up including isokinetic knee muscle strength evaluations at 4 months and 8.months after the surgery
40772245|NCT02678533|DRUG|G-CSF|D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)
40772246|NCT02678533|DRUG|Plerixafor|D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
40772247|NCT03253237|DEVICE|continuous glucose monitoring (CGM)|A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard home blood glucose monitoring (SHBGM) along with the data on eating, physical exercise, drugs. Bayer's Contour® glucometer is used for the SHBGM. On Day 7, CGM device is took of and the data from iPro2 is uploaded to PC. At the end, each patient fill a short query on satisfaction while wearing CGM.
40976476|NCT02245308|BEHAVIORAL|Smoking cessation counseling|Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
41141033|NCT03979937|PROCEDURE|Arthrocentesis|Arthrocentesis to determine the nature of the effusion (septic or aseptic).
41460054|NCT00691756|PROCEDURE|Cold crystalloid renal perfusion|Both kidneys receive intermittent perfusion with cold (4 degrees C) lactated Ringer's solution during thoracoabdominal aortic aneurysm repair. This is the standard renal perfusion technique in our practice.
41460055|NCT00163709|PROCEDURE|BNP test|
41460056|NCT01042873|DRUG|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
41300902|NCT03046472|OTHER|Physical Therapy treatment for Postural Behavior|"Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day."
40772248|NCT03817229|BEHAVIORAL|Education microlearning sessions|mHealth education microlearning sessions
40772249|NCT03817229|BEHAVIORAL|Automated digital reminders|reminders from electronic monitors based on texts or lights/chimes
40772250|NCT03817229|BEHAVIORAL|Problem-solving mHealth module|mhealht problem solving module with 2 telehealth sessions with a therapist
41141034|NCT01101633|DIETARY_SUPPLEMENT|Alginate|a 500 ml alginate beverage per meal test
41141035|NCT01101633|DIETARY_SUPPLEMENT|Alginate|a 330 ml alginate beverage per meal test
41141036|NCT01101633|DIETARY_SUPPLEMENT|Placebo|a 500 ml placebo beverage per meal test
41141037|NCT01101633|DIETARY_SUPPLEMENT|Placebo|a 330 ml placebo beverage per meal test
41141038|NCT06470152|PROCEDURE|Correction strategy in reference to our PI-dependent clustering of sagittal alignment|For type I patients (PI \< 39.56°), the target LL = -0.13\*PI2+9.36\*PI-134.08; for type II patients (39.56° ≤ PI \< 49.16°), the target LL = 0.45\*PI+26.57; for type III patients (49.16° ≤ PI \< 58.31°), the target LL = -0.15\*PI2+17.09\*PI-420.57; for type IV patients (PI \> 58.31°), the target LL = 0.06\*PI2-7.55\*PI+289.77. Prediction intervals of 95% confidence is adopted as the target LL range.
41300903|NCT03625219|DRUG|Prednisone|40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
41460057|NCT05189938|DIAGNOSTIC_TEST|HBA1c data and glucose levels|All subjects will wear the professional FreeStyle Libre Pro for glucose data and HbA1c data will be collected at different time points over the participation period.
40772251|NCT03817229|BEHAVIORAL|Individualized Adherence Feedback Report|Individual Adherence Feedback reports sent to parents weekly
41141039|NCT06470152|PROCEDURE|Correction strategy in reference to the SAAS score|"This new score is composed of three sagittal parameters (PI-LL, PT and TPA). For these three parameters, points were assigned based on offset with age-adjusted targets 0 points if the parameter was within 10 years of the patient's age (Match). For each 20 years above the age-adjusted target, 1 point was added (e.g., + 1 point between + 10 and + 30, + 2 points between +30 and +50). Conversely, 1 point was subtracted for each 20 years below the age-adjusted target (e.g., -1 point between -10 and -30, -2 points between -30 and -50). SAAS was calculated by adding all 3 components, creating a discreet score that could have a negative value (under corrected) or positive value (over corrected). SAAS was sub-categorized into SAAS-Under if it was less than -1, SAAS-Match if it was between -1 and + 1 or SAAS-Over if it was greater than + 1."
41141040|NCT02436070|BEHAVIORAL|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
41141041|NCT02436070|BEHAVIORAL|General text messages|Subjects received text messages generalized to children with asthma
41141042|NCT06500104|DIETARY_SUPPLEMENT|Kefir peptide|Dosage: 1.2 gram kefir peptide daily oral intake for 12 weeks
41141043|NCT06500104|DIETARY_SUPPLEMENT|Placebo|Glucose powder
41460058|NCT01150162|DRUG|Rebamipide and Omeprazole|open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
40772252|NCT03638375|DRUG|Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha|"During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10\^8 T cells i.v.) once every three weeks for three infusions.~In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks."
40976477|NCT02245308|DRUG|Nicotine rescue method|Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
41141044|NCT00486954|DRUG|Lapatinib|6 pills at 250 mg each once daily
41141045|NCT00486954|DRUG|Paclitaxel|Infusion at 80 mg/m2 weekly
40772253|NCT06427980|DRUG|Chinese Herbal formula HuoXue LiShui|The intervention consists of the oral administration of granule with either HXLS or a placebo substance, one bag (28.5 g) twice daily after meals for a period of 8 weeks. The granules are produced from four Chinese herbal pieces: Yi Mu Cao (Leonuri Herbal, 15.0g), Zhi Shui Zhi (Hirudo, 1.5g), Tao Ren (Semen persicae, 6.0g), and Hong Hua (Carthami Flos, 6.0g).
40772254|NCT06427980|DRUG|Chinese Herbal formula Placebo|The placebo will be consistent with the HXLS oral granules in appearance, taste, and weight, to the greatest extent possible. In terms of outer packing, the HXLS and placebo granules will be exactly the same. It included Hu Jing (28.5g)
41141046|NCT00605137|DRUG|insulin detemir|
40772255|NCT02987387|DEVICE|SAPIEN XT THV|SAPIEN XT THV will be implanted in the pulmonic position.
40772256|NCT01489137|DRUG|remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml."
40976478|NCT02245308|DRUG|Bupropion|Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
40976479|NCT03723759|DRUG|Faster Aspart 200 U/mL|A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.
40976480|NCT03723759|DRUG|Faster aspart 100 U/mL|A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
40976481|NCT01191801|DRUG|vosaroxin + cytarabine|"Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
40976482|NCT01191801|DRUG|placebo + cytarabine|"Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
40976483|NCT01727453|DRUG|warfarin|Warfarin in anticoagulant dose
40976484|NCT01727453|DRUG|Bemiparina|"Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.~Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer."
40976485|NCT01180491|DEVICE|K101 nail solution|
41141047|NCT00605137|DRUG|insulin NPH|
41141048|NCT01644604|DEVICE|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
41141049|NCT06080087|BEHAVIORAL|I-TEAM|I-TEAM is a web-based implementation toolkit that supports to enhance cultural responsiveness of EI providers in their EBP delivery with minoritized families of young autistic children
41141050|NCT02043652|DRUG|Chloroquine|Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
41141051|NCT02043652|DRUG|Primaquine|Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
41141052|NCT00374998|BIOLOGICAL|FP9-PP (FP9 polyprotein)|
40772257|NCT05035108|BIOLOGICAL|hiHep bioartificial liver therapy|HiHep cell bioartificial liver treatment was performed 24-48 hours after extensive hepatectomy. Temporary hemodialysis tube for large vein (jugular vein or femoral vein) is indwelled before treatment. Before treatment, prepare hiHeps-BAL in a biological safety cabinet that meets clinical standards, connect the corresponding tubing to the Jianfan DX-10 blood purification machine, and prefill with heparin saline. Half an hour before treatment, the patient was pre-heparinized (heparin about 600iu) and dexamethasone to prevent allergic reactions. The patient enters the ICU, the monitor is connected to the corresponding pipeline, the arterial pump 120-160ml/min, the slurry pump 30-40ml/min, the circulating pump 75-100ml/min, the duration is 6-9h.
40772258|NCT05175157|OTHER|Gut Fellings questionnaire|Answer the Gut Fellings questionnaire
40772259|NCT02891356|DEVICE|DEXA|The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
40772260|NCT02136992|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
40772261|NCT02136992|DRUG|placebo|placebo will be taken two tablets 3 times a day during the whole study process
40772262|NCT06222684|OTHER|Music therapy|Women applying for mammography screening will receive music therapy for 5 minutes before the procedure, during the mammography scan and for 5 minutes after the procedure.
40772263|NCT05724771|DRUG|Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)|OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL
40772264|NCT06185751|BIOLOGICAL|WS-CART-CS1|-Subject will be hospitalized for 7 days
40976486|NCT02782780|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep (e.g., homeostatic regulation, circadian rhythm, age, social and work schedule) and to work with the patients toward minimizing unwanted arousal at bedtime and altering sleep habits to increase sleep propensity and regularity. The intervention is 8-weeks long.
40772265|NCT06185751|DRUG|Lymphodepleting chemotherapy|"* Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3~* Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3"
40976487|NCT02877615|DRUG|S 44819 150 mg twice a day|One sachet of S 44819 150 mg and one sachet of placebo twice a day
40976488|NCT02877615|DRUG|S 44819 300 mg twice a day|Two sachets of S 44819 150 mg twice a day
40976489|NCT02877615|DRUG|Placebo|Two sachets of placebo twice a day
40976490|NCT00899262|OTHER|immunohistochemistry staining method|
40976491|NCT00899262|OTHER|laboratory biomarker analysis|
40976492|NCT00899262|OTHER|sputum cytology|
41141053|NCT00374998|BIOLOGICAL|MVA-PP (Modified Virus Ankara polyprotein)|
41300904|NCT03625219|DRUG|Placebo|8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
40772266|NCT06565338|DRUG|Dexmedetomidine|drug
40772267|NCT06565338|DRUG|Vitamin D3|drug
40772268|NCT03960944|OTHER|Yoga|30 Min Yoga session included of Physical posture, Breathing exercise, Yoga games and Relaxation.
40772269|NCT03183947|PROCEDURE|fMRI|collection of functional brain data for 1 hour per day
40772270|NCT03183947|BEHAVIORAL|Neurofeedback|Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 \& 4; controls: Days 2 \& 3)
40976493|NCT00899262|PROCEDURE|Fourier transform infrared spectroscopy|
40976494|NCT00899262|PROCEDURE|diagnostic bronchoscopy|
40976495|NCT06193720|DRUG|Arnica montana|Assess the effect of arnica montana on pain, swelling ans trismus after impacted third molar surgery
41141054|NCT00777309|DRUG|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
41141055|NCT00777309|DRUG|Erlotinib|Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
41141056|NCT00777309|DRUG|Placebo|The placebo is provided as a capsule
41141057|NCT01681511|DEVICE|ICET™ TIC Foley Catheter|The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
40772271|NCT03183947|OTHER|PANAS|to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
40976496|NCT06193720|OTHER|Placebo|Patients will take placebo drug after surgeries
40976497|NCT05634304|BEHAVIORAL|A mobile app self-management (mSM) program|The mSM program is developed on Bundura's self-efficacy theory, which provides four sources of information for SM. The strategies of the mSM consist of mobile app to management program including peer support, appraisal, goal setting and self-monitoring of exercise for OA and symptom management.
40976498|NCT06248892|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
41300905|NCT03161678|DRUG|Clopidogrel|Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
41460059|NCT01150162|DRUG|Omeprazole|open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
40976499|NCT06248892|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
40976500|NCT06248892|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
40976501|NCT02083952|OTHER|Swaddle Blanket|Two arms involve varying time spent in blanket
40976502|NCT04533698|OTHER|Assessment of reason for resternotomy|No intervention is performed. Reasons for resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
40976503|NCT04533698|OTHER|Assessment of reason for avoidance of resternotomy|No intervention is performed. Reasons for avoidance resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
40976504|NCT02228785|BIOLOGICAL|G17DT|
40976505|NCT02781922|GENETIC|Autologous cardiac stem cells (JRM-001)|3x 10\^5 cells/kg, single treatment
40976506|NCT00425360|BIOLOGICAL|sargramostim|
40976507|NCT00425360|BIOLOGICAL|telomerase peptide vaccine GV1001|
41141058|NCT01681511|DEVICE|BARD® LUBRI-SIL® IC Foley Catheter|The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®\* silver alloy coating and BARD® hydrogel.
41141059|NCT03441464|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.
41141060|NCT06187402|DRUG|LM-24C5|Administered intravenously
41141061|NCT01307306|DRUG|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
41141062|NCT01307306|DRUG|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
41141063|NCT04236297|DEVICE|bite block|Physicians performing transesophageal echocardiogram in patients under sedation or general anesthesia will use either standard or modified bite block.
41141064|NCT02674399|DRUG|JointStem|
41141065|NCT02674399|DRUG|Synvisc-One|
40772272|NCT03183947|OTHER|BDI-II|to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
41141066|NCT03883724|BEHAVIORAL|Brief behavioral treatment of insomnia (BBTI)|The BBTI consists of a 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later and 20-minute telephone calls after 1 and 3 weeks. The brief behavioral treatment component will focus on four behaviors that promote sleep through homeostatic, circadian, or association mechanisms. 50 These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
41300906|NCT03161678|DRUG|Ticagrelor|Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
41300907|NCT01009996|PROCEDURE|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
40976508|NCT00425360|DRUG|capecitabine|
40976509|NCT00425360|DRUG|gemcitabine hydrochloride|
40976510|NCT01516320|PROCEDURE|Roux-en-Y Gastric Bypass|A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.
40976511|NCT01516320|PROCEDURE|Laparoscopic adjustable gastric banding|A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.
40976512|NCT01516320|PROCEDURE|Vertical Sleeve Gastrectomy|A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
40976513|NCT01001377|DRUG|Cetuximab|Administered by intravenous infusion
40976514|NCT01001377|DRUG|Panitumumab|Administered by intravenous infusion
41460060|NCT05701124|DRUG|Ranibizumab (0.25 mg/0.025 mL)|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.
40772273|NCT03183947|OTHER|ERQ|To assess emotion regulation strategies before and after neurofeedback training (patients: day 3\&4; controls: day 2\&3) and after 4 weeks during a telephone interview
40772274|NCT04510857|DEVICE|MOVE-IT Intervention|The MOVE-IT device comprises a custom smart toy and therapy game software to enable repetitive task practice involving the arm and hand.
40772275|NCT04510857|BEHAVIORAL|UCT Control|Participants assigned to the UCT control group will continue to receive their previously prescribed therapy services.
41460061|NCT00110734|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
40772276|NCT04595292|OTHER|older adults, assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
40976515|NCT01879332|DRUG|Placebo|Matching placebo tablets for oral administration
40976516|NCT01879332|DRUG|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
40976517|NCT01879332|DRUG|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
40976518|NCT05322304|DIETARY_SUPPLEMENT|Almond|Intervention (almond supplementation) and Isocaloric diets (control)
41460062|NCT05694117|BEHAVIORAL|self-determine sequence exercise program|The Taichi exercise utilized the simplified eight styles of Taichi. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
40976519|NCT04633460|DIETARY_SUPPLEMENT|Ketone ester|A nutraceutical ketone ester (KE), (R)-3-hydroxybutyl (R)-3-hydroxybutyrate which provides systemic ketosis
40772277|NCT00895505|DRUG|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
40772278|NCT00895505|DRUG|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
40772279|NCT04354857|OTHER|olfactory and gustatory tests|"Participants rate quality of sense of smell and taste.~Olfaction test: Sniff 10ml test tube containing 1.5ml air freshner (Mifleur Citron, Coldis, Entraigues sur Sorgues, France) and rate perception of odor.~Gustatory test: Taste a pinch and sugar and salt and rate perception of sweet or salty taste"
40772280|NCT01558167|DRUG|Bendamustine, Rituximab, Lenalidomide|"Bendamustine: 50 mg/m2, i.v., day 1+2~Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1~Lenalidomide:~* Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28~* Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28~* Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28~* Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28~* Dose level 5: maximal tolerated dose"
40772281|NCT00572559|DRUG|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
40772282|NCT00572559|DRUG|Linezolid|600 mg every 12 hours (intravenously \[IV\] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
40772283|NCT05337189|DIAGNOSTIC_TEST|Urine DNA methylation analysis|Urine specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
40976520|NCT04633460|DIETARY_SUPPLEMENT|placebo drink|KE free placebo drink
40976521|NCT05124301|BEHAVIORAL|Perceptual learning|Reaching task with visual feedback offset from target finger position.
40976522|NCT05124301|BEHAVIORAL|Control|Reaching task with unmanipulated feedback.
40976523|NCT02055690|DRUG|Pazopanib|Tyrosine Kinase Inhibitor
40976524|NCT02055690|DRUG|Fosbretabulin|Vascular Disrupting Agent
40976525|NCT01114178|OTHER|questionnaire|self completed questionnaire supervised by a technician
40976526|NCT04405947|PROCEDURE|Reverse Shoulder Arthroplasty|implantation of a reversed shoulder prostheses through two different surgical approaches
40976527|NCT00823394|BEHAVIORAL|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
40976528|NCT00823394|OTHER|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
40976529|NCT00823394|BEHAVIORAL|Self-help Materials|Information on how to lower risk for developing cancer.
40976530|NCT05131646|DRUG|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101
40976531|NCT05039151|BIOLOGICAL|interstitial fluid sampling|The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.
40772284|NCT05337189|PROCEDURE|medical imaging and/or cystoscopy and/or pathological examination|Subjects will undergo medical imaging and/or cystoscopy and/or pathological examination
40772285|NCT03185026|BEHAVIORAL|Interventional group : PEPSUI psychoeducational program|"The program includes 10 weekly, 2-hours sessions led by two trained animators (nurse, medical doctor/psychologist), each focusing on a specific theme or skill :~1. Education on suicidal behavior (clinic and epidemiology), and conceptualization of the phenomenon on a matrix~2. Education on the suicidal crisis, identification of important life areas and values for the patient, experimentation on the way to use the matrix as a decision-making tool.~3. and 4) Self-assessment of suicidal ideations, coping strategies based on suicide ideation intensity and emotional tension (acceptation, distress tolerance, personal aid kit, and emergency care)~5) Stress-diathesis model of suicidal behavior, innovating cognitive skills (defusion), and valued actions 6) Stress factors (psychiatric diseases and negative life events), resilience, and contact with present moment 7) Suicidal vulnerability, personal strengths 8) Social support, skills to create quality relationships"
40772286|NCT03185026|OTHER|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
40772287|NCT03413800|DRUG|Lenalidomide-Dexamethasone-DLI|Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)
40772288|NCT00830336|DRUG|Azithromycin|Oral Suspension
40772289|NCT00830336|DRUG|Zithromax®|Oral Suspension
40772290|NCT00969020|PROCEDURE|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
40976532|NCT05039151|BIOLOGICAL|blood sampling|A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
41141067|NCT03883724|BEHAVIORAL|Information-only control (IC)|The IC condition is intended to emulate the behavioral treatment information generally to available patients. It includes instructions to review hand out on healthy sleep practices. We will also use patient education videos on insomnia developed locally and widely used in clinical research. The content of these videos overlap substantially with BBTI but without individualized behavioral instructions. Two weeks later, IC participants will receive a 10-minute follow-up telephone call to encourage continued participation. Participants will be referred to the brochures for specific sleep-related questions.
41141068|NCT04619108|BIOLOGICAL|Thrombosomes®|
41141069|NCT05687825|PROCEDURE|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
41141070|NCT05238337|DRUG|[14C]-PBI-200|\[14C\]-radio-labeled-PBI-200
41141071|NCT02823340|DEVICE|Fractional microneedle RF(United, Peninsula Medical, China)|
41300908|NCT04308512|DEVICE|Care4AD system|Eligible subjects will be randomized to intervention, IG, and control groups, CG, with ratio of 1:1 and will be assessed at baseline and six months. All reminders will be activated in the intervention group and de-activated in the control group. Essential ADL tasks will be preprogrammed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
40976533|NCT03377036|DIAGNOSTIC_TEST|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
40976534|NCT03377036|DIAGNOSTIC_TEST|2D-FFDM|2D full-field digital mammography
41300909|NCT01947374|PROCEDURE|Matrix encapsulated chondrocyte implantation|Each implant contains 6,000,000 autologous chondrocytes.
40772291|NCT06419881|BEHAVIORAL|Tele-drama therapy|A 12-week tele-drama therapy group intervention integrating Playback Theater and Life Review Therapy
40772292|NCT06419881|OTHER|Usual Care|This arm continued to receive the routine activities provided by Uniper Care
40772293|NCT02001792|PROCEDURE|Position the patient during colonoscopy|Position the patient either in a left lateral position during colonoscopy
40976535|NCT00976092|DRUG|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
40976536|NCT00976092|DRUG|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
40976537|NCT00976092|DRUG|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
40976538|NCT00976092|DRUG|Heparin|i.v. bolus of 70-100 IU/kg body weight
40976539|NCT02734238|DRUG|Sesame Oil|200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
40976540|NCT02734238|DRUG|testosterone enanthate|200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
40976541|NCT01466855|DRUG|Intra-Ophthalmic Artery Topotecan Infusion|Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
40976542|NCT03425123|OTHER|Regenerative Endodontic Procedure (REP)|Regenerative Endodontic Procedure (REP) involves disinfection of the root canal with the use of acombination of three antibiotics including ciprofloxacin, metronidazole, minocycline. At the second visit, the patient is evaluated for resolution of signs or symptoms of an acute infection and if none then bleeding is induced, the site covered with a plug and the patient is evaluated at follow up.
41141072|NCT06092736|DRUG|Compound Danshen Dropping Pills|Dosage of Compound Danshen Dropping Pills: 20 capsules each time, 3 times a day, after meals. The follow-up period was 6 months.
41141073|NCT06092736|DRUG|Placebo|placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
41300910|NCT01947374|PROCEDURE|Microfracture awl|Is an awl that allow perforation of the subchondral bone.
40976543|NCT03334448|DRUG|LY900014-U200|Administered SC
40976544|NCT03334448|DRUG|LY900014-U100|Administered SC
40976545|NCT01624454|OTHER|Laxabon|4 l PEG solution split dose cleansing
40976546|NCT01624454|OTHER|CitraFleet|Small volume osmotic bowelcleansing
40976547|NCT00865774|BEHAVIORAL|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
40976548|NCT00865774|BEHAVIORAL|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
40976549|NCT01186679|PROCEDURE|laminectomy|surgical laminectomy with glial scar resection
40976550|NCT01186679|PROCEDURE|Intrathecal|direct into the CSF through lumbar puncture
40772294|NCT02001792|DEVICE|pulse oximeter|
40772295|NCT00849992|DRUG|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
41460063|NCT05694117|BEHAVIORAL|resistance training|The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions). Participants in the RTG completed four sets of each movement, with two to three minutes of rest between each set.
41460064|NCT05694117|BEHAVIORAL|Taichi exercise and resistance training|The training of the Taichi exercise and resistance training group consisted of two cycles, the first cycle was aimed at learning and consolidating Taichi exercise, and the second cycle was aimed at improving and consolidating. The Taichi exercise and resistance training group was scheduled for 30 min of Taichi exercise per training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
40772296|NCT00849992|PROCEDURE|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
40772297|NCT06022887|BEHAVIORAL|TRE|daily ad libitum food intake, 8-h 12pm - 8pm, 8 wks active weight loss phase;
40772298|NCT06022887|BEHAVIORAL|MBSR|Completed 30 sessions of a Mindfulness-Based Stress Reduction (MBSR) interventions for 8 weeks
40772299|NCT01210781|PROCEDURE|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
40772300|NCT01269775|OTHER|Teaching Methods|We carried out a randomized controlled trial comparing three methods of teaching. These three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation) regarding medical students' knowledge achievement and satisfaction.
40772301|NCT05099315|OTHER|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
41141074|NCT00689195|DIETARY_SUPPLEMENT|Curcumin powder|oral capsules containing the investigational agent
41141075|NCT00689195|DIETARY_SUPPLEMENT|Ashwagandha extract|4.5% extract of ashwagandha
41141076|NCT05693428|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 5-6 mg/kg/h intravenously on a perfusor.
41141077|NCT05693428|DRUG|Isoflurane|isoflurane was used as anaesthetice of - 1.1-1.2 MAC.
41141078|NCT05693428|DRUG|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
41141079|NCT03029585|DRUG|NanoPac® 100 mg/m2|Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
40772302|NCT03940248|RADIATION|Proton Accelerated Partial Breast Irradiation|38.5 Cobalt Gray Equivalent (CGE) given over 10 fractions
40772303|NCT00071032|BIOLOGICAL|Liberal (10 g/dL) Transfusion Strategy|This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
40772304|NCT00071032|BIOLOGICAL|Restrictive (Symptomatic) Transfusion Strategy|Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
40772305|NCT00003561|BIOLOGICAL|recombinant interferon alfa|
40772306|NCT00003561|BIOLOGICAL|sargramostim|
40772307|NCT04259216|BEHAVIORAL|IMPACT Intervention|Brief remote session + tailored, daily 8-week mobile application facilitated messaging secondary prevention intervention.
40772308|NCT04259216|OTHER|Control: Enhanced Online Resources (EOR)|EOR group participants will receive standardized information on cyberbullying.
40772309|NCT04372485|BEHAVIORAL|mHealth Intervention|Adolescents will receive text messages to facilitate treatment adherence
40772310|NCT02239003|DRUG|DAOIB|
40772311|NCT02239003|DRUG|Placebo|
41141080|NCT03029585|DRUG|NanoPac® 200 mg/m2|Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
41141081|NCT03029585|DRUG|NanoPac® 300 mg/m2|Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
41141082|NCT03029585|DRUG|NanoPac® 400 mg/m2|Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
41141083|NCT03029585|DRUG|Standard of Care Intravenous Chemotherapy|Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
41141084|NCT03855514|OTHER|NuShield|NuShield® is a dehydrated placental allograft.
41141085|NCT02574286|DRUG|Velaglucerase alfa|Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.
41141086|NCT02574286|DIETARY_SUPPLEMENT|Vitamin D|Participants will receive 800 IU vitamin D orally daily.
41141087|NCT01819857|DRUG|Xomolix 0.625 mg intravenously|intravenous administration of 0.625 mg droperidol
41141088|NCT01819857|DRUG|Xomolix 1.25 mg|intravenous administration of 1.25 mg droperidol
40772312|NCT04258748|BEHAVIORAL|Motivational Interviewing (MI)|In each of the four MI counseling sessions that were delivered, the researcher approached mothers in small groups of 5 via three phases, in 15-30 minutes, to establish rapport/ alliance in the first phase, to identify health needs in the second phase and finally to reinforce dental needs in the third phase.
40772313|NCT04258748|BEHAVIORAL|Gaming and MI|In each of the four MI counseling sessions, the researcher approached mothers via three phases, in 15-30 minutes, to establish rapport/ alliance, to identify and finally reinforce dental needs in the same pattern as MI group. In addition, the children were engaged in 'Happy Teeth, Healthy Kids' which is an android tablet game that was included in the MI session scheduled for the mothers. Children were told to follow correct steps of brushing in order to obtain happy bright teeth. This helped the children realize that brushing teeth will give them a bright smile.
40976551|NCT01545986|BEHAVIORAL|Exercise|Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
41141089|NCT01819857|DRUG|Zofran 8 mg|intravenous administration of 8 mg ondansetron
41300911|NCT05447377|BIOLOGICAL|SII Yellow Fever Vaccine|"SII YF vaccine:~Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine.~After reconstitution, 1 dose (0.5 mL) contains:~* Yellow fever virus 17D-213 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~* Excipients with known effects:~* This product contains approximately 5 mg of sorbitol per dose."
40976552|NCT02515058|DEVICE|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
40976553|NCT02515058|DEVICE|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
40976554|NCT00231725|DRUG|insulin lispro injection [rDNA origin] Low Mix|
40976555|NCT03548909|DIAGNOSTIC_TEST|VITROS Immunodiagnostic Products|NT-proBNP II assay
40976556|NCT05776199|DIAGNOSTIC_TEST|Sonoelastography, tensiomyography and mechanosensitivity|To observe the differences between the different trigger points of the levator scapulae muscle by means of different diagnostic options.
40976557|NCT06427031|DRUG|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
40976558|NCT06427031|DRUG|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
40976559|NCT01447095|DRUG|Prostacyclin 1 ng/kg/min|Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
40976560|NCT01447095|DRUG|Prostacyclin 2 ng/kg/min|Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
41141090|NCT03046394|DEVICE|C-SACH|Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
41141091|NCT03046394|DEVICE|B-DER|Dynamic Motion by Otto Bock, advertised for activity category 2-3
41141092|NCT03046394|DEVICE|A-DER|Triton by Otto Bock, advertised for activity category 3-4
40976561|NCT01447095|DRUG|Placebo|Continuous i.v. infusion with placebo day 5-10 after SAH
40976562|NCT00585728|PROCEDURE|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
40976563|NCT02664441|DRUG|Exenatide|Weekly injections of active drug.
40976564|NCT02664441|DRUG|placebo|Weekly placebo injections
40976565|NCT02989675|DRUG|10% dextrose|Bolus of 10% dextrose 5mls/kg
41141093|NCT04678752|OTHER|Weight management care path|"* Documentation and data capture built in the Electronic Health Record~* Clinical data support that suggests weight loss approach(es)~* Tracking of weight loss progress and weight loss maintenance during patient visits to guide the patient-clinician conversation~* Diagnosis and billing in EHR automatically adds the diagnosis of overweight or obesity and links the most common weight-related co-morbidities to ensure adequate provider reimbursement~* Evidence-based online training on weight management for clinicians~* Practice quality improvement and training for use of PATHWEIGH for weight-prioritized visits through practice coaches/facilitators~* Consultation support by practice facilitators with implementing PATHWEIGH and by obesity providers for clinicians with creating patient treatment plans"
41141094|NCT04678752|OTHER|Control|"Within primary care the option to select Obesity brief HPI, this is a brief historical intake of a patient's weight - when either they or their clinician decides to have a weight-prioritized visit. It is intended to initiate a discussion regarding potential strategies for weight loss (often eat less, exercise more). The provider has the discretion to augment or add support as they see fit."
41141095|NCT02590770|BEHAVIORAL|attention modification|participants will receive gaze-continent feedback according to their viewing patterns
41141096|NCT02590770|OTHER|Placebo|participants will receive non-gaze-continent feedback unrelated to their viewing patterns
41141097|NCT01400997|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
41141098|NCT05539118|DRUG|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
40772314|NCT04258748|BEHAVIORAL|Conventional dental health education|It was delivered through a 15-minutes oral health session given to mothers of preschoolers. Mothers were given brief information about causes of dental caries and role of plaque, toothbrush size, diet / frequency of sweet snacks, brushing technique, toothpaste and fluoride use as well as regular dental visits. Participants were then shown a short educational video about prevention of dental caries among children coupled with oral hygiene instructions. At the end of the session, participants were given a leaflet reinforcing the information to take home.
40772315|NCT01969214|DEVICE|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water, to be taken orally~1 tablet, 3 times a day"
40772316|NCT05577156|BEHAVIORAL|Self-questionnaires and semi-structured interview|Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions
40772317|NCT01930500|BEHAVIORAL|Individual neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
40772318|NCT01930500|BEHAVIORAL|Group based neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
40772319|NCT03657485|DIETARY_SUPPLEMENT|containing Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A|we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
40772320|NCT04502914|PROCEDURE|Open-to-air strategy|In open-to-air management, the wound will be washed with a chlorhexidine solution and leave the wound open, or portion of the wound assigned to OTA, to the environment. An electric heat lamp (model no. 53103, 250W, Brandt Industries LLC, Bronx, NY) will be placed at as close to 1 yard (0.91 m) as possible from the wound after daily wound care for 24 hours (+/- 6 hours) to promote drying. However, to prevent excessive drying an hourly spritz of topical solution, e.g., DuoDERM® Hydroactive® gel (ConvaTec Oklahoma City, OK) will be used at the bedside.
40772321|NCT04502914|PROCEDURE|Traditional closed-wound management|In traditional closed-wound management, once a day the wound will be washed with a chlorhexidine solution and closed with a non-adherent dressing such as ADAPTIC® (Acelity, San Antonio, TX) soaked in topical antimicrobial solutions, ointments, and creams designed to promote wound healing.
40772322|NCT06563908|PROCEDURE|Lipiodol® uterine treatment prior to IVF/ICSI|Lipiodol®, treatment will be performed by a HSG technique with X-ray screening on day 3 or day 5 after oocyte retrieval. The contrast medium will be Lipiodol Ultra Fluide® (Guerbet, France), an iodized poppy seed oil obtained by substitution of ethyl esters for the glyceryl esters of Lipiodol®. One millilitre of Lipiodol Ultra Fluide® contains 0.48g iodine. Women will lie in the left lateral or supine position. Radiologists will use a 'no touch' technique after applying antiseptic solution to the cervix. Uterine cannulation using the Cook HSG catheter will be applied to conduct Lipiodol® treatment. Prewarmed (37oC) Lipiodol® will be slowly instilled, with intermittent fluoroscopic X-ray guidance. Up to 10 ml of Lipiodol® will be slowly injected into the uterus and directly monitored by fluoroscopy. If intravasation was observed on X-ray (contrast apparent in the venous system), instillation will be stopped immediately.
40772323|NCT03773484|BEHAVIORAL|Opioid naive|Visit where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days
40772324|NCT03773484|BEHAVIORAL|At-risk for long term use|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days
40772325|NCT03773484|BEHAVIORAL|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days
40772326|NCT05616442|DRUG|Ketotifen|Mast cell stabilizer
40772327|NCT05616442|DRUG|Vitamin E|Dietary supplement
40772328|NCT02971839|DRUG|VX-561|
40772329|NCT02971839|DRUG|Placebo|
40976566|NCT03265275|OTHER|Fast track patient pathway|Prehospital services establish a working diagnosis of hip fracture and initiate first line treatment. In the emergency department a specially trained nurse triages the patient. Patients without signs of other acute disease or trauma and who have not previously been operated in the same hip are directly transported to the x-ray suite. The x-rays are reviewed by the radiographer and in case of an obvious fracture of the hip the patient is transported directly to the orthopedic ward where the patient is received by a nurse and seen by an orthopedic surgeon. The pathway includes standard procedures for blood sampling, pain relief, including a fascia iliaca compartment block, intravenous fluids, transfusion triggers, management of anticoagulants and premedication. The pathway puts focus on prevention of pressure sores, a short preoperative fasting period and early mobilization. Screening tools are used to assess for delirium, nutritional status and fall risk.
40976567|NCT04946838|DEVICE|DS5 electrical stimulator|TENS
41141099|NCT05539118|DRUG|Toripalimab|Toripalimab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
41141100|NCT05539118|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride is a novel oral tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR) and c-kit.
41141101|NCT04405180|DRUG|Placebos|Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
41141102|NCT04405180|DRUG|20mg sodium nitrite tid|Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
40772330|NCT02971839|DRUG|IVA|
41141103|NCT02378584|OTHER|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
41141104|NCT00493688|OTHER|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
40772331|NCT01203397|DRUG|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G|APLIED 4 TIMES/DAY AT LESION
40772332|NCT04907084|DIETARY_SUPPLEMENT|Serine|Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)
40772333|NCT04907084|DRUG|Fenofibrate|Fenofibrate 160mg pill, taken orally
40772334|NCT04666155|DEVICE|Intermittent Colonic Exoperistalsis with MOWOOT device|"Patients under the experimental arm of the study should place the belt of the Mowoot device on the abdomen and use it for 20 minutes every day for 12 weeks. They should continue with their individualized standard of care againts constipation for the first 4 weeks. During the following 8 weeks of the interventional period of 12weeks, their use of SocTAI will be considered rescue intervention. The 8weeks following the 12weeks of intervention, they can keep on using ICE device.or SocTAI or both."
40976568|NCT01354951|OTHER|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
40976569|NCT00162201|DRUG|Abatacept|Parenteral, IV, 500 mg if \< 60 kg; 750 mg if \> 60 \& \< 100 kg; 1000 mg if \> 100 kg, Monthly, 4 months.
40976570|NCT03156543|DEVICE|Jumpstart Dressing|"JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B"
40976571|NCT03156543|OTHER|Standard Dressing|This is a standard of care bandage that will be placed on participants in group A post operatively
40976572|NCT01431560|DEVICE|fixation of the ankle fracture (Solco )|fixation with metallic implant
40976573|NCT01431560|DEVICE|fixation of the ankle fracture (Freedom)|fixation with biodegradable implant
40976574|NCT06145776|OTHER|tDCS + tredmill training (Standart trehab training)|Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.
40976575|NCT06145776|OTHER|Cognitite-motor Dual Task Training (DT training)|The dual-task training protocol (DT) will consist in cognitive exercises (verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks) and motor exercises (walking while carrying a tray with only one empty glasscarrying a glass while walks, change peaces from one pocket to another, looking from one side to another while walking)
40976576|NCT00875212|DRUG|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
40976577|NCT00875212|DRUG|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
40976578|NCT00875212|DRUG|fluoride|use of a dentifrice containing fluoride (1500ppm) only
40976579|NCT00875212|DRUG|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
40976580|NCT00297375|DRUG|tramadol HCl/acetaminophen|
40976581|NCT03578601|OTHER|Thyroid surgery|Patient undergoing thyroid surgery
40976582|NCT04140799|DEVICE|vocal cord ultrasonography|assess vocal cord motion and recurrent nerve function by Transcutaneous laryngeal Ultrasonography in patients scheduled for anterior cervical spine surgeries
41141105|NCT03482999|DEVICE|TissuGlu Surgical Adhesive|
41141106|NCT04501588|BEHAVIORAL|Responsive training with no video feedback|Parents will receive responsive training, but will not watch themselves on video to reflect on their strategy use.
41141107|NCT04501588|BEHAVIORAL|Responsive training with video feedback|Parents will receive responsive training and watch themselves on video to reflect on their strategy use.
40772335|NCT04666155|DEVICE|Standard of care with Trans-Anal Irrigation|Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation for the 12weeks of intervention. The following 8 weeks they can keep on using SocTAI or ICE device or both.
40772336|NCT04409431|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol
41141108|NCT05051709|PROCEDURE|Corrective osteotomy|First metatarsal distal corrective osteotomy
40772337|NCT06477627|OTHER|change of environment|The participants will change from inland to coastal environment to see the effect. We will take VAMS blood samples and nose swabs from the participant to measure this effect.
41141109|NCT05051709|PROCEDURE|Fusion of First ray|Fusion of first ray with soft tissue procedure
41141110|NCT00813709|DRUG|RNF|Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
41141111|NCT00813709|DRUG|RNF|Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
40772338|NCT06477627|OTHER|no intervention|reference groups, stay in their coastal or inland environment
40976583|NCT05397756|OTHER|observer tool|The observer tool used will be the Anaesthetist Non-Technical Skills (ANTS) tool previously published by Fletcher et al. and translated in French. The ANTS scoring system uses four categories assessing task management, teamworking, situation awareness and decision-making. The observers will use an observer tool it when they will be not role role-playing
40976584|NCT05532592|OTHER|Perceptions and attitudes towards COVID-19 and COVID-19 vaccine|Attitude towards COVID-19; Knowledge about COVID-19 vaccine
40976585|NCT02047890|DRUG|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
40976586|NCT02047890|DRUG|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
40976587|NCT06404216|OTHER|Nordic walking group training|"16 60-minute NW group sessions, twice weekly. Sessions will be led by a qualified healthcare professional and a graduating student.~A social worker (SP) will participate in one weekly session aiming to empower the participants and utilize group dynamics techniques to promote successful continuation of independent walking following the guided period.~Communication throughout the study will be conducted via a WhatsApp forum, to motivate and sustain regular walking during and after the training period. Following 2 months of guidance the group will be launched independently, while keeping remote contact. Same frequency and schedule will be encouraged."
40976588|NCT02524795|DIETARY_SUPPLEMENT|Hiomega-3 supplement of Naturalis® company -|Patients (N=22) were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment, and were contacted by telephone in week 6 to check on compliance and any adverse events. Patients received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company - registered in the National Health Department number 4.1480.0006.001-4). All participants were instructed not to take omega-3 rich foods during the study period.
40976589|NCT02569723|DRUG|Carbon C 14 Oxaliplatin|Intravenous infusion
40976590|NCT02569723|DRUG|Oxaliplatin|Intravenous infusion
41141112|NCT00813709|DRUG|RNF|Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
40976591|NCT02037698|DEVICE|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
40976592|NCT06023472|DEVICE|microfluidic chip|Microfluidic chip method has been used for sperm sorting in order to select the most motile and morphologically normal sperm for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
41300912|NCT05447377|BIOLOGICAL|STAMARIL®|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL® is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent.~After reconstitution, 1 dose (0.5 mL) contains:~* Yellow fever virus 17D-204 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~* Excipients with known effects:~* This product contains approximately 8 mg of sorbitol (E420) per dose."
41141113|NCT00813709|DRUG|Placebo|Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
41141114|NCT02359071|OTHER|handover duration, handover rate|To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
41300913|NCT00101192|BIOLOGICAL|cetuximab|
41141115|NCT04617925|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose
41300914|NCT00101192|DRUG|cisplatin|
40772339|NCT03917615|OTHER|pelvic floor contraction|Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function
40976593|NCT06023472|DEVICE|density gradient centrifugation|Density-gradient centrifugation is a commonly used method for sperm separation and purification. It is a technique that involves layering a semen sample on top of a gradient of different densities of a solution, typically a mixture of colloidal silica and sucrose, and then centrifuging the sample. The centrifugal force causes the sperm to migrate through the gradient, where they become separated based on their density.
40976594|NCT00007969|BIOLOGICAL|Detox-B adjuvant|
40976595|NCT00007969|DRUG|verteporfin|
41141116|NCT01760876|DEVICE|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
40772340|NCT06151483|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
40772341|NCT06151483|OTHER|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
40772342|NCT01092650|DRUG|Deuterated phenanthrene|Deuterated phenanthrene 10 micrograms
40772343|NCT05818462|DIAGNOSTIC_TEST|Uroflow testing|Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.
40772344|NCT05818462|DIAGNOSTIC_TEST|Bladder Scan|Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.
40772345|NCT05818462|OTHER|Dysfunctional Voiding Scoring System Survey|The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.
40772346|NCT05818462|DIAGNOSTIC_TEST|DEXA Scan of pelvis and sacral spine|DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.
40772347|NCT05818462|DIAGNOSTIC_TEST|Urine tests for specific biomarkers|Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).
40772348|NCT05902442|DEVICE|3DxSPLINT|Routine immobilization procedure with a patient-specific 3D printed splint instead of the use of a conventional forearm splint after one week of conventional immobilization.
40772349|NCT02485886|DRUG|68Ga-BMV101|68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
40772350|NCT04394494|OTHER|Motor Imagery. Imaging doing Extension exercises without actually doing them.|This study will compare imagining doing specific extension based exercises for LBP vs. actually performing the exercises. This intervention will be just imaging doing the exercises.
40772351|NCT04394494|OTHER|Control: Physically performing extension based exercises.|This study will compare imagining doing specific extension based exercises for LBP vs. actually doing them. This intervention will be actually, physically performing the exercises.
40772352|NCT00933478|DEVICE|Clay|Small dime sized piece of clay.
40772353|NCT06511778|DRUG|Hemoblast Bellows application|Hemoblast bellows is a hemostatic agent clinically proven effective on the validated SPOT GRADE scale for minimal, mild, and moderate bleeding. Patients will have the Hemoblast bellows applied during on pump sternotomy surgery.
40772354|NCT06455904|PROCEDURE|Training sessions|The training program will be performed during 15 weeks, with one session per week.
40772355|NCT00020683|DRUG|incyclinide|High dose given orally
40976596|NCT05782608|DRUG|IV ibuprofen|Group 1 will receive IV ibuprofen 400mg \\ 6 hours the first dose will be administrated immediately post operative.
40976597|NCT05782608|DRUG|IV ketorolac|Group 2 will receive 20 mg IV ketorolac\\ 6 hours the first dose will be administrated immediately post operative
40976598|NCT01533389|DRUG|Silodosin|"Drug: silodosin dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo"
40976599|NCT01533389|DRUG|Placebo|dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks
40976600|NCT05564689|PROCEDURE|Intracoronary flow and pressure|Measurement of absolute coronary flow and resistance
40772356|NCT00020683|DRUG|incyclinide|Low dose given orally
40772357|NCT00020683|OTHER|laboratory biomarker analysis|Correlative studies
40772358|NCT06280989|OTHER|kinesio taping|"Before treatment, all female participants will undergo an allergic test on the anterior surface of the elbow.~To ensure cleanliness, alcohol will be used to clean the areas to be evaluated before applying the tape. The H technique will be employed to apply KT over the lumbar region. Participants will be instructed to bend forwards from the waist, and two vertical strips will be applied. These strips will stretch the Golgi tendon organ on both sides of the spine from the top of the buttock cleft upwards to a mid-point, with less than 25% stretch .~Additionally, a horizontal strip will be attached across the left and right sacroiliac joints. This strip will be stretched to 50% of its maximum capacity,."
40772359|NCT06280989|OTHER|myofascial release technique|"myofascial release technique will be applied from prone on lumbar paravertebral muscles by using the olecranon of the physical therapist for 3 minutes, thoracolumbar fascia by using cross-handed hold, with hands placed on the T12-L1 levels and on the sacrum for 5 minutes without repetition and quadratus lumborum by using elbow with low pressure obliquely towards the center of the column for 7 min.~Additionally, from supine on psoas muscle by transversal sliding of the psoas fascia. The therapist will place the hands laterally 3 cm from the umbilicus."
40772360|NCT06564792|BEHAVIORAL|Contingency management|Once weekly contingency management visit involving 15 minutes+ of motivational interviewing and provision of incentives for stimulant-negative urine tests and/or tenofovir-positive urine tests.
40772361|NCT02449187|DRUG|JLP-1310, Fasted followed by fed|"In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition."
40976601|NCT02405845|RADIATION|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
40976602|NCT01091493|DRUG|Moxifloxacin|Moxifloxacin 400 mg administered once a day for 5 days
40976603|NCT03579160|DRUG|0.25% timolol gel with full-thickness skin grafts|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied.
40976604|NCT03579160|OTHER|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied.
40976605|NCT03823352|DRUG|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
40976606|NCT02297477|DRUG|atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)
40976607|NCT02297477|DRUG|artesunate-atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
40976608|NCT04247360|DEVICE|cuff pressure|maintaining cuff pressure according the groups
40976609|NCT03755102|DRUG|Dacomitinib|"Cohort 1 Dacomitinib Dosing:~Dose level 1: Dacomitinib 45mg daily Dose level -1: Dacomitinib 30mg daily Dose level -2: Dacomitinib 15mg daily~Cohort 2 Dacomitinib Dosing:~Dose level 1: Dacomitinib 30 mg daily Dose level -1: Dacomitinib 15 mg daily"
40976610|NCT03755102|DRUG|Osimertinib|"In cohort 2, participants will begin on dacomitinib orally daily in combination with Osimertinib~Dose level Osimertinib Dosing:~Dose level 1: Osimertinib 80 mg daily Dose level -1: Osimertinib 40 mg daily"
40976611|NCT02763189|OTHER|Expert mentoring|Experts will provide personalized instructional review on how to use the new device for changing endotracheal tubes.
40976612|NCT02763189|OTHER|Self-study|All subjects will receive self-study
40976613|NCT05991076|OTHER|Latin Dance|The Activate Bailando class is a dance-focused exercise class that is offered once per week for one hour. The program has been developed by dance educators in the Madison area.
40976614|NCT02338661|DEVICE|SBG hip stem|
40976615|NCT01266954|DRUG|GSK2141795|GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
40976616|NCT00275054|DRUG|Fludarabine|cycles 1-6: 25 mg/m² i.v., d2-4, q28d
40976617|NCT00275054|DRUG|Cyclophosphamide|cycles 1-6: 250 mg/m² i.v., d2-4, q28d
40976618|NCT00275054|BIOLOGICAL|Rituximab|"cycle1: 375 mg/m² i.v., d1, q28d~cycles 2-6: 500 mg/m² i.v., d1, q28d"
40976619|NCT04880525|OTHER|Dietary intervention|In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
40976620|NCT05748756|OTHER|Enucleation and filling by Bone marrow aspirate|"The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest.~The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated.~Bone marrow aspirate is processed by a dual centrifugation technique."
40976621|NCT05748756|OTHER|Conventional enucleation only|patients were treated conventionally by enucleation and plain collagen sponge only.
40976622|NCT04140292|DRUG|Photodynamic therapy (PDT)|"PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered."
40976623|NCT04140292|DRUG|Vitamin D3|"D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment~Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result"
41460065|NCT05694117|BEHAVIORAL|Randomly selected exercise program|Participants in the randomly selected exercise program group who chose Yijinjing exercise were required to complete one hour of Yijinjing exercise training, and those who chose Yijinjing exercise hybrid strength training had to complete half an hour of Yijinjing training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
41460066|NCT00652002|DRUG|budesonide/formoterol|
41460067|NCT00652002|DRUG|budesonide|
40976624|NCT05255406|DRUG|Furmonertinib (160mg)|160mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (80mg).
40976625|NCT04912050|DEVICE|Tablo Hemodialysis System|Renal Replacement Therapy between 12\< to ≤ 24 hours.
40976626|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Hyoid Bone(DSHB)|Hyoid bone-skin distance Other Name: DSHB
40976627|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Vocal Cord Anterior Commissura(DSAC)|Vocal cord anterior commissura-skin distance Other Name: DSAC
40976628|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Epiglottic(DSE)|Skin-epiglottic distance Other Name: DSE
40976629|NCT02856230|DEVICE|Ranger SL DEB|BTK angioplasty using Ranger SL DEB
40976630|NCT03510884|DRUG|Alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous injection
40976631|NCT03510884|DRUG|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
40976632|NCT03510884|DRUG|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
40976633|NCT03510884|DRUG|Simvastatin|Pharmaceutical form:Tablet Route of administration: Oral
40976634|NCT03510884|DRUG|Pravastatin|Pharmaceutical form:Tablet Route of administration: Oral
40976635|NCT03510884|DRUG|Lovastatin|Pharmaceutical form:Tablet Route of administration: Oral
40976636|NCT03510884|DRUG|Fluvastatin|Pharmaceutical form:Capsule Route of administration: Oral
41141117|NCT02381028|OTHER|Human milk and emollient: Apobase creme® (Actavis Norway AS)|Topical application of human milk followed by emollient
41141118|NCT02381028|OTHER|Emollient: Apobase creme® (Actavis Norway AS)|Topical application of emollient
41460068|NCT00652002|DRUG|formoterol|
40976637|NCT03510884|DRUG|Ezetimibe|Pharmaceutical form:Tablet Route of administration: Oral
40976638|NCT03510884|DRUG|Cholestyramine|Pharmaceutical form:oral suspension Route of administration: oral
40976639|NCT03510884|DRUG|Nicotinic acid|Pharmaceutical form:Tablet Route of administration: Oral
40976640|NCT03510884|DRUG|Fenofibrate|Pharmaceutical form:Tablet Route of administration: Oral
40976641|NCT03510884|DRUG|Omega-3 fatty acids|Pharmaceutical form:capsule Route of administration: oral
40772362|NCT02449187|DRUG|JLP-1310, Fed followed by fasted|"In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition."
40976642|NCT03510884|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous injection
40976643|NCT02709785|DRUG|SmartMouth Clinical DDS mouthrinse|Subjects use SmartMouth Clinical DDS mouth rinse for six weeks.
40976644|NCT02709785|DRUG|0.12% chlorhexidine rinse|Subjects use chlorhexidine mouth rinse for six weeks.
40976645|NCT02709785|DRUG|Placebo rinse|Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
40772363|NCT04604431|OTHER|iREACH CDS Tool|Pediatric clinicians in the intervention arm will 1) receive the iREACH education module, 2) have the iREACH CDS tool integrated into the EHR templates for use at the 4-, 6-, 9-, 12-month WCC, and 3) will be reminded by EHR-embedded prompts at the 9-month WCC to ask caregivers whether peanuts were introduced and tolerated.
40772364|NCT00220662|BEHAVIORAL|Readiness and Motivation Therapy|
40772365|NCT03129906|DIETARY_SUPPLEMENT|Gluten|
40772366|NCT03129906|DIETARY_SUPPLEMENT|Rice protein|
40772367|NCT00960245|DRUG|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
40772368|NCT00960245|DRUG|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
40772369|NCT03741855|DEVICE|Cloud Dx Kit with self-monitoring|Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.
40976646|NCT00173082|PROCEDURE|Glucose tolerance test|
40976647|NCT01852578|DRUG|Cabazitaxel|Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
40772370|NCT03741855|DEVICE|Cloud Dx Kit with remote-monitoring|"* Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.~* A respiratory therapist (RT) will be monitoring asynchronously patient vitals and contacting them when their vitals exceed pre-determined thresholds.~* The RT will also check on patients once a week irrespective of the value of the vitals."
40976648|NCT02625272|PROCEDURE|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
40976649|NCT06066684|OTHER|n/a, observational|n/a, observational study
40976650|NCT04474704|DEVICE|Cheetah® non-invasive cardiac monitoring system|Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))
40976651|NCT04474704|OTHER|Standard of care|24 hours of postpartum magnesium sulfate
40976652|NCT03182101|BEHAVIORAL|Exposure Therapy|Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
40976653|NCT00439660|BIOLOGICAL|Oral Rotavirus Vaccine 116E Live Attenuated|
40976654|NCT02455622|DRUG|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
40976655|NCT02846779|OTHER|Low intensity|Low intensity telepharmacy outreach
40976656|NCT02846779|OTHER|Moderate intensity|Moderate intensity telepharmacy outreach
40976657|NCT02846779|OTHER|High intensity|High intensity telepharmacy outreach
40976658|NCT02280785|DRUG|Brentuximab vedotin|Brentuximab vedotin must not be administered as an IV push or bolus. It must be administered in 100ml-250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
40976659|NCT04449198|DRUG|Resveratrol|500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
40976660|NCT04449198|OTHER|Placebo|placebo for 12 weeks
40976661|NCT01353326|DEVICE|Cormet|Cementless hip resurfacing system
40976662|NCT01353326|DEVICE|Conserve|Cemented hip resurfacing system
40976663|NCT05004766|OTHER|Robot assisted gait training with virtual reality|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
40976664|NCT03454893|DRUG|AVR-RD-01|Single IV infusion of between 3 - 20 x 10\^6 CD34+ cells/kg.
40976665|NCT03239288|OTHER|Control digestible carbohydrate|Single serving of control product
40976666|NCT03239288|OTHER|Test resistant starch type 4|Single serving of test product
40976667|NCT02850029|OTHER|Observational study, no intervention|
40976668|NCT06150560|DRUG|Losartan|50mg administered orally once daily for 52 weeks.
40976669|NCT06150560|DRUG|Amlodipine|5mg Amlodipine administered orally once daily for 52 weeks.
40976670|NCT06150560|DRUG|Placebo|Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
40772371|NCT06164054|DEVICE|Virtual Reality Rehabilitation System|Participants of the experimental group will undergo treatment with Virtual Reality, both IVR and HB. The intervention will consist of 12 sessions lasting about 1 hour each and carried out with a frequency of three days per week within four weeks. Before starting the rehabilitation, arm illusion with the Handbox is inducted to explore the ability of the patients to perceive the virtual arm as their own. During this task, patients sit on a chair with the injured arm inside the Handbox and are invited to perform slow movements with the hand, such as moving the fingers one at a time and moving the wrist up and down. Moreover, they are invited to keep their attention to the virtual arm project on the screen that follows their natural movements. The arm illusion lasts 3 minutes, and the embodiment questionnaire is administered. Then, the treatment starts with IVR and HB sessions, which are counterbalanced to avoid the learning effect
40772372|NCT06164054|BEHAVIORAL|Traditional therapy|Participants randomly assigned to the control group will receive rehabilitation treatment as per usual clinical practice. Specifically, patients will be directed to rehabilitation facilities according to standard clinical rehabilitation pathways. They will be assigned to a physiotherapist who will administer the rehabilitation treatment for the upper limb impairment. Patients in the control group will receive the same amount of rehabilitation for the recovery of upper limb impairment as the treatment group, which means 3 physiotherapy sessions lasting 1 hour 3 times a week for 4 weeks.
40976671|NCT03274440|DRUG|Cannabis|"THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
40976672|NCT03274440|OTHER|Placebo|Placebo control group, not receiving THC or CBD.
40976673|NCT02509156|BIOLOGICAL|Allo-MSCs|20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
40772373|NCT00490711|DRUG|gemcitabine|
40772374|NCT00490711|DRUG|carboplatin|
40772375|NCT00490711|DRUG|paclitaxel|
40772376|NCT01993550|BEHAVIORAL|Telephone counseling|
40772377|NCT01993550|BEHAVIORAL|Education|
40772378|NCT04803565|DEVICE|Custom-made shoe insole|Subjects will receive a custom-made shoe insole designed on the patient's foot and shoes. The subjects should wear the insole for at least 6 hours per day.
40772379|NCT04803565|DEVICE|Sham conventional Insole|Subjects will receive a conventional insole without any specific property (sham insole)
40772380|NCT03289039|DRUG|Neratinib|Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)
40772381|NCT03289039|DRUG|Fulvestrant|Fulvestrant, works in treating breast cancer that has spread to other parts of the body
40772382|NCT05269186|DEVICE|Virtual reality software|The patient will undergo a 20-minute virtual reality session before the planning CT scan
40772383|NCT05349604|DIETARY_SUPPLEMENT|Garlic extracts|One intake in total
40772384|NCT05349604|DIETARY_SUPPLEMENT|Placebo|One intake in total
40772385|NCT06200948|OTHER|Aerobic Exercise|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
40976674|NCT02509156|BIOLOGICAL|Placebo|20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
40976675|NCT04769440|DRUG|mg sulphate|mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes
40772386|NCT06200948|OTHER|Complete Decongestive Treatment|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
40772387|NCT02602145|OTHER|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.
40976676|NCT01120223|DRUG|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|Once daily application
40976677|NCT04938193|DIAGNOSTIC_TEST|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
40976678|NCT04333823|DRUG|Dapagliflozin 5mg|Dapagliflozin tablet
40976679|NCT04333823|DRUG|Placebo|Sugar pill manufactured to mimic Dapagliflozin 5mg tablet
40976680|NCT03054389|OTHER|Qualitative Interview - Participants/ Patients|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
40976681|NCT03054389|OTHER|Qualitative Interview - Investigators and Study Coordinators|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
40772388|NCT05473520|DRUG|Doxycycline|A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
40976682|NCT00450684|DEVICE|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
40976683|NCT00450684|DEVICE|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
40976684|NCT00777478|DRUG|capiri-sutent|A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
40976685|NCT05660772|DEVICE|Microfragmented Adipose Tissue|Microfragmented Adipose Tissue derived using Lipogems® Kit
41460069|NCT03135080|OTHER|Long-Term HEAD START Training|The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
41460070|NCT03135080|OTHER|Standard of Care|All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
40976686|NCT05660772|DRUG|Corticosteroid|intra-articular knee injection of corticosteroid
40976687|NCT03630172|PROCEDURE|Dry needling|Using a thin, filiform needle to penetrate a muscle and its trigger point to produce a local twitch response
40976688|NCT02908503|OTHER|Placebo Film|placebo vaginal films
40976689|NCT05244330|OTHER||
40976690|NCT03875885|BEHAVIORAL|CONNECT|A novel web-based intervention with input from an advisory panel of cancer caregivers, oncology providers, and psychosocial oncology professionals empowering caregivers with needs to seek services by providing education about the benefits of supportive care resources, systematically identifying their unmet needs, and connecting them with tailored supportive care resources.
40976691|NCT03875885|BEHAVIORAL|CONTROL|This group will receive a generic resource list. The generic resource list will be printed for participants and emailed to them, if participants have an email address.
40976692|NCT00326456|DRUG|liposomal doxorubicin|30 mg/m2 gieven intravenously on day 1 every 3 weeks
40976693|NCT00326456|DRUG|carboplatin|AUC 5 intravenously on day 1 every 3 weeks
41460071|NCT05033145|DRUG|AZVUDINE|AZVUDINE 5 tablets QD + standard treatment, for up to 14 days
41460072|NCT05033145|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment, for up to 14 days
40976694|NCT00326456|DRUG|paclitaxel|175 mg/m2 intravenously on day 1 every 3 weeks
40976695|NCT04911530|OTHER|no intervention|no intervention
40976696|NCT03582124|PROCEDURE|Near-Infrared Fluorescence Imaging|Undergo imaging
40976697|NCT03582124|DRUG|Panitumumab-IRDye800|Given IV
40976698|NCT03582124|OTHER|Pharmacokinetic Study|Correlative studies
40976699|NCT03582124|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40976700|NCT02727751|DRUG|Tenapanor|
40976701|NCT00023634|BIOLOGICAL|KLH|100 mcg w/EGFRvIII
40976702|NCT00023634|BIOLOGICAL|GMCSF|arm 1: 100 mcg w/EGFRvIII
40976703|NCT04867603|DRUG|[Ga-68]PSMA|The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.
40976704|NCT04867603|DEVICE|PET/CT imaging|PET/CT imaging procedure
40976705|NCT03276156|DRUG|Apatinib plus S-1|Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
40976706|NCT04455802|DRUG|Buprenorphine or Placebo|The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
40976707|NCT04455802|DRUG|Morphine or Placebo|If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
40976708|NCT01778218|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose|An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
40976709|NCT02985554|DRUG|Nivolumab|Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
40976710|NCT05489055|DRUG|Iopamidol|A contrast bolus of iopamidol-370 (370 mg I/ml) (iopamidol injection; Consun Pharmaceutical, China) was injected at a ﬂow rate of 4.5-6 mL/s through an 18-20-gauge intravenous antecubital catheter by using a power injector (Ulrich, Germany). The total dose of iopamidol-370 was approximately 0.9 ml /kg body weight.
41460073|NCT02793713|PROCEDURE|Endobronchial Ultrasound|Patients undergoing EBUS with TransBronchial Needle Aspiration will be invited to enroll on the day of their procedure. Once informed consent is obtained, the surgeon will assess the sonographic criteria, take pictures, and biopsy every lymph node of interest. All three elements of this assessment will need to be completed for a specimen to be included in the study. After the procedure, the operating surgeon will fill the Lymph Node Assessment questionnaire, assign an aggregate score to every lymph node specimen, and attach the pictures to the form. Pictures from every specimen will stored electronically to be reviewed and secondarily rated by a second blinded surgeon. Patient involvement in the study ends at the completion of the planned procedure.
40772389|NCT05473520|DRUG|Placebo|Placebo + standard anti-tuberculous treatment
40976711|NCT06045767|DRUG|Pembrolizumab 50 MG Injection [Keytruda]|Chemo-immunotherapy combination
40976712|NCT03989453|OTHER|Chi Kung|The duration of the intervention is 12 weeks, with 2 sessions per week of Chi Kung. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up (Based on breathing and concentration exercises), of 10 minutes duration, a 40-45 minute Chi Kung session and finally 10 minutes of guided relaxation.
40976713|NCT04563923|DRUG|Avdoralimab (IPH5401)|Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.
40976714|NCT04563923|OTHER|Control|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~* Patients of less than 45kg of body weight: 2 tubes of 10g/d~* Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion"
40976715|NCT00763477|BIOLOGICAL|ghrelin|subcutaneous injection
40976716|NCT03700671|OTHER|High intensity interval training|Participants performed HIIT twice a week for eight weeks. Findings were compared to moderate intensity continuous training which followed the same exercise frequency and duration
40976717|NCT03700671|OTHER|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80% HRmax twice per week for eight weeks. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated
40976718|NCT05485376|DEVICE|Pulmonary Artery Catheter|The pulmonary artery catheter (PAC) is a diagnostic instrument that enables continuous hemodynamic monitoring of cardiac filling pressures, cardiac output, and pulmonary pressures.
40976719|NCT05812898|OTHER|exercises|strengthening of the gluteus maximus and medius, calf muscles stretching for calf and hamstring muscles
40976720|NCT05812898|OTHER|myofascial release|myofascial release using instrument assisted soft tissue mobilization
40976721|NCT02708121|BEHAVIORAL|Motivational Intervention|Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to weight loss treatment.
40976722|NCT02708121|OTHER|Comparator Intervention|Participants informed that they have access to weight loss treatment.
40976723|NCT06437860|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
40976724|NCT06437860|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
40976725|NCT05384015|DRUG|Lenvatinib|"Lenvatinib is an oral, potent multiple receptor tyrosine kinase (RTK) i that selectively inhibits VEGF-driven VEGFR2 phosphorylation and suppressed proliferation and tube formation in human umbilical vein endothelial cell models. Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals. These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of angiogenesis and may be useful as either monotherapy or in combination with other anticancer drugs.~Part 1 (safety run-in) and Part 2:~The study intervention consists of:~Dose: 8 mg (induction) and 20 mg (maintenance) Dose Frequency: Once daily Dose formulation: Capsule Route of administration: Oral Treatment duration: 4 cycles (induction) and no treatment duration limit (maintenance)."
40976726|NCT05384015|DRUG|Pembrolizumab|"Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).~Part 1 (safety run-in) and Part 2:~Dose: 200 mg Frequency: Day 1, Q3W Route: Intravenous Treatment Period: Up to 35 cycles or until reaching a discontinuation criterion"
40772390|NCT02578901|DRUG|Tranexamic Acid|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
40976727|NCT05384015|DRUG|Etoposide|"Standard first-line treatment for the vast majority of patients with SCLC, regardless of stage, involves combination chemotherapy with etoposide plus cisplatin or carboplatin.~Pharmacotherapeutic group: Cytostatics, plant alkaloids and other natural products, derived from podophyllotoxin. Mechanism of action :The main effect of etoposide appears to be in the late S and early G2 phase of the cell cycle, in mammalian cells.~Part 1 (safety run-in) and Part 2:~Dose: 100 mg/m2 Frequency: Day 1-3, Q3W Route: Intravenous Treatment Period: 4 cycles"
40976728|NCT05384015|DRUG|Carboplatin|"Pharmacotherapeutic group: Other antineoplastic agents, platinum compounds.~Carboplatin, like cisplatin, binds to DNA to produce inter- and intra-strand cross-links cells exposed to carboplatin. DNA reactivity has been linked to cytotoxicity.~Part 1 (safety run-in) and Part 2:~Dose: AUC5 Frequency: Day 1, Q3W Route: Intravenous Treatment Period: 4 cycles"
41141119|NCT01519882|OTHER|Placebo|"Placebo patches size equivalent to 4, 6 \& 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day."
41141120|NCT01519882|OTHER|Rotigotine|"Rotigotine patches of 4,6 \& 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day."
40976729|NCT01624389|DRUG|F18-AV45|"This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
40976730|NCT02031107|DEVICE|cTBS|
40976731|NCT02031107|DEVICE|cathodal tDCS|
40976732|NCT02031107|DEVICE|sham stimulation|
40976733|NCT03571269|PROCEDURE|Optical coherence tomography-guided reperfusion strategy|Optical coherence tomography will be used to detect the detailed characteristics of culprit lesion and to decide and optimize the reperfusion strategy according to the established algorithm in the protocol.
40976734|NCT01283360|OTHER|HEC Placebo Gel|The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
40976735|NCT01283360|DRUG|Tenofovir 1% Gel|Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
40976736|NCT00705653|DRUG|PG-11047|PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
40976737|NCT00081640|DRUG|PRO 2000/5 Gel (P)|
40976738|NCT04723745|BEHAVIORAL|V-TRACTS Assessment/Feedback|The proposed V-TRACTS assessment strategically targets emotional, cognitive and behavioral functions that we have determined are highly predictive of long-term outcome in Veterans. The assessment targets domains of head injury, psychological trauma, depression, suicidality, anxiety, chronic pain and sleep, substance use and activity level. This assessment will, in most cases, be completed online using the Qualtrics platform and online using telehealth or other approved platform for the clinical interview. Once the assessment is complete, the clinical team will convene a consensus meeting to review the case and determine a course of recommended additional assessment and/or rehabilitation action. After a consensus is reached, a V-TRACTS psychologist/supervised fellow will provide comprehensive feedback encompassing the entire assessment battery and offer rehabilitation options that would be targeted to the individual veteran's needs via VA telehealth or other approved online service.
40976739|NCT04723745|BEHAVIORAL|OPTIONAL Brief Assessment of Thinking|A neuropsychological/cognitive assessment will be conducted to gather information about functioning in the areas of memory, attention, and thinking. This assessment is designed to be done online in a single session, and it will take approximately 45-90 minutes to complete. The test battery is designed to focus on the specific cognitive abilities thought to be impacted by blast, mTBI, PTSD, etc. This battery is not intended to be an exhaustive assessment of all neuropsychological functions.
40976740|NCT04723745|BEHAVIORAL|OPTIONAL STEP-Home-Brief|STEP-Home-Brief is a condensed version of the 12-week experimental program STEP-Home that will target four core skills (problem solving, emotional regulation, attention training, and health and wellness). It will be individualized to Veterans' problems: vocation/career, community reintegration, psychoeducation to destigmatize barriers to mental health, substance misuse, anger management, and family and intimate partner relationships. STEP-Home-Brief will include 1-3 sessions using the same treatment modules as the 12-week program in a condensed, targeted format.
40976741|NCT04723745|BEHAVIORAL|OPTIONAL At-home Exercise Program|This is a 5-week, full-body exercise program that can be done in the convenience of the Veteran's home, using only bodyweight as resistance and with household items as equipment. Given the online delivery of this program, they will receive access to instructional videos and materials that demonstrate how to perform each exercise safely and correctly. Participants will be contacted by study staff weekly over the phone to maintain interest and monitor adherence during the study.
40976742|NCT04723745|BEHAVIORAL|OPTIONAL Referral to 12-week STEP-Home|Referral to the experimental 12-week STEP-Home workshop research study (VABHS IRB #3210).
40976743|NCT04723745|BEHAVIORAL|OPTIONAL Clinical Referral|Clinical referrals to VABHS clinical services based on assessment and patient-directed primary problem/complaint.
41141121|NCT05914285|DRUG|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
40772391|NCT02578901|DRUG|Placebo|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
40976744|NCT02041286|DEVICE|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
40976745|NCT03773081|DEVICE|Implantation of the Magmaris scaffold|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of one single ACS-causing de novo lesions in one separate major epicardial vessels is allowed.
40976746|NCT00380614|DRUG|Lamivudine|
40976747|NCT03829982|BEHAVIORAL|Exposure to bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
40976748|NCT03829982|BEHAVIORAL|Exposure to dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
41460074|NCT00214864|DRUG|docetaxel, capecitabine|cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1\&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8
41460075|NCT03397667|OTHER|ABC ANSWERS|Primary Care plus ABC ANSWERS
40976749|NCT02959944|DRUG|ibrutinib|Ibrutinib capsules administered orally daily
40976750|NCT02959944|DRUG|Placebo|Placebo capsules administered orally daily
40976751|NCT02959944|DRUG|Prednisone|Prednisone administered daily
41300915|NCT02610400|COMBINATION_PRODUCT|RACD|"Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) \> 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop"
40976752|NCT03354611|RADIATION|Contrast Enhanced Cone Beam Breast CT Scan|"* Pre-contrast scan~* Begin contrast injection (and saline chaser)~* Post-contrast Scan. Start time of post-contrast CE-CBBCT scan is 90-200 seconds after start of injection, depending on method of contrast delivery (bolus vs hand injection)"
40976753|NCT03354611|DRUG|Contrast Dye, Iodinated|"1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of \~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at \~2 ml/s (20 seconds) to maximize dynamic enhancement."
40976754|NCT00328757|BEHAVIORAL|Regular diet as the first postoperative meal|
40976755|NCT00456521|DRUG|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|
40976756|NCT00456521|DRUG|Placebo|
40976757|NCT00456521|BEHAVIORAL|Intensive group lifestyle modification counseling|
40976758|NCT00990236|DRUG|Enoxaparin dose adjusted Lovenox based on TEG|Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R \< 1.0 min - increase dose by 10 mg BID; delta-R \>/= 1.0 min and \</= 2.0 min - no change; delta-R \> 2.0 min - decrease dose by 10 mg BID.
40976759|NCT00990236|DRUG|Enoxaparin 30 mg BID|Enoxaparin dose of 30 mg twice a day without any adjustments
40976760|NCT05743946|DRUG|Trikafta|Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
40976761|NCT00814190|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
41141122|NCT05914285|DRUG|2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline|After the initiation of OLV, mixture of salbutamol 2.5mg and normal saline 2.5ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
41460076|NCT03397667|OTHER|Control|Primary Care as usual
41460077|NCT00239824|BEHAVIORAL|Strength training of the pelvic floor muscles|"Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.~Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist."
41460078|NCT00239824|BEHAVIORAL|strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist|
41460079|NCT00501332|BIOLOGICAL|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
41460080|NCT00973310|OTHER|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
41460081|NCT01360216|BEHAVIORAL|LARC education and training|A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
40976762|NCT03575793|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.
40976763|NCT03575793|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-\[\[5-(1,1-dimethylethyl)-1H-imidazol-4-yl\[methylene\]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-dehydrophenylahistin).
40976764|NCT03575793|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
40976765|NCT05546645|OTHER|Questionnaire|Hypersecretion questionnaire
40976766|NCT00751751|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
40976767|NCT00751751|DRUG|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
40976768|NCT05626257|OTHER|Xolair|There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.
41460082|NCT03389763|DRUG|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes
41460083|NCT02771392|DRUG|Ophthalmic Tetracaine|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
41460084|NCT02771392|OTHER|Normal Saline|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
40976769|NCT03732001|DRUG|Anlotinib combined Docetaxel|Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)
40976770|NCT03732001|DRUG|Docetaxel|Docetaxel (75mg/m2, IV, d1, 21 days per cycle)
40976771|NCT02837575|BIOLOGICAL|VCL-HB01|Investigational Product
40976772|NCT02837575|OTHER|Phosphate-buffered saline|Placebo
41141123|NCT04633200|OTHER|DOT mobile app|DOT is a mobile phone app that has daily pill reminders and supportive texts, as well as various features designed to support PrEP medication adherence.
41141124|NCT02239614|BIOLOGICAL|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
41141125|NCT02239614|BIOLOGICAL|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
41141126|NCT00690313|DRUG|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
41141127|NCT05991518|COMBINATION_PRODUCT|Injection of IAH0968+Gemcitabine+Cisplatin|Administration of IAH0968 is given once per cycle, with each cycle defined as every 3 weeks.
40772392|NCT06335212|DEVICE|Single vision and multifocal contact lenses|Cycloplegic central autorefraction was conducted with both Grand Seiko WAM-5500 open-field auto-refractor (Grand Seiko Co Ltd) and OPD OPD-Scan III Wavefront Aberrometer (Marco) on the subjects in the following conditions: (1) no CLs, (2) SVCLs, (3) MFCLs (+2.00D Add), and (4) MFCLs (+4.00D Add). Relative peripheral power profiles were measured using the OPD under the same 4 conditions after cycloplegia.
40772393|NCT02394067|OTHER|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
40772394|NCT01775345|PROCEDURE|Isotonic exercises|"20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
40772395|NCT01775345|PROCEDURE|Isokinetic exercises|20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
40976773|NCT01385553|BEHAVIORAL|Fathers for Change|FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
40976774|NCT01385553|BEHAVIORAL|Individual Drug Counseling|Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
40976775|NCT00811538|PROCEDURE|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
40976776|NCT00811538|PROCEDURE|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
40976777|NCT00664976|PROCEDURE|Electroconvulsive therapy|Electroconvulsive therapy
40976778|NCT00664976|OTHER|Treatment as usual|Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
41141128|NCT05991518|COMBINATION_PRODUCT|Gemcitabine+Cisplatin|Gemcitabine is administered at a dose of 1000 mg/m2 on the second day (D2) and ninth day (D9) of each cycle. At least 6 hours after the completion of gemcitabine infusion, cisplatin is administered at a dose of 70 mg/m2 on the second day (D2) of each cycle.
41141129|NCT06244563|DEVICE|Face mask with Hybrid-Hyrax|Participants were treated with face mask using a Hybrid-Hyrax appliance as an anchor in the maxillary arch. The anchorage of hybrid-hyrax appliance was provided by bands adapted to the maxillary first permanent molars and two mini screws in the anterior palate. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the hybrid-hyrax appliance in the maxillary canine region.
41141130|NCT06244563|DEVICE|Face mask with Bonded RME|Participants were treated with face mask using a bonded RME appliance as an anchor in the maxillary arch. The anchorage of bonded RME appliance was provided by maxillary posterior teeth covered with acrylic cap. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the bonded RME in the maxillary canine region.
40772396|NCT01775345|PROCEDURE|Isotonic and isokinetic exercises|20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
40976779|NCT06049784|DEVICE|Visual Biofeedback using self operated home ultrasound device|participants will receive a handheld home ultrasound device, learning to perform self-biofeedback at home. Session records will be sent electronically to the sonographer for assessment and feedback.
41141131|NCT06244563|PROCEDURE|Alternative Rapid Maxillary Expansion and Contraction Protocol (Alt-RAMEC)|In the groups that started with the Alt-Ramec protocol, the parents expanded the appliance screw twice a day in the first week and closed it in the opposite direction in the following week. This process was continued for 7-9 weeks according to the patient's need for expansion.
41300916|NCT02610400|COMBINATION_PRODUCT|RAVC|Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
41300917|NCT02610400|COMBINATION_PRODUCT|rfMDA|"Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. The investigators will administer A-L with dosing as follows (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) \> 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop"
40772397|NCT01775345|PROCEDURE|ST|Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
40976780|NCT06049784|DEVICE|Visual Biofeedback using ultrasound at hospital|A single ultrasound biofeedback session using Transperineal Ultrasound will guide maternal pushing.
40976781|NCT03470818|OTHER|Preparatory instructional videos (flipped classroom model)|"The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
40976782|NCT03470818|OTHER|Sham video|"Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
40976783|NCT05004753|DIETARY_SUPPLEMENT|Artemisinin|a herbal supplement
41141132|NCT06244563|PROCEDURE|Routine Rapid Maxillary Expansion Protocol|In the groups that started with the routine protocol, parents activated the expansion screw twice a day for 1-2 weeks, depending on the patient's need for expansion.
41141133|NCT03276286|DEVICE|Nativis Voyager|Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide
41141134|NCT03223688|BEHAVIORAL|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.
40772398|NCT01417767|DRUG|CHG regimen|cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
40772399|NCT01417767|DRUG|5-aza-deoxycytidine|Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
40976784|NCT05004753|DRUG|Dexamethasone|corticosteroids
40976785|NCT05015127|DRUG|HBM9161 680 mg qw by q2w from week 13|HBM9161 680 mg qw by q2w from week 13
40976786|NCT05015127|DRUG|Placebo|Placebo
40772404|NCT04481841|DRUG|oryzanol + vitamin B2 (riboflavin) + vitamin E|"1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment."
40772405|NCT02386956|OTHER|Active stretching|10 minutes of active stretching of the posterior muscle chain with RPG techniques
40772406|NCT02386956|OTHER|Dynamic Stretching|10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
40772407|NCT02386956|OTHER|Control|10 minutes with the patient lying on a machine off of magnetotherapy
40772408|NCT02699307|BEHAVIORAL|Counseling|OT led counseling
41141135|NCT03223688|BEHAVIORAL|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
41141136|NCT03223688|BEHAVIORAL|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
41141137|NCT05026541|BEHAVIORAL|Nap Practitioners|Regular nappers will be given a 30 minute nap opportunity to nap for as long as they please.
40772409|NCT00095576|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)|"Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10\^10 adenovirus genomes \[ad-vg\]/dose).~This dose is equivalent to 3x10\^10 vp/dose used in study V520-016."
40772410|NCT00095576|DRUG|Comparator: placebo|Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
40772411|NCT04763343|DRUG|Ketamine Hydrochloride|Ketamine hydrochloride will be given as an intravenous infusion using a standard regimen given in most studies conducted: 0.5 mg/kg over 40 minutes. Ketamine infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
40772412|NCT04763343|DRUG|Saline|Subjects randomized to placebo will be administered a saline (0.9% sodium chloride) drip for 40 minutes. Saline placebo infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
40772413|NCT04763343|BEHAVIORAL|CAMS Therapy|CAMS weekly sessions will also be started immediately as an inpatient at the start of the study while receiving ketamine or saline. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has three consecutive outpatient CAMS sessions with an overall risk \< 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).
40772414|NCT02532101|DIETARY_SUPPLEMENT|Oil Palm Phenolics|Palm fruit derived phenolics compound
40772415|NCT03152773|PROCEDURE|MRI Heart guidewire catheterization|to conduct left and right heart guidewire catheterization using real-time MRI fluoroscopy in human research subjects already undergoing medically necessary left and right heart catheterization. We will use only passive MRI-compatible catheters and a specific guidewire shown to be safe under specific conditions. Under the conditions of use, the guidewire is not susceptible to heating.
40772416|NCT04943848|BIOLOGICAL|rHSC-DIPGVax|Off-the-shelf, neoantigen heat shock protein vaccine
40772417|NCT04943848|DRUG|Balstilimab|BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)
40772418|NCT04943848|DRUG|Zalifrelimab|ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)
40772419|NCT05991453|OTHER|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
40772420|NCT05991453|OTHER|Anesthetic technique inhaled agent|Must administer inhaled agent.
40772421|NCT02666053|DRUG|BMS-663068|BMS-663068
40772422|NCT00846157|BIOLOGICAL|NKM injection|NKCell about 100mg IV for 6times in each chemotherapy period.
40772423|NCT06206590|OTHER|Whole-proteomic assay|Whole-proteomic analysis was performed on all the blood samples
40976787|NCT05015127|DRUG|HBM9161 680 mg qw by q2w from week 7|HBM9161 680 mg qw by q2w from week 7
40976788|NCT05015127|DRUG|Placebo|Placebo qw by HBM9161 680mg qw from week 12
40976789|NCT02194205|DRUG|COMBIVENT HFA|
40976790|NCT02194205|DRUG|Placebo HFA|
40976791|NCT02194205|DRUG|COMBIVENT CFC|
40976792|NCT02194205|DRUG|Placebo CFC|
40976793|NCT03951844|DEVICE|BRIDGE/EMPATIA exoskeleton|The participant wears the exoskeleton on his/her left arm, and he/she controls it by means of a joystick or vocal commands.
41141138|NCT05026541|BEHAVIORAL|Shoonya Meditation|This is a 15 minute meditation, described as a process of conscious non-doing.
41300918|NCT02435277|DRUG|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
40976794|NCT06131697|OTHER|McKenzie Exercises without Mulligan Mobilization|McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.
40976795|NCT06131697|OTHER|McKenzie Exercises with Mulligan Mobilization|"McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.~Along McKenzie exercises Sustained Natural Apophyseal Glide will be given with the tip of thumb placed at an angle of 45° along the eyeball direction reinforced by another thumb. This exercise will be performed for three sets of six repetitions twice a week for the time period of four weeks."
40976796|NCT05042167|OTHER|Resistance exercise|4 total resistance exercises that target all major muscle groups.
40976797|NCT02957877|DRUG|Nadroparin|A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
40976798|NCT02957877|DRUG|Unfractionated heparin|The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
40976799|NCT05671185|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex
40976800|NCT00992576|DRUG|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
40976801|NCT00992576|DRUG|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
40976802|NCT00006080|DRUG|fenretinide|
40976803|NCT05127005|PROCEDURE|Trapeziectomy|Surgical excision of trapezoideum
40976804|NCT05127005|PROCEDURE|Sham|Skin incision only
41141139|NCT05205083|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (BBIBP-CorV), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
41141140|NCT05947071|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
41300919|NCT02435277|DRUG|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
41300920|NCT02435277|DRUG|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
41300921|NCT02435277|DRUG|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
41300922|NCT00523822|OTHER|Spinal Manipulative Therapy|
41141141|NCT05947071|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
41141142|NCT06002672|DIETARY_SUPPLEMENT|Placebo comparator: Control group. To the control group was assigned lettuce without any change in salinity but with the same characteristic of eustress lettuce (soil, water, harvesting time).|Lettuce without any eustress was assigned to each participant belonging to the control group which ate 100gr every day for 12 day
41141143|NCT06002672|DIETARY_SUPPLEMENT|Experimental: Eustress group. To the intervention Eustress group was assigned the eustress lettuce.|100gr of eustress lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 12 days
41141144|NCT05553730|BEHAVIORAL|Digital Buddy program|Six months of ICT and psychoeducation delivered by youth mentors via an e-learning platform
41300923|NCT01375504|BEHAVIORAL|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
41300924|NCT01375504|BEHAVIORAL|Mindfulness Training Program|The mindfulness program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
41300925|NCT00430521|BIOLOGICAL|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
41300926|NCT00430521|BIOLOGICAL|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
41300927|NCT05873101|DIAGNOSTIC_TEST|Mobilization With Movement (MWM)|Mobilization With Movement
41300928|NCT05873101|DIAGNOSTIC_TEST|Kelternborn Treatment Technique|Kelternborn Treatment Technique
41300929|NCT01448291|DRUG|Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring|Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
41300930|NCT03213626|DRUG|Cabozantinib 40 MG|To be taken orally once daily
41300931|NCT03213626|DRUG|Erlotinib 100Mg Tab|To be taken orally once daily
41300932|NCT01930799|BEHAVIORAL|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
40976805|NCT02433483|DRUG|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
40976806|NCT02433483|DRUG|Intrathecal Triples|given IT.
40976807|NCT02433483|BIOLOGICAL|HPC-A|Given IV.
40976808|NCT05450341|DEVICE|rTMS over right frontal target|Low frequency (1 Hz) rTMS over right inferior frontal gyrus
40976809|NCT05450341|DEVICE|rTMS over right temporal target|Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus
41300933|NCT06332781|DRUG|Gentamicin|administered via bladder
41300934|NCT06332781|DRUG|Nitrofurantoin|administered PO
40976810|NCT04337125|OTHER|Neuropsychological and attachment/parenting assessment|"Children assessments:~Mental health assessment, Intellectual functioning assessment, Sleep patterns assessment, Behavior assessment, Severity of ADHD symptoms assessment, child attachment assessment, parenting practices assessment, emotional regulation assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment~Parents assessments:~Mental health assessment, Intellectual functioning assessment, ADHD symptoms assessment, Depression symptoms assessment, Attachment style assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment."
40976814|NCT03043131|DRUG|Plasmalyte A|Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
40976815|NCT03043131|DRUG|Ringer Lactate|Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
41460085|NCT06111534|BEHAVIORAL|Holding|Holding is an effective non-pharmacological method for reducing procedural pain. Minor painful procedures, such as heel pricks, are easy to use, practical, non-invasive, and affordable procedures when performed when the neonate is held/cuddled by one of its parents. Neonates held/cuddled by their mothers are likely to experience less pain and cry less during heel pricks. The MHC and PHC methods help neonates experience tactile, auditory, visual, and olfactory sensory inputs that can enhance analgesic effects. These multisensory methods can alleviate the pain experienced by the infant during minor painful procedures and shorten the crying time. This type of analgesia may be mediated by multisensory stimulation associated with the mother/father-infant attachment.
40976816|NCT04918433|PROCEDURE|Regional anaesthesia|Regional anaesthesia for sternotomy incision for congenital cardiac surgery
40976817|NCT03140384|BIOLOGICAL|Assess the efficacy and side effects of Misoprostol according to the route of administration|Assess the efficacy and side effects of Misoprostol according to the route of administration
40976818|NCT03636061|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
40976819|NCT03636061|DRUG|Placebo (vehicle) nasal spray|Placebo
40976820|NCT00137046|DRUG|Subcutaneous Insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
41141145|NCT03914586|DEVICE|oXiris filter|Continuous Renal Replacement Therapy with oXiris filter
40976821|NCT00137046|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
40976822|NCT04208698|DRUG|CIN-102 Dose 1|Deuterated domperidone (deudomperidone)
41141146|NCT06196294|BIOLOGICAL|Cell therapy for solid tumors|Transfer γδT cells into patients for anti-ancer therapy.
41141147|NCT05837689|DRUG|Blinatumomab|IV
41141148|NCT02892318|DRUG|Atezolizumab|Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
40976823|NCT04208698|DRUG|CIN-102 Dose 2|Deuterated domperidone (deudomperidone)
40976824|NCT04208698|DRUG|Placebo for CIN-102|Placebo
40976825|NCT03634449|DEVICE|i-gel|i-gel is a supraglottic airway devices with a gastric suction channel.
40976826|NCT03634449|DEVICE|endotracheal tube|Endotracheal intubation is a traditional use for protect airway during the laparoscopic surgery.
41141149|NCT02892318|DRUG|Guadecitabine|Guadecitabine 60 mg/m\^2 SC on Days 1-5 of every 28-day cycle.
41141150|NCT00774605|DRUG|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
40976827|NCT06471816|OTHER|Dialogue Based Early Detection|Before the biannual parent-teacher meeting, both the kindergarten teacher and the parents will complete the Early Worry Questionnaire containing 39 items related to development and well-being of the individual child. For each item the respondents are asked to indicate if they during the last three months have been concerned. In the parent-teacher meeting they will discuss their possible concerns and try to reach an agreement on how to evaluate the child. If necessary, possible supportive interventions or further assessments locally in the kindergarten or in the public services will be decided.
40976828|NCT06471816|OTHER|Traditional parent-teacher meeting|This is an annual or biannual meeting that is prepared by the kindergarten teacher where (s)he reports on the child's appearance / behaviour and possible challenges as to development and behaviour from an educationalist's view. There are no common templates for the agenda of such meetings, however, usually the kindergarten teacher's perspective and opinion will dominate.
40976829|NCT04378218|BEHAVIORAL|High Intensity Interval Training (HIIT)|A 16 week, 3 sessions per week HIIT program from the subject's personal wheelchair, positioned near an adjustable table with an arm-ergometer affixed.
41141151|NCT00774605|DRUG|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
41141152|NCT06204653|DEVICE|HFNO group|100% oxygen supplied in proportion to body weight using the Optiflow THRIVETM system while maintaining jaw thrust. (0-12 kg; 2 L/kg/min, 13-15 kg; 30 L/min, 16-30 kg; 35 L/min, 31-50 kg; 40 L/min)
40976830|NCT05071456|OTHER|Collects of skin's hydration|Collects of skin's hydration will be made by using patch using electrochemistry.
40976831|NCT01003730|OTHER|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
40976832|NCT00873756|DRUG|FOLFOX regimen|Intravenous repeating dose
40976833|NCT00873756|DRUG|bevacizumab|Intravenous repeating dose
40976834|NCT00873756|DRUG|dulanermin|Intravenous repeating dose
41141153|NCT06204653|DEVICE|MV group|Mask ventilation using the one-hand E-C clamp technique and oropharyngeal airway (fresh gas flow 3 l/min, 100% O2, tidal volume 8-10 ml/kg, respiratory rate 20/min, I:E ratio 1:2, pop-off valve 13 cmH2O).
40976835|NCT03236740|DRUG|Ethinyl Estradiol-cyprosterone acetate|Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
40976836|NCT03236740|DRUG|Metformin Hydrochloride|Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
40976837|NCT06304753|DEVICE|Telebot|"This is a mini-program based on a personal messenger, which is controlled by text commands in a chat on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) related to heart failure.~Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 6 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses."
40976838|NCT03070782|DRUG|ISIS 681257|ISIS 681257 solution for SC injection.
40976839|NCT03070782|DRUG|Placebo|Sterile normal saline (0.9% NaCl)
40976840|NCT01508858|DRUG|liraglutide|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
40976841|NCT01508858|DRUG|placebo|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
40976842|NCT01508858|DRUG|levonorgestrel / ethinylestradiol|One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
40976843|NCT02198742|DEVICE|Miller blade|To participate in the study the subjects must have \>500 intubations with the miller blade.
40976844|NCT02198742|DEVICE|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.
40976845|NCT02198742|DEVICE|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
40976846|NCT05998785|DEVICE|TAPESTRY Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
40976847|NCT04734444|DEVICE|SonoClear ACF|The SonoClear ACF is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
40976848|NCT05122273|DEVICE|Stella BIO|Individually planned therapeutic procedures, using, among others, the concept of EMG biofeedback
40976849|NCT01952275|PROCEDURE|Collection of biological samples|
41300935|NCT06047431|DRUG|QL1706H|QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.
41300936|NCT04353960|DIAGNOSTIC_TEST|electrocardiograph|electrocardiograph monitor during strabismus surgery
40976850|NCT03336853|DEVICE|HybenX|"The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.~A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
40976851|NCT03336853|OTHER|Placebo control|"The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
40976852|NCT02809456|DRUG|Nicorandil|oral intake
40976853|NCT01479699|DIETARY_SUPPLEMENT|Olive leaf extract capsules|Four capsules taken at baseline each containing 4mg oleuropein
41141154|NCT03342261|DRUG|DAA treatment|Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
41141155|NCT01916057|DEVICE|18F-FDG PET Scan|to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
41141156|NCT03431350|DRUG|Niraparib 200 mg|Participants will receive niraparib 200 mg orally.
41141157|NCT03431350|DRUG|Cetrelimab 240 mg|Participants will receive cetrelimab 240 mg IV every 2 weeks.
41141158|NCT03431350|DRUG|Cetrelimab 480 mg|Participants will receive cetrelimab 480 mg IV every 4 weeks.
41141159|NCT03431350|DRUG|Abiraterone acetate 1000 mg|Participants will receive AA 1000 mg orally.
41141160|NCT03431350|DRUG|Prednisone 5 mg|Participants will receive prednisone 5 mg orally.
41141161|NCT04197336|DEVICE|Bariatric Embolization of Arteries with imaging visible Embolics|The BEATLES study is an investigator-initiated, prospective, doubleblind, randomized, sham-controlled study that will assess the impact of bariatric embolization on the systemic levels of obesity related hormones and, as a consequence, on weight loss. The goal of this study is to help treat obesity combining a lifestyle program and a minimally invasive, angiographic (i.e., through blood vessels) approach.
41141162|NCT04197336|OTHER|Control Arm|Participants randomized to the control arm will follow the same screening and pre-procedure assessment, and will also take the same pre-procedure medications. The procedural team instead will follow a prescribed simulated protocol that will mimic an actual embolization procedure.
41300937|NCT01929044|DRUG|654-II (anisodamine)|10mg injection
41300938|NCT01929044|DRUG|Buscopan® (hyoscine butylbromide)|20mg injection
41300939|NCT05796258|DIAGNOSTIC_TEST|NTRK fusion assessment|To evaluate NTRK fusion presence by MCG, Immunohistochemistry or NGS
41300940|NCT02610556|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
41300941|NCT02610556|DRUG|Docetaxel|Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
41300942|NCT02610556|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
40772424|NCT01644435|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
40772425|NCT01644435|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
40976854|NCT05426577|DIAGNOSTIC_TEST|ELISA, LAMP, Cytokine Release Assay|"IgG1 ELISA: ELISA that employs soluble Leishmania lysate or protein antigen.Results are recorded as antibody titres, which are measured by the absorbance values of products generated using enzyme conjugated anti-human antibodies.~Cytokine release assay (CRA): In this assay whole blood is stimulated for 24 hours with leishmania antigen. Cytokine levels are then assessed in the plasma fraction using flow cytometry with the BD™ Cytometric Bead Array for Human Cytokines or standard ELISA kits for human cytokines commercialized by Sigma-Aldrich (RAB0268-IL-2, RAB0222-IFN-g, RAB0224-IL-10, RAB0476-TNF-a, RAB0119-IP-10).~LAMP test for VL: We will use the LoopampTM Leishmania Detection Kit, CE-marked and produced Eiken Chemical Co., Japan."
40976855|NCT00722033|DRUG|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
40976856|NCT01389544|DRUG|danoprevir|200 mg daily (100 mg q12h) orally, Days 1-10
40976857|NCT01389544|DRUG|methadone|stable maintenance therapy: 20-120 mg daily single oral morning dose
40976858|NCT01389544|DRUG|ritonavir|200 mg daily (100 mg q12h) orally, Days 1-10
40976859|NCT00933374|DRUG|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
40976860|NCT00933374|DRUG|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
40976861|NCT02733588|DRUG|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
40976862|NCT04287491|OTHER|Oculus Go Virtual Reality System|The VR system will provide a 3D environment that provides distracting stimulus. Participant will put on the Oculus Go VR system headset 1-2 minutes prior to out-patient bedside procedure up to the completion of procedure which takes typically 3-5 minutes.
40976863|NCT03406104|GENETIC|GS010|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
40976864|NCT03406104|OTHER|Sham Intravitreal Injection|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
40976865|NCT04013724|BEHAVIORAL|Group tobacco cessation interventions|"Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented."
41141163|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
40976866|NCT00004224|DRUG|cyclophosphamide|
41141164|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
40772426|NCT03230214|DIAGNOSTIC_TEST|PCR for bacterial translocation|samples taken from the blood and ascites of patients to search for bacterial DNA
40976867|NCT00004224|DRUG|etoposide|
40976868|NCT00004224|DRUG|vincristine sulfate|
40976869|NCT00004224|PROCEDURE|adjuvant therapy|
40976870|NCT00004224|PROCEDURE|conventional surgery|
40976871|NCT00004224|RADIATION|radiation therapy|
40976872|NCT04675840|PROCEDURE|Robotic-assisted hysterectomy|Robotic-assisted surgery
40976873|NCT05736744|DRUG|MgSO4|The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
40976874|NCT05736744|DRUG|Rocuronium Bromide|Rocuronium will be administered for intubation at a dose of 0.45-0.6 mg/kg IV and Maintenance at a dose of 0.1-0.2 mg/kg IV on fixed interval
40976875|NCT05736744|DRUG|Cis-Atracurium|Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
40976876|NCT05901168|OTHER|Active Video Games Intervention|Participants will complete active video games in the same order until they fill 20 minutes after the first 5 minutes of warm-up. In addition, during the change between games (lasting approximately 20 seconds), patients will be instructed by a therapist to perform combined exercises to minimize immobility time. These exercises are: elbow flexion and foot flexion, shoulder flexion and unilateral hip extension, and arm abduction and squat exercises that will prevent the patient from cooling down.
41141165|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
41141166|NCT01581320|DRUG|Test group|Once a month, administration of DP-R206 \& placebo for 16 weeks
41141167|NCT01581320|DRUG|Reference group|Once a month, administration of Bonviva \& placebo for 16 weeks
41141168|NCT05333835|DRUG|HR17031 injection|HR17031 injection
41141169|NCT05333835|DRUG|INS068 injection|INS068 injection
41141170|NCT05333835|DRUG|SHR20004 injection|SHR20004 injection
41300943|NCT02610556|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
40976877|NCT05901168|OTHER|Traditional Exercise Intervention|"Active exercises for the upper extremities (without support): Shoulder flexion, Shoulder abduction, Elbow flexion at shoulder 90° flexion.~Active exercises for the lower extremities: Ankle-foot movements (ankle pumping exercise), heel raise, Knee extension in sitting high, Hip-knee flexion while lying supine~Body: Bridging, Trunk rotations in sitting~These exercises will be done in 1 set of 8-10 repetitions.~It will take about 20 minutes."
41141171|NCT03450811|PROCEDURE|Inguinal hernia repair|Lichtenstein procedure or laparoscopic method (Total extraperitoneal) inguinal hernia repair
41141172|NCT03492385|DRUG|PB2452 Infusion|30 minute - 12 hour infusion
41460086|NCT06353724|DEVICE|conventional oral positioning stent were used during radiation planning and the PTV will be defined and contoured in computed tomography pre irradiation planning|"Dosimetric analysis: the maxilla (area of the teeth), both parotid glands (ipsilateral and contralateral), the mandible, and the PTV were defined and contoured in computed tomography pre irradiation planning. The mean corresponding dose of each structure were acquired using a dose-volume histogram.~All patients will complete the radiotherapy sessions using the positional radiation prosthesis.~Mucositis assessment: The severity of mucositis will be assessed weekly from the beginning of RT to the end of the treatment (mean time, 7 weeks). It will be scored in accordance with the classification criteria of the National Cancer Institute.~PH of saliva measurement: Collection of saliva sample were done from each patient to measure salivary PH by digital PH meter before beginning of radiotherapy and the measurement will be continued weekly till the end of the treatment."
41141173|NCT03492385|DRUG|Placebo - Sodium Chloride|30 minute - 12 hour infusion
41141174|NCT03492385|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo
41141175|NCT03492385|DRUG|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo
41141176|NCT01058694|BEHAVIORAL|Short Message Services to Support ARV therapy adherence|Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
41300944|NCT02232672|DEVICE|Choline PET/CT and MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
41300945|NCT00002452|DRUG|L-756423|
41460087|NCT06353724|DEVICE|Digital positioning stent|Digital positioning stent
41460088|NCT03911180|DEVICE|Proximal femoral nail with straight parallel blade|Petrochanteric fixation with Heracles proximal femoral nail
41460089|NCT02018796|DRUG|Mifepristone, misoprostol|200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol
41460090|NCT03737916|OTHER|5 cc 5% Dextrose solution|Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
41460091|NCT03737916|OTHER|5 cc salin|Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
41460092|NCT03617419|DEVICE|GE VScan Access R2 Ultrasound System|A diagnostic ultrasound imaging system manufactured by the study Sponsor.
41460093|NCT03617419|DEVICE|GE Corometrics 170 Series Fetal Monitor|A reference device to record a continuous fetal heart rate.
41460094|NCT03617419|DEVICE|GE Corometrics 170 Series Fetal Monitor|A reference device for verification of scanning the fetal heart.
41460095|NCT04884334|DEVICE|VAC-Stent®|treatment with the VAC-Stent®
40976878|NCT05070533|BEHAVIORAL|Individual treatment|Participants will receive 7 home visits to implement the program.
40976879|NCT05070533|BEHAVIORAL|Groupal treatment|Subjects will participate in groups of about 8 - 12 to implement the program.
40976880|NCT05463575|DRUG|Ketohexokinase inhibition|participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
40976881|NCT05463575|OTHER|Placebo|participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
40976882|NCT03970954|DRUG|low-dose IL-2|Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.
41141177|NCT05059145|DRUG|Chlorhexidine Gluconate|Vaginal cream 1%
41141178|NCT05059145|DRUG|Fluconazole|150 mg oral capsule
41141179|NCT02575014|DRUG|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
41141180|NCT06386354|DIAGNOSTIC_TEST|Train-of-four|Patients submitted to general anesthesia with neuromuscular block will be monitored at their arrival to the Post-Anesthesia Care Unit to assess the presence of residual neuromuscular block.
41300946|NCT00002452|DRUG|Indinavir sulfate|
41300947|NCT02280967|BEHAVIORAL|Education about HPV by school nurse|Information about prevention of HPV among adolescents aged 16 at time for the regular health interview with the school nurse.
41300948|NCT03997539|DRUG|Pyrotinib|Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
41300949|NCT03997539|DRUG|Treatment of physician's choice|The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
41300950|NCT03997539|DRUG|vinorelbine|vinorelbine
41460096|NCT06200376|DRUG|T3011|T3011 will be administered intraperitoneally twice a week.
40976883|NCT05485597|DEVICE|Myosuit-based gait training|In a period of four weeks participants will undergo eight individual task-specific overground gait training sessions with the Myosuit. The sessions will be started with a therapist, and if possible and as soon as possible, the patient will train with an assistant. During the therapy sessions, the patient will be asked to perform various task-specific exercises with the Myosuit, such as Sit-to-stand-, Balance- and walking exercises. Depending on the individual skill level of the participant, a higher level of difficulty in task-specific exercises can be performed. The training sessions are set to last 45 minutes. All training sessions will be accompanied by a certified (physio)therapist or trained assistant and a study investigator.
40976884|NCT00155350|DRUG|pioglitazone|
41460097|NCT01590199|DRUG|RAD001|
41141181|NCT01318356|BEHAVIORAL|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
41141182|NCT01318356|DRUG|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
41141183|NCT01318356|DRUG|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
41141184|NCT01074528|BEHAVIORAL|mindfulness based stress reduction program|8-week mindfulness training program
41141185|NCT05668845|OTHER|PG-ANB performed at the outset of LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the outset of the LSG.
41141186|NCT05668845|OTHER|PG-ANB performed at the end of the LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the end of the LSG\>
41141187|NCT05160909|PROCEDURE|Beach Chair Position|Patients positioned in beach chair during arthroscopic shoulder stabilization
41141188|NCT05160909|PROCEDURE|Lateral Decubitus Position|Patients positioned in lateral decubitus position during arthroscopic shoulder stabilization
41141189|NCT01894503|DRUG|S8 Sinus Implant (mometasone furoate, 1350 mcg)|Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
41141190|NCT04345588|DRUG|Dexamethasone injection|we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously.
41141191|NCT04053491|PROCEDURE|Hand surgery under regional anesthesia|In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
41141192|NCT03195998|DIAGNOSTIC_TEST|TcB Measurement|TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
41460098|NCT01590199|DRUG|SOM230|
41460099|NCT03494686|PROCEDURE|LLETZ under local anaesthesia|Conization will be performed under local anaesthesia
41460100|NCT03494686|PROCEDURE|LLETZ under general anaesthesia|Conization will be performed under general anaesthesia
41460101|NCT02835755|OTHER|Educational Intervention|Receive standard HPV and HPV vaccine information
41460102|NCT02835755|OTHER|Educational Intervention|Receive mHealth HPV vaccine intervention
41460103|NCT02835755|OTHER|Survey Administration|Ancillary studies
41460104|NCT00004416|DRUG|botulinum toxin type A|
41460105|NCT00640458|DRUG|Sildenafil 100 mg|
41460106|NCT00640458|DRUG|Placebo|
41460107|NCT03712124|DRUG|CNSA-001|CNSA-001 Powder for Suspension
41460108|NCT03712124|DRUG|Placebo|Placebo Suspension
41460109|NCT00304434|DRUG|Oseltamivir|
41460110|NCT00304434|DRUG|Probenecid|
40772427|NCT06215378|DRUG|Antagonization of heparin with protamine sulfate|A systematic use at the end of procedure of Protamine Sulfate for antagonization of heparine.1 mg of protamine sulfate neutralizes approximately 100 heparin unit. To be administered in slow infusion (10 min) not exceeding 50mg of protamine sulfate to reverse 100% of the anti-IIa activity of heparin sodium. If the ACT is not back to the baseline value after the end of this infusion, additional doses of protamine should be performed depending on the ACT value to obtain complete antagonization of anti-IIa activity of heparin sodium
40772428|NCT02587910|DIETARY_SUPPLEMENT|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
40772429|NCT02587910|DIETARY_SUPPLEMENT|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
40772430|NCT01765400|DRUG|Prasugrel 10 mg daily x 2 weeks|
40772431|NCT01765400|DRUG|Clopidogrel 75 mg daily x 2 weeks|
41141193|NCT03516877|BEHAVIORAL|Enhanced Stress Resilience Training for Faculty Physicians|Enhanced Stress Resilience Training (ESRT) is derived from Mindfulness-Based Stress Reduction with modifications to language, activities and contextualization to tailor the training to physicians involved in the operating room environment. ESRT consists of 5 weekly 1-hour group classes and 2-4 hour retreat. Classes focus on developing sustained attention and open monitoring in addition to training focused on stress and coping. Increasing duration (3-20 minutes per day) of guided mindfulness exercises are assigned each week. A 2-4 hour intensive retreat occurs at week 4 or 5. The central exercises of the training are the body scan, sitting meditation, qi gong and yoga. The weekly teaching sessions will be offered at various days and times each week in order to accommodate complicated physicians schedules that vary at each site. Participants can attend whichever session is most convenient. Daily practice will occur independently, with the duration reported weekly through text or email.
41460111|NCT01279915|DRUG|ASP0456|oral
41460112|NCT01279915|DRUG|Placebo|oral
41460113|NCT05414695|DEVICE|real acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle penetrates the skin 4 mm
41460114|NCT05414695|DEVICE|Placebo acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle does not touch the skin.
41460115|NCT02480634|DRUG|Zoledronic acid|Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
41460116|NCT02480634|RADIATION|Radiotherapy|High dose：30Gy/10f Low dose：15Gy/5f
41460117|NCT02159820|DRUG|Decitabine (DTC Arm)|Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
40772432|NCT05606107|DRUG|Tofacitinib|Tofacitinib combined with other csDMARDs, but no glucocorticoids.
40772433|NCT05606107|DRUG|Glucocorticoid|Glucocorticoid
40976885|NCT05679908|DRUG|TNX-1900|Patients will spray TNX-1900 once into each nostril.
40772434|NCT05095467|PROCEDURE|HIPEC|The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.
40772435|NCT05095467|DRUG|Paclitaxel-albumin|albumin paclitaxel D1, D8; S-1: D1-D14
40772436|NCT05095467|DRUG|Tegafur-gimeracil-oteracil potassium|40mg bid(BSA\<1.5 m2) ，60mg bid(BSA\>=1.5 m2); D1-D14, po, bid.
40772437|NCT05095467|PROCEDURE|Surgery+HIPEC|gastrectomy with D2 lymphadenectomy+HIPEC procedure
40772438|NCT05657847|DEVICE|Photon-counting detector-CT|CT scan
40976886|NCT05679908|DRUG|Placebo Nasal Spray|Patients will spray placebo nasal spray once into each nostril.
40976887|NCT03789045|DIAGNOSTIC_TEST|Metabolic thresholds and fat oxidation points relationship|Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.
40976888|NCT02240160|DRUG|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
40976889|NCT00345345|BIOLOGICAL|Alemtuzumab (Campath)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
41460118|NCT02159820|DRUG|Paclitaxel and Carboplatin (TC Arm)|The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve \[AUC\] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
41460119|NCT04175587|DRUG|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
40976890|NCT02425046|BEHAVIORAL|health coaching|Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
40976891|NCT02425046|BEHAVIORAL|community screening|Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
41300951|NCT04472923|PROCEDURE|Traditional Treatment|"Patients belonging to the control group received conventional physical therapy program in the form of:~1. Dietetic Regulation: The diet was given in the form of the bulk-forming diet, fruits, vegetables, cereals, and bran.~2. Pelvic floor muscle exercises (Kegal exercises): The patient was instructed to lie crock lying position with knees bent. He/she was instructed to pull his/her pelvic muscles upward and inward and hold the contraction for 6 seconds as if to hold back a defecation movement, followed by relaxation for 6 seconds. The exercise was repeated 25 times. Gradually increase the time until reaching 10 seconds of contraction and relaxation for each with repetition up to 30 times. The exercises applied twice per week for 3 months."
41460120|NCT02752854|OTHER|pain threshold measurement|pressure algometer
41460121|NCT02010996|PROCEDURE|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
41460122|NCT02010996|PROCEDURE|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
41460123|NCT00024154|BIOLOGICAL|trastuzumab|Given IV
41460124|NCT00024154|DRUG|gefitinib|Given orally
41460125|NCT00024154|OTHER|laboratory biomarker analysis|Correlative studies
40772439|NCT06324409|BEHAVIORAL|Reminder telephone call|A reminder telephone call with information on colorectal cancer screening in the language of origin (Urdu or Somali) in addition to the reminder letter in Norwegian (usual care)
40976892|NCT02853578|DRUG|Busonid (budesonide 200mcg and 400mcg)|"cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks."
40772440|NCT04267445|PROCEDURE|Embolization of prostatic artery under ultrasound guidance|Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.
40976893|NCT06426121|DIAGNOSTIC_TEST|test Aerobic/F Culture Vials|an additional blood sample will be collected compared to clinical routine of blood culture, inoculated into the test culture vial, and compared with the blood culture results of the control vial collected from the same site and the same puncture point
41460126|NCT01067521|DRUG|Glatiramer acetate (GA)|GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
41460127|NCT01067521|DRUG|Placebo|Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
41460128|NCT04780451|DIETARY_SUPPLEMENT|Omega-3 supplementation in recreational runners|Male recreational runners participated in 12 weeks of endurance training combined with omega-3 fatty acids supplementation. Before starting and at the end of the 12-week cycle, the runners performed an increasing intensity treadmill test where oxygen uptake and VO2 peak were assessed.
41460129|NCT05413733|BEHAVIORAL|Digital care pathway|"Sessions of the digital neuropsychological program:~1. Subjective functional ability and goals~2. Fatigue after ABI~3. Attention and concentration~4. Memory~5. Memory strategies~6. Working memory and executive functions~7. Emotional reactions~8. Summary and future goals"
41141194|NCT05485025|BEHAVIORAL|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
41460130|NCT05413733|BEHAVIORAL|Care as usual|The standard care of patients with ABI including all necessary outpatient rehabilitation visits. Neuropsychological visits may include a short period of psychoeducation with a clinical neuropsychologist.
40772441|NCT00643279|DEVICE|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
40772442|NCT00643279|OTHER|Standard of Care|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
40772443|NCT02577809|DRUG|Morphine100|100mcg added to the spinal anaesthetic
41141195|NCT05485025|BEHAVIORAL|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
41460131|NCT02063815|PROCEDURE|Fissure sealant application|
41460132|NCT03864185|BIOLOGICAL|Rituximab (genetical recombination)|Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
41460133|NCT03864185|OTHER|Placebo|Administer placebo IV infusion once weekly for 4 doses.
41460134|NCT04224948|DEVICE|PET MRI scan|"Standard of care includes a baseline PET-CT and conventional CT after 2 cycles of neoadjuvant chemotherapy, and after 5-6 cycles, of neoadjuvant chemotherapy, as per current practice/ standard of care.~Patients that enroll in the trial will receive two additional PET MRI scans- one at baseline and one after 1 cycle of chemotherapy"
41460135|NCT02910596|DRUG|bethanechol chloride|bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
41460136|NCT02910596|DEVICE|early bladder training|early bladder training start on 3rd - 5thpostoperative day
41460137|NCT02910596|OTHER|early bladder training and bethanechol chloride|bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
41460138|NCT02910596|OTHER|no early bladder training and no bethanechol chloride|no bethanechol chloride and no early bladder training
41460139|NCT04386408|COMBINATION_PRODUCT|Combination of plant extracts (BSL_EP027)|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
41460140|NCT04386408|COMBINATION_PRODUCT|Placebo|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
41460141|NCT01074827|OTHER|Strength training and treadmill training|Eight weeks of intensive strength training or treadmill training
41460142|NCT00201136|BEHAVIORAL|Lifestyle interventions to lower blood pressure for patients|Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
41460143|NCT00201136|BEHAVIORAL|MD CQI-type intervention|CQI-type intervention for MD adherence to JNC guidelines for BP management
40772444|NCT02577809|DRUG|Morphine50|50mcg added to the spinal anaesthetic
40772445|NCT02577809|DRUG|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
40772446|NCT02577809|DRUG|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
40772447|NCT02577809|DRUG|Indomethacin|100mg Indomethacin suppository
40772448|NCT04236076|DEVICE|PulseHaler|PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.
41460144|NCT04045015|DIETARY_SUPPLEMENT|Liqourice|Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
41460145|NCT02308241|DRUG|Ribavirin|self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
41460146|NCT01992874|DRUG|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
41460147|NCT01992874|DRUG|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
41460148|NCT01992874|DRUG|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
41460149|NCT01992874|DRUG|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
40976894|NCT06426121|DIAGNOSTIC_TEST|control Aerobic/F Culture Vials|according to the clinical routine of blood culture, this blood sample should be collected and inoculated into the control vial, and its culture result will be collected
40976895|NCT04049968|DEVICE|Mobile health application (APP)|The mobile health application (APP) was applied to patients with oral cancer.
40976896|NCT04049968|OTHER|Routine health care and instruction|Traditional routine health care and instruction was applied to patients with oral cancer.
41141197|NCT06019767|BEHAVIORAL|Cognitive Processing Therapy|CPT is a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
40772449|NCT04236076|DEVICE|Sham - control|Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.
40772450|NCT03525847|DIAGNOSTIC_TEST|Endosonography|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control. Passage in the same pancreatic mass of first using standard FNA method then contrast enhanced FNA method or vice versa according to the randomization
40772451|NCT01531335|DIETARY_SUPPLEMENT|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
40772452|NCT01531335|DIETARY_SUPPLEMENT|Standard care|25 kcal per kg of body weight
40772453|NCT05825040|BEHAVIORAL|Online guided transdiagnostic cognitive behavioural therapy|The contents of guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. Customized guidance will be provided by coaches once a week based on participants' performance
40772454|NCT05825040|BEHAVIORAL|Online self-guided transdiagnostic cognitive behavioural therapy|The contents of self-guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. No customized guidance will be provided to participants in the self-guided group.
40772455|NCT05825040|BEHAVIORAL|Online self-guided mindfulness-based intervention|The contents of online self-guided mindfulness-based intervention are developed by clinical psychologists and psychological well-being officers. The intervention consists of 6 modules. Contents include mindfulness and auto-pilot, react and respond, aversion, craving, equanimity, and 'suffering', thoughts and letting go, starting with loving kindness, and mindfulness in life.
41141198|NCT05082688|BIOLOGICAL|Herpes zoster vaccination (Shingrix, GSK)|Shingrix is an ASO1-adjuvanted herpes zoster vaccination used to prevent shingles and its associated complications in at-risk populations
40772456|NCT01508767|OTHER|Removal of urethral catheter|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
40772457|NCT02494414|OTHER|Long-term follow-up|Vital and neurological follow-up
40976897|NCT02533427|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily
40976898|NCT02533427|DRUG|VOX|100 mg tablet administered orally once daily
40976899|NCT02533427|DRUG|Norgestimate/ethinyl estradiol|Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
40976900|NCT03144362|PROCEDURE|Bilateral Sliding Techniques|Bilateral Sliding Techniques
41141199|NCT05082688|BIOLOGICAL|Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)|Fluarix Tetra is a quadrivalent inactivated influenza vaccine
41141200|NCT05082688|BIOLOGICAL|Placebo|0.9% NaCl
41141201|NCT02542332|OTHER|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
41141202|NCT04320472|OTHER|Follow up|Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
41141203|NCT01829594|OTHER|Case management|Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
40976901|NCT03144362|PROCEDURE|Unilateral Sliding Techniques|Unilateral Sliding Techniques
40976902|NCT02422511|GENETIC|Genomic sequencing|Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
41141204|NCT03731741|DRUG|Pentoxifylline|a known drug of xanthine derivatives used in intermittent claudication
41141205|NCT01984099|DRUG|Methotrexate|Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
41141206|NCT01984099|DRUG|Vitamin B Complex|Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
41141207|NCT03647449|DIETARY_SUPPLEMENT|Juice|Participants will be drinking 800-900 kcal/day in cold-pressed juices.
41141208|NCT03647449|BEHAVIORAL|Caloric restriction via Plant-based meals|Participants' caloric intake will be limited to 800-900 kcal/day.
40976903|NCT02422511|OTHER|Family history report|Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
40976904|NCT04566224|DEVICE|Macintosh size 2 blade|intubate with Macintosh size 2 blade
40976905|NCT04566224|DEVICE|Macintosh size 3 blade|intubate with Macintosh size 3 blade
40976906|NCT04158440|DRUG|4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab|Biological: Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
41460150|NCT01992874|DRUG|Pimasertib Capsule (Part B and trial extension phase)|Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
40976907|NCT04158440|DRUG|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )|Biological: Placebo by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
41141209|NCT03647449|DIETARY_SUPPLEMENT|Plant-based meal|Participants will be eating \~900 kcal/day in pre-prepared plant-based meals.
41141210|NCT06098833|DRUG|Sildenafil|Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
41141211|NCT06098833|DRUG|Ora-Blend|Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
41141212|NCT02332889|BIOLOGICAL|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be \> 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
41141213|NCT02332889|DRUG|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
41141214|NCT05816707|BIOLOGICAL|PRF|"Teeth will be extracted a-traumatically as possible to avoid any soft tissue or bony damage.~The extracted sockets will be debrided by bone curettes and saline. The three extraction sockets will be divided into three groups: control group, curcumin group, and PRF group.~After curcumin/ PRF placement, all sockets will be closed by simple interrupted suture"
41141215|NCT05816707|BIOLOGICAL|Curcuma Longa gel|Curcuma Longa gel
41141216|NCT05816707|OTHER|extraction socket|extraction socket
41141217|NCT04347889|DRUG|Hydroxychloroquine|Oral loading dose followed by once weekly dosing
41141218|NCT04347889|OTHER|Vitamin C|Once daily vitamin C 1 gm
41141219|NCT00106405|DRUG|Memantine HCl|
41141220|NCT03374423|PROCEDURE|radiofrequency|"The procedure will be done under propofol sedation, under fluoroscopic guidance. The image intensifier will be rotated in a cephalo-caudal direction until the endplates of the thoracic vertebrae are aligned and the transverse processes became discernable from the ribs.~For the intercostal nerve group, the radiofrequency needle 10 cm with 10 ml active tip will then inserted to contact the lower edge of the transverse process of (T2-T5), the needle is walked off to obtain sensory stimulation between 0.3-0.6 mv and motor stimulation less than 1.2 mv .five cycle of pulsed radiofrequency will be delivered."
41460151|NCT01710605|BIOLOGICAL|Circulating tumor cells counting at baseline|20 ml blood sample collected before randomization
41460152|NCT00156650|DRUG|Acyline|Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
41460153|NCT00156650|DRUG|Testosterone Gel|Testosterone (T) gel 10 g daily for 6 months
41460154|NCT00156650|DRUG|Depo-Medroxyprogesterone|300 mg IM every 3 months
40976908|NCT02563353|OTHER|whole-body vibration|"Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week."
40976909|NCT02563353|DRUG|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
40976910|NCT00995826|DRUG|CS-8958|Inhaled CS-8958
40976911|NCT00995826|OTHER|Placebo|Inhaled placebo
41300952|NCT04472923|DEVICE|Biofeedback|"Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training.~Biofeedback was planned after full guardians' education. Local hygiene for perianal skin for soiling episodes and using zinc oxide cream to prevent excoriation. Biofeedback was done using two types of catheters; a 24-channel water-perfused catheter with latex balloon for sensory training and a double-lumen rectal PVC balloon clothed catheter (MMS U-72210) for strength training. Each biofeedback session took 30 minutes with two sessions per week for 3 months."
41300953|NCT00791713|DRUG|Paliperidone ER|
40976912|NCT04339127|OTHER|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
40976913|NCT03016754|DEVICE|Wearable Cardioverter Defibrillator|LifeVest Wearable Cardioverter Defibrillator
40976914|NCT00931762|DRUG|Panobinostat|Panobinostat oral capsules
40976915|NCT06125353|DIETARY_SUPPLEMENT|Melatonin|Patients of the Intervention group (melatonin group) received a personalized dietary plan based on the Mediterranean Diet, together with a booklet of lifestyle guidelines (nutritional and physical activity), all generated by a Clinical Decision Support System (CDSS). Moreover, participants in the Intervention group consumed one melatonin tablet per day, containing 1 mg of melatonin, together with water for a total of three months.
40976916|NCT00314665|DRUG|Thalidomide|
40976917|NCT02192814|DRUG|Lacosamide (200 mg/20 mL)|"Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion"
40976918|NCT01113801|DRUG|LY2382770|Subcutaneous injection given monthly for 12 months
40976919|NCT01113801|DRUG|Placebo|Subcutaneous injection given monthly for 12 months
40976920|NCT05982626|RADIATION|68Ga/131I-SGMIB-ZT-199|68Ga-SGMIB-ZT-199: PET imaging; 131I-SGMIB-ZT-199: SPECT imaging.
40976921|NCT05151146|DRUG|ANJ900|Metformin hydrochloride delayed-release tablets
40976922|NCT05151146|DRUG|Metformin IR|metformin hydrochloride
41141221|NCT03374423|PROCEDURE|radiofrequency|The procedure will be done under propofol sedation, under fluoroscopic guidance.for dorsal root ganglion group, radiofrequency needle 10 cm with 10 ml active tip will inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walked into the thoracic intervertebral foramen. Once correct needle position is confirmed, test stimulation will be performed at 50 Hz, during which time the needles will slightly redirected to optimize stimulation, the point of maximum stimulation will be designated to be the location of the dorsal root ganglion. five cycle of pulsed radiofrequency will be delivered.
41141222|NCT01955499|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41141223|NCT01955499|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41141224|NCT01955499|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41141225|NCT01955499|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
41141226|NCT01955499|DRUG|Ibrutinib|Given PO
41141227|NCT01955499|DRUG|Lenalidomide|Given PO
41141228|NCT01955499|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41141229|NCT01955499|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41141230|NCT05466760|RADIATION|PET/MR|Study 1- pre-NAC PET/MR; Study 2- first follow-up PET/MR is performed after first dose of NAC; Study 3, second follow-up PET/MR is performed after third or fourth dose of the NAC. The NAC protocol is mainly antracycline-based followed by taxane-based regimen for a total of 6-8 cycles.
41141231|NCT01316913|DRUG|GSK573719/GW642444 125/25|125/25 mcg once-daily
41141232|NCT01316913|DRUG|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
41300954|NCT01595737|DRUG|Levosimendan|Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
41300955|NCT01595737|DRUG|Placebo|Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
40976923|NCT00418314|DEVICE|Control|Empiric programming or one-time optimization using a non-IEGM method.
40976924|NCT00418314|DEVICE|QuickOpt|Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
40976925|NCT05615974|DRUG|LM101|Administered intravenously
41141233|NCT01316913|DRUG|GSK573719|125 mcg once-daily
41141234|NCT01316913|DRUG|tiotropium bromide|18 mcg once-daily
41141235|NCT00827294|BEHAVIORAL|Mirror Therapy|The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
41141236|NCT00391651|DRUG|Nitrofurantoin 100mg twice daily x 5 days|Nitrofurantoin 100mg twice daily x 5 days
41141237|NCT00391651|DRUG|TMP/SMX DS twice daily x 3 days|TMP/SMX DS twice daily x 3 days
41141238|NCT03674476|DRUG|BMS-986036|Specified dose on specified days
41300956|NCT05807724|OTHER|Phone-based fall-prevention strategy|Written education material and Phone-Based Fall-Prevention Strategy
41300957|NCT05807724|OTHER|Home-visit fall prevention strategy|Written education material and Home visit-Based Fall-Prevention Strategy
41300958|NCT03726671|OTHER|25% Cho diet|Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
41300959|NCT03726671|OTHER|50% Cho diet|Subjects will consume meals containing 50% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
40976926|NCT05615974|DRUG|Toripalimab|Administered intravenously
40976927|NCT05615974|DRUG|Rituximab|Administered intravenously
40976928|NCT05615974|DRUG|Envafolimab|Administered intravenously
40976929|NCT03198949|DRUG|Afinitor (everolimus)|"Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.~(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)"
40976930|NCT04367220|DIAGNOSTIC_TEST|Diagnostic testing performed as per routine care|
40976931|NCT00335673|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
40976932|NCT03280420|PROCEDURE|Early catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
41141239|NCT05858606|DIAGNOSTIC_TEST|Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation|"1. pre-inclusion consultation~2. inclusion consultation~   * personal history~  * height, weight, cranial perimeters, and spans of both parents~  * clinical examination of the child~  * photographs of the child~  * additional X-rays"
41141240|NCT05858606|PROCEDURE|analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team|"multidisciplinary team (geneticist, orthopedist, radiologist, pediatric endocrinologist) which will assign each patient an orientation:~* either to the non idiopathic short stature group (syndromic diagnostic orientation or to a constitutional bone pathology)~* or to the authentified idiopathic short stature group"
41141241|NCT05858606|GENETIC|Whole genome analysis for authentified idiopathic short stature|"For the first 30 patients included in the authentified idiopathic short stature group, a whole genome analysis in trio (child + parents) will be performed as part of the research.~For these 30 patients in the authentified idiopathic short stature group, the teleconsultation carried out for the submission of the multidisciplinary consultation meeting conclusions will make it possible to establish the family tree, to explain the interest and limits of the analysis, and to submit the consents dedicated to the genetic analysis."
41141242|NCT04155814|DRUG|Iron Sucrose Injection|USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength
41300960|NCT03726671|OTHER|100% Cho diet|Subjects will consume meals containing 100% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
41300961|NCT05416931|DRUG|ACD440 Gel 14mg/g|Topical application to painful area
40772458|NCT01405430|BIOLOGICAL|Bevacizumab + blood samples|"Bevacizumab will be administered according to investigators appreciation.~Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab."
40976933|NCT03280420|PROCEDURE|Late catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
40976934|NCT05431452|OTHER|Pain management|Nonpharmacological pain management during blood collection in preterm infants
40976935|NCT01967121|DEVICE|Compex unit's Active Recovery® program|Compex unit's Active Recovery® program will be performed for 15 minutes once per day.
41300962|NCT05416931|DRUG|Placebo Gel|Topical application to painful area
41460155|NCT05385900|DRUG|Penpulimab combination with anlotinib and chemotherapy|Penpulimab: fixed dose of 200 mg, administered on day 1 of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14 of each cycle, orally once a day, about half an hour before breakfast (the time of daily administration should be the same as possible), with warm water, every 3 weeks Repeat 1 time
41460156|NCT05736250|DIAGNOSTIC_TEST|biopsie|gingival biopsie
41460157|NCT03616691|DRUG|Atezolizumab|Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
40976936|NCT01967121|OTHER|Ice application|Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
40976937|NCT05010031|RADIATION|Palliative radiotherapy|An initial cohort of 12 evaluable patients will be treated with 4Gyx2, with adaptive dosing planned for expansion cohorts pending the number of failures observed after 6 month observation of the initial cohort.
40976938|NCT00053053|DIETARY_SUPPLEMENT|Juven|
40976939|NCT00053053|DIETARY_SUPPLEMENT|Non-Juven Supplement|
40976940|NCT02299609|OTHER|Ultrasound beams Philips HD11 XE®|Ultrasound beams used during standard echocardiography
41141243|NCT04155814|DRUG|Venofer Injection|(Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength
41141244|NCT03121417|BIOLOGICAL|Nivolumab|240 mg given IV
41141245|NCT05341700|BEHAVIORAL|Impact Load Exercises|Participants will complete 50-65 min running protocol on treadmill and 5 sets of 10 jumping exercises for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
41141246|NCT05341700|BEHAVIORAL|No Impact Load Exercises|Participants will complete only a 50-65 min running protocol on treadmill for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
41141247|NCT03612388|PROCEDURE|use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation|use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).
41460158|NCT03616691|DRUG|Bevacizumab|Stage II: Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy every 3 weeks.
40772459|NCT01342666|DIETARY_SUPPLEMENT|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
40772460|NCT01342666|DIETARY_SUPPLEMENT|Cucumber consumption|Daily consumption of 300g of cucumber.
40772461|NCT02141009|BIOLOGICAL|Prevnar 13|
40772462|NCT05385107|DIAGNOSTIC_TEST|Serum procalcitonin concentration|
40976941|NCT03152851|PROCEDURE|Pressure stimulus group|
40976942|NCT01602874|DRUG|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
40976943|NCT01602874|DRUG|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
40976944|NCT01602874|DRUG|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
40976945|NCT01602874|DRUG|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
40976946|NCT03609944|PROCEDURE|ERCP with miES|Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy
40976947|NCT03609944|PROCEDURE|EUS|Endoscopic ultrasound
40976948|NCT05945693|DIETARY_SUPPLEMENT|Placebo|The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule for 16 weeks.
40976949|NCT05945693|DIETARY_SUPPLEMENT|Omega-3|The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA for 16 weeks.
40976950|NCT05945693|DIETARY_SUPPLEMENT|Aerobic exercise|The participants will perform aerobic-type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day for 16 weeks.
40976951|NCT00491998|DRUG|V1512|6 doses of IMP at 2-hourly intervals
40976952|NCT00491998|DRUG|V1512|3-hourly dosing
40976953|NCT00491998|DRUG|V1512 and Entacapone|4 doses of IMP and Entacapone at 3-hourly intervals
40976954|NCT02857933|OTHER|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
40976955|NCT01026467|DRUG|cisplatin|Given IV
40976956|NCT01026467|DRUG|carboplatin|Given IV
40976957|NCT01026467|OTHER|questionnaire administration|
41141248|NCT00966745|DRUG|milrinone|
41141249|NCT00966745|DRUG|placebo|
41460159|NCT04405908|BIOLOGICAL|SCB-2019|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
41460160|NCT04405908|BIOLOGICAL|SCB-2019 with AS03 adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
40772463|NCT02296125|DRUG|AZD9291 80 mg/40 mg + placebo|"The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
40772464|NCT02296125|DRUG|Placebo Erlotinib 150/100mg|The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
40976958|NCT05780112|OTHER|breathing exercise|"* Place one hand on your chest and the other on your stomach.~* Slowly take a deep breath through the nose.~* During inhalation, your hand on your stomach should rise upwards as the air fills the lungs. If it is under your hand on the chest, there should not be much movement.~* Hold your breath and stretch your muscles in a second or two.~* Take air through your nose with your mouth closed and exhale slowly through your mouth by pursing your lips like a whistle.~* Set the time you use when exhaling air to be twice the time you use when exhaling.~* As you exhale, focus on the inward movement of your abdominal hand."
40976959|NCT00142584|DRUG|Nebivolol (NEB)|Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
40976960|NCT00142584|DRUG|Metoprolol (MET)|Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
40976961|NCT03649464|DRUG|OKN-007|"Dose escalation/PK cohort (Phase Ib): 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort (Phase 2): MTD defined in the dose escalation (Phase Ib) study."
40976962|NCT02101476|DRUG|Percocet|10mg/650mg
40976963|NCT02101476|DRUG|Xartemis|15mg/650mg
41300963|NCT01350037|DRUG|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
41300964|NCT01350037|DRUG|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
41300965|NCT04581980|OTHER|Exercise|Participants will exercise on a cycle ergometer
41300966|NCT05195333|OTHER|The exercise program|The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient.
41300967|NCT05195333|OTHER|The exercise program|The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy.
41300968|NCT05599126|DRUG|Mianserin|Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.
41300969|NCT05599126|DRUG|Lorazepam|Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.
41300970|NCT00594152|DRUG|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
41300971|NCT01797107|DRUG|Azasite|Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
41300972|NCT01996735|DRUG|Ticagrelor 180 mg single dose|
41300973|NCT01996735|DRUG|Placebo|
41300974|NCT04125797|OTHER|Application of adhesive|Adhesive will be placed on the subjects skin below the bra. Placement of the adhesive will be randomized.
41300975|NCT05754190|DEVICE|SOMA pain manager smartphone application|SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.
40772465|NCT02296125|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
40772466|NCT02296125|DRUG|Erlotinib 150/100 mg|"The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
40976964|NCT03032094|PROCEDURE|connective tissue graft|palatal connective tissue graft to attain root coverage
40976965|NCT03355521|OTHER|Nordic Walking|Nordic walking Training the total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
40976966|NCT03355521|OTHER|Free Walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
40976967|NCT02156596|DRUG|IV NSAI|100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
40976968|NCT02156596|DRUG|NM|3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
41141250|NCT01214200|DEVICE|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
41300976|NCT03119116|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD
41300977|NCT03119116|DRUG|Dabigatran|Oral direct thrombin inhibitors, 75mg and 150mg capsules BID
41300978|NCT03119116|DRUG|Apixaban|Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
41300979|NCT02676349|DRUG|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
41300980|NCT02676349|RADIATION|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
40772467|NCT02296125|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
40772468|NCT02296125|DRUG|Placebo AZD9291 80 mg/ 40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
40772469|NCT03409809|BEHAVIORAL|Training|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide and facilitator support website.
40976969|NCT02156596|DRUG|IV Serum Saline|50 ml of SS is given by IV root over 30 minutes
40976970|NCT02156596|DRUG|Nebulised Serum Saline|3 nebulisations of 5ml SS each are given over 30 minutes
40976971|NCT05989789|DEVICE|Radioactive Seed Implantation|In patients where initially the tumour lesion could not be identified, a radioactive seed was implanted and intraoperatively detected with a geiger counter sonde.
40976972|NCT05253053|DRUG|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
40976973|NCT05253053|DRUG|Combination Product: Atezolizumab|Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
40976974|NCT05253053|DRUG|Combination Product: Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
40976975|NCT06363968|DEVICE|RETeval|as previous
40976976|NCT03024684|DRUG|Atorvastatin|Atorvastatin 10mg daily
40976977|NCT03024684|DRUG|Placebo Oral Tablet|Placebo one tablet daily
40976978|NCT01437046|DRUG|Doxazosin|Doxazosin 16mg/day
40976979|NCT01437046|DRUG|Placebo|
40976980|NCT02563275|OTHER|motion analysis system|
40976981|NCT02563275|OTHER|parabolic flight|
40976982|NCT01733602|DEVICE|transcranial direct current stimulation|
40976983|NCT04977583|BEHAVIORAL|Unmet Need Screening|"Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization."
40976984|NCT04977583|BEHAVIORAL|Unmet Need Referral - Resource Sheet|Participants receive a Resource Sheet(s) tailored to the unmet need(s) identified in the index screen. For each unmet need, a Resource Sheet will include the names of available resource within the VA and/or the local community that can help address the unmet need and contact information (address, phone, website, email) and hours of operation.
40976985|NCT04977583|BEHAVIORAL|Unmet Need Referral Assistance|Participants receive assistance from a Social Worker (SW) to facilitate connection to resources that can help to address unmet need(s) identified in the index screen. Assistance includes 1) conducting a standardized bio-psychosocial assessment; 2) motivational interviewing methods to uncover details of the Veteran's unmet needs and identify barriers to resolving the unmet needs, and; 3) developing an action plan for the Veteran to connect with resources and address needs. The SW will conduct initial follow-up by phone one week after the interview/action plan development, with planned subsequent phone outreach every two weeks for up to seven weeks.
40976986|NCT05225428|BEHAVIORAL|Video Education|Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
40976987|NCT05225428|BEHAVIORAL|Genetic Counseling|Standard genetic counseling
40976988|NCT00369616|BIOLOGICAL|CYT002-NicQb|
40976989|NCT06439992|DRUG|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.
40976990|NCT01877499|OTHER|Optimization of HDF key parameters|"First, patients actually receiving standard dialysis will be switched to post-dilution HDF.~Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.~Precisely, the following 3 parameters will successively be increased towards a maximal target:~1. Treatment time (up to 4 hours per session);~2. Blood flow rate (up to 400 mL/min;~3. Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).~Maximal values for these parameters will be those achieved within pre-specified safety limits."
41141251|NCT03015688|RADIATION|x-ray images|
41141252|NCT05436041|BEHAVIORAL|Collaborative Diet Goal Setting Clinical Decision Support|Receives Nutri
41141253|NCT00873626|DRUG|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
41141254|NCT00837291|DRUG|CF101|CF101 tablets 1 mg BID
41141255|NCT00837291|DRUG|Placebo|Placebo tablets BID
41300981|NCT02676349|PROCEDURE|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
41300982|NCT02676349|DRUG|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
41300983|NCT04993950|OTHER|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
41300984|NCT04993950|OTHER|SNAGS with thoracic postural correction techniques|thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
41300985|NCT00500786|BIOLOGICAL|CYT006-AngQb|
41300986|NCT06553417|OTHER|Aqua posae and microresyl|"* This intervention involves the use of two topical products:~  * Aqua posae - a moisturizing agent~ * Microresyl - an active ingredient with potential therapeutic effects~* Subjects in Group A will be instructed to apply these two products (aqua posae and microresyl) twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects."
40976991|NCT06060288|DIAGNOSTIC_TEST|Diagnosis by mobile phone imaging|"The photographs will be taken with a smartphone iPhone 14 Pro in a one-year period. Imaging will follow the recommendations regarding intraoral photography in oral mucosal screening set by (Lin et al., 2021).~Personal data and a brief description of the present illness concerning the main complaint will be informed by the patients and recorded in a diagnosis chart of the Oral medicine department Cairo University. Complete intraoral physical examination will be performed by the main investigator under supervision of the main supervisor and the co-supervisor using dental equipment with artificial light."
40976992|NCT05063669|BEHAVIORAL|Cognitive Occupational Therapy|In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
40976993|NCT04224649|DEVICE|HARA Filler(Hyaluronic acid Filler)|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
40976994|NCT04224649|DEVICE|Restylane® Lidocaine|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
40976995|NCT03084029|DRUG|Oxytocin|40 international units
40976996|NCT03084029|DRUG|Placebo|40 international units
40976997|NCT03418415|DEVICE|Renal denervation|multi-electrode catheter-based renal denervation
40976998|NCT03202797|OTHER|audiometric tests|tone and speech audiometry
40976999|NCT03202797|OTHER|Questionnaires|APHAB (Abbreviate Profile of Hearing Aid Benefit), HISQUI (Hearing Implant Sound Quality Index), Munich music questionnaire
40977000|NCT03202797|OTHER|Settings of cochlear implants|pitch matching, evolutionary algorithm setting
40977001|NCT03520803|OTHER|Enhanced recovery after surgery protocol|Experimental enhanced recovery protocol for pre-surgery and post surgery
40977002|NCT01223989|OTHER|hypocaloric diet balanced + nutrition education + ruled physical activity|
40977003|NCT02140229|DEVICE|US power doppler|Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.
40977004|NCT02140229|OTHER|Usual care|Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months
40977005|NCT02140229|OTHER|ACR/EULAR criteria|Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
41300987|NCT06553417|OTHER|Urea 10%|"Intervention 2: Urea 10%~* This intervention involves the use of a 10% urea-based topical moisturizing product.~* Subjects in Group B will be instructed to apply the 10% urea moisturizer twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects."
40977006|NCT04003922|OTHER|Adalimumab treatment|Retrospective observational study initially and then prospective with inclusion of all the patients carrying an ER treated by Adalimumab in France. Follow-up will continue for one year if adalimumab is discontinued.
41300988|NCT01519622|OTHER|Questionnaire|Questionnaire to be distributed among sick elderly in the community
41300989|NCT01461954|DRUG|FST-100|FST-100
41300990|NCT01461954|DRUG|FST-100 Vehicle|FST-100 Vehicle
41300991|NCT04671914|DRUG|Hyaluronic Acid 20 MG/ML Injectable Solution|Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D\&C
41300992|NCT04671914|OTHER|Dilation and curretage|After abortion in II trimester we do D\&C.
40977007|NCT02601508|DRUG|Rocuronium|Continuous infusion of rocuronium for PTC 1 + Sugammadex
40977008|NCT02601508|DRUG|cis-atracurium|Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine \& Glycopyrrolate
40977009|NCT01899690|DRUG|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
40977010|NCT02743559|DEVICE|Mechanical Stimulation using whole body vibration|All participants will undergo whole body vibration (WBV) by standing on the LivMD WBV platform on 5 consecutive mornings
41300993|NCT01005732|DEVICE|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and \<5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
40977011|NCT06376799|OTHER|Self-questionnaire|Provision of a self-questionnaire in digital or paper format for the patient. The patient will be asked to indicate their preferences regarding the primary and secondary objectives of the study.
40977012|NCT06370832|OTHER|IMT and exercise training group|Participants will perform supervised exercise training per usual care and will be provided with a personalized prescription for an IMT program during the pre-transplant phase. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session) 5 days per week in their home environment or in-person visits. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
40977013|NCT03789344|OTHER|acupuncture|Acupuncturists apply the seven-days' electro-acupuncture treatment on the acupoints of Neiguan points and Daling points for 30min per day.
40977014|NCT03789344|OTHER|Psychotherapy|Subjects in psychotherapy group would be accepted 20mins- psychotherapy per day.
41460161|NCT04405908|BIOLOGICAL|SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
40977015|NCT03789344|OTHER|blank control|Blank control subjects would be observed only during this investigation.
41141256|NCT06246890|OTHER|Autism ALERT|Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
41141257|NCT05956093|RADIATION|FAPI PET CT|the utilization of Gallium 68 labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT to accurately stage high-grade epithelial ovarian cancers.
41141258|NCT06482112|DRUG|Efinopegdutide|SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm
40977016|NCT03393741|DRUG|Taxane|Taxane is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
40977017|NCT03393741|DRUG|Vinorelbine|Vinorelbine is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
41141259|NCT04252950|BEHAVIORAL|CB-SET|Community-based structured exercise therapy (CB-SET) programs for PAD have potential merit as an alternative to hospital-based SET, as they may provide similar benefit to hospital-based programs but in a convenient location for the exercise to be completed
41141260|NCT04252950|PROCEDURE|Revascularization|Endovascular revascularization is a primary treatment option for patients with PAD
41141261|NCT00534677|DRUG|Terlipressin|2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide
41141262|NCT00534677|DRUG|Octreotide|Octreotide 50mcg/hr infusion \& a placebo of Terlipressin
41141263|NCT02051218|DRUG|Denosumab (reduced dosing)|3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
41141264|NCT02051218|DRUG|Denosumab (standard dosing)|Denosumab 120mg (XGEVA®) sc. q4w
41141265|NCT04277494|OTHER|Clorethyl cold spray® (Vapocoolant spray)|From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application.
41141266|NCT06506357|DIETARY_SUPPLEMENT|Good Girl Probiotics|Participants will take one capsule of the Good Girl Probiotics supplement daily in the morning for eight weeks.
41141267|NCT04955054|DIAGNOSTIC_TEST|diagnose|Patients from UAP and AMI meet the criteria of UAP or STEMI.
41141268|NCT06160453|DEVICE|Brain-Computer Interface control of robotic arms with augmented reality|The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions
41460162|NCT04405908|BIOLOGICAL|SCB-2019 with Alum adjuvant|SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
40977018|NCT03393741|DRUG|Ixabepilone|Ixabepilone is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
40977019|NCT03393741|DRUG|Eribulin|Eribulin is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
40977020|NCT03393741|DRUG|Chemotherapy|Chemotherapy is used to treat various stages of breast cancer.
40977021|NCT01616524|BIOLOGICAL|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
40977022|NCT01616524|BIOLOGICAL|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
40977023|NCT01616524|BIOLOGICAL|Pegylated interferon alfa-2a (pegIFNα-2a)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
41141269|NCT06160453|DEVICE|Serious game with augmented reality|The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game will be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions
41300994|NCT04645459|OTHER|low phosphorus meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
41300995|NCT04645459|OTHER|control meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
40772470|NCT03409809|BEHAVIORAL|Training and Technical Assistance|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide, and facilitator support website, plus half-day implementation training to further define goals, needs, leadership structure and strategy for adoption and recruitment.
40772471|NCT03409809|BEHAVIORAL|Training, Tech. Assistance, Quality Assurance/Improvement|"Level of Support: As for Training and Technical Assistance arm, plus 1-year of technical assistance, coaching, and quality assurance to enhance skills for implementation and sustainability."
40772472|NCT05617885|DRUG|Darolutamide|Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.
40772473|NCT05617885|DRUG|Abemaciclib|"Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing."
40977024|NCT01616524|DRUG|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 24 weeks
40977025|NCT01616524|DRUG|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 12 weeks
40977026|NCT01616524|DRUG|Daclatasvir|Tablets, Oral, 60 mg, Once daily, 12 weeks
40977027|NCT01616524|DRUG|Placebo matching Daclatasvir|Tablets, Oral, 0 mg, Once daily, 12 weeks
40977028|NCT04755803|PROCEDURE|Penoplasty|"Modified penoplasty technique:~1. Degloved the penile skin and excise the inner prepuce.~2. Advanced penoscrotal skin to cover penile shaft~3. Fixed the penis base and reconstructed the penoscrotal angle"
40977029|NCT00653250|DRUG|celecoxib|400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
40977030|NCT00653250|PROCEDURE|biopsy|in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue
40977031|NCT00653250|PROCEDURE|therapeutic conventional surgery|surgery to remove the lung tumor
40977032|NCT00709046|DRUG|High dose pantoprazole infusion|Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
40977033|NCT00709046|DRUG|Standard dose pantoprazole infusion|Pantoprazole 40mg iv bolus qd x 3 days
40977034|NCT02352714|DRUG|Paracervical Nerve Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
40977035|NCT02352714|DRUG|Sham Paracervical Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
40977036|NCT01293175|DIETARY_SUPPLEMENT|Whole grains|Subjects will consume whole grains at dose of 80 g/die, for two months
41141270|NCT06133569|BEHAVIORAL|ReDirection|Self help program based on principles for cognitive behavioral therapy
40772474|NCT05617885|DRUG|GNRH-A Leuprolide Acetate|Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
40772475|NCT05617885|DRUG|GNRH-A Goserelin|Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
40772476|NCT05617885|DRUG|Degarelix|Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
40772477|NCT05924802|DIETARY_SUPPLEMENT|Ketone Ester|Added to water or lemonade 3 times per day.
40772478|NCT05924802|DIETARY_SUPPLEMENT|Placebo|Added to water or lemonade 3 times per day.
40772479|NCT02478281|DRUG|Methylene Blue|
40977037|NCT01596608|DEVICE|Magnetic Seizure Therapy (MagPro MST)|100% machine output at between 25 and 100 Hz, with coil directed over frontal or vertex brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
40977038|NCT06327451|DRUG|Atorvastatin 20mg|Liptor is a capsule in the form of 20 mg, once daily.
40977039|NCT03398291|PROCEDURE|Synchronous resection of primary pancreatic cancer and liver oligometastasis|Patients undergo surgical exploration. If no extensive metastatic sites are found, the synchronous resection of primary pancreatic cancer and liver metastatic sites will be performed. Adjuvant chemotherapy was recommended, and the regimen selection is recommended to be based on the preoperative chemotherapy.
40977040|NCT03398291|DRUG|Standard chemotherapy|Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1
40977041|NCT00416078|BEHAVIORAL|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
40977042|NCT00416078|BEHAVIORAL|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
40977043|NCT02508402|DRUG|Dexamethasone|"The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using"
40977044|NCT02508402|DRUG|Placebo|two milliliters of normal saline given to placebo group .
40977045|NCT02150798|OTHER|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
40977046|NCT02150798|OTHER|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
40977047|NCT04804410|DEVICE|LCR Meter (Brand: Keysight, Serial Number:E498AL)|The LCR meter is used for electric property analysis of tissues. It works by measuring impedance on multiple sections of excised tissue and translating those measurement into dielectric properties.
40977048|NCT06359067|OTHER|Treated by bispecific antibodies, teclistamab or elranatamab in usual care|Treated by bispecific antibodies, teclistamab or elranatamab in usual care
40977049|NCT06359067|OTHER|Not treated by bispecific antibodies in usual care|Not treated by bispecific antibodies in usual care
40977050|NCT05448833|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
40772480|NCT01533545|DRUG|Mepivacaine with epinephrine|Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
40772481|NCT01533545|DRUG|Plain mepivacaine|Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
40772482|NCT02296099|DRUG|liposomal bupivacaine|Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
40772483|NCT02296099|DRUG|Placebo|Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
40977051|NCT00514540|DRUG|Docetaxel|75 mg/m\^2 IV over 60 Minutes on Day 1 of 21 day cycle.
40977052|NCT00514540|DRUG|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.
40977053|NCT00514540|DRUG|Etoposide|120 mg/m\^2 daily for 3 days of 21 day cycle.
40977054|NCT00514540|DRUG|Cisplatin|25 mg/m\^2 for 3 days of 21 day cycle.
40977055|NCT06182189|OTHER|Observation of patients with a benign prostatic hyperplasia condition|Observation of patients with a benign prostatic hyperplasia condition who have undergone surgery
40977056|NCT04070274|PROCEDURE|different types of surgery platforms|58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
40977057|NCT02224040|DRUG|ceftriaxone|
40772484|NCT04088396|DRUG|Baricitinib|Administered orally
40772485|NCT04088396|DRUG|Tocilizumab|Administered SC
40772486|NCT05670184|DRUG|LSD|Single dose of LSD (50 µg) will be administered in a small amount of alcohol (ethanol, 2ml/95% Vol.) orally.
40977058|NCT02224040|DRUG|ceftriaxone and azithromycin|
40977059|NCT02224040|DRUG|azithromycin|
40977060|NCT02224040|DRUG|azithromycin and cefixime|
40977061|NCT01083394|DEVICE|PTA|PTA using a conventional balloon
40977062|NCT01083394|DEVICE|PTA with PEB|PTA using a paclitaxel eluting balloon
40977063|NCT01083394|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
40977064|NCT01852110|DRUG|MK-7622|MK-7622 capsule
40977065|NCT01852110|DRUG|Placebo|Matching placebo to MK-7622 capsule
40977066|NCT01852110|DRUG|AChEI|"One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally"
40977067|NCT04661657|OTHER|Transthoracic echocardiogram (TTE)|Subjects will undergo TTE imaging.
40977068|NCT04661657|OTHER|Cardiovascular Magnetic Resonance (CMR) Imaging|Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
40977069|NCT03096379|DIAGNOSTIC_TEST|Magnetic resonance imaging|Enterography performed via magnetic resonance imaging
40977070|NCT06259227|OTHER|Cardiorespiratory fitness (CRF) training|The CRF training will take place on an arm cycle ergometer, or on an recumbent cross trainer. The duration and intensity of these 2 CRF gait training sessions will be determined by scientific exercise guidelines. A practical way of increasing vigorous-intensity exercise is high-intensity interval training (HIIT). The HIIT intervention consist of 2-3 trainings per week, with each exercise session including a 5-minute warm-up, 30-second interval periods (with a power output up to 90% of the peak power output (PPO)), and 30-second recovery periods. There are 5 minutes of 50% of PPO between interval periods. The number of interval periods increases during the intervention period, resulting in a maximum total training time of 35 minutes.
40977071|NCT03051035|DRUG|KO-947|Intravenous administration
40977072|NCT04030754|COMBINATION_PRODUCT|amniotic membrane|amniotic membrane is a biological dressing
40772487|NCT05670184|DRUG|Ethanol|Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
40772488|NCT04414943|DRUG|S-ketamine|For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
40772489|NCT04414943|DRUG|Placebo|For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
40772490|NCT02902614|PROCEDURE|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
40977073|NCT04030754|COMBINATION_PRODUCT|duoderm dressing|duoderm dressing is a synthetic dressing
40977074|NCT00330941|DRUG|lidocaine|
40977075|NCT03879122|DRUG|Ipilimumab 5 MG/ML|Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)
40977076|NCT03879122|DRUG|Nivolumab 10 MG/ML|Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
40977077|NCT03879122|DRUG|Docetaxel|"Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1."
40977078|NCT03879122|DRUG|ADT (androgen deprivation therapy)|Androgen deprivation therapy per the standard of care
40977079|NCT00210041|DRUG|Gemcitabine|Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j
40977080|NCT00210041|DRUG|Cisplatin|Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15
40977081|NCT05524155|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
40977082|NCT05524155|DRUG|Sintilimab|200mg IV d1,Q3W
40977083|NCT05524155|DRUG|Regorafenib|80mg/day,PO,QD,d1～21,Q4W
40977084|NCT05887726|DRUG|Zanubrutinib|Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)
40977085|NCT05887726|DRUG|Rituximab|Rituximab 375 mg/m2 i.v d0(21-day cycles)
40977086|NCT05887726|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)
40977087|NCT05887726|DRUG|Epirubicin|Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)
40977088|NCT05887726|DRUG|Vincristine|Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)
40977089|NCT05887726|DRUG|Prednisone|Prednisone 100 mg p.o d1-d5 (21-day cycles)
40977090|NCT04762797|OTHER|Non|This is a retrospective study, without intervention.
40772491|NCT02902614|PROCEDURE|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
40977091|NCT05854082|DRUG|Lidocaine 2% Polyampoule|Three intervention conditions in a repeated measures design - lidocaine; no perturbation, candy (lollipop)
40977092|NCT04415255|OTHER|EABPI plus IABPI|If the patient was assigned to EPABI plus IABPI, while the extrapleural space was reached, \~ 15 ml of autologous blood was injected at the extrapleural space through the coaxial needle. Then the central stylet was reinserted and the coaxial needle was advanced into the lung parenchyma with a single puncture. The needle was stopped inside the proximal part of the target and the center needle was removed. A 20-G/16 cm fully-automated biopsy needle was introduced through the 19-G/13.8 cm coaxial needle and specimens were identically obtained. After specimens were collected, the biopsy needle was removed, and immediately the remaining autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
40977093|NCT04415255|OTHER|IABPI-alone|If the patient was assigned to IABPI-alone, after collecting the biopsy specimens, immediately the autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
40977094|NCT01647815|PROCEDURE|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
40977095|NCT03912116|OTHER|CLARIX FLO|100mg CLARIX FLO
40977096|NCT03912116|OTHER|Saline|Saline
40977097|NCT03506815|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10mg po daily x 90 (+/- 3 days)
40977098|NCT01320761|DRUG|ATX-101-BA-free|ATX-101-BA-free
40977099|NCT01320761|DRUG|ATX-101-BA|ATX-101-BA
40977100|NCT00225160|DRUG|acetyl L-carnitine|
40977101|NCT05037175|BEHAVIORAL|CPT-Text|CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma. Each session includes psychoeducation and introduction of a new skill or module, which builds on the previous information and skills. Participants will receive psychoeducation video links via Talkspace and an electronic workbook with handouts, written explanations of the concepts and activities, and CPT worksheets, which will be embedded in the platform and sent by the therapist at the appropriate point in the protocol. Therapists encourage the client to complete each module using the provided materials and assist clients in reflecting on their beliefs through Socratic questions and feedback on their worksheets \[5,6\]. Clients work at their own pace, with therapists sending the skill or module after the client has practiced the previous one.
40977102|NCT05037175|BEHAVIORAL|Culturally Informed Trauma Treatment (CITT)|CITT will be conducted by Talkspace therapists with a specialty in PTSD treatment. Based on previous research and Talkspace's analysis of TAU and the therapists' training in culturally informed trauma treatment, it is likely CITT will include culturally informed, supportive and client-centered interventions, problem solving, and elements from EBTs such as cognitive-behavioral therapy \[5\].
40977103|NCT05037175|BEHAVIORAL|Retention Incentive|Participants will be told at baseline that they can earn discounts for other individuals with PTSD who are in need of financial assistance if they remain consistently engaged in treatment. If client participants do not re-engage after 24 hours from the RAU (3 days without engagement), they will receive an automated text-message reminding them to message their therapist regularly (on average, every other business day) in order to get a discount donated it to a fund that will offer free or discounted therapy to individuals with PTSD who require financial assistance. Throughout treatment, participants will be sent reminders every other week of what the incentive is and how it can be acquired, in addition to feedback about whether they are on or off track to earn the discount.
40977104|NCT05037175|BEHAVIORAL|Reminder as Usual|As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage.
40977105|NCT02496533|PROCEDURE|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
40977106|NCT02341053|OTHER|Assisted Standing Treatment Program|Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
40977107|NCT03428789|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve of the abdomen was reattached to a donor nerve in the chest area. The sensory branch of usually the 11th intercostal nerve was used as recipient nerve for nerve coaptation and the anterior cutaneous branch of the third intercostal nerve was used as donor nerve. Direct, end-to-end nerve coaptation was performed with two stitches.
40977108|NCT02642952|OTHER|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
40977109|NCT04531293|DEVICE|Respiratory Analysis System|Measurement of total lung capacity using total-breath method
41141271|NCT04212299|DEVICE|Northwestern University Flexible Sub-Ischial Suction Socket (NU-FlexSIS)|"The sub-ischial socket includes a firm, compressive, preferably cylindrical, fabric-covered silicone liner, a flexible inner socket, and a shorter rigid outer socket. The socket has proximal trim lines that do not impinge on the pelvis; they terminate distal to the ischial tuberosity and greater trochanter. For the NU-FlexSIS Socket, passive suction suspension is achieved using a one way valve and a liner with an internal seal.~Since the prosthetic socket is a custom-made device, it is considered Class I exempt by the Food and Drug Administration (FDA)."
40977110|NCT04531293|DEVICE|Respiratory Analysis System|Measurement of total lung capacity using standard method
40977111|NCT01928524|DRUG|DOS2w Dose level 1A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
41141272|NCT02416947|DIETARY_SUPPLEMENT|0 g SCF|0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
41141273|NCT02416947|DIETARY_SUPPLEMENT|10g SCF|10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
41141274|NCT02416947|DIETARY_SUPPLEMENT|20g SCF|20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
40977112|NCT01928524|DRUG|DOS2w Dose level 2A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
40977113|NCT01928524|DRUG|DOS2w Dose level 3A|Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
40977114|NCT01928524|DRUG|DOS2w Dose level 4A|Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
40772492|NCT06563882|OTHER|Home-based exercise program|"The program will comprise of six exercises aimed at improving the mobility of the thoracic spine and shoulders, strengthening the extensor muscles of the spine, and enhancing the flexibility of the chest and anterior shoulders. Progression within the program will involve increasing exercise duration or repetitions/sets, along with implementing postural corrections in compound exercises. Participants will be instructed to perform the exercises at least three times a week.~To heighten participants awareness of their daily posture, they will receive a daily scheduled message via WhatsApp reminding them to focus on their posture. Once a week, participants will be asked to submit a home exercise tracking report to monitor their adherence to the program. Additionally, exercises execution will be reviewed every two weeks, and adjustments to the program will be made accordingly."
40772493|NCT06563882|OTHER|No intervention|No intervention
40772494|NCT02878382|OTHER|Conventional MAL-PDT|Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
40772495|NCT02878382|OTHER|Calcipotriol assisted MAL-PDT|Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
40772496|NCT01333436|OTHER|Test Meal|During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
40772497|NCT03961672|DRUG|Duvelisib|Given PO
40772498|NCT04623593|PROCEDURE|ACDF|Standard operative treatment for anterior cervical discectomy. Through a right or left-sided approach the disc space contents are resected. The endplates are prepared with curettes and the disc space contents are removed. The posterior longitudinal ligament is opened. The dura is visualized to ensure adequate decompression. A cage is implanted in the disc space. The disc removal and cage implantation can be performed at a single level or at multiple levels. The wound is closed in layers, after a prevertebral wound drain is placed.
40977115|NCT01928524|DRUG|DOS3w Dose level 1B|Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
40977116|NCT01928524|DRUG|DOS3w Dose level 2B|Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
40977117|NCT01928524|DRUG|DOS3w Dose level 3B|Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
40977118|NCT00300937|DIETARY_SUPPLEMENT|Coenzyme Q10|100 mg oral BID starting at week 20 until delivery
40977119|NCT05951673|OTHER|Safe Space based life skills training program|This is a Safe Space based life skills training program given to adolescent girls. Girls receive a 12 month long training on life skills such as negotiation skills, communication skills, sexual and reproductive health, gender-based violence and climate change.
41141275|NCT04440956|DRUG|64Cu-SARTATE|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms."
41141276|NCT05829668|BEHAVIORAL|ABA-based functional analysis and treatment|Functional analysis to identify environmental variables maintaining child problem behavior and function-based treatment
41141277|NCT00004400|DRUG|testosterone|
41141278|NCT02304289|DRUG|Artesunate|Oral Artesunate once-daily for 14 days, dose-escalation
41141279|NCT06279416|PROCEDURE|fiberoptic intubation|awake nasal fiberoptic intubation
41141280|NCT06279416|PROCEDURE|laryngeal mask airway-mediated aintree catheter|awake intubation with laryngeal mask airway-mediated aintree catheter
41141281|NCT06279416|PROCEDURE|videolaryngoscopy|awake intubation with videolaryngoscopy
40772499|NCT04623593|PROCEDURE|ACDA|The start of the procedure is the same as in the ACDF group. After the discectomy, a cervical disc prosthesis is placed in the disc space instead of a cage, in accordance with the manufacturer's protocol for implantation and endplate preparation. The disc removal and arthrodesis implantation can be performed at a single level or at multiple levels. Wound closure is similar to the ACDF procedure.
41141282|NCT02721147|BEHAVIORAL|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
40772500|NCT06254833|OTHER|micro dosing of ICG|smaller dose of injection of ICG. All devices used are FDA approved in clinical use.
41141283|NCT02721147|BEHAVIORAL|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
41141284|NCT02721147|BEHAVIORAL|Partner-Assisted Coping Skills Training|Receive couple-based intimacy enhancement intervention
41141285|NCT02721147|BEHAVIORAL|Behavioral, Psychological or Informational Intervention|Receive educational information and support
41141286|NCT06037044|OTHER|Sensory integration therapy for balance and gait training|Sensory integartion Walking pathway with obstacles x10 rep, standing on one leg with eyes op5-10 sec x10 rep)
41141287|NCT06037044|OTHER|Traditional Physiotherapy for balance and gait training|Traditional Physiotherapy walking pathway with obstacles x10 rep, standing on one leg with eyes open 5-10 sec x10 rep
40772501|NCT04118101|DRUG|ESPB block|A total of 25 ml bupivacaine 0.5% will be injected into the ESP.
40772502|NCT04118101|OTHER|control|no ESPB will be given.
40772503|NCT06563999|DRUG|Sunvozertinib|300 mg orally once a day, 28 days as one cycle.
40772504|NCT06563999|DRUG|Crizotinib|300 mg orally once a day, 28 days as one cycle.
40772505|NCT06563999|DRUG|Pralsetinib|400 mg orally once a day, 28 days as one cycle.
40772506|NCT06563999|DRUG|Larotrectinib|100 mg orally twice daily, 28 days as one cycle.
40772507|NCT06563999|DRUG|Savolitinib|600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.
40772508|NCT06563999|DRUG|Pyrotinib|400 mg orally once a day, 28 days as one cycle.
40772509|NCT06563999|DRUG|Dabrafenib+Trametinib|Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.
40772510|NCT06563999|DRUG|Glecirasib|800 mg daily orally, 28 days as one cycle.
40772511|NCT06563999|DRUG|Ensartinib|225 mg daily orally, 28 days as one cycle.
40772512|NCT02743962|DEVICE|Therapeutic Wand|The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
41141288|NCT00617708|BIOLOGICAL|cixutumumab|Given IV
41141289|NCT00617708|DRUG|erlotinib hydrochloride|Given PO
40772513|NCT02743962|OTHER|Routine physiotherapy control|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
40772514|NCT05860244|DRUG|Salbutamol|Salbutamol for 6 months
40772515|NCT05860244|DRUG|Placebo|Placebo Syrup for 6 months
40772516|NCT00392574|DRUG|Prulifloxacin|Tablet
40772517|NCT00392574|DRUG|Placebo|Tablet
40772518|NCT01262105|DEVICE|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
40772519|NCT02474173|OTHER|Laboratory Biomarker Analysis|Correlative studies
40772520|NCT02474173|DRUG|Onalespib|Given IV
40772521|NCT02474173|DRUG|Paclitaxel|Given IV
40772522|NCT02474173|OTHER|Pharmacological Study|Correlative studies
40772523|NCT04365855|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Combines MRI imaging with sound waves to create a visual map (elastogram) showing the stiffness of body tissues.
40772524|NCT04365855|OTHER|Blood draw|Clinical blood tests with a focus on liver function parameters and diabetes
40772525|NCT04365855|PROCEDURE|Liver biopsy|If indicated per MRE results a biopsy will be taken of the liver.
40772526|NCT04365855|PROCEDURE|Fibro Scan|If indicated per MRE results a fibroscan will be performed of the liver.
40772527|NCT03130049|PROCEDURE|Popliteal plexus block|10 mL Marcain-adrenalin 5 mg/mL + 5 microgram/mL. Ultrasound-guided injection into the distal part of the adductor canal
40772528|NCT02935036|DRUG|ADPS topical product|topical product
40772529|NCT02935036|DRUG|Placebo Control|topical product
40772530|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
41141290|NCT00617708|DRUG|gemcitabine hydrochloride|Given IV
41141291|NCT00006200|DRUG|thalidomide|
41141292|NCT00006200|DRUG|dacarbazine|
41141293|NCT06430086|OTHER|Walnut consumption|Participants will add one serving (1 oz) of walnuts at their self-defined breakfast, lunch, and dinner for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.
41141294|NCT06430086|OTHER|HCHS consumption|"Participants will add one HCHS food (one PopTarts® pastry) to each of their 3 main meals of the day for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.~An energy-matched high-carbohydrate, high-sugar (HCHS) alternative, representative of a common US snack food, on sleep quality in adults with habitually poor sleep quality."
41141295|NCT00708266|DEVICE|Openflow microperfusion catheter|Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
41141296|NCT00708266|DIETARY_SUPPLEMENT|Intralipid 20%|"Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits."
41300996|NCT05742464|BEHAVIORAL|RUBI|"RUBI teaches caregivers a range of skills to support the building of a behavioral management toolbox. The intervention emphasizes: 1) tailoring the intervention to the child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice (i.e., targeting what is driving the behavior, instead of the behavior itself); 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g. use of visual supports), reinforcement, and functional communication strategies as the means to modify behaviors. RUBI uses a behavioral skills training approach, which includes direct instruction, modeling, role-play and practice with feedback in order to train caregivers in the various RUBI skills. Sessions also have accompanying video vignettes that are used to illustrate skills or test parental understanding of session materials."
41300997|NCT01323257|DRUG|erythromycin|500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
41460163|NCT05984823|OTHER|Home based body weight type exercises with blood flow restriction|"The participant will be asked to complete blood flow restricted exercises described below three times per week for 6 weeks.~Exercise protocol: Two tourniquets will be placed around the upper part of each thigh, these tourniquets will be inflated to an individualised and maintained for the duration of each exercise (including the inter-set rest period) but deflated during the 5 min rest in between. Five Body weight Exercises will be performed: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand."
41460164|NCT05984823|OTHER|Home based body weight type exercises|The participant will be asked to complete body weight exercises for three times per week for 6 weeks. These exercises include: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand.
41460165|NCT04943822|OTHER|A new APP|A new APP for prevention and treatment of complications of intestinal peristomal skin
41460166|NCT04598607|DRUG|Hypidone Hydrochloride tablets|30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.
41460167|NCT04598607|DRUG|Placebo|3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
41460168|NCT00084864|DIETARY_SUPPLEMENT|calcitriol|Given orally
41460169|NCT00084864|DRUG|dexamethasone|Given orally
41141297|NCT00708266|OTHER|0.9% Saline Solution|"0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits."
41141298|NCT04997408|DEVICE|Customized exercise app|A Wearable Device-Based Assisted Post-Stroke Rehabilitation system
41141299|NCT04997408|OTHER|In-person therapist-supervised rehabilitation|In-person therapist-supervised rehabilitation
41300998|NCT01323257|DRUG|Ritonavir|100 mg tablet once daily for 7 days (Trt E, F)
41300999|NCT01323257|DRUG|TMC435|150 mg capsule once daily for 7 days (Trt A, C, D)
41301000|NCT01323257|DRUG|Darunavir|2 x 400 mg tablet once daily for 7 days (Trt E, F)
41301001|NCT01323257|DRUG|TMC435|50 mg capsule once daily for 7 days (Trt F)
41301002|NCT01323257|DRUG|erythromycin|500 mg tablets three times a day for 7 days (Trt C)
41460170|NCT00084864|OTHER|clinical observation|No intervention before surgery
41460171|NCT03926416|BIOLOGICAL|CodaVax-H1N1|Live-attenuated vaccine against influenza A H1N1, A/California/07/2009
41460172|NCT03926416|BIOLOGICAL|Fluzone quadrivalent|Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine
41460173|NCT04491838|DRUG|Pozelimab|Single subcutaneous (SC) injection
41460174|NCT06209034|OTHER|Optic nerve sheath measurement|ONSD was measured bilaterally 3 mm posterior to the papilla. Transverse measurements were made for each optic nerve.
41460175|NCT01591915|OTHER|MBSR|Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
41460176|NCT06144060|DRUG|HRS -8427|The dose and frequency of administration were adjusted according to the eGFR.
41460177|NCT06144060|DRUG|Imipenem and Cilastatin Sodium|The dose and frequency of administration were adjusted according to the eGFR .
41460178|NCT05702762|DRUG|Gentamicin|5 mg/kg intramuscular injection
41460179|NCT05702762|DRUG|Standard of Care|Usual oral antibiotic multi-day dosing based on local antibiogram
41460180|NCT04899076|DEVICE|Stool Processing Kit|The Stool Processing Kit is a centrifuge-free stool processing solution that allows preparation of stool samples for testing with the Xpert Ultra MTB/RIF assay
41460181|NCT02906813|DRUG|TAK-935 Tablets|Tablets
41460182|NCT02906813|DRUG|TAK-935 Oral Solution|Oral solution
41460183|NCT00950716|BEHAVIORAL|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
41460184|NCT00950716|BEHAVIORAL|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
41460185|NCT04540692|DRUG|Docetaxel or Paclitaxel|Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks
41460186|NCT04540692|DRUG|Cyclophosphamide + Doxorrubicin|Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles
41460187|NCT00844350|DRUG|letrozole , oxytocin,hCG,clomiphene citrate|
41460188|NCT03391115|BEHAVIORAL|Storytelling Intervention for Patient Participants|The storytelling intervention consists of an audio-recorded interview with each patient participant prompted the participant to share their story with questions such as: tell me about your illness, tell me how your illness has affected your emotions, relationships, and spirituality. The interview transcripts will be used to co-create a 1 page patient story using these criteria:1) written in the first person; 2) nonjudgmental; 3) captures the participant's voice; 4) accurately reflects content of the interview; and 5) non-labeling. Once the story has been approved by the participant, I will upload it to the EHR.
40772531|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
40772532|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
41301003|NCT06142253|BEHAVIORAL|WATER+CT|This is an 8-month long two phase intervention. The first phase consists of 6 months of thrice weekly pool-based exercise occurring at VA Palo Alto. After completion of the 6 month long pool based exercise, participants transition to ten sessions of cognitive training that will occur over 2 months at the VA Palo Alto.
41301004|NCT06142253|BEHAVIORAL|Usual Care|This condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
41301005|NCT04962542|OTHER|ventilation|low volume positive pressure ventilation is better than continuous positive airway pressure and passive deflation on arterial oxygenation and PPD after CPB in pediatrics undergoing cardiac surgeries for non-cyanotic congenital heart defects.
41301006|NCT03798444|RADIATION|dual energy X-ray absorptiometry|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry. The lumbar spine, left femoral neck, or total hip of T-score ≤-2.5 as the osteoporosis
41301007|NCT03798444|RADIATION|lateral spine imaging from T4 to L4 on X-ray|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray .A visual semi-quantitative method was used, with fractures defined as a vertebral Vertebral fractures should be diagnose if height ratio \<0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra
41301008|NCT03252704|OTHER|resistant starch (high fiber muffin top)|Muffin top contained 11 g of fiber per portion
41301009|NCT03252704|OTHER|control (low fiber muffin top)|Muffin top contained 1 g of fiber per portion
41301010|NCT04541849|OTHER|Critical Care|Critical care in the intensive care units
41301011|NCT05508776|DRUG|LEO 152020|"Film-coated tablet~Route of administration: Orally~50 mg tablets"
41301012|NCT05508776|DRUG|Moxifloxacin|"Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet"
41301013|NCT05508776|DRUG|Placebo|"Film-coated tablet~Route of administration: Orally~No active ingredient"
41301014|NCT05413499|OTHER|Biomarkers research|For a part of the included population, the children with a mTBI and without indication of CT scan, a non-routine blood sample will be planned
41301015|NCT01143350|OTHER|Bras A (EHPAD Training and stimulation)|"EHPAD of the group of Training / Stimulation will benefit:~* after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~* of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
41301016|NCT01143350|OTHER|EHPAD Control|EHPAD of the reference group, will have their habitual functioning
41301017|NCT02309736|DEVICE|ReSure Sealant|
41301018|NCT03833674|OTHER|Daily AIH Block|Daily sessions of AIH (dAIH) with use of short episodes of low oxygen (9% O2)
41301019|NCT03833674|OTHER|Sham dAIH Block|Daily sessions of sham dAIH which includes breathing room air (21% O2)
41301020|NCT03833674|OTHER|Respiratory Strength Training Block|Respiratory strength training using a hand-held device that resists inspiration or expiration.
41301021|NCT03833674|OTHER|AIH + Strength Training Block|AIH followed by respiratory strength training.
41301022|NCT00815412|BEHAVIORAL|Counseling in use of health care|
41301023|NCT00815412|BEHAVIORAL|Counseling in diet, exercise|
41301024|NCT00815412|OTHER|Control|
41301025|NCT02508701|BEHAVIORAL|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
41301026|NCT00194636|PROCEDURE|nerve block|
41460189|NCT03391115|BEHAVIORAL|Storytelling Intervention for Nurse Participants|"Once the patient's story is uploaded to the EHR, automatic alerts will be sent to the participant's EHR-assigned nurses. For usability testing, nurse participants will 1) provide content expertise of the workflow processes, and 2) put the storytelling intervention through in-house usability testing to check the strength of EHR features and user-friendliness. Data will be collected with exit interviews and completion of a questionnaire: the System Usability Scale which asks them to rank their satisfaction with specific elements such as: how the story is labeled and presented in the EHR, any technical navigation EHR difficulties, and use of the material."
41460190|NCT00695045|DRUG|intra thecal morphine|100 mcg intrathecal morphine given once .
41460191|NCT00695045|DRUG|intra thecal morphine|200 mcg intrathecal morphine given once
41460192|NCT00695045|DRUG|intra thecal morphine|300 mcg intrathecal morphine given once
41460193|NCT02332005|DRUG|diepalrestat choline|aldose reductase inhibitor
41460194|NCT02332005|DRUG|Placebo|Placebo
41460195|NCT03710551|OTHER|Experimental Infant Formula|Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
41460196|NCT03710551|OTHER|Standard Infant Formula|Standard bovine milk-based infant formula, fed ad libitum
41460197|NCT01556906|DRUG|Lomitapide|Oral administration with escalating doses administered once daily
41460198|NCT05278858|COMBINATION_PRODUCT|MedJet Device with intralesional triamcinolone|A standard sterile disposable 5 ml syringe will be used to draw TAC using standard sterile protocol. This syringe will be attached to the Med-Jet along with a sterile barrel and disposable sterile tip. The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.1 ml of injected fluid). The optimal injection pressure used on the subject will start at 110 pounds per square inch (psi) and increased by 10 psi until a blanching wheal is observed. The optimal pressure will be recorded. The injections will be repeated multiple times at the optimal pressure until the targeted patch is completely treated.
41460199|NCT00006258|BIOLOGICAL|filgrastim|
41460200|NCT00006258|DRUG|cisplatin|
41460201|NCT00006258|DRUG|cyclophosphamide|
41460202|NCT00006258|DRUG|etoposide|
41460203|NCT00006258|DRUG|methotrexate|
41460204|NCT00006258|DRUG|vincristine sulfate|
41460205|NCT00006258|PROCEDURE|adjuvant therapy|
40772533|NCT02526290|DEVICE|Intranasal Lacrimal Neurostimulator (Oculeve)|Neurostimulation device
40977120|NCT05951673|OTHER|Safe Space based life skills training program + Digital Skills|This is a Safe Space based life skills training program given to adolescent girls complemented with a digital literacy training program. Girls receive a 12 month long training on life skills such as negotiation skills, communication skills, sexual and reproductive health, gender-based violence and climate change. The adolescent girls in this group also receive a digital literacy training program that covers content on word processing. database management and analysis, online marketing, online safety and programming.
40977121|NCT05956860|PROCEDURE|abdominopelvic vascular intervention through the radial artery access|"According to the pathological changes and needs of the subjects (any abdominal and pelvic arterial intervention that can be performed through the radial artery access, including but not limited to:~1. hepatic intervention, such as transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), etc.;~2. Other visceral intervention, such as spleen, kidney, mesentery, etc.;~3. Pelvic intervention, such as uterine artery embolism, prostatic artery embolism, etc.;~4. Others, such as preoperative embolization of bone tumors (lumbar, sacral vertebra), etc."
41460206|NCT00006258|RADIATION|radiation therapy|
41460207|NCT03835845|DEVICE|PICO7Y|The PICO 7Y pump maintains NPWT at -80 mmHg (nominal) to two wound surfaces simultaneously. Exudate is managed by the dressings through a combination of absorption and evaporation of moisture through the outer film. The PICO 7Y kit is intended to be used for up to 7 days on low exuding wounds. For moderately exuding wounds the system is intended to be used for up to 4 days without a dressing change. For 7 days use on moderately exuding wounds additional dressings will be supplied.
40772534|NCT03512730|DEVICE|Titanium brush|a titanium brush will be tested as mechanical decontamination in regenerative treatment of peri-implantitis
40772535|NCT03512730|OTHER|Classic decontamination|Classic decontamination will be performed by means of H2O2 3% and plastic curettes
40977122|NCT01694641|OTHER|time-lapse morphokinetic evaluation|embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
40977123|NCT05430737|RADIATION|stereotactic body radiotherapy|The radiation dose to the primary tumor was 40 or 45 Gy in five fractions according to the clinical determination of the radiologist. The dose to the positive lymph nodes and the prostate and seminal vesicles was 37.5Gy in five fraction. And internal iliac, external iliac, obturator, and presacral pelvic drainage regions received 25 Gy/5f, simultaneously. The treatment was delivered every other day. The volumetric modulated arc radiotherapy (VMAT) or intensity-modulated radiotherapy (IMRT) was used to complete treatment. Image-guided radiotherapy(IGRT) was performed for every treatment.
40977124|NCT01740986|DRUG|SA09012 Low dose|Tablet, b.i.d
40977125|NCT01740986|DRUG|SA09012 High dose|Tablet, b.i.d
41460208|NCT01603667|DRUG|PG2|"STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
41460209|NCT01603667|DRUG|placebo|"STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
41460210|NCT00380796|DRUG|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
41460211|NCT04337229|OTHER|Artifical intelligent|it is planned to create a technology that determines the comfort level of the newborn quickly and simply, easy to use, time-saving and can be used by the mobile device.
40772536|NCT00601367|DRUG|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
40772537|NCT00689884|DRUG|Pegfilgrastim|Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
40772538|NCT01467557|DEVICE|narafilcon B daily disposable soft contact lenses|daily disposable soft contact lenses
40772539|NCT01467557|DEVICE|etafilcon A daily disposable soft contact lenses|daily disposable soft contact lenses
41460212|NCT03343639|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
41460213|NCT03343639|DRUG|Matching Placebo Tablets|Placebo Tablets
40772540|NCT03572283|DRUG|Bethanechol|Supplied as 50mg oral tablets. Take 2 tablets (total 100mg) twice daily from day 1 for a minimum of 1 week and a maximum of 4 weeks (or 2 days prior to scheduled surgery). Medication should be taken 1 hour before meals in the morning and the evening. Although bethanechol is FDA approved, in this study its use is experimental.
40772541|NCT00003451|BIOLOGICAL|recombinant interferon alfa|
40772542|NCT00003451|BIOLOGICAL|recombinant interleukin-12|
40772543|NCT02735460|DEVICE|Andago V2.0|The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
40772544|NCT06052592|OTHER|Milk|Newborns will be fed with breast milk, formula milk or postbiotic formula milk
41460214|NCT04435054|DIAGNOSTIC_TEST|Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.|"Non-invasive blood biological tests - NAFLD Fibrosis Score, FIB-4, Fibrotest, FibrometerNAFLD~Non-invasive imaging:~- Transient elastography (FibroScan), Shear Wave imaging, Magnetic resonance imaging (MRI-PDFF and MRE) in a subgroup of participants."
40772545|NCT02298621|OTHER|pomegranate juice|Randomized clinical trial or RCT
40772546|NCT02298621|OTHER|placebo|Randomized clinical trial or RCT
40977126|NCT01740986|DRUG|Placebo|Tablet, b.i.d
40977127|NCT04326348|DRUG|TQ05105|TQ05105 is a JAK2 inhibitor.
41460215|NCT01702415|DRUG|Zoledronic acid|Single dose, intravenous solution 5mg
41460216|NCT01702415|DRUG|Placebo|
40772547|NCT04514835|DRUG|Cisplatin+Capecitabine+Sintilimab|"The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months."
40772548|NCT03114865|DRUG|Blinatumomab 9ug|Cycle 1 - Days 1-7: 9 ug/day IV daily
40772549|NCT03114865|DRUG|Blinatumomab 28 ug|Cycle 1 - Days 8-28: 28 ug/day IV daily
40772550|NCT03114865|DRUG|Blinatumomab|Cycle 2 - Days 1-28: 28 ug/day IV daily
40977128|NCT05854732|OTHER|Inclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a experimental group with fixed speed of 5.0 mph and increased inclination of 1% after every one minute. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and increased inclination of 1% after every one minute for 30 minutes ending with Cool down for 5 minutes.
41460217|NCT02103101|OTHER|Measurement of Plasma Concentrations of NOACs|Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
40772551|NCT03114865|DRUG|Dexamethasone|Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV
40772552|NCT02194179|DRUG|NVP XR 400 mg (KCR 25%)|
40772553|NCT02194179|DRUG|NVP XR 400 mg (KCR 20%)|
40772554|NCT02194179|DRUG|NVP XR 300 mg (KCR 25%)|
40772555|NCT02194179|DRUG|NVP XR 300 mg (KCR 20%)|
40772556|NCT02194179|OTHER|high-fat breakfast|
40772557|NCT02194179|DRUG|NVP IR 200 mg (Viramune®)|
40772558|NCT06109727|DEVICE|cerebellar transcranial electrical stimulation|Cerebellar transcranial electrical stimulation - 20 mA - 20 min
40772559|NCT01763762|BEHAVIORAL|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
40772560|NCT01763762|BEHAVIORAL|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
40772561|NCT01763762|BEHAVIORAL|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
41301027|NCT03539172|DRUG|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily from 2 weeks before the beginning of radiotherapy until the end of whole radiotherapy course
40772562|NCT05406583|DRUG|Dolutegravir 0.5 mg/kg oral suspension|DTG 0.5 mg/kg liquid suspension administered orally
40772563|NCT05406583|DRUG|Dolutegravir 5 mg Dispersible Tablets|DTG 5 mg DT administered orally
40772564|NCT02424162|DEVICE|+2.75 diopters multifocal intraocular lens|
40772565|NCT02424162|DEVICE|+3.25 diopters multifocal intraocular lens|
40772566|NCT05709847|OTHER|Coffee|24 ounces of coffee will be consumed daily
40772567|NCT03560388|OTHER|Acupuncture and touch/relaxation|Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture
40772568|NCT01631266|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
40772569|NCT01631266|BIOLOGICAL|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
40772570|NCT03589742|DEVICE|AblaView® Ablation Catheter|The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
40772571|NCT00633958|DRUG|18F-FLT|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
40772572|NCT00633958|RADIATION|PET Imaging|
41301028|NCT03645408|DRUG|Exenatide|Subject received an injection of 5 mcg of immediate release exenatide.
41301029|NCT03645408|OTHER|Sham injection|Subjects received a sham injection with no study drug.
41301030|NCT03630640|DRUG|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
41460218|NCT02103101|GENETIC|Identification of ABCB1 polymorphisms coding for P-gp|To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
41460219|NCT01066130|BEHAVIORAL|Intensive individualized psychosocial treatment|Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
41460220|NCT01066130|BEHAVIORAL|Minimal treatment arm|Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
41460221|NCT00089973|DRUG|Ispinesib|Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).
41460222|NCT02946255|BEHAVIORAL|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
41460223|NCT02946255|BEHAVIORAL|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
41460224|NCT02946255|BEHAVIORAL|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
41301031|NCT05896761|DRUG|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
41301032|NCT05896761|DRUG|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
40772573|NCT06564571|DEVICE|Patients undergoing endoscopic ultrasound procedures|Patients will undergo endoscopic ultrasound procedures as planned. Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.
40772574|NCT03246880|DRUG|Tamsulosin 0.2mg|per oral for 12weeks after 2\~4weeks run-in period
41301033|NCT04390698|PROCEDURE|paravertebral block|Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.
41301034|NCT04390698|DRUG|opioid free anesthesia|propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
40772575|NCT03246880|DRUG|Tadalafil 5mg|per oral for 12weeks after 2\~4weeks run-in period
40772576|NCT04273061|DRUG|Atezolizumab|1200 mg by intravenous infusion every 3 weeks as tolerated
40772577|NCT03439488|DRUG|JNJ-440|JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.
40772578|NCT03439488|DRUG|Placebo|Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
40772579|NCT04942145|DEVICE|virtual reality in dental patients|"The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires"
40772580|NCT04906343|PROCEDURE|Colonoscopy|Colonoscopy surveillance in SPS patient after 3 years of the last colonoscopy.
41301035|NCT04390698|PROCEDURE|sham block|Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.
41301036|NCT04390698|PROCEDURE|opioid general anesthesia|propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained .
40772581|NCT00943137|DRUG|5-Fluorouracil|"Chemotherapy will be one of the following:~1. de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~2. FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~3. Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2."
41301037|NCT04530812|OTHER|Best Practice|Maintain usual diet
41301038|NCT04530812|DIETARY_SUPPLEMENT|Kefir|Consume commercial kefir beverage
41301039|NCT04530812|OTHER|Quality-of-Life Assessment|Ancillary studies
41141300|NCT04856384|OTHER|synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations
41301040|NCT04530812|OTHER|Questionnaire Administration|Ancillary studies
41301041|NCT04857073|OTHER|Glucose Monitoring|Glucose monitoring consists of finger stick fasting and 2 hours post prandial
41301042|NCT02783274|DEVICE|Actis Total Hip System|Total Hip Replacement and Hemi-hip Replacement
41301043|NCT04757935|BEHAVIORAL|Yoga|Yoga for 30 minutes three times weekly for 8 weeks in addition to three, 1-hour in-studio yoga sessions.
41301044|NCT02100748|DRUG|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
41301045|NCT02100748|DRUG|Morphine|Morphine 4 mg will be administered every 4 hours
40772582|NCT05547035|BEHAVIORAL|Patient follow-up of depression|"All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists:~* assess the depression severity by using MADRS scale~* assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures~* the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression."
40772583|NCT04513236|OTHER|Pre-survey incentive|An incentive of is given in the form of airtime to motivate participants to complete the survey. Participants were sent 0.1X before the were sent a mobile phone survey and an additional 1X after completing the survey.
40772584|NCT04513236|OTHER|Post-survey incentive|An incentive in the form of airtime to motivate participants to complete the survey. Participants were given Bangladeshi Taka or Ugandan Shillings worth of certain airtime for completing the survey.
40772585|NCT04152239|PROCEDURE|Motorized spiral enteroscopy (MSE)|Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.
41301046|NCT02100748|DRUG|Placebo|Placebo will be administered every 4 hours
41301047|NCT01313104|PROCEDURE|colposcopy|Undergo colposcopy
41301048|NCT01313104|OTHER|cervical Papanicolaou test|Undergo cervical Pap smear
41301049|NCT01313104|PROCEDURE|screening method|Undergo anal Pap smear
41301050|NCT01313104|PROCEDURE|screening method|Undergo high resolution anoscopy
41301051|NCT02500199|DRUG|Pyrotinib|Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
41301052|NCT05264571|DIAGNOSTIC_TEST|calscreener|The calscreener (SYMCEL®) is a new diagnostic tool to rapidly identify the presence of pathogens in biological samples based on micrometabolic activity detection. All living cells produce heat by the chemical and physical processes of life; by monitoring the heat flow over time (J/s, W) a significant amount of information can be obtained regarding the biological system.
41301053|NCT05264571|OTHER|Metabolic profile|"The cal screener allows the measure of metabolic activity of pathogens directly from a sample (here, the peritoneal fluid).~The heat production will be compared between peritoneal fluid, with or without addition of bacteria"
41301054|NCT05264571|OTHER|optical microscopy|To explain the metabolic activity, growth and yeast-to-hyphae transition will be analysed using optical microscopy and conventional culture
41301055|NCT05264571|OTHER|RTqPCR|To explain the metabolic activity, level of expression of 5 Candida albicans virulence genes (UME6, ALS3, SFL2, HWP1 and ECE1) will be address and compared between peritoneal fluid.
41301056|NCT04653909|OTHER|Rehabilitation|The abdominal and back strengthening exercises on the mat, the open-closed perturbation training in sitting and standing positions for trunk control. Functional exercises were performed in the same positions for simulating daily living activities. The stretching and strengthening exercises were applied to her scoliosis and also given trunk orthoses.
41301057|NCT04323761|DRUG|Remdesivir|Intravenous infusion administered over a 30 to 120 minute period
40772586|NCT03462745|DEVICE|AccuVein AV 300|Assess the effectiveness of the AccuVein AV300 device over the standard technique in increasing the ﬁrst-time success rate (SR) for pediatric patients who needed IV cannulation
41301058|NCT03751995|BEHAVIORAL|Mindfulness meditation|"Participants in the intervention group will have their choice of two commercially available mindfulness programs, HeadspaceTM and eMindful for 6 weeks.~The Headspace program provides progressive guided mindfulness meditation instruction via a website and mobile app to help users learn the skills of mindfulness for use in everyday life. Sessions last 3-20 minutes. Videos encourage the integration of mindfulness into daily life.~eMindful offers an online virtual classroom where participants can participate in synchronous, 1-hour mindfulness classes 1-2 times per week. The program is modeled after the mindfulness-based stress reduction (MBSR) program. eMindful also offers a cancer-specific meditation course that participants may choose to participate in."
40772587|NCT02958865|DRUG|PF-06651600 or Placebo|Delivered orally for 8 weeks.
40772588|NCT02958865|DRUG|PF-06700841 or Placebo|Delivered orally for 8 weeks.
40772589|NCT02958865|DRUG|PF-06700841|Delivered orally for 24 weeks.
40772590|NCT02958865|DRUG|PF-06651600|Delivered orally for 24 weeks.
40772591|NCT03952637|BIOLOGICAL|AAV9-GLB1|The risks of administering this treatment in a subject with GM1 gangliosidosis are not completely known. The major risk associated with intravenous infusion is from the subject s immunological response to the viral capsid and/or the beta-gal protein. To reduce this possibility, immune modulation therapy is being started prior to vector delivery and maintained for six months afterward. There is a theoretical risk that the integration of a small percentage of the rAAV vector DNA into the host cell genome could cause cellular transformation to cancer cells and lead to a malignancy. This has never been seen in subjects receiving intravenous AAV9 gene therapy so the risk of this complication, is likely very low.
40772592|NCT03952637|PROCEDURE|Abdominal ultrasound|Abdominal ultrasound will be performed as part of screening and safety follow- up studies. The ultrasound will be performed in a radiology department and will take approximately 20-30 minutes.
40772593|NCT03952637|DRUG|Rituximab|We are proposing the use of immune modulation to transiently deplete B-cells using rituximab. It will be infused at -21 days and -14 days before gene transfer.
40772594|NCT03952637|DRUG|Sirolimus|Sirolimus is a macrocytic lactone that inhibits T lymphocyte activation and proliferation by inhibiting activation of mammalian Target of Rapamycin (mTOR) kinase that suppresses cytokinedriven T-cell proliferation. We plan to give sirolimus from day -21 to Day 90 with option to extend to day 365 if clinically indicated.
40772595|NCT03952637|DRUG|Methylprednisolone|Subjects will receive IV methylprednisolone 1 mg/kg or a maximum dose of 50 mg, 60-120 minutes prior to vector administration on day 0 to mitigate potential acute innate immune response against the vector.
40772596|NCT03952637|DRUG|Prednisone|Prednisone (oral solution, dose 0.5 mg/kg) will be taken daily on Days 1-3.
40772597|NCT03952637|DIAGNOSTIC_TEST|Audiology assessment with ABR|The audiology assessment will be performed in the Audiology Clinic using a standard audiogram to measure thresholds for pure tones and speech, word recognition, tympanometry, and otoacoustic emissions if the subject is capable and tolerant of these measures. The assessment will take approximately 30 minutes. The ABR is a noninvasive neurophysiologic test to evaluate electrical signal transmission from the 8th cranial nerve to the brainstem and the cortex in response to specific tones. Electrodes are placed on the scalp and on each earlobe. An earphone gives off a brief click or tone and the electrodes pick up the brain's responses to these sounds and record them. This will be performed by a trained neurophysiology technician to monitor possible change in hearing during treatment. The procedure will be performed in the Interventional Radiology suite while the subject is sedated following the MRI, fMRI, and MRS of the brain.
40977129|NCT05854732|OTHER|Uninclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a active comparator with fixed speed of 5.0 mph and fixed inclination. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and fixed inclination for 30 minutes ending with Cool down for 5 minutes.
41141301|NCT01707914|DIETARY_SUPPLEMENT|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
41141302|NCT01707914|DIETARY_SUPPLEMENT|placebo|
41460225|NCT02464904|PROCEDURE|Cryotherapy|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
41460226|NCT02464904|OTHER|Control|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
40772598|NCT03952637|DIAGNOSTIC_TEST|Bone density scan (DEXA)|Type II subjects - This is a noninvasive enhanced form of X-ray that is used to measure bone loss. Loss of bone density is a known complication with GM1 gangliosidosis due to decrease in weight-bearing activities with disease progression. The procedure will be performed in the Nuclear Medicine Department. The subject s femur, spine, and whole body will be scanned at baseline and then yearly for 3 years. The procedure will take approximately 10 minutes and may be limited due to the subject s cooperation.
40772599|NCT03952637|DIAGNOSTIC_TEST|Electrocardiogram (EKG)|Performed as part of screening and for safety before sedated procedures. The ECG will take approximately 10 minutes and may be limited due to the subject s cooperation.
41141303|NCT05346588|OTHER|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
41141304|NCT05346588|OTHER|Anesthetic technique inhaled agent|must administer inhaled agent.
40772600|NCT03952637|DIAGNOSTIC_TEST|Echocardiogram|Performed as part of screening. The Echo will be done in the Echo Lab and may take approximately 20-30 minutes. The exam may be limited due to the subject s cooperation level.
41460227|NCT05034185|DEVICE|Computer-aided diagnosis (CADx) support tool|"The CADx support tool operates when the Clinician switches the preconfigured CAD EYE function on using a button on the controller while the scope system is in BLI mode. This is performed after the Clinician first makes an optical prediction of polyp histology using IEE as described. The CADx support tool will make a prediction of polyp histology as hyperplastic or neoplastic."
40772601|NCT03952637|OTHER|Electroencephalogram (EEG) awake and extended overnight|Completed at baseline. The subject will also have an EEG if clinically indicated (for example encephalopathy, seizures, or other change in neurological status or if changes on the previous study are deemed to warrant a follow up study) during post treatment follow up. The procedures will be conducted in the Neurology Testing Department. The total time for an awake EEG, including lead placement, is approximately 40 minutes. An extended overnight EEG will take approximately 12 hours. The exam may be limited due to the subject s cooperation level.
41141305|NCT00670488|DRUG|MK-2206|MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
41301059|NCT00913978|DEVICE|Group 1: VitaHeat|Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
41301060|NCT00913978|DEVICE|Group 2: Bair Hugger|Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
41301061|NCT04093739|DEVICE|G7 Freedom Constrained Liners|Patients that have been implanted with the G7 Freedom Constrained Liners to repair hip malfunction and/or disease.
41301062|NCT04329611|DRUG|Hydroxychloroquine|COVID19
41301063|NCT02304783|DRUG|Piroxicam|Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
40772602|NCT03952637|DIAGNOSTIC_TEST|Laboratory tests|Performed on blood and urine include safety labs, clinically indicated labs and research collections. Additional specimens may be collected for the PI s biorepository or as clinically indicated. Blood volumes for clinical diagnostic testing and research will be consistent with Clinical Center laboratory guidelines.
41301064|NCT02304783|DRUG|Placebo|Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
41301065|NCT02304783|DRUG|paracetamol|Patients allocated to this arm received a five days treatment with Paracetamol and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
41301066|NCT01729910|BEHAVIORAL|Parent education / behavioral counseling|Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.
41460228|NCT05150405|DRUG|QLF31907|In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.
40772603|NCT03952637|PROCEDURE|Lumbar puncture|Performed to obtain cerebrospinal fluid (CSF) to measure GM1 ganglioside, beta-gal enzyme, AAV antibodies, Pentasaccharide biomarkers and other research tests. CSF will also be sent for cell count and differential, glucose, protein, and culture as well as CSF neurotransmitters. The amount of CSF obtained will be less than or equal to 0.75 mL/kg body weight. The procedure will be performed while under sedation following MRI imaging. If a sedated MRI is not being performed, then the LP will be performed in consultation with the pediatric consult service using conscious sedation and local anesthesia. The procedure will take approximately 15 minutes.
40977130|NCT03919214|OTHER|Automated Messaging|This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg.
41301067|NCT01729910|BEHAVIORAL|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
41460229|NCT05587257|DEVICE|Fractional CO2 laser|"Each patient will receive 6 sessions 2 weeks apart, after the laser treatment, a topical 5% minoxidil tincture will immediately applied.~All patients will advised not to use any other treatment during the study"
41141306|NCT02789488|DIETARY_SUPPLEMENT|Fenugreek seeds extract 500 mg|Furocyst one caps BID
41141307|NCT02555397|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-hIL12|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1
41141308|NCT00325845|PROCEDURE|Synvisc viscosupplementation|
40772604|NCT03952637|PROCEDURE|Brain MRI/MRS/fMRI|Magnetic resonance imaging (MRI), functional MRI (fMRI) and spectroscopy (MRS) Procedure/Surgery - The subject will undergo noncontrast MRI, including DTI sequences, fMRI, and MRS in the 3T scanner using the same image acquisition sequences and the same MRS voxels to capture the same metabolites as prior sequencing under natural history protocol 02-HG0107. The MRI, fMRI, and MRS will be interpreted for signs of disease progression or stabilization and any signs of treatment toxicity by two board-certified radiologists with specialty training in neuroradiology. The scan will require anesthesia. Sedation will be administered by the anesthesia service after a preanesthesia consultation to assess risk. The type of sedation and whether the subject will be intubated for the procedure will be at the discretion of the anesthesia service.
40772605|NCT03952637|BEHAVIORAL|Neurocognitive testing|Type II Subjects - The Vineland-3 will be administered under the supervision of a psychologist. The Vineland-3 provides several types of scores, measure of personal and social independence designed to examine the domains of communication, daily living skills, social skills and motor development. Other standard neurocognitive instruments may be used depending on the subject s ability, and some visits will (may) include a measure of intelligence /cognitive development if the child is able to achieve a basal score. Neurocognitive testing will take approximately 2-3 hours depending on subject cooperation. The assessments will not address sensitive topics. Type I Subjects - Bayley Scales of Infant and Toddler Development (BSID-III), a well-normed and validated, examiner-administered evaluation of cognition, language, and motor skills for children from birth to 42 months of age.
41141309|NCT05749120|PROCEDURE|Recipient vessel selected for microanastomosis|Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.
40772606|NCT03952637|OTHER|Neurology exam|Neurology exam will be performed by a neurologist in the screening and followup appointments to monitor for any adverse reactions and to assess for clinical response to the treatment. The exam will be scripted for consistency within subject visits and between subjects and will take approximately 30 minutes to one hour. The exam will be videotaped. The exam may be limited due to the subject s cooperation level.
41141310|NCT01995734|DRUG|Pasireotide long acting release formulation|Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.
41141311|NCT02382640|DRUG|Febuxostat XR|Febuxostat extended-release (XR) capsules
41141312|NCT02382640|DRUG|Maalox Advance Regular Strength liquid|Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
41460230|NCT05587257|DEVICE|Derma pen|, will be treated by microneedling using dermapen ( automated Derma Pen, DR Pen Ultima A6, China) which under complete aseptic precaution with a cartridge containing 12 needles moved diagonally, vertically, and horizontally for 4-5 times in each direction with 1.5 mm depth and speed 4-5(new cartridge every session), the application has been extended 1-2 cm perilesionally. The pinpoint bleeding will be considered an endpoint. topical 5% minoxidil tincture will immediately applied. Each patient will receive 6 sessions 2 weeks apart.
40772607|NCT03952637|BEHAVIORAL|PICC or other Central line placement|PICC line or other central line placement will be done under sedation in Interventional Radiology. The procedure will be done under sedation and may take 20 minutes. A chest Xray will be done after placement to confirm correct positioning of the catheter.
40772608|NCT03952637|PROCEDURE|Skeletal survey|A skeletal survey will be performed to assess the degree of skeletal involvement of the disease. This will include X-rays of the a/p lateral spine, chest, and pelvis. The exam will take approximately 30 minutes. The exam may be limited due to the subject s cooperation level.
40772609|NCT03952637|PROCEDURE|Skin biopsy|Skin biopsy will be performed on subjects who have not already had a skin biopsy under the 02-HG-0107 protocol. The procedure will be done under sedation using local anesthetic. After washing the skin with chlorhexidine and numbing the skin with injectable lidocaine, a 3mm circle of skin is removed under sterile conditions and the wound is dressed. The entire procedure takes approximately 5 minutes.
40772610|NCT03952637|PROCEDURE|Speech and modified barium swallow study|Performed as a marker of response to treatment and safety. The swallow assessments will include a parental swallowing questionnaire and cranial nerve assessment. The NIH Swallowing Questionnaire from the Speech Language Pathology Section is designed to identify the presence and or absence of functional swallowing dysfunction as perceived by the subject and or caregiver. This 4point scale assists with further identification of clinical/research assessments of oral pharyngeal swallowing function if indicated in the form of a modified barium swallow. In addition to swallow assessments, tape recording of speech will also be included with diadochokinetic tasks and sustained phonations as well as speech if able. Recordings will be stored on a shared drive accessible only by the study team. The assessment may take approximately 30 minutes to 1 hour.
41141313|NCT03662009|OTHER|multilimb dual task|control of arm and foot in two attentional contexts of simulated driving
41460231|NCT05587257|DRUG|Niosome minoxidil|The patient of alopecia areata will be treated by topical nanominoxidil preparation twice daily for 3 months with no other treatment.
41460232|NCT05587257|DRUG|Minoxidil Topical Spray|The patient of alopecia areata will be treated by topical minoxidil 5% preparation twice daily for 3 months with no other treatment.
41460233|NCT02894827|BIOLOGICAL|Blood sample|
41141314|NCT02951806|DRUG|(R) Rapid spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.
41460234|NCT02894827|OTHER|Flow cytometry|
41460235|NCT02894827|OTHER|western blot|
41460236|NCT02463487|DEVICE|Cardinal Pro +Simultaneous Irrigation (NPWTi)|NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
41460237|NCT02463487|DEVICE|Cardinal Pro (NPWT) Therapy|NPWT 125 mm Hg continuous pressure with foam interface
40977131|NCT03327649|DEVICE|low level transcutaneous vagus nerve stimulation|Stimulation of the auricular branch of the vagus nerve
41141315|NCT02951806|DRUG|(S) Slow spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
41141316|NCT03165305|OTHER|Sustained Inflation|Administering a pressure of 30 cm H20 by a T-piece resuscitator for 5 seconds immediately after birth.
40977132|NCT00856154|BIOLOGICAL|Peptides on autologous Dendritic Cells|"10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.~1. Gag150 RLLNAWVKV~2. Gag433 FLGKIWPV~3. Env 67 NIWATHACV~4. Pol606 KLGKAGYVV~5. Vpu66 ALVEMGHHV~6. Vif101 GLADQLIHL~7. Vif23 SLVKHHMYV~8. Gag298 KRWIILGLNKIVRMY~9. gp41 VWGIKQLQARVLAVERYLKD~10. Padre AKXVAAWTLKAAA"
40977133|NCT06074211|BEHAVIORAL|Safety in Seconds mobile app: Safe Sleep Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education. This intervention will be testing the effectiveness of a newly developed educational module on safe sleep education.
40772611|NCT03952637|PROCEDURE|Ophthalmology exam|The ophthalmology exam will be performed by an ophthalmologist in the screening and follow-up appointments to support subtype diagnosis and assess efficacy. Pictures of bilateral macula will be taken and saved to a secure database. OCT will also be performed. These exams will only be administered to Type I subjects.
40772612|NCT00135083|DRUG|insulin glulisine|"* Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below."
40772613|NCT02625428|DRUG|Optison|
40772614|NCT02625428|DIAGNOSTIC_TEST|Ultrasound (US)|A routine diagnostic and color-Doppler US. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through your blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A regular ultrasound uses sound waves to produce images, but can't show blood flow.
40772615|NCT02625428|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure.
40772616|NCT03650023|DIETARY_SUPPLEMENT|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
40772617|NCT03650023|DIETARY_SUPPLEMENT|White egg|White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
40772618|NCT01516372|DRUG|GEn 1200mg|1200 mg of Gen administered as a single dose
40772619|NCT01516372|DRUG|Gen 6000 mg|6000 mg of Gen administered as a single dose
40772620|NCT01516372|DRUG|GEn Placebo|Placebo to match GEn Tablets
40772621|NCT01516372|DRUG|Moxifloxacin Placebo|Placebo to match Moxifloxacin
40977134|NCT06074211|BEHAVIORAL|Safety in Seconds mobile app: Car Seat Safety Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education, including fire and car seat safety.
40772622|NCT01516372|DRUG|Moxifloxacin|400 mg Moxifloxacin administered as a single dose
40977135|NCT05050604|DRUG|Choline Alfoscerate 400mg|Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
40977136|NCT05050604|DRUG|Placebo of Choline Alfoscerate 400mg|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
41141317|NCT04562883|OTHER|The way of Cumulus-oocyte complexes (COC) culture|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
41141318|NCT03868774|PROCEDURE|repetitive transcranial magnetic stimulation|rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.
41141319|NCT01169402|DRUG|Fluconazole|25mg/kg intravenously once weekly while on ECMO
41301068|NCT02918188|DRUG|Hydrogen|Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
41301069|NCT01259297|DRUG|Aliskiren|Aliskiren 150/300 mg once daily
41301070|NCT01259297|DRUG|Amlodipine|Amlodipine 5 mg
40772623|NCT01336699|OTHER|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
40772624|NCT01336699|BIOLOGICAL|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
40772625|NCT01336699|BIOLOGICAL|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
40772626|NCT03280602|PROCEDURE|Tension band wiring (TBW)|2 x K-wire fixation (1.6 mm) and wire cerclage.
40772627|NCT03280602|PROCEDURE|Plate fixation|Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.
40772628|NCT00654732|DRUG|Bleomycin|Given IV
40772629|NCT00654732|DRUG|Dacarbazine|Given IV
40772630|NCT00654732|DRUG|Doxorubicin Hydrochloride|Given IV
40772631|NCT00654732|BIOLOGICAL|Rituximab|Given IV
40772632|NCT00654732|DRUG|Vinblastine|Given IV
40772633|NCT06008444|OTHER|Physical Evaluations of post-COVID-19 individuals|In this research, the data of Parkinson's patients who have had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
40772634|NCT06008444|OTHER|Physical Evaluations of non-post-COVID-19 individuals|In this research, the data of Parkinson's patients who have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
40772635|NCT05558579|OTHER|No sling use|Patients will not use standard of care sling
40772636|NCT02427932|DRUG|Ampicillin|Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
40772637|NCT02427932|DRUG|Ampicillin and Gentamicin|Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
40772638|NCT02427932|DRUG|Gentamicin|Prescribed to non-pregnant participants
40977137|NCT03626623|DEVICE|Cytal Wound Matrix 1-Layer|Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.
40977138|NCT03626623|OTHER|Standard of Care (SOC)|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
40977139|NCT02921854|OTHER|Blood withdrawal|For each patient, 3 blood withdrawals of 25 ml each will take place during treatment
41141320|NCT01626833|DRUG|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE\* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
40772639|NCT04728425|DRUG|subcutaneous immunoglobulin (SCIG)|20% subcutaneous immunoglobulin
41301071|NCT01259297|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
40977140|NCT00766480|DRUG|cisplatin|Given IV
41301072|NCT01259297|DRUG|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
41301073|NCT01259297|DRUG|Placebo for Amlodipine|Placebo for Amlodipine
41301074|NCT01259297|DRUG|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
41301075|NCT02776696|DEVICE|Advanced Hybrid Closed Loop System|
41301076|NCT02776696|DEVICE|Hybrid Closed Loop System|
41301077|NCT06168864|DIAGNOSTIC_TEST|Artificial intelligence models for segmentation and characterization of prostate cancer|rtificial intelligence algorithms for the automatic segmentation of prostate cancer lesions on medical images.
40772640|NCT04728425|DRUG|intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)|10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin
40772641|NCT06375447|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for insomnia.
40772642|NCT06306183|DIETARY_SUPPLEMENT|Acetaminophen and Vitamin C with Naproxen rescue|"900 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen."
40772643|NCT06306183|OTHER|Acetaminophen and Placebo with Naproxen rescue|"Placebo taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen."
40772644|NCT04884802|PROCEDURE|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.
40772645|NCT04884802|PROCEDURE|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
40772646|NCT00851084|DRUG|aflibercept|administration: IV infusion
40772647|NCT00851084|DRUG|oxaliplatin|administration: IV infusion
40772648|NCT00851084|DRUG|5-FU|administration: IV infusion
40772649|NCT00851084|DRUG|Folinic Acid|administration: IV infusion
40977141|NCT00766480|DRUG|fluorouracil|Given IV
40977142|NCT00766480|RADIATION|radiation therapy|Patients undergo radiotherapy
40772650|NCT04994613|OTHER|Sensory adaptive environment|A dedicated, private room that is set up in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli.
40772651|NCT06563765|OTHER|FAP-targeting PET/CT imaging will be performed on the enrolled patients.|FAP-targeting PET/CT imaging will be performed on the enrolled patients.
40772652|NCT04817956|DRUG|Atezolizumab|drugs used outside indication, based on biomarker
40772653|NCT01156350|DRUG|Busulfan - Fludarabine - TBI|This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+ cells/kg were infused on day 0. No post grafting immunosuppression was applied if the graft contained \< 2.5 x 104 CD3+ cells/kg
40772654|NCT05036109|DRUG|Aspirin|by mouth every day for up to 90 days
40772655|NCT05036109|DRUG|Vitamin D|by mouth every day for up to 90 days
40772656|NCT05036109|DIETARY_SUPPLEMENT|Diet|Patients will receive counseling promoting a plant-based diet and avoidance of Western dietary patterns in a one on one session with a licensed dietitian prior to day 1.
40772657|NCT05036109|OTHER|Physical Activity|The exercise goal is to increase recreational physical activity from baseline by at least 10 MET hours per week, which is equivalent to 150 minutes of moderate activity weekly
40772658|NCT05036109|BEHAVIORAL|Behavioral Support Counseling Sessions|Patients will undergo a one-on-one counseling session prior to day 1
40772659|NCT00470522|DRUG|Methotrexate and folic acid|
40772660|NCT04049513|BIOLOGICAL|WZTL002-1 (1928T2z CAR-T cells)|WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.
40772661|NCT04049513|DRUG|Cyclophosphamide and Fludarabine lymphodepleting chemotherapy|Cyclophosphamide 500 mg/m\^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m\^2 IV on days -5 to -3, inclusive
40772662|NCT02445911|DRUG|KQ-791|Capsules administered orally
40772663|NCT02445911|DRUG|Placebo|Capsules administered orally
40772664|NCT01651208|BEHAVIORAL|Motivational Interviewing (MINT)|"We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:~a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment."
40772665|NCT01651208|BEHAVIORAL|Mailed DVD|The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
40772666|NCT03350464|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
40772667|NCT05467410|BEHAVIORAL|COG-AM|Participants who are randomized to the COG-AM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during morning hours (between 09:00-12:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
40772668|NCT05467410|BEHAVIORAL|COG-PM|Participants who are randomized to the COG-PM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during late afternoon/early evening hours (between 15:00-18:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
40772669|NCT00304161|DRUG|Atomoxetine|40 to 80 mg orally once daily for 8 weeks
40772670|NCT00304161|DRUG|Placebo|40 to 80 mg orally once daily for 8 weeks
40772671|NCT01064726|DRUG|Ibuprofen|800 mg oral
40977143|NCT06508125|DRUG|cross-linked hyaluronic acid|cross-linked hyaluronic acid injection with physical therapy
40977144|NCT06508125|DRUG|non-cross-linked hyaluronic acid|non-cross-linked hyaluronic acid injection with physical therapy
40977145|NCT02364973|OTHER|PET-MRI|The study patients undergo positron emission tomography (PET) after informed consent is obtained
40977146|NCT02520050|BEHAVIORAL|Traditional MNT|Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
41301078|NCT04242017|DRUG|Triptoreline|Comparison of the duration of ADT (Triptoreline)
40772672|NCT01064726|DRUG|Fluticasone propionate|200 mcg intra-nasal
40772673|NCT01064726|DRUG|Placebo|Placebo
40772674|NCT02798887|PROCEDURE|Ridge preservation|Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
40977147|NCT02520050|BEHAVIORAL|Structured MNT|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.
41301079|NCT02685384|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
40772675|NCT00031733|BIOLOGICAL|MART-1 antigen|
40772676|NCT00031733|BIOLOGICAL|gp100 antigen|
40772677|NCT00031733|BIOLOGICAL|incomplete Freund's adjuvant|
40772678|NCT00031733|BIOLOGICAL|recombinant interleukin-12|
40772679|NCT00031733|BIOLOGICAL|sargramostim|
40772680|NCT00031733|BIOLOGICAL|tyrosinase peptide|
40772681|NCT00031733|DRUG|alum adjuvant|
40772682|NCT00031733|PROCEDURE|adjuvant therapy|
40772683|NCT03257501|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
40772684|NCT04818710|PROCEDURE|skin incision with a scalpel|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 1 (skin incision with a scalpel)"
40772685|NCT04818710|PROCEDURE|skin incision with diathermy|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 2 (skin incision with diathermy)"
40772686|NCT04958096|DEVICE|Standard Therapeutic Deep Brain Stimulation|DBS to the standard subcortical targets (anterior limb of the internal capsule- ALIC) will be used to treat OCD
40772687|NCT04958096|DEVICE|Cortical Stimulation for PFC|Patients enrolled in this study will have a second pair of leads placed in the prefrontal cortex (PFC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
40772688|NCT04958096|DEVICE|Cortical Stimulation for ACC|Patients enrolled in this study will have a second pair of leads placed in the anterior cingulate cortex (ACC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
40772689|NCT01101126|OTHER|Pulmonary disease management|Comprehensive pulmonary care including patient education of self-care, coordination of care, monitoring of patient adherence, providing advice in acute exacerbations
40772690|NCT01101126|OTHER|Usual care|Pulmonary disease is managed by the primary practitioner and a consultant pulmonologist
40772691|NCT00784017|DRUG|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
40772692|NCT00784017|DRUG|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
40772693|NCT01144650|DRUG|Dapsone|Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
40772694|NCT01144650|DRUG|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
40772695|NCT03088033|DEVICE|IASD System II implant|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
40772696|NCT03088033|OTHER|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
40772697|NCT03286699|BEHAVIORAL|Dietary Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
40977148|NCT02520050|BEHAVIORAL|Structured MNT plus Weekly Support|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian
41301080|NCT03099369|BEHAVIORAL|Daily Step-based Exercise|A 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day.
40772698|NCT03286699|BEHAVIORAL|Physical Activity Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
40772699|NCT00829868|DRUG|Zaleplon 10 mg Capsules|1 x 10 mg
40772700|NCT00829868|DRUG|SONATA® 10 mg capsules|1 x 10 mg
40772701|NCT05703399|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
40772702|NCT05703399|OTHER|Questionnaire Administration|Complete questionnaire
40772703|NCT05945225|DEVICE|Sonicare DiamondClean 9000 Philips®|Brush teeth with the electric toothbrush daily during 3 months
40772704|NCT05945225|DEVICE|HydroSonic Easy Curaden®|Brush teeth with the hydrosonic toothbrush daily during 3 months
40772705|NCT05945225|DEVICE|Manual toothbrush Oral-B 123|Brush teeth with the manual toothbrush daily during 3 months
40772706|NCT05945225|DEVICE|Manual toothbrush Curaprox CS 5460|Brush teeth with the manual toothbrush daily during 3 months
40977149|NCT03791840|DIAGNOSTIC_TEST|Ultrasound evaluation|High-frequency ultrasound is used to detected the lymph node metastasis in vivo and vitro. The lymph node number, morphology and elastographic parameters are collected in the patients and in fresh lymph node specimens.
40977150|NCT02659306|DRUG|Metformin|Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
40977151|NCT00001995|DRUG|Rifabutin|
41301081|NCT03099369|BEHAVIORAL|Symptom-based Exercise|A 12-week symptom-based exercise prescription adapted from clinical practice guidelines.
40772707|NCT03242434|OTHER|Lactulose and Mannitol solution|Participants will receive 100 milliliter (mL) oral solution of Lactulose \[5 grams (g)\]/ Mannitol (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
40772708|NCT03242434|OTHER|Sucralose|Participants will receive 3 capsules of Sucralose (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
40977152|NCT01721382|DRUG|Sitagliptin|
40977153|NCT00844688|DRUG|sorafenib|"Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~1. Progression of disease.~2. The patient is unlikely to benefit from further treatment as~   Judged by the Investigator.~3. Intolerable toxicity of the drugs.~4. Withdrawal of consent for any reason."
41141321|NCT01626833|BIOLOGICAL|Placebo|Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
41301082|NCT03099369|OTHER|Fitbit Fitness Monitor|Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
41301083|NCT03638947|DEVICE|Swab and decolonization using povidone-iodine cleansing|Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
41301084|NCT06555367|DEVICE|scleral lenses|Wear scleral lenses
41301085|NCT02490150|DRUG|Corifollitropin alfa|
41301086|NCT01253512|DRUG|THR-18|A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
41301087|NCT01253512|DRUG|Placebo|Intravenous
41301088|NCT05722899|OTHER|Football training|10-week progressive football training with small-sided games, 2x/week, 45min-1h sessions
41301089|NCT02133235|PROCEDURE|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
41301090|NCT02133235|PROCEDURE|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
41301091|NCT02890199|DRUG|Bupivacaine liposomal|
41301092|NCT02890199|DRUG|Lidocaine|
41301093|NCT00635947|OTHER|isotonic solution|1.5 L- during 2-4hours
40977154|NCT00844688|DRUG|Gemcitabine|"Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 \& 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason."
41301094|NCT00635947|OTHER|water|1.5 L- during 2-4hours
41301095|NCT00635947|OTHER|water|200mL- during 2-4hours
41301096|NCT04604106|DIAGNOSTIC_TEST|Eyetracker|Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
40977155|NCT01569490|BEHAVIORAL|Incentives for abstinence and treatment engagement|Treatment Incentives - incentives for biochemical verification visits, treatment engagement, and abstinence
40977156|NCT01569490|BEHAVIORAL|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
40977157|NCT00165347|DRUG|PTK787/ZK222584|
41301097|NCT04604106|DIAGNOSTIC_TEST|Ages & Stages questionnaire|The Ages \& Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.
41301098|NCT04604106|DIAGNOSTIC_TEST|Bayley Scale of Infant Development|The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
41301099|NCT03295097|OTHER|Clinical Decision Support System|The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.
41301100|NCT04316689|BIOLOGICAL|S-488210|S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).
41301101|NCT04316689|BIOLOGICAL|S-488211|S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).
41301102|NCT01552928|DRUG|Anagrelide 0.5 mg|0.5mg Anagrelide single oral dose
41301103|NCT01552928|DRUG|Anagrelide 2.5 mg|2.5mg Anagrelide single oral dose
41301104|NCT01552928|DRUG|Moxifloxacin|400 mg Moxifloxacin single oral dose
41301105|NCT01552928|DRUG|Placebo|Anagrelide placebo + Moxifloxacin placebo single oral dose
40977158|NCT04154020|PROCEDURE|Flexor tenotomy|Tenotomy(cutting) of flexor tendons is performed with needle
40977159|NCT01941901|DRUG|Calcium electroporation|Intratumoral injection, once only treatment.
40977160|NCT01941901|DRUG|Electrochemotherapy with bleomycin|Intratumoral injection, once only treatment
40977161|NCT01922206|BEHAVIORAL|TRACK Intervention|"TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child"
40977162|NCT02949102|DIETARY_SUPPLEMENT|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
40977163|NCT02949102|DIETARY_SUPPLEMENT|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
40977164|NCT04533438|DEVICE|RhinAer Stylus|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session.
40977165|NCT04533438|DEVICE|Sham|The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
40977166|NCT03181568|DEVICE|MolecuLight i:X™ Imaging Device|Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
40977167|NCT03181568|PROCEDURE|Wound care|Standard wound care of chronic wounds e.g. sampling, debridement, infection control
40977168|NCT01102400|DRUG|MEDI-575|MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
40977169|NCT03309150|DRUG|M6620|Participant will either receive M6620 intravenously as a monotherapy on Day 1, 8 and 15 OR as a combination therapy on Day 2 and 9 of the study.
40977170|NCT03309150|DRUG|Carboplatin|Participant will receive carboplatin intravenous infusion as a combination therapy on Day 1 of the study.
40977171|NCT03309150|DRUG|Paclitaxel|Participant will receive paclitaxel intravenous infusion as a combination therapy on Day 1, 8 and 15 of the study.
40977172|NCT03128892|DEVICE|Oxygen Reserve Index - RD Lite Sensors|
40977173|NCT02338414|DRUG|Romiplostim|Subcutaneous Romiplostim (weekly injection) -\> if titrated with maintaining PLT count between 50-200 x 10\^9/L -\> Subcutaneous Romiplostim (biweekly injection)
40977174|NCT00004482|DRUG|Cyclosporine|
40977175|NCT00004482|DRUG|methylprednisolone|
40977176|NCT00004482|DRUG|Muromonab-CD3|
40977177|NCT00004482|DRUG|prednisone|
40977178|NCT06379295|OTHER|Questionnaire|Self-administered questionnaire to assess the participants risk factors, history of heart disease and medications.
40977179|NCT01442233|PROCEDURE|plasma exchange|6 plasma exchange each 48 hours during 2 weeks after randomization
40977180|NCT01442233|PROCEDURE|sham exchanges procedure|6 sham exchanges each 48 hours during 2 weeks after randomization
41141322|NCT00900302|GENETIC|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
41141323|NCT00900302|OTHER|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
41460238|NCT05695651|DIAGNOSTIC_TEST|triglyceride glucose index and HOMA IR|"TyG index was calculated as formula: ln\[fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2\].~an insulin resistance score (HOMA-IR) was computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance)."
41460239|NCT04926701|DRUG|ETD001 single dose|Single ascending doses of inhaled ETD001
41460240|NCT04926701|DRUG|Placebo single dose|Single doses of inhaled placebo
40977181|NCT00676351|PROCEDURE|body plethysmography|Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
40977182|NCT05040997|DIAGNOSTIC_TEST|Small airways assessment|Small airways assessment
40977183|NCT01352299|DEVICE|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
40977184|NCT01352299|DEVICE|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
40977185|NCT01352299|DEVICE|Miller|Laryngoscopy performed with Miller Laryngoscope
40977186|NCT01352299|DEVICE|TrueView|Laryngoscopy performed with TrueView laryngoscope
40977187|NCT04334161|COMBINATION_PRODUCT|Administration of glucose and controlled induction of hypoglycaemia.|Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.
41460241|NCT04926701|DRUG|ETD001 multiple twice daily doses|Ascending doses of inhaled ETD001 administered twice daily
41460242|NCT04926701|DRUG|Placebo multiple twice daily doses|Doses of inhaled placebo administered twice daily
41460243|NCT04926701|DRUG|ETD001 multiple once daily doses|Doses of inhaled ETD001 administered once daily
41460244|NCT04926701|DRUG|Placebo multiple once daily doses|Doses of inhaled placebo administered once daily
40977188|NCT04006249|DIAGNOSTIC_TEST|dental probes|Measurement of the depth of the periodontal pockets and clinical loss
40977189|NCT03557151|OTHER|Usual Care|Usual Care participants will receive the same excellent multidisciplinary Care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is \< 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
41460245|NCT00566280|PROCEDURE|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
40977190|NCT03557151|BEHAVIORAL|Transdisciplinary Care-In Person & Telehealth|TC participants will receive all elements of the Usual Care intervention but they will do so in the context of face to face or telehealth delivery of TC follow-up visits with simultaneous involvement of an advanced practice nurse, dietitian and psychologist at each visit.
40977191|NCT04256070|BEHAVIORAL|education and tele-consultation|education and tele-consultation based on Watson's Human Care Theory
40977192|NCT01618994|PROCEDURE|Performing robotic supracervical hysterectomy|All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
40977193|NCT01721616|DRUG|Azithromycin|
40977194|NCT01721616|DRUG|Cefazolin|
40977195|NCT00967772|DRUG|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
40977196|NCT02202408|DRUG|SKI2670|Oral, Single Dose
40977197|NCT02202408|DRUG|Placebo|Same shape as the experimental drug
40977198|NCT04199572|DRUG|Diclofenac and Paracetamol|analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo
40977199|NCT00387439|BEHAVIORAL|standard medical treatment + anoperineal physiotherapy.|
40977200|NCT00387439|BEHAVIORAL|Standard medical treatment|
40977201|NCT01829230|DEVICE|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
40977202|NCT06498947|OTHER|This study was observational with no intervention.|This study was observational with no intervention.
40977203|NCT01330589|DRUG|Placebo|Non-active placebo for 7 days: PO/TID
40977204|NCT01330589|DRUG|St. Johns Wort|For 7 days: 300mg PO/TID
41460246|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
41460247|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
41460248|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
41460249|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
41460250|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
41460251|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
41460252|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
41460253|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
41460254|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
41460255|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
41460256|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
40772709|NCT02957240|BEHAVIORAL|Standard Care|"This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.~Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury."
40772710|NCT02957240|BEHAVIORAL|Motor Representation Techniques|"Those in this group will receive 4 clinic-based intervention session (one 1-hr. and three subsequent 30-minute sessions) where the focus will be on home program competency and advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home Program will be performed 3x daily for 15 minutes. A Motor Representation Technique (i.e., modified GMI) protocol described by Lagueux et al. will be employed. As originally designed the program was broken into three stages 1) Laterality, 2) Explicit Motor Imagery, 3) Mirror therapy with unaffected hand only and 4) Mirror Therapy with bilateral hands. For the purpose of this study, and given the restraint offered by cast immobilization, the 4th phase will not be used. Each phase will require 1-2 weeks and will be progressed at the discretion of the hand therapist interventionist."
40772711|NCT05151926|PROCEDURE|Full weight-bearing|Instruction for full and immediate weight-bearing postoperatively
40772712|NCT05151926|PROCEDURE|Partial weight-bearing|Instruction for partial weight-bearing for 6 weeks postoperatively
40772713|NCT05151926|PROCEDURE|Intramedullary nailing|Intramedullary nailing of the fractured tibial shaft.
40772714|NCT03781063|DRUG|Lasofoxifene|Estrogen receptor antagonist antineoplastic agent
40772715|NCT03781063|DRUG|Fulvestrant|Estrogen receptor antagonist antineoplastic agent
40772716|NCT04150497|BIOLOGICAL|UCART22|Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
40772717|NCT04150497|BIOLOGICAL|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
40772718|NCT05264454|DEVICE|high flow nasal cannulae|The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
40772719|NCT01358734|DRUG|Azacitidine|Azacitidine at 75 mg/m\^2/day subcutaneous on Days 1-7
40772720|NCT01358734|DRUG|Lenalidomide|Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily
40772721|NCT01358734|OTHER|Best Supportive Care (BSC)|"The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.~BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support"
40772722|NCT04797884|DEVICE|TheraBionic Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at one of the recruiting site, all other treatments will be self-administered at the patient's home.
40772723|NCT04797884|DEVICE|Placebo Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at the recruiting site, all other treatments will be self-administered at the patient's home.
40772724|NCT04797884|DEVICE|Quality of Life Assessment|Ancillary services
40772725|NCT05701826|DRUG|HRS3797|HRS3797 for injection, low dose
40772726|NCT05701826|DRUG|HRS3797|HRS3797 for injection, medium dose
40772727|NCT05701826|DRUG|HRS3797|HRS3797 for injection, high dose
40772728|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Microencapsulated Magnesium|Volunteers will be provided with the product Microencapsulated Magnesium. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
40772729|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Oxide|Volunteers will be provided with the product Magnesium Oxide. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
40772730|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Citrate|Volunteers will be provided with the product Magnesium Citrate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
40772731|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Bisglycinate|Volunteers will be provided with the product Magnesium Bisglycinate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
40977205|NCT05295043|DRUG|(CDK)4/6 inhibitor|CDK4/6 inhibitor + AI/fulvestrant therapy，According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
40977206|NCT01739478|OTHER|Packing of abscess cavity|
40977207|NCT01739478|OTHER|External dressing|Application of external dressing whilst abscess cavity heals
40977208|NCT00872534|DRUG|acetylsalicylic acid|325mg once a day for 7 days
40977209|NCT03910842|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
41460257|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
40772732|NCT03242447|BEHAVIORAL|e-Practice Self-Regulation|e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.
40772733|NCT03242447|BEHAVIORAL|Video Health Group|The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
40772734|NCT01074346|DRUG|Interferon-β-1a|Interferon-β-1a according to the standard practice
40772735|NCT04726501|OTHER|Combined chemotherapy with or without involved-field radiotherapy|Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.
40772736|NCT06036368|DEVICE|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct trancutaneous, electrical stimulation of the peroneal nerve
40772737|NCT03589833|DRUG|Tripterygium Wilfordii|Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.
40772738|NCT03589833|DRUG|Methotrexate|Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
40772739|NCT03589833|DRUG|Yisaipu|Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
41301106|NCT04755296|DEVICE|Low level laser therapy|Low level laser therapy was applied immediately before each aerobic exercise training session by using a multidiode cluster (with four diode spots; Polaris2, manufactured by Astar ABR, Poland) )on 12 sites on the lower limb (6 on quadriceps ( 2 centrally on rectus femoris and vastus intermedius,2 laterally on vastus lateralis, and two medially on vastus medialis), 4 on hamstrings and 2 on gastrocnemius) with the following parameters: 808 nm, continous output, 200 mW each diode (total of 800 mW) power output, 24 J energy on each site (6 J for each spot) , 40 seconds at each site (8 minutes of total treatment time in lower limb) and 288 J total energy delivered per lower limb, 48 irradiation points per lower limb ,3 sessions weekly for 12 weeks.
41301107|NCT04755296|OTHER|Aerobic exercises|Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of \<50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of\<50% of the previously determined VO2max of each participant.
41301108|NCT04755296|OTHER|Traditional physical therapy program|Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
41460258|NCT02611323|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 milligrams (mg) via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month (starting from Month 2) for up to 24 months, until disease progression or unacceptable toxicity.
40772740|NCT06375148|OTHER|Enteral nutrition|prone position ventilation
40772741|NCT00270387|DRUG|Natrecor (nesiritide)|
40772742|NCT00001382|BIOLOGICAL|PROSTVAC|
40772743|NCT01117779|DEVICE|Cryoablation|Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
40772744|NCT00633685|DRUG|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
40772745|NCT00633685|DRUG|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
41301109|NCT04749979|DRUG|Agonist (decapeptyl )|giving agonist
41301110|NCT04749979|DRUG|HCG ( eg. Choriomon )|giving HCG
41301111|NCT05399238|DEVICE|The objective is to measure the temperature of the lingual dorsum|Subjects will make one visit to our clinic with burning mouth syndrome and control healthy . They will be asked to acclimate to room temperature for at least 20 minutes. Subjects are requested not to consume hot drinks or food for at least an hour before imaging and not to use any skin preparations.
40772746|NCT04763109|OTHER|Whole-body Magnetic Resonance Imaging|Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months
41301112|NCT04224740|DRUG|Pembrolizumab|Patients will receive pembrolizumab at the dose of 200mg IV Q3W with maximum duration of 2 years (34 cycles-counting the part combined with chemotherapy)
41301113|NCT04224740|DRUG|Standard of care therapy|Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
41301114|NCT00331825|DRUG|Risperidone and Olanzapine|
41301115|NCT04200105|DEVICE|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 22G EBUS needle
41460259|NCT02611323|DRUG|Rituximab|Participants will receive a fixed dose of rituximab, 375 milligrams per square meter (mg/m\^2) via IV infusion to be given on Day 1 of Cycles 1 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month (starting from Month 2) for up to 8 months, until disease progression or unacceptable toxicity.
40977210|NCT04893967|DEVICE|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
40977211|NCT04893967|DEVICE|kinesiology tape|Kinesiology Tape is applied without creating any tension over low back
40977212|NCT02538250|DIETARY_SUPPLEMENT|Nutricomp Drink Plus|Oral nutritional supplementation
41301116|NCT04200105|DEVICE|Acquire TBNB|Mediastinal and hilar lymph node sampling using the Acquire TBNB needle
41301117|NCT04446234|DRUG|Risperidone|Use medicine according to patients condition
40977213|NCT06215040|PROCEDURE|Endoscopic retrograde cholangiopancratography|common bile duct stone removal
40977214|NCT05046171|OTHER|Pharmacist-led deprescribing|A pharmacist recruited onto the study will review the patient's current medication list and develop a list of targeted recommendations for deprescribing using the 3-step potentially inappropriate medications identification method.
41141324|NCT00900302|OTHER|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
40772747|NCT03517605|OTHER|Exercise for cardiac rehabilitation|An exercise program was designed according to the American College of Sports Medicine and performed by the Specialist Nurses in Rehabilitation Nursing. Comprises aerobic and recovery/stretching. Started in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min). Possible symptoms will be controlled during exercise sessions.
40772748|NCT04189614|DRUG|Cofetuzumab Pelidotin|Intravenous (IV) infusion
40772749|NCT06363292|DRUG|PRO-231|Moxifloxacin 0.5% Ophthalmic solution.
40772750|NCT06363292|DRUG|VIGAMOXI®|Moxifloxacin 0.5% Ophthalmic solution.
40772751|NCT04918082|OTHER|Quality of life questionnaires|Patients' quality of life will be assessed with self-reported items through both the EORTC-QLQ-C30 and EORTC-QLQ-BR23 modules.
40772752|NCT02129621|PROCEDURE|Urinary and blood lipococalin levels determination|Blood test on an empty stomach. Urinary taking on arrival in the service
40772753|NCT02129621|DRUG|Spironolactone|For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
40772754|NCT05759767|DRUG|Tamsulosin|Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
40772755|NCT05759767|DRUG|Placebo|Children in this group will receive placebo once daily for 3 weeks after ESWL session.
40772756|NCT05129735|DIETARY_SUPPLEMENT|Meal replacement shake|Each day for the study period (12 weeks), the participants will take one meal-replacement shake per day for breakfast. The breakfast will be replaced by the shake entirely.
40772757|NCT04779008|OTHER|remote ischemic preconditioning （RIPC）|Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
40772758|NCT01532154|DRUG|Fampridine|As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy
40772759|NCT02448381|DRUG|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
41141325|NCT00900302|PROCEDURE|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
40772760|NCT02448381|DRUG|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
40772761|NCT02395276|DEVICE|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
40772762|NCT03240328|BIOLOGICAL|CAR-T cells|HIV-1 specific chimeric antigen receptor cells
40772763|NCT01908010|DRUG|ABT-354|ABT-354 Low Dose
40772764|NCT01908010|DRUG|ABT-354|ABT-354 High Dose
40772765|NCT01908010|DRUG|Placebo|Placebo
40772766|NCT03840967|DRUG|Niraparib|Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
40772767|NCT04183686|DRUG|ACT-1014-6470 (SAD)|Single dose of ACT-1014-6470; soft capsules for oral use.
40772768|NCT04183686|DRUG|ACT-1014-6470 (MAD)|Multiple doses of ACT-1014-6470; soft capsules for oral use.
40772769|NCT04183686|DRUG|Placebo (SAD)|Single dose of matching placebo; soft capsules for oral use.
41141326|NCT01986348|DRUG|Selinexor|One cycle is 28 days (4 weeks).
40772770|NCT04183686|DRUG|Placebo (MAD)|Multiple doses of matching placebo; soft capsules for oral use.
40772771|NCT04183686|DRUG|14C-ACT-1014-6470 microtracer|Single dose of 14C-ACT-1014-6470 microtracer; soft capsules for oral use.
40772772|NCT04183686|DRUG|14C-ACT-1014-6470 microtracer placebo|Single dose of matching placebo; soft capsules for oral use.
40772773|NCT02644070|DEVICE|alveolar bone preservation with mp3|graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)
40772774|NCT02644070|DEVICE|alveolar bone preservation with apatos|graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )
40772775|NCT02644070|DEVICE|stabilization with membrane|socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
40772776|NCT05585320|DRUG|IMM-1-104 Monotherapy (Treatment Group A)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met
40977215|NCT05046171|OTHER|Patient education|Subjects receive a written pamphlet about deprescribing.
40977216|NCT06138301|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a psychotherapeutic intervention that focuses on challenging and changing cognitive distortions (such as thoughts, beliefs, and attitudes) and their associated behaviours to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, patients with SI will undergo 8 sessions of CBT (45 min, once a week), remotely. Techniques and strategies of the intervention will be based on a short telepsychotherapy protocol previously published by our group (Biagianti et. al., 2021). Instead, the content of each session will be adapted to the psychopathology associated with social isolation and the age of the subject. The psychotherapeutic sessions of the patients will be audio-recorded in order to conduct retrospective analyzes of the patient's speech.
40977217|NCT06138301|BEHAVIORAL|Cognitive Remediation (CR)|The cognitive training will consist of 10 hours (30 minutes/session) of computer-based exercises focusing on working memory, attention, executive functions and social cognition, which will be performed online using BrainHQ software. This software allows for the customization of the training based on the specific characteristics of each subject. For example, it allows automatic adjustment of the difficulty of the exercises, trial by trial and session by session, in order to guarantee an adequate level of attention and motivation for the entire duration of the training and therefore favor optimal learning rates.
40977218|NCT03542981|DEVICE|Interferential Current|
40977219|NCT03542981|DEVICE|Sham Interferential Current|
41460260|NCT02611323|DRUG|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) (for FL), and 1.8 mg/kg (for DLBCL) on Day 1 of each 21-day cycle for up to 18 weeks during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
40772777|NCT05585320|DRUG|IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met.~Gemcitabine will be administered at a dose of 1000 mg/m\^2 nab-Paclitaxel will be administered at a dose of 125 mg/m\^2"
40772778|NCT05585320|DRUG|IMM-1-104 + modified FOLFIRINOX (Treatment Group C)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met.~FOLFIRINOX will be administered as follows:~Folinic Acid will be administered at 400 mg/m\^2 Fluorouracil will be administered at 2400 mg/m\^2 Irinotecan will be administered at 150 mg/m\^2 Oxaliplatin will be administered at 85 mg/m\^2"
40772779|NCT04482127|OTHER|SubEpithelial connective graft|Connective tissue graft harvested from hard palate, to be placed buccal to extraction sockets in the intervention group
40772780|NCT03645460|GENETIC|Direct intravenous injection of ivlv-ADA lentiviral vector|Injection of ivlv-ADA lentiviral vector at \~1x10\^9 per kg body weight
40772781|NCT04998630|DEVICE|Extracorporeal shockwave therapy|Treatment Location: Painful Area Treatment intensity: 2000 pulses, low energy (0.08\~0.28 mJ/m2) the degree to which the subject can tolerate
40772782|NCT01937065|OTHER|No treatment|
40772783|NCT01596920|OTHER|Tissue|Allograft Tissue Cellular Repair Matrix
40772784|NCT01596920|OTHER|Control|Non-adherent Dressing
40772785|NCT05970328|DEVICE|Hexoskin Medical System|Participant wears both the Hexoskin Medical System and the Nasiff Holter Monitor at the same time to acquire ECG recordings.
40772786|NCT02150746|PROCEDURE|Peripheral/Central Venous Blood Draw|Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.
40772787|NCT02150746|PROCEDURE|Peritoneal Wash|Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.
40772788|NCT06451146|PROCEDURE|PCI Facilitated with Orbital Atherectomy Device|Percutaneous coronary intervention for coronary artery disease supported by the Orbital Atherectomy Device
40772789|NCT05880524|DRUG|Dornase Alfa|Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.
40772790|NCT05880524|DRUG|Isotonic Saline Solution|Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
40772791|NCT06565013|DRUG|Cabenuva 600/900|Participants will switch to Cabenuva at baseline. The visit schedule, the product administration and the clinical follow-up will be done according to standard of care.
40772792|NCT06565013|OTHER|Self administered questionnaires|Questionnaires on treatment satisfaction (HIVTSQs), quality of life (WHOQoL-HIV-BREF) and drug use assessment (DEBA-D) will be administered at baseline, M5 and M11
40772793|NCT06565013|OTHER|Semi-directed interview|At baseline and M11, participants will conduct a semi-directed interview about the perception of their HIV treatment and the global care they receive as a person living with HIV who is practicing chemsex.
40772794|NCT02465008|DRUG|Levobupivacaine|
40977220|NCT02448420|DRUG|Palbociclib|"Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles."
40977221|NCT02448420|DRUG|Trastuzumab|Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
40977222|NCT02448420|DRUG|Endocrine therapy|Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
40977223|NCT02448420|DRUG|Chemotherapy|Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
41460261|NCT02611323|DRUG|Venetoclax|Participants will receive venetoclax film-coated tablets at doses of 200, 400, 600, or 800 mg (for FL), and 400, 600, or 800 mg (for DLBCL) on Days 1 to 21 of each 21-day cycle. Post-induction venetoclax may continue for up to 8 months, until disease progression or unacceptable toxicity.
40772795|NCT02465008|DRUG|Placebo|
40772796|NCT06418061|DRUG|IBI3005|Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
40772797|NCT05229614|RADIATION|Carbon Ion Therapy|After confirming the disease stability and upon patient inclusion in the study, hypofractionated carbon ion boost will be administered to one site of disease previously untreated. Patient will be irradiated to a single lesion with a total dose of 24 Gy\[RBE\], 8 Gy\[RBE\]/fraction, one fraction/day, for 3 days.
40772798|NCT05229614|DRUG|Immunotherapy (Pembrolizumab)|Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.
40772799|NCT03097640|OTHER|CHAMP|CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
40772800|NCT04432779|OTHER|no intervention|no intervention
40772801|NCT00032812|DRUG|Raclopride|
40772802|NCT06564818|DRUG|CYB003|CYB003 is a synthetic psilocybin analog.
40772803|NCT06564818|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
41301118|NCT04446234|DRUG|Aripiprazole|Use medicine according to patients condition
40772804|NCT06564818|DRUG|Placebo|Placebo
40772805|NCT01324973|BEHAVIORAL|eWellness|A weight management program that includes computerized delivery of evidence-based education regarding diet and physical activity, and peer coaching.
40772806|NCT05807594|BEHAVIORAL|HMZ 2.0 Intervention|The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will receive adaptation). The model-based predictive control system in the HMZ 2.0 digital platform will continually and automatically evaluate GWG, identify when a woman may exceed GWG guidelines, and recommend an adaptation. The registered dietitian will review the data and behavior strategies that are suggested (guided PA workouts, EI cooking demonstrations, customized grocery planning, portion size control, food scales, and meal replacements). Practical, easy-to-adopt examples will be provided (walking in 5-10 min increments throughout the day to increase PA kcal, reduce sitting by 5 min/hour; replace 8 oz of whole milk with skim milk to reduce EI kcal) to facilitate behavior change while adhering to safety standards. Each woman's unique preferences and past successes with strategies are also considered when personalizing the dosage.
40772807|NCT05807594|BEHAVIORAL|Attention Control Intervention|Consistent with guidelines for comparator groups, all women will receive prenatal care offered by recruitment sites with routine provider visits, counseling about prenatal behaviors (e.g., no smoking), and clinical oversight of health. Women randomized to the attention control group will complete the same measurement procedures as the intervention group.
40772808|NCT02085720|DEVICE|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
40772809|NCT04402216|BEHAVIORAL|Child Life-led preparation|Support from a certified child life specialist in preparation for MRI
40772810|NCT04402216|BEHAVIORAL|MRI preparation video|A descriptive video about what to expect when undergoing MRI
40772811|NCT04402216|BEHAVIORAL|KindVR Virtual Reality MRI Preparation Experience|A VR experience to prepare pediatric patients for MRI, to be used in addition to support from a certified child life specialist
40977224|NCT02448420|DRUG|Antibody-Drug Conjugates|3.6 mg/kg iv every 3 weeks
41301119|NCT04446234|DRUG|Ziprasidone|Use medicine according to patients condition
40977225|NCT05248191|BIOLOGICAL|Capsule fecal microbiota material (cap-FMT)|Cap-FMT consists of Lyophilized FMT administered at 5 x 10\^11 bacteria per capsule daily for five days, for a total dose of 2.5 x 10\^12 bacteria.
40977226|NCT05248191|BIOLOGICAL|Colonoscopic fecal microbiota material (colo-FMT)|Colo-FMT consists of rehydrated Lyophilized FMT material administered as a single dose of 2.5 x 10\^12 bacteria as liquid.
40977227|NCT03398395|PROCEDURE|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
40977228|NCT03398395|PROCEDURE|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
41301120|NCT04446234|DRUG|Amisulpride|Use medicine according to patients condition
41301121|NCT04446234|DRUG|Quetiapine|Use medicine according to patients condition
41301122|NCT05657743|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
41301123|NCT02776280|OTHER|Meal|Typical Brazilian meal consisting of rice, beans and meat with vegetables
41301124|NCT04708392|DEVICE|Spinal Cord Stimulator|A spinal cord stimulator is a surgically implanted device that delivers an electrical signal to a patient's spinal cord to reduce the perception of pain
41301125|NCT01054677|BEHAVIORAL|Educational intervention on antibiotic prescribing|Small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials
40977229|NCT05153239|DRUG|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
40977230|NCT05153239|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
40977231|NCT05153239|DRUG|Irinotecan|For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk
41301126|NCT02391506|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
41301127|NCT00003117|DRUG|carboplatin|
41301128|NCT00003117|DRUG|paclitaxel|
41301129|NCT03112213|DRUG|Tocilizumab|Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.
41301130|NCT03112213|DRUG|NSAIDs|Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
41301131|NCT00175175|BEHAVIORAL|"Allied health professional-run osteoporosis service (case-management)"|
41301132|NCT00659919|DRUG|Placebo|
41301133|NCT00659919|DRUG|Trazodone|
41301134|NCT03440216|DRUG|blood sampling|"* temocillin: blood sampling every day for 7 days~* ceftriaxone: blood sampling 12h after administration for 7 days~* meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7"
41301135|NCT03440216|DRUG|Tissue sampling (lung)|Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)
41301136|NCT03440216|DRUG|Collection of fluid samples|Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic ((temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient) concentration when possible during treatment
41460262|NCT04534140|DIETARY_SUPPLEMENT|HBKB Capsule|The botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB) taken daily orally.
41460263|NCT04534140|OTHER|HBKB Supplement Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
40772812|NCT02881827|RADIATION|Low level laser therapy|Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
40772813|NCT02881827|OTHER|Placebo|Simulation of treatment with the device switched off
40772814|NCT02881827|OTHER|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs."
40772815|NCT00982280|DRUG|Tapentadol PR|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
40772816|NCT03078868|DEVICE|Magnetic Resonance Scanner|MRI
40772817|NCT00303407|DRUG|nadroparin|
40772818|NCT05011383|DRUG|High dose testosterone|High dose testosterone is administered subcutaneously once monthly until progression or toxicity
40772819|NCT05986292|DRUG|LY3016859 ISA|Administered intravenously (IV)
40772820|NCT05986292|DRUG|LY3556050 ISA|Administered orally
40772821|NCT05986292|DRUG|LY3526318 ISA|Administered orally
40772822|NCT05986292|DRUG|LY3857210 ISA|Administered orally
40772823|NCT05986292|DRUG|Placebo Oral|Placebo administered orally
40772824|NCT05986292|DRUG|Placebo|Placebo administered IV
40772825|NCT02985944|PROCEDURE|Colonoscopy|Colonoscopy performed in adult consecutive patients for different indications
40772826|NCT04123704|DRUG|Sitravatinib|sitravatinib capsule
40772827|NCT01483170|DRUG|Tablets Fexinidazole|Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
40977232|NCT05153239|DRUG|Topotecan|Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk
41301137|NCT02692820|DIETARY_SUPPLEMENT|Probiotic|The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;
41301138|NCT02692820|OTHER|Placebo Comparator|The placebo contains excipients alone in a gelatin capsule
41301139|NCT05616767|OTHER|Training on self-screening and HPV vaccination administration|Participants will be taught how to do self-screening for HPV-associated cancers using Training on self-screening and HPV vaccination administration. They will also be given HPV vaccination series.
41301140|NCT05232942|OTHER|Headache calendar completion|The patient will complete an in-paper or electronic calendar, depicting the presence/absence of headache, the median intensity and the need of acute medication.
41301141|NCT00524316|DRUG|doxorubicin hydrochloride|Transarterial chemoembolization
41301142|NCT00524316|DRUG|sunitinib malate|Given Orally
41301143|NCT00524316|OTHER|laboratory biomarker analysis|Correlative Study
40772828|NCT01483170|DRUG|Placebo|Placebo fexinidazole
40772829|NCT05034081|PROCEDURE|body contouring|any post-bariatric body contouring surgery included
40772830|NCT01342315|DRUG|33525|Daily dosing
41301144|NCT00524316|PROCEDURE|hepatic artery embolization|Surgical procedure
41301145|NCT00524316|PROCEDURE|quality-of-life assessment|Correlative Study
41301146|NCT03817567|DRUG|recombinant anti-EGFR monoclonal antibody|Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
41301147|NCT03204227|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
41301148|NCT03204227|BIOLOGICAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
41460264|NCT03493035|DIAGNOSTIC_TEST|Computed tomography angiography (3D CTA)|CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.
41460265|NCT03493035|DIAGNOSTIC_TEST|Transcranial color-coded sonography (TCCS)|TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.
40772831|NCT01342315|DRUG|Placebo|Daily dosing
40772832|NCT06315998|DEVICE|Magnetocardiography|Magnetocardiography
40772833|NCT01980264|DEVICE|Harmonic Generation Microscopy|Harmonic Generation Microscopy is a nonlinear optical microscopy.
40772834|NCT03109457|OTHER|oral squamous cell carcinoma|Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
40772835|NCT04023019|BIOLOGICAL|Nuwiq|Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
40772836|NCT04023019|BIOLOGICAL|Octanate|Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
40772837|NCT04023019|BIOLOGICAL|Wilate|Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
40772838|NCT04023019|BIOLOGICAL|Emicizumab|Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
40772839|NCT04023019|BIOLOGICAL|Recombinant factor VIIa (rFVIIa)|Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
40772840|NCT04023019|BIOLOGICAL|Activated prothrombin complex concentrate (aPCC)|Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
40772841|NCT00321932|DIETARY_SUPPLEMENT|calcium|All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
40772842|NCT00321932|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
40772843|NCT00321932|DRUG|zoledronic acid|Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
40772844|NCT03424343|OTHER|Questionnaire bundle|Questionnaires on identity formation and psychosocial functioning, assessed and reported at baseline, one year later, two years later, and five years later.
40772845|NCT03424343|OTHER|Obtaining information from survivors' medical file|After obtaining informed consent, we will access the medical file of participants to obtain information on the diagnosis, time of diagnosis, treatment duration, type of treatment, and relapse (when applicable).
40772846|NCT06167239|OTHER|Threshold inspiratory muscle trainer or ventilator pressure setting inspiratory muscle training techniques|New techniques to train inspiratory muscles in mechanically ventilated patients
40772847|NCT05935137|DIAGNOSTIC_TEST|Coagulation test on device ClotPro|The blood sample for coagulation test on device ClotPro will be take for both group and the test will be provided.
41460266|NCT00605150|RADIATION|TheraSphere-Yttrium 90 microsphere|TheraSphere is delivered to the liver via a catheter placed into the femoral artery and guided by fluoroscopy to the hepatic artery. Once the catheter is properly positioned, the physician infuses TheraSphere, which localizes preferentially in the tumor.
40772848|NCT06135090|BEHAVIORAL|Trauma Recovery Program (official title TBD)|See arm description
40772849|NCT05614882|BEHAVIORAL|Written Stroke Education|The written education will be provided in the stroke folder currently in use by the Yale New Haven Health system. This written information is presented in a stroke folder and includes how to respond to the signs of stroke, dialing 9-1-1, following up with a health care provider after hospitalization due to a stroke and the importance of medication management as well as stroke risk factors, healthy eating habits, exercise habits, common changes following a stroke, stroke recurrence and stroke types. After being given two days to review the materials, patients will be asked to complete the stroke knowledge test (SKT). All participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
40977233|NCT05153239|DRUG|Lurbinectedin|Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
40977234|NCT04461730|DEVICE|deep brain stimulation|Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation
40977235|NCT06372782|DEVICE|Restylane Skinboosters Vital Lidocaine|Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.
41460267|NCT01234961|BEHAVIORAL|Redesigning Daily Occupations|The ReDO is a 16-week group-based programme, comprising three phases. Phase I covers five weeks and has a special focus on occupational self-analysis, while Phase II, also comprising five weeks, is concentrated around goal setting and strategies for accomplishing desired changes in the patterns of everyday activities. During these ten weeks the group meets twice a week and each session lasts for 2½ hrs. Phase III consists of work placement for six weeks, if possible in relation to the woman's ordinary work but otherwise at another relevant work place. During Phase III the group meets three times (weeks two, four and six) in order to monitor the group placement. The groups are led by two licensed occupational therapists specifically trained for the ReDO programme.
41460268|NCT01234961|OTHER|Care as usual|The CAU group gets follow-ups by an officer at the Social Insurance Office, including contacts with the employer, but the additional support varies largely, from receiving relevant medical care, if any, to physical therapy and to more comprehensive rehabilitation programmes.
41460269|NCT05257694|PROCEDURE|Surgery|hepatectomy
40772850|NCT05614882|BEHAVIORAL|Verbal Stroke Education|Participants in the verbal education group will be provided with education over two days from therapists including occupational therapy, physical therapy, speech therapy as well as a physician or nurse. The disciplines will present general stroke information including causes, risk factors, prevention, nutrition and exercise recommendations, importance of managing chronic conditions and the significance of medication compliance. After the verbal education topics are presented, the participants will be tested with the stroke knowledge test (SKT) to measure learning. All the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
40772851|NCT01260779|DRUG|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
40772852|NCT02631785|OTHER|Cognitive Behavioral Therapy|"Psychologists will deliver the COPING CAT treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session."
40772853|NCT05844982|DRUG|Faricimab|6.0 mg intravitreal injection at randomization and every 3 months
40772854|NCT05844982|DRUG|fluocinolone acetonide|0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
40772855|NCT03427619|DRUG|OK432|OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
40772856|NCT05838287|DRUG|Pioglitazone|Participants will be taking Pioglitazone tablets 1/day for 24 weeks.
41460270|NCT05257694|PROCEDURE|Ablation (Microwave ablation or Radiofrequency ablation)|image-guided ablation
41460271|NCT00772148|DRUG|LCP -Tacro|"LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)"
41460272|NCT00772148|DRUG|Prograf|"Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)"
41301149|NCT02687594|DRUG|sucroferric oxyhydroxide|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
41460273|NCT05653362|DEVICE|Coconut Oil|Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.
41460274|NCT05653362|DEVICE|Commercial Ultrasound Gel|Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.
41460275|NCT05355519|OTHER|Electronic curriculum and instructor-led course, then placebo|Electronic curriculum and instructor-led course
41301150|NCT04971395|DRUG|XTMAB-16 2mg/kg|Biological XTMAB-16 IV infusion single dose
40772857|NCT05838287|DRUG|Placebo|Placebo for Pioglitazone
40772858|NCT02552225|DRUG|Amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
40772859|NCT02552225|OTHER|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
40772860|NCT05706350|BIOLOGICAL|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
40772861|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (2g per day)|Participants have to consume 4 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 2g daily
40772862|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (3g per day)|Participants have to consume 6 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 3g daily
40772863|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (4g per day)|Participants have to consume 8 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 4g daily
40772864|NCT05706350|DIETARY_SUPPLEMENT|Control soft chews|Participants have to consume 6 control soft chews per day that does not contain plant stanols
40772865|NCT06053372|DEVICE|Apple Watch|Wearable monitor for heart rate and arrhythmia detection
41141327|NCT01499251|DRUG|Phase 1 Dose Escalation|Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
41141328|NCT01499251|DRUG|Phase 1b|Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
41141329|NCT01499251|DRUG|Ancillary Study|Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
40977236|NCT06372782|DEVICE|Restylane Vital|Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned
41460276|NCT05355519|OTHER|Placebo, then electronic curriculum and instructor-led course|Electronic curriculum and instructor-led course
40772866|NCT04778566|DIAGNOSTIC_TEST|Cologuard test|Cologuard is a stool-DNA screening test for detecting colon cancer
40772867|NCT03033784|DRUG|8 International Units (IU) of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 8IU.
40772868|NCT03033784|DRUG|24IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 24IU.
40772869|NCT03033784|DRUG|48IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 48IU.
40772870|NCT03033784|DRUG|Placebo|Participants will receive an intranasal placebo to match the oxytocin doses.
40772871|NCT04598425|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
40772872|NCT05450211|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in group SFI.
40977237|NCT02113592|BEHAVIORAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
40977238|NCT04980690|BIOLOGICAL|IBC0966|IBC0966 is an investigational product.
40977239|NCT06506227|BEHAVIORAL|Low risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine
41301151|NCT04971395|DRUG|Placebo|Placebo; IV infusion single dose
41460277|NCT00344513|DRUG|Beta-blockers including Carvedilol|
41460278|NCT00344513|DRUG|ACE inhibitors|
41460279|NCT02293486|DIETARY_SUPPLEMENT|Pomegranate juice|Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
40977240|NCT06506227|BEHAVIORAL|Medium risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces
40977241|NCT06506227|GENETIC|High risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces + Specialized Inpatient Rehabilitation
40772873|NCT05450211|DEVICE|Patient controlled analgesia|Patient-controlled analgesia will be used for pain control after surgery in both groups.
40772874|NCT01058746|OTHER|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
40977242|NCT06506227|BEHAVIORAL|Control group COBB 10-20°|Specific Exercise Therapy
40977243|NCT06506227|BEHAVIORAL|Control group COBB 20-45°|Orthopedic Braces + Specific Exercise Therapy
40977244|NCT06506227|BEHAVIORAL|Control group COBB >45°|Orthopedic Braces + Specific Exercise Therapy + Recommended Surgery
40977245|NCT06506227|OTHER|Experimental group (AIS group)|Molecular marker exploration and validation
41141330|NCT06417372|DIAGNOSTIC_TEST|intraoperative fluorescent staining combined with microscopy|Through the modified formulation of sodium fluorescein and methylene blue, the surface of the suspected cut edge of the patient's glioma was stained intraoperatively, and the surgical microscope image acquisition and processing system was used to determine whether the cut edge of the surgically resected tissue was positive or not.
41141331|NCT06425289|OTHER|Macrohemodynamic parameters|"Macrohemodynamic parameters will be estimated with transpulmonary thermodilution every 6 hours during the intervention period (5 days).~* Cardiac index~* Extravascular lung water index~* Pulmonary vascular permeability index~* Cardiac function index~* Global end-diastolic volume index~* Central venous pressure~* Fluid responsivness status (passive leg rising test)"
41141332|NCT03488498|OTHER|questionnaires|Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.
41141333|NCT00605605|DRUG|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
41141334|NCT01071317|DRUG|Naproxen|Naproxen 500mg PO bid prn headache
41141335|NCT01071317|DRUG|Sumatriptan|100mg po q day prn headache
41141336|NCT01071317|BEHAVIORAL|Migraine education|Educational program available through NIH/ national library of medicine/ X-plain
41141337|NCT01071317|BEHAVIORAL|Reenforcement of diagnosis|Patient advised has migraine headache and how the headache meets migraine criteria
41141338|NCT01071317|OTHER|Typical care|Care to be determined by attending physician
41141339|NCT00228657|DRUG|4% Albumin / 0.9% Sodium Chloride|
41141340|NCT06157684|BEHAVIORAL|Postprandial ambulation|See arm description
41141341|NCT03677167|OTHER|walking on a treadmill|Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
41141342|NCT05897307|DRUG|Ropivacaine|dexmedetomidine
41301152|NCT04971395|DRUG|XTMAB-16 4mg/kg|Biological XTMAB-16 IV infusion single dose
41301153|NCT02908958|BIOLOGICAL|PEG-somatropin|High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
40977246|NCT06506227|OTHER|Control group (healthy control)|Molecular marker exploration and validation
40977247|NCT06506227|OTHER|Controlled follow-up before and after AIS|Construction and validation of AIS risk prediction model completed
40977248|NCT04218305|DIAGNOSTIC_TEST|Serum Level Of Fetuin A|
40977249|NCT03171792|OTHER|semi-structured interviews|Semi-structured face to face or telephone interviews with an open-ended approach. Duration: about 45 minutes. Audio-recorded. Exploration of the experience of taking care of the suffering adolescents.
40977250|NCT04520737|BEHAVIORAL|Physical Prehabilitation|The prehabilitation program consists of the following interventions: in-hospital high-moderate intensive exercise training, nutritional assessment and high-protein supplementation, smoking cessation, psychological support and Comprehensive Geriatric Assessment.
40977251|NCT01464489|DRUG|Atropine|"Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.~Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition"
40977252|NCT01464489|DRUG|Normal saline|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
40977253|NCT03668314|DRUG|RDN-929|Single dose from 2 mg to TBD
40977254|NCT03668314|DRUG|Placebo oral capsule|Matching placebo Single dose
41301154|NCT02908958|BIOLOGICAL|PEG-somatropin|Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
41301155|NCT04129684|OTHER|Probiotics|subgingival delivery and lozenges
41301156|NCT02948140|PROCEDURE|MRI|
40772875|NCT01058746|OTHER|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
40772876|NCT02478541|OTHER|Sugar study|Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
40772877|NCT05562427|BEHAVIORAL|Gold-Standard Online Behavioral Obesity Treatment|Rx Weight Loss (RxWL) is an online BOT that consists of: (a) tailored weight loss, calorie, and physical activity goals. (b) 12 weekly 10-15 minute multimedia lessons for training in behavioral weight loss skills followed by 9 monthly lessons for continued weight loss. Lessons incorporate video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving. Example topics include restaurant eating, changing the home environment, and obtaining social support. (c) Online tools for self-monitoring weight, diet, and physical activity that interface with popular tracking apps; and (c) Weekly, and eventually monthly, automated feedback on progress to date (delivered as text appearing on the platform). If goals are not met participants receive strategies to improve weight loss, along with encouragement. To ensure engagement, email reminders are sent to participants who have not visited the platform on a given week.
40772878|NCT01232140|OTHER|CRP-guided antibiotic treatment|If CRP\> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =\< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
40772879|NCT03453216|BEHAVIORAL|neuropsychological tests|"Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone)."
40772880|NCT05575102|OTHER|Walking Football|"Walking Football (Soccer): Typical football rules apply but without running.~Participants will play at a local sports hall for 6-weeks, (2-hour per week). Time will be split between warm-up, football practice drills, and small-sided games."
40772881|NCT02363166|OTHER|Acute Abscess Group|Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection.
40772882|NCT04446052|DRUG|GM-CSF priming|
40772883|NCT04446052|DRUG|Placebo|Placebo
40772884|NCT05594186|DRUG|Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.|Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.
40772885|NCT06325631|PROCEDURE|Intra-articular injection to lumbar facet joint|to treat low back pain caused by facet joint syndrome
40772886|NCT03601026|BEHAVIORAL|Genetic counselling|Participants will receive information on risk/protective factors and causes of mental illness. Participants are not required to receive numeric/genetic risk information. Participants who choose to receive genetic and/or numeric risk information will be counselled on their risk of NOT developing and of developing SMI based on their genetic test results and/or family history information they provide. Risk estimates will be derived by genetic counsellors, according to standard practice guidelines. Participants who receive genetic information will be counselled on the possible influence of cannabis use on risk of mental illness based on their genotype. Participants who choose to not receive genetic information will be counselled on the influence of cannabis on mental health.
40772887|NCT05634005|BEHAVIORAL|Clinical Decision Support|In blood product order entry within the electronic health record, the ordering provider is required to select an indication for the blood product order. If the patient's laboratory values are not in line with the guideline indication selected, a clinical decision support alert will fire and be shown to the ordering provider. This alert will inform the provider that the order is outside institutional guidelines and the provider has the option to cancel the order (or bypass the order and select a reason for proceeding with the order).
40772888|NCT01527032|DRUG|melphalan, thalidomide and dexamethasone|
40772889|NCT02943161|DIETARY_SUPPLEMENT|L-Citrulline|The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
40772890|NCT03346837|DRUG|BMS-986205|BMS-986205
40772891|NCT03346837|DRUG|Itraconazole|Oral solution
40772892|NCT03346837|DRUG|Rifampin|Tablet
40772893|NCT06015932|BEHAVIORAL|Cognitive Behavior Therapy|Participate in CBCSM group sessions
40772894|NCT06015932|OTHER|Questionnaire Administration|Complete questionnaires
40772895|NCT02947971|DEVICE|Experimental OFDI Imaging|Imaging of the esophagus with a compact OFDI system and distal scanning catheter
40772896|NCT03220633|DRUG|ATB-346|
40772897|NCT03220633|DRUG|Placebo|
40772898|NCT06179537|DRUG|BLU-5937|Single and multiple doses assessment
40977255|NCT03668314|DRUG|RDN-929 TBD dose|Fed vs fast dose TBD based upon results of previous cohorts
40977256|NCT03668314|DRUG|RDN-929|Multiple dose based on results of previous cohorts
40772899|NCT03456076|DRUG|Alectnib|Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
40977257|NCT03668314|DRUG|Placebo oral capsule|Matching placebo multiple dose
40772900|NCT03456076|DRUG|Cisplatin|"Participants will receive Cisplatin 75 milligrams per square meter (mg/m\^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
40772901|NCT03456076|DRUG|Vinorelbine|Participants will receive Vinorelbine 25 mg/m\^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
40977258|NCT05803057|DEVICE|TMS stimulation treatment|Using the TMS treatment coli to stimulation with high frequency
40977259|NCT05803057|DEVICE|TMS stimulation sham-treatment|Using the TMS sham-treatment coli to stimulation with high frequency
40977260|NCT00525460|BEHAVIORAL|Fertility-Sparing Survey|A questionnaire completed either in the clinic or at home
40977261|NCT05240456|DRUG|Beta3-Agonists, Adrenergic|The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.
40977262|NCT05240456|DRUG|Anticholinergic drug, Solifenacin|Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
40977263|NCT03916328|DRUG|B/F/TAF|A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
40977264|NCT03916328|DRUG|TDF/3TC/EFV or DTG or NVP|A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.
40977265|NCT03916328|OTHER|DMPA|Two thirds of the women will be on DMPA for contraception.
40977266|NCT02120729|OTHER|Genotype-guided care|Pharmacogenetic alerts are furnished to the clinician within 2 days of admission. Buccal cell DNA is analyzed for 21 common CYP2D6 polymorphisms and results quantified into a drug metabolism reserve index to establish levels of sub-normal function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated 50% of patients who are poor or rapid metabolizers, CEMS will proscribe medications which are major CYP2D6 substrates.
40977267|NCT03227029|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L|10\^6 plaque-forming units (PFU); administered as nose drops
41141343|NCT02822599|DRUG|RiaStAP|To decrease post-operative bleeding volume.
41141344|NCT02822599|DRUG|Saline|Placebo consisting of normal saline 0.9%
40977268|NCT03227029|BIOLOGICAL|RSV 276|10\^5 PFU; administered as nose drops
40977269|NCT03227029|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
40977270|NCT00634894|DRUG|Femara|2.5 mg by mouth daily x 12 weeks
40977271|NCT00634894|DRUG|Placebo|Placebo capsule by mouth daily x 12 weeks
40977272|NCT03906123|DRUG|NBP|NBP soft capsules
40977273|NCT03906123|DRUG|Placebos|Soft capsules manufactured to mimic NBP
41141345|NCT03390166|BIOLOGICAL|GPO Tri Fluvac vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
41141346|NCT03390166|BIOLOGICAL|Licensed influenza vaccine|The comparator licensed influenza vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
41141347|NCT03471117|DRUG|Pioglitazone|Pioglitazone 15mg daily for 1 month
41141348|NCT03471117|OTHER|Placebo|Placebo pills for 1 month
41301157|NCT02948140|PROCEDURE|Abdominal scanner|
41301158|NCT05863689|DIAGNOSTIC_TEST|Spectralis SD-OCT|Optical Coherence Tomography
40772902|NCT03456076|DRUG|Gemcitabine|Participants will receive Gemcitabine 1250 mg/m\^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
40772903|NCT03456076|DRUG|Pemetrexed|"Participants will receive 500 mg/m\^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
40772904|NCT03456076|DRUG|Carboplatin|For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
40772905|NCT05450978|DRUG|Lamotrigine|Anti-seizure concentrations
40772906|NCT05450978|DRUG|Levetiracetam|Anti-seizure concentrations
40772907|NCT01896973|DEVICE|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
40772908|NCT05970367|OTHER|Intensive rehabilitation programme|"Intensive rehabilitation using advanced technology, based on the patient's goals.~Including cardiovascular fitness training, goal-oriented training, physiotherapy with and without advanced technology and self-management."
40772909|NCT05053685|DIAGNOSTIC_TEST|Measurement of Urine and plasma metanephrines|Measurement of Urine and plasma metanephrines
40772910|NCT06571942|DRUG|Vilanterol / Umeclidinium (25/62.5 mcg)|One inhalation daily from Ellipta device for three months
40772911|NCT06571942|DRUG|Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)|One inhalation daily from Ellipta device for three months
40772912|NCT06571942|DRUG|Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg|Two inhalations twice daily form pMDI device for three months
40772913|NCT06571942|DRUG|Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg|Two inhalations twice daily form pMDI device for three months
40772914|NCT06183021|PROCEDURE|Vital pulp cryotherapy|Shaved ice made from sterile distilled water will be applied around the treated tooth especially in contact with amputated pulp tissue until totally dissolves.
40772915|NCT06183021|PROCEDURE|Intracanal cryotherapy|After mechanical preparation, a 5-minute final irrigation with 20 mL cold saline (2.5 Centigrade degrees) will be applied using a negative pressure irrigation technique per canal.
40772916|NCT04977232|DRUG|Escitalopram|Selective serotonin reuptake inhibitors (SSRI) were most commonly used first line pharmacotherapy for depression.
40772917|NCT04977232|BEHAVIORAL|Game intervention|Participants will be instructed to play the commercial video game for about 30-60 minutes at least three times per week.
40772918|NCT05600855|DRUG|Ruxolitinib|"Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens."
40772919|NCT04150445|BEHAVIORAL|Internet treatment for overweight and obese patients|The behavioral treatment is provided via the Internet and comprises 12 modules that the patient follows for 6 months. The treatment modules include self-monitoring, goal setting, relapse prevention, psycho-education about nutrition, eating behavior, physical activity, sleep and stress management. Each module ends with one or more exercises to be completed before the next module is activated.
40772920|NCT03947463|PROCEDURE|PECS block|After the induction of general anesthesia, PECS block was administered patients via ultrasound guided technique. We used Mindray M7 Portable ultrasound system using linear probe with (5-10 MHz) frequency. After cleaning the infra clavicular and axillary region with 2% chlorhexidine in 70% Alcohol solution, ultrasound probe was placed in the infraclavicular region and pectoral major and minor were identified. After identification of the landmarks, 20 gauge 50mm Visoplex needle was inserted in-plane direction. 20ml of 0.25% bupivacaine (within the safe limit of its dose) was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualized on the ultrasound screen.
40772921|NCT00091156|DRUG|gefitinib|
40772922|NCT00091156|PROCEDURE|adjuvant therapy|
40977274|NCT06124144|DRUG|Oleylphosphocholine|The trial is a dose escalation trial that follows a 3+3 approach. The sample size is determined by a decision-making algorithm and by the tolerability of the study drug in the study participants. This design follows predetermined rules that help identify notable toxicities in time with a reasonable degree of accuracy. The initial dose will be 50mg OlPC (1 capsule) and participants in subsequent cohorts will receive 100mg (2 capsules), 150mg (3 capsules), 200mg (4 capsules), 250mg (5 capsules), or 300mg (6 capsules) if the previous doses are tolerated. The study ends when the last cohort is completed or when it is determined that a dose (within a cohort) is not tolerable.
40977275|NCT00208611|DIETARY_SUPPLEMENT|Vitamin B12 Supplementation|1000 micrograms daily
40977276|NCT01195415|DRUG|Gemcitabine Hydrochloride|Given IV
40977277|NCT01195415|OTHER|Laboratory Biomarker Analysis|Correlative studies
41301159|NCT04356144|DIAGNOSTIC_TEST|Thrombin Generation Assay (TGA)|"TGA via a fluorimetric module. Coagulation cascade is activated upon addition of different concentrations of tissue factor and phospholipids. The fluorogenic substrate Z-Gly-Gly-Arg-AMC (ZGGR-AMC) is cleaved by formed thrombin over time. By plotting the changes in fluorescence as a function of time (cnt/min), it depicts the Thrombin Generation Curve (thrombin generated - plotted against time). The area under the thrombin curve is defined as the endogenous thrombin potential (ETP)."
41301160|NCT04356144|DIAGNOSTIC_TEST|Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)|Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.
41460280|NCT02873260|BIOLOGICAL|TetraVax-DV-TV005|TetraVax-DV-TV005 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^4.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10\^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10\^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
41301161|NCT03488472|DEVICE|NovoTTF-200A|Begins within 7 days of SRS and continues until progression, death, or unacceptable toxicity.
41301162|NCT03488472|RADIATION|Stereotactic Radiosurgery (SRS)|SRS will begin within 21 days of study enrollment for 5-6 Gy per fraction for a total of 25 or 30 Gy.
41460281|NCT02873260|BIOLOGICAL|rDEN3Δ30|Administered at a dose of 10\^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
41460282|NCT02873260|BIOLOGICAL|Placebo|Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
41460283|NCT01613937|BEHAVIORAL|Dulce Mother lifestyle training program|12 once weekly culturally tailored lifestyle management sessions
40772923|NCT01655056|DRUG|YM150|oral
40772924|NCT01655056|DRUG|Placebo|oral
40772925|NCT00221858|PROCEDURE|Ultrasound guided blocks|
40772926|NCT00730327|DEVICE|BioEnterics® Intragastric Balloon|Inflatable balloon inserted into the stomach.
40772927|NCT00730327|OTHER|Behavioral modification|Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
40772928|NCT06565130|OTHER|Attention skills training|Attention skills program planned with occupational therapy principles
40772929|NCT01869673|DEVICE|Face Mask|Patients will be ventilated trough a face mask first and trough a oral mask thereafter
40772930|NCT01869673|DEVICE|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
40772931|NCT06101485|DEVICE|Telerehabilitation|Telerehabilitation platform: Hjerteportalen, blood pressure monitor (iHealth(neo/BP5s), weight scale (iHealth Lina), Activity tracker (FitBit inspire 3), ECG monitor (AliveCor KardiaMobile), sleep sensor (Emfit QS), video consultation (VDX by MedCom)
40772932|NCT00506766|BEHAVIORAL|Bladder Health Class consisting of 6 weekly group sessions|1 time
40772933|NCT00506766|BEHAVIORAL|Practice PFMT and BT|As needed for 4 years
40772934|NCT00506766|BEHAVIORAL|Clinic examination for pelvic muscle function|1/year for 4 years
40772935|NCT00506766|BEHAVIORAL|Record keeping in 3-day voiding diary|Every 6 months for 4 years
40772936|NCT03895372|DRUG|PF-06826647 or Placebo|Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
40772937|NCT03895372|DRUG|PF-06826647|Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
40977278|NCT01195415|DRUG|Vismodegib|Given PO
40977279|NCT02566226|DRUG|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
41460284|NCT03275857|DRUG|Cisplatin|Weekly IV
41460285|NCT00063609|DRUG|zoledronic acid|
41460286|NCT01887795|DRUG|Erlotinib|
41460287|NCT01887795|DRUG|WBRT|
41460288|NCT00550147|DRUG|Oros Methylphenidate|"Oros methylphenidate will be titrated over 3 visits according to the following schedule:~* Visit 2 dose of 18 mg QAM~* Visit 3 dose of 36mg QAM~* Visit 4 dose of 54mg QAM."
40977280|NCT02566226|DRUG|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
41301163|NCT03417284|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HSCT
41301164|NCT03417284|BIOLOGICAL|Filgrastim-sndz|Given SC
41301165|NCT03417284|DRUG|Melphalan Hydrochloride|Given IV
41460289|NCT00550147|DRUG|quetiapine|"Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~* Visit 5 dose of 25mg BID~* Visit 6 dose of 50mg BID~* Visit 7 dose of 100mg BID~* Visit 8 dose of 200mg BID~* Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule."
40772938|NCT05135754|DEVICE|Heylo|Test of the supporting product (test product) for a 12 weeks period. No additional intervention will be conducted. A few follow up nurse calls to assess few endpoints together with subject. All remaining endpoints are captured via surveys send to the subjects every 14 days.
40772939|NCT04990583|BEHAVIORAL|Face-to-Face PrEP Adherence Intervention Based on LifeSteps|This single session intervention, based on LifeSteps, will occur with a study adherence coach either in-person or remotely via HIPAA compliant videoconferencing software. The topics covered during the session will include: experience taking PrEP, risk behavior education, mental health and substance use as barriers to adherence, other barriers to adherence, formulating a dosing schedule, storing and transporting medications, and response to slips in adherence. Participants assigned to the Carium condition will also receive an introduction to the Carium app.
41301166|NCT05516901|PROCEDURE|The erector spinae plane block group|The probe should then slowly be moved laterally until the transverse process is visible. The 100 mm, 25-gauge needle should be inserted using an in-plane approach in the cephalad to caudal direction and advanced under ultrasound guidance towards the transverse process; once the needle tip is below the erector spinae muscle, a small bolus of local anesthetic should be given. The erector spinae muscle should be visualized, separating from the transverse process. After aspiration the local anesthetic (20 ml of 0.25% bupivacaine was injected. Technique was repeated on the other side.
41301167|NCT05516901|PROCEDURE|Control group|Patients in this group will receive general anesthesia alone.
41301168|NCT06100471|OTHER|Observational study|Observational study in different tissues in identifing new genetic markers related to endometriosis disease
41301169|NCT00307515|DRUG|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
40772940|NCT04990583|BEHAVIORAL|Adherence Coaching Facilitated by Carium Adherence App|The Carium app will be used to deliver medication reminders to participants, track medication adherence, engage in two-way secure messaging with participants, and connect with participants through a secure video feature. The adherence coach will use the secure messaging feature to support the participant with their adherence
40772941|NCT05994287|DRUG|Aspirin|The patients received aspirin in a dose of 100 mg orally daily.
41460290|NCT01867190|BIOLOGICAL|ASCT01 (Autologous Stem Cell Transplantation)|Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
40772942|NCT05994287|DRUG|Ketorolac|The patients received ketorolac in a dose of 90 mg mg orally daily.
40772943|NCT05994287|DRUG|Celecoxib|The patients received celecoxib in a dose of 400 mg orally daily.
40772944|NCT02989857|DRUG|AG-120|Tablet administered orally
40772945|NCT02989857|DRUG|Placebo|Tablet administered orally
40772946|NCT00655655|DRUG|everolimus|Given orally
40772947|NCT00655655|DRUG|vatalanib|Given orally
40772948|NCT00655655|OTHER|pharmacological study|Correlative study (Cohort IIA only)
40772949|NCT00655655|OTHER|laboratory biomarker analysis|Correlative study (Cohorts IIA and IIB)
40772950|NCT00655655|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative study (Cohort IIA only)
40772951|NCT00655655|PROCEDURE|ultrasound imaging|Correlative study (Cohorts IIA and IIB)
40772952|NCT03511846|DRUG|Oral capsaicin|Subjects will drink a solution with capsaicin
40772953|NCT03511846|DRUG|Topical capsaicin|Capsaicin cream will be applied to the skin of the forehead, cheek, or leg
40772954|NCT03511846|DRUG|Intranasal capsaicin|Capsaicin cream will be applied to the nostril
40772955|NCT03511846|OTHER|Cold Water Irrigation|Subjects will be asked to drink up to 2000 ml of cold water or ice water (temperature 0-10 degrees Celsius) as fast as possible, either continuously or intermittently (i.e. 200-800 ml at a time)
41460291|NCT03133728|DIAGNOSTIC_TEST|Alere Q Testing|Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite (i.e. community, household, or facility level). Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 4 routine visits after ART initiation (3 months). Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation.
41460292|NCT00514150|DRUG|Sodium Bicarbonate plus normal saline 0.9%|IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
41460293|NCT00514150|DRUG|normal saline 0.9%|IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
41460294|NCT00338390|DRUG|Abacavir|Change tenofovir to abacavir
41460295|NCT00338390|DRUG|Didanosine|Increase didanosine dose to 400 mg/day if weight is \> 60 Kg. or to 250mg/day if weight is \< 60 kg.
41460296|NCT00338390|DRUG|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
40772956|NCT03511846|OTHER|Medical Air|Subjects will be exposed to medical air
40772957|NCT03511846|DRUG|Low Flow Oxygen|Subjects will be exposed to oxygen gas between 1-9 L/min
40772958|NCT03511846|DRUG|High Flow Oxygen|Subjects will be exposed to oxygen gas between 10-25 L/min
40772959|NCT01613651|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
40772960|NCT01613651|OTHER|questionnaire administration|Ancillary studies
40772961|NCT01613651|OTHER|intraoperative complication management/prevention|Undergo placement of pelvic drain
41301170|NCT00307515|DEVICE|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
41301171|NCT06187844|PROCEDURE|Inguinal exploration|Inguinal exploration will be done for all the included patients.
40772962|NCT03552029|DRUG|Quizartinib|20 or 30 mg tablets for oral administration
40772963|NCT03552029|DRUG|Milademetan|5, 20, 80 or 200 mg capsules for oral administration
40772964|NCT03552029|DRUG|Milademetan|5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized
40772965|NCT02600650|DIETARY_SUPPLEMENT|Testosterone boosting supplement|Proprietary formulation of Testosterone boosting supplement administered daily
40772966|NCT02600650|DIETARY_SUPPLEMENT|Placebo Comparator|Daily administration of Placebo Comparator
40772967|NCT00302822|DRUG|enfuvirtide|from week 0 to 24
40772968|NCT00302822|DRUG|emtricitabine/tenofovir|1 pill/day
40772969|NCT00302822|DRUG|lopinavir or efavirenz|investigator choice
40772970|NCT01356368|DRUG|Cisplatin, Gemzar, Docetaxel, Alimta|Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
40772971|NCT06219707|DEVICE|Acupuncture needles|The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
40772972|NCT01033669|DEVICE|CRC-749|There is no drug being used. This is a device.
40772973|NCT01033669|DEVICE|Diskus|There is no drug being used. This is a device.
41301172|NCT06187844|PROCEDURE|Laparoscopy|All patients will have abdominal laparoscopy first to assess the location of the impalpable testis, the inguinal canal and the cord structures.
40772974|NCT01033669|DEVICE|Twisthaler|There is no drug being used. This is a device.
40772975|NCT01033669|DEVICE|Miat Monohaler|There is no drug being used. This is a device.
40772976|NCT00829244|DRUG|GONAL f® prefilled pen|GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
40772977|NCT00829244|DRUG|GONAL f® prefilled pen|GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
40772978|NCT03925467|OTHER|Acupuncture|"Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21."
40772979|NCT03208790|DRUG|Nigella sativa buccal tablets 10mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg
40772980|NCT03208790|DRUG|Nigella sativa buccal tablets 5mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg
40772981|NCT03208790|DRUG|Placebo buccal tablets|capsules with the same color and form as the active ones but without active ingredient will be given to the patients
40772982|NCT04093453|OTHER|Placebo (Sodium Chloride)|Participant receive Placebo (Sodium Chloride)
40772983|NCT04093453|OTHER|Exercise|1 hour exercise
40772984|NCT04093453|DIETARY_SUPPLEMENT|Sodium Propionate|Participant receive Sodium Propionate
40772985|NCT02081703|DRUG|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
40772986|NCT02081703|DRUG|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
40772987|NCT02081703|DRUG|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
40772988|NCT02081703|DRUG|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
40772989|NCT00889330|DRUG|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
40772990|NCT00889330|DRUG|Placebo|Vehicle without active, one drop in each eye at each of two visits.
40772991|NCT05844618|DRUG|Triamcinolone Acetonide (Aristocort® C)|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
40977281|NCT00258531|DEVICE|Olympus ScopeGuide®, 3-dimentional magnetic imager|
40772992|NCT05844618|DRUG|Vehicle|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
40772993|NCT03661099|DIAGNOSTIC_TEST|colonoscopy|endoscopists' performance outcome
40977282|NCT03856164|DRUG|Tranexamic Acid|Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
40977283|NCT03856164|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
40977284|NCT04343261|BIOLOGICAL|Convalescent Plasma|treatment with 2 Units of convalescent plasma
40977285|NCT03966378|OTHER|Grape seeds extract|Grape seeds extract powder
40977286|NCT03966378|OTHER|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste
40977287|NCT00845689|DRUG|placebo|NaCl 0,9 %
41141349|NCT05684809|OTHER|Post Isometric relaxation Technique (PIR)|In PIR intervention, the patients were requested to lie down in a supine position and their neck was in a lateral flexion to the opposite side so that the target upper Trapezius muscle fibers would be in a lengthened position. The therapist performed a moderate isometric contraction (approximately 75% of maximal) of upper Trapezius muscles, held it for 5 seconds, then relaxed for 3 seconds before moving the cervical spine into the new barrier. In each session, this technique was repeated for four times, on alternate days for three weeks.
40772994|NCT05007704|BEHAVIORAL|Global Experts Consensus opinion using Delphi Methodology|The Investigators will conduct iterative Delphi Rounds with Global experts to achieve consensus on Competencies required for Anesthesiologists to manage critically ill medical and surgical patients in ICU
40772995|NCT02670291|DEVICE|MagPro Cool-B65A/P, Magventure|combined active and sham coil
40772996|NCT02670291|DEVICE|MagPro Cool-B65A/P, Magventure|combined active and sham coil
40772997|NCT03757494|DEVICE|Alpha Stim|Use of Alpha Stim Device
40772998|NCT04846946|BEHAVIORAL|Hey, Friend|"Intervention in development. However, we will use intervention mapping and the designing for dissemination approach, informed by self-reported qualitative data, to develop the Hey, Friend modules. The mHealth intervention will include three modules that include multiple sub-topics (e.g., What is HIV?; How do I protect myself from HIV?; What is PrEP?, etc.), deliver culturally appropriate counseling content in community settings, juvenile court system, clinics, and schools; will include Motivational Interviewing components that are effective in evoking behavior change while being acceptable to adolescents and parents, and will include ongoing support through a text reminder to maximize the likelihood of initiating HIV prevention through testing and PrEP."
40772999|NCT06569823|BIOLOGICAL|Z-1018|Formulation for injection
40773000|NCT06569823|BIOLOGICAL|Shingrix|Formulation for injection
40977288|NCT00845689|DRUG|adenosine|intravenous infusion of adenosine 0, 2 %
40977289|NCT00845689|DRUG|adenosine|intravenous infusion of adenosine 0,2 %
40977290|NCT00845689|PROCEDURE|Liver resection|Liver resection with Pringle maneuver
40977291|NCT03599024|PROCEDURE|PCEA|The patients were able to control the administration of analgesics by themselves.
40977292|NCT03599024|PROCEDURE|Non-PCEA|The patients were receiving analgesics according to the physician's prescription.
40977293|NCT03599024|PROCEDURE|Total hip replacement|All patients enrolled in the study were indicated for total hip replacement surgery.
40977294|NCT00734903|BEHAVIORAL|A Woman's Path to Recovery|WPR is a gender-specific therapy model for women with substance use disorder. It uses A Woman's Addiction Workbook to provide education and coping skills. In this trial it was conducted in 12 weekly individual sessions.
40977295|NCT00734903|BEHAVIORAL|12-Step Facilitation|12SF is an evidence-based therapy designed to facilitate early recovery from substance addiction. It is an individual model consisting of 12 sessions that use the principles of 12-step groups such as Alcoholics Anonymous, and strongly emphasizes participation in those. In this trial the model was conducted weekly.
40773001|NCT01535482|BEHAVIORAL|Cognitive Therapy|Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
40773002|NCT01535482|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
40773003|NCT00105066|DRUG|Metformin|850mg tablet once a day for one month, then twice a day for 3 months
40773004|NCT00105066|DRUG|Placebo|placebo tablet once a day for one month, then twice a day for 3 months
40773005|NCT00936936|DRUG|Gemcitabine|1800 mg/m\^2 IV over 3 hours on Days -5 to Day -2.
40773006|NCT00936936|DRUG|Docetaxel|Docetaxel 300 mg/m\^2 IV over 2 hours on Day -5.
40773007|NCT00936936|DRUG|Melphalan|50 mg/m\^2 IV over 15 minutes on Days -4 to Day -2.
40773008|NCT00936936|DRUG|Carboplatin|"Cycle 1: 333 mg/m\^2 IV over 2 hours on Days -4 to -2.~Cycle #2: 300 mg/m\^2 IV over 2 hours on Days -6 to -3."
40773009|NCT00936936|DRUG|Mesna|3,000 mg/m\^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.
40773010|NCT00936936|DRUG|Ifosfamide|3,000 mg/m\^2 IV over 6 hours on Days -6 to -3
40773011|NCT00936936|DRUG|Etoposide|200 mg/m\^2 IV over 3 hours, every 12 hours on Days -6 to -4.
40773012|NCT00936936|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
40773013|NCT04932772|OTHER|Kinesiotaping|Technique: Include Rectus Abdominas Muscles (RAM), Oblique Abdominal Muscles (OAM). Tape will be applied on RAM using muscles technique from origin to insertion of muscle with a tension between15-35%. Band will be start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xyphoid process. Finally will perform on the right and left external oblique muscles the procedure will be start with no tension from bottom and of 6-12 ribs and then the hip will be place in flexion and rotation to opposite direction and the band will tape on pubic bone with tension between 15-35% (Kase et al., 2003).
40773014|NCT04932772|OTHER|Abdominal Exercises|Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.
40977296|NCT03719976|OTHER|Group-based educational intervention|The group-based educational intervention will use a bilingual Community Health Worker (CHW) who will teach parents key skills needed to access health care for children. Parents will be invited to attend 6 small, closed-group sessions held over 12 weeks and lasting no more than 75 minutes. Sessions will be interactive, culturally-appropriate, and held in parents' preferred language.
41141350|NCT05684809|OTHER|Cervical Mobilization (CM)|Cervical Mobilization was delivered in prone lying with their foreheads resting comfortably on his hands, and the chin was tucked in.The treatment session was done on alternate days (3 days a week) for 3 weeks, hence the total number of sessions were 9.
41141351|NCT05684809|OTHER|conventional treatment|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10-second relaxation) were given, and isometric exercise of the neck((10 repetitions of two sets with 10 seconds hold) alternate days for three weeks.
41141352|NCT01760005|DRUG|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
41141353|NCT01760005|DRUG|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
41141354|NCT01760005|DRUG|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
41141355|NCT01760005|DRUG|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
41141356|NCT01760005|DRUG|Gantenerumab|Open-label administered Subcutaneously every 4 weeks at escalating doses
41141357|NCT01760005|DRUG|E2814|Administered intravenously in a blinded fashion
41141358|NCT01760005|DRUG|Lecanemab|Administered intravenously
40773015|NCT02386241|OTHER|saliva or blood sample collection|Single saliva or blood sample measuring 10mL for genomic analysis.
40773016|NCT06570044|DIAGNOSTIC_TEST|PerioMonitor|Collection of oral rinse specimen and perform the PerioMonitor test as per the method described in the instructions for use
40977297|NCT02518750|DRUG|Dexamethasone|Given orally (PO).
41141359|NCT01760005|DRUG|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
40977298|NCT02518750|DRUG|Panobinostat|Given PO.
40977299|NCT02518750|DRUG|Liposomal vincristine|For intravenous (IV) use only.
40977300|NCT02518750|DRUG|Mitoxantrone|Given IV.
41141360|NCT03814226|OTHER|Evaluation of headache inducing capabilities of PACAP38|We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.
41141361|NCT06430853|BEHAVIORAL|Step count goal|The step count goal will be discussed at the beginning of the study, and participants will be able to see their step count on the Actigraph watch to facilitate achieving this goal. All participants will receive monthly reminders that are tailored for their intervention arm.
41141362|NCT06430853|DEVICE|Actigraph watch|Both groups will wear the watch. Adherence will be assessed via step counts from accelerometer watch.
41141363|NCT01029925|DRUG|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
41141364|NCT00276679|DRUG|temozolomide|
40977301|NCT02518750|DRUG|Peg-asparaginase|"Given IV or intramuscularly (IM).~In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection."
40773017|NCT03664544|DRUG|MCI-186|30 mg MCI-186 will be administered intravenously over 60 minutes.
40773018|NCT01021527|OTHER|Comparator: Treatment A|No Treatment
40773019|NCT01021527|DRUG|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
40773020|NCT01021527|DRUG|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
40773021|NCT01021527|PROCEDURE|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
40773022|NCT01606241|DRUG|Cyclophosphamide|Given PO
40773023|NCT01606241|OTHER|Laboratory Biomarker Analysis|Correlative studies
40773024|NCT01606241|BIOLOGICAL|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
40773025|NCT06512558|PROCEDURE|Additional MRI with gadolinium injection and 3D camera imaging|The study includes an additional MRI with gadolinium injection, performed in addition to standard practice. In addition, 3D camera images will be acquired at the time of surgery.
40773026|NCT04240509|DRUG|Emtricitabine / Tenofovir|Incarcerated men identified at high risk for HIV transmission will be given a 30-day supply of the study drug and will be provided with patient navigation to follow up care upon release.
40773027|NCT05078957|OTHER|Stool sampling|Stool samples will be collected from participants at baseline and annually during 5 years
40977302|NCT02518750|DRUG|Bortezomib|Given by IV push over 3 to 5 seconds. For IV use only.
40977303|NCT02518750|DRUG|Intrathecal Triples|Given IT as ITMHA.
40977304|NCT02518750|DRUG|High-dose methotrexate|Given intrathecally (IT) or IV.
41301173|NCT03637842|DRUG|Lorcaserin|Lorcaserin XR 20mg per day
40773028|NCT05078957|OTHER|Frailty phenotype|According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.
40773029|NCT05078957|OTHER|Blood plasma collection|Blood plasma collection to measure persistent inflammation and immune activation
40773030|NCT02213926|DRUG|ACP-196 (acalabrutinib)|
40977305|NCT02518750|DRUG|6-Mercaptopurine|Given PO at consistent time each day.
40977306|NCT02518750|DRUG|High-dose cytarabine|Given IT or IV.
40977307|NCT02518750|DRUG|Nelarabine|Given IV
40977308|NCT02518750|DRUG|Cyclophosphamide|Given IV.
40977309|NCT02518750|DRUG|Etoposide|"Given IV.~In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used."
40977310|NCT02518750|DRUG|Clofarabine|"Given IV.~Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II."
40977311|NCT02326961|DEVICE|Celution Device|ADRCs Prepared using the Celution Device
40977312|NCT02326961|OTHER|Placebo|Inactive Placebo
40977313|NCT01549860|DEVICE|MIST Therapy|Non-contact low frequency ultrasound therapy
40977314|NCT01972503|DRUG|5-FU and oxaliplatin|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.
41301174|NCT03637842|DRUG|Placebo oral capsule|Placebo
40773031|NCT00932607|DRUG|sublingual immunotherapy|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
40773032|NCT04344873|OTHER|Placebo|Placebo injection at day one and day fourteen.
40773033|NCT04344873|DRUG|Abatacept 10 mg/kg|Abatacept injection at day twenty eight and day forty two.
40773034|NCT01383876|BEHAVIORAL|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
40773035|NCT01383876|BEHAVIORAL|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
40773036|NCT05769062|PROCEDURE|Single digit pelvic exam|The exam takes approximately 5 minutes and uses a single digit to palpate the pelvic floor muscles, during which patients will rate pain on a scale of 0-10 at 5 paired locations.
40773037|NCT03477422|DRUG|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was Experimental in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. Patients were given either CSE-1034 or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Placebo) was given at 8th hour from first dose, third dose (Drug) at 12th hour from first dose and the fourth dose (Placebo) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
40773038|NCT03477422|DRUG|Meropenem|Meropenem was the Comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg.Patients were given either Meropenem or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Drug) was given at 8th hour from first dose, third dose (Placebo) at 12th hour from first dose and the fourth dose (Drug) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
40773039|NCT05721079|DEVICE|ECP (Extracorporeal Photopheresis System)|Patients who are assigned to the ECP group receive treatments by means of the THERAKOS ® CELLEX ® Photopheresis System (Mallinckrodt Pharmaceuticals Inc.) with either double- or single-needle access. During the leukapheretic processing, 1500 ml of whole blood is processed, and peripheral blood mononuclear cells (MCNs) are separated by centrifugation and collected in the buffy coat. 8-methoxypsoralen (Uvadex®, Mallinckrodt Pharmaceuticals Inc.) at a dose of 20 μg/ml is added to the MNC collection bag and cells are irradiated with ultraviolet A light (1.5 J/cm2) in a 1-mm-thick film through a photoactivation plate. After exposure of the cells to the ultraviolet light, the buffy coat is reinfused into the patient.
40977315|NCT01972503|PROCEDURE|colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
40977316|NCT04803825|OTHER|Heavy Slow Exercises|"* Load magnitude: A dumbbell as heavy as possible within the given repetitions and sets.~* Number of repetitions: week 1: 15 reps, Week 2-3: 12 reps, Week 4-5: 10 reps, Week 6-8: 8 reps, Week 9-12: 6 reps~* Number of sets: 3~* Rest between sets: 2 - 3 min.~* Number of exercise interventions: 2~* Duration of experimental period: 12 weeks~* Fractional and temporal distribution of the contraction modes per repetition and duration of one repetition: 3s concentric, 2s isometric: while change concentric/eccentric phase, 3s eccentric.~* Rest in-between repetitions: No~* Range of motion: Full range of motion~* Intervention frequency: 3 times a week, with minimum 48 h recovery time in-between."
40977317|NCT04803825|DEVICE|Extracorporeal Shock wave therapy|Two thousand impulses of shock waves are applied to the painful tendon, with a pressure between 1.5 and 3.0 bar (depending on what the patient tolerates). We use a power hand piece that provides energy of 0.01-0.35 mJ/mm2
40977318|NCT04803825|OTHER|Information and advice|Information and advice are based on assessment and will comprise the standardized oral and written information. Participants will be educated regarding pain during and after activities and encouraged to be physically active. With only one session, there is great reliance on self-management. Thus, information and advice are made available through a handout.
41460297|NCT03610386|OTHER|Adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back ...). One of the two biopsies will receive menthoxypropanediol topically.
40977319|NCT01897740|DRUG|sildenafil|tablets of sildenafil 20 mg 3 times a day for subjects with body weight \> 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
41301175|NCT02713230|DRUG|bupivacaine liposome injectable suspension|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline
41301176|NCT02713230|DRUG|bupivacaine liposome injectable suspension|20 mL EXPAREL (bupivacaine liposome injectable suspension)
41301177|NCT02713230|DRUG|Placebo|20 mL normal saline as single-injection
41460298|NCT03610386|OTHER|No adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back ...). One of the two biopsies will not receive menthoxypropanediol.
40773040|NCT03713801|DRUG|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.
40773041|NCT03713801|DRUG|Placebo|Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
41460299|NCT02500615|OTHER|ECIG liquid vehicles|The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
41460300|NCT02942810|DRUG|WCK 5222|IV infusion over a period of 60 minutes
40773042|NCT00937105|DEVICE|lotrafilcon A contact lenses|FDA approved soft contact lenses
40773043|NCT00937105|DEVICE|Renu Multiplus|
41460301|NCT00833534|BIOLOGICAL|rituximab|Given IV
41460302|NCT00833534|DRUG|lenalidomide|Given orally
40977320|NCT05127473|DRUG|Mim8 B, 10 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
40977321|NCT05127473|DRUG|Mim8 B, 100 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
40977322|NCT05127473|DRUG|Mim8 B, placebo|Placebo will be used to dilute the IMP to different Mim8 concentrations
40977323|NCT01325415|DRUG|NKTR-118|25 mg tablet
40977324|NCT01325415|DRUG|moxifloxacin|400 mg tablet
40977325|NCT01325415|DRUG|Placebo|tablet
40977326|NCT00003081|BIOLOGICAL|filgrastim|
40977327|NCT00003081|DRUG|busulfan|
40977328|NCT00003081|DRUG|melphalan|
40977329|NCT00003081|DRUG|thiotepa|
40977330|NCT00003081|PROCEDURE|peripheral blood stem cell transplantation|
40977331|NCT00003081|RADIATION|radiation therapy|
40977332|NCT03132207|OTHER|Non interventionel study|Only one questionnaire will be done for women and professional
40977333|NCT05304065|BEHAVIORAL|SAFETY-A within usual ED Care|SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.
41141365|NCT05141968|DIETARY_SUPPLEMENT|vitamin D supplements (2000 IU/day)|The interventional (experimental) group received vitamin D supplements (2000 IU/day). According to previous studies and after the direct supervision from the treating pediatrician and endocrinologist, the best preparation and dosage of vitamin D was used (According to FDA the recommended dose for children age 1 year and older is 2,000 IU/day).
41141366|NCT04265872|DRUG|Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis|injection into a vein
41141367|NCT03169855|DIAGNOSTIC_TEST|Slit lamp (LOCS III Score)|Diagnostic procedure only
41141368|NCT05973864|DRUG|Pembrolizumab injection|On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion
41460303|NCT04985955|DRUG|Tofacitinib|Tofacitinib tablet will be administered orally.
41460304|NCT01232049|DRUG|Multiple Oral Dose of|Pitavastatin 4mg
41460305|NCT01232049|DRUG|Multiple Oral Dose of|Valsartan 320mg
41460306|NCT05659316|OTHER|MRI imaging|Knee MRI imaging
41460307|NCT04631380|OTHER|PRAYER|THE PRAYER GROUP WILL RECEIVE ABSOLUTELY THE SAME CARE AS THE CONTROL GROUP PLUS PRAYERS
41141369|NCT05973864|DRUG|Capecitabine tablets|1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated
41460308|NCT03622229|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected by EUS-FNB without ROSE will be processed as histologic samples
41460309|NCT00222040|RADIATION|Ultrasound|2-MHz, low intensity transcranial ultrasound
41460310|NCT00222040|DRUG|Levovist|D-Galactose and palmitic palmitique intravenous 4 g
41460311|NCT00481169|DRUG|Bazedoxifene Acetate (TSE-424)|
41460312|NCT00440622|DRUG|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
40773044|NCT00937105|DEVICE|Clear Care|
40773045|NCT04831346|OTHER|Low level laser|940 nm wavelength with 0.2 W output power and 2 J energy applied for 10 seconds with an energy density of 2.5 J/cm2.
40773046|NCT04831346|DEVICE|Soft occlusive splint|"A vacuum-formed soft occlusal splint made from a 2-mm-thick elastic rubber sheets.~Participants are instructed to always wear the splint except during mealtimes and oral hygiene."
40977334|NCT05304065|BEHAVIORAL|Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts|COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
41460313|NCT00440622|DRUG|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
41460314|NCT00440622|DRUG|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
41460315|NCT06394492|DRUG|SHR-A1921|SHR-A1921 dose 1
41460316|NCT06394492|DRUG|Doxorubicin|Doxorubicin dose 2
41460317|NCT06394492|DRUG|Paclitaxel|Paclitaxel dose 3
40977335|NCT05575986|DRUG|Hetrombopag Olamine|Hetrombopag Olamine 7.5mg orally, once a day, for 14 days. This product should be taken on an empty stomach, 2 hours after oral administration before eating, avoid taking it with meals.
41460318|NCT06394492|DRUG|Topotecan|Topotecan dose 4
40773047|NCT04016714|DRUG|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
40773048|NCT04016714|DRUG|Prevenar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
40773049|NCT04016714|DRUG|Vaxelis™|Intramuscular 0.5 mL single dose
40773050|NCT04016714|DRUG|M-M-R®II|Subcutaneous 0.5 mL single dose
40773051|NCT04016714|DRUG|VARIVAX™|Subcutaneous 0.5 mL single dose
40977336|NCT04745754|OTHER|Embedded primary care in cancer survivorship model|Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.
40977337|NCT00221598|PROCEDURE|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
41460319|NCT05681819|DRUG|SHR-1707|Multiple-ascending Dose
40773052|NCT01416337|DRUG|GSK1120212|2 mg single dose tablet on Day 1 of study
40773053|NCT01416337|DRUG|GSK1120212B|A single administration of a slow 1 minute IV push on Day 1.
40773054|NCT06220084|BEHAVIORAL|Dance for PD®|The intervention consists of 16 60-min adapted to Greek culture DfPD® classes, which will be performed twice weekly for 8 weeks and instructed by a single researcher, who has the approval to use it for research reasons. The intervention will be delivered both live and online in separate periods for each participant.
40773055|NCT06440837|BEHAVIORAL|IMB stress self-management health education|The health education intervention program contains eight module topics: stress-related knowledge, the thinking and mentality under stress, social support, take care of your suffering, manage your difficult emotions, acceptance, embrace a better life, ending. One topic or session is delivered by weeks, each session lasting 30-40 minutes.
40977338|NCT00295906|OTHER|educational intervention|
40977339|NCT00295906|OTHER|internet-based intervention|
40977340|NCT04311424|DRUG|14C Tirzepatide|Administered SC.
40977341|NCT00450450|PROCEDURE|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
41460320|NCT05681819|DRUG|SHR-1707 placebo|Multiple-ascending Dose
41460321|NCT03668457|BEHAVIORAL|Intervention to Patients|"Multifaceted intervention consisting of:~1. A collaborative care management intervention, including depression education, medication management and behavioral activation.~2. Use of a medication reminder mobile app."
40773056|NCT02015130|OTHER|Individual treatment|See detailed description
40773057|NCT05993884|DRUG|iEPCs|Given: IV
40773058|NCT05993884|COMBINATION_PRODUCT|Clinical standard treatment (CST)|Clinical standard treatment
40773059|NCT00781261|DRUG|Zoledronic Acid|Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
40773060|NCT00781261|DRUG|Placebo|Subjects in the control group will receive a placebo drug for a similar period
40773061|NCT04765397|PROCEDURE|Effect of different resectoscope fluids on optic nerve diameter measured by ultrasound|During the operation Blood pressure, pulse minute the number of irrigation solutions used, and intravenous serum amounts, operation time will be saved. If there is an abnormal parameters or increased optic nerve sheath surgical team will be informed.
40773062|NCT04692506|OTHER|Probiotic|The study product is probiotic
40977342|NCT00450450|OTHER|laboratory biomarker analysis|Correlative studies
40977343|NCT00450450|BIOLOGICAL|filgrastim|Given IV
40773063|NCT06395558|BEHAVIORAL|Lifestyle intervention|Multimodal web-based intervention programme on anxiety, depression and cognitive impairment consisting of knowledge development sessions and practical/gaming sessions focused on different domains: cognitive competence, socio-relational competence and emotions/affectivity, and physical activity-nutrition
41301178|NCT05818124|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
41301179|NCT05818124|DRUG|Placebo molnupiravir|Four placebo capsules matched to molnupiravir taken twice daily by mouth.
41301180|NCT05818124|DRUG|Placebo oseltamivir|Placebo capsule matched to oseltamivir taken twice daily by mouth.
40773064|NCT01672775|DRUG|AGS-16C3F|intravenous (IV) infusion
40773065|NCT03847584|OTHER|Survey|The survey is based on the Theory of Planned Behaviour and assesses intention to participate in NutriQuébec as well as attitude, subjective norm, and perceived behavioural control. The salient beliefs underlying the determinants of individual's intention to participate in the NutriQuébec study most frequently cited in the focus groups (from a preliminary elicitation study: 2018-042 A-1/18-05-2018) were used to develop the survey questions. The survey also assesses the preferences regarding the recruitment. Sociodemographic questions are also asked.
40773066|NCT05797623|DRUG|Trappa ethanolamine tablets ; ciclosporin|Trappa ethanolamine tablets combined with ciclosporin
40773067|NCT05797623|DRUG|Placebo ; ciclosporin|Placebo combined with ciclosporin
41460322|NCT03668457|BEHAVIORAL|Intervention to Psychiatrists|Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.
41460323|NCT03668457|OTHER|Control|Other: Usual care Usual care for depressive disorder received in mental health units
40773068|NCT02686944|BIOLOGICAL|Intuvax (ilixadencel)|Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection
40773069|NCT01542944|DRUG|TevaGastrim|TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
40773070|NCT04774666|BEHAVIORAL|Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening|Oral fluid-based HIV test
40977344|NCT03878342|RADIATION|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
40977345|NCT03878342|OTHER|No Radiotherapy|No Irradiation- Active surveillance
40977346|NCT01503151|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
41301181|NCT05818124|DRUG|Oseltamivir|One capsule of oseltamivir 75 mg taken twice daily by mouth.
41301182|NCT05818124|BIOLOGICAL|Influenza A Virus|Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
41301183|NCT05396066|DIAGNOSTIC_TEST|Muscle evaluation|Repeated maximal voluntary contraction
41301184|NCT04352322|DIETARY_SUPPLEMENT|A+HA(tm)|oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin
41301185|NCT04352322|DIETARY_SUPPLEMENT|Placebo|oral solution with no active ingredients
41301186|NCT01474330|DRUG|Pomalidomide|0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
41301187|NCT01474330|DRUG|Placebo|Placebo capsule
41301188|NCT02294149|DRUG|mammalian Omega 3 Fatty acids|A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
41301189|NCT02294149|DRUG|placebo|
40773071|NCT01980147|BEHAVIORAL|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
41301190|NCT06434103|DRUG|SHR-A1921；Adebrelimab；SHR-8068；carboplatin|SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days.
41301191|NCT01427569|DRUG|IZN-6D4 Gel|Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
41301192|NCT01427569|OTHER|Placebo hydrogel|Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
41301193|NCT05436613|DEVICE|Transcranial Direct Current Stimulation|tDCS at 2mA in 30 minute sessions for 5 sessions per week for 3 weeks and then 2 sessions per week for 3 weeks.
41301194|NCT00296959|DRUG|topiramate (drug)|
41301195|NCT02656992|DEVICE|Inspiratory muscle training group|
41460324|NCT01478516|PROCEDURE|Intravitreal injection|autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
40773072|NCT00381641|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
40773073|NCT00381641|OTHER|Pharmacogenomic Study|Optional correlative studies
40977347|NCT01503151|BEHAVIORAL|Interpretation Bias Modification (IBM)|Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
40773074|NCT00381641|DRUG|Sunitinib|Given PO
40773075|NCT00381641|DRUG|Sunitinib Malate|Given PO
40773076|NCT01847014|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
40773077|NCT04899687|DRUG|Fluoxetine|Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
40977348|NCT01503151|BEHAVIORAL|Control Condition|Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
40977349|NCT01503151|BEHAVIORAL|Attention and Interpretive biases modification (CBM)|Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
40977350|NCT00085631|DRUG|cisplatin|Given IV
40977351|NCT00085631|PROCEDURE|hyperthermia treatment|Patients undergo hyperthermia treatment over 60-90 minutes
40977352|NCT00085631|RADIATION|brachytherapy|Patients undergo brachytherapy for 2-3 days
41301196|NCT02588274|DEVICE|Acupuncture|Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
40977353|NCT00085631|RADIATION|external beam radiation therapy|Patients undergo external beam radiation therapy once daily on days 1-5
40977354|NCT02527460|DRUG|Anakinra|Participants will self-administer daily subcutaneous injections of anakinra for 8 weeks. The dose will be increased over the first four weeks to minimize injection site reactions. The target dose after four weeks is 300mg daily.
40977355|NCT04399577|BIOLOGICAL|Candida antigen|Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention
40977356|NCT04252456|PROCEDURE|Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label
40977357|NCT03724084|DRUG|Cytarabine|Given IV
40977358|NCT03724084|DRUG|Daunorubicin|Given IV
41301197|NCT02588274|DEVICE|placebo needle|Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
40977359|NCT03724084|DRUG|Daunorubicin Hydrochloride|Given IV
40977360|NCT03724084|DRUG|Pinometostat|Given IV
41301198|NCT01784406|BEHAVIORAL|Autonomy supportive counselling|
41301199|NCT00246038|DEVICE|Boston Scientific ENOVUS AAA Endograft|
41460325|NCT04015024|DRUG|SKLB1028 150mg bid|150mg oral administration twice a day
41460326|NCT04015024|DRUG|SKLB1028 200mg bid|200mg oral administration twice a day
40773078|NCT04899687|DRUG|Dextromethorphan|Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.
40773079|NCT06296498|PROCEDURE|Leukocyte Platelet-rich fibrin|Leukocyte-PRF (L-PRF) contains neutrophils and macrophages that facilitate bacteria and necrotic tissue elimination via phagocytosis
40977361|NCT05619081|BEHAVIORAL|POWERNAP|POWERNAP of max 30min while participants ly down comfortably
40977362|NCT04084301|PROCEDURE|High CPB flow|Target CPB flow 2.9 L/min/m2 throughout the CPB period
40977363|NCT05037591|DRUG|Sea grapes extract 1.68 g/70kg BW|Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.
40977364|NCT05037591|DRUG|Placebo|placebo lactose powder (1.68 g/70kg BW day-1).
40977365|NCT05495256|DEVICE|Respimetrix|The Respimetrix device has a low resistance airflow sensor with an inhaler to measure patients inspiratory airflow and volume. This device will thereby provide quantifiable measures of lung function and bronchodilator delivery.
41301200|NCT04008589|DEVICE|repetitive transorbital AC Stimulation|Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day
41460327|NCT04015024|DRUG|SKLB1028 300mg qd|300mg oral administration once a day
40773080|NCT06296498|OTHER|Standard of care OFD|Open flap debridement (OFD) is one periodontal surgical procedure that is used to improve periodontal health by providing access to the tooth roots and alveolar bone.
40773081|NCT05130593|DIETARY_SUPPLEMENT|Nutrasorb bar|250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
40773082|NCT00245479|DRUG|Primary nocturnal enuresis|Desmopressin
40977366|NCT02749981|PROCEDURE|blood and tissue sampling|
40977367|NCT00070278|DRUG|cyclophosphamide|
40977368|NCT00070278|DRUG|epirubicin hydrochloride|
40977369|NCT00070278|DRUG|gemcitabine hydrochloride|
40977370|NCT00070278|DRUG|paclitaxel|
40977371|NCT00070278|GENETIC|comparative genomic hybridization|
40977372|NCT00070278|GENETIC|microarray analysis|
40977373|NCT00070278|GENETIC|mutation analysis|
40977374|NCT00070278|PROCEDURE|conventional surgery|
40977375|NCT00070278|PROCEDURE|neoadjuvant therapy|
40977376|NCT03773679|PROCEDURE|Daily Exercise|Daily Exercise Programme
41141370|NCT05973864|RADIATION|Local radiotherapy|Local radiotherapy will be performed as per standard practice if indicated.
41141371|NCT02568059|DRUG|Sahastara remedy alcoholic extract|comparison of different dose of drug
41141372|NCT05024266|DRUG|Tislelizumab|Participants received 2 cycles Tislelizumab 200mg d1 + Albumin Paclitaxel 260mg/m2 d1 + Carboplatin AUC5 d1 every 3 weeks, and then were evaluated for surgery.
41301201|NCT04008589|DEVICE|combination of transcranial direct current stimulaton and rtACS|Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS
41301202|NCT05858736|DRUG|AI-061|A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
41301203|NCT04720508|DIAGNOSTIC_TEST|blood sample collection.|venipuncture procedure
41301204|NCT00511407|DEVICE|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
41460328|NCT04229914|OTHER|stroke patinets|3-m backwards walk test, timed up and go test, 10 m walk test, Berg BalanceTest, Functional Reach Test
41460329|NCT02838251|OTHER|No intervention|
41460330|NCT01577173|DRUG|MEHD7945A|1100 mg iv every 2 weeks
41460331|NCT01577173|DRUG|cetuximab|400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
40773083|NCT06424002|BIOLOGICAL|Mosquirixs|RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen. The adjuvant is AS01. Three doses of the vaccine will be administered, each with one month interval.
40773084|NCT06424002|DRUG|artemether-lumefantrine|A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
40773085|NCT03662607|BEHAVIORAL|Virtual reality experience|"* Baseline wellness self-assessment administered (reporting on absence or presence and degree of severity of headache, nausea, dizziness, fatigue and vision abnormalities)~* Seated comfortably and free of direct obstruction~* Shown individual components of the VR system (View-Master with smartphone; headphones); given instructions; encouraged to ask questions.~* Begin the VR experience. Study personnel stay in the room \& provide guidance and answer questions regarding the technology~* When VR experience concluded, wellness self-assessment will be administered again."
40773086|NCT03682744|BIOLOGICAL|anti-CEA CAR-T cells|Intraperitoneal delivery of anti-CEA CAR-T cells
40773087|NCT00835172|DRUG|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose non-fasting
40773088|NCT00835172|DRUG|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose non-fasting
40773089|NCT01014312|BEHAVIORAL|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
41301205|NCT01574313|PROCEDURE|stellate ganglion block|stellate ganglion block
40773090|NCT01014312|BEHAVIORAL|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
41460332|NCT05513469|DRUG|Lutathera|regulair PRRT of 4 cycles with 7.4GBq
40773091|NCT05510934|BEHAVIORAL|Shared-care model|A Shared care follow-up strategy involving patients, PCPs and specialists that uses an automated reminder system (TCARS).
40773092|NCT00737789|DRUG|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
40773093|NCT00737789|DRUG|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
40773094|NCT04388631|OTHER|Coronavirus Disease 2019|male patients who have developed COVID-19
40773095|NCT04198428|OTHER|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers to help assess, diagnose, and treat OUD in primary care (where appropriate).
41460333|NCT01087034|DEVICE|Acoustic reflection method evaluation|Evaluation of airways by acoustic relection method, with and without the bracing device
41460334|NCT01087034|RADIATION|EOS™|Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device
41460335|NCT01087034|OTHER|Non invasive respiratory muscle assessment|Non invasive respiratory muscles assessment, with and without the bracing device.
41460336|NCT00003615|BIOLOGICAL|denileukin diftitox|
40773096|NCT02886962|BIOLOGICAL|No oral anticoagulation|No oral anticoagulation, and no monitoring of the INR.
40773097|NCT02886962|DRUG|Oral anticoagulation with vitamin K antagonists|"Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.~Administration once daily or at the end of each dialysis session, according to the nephrologist choice.~INR monitoring at least once per week"
41301206|NCT01574313|DRUG|0.25mg, fludiazine|0.25mg of erispan@ (fludiazine), p.o. one dose only.
41301207|NCT01574313|DRUG|25mg cephadol@ (diphenidol)|25mg cephadol@ (diphenidol) p.o. one dose only.
40773098|NCT04164719|DRUG|TNX-102 SL|Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
40773099|NCT00003455|DRUG|antineoplaston A10|
40773100|NCT00003455|DRUG|antineoplaston AS2-1|
40773101|NCT00003455|PROCEDURE|alternative product therapy|
40773102|NCT00003455|PROCEDURE|biological therapy|
40773103|NCT00003455|PROCEDURE|biologically based therapies|
41301208|NCT01574313|DRUG|200mg kentons@ (tocopherol nicotinate).|200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
41301209|NCT04009096|BIOLOGICAL|ChAd63 PvDBP and MVA PvDBP|one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
41301210|NCT06336031|OTHER|blood-injection-injury (BII) phobia stimuli|498 seconds of BII phobia-related images and videos will begin two-minutes prior to head-up tilt test, while in supine.
41460337|NCT00929006|DRUG|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
41460338|NCT00929006|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
41460339|NCT03473002|OTHER|Placebo|0.9% Sodium Chloride
41301211|NCT06336031|OTHER|neutral stimuli|498 seconds of neutral images and videos will begin two-minutes prior to head-up tilt test, while in supine.
40977377|NCT06460857|OTHER|Manual Diaphragmatic Release Technique|Manual Diaphragmatic Breathing Technique, 2 sets with a 5 min rest interval between sets will be given, patient will lie supine in a relaxed position, Therapist will stand behind the patients head with the therapist forearm aligned towards patient shoulders, the hypothenar and the last three fingers of therapist hand will make contact bilaterally with underside of 7th, 8th, 9th, and 10th ribs costal cartilages, Patient is instructed to inhale deeply, therapist will pull the contact sites towards head and slightly in a lateral direction, during expiration therapist increases the contact depth beneath costal margins and maintain the resistance, therapist will continue to increase the depth of contact in the coming deep breath. Initially patient will be asked to take 5 deep breath/ set in the first week then it will progress to 10 deep breaths in the second,third and fourth week.
41460340|NCT03473002|BIOLOGICAL|SeVRSV Vaccine|Recombinant Sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine. SeVRSV is a replication-competent Sendai virus that carries the RSV F gene produced by reverse genetics technology.
41460341|NCT03213548|PROCEDURE|Alar facial groove incision|All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.
41460342|NCT03213548|PROCEDURE|Alar facial groove spared|The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
40977378|NCT06460857|OTHER|Chest Wall Expansion Exercises|Four different types of chest exercises will be given to second group for 2-3 days/week for 4 weeks along with generalized body stretching
40977379|NCT03551054|BEHAVIORAL|Healthy for Two, Healthy for You|Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.
41301212|NCT04398719|RADIATION|[11C]PBR28|The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan
41301213|NCT04398719|DRUG|Low-dose lipopolysaccharide|Subjects will receive intravenous lipopolysaccharide.
40977380|NCT03551054|BEHAVIORAL|Health Education|
41301214|NCT04398719|DRUG|Intradermal Capsaicin|A small dose of capsaicin will be administered by intradermal injection.
41301215|NCT04056364|BIOLOGICAL|sputum cytology|Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.
41301216|NCT06208982|DIAGNOSTIC_TEST|Colonoscopy images and videos|A CADx system in real-time characterization of colonic ulcer diseases was constructed using artificial intelligence to extract endoscopic features from the training set. Subsequently, the performance of the CADx system was preliminarily tested through the validation set.
41460343|NCT05616455|DRUG|Propionibacterium Acnes|Application of the gel every 12 hours for 40 days
41460344|NCT05616455|DRUG|glyceryl trinitrate|Application of the gel every 12 hours for 40 days
41460345|NCT01992913|BEHAVIORAL|integrated Cognitive Behavioral Therapy|Novel CBT paradigm for schizophrenia/schizoaffective disorder
40977381|NCT02726646|DRUG|Doxycycline|Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
40977382|NCT02726646|PROCEDURE|Mechanical debridement|Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.
40977383|NCT02726646|DRUG|Placebo|The application of 1 mg of microspheres placebo
40977384|NCT05392998|DEVICE|Cataract surgery with Vivity intraocular lens implantation|Cataract surgery with Vivity intraocular lens implantation
41301217|NCT03569293|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
41301218|NCT03569293|DRUG|Upadacitinib|Tablets taken orally once a day
41301219|NCT03653702|DRUG|Lumason|Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection
41301220|NCT02087319|OTHER|hair loss, baldness (patient's own platelet-rich plasma)|hair loss, baldness
41301221|NCT00711399|DEVICE|PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies|wheeze and cough detection in hospitalized patients.
41301222|NCT04792853|BEHAVIORAL|Tab-G|Participants receive a tablet preloaded with Tab-G application and an accelerometer.
40977385|NCT06224101|BEHAVIORAL|Simulation-based training|simulation training consists of practicing diagnostic coronary angiography with 3D printed simulator-SimulHeart.
41301223|NCT01785433|DRUG|Tiotropium HFA BAI 4.5 mcg|
41301224|NCT01785433|DRUG|Tiotropium HFA BAI 9.0 mcg|
41301225|NCT01785433|DRUG|SPIRIVA® HandiHaler® 18 mcg/day|
41301226|NCT01785433|DRUG|Spiriva® Respimat® 5 mcg/day|
41301227|NCT04023513|OTHER|High protein intake|6 weeks of high protein intake mainly via food (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
41301228|NCT04023513|OTHER|Control, no intervention|No Intervention, control
41301229|NCT04023513|OTHER|Low protein intake|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
41301230|NCT04023513|OTHER|Strength training|6 weeks of different protein intake followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
41301231|NCT04738513|PROCEDURE|Vertical preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using vertical preparation technique.
41301232|NCT04738513|PROCEDURE|Conventional Preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
41301233|NCT03535701|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo ketogenic diet
41301234|NCT03535701|OTHER|Laboratory Biomarker Analysis|Correlative studies
41301235|NCT03535701|DRUG|Paclitaxel|Given standard of care therapy with paclitaxel
41301236|NCT03535701|OTHER|Quality-of-Life Assessment|Ancillary studies
41460346|NCT01992913|OTHER|Usual Care|The usual care that Veterans receive - not limited in scope (i.e., subjects may participate in any/all available treatments, outside the study condition)
41301237|NCT03535701|OTHER|Questionnaire Administration|Ancillary studies
41301238|NCT01222338|BIOLOGICAL|V-5 immunitor|once per day dosing for 2 months
41301239|NCT00520195|BEHAVIORAL|Physical activity|Climbing stairs instead of taking elevators at worksite during 12 weeks.
41460347|NCT01992913|BEHAVIORAL|Computerized cognitive remediation (CCR)|Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
41460348|NCT05232487|OTHER|Swiss low back acupuncture (SLBA)|"Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes.~Swiss low back pain acupuncture The SLBA method is a further developed method from the Jiu Gong acupuncture technique, also known as the Nine Palace-Points on the spine. The following acupuncture points will be used: LV3/ LV5, Tai Xi (Kl 3), Fe Yang (BL 58), Tai Chong (LR 3), Guang Ming (GB 37), Tai Xi (Kl 3) and Fe Yang (BL 58)."
40773104|NCT00003455|PROCEDURE|cancer prevention intervention|
40773105|NCT00003455|PROCEDURE|complementary and alternative therapy|
40773106|NCT00003455|PROCEDURE|differentiation therapy|
41141373|NCT02529605|DIETARY_SUPPLEMENT|Product B® IsaGenesis®|This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
41301240|NCT02773719|OTHER|True Biofield therapy|
41301241|NCT02773719|OTHER|Fake Biofield therapy|
41301242|NCT06396325|OTHER|Exergaming|Play the exergame a minimum of three times a week for 20 minutes over 8 weeks (8 hours total)
41301243|NCT00100633|DRUG|CpG7909 oligodeoxynucleotides (ODN)|
41301244|NCT00100633|BIOLOGICAL|Hepatitis B virus vaccine|
41301245|NCT03934086|DRUG|rimegepant|rimegepant 75 mg
41301246|NCT06428643|OTHER|Chlamydia, gonorrhea, syphilis, and HIV screening|Individuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment.
41301247|NCT02735317|DRUG|Oral Ulcer Gargle (FORRAD®)|Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
40773107|NCT03709667|BEHAVIORAL|EX|An individualized aerobic and resistance-exercise program will be developed for each participant on the basis of a maximal incremental exercise test and strength assessments performed at baseline. This test will measure aerobic capacity (VO2 max) and the metabolic or lactate threshold (VO2θ) (i.e., the level of O2 uptake that defines one's ability to perform prolonged work), using indirect calorimetry with an automated metabolic-measurement system. The intervention will comprise 24 sessions over 8 wk (3x/wk), supervised by a credentialed exercise specialist. Each session will consist of a 5-min warm-up, 30-40 min of aerobic activity on a treadmill, 15-20 min of resistance training, and a 5-min cool-down.
40773108|NCT03709667|BEHAVIORAL|CON|Participants attend 50-min sessions 3x/wk matched to EX for staff contact. A counselor will facilitate integrative group discussions, and will conduct a multimedia program addressing various health, wellness and lifestyle topics, such as nutrition, dental care, stress relief, sleep hygiene, relationships, immunizations, health screening, smoking, environmental health, and time management.
40773109|NCT00938626|BIOLOGICAL|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
40773110|NCT00938626|PROCEDURE|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
40773111|NCT00938626|PROCEDURE|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
40773112|NCT01202084|DRUG|Formoterol/Fluticasone|
40773113|NCT01202084|DRUG|Foraseq®|
40773114|NCT01202084|DRUG|Fluticasone|
40773115|NCT06177184|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking Association of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
41301248|NCT02735317|DRUG|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
41301249|NCT04323748|DRUG|rituxan|"The dose dense administration of rituximab will consist of 5 doses total~Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2"
41301250|NCT03800706|DRUG|TQB2450|TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
41301251|NCT05055739|DEVICE|Rigid plate X steel wires|Compare the sternal alignment between the fixation with rigid plate X steel wires.
41301252|NCT00426049|DRUG|Everolimus|
41301253|NCT02388061|DRUG|Tenecteplase|
41301254|NCT02388061|DRUG|Tissue Plasminogen Activator|
41301255|NCT03189576|DIAGNOSTIC_TEST|blood draw|
41301256|NCT03273075|DRUG|Cangrelor|The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
41301257|NCT03273075|DRUG|Placebo|The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
41301258|NCT03273075|DRUG|Prasugrel|The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
40773116|NCT00618787|DEVICE|COPA AMD (note: name is not an acronym)|Foam dressing impregnated with Polyhexamethylene Biguanide
40773117|NCT00618787|DEVICE|COPA (note: name is not an acronym)|Regular foam dressing without PHMB
40773118|NCT02085980|DEVICE|Laser treatment|The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
40773119|NCT01659294|BEHAVIORAL|Nurse Case Management|
41141374|NCT02529605|DIETARY_SUPPLEMENT|IsaGenesis®|This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
41141375|NCT02237456|PROCEDURE|Comparison of OCT scans|
41301259|NCT03273075|DRUG|Ticagrelor|The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
41301260|NCT01959737|PROCEDURE|skin-to.skin-contact|Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
41460349|NCT05232487|OTHER|Standard acupuncture (SA)|Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes. The SA method is described in the acupuncture textbook for TCM in China and all acupuncture points are selected based on TCM principles, international literature, and the opinion of national and international TCM experts. The following points have been selected: Ming Men (GV 4), Zhi Shi (BL 52), Tai Xi (KI 3) Yao Guan (GV 3), Guan Yuan Shu (BL 26), Ge Shu (BL 17), Ci Liao (BL 32), Wei Zhong (BL 40), Ji Zhong (GV 6), Yao Yang Guan (GV 3), Shen Shu (BL 23), Da Chang Shu (BL 25) and A-Shi points.
40977386|NCT06234007|DRUG|Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine|"Safety run-in phase: Fruquintinib 4mg/d, oral, once daily, continuous treatment for 2 weeks, 1 week off, q3w, 6 cycles; If the number of patients experiencing dose-limiting toxicity (DLT) was ≤1, the study would continue at that dose level. If the number of patients with DLTs was \>1, the dose of fruquintinib was decreased to 3mg/d, qd po, d1-14, q3w, and the dose expansion phase was continued；Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;~Dose expansion phase: Fruquintinib RP2D, qd po, d1-14, q3w, 6 cycles; Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;"
40977387|NCT00311610|DRUG|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
41460350|NCT02871050|OTHER|Sample Collection|Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
40977388|NCT03542968|PROCEDURE|magnetic resonance imaging|Acquisition 4D Flow magnetic resonance Imaging-8 minutes
41460351|NCT05425368|DRUG|Silver diamine fluoride|First permanent molars in this group will receive 38% silver diamine fluoride as an indirect pulp capping material.
40977389|NCT06190223|PROCEDURE|Anterior cruciate ligament (ACL) reconstruction with a periost-patellar-tendon-bone (PPTB) autograft and a tibial press-fit technique|A longitudinal incision will be performed starting from the central part of the patella. A ruler will be used to mark a tendon thickness of 10mm from the middle of the patellar tendon. Superiorly, the patellar periosteum will be marked with a length of 30-40mm and a width of 10mm. Inferiorly, the tibial tubercle will be marked in a trapezoidal shape with a length of approximately 35mm, a superior narrow base of 10mm and an inferior wider base of 12mm. After extraction, the superior part of the graft will be prepared with reinforced sutures in a whipstitch pattern, while the bone block will be shaped according to the planned tunnel width. After adequate preparation, the femoral end of the graft will be shuttled in with an adjusted fixation device, while the tibial end will be hammered in with a small mallet, in a press-fit fashion, stopping short of the joint surface, but tensioned appropriately. The femoral adjustable device will then be tensioned to ensure proper graft sitting.
41141376|NCT02237456|PROCEDURE|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
41301261|NCT04869956|OTHER|Dietary pattern : High-fiber diet rich in PUFA|High-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
41301262|NCT04869956|OTHER|Dietary pattern: Standard diet|standard nutritional recommendations
41301263|NCT05345834|BEHAVIORAL|Patient Navigation|Participants in arm 2 will receive patient navigation provided by humans (rather than e-navigation) to provide personalized care to include support, resources, and referrals to address psychosocial issues that arise during the perinatal period. Patient navigation is available to participants through 12 months postpartum.
40773120|NCT01659294|BEHAVIORAL|standard diabetologist care|routine care by diabetologist \& team
40773121|NCT05470166|DRUG|Lidocaine IV|lidocaine infusion as bolus 1.5mg/kg then 2mg/kg/hr
41141377|NCT00803985|PROCEDURE|Total Extraperitoneal repair (TEP)|Operation for primary inguinal hernias i men
41141378|NCT00803985|PROCEDURE|Lichtenstein|Operation for primary inguinal hernias i men
41460352|NCT05425368|DRUG|Mineral trioxide aggregate|First permanent molars in this group will receive mineral trioxide aggregate as an indirect pulp capping material.
41460353|NCT02208336|OTHER|medical chart review|Ancillary studies
40773122|NCT05470166|OTHER|saline IV|saline infusion same volume as lidocaine
40773123|NCT02527512|DRUG|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
40773124|NCT02527512|OTHER|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
40773125|NCT06527274|DEVICE|Experimental: Myopic defocus soft lens design (MDSL)|An optical device designed to provide a myopic defocus to control myopia progression
41460354|NCT06214637|DRUG|Melissa|The test solutions will be administered once a day through administration in drops for children between 5 and 10 years old and for adolescents between 11 and 16 years old. As participants will be between 5 and 16 years old, children will be given a minimum of 5 and a maximum of 10 drops of the solutions per individual (Tavares-Silva, Holandino et al. 2019) as well as a maximum of 10 drops for adolescents of solutions per individual (Taylor, Lancaster et al. 2000). Highlighting that the prescription of Melissa officinalis will be at night, around 20/30 minutes before bedtime, respecting the indications for the medications described in the Hahnemannian Materia Medica (Vijnovsky, 2003). All medications must be taken away from meals and they will be instructed not to use mentholated substances, respecting a minimum time of 30 minutes.
41460355|NCT06214637|DRUG|Placebo|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
41460356|NCT03786705|OTHER|Massive transfusion|Trauma patients who had received blood transfusion≥10 U
41460357|NCT03786705|OTHER|Non-Massive Transfusion|Trauma patients who had received blood transfusion\<10 U
41460358|NCT02105701|DRUG|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
41460359|NCT02105701|DRUG|Ribavirin|200 mg capsule
41460360|NCT02591849|DIETARY_SUPPLEMENT|Glucagon-like peptide-1 (GLP-1)|
41460361|NCT02591849|OTHER|Isotonic saline|
40977390|NCT04691492|BEHAVIORAL|Friend-Based Motivational Interview|The intervention will use Motivational Interviewing's (MI) collaborative conversation style for strengthening commitment to change, to motivate and prepare women to work together to reduce Sexual Assault (SA) risk. This intervention will target ways that the friend dyad may support, encourage, and share responsibility with one another in protecting against SA. The Friend-based MI (FMI) will then use the responsibility and relationship of friends as a framework to foster collaborative efforts to increase readiness and decrease barriers to helping behavior. As part of this, the FMI will focus on the identification and implementation of skills friends can use to help one another prevent sexual assault. FMI will include a focused discussion of the ways drinking may impede helping efforts. Moreover, the FMI will encourage women to identify personal, specific strategies for reducing the effects of alcohol on helping.
40977391|NCT02373202|DRUG|Sarilumab|Pharmaceutical form:solution
40977392|NCT02373202|DRUG|Sulfasalazine|Pharmaceutical form: Tablet Route of administration: Oral
40977393|NCT02373202|DRUG|Leflunomide|Pharmaceutical form: Tablet Route of administration: Oral
40977394|NCT02373202|DRUG|Bucillamine|Pharmaceutical form: Tablet Route of administration: Oral
41301264|NCT05345834|BEHAVIORAL|Adapted Cognitive-Behavioral Therapy|Participants who do not meet diagnostic criteria (Group 2a) will participate in a prevention group which includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Participants who meet diagnostic criteria (Group 2b) will participate in individual treatment which includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations.
41460362|NCT02591849|OTHER|Hyperglycemic clamp|
41460363|NCT02172469|DRUG|Tiotropium inhalation powder capsule|
41460364|NCT02172469|DRUG|Placebo Metered Dose Inhaler|
41460365|NCT02172469|DRUG|Ipratropium Bromide Metered Dose Inhaler|
41460366|NCT02172469|DRUG|Placebo inhalation powder capsule|
40977395|NCT02373202|DRUG|Tacrolimus|Pharmaceutical form: Capsule Route of administration: Oral
40977396|NCT02373202|DRUG|Mizoribine|Pharmaceutical form: Tablet Route of administration: Oral
41141379|NCT06091969|DIETARY_SUPPLEMENT|Active multi-ingredient supplement (Fertility Enhancer, FE)|Consuming a multi-ingredient supplement targeting multiple cell pathways daily for 3 months.
41460367|NCT04662476|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 supplement
41460368|NCT05245955|DEVICE|Assessments of the hand sensory function with the ReHapticKnob|During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).
41460369|NCT01990807|DRUG|Idarubicin(IDA)|6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
41460370|NCT04917393|DEVICE|iRF System Multi-organ Denervation|If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries
40773126|NCT06527274|DEVICE|Active Comparator: Single vision soft lens design (SVSL|An optical device designed to correct refractive error like myopia
40773127|NCT02615288|DIETARY_SUPPLEMENT|Vitamin D3|
40773128|NCT04539288|OTHER||There is no intervention in this study.
40773129|NCT05170334|DRUG|Binimetinib|Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.
41301265|NCT04183842|DIETARY_SUPPLEMENT|LACIME Anti-hangover|"LACIME Anti-hangover contains the following excipients:~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~LACIME Anti-hangover contains the following plant extracts and vitamin:~* Curcuma longa rhizome extract (Curcuma),~* Panax quinquefolius extract (Ginseng panax),~* Malpighia punicifolia extract (Acerola),~* Silybum marianum extract (Milk thistle),~* Desmodium adscendens extract (Desmodium),~* Pyridoxine chlorhydrate (Vitamin B6)."
41301266|NCT04183842|OTHER|Placebo|"Placebo contains the following excipients :~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~Placebo contains :~- Carrot juice"
41301267|NCT05184296|PROCEDURE|Extracorporeal Membrane Oxygenation (ECMO)|All patients in cohort 1 will initiate ECMO as fast as possible. A maximum of 6 hours is allowed between enrollment and the actual initiation of ECMO. ECMO catheterization and management will be operated by an experienced ECMO team and carried out at the bedside. VA or VAV mode will be chosen according to the patient's condition.
41301268|NCT06386653|DRUG|Diagnostic injection of [123I]I-DARPIN-Ec1|A single intravenous injection of \[123I\]I-DARPIN-Ec1
40977397|NCT05137106|OTHER|Active Dry Needling|All participants in this group received an ADN session with an intramuscular insertion of a 25 mm X 0.22 mm acupuncture needle into the infraspinatus muscle. The dry needling was performed with the rapid entry and exit technique.
41301269|NCT06386653|DIAGNOSTIC_TEST|Whole-body planar scintigraphy with [123I]I-DARPIN-Ec1|Gamma camera-based whole-body planar scintigraphy imaging 2, 4, 6, and 24 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
41301270|NCT06386653|DIAGNOSTIC_TEST|Whole-body SPECT with [123I]I-DARPIN-Ec1|Whole-body SPECT at 2, 4, and 6 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
41301271|NCT03255291|BEHAVIORAL|Risk Assessment App|The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.
40773130|NCT05170334|DRUG|Belinostat|Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles
40773131|NCT05442697|DEVICE|PEMF treatment|Patient will receive a PEMF treatment. The involved leg will be exposed to PEMF for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of PEMF exposure in total.
40773132|NCT05442697|DEVICE|Placebo treatment|Patient will receive a placebo treatment. The involved leg will be exposed to placebo treatment for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of placebo exposure in total.
40773133|NCT03190876|PROCEDURE|Variable drain usage|Influence of drain usage on seroma formation rate
40977398|NCT05137106|OTHER|Sham Dry needling|All participants in this group received one session of SDN with a 25 mm X 0.22 mm acupuncture needle over the infraspinatus region. To ensure that the blunt needles did not puncture the skin during the experimental session (and for patient comfort), each needle was individually cut and polished and checked for sharpness against the investigator's fingertip. As a precaution against infection, each patient was treated with a separate dummy needle.
41301272|NCT03255291|BEHAVIORAL|Audio Recording - Sleep|-Participants imagine themselves improving sleep hygiene
41460371|NCT04917393|OTHER|Control Procedure|If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
41460372|NCT05147987|DEVICE|Hands free wearable breast pump|Use of a supplementary breast pump which can be discreetly worn and is hands free
41460373|NCT04288128|PROCEDURE|Lumbar puncture|Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)
40977399|NCT02656979|DRUG|Latanoprost|Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
41301273|NCT03255291|OTHER|Surveys|Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.
40977400|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
41301274|NCT03255291|BEHAVIORAL|Audio Recording - Exercise|Participants imagine themselves improving exercise
41460374|NCT04288128|OTHER|Magnetic Resonance Imaging (MRI)|Each participant will undergo scanning at 3 visits (M0, M6 and M12)
41460375|NCT00743145|DRUG|Inactive Marijuana (0% THC)|Marijuana cigarette containing 0% THC
41460376|NCT00743145|DRUG|Active Marijuana (5.5% THC)|Marijuana cigarette containing 5.5% THC
41460377|NCT00743145|DRUG|Active Marijuana (6.2% THC)|Marijuana cigarette containing 6.2% THC
41460378|NCT00743145|DRUG|Naltrexone|Naltrexone (12mg/70kg)
41460379|NCT00743145|DRUG|Placebo naltrexone|Naltrexone (0mg)
41460380|NCT01119625|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
41460381|NCT01119625|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, one dose
41460382|NCT00562120|DRUG|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
41460383|NCT00562120|DRUG|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
41460384|NCT00562120|DRUG|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
40773134|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|187.5 mg/60 g
40773135|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|375 mg/60 g
40773136|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|750 mg/60 g
40977401|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
41460385|NCT00562120|DRUG|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
41460386|NCT04668274|DRUG|200 mg resveratrol as JOTROL|Low (first) dose of single ascending dose study
41460387|NCT04668274|DRUG|500 mg resveratrol as JOTROL|Second (intermediate) dose of single ascending dose study
40773137|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|1500 mg/60 g
40773138|NCT03709017|DRUG|Ponatinib|Iclusig 45mg, 15mg
40977402|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
40977403|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops|Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops
40977404|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray|Single intranasal dose on Day 1, by intranasal spray
40977405|NCT00720837|PROCEDURE|Visualase® Thermal Therapy System|An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
41301275|NCT03255291|OTHER|Text message reminders|-Reminders to practice mental imagery
41301276|NCT03255291|OTHER|Text Message Survey|-Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.
41301277|NCT03537339|OTHER|Record general information|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients
41301278|NCT06419036|DEVICE|Pneumowave DC|Pneumowave biosensor(s) will be used to collect data from chest +/- movement.
41460388|NCT04668274|DRUG|700 mg resveratrol as JOTROL|Third (highest) dose of single ascending dose study
41460389|NCT04668274|DRUG|500 mg resveratrol as JOTROL administered to assess influence of food|500 mg resveratrol as JOTROL administered to assess influence of food
41460390|NCT04038606|OTHER|Determination of acceptance and / or rejection of mastectomy|Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
40773139|NCT04510311|DRUG|3-[18F]Fluoro-para-hydroxyphenethylguanidine|Single IV injection of 12.0 mCi (+/- 10%) \[18F\]3F-PHPG
40773140|NCT04510311|DRUG|[123I] metaiodobenzylguanidine|Single IV injection of 10.0 mCi \[123I\]MIBG
40773141|NCT04510311|DIAGNOSTIC_TEST|Positron emission tomography/computed tomography scan|Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of \[18F\]3F-PHPG
40773142|NCT04510311|DIAGNOSTIC_TEST|Planar scintigraphy scan|Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of \[123I\]MIBG
40773143|NCT04510311|DIAGNOSTIC_TEST|Single photon emission computed tomography/computed tomography scan|SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of \[123I\]MIBG
41460391|NCT05214677|DRUG|DW1809|pelubiprofen 30mg
41460392|NCT05214677|DRUG|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
41460393|NCT04903652|DRUG|Pyrotinib Maleate|Pyrotinib p.o. 400 mg once daily
41460394|NCT04903652|DRUG|Vinorelbine|Vinorelbine p.o. 40 mg once every other day
41460395|NCT04431973|DEVICE|Medacta Shoulder System|Surgical placement of the Medacta Shoulder System prothesis on patients with pathologies requiring the insertion of a total reverse shoulder prothesis for primary omarthrosis, cuff tear arthropathy, massive cuff rupture or post instability arthropathy
41460396|NCT04169555|PROCEDURE|Ultrasound|"The emergency physician will perform a point of care ultrasound. If signs of expansions of the pelvicalyceal cavities are found, an early CT scan will follow"
41460397|NCT04169555|OTHER|Standard care|Standard clinical care of patients. In regards of the clinical evolution and of biological results, a CT scan could be performed by the physician.
41301279|NCT01883440|DRUG|Glucose oxidase + glucose|Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
41301280|NCT01883440|DRUG|Saline+glucose|Placebo arm
41301281|NCT03616080|BEHAVIORAL|soccer play program|once a week for an hour of a soccer program for 8 weeks
40773144|NCT02266771|DEVICE|NPWT with Instillation|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation
40773145|NCT02266771|DEVICE|NPWT|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
41301282|NCT05257239|OTHER|no intervention|National University Health System,
41301283|NCT05121077|OTHER|Training|2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.
40773146|NCT03085953|BEHAVIORAL|Veteran Supportive Supervisor Training|"The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period."
40773147|NCT03085953|OTHER|Waitlist Control|Control group will receive training following all measurements points to serve as a comparison group
41301284|NCT01231633|DRUG|Ozurdex|Ozurdex, 0.7mg dexamethasone
41460398|NCT04894630|OTHER|antimicrobial treatment|Detailed history taking and all clinical findings were collected. Corneal scrapings were obtained from patients and subjected to staining and culture for bacterial and fungal pathogens; Bacterial and fungal growth were identified by standard laboratory procedures.
41460399|NCT01940445|DEVICE|M22 ResurFX|Fractional NA treatment (ResurFX) on one side of the face
40773148|NCT05849467|DRUG|89 Zr-Df-crefmirlimab|"an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours)."
40773149|NCT04873557|OTHER|Copper-based surfaces plus copper-enriched linen|We will assess the efficacy of our intervention to decrease the acquisition of nasal and intestinal colonization with MDROs and the development of HAIs in the ICU setting.
40773150|NCT06291779|DEVICE|Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio|"* Collect urine from the patient to measure urinary hypoxia, xanthine concentration.~* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).~* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.~* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample."
40773151|NCT06565247|DRUG|[18F]PSMA-PET|Pre-surgical imaging using \[18F\]PSMA-PET at Umea University Hospital, 3.5 MBq/kg, i.v. injection.
40773152|NCT06565247|DEVICE|MRI sequences optimized for prostate cancer examinations|T2-WI, T1-WI, DCE and DWI at Umea University Hospital and at Skåne University Hospital
40773153|NCT00950521|PROCEDURE|Intercerebral implantation of Autulogous Stem Cells|2-8 millions Stem cell per patients plus convention therapy
40773154|NCT00950521|DRUG|convention therapy|antiplatelet
40773155|NCT04199390|PROCEDURE|total hip arthroplasty|each patient is expected to undergo an anterior total hip arthroplasty procedure and some sort of physical therapy postoperatively
40773156|NCT05316844|OTHER|There will be no interventions.|Measurements and performance tests were conducted to investigate predictors of work-related performance
41301285|NCT01231633|DRUG|Avastin|Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
41301286|NCT01251172|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
41301287|NCT01251172|DRUG|Gamma-Secretase Inhibitor RO4929097|Given orally
41301288|NCT01251172|PROCEDURE|Hematopoietic Stem Cell Mobilization|Undergo standard mobilization
41301289|NCT01251172|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
41460400|NCT01940445|DEVICE|M22 ResurFX and QS|Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
40773157|NCT04452916|OTHER|Buchinger fasting|Caloric intake of \< 250 kcal/d for 5 days
40773158|NCT03281213|OTHER|Thoracotomy|
40773159|NCT01827020|DRUG|Lidocaine 2 %|12 mL lidocaine 2% 1mg/kg
40773160|NCT01827020|DRUG|Ketamine plus Lidocaine|ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
40773161|NCT01827020|DRUG|Saline|12 mL saline (0.9% isotonic solution)
41301290|NCT01251172|OTHER|Laboratory Biomarker Analysis|Correlative studies
41301291|NCT01251172|DRUG|Melphalan|Given IV
41301292|NCT03977285|PROCEDURE|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
41301293|NCT05906641|DIETARY_SUPPLEMENT|High-protein diet|Protein intake will be increased to be 30% calories from protein with calcium caseinate.
41301294|NCT01848964|DEVICE|Clinical and instrumented measurements|"Clinical examination will include stump pain, wound, scar and unusual shape.~Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)~After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.~Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.~Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate."
41460401|NCT01842555|OTHER|Registry|Registry
41460402|NCT02260258|DRUG|Rocuronium|Neuromuscular Blockade
41460403|NCT02260258|DRUG|Normal Saline|Normal Saline
41460404|NCT05285319|RADIATION|Prostate Only Radiation|Prostate Only Radiation for Intermediate and High Risk Prostate cancer
41460405|NCT05285319|RADIATION|Prostate and Pelvic Lymph Node Radiation|Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
40773162|NCT03802916|DRUG|Deferiprone DR tablets 1000 mg (Low dosage)|Deferiprone DR tablets 1000 mg
41141380|NCT06091969|DIETARY_SUPPLEMENT|Inactive placebo (Placebo; PLA)|Consuming an inactive placebo that is calorie-matched to the active supplement daily for 3 months.
41301295|NCT04495452|DRUG|Fentanyl Drug Administration|Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
41460406|NCT03066895|DEVICE|BabyGentleStick|Experimental device.
41460407|NCT03066895|DEVICE|Standard Lancing Device|HMC standard of care.
41460408|NCT05070754|DEVICE|Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)|The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
40773163|NCT03802916|DRUG|Deferiprone DR tablets 1000 mg (High dosage)|Deferiprone DR tablets 1000 mg
40773164|NCT02689557|OTHER|plethysmography|Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
40773165|NCT04398225|DRUG|Centanafadine|Extended release capsule
40977406|NCT02485574|PROCEDURE|transforaminal lumbar interbody arthrodesis|Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in right side of disc space and anterior bridging cages augmented with auto bone in left side of disc space in transforaminal lumbar interbody arthrodesis.
40977407|NCT00137748|DRUG|CMV-Ig|Drug: CMV-Ig
40977408|NCT00531999|DRUG|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
40977409|NCT00531999|DRUG|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
41141381|NCT01868555|DRUG|insulin degludec|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
41141382|NCT01868555|DRUG|insulin degludec/insulin aspart 30|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
41141383|NCT01868555|DRUG|insulin degludec/insulin aspart 45|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
41141384|NCT01868555|DRUG|placebo|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
41141385|NCT05080556|DRUG|Carboplatin|Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
41141386|NCT05990556|PROCEDURE|interventional procedure to block bilateral meningeal blood supply|"The embolic agent used in bilateral meningeal blood supply occlusion through interventional surgery is Onyx glue (liquid embolic system). After the location of bilateral middle meningeal artery was determined by femoral artery puncture angiography, SL-10 was sent to the opening of bilateral middle meningeal artery through guiding catheter, and Onxy glue was used to block the bilateral middle meningeal artery. The standard of embolization was that the middle meningeal artery was not seen and Onyx glue was not diffused to the petrous branch of the middle meningeal artery. In order to avoid dangerous anastomotic branches and complications, attention should be paid to superselecting the middle meningeal artery and slowly injecting Onyx glue during the operation. After embolization of the middle meningeal artery by interventional surgery, glioblastoma was removed immediately under the guidance of multimodal imaging."
41141387|NCT06527404|DRUG|Rocatinlimab|SC Injection
41141388|NCT06527404|DRUG|Placebo|SC Injection
41141389|NCT03994809|OTHER|Okada Purifying Therapy|The practitioner raises his/her hand forward towards the recipient with the palm directed toward the recipient. The practitioner uses his/her hands alternately during the administration of Okada Purifying Therapy. The distance between the palm and the body is usually 1-2 feet, with each session typically lasting 30 to 60 minutes.
41141390|NCT05814809|DRUG|JP-1366 20mg tablet|T : JP-1366 20mg tablet
41141391|NCT05814809|DRUG|JP-1366 20mg capsule|R : JP-1366 20mg capsule
41141392|NCT02099058|DRUG|Osimertinib|It is administered orally everyday.
41141393|NCT02099058|DRUG|Nivolumab|It is an intravenous infusion administered every 14 days.
41141394|NCT02099058|DRUG|Telisotuzumab vedotin|It is administered by infusion in 21-day dosing cycles.
41141395|NCT02099058|DRUG|Telisotuzumab vedotin|It is administered by infusion in 28-day dosing cycles.
41141396|NCT02099058|DRUG|Erlotinib|It is administered orally everyday.
41141397|NCT03507504|OTHER|SCU-B|"SCU-B is a residential medical structure lying outside of a nursing home, in a general hospital or elsewhere, e.g. in a private hospital, where patients with BPSD are temporarily admitted when their behavioural disturbances are not amenable to control at home."
41301296|NCT05913427|DRUG|Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG|"EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.)."
40773166|NCT05334797|OTHER|hot application|a thermophore filled with hot water will be placed on the patient's shoulder according to the presence of shoulder pain and it will be ensured that he stays for 15 minutes.
40773167|NCT01292031|DRUG|Colistin|Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion
40773168|NCT01292031|DRUG|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
40773169|NCT03514940|DIAGNOSTIC_TEST|ultrasound|second trimester us scan will be made to pregnant women
40773170|NCT01957384|DEVICE|Coloplast Test product 1|Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
40773171|NCT01957384|DEVICE|Coloplast Test product 2|Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
40773172|NCT01957384|DEVICE|Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)|"Standard Care was the subject usual ostomy appliance and had to be one of the following:~* Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,~* Dansac: Nova 1 \& Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate~* Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate~* ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate~* B. Braun: Flexima Active \& Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate"
40773173|NCT00457626|DRUG|Valsartan|Extemporaneous suspension of valsartan, orally.
40773174|NCT00667121|DRUG|citalopram hydrobromide|
41301297|NCT05913427|DRUG|Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
41301298|NCT06409052|BEHAVIORAL|Qualitative interviews|Interviews will be conducted for approximately 45-60 minutes
40773175|NCT00667121|DRUG|escitalopram oxalate|
40773176|NCT00667121|DRUG|gabapentin|
40773177|NCT00667121|DRUG|sertraline hydrochloride|
40773178|NCT00667121|DRUG|tamoxifen citrate|
40773179|NCT00667121|DRUG|venlafaxine|
40773180|NCT00667121|GENETIC|molecular genetic technique|
40773181|NCT00667121|OTHER|high performance liquid chromatography|
40773182|NCT00667121|OTHER|laboratory biomarker analysis|
40773183|NCT00667121|OTHER|pharmacological study|
40773184|NCT00667121|PROCEDURE|adjuvant therapy|
40773185|NCT04602845|DRUG|Fentanyl|50ug Fentanyl intravenously
40773186|NCT04602845|DRUG|Flurbiprofen|50mg Fentanyl intravenously
40773187|NCT04602845|DRUG|Midazolam|2.5mg midazolam in 2ml normal saline intravenously
40773188|NCT04602845|DRUG|Remimazolam|3mg Remimazolam in 2ml normal saline intravenously
40773189|NCT05828173|DEVICE|LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)|Vessel preparation of moderately to severely calcified coronary artery lesions prior to stenting allows for full stent expansion and apposition to the vessel wall
40773190|NCT06240676|BEHAVIORAL|AWARENESS-BASED COGNITIVE THERAPY|A 6-week training program based on mindfulness practices will be applied to the experimental group determined by the single-blind method, after the 3rd month after birth. In order to observe the change in the experimental group, breast milk will be taken for pre-test (morning and evening) before training. After 6 weeks of training, a cortisol test will be performed by taking breast milk at 09:00 in the morning and 09:00 in the evening. Taken milk will be stored in the deep freezer for 1 week at -18 degrees. After the samples are prepared for testing under appropriate conditions (centrifuge), biochemical measurements will be made and recorded with the help of the SUNREDBIO brand human cortisol kit (the serial number is not known since we did not purchase the cortisol kit).A sleep diary will be used to measure newborn circadian rhythm.
40773191|NCT01676870|BEHAVIORAL|1x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down."
40773192|NCT01676870|BEHAVIORAL|4x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down."
41301299|NCT05794997|DRUG|Propranolol or Carvedilol|Propranolol or Carvedilol claim is used as the exposure group.
41301300|NCT05794997|DRUG|Atenolol, Bisoprolol or Sotalol|Atenolol, Bisoprolol or Sotalol claim is used as the reference group.
40773193|NCT01676870|BEHAVIORAL|traditional moderate training|moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
40773194|NCT05840263|BEHAVIORAL|Qualitative interview|Qualitative interviews will cover four main goals including: (1) key sources of distress in mCRC patients and partners; (2) perceptions of mindfulness, including benefits, definitions, and applications; (3) barriers and facilitators of participation (e.g. home-based and couple-based skills practice, enrollment); and (4) session format preferences, such as session length and frequency.
41301301|NCT06531382|OTHER|Nurses attitudes toward adressing sexual health in patients with cancer|"Health professionals, within the field of cancer, attitude towards addressing sexual health with patients is unknown.~The aim is to investigate the attitudes of Danish cancer nurses towards addressing sexual health in their clinical work, as well as to assess differences in perceived competences and knowledge.~Method: The questionnaire Health professionals Attitudes towards Sexual Health-Danish version (PA-SH-D) is sent out to Danish cancer nurses via the Professional Society for Cancer Nurses. The questionnaire is sent out via a link via the RedCap database.~The questionnaire link is sent out to members of the Professional Association for Cancer Nurses under the Danish Nursing Council, and it is sent out via their membership register."
41301302|NCT05698771|DIETARY_SUPPLEMENT|nicotinamide riboside|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6-10 healthy individuals (3-5 men and 3-5 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using HPLC-MS. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans. Based on these results we will determine the optimal dosing frequency of NRT in healthy individuals.
40773195|NCT05840263|BEHAVIORAL|Cognitive Interviews|The objective of the cognitive interviews (60 minutes, led by the PI) is to ensure the comprehensibility and appropriateness of the drafted participant materials. Published guidelines note a sample size of 12 participants (6 mCRC couples) should be sufficient. Participants will be asked to read, review, and mark up the participant materials in order to identify sections that were difficult to understand. They will also be asked to test playing segments of the audio/video recordings to ensure ease of use. A semi-structured interview format will be used to elicit feedback, including a standard verbal survey assessing ease of reading the material, any difficulties experienced, and suggestions they have for improving the ease of material use. Information generated will be used to update materials as necessary.
40773196|NCT06563739|PROCEDURE|Divergent low energy shock wave|Receive divergent low energy shock wave once a week
41460409|NCT05070754|DEVICE|Cryotherapy|Cryotherapy refers to the application of liquid nitrogen using a cryospray device in order to freeze a lesion of interest. Treatment is repeated every few weeks until the lesion of interest has disappeared. It is considered SOC for the treatment of warts.
40773197|NCT06563739|PROCEDURE|Divergent low energy shock wave|Receive divergent low energy shock wave twice a week
40773198|NCT06563739|PROCEDURE|Divergent medium and low energy shock wave|Receive divergent medium and low energy shock wave once a week
40773199|NCT06563739|PROCEDURE|Divergent medium and low energy shock wave|Receive divergent medium and low energy shock wave twice a week
40773200|NCT06563739|PROCEDURE|Focused low energy shock wave|Receive focused low energy shock wave once a week
40773201|NCT06563739|PROCEDURE|Divergent medium energy shock wave|Receive divergent medium energy shock wave once a week
40773202|NCT06563739|PROCEDURE|Divergent medium energy shock wave|Receive divergent medium energy shock wave twice a week
40773203|NCT06563739|PROCEDURE|Non-exposed group|Traditional rehabilitation assessment and training guidance
40773204|NCT04450550|DEVICE|VeNS device|VeNS treatment
40773205|NCT04450550|DEVICE|Sham VeNS device|Sham treatment of VeNS
40773206|NCT05073588|OTHER|Indo Mediterranean diet|Mediterranean diet has been shown to be effective in NAFLD adult patients. In India, it is very difficult to follow Mediterranean diet, so one group will be given Indianized version of mediterranean diet.
40773207|NCT05073588|OTHER|Calorie restricted diet|One group will be given diet restricted in calories, which most of the patients follow to lose weight
40773208|NCT00674102|DRUG|ASA404|
40773209|NCT00652834|PROCEDURE|Small bowel capsule endoscopy (SBCE)|SBCE will be performed at Day 2 and Day 30.
40773210|NCT00652834|DRUG|myfortic|switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
40977410|NCT04142853|OTHER|Training intervention + Dance intervention|Training intervention + Dance intervention
41460410|NCT05070754|DRUG|Canthardin Collodion|Chemical compound that acts as a vesicant to form a blister around treatment area. The blister lifts the lesion of interest away from the skin, causing it to slough off in a few days. It is used as SOC for the treatment of Molluscum Contagiosum.
41460411|NCT01534754|DRUG|Mesalazine plus Lactobacillus casei|Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
41460412|NCT01534754|DRUG|Mesalazine placebo plus Lactobacillus casei placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
41460413|NCT01534754|DRUG|Mesalazine 800 mg|Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
41460414|NCT01534754|DRUG|Lactobacillus casei|Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
41460415|NCT04409054|OTHER|Cough and Valsalva effort|Three increasingly cough effort and three Valsalva type effort at four different volumes of rectal distension (empty rectum, volume for a first sensation of filling, volume for desire to defecate and maximal tolerable volume) while recording the external anal sphincter activity
40773211|NCT06055283|OTHER|Aerobic exercise|The training group will receive aerobic exercise and the intensities will be controlled considering the percentage of estimated maximum heart rate. The training will be performed with a cycle ergometer with a total of 40 minutes of intradialytic aerobic exercise in the training group. To reduce the effects of intolerance to aerobic exercise, a week of adaptation will be performed, with a frequency of three sessions, in the first two hours of hemodialysis, lasting 40 minutes at maximum heart rate intensity of up to 74% and BORG up to 4 (low intensity). Afterwards, the patients will perform the prediction training for 12 weeks, at the frequency of three training sessions per week in the first two hours of hemodialysis. Each training session will start with a 5-minute warm-up at low intensity, 30 minutes of main training with maximum heart rate intensity 55% to 74% and BORG 5 to 7 (moderate intensity) and will end with a 5-minute cool-down at low intensity.
41460416|NCT06095596|DRUG|Upadacitinib|Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.
40773212|NCT06398184|OTHER|Exercise + motor imagery and action observation|A total of 8 sessions of 4 sets of knee extension exercises will be performed. During the breaks between each series, participants will perform a progressive protocol of action observation and motor imagery.
40773213|NCT06398184|OTHER|Exercise|A total of 8 sessions of 4 sets of knee extension exercises will be performed.
40773214|NCT02648945|OTHER|Exercise|first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
40773215|NCT00737360|DRUG|TAS-106|6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
40977411|NCT05927090|PROCEDURE|Conservative Root- Sparing Aortic Valve Resuspension with or without Hemiarch Repair|Cardiac arrest will be performed by administering a potassium-rich antegrade cardioplegia solution delivered directly into the coronary ostium or in the case of aortic regurgitation after insertion of the coronary sinus cannula.The aorta will be resected up to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion can be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget above every commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients demonstrating normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferable.
40977412|NCT05927090|PROCEDURE|Extensive Ascending Aorta Replacement (AAR) with Aortic Root Replacement (ARR)|Patients who experienced dilatation of the sinuses of Valsalva \> 4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will receive replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure associated to AAR
40977413|NCT05927090|PROCEDURE|Extensive Ascending Aorta Replacement (AAR) with Total Arch Replacement (TARP)|Total arch replacement procedures (TARP) will performed with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
41141398|NCT05503485|BEHAVIORAL|Existential group treatment|The existential group treatment follows a manualised structure focusing on aging-related challenges related to existential themes such as story of life, freedom, loneliness, and death. In order to support patients in finding new, productive ways of engaging in the existential process of aging literary texts, therapy practices and assignments between the sessions are used and each group will be accompanied by two therapists who facilitate the group climate, gently bring the group back on topic and help group members to see different ways of dealing with existential concerns related to aging.
41141399|NCT05503485|BEHAVIORAL|Supportive telephone calls|"The supportive caller will provide empathetic basic support, equivalent to the telephone support provided within the Swedish non-governmental organization Mind's Äldrelinjen. No psychotherapeutic techniques will be applied and there will be no interventions beyond the phone call itself."
41460417|NCT06095596|DRUG|Vedolizumab|Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
41141400|NCT02776124|DIETARY_SUPPLEMENT|Healing Elements,Methuselah Medical Technology|ONS group will receive Healing Elements ONS everyday during CRT
41141401|NCT03690609|DIETARY_SUPPLEMENT|CytoQuel|3 capsules daily.
41460418|NCT05428696|DRUG|ALXN2080|Powder-in-capsule
41460419|NCT05428696|DRUG|Placebo|Powder-in-capsule
41141402|NCT03690609|DIETARY_SUPPLEMENT|CytoQuel|2 capsules twice daily.
40773216|NCT06563986|DRUG|Systemic treatment (FTD-TPI and bevacizumab)|"Systemic treatment (FTD-TPI and bevacizumab) administration is according to standard clinical practice. Each treatment cycle will be 28 days in duration.~One treatment cycle consists of the following:~* Days 1-5: oral intake of FTD-TPI and bevacizumab IV infusion on day 1~* Days 8-12: oral intake of FTD-TPI~* Day 15: bevacizumab IV infusion~Bevacizumab 5.0mg/kg i.v. is repeated every 2 weeks. If toxicity occurs, dose modifications and dose delays should be administered and applied according to standard practice."
40773217|NCT06563986|DEVICE|Radioembolization with 166-Ho microspheres|"Individualized 166Ho radioembolization will be performed via a catheter during angiography. Before the treatment, a scout procedure will be performed to determine individualized 166Ho dose of the treatment. Dosimetry-based treatment planning will be individualized using Q- Suite software.~In case of bilateral disease, patients will be treated in two procedures to each hemi-liver, separated by 1 month. Before the first procedure, a scout procedure will be performed in which the individualized 166Ho dose of the first and second procedure will be calculated."
40773218|NCT03906409|OTHER|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
40773219|NCT03906409|OTHER|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
40977414|NCT05927090|PROCEDURE|Extensive Root and Ascending Aorta Replacement with Total Arch Replacement|This extensive procedure will include complete replacement of the anterior thoracic aorta extending to part or all of the aortic arch. It will be performed with the previously reported techniques
40977415|NCT01396148|DRUG|sunitinib malate dose escalation|sunitinib starting dose will be 15mg/m\^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).
40977416|NCT01396148|DRUG|sunitinib malate|sunitinib 50mg daily on Schedule 4/2
40977417|NCT06055647|GENETIC|immunohistochemical approach|Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.
40977418|NCT03898141|OTHER|Placebo (PL)|"Participants will get deceptive and receive an inert cream (=placebo intervention) that reduces pain."
40977419|NCT03898141|OTHER|Dog only (DO)|In the dog intervention a dog will be present during the second measurements. However, participants will only learn the true aims of the presence of the dog after the study (delayed informed consent).
40977420|NCT03898141|OTHER|Animal-assisted placebo (AAPL)|Participants receive the placebo intervention in the presence of a dog.
41460420|NCT00004441|DRUG|tauroursodeoxycholic acid|
40977421|NCT06040112|DEVICE|Atelocollagen|Tendoregen (Atelocollagen) injection
41141403|NCT04195789|OTHER|Lung sonography|"Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.~Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist."
41460421|NCT00004441|DRUG|ursodiol|
41460422|NCT01397266|PROCEDURE|Transcranial Magnetic Stimulation|ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex
41460423|NCT01397266|PROCEDURE|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
40977422|NCT04161989|DRUG|omega-3 fatty acids|. The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% \& Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.
40977423|NCT04161989|DRUG|vaginal progesterone|Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
41141404|NCT06356883|DRUG|IA Carboplatin + IA Caelyx|Intraarterial infusion of carboplatin combined with liposomal doxorubicin
41141405|NCT06356883|DRUG|IA Carboplatin + IA Etoposide Phosphate|Intraarterial infusion of carboplatin combined with etoposide phosphate
41460424|NCT02993705|DRUG|Trabectedin|Chemotherapy drug
41460425|NCT00697619|DRUG|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
40773220|NCT02731560|DRUG|Rituximab|"Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours.~This was done either by a specialist nurse or a trained doctor."
40977424|NCT04926350|BEHAVIORAL|Resistance Exercise|8 total resistance exercises that target all major muscle groups
40977425|NCT03234764|OTHER|Immunotherapy|
41301303|NCT05698771|DIETARY_SUPPLEMENT|nicotinamide mononucleotide|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6-10 healthy individuals (3-5 men and 3-5 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using HPLC-MS. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans. Based on these results we will determine the optimal dosing frequency of NRT in healthy individuals.
41301304|NCT01841658|DIETARY_SUPPLEMENT|Folic acid|Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
41301305|NCT06512441|DRUG|Vitamin B6 Tablets|The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.
41301306|NCT06512441|DRUG|Placebo|The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.
41460426|NCT00651651|DRUG|budesonide/formoterol|
41460427|NCT00651651|DRUG|budesonide|
41460428|NCT00651651|DRUG|formoterol|
40977426|NCT03329950|DRUG|CDX-1140|CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
40977427|NCT03329950|DRUG|CDX-301|CDX-301 will be injected once a day for five days before Cycles 1 and 2.
40977428|NCT03329950|DRUG|pembrolizumab|pembrolizumab will be administered every 3 weeks.
41460429|NCT00213590|DRUG|cyclosporine A|The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
41460430|NCT02413034|DRUG|Cefazolin|Cefazolin (vancomycin in the case of allergy to cefazolin)
40977429|NCT03329950|DRUG|Chemotherapy|Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
40977430|NCT06363851|DRUG|Kylo-11|Administered SC.
40773221|NCT03685149|DRUG|Flecainide Pill|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
40773222|NCT03685149|DRUG|Placebo|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
40773223|NCT03798210|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Study group split in two arms for experimental treatment with Lactobacillus reuteri or placebo.
40773224|NCT03798210|DIETARY_SUPPLEMENT|Placebo|Placebo
40977431|NCT06363851|DRUG|Placebo|Administered SC.
40977432|NCT04022772|OTHER|Best Practice|Receive standard of care
40977433|NCT04022772|OTHER|Medical Chart Review|Ancillary studies
40977434|NCT04022772|OTHER|Quality-of-Life Assessment|Ancillary studies
40977435|NCT04022772|OTHER|Questionnaire Administration|Ancillary studies
40977436|NCT04022772|PROCEDURE|Supportive Care|Participate in PACK Health program
40977437|NCT04235270|COMBINATION_PRODUCT|FDC of Macitentan and Tadalafil|Fixed dose combination (FDC) of 1 film-coated tablet containing 10 mg of macitentan and 40 mg of tadalafil will be administered orally.
40977438|NCT04235270|DRUG|Macitentan|Macitentan 10 mg tablet will be administered orally as free combination.
40977439|NCT04235270|DRUG|Tadalafil|Tadalafil 40 mg tablet will be administered orally as free combination.
40977440|NCT00853866|DRUG|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
40977441|NCT00853866|DRUG|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
40977442|NCT00853866|DEVICE|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
41301307|NCT01703286|DRUG|Placebo|Placebo matching Glimepiride
41301308|NCT01703286|DRUG|Linagliptin|given once daily for 28 days
41301309|NCT01703286|DRUG|Placebo|Placebo matching Linagliptin
41301310|NCT01703286|DRUG|Placebo|Placebo matching Linagliptin
41301311|NCT01703286|DRUG|Placebo|Placebo matching Glimepiride
41301312|NCT01703286|DRUG|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
41301313|NCT05745896|OTHER|Telemedicine appointment|Three online appointments for pregnancy monitoring at prenatal care.
41460431|NCT02413034|OTHER|Control group|no antibiotic prophylaxis
41460432|NCT05395416|DRUG|HEC74647PA+HEC110114|administered orally once daily for 12 weeks
41460433|NCT05395416|DRUG|Placebo|administered orally once daily for 12 weeks
41460434|NCT06214416|BEHAVIORAL|Abstention|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote abstention.
40773225|NCT02374255|BEHAVIORAL|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
40773226|NCT04354233|DEVICE|Physical activity intervention with connected devices|"Participants randomized in the intervention arm will receive recommandations in physical activity. They will also receive an activity tracker Withings Steel to wear during 6 months. The tracker will be connected to the Withings Health Mate application and the ABLE02 application. Participants will be encouraged to practice at least three walking sessions weekly of more than 10 consecutive minutes. Concerning the number of steps per day, the first objective will be determined according to the 6-min walking distance and to participants' preferences and capacities. The objective will be recalculated monthly according to the number of steps performed the previous week and will be adapted by the physical activity (PA) instructor and participants. Phone calls with the participants are regularly planned. Weekly quizzes on PA and nutrition will be proposed through the ABLE02 application. A messaging system and a phone line will be available for participants to contact the study team."
40773227|NCT03134209|DEVICE|Zipper surgical skin closure|The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
40773228|NCT03134209|OTHER|Monocryl + Dermabond|conventional sutures and skin adhesive glue
40773229|NCT03134209|OTHER|Polyester mesh + Dermabond|conventional sutures and skin adhesive glue
40773230|NCT00182650|BIOLOGICAL|aldesleukin|
40773231|NCT00182650|BIOLOGICAL|rituximab|
40773232|NCT00182650|BIOLOGICAL|therapeutic autologous lymphocytes|
40773233|NCT00182650|DRUG|fludarabine phosphate|
40773234|NCT06022926|PROCEDURE|warmed with electric blankets|warmed with electric blankets
40773235|NCT06022926|OTHER|patients without warming|patients without warming: no electric blanket will be used, and no heating will be applied to this group of patients.
41141406|NCT05483985|DEVICE|Hera Score|The device uses patient metadata (patient age, day of image capture) and a software algorithm to analyze features of the blastocyst morphology to provide adjunctive information that may predict further development of the embryo to clinical pregnancy after embryo transfer.
41141407|NCT05659836|DEVICE|Abbott SCS Systems|Patients will be implanted with Abbott spinal cord stimulation (SCS) systems (both trial and permanently-implanted systems) and provided with wearable sensors, and software applications presented on a mobile device.
41141408|NCT04396938|DRUG|Lamotrigine|Active Drug Capsule
40773239|NCT00019448|DRUG|gp100 antigen|
40773240|NCT00019448|DRUG|interleukin-2|
40773241|NCT06243770|DRUG|mRNA-0184|Intravenous infusion
40773242|NCT00684385|DRUG|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H\&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H\&NC will take two tablets at each dose administration.
40773243|NCT02892279|OTHER|Diesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
40773244|NCT02692534|OTHER|Urine cocaine negative|Preoperative urine cocaine negative
41301314|NCT05745896|OTHER|Face-to-face appointment|Six to nine face-to-face appointments for pregnancy monitoring at prenatal care.
41301315|NCT04845698|DEVICE|i-Dashboard|i-Dashboard is a team-designed, patient-centered electronic medical record viewer, which retrieves data from multiple databases and provides a quick representation of essential metrics for each patient.
40977443|NCT00853866|DEVICE|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
41141409|NCT04396938|DRUG|Placebos|Placebo Capsule
41141410|NCT05172232|DIAGNOSTIC_TEST|Dermalyzer|To evaluate the diagnostic accuracy of the Dermalyzer device to detect melanoma among cutaneos skin lesions by dermoscopy.
41141411|NCT04738370|OTHER|Sample collection|Bloods +/- urine +/- vaginal swabs taken
41301316|NCT04368806|DRUG|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
40773245|NCT02692534|OTHER|Urine cocaine positive|Preoperative urine cocaine positive
40773246|NCT04743648|BEHAVIORAL|Innovative Thinking Development Program (ITDP)|With the implementation of the program, nursing students are expected to develop innovative thinking skills.
40773247|NCT01230411|OTHER|saline placebo|250 cc of placebo administered IV
40773248|NCT01230411|DRUG|Ibuprofen|800 mg ibuprofen in 250 cc saline administered IV
40773249|NCT01276951|DIETARY_SUPPLEMENT|Delivery and return of chocolate|At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
40773250|NCT01276951|PROCEDURE|Determination of blood pressure|Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
41141412|NCT01681563|DRUG|Pentostatin|Lyophilized powder for intravenous administration.
41141413|NCT01681563|DRUG|Cyclophosphamide|IV
41141414|NCT01681563|DRUG|Ofatumumab|Liquid concentrate for solution for infusion.
41301317|NCT04368806|OTHER|Placebo Control|Normal Saline with autologous Serum
41301318|NCT04527354|DRUG|Treamid|Participants will receive Treamid 50 mg once a day during 4 weeks
41301319|NCT04527354|DRUG|Placebo|Participants will receive Placebo once a day during 4 weeks
41301320|NCT05346952|DRUG|TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection|PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.
41301321|NCT04286542|DIAGNOSTIC_TEST|Cold, dry air|Participants will be exposed to cold (\<-10°C, \<10% relative humidity), dry air for 15 minutes.
41301322|NCT03308084|DRUG|Methylprednisolone|Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
41460435|NCT06214416|BEHAVIORAL|Mediterranean alcohol-drinking pattern|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote the Mediterranean alcohol-drinking pattern.
41460436|NCT05762016|PROCEDURE|Bedside Mini-Incision and Self-Express (MISE)|To perform bedside mini incision and encourage patients to self express the pus following the intervention
40773251|NCT01276951|PROCEDURE|Anthropometric Measurements|The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
40977444|NCT05789979|DEVICE|The resident-handling device|Care staff will perform resident-handling tasks using the new resident-handling devices. For low dependency during trial, the device helps care staff to assist residents in making a transition from a sit to a standing posture, vice versa. This device is used for functional activities and transferring and lifting participants. For high dependency during trial, when care staff are performing resident-handling tasks, the device moves with little force in any direction.
40977445|NCT02756689|OTHER|Inpatient cervical ripening|Subjects will undergo cervical ripening in the inpatient setting.
40977446|NCT02756689|OTHER|Outpatient cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
40977447|NCT06069245|DIETARY_SUPPLEMENT|MitoQ|80mg of MitoQ taken in one dose on one occasion.
40977448|NCT06069245|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
41301323|NCT03308084|DRUG|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
41460437|NCT05497557|DRUG|Omeprazole|Omeprazole will be administered as an oral capsule.
41460438|NCT05497557|DRUG|Sotorasib|Sotorasib will be administered as an oral tablet.
41301324|NCT05922423|BEHAVIORAL|MBSR|Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
41301325|NCT05922423|BEHAVIORAL|health education|For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
41301326|NCT00416637|BIOLOGICAL|Bevacizumab (Avastin)|
41460439|NCT02687789|OTHER|Medical Device: WO3191|application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
41460440|NCT02687789|OTHER|Medical Device: Vagisan® Lactic Acid|application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
40773252|NCT01276951|PROCEDURE|Food Anamnesis|With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.
41141415|NCT02635399|PROCEDURE|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
41141416|NCT02635399|PROCEDURE|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
41141417|NCT04251455|PROCEDURE|Arthroscopy or discectomy with sampling of synovial fluid and synovial tissue|"Arthroscopic lysis and lavage: performed under general anaesthesia. Before initiation of arthroscopy synovial fluid was sampled with a push-and-pull method. The TMJ was investigated with an arthroscope during irrigation with sterile saline solution. Adhesions were addressed with a coblator. Synovial tissue biopsies were taken from the posterior attachment of the disc.~Discectomy without replacement: performed under general anaesthesia. Before initiation of surgery, synovial fluid was sampled as above described. During surgery synovial tissue biopsies were taken as described above."
41460441|NCT05702255|OTHER|Active acupressure|Participants will receive training (2 sessions, 2 days a part) by a training researcher. Patients will be taught on the acupoints location and the acupressure technique. Participants will be verified for the correct location of the acupoints, acupressure technique and strength. Participants will be instructed to use thumb or middle finger to self- press each acupoint using circular movements. The force of pressing must be sufficiently strong but still within a comfortable range. A lubricant will be uses to decrease friction between the acupoints and the finger. Follow up evaluation will be at the end of the week 2 and week 4 .The training researcher will make weekly calls to remind participants to perform acupressure and to answer questions
41460442|NCT05702255|OTHER|Sham acuptressure|The same protocol as the active acupressure group.
41460443|NCT00268515|DRUG|cyclosporine|
41460444|NCT00268515|DRUG|tacrolimus|
41460445|NCT00268515|DRUG|prednisone|
41141418|NCT01622049|DEVICE|Selective Laser Photocoagulation of Communicating Vessels|Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
41460446|NCT00268515|DRUG|azathioprine|
41460447|NCT05442437|BIOLOGICAL|hUCMSCs|Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells
41460448|NCT06161701|OTHER|no intervention|no intervention
41460449|NCT03868111|DRUG|Sufentanil|The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
41460450|NCT03868111|DRUG|Remifentanil|The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
41460451|NCT03045016|DRUG|Prazosin, ALPRESS® LP 2,5 et 5 mg|"Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~* PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~* PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days."
41460452|NCT06030128|BEHAVIORAL|core stabilization exercise|All participants will undergo a 16 session exercise program for 2 months. Each session will last for 60minutes. The exercise program will be arranged in a group format with class size ranging from 6-8 per class. Subjects will be divided into experimental and control groups.
41460453|NCT00476307|BIOLOGICAL|Fluarix™/Influsplit SSW® 2007/2008|
41460454|NCT04225260|BIOLOGICAL|botulinum toxin neuromodulator|A dose of QM1114-DP will be injected in the GL area and in the LCL area.
41460455|NCT02448563|BEHAVIORAL|Nutrition and physical activity education|Eight weekly in-person groups
41460456|NCT02864550|DRUG|Doxycycline|doxycycline 100mg orally daily
41460457|NCT02864550|OTHER|Placebo|placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group
41460458|NCT00534430|DRUG|busulfan|
40773253|NCT01276951|PROCEDURE|Samples: serological tests and culture of mononuclear cells|At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
40773254|NCT01276951|PROCEDURE|Analysis of cytokine production|We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
41460459|NCT00534430|DRUG|cyclosporine|
41460460|NCT00534430|DRUG|etoposide|
41460461|NCT00534430|DRUG|mycophenolate mofetil|
40773255|NCT02009787|DRUG|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 months
40773256|NCT02009787|DRUG|placebo tablets|2000 IU placebo tablets were taken daily for 6 months
40773257|NCT03317873|DIETARY_SUPPLEMENT|Testmeal A|The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
40773258|NCT03317873|DIETARY_SUPPLEMENT|Testmeal B|The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
41141419|NCT00629564|DRUG|Esomeprazole|20mg oral
41141420|NCT00629564|DRUG|Esomeprazole|15 minute intravenous infusion
41141421|NCT02124044|DRUG|Asunaprevir and Daclatasvir|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
41460462|NCT00534430|PROCEDURE|allogeneic bone marrow transplantation|
41460463|NCT00534430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41460464|NCT00534430|PROCEDURE|peripheral blood stem cell transplantation|
41460465|NCT00534430|RADIATION|total-body irradiation|
41460466|NCT00467805|PROCEDURE|Light therapy|
41460467|NCT01224457|DRUG|Phenobarbital|phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
41460468|NCT02214563|DIETARY_SUPPLEMENT|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
41460469|NCT02214563|DIETARY_SUPPLEMENT|Olive oil|
41460470|NCT00973050|DRUG|Bicalutamide|50 mg Tablet
41460471|NCT00973050|DRUG|Casodex®|50 mg Tabelt
40977449|NCT05084274|BEHAVIORAL|Lifestyle program|If the patient is allocated to the interventional group, the lifestyle modification program will be planned/started immediately after the intake at the fertility clinic. The lifestyle modification program has a duration of 12 weeks in which the subject will receive follow-up by the endocrinologist/diabetologist and dietitian to re-ceive an active dietary intervention plan, follow-up by the physiotherapist where sessions to start with physical exercise will be given. Monthly follow-up visits with the coordinating PCOS-midwife will be planned to enhance the subject's knowledge about PCOS and give emotional support. At the moment of randomization, the PCOS coordinating midwife will immediately plan all necessary appointments, with the endocrinologist and dietitian, physiotherapist and PCOS-coordinator, for the 12-week lifestyle program. This way, patients will have a clear overview of the following 12 weeks.
40773259|NCT06183970|DEVICE|AssistI patients|The AsistI software package rehabilitation involves tailored upper limb exercises under an individual program. The regimen consists of 10-12 sessions, each lasting 30 minutes. Patients execute 10 exercises sequentially with their unaffected and affected limbs, involving tasks like touching mouth, forehead, and trunk parts with hand's brush, and amplitude movements in upper limb joints. AsistI assesses exercise accuracy, prevents unfavorable patterns, and logs target achievement, considering speed, accuracy, and repetitions.
40773260|NCT06183970|DEVICE|Habilect patients|The Habilect rehab program involves 10-12 sessions using software and hardware. Patients perform upper limb exercises for 30 minutes individually, focusing on specific movements. They repeat 10 exercises, first with the healthy limb, then the affected one. Tasks include touching mouth, forehead, and trunk, along with joint movements like shoulder flexion. Habilect assesses exercise accuracy, preventing wrong moves, and tracks progress, considering speed, accuracy, repetitions.
41301327|NCT04171544|DEVICE|Streamline Occipito-Cervico-Thoracic Spinal Fixation System|Spinal Fixation
40773261|NCT04883944|OTHER|Intervention group|"Mother will be involved in implementing the non-pharmacological techniques during the performance of the heel stick procedure as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding;~* exposure to maternal voice."
41301328|NCT02437097|OTHER|Aerobic exercise|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
41301329|NCT02437097|OTHER|Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
41301330|NCT02437097|OTHER|Aerobic exercise and Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
41301331|NCT02437097|OTHER|Control|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
41301332|NCT00807846|DRUG|Celecoxib|Celecoxib 50 mg or 100 mg PO BID for 6 weeks
41301333|NCT00807846|DRUG|Naproxen|Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks
41301334|NCT02773069|BEHAVIORAL|Church Bridge Project|Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
41301335|NCT01566123|RADIATION|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
40977450|NCT03256565|DIAGNOSTIC_TEST|Q-tip test|A Q-Tip lubricated with anesthetic gel is inserted into the urethra, woman is then asked to cough and strain, and the angle of the Q-tip rotates is recorded.
41301336|NCT01566123|RADIATION|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
41301337|NCT01295905|DEVICE|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
41301338|NCT01295905|DEVICE|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
41301339|NCT04893746|DIETARY_SUPPLEMENT|Lactobacillus plantarum TWK10-L|Low dose: 2x1010 CFU/day
40773262|NCT04883944|OTHER|Standard care group|"A second nurse will perform the non-pharmacological techniques during the performance of the heel stick procedure without the maternal involvement as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding."
40773263|NCT06527677|DRUG|ANT3310|ANT3310 will be administered as a single intravenous infusion over 3 hours at a constant rate.
40773264|NCT06527677|DRUG|Meropenem|meropenem will be administered as a single intravenous infusion over 3 hours at a constant rate.
40773265|NCT05936658|DRUG|[F-18]Florastamin|A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is intravenously administered only to the subjects who meet the inclusion/exclusion criteria, and then \[F-18\]Florastamin PET/CT imaging is performed from the head to thigh after 105 ± 15 minutes (care should be taken to prevent extravasation of the radiopharmaceutical product).
40977451|NCT00708006|DRUG|HGS1029|Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
41301340|NCT04893746|DIETARY_SUPPLEMENT|Maltodextrin|0x1010 CFU/day
41301341|NCT04893746|DIETARY_SUPPLEMENT|Lactobacillus plantarum TWK10-H|High dose: 6x1010 CFU/day
41301342|NCT01429987|DRUG|plecanatide|Subjects receive experimental study drug for 12 weeks.
41301343|NCT01429987|OTHER|Placebo|Subjects receive experimental study drug for 12 weeks.
41301344|NCT03227848|DEVICE|Automated Heart Murmur Detection AI|Automated AI algorithm-based analysis of digital heart sound recordings to detect and classify heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. AI algorithm results for each recording include: AHA classification (Class I (pathologic heart murmur) versus class III (innocent heart murmur or no heart murmur), murmur timing, murmur grade, heart rate and S1/S2 identification.
41301345|NCT03765346|DRUG|Oxycodone IR ADF|Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.
41301346|NCT03765346|DRUG|Oxycodone API powder|Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
41301347|NCT03765346|DRUG|Placebo to match oxycodone API powder|Placebo to match oxycodone API powder (mass of 30 mg).
41301348|NCT03765346|DRUG|Placebo to match manipulated oxycodone IR ADF.|Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
41301349|NCT04099316|DEVICE|Eccentric exercise|Eccentric exercise with Eccentron electronic device. Exercise intervention: The exercise intervention is performed to twice a week (Total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage),(5-8 weeks; 2nd stage).
41301350|NCT04099316|DEVICE|Conventional resistance exercise|Leg press exercise with leg press machine. Exercise intervention: The exercise intervention is performed to twice a week (total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage), (5-8 weeks; 2nd stage).
41301351|NCT03859986|DRUG|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle
41301352|NCT03859986|DRUG|ALX-101 Gel 5%|ALX-101 Gel 5%
41301353|NCT01502657|DEVICE|Ultrasonography (EnVisor Philips Medical Systems)|Percutaneous tracheostomy is performed using the dilatational method with ultrasonography guidance;
41301354|NCT00441558|DRUG|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
41301355|NCT02629523|DRUG|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
41301356|NCT00956475|BEHAVIORAL|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
41301357|NCT00956475|OTHER|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
41301358|NCT00956475|PROCEDURE|assessment of therapy complications|questionnaire via telephone
41301359|NCT00956475|PROCEDURE|fatigue assessment and management|questionnaire via telephone
41301360|NCT00956475|PROCEDURE|psychosocial assessment and care|questionnaire via telephone
41301361|NCT00956475|PROCEDURE|quality-of-life assessment|questionnaire via telephone
41301362|NCT01248234|DRUG|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
40773266|NCT04746898|OTHER|Virtual Reality Training|Students received their basic life support application training through virtual reality glasses with special software.
40977452|NCT05502393|DRUG|JS107|JS107, i.v., q3w
41301363|NCT01248234|DRUG|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
41301364|NCT01248234|DRUG|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
41301365|NCT00648843|DRUG|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fed
41301366|NCT00648843|DRUG|Ditropan XL® Tablets 5 mg|4x5mg, single dose fed
41301367|NCT03233490|OTHER|web course|Web course Help Brain Heart was conducted Before CPR training.
41301368|NCT03233490|OTHER|CPR training|No web course was conducted
41460472|NCT01050764|DRUG|Regulatory T-cells|"To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~* T-reg: 1 x 10e5/kg~* T-con: 3 x10e5/kg~Cohort 2~* T-reg: 3 x 10e5/kg~* T-con: 1 x 10e6/kg~Cohort 3~* T-reg: 1 x 10e6/kg~* T-con: 3 x 10e6/kg~Cohort 4~* T-reg: 3 x 10e6/kg~* T-con: 1 x 10e7/kg"
40773267|NCT04746898|OTHER|High Fidelity Simulation Training|Students received their basic life support application training through high fidelity simulator mannequins.
41460473|NCT01050764|DRUG|Conventional T-cells|These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
41460474|NCT01050764|DRUG|Melphalan|Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
40773268|NCT04746898|OTHER|Low Fidelity Simulation Training|Students received their basic life support application training through low fidelity simulator mannequins.
40773269|NCT06501898|DIETARY_SUPPLEMENT|CoreBiome|300 mg, once daily of tributyrin for 4 weeks
40773270|NCT06501898|DIETARY_SUPPLEMENT|Placebo|300 mg, once daily of placebo for 4 weeks
40773271|NCT05876520|PROCEDURE|Total pulpotomy with I-prf mixed with Nano-bioactive glass|Total pulpotomy is done in mature permanent molars followed by I-prf mixed with Nano-Bioactive glass application. Topped with BC putty for coronal seal, RMGI and restored with composite as final restoration
41301369|NCT01400334|RADIATION|Positron Emission Tomography|Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine \[HED, 20 mCi (740 MBq)\] to quantify sympathetic nerve function, b) 13N-ammonia \[NH3, 20 mCi (740 MBq)\] for regional perfusion, and c) 18F-2-deoxyglucose \[FDG; 6.5 mCi (241 MBq)\] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
41301370|NCT05682664|OTHER|Luchtbrug Junior (online monitoring)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
41301371|NCT05682664|OTHER|Usual care|Routine outpatient clinical visits every 3 months.
41460475|NCT01050764|DRUG|Thiotepa|Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
41460476|NCT01050764|DEVICE|Fludarabine|Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
40977453|NCT05502393|DRUG|Toripalimab|Toripalimab i.v., q3w
41460477|NCT01050764|DRUG|Anti-thymocyte globulin, rabbit|Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
41460478|NCT01050764|DRUG|CliniMACS CD34 Reagent System|An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
41460479|NCT02033317|DRUG|patiromer|15 grams/day (5 grams 3 times daily) administered orally
40773272|NCT05382130|DIAGNOSTIC_TEST|Test all|"In the test all arm, SARS-CoV-2 infection screening questions will be administered to all clinic attendees followed by SARS-CoV-2 Ag-RDT testing irrespective of screening results."
40773273|NCT02921256|DRUG|Capecitabine|Given PO
40773274|NCT02921256|DRUG|Fluorouracil|Given IV
41460480|NCT03573336|DRUG|Vilaprisan (BAY1002670)|Intake orally, once daily
41141422|NCT02124044|DRUG|Asunaprevir and Daclatasvir with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
41460481|NCT03573336|DRUG|Matching Placebo|Intake orally, once daily
41460482|NCT01833169|DRUG|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
41460483|NCT04951856|DRUG|Evolocumab 140 MG/ML|Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
41460484|NCT04951856|DRUG|Standard of care (SOC)|management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
41460485|NCT02474654|DRUG|Bupivicaine|15mg
41460486|NCT02474654|DRUG|Fentanyl|15mcg
41460487|NCT02474654|DRUG|Epimorphine|150mcg
41460488|NCT02474654|DRUG|Normal Saline|0.3 ml
41460489|NCT02474654|DRUG|Normal Saline|30ml
41460490|NCT02474654|DRUG|Normal Saline|100 ml
41460491|NCT02474654|DRUG|Ropivicaine|100 ml
41460492|NCT02474654|DRUG|Epinephrine|600 mcg
41460493|NCT02474654|DRUG|Ketorolac|30 mg
41460494|NCT02474654|DRUG|Ropivicaine with Epinephrine|0.5% 1:400,000 30ml
41460495|NCT03215641|DEVICE|Fitbit|The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
41460496|NCT02525263|BIOLOGICAL|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
40773275|NCT02921256|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity modulated radiation therapy
40773276|NCT02921256|DRUG|Leucovorin|Given IV
40773277|NCT02921256|DRUG|Oxaliplatin|Given IV
40773278|NCT02921256|BIOLOGICAL|Pembrolizumab|Given IV
40773279|NCT02921256|DRUG|Veliparib|Given PO
40773280|NCT02014376|DRUG|SD-101 dermal cream (3%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
40773281|NCT02014376|DRUG|SD-101 Dermal Cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
40977454|NCT03569540|DRUG|Glibenclamide|Placebo-controlled; Double blind test
41460497|NCT02701608|DRUG|Levofloxacin|levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients \>70kg)
41460498|NCT02701608|DRUG|Rifampicin|rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients \>70kg)
40773282|NCT02014376|DRUG|Vehicle (SD-101 0%)|A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
40773283|NCT04869137|DRUG|Lenvatinib Oral Product|20mg of Lenvatinib will be taken orally once daily
40773284|NCT04869137|DRUG|Pembrolizumab|200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
40977455|NCT03569540|OTHER|Placebo|Amylum
40977456|NCT04128267|DEVICE|IPC-1000|Delivers pressure to thumbnail for five seconds at a time
40977457|NCT04128267|DEVICE|Magnetic resonance imaging|Scan of brain using Magnetic resonance imaging
40977458|NCT04128267|OTHER|Correlative Studies|Administration of questionnaires via computer
40977459|NCT04850131|PROCEDURE|Desarda repair|Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis
40977460|NCT00402766|DRUG|Cisplatin|Starting Dose: 60 mg/m\^2 by vein, Over 2 Hours
41141423|NCT06153706|DRUG|Subgingival application of L-PRF loaded with metronidazole|After phase I therapy, L-PRF loaded medical grade metronidazole was applied sub gingivally into the pockets using blunt gauge needle and Perio-pack was placed (two applications with one week apart were applied subgingivally.
41460499|NCT02701608|PROCEDURE|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
40773285|NCT03321942|DRUG|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
40773286|NCT03321942|DRUG|Control group|Conventional treatment were used to treat patients with chronic renal failure.
40773287|NCT03629704|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
40773288|NCT01784484|OTHER|No intervention|
40773289|NCT03135860|DRUG|Inhaled Nitric Oxide 30mcg/kg IBW/hr|Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
40773290|NCT04438824|DRUG|INCMGA00012|INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)
40773291|NCT04438824|DRUG|Palbociclib|Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days
40773292|NCT02053155|BEHAVIORAL|Computer based patient education|
40773293|NCT06288438|BEHAVIORAL|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
40773294|NCT06288438|OTHER|Physical Therapy Interventions|Strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise.
40773295|NCT06288438|OTHER|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene, etc.
40773296|NCT06288438|OTHER|Health Status Updates|Health Status Updates will be completed by a trained assessor. The assessor will ask about adverse events, general health topics, medication changes, and changes in social circumstances.
40773297|NCT06288438|OTHER|Physical Therapy Consult|Participants in the control condition will be offered a physical therapy consult at the end of their 24 week study involvement.
40773298|NCT02014987|BEHAVIORAL|Training programmes|"Runners with a high body mass index follow two types of training programmes:~1. a running programme of 3 kilometres per week~2. a running programme 6 kilometres per week~The amount of running will be increased with 10 % per week."
40773299|NCT01415947|DEVICE|V Chordal|"V-Chordal system, consists in the ability to adjust (elongate or shorten) the neochordae off-pump . The adjustment mechanism allows overcoming the main problem of chordal replacement by enabling accurate sizing of the chords."
40773300|NCT05393492|BEHAVIORAL|Dialectical Behavior Therapy and Radically Open dialectical behavior therapy|"Dialectical Behavior Therapy is a third wave cognitive-behavioral therapy. It focuses on emotional dysregulation and interactions between the patient and his family in genesis and maintenance of challenging behaviors. It is used here in an adapted form for cognitive problems.~Delivered in a group format of 19 weeks + individual sessions."
40773301|NCT03209258|OTHER|Care bundle of active management|"1. Intensive BP lowering to systolic target of \<140mmHg;~2. Glucose control target 6.1-7.8 mmol/l for non-diabetic; 7.8-10.0 mmol/l for diabetic patients;~3. Treatment of pyrexia to a target body temperature ≤37.5 ℃;~4. Reversal of anticoagulation to target INR \<1.5 involving use of vitamin K and prothrombin complex concentrate (PCC) or alternatively, fresh frozen plasma (FFP).~As the trial is an assessment of care bundle of physiological management, there is some flexibility in the use of particular BP lowering agents and antipyretic agents to achieve targets."
40773302|NCT03209258|OTHER|Usual care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
40773303|NCT05112640|DEVICE|INSORB: subcuticular stapling device|Under the skin stapling device that delivers absorbable staples
40977461|NCT00402766|DRUG|Imatinib Mesylate|Starting Dose: 300 mg PO Daily
41141424|NCT06153706|OTHER|Subgingival application of L-PRF|The L-PRF alone was applied subgingivally into the pockets and Perio-pack was placed (two applications with one week apart.
41141425|NCT00623714|DRUG|Comparator: fluticasone|Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
41141426|NCT00623714|DRUG|Placebo|Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
41141427|NCT00923169|DRUG|Anti-Transforming Growth Factor-beta (GC 1008)|
41141428|NCT01123005|PROCEDURE|PET Scan|radiation calculated per patient
41141429|NCT01123005|DRUG|EF5|10 mCi, IV
40773304|NCT05112640|DEVICE|Subcuticular monocryl suture manufactured by Ethicon|Under the skin suture placed by hand
40773305|NCT06067698|DRUG|"Mesalamine and alpha-lipoic acid"|Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months
40773306|NCT06067698|DRUG|"Mesalamine and Placebo"|Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months
40773307|NCT06024538|PROCEDURE|Tumor samples|Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
40773308|NCT05543317|DIAGNOSTIC_TEST|18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
40773309|NCT03193580|DEVICE|Anodal Conventional tDCS|tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
40773310|NCT03193580|DEVICE|Anodal High Definition tDCS|HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
40977462|NCT00402766|DRUG|Pemetrexed|Starting Dose: 500 mg/m\^2 by vein, Over 40 Minutes
40977463|NCT00402766|DRUG|Dexamethasone|20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
40977464|NCT05830851|OTHER|real tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with therapeutic parameters
40773311|NCT03193580|DEVICE|Sham tDCS|tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
40773312|NCT05497687|OTHER|Resistance exercise|The training schedule for supervised sessions (including community-based and home-based) will last for 60 minutes per session, two sessions per week. From Week 3 and 4, the exercise specialist will deliver supervised home-based training, with one in-person session via home visits and one session to be delivered remotely via an online platform (Zoom). Then the supervision will gradually tail off from Week 5 and onwards, from online supervised sessions, to unsupervised self-practice sessions. An in-person supervised home visit as a booster session will be given at Week 9, the beginning of the habituation phase. Telephone follow-ups will be arranged at Week 10 - 12 by the exercise specialist. All participants in the intervention group will be invited to take part in a qualitative interview to explore the feasibility and acceptability of the intervention.
40773313|NCT00004682|DRUG|immune globulin|
40773314|NCT03774381|DIETARY_SUPPLEMENT|Bifidobacterium breve B-3|160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.
40773315|NCT03774381|DIETARY_SUPPLEMENT|Control group|160 mg of placebo is orally administered per day for 12 weeks.
40773316|NCT06564935|DRUG|Heptaminol Hydrochloride|heptaminol hydrochloride will be administrated in its solution form 4ml/kg. The mean dose used will be 25 drops = 150 mg and will be given 1.5 to 2 hours before spinal anesthesia
40773317|NCT06564935|DRUG|Placebo|Placebo drops (identical to heptaminol drops, prepared by the hospital pharmacy) will be administered 1.5 to 2 hours before spinal anesthesia.
40773318|NCT04847882|BEHAVIORAL|Questionnaire|Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes
40773319|NCT06126159|DIAGNOSTIC_TEST|multiparametric and fat-detection magnetic resonance imaging (MRI)|Differentiating of renal AMLs with minimal fat and RCCs
40773320|NCT01019941|DRUG|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
40773321|NCT01019941|DRUG|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
40773322|NCT03622983|OTHER|collection of sample and data|Recovery of surgical waste during surgery planned in the current care and clinical data collection
40773323|NCT00829998|DRUG|Zaleplon 10 mg Capsules|1 x 10 mg, single-dose fasting
41141430|NCT01123005|DRUG|Carbogen|Calculated per patient
41141431|NCT01123005|DRUG|Dichloroacetate|
41141432|NCT03060785|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine|
41141433|NCT06498232|OTHER|Active Video Based Exercises|Warm-up and cool-down will consist of aerobic games (Step, Hula Hoop, Rhythm Parade Dance, Run) available in Nintendo Wii. Balance games will consist of Penguin Slide, Soccer Heading, Table Tilt, Balance Bubble, Ski Slalom, Ski Jump, Tilt City, and Snowboard Slalom. Among the sports games, Bowling, Boxing, Tennis, and Baseball will be included in the program. In all games, progress will be made by increasing the difficulty levels, and in balance games, the game will be made more difficult with an additional balance board and bosu.
41301372|NCT01998581|DEVICE|JUVEDERM VOLBELLA® XC|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL. Up to 6.0 mL allowed for repeat treatment.
41141434|NCT06498232|OTHER|Stabilization and Strengthening Exercises|Warm-up exercises will consist of active dynamic warm-up exercises. Stabilization and strengthening exercises; extremity movements will begin with teaching respiratory control in supine, prone, sitting, crawling, squat, and standing positions, and will be made more difficult with the addition of exercise tires and exercise balls. Balance exercises will start from static positions and move on to dynamic positions with the inclusion of different surfaces. In the cooling exercises, in addition to breathing exercises, stretching exercises will be performed for the trunk, upper and lower extremities.
40773324|NCT00829998|DRUG|Sonata® 10 mg Capsules|1 x 10 mg, single-dose fasting
40773325|NCT01539031|DRUG|E2020|"Subjects in the Group-10 mg:~Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg"
40773326|NCT01539031|DRUG|E2020|"Subjects in the Group-23 mg:~Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg"
40773327|NCT03003663|DEVICE|SensableCare System|The SensableCare System is evaluated for reducing bed falls.
40773328|NCT04862312|BEHAVIORAL|VideoDine|Participants will VideoDine with a dining partner at least six times during an eight week period. VideoDining involves sharing a meal with someone not physically present using video chat technology. Dining partners will be recruited, trained and paired with participants. Participants will be provided Amazon Echo Show devices for video chat.
40773329|NCT03344484|OTHER|Surgical approach|Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion
40773330|NCT03360344|DEVICE|Kinesio 12 inch Tape|Kinesio Tape approximately 12-inch strip will be applied to the dorsal surface of the forearm of the affected side for three-day increments over three weeks of the study.
40773331|NCT03360344|DEVICE|Kinesio 4 inch Tape|Kinesio Tape for the control group will be a 4 inch Kinesio Tape applied to the scapular spine for three day increments over three weeks of the study.
40977465|NCT05830851|OTHER|sham tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with sham tDCS
40977466|NCT05069831|DRUG|Abrocitinib|Abrocitinib daily for 4 months
40977467|NCT01103011|DRUG|ND0611|Continuous delivery of ND0611
40977468|NCT01103011|DRUG|ND0611|Solution of ND0611 delivered continuously
40773332|NCT03360344|DEVICE|Cock up Splint and Lumbrical exercises|A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
41460500|NCT04666753|DIETARY_SUPPLEMENT|ImmunoFormulation|The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at \<10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).
40977469|NCT05552950|BIOLOGICAL|BioBlock® antiviral nasal spray|SARS-CoV-2 BioBlock is a natural preparation derived from bovine colostrum, where animals have an immune response against the SARS-CoV-2 spike protein in addition to conventional vaccines. The antiviral colostrum preparation was made from colostrum of cows immunized with SARS CoV-2 spike protein. Pregnant cows were immunized during the third trimester of gestation using a non-infectious recombinantly produced and purified SARS CoV-2 spike protein. Colostrum, which is milked after calving, concentrates most of the antibodies produced in the cow's body at very high concentrations, including neutralizing antibodies to SARS CoV-2 produced as a result of immunization.
41460501|NCT06016153|OTHER|Software based feedback|Feedback is given by the data of a software (InnoMed CardioAid-1 Trainer AED, Innomed Inc., Budapest, Hungary).
40977470|NCT04471012|OTHER|Individual counselling program|"An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.~Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet was given during their first counseling session."
41141435|NCT06498232|OTHER|Waiting List-Spine protection principles training|Participants will be placed on a waiting list. Following the initial evaluations, participants will be informed that they will be included in an exercise program at the end of 6 months. During this process, participants in the control group will be called by phone at the 6th, 12th, and 18th weeks to question their status and to remind them that they will start the exercise program after a while. It will be evaluated at the end of 6 months, and the end of the study, exercise training approaches in the intervention group will be applied to participants who wish to do so, with the same protocol and duration.
41460502|NCT06016153|OTHER|Instructor feedback|Feedback is given by the opinion and observation of an experienced instructor.
40773333|NCT05136755|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
40773334|NCT05136755|DRUG|Placebo Cap|Use of placebo as a comparator
40773335|NCT00811460|DRUG|Placebo|sc for 4 days
40773336|NCT00811460|DRUG|taspoglutide|300micrograms/day sc for 2 days
40773337|NCT00811460|DRUG|taspoglutide|800 micrograms/day sc for 2 days
40773338|NCT02738619|DRUG|Vitamin D3|1600 UI
41141436|NCT03732456|PROCEDURE|Shoulder surgery and post-op pharmacological treatment|Usual care surgery (shoulder arthroscopy) and post-operative pain management protocol
41301373|NCT01998581|DEVICE|Restylane-L®|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL.. Up to 6.0 mL allowed for repeat treatment.
40773339|NCT02738619|DRUG|placebo|placebo
40773340|NCT00556114|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography
40773341|NCT01929694|DIETARY_SUPPLEMENT|Berocca Boost|
40773342|NCT01929694|DIETARY_SUPPLEMENT|Placebo|
40977471|NCT01355341|DRUG|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
40773343|NCT04956887|BEHAVIORAL|AKL-T01|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
40773344|NCT04956887|OTHER|Control Group|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning
40773345|NCT06043154|OTHER|Patients with severe to extreme anorexia nervosa admitted to hospital for refeeding|Clinical and biological measurements, blood and stool sample collection
41301374|NCT00756587|DEVICE|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
41460503|NCT02578290|OTHER|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default."
41460504|NCT00494351|PROCEDURE|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
41460505|NCT01353716|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
41460506|NCT04873245|BEHAVIORAL|Intensive Behavioral Program|Participants randomized to this group will receive intensive behavioral therapy.
41460507|NCT04873245|DRUG|Semaglutide and Behavioral Program|Participants randomized to this group will receive semaglutide and behavioral therapy.
41460508|NCT01812473|OTHER|Blood sampling|During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.
41460509|NCT04402606|OTHER|Evaluation on skin toxicities|Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).
41460510|NCT00112216|BIOLOGICAL|Melan-A analog peptide|
41460511|NCT00112216|BIOLOGICAL|FluMa peptide|
41460512|NCT00112216|BIOLOGICAL|Mage-A10 peptide|
41460513|NCT00112216|BIOLOGICAL|SB AS-2 adjuvant|
41460514|NCT00112216|BIOLOGICAL|Montanide adjuvant|
41460515|NCT05100680|OTHER|Multicomp|Daily dietary supplementation over 12 weeks with test product: food supplement - 2 capsules / day containing together: 20 mg coenzyme Q10,500 mg methyl sulfonyl methane (MSM), 100 mg L-proline, 10 mg L-cysteine (as HCl monohydrate), 2 mg thiamine , 2.4 mg riboflavin, 19 mg niacin, 8.5 mg pantothenic acid, 2.3 mg vitamin B6, 0.15 mg, biotin, 0.0125 mg vitamin B12, 80 mg vitamin C, 5.5 mg vitamin A , 22 mg vitamin E, 10 mg zinc, 0.07 mg selenium, 1.1 mg copper.
41460516|NCT05100680|OTHER|Placebo|Daily dietary supplementation over 12 weeks with placebo product: dietary supplement - 2 capsules / day, containing only modified starch.
41460517|NCT02364986|DRUG|Rebif®|Rebif® 44µg (day 1, 3, 5 and 8) s.c.
41460518|NCT02364986|DRUG|Avonex|Avonex 30µg (day 1 and 8) i.m.
41460519|NCT04924751|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine needle biopsy|Under endoscopic ultrasound guidance, fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions.
41460520|NCT00217334|BEHAVIORAL|Volunteer-led pharmacy sessions with feedback to physicians|
41460521|NCT03868631|DIETARY_SUPPLEMENT|Whey protein supplement|19 g whey protein isolate (contains 2 g leucine) was consumed daily by one intervention group.
41460522|NCT03868631|DIETARY_SUPPLEMENT|Soy protein supplement|26 g soy protein isolate (contains 2 g leucine) was consumed daily by the other intervention group.
41460523|NCT04995354|DRUG|EGF loaded Hydrogel|Patients will receive 25 Ug/day of EGF. This is the estimated daily dose that will be obtained when the patient applies the gel thrice daily. Patients will receive the treatment for one week
41460524|NCT04995354|DRUG|Hydrogel|Non-medicated self-healing hydrogel to be applied three times a day for 1 week
41460525|NCT01833039|DRUG|Ibrutinib|Ibrutinib
41460526|NCT06086353|DRUG|Tafamidis|Patients on tafamidis will be observed
40773346|NCT04038879|DIAGNOSTIC_TEST|MRI|MRI of the heart
41301375|NCT00756587|DEVICE|Bottle Feeding|receiving all feeding by bottle
41301376|NCT02388529|DRUG|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
41301377|NCT02388529|DRUG|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
41301378|NCT02388529|DRUG|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
41460527|NCT04761445|OTHER|Straumann Standard Plus implant and JDental care (JD) Octa implant|Two different implant systems were used. The above-mentioned implants share many features in common, such as implant design. They both have a machined implant collar of 1.8 mm.
41460528|NCT02721368|DEVICE|Neuramis® Volume Lidocaine|hyaluronic acid filler
41460529|NCT02721368|DEVICE|Juvederm® Voluma® with Lidocaine|hyaluronic acid filler
41460530|NCT03232450|DRUG|Aspirin|Subjects will receive 81 mg enteric coated aspirin
41460531|NCT03232450|DEVICE|Cardiovascular Implantable Device (CIED)|All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
41460532|NCT03232450|DEVICE|Gore Cardioform Septal Occluder|The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
41460533|NCT02684539|DEVICE|tilt table Erigo®|tilting table with onset of syncope
41460534|NCT03588260|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
41460535|NCT03929016|DRUG|DNDI-0690|capsules of 10, 100 and 200 mg
41460536|NCT03929016|DRUG|Placebo of DNDI-0690|capsules of matching placebo
41460537|NCT03258996|PROCEDURE|Modified vestibular incision subperiosteal tunnel access|"Single vertical mucosal incision, in the middel of the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.~With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.~Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.~All is stabilized by means of suspensory sutures of coronal traction on each point of contact.~Finally the vertical incision made is sutured."
41460538|NCT03258996|PROCEDURE|Coronally advanced flap|"Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.~A partial-total-partial thickness flap is elevated in the coronal-apical direction.~A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.~Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area."
41460539|NCT05548920|OTHER|Ultrasound guided Superior Vena Cava Collapsibility Index|Preoperative Ultrasound guided Superior Vena Cava Collapsibility Index will be measured
41301379|NCT02388529|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
41301380|NCT05091489|OTHER|Qualitative assessment about PrEP acceptability|Qualitative research among key-populations, community and healthcare workers, and decision and policy makers, including focus group and semi-directive interviews
41460540|NCT05548920|OTHER|Inferior Vena Cava Collapsibility Index|Preoperative Inferior Vena Cava Collapsibility Index will be measured.
41460541|NCT00370851|DRUG|Avastin (Bevacizumab)|Intravitreal injection of 125 mg Avastin
41460542|NCT06222658|DEVICE|pharmaco-mechanichal thrombectomy|pharmaco-mechanichal thrombectomy in acute limb ischemia
41460543|NCT05908617|OTHER|Video Discharge|Patient will watch a video discharge instructions in addition to the standard paper instructions. They will also take the pre and post test as the control group
41460544|NCT00003387|DRUG|carboplatin|
41460545|NCT00003387|DRUG|chemotherapy|
41460546|NCT00003387|DRUG|paclitaxel|
41460547|NCT00003387|RADIATION|radiation therapy|
41460548|NCT00240734|DRUG|Epoetin alfa|
40773347|NCT04388228|OTHER|Extended audit and feedback in GPs electronic health record|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~* Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~* A low cognitive load of the feedback where the results will be presented with the help of graphs.~* Action plans to improve the quality of registration~* A push system to minimize the effort the GP must make to consult the feedback."
41141437|NCT05790135|DEVICE|shear wave elastography|Shear wave elastography and CEUS will be used to evaluate the reliability in diagnosing graft versus host disease of the gut after hematopoietic stem cell transplantation
41141438|NCT06030739|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
41141439|NCT02487680|DIETARY_SUPPLEMENT|Amino Acids and chromium-picolinate containing drink|Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
41141440|NCT02487680|DIETARY_SUPPLEMENT|Placebo drink|Evaluation of the placebo supplement drink containing only aroma
41141441|NCT01728857|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
41141442|NCT01128439|OTHER|No intervention|No intervention
41141443|NCT06031506|DEVICE|Implant supported hybrid maxillary prosthesis|All patients will receive immediately loaded hybrid prosthesis supported by 4 zygomatic implants.
41141444|NCT05343936|OTHER|Active surveillance|"The active surveillance protocol involves a TRUS prostate biopsy at eligibility, at 12 months and then every two years. MRI with or without biopsy at eligibility and then every two years. Clinical evaluation with digital rectal examination and PSA every 6 months. Every year a quality of life and anxiety evaluation are planned.~A new prostate biopsy is indicated if biochemical progression by PSA or changes in multiparametric MRI. Triggers for definitive intervention are biopsy pathological reclassification with Gleason score greater than 6, clinical progression or patient's request."
41301381|NCT04775212|DRUG|Desﬂurane|compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.
41460549|NCT06172439|OTHER|acupressure|Women in the intervention group will receive acupressure for 12 minutes.The acupressure pressure points related to the gynecologic surgery to be performed are named as the large intestine (LI4), stomach (ST36) and spleen (SP6) meridians, respectively. These points are determined by expert opinion and are used for pain control.
41460550|NCT01476501|DRUG|Vitamin D3|Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
41301382|NCT04775212|DRUG|Sevoflurane|Sevoflurane
41301383|NCT03827473|DRUG|Abiraterone Acetate|Given PO
41301384|NCT03827473|DRUG|Antiandrogen Therapy|Given per standard of care
41301385|NCT03827473|DRUG|Docetaxel|Given IV
41301386|NCT03827473|DRUG|Prednisone|Given PO
41301387|NCT03827473|OTHER|Quality-of-Life Assessment|Ancillary studies
41460551|NCT05710588|OTHER|motor-motor dual-task training|The intervention compromises balance-related tasks which are selected among the tasks often used in balance rehabilitation and motor secondary tasks might be required hand dexterity like popping a fidget toy or reaching ability like touching wall. All sessions will be individual. The initial training session will be undertaken in University of Plymouth. This will be followed by a recorded training video programme which can be accessible through Panopto- a University-led, web-based platform- undertaken in the participants' home for 30 minute sessions, three times a week over 6 weeks.
41460552|NCT05710588|OTHER|motor-cognitive dual-task training|The intervention compromises (1) balance-related tasks which are selected among the tasks often used in balance rehabilitation and (2) cognitive secondary tasks might required to activate sensory and cognitive systems like listening podcast and memorizing the details about it or reading a tongue twister and repeating. intervention delivery will be the same with M-DTT group.
41460553|NCT03013036|DEVICE|Ultrasonography|
41460554|NCT03013036|DRUG|Sevoflurane|
41301388|NCT03827473|OTHER|Questionnaire Administration|Ancillary studies
41301389|NCT02633995|PROCEDURE|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
41301390|NCT01727635|OTHER|body-mind-spirit group therapy|8-session therapy
41301391|NCT05092971|DEVICE|Shock or startle device|Shock and startle devices were used as aversive stimulus (shock and startle)
40773348|NCT06496724|BIOLOGICAL|Albumin paclitaxel/neutrophil drug|Isolate the patients' autologous neutriphil cells, induce and culture them with albumin paclitaxel in vitro. The final product for Albumin paclitaxel/neutrophil drug.
41301392|NCT00952289|DRUG|Ruxolitinib|Ruxolitinib phosphate tablets 5 mg administered as oral doses.
41460555|NCT03013036|DRUG|intravenous midazolam|
41141445|NCT00925548|BIOLOGICAL|Tecemotide (L-BLP25) and Hormonal Treatment|"Investigational Arm:~Pretreatment (Single Dose) 300 mg/m\^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).~Primary treatment phase:~Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* (Week 1 to 8).~Maintenance treatment phase:~Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).~\*calculated as mass of lipopeptide (antigen)"
41460556|NCT03013036|DRUG|Propofol|
41460557|NCT03013036|DRUG|fentanyl and rocuronium|
41460558|NCT04450264|BEHAVIORAL|African Immigrant Breast Cancer Education Program|African immigrant women are at significant risk for not participating in preventive screening, such as for breast cancer. Thus, this project will culturally adapt an existing evidenced-based, the Witness Project, by identifying potential barriers and guided by the Health Belief Model incorporate those findings into a group-based narrative education program for English and French-speaking African immigrant women. The program content will include: (1) information about the benefits of early detection of breast cancer screening, (2) education about disparities in breast cancer, (3) disparities in breast cancer screening among African immigrant women, and (4) will address the unique barriers and facilitators of African immigrant women identified in Aim 1 of this study. The program will use a culturally matched peer approach to educate and model successful experiences with mammography screening.
41141446|NCT00925548|BIOLOGICAL|Placebo of tecemotide (L-BLP25) and Hormonal Treatment|"Control Arm:~Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.~Primary treatment phase:~Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).~Maintenance treatment phase:~Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD)."
41141447|NCT00925548|DRUG|cyclophosphamide|300 mg/m\^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
41141448|NCT00925548|DRUG|sodium chloride (NaCl)|NaCl 9 g/L infusion
41141449|NCT04361240|RADIATION|Proton vs Photon Radiation|Assignment to proton vs photon by randomization on RadComp parent study.
41141450|NCT04349709|BEHAVIORAL|Brief school-based DBT-A|The intervention is inspired to Dialectical Behavior Therapy for Adolescents (DBT-A) (Rathus \& Miller, 2015, Mazza et al, 2016; Cappelluccio, 2019). It consists in four monthly 2-hour sessions (for a total of 8 hours) scheduled during school-time. All the sessions are conducted by two psychotherapists trained about DBT. During the sessions, the model of emotions is described through a role-play between conductors. Subsequently, teens are trained about main emotional regulation skills. Moreover, basic elements of distress tolerance, mindfulness and interpersonal efficacy are introduced too.
41141451|NCT04535440|OTHER|No intervention|No intervention
41301393|NCT00952289|DRUG|Placebo|Matching placebo tablets were administered as oral doses in the same manner as active drug.
41301394|NCT03140800|DEVICE|intrauterine device|a method of contraception inserted in the uterus
41301395|NCT03699852|RADIATION|Membracel and LED photobiomodulation|Participants were positioned so that the skin graft donor area was accessible. A light-emitting diode (LED) plate was covered with sterile transparent and waterproof film to prevent contamination when in contact with the donor area. The application was in contact, with full coverage of the surgical wound and was irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. It is worth mentioning that the LED plate was applied in direct contact with the skin graft donor area in the immediate postoperative period and on the primary cover used (Membracel®) on the 1st, 3rd, 5th and 7th postoperative days. Coverage remained until spontaneous departure. The researcher and the participants used specific goggles for this procedure.
41301396|NCT03699852|OTHER|Membracel|This group did not receive LED application, remaining with the skin donor area covered by Membracel® and were evaluated under the same conditions.
41301397|NCT02746393|OTHER|Health Advocates Program|Provided services and support to address identified social needs from health advocate navigators.
41301398|NCT02746393|OTHER|211 Information Sheet|Receive a printed list of community resources to address social needs.
41460559|NCT01135940|DEVICE|2-octylcyanoacrylate (Dermabond) closure|Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
41460560|NCT01135940|DEVICE|Standard staple closure|Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
41460561|NCT00949091|DRUG|TAK-875|"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally."
41301399|NCT04355091|BEHAVIORAL|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage forms, rather than using acupuncture needles.
41301400|NCT03468283|OTHER|mobile application for diabetes|Intervention was mobile application and individualized regular message feedback sent by healthcare professionals.
41301401|NCT05590195|DRUG|Preforpro|Preforpro will be investigated to improve vaginal health in women with BV.
40773349|NCT06281418|DRUG|Granisetron 1 Mg/mL Intravenous Solution|2mL intraperitoneal adminstration of granisetron (1 mg/mL)
40773350|NCT06281418|OTHER|Normal saline|2 ml IP normal saline (0.9% NaCl)
41141452|NCT04725266|BEHAVIORAL|Family-based intervention|The intervention aims to motivate drug abusers to stay drug abstinence and improve family functioning with the support of their own families. In the component of engagement, we will use effective and appropriate skills to engage clients, understand their concerns, and provide necessary resources to them. In the component of role identification, we will help drug abusers identify their family roles through providing education on family roles and responsibilities. The component of affection is designed to learn affective responsiveness and enhance their emotional bonds with each other, while in the component of competence, we will enhance their competency to take care of the family. The intervention will be conducted in group sessions with 4-6 families per group. A total of 17 sessions will be delivered with 1.5-2 hour for each session (6 sessions for Engagement, 3 sessions for Role identification, 3 sessions for Affection, and 3 sessions for Competence).
41301402|NCT05590195|OTHER|Placebo|Placebo capsules manufactured to look like Preforpro capsules
41301403|NCT01029288|OTHER|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
41301404|NCT01029288|OTHER|Statin Choice Decision Aid|Statin Choice Cards
41301405|NCT01029288|OTHER|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
41141453|NCT04725266|OTHER|routine care|Routine care includes individual-session components of engagement, case assessment, drug education, service referral, family support, and etc.
41141454|NCT04221321|DRUG|Atorvastatin 40 mg|Atorvastatin 40 mg
41141455|NCT04221321|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
41141456|NCT04221321|DRUG|RAPA114|RAPA114 tablet
41141457|NCT00175253|DRUG|alemtuzumab|
41141458|NCT00175253|PROCEDURE|islet transplant|
41141459|NCT05837728|BEHAVIORAL|Health promoting assessment of older adults living at home|Based on the results of the first assessment of the older person's health determinants, healthcare professionals will recommend and tailor measures to the individual's needs to reduce the risk of functional decline and maintain their health while living at home.
41141460|NCT02486939|DRUG|CHS-0214|Open label
41301406|NCT01029288|OTHER|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
41301407|NCT04089605|DRUG|dexamethasone implant|intravitreal dexamethasone implant injections in vitrectomized patients with DME
40773351|NCT05494086|PROCEDURE|DPLDG|Dual-port laparoscopic distal gastrectomy
41301408|NCT04089605|DRUG|Ranibizumab|intravitreal ranibizumab injections in vitrectomized patients with DME
41301409|NCT02764632|PROCEDURE|Digital facilitation|
41301410|NCT02934412|DRUG|SHR-1314|Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
41301411|NCT02934412|DRUG|placebo|Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
40773352|NCT05494086|PROCEDURE|LDG|Laparoscopic distal gastrectomy
40773353|NCT04548960|OTHER|cancer patients|Blood sample RNA_seq at time of diagnostic, best response and relapse ; Biopsy Exom_seq and RNA_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse
40773354|NCT05177380|PROCEDURE|Personalized rehabilitation program of facial involvement in systemic sclerosis|Personalized rehabilitation program of facial involvement in systemic sclerosis
41141461|NCT02991573|DEVICE|Prime & Bond Universal|Prime \& Bond Universal
40773355|NCT05177380|OTHER|Delivery of a standard prescription for facial rehabilitation|Delivery of a standard prescription for facial rehabilitation
40773356|NCT03298893|DRUG|Nivolumab Injection|2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks
40773357|NCT03298893|DRUG|Cisplatin|40 mg/m2, once a week during radiotherapy
41141462|NCT02991573|DEVICE|Ceram X|
41141463|NCT02991573|DEVICE|Prime & Bond XP|Control
41141464|NCT02991573|PROCEDURE|technique 1|
41141465|NCT02991573|PROCEDURE|technique 2|
41141466|NCT00007826|BIOLOGICAL|BCG vaccine|
41141467|NCT00007826|BIOLOGICAL|monoclonal antibody 105AD7 anti-idiotype vaccine|
41301412|NCT02292303|DIETARY_SUPPLEMENT|zinc-enriched yeast|
41301413|NCT02292303|DIETARY_SUPPLEMENT|Zinc references|
41301414|NCT04743206|DEVICE|Standard Airway Clearance device|A large majority of our patients will be using VEST therapy as their standard of care airway clearance
41301415|NCT04743206|DEVICE|Portable Internal Airway Percussion device|Smart One® portable home spirometer
41301416|NCT01386580|DRUG|2B3-101|IV every 21 days
41301417|NCT01386580|DRUG|Trastuzumab|IV every 21 days
41301418|NCT01386580|DRUG|2B3-101 60 mg/m2 every 4 weeks|IV every 28 days
41301419|NCT01386580|DRUG|2B3-101 50 mg/m2 every 3 weeks|IV every 21 days
41301420|NCT02150824|DRUG|Placebo|BI 187004 high dose matching placebo once daily
41301421|NCT02150824|DRUG|Placebo|BI 187004 medium dose matching placebo once daily
41301422|NCT02150824|DRUG|Placebo|BI 187004 high dose matching placebo once daily add on to background metformin
41301423|NCT02150824|DRUG|BI 187004|BI 187004 high dose once daily add on to background metformin
41301424|NCT02150824|DRUG|Placebo|BI 187004 low dose matching placebo once daily
41301425|NCT02150824|DRUG|BI 187004|BI 187004 medium dose once daily
41301426|NCT02150824|DRUG|BI 187004|BI 187004 low dose once daily
41460562|NCT03935737|DIAGNOSTIC_TEST|Full Dose Chest X-Ray|Full dose X ray at Day 1
41460563|NCT03935737|DIAGNOSTIC_TEST|Low Dose Chest X-Ray|Low dose X ray within 3 months from full dose
41460564|NCT01323127|PROCEDURE|Sagital xrays|5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
41460565|NCT00004162|BIOLOGICAL|sargramostim|
41460566|NCT00004162|DRUG|methotrexate|
41460567|NCT00004162|DRUG|pegylated liposomal doxorubicin hydrochloride|
41460568|NCT00004162|DRUG|vincristine sulfate|
41460569|NCT00236886|DRUG|topiramate|
41141468|NCT00007826|DRUG|alum adjuvant|
41141469|NCT02245620|DRUG|Elamipretide|Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
41141470|NCT02245620|DRUG|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
41141471|NCT02932150|DRUG|TAF|Administered orally once daily
41141472|NCT02932150|DRUG|Placebo|Administered orally once daily
41301427|NCT02150824|DRUG|BI 187004|BI 187004 high dose once daily
41301428|NCT02973464|DRUG|Valganciclovir|Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
41301429|NCT02973464|DRUG|Ganciclovir|intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
41460570|NCT02586324|BIOLOGICAL|global medium|
41460571|NCT02586324|BIOLOGICAL|SSM|
41460572|NCT06356987|PROCEDURE|Herniotomy|In Group A Laparoscopic assisted needle herniotomy was done
41460573|NCT02301741|BEHAVIORAL|Game|We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
41460574|NCT05636891|BIOLOGICAL|Stimus|"* NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~* Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously for patients with PK-PD in the previous IV group), at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~IPs will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
41141473|NCT04785794|BIOLOGICAL|Sing2016 M2SR H3N2 influenza vaccine|This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later.
41141474|NCT04785794|OTHER|Placebo|This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later.
41141475|NCT03955406|PROCEDURE|Conventional Low flow Anesthesia|During the initial wash-in period 4 L/min Fresh gas flow will be used.
41460575|NCT06113549|PROCEDURE|Knee Joint Distraction (KD)|Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame.KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.
41460576|NCT06113549|PROCEDURE|Knee Prosthesis|A total or unicompartmental knee prosthesis
41460577|NCT04809506|BIOLOGICAL|additional blood samples|2 additional blood samples (2 x 7ml) at every visit
41460578|NCT05722249|BEHAVIORAL|Mindfulness and Sleep Hygiene|Participants will experience demonstrations and explanations regarding sleep hygiene, mindfulness alerts for at work and mindfulness rest for at home.
41460579|NCT05722249|BEHAVIORAL|Phyical activity and Sleep Hygiene|All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods
41141476|NCT03955406|PROCEDURE|Low Flow Anesthesia with fixed fresh gas flow rate|Fresh gas flow rate will be 1 L/min throughout the procedure.
41141477|NCT02209376|BIOLOGICAL|CART-EGFRvIII T cells|
41141478|NCT03650114|BIOLOGICAL|Ofatumumab|subcutaneous injection of 20 mg ofatumumab every 4 weeks
41141479|NCT03650114|BIOLOGICAL|Tetanus toxoid (TT) containing vaccine (Td, Tdap)|0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid
41141480|NCT03650114|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13-PCV)|0.5mL Vial/Syringe
41141481|NCT03650114|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine (23-PPV)|0.5mL Vial/Syringe
40773358|NCT03298893|RADIATION|radiotherapy|"Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy.~An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT.~An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center."
41301430|NCT03738566|DEVICE|Esophageal self-dilation therapy|Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.
41460580|NCT06248151|BEHAVIORAL|Exercise session|Session will included aerobic, resistance and flexibility exercises and will last approximately 45 minutes. The session will begin with aerobic exercises (5 min jumping jacks and 5 min stationary walking). Then, nine strength exercises will be performed for the main muscle groups (3 times of 12 to 15 repetitions, with a 1-minute rest interval) and finally stretching for the main muscle groups
41460581|NCT06248151|BEHAVIORAL|Control session|Remain seated for 60 min
41460582|NCT00608634|DRUG|perillyl alcohol|Applied as topical cream
41460583|NCT00608634|OTHER|placebo|Applied as topical cream
40773359|NCT00853684|DRUG|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
40773360|NCT00853684|DRUG|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
40773361|NCT04748887|OTHER|oxidative stess markers|markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
40773362|NCT05388851|OTHER|Educational Intervention|Complete educational training module
40773363|NCT05388851|OTHER|Questionnaire Administration|Complete questionnaire
40773364|NCT04935593|OTHER|The RENEW Intervention|An game-based intervention that will provide lessons and activities in social-awareness, self-management, self-awareness, relationships and decision making in effort to strengthen social, emotional and behavioral competence. The intervention will be administered tri-weekly for 20 minutes each session.
40773365|NCT05835648|DIETARY_SUPPLEMENT|Nutrasumma|On the basis of daily diet, dietary fiber supplement (Nutrasumma) was given once a day, 1 strip each time, before meals, and the intervention lasted for 3 months.
40773366|NCT01107886|DRUG|Saxagliptin|5 mg or 2.5 mg once daily
40773367|NCT01107886|DRUG|Placebo|
40773368|NCT00552136|PROCEDURE|Ankle Arthroplasty|
40773369|NCT00552136|PROCEDURE|Ankle Arthrodesis|Ankle fusion surgery
40773370|NCT01630109|DRUG|Metoclopramide|A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.
40773371|NCT01630109|DRUG|Placebo|A placebo capsule made to look like the metoclopramide capsule.
40773372|NCT05482451|DRUG|Nivolumab|Nivolumab, an immune checkpoint inhibitors targeting PD-1, represents a popular treatment option for patients with cancers via immunological mechanism. However, previous studies using nivolumab alone in pancreatic cancer have failed.
40773373|NCT05482451|DRUG|all trans retinoic acid|Our previous basic studies revealed that all-trans retinoic acid repressed pancreatic adenocarcinoma cell growth and colony formation. All-trans retinoic acid represses ADAR1, a member of interferon-stimulated genes and a negative regulator of IFNs signaling. On the other hand, all-trans retinoic acid simultaneously increases PD-L1 expression for cancer cells to evade immune surveillance. Since combination of anti-PD1 antibody and all-trans retinoic acid may block self-regulating negative feedback loops of IFNs response, this therapeutic strategy may improve outcomes of pancreatic adenocarcinoma patients.
40773374|NCT00146822|DEVICE|ENDOTAK RELIANCE G lead|
41141482|NCT03650114|BIOLOGICAL|Seasonal Quadrivalent influenza vaccine|Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)
41141483|NCT03650114|BIOLOGICAL|Keyhole limpet hemocyanin (KLH) neo-antigen|1mg Vial
41301431|NCT03738566|PROCEDURE|Endoscopic therapy with esophageal dilation|A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.
41301432|NCT04367116|PROCEDURE|Spinal Cord Stimulation|Spinal cord stimulation is a treatment that implants a electrode in posterior epidural space of patient's spinal canal to send mild electric current to stimulate conducting bundle of the posterior column of the spinal cord and posterior horn sensory neurons.
41460584|NCT01978964|BIOLOGICAL|ONT-10|ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
40773375|NCT04448379|DRUG|JMT101|IV infusion Q2W for 4 weeks (28-day cycles)
40773376|NCT06449118|BEHAVIORAL|Mindfulness Stress Reduction Program|Mindfulness based-Stress Reduction Program an 8-week program
40773377|NCT04543851|DEVICE|CARA - carbon fibre adjustable re-usable accessory for breast positioning|Breast positioning to alleviate infra-mammary fold and lateral breast sag
40773378|NCT04711889|DRUG|Ulinastatin|Ulinastatin is taken three times a day.
40773379|NCT04711889|DRUG|Blank control|Blank control
40773380|NCT04628806|DIAGNOSTIC_TEST|CTC isolation by HSP70|patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.
41141484|NCT06307054|DRUG|anti-CLL-1 CAR NK cells|Eligible patients enrolled in the study after screening will receive lymphocyte collection(from the patient or a donor ) and receive single dose CLL-1 CAR NK cells infusion after a successful cell production. There are a total of four cell dose level:5×10\^6 CAR-NK cells/kg,1×10\^7CAR-NK cells/kg,2×10\^7CAR-NK cells/kg,4×10\^7CAR-NK cells/kg
41141485|NCT04515550|DIAGNOSTIC_TEST|lumbar puncture|Some participants will have an optional lumbar puncture
41141486|NCT02085941|DEVICE|Cryoablation|Cryoablation using 17G Galil cryoprobe
41141487|NCT02085941|DEVICE|Biopsy|Biopsy using 18G Temno core biopsy needle
41301433|NCT00292474|DEVICE|percutaneous coronary intervention|
40977472|NCT01934530|PROCEDURE|Soft Tissue Grafting|"All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.~Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement."
40977473|NCT02520843|DRUG|stromal vascular fraction (SVF)|stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
40977474|NCT03314402|DRUG|Jaktinib Dihydrochloride Monohydrate|Active Substance
40977475|NCT03314402|DRUG|placebo|Placebo
40977476|NCT02013791|DRUG|Vehicle|Vehicle of cyclosporine administered as per protocol
40977477|NCT02013791|OTHER|Sham|Sham administered to non-study eye as per protocol on Day 1
40977478|NCT02013791|DRUG|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
40977479|NCT00503802|PROCEDURE|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
40977480|NCT00503802|PROCEDURE|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
40977481|NCT03927131|BIOLOGICAL|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
40977482|NCT03927131|BIOLOGICAL|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
40977483|NCT03927131|BIOLOGICAL|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
40977484|NCT03927131|BIOLOGICAL|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
40977485|NCT03927131|BIOLOGICAL|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
40977486|NCT03927131|BIOLOGICAL|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
40977487|NCT00983021|DRUG|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
40977488|NCT00983021|DRUG|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
40977489|NCT00983021|DRUG|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
40977490|NCT00983021|DRUG|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
40977491|NCT01619774|DRUG|GSK2118436|Starting dose 150 mg by mouth twice a day.
40977492|NCT01619774|DRUG|GSK1120212|2 mg by mouth daily.
40977493|NCT00869895|DRUG|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
40977494|NCT05508191|DEVICE|Fractional CO₂ Laser|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. Half of the face will be irradiated with AMIⓇ fractional CO₂ laser according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
41460585|NCT06335186|DIAGNOSTIC_TEST|upper endoscopy|to detect esophageal or gastric varices
41141488|NCT05588297|DRUG|CapOx(Capecitabine+ Oxaliplatin)|CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles
41141489|NCT05588297|DRUG|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles
41141490|NCT05588297|DRUG|Nivolumab|Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles
41141491|NCT02163850|DEVICE|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
41141492|NCT02163850|DEVICE|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
41141493|NCT04510493|DRUG|Canakinumab|Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours
41460586|NCT00292591|DRUG|cholecalciferol (vitamin D3)|randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
41460587|NCT00292591|DRUG|cholecalciferol|comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
41460588|NCT06408636|OTHER|Cardiac MRI|All selected patients completed a cardiac magnetic resonance examination without other interventions.
41460589|NCT00000564|PROCEDURE|oxygen inhalation therapy|
41460590|NCT02412722|DRUG|Sapanisertib|Sapanisertib capsules
41460591|NCT02412722|DRUG|Paclitaxel|Paclitaxel injection
41460592|NCT02806791|DRUG|FILGRASTIM|
41460593|NCT00504179|PROCEDURE|Osteopathic Manipulative Treatment|
41460594|NCT04965831|DRUG|Furmonertinib|Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.
40977495|NCT05508191|DEVICE|Microneedle|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. The other half of the face will be treated with DrPenⓇ dermapen according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
40977496|NCT01920789|RADIATION|Stereotactic radiotherapy|Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (\<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
40977497|NCT01920789|RADIATION|Conventionally fractionated radiotherapy|Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
40977498|NCT03758274|BEHAVIORAL|CBT by Phone to Promote Treatment|Structured phone intervention to identify concerns about getting alcohol use disorder treatment and to work through those concerns using cognitive behavioral principles.
40977499|NCT03758274|OTHER|Reading the Subject a Pamphlet on Obtaining Alcohol Use Disorder Treatment|The pamphlet was created by the National Institute on Alcohol Abuse and Alcoholism to describe evidence based treatments available for alcohol use disorder and how to obtain such treatment.
40977500|NCT01708733|DRUG|KSY|Chinese herbal formula
40977501|NCT06335979|DRUG|PIT565|In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.
40977502|NCT02279173|DRUG|Romiplostim|Romiplostim subcutaneous weekly injection
40977503|NCT04246008|OTHER|Neuromuscular training|The exercise training was developed based on assuring the correct performance of the exercise focusing in motor control.
40977504|NCT04246008|OTHER|Conventional strength training|The exercise training was developed based on standard strength training used in cardiac rehabiliation programmes
40977505|NCT06255314|PROCEDURE|ventral hernia repair|"Laparoscopic transabdominal retromuscular repair is a minimally invasive approach to the open Rives Stoppa retromuscular sublay repair for ventral hernia.~In ventral hernia repair, it relies on initiation of dissection in one retrorectus space and then crossover to the contralateral retrorectus space The sublay mesh technique is an open surgical procedure for ventral and incisional hernias"
40977506|NCT04209153|OTHER|Transcranial Direct Current Stimulation|tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics
41141494|NCT04510493|DRUG|Placebo|Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours
41141495|NCT02567591|OTHER|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
41141496|NCT04188457|OTHER|Usual follow-up|2 medical consultations (nurse and doctor) over 24 months
41141497|NCT04188457|OTHER|Intensive follow-up|10 medical visits (nurse, doctor, pharmacist) over 24 months
41141498|NCT03763968|OTHER|treatment and outcome|
41301434|NCT03659747|DIETARY_SUPPLEMENT|Probiotic|- 6 g sachet containing probiotic powder (1.8 x 10\^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
41301435|NCT03659747|DIETARY_SUPPLEMENT|Lactrase|- 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
41460595|NCT00307723|DRUG|bevacizumab|Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
40773383|NCT02752542|BEHAVIORAL|Cognitive Behavioral Therapy|CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.
40773384|NCT02752542|DRUG|Pharmacotherapy|Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
41460596|NCT00307723|DRUG|5-Fluorouracil|Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
40773385|NCT02498366|OTHER|physical tests|"each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.~day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3."
40773386|NCT04831229|OTHER|Children will perform activities on interactive tablet|AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.
40773387|NCT04831229|OTHER|Children will perform passive on interactive tablet|"The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions."
40977507|NCT01896531|DRUG|5-Fluorouracil|Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
41141499|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
41141500|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
41301436|NCT03659747|OTHER|Placebo|- 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.
41301437|NCT04284982|BEHAVIORAL|16-week supervised heavy resistance training program with weekly undulating periodization|Participants trained a whole-body program consisting of squat, bench press, deadlift and pendlay row two times per week for 16 weeks
41460597|NCT00307723|DRUG|Oxaliplatin|Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
41460598|NCT00307723|DRUG|gemcitabine|Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
41460599|NCT00307723|PROCEDURE|External Beam Radiation Therapy|Monday through Friday ending on day 38 of cycle 1
40773388|NCT05068583|OTHER|Blood Draw|Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.
40773389|NCT03333187|PROCEDURE|Allogeneic stem cell transplantation|
40773390|NCT03333187|DRUG|Ruxolitinib continuous therapy|
40773391|NCT00164281|DRUG|Isoniazid|Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.
40773392|NCT04507204|DRUG|Adhansia XR|Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
41301438|NCT00859898|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 24 weeks
41460600|NCT02464670|BIOLOGICAL|INO-4201|INO-4201 delivered IM followed by Electroporation
41460601|NCT02464670|BIOLOGICAL|INO-4202|INO-4202 delivered IM followed by Electroporation
41460602|NCT02464670|BIOLOGICAL|INO-4201|INO-4201 delivered ID followed by Electroporation
41460603|NCT02464670|BIOLOGICAL|INO-4212|INO-4212 delivered IM followed by Electroporation
41460604|NCT02464670|BIOLOGICAL|INO-4212 + INO-9012|INO-4212 + INO-9012 delivered IM followed by Electroporation
41460605|NCT02464670|BIOLOGICAL|INO-4201 + INO-9012|INO-4201 + INO-9012 delivered ID followed by Electroporation
41460606|NCT04089462|BEHAVIORAL|"Five sessions per period - Two sessions per period"|"Period 1: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)~Period 2: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)"
40773393|NCT04507204|DRUG|Concerta|An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
40773394|NCT05416814|DIETARY_SUPPLEMENT|Kefir|Oral route (via feeding tube in intubated patients). Serving size 240mL to be given in an ascending dosing regimen if tolerated starting at 60 mL/day, 120 mL/day until single 240 mL/day; if evidence of intolerance, dose will be reduced to previously tolerated dose.
40773395|NCT05258292|DEVICE|Continuous glucose monitoring|Glucose levels will be measured using continuous glucose monitoring
40773396|NCT05258292|DRUG|Insulin|Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)
40977508|NCT01896531|DRUG|Ipatasertib|Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
40977509|NCT01896531|DRUG|Leucovorin|Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
41141501|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
41141502|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
41460607|NCT04089462|BEHAVIORAL|"Two sessions per period - Five sessions per period"|"Period 1: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)~Period 2: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)"
41460608|NCT03916562|BEHAVIORAL|Manipulation of spatiotemporal coordination during walking|A description of the intervention is included in the description of the study arms.
40773397|NCT05258292|OTHER|Premenstrual symptoms|Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool
40773398|NCT05258292|OTHER|Ovulation kits|Ovulation testing will be done using ovulation kits
40773399|NCT05258292|DEVICE|Fitbit Inspire 2|Physical activity will be assessed using the Fitbit Inspire 2
40773400|NCT05258292|OTHER|Keenoa|Food intake will be assessed using the Keenoa phone application
40773401|NCT05258292|OTHER|Menstrual cycle|The application My Calendar will be used to record information on the menstrual cycle
40773402|NCT01900184|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
40773403|NCT01900184|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
40773404|NCT01076699|DRUG|0.075 mg RVX-100|This group is taking the lowest dose of RVX-100
41141503|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
41141504|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
41141505|NCT03122860|DRUG|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
41141506|NCT03122860|OTHER|Placebo|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
41141507|NCT03122860|OTHER|Sham|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
41301439|NCT00859898|DRUG|Metformin XR|Tablets, Oral, up to 2000 mg, once daily, 24 weeks
41301440|NCT00859898|DRUG|Metformin XR|Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
41301441|NCT00859898|DRUG|dapagliflozin matching Placebo|Tablets
40773405|NCT01076699|DRUG|0.125 mg RVX-100|This group is taking an average dose of RVX-100
40773406|NCT01076699|DRUG|0.250 mg RVX-100|This group is taking the highest dose of RVX-100
40773407|NCT01076699|DRUG|placebo|This group is taking a placebo
40773408|NCT03035747|PROCEDURE|conventional surgery|high ligation and stripping of incompetent saphenous veins
40773409|NCT03035747|PROCEDURE|endovenous laser ablation|endovenous laser ablation of incompetent saphenous veins
40773410|NCT03035747|PROCEDURE|sclerotherapy|ultrasound guided or catheter or or any other methods sclerotherapy of incompetent saphenous or varicose veins
40773411|NCT03035747|PROCEDURE|endovenous radiofrequency ablation|endovenous radiofrequency ablation of incompetent saphenous veins
40773412|NCT03035747|PROCEDURE|phlebectomy|hooks phlebectomy of varicose veins
40773413|NCT04893733|DRUG|Vitamin B Complex|"Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo.~Every patients will also received Institution standard of care for AKI"
40773414|NCT01604317|PROCEDURE|Resuscitation-torso plastic bag|Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
40773415|NCT01604317|PROCEDURE|Resuscitation-partial-head plastic bag|Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
40773416|NCT02494115|PROCEDURE|subcutaneous drainage|
40977510|NCT01896531|DRUG|Oxaliplatin|Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
40977511|NCT01896531|DRUG|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
40977512|NCT01352689|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
40977513|NCT01352689|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
40977514|NCT02655562|DRUG|Montelukast|"Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO\<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO\<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients."
40977515|NCT00759811|DRUG|Methotrexate|"Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
41141508|NCT03187249|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks cognitive-behavioral lessons, once a week
41141509|NCT03187249|BEHAVIORAL|Pulmonary Rehabilitation Therapy|12 weeks pulmonary rehabilitation exercise
41301442|NCT00859898|DRUG|metformin HCl Modified Release matching Placebo|Tablets
41460609|NCT02857387|BIOLOGICAL|blood sample withdrawn|
41460610|NCT03236363|BEHAVIORAL|MOVI-da10! active breaks|MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
41141510|NCT03187249|BEHAVIORAL|Combined Therapy|cognitive-behavioral lessons and pulmonary rehabilitation exercise for 12 weeks
41301443|NCT01957826|OTHER|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
41460611|NCT03236363|BEHAVIORAL|MOVI-da10! integrated physical activity|MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate \<150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
41460612|NCT02943096|DIETARY_SUPPLEMENT|CocoaVia|Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa.
41141511|NCT02705729|DEVICE|Ketac Universal|High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.
41460613|NCT02943096|OTHER|Placebo|"The placebo looks like the other intervention pills, but does not contain any flavanols (it is sometimes called a sugar pill)."
41141512|NCT02705729|DEVICE|Ketac Molar Quick|High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
41141513|NCT01314482|DRUG|Minocycline|200mg bd for 3 days before surgery
41141514|NCT05100511|DEVICE|ERG electrode tests for fundus image-guided focal ERG|Investigate the patient comfort, usability and signal-to-noise ratio of different commercial CE marked ERG electrodes.
41141515|NCT05100511|DEVICE|Fundus image-guided focal ERG|Record focal ERG from a healthy retinal area and from an area with visible symptoms.
41141516|NCT03823690|DEVICE|EUS-guided gastrojejunstomy|As listed in the arms description
41141517|NCT03823690|DEVICE|The pyloro-duodenal stent|As listed in the arms description
41141518|NCT05508477|BIOLOGICAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARS-CoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
41460614|NCT03303417|DIAGNOSTIC_TEST|MRI Scan|Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content
41460615|NCT03303417|OTHER|Kiwifruit|Kiwifruit
40773417|NCT06347978|DEVICE|Deep Brain Stimulation|"Subjects will be randomized to either ON-OFF (Stimulation-Sham) or OFF-ON (Sham-Stimulation) arms. Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period. Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.~After completion of the first phase of the trial, patients will undergo another washout phase until they are within 20% of their pre-treatment Y-BOCS II score or 4 weeks have passed, whichever comes first. The purpose of the washout is to eliminate any residual effect of stimulation in the ON group.~Patients will then be advanced to the crossover phase. The participants who were initially randomized to the ON-OFF arm will be moved onto the sham (OFF) period, and the participants who were initially randomized to the OFF-ON group will be moved onto stimulation (ON) period for up to 12 weeks."
40773418|NCT01362790|DRUG|Pentostatin|Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m\^2 or 2 mg/m\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\^2 on days 1 and 5 of 25 day cycle
40977516|NCT00759811|DRUG|Placebo|"Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
40977517|NCT00741637|BIOLOGICAL|CholeraGarde®|"Live attenuated oral Cholera vaccine~Each vial of CholeraGarde® contains 5x107 to 1x109 CFU of Peru-15, 6.75 mg KH2PO4, and 300 mg trehalose as a lyophilized cake in 5 mL single-dose vials"
40977518|NCT00741637|BIOLOGICAL|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
40977519|NCT05855460|DIAGNOSTIC_TEST|Skin biopsy|biochemical assessment for measurement IL35 by ELISA (Enzyme linked immunosorbent assay) technique in tissue and serum samples of all thirty patients and healthy controls.
40977520|NCT04684355|OTHER|Real-time colonoscopic optical diagnosis for colorectal neoplasm|Colonoscopic optical diagnosis by image enhanced technology has been validated as an excellent tool to predict the histology of colorectal polyps and to differentiate the invasion depth of colorectal cancer.
40977521|NCT02845544|OTHER|Pilates-based exercises|
40977522|NCT05924295|DIETARY_SUPPLEMENT|Ketone Supplement|Participants will be given 360mg/kg
40977523|NCT05924295|BEHAVIORAL|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
40977524|NCT05924295|BIOLOGICAL|Blood Draw|IV cannula will be inserted at the start of Test Day, and removed at the end of Test Day. Blood samples will be collected at 7 timepoints (possibly 1 more). Cannula will be flushed with a small volume of saline after each sample to maintain patency.
40977525|NCT05924295|OTHER|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
40977526|NCT02855333|OTHER|EORTC and QLQ-C30 / QLQ-OES24 questionnaire|EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure
40977527|NCT05599607|DIETARY_SUPPLEMENT|Probiotic mixture|Mixture of strains of lactobacillus and bifidobacteria
40977528|NCT05599607|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
40977529|NCT05891314|PROCEDURE|Botox Injectable Product|one group will have botox injection in the internal sphincter
40977530|NCT05891314|PROCEDURE|Internal sphincterotomy|this group will have internal sphincterotomy
41141519|NCT05508477|BIOLOGICAL|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia
41301444|NCT01957826|OTHER|placebo intervention|placebo administration
40773419|NCT01362790|DRUG|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
41141520|NCT02204202|DRUG|[18F]FDG|10 millicuries (mCi) of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
41141521|NCT02204202|DRUG|[18F]ISO-1|8 mCi of \[18F\]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
41301445|NCT02200458|DEVICE|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
41460616|NCT03303417|OTHER|calorie-matched sugar drink|calorie-matched sugar drink
40773420|NCT01362790|BIOLOGICAL|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: Cycle 1: 35mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles Regimen B: Cycle 1: 35mcg/kg days 18, 20 and 22 Cycles 2-4: (Days 6, 8 and 10), for a maximum of six treatment cycles
41460617|NCT00238615|DRUG|Docetaxel|20 mg/m2, 75 mg/m2 infusion
41460618|NCT00238615|DRUG|Carboplatin|AUC of 2 and 6 infusion
40773421|NCT01362790|BIOLOGICAL|SS1(dsFv)PE38 - lot FIL129J01|"Regimen A:~Cycle 1: Cycle 1:35mcg/kg or 25 mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles"
40773422|NCT06508619|DEVICE|Corsano CardioWatch 287-2 non-invasive blood pressure (NIBP) monitoring|Patients receive Corsano CardioWatch 287-2 for continous NIBP monitoring and perform several spot-checks using an automated BP cuff as a reference during the start or uptitration of BP lowering medication
40773423|NCT03484897|OTHER|P927 - LICHTENA DermAD CREMA CORPO|The study cream was applied once a day (at the morning or at the evening), preferentially always at the same hour, with a mild massage, for an uninterrupted period of 1 month
41460619|NCT00238615|PROCEDURE|Radiation therapy|NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period.
41141522|NCT02757378|PROCEDURE|Neuroplasticity Explanation (Experimental)|Patients were given an explanation of how the brain uses the information from a manual therapy technique to help it remain sharp in identifying where this input is coming from.
41141523|NCT02757378|PROCEDURE|Biomechanical Explanation (Control)|Patients were given an explanation of how the manual therapy technique affects the anatomy and physiology of the back.
41460620|NCT00238615|PROCEDURE|Surgical resection|All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.
41460621|NCT03623893|PROCEDURE|Contralateral exploration|Surgery eventually performed when a patent processus vaginalis or hernia exists on the other side than the side on which the child has to be operated on, will be exactly the same as the inguinal hernia repair on the 'symptomatic' side. Exploration of the contralateral side will increase anaesthesia time by 10-15 minutes.
40773424|NCT04519333|PROCEDURE|drug(intradermal injection)|"The mesotherapy was performed by an experienced and trained physician using a disposable 4 mm and 6 mm long, 30 Gauge needles. Initially, a pharmacological mixture of 1 cc (2 mg) thiocolchicoside, 1 cc (16.2 mg) lidocaine and 1 cc (5 mg) tenoxicam was prepared for each treatment session, and 0.1-0.2 cc of this mixture was applied to each injection point with a depth of 1-3 mm using point by point intradermal method without causing papules.~In the systemic therapy group, we applied a 50 mg dexketoprofen (Revafen, Haver Pharma Pharmaceutical Co., Turkey) in 100 cc isotonic solution intravenously for 5 minutes."
40773425|NCT04078867|PROCEDURE|tricuspid valve repair|Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
40773426|NCT04372953|PROCEDURE|Positive End-Expiratory Pressure (PEEP)|"PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV)."
41141524|NCT01858688|DEVICE|Multiparametric MRI|an MRI of the prostate will be performed
41141525|NCT01858688|PROCEDURE|Prostate biopsy|a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
41141526|NCT05763576|DRUG|RO7565020|RO7565020 will be administered by subcutaneous injection or intravenous infusion.
41141527|NCT05763576|OTHER|Placebo|Matching placebo will be administered by subcutaneous injection or intravenous infusion.
41141528|NCT05763576|DRUG|Nucleos(t)ide analogue (NUC) treatment|NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
40773427|NCT03622151|OTHER|Primer la Llar program|Housing First model: permanent housing without previous requirements such as abstinence, sobriety or compliance with treatment.
40773428|NCT00584857|DRUG|Paclitaxel ,Carboplatin , Megesterol Acetate|Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
41141529|NCT04850092|OTHER|Positional change from supine to prone|Patient is turned from supine to prone position for spine surgery
41301446|NCT04307147|DRUG|Capecitabine|Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
41301447|NCT04307147|DRUG|Vinorelbine|Intravenous vinorelbine (at a dose of 25 mg/m² on day 1, day 8) every 3 weeks for 4 cycles.
41301448|NCT03781882|PROCEDURE|Platelet rich plasma infiltration in the wound edges|platelet rich plasma will be injected in the wound edges
41460622|NCT05157750|OTHER|Recording of major clinical events|During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.
41460623|NCT00008060|DRUG|FOLFIRI regimen|
41460624|NCT00008060|DRUG|FOLFOX regimen|
41301449|NCT03781882|PROCEDURE|Closure of wound without platelet rich plasma infiltration|No infiltration of platelet rich plasma is done
41301450|NCT02512003|DEVICE|Fantom Scaffold|
41301451|NCT01011920|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
41301452|NCT01011920|DRUG|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
41301453|NCT01011920|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 \& 0 every 3 weeks for a maximum of 4 cycles
41460625|NCT00008060|DRUG|fluorouracil|
40773429|NCT04881084|OTHER|Digital storytelling group|Participants (intervention- group 1) will watch digital stories, short videos describing the experience of recovering from mental illness created as part of this project. Participants in the control group (group 2) will watch social marketing and/or fundraising campaigns on similar topics and complete a few questionnaires. The following standardized scales will be used: The Level of Familiarity Scale (LOF) (which will be used only before exposure to movies); Toronto Empathy Questionnaire (16 items; internal consistency coefficient .79; test-retest reliability coefficient .73), Compassionate Love Scale (21 items; Cronbach's alpha: .95; item-to-total correlations ranging from .46 to .81), Dispositional Positive Emotions Scale (DPES) (5 items; Cronbach's alpha for the compassion subscale: .80; inter-scale correlations: .44), Self-Stigma of Mental Illness Scale-Short Form (SSMIS-SF) (20 items; Cronbach's alpha: 0.91); Difference and Disdain Scales for Public Stigma (DDSPS) (9 items).
41141530|NCT05817513|OTHER|Myofascial release.|Myofascial release (MFR) is a therapeutic treatment that uses gentle pressure and stretching to facilitate the release of fascial restrictions caused by accidents, injury, stress, repetitive use, and traumatic or surgical scarring. The fascial restrictions are palpated by the practitioner and the techniques are applied directly to the skin of the patient without lotions or oils. The pressure is applied into the direction of the restriction just until resistance is felt or the tissue is perceived to stop moving. The pressure is sustained at this point of resistance, without sliding over the skin or forcing the tissue, for a minimum of 90-120s. As the tissue begins to release, the practitioner maintains the same amount of pressure and follows the release three dimensionally through multiple releases.
41141531|NCT05817513|OTHER|Traditional exercises for scoliosis treatment.|"The exercises are:~1. Pelvic tilt.~2. Arm and leg raises.~3. Cat-cow.~4. Bird dog.~5. Latismus dorsi stretch.~6. Abdominal press.~7. Practice a good posture.~8. Stretching and scapular exercises."
41301454|NCT01011920|DRUG|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \& -4
41301455|NCT01011920|RADIATION|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
41301456|NCT01011920|DRUG|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
41301457|NCT01011920|OTHER|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
41301458|NCT03184909|DRUG|Ocimum Sanctum|Active capsules containing leaves of organically prepared ocimum sanctum
41301459|NCT03184909|DRUG|Placebo|Placebo capsules of look alike inert substance for control
41301460|NCT01186146|DRUG|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
41301461|NCT01186146|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
41301462|NCT00530322|PROCEDURE|Laparoscopy|"A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy)."
41301463|NCT05876780|GENETIC|SRP-9003|Single IV infusion of SRP-9003
41301464|NCT00051558|DRUG|Teriparatide|20 micrograms/day, injection, 36 months
41301465|NCT00051558|DRUG|Alendronate Sodium|10 mg/day, oral, 36 months
41301466|NCT00051558|DRUG|Placebo|Oral placebo, daily, 36 months
41301467|NCT00051558|DRUG|Placebo|Injection placebo, daily, 36 months
41460626|NCT00008060|DRUG|irinotecan hydrochloride|
41460627|NCT00008060|DRUG|leucovorin calcium|
41460628|NCT00008060|DRUG|oxaliplatin|
41460629|NCT02914457|PROCEDURE|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
41460630|NCT02438696|DRUG|BI 1060469, iFF, Test|
41460631|NCT02438696|DRUG|BI 1060469, iFF, Test|
41460632|NCT02438696|DRUG|BI 1060469, TF1, Reference|
40773430|NCT04881084|OTHER|Social marketing/fundraising group|Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
40773431|NCT00058747|DRUG|Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.|
40773432|NCT01347060|DRUG|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
40773433|NCT01347060|DRUG|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
40773434|NCT05674955|DIAGNOSTIC_TEST|Circuit weight versus aerobic training|"Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C."
40773435|NCT04144920|BEHAVIORAL|CS: Continuous sitting|Participants were asked to sit continuously throughout the duration of the lab visit.
40773436|NCT04144920|BEHAVIORAL|HFLD: HIgh frequency, low duration standing breaks|Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
40977531|NCT02303288|DEVICE|Argus II Retinal Prosthesis System|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
40977532|NCT01489592|DRUG|curcuma longa|oral administration of 6 grams of curcumin
40773437|NCT04144920|BEHAVIORAL|LFHD: Low frequency, high duration standing breaks|Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
40773438|NCT05086380|BEHAVIORAL|Mindfulness-based stress reduction therapy|MBSR Therapy is a structured 8-week program that employs mindfulness meditation to alleviate suffering associated with physical, psychosomatic and psychiatric disorders. The program is based upon a systematic procedure to develop enhanced awareness of moment-to-moment experience of perceptible mental processes.
40773439|NCT05086380|DEVICE|Inhibitory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using cTBS stimulation protocol for transcranial magnetic stimulation
40773440|NCT05086380|BEHAVIORAL|Psychoeducation|Participants will learn about the symptoms and how to cope with the symptoms
40773441|NCT05086380|DEVICE|TMS sham|The device will be used to neuromodulate the right TPJ of participants' brain using transcranial magnetic stimulation over the vertex
40773442|NCT05086380|DEVICE|Excitatory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using iTBS stimulation protocol for transcranial magnetic stimulation
40773443|NCT05086380|DEVICE|Virtual Reality|The device will be used to manipulate the perception of symptoms of patients while they are playing a game in virtual/augmented reality.
40773444|NCT05086380|BEHAVIORAL|Neurofeedback|Neurofeedback training will be applied in patients while laying in an MRI scanner. Patients will play a game, which targets the sense of agency, and will receive a real-time feedback about their performance and brain activity. They will learn to self-regulate their performance on the game in order to increase brain activity relevant for the sense of agency.
40773445|NCT03947957|DIAGNOSTIC_TEST|collection of expectoration, stools and blood|collection of expectoration, stools and blood
40773446|NCT04113889|DRUG|Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)|72 patients with PCOS receiving metformin, pioglitazone and Acetyl L-Carnitine 500 mg, 15 mg and 1.5 gm BD daily respectively.
40977533|NCT02988531|OTHER|PET/MR scan|Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.
41141532|NCT06129188|DRUG|Remimazolam|Remimazolam is an ultra-short acting benzodiazepine medication. Benzodiazepines are a class of drug that directly interact with gamma-aminobutyric acid (GABA) and modifiable chloride channels through polysynaptic pathway inhibition. The anxiolytic properties of benzodiazepines make them useful as sedatives.
41141533|NCT06129188|DRUG|Propofol|Standard of care usage of the intravenous anesthetic agent propofol to achieve adequate sedation conditions for the procedure.
41301468|NCT03514303|DIAGNOSTIC_TEST|Spiriplex Allergenex Microassay|A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
41460633|NCT02438696|DRUG|BI 1060469, TF2, Test|
40773447|NCT04113889|DRUG|Metformin, pioglitazone and placebo|72 patients with PCOS receiving metformin, pioglitazone and placebo 500 mg, 15 mg and placebo BD daily respectively.
41301469|NCT02396823|BEHAVIORAL|Respiratory Muscle Training|Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
41301470|NCT00878540|DRUG|mirtazapine|30 mg mirtazapine once daily for 7 days
41301471|NCT03190720|DEVICE|Mobile community|A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
41301472|NCT04217577|DIETARY_SUPPLEMENT|Dried plums|10-16 dried plums/day, approximately 100-120 g/day
41301473|NCT00947570|BEHAVIORAL|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
41301474|NCT05567835|DRUG|Fluorouracil|2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15
40773448|NCT04035226|OTHER|No intervention|No intervention will be administered as a part of this study.
40773449|NCT04331639|DIETARY_SUPPLEMENT|vitamin D3|Subjects will receive oral high dose interval vitamin D3, concurrently when they are receiving their biologic treatment for their inflammatory bowel disease every 4-8 weeks.
41301475|NCT05567835|DRUG|Leucovorin|200 mg mg/m2 IV over 2 hours Day 1,15
41301476|NCT05567835|DRUG|Oxaliplatin|85 mg/m2 IV over 2 hours Day 1,15
41301477|NCT05567835|DRUG|Docetaxel|60 mg/m2 IV over 60 minutes Day 1,15
40773450|NCT04765098|DRUG|Tamoxifen|Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
40773451|NCT04765098|DRUG|Etoposide|etoposide 50mg/m2 daily
40773452|NCT02644304|DRUG|Clomiphene citrate|50 mg tablet twice daily from the second day of menses to the sixth day
40773453|NCT02644304|DRUG|Cabergoline|Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).
40773454|NCT02644304|OTHER|Placebo|placebo(half tablet) every 3 days (4 doses).
40773455|NCT04641026|OTHER|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
40773456|NCT04641026|OTHER|Deuterium oxide-labelled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
41141534|NCT01571947|OTHER|Acute Effects of Fats and Carbohydrate|Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
41141535|NCT02881086|DRUG|Rituximab|
41141536|NCT02881086|DRUG|Nelarabine|
41141537|NCT02881086|DRUG|PEG-Asparaginase|
41141538|NCT02881086|PROCEDURE|Cranial irradiation|
41141539|NCT02881086|DRUG|Imatinib|
41141540|NCT02881086|DRUG|Idarubicin|
41141541|NCT02881086|DRUG|Dexamethasone|
41141542|NCT02881086|DRUG|Cyclophosphamide|
41141543|NCT02881086|DRUG|Fludarabine|
41141544|NCT02881086|DRUG|Vincristine|
41141545|NCT02881086|DRUG|Mercaptopurine|
41141546|NCT02881086|DRUG|VP16|
41141547|NCT02881086|DRUG|Daunorubicin (DNR)|
41141548|NCT02881086|DRUG|Methotrexate|
41301478|NCT05567835|BIOLOGICAL|GSCF|Recommended on day 2 and 16 of C1 of the protocol while getting chemotherapy Day 2,16
41301479|NCT05205434|OTHER|Synchronous telerehabilitation programme|Exercise program and educational program
41301480|NCT05205434|OTHER|Asynchronous telerehabilitation programme|Exercise program educational program
40773457|NCT04641026|OTHER|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
41141549|NCT02881086|PROCEDURE|Stem cell transplantation|
41141550|NCT02881086|DRUG|Cytarabine|
41141551|NCT02881086|DRUG|Vindesine|
41141552|NCT02881086|DRUG|Adriamycin|
41141553|NCT02881086|DRUG|Prednisolone|
41141554|NCT05576701|BEHAVIORAL|Laughter Therapy|In this study, laughter therapy was applied to the experimental group three times a week (on Mondays, Wednesdays, and Fridays) for a total of 12 sessions. Each session started with other patients in the HD unit while the patient was receiving HD treatment (1 hour after HD started) and lasted 30-45 minutes. The number of patients who will take part in each laughter session is based on the number of patients attending that session in the hemodialysis unit.
41141555|NCT05576701|OTHER|Control|The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. Laughter therapy was applied for four weeks to HD patients in the control group who wanted the results of the research.
41141556|NCT04917601|BEHAVIORAL|Evira Care treatment|The intervention aim to examine the effectiveness of using a digital support system (Evira) in treatment of childhood obesity. Through daily weighings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored. Participants can be randomized to either the intervention group or the control group. The control group will receive local standard treatment.
41301481|NCT02064439|DRUG|BAY 59-7939|10 mg tablet once daily for 12 months
41301482|NCT02064439|DRUG|BAY 59-7939|20 mg tablet once daily for 12 months
41301483|NCT02064439|DRUG|ASA|100 mg tablet once daily for 12 months
41301484|NCT03465735|COMBINATION_PRODUCT|Vascular Boot|The Vascular Boot is one size fits all, insulated fleece padding, and cell foam to enhance and maintain lower limb warmth while maintaining no pressure points on the lower extremity.
41301485|NCT03465735|DRUG|Standard of Care|Anticoagulant therapy will be decided by physician and patient.
41301486|NCT02216253|DRUG|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
41301487|NCT02216253|OTHER|Placebo|Placebo tablet twice a day 7 days before and after surgery
41460634|NCT02438696|DRUG|BI 1060469, TF2, Test|
41460635|NCT02438696|DRUG|BI 1060469, iFF, Test|
41460636|NCT02438696|DRUG|BI 1060469, TF1, Reference|
41460637|NCT02438696|DRUG|BI 1060469, iFF, Test|
41460638|NCT02438696|DRUG|BI 1060469, iFF, Test|
40977534|NCT04473014|BEHAVIORAL|Heat Pain Paradigm|A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.
40977535|NCT02159495|DRUG|cyclophosphamide|Given IV
40773458|NCT04641026|OTHER|Deuterium oxide-labelled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
40773459|NCT04342247|DRUG|external testosteron|external testosteron
40773460|NCT04395547|DIETARY_SUPPLEMENT|JointAlive™|Combination herbal extract
40773461|NCT04395547|DIETARY_SUPPLEMENT|Placebo|Combination placebo product
40773462|NCT05072379|DEVICE|colostomy self-care app|The study will use mixed methods as the study design in which content analysis will be used to identify the content suited for the App based on interviews with participants. A systematic research and development process will be utilized to design the text, videos, and images in the App's simulations to provide accurate, consistent, and complete knowledge of the skills needed for colostomy self-care and contending with any potential emergency.
40773463|NCT02852915|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery for T4 cancer
40773464|NCT01854450|OTHER|Asymmetrical Lateral Decubitus|"After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).~Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position"
40773465|NCT01854450|OTHER|control|usual obstetrical care
40773466|NCT04433195|DIAGNOSTIC_TEST|Xpert MTB/RIF test|Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB
40773467|NCT04435626|DRUG|Finerenone (BAY94-8862)|"For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD.~For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD. Finerenone is administered orally as immediate release tablets."
40773468|NCT04435626|OTHER|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
40773469|NCT04998942|BEHAVIORAL|virtual cardiac wellness program|Participants assigned to this arm will participate in the experimental intervention.
40773470|NCT04998942|BEHAVIORAL|Placebo comparator|Participants assigned to this arm will participate in a placebo intervention.
40773471|NCT06557304|DRUG|BTK inhibitor|patients with treatment naive or R/R CLL who treatment with BTK inhibitor
40773472|NCT05206370|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
40773473|NCT05206370|DRUG|Placebo|film-coated oral tablets containing matched placebo
40977536|NCT02159495|BIOLOGICAL|Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
41460639|NCT02438696|DRUG|BI 1060469, TF1, Reference|
41460640|NCT02438696|DRUG|BI 1060469, TF2, Test|
41460641|NCT02438696|DRUG|BI 1060469, TF1, Reference|
41460642|NCT02438696|DRUG|BI 1060469, TF1, Reference|
40773474|NCT05206370|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
40773475|NCT00688740|DRUG|Docetaxel|intravenous
40773476|NCT00688740|DRUG|5-fluorouracil|intravenous
40773477|NCT00688740|DRUG|Doxorubicin|intravenous
40773478|NCT00688740|DRUG|Cyclophosphamide|intravenous
40773479|NCT01121757|DRUG|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
40773480|NCT01121757|DRUG|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
40977537|NCT02159495|OTHER|laboratory biomarker analysis|Correlative studies
40977538|NCT02159495|BIOLOGICAL|Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Given IV
40977539|NCT02159495|DRUG|Fludarabine Phosphate|Given IV
40977540|NCT05999045|OTHER|Singing activity|The singing activity will involve a 1-hour performance, rehearsal, or lesson.
41460643|NCT02438696|DRUG|BI 1060469, TF2, Test|
41460644|NCT02438696|DRUG|BI 1060469, TF2, Test|
41460645|NCT02438696|DRUG|BI 1060469, iFF, Test|
41460646|NCT02438696|DRUG|BI 1060469, TF2, Test|
41460647|NCT02438696|DRUG|BI 1060469, TF1, Reference|
41460648|NCT05492292|DIAGNOSTIC_TEST|Perfusion brain scintigraphy imaging|The cerebral perfusion scintigraphy via a SPECT examination aims to analyze the cerebral blood flow and detect possible lesions or inflammations.
40977541|NCT02664454|OTHER|health care organization|"Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice~Interactive educational seminar Primary care"
40977542|NCT03258489|DEVICE|Transcutaneous nervous electric stimulation (TENS)|TENS (Frequency 10 Hz or 100Hz /duration 200μs, Endophasys nms 0501® model, KLD Biosystems, Amparo, SP, Brazil) will be applied with intensity between 1 to 60 mA and the current will be adjusted every 5 minutes at the sensory threshold level muscle contraction or according to the tolerance to the stimulus informed by the volunteers. TENS will be applied in bilateral paravertebral region of C7 to T4 or long the brachial plexus and sciatic plexus.
41460649|NCT01614262|OTHER|Continuous Glucose Monitoring with treatment algorithm|those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
41460650|NCT04046094|DRUG|Ascorbic Acid|Ascorbic Acid Intravenous
41141557|NCT04917601|BEHAVIORAL|Standard Lifestyle Care|The control group will receive the local standard care of treatment addressing lifestyles for childhood obesity without any restriction in visits or clinical support. This is the current standard care of treatment for childhood obesity.
41141558|NCT02090205|PROCEDURE|Non-ventilation during CPB|Patients that will not be ventilated during cardio-pulmonary bypass
41301488|NCT05588362|OTHER|Fitz Frames 3-D Printed Glasses|The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
41460651|NCT06504121|DEVICE|Septal Occluder Device|Transcatheter PFO closure with any commercially available septal occluder device
41460652|NCT03061903|DEVICE|Prevena|"Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.~Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device."
41460653|NCT03061903|DEVICE|Aquacel|"Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.~AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device."
41460654|NCT02339363|BEHAVIORAL|Sitting Meditation|4 weeks Sitting Meditation
41460655|NCT02339363|BEHAVIORAL|Hatha yoga|4 weeks of Hatha yoga
41460656|NCT01578317|BIOLOGICAL|H5N1 vaccine plus AS03 adjuvant|H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.
41460657|NCT01578317|BIOLOGICAL|H5N1 vaccine without adjuvant|H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.
41141559|NCT02090205|PROCEDURE|Ventilation with CPAP|These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
41141560|NCT02090205|PROCEDURE|Ventilation with 5 act/minute|These patients will receive mechanical ventilation (5 acts/minute) during CPB
41141561|NCT02090205|DEVICE|CPAP|Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
41141562|NCT02090205|DEVICE|Ventilator: 5 act/minute|Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
41141563|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 2 capsules
41460658|NCT01652963|OTHER|Reed and Clements Training Task|see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
41460659|NCT04067154|DIAGNOSTIC_TEST|ALPE|Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
41460660|NCT03127241|DEVICE|Assistive device (Armon Ayura) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
41460661|NCT03127241|DEVICE|Assistive device (Jaeco Wrex) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
40773481|NCT04910867|BEHAVIORAL|Components of Genetic Counseling|"The APOL1 testing program is designed to help living donor candidates to reduce their decisional conflict and enhance their informed consent regarding living donation. This intervention component entails: (1) an artificial intelligence-based conversational agent chatbot providing foundational information about the relationship between APOL1 and kidney disease and living donor outcomes, and APOL1 testing. The chatbot helps to relieve the workload on clinicians and scale up information giving. (2) The transplant nephrologist counseling component includes discussion about the APOL1 test results and shared decision making about donation, in a culturally competent manner, so as to enhance donor candidates' informed consent for living donation."
40773482|NCT04910867|DIAGNOSTIC_TEST|APOL1 genetic testing|APOL1 genetic testing will be performed while live kidney donor candidates are undergoing donor evaluation to identify whether they are at elevated risk of kidney disease post-donation. This risk information is expected to better enable donor candidates to make meaningful informed decisions about donating.
40773483|NCT04910867|OTHER|EHR integration|APOL1 genetic test results will be integrated into the electronic health record to provide clinical decision support to transplant nephrologists in evaluating donor candidates.
40773484|NCT00548886|DRUG|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
40773485|NCT02056769|RADIATION|CT Perfusion|Quantitative CT Perfusion imaging
40773486|NCT00163189|DRUG|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
40773487|NCT02642757|BEHAVIORAL|AUDIT brief intervention|Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.
41141564|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 1 capsule
41141565|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch B Ultibro Breezhaler 85/43 μg 2 capsules
41460662|NCT06109805|OTHER|Gastric cancer|Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
40773488|NCT02642757|OTHER|Pamphlet on alcohol use|Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
40773489|NCT00966108|DEVICE|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
40773490|NCT00973128|DRUG|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
40773491|NCT00973128|DRUG|Meglumine antimoniate|20mg/daily for 20 days
40773492|NCT05967624|OTHER|Teleconsultation|Each subject will be remotely assessed by a Medical Control Physician (MCP) using Zoom Pro (HIPAA-compliant video-conferencing software) on tablet devices as a low-cost mobile telemedicine platform and the Respiratory Observation Checklist, validated for telemedicine use in emergency settings. All prehospital clinical decision making will be made at the discretion of evaluating paramedics as per standard state-approved protocols and procedures, independent of checklist results.
41460663|NCT00570206|BEHAVIORAL|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
41460664|NCT05184179|DRUG|Olmesartan Medoxomil|Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
40773493|NCT03935347|DRUG|Cyclophosphamide|Given IV
40773494|NCT03935347|DRUG|Fludarabine|Given IV
40773495|NCT03935347|DRUG|Fludarabine Phosphate|Given IV
40773496|NCT03935347|BIOLOGICAL|Pembrolizumab|Given IV
40773497|NCT03935347|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
40773498|NCT03935347|BIOLOGICAL|Aldesleukin|Given IV
40773499|NCT00916916|OTHER|Blood draw|A blood draw will occur to take 10cc of blood to measure lanreotide levels.
40773500|NCT04039932|BEHAVIORAL|FLAME|The FLAME intervention trains pairs of faith leaders and community health workers and deploys them to conduct behavior change outreach in their communities.
40773501|NCT02180789|DRUG|Tamsulosin OCAS|oral
40773502|NCT03730350|BEHAVIORAL|Clinical Hypnosis|Hypnosis guidance and audio tracks aimed at promoting pain relief, reducing distress and anxiety, and facilitating sleep will be provided for independent use, with daily practice recommended. Each hypnosis session will be 20-25 minutes long. The scripts for these sessions have been developed based on the clinical literature (e.g., Elkins, 2014) and are already in use with patients of the pain service.
40773503|NCT05458739|DEVICE|ClearCoast MR System|The removed specimen is scanned using the ClearCoast MR System.
40773504|NCT01266980|DRUG|Inhaled FF/ GW642444M (200/25mcg)|All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
40773505|NCT05023109|DRUG|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
40773506|NCT02845882|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
41460665|NCT00522041|DRUG|Cellegesic|Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
41460666|NCT00522041|DRUG|Placebo|Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
41460667|NCT02651064|OTHER|HIP|
41460668|NCT04889365|DIAGNOSTIC_TEST|SG Diagnostics COVID-19 Antigen Rapid Test Kit|SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)
40773507|NCT02845882|DRUG|6-mercaptopurine,Methotrexate|6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;
40773508|NCT02845882|DRUG|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;
40773509|NCT02845882|DRUG|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
40773510|NCT02845882|DRUG|Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
41141566|NCT04856098|DRUG|Ultibro Breezhaler with oral charcoal|Activated charcoal suspension, granules 50 g / bottle
41141567|NCT06336798|DRUG|Pioglitazone 30mg|Study participants will take Pioglitazone 30 mg PO daily
41141568|NCT06336798|DRUG|Placebo|Study participants will take a placebo PO daily
41141569|NCT06336798|DIAGNOSTIC_TEST|Labs|Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).
41141570|NCT04669366|DRUG|sunitinib|As provided in real world
41141571|NCT04669366|DRUG|axitinib|As provided in real world
41141572|NCT02520336|BEHAVIORAL|Reminder|
41460669|NCT04889365|DIAGNOSTIC_TEST|Polymerase chain reaction (PCR) test|Professional collection of a second swab sample, for confirmation by PCR
41460670|NCT04621617|DRUG|Albumin|Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days
41460671|NCT04621617|DRUG|Midodrine|Oral Midodrine will be given at a dose of 7.5 mg three times in a day
41460672|NCT04621617|DRUG|Standard medical therapy (SMT)|SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
40773511|NCT02845882|DRUG|Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
40773512|NCT02845882|DRUG|Methotrexate, 6-mercaptopurine|6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
40977543|NCT03258489|DEVICE|Interferential electrical stimulation (IES)|The IES (Endophasys nms 0501®, KLD Biosystems, Amparo, SP, Brazil) will be applied in continuous mode with biphasic pulses. Bipolar electrodes with slope of 1/5/1. The rest of the parameters will be set to 4000 Hz, AMF of 100 Hz and the AMF variation of 25 Hz. The effect of the current will be adjusted by the intensity, it should produce paresthesia stimuli, without pain and below the motor threshold. Adhesive electrodes (MultiStick®, Axelgaard Manufacturing CO, Ltd, Fallbrook, CA, USA) will be housed in the paravertebral region, between C7 (Channel 1) and T4 (Channel 2). (SANTOS et al., 2013)
40977544|NCT03258489|DEVICE|TENS and IES Placebo|Same protocol without electrical output.
40977545|NCT04069611|OTHER|Probiotic|Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
40977546|NCT04069611|OTHER|Placebo|Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.
40977547|NCT04069611|PROCEDURE|Scaling and root planing|Mechanical debridement with US and curettes of hard and soft plaque deposits
40977548|NCT04270123|OTHER|EORTC QLQ-BR45 questionnaire|The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.
40977549|NCT00967525|PROCEDURE|cord blood infusion|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
40977550|NCT03750812|BEHAVIORAL|Aerobic Exercise|Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes
40977551|NCT03750812|BEHAVIORAL|Watching television|Sitting and watching television for 30 minutes
40977552|NCT06506760|BEHAVIORAL|Immersive Virtual Reality Therapy|"8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation."
40977553|NCT06506760|BEHAVIORAL|Conventional rehabilitation|"Four weeks of conventional rehabilitation including:~Two hours of kinesiotherapy (120 minutes, including gait training). Thirty minutes of ergotherapy. Three physical therapy procedures (i.e. laser therapy, magnetic therapy, electrotherapy) tailored to individual ailments and needs."
41301489|NCT03614429|DRUG|Chlorhexidine gel will be prepared according to an international product Instillagel®|"Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed.~Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition:~6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216)~The other ingredients are:~Hyetellose, propylene glycol\* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not."
41301490|NCT02848690|BEHAVIORAL|Educational Intervention|The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
41460673|NCT03614455|DRUG|Milademetan|Milademetan 100 mg capsule for oral administration
40773513|NCT06388616|DRUG|Balcinrenone|50 mg, Immediate release capsule to be taken orally.
40773514|NCT05534867|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 1 month, 2 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
40773515|NCT05434468|OTHER|Sustained neutral apophyseal glides|gong mobilization
40977554|NCT02157298|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
40977555|NCT02157298|DRUG|Placebo tablet|Placebo tablet. Oral dose
40977556|NCT01721330|DRUG|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
40977557|NCT01721330|DRUG|Placebo|Placebo twice a day for 6 weeks
40977558|NCT00636142|BIOLOGICAL|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
40977559|NCT00016016|DRUG|cytarabine|Given IV
41460674|NCT03614455|DRUG|Itraconazole|Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)
41460675|NCT03614455|DRUG|Posaconazole|Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)
41460676|NCT05543551|OTHER|Diaphragmatic breathing with Resistance Training|"Wall press-up:~Stand arm's length from the wall. Place your hands flat against the wall at chest level, with your fingers pointing upwards. With your back straight, slowly bend your arms, keeping your elbows by your side.~Dumbbell biceps curls:~Hold a pair of light weights and stand with your feet hip-width. Keeping your arms by your side, slowly bend them until the weight in your hand reaches your shoulder. Slowly lower again.~Back squats:~Place barbell with weights onto the squat rack. Bring your body under the bar. Rest barbell over your traps and shoulders. Make sure hands are even on each side of the bar. Keep your feet in the same position as they would be for an air squat. Brace your midline and keep your chest up.~Leg press:~Position feet about shoulder width apart. Try to push through your heels, keeping the knees lined up over the toes. Extend the legs until nearly straight, avoiding locking the knees."
41460677|NCT05543551|OTHER|diaphragmatic breathing with out resistance training|"Diaphragmatic Breathing:~1. Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~2. Place one hand on your upper chest and the other on your belly, just below your rib cage.~3. Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~4. Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
41141573|NCT03137459|BEHAVIORAL|Transtheoretical Model (TTM) of health behavior change|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.
41141574|NCT03137459|OTHER|Usual Care|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
41460678|NCT01958476|DRUG|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
41460679|NCT01958476|DRUG|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
41460680|NCT01958476|DRUG|Phenobarbital|"A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally \>8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.~Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores \<8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period."
40977560|NCT00016016|DRUG|mitoxantrone hydrochloride|Given IV
41141575|NCT05031052|DEVICE|End-ischemic normothermic oxygenated machine perfusion|Application of end-ischemic normothermic oxygenated machine perfusion at physiological temperatures for 4 hours.
41141576|NCT05031052|PROCEDURE|Static cold storage|Immediate implantation of kidney allograft after conventional and static preservation on ice
41141577|NCT05095077|DRUG|Tadalafil 40 MG|Single dose on study day 1/2
41141578|NCT05095077|DRUG|Placebo|Identical to active IMP
40773516|NCT04336189|DRUG|Sulfadoxine-pyrimethamine (SP)|SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda. SP will be given as a single dose consisting of 3 full strength tablets.
41460681|NCT04752527|DRUG|venetoclax combined with decitabine|combination of venetoclax plus decitabine, and sorafenib for patients with high FLT3-ITD allelic ratio. (On day 1 of cycle 1, decitabine 20 mg/m2 will be given intravenously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 28 day cycle is finished. For patients with high FLT3-ITD allelic ratio, sorafenib was administered at a dose of 400mg orally twice daily, on days 3 through 28.
40773517|NCT04336189|DRUG|Dihydroartemisinin-piperaquine (DP)|DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China. DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
40773518|NCT06563778|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
40773519|NCT06563778|DRUG|Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody|Brentuximab Vedotin 1.2-1.8mg/kg day 1, Bendamustine 70-90mg/m2 day1-2, Anti-PD-1 antibody day 2. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
40977561|NCT00016016|DRUG|alvocidib|Given IV
40977562|NCT00016016|OTHER|pharmacological study|Correlative studies
40977563|NCT00016016|OTHER|laboratory procedure|Correlative studies
40977564|NCT04909320|BEHAVIORAL|AWARD advice|Ask about smoking history; Warn about the high risk; Advise to quit; Refer smokers to smoking cessation services (with a referral card); Do it again
40977565|NCT04909320|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking and remind them to call the Department of Health SC hotline 183 3183.
41141579|NCT03560154|OTHER|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
41460682|NCT01903057|DRUG|azithromycin|
40773520|NCT05004415|DRUG|AT-527 (R07496998)|Study participants will receive a single radiolabeled dose of 550 mg AT-527.
40773521|NCT04434755|OTHER|health care professionals' exposure to bioethical issues|health care professionals were differentiated considering the work context and the type of patients cured
40773522|NCT00808873|OTHER|socio-educational intervention|brief mental health education and 6 follow-up visits
40773523|NCT05182918|OTHER|Substance use disorder treatment|The study followed a heterogenous sample of patients in opioid maintenance treatment (OMT) and other substance use disorder treatment. The main focus was on health related problems in this cohort, with focus on tobacco use and substance use.
41141580|NCT01927484|DRUG|25 mg/week oral methotrexate tablets|active oral methotrexate drug
41141581|NCT01927484|DRUG|25mg/week oral placebo tablets|placebo comparator oral drug
41141582|NCT02365597|DRUG|Erdafitinib|8 mg orally once daily for 28 days on a 28 day cycle.
41141583|NCT02365597|DRUG|Midazolam|Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.
41460683|NCT01903057|DRUG|ivermectin|
41460684|NCT01903057|DRUG|albendazole|
41460685|NCT01903057|DRUG|placebo|
40773524|NCT00000340|DRUG|Pemoline|
40773525|NCT06408376|PROCEDURE|Physiological cord clamping|Immediately after birth, the newborn with prenatal diagnosis of CDH will be placed on a mobile table, made to receive these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact and intubated. The patient will be gently ventilated (PIM 15/25 - PEEP 4 - Fio2 50%), until saturation \>85% and HR\>100 or 10 timed minutes have elapsed, whichever occurs first, the umbilical cord will be clamped.
40977566|NCT04909320|OTHER|Referral card|The contents consist of brief information and highlights of existing SC services, contact methods, motivation information, and strong supporting messages or slogans.
40977567|NCT04909320|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
41141584|NCT02365597|DRUG|Metformin|Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.
41141585|NCT02949297|DEVICE|Ovation Alto Abdominal Stent Graft System|Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System
41141586|NCT05121285|OTHER|Delivery of contrast fluid by lower GI endoscopy|Each participant will receive one delivery of 440 ml contrast fluid by lower GI endoscopy to the cecum of the colon. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. An colon X-ray is obtained within 10 minutes after the contrast fluid is delivered. The participants is in a supine position fram delivery and until the colon x-ray is obtained.
41141587|NCT05121285|OTHER|Delivery of contrast fluid by enema with and without positioning|"Each participant will receive one delivery of 440 ml contrast fluid by enema. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. The enema procedure includes:~1. The participant lies on his/her left side in neutral position when the enema is delivered~2. X-ray of the colon is obtained with the participant lying on his/her back.~3. The participant is positioned back to his/her left sided position and tilted in a Trendelenburg position. The position is held for two minutes~4. The participant is turned to an abdominal position while the bed remains tilted in Trendelenburg position.~5. Participant turne to the right side. When positioned the bed is tilted the opposite way (anti-Trendelenburg.) The position is held for two minutes.~6. A second colon X-ray is obtained after the participants has rested for ten minutes in a supine neutral position"
41141588|NCT01065779|DRUG|FOSAMAX PLUS|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
41301491|NCT02848690|OTHER|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI\> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
41301492|NCT05238896|DRUG|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg/d oral route for 42 days
40977568|NCT04909320|BEHAVIORAL|Positive psychological support through 3-people group chat using instant messaging apps|Each IM chat group will consist of a trained SC counselor (HKU staff), a peer supporter (former smoker), and a participant (smoker). The 3-month group chat-based intervention will consist of regular messages and real-time support through group chat. Regular messages will generally include goal setting, health warnings, abstinence support, positive psychological exercises, and encouragement and will be delivered in a tapering style. During the real-time chatting, SC counsellors and peer supporters will provide real-time chat-based support, and peer supporters will share their quitting experience as appropriate.
41141589|NCT01065779|DRUG|FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
41301493|NCT05238896|DRUG|Placebo|Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
41301494|NCT02024711|DEVICE|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
41301495|NCT02024711|DEVICE|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
41301496|NCT05375903|DRUG|UGN-301|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
41301497|NCT05375903|DRUG|UGN-201|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
41301498|NCT05375903|DRUG|Gemcitabine|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
41301499|NCT06219317|DRUG|Cemiplimab|Cemiplimab is provided in a 10 ml glass vial
41301500|NCT06219317|DRUG|Placebo|standard saline solution
41301501|NCT04890574|DEVICE|CellMist™ System|Open Label, Safety and Feasibility
41301502|NCT01441440|DRUG|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
40773526|NCT04442009|OTHER|Group SCPB|In group SCBP, SCBP block will be performed. Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
40773527|NCT01683812|DEVICE|Cranial Cup|Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
41301503|NCT01441440|DRUG|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
41301504|NCT01441440|DRUG|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
41301505|NCT03158649|OTHER|"Embarazo y Bienestar"|"The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page."
41141590|NCT01821040|DRUG|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
41141591|NCT01821040|DRUG|Prednisone IR (immediate release)|Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
41141592|NCT05197179|DRUG|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
41141593|NCT05197179|OTHER|FB2001 placebo|Subjects will be administered with FB2001 by intravenous (IV) infusion
41141594|NCT00693836|GENETIC|genetic linkage analysis|
41141595|NCT00693836|GENETIC|loss of heterozygosity analysis|
41141596|NCT00693836|GENETIC|mutation analysis|
41141597|NCT00693836|GENETIC|polymerase chain reaction|
41141598|NCT00693836|GENETIC|polymorphism analysis|
41141599|NCT00693836|OTHER|biologic sample preservation procedure|
41141600|NCT00693836|OTHER|medical chart review|
41141601|NCT00693836|OTHER|questionnaire administration|
41141602|NCT00693836|PROCEDURE|evaluation of cancer risk factors|
41301506|NCT06287736|DEVICE|Spinal Cord Stimulator Implantation (SCS)|Spinal cord stimulator implantation is broken up into two parts. The first part involves placement of temporary SCS leads for a one-week trial. If the participants respond favorably to the SCS, then they will undergo the second part and the device is implanted
41301507|NCT01004783|GENETIC|DNA methylation analysis|
41301508|NCT01004783|GENETIC|gene expression analysis|
41301509|NCT01004783|GENETIC|loss of heterozygosity analysis|
41301510|NCT01004783|GENETIC|microarray analysis|
41301511|NCT01004783|GENETIC|mutation analysis|
41301512|NCT01004783|GENETIC|polymerase chain reaction|
41301513|NCT01004783|GENETIC|reverse transcriptase-polymerase chain reaction|
41301514|NCT01004783|OTHER|laboratory biomarker analysis|
41301515|NCT04866420|BEHAVIORAL|The MenFAS Study|A cross over repeated exposure randomized design observational study
40977569|NCT04909320|BEHAVIORAL|E-messages via SMS|Regular e-messages via SMS at twice per month within 3 months (total 6).
40977570|NCT03455920|OTHER|Clinical nurse (supernurse) evaluation|The first evaluation of the patient refered to the sleep clinic will be performed by the clinical nurse then discussed with the pulmonologist in charge.
41301516|NCT04575857|DRUG|Atorvastatin|Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.
40977571|NCT03455920|OTHER|Pulmonologist evaluation|The first evaluation of the patient refered to the sleep clinic will be performed only by the pulmonologist.
40977572|NCT03867006|DIETARY_SUPPLEMENT|Protein|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days.
40977573|NCT03867006|DIETARY_SUPPLEMENT|Protein and Carbohydrate|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days and eat 60g of carbohydrates 2h after every diner during 90 days.
40977574|NCT00268957|DRUG|Sevelamer carbonate (Renvela®)|sevelamer carbonate powder dosed once per day with largest meal
40977575|NCT00268957|DRUG|Sevelamer hydrochloride (Renagel®)|Sevelamer hydrochloride tablets dosed three times a day with meals
40977576|NCT06285981|DEVICE|Chimaera Long Nail|The CHIMAERATM, is an internal fixation system intended intended for insertion into the medullary canal of a femur in individuals suffering from stable and unstable pertrochanteric, intertrochanteric and subtrochanteric fractures of the femur alone or when these fractures occur in combination with shaft fractures extending distally to a point approximately 10cm proximal to the intercondylar notch.
41460686|NCT04158778|DRUG|MDMA|Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy. An initial dose of 125mg MDMA will be followed by an optional dose of 62.5mg 2 hours later.
41460687|NCT04158778|OTHER|Psychotherapy|Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy.
41460688|NCT02959840|DEVICE|Acupressure Point P6 stimulator|This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.
41460689|NCT02959840|DRUG|Metoclopramide|10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
41460690|NCT02959840|DRUG|Ondansetron|8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
40977577|NCT03905746|OTHER|blood sample at Day 0|"40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.~(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)"
40977578|NCT03905746|OTHER|blood sample at Day 2 and Day 7|20mL blood (plasma and PBMCs) will be performed at Day 2 and Day 7 from recruitment, at the time of routine exams. These two samples will constitute the biological collection.
41460691|NCT03008655|PROCEDURE|intradermal tranexamic acid|intradermal tranexamic acid injection
41460692|NCT03008655|DEVICE|Nd-YAG|six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)
41460693|NCT04496037|DRUG|Rituximab|See NCT03994783
40977579|NCT03905746|OTHER|stool sample at Day 0|stool sample (2mL) will be performed at D0 (inclusion), at the time of routine exams.
40977580|NCT02861794|PROCEDURE|Medacta International, GMK Sphere medially stabilized knee|Total Knee Replacement
40977581|NCT00438698|OTHER|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
40773528|NCT05367947|BEHAVIORAL|In-phase Bilateral Exercises of the upper limbs|"The intervention protocol consists of in-phase bilateral exercises for the upper limbs, which are adapted to different sport activities and to fitness functional exercises, organized in a circuit training. Specifically, each session will consist of 1-3 sets, consisting of 10-15 repetitions of 9 different exercises targeting large muscle groups of the upper limbs.~The specific exercises will include sports activities of basic technical skills of basketball (e.g., different types of passing, catching and throwing the ball) and volleyball (e.g., different types of passing and receiving the ball), whereas the fitness exercises will include shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, using resistance elastic bands, as well as exercises with the patients' own body weight (e.g., pushups, TRX).~The intervention phase for each participant will consist of 12 consecutive weeks, for 3 times per week, 30-60 minutes each session."
40773529|NCT02083978|OTHER|MRI scanning|
40977582|NCT00438698|OTHER|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
41301517|NCT04575857|DRUG|Placebo|Participants in the control arm will receive a pill packet with placebo x 18 months.
41301518|NCT00000451|DRUG|sertraline|16 week outpatient study
41301519|NCT00000451|DRUG|naltrexone|16 week outpatient study
41301520|NCT02647762|DRUG|CF101 1 mg|CF101 tablets, 1mg BID for 12 weeks
41301521|NCT02647762|DRUG|CF101 2 mg|CF101 tablets, 2 mg BID for 12 weeks
41301522|NCT02647762|DRUG|Placebo|Placebo tablets, 1mg BID for 12 weeks
41301523|NCT02647762|DRUG|MTX|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
41301524|NCT01399801|PROCEDURE|Doppler flow measurement|use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement
41301525|NCT01399801|PROCEDURE|standard implantation of the LV lead|Standard implantation of the LV lead with measurements of flow
40977583|NCT00292695|OTHER|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
40773530|NCT06058416|BIOLOGICAL|Healive (hepatitis A vacine(human diploid cell), inactivated)|"The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively."
40773531|NCT06295419|OTHER|dual task|cerebral palsy and healthy controls will be evaluated dual task conditions
40773532|NCT06295419|OTHER|single task|cerebral palsy and healthy controls will be evaluated single task conditions
40773533|NCT02629861|DRUG|Fremanezumab|"Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site."
40773534|NCT02629861|DRUG|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
40773535|NCT00294749|DRUG|Ciprofloxacine|
40773536|NCT05298930|OTHER|Physical activity program|"The supervised sessions will be offered 4 times a week in the participants' rooms by the APA teachers and will include moderate intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient will also be able to perform unsupervised sessions (on their own), following the advice given by the APA teacher. These unsupervised sessions can be done independently on the bike.~In order to encourage patients to perform these unsupervised sessions, patients and their relatives will be given a connected device and will have access to a mobile application developed by the Kiplin company, which offers connected physical activity games to be performed in teams (from 2 to 4 participants). These games, lasting from 1 to 3 weeks, use the participants' daily PA level as a unit of animation and are punctuated by challenges."
40773537|NCT01775384|DIETARY_SUPPLEMENT|Nutrasorb|from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
40773538|NCT01775384|DIETARY_SUPPLEMENT|Placebo|
41141603|NCT02354144|OTHER|Carrageenan-based gel|Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
41141604|NCT02354144|OTHER|Control gel|A gel not containing carrageenan
41141605|NCT02391259|DRUG|AMG 557|AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
41301526|NCT00817986|DRUG|Arbaclofen placarbil, 20 mg|tablets
41301527|NCT00817986|DRUG|Placebo|tablets
41460694|NCT00259194|BEHAVIORAL|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
40773539|NCT03469895|DRUG|ibrutinib ou idelalisib|treatment by ibrutinib or idelalisib for autoimmune cytopenia
40773540|NCT03822611|BEHAVIORAL|Targeted Subsidy|Voucher
40773541|NCT01846702|DRUG|Placebo|Given as a SC injection.
40773542|NCT01846702|DRUG|LY3084077|Given as a SC injection.
40977584|NCT02041611|PROCEDURE|Blood collections|pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
41141606|NCT02391259|DRUG|Placebo|contains no active drug
41141607|NCT03775915|OTHER|Neurofeedback|A visual representation of the participants brain activity during movement of their affected hand in the MRI scanner.
41141608|NCT03775915|OTHER|Sham Neurofeedback|A visual representation of brain activity pre-recorded from a previous participant
41141609|NCT05200286|DRUG|Olorofim|Single oral dose
41141610|NCT05438875|DRUG|all-trans retinoic acid|ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.
41141611|NCT05438875|DRUG|Eltrombopag|The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.
41141612|NCT04780607|DEVICE|mitral valve repair|different repair techniques to construct rheumatic mitral valve lesion
40773543|NCT02546323|DRUG|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
41301528|NCT00817986|DRUG|Arbaclofen placarbil, 30 mg|tablets
41301529|NCT00817986|DRUG|Arbaclofen placarbil, 40 mg|tablets
41301530|NCT01105416|BEHAVIORAL|Brief Prevention Intervention (BPI)|Brief Prevention Intervention: Participants will receive the BPI, a brief, family-focused prevention intervention in the Pediatric ED. The session will be comprised of parent-targeted skill building directed primarily at parental monitoring and the importance of parent-adolescent communication as the precursor to successful monitoring.
41301531|NCT01105416|BEHAVIORAL|ESC|Enhanced standard care
41301532|NCT02225067|DRUG|Calcium (13C)Carbonate|Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
41301533|NCT05029596|DRUG|Normal Saline Group|A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.
41460695|NCT00259194|BEHAVIORAL|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
41460696|NCT01597349|DRUG|FP01|Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
41301534|NCT05029596|DRUG|Heparin Group|All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
40773544|NCT02546323|DRUG|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
40773545|NCT02784340|DRUG|Dexamethasone|16 mg Dexamethasone IV drip
40773546|NCT02784340|DRUG|Dexamethasone|16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
40773547|NCT02784340|DRUG|Saline (IV fluids)|IV fluids 500 cc saline infusion
40773548|NCT02784340|DRUG|Bupivicaine and Fentany|
40773549|NCT02784340|DEVICE|25G spinal needles|
40773550|NCT05077384|DRUG|Surufatinib|Surufatinib 300 mg oral once daily
40773551|NCT05523908|RADIATION|High-dose hypofraction Arm|Patients in this arm would receive high-dose fractionated radiotherapy with 60Gy/15f
40773552|NCT05523908|RADIATION|Low-dose hypofraction Arm (Standard BED)|Patients in this arm would receive low-dose fractionated radiotherapy with 48Gy/12f
41301535|NCT01532323|OTHER|Taking of saliva before and after gustatory stimulation|Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
41301536|NCT05392127|DRUG|SHR0302 Tablets|SHR0302 Tablets once daily
40977585|NCT01635192|BIOLOGICAL|VSL#3|"The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide."
41141613|NCT00680654|DRUG|Riociguat (Adempas, BAY63-2521)|The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
41141614|NCT04008953|DEVICE|ultrasonography|Intravascular volume assessment using ultrasonography, CVP and echocardiography
41141615|NCT01884571|DRUG|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
41141616|NCT01884571|DRUG|Methylprednisolone|125 mg, IV (in the vein) on day 1.
41141617|NCT01884571|DRUG|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
41141618|NCT01884571|DRUG|Tacrolimus|1-5 mg PO, twice a day (BID) days 2-180.
41141619|NCT01884571|DRUG|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
41141620|NCT05939505|OTHER|Su Jok therapy|Sujok therapy will be applied with Mexican bean seeds 14 times with an interval of one day.
41141621|NCT05939505|OTHER|placebo|Instead of the Mexican bean seed applied in sujok therapy, plastic beans will be applied 14 times with an interval of one day.
41141622|NCT05939505|OTHER|routine interventions|routine applications in the hemodialysis unit
41141623|NCT03966456|DRUG|Chemotherapy|compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
41141624|NCT01106807|DRUG|Epiduo vehicle gel|500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks
41141625|NCT01106807|DRUG|CD07223|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks
41141626|NCT01106807|DRUG|CD07223|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
41141627|NCT01106807|DRUG|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters Epiduo Gel on one of the half-face for the morning dose
41141628|NCT02704052|DRUG|Real time enoxaparin dose adjustment|Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
41301537|NCT05392127|DRUG|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
41301538|NCT05392127|DRUG|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
41141629|NCT02704052|DRUG|Standard enoxaparin dose|Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
41301539|NCT05392127|DRUG|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
41301540|NCT05392127|DRUG|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
41301541|NCT05392127|DRUG|Repaglinide Tablets|Repaglinide Tablets single dose
41301542|NCT01008254|BEHAVIORAL|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
40773553|NCT06108947|DRUG|Aspirin|Aspirin discontinuation
40773554|NCT06030635|DEVICE|Measurement of compartment compressibility using the CPMX1 device|Patients will be monitored about every hour (+/- 30 min) for a total of 8 hours. Measurement time might be extended in case the patient undergoes trauma-related surgery during the measurement period and/or in case measurements are spaced further apart. Remaining measurements will be completed after the surgery. At each time point, three measurements of compartment compressibility will be conducted using the CMPX1 on both the affected (potential ACS) and healthy limb.
41301543|NCT01008254|BEHAVIORAL|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
41301544|NCT01008254|OTHER|No musical prompt|No intervention.
41301545|NCT00190203|PROCEDURE|Decompressive hemicraniectomy and duraplasty|Decompressive hemicraniectomy and duraplasty
41460697|NCT04754555|OTHER|Arm Activity Measure (ArmA) in french|The Arm Activity Measure (ArmA) provides a standardized assessment of upper limb passive and active perceived performance
41141630|NCT06285578|DIETARY_SUPPLEMENT|Probiotics supplementation|Probiotics, Lactiplantibacillus plantarum TWK10, are packaged in powder form. Each participant consume one packet every day on a fasting status for 8 weeks.
41141631|NCT06285578|BEHAVIORAL|HIIT training|HIIT training is conduct at the intensity of 85-90% VO2max for 2 minutes with 1-minute inactive resting interval, repeating for 7 times. 3 sessions per week for 8 weeks.
41301546|NCT00190203|PROCEDURE|hemicraniectomy|hemicraniectomy
41301547|NCT00395252|DRUG|Cetuximab (Erbitux®) and Gemcitabine|"Cetuximab:~Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)~Gemcitabine:~1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered~Mode of administration:~Intravenous infusion"
41301548|NCT02350894|BEHAVIORAL|Graded and behavevial theraphy|Graded and behavevial theraphy
41301549|NCT03165136|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200 mg twice a day
41301550|NCT03165136|DRUG|Placebo|placebo of hydroxychloroquine
41301551|NCT00206999|DRUG|imipramine|Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
41301552|NCT01150877|DRUG|Vitamin D|We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
41301553|NCT00942773|DRUG|Voriconazole|
40773555|NCT03048682|DEVICE|Foley catheter - Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator."
40773556|NCT03048682|DEVICE|Foley catheter - Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice"
40773557|NCT05750407|BEHAVIORAL|Lifestyle change|Three modules target healthy eating, activity, and weight control behaviors
40773558|NCT01937702|OTHER|0.9% NaCl (sodium chloride)|
40773559|NCT06163339|OTHER|Cultural Formulation Interview|Usual Care is enhanced with the Cultural Formulation Interview (CFI) aimed at strengthening assessment and treatment adherence
40773560|NCT06571435|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST), and Posterior Shoulder Endurance Test|"The modified closed kinetic chain upper extremity stability test is reliable and is performed in an individualized manner by placing the hands on the floor at shoulder level. The evaluation process is the same as the original test; the total number of touches in 15 seconds is noted by lifting one hand, touching the other and placing it back. A total of 3 measurements are taken with a 45-second rest interval. The endurance capacity of the muscle group is an important factor for sports performance as it requires specific sports movements repeated in a certain period of time.~For posterior shoulder endurance test participants will lie with their face down. While the shoulder is hanging from the stretcher, individuals will be asked to lift the dumble calculated with the weight appropriate for their weight to 90 degrees abduction in accordance with the 60 bpm metronome. Their duration in seconds will be noted. 1 measurement will be made with each arm."
40773561|NCT03790748|PROCEDURE|Standard Lumbar Epidural Technique|Standard Lumbar Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
40773562|NCT03790748|PROCEDURE|25G Dural Puncture Epidural Technique|25G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
40773563|NCT03790748|PROCEDURE|27G Dural Puncture Epidural Technique|27G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
41301554|NCT05892133|BEHAVIORAL|Maximal strength training|3 sessions/ week. leg press at \~85% of one repetition maximum for 8 weeks
41301555|NCT04985708|OTHER|data collection of clinically available procedures|when to place Impella related to PCI in patients with AMICS
41301556|NCT02899793|DRUG|Pembrolizumab|Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
41301557|NCT02151409|DRUG|NNC 0151-0000-0000|A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
40773564|NCT02993263|DEVICE|VectraplexECG System with CEB®|The device will be used after noncardiac surgery
40773565|NCT04806152|OTHER|High intensity exercise|Supervised high-intensity combined-modality exercise was administered to participants in the exercise arm for 3 times per week for 6 months. A post-exercise recovery protein drink (31g whey-based) was given within 15 minutes after each supervised exercise session.
40773566|NCT04806152|OTHER|Usual care home exercise|Walking 30 minutes, chair rises and flexibility exercises for trunk and upper extremities 5 days per week
40977586|NCT01635192|BIOLOGICAL|Placebo|Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
40977587|NCT06083116|DRUG|Hydrochlorothiazide、Henagliflozin Proline|Hydrochlorothiazide and Henagliflozin Proline
40977588|NCT04203784|OTHER|Plasma concentration measurements|Plasma concentration measurements
40977589|NCT05609240|DRUG|Cefuroxime|See arm/group description
41301558|NCT02151409|DRUG|NNC 0151-0000-0000|A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
41301559|NCT02151409|DRUG|placebo|A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
41301560|NCT03343431|DRUG|Anti-HBV antiviral prophylaxis|Tenofovir disoproxil fumarate (TDF), one 300 mg tablet once a day from 28 weeks' gestation through two months postpartum
41301561|NCT06470100|DRUG|0.9% Sodium Chloride Injection|unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
41301562|NCT06470100|DRUG|Dexamethasone|unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
41301563|NCT06470100|DRUG|Dexmedetomidine|unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
41301564|NCT01204840|DRUG|Growth Hormone|Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
40773567|NCT01675947|DRUG|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
40773568|NCT01675947|DRUG|Lidocaine|Lidocaine 2%
40977590|NCT05779293|DEVICE|Non-invasive auricular vagus nerve stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased. The application will take 30 minutes three days a week for four weeks.
40977591|NCT05779293|OTHER|Conventional therapy|"Conventional approaches are approaches that cover range of motion, strength, balance and ambulation training, continuing from passive to resistant exercises.~Neuromuscular electrical stimulation; It is applied to reduce pain, prevent spasticity and strengthen muscles. This newly formed type I fiber functionally shows an increase in resistance to fatigue and a decrease in maximum contraction velocity. The application will take 30 minutes three days a week for four weeks."
40977592|NCT04216095|DEVICE|Electroconvulsive Therapy (n=30)|Right unilateral (RUL) ECT (n=15) or bitemporal (BT) ECT (n=15) using a Thymatron IV device (Somatics LLC, USA) twice weekly.
40977593|NCT04216095|DEVICE|Magnetic Seizure Therapy (n=30)|High-dose magnetic seizure therapy (HD-MST) over the vertex using Magstim Theta device (Magstim Company Limited, Whitfield, Wales, UK) at 100% maximal output of the device (constant), with pulse frequency 100Hz and train duration 10 seconds twice weekly.
40977594|NCT04327557|BEHAVIORAL|MBCP Childbirth Education Course|The MBCP program is a fully manualized childbirth and parenting preparation course. Developed in 1998 in a clinical context, MBCP is an enhanced version of the Mindfulness Based Stress Reduction (MBSR) program tailored for addressing the concerns of pregnancy and early parenting. Through MBCP, pregnant women and their partners learn mindfulness skills for coping with the anxiety and stress of pregnancy and parenting, and the pain and fear of childbirth. They are given explicit instruction in skills for cultivating positive emotion and developing mindful, sensitive parenting. MBCP groups meet weekly for 9 weeks, with a retreat day between weeks 6 and 7.
40977595|NCT04327557|BEHAVIORAL|Non-MBCP Childbirth Education Course|TAU control participants will undergo standard (real-world) hospital- or community-based childbirth education that does not have a mindfulness focus. They will be able to choose whichever class they want from the list. If they prefer a class that is not on the list, then study staff will obtain the syllabus for that class to check whether there is a mindfulness component.
41141632|NCT06285578|DIETARY_SUPPLEMENT|Placebo supplementation|Yeast powder replaces probiotics in each packet. Each participant consume one packet every day on a fasting status for 8 weeks.
41141633|NCT02803866|BEHAVIORAL|Training program CAP-PREM|1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
41141634|NCT05350709|OTHER|mirror therapy|15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.
41141635|NCT05871788|DIAGNOSTIC_TEST|identify biomarkers|Identify the epidemiological profile of the biological signature (PD-L1 / TMB / MSI/HRD/ TILs) of patients with locally advanced or metastatic breast carcinoma
41141636|NCT05180175|DRUG|Top down treatment if patient at high risk|Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
41141637|NCT05575687|OTHER|Water (reference)|Ingestion of 500 ml mineral water
41141638|NCT05575687|OTHER|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
41141639|NCT05575687|OTHER|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
41141640|NCT05575687|OTHER|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
41141641|NCT05575687|OTHER|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
41141642|NCT05575687|OTHER|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
41141643|NCT02948309|DRUG|Mistletoe extract (Iscador Qu)|1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
40977596|NCT04156425|DRUG|Escitalopram+golimumab|Escitalopram will be administered at 10-20 mg/d during the acute phase. Golimumab will be administered at the dose of 50mg every month during the acute phase.
41141644|NCT02948309|DRUG|Placebo|1ml subcutaneous injection 3 times/week
41141645|NCT04063449|DRUG|endostar/PD-1 inhibitor|Antiangiogenic therapy plus immunotherapy and chemotherapy
41141646|NCT04063449|DRUG|endostar|Antiangiogenic therapy plus chemotherapy
41141647|NCT00663923|PROCEDURE|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
41141648|NCT05125614|OTHER|No adjuvant chemotherapy|There is no intervention differences between 2 groups. We analyzed the data of the patients who did not receive adjuvant chemotherapy.
41141649|NCT06402292|PROCEDURE|OSTEOMYELITIS SURGICAL TREATMENT WITH LOCAL ANTIBIOTICS AND PEROSSAL|25 PATIENTS WITH FRI WILL BE SURGICALLY TREAT WITH DESBRIDMENT AND PEROSSAL WITH ANTIBIOTCS
41141650|NCT02133131|DRUG|Grazoprevir/Elbasvir FDC|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
41141651|NCT02133131|DRUG|Sofosbuvir|Sofosbuvir 400mg tablet taken q.d. by mouth.
40773569|NCT04217434|PROCEDURE|400 µm fibre length will be used in continuous contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
40773570|NCT04217434|PROCEDURE|400 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
40773571|NCT04217434|PROCEDURE|300 µm fibre length will be used in continuous mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used continous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
40773572|NCT04217434|PROCEDURE|300 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. .Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
40773573|NCT04362735|DRUG|Vedolizumab|Vedolizumab 300 mg at weeks 0, 2 and 6 as induction. Maintenance every 4 or 8 weeks, as on-label recommendations.
41460698|NCT05642130|OTHER|exersice program (Muscle energy technique)|Post isometric relaxation for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks, In addition to the program designed for control group
41460699|NCT05642130|OTHER|exersice program (stretching and strengthening exercises ) In addition to postural advices|static stretching exercise for upper trapezius and sternocleidomastoid . Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles, 3sets of 12 repetitions with 6 sec hold. In addition to postural advices
40773574|NCT04613388|OTHER|Assesment of Effectiveness and side effects|Case Report forms, Quality of life questionaire
40773575|NCT05452668|DEVICE|Laser Therapy|- Laser will be applied with the specified wave length using a diode laser device over 4 consecutive days.
40773576|NCT05452668|DEVICE|Sham procedure|Seventeen patients will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission plus the current Protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file
40773577|NCT01148771|DRUG|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
40977597|NCT04156425|DIETARY_SUPPLEMENT|Escitalopram+Calcium Tablet|Escitalopram will be administered at 10-20 mg/d during the acute phase. Calcium tablet will be administered at 2000mg/d during the acute phase.
40977598|NCT04156425|DRUG|Escitalopram|Escitalopram will be administered at 10-20 mg/d during the acute phase.
40977599|NCT03156673|BIOLOGICAL|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10\^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
41141652|NCT06080802|DRUG|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily 1 gm daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner) during the rest of the follow-up. Patients will be followed up by telephone call 2 weeks intervals during the study period 5 SGL-2 will be prescribed to group 1 after diagnosis with HFpEF while group 2 will have SGL-2 and Metformin
41141653|NCT03659942|OTHER|CAST questionnaire|the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
41141654|NCT04483102|DEVICE|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study.
40773578|NCT01148771|DRUG|ertapenem|1 gram 30 minute infusion q24h for 3 days
40773579|NCT04942847|DEVICE|Sucking trainer|Repeated sucking for tongue flexibility training can improve the tongue muscle's ability to control and transmit food, and improve the swallowing function.
40773580|NCT04942847|DEVICE|Cognitive card|To measure the patient's ability to focus, to calculate, to remember and to judge
40773581|NCT00441324|PROCEDURE|recombinant human LH|
41460700|NCT05192096|BEHAVIORAL|Train-the-trainer workshop|To deliver health-related information to trainees, which facilitate improving their knowledge, confidence, and ability to share and discuss health-related information with others, including service users, families and friends.
41460701|NCT01013818|DRUG|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
40773582|NCT03363529|DEVICE|Dynamic light|Dynamic lighting is light that changes in intensity and spectral distribution during the day
40773583|NCT03363529|DEVICE|Standard|Standard lighting is non-dynamical light corresponding to standard hospital lighting.
40773584|NCT02001246|BEHAVIORAL|Real Deal program for Anger Management|Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
40773585|NCT02001246|BEHAVIORAL|Mind-body Bridging (MBB) program|MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
40773586|NCT05140421|BEHAVIORAL|Data to Suppression (D2S)|Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
40773587|NCT00261339|DRUG|Pantoprazole|
40773588|NCT03769155|BIOLOGICAL|Ipilimumab|Given IV
41141655|NCT04483102|PROCEDURE|Standard cold preservation of liver|"The study will have three comparison groups - one local comparison group and two comparison groups from the national UNOS data.~Comparison group 1 will be patients who received a standard liver transplantation and follow-up care at the Washington University/ Barnes Jewish Hospital (n=50). Patients will be matched by a 5-year age category, sex, MELD score, donor liver graft type (e.g., DCD, DBD), donor age (5-year category), and donor sex. Washington University/ Barnes Jewish Hospital maintains a liver transplantation database that prospectively collects pre- and post-transplantation patient data.~Comparison group 2 will be patients who received DBD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex.~Comparison group 3 will be patients who received DCD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex."
41460702|NCT01388257|PROCEDURE|All types of surgery procedures|All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
41460703|NCT01388257|PROCEDURE|Simple seton drain removal|Patients are simply followed after seton drain removal.
40773589|NCT03769155|BIOLOGICAL|Nivolumab|Given IV
40773590|NCT03769155|BIOLOGICAL|VX15/2503|Given IV
40773591|NCT03769155|PROCEDURE|Surgery|Undergo therapeutic conventional surgery
40773592|NCT03122184|BEHAVIORAL|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
40773593|NCT03122184|BEHAVIORAL|Motivational Interviewing Health Education|Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
40773594|NCT04637061|COMBINATION_PRODUCT|intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis|Extra-luminal (serosa) and Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative NIR-ICG-induced FA. This will be conducted administering IV a bolus of 3.75 to 7.5 mg of ICG and evaluated using a Fluorescence Imaging System; following after completion of the anastomosis a second bolos of 3.75 to 7.5 mg of ICG will be administered IV and the anastomosis will be visualized by insertion of the system trans-anally. Colon and rectal segments and quadrants will be scored for any defect of perfusion.
41460704|NCT03638596|BEHAVIORAL|Contingency Management|Incentive provided for changing alcohol drinking patterns based on ankle monitor
40977600|NCT00399854|DEVICE|Dhermia® - Industra Mecânica Fina Ltda|
41460705|NCT03638596|BEHAVIORAL|Control|Incentive provided is not contingent on alcohol drinking patterns based on ankle monitor
40773595|NCT04637061|DIAGNOSTIC_TEST|Air Leak test|This will be conducted insufflaying air in the anastomosis through a proctoscope, tube or a flexible endoscope, after filling of the pelvis with saline solution and luminal occlusion of the intestine proximal to the anastomosis. Also, the anastomosis will be checked transanally for the presence of air leak.
40977601|NCT03281681|DRUG|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
40977602|NCT00400751|BEHAVIORAL|FAMCON (Family Consultation)|
40977603|NCT01906203|DEVICE|body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France|
40977604|NCT02461563|DRUG|200 mg MK-1075|Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
40773596|NCT04637061|DIAGNOSTIC_TEST|Evaluation of the anastomotic rings|The assessment of the anastomotic rings following mechanical anastomosis will be recorded as complete/incomplete
40773597|NCT04434183|DEVICE|Exercises of rehabilitation|Compare and evaluate of the effects of the routin physical medicine and rehabilitation programs in impingement patients
40773598|NCT06464367|DRUG|Psilocybin|synthetic psilocybin 10 mg (oral)
40773599|NCT06464367|DRUG|Placebo|synthetic THC 2.5 mg (oral)
40977605|NCT02461563|DRUG|400 mg MK-1075|Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
41460706|NCT05960422|PROCEDURE|Popliteal Sciatic Nerve Block|Patients undergoing popliteal sciatic block, the side where the procedure would be performed in the prone position was sterilized after appropriate antisepsis. After visualizing the popliteal artery in the popliteal fossa with the probe it was advanced proximally in a horizontal and minimally lateral position to determine the point of separation of the tibial and peroneal nerves from the sciatic nerve. Subcutaneous local anesthesia was applied at this point after the skin, and the stimulator needle was advanced towards the sciatic nerve in an in-plane approach, passing through the skin and subcutaneous tissue, and then the nerve stimulator was opened up to 1 mA. After observing motor movement in the foot, the stimulator was reduced to 0.3-0.5 mA, and after observing motor movements for duration of 0.1 ms, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were administered to the target tissue
40977606|NCT02461563|DRUG|800 mg MK-1075|Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
40977607|NCT05244577|DRUG|Olanzapine Tablets|Olanzapine,Ondansetron,Dexamethasone,Fosaprepitant
40977608|NCT05244577|DRUG|Placebo|Placebo,Ondansetron,Dexamethasone,Fosaprepitant
40773600|NCT00404248|DRUG|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
40977609|NCT03981263|DEVICE|MEAVANTI prothesis|"The experimental prosthesis is the MEAVANTI prosthesis (custom-made non-adherent prosthesis in silicone) which can be calibrated to 5 grams near the breast that remains after a mastectomy to create a visual symmetry but also a weight symmetry.~This prosthesis takes into account the curve of the breasts and the morphological details such as: skin color of the patients, size of the nipples, height of the nipples, shape of the breast.~The measurements of the patients will be taken using a 3D scanner (i.e. a scanner that corresponds to a 3d scanning and acquiring device (images), not irradiating), a scale and a colour chart."
40977610|NCT03981263|DEVICE|Standard prothesis|This prosthesis will be compared with a standard non-adherent prosthesis (class I, silicone and polyurethane film), among the models available in the three ranges of standard prostheses (Amoena, Anita and Thuasne). The brand and model will be left to the patient's choice.
40977611|NCT02187250|DRUG|metformin|
40977612|NCT02187250|DRUG|liraglutide|
40977613|NCT02187250|DRUG|roflumilast|
40773601|NCT00404248|OTHER|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
40773602|NCT02957838|DIETARY_SUPPLEMENT|C18:0|Receives 24g of C18:0 in a low-fat banana milkshake.
40773603|NCT02957838|DIETARY_SUPPLEMENT|mock|Low fat banana milkshake without C18:0 supplement.
40773604|NCT04908228|DRUG|Ibrutinib and obinutuzumab|Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
40773605|NCT05150626|DRUG|DBPR108 tablets|Drug: DBPR108, tablets, oral
40773606|NCT03058874|DEVICE|Extra-vascular lung water measurements by ultrasound|Lung congestion measured by lung ultrasound (US-B lines) to guide dry-weight probing and UF intensification
40977614|NCT06289608|OTHER|No intervention|No dental intervention was made. Only a clinical examination
40977615|NCT03352206|DRUG|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
40977616|NCT03352206|DRUG|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
40773607|NCT03058874|OTHER|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
40773608|NCT05669365|BEHAVIORAL|Care Ecosystem|"Applying the principles of person-and-family centered and collaborative care to dementia, the Care Ecosystem (CE) offers proactive, protocol-guided phone- and web-based caregiver support, guidance, and care coordination that extends the reach of dementia primary and specialty care. Care is delivered primarily via the phone and web by unlicensed Care Team Navigators (CTNs), who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. Care Protocols guide proactive, quality care that is documented in the electronic health record (EHR).~The CTN is an unlicensed, trained dementia care guide who served as the PWD's and caregiver's primary point of contact to the program under nurse supervision. Care team navigators respond to caregivers' immediate needs first, then screen for common problems and provide personalized support and standardized education using the care plan protocols."
41460707|NCT05960422|PROCEDURE|Adductor canal block|Patients in the group undergoing popliteal sciatic block + adductor canal block, with the extremity to be blocked slightly externally rotated, the anterior part of the thigh was prepared with the necessary antiseptic procedures while the patient was in the supine position. Using an ultrasound probe, the femoral artery was visualized by advancing the ultrasound probe distally, and the saphenous nerve was identified just lateral to the femoral artery, beneath the sartorius muscle. At the junction of the sartorius muscle and vastus medialis, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were applied to the periphery of the saphenous nerve. Subsequently, the patient was turned prone, and a popliteal sciatic block was performed.
40773609|NCT01468155|DRUG|dabigatran|30 days pre ablation and 90 days post ablation
40773610|NCT00020748|DRUG|epirubicin hydrochloride|
40773611|NCT00020748|DRUG|irinotecan hydrochloride|
40773612|NCT05129800|OTHER|Platelet-rich plasma|"PRP preparation involved, withdrawal 8-10ml from each patient into a tube containg either 3,8 % sodium citrate and either enoxaparin gel or thixotropic cell-separation gel. The tubes were centrifuged at either 3900 rpm for 10 minutes or at 1500g for 5 minutes, resulting in four layers: a cell-rich layer at the bottom of the tube covered by the separating gel, a PRP layer on top of the gel, and a platelet-poor plasma (PPP) layer at the top. The tube was gently agitated in order to mix the PPP with the PRP. The solution, cca 4-5ml, was withdrawn with a needle and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or an injector. According to the protocol of our hospital, the injections to the scalp were spaced 0.5-1cm apart.~PRP was applied once every month for 3 months. Macroscopic and digital phototrichographic photos were taken before the beginning of treatment, 1 month after the last injection, and 3 months after the end of treatmert."
40773613|NCT05129800|OTHER|Mesotherapy|"For mesotherapy, usually around 5ml of saline solution was withdrawn using a needle and released to the selected ampule containing adipose tissue stem-cell conditioned media and mixture of recombinant growth factors, in a powder form. We used preparations from two different companies, differing in the combination and concentration of ingredients. After the injection of normal saline, the ampule was gently agitated in order to disperse the powder and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or a gun injector. The injections were spaced 0.5-1cm apart.~Mesotherapy was repeated every 1-2 weeks for 6-7 times according to the protocol recommended for each preparation. Macroscopic and phototrichographic photos were taken before the beginning of treatment, a month after the last injection and 3 months after the end of treatment."
40773614|NCT03505060|BIOLOGICAL|DNA CON-S env|Administered by intramuscular injection in the deltoid.
40773615|NCT03505060|BIOLOGICAL|IHV01|Administered by intramuscular injection in the deltoid.
40773616|NCT03505060|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
40773617|NCT05537727|DEVICE|robotic-assisted surgery|Gynecology: robot-assisted and laparoscopic hysterectomy for benign or low risk malignant disease
40773618|NCT05537727|DEVICE|robotic-assisted surgery|Urology: robot-assisted and laparoscopic partial nephrectomy
40773619|NCT05537727|DEVICE|robotic-assisted surgery|General surgery: robot-assisted and laparoscopic right colectomy
40773620|NCT02180828|DRUG|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
40773621|NCT02180828|DRUG|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
40773622|NCT02104193|DRUG|simvastatin in addition to radiation therapy|simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
40773623|NCT02104193|RADIATION|radiation therapy|radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
40773624|NCT06561139|BEHAVIORAL|Mindfulness|Weekly group sessions of mindfulness, for eight weeks
40977617|NCT05816512|DRUG|Gold Nano particle from Pelargonium Graveolens Mouthwash|Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
40773625|NCT02630641|DRUG|Gonadotropin-releasing Hormone (GnRH) agonist therapy|This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
40773626|NCT02103465|DRUG|Rotigotine|transdermal patch
40773627|NCT02103465|DRUG|Placebo|transdermal patch
40773628|NCT03391882|DRUG|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
40773629|NCT03391882|DRUG|subcutaneous apomorphine|subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
40773630|NCT05875857|BEHAVIORAL|Opioid destruction education|Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
40773631|NCT05790356|DRUG|Fecal Microbial transplant|Fecal microbial transplant will be investigated for its effect on gut bacterial composition in patients with rheumatoid arthritis.
40773632|NCT05790356|OTHER|Placebo capsules|The placebo capsules will not contain FMT but will have the same appearance.
40773633|NCT01657981|DRUG|YM150|14C-labeled YM150, oral solution
40773634|NCT05152602|PROCEDURE|Bilateral Erector spinae plane block|Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
40773635|NCT05152602|PROCEDURE|Unilateral Erector spinae plane block|Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
40773636|NCT01669512|BIOLOGICAL|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
40773637|NCT01669512|BIOLOGICAL|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
40773638|NCT01669512|BIOLOGICAL|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
40773639|NCT02257684|DRUG|pegcrisantaspase|
40773640|NCT03022721|OTHER|No interventions are planned for this study.|No interventions are planned for this study, it is purely observational.
40773641|NCT04549454|BEHAVIORAL|FITSTART+ PBI|Personalized normative feedback on other parents behaviors + alcohol-specific parenting advice + general parenting advice
40773642|NCT04549454|BEHAVIORAL|General Parenting Advice|General parenting advice
40773643|NCT03683979|BEHAVIORAL|Interpretation Bias Modification|A computer based interpretation bias modification program that aims to reinforce neutral interpretations of ambiguous social situations.
40773644|NCT03683979|BEHAVIORAL|Control Training Program|A sham training program that is similar in design and delivery to the experimental training condition.
40773645|NCT06120205|DEVICE|Teal Wand Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of vaginal cells and material using the Teal Wand Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A healthcare provider collected sample will be performed by a clinician after self-collection. The patient will serve as their own comparator/control.
40977618|NCT05816512|DRUG|Chlorhexidine gluconate mouthwash .|Chlorhexidine gluconate mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
40977619|NCT00254813|DRUG|Quetiapine|
40977620|NCT01171339|OTHER|Optimization strategy (complex intervention)|"Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
40977621|NCT03903445|BEHAVIORAL|Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids)|"MaPa Kids is an 8-session parenting program delivered weekly to groups of parents (N=15 per group).~The program includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behavior; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behavior, and consequences for noncompliance, rule-breaking, and aggressive behavior; 6) problem solving with children; and 7) mindfulness based stress reduction."
40977622|NCT03903445|BEHAVIORAL|Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens)|"MaPa Teens is a 9-session parenting program delivered to groups of parents and children aged 10-17 (N=15 dyads per group).~The program includes the following content: 1) one-on-one time with parents and teens, 2) positive reinforcement of positive behavior, 3) managing anger and stress, 4) establishing rules and routines, 5) family budgeting, 6) accepting responsibility for actions, 7) resolving family conflicts, 8) keeping safe in the community and resolving conflicts, and 9) reflection and moving on."
40977623|NCT06381050|DRUG|SHR-7631|The total dosage of SHR-7631 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
40977624|NCT06197854|PROCEDURE|Hernioplasty|Surgical hernioplasty
40977625|NCT02043249|OTHER|CORD MILKING|MILKING OF UMBILICAL CORD OF THE BABY
40773646|NCT02908217|DRUG|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
40773647|NCT02908217|DRUG|Placebo|6 Intravenous infusions of placebo every 4 weeks.
40773648|NCT02487511|OTHER|Duration of HP therapy|the comparison of HP eradication rate between 7 days and 14 days
40773649|NCT04787315|DEVICE|Conventional intensive functional rehabilitation + Workstations|Equipment will be provided to participants where they can do exercises to increase their motor abilities at the lower limbs, trunk and upper limbs, in addition to conventional intensive functional rehabilitation
40773650|NCT04787315|BEHAVIORAL|Conventional intensive functional rehabilitation|Includes rehabilitation interventions provided by professionnals (OT, PT, speech language therapy, neuropsychologists...)
40773651|NCT03271333|OTHER|lung function tests|Patients hospitalized realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes)
40773652|NCT04107857|BEHAVIORAL|ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer|"* Brief advise to quit smoking~* Referral to Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov"
41301565|NCT01204840|DRUG|Patch protocol|"Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped."
41460708|NCT01230229|PROCEDURE|Stenting|The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.
41460709|NCT01230229|OTHER|Best medical treatment|Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
41460710|NCT05187325|OTHER|no intervention|there is no intervention
40773653|NCT04107857|BEHAVIORAL|ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer|-Nicotine replacement therapy, varenicline, bupropion, or combination therapy (not provided by study)
40773654|NCT04107857|BEHAVIORAL|Data Driven Feedback reports|-Feedback reports will be based on data
41460711|NCT01557920|DRUG|Propofol|Propofol administration for induction of general anesthesia. Administration will be performed IV, using a Target Controlled Induction Pump.
41460712|NCT01557920|DRUG|Sevoflurane|Sevoflurane will be administered via mask inhalation to achieve anesthesia.
40773655|NCT04626934|OTHER|specific cognitive intervention|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
41460713|NCT00804999|DRUG|Clear Care|neutralized Clear Care
41460714|NCT00804999|DRUG|ReNu|overnight soak in solution
40773656|NCT04626934|OTHER|conventional occupational therapy treatment|The intervention will include all together 12 sessions of conventional occupational therapy treatments, each being 45 minutes, for a total of 3 weeks.
40773657|NCT06481631|BEHAVIORAL|The PEN-3 Intervention Model|The PEN-3 Model is a sociocultural model for planning and assessing participant behavior within the context a cultural phenomenon. It will be used to assess intervention impact on patient-clinical linkages in the Mississippi Delta.
40773658|NCT04741906|PROCEDURE|Dental implant surgery|Dental surgery in patients treated with antiresorptive medication
40773659|NCT04741906|PROCEDURE|Prosthetic treatment|Prosthetic treatment and loading of the dental implants
40773660|NCT03549520|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
40773661|NCT06563557|OTHER|Hemodynamic changes between epidural and paravertebral during esophagectomy|The thoracic epidural technique remains the gold standard for perioperative pain management for this procedure. The placement of a paravertebral catheter homolateral with the thoracic incisions is strongly recommended. A goal directed fluid therapy is proposed to guide fluid management and limit postoperative complications. Few studies suggested less side effects in the paravertebral group. The vasoplegia due to the epidural can cause significant hypotension especially as reverse Trendelenburg position is required during surgery. The aim is to bring more light to the hemodynamic changes caused by two different locoregional techniques. An algorithm for fluid and vasopressor management has been proposed. We defined hypotension as 20% of decrement of the median arterial pressure during anesthesia. To reduce bias, the locoregional techniques is performed by an experienced anesthesiologists and the rest of the perioperative management is conducted by another blinded anesthesiologist.
40773662|NCT03830879|OTHER|No intervention|This cohort study have any no intervention.
40773663|NCT00157872|DRUG|MK0966; rofecoxib|
40773664|NCT00157872|DRUG|Comparator: naproxen tablet 500 mg|
40977626|NCT01698801|DRUG|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
40977627|NCT01698801|DRUG|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
40977628|NCT06420479|PROCEDURE|Bariatric surgery|A well-known intervention known to induce substantial weight loss
40977629|NCT00462774|PROCEDURE|Intramyocardial injection of autologous CD133+ marrow cells|
40773665|NCT04260477|DRUG|6EH³R³Z|"A triple dose is defined as the triple of the routine dose used for a specific WHO weight band. Hence, the mg/kg within a weigh-band varies, as is the case in routine practice.~Dosing takings into consideration the fixed dose combination (FDC) tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E). Dosage relies on tables with dosage by weight-bands used by WHO for the Cat. 1 regimen. The dosage used for the intensive phase of the Cat. 1 regimen applies for the whole treatment duration. A double dose of H and R is added to the recommended normal dose for adults (WHO,2003)"
40773666|NCT04260477|DRUG|6EHRZ|"Recommended normal dose adults (WHO, 2003)~* H: 5 (4-6) mg/kg/day~* R: 10 (8-12) mg/kg/day~* Z: 25 (20-30)mg/kg/day~* E: 15 (15-18)mg/kg/day"
40773667|NCT05994846|DEVICE|RISES-T System|The RISES-T system is a hardware and software platform that has been designed and developed to help people living with movement impairment due to Spinal Cord Injury (SCI) to improve and/or restore mobility. The hardware consists of a functional electrical stimulation device that delivers stimulation to the skin through surface electrodes; a series of wearable sensors that collect kinematic (IMU) data and muscle activity (EMG) data, and RISES Software, which incorporates algorithms that utilizes the streaming IMU and EMG sensor data to inform the electrical stimulation parameters and enables real-time visualization of the sensor data and stimulation parameters via Graphical User Interface (GUI).
41301566|NCT06472505|DEVICE|polyglycolic acid(Neoveil)|This study plans to enroll patients with pituitary tumors who need to undergo surgical treatment according to current routine medical standards. After the tumor tissue is removed, the integrity of the spider web or skull base will be thoroughly checked by endoscopy during the operation to confirm whether there is any cerebrospinal fluid leakage. At the end of the operation, use a 100\*50\*0.15mm, green sheet-like Navi tissue repair patch, cut it aseptically to fit the size of the defect for repair (the common case is 2\*3.5cm defect), and place it on the spider web or skull base Tissue repair at the surgical site to prevent cerebrospinal fluid leakage.
41301567|NCT01592851|DRUG|Stannous Fluoride|dentifrice containing stannous fluoride
40773668|NCT04372563|OTHER|aortic prosthetics|aortic prosthetics
40773669|NCT00060125|DRUG|tipifarnib|Given orally
40773670|NCT00060125|OTHER|laboratory biomarker analysis|Correlative studies
40977630|NCT04544254|PROCEDURE|Bilateral transversus thoracis muscle plane block|The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided. Twenty milliliters bupivacaine 0.5% 1mg/body weight will be injected between internal intercostal muscle and transversus thoracis muscle on both sides.
40977631|NCT04544254|PROCEDURE|Control|A needle will be place in the similar area to the transversus thoracis muscle plane block, but no drugs will be injected to the area
40977632|NCT04197089|DRUG|Vitamin D|First dose of 10.000 IU Vitamin D at baseline visit for all patients; stratification of treatment (10.000 or 50.000 IU Vitamin D) depending base 25(OH)Vitamin D levels. Treatment weekly during 4 weeks before scheduled cystectomy
41301568|NCT01592851|DRUG|Sodium Monofluorophosphate|dentifrice containing Sodium Monofluorophosphate
40977633|NCT03178981|OTHER|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
41301569|NCT00184106|DRUG|Seroxat, Cognitive therapy, Seroxat+ cognitive therapy|Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
41301570|NCT00443339|DRUG|Darbepoetin|
41460715|NCT00804999|DRUG|OPTI-FREE|overnight soak in solution
40773671|NCT05843604|OTHER|Functional MRI|Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task
40773672|NCT02643485|PROCEDURE|Forefoot surgery|Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
40773673|NCT02305186|DRUG|Pembrolizumab|Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
40773674|NCT02305186|RADIATION|Neoadjuvant Chemoradiation|Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
40773675|NCT03045952|PROCEDURE|microwave ablation device|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
40977634|NCT03355651|DIETARY_SUPPLEMENT|PROGEN|Dietary supplement based on plasma proteins, hydrolyzed collagen, a complex of Hyaluronic Acid - Chondroitin Sulfate (HC-15), and vitamin C
40977635|NCT02637453|PROCEDURE|PVI|Pulmonary vein isolation
40977636|NCT02637453|PROCEDURE|CPVI+6L|After PVI, 6 ablation lines were added with an extension from pulmonary vein ostium at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
40977637|NCT05576714|OTHER|delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis|We will delineate the clinical and laboratory characteristics of COVID-19 associated encephalopathy and encephalitis, the role of immune, virology, genetics mechanism in pathophysiology, and will optimize the treatment algorithm based on the result of this study. We also expect that the important biomarkers and risk factors associated with clinical outcome and severity, the immunopathogenesis of MIS-C, host genetic factors and the viral pathogenesis and microbiota associated with MIS-C will be found.
40977638|NCT03441776|OTHER|Generalized Vestibular Rehabilitation Treatment|These treatment visits are available twice a week and each visit lasts 45 minutes. Individuals receiving GVRT are allowed to choose the frequency at which they want to attend and the program is designed for each subject to complete 8 visits within a period between 4 and 8 weeks. The ideal number of patients receiving treatment at each class is from 3 to 6 but the system has capacity for a maximum of 8. GVRT is a standard of care treatment option and is not considered research.
40773676|NCT01186276|DIETARY_SUPPLEMENT|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
40773677|NCT01186276|DIETARY_SUPPLEMENT|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
40773678|NCT04390282|BEHAVIORAL|Application-based support system|All participants (experimental and control group) will be invited to a separate appointment at the vascular open clinic at baseline and after three months and measured regarding weight, blood pressure, Ankle Brachial Pressure Index, six minutes walking test and pain. To calculate the estimate 10-year risk of manifesting clinical cardiovascular disease, the Framingham Risk Score will be used. Further, a questionnaire will be answered at baseline and after three months containing the instruments, VascuQoL-6, Health Education Impact Questionnaire and Medication Adherence Report Scale-5.
40977639|NCT03441776|OTHER|Individualized Vestibular Rehabilitation Treatment|Individuals receiving IVRT are scheduled depending on their individual needs and PT availability. These visits require one-on-one time with a PT. Individuals are commonly seen by the PT 3 times at two week intervals. These visits last 30 minutes and include PT evaluation designed to instruct patients on exercises for them to perform on their own. IVRT is a standard of care treatment option and is not considered research.
41460716|NCT03908307|DRUG|OZURDEX|Implant 700 μg
40977640|NCT02468544|OTHER|Text messaging|Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
41141656|NCT04330612|OTHER|Perioperative Updates|In the intervention group, the families received additional standardized electronic updates via pagers at three pivotal moments: 1) Initial skin incision has been made; 2) Critical part of the case is completed and closure has begun; and, 3) Closure is complete, and patient will be transferred to the recovery room when ready.
40773679|NCT04941885|DRUG|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab plus cyclophosphamide metronomic chemotherapy plus AI.
40773680|NCT04933422|DRUG|CM93|oral capsule of CM93 administered once daily
40977643|NCT04081168|DEVICE|Stereotactic Body Radiotherapy|Patients will undergo Stereotactic Body Radiotherapy (SBRT)
40977644|NCT04081168|DEVICE|Microwave Ablation|Patients will undergo Microwave Ablation (MWA)
40773681|NCT03137823|DIAGNOSTIC_TEST|throat culture|throat culture - from the tonsills and from the bucal surface
40773682|NCT02328495|DRUG|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
40977645|NCT05116761|BIOLOGICAL|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
40977646|NCT05116761|OTHER|Saline|Placebo Saline
40977647|NCT01986985|DEVICE|PET/MRI system|Compared to PET CT
40977648|NCT02911753|OTHER|Mediterranean Lemonade|All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
41141657|NCT06074354|BEHAVIORAL|Attention-control group|Participants will receive a one-hour general health promotion session from a nurse and be issued a phone that will deploy the EMA on the same schedule as the intervention arm. They will also receive usual care from the clinics, drop-in center, and shelter recruitment sites. Usual care includes accessing social workers and case managers for immediate housing, food, and clothing needs and assistance in navigating the local Continuum of Care system to access social services.
41301571|NCT02998437|DRUG|Ilaprazole 10mg|Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
40977649|NCT02911753|OTHER|Green Tea|All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
40977650|NCT02911753|OTHER|Flavored Water|All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
40977651|NCT00505531|DRUG|Tramadol Extended Release Oral Capsule|Tramadol ER- up to either 200 mg or 300 mg based on randomization
40977652|NCT00505531|DRUG|Benadryl|Placebo group will take up to 25 mg of Benadryl
41460717|NCT01375309|DIETARY_SUPPLEMENT|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5\*10to9th bacteria per day
40977653|NCT04094519|DRUG|enzalutamide|oral
40977654|NCT04094519|DRUG|enzalutamide Placebo|oral
40977655|NCT04094519|DRUG|digoxin|oral
40977656|NCT04094519|DRUG|rosuvastatin|oral
41460718|NCT01375309|DIETARY_SUPPLEMENT|Placebo contains dextrin|0.5 of dextrin
41460719|NCT04560231|DRUG|Remdesivir|200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
40977657|NCT00075140|GENETIC|Mutation in the gene|
40977658|NCT01294293|DRUG|TLR8 Agonist VTX-2337|Given SC
40977659|NCT01294293|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
40977660|NCT01294293|OTHER|Pharmacological Study|Correlative studies
40977661|NCT01294293|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
40977662|NCT01294293|DRUG|Paclitaxel|Given IV
40977663|NCT00856284|DRUG|Alogliptin|Alogliptin tablets
40977664|NCT00856284|DRUG|Metformin|Metformin tablets
40977665|NCT00856284|DRUG|Glipizide|Glipizide tablets
40977666|NCT04817371|DEVICE|Volatile Organic Compounds analysis (e-noses)|VOC analysis in exhaled air with e-noses.
40977667|NCT04817371|OTHER|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
40977668|NCT04817371|DEVICE|Volatile Organic Compounds analysis (mass spectrometry)|VOC analysis in exhaled air with mass spectrometry.
40977669|NCT04817371|DEVICE|Volatile Organic Compounds analysis in sweat (mass spectrometry)|VOC analysis in sweat with mass spectrometry.
40977670|NCT04933942|DRUG|Lomustine|Oral administration of Lomustine
40977671|NCT04933942|DRUG|Romiplostim|Subcutaneous administration of Romiplostim
40977672|NCT02891850|DRUG|Riociguat (Adempas, BAY63-2521)|Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
41141658|NCT06074354|BEHAVIORAL|MY-RIDE group|MY-RIDE has three main components: 1) One nurse-led face-to-face session; 2) three months of Ecological Momentary Assessments (EMA) with personalized messaging delivered by phone in real-time in response to one's current risk; and 3) access to on-demand healthcare/PrEP navigation and referrals.
40977673|NCT02891850|DRUG|Sildenafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
40977674|NCT02891850|DRUG|Tadalafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
40977675|NCT05182489|DEVICE|Medtronic Adaptix™ titanium implants|Patients who will be having a spinal fusion procedure as part of their standard of care treatment will be randomized to receive either the Medtronic titanium or the PEEK cage supplemented with a pedicle screw system and milled local autograft bone supplemented with GRAFTON DBM DBF. In order to assess fusion, patients will undergo a research-only CT Scan at 6 months post-surgery.
40977676|NCT05182489|DEVICE|Medtronic CAPSTONE® PEEK cage|Medtronic CAPSTONE® PEEK cage
40977677|NCT04395469|DRUG|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after radiation treatment.
41460720|NCT02346825|BEHAVIORAL|Neurorehabilitation therapy with cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
40773683|NCT02328495|OTHER|Bladder Filling|"Patients in bladder filling group will be instructed to drink one liter of water and to avoid urination during the one and half hour period before office hysteroscopy procedure..A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used."
40773684|NCT00006163|BEHAVIORAL|Personalized Self-management|
40773685|NCT00006163|BEHAVIORAL|Community Resources|
40773686|NCT06563583|OTHER|Group 1 will include patients aged 18-40 years|Group 1 will include patients aged 18-40 years.
40773687|NCT06563583|OTHER|Group 2 will include patients aged 40-64 years|Group 2 will include patients aged 40-64 years, and finally.
40977678|NCT04912947|DIETARY_SUPPLEMENT|Immusystem|Dietary supplement containing: Piceid, Glycine, Glutamine, Acetylcysteine, Zinc and Vitamin B6
40977679|NCT04912947|OTHER|Placebo|Maltodextrin placebo capsule
40977680|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
40977681|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
40977682|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
40977683|NCT00556712|DRUG|erlotinib [Tarceva]|150mg po daily
40977684|NCT00556712|DRUG|Placebo|po daily
40977685|NCT05376969|DRUG|DWP16001|DWP16001 Tablets
41460721|NCT02346825|BEHAVIORAL|Neurorehabilitation therapy with splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
40773688|NCT06563583|OTHER|Group 3 will include patients aged 65-85 years|Group 3 will include patients aged 65-85 years.
40773689|NCT01575574|DRUG|GADOXETIC ACID|all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
40773690|NCT04448951|OTHER|transcriptomics|transcriptomics
40773691|NCT04448951|OTHER|flow-cytometry|peripheral blood myeloid cells and lymphocytes flow-cytometry
40773692|NCT04448951|OTHER|cytokines|peripheral blood cytokine analysis
40773693|NCT04313582|BEHAVIORAL|SmartPrompt smartphone application|The SmartPrompt is a smartphone application designed specifically for older adults with difficulties remembering to do daily tasks due to cognitive difficulties.
40977686|NCT03030872|DEVICE|Investigational software|The study evaluated retrospective de-identified cases that were processed after the imaging procedure had been completed (off-line) using a dedicated workstation.
40977687|NCT02211521|BIOLOGICAL|PRP|3ml of PRP
40977688|NCT02211521|DRUG|Hyaluronic acid|3ml hyaluronic acid
40977689|NCT03408756|DRUG|methotrexate|Participants will receive methotrexate through oral or subcutaneous route of administration
41460722|NCT02346825|BEHAVIORAL|Neurorehabilitation bimanual|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
40773694|NCT05488483|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography Imaging|Each participants will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. Melanoma participants with pathologically confirmed ITM will undergo MSOT imaging following physical exam and biopsy. Melanoma patients receiving immunotherapy will undergo MSOT imaging prior to and following immunotherapy.
40977690|NCT04165434|OTHER|Concurrent Training|Strength training and interval aerobic training in the same training session
40977691|NCT03957382|DEVICE|Accero® (heal) Stent|The Accero® (heal) Stent will only be used in line with the Instructions For Use (IFU). Patients participating in this PMCF (Post- Market Clinical Follow-up) will not be exposed to any additional risk. There are no additional treatments or investigations other than done in the clinical routine.
40977692|NCT02181023|DRUG|Aclidinium Bromide|Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
40977693|NCT02181023|DRUG|Glycopyrronium Bromide|Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
40977694|NCT01282268|DRUG|arbaclofen|orally disintegrating tablet
40977695|NCT01282268|DRUG|placebo|orally disintegrating tablet
41301572|NCT02998437|DRUG|Clarithromycin 500mg|Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
41460723|NCT05468957|DEVICE|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
41460724|NCT05468957|DRUG|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
41460725|NCT01158313|DIETARY_SUPPLEMENT|Thickened supplement|New thickener to be mixed to liquid to obtain different viscosities such as nectar viscosity, honey viscosity, conservative spoon-thick viscosity (CST) and extreme spoon-thick viscosity (EST
41460726|NCT03004157|PROCEDURE|cardiopulmonary resuscitation|CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
41460727|NCT02973906|OTHER|ADAPT Self Directed web|In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
40977696|NCT01823523|DRUG|Cefazolin, Cephalexin, Clindamycin|
41141659|NCT02383797|BIOLOGICAL|Varilrix|Vaccination against varicella in selected cartilage-hair hypoplasia patients
41141660|NCT02400528|BEHAVIORAL|quality of life questionnaires|
41141661|NCT05868356|DRUG|Treatment A|Oral adagrasib 200 mg twice daily (BID) for 8 days (Days 1 to 8). Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 2 to 7. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Days 1 and 8.
41301573|NCT02998437|DRUG|Amoxicillin 500 Mg|Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
41301574|NCT03493308|OTHER|Pain neuroscience education|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
40773695|NCT00779909|DRUG|vitamin D3|oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
40977697|NCT01569178|PROCEDURE|Bone Marrow aspiration and intracoronary reinfusion|Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
40977698|NCT05791344|DEVICE|ECG monitoring|Intra-procedural ECG changes during TAVR
41301575|NCT03493308|OTHER|Exercise|Exercise will be provided in different formats including general exercise, strengthening, dance.
41301576|NCT02756715|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation.
41301577|NCT02756715|DRUG|Desflurane group|Patient will be anesthetized by using desflurane inhalation during operation.
41460728|NCT02973906|OTHER|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
41460729|NCT02973906|OTHER|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
41460730|NCT05958433|BEHAVIORAL|Rehabilitation with stoma appliance|The rehabilitation group will receive preoperative stoma education in addition, a water-filled ostomy appliance (50-100 ml) will be attached 48 hours before surgery. These pouches will not be removed until surgery, and the EST nurse will teach the patients preoperatively how to manage the ostomy appliance with similar standards as described in the usual postoperative stoma care.
40773696|NCT00779909|OTHER|Placebo|oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
40773697|NCT06048458|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance with stress perfusion|Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
40773698|NCT06048458|DIAGNOSTIC_TEST|CT coronary angiography|CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease
40773699|NCT06048458|DIAGNOSTIC_TEST|Retinal OCT angiography|Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
40773700|NCT06048458|DIAGNOSTIC_TEST|Sublingual microscopy (GlycoCheck)|To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
40773701|NCT06048458|DIAGNOSTIC_TEST|Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)|Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
40773702|NCT03532347|DEVICE|EUS-FNA needle (Beacon)|Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
40773703|NCT04669067|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
40773704|NCT04669067|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
40773705|NCT02969577|BEHAVIORAL|Exercise Program|Participants will have a personal training session at the first visit. A member of the study team will discuss strength training and cardiovascular workouts for them to complete over the first 6 months of the study. A member of the study team will then talk with the participant every week for the first 3 months and monthly afterwards until month 6. Participants will be sent exercise videos and be given recommendations for the exercise program via phone calls and will be tailored to the individual. Videos and recommendations will be sent directly to the participant's smartphone.
40773706|NCT02969577|BEHAVIORAL|Diet and Nutrition Coaching|Diet and nutrition coaching session with an overview of resources on the smartphone. Over the first 6 months, participants will receive healthy recipes and nutritional information on the smartphone.
40773707|NCT02969577|OTHER|Usual Care with Attention|Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
40773708|NCT01695603|DEVICE|Intellivent|
40773709|NCT02208765|DEVICE|Stress Single Photon Emission Computed Tomography|
40773710|NCT04085250|OTHER|Neoadjuvant therapy|The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.
40773711|NCT04085250|OTHER|Chemotherapy concurrent with radiotherapy|Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)
40773712|NCT04085250|RADIATION|Radiotherapy|Hypofractionated radiation technique was used to deliver a definitive radiation dose
40773713|NCT04085250|DRUG|Nivolumab|Nivolumab consolidation (360 mg) via iv infusion once every 3 weeks (Q3W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 12 months.
41460731|NCT05324891|DRUG|Dexmedetomidine|Infants received dexmedetomidine IV loading dose: 0.5 mcg/kg given over 20 minutes followed by maintenance dose 0.3 µg/kg/hour by infusion over 24 hours.Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
41301578|NCT02703116|BEHAVIORAL|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
41460732|NCT05324891|DRUG|Fentanyl|Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
40773714|NCT04085250|OTHER|Observation|Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
40773715|NCT00143884|PROCEDURE|Reduced intensity conditioning|
40773716|NCT00143884|PROCEDURE|Prophylactic donor leukocyte infusions|
40773717|NCT04615546|BEHAVIORAL|Use of Continuous Glucose Monitor (CGM)|Participants will wear CGM
40773718|NCT04615546|OTHER|"Use of Cardea Solo monitoring"|"Participants will wear a Cardea Solo patch during blinded CGM use"
40773719|NCT00318682|DEVICE|FIBROSCAN|diagnostic examination of the hepato fibrosis
40773720|NCT02965781|DRUG|SADBE|Topical solution
40773721|NCT02965781|OTHER|Placebo|Topical solution
41301579|NCT02703116|BEHAVIORAL|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
41301580|NCT04492956|DRUG|Ecopipam|Oral tablet
41301581|NCT04492956|DRUG|Placebo|Oral tablet
41301582|NCT01301742|DRUG|BI 10773|1 tablet single dose BI 10773 in the morning
41301583|NCT01301742|DRUG|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
41301584|NCT01301742|DRUG|BI 10773|1 tablet single dose BI 10773 in the morning
41301585|NCT01457118|DRUG|NKTR-102 145 mg/m2|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
41301586|NCT01457118|DRUG|NKTR-102 120 mg/m2|A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
41301587|NCT01457118|DRUG|NKTR-102 95 mg/m2|A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
41301588|NCT01457118|DRUG|NKTR-102 50 mg/m2|A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
41301589|NCT02467595|DRUG|Rocuronium bromide 0.15 mg kg-1|Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.
41301590|NCT02467595|DRUG|Rocuronium bromide 0.3 mg kg-1|Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.
41301591|NCT02467595|DRUG|Fentanyl|Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
41301592|NCT02467595|DRUG|Propofol|Propofol 2.5 mg kg-1 was injected at I.V. line to patients
40977699|NCT05254067|DEVICE|Codman Enterprise 2 Vascular Reconstruction Device|a self-expanding nitinol, compliant, closed-cell, recapturable design that can be deployed by a single operator designed to assist in the stent-assisted coil embolization of intracranial aneurysms, specifically those that have a wide neck that would not otherwise maintain the coil embolization material within the aneurysm because of the wide opening at the base of the aneurysm.
41301593|NCT02467595|DRUG|Sevoflurane|After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
41301594|NCT05108909|DEVICE|MRI, CT, and serum biomarkers|magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.
41301595|NCT00337467|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
41301596|NCT05469932|DEVICE|Rexon device|Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
41301597|NCT03524677|DIAGNOSTIC_TEST|Liquid Biopsy|K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA
40773722|NCT02662751|OTHER|Routine Imaging Assessment|"Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers."
40977700|NCT01709890|DEVICE|YO2(R) catheter|
40977701|NCT01790256|DEVICE|Cereve Sleep System at 30 degrees C|
40977702|NCT01790256|DEVICE|Cereve Sleep System at 14-16 degrees C|
41301598|NCT04209296|DRUG|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.
41301599|NCT03244891|OTHER|Increase of central volume|"Mild hypovolemia will be induced in healthy volunteers by 12 hours fasting. Three conditions will be considered for the analysis, each of them both during spontaneous breathing and positive pressure ventilation:~1. baseline~2. after fluid shift induced by passive head down position at 15 degrees~3. after fluid challenge with Ringer acetate 15ml\*kg in head down position~A total of six steps will be considered for the analysis"
41301600|NCT03244891|OTHER|Ventilation mode|"Each previous step will be done in two respiratory conditions:~1. spontaneous breathing~2. noninvasive ventilation via facial mask in pressure support mode at 8 cmH2O above positive end expiratory pressure of 5 cmH2O, inspiratory fraction of oxygen of 0.25 In both conditions respiratory rate will be set at 18 breaths per min following a metronome"
41301601|NCT03695432|BIOLOGICAL|Flubio|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
41301602|NCT03695432|DIETARY_SUPPLEMENT|Lacidofil|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months
41301603|NCT03695432|OTHER|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
41301604|NCT03695432|OTHER|Placebo probiotic|Capsul
41301605|NCT04279561|PROCEDURE|Computed Tomography|Undergo 68Ga-PSMA-11 PET/CT
40977703|NCT00378196|DRUG|Ranibizumab|0.3 mg/0.05 ml dose
41301606|NCT04279561|DRUG|Gallium Ga 68 Gozetotide|Given IV
41301607|NCT04279561|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET/CT
40977704|NCT00378196|DRUG|Ranibizumab|0.5 mg/0.05 ml dose
40977705|NCT02323477|BIOLOGICAL|stem cell transplantation|Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation
40977706|NCT01579175|OTHER|Chewing gum|Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
41301608|NCT03785873|DRUG|Nivolumab|Intravenous (IV) infusion
41301609|NCT03785873|DRUG|Nanoliposomal-Irinotecan|Intravenous (IV) infusion
41301610|NCT03785873|DRUG|5-Fluorouracil|Intravenous (IV) infusion
41301611|NCT03785873|DRUG|Leucovorin|Intravenous (IV) infusion
41301612|NCT03352414|DRUG|Alvimopan|alvimopan pill
41301613|NCT03352414|DRUG|Placebo|placebo pill
40977707|NCT01514812|DRUG|YM150|oral - modified release formulation of YM150
40977708|NCT01514812|DRUG|placebo|oral
40977709|NCT01514812|DRUG|digoxin|oral
40977710|NCT06494839|PROCEDURE|Bipolar electrocautery tonsillectomy technique|The BED tonsillectomy procedures were done under general anesthesia, and the patient's position was the same as in the other method. The bipolar machine was adjusted to 30 watts, and a mucosal incision was cauterized with a single straight or stepped bipolar forceps. After carefully cauterizing the tissue, the palatine tonsil was located and removed from the superior to the inferior pole. Most of the identifiable vessels supplying the tonsil were cauterized before being separated from the tonsil. Point coagulation was used to maintain hemostasis. By using point coagulation, hemostasis was maintained. To avoid bias stemming from competence, consultants performed all of these tonsillectomies.
40977711|NCT06494839|PROCEDURE|Cold steel dissection technique|The cold steel blunt dissection tonsillectomy was carried out under general anesthesia while the patient was in the Rose position and had an endotracheal intubation. The tonsil was retracted medially with a tonsil holding forceps, and in the upper pole, the mucosal incision was made. To protect the tonsillar pillars, a delicate dissection was performed, and the suction tip was used to stop the hemorrhage. The tonsillar fossa was packed with swabs. The other palatine tonsil was then similarly removed. Hemostasis was secured by silk ligation and bipolar electrocautery.
40977712|NCT02663674|DRUG|Fluconazole|Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
40977713|NCT02663674|OTHER|Placebo|Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
40977714|NCT03852355|DRUG|Radiofrequency|), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level
40977715|NCT03852355|DRUG|Steroids|received systemic steroids oral prednisolone tablet, 10 mg/day
40977716|NCT05456464|OTHER|Reiki|Reiki is applied touching the energy centers of the body (chakras). There are seven main and many small chakras on a body. Chakras are located on the front and back sides of the body in a vertical line that runs along the middle of the body in humans. A complete Reiki therapy includes all the chakras and organs.
40977717|NCT02115789|BEHAVIORAL|Visual Analog Scale|"Subjects will review examples of both linear and zigzag scars and rate the aesthetic appearance of both configurations of scars on a scale of 1 through 10, with 1 being normal skin and 10 being the worst scar imaginable."
40977718|NCT05944874|DEVICE|high definition transcranial direct current stimulation|Transcranial direct current stimulation, in recent decades, has been identified as a non-invasive tool for transiently modulating human brain activity. The technique consists of the application of a low-intensity continuous electric current, through electrodes applied to the scalp, acting in a regulatory way on the frequency of triggered action potentials, however, without interacting directly with the neurons.
40977719|NCT06351189|DEVICE|Observation|Patients will be filmed in sitting position in the NETTI DYNAMIC chair, either in static mode or dynamic mode for a period of 3 hours each time.
40977720|NCT01942291|DRUG|Niacin|The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
40977721|NCT01366690|BEHAVIORAL|Peer Support|A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
40977722|NCT00053040|BIOLOGICAL|cintredekin besudotox|IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
40977723|NCT00053040|PROCEDURE|conventional surgery|Conventional surgery is used for tumor resection prior to catheter placement for IL13-PE38QQR infusion.
40977724|NCT02176876|DRUG|GS-5745|GS-5745 400 mg administered intravenously
40977725|NCT02176876|DRUG|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
40977726|NCT00277888|PROCEDURE|Femoral route for hemodialysis|
40977727|NCT00277888|PROCEDURE|Jugular route for hemodialysis|
40977728|NCT02999854|BIOLOGICAL|ATIR101|ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
40977729|NCT02999854|DRUG|Cyclophosphamide|High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
40977730|NCT02999854|PROCEDURE|T-cell depleted HSCT from a related, haploidentical donor|T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
40977731|NCT02999854|PROCEDURE|T-cell replete HSCT from a related, haploidentical donor|T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
40977732|NCT04897932|DEVICE|RS - WP06|Ad hoc use of handheld urinal
40977733|NCT05211791|PROCEDURE|erector spinae block|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
40977734|NCT05211791|PROCEDURE|paravertebral block anesthesia|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
40977735|NCT05211791|PROCEDURE|Thoracic epidural anesthesia|insertion of Thoracic epidural catheter for anesthesia analgesia at level of T6
40977736|NCT04519710|BIOLOGICAL|o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B|to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
41301614|NCT02472548|BIOLOGICAL|DPX-RSV(A)|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
41301615|NCT02472548|BIOLOGICAL|RSV(A)-Alum|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
40977737|NCT04013139|DIAGNOSTIC_TEST|CPET|CPET
41460733|NCT05012462|DEVICE|CM-1500|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.
40977738|NCT02972489|DEVICE|3D OFDI guidance arm|Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.
40977739|NCT02972489|DEVICE|Angio guidance arm|In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
40977740|NCT03495076|OTHER|Saline injection|In the saline injection condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute pain. Saline will be injected into the right (or left) trapezius muscle at the level of C7 cervical level. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at the same depth. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster to ensure blinding.
40977741|NCT03495076|OTHER|Sham injection|In the sham-injection condition (nocebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin without piercing the skin. A stimulus of 512 millinewtons (mN) will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided. The stimuli will be applied in exactly the same spot as the real injection in previous experimental condition.
41301616|NCT02472548|OTHER|Placebo|Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
41301617|NCT04169334|BEHAVIORAL|Prolonged planned program for the stay at the obstetric department|A five day planned and designed program delivered to the family while at the obstetric department.
41301618|NCT05895825|DRUG|EOC237|EOC237 for orally
41301619|NCT06168721|OTHER|Expert survey|The expert group will participate in a two-round survey using the Delphi method. The first round aims to assess the relevance of the proposed ICF categories and to identify missing concepts. The second round will aim to confirm the appropriateness of including the selected categories in the ICF core set. Each round will last 3 weeks and the experts will be provided with feedback on the results obtained.
41460734|NCT01591824|OTHER|Resonant oscillation|"Resonant sustained oscillations are applied in the following areas~* general column.~* lumbar muscles, and paraspinal muscles,~* sacral decompression oscillatory~* Opening by lateral vertebral lumbar rhythmic swing.~* Balancing and pelvic decompression~* Swing-lumbar vertebral rotation."
41301620|NCT03167580|PROCEDURE|restricted PEEP|Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
41460735|NCT01591824|OTHER|column exercise group|"* paraspinal muscle stretching exercises~* postural correction~* mobilization exercises thoracic and lumbar~* Motor control exercises"
41301621|NCT03167580|PROCEDURE|liberal PEEP|Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
41301622|NCT04775797|DRUG|AB-836|Capsules or Tablets
41301623|NCT04775797|DRUG|Placebo|Capsules of Tablets
41301624|NCT04775797|DRUG|AB-836|Tablets
41301625|NCT04775797|DRUG|Placebo|Tablets
41301626|NCT04775797|DRUG|Nucleos(t)ide Analogue|Tablets
41301627|NCT01680406|DRUG|Artemether-lumefantrine combination|
41301628|NCT01680406|DRUG|Primaquine|
41301629|NCT01680406|DRUG|Chloroquine|
41301630|NCT03523832|DRUG|Celecoxib and Pregabaline|Single dose versus repetition dose
41301631|NCT03523832|OTHER|Placebo|Placebo
41301632|NCT01062451|DRUG|Perindopril|8 mg taken orally from days 0 through 7.
41301633|NCT01062451|DRUG|Placebo|Placebo treatment daily.
41301634|NCT01062451|DRUG|Candesartan|16 mg taken orally from days 0 through 7.
41301635|NCT00934557|DRUG|ATG Fresenius|
41301636|NCT00934557|DRUG|ATG Fresenius|
41301637|NCT00934557|DRUG|ATG Fresenius|
41301638|NCT00934557|DRUG|ATG Fresenius|
41301639|NCT00934557|DRUG|ATG Fresenius|
41301640|NCT00934557|DRUG|ATG Fresenius|
41301641|NCT00934557|DRUG|ATG Fresenius|
41301642|NCT00934557|DRUG|ATG Fresenius|
41301643|NCT01893190|DRUG|Nimodipine|Based upon Investigator Judgement
40773723|NCT02662751|DEVICE|LDWBA first (CT scan)|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient."
40773724|NCT05478278|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains psilocybin (API only in a capsule).
41301644|NCT01893190|DRUG|Nimodipine Microparticles|Based upon Investigator Judgement
41301645|NCT02421367|BIOLOGICAL|TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.|Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
41301646|NCT02307019|OTHER|Program on specific prevention of health|The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
41301647|NCT02307019|OTHER|Program on general prevention of health|The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
41301648|NCT06116435|BEHAVIORAL|Prevent T2|The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.
41301649|NCT06116435|BEHAVIORAL|Move group-based classes|The Move physical activity support program group-based classes are based on Self-Determination Theory and encourage improvements in autonomous motivation for physical activity. These group-based classes are integrated within the Prevent T2 program curricula.
41301650|NCT06116435|BEHAVIORAL|Fitness Membership|Participants will receive 6 months of the Peloton fitness membership. This includes access to livestream and on-demand fitness classes including walking, strength training, yoga, meditation, stretching, etc.
41301651|NCT06116435|BEHAVIORAL|Mental Imagery|Participants will receive access to positive mental guided imagery recordings. Recordings describe a pleasant experience while walking and range from 2-8 minutes in duration.
41460736|NCT04238962|DRUG|Semaglutide (administered by DV3396 pen-injector)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks
40773725|NCT05478278|DRUG|Moxifloxacin|The positive comparator used in this study is a 400 mg moxifloxacin tablet.
40773726|NCT05478278|DRUG|Micro-Crystalline Cellulose|The placebo used in this study is encapsulated using a HPMC capsule and contains micro-crystalline cellulose.
40773727|NCT04418245|DIAGNOSTIC_TEST|Imaging by thoracic scanner|Low-dose computed tomography
40977742|NCT06436508|BEHAVIORAL|Early mobilization protocol|"* Step 1 - Day 1: Bed rest, elevation of the head end to 30°~* Step 2 - Day 2: Bed rest, elevation of the head end to 60°~* Step 3 - Day 3: Bed rest, elevation of the head end to 80°~* Step 4 - Day 4: Sitting on the edge of the bed~* Step 5 - Day 5: Sitting in a chair, standing up~* Step 6 - Day 6: Walking with or without assistance~* Step 7 - Day 7: Walking with or without assistance from today"
41460737|NCT04238962|DRUG|Semaglutide (administered by PDS290 pen-injector)|Increasing doses of semaglutide given sc in the stomach for 7 weeks
40977743|NCT06436508|BEHAVIORAL|Standard care|During standard care, early mobilization does not take place in the intensive care unit; the patient receives only standard supportive care in bed rest.
41301652|NCT06116435|BEHAVIORAL|Move 1:1 Support|Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.
41301653|NCT02496728|BEHAVIORAL|Mobile Health Application|An application on a smart phone that is designed to help individuals self-monitor health behaviors.
41301654|NCT02496728|BEHAVIORAL|Environmental Cues|Text messages, informational posts and reminders supporting healthy behaviors.
41460738|NCT04219527|PROCEDURE|Dual-target injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid) + 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
41460739|NCT03971734|DRUG|Regadenoson 0.05mg|Regadensoson 0.05mg administered prior to MRI
40977744|NCT03032731|BEHAVIORAL|Website and pedometer intervention|Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
40977745|NCT03032731|OTHER|Control|Standard, publicly available NHS resources for healthy lifestyles.
41301655|NCT02496728|BEHAVIORAL|Social Support|Participants may interact with each other through a private Facebook group.
41301656|NCT02496728|BEHAVIORAL|Educational Materials|Educational materials regarding healthy behaviors.
41460740|NCT03971734|DRUG|Regadensoson 0.1mg|Regadensoson 0.1mg administered prior to MRI
41460741|NCT03971734|DRUG|Regadensoson 0.2mg|Regadensoson 0.2mg administered prior to MRI
41460742|NCT03971734|DRUG|Regadensoson 0.4mg|Regadensoson 0.4mg administered prior to MRI
41460743|NCT03971734|DRUG|Regadensoson 0.7mg|Regadensoson 0.7mg administered prior to MRI
41460744|NCT03971734|DRUG|Regadensoson 1.0mg|Regadensoson 1.0mg administered prior to MRI
41460745|NCT03971734|DRUG|Regadensoson 1.4mg|Regadensoson 1.4mg administered prior to MRI
41460746|NCT03254732|DRUG|ADI PEG20|ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
41460747|NCT03254732|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
40773728|NCT05533840|DIAGNOSTIC_TEST|ultra-high-resolution computed tomography exams|Participants in the age groups undergo ultra-high-resolution computed tomography exam
40773729|NCT06545006|OTHER|isometric contractions|Participants will perform 20 minutes of isometric contractions in different positions, with contraction durations of 10 seconds and a number of repetitions between 4 and 10, depending on their progress in the training program.
40773730|NCT06545006|OTHER|stroboscopic glasses|"This training involves performing skill exercises with a rugby ball while wearing stroboscopic glasses. The glasses have alternating opaque and clear sections, causing multiple and/or fragmented vision.~The goal is to improve the processing of visual information at the level of higher functions. This aids in decision-making. It does not involve the same structures and functions implicated in reflexive muscle recruitment strategies as the Quick Release, so it should not be a confounding factor. However, it provides a beneficial, stimulating, and enjoyable training session, increasing subject adherence as they work on a skill useful in their sport."
40773731|NCT06545006|OTHER|Quick Release|"The distance (in mm) of the anterior head translation will be measured using a linear displacement sensor. The subject will be instructed to recruit their extensor muscles as quickly and as strongly as possible to minimise the head displacement distance. They will be aware of their score after each repetition (real-time feedback).~Subjects must react to a rapid forward displacement of the cervical spine, without impact. To generate this forward displacement without impact, subjects are positioned with support in front of the forehead, holding their head and neck. The subject must exert an isometric flexion effort against this frontal support (energy storage), with the intensity set by the examiner based on the Maximum Isometric Force measured during a prior maximal isometric test. The frontal resistance will suddenly release, and the head displacement in the sagittal plane will be measured until the recruitment of the cervical spine extensor muscles stops this displacement"
41301657|NCT03927534|BEHAVIORAL|Mindful Eating|The ME group will be composed by 7 weekly group sessions with a minimum duration of two hours, mixing theoretical contents with practices. Sessions will always be the same day of the week, except for bank holidays or eventualities, and will be conducted by a psychologist specially trained and certified in ME with experience in leading mindfulness groups. Group sizes will range between 10 and 12 participants. At the end of each session, participants will receive theoretical contents and homework activities to be practiced along the week.
41301658|NCT00587418|DIETARY_SUPPLEMENT|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
41301659|NCT00587418|DIETARY_SUPPLEMENT|Placebo|Placebo powder 9.2g bid for 7 days
40773732|NCT04336826|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
40773733|NCT03005002|BIOLOGICAL|Durvalumab|Given IV
41301660|NCT00541086|DRUG|anastrozole|1 mg per day, orally
41301661|NCT00541086|DRUG|exemestane|25 mg per day, orally
41301662|NCT00541086|DRUG|letrozole|2.5 mg per day, orally
41301663|NCT00541086|DRUG|tamoxifen citrate|20 mg per day, orally
41301664|NCT01958736|OTHER|Ballistic Strength Training|The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.
41301665|NCT01958736|OTHER|Usual Care Physiotherapy|This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
41301666|NCT02636348|DIETARY_SUPPLEMENT|Calcium/Vitamin D|2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
41460748|NCT02275754|BEHAVIORAL|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
41460749|NCT02275754|BEHAVIORAL|PN Only|Participants will be navigated by PN on request
41460750|NCT03474393|OTHER|systematic intensive therapy|intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
40773734|NCT03005002|OTHER|Laboratory Biomarker Analysis|Correlative studies
40773735|NCT03005002|BIOLOGICAL|Tremelimumab|Given IV
41460751|NCT03381586|DRUG|ALT-803|Subjects randomized to Group A (n=8) will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B (n=8) will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
41460752|NCT03602027|DRUG|Anlotinib|Anlotinib 8mg p.o. qd in low-dose groups (3 subjects). 10mg p.o. qd in middle-dose groups (3 subjects). 12mg p.o. qd in high-dose groups (3 subjects).
40773736|NCT02663193|OTHER|No Intervention|Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
40977746|NCT04426981|BEHAVIORAL|Behavioral Activation|Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities. In the first session, participants will begin to identify domains of their life which are important to them. In the second session, participants will be assisted in creating an action plan to engage in more activities in one or more domains of importance. In session 3-8, participants will be assisted in problem solving any challenges they encountered in implementing their previous action plan and will develop a new action plan. The intervention will continue until participants achieved three action plans or reach the eight-session limit, whichever comes first.
40977747|NCT04220684|DRUG|Cytarabine Hydrochloride|Given IV
40977748|NCT04220684|DRUG|Fludarabine|Given IV
41301667|NCT02636348|DIETARY_SUPPLEMENT|Placebo|Administered daily as 8 placebo pills or 2 unfortified snack bars.
41301668|NCT04446936|PROCEDURE|Flap covering for pressure ulcer|Flap covering for pressure ulcer
41301669|NCT05496426|DRUG|KL130008/Placebo|Drug: KL130008 Drug: Placebo
41301670|NCT00879268|DEVICE|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
41301671|NCT05894473|OTHER|Motor-Motor Dual Task Physical Exercises|Only physical exercise and motor dual tasks will be given
41301672|NCT01402284|DRUG|Carfilzomib|Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
41301673|NCT01402284|DRUG|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
41301674|NCT01402284|DRUG|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
41301675|NCT01402284|DRUG|Lenalidomide|After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
41460753|NCT03602027|DRUG|Gefitinib|Gefitinib 250mg orally daily for three weeks
41460754|NCT02017873|DRUG|Peroxide Carbamide 10% - Dental bleaching treatment|During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
40977749|NCT04220684|BIOLOGICAL|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given via infusion
40977750|NCT03755492|OTHER|Absorbent pad for urinary incontinence|6 month supply provided to patients as needed for urinary incontinence after radical prostatectomy
40977751|NCT00788476|OTHER|Survey|"Survey packets to adult (\>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18."
40977752|NCT05060055|PROCEDURE|Immediate dental implant placement|Immediate dental implant placement
40977753|NCT06043440|DRUG|Oxygen|Active nocturnal oxygen concentrator
41460755|NCT05360849|BEHAVIORAL|Practice Facilitation|Participating clinics will work with a Practice Facilitator to modify clinic processes to improve delivery of PrEP to women who inject drugs
40773737|NCT04692922|DIAGNOSTIC_TEST|MRI|MRI will include structural sequences (e.g., T1 weighted imaging, T2 weighted imaging, T2 FLAIR, diffusion weighted imaging with apparent diffusion coefficient, susceptibility weighted imaging, and diffusion tensor imaging). Using the structural sequences we will make note of the types of brain lesions (e.g., ischemic stroke, hemorrhage, hypoxic-ischemic brain injury), and the locations of these brain lesions. MRI will also include fMRI under three conditions: while the patient is at rest (to evaluate resting state functional connectivity), while the patient is exposed to auditory stimuli (to evaluate passive fMRI responses to stimuli), and while the patient is asked to follow commands (to evaluate active fMRI responses to tasks).
40773738|NCT04692922|DIAGNOSTIC_TEST|EEG|The EEG will include resting, stimulus-based, and task-based assessments of brain function.
40977754|NCT01770626|OTHER|Nutrition|Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
41301676|NCT01402284|DRUG|Lenalidomide|After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
41460756|NCT01656876|BEHAVIORAL|Mirror box training|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
40773739|NCT05932498|PROCEDURE|Hip surgery|"Ultrasound-guided PENG block was administered to patients undergoing hip surgery intraoperatively.~OR~Ultrasound-guided QL block was administered to patients undergoing hip surgery intraoperatively."
41301677|NCT04438746|BEHAVIORAL|Emotion discussion|General discussion of emotions; no therapy or training is offered
40977755|NCT01082406|DRUG|catridecacog|Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
40977756|NCT01082406|DRUG|recombinant factor XIII|Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
40977757|NCT06125015|DIAGNOSTIC_TEST|Hearing Thresholds Assessments|Auditory Neuropathy Spectrum Disorder (ANSD) is a type of hearing disorder that affects the transmission of sound signals from the inner ear to the brain. In individuals with ANSD, the outer hair cells in the cochlea, which are responsible for amplifying sound, typically function properly. However, there is a disruption in the transmission of auditory information from the cochlea to the auditory nerve and then to the brain. It is characterized by a mismatch between the results of objective hearing tests, such as Auditory Brainstem Response (ABR), and subjective hearing experiences. In ABR tests, the responses of the auditory nerve to sounds may be abnormal, while the individual perceives their hearing to be better than suggested by the test results. In this study we showed ANSD patients with abnormal ABR results by using ABR, Otoacoustic Emissions, Tympanometry and behavioral test batteries.
41460757|NCT01656876|OTHER|mesh glove stimulation|The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
41460758|NCT01656876|BEHAVIORAL|conventional intervention|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
41460759|NCT02861833|OTHER|nursing support|Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
41460760|NCT03306238|PROCEDURE|Open approach to port insertion|This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope
41460761|NCT03306238|PROCEDURE|Closed approach to port insertion|This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
40773740|NCT01295047|DRUG|Atenolol|
40773741|NCT01295047|DRUG|VERAPAMIL|240 MG SR
40773742|NCT01295047|DRUG|Perindopril|4 MG
41301678|NCT04438746|BEHAVIORAL|Cognitive Behavioral Affective Therapy|Active training in regulating anger
41301679|NCT05304182|DEVICE|EYESTAR 900|The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.
41460762|NCT03310593|DRUG|Cannabidiol|Cannabidiol as active intervention.
41460763|NCT03310593|DRUG|Placebo|Placebo intervention.
41460764|NCT01808248|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
40773743|NCT06288893|DRUG|SHEN211 Tablets|SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.
40773744|NCT06288893|PROCEDURE|Placebo for SHEN211 Tablets|Placebo tablets, participants will receive 3 tablets QD (once daily) on Day 1 and 1 tablet QD orally on Days 2-5
40773745|NCT00565747|DEVICE|Test culture|A standard culture medium with added GM-CSF (ready-to-use)
40773746|NCT00565747|DEVICE|Control culture|The same standard culture medium, but without any additions (ready-to-use)
40773747|NCT06136598|DRUG|Opevesostat|Tablets to be taken orally.
40773748|NCT06136598|DRUG|Dexamethasone|Tablets to be taken orally
40773749|NCT06136598|DRUG|Fludrocortisone|Tablets to be taken orally.
41301680|NCT05304182|DEVICE|LENSTAR LS 900|"The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'."
41301681|NCT02074579|DRUG|TU-100|15g daily, orally as 5g three times daily for 4 consecutive weeks
41301682|NCT02074579|DRUG|Placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
41301683|NCT05099757|BIOLOGICAL|20 µg dose hepatitis B vaccine|one-dose, two-dose or three-dose, 20 µg per dose
41460765|NCT01808248|DRUG|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
41460766|NCT01808248|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
41460767|NCT05830682|DEVICE|using a walking aid|The walking aid utilized for mobilizing patients in the intervention group during the study is a four-wheeled device that allows for movement in all directions. The height of the device can be adjusted according to the patients' height. It features a seat for resting when needed and a braking system that is controlled from the hand grips.
41460768|NCT06476782|OTHER|Motor Relearning Program(MRP) and aerobic exercise|Participants of this group received training for a total of 8 weeks in the form of 3 sessions per week each session of 40 minutes, with a total of 24 sessions.
41460769|NCT06476782|OTHER|Motor Relearning Program(MRP)|the week 8 session was held in which patients were involved in 60-minute activities that involved practicing functional tasks without explicitly giving any type of relationship between those learned skills and the remedial tasks.
41460770|NCT02571933|OTHER|Pre-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
41460771|NCT02571933|OTHER|Post-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
41460772|NCT02571933|OTHER|Cognitive interview|Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
41460773|NCT00162929|BIOLOGICAL|AdHer-2/neu transduced dendritic cells|Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)
41460774|NCT01350596|DRUG|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
41460775|NCT01350596|DRUG|Ibuprofen|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
41460776|NCT00236145|DRUG|ACTIQ (Oral transmucosal fentanyl citrate)|
41460777|NCT01097694|DRUG|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
41460778|NCT01097694|DRUG|Placebo|Placebo
40773750|NCT06136598|DRUG|Hydrocortisone|Tablet to be taken orally as a rescue medication.
40773751|NCT00105898|PROCEDURE|Web-based care management|Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
40773752|NCT00105898|PROCEDURE|Telephone and face-to-face care management|Participants interact with a care manager via face-to-face and telephone contact
40773753|NCT00105898|PROCEDURE|Internet access alone|Participants are given internet access and encouraged to seek diabetes information to help in their self management
40773754|NCT05982093|DRUG|Elacestrant|Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).
40977758|NCT01549444|OTHER|presence of maternal risk factor for hypertension|
40977759|NCT03069807|OTHER|Community/Primary Care|The treatment of Latent Tuberculosis Infection (LTBI) in the community by General Practitioners (Family Doctors) and Pharmacists
41301684|NCT04990245|DIAGNOSTIC_TEST|endoscopic biopsies|patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests
41301685|NCT05488561|DIAGNOSTIC_TEST|CBC with differential ,ESR ,CRP, Amyloid level , FMF gene|leucocytosis , high ESR and CRP ,amyloid level indicates inflammation positive FMF gene indicates having the disease .
41301686|NCT02689219|DRUG|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
41460779|NCT06222229|OTHER|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
41460780|NCT06222229|PROCEDURE|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended"
41460781|NCT01897324|DRUG|Growth hormone (Norditropin, Novo nordisk)|
41460782|NCT01824576|DEVICE|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
41460783|NCT04487964|DIETARY_SUPPLEMENT|Licorice extract|"LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour"
41460784|NCT00623636|DRUG|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
41460785|NCT00623636|DRUG|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
41460786|NCT03742063|DRUG|first-line chemotherapy|patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
41460787|NCT01900457|OTHER|electromyography|
41460788|NCT01900457|OTHER|electroencephalography|
40977760|NCT03069807|OTHER|Hospital/TB Clinic|The treatment of Latent Tuberculosis Infection (LTBI) in the Hospital TB Clinic by specialist doctors and nurses
41141662|NCT05868356|DRUG|Treatment B|Oral adagrasib 200 mg BID and gemfibrozil 600 mg BID for 10 days (Days 9 to 18), with no evening dose of adagrasib or gemfibrozil on Day 18. Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 9 to 17 before the morning dose of adagrasib. Predose PK blood samples for the measurement of gemfibrozil trough concentration will be collected on Days 15 to 18 before the morning dose of gemfibrozil. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Day 18.
41141663|NCT03757767|OTHER|Fasting for 26-hours|"All research subjects will have to fast for 26 hours in total.~All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points."
41141664|NCT01289834|DEVICE|Hi-Fatigue Bone Cement|"Hi-Fatigue bone cement is a new development of Aap Biomaterials, GmbH \& Co that has not yet been tested in the clinical setting. Hi-Fatigue has a medium to low viscosity. Laboratory tests confirm Hi-Fatigue bone cement to have properties equivalent to or better than the golden standard bone cement Palacos. Hi-Fatigue is to be used without pre-chilling. When mixed at a room temperature of 21°C Hi-Fatigue has a low initial viscosity improving mixing and theoretically reducing the porosity of the cured cement."
41301687|NCT03121222|DRUG|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.
40977761|NCT02235480|DRUG|Experimental Tazarotene Gel|
40977762|NCT02235480|DRUG|Placebo|
40977763|NCT05940207|DEVICE|e-Bandages|A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.
40977764|NCT05178524|DRUG|BIFICO|Live combined Bifidobacterium, Lactobacillus and Enterococcus Capsules
40977765|NCT01569789|DEVICE|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
40773755|NCT05982093|DRUG|Triptorelin|Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.
40773756|NCT01706185|OTHER|Data acquisition and analysis|Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
40773757|NCT00895921|DRUG|Olanzapine|Single intramuscular 10-mg dose
40773758|NCT00895921|DRUG|Aripiprazole|Single intramuscular 9.75-mg dose
40773759|NCT03889379|DRUG|Administration of albuterol|Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
40773760|NCT06564285|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
41301688|NCT03121222|DRUG|Lactose|The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
40773761|NCT06564285|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
40773762|NCT06565351|OTHER|eGFR estimated from creatinine and cystatin C|eGFR estimated from creatinine and cystatin C was compared to GFR measured by 99mTc-DTPA clearance (gold standard)
40773763|NCT01842659|GENETIC|Methylation Index|To calculate the methylation index (MI) of imprinted regions.
40773764|NCT04375358|BIOLOGICAL|Blood and urine samples|To measure the clearance of creatinine, urea, potassium, magnesium, sodium, chlorine...
40773765|NCT03606577|DRUG|Carfilzomib|Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)
41460789|NCT01900457|OTHER|approaches from psychophysics|
41460790|NCT05632796|PROCEDURE|Adjusting the Pfannenstiel skin incision according to the occipitofrontal diameter (OFD) of the fetal head.|All women will be subjected to regional spinal anesthesia. Pfannenstiel incision will be made according to the fetal occiputofrontal diameter, marked on the skin (Pfannenstiel incison with Kaya modification) Following blunt entry to the abdominal cavity, the uterine lower segment Kerr incision will be performed. Folllowing delivery of the baby, umblical cord will be cut and an arterial umblical cord blood sample will be taken. Placenta will be removed. 1st and 5th min. Apgar scores will be noted. Uterine incison will be sutured double-layer with 1 polyglactin 910 suture . Peritoneum and fascia, will be closed with 2-0 and 1 polyglactin 910 suture respectively. Skin incision will be sutured with continuous 3-0 rapid polyglactin 910 suture and measured with flexible ruler in centimeters following completing the skin incision closure.
40773766|NCT03606577|DRUG|Daratumumab|induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 \& D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)
40773767|NCT03606577|DRUG|Lenalidomide|induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)
40773768|NCT03606577|DRUG|Dexamethasone|induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22
40773769|NCT06565117|DRUG|White yu green skin lotion|Group A: Systemic emollient was applied twice daily for 8 weeks Group B: Continue applying skin lotion twice daily in locally affected skin areas or in areas previously affected by AD for 8 weeks
40773770|NCT02510586|DRUG|Sevoflurane|administer 1.0 MAC (1.7\~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
40773771|NCT00756340|DRUG|Bevacizumab|"* Bevacizumab IV every 2 weeks~* Dose Level 0- 8 mg/kg~* Dose Level 1 (starting dose)- 10 mg/kg~* Dose Level 2- 10 mg/kg"
40773772|NCT00756340|DRUG|Everolimus|"* Everolimus~* Dose Level 0- 4 mg/m2~* Dose level 1 (starting dose)- 4 mg/m2~* Dose Level 2- 5 mg/m2"
41460791|NCT01874041|OTHER|Massage|
40773773|NCT02899403|OTHER|Rapid Visual Information Processing (RVIP) test|Rapid Visual Information Processing is a measure of sustained attention.
40773774|NCT01370044|DRUG|Carbogen|3 minutes administration of carbogen
40773775|NCT01370044|DRUG|Placebo|3 minutes administration of oxygen
40773776|NCT00800735|DRUG|Pegylated-interferon alfa-2a|Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
40773777|NCT00800735|DRUG|Ribavirin|Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing \< 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
41301689|NCT00942045|BIOLOGICAL|Biologic - Osteocel Plus|Osteocel Plus
40773778|NCT02587455|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
40773779|NCT02587455|RADIATION|Radiotherapy|Radiotherapy - Standard Treatment
41301690|NCT04111276|DEVICE|Breg Osteoarthritis Brace gait fluoroscopy|Gait under fluoroscopy surveillance with brace
40773780|NCT05751304|DRUG|Dexmedetomidine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg Dexametomidine.
40773781|NCT05751304|DRUG|Ketamine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
40773782|NCT00800826|DRUG|dexmedetomidine|
40773783|NCT03089294|DEVICE|Aries ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)
40977766|NCT01569789|DEVICE|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
41301691|NCT04111276|OTHER|Gait fluoroscopy without brace|Gait under fluoroscopy surveillance without brace
41301692|NCT04111276|DIAGNOSTIC_TEST|JointVue ultrasound|JointVue ultrasound procedure to reconstruct 3D femoral and tibial bones
40773784|NCT06376825|BEHAVIORAL|MyLife: An internet-based self-help program to reduce burnout|MyLife is a internet-based and Acceptance and Commitment Therapy oriented self-help program to reduce burnout. In this study a tailored to teachers version of the program will be used.
40773785|NCT04844931|PROCEDURE|RIC + PostC + Standard PCI|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery
40773786|NCT04844931|PROCEDURE|Standard PCI|Standard PCI
40773787|NCT02347410|DEVICE|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
40773788|NCT00864357|DRUG|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
40773789|NCT00864357|DRUG|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
40773790|NCT05458960|BEHAVIORAL|Social needs navigator program|4 months of assistance tailored to the needs of the participant
40773791|NCT05458960|BEHAVIORAL|Enhanced usual care|Referral to United Way 2-1-1
41460792|NCT01874041|OTHER|Occlusal splint|
41460793|NCT00769496|DRUG|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
41460794|NCT05123053|DRUG|Amifampridine|10mg tablet
40773792|NCT04282148|DEVICE|ABT NG DES 48 EECSS|Each participant will receive ABT NG DES 48 EECSS with appropriate diameter
40773793|NCT01332656|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
40773794|NCT01332656|DRUG|Placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
40773795|NCT01332656|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
40773796|NCT01332656|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
40773797|NCT01196715|DRUG|Darbepoetin alpha|Aranesp 500 mcg vials once every 2 weeks.
40773798|NCT01196715|DRUG|Filgrastim|300 mcg vials twice a week, 3-4 days apart
40773799|NCT01196715|PROCEDURE|Blood Red Cell Transfusion|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl or such that the patient is never excessively symptomatic, according to local transfusion guidelines/policy.
40773800|NCT05599100|BEHAVIORAL|STAR-Caregivers Virtual Training & Follow-up (STAR-VTF)|For 6-8 weeks, caregivers will complete online training modules asynchronously. Caregivers will be instructed to complete one module per week. The content of the modules is as follows: Module 1 introduces caregivers to the behavioral treatment of dementia, realistic expectations, and effective communication; Module 2 covers the ABC (antecedents, behaviors, consequences) approach to problem-solving, including rationale and development of an ABC plan; Module 3 instructs caregivers to review the ABC plan and revise as needed; Module 4 covers pleasant events and managing negative thinking; Module 5 instructs caregivers to review the ABC plan, pleasant activities schedule, and to revise as needed; Module 6 covers coping with caregiving and maintaining gains. Each module takes about 45 minutes to complete. The modules use text, pictures, and illustrations with a voiceover presentation. Caregivers will receive the online training modules in their preferred language (English or Spanish).
41301693|NCT04111276|DIAGNOSTIC_TEST|Computer Tomography|Computer Tomography scan limited to the study knee and will image 6 inches distal on the tibia and 6 inches proximal on the femur
40773801|NCT05586750|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
40773802|NCT05586750|DRUG|Placebo|2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
40773803|NCT04468360|BEHAVIORAL|3-day differential fear conditioning, extinction, and extinction retention testing paradigm|Day 1: Fear acquisition involving the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a conditioned stimuli (CS) (Expts. 1 and 2). The CS will be different colored shapes appearing on a computer monitor. An auditory stimulus will serve as the startle probe. Day 2: Either extinction training (Expt. 1) or fear memory reactivation by a single CS+ with no US (Expt. 2) will occur followed by IV Allo vs. IV placebo administration. Day 3: The effects of IV Allo vs. IV placebo (administered on Day 2) on extinction retention (Expt. 1) or reconsolidation blockade (Expt. 2), as well as reinstatement of conditioned fear (Expts. 1 and 2) will be assessed.
40977767|NCT00139399|PROCEDURE|Coronary artery bypass graft (CABG) surgery|Patients were randomized to receive either a radial artery or a long saphenous vein graft to the left circumflex coronary artery territory during CABG surgery
41301694|NCT04477304|BEHAVIORAL|Opioid Naive, OR|Visits where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days and clinician is on the clinic list as a treating member of the clinic
41460795|NCT06428955|DEVICE|CT LUCIA 621P|The device under investigation, CT LUCIA 621P IOL (Carl Zeiss Meditec, Jena, Germany) is a posterior chamber intraocular lens which is indicated for aphakia after surgical extraction of the cataractous natural lens. It is a monofocal aspheric IOL made of hydrophobic material and coated with heparin. The modified C-loop haptic is step-vaulted.
41460796|NCT00030511|DRUG|fluorouracil|
40977768|NCT01127074|BIOLOGICAL|KS24.22 cells|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
40977769|NCT04981951|DRUG|Dexmedetomidine|Highly selective α2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.
41141665|NCT01289834|DEVICE|Palacos Bone Cement|"Palacos Bone Cement has been used for 48 years and has a good reputation as the gold standard among bone cements (3). It is a high-viscosity cement with rapid application that makes it advantageous for use in orthopedic joint surgery. Palacos cement was developed in order to allow hand mixing of monomers and polymers in a dish in the operating room. Air pollution with toxic monomers in the operating room was a problem that was primarily solved by exhaust ventilation, later supplemented with vacuum mixing"
41141666|NCT06505096|PROCEDURE|cataract surgery|Phaco+IOL implention
40773804|NCT04468360|DRUG|Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis|Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of Allo will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of Allo will be infused over 30 minutes immediately following presentation of a single CS+.
40773805|NCT04468360|OTHER|Matching IV Placebo|Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of the matching placebo formulation will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of the matching placebo formulation will be infused over 30 minutes immediately following presentation of a single CS+.
40773806|NCT02647502|OTHER|Diet|Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
40773807|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 25 mg.
40773808|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 50 mg.
41141667|NCT00604396|DRUG|insulin detemir|
41141668|NCT00604396|DRUG|insulin NPH|
41141669|NCT06085833|DIAGNOSTIC_TEST|Nanomechanical Phenotype Test|The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.
41141670|NCT05534776|OTHER|Investigator Global Assessments (IGAs)|5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.
41301695|NCT04477304|BEHAVIORAL|At-risk for long-term use, OR|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days and clinician is on the clinic list as a treating member of the clinic
41301696|NCT04477304|BEHAVIORAL|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days and clinician is on the clinic list as a treating member of the clinic
40773809|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 75 mg.
40773810|NCT03772535|DIAGNOSTIC_TEST|Pharmacogenomics Testing|The doctor will use genetic test results to prescribe medications that are a most effective for subject.
41301697|NCT04005209|DRUG|Ketamine|The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
41301698|NCT04005209|OTHER|Pain management|Pain management
41301699|NCT02207530|DRUG|MEDI4736|MEDI4736 monotherapy
40773811|NCT02323711|DEVICE|2-octyl cyanoacrylate|If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
40773812|NCT04120987|DRUG|Lifitegrast 5% Ophthalmic Solution|BID OU
40773813|NCT01447784|BIOLOGICAL|ToleroMune HDM|Intradermal injection 1 x 11 administrations 4 weeks apart
40773814|NCT01447784|BIOLOGICAL|Placebo|Intradermal injection 1 x 11 administrations 4 weeks apart
40773815|NCT06563921|BEHAVIORAL|physical exercise programme|resistance/hypertrophy-oriented resistance programme
40773816|NCT06563921|DIETARY_SUPPLEMENT|probiotics supplementation|probiotics supplementation
40773817|NCT06563921|DIETARY_SUPPLEMENT|placebo|placebo
40773818|NCT00209131|DRUG|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
40773819|NCT00209131|DRUG|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
40773820|NCT05718739|DEVICE|AX6 6-axis logging accelerometer|The device is collecting longitudinal movement data.
40773821|NCT00760552|OTHER|High Intensity Intervention|High Intensity patients will be seen by the pharmacist at 3-6 month intervals, depending upon if patient is at goal BP. During these visits, the pharmacist will: 1) review barriers to BP control; 2) assess progress toward overcoming such barriers; 3) determine adherence; and 4) assess potential side effects. If the BP is at goal, the patient will be given encouragement and told to continue the regimen. If the BP is not at goal, the pharmacist will develop a new treatment strategy. If the treatment changes were in the plan negotiated with the physician, the PCP will simply be informed. If new changes are recommended, the pharmacist will develop a new treatment plan and review it with the PCP.
40773822|NCT00760552|OTHER|Low Intensity Intervention|Low intensity group will receive management by their PCP and a 3-part intervention that was effective in a recent VA study. This one-time intervention will occur 3 months after completion of the initial 6-month pharmacist intervention and will include: Provider education including an email message to re-evaluate the specific patient's BP regimen and a web link to the VA/JNC-7 hypertension guidelines. 1-time patient-specific computerized alert reminding the PCP of the goal BP, values of the patient's last 3 BP assessments, \& possible options for medication changes if BP does not remain at goal. Patient education including a personalized letter with information on strategies to improve BP control, including medication adherence, Dietary Approaches to Stop Hypertension (DASH) diet/exercise. The letter will note that many patients require more than one medication and will provide a link to the VA patient education web library and American Heart Association (AHA) site.
40977770|NCT05977582|BEHAVIORAL|Spanish version eBodyProject|"The Spanish adaptation of the eBodyProject program will be modified (Stice et al., 2012b). This program consists of 4 modules adapted from the most recent version of the original program The Body Project, presented by the original authors who have given their consent and suggestions for the realization of the Spanish version.~The activities proposed through the different modules will be in written format or behavioral activities aimed at criticizing the ideal of feminine beauty imposed by today's society and promoting self-acceptance."
40977771|NCT05977582|BEHAVIORAL|Psychoeducationa Prevention Program|Participants in this group will receive a weekly newsletter with information about the beauty ideal, the costs of pursuing it, and tips for resisting the pressure to pursue this ideal, as well as tips for managing the emotions associated with it. However, they will not have to perform exercises related to this information, a psychoeducational intervention. Once the study is finished, these participants will receive an email again in case they are interested in taking part in the eBodyProject prevention program.
40977772|NCT01737944|DRUG|Methotrexate (MTX)|Vibex MTX Device
40977773|NCT00004182|DRUG|irinotecan hydrochloride|
40977774|NCT05313594|DIAGNOSTIC_TEST|Mixed meal challenge test|Mixed meal consumption followed by postprandial blood sampling
40977775|NCT05313594|DIAGNOSTIC_TEST|MRI|MRI imaging
40977776|NCT05313594|DIAGNOSTIC_TEST|DEXA|DEXA scan
41141671|NCT01350167|PROCEDURE|Screening|"Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years."
40977777|NCT05313594|DEVICE|Freestyle Libre|Continuous blood glucose measurement
40977778|NCT05313594|DEVICE|ActivPAL3|Continuous physical activity measurement
41141672|NCT01223053|DRUG|Ketoprofen 10% cream|100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
41141673|NCT01223053|DRUG|Placebo|Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
41141674|NCT05409170|PROCEDURE|COVID|Each surgical procedure was considered an independent event. Moreover, the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
41141675|NCT00368602|DRUG|Timoptic|Timoptic to be applied to the target wound daily for up to 12 weeks.
41141676|NCT00368602|OTHER|Placebo|Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
41141677|NCT02330900|OTHER|Study group|Exposure to cell phone interference of the ICD
41141678|NCT04305496|DRUG|Fulvestrant|Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
41460797|NCT00030511|PROCEDURE|conventional surgery|
41460798|NCT00030511|RADIATION|radiation therapy|
41460799|NCT02227615|DIETARY_SUPPLEMENT|Mango polyphenolics|Frozen Mango (Keitt) packs provided to subjects.
40773823|NCT00760552|OTHER|All- 6 month pharmacist intervention|All patients will receive the initial 6-month pharmacist intervention. The intervention: 1) co-management of HTN by pharmacists can improve BP control; and 2) active follow-up is needed to reinforce progress and proactively identify and resolve problems. The intervention will include structured visits at baseline 1, 2, 4, and 6 months after baseline and telephone calls at 2 weeks and between the visits. At baseline, the pharmacist will review the computerized patient record system (CPRS) medical record and perform a structured interview, including: a detailed medication history of all prescription and non-prescription therapies; an assessment of patient knowledge of all meds, the purpose of each med, medication dosages and timing, and potential side effects; potential contraindications to specific medications; and expectations for future dosage changes and of the need for future monitoring potential barriers to BP control.
40977779|NCT06476561|OTHER|- Sociodemographic Assessment - Psychological Assessment - Quality of Life Assessment - D|"The study involves several assessments to evaluate the impact of various factors on dual-task performance in elderly individuals:~1. Sociodemographic Assessment: Collection of data on age, gender, education, income, marital status, and other relevant factors.~2. Psychological Assessment: Use of the Depression Anxiety Stress Scales-21 (DASS-21) to measure levels of depression, anxiety, and stress.~3. Quality of Life Assessment: Utilization of the World Health Organization Quality of Life Brief Form (WHOQOL-BREF) to assess physical health, psychological health, social relationships, and environment.~4. Dual-Task Performance Evaluation: Measurement of the ability to perform a cognitive task (counting backward by threes) simultaneously with a motor task (Nine-Hole Peg Test). The dual-task cost (DTC) is calculated to quantify the impact of cognitive load on motor performance."
40977780|NCT00289315|BEHAVIORAL|Primary (Environmental) Weight Gain Prevention|School-based program that modifies the school environment to promote healthy eating and physical activity
40977781|NCT00289315|BEHAVIORAL|Secondary (Behavioral) Weight Gain Prevention|School-based environmental program to promote healthy eating and physical activity in the overweight students.
40977782|NCT00289315|BEHAVIORAL|Control|Control program that does not include an active intervention for promoting healthy eating and physical activity.
40977783|NCT02999945|DIETARY_SUPPLEMENT|SGA-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
40977784|NCT02999945|DIETARY_SUPPLEMENT|IUGR-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
40773824|NCT02006511|DEVICE|Incisional Neg Pressure Wound Therapy (Prevena™)|Negative pressure wound therapy dressing applied over closed surgical incision
40773825|NCT02006511|OTHER|Standard of Care wound therapy|Gauze type dressing.
40977785|NCT02999945|OTHER|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
40773826|NCT05470296|BEHAVIORAL|Move & Eat 2 Live|American Indians suffer disproportionately from several chronic diseases that may be prevented with healthier modifiable factors. Nutrition, physical activity and a healthy weight are key factors that may prevent and reduce risk of disease incidence. The major goals of this project are to develop a culturally adapted intervention that addresses barriers and uses positive cultural values as guiding principles for behavior changes to enhance program retention and improve behaviors. This project will pilot a 12-week standard lifestyle intervention in American Indians.
40977786|NCT02999945|OTHER|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
40977787|NCT03591198|BEHAVIORAL|Qigong Training|Eight-Section Brocades
40977788|NCT03591198|BEHAVIORAL|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
41141679|NCT04305496|DRUG|Capivasertib|400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
41141680|NCT04305496|DRUG|Placebo|Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
41141681|NCT02428595|DEVICE|Eclipse™ System|"The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System."
40773827|NCT03218865|DEVICE|VIE high flux dialyzer|Asssesment of the therapeutic effect of the vitamin E coating
40773828|NCT03218865|DEVICE|Leoceed H high flux dialyzer|Use of the Leoceed H dialyzer during one year per patient enrolled in the control group
40773829|NCT06388629|DEVICE|Rook Epicardial Access Kit|Access the epicardial surface of the heart via a subxiphoid approach with the subject device to facilitate guidewire placement into the pericardium.
41141682|NCT04881656|OTHER|Help is in Your Hands|HIIYH is a set of 16 online educational modules for caregivers of children with social-communication delays or elevated likelihood of ASD.
41141683|NCT02799537|OTHER|Randomized clinical study|Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
41141684|NCT03162614|BIOLOGICAL|RTS,S/AS01E|Subjects will receive intramuscular injection of RTS,S/AS01E.
41141685|NCT03162614|BIOLOGICAL|RTS,S/AS01B|Subjects will receive intramuscular injection of RTS,S/AS01B.
40773830|NCT05766605|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
40773831|NCT05766605|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
41301700|NCT00305643|DRUG|Capecitabine|Initial dose of 750-1500 mg/m\^2 orally twice a day for each 21 day cycle.
41301701|NCT00305643|DRUG|Celecoxib|200 mg given orally twice a day for each 21 day cycle.
41301702|NCT00305643|PROCEDURE|Radiation Therapy|Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.
41301703|NCT00305643|DRUG|Placebo|Oral placebo twice daily on days 1-21
41301704|NCT03154723|DRUG|Vitamin A|Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.
41460800|NCT02227615|DIETARY_SUPPLEMENT|Sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
40773832|NCT05766605|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
40773833|NCT05766605|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
40773834|NCT05766605|DRUG|Oxaliplatin, Leucovorin, fluorouracil|"Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions"
40773835|NCT05766605|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
40773836|NCT03612570|DEVICE|Nano-Pulse Stimulation Device|NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
40773837|NCT00255502|DRUG|metoprolol succinate|
40773838|NCT03747367|BEHAVIORAL|Insufficient Sleep|
40773839|NCT00004128|BIOLOGICAL|aldesleukin|
40977789|NCT03092154|DRUG|Lipid-lowering agents (Artovastatin)|Artovastatin 20 mg /day, orally, 12 consecutive weeks.
40977790|NCT04990154|BEHAVIORAL|a 12-week intradialytic exercise|a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
40773840|NCT00004128|BIOLOGICAL|filgrastim|
40773841|NCT00004128|DRUG|busulfan|
40977791|NCT00757744|BEHAVIORAL|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|once weekly individual counseling
41301705|NCT06017063|OTHER|Psychological intervention|The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
41301706|NCT03302793|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
41301707|NCT03302793|DEVICE|tDCS|tDCS will be applied for 20 minutes.
41301708|NCT03302793|DEVICE|tDCS sham|
40773842|NCT00004128|DRUG|cyclophosphamide|
40773843|NCT00004128|DRUG|cytarabine|
40773844|NCT00004128|DRUG|daunorubicin hydrochloride|
40773845|NCT00004128|DRUG|etoposide|
41301709|NCT02470013|DIETARY_SUPPLEMENT|Balanced, energy dense, moderate protein sip feed|2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
40773846|NCT00004128|PROCEDURE|autologous bone marrow transplantation|
40773847|NCT00004128|PROCEDURE|peripheral blood stem cell transplantation|
40773848|NCT00004128|RADIATION|radiation therapy|
40773849|NCT05496049|DEVICE|Triburter|Patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day for four weeks. And they have to fill a calendar to ensurance the intervention.
40773850|NCT05496049|DEVICE|Incentive spirometry|They will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks. They have to fill a calendar to ensurance the intervention.
40773851|NCT03781986|DRUG|APG-115|APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
40773852|NCT03781986|DRUG|Carboplatin|Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
40773853|NCT06132919|DRUG|MC2-25 cream|Topical application
40773854|NCT06132919|DRUG|MC2-25 vehicle|Topical application
40977792|NCT00757744|BEHAVIORAL|Drug counseling|individual drug counseling
41301710|NCT01273688|BEHAVIORAL|Eccentric training (Flex-Bar)|6x15 repetitions of supination and pronation daily over 12 weeks
41301711|NCT01273688|DEVICE|EpiHit elbow brace|daily wearing of the EpiHit elbow brace
41301712|NCT02951611|PROCEDURE|Acupuncture stimulation|Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4
41301713|NCT02951611|PROCEDURE|Sham stimulation|Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation
41301714|NCT02013934|DIETARY_SUPPLEMENT|Probiotic|
41301715|NCT02013934|DIETARY_SUPPLEMENT|Placebo|
40773855|NCT03375242|DRUG|crizotinib|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
40773856|NCT03057756|COMBINATION_PRODUCT|Km+ Mfx+ Pto + H + Cfz +E+Z|Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide
40773857|NCT02400684|BIOLOGICAL|blood samples|Evolution of AMH before and after deep endometriosis surgery
40773858|NCT01518413|DRUG|sorafenib|sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
41460801|NCT05307276|OTHER|Heliox|"Participants will then complete 1 FAM (#V3) to Neuromuscular Function Assessment (PRE-POST), Pre- and Post- Exercise Ventilatory Function Assessment, and a Constant Load Ergocycle Test to Tolerance Limit (intensity fixed at 90% of the maximum aerobic power, PMA). The following two experimental visits (#V4 and #V5) will replicate the tests described in #V3. However, during the constant load exercise, participants will breathe either ambient air or heliox (a mixture in which the nitrogen in the air is replaced by the inert gas helium) in a random order. During a final Experiential Visit (#V6), participants will replicate the Medical Gas Administration visit but the exercise will be interrupted when a similar amount of time/work as the ambient air condition is achieved."
40773859|NCT01518413|DRUG|irinotecan|irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
40773860|NCT06565143|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak alternating currents.
40773861|NCT06565143|DEVICE|Sham transcranial alternating current stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
40773862|NCT05072899|PROCEDURE|platelet rich plasm|local injection of shoulder joint by platelet rich plasm
40773863|NCT05072899|PROCEDURE|Hyaluronic acid|local injection of shoulder joint by Hyaluronic acid
40773864|NCT04028258|DIETARY_SUPPLEMENT|Mixture of fibers + Placebo|Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)
40773865|NCT04028258|DIETARY_SUPPLEMENT|Placebo + Mixture of fibers|Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)
40773866|NCT04053504|BEHAVIORAL|Family Teamwork-Peer Delivery|Children with T1D and their parent will participate in 6 in-person FT-P group sessions during a 12-month period. Parents will also participate in monthly telephone support calls with a Parent Leader during the 12-month intervention period.
40773867|NCT01920113|DRUG|Dexmedetomidine - remifentanil group|
40773868|NCT01920113|DRUG|Propofol - remifentanil group|
40773869|NCT01580787|DEVICE|Balance Training with Nintendo Wii Fit|The participants of the study trained 10 balance games during 14 sessions.
40773870|NCT01580787|OTHER|Physical Therapy|Patients of the control group was trained with balance exercises.
40773871|NCT06244589|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy: Cholecystectomy that performed with laparoscopic method
41301716|NCT05868993|DRUG|Dose of 0.5% Ropivacaine|Dose varied by 5mL of 0.5% Ropivacaine
41301717|NCT01743586|OTHER|Chest physiotherapy education intervention|breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
40773872|NCT06244589|PROCEDURE|Open-conversion cholecystectomy|Open-conversion cholecystectomy: Cases in which laparotomy (Generally right subcostal incision) was performed based on intraoperative findings.
40773873|NCT05164653|DRUG|Sacubitril Valsartan Sodium Hydrate|"Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation."
40773874|NCT05164653|DRUG|Standard treatment|Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
40773875|NCT03178682|DIAGNOSTIC_TEST|ultrasound parameters|ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery Doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss.
40773876|NCT06564428|GENETIC|Suspective gene mutations and family history|To observe if the patients with suspective gene mutations or family history take higher risk of suffering from ovarian cancer.
40773877|NCT02399293|BEHAVIORAL|N-back|"The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
40773878|NCT02399293|BEHAVIORAL|Visual Search|"The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
40773879|NCT01622478|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
40773880|NCT01622478|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
40773881|NCT01622478|PROCEDURE|complete axillary lymph node dissection|Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
40773882|NCT01622478|PROCEDURE|positron emission tomography and ultrasonogram|Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
40977793|NCT00647790|PROCEDURE|PET scan with injection of 5-8 mCi of 18FES|Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
41460802|NCT05307276|OTHER|Air|Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular VO2 MAX estimation test in Ambient Air or Heliox conditions (depending on randomization).
41460803|NCT03380130|DRUG|Nivolumab|An anti-programmed death 1 monoclonal antibody
41460804|NCT03380130|DEVICE|SIR-Spheres|Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation
40773883|NCT02228928|DRUG|CAPNP, 50 ug/cm2 capsaicin patch|
40773884|NCT02228928|DRUG|CAPNP, 100 ug/cm2 capsaicin patch|
40773885|NCT02228928|DRUG|0.075% capsaicin cream|
40773886|NCT02228928|OTHER|Placebo patch|
40773887|NCT03577457|DRUG|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
40773888|NCT03577457|DRUG|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
40773889|NCT03577457|DRUG|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
40773890|NCT03577457|DRUG|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
40773891|NCT03592355|OTHER|Virtual Visit|Clinicians will have a synchronous video visit with their patients.
40773892|NCT04026802|OTHER|In-Bed Resistance Training Device|Physical Therapy using the in bed training device
40773893|NCT04026802|OTHER|Standard of Care|Does not include early implementation of physical therapy
40773894|NCT01958086|DEVICE|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
40773895|NCT04311307|BIOLOGICAL|[6,6-2H2]glucose|Each subject will be administered two oral \[6,6-2H2\]glucose loads (pre-prandial, fed) in the hospital setting and one oral \[6,6-2H2\]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral \[6,6-2H2\]glucose load.
40773896|NCT06453577|DRUG|Recompensation (guideline directed medical therapy)|Recompensation mainly achieved by intravenous diuretics and/or vasodilators but no requirement for positive inotropic drugs such as catecholamines or levosimendan.
40773897|NCT05605249|DEVICE|Cue X|The Cue X movement training module includes several games that can be performed in someone's home environment. The games are designed based on known physiotherapy guidelines and evidence for improving motor symptoms for people with PD and delivered in AR. Some of the games also have integrated cueing to allow people with more severe mobility impairments to participate. Feedback of performance can be given using the movement data of the AR headsets.
40773898|NCT04064905|BIOLOGICAL|mRNA-1893|Zika vaccine
40773899|NCT04064905|OTHER|Placebo|0.9% sodium chloride
40773900|NCT00666263|BIOLOGICAL|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
40977794|NCT00508807|DRUG|RTA 402|5 mg by mouth (PO) daily for 21 days
40977795|NCT05768880|BIOLOGICAL|SC-CAR4BRAIN|Courses of weekly intraventricular CNS administered SC-CAR4BRAIN infusions for 3 weeks, then 1 week off
40773901|NCT00666263|BIOLOGICAL|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
40977796|NCT02743520|DEVICE|The Lifestar Act III|The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.
40977797|NCT03568760|BEHAVIORAL|Semantic feature analysis|Confrontation naming training and training in doing circumlocutions
40773902|NCT01505088|DRUG|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
40773903|NCT01505088|DRUG|Prednisolone Acetate (1%) Eyedrops|Prednisolone acetate (1%) eyedrops
40977798|NCT03568760|BEHAVIORAL|Comprehension training|Reading and hearing comprehension
40977799|NCT03130868|OTHER|Characterizing changes in the microbiome|Analyzing the microbial content from stool samples
40977800|NCT03663205|DRUG|Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed|Treatment for advanced NSCLC
40773904|NCT01505088|DRUG|100 mM sodium citrate buffer solution|Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
40773905|NCT01505088|DRUG|Placebo Eyedrops|Placebo Eyedrops
40977801|NCT03663205|DRUG|Cisplatin or Carboplatin,Pemetrexed|Treatment for advanced NSCLC
40977802|NCT05368857|DRUG|Afamelanotide|Up to 10 adult healthy volunteers will be enrolled in this study in which small areas of their skin will be exposed to UVR and skin samples taken. UV-induced DNA damage and repair will be analysed.
40977803|NCT04894773|OTHER|Imaginary Resistance Exercises|In imaginary resistance exercises, resistive force is assumed to get applied by the patient after demonstrating some resistive objects and the kind of force exerted by them.
41460805|NCT00498316|PROCEDURE|Cord Blood Infusion|Cord blood transplantation performed on day 0.
41460806|NCT00498316|DRUG|Busulfan|32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
41460807|NCT00498316|DRUG|Fludarabine|"10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).~40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
41460808|NCT00498316|DRUG|Rituximab|375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
41460809|NCT00498316|OTHER|ATG|"1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
41460810|NCT00498316|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
41460811|NCT00498316|DRUG|Clofarabine|30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
41460812|NCT00498316|RADIATION|Total Body Irradiation (TBI)|200 cGy at 25 cGy/minute delivered on Day -3.
41460813|NCT00498316|DRUG|Melphalan|140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
41460814|NCT00498316|DRUG|Tacrolimus|0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present.
41460815|NCT00498316|DRUG|Mycophenolate Mofetil|1 gram by vein twice a day Days -3 through Day 100.
41460816|NCT00498316|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is \> 2.5 x 109/L.
41460817|NCT01861990|DRUG|Valproic Acid|All participants enrolled on valproic acid arm.
41460818|NCT02671877|PROCEDURE|Transnasal fiberoscopy|Minimally invasive exploration ot the upper airways, performed in an awake or minimally sedated patient.
41460819|NCT05124496|DEVICE|Screening Device|Screening device comparing Rt-PCR positive and negative results to HyperDetector results
41460820|NCT06452758|OTHER|2000 meter ergometer test|Rowers will perform 2000m ergometer test. A 2,000-meter trial is a standard test used to assess performance in rowers.
41460821|NCT05184803|DRUG|Docetaxel injection, oxaliplatin, S-1|As a prior chemotherapy, intravenous administration is performed every 3 weeks for docetaxel 50 mg/m2 D1, intravenous administration for oxaliplatin 100 mg/m2 D1, and oral administration twice a day for S-140 mg/m2 D1 to 14.
41460822|NCT05878522|DRUG|sisunatovir|6 capsules administered Q12 hours for 5 doses
40773906|NCT05728554|OTHER|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
40977804|NCT04894773|OTHER|Physical Resisted Exercises|In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects.
40977805|NCT02329249|BEHAVIORAL|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
41460823|NCT05878522|DRUG|placebo|6 capsules administered Q12 hours for 5 doses
41460824|NCT05878522|DRUG|moxifloxacin|6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin
41460825|NCT05878522|DRUG|sisunatovir|7 capsules administered Q12 hours for 5 doses
41460826|NCT00779441|DRUG|Zolpidem 10mg tablets|
40977806|NCT02329249|OTHER|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
41460827|NCT04817995|BEHAVIORAL|FOREST|Intervention is going to take the form of an internet-based stress recovery intervention consisting of six modules. The themes include introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These themes were chosen after considering topics that might be the most useful for healthcare staff experiencing high levels of stress. Each module consists of psychoeducation and exercise parts. Psychologist provide individual feedback on completed exercises as well as can be reached on demand.
41460828|NCT01402934|PROCEDURE|Hydroxyethyl starch solution (Voluven) infusion|fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
41460829|NCT03968016|DEVICE|SYSMEX HLSCL|Diagnostic device
40773907|NCT05728554|OTHER|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
40977807|NCT00000507|DRUG|streptokinase|
41460830|NCT04371263|OTHER|Emotional Change of Nursing Manpower in Emergency and Critical Unit After Keen Election And What's The Influence of Emotional Change|use the emotion regulation questionnaire (ERQ) to realize the influence in duty work
41460831|NCT05336487|OTHER|Physical activity|2 hours of physical activity per day, 5 days per week, for the intervention period
41460832|NCT06465979|BEHAVIORAL|Speech Manipulation|"The acoustic properties of speech sounds will be modified in two main ways. The first way is to introduce gradual changes to the perceived articulation of the target speech sound, such as changing from sh to s by various types of signal processing and filtering. The second type of change is to modify acoustic properties of the sounds that immediately precede the target speech sound, such as changing the speaking rate or its frequencies composition."
40977808|NCT02894918|DRUG|Peginterferon alfa-2a|180ug/0.5ml,hypodermic injection once a week
40773908|NCT05728554|OTHER|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
40773909|NCT00004200|DRUG|prinomastat|
40773910|NCT00004200|DRUG|temozolomide|
40977809|NCT03980106|OTHER|Reciprocal Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract antagonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
40977810|NCT03980106|OTHER|Post-Isometric Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract agonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
40977811|NCT03839745|OTHER|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
41460833|NCT01985724|DRUG|Docetaxel|ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
41460834|NCT01985724|DRUG|Epirubicin|ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
41460835|NCT01985724|DRUG|Cyclophosphamide|ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
41460836|NCT01985724|DRUG|5-fluoruracil|ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
41460837|NCT01985724|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
40773911|NCT01285102|COMBINATION_PRODUCT|irinotecan-eluting beads|Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment
40977812|NCT03982927|OTHER|Laparoscopic skills workshop|One day laparoscopic skills workshop was offered to the surgical residents
40773912|NCT01285102|PROCEDURE|hepatic artery embolization|Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
40773913|NCT02740270|DRUG|GWN323|
41301718|NCT05323552|PROCEDURE|Laparoscopic TEP hernia repair without curare and without orotracheal intubation.|"All the techniques and protocols used for this monocentric study are standardized:~* The anesthesia is general, the anesthetic products administered are identical,~* ventilation is ensured by the use of a laryngeal mask airway, without curare administered~* the surgery is an extraperitoneal laparoscopy with an optical trocar under the umbilical and two operators with the placement of a preformed type 3G polypropylene prosthesis~* the analgesic protocol is free of opioids (Opioid Free Anesthesia - OFA)"
40773914|NCT02740270|DRUG|PDR001|
40773915|NCT02774694|DEVICE|"nociceptive flexion reflex (NFR) threshold (Paintracker, Dolosys GmbH, Berlin, Germany)"|"measurement of the NFR threshold using the Paintracker device"
40773916|NCT03699202|DRUG|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.
40773917|NCT03699202|DRUG|Placebo|The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
40773918|NCT05424588|DIAGNOSTIC_TEST|clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection|Total body dual-energy X-ray absorptiometry (DEXA) was taken BN and AN to measure total (FM) and segmental fat (truncal FM), visceral adipose tissue (VAT) and lean mass (LM). Tetra-polar dual frequency BIA (InBody 120; Cerritos, USA) was used BPP, BN and AN to measure weight and to estimate FM, FFM, and MM. Impedance measurements were performed. CPET was carried out on a cycle ergometer with clip-on pedals. Blood samples were collected in the morning BPP, BN, AN. Biochemical parameters considered in this study were: ALT, AST, creatinine, 25-hydroxy vitamin D, total cholesterol, HDL, LDL, triglycerides concentrations. We isolated CPCs from heparinized blood, as previously reported (14). After the collection of peripheral blood mononuclear cells (PBMCs) by a gradient centrifugation. (15). Differentiating Human Skeletal muscle cells were cultured with or without pooled sera of participants at 5% final concentration. 146b and 34a miRNAs were extracted from PBMCs.
40773919|NCT01502527|DIETARY_SUPPLEMENT|Femarelle|Twice daily oral treatment with Femarelle
40773920|NCT03495414|OTHER|Brain Imaging|"* Structural MRI (T1 weighted)~* Diffusion Tensor Imaging (DTI)~* resting state functional MRI (rs-fMRI)~* functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation)."
40773921|NCT03495414|OTHER|Cognitive testing|"We will administer neuropsychological tests assessing objective measures for~* intelligence (Ravens Matrices)~* impulsivity and risk-taking behavior (Balloon Analogue Risk Task)~* inhibitory control (Stop Signal Task)."
40773922|NCT03495414|OTHER|Psychometric|Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).
40773923|NCT03495414|OTHER|Blood test|Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.
40977813|NCT06072729|OTHER|comparison of magnesium sulphate versus cold compression|This study will involve a total of 70 participants who will be divided into two groups. One group will receive magnesium sulphate, while the other group will receive cold compression. The severity of phlebitis will be assessed in both groups using a visual phlebitis (VIP) rating scale.
41301719|NCT04964024|DIAGNOSTIC_TEST|SARS-CoV-2 antibodies|Analysis of the results of the serological response to COVID-19 and/or Vaccine
41301720|NCT02026622|BEHAVIORAL|psychometric tests|NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
41301721|NCT02026622|DEVICE|MRI|ASL, rest f-MRI, FLAIR, white matter hyper intensities load
41301722|NCT02026622|DEVICE|transcranial doppler and TPI|transcranial doppler TPI
40773924|NCT04940078|DRUG|Cagrilintide|Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks
40977814|NCT06220682|DIAGNOSTIC_TEST|The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs|using Real-Time PCR (QuantStudioTM 3 Real-Time PCR) with an allele-specific fluorogenic oligonucleotide probe and a TaqMan pre-designed SNP Genotyping assay
41301723|NCT02026622|BEHAVIORAL|explicitative interview|
41301724|NCT06336577|OTHER|lower respiratory tract disease|lower respiratory tract disease
41301725|NCT03293277|DRUG|Intranasal Dexmedetomidine|Intranasal Dexmedetomidine
41301726|NCT03293277|DRUG|Intravenous Dexmedetomidine|Intravenous Dexmedetomidine
41301727|NCT03293277|DRUG|Intranasal Placebo|Intranasal Placebo
41460838|NCT03092388|DIAGNOSTIC_TEST|Multi Frequency Bioimpedance Analysis (mfBIA)|Multi Frequency Bioimpedance Analysis (mfBIA) uses very small electric current at different frequencies (5, 50, 100 kHz) to measure the resistance and reactance of the entire body and different segmental body compartiments. With a special software total body fluid can be calculated. By analyzing raw data at different frequencies a detailed view on body and segments fluid distribution is possible.
41460839|NCT03092388|DIAGNOSTIC_TEST|Polysomnography/Polygraphy (PSG/PG)|Sleep is digital recorded by using PSG/PG in hospital and manually analyzed by physicians according to current AASM guidelines.
40773925|NCT04940078|DRUG|semaglutide|Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks
40773926|NCT04940078|DRUG|Cagrilintide and semaglutide|Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe
40977815|NCT04671407|DRUG|Hypertonic Saline|Hypertonic Saline 3% and 0.9%
40977816|NCT01732250|DRUG|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
40977817|NCT01732250|DRUG|Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
40977818|NCT03916276|BEHAVIORAL|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts; recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
41141686|NCT03162614|PROCEDURE|Sporozoite-infected mosquitoes challenge.|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs."
41141687|NCT03917732|BEHAVIORAL|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
41141688|NCT03917732|BEHAVIORAL|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
41141689|NCT02318628|DEVICE|Cardio Ankle Vascular Index (CAVI) of the Vasera system VS1500N|"CAVI will be measured using the Vasera device (VS1500 n - Fukuda Denshi co, Japan). This device is easy to use and calculates automatically the CAVI.~CAVI measurements will be performed according to the manufacturer Measurements will be performed after five to ten minute - period of rest in order to obtain a steady hemodynamic state and to limit measurements variability."
41460840|NCT03092388|DIAGNOSTIC_TEST|Capillary Blood Gas Analysis (CBGA)|CBGA is a less invasive method to gain arterial blood like gas samples without the punctation of an artery. After inducing a good capillary perfusion, capillary blood is taken by a small punctation of the tip of one ear. The sample is automatically analysed in a blood gas analyzer.
41460841|NCT03092388|DIAGNOSTIC_TEST|Tilting Table with Hemodynamic Monitoring|A tilting table offers the opportunity to turn a study subject automatically from vertical into horizontal position and back. By using non-invasive monitoring technique, hemodynamic parameters are recorded permanently.
41460842|NCT01007409|DRUG|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
41460843|NCT01007409|DRUG|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
41460844|NCT04634630|GENETIC|Exposure to lung cancer stem cells|The exposure to lung cancer stem cells was measure as the percentage of Aldehyde dehydrogenase (ALDH) on all viable cells extracted from surgically resected tumor specimens
40773927|NCT03761550|COMBINATION_PRODUCT|pMDT(Process Implementation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
40977819|NCT03916276|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
40773928|NCT03586531|PROCEDURE|renal biopsy|Renal biopsy samples will be obtained by a percutaneous method using a spring-loaded Trucut® biopsy needle under real time ultrasound guidance. Biopsy samples will be processed for light microscopy with special staining will be done: Schiff periodic acid, Masson trichrome and methenamine silver.and immunofluorescence studies to evaluate IgA, IgG, IgM, complement C1q and C3, fibrin, and kappa and lambda light chain deposits.
40773929|NCT02264314|BEHAVIORAL|Active Communication Education Program|A behavioral intervention aimed to improve the adherence to the hearing aid in older adults with hearing loss
40773930|NCT02264314|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
40773931|NCT03152448|BEHAVIORAL|Prolaris|Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
40773932|NCT04146155|DRUG|Liraglutide+standard-of-care treatment|"Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.~Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies in accordance with local clinical practice guidelines."
40773933|NCT04146155|OTHER|standard-of-care treatment|Standard-of-care treatment including: metformin should be given as the first line therapy as long as it is tolerated and not contraindicated; other agents, including sulfonylureas or glucosidase inhibitor or insulin, should be added to metformin .Glycemic control will be managed by the investigators in accordance with local clinical practice guidelines by the adjustment of concomitant glucose-lowering agents or the addition of new antidiabetic medications with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
40773934|NCT05704387|PROCEDURE|individualized GDFT|In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommandation of the AFM software in order to optimize patient's SV
40773935|NCT05704387|PROCEDURE|Restrictive fluid therapy strategy|from anesthesia induction until end of the liver resection, patient will have a restrictive fluid therapy strategy
40773936|NCT00317122|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
40773937|NCT03411187|DEVICE|used of the Pressure adjustable foot-control method|Whether The Pressure adjustable foot-control method is used.
40773938|NCT03411187|DEVICE|direct exhaust|direct exhaust through the trocar.
40773939|NCT04661488|DEVICE|AI driven triage-system|AI driven triage-system
40773940|NCT04946214|BEHAVIORAL|Smart Water Bottle|Patients will be given a smart water bottle and coached on its use. The device is a 24 oz non-bisphenol A acrylic water bottle with the ability to track water consumption from the bottle, alert its users via a smartphone-based notification system, as well as visually remind patients with a light-emitting diode in the device. Participants will be alerted to drink patient-specific volumes of room temperature water 45 minutes prior to daily standard of care radiotherapy.
40977820|NCT03916276|BEHAVIORAL|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
40977821|NCT00113217|DRUG|Bevacizumab|10 mg/kg IV on day 1 of each 14-day cycle.
40977822|NCT03724955|DRUG|Estradiol 2 mg|Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
41301728|NCT03293277|DRUG|Intravenous Placebo|Intravenous Placebo
41301729|NCT03766750|DRUG|LIMA association|1 coated tablet, oral, once a day.
41301730|NCT03766750|DRUG|Tradjenta|1 coated tablet, oral, once a day.
41301731|NCT03766750|DRUG|Forxiga|1 coated tablet, oral, once a day.
41301732|NCT04735367|DRUG|palbociclib plus letrozole|palbociclib plus letrozole
41301733|NCT06055881|OTHER|Non-Interventional Study|Non-interventional study
41301734|NCT02167568|GENETIC|Genetic|
41301735|NCT03615755|OTHER|Hyperbaric Oxygen Therapy (HBOT)|The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.
41301736|NCT04163146|DIAGNOSTIC_TEST|Measurements of PEF and FEV1|Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone
41301737|NCT06286787|OTHER|Intervention|The training programme will consist of a 3-hour lecture. The contents of the lecture will include knowledge of mountaineering in Hong Kong, country codes and care for the environment, environmental awareness when undertaking outdoor activities, hiking skills, knowledge and choice of hiking equipment and clothing, trip planning, mountain safety, map reading, the use of a compass, mountain safety, basic first aid, methods of calling for help in an emergency and sources of weather data. After completing the lecture, participants will be required to join a 6-day hiking training programme on weekends within a 3-month period (each training will be at least 5 kilometres and the duration will be at least 4 hours).
41301738|NCT06286787|OTHER|Placebo|Control participants will be asked to join six day-time leisure activities on weekends within a 3-month period. Leisure activities will be organised by the Asbury Methodist Social Service and will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and eating a healthy diet, and day visits to a museum and theme park. Children in the placebo control group will receive free access to leisure activities, including visits to museums and theme parks as an incentive for his/her participation.
41301739|NCT01864759|BIOLOGICAL|ICOVIR-5|
41301740|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
41301741|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
41301742|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
41301743|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
41301744|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
41301745|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
41301746|NCT04664920|DEVICE|exergame|motor-cognitive training device
40977823|NCT03724955|OTHER|Placebo|The placebo group will receive placebo oral daily for 6 months
40977824|NCT02250365|OTHER|Continuous, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
41141690|NCT01774240|OTHER|systematic screening and treatment of delirium|systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
41141691|NCT02769130|DRUG|Losartan|Losartan is given for 12 months
41141692|NCT02399956|OTHER|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
41301747|NCT00137774|DRUG|Bevacizumab|Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.
41301748|NCT00137774|DRUG|Temozolomide|Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.
41301749|NCT06227390|PROCEDURE|partial pulpotomy|2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
41301750|NCT02639793|PROCEDURE|catheter ablation|Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
41301751|NCT02692339|DRUG|Lenalidomide|Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
41301752|NCT02692339|DRUG|Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
41301753|NCT05625425|BEHAVIORAL|LabyrinthVR software|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, highly engaging regimen of wayfinding in novel urban and village neighborhoods.
41301754|NCT05625425|BEHAVIORAL|Placebo Games software|Commercially-available, narrative computer games marketed as cognitively enriching. Can be tablet-based or wireless VR headset-based.
41460845|NCT02702986|PROCEDURE|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
40773941|NCT04725838|DEVICE|Medtronic Intellis™ and Vanta™|Differential Target Multiplexed (DTM®) programming using Medtronic's Intellis™ or Vanta™ Spinal Cord Stimulation systems
40773942|NCT03611686|DRUG|Local chemotherapy|Local chemotherapy will be administrated according to local recommendation
40977825|NCT02250365|OTHER|Intermittent, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
40977826|NCT01639651|OTHER|Posterior capsule stretching|Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
40977827|NCT01639651|OTHER|Mobilization with movement|Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
40977828|NCT05629624|DIETARY_SUPPLEMENT|Chickpea based RUSF|One group will receive locally produced RUSF, approximate at 50-100 kcal/kg/day, two of 50g packets daily (42) until anthropometric recovery ( WHZ \> - 1SD) has been achieved or for maximum 3 months then immediately 1 packet / day SQLNS will be given throughout the study till the end of 2 years of follow-up.
40977829|NCT05629624|DIETARY_SUPPLEMENT|E-RUSF|The other group will receive the E-RUSF at 50-100 kcal/kg/day which in this age group approximates one 92 g sachet daily until anthropometric recovery ( WHZ \> - 1SD) has been achieved or for a of maximum 3 months, then immediately E-SQLNS 1 packet daily provided throughout the study till the end of 2 years of follow-up.
41141693|NCT06330701|DEVICE|Robotic-assisted mini-PCNL|This robotically enabled hybrid procedure called the MONARCH Mini-PCNL will allow the clinician to obtain retrograde and percutaneous access to participant's kidney under continuous visualization for therapeutic applications (i.e., stone removal).
41141694|NCT03145545|DEVICE|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
41141695|NCT00805792|DRUG|Donepezil|Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
41141696|NCT01970527|BIOLOGICAL|Ipilimumab|Given IV
41301755|NCT05625425|BEHAVIORAL|Labyrinth Tablet software|Tablet computer playing Labyrinth spatial wayfinding game in 2.5D
41301756|NCT05625425|BEHAVIORAL|Labyrinth VR wireless|Wireless head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, engaging regimen of wayfinding in novel urban and village neighborhoods.
41460846|NCT02702986|DEVICE|Laser|
41460847|NCT03433703|DRUG|Lenvatinib|"Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW \<60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)"
41460848|NCT02663661|PROCEDURE|Metabolic Challenge Admission|A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.
41460849|NCT02663661|OTHER|CGM home test|A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
41460850|NCT05777694|PROCEDURE|Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle|the investigators performed spinal anesthesia with 25 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
41460851|NCT05777694|PROCEDURE|Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle|the investigators performed spinal anesthesia with 26 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
40773943|NCT05197842|DRUG|BDB-001 injection|Intravenously administered
40773944|NCT05197842|DRUG|Cyclophosphamide|Intravenously administered
41141697|NCT01970527|OTHER|Laboratory Biomarker Analysis|Correlative studies
41141698|NCT01970527|OTHER|Pharmacological Study|Correlative studies
41141699|NCT01970527|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41141700|NCT00249366|DRUG|Lorazepam (drug)|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
41141701|NCT00249366|DRUG|Lorazepam|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
41141702|NCT01721109|DRUG|EVG/COBI/FTC/TDF|150/150/200/300 mg STR administered orally once daily with food
41141703|NCT00330499|DRUG|Cisplatin|Weekly Cisplatin 35mg/m2 x 6 doses, IV administration
41141704|NCT00330499|RADIATION|External beam radiation treatment|64Gy reference dose in 32 fractions over 6.5 weeks
41141705|NCT00567606|OTHER|Strength/Weight Training & Drug/Supplement|G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
41141706|NCT00567606|COMBINATION_PRODUCT|Drug/Supplement only|G2 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week, but do not participate in strength/weight training exercises.
41141707|NCT03531892|DRUG|AJM300|AJM300 film-coated tablets.
41141708|NCT03531892|DRUG|Placebo|Placebo matched to AJM300 tablets.
41141709|NCT03688087|DEVICE|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
40977830|NCT05629624|DIETARY_SUPPLEMENT|Outcome reference group/RUSF|We will also recruit 70 three-year-old previously untreated MAM children WHZ \<-2 and ≥-3 z-score, and/or MUAC \<12.5 and ≥11.5 cm as an outcome reference group for a singular assessment. All children (both case \& control) will undergo a baseline nutritional, medical, biological and neuropsychological assessment (EF, ER, EEG and fNIRS). After all the assessments chick-pea based RUSF will be given for 2 months for nutritional rehabilitation.
40977831|NCT00799240|DRUG|Arm A: Pemetrexed Cisplatin|Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
40977832|NCT00799240|DRUG|Arm B Pemetrexed, Cisplatin and MK-0646|Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
40977833|NCT02042885|DRUG|OPB-111001|
40977834|NCT06502574|OTHER|mobile application|The mobile application prepared for rational drug use andchronic disease self-management, suitable for use by olderadults, will be required to be used for 6 months.
40977835|NCT02029625|DRUG|NVP-1205|rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
40977836|NCT02029625|DRUG|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
40977837|NCT02342327|OTHER|switch to non-menthol cigarettes prior to cessation attempt|
40977838|NCT02342327|OTHER|continue smoking menthol cigarettes prior to cessation attempt|
40977839|NCT05533021|OTHER|Training and Consultancy|In order to facilitate the transition to motherhood, theory-based training and counseling was provided to primiparous mothers on self and infant care.
40977840|NCT02582502|OTHER|Hyperbaric Oxygen|The only intervention given will be 100% oxygen under hyperbaric pressure.
40977841|NCT02733991|DEVICE|MiniMed™640G and Suspend before low|"All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.~Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase."
40977842|NCT02733991|DEVICE|MiniMed™640G|Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.
40977843|NCT02024633|DRUG|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
40977844|NCT02024633|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
40977845|NCT01651195|DIETARY_SUPPLEMENT|Probiotic|
40977846|NCT01651195|OTHER|Placebo|
41301757|NCT01364571|BIOLOGICAL|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
41301758|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
41301759|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
41301760|NCT01364571|BIOLOGICAL|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
41301761|NCT01364571|PROCEDURE|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
41301762|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
41301763|NCT01364571|BIOLOGICAL|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
41301764|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
41301765|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
41301766|NCT01364571|BIOLOGICAL|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
41301767|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
40977847|NCT00125801|DRUG|Subcutaneous hydromorphone delivered by pain pen|Subcutaneous hydromorphone delivered by pain pen during breakthrough pain episodes, at max 4 daily. Dose established by opioid conversion from baseline opioids.
40977848|NCT03131050|DRUG|Scopolamine|Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;
40977849|NCT03131050|DRUG|Escitalopram|Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
41301768|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
40977850|NCT03131050|DRUG|Saline|Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
41301769|NCT00108927|BEHAVIORAL|TRANSLATE|
40773945|NCT05197842|DRUG|Glucocorticoids|Orally administered
41141710|NCT03688087|DEVICE|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
41141711|NCT05034237|DEVICE|ND;YAG 1064NM LASER|laser hair removal sessions
41141712|NCT01722097|DRUG|Rocuronium|
41301770|NCT05689658|BEHAVIORAL|Brazilian Diabetes Prevention Program|A Program structured in 7 visits (in group and individual) to guide the improvement of diet quality, self-care, and practice of physical activity
40773946|NCT03906357|DRUG|Pemigatinib|
40977851|NCT02155842|BEHAVIORAL|High intensity endurance exercise|
40977852|NCT02155842|BEHAVIORAL|Moderate continuous endurance exercise|
41141713|NCT01722097|DRUG|placebo|
40977853|NCT06495047|DRUG|Long-acting bronchodilator therapy (LABD)|Long-acting inhaler therapy
40977854|NCT06495047|DRUG|Short-acting bronchodilator therapy (SABD)|Short-acting inhaler therapy
40977855|NCT03632525|DRUG|Ferric carboxymaltose|Single dose of 20 mg/kg ferric carboxymaltose (maximum 1000 mg for patients with haemoglobin \<14 g/dL or 500 mg for patients with haemoglobin ≥14 g/dL).
40977856|NCT00890006|PROCEDURE|Advanced imaging for radiotherapy planning and guidance|Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
40977857|NCT02284594|BEHAVIORAL|text message|series of text messages regarding influenza vaccination
40977858|NCT04931108|DRUG|Nitrendipine/Atenolol|Nitrendipine/Atenolol 5mg/10mg single-pill combination, oral tablet, one pill daily.
40977859|NCT04931108|DRUG|Nitrendipine|Nitrendipine 5mg, oral tablet, one pill daily.
40977860|NCT04931108|DRUG|Atenolol|Atenolol 25mg, oral tablet, one pill daily.
40977861|NCT06023420|DRUG|4 Herbs Formula|4 herbs formula dose: 5g/day
40977862|NCT06208891|PROCEDURE|Robotic myomectomy|Robotic assisted laparoscopic myomectomy
40977863|NCT05151484|DRUG|Teriparatide|Participants will receive 20 μg teriparatide per day via subcutaneous injections. Participants, and if needed a caregiver, will be trained in the subcutaneous administration of teriparatide according to the manufacturer's guidelines. The investigators will measure serum calcium, BSAP and TRAP-5b levels via blood draws at quarterly monitoring visits. If BSAP or TRAP-5b do not increase compared to baseline or decrease after any quarter, participants will be contacted and correct administration will be reviewed. Serum calcium is measured for safety to avoid hypo- and hypercalcemia. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
40977864|NCT05151484|DRUG|Alendronate|Participants will receive 70 mg alendronate p.o. once per week. Participants will be carefully instructed to follow the manufacturer's recommendations for administration. Compliance will be assessed by measurement of the bone turnover markers BSAP and TRAP-5b from blood drawn at quarterly monitoring visits. These markers have been shown to be useful for assessment of turnover changes with treatment. If these markers do not decrease compared to baseline or rise after any quarter, participants will be contacted and correct administration will be reviewed. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
40977865|NCT05505214|DRUG|Bacterial decolonization|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.
40977866|NCT05505214|DRUG|Mometasone furoate 0.1% cream|Mometasone furoate 0.1% cream to be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
40977867|NCT05505214|DRUG|Bacterial decolonization and Mometasone furoate 0.1% cream|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT. Also, mometasone furoate 0.1% cream will be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
40977868|NCT04147221|DRUG|Imipenem-relebactam|After receipt of imipenem-relebactam, participants will have six blood samples collected over 6 hours for determination of imipenem and relebactam concentrations.
40977869|NCT05281991|DEVICE|Doppler ultrasonography|color flow Doppler ultrasonography
40977870|NCT05281991|DEVICE|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
40977871|NCT00817024|DRUG|Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,|3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
40977872|NCT00817024|DRUG|Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules|3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
40977873|NCT00817024|DRUG|Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules|3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
40977874|NCT04430114|DEVICE|branched prosthesis for surgical treatment of thoraco-abdominal aortic aneurysms|"Jotec TAAA spinal loop graft custom made CE equivalent branched prosthesis, compared with the cohort of patients already treated with standard prostheses and / or Gelweave ™ Coselli Thoracoabdominal Grafts."
40977875|NCT01304901|DRUG|montelukast 4 mg granule|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
40977876|NCT01304901|DRUG|Montelukast placebo granüle|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
40977877|NCT06039826|DRUG|LY3437943|Administered SC.
41301771|NCT05689658|BEHAVIORAL|Diet|Hypocaloric diet prescription
41460852|NCT05777694|PROCEDURE|Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle|the investigators performed spinal anesthesia with 27 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
40977878|NCT06039826|DRUG|Ethinyl Estradiol|Administered orally
41141714|NCT05888844|DRUG|INCB099280|Administered as specified in the treatment arm description.
41141715|NCT02393456|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
41460853|NCT03368482|BEHAVIORAL|Brain Gym Exercises|"Participants in the BrainGym Exercises group performed six of the following BG exercises in every training session they took part in: Cross Crawl, Gravity Glider, Arm Activation, Belly Breathing, Hook-ups, Think of an X, Lazy Eights, Elephant, Space Buttons, The Owl, Energy Yawn, Balance Buttons and The Energizer. All exercises were executed from a sitting position but following the main tenets of the Brain Gym® work routine."
41460854|NCT03368482|BEHAVIORAL|Standard exercise program for institutionalized older adults.|Participants in the Standard Exercise group took part in a traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
41460855|NCT01992094|BIOLOGICAL|QIVc|Novartis Investigational Quadrivalent Vaccine
40977879|NCT06039826|DRUG|Drospirenone|Administered orally
40977880|NCT00539448|DRUG|insulin glargine|in combination with insulin Glulisine as bolus regimen
41460856|NCT01992094|BIOLOGICAL|TIV1c|Licensed Influenza Vaccine
41460857|NCT01992094|BIOLOGICAL|TIV2c|Novartis Investigational Vaccine
41460858|NCT02174276|DRUG|Tenofovir disoproxil fumarate|TDF 300 mg tablet administered orally once daily
41460859|NCT02174276|BIOLOGICAL|GS-4774|GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
40977881|NCT00539448|DRUG|insulin glulisine|in combination with insulin Glargine as bolus regimen
40977882|NCT01031069|BIOLOGICAL|GSK Biologicals' HPV vaccine 580299|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
40977883|NCT01031069|BIOLOGICAL|Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
40977884|NCT02760199|DRUG|89Zr-AMG211|Injection of 89Zr-AMG211 for imaging.
40977885|NCT02760199|DEVICE|89-ZrAMG211 PET|89Zr-AMG211 PET scan(s).
40977886|NCT03259204|DEVICE|Adjuvant IPC|This IPC-system delivers sequential circumferential compression. The IPC device is mobile and should therefore not restrict patient mobilization, but can be taken off if the patient wants to mobilize independently.
40977887|NCT02511184|DRUG|Crizotinib|To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
40977888|NCT02511184|DRUG|Pembrolizumab|To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
40977889|NCT03999372|BIOLOGICAL|Hyaluronan binding system|Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)
40977890|NCT03999372|OTHER|ICSI|Normal ICSI procedure
40977891|NCT02519192|DEVICE|V.A.C.Ulta™ Negative Pressure Wound Therapy System|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
40977892|NCT02519192|PROCEDURE|Vac sponge irrigations|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
40977893|NCT02519192|PROCEDURE|ostomy bag|Non Vac Arm will receive ostomy bag applications.
40977894|NCT02519192|PROCEDURE|wet to dry dressings|Non Vac arm will receive wet to dry dressing changes.
40977895|NCT06417476|RADIATION|Short-course radiotherapy|The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose
40977896|NCT06417476|DRUG|Irinotecan|150 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
40977897|NCT06417476|DRUG|Oxaliplatin|85 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
40977898|NCT06417476|DRUG|Calcium Formate|400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
40977899|NCT06417476|DRUG|Fluorouracil|2400 mg/m² iv drip over 48 hours on day 1-2, repeated every 14 days.
40977900|NCT06417476|RADIATION|Long-course chemoradiation|The total dosage was 50Gy consisted of 25 fractions of 2 Gy to clinical target volume without a boost dose
40977901|NCT06417476|DRUG|Capecitabine|825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
40977902|NCT02630550|DEVICE|Cheetah NICOM|The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.
40977903|NCT02630550|DEVICE|Transesophageal echocardiography (TEE)|TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
40977904|NCT03079908|OTHER|da Vinci Skills Simulator®|Initial robotic virtual reality surgical simulator Training (da Vinci Skills Simulator ® System), then laparoscopic dry box evaluation
40977905|NCT03079908|OTHER|LapSim®|Initial laparoscopic virtual reality surgical simulator training (LapSim ® System), then laparoscopic dry box evaluation
40977906|NCT03079908|OTHER|Dry lab box laparoscopic training|No initial simulator training. Dry lab box laparoscopic Training only.
41460860|NCT02248012|DRUG|Everolimus , temozolomide|
40977907|NCT05652946|DEVICE|Tyromotion, Fourier Intelligence, Thera-Trainer, EKSO Bionics|Participants to receive at least 5 sessions with advanced rehabilitation technology including at least one, or multiple, of the following devices: Amadeo, Diego, Myro, Arm Motus EMU, Pelma Motus, Tigo, Balo, EKSO NR. Sessions are 45 (+/- 5) minutes
40977908|NCT05652946|OTHER|Standard inpatient rehabilitation therapy|Standard inpatient rehabilitation therapy without advanced rehabilitation technology
40977909|NCT03033511|DRUG|Placebo for dexamethasone|Placebo for dexamethasone PO twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
40977910|NCT03033511|DRUG|Placebo for rovalpituzumab tesirine|Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
40977911|NCT03033511|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
41460861|NCT05389241|OTHER|Method A|The subjects will perform tasks on the liver phantom (identification of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method A means that the trainings set up is performed first with Method A an after that with Method B.
41460862|NCT05389241|OTHER|Method B|The subjects will perform tasks on the liver phantom (identifikation of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method B means that the trainings set up is performed first with Method B an after that with Method A.
41460863|NCT02111109|DEVICE|Side Stream Dark Field Microscopy|
40977912|NCT03033511|DRUG|Dexamethasone|Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
41460864|NCT02375945|DEVICE|New non-elastic compression kit|Comparison of new non-elastic bandage kit with the currently accepted method
41460865|NCT02375945|DEVICE|current compression stocking Comprinet®|Comparison of new non-elastic bandage kit with the currently accepted method
40977913|NCT02266121|DEVICE|tDCS|Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
41141716|NCT02393456|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
41141717|NCT05800743|DEVICE|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
41301772|NCT05676528|OTHER|Exercise intervention|The participants will carry out a physiotherapeutic exercise intervention over a period of 6 weeks. The exercise intervention is stored in a smartphone app (PhysiApp) and consists of different neck and shoulder exercises. The investigators will provide the training material to the participants and they may keep it after the end of the study. Participants can choose which and how many exercises they would like to do. However, the investigators ask participants to exercise at least three times a week for 20 minutes each time (a total of one hour per week) and to document the training afterwards in the smartphone app. In the first, third and sixth week, the investigators train together with the participants via a virtual platform (e.g. video call via Microsoft Teams) so that the correct execution of the exercise can be checked and questions can be clarified.
41301773|NCT01052168|OTHER|skills training|participants will train using different performance goals (based on different metrics)
41301774|NCT02634879|BEHAVIORAL|Incentive Change|
41301775|NCT03743584|PROCEDURE|Targeted temperature management|Target temperature management at 33°C
41301776|NCT03743584|PROCEDURE|Standard care, early treatment of fever|Standard of care with early treatment of fever
41301777|NCT00029848|DRUG|Rimonabant (SR141716)|
41301778|NCT04031378|RADIATION|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation|SBRT to a single dose of 24 Gy to up to 3 sites
41301779|NCT04031378|DRUG|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months|SBRT 24 Gy to up to 3 nsites, followed by by systemic therapy based on phenotype.
41301780|NCT04041778|OTHER|Catheter ablation|Substrate ablation. Pulmonary vein isolation.
41301781|NCT01300611|DRUG|TXA127 300 mcg/kg/day|Injection, 300 mcg/kg/day for 28 days
41301782|NCT01300611|DRUG|TXA127 1000 mcg/kg/day|Injection, 1000 mcg/kg/day for 28 days
41301783|NCT04460378|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy with Focus on guided exposure
41301784|NCT03665350|DRUG|Insulin|"Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.~The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile."
41301785|NCT05267353|BEHAVIORAL|Exercise intervention program|"It was developed, along with usual care, to prevent restricted ROM in both upper body and limited general physical functioning. Patients in exercise intervention group received verbal instructions about stretching major muscles and phsical activity recommendations from a trained nurse (intervenor), and then received the booklet plus DVD.~The physical therapist who developed and adjusted this program also trained the intervenor. After verifying the intervenor has performed exercise interventions were consistent with the physical therapist, he/she was responsible for all interventions. Therefore, if pain or discomfort persists for more than an hour, the patient should inform the intervenor. The intervention group patients also received telephone follow-up from the intervenor every two weeks until the end of the intervention."
41301786|NCT04769960|DIAGNOSTIC_TEST|MRI Studies|MRI scans will be performed on a 1.5T MRI scanner. Department of Radiology MRI SafetyGuidelines will be followed except regarding breast tissue expanders. Conventional MRIstudies will be performed using the standard of care clinical sequences.
41301787|NCT04769960|BEHAVIORAL|Patient Reported Outcomes|Participants will fill out questionnaires before, immediately after, and approximately 3 months following the MRI examination +/- 1 month to evaluate for any pain or perceived changes with the breast tissue expander. The first questionnaire will obtain background participants information as well as establish a baseline pain level, the second questionnaire will evaluate any changes in pain after undergoing the MRI examination, and the last questionnaire will evaluate long term changes in pain. The patient reported outcome questionnaire will be optional at 3 months post-MRI +/-1 month.
41301788|NCT02742077|DEVICE|Robotic-assisted peripheral vascular intervention|Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
41301789|NCT05590663|OTHER|Physiotherapy|routine referral-based physiotherapy treatment for patients with knee osteoarthritis
41301790|NCT03740841|BEHAVIORAL|Interactive story teller LUNII|Use of the interactive story teller LUNII by the child from the pre-operative visit to the discharge.
41301791|NCT02118610|DRUG|L-tetrahydropalmatine (30mg)|Active comparator
40977914|NCT01280916|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
40977915|NCT05651451|DEVICE|Laser acupuncture|24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point
41141718|NCT05800743|DEVICE|GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)|Endovascular aortic repair of the ascending aorta/aortic arch
41141719|NCT05800743|PROCEDURE|Surgery|Open surgical repair of the ascending aorta and/or the aortic arch
41301792|NCT02118610|DRUG|Sugar pill|Placebo
40977916|NCT05651451|DIETARY_SUPPLEMENT|energy-restricted diet|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
40977917|NCT05713721|DEVICE|Transcranial magnetic stimulation (TMS)|TMS over the left primary motor cortex will be performed. To investigate sensorimotor integration, an electrical stimulus on the right index finger will precede the TMS pulse.
40977918|NCT05713721|OTHER|Video-based clinical examination|A standardized neurological examination will be performed and video taped. The videos will be rated by movement disorder specialists, wo are blinded for the symptom and mutation status of the participants.
40977919|NCT05713721|OTHER|24 hours drug withdrawal of dopaminergic medication|Examinations will be done under chronic dopaminergic treatment and after a 24 hours dopaminergic drug withdrawal.
40977920|NCT05713721|OTHER|Evaluation of deep brain stimulation|Examinations will be done before and after implantation of deep brain stimulation (clinically optimal stimulation vs. switched off stimulation)
40977921|NCT05615389|DRUG|Medicinal Cannabis - C12T12|"Participants randomised to receive C12T12 Ruby Balanced Oil will commence with 0.008ml/kg/day (0.1 mg/kg/day THC) in two divided doses, and titrate up in four steps (increase by 0.008ml/kg/day every four days) over 16 days up to a maintenance dose of 0.04ml/kg/day (0.5mg/kg/day THC) in two divided doses, with a ceiling dose of 2ml/day (25mg/day THC) for participants weighing 50kg or more. The maintenance dose will then be continued from day 17 until day 42.~Down-titration will occur for 16 days after the end of study visit, in the reverse of the up-titration period."
40977922|NCT05615389|DRUG|Medicinal Cannabis - C20T5|Participants randomised to the C20T5 Ruby CBD Oil will receive a matched volume to the C12T12 arm during the up-titration, maintenance, and down-titration phases.
40977923|NCT05985018|OTHER|Traditional Diet|Provided as an educational leaflet
40977924|NCT05985018|OTHER|Mediterranean Diet|Provided as an educational leaflet
40977925|NCT03559257|DRUG|Galcanezumab|Administered SC.
40977926|NCT03559257|DRUG|Placebo|Administered SC.
40977927|NCT05601258|OTHER|Age, gender, hospitalization and mortality rates will be compared|Age, gender, hospitalization and mortality rates will be compared
40977928|NCT05976750|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
40977929|NCT05976750|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
40977930|NCT01183897|BIOLOGICAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|"This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops."
40977931|NCT05796765|BIOLOGICAL|Micronized DHACM 40 mg|Injection of 40 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
40977932|NCT05796765|BIOLOGICAL|Micronized DHACM 100 mg|Injection of 100 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
40977933|NCT05796765|DRUG|Saline|Injection of 2.5 ml, 0.9% Sodium Chloride, USP
40977934|NCT01373437|DEVICE|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
40977935|NCT05439226|OTHER|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
40977936|NCT00115050|DRUG|TMC114|
40977937|NCT00634166|DRUG|Sulfamylon® For 5 % Topical Solution|Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
40977938|NCT00634166|DRUG|Topical Antimicrobial/Antifungal Medications|'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.
40977939|NCT04071730|DIETARY_SUPPLEMENT|Immulina Dietary Supplementation|Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
40977940|NCT04597827|OTHER|Metacognition tests|Test on episodic or semantic memory
40977941|NCT04693325|PROCEDURE|Prolonged normothermic machine perfusion|First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted \[NMP1\]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) \[PNMP3\] and consequently 6 hours (n=6) \[PNMP6\].
40977942|NCT05738005|OTHER|Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)|Amyloidosis patients will use MyFitnessPal application to track dietary intake and use of herbal/alternative supplements in from week 2-9. Patient's usage of the application and questionnaires completed by the patient at the start, Week 2 and Week 10 will determine feasibility.
40977943|NCT01051024|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
40977944|NCT01051024|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
40977945|NCT05513508|PROCEDURE|Protocolized rotational use of interfaces|The NIV mask will be changed every 6 hours, alternating two different interfaces between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask.
40977946|NCT05513508|PROCEDURE|Standard of care|Mask will be chosen according to the standard of care of the participating centers among the three types of masks available i.e., oro-nasal, total face or hybrid mask. Interface will be changed in case of discomfort judged by the patient as unbearable or in case of the presence of a pressure sore.
40977947|NCT02175589|OTHER|Colchicine Cessation|Colchicine Cessation
40977948|NCT03626922|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
40977949|NCT03626922|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
40977950|NCT03626922|DRUG|Oxaliplatin|"Oxaliplatin-Dose level1: 85 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~Dose level 2: 120 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~The MTD dose of oxaliplatin in the study combination of Cohort 2 will be the recommended Phase II dose (RP2D) for the cohort expansion."
40977951|NCT03626922|DRUG|Dexamethasone|Dexamethasone-4 mg by mouth twice daily on: the day before, the day of, and the day after each dose of pemetrexed.
40977952|NCT03626922|DIETARY_SUPPLEMENT|Folic Acid|Folic Acid-400 micrograms by mouth daily starting 5 days prior to first dose of pemetrexed and continue daily to include 21 days after the last dose of pemetrexed.
40977953|NCT03626922|DIETARY_SUPPLEMENT|Vitamin B-12|1000 micrograms administered intramuscularly 7 days prior to the first dose of pemetrexed, every 9 weeks, and should continue until 3 weeks after the last dose of pemetrexed.
40977954|NCT02311010|DRUG|Advagraf|daily dose adapted according to Cyp 3A5 polymorphism
40977955|NCT01327885|DRUG|Eribulin mesylate 1.4 mg/m^2 intravenous|Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
40977956|NCT01327885|DRUG|Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV|Administration of dacarbazine at a dose of 850 mg/m\^2, or 1,000 mg/m\^2, or 1,200 mg/m\^2 selected by the Principal Investigator \[PI\] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
40977957|NCT03029377|OTHER|Posture Study, Autonomic Function Tests, and a Stress Test|Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
40977958|NCT00926276|PROCEDURE|Fundoplication|Fundoplication
40977959|NCT03090152|PROCEDURE|Periarticular injection (Deep injection)|"Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata."
40977960|NCT03090152|PROCEDURE|Periarticular injection (Superficial injection)|Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.
40977961|NCT03090152|DRUG|Bupivacaine|EPCA: Bupivacaine 0.06%.
40977962|NCT03090152|DRUG|Placebo|EPCA: Saline.
40977963|NCT03981211|DRUG|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
40977964|NCT03981211|DRUG|Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily
41141720|NCT03367416|BEHAVIORAL|NIATx model|"The NIATx model engages organizations through a multi-clinic learning collaborative and coaching. NIATx teaches organizations how to implement change by using their own organization as the teaching mechanism. Key components of the model include:~1. educating executives on how to promote effective process change techniques~2. training staff teams in the theory and practice of organizational change techniques~3. training staff to develop and implement a process improvement intervention~4. implementing a sustainability plan to institutionalize change and avoid reverting to previous methods"
40977965|NCT05083442|DEVICE|Low Level Laser Therapy|Non-surgical cosmetic treatment which can be used by individuals intending to reduce size of the mid-section
40977966|NCT05083442|OTHER|Sham (placebo)|Use of sham (placebo) option
41301793|NCT04019093|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
40977967|NCT03187093|DRUG|Vortioxetine|10-20 mg once daily for 8 weeks
41301794|NCT04019093|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
40977968|NCT03187093|DRUG|Escitalopram|10-20 mg once daily for 8 weeks
40977969|NCT03064360|OTHER|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.
40977970|NCT03064360|DEVICE|Patient Activity|Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
40977971|NCT03064360|BEHAVIORAL|Questionnaires|Symptom and quality of life questionnaire at baseline, and every week following to study completion
40977972|NCT00589563|BIOLOGICAL|anti-thymocyte globulin|0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
40977973|NCT00589563|DRUG|cyclophosphamide|60mg/kg on days -5 and -4 from stem cell transplant
40977974|NCT00589563|DRUG|etoposide|60mg/kg on day -4 from stem cell transplant
40977975|NCT00589563|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
40977976|NCT00589563|DRUG|melphalan|Melphalan 140 mg/m2 on day -4 from stem cell transplant
40977977|NCT00589563|DRUG|methotrexate|For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
40977978|NCT00589563|DRUG|sirolimus|"Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.~Pediatric Patients \<40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose"
40977979|NCT00589563|DRUG|tacrolimus|0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
40977980|NCT00589563|PROCEDURE|allogeneic hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
40977981|NCT00589563|PROCEDURE|hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
40977982|NCT00589563|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
40977983|NCT00589563|PROCEDURE|peripheral blood stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
40977984|NCT00589563|RADIATION|total-body irradiation|1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
41301795|NCT06242236|OTHER|The respiratory effort parameters guide sedative dosage.|The intervention involves the measurement of respiratory effort using P0.1 and Pocc then calculating to dynamic transpulmonary pressure swing (Predicted ΔPL) to adjust sedative drug dosage.
41301796|NCT00900380|OTHER|flow cytometry|
41301797|NCT00900380|OTHER|immunological diagnostic method|
41301798|NCT00900380|OTHER|laboratory biomarker analysis|
41301799|NCT05528042|OTHER|Heart rate and respiratory rate measurement|"Validation of the performance of the heart rate (HR) measurement using COBOX medical device compared to a measurement carried out by applying the reference processes for taking measurements via a CE marked device.~Evaluation of the performance of the respiratory rate (RR) measurement using COBOX medical device compared to a measurement carried out by a reference method of manual counting"
41301800|NCT05128435|DIAGNOSTIC_TEST|Blood sample|Blood sample taken 3 to 5 months after the infection
41460866|NCT04809714|DEVICE|Blood Flow Restriction with Delfi Tourniquet System Cuff|Postoperative rehabilitation will occur up to twice a day for 5 days a week for 2 weeks using a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of 60-100%. For each physical therapy session, participants will undergo therapy following a standardized protocol of 3-5 difference exercises each with 4 sets total in addition to NMES.
41460867|NCT04809714|OTHER|Routine Post-operative Physical Therapy|The control group with undergo a post-op therapy protocol that mirrors that of the intervention group except that they will use a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of only 10%. Participants will use a neuromuscular electrical stimulation device operating at a sub-therapeutic level.
41460868|NCT05047185|DRUG|Deucrictibant low dose|Deucrictibant softgel capsules for oral use (PHVS416)
41460869|NCT05047185|DRUG|Deucrictibant high dose|Deucrictibant softgel capsules for oral use (PHVS416)
40977985|NCT03530098|DEVICE|BoneAgeModel|BoneAgeModel is an Artificial Intelligence tool that takes in a hand radiograph and gender, and outputs the skeletal (bone) age. The intervention involves using this tool as a factor in the clinical decision making process of the participating radiologists. The radiologist's decision will be considered final.
40977986|NCT00814528|DRUG|5-ALA plus Blu-Light|20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
40977987|NCT00814528|DRUG|5-FU, Imiquimod or treatment with cryotherapy|Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
40977988|NCT02645110|DEVICE|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
40977989|NCT02645110|DEVICE|Tap water|Washing hand with water alone in comparison to hand washing with soap
40977990|NCT04638023|DEVICE|Arabin pessary|Arabin pessary was inserted intravaginally electively in women with cervical insufficiency (history based) or as emergency in those with short cervix on ultrasound.
40977991|NCT01842698|DEVICE|ultrasoundguided paravertebral catheter|
40977992|NCT06030791|DIAGNOSTIC_TEST|MRI|MRI of operated knee
40977993|NCT01322360|DRUG|Morphine Sulfate|
41301801|NCT01842893|DRUG|Fentanyl Ethypharm|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
41301802|NCT04090931|PROCEDURE|Orthodontic treatment|leveling and aligning stage in orthodontics
41301803|NCT02269059|DRUG|MK-7680|MK-7680 10 mg and 100 mg capsules
41301804|NCT05424900|BEHAVIORAL|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
41301805|NCT03293199|PROCEDURE|Chest tube drainage|In this group, in the supine position and subsequent to prepping and draping and local anesthesia administration via lidocaine 2%, F16 or F20 (based on patients physical status) sterile plastic tube will be implemented at the level 4th or 5th intercostal space through the midaxillary line. Subsequently, the external end of the tube will be connected to water sealing bottle and water bubbles coming out will be considered as proper chest tube insertion.
41460870|NCT05047185|DRUG|Placebo|Matching placebo capsules for oral use
41460871|NCT02992457|DRUG|Sofosbuvir|Sofosbuvir 400 mg daily.
41460872|NCT02992457|DRUG|Ribavirin|Ribavirin 1000-1200 mg daily
41460873|NCT02992457|DRUG|Pegylated-interferon alfa-2a|Pegylated interferon alfa-2a once weekly for 3 months
41460874|NCT02992457|DRUG|Simeprevir|Olysio once daily.
41460875|NCT02992457|DRUG|Daclatasvir|Dakla once daily for three months.
41460876|NCT02992457|DRUG|Ritaprevir, paritaprevir, ombetasvir|Querevo for three months
41460877|NCT02992457|DRUG|Sofosbuvir and Ledipasvir|Once daily for three months
41460878|NCT02992457|DRUG|Salvage therapy|three months in repeated treatment failure
41460879|NCT02364869|DIETARY_SUPPLEMENT|Fructooligosaccharide|Patients will be evaluated at baseline, week 6 and 12.
41460880|NCT02364869|DIETARY_SUPPLEMENT|Maltodextrin|Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
41301806|NCT03293199|PROCEDURE|Repetitive needle aspiration|In this group, prior to needle aspiration, patients will take the semi-supine position. Subsequent to local anesthesia via lidocaine 2%, as well as prepping and draping, G16 intravenous angiocath will be inserted through midclavicular line at the level 2nd or 3rd intercostal space. Air bubble inside the lidocaine syringe will be considered as needled entrance to pleural cavity, thus 5-10 cm of the angiocath will be import to inside of the cavity. The catheter needle will be removed and catheter will be fixed using sterile sticks. A three-way valve will be connected to external end of the catheter and a 50 ml syringe will be connected to the valve. The air suction will be performed using 50 ml syringe till end of the air suction or up to 3.5 liters of air suctioning.
41301807|NCT03516292|DIAGNOSTIC_TEST|Urinary Nerve Growth Factor|The subjective patient's discomfort regarding the vaginal prolapse problems and urinary incontinency symptoms will be assessed through the following questionnaires: (a) ICIQ-OAB (b) ICIQ FLUTS (c) ICIQ-VS. Determination of the bladder neck of urethra in midsagittal plane using a transvaginal two-dimensional ultrasound machine at lithotomy position in rest (point OA) and on Valsalva maneuver (point OB). Bladder Neck Mobility is defined as the difference from point OA to OB. BWT is determined and measured as the hypoechoic layer between two hyperechoic layers that is recognized as the urothelium and the perivesical tissue using a transvaginal two-dimensional ultrasound machine at lithotomy position. The measurement is performed with a bladder volume \<30 ml and is taken place in 3 different bladder sites: (a) the thickest part of the bladder triangle, (b) the dome of the bladder in the midline, (c) the anterior wall of the bladder. NGF will be measured in urine sample.
40977994|NCT01059799|DRUG|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
40977995|NCT01059799|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
40977996|NCT02366520|DEVICE|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
40977997|NCT05370222|BEHAVIORAL|Dietary weight loss intervention|Based on an energy assessment from the data collected at T0 (energy intake, physical activity level, and resting metabolism), individualized nutritional advice will be given during an interview in order to propose a dietary rebalancing and a light caloric restriction. Caloric restriction will be generated to decrease body weight by ≈ 0.5 to 1 kg per week, as advised in several publications. As for the dietary rebalancing, it will concern in particular the distribution of macronutrients and their nature (glycemic index, nature of lipids), the fibers intake, or the reduction of consumption of refined and/or energy-dense foods based on the ANSES Recommended Dietary Allowances and on the food consumption guidelines of the National Nutrition and Health Program.
40977998|NCT01850550|BEHAVIORAL|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
40977999|NCT00809276|DRUG|Busulfan, Fludarabine, Cytoxan|"Busulfan once a day for 4 days~Fludarabine once a day for 4 days~Bone marrow transplant~Cytoxan two doses"
40978000|NCT03876197|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells|Autologous adipose-derived mesenchymal stem/stromal cells
40978001|NCT03876197|OTHER|Placebo|Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%
40978002|NCT06302504|BEHAVIORAL|Nature-based mindfulness program|only one arm is included in this study
40978003|NCT01647620|DRUG|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
41141721|NCT00623649|DRUG|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
41141722|NCT00623649|DRUG|Placebo|Dose escalation study with a full review of all safety data following each cohort.
41141723|NCT06303128|DRUG|Amoxicillin 250 MG|Liquid amoxicillin 250mg PO
41141724|NCT06303128|DRUG|Placebo|Given prior to amoxicillin 250mg in one-dose group
41141725|NCT06303128|DRUG|Amoxicillin 62.5mg|Given first in two-dose group, liquid amoxicillin 62.5mg PO
41141726|NCT06303128|DRUG|Amoxicillin 187.5mg|Given second in two-dose group, liquid amoxicillin 187.5mg PO
41141727|NCT00303537|DRUG|metformin|
41141728|NCT01030263|OTHER|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
41141729|NCT01030263|OTHER|Random four-quadrant biopsies.|Random four-quadrant biopsies.
41141730|NCT01231074|DRUG|Metformin|Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
41141731|NCT02132195|DRUG|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
41141732|NCT05086432|OTHER|Sputum-guided management|As previously described.
41141733|NCT05086432|OTHER|Standard of Care|As previously described.
41141734|NCT02932124|DEVICE|mechanical chest compression device|
41141735|NCT03942094|DRUG|Nilotinib|"Nilotinib (Tasigna ®), capsules of 150 mg~Nilotinib 2 capsules of 150 mg, orally, twice daily"
41141736|NCT00000178|DRUG|Prednisone|
40978004|NCT01647620|DRUG|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
41141737|NCT05911243|PROCEDURE|Acupressure Therapy|Undergo auricular acupressure
41141738|NCT05911243|OTHER|Best Practice|Receive usual care
41141739|NCT05911243|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41141740|NCT05911243|OTHER|Questionnaire Administration|Ancillary studies
41141741|NCT01073722|DEVICE|Placement of double lumen tube for one-lung ventilation|The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.
41141742|NCT01073722|DEVICE|Placement of EZ- Blocker for one-lung ventilation|Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
41301808|NCT06179654|BEHAVIORAL|Preoperative pelvic floor physical therapy|Pelvic floor physical therapy to start before prostate surgery rather than after surgery.
41301809|NCT03689283|OTHER|Dry Needling|Individuals randomized to the Dry Needling Group will receive dry needling to latent trigger points of the gastrocnemius muscle
41301810|NCT03689283|OTHER|Sham Dry Needlling|Individuals randomized to the Control group will receive sham needling to the gastrocnemius muscle
41460881|NCT03117205|OTHER|Application of Kinesio Taping®|The technique was applied following the methods described in the original method for patellofemoral instability
41460882|NCT03117205|OTHER|Kinesio Taping® placebo application|Simulation of the application of the Kinesio Taping® technique.
40773947|NCT05041504|BEHAVIORAL|Peer navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for prostate cancer via the True North Peer Navigation website. Participants will be matched with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Participants will also have access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer.
40773948|NCT05041504|OTHER|Active wait list control|Participants in the active wait list control group will receive usual care and access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer. After completion of the study, patients in the active wait list control group will be matched with a peer navigator.
41141743|NCT02589613|DIETARY_SUPPLEMENT|tap water|300ml tap water via nasogastric tube
41141744|NCT02589613|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g Glucose via nasogastric tube
41301811|NCT02274324|DIETARY_SUPPLEMENT|different diets|3 different diets: A\\B\\C
41301812|NCT01778088|DRUG|I-131-CLR1404 Injection|
41301813|NCT00985855|DRUG|cisplatin, vinorlebine, cetuximab|patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
41301814|NCT00985855|DRUG|cisplatine, etoposide, cetuximab|patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
41301815|NCT01798706|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
41301816|NCT01798706|DRUG|Placebo|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
41141745|NCT02589613|DIETARY_SUPPLEMENT|Fructose|300ml tap water with 25g Fructose via nasogastric tube
41301817|NCT01798706|DRUG|Antidiabetic background therapy|Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide \>10 mg, gliclazide \>160 mg), meglitinides (except repaglinide \>6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
41301818|NCT04593940|DRUG|Infliximab|study drug or matching placebo
41460883|NCT01135264|BEHAVIORAL|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur \& Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
40773949|NCT01972659|DRUG|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
41141746|NCT06359977|OTHER|Quantitative EEG monitoring and beside ultrasound evaluation|After successful spontaneous breathing trial, neurocritical patients undergo at least 2 hours of quantitative EEG monitoring before extubation. Additionally, bedside ultrasound assesses the thickness and variability of the diaphragm, intercostal muscles, rectus abdominis, transversus abdominis, and external oblique muscles. The sputum volume for the 24 hours prior to extubation is also recorded. Reintubation within 48 hours after extubation is defined as weaning failure.
41141747|NCT04867772|OTHER|Home based rehabilitation|
40773950|NCT01972659|DRUG|Magnesium Sulphate|"Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion"
40773951|NCT01972659|DRUG|sugammadex|4 mg/kg iv bolus at the end of the surgery
41141748|NCT03681067|DRUG|GSK1070806|GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
41141749|NCT03681067|DRUG|Placebo- sodium chloride|Placebo injectable solution will be delivered via intravenous infusion as a single infusion
41301819|NCT04593940|DRUG|Abatacept|study drug or matching placebo
41301820|NCT04593940|DRUG|Remdesivir|Standard of Care
41301821|NCT04593940|DRUG|cenicriviroc (closed to enrollment as of 3-Sep-2021)|study drug or matching placebo
41301822|NCT03041116|DRUG|Fosmetpantotenate|Daily dosing
41301823|NCT03041116|DRUG|Placebo|Daily dosing
41460884|NCT01135264|BEHAVIORAL|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
41460885|NCT03857724|PROCEDURE|prolapse surgery|prolapse surgery
41460886|NCT01691430|DIETARY_SUPPLEMENT|2 cranberry capsules|Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
41460887|NCT01691430|DIETARY_SUPPLEMENT|Placebo|Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
41301824|NCT04313335|DRUG|Duloxetine|Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.
41301825|NCT01913249|PROCEDURE|LIFT|Ligation of intersphincteric fistula tract
41301826|NCT05391984|OTHER|Activity oriented treatment|15 patients will be treated with activity oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
41301827|NCT05391984|OTHER|Structural oriented treatment|15 patients will be treated with structural oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
41301828|NCT03445013|DRUG|SB414 6%|Twice daily
41301829|NCT03445013|DRUG|Vehicle|Vehicle Comparator
41301830|NCT02996539|OTHER|Clinical examination and laboratory measurements|Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
41301831|NCT05649072|BEHAVIORAL|Genetic Testing and Counseling|Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
41460888|NCT04347096|BEHAVIORAL|mHealth Intervention|"The mHealth Intervention will provide sedentary workers with evidence-based information on diet, physical activity and sedentary behavior, and tailored feedback on their responses to daily records. Key features of this intervention will include individualized feedback and multimedia presentation in the form of web app. The intervention group will also receive a reliable device for wireless physical activity tracking for monitoring step counts.~The web app will consist of seven major components: (1) daily healthy eating goals and records; (2) daily physical activity goals and records; (3) daily stand-up goals and records; (4) advice and reminder; (5) educational and motivational tools; (6) personal and team health ranking; and (7) online social network. In addition, the intervention will be enhanced with follow-up booster coaching calls bi-monthly at 2, 4, 6, 8 months after the 12-week intervention."
40978005|NCT05526495|BEHAVIORAL|Reducing preoperative low-value test ordering|A multi-component approach will be used:1) An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing non-urgent surgery will be ordered at the discretion of an anesthesiologist based on their clinical assessment. Adoption of the policy change will be facilitated by a local champion using an engagement and education program for anesthesiologists, surgeons, pre-admission clinic nurses and administrative staff; 2) The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies. A train-the-trainer model will be used; 3) The departments will commit to supporting the change in policy. Nurses within preoperative clinic will be coached to feel comfortable calling the anesthesiologist about any pre-op tests ordered, and the Pre-Admission Unit will have the authority to cancel tests that deem unnecessary. Check boxes will be removed from medical order forms
40978006|NCT05511051|DRUG|Fruquintinib|Fruquintinib
40978007|NCT05511051|DRUG|HAIC|HAIC
40978008|NCT04217876|DIAGNOSTIC_TEST|post-processing analysis of cardiac imaging (strain echocardiography)|"A dedicated software package for two-dimensional speckle tracking strain analysis (XStrain™, Esaote, Florence, Italy) was used to quantify both ENDO and EPI strains. Our echocardiographic imaging acquisition protocol for 2DSTE consisted in the acquisition of three consecutive cardiac cycles from non-foreshortened apical views (4, 2, and 3 chambers) obtained during breath hold. Frame-by- frame displacement of ENDO and EPI points was automatically evaluated, generating strain curves for each segment.~The tracking quality was verified for each segment, and subsequent manual adjustments were performed, when required. All data were analyzed with the aid of Fourier techniques, which ensure greater accuracy using the periodicity of the heart motion."
40978009|NCT00632411|DRUG|Nicotine Patch|"Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment."
40978010|NCT00632411|BEHAVIORAL|Tobacco Quit Line Program|"Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention."
40978011|NCT06049498|DRUG|Mongolian Medicine ZhenBao Pills|Mongolian Medicine ZhenBao Pills, orally, 15 pills each time, twice a day.
40978012|NCT06049498|DRUG|Mongolian Medicine ZhenBao Pills Placebo|Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
41141750|NCT05918549|DEVICE|Motion Analysis in Musculoskeletal Oncology|Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques
41301832|NCT05649072|BEHAVIORAL|Screening Form|Participant will be answering demographic details
41460889|NCT04347096|BEHAVIORAL|Control Intervention|The control intervention group will receive educational tools, which will provide knowledge on benefits of physical activity and healthy eating, health risks of sitting and unhealthy diets, and recommendations on physical activity and a balanced healthy diet for good health.
41460890|NCT00404625|BEHAVIORAL|Risk factors for infections due to ESBL+ Enterobacteriaceae|
41460891|NCT00404625|BEHAVIORAL|Risk factors for inadequate initial antimicrobial therapy|
41460892|NCT00404625|BEHAVIORAL|Overall and 30-day mortality in bad first antibiotic therapy|
40773952|NCT04967456|DIAGNOSTIC_TEST|Measurement of pulpal blood flow of traumatised tooth|"Measurement of the blood flow of the dental pulp will be performed, using a laser doppler flow monitor mVMS-LDF2TM (Moor Instruments Ltd Millwey Axminster Devon, UK), emission wavelength 785nm±10nm, dual-channel laser Doppler monitoring option. Two probes will be used, each consisting of one afferent and one efferent optic fiber to conduct the light to and from the tooth surface. The probe is stainless steel needle-like tube, which is 10-80 mm long and 1.5 mm in the diameter. The utilised parameter settings will be: Average power - 1.0 mV; Diameter of the probe - 1.5 mm; Frequency - 40 Hz; Monitoring time-180 seconds (sec)"
40773953|NCT04282915|OTHER|Reducing Stigma among Healthcare Providers (RESHAPE)|Mental health service users are trained using Photo Voice to develop recovery story testimonials. They then participate in primary care providers mental health Gap Action Programme training. In addition, aspirational figures are trained to provider testimonials and conduct myth-busting.
40773954|NCT04282915|OTHER|mental health Gap Action Programme|The mental health Gap Action Programme is a training program for primary care providers in mental health services. The curriculum has been developed by the World Health Organization and was adapted in Nepal and certified by the Ministry of Health.
40773955|NCT05638113|PROCEDURE|Pleural injection of autologous blood|120 ml autologous blood will be drawn from simple venous puncture and immediately injected through the drain into the pleural cavity followed by flushing with 50ml of saline.
41141751|NCT05766202|OTHER|An group intervention for multiparas with fear of childbirth|The intervention consists of 4 group meetings, three during pregnancy and once after giving birth. It also includes a phone call.
41141752|NCT05513027|DEVICE|Augmented Whole-body Scanning via Magnifying PET|-Added at the end of the SOC PET/CT scan. Will take approximately 3-5 minutes longer.
40773958|NCT04488419|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
40773959|NCT04488419|DRUG|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
40773960|NCT04462289|BEHAVIORAL|Proactive Outreach|Motivational electronic offer of tobacco cessation support via motivational texting program with care connection to patient's choice of smoking cessation programs
40773961|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 21 mg administered SC
40773962|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 35 mg administered SC
40773963|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 70 mg administered SC
40773964|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 140 mg administered SC
40773965|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 15 mg administered SC
40773966|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 25 mg administered SC
40773967|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 50 mg administered SC
40773968|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 100 mg administered SC
40773969|NCT04189484|BIOLOGICAL|Placebo|Placebo administered SC
40773970|NCT00797303|DRUG|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
41141753|NCT05513027|DEVICE|PET/CT|-Standard of care
41141754|NCT00210145|BEHAVIORAL|Aesthetic care|
41141755|NCT02411188|BEHAVIORAL|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
41141756|NCT04690309|DRUG|Treatment with human insulin preparations or treatment with insulin analogues|The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting \< 100 mg/dl (5.5 mmol/L) and postprandial \< 140 mg/dl (7.8mmol/L)
41141757|NCT00300339|DRUG|SL650472, Clopidogrel|
41141758|NCT05637944|PROCEDURE|oro tracheal intubation|chest trauma requiring oro tracheal intubation
40773971|NCT05295472|BEHAVIORAL|Grapholearn|GL is a computer game based on the phonics-method (i.e., graphem-phoneme correspondence). It was developed at Jyväskylä University in Finland, in several languages, among others also for Swedish.
40773972|NCT05295472|BEHAVIORAL|Vector|A computer game focusing on children's development of mathematic skills
40773973|NCT05295472|BEHAVIORAL|Usual schooling|No GL or Math computer games, only the usual schooling
40773974|NCT00690339|DEVICE|Style 410 Silicone-Filled Breast Implants|Breast Implant Surgery
40773975|NCT04894682|BIOLOGICAL|Vaccine inoculation against SARS-CoV-2|Inoculation with any type of approved vaccines according to the standard or recommended dose
40773976|NCT06560788|OTHER|collection of cerebrospinal fluid|CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis
41141759|NCT01721694|DRUG|azithromycin 1.5%/Loteprednol 0,5% + placebo|1 drop, AO, QID
41141760|NCT01721694|DRUG|azithromycin 1.5% + Loteprednol 0,5% (separately)|1 drop, QID, AO
41141761|NCT01527643|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
41141762|NCT06341309|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
40773977|NCT03741270|BIOLOGICAL|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).
40773978|NCT00279695|PROCEDURE|high frequency ultrasound examination|high frequency ultrasound examination of the eye
40773979|NCT04605666|BIOLOGICAL|CD19-CAR-T2 Cells|CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.
40773980|NCT02076711|DRUG|Metoprololsuccinate|
40773981|NCT02076711|DRUG|Placebo|Placebo
40773982|NCT04392076|PROCEDURE|Image Guided Ablation|Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer
40773983|NCT04667156|DRUG|SHR6390|SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles
40773984|NCT03064607|OTHER|Fluid collection|Fluids tested for biomarker S100beta
40773985|NCT03869112|BEHAVIORAL|Physical activity intervention|Physical activity group will be given a charge 2 FitBit device to monitor their PA specially steps count, step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home-based intervention.
40978013|NCT04489667|OTHER|+STEP Implementation|All patients receiving care at five RWHAP-funded clinics will receive the intervention (+STEP), in which patient-reported outcomes (PROs) on mental health and substance use disorder (SUD) will be integrated into routine care, targeted training will be provided for frontline clinicians on best practices for mental health and SUD treatment, and telemedicine for mental health and SUD will be offered to patients in need of expanded access to services.
40978014|NCT01829334|OTHER|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
41301833|NCT02839967|OTHER|Photobiomodulation|Intraoral photobiomodulation is applied in the temporal, medial and lateral pterygoid, bilateral, totaling 4 points of application of phototherapy. The researcher who will perform the treatments will receive the equipment with the stylus activates and pre-programmed dose, an eye protection (glasses, opaque) will be used by the participants, to protect the eyes, because the same does not cause any sensation to volunteer. The technique is used, contact an area. The individual is positioned supine on a stretcher, with the legs supported on a foam roller 20 cm in diameter, the head supported on a pillow, to accommodate her comfortably in a resting posture, prompted the opening of the mouth and placing the tip of photobiomodulation in sections as described below, with 2 minutes interval between one application and another for rest with the mouth closed.
41301834|NCT02839967|OTHER|Photobiomodulation placebo|The volunteers will be subjected to the same Group intervention, Photobiomodulation and the researcher will receive the equipment unaware if the pen that will apply the phototherapy is active or placebo, only the research coordinator will have this knowledge, and for this group the researcher will receive placebo pen. Fits the caveat that, when the voluntary participation, will be held with the active pen treatment.
41301835|NCT01234012|BIOLOGICAL|IMF-001|subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
41301836|NCT05664048|BEHAVIORAL|Dry heat application|Self- dry heat application on the foot during menstrual period with pain.
41301837|NCT02998554|DRUG|SHP640|Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
41301838|NCT02998554|DRUG|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
41301839|NCT01158495|PROCEDURE|Intubation with a cuffed ET Tube|
41301840|NCT01158495|PROCEDURE|CT scan Radiation|
41301841|NCT04691752|OTHER|Audit|Audit from clinical records
41301842|NCT01576016|DEVICE|Accent MRI system (lead safety)|Patients implanted with an Accent MRI system
40978015|NCT01829334|OTHER|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
40978016|NCT01829334|OTHER|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
40978017|NCT01829334|OTHER|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
40978018|NCT03413566|OTHER|Clinical diagnosis|A clinical diagnosis of cerebral palsy given by a pediatrician at a habilitation center in Norway.
40978019|NCT02159014|BEHAVIORAL|Facilitated group-based aerobic dance|Physical activity facilitated by instructor
40978020|NCT02159014|BEHAVIORAL|Online, video prompted, individual aerobic dance|Supported online activity intervention
40978021|NCT02159014|BEHAVIORAL|Facilitated group-based nutritional intervention|Education, skill training, access and use of NHS Change4Life Eat Well web resource
40978022|NCT02159014|BEHAVIORAL|Self-paced online aerobic dance activity|Self paced physical activity
40978023|NCT02159014|BEHAVIORAL|Individual self-paced nutritional intervention|Individual use of online nutritional advice resources.
41301843|NCT01576016|DEVICE|Accent MRI system (with MRI scan)|Patients implanted with an Accent MRI system will receive an MRI scan
41301844|NCT05118958|DRUG|KVD824 Prototype 1 modified-release tablet|300 mg modified-release tablet
41301845|NCT05118958|DRUG|KVD824 Prototype 2 modified-release tablet|300 mg modified-release tablet
41301846|NCT05118958|DRUG|KVD824 Immediate-Release Capsule|300 mg immediate-release capsule
41301847|NCT05118958|DRUG|Placebo to KVD824 Prototype 1|Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
41301848|NCT05118958|DRUG|KVD824 Prototype 3 modified-release tablet|300 mg modified-release tablet
41301849|NCT02027688|OTHER|q6 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.
41301850|NCT02027688|OTHER|q3 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
41460893|NCT04392934|PROCEDURE|a conservative physiotherapy protocol|5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.
41460894|NCT00701194|BEHAVIORAL|Early Intervention Foster Care (EIFC)|The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
41301851|NCT02619019|DRUG|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
41460895|NCT02166801|BEHAVIORAL|Early intervention for infants|Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand \& Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
41460896|NCT02166801|BEHAVIORAL|usual care|Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
40978024|NCT04798924|DEVICE|Subacute Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the intact field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
40978025|NCT04798924|DEVICE|Subacute Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
41141763|NCT06341309|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
41301852|NCT02619019|DRUG|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
41301853|NCT02619019|DRUG|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
41301854|NCT03886727|DEVICE|Rubber Dam Set|Rubber dam set is the generic name of an isolation device that consists of a rubber sheet that isolates the tooth from saliva, a clamp to hold the rubber sheet on the tooth to be isolated, and a metal frame to keep the rubber sheet in a stretched position during dental procedures.
41141764|NCT00297713|DRUG|ALTU-238|
41141765|NCT04660110|DRUG|IPT with Dihydroartemisinin Piperaquine|A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
41141766|NCT04524676|PROCEDURE|Individualized Treatment|Patients under evaluation including hepatic venous pressure gradient (HVPG) and contrast-enhanced computed tomography of portal venous. For those patients with a HVPG ≥12mmHg or with extraluminal para-gastric vein will under transjugular intrahepatic portosystemic shunt and others receive endoscopic treatment.
41141767|NCT02052167|DEVICE|methotrexate prefilled pen|
41141768|NCT00165048|DRUG|Vioxx (Rofecoxib)|
41301855|NCT03886727|DEVICE|Dental Cotton Roll|Cotton roll is the generic name of a disposable isolation device made of cotton in a cylindrical form. Cotton rolls are used to isolate the teeth from saliva, by being placed in the cheek and tongue during placement of sealants or filings.
41301856|NCT00000404|BEHAVIORAL|Patient education in self-care of knee OA|
41301857|NCT02053272|DRUG|GWP42004|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
41301858|NCT02053272|DRUG|Placebo|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
41301859|NCT00415714|DEVICE|Portable Biofeedback|
41301860|NCT03778177|PROCEDURE|transcranial electrical brain stimulation|Pain ratings will be recorded before and after transcranial brain electrical stimulation procedures using a Visual Analog Scale (VAS).
40978026|NCT04798924|DEVICE|Chronic Training in the blind field|After the initial training period of one to six months, the same computer software will continue to be used for all subjects. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.
40978027|NCT01457521|DRUG|Ibuprofen|Ibuprofen
40978028|NCT02315378|BEHAVIORAL|TAU|Treatment as Usual for patients presenting after accidents and assaults as it pertains to mental health, is a brief intervention that varies in length depending on the patient's needs. If the patient is highly distressed, the social worked will provide brief crisis management support. The social worker also performs case management functions such as attempting to get in touch with family, contacting shelter or hotel if the patient is homeless, contacting other social service agencies if needed, and providing the patient referrals for mental health services in the community. A psychiatrist will also be called to assess the patient only if he or she appears to be a threat to self (suicidal) or others, and exclusion criteria for this study.
40978029|NCT02315378|BEHAVIORAL|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
40978030|NCT05853198|OTHER|ctDNA analysis|ctDNA amount and mutations analysis
40773986|NCT03869112|OTHER|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
40773987|NCT00895804|DRUG|MDMA|capsule, 1.6 mg/kg body weight, single dose
40978031|NCT00859053|DRUG|BMS-790052|Capsules, Oral, 30 mg, single dose, one day
40978032|NCT01996982|DEVICE|CCS Device|Core Cooling System Device
40978033|NCT02561650|DRUG|COV155|COV155 tablets
40978034|NCT06320028|DEVICE|Non-Invasive Transcranial Focused Ultrasound|The ultrasound will be delivered for 10 minutes per treatment session targeting to the participant's amPFC.
40978035|NCT04034420|OTHER|Online training platform|Self-paced training and learning materials in relation to family services
40978036|NCT05908474|DIETARY_SUPPLEMENT|Enriched fibre water|Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%\* of your recommended daily fibre intake and 100%\* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
40978037|NCT00004814|DRUG|copolymer 1|
40978038|NCT00704054|DRUG|ridaforolimus|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
40978039|NCT00750204|DEVICE|APRV|"APRV Protocol~* Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used~* Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).~* Respiratory rate (RR) to equal 60-65% of RR on conventional MV.~* P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.~* Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).~* If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV."
40773988|NCT00895804|DRUG|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
40773989|NCT06327438|OTHER|Complex decongestive therapy|"1. Manual lymphatic drainage (MLD).~2. Compression bandage.~3. Exercises to enhance lymphatic drainage.~4. Skin care."
40773990|NCT06327438|DEVICE|Cryotherapy|It is a mature and safe-to-use system that cools the air to -32°C. Steps of application included: 1) Apply oil or cream to moisture the skin before cryotherapy application; 2) Initialize the mini cryo-air equipment at level 6.
40773991|NCT06327438|OTHER|Kinesio taping|It is a new choice in the field of physical therapy. The material used for the KT and the original concept of the taping technique were introduced by Dr Kenso Kase in 1973.
40773992|NCT03814759|DRUG|TS-1 + cisplatin|S-1 20mg/m2, bid (D1\~14, D22\~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)
40773993|NCT03814759|RADIATION|radiation|radiation 45Gy per 5 weeks
40773994|NCT01928433|DRUG|Finafloxacin 800 mg i.v. once daily|Infused over 60 mins \[i.v. pump\]) for at least 3 days.
40978040|NCT00750204|DEVICE|Conventional MV|Low tidal-volume mechanical ventilation
40978041|NCT03132532|DRUG|Carboplatin|Chemotherapy
40978042|NCT03132532|DRUG|Cisplatin|Chemotherapy
40978043|NCT03132532|DRUG|Etoposide|Chemotherapy
40978044|NCT03132532|DRUG|Paclitaxel|Chemotherapy
40978045|NCT03132532|DRUG|Pemetrexed|Chemotherapy
40978046|NCT03132532|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
41301861|NCT04126967|DIAGNOSTIC_TEST|NGS patients|The next generation sequencing technique (NGS) was used to monitor the minimal residual lesions after allogeneic hematopoietic stem cell transplantation
40773995|NCT01928433|DRUG|Finafloxacin placebo i.v. once daily|Infused over 60 mins \[i.v. pump\]) for at least 3 days.
40773996|NCT01928433|DRUG|Finafloxacin 800 mg tablets once daily|Administered as four 200 mg tablets
40773997|NCT01928433|DRUG|Finafloxacin placebo tablets once daily|Administered as four tablets
40773998|NCT01928433|DRUG|Ciprofloxacin 400 mg i.v. twice daily|Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
40773999|NCT01928433|DRUG|Ciprofloxacin placebo i.v. twice daily|Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
40774000|NCT01928433|DRUG|Ciprofloxacin 500 mg oral twice daily|Administered as two 250 mg capsules.
40774001|NCT01928433|DRUG|Ciprofloxacin placebo oral twice daily|Administered as two capsules.
40978047|NCT03132532|OTHER|Quality-of-Life Assessment|Ancillary studies
40978048|NCT03132532|OTHER|Questionnaire Administration|Ancillary studies
41460897|NCT02399891|OTHER|Quality Assurance Implementation|
41460898|NCT02399891|OTHER|Standard of Care|
40978049|NCT04348929|OTHER|Self-administered questionnaires|Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)
40978050|NCT03516591|DRUG|AMV564 14-Day CIV|A 14-Day Continuous Intravenous Infusion regimen
40978051|NCT03249298|DRUG|Sterofundin (Bolus of crystalloids)|Bolus of 250 ml crystaloids infused regarding the measures
40978052|NCT03249298|DRUG|Voluven (Bolus of colloids)|Bolus of 250 ml colloids infused regarding the measures
40978053|NCT02532933|DEVICE|DePuy Synthes Attune PS RP|
40978054|NCT04334629|DRUG|Ibuprofen|Lipid ibuprofen 200 mg
40978055|NCT04425161|OTHER|Fluid challenge (0.9 % NaCl)|500 ml Fluid challenge of (0.9 % NaCl) will be given
40978056|NCT00727181|DEVICE|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
40978057|NCT05484518|BEHAVIORAL|Method of Levels Therapy|"Method of Levels (MOL) is a therapy that is the direct application of Perceptual Control Theory (PCT) (Powers, 2008) which proposes that psychological distress results from a person's reduced control over important life goals. A conflict between two or more goals can occur outside of a person's awareness (Carey, Mansell \& Tai, 2014) and the achievement of one goal leaves the other incompatible goal unachievable, leading to distress (Mansell, 2012). MOL therapy aims to help people develop awareness of important goals and conflicts between them, to increase their chances of developing potential solutions. Conflict can be resolved through reorganisation; a mechanism through which random change is continuously generated until control is restored (Tai, 2016).~Therapy uses a questioning style to help clients bring their attention to their problems long enough for them to restore control. In practice clients choose the number, frequency and duration of therapy sessions"
40978058|NCT02322567|OTHER|medical records|review of medical records
40978059|NCT02573857|DRUG|DSM265|Oral suspension from bulk powder
40978060|NCT02573857|DRUG|OZ439|Oral suspension from powder in a bottle
40978061|NCT02204163|DRUG|Eutropin|
40978062|NCT02204163|DRUG|Genotropin|
40978063|NCT01519414|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
40978064|NCT01519414|OTHER|Placebo|Given PO
40978065|NCT01519414|DRUG|Tivantinib|Given PO
41141769|NCT06092177|PROCEDURE|Periodontal surgery with virtual reality distraction|Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
41460899|NCT01728116|DEVICE|EndoBarrier|Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
41460900|NCT01728116|PROCEDURE|Sham Procedure|Endoscopic evaluation but no device placement
41460901|NCT04590339|PROCEDURE|Guided inferior Alveolar Nerve lateralization|Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique
41460902|NCT02374216|PROCEDURE|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
40978066|NCT01010516|DRUG|High-dose rosuvastatin|40 of rosuvastatin daily
40978067|NCT01010516|DRUG|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
40978068|NCT01010516|DRUG|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
40978069|NCT04702334|DRUG|Hyaluronic Acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group . The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
40978070|NCT04702334|DRUG|Lidocain|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
40978071|NCT05949060|BEHAVIORAL|Compassion Intervention|The compassion intervention is a single-session 40-min intervention in which the participants practiced soothing rhythm breathing (i.e., they are directed to slow their breathing using a five-count inhale and five-count exhale). They will then be provided didactic instruction on compassion, and will then be guided through an experiential compassion practice adapted that encompasses cultivating feelings of compassion for a loved one and then for oneself.
40978072|NCT04340401|DRUG|SHR-1210|Patients will receive 3 cycles induction CapeOX and SHR-1210
40978073|NCT04340401|DRUG|Oxaliplatin|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
40978074|NCT04340401|DRUG|Capecitabine|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
40978075|NCT04340401|RADIATION|Intensity modulated radiotherapy|patients will receive intensity modulated radiotherapy with capecitabine
40978076|NCT04340401|PROCEDURE|Total mesorectal excision|Patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs.
40978077|NCT03912285|DRUG|Amlodipine10mg|Amlodipine 10mg will be administered orally twice a day for 9 days
41141770|NCT06092177|PROCEDURE|Periodontal surgery without virtual reality distraction|Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
41141771|NCT01157624|DRUG|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
41301862|NCT02505555|DEVICE|four dimensional hysterosalpingo-contrast sonography|compare accuracy and tolerability of 4D-HyCoSy with that of laparoscopy and chromotubation
41301863|NCT03792750|DRUG|BMS-986205|Specified Dose on Specified Day
41301864|NCT03792750|BIOLOGICAL|Nivolumab|Specified Dose on Specified Day
41460903|NCT02828280|DEVICE|NuMask|The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.
41460904|NCT02828280|DEVICE|Traditional mask|A traditional air inflated facemark used to ventilate patients
41460905|NCT02991313|DEVICE|Endocardial Ablation Procedure|
41460906|NCT04509232|PROCEDURE|Silver diamine fluoride|"Group A~* Excavation of soft carious dentin will be done to minimize the staining.~* The selected teeth should be cleaned, dried and isolated. Vaselline should be applied to surrounding soft tissues to avoid their staining.-~* 38% Silver diamine fluoride will be applied to carious lesions by microbrush~* Apply gentle flow of air until medicament is dry, Try to keep isolated for three minutes,remove excess SDF with cotton pellet to decrease systemic absorption.~After silver diamine fluoride application Assessement of parental acceptance to staining will be done though a 5 point likert scale For anterior and posterior teeth separately ."
40978078|NCT03912285|DRUG|Losartan potassium 100mg|Losartan 100mg will be administered orally once a day for 9 days
40978079|NCT03912285|DRUG|Amlodipine plus Losartan|"Amlodipine plus Losartan same way as arm: amlodipine and arm: losartan"
41141772|NCT01157624|DRUG|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
40978080|NCT01705821|DEVICE|Use of force sensing surgical curette|Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
40978081|NCT01705821|PROCEDURE|Removal of pituitary tumor using modified curette|
40978082|NCT05493527|DEVICE|noninvasive high frequency oscillatory ventilation|"A time-cycled, pressure-limited, and continuous-flow neonatal ventilator (SLE6000; SLE) was used for neonates assigned to the NHFOV group. The settings were as follows:~1. a frequency of 10 Hertz ( range, 8-12 Hz);~2. an inspiratory time of 50% (1:1)~3. an oscillation amplitude of 35 centimeter of water column (cmH2O) (subsequent regulation range, 20-40 cmH2O) Oscillation amplitude would be regulated according to the level of carbon dioxide(CO2). Visible chest oscillation was not necessary because elimination of CO2 during NHFOV could also occur in the upper respiratory airway dead space~4. Mean airway pressure (MAP) of 10 cm H2O ( range, 7-15) MAP was regulated according to an open lung recruitment strategy~5. fraction of inspired oxygen (FIO2) regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
40978083|NCT05493527|DEVICE|noninvasive positive pressure ventilation|"NIPPV will be delivered by ventilator generating the targeted pressures. Infants will be on:~1. Peep ranging from 5 to 10 cmH2O,~2. Peak inspiratory pressure range 15-25 cmH2O~3. Rate range 40-50 breath/minute~4. FIO2 regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
40978084|NCT04768231|DRUG|Rifampin|The target dose of 35mg/kg will be reached supplementing fixed-dose combination tablets (standard dose) with rifampin-only tablets.
40978085|NCT05894629|BEHAVIORAL|Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|12-week program consisting of PNE and TE
41141773|NCT03392844|OTHER|Beds for Kids program|"The Beds for Kids program, which is part of the non-profit organization One House at a Time, gives every child in the program a new twin-size bed mattress, metal bed frame, and a bedtime bag, which contains a sheet set, blanket, pillow, several books, stuffed animal, and toothbrush. Children also receive educational messages about healthy sleep habits via a magnet and color-your-own bookmark. All of the items are sorted, packaged, and delivered directly to program recipients in their homes."
41141774|NCT00007306|DRUG|Parathyroid hormone ointment|
41141775|NCT04187456|DRUG|Savolitinib|Single dose (together with midazolam) on Study Day 5 after a high fat, high calorie breakfast.
41141776|NCT04187456|DRUG|Midazolam|Single dose (alone) on Study Day 1 and single dose (together with savolitinib) on Study Day 5, both after a high fat, high calorie breakfast.
41141777|NCT00579839|PROCEDURE|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
41141778|NCT00579839|PROCEDURE|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
41141779|NCT01347294|DRUG|Bleomycin|Intralesional
41141780|NCT01347294|DRUG|Fibrovein|Intralesional
41141781|NCT01347294|DRUG|Bleomycin + Fibrovein|Intralesional
41141782|NCT04017364|DEVICE|PCB PTCA|Predilatation of coronary de-novo stenosis followed by a PCB
41141783|NCT04017364|DEVICE|SCB PTCA|Predilatation of coronary de-novo stenosis followed by a SCB
41141784|NCT04285645|OTHER|Warmup|The intervention through exercises will consist in the application of the protocol described by Waldén et al. The objective of the application of this exercise protocol is to produce an improvement in the stability of the knee and the strength of the quadriceps. Before carrying out the exercises, a continuous race will be carried out for 5 minutes, once this first step is finished we will proceed to the realization of the exercises that will be, squats with both legs placing the hands on the hips, feet placed at the width of the shoulders, lowering with a straight back and without raising the heels of the floor, 3 series of 15 repetitions, squats on one leg with the hands on the hips and leg not supported extended forward, 3 sets of 10 repetitions with each leg and jump forward with one leg with the hands on the hips and jump back to return to the starting position, 3 sets of 10 repetitions with each leg
41141785|NCT04148885|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
41141786|NCT04148885|DRUG|carboplatin|Patients secondly receive carboplatin AUC=5 (iv, 30 minutes) on days 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
41141787|NCT00910962|DRUG|GW856553|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
41141788|NCT00910962|DRUG|GW856553|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
41460907|NCT04509232|PROCEDURE|Silver diamine fluoride and glass ionomer|"* 38% Silver diamine fluoride will be applied by the same protocol as in group A Then Glass Ionomer restoration is applied~* Parental acceptance to staining will be assessed thought 5 point likert scale after application of SDF and once more after application of Glass Ionomer restoration."
41460908|NCT03581994|DIAGNOSTIC_TEST|DDI Test Report|Test results of simulated patients
40978086|NCT05894629|BEHAVIORAL|Active Comparator: Usual treatment|12-week program consisting of home exercises, performed 3 days/week.
40978087|NCT05759650|OTHER|Execution of different motor tasks typical of daily life and work|Patients with obesity will carry out different motor tasks typical of daily life and work and, using optoelectronic systems based on passive markers, force platforms and electromyographic systems, kinematic and kinetic parameters of movement will be recorded and analysed for the implementation of an integrated protocol for the clinical evaluation of subjects with obesity.
41460909|NCT01198873|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
40978088|NCT04918264|DRUG|Fluoropyrimidine treatment (5-FU or capecitabine) and dosage|In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database
40978089|NCT04918264|OTHER|Uracil dosage|For each patient, uracil concentration will be evaluate and patients will be compared based on 16 ng/mL as threshold.
41141789|NCT00910962|DRUG|Placebo|Placebo
41141790|NCT02876653|OTHER|Polysomnography , blood collection, bone densitometry and Functional respiratory explorations|"Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers "
41460910|NCT01198873|DRUG|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
41460911|NCT01165749|BEHAVIORAL|stop exercising|
41460912|NCT04681586|DEVICE|bright light therapy|using a bright light therapy device (10.000 lux) for 30min every morning for two weeks
41141791|NCT03014349|OTHER|Analysis of medical records|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
41141792|NCT01295099|DRUG|5- fluorouracil|5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
41141793|NCT01295099|RADIATION|radiotherapy|after complete excision of keloid they have a single session of radiotherapy
41460913|NCT04681586|DEVICE|dim red light|using the same device as the active group, but with an installed filter that dims light to \<300 lux for 30min every morning for two weeks
40978090|NCT04918264|BEHAVIORAL|Overall survival|For each group of patient, on 16 ng/mL as threshold for uracil concentration, overall survival will be compared betwen the two groups of patients (Uracil \<16 vs Uracil ≥16).
40978091|NCT05398211|BEHAVIORAL|Preferred Recorded Music (PRM)|Preferred Recorded Music (PRM) involves a credentialed music therapist in planning and administering, which qualifies it as music therapy, which is defined as a professional use of music and its elements to improve physical, social, communicative, emotional, intellectual, and spiritual health, optimize quality of life and wellbeing(Aigen, 2013; Bruscia, 2014). PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. During the PRM intervention the MT will start/stop the music and otherwise not engage with the participants during the listening session.
41141794|NCT01295099|DRUG|Triamcinolone|TAC 10mg in 1ml injected intralesional
41141795|NCT00002405|DRUG|Amprenavir|
41141796|NCT00028600|BIOLOGICAL|filgrastim|PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC \>= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC \> 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2
41141797|NCT00028600|BIOLOGICAL|CD34+ cells|2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant
41141798|NCT00028600|DRUG|cyclophosphamide|4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
41141799|NCT00028600|DRUG|fludarabine phosphate|30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl
41141800|NCT00028600|DRUG|melphalan|200mg/sq m IV infusion over 15-30 min D 2 auto transpl
41141801|NCT00028600|DRUG|methotrexate|5mg/sq m/d IV infusion D 1,3,\& 6: allo transpl
41141802|NCT00028600|DRUG|tacrolimus|0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150
41141803|NCT02128269|BIOLOGICAL|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
41141804|NCT04433052|BEHAVIORAL|personalised prevention program (PPP)|Study subjects in the PPP arm will be invited to return to the study site six times over a three-year period (at V2/start of the study, V3/mo2, V4/mo6, V5/mo12, V6/mo18 and V7/mo36) to receive lifestyle coaching and exercise prescriptions led by a delegated member of the site staff and supervised by the investigator. Information on drug treatment will also be given by the investigator. These activities will be assisted by digital tools specifically designed for this study, the CoroPrevention Tool Suite.
41141805|NCT03129009|DRUG|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
41141806|NCT03129009|DRUG|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
41141807|NCT04970459|BIOLOGICAL|collection of samples of blood and urine|extra samples of blood and urine will be collected and stored for research utilisation
41460914|NCT02597257|DRUG|Lidocaine HCl|lidocaine continuous infusion
41460915|NCT02597257|DRUG|Normal saline|Normal saline continuous infusion
41460916|NCT01361633|DRUG|d-cycloserine|single oral administration of 250 mg d-cycloserine
41460917|NCT01361633|DRUG|Sugar Pill|Single oral administration 250 mg Sugar Pill
40774002|NCT05467657|DEVICE|repetitive Transcranial Magnetic Stimulation|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
40774003|NCT06220175|DRUG|Strepsils Intensiv plus Xilocaine spray Arm|After Stepsils Intensiv ingestion, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
40774004|NCT06220175|DRUG|Xilocaine Spray Arm|After Xilocaine Spray pharyngeal topical anestesia, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
40774005|NCT03404882|BEHAVIORAL|Supportive/reminder text messaging plus peer support|Regular supportive/reminder text message will be delivered to patients who will also receive face to face and interactive text message support from peer support workers
40774006|NCT03404882|BEHAVIORAL|Supportive/reminder text messaging|Regular supportive/reminder text message will be delivered to patients who will NOT receive any face to face or interactive text message support from peer support workers
40774007|NCT03404882|BEHAVIORAL|Peer support only|face to face support from peer support workers but no interactive or daily supportive/reminder text messages
40774008|NCT02149966|DRUG|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
40774009|NCT02149966|DRUG|Placebo|Placebo will be administered by mouth (orally) each day for a period of 14 days.
40774010|NCT03254784|DRUG|BMS-986165 Capsule|Oral capsule
40774011|NCT03254784|DRUG|BMS-986165 Tablet|Oral tablet
41141808|NCT00570622|DRUG|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
41141809|NCT00570622|DRUG|Placebo|Patients receive placebo once a day orally for 9 days
41141810|NCT01489683|DRUG|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea
41141811|NCT01489683|DRUG|normal saline|3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
41141812|NCT03802279|OTHER|Effort test|"Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~* CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~* Muscle oxygenation is measured using a near-infrared spectroscopy device.~* VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated."
41141813|NCT03802279|OTHER|Functional tests on fibroblasts|Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.
41141814|NCT06073470|DRUG|methylphenidate|The patients with ADHD will receive 12-week treatment with methylphenidate.
41141815|NCT01794273|DRUG|ephedrine and phenylephrine|
41141816|NCT06010173|DRUG|Gadopiclenol|Dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.05 mmol/kg BW
41141817|NCT06010173|DRUG|Comparator|Dose/volume of comparator to be administered will be calculated based on patient's weight at the dose of 0.1 mmol/kg BW
41301865|NCT01728584|DRUG|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
41301866|NCT01728584|OTHER|Insufflation|"Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.~* Standard insufflation pressure - a starting pressure of 12 mmHg will be used.~* Low insufflation pressure - a starting pressure of 8 mmHg will be used."
40774012|NCT01155050|DEVICE|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
40774013|NCT01155050|BEHAVIORAL|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
40774014|NCT01155050|DEVICE|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
40774015|NCT01971918|BIOLOGICAL|anti drug antibodies dosage|anti drug antibodies dosage
40774016|NCT03527667|BEHAVIORAL|Financial incentives|Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.
40774017|NCT04277312|BEHAVIORAL|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
40978092|NCT05398211|BEHAVIORAL|Preferred Live Music (PLM)|Preferred Live Music (PLM) involves a credentialed music therapist in planning and administering which qualifies it as music therapy, which is defined as professional use of music and its elements to improve physical, social, communicative, emotional, intellectual and spiritual health, optimize quality of life and wellbeing (Aigen, 2013; Bruscia, 2014).PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. The MT will be more actively engaged in a musical interaction with the participants in the PLM interventions.
40978093|NCT04492839|DEVICE|Intestinal adsorbent|Participants will consume the 15ml of the intestinal adsorbent (3.5 g Silicon dioxide in 100 ml Silicic acid gel, Preservatives: Sorbic acid (E 200), Sodium benzoate (E 211). ) three times daily for 10 days. There are no known side effects of the medical device. The product is a class IIa medical device under the European council directive and the product will be used within it's current indications.
40978094|NCT03929575|DIETARY_SUPPLEMENT|Placebo of calcium|Ingestion of 250 mg of calcium
40978095|NCT03929575|DIETARY_SUPPLEMENT|Rhodiola|Ingestion of 250 mg of Rhodiola
40978096|NCT03929575|DIETARY_SUPPLEMENT|Rhodiola and Cordyceps|Ingestion of 250 mg of Rhodiola and 225 mg of Cordyceps
40978097|NCT04867850|OTHER|Usual Care|Individual clinicians will receive an automated weekly email detailing a weekly roster of their upcoming repeat-patient visits (Index Visit) with patients at high risk of 6-month mortality as determined by a validated machine learning prognostic algorithm. Clinicians will receive a HIPAA compliant text message on the morning of the appointment reminding them to consider a serious illness conversation with patients on the list.
40978098|NCT04867850|OTHER|Clinician Nudge|Clinicians will receive the usual care weekly email and text message described above under Usual Care. In addition, embedded in the weekly email, clinicians will receive performance feedback information detailing their documented SICs relative to those documented by peers.
40978099|NCT04867850|OTHER|Patient Nudge|Ahead of the Index Visit, high risk patients as identified by the prognostic algorithm will receive a nudge via personal text message and email consisting of a normalizing message prompting patients with a personalized link to a short electronic questionnaire on SIC topics.
40978100|NCT04626297|DRUG|Lebrikizumab|Given SC
40978101|NCT04626297|DRUG|Placebo|Given SC
40978102|NCT04637789|BEHAVIORAL|the whole body vibration|most people stand on the platform with knees bent at about a 30-degree angle, while the surface beneath their feet vibrates an astounding 30 times per second.
40978103|NCT04637789|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
40978104|NCT06454110|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
40978105|NCT04876274|BEHAVIORAL|TMU-LOVE|Patients in intervention group could attend diabetes-related health educational video through the TMU-LOVE platform. Researcher would also send 2-3 videos per week with care massage every 2 weeks to the patients.
40978106|NCT03381846|PROCEDURE|MOHS micrographic surgery|Mohs surgery is a precise surgical technique used to treat skin cancer. Thin layers of cancer-containing skin are progressively removed and examined microscopically until only cancer-free tissue remains.
40978107|NCT03381846|PROCEDURE|Wide local excision|A surgical technique in which the skin cancer is excised along with 2-3 cm of clinically normal appearing surrounding tissue.
41301867|NCT01728584|DRUG|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
41301868|NCT04991506|DRUG|ES102|The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
41301869|NCT04991506|DRUG|JS001|JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
41301870|NCT02844023|BEHAVIORAL|Clinical evaluation|With questionnaire.
41301871|NCT02844023|OTHER|Paraclinical evaluation|Symptom inflammatory, biomarkers.
41301872|NCT02844023|DEVICE|Imaging|Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.
40978108|NCT00563511|PROCEDURE|adherence intervention|
40978109|NCT00563511|PROCEDURE|intervention without adherence advice|
40978110|NCT00563511|PROCEDURE|control|
40978111|NCT00686660|BEHAVIORAL|cycling, walking|"In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years."
40978112|NCT00686660|BEHAVIORAL|cycling, non-walking|"In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't receive walk training."
40978113|NCT00686660|BEHAVIORAL|walking, walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years."
41301873|NCT02844023|OTHER|Ophthalmologic examination|
41301874|NCT02844023|BIOLOGICAL|Dosage of biomarkers|Control patients.
41301875|NCT01630044|DEVICE|TNM device|Non-invasive neurostimulator, home-use treatment for up to 43 days.
41301876|NCT01512394|PROCEDURE|standard bowel prep|standard bowel prep
41301877|NCT01512394|PROCEDURE|no bowel prep|no bowel prep
41301878|NCT02008929|BIOLOGICAL|MG4101|Ex vivo expanded allogeneic NK cell
41301879|NCT04339075|OTHER|Questionnaires|Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survey)
41301880|NCT01444495|RADIATION|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
41301881|NCT01444495|PROCEDURE|Surgery|Total mesorectal excision of rectal cancer
41301882|NCT04852588|PROCEDURE|Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA)|Chest lymph node sampling procedure by EBUS
41301883|NCT04852588|PROCEDURE|Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)|Chest lymph node sampling procedure by EUS
41301884|NCT02000986|BEHAVIORAL|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy|Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
41301885|NCT01956409|DRUG|18F-FCH|
41301886|NCT01956409|DRUG|Magnevist|
41301887|NCT01106534|DRUG|placebo + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
40774018|NCT04277312|BEHAVIORAL|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
40774019|NCT00505687|DRUG|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~The maximum rotigotine dose allowed is 16 mg/24 hours."
40774020|NCT05913674|DRUG|Modified early post-operative intraperitoneal chemotherapy (mEPIC)|"On post-operative days 1 and 2, an abdominal reservoir is obtained by administering 1000 mL of plasmalyte with 50 mEq NaHCO3 via a Tenckhoff catheter. Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil infusion of 1200 mg/m2 over the next 24 hours. During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.~After completion of mEPIC day 1, the perfusate is drained out before starting mEPIC day 2."
40774021|NCT00568009|DRUG|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
40774022|NCT02059447|OTHER|No treatment waiting period|All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
40774023|NCT02059447|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
40774024|NCT02059447|BEHAVIORAL|Relaxation Therapy|
40774025|NCT06029790|OTHER|gum chewing|For the patients in the experimental group, sugar-free xylitol gum containing 1.2-1.37 grams of xylitol per piece, available in the market, will be used. Participants in the experimental group will start chewing gum on the first postoperative day and will be allowed to chew a single piece of gum 3 times a day at 9:00, 14:00 and 19:00, respectively, for 15 minutes. The gum will be given to the participants regularly by a researcher until the first reported flatulence.
40774026|NCT00800644|PROCEDURE|CT or MRI + Blood Test|"During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.~Blood (about 1 tablespoon) will be drawn to test for bone turnover."
40774027|NCT04192708|PROCEDURE|intercostal nerve block under direct vision|When the intercostal nerve is adequated exposed，a surgeon use a 5ml syringe to perform the block and the needle is tilted 15 degree cephalad and advanced towards the caudal rim of the lib，and penetration depth is about 5mm.Then 1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
40774028|NCT04192708|PROCEDURE|intercostal nerve block under ultrasound guidance|After induction ，an ultrasonographic probe (M-Turbo with the L25 transducer; SonoSite Inc.) is used to scan laterally from the midaxillary line to identify the required anatomic landmarks, while the patients are in a lateral decubitus position. The ribs are identified as hyperechoic streaks, while the pleura appeared as hyperechoic lines between and below the ribs.The needle was advanced towards the caudal rim of the rib until the distal tip is just between the innermost and inner intercostal muscle.1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
40774029|NCT04192708|PROCEDURE|paravertebral block under ultrasound guidance|"Paravertebral block is performed between the thoracic segments T7-8,A linear ultrasound transducer (M-Turbo with the L25×transducer; SonoSite Inc.) is placed to parallel the T7 transverse process so as to identify the T7 spinous process，the T7 transverse process and 7th lib.Then move the probe caudally until the thoracic paravertebral space (TPVS) which is bounded by transverse process,pleura and internal intercostal membrane.Using in-plane technique, we advance the 20-gauge needle(Becton Dickinson Infusion Therapy Sysstems Inc.Sandy,Utah 84070,USA.1.88，1.1×48mm) until the needle tip penetrates the internal intercostal membrane,9ml mixture of 1% lidocaine and 1/200000 epinephrine after no blood or gas is aspirated.Both PVB and ultrasound-guided ICNB is performed by the same anesthesiologist"
40774030|NCT01811420|PROCEDURE|Chemomechanical Caries Removal|Chemomechanical Caries Removal Using A Papain-Based Gel
40978114|NCT00686660|BEHAVIORAL|walking, non-walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't walking at community."
40978115|NCT01529255|DRUG|telbivudine (ROADMAP)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
41141822|NCT01526486|PROCEDURE|Videoscopic procedure|Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
41141823|NCT01526486|PROCEDURE|Open, traditional approach|Open surgical procedure, with sartorius muscle transfer.
41141824|NCT04509102|DRUG|Adderall-XR|Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
40774031|NCT01811420|PROCEDURE|Conventional method|Dental caries removal using rotatory instrument
40774032|NCT00217802|BEHAVIORAL|six-session telephone counseling program|
41141825|NCT04509102|DRUG|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
41141826|NCT03605147|DIETARY_SUPPLEMENT|CaHMB|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by abdominal CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
41141827|NCT03605147|DIETARY_SUPPLEMENT|Placebo|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
41141828|NCT03307356|OTHER|Uterine Transplant|Transplant of a uterus from a donor, deceased or living
41141829|NCT02817360|DRUG|RAS-antagonist and beta-blocker up-to maximal dosages|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
41141830|NCT02817360|OTHER|RAS-antagonist and beta-blocker none or at stable dose|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
41141831|NCT05316324|PROCEDURE|Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction with (ADM)
41141832|NCT05316324|PROCEDURE|Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction without ADM
41141833|NCT02170207|DRUG|Lansoprazole|Lansoprazole 30 mg injection
41141834|NCT00913055|DRUG|octreotide acetate|subcutaneous implant
41141835|NCT01750788|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
41141836|NCT02592902|PROCEDURE|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
41141837|NCT02592902|PROCEDURE|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
41141838|NCT04834804|OTHER|Physical activity|12 weeks of exercise training
41141839|NCT06288685|PROCEDURE|percutaneous A1 pulley release|Treatment trigger finger by release A1 pulley by percutaneous procedure
41141840|NCT06288685|DRUG|Triamcinolone|Triamcinolone 40mg/ml 1 ml injection concomitant percutaneous A1 pulley release
41141841|NCT04865744|DRUG|Semaglutide 7 MG Oral Tablet|Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
41141842|NCT04865744|DRUG|Placebo|Placebo tablet is taken after an overnight fast with up to120 ml of water.
41141843|NCT04865744|DRUG|Semaglutide 14 MG Oral Tablet|Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.
41141844|NCT01444690|DRUG|Dimiracetam|Capsules for oral administration twice daily
41141845|NCT01444690|DRUG|Dimiracetam 25 mg|Inactive dose level in capsules administered orally twice daily
41141846|NCT06554509|DRUG|SHR-1819 injection|SHR-1819 injection
41141847|NCT06554509|DRUG|Placebo|placebo
41141848|NCT03559777|OTHER|closed sinus lifting by Osteotome|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~* The widening drills can be sequentially used to widen the osteotomy site to the same level~* An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~* The osteotome will be tapped gently to fracture up the sinus floor.~* Xenograft will be added to the osteotomy as the grafting material.~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
41141849|NCT03559777|OTHER|closed sinus lifting by Densah bur|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~* Change the drill motor to reverse- densifying Mode~* with the densah bur (2.5mm) until 1 mm short of the sinus floor.~* Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~* densah burs (3.5mm) advance in the osteotomy.~* Xenograft will be added to the osteotomy .~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
41141850|NCT02065297|OTHER|1 blood sample|
41141851|NCT02065297|OTHER|2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)|
41141852|NCT05058157|DIETARY_SUPPLEMENT|different ketogenic formulae|The research product may be in a form of powder to reconstitute or in a ready-to-drink format.
40774033|NCT02853136|DRUG|Fluvoxamine|Fluvoxamine
40774034|NCT02853136|DRUG|BI 409306 - Powder for oral solution (PfOS)|BI 409306 - Powder for oral solution (PfOS)
40774035|NCT02853136|DRUG|BI 409306 - film coated tablet|BI 409306 - film coated tablet
40774036|NCT04849897|DEVICE|Experimental: Virtual Reality Guided Imagery|Platform and VR Goggles
40774037|NCT04849897|OTHER|Active Comparator: Audio Only Guided Imagery|Audio Recordings of Guided Imagery via an iPAD
40774038|NCT06259019|DEVICE|Liquid Biopsy System (LBS)|Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
40774039|NCT04405531|OTHER|task-oriented training (TOT)|The study group received a TOT together with a conventional occupational therapy (COT). The study groups received a treatment for 20 sessions at a hospital setting.
40774040|NCT04405531|OTHER|conventional occupational therapy (COT)|The control group received only a COT program. The control groups received a treatment for 20 sessions at a hospital setting.
40774041|NCT05425160|OTHER|Progressive lower limb activities (Chair rise and Step ups)|Progressive lower limb activities (Chair rise and Step ups) were be carried out weekly for upto 6 weeks. Before initiation, cardiopulmonary parameters i.e. Heart rate, oxygen saturation, cardiac output and stroke volume were measured at baseline and later at the termination of activity on each week. Initially, five repeated chair rise were conducted through SPPB and the time was noted to complete the task and step ups through 6MWD for a total period of 30 min. Lastly, fatigue component was assessed via FAS.
40774042|NCT05425160|OTHER|Standard aerobic exercise i.e. low intensity walking|Standard aerobic exercise i.e. low intensity walking were conducted in both the groups. Follow up phone calls and 1 OPD visit were scheduled accordingly
40774043|NCT00443456|DRUG|Amlodipine|Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
40774044|NCT02551783|PROCEDURE|Urethroplasty with buccal mucosa graft|A surgery to correct urethral stricture
40774045|NCT02551783|PROCEDURE|Ventral Buccal|Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
40774046|NCT03094052|DRUG|Neratinib|Given orally (PO)
40774047|NCT03094052|BIOLOGICAL|Trastuzumab|Given Intravenously (IV)
40774048|NCT03094052|DRUG|Loperamide|Given PO
40774049|NCT03094052|DRUG|Diphenoxylate Hydrochloride/Atropine Sulfate|Given PO
40774050|NCT02640300|DRUG|Clozapine|Switching to clozapine with immediate or gradual antipsychotic discontinuation
40774051|NCT06454656|OTHER|MOBILE|"Intensive motor learning based intervention to target specific walking goals as identified using the Gait Outcome Assessment List.~Full Protocol outlining strategies available on request.~Three key principles underpin the intervention:~Principle 1: The type of task~Principle 2: The type of practice~Principle 3: The type of Feedback"
40774052|NCT03014115|DIETARY_SUPPLEMENT|combination ARA + DHA|combination ARA + DHA supplemented infant formula
40774053|NCT03014115|DIETARY_SUPPLEMENT|DHA|DHA supplemented infant formula
40774054|NCT06246396|DRUG|Minocycline Hydrochloride|Minocycline Hydrochloride 100 mg twice daily
40774055|NCT06246396|DRUG|Placebo|Placebo
40774056|NCT04669795|DRUG|Cissus Quadrangularis|Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
40774057|NCT03484104|DIAGNOSTIC_TEST|Measurement of tissue oxygenation index (TOI)|TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest
40774058|NCT01312831|OTHER|Vitamin B12 (cyanocobalamin)|
41301888|NCT01106534|DRUG|clopidogrel + aspirin OR prasugrel + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.
40774059|NCT05903703|DRUG|Canagliflozin and Gemcitabine|"on the first, 8th and 15th day of treatment, patients were given intravenous drip of 1000mg/m2 gemcitabine, and 21 days was a course of treatment, lasting for 6 courses.~Take 400mg canagliflozin orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of canagliflozin can be re-evaluated during the treatment, and the highest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 4 weeks as a cycle"
40774060|NCT05903703|DRUG|Gemcitabine|on the first, 8th and 15th day of treatment, patients were given 1000mg/m2 gemcitabine intravenously, and 21 days was a course of treatment, lasting for 6 courses.
40774061|NCT01160185|DRUG|paclitaxel|paclitacel
40774062|NCT01160185|DRUG|cisplatin|cisplatin monotherapy
40774063|NCT01160185|DRUG|topotecan|topotecan
40774064|NCT02796651|DRUG|Formoterol fumarate (6 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
40774065|NCT02796651|DRUG|Formoterol furmarate (20 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
40774066|NCT02796651|DRUG|Placebo for formoterol fumarate|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
40774067|NCT02796651|DRUG|Formoterol fumarate (12 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
40774068|NCT02796651|DRUG|Formoterol fumarate (40 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
40774069|NCT00427700|DRUG|clomiphene citrate|100mg PO on days 5-9 of the menstrual cycle
40774070|NCT00427700|DRUG|raloxifene|100mg PO on days 5-9 of the menstrual cycle
40774071|NCT01701882|DRUG|tenofovir/emtricitabine/rilpivirine|
40774072|NCT03801525|DRUG|Ublituximab|"* recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~* administered as an IV infusion"
40774073|NCT03801525|DRUG|Umbralisib|"* inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~* Tablet form"
40774074|NCT03801525|DRUG|Venetoclax|"* B-cell lymphoma 2 (BCL-2) inhibitor~* Tablet form"
40774075|NCT02383784|DIETARY_SUPPLEMENT|Low GI index diet|Low glycemic index diet
40774076|NCT02383784|DIETARY_SUPPLEMENT|High GI diet|High glycemic index diet
40774077|NCT01188967|DRUG|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
40978116|NCT01529255|DRUG|Telbivudine (Standard of Care)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
40774078|NCT01188967|DRUG|Placebo|Placebo
40774079|NCT04955041|OTHER|MRI|T2\* MRI
40774080|NCT05930639|OTHER|Surgical Site Infection (SSI) prevention package|"Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.~Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.~Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.~In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.~Before the operation and before discharge, the patient is educated about infection prevention measures."
40774081|NCT03107845|BEHAVIORAL|Cognitive Behavior Therapy|Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.
40774082|NCT03107845|BEHAVIORAL|CBT plus Feedback|Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI \& OQ-30), interpersonal functioning (IIP-32 \& OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.
40774083|NCT03107845|BEHAVIORAL|CBT plus Feedback plus CST|"Additional to the intervention group CBT and Feedback therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation."
40774084|NCT00574015|DRUG|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
40774085|NCT00574015|DRUG|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
40774086|NCT02040909|DRUG|Propofol|Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
40774087|NCT05152823|BIOLOGICAL|Gene Therapy|AAV9 carrying the IGHMBP2 gene.
40774088|NCT01434940|OTHER|Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam|. The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
41141853|NCT01098409|DRUG|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
41141854|NCT01098409|DRUG|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
41141855|NCT02877524|OTHER|Adaptive support ventilation|ASV during NIV
41141856|NCT02877524|OTHER|Pressure support ventilation|PSV during NIV
41141857|NCT04420351|DRUG|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
41141858|NCT04420351|DRUG|Aspirin;Clopidogrel|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.
41141859|NCT00114452|BIOLOGICAL|Provacel|ex vivo cultured adult mesenchymal stem cells
41141860|NCT00114452|BIOLOGICAL|Placebo|Placebo
41141861|NCT04920968|DRUG|Obinutuzumab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland. Patients in experimental arm will receive obinutuzumab .Obinutuzumab: 1000 mg i.v. (first infusion divided into 100 mg on d. 1 and 900 mg on d. 2).
41141862|NCT04920968|DRUG|Rituximab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland.The protocol includes the use of rituximab in combination chemotherapy. Rituximab: 375 mg/m2 intravenously (i.v.)
41141863|NCT02806752|DRUG|Triamcinolone Acetonide|Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
41301889|NCT01106534|DEVICE|XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)|XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
41141864|NCT02806752|DRUG|Ranibizumab|Intravitreal inject 0.5mg of Ranibizumab.
41141865|NCT04470089|DRUG|Myramistin|Oromucosal application
41141866|NCT04836871|COMBINATION_PRODUCT|DFPP combined with chemotherapy|Double filtration plasmapheresis combined with chemotherapy
41141867|NCT05643222|DEVICE|red tint contact lenses|to compare the performance of these lenses.
41141868|NCT05698563|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI scan with contrast of the foot or feet
41301890|NCT05602259|DIAGNOSTIC_TEST|induced sputum|After premedication with 400 μg inhaled salbutamol, sputum will be induced by inhalation of hypertonic (NaCl 3%) or isotonic (NaCl 0.9%) saline combined according to the FEV-1 value (\> or ≤ than 65% predicted). Saline will be combined with additional salbutamol delivered by an ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9 ml/min. Each subject will inhale the aerosol for three consecutive periods of 5 min for a total of 15 min. For safety reasons, FEV-1 will be monitored throughout the induction and will be stopped if FEV-1 would fall by more than 20% from baseline.
40774089|NCT05249959|DRUG|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))|"Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
40774090|NCT05249959|DRUG|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)|"Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2 and 3~or~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 100 mg, Days 2 and 3~* Cytarabine 500 mg, Day 2 and 3~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
40774091|NCT04835259|DRUG|Selenium Amino Acid Chelate (Selenium ACE cream)|application of a topical agent over the whole face for 6 months
40774092|NCT00833521|DRUG|Zolpidem 10 mg tablets|1 x 10 mg
40774093|NCT00833521|DRUG|AMBIEN® 10 mg tablets|1 x 10 mg
40774094|NCT05493410|OTHER|TREATMENT GROUP (TG)|In addition to muscle strengthening and aerobic exercise, patients from the TG will undergo IMT for six weeks, performing two sets of 30 repetitions daily using the device POWERbreathe classic medic® (POWERbreathe International Ltd., Southam, United Kingdom). MIP will be measured in all patients before the intervention as described earlier, and patients will exercise at 40% MIP in the first week and 60% MIP in the subsequent five weeks. The patients will be instructed to inhale using the diaphragm muscle, trying to expand the rib cage to avoid using accessory muscles A nose clip will be used to ensure patients breathe exclusively through the training device.
40774095|NCT05493410|OTHER|CONTROL GROUP (CG)|"For six weeks the CG will perform muscle strengthening through a sit and stand up from a chair routine, abduction of upper and lower limbs, and rowing; three sets of 10 repetitions of each exercise will be performed. Elastic tubes will be used, with elasticity defined by color and indicating the greatest resistance the participant can endure with an effort between 4 and 8 on the OMNI-RES scale for perceived exertion.~In addition, aerobic exercise will be performed, through walking on flat terrain for five minutes in the first week, 10 minutes in the second week, and 20 minutes in the subsequent week, with intensity between 40-60% of the reserve heart rate and respecting the patients' symptoms.~Aerobic training intensity will be calculated by the modified BORG exertion scale maintaining a score between 6 and 7 - with the progression respecting the patients' symptoms - and by the reserve heart rate."
40774096|NCT02258490|BIOLOGICAL|G-CSF mobilized CD34+ selected cells for transplantation|After screening and enrollment, donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using standard National Marrow Donor Program guidelines. CD34+ cell selection will be performed according to procedures given in CliniMACS Operating Manual and institutional Standard Operating Procedures. If storage after CD34+ selection is necessary, product will be kept in a monitored refrigerator. During storage, leukocyte concentration should not exceed 2 x 108 cells/ml using platelet poor plasma to adjust cell concentration. If donor's plasma is not available, CliniMACS buffer will be used. Cell processing will be performed by personnel trained by Miltenyi on CliniMACS system prior to initiation of clinical product selection. After tests are performed and product passes release criteria, patient will receive final product. No conditioning regimen will be administered prior to cell infusion.
40774097|NCT03656354|DEVICE|Seismocardiography|Seismocardiography recording
40774098|NCT01510574|DRUG|Misoprostol|3 x 200mcg tablets of oral misoprostol
40774099|NCT01510574|DRUG|placebo|3 x placebo tablets resembling misoprostol taken orally
40774100|NCT04245189|OTHER|Endoscopic ultrasound for detection of Chronic pancreatitis|Presence of Chronic pancreatitis in alcoholic cirrhosis patients.
40774101|NCT05549544|DEVICE|Left bundle branch area pacing|Left bundle branch area pacing is a novel physiological pacing modality and is reported to be feasible and safe in patients with heart failure and left bundle branch block.
40774102|NCT05549544|DEVICE|Biventricular pacing|Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure
41301891|NCT05602259|DIAGNOSTIC_TEST|lung biopsy|As per standard practice, biopsies will be taken from the primary tumour site or from a metastatic site.
41301892|NCT05602259|DIAGNOSTIC_TEST|bronchoalveolar lavage|When available, the remaining material from a patient's bronchoalveolar lavage will be collected.
41301893|NCT05602259|DIAGNOSTIC_TEST|blood draw|As per standard practice, blood will be drawn from patients before and during treatment. Data on white blood cells will be collected.
41301894|NCT02580916|OTHER|SCQOLIT questionnaire|"Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires \[Appendices C \& D) at:~1. baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~2. 3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~3. at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)"
41301895|NCT04833985|PROCEDURE|LAAC combined with radiofrequency ablation|Each patient received the same group of patients with simple radiofrequency ablation and LAAC
41301896|NCT00818324|DRUG|OPC-12759 Ophthalmic suspension|Instillation,4times/day,for 52weeks
41301897|NCT03671759|BEHAVIORAL|Start: On Caffeine|In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.
41301898|NCT03671759|BEHAVIORAL|Start: Off Caffeine|In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
41301899|NCT00854763|DRUG|olmesartan|olmesartan
41301900|NCT02704728|OTHER|Thetanix|Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
41301901|NCT02704728|OTHER|Placebo|Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
40774103|NCT02583841|PROCEDURE|Scaling and root planing|scaling and root planing as an intervention was done in patients of the test group
40978117|NCT06277921|PROCEDURE|Elective Surgery for gastric cancer|Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach
40978118|NCT05486104|DRUG|Hemay005 tablets|Hemay005 tablets (15mg/tablet）will be orally administered twice daily.
40978119|NCT05486104|DRUG|Hemay005 placebo tablets|Hemay005 placebo tablets will be orally administered twice daily.
40774104|NCT03087071|OTHER|Laboratory Biomarker Analysis|Correlative studies
40774105|NCT03087071|BIOLOGICAL|Panitumumab|Given IV
40774106|NCT03087071|DRUG|Trametinib|Given PO
40978120|NCT01851616|DIETARY_SUPPLEMENT|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)|
40978121|NCT01851616|DIETARY_SUPPLEMENT|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)|
40978122|NCT00678054|DRUG|GM-CSF|Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
40978123|NCT00851383|BIOLOGICAL|Ad35-GRIN/ENV|This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.
40978124|NCT00851383|BIOLOGICAL|Ad35-GRIN|This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
40978125|NCT01314443|OTHER|Nicotine Replacement Therapy (NRT)|Participants will quit smoking with nicotine patches
40978126|NCT01314443|DIETARY_SUPPLEMENT|Gamma-Tocopherol|Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
40978127|NCT01314443|OTHER|Placebo|Participants will take placebo for 7 days
40978128|NCT01314443|BEHAVIORAL|Smoking cessation|Participants will quit smoking without any pharmacological aids
40978129|NCT00822250|OTHER|analysis of pigmentation|cutting hair, skin description, skin biopsy for only 4 patients
40774107|NCT06490159|DRUG|Paclitaxel|Gastric cancer second-line chemotherapy
40978130|NCT01252108|DRUG|SQ109|300 mg SQ109 daily for 14 days
40978131|NCT06399978|BEHAVIORAL|Brain Blossom - Gamified Differential Outcome Training|Digital cognitive training with a gamified DOT task for 20 minutes per day 3-4 times a week for 6-8 weeks.
40978132|NCT06399978|BEHAVIORAL|Gamified Non-Differential Outcome Training|Digital cognitive training with a gamified NDOT task for 20 minutes per day 3-4 times a week for 6-8 weeks.
40978133|NCT00306605|BEHAVIORAL|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
41141869|NCT05698563|DIAGNOSTIC_TEST|Ultrasound|Ultrasound scan of the feet
41141870|NCT05698563|DRUG|Corticosteroid injection|Administered ultrasound guided to patients with intermetatarsal bursitis
41141871|NCT05698563|OTHER|Clinical foot evaluation|An examination of the feet
41141872|NCT05698563|OTHER|Picture of the feet|To evaluate the presence of V-sign/spreading toes
41141873|NCT06290024|DEVICE|A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function|Using the use of pain visual analog scale (VAS), digital pain grading method (NRS), neuropathic pain assessment scale (DN4), sleep quality (Pittsburgh sleep quality index, Ascens insomnia scale), social support assessment scale (SSQ), Montreal cognitive assessment scale (MoCA), Barrett impulse scale (BIS), anxiety and depression score (GAD-7, PHQ-9), emotional tasks, cognitive function (N-back, time perception, delay-discount), electroencephalogram (EEG), near-infrared brain function imaging (fNIRS) and other indicators to study the dynamic changes of various factors in the process of acute pain.
41141874|NCT00033241|DRUG|erlotinib hydrochloride|
41141875|NCT00033241|DRUG|gemcitabine hydrochloride|
41141876|NCT05713136|DEVICE|Diagnostic Test: Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
41141877|NCT01856062|DRUG|Placebo|A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
41141878|NCT01856062|DRUG|Dexamethasone|Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
41141879|NCT06562881|OTHER|Scheduling Navigation|Participants will be connected to a scheduler to schedule a surgical consultation visit at time of recruitment. Participation does not guarantee or require surgery.
41301902|NCT06050512|DRUG|Mezigdomide|Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells.
40774108|NCT05763667|DRUG|Liposomal bupivacaine|"Liposomal bupivacaine is FDA-approved for use single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
40978134|NCT03847454|COMBINATION_PRODUCT|REACH|The intervention consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity.
40978135|NCT03847454|OTHER|Standard of care|Standard of care for rehabilitation treatment for musculoskeletal patients.
40978136|NCT02530554|DRUG|CHG|Single application
40978137|NCT00822835|BIOLOGICAL|ILV-095|
40978138|NCT00822835|BIOLOGICAL|Placebo|
40978139|NCT06372860|BEHAVIORAL|Diabetes Prevention Program|"The intervention will be administered by professionally trained, certified health coaches. Phase I consists of four 1-hour DPP-based sessions to be completed during pregnancy. Each session will be pre-recorded and archived on a secure, private mHealth application. Participants will be asked to complete each session on their own time. A health coach will follow up weekly via phone to check on progress and will work with the participant 1-on-1, if needed. Phase I will be completed by week 36 of pregnancy. Prior to delivery, participants are invited to a virtual focus group about their experiences.~Phase II consists of two 1-hour DPP-based sessions to be completed after delivery. Each session will be pre-recorded and archived on the same mHealth application. Participants will begin Phase II within 1 week of delivery with the same health coach. Phase II will be completed by week 12 postpartum. Upon completion, participants are invited to a virtual focus group about their experiences."
40978140|NCT06372860|BEHAVIORAL|Breastfeeding|"Phase I also consists of six (6) breastfeeding videos that are pre-recorded into 15-20 minute sessions and will be available on the mHealth application. Participants will have access to the first 2 sessions by week 28 of pregnancy and need to complete the remaining 4 sessions by week 36 of pregnancy. Each session is taught by an International Board Certified Lactation Consultant (IBCLC).~Participants will receive 1-on-1 lactation support by the same DPP health coach. The health coach is a professionally trained Certified Breastfeeding Specialist (CBS). She will assist participants with any questions related to lactation. If the health coach is unable to help with a specific issue, she will contact the IBCLC-of-record, who will provide assistance to the health coach only. If the health coach or IBCLC deems additional care necessary, the participant will be referred to their primary care physician. The IBCLC will not have direct contact with the study participants."
40978141|NCT06372860|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
40978142|NCT06380907|DRUG|ZL-1102 1% w/w gel BID for 16 weeks|"ZL-1102~1% w/w gel BID for 16 weeks"
41141880|NCT06562881|OTHER|Without Scheduling Navigation|Patients will work with clinic staff in the usual fashion for their treatment for primary hyperparathyroidism. They will not be connected directly to a scheduler to help schedule a surgical consultation visit at time of recruitment. With our crossover design, if patients have not yet received surgical consultation after 3 months, they will be called and connected with a scheduler at that time. Participation does not guarantee or require surgery.
41141881|NCT06332118|OTHER|ice massage group|Measurement surveys will be applied to obtain pre-test data from hemodialysis patients who meet the research criteria. After the preliminary test data are obtained, ice cubes prepared by the researchers before the needle insertion into the arteriovenous fistula for the hemodialysis procedure will be wrapped in a thin sponge and an ice massage will be applied to the needle insertion area of the patient in a direction that will not disrupt the circulation. This process will take approximately 3-5 minutes or the massage will be terminated when the patient feels drowsiness. In the next stage, the patient will undergo needle intervention for hemodialysis. At the end of this stage, the patient's pain will be evaluated. Patients will be re-evaluated at 24, 48 and 72 hours for ecchymosis and hematoma and relevant measurements will be provided.
41141882|NCT03056170|DEVICE|real tDCS|"In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code."
41141883|NCT02214914|DRUG|BI 11634 drinking solution|
41141884|NCT02214914|DRUG|BI 11634 tablet|
41141885|NCT02214914|DRUG|Placebo|
41301903|NCT06050512|DRUG|Ixazomib|Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma.
40978143|NCT06380907|DRUG|ZL-1102 3% w/w gel BID for 16 weeks|ZL-1102 3% w/w gel BID for 16 weeks
40978144|NCT06380907|DRUG|ZL-1102 3% w/w gel QD for 16 weeks|ZL-1102 3% w/w gel QD for 16 weeks
40978145|NCT06380907|DRUG|Placebo ZL-1102 0% w/w gel BID for 16 weeks|Vehicle 0% w/w gel BID for 16 weeks
40978146|NCT06380907|DRUG|Placebo ZL-1102 0% w/w gel QD for 16 weeks|Vehicle 0% w/w gel QD for 16 weeks
40978147|NCT06503224|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.
40978148|NCT04711408|DEVICE|SootheVR: AppliedVR, Los Angeles, California a head-mounted displa|"For the study group, virtual reality content will be administered to the participant for the duration of the examination through a head-mounted display, RelieVRTM. The VR content for the trial will be swimming with dolphins."
40978149|NCT02642289|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|"Probiotic 5000, a commercial probiotic product provided by the company Complementos Fitonutricionales, S.L."
41301904|NCT06050512|DRUG|Dexamethasone|Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.
41301905|NCT02531035|DRUG|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
40774109|NCT05763667|DRUG|Bupivacain|"Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery. It is widely used in TAP blocks.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
40774110|NCT01446523|DRUG|placebo|Syrup, 30 ml BD for 3 months in Gr. NL
40774111|NCT01446523|DRUG|Lactulose|Syrup 30 ml BD for 12 weeks
40774112|NCT04454515|DRUG|Dexmedetomidine|Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge.
40774113|NCT04454515|DRUG|placebo|normal saline infusion
40774114|NCT05790447|DRUG|Thymalfasin|loading dose with thymalfasin based on the amounts of T lymphocyte
40774115|NCT05790447|RADIATION|Radiotherapy|hypofractionated radiotherapy/SBRT
40774116|NCT05790447|DRUG|PD-1/PD-L1 inhibitor|The PD-1/PD-L1 inhibitors are used within one week after radiotherapy
40774117|NCT05790447|DRUG|GM-CSF|subcutaneous injection daily for 7 consecutive days
40774118|NCT05980702|DRUG|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab, Carboplatin, albumin-bound paclitaxel:4 cycles"
40774119|NCT05980702|DRUG|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab , Carboplatin, albumin-bound paclitaxel:2 cycles"
40774120|NCT00693550|OTHER|metal patch tests|Twenty - seven (27) metal patch tests will be applied to the patient's back and left in place for 3 days
40774121|NCT06263699|PROCEDURE|ROM measurement of the MCP and PIP joints in digits 4 and 5|standardised picture of the hand in maximal active extension, with the back of the hand positioned on the table's surface
40774122|NCT03723473|DEVICE|Magnetic Resonance Imaging (MRI)|MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.
40774123|NCT02857972|DEVICE|Wondaleaf®|Use of Wondaleaf® during menstruation every night in one menstrual cycle.
40978150|NCT02642289|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG ®|"Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab Laboratorios Nutergia"
40978151|NCT02642289|OTHER|Placebo|Innocuous substance
40978152|NCT00459784|PROCEDURE|Dementia Training Program|
40978153|NCT00132587|DEVICE|cement Palacos R40 and LV40|
40978154|NCT02282020|DRUG|OLAPARIB|300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
40978155|NCT02282020|DRUG|Single agent chemotherapy|Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
40978156|NCT05356494|OTHER|Postural drainage|(Group A will be treated with postural drainage)
40978157|NCT05356494|OTHER|Positive expiratory pressure|(Group B will be treated with positive expiratory pressure technique).
40978158|NCT01321515|DRUG|famciclovir|500 mg tablet
40978159|NCT06151834|PROCEDURE|KeriFuse implant implantation|The surgery is an arthrodesis of finger or thumb (for patients with finger osteoarthritis) and involves implanting the KeriFuse implant.
41301906|NCT02531035|DRUG|Placebo|Placebo, once daily, before the first meal of the day
40978160|NCT04580953|DEVICE|CardiaCareTM RR2|Treatment with CardiaCareTM RR2
41301907|NCT05634590|DRUG|Fruquintinib|4mg, orally, once daily, 3 weeks on/ 1 week off
41301908|NCT05634590|DRUG|FOLFIRI|Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
41301909|NCT05634590|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
40978161|NCT01901198|BIOLOGICAL|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.|Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
40978162|NCT01901198|BIOLOGICAL|Peginterferon 180 mcg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
40978163|NCT01585194|BIOLOGICAL|Ipilimumab|Given IV
40978164|NCT01585194|OTHER|Laboratory Biomarker Analysis|Correlative studies
41141886|NCT03236779|OTHER|dry needling|The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
41141887|NCT03606863|DRUG|Perioperative peripheral parenteral nutrition|
41141888|NCT02450084|PROCEDURE|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
40774124|NCT04666792|DRUG|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
40774125|NCT00057148|PROCEDURE|massage treatment|
40774126|NCT00642044|PROCEDURE|Corneal Collagen Crosslinking|UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
40774127|NCT02128035|PROCEDURE|With Lead Shield|"A pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
40978165|NCT01585194|BIOLOGICAL|Nivolumab|Given IV
40978166|NCT03481322|DIETARY_SUPPLEMENT|Cooked diet with controlled amount of salt|Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
41141889|NCT02450084|DRUG|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
41141890|NCT02450084|OTHER|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
41141891|NCT02450084|DRUG|IV-PCA containing Fentanyl|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
41301910|NCT03919916|PROCEDURE|Serratus plane block|Placement of initial local anaesthetic bolus and catheter for continuous infusion in the plane between latissimus dorsi and serratus anterior in the midaxillary line at the level of the 5th rib
40774128|NCT04872439|DIAGNOSTIC_TEST|Blood sample collection|Patients with autoimmune gastrointestinal dysmotility will provide 20 mL of blood to isolate serum, plasma and peripheral blood mononuclear cells for whole exome sequence. Antibodies to be isolated are: Antineuronal nuclear antibody type 1,Collapsing response-mediator family immunoglobulin G, Ganglionic Acetylcholine Receptor Antibody, Muscle Acetylcholine Receptor Antibody, Striational, Voltage-gated calcium channel, N- type, Voltage-gated calcium channel, P/Q- type, Voltage-gated potassium channel, Glutamic Acid Decarboxylase 65, Gastric parietal cell, Thyroperoxidase, Thyroglobulin
40774129|NCT06141421|PROCEDURE|procedure|procedure
40978167|NCT04774640|DEVICE|MaterniT GENOME|
41141892|NCT00558441|DEVICE|IVMRI|Intra Vascular Magnetic Resonance Imaging
41141893|NCT02035852|OTHER|MRI|3T MRI vs. 7T MRI
41141894|NCT03956927|OTHER|S-TPE|S-TPE stimulation session with groups of 8 patients. The simulation is performed by a single patient, the others are observers in a neighbouring room where the scene is projected.
40978168|NCT04462549|BEHAVIORAL|Resource Facilitation|"RF involves working one on one with a brain injury specialist. This specialist is called a Resource Facilitator and works with clients to help set and achieve their own goals along with a team of professionals that specialize in this kind of injury. This may include brain injury education, family education, needs assessments, and service identification."
40978169|NCT01497132|DRUG|Vitamin D3|Oral drops 30000 IU weekly
40978170|NCT01497132|DRUG|Placebo|Matching placebo
40978171|NCT04138420|DRUG|Bevacizumab Injection|Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
41141895|NCT03956927|OTHER|Questionnaires|Pre- and post-simulation administration of self-efficacy and anxiety questionnaires (IASTA Y1 and Y2)
41141896|NCT01558726|BEHAVIORAL|Case Management (Strength-Based)|To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
40978172|NCT05277740|DEVICE|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
40978173|NCT02559245|OTHER|Descurainia Sophia|
40978174|NCT02559245|OTHER|Ficus carica|
41141897|NCT01558726|BEHAVIORAL|Usual Treatment|The usual treatment used for regular patients of CAPSad
41141898|NCT04917185|OTHER|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
41141899|NCT03958266|DEVICE|MyIBD Care|Novel mobile phone application
41301911|NCT03919916|OTHER|Patient controlled analgesia|Computerised pump device facilitating the patient self administration and titration as needed of morphine
41301912|NCT00920465|DRUG|mifegyne and cytotec|One day dosage versus two days dosage
41301913|NCT04378309|BEHAVIORAL|ePREP|6-session online psychoeducational program with supporting coach calls
41301914|NCT04276311|DEVICE|Percutaneous transluminal angioplasty|The purpose of this study is to evaluate the efficacy and the feasibility of atherectomy, using the Jetstream™ artery preparation associated to DCB treatment (Ranger™ Paclitaxel-Coated balloon), in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo femoropopliteal arterial lesions (TASC C).
40774130|NCT01061788|DRUG|AMG 479, Everolimus, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~1. 3-6 subjects, Study drug administered per dose level~2. 3-6 subjects, Study drug administered per dose level~   Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~   Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3. 3-6 subjects, Study drug administered per dose level~4. 3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
40774131|NCT06078345|OTHER|Carbohydrate|400 Kcal glucose (100g oGTT)
40774132|NCT06078345|OTHER|Fat|400 Kcal glucose rapeseed oil.
40774133|NCT06078345|OTHER|Protein|400 Kcal Moltein PURE (111g)
40774134|NCT06364072|DRUG|CT001|Intranasal
40774135|NCT03362671|DEVICE|Implant Supported Mandibular Advancement Oral Appliance|This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
40774136|NCT03362671|DEVICE|Orthodontic Mini Implant|Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
40774137|NCT01150032|OTHER|Bone quality complementary exams|"realisation of following exams to evaluate fracture risk in osteopenic women:~* hip and wrist Dual energy X-ray Absorptiometry (DXA)~* wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)~* hip Quantitative Computed Tomography (QCT)~* High Resolution Digital X-Ray of calcaneum using BMA(tm) system~* low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)"
40774138|NCT03923868|DRUG|D-0120|D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
40774139|NCT02867137|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
41141900|NCT05497167|OTHER|Period Kit|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
41141901|NCT05352555|DEVICE|Automated vertigo repositioning chair|"Patients are strapped to the chair with a safety harness, and video fenzel goggle are worn.~Automated diagnostic procedures are performed to determine vertigo subtype and orientation (Left/Right) (described below).~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll (for horizontal canal involvement)~3. (Optional) Deep Head Hanging (for anterior canal involvement)~If nystagmus is detected during automated diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding automated treatment maneuver will be performed (described below).~1. Epley's and/or Semont's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~3. Yacovino's maneuver (for anterior canal involvement)~10 minutes after performing automated treatment maneuver, provocative diagnostic test maneuver was performed once again to ensure successful intervention.~A follow-up was done one week later at the earliest."
41141902|NCT05352555|OTHER|Canalith Reposition Maneuver|"Patients were seated on a examination table and given videonystagmography goggles (VNG).~Manual diagnostic procedures are performed to determine vertigo subtype and orientation.~The manual diagnostic procedures for Left and Right sided semicircular canals are:~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll and Bow and Lean (for horizontal canal involvement)~If nystagmus is detected during diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding treatment maneuvers will be performed manually.~The automated treatment maneuvers are:~1. Epley's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Patients were called back for a follow up 2 days after performing manual treatment maneuvers. Provocative diagnostic testing maneuvers were performed again to ensure successful intervention.~A second follow-up was done one week later at the earliest."
41141903|NCT06466551|OTHER|intravenous catheterization|This randomized experimental study was planned to examine the effect of virtual reality goggles and squeezing a stress ball as a distraction method during intravenous catheter application on pain and fear in children aged 6-12 years.
41141904|NCT02983721|PROCEDURE|transradial|transradial route for coronary angiography and PCI
41141905|NCT02983721|PROCEDURE|Transfemoral|transfemoral route for coronary angiography and PCI
41141906|NCT01802333|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplant
41141907|NCT01802333|DRUG|Cytarabine|Given IV
41141908|NCT01802333|DRUG|Daunorubicin Hydrochloride|Given IV
41141909|NCT01802333|DRUG|Idarubicin|Given IV
41141910|NCT01802333|OTHER|Laboratory Biomarker Analysis|Correlative studies
41141911|NCT01802333|DRUG|Vorinostat|Given PO
41141912|NCT02535585|DEVICE|knotted anchors (SutureTak biocomposite 3.0 mm)|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
41141913|NCT02535585|DEVICE|knotless anchors (PushLock biocomposite 2.9 mm knotless)|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
41141914|NCT00568087|DRUG|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
41301915|NCT04065230|DRUG|Tenofovir Alafenamide Fumarate tablets|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
41301916|NCT00473161|DEVICE|surface EMG biofeedback|
41301917|NCT01081223|BIOLOGICAL|Cancer vaccine plus immune adjuvant|Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.
41301918|NCT05992519|DIAGNOSTIC_TEST|¸FeNO|FeNO measured with a NIOX VERO device after the methacholine challenge
41301919|NCT03013777|BEHAVIORAL|8-week CBT Program|
41301920|NCT05980117|DRUG|Remimazolam|Remimazolam (1.0mg IV) titrated to modified observer's assessment of sedation score of 3 -4 during cataract surgery.
40978175|NCT01700725|OTHER|Nasal Irrigation - Saline|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the saline solution by themselves using the study-provided kit which will include packets of salt powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 2% buffered saline solution. The solution is then delivered to the nasal cavity using neti pot."
40978176|NCT01700725|DRUG|Nasal Irrigation - Xylitol|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot."
40978177|NCT01953588|DRUG|fulvestrant|Fulvestrant 500 mg IM
40978178|NCT01953588|DRUG|anastrozole|Anastrozole 1 mg oral tablet
40978179|NCT02593474|DRUG|Naltrexone|Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
40978180|NCT03037411|DEVICE|Peripheral stenting|stent implantation during the index procedure
40978181|NCT03007381|DRUG|Ketorolac Tromethamine|Intravenous analgesic
40978182|NCT03007381|DRUG|Normal Saline|Sham comparator
40978183|NCT02804620|BEHAVIORAL|Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes|The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
40978184|NCT00877383|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
40978185|NCT00877383|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
40978186|NCT00877383|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
40978187|NCT01943292|DRUG|Defactinib|
40978188|NCT03498040|OTHER|Study of the occurrence of Carcinoid Heart Disease|"Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, ...) biological parameters (urinary 5HIAA, NT-ProBNP ...) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease."
41301921|NCT05980117|DRUG|Midazolam|Midazolam (0.5-2mg IV) titrated to modified observer's assessment of sedation score of 3 - 4 during cataract surgery.
41301922|NCT02547077|PROCEDURE|Wound Closure with 2-octylcyanoacrylate|
40978189|NCT04666584|DEVICE|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon
40978190|NCT04666584|DEVICE|Device: standard non-compliant balloon|Pre-dilatation with a standard non-compliant balloon
40978191|NCT05018299|BIOLOGICAL|FB704A placebo|Placebo
40978192|NCT05018299|BIOLOGICAL|FB704A|Anti-IL-6 antibody
40978193|NCT05072574|OTHER|Specific dietary treatment and follow-up using coaching techniques|Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
40978194|NCT03590379|DRUG|CHF 5993 DPI|BDP/FF/GB DPI
40978195|NCT03590379|DRUG|CHF5993 pMDI|BDP/FF/GB pMDI
40978196|NCT03590379|DRUG|CHF 1535 pMDI|BDP/FF pMDI
41301923|NCT02547077|PROCEDURE|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
41301924|NCT01029002|DRUG|Vitamin D|Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
41301925|NCT01029002|OTHER|Placebo|Patients randomized to this arm will receive one placebo pill once weekly.
41301926|NCT03008408|DRUG|Everolimus|Given PO
41301927|NCT03008408|DRUG|Letrozole|Given PO
41301928|NCT03008408|DRUG|Ribociclib|Given PO
41301929|NCT00174616|DRUG|Oxaliplatin, capecitabine, radiotherapy|"* Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses~* Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks~* Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks"
40978197|NCT03590379|DRUG|Placebo DPI|CHF 5993 DPI matched placebo
40978198|NCT03590379|DRUG|Placebo pMDI|CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
40978199|NCT01659515|DRUG|Arbekacin Sulfate|Intravenous arbekacin in a total daily dose of 5-7 mg/kg
40978200|NCT03483051|DRUG|Potassium Nitrate|Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals \[610 mg, corresponding to 6.03 mmoles of NO3-\] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.
40978201|NCT03483051|DRUG|Potassium Chloride|Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
40978202|NCT03137472|DEVICE|Transcranial Magnetic Stimulation (TMS)|The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
40978203|NCT00110149|BIOLOGICAL|rituximab|
40978204|NCT00110149|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
40978205|NCT01722071|DRUG|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
40978206|NCT01722071|DRUG|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
40978207|NCT06023823|OTHER|Toe spread out|toe-spread-out exercise.
40978208|NCT06023823|OTHER|Dry needling+Toe spread out|The group will be given 3 sessions of dry needling with Seirin branded 0.6\*50 mm acupuncture needles for trigger pointe in the abductor hallucis muscle and additionally toe-spread-out exercise.
40774140|NCT03360994|OTHER|WATChmAN Active Surveillance|WATChmAN Active Surveillance uses an electronic tool used to provide active surveillance care to testicular cancer patients. This virtual active surveillance care is delivered with an identical schedule to in-person care without the need to come into clinic.
40978209|NCT05954026|DEVICE|ExVent|ExVent Accessory (inserted into the O2Vent Optima device) for treatment of sleep apnea
40978210|NCT06151795|DIAGNOSTIC_TEST|XTR006|Single dose intravenous injection of XTR006. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
41141915|NCT00568087|DRUG|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
41141916|NCT05703659|DIETARY_SUPPLEMENT|B. longum subsp. infantis|Infants will receive 1 dose of a B. infantis probiotic daily for 4 weeks
41141917|NCT05703659|DIETARY_SUPPLEMENT|L. reuteri probiotic|Infants will receive 1 dose of an L. reuteri probiotic daily for 4 weeks
41141918|NCT04326894|DRUG|25 mg/week oral methotrexate tablets|
41141919|NCT04326894|DRUG|25mg/week oral placebo tablets|
41141920|NCT05064072|DEVICE|Water-based barrier tape|"The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure."
40774141|NCT03360994|OTHER|In-person Active Surveillance|In-person active surveillance is the current recommended management option for all Stage I testicular cancer patients at Princess Margaret. Patients are monitored clinically with imaging and blood work, and active treatment only begins if relapse occurs.
40774142|NCT06255769|DEVICE|Magnetocardiography|Magnetocardiography
40774143|NCT06255769|DEVICE|Single photon emission computed tomography (SPECT)|Single photon emission computed tomography (SPECT)
40978211|NCT05633420|DRUG|Pyramax|"Participant body weight~* ≥65 kg (Pyramax 4 tablets)~* ≥45 kg and \<65 kg (Pyramax 3 tablets)"
40978212|NCT05937347|BEHAVIORAL|TAU + UP4H|Group treatment protocol of 8 weeks (approximately 105 minutes per week, 75 of face-to-face and 30 of virtual intervention).
40978213|NCT05937347|BEHAVIORAL|TAU + M4H|Group treatment protocol of 8 weekly 75 minute sessions (face-to-face intervention).
41141921|NCT05064072|DEVICE|Hydrocolloid barrier tape|"As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the pain felt by the infants evaluated with Neonatal Infant Pain Scale and the score recorded in the chart. Since the hydrocolloid barrier tape can stay on the skin for 7 days and the assessment of the pain realized in 7th day and noted down to the chart. Pain score evaluated in 7th day 3 min. before procedure, during and 3 min after procedure"
41141922|NCT05064072|DEVICE|Silk tape|"The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape on the silk tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure"
41141923|NCT01612897|OTHER|Computer based care reminders|Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
41141924|NCT04105699|DEVICE|Blood sampling|Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
41141925|NCT01973361|DEVICE|Ultrasound debridement|Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
41141926|NCT01973361|DEVICE|Best practice wound care|Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
40774144|NCT01115504|DRUG|Thiamine|300 mg daily for 30 days
40978214|NCT05937347|BEHAVIORAL|TAU + CT|Group treatment protocol of 8 weekly 60 minutes sessions (virtual intervention).
41141927|NCT05124210|BIOLOGICAL|Sotrovimab|Sotrovimab will be administered.
41141928|NCT01583959|DRUG|Folic Acid|Folic acid tablets 5 mg
41141929|NCT01583959|DRUG|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
41141930|NCT04235920|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition
40978215|NCT05937347|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to children with ADHD.
40978216|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
40978217|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
41141931|NCT03937752|OTHER|3D endodanal ultrasound|Endoanal ultrasound performed with two different transducers preoperatively during a fistula treatment procedure.
40774145|NCT01478425|DEVICE|Lipidic Microemulsion|Topical nasal, twice a day
40774146|NCT01478425|DEVICE|Saline|Topical Nasal, twice a day
40978218|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
40774147|NCT06564025|BEHAVIORAL|Pilot program study|To assess program feasibility, acceptability, and preliminary efficacy, we will pilot the intervention with a purposive sample of 50 father-teen pairs (100 participants total). All participants will receive the program.
40774148|NCT02783833|DRUG|MMV390048 40mg|
40774149|NCT02783833|DRUG|MMV390048 dose to be determined mg|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
40978219|NCT00632242|DRUG|ARC1779|"Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment."
40978220|NCT00632242|DRUG|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
40978221|NCT00764153|PROCEDURE|Bipolar hemiarthroplasty|Lateral approach. FWB.
40978222|NCT00764153|PROCEDURE|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
40978223|NCT03837106|OTHER|Rehabilitation program|3-month rehabilitation program comprising exercise and education specific to musicians. The program will be supported by an online platform containing more than 50 exercise videos, narrated powerpoint presentations, informative videos, quizzes, and forums for communicating with a physiotherapist and for organizing group exercise sessions.
40978224|NCT01961388|DRUG|Bay G5421 Glucobay|Oral, dosage of Acarbose as per the directions of treating physician
40978225|NCT01961388|DRUG|Metformin|Oral, dosage of Metformin as per the directions of treating physician
40978226|NCT04993456|PROCEDURE|Caridac surgery|Cardiac surgery
40978227|NCT02739204|DRUG|Celecoxib|200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
40774150|NCT00654355|DRUG|tacrolimus ointment|tacrolimus ointment to be applied twice daily to affected areas during duration of study
40774151|NCT05492877|DRUG|Mitiperstat (AZD4831)|Oral dosage, once daily.
40978228|NCT01737515|OTHER|Abdominal waist and hip circumference|Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
40978229|NCT00699621|BIOLOGICAL|platelets|Four units of fresh platelets will be infused immediately
41141932|NCT00257556|DRUG|Menotrophin|150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
40978230|NCT02190357|DRUG|Rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
41141933|NCT00257556|DRUG|Follitropin alfa|150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
41141934|NCT02471872|BEHAVIORAL|Air Pollution Education|Students are presented with a one-hour interactive session on air pollution.
40774152|NCT05492877|OTHER|Placebo|Oral dosage, once daily.
40774153|NCT00758563|DRUG|Fluoride|Brush twice daily
40774154|NCT00758563|DRUG|Triclosan/Fluoride|Brush twice daily
40774155|NCT03331887|PROCEDURE|E-max CAD endocrown|endocrown used to restore endodontically treated teeth with E-max CAD endocrowns
40774156|NCT03331887|PROCEDURE|E-max CAd crowns retained with fiber reinforced composite post|fiber reinforced composite post need to restore endodontically treated tooth with E-max crown
40978231|NCT03590236|OTHER|Graded exposure therapy|Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.
40978232|NCT03590236|OTHER|Physiotherapy|Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
40978233|NCT03446183|BEHAVIORAL|Smoking cessation workshops|All the participants took part in smoking cessation workshops. The comparison of metabolic aspects was made between the smokers and non-smokers
40774157|NCT01716702|BEHAVIORAL|Couples Prostate Cancer Support Group|"The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).~In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
40774158|NCT05299190|OTHER|Yoga intervention plus TAU|The yoga intervention consists of 8 weekly group sessions. The intervention is based on hatha yoga system. TAU is usual care participants receive from their health care provider
41301930|NCT00590018|DRUG|Hydrocortisone|Hydrocortisone taper (100mg/m2/day --\> 25mg/m2/day) over 5 days intravenously.
40774159|NCT05299190|OTHER|Clinical Monitoring plus TAU|clinical monitoring includes bi-weekly 15-20 minute telephone contact with participants. TAU is usual care participants receive from their health care provider.
40774160|NCT01427673|PROCEDURE|Bipap procedure|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
40774161|NCT00497497|DRUG|bevacizumab|(Only for patients not previously treated with bevacizumab) Intravenous repeating dose
40774162|NCT00497497|DRUG|cetuximab|Intravenous repeating dose
41301931|NCT00590018|DRUG|Placebo|Placebo for 5 days intravenously.
41301932|NCT05622500|PROCEDURE|Deep venous stenting|Endovascular reconstruction encompasses balloon venoplasty and venous stenting. A dedicated venous stent will be used, the brand of which the individual interventionist will decide.
41460918|NCT05803824|OTHER|exercise therapy program|"patients will receive Baduanjin Qigong exercise plus selected exercise. the subjects will recive Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks.~The whole set of Baduanjin exercise consists of 9 postures: (1) ready position, (2) holding the hands high with palms up. (3) posing like an archer shooting on left and right sides, (4) holding one arm aloft . (5) looking backwards to prevent sickness and strain, (6) swinging the head and lowering the body t. (7) moving the hands down the back and legs and touching the feet . (8) thrusting the fists and making the eyes glare . and (9) raising and lowering the heels .~Selected Exercise Program: Patients will receive~* balance exercises is composed of three phases, including warm-up, balance training and cool down.~* Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises"
41460919|NCT02729207|DRUG|Esflurbiprofen Hydrogel Patch|One patch per day for 7 days
41460920|NCT00806962|DRUG|Adjuvant/Excipients|intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
41460921|NCT00806962|DEVICE|placebo|intranasal, puff of air, 2 doses, 21 days apart
40978234|NCT05793476|DEVICE|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 15-21 days. She receives 3 sessions, in total. 5% Lidocaine cream is applied 30 minutes before each procedure. Each session consists of application of R11 handpiece to the episiotomy scar at Turbo3 Micro Short Pulse mode, with spot size of 2 mm, fluence of 9.5-10 j/cm2, frequency of 2 Hz and 4 pulses per point and 3 passes followed by PS03 handpiece at Basic Long Pulse mode, with spot size of 5 mm, energy of 800 mJ, frequency of 1.4 Hz and 4 pulses per point and 2 passes.
40978235|NCT05793476|DEVICE|Fotona Dynamis Er:YAG Laser System with Sham handpiece|The same procedure is applied above but with a sham handpiece and parameter presentations masked.
41460922|NCT00806962|BIOLOGICAL|Norwalk VLP Vaccine|intranasal, 50mcg, 2 doses--21 days apart
41460923|NCT00806962|BIOLOGICAL|Norwalk VLP Vaccine|Intranasal, 100 mcg, 2 doses, 21 days apart
41460924|NCT01067794|DRUG|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
41141935|NCT02471872|OTHER|Non-Air Pollution Education|Students are presented with a one-hour interactive session on vaccines.
41141936|NCT05526937|OTHER|Bread|Bread portions of 50 gram available carbohydrates.
41141937|NCT04737993|DRUG|licocain|pulsed radiofrequency stimulation
41141938|NCT04737993|OTHER|pulsed radiofrequency stimulation|pulsed radiofrequency stimulation of joint capsel
41460925|NCT00545116|OTHER|Hesperidin|250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
41460926|NCT03831490|DIAGNOSTIC_TEST|history|combining these 4 interventions will great an algorithm predicting preeclampsia
41460927|NCT05692115|DIAGNOSTIC_TEST|stress ECG|stress ECG to patients suspected to be ischemic patients .
41460928|NCT03727139|DRUG|Rasagiline|Rasagiline Tablets
41460929|NCT00196820|DRUG|Capecitabine|
41460930|NCT05569109|DEVICE|doppler ultrasound|doppler ultrasound on arteriovenous fistula in hemodialysis patients
41460931|NCT04084990|DEVICE|S9 VPAP Adapt|Auto-titrated positive airway pressure
41460932|NCT06230380|PROCEDURE|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PTGs during surgery. The surgical field will be visualized with AF as a minimum of two times during surgery on each side of the neck: First upon exposing the undersurface of the thyroid gland, and secondly before removal of a pathological PTG. Also, removed PTGs will be examined ex vivo to document AF pattern.
41460933|NCT03512249|BIOLOGICAL|H56:IC31|5ug H56/500 nmol IC31
41460934|NCT03512249|BIOLOGICAL|Placebo|Sterile saline for injection
41460935|NCT05878041|DIAGNOSTIC_TEST|Molecular and genetic screening|Molecular and genetic screening
41460936|NCT06237101|DRUG|High dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
41460937|NCT06237101|DRUG|Medium dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
40774163|NCT00497497|DRUG|FOLFIRI regimen|Intravenous repeating dose
40774164|NCT00497497|DRUG|irinotecan|Intravenous repeating dose
40774165|NCT00497497|DRUG|PRO95780|Intravenous repeating dose
40774166|NCT05378464|BIOLOGICAL|Dendritic Cell (DC1) Vaccine|Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10\^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15. Participants will receive DC1 vaccine boosters every 3 weeks x 3.
40774167|NCT05378464|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
40774168|NCT05378464|DRUG|Pepinemab|Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
40978236|NCT05100524|OTHER|Motivational interview|The motivational interviewing technique is a client-focused, directive form of counseling to create behavior change. Its main goal is to discover and solve ambivalence. This method is especially useful for people who are reluctant or ambivalent to change.
41301933|NCT05622500|COMBINATION_PRODUCT|Best medical therapy|Compression stockings encompass a range of therapies used to provide an externally applied graduated-pressure up the length of the limb aiming to improve venous function and decrease lower limb swelling. Compression stockings can be classified by size and grade, i.e. the pressure the stockings applies to the limb. For the purpose of this trial Class II and Class III graduated compression stockings should be used, with the aim of providing Class III if tolerated. Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.
41301934|NCT05505578|BEHAVIORAL|GamerFit Condition|Participants receive a Fitbit device, the GamerFit app on their mobile device, exergaming console and games (Nintendo Switch) (where applicable), and follow a 12-week exergaming curriculum provided by the app. Physical activity (PA) increases during the intervention up to 60 minutes/session. Other interventional aspects include weekly reminders, exercise and health related video materials, and weekly telehealth sessions with an intervention coach.
41301935|NCT05505578|BEHAVIORAL|Comparator Condition|Participants receive a Fitbit device, instructions on how to use it, and a booklet of healthy tips. They also get weekly reminders to charge, sync, and review their Fitbit data.
41301936|NCT05646303|DRUG|Psilocybin|Psilocybin and psychotherapy
40774169|NCT05378464|BIOLOGICAL|T-Cell therapy|Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
40774170|NCT00208338|DEVICE|RESTORE SIS Patch|Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
40774171|NCT00208338|PROCEDURE|Rotator cuff repair|Standard surgical repair of torn rotator cuff
40774172|NCT02318433|DRUG|Dexamethasone|Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
40774173|NCT02318433|DRUG|Saline|
40774174|NCT01168596|DRUG|Rasagiline|"Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks."
40774175|NCT01168596|DRUG|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
40774176|NCT02106832|DRUG|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.
40774177|NCT02106832|DRUG|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.
40978237|NCT05100524|OTHER|Ongoing treatment|Patients with total knee replacement receive standard nurse care. Treatment is applied. He does his own exercises at home.
41301937|NCT05646303|DRUG|Placebo|Placebo and psychotherapy
41301938|NCT02184143|BEHAVIORAL|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
41301939|NCT02184143|OTHER|Education|Patient education
41460938|NCT04733508|DRUG|111In-DTPA-exendin-4|Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography
41460939|NCT04733508|DRUG|IRDye800CW-exendin-4|Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy
41460940|NCT06266754|BIOLOGICAL|Oral polio vaccine|Standard oral polio vaccine
41460941|NCT06266754|OTHER|Placebo|Saline 0.9%
41460942|NCT00250705|DRUG|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; \> 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
41460943|NCT03869294|DRUG|GS|Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer
41460944|NCT02441322|DEVICE|Novo-TTF|Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
41460945|NCT00008398|BIOLOGICAL|sargramostim|
41460946|NCT00008398|PROCEDURE|quality-of-life assessment|
40774178|NCT02106832|DRUG|Placebo|Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
40774179|NCT02106832|DRUG|Placebo|Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
40774180|NCT05643404|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.
40774181|NCT05643404|DIAGNOSTIC_TEST|Echocardioghaphy|Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography
40978238|NCT02353598|DRUG|Crenezumab dose level 1|Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
40978239|NCT02353598|DRUG|Crenezumab dose level 2|Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
40978240|NCT02353598|DRUG|Crenezumb dose level 3|Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
40774182|NCT06143189|OTHER|Hosting conditions|"Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments."
40978241|NCT02353598|DRUG|Placebo|Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
40978242|NCT02465801|DRUG|HSA-GCSF 1.2 mg|Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
40978243|NCT02465801|DRUG|HSA-GCSF 1.5 mg|Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
40774183|NCT06143189|OTHER|Hospital Clowns|"The HCs Palhaços D'Opital (PdO) have a program aiming to bring joy, affection and good mood to adults and elders in hospital environment. They work in pairs, dressed in colorful costumes and they prepared sketches in advance. Their performances recreate day-to-day situations (e.g., clowns trying to install a new TV screen; planning a wedding between the clowns and asking the public for their ideas), ending with specific closure, in order to indicate to the audience that the session had finished and to promote a positive environment after their departure. Each intervention lasted around 15 minutes."
40774184|NCT02106806|DIETARY_SUPPLEMENT|Zinc|35 mg of elemental zinc twice daily for 16 weeks
40978244|NCT02465801|DRUG|GCSF|GCSF 5 mcg/kg/day
40978245|NCT02555189|DRUG|Enzalutamide|Given PO
40978246|NCT02555189|DRUG|Ribociclib|Given PO
40978247|NCT02555189|OTHER|Laboratory Biomarker Analysis|Correlative studies
40978248|NCT02555189|OTHER|Pharmacological Study|Correlative studies
40978249|NCT02555189|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40978250|NCT02555189|PROCEDURE|Biopsy|Undergo tumor biopsy
40978251|NCT02555189|PROCEDURE|Echocardiography|Undergo ECHO
40978252|NCT02555189|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40978253|NCT02555189|PROCEDURE|Bone Scan|Undergo bone scan
40978254|NCT02555189|PROCEDURE|Computed Tomography|Undergo CT
41460947|NCT00008398|RADIATION|radiation therapy|
40774185|NCT02106806|OTHER|Placebo|One capsule, twice daily for 16 weeks
40774186|NCT02625779|DRUG|Valproate and Placebo|
40774187|NCT02625779|DRUG|Valproate and Cytidine-containing Drug|
40774188|NCT02625779|DRUG|Valproate and Creatine-containing Drug|
40774189|NCT03538847|OTHER|Numerical rating scale|Measure of postoperative pain
40978255|NCT02555189|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40978256|NCT04672928|DRUG|paclitaxel|80mg/m\^2,iv,Q4W
40978257|NCT04672928|DRUG|IBI318|300mg,iv,Q4W
40978258|NCT06434844|PROCEDURE|Auricular acupunctures|After disinfection of the external ear with 75% alcohol wipes, 018x 13 filiform needles (Mocm International Limited) will be used to perform the auricular acupunctures at the relaxation point, tranquilizer point and master cerebral point at the left and right external ears.
40978259|NCT06434844|PROCEDURE|Sham acupunctures|The auricular acupoints of finger, shoulder and tonsil will be targeted instead. These points are also located at the external ear and comparable to those in the intervention group. The external ear will be disinfected with 75% alcohol wipes. Auricular acupunctures with 018x 13 filiform needles (Mocm International Limited) will be carried out at the finger point, shoulder point and tonsil point of the left and right external ears.
40978260|NCT04683536|PROCEDURE|Obturator nerve blockade|We performed spinal anesthesia combined with ultrasound guided obturator nerve blockade according to the localization of bladder cancer in patients with lateral wall localized non-muscle invasive bladder cancer
40978261|NCT03848650|DEVICE|OpSens Medical OptoWire|"The OptoWire is FDA approved to measure pressure in coronary vessels during diagnostic angiography and coronary interventions.~The OptoWire Deux pressure wire (OpSens Medical, Quebec, Canada) is a novel technology utilizing optical coherence technology to enhance FFR assessment of the coronaries."
40978262|NCT03848650|PROCEDURE|FFR|A guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR is done through a standard diagnostic catheter at the time of a coronary angiogram (a.k.a. cardiac catheterization).
41460948|NCT03150901|DIAGNOSTIC_TEST|no drug|laboratory tests
41460949|NCT04218487|DRUG|Xuefu-Zhuyu Capsule|treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
41460950|NCT04218487|DRUG|placebo|treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
41460951|NCT04218487|OTHER|conventional therapy|conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
40774190|NCT02090764|DRUG|Ozenoxacin|
40774191|NCT02090764|DRUG|Placebo|
40774192|NCT04198649|DRUG|Non-surgical periodontal treatment and azithromycin treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions
40774193|NCT04198649|OTHER|Non-surgical periodontal treatment and placebo treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Placebo: two 250mg starch tablets one time daily for 3 days after scaling and root planning sessions
40774194|NCT01140204|DEVICE|Implantation of a bare metal stent|Bare Metal Stent
40774195|NCT00691509|GENETIC|gene expression analysis|
40774196|NCT00691509|GENETIC|polymorphism analysis|
40774197|NCT00691509|OTHER|high performance liquid chromatography|
40774198|NCT00691509|OTHER|laboratory biomarker analysis|
40774199|NCT00691509|OTHER|mass spectrometry|
40774200|NCT00691509|OTHER|questionnaire administration|
40774201|NCT04770584|OTHER|Fear Conditioning|Participants will be administered increasing intensities of mild electric shock via electrodes connected to the foot. New Biopac stimulators that can deliver higher shock intensity, provided participants agreement will be used to assure adequate conditioning levels. Stimulation is measures in milliamps (mA), and each delivered stimulation will be 0.5 seconds long (500 milliseconds). To colored (blue, red, \& yellow) light stimuli (CS). The light stimulus is followed by a shock or no shock depending on color (blue \& red - shock; yellow - no shock).
40774202|NCT04770584|OTHER|Avoidance conditioning|Via button pressing. Only one stimulus-CS (i.e. blue colored light) will enable control over experiencing the shock: the participant can press the button during the first 2 seconds of the light presentation to avoid the shock. CS stays on for 6 seconds after the button is pressed. If the button is pressed, no shock will be administered. After 6 seconds, the light ends and the relief epoch ('good feeling') begins. Pressing the button to the other CS (i.e. red colored light) will not prevent the shock from occurring- the participant will still receive the mild shocked at CS offset (after 6 seconds). The third CS (i.e. yellow light) will serve as a control CS, so while the button is available, pressing it or not is of no consequence.
40774203|NCT04770584|OTHER|Pavlovian fear extinction learning|After avoidance conditioning, the CS+ associated with avoidance responding (i.e. blue light) appears with no button to press and no shock is administered.
40774204|NCT04770584|OTHER|Willingness to pay to avoid shock|"On the next day, participants receive a monetary stipend to use to pay to guarantee that they are not to receive any shocks if they press a button from the CS+. No shocks will be delivered on day 2, regardless of money paid.~This and all previously described experimental phases noted above will occur inside of the fMRI scanner."
40774205|NCT06145412|DRUG|Xevinapan|Xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles)
40774206|NCT06145412|DRUG|Cisplatin|Cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks)
40774207|NCT06145412|RADIATION|External beam|60 - 66 Gy in 2 Gy fractions for patients without gross disease and 70 Gy for patients with early recurrence) with concurrent cisplatin (40 mg/m2 once weekly)
40774208|NCT03224884|PROCEDURE|Interscalene block|Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.
41141939|NCT05224245|DEVICE|ACURATE Prime XL Transfemoral Aortic Valve System|ACURATE Prime™ Transfemoral Aortic Valve system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
41141940|NCT00121589|DRUG|Lutein|
40774209|NCT03224884|PROCEDURE|Supraclavicular block|"Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus)."
40774210|NCT04579367|DRUG|Bempedoic acid and/or its fixed-dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.
40774211|NCT03378960|DRUG|Omeprazole 20mg|
40774212|NCT00331721|DRUG|Enecadin|Dose escalating
40774213|NCT00331721|DRUG|Placebo|Placebo comparator
40774214|NCT00738127|PROCEDURE|Open reduction and internal fixation|Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
40774215|NCT05014919|DRUG|Vortioxetine|Tablets
40774216|NCT05014919|DRUG|Placebo|Tablets
40774217|NCT04570202|BEHAVIORAL|EMDR|The EMDR therapy is organized in eight different phases, requiring attending multiple sessions, usually 12 separate sessions.
40774218|NCT03758521|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
40774219|NCT03758521|DEVICE|Magnetic resonance imaging (MRI)|These will be outpatient MRI studies that are planned without sedation. Subjects enrolled at BCH will undergo brain MRI, including volumetric MRI, MRS, and diffusion tensor imaging (DTI). The data will help define the natural history of brain volume, brain myelination and spectroscopic (e.g. GABA) abnormalities.
40774220|NCT03758521|DEVICE|Electroencephalogram (EEG)|These will be outpatient EEG recordings that span 20-60 minutes and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
40774221|NCT03758521|PROCEDURE|Bio-specimen Collection|Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.
40774222|NCT04118660|OTHER|Tissue Banking|Blood, tissue, and fluid collection
40774223|NCT04810624|BEHAVIORAL|Relapse Prevention and Changing Habits (REACH+)|Psychotherapy
40774224|NCT00129974|DRUG|pemetrexed and gemcitabine|
40978263|NCT05245370|BEHAVIORAL|Control video|Control group 1 will see a control video consisting of basic information about the different types of psychotherapy that are covered by insurance in Germany and the process of applying for psychotherapy with the insurance. The control video is matched in duration (10 minutes), set-up and the overall topic (psychotherapy) to the intervention video testimonials.
40978264|NCT05245370|BEHAVIORAL|Rationale video|The active control group 2 will see a short rationale and the control video. The rationale is a 2:45 minute-long animated video (designed via the visual communication platform powtoon, https://powtoon.com/) explaining some of the underlying mechanisms of depression.
40978265|NCT05245370|BEHAVIORAL|Clinician testimonial|This group will see the rationale video first, followed by testimonial of a professional clinician/psychotherapist.
40978266|NCT05245370|BEHAVIORAL|Patient testimonial|This group will see the rationale video first, followed by testimonial of a patient who is being treated for depression with psychotherapy.
40978267|NCT00106392|DRUG|Tacrolimus|oral
40978268|NCT00106392|DRUG|Placebo|oral
40978269|NCT05268939|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B test|Swab Samples for Diagnostic test
40978270|NCT05268939|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & RSV test|Swab Samples for Diagnostic test
40978271|NCT06264167|DIAGNOSTIC_TEST|High-resolution bilateral groin ultrasound surveillance|Participants in the Interventional Treatment (serial ultrasounds) group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, follow-up appointments occur bi-monthly for 12 months, involving a clinical examination and groin ultrasound. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
40978272|NCT03473808|BEHAVIORAL|task-practice therapy|Standardized hand therapy program
40978273|NCT03473808|OTHER|Vibration|Peripheral vibration applied to the wrist skin at an imperceptible level
40978274|NCT05715593|OTHER|health education intervention|health education intervention
40978275|NCT00791167|DRUG|Paliperidone ER|
40978276|NCT05733624|DRUG|SCAI-001 0.01% eyedrop|BID for 12weeks
40978277|NCT05733624|DRUG|SCAI-001 0.02% eyedrop|BID for 12weeks
40978278|NCT05733624|DRUG|Restasis 0.05% eyedrop|BID for 12weeks
40978279|NCT00607412|BEHAVIORAL|Integrated psychotherapy for PTSD and substance use|integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence
40978280|NCT00607412|BEHAVIORAL|12-step based supportive therapy|supportive psychotherapy based on 12-step model
40978281|NCT00002990|BIOLOGICAL|BCG vaccine|
40978282|NCT00684307|DRUG|AZD0837|ER tablet, PO, once daily for a period of 3-9 months.
40978283|NCT00684307|DRUG|Vitamin-K antagonist at INR 2-3|Tablet, PO for a period of 3-9 months.
40978284|NCT00684307|DRUG|AZD0837|ER tablet, PO, twice daily for a period of 3-9 months
40978285|NCT03867305|DEVICE|MOBIDERM|Use of a MOBIDERM mobilizing band after total knee prosthesis
40978286|NCT00820690|DRUG|doxorubicin|4 cycles AC: doxorubicin 60mg/m2
40978287|NCT00820690|DRUG|cyclophosphamide|4 cycles AC: cyclophosphamide 600mg/m2
41141941|NCT02216994|DRUG|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
41460952|NCT06323616|PROCEDURE|MAC adjustment to PSI between 25 and 50|According to SedLine monitoring, the depth of anesthesia will be adjusted by changing the amount of sevoflurane so that the PSI median value is between 25 and 50.
40978288|NCT00820690|DRUG|paclitaxel|4 cycles T: paclitaxel 175mg/m2 after 4 AC
40978289|NCT00820690|PROCEDURE|Surgery|"The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.~The oncoplastic surgery rate will be reported"
40978290|NCT02390401|DEVICE|Vacuum-assisted closure|Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
40978291|NCT02390401|DEVICE|Standard sterile dressing|Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
40978292|NCT00221728|DEVICE|Radiofrequency|
40978293|NCT00221728|PROCEDURE|conservative surgery|
40978294|NCT04492618|DRUG|Ruxolitinib|Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica
40978295|NCT00592384|DRUG|venlafaxine XR|Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
40978296|NCT00592384|DRUG|placebo|Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
40978297|NCT04488289|OTHER|Lifestyle|Cardiovascular risk and lifestyle
40978298|NCT06037434|DRUG|Captopril Tablets|0.3mg/kg, tid
40978299|NCT06037434|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
40978300|NCT06037434|DRUG|Spironolactone Tablets|2-4mg/kg, bid
40978301|NCT06037434|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
40978302|NCT06037434|DRUG|Potassium citrate powder|0.06g/kg, tid
40978303|NCT02107482|DEVICE|Levia Narrow Band UVB|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
40978304|NCT02107482|DEVICE|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
40978305|NCT02000973|DRUG|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine
40978306|NCT02000973|DRUG|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine
40978307|NCT02000973|DRUG|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine
40978308|NCT02000973|DRUG|Normal Saline|General anesthesia combined with thoracic epidural 0.9% normal saline
40978309|NCT04166435|DRUG|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
41460953|NCT05588063|DEVICE|Transcutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
41460954|NCT05588063|DEVICE|Sham device|The device will appear to function but no electrical stimulation will be delivered.
41460955|NCT04158687|DRUG|CTP-692|Administered as powder for oral solution.
41460956|NCT04158687|DRUG|Placebo|Administered as powder for oral solution.
40774225|NCT01600287|OTHER|IAADS|"In automatic mode, the system requests an update of the BIS data every 5 seconds and calculates the BIS error (difference between the target and actual BIS value). This value along with the trends of BIS in the epoch of the last 30 seconds as well as in the last 5 minutes is passed on to a patient individualized, model based adaptive control algorithm. The algorithm uses the error to calculate an adjustment to the propofol delivery rate, but does not apply it immediately. Adjustments to the propofol delivery rate are only made every 30 seconds, taking into account the sum of previous six BIS error values, the trends of BIS in the epoch of last 30 seconds as well as in the last 5 minutes, time elapsed since the initiation of infusion, pharmacokinetics, the time delay factor between sensing and averaging of BIS data, the time delay factor between the change in infusion rate and the actual change in the plasma concentration of propofol as well as the peak effect of propofol."
41460957|NCT04193579|BEHAVIORAL|Language Treatment|Recording of a mother's voice reading a children's storybook.
41460958|NCT04193579|BEHAVIORAL|Control Treatment|Standard of Care
40774226|NCT01600287|OTHER|Manual propofol administration|"In manual mode, the user can also control the propofol infusion rate manually, using the keyboard or the mouse of the PC. The PC displays a graph of the propofol delivery rate and trend of BIS value."
41460959|NCT05535920|DRUG|LOKELMA 5 GM Powder for Oral Suspension|Patients will use Lokelma supplementation on off-dialysis days (4 days/week) while receiving hemodialysis with 3.0 K+/2.5 Ca++ mEq dialysate bath. The individual starting dose will be 5.0 grams, and may be titrated weekly in 5.0 gram increments up to 15.0 grams to maintain K+ between 4.0 and 5.5 mEq/L.
40774227|NCT01927614|RADIATION|Cardiac CT|"A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~1. Prospectively gated calcium scoring.~2. Stress-myocardial CT perfusion.~3. Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus."
40774228|NCT05607472|OTHER|blood sampling|blood samples for bio collection
40774229|NCT05607472|OTHER|questionnary of health estate during 18 month|clinical exam Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation) during 18 months
40774230|NCT04492384|OTHER|non-interventional|Interview on health conditions
40774231|NCT04102566|DRUG|Ibuprofen 600 mg|We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
40774232|NCT04102566|BEHAVIORAL|Education|We'll be adding education to patient's post-operative instructions to aid in their pain control management.
40774233|NCT06225206|BEHAVIORAL|donor-derived cell free DNA in liver|Determine the difference in age, gender, LFTs, IS regimen (tacrolimus/sirolimus/cyclosporin with mycophenolate mofetil (MMF) and /or prednisone) between patients who underwent liver transplant \<1 year PTX and \>1 year PTX
40774234|NCT06092892|PROCEDURE|Breast Surgery (BCS or mastectomy) with TAD/SNB|Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
40978310|NCT01765205|DEVICE|Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter|Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
40978311|NCT05263323|OTHER|Patient education|Providing patient education to hemodialysis patients according to Neuman Systems Model by the researcher.
40978312|NCT05263323|OTHER|Data Collecting, No Education|Data were collected at the beginning and end of the study without training the control group.
40978313|NCT02536040|DRUG|38% diammine silver fluoride|treatment of cavity with study agent
40978314|NCT02536040|OTHER|Water|Fluoride free, distilled water
40978315|NCT01179854|DRUG|Remegal|Drug/ placebo
40978316|NCT05543525|OTHER|Echocardiography|Transthoracic echocardiography
40978317|NCT05543525|OTHER|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing
40978318|NCT03067649|BEHAVIORAL|Motivational Interview|90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
41460960|NCT00162968|DRUG|escitalopram|
41460961|NCT05731024|DEVICE|close-loop synchronization controller with SPONT mode|One-hour period where the pressure support of spontaneous breath will be automatically titrated based on pressure and flow waveform analysis obtained from the patient.
41460962|NCT05731024|DEVICE|Conventional synchronization settings with SPONT mode|One-hour period where the pressure support of spontaneous breath will be manually set.
41460963|NCT02583048|DRUG|Bedaquiline|Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.
41460964|NCT02583048|DRUG|Delamanid|Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.
41460965|NCT02583048|DRUG|Dolutegravir|For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)
41460966|NCT02583048|DRUG|Multidrug Background Treatment (MBT) for TB|A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
41460967|NCT02245698|BIOLOGICAL|Stem cell|Intrathecal autologous bone marrow mononuclear cell transplantation
41301940|NCT05875935|PROCEDURE|ECoG : electrocorticography|"The skull and the dura are opened under general anesthesia and the two grids of 64 cortical electrodes will be applied to the cortex, one facing the glial lesion, and the other at a distance from the glial lesion in the so-called area. Healthy (non-tumor), before the patient wakes up. They consist of 8 recording slides each comprising 8 electrodes of 2 mm in diameter each spaced 0.5 mm (DispoMed®, USA)."
41460968|NCT00003906|DRUG|Raloxifene|60 mg/day plus placebo for 5 years
41460969|NCT00003906|DRUG|Tamoxifen|20 mg/day plus placebo for 5 years
40774235|NCT06092892|RADIATION|Adjuvant Radiation Therapy|Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
41141942|NCT02216994|BEHAVIORAL|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
41141943|NCT02216994|DRUG|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
41141944|NCT03311997|PROCEDURE|Surgical reattachment of hamstring tendons|operatively reattachment of the tendons using suture anchor
41141945|NCT04614129|DIAGNOSTIC_TEST|Low Dose CT|All participants will have a low dose chest CT either within one year of enrollment or after enrollment
41141946|NCT03933241|BEHAVIORAL|nasal irrigation|nasal irrigation after Transnasal transsphenoidal surgery for pituitary tumor
41141947|NCT05939830|PROCEDURE|Stained region Lymph Node Biopsy (SrLNB)|Before NST, positive lymph nodes would be marked with localized titanium clips under ultrasound guidance, and carbon nanoparticles suspension would be injected into the cortex of the marked lymph nodes and surrounding suspicious lymph nodes for staining. Marked and stained lymph nodes will be removed and biopsied after NST.
41141948|NCT05939830|RADIATION|Regional lymph node radiotherapy (RNI) including the axilla|RNI including the axilla covers the supraclavicular region and entire axillary lymphatic drainage area (region I, II and III) ,and is at a dose of 50 Gy/25 times, with additional prophylactic irradiation of the internal breast lymphatic drainage area for eligible patients.
41141949|NCT05830032|DIETARY_SUPPLEMENT|Soluble corn fibre|As a powdered beverage
41141950|NCT05830032|DIETARY_SUPPLEMENT|Inulin|As a powdered beverage
41141951|NCT05830032|DIETARY_SUPPLEMENT|soluble corn fibre and inulin|As a powdered beverage
41141952|NCT05830032|DIETARY_SUPPLEMENT|Maltodextrin|As a powdered beverage
41141953|NCT00006084|BIOLOGICAL|lintuzumab|
41141954|NCT02008214|DRUG|Pentoxifylline|Addition of pentoxifylline to current HCV treatment
41141955|NCT02008214|DRUG|Placebo|Placebo matching pentoxifylline dosage
41141956|NCT01354288|OTHER|Educational tool|Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
41141957|NCT03980236|DEVICE|Livongo-Insulia Study App|Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
41141958|NCT06395207|BEHAVIORAL|Proactive community case management|Community health workers conduct proactive visits to households in their community every two weeks for two months to screen for fever and test and treat febrile individuals for malaria.
41141959|NCT06395207|BEHAVIORAL|Strengthened SBCC and stock out mitigation|Ensure CHWs have all commodities needed for malaria testing and treatment and are adequately trained on SBCC messages to ensure activities are implemented as designed in the national strategy.
41141960|NCT06030037|BIOLOGICAL|Responder-Derived Fecal microbiota transplantation (R-FMT|R-FMT (induction) via colonoscopy on C1D1 and C3D1. R-FMT (maintenance) via sigmoidoscopy will be repeated every 9 weeks.
41141961|NCT06030037|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity)
41301941|NCT03572543|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
41301942|NCT04626024|OTHER|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal|Stop taking TKI medication
41460970|NCT03942211|DRUG|Selexipag|Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
41460971|NCT03942211|DRUG|Placebo|Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
41460972|NCT04674150|DEVICE|ARISE with AR|An augmented reality game for mobile devices with AR experiences enabled
41460973|NCT04674150|DEVICE|ARISE without AR|An augmented reality game for mobile devices with AR experiences disabled as an control
41460974|NCT05079841|DEVICE|Electric breast pump|Participants randomized to the intrapartum nipple stimulation will use electric breast pump or nipple stimulate by hand (if preferred) (intervention) to induce labor for at least 2 hours
41141962|NCT06030037|DRUG|Lenvatinib|Lenvatinib will be administered at 20 mg daily
41141963|NCT01775878|DEVICE|Telemonitoring Device|Telemonitoring device was installed in patients' homes
41460975|NCT05079841|DRUG|Exogenous oxytocin intravenous infusion without nipple stimulation.|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor as current standard of care
41460976|NCT02849106|PROCEDURE|biopsy to obtain a chemogram|All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
41460977|NCT05920954|PROCEDURE|ERCP|Repeat ERCP
40978319|NCT03067649|BEHAVIORAL|Information only control|Participants are provided with a pamphlet containing referral information
40978320|NCT00937157|DRUG|Copaxone|12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
40978321|NCT01744054|DEVICE|PET/MR|
41141964|NCT03575507|DEVICE|Treatment with BTL EMSCULPT device.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
41141965|NCT01707563|PROCEDURE|skin punch biopsy and molecular biology|
41141966|NCT01707563|OTHER|fibroblast culture and molecular biology|
41141967|NCT03544047|DRUG|Paclitaxel|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen). If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks).
41141968|NCT05935306|DRUG|Ibuprofen|All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group.
41141969|NCT05935306|OTHER|Photobiomodulation simulation|The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off.
41141970|NCT05935306|DEVICE|Photobiomodulation|. Patients will receive FBM and will be treated identically to the G2 group. The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away.
41141971|NCT05935306|OTHER|Ibuprofen simulation|Placebo ibuprofen will be manipulated by pharmacy (Matias Gonzalez)
41141972|NCT05076825|OTHER|Neurodynamic Sliding|Participants supine with their cervical and thoracic spine supported in a forward flexed position. Simultaneous hip and knee flexion will be alternated dynamically with simultaneous hip and knee extension. The therapist will change the arrangement of movement depending on the tissue resistance level.
41141973|NCT05076825|OTHER|Static Stretching|Participent lying supine, the therapist will passively position the subject into the straight leg raise position without discomfort or pain to the point where resistance to movement will be first felt.
41141974|NCT05033756|DRUG|Pembrolizumab Injection [Keytruda]|The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type.
41141975|NCT05033756|DRUG|Olaparib Oral Tablet [Lynparza]|All patients will receive olaparib treatment as an addition to pembrolizumab. The dose of olaparib used in this study is 300 mg twice daily (total daily dose of 600 mg) which is the currently approved dose.
41141976|NCT00898313|GENETIC|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
41141977|NCT00898313|GENETIC|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
41141978|NCT00898313|GENETIC|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
41141979|NCT00898313|OTHER|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
41141980|NCT00898313|PROCEDURE|nasal brushing|Using a brush, superficial cells are removed from the nose.
41460978|NCT02795676|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
41460979|NCT02795676|BIOLOGICAL|agalsidase beta|agalsidase beta 1 mg/kg every 2 weeks
41460980|NCT01713166|DRUG|plasmalyte solution|plasmalyte solution
40978322|NCT01744054|DEVICE|PET/CT|
40978323|NCT05070598|DRUG|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle
40978324|NCT01405599|DRUG|Ulimorelin|Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
40978325|NCT01378078|DEVICE|eldith DC-stimulator (neuroconn, Ilmenau, Germany)|daily tDCS treatment over left DLPFC, 20 min, 2 mA
40978326|NCT01378078|DEVICE|eldith DC-stimulator (Neuroconn, Ilmenau, Germany)|same as sham stimulation
40978327|NCT00231595|DRUG|topiramate|
41460981|NCT01713166|DRUG|Hextend|Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
41141981|NCT00898313|PROCEDURE|Blood draw|Venous blood will be collected
41141982|NCT00898313|PROCEDURE|Urine collection|Subjects will be asked to provide a urine specimen.
41141983|NCT00898313|PROCEDURE|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
41141984|NCT00898313|PROCEDURE|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
40978328|NCT01772238|DRUG|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Reference product
40978329|NCT01772238|DRUG|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Test product
40978330|NCT02329561|DRUG|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
40978331|NCT02329561|BEHAVIORAL|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
40978332|NCT02329561|DRUG|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
40978333|NCT02867033|PROCEDURE|biopsy|pre-therapeutic or post-therapeutic biopsy or resected tissues
40978334|NCT02867033|OTHER|biobank constitution|Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues
40978335|NCT02867033|PROCEDURE|Coloscopy|For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed
40978336|NCT02867033|PROCEDURE|Blood sampling (facultative)|Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)
40978337|NCT02867033|OTHER|Pain evaluation|Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)
40978338|NCT02867033|PROCEDURE|Tumor biobank realization|Realization of a tumor biobank is part of classical procedure of participating centers
40978339|NCT03705676|BEHAVIORAL|Rapid Arm Movements|240 trials of RAM in either a forward (50%) or backward (50%) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
40978340|NCT03705676|DEVICE|Unpleasant stimulus|An unpleasant, but harmless, electrocutaneous stimulus is administered to the low back region in 25% of the threat trials during the fear condition. Due to a conditioning phase before testing, participants know to expect this stimulus after the presentation of a warning cue related to the fear trials (either pink or blue dot dependent on randomization).
40978341|NCT03705676|DEVICE|Vibrotactile stimulus|In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
40978342|NCT00227695|BIOLOGICAL|rituximab|comparing two maintenance schedules of Rituximab
40978343|NCT02548650|DRUG|Vorapaxar|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
40978344|NCT02548650|DRUG|Clopidogrel|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
40978345|NCT02548650|DRUG|Aspirin|Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
40978346|NCT04450966|BEHAVIORAL|Computer-facilitated Screening and Brief Intervention|cSBI includes: 1) computer self-administered screening that adolescents complete prior to seeing their clinician, immediately followed by 2) computer-delivered brief psychoeducation on the health risks of substance use to prime patients for the clinician encounter, and 3) a Clinician Report Form with screen results and prompts that clinicians use to provide motivational interviewing-based individualized counseling during the visit.
40978347|NCT01286181|BEHAVIORAL|Twice daily practice of device-guided slow breathing.|Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
40978348|NCT04219631|DEVICE|expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate.|women enrolled in WINNER-FLOW-URO-MG group will freely use the expiratory mouthpiece device during all their childbirth process.
40978349|NCT00754624|DRUG|Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler|Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
40978350|NCT00791466|DIETARY_SUPPLEMENT|Placebo|Daily placebo supplementation from enrolment \<14 wk of gestation until delivery
41460982|NCT03890757|OTHER|ultrasound guided paravertebral or serratus anterior block|"Patients groups will be as follow:~Group (I): Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe ,Group (II): thoracic paravertebral block will be performed in the sitting position. The spinal level chosen for needle insertion will be two segments below the upper most fractured rib or midway between the upper most and lowest fractured rib, 2-2.5 cm distance from the midline in the same injury site"
41460983|NCT01632449|DRUG|Test product|Dimethyl Fumarate (BG00012)
40978351|NCT00791466|DIETARY_SUPPLEMENT|Iodine|Daily supplementation with 200 µg iodine from enrolment \<14 wk of gestation until delivery
41460984|NCT01632449|DRUG|Reference product|Dimethyl Fumarate (BG00012)
40978352|NCT05109650|DRUG|BAT6026|IV infusions
40978353|NCT05109650|DRUG|BAT1308|Ⅳ infusions
40978354|NCT05328973|OTHER|ELEQUIL|patch placed on skin
41460985|NCT03695211|PROCEDURE|Conventional landmark technique|inject at the midpoint of the posterior border of the sternocleidomastoid muscle
41460986|NCT03695211|PROCEDURE|Precise block technique|inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
40978355|NCT01217840|DRUG|Drisdol (Ergocalciferol) Vitamin D2|Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
40978356|NCT01217840|DRUG|Placebo|Placebo pill - 3 pills every 12 weeks for total of 24 weeks
40978357|NCT00194064|DRUG|Olanzapine|
41141985|NCT00898313|PROCEDURE|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
41141986|NCT00898313|PROCEDURE|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
41141987|NCT00689416|DRUG|rosuvastatin|40 mg, tablet, once daily for 3 months.
40774236|NCT05991713|BEHAVIORAL|Modifying Exploration|Participants in this group will use a mobile phone sensor data application that uses an accelerometer, Wireless Fidelity (WiFi) and/or GPS designed for smartphone devices. This technology allows the phones to capture information automatically and passively on the participant's activity. The application will be collecting participants' data 24 hours a day, 7 days a week. Participants will be asked to make alterations to their exploration levels approximately 20 days of their participation in the study.
41460987|NCT05696041|OTHER|Static strength training program or/and Dynamic strength training program of the hand|Four of the five exercises included in the static or dynamic training program were based on holding the weight over the edge of the table and maintaining the position for 10 seconds, then resting briefly and changing to the next position. The training was performed in the following assumed positions, pronation, supination, radial and ulnar position. In the fifth and final exercise, you would squeeze an exercise ball as hard as possible without pain. The starting weight was 0.5 kilogram, and each exercise (1-4) was performed in three sets in the first week. The training increased by one set per week for up to eight sets/week if pain or paresthesia got worsened. If the training worked, the OT and the subject could choose to increase the weight to 1 kilogram and start over with three sets/day and gradually increase the training or switch to a dynamic training program.
41460988|NCT04625673|DEVICE|OsciPulse|OsciPulse device and standard IPC device
41460989|NCT04781244|DEVICE|EndWarts® FREEZE|EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.
41460990|NCT04781244|DEVICE|Liquid nitrogen|Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.
41141988|NCT00689416|DRUG|placebo|40 mg, tablet, once daily for 3 months
41460991|NCT03904836|DRUG|Tobramycin|5 milligrams per kilogram intravenous for one dose
41460992|NCT04795466|BIOLOGICAL|Canakinumab|Biological sub-cutaneous injection
41460993|NCT04795466|OTHER|Placebo|Matching placebo subcutaneous injection
40774237|NCT05718531|DRUG|Rivaroxaban 2.5 Mg Oral Tablet twice daily|effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.
40774238|NCT05718531|DRUG|Clopidogrel 75 Mg Oral Tablet|Used as control group in 2nd arm and 5th arm
40774239|NCT05718531|DRUG|Aspirin tablet 75 mg|Used as control group in 2nd arm and 5th arm
41460994|NCT02400463|DRUG|Ruxolitinib|
41460995|NCT01122316|DRUG|Metformin|3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
41460996|NCT06402227|OTHER|gamified instruction|"At the beginning, the speaker played the role of a laboratory rescue team, narrated the background story of the board game, and led the children into the game situation. Then, the speaker explained four types of pathogens, which the investigators defined them according to different types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker explained their characteristics and key points, representative diseases in real life, corresponding prevention methods and so on. The lecture lasted for 15 minutes, then the children were divided into different groups to play the board game for about 20 minutes. During the game, students were required to collect Prevention Method Cards made by the research team. Students must perform the correct behavior of infection control or answer questions related to the class content in order to obtain the card and win."
40774240|NCT02900014|PROCEDURE|sampling mesenchymal stem cells|nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
40774241|NCT04854304|DIAGNOSTIC_TEST|Fast Breast Abbreviated Magnetic Renounce Imaging|Fast Breast MRI Imaging
40774242|NCT04995341|DEVICE|Investigational ultracompact OCT and OCTA system|Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece
40774243|NCT04995341|DEVICE|retinal photographs|retinal photographs with a commercial portable bedside widefield fundus camera system
40774244|NCT04975620|DEVICE|Fine needle biopsy|Taking biopsy from solid pancreatobiliary mass lesions with 8 back and forth movement of the needle within the lesion with slow withdrawal of the stylet
40774245|NCT04162834|DRUG|Papaverine|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
40774246|NCT04162834|DRUG|Normal saline|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
41141989|NCT02399072|OTHER|No intervention|No intervention administered in this study
41141990|NCT00578344|DRUG|Busulfan|Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
41141991|NCT00578344|BIOLOGICAL|Campath 1H|Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.
41141992|NCT00578344|DRUG|Cyclophosphamide and MESNA|Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
41141993|NCT01594606|BEHAVIORAL|Animal-assisted intervention|The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
41141994|NCT05211726|OTHER|Low Added Sugar Diet|Consumption of 10 days of a diet low in added sugars (5% of total caloric intake)
41141995|NCT05211726|OTHER|High Added Sugar Diet|Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
41301943|NCT04626024|DRUG|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation|Re-start TKI medication
41460997|NCT06402227|OTHER|conventional lesson lecture|The lecture was about 35 minutes. At the beginning, the speaker explained the terms to children, including infectious diseases, symptoms and pathogens. Next, the speaker introduced the components of the infection chain and how to make infection control behaviors for different parts of it. Then the speaker focused on the four types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker illustrated their characteristics and key points, representative diseases in real life, and corresponding prevention methods. In the end, the speaker led the students to practice infection control behaviors, such as the seven correct steps of washing hands, the right steps for wearing and taking off masks, and exercises that can be done to increase immunity.
41460998|NCT02521051|DRUG|Alectinib|
41141996|NCT02723799|BEHAVIORAL|Hope Promotion Program (HPP)|"HPP is based on literature review and qualitative research in hope at the end-of-life. The film Hopeful living reflects the findings of the grounded theory study. Hope activity book is the final product of the literature review on hope interventions and its activities were tested in their feasibility and suitability in our previous research with persons with advanced cancer and their families."
41141997|NCT02723799|OTHER|Standard Treatment Protocol|Regular assessment and care by the hospital outpatient health care team.
41141998|NCT03040973|DRUG|Capmatinib|Tablet for oral use; 150 mg, 200 mg; twice a day
41141999|NCT03040973|DRUG|Nazartinib|Capsule for oral use; 25 mg, 50 mg; once a day
41142000|NCT03040973|DRUG|Gefitinib|tablets for oral use; 250mg; once a day
41142001|NCT03040973|DRUG|Osimertinib|Tablets for oral use; 40 mg, 80 mg; once a day.
41142002|NCT01811615|OTHER|alcohol-free experimental mouth rinse|
41142003|NCT01811615|OTHER|alcohol-containing mouth rinsing|
41142004|NCT04827849|OTHER|Structured education and follow-up|"The women in the intervention groups will administer a seven-session intervention program in addition to the routine care they will receive.~The training including preparation practices for the transition with the mother, which is planned to last for 7 weeks encompassed providing the women with an educational programme that were created to increasing women's adaptation to motherhood and perceptions of newborn baby~Nursing-recommended follow-up and physical examination of the pregnant woman will be performed at 28th and 34th week of pregnancy. In addition, postpartum and newborn follow-up, and mother-newborn physical examinations will be performed at the postpartum period."
41142005|NCT02981953|DEVICE|Cardioband Tricuspid|The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
40774247|NCT00757016|DRUG|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
41146940|NCT05235815|PROCEDURE|Retro SCTL compartment block|"For phase 1, healthy human volunteers will be positioned in the lateral position with the side to be scanned in the non-dependent position. An ultrasound scan sequence to describe the retro SCTL space will be performed on both sides.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block. After positioning the participants, cleaning and draping the injection site, under sterile aseptic precautions and local anaesthetic infiltration, the block needle is inserted at the corresponding vertebral level (T7-T8) under ultrasound guidance in-plane to the ultrasound beam. Once the needle tip reaches the lateral aspect of the inferior articular process and behind the SCTL ligament, the desired volume (6ml/each level) of LA will be injected. This process will be continued at the remaining two vertebral levels (T5-T6 and T3-T4)."
40774248|NCT00757016|DRUG|Saline solution|Saline solution
41146941|NCT00582920|RADIATION|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
41146942|NCT04707885|DEVICE|Electrocochleography|"The use of ECochG monitoring will be employed. This will be conducted intraoperatively during the entire portion of the CI electrode insertion component.~For the purposes of this clinical trial, the stimulus will consist of a 500 Hz tone burst presented at \~105-110 dB SPL. This was chosen due to the time and resource limitations in the operating room. Hence, the surgical team can only utilize a very limited dataset for intraoperative decision making and previous studies have demonstrated that 500 Hz stimulation offers the most robust, reliable, and useful ECochG signal during electrode insertions."
41146943|NCT03402399|OTHER|Molecular analysis|Blood test
41301944|NCT03983876|DRUG|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory disease"
41460999|NCT02521051|DRUG|Bevacizumab|
40774249|NCT03624725|PROCEDURE|modified BII+Braun|modified BII+Braun digestive tract reconstruction
40774250|NCT01537432|DRUG|secukinumab|secukinumab
40774251|NCT01537432|DRUG|placebo|placebo comparator
40774252|NCT05697224|DIAGNOSTIC_TEST|urinary micro RNA detection|Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR_71a gene expression analysis MAPK-3 gene expression analysis
40774253|NCT01290991|DEVICE|Augment Bone Graft|Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
40774254|NCT01331655|DRUG|EE20/DRSP (BAY86-5300)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
40774255|NCT01331655|DRUG|EE20/DRSP/L-5-MTHF (BAY98-7071)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
40774256|NCT01331655|DRUG|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)|Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
40774257|NCT03498716|DRUG|Atezolizumab|"Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year"
41461000|NCT00879541|BIOLOGICAL|Biostate® [SP]|Single bolus intravenous dose of 50 IU/kg
41461001|NCT00879541|BIOLOGICAL|Biostate® [SP]|The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.
41461002|NCT00879541|BIOLOGICAL|Biostate® [RP]|Single bolus intravenous dose of 50 IU/kg.
41461003|NCT02505724|BEHAVIORAL|conventional training|After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
40774258|NCT03498716|DRUG|Paclitaxel|Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.
41461004|NCT02505724|BEHAVIORAL|peer-coaching|Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
41461005|NCT03526562|BEHAVIORAL|Exercise|Exercise according to dose escalation
40774259|NCT03498716|DRUG|Dose-dense Doxorubicin or dose-dense Epirubicin|"Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses"
40774260|NCT03498716|DRUG|Cyclophosphamide|Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
40774261|NCT02168556|BEHAVIORAL|Music|Subject listens to music that is 60bpm while undergoing urodynamic testing.
40774262|NCT02168556|BEHAVIORAL|Video|Subject watches an informational video prior to undergoing urodynamic testing.
40774263|NCT02168556|OTHER|Standard of care|Standard of care
41301945|NCT02329522|DEVICE|Ultrasonic Cardiac Output Monitor|"An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow."
41461006|NCT06022588|DRUG|Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA|a solution containing butyrate of which 12C of the last 4 carbon positions of butyrate were replaced by 13C butyrate. Participants received 0.80 gram 13C-butyrate (7.3 mMol butyrate / 29 mMol 13C) dissolved in 50 mL water at baseline
41461007|NCT06022588|DRUG|U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA|a glucose solution in which all six 12C carbons were replaced by 13C D-Glucose. Participants received 0.75 gram 13C-glucose (4.2 mMol D-glucose/ 25 mMol 13C) dissolved in 50 mL water at baseline
40774264|NCT06239558|OTHER|Qualitative exploration|Semi-structured Interviews and focus group
40774265|NCT05790694|DRUG|HBM9378 (SKB378) Injection|Strength: 225 mg (1.5 mL)/vial
40774266|NCT05790694|DRUG|Placebo|Strength: 225 mg (1.5 mL)/vial
40774267|NCT02699411|DEVICE|Dry needling|dry needling Travell and Simons
40774268|NCT02699411|OTHER|Stability and propioception|Start excursion balance test, WOMAC; ROM, EVA.
40774269|NCT03303729|DIETARY_SUPPLEMENT|Meat Hydrolysate|25 grams of meat hydrolysate to maximally stimulate protein synthesis.
40774270|NCT03303729|DIETARY_SUPPLEMENT|Cluster Dextrin|75 grams of Cluster Dextrin
40774271|NCT03303729|DIETARY_SUPPLEMENT|Placebo|75 grams of Glucose
41142006|NCT04526132|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
41146944|NCT00966641|DRUG|Naproxen|Single orally administered dose of 500 mg naproxen
41146945|NCT00966641|DRUG|PL 3100|Single orally administered dose of PL 3100 (500 mg naproxen)
41146946|NCT02147652|OTHER|Personalized music|
40774272|NCT01690273|OTHER|mobility exercise|30 minutes, twice a week
40774273|NCT01690273|OTHER|mobility and elastic resistance exercise|30 minutes, twice a week each exercises group. (total 1 hour)
40774274|NCT03493165|DRUG|Everolimus|mTOR inhibitor
40774275|NCT03145220|DRUG|EA-230|Active intervention
40774276|NCT03145220|OTHER|Placebo (NaCl)|Placebo intervention
40774277|NCT04617860|DRUG|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide. It is administered monthly via intrathecal injection.
40774278|NCT01781988|DRUG|carboplatin, gemcitabine , pametrexed|"A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression."
40774279|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment.
40774280|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment if lung cancer has not been confirmed.
41301946|NCT02329522|DEVICE|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
41461008|NCT06022588|DIAGNOSTIC_TEST|Breath test|Breath tests were performed at the following time points baseline, 0.5, 1, 1.25 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5 and 4 hours after ingestion of 13C-butyrate and 13C-glucose. Breath samples were obtained by blowing a single breath of air through a straw into a test tube. Two breath samples were collected at all mentioned time points. Measurement of 13CO2 is performed using mass spectrometry (IDMicro Breath, Compact Science Systems, Newcastle-Under-Lyme, United Kingdom) using procedures described earlier for galactose and methacetin breath tests, and expressed as an absolute increase in the 13CO2-to-12CO2 ratio in delta permil (δ‰).
40978358|NCT06073353|BEHAVIORAL|THRIVE-M|"THRIVE-M is a self-administered psychosocial mobile application for patients living with multiple myeloma that includes the following five modules:~1. Health module - teaching patients about physical symptoms and strategies to cope with physical symptoms~2. Relationships module - helping patients articulate different support needs and communication styles in navigating relationships~3. emotions module - helping patients identify connections between thoughts, feelings, and behaviors, as well as helpful states of mind and gratitude~4. Lifestyle module - helping patients practice skills for saving up energy and using self-care strategies~5. Reflection module - teaching patients to reflect on their lives, meaningful relationships, and sense of purpose.~Each module takes about 15-20 minutes to complete and participants will be instructed to complete all modules within an eight-week period."
40978359|NCT00426491|DRUG|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
40978360|NCT04341454|DRUG|DWP14012 X mg|DWP14012 X mg, tablet, orally, once daily for 2 weeks
40978361|NCT04341454|DRUG|DWP14012 X mg placebo|DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks
40978362|NCT04341454|DRUG|DWP14012 Y mg|DWP14012 Y mg, tablet, orally, twice daily for 2 weeks
40978363|NCT04341454|DRUG|DWP14012 Y mg placebo|DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks
40978364|NCT00895323|OTHER|enzyme-linked immunosorbent assay|
40978365|NCT00895323|OTHER|pharmacological study|
40978366|NCT00895323|PROCEDURE|whole-body scintigraphy|
40978367|NCT00895323|RADIATION|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
40978368|NCT02093754|PROCEDURE|MRI and biopsy|
40978369|NCT03145350|OTHER|High-fat, low-carbohydrate|Dietary intervention: 4 week
40978370|NCT03145350|OTHER|Low-fat, high-carbohydrate|Dietary intervention: 4 week
40978371|NCT02031926|DEVICE|Positive expiratory pressure|
41461009|NCT06022588|DIAGNOSTIC_TEST|Exercise + breath test|The intervention groups performed a standardized bicycle ergometer exercise test of 30 minutes and semi-continuous peripheral blood lactate monitoring. The bicycle ergometer protocol consists of three phases. The first 10 minutes of exercise was used to gradually increase the workload until submaximal exercise intensity was reached which is defined as a circulating blood lactate level between 3 and 5.5 mmol/L. From minute 10 to 20 submaximal exercise intensity was maintained by adjusting the workload based on lactate measurements. Minute 20 to 30 was used to reach maximal exercise intensity, the workload was increased by 10% of the submaximal workload until exhaustion
40978372|NCT03577353|BEHAVIORAL|Dual Task Walking (DTW)|Each training session began with 8 min of general warm-up and 2 min walk around the gym. Then, for safety reasons, the participants were attached to a harness. The participants began walking slowly on the treadmill for 3 min. In the following phases the participants walked at the same speed, while training with 3 VR games. Each session lasted 3 min, and 3 min of single walking was performed between VR sessions. After the final VR session, 2 min of single-task walking was performed in order to allow for recovery. The time walked in each trial from the starting point to the destination was kept constant at 20 min.
40774281|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
40774282|NCT00455702|DRUG|d-cycloserine|50mg dose d-cycloserine v placebo
40774283|NCT02071589|DRUG|Nifedipine soft gelatine capsules|3 Adalat capsules of 10 mg each one
40978373|NCT03577353|BEHAVIORAL|Single-task Treadmill Walking (TMW)|this intervention, participants performed 8 min of general warm-up and 2 min walk around the gym, and then continued to walk for another 20 min on the treadmill at a speed that was equivalent to the intensity of 60%-70% of their heart rate reserve.
40978374|NCT02303301|DIETARY_SUPPLEMENT|Probiotics|Cultures from the oropharynx
40978375|NCT02303301|DIETARY_SUPPLEMENT|Placebo|Cultures from the oropharynx
40978376|NCT01487226|DRUG|paclitaxel|Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks \* 6 cycles
40978377|NCT01487226|DRUG|Cisplatin 50mg/m2|"Cisplatin 50mg/m2~Repeat every 3 weeks \* 6 cycles"
40978378|NCT00001054|DRUG|Valacyclovir hydrochloride|
40978379|NCT04384328|OTHER|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
40978380|NCT00949897|DEVICE|Biofoam|Device
40978381|NCT00949897|OTHER|Iliac Crest Allograft with locked plate|
40978382|NCT04481750|DRUG|MT-1186|Solution or suspension
40978383|NCT04481750|DRUG|MT-1186-matching placebo|Solution or suspension
40978384|NCT02005445|DEVICE|CPAP|Continuous positive airway pressure
40978385|NCT02005445|BEHAVIORAL|HLSE|Healthy living and sleep education
40978386|NCT04775602|DRUG|18F-PSMA|18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
41146947|NCT06327997|BIOLOGICAL|Fast CAR T cells|This study designed three dose groups, each with a dosage of 5.0 × 10\^5/kg、1.0×10\^6/kg、5.0×10\^6/kg
41146948|NCT06505499|OTHER|Gait Profile Score|Gait Profile Score in degrees, calculated from kinematic raw data with the Gdi_GPS_calculator spreadsheet developed by Baker (2009).
40978387|NCT01141907|BEHAVIORAL|Heart Failure Self Care Support|The intervention is aimed at preventing HF exacerbations and hospitalizations by improving self management with the support of the Home Automated Telemonitoring (HAT) system. The intervention was delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention was initiated during the index hospitalization. The RN-CHN team collaborated with participants, caregivers, and their usual source of HF care. Intervention strategies included tracking of weight and HF symptoms to provide feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and promoting communication with providers.
40978388|NCT01141907|OTHER|Usual heart failure care|Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
40774284|NCT02071589|DRUG|Nifedipine oral solution|6 mL of Nife Par solution
40978389|NCT02667574|DRUG|ERIVEDGE|
40978390|NCT01124422|DRUG|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
40774285|NCT03373435|DRUG|exendin 9-39|Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
40978391|NCT01124422|DRUG|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
40978392|NCT02596191|OTHER|Clinical evaluation|
40978393|NCT02596191|OTHER|electrophysiological record|
40978394|NCT02596191|OTHER|Muscle MRI|
40978395|NCT02596191|OTHER|blood samples analysis|
41142007|NCT04526132|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
41301947|NCT05878808|DIAGNOSTIC_TEST|Psychometric assessment|Eighty subjects diagnosed with bipolar I disorder were enrolled in this study, subjects were divided according to the presence or absence of OCD to Group A: Bipolar disorder patients with OCD (n = 26), Group B: Bipolar disorder patients without OCD (n = 54). The following scales were applied: Dimensional Yale-Brown obsessive compulsive scale (DYBOCS)- Beck scale for Suicidal ideations (BSSI) - Hamilton depression rating scale (HDRS) and Young mania rating scale (YMRS).
41461010|NCT04104360|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
40774286|NCT03373435|OTHER|Placebo|Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
40774287|NCT04164277|BEHAVIORAL|Caregiver Component.|Facebook-based program including four new habit-formation tasks/week. Three face-to-face or virtual caregiver meetings: Meeting 1: Study orientation and healthy cooking education will be offered, and each family will receive a small bag of groceries to facilitate preparation of a recipe at home. Each caregiver will also receive an intervention cookbook containing affordable slow-cooking recipes, quick-fix recipes, and healthy snack ideas. Meeting 2: Study interveners will demonstrate how to spend less and shop healthy and how to read nutrition fact labels to promote healthy purchasing behaviors. Meeting 3: Study interveners will present healthy eating and PA community resources (e.g., farmer's markets, community gardens, nearly parks or other free or affordable PA facilities) and provide caregivers a resource booklet.
40774288|NCT04164277|BEHAVIORAL|Caregiver-Preschooler Learning.|Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent by the PM privately to each caregiver via Facebook messenger on two weekdays. Caregivers will be asked to answer two Facebook multiple-choice questions related to the letters each week by Sunday midnight (e.g., what foods listed in the their child's letter did the participant provide? and what activities listed in the their child's letter did the participant's family try?). Caregiver responses to the questions will be summed to indicate caregiver responses to child requests. Each preschooler's letters will be kept in his/her intervention binder with other intervention materials to present to his/her caregiver at Meeting 3. Weekly preschooler activities, with pictures or videos, will be shared with caregivers via the Facebook private group every week.
40978396|NCT01948453|DIETARY_SUPPLEMENT|Garlic|Garlic tablet in adjunct to medical treatment
40978397|NCT04666051|BIOLOGICAL|Application of fibrin glue sealant|
40978398|NCT00263133|DRUG|Sertraline|
40978399|NCT04183595|DRUG|(N1, N3-bis(2- mercaptoethyl)isophthalamide)|600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.
40978400|NCT04183595|OTHER|Excipients microcrystalline cellulose, silica and magnesium stearate|6 Capsules will be administered every 24 hours for 14 days.
40978401|NCT05014763|PROCEDURE|connective tissue graft|Connective tissue graft surgery will be done for increasing soft tissue volume. In this methods connective tissue will be harvested from lateral palate or tuberosity area.
40978402|NCT05696678|DRUG|Intrathecal Morphine|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
41301948|NCT00193440|DRUG|Rituximab|
41301949|NCT00193440|DRUG|CHOP|
41301950|NCT00193440|DRUG|CVP|
41301951|NCT00193440|DRUG|Ibritumomab Tiuxetan|
41461011|NCT04104360|DIETARY_SUPPLEMENT|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
41301952|NCT05915819|OTHER|Plyometric Training|Exercise prescription according to weeks, sets and repetition. Weeks 1 and 2 1-2 sets / 10 repetitions Double leg jump Medicine ball(MB) stuffer flutter MB overhead throw MB single leg dip, Arrow cone drill Figure 8 drill Weeks 3 and 4 1-2 sets / 8 repetitions Ankle jumps Lateral cone hops Zigzag jump drill MB chest pass Jump \& turn 90° High-5 drill MB split squat Power skipping Clock drill T-drill Weeks 5 and 6 1-2 sets / 6 repetitions Dot drill Single leg cone hops Long jump and sprint Single leg zigzag drill MB lunge chest pass Jump and turn 180° Split squat jump Alternate bounding X-drill Shuttle drill
41301953|NCT05915819|OTHER|Eccentric Training|The eccentric training will be Pull-ups 3-5 sets X 6-8 reps Glute-ham raise 3-5 sets x 10rep Manual glute-ham raise 3-5 sets x 10rep single-leg Romanian dead lift or good morning(barbell or dumbbell) 3-5 sets x 10rep Glute-bridge and hip thrust (can also perform single leg movement) 3-5 sets x 10rep Half-kneel-bottom-up press-eccentric only. 3-5 sets x 8rep The eccentric exercise technique will be 2/1 technique, Two-movement technique, Slow/super slow, Negative (supramax)
41301954|NCT00047281|DRUG|celecoxib|
41461012|NCT03114345|OTHER|Measurement of interface pressure|A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
41461013|NCT03114345|OTHER|Measurement of micro-vascularization related parameters|A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
41461014|NCT00571480|OTHER|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
40978403|NCT05696678|DRUG|Ropivacaine 0.2%|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
40978404|NCT01714635|DEVICE|Tecnis Multifocal Intraocular Lens|
40978405|NCT01714635|DEVICE|Monofocal Intraocular Lens|
40978406|NCT02829450|OTHER|peritoneal ultrafiltration|Peritoneal fluids should be inserted intraperitoneally for several hours dwell
40978407|NCT01324999|DRUG|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
40978408|NCT03041402|OTHER|PSP|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
40978409|NCT03041402|OTHER|NAVA|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
40978410|NCT03041402|OTHER|PSN|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
40978411|NCT02655939|DIETARY_SUPPLEMENT|Reflex Plus|Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
40978412|NCT02655939|DIETARY_SUPPLEMENT|Placebo|Fructose,Orange flavor and sucralose
40978413|NCT02638727|DRUG|L-Citrulline|This group treat with L-Citrulline (3 grams per day)
40978414|NCT02638727|DRUG|placebo|This group treat with placebo dayley
41461015|NCT00571480|OTHER|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
40978415|NCT04359433|BEHAVIORAL|Exercise programme|"Exercise programme includes 8 anaerobic movements choosen from Tabata. This exercise programme workout is aimed at body fat reduction, and the structure is as follows:~* 8 anerobic movements in 20 seconds is a set~* Rest for 10 seconds before another set~* Finish 4 sets every time, it shall take you 4 minutes~* Do 4 sets 2 to 3 times a week"
40978416|NCT04766125|BEHAVIORAL|Adverse event information|All patients have access to the standard material about adverse events related to the surgery. One arm will additionally receive elaborated adverse event information from a nurse and a surgeon
40978417|NCT05261074|OTHER|No intervention|No intervention (retrospective study)
40978418|NCT02458820|PROCEDURE|DSA EEG|Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
40978419|NCT02710565|OTHER|Cohort|Obtaining additional EBUS TBNA samples for cell culture
40978420|NCT03241342|DRUG|GTx 024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
40978421|NCT03241342|DRUG|Placebo|Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
41142008|NCT05320133|DRUG|JWC containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.
41142009|NCT05320133|DRUG|Bismuth-containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and bismuth potassium citrate 220mg twice daily for 14 days.
41142010|NCT03122314|DRUG|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients
41142011|NCT03122314|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
41301955|NCT00047281|DRUG|cyclophosphamide|
41301956|NCT00047281|DRUG|etoposide|
41301957|NCT00047281|DRUG|thalidomide|
41301958|NCT02892461|PROCEDURE|Umbilical cord milking|As same as that in arm descriptions.
41301959|NCT05883592|DEVICE|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
41301960|NCT01864642|PROCEDURE|osteopathic manipulative treatment (OMT)|
40978422|NCT04052893|PROCEDURE|Expanded Mckissock surgery|Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
40978423|NCT04052893|PROCEDURE|Modified radical mastectomy|The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
40978424|NCT04688710|BEHAVIORAL|Self-Hypnosis (HYP)|"Self-Hypnosis (HYP) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn new strategies for influencing fatigue and its effects on their lives. The Self-Hypnosis recordings will start with a relaxation hypnotic induction (e.g., Notice how with each breath, you are feeling more and more relaxed ...) followed by hypnotic suggestions (e.g., for experiencing more energy, improved sleep, more comfort or less pain, etc.). The goal of Self-Hypnosis is to change participant's experiences. To the extent that participants respond to the suggestions, participants would then get more control over their feelings of energy, sleep quality, and comfort levels."
40978425|NCT04688710|BEHAVIORAL|Mindfulness Meditation (MM)|"Mindfulness Meditation (MM) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn about a new way to live with chronic fatigue and new ways to relate to how fatigue may influence their thoughts, feelings, and behavior. The mindfulness techniques train the mind to non-judgmentally observe experience (e.g., symptoms of fatigue or pain, etc.) on a moment-to-moment basis, with an attitude of acceptance. The goal of Mindfulness Meditation is not to alter experiences, but rather to change how someone responds to their experiences. With practice, automatic, kneejerk reactions to symptoms are replaced with mindful choices about how best to respond to symptoms. This will lighten the load of living with the symptoms, moving participants in the valued direction of their choosing."
40978426|NCT02309879|DRUG|Remifentanil infusion|Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
40978427|NCT02309879|DRUG|Lidocaine infusion|Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
40774289|NCT04164277|BEHAVIORAL|Center-based Preschooler Component.|"Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators. Session duration will be 20 minutes because children's normal attention span is 3-5 minutes per year of age, and 20 min/session is recommended for preschoolers. The already developed Eat \& Walk My ABCs curriculum will be implemented. The curriculum includes four components: healthy eating learning, taste-testing activities, movement skill training, and fun physical activity."
40978428|NCT02309879|DRUG|Magnesium sulphate infusion|Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
40978429|NCT02309879|DRUG|Magnesium sulphate and Lidocaine infusion|Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
40978430|NCT01923220|DRUG|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
40978431|NCT01923220|OTHER|Aloe Vera Jel|To be applied topically once daily
40978432|NCT01868750|DIETARY_SUPPLEMENT|Calcitriol|1.0ug twice daily for 7 days before surgery
40978433|NCT01868750|DIETARY_SUPPLEMENT|Control Pill|placebo pill taken twice daily for 7 days before surgery
40978434|NCT02597894|PROCEDURE|Biopsy of Prostate|Undergo biopsy
40978435|NCT02597894|OTHER|Laboratory Biomarker Analysis|Correlative studies
40978436|NCT00258882|BIOLOGICAL|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
41142012|NCT00424476|DRUG|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
41142013|NCT00424476|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
41142014|NCT00424476|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
41142015|NCT05605158|DRUG|Pioglitazone 30mg|Pioglitazone 30 mg will be administered orally once daily for 24 weeks.
41142016|NCT05605158|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg will be administered orally once daily for 24 weeks.
41142017|NCT02558543|DRUG|Stromal Vascular fraction|
41142018|NCT02558543|DRUG|Ringer lactate|
41142019|NCT06390462|BEHAVIORAL|Interpersonal counseling|A structured psychotherapeutic intervention to prevent depression or treat mild to moderate depression. IPC-A is a brief, individual-based intervention (3-8 sessions). The focus is on interpersonal relations as a factor of resilience in depressive symptoms. IPC-A is a shorter form of IPT-A, developed by prof. Myrna Weissman and team.
41142020|NCT06390462|BEHAVIORAL|Treatment as usual|Any other behavioral or medical support or depression indicated by depressive symptoms or depression. This is based on adolescent, caretaker and professional's report.
41142021|NCT06390462|OTHER|No support, intervention or other treatment|The group will comprise those adolescents who report sustained depression but do not seek or receive support over 6 months of follow-up based on adolescent and caretaker's report
41142022|NCT00412178|DEVICE|telecommunication based glucose monitoring system|
41142023|NCT04518397|BEHAVIORAL|Theatre|6-week participatory arts culturally-informed theatre program
41142024|NCT02770274|DRUG|Cilostazol|Dual therapy with Cilostazol 100 mg twice daily
40978437|NCT05242848|BEHAVIORAL|Exercise intervention|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is \>13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
40978438|NCT06378567|DIETARY_SUPPLEMENT|Dietary supplement liquid shot beverage products|Participants will use their product as instructed for 3 of the 4 study weeks
41142025|NCT02770274|DRUG|Aspirin|Monotherapy with aspirin 100 mg once daily
41142026|NCT04478552|PROCEDURE|Fascia iliaca compartment block|It involves injecting local anaesthetic agent (levobupivacaine) into the fascia iliaca compartment of the patient, infiltrating three major nerves that supply the medial, anterior and lateral thigh, namely the femoral and lateral femoral cutaneous nerves. This procedure can be done with anatomical landmark approach or under image guidance.
41142027|NCT04478552|PROCEDURE|Placebo injection|same volume of normal saline, instead of levobupivacaine, will injected using the same technique.
41142028|NCT03754166|OTHER|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
41461016|NCT00571480|OTHER|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
40978439|NCT00063973|DRUG|cilengitide|Given IV
40978440|NCT00063973|OTHER|laboratory biomarker analysis|Correlative studies
40978441|NCT05631886|BIOLOGICAL|TP53-EphA-2-CAR-DC|5\~10 × 10\^6 CAR DCs per dose will be administered by intravenous injection.
40978442|NCT05631886|DRUG|Abraxane|Intravenous abraxane 125 mg/m\^2/day on day-5.
40978443|NCT05631886|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
40978444|NCT05631886|DRUG|anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
40978445|NCT05631886|DRUG|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
40978446|NCT01397123|OTHER|Training teachers on healthier lifestyles|During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
40978447|NCT00819221|DRUG|AZD2281|capsules, oral, bd, 2 months
40978448|NCT00819221|DRUG|liposomal doxorubicin|once every 4 weeks at 40mg/m2
40978449|NCT03383679|DRUG|Darolutamide|treatment with darolutamide
40978450|NCT03383679|DRUG|Capecitabine|treatment with capecitabine
40978451|NCT01428089|DRUG|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
40978452|NCT01428089|DRUG|Placebo|Placebo
40978453|NCT02990091|DRUG|Omega 3 fatty acid|LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.
40978454|NCT02990091|DIETARY_SUPPLEMENT|Safflower seed oil|Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
40978455|NCT03224572|DRUG|high-dose vitamin C 30gm|High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
40978456|NCT03224572|OTHER|normal saline|500ml normal saline, once per week, and total 4-week treatment
41142029|NCT00955097|DRUG|Definity®|Definity® injections given both pre-ablation and post-ablation
41142030|NCT05847114|OTHER|Stres ball|Stress ball compression for 15 minutes during surgery
41142031|NCT06443099|OTHER|Different methods used after intramuscular injection|Different methods will be used during intramuscular injection. One of them is shotblocker. There are studies reporting that it reduces pain according to the gate control theory. The other method is cold injection. In this method, the injector tips will be cooled to 0-2 degrees and used in injection application.
41142032|NCT03316170|BEHAVIORAL|Social Support|A brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs, and a written directory of a range of social support resources delivered via mail.
41461017|NCT00640393|DRUG|Etanercept|Etanercept 50 mg, subcutaneous (SC) injection.
41461018|NCT00640393|DEVICE|nbUVB|
41461019|NCT05664451|BEHAVIORAL|UI-Assist|"To support primary care in implementing guideline-based care, it is helpful to distill interventions to their key components, such as the five major intervention steps for tobacco use and dependence (the 5 A's). The 5 A's (Ask, Advise, Assess, Assist, Arrange) has been shown to help primary care providers implement clinical practice guidelines with minimal additional burden. The 5 A's can be similarly simplified for urinary incontinence (UI) screening and treatment to Ask (screen for UI); Advise (inform that effective nonsurgical treatments exist); and Assist (help patient get treatment with pharmacotherapy, referral to community classes, physiotherapy or urology / urogynecology)."
40774290|NCT01910454|BEHAVIORAL|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.
40774291|NCT01910454|BEHAVIORAL|Task Specific Training (TST)|The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
40774292|NCT06564584|DRUG|TLC-2716 Dose 1|Capsules administered orally
40774293|NCT06564584|DRUG|TLC-2716 Dose 2|Capsules administered orally
40774294|NCT06564584|DRUG|Placebo|Capsules administered orally
40774295|NCT01779960|OTHER|Londrina|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
40774296|NCT01779960|OTHER|Leuven|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
40774297|NCT03984240|DRUG|Midazolam|Participant will be sedated by midazolam.
40774298|NCT03984240|DRUG|Dexmedetomidine|Participant will be sedated by dexmedetomidine.
40774299|NCT05158010|OTHER|HELIX's follow-up|"* Visit 1 (Day 0): clinical examination (anthropometry, bioimpedance, blood pressure,spirometry), neurodevelopment computer testing, questionnaires (Physical activity,diet, psychological distress, tobacco exposure, pubertal development, sleeping patterns, light exposure before going to sleep, outdoor environment (green spaces, noise), address history, home environment, socio-economic status, noise, psychological distress, medical history, medication use) 7 consecutive days (minimum) of personal exposure monitoring including wearing an actigraph, a Smartphone (GPS data), carrying a NO2 diffusion tube, collection of hair, stool, urines (2 urines during 6 consecutive days) and filling a sleep and physical activity diary~* Visit 2 (Day 8): blood collection early in the morning and collection of all the 7- days personal monitoring material, and stools and urines samples."
40774300|NCT01005290|DRUG|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
40774301|NCT01005290|DRUG|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
40774302|NCT00153231|DEVICE|IVS|Infracoccygeal sacropexy
40774303|NCT00153231|PROCEDURE|Sacrospinofixation|
40774304|NCT01731782|DRUG|bupivacaine|
40774305|NCT01731782|DRUG|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
40774306|NCT03676387|OTHER|ultrasound guided|"Ultrasonography technique:~The subglottic diameter was estimated with B-mode ultrasonography (Korean, Siemens, Acuson, x300) with a 10-13-MHz linear probe positioned on the midline of the anterior neck (figure1). The evaluation began by identifying the true vocal folds as paired hyperechoic linear structures that moved with respiration and swallowing before patients were paralyzed. The probe was then moved caudally to visualize the cricoid arch which appears as an arched, rounded and hypoechoic structure (figure2). The transverse air-column diameter was measured at the lower edge of the cricoid cartilage after patients were paralyzed (figure3).~The measurements of the subglottic diameter was used to select the outer diameter of endotracheal tube by the equation \[ETT OD=0.55\*(subglottic diameter)+1.16\] (Shibasaki et al., 2010), since the outer diameter of endotracheal tube differs among different manufactures, we used uncuffed Mallinckrodt tracheal tube with a Murphy's eyes."
40774307|NCT00492544|BIOLOGICAL|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
40774308|NCT03594474|OTHER|Intravenous lipid emulsion|using higher dose of IV lipids after birth
40978457|NCT02311582|BIOLOGICAL|MK-3475|-Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).
40774309|NCT02476227|PROCEDURE|Ablation using CARTO system|automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
40774310|NCT05618925|DRUG|N803|nogapendekin alfa inbakicept (also known as ALT-803; recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\])
40774311|NCT05618925|BIOLOGICAL|CD19t-haNK suspension|Derived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).
40774312|NCT05618925|DRUG|Cyclophosphamide|Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate and has the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1.
40774313|NCT05618925|DRUG|Fludarabine|Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. The chemical name for fludarabine phosphate is 9H-Purin-6-amine, 2-fluoro-9-(5-0-phosphono β-D-arabino-furanosyl) (2-fluoro-ara-AMP). The molecular formula of fludarabine phosphate is C10H13FN5O7P and it has a molecular weight of 365.2.
40774314|NCT05618925|DRUG|Rituximab|Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM.
40774315|NCT05819359|DRUG|BIA 28-6156 10 mg|BIA 28-6156 10 mg, once daily, oral administration.
40774316|NCT05819359|DRUG|BIA 28-6156 60 mg|BIA 28-6156 60 mg, once daily, oral administration.
40774317|NCT05819359|DRUG|Placebo|Placebo, once daily, oral administration.
40774318|NCT02978495|DRUG|Doxorubicin|Doxorrubicin 60 mg/m2 4 cycles each 21 days
40774319|NCT02978495|DRUG|Carboplatin|Carboplatin AUC 1,5 once a week, for 12 weeks
40774320|NCT02978495|DRUG|Paclitaxel|80mg/m2 weekly for 12 weeks
40774321|NCT02978495|DRUG|Cyclophosphamide|600mg/m2 4 cycles each 21 days
40774322|NCT01139151|DRUG|3 Day Thiarabine|Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3
40978458|NCT02311582|DEVICE|MRI-guided laser ablation|
41301961|NCT01864642|PROCEDURE|osteopathic manipulative treatment (OMT)|OMT is a form of manual medicine performed by osteopathic physicians
40774323|NCT01139151|DRUG|5 Day Thiarabine|Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
40774324|NCT04210960|RADIATION|Magentic resonanace imaging|The brain MR imaging examinations were done by using a 3 tesla scanner (Acheiva; Philips Medical Systems, Best, Netherlands). All patients were examined in the supine position using head coil. Routine images (T2, T1, FLAIR) and double inversion recovery sequence (DIR) were done to all patients: repetition time (TR) _ 9583 sec, echo time (TE) _ 25 sec, inversion time (TI) _ 3400 sec, IR delay _ 325 sec, echo train length (ETL) _ 17, 50 contiguous axial slices, thickness _ 3 mm, matrix size 240× 142 mm2, field of view (FOV) 230× 184 mm2.
40774325|NCT04210960|RADIATION|Magentic resonanace spectroscopy|Magnetic Resonance (MR) spectroscopy is a noninvasive diagnostic test for measuring biochemical changes in the brain.While magnetic resonance imaging (MRI) identifies the anatomical location of a lesion, MR spectroscopy compares the chemical composition of normal brain tissue with abnormal brain tissue. This test can also be used to detect tissue changes in stroke and epilepsy.
40774326|NCT03000881|OTHER|standard adhesive|This is a standard adhesive (hydrocolloid)
40774327|NCT03000881|OTHER|New adhesive strip|This is a newly developed adhesive strip
40978459|NCT02311582|PROCEDURE|Surgical resection/debulking|"* Optional~* Standard of care"
40978460|NCT02311582|PROCEDURE|Biopsy|"* If no surgical resection/debulking~* Phase II patients only"
40978461|NCT02311582|PROCEDURE|Blood draw for research purposes|"* Phase II patients only~* Drawn prior to MLA or biopsy/surgical resection procedure, and immediately prior to each the first dose of MK-3475. Subsequently, research blood will be drawn at doses 2, 4, 6, 9, 18, 36, and at the end of treatment"
40774328|NCT06068621|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"1. Azacytidine (75 mg/m2/day, days 1 to 7).~2. Cytarabine (75-100 mg/m2 bid, days 1 to 5).~3. Aclacinomycin(20 mg/day, days 1,3,5).~4. Chidamide (30 mg/day , days 1,4,8,11).~5. Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~6. Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
40774329|NCT06068621|DRUG|"3+7"|"IA regimen:~1. Idarubicin (8-10 mg/m2) for 3 days .~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~1. Daunorubicin(60 mg/m2) for 3 days.~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days."
40774330|NCT05453084|BEHAVIORAL|Exercise Program|The intervention includes an individualized exercise program in terms of Frequency, Intensity, Time, Type, Volume and Progression (FITT-VP).
40774331|NCT01263210|BIOLOGICAL|Prevenar|
40774332|NCT01448616|DRUG|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
40774333|NCT01448616|DRUG|Placebo Vaginal Gel|"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints."
40774334|NCT01448616|DRUG|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
40774335|NCT01448616|DRUG|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
40774336|NCT06563531|PROCEDURE|Pharmacological thromboprophylaxis and elastic compression|Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis and elastic restraint after total hip or knee arthroplasty.
40774337|NCT06563531|PROCEDURE|Pharmacological thromboprophylaxis without elastic compression|Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis only after total hip or knee arthroplasty.
40774338|NCT00005830|DRUG|Doxorubicin Hydrochloride|Given IV
40978462|NCT02311582|PROCEDURE|Cervical lymph node fine needle aspiration|"* Optional~* Time of surgical procedure and 6 weeks +/- 1 week after surgical procedure"
40774339|NCT00005830|DRUG|Cisplatin|Given IV
40774340|NCT00005830|RADIATION|Radiation Therapy|Undergo radiation therapy
40978463|NCT02890446|BEHAVIORAL|upper arm training on the InMotion 2 shoulder robot|"Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.~Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.~12 sessions--3 times a week for 4 weeks"
40978464|NCT05375643|BEHAVIORAL|SURGE|Video with or without person to person guidance to support decision making around genetic testing
40978465|NCT05870020|OTHER|Questionnaire (DBS-QoLs)|"The DBS-QoLs questionnaire will be sent to the patients for answer:~The questonnaire will be sent at :~* the inclusion~* 15 days after the inclusion~* 1 year after the inclusion"
40978466|NCT02603614|DRUG|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
41301962|NCT01661400|DRUG|Metronomic Cyclophosphamide|
40774341|NCT05638828|DRUG|RD14-01 Cell injection|RD14-01 Cell injection
40774342|NCT03375437|GENETIC|Blood and tumor samples|"FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.~Blood sampling for Translational Research (optional) (2\*10mL EDTA)"
40774343|NCT03026179|BEHAVIORAL|Play Nicely|Play Nicely is a multimedia program that teaches parents about appropriate methods to discipline.
40774344|NCT06563518|DRUG|Meridol|toothpaste
40774345|NCT06563518|DRUG|Colgate Cavity Protection|toothpaste
40774346|NCT02075060|PROCEDURE|IPOI (pre-operative)|
40978467|NCT02603614|DRUG|Placebo|Placebo control
40978468|NCT05205733|OTHER|Mail-in semen analysis kit|Presumably an easier, convenient, and more comfortable way to provide a semen analysis with an in-home mail-in semen analysis kit
40978469|NCT02606604|DEVICE|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
41301963|NCT01661400|DRUG|Thalidomide|
40774347|NCT02075060|PROCEDURE|IPOP (post-operative)|
40774348|NCT01784302|DIETARY_SUPPLEMENT|Multivitamins|
40774349|NCT01784302|DIETARY_SUPPLEMENT|Sodium bicarbonate|
41461020|NCT05664451|OTHER|Partnership Building|In addition to the strategies described above, those practices allocated to streamlined practice facilitation and partnership building will have facilitation and configurable solutions that engage community resources and enable coalition building. In addition to a practice facilitator, a partnership facilitator from the Wisconsin Institute for Healthy Aging (WIHA) will identify existing local community resources with which the practice may choose to partner. After initiating academic detailing, these practices will have further access to Drs. Brown and Neuner for ongoing consultation. An online learning community will also be created where information can be shared and exchanged throughout the duration of the project and beyond the maintenance phase.
41461021|NCT00438750|OTHER|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
41461022|NCT00438750|OTHER|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
40774350|NCT01784302|DRUG|Maalox Plus extra|
40774351|NCT01784302|DRUG|Raltegravir 400 mg|
40774352|NCT06563726|DIAGNOSTIC_TEST|point-of-care milk sodium testing|Data-driven interventions to improve early lactation success are lacking, and parents who deliver preterm are at high risk of lactation challenges. We will be studying feasibility, acceptability, and time cost of teaching lactating parents of hospitalized preterm infants how to test their breastmilk sodium (Na) using point-of-care (POC) meters. As a secondary aim, we will assess the potential to use these POC sodium results to guide personalized lactation care in the form of altered pumping schedules in an attempt to reduce breastmilk Na. A drop in Na is a sign of secretory activation in the breast that is associated with adequate short and long-term breast milk volumes in this vulnerable population.
40774353|NCT00410683|OTHER|clinical observation|
40774354|NCT00410683|PROCEDURE|adjuvant therapy|
40774355|NCT00410683|RADIATION|3-dimensional conformal radiation therapy|
40774356|NCT04013854|DRUG|nivolumab|All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.
40774357|NCT04013854|DRUG|Ipilimumab|Only subjects who fail to achieve a complete, or near complete, pathological response, and are then randomized to Arm C will receive Ipilimumab (1 mg/kg) )
40774358|NCT06564545|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
40978470|NCT01759667|OTHER|A standard mixed Meal|All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
40978471|NCT02715414|BEHAVIORAL|Multiple Family Group + Clinic Implementation Team|Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.
40978472|NCT02715414|BEHAVIORAL|MFG|MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
40978473|NCT01610544|DRUG|3'-deoxy-3'-18F fluorothymidine (FLT)|
40774359|NCT06564545|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
40774360|NCT06564545|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
40978474|NCT01610544|OTHER|PET/CT scan|
40978475|NCT03583489|DRUG|APD421|10 mg IV
40978476|NCT03583489|DRUG|Placebo|IV
40978477|NCT03583489|DRUG|Ondansetron|4 mg IV
40978478|NCT01894451|DRUG|89Zr-bevacizumab|89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance. The amount of the compound or drug in a radiotracer is also very small. Radiotracers are used to make images of processes that are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr). 89Zr-bevacizumab is used for an imaging procedure called positron emission tomography/computed tomography (PET/CT). 89Zr-bevacizumab-PET/CT will be performed in this study at baseline, after 2 cycles of preoperative chemotherapy and at the completion of chemotherapy.
40978479|NCT01894451|PROCEDURE|FDG-PET/CT|FDG-PET/CT scan: Pictures of your organs will be taken using a PET (Positron Emission Tomography) scanner. At the same time, a CT (computed tomography) scan will be performed. FDG, a radioactive substance similar to glucose (or sugar), will be injected into your vein using a needle prior to performing the PET/CT scan. After the injection, you will be asked to sit quietly for one hour to let the FDG absorb into the body. After this hour, you will be asked to lie flat on your back for up to 50 minutes while the PET and CT images are being taken. This FDG-PET/CT scan is part of regular cancer care. If you have had this test within 14 days of study enrollment, you may or may not have to have this test repeated.
41146949|NCT06505499|OTHER|Gait Visual Score|Gait Visual Score in degrees, calculated from kinematic raw data with the Gdi_GPS_calculator spreadsheet developed by Baker (2009)
40774361|NCT01627184|DEVICE|Dexcom G4 CGM System|
40774362|NCT01409408|DRUG|Aliskiren|300 mg of aliskiren daily for 8 weeks.
40774363|NCT01409408|DRUG|Amlodipine|Amlodipine 5 mg daily for 8 weeks.
40774364|NCT02371889|DRUG|Topiramate|Max therapeutic dose of 200mg/day
41142033|NCT03316170|DRUG|NRT Sampling|"A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail."
41301964|NCT05159583|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
41301965|NCT05159583|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
41301966|NCT03005847|DIETARY_SUPPLEMENT|fermented papaya preparation|dietary supplementation with fermented papaya preparation
41301967|NCT05689021|DRUG|Abiraterone Acetate/Niraparib|Given PO
41301968|NCT05689021|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
41301969|NCT05689021|PROCEDURE|Bone Scan|Undergo technetium-99m bone scan
41301970|NCT05689021|PROCEDURE|Computed Tomography|Undergo CT scan
41301971|NCT05689021|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41301972|NCT05689021|DRUG|Prednisone|Given PO
41301973|NCT00236639|DRUG|topiramate|
41301974|NCT01921270|DRUG|Low Dose - AbobotulinumtoxinA|"Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units"
41301975|NCT06195384|BIOLOGICAL|Neoantigen mRNA Vaccine|Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.
41301976|NCT06306612|DRUG|Systemic Chemohormonal Therapy|Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.
41301977|NCT06306612|DRUG|Systemic Hormonal Therapy|Under continuous ADT, oral darolutamide 600mg twice per day
41461023|NCT04437277|DIAGNOSTIC_TEST|Hepatitis C, serology|Inclusion of patients in conventional hospitalization at Saint Joseph Hospital. Each consenting patient benefits from a screening HCV serology carried out during a biological sample indicated by his state of health. In the case of positive HCV serology, an additional sample will be taken in search of viral replication. All detectable HCV PCR patients will be admitted to hepatology consultation for assessment of liver status including non-invasive methods and possible treatment according to the conditions of the Marketing Authorization and recommendations for routine clinical practice. Data on management (treatment or non-treatment and treatment outcome: prolonged virological response 12 weeks after completion of treatment) will be collected.
41142034|NCT05140499|DRUG|Liposomal bupivacaine|Popliteal nerve block
41142035|NCT05140499|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution|Continuous nerve catheter
41142036|NCT05210985|BEHAVIORAL|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
41142037|NCT05210985|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years."
41142038|NCT05210985|BEHAVIORAL|Test Of Sensory Functions In Infants (Tsfı)|This test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
41142039|NCT05044286|OTHER|no intervention|no intervention
41142040|NCT05620199|PROCEDURE|Upfront resection|Resection of the primary tumor
41142041|NCT05817292|DIETARY_SUPPLEMENT|Probiotics|Assumption of commercial probiotics
41142042|NCT05817292|OTHER|No intervention|No assumption of probiotics
41142043|NCT00002599|BIOLOGICAL|filgrastim|
41142044|NCT00002599|BIOLOGICAL|recombinant interferon alfa|
41142045|NCT00002599|BIOLOGICAL|sargramostim|
41142046|NCT00002599|DRUG|carmustine|
41142047|NCT00002599|DRUG|cyclophosphamide|
41142048|NCT00002599|DRUG|doxorubicin hydrochloride|
41142049|NCT00002599|DRUG|melphalan|
41142050|NCT00002599|DRUG|methylprednisolone|
41142051|NCT00002599|DRUG|prednisone|
41142052|NCT00002599|DRUG|vincristine sulfate|
41142053|NCT00002599|RADIATION|low-LET cobalt-60 gamma ray therapy|
41142054|NCT00002599|RADIATION|low-LET photon therapy|
41142055|NCT03262389|DRUG|Fludeoxyglucose PET CT|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
41142056|NCT03262389|DRUG|Sodium Acetate C11 PET CT|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
41142057|NCT03262389|DRUG|Fludeoxyglucose PET MRI|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
41142058|NCT03262389|DRUG|Sodium Acetate C11 PET MRI|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
41142059|NCT03607851|DRUG|Lacosamide - conventional titration|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID
40978480|NCT01894451|PROCEDURE|MRI scan|• MRI Scan: MRI (Magnetic Resonance Imaging) scans of the breast will be taken. You will receive an injection of a dye before the MRI. You will be asked to lie flat on your back in the scanner for up to 30 minutes for pictures to be taken. This MRI scan is part of regular cancer care. If you have had this test within 14 days of study enrollment , you may or may not have to have this test repeated.
40978481|NCT01894451|PROCEDURE|Tumor biopsies|Tumor biopsies: Prior to starting your treatment, a radiologist will use breast MRI or ultrasound imaging to localize an area of your tumor in the breast for a research biopsy. The biopsy procedure is done in an outpatient setting using a done using a needle to obtain tissue. A local anesthetic will be given to minimize any pain; however, after the procedure you can expect some discomfort and possible bruising. This biopsy is part of research.
40978482|NCT05565651|OTHER|Fecal microbiota analysis|Data analysis
40978483|NCT01252017|DRUG|nilotinib|nilotinib (200mg/tab) 1 tab everyday
41142060|NCT03607851|DRUG|Lacosamide - rapid titration 1|Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week
41142061|NCT03607851|DRUG|Lacosamide - rapid titration 2|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID
41142062|NCT00003754|DRUG|cyclophosphamide|
41142063|NCT00003754|DRUG|thalidomide|
41142064|NCT02764320|OTHER|Migraine Prophylactic Therapy Only|Start of new migraine preventive therapy or adjustment of current preventive therapy without immediate discontinuation of the overused medication(s)
41142065|NCT02764320|OTHER|Discontinuation of Overused Medication|Immediate discontinuation of the overused medication(s) and the start of new migraine preventive therapy or adjustment of current preventive therapy
41142066|NCT00807079|DRUG|carboplatin|
41461024|NCT02244554|DEVICE|enLighten Laser|Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
40978484|NCT04290884|DRUG|Tranexamic Acid|The recruited patients will be randomly assigned to two groups, 50% chance to the experimental group (use of tranexamic acid) and 50% chance to the control group (use of normal saline). After the reduction of the intertrochanteric fracture, 10ml of tranexamic acid is injected under the deep fascia around the fracture area before inserting a drain. As for the control group, 10ml of normal saline is injected instead. Blood will be taken on the third day post operation, and the patient will be seen at 6 weeks, and 3 months.
40978485|NCT05008497|OTHER|Questionnaire|Questionnaire
40978486|NCT01144923|OTHER|Gabapentin and/or Nortriptyline, Physical therapy|Nortriptyline up to 125 mg po qhs, and / or Gabapentin up to 1200 mg po q8h, Physical therapy (e.g. range of motion, strengthening, therapeutic massage, TENS)
40978487|NCT01144923|PROCEDURE|Epidural Steroid Injections (ESI)|Series of up to 3 cervical epidural steroid injections (ESI) with depo-methylprednisolone
40978488|NCT01144923|OTHER|Combination treatment|Series of up to 3 cervical epidural steroid injections with depo- methylprednisolone plus Nortriptyline up to 125 mg po qhs and /or Gabapentin up to 1200 mg po q8h, and Physical therapy (e.g. TENS, exercise, range of motion)
40978489|NCT04190394|OTHER|Intermittent retraining program.|Patient benefits from an intermittent retraining program for 8 weeks, with three 45-minute sessions per week.
40978490|NCT01626560|DRUG|Daptomycin|daptomycin 4-6mg/kg qd 10 - 14 days
40978491|NCT01626560|DRUG|Vancomycin|Vancomycin 1g q12h 10 - 14 days
40978492|NCT00697762|DRUG|RWJ-333369|200 mg tablet twice daily for 12 weeks
40978493|NCT00697762|DRUG|RWJ-333369|100 mg tablet twice daily for 12 weeks
41142067|NCT00807079|DRUG|topotecan hydrochloride|
41142068|NCT00002409|DRUG|Lamivudine/Zidovudine|
41142069|NCT00002409|DRUG|Abacavir sulfate|
41142070|NCT05863676|PROCEDURE|Oophorectomy|Ovary will be removed for fertility preservation.
41142071|NCT05863676|DIAGNOSTIC_TEST|Infectious Disease Testing|Infectious Disease Testing will be done on participants.
41142072|NCT01821599|OTHER|Nonaccelerated Rehabilitation|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
40978494|NCT00697762|DRUG|Placebo|Placebo tablet twice daily for 12 weeks
41142073|NCT01821599|OTHER|Accelerated Rehabilitation|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.
40978495|NCT02943720|DRUG|AllerT|Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
40978496|NCT02943720|DRUG|placebo|placebo
41142074|NCT02837705|OTHER|blood draw|
41142075|NCT04804202|OTHER|Bicycling with and without virtual reality|In one session: Exercise intensity and enjoyment are measured while participants bicycle in a virtual compared to non-virtual environment. Cycling takes places in two modes continous and interval. In a second session exercise intensity and enjoyment are compared during bicycling with virtual reality presented in two different ways.
41142076|NCT03571906|BEHAVIORAL|Tele - Cardiac Pre-Rehabilitation|We intend to enroll 50 stable subjects with valvular heart disease scheduled for surgical intervention. Following a comprehensive clinical and physiological evaluation subjects will be randomized (1:1) to a Prehab arm (PHB) vs. usual care (UC). Subjects in the prehab arm will receive a hybrid institution and home-based exercise prescription, nutritional and psychological intervention and periodic calls. Adherence will be assessed and encouraged by smartwatch and matching smartphone software. In the usual care arm subjects will receive general recommendations following the baseline stress test performed by both groups (prehab is not standard of care or guideline based). Another stress test will be performed days prior to valve surgery Adherence to the rehab program will be assessed and a structured motivational program and follow-up will be provided in order to maximize goal completion.
41142077|NCT02362789|BIOLOGICAL|Secukinumab|150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
40978497|NCT06471998|DRUG|Sodium Chloride injection|"Patients will receive a localized subcutaneous injection of 0.9% sodium chloride over 10 sessions (1 session per week), combined with standard treatment including stage I and II analgesics and physiotherapy in line with the recommendations of the French National Authority for Health.~At each session, 250ml to 500ml of physiological serum will be injected subcutaneously using a Meso-Kit-Perfuser\* or injection octopus positioned by the nurse according to the injection points defined by the investigating physician during the inclusion visit, with a dermographic tracer for surgical use."
40978498|NCT03507894|BEHAVIORAL|Multimodal Exercise Rehabilitation Program|Rehabilitation program based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
40978499|NCT04811391|BIOLOGICAL|COVID-19 vaccine|Observation of individuals who receive the COVID-19 vaccine (2 doses of PfizerBioNtech COVID-19 vaccine).
40978500|NCT01748643|DRUG|deep neuromuscular blockade with rocuronium, reversal with sugammadex|after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio \> 0.9.
40978501|NCT01748643|DRUG|normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is \> 0.9.
40978502|NCT06119360|PROCEDURE|Face-to-face approach|A front-facing approach and insert the lightwand following the patient's tongue base curvature without scooping movement
40978503|NCT06119360|PROCEDURE|Conventional approach|Patients were positioned supine and the intubator stood above the patient's head. Opening the mouth and slightly pulling the mandible with one hand, the intubator inserted the lightwand-tracheal tube assembly at midline into the patient's mouth under the ambient light being turned off. To identify the location of the lighted tip, the intubator could move the lightwand back and forth gently, Once the red light of the tip was located at the midline of the patient's neck, the pre-launched tube was inserted smoothly into the patient's airway unless there was no resistance
40978504|NCT00089765|DRUG|Ranibizumab|
40978505|NCT02887521|OTHER|education|pulmonary rehabilitation participant manual
40978506|NCT02887521|PROCEDURE|rehabilitation|pulmonary rehabilitation
40978507|NCT02887521|DEVICE|pedometer|receive a pedometer
40978508|NCT02887521|OTHER|education|receive a pamphlet with exercises plus the standard course of care
41301978|NCT06306612|PROCEDURE|Cytoreductive Prostatectomy|Cytoreductive prostatectomy was performed after six cycles of neoadjuvant systemic chemohormonal therapy.
41301979|NCT06306612|PROCEDURE|Postoperative Adjuvant Radiotherapy|Postoperative adjuvant radiotherapy of prostate bed is performed, if margin positive, with conventional segmentation and the dose of 64-72Gy.
41461025|NCT06002958|DEVICE|Horyzons USA|Client participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes therapeutic content that is tailored to each individual and their current needs and experiences, including social anxiety, generalized anxiety, mood, and social functioning, and distress intolerance. Further, the platform includes a moderated social media function, where individuals and peer support specialists can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
40978509|NCT02887521|PROCEDURE|surgery|patients undergo surgery
40978510|NCT03097874|BEHAVIORAL|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
40978511|NCT03097874|BEHAVIORAL|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
40978512|NCT01892228|BEHAVIORAL|Immediate post-screening treatment education|immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
40978513|NCT05294445|PROCEDURE|Ablation of atrial fibrillation (AF)|Cryo-AF-ablation of pulmonary vein (pulmonary vein isolation = PVI)
41142078|NCT02362789|BIOLOGICAL|Placebo|Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
41142079|NCT05676372|PROCEDURE|CRC+HIPEC|Sample prelevation of cytoreductive surgery
41142080|NCT05911841|DRUG|LY3454738|Administered SC
41301980|NCT04705025|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBSM using the BNT001 app
40978514|NCT01057654|DRUG|Pravastatin|Pravastatin 40 mg
40978515|NCT01057654|DRUG|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
40978516|NCT03096054|DRUG|LY3143921 hydrate|LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
40978517|NCT06347536|COMBINATION_PRODUCT|Supported rescue pack|1) a rescue pack (prednisolone and antibiotics for 5 days); 2) a written rescue pack management plan based on the Asthma-Lung UK plan; and 3) twice-weekly automated telephone symptom reminder calls for 90 days (with preferred language as needed). The reminder phone calls (to home telephone or mobile) will ask questions aligned to the written management plan
40978518|NCT04945551|BEHAVIORAL|Aerobic exercise training|12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.
40978519|NCT04588948|DRUG|Intravitreal Aflibercept|Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection
41142081|NCT05911841|DRUG|Placebo|Administered SC
41301981|NCT04705025|OTHER|Interview|Complete interview
41301982|NCT04705025|OTHER|Quality-of-Life Assessment|Ancillary studies
41301983|NCT04705025|OTHER|Questionnaire Administration|Ancillary studies
41301984|NCT03408496|OTHER|Myofascial release|Manual therapy
40978520|NCT04811625|DRUG|PL-ASA|Pharmacologic profile of different aspirin formulations
40978521|NCT02705495|OTHER|acupuncture|"Acupuncture will be performed according to the physiological concept of segmental acupuncture. A fixed schema of acupuncture points will be used irrespective of TCM diagnosis. Needles will be inserted approximately 10 mm under the skin. The deqi sensation (a sensation described as numbness, heaviness, and distension) may be obtained, but will not be specifically aimed for. The acupuncture protocol includes body and ear acupuncture."
40978522|NCT02705495|DRUG|Cranberry products|Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
40978523|NCT03532334|DIAGNOSTIC_TEST|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
40978524|NCT04413409|PROCEDURE|Metastasectomy for the metastatic sites|patients randomized to this group will receive metastasectomy for the metastatic sites then followed by the systemic therapy
40978525|NCT01948050|DEVICE|non-invasive transcranial direct current stimulation (tDCS)|
40978526|NCT02703584|DRUG|Buseralin|
41461026|NCT00873834|DRUG|fluoxetine|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
41461027|NCT00873834|DRUG|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
41461028|NCT05434091|DRUG|PF-07291177|PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
40978527|NCT02703584|OTHER|Placebo|
40978528|NCT02703584|DRUG|pregnyl|
40774365|NCT02371889|BEHAVIORAL|Medical Management|Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
40774366|NCT02371889|DRUG|Inactive Placebo|In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
40774367|NCT01936558|OTHER|Far infrared ray to the sole|exposure 40-minute far infrared ray to the sole for each person/amputee.
40774368|NCT03573050|DRUG|RIV-TDS 13.3 mg/24 h|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
40978529|NCT05299125|DRUG|Amivantamab|Low fucose, fully human immunoglobulin gamma-1-based bispecific antibody directed against EGFR and MET tyrosine kinase receptors. It shows clinical activity against tumors with the primary activating EGFR mutations Exon 19del or Exon 21 L858R substitution, EGFR Exon 20ins mutations, the EGFR resistance mutations Threonine790Methionine (T790M) or Cysteine797Serine (C797S), and activation of the Mesenchymal Epithelial Transition (MET) pathway.
40978530|NCT05299125|DRUG|Lazertinib|It selectively inhibits both primary activating EGFR mutations (Exon 19del, Exon 21 L858R substitution) and the EGFR T790M resistance mutation, while having less activity versus wild-type EGFR.
41461029|NCT05434091|DRUG|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
40774369|NCT03573050|DRUG|Exelon® 13.3 mg/24 hours transdermal patch|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
40774370|NCT06547931|OTHER|Data collection and analysis|Retrospective collection of clinical and laboratory data relating to the definition of the nature of neutropenia
40774371|NCT01229566|DRUG|AKR-963|3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
40774372|NCT06513351|BEHAVIORAL|Novel PPH Risk Prediction Model - Comparator Arm B|Patients in this group will receive the standard care risk assessment with the addition of a recently developed, novel PPH risk prediction model, which will automatically calculate a patient's numerical risk of hemorrhage based on 21 risk factors. Elevated risk of hemorrhage (\>=3% predicted risk), as predicted by the model, will be linked to clinical decision support, including a best practice advisory with recommendations presented to providers for consideration when they access the patient's electronic health record.
40978531|NCT05299125|DRUG|Pemetrexed 500 mg|Inhibits enzymes involved in folate-dependent metabolism, thereby disrupting cellular replication.
40978532|NCT00547092|DRUG|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
40978533|NCT00547092|DRUG|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
41142082|NCT03541369|DRUG|AMG 427|AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
41142083|NCT06425991|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
41461030|NCT02568280|DRUG|Faster-acting insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
40978534|NCT01800240|DRUG|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
40978535|NCT06385223|DEVICE|Beam F3 targeted accelerated iTBS|Magpro X100, Axilium Cobot, Localite camera
40978536|NCT06385223|DEVICE|Individualized connectome-guided accelerated iTBS|Magpro X100, Axilium Cobot, Localite camera
40978537|NCT05283057|DRUG|Empagliflozin 25 MG|single dose of the SGLT inhibitor Empagliflozin was given
41461031|NCT02568280|DRUG|insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
40978538|NCT05283057|DRUG|placebo|single dose of placebo that is similar to Empagliflozin in physical appearance
40978539|NCT01116154|DRUG|lenalidomide|Given orally
40978540|NCT01116154|DRUG|vorinostat|Given orally
40978541|NCT01116154|OTHER|laboratory biomarker analysis|Correlative studies
40774373|NCT05840302|DEVICE|Activity monitor|Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention
40774374|NCT05840302|OTHER|Questionnaire|Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity
40978542|NCT05780567|DRUG|TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|"TQB3616 is a novel Cyclin-dependent kinase (CDK) 4/6 inhibitor and currently being used in the treatment of a variety of malignant solid tumors.~Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer."
40978543|NCT05780567|DRUG|Placebo capsules, Letrozole, Anastrozole, Tamoxifen|Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.
40978544|NCT05451368|OTHER|Coronary artery calcification lesions|Calcification of atherosclerosis, a complex, organic, regulated and active process, is one of the manifestations of atherosclerosis. The progression of coronary atherosclerosis is a strong independent predictor of future coronary events. It has been shown that coronary artery calcification affects the healing of the neointima and the function of the endothelium after stenting. This may lead to changes in neointimal morphology and the development of neoatherosclerosis after stent implantation.
40978545|NCT01636401|DRUG|aclidinium bromide 400 μg|
40978546|NCT01636401|DRUG|aclidinium bromide placebo|
40978547|NCT01204164|DRUG|TG02 citrate|TG02 citrate capsules given orally.
40774375|NCT03309202|DRUG|PF-05221304|25 mg dose
40774376|NCT00123630|DRUG|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
40774377|NCT00123630|DRUG|Placebo|Placebo given IV once every 2-4 weeks based on weight
40774378|NCT01441492|PROCEDURE|No Drains|A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
40774379|NCT01441492|PROCEDURE|Drains|A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
40774380|NCT04863404|OTHER|Face mask with hybrid-hyrax|Face mask with hybrid-hyrax
40978548|NCT01204164|DRUG|Carfilzomib|Carfilzomib per PI
40978549|NCT01204164|DRUG|Dexamethasone|Dexamethasone (Oral or IV)
41301985|NCT03408496|OTHER|Muscle stretching|Muscle stretching
40774381|NCT04863404|OTHER|Face mask with conventional bonded RME|Face mask with conventional bonded RME
40774382|NCT06350279|DRUG|HSK39297|50-600mg
40774383|NCT05012579|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
40774384|NCT05041829|OTHER|Dietary sodium|Low sodium diet with sodium of \<2.3 g/day (\<100 mmol/day) and high sodium diet with sodium of ≥4 - \<6 g/day (≥174 - \<261 mmo/day)
40774385|NCT06005948|OTHER|exercise|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 8 weeks
40774386|NCT06005948|OTHER|control|No intervention will be made.
40978550|NCT05072561|DIAGNOSTIC_TEST|Sentinel lymph node scintigraphy|"During the surgery, right after the identification of the primary, 18-37 MBq of 99mTc-Nanocolloids in two ml will be injected at four peritumoral locations. After a brief waiting time (5-10'), the thoracic surgeon will perform the clinical intervention, including the lobectomy (the injection sites will be resected alongside the tumour) and lymphadenectomy, according to the best clinical practice. All the excised lymph nodes will be ex vivo counted using a gamma probe: those with a detectable activity (at least 10% of the hottest lymph node) will be considered as SLN. Thereafter, the mediastinum will be scanned using the gamma probe and a handheld gamma-camera (the latter will not be employed in case of robotic-assisted surgery); any further source of radioactivity will be investigated and, should further lymph nodes be identified, these will be also resected and classified in SLN or non-SLN, based on ex vivo activity."
40978551|NCT00934973|DRUG|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
40978552|NCT00934973|DRUG|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
40978553|NCT00934973|DRUG|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
40978554|NCT00934973|BEHAVIORAL|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
40978555|NCT00934973|BEHAVIORAL|No website|No CBT website
41301986|NCT03408496|OTHER|Control|Medical appointment
41301987|NCT01935908|DRUG|levetiracetam|
41301988|NCT04769583|DRUG|metronidazole based quadriple therapy|patient randomized in QC will be treated by a double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day)
40774387|NCT01401673|DRUG|Indantadol|Titration
40774388|NCT04129398|DRUG|Letermovir tablet|A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks
40774389|NCT04129398|DRUG|Letermovir IV|IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks
40774390|NCT00954447|DRUG|Placebo|Placebo, identical to Linagliptin tablet
40774391|NCT00954447|DRUG|Linagliptin|intended final marketed dose
40774392|NCT05156528|BIOLOGICAL|S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine|Single intramuscular dose contains 10 µg of S. flexneri 2a polysaccharide and S. sonnei polysaccharide respectively.
40774393|NCT05156528|BIOLOGICAL|Placebo|Single intramuscular dose contains 0.15\~0.25 mg of aluminum ion
40774394|NCT00309283|DRUG|Long-acting somatostatin|Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
40774395|NCT00309283|OTHER|Saline solution|Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
40978556|NCT00934973|BEHAVIORAL|CBT website with minimal support|
40774396|NCT05478317|PROCEDURE|ECL- mPZ|"Flapless Technique using Piezoelectric (PZ):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. However, no flap will be reflected the osseous recontouring will be carried using special piezoelectric tip below gingival margin. The required distance between the bone crest and the gingival margin will be checked by inserting a periodontal probe into the incision below gingival margin."
41461032|NCT03388008|DRUG|Belatacept|Belatacept will be dosed at 10 mg/kg of actual body weight on days 0, 7, 14, 28, 56, and 84 then at 5 mg/kg on day 112 and every 28 days through day 364 (i.e., on days 140, 168, 196, 224, 252, 280, 308, 336, and 364)
40774397|NCT05478317|PROCEDURE|ECL-OF|"Open Flap Technique (OF):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. Full mucoperiosteal flap will be elevated to preform ostectomy and/or osteoplasty until the desired distance achieved between the bone crest and the gingival margin. After achieving the new supracrestal distance, the flap will be sutured."
40774398|NCT03038087|DEVICE|SENSE Device|"The SENSE device transmits a low power tailored electro-magnetic pulse across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~1. A molded plastic headpiece containing the antenna array, and~2. A processing control unit.~The SENSE device will be placed on the subject within 15 minutes of a baseline head CT, or as soon as practicable. The SENSE device will be set to scan every 10 minutes until the device is removed after completion of the SENSE measurement corresponding to the 72 hour CT scan. The investigator will be blinded to the data collected from the SENSE device."
40774399|NCT01011608|OTHER|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
40774400|NCT01011608|OTHER|standard hospital food|standard hospital diet ad. lib.
40978557|NCT06087666|PROCEDURE|FICare|The Family Integrated Care (FICare) programme has been developed in a multicenter cluster randomised controlled trial, with 26 tertiary NICUs from Canada, Australia and New Zealand, comparing standard NICU care (which was mainly care by nurses) (891 infants) to FICare programme (895 infants). FICare model and showed that the involvement of parents in the direct care improved weight gain and increased breastfeeding rates in the preterm infants. In addition, their parents had lower rates of stress and anxiety. These results were confirmed in a cluster-randomised controlled trial. Subsequent studies carried out so far have shown promising positive effects on a variety of domains. Maturation profiles have been shown to accelerate with the FICare intervention as a shorter time to achieve exclusive enteral nutrition as well as oral nutrition has been shown in the preterm infants included in FICARE programmes compared to control babies
40978558|NCT06131307|PROCEDURE|Education|Paternalistic leadership training will be given to clinical manager nurses.
40978559|NCT01239654|DEVICE|stent implantation|implantation of everolimus-eluting stent vs zotarolimus-eluting stent
40978560|NCT02557646|BIOLOGICAL|Peginterferon alfa-2a|Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P
40978561|NCT02557646|DRUG|Ribavirin|Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
40978562|NCT01443650|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
40978563|NCT01083576|DRUG|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
40978564|NCT01083576|DRUG|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
40978565|NCT04242615|OTHER|Prognostic score|
40978566|NCT02295150|DRUG|Nadroparin|Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
40978567|NCT02066233|DEVICE|EG Scan II (transnasal endoscopy)|
40978568|NCT02066233|PROCEDURE|Standard Endoscopy|
40978569|NCT04850599|DRUG|Carfilzomib|Given IV
40978570|NCT04850599|BIOLOGICAL|Isatuximab|Given IV
40978571|NCT04850599|DRUG|Pomalidomide|Given PO
41142084|NCT01263522|OTHER|different training programs|two different endurance programs and one strength endurance program
41461033|NCT03388008|DRUG|Tacrolimus|Tacrolimus will be dosed enterally or sublingually within 48 hours of transplantation and the dose will be adjusted to target a trough blood level of 8-15 ng/ml
41461034|NCT03388008|DRUG|ATG|Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation
40774401|NCT04253600|BEHAVIORAL|Risk profile screening questionnaire|Families will be asked to complete a LimeSurvey questionnaire that aims at evaluating general risk profiles associated with DLD (e.g., no elevated risk, behavioral risk, environmental risk, familial risk), as well as our exclusion criteria (e.g., hearing deficit).
40774402|NCT04253600|PROCEDURE|Investigation of the neural correlates of DLD using Magnetic Resonance Imagery (MRI)|MRI data acquisition will take place during natural sleep in infants aged from 6 to 12 months. First, families will have to complete a security questionnaire to make sure that neither the children nor the accompanying parent have any known contraindication preventing the MRI session and that none of them is wearing any ferro-magnetic elements. Then, families will be welcomed in a calm and child-friendly environment where we will propose them some preparatory games known to facilitate sleep in children. MRI protocol will comprise structural and functional images and won't exceed 30 minutes.
41301989|NCT04769583|DRUG|placebo based quadriple therapy|patient randomized in TT will be treated by double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), clarithromycin (500 mg x 2 per day) and a placebo of metronidazole.
40774403|NCT04253600|BEHAVIORAL|Online investigation of predictive factors associated with DLD and LANCOM app development|Parents will be asked to complete a series of online questionnaires every six months. Questionnaires will be created on LimeSurvey and will include different questionnaires, scales, and observations that aim at evaluating children's development, and especially language development, as well as parental and environmental characteristics.
40774404|NCT04253600|BEHAVIORAL|Individual behavioral and cognitive assessment|Individual cognitive and behavioral assessment will be scheduled once a year, around the child's birth date, and will comprise an extensive battery of standardized evaluation appropriate for the child's age. This individual evaluation will focus on several developmental aspects including language, psychomotor, behavioral and cognitive development, as well as executive and socio-emotional functioning, depending on the age of the children. Evaluations will be adapted to each child's specific profile, while respecting the following administration rules: (1) we will prioritize language development testing, (2) testing sessions will be adapted to each child's pace and possibilities, (3) if a child does not want to take part in the assessment, feels tired, or does not seem to be comfortable with the investigator, tests won't be administered.
40774405|NCT04253600|BEHAVIORAL|Automated analysis of language development and environment|"Following the individual assessment, families will be asked to record their child's language environment over a 2-days' timeframe using the LENA® device, a small wearable device allowing for large-scale all-day audio recording and automated vocal analyses of speech segments. An automatic analysis of the recordings, performed by the LENA pro software algorithms, will provide amongst others, a direct and natural measure of the child's number of vocalizations, adult word counts, conversational turns, duration of exposure to electronic media versus to meaningful language. Data acquisition will take place once a year following our sample selection, with a required recording time per day ranging from 12 to 16 hours."
40774406|NCT01212900|DRUG|Statins, HMG CoA|Statin therapy
40774407|NCT01577316|BIOLOGICAL|Seasonal influenza vaccination|"2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus;~* a B/Wisconsin/1/2010-like virus."
40774408|NCT04000880|BEHAVIORAL|Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.
40774409|NCT04000880|OTHER|Diet-Exercise|Diet-Exercise
40774410|NCT04000880|OTHER|Exercise-Diet|Exercise-Diet
40774411|NCT04000880|OTHER|Combined Diet and Exercise|Combined Diet and Exercise
40774412|NCT05611346|BEHAVIORAL|Hypnosis|"The experimental group will receive 2 standardized hypnosis sessions via the superhero costume technique performed during this collective therapeutic education program, completed by a reinforcement through the practice of self-hypnosis at home guided by the listening of an audio recording"
40774413|NCT05291910|DRUG|Inetetamab|Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks
40774414|NCT05291910|DRUG|Toripalimab|240mg intravenously every 3 weeks
41142085|NCT01263522|OTHER|control condition|unchanged lifestyle
40774415|NCT05291910|DRUG|Albumin-Bound Paclitaxel|130mg/m2, IV , D1, D8, q3w
41142086|NCT05691400|DRUG|Palbociclib 125Mg Tab|125 mg single dose
41142087|NCT05691400|DRUG|Ribociclib 200Mg Oral Tablet|200 mg single dose
41142088|NCT05691400|DRUG|Abemaciclib 150 MG Oral Tablet|150 mg single dose
41142089|NCT06364514|OTHER|Clinical Stability Assessment|Base total days of antibiotics on clinical stability vs utilizing predetermined total days of antibiotics
41142090|NCT05597215|RADIATION|Tc-99m MDP and gamma camera|Injection of radioactive element (Tc-99m MDP) then imaging with gamma camera and low dose CT (SPECT/CT)
41142091|NCT01450774|DRUG|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
41142092|NCT01450774|DRUG|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
41142093|NCT05779696|OTHER|No-intervention|This is a non-intervention study.
41142094|NCT03466775|DIAGNOSTIC_TEST|Anti-angiotensin II type 1 receptor antibody measurement|Anti-angiotensin II type 1 receptor antibodies are assessed using quantitative ELISA in stored serum samples obtained within the first year after transplantation
41142095|NCT03466775|DIAGNOSTIC_TEST|Measurement of ENDAT expression level allograft|Endothelial-associated transcript expression level is assessed using microarray in stored kidney allograft biopsies obtained within the first year after transplantation
41142096|NCT03466775|OTHER|Allograft survival|
41142097|NCT03466775|OTHER|Allograft rejection appearance|
40774416|NCT02256748|DRUG|BIRT 2584 XX|
40774417|NCT02256748|DRUG|Midazolam|
40774418|NCT02340195|DRUG|Idalopirdine (Lu AE58054) 60 mg|encapsulated film-coated tablets for oral use once daily for 10 days
40774419|NCT06434493|RADIATION|Proton Beam Therapy|All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy)
40774420|NCT06434493|DRUG|Concurrent oral capecitabine chemotherapy|All patients to be offered concurrent oral capecitabine 625mg/m2 twice daily on radiation days
40774421|NCT06434493|DRUG|Cisplatin & Gemcitabine intravenous chemotherapy|Following chemoradiotherapy (PBT + capecitabine), and whilst on the liver transplant waiting list, patients will be offered up to 6 cycles of standard chemotherapy with cisplatin and gemcitabine.
40774422|NCT06434493|PROCEDURE|Orthotropic Liver Transplant|If still eligible after neoadjuvant treatment (PBT + capecitabine), patients will be added to the liver transplant waiting list.
40978572|NCT03401424|PROCEDURE|improved Warren-type style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision plus modified Warren cholangiobiliary reconstruction.
40978573|NCT03401424|PROCEDURE|Roux-en-Y style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision Roux-en-Y cholangiobiliary reconstruction.
40978574|NCT02432404|DRUG|NuvaRing|
40978575|NCT05752279|DRUG|Plasma-Lyte 148|Plasma-Lyte® 148 intravenous fluid for resuscitation in patients with keto-acidosis
40978576|NCT05752279|DRUG|0.9% sodium chloride|0.9% sodium chloride intravenous fluid for resuscitation in patients with keto-acidosis
40978577|NCT02148692|PROCEDURE|Higher PEEP|
40978578|NCT02148692|PROCEDURE|Lower PEEP|
41461035|NCT03388008|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation
40774423|NCT03898427|DEVICE|Wrist Actigraphy Devices|A watch-like wearable sensor
40774424|NCT03898427|DEVICE|Polysomnography|Sleep Monitor
40774425|NCT03898427|DEVICE|Videography|Thermal Camera
40774426|NCT06123299|DEVICE|pHyph|vaginal tablet
40774427|NCT00001854|DRUG|Ribavirin|
40978579|NCT06430658|COMBINATION_PRODUCT|Tislelizumab (BGB-A317) with chemoradiotherapy|Different sequences and methods of treatment to convert surgery
40978580|NCT04565028|BEHAVIORAL|Contingency Management (CM)|Contingency management is an intensive behavioral therapy in which participants are paid to reduce substance use.
40978581|NCT00329381|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
41142098|NCT04894942|OTHER|American Orthopaedic Foot and Ankle Society Score (AOFASS)|calculation of the score AOFASS before and after the surgery
40774428|NCT04272801|DRUG|tamoxifen, letrozole, anastrozole, or exemestane|choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
40774429|NCT04272801|BEHAVIORAL|Patient reported outcomes|"Questionnaire inquiries include the following:~* how cancer affects daily living~* beliefs about medicines and sensitivity to medicine~* symptoms~* adherence to endocrine therapy~* general health and well being~* depression and anxiety~* preference regarding radiation therapy"
40774430|NCT06039514|DEVICE|GGTCA-AD mobile app|The intervention will be done through an adaptation of the GGTCA app for teenagers: GGTCA-AD. This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in cognitive behavior therapy (CBT) in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
40774431|NCT06039514|DEVICE|GGNeutra mobile app|"the control group will complete another module belonging to the GGTUDE digital platform. Specifically, this app is called GGNEUTRA, and the statements that compose it are totally independent of the target of the study. The operation is similar, sentences appear in the center of the screen, but in this case, the person must accept those sentences that are true, for example: Madrid is the capital of Spain, by dragging it to the top of the screen; and reject those that are false, for example: Tokyo is the capital of Spain, by dragging it to the bottom of the screen."
40774432|NCT05737979|OTHER|Study chart review|Evaluation of the IVF cycle using the prescribed medication
40978582|NCT00329381|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
40978583|NCT04404751|COMBINATION_PRODUCT|Iodised salt with Iron, Folic acid and Vitamin B12|Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt
40978584|NCT05497674|DRUG|Rongliflozin|oral administration, single dose on Day 1 and Day 11
40978585|NCT05497674|DRUG|Rifampin|QD for 10 days
40978586|NCT05497674|DRUG|Rongliflozin|oral administration, single dose on Day 1 and Day 6
41142099|NCT03938792|DRUG|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
41142100|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone|
41142101|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone|
40978587|NCT05497674|DRUG|Probenecid|twice a day, for 5 days
40978588|NCT03842124|OTHER|Force gauge|The investigators postulate that use of bidirectional traction (superior and inferior directions) and feedback from a digital force gauge is associated with minimal lead displacement compared to conventional lead extraction.
40978589|NCT04161560|DRUG|Cetuximab-IRDye800|does of Cetuximab-IRDye800
40978590|NCT03874897|DRUG|CAR-CLDN18.2 T-Cells|"Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2"
40978591|NCT03874897|DRUG|PD-1 Monoclonal Antibody|Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1
41142102|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
41142103|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
40774433|NCT04587492|DRUG|Nusinersen|Treatment with nusinersen
41301990|NCT00748826|BIOLOGICAL|Infliximab|"Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of~Infliximab therapy with additional infusions of 5 mg/kg at week 2"
40774434|NCT05593055|DRUG|Eplerenone|After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
40774435|NCT05593055|DRUG|Chlorthalidone|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
40774436|NCT05593055|DRUG|Potassium|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
40774437|NCT03371017|DRUG|Atezolizumab|"Atezolizumab will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
40774438|NCT03371017|DRUG|Placebo|"Placebo will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
40774439|NCT03371017|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
40774440|NCT03371017|DRUG|Capecitabine|Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
40774441|NCT03371017|DRUG|Carboplatin|Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
41301991|NCT05994014|DIAGNOSTIC_TEST|PET/CT|Experimental test for detecting atherosclerosis
41301992|NCT03774745|DRUG|Mifepristone 200 MG|All subjects receive mifepristone tablet on treatment day 1.
41301993|NCT03774745|DRUG|micronized Progesterone|Subjects randomized to progesterone receive treatment starting day 2.
41301994|NCT03774745|DRUG|Placebo oral capsule|Subjects randomized to placebo receive treatment starting day 2.
41301995|NCT01931462|DEVICE|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
40774442|NCT00855101|DRUG|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
40774443|NCT00122473|DRUG|Imatinib (Glivec)|
40774444|NCT05664529|DIAGNOSTIC_TEST|Chatoor Feeding Scale|Chatoor Feeding Scale will be used to evaluate mother infant relationship during feeding. Mothers will be asked to record a natural feeding session at home by video. The videos will be sent to the investigators by the parents. The first 20 minutes of the video will be evaluated for scoring.
40774445|NCT00244985|BIOLOGICAL|rituximab|IV
40774446|NCT00244985|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
40774447|NCT04103450|DRUG|Vibegron|oral administration
40774448|NCT04144907|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
41301996|NCT05509205|OTHER|Turkish Validity and Reliability of The PSS Scale|This study is about validation of the Pound Satisfaction Scale to Turkish. The level of satisfaction with the rehabilitation service and treatment of 130 stroke patients undergoing stroke rehabilitation will be evaluated with the Pound satisfaction scale.
41301997|NCT03694574|BEHAVIORAL|instruction to suppress|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don't think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It's very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated. (Szasz, Szentagothai, \& Hoffmann, 2011)"
40774449|NCT00301860|BIOLOGICAL|anti-thymocyte globulin|
40774450|NCT00301860|BIOLOGICAL|filgrastim|
40774451|NCT00301860|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40774452|NCT00301860|DRUG|cyclosporine|
40774453|NCT00301860|DRUG|fludarabine phosphate|
41301998|NCT03694574|BEHAVIORAL|instruction to reappraise|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it's more difficult at the beginning. (Szasz et al., 2011)"
40774454|NCT00301860|DRUG|melphalan|
40774455|NCT00301860|DRUG|methotrexate|
40774456|NCT00301860|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40774457|NCT00301860|PROCEDURE|peripheral blood stem cell transplantation|
40774458|NCT06564909|DRUG|L-Carnitine|L-Carnitine 5 g intravenous administered as slow IV push over 2-3 minutes (L-Carnitine 1 gm / 5 mL Injection®, MEPACO, Egypt) and Carnitol 500 mg® Oral, Global Napi, Egypt)
40978592|NCT03874897|DRUG|Chemotherapy|First-line systemic therapy according to physician's choice
40978593|NCT01753856|DRUG|Teriparatide|Administered SC
40774459|NCT06564909|DRUG|The standard care for the management of myocardial infarction post PCI|include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
40774460|NCT05334836|DIAGNOSTIC_TEST|MRI for pancreatic fat and liver fat quantitation|MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2\* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.
40774461|NCT04063202|OTHER|Observation|The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
40774462|NCT01511302|DRUG|RNS60|RNS60, 2ml, nebulized twice daily.
40774463|NCT01511302|DRUG|Normal Saline|Normal Saline placebo, 2 ml, nebulized twice daily.
40774464|NCT01511302|DRUG|Budesonide|Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
40774465|NCT04194242|DRUG|HEC96719 tablets|0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1
40774466|NCT04194242|DRUG|Placebo tablet|0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1
40774467|NCT02279927|DEVICE|Ureteroscopy|Ureteroscopy with laser stone fragmentation
40978594|NCT01753856|DRUG|Denosumab|Administered SC
40978595|NCT01753856|DRUG|Demeclocycline|Administered orally
40978596|NCT01753856|DRUG|Tetracycline|Administered orally
40978597|NCT01753856|DRUG|Calcium Supplement|Administered orally
40978598|NCT01753856|DRUG|Vitamin D|Administered orally
40978599|NCT03061838|DRUG|MabThera®|1000 mg intravenously
40978600|NCT03061838|DRUG|Ritumax®|1000 mg intravenously
40978601|NCT03903731|DEVICE|Total knee arthroplasty with Journey II BCS Total Knee System|Journey II BCS Total Knee System
41461036|NCT03388008|DRUG|Methylprednisolone|Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses
40978602|NCT04646889|DRUG|AR882 Single Dose|A single dose of AR882
40978603|NCT04646889|DRUG|AR882 Multiple Dose|AR882 taken once daily for 14 days
40978604|NCT03045328|DRUG|Ibrutinib|Administered at 420 mg/day, as oral capsules (3 x 140 mg), starting Day 1, Week 1.
40978605|NCT03045328|DRUG|Venetoclax|Administered as tablets, starting Day 1, Week 9, with dose increasing every 7 days through 5 dose levels (20 mg; 50 mg; 100 mg; 200 mg; 400 mg).
40978606|NCT02957422|DIETARY_SUPPLEMENT|1% Milk|1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.
40978607|NCT02957422|DIETARY_SUPPLEMENT|Control|Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
40978608|NCT01267734|DEVICE|Everolimus-eluting coronary stenting system (EECSS, Promus Element)|Everolimus-eluting stent
40978609|NCT01267734|DEVICE|Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)|Zotarolimus-eluting stent
40978610|NCT01267734|DRUG|Triple anti-platelet therapy (TAT)|100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
41461037|NCT03388008|DRUG|Prednisone|Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365
41461038|NCT02751892|BEHAVIORAL|Active lifestyle programme|The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
40774468|NCT04533945|DEVICE|FreeStyle Libre|The Freestyle Libre is a device worn on the back of the arm to measure glucose levels in the interstitial fluid. The device is applied by the patient and can be worn for 14 days, at which time it is replaced with a new device. The device does not require calibration with blood glucose testing. A scan with the receiver or a cell phone can be used to obtain glucose levels. The device does not alarm, so scanning is the only way for a patient to know if they are hypo or hyperglycemic. Studies have shown that the use of this technology can improve glycemic control as measured by Hemoglobin A1c and glucose variability in some patients. In addition, use of this technology in the outpatient setting has been associated with both improved patient satisfaction and increased glucose monitoring
40774469|NCT06384963|DEVICE|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.
40774470|NCT06384963|DEVICE|Monotonic right atrial overdrive pacing|Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
40774471|NCT02158858|DRUG|Pelabresib (CPI-0610)|
40774472|NCT02158858|DRUG|Ruxolitinib|
40774473|NCT06558435|OTHER|FEES|Single group
40774474|NCT06230965|PROCEDURE|Lung protective ventilation strategy|They were divided into 2 groups: traditional ventilation strategy group (control group) and lung protective ventilation strategy group (experimental group), with 30 cases in each group. In the conventional ventilation strategy group, the conventional ventilation strategies were followed: tidal volume （VT）=10-12ml/kg, respiratory rate（f） =12 times/minute, PEEP=0 cmH₂O, fraction of inspired oxygen=0.5; Lung protective ventilation strategies were implemented in the Lung protective ventilation strategy group: VT=6-8ml/kg, f=12 times/min, PEEP=6-8 cm H₂O,fraction of inspired oxygen=0.5 Manual lung reexpansion was performed every 30 minutes after mechanical ventilation (continuous positive airway pressure of 30 cm H₂O for 30 seconds).
40774475|NCT05896371|DRUG|177Lu-PSMA-I&T - escalating renal absorbed dose|Personalized 177Lu-PSMA-I\&T injected activity
41461039|NCT03157349|OTHER|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
41461040|NCT03157349|OTHER|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
41461041|NCT01889550|BEHAVIORAL|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
41461042|NCT01889550|BEHAVIORAL|Access to the website www.ouh.dk|Access to the usual information from the hospital website
41461043|NCT05761587|OTHER|Questionnaires|questionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.
40978611|NCT01267734|DRUG|Double-dose clopidogrel anti-platelet therapy (DDAT)|100mg Aspirin QD + 150mg Clopidogrel QD for 1 month
40978612|NCT03502408|PROCEDURE|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
41142104|NCT01381549|DRUG|GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
41142105|NCT01381549|DRUG|imipenem-cilastatin|Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
41142106|NCT01381549|OTHER|Placebo|saline placebo
41461044|NCT01391650|PROCEDURE|'biomechanic of the knee'|20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
41461045|NCT02476188|PROCEDURE|Sample of Blood|
40774476|NCT05896371|DRUG|177Lu-PSMA-I&T - recommended phase 2 regime|Personalized 177Lu-PSMA-I\&T injected activity
40774477|NCT04425239|DRUG|Panitumumab|Continuous administation
40774478|NCT04425239|DRUG|Panitumumab|Intermittent administation
40774479|NCT06479356|BIOLOGICAL|Relma-cel|Relma-cel will be administered at one dose level:1×10\^8 CAR+T cells
40774480|NCT05992272|BIOLOGICAL|fMRI imaging (BOLD)|Will be used to investigate neural correlates of PIT effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
40774481|NCT05992272|BIOLOGICAL|sMRI (structure)|Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
40774482|NCT05992272|BEHAVIORAL|Trier Social Stress Test|Will be used to assess the effect of acute stress induction on behavioral and neural PIT effects. The induced stress is generated in a social context, where the participants are asked to prepare a job interview for their dream job and to present it in front of a three-member jury.
41301999|NCT03694574|BEHAVIORAL|control|No instruction
40774483|NCT05992272|BEHAVIORAL|PIT paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
40774484|NCT05992272|BEHAVIORAL|Counting Stroop task|Will be used to assess interference at stimulus level. Here either one, two, three or four identical digits from 1 to 4 are shown. Number and denotation of digits are either congruent (1, 22, 333, 4444; 88 trials) or incongruent (111, 2222, 3, 4444; 88 trials). Subjects have to indicate how many digits were shown
40774485|NCT05992272|BEHAVIORAL|No-go Simon task|Will be used to measure interference at the response level and response inhibition. We will show arrows either pointing to the left or right. The arrow can either be shown on the left or the right side of the display. In congruent trials, direction and position are the same, whereas they differ in incongruent trials. Participants have to indicate the direction of the arrow and ignore the position.
40774486|NCT05992272|DIAGNOSTIC_TEST|Stop Signal Task|"Will be used to examine inhibitory control. The participants tap the left and right side of the screen to smash two falling fruits. When the fruits pass two circles, subjects are required to tap both sides of the screen. In stop trials one of the fruits turns brown (rotten), indicating the corresponding side of the screen should not be tapped."
40774487|NCT05992272|DIAGNOSTIC_TEST|blood samples|for genetic and epigenetic testing, especially for exploratory outcome prediction using polygenic risk scores.
40774488|NCT05992272|DIAGNOSTIC_TEST|questionnaires for chronic stress|"* Perceived Stress Scale~* Social Readjustment Rating Scale~* Trier Inventory for the Assessment of Chronic"
40774489|NCT05992272|DIAGNOSTIC_TEST|hair samples|Hair cortisol measurement (3 cm hair segments) will be used to assess chronic stress.
40774490|NCT05992272|DIAGNOSTIC_TEST|saliva samples|Assessing acute stress effects in AUD.
40774491|NCT05992272|DIAGNOSTIC_TEST|EMA assessment|We will use smartphones with additional mobile sensors (wearables), which will be used to measure physical activity, data on location (GPS), geolocation-based triggering of e-Diaries, self-reported stress reactivity, cue exposure (encounters with drug-related stimuli in real life), drug craving, impulsivity and drug consumption (priming doses, binges and continuous use of all drugs of abuse).
40774492|NCT05992272|DIAGNOSTIC_TEST|clinical diagnostic|SKID-I Interview neurocognitive and psychopathological testing
40978613|NCT03502408|PROCEDURE|Endovascular Thrombectomy|Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
41302000|NCT03017586|DEVICE|Beijing Pins Medical Co., Ltd. Deep Brain Stimulator|Deep Brain Stimulation for primary dystonia subjects
41302001|NCT06215339|BEHAVIORAL|diet therapy training|diet education
41302002|NCT00536731|DRUG|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
41302003|NCT00536731|DRUG|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
41302004|NCT00536731|DRUG|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
41302005|NCT01230671|OTHER|Yoga|A 12 week yoga session will be offered to women with breast cancer.
40774493|NCT05957627|PROCEDURE|Saleem's protocol|It involved 2 principal tenotmies and 2 accessory tenotmies. Principal tenotmies include tendo achillies and planter fascia release. 2 Accessory tenotmies include tibialis posterior and abductor hallucis. All tenotmies are done under local anesthesia
40774494|NCT06560944|DRUG|Combined oral contraceptive pill|Ingesting their existing combined oral contraceptive pill at a specific time of day in relation to assessment of outcome measures
40774495|NCT04826380|PROCEDURE|Trapeziectomy|Simple trapeziectomy (without LRTI)
41302006|NCT04964063|OTHER|Potassium Nitrate + Sodium Fluoride|Potassium Nitrate 5% weight/weight (w/w) and Sodium Fluoride 0.15% weight/volume (w/v) fluoride ion.
40774496|NCT01156844|DRUG|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
40978614|NCT06336850|PROCEDURE|Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement|The endoscopic ultrasound (EUS)-guided 25G fine needle aspirate (FNA) needle procedure is a straightforward minimally invasive technique for direct portal pressure measurements.
40978615|NCT02604108|BEHAVIORAL|Physical Exercise|"The Physical Exercise arm includes a training workshop and electronic health messages related to positive psychology and physical activity for all participants in physical exercise group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
41142107|NCT01684540|OTHER|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
41142108|NCT01684540|DRUG|Sinupret forte|
41142109|NCT03610984|OTHER|type 1 diabetes structured education|The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
41142110|NCT06012214|PROCEDURE|ROBOTIC-ASSISTED ESOPHAGECTOMY|Comparison between robotic and conventional minimally invasive esophagectomy
41302007|NCT00538876|DRUG|decitabine|"Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard 7+3 induction chemotherapy will begin."
41302008|NCT01987986|BIOLOGICAL|Collagenase Clostridium Histolyticum|injectible intervention
41302009|NCT01987986|BIOLOGICAL|Placebo|
40774497|NCT01156844|DRUG|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
40774498|NCT03681756|BEHAVIORAL|WALK|Walking program
40774499|NCT02811887|BEHAVIORAL|Supervised exercise|A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
41142111|NCT05234489|BIOLOGICAL|Signature Cord Prime|"Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.~High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate."
41142112|NCT02680314|DRUG|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
40774500|NCT02811887|OTHER|Usual Care|Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.
40978616|NCT02604108|BEHAVIORAL|Healthy Diet|"The Healthy Diet arm includes a training workshop and electronic health messages related to positive psychology and health diet for all participants in healthy diet group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
40978617|NCT01898611|DRUG|Ghrelin|Ghrelin
40978618|NCT01898611|DRUG|Placebo|Saline will be used as a placebo
41142113|NCT03240588|DEVICE|Neurostimulation System|Spinal cord stimulation
41142114|NCT01406041|BIOLOGICAL|Chemical and physical detection|CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
41142115|NCT05351411|OTHER||Participants in the control group maintained their therapeutic routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
41302010|NCT00843310|DRUG|Lenalidomide (Revlimid)|
41302011|NCT00843310|DRUG|Melphalan|
41302012|NCT00843310|DRUG|Dexamethasone|
41302013|NCT00003207|DRUG|pegylated liposomal doxorubicin hydrochloride|
41302014|NCT00003207|DRUG|PSC 833|
41302015|NCT01035606|BEHAVIORAL|training in goal-directed attention regulation|training in goal-directed attention regulation
41302016|NCT01035606|BEHAVIORAL|brain health education|brain health education workshops
41302017|NCT01035606|BEHAVIORAL|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
40978619|NCT00731289|DRUG|hyaluronic acid|one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
40774501|NCT02811887|BEHAVIORAL|SMS-messages|"Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care)."
40774502|NCT05503277|DEVICE|LTSD|measuring seal pressure
40774503|NCT05503277|DEVICE|i-gel|measuring seal pressure
40774504|NCT03901040|DEVICE|endoscopic ultrasound|endoscopic ultrasound with boutlinum toxin injection in the antrum of the stomach to decrease satiety
40774505|NCT00508456|DRUG|Temodar (Temozolomide)|150 mg/m\^2 orally once a day for 7 consecutive days (days 8 through 15).
40774506|NCT00508456|DIETARY_SUPPLEMENT|Hominex-2|"Methionine free diet during Days 1 - 7 and Days 15 - 21 by consuming only shakes containing Hominex-2®."
40774507|NCT06197581|RADIATION|Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)|Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.
40978620|NCT00731289|DRUG|triamcinolone|"one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)~antiinflammatory intervention"
40978621|NCT00388271|DRUG|Alfuzosin (Xatral)|standard treatment plus alfuzosin
40978622|NCT00388271|DRUG|standard treatment|standard treatment
40978623|NCT03071770|DRUG|ivosidenib (AG-120)|A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
40978624|NCT06101979|DEVICE|Fortiva Tissue Matrix|Acellular Dermal Matrix used in hernia surgery
40978625|NCT02942394|DEVICE|sinus-Obliquus Stent System|
40978626|NCT03566394|DRUG|Gabapentin 300mg|Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
40978627|NCT03231865|DIAGNOSTIC_TEST|Non-invasive measurement of ZincProtoporphyrin IX|Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value
40978628|NCT04034381|OTHER|No intervention (descriptive survey only)|No intervention
40978629|NCT05061810|BEHAVIORAL|Smartphone application self-management programme|The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.
40978630|NCT04268810|PROCEDURE|Bladder instillations|bladder instillations with either solution (DMSO or Uracyst)
40978631|NCT00230568|DRUG|Aricept|
40978632|NCT04519684|DRUG|Mesenchymal stem cells|Allogeneic bone marrow derived mesenchymal stem cells
40978633|NCT04519684|OTHER|Placebo|Normal Saline
40978634|NCT01160250|DRUG|vismodegib (GDC-0449)|Oral repeating dose
40978635|NCT02144389|DRUG|Praziquantel (PZQ)|"40 mg/kg, a single dose, administered orally~1 g of corn/soybean oil (50%/50%), administered orally"
41302018|NCT00443404|PROCEDURE|perioperative epidural catheter|Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
40774508|NCT03896763|OTHER|Either supine or prone positioning and either CMV or HFOV|"Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver."
40978636|NCT02144389|DIETARY_SUPPLEMENT|Arachidonic acid (ARA)|ARA (40% of total fatty acid)
40978637|NCT02144389|DIETARY_SUPPLEMENT|PZQ+ARA|A single dose of PZQ administered seven days in advance of initial treatment with ARA.
40978638|NCT05010577|DRUG|BX004-A|Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
40978639|NCT05010577|DRUG|Placebo|Nebulized placebo
40978640|NCT03766555|PROCEDURE|Microwave ablation|Microwave ablation will be performed in operation theatre under general anesthesia via laparoscopic or open approach according to the tumors' locations. In case of open approach, it will be done via a right subcostal incision with possible upper midline extension was necessary. After diagnostic laparoscopy in laparoscopic approach and exploratory laparotomy in open approach to exclude the presence of extra-hepatic disease, operative ultrasound (Aloka, Tokyo, Japan) will be performed to exclude preoperatively undetected lesion; guide insertion of the microwave applicator; and monitor the whole ablation process. Surrounding organs were cooled by constant irrigation of ice-cold saline to prevent thermal injury. The ablation will be carried out according to the standard protocol with the aim to create a 1cm ablation margin around the tumor. The insertion track will be burnt after ablation in order to prevent bleeding and tumor seeding.
40978641|NCT03766555|PROCEDURE|Liver resection|Liver resection will be performed as described previously. Liver parenchymal transection would be performed with CUSA (cavitron ultrasonic surgical aspirator) and TissueLink (a radiofrequency saline-linked dissecting sealer) in both arms. Vascular staplers would be used to divide major vascular pedicles. Fibrin glue (Tisseel) spray would be applied to the parenchymal cut surface of the liver before closure of abdomen.
40978642|NCT03553134|DIAGNOSTIC_TEST|transcranial doppler ultrasound scan|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 10 minutes)
40978643|NCT03553134|DIAGNOSTIC_TEST|ultrasound scan centered on the arterial canal|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 5 minutes)
40978644|NCT05104892|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
40978645|NCT05104892|DRUG|placebo|Pharmaceutical form: Tablet Route of administration: Oral
40978646|NCT02335294|DRUG|TRV130|Rescue: Ibuprofen, oxycodone
40774509|NCT04588142|DIETARY_SUPPLEMENT|Probiotic|Non-elite athletes receive probiotic for 6 weeks
40774510|NCT04588142|DIETARY_SUPPLEMENT|Placebo|Non-elite athletes receive placebo for 6 weeks
40978647|NCT02335294|DRUG|Morphine|Rescue: Ibuprofen, oxycodone
40978648|NCT02335294|DRUG|Placebo|Rescue: Ibuprofen, oxycodone
40978649|NCT05700045|DRUG|Dexmedetomidine|each side dexmedetomidine 0.5ug/kg TAP block
40978650|NCT03283228|DIAGNOSTIC_TEST|Cd11b and Cd56 markers|The expression of CD11b and CD56 in newly diadnosed cases of AML
40978651|NCT04069494|OTHER|questionnaires|Two questionnaires in patients and another two questionnaires in carer.
40978652|NCT03481036|DRUG|Direct Acting Antivirals|Sofosbuvir and Daclatasvir
40978653|NCT03481036|DRUG|DAAs in Cirrhotics Genotype 2/3|Sofosbuvir and Daclatasvir with weight based ribavirin
41302019|NCT03801304|DRUG|Atezolizumab|Atezolizumab in IV infusions
41302020|NCT03801304|DRUG|Vinorelbine|Vinorelbine capsules
40978654|NCT03481036|DRUG|DAAs in Cirrhotics Genotye 1,4,5,6|Sofosbuvir and Ledipasvir with weight based ribavirin
40978655|NCT05693441|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
40978656|NCT05693441|OTHER|Reference berry-like product|Subjects should consume a reference product (isocaloric to active product, containing berry aromas and colouring but no actual berry compounds) daily during the 12 week intervention period.
41142116|NCT00629993|BEHAVIORAL|Academic Detailing|It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
40774511|NCT02169596|DRUG|Ticagrelor|Blood tests taken for flow cytometry
40774512|NCT02169596|OTHER|EndoPAT - endothelial assessment|
40774513|NCT01605097|RADIATION|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
40774514|NCT03261804|BEHAVIORAL|relation between vaginal douching and vaginal infection|personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
40978657|NCT03661632|DRUG|BMS-986310|Specified dose on specified days
41142117|NCT01736488|DRUG|Fimasartan|Fimasartan 60mg
41302021|NCT04422665|OTHER|Resistance exercise|Single-legged resistance exercise
41302022|NCT04285346|DRUG|Ganaxolone|titration followed by maintenance and extension period
41302023|NCT04552535|DRUG|Second line (2L) afatinib|Afatinib
41302024|NCT04552535|DRUG|Second line chemotherapy|Chemotherapy
41302025|NCT00403702|DRUG|Oxane HD [oil-RMN3-mixture]|
41302026|NCT00403702|DRUG|Densiron [(F6H8)|
40978658|NCT03661632|BIOLOGICAL|Nivolumab|Specified dose on specified days
40978659|NCT02468323|DRUG|Placebo|Patients will receive regular spinal anesthesia
40978660|NCT02468323|DRUG|Ondansetron|Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
40978661|NCT02468323|DRUG|Palonosetron|Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
40978662|NCT03782272|DIETARY_SUPPLEMENT|Enterade|enterade® (an amino acid-based oral rehydration solution \[AA-ORS\]) is a medical food product that consists of oral rehydration salts, natural flavor, steviol (sweetener), purified water, and a blend of amino acids that drive the uptake of water and electrolytes.
41142118|NCT01736488|DRUG|Atenolol|Atenolol 50mg
41142119|NCT04401943|OTHER|online fatigue intervention|on line teleconferencing fatigue intervention for 6 weeks on causes of fatigue, ways to protect joint and save energy, ways to manage stress, pain, good eating habits, and exercise.
41302027|NCT03636776|OTHER|Quality of life in metastatic BC|"1 month after metastatic stage diagnosis, patients complete their 1st therapeutic sequence evaluation visit (T1) within the recommended standard time frames. If the disease remains stable or if a response to treatment is observed then patients continue their follow-up in the same therapeutic sequence (T1).~If progression occurs, treatment is modified and patients move on to the next therapeutic sequence (T2).~And so on as many times as necessary. Before each evaluation visit with investigator, patients complete the questionnaires QLQ-C30, BR23, STAI, BDI II"
40774515|NCT02129972|DEVICE|Colon videocapsule endoscopy (PillCam colon 2)|"This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy."
40774516|NCT02429960|DEVICE|Analgesia monitor (PhysioDoloris®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
40774517|NCT02429960|DEVICE|Analgesia monitor (SPI®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
40978663|NCT03782272|DIETARY_SUPPLEMENT|Placebo|a placebo solution containing natural flavor, steviol (sweetener), and purified water.
40978664|NCT00461682|DRUG|SB-705498|
40978665|NCT03942848|DRUG|zicotinide followed by placebo|The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL
40774518|NCT02429960|DEVICE|Analgesia monitor (AlgiScan®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
40774519|NCT02429960|DRUG|Remifentanil|Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
40774520|NCT04373200|BIOLOGICAL|Blood samples collection|Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients
40774521|NCT04373200|OTHER|Saliva collection|Saliva collection at Month 4 for 25 survivors COVID-19 patients
40774522|NCT01818778|OTHER|Cognitive stimulation program|The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
40774523|NCT01818778|OTHER|Standard Friendly Visit|"Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident."
40774524|NCT06563648|OTHER|shotblocker|A ShotBlocker was placed on the arm of the patients in the ShotBlocker group during the injection, and the injection was performed from the part where the opening was located by lightly pressing with the fingertips throughout the injection.
41142120|NCT02025712|DRUG|Exemestane|Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.
40774525|NCT06563648|OTHER|local cold application|Local cold application was applied to the arm of the patients in the local cold application group for five minutes using a cold pack, and then the injection was performed.
40774526|NCT06563648|OTHER|ShotBlocker placebo group|During the injection, the back side of the ShotBlocker was placed on the arm of the patients in the ShotBlocker placebo group and the injection was performed by gently pressing with the fingertips throughout the injection.
40774527|NCT06355310|DRUG|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
40774528|NCT06355310|DRUG|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
40774529|NCT01081392|BIOLOGICAL|LPS|LPS 20mcg sd inhaled via nebulizer, 3 periods
40978666|NCT03942848|DRUG|Placebo followed by zicotinide|The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
41142121|NCT02025712|DRUG|Everolimus|Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.
41142122|NCT03258788|PROCEDURE|Biopsy and blood samples|"Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archival biopsy is not suitable.~Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week. Patients must have completed at least 1 week of the planned treatment before taking the biopsy.~Participants will also be asked for consent to donate 50ml blood pre biopsy (at baseline and week 2) and at the end of radiotherapy; as well as 10ml blood before #2 radiotherapy and weekly throughout treatment."
41142123|NCT03823794|OTHER|No intervention|Observational analysis of usual care only
41142124|NCT00591136|DRUG|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
40774530|NCT00425620|DRUG|SinuNase|Lavage
40774531|NCT05716113|DRUG|RD13-02 cell infusion|CAR-T cells
40774532|NCT04037215|OTHER|STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|"Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~* children controls not achieved with normal BMI;~* children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders."
40774533|NCT05938686|OTHER|Home_Based Digital Mindful Dance Program|Home_Based Digital Mindful Dance Program including warm up, dance and cool down for 60 minute with 12 weeks.
40774534|NCT02784587|PROCEDURE|Stellate Ganglion Block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
40774535|NCT02746809|DEVICE|CoreValve Evolut 34R TAVR system|"The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:~1. Evolut 34R Transcatheter Aortic Valve (TAV)~2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~3. EnVeo R Loading System (LS)"
40774536|NCT06122168|OTHER|Mandala|verbal interview, standard health care, sheet of paper showing a mandala to be colored at will
40774537|NCT06122168|OTHER|Standard care|verbal interview and standard health care
40774538|NCT04409444|DIAGNOSTIC_TEST|Lung Cancer Screening|The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)
40774539|NCT04409444|DIAGNOSTIC_TEST|Biomarkers|This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers.
40978667|NCT03512509|OTHER|Low glycaemic potato|The Carisma potato variety is used as the low glycaemic index potato.
40774540|NCT05339555|OTHER|Instructions for IUD Self-Removal Provided to Participant|The provider will offer any individual presenting for in-person IUD removal or exchange (removal-replacement) the option for self-removal. The participant will be provided a 'how to' instruction sheet with information on positioning and what to expect. The participant will first attempt removal with clean hands if desired, then utilizing non-sterile, clean gloves (not explicitly tested in prior studies) and if that fails, the use of a menstrual cup (a novel technique). If not successful, the provider will perform standard IUD removal in the clinic.
40774541|NCT06234514|DRUG|Jueling Mingmu decoction|Jueling Mingmu decoction comprises stone cassia, grass cassia, Leonurus, chrysanthemum, red peony, Schizonepeta, poria, plantago, salvia miltiorrhiza, rice bud, licorice. It is designed to clear liver heat, promote diuresis, activate blood circulation, strengthen the stomach, and harmonize spleen functions.
40774542|NCT06234514|DRUG|intravitreal injections of 0.5mg ranibizumab|Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
40774543|NCT06508346|BIOLOGICAL|anti-CD19-CAR-T cells|Intravenous injection
40774544|NCT03207347|DRUG|Niraparib|Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.
40774545|NCT06563856|DRUG|TEPEZZA|Administered as a SubQ injection or IV injection.
40774546|NCT06563856|DRUG|EDP|Administered as a SubQ injection.
40774547|NCT06564324|DRUG|Taletrectinib|"Approximately 138 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD), continuously; Arm B: Crizotinib monotherapy at 250 mg twice daily (BID), continuously.~Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met."
40774548|NCT06564324|DRUG|Crizotinib|"Approximately 138 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD), continuously; Arm B: Crizotinib monotherapy at 250 mg twice daily (BID), continuously.~Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met. Crossover from control group (crizotinib) to taletrectinib is also permitted, at the Investigator's discretion with the Sponsor's approval, for qualifying participants who have experienced objective progression confirmed by the BIRC."
40774549|NCT05946551|DRUG|Cetirizine|Cetirizine will be dispensed as a 10mg capsule with instructions for patients to take one capsule daily by mouth, preferably at bedtime.
40774550|NCT05946551|DRUG|Famotidine|Famotidine will be dispensed in 20mg capsules with instructions for patients to take one capsule twice daily, as close to the same times every day as possible.
40774551|NCT05946551|DRUG|Cetirizine Placebo|The cetirizine placebo will be designed as a capsule of an inert substance and will match the morphology of the cetirizine treatment capsule. Administration instructions to match that of cetirizine.
40774552|NCT05946551|DRUG|Famotidine Placebo|The famotidine placebo will be designed as a capsule of an inert substance and will match the morphology of the famotidine treatment capsule. Administration instructions to match that of famotidine.
40774553|NCT06301373|DRUG|Methotrexate Combined With Tofacitinib|Methotrexate Combined With Tofacitinib
40774554|NCT06301373|DRUG|Methotrexate|Methotrexate
40774555|NCT01715116|DEVICE|Enhanced ICD programming|"* VT monitor: \> 166/min~* fVT: \> 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.~* VF: \> 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals~* SVT/VT discrimination is turned on, high rate time out is OFF~* SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min~* SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min~* T wave-oversensing and lead noise discrimination is turned on in all devices."
40774556|NCT01217892|DRUG|dapagliflozin|2.5 mg tablet, taken orally, twice daily
40774557|NCT01217892|DRUG|dapagliflozin|5 mg tablet taken orally, twice daily
40774558|NCT01217892|DRUG|dapagliflozin|10 mg tablet taken orally, once daily
40774559|NCT01217892|DRUG|metformin|\>/= 1500 mg total daily dose, tablets taken orally, twice daily
40774560|NCT01217892|DRUG|placebo|placebo
40774561|NCT03308279|DIAGNOSTIC_TEST|Ultrasound|Ultrasound and Anthropometric meassures
40774562|NCT06054308|OTHER|MSLN CART|Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
40774563|NCT02135484|DRUG|Alpharadin|50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
40774564|NCT03748550|BEHAVIORAL|Aerobic exercise|All participants will receive standard of care for their cancer as well as given a 12-week, home-based progressive aerobic exercise (AE) program. A nonlinear progressive training approach will be used whereby each participant will perform two AE sessions (e.g. walking), on non-consecutive days, per week. AE sessions will vary between low (35-45% heart rate reserve (HRR)), low-moderate (46-55% HRR), high-moderate (56-70% HRR) and high (71-85% HRR) intensity.
40774565|NCT00453492|DRUG|risedronate sodium|
40774566|NCT04185779|DIAGNOSTIC_TEST|Colonoscopy|Diagnostic colonoscopy
40978668|NCT03512509|OTHER|High glycaemic potato|The Arizona potato variety is used as the high glycaemic index potato.
40978669|NCT01199523|DRUG|Placebo|oral
40978670|NCT01199523|DRUG|mirabegron|oral
40978671|NCT01199523|DRUG|moxifloxacin|oral
40978672|NCT06228560|BIOLOGICAL|LP-003|Liquid in vial
40978673|NCT06228560|BIOLOGICAL|Placebo|Liquid in vial
40978674|NCT06228560|BIOLOGICAL|Omalizumab|Liquid in vial
40978675|NCT05195125|PROCEDURE|Direct Peritoneal Resuscitation|Direct peritoneal resuscitation involves the abdominal infusion and drainage of a peritoneal dialysate in high-risk liver transplant patients, for up to 24 hours after surgery.
40978676|NCT04276597|DRUG|177Lu-DOTATOC|177Lu labeled somatostatin receptors targeting ligand
40978677|NCT00658593|DRUG|capecitabine|
40978678|NCT00658593|DRUG|gemcitabine hydrochloride|
40978679|NCT00658593|PROCEDURE|quality-of-life assessment|
40774567|NCT03825705|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
40774568|NCT03825705|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
40774569|NCT06405633|DRUG|WVE-006|RNA editing oligonucelotide
40774570|NCT03112902|DEVICE|Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
40774571|NCT00212602|DRUG|ONO-7436|
40774572|NCT02227745|DRUG|Dorzolamide hydrochloride (2%)|"Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed"
40774573|NCT02227745|DRUG|Placebo Sodium hyaluronate 4mg|"Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed."
40774574|NCT03952845|OTHER|Capsaicinoid|This is a tolerability study on doses lower than previously published for the use of intranasal capsaicinoid in the treatment of rhinitis
40774575|NCT03198403|DRUG|Bupivacaine-epinephrine|Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
40774576|NCT05212909|BEHAVIORAL|General Anxiety Disorder-7 scale|The General Anxiety Disorder-7 scale was used to evaluate the level of anxiety in anesthesiology providers.
40774577|NCT01868412|DEVICE|Abilar 10% resin salve|The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
40774578|NCT01868412|DEVICE|Activon Tube 25 g|Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
40774579|NCT06033560|DEVICE|High flow nasal oxygen (HFNO, more than 15 L/min)|Non-invasive respiratory support strategy
41142125|NCT05886465|DRUG|Atezolizumab|1200 mg, iv.drip, Q3W
41142126|NCT05886465|DRUG|Bevacizumab|15mg/kg, iv.drip, Q3W
40774580|NCT01923922|RADIATION|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
40774581|NCT03465683|OTHER|ESBL-producing Enterobacteriaceae|Data and biological sample collection
40774582|NCT05238792|BIOLOGICAL|Tumor-associated antigen-specific T cell (TAA-T)|"Patients will receive an infusion of partially HLA-matched TAA-T any time \>1 week after completing most recent course of conventional (non-investigational) therapy for their disease. For the lymphodepletion cohort, patients will receive lymphodepletion (LD) chemotherapy \>2 weeks from most recent course of conventional therapy and will nadir and recover before beginning TAA-T therapy. Patients will be enrolled to one of the following TAA-T dose levels:~BSA \<1.20 BSA ≥1.20 Dose level 1 without LD (low dose) 2x107 cells 4x107 cells Dose level 2 (LD + Low dose) 2x107 cells 4x107 cells Dose level 3 (LD + High dose) 4x107 cells 8x107 cells"
40774583|NCT04932148|OTHER|Incremental HD|Starting haemodialysis at twice weekly frequency
40774584|NCT04932148|OTHER|Conventional HD|Starting haemodialysis at thrice weekly frequency
41142127|NCT05886465|PROCEDURE|HAIC with FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries, Q3W
41142128|NCT01572896|BEHAVIORAL|Taking Charge: Managing JIA Online|"In addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing JIA Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French."
41302028|NCT00872170|DRUG|Sildenafil|"Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg"
40774585|NCT06332157|DRUG|Remimazolam besylate|In Remimazolam group, anesthesia was induced with remimazolam besylate at a rate of 6mg/min and maintained with 1.0-2.0mg/min until the end of surgery.
40774586|NCT06332157|DRUG|Propofol Injection Emulsion|In Propofol group, anesthesia was induced with propofol injection emulsion at a rate of 2mg/kg and maintained with 6-8mg/kg/h until the end of surgery.
40978680|NCT05711173|BIOLOGICAL|Additional blood sampling|The procedure will consist of an additional blood sample for ETDA tube collection (NGS analysis) and citrate tube collection (NETose analysis)
40978681|NCT04844632|BIOLOGICAL|Vaccine anti-Covid19|Vaccination with AstraZeneca or Pfizer-Biontech anti-Covid19 vaccine
41302029|NCT00122005|BIOLOGICAL|GM-CSF gene transduced allogeneic vaccine GVAX|
40774587|NCT03005886|PROCEDURE|Periodontal examination|"periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements"
40774588|NCT03005886|PROCEDURE|GCF sampling|GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
40774589|NCT03005886|PROCEDURE|phase I therapy|comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
40774590|NCT04281667|DRUG|Oral Antibiotics|Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)
40774591|NCT04281667|DRUG|Placebo|Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)
40774592|NCT04281667|DRUG|Mechanical Bowel Preparation|Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
40774593|NCT04940169|PROCEDURE|anterior cruciate ligament recontruction|Firstly graft is harvested with help of arthroscopy femoral and tibial tunnels created then graft placed into tunnels
40774594|NCT00437073|DRUG|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
40774595|NCT00437073|DRUG|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
40774596|NCT00437073|DRUG|lapatinib|lapatinib administered 1250mg once daily orally
40774597|NCT01296204|DRUG|BB4 antibody-Iodine 131|Injection of an antibody after labelling with Iodine 131
40774598|NCT02947048|DRUG|L1-79|
40774599|NCT02947048|DRUG|Placebo|
40774600|NCT02997202|DRUG|gilteritinib|oral
40774601|NCT02997202|DRUG|Placebo|oral
40774602|NCT06564597|OTHER|Patient education|Patient education and counseling are offered one-on-one at the bedside during discharge and are also provided in the second week after discharge in an outpatient clinic setting.
40774603|NCT00319189|DRUG|Nateglinide|
40774604|NCT00388609|DRUG|BMS-646256|Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
40774605|NCT00388609|DRUG|Placebo|Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
40774606|NCT00001055|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
40774607|NCT00001055|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
40774608|NCT00001055|BIOLOGICAL|rgp120/HIV-1 SF-2|
41142129|NCT01572896|BEHAVIORAL|Standard Medical Care and JIA Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA (JIA Resource Centre) and online assessments."
41142130|NCT05889832|DIAGNOSTIC_TEST|measurement of physiological parameters wih Shen.AI Vitals software on various camera-equipped devices (smartphones, tablets, laptops)|"Resting heart rate (HR), heart rate variability (HRV) and breathing rate (BR) will be measured (estimated) with the use of remote photoplethysmography (1-minute face video analysis with Shen.AI Vitals software).~Reference measurements will be taken simultaneously (chest ECG for the calculation of HR and HRV; impedance pneumography for BR)."
41142131|NCT00224913|PROCEDURE|Neuromuscular electrical stimulation|
41142132|NCT00224913|PROCEDURE|Voluntary exercise|
41142133|NCT02525185|OTHER|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
40774609|NCT04417985|DEVICE|18F-FDG PET/CT, MRI|
40774610|NCT01203345|DRUG|IVIG|The infants received their first dose of study drug within 24 hours of randomization.
40774611|NCT01203345|DRUG|Placebo|An equal volume of 5 percent albumin solution
40774612|NCT01128517|BEHAVIORAL|Maternal education on complementary feeding|"CF education to the mothers in intervention arm.~* Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 \& 2006).~* First session --\> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.~* Second session --\>breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.~* Third session --\> previous sessions recall. protein based and iron rich food encouragement.~* The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm"
40774613|NCT01128517|BEHAVIORAL|Education|Maternal education on complementary food
40774614|NCT05650996|BEHAVIORAL|ADL/Cast Care instruction|Participants in the experimental group will watch a video instructing them on early ADL participation after DRF fracture treated in a cast and cast care. Participants in the experimental group will also receive a handout on ADL participation and cast care.
40774615|NCT05650996|BEHAVIORAL|Cast Care Instruction|Participants in the control group will watch a video instructing them on cast care. Participants in the control group will receive a handout on cast care.
40774616|NCT03255616|OTHER|mechanical stimulation|mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients
40774617|NCT03255616|OTHER|vibrotactile stimulation|non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients
40774618|NCT03765931|DRUG|Doxycycline|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
40774619|NCT03765931|DRUG|Amoxicillin|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
41302030|NCT03105440|OTHER|Virtual reality|"This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
41302031|NCT03105440|OTHER|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
41302032|NCT03105440|OTHER|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
41302033|NCT03105440|OTHER|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
41302034|NCT03105440|OTHER|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
41302035|NCT03105440|OTHER|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
41302036|NCT02695485|PROCEDURE|innervated sensate flap|sensory reconstruction via digital nerve repair with the donor nerve of the flap
41302037|NCT02588248|DRUG|Peppermint Oil|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 640 mg of L-Menthol).
41302038|NCT02588248|OTHER|Placebo|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 80 ml of Solution B, also has 0 mg of L-Menthol).
41302039|NCT03475888|DEVICE|Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Implantation of Medtronic Reveal LINQ™ ICM
41302040|NCT03023982|DRUG|Bupivacaine Hydrochloride|40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
41302041|NCT03023982|DEVICE|Ultrasound|All blocks will be done under ultrasound
41302042|NCT03023982|PROCEDURE|Thoracotomy|The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
40774620|NCT05719220|BEHAVIORAL|Group preoperative pelvic floor training|Patients will receive PFT from a trained physical therapist delivered in a group setting of 8-10 people. The investigators allow patients in the PFT group to attend group classes as many times as they want prior to surgery to see if the frequency of training has an effect on outcomes. The treatment group could be required to go to at least 1 group class 4 weeks prior to their procedure, but they could be welcome to attend more if they want further practice and review of the material. A 45-minute group class with basic PFT guidelines could be presented weekly during the study.
40774621|NCT05222711|DEVICE|Use of the PICO(TM) monitoring device|The aim is to record if the outcome (referral or not) is influenced by the results of the parameters and/or the ECG.
40774622|NCT03873545|PROCEDURE|Cryopreserved Osteochondral Allograft|This tissue is a laser-etched, cryopreserved fresh osteochondral allograft that was developed as a single-stage alternative for articular cartilage restoration.
40774623|NCT03106714|DIAGNOSTIC_TEST|RT-PCR|Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
40774624|NCT00318617|DRUG|GW510516X|
40774625|NCT06352346|BEHAVIORAL|Compensatory brain game supporting Goal Management Training intervention|o The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently outside the therapy session. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
40774626|NCT02382146|DRUG|dexamethasone ondansetron|dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
40774627|NCT02382146|DRUG|Dexamethasone dimenhidrinate|dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
41142134|NCT03575494|OTHER|Intraoral and Radiographic Dental Examination|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
41302043|NCT03023982|DRUG|Opioids|standard pain control with opioids
41461046|NCT01470898|DEVICE|bispectral index monitoring|A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
41461047|NCT05138926|OTHER|Cervical Manipulation|high speed, low amplitude cervical manipulation
41461048|NCT05138926|OTHER|Sham Cervical Manipulation|Cervical mobilization without performing spinal manipulation
41461049|NCT05855824|OTHER|Applesauce Pouch|One 90 g pouch of applesauce provides 0 mg carotenoids/d and 40 kcal, 10 mg vitamin C, and 1 g dietary fiber.
41461050|NCT05855824|OTHER|Fruit-vegetable puree blend|One 120 g pouch of fruit-vegetable puree blend provides 5 mg mixed carotenoids, 70 kcal, 4 mg vitamin C, and 2 g dietary fiber.
41461051|NCT06249451|OTHER|Checklist-based phone calls|"The treating doctor will be called on day 1 and 12 after SAB diagnosis to point out the standard of care (as per our evidence-based in-hospital standard operating procedure (SOP)) for SAB.~On day 2 and 6 after SAB diagnosis, there will be additional phone calls if clinical management does not follow hospital guidelines.~The study team will also leave comments in the medical charts of the respective patients if the management does not follow hospital guidelines."
41461052|NCT02670785|DRUG|Estradiol Vaginal Capsule (EVC)|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
41302044|NCT03023982|DRUG|NSAID|standard pain control with NSAIDs
41461053|NCT02670785|DRUG|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
40774628|NCT02369536|DIETARY_SUPPLEMENT|nutraceutical mixture|Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)
40774629|NCT02369536|DIETARY_SUPPLEMENT|placebo|Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
40774630|NCT03870633|OTHER|Medical Chart Review|Undergo medical chart abstraction
40774631|NCT03870633|OTHER|Interview|Complete telephone interview
40774632|NCT03870633|OTHER|Questionnaire|Ancillary studies
40774633|NCT03870633|OTHER|Quality-of-Life Assessment|Ancillary studies
40774634|NCT04198402|BIOLOGICAL|Biological sampling|Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
40774635|NCT05174806|DRUG|Topical Pravibismane|Topical Pravibismane
40774636|NCT05174806|OTHER|Standard of Care|Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.
40774637|NCT01710566|DRUG|Misoprostol|600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
40774638|NCT01710566|DRUG|Oxytocin|10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
40774639|NCT05713487|OTHER|preventive treatment group|each athlete belonging to the preventive treatment group performed the protocol of preventive treatment 2 times a week, before or after the training session for five months
40774640|NCT02294864|DEVICE|Percutaneous Pulsed Radiofrequency|Pulsed Radiofrequency
40774641|NCT02294864|PROCEDURE|Physical Therapy|
40774642|NCT03707392|OTHER|Ostomy Education Video|Ostomy education video in addition to standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
41302045|NCT06330272|PROCEDURE|Application of dental mousse based on CPP-ACPF|"Treatment will begin with pumice prophylaxis of incisors with IMH lesions. After this step, the teeth will be dried before applying dental foam based on CPP-ACPF (Tooth Mousse PlusTM, GC Corporation, Tokyo, Japan).~The application of Tooth Mousse PlusTM to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush. The cream will remain on the surface for 1 minute, which will be timed. The application will be carried out once a week, for four consecutive weeks."
41461054|NCT05435833|PROCEDURE|bilateral ultrasound guided GPN block|a linear high frequency ultrasound probe will be initially positioned over the hyoid bone in the transverse plane, then the probe will be rotated to keep in line with the mandibular angle and the pharyngeal wall is identified by US. Using an in plane approach, a 22 G ,5 cm needle will be advanced till it reaches just superficial to the pharyngeal wall and 2.2 ml of 0.25% bupivacaine will be injected.
41461055|NCT03496298|DRUG|Efpeglenatide (SAR439977)|"Pharmaceutical form: Solution for injection,~Route of administration: SC"
41461056|NCT03496298|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: SC"
41461057|NCT05550740|DEVICE|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
41461058|NCT03844230|OTHER|Control - Inhibition|Taste and spit up water 10 minutes before drinking a glucose load
41461059|NCT03844230|OTHER|Experimental I- Inhibition|Taste and spit up water 10 minutes before drinking a glucose load mixed with lactisole
41461060|NCT03844230|OTHER|Experimental II- Inhibition|Taste and spit up sucralose 10 minutes before drinking a glucose load mixed with lactisole
41461061|NCT03844230|OTHER|Control- Stimulation|Taste and spit up water 10 minutes before drinking a glucose load
41461062|NCT03844230|OTHER|Experimental I- Stimulation|Taste and spit up sucralose 10 minutes before drinking a glucose load
41461063|NCT03844230|OTHER|Experimental II- Stimulation|Drink sucralose 10 minutes before drinking a glucose load
41461064|NCT03844230|OTHER|Sensory Evaluation|Taste different solutions to evaluate sweet taste preference, suprathreshold intensity and detection threshold
41461065|NCT00099580|DRUG|AC2592|continuous subcutaneous infusion (via pump), dose based on subject body weight
41461066|NCT00099580|DRUG|placebo|continuous subcutaneous infusion (via pump), dose based on subject body weight
40774643|NCT03707392|OTHER|Control - Standard ostomy education|Standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
41461067|NCT05798637|OTHER|Standard of care|No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)
40978682|NCT06204718|OTHER|Standard pelvic floor exercises|Pelvic floor muscle exercises will be given as 2 separate exercises including fast and slow contractions. For fast contractions, participants will be asked to contract their pelvic floor muscles strongly, hold them contracted for 5 seconds, and then relax them. For slow contractions, participants will be asked to gradually contract the pelvic floor muscles, hold them at maximum contraction for 5 seconds, and relax them gradually. Participants will be asked to perform 10 slow contractions after every 10 fast contractions. The aim is to train strength, coordination, endurance, and symmetry of pelvic floor muscles, motor learning and control, dynamic lumbopelvic stability, pelvic floor, and abdominal co-contraction. Every day, 10 fast, and 10 slow contractions with a total of 20 repetitions will be applied without changing the number by modifying the exercises every week. It will be applied for a total of 12 weeks.
40774644|NCT05593939|BEHAVIORAL|Exercise|Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.
40774645|NCT05593939|BEHAVIORAL|Time restricted feeding|Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.
40978683|NCT06204718|OTHER|Involuntary reflexive pelvic floor exercises|Reflexive exercises (jump, squat jump, etc.) with 20 repetitions per day will be applied to the participants for 12 weeks with modifications every week.
40978684|NCT05147116|OTHER|Sleeping in a tent|Participants will spend 10 consecutive nights of sleeping in a tent
40978685|NCT05782465|PROCEDURE|Blood Collection, processing and analyses|20ml of blood will be drawn from study participant at the baseline visit for molecular analyses.
40978686|NCT05782465|PROCEDURE|Gastroscopy and biopsies collection|Study participant will undergo gastroscopy with collection of gastric mucosal biopsies at the baseline visit to ascertain OLGIM status and for molecular analyses. Study participant will undergo surveillance gastroscopy for gastric cancer at years 2 and 4 to assess whether they have reached endpoint.
40978687|NCT05782465|DIAGNOSTIC_TEST|Urea Breath Test|Study participant will fast for 6 hours or overnight before undergoing the Urea Breath Test (UBT) to test for current H. pylori infection. Breath collection will be performed before ingestion of 13C urea, and at specified time intervals after ingestion.
40978688|NCT01463553|PROCEDURE|VATS pleurodesis|Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
40978689|NCT00197041|BIOLOGICAL|RTS,S/AS02A|
40978690|NCT02235012|DRUG|Ketamine|"KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
40978691|NCT02235012|DRUG|Placebo|"CHLORURE DE SODIUM 0,9 % MACOPHARMA :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
40774646|NCT05593939|DIETARY_SUPPLEMENT|Nicotinamide riboside|Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
40774647|NCT05020587|BEHAVIORAL|Open pilot trial of a group therapy manual.|Open pilot trial of a group therapy manual.
40978692|NCT00426855|DRUG|Bendamustine|starting with 60 mg/m\^ 2, IV, dose escalation, weekly d1,8,15 q5w
40978693|NCT00426855|DRUG|Bortezomib|weekly 1.5mg/m\^2, IV, d1,8,15,22 q5w
40978694|NCT05073991|PROCEDURE|Lung surgery|Patients underwent lung surgery including wedge resection, lobectomy, segmentectomy, and pneumonectomy.
41461068|NCT04972851|BEHAVIORAL|Self-Determined Learning Model of Instruction (SDLMI)|"SDLMI is a teaching model that enables providers to teach students to:~* make choices and decisions about setting a goal~* develop action plans for academic or other goals~* self-monitor and self-evaluate progress toward goal attainment~* adjust the goal or plan"
40978695|NCT05073991|PROCEDURE|Open aortic surgery|Patients underwent open thoracic surgery or thoracoabdominal aortic surgery.
40978696|NCT05073991|PROCEDURE|TEVAR|Patients underwent TEVAR.
40978697|NCT05073991|PROCEDURE|EVAR|Patients underwent EVAR.
40978698|NCT06337331|DRUG|Venetoclax|400mg/day PO Days -8 to -2
40978699|NCT06337331|DRUG|Decitabine|20mg/m2/day IV Days -7 to -3
40978700|NCT06337331|DRUG|Fludarabine|30mg/m2/day IV Days -7 to -3
40978701|NCT06337331|DRUG|Busulfan|3.2mg/kg/day IV Days -5 to -4
40978702|NCT06337331|RADIATION|Total Body Irradiation|200cGy Day -2
40978703|NCT01486251|DRUG|axitinib|"Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade \> 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
41461069|NCT04320745|DRUG|Androderm®|Androderm® transdermal dose.
41461070|NCT00483145|DEVICE|Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)|
41461071|NCT00483145|DEVICE|Long-pulsed dye laser|
40774648|NCT03222570|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|IPT-A is an evidence-based intervention that aims to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal interactions. It addresses one or more of four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. The primary treatment techniques in IPT-A include emotion identification/expression, linking interpersonal events to mood, communication analysis, communication skill building, decision analysis, role playing, and assignment of interpersonal experiments (i.e. homework). In clinical trials, depressed adolescents treated with IPT-A demonstrated fewer depressive symptoms and better psychosocial functioning post-treatment than adolescents in control conditions.
40978704|NCT04667767|OTHER|WASH kit|WASH kit containing a plastic container and a supply of Aquatabs® (effervescent chlorine tablets) and training in their use and associated hygiene practices.
40978705|NCT04667767|OTHER|Standard treatment|National standard outpatient treatment for uncomplicated severe acute malnutrition
40978706|NCT04827927|PROCEDURE|Procedure: INTELLiVENT-ASV|With INTELLiVENT-ASV, the patient's conditions, 'ARDS', 'Chronic Hypercapnia' or 'Traumatic Brain Injury' can be chosen, if applicable. The controllers for minute volume, PEEP and FiO2 are all activated, and the target shifts for etCO2 and SpO2 are adjusted, if necessary.
40978707|NCT04827927|PROCEDURE|Procedure: Conventional ventilation|With conventional ventilation, the same etCO2 and SpO2 levels are targeted as with INTELLiVENT-ASV, but here the caregiver is fully responsible for choosing the settings.
40978708|NCT04468204|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
40978709|NCT04468204|DEVICE|Sham SinuSonic Device|Sham positive expiratory pressure intervention using the SinuSonic Device.
40978710|NCT05450783|OTHER|Biocollection|serum
40978711|NCT05893407|DIAGNOSTIC_TEST|Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging|Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
40978712|NCT02683889|DRUG|Acthar|patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
40978713|NCT03902197|BIOLOGICAL|CD19 hsCAR-T|CD19 hsCAR-T will be administered by I.V. infusion
40978714|NCT00709683|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40978715|NCT04083170|DRUG|Fludarabine|Given IV
40978716|NCT04083170|DRUG|Cyclophosphamide|Given IV
40978717|NCT04083170|DRUG|Thiotepa|Given IV
40978718|NCT04083170|RADIATION|Total-Body Irradiation|Undergo TBI
40978719|NCT04083170|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
40978720|NCT04083170|BIOLOGICAL|Dilanubicel|Given IV
41142135|NCT01455779|DEVICE|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
41142136|NCT03233997|OTHER|FT21018|An electronic cigarette
41142137|NCT03233997|OTHER|FT21033|An electronic cigarette
41142138|NCT03233997|OTHER|FT21034|An electronic cigarette
41142139|NCT03233997|OTHER|FT21035|An electronic cigarette
41142140|NCT06173167|DEVICE|Crowns self-adhesively luted|After cavity preparation, the zirconia chairside crown will be placed using SpeedCEM Plus. The excess will be light cured with Bluephase G4 in PreCure mode (950 mW/cm\^2). After removal of the excess, the luting material margins will be light-cured again for 20s (1200 mW/cm\^2).
41142141|NCT06173167|DEVICE|Crowns conventionally cemented|After cavity preparation, the zirconia chairside crown will be placed using ZirCAD Cement. The excess cement will be removed in the gel phase, either following light curing (5 - 10 seconds per segment) or following self-curing (approximately 2 min after placement). The restoration will be held in position during final curing that is complete 4 min 30 s after placement.
41142142|NCT06210555|PROCEDURE|Renal transplantation|Operative procedure - receipt of a kidney
41142143|NCT06210555|PROCEDURE|Living kidney donation|Operative procedure - donation of a kidney
41142144|NCT01896609|BIOLOGICAL|Reiferon Retard in Arm 1|Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
41142145|NCT01896609|DRUG|Bon one in Arm 3|Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
41142146|NCT01896609|DRUG|Xerovirinc in Arm 2|Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
41142147|NCT01896609|DRUG|Ribavirin in Arm 1|Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
41142148|NCT02635698|OTHER|Optifast|medically-supervised weight management program
41142149|NCT02635698|OTHER|Food-Based|low-energy, low-fat diet
41142150|NCT02560155|DRUG|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
41142151|NCT02560155|DRUG|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
41142152|NCT03989232|DRUG|Semaglutide|Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.
41142153|NCT03989232|DRUG|Placebo (semaglutide)|Semaglutide placebo injected once-weekly from week 13 to week 40.
41461072|NCT00483145|DEVICE|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)|
40774649|NCT03222570|DRUG|Selective Serotonin Reuptake Inhibitor|Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline
40978721|NCT02366845|BIOLOGICAL|Fresh Frozen Plasma|An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.
40978722|NCT02366845|DIAGNOSTIC_TEST|Pre-Transfusion International Normalized Ratio (INR)|INR result prior to Fresh Frozen Plasma (FFP) transfusion determined by clinical lab testing performed within 6 hours to 1 day before transfusion start time.
40978723|NCT02366845|DIAGNOSTIC_TEST|Post-Transfusion International Normalized Ratio (INR)|INR result after Fresh Frozen Plasma (FFP) transfusion completed, determined by clinical lab testing performed within 1 hour after transfusion completed.
40978724|NCT03393546|BEHAVIORAL|Auricular Point Acupressure|It includes 4 weekly auricular point acupressure treatments.
40978725|NCT06036459|OTHER|uterine peristalsis|Transabdominal us followed by Transvaginal ultrasonography scans (Sono Ace R5 ) of uterine peristalsis will performed on the day of embryo transfer while the patient lying relaxed in lithotomy position. The probe will be introduced into the vagina as gently as possible to avoid stimulating the cervix. After scanning the mid-sagittal plane of the uterus, the probe will be fixed as steady as possible while a 3 min video of uterine peristalsis will be recorded simultaneously. The records will be analyzed at 4X regular speed using a Video player application by two independent experienced observers. The uterine peristaltic wave frequency will be the mean of the results from each observer.
40978726|NCT05908370|PROCEDURE|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
40978727|NCT03061331|DRUG|LUM/IVA|LUM 400 mg/IVA 250 mg every 12 hours (q12h)
40774650|NCT03222570|OTHER|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI
40978728|NCT03061331|DRUG|Placebo|No Active Drug
40978729|NCT02319746|BEHAVIORAL|Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
41142154|NCT02953756|RADIATION|Gamma Knife radiosurgery|Gamma Knife radiosurgery will be performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the tumor volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target
41142155|NCT05192902|DEVICE|Computer-controlled Local Anaesthesia (CCLA)|The computer-controlled local anesthetic injector Calaject®, (Rønvig Dental MFG, Daugaard, Denmark), which is designed to reduce the pain of performing local anaesthesia. The principle of this device is based on the fact that the less pressure and flow of a local anaesthetic injection, the less painful will be the procedure. Each device has an installed pressure sensor as well as a three-button display that allows choosing the most appropriate program in terms of different speeds and pressure. According to the anaesthesia technique, the manufacture recommends program I for intraligamentary and palatally injections, program II for infiltration and III for alveolar nerve block techniques. Conventional carpules and needles can be used in a pen-shaped part connecting to the main unit. The administration of the anaesthetic can be achieved using a foot control pedal which is adapted to the main unit, the speed of injection is related to acoustic signals.
40774651|NCT02439957|DRUG|Brincidofovir|
41142156|NCT05192902|DEVICE|Conventional Local Anaesthesia|Conventional dental local anaesthetic injections.
41142157|NCT01137682|DRUG|Pasireotide|"* Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~* Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks"
41302046|NCT02549911|OTHER|HIPEC,Chemotherapy AND surgery|"1. HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~2. chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~3. surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~4. after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
40774652|NCT02439957|DRUG|Valganciclovir|
40774653|NCT01817777|DRUG|Metformin Small Pack|A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
40774654|NCT01817777|DRUG|Metformin Large Pack|The large pack will consist of 1 month's supply of metformin.
41142158|NCT01137682|DRUG|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
41302047|NCT01145027|OTHER|Breakfast tray|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
40774655|NCT06327815|DRUG|Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets|10 mg Dapagliflozin/1000 mg Metformin HCl extended-release
40774656|NCT06327815|DRUG|Dapagliflozin tablets and Metformin HCl extended-release tablets|Dapagliflozin tablets: 10 mg Metformin HCl extended-release tablets: 1000 mg
40774657|NCT00363298|DRUG|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
41461073|NCT05761392|OTHER|Precise management|The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.
40774658|NCT00363298|DRUG|Sham Comparison|caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
40774659|NCT04786964|DRUG|Cosibelimab|IV infusion
40774660|NCT04786964|DRUG|Cisplatin|IV infusion
40774661|NCT04786964|DRUG|Carboplatin|IV infusion
40774662|NCT04786964|DRUG|Pemetrexed|IV infusion
40774663|NCT04786964|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
40774664|NCT04786964|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
40774665|NCT04786964|DRUG|Dexamethasone 4mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
40774666|NCT02743741|DRUG|Lutetium-177 Octreotate|Radiopharmaceutical
40774667|NCT06565026|GENETIC|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
40978730|NCT02319746|BEHAVIORAL|Psychoeducation|The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
40774668|NCT01657357|OTHER|Routine followup|questionnaires
40774669|NCT05694494|BEHAVIORAL|internet-based Lifestyle-integrated Functional Exercise (iLiFE)|receiving internet-based LiFE training and home safety assessment
40774670|NCT05694494|BEHAVIORAL|upper limb exercise training|upper limb exercise training
40774671|NCT05194995|DRUG|JAB-21822|JAB-21822 administered orally as a tablet.
40774672|NCT05194995|DRUG|Cetuximab|Cetuximab administered as an intravenous (IV) infusion.
40774673|NCT05975424|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
40774674|NCT02998307|PROCEDURE|CPR Training|Brief CPR assessment and training done during working hours with real-time performance feedback
40774675|NCT03410160|DIAGNOSTIC_TEST|Clinical and biochemical examination.|Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.
40774676|NCT01846312|OTHER|No treatment given|The participants will not receive any treatment.
40774677|NCT01634152|DRUG|Placebo|2 actuations once daily in the evening
40774678|NCT01634152|DRUG|Tiotropium low dose mcg|2 actuations once daily in the evening
40774679|NCT01634152|DRUG|Tiotropium high dose|2 actuations once daily in the evening
40774680|NCT03770702|DRUG|Angiotensin receptor blockers|Candesartan
40774681|NCT03770702|DRUG|Statins|Atorvastatin
40978731|NCT01075724|DEVICE|Patient Warming with Forced Air|Forced Air warming via BairHugger
40978732|NCT01075724|DEVICE|Resistive Warming|Resistive Warming via HotDog device
40774682|NCT01645202|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
40978733|NCT04411875|DRUG|Amlodipine 10 mg|The subjects randomly received single oral administration of amlodipine 10 mg.
40978734|NCT04411875|DRUG|Levamlodipine 5 mg|The subjects randomly received single oral administration of levamlodipine 5 mg.
40978735|NCT05843981|DEVICE|Implant placement TS III|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with TSIII Implant. . After osseointegration, dental implants will receive definitive prosthesis.
40978736|NCT05843981|DEVICE|Implant placement ks|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with KS Implant. After osseointegration, dental implants will receive definitive prosthesis.
40978737|NCT04160091|DRUG|FX006|Single intra-articular injection
40978738|NCT04160091|DRUG|Normal Saline|Single intra-articular injection
40978739|NCT04823650|DEVICE|COHORT A: Actigraph|The ActiGraph CentrePoint Insight Watch is a small worn activity monitor designed for documenting physical movement associated with applications in physiological monitoring.
41302048|NCT02533648|DRUG|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
41302049|NCT02533648|DRUG|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
41302050|NCT01397669|PROCEDURE|Colon biopsy, lymph node biopsy, lumbar puncture|Eligible subjects will undergo a flexible sigmoidoscopy and biopsy, lumbar puncture, lymph node biopsy at Chulalongkorn University Hospital.
41302051|NCT02379156|DRUG|Midodrine Hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
41302052|NCT02379156|OTHER|Cool Temperature|Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
40774683|NCT05954884|OTHER|Telemedicine-based WHO HEARTS package|"Interventions in this study will include-~1. Community- and team-based model of hypertension care delivery~2. Opportunistic hypertension screening at Community Clinic (CC) by Community Health Care Provider (CHCP)~3. Use of a hypertension treatment protocol with amlodipine and losartan and standardized approach to measuring and monitoring BP, retaining participants in care, and promoting adherence~4. Use of Simple App to document BP readings and medications/dosage and to monitor hypertension care delivery at the CC through utilities including dashboards~5. Establishment of telemedicine service between CC and Upazila Health Complex (UHC)~6. Community-based, multi-month prescription refills from CC~7. Training of clinic and research staff on BP measurement following standard techniques~8. Site monitoring and mentorship to ensure screening and patient enrollment/registration~9. Use of text messages to promote follow-up visits and medication adherence"
40774684|NCT04443114|OTHER|Organ Donation Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Biomedical Aspects of Living Donation Didactic Session 2: Organ Donation and Transplantation in the US- Statistics and Procedures Moderated Debate: Living Organ Donation: Halal or Haram? Facilitated Group Discussions with Peer Educators
41142159|NCT01137682|DRUG|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
41142160|NCT05434559|DRUG|Insulin Degludec|Switch during standard routine care to Insulin Degludec.
41142161|NCT02144285|DRUG|LY3113593|Administered IV
41142162|NCT02144285|DRUG|LY3113593|Administered SC
41142163|NCT02144285|DRUG|Placebo|Administered IV
41142164|NCT02144285|DRUG|Placebo|Administered SC
41142165|NCT02267122|PROCEDURE|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound
41142166|NCT02267122|PROCEDURE|Mupirocin ointment application|After placing the staples, Mupirocin ointment application over the wound was performed
41142167|NCT00048477|DRUG|L-NMMA and Sodium Nitrite|
41142168|NCT01236898|DRUG|NPC-09|NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
41142169|NCT02743039|BEHAVIORAL|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
41142170|NCT00439218|DRUG|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
41142171|NCT05701176|DIAGNOSTIC_TEST|[18F]F-AraG PET scan|\[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
41142172|NCT05963113|BEHAVIORAL|Pharyngeal Swallowing Exercises|12-weeks of proactive pharyngeal swallowing exercises conducted 5 times per week. The exercise program will include the following four exercises: effortful saliva swallows, tongue-hold swallows, effortful pitch glides and posterior lingual resistance. Each exercise set will include 10 repetitions of each exercise (40 reps per set). The number of sets will be gradually increased as tolerance builds.
41142173|NCT05963113|DIETARY_SUPPLEMENT|Protein Supplementation|12-week supply of the commercially-available Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink). Participants will be asked to consume one drink per day for the 12-week intervention period.
41142174|NCT05963113|DEVICE|MRI|Participants will be scanned using a 3T MRI scanner and a 16-channel phased array neck coil.
41142175|NCT06593691|OTHER|conventional treatment|Hot Pack, TENS, therapeutic ultrasound, and exercise
41142176|NCT06593691|OTHER|Conventional treatment + multi-wave locked system laser treatment|Hot Pack, TENS, therapeutic ultrasound, and exercise + multi-wave locked system laser treatment
41142177|NCT05610878|BIOLOGICAL|Cultured ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs and grafted into recipient site with 1,00,000 cells/ml injected fat
41142178|NCT05610878|BIOLOGICAL|Curcumin-preconditioned ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs preconditioned with curcumin and grafted into recipient site with 1,00,000 cells/ml injected fat
41142179|NCT05610878|OTHER|Conventional fat grafting|Patients will undergo conventional fat harvesting and grafting of fat into recipient site
41142180|NCT06037577|DRUG|CM-101|Anti-human CCL24 monoclonal antibody (CM-101)
41142181|NCT06037577|DRUG|Placebo|Placebo Comparator
41142182|NCT03481153|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS is a safe, non-invasive neurostimulation technique that can modulate neural excitability in the brain to positively impact cognition, behaviour and mood, particularly when combined with a behavioural intervention
41142183|NCT04372732|DIAGNOSTIC_TEST|Serum tumor autoantibody detection|All enrolled patients will be tested for ten kinds of tumor autoantibodies using peripheral blood before PD-1 bloackade treatment.
41142184|NCT05590026|DRUG|Pectointercostal and ESP block|Both Pectointercostal at between 4th and 5th costa and ESP block will apply at thoracal 6 level to the patient.
41142185|NCT04311983|BEHAVIORAL|Tobacco Quitline|"Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back)."
41142186|NCT04311983|BEHAVIORAL|Smoke Free Home|The intervention guides participants though a 5-step process: (1) deciding to create a smoke-free home; (2) talking about it with household members; (3) setting a date for the home to become smoke-free; (4) making the home smoke-free; and (5) keeping the home smoke-free. Progress from one step to the next is facilitated over a 6-week period by three mailings sent to participants' homes and one telephone counseling call delivered by a trained smoke free homes coach.
41142187|NCT00651599|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
41142188|NCT00651599|DRUG|Placebo|Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
40774685|NCT04443114|OTHER|End of Life Care Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Critical Theological Concepts about Sickness and Health in Islamic Bioethics Didactic Session 2: Islamic Rulings about Brain Death, and Withdrawing/Withholding Life Support Moderated Panel Discussion: End-of-life Decision Making Facilitated Group Discussions with Peer Educators
41142189|NCT04927507|BEHAVIORAL|Internet plus nursing home rehabilitation|"The observation group was given the Internet plus nursing home rehabilitation mode.~Relying on mobile app and wechat public service platform, patients can get online guidance of rehabilitation training video through app and wechat, and get professional rehabilitation guidance at any time."
40774686|NCT06263803|OTHER|Music listening, classic physical therapy|Participants will listen to the music pieces Pachabel Canon in D major (20 minutes) and Mozart - Sonata for Two Pianos in D, K. 448 (25 minutes), free from external sounds (max 70 dB through headphones).
40774687|NCT06247748|DRUG|Exendin-4 Fc fusion protein (JY09) injection|D22 received a single subcutaneous abdominal injection of 1.2 mg of JY09 injection after completion of PK blood sampling; D29, D36, D43, D50, D57, D64, D71, and D78 subjects returned to the study center to receive a subcutaneous abdominal injection of 2.4 mg of JY09 injection(total of 8 administrations).All doses were to be administered within 3 min.
40774688|NCT06247748|DRUG|Metformin Hydrochloride tablet|D1 to D4 continuous oral administration of 0.5 g metformin hydrochloride tablets twice daily (D4 was administered only in the morning, with a total of 7 administrations) for a washout period of 96 h;0.5 g metformin hydrochloride tablets orally twice a day continuously from D85 to D88 (D88 was given only in the morning, for a total of 7 doses).
40774689|NCT06247748|DRUG|Rosuvastatin calcium tablets|D8 received a single oral administration of 10 mg of Rosuvastatin calcium tablets in the morning, with a washout period of 168 h,and 10 mg Rosuvastatin calcium tablets orally at 72 h ± 0.5 h (D95) after JY09 administration.
41142190|NCT04998266|OTHER|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
41461074|NCT02979041|BEHAVIORAL|Interactive virtual reality training|"The proposed VR intervention program will provide active training to be performed individually 4 times a week for 20 minutes a session.~The intervention program will be supervised by qualified, experienced physiotherapists, and will include individual training and two follow up meetings during the study period. The intervention program will include strengthening and endurance exercises for the cervical and shoulder girdle muscles. Training will include sensorimotor control and functional, quick, accurate, neck motion, using interactive VR training systems. This type of advanced training is very relevant to the pilots function in the cockpit as it includes interactive tasks aimed to increase range, speed, smoothness, accuracy, and control of cervical motion."
40774690|NCT06247748|DRUG|Digoxin tablet|D15 received a single oral administration of 0.25 mg digoxin tablets in the morning, with a washout period of 168 h,oral 0.25 mg digoxin tablets 72 h±0.5 h after JY09 administration (D102)
40774691|NCT04378868|DRUG|Antibiotics, cefuroxime and metronidazole|Patient receives antibiotics while waiting appendectomy
40774692|NCT04378868|DRUG|No antibiotics|No antibiotics are given while waiting surgery.
40774693|NCT04378868|OTHER|urgent schedule|Patients can wait up to 8 hours for surgery.
40774694|NCT04378868|OTHER|less urgent schedule|Patients can wait up to 24 hours for surgery.
40774695|NCT02781363|OTHER|Thoracic ultrasound|
40774696|NCT02781363|OTHER|CXR|
40774697|NCT05541718|BEHAVIORAL|Reiki|Reiki will be provided by a trained Reiki master with the aim of balancing the flow of energy in the patient's body.
40774698|NCT05541718|BEHAVIORAL|Sham Reiki|Sham Reiki will be delivered by an individual trained to simulate the Reiki interventionist's movements, but they will not visualize patient healing
41142191|NCT04998266|OTHER|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
41142192|NCT04371406|DRUG|Hydroxychloroquine and Azithromycin|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
41142193|NCT04371406|DIETARY_SUPPLEMENT|Azinc|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
41142194|NCT05796791|DRUG|Ketamine Hydrochloride|IM ketamine given in weekly session for a total of 3 weeks
41142195|NCT05796791|BEHAVIORAL|Motivational enhancement therapy|Brief motivational based therapy
41142196|NCT04274127|DIAGNOSTIC_TEST|early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC)|completion of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
41142197|NCT00635323|DRUG|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
41142198|NCT03191097|DRUG|Ingavirin|Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.
40774699|NCT05541718|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation intervention will be adapted from a standardized mindfulness induction script validated in prior research. The mindfulness practice will guide patients to focus attention on breath and body sensations while monitoring and accepting discursive thoughts, negative emotions, and pain. The MM interventionist will be a trained mindfulness provider and have experience using MM in medical settings.
40774700|NCT05309629|DRUG|QL1706|Intravenous infusions of QL1706 5mg/kg on Day 1 of every 21-day cycle.
41142199|NCT03191097|DRUG|Placebo oral capsule|Placebo, capsules daily for 5 days.
41142200|NCT00554814|DRUG|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
41302053|NCT06227234|OTHER|Dechoker|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
40978740|NCT04823650|DEVICE|Panoramic Bracelet and GENEActiv|"Panoramic Bracelet:~The Panoramic Digital Health Bracelet is a wearable inertial measurement unit intended for use by researchers and healthcare professionals for high frequency or continuous collection of physical data in home and professional healthcare settings during research studies. It includes a 3 axis accelerometer and gyroscope, as well as magnetometer, pressure, and temperature sensors. The bracelet has no interface or screen for participants to interact with.~GENEActiv:~The GENEActiv device is a wearable inertial measurement unit designed for public health research and clinical trials. The device is a circular unit with attachable wrist-bands, and has no interface or screen for participants to interact with. The GENEActiv device is FDA 510(k) exempt. The device records acceleration data and can collect data remotely for up to 1 month."
40978741|NCT05485298|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
41461075|NCT02979041|OTHER|Standard Care|physiotherapy and medical care as provided currently
41461076|NCT05922709|DRUG|CS12192 capsule|Participants receive CS12192 orally single or multiple doses
41461077|NCT05922709|DRUG|Placebo capsule|Participants receive placebo matching CS12192 orally single or multiple doses
41461078|NCT00653016|DRUG|norelgestromin; ethinyl estradiol|
41461079|NCT01234324|DRUG|Epirubicin, Cisplatin, Capecitabine, Panitumumab|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
41461080|NCT01234324|DRUG|Epirubicin, Cisplatin, Capecitabine|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
41461081|NCT04565496|DRUG|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
41461082|NCT02257437|DIETARY_SUPPLEMENT|LNS snack|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
40978742|NCT03585504|DRUG|Etonogestrel contraceptive implant|Etonogestrel contraceptive implant
40978743|NCT01564797|BEHAVIORAL|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
40978744|NCT00900497|BIOLOGICAL|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
41142201|NCT00554814|DRUG|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
41142202|NCT00554814|DRUG|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
41302054|NCT06227234|OTHER|LifeVac|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
41302055|NCT06227234|OTHER|Abdominal Thrusts|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
41302056|NCT02869867|OTHER|refrigerated cushion|refrigerated cushion
41302057|NCT00239200|DRUG|Lapatinib|
41302058|NCT04802850|OTHER|Mulligan mobilization with movement|
41302059|NCT00303342|BEHAVIORAL|mind body treatment|regulation of attention, respiration and posture
41461083|NCT02257437|DIETARY_SUPPLEMENT|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
41461084|NCT02257437|DIETARY_SUPPLEMENT|Sprinkles|Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
41461085|NCT02257437|DIETARY_SUPPLEMENT|LNS + borbor|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
41461086|NCT02092701|DRUG|Cholecalciferol|
41461087|NCT04202458|DRUG|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.
41461088|NCT06481982|DIAGNOSTIC_TEST|MRI|MRI sequences
41461089|NCT00219986|DRUG|Potent HAART during acute or early HIV-1 infection|
41461090|NCT01696136|DEVICE|Cardiac ablation for Atrial Fibrillation|Cardiac ablation for Atrial Fibrillation
40978745|NCT05153044|OTHER|severe acute respiratory syndrome CoV-2 serology|diagnostic serology of severe acute respiratory syndrome-CoV-2 infection performed during the inclusion visit Regarding follow-up visits, only seropositive patients will be called for sampling, for serological follow-up at 3 months then 6 months.
40978746|NCT03055351|BEHAVIORAL|Stop&Go Intervention|Stop\&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
40978747|NCT03362476|BEHAVIORAL|Computer-based alcohol reduction intervention|Brief computer-based version of motivation enhancement therapy (MET) used in conjunction with clinician-delivered MET and standard clinical care for current substance users. Modules and follow up assignments focus on key concepts in substance use, including cravings, problem solving and decision making skills. The multimedia presentation, based on elementary level computer learning games, requires no previous experience with computers.The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
41142203|NCT03471637|OTHER|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy \[based on Compassion-Focused Therapy for Dummies (Welford, 2016)\]"
41142204|NCT04985903|BEHAVIORAL|Clinician Communication Intervention|The focus of the communication program is to help clinicians increase their use of the 5 A's by improving knowledge, self-efficacy, outcome expectations, and communication skills. Training modules include didactic information with video clips of sample conversations showing specific communication skills, feedback on clinician's usage of the 5A's, and audio clips from their Pre-Intervention recorded conversations.
41142205|NCT04985903|OTHER|5A's lecture|a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
41142206|NCT05130099|OTHER|Interdisciplinary complex intervention|"The interdisciplinary complex intervention lasts 12 weeks and includes the 4 following components;~Patient-education: a 2-hours group-based digital session, including information about fatigue, training theory, psychological strategies and nutrition, all in relation to chronic fatigue (CF).~Physical exercise program: two weekly sessions with aerobic exercise and resistance training. The participants are instructed to do the same program in the unsupervised sessions as in the supervised sessions. After the first 12 weeks exercise period, the participant and the physiotherapist makes an individually tailored plan for exercise and follow-up the next 12 weeks.~Cognitive behavioral program: 6 group-based online sessions lead by two psychologists, based on elements from cognitive behavioral therapy to reduce and/or manage CF. Each session lasts for 135 minutes.~Nutritional counselling: 3 individual sessions by a clinical dietitian. Each session lasts for 30-60 minutes."
41142207|NCT03921775|DRUG|Remimazolam Tosilate|For induction and maintenance of general anesthesia
41142208|NCT03921775|DRUG|Propofol|For induction and maintenance of general anesthesia
41142209|NCT06275256|PROCEDURE|Rezum|The Rezum device is inserted, a needle is deployed, and vapor is injected into the prostate for nine seconds. This vapor disperses between cells, then cools, releases heat, and gently disrupts the prostate's cells. Because of the initial swelling, a catheter is then inserted, which will remain for two to five days.
41142210|NCT06275256|DEVICE|iTind|The iTind device is temporarily placed inside the prostatic urethra (the narrowed portion of the prostate), where it slowly expands and exerts gentle pressure at three precise points. The effect of the iTind is to widen the prostatic urethral opening through which urine can now flow more easily.
41142211|NCT05842330|DRUG|Concerta|"Dosages of Concerta® will be defined according to the Swiss Compendium (from 18 to 72 mg/d).~The psychiatrist will start with the smallest dosage (18 mg) and will adapt it on a weekly basis or on need, depending on tolerance (side effects measured at each visit), clinical response (subjective improvement felt by the patient in terms of attention, impulsivity, and hyperactivity), and according to the observations made by the professionals or patient's entourage in term of attention, impulsivity, hyperactivity, and for this project, behavioral problems. In general, the dose can be increased in 18 mg at weekly intervals.~The treatment will be monitored weekly the first month, and then monthly, except for side effects which will be monitored daily in prison and every two weeks after release."
41142212|NCT05842330|DRUG|Placebo|"The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label).~Procedure for adjustment of dosage will be the same as in the Concerta arm."
41142213|NCT04310020|DRUG|Atezolizumab|Given IV
40774701|NCT05309629|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle for 4-6 cycles.
40978748|NCT03362476|BEHAVIORAL|Brief clinician-delivered MET|Clinician-delivered MET used in conjunction with standard clinical care for current substance users. The brief intervention is focused on goals, cravings, problem-solving and decision-making. The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
40978749|NCT03362476|BEHAVIORAL|Standard of care|Clinicians ask about substance use and provide evidence-based recommendations promoting abstinence.
40978750|NCT02520401|OTHER|Probiotic - BioGaia|Use of a probiotic tablet
40978751|NCT02520401|OTHER|Placebo|Use of a placebo tablet
40978752|NCT00615095|OTHER|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
40978753|NCT00615095|OTHER|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
41142214|NCT04310020|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41461091|NCT01302509|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
41461092|NCT00298987|DRUG|Dasatinib|Tablets, Oral, 70 mg, Twice daily, 2 months.
41461093|NCT05578794|OTHER|Straining types|Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
41461094|NCT00003348|DRUG|O6-benzylguanine|
41461095|NCT00003348|DRUG|carmustine|
41461096|NCT04403945|DEVICE|Sidestream dark field(SDF) imagining|SDF imaging consists of a hand-held device that illuminates a region by surrounding a central light guide with concentrically placed light emitting diodes,which thus provide SDF illumination.
41461097|NCT04702035|DEVICE|Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)|All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.
40978754|NCT00615095|OTHER|health questionnaire, blood draw and skin exam|Numbers will be randomly selected from a pool of prefixes. Numbers will be screened by computer for being working, non-business, non-fax, and non-modem numbers. After establishing eligibility for the study, we will send the potential control a letter further explaining the purpose of the study and its requirements. An interviewer will then call to arrange an appointment. During the interview, the subject will sign informed consent, be given the public health questionnaire, have 30 ml of blood drawn, and undergo the skin examination of arms and back.
40978755|NCT01020851|BEHAVIORAL|tailored intervention|6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
41461098|NCT04505735|DRUG|11C-PiB|Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.
41461099|NCT02473055|OTHER|Kangaroo Care|skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
41461100|NCT00050076|DRUG|MCC-135|MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks
41461101|NCT00050076|DRUG|MCC-135|MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks
40978756|NCT01020851|BEHAVIORAL|attention placebo|6 monthly telephone-delivered sessions focusing on general health topics
40978757|NCT04687878|DRUG|Insulin|20 IU twice a day, intranasally, every day for 12 weeks
40978758|NCT04687878|DRUG|Normal saline|twice a day, intranasally, every day for 12 weeks
40978759|NCT05989126|DRUG|aflibercept 8 mg PFS|Sterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection
40978760|NCT01285310|DRUG|Apremilast 30 mg|30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
41461102|NCT00050076|DRUG|MCC-135|MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks
41142215|NCT04310020|PROCEDURE|Computed Tomography|Undergo CT scan
41142216|NCT04310020|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
41142217|NCT04310020|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41142218|NCT05858359|BEHAVIORAL|ImPACT program|"During the ImPACT program, the brain cancer survivor and a carer collaborate on:~1. Becoming aware of the patient's core strengths and difficulties~2. Helping the patient to be optimally responsive to the guidance of the carer, and~3. Creating compensatory strategies to respond to real-world manifestations of the patient's difficulties and helping the patient implement these strategies at home."
41142219|NCT01267188|DRUG|NBI-98854|powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
41142220|NCT01505309|DEVICE|Stent Graft (Medtronic, Microport, Ankura)|Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
41142221|NCT00003167|BIOLOGICAL|Ad5CMV-p53 gene|Given intravesically
41142222|NCT05967845|PROCEDURE|cartilage tympanoplasty|cartilage tympanoplasty procedure entails repairing the tympanic membrane perforation by using a piece of cartilage harvested from the patient's auricle.
41461103|NCT00050076|DRUG|Placebo|MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
40774702|NCT05309629|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle for 4-6 cycles.
40978761|NCT01285310|DRUG|Apremilast 20 mg|20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
41142223|NCT05967845|PROCEDURE|platelet rich fibrin augmented tympanoplasty|platelet rich fibrin augmented tympanoplasty entails performing the traditional tympanoplasty using the tempralis fascia as a grafting material. However, platelet rich fibrin clot is obtained from the patient's own blood, and applied to the graft to enhance healing process.
41142224|NCT02527694|DEVICE|Flexible EMS stretcher cart|The flexible EMS stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
41142225|NCT02527694|DEVICE|mechanical CPR|
41302060|NCT00303342|BEHAVIORAL|desensitization|mentation on insomnia behaviors and cognitive activity
40774703|NCT03463187|BIOLOGICAL|SHR-1314|Administered subcutaneously
41461104|NCT03617120|DEVICE|Ergonomic Brace vs hard brace|"Visit 1:~1. Usual check-up: standing in-brace radiograph of hard brace and doctor consultation~2. Pressure measurement of participant wearing their hard brace~Visit 2:~1. Brace Questionnaire (BrQ) for hard brace; Trunk Appearance Perception Scale (TAPS)~2. 3D body scanning (before wearing the Ergonomic Brace)~3. Fitting of the Ergonomic Brace~4. Pressure measurement of participant wearing the Ergonomic Brace (instant)~5. Pressure measurement of participant wearing the Ergonomic Brace (after 2 hours)~6. 3D body scanning (after wearing the Ergonomic Brace for 2 hours)~7. Brace Questionnaire (BrQ) for the Ergonomic Brace~Visit 3:~1. Standing in-brace radiograph of the Ergonomic Brace~2. Doctor consultation"
41461105|NCT01550367|DRUG|Hydroxychloroquine|Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.
41461106|NCT01550367|DRUG|IL-2|600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
41461107|NCT00579631|BEHAVIORAL|Questionnaire or Interview|Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
40774704|NCT03463187|DRUG|Placebo|Administered subcutaneously
40774705|NCT06564103|COMBINATION_PRODUCT||
40774706|NCT04840511|DRUG|lidocaine group|lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)
40774707|NCT04840511|DRUG|control group|normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
40774708|NCT04754490|DIAGNOSTIC_TEST|Speech Recognition|Speech Recognition
40774709|NCT04282785|DIAGNOSTIC_TEST|Concentration monitoring of antibiotics in plasma|Plasma antibiotic concentration will be measured using a bedside method with UV-VIS spectroscopy. These measurements will be validated with golden standard that is HPLC-MS.
40774710|NCT05781451|DRUG|LY3361237|All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
40978762|NCT01285310|DRUG|Placebo|Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
40978763|NCT00468572|BEHAVIORAL|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
41142226|NCT01473459|PROCEDURE|IVM (In Vitro Maturation) Treatment|There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
41461108|NCT00924586|DRUG|ONO-1101|Placebo for one minute IV
41142227|NCT01473459|PROCEDURE|IVF (In Vitro Fertilization) Antagonist Protocol|The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
41142228|NCT04328467|DRUG|Hydroxychloroquine|Hydroxychloroquine; 200mg tablet; oral
40774711|NCT02128776|OTHER|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
41142229|NCT04328467|OTHER|Placebo|Placebo; tablet; oral
41142230|NCT02705885|DIETARY_SUPPLEMENT|lozenges containing IgY|Patients consumed food supplement lozenges containing IgY after nonsurgical periodontal therapy
41461109|NCT00924586|DRUG|ONO-1101|0.125 mg/kg for one minute IV
40774712|NCT02128776|OTHER|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
40774713|NCT06526273|BEHAVIORAL|PILI 'Āina|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker. At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks).
41142231|NCT02705885|DIETARY_SUPPLEMENT|Placebo IgY|Placebo IgY
40774714|NCT06526273|OTHER|Control|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker based on previously tested materials and protocols. At 3 months, participants randomized to the control group will receive monthly untailored health education information and links to community resources from the community health worker via United States Postal Service or electronic messaging. Examples include information on food assistance programs, farmers' markets, cultural events, and physical activity events.
40774715|NCT05433142|BIOLOGICAL|XmAb819|Monoclonal Bispecific Antibody
40774716|NCT05790655|OTHER|oPRP|Prepared sample from patient's own blood collected and processed
40774717|NCT00754572|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv, every 4 weeks
40774718|NCT00754572|DRUG|methotrexate|10-25mg oral or parenteral weekly.
40774719|NCT05965219|DRUG|Emraclidine|Emraclidine tablets.
40774720|NCT05965219|DRUG|Itraconazole|Itraconazole oral solution.
40774721|NCT05965219|DRUG|Carbamazepine|Carbamazepine tablets.
40774722|NCT05965219|DRUG|Metformin|Metformin tablets.
40774723|NCT02896946|RADIATION|Diffusion-weighted nuclear magnetic resonance imaging|All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
40774724|NCT04631692|BEHAVIORAL|Health literacy intervention|"We will translate and adapt an intervention developed by Ferreira et al. to address health literacy and improve CRC screening. This intervention combined a 2-hour health literacy training targeting primary care physicians (which also included information about CRC screening) and a patient level intervention that consisted of a brochure and video.~In order to promote generalizability, large-scale diffusion, dissemination and sustained use beyond the funded-research period, we will use blended learning to develop a 2-hour e-learning health literacy training in French and a one-hour booster session.~The patient-facing intervention (video + brochure) will follow key plain language and health literacy principles to translate evidence-based information in content that all patients can understand. Existing materials developed in France will be used and adapted as relevant."
40774725|NCT01895192|OTHER|Assessment of sperm morphology (contrast microscopy).|Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
40774726|NCT00916487|DIETARY_SUPPLEMENT|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
40774727|NCT01194596|BEHAVIORAL|Smoking cessation advice|Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine), will be given in both arms.
40774728|NCT01194596|BEHAVIORAL|Spirometry and smoking cessation advice|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
40774729|NCT03049644|PROCEDURE|Mechanical Diagnosis and Therapy|Identification of directional preference.
40774730|NCT03049644|PROCEDURE|Manual Therapy|Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
40774731|NCT04667689|BEHAVIORAL|CAMPFIRE Online Cognitive Assessment for Cancer Patients|Subjects will complete PROMIS Cognitive Function/Anxiety/Depression survey assessments and a short neuropsychological battery (NIH Toolbox) on an iPad while in clinic prior to beginning chemotherapy, again before a clinic visit scheduled between 6 - 9 weeks and, lastly, before a post-chemotherapy follow-up clinic visit. Within two weeks of their post-chemotherapy assessment, subjects will be asked to complete a feedback survey. The physician providers and/or their clinical team (e.g., nurse practitioners, registered nurses) will be asked to review subjects' cognitive assessment results and discuss referrals and/or recommendations, if appropriate.
40774732|NCT04345614|DRUG|Auxora|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
40978764|NCT00468572|BEHAVIORAL|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
40978765|NCT00229060|DRUG|doripenem|
40978766|NCT00371423|DEVICE|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
40978767|NCT00371423|DEVICE|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
40978768|NCT05947812|DRUG|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
40978769|NCT05947812|DRUG|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
40978770|NCT06458608|DEVICE|virtual reality glasses|virtual reality glasses
40978771|NCT05534997|OTHER|intensive combined rehabilitation therapy|graded exercise therapy and cognitive behavioral therapy
40774733|NCT04345614|DRUG|Placebo|Placebo will be given at 1.25 mL/kg on Day 1 and then 1.0 mL/kg on Days 2 and 3. All doses of placebo will be administered intravenously over 4 hours.
40774734|NCT05170802|OTHER|NanoKnife procedure|clinical data regarding use of the NanoKnife system intraoperatively (via laparotomy) to ablate the pancreatic tumors per the treating physicians discretion will be collected.
40978772|NCT06061653|COMBINATION_PRODUCT|IPT plus HD-tDCS|psychotherapy plus device
40978773|NCT06061653|COMBINATION_PRODUCT|IPT plus sham HD-tDCS|psychotherapy plus sham device
40978774|NCT01348945|OTHER|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
40774735|NCT01596426|DRUG|Sancuso|granisetron transdermal system
40774736|NCT01596426|DRUG|IV granisetron|IV granisetron
40774737|NCT02257320|DEVICE|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
40774738|NCT04638309|DRUG|APR-548 + Azacitidine|APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
40774739|NCT04013178|BEHAVIORAL|Accentuated eccentric loading + electromyostimulation|An innovative training intervention to optimize muscle strength and muscle mass
40774740|NCT04013178|BEHAVIORAL|Conventional resistance training|A conventional approach to resistance training
40774741|NCT06063655|DIETARY_SUPPLEMENT|Control: Water|Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
40774742|NCT06063655|DIETARY_SUPPLEMENT|Liquid IV hydration multiplier|Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
40774743|NCT06063655|DIETARY_SUPPLEMENT|Liquid IV sugar-free hydration multiplier|Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
40774744|NCT01520181|DRUG|Beta-lactam oral challenge|Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days
40774745|NCT00200239|BEHAVIORAL|Eating breakfast with portion and unportioned foods|Behavioral: eating breakfast with portion and unportioned foods
40774746|NCT06044792|OTHER|differences in CD4 reconstruction|Differences in the increase in CD4 lymphocyte count and CD4:CD8 ratio between patients with primary drug resistance mutations and those without these mutations.
40774747|NCT04406454|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 3 quality OCT images of B-scan (cross-section) and E-scan (en face) with 4 depths for each skin site respectively for each skin site. There is a total of 6 skin sites.
40774748|NCT04856878|DRUG|Vancomycin|The investigational drug vancomycin is administered intravenously through a newly inserted peripheral or central venous catheter directly after removal of the 'old' catheters. The investigational drug is administered with a volume of 500ml normal saline (NaCl 0.9%) with a rate of maximal 1g per hour.
40774749|NCT05755750|DRUG|Genipin|Intratendinous genipin injection
40774750|NCT01542788|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
40774751|NCT01542788|DRUG|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
40774752|NCT01542788|DRUG|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
40774753|NCT01542788|DRUG|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
40774754|NCT00048984|OTHER|laboratory biomarker analysis|Correlative studies
40774755|NCT06537388|PROCEDURE|Ventilation type|Type of ventilation used during the EBUS procedure, either HFJV or IPPV
40774756|NCT06459440|BEHAVIORAL|Group Task oriented Training|Group Task-Oriented Training for individuals with Down syndrome is an approach that focuses on improving specific skills and promoting social interaction through collaborative activities. This training method involves organizing individuals with Down syndrome into small groups to work on tasks that target various developmental areas, such as motor skills, communication, and socialization. The tasks are designed to be meaningful, engaging, and relevant to the participants' daily lives.
40774757|NCT06459440|OTHER|Routine Treatment|"1.Week 1-2 : Foundation building (4 sessions per week) Gentle stretching exercises (20 minutes). Basic strengthening exercises (20 minutes) (26). Weeks 3-4: Balance and coordination (4 sessions per week ) Balance exercises and core stability (20 minutes). Coordination drills (20 minutes) (26). Weeks 5-6: Functional activities (4 sessions per week )~Incorporate functional activities into therapy (e.g., walking, reaching) (20 minutes)"
40774758|NCT00375713|DRUG|Levocetirizine|1 Levocetirizine 5mg tablet per day before bedtime for 14 days
40774759|NCT00375713|DRUG|Cetirizine|1 Cetirizine 10mg tablet per day before bedtime for 14 days.
40774760|NCT00375713|DRUG|Placebo-Levocetirizine|1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
40978775|NCT02381249|DRUG|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
40978776|NCT02381249|DRUG|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
40978777|NCT04226378|DEVICE|Omnipod|Switch from MDI therapy to an Omnipod as part of usual clinical practice. An Omnipod is a patch pump that consists of a handheld controller and a disposable pod that delivers insulin.
40978778|NCT04226378|OTHER|MDI|Continued use of MDI therapy (traditional basal/bolus insulin regimen).
40978779|NCT02301884|BIOLOGICAL|Allergen extract|Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
40978780|NCT05279898|DEVICE|EEG Monitoring|Perioperative monitoring, MMGA guided by EEG for intervention group
40774761|NCT00375713|DRUG|Placebo-Cetirizine|1 Placebo-Cetirizine tablet per day before bedtime for 14 days
40774762|NCT00375713|DRUG|Standard topical steroid (1% hydrocortisone) ointment|1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
40774763|NCT03230188|OTHER|functional Magnetic Resonance Imaging (research grade)|Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.
40774764|NCT03230188|OTHER|Cognitive Function Testing (non-diagnostic)|Subjects will take non-diagnostic cognitive function tests
40774765|NCT03230188|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
40774766|NCT06409260|OTHER|Acceleromyography (AMG)|Philips IntelliVue NMT Module
40774767|NCT06409260|OTHER|Electromyography (EMG)|Senzime TetraGraph
40774768|NCT06456658|OTHER|Interruptive Reminder|"The reminder will display at the time the chart is opened for eligible patient visits and alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
40774769|NCT06456658|OTHER|Non-interruptive Reminder|"The reminder will have the same format as the interruptive reminder group, but it will not be displayed unless providers seek out the education at their own initiative. The reminder will alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
40774770|NCT06456658|OTHER|No Reminder|No reminder recommending a statin will be displayed/available to the provider.
40774771|NCT05168293|OTHER|Detection of HBV-DNA in Peripheral Blood Mononuclear cells|Detection of HBV-DNA level in Peripheral Blood mononuclear cells
40774772|NCT04992273|DRUG|casirivimab+imdevimab|Single dose administered based on weight
40774773|NCT02196922|DEVICE|Telehealth Self Management (TSM)|Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
40774774|NCT02196922|OTHER|Standard of Care|Patients receiving standard of care experience typical chronic care management received by Medicare patients.
40774775|NCT04892589|OTHER|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
40774776|NCT05872412|DRUG|Doxorubicin|60 mg/m2 IV bolus on day 1 every three weeks for four cycles.
40774777|NCT05872412|DRUG|Cyclophosphamide|600 mg/m2 IV over 1 hour on day 1 every three weeks for four cycles.
40774778|NCT05872412|DRUG|Paclitaxel|80 mg/m2 IV over 1 hour weekly for 12 weeks
40774779|NCT05872412|DRUG|Carboplatin|Area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles
40774780|NCT04125602|OTHER|High fat low carbohydrate diet|Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.
40774781|NCT04125602|OTHER|Low fat high carbohydrate diet|Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
40774782|NCT05775939|OTHER|Fludeoxyglucose F-18|Given FDG
40978781|NCT05279898|DRUG|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.2% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision (total of 40mL) PIFB on postoperative day 1 (provided they are extubated or getting ready to be extubated) to help with mobilization (for intervention group)
40978782|NCT05279898|DRUG|Ketamine|Intraoperative infusion
40978783|NCT05279898|DRUG|Remifentanil|Intraoperative infusion
40774783|NCT05775939|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
40774784|NCT05775939|PROCEDURE|Computed Tomography|Undergo PET-CT
40978784|NCT05279898|DRUG|Dexmedetomidine|Intraoperative infusion
40978785|NCT05279898|DRUG|Rocuronium|Intraoperative intermittent bolus
40978786|NCT05279898|DRUG|Propofol|Intraoperative infusion
40978787|NCT01717404|DRUG|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
40774785|NCT05775939|OTHER|Questionnaire Administration|Ancillary studies
40774786|NCT04509388|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
40774787|NCT03257384|OTHER|Black box recording of surgery|Time delays will be recorded from the moment the patient is draped and enters the operating room to the moment they exit the operating room.
40774788|NCT00693758|DRUG|adenosine|intravenous infusion of adenosine (140microgr./min/kg)
40774789|NCT00693758|OTHER|modified end-tidal forcing system|changes in partial pressures of O2 and CO2 in inspired air
40774790|NCT00693758|OTHER|arm cuff occlusion|3 min. lasting upper arm cuff occlusion
40774791|NCT00693758|DEVICE|Breathing gas|Changes in pO2 and pCO2 in inspired air mix
40774792|NCT00693758|DEVICE|Blood pressure cuff|supra-systolic arm occlusion with pressure cuff
40774793|NCT02065284|OTHER|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
41302061|NCT03657680|OTHER|Evaluation|The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
41302062|NCT00713401|DRUG|Tecadenoson|Tecadenoson administered intravenously (i.v.)
41302063|NCT00713401|DRUG|Esmolol|Esmolol low dose infusion according to manufacturer's instructions
41302064|NCT03896399|PROCEDURE|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
40978788|NCT02511366|OTHER|Ileal infusion of casein|Intraileal infusion of casein
41302065|NCT03575520|DRUG|Pegfilgrastim|A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
41302066|NCT03575520|DRUG|Doxorubicin/Cyclophosphamide(AC) treatment|"doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks."
40978789|NCT02511366|OTHER|Ileal infusion of tap water|Intraileal infusion of tap water
41302067|NCT05012319|DRUG|to be given as a treatment|"Nitric Oxide Nasal Spray Enovid"
40774794|NCT03770611|DIETARY_SUPPLEMENT|Probiotic|The probiotic supplement is composed of the following bacterial strains: Bacillus coagulans, Bacillus subtilis, Bifidobacterium (B) bifidum, B. breve, B. longum, Lactobacillus (L) acidophilus, L. brevis, L. casei, L. helveticus, L. Paracasei, L plantarum, L. rhamnosus, L. salivarus, Lactococcus lactis, Pediococcus acidilactici, Pediococcus parvulus, Weisella confusa, Weisella paramesenteroides
40774795|NCT03770611|DIETARY_SUPPLEMENT|Prebiotic|The prebiotic fiber is Agave inulin
40978790|NCT04307693|DRUG|Lopinavir/ritonavir|Lopinavir / Ritonavir tablet
40978791|NCT04307693|DRUG|Hydroxychloroquine sulfate|Hydroxychloroquine sulfate tablet
41142232|NCT06134557|PROCEDURE|conventional stents|performed the study to compare the safety and efficacy between flow diverters and conventional stents in IVADA patients undergoing endovascular therapy. Stent-assisted coiling is the preferred option for most surgeons. In addition,It is believed that dense packing is not necessary as long as the aneurysm neck is covered to isolate the dissection. How ever,whether it is really necessary to adjunct coil,and if it is necesary, what is the ideal packing density of coils, there is no clear conclusion at present.This study aimed to compare the safety and efficacy between flow diverter and conventional stents in patients with IVADA, determine the ideal packing density of coils after FD stent placement,and to observe the hemodynamic changes before and after the treatment of FD stent.
41142233|NCT00545909|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
41142234|NCT00545909|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
41142235|NCT01566383|PROCEDURE|24-hr pH monitoring|"Visit 1~The following will be done:~* A medical history including review of your current drugs;~* Collection of demographic information;~* A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;~* 24-hour pH testing will be done~Visit 2~You will return to the clinic 24 hours after the visit 1 and the following will occur:~* The catheter will be removed from your nose; and~* You will return the recording device"
41142236|NCT05904210|DRUG|SEVENFACT®|Coagulation Factor VIIa (Recombinant)
41142237|NCT05297097|DIETARY_SUPPLEMENT|Trulacta breastmilk supplement|one supplement daily
41142238|NCT04838509|OTHER|no intervention|retrospective descriptive without intervention
41302068|NCT00118482|DRUG|fludrocortisone acetate|Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
41302069|NCT05784948|OTHER|Virtual Reality Mindfulness Treatment|once a week for 30 minutes, over 8 weeks
41302070|NCT05784948|OTHER|Experience relaxing scenery and music|once a week for 30 minutes, over 8 weeks
41302071|NCT01588145|DRUG|HM61713|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
41302072|NCT00619411|BEHAVIORAL|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
41302073|NCT03356158|BIOLOGICAL|CPGJ602|Injection, q.w., 20 mg: 100 ml
41302074|NCT03356158|BIOLOGICAL|Cetuximab|Injection, q.w., 20 mg: 100 ml
40774796|NCT03770611|DIETARY_SUPPLEMENT|Symbiotic|The supplement is a combination of the probiotic product + the prebiotic fiber
40978792|NCT04425733|DRUG|MK-5475|MK-5475 administered at a dose of 180 µg or ≤360 µg QD via inhalation
40978793|NCT04425733|DRUG|Placebo|MK-5475-matching placebo administered QD via inhalation
40978794|NCT06128395|OTHER|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
40978795|NCT01832376|PROCEDURE|Ultrasound guided needle lavage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
40978796|NCT03991715|BEHAVIORAL|Activity Tracker|Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
40978797|NCT01548482|OTHER|Laboratory Biomarker Analysis|Correlative studies
41302075|NCT01762293|DRUG|Famitinib|Famitinib 25 mg p.o. qd
41302076|NCT01762293|OTHER|placebo|p.o. qd
41302077|NCT05269134|DRUG|Bacteriophage|Phage Therapy
41302078|NCT05269134|DRUG|Placebo|Placebo
41302079|NCT01849250|DRUG|Docosahexaenoic Acid|Given PO
41302080|NCT01849250|OTHER|Placebo|Given PO
41302081|NCT01951014|OTHER|Social Media Education|Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
41302082|NCT01247220|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
41302083|NCT01247220|PROCEDURE|Peripheral Laser|Angiography-directed peripheral laser
41302084|NCT01249183|BIOLOGICAL|Concomitant administration|1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)
41302085|NCT01249183|BIOLOGICAL|Separate administration|1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later
41302086|NCT04066816|OTHER|Walnuts|Participants will consume 2 ounces of walnuts for 21 days
40774797|NCT03770611|DIETARY_SUPPLEMENT|Placebo|The supplement is a combination of probiotic placebo and prebiotic fiber placebo. Placebo will consist on maltodextrin for both cases.
40774798|NCT06132464|BEHAVIORAL|Expanding Communication and Language Generated in Conversation Treatment|ECoLoGiC Treatment is a behavioral therapy developed to improve language abilities in everyday conversation for people with aphasia. It is delivered through therapeutic use of spontaneous conversational interactions between a speech-language pathologist and a person with aphasia. ECoLoGiC Treatment is based on theories of conversational interaction in adults without communication disorders, as well as on theories of neuroplasticity, rehabilitation, and learning. The therapy consists of two components: a) Therapeutic Conversation, during which the pair discuss any topic of interest to the person with aphasia, while the speech-language pathologist uses techniques to promote social interaction; and b) Therapeutic Repair, used when communication breakdown occurs. At this time, the speech-language pathologist implements the intervention's 7-step least-to-most hierarchy, supporting the person's independence and learning in communicative problem-solving to communicate the desired idea.
40774799|NCT06172140|DRUG|Ciprofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of ciprofol, followed by intravenous injection of ciprofol (0.4mg/kg). When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
41302087|NCT05896982|OTHER|Care as usual with information support|Comprises of additional visual information in the form of two videos that show details about the procedure on both days of the MPI diagnostic procedure. Each of these two videos are approximately 5 minutes long and are made available to the patients before the first day (video 1), and in between the first and second day (video 2).
41302088|NCT05896982|OTHER|Care as usual with supportive coaching|Patients receive coaching from one person who is present throughout the complete diagnostic process. The coach is available for answering questions as well as comforting the patients when necessary (e.g., to reassure patients if they are anxious or stressed).
41302089|NCT05896982|OTHER|Care as usual with information support and supportive coaching|This intervention comprises additional visual information in the form of two videos and coaching throughout the diagnostic process as described above.
41302090|NCT01233401|OTHER|Survey|Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
41302091|NCT05368285|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
41302092|NCT05368285|DRUG|Matching Placebo|Subcutaneous Administration
40978798|NCT01548482|OTHER|Pharmacological Study|Correlative studies
40978799|NCT01548482|DRUG|Temsirolimus|Given IV
40978800|NCT01548482|BIOLOGICAL|Trebananib|Given IV
41142239|NCT02354417|BIOLOGICAL|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
41142240|NCT02939742|DRUG|Betamethasone|Betamethasone 12mg IM given every 24 hours for two doses
41142241|NCT02939742|DRUG|Placebo|Sterile 0.9% normal saline solution given IM every 24 hours for two doses
41302093|NCT01044381|DRUG|Luliconazole Solution, 10%|28 days of daily application
41302094|NCT06334029|DIAGNOSTIC_TEST|Functional and structural Connectome|Reconstruction of EEG derived functional relationship between brain regions (functional connectome). Reconstruction of thickness covariance across brain regions (structural connectome)
41302095|NCT04723524|COMBINATION_PRODUCT|Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
41302096|NCT04723524|OTHER|Placebo Comparator|Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
41302097|NCT03680794|OTHER|sampling of ophthalmic liquid|aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery
41302098|NCT04579055|OTHER|1-min STS test: adjusted|Individually adjusted chair seat height of 90° knee joint flexion
41302099|NCT04579055|OTHER|1-min STS test: standardized|Standardized chair seat height of 46 cm
41302100|NCT04290962|BEHAVIORAL|Lifestyle Therapy|Complete web-based lifestyle intervention
41302101|NCT04290962|OTHER|Quality-of-Life Assessment|Ancillary studies
41302102|NCT04290962|OTHER|Questionnaire Administration|Ancillary studies
40774800|NCT06172140|DRUG|Propofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of propofol, followed by intravenous injection of propofol (2 mg/kg) for 30 seconds. When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
40774801|NCT02482311|DRUG|AZD 1775|"AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food."
40774802|NCT05010473|BEHAVIORAL|Speech and non-speech sound stimulation|Listening to repetitive and extended sound presentation induces specific neural and physiological activity that we will measure via electroencephalography and pupillometry
40774803|NCT01220687|DRUG|iNO|Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
40774804|NCT01220687|OTHER|Nitrogen|Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
40774805|NCT04853121|PROCEDURE|Tapered Implants|Tapered Implants are placed in fresh socket via dynamic navigation
40774806|NCT04853121|PROCEDURE|Straight Implants|Straight Implants are placed in fresh socket via dynamic navigation
40774807|NCT05175729|DIAGNOSTIC_TEST|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
40774808|NCT01734525|DRUG|Anidulafungin|Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards
40978801|NCT06064604|OTHER|Control|The stroke survivors will serve as their own control group. The participants will complete the required tasks without an exoskeleton device.
40774809|NCT04724837|DRUG|Zibotentan|Participants will receive zibotentan as per the arms they are randomized.
40774810|NCT04724837|DRUG|Dapagliflozin|Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
40774811|NCT04724837|DRUG|Placebo|Participants will receive placebo as per the arms they are randomized to.
40774812|NCT00616720|BIOLOGICAL|aldesleukin|
40774813|NCT00616720|BIOLOGICAL|idiotype-pulsed autologous dendritic cell vaccine APC8020|
40978802|NCT06064604|DEVICE|Hip Exoskeleton|The Georgia Tech Hip Exo is a wearable robotic device for hip extension/flexion assistance. This device will be used to study the lower limb movement and how to effectively assist users. It makes use of a responsive controller that considers information such as joint angles to understand the user's state and assists with the appropriate level of power accordingly.
41142242|NCT02173756|DRUG|morphine gel|1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
41142243|NCT02173756|DRUG|placebo gel|Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
40774814|NCT00616720|BIOLOGICAL|recombinant interferon gamma|
40774815|NCT00616720|GENETIC|polymerase chain reaction|
40774816|NCT00616720|GENETIC|reverse transcriptase-polymerase chain reaction|
40774817|NCT00616720|OTHER|flow cytometry|
40774818|NCT00616720|OTHER|laboratory biomarker analysis|
40774819|NCT00091975|DRUG|Zemplar Capsule|
40774820|NCT00952692|BIOLOGICAL|dHER2 + AS15 ASCI|"Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.~For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:~* One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.~* One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml."
40774821|NCT00952692|DRUG|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
40774822|NCT04331522|DIAGNOSTIC_TEST|Oral provocation test|Titrated provocation with allergen
41142244|NCT03230084|DEVICE|Urine PDG test|Urine dipstick test that detects the presence of the urinary metabolite of progesterone, PDG.
41142245|NCT01781923|BEHAVIORAL|Cognitive remediation program|Subject plays for 30 minutes, 4 times per week, for 12 weeks.
40774823|NCT01807884|PROCEDURE|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
40978803|NCT06064604|DEVICE|Ankle Exoskeleton|The Dephy Exoboot is a lower limb exoskeleton which attaches to the user below the knee through a cuff at the proximal calf and a provided shoe. This investigational device is used to make it easier for able-bodied and impaired individuals to walk and run under a variety of conditions. The exoskeleton provides assistance at the ankle joint during movement. The purpose is to assist the user in lower limb movements such as ground level walking, climbing stairs/ramps, and sit-to-stand.
40978804|NCT01598051|DRUG|Rivaroxaban (Xarelto_ BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
40978805|NCT04698902|DEVICE|Intracoronary lithotripsy|Intracoronary lithotripsy involves the use of sonic pressure waves generated from emitters enclosed within a balloon delivery system. The generated sonic waves act to fracture calcium within the coronary artery wall.
40978806|NCT03569553|DRUG|AIGIV|Anthrax Immune Globulin Intravenous (Human)
40978807|NCT00861432|OTHER|additive homeopathic treatment|These patients receive additive homeopathic treatment
40978808|NCT01228331|DRUG|Amsacrine|one block amsacrine together with etoposide and methylprednisolone for very high risk patients
40978809|NCT01228331|DRUG|Clofarabine|one block clofarabine with Asparaginase for MRD positive patients after induction
40978810|NCT01228331|DRUG|Cyclophosphamide|together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
40978811|NCT01228331|DRUG|Cytarabine|part of different chemotherapy blocks in consolidation and reinduction
40978812|NCT01228331|DRUG|Daunorubicin hydrochloride|part of induction and reinduction therapy
40978813|NCT01228331|DRUG|Dexamethasone|part of reinduction therapy
40978814|NCT01228331|DRUG|Doxorubicin hydrochloride|part of reinduction therapy
40978815|NCT01228331|DRUG|Etoposide phosphate|part of different chemotherapy blocks
40978816|NCT01228331|DRUG|Mercaptopurine|part of different chemotherapy blocks
40978817|NCT01228331|DRUG|Methotrexate|part of different chemotherapy blocks
40978818|NCT01228331|DRUG|Methylprednisolone|part of different chemotherapy blocks
40978819|NCT01228331|DRUG|Pegaspargase|part of different chemotherapy blocks
40978820|NCT01228331|DRUG|Thioguanine|part of different chemotherapy blocks
40978821|NCT01228331|DRUG|Vincristine sulfate|part of intravenous chemotherapy
40978822|NCT01228331|RADIATION|Whole-brain radiation therapy|patients with initial cns involvement receive cranial irradiation
40978823|NCT00002531|DRUG|asparaginase|
40978824|NCT00002531|DRUG|cyclophosphamide|
40978825|NCT00002531|DRUG|cytarabine|
40978826|NCT00002531|DRUG|daunorubicin hydrochloride|
40978827|NCT00002531|DRUG|dexamethasone|
40978828|NCT00002531|DRUG|doxorubicin hydrochloride|
40978829|NCT00002531|DRUG|etoposide|
40978830|NCT00002531|DRUG|ifosfamide|
40978831|NCT00002531|DRUG|leucovorin calcium|
40978832|NCT00002531|DRUG|mercaptopurine|
41142246|NCT01781923|BEHAVIORAL|Small group social skills training|Meet once per week for duration of 40 weeks.
40978833|NCT00002531|DRUG|methotrexate|
40978834|NCT00002531|DRUG|mitoxantrone hydrochloride|
40978835|NCT00002531|DRUG|prednisolone|
40774824|NCT01807884|OTHER|Routine oral care|Oral suction followed by mouth care and tracheal suction without any subglottic suction
40774825|NCT03958331|BEHAVIORAL|Automated Digital Reminders|Reminders from electronic monitors via texts or alarms/lights
40774826|NCT03958331|BEHAVIORAL|Individualized Adherence Feedback Report|Feedback report on individual adherence behaviors
40978836|NCT00002531|DRUG|teniposide|
40978837|NCT00002531|DRUG|thioguanine|
40978838|NCT00002531|DRUG|vincristine sulfate|
40978839|NCT00002531|DRUG|vindesine|
40978840|NCT00002531|PROCEDURE|allogeneic bone marrow transplantation|
40978841|NCT00002531|PROCEDURE|peripheral blood stem cell transplantation|
40978842|NCT00002531|RADIATION|radiation therapy|
40978843|NCT03951740|DEVICE|Fitbit Charge 2|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
40978844|NCT03951740|DEVICE|Mio Slice|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
40978845|NCT03951740|DEVICE|Oxycon Mobile|"The Oxycon Mobile will be used as the reference method/golden standard to calculate energy expenditure (kcal). This device (consisting of a face mask and gas analyzer unit) will be worn during the entire laboratory activity protocol.~Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF)."
40978846|NCT01991028|DRUG|Radiolabelled OligoG CF-5/20 DPI|Inhalation with dry powder by Mia Monodose Inhaler
40978847|NCT01991028|DRUG|Radiolabelled OligoG CF-5/20 6% Solution|Inhalation with aerosolised solution by nebuliser
40978848|NCT04054388|BEHAVIORAL|LINE re-education|
40978849|NCT04776499|DRUG|Propylthiouracil, Riociguat, Perphenazine|"Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg"
40978850|NCT06401616|DRUG|OAC will be discontinued for the duration of the trial|Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
40978851|NCT04648345|PROCEDURE|Erector spinal plane block|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
40978852|NCT02895906|DRUG|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
40978853|NCT05316753|PROCEDURE|Cardioversion with a pulsed biphasic waveform|Cardioversion with a pulsed biphasic waveform
41302103|NCT03593967|BEHAVIORAL|ARTISAN|"In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~* Week 1: Food and Play as our National Heritage~* Week 2: Our Voices, Our Singapore: Strengthening Bonds~* Week 3: Overcoming Adversities: Stories of Resilience~* Week 4: Beholding the Future: Dreams and Aspirations~* Week 5: Passing It On: The Stories We Share"
41302104|NCT05050630|DRUG|TR2-ICE|Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
41302105|NCT01977209|DRUG|Gossypol|
41302106|NCT01977209|DRUG|Placebo|
40774827|NCT03958331|BEHAVIORAL|Individual Adherence Feedback Report with Social Norms|Feedback report on individual adherence behaviors compared to other adolescents with epilepsy
40978854|NCT05316753|PROCEDURE|Cardioversion with a biphasic truncated exponential waveform|Cardioversion with a biphasic truncated exponential waveform
40978855|NCT02902640|DRUG|Guaifenesin|Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
40978856|NCT02902640|DRUG|Sulfamethoxazole|Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
40978857|NCT02902640|DRUG|Trimethoprim|Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
40978858|NCT02968251|BEHAVIORAL|Hand Washing Program (HWP)|HWP consists of integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
40978859|NCT02581449|DIETARY_SUPPLEMENT|omega-3|dietary supplement
41142247|NCT04213768|PROCEDURE|Lateral rectus plication|The technique is the same as resection up to the muscle suturing, in the next step, the sutures is passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle is folded anteriorly by Stevens muscle hook during tightening and fixing the sutures. At the end, conjunctiva is repaired by Vicryl 8-0.
41142248|NCT04213768|PROCEDURE|Lateral rectus Resection|Following conjunctiva and tendon capsule incision, lateral rectus is hooked and dissected from its surrounding tissues. Then, the muscle is sutured according to the amount of supposed resection from lateral rectus insertion by Vicryl 6-0 (polyglation 910, coated Vicryl®, Ethicon, Blue Ash, OH). Afterwards, the muscle is cut at 1mm anterior to these sutures and the residual muscle is re-sutured to the sclera at its primary insertion. Finally the conjunctiva is repaired using Vicryl 8-0.
41142249|NCT05054751|DRUG|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, BID, which should be taken with a meal. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
41146950|NCT04972318|PROCEDURE|Positive end-expiratory pressure titration with driving pressure control|Positive end-expiratory pressure will be tailored during a decremental maneuver (without a formal alveolar recruitment maneuver). The best positive end-expiratory pressure will be defined as the one associated with the higher respiratory system compliance, up to 20 cmH2O. Plateau pressure limit will be 30 cmH2O. If driving pressure remains elevated after optimal PEEP setting, tidal volume will be reduced to keep driving pressure below 14 cmH2O.
41302107|NCT01270581|OTHER|High Flow Nasal Cannula|Humidified high flow nasal cannula (HFNC) has emerged as an alternative respiratory modality for late preterm newborns with respiratory distress. Like NCPAP, oxygen is delivered to the infant via nasal prongs and provides a continuous distending pressure. Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7.
40774828|NCT01765387|BEHAVIORAL|Spa session|
40774829|NCT03171948|BEHAVIORAL|Almond Group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
40774830|NCT03171948|BEHAVIORAL|Nut Free group|continue their diet without any nut consumption.
40774831|NCT04600284|DRUG|AD-2101|AD-2101 16/5mg
40774832|NCT04600284|DRUG|AD-2102|AD-2102 25mg
40774833|NCT04600284|DRUG|AD-2101 + AD-2102|AD-2101 16/5mg + AD-2102 25mg
40774834|NCT04781179|BEHAVIORAL|CM-II|It is an intervention of 4 two-hour sessions with a psychologist, MC-II technique
40774835|NCT04781179|BEHAVIORAL|Psychoeducation|It is an intervention of 4 two-hour sessions with a psychologist, psychoeducation
40978860|NCT02581449|OTHER|empty soft gelatin capsules|empty softgels of matched size, shape and color
40774836|NCT03735355|PROCEDURE|Surgery|Surgical resection of fibrostenotic area
40774837|NCT03735355|PROCEDURE|TTS balloon dilation|Dilation of a stricture using TTS balloon
40774838|NCT03032484|DRUG|Bevacizumab|Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
40774839|NCT03032484|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
40978861|NCT03922425|OTHER|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
40978862|NCT04432662|DRUG|Darbepoetin Alfa|Administration of Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.
40978863|NCT02818322|DEVICE|telemedical monitoring ( T)|
40978864|NCT02818322|DEVICE|classic monitoring|
40978865|NCT04472624|OTHER|Fasting|Acute fasting for 72 hours
41302108|NCT01270581|OTHER|Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
41461110|NCT04666597|PROCEDURE|Modified CariesCare International management|"Interventions of this single-group study correspond to the 4D, to be implemented by the external DP, when possible with remote care and only with non-AGP:~1. D-DETERMINE risk assessing the protective and risk factors (social/medical/behavioural and clinical), using remote tools. Additionally, the description of tooth brushing behaviours and consumption of free sugars is included.~2. D-DETECT \& ASSESS: Caries staging and activity: ICDAS-merged visual criteria Caries OUT (without using compressed air, and avoiding radiographs). Clinical risk factors are assessed as well.~3. D-DECIDE a personalized care plan: individually designed for caries management home and clinical approaches.~4. D-DO: Appropriate Tooth-preserving \& Patient-level caries: Management plan at the Patient and at the Lesion level and the implementation of the Change Behaviour Tool (CBT) designed for this protocol.~The follow-up data will include a T1, T2 and T3 assessment."
40978866|NCT04472624|OTHER|Ketogenic diet|Intake of a ketogenic diet for 14 days
40978867|NCT06293170|OTHER|DETECT|DETECT periodically processes real-time data from the corresponding electronic medical record system to screen for a combination of coma, indicated by a Richmond Agitation Sedation Scale (RASS) score of - 4 or - 5 or Glasgow Coma Scale (GCS) score of 6-3, along with manually assessed absence of bilateral pupillary light reflexes. Both findings are considered early indicators of impending ILBF. In case of positive screening results, an automated notification will be sent via the hospital's email server to the corresponding transplant coordinators and intensivists. The email sent aims to prompt clinical assessment of the reported patient and, if necessary, initiate a guideline-based ILBF examination.
40774840|NCT01817387|BEHAVIORAL|PRIME|Mobile application designed to improve psychosocial functioning and motivational deficits
40774841|NCT01817387|BEHAVIORAL|Cognitive Training|Auditory processing, verbal learning, memory, processing speed, and social cognition
40774842|NCT03386773|BEHAVIORAL|16-week program|16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
40774843|NCT03386773|BEHAVIORAL|Patient generated health data|Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
40774844|NCT00867152|DRUG|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
40774845|NCT00867152|DRUG|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
40978868|NCT06293170|OTHER|Conventional care|Conventional care
40978869|NCT01164956|DRUG|methylphenidate|
40978870|NCT01164956|OTHER|Placebo|
40978871|NCT01899794|PROCEDURE|TVT-O/Oxytrol|
40978872|NCT01899794|DEVICE|TVT-O|
40978873|NCT01899794|DRUG|Oxytrol|
40978874|NCT00478569|DRUG|Parathyroid Hormone (PTH) (1-84)|Adherence to PTH(1-84) treatment in Usual Clinical Settings
40774846|NCT00867152|DRUG|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
40978875|NCT05859789|PROCEDURE|kegel exercise|"* Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~* The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A\&B).~* Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~* They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises."
40774847|NCT00867152|DRUG|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
40774848|NCT00867152|DRUG|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
40774849|NCT02988076|DEVICE|PEER Interactive Report|A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
40774850|NCT04997850|DRUG|lenvatinib + sindilimab/carrelizumab|4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.
40774851|NCT04997850|PROCEDURE|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
40774852|NCT01239940|DEVICE|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
40774853|NCT01239940|DEVICE|Coronary angioplasty using the Everolimus-eluting stent|Stent implantation
40774854|NCT05103436|OTHER|TENS|Electrical nerve stimulation
40774855|NCT00718185|PROCEDURE|Obtain blood specimens|Obtain blood samples at multiple timepoints.
41302109|NCT04989829|DRUG|SHR6390、Omeprazole|SHR6390 tablet single dose、Omeprazol single dose.
40774856|NCT01827189|OTHER|Comprehensive primary care|Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
40774857|NCT01078948|DEVICE|transcranial direct current stimulation (tDCS)|Delivery of mild current to specified brain regions.
40978876|NCT05859789|OTHER|Mediterranean diet regimen for 12 weeks.|kegel ex in addition to mediterrian diet . The recommended composition of the dietary regimen was the following: carbohydrates 50-60%, proteins 15-20%, total fat o30%, saturated fat 10% and less than 300 mg of cholesterol consumed per day. Moreover, subjects Will be advised to consume at least 250-300 g of fruits, 125-150 g of vegetables and 25-50 g of nuts per day.
41302110|NCT04366986|OTHER|Tested for SARS-CoV-2 (regardless of the result)|This is an observational study with no intervention
40774858|NCT04597801|DRUG|Alcon|Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.
40774859|NCT05453461|DIAGNOSTIC_TEST|Validation of new COMs for non ambulant FSHD patients|Monitoring of commonly used and news COMs in non ambulant patients with facioscapulohumeral muscular dystrophy
41146951|NCT04972318|PROCEDURE|ARDSNet ventilatory strategy|Positive end-expiratory pressure will be set according to fixed inspired oxygen fraction values.
41302111|NCT04366986|OTHER|Clinical diagnosis of COVID-19 by a health care professional|This is an observational study with no intervention
40978877|NCT04211051|DEVICE|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
41302112|NCT02272322|DEVICE|cystocele repair with biomesh soft prolaps and endofast reliant|
41461111|NCT05955326|DRUG|Sovateltide|Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.
40978878|NCT01822405|DRUG|pentoxifylline with tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
41461112|NCT05955326|OTHER|Normal Saline|Three doses of Normal Saline (0.9% NaCl solution) with a volume equal to the volume of sovateltide will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.
41302113|NCT05549882|OTHER|no intervention|no intervention
41461113|NCT00544167|DRUG|Doxorubicin|
41302114|NCT03200457|DEVICE|1,5 Tesla abdominal MRI|Measurement of the fat and iron
41461114|NCT00544167|DRUG|Cyclophosphamide|
41302115|NCT03200457|DEVICE|3 Tesla abdominal MRI|Measurement of the fat and iron
41461115|NCT00544167|DRUG|Paclitaxel|
41461116|NCT00544167|DRUG|Sorafenib|
41461117|NCT01136928|DRUG|American ginseng|Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
41461118|NCT06465875|OTHER|Reading a book|Individuals in the intervention group will be read a storybook for three nights.
40978879|NCT01822405|OTHER|pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy|"pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.~Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment."
40978880|NCT00969150|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.
40978881|NCT00969150|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
40978882|NCT02189746|OTHER|Continuous Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
40978883|NCT02189746|OTHER|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
41146952|NCT05264649|DEVICE|acupuncture|"The acupuncture group were consisted of twelve 30 minutes sessions 2 times per week sessions for 6 weeks. The acupoints were included full body protocol (LI4, LR3, and PC7) and joint-specific protocol tailored as many as three of the patient's most painful joint areas. After 20 minutes De Qi reported by patients, needles were restimulated manually and removed after an additional 10 minutes."
41302116|NCT00836680|DEVICE|Colorectal Stent|"Diagnosis of an internal rectal prolapse:~The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.~An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch."
41302117|NCT03988829|BEHAVIORAL|Low-C|This is the active control group, where participants will be trained to play an experimenter developed game that requires least attentional control among all arms.
40774860|NCT03981510|DIAGNOSTIC_TEST|3D-Transit|3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
40774861|NCT06296680|OTHER|Reiki|The patients in the intervention group received Reiki to the seven chakra regions and additional areas with pain for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
40774862|NCT06296680|OTHER|Sham Reiki|The patients in the placebo group received Sham Reiki to the seven chakra regions for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
40774863|NCT06296680|OTHER|Progressive Relaxation Exercise|PRE group patients received PRE for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
41302118|NCT03988829|BEHAVIORAL|High-C|In this intervention, participants will be trained on this experimenter developed game which requires a lot of attentional control.
41302119|NCT03988829|BEHAVIORAL|High-C+|A commercial video game will be used that requires a lot of demand on attentional control.
41302120|NCT06052735|OTHER|Correlation research|The relationship among pain perception, temporomandibular disorder severity and spine health
41461119|NCT01209988|DRUG|tamsulosin 0.4mg|perioperative tamsulosin 0.4mg daily for three weeks
41461120|NCT01209988|OTHER|No medication|No medication
41302121|NCT01341652|BIOLOGICAL|pTVG-HP|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
40774864|NCT00347269|BEHAVIORAL|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
40774865|NCT00347269|DRUG|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
40774866|NCT00347269|BEHAVIORAL|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
40774867|NCT01096004|DRUG|AZD4017|oral suspension, 1200mg, once daily, for 10 days
40774868|NCT01096004|DRUG|Placebo|
40774869|NCT02803905|BIOLOGICAL|Biological: Islet transplantation|This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
40774870|NCT01344226|DRUG|loteprednol 0.5% ophthalmic solution|Lotemax to be used QID starting day of cataract surgery and 21 days after for total of 22 days.
40774871|NCT04389697|DIETARY_SUPPLEMENT|Clear fluids and food up to up to 1 hour before the procedure|Clear fluids and food up to up to 1 hour before the start of the procedure
40774872|NCT06363760|OTHER|Safety and efficacy assessments|Assessed throughout the duration of the study.
40774873|NCT04643379|DRUG|Olaparib|Supplied by Merck \& Co.
40774874|NCT04643379|DRUG|Pembrolizumab|Supplied by Merck \& Co.
40774875|NCT04643379|DRUG|Carboplatin|Commercially available
40774876|NCT04643379|PROCEDURE|Peripheral blood draw|Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression
40774877|NCT02176915|BEHAVIORAL|Group program|
40774878|NCT02176915|BEHAVIORAL|Print Materials|
40978884|NCT02189746|OTHER|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
40978885|NCT02189746|OTHER|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
40978886|NCT03958721|DRUG|Capecitabine|1,000 mg/m2 twice daily taken by mouth every other week
41302122|NCT01341652|BIOLOGICAL|rhGM-CSF|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
41302123|NCT03887559|BEHAVIORAL|Group-based stabilization and skill training in addition to individual treatment|"Group-based stabilization and skill training, weekly 2-hour sessions during 20 weeks. Based on the manual Tilbake til Nåtid (Back to here and now) (Holbæk, 2014) developed by clinicians in the highly specialized national trauma clinic 'Modum Bad's Trauma Clinic'."
41302124|NCT03887559|OTHER|Treatment as usual|Treatment as usual: conventional individual treatment (outpatient). Not standardized.
41302125|NCT02759146|OTHER|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
41302126|NCT02759146|OTHER|Meditative Practices|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
41461121|NCT03947398|DEVICE|BLIMP balloon|Using BLIMP balloon to cross lesion
40774879|NCT05296161|DRUG|Ocrelizumab|Personalized B cell tailored ocrelizumab treatment
40774880|NCT01006733|GENETIC|Pharmacogenetic|The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
40774881|NCT01006733|DRUG|Target INR 1.8|We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
40774882|NCT05309655|DRUG|Adenosine Stress Cardiac Magnetic Resonance Imaging|Adenosine stress CMR test with contrast to include cardiovascular structural and functional measures including myocardial blood flow through quantitative perfusion mapping. Participants will have 3 stress tests as a part of this research. These tests will happen when at the beginning of the study, and then every year for 2 years.
40774883|NCT05309655|DIAGNOSTIC_TEST|Electrocardiogram|A 12-lead electrocardiogram will be done when at the start of the study and at the participant's 2 year stress test to look at the electrical signals of your heart.
40774884|NCT05309655|DIAGNOSTIC_TEST|Computed Tomography Angiogram|Contrasted coronary CT angiography will be performed for visual and quantitative analysis of coronary artery plaque burdens.
40774885|NCT05309655|OTHER|Laboratory Testing|10 teaspoons of blood will be withdrawn at every visit that participants receive a stress test. Participants may have up to six blood draws associated with each imaging visit.
40978887|NCT03958721|RADIATION|Radiotherapy|Once daily (Monday through Friday) for six weeks
40774886|NCT05309655|BEHAVIORAL|Quality of Life Survey|A general health status survey with 10 questions and should take about 5-10 minutes to finish. This survey is related to research.
40774887|NCT00319007|DRUG|Sulindac (drug)|
40978888|NCT02344160|OTHER|Phlebotomy|Phlebotomy will be performed at study follow up visits to obtain blood for metal ion analysis which will monitor levels for safety outcome measures
40978889|NCT00098085|BIOLOGICAL|HSPPC-96|
40978890|NCT04763915|OTHER|Correlative Studies (Survey)|Administer surveys
40978891|NCT04763915|OTHER|Correlative Studies (Interview)|In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention
41302127|NCT02819310|DRUG|BLI400 Laxative|oral laxative
40978892|NCT04763915|BEHAVIORAL|GeneSHARE|Access to GeneSHARE, a web-based toolkit which includes interactive and narrative components to enhance FC of genetic test results.
41461122|NCT03947398|DEVICE|Low profile balloon|using low profile balloon to cross lesion
40978893|NCT04763915|BEHAVIORAL|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
41302128|NCT05490953|DRUG|Pentoxifylline|Patients will be treated pentoxifylline during the first two chemotherapy cycles of their respective treatment.
41302129|NCT05490953|DRUG|Placebo|Patients will be treated with placebo during the first two chemotherapy cycles of their respective treatment.
41461123|NCT06458751|OTHER|electrophysiological study|Antidromic sensory nerve conduction studies of median and ulnar nerves will be performed on both hands of 30 healthy subjects with no history of previous neuromuscular disease and no abnormalities on neurological examination., by using surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
41302130|NCT05289908|DRUG|Pemetrexed (1)|Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....
41461124|NCT06458751|DEVICE|electromyograph|surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
41461125|NCT03562845|OTHER|NA-Observational only|NA-Observational only
40774888|NCT00319007|DRUG|VSL#3 (probiotic)|
40774889|NCT00319007|DRUG|Inulin (probiotic)|
40774890|NCT03561311|DEVICE|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
40978894|NCT04763915|BEHAVIORAL|Standard-of-care & Adaptive Intervention|Receive standard-of-care from their treating healthcare provider. A subset of individuals will also be asked to test and pilot the adaptive intervention, which will consist of tailored resources to promote CRM and FC, after the 12-month follow-up survey.
40978895|NCT04763915|OTHER|Access to Education Materials|Receive access to VUS educational materials
40978896|NCT06261554|DIETARY_SUPPLEMENT|Dietary Supplement: Low dose OIT|Following the building-up phase (up to 14 months), patients will receive a daily low dose of sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread for 3 months (12 +/- 3 weeks).
40774891|NCT03561311|DEVICE|sham remote ischemic conditioning|Sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
40774892|NCT03715907|BEHAVIORAL|Financial Incentives|Incentives for gap closure.
40774893|NCT03715907|BEHAVIORAL|Information|Information on care gap and closure process.
40774894|NCT01334255|DRUG|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
40978897|NCT01321268|DIETARY_SUPPLEMENT|dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)|oral, twice daily in morning and evening for 6 months
40774895|NCT05943821|DRUG|Allopurinol 200 mg|The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
40774896|NCT05943821|DRUG|Optional intervention|"Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels \>5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up."
40774897|NCT05593289|OTHER|telerehabilitation|Physical activity that is planned, structured with repeated muscle movements with the aim of relearning motor skills, resistance of neck muscles and postural correction.
40774898|NCT06564116|BIOLOGICAL|Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of thiomersal-free hepatitis E vaccine intramuscularly at month 0, 1 and 6.
40774899|NCT06564116|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of licensed hepatitis E vaccine intramuscularly at month 0, 1 and 6
40774900|NCT02012517|DRUG|Prolonged antibiotic treatment|
40774901|NCT02012517|DRUG|Short antibiotic course (standard of care)|
40774902|NCT00863590|DRUG|odanacatib|\[Intervention Name: odanacatib (Panel A)\] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
40774903|NCT00863590|DRUG|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
40774904|NCT00863590|DRUG|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
40774905|NCT00863590|DRUG|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
40774906|NCT02418091|BEHAVIORAL|Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
40774907|NCT00955578|PROCEDURE|Punch Biopsy|5-6 punch biopsies of affected areas
40774908|NCT01734044|DRUG|recombinant human thrombopoietin (rhTPO); dexamethasone|Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
40774909|NCT01734044|DRUG|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
40774910|NCT03493152|DRUG|Everolimus|mTOR inhibitor
40774911|NCT03378102|BIOLOGICAL|IFN-gamma-secreting HAdV antigen specific T cells|Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant
40774912|NCT02051192|BEHAVIORAL|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
40978898|NCT01321268|DIETARY_SUPPLEMENT|Viatmin E|oral, twice daily in morning and evening for 6 months
40978899|NCT00617565|DRUG|biphasic insulin aspart|
40978900|NCT00617565|DRUG|biphasic human insulin|
40978901|NCT02180152|BEHAVIORAL|Postprandial walks|Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
41146953|NCT05264649|DRUG|Guizhi-Shaoyao-Zhimu decoction|The patients consumed GZSD (4g paper bagged medicine) three times per day (total daily dose was 12 g/day) continuously during the 6-week intervention period.
41302131|NCT05289908|DRUG|Pemetrexed (2)|The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
41302132|NCT05289908|DRUG|Folic Acid|Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
40978902|NCT06479798|DIAGNOSTIC_TEST|Endo bronchial ultrasound transbronchial needle aspiration(EBUS-TBNA)|Endo bronchial ultrasound enables visualization of parabronchial structures throughout a bronchoscopic procedure. EBUS-TBNA, which is considered a less invasive diagnostic tool for nodal staging compared to mediastinoscopy, allows real-time, direct sampling of hilar \& MLNs under sonograghic guidance with concurrent cytological and histopathological examination
40978903|NCT00203177|DRUG|rasagiline mesylate|0.5 rasagiline mesylate
40978904|NCT00203177|DRUG|rasagiline mesylate 1.0 mg|1.0 mg rasagiline mesylate
40978905|NCT04498611|DIAGNOSTIC_TEST|contrast-enhanced breast MRI|Contrast-enhanced MRI will be performed on patients diagnosed with ductal carcinoma in-situ (DCIS) by preoperative biopsy.
40978906|NCT00097110|DRUG|Vitamin C and E|
40978907|NCT01267812|DRUG|bortezomib|Given SC or IV
40978908|NCT01267812|BIOLOGICAL|rituximab|Given IV
40978909|NCT01267812|OTHER|laboratory biomarker analysis|Correlative studies
40978910|NCT01267812|OTHER|immunohistochemistry staining method|Correlative studies
41142250|NCT05054751|DRUG|Placebo+Fulvestrant|"Placebo: The dose of Placebo is 150 mg, BID, which should be taken with a meal. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
41302133|NCT05289908|DRUG|Vitamin B12|A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
41302134|NCT05289908|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
41302135|NCT01798784|BEHAVIORAL|Sweepstake Incentive 1|Daily sweepstake conditional on daily medication adherence
41302136|NCT01798784|BEHAVIORAL|Sweepstake Incentive 2|Daily sweepstake conditional on daily medication adherence
41302137|NCT01798784|BEHAVIORAL|Sweepstake Incentive 3|Daily sweepstake conditional on daily medication adherence
41302138|NCT04583566|GENETIC|COVID-19 Diagnostic and Assessment Tests|Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.
41142251|NCT00689637|DRUG|AZD3480|AZD3480 capsules qd, 12 days
41302139|NCT00264316|PROCEDURE|bone marrow-derived stem cell transfer|
41302140|NCT01331239|DRUG|LCI699|Osilodrostat 1 mg and 5 mg capsules, was prepared by Novartis and supplied to the Investigator. The capsule formulation of osilodrostat was later changed to tablets and this change was implemented in the study with Protocol amendment 6. Osilodrostat was open labeled 1 mg, 5 mg, 10 mg and 20 mg tablets.
41302141|NCT06515652|DRUG|rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun|Comparing allopathic and herbal group of drugs for metabolic syndrome
40978911|NCT01267812|GENETIC|RNA analysis|Correlative studies
40978912|NCT01267812|GENETIC|gene expression analysis|Correlative studies
40978913|NCT01267812|GENETIC|DNA analysis|Correlative studies
40978914|NCT01267812|OTHER|pharmacological study|Correlative studies
40978915|NCT01267812|OTHER|pharmacogenomic studies|Correlative studies
40978916|NCT01267812|OTHER|Questionnaire Administration|
40978917|NCT03479606|BEHAVIORAL|Online Emotion Regulation Skills-training|Emotion Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. The intervention is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the intervention, to increase their familiarity with the terminology, and to the emotion regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotion regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
40978918|NCT02801292|DRUG|Ketamine|Single bolus of Ketamine .25 milligrams per kilogram of weight.
40978919|NCT04169321|DRUG|Single Arm|\[68Ga\]-NOTA-hGZP is a PET imaging agent.
40978920|NCT04461171|PROCEDURE|Enhanced Recovery After Surgery|Undergo an enhanced recovery after surgery program
40978921|NCT03221400|DRUG|PEN-866 Sodium|PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
40978922|NCT03221400|DRUG|fluorouracil|Fluorouracil 2400 mg/m2 IV
41142252|NCT00689637|DRUG|Placebo|Placebo capsules qd, 12 days
41302142|NCT01999413|DRUG|OMEGAVEN|AML Study treatment induction phase
41302143|NCT01999413|DRUG|Daunorubicin|AML Study treatment induction phase
41302144|NCT01999413|DRUG|Cytarabine|AML Study treatment induction phase
41302145|NCT03571334|DRUG|IncobotulinumtoxinA (Xeomin®, Merz) (INA)|IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units. Study participants will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, INA will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
41461126|NCT02727192|DEVICE|PAP (CPAP or ASV)|Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
41461127|NCT00762411|DRUG|LY450139|Administered orally once daily.
41461128|NCT00762411|DRUG|Placebo|Administered orally once daily.
41461129|NCT05603858|PROCEDURE|Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
40978923|NCT03221400|DRUG|Folinic acid|Folinic acid 400 mg/m2 IV
40978924|NCT03221400|DRUG|Niraparib|Niraparib
40774913|NCT02051192|OTHER|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
40774914|NCT06319287|BIOLOGICAL|PEP (Purified Exosome Product) / TISSEEL|"PEP Drug Product is a lyophilized powder contained within a 10R glass vial. PEP Drug Product is a lyophilized powder derived from apheresed platelets in plasma. The powder cake weighs approximately 75 mg per vial. This protocol will evaluate 2 vials of PEP Drug Product delivered in 10 mL TISSEEL fibrin sealant (15mg/mL PEP-TISSEEL) for 12 weeks.~TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies"
40774915|NCT01241123|PROCEDURE|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
40774916|NCT01241123|DRUG|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
40774917|NCT01241123|RADIATION|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
40774918|NCT01241123|DEVICE|pedometers|to record the amount of ambulation
40774919|NCT02279056|BEHAVIORAL|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
40774920|NCT02279056|BEHAVIORAL|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
40774921|NCT03527784|DEVICE|Parietene Macro|Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.
40774922|NCT03527784|DEVICE|Parietex Parastomal|Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.
40774923|NCT03527784|DEVICE|Dynamesh IPST|Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia
40774924|NCT02216526|OTHER|Cetaphil® Restoraderm|
40774925|NCT02216526|OTHER|Excipial|
40774926|NCT03152201|DIAGNOSTIC_TEST|electrophysiological signal|trasmit the electrophysiological signals to the neurosurgeon through the hardware
40774927|NCT02692027|OTHER|Same-day ART initiation|"Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation."
40774928|NCT02692027|OTHER|Standard of care|"Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis."
40978925|NCT05346341|PROCEDURE|Minimally invasive techniques|"All patient will be treated under general anaesthesia An appropriate gland-preserving minimally-invasive surgical procedure will be performed for all patients according to the nature and extent of the disease for either submandibular or parotid ducts.~Minimally invasive techniques for ductal salivary gland pathologies include:~1. Sialolithotomy through a simple cutdown~2. Sialendoscopy~3. Transoral microscopic-assisted sialolithotomy."
41142253|NCT00689637|DRUG|Warfarin|Warfarin: single dose on day 6
41142254|NCT05164926|OTHER|perineal massage with St. John's Wort oil|perineal massage with St. John's Wort oil during labor
41142255|NCT03140709|DRUG|Oxytocin|"Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr"
41461130|NCT00002244|DRUG|WF10|
41461131|NCT05970731|DRUG|Beclomethasone|84 mcg of Beclomethasone administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
40774929|NCT01940055|BEHAVIORAL|Dual task treadmill walking exercise program|Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
40774930|NCT01940055|BEHAVIORAL|Dual task recumbent cycling exercise program|Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
41142256|NCT04449822|PROCEDURE|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
41142257|NCT04449822|PROCEDURE|Colonic stenting|The colonic stent placement to relieve the colonic obstruction.
40978926|NCT00643682|OTHER|Educational card|"A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
40978927|NCT04021589|DRUG|Weileshu|a probiotics products which help to rebuild homeostasis of gut microbiome
40978928|NCT04021589|DRUG|Chemotherapy|chemotherapy
40978929|NCT05755685|DRUG|Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)|5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
40978930|NCT05012839|OTHER|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.
40978931|NCT03813979|DRUG|Dolutegravir|Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach
40978932|NCT05417165|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|Given IM
40978933|NCT05417165|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM
40774931|NCT06247137|DIETARY_SUPPLEMENT|Dietary Supplement|"Dietary supplement formulated with components of natural origin: artichoke, bergamot, folic acid, astaxanthin, Chromium picolinate and excipients.~Oral administration: 1 tablet/day at evening meal"
40774932|NCT06247137|OTHER|Placebo|"Placebo (microcrystalline cellulose, calcium carbonate, magnesium stearate, silica dioxide and iron oxides).~Oral administration: 1 tablet/day at evening meal."
40774933|NCT04697927|OTHER|Questionnaires|The epidemiologic questionnaires used in this study are a composite of validated questions from multiple sources. Many of the questions are an expansion of the MSK General Medical Health clinical questionnaire. Validated questions capturing demographics, employment, risk behaviors, family history, as well as, specific research domains including psychosocial, food security, and financial toxicity have already been utilized in other MSK minimal risk studies. The COVID-19 symptom and history tracker questions were largely drawn from the COronavirus Pandemic Epidemiology (COPE) consortium study.
40774934|NCT06256900|OTHER|Flow-controlled ventilation|FCV mode during robot-assisted laparoscopic surgery
40774935|NCT06256900|OTHER|Pressure-controlled ventilation|PCVmode during robot-assisted laparoscopic surgery
40774936|NCT00078260|DRUG|pemetrexed|"A: 500 mg/m2, IV, q 21 days until disease progression~B: 900 mg/m2, IV, q 21 days until disease progression"
40978934|NCT03861715|DIAGNOSTIC_TEST|live birth rate|The blastulation rate and live birth rate according to the protocol of COS
40978935|NCT02446990|DRUG|Ivabradine|5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
40978936|NCT02446990|DRUG|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
40978937|NCT01105195|OTHER|DuraPrep|DuraPrep is used for skin preparation prior to surgery.
40978938|NCT01105195|OTHER|ChloraPrep|ChloraPrep is used for skin preparation prior to surgery.
40978939|NCT05608889|BEHAVIORAL|Total Worker Health Mindfulness Enhanced Program|"The intervention will be delivered during 12, 45-minute weekly meetings of Correctional Professionals while on shift. Those sessions will be a combination of a video, mindfulness activity, and a group learning activity. It will conclude with members stating personal goals that will be followed up at the next meeting.~Sessions will be scripted to make them easy to implement with high fidelity, and include tasks, learning activities, and wrap-up with practice instructions for each week. Coworkers will be responsible for running the sessions, which promotes shared norms and social support."
40774937|NCT05207384|PROCEDURE|Ozone (O2-O3) injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
40774938|NCT05207384|PROCEDURE|Corticosteroid injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
40774939|NCT04768244|OTHER|maternal SARS-CoV-2 infection|positive PCR in nasopharinx and/or presence of antibodies in serum
40774940|NCT06486220|DRUG|Intestinal bacteria freeze-dried powder capsules|Oral healthy intestinal bacteria freeze-dried powder capsules, tid
40978940|NCT03835494|OTHER|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
40978941|NCT03807063|BIOLOGICAL|Rivogenlecleucel|Given IV
40978942|NCT03807063|DRUG|Rimiducid|Given IV
41142258|NCT00700557|DIETARY_SUPPLEMENT|Probiotics - Lactobacillus casei and Bifidobacterium breve|Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.
41461132|NCT05970731|OTHER|Placebo|Placebo (0.9% sodium chloride) administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
40978943|NCT05756946|PROCEDURE|periodontal dressing (coe-pak)|Guided tissue regeneration and periodontal dressing
40978944|NCT05756946|PROCEDURE|Guided Tissue Regeneration|Regeneration of lost periodontal tissues
40978945|NCT04676646|DRUG|Sodium zirconium cyclosilicate|Investigational medicinal product
40978946|NCT04676646|DRUG|Placebo|Placebo comparator
41142259|NCT00700557|DIETARY_SUPPLEMENT|Maize starch|Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
41461133|NCT05970731|DEVICE|Microsponge|Drug delivery using chitosan-based biocompatible microsponge
41461134|NCT02698930|DRUG|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
41461135|NCT02698930|DRUG|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
40774941|NCT04223271|DIAGNOSTIC_TEST|Indicor|Handheld device with attached PPG sensor that is paired with a tablet to estimate left ventricular end diastolic pressure. Subjects will blow into the device in order to perform a standardized Valsalva maneuver for 10 seconds. The index finger will be resting in the PPG sensor during the test. Each test requires three efforts, with 45 seconds rest between efforts.
40774942|NCT04584723|OTHER|Observation of flap survival and complications|We will report the flap survival and complications in this population group underwent to microsurgical procedures in a private practice setting
40774943|NCT02329587|OTHER|ERP plus tDCS|Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
40774944|NCT02329587|OTHER|ERP plus sham tDCS|Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
40774945|NCT02480049|DRUG|Asmakast|1 tablet contains 10 mg of montelukast
40774946|NCT02480049|DRUG|Singulair|1 tablet contains 10 mg of montelukast
40774947|NCT05530525|DIAGNOSTIC_TEST|The Computerized Adaptive Testing system of the Functional Assessment of Stroke|The Computerized Adaptive Testing system of the Functional Assessment of Stroke comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper limb, 11 items from the Fugl-Meyer Assessment-Lower limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. Results are automatically reported as Rasch scores (i.e., the minimum and maximum values are negative and positive infinity, respectively). A higher score indicates greater physical functions.
40774948|NCT05530525|DIAGNOSTIC_TEST|The Barthel Index|The Barthel Index has 10 items, and the total score ranges from 0 to 100. Higher score indicates less disability on activity of daily living functions.
40774949|NCT05530525|DIAGNOSTIC_TEST|The National Institutes of Health Stroke Scale|The National Institutes of Health Stroke Scale comprises 11 items and was used to monitor the severity in the patients with stroke. The total score ranges from 0 to 42, with a higher score indicating greater severity. A National Institutes of Health Stroke Scale score of 1-5 indicates mild severity; 6-14, mild to moderate severity; 15-24, severe severity; and equal to or greater than 25, very severe severity.
40774950|NCT04312802|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|"The participant will undergo a cardio-pulmonary exercise test (CPET) on a cycle ergometer (Ergoline) connected to a 12-lead electrocardiogram, oxygen saturation monitor and continuous non-invasive blood pressure cuff. Respiratory gas exchanged will be measured from a tight fitting facemask. An initial 2-min period of baseline data will be collected at rest before a 180-s period of unloaded cycling. A ramp protocol will then be applied and the participant will be instructed to continue cycling at a constant cadence of 60 rpm as long as they can. The test will be terminated if the participant indicates that:~* they cannot continue~* cadence falls to \<55 rpm due to fatigue or dyspnoea~* they develop abnormal cardiac signs or symptoms, such as ischaemia and arrhythmia."
40774951|NCT02666560|DEVICE|Auditory Cueing|Auditory cueing set at different frequency rates
40774952|NCT00000438|DRUG|naltrexone (Revia)|
40774953|NCT03599765|OTHER|Best Practice|Receive routine therapy
40774954|NCT03599765|PROCEDURE|Local Consolidation Therapy|Receive LCT
40978947|NCT04676646|OTHER|Spironolactone|"Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained."
40978948|NCT01913912|DRUG|LDX.|"In this study 3 different doses of LDX will be used:~* 30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~* 50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~* 70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine"
40978949|NCT01913912|DRUG|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
41142260|NCT04878679|OTHER|Strenght training combined with WB-EMS|Bodyweight exercise training combined with WB-EMS (2 times/week) with a 85Hz electrical impulse
41142261|NCT04878679|OTHER|Cardiovascular training with WB-EMS|Cardiovascular training , using the rowing machine, combined with WB-EMS (2 times/week) with a 7Hz electrical impulse
41461136|NCT05443919|DEVICE|TwiFlow-Thrombectomy Catheter System|Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'.
41461137|NCT04384224|OTHER|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
41461138|NCT00840190|DRUG|P1446A-05|P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
40978950|NCT01913912|DEVICE|computer task (Go/No-Go task)|
41142262|NCT04878679|OTHER|Control group|No physical activity
41142263|NCT02637063|BEHAVIORAL|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
40774955|NCT06441487|BEHAVIORAL|Mobile Health Decision Support|Subjects randomized to this arm receive a link to a mobile health decision support tool (mPATH™- Cloud). Within mPATH™-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who select FIT, as well as subjects who do not click on the link or select a screening test receive a FIT mailed to their home address.
40978951|NCT01913912|DEVICE|EEG|event-related potentials (ERP) and heart rate measurements
41302146|NCT03571334|DRUG|Normal saline|Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
41302147|NCT05054933|OTHER|ultrasound capsule endoscopy|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
41302148|NCT03075397|OTHER|blood sample|A sample of HIV-1 infected patients's blood is collected
41302149|NCT03075397|OTHER|sperm sample|A sample of HIV-1 infected patients's sperm is collected
40774956|NCT06441487|BEHAVIORAL|Usual care|The study team will send subjects a prompt to visit the mobile health decision support tool (mPATH™-Cloud). Subjects with a mobile phone (as determined by their electronic health record) will receive a link to mPATH-Cloud by text. Subjects with a mailing address, but no mobile phone number in the EHR, will receive a letter inviting them to access mPATH-Cloud via URL code. Within mPATH-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who do not click on the link or select a screening test receive a FIT.
40774957|NCT02171728|DRUG|BIBW 2992|
40978952|NCT01913912|DEVICE|pupil size measurements (by using eye tracking)|
40978953|NCT06108791|DRUG|FIO2=0.8|the concentration of intraoperative inspired fraction of oxygen is 80% oxygen + 20% air
40978954|NCT06108791|DRUG|FIO2=0.33|the concentration of intraoperative inspired fraction of oxygen is 33% oxygen + 66% air
41302150|NCT01856595|DRUG|PF-06291874|The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
41302151|NCT01856595|DRUG|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
41302152|NCT02653378|BEHAVIORAL|DIET|25% Energy Depletion by Diet only for 3 Days
41302153|NCT02653378|BEHAVIORAL|EX|25% Energy Depletion by Exercise only for 3 Days
41302154|NCT06131346|OTHER|Evaluation of clinical and paraclinical data.|Retrospective data collection from available medical files of patient.
41302155|NCT05597436|DRUG|Trehalose|Once weekly 0.75g/kg administration
41461139|NCT02725996|BIOLOGICAL|NK cells|Adjuvant adoptive immune therapy using NK cell 4 times
40978955|NCT03970161|DEVICE|routine ophthalmic examination|Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.
41302156|NCT04531319|DIAGNOSTIC_TEST|Flow cytometric analysis|Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes
41302157|NCT02361749|DRUG|Botulinum Toxin|Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
41302158|NCT02361749|PROCEDURE|Anal Myectomy|Longitudinal anal myectomy will be performed under general anesthesia as a day case.
41302159|NCT03924024|DEVICE|Accelerated intermittent theta burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Stimulation intensity will be standardized to 80% of resting motor threshold.~Stimulation will be delivered to L-DLPFC using the Brainsway stimulator."
41302160|NCT05373706|BEHAVIORAL|Alcohol Cue Reactivity Personalized Feedback Intervention|This online brief intervention provides personalized feedback using EMA data focused on alcohol cue reactivity to reduce alcohol misuse among young adults.
40774958|NCT05677633|DRUG|Sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
40774959|NCT01335607|DRUG|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
40774960|NCT01335607|DRUG|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
40978956|NCT01778829|PROCEDURE|CPAP ventilation mode|Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
41302161|NCT05142657|OTHER|diet survey|Dietary survey applied to all participants
41461140|NCT02725996|OTHER|Curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
41461141|NCT01898234|DEVICE|Revaclear|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
40774961|NCT01722669|DRUG|isoquercetin or quercetin|Single dose PK/PD study
40774962|NCT02878863|DRUG|Paeoniflorin + phosphatidylcholine or silymarin|
40774963|NCT02878863|DRUG|Phosphatidylcholine or silymarin|
40774964|NCT03100526|BEHAVIORAL|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
40774965|NCT01862354|PROCEDURE|Transverse abdominal plan block|Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
41142264|NCT02637063|BEHAVIORAL|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
41142265|NCT02637063|OTHER|Usual care|No intervention beyond participants' own medical care.
41142266|NCT02696109|BEHAVIORAL|Treatment As Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
41142267|NCT02696109|BEHAVIORAL|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
41302162|NCT05871125|BEHAVIORAL|Reimbursement|Patients will be dosed in cohorts of 5, with a maximum available sample size of 30. The first cohort of 5 patients will be enrolled at the first reimbursement dose level of $1000 per month for 4 months ($4000 per patient in total). At the end of the 4-month period, reimbursement dose suitability will be determined as suitable by a cumulative negative financial toxicity screen and reimbursement dose deemed acceptable and appropriate in at least 4 patients. If the reimbursement dose is found suitable, we will de-escalate the reimbursement dose for the next cohort of 5 patients. If the reimbursement dose is found unsuitable, the next cohort of 5 patients will be enrolled at the same reimbursement amount ($1000 per month for 4 months).
41302163|NCT01057199|GENETIC|RNA analysis|
41302164|NCT01057199|GENETIC|gene expression analysis|
41302165|NCT01057199|GENETIC|mutation analysis|
41142268|NCT04089202|OTHER|eConsult|Completion of electronic consult utilizing data collected from flash glucose monitoring
41302166|NCT01057199|GENETIC|protein expression analysis|
40774966|NCT01862354|PROCEDURE|Continuous wound infusion|In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
40774967|NCT06278324|DEVICE|Nasal Spray HSV Treatment|Nasal treatment with the nasal spray Humer Stop Virus for 7 days, 2-3 puffs per nostril, 3-4 per day, space applications 4 hours apart.
40774968|NCT00770679|DRUG|lipitor|80 mg everyday (QD) for 3 weeks
40774969|NCT01836354|BEHAVIORAL|DESERVE education|Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
41302167|NCT01057199|OTHER|fluorescence activated cell sorting|
40774970|NCT00913822|DRUG|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)|
40774971|NCT00913822|DRUG|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)|
40774972|NCT00785720|DRUG|Dermacyd PH_DETINBACK (Lactic Acid)|
40774973|NCT04329884|PROCEDURE|Cooled RFA treatment with COOLIEF* device|Patients who are randomized to receive CRFA will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
40978957|NCT01778829|PROCEDURE|NIPPV ventilation mode|Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
40978958|NCT05534750|DRUG|Tedizolid arm (SIVEXTRO®)|Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
40978959|NCT05534750|DRUG|Linezolid arm (ZYVOXID®)|Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
40978960|NCT05534750|DRUG|Standard quadruple therapy arm|"Patients will be taken :~ISONIAZIDE :~o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms."
40978961|NCT06221540|BEHAVIORAL|"Myth busting information leaflet"|A written patient information leaflet displaying ten food allergy myths with the myth-busting evidence-based information clearly stated, focusing on themes pertinent to the myth-busting information
40774974|NCT04329884|DRUG|intra-articular corticosteroid injection|Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
40774975|NCT03361449|OTHER|Flamingo exercise|Flamingo exercise
41142269|NCT04089202|OTHER|Standard of care|Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
41142270|NCT06418594|DRUG|Adebrelimab|Adebrelimab: 1200mg, ivgtt, administered on the first day of each cycle, with a cycle of 21 days
41142271|NCT06418594|DRUG|Apatinib|Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days
41142272|NCT06418594|DRUG|Etoposide|Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days
40774976|NCT03361449|OTHER|training with kinesthetic ability trainer|training with kinesthetic ability trainer
40774977|NCT04451798|DEVICE|Impella CP microaxial pump|ramp test
40774978|NCT05026801|DRUG|Azithromycin plus hydroxychloroquine|All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.
40774979|NCT03412955|DRUG|Eribulin Mesylate|1.4mg/m2/dose on days 1 and 8 of a 21-day treatment cycle.
40774980|NCT04186832|DEVICE|FitBit|Wear FitBit
40774981|NCT04186832|DEVICE|Pedometer|Wear pedometer
40978962|NCT04937829|DRUG|BI 1569912|BI 1569912
40978963|NCT04937829|DRUG|Placebo|Placebo
40978964|NCT03944954|DEVICE|Placebo TMS Sham|Individuals will receive placebo dose and sham TMS.
40978965|NCT03944954|DRUG|Marinol 10Mg Capsule TMS Sham|Individuals will receive 10mg dose and sham TMS.
40978966|NCT03944954|DRUG|Marinol 30Mg Capsule TMS Sham|Individuals will receive 30mg dose and sham TMS.
40978967|NCT03944954|DEVICE|Placebo TMS Real|Individuals will receive placebo and real TMS.
40978968|NCT03944954|OTHER|Marinol 10Mg Capsule TMS Real|Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
40978969|NCT03944954|OTHER|Marinol 30Mg Capsule TMS Real|Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
41142273|NCT06199011|DRUG|Esketamine hydrochloride|A standardized non-opioid anesthesia will be achieved by using continuous intraoperative infusion of esketamine.
41142274|NCT06199011|DRUG|Opioid|A standardized opioid anesthesia will be achieved by using continuous intraoperative infusion of opioids.
41142275|NCT00419172|DRUG|Deferasirox|
41142276|NCT00419172|DRUG|Rifampicin|
41142277|NCT03949959|OTHER|Multimodal physiotherapy|Participants will undertake their usual activities for the 5, 8 or 11 day baseline period following PRP. Participants will begin the 6 week intervention period following this period during which time they will participate in 10 sessions with an experienced postgraduate physiotherapist. After these 6-weeks, participants will have no contact with intervention personnel during the 6-week follow-up period.
41302168|NCT01057199|OTHER|laboratory biomarker analysis|
40774982|NCT04186832|OTHER|Quality-of-Life Assessment|Ancillary studies
40774983|NCT04186832|OTHER|Questionnaire Administration|Ancillary studies
40774984|NCT05161468|DRUG|Lidocaine injection|2ml of 1% lidocaine will be drawn into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
40978970|NCT05562076|DEVICE|the spot stent(ZENFLEX ® Pinto) system|the spot stent(ZENFLEX ® Pinto) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
40978971|NCT05562076|DEVICE|the bare stent( Everflex) system|the bare stent( Everflex) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
40978972|NCT01957644|DRUG|Azacitidine|
40978973|NCT01957644|DRUG|Volasertib|
40978974|NCT00551733|DRUG|carboplatin|Given IV
40978975|NCT00551733|DRUG|paclitaxel|Given IV
40978976|NCT00551733|DRUG|paclitaxel poliglumex|Given IV
40978977|NCT05922150|RADIATION|low level laser therapy|LLLT induces cellular biostimulation, speeds up tissue regeneration, enhances wound healing, and reduces pain and swelling through an anti-inflammatory effect. This is because the LLLT increases phagocytic activity, and the number and diameter of lymphatic vessels, decreases the permeability of blood vessels and restores microcapillary function
41302169|NCT03807739|DRUG|GDC-0134 F09 Formulation|Participants will receive a single oral dose of GDC-0134 reference capsule F09.
41302170|NCT03807739|DRUG|GDC-0134 F15 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F15.
41302171|NCT03807739|DRUG|GDC-0134 F16 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
41302172|NCT01432314|OTHER|Radiation therapy|"A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.~C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).~D. Dose:~i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT."
40978978|NCT05922150|DRUG|ozone gel|ozone is effective antimicrobial (viricidal, bactericidal, and fungicidal). Other well-known benefits include immunological modulatory and stimulating effects and anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergeticseffects
40978979|NCT02387853|DRUG|LEO 90100|
40978980|NCT01252940|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
40978981|NCT01252940|DRUG|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
40978982|NCT01252940|DRUG|RTV|Ritonavir (RTV) was administered according to prescribing information.
40978983|NCT01252940|DRUG|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
40978984|NCT01866501|PROCEDURE|Proximal Humerus Intraosseous Vascular Access|Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
40978985|NCT01866501|DEVICE|EZ-IO|
40978986|NCT01572194|BIOLOGICAL|Urinary levels of PIIINP as a marker of changes in renal function|The act under consideration is the determination of PIIINP urinary. The aim of the study is to show the predictive value of PIIINP urinary in assessing renal function in patients with mucoviscidosis receiving a lung transplant.
40978987|NCT02060149|DRUG|C/S plus minocycline.|Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
40978988|NCT02060149|DRUG|nebulization with pH 7.4 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
41142278|NCT05751720|DRUG|GIP/GLP-1a|The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
41142279|NCT03967457|DIAGNOSTIC_TEST|questionnaires survey|Including four kinds of questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3); EORTC QLQ-CX24; Eligibility Criteria (FSFI); and Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFIQ-7)
41142280|NCT03967457|DIAGNOSTIC_TEST|Urodynamic testing|"Urodynamic testing consists of important urodynamic parameters including:~Bladder capacity at the first void sense Bladder capacity at normal desire to void Bladder capacity at strong desire to void Qmax Qave Pves at Qmax Pdet at Qmax Cves at SDV Cdet at SDV Residual urine volume"
41142281|NCT03967457|DIAGNOSTIC_TEST|Rectum dynamics testing|Rectum dynamics testing consists of important parameters of rectum activities
41142282|NCT03967457|DIAGNOSTIC_TEST|ovarian reserve function|"Testing for ovarian reserve function consists of:~Follicle-stimulating hormone Estradiol Anti-mullerian hormone Inhibin B"
41142283|NCT00021099|DRUG|ixabepilone|Given IV
41142284|NCT03709225|BEHAVIORAL|Music-based meditation|The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment
41142285|NCT05076838|DRUG|Diazepam Nasal Spray [Valtoco]|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
41142286|NCT01270906|DRUG|CHIR-258 (TKI258)|
41142287|NCT05575349|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 12 mandala coloring pages given to each participant by the researcher for 6 weeks, 1 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
41142288|NCT05271045|DIETARY_SUPPLEMENT|fortified canola oil with vitamins A and D and γ-oryzanol|30 g fortified canola oil with vitamins A and D and γ-oryzanol
41142289|NCT05271045|DIETARY_SUPPLEMENT|Active comparator|30 g fortified canola oil with vitamins A and D
41302173|NCT01432314|OTHER|Transarterial chemoembolization|"A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.~C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop."
41302174|NCT03661268|OTHER|fluid chanllenge|A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg.
40978989|NCT02060149|DRUG|nebulization with pH 7.8 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
40978990|NCT02060149|DRUG|No nebulization|No nebulization will be given to the patients.
40978991|NCT03645551|DIAGNOSTIC_TEST|checkup, no test|In this study we would like to examine if existing restorations already applied in teeth which we treated with laminate veneers had an effect. We will evaluate the laminate veneers by sight and take pictures and use a questionnaire
40978992|NCT02057198|DRUG|Fidaxomicin|
41302175|NCT06555614|OTHER|Acellular Dermal Matrix(ADM)|A comparison of the short-term complications associated with acellular dermal matrix in the test group and the control group.
41302176|NCT02427477|DEVICE|senofilcon A|Subjects will wear the contact lenses in both eyes for seven days
41302177|NCT02427477|DEVICE|delefilcon A|Subjects will wear the contact lenses in both eyes for seven days
41302178|NCT01887899|DEVICE|transcranial direct current stimulation|
41302179|NCT01887899|DEVICE|sham stimulation|
41302180|NCT02448901|DRUG|Edoxaban|In vitro study. Various concentrations of Edoxoban added to blood sample and tested
41302181|NCT00002206|DRUG|Adefovir dipivoxil|
41302182|NCT01540188|BEHAVIORAL|Family Intervention to Address Drug Use and HIV in Vietnam|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
41302183|NCT01560546|DRUG|Testosterone|50 mg/dose/day for 24 weeks
41302184|NCT01560546|DRUG|Placebo|placebo on the skin for 24 weeks
41302185|NCT06512415|DRUG|10 mcg Norepinephrine|The assigned dose (10 mcg) will be diluted with normal saline in a 10-cc syringe
41302186|NCT06512415|DRUG|15 mcg Norepinephrine|The assigned dose (15 mcg) will be diluted with normal saline in a 10-cc syringe.
41302187|NCT01315119|PROCEDURE|SPY Intra-Operative Angiography|Calculated per patient
41302188|NCT01072097|DRUG|Atorvastatin|Atorvastatin 20mg/day for 6 months
41302189|NCT01072097|DRUG|Placebo|Placebo for 6 months
41302190|NCT05429723|DRUG|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 450 mg and 900 mg tablet once daily, depending upon randomization.
41302191|NCT05429723|DRUG|HS-10383 Placebo|Placebo for HS-10383
41302192|NCT05151328|DRUG|Plecanatide|Plecanatide or Placebo; Route of Plecanatide/placebo administration: tablet; dosage: 3mg, dosage form oral; Frequency of administration: QD
41302193|NCT00764842|DEVICE|Encore CLP® Hip stem|Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
41302194|NCT03914287|OTHER|Self-Myofascial release|The Self-Myofascial release protocol for the lower limbs using a Foam Roller will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; release of the myofascial components of the back of the leg using a Foam Roller; release of the myofascial components of the anterior part of the leg using a Foam Roller; release of myofascial components of the hamstring region using a Foam Roller; release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; and release of the myofascial components of the pelvitrochanteric muscles using a Foam Roller in a sitting position.
41302195|NCT05106660|PROCEDURE|Ambulatory Laparoscopic Sleeve Gastrectomy|Same-day discharge
41302196|NCT05106660|PROCEDURE|Conventional Laparoscopic Sleeve Gastrectomy|Next-day discharge
41302197|NCT00733356|DRUG|Vyvanse|Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
41302198|NCT00926055|DRUG|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
41302199|NCT00926055|DRUG|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
41302200|NCT02583789|DRUG|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
41302201|NCT02583789|DRUG|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
41302202|NCT02941107|DRUG|Rotarix (RV1)|ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P\[8\] human rotavirus strain sponsored and distributed in Australia by GlaxoSmithKline Biologicals where it is licensed for the prevention of rotavirus gastroenteritis.
40978993|NCT02057198|DRUG|Metronidazole|
40978994|NCT02057198|DRUG|Vancomycin|
40978995|NCT00613249|DRUG|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
40978996|NCT00613249|DRUG|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
40978997|NCT00613249|DRUG|HEC-based Placebo Gel|intravaginal gel, dosed daily
40978998|NCT04769544|DEVICE|total knee arthroplasty with medial pivot tibial insert or symmetrical insert|standard surgical implantation of total knee arthroplasty
40978999|NCT00875251|DEVICE|body composition|Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
41142290|NCT05271045|DIETARY_SUPPLEMENT|Placebo|30 g fortified sunflower oil with vitamins A and D
41142291|NCT05963074|DRUG|Ibrutinib|Ibrutinib capsules will be administered orally.
40979000|NCT06092489|OTHER|graded motor imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
40979001|NCT06092489|OTHER|traditional physiotherapy method|This protocol included stretching and strengthening exercises. Self-stretching will encapsulate the upper trapezius, pectoralis minor, posterior. Each stretch will consist of 3 repetitions of 30 seconds with a 30 second break between repetitions. Strengthening exercises will be performed using elastic resistance bands (Theraband ®) with 4 levels of resistance (red, green, blue and grey). Sets can be easily changed (without the person reporting muscle fatigue) and progressed with resistance. The therapist will ask about the level of effort required for exercise exercises and whether it would be possible to increase the resistance level. The exercise consists of three sets of 10 repetitions and is completed with 1 rest between them. Strengthening exercises will include prone extension, prone external rotation with abduction, side lying external rotation and serratus anterior strengthening.
40979002|NCT04044612|OTHER|Medial Unloader Brace|medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
40979003|NCT02213016|DEVICE|Transcranial Magnetic Stimulation|
40979004|NCT02213016|DEVICE|Sham Transcranial Magnetic Stimulation|
40979005|NCT00987077|DEVICE|Selective Retina Therapy (SRT)|SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
40979006|NCT00951990|BEHAVIORAL|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
40979007|NCT00951990|BEHAVIORAL|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
40979008|NCT02401594|DRUG|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
40979009|NCT02401594|DRUG|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
40979010|NCT04690751|DRUG|Cenobamate 200Mg Tab Fasted|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
40979011|NCT04690751|DRUG|Cenobamate Oral Suspension Fed|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
40979012|NCT04690751|DRUG|Cenobomate Oral Suspension Fasted|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
40979013|NCT05743179|DRUG|Zoledronate|Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
40979014|NCT05675943|BIOLOGICAL|Anti-COVID-19 Antibody SA55 for Injection|After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
40774985|NCT05161468|DRUG|Corticosteroid Injection|1 ml of triamcinolone acetonide (40 mg/ml) will be drawn with 1 ml normal saline into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
40774986|NCT05161468|DRUG|Protein Rich Plasma(PRP) Injection|30 ml of acid-citrate-dextrose (ACD) will be drawn into a 30 ml syringe to coat the syringe. 3 ml will be left in the syringe and then 27 ml of blood will be drawn via standard venipuncture. The 30 ml mixture of blood and ACD will then be prepared in the Peak PRP system as described in the manufacturer's instruction (PEAK® PRP System). After preparation, PRP will be withdrawn (2 mls) into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
40979015|NCT05066594|DEVICE|Transoral incisionless fundoplication|The intervention of transoral incisionless fundoplication using the EsophyX (EndoGastric Solutions) system allows, through the endoscopic route, the creation of a cardial neovalve of approximately 270 ° by placing 20-28 polyethylene sutures on the cardial circumference, resulting in an anti-reflux plastic functionally similar to that obtained with the surgical fundoplication.
40979016|NCT03675607|OTHER|Complementary feeding behaviours|Any kind of complementary feeding practice
40979017|NCT03398681|DRUG|Ferric carboymaltose|Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]
40979018|NCT03398681|DRUG|Placebo (Normal saline)|Normal saline (0.9% weight/volume (w/v) NaCl)
40979019|NCT03398681|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Cardiac magnetic resonance including T2\* and T1-mapping sequences
40979020|NCT05815472|DEVICE|Fitbit charge|Internet of Things Technologies Device
40979021|NCT02136186|DEVICE|Philips Telehealth|patients will be provided with a philips home telemonitoring system post hospital discharge
40979022|NCT00111618|DRUG|AS1404 (DMXAA)|
40774987|NCT01959932|OTHER|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
40774988|NCT01959932|OTHER|Smoking abstinence (SA)|SA for 5 days in confinement
40774989|NCT01959932|OTHER|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
40774990|NCT03965923|DRUG|Dapivirine (DPV) Vaginal Ring (VR)|Vaginal ring containing 25 mg of DPV
40774991|NCT03965923|DRUG|Truvada Tablet|Tablet taken orally
40774992|NCT02200601|DEVICE|Seipher Wellness|
40979023|NCT01680523|PROCEDURE|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
40979024|NCT01680523|RADIATION|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
40774993|NCT05419245|OTHER|Guided Health History for Freeman-Burian Syndrome Questionnaire|Completed during the interview. The Guided Health History for Freeman-Burian Syndrome Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
40774994|NCT05419245|OTHER|Freeman-Burian syndrome Semi-Structured Quality of Life Interview|Completed during the interview. Freeman-Burian syndrome Semi-Structured Quality of Life Interview is a quality of life interview for Freeman-Burian syndrome, taking into consideration individual's total health.
40979025|NCT01680523|RADIATION|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
40979026|NCT03814291|DRUG|IBI302|0.05mg/eye;Intraocular injection
40979027|NCT03814291|DRUG|IBI302|0.15mg/eye;Intraocular injection
40979028|NCT03814291|DRUG|IBI302|0.5mg/eye;Intraocular injection
40979029|NCT03814291|DRUG|IBI302|1mg/eye;Intraocular injection
40979030|NCT03814291|DRUG|IBI302|2mg/eye;Intraocular injection
40979031|NCT03814291|DRUG|IBI302|4mg/eye;Intraocular injection
40979032|NCT02068833|PROCEDURE|Gastrectomy|
40979033|NCT02068833|PROCEDURE|BPD-DS|
41302203|NCT02941107|DRUG|Placebo|The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
40774995|NCT05419245|OTHER|Medical Records Review|Review of medical records will be used, along with Guided Health History for Freeman-Burian Syndrome Questionnaire to assess patient histories and outcomes.
40774996|NCT05419245|OTHER|PTSD Checklist for DSM-5|"Completed by patients before the interview. The PTSD Checklist for DSM-5 is a 20-item questionnaire. Each item is rated 0-4, with 0 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms."
40774997|NCT05419245|OTHER|Modified Flanagan Quality of Life Scale|"Completed by patients before the interview. The Modified Flanagan Quality of Life Scale is a 16-item survey designed for use in persons with chronic illness. Each item is rated 1-7, with 1 being Terrible and 7 being Delighted. Higher scores suggest the person may be experiencing a better quality of life."
40774998|NCT05419245|OTHER|Center for Epidemiologic Studies Depression Scale|"Completed by patients before the interview. The Center for Epidemiologic Studies Depression Scale is a 20-item survey that asks about depressive feelings and behaviours in the past week. Each item is rated 0-3, with 0 being Rarely or none of the time (less than 1 day) and 3 being Most or all of the time (5-7 days). Lower scores suggest the person may be experiencing fewer symptoms."
40774999|NCT05419245|OTHER|Review of Systems|Completed during the interview. A review of systems is a checklist of medical problems.
40775000|NCT05419245|OTHER|"FACE-Q | Craniofacial - Appearance of the Face"|"Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face."
40775001|NCT05419245|OTHER|"FACE-Q | Craniofacial - Appearance Distress"|"Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face."
40775002|NCT05419245|OTHER|"FACE-Q | Craniofacial - Facial Function"|"Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning."
40775003|NCT02385071|DRUG|Treatment A|150 milligram (mg) SMV capsule with water under fed conditions.
40775004|NCT02385071|DRUG|Treatment B|Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
40775005|NCT02385071|DRUG|Treatment C|Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions).
40775006|NCT02385071|DRUG|Treatment D|\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fed conditions.
40979034|NCT00210002|DRUG|Darbepoetin alfa (Aranesp®)|
40979035|NCT00210002|DRUG|Ferric saccharose(Venofer®)|
40979036|NCT06423820|DRUG|Ondansetron lozenge|Pediatric patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
40979037|NCT01709591|BEHAVIORAL|Prenatal education|
40979038|NCT02447549|RADIATION|WBRT|One RT plan with whole bladder treated to standard dose.
40979039|NCT02447549|RADIATION|SART|Three plans (small, medium \& large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
41142292|NCT05963074|DRUG|Venetoclax|Venetoclax tablets will be administered orally.
41142293|NCT05179772|DRUG|Olanzapine|Olanzapine (2.5 mg to 20 mg)
41302204|NCT03587675|DIAGNOSTIC_TEST|EVH test|
41302205|NCT04397393|DRUG|Midazolam|Dosage of Midazolam (in mg) needed to achieve satisfactory level of sedation to perform OPU
41302206|NCT02431585|DIETARY_SUPPLEMENT|gluten|
41302207|NCT02431585|DIETARY_SUPPLEMENT|placebo|
41461142|NCT01898234|DEVICE|Helixone high flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
41142294|NCT04922359|DRUG|Lidocain|Patients received 1.5mg/kg of intravenous lidocaine during induction of anesthesia and 1.5 mg/kg/h for anesthesia maintenance.
41142295|NCT04922359|DRUG|normal saline|Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
41142296|NCT02697656|BEHAVIORAL|IPS|Individualized job support provided by an employment specialist
41142297|NCT02697656|BEHAVIORAL|Self-help|Self-help resources on obtaining employment and coping with chronic pain
41142298|NCT02697656|BEHAVIORAL|Treatment as usual|Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
41142299|NCT04673032|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation for treatment of chronic pain
41142300|NCT02249156|BEHAVIORAL|Financial incentive for choosing a lower-cost provider|Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
41142301|NCT00512265|DRUG|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
41142302|NCT00512265|DRUG|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
41142303|NCT01049633|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|200mL sterile suspension of allogeneic human pancreatic islets
41142304|NCT01049633|DRUG|Sirolimus|Dosed to maintain whole blood 24-hr trough levels 10-15ng/mL for first 3 months and 8-12ng/mL thereafter daily. Sirolimus is used to prevent transplant rejection.
41142305|NCT01049633|BIOLOGICAL|Basiliximab|20mg intravenously (IV) 2hrs prior to islet infusion and on Day 4 post-transplant. Basiliximab is used to prevent transplant rejection
41142306|NCT01049633|DRUG|Tacrolimus|Initial dose of 0.015mg/kg p.o. daily on Day 1 post transplant, and adjusted to maintain 12-hr trough levels 3-6ng/mL. Tacrolimus lowers the risk of organ rejection
41142307|NCT01049633|DRUG|Antibacterial, Antifungal, and Antiviral Prophylaxis|Broad spectrum antimicrobial prophylaxis administered preoperatively
41142308|NCT01049633|DRUG|Trimethoprim/sulfamethoxazole|80mg/400mg by mouth once a day starting on Day 1 for duration of the study follow-up. This medication is used to prevent bacterial infections.
41302208|NCT01952197|OTHER|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
41302209|NCT06346288|PROCEDURE|Breast Milk Sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of commercial risankizumab at pre-dose and 1 hour after dosing on Day 1, on Days 4 (± 1), 8 (± 2), 15 (± 3), 29 (± 3), and pre-dose on Day 57 (± 3)
40775007|NCT02385071|DRUG|Treatment E|3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
40775008|NCT02385071|DRUG|Treatment F|3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3\*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
41142309|NCT01049633|DRUG|Clotrimazole|1 troche by mouth 4 times daily starting two days prior to transplant until 3 months after the transplant. This medication is used to prevent fungal infections.
41142310|NCT01049633|DRUG|Valganciclovir|450mg dose by mouth once a day starting two days pre-transplant and increasing to 900 mg once a day by Day 12 and continuing for 14 weeks post-transplant. This medication is used to prevent cytomegalovirus infections.
41142311|NCT01049633|DRUG|Heparin|70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
41142312|NCT01049633|DRUG|Enoxaparin|30mg subcutaneously twice a day from 48 hrs post-transplant through Day 7 post-transplant. This medication is used to prevent the formation of blood clots.
41142313|NCT01049633|DRUG|Pentoxifylline|400mg slow release tablet by mouth three times a day beginning 2 days prior to transplant and continue for 7 days post transplant. This medication improves blood flow.
41142314|NCT01049633|DRUG|Aspirin|81mg enteric coated aspirin by mouth every night, starting 24hrs post-transplant. This medication prevents blood clots.
41142315|NCT04913194|BEHAVIORAL|ARFID-PTP|ARFID-PTP is a two-session virtual protocol using psychoeducation, parent training skills, and exposure to decrease picky eating symptoms consistent with an ARFID diagnosis.
41142316|NCT04459156|DIETARY_SUPPLEMENT|Fiber Inulin|Commercially available inulin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
41142317|NCT04459156|DIETARY_SUPPLEMENT|Placebo Maltodextrin|Commercially available maltodextrin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
41142318|NCT01845337|DRUG|Teysuno|
41142319|NCT01845337|DRUG|Capecitabine|
40775009|NCT01233947|DRUG|AFP464|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
40775010|NCT01233947|DRUG|AFP464 + Faslodex|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
40775011|NCT05119816|OTHER|music therapy intervention|Received a customize playlists prepared by a certified music therapist to listening to during KB
40775012|NCT02903147|BEHAVIORAL|Functional Meta-Cognitive Intervention|Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
40775013|NCT02903147|BEHAVIORAL|The employer's training|
41302210|NCT06346288|DRUG|Risankizumab|Participants will have already been taking commercial risankizumab and will continue on commercial risankizumab. Participants will not be provided risankizumab from the study. Participants must have received at least 2 doses of 360 mg of risankizumab SC every 8 weeks postpartum prior to start of participation in this study.
40979040|NCT02447549|RADIATION|DART|Three plans (small, medium \& large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
40979041|NCT00280462|DRUG|Nifedipine (drug)|Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
40979042|NCT00280462|DRUG|L-Arginin (drug)|L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
40979043|NCT00280462|DRUG|Placebo|Placebo
40979044|NCT06003790|DEVICE|MR-001|Use of device 3 times per week for 8 weeks - for a total of 24 sessions.
41302211|NCT06416059|BEHAVIORAL|Mobile Application|The mobile application is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety,
40979045|NCT00426192|DRUG|i.v. mannitol|
41302212|NCT05118386|DRUG|RSM01|"Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 600 mg IM"
41302213|NCT05118386|OTHER|Placebo|"Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM"
41302214|NCT02843867|OTHER|blood sample|36 ml of blood sample at D0 and 1 year after transplantation
41302215|NCT04688346|DRUG|HemeRX epinephrine pellets|Racemic Epinephrine Pellet
41302216|NCT04534062|OTHER|PNF D2 technique|PNF D2 technique of bilateral upper limb will be performed
41302217|NCT04885491|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
41302218|NCT04885491|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
40775014|NCT03610048|DRUG|ALKS 5461|samidorphan + buprenorphine administered sublingually
40979046|NCT00426192|PROCEDURE|hemofiltration|
40979047|NCT03527966|BIOLOGICAL|5cc Vivigen and local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft
40979048|NCT03527966|BIOLOGICAL|Small kit rhBMP-2 with local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft
41302219|NCT04661930|DRUG|TriCor® 145mg tablets|Fenofibrate; 145 mg daily (1/day); oral administration; 10 days
41302220|NCT04661930|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
40979049|NCT01334814|DEVICE|Deep Brain Stimulation (Model 7438 Therapy Controller)|Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms
40979050|NCT04878588|OTHER|patients received high resolution impedance manometry|patients received the above two examination at the same time
40979051|NCT02865187|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 600IU/day
40979052|NCT02865187|DRUG|Hormonal contraception|Hormonal contraceptives
41302221|NCT04661930|OTHER|Usual care|All participants will otherwise receive usual medical care
41302222|NCT01916122|DRUG|Fluorestradiol (FES)|
41302223|NCT01916122|PROCEDURE|PET/CT Imaging|
41302224|NCT02794051|BEHAVIORAL|Group Therapy|Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
41302225|NCT02733692|BEHAVIORAL|Understanding Reproductive Health for Ladeez (GURHL) Code|Understanding Reproductive Health for Ladeez (GURHL) Code is an acceptability study to test a web-based application designed with and for young women of color 18 to 25 years old.
41302226|NCT06365814|OTHER|enhanced recovery after surgery|ERAS is a comprehensive perioperative interventions, including preoperative patient education, prehabilitation, nutritional support, minimally invasive surgery and other methods, can reduce surgical stress and promote patient recovery
40979053|NCT02884674|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
40979054|NCT02884674|DEVICE|Placebo Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
40979055|NCT01373372|DRUG|Acthrel|Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
41142320|NCT01672242|DEVICE|HFNC|Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
41302227|NCT06365814|OTHER|conventional perioperative management|conventional perioperative management
41302228|NCT04053543|DRUG|CXA-10|(10-nitro-9(E)-octadec-9enoic acid)
40775015|NCT03981276|OTHER|Clinical rating scale to measure disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
41461143|NCT01898234|DEVICE|Xevonta|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
40775016|NCT03981276|DIAGNOSTIC_TEST|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
40979056|NCT01288248|DEVICE|Airway laryngeal mask classic|"This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.~The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned"
40979057|NCT01288248|DEVICE|endotracheal tube|"This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.~The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age."
41142321|NCT01672242|DEVICE|CPAP|Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
41142322|NCT05201625|DIAGNOSTIC_TEST|real time PCR|real time PCR
41142323|NCT00423215|DRUG|Insulin glargine (LANTUS)|"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months."
41142324|NCT01787409|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
41142325|NCT01787409|OTHER|Laboratory Biomarker Analysis|Correlative studies
41142326|NCT03080337|OTHER|Group Care|Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
41142327|NCT02827110|DEVICE|fiberoptic bronchoscope|Tracheal intubation using fiberoptic bronchoscope
41142328|NCT02827110|DEVICE|pentax-airway scope|Tracheal intubation using pentax-AWS
40775017|NCT06253650|DRUG|Experimental|6 cycles of: T-DXd at the dose of 6.4 mg/kg intravenous every 3 weeks plus capecitabine 1000 mg/sqm BID orally on days 1-14 every 3 weeks or 5-fluorouracil 600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks as per Investigator's choice
40775018|NCT06253650|DRUG|Control|4 cycles of: 5-fluorouracil 2600 mg/m2 continuous intravenous infusion day 1 for 24 hours every 2 weeks, leucovorin 200 mg/m2 intravenous infusion on day 1 every 2 weeks, oxaliplatin 85 mg/m2 intravenous infusion on day 1 every 2 weeks, and docetaxel 50 mg/m2 intravenous infusion on day 1 every 2 weeks.
40979058|NCT06125587|DRUG|Chiglitazar|Chiglitazar is a novel PPAR agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization.
40979059|NCT06125587|DRUG|Metformin|Metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome.
40979060|NCT00017498|DRUG|gemcitabine hydrochloride|
41142329|NCT02827110|PROCEDURE|semi-rigid collar|semi-rigid collar immobilization of the cervical spine
41142330|NCT02313077|BIOLOGICAL|MVA-BN-filo|One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
41142331|NCT02313077|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
41142332|NCT02313077|OTHER|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
41142333|NCT00901459|DEVICE|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
41461144|NCT01898234|DEVICE|Helixone low flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
41461145|NCT06265558|PROCEDURE|Negative pressure therapy (NPT)|Negative pressure therapy (NPT) involves placing the surface of a wound under a pressure lower than the ambient atmospheric pressure. To achieve this, a specially designed dressing is connected to a vacuum source and an exudate collection system.
41461146|NCT06265558|PROCEDURE|Dressing|Fatty dressing or hydrocolloid dressing
40775019|NCT03205267|DRUG|Bosulif|Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to \<G2.
40775020|NCT00470015|BIOLOGICAL|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
40775021|NCT00470015|BIOLOGICAL|IL-2|0.5x10\^6/m\^2
40775022|NCT00470015|BIOLOGICAL|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
40775023|NCT00470015|BIOLOGICAL|GM-CSF|300mcg
40979061|NCT04204954|OTHER|Tea Tree Oil Shampoo|Twice a day eyelid margin cleansing for three days.
41142334|NCT00901459|DEVICE|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
41142335|NCT00901459|DEVICE|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
41142336|NCT04943614|OTHER|Biodex balance system|BIODEX stability system (BIODEX Medical Systems Inc; Shirley, New York) offers a system that can deliver particular hip and ankle postural training strategy with external biofeedback as a monitor to enhance the reduced subclinical limitations of patients with diabetic neuropathy
41142337|NCT04943614|OTHER|conventional exercises|balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program. Same duration treatment
41142338|NCT04803253|DEVICE|ORTHOPUS prosthetic accessory: 0109 - Universal Wrist|"The ORTHOPUS mechanical wrist device is intended to provide an external wrist joint only for external upper limb prostheses with pronation/supination passive motion (activation with external force), a quick connection (with automatic lock) and manual disconnection of the mechanical wrist connectors.~The mechanical wrist connector allows to quickly switch between different type of terminal devices (hand or tools)."
41142339|NCT04803253|DEVICE|ORTHOPUS prosthetic terminal device: 0112 - Hook|The ORTHOPUS body-powered hook is a Voluntary Opening (VO) device made of aluminium intended to provide high grasping capabilities under harsh environments.
41142340|NCT04803253|DEVICE|ORTHOPUS prosthetic terminal device: 0105 - Cosmetic Articulated Hand|The ORTHOPUS cosmetic articulated hand is intended to provide a replacement limb in order to hide the loss of the original one. It is composed of an aesthetic glove (18 colors and 3 sizes, silicone made) and of an internal structure that can be bent to achieve a given position allowing the user to grasp small and light objects.
41142341|NCT04803253|DEVICE|ORTHOPUS prosthetic accessory: 0104 - body powered harness|The ORTHOPUS body powered harness is intended to allow the patient to actuate the 0112 - Hook device. It will be installed on the patient's contralateral shoulder and linked to the 0112 - Hook device with a cable.
41142342|NCT05844306|PROCEDURE|Computed Tomography|Undergo \[18F\]-FDG PET-CT
40775024|NCT00470015|BIOLOGICAL|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
40775025|NCT01766102|PROCEDURE|Intra-operative Mammography|The patient's breast specimen will be imaged in the operating room in an intra-operative imaging device - Biovision SN #30042
40775026|NCT01766102|PROCEDURE|Standard Mammography|There is not an added device associated with this arm.
40775027|NCT03120845|PROCEDURE|One visit RCT|Root canal treatment in one vist
40775028|NCT03120845|PROCEDURE|Post operative pain in two-visits RCT|Root canal treatment in Two visits
40775029|NCT00725985|DRUG|Cladribine|Cladribine tablets were administered until CDMS conversion, whichever occur first.
40775030|NCT00725985|DRUG|Placebo|Placebo matched to cladribine tablets were administered.
40775031|NCT00725985|DRUG|Rebif® new formulation (RNF)|Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
40775032|NCT02196350|BEHAVIORAL|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
40775033|NCT02196350|BEHAVIORAL|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
40979062|NCT04204954|DRUG|Ciprofloxacin Ophthalmic Ointment 0.3%|Applied topically in the eyelid margin every four hours for three days.
40979063|NCT04204954|OTHER|Baby shampoo|Twice a day eyelid margin cleansing for three days.
40979064|NCT04204954|OTHER|Blephaclean|Twice a day eyelid margin cleansing for three days.
41142343|NCT05844306|OTHER|Fludeoxyglucose F-18|Given via injection
41142344|NCT05844306|OTHER|Medical Device Usage and Evaluation|Undergo X1 RMRS PET-CT
41142345|NCT05844306|DEVICE|Positron Emission Tomography|Undergo \[18F\]-FDG PET-CT
41142346|NCT01583855|PROCEDURE|Catheter ablation for atrial fibrillation, manual|Ablation for atrial fibrillation will be performed manually
41142347|NCT01583855|DEVICE|Ablation using Amigo remote catheter system|Atrial fibrillation ablation will be performed using the Amigo remote catheter system
41142348|NCT05142189|BIOLOGICAL|BNT116|intravenous injection
41142349|NCT05142189|BIOLOGICAL|Cemiplimab|intravenous infusion
40979065|NCT05422014|BEHAVIORAL|Life Care Specialist (LCS)|"Life Care Specialist (LCS) will :~* Provide patients with individualized risk assessment for opioid misuse.~* Act as patient's Pain Coach. Providing targeted education and behavior-based pain treatment options.~* Train and provide CWC evidence based non-pharmaceutical pain management techniques, using the Community Resiliency Model.~* Use the Opioid Risk Tool (ORT) as the method to identity the risk of substance misuse.~* Provide education, support and resources, as well as local, state, and national resources to enhance the whole health aspect of the position. These resources include but are not limited to: written documents that outline the key concepts of the pain management techniques taught by the LCS and a list of hotlines and websites.~* LCS, when applicable, will provide education for caretakers on the risk of opioid use and the non -pharmaceutical pain management protocol.~* Provide follow up for all patients in intervention group."
40979066|NCT01036035|DRUG|Tolterodine|Comparison of different dosages of drug
40979067|NCT01036035|DRUG|Pilocarpine|Comparison of different dosages of drug
40979068|NCT01036035|DRUG|THVD-201|Comparison of different dosages of drug
41461147|NCT05183451|PROCEDURE|En- masse retraction and LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs. LLLT will be applied on days 0,3,7,14 from extraction then repeated biweekly till the end of retraction."
41461148|NCT05183451|PROCEDURE|En- masse retraction without LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs."
41461149|NCT03275623|DRUG|Antibiotic|Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
41461150|NCT03275623|OTHER|Standard Prenatal Care|Continued surveillance of urinary cultures
41461151|NCT00198536|DRUG|Ecabet 2.83%|
41461152|NCT00198536|DRUG|Ecabet 3.70%|
40775034|NCT02196350|BEHAVIORAL|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
40775035|NCT00922961|BIOLOGICAL|Blood sample|Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
40775036|NCT00922961|PROCEDURE|Clinical exam|Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
40775037|NCT03817684|DRUG|BPN14770|Drug BPN14770
40775038|NCT03817684|DRUG|Placebo|Placebo
40775039|NCT05332704|DRUG|ONO-4685|-Part A: Single ascending doses of ONO-4685 as a single IV dose (Cohort A1-A5).
40775040|NCT05332704|DRUG|Placebo|-Part A: Single ascending doses of placebo as a single IV dose (Cohort A1-A5).
40775041|NCT05332704|DRUG|ONO-4685|-Part B: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort B1 and B2)
41302229|NCT01452958|BIOLOGICAL|TNF-alpha|Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
41302230|NCT01452958|BIOLOGICAL|Endotoxin|Study protocol 2:0,075 ng/kg/h intravenous
41302231|NCT04321694|DRUG|KHK2455|
41302232|NCT03965988|DRUG|DHA|Docosahexaenoic acid
41302233|NCT03965988|DRUG|Placebo|Placebo
40775042|NCT05332704|DRUG|Placebo|-Part B: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort B1 and B2).
40775043|NCT05332704|DRUG|ONO-4685|-Part C: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort C1 and C2).
40775044|NCT05332704|DRUG|Placebo|-Part C: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort C1 and C2).
40775045|NCT01230060|DEVICE|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
40775046|NCT04970914|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
40775047|NCT04970914|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
40979069|NCT01036035|DRUG|THVD-201|Comparison of different dosages of drug
40979070|NCT01036035|DRUG|placebo capsule|Comparison of different dosages of drug
40979071|NCT03330808|OTHER|Epidural anesthesia|After anesthesia induction, epidural catheter is inserted into lumbar epidural in epidural with general anesthesia group. A 10 ml of 0.2% ropivacaine should be given in epidural space via a catheter when anastomosis of free flap is finished in epidural with general anesthesia group.
40979072|NCT03815331|DRUG|Xiaflex®|medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced
40979073|NCT03815331|DRUG|Aveed|Aveed® is an FDA-approved medication for treatment of hypogonadism (low testosterone). It is not approved for the treatment of Peyronie's Disease. Aveed® 750 mg/3mL injection will be placed intramuscularly at the beginning of study, at four weeks, at 10 weeks thereafter.
40979074|NCT00789451|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
41142350|NCT05142189|DRUG|Docetaxel|intravenous infusion
41302234|NCT03971461|DRUG|Lutathera|administered intravenously every 8 weeks for a total of 4 doses
41461153|NCT00198536|DRUG|Vehicle|
40775048|NCT05901272|OTHER|Local clinical champion|A clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC.
40979075|NCT05728450|DEVICE|Light amplification by stimulated emission of radiation (LASER)|"* The points for application of laser acupuncture will be cleaned before application. All patients in the study group will be submitted to infrared diode laser, wavelength 808 nm, Pulse duration: 200 ms, Power density: 0.4 W/cm2, energy density 4 J/cm2 (Chow, 2001).~* The plug of the laser unit will inserted into the main current supply and on/off switch will be switched on. The therapy form will be selected from the main menu and then the parameters will be set.~* Acupuncture detector (Pointer Excel II) will be used for definite location of acupuncture points"
40979076|NCT03965910|OTHER|Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data|"Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic."
40979077|NCT00829946|BEHAVIORAL|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of \~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
40979078|NCT03643094|DIETARY_SUPPLEMENT|Golden Black Seed|1 capsule per day for 8 weeks.
40979079|NCT03630627|DRUG|SB26|SB26 administered intravenously
40979080|NCT03630627|DRUG|Placebo|Placebo administered intravenously
40979081|NCT04202692|DEVICE|Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
40979082|NCT04202692|DEVICE|Placebo 1100 mg, identically-looking melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
40979083|NCT02890706|DEVICE|Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography|Compare two techniques of the CT scanner
40979084|NCT00180414|DEVICE|CRT devices with ventricular rate regulation [VRR] (CE labeled)|
40979085|NCT00863603|OTHER|oxygen|5 Liter/minute by nasal cannula for 6 wks
40979086|NCT06493721|PROCEDURE|Clear Aligner Treatment|Clear aligner therapy to treat incisors crowding
40979087|NCT06493721|PROCEDURE|Low level laser|Apply clear aligner therapy with low level laser application on incisors
40979088|NCT02242409|DRUG|Gemcitabine and Abraxane|Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
40979089|NCT00563251|DRUG|Azithromycin|
40775049|NCT05901272|OTHER|Learning collaborative|Learning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation.
40979090|NCT00563251|DRUG|Placebo tablet|
40979091|NCT05548725|OTHER|Reguired field|Investigations to know relationship between acute kidney injury and mineral bone disease
40979092|NCT02430584|OTHER|Observational - no intervention|
40979093|NCT02529514|DRUG|Baclofen|25 mg for 7 days at 10 pm every day
40979094|NCT02529514|DRUG|Placebo|Placebo for 7 days at 10 pm every day
40979095|NCT01359657|BIOLOGICAL|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
40979096|NCT01359657|BIOLOGICAL|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
40979097|NCT01359657|BIOLOGICAL|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
40979098|NCT01359657|BIOLOGICAL|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
40979099|NCT01359657|BIOLOGICAL|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
40979100|NCT01359657|BIOLOGICAL|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
40979101|NCT01988805|OTHER|Blood Draw|
40775050|NCT05901272|OTHER|External facilitation|. External facilitation will be provided by a trained external facilitator who is given the HITIDES Operations Guide and Consumer Voice tools for Veteran engagement in quality improvement. Facilitation is a process to enable sites to increase uptake of HITIDES through supportive relationships and strategies to navigate the implementation process. Virtual external facilitation is a recognized modality of facilitation delivery in VHA. The external facilitator will work with the clinical champion, site personnel, and Veterans-not conducting research activities but engaging in quality improvement processes with these individuals. The addition of a facilitator allows problem identification and problem-solving, using processes based on supportive relationships.
40775051|NCT05002725|DRUG|Lidocain|300mg (20ml) will be injected
40775052|NCT02010502|DIETARY_SUPPLEMENT|Beetroot juice|
40979102|NCT01641770|OTHER|Nutritional beverage 10003RF|2 sachets per day
40979103|NCT01641770|OTHER|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
40979104|NCT01641770|OTHER|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
40979105|NCT02953054|DRUG|DMTS|DMTS applied before surgery and worn for 72 hours
40979106|NCT02953054|DRUG|Placebo|Matching patches that have no active drug applied before surgery and worn for 72 hours.
40775053|NCT02010502|DIETARY_SUPPLEMENT|Beetroot powder|
40775054|NCT02010502|DIETARY_SUPPLEMENT|Placebo|
40775055|NCT01342055|DRUG|Apetrol ES|sequences of administered drugs
40775056|NCT06022640|BEHAVIORAL|Educational and supportive care|The trial had a total of 75 participants assigned to the intervention group, whereby they were provided with an educative and supporting program specifically developed by a clinical pharmacist. The intervention group was provided with assistance via a series of five visits, which included an initial visit upon admission, subsequent visits for monitoring medication, ovulation, and negative effects, as well as visits dedicated to giving emotional support. Additionally, a follow-up visit was conducted after the egg collecting process and embryo transfer.
40775057|NCT05242939|OTHER|Video game|The child will be allowed to play the game they want to play throughout the entire procedure, starting 5 minutes before the inhalation therapy. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
40775058|NCT05242939|OTHER|Watching cartoons|The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
40775059|NCT00499044|OTHER|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
40775060|NCT00499044|OTHER|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
40979107|NCT02642614|DRUG|BI 1026706|
40979108|NCT02642614|DRUG|Placebo|
40979109|NCT02642614|DRUG|Placebo|For blinding purposes
40979110|NCT03149185|BEHAVIORAL|Technology based cognitive behavioral stress management|Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
40979111|NCT03149185|BEHAVIORAL|Technology based health promotion group-based attention matched control condition|Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
40979112|NCT03251768|DRUG|rHSA-GCSF 2.4mg|Human Serum Albumin GCSF 2.4mg at day 3 and day 7
40979113|NCT03251768|DRUG|GCSF|GCSF 5 mcg/kg/day
41142351|NCT05142189|DRUG|Carboplatin|intravenous infusion
41142352|NCT05142189|DRUG|Paclitaxel|intravenous infusion
41142353|NCT05142189|BIOLOGICAL|CTLA4 antibody|intravenous infusion
41142354|NCT04222400|DIAGNOSTIC_TEST|Frailty Assessment|Bioelectrical Impedance Analysis 6 Minute Walk Test Grip Strength Questionnaires Muscle Mass Evaluation via CT
41142355|NCT04518865|DEVICE|Herbst appliance|The bottom line of the study is to investigate the changes after Herbst appliance treatment and relate it to the pubertal status of the skeletal class II patients using CBCT.
40775061|NCT05672901|DEVICE|StrataMGT|StrataMGT is a 100% medical grade film-forming silicone gel for the treatment of cutaneous skin lesions and Genitourinary Syndrome of Menopause. StrataMGT is a flexible wound dressing used on compromised skin. It dries to form a thin, flexible wound dressing which hydrates and protects affected areas. StrataMGT is used to relieve low grade inflammatory changes such as dry, itching, flaking, peeling and irritated skin. StrataMGT is designed for partially epithelized skin and is suitable for children and patients with sensitive skin.
40775062|NCT05672901|DRUG|Estrace 0.01% Vaginal Cream|Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
40775063|NCT03276442|OTHER|Low-fat dietary intervention|Low-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
40775064|NCT03276442|OTHER|High-fat dietary intervention|High-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
40775065|NCT06087835|DRUG|Zibotentan/Dapagliflozin|Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
40775066|NCT06087835|DRUG|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized to
40775067|NCT01798602|DRUG|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
40775068|NCT01798602|DRUG|Placebo|Identical placebo for rosuvastatin
40775069|NCT05205863|BIOLOGICAL|Cofact|Human prothrombin complex concentrate
40775070|NCT00222820|DRUG|escitalopram|
40775071|NCT00222820|BEHAVIORAL|Interpersonal Psychotherapy|
40775072|NCT04345393|BEHAVIORAL|Digital Transformation Network (DTN) Program|Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.
40775073|NCT03007433|OTHER|400ml of Liquid Nutrient Drink|12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
40979114|NCT02622516|OTHER|Intervention Group (IG)|"Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
41142356|NCT06092905|OTHER|Endoscopic clearance of common bile duct stones|Under general anesthesia, in left lateral decubitus, endoscopic clearance of common bile duct stones was done. Ultrasonography was used to ensure right positioning of the guide wire in the common bile duct, and ensure stone clearance.
41461154|NCT03252717|BIOLOGICAL|Blood sample|"Pre-treatment blood samples will be collected for downstream analyses:~* Three 6 ml EDTA samples for proteomic and genomic work package~* One 6 ml dry sample for auto-antibodies analysis in the immunology work package~* Two 4 ml EDTA samples for DNA extraction in the immunology work package~* Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package"
41461155|NCT06094894|OTHER|sucralose|Food additive used to replace sugar providing a sweet taste without calories.
41461156|NCT06094894|OTHER|placebo|Cornstarch without significant physiological effects
41461157|NCT02228889|PROCEDURE|Abdominal wall reconstruction with Strattice|Abdominal wall reconstruction using Strattice
40775074|NCT02167776|BEHAVIORAL|Church-based teaching|In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
40775075|NCT00460213|DRUG|Valsartan 80mg daily|
40775076|NCT00460213|DRUG|Valsartan 160mg daily|
40775077|NCT03586921|BEHAVIORAL|Psychosocial Group Intervention|The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party.
40979115|NCT02622516|OTHER|Control Group (CG)|"The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
40775078|NCT03586921|OTHER|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
40775079|NCT00763828|DEVICE|Life Recovery Systems ThermoSuit|Hypothermia induction (cooling to 32 to 34 degrees C core temperature) using the Life Recovery Systems ThermoSuit System (a device which cools patients using direct skin contact with cold water) followed by PCI (percutaneous coronary intervention) and maintenance of hypothermia for 3 hours following PCI.
40775080|NCT05325684|DRUG|PD-L1 inhibitor|Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day as a cycle.)
40775081|NCT06537791|BEHAVIORAL|Home-Based Rehabilitation Program|Physical Therapy: 32 sessions, 60 minutes each Occupational Therapy: 8 sessions, 60 minutes each Nutrition Counseling: 4 sessions, 60 minutes each Psychological Support: 8 sessions, 60 minutes each Nursing and Podiatry Care: 4 sessions, 60 minutes each Total Duration: Approximately 4 months
40979116|NCT04271605|BEHAVIORAL|diet and exercise suggestion|diet and exercise suggestion according to blood biochemistry data and bone mineral density
40979117|NCT04362787|DEVICE|High pressure non invasive ventilation in acute hypercapnic respiratory failure|Usage of High pressure non invasive ventilation in acute hypercapnic respiratory failure
40775082|NCT02399852|DRUG|Lomitapide|
40775083|NCT06079983|DRUG|JSKN003|Administered intravenously according to protocol.
40979118|NCT05802667|DIAGNOSTIC_TEST|Tryptase|Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa
40979119|NCT05550402|DRUG|Salbutamol|Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
40979120|NCT05550402|DRUG|Ipratropium Bromide|Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
40979121|NCT05550402|DRUG|Salbutamol plus Ipratropium Bromide|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)
40979122|NCT05550402|OTHER|Placebo|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
40979123|NCT04159844|DEVICE|URGOBD001|Application with 50% overlapping
40979124|NCT04159844|DEVICE|URGOBD001 associated with wading|Application with 50% overlapping in association with wading
40979125|NCT00433849|DRUG|R744|100μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
40979126|NCT00433849|DRUG|R744|150μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
40775084|NCT06079983|DRUG|Capecitabine tablets|Administered according to protocol, as one option for investigator's choice (determined before randomization).
40775085|NCT06079983|DRUG|Gemcitabine hydrochloride for injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
40979127|NCT05546567|DIETARY_SUPPLEMENT|Nicotinamide Riboside|1200mg x1 Nicotinamide Riboside
41142357|NCT06355934|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
40775086|NCT06079983|DRUG|Vinorelbine tartrate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
40979128|NCT02724475|PROCEDURE|LA|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated
40979129|NCT02724475|PROCEDURE|3D-CRT|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
40979130|NCT06469866|DEVICE|low-pressure pneumoperitoneum|low-pressure pneumoperitoneum (LPP) with deep NMB.
40979131|NCT06469866|DEVICE|standard-pressure pneumoperitoneum|standard-pressure pneumoperitoneum (SPP) with moderate NMB.
40979132|NCT05744544|PROCEDURE|External Oblique Block|Patients will be followed after EOIB which are routinely performed in our clinic.
40775087|NCT06079983|DRUG|Paclitaxel for injection (albumin-bound type)|Administered according to protocol, as one option for investigator's choice (determined before randomization).
40979133|NCT05744544|PROCEDURE|m-TAPA block|m-TAPA block
40979134|NCT01628601|DRUG|Fixed combination 0.3 mg bimatoprost and 5 mg timolol|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
40979135|NCT06175260|DIAGNOSTIC_TEST|oral carnitine challenge test|Urine samples will be collected to quantify trimethylamine N-oxide (TMAO) levels at four time points: before, and 24, 48, and 72 hours after the oral administration of 1500 mg of L-carnitine.
41142358|NCT05073393|BEHAVIORAL|Sugar stress|Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
40775088|NCT06079983|DRUG|Docetaxel injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
40775089|NCT06079983|DRUG|Eribulin mesylate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
40775090|NCT03524066|DRUG|Inhalation|Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation
40775091|NCT03524066|DRUG|Systemic|Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally
40775092|NCT03524066|OTHER|Bronchoscopy|Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy
40775093|NCT02457065|BEHAVIORAL|"Melanoma Survivor plaque"|The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
40775094|NCT03182855|DRUG|Ticagrelor|ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
40775095|NCT03182855|DRUG|Cangrelor Tetrasodium|Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
40775096|NCT05751109|PROCEDURE|ipack+adduktor kanal|nerve block
40775097|NCT06109935|DRUG|Somapacitan|Sogroya® treatment regimen will be in accordance with the approved product labelling in Japan.
40775098|NCT03741673|OTHER|Quality-of-Life Assessment|Ancillary studies
40775099|NCT03741673|OTHER|Questionnaire Administration|Ancillary studies
40775100|NCT03741673|RADIATION|Stereotactic Radiosurgery|Undergo SRS
40979136|NCT05352334|DIAGNOSTIC_TEST|self-report Emotional Intelligence test (SSCEIT)|The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.
40979137|NCT06494683|DRUG|Pueraria lobata radix|The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.
40979138|NCT04737343|DRUG|Leflunomide|Patient will be treated with Leflunomide(Tuoshu, the commericial name) 30mg QD for 18 months
40979139|NCT04737343|DRUG|Azathioprine Tablets|Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
40979140|NCT00128778|DRUG|Pegylated liposomal doxorubicin|
40979141|NCT00884312|DRUG|Carfilzomib|Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
40979142|NCT00523354|DRUG|Infliximab|Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
40979143|NCT05067829|DEVICE|Train of four(TOF)|Train of four(TOF) monitoring after anesthesia induction
40979144|NCT02746016|OTHER|Infant Formula supplemented with Oligosaccharides|sole source nutrition
40979145|NCT01128257|DRUG|alendronate|As prescribed by physician
40979146|NCT01128257|DRUG|ibandronate [Bonviva/Boniva]|As prescribed by physician
40979147|NCT01668550|DRUG|AZD0424|"AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.~Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date."
41142359|NCT04037072|DRUG|Mitomycin C|Topical application of Mytomycin C (MMC)
41142360|NCT04037072|OTHER|Control|Topical application of Normal Saline
41142361|NCT00457314|BEHAVIORAL|Exercise|Regular exercise training
40979148|NCT02409992|BEHAVIORAL|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.
40979149|NCT02409992|BEHAVIORAL|Parent Training only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
41461158|NCT02228889|OTHER|Assess pain intensity at last office visit preoperatively|Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
41461159|NCT02228889|OTHER|Assess pain interference at last office visit preoperatively|Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
41461160|NCT02228889|OTHER|Assess physical functioning at last office visit preoperatively|Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
41461161|NCT02228889|OTHER|Assess patient quality of life at last office visit preoperatively|Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
40979150|NCT01214356|DIETARY_SUPPLEMENT|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
41461162|NCT02228889|OTHER|Assess patient pain intensity postoperatively|Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
41461163|NCT02228889|OTHER|Assess pain interference postoperatively|Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
41461164|NCT02228889|OTHER|Assess physical functioning postoperatively|Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
41461165|NCT02228889|OTHER|Assess quality of life postoperatively|Assess quality of life at 1 year postoperatively using the HerQLes survey
41461166|NCT02228889|OTHER|Assess hernia recurrence at 30 days postoperatively|Assess hernia recurrence at 30 days
41461167|NCT02228889|OTHER|Assess bulge at 30 days postoperatively|Assess bulge at 30 days
41461168|NCT02228889|OTHER|Assess Surgical Site Occurrences at 30 days postoperatively|Assess Surgical Site Occurrences at 30 days
41461169|NCT02228889|OTHER|Assess hernia recurrence at 1 year postoperatively|Assess hernia recurrence at 1 year postoperatively
41461170|NCT02228889|OTHER|Assess bulge at 1 year postoperatively|Assess bulge at 1 year postoperatively
41461171|NCT02228889|OTHER|Assess Surgical Site Occurrences at 1 year postoperatively|Assess Surgical Site Occurrences at 1 year postoperatively
41461172|NCT02228889|OTHER|Assess overall complications at 30 days postoperatively|
41461173|NCT02228889|OTHER|Assess overall complications at 1 year postoperatively|
41461174|NCT02228889|PROCEDURE|Abdominal wall reconstruction with XenMatrix|Abdominal wall reconstruction with XenMatrix
40979151|NCT01214356|DIETARY_SUPPLEMENT|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
41461175|NCT02228889|DEVICE|Strattice|Strattice mesh
41461176|NCT02228889|DEVICE|XenMatrix|Xenmatrix mesh
41461177|NCT01609270|DEVICE|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
41461178|NCT05400798|DEVICE|Adipose Derived Regenerative Cells|single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear
41461179|NCT05400798|DEVICE|Corticosteroid|a single corticosteroid injection into the associated subacromial space
41461180|NCT00052949|DRUG|imatinib mesylate|Given orally
41461181|NCT00052949|OTHER|laboratory biomarker analysis|Correlative studies
41461182|NCT04305990|DEVICE|Demand-driven delivery method|The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.
41461183|NCT04305990|DEVICE|Free-flow delivery method|The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.
41142362|NCT04022707|OTHER|High-speed circuit resistance training|The program will include three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three week from 1 to 3 circuits.
41142363|NCT04022707|OTHER|Educational control|Lectures on health and fitness
41142364|NCT04712032|DRUG|ICG-guided bowel perfusion assessment|ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.
41142365|NCT02045914|OTHER|calcium ionophore solution|After microinjection of sperm into the oocyte, oocytes are incubated for 15 minutes in a 30 microlitre droplet of calcium ionomycin solution
41461184|NCT00867854|OTHER|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
41461185|NCT05003882|OTHER|Commercially available, orally ingestible CBD product|botanically-derived CBD extract product
41461186|NCT04334096|BEHAVIORAL|quality of life pathway|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
41461187|NCT04485819|OTHER|Cleavage stage transfer|transferring embryos through ICSI procedures for poor responders on cleavage stage of embryonic development.
40979152|NCT04669639|OTHER|Block procedures for shoulder surgery analgesia|"The patients in group (a) will be placed in lateral decubitus. Then, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used to locate the transverse process of T2, where a needle will be inserted in a cephalocaudal direction until reaching the space between the fascia of the erector spinae and the transverse process of T2 and 30 ml of local anesthetic of bupivacaine 0.5% will be injected.~* In group (b), SSC nerve block will be done as follow: In the suprascapular notch, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used. The linear probe, enveloped in a sterile sheath, will be placed parallel to the spine of the scapula to visualize it and then will be moved cephalic to the supraspinatus fossa. The probe will then be moved laterally up to the scapular notch, where the nerve will be identified by its round hyperechogenic shape 4 cm deep.~* control group: patients will receive only general anesthesia"
40979153|NCT04044716|DEVICE|Auricular acupressure|Trained nurses in auricular acupressure will place acupressure beads on 5 acupoints on each ear (cingulate gyrus, thalamus, omega-2, point zero, and Shen Men). The nurse will do the initial activation of the acupressure site by applying pressure for 30 seconds to each point until the participant reports tingling or moderate degree of pressure. Participant will be given instructions to do this three times a day for a total of 5 days. Acupoints were selected based on recommendation of faculty acupuncturist.
40775101|NCT05526729|OTHER|Beovu|Prospective observational study. There is no treatment allocation. Patients prescribed with Beovu for the first time for diabetic macular edema are eligible to enroll into this study.
40775102|NCT01313533|DRUG|Polyarginine|Vein soak treated with polyarginine
40775103|NCT01313533|DRUG|Vein soak treated with Lactated Ringers Solution|Vein soak
40775104|NCT05391776|DRUG|TST002 Injection|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
40979154|NCT04044716|OTHER|Standard of care pain management|The participant post-operative pain will be managed following the standard protocol by the treating physician.
40979155|NCT00036504|DRUG|Insulin Lispro low mixture|
40979156|NCT02579044|DRUG|Everolimus and lonafarnib|
40979157|NCT02562430|DRUG|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
40979158|NCT02562430|DRUG|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
40979159|NCT04045340|DEVICE|Philips QLAB Ultrasound Quantification Software|Offline processing of intraoperative transesophageal echocardiography would be performed with Global Longitudinal Strain on apical 4 chamber, apical 2 chamber and long axis views in order to analyze left ventricle and left atrium contractility and right ventricle free wall motion
40979160|NCT02845453|DRUG|Quetiapine|Participants will be randomly assigned Quetiapine and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
40979161|NCT02845453|OTHER|Placebo|Participants will be randomly assigned to placebo and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
40979162|NCT00820131|PROCEDURE|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
40979163|NCT00820131|PROCEDURE|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
40979164|NCT05947370|DRUG|Berberine Chloride|Traditional Chinese medicine
40979165|NCT05947370|DRUG|Placebo|Placebo control
40979166|NCT00848367|BEHAVIORAL|Group Psychodynamic Interpersonal Psychotherapy|This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.
40979167|NCT01659775|DRUG|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy."
40979168|NCT01659775|DRUG|Zofran inj.+Zofran tab.|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5."
40979169|NCT00594984|DRUG|Cetuximab|IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
40979170|NCT00594984|DRUG|Irinotecan|IV solution, IV, Q3W, 350 mg/m2, until progression
41142366|NCT06517576|DEVICE|Blood glucose monitor with Digital Platform and Health Coaching|Blood glucose monitors will be used daily to measure blood glucose measurements.
41142367|NCT06517576|DEVICE|Continuous glucose monitor|Continuous glucose monitors will be used daily to measure blood glucose measurements.
41142368|NCT06517576|OTHER|Usual Care|Usual care for type 2 diabetes
41142369|NCT03376763|DRUG|Abilify maintena|Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)
41142370|NCT06541795|DEVICE|AcrySof IQ Vivity Extended Vision IOL|UV-absorbing, with or without blue light filtering, foldable IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients from whom a cataractous lens has been removed. The IOL mitigates the effects of presbyopia by providing an extended depth of focus. The toric models in addition reduce residual refractive astigmatism in patients with pre-existing corneal astigmatism.
41146954|NCT03800563|DEVICE|LipoLife system|Abdominal/ Outer thighs Laser Assisted Liposuction. Five to twenty subjects out of the study group will also undergo facial fat grafting.
41302235|NCT04868461|DIETARY_SUPPLEMENT|Unheated Whey Protein (UWP) beverage|The preload is made from whey protein powder. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
40775105|NCT05391776|DRUG|placebo|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
40979171|NCT00594984|DRUG|Brivanib|Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
40979172|NCT00594984|DRUG|Brivanib|Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
41302236|NCT04868461|DIETARY_SUPPLEMENT|Heated Whey Protein (HWP) beverage|The preload is made from whey protein powder of 95% and it is heated for a certain amount of time. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
40979173|NCT00594984|DRUG|Brivanib Placebo|Oral, tablet, QD, until progression
40979174|NCT04891783|DEVICE|ultrasonography|The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus\[26\]. Plaque is defined as a focal protrusion in the lumen at least cIMT\>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching \>0.5 mm \[26\]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .
40979175|NCT03779204|BEHAVIORAL|Mentorship|The mentors will be encouraged to incorporate the key relationship-based components of natural mentors (e.g., a 'coach' or 'cheerleader' role) to assist with mainstream integration. The mentors will have more flexibility than a typical formal mentorship program in the types of activities they pursue with their mentees. They will not be mandated to attend shelter-based social events, but rather engage in activities that direct their mentees away from the shelter system (and their old identities as homeless youth) and toward the mainstream (e.g., meeting for coffee at a local university campus). All of the mentors will meet monthly with their mentees for two years. In addition, the mentor will be encouraged to touch base with their mentee via phone or text message every week. If a mentor is unable to continue their role and there are at least six months left in the study, the study participant will be matched with a new mentor.
40979176|NCT03779204|BEHAVIORAL|Rent Subsidies|Participants will receive rent subsidies ($500 for those living in Toronto, $400 for those living in Hamilton or St. Catherine's due to differences in cost of living) for 24 months.
40775106|NCT03827317|RADIATION|[18F]GE-226|\[18F\]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
40775107|NCT01103414|DRUG|Mitoglitazone|50 mg capsules, once daily for 84 days
40775108|NCT01103414|DRUG|Mitoglitazone|Mitoglitazone 100 mg capsules, once daily for 84 days
40979177|NCT02335723|DEVICE|Alteco LPS Adsorber|"Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species."
40979178|NCT02335723|DEVICE|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
40979179|NCT01503268|DEVICE|Implantation of implantable loop recorder|An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
40979180|NCT01503268|PROCEDURE|Percutaneous ablation of atrial fibrillation|Catheter-based percutaneous ablation of atrial fibrillation
40775109|NCT01103414|DRUG|Mitoglitazone|Mitoglitazone 150 mg capsules, once daily for 84 days
40775110|NCT01103414|DRUG|Pioglitazone|Pioglitazone 45 mg, once daily for 84 days
40775111|NCT01103414|DRUG|Placebo|Placebo, once daily for 84 days
40979181|NCT01503268|PROCEDURE|Surgical ablation of atrial fibrillation|Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
40979182|NCT00468416|DEVICE|Compression Anastomosis Ring (CAR)|
41142371|NCT02734784|PROCEDURE|Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
41146955|NCT05360771|DEVICE|SnowyTM PFO closure system|Percutaneously occlusion of PFO with SnowyTM PFO closure system
41302237|NCT04868461|DIETARY_SUPPLEMENT|Casein (Cas) beverage|The preload is made from casein powder. The energy load of the preload is 105 kcal and has banana flavor and sweetener.
41302238|NCT04868461|DIETARY_SUPPLEMENT|Water|The preload is water acting as a control and contain the same banana flavor and sweetener to match the other three intervention - protein beverages.
40775112|NCT06153563|OTHER|Data collection on patient history and intraoperative results.|Data collection on patient history and intraoperative results.
40775113|NCT02489084|OTHER|Blood sampling|
40775114|NCT00005835|DRUG|buthionine sulfoximine|Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.
40775115|NCT00005835|DRUG|melphalan|The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.
40775116|NCT00005835|PROCEDURE|Peripheral blood stem cell infusion|Stem cells will be infused intravenously on day 0 , 24 hours after BSO continuous infusion is completed.Infused within 1.5 hours of thawing via a central venous catheter over 15-30 minutes.
40775117|NCT00005835|OTHER|Filgrastim|5 microgram/kg/day , subcutaneous or intravenous, given daily beginning day 0. First dose to begin 4 hours after completion of stem cell infusion and then to continue till ANC \>/= 1500 mm3 for three consecutive days.
40775118|NCT02398019|DEVICE|OXIRIS®|"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[OXIRIS® (Baxter Gambro)\].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
40775119|NCT02644551|DRUG|CELEXT07|
40775120|NCT02644551|DRUG|Penlac|
40775121|NCT02644551|OTHER|vehicle solution|
40775122|NCT00158106|PROCEDURE|Speech and Language therapy for dysarthria and/or aphasia|
40775123|NCT03615885|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Capsules|Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.
40979183|NCT02069301|BEHAVIORAL|Integrated Depression/Microfinance Group|LIFE-DM Integrated Depression and Microfinance group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
40979184|NCT02069301|OTHER|Treatment as Usual|National Guideline for antidepressant care
40775124|NCT03615885|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
40775125|NCT03615885|DIETARY_SUPPLEMENT|Placebo|"130ml serving~Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
40775126|NCT00441025|DRUG|Alemtuzumab|
40775127|NCT06450743|DIAGNOSTIC_TEST|Lymphocyte Immunophenotyping Test|Absolute enumeration of peripheral blood lymphocyte subpopulations
40979185|NCT02069301|OTHER|Livelihood Support|Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
40979186|NCT00941473|DRUG|Triamcinilone (kenalog)|Epidural steroid injection of 80mg of Triamcinilone.
40979187|NCT01936688|DRUG|MK-3222 200 mg|MK-3222 200 mg administered SC.
40979188|NCT01936688|DRUG|MK-3222 100 mg|MK-3222 100 mg administered SC.
40979189|NCT01936688|DRUG|Placebo to MK-3222|Matching placebo to MK-3222 administered SC.
40979190|NCT01936688|DRUG|Placebo to Etanercept|Matching placebo to etanercept for subcutaneous injection.
40979191|NCT01936688|DRUG|Etanercept 50 mg|Etanercept 50 mg for subcutaneous injection.
40775128|NCT01676233|DRUG|insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
40775129|NCT01676233|DRUG|insulin glargine- new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
40775130|NCT06341647|DRUG|AB-201|NK Cell Therapy
40775131|NCT06341647|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
40775132|NCT06341647|DRUG|Fludarabine|Lymphodepleting chemotherapy
40775133|NCT04143776|PROCEDURE|Abdominal reconstruction|No restrictions are set on surgical procedures or anaesthetic management.
40979192|NCT02589574|OTHER|electronic text message|"Besides the reminder of the free vaccination, the messages included information that vaccination reduces the personal risk of influenza illness. It also reduces the risk to infect patients and family members. It is also the social expectation on and professional as well as personal responsibility of nurses in protecting own selves and their patients from contacting influenza.~it is a safe vaccine. The reminders are developed with reference to promotion messages from Hospital Authority."
40979193|NCT01094223|BEHAVIORAL|Mindfulness Based Relapse Prevention|Meditation based therapy group incorporating relapse prevention skills training
40979194|NCT01094223|BEHAVIORAL|Health Education|Psychoeducation group focused on various topics pertaining to physical health
40979195|NCT03358290|DRUG|JTE-051|Active drug tablets containing JTE-051
40979196|NCT03358290|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
40775134|NCT02714348|OTHER|Effect of helminth infection on vaccine immunogenicity|Observational; immunology
40775135|NCT00506623|DRUG|Capecitabine, Irinotecan|
40775136|NCT01737905|DRUG|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
40775137|NCT01737905|DRUG|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
40775138|NCT05950321|PROCEDURE|Paramedian cervical epidural steroid injection|For paramedian cervical epidural steroid injection, the cervical 7 (C7) - thoracic 1 (T1) interval is determined by taking an appropriate angle with C-arm fluoroscopy to determine the interlaminar space from the posterior cervical region. The epidural space is recognized by the negative pressure reflected on the resistance syringe.
40775139|NCT05950321|PROCEDURE|Selective nerve root pulsed radiofrequency|For selective nerve root PRF, an 8-12 Hz linear ultrasound probe is first placed posterolateral to the neck. The level of the cervical nerve roots is determined according to the morphology of the anterior and posterior vertebral tubercles. The corresponding nerve root is visualized hypoechoically between the tubercles. The radiofrequency cannula is inserted in the same plane as the ultrasound probe (in plane) and the relevant nerve root is approached. Pulsed radiofrequency current, which has therapeutic properties in chronic pain, is applied to the relevant nerve root for 240 seconds.
40775140|NCT06416475|DIETARY_SUPPLEMENT|Mankai supplementation|The overall dose of the three Mankai duckweed beverages/day contains \~10 grams of dry matter.
40775141|NCT06416475|OTHER|Water consumption|Water consumption
40775142|NCT05056857|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
40979197|NCT01147029|DRUG|angiogenesis inhibitor GSAO|
40979198|NCT01147029|OTHER|laboratory biomarker analysis|
40979199|NCT01147029|OTHER|pharmacological study|
40979200|NCT01147029|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
41142372|NCT02734784|PROCEDURE|Sham Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
40979201|NCT06463327|DRUG|TCB008|TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
40979202|NCT00492661|DRUG|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
40979203|NCT00710710|DRUG|BI 2536|Intravenous Infusion
40979204|NCT03266107|DEVICE|Intracept|Radiofrequency ablation of the basivertebral nerve using the Intracept System
40979205|NCT02070692|DRUG|Tamoxifen|7 day course of tamoxifen during an episode of irregular vaginal bleeding
40979206|NCT02070692|DRUG|Placebo|7 day course of placebo during an episode of irregular vaginal bleeding
40979207|NCT03859349|DIAGNOSTIC_TEST|Selective Targeted Sampling|After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
40979208|NCT03859349|DIAGNOSTIC_TEST|Systematic Sampling|Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
40979209|NCT01690247|DRUG|Conventional plus UC-MSC|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
41302239|NCT05433389|BEHAVIORAL|Breath Counting|Patients will listen to a 5-minute, audio-recorded breath counting practice.
41302240|NCT05433389|BEHAVIORAL|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
41302241|NCT05433389|BEHAVIORAL|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
41461188|NCT04485819|OTHER|Blast stage transfer|transferring embryos through ICSI procedures for poor responders on blast stage of embryonic development.
40775143|NCT05056857|OTHER|Electronic Health Record Review|Medical charts are reviewed
40979210|NCT01690247|DRUG|Conventional plus placebo|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
40979211|NCT05571098|BEHAVIORAL|individualized colorectal cancer education|"Subjects taught within the scope of individualized colorectal cancer education:~* Common symptoms and management related to disease and treatment,~* Importance of nutrition in the treatment process."
40979212|NCT05571098|BEHAVIORAL|psycho-oncological counseling|"Topics discussed within the scope of psycho-oncological counseling:~* Psychological state (anxiety, depression, etc.),~* Coping strategies about the process,~* Presence of fear about the disease and/or treatment,~* Lifestyle changes/problems,~* Changes in body image,~* Family/friendship/work-related concerns,~* Additional issues, comments he wishes to convey"
41142373|NCT06022653|OTHER|Treatment|EVAR,TEVAR,PTA
41142374|NCT02346786|DIETARY_SUPPLEMENT|eau minérale d'Aix-Les-Bains|Sodium 0.44 mg Magnésium 2.25 mg Phosphore 0.003 mg Potassium 0.08 mg Calcium 8.23 mg Manganèse 0.0001 mg Fer 0.001 mg Cuivre 0.0005 mg Zinc 0.0005 mg Sélénium 1 µg Iode 0 µg
41302242|NCT05433389|BEHAVIORAL|Mindfulness of Pain|Patients will listen to a 5-minute, audio-recorded mindfulness of pain practice.
41302243|NCT05433389|BEHAVIORAL|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
40775144|NCT00293176|DRUG|Donepezil Hydrochloride|Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
40775145|NCT00293176|DRUG|Placebo|Subjects will receive matching placebo tablets.
40775146|NCT04801576|OTHER|Flouride in mouthrinses|Custom made toothpastes and mouthrinses that do or do not contain flouride as sodium fluoride in different concentrations.
41142375|NCT02346786|DIETARY_SUPPLEMENT|tap water|
41142376|NCT01039909|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
41142377|NCT01039909|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
41142378|NCT01709630|DRUG|Magnesium sulfate infusion|Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
41302244|NCT04293042|BIOLOGICAL|BK-virus specific CTLs|"HLA Matched Related Donors: BK-virus specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~HLA Mismatched Related Donors: BK-virus specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
41461189|NCT00865449|DRUG|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
41461190|NCT00865449|DRUG|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
41142379|NCT06558279|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
41142380|NCT06558279|OTHER|Placebo PH20 SC|Subcutaneous placebo PH20 SC given by prefilled syringe
41142381|NCT01826994|DEVICE|heart type fatty acid binding protein testing|
41142382|NCT00169923|DRUG|rosiglitazone|
41142383|NCT02346409|DEVICE|tACS of the cerebellum|tACS of the cerebellum
40775147|NCT04801576|OTHER|Placebo mouthrinse|Mouthrinses without flouride
40775148|NCT02676037|DEVICE|foot pressure plate form|
40775149|NCT04066959|BEHAVIORAL|Motivational Enhancement System (MES)|MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.
40775150|NCT04066959|BEHAVIORAL|Question Prompt List (QPL)|A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.
40979213|NCT05571098|BEHAVIORAL|telephone support hotline service|Within the scope of the NNP, a telephone support hotline service was provided to the participants, where they could consult at any time about the subject they wanted.
40979214|NCT02442362|DRUG|paclitaxel+oxaliplatin+fluorouracil|"Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14."
40979215|NCT02442362|DRUG|oxaliplatin+S1|"Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area \< 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14"
40979216|NCT00150722|DRUG|atorvastatin (or other tolerated statin + Niaspan/placebo)|atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
40979217|NCT06364540|DRUG|Ketamine|Nebulized ketamine administered at 0.75 mg/kg via BAN
40979218|NCT06364540|DRUG|Fentanyl|Nebulized fentanyl administered at 3 mcg/kg via BAN
40979219|NCT01601626|DRUG|Standard-dose Lopinavir/Ritonavir|Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
40979220|NCT01601626|DRUG|Double-dose Lopinavir/Ritonavir|Four LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry through Week 72.
40979221|NCT01601626|DRUG|Raltegravir|One 400 mg tablet orally twice daily from entry to Week 72.
40979222|NCT01601626|DRUG|Isoniazid|300 mg orally once daily from entry through Week 24.
40979223|NCT01601626|DRUG|Pyridoxine|25 mg orally once daily from entry to Week 24.
40979224|NCT01601626|DRUG|Pyrazinamide|20 to 30 mg/kg orally once daily (not to exceed 2 g per day) from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
40775151|NCT04066959|BEHAVIORAL|Text Message Reminders (TXT)|TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.
40775152|NCT03685942|DEVICE|active light therapy (LUMINETTE®)|light therapy on a portable light visor device
40979225|NCT01601626|DRUG|Ethambutol|15 to 20 mg/kg orally once daily from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
40775153|NCT03685942|DEVICE|placebo light therapy|placebo portable light visor device
40979226|NCT01601626|DRUG|Rifabutin|300 mg of rifabutin orally once until LPV/RTV is started; then the dose will be reduced to 150 mg daily from the start of LPV/RTV through Week 24.
40979227|NCT01601626|DRUG|Rifampin|Weight-based dose; for weight \< 45 kg: 450 mg orally once daily; for weight \> 45 kg: 600 mg orally once daily, from entry to week 24.
40979228|NCT05248022|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres can be loaded with vinorelbine, gemcitabine, irinote Kang, raltitrexed. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is vinorelbine 25mg/m2, gemcitabine generally 1000mg/m2, irinotecan 80mg/ m2, raltitrexed 4mg. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
40979229|NCT05248022|DRUG|Programmed Cell Death Protein 1 Inhibitor|Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
41146956|NCT05360771|DEVICE|Cardi-o-fix PFO occluder|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
41146957|NCT00472199|DRUG|Pramipexole|
41302245|NCT02458690|BEHAVIORAL|Beating the Blues (BtB)|BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
40979230|NCT03235154|DRUG|sofosbuvir/velpatasvir|12 week treatment with once daily sofosbuvir/velpatasvir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.
40979231|NCT04035681|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.
40979232|NCT04035681|OTHER|Stroke-Related Health Education|The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
40979233|NCT01058109|OTHER|calcium-rich diet|dietary calcium intake of 1500 mg/d
40979234|NCT01058109|OTHER|Calcium rich diet|dietary intake of 1500 mg/d from food
40979235|NCT02379806|DRUG|Enoxaparin|
40979236|NCT02379806|DRUG|Placebo|
40979237|NCT04667650|OTHER|Use of nomogram for predictions of Ocular Mysathenia Gravis generalization|The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.
40775154|NCT03643237|BEHAVIORAL|Video game-based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated depression prevention program based on the model by Lewinsohn, Hoberman, Teri, \& Hautzinger, which is effective in short and long terms. The cognitive stimulation component is based on cognitive reserve and cerebral neuroplasticity. The healthy habits promotion component is based on the social learning and social cognitive theories. The App will allow participants to expand information, check progression, and receive reminders about homework
40979238|NCT04573816|OTHER|Use of an internet plateform|Use of an internet platform for remote monitoring of patients.
40979239|NCT02727023|OTHER|Osteopathic Manipulative Medicine|The procedures are picked for their generalized effect on the lymphatic system based on osteopathic literature and research. Our goal is to mobilize the lymphatic fluid to induce an increase of endocannabinoids. These procedures are similar to mechanical motion seen in exercise in regards to lymphatic movement. Each technique will be performed for a total of four minutes each
40979240|NCT04170114|OTHER|Comprehensive Respiratory Physiotherapy|"All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.~Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control."
40979241|NCT04104412|BIOLOGICAL|human umbilical cord mesenchymal stem cell|2\*10\^7
41146958|NCT00472199|DRUG|Placebo|
41302246|NCT02458690|BEHAVIORAL|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
40775155|NCT03643237|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
40775156|NCT05641766|DRUG|THC|Participants will receive THC into a rapidly flowing IV infusion.
40775157|NCT05641766|OTHER|Placebo|Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.
40775158|NCT06526234|DEVICE|MRI|MR enterography
40775159|NCT02771301|BIOLOGICAL|dendritic cells|Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
40775160|NCT05613231|BEHAVIORAL|Aerobic plus muscle-strengthening physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting both aerobic and muscle-strengthening physical activity for Latina women.
40775161|NCT05613231|BEHAVIORAL|Original physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting aerobic physical activity for Latina women.
40775162|NCT02112656|DRUG|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
40775163|NCT02112656|DRUG|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
40775164|NCT03232788|PROCEDURE|Bone regeneration|Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
40775165|NCT03232788|DEVICE|Collagen membrane|A collagen membrane will be used to cover the autogenous bone.
40775166|NCT03232788|DEVICE|Scaffold|A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
40775167|NCT00791648|DRUG|atorvastatin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
40775168|NCT00791648|DRUG|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
40775169|NCT02331758|BEHAVIORAL|Lifestyle Counseling|The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
40775170|NCT04656561|DRUG|ANX007|Form: solution for injection; Route of Administration: IVT
40775171|NCT04656561|OTHER|Sham comparator|Form and Route of Administration: pressure to mimic IVT injection
40775172|NCT00726908|DIETARY_SUPPLEMENT|Low carbohydrate|43% CHO
40979242|NCT02152839|BEHAVIORAL|Resistance Exercise|6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
40979244|NCT01534871|BEHAVIORAL|Exercise|Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
40979245|NCT05567692|DIAGNOSTIC_TEST|OGTT|Oral Glucose Tolerance Test
40979246|NCT05567692|OTHER|HbA1c|HbA1c measurement
40979247|NCT05567692|OTHER|Questionnaire|Follow-up questionnaire
40979248|NCT03012412|BEHAVIORAL|Mindfulness Based Program for Infertility|The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 13 participants).
40979249|NCT01413750|DRUG|Paclitaxel|Given IV
40979250|NCT01413750|DRUG|Carboplatin|Given IV
40979251|NCT01413750|DRUG|Vorinostat|Given PO
40979252|NCT01413750|OTHER|Placebo|Given PO
41302247|NCT02458690|DRUG|Antidepressant Medications|The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. To optimize eIMPACT for CVD risk reduction, we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These medications are FDA approved for the treatment of depression and are the safest from a cardiovascular perspective.
41461191|NCT00499824|BEHAVIORAL|Education of general practitioners on the IDF-WPR guidelines|"The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient."
41461192|NCT02919020|OTHER|Proprioceptive neuromuscular facilitation (PNF)|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
40979253|NCT01413750|OTHER|Laboratory Biomarker Analysis|Correlative studies
41461193|NCT02919020|OTHER|Resistance exercise|resistance exercise to strengthen lower limbs
40979254|NCT00213798|PROCEDURE|Biopsy samples|
40979255|NCT04802460|DEVICE|Virtual reality headset (The Guided Meditation VR App through Oculus Go headset)|Patients assigned to the VR condition will engage with the VR using The Guided Meditation VR App through Oculus Go headset. They will enjoy up to a 10 minute video of an environment of their choosing. During this video they will listen to calming music and a guided meditation session.
40979256|NCT02759471|DEVICE|comfilcon A sphere lens (control)|contact lens
40979257|NCT02759471|DEVICE|comfilcon A asphere lens (test)|contact lens
40979258|NCT03601689|PROCEDURE|rectal resection|total mesorectal excision
40979259|NCT01830699|DRUG|Rilonacept|160 mg intra-bursal once
40979260|NCT01830699|DRUG|Corticosteroid|2 cc (40 mg/mL) triamcinolone intra-bursal once
41142384|NCT06035627|OTHER|Prevention hypothermia|Hypothermia was prevented by warming the case group. control group remained stable. As a result, the presence of surgical site infection was followed.
40979261|NCT01138033|DRUG|GSK2256098|GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
40979262|NCT01074957|DEVICE|Incentive Spirometry|Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
40979263|NCT01074957|DEVICE|Breath-Stacking Technique|An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
40979264|NCT01074957|OTHER|Exercise|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
40979265|NCT05551559|PROCEDURE|bariatric surgery|bariatric surgery
40979266|NCT04350788|OTHER|Survivorship Care Plan|Participants visit the NCI prostate cancer website in addition to their standardized post-treatment survivorship care
40979267|NCT04350788|OTHER|Enhanced Survivorship Care Plan|In addition to their standardized post-treatment survivorship care, participants visit the prostate cancer education resources for couples (PERC) website that was based on scientific evidence and input from stakeholders including PC patients, partners, and cancer care providers. Participants learn about skills and knowledge about how to enhance their positive appraisals of symptoms and self-efficacy in symptom management through information and skills training, fostering healthy behaviors, and facilitating social support
41142385|NCT06343636|DRUG|VG-3927|Dose Escalation
41142386|NCT06343636|DRUG|Placebo|Dose Escalation
41142387|NCT06343636|DRUG|VG-3927|One Dose Level
41142388|NCT04471805|DEVICE|Sham transcranial direct current stimulation 4 mA|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
41142389|NCT04471805|DEVICE|Transcranial direct current stimulation 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
40979268|NCT06291025|PROCEDURE|PEX-FREE|The study/experimental procedure consists in replacing daily PEX with daily plasma infusions (ie. Quarantine fresh frozen plasma (PFC-Se), solvent detergent/viral inactivated plasma (PFC-SD = OCTAPLASLG) or amotosalen-inactivated plasma (PFC-IA); volume 15mL/kg/day).
40979269|NCT02257788|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCR5
40979270|NCT01096121|DRUG|Enalapril|"* during 1 month : 0,2 mg/kg/day~* then during 2 months (if no adverse event): 0,35 mg/kg/day~* and then during 6 months (if no adverse event): 0,5 mg/kg/day"
40979271|NCT01096121|DRUG|Placebo|Glucose
40979272|NCT03489720|BEHAVIORAL|Prescribed Exercise Program|"Brief cardiovascular exercise training (\>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~* Walking quickly or running up and down stairs~* Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~* Walking up an incline on a treadmill~* Jogging or running on a treadmill or elliptical~* Stationary cycling or rowing"
40979273|NCT03489720|BEHAVIORAL|Usual Exercise Program|Usual exercise activity for 8 weeks
41302248|NCT02458690|OTHER|Usual Care|Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their Eskenazi Health primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
41302249|NCT03144141|OTHER|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization
41302250|NCT01850784|DIETARY_SUPPLEMENT|High energy formula|The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
41302251|NCT01850784|DIETARY_SUPPLEMENT|Standard formula|The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
41302252|NCT00595699|DRUG|escitalopram|10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
41302253|NCT00595699|DRUG|placebo|Placebo
41302254|NCT03253991|DEVICE|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
40775173|NCT01852981|BEHAVIORAL|Lifestyle counseling|Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.
40979274|NCT01782144|OTHER|NutriSystem portion-controlled pre-packaged meals|
40979275|NCT02154490|DRUG|Docetaxel|Given IV
40979276|NCT02154490|BIOLOGICAL|Durvalumab|Given IV
41302255|NCT02218814|PROCEDURE|Adductor Canal Block, Bupivacaine|"Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease."
41302256|NCT02218814|PROCEDURE|Femoral Nerve Block, Bupivacaine|"Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration."
41302257|NCT01772342|OTHER|HEPA filtration|Night time air purification with the PureNight air purification system with the HEPA filter in place
41302258|NCT01772342|OTHER|SHAM|Night time air purification with the PureNight air purification system with the HEPA filter removed
41302259|NCT00988559|BIOLOGICAL|DNA vaccination|vaccination with pNGVL4a-CRT/E7(detox)
41302260|NCT00988559|DEVICE|Gene gun vaccine|8 micrograms (group 1) or 16 micrograms (group 2)
41302261|NCT00988559|BIOLOGICAL|intramuscular vaccination|1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
40979277|NCT02154490|DRUG|Erlotinib Hydrochloride|Given PO
40979278|NCT02154490|DRUG|FGFR Inhibitor AZD4547|Given PO
40979279|NCT02154490|BIOLOGICAL|Ipilimumab|Given IV
40979280|NCT02154490|OTHER|Laboratory Biomarker Analysis|Correlative studies
40979281|NCT02154490|BIOLOGICAL|Nivolumab|Given IV
40979282|NCT02154490|DRUG|Palbociclib|Given PO
40979283|NCT02154490|OTHER|Pharmacological Study|Correlative studies
41302262|NCT00988559|BIOLOGICAL|intra-lesional vaccine administration|1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
41302263|NCT00988559|PROCEDURE|therapeutic resection of the lesion|at week 15, all residual lesions will be resected
41302264|NCT00988559|DRUG|imiquimod|imiquimod applied to the cervix by the physician
40979284|NCT02154490|BIOLOGICAL|Rilotumumab|Given IV
40979285|NCT02154490|DRUG|Talazoparib|Given PO
40979286|NCT02154490|DRUG|Taselisib|Given PO
40979287|NCT02154490|BIOLOGICAL|Tremelimumab|Given IV
41302265|NCT03212131|DRUG|Somapacitan|3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg
41302266|NCT06233032|DRUG|Ephedrine|Patient Will receive 6mg IV
41302267|NCT06233032|DRUG|Dexmedetomidine|Patient Will receive 30mcg IV
41302268|NCT05511246|DRUG|Venous ethanol|Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol
40979288|NCT05548829|BIOLOGICAL|Disease severity|Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.
40979289|NCT01637467|OTHER|Electrical muscle stimulation (EMS)|EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
40979290|NCT01637467|OTHER|Sham EMS|Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
40775174|NCT01852981|BEHAVIORAL|Supervised exercise|Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
40775175|NCT05568862|DIAGNOSTIC_TEST|Doppler ultrasound, Urodynamic assessment.|The patients included in the study group were given 600 cc of water in the morning and the Doppler ultrasound was performed 30 minutes later
40775176|NCT05568862|DIAGNOSTIC_TEST|Urodynamic assessment.|A transurethral double lumen catheter was used to measure intravesical pressure in the urodynamic unit for the patients in the study group immediately after the use of the Doppler USG
40979291|NCT02935088|DEVICE|Fractional Flow Reserve|Measurement of physiologic parameters
40979292|NCT03934931|OTHER|Streamlined weekly DOT visits|Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects
40979293|NCT03934931|OTHER|Weekly DOT visit reminders|Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits
40979294|NCT03934931|OTHER|Cost reimbursement DOT|Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)
40979295|NCT03934931|OTHER|99DOTS|99DOTS-based digital adherence technology to monitor and promote adherence
40979296|NCT03934931|OTHER|Weekly SAT dosing reminders/check-ins|Weekly SMS or IVR phone call dosing reminder/check-in for side effects
40979297|NCT03934931|OTHER|Cost reimbursement SAT|Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)
41302269|NCT05511246|PROCEDURE|Catheter ablation|Endocardial catheter ablation of VT substrate
41302270|NCT00417976|DRUG|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
40775177|NCT00951392|DRUG|euglycemic hyperinsulinemic clamp|"Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests"
40775178|NCT00951392|PROCEDURE|muscle biopsy|"Gene expression in muscle tissue will be studied with two approaches :~* Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~* Global transcriptome analysis by DNA Chip"
40775179|NCT00951392|DEVICE|indirect calorimetry|energy expenditure measurement
40775180|NCT05903079|DEVICE|s-Tdcs|Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
40979298|NCT03124433|DRUG|Apalutamide|Participants will receive oral apalutamide 240mg daily for 12 weeks
40979299|NCT04059094|DRUG|BI 1265162|Inhalation solution
40979300|NCT04059094|DRUG|Placebo|Inhalation solution
40979301|NCT00548925|DRUG|ABT-894|6 mg BID tablets, 8 weeks of treatment
40979302|NCT00548925|DRUG|placebo|BID tablets, 8 weeks of treatment
40979303|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle Slow-pull capillary sampling|The slow-pull capillary technique was performed as follows: after identification and measurement of the target lymph node, a needle was used to puncture the lymph node with the stylet in place.At the same time, the stylet was slowly and continuously pulled to create weak negative pressure.
40979304|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration|The operation steps are the same as above, but the negative pressure device of 10ml syringe is connected behind the puncture needle.
40979305|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle capillary sampling|The operation steps are the same as above, but there is no negative pressure device behind the puncture needle
41142390|NCT05963802|OTHER|Artificial Intelligence (ChatGPT) Group|Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process.
41142391|NCT01652014|DRUG|cyclophosphamide|Given IV over 1 hour on Day -6; after pre-hydration
41142392|NCT01652014|DRUG|fludarabine phosphate|Given IV daily over 30 minutes for 5 days (Days -6 to -2)
41142393|NCT01652014|DRUG|mycophenolate mofetil|Given PO 1.0 g BID Day 1-30
41302271|NCT00417976|DRUG|Bevacizumab|10 mg/kg every 2 weeks.
41302272|NCT00417976|DRUG|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
41302273|NCT05288634|OTHER|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
41302274|NCT03709888|DRUG|Memantine XR-pregabalin combination therapy|Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.
41302275|NCT02940054|OTHER|Red-flags questionnaire|A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
40979306|NCT02747901|OTHER|KINESIOTAPING|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
40979307|NCT02747901|OTHER|COLD THERAPY|Cold therapy group received cold packs immediately after operation and following postoperative days
40979308|NCT03144388|PROCEDURE|Variable Stepping Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
40979309|NCT03144388|PROCEDURE|Variable Non-specific Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
40979310|NCT03080311|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
40979311|NCT04980859|DRUG|Zebutinib&BR or Zebutinib&FCR|Introduction period: Zebutinib 160 mg bid oral treatment for 3 months;Joint stage :6 sessions of Zebutinib FCR( under 60 years of age,Fludarabine 25 mg/m² Q3W, Cyclophosphamide 250 mg/m² Q3W,Rituximab 375 mg/m² Q3W) or BR (over 60 years of age, )(28 days and 1 cycle);Maintenance treatment: after the end of the combined phase, continue the treatment of zebutinib.
40979312|NCT06315439|PROCEDURE|Endoscopic ultrasound fine needle biopsy|"EUS FNA/B for solid pancreatic lesions. After the FNA/FNB, the needle was removed from the EUS endoscope and the specimen obtained after the first needle pass was expelled and placed directly in a dedicated scaffold (Cytomatrix, UCS Diagnostics).~a drop of ethanol was put on it and the liquid was drained away thanks to the porous structure of the matrix. This step was followed by the deposition of a drop of acridine-orange for 20 and a rapid washing with buffered saline. After that, the Cytomatrix was put on a dedicated microscopic slide and covered with a second slide before the introduction in the slot of the machine.~The FCM VivaScope® 2500 (2500M-G4; VivaScope, Munich, Germany) was used for immediate imaging."
40979313|NCT06144489|DIETARY_SUPPLEMENT|Tart Cherry|Tart cherry supplementation in two doses
40979314|NCT06144489|DIETARY_SUPPLEMENT|Placebo|Control group
40979315|NCT05281185|DRUG|Extended half-life FVIII concentrates with PK-guided dosing|Extended half-life FVIII concentrates with PK-guided dosing as low-dose factor replacement prophylaxis (10-20u/kg, 2-3 times/week) for 6 months in severe haemophilia A patients that previously receive weight-based factor replacement prophylaxis
40979316|NCT05281185|DRUG|standard half-life FVIII concentrates with weight-based dosing|standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study
40979317|NCT06166498|DRUG|SP (Macleods Pharmaceuticals Ltd)|Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
40979318|NCT06166498|DRUG|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
40979319|NCT02633644|DEVICE|Harmony System|Percutaneous neuromodulation of the aortic wall
40979320|NCT01859533|DEVICE|Neopuff|"* Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).~* Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010)."
40979321|NCT00569699|DRUG|S-1, Bevacizumab|"S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25 m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15."
40979322|NCT02132325|BEHAVIORAL|Dignity Therapy|Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
40979323|NCT04014842|DEVICE|RapidShock|Use of the Reconfirmation Analysis Mode algorithm
40979324|NCT05939986|BEHAVIORAL|Virtual reality-based exposure treatment with multimodal feedback (VRET-M)|The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.
40979325|NCT05939986|BEHAVIORAL|Virtual reality-based exposure treatment with bimodal feedback (VRET-B)|The VRET-B group will experience visual and auditive cues in the exposure sessions.
40979326|NCT05939986|BEHAVIORAL|Imagery exposure treatment (IET)|The IET group will experience its own subjective imagined environment without any external stimulation.
40979327|NCT05822531|BEHAVIORAL|Maternal CVH Intervention|All participants will be enrolled into the intervention arm of this pilot study.
40979328|NCT01463878|DIETARY_SUPPLEMENT|Glycerna|Diabetes specific formula
40979329|NCT01463878|DIETARY_SUPPLEMENT|Jevity - Control Diet|Control Diet
40979330|NCT06184815|BEHAVIORAL|Educational programme 12|Consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months and multidisciplinary treatment
40979331|NCT06184815|BEHAVIORAL|Standard education and treatment|Outpatient management and education in the office and consultation referral to nutrition and psychology
40979332|NCT00859768|OTHER|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
40979333|NCT05639374|BEHAVIORAL|BASICS_HealthyClassroom|First, they will complete a 22-item online questionnaire, collecting all the variables of the research. After completing it, the students in the intervention group will receive personalized feedback by mail that visually summarizes the content of the questionnaire. Students will receive a motivational intervention with the aim of increasing the university's awareness of their alcohol consumption. In the intervention session of the program, the following aspects may be addressed, whenever the participant wishes: 1) Pattern of alcohol consumption of the student; 2) Social norm of alcohol consumption; 3) Negative consequences of alcohol; 4) Costs of alcohol consumption; 5) The change; 6) Specific education on alcohol; and 7) Advice and recommendations.
40979334|NCT00523003|DIETARY_SUPPLEMENT|high protein|2.2 g protein/kg of LBM per day
40979335|NCT00523003|DIETARY_SUPPLEMENT|standard protein|1.1 g protein/kg LBM/day standard protein diet
40979336|NCT01453712|RADIATION|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
40979337|NCT01453712|RADIATION|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
40979338|NCT04384666|DRUG|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)|LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
40979339|NCT04384666|OTHER|Neupro 4 mg / 24 Hr. Transdermal Patch|Neupro 4 mg /24 Hr. Transdermal Patch
40979340|NCT03182829|DIAGNOSTIC_TEST|DOAC Dipstick|"Patients collect a sample of urine for analysis.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. \[Epub ahead of print\]"
40979341|NCT03551860|PROCEDURE|TQL|"For the intervention of TQL peripheral nerve block the needle tip will be advanced by in-plane technique and local anaesthetic will be deposited between psoas major and quadratus lumborum muscles. 20 ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
40979342|NCT03551860|PROCEDURE|FIB|"The needle tip will be advanced by in-plane technique and local anaesthetic will be deposited deep to the fascia iliaca. 20ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
40979343|NCT01050868|DEVICE|Accu-Chek Combo Kit mg DE/de|
40979344|NCT05205421|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Intravenous injection a single dose of RT-01
40979345|NCT04840290|DRUG|Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin|Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
40979346|NCT01176084|BEHAVIORAL|low carbohydrate diet|
40979347|NCT01176084|BEHAVIORAL|low carbohydrate diet and exercise|
40979348|NCT01503944|DRUG|18F-AV-133|185 MBq
40979349|NCT01503944|DRUG|18F-AV-45|185-370 MBq
40979350|NCT03676595|OTHER|interactive video game-based exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
40979351|NCT03676595|OTHER|no exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
40979352|NCT02188212|DEVICE|NobelProcera Crown Shaded Zirconia|
40979353|NCT03305822|DRUG|LY900014|Administered SC
41302276|NCT04799405|DEVICE|tDCS|"Daily sessions (28 daily sessions): The device will be used to apply 30 minutes of tDCS to the participant with MDD's scalp in each of 28 daily sessions.~Thereafter, participants with MDD will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:~1. First taper phase: three 30 minutes tDCS sessions applied every other day;~2. Second taper phase: three 30 minutes tDCS sessions applied one every third day;~3. Third and final taper phase: three final 30 minutes tDCS sessions applied one every fourth day."
41302277|NCT02024893|OTHER|Observational study|"Observation and type of data collected are listged in detail under 'description"
41302278|NCT00748540|DEVICE|Vibrant Soundbridge|Mixed and conductive hearing loss using round window stimulation
40775181|NCT04321655|OTHER|High Intensity LASER Therapy (HILT)|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ (millijoule)/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J"
40979354|NCT03305822|DRUG|Insulin Lispro|Administered SC
40979355|NCT06506604|DEVICE|CLEVER|"CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes."
40979356|NCT00184691|DRUG|somatropin|
40979357|NCT01607086|DRUG|Cherry lamotrigine ODT|25mg, taken orally on one study visit
40979358|NCT01607086|DRUG|Cherry Placebo|Taken orally on one study visit
40979359|NCT04974710|DIAGNOSTIC_TEST|Outpatient MRI|All participants will undergo a standardised imaging protocol in a MRI scanner. This will take place during the same visit or following the transvaginal ultrasound (TVUS) and in advance of any surgical procedure (laparoscopy).
40979360|NCT01808053|DEVICE|BodyGuardian remote health monitoring system|The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
40979361|NCT00536601|DRUG|etoposide|Given IV
40979362|NCT00536601|DRUG|cyclophosphamide|Given IV
40979363|NCT00536601|DRUG|carmustine|Given IV
41302279|NCT01958671|DRUG|Ertugliflozin 5 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
41302280|NCT01958671|DRUG|Ertugliflozin 10 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
40979364|NCT00536601|DRUG|melphalan|Given IV
40979365|NCT00536601|DRUG|busulfan|Given IV
40979366|NCT00536601|DRUG|carboplatin|Given IV
40979367|NCT00536601|DRUG|thiotepa|Given IV
40979368|NCT00536601|RADIATION|total-body irradiation|Undergo TBI
40979369|NCT00536601|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo ASCT
40979370|NCT00536601|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo tandem ASCT
40979371|NCT03442907|PROCEDURE|24 hour blood pressure measurement, fluids, vasopressors|Targeting individual blood blood pressure values during surgical procedures
40979372|NCT03442907|PROCEDURE|Standard of Care|Treatment according to Standard of care at the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf
40979373|NCT00874965|DEVICE|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
40979374|NCT00874965|DEVICE|Sham stimulation|30 min; 5 times / week
40979375|NCT00003596|DRUG|cisplatin|
40979376|NCT00003596|DRUG|fluorouracil|
40979377|NCT00003596|DRUG|mitomycin C|
40979378|NCT00003596|RADIATION|radiation therapy|
40979379|NCT05585528|PROCEDURE|Functional or surgical management in 1st intention|Proportion of patients after rupture of the anterior cruciate ligament of the knee, who will have functional or surgical management in 1st intention
40979380|NCT02772081|COMBINATION_PRODUCT|LISA combination product (Curosurf+catheter CHF6440)|Curosurf administration through brief insertion of a thin catheter into the trachea
40979381|NCT02772081|DRUG|Curosurf through conventional administration (endotracheal tube)|Curosurf through conventional administration (endotracheal tube), followed by rapid extubation
40979382|NCT05226663|PROCEDURE|Computed Tomography|Undergo \[18F\]FFT PET/CT
41302281|NCT01958671|DRUG|Placebo to Ertugliflozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
40979383|NCT05226663|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
40979384|NCT05226663|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FFT PET/CT
41461194|NCT01875887|PROCEDURE|rapid prototyping technology|Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
40775182|NCT04321655|OTHER|Ibuprofen Gel Phonophoresis (IGP)|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. (8 min/ one session each day for 3 days/week for 8 weeks).
40979385|NCT00834860|DRUG|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
40979386|NCT05810623|DRUG|Intravesical Solution|Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
40979387|NCT02694874|DRUG|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
40979388|NCT02694874|DRUG|Placebo|This is the placebo control
40979389|NCT01545284|DRUG|Acitretin|All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
40979390|NCT04827329|OTHER|Questionnaire|Patients will complete a questionnaire regarding their anesthesia history, course and possible complications, and Questions about their treatment for their sleep disorder.
40979391|NCT06380088|OTHER|Isometric Task|The exercise required participants to keep their arm flexed at a 90° angle while holding a dumbbell loaded to 80% of their 1RM (One Rep Max) in a supine position on the dominant side of the body for as long as possible.
40979392|NCT03272074|OTHER|Egg and egg white|Participants will consume either one large eggs or equivalent amount of egg white (3/4 cups) for 12 weeks. Participants will maintain their regular diet and physical activities.
40979393|NCT06392503|DIAGNOSTIC_TEST|different diagnostic models|the patients were screened by different diagnostic models
40979394|NCT02600377|OTHER|Vegetarian diet|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
40979395|NCT03867604|PROCEDURE|Sham injection|Injection to the subcutaneous layer at upper trapezium level
40979396|NCT03867604|PROCEDURE|Fascia injection|Injection to the fascia below upper trapezium muscle
40979397|NCT06001424|OTHER|physical therapy|Frenkel's exercises for lower limb, Proprioceptive neuromuscular facilitation for upper limb in the form of rhythmic stabilization
40979398|NCT06001424|OTHER|life kinetic exercises|A multimodal training that combines coordinative, cognitive and visual tasks.
40979399|NCT04533308|BEHAVIORAL|Relaxation in virtual reality|Natural 360-degrees scenes from different locations in the world with or without interactions with animals in the virtual reality
40979400|NCT03592108|OTHER|CSR remote monitoring|The intervention will consist to modify the method used to analyse the data collected by remote monitoring in OSA-patients treated by CPAP (device : AirSense™10 Autoset™, ResMed) in order to alert physicians when Cheynes-Stokes respiration (CSR) occurs during sleep and then to set up emergency pulmonology and cardiology consultations to screen the onset of a significant cardiac event (heart failure, rhythm disorder, diastolic dysfunction).
40979401|NCT05693246|DRUG|Glycopyrrolate|At 10 minutes after endotracheal intubation, the Glycopyrrolate group was injected intravenously with 0.004mg/kg glycopyrrolate.
40979402|NCT05693246|OTHER|normal saline|At 10 minutes after endotracheal intubation, the Control group was intravenously injected with equal dose of normal saline.
40979403|NCT05105061|DRUG|Ketamine (Ketalar)|0.5 mg/kg of body weight
40979404|NCT05105061|DRUG|Placebo|IM injection of matching placebo
40979405|NCT05701150|OTHER|Minimal documentation|Minimal data documentation only of patients without targeted therapy based on NGS results
40979406|NCT05701150|OTHER|Extended documentation|Extended data documentation of patients with targeted therapy based on NGS results
40979407|NCT06164223|DEVICE|VR Baby Pump|VRBaby-Pump application is a video application specially prepared with virtual reality glasses and a milking pump placed inside a toy doll. In the video content, the mother is breastfeeding her baby on an armchair in the baby room prepared for a newborn baby.
40979408|NCT03696511|DEVICE|Orthodontic miniscrew insertion|orthodontic treatment using miniscrews as anchorage reinforcement
40775183|NCT04321655|OTHER|Transcranial Direct Current Stimulation (tDCS)|Anode electrode -C3/C4 (contralateral side of the most affected knee), Cathode electrode- contralateral supraorbital area. (2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
40979409|NCT01824901|DRUG|docetaxel|Given IV
40979410|NCT01824901|DRUG|AZD4547|Given PO
40979411|NCT05891509|PROCEDURE|Minimally Invasive Hematoma Evacuation|Procedure of minimally invasive hematoma evacuation PLUS best medical therapy
40979412|NCT05891509|OTHER|Best Medical Therapy|Best medical therapy
40979413|NCT03858088|PROCEDURE|Liver transplantation|Liver transplantation from deceased donors
40979414|NCT03857191|DIETARY_SUPPLEMENT|Nutritional psychocomportemental rehabilitation|Nutritional psychocomportemental rehabilitation
40979415|NCT04921254|DRUG|BSG005 or placebo|"SAD part is a single IV infusion of ascending doses of BSG005 or placebo - a 30 minutes infusion that may be extended to 2 hours if infusion reactions occur.~The MAD part is single daily infusions of the cohort dose over 30 minutes (that may be delayed up to 2 hours in case of infusion reactions) and which will be repeated daily for 7 days. Objective is safety, tolerability and PK on day 1 and day 7 and to establish steady state plasma level."
40979416|NCT01816633|DEVICE|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
40979417|NCT00330616|DRUG|323U66 SR|
40979418|NCT05877833|OTHER|Vibrancy Assessment|Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
40979419|NCT05163353|DEVICE|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
40979420|NCT04304807|DRUG|Melatonin 20 mg|Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.
40979421|NCT04304807|DRUG|Traditional antibiotic treatment|Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
40979422|NCT00170053|DRUG|Sirolimus|10 mg oral loading dose followed by 5 mg/day. Measure Sirolimus level weekly and adjust to level of 10-15 ng/ml.
40979423|NCT00003514|DRUG|antineoplaston A10|
40979424|NCT00003514|DRUG|antineoplaston AS2-1|
40979425|NCT00003514|PROCEDURE|alternative product therapy|
40979426|NCT00003514|PROCEDURE|biological therapy|
40979427|NCT00003514|PROCEDURE|biologically based therapies|
40979428|NCT00003514|PROCEDURE|cancer prevention intervention|
40979429|NCT00003514|PROCEDURE|complementary and alternative therapy|
40979430|NCT00003514|PROCEDURE|differentiation therapy|
40979431|NCT03226392|DRUG|QAW039|QAW039 once daily
40979432|NCT03226392|DRUG|Placebo|Placebo once daily
40979433|NCT05620004|DRUG|Bifidobacterium Bifidum Oral Product|experimental group use Bifidobacterium Bifidum Oral Product and control group without Bifidobacterium Bifidum Oral Product
40775184|NCT04321655|OTHER|Conventional Physiotherapy (CPT)|"1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
40775185|NCT02278003|OTHER|memory test|
40775186|NCT02278003|DRUG|Propofol|
40979434|NCT03232021|DRUG|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
40979435|NCT03232021|DRUG|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
40979436|NCT03232021|DRUG|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
40979437|NCT01723852|DIETARY_SUPPLEMENT|Vitamin D at 30 ug/day|
40979438|NCT01723852|DIETARY_SUPPLEMENT|Vitamin D at 10 ug/day|
40979439|NCT00820157|PROCEDURE|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
40979440|NCT00820157|PROCEDURE|TACE|TACE alone or TACE followed by downstage resection for MNHCC
40979441|NCT03447756|DRUG|ABX-1431|Capsules of either 2mg, 10mg, or 50mg
40979442|NCT03447756|DRUG|Placebo oral capsule|placebo to match
40979443|NCT02259582|DRUG|Pemetrexed|
40979444|NCT02259582|DRUG|Carboplatin|
40979445|NCT02259582|DRUG|demcizumab|
40979446|NCT04832685|DEVICE|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
40979447|NCT02308085|OTHER|Endocrine therapy interruption|"3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.~Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference."
40979448|NCT03468257|BEHAVIORAL|Pavlovian Conditioning|Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit
40979449|NCT04151667|DRUG|Daratumumab Injection|Patient will receive daratumumab (1800 mg in 15 ml) administered by manual subcutaneous injections weekly for the first 8 weeks, every other week for the next 16 weeks and every 4 weeks after.
40979450|NCT04151667|DRUG|Dexamethasone Oral|The dexamethasone starting dose will be 20 mg PO once a week. Commercial dexamethasone will be used. Dexamethasone is often supplied in 4 mg tablets. Accordingly, patients will take 5 (4 mg tablets) one day of the week prior to the administration of daratumumab if this corresponds to a daratumumab dosing days. In non daratumumab dosing days, dexamethasone will be taken by the patient at home, usually in the morning with breakfast.
40979451|NCT04151667|DRUG|Lenalidomide Pill|"Lenalidomide will be given orally on days 1-21 of a 28 days cycle. The starting dose of lenalidomide will be based on the patient creatinine clearance per the package insert.~Specifically patients with a creatinine clearance ≥ 50 ml/min will receive 25 mg of lenalidomide PO Days 1-21. Patients with a creatinine clearance ≥ 30 but less than 50 ml/min will receive 10 mg of lenalidomide.~Patients with a creatinine clearance \< 30 ml/min are not eligible but patients who experience a deterioration in the renal function during screening or treatment may continue on lenalidomide therapy as long as the risk / benefit profile is deemed acceptable, that study therapy is in the best interest of the patient and after discussion with the study principal investigator / sponsor."
40979452|NCT04151667|DRUG|Bortezomib Injection|Bortezomib will be given weekly subcutaneously in an effort to decrease the toxicity of the therapy. Specifically patients will receive a starting dose of bortezomib of 1.3 mg/m\^2 Days 1,8,15 of a 28 day cycle. Bortezomib will be administered in the cancer center per standard of care procedures.
40979453|NCT00541489|DRUG|Naproxcinod|750 mg, bid
40979454|NCT00541489|DRUG|Naproxen|500 mg, bid
40979455|NCT00541489|DRUG|Placebo|bid
40979456|NCT06334692|DIAGNOSTIC_TEST|"In-house ELISA, and ELISA kits from DBA Italy (Abbexa)."|"Nunc MaxiSorp ELISA plates will be coated with recombinant extracellular domain of human nephrin. Patient serum samples will be added in appropriate dilution. Plates will be then incubated with biotin-conjugated anti human IgG antibody followed by incubation with horseradish peroxidase (HRP)-avidin conjugate. Then tetramethylbenzidine substrate will be added, and absorbance read at 450 nm."
40979457|NCT03388879|DEVICE|Taylor Spatial Frame|Circular external fixator
40979458|NCT03388879|DEVICE|Intramedullary nail|Antegrade intramedullary nail
40979459|NCT06208033|DRUG|SMET12|"1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
40979460|NCT06208033|DRUG|SMET12|"1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
40979461|NCT06208033|DRUG|SMET12|"1. chemotherapy：Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
40979462|NCT02528656|DEVICE|Vacuum Bell|Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
40979463|NCT02528656|DEVICE|Dynamic Compression System|Patients will be submitted to a dynamic compression system.
40979464|NCT00768807|DEVICE|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
40979465|NCT00512993|DRUG|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
40979466|NCT01453114|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
40979467|NCT06397014|PROCEDURE|D-type stoma lateral hernia repair|underwent D-type stoma lateral hernia repair
40979468|NCT00237874|DRUG|Aripiprazole|
40979469|NCT05118906|DRUG|BP1.4979 active drug|2 tablets 15 mg of BP1.4979 per day
41461195|NCT01003951|PROCEDURE|Acupuncture|"Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.~Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol."
40979470|NCT05118906|DRUG|Placebo|2 tablets of placebo per day
40979471|NCT06395974|OTHER|fetal ultrasound|2D, 3D , Doppler ultrasound
40979472|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237mL
40979473|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237 mL
40979474|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237mL
40979475|NCT02599272|OTHER|Rice with tomatoes and peeled aubergine (no spice)|Dose 0
40979476|NCT02599272|OTHER|Rice with vegetables and low spice|Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
40979477|NCT02599272|OTHER|Rice with vegetables and high spice|Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
40979478|NCT05604222|DRUG|Mirabegron 50 MG|Medication to treat overactive bladder
40979479|NCT05604222|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|A behavioral intervention for insomnia
40979480|NCT03489447|OTHER|ICU care|exposure to ICU treatment with or without diagnosed sepsis
40979481|NCT05403125|DEVICE|silver diamine fluoride, 38%|Topical application to all surfaces of the teeth
40979482|NCT05403125|DEVICE|Sodium fluoride gel, 5000 PPM|Gel applied after application of silver diamine fluoride and dispensed for home use
40979483|NCT01380873|DRUG|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
40979484|NCT01380873|DRUG|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
40979485|NCT01380873|DRUG|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
40979486|NCT02130973|DRUG|Standard Clinical Practice Regimen|Standard Clinical Practice Regimen
40979487|NCT02130973|DRUG|Experimental Cyclic Regimen|Experimental Cyclic Regimen
40979488|NCT01509430|OTHER|Progressive Resistance Exercise Training|12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
40979489|NCT01509430|OTHER|Progressive Resistance Exercise Training|12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
40979490|NCT02837094|DRUG|C19-A3 GNP|C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold.
40979491|NCT01412346|OTHER|Effects of a Nordic diet rich in plant-based foods and fish|The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
40979492|NCT00105482|DRUG|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
40979493|NCT00105482|DRUG|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
40979494|NCT00105482|BEHAVIORAL|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
40979495|NCT00225173|DRUG|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
40979496|NCT00225173|DRUG|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
40979497|NCT00225173|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
40979498|NCT00225173|DRUG|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
40979499|NCT00225173|DRUG|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
41302282|NCT01958671|DRUG|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
41302283|NCT01958671|DRUG|Placebo to Metformin|1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
41302284|NCT01958671|DRUG|Glimepiride|Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
41461196|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (10ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)
40979500|NCT00225173|DRUG|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
40979501|NCT00225173|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
40979502|NCT00225173|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
40979503|NCT00225173|DRUG|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
40979504|NCT04236011|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
40979505|NCT05549206|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose|50μg/dose
40979506|NCT05549206|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose|100μg/dose
40979507|NCT05549206|DRUG|Placebo|Saline solution
40979508|NCT00001576|DRUG|Melphalan|
40979509|NCT00001576|DRUG|Floxuridine|
40979510|NCT00001576|DRUG|Leucovorin|
40979511|NCT05241067|DRUG|Normal Saline|Placebo (Dose: equal volume saline) + Standard of care
40979512|NCT05241067|DRUG|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
40979513|NCT01411228|DRUG|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
40979514|NCT02598076|BEHAVIORAL|motivational interviewing|Motivational interviews will include the classical 4 steps of MI: 1) engagement (in which the patient's goals and interests are elicited and the therapeutic alliance is established); 2) focusing (in which the specific subjects of discussion and intervention are negotiated); 3) strengthening motivation (in which the patients' reasons for healthcare intervention are made explicit, discussed, and reinforced); and 4) planning (in which actions for healthcare intervention are planned out based on the patients' own goals and interests). MI will be performed by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
40979515|NCT02598076|BEHAVIORAL|standard psychotherapy|Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES
40979516|NCT06257810|DIAGNOSTIC_TEST|VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG|"For patients managed in an intervention site, a diagnostic test for dengue and chikungunya using VIDAS® as well as a screening test for malaria will be carried out. An awareness campaign on the use of VIDAS® diagnostic tests will be implemented as well.~The diagnosis will be based on the patient's clinical symptoms, the biological results of the VIDAS® tests for dengue and chikungunya, as well as the results of the tests for malaria."
40979517|NCT06257810|OTHER|Standard of care practices|"For patients managed in a control site, the standard of care practices will be applied in the case of a febrile condition of undetermined etiology. This includes clinical diagnosis and, where appropriate, the use of routinely available diagnostic tests. At the end of the study, the collected samples will be tested using VIDAS® differential diagnosis tests to estimate the number of cases of dengue and chikungunya that have not been correctly diagnosed."
40979518|NCT01443754|PROCEDURE|LIMA-LAD surgical revascularization|"Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:~* use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;~* minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another."
40979519|NCT01443754|PROCEDURE|PCI|"State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.~Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites."
40979520|NCT02715076|OTHER|Ambient Temperature 19°C|Ambient Temperature 19°C
40979521|NCT02715076|OTHER|Ambient Temperature 21°C|Ambient Temperature 21°C
40979522|NCT02715076|OTHER|Ambient Temperature 23°C|Ambient Temperature 23°C
41302285|NCT01617434|DRUG|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
41461197|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (50ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)
40979523|NCT02715076|DEVICE|Forced-air cover (Bair hugger 63500, 3M)|Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
40979524|NCT02715076|OTHER|Passive insulation|Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
40979525|NCT06166849|DEVICE|Experimental Fluoride Application|The two-step system, consisting of Component A and Component B, will be applied once on the white spot lesions
40979526|NCT03223246|OTHER|Additional teaching|A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
40979527|NCT06157814|OTHER|STOMA Care web-based application|The STOMA Care App, with program software developed in collaboration with the Information Technology Department at Mount Sinai, is organized in a web-based app accessible on any smart-phone (e.g., Android and iOS), tablet, or computer device and consist of: 1) provision of information through text, and graphics; 2) videos of physicians and nurses answering questions; and 3) videos of patients describing their experiences and modelling competencies 4) mental health, support group, and ostomy supplier resources.
40979528|NCT06157814|OTHER|Usual Care|Patients and caregivers NOT given access to the web-based application.
40979529|NCT00661882|OTHER|medical chart review|"Medical information, called protected health information (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record."
40979530|NCT00661882|OTHER|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
40979531|NCT00661882|OTHER|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
40979532|NCT00661882|PROCEDURE|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
40979533|NCT03211689|OTHER|Exercise Program|Participants will utilize the Physitrack exercise program to engage in up to 150 minutes of exercise at a rating of 11-14 on the Borg Rate of Perceived Exertion scale, per week.
40979534|NCT02255981|OTHER|Acupuncture and massage|"Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.~Periocular massage is taught and is practiced daily by the patient him or herself."
40979535|NCT00827424|BEHAVIORAL|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
40979536|NCT05825846|DEVICE|Virtual- reality active shooter drill|"The stress protocol used for this experiment utilized a previously studied virtual reality active shooter drill (VR-ASD). The VR-ASD scenario (\~2 min) involves the participant physically walking down a \~10-foot-long virtual hallway where they will encounter wounded victims. Once at the threshold of to the attack room, they will observe one victim on the ground with a traumatic head injury and the shooter firing his handgun at the last victim, the participant will fire a shot, and the shooter will fall after being shot."
40979537|NCT01599234|DRUG|Sativex|Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.
40979538|NCT01599234|DRUG|Placebo|Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
40979539|NCT02526745|BIOLOGICAL|the vaccine with high doses of virus content between 4.7～5.0 lgPFU|
40979540|NCT02526745|BIOLOGICAL|the vaccine with low doses of virus content between 4.7～5.0 lgPFU|
40979541|NCT02526745|BIOLOGICAL|the vaccine with high doses of virus content between 4.3～5.0 lgPFU|
40979542|NCT02526745|BIOLOGICAL|the vaccine with middle doses of virus content between 4.3～5.0 lgPFU|
41302286|NCT01617434|DRUG|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
41302287|NCT02909166|DRUG|aliskiren|
41302288|NCT04832841|DIAGNOSTIC_TEST|anti-spike SARS-CoV-2 IgG|Immunochemiluminescent assay by DiaSorin S.p.A. Italy
41302289|NCT05169645|OTHER|Physical activity monitoring - Symptom monitoring|"This is an observational study. There is no intervention outside the collection of data from participants. Consenting participants in the study will be provided with a Fitbit activity tracker and asked to wear it for a period of three months.~The Fitbit measures:~* Physical activity using daily step count~* Additional physical activity entries~* Heart rate~* Sleep quality~* Calories burned~* Food log~Participants will be asked to download an app onto their smart phone entitled Athena CX. This app is designed to capture:~* Urticaria symptomatology using the urticaria control test~* Symptoms of depression using 2 items from the PHQ 9~* Symptoms of anxiety using two items from the GAD~* Short form self-compassion scale"
41302290|NCT05808998|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy using TomoTherapy
40979543|NCT02526745|BIOLOGICAL|the vaccine with low doses of virus content between 4.3～5.0 lgPFU|
40775187|NCT04190368|OTHER|Team Clinic Care|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient.~Selected providers will be trained in the Team Clinic Care protocol for completing medical appointments. Team Clinic Care key components:~(1) Shared decision making: Providers, AYA, parent/caregiver will mutually agree on priorities for each medical visit using a shared decision making tool (2) Autonomy supportive care: Providers will be trained in skills building, patient centered key elements, intervention bites, reviewing plans, designed to support AYA autonomy and intrinsic motivation. AYA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach AYA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate. (4) Fidelity Review and process for self-assessment"
40775188|NCT04190368|OTHER|Standard Care|Participants attend quarterly visits (1 visit every 3 months) and see their diabetes care provider. They do not participate in Team Clinic group visits but if they need diabetes education or supportive services they will be referred for necessary care per usual methods.
40775189|NCT06325215|OTHER|Hidrocolloid Bant|In this group, after the columella and nasal area of preterm infants were cleaned and dried with sterile water, hydrocolloid dressings were applied to the areas in contact with the nasal cannula. NasalNem nasal ointment was applied twice a day to the nasal passages in contact with the cannula. If the hydrocolloid dressings melted or peeled off, they were removed, the area was cleaned, and then reapplied.
40979544|NCT02526745|BIOLOGICAL|placebo|
40979545|NCT01905657|BIOLOGICAL|Pembrolizumab|IV infusion
40979546|NCT01905657|DRUG|Docetaxel|IV infusion
40979547|NCT02360956|DRUG|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
40979548|NCT02360956|DRUG|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
40979549|NCT01366170|GENETIC|microarray analysis|
40979550|NCT01366170|GENETIC|protein expression analysis|
41302291|NCT03084575|PROCEDURE|Thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy|Thermal RF lesioning is done using Bailys RF generator. TRF parameters are 80 C, 120 seconds the TRF lesion is repeated after 180 rotation of the needle tip again after sensory and motor pre-stimulation.
41302292|NCT03084575|DRUG|hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)|L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.
40979551|NCT01366170|GENETIC|western blotting|
40979552|NCT01366170|OTHER|flow cytometry|
40979553|NCT01366170|OTHER|immunohistochemistry staining method|
40979554|NCT01366170|OTHER|laboratory biomarker analysis|
40979555|NCT01366170|OTHER|mass spectrometry|
40979556|NCT01031732|PROCEDURE|MIS-2 THA|MIS two-incision THA
40979557|NCT01031732|PROCEDURE|MIS-WJ|MIS-Watson Jones THA
40979558|NCT01031732|PROCEDURE|MIS-AL THA|Transgluteal approach
40979559|NCT01031732|PROCEDURE|MIS-PL THA|Posterolateral approach
40979560|NCT05035550|BEHAVIORAL|Non-Deceptive Placebo|"The placebos were ordered through Amazon from Zeebo® (Zeebo, Zeebo Effect, LLC, South Burlington, Vermont, USA). The placebos in this study were blue and white capsules containing Microcrystalline cellulose (an inert fiber). Ingredients include ones that are typically used to make pills including silica, gelatin, titanium dioxide, red #3 food coloring, and blue #1 food coloring. Placebo capsules were free of any active ingredients. These bottles were not branded specifically for the experiment, including the brand name (Zeebo Relief), description of the contents, directions, and a disclaimer. The investigators chose to not include a custom label for transparency and in order to increase non-deceptive placebo effects. Participants were instructed to take two pills a day, one in the morning and one in the evening."
40979561|NCT03103633|PROCEDURE|mean artery pressure|mean artery pressure declined with less than 20% of baseline
40979562|NCT03103633|PROCEDURE|bispectral index|BIS 45-60 before and after CPB; and BIS 40-45 during CPB
40979563|NCT03103633|PROCEDURE|Brain oxygen saturation|Brain oxygen saturation declined with less than 20% of baseline
40979564|NCT03103633|OTHER|Controlled|receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
40979565|NCT01521208|DEVICE|LUCAS (Lund University Cardiac Assist Sysrem)|LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied
41302293|NCT03084575|DEVICE|Thermal RF lesioning is done using Bailys RF generator|
41302294|NCT03986346|DEVICE|pulsed dye laser|The scar will receive PDL 585 nm using a 7 mm spot size. First treatment will be within 1 year post injury.
41302295|NCT03986346|OTHER|standardized care|the scar will receive standardized care such as scar massage.
40979566|NCT01521208|OTHER|Manual chest compressions|Manual CPR according to 2010 ERC guidelines will be performed
40979567|NCT01710254|DRUG|Regadenoson MRI|AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
41142394|NCT01652014|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo double-unit allogeneic UCB transplant
41302296|NCT00553059|DRUG|dexamethasone|10 mg IV 30 minutes prior to administration of chemotherapy
41302297|NCT00553059|DRUG|dronabinol|5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
41302298|NCT00553059|DRUG|palonosetron hydrochloride|0.25 mg IV 30 minutes prior to administration of chemotherapy
41302299|NCT00553059|OTHER|placebo|1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
40775190|NCT04866719|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
40775191|NCT03088683|DEVICE|Nathanson Retractor|Liver will be retracted with Nathanson retractor
40775192|NCT03088683|DEVICE|Reveel Retractor|Liver will be retracted with Reveel retractor
40775193|NCT06562829|DEVICE|Virtual reality technology|Group B (Lidocaine injection after puncture): ①Download games in the VR headset in advance,The games last approximately 10-15 minutes. Games were selected based on children's preferences, and the VR headset was worn in the optimal state 5 minutes before catheterization.②Sterilized skin -maximum sterile barrier-ultrasound-guided puncture insertion of guidewire -local infiltration anesthesia with 2% lidocaine -broad skin, insertion of skin expansion sheath -insertion of catheter.
40775194|NCT06562829|OTHER|different timing of lidocaine injection|Group C (Lidocaine injection before puncture): Steps①was the same as in group B, After disinfecting the skin, local infiltration anesthesia was administered at the prepuncture site under ultrasound guidance using 0.5ml of 2% lidocaine. Approximately 2 minutes later, a skin puncture was performed and a guidewire was inserted. A broad incision was made to accommodate the torn vascular sheath for delivering the catheter to the predetermined length.
40775195|NCT00357955|BEHAVIORAL|Behavioral counseling and peer support|Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention
40775196|NCT00357955|BEHAVIORAL|Interactive Education|interactive lectures with hands-on learning
40775197|NCT00357955|BEHAVIORAL|Role modeling|learning from peers with similar disease and problems
40775198|NCT00357955|PROCEDURE|Pharmacologic case management|provided by clinical pharmacists following pre-established algorithms
40775199|NCT02786056|OTHER|Lung MRI examination|Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
40775200|NCT05482022|DEVICE|Shiley™ phonate speaking valve|The device connects to the tracheostomy tube. Usually used to aid vocalization.
40775201|NCT05482022|OTHER|control|no intervention
40775202|NCT05047263|DRUG|Finerenone (BAY94-8862)|Tablet, 10 mg or 20 mg, once daily (OD), oral
40775203|NCT05047263|DRUG|Placebo|Tablet, once daily, oral
40775204|NCT01907282|BEHAVIORAL|Family Focused Treatment|Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
40775205|NCT01907282|BEHAVIORAL|Enhanced Care|This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
40775206|NCT06399055|DRUG|CKD-387|1 Tablet
40775207|NCT06399055|DRUG|D484|1 Tablet
40775208|NCT00654108|DRUG|Ciprofloxacin|500 milligrams(mg) will be administered orally twice daily for 5 days.
40775209|NCT00654108|BIOLOGICAL|Peru-15-pCTB|Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10\^7; 1 X 10\^8; 1 X 10\^9; and 1 X 10\^10.
40775210|NCT00654108|OTHER|Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer|Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
40775211|NCT03893357|OTHER|Data extraction from medical files|Retrospective data extraction from the medical files
40775212|NCT01131052|DRUG|Insulin Glargine|glargine once a day
40775213|NCT01131052|DRUG|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
40775214|NCT01131052|DRUG|Insulin glulisine|glulisine given as needed before meals
40775215|NCT02884102|GENETIC|genetic sequencing|
40775216|NCT04214392|BIOLOGICAL|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)|Given via ICT delivery
40979568|NCT01710254|DRUG|Gadobenate dimeglumine|Resting perfusion with Multihance Gd-BOPTA contrast agent will be performed first, then a regadenoson injection will be given and MR imaging performed with a Gd-BOPTA contrast agent bolus 60-100 seconds later.
40979569|NCT03467841|DEVICE|CMV IgM, IgG in blood real time PCR for serum CMV DNA .|Colonoscopic examination will be done for all studied patients after standardbowel preparation using a Pentax videoscope to= Assess the endoscopic lesions using Mayo endoscopic subscore
40979570|NCT02398851|BEHAVIORAL|TacTic care model|Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones
40979571|NCT02398851|BEHAVIORAL|Standard of care|Patients receive care in a patient-centered, coordinated care model without the integration of technology
40979572|NCT05781607|COMBINATION_PRODUCT|Patient education combined with drug therapy|Receive a health education by a specialist therapist, including explaining the anatomy and function of TMJ; Explain the etiology, prognosis, treatment plan and prognosis of TMD; Correct the patients' daily oral habits, such as unilateral chewing, habitual clenching, eating too much hard food, etc; Instruct the patient to understand the rest position of the temporomandibular joint and correct the bad posture of the neck and shoulder. At the same time, corresponding medication should be given, and NSAIDS should be taken orally or externally for patients with pain.
40979573|NCT05781607|COMBINATION_PRODUCT|Individualized comprehensive physical therapy|Physical factor therapy and/or manual therapy
40979574|NCT03109301|DRUG|Selumetinib (AZD6244 hyd sulfate) 50mg/dose|Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
40775217|NCT04214392|BIOLOGICAL|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)|Given via ICT/ICV dual delivery
40775218|NCT01888016|OTHER|fascial manipulation|• 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.
40979575|NCT03109301|DRUG|Selumetinib (AZD6244 hyd sulfate) 25mg/m2|Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children \< 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
40979576|NCT04883502|BIOLOGICAL|Blood sample collection|A blood sample will be collected at enrollment.
40979577|NCT04883502|BIOLOGICAL|Other biological sample collection|"The following biological samples will be collected during the first surgery:~* 1 blood sample~* 3 fragments of induced membrane~* 1 fragment of periosteum"
40979578|NCT04883502|DIAGNOSTIC_TEST|Surgical waste collection|The pieces of polymethylmethacrylate surgical cement will be collected during the second surgery.
41302300|NCT04760353|DIETARY_SUPPLEMENT|Probiotic mixture (OMNi-BiOTiC STRESS)|OMNi-BiOTiC STRESS containing 9 human bacterial strains \[Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)\] and vitamin B (B2, B6, B12),
41461198|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)|2 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg) followed by one at Pfs25-IMX313(10µg)/Matrix-M (50µg)
41461199|NCT02745860|DRUG|Selexipag (adult formulation)|One selexipag film-coated tablet of 200 µg
40775219|NCT01888016|OTHER|standard physiotherapies treatment|"10 standard treatments in 2 weeks~* Deltoid and infraspinatus muscles electrotherapy~* Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day~* Scar massage~* Upper limb, cervical spine and scapula massages~* Passive and assisted/active shoulder mobilization exercises~* Scapula micro-mobilizations~* Gleno-humeral decoaptation~* Elbow, wrist and hand active mobilization~* Proprioceptive exercise with and without the aid of the mirror"
40775220|NCT04961905|DRUG|NVP-2002-R1+NVP-2002-R2|NVP-2002-R1 1 tablet, once daily and NVP-2002-R2 1 tablet, once daily
40775221|NCT04961905|DRUG|NVP-2002|NVP-2002 is a combination of NVP-2002-R1 and NVP-2002_R2 NVP-2002, 1 tablet, once daily
40775222|NCT05383261|OTHER|exercise|aerobic and resisted ex
40775223|NCT04768153|BIOLOGICAL|Serology|Serological diagnosis of COVID-19 in patients with cancer from a sample of cancer patients, at 3 and 6 months after implementation of confinement in France
40775224|NCT04096066|DRUG|Carfilzomib|"* 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~* 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~* 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards."
40775225|NCT04096066|DRUG|Lenalidomide|- 25 mg orally on days 1-21 of each cycle.
40979579|NCT04883502|DIAGNOSTIC_TEST|Radiological examination and functional exploration|A radiological examination and a functional exploration will be performed 6 weeks, 3 months and 6 months after the first surgery
40979580|NCT03668912|BEHAVIORAL|Guided participation discharge programme|A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
40979581|NCT01725620|DRUG|LBEC0101 (Etanercept 25mg)|
40979582|NCT01725620|DRUG|Enbrel (Etanercept 25mg)|
40979583|NCT05432414|DRUG|pomalidomide|Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.
40979584|NCT05432414|DRUG|Bortezomib|Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
40979585|NCT05432414|DRUG|Dexamethasone|Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
40979586|NCT02872467|DRUG|Syntocinon treatment|24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
40979587|NCT02872467|OTHER|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
40979588|NCT03993340|DEVICE|Rescue stenting|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
40979589|NCT05964244|DEVICE|Vela Investigational Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
40979590|NCT05964244|DEVICE|Nivairo Standard Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
40979591|NCT02408640|BEHAVIORAL|Cannabishjalpen.se|
40979592|NCT04288323|DRUG|Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid|This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
40979593|NCT04845789|OTHER|Non-interventional|Non-interventional. Interview would be conducted for data collection.
40979594|NCT03414424|DEVICE|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
40979595|NCT03414424|DEVICE|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
40979596|NCT03520231|DRUG|Denosumab|RANK Ligand Inhibitor
40979597|NCT03520231|OTHER|Denosumab Placebo|Placebo
40979598|NCT03520231|DRUG|Gemcitabine|Antineoplastic Agent
40979599|NCT03520231|DRUG|Carboplatin|Antineoplastic Agent
40979600|NCT03520231|DRUG|Cisplatin|Antineoplastic Agent
41461200|NCT02745860|DRUG|Selexipag (pediatric formulation)|Four selexipag film-coated tablets of 50 µg
41461201|NCT00347048|DRUG|tacrolimus|oral
41461202|NCT00347048|DRUG|Placebo|oral
41461203|NCT05077501|DRUG|ACD856|Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
40979601|NCT03520231|DIETARY_SUPPLEMENT|Calcium|Calcium Supplement
40775226|NCT04096066|DRUG|Dexamethasone|"- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients \>75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle."
40775227|NCT02825108|DRUG|Intra uterine injection of tissue culture medium containing HCG+ET|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
40775228|NCT02825108|DRUG|Intra uterine injection of tissue culture medium +ET|) only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
40979602|NCT03520231|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D Supplement
40979603|NCT03662685|OTHER|Goeckerman Therapy|The Goeckerman regimen consists of exposure to narrowband ultraviolet B (NB-UVB) light phototherapy and application of crude coal tar to the skin 5 days per week. The treatment will occur the UCSF outpatient skin treatment center for approximately 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions). The treatment is consistent with the standard of care Goeckerman treatment protocol at UCSF.
40979604|NCT03662685|DRUG|Crude Coal Tar Only|A topical medication consisting of crude coal tar will be applied to the psoriatic skin under plastic wrap occlusion for approximately up to 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions), at the outpatient skin treatment center at UCSF.
40979605|NCT03662685|DEVICE|Phototherapy Only|Light treatment with narrowband ultraviolet B (NB-UVB) phototherapy three days per week for 12 weeks at the UCSF Phototherapy Center per the standard UCSF phototherapy protocol, in which starting dose is based on the subject's Fitzpatrick skin type and gradually increased as tolerated. Each phototherapy treatment will last approximately from under 1 minute to less than 15 minutes.
40979606|NCT04501666|DRUG|Nemolizumab 30 mg|Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
40979607|NCT04501666|DRUG|Placebo|Participants received matching placebo as SC injection.
40979608|NCT05898555|DEVICE|Skiin garment and pods|"Participants will be asked to wear a Skiin smart garment over their own clothes.~Small motion capture markers will be placed on their body and pressure-sensitive insoles placed into their shoes to measure the pressure underneath their feet during the study tasks.~Once the sensors are ready for collection, participants will be asked to complete 5 tasks associated with their daily activities: 1. Locomotion; 2. Lower limb strength - repeated sit-to-stand-to-sit transitions; 3. Lower limb strength and locomotion - Timed Up and Go; 4. Free walking during a 2min walk; 5. Standing balance, postural control."
40979609|NCT02723669|DRUG|AR10|effervescent tablet
40979610|NCT02723669|DRUG|acetylcysteine|oral solution
40775229|NCT02825108|PROCEDURE|ET|the embryo transfer ( ET) is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
40775230|NCT06544720|BIOLOGICAL|SCG142 TCR-T cells|Monotherapy of SCG142
40979611|NCT00398892|DRUG|Lipoic acid|Lipoic acid capsules
40979612|NCT03244345|BEHAVIORAL|Self-measurement scale of sensitivity to stress/emotion|Patient will answer self-questionner on Depression
40979613|NCT03578991|DEVICE|Smart pillbox|The smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app).
40979614|NCT03578991|OTHER|Interactive digital platform|The digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it.
40979615|NCT04425174|PROCEDURE|Quadratous lumborum block|Quadratus Lumborum (QL) block is a new technique for analgesia of the abdominal wall muscles. Its mechanism depends on the injection of the local anesthetic agent between the abdominal wall muscles into the thoracolumbar fascia surrounding the Quadratus Lumborum muscle by ultrasound (US) guided technique.
40979616|NCT04425174|PROCEDURE|Epidural anesthesia|Epidural analgesia is a gold standard analgesic technique for the majority of abdominal surgeries, yet it has some limitations in some surgeries as colorectal surgeries due to delayed ambulation due to muscular weakness and postural hypotension.
40979617|NCT02730455|DRUG|natalizumab|Administered as specified in the treatment arm
40979618|NCT02730455|DRUG|Placebo|Matched placebo
40979619|NCT01558830|DRUG|ranolazine|ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
40979620|NCT01558830|DRUG|placebo|one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
40979621|NCT00111592|PROCEDURE|current usual care|current usual care
40979622|NCT00111592|PROCEDURE|treatment protocol with clear indications for therapy|treatment protocol with clear indications for therapy
40979623|NCT03336333|DRUG|Zanubrutinib|Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)
40979624|NCT03336333|DRUG|Bendamustine|Administered intravenously (IV) at a dose of 90 mg/m\^2/day on the first 2 days of each cycle for 6 cycles.
41142395|NCT01652014|PROCEDURE|umbilical cord blood transplantation|Undergo single allogeneic UCB transplant
40775231|NCT02284191|RADIATION|CT Coronary Angiogram|Completion of a CT Coronary Angiogram
41302301|NCT04760353|OTHER|Placebo|"one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.~* Powder portion bags are suitable for participants with intolerance to yeasts or lactose~* Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks)."
40979625|NCT03336333|DRUG|Rituximab|Administered intravenously (IV) at a dose of 375 mg/m\^2 on day 0 of cycle 1, and at a dose of 500 mg/m\^2 on day 1 of cycles 2 to 6
40979626|NCT03336333|DRUG|Venetoclax|400 mg tablets administered orally once daily.
40979627|NCT00115687|DRUG|placebo|
40979628|NCT00115687|DRUG|2 mg nicotine polacrilex|
40979629|NCT03171129|DEVICE|Adaptive Dynamic Inspiratory Nasal Apparatus|Oxygen will be administered via ADINA
40979630|NCT03171129|DEVICE|High flow Nasal Canula|Oxygen will be administered via nasal canula
40979631|NCT01617174|BEHAVIORAL|Webcore telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
40979632|NCT01777256|DRUG|GSK2586184 50 mg|GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
40979633|NCT01777256|DRUG|GSK2586184 100 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
40979634|NCT01777256|DRUG|GSK2586184 200 mg|GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
40979635|NCT01777256|DRUG|GSK2586184 400 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
40979636|NCT01777256|DRUG|Placebo|Matching placebo tablet will be administered orally twice daily up to 12 weeks.
40979637|NCT04969120|DRUG|Metoclopramide 10mg|this group receive 10mg intravenous metoclopramide slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
41142396|NCT01652014|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo double-unit allogeneic UCB transplant
41142397|NCT01652014|RADIATION|total-body irradiation|Undergo TBI
41302302|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.
41302303|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days
41302304|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
41461204|NCT05077501|DRUG|Placebo|Placebo oral solution
40979638|NCT04969120|DRUG|Placebo (0.9 sodium chloride)|this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
40979639|NCT00662363|DRUG|Lubiprostone|24 µg po BID given with meals for 6 days
40979640|NCT00662363|DRUG|Senna|2 tabs daily for 6 days
40979641|NCT03485768|PROCEDURE|percutaneous disc decompression with coblation nucleoplasty|PDCN was performed using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA) under local anesthesia. The introducer cannula was then pierced into the target intervertebral disc through an anterior lateral approach. The tip of the cannula stylet was aimed for the center of the nucleus in both the coronal and sagittal planes. The stylet was withdrawn from the introducer cannula and replaced with the Perc-DC SpineWand. The wand was advanced until its tip extended approximately 5 mm beyond the tip of the cannula. A short initial coagulation was performed upon wand insertion to ensure correct placement, if stimulation or movement was detected, the wand was repositioned. As the wand was drawn back out through the disc, ablation energy was set to level three and three ablation cycles of 5-12soconds each were performed, rotating the wand tip 180 degree each time to form three consecutive pockets within the disc.
41302305|NCT05876650|OTHER|Pilates exercises|Pilates exercises starts with warm up, followed by 6 main exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow. The session will end with the cool down exercises. Each exercise will be repeated 10 times for 5 sets. Patients will be treated 3 times per week for 4 consecutive weeks.
41302306|NCT05876650|OTHER|Yoga|Yoga will start with warm up followed by 6 yoga poses which are Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow poseThe session will end with a cool down pose. Each yoga pose will be held for 8-10 breathes Patients will be treated 3 times per week for 4 consecutive weeks.
41461205|NCT00506012|DRUG|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
41461206|NCT02647515|DRUG|ranibizumab|
41461207|NCT00746486|DRUG|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
40775232|NCT05943678|DEVICE|Siemens Magnetom 7T Plus|Magnetic Resonance Spectroscopy
40979642|NCT03485768|PROCEDURE|Manual Therapy (SNAGs plus PJMs)|"(1) sustained natural apophyseal glides (SNAGs): Use the methods described in Mulligan BR. Manual therapy NAGS, SNAGS, MWMS etc. 5th ed. Wellington, New Zealand: Plane View Services; 2004. Three sessions per week and for a total of four to six weeks according to the patients' condition, they were asked to continue the self-SNAG once daily until the last follow-up, and recorded in a diary. (2) passive joint mobilisations (PJMs): Use the methods described in Maitland G. Vertebral manipulation. 6th ed. Oxford: Butterworth Heinemann; 2001. For three repetitions weekly and for a total of four to six weeks according to the patients' condition, then once a day were commenced as a home exercise to be continued until the last follow-up, and recorded in a diary."
41142398|NCT01652014|DRUG|tacrolimus|Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml
41142399|NCT01652014|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo single allogeneic UCB transplant
41142400|NCT01652014|PROCEDURE|peripheral blood stem cell transplantation|Undergo irradiated allogeneic peripheral blood stem cell transplant
41142401|NCT04979702|BEHAVIORAL|Active Control|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses
41461208|NCT00746486|DRUG|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
41461209|NCT06239428|BEHAVIORAL|i-TREAT|A 12-session internet-based cognitive behavioral intervention for Danish adolescents and adults with Other Specified Feeding or Eating Disorders.
41302307|NCT03260205|DRUG|Placebo|Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
41461210|NCT06239428|OTHER|Waitlist|A 12-week waitlist with access to online mindfulness material.
41461211|NCT00856349|BEHAVIORAL|Therapy Programming Report (TPR)|Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
41461212|NCT04338334|OTHER|Manual drainage & arm therapeutic exercise|See arm/group descriptions.
41461213|NCT04338334|OTHER|Cohesive bandaging & arm therapeutic exercise|See arm/group descriptions.
41461214|NCT04615494|PROCEDURE|Position|Pneumoperitoneum with Steep Trendelenburg position
41461215|NCT03693950|BIOLOGICAL|BCD-066|BCD-066 will be administered once a week intravenously in a dose 1 µg/kg
40775233|NCT02724839|BEHAVIORAL|Group nutrition sessions|The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Three non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (Arm 1), monthly (Arm 2) and weekly (Arm 3).
40775234|NCT02724839|DEVICE|Fitbit|Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 9 months.
40979643|NCT06356155|DRUG|Enfortumab vedotin|1.25 mg/kg IV
40979644|NCT06356155|DRUG|Pembrolizumab|200 mg IV
40979645|NCT06408532|DRUG|IDegLira|The participants in this group will be switched to IDegLira once daily injection therapy.
40979646|NCT06408532|DRUG|Premixed insulin|The participants in this group will be have optimized premixed insulin regimen.
40979647|NCT05914714|DRUG|Ruxolitinib 5 MG BID Oral Tablet|ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
40979648|NCT05778123|OTHER|Type of disease|Different types of pathogen: brain injury by trauma or hydrocephalus due to various diseases.
40979649|NCT02338284|OTHER|ultrasound of globe|"* A high resolution 7.5 -10 MHz linear array ultrasound transducer probe will be used. A large amount of standard water-soluble ultrasound transmission gel will be applied to the patient's closed eyelid. The globe will be scanned in the transverse plane.• The ONSD will be measured at a predefined point 3 mm posterior to the globe in both eyes. • Measurement of the ONSD for both eyes will be done and the average the two measurements will be taken.~* A value \> 58mm (from reference 1) will be considered as indicative of increased ICP and the primary ICU team will be informed for rapid measures to decrease ICP or urgent imaging of the CNS."
40979650|NCT05460117|DEVICE|Radiofrecuency|he use of 448kilohertz capacitive resistive monopolar radiofrequency as the focus of the treatment looking for improve the quality of the tissue is still to be explored.
40979651|NCT06187727|DRUG|Henagliflozin|After primary PCI, Henggliflozin or Placebo was administered within 24 hours, followed by daily oral administration until 6 months post-acute myocardial infarction.
41142402|NCT04979702|BEHAVIORAL|mHealth technology assisted exercise counselling|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses, exercise counselling sessions and mHealth technology
41142403|NCT05664776|DEVICE|Dynamic office chair|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
41142404|NCT05401188|OTHER|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day-surgery unit where they were discharged according to ALDRETE criteria.
41142405|NCT05401188|OTHER|hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward.
41302308|NCT03260205|DRUG|SPD489 (Lisdexamfetamine dimesylate)|SPD489 capsule in a 5:5:5:5:6 ratio to 5, 10, 20, 30 mg orally once daily for 6 weeks.
41302309|NCT03260205|DRUG|SPD489|SPD489
40979652|NCT01890551|OTHER|Dynamic kine-mri|Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.
41302310|NCT05723549|DRUG|HCP1803-3|Take it once per period
41302311|NCT05723549|DRUG|RLD2002|Take it once per period
41302312|NCT05723549|DRUG|HCP1904-1|Take it once per period
41302313|NCT03375112|PROCEDURE|Fascia iliaca compartment block|The patient will be brought to the block room within 30 minutes of arriving in recovery. An injection of local anesthetic into the fascia iliaca compartment using ultrasound guidance will be administered. The patient will then be transported back to recovery.
41461216|NCT03693950|BIOLOGICAL|Aranesp|Aranesp will be administered once a week intravenously in a dose 1 µg/kg
41461217|NCT05241314|BEHAVIORAL|Learning to BREATHE|A 6 session group-based intervention targeting adolescent mindfulness. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
41461218|NCT05241314|BEHAVIORAL|After Deployment Adaptive Parenting Tools (ADAPT)|A 14 session group-based mindful parenting intervention originally developed to increase emotion regulation among military caregivers with young children and improve youth adjustment. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
41302314|NCT03375112|DRUG|Placebo|The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
40775235|NCT06478862|DRUG|Promitil|The 10 patients recruited in each of the cohorts will receive intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Subjects who complete the 6-cycle Treatment Phase have the option to continue to receive Promitil until disease progression, death, unacceptable toxicity or withdrawal of consent.
40775236|NCT04827030|DRUG|Ropivacaïne Hydrochloride by Erector Spinae block|Ropivacaïne Hydrochloride Erector Spinae puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
40979653|NCT00004443|DRUG|NTBC|
40979654|NCT03229161|BEHAVIORAL|IWT-group|
40979655|NCT01435954|DRUG|Early combination therapy|If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
40979656|NCT01435954|DRUG|Delayed combination therapy|If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
40979657|NCT06473766|DIAGNOSTIC_TEST|RF data extraction|"To will be acquired:~10 S-Harmonic images (5 in longitudinal plane, 5 in orthogonal plane), 10 B-mode fundamental images (without Harmonic), 1 gray-scale video clip, 1 gray-scale 3D vol will be stored in Harmonic settings and RF-preset.~The Region of interest (ROI) of each image will be manually segmented by a trained gynecologist using the software Aliza version 1.48. The ROI will include only the solid component of the mass. Additional analysis will be performed by using a predefined ROI (area 2x2 cm2). Radiomic features will be extracted using the MODDICOM, an open-source in-house software solution developed by the Knowledge Based Oncology Labs (Rome, Italy) for quantitative imaging analysis fully compliant with the Image Biomarker Standardization Initiative recommendations. The features will be considered: intensity-based statistical and textural."
40979658|NCT05620563|DRUG|LY3857210|Administered orally
40979659|NCT05620563|DRUG|Placebo|Administered orally
40979660|NCT01157936|DRUG|Allopurinol|daily dosage
40979661|NCT01157936|OTHER|placebo|daily dosage
40979662|NCT03294057|BEHAVIORAL|Tele-coaching programs|Tele-coaching program conducted 12 times (one time for one week), and more than 20 minutes each by a trained nurse. Coaching content specifically, 1) evaluation, 2) facing and accepting the health crisis, 3) setting up new goals, 4) making decisions and plans, and 5) practice.
40979663|NCT03294057|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH)
40979664|NCT03294057|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
40979665|NCT00233103|DRUG|Sertraline|Sertraline arm
40979666|NCT00233103|DRUG|Placebo|Placebo
40979667|NCT04445324|BEHAVIORAL|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
41142406|NCT02482324|DRUG|ALZT-OP1a|Mast cell stabilizer
40979668|NCT04445324|OTHER|Control Group (pharmacotherapy and/or psychotherapy, n=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
41142407|NCT02482324|DRUG|ALZT-OP1b|anti-inflammatory
41142408|NCT02482324|DEVICE|Dry Powder Inhaler|The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
41146959|NCT06032416|RADIATION|Preoperative CT Scan|Preoperative CT Scan including a bone density calibration phantom. This data will be compared with surgeon intra-operative CRF responses.
40775237|NCT04827030|DRUG|Ropivacaïne Hydrochloride by Paravertebral block|Paravertebral puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
40775238|NCT03732755|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
40775239|NCT04435158|DRUG|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous injection
40979669|NCT05625672|OTHER|Training|Hemovigilance module training
40979670|NCT00924456|BEHAVIORAL|Transcendental Meditation program|a natural effortless mental technique
40979671|NCT03836612|OTHER|No intervention|Observation of routine clinical practice
40979672|NCT01117831|OTHER|Epidemiological intervention|An analysis of 600 diabetic patients in the Island of PR to evaluate metabolic control.
40979673|NCT00853801|BEHAVIORAL|Lifestyle intervention and provider feedback|"Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.~Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months."
40979674|NCT01318304|OTHER|Vaginal lavage specimen|Collection of 3cc of saline used in the vagina to collect innate immunity markers
40979675|NCT03249766|OTHER|Observational|Observational study
40979676|NCT01988792|DIETARY_SUPPLEMENT|Human milk fortifiers|
40979677|NCT01550640|DRUG|Remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
40979678|NCT04850690|DIAGNOSTIC_TEST|2D Gait analysis|"The gait with four different conditions (single gait, Cognitive Task, Motor Task and Cognitive Task\&Motor Task) was evaluated by Kinovea video analysis method on a 10-meter course.~* Single: Walking without task at a self-selected speed~* Cognitive Task (CT): Walking while counting down rhythmically from 20 in threes~* Motor Task (MT): Walking while carrying an empty box~* CT + MT: Walking while carrying an empty box and counting down rhythmically from 20 in threes"
40979679|NCT00865124|DRUG|Spironolactone|25 mg capsule daily for 6 months
40979680|NCT00865124|DRUG|Hydrochlorothiazide + potassium|hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
40979681|NCT00865124|OTHER|Placebo|Placebo capsule daily
40979682|NCT06377228|BIOLOGICAL|TAK-007|TAK-007 IV infusion.
40775240|NCT04435158|DRUG|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous injection
40979683|NCT06377228|DRUG|Chemotherapy Agents|Fludarabine and cyclophosphamide as per standard of care.
40979684|NCT02484963|DRUG|Zolpidem|
40979685|NCT02484963|DRUG|placebo|
40979686|NCT02697786|DEVICE|Transcranial doppler|Prolonged de airing to decrease the number of MES
40979687|NCT01806545|BIOLOGICAL|SRM003|One time implant (2 SRM003 pieces) on surgery day.
40979688|NCT01806545|OTHER|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
40979689|NCT04769024|DEVICE|LUMEEN Virtual Reality sessions|"It will consist in carrying out 12 virtual reality sessions in groups of 6 participants, at a rate of 2 per week for approximately 6 weeks, using the LUMEEN EVASION module. Each session lasts approximately 45 minutes. This module allows the simultaneous broadcasting in virtual reality headsets of 360° videos accompanied by music about different themes: nature, animals, travel, art and live performance.~The course of an EVASION session is as follows:~1. The participants are seated in armchairs in an open environment and sufficiently spaced so that they can move their arms without bumping into each other.~2. The facilitator announces the immersion theme of the session~3. Participants are equipped with virtual reality head-mounted displays.~4. Participants watch the content.~5. The head-mounted displays are removed.~6. A group discussion encouraging participants to share their feelings and what they have learned from the immersion is conducted by the facilitator."
40979690|NCT04769024|BEHAVIORAL|Control/non-digital stimulation sessions|It will consist in non-digital stimulation (sensory, social, cognitive, creative) group sessions offering various typical pen-and-paper activities for this public which mainly stimulate language, immediate memory, semantic memory, and visual recognition (e.g., definitions, games of 7 differences, reconstruction of proverbs, quizzes...). A set of activities with instructions will be provided to the investigating centres but the choice of activities in each session will be left to the facilitator's decision in order to adapt the sessions to the participants' desires and abilities, as is usually done in such stimulation groups. The sessions will last 45 minutes and will be offered twice a week for 6 weeks by a facilitator or a caregiver with group care training. The sessions will be organized in groups of 6 participants to match the group size of the intervention groups.
40979691|NCT01059825|DRUG|Placebo to Ertugliflozin|Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
40979692|NCT01059825|DRUG|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
40979693|NCT01059825|DRUG|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
40979694|NCT01059825|DRUG|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
40979695|NCT01059825|DRUG|Sitagliptin 100 mg|Tablet, 100 mg, once daily for 84 days
40979696|NCT01059825|DRUG|Placebo to Sitagliptin|Tablet, matching placebo to 100 mg, once daily for 84 days
40979697|NCT01059825|DRUG|Metformin|Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
40979698|NCT01831544|DEVICE|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
40979699|NCT04857242|DIAGNOSTIC_TEST|Apnea test, alveolar recruitment|Alveolar recruitment following the phase of apnea testing
40979700|NCT04234321|DRUG|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
41142409|NCT05689424|DRUG|HDV-Insulin Lispro|The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS). It is a nano-carrier-based formulation of insulin which is the active therapeutic ingredient in the product. The nano-carrier component of the formulation contains a hepatic target molecule, biotin phosphatidylethanolamine, which has an affinity for hepatocytes and enables the product to deliver insulin directly to the liver.
40775241|NCT06149169|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor(CAR) T Cells|Relma-cel be administered at one dose level:1×10\^8 CAR+T cells
40979701|NCT04234321|DRUG|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
40979702|NCT04234321|DRUG|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
40979703|NCT05336955|OTHER|Intake and quarterly assessment:|The START Plan is designed to evaluate the mental health needs of persons with IDD and measure the capacity of the formal and natural support systems. Family caregivers, or the person primarily responsible for day-to-day care of the person, participate in a formatted interview conducted by START coordinators. The START coordinator completes the initial START Plan during intake and quarterly thereafter. Based on informant responses, an intensity rating is assigned to determine the type, frequency, and duration of services to be provided. Quarterly assessment is conducted to inform development or modification of the Cross-Systems Crisis Prevention and Intervention Plan (D.2.b.2.). Hypothesized causal pathway: Family caregiver engagement in assessment enables the START team to efficiently and effectively identify needs and socially valid solutions that strategically reduce use of emergency services and increase mental health stability.
40979704|NCT05336955|OTHER|Consultation & coping skills coaching:|Mental health service consultation is provided by START clinical and medical directors in order to prevent and de-escalate crises. Coping skills coaching, provided by START coordinators, helps to determine with the person, their family, and the system of care how to promote well-being and stability. Successful coping skills for the person are incorporated into the Cross-Systems Crisis Prevention and Intervention Plan. All methods are manualized and reported to meet model fidelity. Hypothesized causal pathway: Providing consultation and coping skills coaching to youth and young adults with IDD, their families, and their system of care increases capacity for crisis prevention and stabilization, reduces emergency service use, and increases quality of care, leading to long-term stability.
40979705|NCT05336955|OTHER|24-hour urgent crisis response and intervention:|START teams have 24-hour, in-person mobile crisis intervention services. Emergency calls come from a variety of sources; clients, emergency rooms, service providers, families, and law enforcement. START provides immediate telephonic response and in-person evaluation within two hours of the initial contact. Hypothesized causal pathway: Real-time, immediate support enables the successful enactment of crisis evaluation and stabilization. This reduces severity of the crises and allows for diversion from emergency service use.
40979706|NCT05336955|OTHER|Service linkages, referrals, outreach, & training:|START teams work with stakeholders to develop and maintain linkage agreements. The purpose of these agreements is to enhance the capacity of the system as a whole and develop partnerships to reduce disparities and gaps in the service array. START coordinators conduct crisis prevention-focused outreach visits with the person and/or their system of care. Examples include training during home- and school-based visits, family caregiver coaching to implement new plans or strategies, and checking in with the person to monitor their level of stability. Hypothesized causal pathway: Increased person-centered collaboration and dialogue across systems of care promotes patient perceived quality of care, the identification of more effective strategies that support their mental health needs, and results in reduced use of emergency services.
40979707|NCT00132145|BEHAVIORAL|Vascular Management Program|
40979708|NCT00132145|BEHAVIORAL|Clinical Care Coordinators|
40979709|NCT00132145|BEHAVIORAL|Web-based Vascular Tracker for Patient and Physician|
40979710|NCT00132145|BEHAVIORAL|Automated Telephone Reminder System|
40979711|NCT02317185|DEVICE|genex bone graft with bone graft|
40979712|NCT02317185|OTHER|autogenous bone graft|
40979713|NCT06464081|OTHER|Sleep quality assessment|1. Pediatric Sleep Questionnaire.
40979714|NCT06464081|OTHER|Anthropometry|2. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate The measures 2.3 and 2.4 will be realized via the Quick Tongue-Tie assessment tool
40979715|NCT06464081|OTHER|Tongue strength assessment|3. Tongue pressure while swallowing. 4. Tongue peak pressure during tongue elevation. 5. Tongue peak pressure during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device.
40979716|NCT06464081|OTHER|Tongue endurance assessment|6. The tongue endurance during tongue elevation. 7. The tongue endurance during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device and a timer.
40979717|NCT06464081|OTHER|Orofacial praxis assessment|8. Motricité Bucco-Linguo-Faciale (MBLF) test.
40979718|NCT01024803|DEVICE|"Device name: Retina Implant model Alpha. Surgical implantation of medical device into eye"|"Surgical implantation of medical device named Retina Implant into eye to restore vision partially.~Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL."
40979719|NCT01374620|DRUG|Paclitaxel dose escalation|"Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~* 40~* 60~* 70~* 75~* 80~* 85~* 90"
40979720|NCT01374620|DRUG|Paclitaxel|Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
40979721|NCT01374620|DRUG|Cyclophosphamide|"D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days"
40979722|NCT01374620|BIOLOGICAL|Blood collection|At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
40979723|NCT00869531|OTHER|wholegrain|wholegrain wheat vs. refined wheat products
40979724|NCT00869531|OTHER|refined wheat|refined wheat products
40979725|NCT03838640|DEVICE|EPIQ 5|As described in summary Trade name of the device Philips EPIQ 5
40979726|NCT00099346|DRUG|MK0457, VX-680 (Aurora Kinase Inhibitor)|
40979727|NCT00703989|DIETARY_SUPPLEMENT|benfotiamine, α-lipoic acid|benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
40979728|NCT05442320|DEVICE|Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)|Toothpaste with 500 or 1000 ppm of fluoride
40979729|NCT06123104|DEVICE|Occlusion of blood flow diagnosed by Point of Care UltraSound (POCUS)|Tourniquets will be applied until peripheral blood flow occlusion is achieved. Total intervention time: up to 60 seconds
41142410|NCT02454556|DRUG|FOLITIME®|
41142411|NCT02454556|DRUG|Gonal-F®|
41142412|NCT03743688|BIOLOGICAL|Influenza Vaccine Recipients|0.5 mL intramuscular injection
41142413|NCT03506802|RADIATION|18F-FHBG|Given IV
41142414|NCT03506802|BIOLOGICAL|Aldesleukin|Given SC
40979730|NCT04039815|DRUG|Ascorbic acid-Vitamin B1-Hydrocortisone|intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
40775242|NCT02538796|OTHER|TEA + Grober Test + Task 1 + Grober Test|"The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
40775243|NCT02538796|OTHER|TEA + Grober Test + Task 2 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
40979731|NCT04039815|DRUG|Placebo|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
40775244|NCT02538796|OTHER|TEA + Grober Test + Implicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer)."
40979732|NCT03552653|DIETARY_SUPPLEMENT|Vitafusion Extra Strength Vitamin D|Monitor Vitamin D blood levels
40979733|NCT03031977|OTHER|visceral mobilization|
40979734|NCT04953546|OTHER|No Intervention|This is an observation study, with no intervention
40979735|NCT03958955|DRUG|Delgocitinib cream|Cream for topical application.
40979736|NCT03958955|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
40979737|NCT00042172|DRUG|Donepezil|
40979738|NCT00042172|DRUG|Ginkgo Biloba Extract|
40979739|NCT06471894|RADIATION|Magnetic resonance imaging scanning|Perform brain diffusion imaging, magnetic resonance spectroscopy, and functional magnetic resonance imaging scans on all individuals
40979740|NCT06471894|DRUG|FMT Protocol|Treatment of disease groups (UC and CD) using prepared fecal microbiota transplantation solution
40979741|NCT06346496|OTHER|Douyin Xinqing AI dialog bot|"Douyin Xinqing is an AI dialog bot. Users can start chatting with the Douyin companion bot by clicking on the Direct Message on the homepage of their accounts on Douyin app.~After a user sends any message to the Douyin companion bot, it first asks the user about his or her mood and guides him or her to start chatting around his or her emotions. According to the situation described by the user, the companion bot expresses empathy, asks questions to guide the user to talk, and provides suggestions at the appropriate time. Users can also record their emotions every day and look back regularly to observe changes in their inner feelings. In addition, the Douyin companion bot can also identify crisis situations such as suicide and severe mental illness and, if necessary, guide users to call the hotline to obtain professional psychological assistance."
40979742|NCT06346496|OTHER|Douyin Xinqing AI dialog bot for delayed intervention|Only the users in the waiting group had the task of waiting for the first four weeks, and they completed the three questionnaires at exactly the same point in time as those in the intervention group. Only after the first four weeks of intervention did the waiting group begin to receive the 28-day conversational intervention, and no additional questionnaires were interspersed in between.
40979743|NCT02516215|OTHER|No intervention|
40979744|NCT02496273|BIOLOGICAL|CTL|Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
40979745|NCT01308346|DEVICE|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)|Bioabsorbable Everolimus Eluting Coronary Stent
40979746|NCT01308346|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
40979747|NCT03445338|DRUG|K0706|Study
40979748|NCT03445338|DRUG|K0706|Study
40979749|NCT03445338|DRUG|K0706|Study
40979750|NCT05816551|OTHER|Controlled hyperthermia|Individuals will be exposed to a control trial (no hyperthermia) and a controlled hyperthermia trial.
40979751|NCT01879150|DEVICE|Cyclaplex bone anchor|Device implantation
40979752|NCT05219656|DRUG|Cyclosporine A|Rescue therapy in acute severe ulcerative colitis
40979753|NCT03187262|DRUG|Daratumumab|Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
40979754|NCT04075565|BEHAVIORAL|Terrestrial altitude|Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.
40979755|NCT04075565|BEHAVIORAL|Cloud 9|"Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application.~Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined."
40979756|NCT04435015|DRUG|Camostat Mesylate|Participants will be given Camostat mesylate three times daily.
41461219|NCT03484234|DEVICE|Ultimaster stent|Percutaneous coronary intervention with Ultimaster stent for long lesion
41461220|NCT03484234|DEVICE|Xience alpine stent|Percutaneous coronary intervention with Xience alpine stent for long lesion
40775245|NCT02538796|OTHER|TEA + Grober Test + Explicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer)."
40775246|NCT02568657|DEVICE|Celox group|
40775247|NCT02568657|DEVICE|Bakri Balloon|
40775248|NCT01038323|OTHER|CBT and milnacipran|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
40775249|NCT01038323|BEHAVIORAL|CBT with a placebo|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of a placebo. Dosing for the placebo begins with a one week starter pack. Dosage: 12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
40775250|NCT01038323|DRUG|Educational with milnacipran|"Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
40775251|NCT03674281|DEVICE|SAP|Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).
40775252|NCT03674281|DEVICE|CLC|The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.
40775253|NCT02756052|DEVICE|Anodal Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
40775254|NCT02756052|DEVICE|Sham Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
40775255|NCT02903485|OTHER|nurses perform presurgical assessement and surveillance during surgery|
40775256|NCT02903485|OTHER|the anesthetic team performs presurgical assessement and surveillance during surgery|
40775257|NCT02688439|OTHER|Sciatic Nerve block|
40775258|NCT02688439|OTHER|Leg raised 30°|
40775259|NCT02688439|OTHER|Distal tourniquet placed on the lower part of the leg|
40775260|NCT02688439|OTHER|Leg in a neutral position|
40775261|NCT06130033|DEVICE|Neuromonitoring|"Multimodal Neuromonitoring:~Transcranial Doppler - middle cerebral artery blood flow velocity Jugular venous bulb oximetry - hemoglobin oxygen saturation at the jugular venous bulb Arterial blood pressure monitoring - mean arterial, systolic and diastolic pressure monitoring at the radial artery via an in situ radial arterial line catheter Pulmonary artery catheter - to measure continuous cardiac output and mixed venous oxygen saturation Near infrared spectroscopy - to measure regional cerebral saturation of oxygen"
40775262|NCT05759403|DIAGNOSTIC_TEST|Cortical excitability using transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive neurophysiological technique for assessing human motor cortical function. With TMS, the underlying motor cortex is stimulated by an electric current induced by a transient magnetic field, generated in response to the passage of a large current through the stimulating coil located on the patient's scalp.
40775263|NCT02873156|DRUG|E2027|Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.
40775264|NCT02873156|DRUG|E2027 matched placebo|Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
41142415|NCT03506802|BIOLOGICAL|Cellular Therapy|LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV
41142416|NCT03506802|PROCEDURE|Computed Tomography|Undergo PET/CT
41142417|NCT03506802|BIOLOGICAL|Filgrastim|Given SC
41142418|NCT03506802|OTHER|Laboratory Biomarker Analysis|Correlative studies
41142419|NCT03506802|DRUG|Lenalidomide|Given PO
41142420|NCT03506802|PROCEDURE|Leukapheresis|Undergo leukapheresis
41142421|NCT03506802|DRUG|Melphalan|Given IV
41142422|NCT03506802|DRUG|Plerixafor|Given SC
41142423|NCT03506802|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41142424|NCT01924117|OTHER|Linear Array HPV Genotyping assay|All samples with the suspicion of squamous intraepithelial lesion were processed with the Linnear Array methodology to identify HPV genotypes
41142425|NCT03331978|BEHAVIORAL|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if \<85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
41461221|NCT03944109|DRUG|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
41461222|NCT03944109|DRUG|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
41461223|NCT02664987|OTHER|Patients receiving cancer pain treatment|
41461224|NCT04511156|OTHER|Foundational Helping Skills|Each site will implement three waves of Foundational Helping Skills training. Each training will include 12 trainees each, with a minimum of 2 trainers per training. Each site will include pre and post research days, where they will collect primary and secondary outcomes with support from research staff (trained raters, actors, and qualitative researcher). Each site will qualitatively assess the training after the first wave to identify any areas for modification, and after the second and third waves to develop recommendations for future implementation.
41461225|NCT03319160|DEVICE|Defibrillation|Wearable Cardioverter Defibrillator
40775265|NCT06446128|BIOLOGICAL|CD19/CD20/BCMA CAR T cells|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CD19/CD20/BCMA CAR T cells.~Cyclophosphamide and fludarabine will be given from day-5 to day-3 before the infusion for lymphodepletion. On day0 subjects will receive one dose treatment with CD19/CD20/BCMA CAR T cells by intravenous (IV) injection"
40775266|NCT00649584|DRUG|SGN-35|IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
40775267|NCT00649584|DRUG|gemcitabine|IV; 1000 mg/m2 weekly 3 out of 4 weeks
40775268|NCT03894085|DRUG|Paroxetine|Paroxetine treatment for 4 weeks usage:20-80mg Qd
40979757|NCT04435015|DRUG|Microcrystalline Cellulose, NF|Participants will be given Microcrystalline Cellulose (placebo) three times daily.
40979758|NCT01409564|DRUG|Cilostazol|Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
41302315|NCT03375112|DRUG|Bupivacaine|A one time dose of 40 milliliters of 0.5% bupivacaine will be injected into the fascia iliaca compartment
41461226|NCT00490321|DEVICE|VentrAssistTM Left Ventricular Assist Device|
40775269|NCT02244515|DRUG|dexmedetomidine|dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
40775270|NCT06349408|DRUG|IBI3001|"The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.~IBI3001 is proposed to be administered by intravenous infusion (IV)"
40775271|NCT00168376|DEVICE|Transcranial Magnetic Stimulation|
40979759|NCT01409564|DRUG|Placebo|Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
40979760|NCT05725850|OTHER|EG (Experimental A. Oleracea extract gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the EG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
40979761|NCT05725850|OTHER|GP (Gel placebo)|Prior to bleaching treatment with 35% hydrogen peroxide, the GP group also received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
41142426|NCT02980432|OTHER|changes in whole-body roll position and visual/haptic stimuli presented|In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
41142427|NCT03987815|DRUG|Nivolumab|Nivolumab
41142428|NCT00139360|DRUG|Bevacizumab|Anti angiogenesis treatment
41142429|NCT02020902|OTHER|Cetrizine hydrochloride|As provided on the patient information leaflet
41142430|NCT01351675|DRUG|Placebo|Oral, once daily
41142431|NCT01351675|DRUG|Bardoxolone Methyl: 20 mg|20 mg, oral, once daily
41142432|NCT00483457|DRUG|enzyme inhibitor therapy|enzyme inhibitor therapy
41142433|NCT00483457|GENETIC|protein expression analysis|protein expression analysis
41142434|NCT00483457|OTHER|immunohistochemistry staining method|immunohistochemistry staining method
41142435|NCT00483457|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
41142436|NCT00483457|PROCEDURE|biopsy|biopsy
41142437|NCT02386085|PROCEDURE|Osteopathic manipulative treatment (OMT)|OMT will be provided as part of the patient's health care, prior to enrollment in the study. All participants would have received the same intervention (OMT) if they had not enrolled in the study.
41142438|NCT03489356|BEHAVIORAL|Addressing Behavior Change (ABC)|The ABC is a 3-minute brief, dermatologist delivered intervention for dermatological patients that takes place during a skin examination. During the ABC intervention, dermatologists specifically assess patients' UV risk behaviors, discuss patients' motivation to use UV protection, and explore solutions to patient-reported barriers interfering with effective sunscreen use. Based on our previous research, the ABC intervention does not add additional time to the visit, but rather replaces treatment as usual conversations about sun protection.
41142439|NCT06429956|BEHAVIORAL|Mindful emotion awareness|"The mindful emotion awareness module will follow the manual by Barlow et al. (2018). In session 1, the participant will receive psychoeducation about the purpose of mindful emotion awareness (i.e., to cultivate present-focused, non-judgmental attention to one's emotional experiences) and will complete an in-session guided meditation exercise which they will be asked to practice daily using an audio file. In session 2 and 3, two additional exercises are introduced. With mindful mood induction, the participant is instructed to induce emotions and then practice mindful emotion awareness in this context. With anchoring in the present, the participant is taught four steps to help them use mindful emotion awareness to pull themself back to the present whenever they feel an emotional response start to build in their everyday life. For homework, the participant will practice mindful emotion using these exercises and the audio file."
41146960|NCT02301078|PROCEDURE|Percutaneous Needle Aponeurotomy|single procedure (day 0)
41461227|NCT00274495|DRUG|Rosiglitazone and Pegasys/Ribavirin|
41461228|NCT01174667|PROCEDURE|Specific massage for fascial release|Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
41461229|NCT01174667|OTHER|Quiet non-instructed rest for 3 minutes|Patient will lay quietly without any instructions on how to relax.
41461230|NCT02435433|DRUG|Ramucirumab|Administered IV
41461231|NCT02435433|DRUG|Placebo|Administered IV
41461232|NCT02254109|DRUG|BEA 2180 BR - rising dose|
41461233|NCT02254109|DRUG|Placebo|
41461234|NCT00248092|DRUG|NRP104|
40979762|NCT05752903|DRUG|Dexmedetomidine-propofol|1 microgram/kg dexmedetomidine+2.5 mg/kg propofol intravenous (IV) bolus, 0.5 microgram g/kg/h dexmedetomidine+2.5 mg/kg/h propofol infusion
40775272|NCT00773084|DRUG|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
40775273|NCT02423694|DEVICE|electro-acupuncture|"8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.~Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5\~1.0 mA"
40979763|NCT05752903|DRUG|Ketamine-Propofol|1 mg/kg ketamine+2.5 mg/kg propofol iv bolus, 0.25 mg/kg/h ketamine+2.5mg/kg/h propofol infusion
40979764|NCT04322253|DRUG|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
40979765|NCT02105428|BEHAVIORAL|Aerobic Exercise Training|A progressive increase in duration, frequency and intensity so the last 8 weeks of exercise are performed for 60 min, 5 days per week and at 80% of aerobic capacity. The duration includes a 5 minute warm up and 5 minute cool down. All exercise will be performed on a stationary bicycle (i.e., cycle ergometer).
40979766|NCT01508650|BEHAVIORAL|Usual care|Usual care control group
40979767|NCT01508650|BEHAVIORAL|Rehabilitation intervention|Multi-domain rehabilitation intervention
40979768|NCT00165243|PROCEDURE|Tangential radiation|Radiation given over 6 1/2 weeks
40979769|NCT02590653|DRUG|Atorvastatin|Lipid-lowering therapy
40979770|NCT02769247|DRUG|Naproxen|Oral naproxen vs placebo
40979771|NCT02769247|DRUG|Lidocaine|Intrauterine lidocaine vs normal saline
40979772|NCT02769247|DRUG|placebo|either normal saline or empty oral capsule
40979773|NCT00144963|DRUG|Vincristine Sulfate Liposomes Injection|Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
40979774|NCT00144963|DRUG|Dexamethasone|Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
40979775|NCT00616954|DRUG|ATG-F|ATG-f
41302316|NCT01193348|DRUG|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
40979776|NCT06474052|DRUG|Gelofusine 4%|Gelofusine 4% 10 ml/kg is administered following anaesthesia induction in 30 minutes.
40979777|NCT00143403|DRUG|Irinotecan + 5 FU + folinic acid|irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
40979778|NCT00143403|DRUG|Folinic Acid + 5 FU|folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
41461235|NCT04697316|DEVICE|Transcranial Direct Current Stimulation|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.
41461236|NCT04697316|DEVICE|Sham|For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.
40979779|NCT00568074|DRUG|repaglinide|
41461237|NCT02636673|PROCEDURE|Sigmoid Resection|
40979780|NCT00568074|DRUG|Glurenorm®|
40979781|NCT00568074|DRUG|Glucobay®|
40979782|NCT03276884|OTHER|Experimental Infant Formula|amino acid-based infant formula powder
40979783|NCT03276884|OTHER|Control Infant Formula|amino acid-based infant formula powder
40979784|NCT04445922|DRUG|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
40979785|NCT04445922|DRUG|reference-anastrozole tablet|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
40979786|NCT02927080|DRUG|ACE-083|Recombinant fusion protein.
40979787|NCT02927080|DRUG|ACE-083 or placebo|Recombinant fusion protein or normal saline.
40979788|NCT03855098|OTHER|Biomarkers of Fruit and Vegetable Intake|"Cross-over study where participants will visit the Human Intervention Centre (in UCD) on 3 occasions (3 study days) with a minimum one week between each visit. The order of consumption of the test foods will be randomized. The test foods are mixed vegetables (spinach and lettuce), green beans and mixed berried (strawberries and blueberries). The following definition of portion sizes will be used; green beans (120g), lettuce (20g), spinach (90g), strawberries (96g) and blueberries (75g).~For each study day, the participants will arrive fasting and provide a urine sample (0h sample). For 24h prior to the study day participants will avoid the test foods. Participants will consume the food and urine samples will be taken at 2, 4, 6 and 24 h post consumption."
40979789|NCT03982823|PROCEDURE|Hand-Sewn Sleeve Gastrectomy|After laparoscopic sleeve gastrectomy, gastrectomy site is hand-sewn with 3/0 polypropylene suture and the specimen is removed transorally.
40979790|NCT03982823|PROCEDURE|Stapled Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy is performed via 60 mm linear stapler (Endo GIATM Ultra, Covidien) .
41461238|NCT00006034|BIOLOGICAL|keyhole limpet hemocyanin|Given intradermally and IV
41461239|NCT00006034|DRUG|doxorubicin hydrochloride|Given IV
41461240|NCT02806063|PROCEDURE|intraoperative samples|
40775274|NCT02423694|DRUG|escitalopram oxalate tablets|escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
40979791|NCT04604821|BEHAVIORAL|Enhanced Milieu Teaching|A behavioral language intervention that uses naturally occurring interactions to facilitate young children's language skills.
40979792|NCT04604821|BEHAVIORAL|Parent Education|Parents receive information on child developmental milestones.
40979793|NCT05827523|DRUG|Cisplatin|Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery
40979794|NCT04997785|PROCEDURE|Ultrasound-guided Pericapsular Nerve Group (PENG) Block|PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
41302317|NCT02493309|OTHER|Prolonged sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow us to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. We will then provide a lunch meal and will continue taking blood samples and blood pressure at 30, 60, 120, 180 and 210 minutes after this lunch meal. In total, we will take 11 blood samples over the 7 ½ hour testing period.
41302318|NCT02493309|OTHER|Light activity breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of slow walking on a treadmill every 30 minutes following breakfast and lunch. In total they will do 12 five minute walks on the treadmill throughout the 7 ½ hour test period (60 minutes of walking in total). In total, we will take 11 blood samples on the day.
41302319|NCT02884791|DIETARY_SUPPLEMENT|oral carbohydrate challenge|Participants will fast for 8 hours and then drink a beverage containing fructose.
41302320|NCT03492463|DRUG|Nicotine patch|Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
41302321|NCT03492463|OTHER|Placebo patch|Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
41302322|NCT03492463|OTHER|E-cigarettes|Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
41302323|NCT03492463|OTHER|Non-nicotine e-cigarettes|Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
41461241|NCT03595241|DEVICE|Spinal cord stimulation by implanted device.|Spinal cord stimulation (SCS) protocol from the implanted device. This involves activation of the device for the (SCS) protocol including Burst DR therapy.
40775275|NCT03185221|DEVICE|Cordimax|One rapamycin eluting stent for treating the adapted coronary patients
40979795|NCT04405986|PROCEDURE|Auditory Evoked Potentials (AEP)|Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).
40979796|NCT04405986|PROCEDURE|Blink and Masseter Inhibitory Reflex|Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).
40979797|NCT04704167|OTHER|fixation of double barrel vascularised fibula|3D titanium miniplate or 3D titanium mesh tray are used as a method of fixation for double barrel vascularized fibula
40979798|NCT01943994|DRUG|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
40979799|NCT01943994|DRUG|Nicotine Replacement Therapy (NRT)|
40775276|NCT03185221|DEVICE|XIENCE V|One everolimus eluting stent for treating the adapted coronary patients
40979800|NCT00754819|DRUG|Colchicine|1mg once daily
40979801|NCT00754819|DRUG|Placebo|1 capsule daily
40979802|NCT04012385|BEHAVIORAL|lifestyle counseling|Nutritional plan and Physical activity goals
40979803|NCT03252301|DEVICE|PMD 200|finger sensor which estimate objectively the pain level
40979804|NCT04480437|DEVICE|mp-BUS data collection|Collect ultrasound raw data and B-mode images of all kind of breast lesions to external storage device.
40979805|NCT00989014|DRUG|CD07805/47|0.5% Topical Gel
40979806|NCT00989014|DRUG|CD07805/47|0.18% Topical Gel
40979807|NCT00989014|DRUG|CD07805/47|0.07% Topical Gel
40979808|NCT00989014|DRUG|CD07805/47 placebo|Vehicle Topical Gel
40979809|NCT00580606|DRUG|Glycerinated peanut allergenic extract|Glycerinated peanut extract delivered sublingually.
40979810|NCT00580606|DRUG|Placebo for peanut extract (glycerin)|Placebo (glycerin) delivered sublingually.
40979811|NCT00120770|DRUG|Cellulose Sulfate Vaginal Gel (Microbicide)|
40979812|NCT03487029|OTHER|Short duration|exercise Short duration high intensity training
40979813|NCT03487029|OTHER|Long duration|exercise Long duration high intensity training
40979814|NCT02584114|BEHAVIORAL|Peak app for memory training|
40979815|NCT02584114|BEHAVIORAL|Non-memory training group|
40979816|NCT02118051|DRUG|Ganirelix 0.25 mg.|Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle\> 14mm.
41146961|NCT02301078|DRUG|Collagenase clostridium histolyticum|Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
41146962|NCT03583944|DRUG|Eribulin Mesylate|Eribulin mesylate IV infusion.
41146963|NCT04733417|DRUG|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
41146964|NCT04733417|DRUG|famitinib|Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3.
41146965|NCT00992849|DRUG|Bevacizumab|Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
41146966|NCT05077046|OTHER|Ergonomic handwriting pen|An ergonomic handwriting pen called AWP-pen designed to reduce perceived muscle fatigue, finger tip pressure and discomfort during handwriting activities.
40979817|NCT02118051|DRUG|Recombinant choriogonadotropin alfa|Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles\> 17 mm are observed
40979818|NCT02118051|DRUG|Micronized natural progesterone.|Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
40979819|NCT05395806|OTHER|Health App|The intervention will include training health teams and patients in accessing and using a gamified health App 2-3 times a week. The App is based on a gamified character that improves its health if a patient checks its App, complies with her therapy, does regular exercise, and introduces normal levels of blood pressure, lipids level, and HbA1c levels. On the other hand, the character gets sick if the patient does not comply with her therapy or does not achieve certain levels of physical activity (i.e. 30 min moderate exercise 5 times a week or 2.5 hs a week or more than 9000 steps/day).
40979820|NCT05395806|OTHER|Usual Care|In this group, participants will receive their usual cardiovascular care according to the national guidelines. All patients receive free care at the primary care clinics and also receive free medications prescribed according to the national guidelines at the clinics. In addition, participants in this group will receive specific written information to improve their medication compliance, level of physical activity, blood pressure, HbA1c, and lipids level control.
40979821|NCT04882267|BEHAVIORAL|Team and Technology|Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
40979822|NCT04941001|DEVICE|ReferID|The ReferID tool is a digital tool which can be used to facilitate a review of asthma in primary care
40979823|NCT02452398|DEVICE|Treatment group|The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.
40979824|NCT02452398|OTHER|No intervention|Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.
40979825|NCT03220516|PROCEDURE|single use digital ureteroscope|All participants in this arm will undergo RIRS using a single use digital ureteroscope.
40979826|NCT03220516|PROCEDURE|reusable fiberoptic ureteroscope|All participants under this arm will undergo RIRS using a reusable fiberoptic ureteroscope
40979827|NCT03220516|PROCEDURE|reusable digital flexible ureteroscope|All participants under this arm will undergo RIRS using reusable digital flexible ureteroscope
40979828|NCT01114321|BEHAVIORAL|Protein and calorie controlled diet|Protein and calorie controlled diet Self-hypnotic relaxation
40979829|NCT05948254|PROCEDURE|Triple function scan body|The scan bodies were used to scan the implant position, Jaw registration and facial scan alignment, First of all scan bodies were selected according to vertical dimension of occlusion, then the emergence profile together with the selected scan body were scanned,All scan bodies were then removed from the patient mouth except one or even two that were scanned in the jaw scan step, this scan body was utilized as a stopper, the patient was asked to bite until the scan body came in contact with the lower or upper teeth in case of edentulous upper or lower arch respectively, scan body in place (in the same orientation of the previous jaw scan ) provided that at least the tip of the scan body appeared when the patient is asked to smile which would be used as a common area so that the intra oral scanner can relate the jaw scan to the lips and face.
40979830|NCT04406961|PROCEDURE|Endoscopic transpapillary antegrade sphincterotomy developed by Dr. Dovbenko.|Sph. Oddi consists of a longitudinal and circular smooth muscle layers. Circular muscle fibers form the pancreatic and duodenal parts. Anatomical justification was cutting of only the circular layer of sph Oddi by special sphincterotome. Papillary stenosis and stenosis terminal part of common bile duct due to damage only circular layer sph Oddi. Anterograde direction and hooked form of sphincterotome (endoscopic antegrade sphincterotomy- ASD) allows to capture only need layer and control depth. Also ASD was performed patient with SOD (I-III) with preservation of the longitudinal muscular layer sph Oddi and septum of papilla.
40979831|NCT04406961|DEVICE|The antegrade sphincterotome developed by Dr. Dovbenko.|A device is represented by a teflon catheter in the distal part of which a double tube of variable shape is created. The proximal part of the ASD sphincterotome consists of a handle, and a metal wire is located inside the teflon catheter for connection to an electrosurgical unit. On the distal part, the teflon catheter is formed of a double tube length is 10 to 35 mm. The metal wire exits the catheter at a distance 10 to 35 mm from the tip and enters into the tip the second teflon tube. The distal part of the knife is formed shape a hook. A metal cutting wire is located between two tubes. Moving the handle the metal wire is shifted. Pushing the metal wire or approaching in the distal part the second tube sets the depth of cut. The incision is made by moving on guidewire in bile duct. The power settings vary.
40979832|NCT04406961|PROCEDURE|Endoscopic sphincterotomy.|Endoscopic standard sphincterotomy aims at opening bile duct or pancreatic duct by cutting the papilla and sphincter muscles. After deep bile duct cannulation, the standard sphincterotome is retracted until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary. The extent of the sphincterotomy is limited by the length of the intraduodenal portion of the common bile duct.
40979833|NCT04406961|DEVICE|The standard sphincterotome.|"The standard sphincterotome, the Erlangen pull-type model, consists of a catheter containing a cautery wire exposed 15 to 25 mm near the tip of the instrument. The leading tip distal to the wire, the nose, is 5 to 10 mm in diameter. After deep bile duct cannulation, the sphincterotome is retracted slowly, until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made by lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary."
41461242|NCT00851006|DRUG|Creatine Monohydrate|Creapure brand of creatine monohydrate
41461243|NCT00842309|DRUG|d-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
41461244|NCT00842309|DRUG|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
41461245|NCT03405064|DRUG|Oral Levonadifloxacin/Linezolid Tablet|oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
41461246|NCT03405064|DRUG|Intravenous Levonadifloxacin/Linezolid Infusion|IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
40775277|NCT06443853|DIAGNOSTIC_TEST|Dental plaque scoring and dental plaque coated tooth surface measuring|"The Turesky Modified Quigley Hein Plaque Index of anterior teeth of the volunteers' was recorded using clinical visual examination.~Intraoral photographs of the volunteers were taken by using a digital camera and 3D images were recorded by an intraoral scanner. The plaque-covered area and the total surface area of the teeth were marked in the manual mode of the Image J program and the areas were measured in square pixels. The correlation between clinical visual scoring, dental plaque areas on images were compared."
40775278|NCT02755350|DRUG|Truvada|Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.
40775279|NCT06324656|PROCEDURE|crystallized phenol + platelet rich plasma application|"At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.~For enhanced healing, crystallized phenol + platelet-rich plasma application patients will receive platelet-rich plasma injections to minimize infection risk and promote tissue regeneration, all under strict sterilization to maintain cleanliness and efficacy."
40979834|NCT06306040|DRUG|Nalbuphine Versus Magnesium Sulfate|"Nalbuphine is a synthetic opioid receptor agonist-antagonist (agonist К receptor, antagonistic part μ receptor) that can produce a central analgesic effect and partial sedation. Nalbuphine is a medication that is indicated for moderate to severe pain where the patient requires an opioid agent, and other alternative treatments have been insufficient. The inhibitory effect of nalbuphine on respiration is slight and it has a capping effect. Owing to these advantages, it is widely used in pediatric surgical analgesia.~Magnesium sulphate, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, has been reported to improve hypo-magnesia and pre-eclampsia. Recently, magnesium sulphate has been gradually used as an adjuvant for sedation and analgesia during general anesthesia. Magnesium sulphate is a medication used to manage and treat multiple clinical conditions."
40775280|NCT06324656|PROCEDURE|crystallized phenol|At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.
40979835|NCT04464512|DRUG|Sufentanil|IV buprenorphine plus IV sufentanil treatment group.
40979836|NCT05329272|OTHER|Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display \[HMD\] in delivering the VR intervention), audio, and motor equipment.
40979837|NCT03498690|BEHAVIORAL|Integrative|Stakeholder groups: a-b
40979838|NCT03498690|BEHAVIORAL|Role specific|Stakeholder groups: a or b
40979839|NCT03498690|BEHAVIORAL|Consecutive|Stakeholder groups: a=\> b
40979840|NCT01335581|DEVICE|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
40979841|NCT01335581|DRUG|Retin-A and microdermabrasion|Microdermabrasion and topical lightening agent regimen
40979842|NCT01432886|DRUG|E7389|Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.
40775281|NCT02526784|DRUG|degarelix|
40775282|NCT04955821|DIAGNOSTIC_TEST|mNGS diagnose of VAP|This study is an observational study to evaluate the accuracy of pathogens in children with VAP tested by mNGS with no intervention. All patients from the cohort accept mNGS test and bacterial culture or virus PCR detection. A double sputum specimens are used for test.The reference standard is bacterial culture or virus PCR detection.
40775283|NCT06278454|DRUG|NRT6008 Injection + Systematic chemotherapy|"-Systematic chemotherapy The chemotherapy regimen is selected by the investigators at the consideration of participants' conditions, with either GN or (m)FOLFIRINOX.~GN: gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, every 21 days (3 weeks/cycle).~FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~mFOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2, and fluorouracil 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~-NRT6008 injection administration: NRT6008 injection is implanted into pancreatic tumor via endoscopic ultrasound (EUS)-guided fine-needle injection, at the instruction of the investigator. The dose of NRT6008 injection is determined by tumor volume and estimated tumor average absorbed dose."
40775284|NCT03534492|DRUG|Durvalumab|Infusion
40775285|NCT03534492|DRUG|Olaparib|P.O.
40979843|NCT00793403|OTHER|As per routinary clinical care|As per routine clinical care
40979844|NCT04037605|DRUG|Ketoconazole Pill (also known as nizoral)|Ketoconazole pill is taken 4 times per inpatient visit
40979845|NCT04037605|DRUG|Ganirelix|Ganirelix subcutaneous injection is administered twice per inpatient visit
40979846|NCT04037605|DRUG|Dexamethasone Pill|Dexamethasone pills is taken twice per inpatient visit
41461247|NCT00279760|DRUG|Belatacept|
41461248|NCT00279760|DRUG|Abatacept|
40775286|NCT03377751|PROCEDURE|Additional posterior wall isolation|"PVI and additional posterior wall isolation will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + Posterior wall isolation~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
40979847|NCT04037605|DRUG|Dexamethasone injection|Dexamethasone IV injection is given twice per inpatient visit
41461249|NCT00913536|OTHER|Using Cone beam CT in patients with Bladder Cancer|Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
41461250|NCT05814068|DRUG|antihypertensive drug treatment|Patients with hypertension will be treated for it by their physician
41461251|NCT05757700|BIOLOGICAL|19(T2)28z1xx TRAC T cell|"Participants will be treated with escalating doses of modified T cells.~Dose level -1: 3 x 10\^6 Dose level 1: 10 x 10\^6 Dose level 2: 30 x 10\^6 Dose level 3: 100 x 10\^6"
40775287|NCT03377751|PROCEDURE|Voltage-guided substrate homogenization|"PVI and additional substrate modification at low voltage areas will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + substrate homogenization at low voltage areas~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
40775288|NCT03377751|PROCEDURE|PVI only group|PVI will be performed in this arm.
40775289|NCT05284643|RADIATION|Intensity Modulated Proton Therapy (IMPT)|Participants will receive radiation therapy delivered via intensity modulated proton therapy (IMPT) simultaneous integrated boost technique over a period of 10 days, 5 days per week for approximately 2 weeks.
40775290|NCT05284643|DRUG|Bevacizumab|Bevacizumab will be administered intravenously (IV), beginning at a dose of 10 mg/kg every 2-3 weeks until disease progression.
40775291|NCT00569179|DEVICE|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
40775292|NCT01272427|DIETARY_SUPPLEMENT|water with glucose|0.75 g/kg body weight of glucose added to water
40775293|NCT01272427|DIETARY_SUPPLEMENT|water and whey protein|0.75 g/kg body weight of whey protein added to water
40775294|NCT01272427|DIETARY_SUPPLEMENT|water with noncaloric sweetener|0.15 g of sucralose added to water
41461252|NCT02563249|OTHER|Parabolic flight|
41461253|NCT02563249|OTHER|movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements|
41461254|NCT03400436|OTHER|No intervention in observational studies|No intervention in observational studies
41461255|NCT03440333|DRUG|surfactant|Pulmonary surfactant was administrated if the baby was diagnosed with respiratory distress syndrome
41461256|NCT04155073|BEHAVIORAL|smoking cessation, early COPD detection, electronic visit|electronic visits (e-visits) for smoking cessation and early detection of chronic obstructive pulmonary disease (COPD)
41461257|NCT04155073|OTHER|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
40775295|NCT05647811|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.
40775296|NCT02271880|OTHER|Medication as usual|Physicians will prescribe medication as usual to the adolescent.
40775297|NCT02271880|OTHER|STAR|Adolescents and their parents will receive 6 sessions of psychosocial treatment to improve adolescents' motivation to use medication and to develop parent/teen contracting with the goal of setting medication adherence goals.
40775298|NCT06560333|DRUG|N0892|1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg
40775299|NCT06560333|DRUG|Januvia® + Glifage XR® + Placebo|1 tablet of Januvia® 100mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Forxiga ®10mg
40775300|NCT06560333|DRUG|Forxiga® + Glifage XR® + Placebo|1 tablet of Forxiga ®10mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Januvia ® 100mg
40979848|NCT04037605|DRUG|Cosyntropin Injectable Product|Cosyntropin injection is given twice per inpatient visit
41461258|NCT02335372|PROCEDURE|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
41461259|NCT02335372|DRUG|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
41461260|NCT02335372|DRUG|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
41461261|NCT02335372|PROCEDURE|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
41461262|NCT05772286|BIOLOGICAL|763SIP8/MPLA-5 vaccine|763SIP8/MPLA-5 vaccine at day 0, week 8, week 24 and week 48.
41461263|NCT05683782|DRUG|Split thickness Apically positioned flap with Chitosan based Erythropoietin Gel application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva .1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used by the patient two times daily for 14 days.
41461264|NCT05683782|DRUG|Split thickness Apically positioned flap without Erythropoietin application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva.The patient will use a Chitosan gel without being loaded with erythropoietin two times daily for 14 days
41461265|NCT05507996|DRUG|Recombinant adeno-associated virus administration|The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.
41461266|NCT00789776|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor bone marrow transplantation
41461267|NCT00789776|DRUG|Cyclophosphamide|Given IV
41461268|NCT00789776|DRUG|Fludarabine Phosphate|Given IV
41461269|NCT00789776|OTHER|Laboratory Biomarker Analysis|Correlative studies
41461270|NCT00789776|DRUG|Mycophenolate Mofetil|Given PO
41461271|NCT00789776|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
41461272|NCT00789776|DRUG|Tacrolimus|Given IV or PO
41461273|NCT00789776|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
41461274|NCT05717387|BEHAVIORAL|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
40979849|NCT04037605|DRUG|Recombinant Human Luteinizing Hormone (also known as luveris)|Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit
40979850|NCT04037605|DRUG|Hydrocortisone Injection (also known as solu-cortef)|Hydrocortisone IV push is given twice per inpatient visit
40979851|NCT04037605|DRUG|Gonadorelin (also known as Lutrepulse)|Gonadorelin IV injection is given twice per inpatient visit
41302324|NCT06241599|DRUG|GP/PFLL+AK104|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; AK104: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; AK104 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive AK104 (once every 2 weeks)."
41302325|NCT06241599|DRUG|GP/PFLL+placebo|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; placebo: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; placebo 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive placebo (once every 2 weeks)."
41461275|NCT05717387|BEHAVIORAL|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
41461276|NCT05587023|PROCEDURE|stellate ganglion block|The experimental group was given 6ml ropivacaine for stellate ganglion block. In the control group, 6ml saline was used for stellate ganglion block.
41461277|NCT01500616|DRUG|Telaprevir|type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
41461278|NCT01500616|DRUG|Telaprevir|type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
41461279|NCT03247699|OTHER|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
41461280|NCT03247699|OTHER|"Basel phenotyping cocktail individual components"|"Oral intake of Basel phenotyping cocktail individual components and PK sampling"
41461281|NCT02876133|DEVICE|narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
41461282|NCT02876133|DEVICE|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
40979852|NCT04037605|DRUG|Corticorelin (also known as Acthrel)|Corticorelin IV injection is given twice per inpatient visit
41461283|NCT00609154|DRUG|glucagon like peptide-1|GLP-1 1 pmole/kg/min
41461284|NCT00609154|DIETARY_SUPPLEMENT|glucose control|glucose without GLP-1
40775301|NCT03707821|DEVICE|senofilcon A TEST Lens|JJVC Investigational Contact Lens
40979853|NCT04037605|DRUG|Placebo oral tablet|Placebo for Ketoconazole are given 4 times per inpatient visit
41461285|NCT04505826|DRUG|OP-1250|Complete Estrogen Receptor ANtagonist (CERAN)
41461286|NCT04979845|OTHER|Telerehabilitation|Patients will receive telerehabilitation sessions for 12 weeks including aerobic and strengthening exercises
40775302|NCT03707821|DEVICE|senofilcon A CONTROL Lens|Acuvue Oasys
40979854|NCT04037605|DRUG|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
40979855|NCT04037605|DRUG|Saline solution for injection|Saline Solution (placebo) for ganirelix subcutaneous injection
40979856|NCT02289079|DRUG|Bupivacaine|
41461287|NCT04979845|OTHER|Video exercise|Patients will receive video instructions for home based exercises
41461288|NCT06074757|DRUG|Fulvestrant injection|phosphate ester of fulvestrant for test arm
40775303|NCT02006927|DEVICE|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
40775304|NCT02390076|DEVICE|Left Low Level Light Therapy|Administration of left LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Left LLLT will target the left forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
40775305|NCT02390076|OTHER|Attention bias modification|The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
40979857|NCT02289079|DRUG|liposomal bupivacaine|
40979858|NCT04406727|BIOLOGICAL|UB-421|UB-421 in combination with their ARV
40979859|NCT04406727|OTHER|Antiretroviral (ARV)|Antiretroviral (ARV)
41461289|NCT06468722|BEHAVIORAL|Exercise-based rehabilitation|Patients performed regular physical exercise during inpatient rehabilitation
40979860|NCT01878058|OTHER|MRI Scan|Patient will receive an additional MRI scan in addition to their standard of care imaging
41302326|NCT02284958|BEHAVIORAL|Standard|Back care advice
41302327|NCT02284958|BEHAVIORAL|Walking|Back care advice, individualized 12 week pedometer-driven walking program
41302328|NCT00121355|DEVICE|safety glide|
41302329|NCT00121355|DEVICE|autocover needle|
41302330|NCT03114982|BIOLOGICAL|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
41302331|NCT03114982|BIOLOGICAL|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
41302332|NCT03104335|DRUG|Apatinib|750 mg daily once oral administration of apatinib for body surface area (BSA) \> 1.5 and 500mg daily for BSA \<1.5. Half an hour after meal and everyday at the same time is usually advised.
41302333|NCT06275971|DEVICE|Dexcom G6|Glycemic control was monitored using CGM data for seven days following cardiac surgery
41302334|NCT06275971|DEVICE|SMBG or venous/arterial blood glucose|Glycemic control was monitored using SMBG or venous/arterial blood glucose data for seven days following cardiac surgery
41302335|NCT05367687|DRUG|Camrelizumab、Rivoceranib|Camrelizumab: 200 mg, intravenous infusion. Rivoceranib: 250 mg, oral.
41302336|NCT05367687|DRUG|Camrelizumab|Camrelizumab: 200 mg, intravenous infusion.
41461290|NCT00473616|DRUG|AZD7762|intravenous infusion
41461291|NCT00473616|DRUG|Irinotecan|intravenous injection
40979861|NCT03992742|BEHAVIORAL|Initial phase: personalized instant messaging (PIM)|"intervention Group participants will receive three months of personalized interaction through IM Apps (e.g. WhatsApp, WeChat). Our counsellors will trigger the conversation and encourage the participants to set a quit day. A total of pre-set 26 messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. These messages covered generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and encouragement to quit and use SC services.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PIM (subgroup C). Incomplete responders (smokers) will be randomized to continue PIM (subgroup B) or receive OCI (subgroup A)."
40979862|NCT03992742|BEHAVIORAL|Second phase: optional cocktail interventions (OCI)|For incomplete respondents (subgroup A) randomized to OCI, the available intervention options include multi-media messages, active referral plus financial incentive, phone counseling, family/peer support and medications (NRT). Participants will be guided by cessation counsellors at 1-month follow-up telephone survey to choose any combination of OCI based on their preference. If OCI participants cannot be followed up at 1-month, they will receive multi-media messages by default.
40979863|NCT03992742|BEHAVIORAL|Initial phase: regular instant messaging (RIM)|"Participants enrolled in the Control Group will receive regular messages via IM services (e.g. WhatsApp, WeChat) since initial contact and until 3-month after baseline with a tapering schedule: 1) Baseline to 4-week (1-month): 2 times/ week (8 in total); 2) 4-week to 12-week (2- \& 3-month): 1 time/week (8 in total).~SC messages will generally include benefits of SC, encouragement on abstinence and use of SC services, tips on avoiding/ handling craving and reminder of participating in telephone follow-up. A reminder to participate in the telephone follow-up will also be sent at 1-, 2-, 3- and 6-month, making up a total of 20 messages.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive RIM (subgroup F). Incomplete responders (smokers) will be second randomized to continue RIM (subgroup E) or receive PIM (subgroup D). Those who are unable to follow up at 1-month will be considered as nonresponsive to the intervention."
40979864|NCT03992742|BEHAVIORAL|Second phase: personalized instant messaging (PIM)|"For incomplete responders allocated to PIM (subgroup D), participants will receive the same intervention as the Group A delivered at the initial stage. Participants will receive two months of personalized interaction through IM application. Please refer to Intervention Group Initial phase: personalized instant messaging (PIM) for details."
40979865|NCT03992742|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
40979866|NCT03992742|BEHAVIORAL|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
41302337|NCT01109004|DRUG|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
41461292|NCT05598164|OTHER|Botulinum toxin type A|"Patients of main group are treated with injection in internal sphincter botulinum toxin type A.~In the control group, the fissure is excised in combination with a injection in internal sphincter botulinum toxin type A."
40775306|NCT02390076|DEVICE|Right Low Level Light Therapy|Administration of right LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Right LLLT will target the right forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
40775307|NCT02390076|DEVICE|Sham Low Level Light Therapy|Administration of sham LLLT is designed to resemble active LLLT from the participant's perspective, but uses a dosage markedly below the minimal necessary threshold to elicit a response.
40775308|NCT05432310|COMBINATION_PRODUCT|A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme|Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan
40775309|NCT03064009|OTHER|Infection|This is an observational trial
40775310|NCT01728246|DRUG|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
40775311|NCT01728246|DRUG|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
40775312|NCT03810976|DRUG|Eribulin, gemcitabine|Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1\& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1\& Day 8 every 3 weeks
41461293|NCT04016194|DIAGNOSTIC_TEST|Lung function testing|Multiple-breath washout (MBW) is a safe, easy and sensitive lung function test using inert gases such as Nitrogen (N2) to assess efficiency of ventilation distribution. The latter can be estimated by the lung clearance index (LCI), an established study end-point in patients with CF
41461294|NCT05155527|DRUG|Ivermectin Tablets|6 mg/tablet
41461295|NCT05155527|OTHER|Placebo|The placebo has same form as Ivermectin.
41461296|NCT02544139|OTHER|Chagas Detect Plus|
40775313|NCT05524233|DEVICE|Active Transcranial Direct Stimulation|Subjects will receive a stimulation device to use up to 20 minutes daily for 4 weeks.
40775314|NCT06426407|DRUG|Vasopressin|Fixed dosage vasopressin ordered as an adjunctive vasopressor to norepinephrine
40775315|NCT03100279|BEHAVIORAL|Coping Cat/CAT Project|"The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, \& Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes."
40979867|NCT03992742|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
40979868|NCT03992742|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
40979869|NCT05748977|DRUG|SABA SAMA ICS Vs LABA LAMA ICs|Short acting agents,long acting agents ,ics
40979870|NCT05340868|DRUG|Semaglutide Pill|Oral semaglutide treatment
40979871|NCT03306680|RADIATION|SBRT|Patients will be assigned to treatment doses using the TITE-CRM model.
40979872|NCT00711854|DRUG|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
40979873|NCT00711854|DRUG|Linezolid|Linezolid (600 mg IV or PO twice daily)
40979874|NCT00711854|DRUG|Rifampicin|Rifampicin (600 mg IV or PO once daily)
40979875|NCT01973166|DEVICE|Picosecond Q-switched Laser Treatment|
40979876|NCT01973166|DEVICE|Nanosecond Q-switched Laser Treatment|
40979877|NCT00267046|DRUG|Palifermin|180 mcg/kg 3 days prior to chemotherapy
40979878|NCT00267046|DRUG|Placebo|Single dose 3 days prior to chemotherapy
41461297|NCT01897064|BEHAVIORAL|Aerobic Exercise|36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
41461298|NCT01897064|OTHER|Standard Psychiatric Treatment|Standard psychiatric treatment.
41461299|NCT00361686|DRUG|tramadol|
41461300|NCT00361686|DRUG|remifentanyl|
41461301|NCT00361686|DEVICE|patient contolled analgesia|
40775316|NCT03100279|BEHAVIORAL|Primary and Secondary Coping Enhancement Therapy|PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
40775317|NCT05558904|DRUG|Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|Given IV
40775318|NCT05558904|PROCEDURE|Computed Tomography|Undergo PET/CT
40775319|NCT05558904|OTHER|Laboratory Biomarker Analysis|Correlative studies
40775320|NCT05558904|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40775321|NCT01057979|BEHAVIORAL|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
40775322|NCT01057979|BEHAVIORAL|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
40775323|NCT01621646|OTHER|eggs or egg whites|2 eggs/day or 4 oz egg whites/day for 6 months
40775324|NCT05437991|DIAGNOSTIC_TEST|Independent morphological quantifications by echo-doppler using ECST method|The physician who is usually in charge of patient follow-up performs a first evaluation of carotid stenosis percentage by echo-doppler using ECST method. Then a second physician immediately performs a second evaluation using the same echo-doppler device without knowing first evaluation conclusions.
40775328|NCT02895555|PROCEDURE|i-FACTOR|Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested allograft.
40775329|NCT02895555|PROCEDURE|Allograft|Approx 50 g of allograft bone in the fused site
40775330|NCT05960578|DRUG|Apalutamide|Given PO
40775331|NCT05960578|PROCEDURE|Biopsy|Undergo tumor biopsy
40775332|NCT05960578|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40775333|NCT05960578|PROCEDURE|Computed Tomography|Undergo CT scan
40775334|NCT05960578|DRUG|Golimumab|Given SC
40775335|NCT05960578|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40979879|NCT00267046|DRUG|Adriamycin (Doxorubicin)|30 mg/m\^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m\^2).
40979880|NCT00267046|DRUG|Ifosfamide|2.5 g/m\^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m\^2); for patients receiving the AI Regimen.
40775336|NCT05960578|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
40979881|NCT00267046|DRUG|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
40775337|NCT05375422|OTHER|SARAH|Set of exercises with components of muscle strengthening, range of motion gain and home exercises.
40775338|NCT05375422|OTHER|Educational intervention|Information related to joint protection, use of splints, assistive devices and other general advice, as needed.
40775339|NCT04389060|DIETARY_SUPPLEMENT|Grape seed extract|Two capsule grape seed extract (total 600 mg)
40979882|NCT00267046|DRUG|Cisplatin|120 mg/m\^2 on day 0, for patients receiving the AP Regimen.
40979883|NCT04889716|DRUG|mosunetuzumab|1 mg IV on Cycle 1 Day 1; 2 mg IV Cycle 1 Day 8; 60 mg IV Cycle 1 Day 15; 60 mg IV on Cycle 2 Day 1 and then 30 mg IV every 21 days beginning Cycle 2 Day 1 through Cycle 17.
40979884|NCT04889716|DRUG|glofitamab|2.5 mg IV Cycle 1 Day 8; 10 mg IV Cycle 1 Day 15 then 30 mg every 21 days beginning Cycle 2 Day 1 through Cycle 12
40979885|NCT04889716|DRUG|obinutuzumab|1000 mg IV on Cycle 1 Day 1.
41461302|NCT05568173|OTHER|Boxing Training|"In addition to boxing training, stretching exercises and posture training will be given at BG. A physiotherapist with a boxing training certificate will perform modified boxing training that progresses according to the degree of difficulty. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~In the first level, patients will be asked to punch the fixed boxing mat hanging on the wall with various instructions. Then, in levels 2-4, target gloves and heavy punching bags will be used to increase the difficulty level. As the sessions progress, the resistance and frequencies between the levels will be increased by the physiotherapist. There will be 3 sessions of 30-minute boxing training per week for 8 weeks at BG."
40775340|NCT05111067|GENETIC|DNA and whole transcriptome mRNA sequencing|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc).
40775341|NCT06564233|BEHAVIORAL|care.coach Avatar™|"care.coach Avatar™ (avatar) is a conversational relational agent that serves as a virtual companion and appears on a tablet device as an animated pet avatar. Each avatar is supervised by a 24x7 remote team of trained human staff whose abilities are augmented by artificial intelligence (AI) and software-driven health coaching and clinical protocols for consistency, automation, and scale. This unique human-in-the-loop design enables safe, empathic, natural conversations that form the basis for trusting relations and lasting behavior change. In addition to being a companion, the avatar educates patients about their condition, helps manage symptoms, and reinforces other healthy habits. Independent studies have demonstrated improved outcomes at a reduced cost of care. A pilot study demonstrated the feasibility of care.coach Avatar™ as a psychosocial support and health coach in hospitalized HCT patients. More research is needed to assess efficacy and applications in other HCT settings."
40775342|NCT05105724|BIOLOGICAL|PRP|PRP was prepared using double centrifugation of the patient's autologous whole blood, and 400 µL of PRP was injected via vaginal puncture into the ovarian parenchyma.
40775343|NCT02727608|DRUG|Eculizumab|Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.
40775344|NCT01088685|DEVICE|Experimental Blister Patch|Experimental hydrogel blister patch to be applied as needed (at least every 2 days) consecutively until blister heals
40979886|NCT02064647|OTHER|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.
40979887|NCT02064647|OTHER|10/20% bolus adjustment|The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
40979888|NCT03792282|BEHAVIORAL|Time Restricted Feeding|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm).
40775345|NCT01088685|DEVICE|Marketed Pflaster|Foot Blister Patch to be applied as needed (at least every 2 days) until blister heals
40775346|NCT02682056|DEVICE|Microneedle patch|The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
40775347|NCT02682056|DEVICE|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
40775348|NCT02682056|DEVICE|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
40775349|NCT01300026|DRUG|AMG 319|AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.
40775350|NCT03015285|BEHAVIORAL|Cognitive Behavioural Therapy|A type of talk therapy called cognitive behaviour therapy (CBT) will be delivered to both groups.
40979889|NCT03792282|BEHAVIORAL|Usual care|Participants receive a general lifestyle counseling.
40979890|NCT03912766|DIAGNOSTIC_TEST|serum copeptin|routine surgical method using resectoscope inserted into the urinary bladder
40979891|NCT01506479|BEHAVIORAL|Moderate Exercise|Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.
40979892|NCT01506479|BEHAVIORAL|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
40979893|NCT01506479|BEHAVIORAL|No Intervention|No-exercise control (i.e., usual care);
40979894|NCT02226406|OTHER|A: Chair - Leg Cycle ergometer|
40979895|NCT02226406|OTHER|B: Chair - Arm Cycle ergometer|
40979896|NCT02226406|OTHER|C: Walk in place|
40979897|NCT02936245|OTHER|no specific intervention|We will not assign specific intervention in this research. We will record their baseline characteristics, received treatment, and assess the outcomes to analysis the predictors of outcome and natural history in patients with cervical spondylotic myelopathy.
40979898|NCT03382392|OTHER|Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.|
40979899|NCT00026351|BIOLOGICAL|rituximab|
40979900|NCT00026351|DRUG|pentostatin|
40979901|NCT00679146|DRUG|Thiocolchicoside+Ketoprofen|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
40979902|NCT00679146|DRUG|Thiocolchicoside|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
40979903|NCT04159025|DEVICE|CoreDx Pulmonary Mini-Forceps|Manufactured by Boston Scientific
40979904|NCT04063709|DIAGNOSTIC_TEST|Acoustic Radiation Force Impulse (ARFI) ultrasound|ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.
40979905|NCT00775151|DRUG|amlodipine 10 mg tablet|
40979906|NCT00533845|DRUG|On-Q Pain Pump|Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
40979907|NCT05613985|OTHER|Usual Care alone|"Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:~Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) \[If, during the study, PEDIS is \< 2, the ulcer will be covered with nonadherent paraffin gauze\].~Treatment 2 times a week (4 treatment weeks, 8 treatments)."
40979908|NCT05613985|DEVICE|System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|"System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.~Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®)."
40979909|NCT01490957|OTHER|Database|Database
40979910|NCT05265000|DEVICE|tSpinalStim|Patients will undergo 12-21 sessions of spinal cord stimulation therapy (30 minutes per session, 3 times a week). Up to five round stimulating electrodes will be placed on the skin midline between spinous processes in cervical, thoracic and/or lumbar region, as cathodes and rectangular pads will be placed symmetrically on the skin over the iliac crests as anodes. The stimulator generates pain-free biphasic rectangular waveform with 1 ms width pulses filled with 5-10 kHz (kilohertz) carrier frequency. A range of stimulation intensities from 0-250 mA (milliamps) may be used. We expect that the stimulation intensities needed for therapeutic effect may differ based on individual's body mass index and/or the amount of subcutaneous fat present at the stimulation site.
40979911|NCT04328584|PROCEDURE|surgical navigation system|Navigation system providing surgeons with an additional view of the chest wall lesion
40979912|NCT02924779|OTHER|No intervention|Retrospective observational study
40979913|NCT02855554|OTHER|Cardiac Magnetic Resonance (CMR) imaging techniques|Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
40979914|NCT03935906|OTHER|Reach Pathway|Trial of outreach nurse offering point-of-care Hepatitis C (HCV) testing to opiate substitution therapy patients in community pharmacies, which is hypothesised to improve number of patients tested and cured of HCV.
41302338|NCT01109004|DRUG|lenalidomide, bortezomib and dexamethasone|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
41302339|NCT01109004|DRUG|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
41302340|NCT05862324|BIOLOGICAL|TAC01-CLDN18.2|TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.
41302341|NCT00429377|DRUG|tacrolimus|
40775351|NCT04224519|BIOLOGICAL|sIPV batch 1|Type I 30 DU, Type II 32 DU, Type III 45 DU
40979915|NCT03935906|OTHER|Education-only Pathway|Trial of community pharmacists advising opiate substitution therapy patients to attend a local blood-borne virus clinic to be tested for Hepatitis C by a specialist nurse, which represents the standard care pathway for HCV patients in the countries included in the study.
40979916|NCT01572545|DRUG|Denosumab|Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
40979917|NCT01572545|DRUG|Zoledronic acid|Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
40979918|NCT06366568|DRUG|fluoride toothpaste containing 1450 ppm of MFP in a PCC base and eugenol gum product|PARTICIPANTS WILL USE A EUGENOL BASED product PRIOR TO TOOTHBRUSHING
40979919|NCT06366568|DRUG|fluoride toothpaste containing 1450 ppm of MFP in a PCC base|toothbrushing 2x a day for 2 minutes each time
40979920|NCT01647633|OTHER|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
40979921|NCT04080817|DEVICE|Neolexon|Application (Neolexon) on Tablet. Same frequency \& intensity as in the other interventions
41461303|NCT05568173|OTHER|Scapular Stabilization|"In addition to scapular stabilization training, stretching exercises and posture training will be given in SSG. Progressive strengthening training for the scapular muscles will be used in the SSG. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~At the first level, scapular clock exercise, obstacle crossing exercise, wall gliding exercise with teraband, push up exercise, trunk rotation and maximum hip flexion will be performed. Then at levels 2-4, as the levels increase, the exercises at the first level will be more difficult (ball weight, surface, number of hurdles and hurdle crossing exercise position, by changing the teraband elasticity, push-up position). In SSG, 3 sessions of 30-minute scapular stabilization training will be applied per week for 8 weeks."
40979922|NCT04080817|OTHER|Speech therapy|standard logopedic speech therapy. Same frequency \& intensity as in the other interventions
40979923|NCT04080817|OTHER|Self training|Same frequency \& intensity as in the other interventions
40979924|NCT05296759|DRUG|botulinum toxin A|botulinum toxin A injection
40979925|NCT05296759|DRUG|Gabapentin|Gabapentin oral intake
40979926|NCT05296759|DRUG|Duloxetine|Duloxetine oral drug intake
40979927|NCT02864953|DRUG|BIIB093|Administered as specified in the treatment arm.
40979928|NCT02864953|DRUG|Placebo|Administered as specified in the treatment arm.
40979929|NCT05759923|DRUG|OATD-02|Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
40979930|NCT01907204|DRUG|methylprednisolone|Oral 32mg/8d-16mg/4d-8mg/4d
40979931|NCT01907204|DRUG|Budesonide|Budesonide by metered dose inhaler
40979932|NCT01907204|DRUG|Budesonide|Budesonide by nebulization
40979933|NCT01554384|PROCEDURE|Xpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
40979934|NCT01554384|PROCEDURE|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
40979935|NCT01064401|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
40979936|NCT01064401|DRUG|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
41302342|NCT01869829|DRUG|Observational antifungal therapy|"Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care."
41302343|NCT01619384|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week validated stress reduction program, designed to teach mindfulness.
41302344|NCT05523362|DEVICE|Dexcom continuous glucose monitor|The investigational device used in this study is the Dexcom G6 Pro/Personal Continuous Blood Glucose Monitoring system.
41302345|NCT06126653|DRUG|Low Dose ARD-501|Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.2 mg/kg dosing.
41461304|NCT05228249|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood ASCT
41461305|NCT05228249|DRUG|Carmustine|Given IV
41461306|NCT05228249|DRUG|Cytarabine|Given IV
41461307|NCT05228249|DRUG|Etoposide|Given IV
41461308|NCT05228249|BIOLOGICAL|Loncastuximab Tesirine|Given IV
41461309|NCT05228249|DRUG|Melphalan|Given IV
40775352|NCT04224519|BIOLOGICAL|sIPV batch 2|Type I 30 DU, Type II 32 DU, Type III 45 DU
40979937|NCT01064401|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a for intramuscular injection
40979938|NCT01064401|DRUG|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
40979939|NCT03314428|BEHAVIORAL|Gait retraining|Over a 4-week period, runners will be asked to increase their step rate to reduce knee loading during running. Specifically, they will have to increase their preferred step rate by 10% during weekly laboratory running sessions as well as during habitual running training. In the laboratory, runners will be provided with live visual/auditory biofeedback on step rate and asked to target a specific value representing 110% or preferred step rate. During their individual running sessions, runners will be wearing a GPS-enabled watch that will provide feedback on live step rate, and they will be asked to maintain the same value as in the laboratory.
40979940|NCT02697695|OTHER|Laboratory Examination|Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
40979941|NCT03491241|DIETARY_SUPPLEMENT|hypocaloric diet therapy|all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.
40979942|NCT02031666|DRUG|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
40979943|NCT02031666|DRUG|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
40979944|NCT02916342|PROCEDURE|Interscalene brachial plexus block|Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
40979945|NCT02916342|PROCEDURE|Supraclavicular-axillary nerve blocks|Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
40979946|NCT03453944|DEVICE|VentFree prototype (VF03-K) active stimulation|Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)
40979947|NCT03453944|DEVICE|VentFree prototype (VF03-K) sham stimulation|Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
40979948|NCT04334551|DRUG|Doravirine|switches from etravirine to doravirine, in experienced HIV patients
40979949|NCT00141076|BEHAVIORAL|low vs high glycemic index diet|
40979950|NCT00022009|DRUG|gemcitabine hydrochloride|
40979951|NCT00894049|DRUG|reduced intensity conditionings|comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
40979952|NCT02054416|DEVICE|ArtAssist© Device|The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
41461310|NCT01129323|DRUG|Cyclophosphamide, Fludarabine, Rabbit ATG|Fludarabine 30mg/m2/dose IV and cyclophosphamide 10mg/kg/dose IV are given once per day from day -5 to -2. rATG 1.5 mg/kg/dose IV is given from day -4 to -1.
41461311|NCT02369354|BEHAVIORAL|TALKS Social Worker Intervention|TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
41302346|NCT06126653|DRUG|High Dose ARD-501|Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.5 mg/kg dosing.
41461312|NCT02369354|OTHER|Financial Assistance Intervention|"The financial assistance intervention offers potential donors the ability to draw from a bank of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating."
41461313|NCT02269735|DRUG|MK-2640|MK-2640 intravenous infusion administered to participant in a fasted state
40775353|NCT04224519|BIOLOGICAL|sIPV batch 3|Type I 30 DU, Type II 32 DU, Type III 45 DU
40775354|NCT02327377|BEHAVIORAL|Online Cognitive Behavior Therapy|
41302347|NCT06126653|DRUG|Placebo|Titratable, liquid formulation, taken orally.
41302348|NCT00114972|DEVICE|Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent|Drug Eluting Stent
41461314|NCT02269735|BIOLOGICAL|Regular Human Insulin (RHI)|RHI 100 units/mL intravenous infusion to maintain target glycemic level
41461315|NCT02269735|DRUG|Dextrose|Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
41461316|NCT02269735|BIOLOGICAL|Insulin aspart|Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
40775355|NCT02327377|BEHAVIORAL|Online Education|
40775356|NCT02897336|PROCEDURE|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
40775357|NCT02897336|PROCEDURE|interlaminar|interlaminar epidural corticosteroid injection
40775358|NCT00243035|DRUG|bortezomib|Given IV
40775359|NCT00243035|DRUG|tipifarnib|Given orally
41142440|NCT06429956|BEHAVIORAL|Cognitive flexibility|The cognitive flexibility module will follow the manual by Barlow et al. (2018) which is based on the principles by Beck (1976). In session 1, the participant will be psychoeducated about the purpose of cognitive flexibility (i.e., to encourage flexible thinking through reappraisal of one's automatic thinking), and how their thoughts influence their emotional reactions. For homework, the participant will be asked to monitor their automatic thoughts. In session 2, the participant will be introduced to the technique of cognitive flexibility (i.e., generating other possible interpretations), and this technique will be practiced throughout session 2 and 3. For homework, the participant will continue to monitor their automatic thoughts and generate and record other possible interpretations.
41302349|NCT00114972|PROCEDURE|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
41302350|NCT03010423|DRUG|Nicorandil|Participants received Nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks.
41302351|NCT02739594|DRUG|Ibandronate|Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
41461317|NCT02269735|DRUG|Rescue medication|Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
41461318|NCT02061358|DRUG|UV-4B 3 mg|Oral solution, single dose
41461319|NCT02061358|DRUG|UV-4B 10 mg|Oral solution, single dose
41302352|NCT02739594|DRUG|Zoledronate|Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
41461320|NCT02061358|DRUG|UV-4B 30 mg|Oral solution, single dose
40775360|NCT00243035|OTHER|laboratory biomarker analysis|Correlative studies
40775361|NCT06564415|PROCEDURE|Transperineal Laser Ablation of Prostate|Transperineal Laser Ablation of the Prostate is an ultra minimally-invasive procedure that consists in the insertion trough the perineum skin of laser fibers into the prostatic adenoma, under US guidance. Laser energy generates an area of coagulative necrosis that will bring to a reduction of the prostatic volume.
40775362|NCT05714982|OTHER|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
40775363|NCT05714982|OTHER|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
40775364|NCT05714982|OTHER|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 statements based on their assigned trial arm; at Visit 3, they will get 2 additional statements based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
41302353|NCT01428063|DRUG|Daclatasvir|
41302354|NCT01428063|DRUG|Asunaprevir|
41302355|NCT01428063|DRUG|Pegylated interferon alfa-2a|
41302356|NCT01428063|DRUG|Ribavirin|
41302357|NCT03484923|DRUG|PDR001|400 mg of PDR001 administered every 4 weeks intravenously
41461321|NCT02061358|DRUG|UV-4B 90 mg|Oral solution, single dose
41461322|NCT02061358|DRUG|UV-4B 180 mg|Oral solution, single dose
41461323|NCT02061358|DRUG|UV-4B 360 mg|Oral solution, single dose
40979953|NCT05872672|BEHAVIORAL|Sleep Program|Participants will complete the Headspace Health Sleep Program, which is an 18 day program based on CBTi, and includes the following intervention components: 1) a sleep diary to monitor sleep and associated factors; 2) cognitive interventions to address maladaptive thoughts related to sleep; 3) behavioral interventions to address maladaptive behaviors related to sleep (e.g., sleep hygiene, stimulus control, and sleep restriction); 4) de-arousal techniques (e.g., mindfulness, breathing, and muscle relaxation exercises).
40979954|NCT05872672|OTHER|Waitlist|Participants will continue their regular sleep routines for an 18 day period and will not be assigned to an intervention.
40979955|NCT05353231|BEHAVIORAL|Attention Feedback Awareness and Control Training (A-FACT)|"A-FACT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control.~Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Following a fixation que, the auditory neutral or negative simulated thought stimulus is delivered, and 500ms prior to termination of the auditory stimulus, a visual stimulus is presented until participants categorize the visual stimulus as greater than or smaller than 5 objects. Latency to disengage attention from each thought stimuli, at the trial-level, is repeatedly measured, and after each negative thought stimulus, trial-level feedback on the latency to disengage is delivered back to participants through a visual scale representing their attentional bias. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial."
41461324|NCT02061358|DRUG|UV-4B 720 mg|Oral solution, single dose
40979956|NCT05353231|BEHAVIORAL|Mindful Disengagement from Thoughts Training (MDTT)|MDTT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Participants will first learn and practice a focused attention on the breath meditation. Then, participants will practice pressing a button each time they notice an inhalation or exhalation during the focused attention meditation. Next, during the meditation, participants will be presented the auditory neutral or negative simulated thought stimuli and will train internal attentional control by repeatedly disengaging their attention from these stimuli and back to their breath MDTT will thus entail 80 trials (40 negative, 40 neutral, ITI ≈ 10sec) during the focused attention on the breath meditation.
40979957|NCT05353231|BEHAVIORAL|Placebo-Control|The condition is designed as a placebo control for the Attention Feedback Awareness and Control Training (A-FACT) training condition. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Rather than the quantity categorization task with trial-level feedback, participants only engage in the quantity categorization task. The task is identical in all other ways to the A-FACT condition. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial.
40979958|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Mildly Hepatic Impaired Subjects
40979959|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Moderately Hepatic Impaired Subjects
40979960|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Healthy Subjects
40979961|NCT05734625|DRUG|Bupivacaine HCl 0.5% Injectable Solution|Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
41461325|NCT02061358|DRUG|UV-4B 1000 mg|Oral solution, single dose
41461326|NCT02061358|DRUG|Placebo|Oral solution, single dose
41461327|NCT05039424|PROCEDURE|Endoscopic per-oral pyloromyotomy (POP)|Per-oral pyloromyotomy (POP), alternatively knows as gastric per-oral endoscopic myotomy (G-POEM), accomplishes longitudinal division of the pylorus using an endoscope. This procedure involves utilizing endoscopic electrosurgical knife to make an incision in the gastric mucosa and develop a submucosal tunnel to visualize the pyloric ring. The pyloric ring is divided longitudinally, and the mucosotomy incision is sealed with endoscopic clips.
41461328|NCT05039424|PROCEDURE|Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption|While under general anesthesia, a standard gastroscope is introduced and a diagnostic upper endoscopy is performed. The operator talks through the procedure steps as if completing POP. The gastroscope is withdrawn and the patient is extubated.
41461329|NCT05581134|DEVICE|Virtual Reality intervention|Virtual reality (VR) is a powerful tool to create an illusory state in which the user can feel that they have been transported to a new location (place illusion), that events happening are real (plausibility illusion), and even that bodies have been substituted by an avatar (embodiment illusion). VR illusions are driven by the same neurological mechanisms of everyday perception of the body in the world and induce realistic responses to VR.
41461330|NCT05581134|BEHAVIORAL|Control Group intervention|Treatment will follow general treatment principles in physiotherapy for FMDs: (1) education; (2) exploration of how symptoms affect movement and posture; (3) retraining movement using strategies based on redirection of attention; and (4) development of a self-management plan.
41461331|NCT01465113|DRUG|Omeprazole|28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).
41461332|NCT01465113|DRUG|Vitamin D3|These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.
40979962|NCT05734625|DRUG|Methylprednisolone 40 MG Injection|Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
40979963|NCT00901446|DEVICE|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
40979964|NCT05615272|BIOLOGICAL|Bio-PRF|Intervention group
40979965|NCT05615272|DRUG|Alveogyl|Control group
41461333|NCT01465113|DRUG|Vitamin D3|Due to the risk of progression, subjects with Barrett's esophagus with high grade dysplasia will take vitamin D3 50,000 IU once a week for 2 weeks.
41142441|NCT06128629|BIOLOGICAL|NTLA-2001|NTLA-2001 (55mg) by IV infusion
41142442|NCT06128629|DRUG|Placebo|Normal saline (0.9% NaCl) by IV infusion
40775365|NCT03512093|OTHER|Retrospective chart review|A retrospective chart review of preterm neonates born in one of the birthing SMRU unit between January 2008 and December 2017 and for whom a medical chart is available. In addition we propose to analyze the growth trajectory, the prevalence of anemia (Hct \< 33%) and the level of neurodevelopment achieved in the first year of life reported in the clinical charts of preterm neonates born \< 34+0 weeks of gestation.
40979966|NCT04062331|DEVICE|Transcranial Magnetic Stimulation (TMS)|"By means of the magnetic stimulator we induce a cerebral electric current that is able to obtain a motor potential in the first dorsal interosseous bone of the left hand.~The intervention procedure consists of two steps: First step: Obtaining the Motor Evoked Threshold at Rest: Each patient, regardless of to the group to which they belong will have his/her threshold evoked motor calculated at rest, by stimulation of the right motor cortex, evoking electromyographic responses in the contralateral muscles. Second step: Administration of TMS: To calculate the motive threshold as the percentage of the same to which the treatment will have to be applied, a device equipped with a coil. The treatment will be administered for 5 consecutive days, with 3 weeks of rest, between each stimulation. To complete a treatment period of 14 months. The stimulation with TMS will be carried out every day in the same time slot for 5 consecutive days every 4 weeks, during a period of 14 months."
40979967|NCT04062331|DRUG|Placebos|Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
40979968|NCT05745350|DRUG|Pembrolizumab, Plinabulin plus Etoposide and Platinum|Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1; Etoposide 100 mg/m2 IV Q3W on Days 1, 2, and 3; Carboplatin AUC 5 IV Q3W on Day 1 or Cisplatin 75 mg/m2 IV Q3W on Day 1; Plinabulin 30mg/m2 IV Q3W on Day 1.
40979969|NCT03883620|BIOLOGICAL|Dengushield 1 mg/kg (Cohort 1) intravenous|Participants will be administered Dengushield 1 mg/kg as slow intravenous injection.
40979970|NCT03883620|BIOLOGICAL|Dengushield 3 mg/kg (Cohort 2) intravenous|Participants will be administered Dengushield 3 mg/kg as slow intravenous infusion.
40979971|NCT03883620|BIOLOGICAL|Placebo 3 mg/kg (Cohort 2) intravenous|Participants will be administered Placebo 3 mg/kg as slow intravenous infusion.
40979972|NCT03883620|BIOLOGICAL|Dengushield 7 mg/kg (Cohort 3) intravenous|Participants will be administered Dengushield 7 mg/kg as slow intravenous infusion.
40979973|NCT03883620|BIOLOGICAL|Placebo 7 mg/kg (Cohort 3) intravenous|Participants will be administered Placebo 7 mg/kg as slow intravenous infusion.
40979974|NCT03883620|BIOLOGICAL|Dengushield 12 mg/kg (Cohort 4) intravenous|Participants will be administered Dengushield 12 mg/kg as slow intravenous infusion.
40979975|NCT03883620|BIOLOGICAL|Placebo 12 mg/kg (Cohort 4) intravenous|Participants will be administered Placebo 12 mg/kg as slow intravenous infusion.
40979976|NCT05047510|DRUG|Anti-GPC3-IRDye800CW|Drug Injection: Anti-GPC3-IRDye800CW
40979977|NCT05459324|DEVICE|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
40979978|NCT06080607|BEHAVIORAL|Patient Reported Outcome (PRO)|Quality of Life evaluation
40979979|NCT05937191|DRUG|Leflunomide|Leflunomide+Glucocorticoids treatment Group
40775366|NCT03512093|OTHER|Focus Group Discussion (FGD) of the medical staff|Focus Group Discussion (FGD) of the medical staff working in the SCBU firstly on the benefits and difficulties in using existing guidelines for preterm care and secondly on the feasibility and acceptability of changes in the guidelines 3-6 months after their implementation.
40775367|NCT03512093|OTHER|Interviews of mothers|Interviews of mothers who delivered preterm neonates (\< 37+0 weeks of gestation) to understand the challenges they faced while caring for their child.
40979980|NCT05937191|DRUG|Steroid Drug|Steroid Treatment
40979981|NCT05604690|BIOLOGICAL|Avacc 10|Intranasal application of either low dose or high dose of Covid 19 vaccine.
40979982|NCT05604690|COMBINATION_PRODUCT|Outer Membrane Vesicles (OMV) : OMV alone in vehicle|OMV will be administered via intranasal route.
40979983|NCT05604690|OTHER|Placebo|Placebo will be administered via intranasal route.
40979984|NCT03867929|OTHER|25-Hydroxy vitamin D|27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency
40979985|NCT02818686|DRUG|TD-1473|
40979986|NCT02818686|DRUG|Placebo|
40979987|NCT05871827|PROCEDURE|Intraoperative Fluoroscopic Computer Navigation|Computer technology used during surgery
40979988|NCT01914744|DRUG|Entecavir|entecavir 0.5 mg/day PO
40979989|NCT01914744|DRUG|Lamivudine|lamivudine 100 mg/day PO
40979990|NCT04949126|BEHAVIORAL|questionnaire|questionnaires of precarity, dental anxiety, self medication, pain
40979991|NCT05147493|DRUG|Isatuximab|Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.
40979992|NCT05147493|DRUG|Bortezomib|Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
40979993|NCT05147493|DRUG|Cyclophosphamide|Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
40979994|NCT05147493|DRUG|Dexamethasone|Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.
40979995|NCT05147493|DRUG|Lenalidomide|Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
40979996|NCT03263494|DEVICE|Continuous Glucose Monitor (CGM)|Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.
41142443|NCT05308888|DIAGNOSTIC_TEST|18F-FDG PET-CT|The 18F-FDG PET-CT will be performed in the nuclear medicine department of the CHU of Brest. For this exam, the administration of 2-3 MBq/kg of 18F-FDG (\[18F\]F-fluorodeoxyglucose) will be performed to the patient in a single intravenous injection.
41142444|NCT06150820|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
41302358|NCT03484923|DRUG|LAG525|600 mg of LAG525 administered every 4 weeks intravenously
41302359|NCT03484923|DRUG|INC280|400 mg of INC280 administered twice daily orally
40775368|NCT05554679|DRUG|Metformin|Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. It inhibits pathways in the liver that stimulate glucose production and also acts to increase glucose uptake into skeletal muscle and fat cells . Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome , and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of neonatal hypoglycaemia and no increased risk of adverse maternal outcomes when compared with insulin.
41302360|NCT03484923|DRUG|ACZ885|200 mg of ACZ885 administered every 4 weeks subcutaneosuly
40979997|NCT05687591|DEVICE|Amplatzer Amulet Left Atrial Appendage Occlusion Device|The Amplatzer Amulet LAAO is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constucted from a nitinol mesh and consists of a lobe and a disc connected by a central waist. Polyester patches are sewn into both the lobe and disc to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires that permit visibility during fluoroscopy.
40775369|NCT04490681|DRUG|Ertugliflozin|Fixed dose Ertugliflozin (5mg)
40775370|NCT04490681|DRUG|Placebo|Placebo group
40775371|NCT02553096|DEVICE|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
40775372|NCT02725684|OTHER|Observational study, no intervention|Observational study, no intervention
40979998|NCT00006337|DRUG|KW-6002|
40979999|NCT00006337|DRUG|IV Levodopa|
40980000|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
40980001|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
40980002|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
40980003|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
40980004|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
40980005|NCT00362115|DRUG|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
40980006|NCT00362115|DRUG|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
40775373|NCT00062257|DRUG|irofulven|
40775374|NCT04955288|PROCEDURE|Aortic balloon assisted resuscitation|On the basis of the traditional resuscitation mode, the aortic balloon occlusion technology is used, that is, at the same time when the cardiopulmonary resuscitation starts, the aortic balloon catheter is quickly punctured to the distal end of the aortic zone I (septum level) through ultrasound assistance, and then Continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
40775375|NCT04955288|PROCEDURE|Traditional cardiopulmonary resuscitation|"Use the traditional manual chest compression mode, that is, refer to the latest version of the CPR Guidelines.~Artificial chest compressions are performed under the monitoring of the pressure quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, the compression position is fixed, and the chest wall fully rebounds."
40775376|NCT04955288|PROCEDURE|Esophageal cooling|The new transesophageal cooling method is adopted, that is, the esophageal cooling catheter is indwelled after resuscitation in patients with cardiac arrest, and then connected to a small temperature-controlled water circulation system to continuously infuse 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature-controlled water circulation system is adjusted Maintain the target body temperature of (33±0.5)°C for 24 hours, and then rewarm to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
40775377|NCT04955288|PROCEDURE|traditional cooling|The traditional body surface ice blanket cooling method is adopted, that is, the patient with cardiac arrest lies on the temperature control blanket after resuscitation, and then uses the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃. The temperature of the circulating water is controlled by adjusting the ice blanket host to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
41142445|NCT01124942|DEVICE|MGuard net protective coronary stent|It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
41142446|NCT01124942|DEVICE|Bare-metal stent and manual thrombectomy device|Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
41302361|NCT03484923|DRUG|LEE011|600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
41302362|NCT00895349|PROCEDURE|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
41302363|NCT00895349|PROCEDURE|CT Abdomen and Pelvis scan|Pre-treatment scan
41302364|NCT00092040|DRUG|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
41302365|NCT00092040|DRUG|Comparator: risedronate / Duration of Intervention: 12 mo|
41461334|NCT01465113|PROCEDURE|upper endoscopy|After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.
40775378|NCT05342168|DIAGNOSTIC_TEST|Using a swallowed expanding sponge (Cytosponge TM) to obtain sampling of the esophageal musosa|A gelatin capsule containing the collapsed mesh sponge is swallowed with an attached string fixed to the cheek. After 8 minutes the gelatin capsule will have dissolved and the expanded soft mesh sponge can be with drawn sampling the surface of the esophagus on the way out. The sponge then will be spun and the supernant fixed, processed and stained.
40775379|NCT02769793|DRUG|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
40775380|NCT02769793|DRUG|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
40775381|NCT04541524|DEVICE|Santen Preserflo Microshunt|The PMS is 8.5 mm long has an outer diameter of 350 μm and a lumen diameter of 70 μm. It has a fin sized 1.1 mm located 4.5 mm distally from the internal tip of the device and it consists of poly(styrene-b-isobutylene-b-styrene) SIBS. The device was implanted 1 year prior to the present study via an ab externo approach. At the beginning of the surgery, the conjunctiva was opened. In the first group of patients (group 1) we made a fornix based conjunctival opening, prepared a 1mm wide and long scleral pocket in 3mm distance from limbus and placed the PMS in the anterior chamber via a 25G needle track. In the second group (group 2) the conjunctival opening was 3.5 mm from the limbus, the scleral pocket was prepared at 3.5 mm distance from the limbus and a 27G needle was used. PMS guides aqueous humor from the anterior chamber to the subconjunctival space. The forming filtering bleb absorbs aqueous humor which leads to IOP reduction.
40775384|NCT01146002|DRUG|Guanfacine (sustained release)|Treated with study drug once screening and initial testing is completed (see protocol above)
40775385|NCT03924414|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.
40775386|NCT03924414|OTHER|Placebo|Normal Saline 100 ml (placebo) IV infusion
40775387|NCT01365455|DRUG|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
40980007|NCT00264329|OTHER|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
40980008|NCT01614054|OTHER|Survey of patient's smoking habits|Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
40980009|NCT04217473|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
40980010|NCT00758082|DEVICE|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
40980011|NCT00758082|DEVICE|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
40980012|NCT02309489|BEHAVIORAL|Partner involvement|Partner is involved in maternity care
40980013|NCT01434069|DRUG|SOM230C LAR|Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
40980014|NCT01434069|DRUG|FOLFIRI Infusion|Standard therapy of FOLFIRI
41461335|NCT01465113|DRUG|Metformin|500mg for the first week, 1000mg during the second week, 1500mg during the third week, maximum dose of 2000mg in the fourth week
41461336|NCT04037397|DRUG|Anti Arrhythmics|Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
40775388|NCT01365455|DRUG|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
40775389|NCT03663582|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
40775390|NCT03663582|DEVICE|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).
40775391|NCT03663582|DEVICE|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
40775392|NCT03663582|DEVICE|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
40775393|NCT01731925|DRUG|Lanreotide|Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
40775394|NCT01731925|DRUG|Placebo (for sunitinib)|
40775395|NCT01731925|DRUG|Sunitinib|Sunitinib 37.5 mg daily
40775396|NCT01348893|BEHAVIORAL|Yoga|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
40775397|NCT06312215|OTHER|Closed-system catheter|Closed-system catheters was applied
40980015|NCT01108705|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
41461337|NCT04037397|PROCEDURE|Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation|Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins
41461338|NCT00006434|BIOLOGICAL|tumor-pulsed dendritic cells|
40775398|NCT03906526|DRUG|VTX-2337|Motolimod
40980016|NCT01108705|DRUG|Placebo|Tablets, Oral, 0mg, once daily, until disease progression or toxicity
41302366|NCT00778752|DRUG|Revlimid (Lenalidomide)|"3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials."
41302367|NCT00002410|DRUG|Indinavir sulfate|
40775399|NCT03906526|DRUG|Nivolumab|IV Nivolumab
40775400|NCT05481684|OTHER|Normal Progesterone group|No progesterone supplementation
40775401|NCT05481684|OTHER|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, vaginal pills (Lutinus 2\*1) or SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day. Progesterone supplementation was discontinued if there was no pregnancy. Progesterone supplementation at the same dose was continued until 10 gestational weeks for viable pregnancies.
40775402|NCT02652247|PROCEDURE|molecular analysis of exhaled breath condensate|
40775403|NCT02652247|PROCEDURE|molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate|
40775404|NCT02652247|PROCEDURE|molecular analysis of bronchoalveolar lavage (BAL) aspirate|
40775405|NCT04417530|DRUG|AU-011|AU-011 Via Suprachoroidal Administration with laser treatment
40775406|NCT04417530|DEVICE|Suprachoroidal Microinjector|Suprachoroidal Injection Device
40775407|NCT04417530|DEVICE|PDT Laser|Laser Administration
40775408|NCT04958057|BEHAVIORAL|SAIL|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
40775409|NCT06563843|PROCEDURE|Robotic-assisted TKA|Robotic-assisted Total Knee Arthroplasty or total knee replacement is a surgical procedure using a robot to resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.
40775410|NCT06563843|PROCEDURE|Conventional TKA|Conventional Total Knee Arthroplasty or total knee replacement is a surgical procedure to manually resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.
40775411|NCT06531681|DEVICE|MR-Linac|Radiation therapy with the MR-Linac
40775412|NCT00431964|DRUG|azithromycin 250 mg tablets|"* One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
40775413|NCT00431964|DRUG|placebo tablets|"* One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
40775414|NCT02161536|DEVICE|Motus Cleansing System|
40775415|NCT06014762|BIOLOGICAL|P-CD19CD20-ALLO1|Single weight-based IV administration
40775416|NCT06014762|DRUG|Rimiducid|Single weight-based IV administration
40775417|NCT04829513|PROCEDURE|Home Exercise|This is a home exercise programme that involves flexibility and strengthening of the waist, hip girdle and sacroiliac region. These exercises are first shown by the physiotherapist in hospital, and then they are asked to do the exercises at home using illustrated forms. Patients continue the exercises as a home programme once a day for 1 month.
40775418|NCT04829513|PROCEDURE|Ligament Correction Kinesiotaping|Ligament correction kinesiotaping will be applied to the patients' sacroiliac region. Taping will be done once a week. It will be kept for 5 days. This application will be repeated 3 times.
40775419|NCT04829513|PROCEDURE|Lymphatic Correction Kinesiotaping|Lymphatic correction kinesiotaping will be applied to the patients' sacroiliac region. Taping will be done once a week. It will be kept for 5 days. This application will be repeated 3 times.
41302368|NCT00002410|DRUG|Lamivudine|
41461339|NCT03848858|BEHAVIORAL|EMDR plus TAU|The standard EMDR protocol will first be applied, consisting of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation. The specific protocol for the sequelae of somatic illness and medical trauma is next applied. It first focuses on processing past memories related to diagnosis, symptom development, medical procedures and unjust or stressful behaviour with the medical system. Once these are processed, the intervention addresses current symptoms, impairments and triggers. Finally, the patient is helped to face the future and reduce avoidance of medical procedures, avoidance of social life and fear of dying.
40775420|NCT00212004|DRUG|pioglitazone|
40775421|NCT00212004|OTHER|control|
41461340|NCT05459116|DEVICE|Placement of nasogastric balloon|A nasogastric balloon catheter will be inserted after inclusion. This will be a NutriVent (Sidam S.R.L., Mirandola, Italy) for patients \>40kg, and a SmartCath Esophageal pressure catheter (Vyaire/Carefusion) for patients \<40kg. This placement is similar to a standard nasogastric tube placement, which is a common procedure in an ICU. Potential minor side effects include a nosebleed, sore throat and erosion of the nose where the tube is anchored. All patients will receive this intervention. When the esophageal catheter becomes displaced or is accidentally removed during the study period, it will be replaced.
40775422|NCT02398214|BEHAVIORAL|Sleep hygiene|LAST intervention (light, activity, and sleep training) consists of behavioral and educational strategies for increasing light exposure and physical activity, minimizing television viewing and reducing television viewing time to \< 2 hours per day, and engaging activities suitable to the child's motor development to minimize sleep disturbance.
41302369|NCT00002410|DRUG|Zidovudine|
41302370|NCT04436224|DRUG|Hydromorphone|Intravenous analgesia using hydromorphone in ICU patients with non-mechanical ventilation(NS 40ML+ hydromorphone 10mg ，IV-Pump)
41302371|NCT04436224|DRUG|Fentanyl|Intravenous analgesia using fentanyl in ICU patients with non-mechanical ventilation(NS 40ML+ fentanyl 0.5mg, IV-Pump)
41302372|NCT04436224|DRUG|Butorphanol|Intravenous analgesia using butorphanol in ICU patients with non-mechanical ventilation(NS 40ML+ butorphanol 10mg，IV-Pump)
41302373|NCT00824499|OTHER|Complex regional intervention|"Components of the complex intervention:~* Introduction of a program coordinator~* Introduction of a self-management education program~* Bottom up development of a interdisciplinary care protocol~* Support program for the intiation of insulin therapy in primary care~* Regional audit"
40775423|NCT04933149|DRUG|Ketamine Infustion|Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
40775424|NCT02647684|BEHAVIORAL|Self-Directed Triple P|10 Week Triple P Self directed workbook
40775425|NCT02872038|DRUG|Cefepime|Cefepime intraperitoneal continuous dosing
40775426|NCT02872038|DRUG|Cefazolin plus Ceftazidime|
40775427|NCT05595239|DEVICE|blood purification(CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode, 24 hours per day, for 3 consecutive days
40775428|NCT05595239|DEVICE|blood purification(TPE+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in TPE mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
40980017|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
41302374|NCT02918487|DRUG|Polyherbal|Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
41302375|NCT02918487|DRUG|Placebo|Inactive compound that is similar looking as the intervention
41302376|NCT00920608|DRUG|AZD9056|Tablets for oral use. 400 mg once daily for 7 days
40775429|NCT05595239|DEVICE|blood purification(HP+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in HP mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
40775430|NCT00563732|DRUG|Lecozotan|
40775431|NCT01891279|OTHER|elemental formula Elecare®|Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
40980018|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
40980019|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
40980020|NCT03258151|GENETIC|detection of genotype|detection of genotype by next generation sequencing
40980021|NCT04305483|PROCEDURE|Laser Bleaching|Content; There are 35% hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative. The way of application; Gingival protection is applied. The gel is applied to the labial surfaces of the teeth with a thickness of 1-2 mm. The use of laser increases the effectiveness of the gel. Operator and patient use protective glasses during laser application. The gel shows its effectiveness in about eight minutes. Then the gel is removed with the help of saliva absorber. The procedure is repeated until the desired degree of whitening is achieved. Then it is checked with a color scale.
41302377|NCT00920608|DRUG|Methotrexate|Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
41302378|NCT01640587|DRUG|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
41461341|NCT01894009|PROCEDURE|Foot manipulation|The subtalar joint was treated with gapping thrust with patient lying on the contra-lateral side. Mobilisation of the distal tibia-fibula was performed with the patient squatting and was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given.
40980022|NCT04305483|PROCEDURE|Chemical Bleaching|"Total Blanc Office Teeth Whitening System (H35) will be used as chemical whitening agent. Content; There are 35% hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water. Method of Application; Gingival protection is applied. A 1 mm thick layer of gel is applied to all of the labial surfaces of the tooth. The whitening agent remains on the tooth surface for 20 minutes. At the end of this period, the gel is removed with saliva absorber and the surface is cleaned with a moist gauze."
41142447|NCT04894136|PROCEDURE|ICSI-TESE; embryo-transfer|The sperm injected into the cytoplasm of an oocyte (Intracytoplasmatic Sperm Injection) is obtained by testicular extraction. Ultrasound guided transvaginal embryo transfer.
41302379|NCT01640587|DRUG|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
41302380|NCT02017678|BIOLOGICAL|JX-594|5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
41302381|NCT03408847|COMBINATION_PRODUCT|Beclomethasone dipropionate in addition to MC-EVOO|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
41302382|NCT03408847|COMBINATION_PRODUCT|Beclomethasone dipropionate in addition to refined oil|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
41142448|NCT00749827|DRUG|Bicarbonate Hydration|"Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.~Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours."
41142449|NCT00749827|DRUG|Hypotonic hydration|Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
41302383|NCT01911624|DRUG|direct thrombin inhibition|
41302384|NCT01911624|DRUG|enoxaparin|
41302385|NCT00002442|DRUG|Indinavir sulfate|
41302386|NCT00002442|DRUG|Nelfinavir mesylate|
41302387|NCT00002442|DRUG|Lamivudine|
41302388|NCT00002442|DRUG|Stavudine|
41302389|NCT01707069|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals."
41302390|NCT04192448|OTHER|Alcohol Administration|The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).
41302391|NCT04192448|OTHER|Mood Induction|The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.
40980023|NCT02700815|DRUG|Diclofenac|
41142450|NCT04665843|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
41142451|NCT04665843|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
41142452|NCT04665843|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
41142453|NCT00911716|BIOLOGICAL|bevacizumab|
41142454|NCT00911716|DRUG|cyclophosphamide|
41142455|NCT00911716|DRUG|docetaxel|
41142456|NCT00911716|PROCEDURE|adjuvant therapy|
41142457|NCT04344886|PROCEDURE|Conventional (dual-phase) SPECT/CT|Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
41302392|NCT00457054|DRUG|Lithium|starting dose 600 mg increase as tolerated
41302393|NCT02549690|DRUG|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
41302394|NCT02549690|DRUG|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
41302395|NCT02948777|DRUG|Evolocumab|
41302396|NCT04272619|BEHAVIORAL|LIVE-R Life Education|A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
40980024|NCT02700815|DRUG|Capsaicin|
40980025|NCT02700815|DRUG|Placebo|
40980026|NCT04484792|OTHER|green tea mouthwash|green tea bags in 100 ml warm water for 5 min
41142458|NCT04344886|PROCEDURE|Multi-phase SPECT/CT|Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
40980027|NCT04484792|OTHER|green tea mouthwash|, in Group B its prepared by soaking tea bags in 100 ml hot water followed by ice addition.
40980028|NCT04484792|OTHER|placebo|Plain water
41302397|NCT01506414|DRUG|rhTPO in combination with Rituximab|Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
41142459|NCT04344886|PROCEDURE|Conventional minimally-invasive radio-guided parathyroidectomy|Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
41142460|NCT04344886|PROCEDURE|Individualised minimally-invasive radio-guided parathyroidectomy|Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
40775432|NCT01891279|OTHER|partially hydrolyzed formula|Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
40775433|NCT00789555|DRUG|Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
40775434|NCT00789555|OTHER|Olopatadine nasal spray vehicle, pH 3.7|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
40775435|NCT00789555|OTHER|Olopatadine nasal spray vehicle, pH 7.0|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
40775436|NCT03332147|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
40775437|NCT03332147|DEVICE|reference group-Earlysense system|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
40775438|NCT01777867|PROCEDURE|Cough Reflex Sensitivity|Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
40775439|NCT01777867|PROCEDURE|Methacholine Challenge|A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
41461342|NCT01894009|PROCEDURE|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones. Sham manipulations were repeated 10 times. This group was also recommended home exercises in the mornings.
40775440|NCT01943227|OTHER|controlled positive pressure ventilation 9ml/kg tidal volume|controlled positive pressure ventilation 9ml/kg tidal volume
40775441|NCT01943227|OTHER|controlled positive pressure ventilation 6ml/kg tidal volume|controlled positive pressure ventilation 6ml/kg tidal volume
40775442|NCT02300545|DRUG|Pazopanib|
40775443|NCT05323656|DRUG|Setanaxib|Oral tablets, 400 mg per tablet
40980029|NCT05861856|OTHER|Manual therapy|Mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine will be performed.
41142461|NCT01205126|DRUG|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
41461343|NCT02970149|OTHER|NA (observational)|
41461344|NCT03782662|DRUG|Itraconazole|Itraconazole capsules
40775444|NCT05323656|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
40775445|NCT05323656|DRUG|Placebo|Oral tablets
40775446|NCT04863742|DRUG|Dextenza 0.4Mg Ophthalmic Insert|sustained released dexamethasone, 0.4mg
40775447|NCT04863742|DRUG|Prednisolone Acetate|Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.
40775448|NCT04954664|BIOLOGICAL|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
40775449|NCT04954664|BIOLOGICAL|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane
40775450|NCT01528592|DRUG|Carbidopa-Levodopa|Equivalent amount of carbidopa-levodopa will be provide to you
40775451|NCT04203472|DEVICE|Budesonid or budesonide/fomoterol administered by DPI|Miflonide Breezhaler 200 mcg or Oxodil Aerolizer 12 mcg
40775452|NCT04203472|DEVICE|Budesonid or budesonide/fomoterol administered by MDI|Budiair 200 mcg or Atimos 12 mcg
40775453|NCT06561204|DEVICE|FMET|A full-mouth electronic toothbrush
40775454|NCT04846179|DIETARY_SUPPLEMENT|Ginkgo biloba extract|Patients recruited to Ginkgo Biloba Extract (GBE) group will be advised to take Webber Natural Ginkgo Biloba 120 mg soft gel, 1 tablet twice a day for 4 months.
40775455|NCT05892900|DEVICE|Transcutaneous vagus nerve stimulation (tVNS)|The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve
40775456|NCT05892900|DEVICE|Sham transcutaneous vagus nerve stimulation (Sham tVNS)|The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation
40775457|NCT00867607|DRUG|MRX-6|b.i.d treatment for 21 days
40980030|NCT05861856|OTHER|Virtual reality|Virtual reality supported core stabilization exercises will be performed.
40980031|NCT04661085|DIAGNOSTIC_TEST|Broader Medical history and clinical tests|Patients will be treated with standard care plus additional blood tests, urine culture and urine flow cytometry,
40980032|NCT01397474|OTHER|PPTFM|Peripheral Perfusion Targeted Fluid Management
40980033|NCT00066950|DRUG|Chlorhexidine gluconate|0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
40980034|NCT00066950|DEVICE|Fluoride Varnish|0.25ml FV every 6 months from age 12 to 30 months
41461345|NCT03782662|DRUG|Verapamil|Verapamil tablets
41461346|NCT03782662|DRUG|Rifampicin|Rifampicin capsules
41461347|NCT03782662|DRUG|Midazolam|Midazolam oromucosal solution
41461348|NCT03782662|DRUG|Placebo for RV521|Placebo for RV521 capsules
41461349|NCT03782662|DRUG|RV521|RV521 capsules
41461350|NCT02855840|OTHER|completion of the quality of life questionnaire|
41461351|NCT03581162|DIAGNOSTIC_TEST|Carotid Ultrasound and venous blood sampling|Carotid ultrasound and blood sampling
40775458|NCT00867607|DRUG|Steroid|b.i.d. 21 days
41302398|NCT00532883|DRUG|Hydroxyurea|HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
41302399|NCT00532883|DRUG|Magnesium Pidolate|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
41302400|NCT00532883|OTHER|Placebo Pills and Placebo Liquid|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
41302401|NCT01544777|DEVICE|Study IOL|Aspheric IOL for correction of aphakia
40775459|NCT04368208|OTHER|Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery|The Edinburgh questionnaire is a self questionnaire validated for postnatal depression between 4 and 6 weeks postnatal
40775460|NCT06254261|DRUG|RAY1225|Administered SC
40775461|NCT06254261|DRUG|Placebo|Placebo
40775462|NCT00587119|DRUG|Budesonide|Oral Budesonide, 3 mg three times daily, will be given for 1 year.
40775463|NCT03585387|PROCEDURE|Navigation|Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
40775464|NCT06417060|DRUG|Caudal block anesthesia|Anesthesia will be administered via inhalation induction with air/nitrous oxide and sevoflurane, followed by an injection of 0.25% bupivacaine (1 mL/kg) without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
40775465|NCT06417060|DRUG|Dorsal penile block anesthesia|Anesthesia will be administered using an inhalation induction method with air/nitrous oxide and sevoflurane, followed by the injection of 0.25% bupivacaine without epinephrine into the dorsal part of the penis.
40775466|NCT05189665|PROCEDURE|Extraperitoneal high sacral ligament suspension surgery|The extraperitoneal high sacral ligament suspension surgery is to shorten the bilateral uterosacral ligaments .
40775467|NCT05189665|PROCEDURE|Sacrospinous ligament fixation|The sacrospinous ligament fixation surgery is to open the front and back peritoneum through the vagina and shorten the bilateral uterosacral ligaments.
40775468|NCT03060889|DRUG|Tranexamic acid|10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
41302402|NCT01544777|DEVICE|Hoya iSert 751|Model 751 in one eye, standard IOL in other eye
41302403|NCT01544777|DEVICE|Negatively aspheric IOL|Negatively aspheric IOL in both eyes
40775469|NCT00629603|GENETIC|cytokine|polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
40775470|NCT00629603|GENETIC|cytokine polymorphisms|Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
40775471|NCT00629603|GENETIC|cytokine polymorphism|fibrosis-relating cytokine polymorphism
40775472|NCT05093608|DRUG|Selinexor Pill|Selinexor 60 mg or 80 mg (oral table) will be administered once a week.
41302404|NCT00300300|PROCEDURE|Computer-assisted surgery|no description
41302405|NCT02688842|DEVICE|Rapamycin target-eluting coronary stent systems (38mm)|
41302406|NCT05935904|OTHER|Exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
41302407|NCT05935904|OTHER|Non exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
40775473|NCT05093608|DRUG|Bevacizumab|Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.
40775474|NCT05093608|DRUG|Atezolizumab|Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.
40775475|NCT05458531|OTHER|Questionnaire|A single questionnaire
40775476|NCT05458531|OTHER|Semi-structured interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
40775477|NCT03578055|DRUG|BDD with UDCA|Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
40775478|NCT03578055|DRUG|Placebo|Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
40775479|NCT01349478|DEVICE|LOKOMAT|Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
40775480|NCT01287299|OTHER|Low Glycemic Load diet|Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
41302408|NCT02052960|DRUG|CetuGEX™|60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
41302409|NCT02052960|DRUG|Cetuximab|400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
41302410|NCT02052960|DRUG|Chemotherapy|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
41302411|NCT06534944|DRUG|Nicotinamide riboside|NR 1g daily for 4 weeks
41302412|NCT05111496|RADIATION|Gafchromic film|Before the X-ray radiation, a Gafchromic film will be placed on the patient's back at the start of the operation
41302413|NCT00057616|DRUG|CC-5013|
40775481|NCT01287299|OTHER|Low Fat Diet|Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
40775482|NCT03249818|DEVICE|HITT device|Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
40775483|NCT02733094|DRUG|Secukinumab|
40775484|NCT06173089|DEVICE|Remote monitoring|Remote monitoring for patients with an ICD/CRT device
40775485|NCT06513208|DRUG|Ketorolac Tromethamine|IV Ketorolac 15mg every 6 hours, x 4 doses
40775486|NCT06513208|DRUG|Placebo|IV saline as placebo
40980035|NCT04043091|PROCEDURE|percutaneous coronary intervention (stenting)|percutaneous stent implantation in coronary artery
40980036|NCT00310531|DRUG|Menostar (Estradiol, BAY86-5435)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
41302414|NCT05418062|BEHAVIORAL|Acceptance and commitment therapy (ACT)|8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request
40775487|NCT05121090|BEHAVIORAL|Educational program|"The educational program is based on dietary, physical activity, psychology, and sophrology approaches dispensed by health care professionals. Evaluations will consist of anthropometric measurements (height, weight, body mass index), behavioural questionnaires, and basic physical tests (handgrip, squats, balance, ...).~Optionally, a saliva collection will be proposed to obtain the DNA required for genetic analyses."
40775488|NCT00180284|DEVICE|SITELINE 2 Polyurethane (pacing lead)|SITELINE 2 Polyurethane (pacing lead)
41302415|NCT02157831|BIOLOGICAL|CP-870,893|
41461352|NCT01402973|OTHER|Dietary|The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
41461353|NCT00680524|OTHER|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
40980037|NCT00310531|DRUG|Raloxifene|Raloxifene tbl. (60 mg/day)
40980038|NCT06124586|PROCEDURE|percutaneous transluminal angioplasty|percutaneous transluminal angioplasty
40980039|NCT06391151|OTHER|exposure: OSA resulting from chronic tonsillitis|exposure: OSA resulting from chronic tonsillitis
40980040|NCT02275650|RADIATION|nbUVB|2 SED nbUVB exposure will be given every other week
40980041|NCT00000854|DRUG|Nandrolone decanoate|
40980042|NCT00742001|BIOLOGICAL|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
40980043|NCT02237950|DRUG|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
40980044|NCT02237950|DRUG|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
40980045|NCT02237950|DRUG|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
40980046|NCT05183373|OTHER|Evaluation of inflammation and clotting|Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)
41142462|NCT01205126|DRUG|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
41302416|NCT02379234|OTHER|simulation|Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
41302417|NCT06253351|DEVICE|Hybrid closed loop (HCL)|"* Control IQ : T-Slim pump with Dexcom G6~* Smartguard : Medtronic 780G pump with Guardian G4S~* Diabeloop : Kaliedo pump with Dexcom G6"
41461354|NCT00329160|DRUG|Rosuvastatin|2.5-20 mg
41461355|NCT00329160|DRUG|HMG CoA inhibitor|3-hydroxy-3-methylglutaryl-coenzyme A
41461356|NCT00225849|DRUG|Aspirin|
41461357|NCT05643833|OTHER|no intervention|no intervention
41461358|NCT04847401|DIAGNOSTIC_TEST|H. pylori stool antigen|using H. pylori antigen kits in stool
41461359|NCT00391534|DRUG|modified release formulation of oxcarbazepine (OXC MR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
41461360|NCT00391534|DRUG|immediate release formulation of oxcarbazepine (OXC IR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
40980047|NCT02533154|DRUG|Prosicca|Prosicca eyedrops Dosage: on demand Route of administration: topical
40980048|NCT02533154|DRUG|Prosicca sine|Prosicca sine eyedrops Dosage: on demand Route of administration: topical
40980049|NCT02533154|OTHER|Bacterial culture|bacterial cultures obtained with conjunctival swabs
40980050|NCT00315198|DEVICE|Eye Patch|2 hours daily patching
40980051|NCT00315198|PROCEDURE|Near activities|near visual activities while patching
40980052|NCT00315198|PROCEDURE|Distance activities|distance visual activities while patching
40980053|NCT06369376|DIAGNOSTIC_TEST|New nerve conduction protocol|We opted for three different recording sites, each mimicking distinct parts of the pectoral muscle, allowing for a comprehensive assessment of nerve conduction across various regions.
40980054|NCT02543645|DRUG|Combination of Varlilumab and Atezolizumab|"Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg."
40980055|NCT00847054|DRUG|MORAb-004 (monoclonal antibody to TEM1)|Intravenous administration
41302418|NCT05857202|DRUG|Analgesics, Opioid|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
40980056|NCT03655691|BIOLOGICAL|Vehicle|Vehicle Formulation
40980057|NCT03655691|BIOLOGICAL|botulinum toxin, Type A|botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
40980058|NCT03655691|BIOLOGICAL|botulinum toxin, Type A|botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline
40980059|NCT00901160|PROCEDURE|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
40980060|NCT00182377|DRUG|Pentastarch (displace either 500 ml or 1000 ml of pump prime with pentastarch)|
40980061|NCT00075049|BIOLOGICAL|RTS,S with AS02A/AS01B adjuvant|
40980062|NCT00612924|DEVICE|Anaconda Stent Graft System|Endovascular device
40980063|NCT00612924|DEVICE|Anaconda ONE-LOK Stent Graft System|Endovascular device
40980064|NCT05061030|BIOLOGICAL|the ATMP Protrans|Protrans consists of Wharton's jelly derived mesenchymal stromal cells
41302419|NCT05857202|DRUG|Analgesics, Non-Narcotic|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
41302420|NCT03744676|BIOLOGICAL|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
41302421|NCT03865355|OTHER|Non- interventional|Translational, observational study
41461361|NCT01853540|DRUG|Sildenafil|
41461362|NCT06076109|OTHER|Prone position|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the prone position.
41461363|NCT06076109|OTHER|Standard treatment|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the supine position with the head of the bed between 30-60º.
40980065|NCT04608526|DIAGNOSTIC_TEST|Fractal analysis|Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.
40980066|NCT01005420|DIETARY_SUPPLEMENT|Blueberry Powder|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
40980067|NCT01005420|DIETARY_SUPPLEMENT|Placebo|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
40980068|NCT01414907|BEHAVIORAL|Health promotion activities|Counselled activities on tobacco smoking secession, diet correlation and physical activities
40980069|NCT05647954|DRUG|HX008 + TACE|HX008 Subjects receive HX008 200 mg intravenous (IV) ,day1,every 3 weeks (Q3W) Procedure: TACE cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions).
41142463|NCT01205126|DRUG|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
41302422|NCT01734941|DRUG|TSO|There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
41302423|NCT01734941|DRUG|Placebo|
40980070|NCT05647954|DRUG|Temozolomide + TACE|"Temozolomide Subjects receive Temozolomide 200 mg/sqm intravenous (IV),day1-5, every 3 weeks (Q3W)~Procedure: TACE :~cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions)."
40980071|NCT05647954|DRUG|Pembrolizumab|Subjects receive Pembrolizumab 2 mg/kg intravenous (IV),day1, every 3 weeks (Q3W)
40980072|NCT03902067|BIOLOGICAL|UC-MSC|0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU， at the concentration of 2x10(7) cells/ml.
40980073|NCT03902067|BIOLOGICAL|Control Group|Routine treatment without catheter infusion
40980074|NCT00558025|DRUG|Pramipexole Extended Release|
40980075|NCT00558025|DRUG|Pramipexole Immediate Release|
41142464|NCT02995707|DRUG|Thalidomide|thalidomide:50mg/d p.o at bedtime
41142465|NCT03054506|DEVICE|CSP01|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
41142466|NCT03054506|DEVICE|Carboxymethylcellulose (CMC)|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
41142467|NCT03054506|DEVICE|Placebo|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
41142468|NCT05041894|OTHER|tilt table|The tilt table provides passive standing for the stroke patients with tracheotomy
40980076|NCT00001008|DRUG|Methadone hydrochloride|
41142469|NCT02492126|OTHER|Citric Acid|Subjects will undergo cough reflex sensitivity testing to citric acid.
41142470|NCT05792683|DEVICE|lumbar drain|"Patient will be placed in the lateral decubitus position; catheter will be inserted by using a Tuohy needle in the interspinous area of lumbar spine. The LD catheter will reach the lumbar subarachnoid space.The remaining part of the drainage kit will be placed along the back of the patient. The catheter insertion site will be sutured and treated with povidone-iodine ointment. Sterile drape will be used to cover the entire external part of the LD.~The CSF will be collected within the closed beg. CSF drainage through LD will be around 10 ml per hour or 200-250 ml/day."
41142471|NCT01465399|BIOLOGICAL|Plasma Rich in Growth Factors PRGF-Endoret|
41142472|NCT01465399|PROCEDURE|Conventional closure of the lesion|
41142473|NCT00807053|DRUG|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
41142474|NCT00807053|DRUG|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
41142475|NCT00807053|DRUG|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
41142476|NCT00807053|DRUG|Placebo|Placebo
41142477|NCT05822791|DIAGNOSTIC_TEST|Prolonged cardiac monitoring|Prolonged cardiac monitoring
41142478|NCT05822791|DIAGNOSTIC_TEST|ECG|Electrocardiogram
41142479|NCT00405834|DEVICE|Envision® Patient Support System|
41142480|NCT05512299|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
41142481|NCT04301713|OTHER|Evaluation of rik of falls|An evaluation of the risk of falls will be carried out in the elderly in the province of Salamanca. This will attempt to identify the risk of falling as well as to be able to establish protocols for action of a preventive and rehabilitative nature.
41142482|NCT01941706|BEHAVIORAL|Project UPLIFT|Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.
41142483|NCT03841253|PROCEDURE|Trans-epithelial PTK|The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
41142484|NCT03841253|DEVICE|EpiMaster Application Software|The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.
41142485|NCT02355106|DEVICE|PolarStart System|Atrial flutter Ablation
41142486|NCT04686357|DIAGNOSTIC_TEST|EMMA/ALICE|"Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the EMMA/ALICE test will be provided to participants and their gynecologists. Depending on the test results, there are 3 different possibilities:~1. Normal result~2. Ultralow or Dysbiotic result~3. Abnormal result (pathogens) All probiotics and antibiotics that will be used in the study are already authorized by the local health authorities and will be prescribed under their technical data sheet/brochure conditions following the medical indications."
40980077|NCT00001008|DRUG|Zidovudine|
40980078|NCT02345850|PROCEDURE|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
40980079|NCT02345850|PROCEDURE|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
40980080|NCT02345850|PROCEDURE|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
40980081|NCT02345850|DRUG|Cyclophosphamide|"Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
41302424|NCT03253406|BEHAVIORAL|Polar M400 + Facebook Group (PM400+FG)|Throughout the intervention period experimental group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page. Additionally, experimental group participants will be asked to track all physical activity with the Polar M400 smartwatch and use this information to set physical activity-related goals conducive to improved health.
41302425|NCT03253406|BEHAVIORAL|Facebook Only Group (FG)|Throughout the intervention period comparison group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page.
41302426|NCT03483688|BIOLOGICAL|CD19-directed CAR-T cells|CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
41461364|NCT04020016|DRUG|Nalbuphine ER|Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days.
41461365|NCT04020016|DRUG|Nalbuphine ER -|Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days.
41461366|NCT01600339|DRUG|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
41461367|NCT00535353|DRUG|irinotecan hydrochloride|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
41461368|NCT00535353|DRUG|olaparib|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
41461369|NCT00160745|DRUG|Rosuvastatin|
41142487|NCT04686357|DIAGNOSTIC_TEST|EMMA/ALICE|Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
41302427|NCT01842620|DRUG|Metformin|Oral antidiabetic agent
41302428|NCT04150874|DIAGNOSTIC_TEST|Lumason®|Hepatic artery embolization using standard of care radioembolization and assessment of tumor and hepatic parenchymal perfusion kinetics before, during and after treatment with standard of care iodinated contrast (at the time of Y90 radioembolization treatment) and standard of care follow-up with multiphase CT or MRI with the addition of study agent Lumason microbubbles for contrast-enhanced ultrasound (which will be performed concurrently with standard evaluation).
41302429|NCT03756974|DRUG|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
41302430|NCT03756974|DRUG|Placebo|Placebo of BX-1, oral solution
41302431|NCT04098952|OTHER|Group 1: Manual Therapy|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.
41142488|NCT03483714|PROCEDURE|Spinal Manipulation|HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints
41461370|NCT05793645|DEVICE|personalized care plan|Algorithm that defines personalized care plan
41461371|NCT01358253|DRUG|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
41461372|NCT01358253|DRUG|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
41142489|NCT02040038|BEHAVIORAL|LIVE|3-D Virtual Environment for DSMT/S
41461373|NCT01358253|DRUG|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
41461374|NCT01358253|DRUG|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
41461375|NCT01358253|DRUG|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
41461376|NCT01358253|DRUG|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
41461377|NCT01358253|DRUG|Rituximab|"Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month."
41461378|NCT01358253|DRUG|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
40980082|NCT02345850|DRUG|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
40980083|NCT02345850|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
40980084|NCT00227435|DRUG|val-mCyd|
41142490|NCT02040038|BEHAVIORAL|Website|2-D Website participation for DSMT/S
41142491|NCT02788435|BEHAVIORAL|Absolute Voice Rest|Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
41142492|NCT03616522|OTHER|a novel mobile phone-based intervention for automated electronic PRO collection|Over the three-month study period, patients will be prompted weekly via text message to self-report up to eleven common symptoms, as well as their performance status and quality of life.
41142493|NCT01595425|DRUG|D961H Sachet 20 mg|Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
41302432|NCT04098952|OTHER|Group 2: Interferential massage plus Manual Therapy|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
41302433|NCT03397797|DRUG|Rocuronium|In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
41302434|NCT00000615|BEHAVIORAL|diet, reducing|
41461379|NCT01358253|DRUG|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
41461380|NCT01358253|DRUG|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
41461381|NCT02180230|DEVICE|Shorty implants|Dental implant insertion to maxilla or mandible
40980085|NCT03984591|DRUG|Eplerenone|Eplerenone according to guidelines
40980086|NCT03984591|DRUG|Spironolactone|Spironolactone according to guidelines
40980087|NCT03171623|DRUG|globalagliatin hydrochloride|orally administration, single dose
41142494|NCT01595425|DRUG|D961H HPMC capsule 20 mg|Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
41142495|NCT04492085|OTHER|Questionnaire survey|A customized questionnaire will be delivered by the social software WeChat to explore the prevalence, potential reasons and solutions of workplace violence against physicians of obstetrics and gynecology in China
41142496|NCT05264714|DRUG|Rimegepant|150 mg oral disintegrating tablet every other day for one week
41302435|NCT06333470|OTHER|Primary angle closure diseases|Primary angle-closure suspect (PACS), which is characterized by appositional angle closure, is the earliest stage of primary angle closure diseases and can finally progress to primary angle-closure glaucoma (PACG).
41302436|NCT00109733|BIOLOGICAL|recombinant human growth hormone|0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
41302437|NCT00109733|BIOLOGICAL|recombinant human growth hormone|0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
41302438|NCT00141635|BEHAVIORAL|physio,pain,psychotherapy;social,nutrit.counselling&sports|
41302439|NCT05833893|DRUG|XPO1 inhibitor|COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
41302440|NCT04833075|OTHER|blood sampling|A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.
41302441|NCT01815710|OTHER|Pediatric Asthma Clinical Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
40980088|NCT03171623|DRUG|placebo|orally administration, single dose
41302442|NCT01815710|OTHER|Vomiting & Diarrhea Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
41302443|NCT03537768|DRUG|Ulipristal Acetate|UPA Tablet
41302444|NCT03537768|DRUG|Levonorgestrel|LNG Tablet
41302445|NCT03537768|DRUG|Levonorgestrel|LNG Tablet (x2)
41461382|NCT02629016|OTHER|Mindfulness|
41461383|NCT02629016|OTHER|Wellness|
41461384|NCT03727945|OTHER|abdominopelvic exercise and posture|n=21 women received supervised abdominopelvic exercise with previous postural correction. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises, previous explain postural correction pelvis, cervical and dorsal zone.
41461385|NCT03727945|OTHER|abdominopelvic exercise|n=21 women received supervised abdominopelvic exercise. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises.
41461386|NCT01872624|PROCEDURE|Bronchoscopy|Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.
41461387|NCT06033586|DRUG|Open-label rusfertide|subcutaneous rusfertide
41461388|NCT01109849|BEHAVIORAL|behavior therapy|combination of individual and group parent training plus school consultation
41461389|NCT01109849|DRUG|Extended release (ER) methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
41461390|NCT01109849|OTHER|monitoring|monthly weight, height and BMI checks
41461391|NCT01109849|OTHER|drug holiday|switch from seven day a week dosing to medication only on school days
41461392|NCT01109849|DIETARY_SUPPLEMENT|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
41461393|NCT05248399|BEHAVIORAL|COVID-19 Group Problem Solving|The COVID-19 Group Problem Solving component incorporates popular education activities aimed at: developing social cohesion among LDLs; building awareness about COVID-19 risks and protective behaviors; and developing a plan of action to reduce theirs and their peers' risk for COVID-19 transmission. The intervention will be developed to take place over a \~30-45-minute period in order to fit within the corner context of LDLs waiting for employment, and will be delivered by promoters from our team and the community partner agency, Fe \& Justicia Workers Center. Following the completion of the intervention, a health promoter will be trained as a navigator assist participants who wish to get vaccinated by providing them with information about near-by vaccination sites that they can visit to get vaccinated. If needed, the promotor will assist them with making their vaccine appointment.
41461394|NCT05248399|BEHAVIORAL|Standard of Care|The standard of care consists of the distribution of brochures containing COVID-19 prevention information.
41461395|NCT03336788|DEVICE|Transcranial Magnetic Stimulation (TMS - ) MagPro®|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
40775489|NCT05495022|BEHAVIORAL|Mindfulness-based stress reduction (MBSR) program|Mindfulness-based stress reduction (MBSR) program will be applied by the researcher to the midwives in the experimental group. Conscious Awareness-Based Stress Reduction will be applied by the researcher (S.Ö.C.) who has received training (16 hours) and has a certificate in this field. Stress reduction program based on mindfulness is planned as 2 sessions per week for 4 weeks, a total of 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individual and group sessions by determining the days when midwives are available online.
40775490|NCT04548908|DIAGNOSTIC_TEST|Serelogy testing, RT PCR|Serology testing for all the participants and RT PCR for participants with symptoms
40775491|NCT02891226|DRUG|Mirikizumab|
40775492|NCT02891226|DRUG|Placebo|
40775493|NCT01691911|PROCEDURE|Remote preconditioning|Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
41461396|NCT03336788|DEVICE|virtual reality for displaying interactive virtual environments|20 sessions navigated with virtual reality
41461397|NCT05341856|DRUG|isosorbide mononitrate|insert vaginal tablet of isosorbide mononitrate in cases of unexplained recurrent pregnancy loss
41461398|NCT05341856|DRUG|Placebo|insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
41461399|NCT02498691|BIOLOGICAL|Biological collection|Blood and saliva samples, placenta and cord blood collection
41461400|NCT00880334|DRUG|Docetaxel|Given intravenously on Day 1 of each 21-day cycle
41461401|NCT00880334|DRUG|vandetanib|taken orally once a day, every day
41461402|NCT00880334|DRUG|Placebo|Taken orally once a day every day
41461403|NCT05259956|BEHAVIORAL|Schroth based scoliosis specific exercise|The intervention is set to be delivered in a one-hour Schroth-based exercise session, with the frequency of twice a week for five weeks. The exercise consists of active auto-correction in 3D, stabilizing the corrected posture, and training in ADL.
41461404|NCT05259956|BEHAVIORAL|"3 plus 1 multidimensional exercise therapy"|The intervention is set to be delivered in a 90-minute exercise session, with a frequency of twice a week for five weeks. The exercise consists of a one-hour Schroth-based exercise session and an additional 30-minute manipulative therapy of pelvic asymmetry.
41461405|NCT04547036|DEVICE|XEN45|Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.
41461406|NCT01214980|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
41461407|NCT01214980|OTHER|Standard of care|Standard of care provided per site-specific protocol
41461408|NCT06048887|DRUG|CRN04894 Oral Solution|CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
41461409|NCT06048887|DRUG|Placebo Oral Solution|Placebo
41461410|NCT01685216|BIOLOGICAL|velaglucerase alfa|lyophilized powder, intravenous infusion, units, Every other week (EOW)
41461411|NCT02046317|DRUG|Femoral Nerve Block|Femoral Nerve Block for isolated femur fractures
41461412|NCT02046317|DEVICE|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
41461413|NCT02046317|DEVICE|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
41461414|NCT02046317|DEVICE|Ultrasound|"The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles."
41302446|NCT04793672|OTHER|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
41302447|NCT06247592|PROCEDURE|Greater occipital nerve block|Pulse Radiofrequency application to the greater occipital nerve will be applicated after radiofrequency cannula placed near the greater occipital nerve location at 42 degree, for 240 seconds.
41302448|NCT06247592|PROCEDURE|Greater occipital nerve pulse radiofrequency|The greater occipital nerve will be blocked with 5 cc 2% prilocaine.
41302449|NCT04362579|DEVICE|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing or in the home setting
41302450|NCT06312267|DEVICE|Bioelectric dressing|Participants randomized into the experimental arm will have a bioelectric dressing applied 3 days before surgery, and 3 days post-surgery.
41302451|NCT02184416|OTHER|observational|The study is non interventional. All drugs will be prescribed
41302452|NCT01270672|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
41302453|NCT01270672|DRUG|carvedilol|50 mg per os, single dose
41461415|NCT00005958|BIOLOGICAL|filgrastim|
41461416|NCT00005958|DRUG|docetaxel|
41302454|NCT01270672|DRUG|placebo|capsules identical to MDMA or carvedilol
41302455|NCT02485366|DRUG|Rejuvesol|Blood transfused during surgery will be treated with Rejuvesol.
41461417|NCT00005958|DRUG|gemcitabine hydrochloride|
41461418|NCT04457115|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block performed at T2-T3 and T4-T5 levels with administration of Ropivacaine 0.7% 8 ml for each level
41461419|NCT04457115|PROCEDURE|Erector spinae plane Block|Erector spinae plane block performed at T2 and T5 levels with administration of Ropivacaine 0.5% 12 ml for each level
41461420|NCT04267692|OTHER|HaRTC|HaRT-C participants will attend 8, virtual, adapted, low-barrier, weekly, closed-group Talking Circles-- named Harm Reduction Treatment Circles or HaRTC -- lasting approximately 2 hours each. During the HaRTC, the circle keeper will present the day's harm reduction topic, smudge the space, and allow participants to open themselves up to the circle. Topics presented by the Circle Keeper focus on harm-reduction and improving overall quality of health. Abstinence from alcohol use is not a requirement. We will not limit participants' access to treatment or services in either arm.
41461421|NCT06120660|OTHER|Music Therapy|Music Therapy
41461422|NCT04090658|BIOLOGICAL|RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B|Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
41461423|NCT04090658|DRUG|Placebo|Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
41461424|NCT03019562|DRUG|Oxycodone|4mg of oxycodone iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA)
41461425|NCT03019562|DRUG|Fentanyl|50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
41461426|NCT02966730|DRUG|Ibrutinib|Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.
41302456|NCT02485366|PROCEDURE|Cardiac surgery|The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
41302457|NCT03357276|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
41302458|NCT04039685|OTHER|Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks aerobic exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
41302459|NCT04039685|OTHER|Effects of an eight weeks resistance exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks resistance exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
41302460|NCT04039685|OTHER|Effects of an eight weeks combined (aerobic+resistance) exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks combined (aerobic+resistance) exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
41302461|NCT05821257|OTHER|Evaluation of the arm swing during gait|Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.
41461427|NCT03545334|DIAGNOSTIC_TEST|Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)|Injection of ICG intradermally around the scar of the primary excision of the tumour and transcutaneous assessment of fluorescence with the VS3-3DHD camera (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System ).
41461428|NCT04448041|OTHER|Malnutrition screening|Primary comparison: Prevalence of malnutrition and impact on 30-day outcomes in patients undergoing surgery for cancer
41461429|NCT04801420|BIOLOGICAL|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
41302462|NCT05821257|OTHER|Functional Tests|To understand the changes in functional mobility, Two Minute Walk Test (2MWT), Timed Up and Go (TUG) and Timed 25Foot Walk Test (T25FW) were conducted.
41461430|NCT04801420|BIOLOGICAL|Placebo|PBS (Phosphate Buffered Saline)
41461431|NCT01459198|BIOLOGICAL|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.
41461432|NCT01459198|BIOLOGICAL|Placebo vaccine|Given intranasally once at a baseline study visit
41461433|NCT05122351|DRUG|Bupivacaine infiltration at the Quadratus Lumborum muscle Versus Paracetamol injection as analgesia in post operative Open Inguinal Hernia surgeries|Comparative Study Between The Efficacy Of Quadratus Lumborum Block VS Conventional Analgesia In Patients Undergoing Open Inguinal Hernia Surgical Repair
41461434|NCT00271557|DRUG|nesiritide|
41461435|NCT01264198|BEHAVIORAL|Resistance Training|Supervised Resistance Training
41461436|NCT02221063|OTHER|Thiamin fortified fish sauce (low concentration)|Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
41461437|NCT02221063|OTHER|Thiamin fortified fish sauce (higher concentration)|Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
41302463|NCT04374825|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|This intervention consists of 8, 90-minute online group sessions delivered via video conference. Content will be developed by tailoring an ACT intervention to the specific needs of women with MBC, by using qualitative data gathered in patient focus groups. The intervention will incorporate key concepts of ACT (i.e., creating meaning and purpose in life via coping skills, activities in line with patients' values, and mindfulness meditation).
41142497|NCT06374082|OTHER|WhatsApp message|"Participants in the intervention group will receive 3 WhatsApp messages per week for six weeks after attending the standardized course training Tobacco Dependency Nursing Intervention and Management (NURS8205). These messages are about the core content of the course, including (1) Knowledge Themes: harmfulness of smoking and benefits of quitting, the fundamentals of nicotine addiction, smoking cessation counselling with the 5A model, and pharmacotherapy for smoking cessation; (2) Attitude Themes: nurses' role in smoking cessation and the importance of smoking cessation; and (3) Practice Themes: practical advice on counseling techniques, communication skills by motivational interviewing, local smoking cessation resources for referral.~Participants in the control group will receive 3 WhatsApp messages about generic mental health information per week for six weeks after attending the standardized course training Tobacco Dependency Nursing Intervention and Management (NURS8205)."
41142498|NCT04640805|DIETARY_SUPPLEMENT|Protein supplementation|Liquid protein fortifier (Similac) will be added at 1ml per 25ml of PDHM at 130ml/kg/day of feed volume.
41302464|NCT04374825|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|This intervention consists of 8, 90-minute online group sessions delivered via videoconference. Content is drawn from a standard published CBSM intervention previously tested in other studies. The intervention incorporates key concepts of CBSM (i.e., managing stress via deep breathing and relaxation, identifying distorted thoughts,cognitive restructuring, and effective interpersonal communication).
41302465|NCT02016157|DRUG|Moxifloxacin|TO ASSESS THE EFFICACY OF MOXIFLOXACIN IN SITU GEL IN THE TREATMENT OF PERIODONTAL POCKET.
40775494|NCT00529295|DRUG|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
41302466|NCT03837756|DRUG|Saline|Placebo
41302467|NCT03837756|DRUG|Lefitolimod|A TLR9 agonist administered s.c. once weekly for 8 weeks.
41302468|NCT03837756|DRUG|3BNC117 and 10-1074|Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
41302469|NCT04289129|DIAGNOSTIC_TEST|Myotonometric evaluation|Vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.
41302470|NCT02558153|DEVICE|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
41302471|NCT02558153|DEVICE|standard PTA|Percutaneous angioplasty performed with a standard balloon
41302472|NCT04529551|OTHER|1601A|A filtered, king size cigarette with a menthol capsule in the filter.
41302473|NCT04529551|OTHER|1601B|A filtered, king size cigarette with a menthol capsule in the filter.
41302474|NCT03120390|OTHER|Best Practice|Undergo usual care
41302475|NCT03120390|BEHAVIORAL|Exercise Intervention|Undergo AE
41302476|NCT03120390|BEHAVIORAL|Exercise Intervention|Undergo RE
41302477|NCT03120390|OTHER|Laboratory Biomarker Analysis|Correlative studies
41302478|NCT03120390|DEVICE|Monitoring Device|Receive Polar heart rate monitor
41302479|NCT03120390|OTHER|Quality-of-Life Assessment|Ancillary studies
41302480|NCT03120390|OTHER|Questionnaire Administration|Ancillary studies
41302481|NCT00130208|DRUG|Sulodexide|100 mg sulodexide gelcaps
41302482|NCT00130208|DRUG|Placebo|0 mg gelcap
41302483|NCT06363448|PROCEDURE|Yamani Technique versus Prolene Mesh for Intraocular Lens Scleral Fixation in Aphakia|Patients were divided into two groups to undergo classic ab externo two-point scleral fixation or flanged haptics as described by Yamani or the 2\*2 proline mesh technique.
41302484|NCT00200525|DRUG|apomorphine HCl injection|
41302485|NCT04003506|DRUG|Liposomal bupivacaine|LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine + 10ml 0.5% standard bupivacaine
41302486|NCT04003506|DRUG|Bupivacaine Injection|LIA with ACB will be given using 20ml 0.5% standard bupivacaine
41302487|NCT02186327|BEHAVIORAL|Integrative Health Coaching|Coaching sessions will guide subjects in establishing and maintaining behavior change goals related to their health and overall well-being.
41302488|NCT04464980|DRUG|SL-BUP|Daily dosing of sublingual buprenorphine-naloxone
41302489|NCT04464980|DRUG|XR-BUP|Weekly/monthly dosing of extended-release injectable buprenorphine
41302490|NCT04464980|DRUG|XR-NTX|Monthly dosing of extended-release injectable naltrexone
40980089|NCT03218553|DRUG|Dexamethasone|Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
40980090|NCT03218553|DRUG|Placebos|placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
40775495|NCT04120467|OTHER|Dance|"One group will receive a 60-minute dance class weekly over a 6 weeks period. A physiotherapist - dance teacher will lead the classes, supported by at least one volunteer.~The class structure will consist of five components: warm up (10 minutes), technical exercises (10 minutes), improvisation (15 minutes), a short routine (15 minutes) and a cool down/feedback time (10 minutes). Dance exercises will be targeting flexibility, balance, endurance, upper and lower limbs functions, interaction between dancers, perception and memory. Using choreography or short routine, the class will include repeating the dance moves - which fosters memorization - and also the additional challenge of remembering a sequence of moves.~Given the great variability of each participant's functional ability, the complexity and the intensity of the dance exercises will progress according to each participant's capacity, in order to fulfill an appropriate challenge at moderate treatment intensity."
40775496|NCT04120467|OTHER|Standard rehabilitation|The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.
40775497|NCT02725463|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant|
40775498|NCT00815633|DRUG|Alefacept|15mg intramuscular injection weekly for 12 weeks
40775499|NCT00787150|DRUG|Apixaban|Apixaban 5 mg tablet BID for 12 weeks
40775500|NCT00787150|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 12 weeks
40775501|NCT00787150|DRUG|Warfarin sodium|At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
40980091|NCT04028206|DIETARY_SUPPLEMENT|Hydroxymethylbutyrate|Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.
41142499|NCT04640805|OTHER|Analysis with Miris Human Milk Analyzer|PDHM macronutrient content will be analyzed using the Miris Human Milk Analyzer and PDHM with fat content of 3.8g/dL or higher will be selected and provided.
40980092|NCT04028206|DEVICE|Low-magnitude High Frequency Vibration (LMHFV)|Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone showed that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.
41142500|NCT05120505|DRUG|Metformin|The patients in this group will be obtain Metformin starting from 50mg everyday at night, and gradually increase to maximum tolerable dose of 1-2g per day according to weights of patients for 6 months.
41142501|NCT05120505|DRUG|Placebo|The patients in this group will be obtain starch tablets (which had same appearance and size comparing to Metformin) starting from 50mg everyday to 1-2g per day according to weights of patients for 6 months.
41142502|NCT05589831|DEVICE|Non-invasive Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist (NAVA) is a new non-invasive ventilation mode that uses the electrical activity of the diaphragm (EAdi) to offer ventilatory assistance in synchrony with patient effort, thus potentially reducing stress and discomfort. It uses electrodes placed on a modified nasogastric feeding tube to detect the electrical activity of the diaphragm (EAdi), such that both the initiation and termination of a breath during each respiratory cycle is in synchrony with the infant's effort
41142503|NCT00576485|PROCEDURE|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
41142504|NCT01448928|DRUG|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
41142505|NCT04889326|OTHER|Retrospective data and biological samples|Analysis of data and biological samples collected during hospitalization:
41142506|NCT00952523|DRUG|Tretinoin Facial Gel|A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
41142507|NCT00952523|DRUG|Adapalene/Benzoyl Peroxide Facial Gel|A marketed facial gel containing Adapalene .1% and Benzoyl peroxide 2.5% is applied to the other side of the face daily for three weeks
41302491|NCT04464980|BEHAVIORAL|MM|MM consists of standard Medical Management and the usual counseling at the treatment program.
41302492|NCT04464980|BEHAVIORAL|MMR|MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.
41302493|NCT04464980|BEHAVIORAL|MMD|MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.
40775502|NCT06089603|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed)
40980093|NCT04028206|BEHAVIORAL|Elastic-band Exercise|"Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed exercises 3 times per week, one hour after HMB intake, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by a qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching."
40980094|NCT02845245|OTHER|3D printed plastic model prototype|
40980095|NCT02845245|OTHER|3D CT scan|
40980096|NCT02845245|OTHER|Plain film radiographs|
40980097|NCT01898728|DRUG|topical povidone-iodine after premedication with topical liquid eye drops|
40980098|NCT01898728|DRUG|topical povidone-iodine after premedication with topical gel|
41302494|NCT00188500|BEHAVIORAL|atkins diet|
41302495|NCT00188500|BEHAVIORAL|ability to follow low carbohydrate diet|
41302496|NCT02926573|DRUG|Gabapentin|
41302497|NCT02926573|DRUG|Placebo|
40980099|NCT03862820|DIAGNOSTIC_TEST|dynamic ultrasound|move abdomen with ultrasound probe to predict intraabdominal adhesions
40980100|NCT00358228|DRUG|Rimonabant|
40980101|NCT02090660|OTHER|ICG Localization with Spy thoracoscope localization|
40980102|NCT02706470|DRUG|Cyclosporin A|Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.
40980103|NCT02706470|DRUG|Dydrogesterone|Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
40980104|NCT06371118|DEVICE|Directly mailed self-sampling kit to collect a vaginal sample|"The HPV self-sampling test will be sent by post directly to the woman's address. If the woman does not return the sample within 20 days, she will be sent a SMS reminder.~The returned samples will be analysed. If high-risk HPV is present, women will be invited to be screened for cervical cancer in a clinical setting by their family doctors.~Self-samples in which high-risk HPV is present will also be subjected to HPV DNA methylation test. If an abnormal HPV DNA methylation is detected and the woman has not attended the screening in a clinical setting yet, she will be informed by her family doctor that a new test has indicated the need to attend a medical appointment."
40980105|NCT06371118|DEVICE|Mailed self-sampling kit to collect a vaginal sample after opt-in prodecure|"Women will initially receive an invitation letter in their home addresses to receive the self-sampling kit, as well as a pre-paid envelope to return the answer to this invitation. If the woman does not return the answer within 10 days, she will be sent a SMS reminder. Only those who respond affirmatively to the question will receive the self-sampling kit.~The steps that follow will be the same as in intervention 1."
40980106|NCT06371118|DIAGNOSTIC_TEST|Standard of care - screening in a clinical setting|Corresponds to the standard of care. An invitation to attend the conventional cervical cancer screening (clinician-collected cervical sample for HPV test and reflex cytology) will be sent by post to the woman's address.
40980107|NCT03021421|PROCEDURE|intratechal (subarachnoidal )injection|10 mg (2 cc) intrathecal single shot injection
40980108|NCT03021421|PROCEDURE|lombar plexus and sciatic nerve injection|USG -guided lumbar plexus visualised and 20 ml local anaesthetic mixture (15 cc %0,5 Bupivacaine Hydrochloride 5 cc and %2 Lidocaine 5 cc ) for lombar plexus single shot injection
40980109|NCT05152901|DRUG|EpiPen ®.|A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.
40980110|NCT05152901|DRUG|Epinephrine (0.3mg) inhaled|Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2
41142508|NCT06207383|DEVICE|Conduction system pacing|Conduction system pacing (either His bundle pacing or left bundle branch area pacing)
41302498|NCT05897138|DRUG|Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle|"Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle"
40775503|NCT06089603|DRUG|Conventional pharmacological treatment|Usual treatment of the patient
40775504|NCT06089603|OTHER|Sleep ,diet and life style recomendations|Daily recomendatios
40980111|NCT05152901|DRUG|Epinephrine (1.3mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.
40980112|NCT05152901|DRUG|Epinephrine (4mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine
41142509|NCT06207383|PROCEDURE|Atrioventricular nodal ablation|Catheter ablation of the atrioventricular node
41142510|NCT06207383|PROCEDURE|Atrial fibrillation ablation|Catheter ablation of atrial fibrillation with pulmonary vein isolation (using technique of operator's choice, with additional lesions if deemed necessary)
41142511|NCT01624532|BIOLOGICAL|GC1109 or Placebo of GC1109|"Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks."
41302499|NCT01224912|BEHAVIORAL|Cognitive Behavioral Treatment|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
41302500|NCT02855346|COMBINATION_PRODUCT|200 mg of DPV + 320 mg LNG|DPV VR, containing 200 mg DPV
41302501|NCT02855346|COMBINATION_PRODUCT|200 mg of DPV|DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG
41302502|NCT05645484|DRUG|18F-PFPN|18F-PFPN (dose: 3.0-5.4 MBq/kg) will be injected intravenously prior to imaging.
41302503|NCT05645484|DRUG|18F-FDG|18F-FDG (dose: 3.7-5.4 MBq/kg) will be injected intravenously prior to imaging.
40980113|NCT05769881|PROCEDURE|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
40980114|NCT05769881|PROCEDURE|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access
40980115|NCT05999136|OTHER|Pulses diet|Subjects in the PulD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PulD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with servings of pulses.
40980116|NCT05999136|OTHER|Plant proteins diet|Subjects in the PPD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PPD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with a mixture of pulses and plant-based meat substitutes.
40980117|NCT05999136|OTHER|Habitual diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
40980118|NCT06494943|DRUG|Sintilimab|PD-1 inhibitor
41461438|NCT02221063|OTHER|Placebo fish sauce|Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
40980119|NCT06494943|DRUG|IBI110|LAG-3 inhibitor
40775505|NCT01055951|DEVICE|Solo MicroPump|30 days treatment days with an optional extension period of up to 6 month of treatment.
40775506|NCT02009267|DEVICE|Patient controlled analgesia|A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
40980120|NCT06494943|DRUG|Paclitaxel|Chemotherapy
40980121|NCT06494943|DRUG|Cis Platinum|Chemotherapy
40980122|NCT06494943|PROCEDURE|Surgery|Definitive surgery
40980123|NCT06494943|RADIATION|Adjuvant radiation|Adjuvant radiotherapy or chemoradiotherapy based on post-operative pathologic findings.
40980124|NCT00996216|DRUG|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
40980125|NCT00996216|DRUG|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
40980126|NCT00258245|DIETARY_SUPPLEMENT|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide \[ATO\] days 1, 4, 8, 11
40980127|NCT00258245|DRUG|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
40980128|NCT00258245|DRUG|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
40980129|NCT00258245|DRUG|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
40980130|NCT00258245|DRUG|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
40980131|NCT00258245|DRUG|Aspirin|Aspirin - 325 mg by mouth (PO) every day
41302504|NCT03064529|DEVICE|Accelerometer|All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
41302505|NCT03502252|BEHAVIORAL|Semillas de Apego|Group-based Primary Caregiver Intervention: Group-based psychosocial program for victimized mothers (or alternative primary caregivers) with children 2 to 5, that aims at promoting healthy child-parent attachments as a pathway for a proper development among children exposed to violence.
41461439|NCT01944553|DEVICE|The ROSA™ robot|"The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.~Stabilisation in treatment for spine degenerative disease"
41302506|NCT05670964|DEVICE|Connecting valve system|UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter
41461440|NCT04893096|DRUG|MOR202|Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.
41461441|NCT00166452|DRUG|Lenalidamide|
41461442|NCT04792489|BIOLOGICAL|zamtocabtagene autoleucel (MB-CART2019.1)|Chimeric antigen receptor (CAR) T cell therapy
41461443|NCT04792489|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
40775507|NCT02009267|PROCEDURE|Continuous thoracic epidural infusions|Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation-including the sensation of pain-by blocking the transmission of signals through nerve fibers in or near the spinal cord.
40980132|NCT00065507|DRUG|Entecavir (ETV)|Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized
40980133|NCT00065507|DRUG|Adefovir (ADV)|Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
41461444|NCT04792489|DRUG|Fludarabine|Lymphodepleting chemotherapy
41461445|NCT04792489|DRUG|Bendamustine|Lymphodepleting chemotherapy
41461446|NCT03093025|DRUG|TS-121 10 mg|Orally taken once daily
41461447|NCT03093025|DRUG|TS-121 50 mg|Orally taken once daily
41461448|NCT03093025|DRUG|Placebo|Orally taken once daily
41461449|NCT01316432|DRUG|Cenderitide|Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
41461450|NCT01316432|OTHER|Placebo|Placebo will be administered as a 24-hour SQ infusion
41461451|NCT00800618|DRUG|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
41461452|NCT00800618|DRUG|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
41461453|NCT00800618|DRUG|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
40775508|NCT02009267|PROCEDURE|Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
40775509|NCT04618471|DEVICE|Boston Scientific WaveWriter SCS System|WaveWriter SCS Programming
40775510|NCT00894881|PROCEDURE|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
41302507|NCT05670964|DEVICE|Central haemodialysis Venous Catheter|Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
40775511|NCT06495567|DIETARY_SUPPLEMENT|Creatine|For 7 days, participants will take a 20mg creatine supplement each day.
40775512|NCT06495567|DIETARY_SUPPLEMENT|Dietary methionine tracer and protein intake|On the study days participants will ingest 8 hourly meals of controlled amino acid intake, fortified with the necessary macronutrients. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g/kg/d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
41302508|NCT00501033|DEVICE|Mechanical induction of labor|
41302509|NCT00501033|DEVICE|Double Balloon|
41302510|NCT00501033|DEVICE|Foley Catheter|
41461454|NCT00800618|DRUG|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
40775513|NCT04277247|DRUG|Botulinum toxin type A|A standardized dose will be injected in each muscle: 25 Units of BTXA in the extensor hallucis longus in 1 site, 50 Units of BTXA in the flexor digitorum brevis in 2 sites and 25 Units of BTXA in the tibialis posterior in 1 site.
40775514|NCT04277247|DRUG|Placebo|0.9% saline placebo injection
40775515|NCT04885621|DIETARY_SUPPLEMENT|nutrisystem-D|Nutrisystem meal replacements and Glytec glucomander-outpatient algorithm for insulin management decisions
40980134|NCT03886012|DEVICE|Otoband|The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.
40980135|NCT03886012|DEVICE|Otoband sham|The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.
41142512|NCT01560429|PROCEDURE|Patient controlled epidural analgesia|Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
41302511|NCT05240950|DRUG|Anti-CEA CAR-T Cells|"The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10\^6/kg, 3×10\^6/kg, and 6×10\^6/kg using a standard 3+3 design and preliminarily observe the efficacy."
41302512|NCT02928406|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
41302513|NCT06215898|OTHER|LSVT-BIG Group via Telerehabilitation|An aerobic supervised exercise protocol was implemented four times a week for four weeks in LSVT-BIG Group via a Tele-rehabilitation model.
41302514|NCT02151006|DRUG|DHEA|
41461455|NCT00800618|DRUG|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
40775516|NCT05509348|BEHAVIORAL|Phase 1: ADAPT Workshop|2 day workshop
40775517|NCT05509348|BEHAVIORAL|Phase 1: ADAPT Online|Online curriculum
40775518|NCT05509348|BEHAVIORAL|Phase 2: ADAPT Group|3 in person group sessions
41302515|NCT00187837|PROCEDURE|SW|Stepwise removal of carious tissue in 2 stages
41302516|NCT00187837|PROCEDURE|DCE|one complete excavation
41302517|NCT04929262|BEHAVIORAL|Supporting Anxious Youth: Strategies for Caregivers|The outreach presentation will last 75 minutes with an additional 15 minutes for caregiver questions. The presentations will occur in the evening via Zoom. The presentation will include information about identifying anxiety disorders, strategies for caregivers to help their youth with anxiety, evidence-based practices to treat youth anxiety, and strategies for finding a therapist who uses cognitive behavior therapy with exposures. The text on the presentations is written at a 5.3 grade reading level. Presentations will incorporate stigma reduction strategies, such as education to dispel myths, and behavioral decision-making tools to elicit hope, empowerment, and motivation.
41302518|NCT02819648|DRUG|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
41302519|NCT02819648|OTHER|Control|Milk Tablet
41302520|NCT04174638|OTHER|Motivational Interviewing and Education Based on Watson's Theory of Human Caring|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring. The intervention performed before the hemodialysis session in a separate room in the hemodialysis unit.
41302521|NCT01419249|OTHER|Blood sampling|Subjects with pre-established diagnosis of IGHD and TS and were treated with r-hGH therapy for 1 year, will be observed in this retrospective cohort study wherein blood sampling will performed for genotyping of the various genetic markers along with collection of retrospective data relative to the r-hGH treatment.
41461456|NCT02810249|OTHER|No intervention used|
41461457|NCT00959439|DRUG|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
41461458|NCT00959439|DRUG|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
41461459|NCT06122155|DEVICE|Transcranial direct current stimulation (Anodal)|20-minutes, 2 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
41461460|NCT06122155|DEVICE|Transcranial direct current stimulation (Sham)|20-minutes, 0 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
41461461|NCT00170703|DEVICE|Cortical Electrical Stimulation|
40980136|NCT05789446|BEHAVIORAL|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action
41302522|NCT01160055|PROCEDURE|Middle ear fluid and urine.|Middle ear fluid and urine collection.
41302523|NCT03257072|BIOLOGICAL|50 Necator americanus L3 larvae|1x50 Necator americanus L3 larvae
41302524|NCT03257072|BIOLOGICAL|100 Necator americanus L3 larvae|2x50 Necator americanus L3 larvae
41461462|NCT04599166|BEHAVIORAL|Who Would You Choose: Serious Fun|"Who Would You Choose: Serious Fun is a conversation activity that prompts players (using scenarios and metaphors) to choose a spokesperson whose qualities are best suited to the role. At the end of the activity, players identify a real-life spokesperson based on the qualities considered during gameplay."
41302525|NCT03257072|BIOLOGICAL|150 Necator americanus L3 larvae|3x50 Necator americanus L3 larvae
41302526|NCT02042404|DEVICE|Sound amplification provided via EarLens System.|The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
41302527|NCT03282201|OTHER|Transfusion|Transfusion of red blood cells, fresh frozen plasma, platelets
41302528|NCT03637192|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
41461463|NCT01557751|GENETIC|Whole blood for genotyping|This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
41302529|NCT03637192|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
40980137|NCT01073982|DIETARY_SUPPLEMENT|tart cultivar Montmorency cherry juice|21 ounces of experimental or placebo juice, consumed daily for 21 days.
41302530|NCT00528346|BEHAVIORAL|cognitive training using fMRI|Participants will be scanned using fMRI while they employ the cognitive training strategies-allowing them to view their brain activity.
41302531|NCT00528346|BEHAVIORAL|placebo|Some participants will see simulated data that does not come from their own brains.
41302532|NCT02891031|DRUG|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
41302533|NCT02891031|DRUG|Placebo|500 mg twice daily after meal for 6 weeks
41461464|NCT00689845|BIOLOGICAL|bleomycin sulfate|Given IV
41461465|NCT00689845|BIOLOGICAL|filgrastim|Given subcutaneously
41461466|NCT00689845|BIOLOGICAL|rituximab|given IV
41461467|NCT00689845|DRUG|cyclophosphamide|Given IV
41461468|NCT00689845|DRUG|cytarabine|Given subcutaneously
41461469|NCT00689845|DRUG|doxorubicin hydrochloride|Given IV
41461470|NCT00689845|DRUG|etoposide phosphate|Given IV
41461471|NCT00689845|DRUG|ifosfamide|Given IV
41461472|NCT00689845|DRUG|methotrexate|Given IV
41461473|NCT00689845|DRUG|prednisolone|Given orally
41461474|NCT00689845|DRUG|prednisone|Given orally
41302534|NCT03471767|DRUG|AXS-05|Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
41461475|NCT00689845|DRUG|vincristine sulfate|Given IV
41461476|NCT00689845|DRUG|vindesine|Given IV
41461477|NCT06207253|DRUG|Diclofenac Sodium|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
40980138|NCT04421222|DRUG|EPI-7386 (QD)|Once daily oral dose of EPI-7386
40980139|NCT04421222|DRUG|EPI-7386 (BID)|Twice daily oral dose of EPI-7386
40980140|NCT04421222|DRUG|Abiraterone acetate|Once daily dose of abiraterone acetate
40980141|NCT04421222|DRUG|Apalutamide|Once daily dose of apalutamide
40980142|NCT05557461|DEVICE|End-tifdal co2, systolic, diastolic blood pressure, ppv values and vci distensibility|"(0,1,3,5 minutes measurements will be taken) measured before and after the test will be recorded and compared.~Cardiac output and stroke volume variation, vci distensibility will be measured and recorded by a specialist cardiologist using siemens ocuson cv70 (Siemens AG Medical Solutions, Henkestrasse, the Germany) echocardiography before and after the test."
41302535|NCT03471767|DRUG|Bupropion SR|Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
41302536|NCT05201859|DRUG|Sintilimab|Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).
41302537|NCT05201859|DRUG|Capecitabine|An oral anticancer agent that can be converted into 5-Fu in vivo.
41302538|NCT01045772|DRUG|rilonacept|160mg of rilonacept 1x/week
41302539|NCT04115241|DEVICE|Actigraph|Actigraphs are non-invasive, wearable devices that measure activity levels using an accelerometer
41302540|NCT04115241|OTHER|Grip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles
41302541|NCT04106427|DEVICE|continuous theta burst stimulation (cTBS)|"cTBS stimulation of 17 mins over right inferior parietal lobe (IPL) with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 100% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
41461478|NCT06207253|DRUG|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
41461479|NCT00448227|DRUG|famciclovir|Administered orally as a single individualized dose between 25-200 mg based on body weight.
41461480|NCT00808262|BIOLOGICAL|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
41461481|NCT04492397|DEVICE|Test Contact Lens|Subjects will be randomized to wear test lenses.
41461482|NCT04492397|DEVICE|Control Contact Lens|Subjects will be randomized to wear control lenses.
41461483|NCT06256549|DRUG|GZR18|Titrated to low dose or middle or high dose
40775519|NCT05509348|BEHAVIORAL|Phase 2: ADAPT Individual|3 sessions in person one on one
40775520|NCT03890211|DEVICE|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
40775521|NCT04212663|PROCEDURE|The tendon release of musculi tibialis posterior|To release the tendon of musculi tibialis posterior.
40980143|NCT03931291|DRUG|APR-246|APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
40980144|NCT03275051|OTHER|Safety and Efficacy assessments|Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
40980145|NCT05688189|DEVICE|different starting temperature setting of HFNC|The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)
40980146|NCT04582708|DEVICE|NERv's Inline Device|NERv's Inline Device is comprised of multiple sensors. It attaches in line to existing catheters or peritoneal drains that are currently approved for medical use. This allows the device to measure the pH and electrical conductivity of effluent fluids that are drained through peritoneal drains.
40980147|NCT01730157|BIOLOGICAL|ipilimumab|Given IV
40980148|NCT01730157|RADIATION|yttrium Y 90 glass microspheres|Given via hepatic arterial infusion
40980149|NCT01730157|OTHER|laboratory biomarker analysis|Correlative studies
40980150|NCT02086994|DRUG|misoprostol|given after the delivery of the anterior shoulder of the baby.
40980151|NCT02086994|DRUG|carbetocin|given after delivery of anterior shoulder
40980152|NCT04326231|DEVICE|Usability assessment of Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
41142513|NCT01560429|PROCEDURE|Continuous epidural analgesia|The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
41302542|NCT04106427|DEVICE|placebo cTBS|"Placebo stimulation of 17 mins over right IPL with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 0% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
41302543|NCT04106427|BEHAVIORAL|social cognitive remediation therapy (SCRT)|16 sessions of group SCRT will be scheduled within 8 weeks, comprising 6-8 participants per group with 2 therapists. Duration of group sessions will be 60-90 mins. The content will follow the manual of SCRT and we will add a short intervention to practice the use of co-speech gestures at each session
41302544|NCT04106427|BEHAVIORAL|Sham group therapy|Group activities in closed groups of 6 participants. Schedule of two sessions per week for 8 weeks. Two therapists are guiding different leisure activities, e.g. group walks, going to museums/movies, games.
40775522|NCT04212663|PROCEDURE|Anterior tibial tendon transfer(TATT)|To transfer the the tendon of anterior tibial from the navicular to the third cuneiform.
41302545|NCT06144528|OTHER|QT robot|In a single session each child will be video-recorded while performing the task. The participant subjects will perform the same task at two different times, once with the human operator and once with the Qt robot. Both tasks will have a duration of approximately 4 minutes. During the first minute, both the operator and the Qt will introduce themselves and ask four questions to the child to deepen the acquaintance. In the second minute, the operator/Qt will tell a story. In the third minute, the operator/Qt will ask to imitate 4 motor movements, while in the fourth minute, the operator/Qt will ask to imitate 4 facial expressions.
41302546|NCT01419665|BIOLOGICAL|GP2013|Type: Biological/Vaccine
41302547|NCT01419665|BIOLOGICAL|rituximab|Type: Biological/Vaccine
41302548|NCT01893944|OTHER|virtual reality|customized applications using virtual and augmented reality to be developed.
41302549|NCT06175611|DEVICE|COVID-19/Flu A/Flu B/RSV Test Kit|"The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.~Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.~This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants."
41461484|NCT06256549|DRUG|Semaglutide|Titrated to 1.0 mg once a week
41461485|NCT00590694|DRUG|ranibizumab|0.5mg injection monthly according to protocol for one year
40980153|NCT03557463|DIETARY_SUPPLEMENT|Dairy protein|A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
40980154|NCT05162131|DRUG|Bentracimab (PB2452) 100 mg or Placebo|"Experiment 1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
40980155|NCT05162131|DRUG|Bentracimab (PB2452) 300 mg or Placebo|"Experiment 1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
40980156|NCT05162131|DRUG|Bentracimab (PB2452) 1000 mg or Placebo|"Experiment 1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)~Drug: PB2452 Infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion"
40980157|NCT05162131|DRUG|Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
40980158|NCT05162131|DRUG|Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
41142514|NCT03880981|DRUG|Ibuprofen 600 mg|ibuprofen 600mg Po q 6 hours prn pain
41142515|NCT03880981|DRUG|Acetaminophen|acetaminophen 600mg po q6 hours prn pain
40980159|NCT05162131|DRUG|Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
40980160|NCT05162131|DRUG|Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
40980161|NCT01716351|BEHAVIORAL|Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients|A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
41302550|NCT01262261|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
40980162|NCT01325389|DIETARY_SUPPLEMENT|Myo-Mel|
40980163|NCT01325389|DIETARY_SUPPLEMENT|Placebo|
40980164|NCT03311815|DIAGNOSTIC_TEST|NGS techniques|Using NGS techniques we will detect the recurrently mutated genes in AML to establish the biological role of each mutation
40980165|NCT00429273|DRUG|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
40980166|NCT00429273|DRUG|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
41142516|NCT01255709|DRUG|Arm T1: Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
41461486|NCT01720849|DRUG|Fampyra|The will be given as per normal patient treatment plan
40980167|NCT03595033|DEVICE|iPad app-based intervention|The 1-hour of home based intervention will break into three 20-min sessions, each including iPad apps targeting one of the three domains of deficits: visual attention, visual-spatial reasoning, and visual-motor skills.
40980168|NCT02129725|DRUG|Sildenafil citrate|Sildenafil citrate 25 mg, 1 capsule three times a day for 3 months
40980169|NCT02129725|DRUG|Placebo Oral Capsule|placebo capsules, 1 capsule po three times a day for 3 months
41142517|NCT01255709|DRUG|Arm T2: Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
41142518|NCT01255709|DRUG|Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
41142519|NCT06157099|DRUG|Atorvastatin|Given PO
41142520|NCT06157099|DRUG|Placebo Administration|Given orally (PO)
41142521|NCT06157099|PROCEDURE|Computed Tomography|Undergo CT
41142522|NCT06157099|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41302551|NCT03008746|OTHER|water used for oral wash|
41302552|NCT03008746|OTHER|sputum|
41302553|NCT03008746|OTHER|oral wash|
41302554|NCT00148460|DRUG|TNK-tPA|
40980170|NCT04998461|BIOLOGICAL|urine collection|To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.
40980171|NCT02496897|BIOLOGICAL|FP-02.2 Vaccine|Synthetic Peptide Hepatitis B Vaccine
40980172|NCT02496897|OTHER|Placebo|Placebo
41142523|NCT06157099|OTHER|Electronic Health Record Review|Ancillary studies
41302555|NCT00148460|DRUG|rt-PA|
41142524|NCT06163157|OTHER|Connective tissue massage(CTM)|CTM will be applied by a trained physiotherapist for 3 days/week for 4 weeks. Application time will be approximately 15-20 minutes.
41142525|NCT02166632|PROCEDURE|Intracapsular Injection|"The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication."
41142526|NCT02166632|PROCEDURE|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
41142527|NCT05147207|PROCEDURE|Superpath Approach|This is a minimally invasive surgical approach for THA.
41142528|NCT06052943|BEHAVIORAL|Mindfulness-Based Intervention|Learning 2 BREATHE (L2B) is an evidence based curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
41142529|NCT06052943|BEHAVIORAL|Parent Education|The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition and 3) physical activity. The parents set weekly goals to implement the parent education lessons into everyday living.
41142530|NCT06052943|BEHAVIORAL|Physical Activity|Combines aerobic and resistance training though game play.
41302556|NCT04559152|DIETARY_SUPPLEMENT|Zinc Supplementation Group|Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks
41302557|NCT04559152|DIETARY_SUPPLEMENT|Placebo Group|Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks
41302558|NCT01076842|DRUG|Insulin-Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
41461487|NCT00943033|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence
41461488|NCT03818386|DRUG|AGuIX®|"3 intravenous injection at 100mg/kg~* D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~* Fr1: AGuIX® injection before the first radiation session~* Fr6: AGuIX® injection before the sixth radiation session"
40980173|NCT02496897|OTHER|IC31® Adjuvant|IC31® Adjuvant
40980174|NCT02915276|PROCEDURE|Blastocentisis|Removal of blastocoelic fluid from the blastocoelic cavity
40980175|NCT02915276|PROCEDURE|Trophectoderm biopsy|Removal of trophectoderm cells from the blastocyst
40980176|NCT04155112|BEHAVIORAL|Physical activity|Increased physical activity to the minimum recommended by health authorities (≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week).
40980177|NCT04155112|BEHAVIORAL|Hypocaloric Mediterranean diet|Energy deficit to reach 5-10% weight loss within 6 months, based on the Mediterranean diet pattern.
40980178|NCT02610179|DIETARY_SUPPLEMENT|Standard Glucola GCT|Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.
40980179|NCT02610179|DIETARY_SUPPLEMENT|Twizzlers challenge|Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
41142531|NCT06052943|BEHAVIORAL|Brief Mindfulness Intervention for Parents|Parent-based mindfulness education based on the Learning to BREATHE curriculum.
40980180|NCT05232240|DIAGNOSTIC_TEST|blood pressure variability measured by ambulatory 24-hour blood pressure monitoring|The ambulatory 24-hour blood pressure monitoring will be performed at baseline and one year after the enrollment. Various blood pressure variability characteristics will be obtained from these examinations.
40980181|NCT01941641|DRUG|neoadjuvant FOLFOXIRI|
40980182|NCT01941641|DRUG|Capecitabine|
40980183|NCT06504758|OTHER|Breathing Retraining Program|"* 1st to 5th week - Breathing Retraining 10 repetitions (Pursed Lip Breathing, Diaphragmatic Breathing)~* Two days / a week The total duration of 5 weeks."
40980184|NCT06504758|OTHER|Postural Exerises Program (Stretching and Strengthening Exercises)|"* TheraBand® or Free Weight~* 1st week - neck isometrics, chin tuck, SCM - upper trapezius - pectoral major stretching, scapular retraction without weight, rowing with yellow TheraBand®, wall squat / mini squat (5 repetitions - 15 second hold for stretching exercises, 10 repetitions for strengthening exercises)~* 2nd and 3rd week - same exercises (5 repetitions - 15 second hold for stretching exercises, 15 repetitions for strengthening exercises)~* 4th and 5th week - same exercises (10 repetitions - 15 second hold for stretching exercises, 20 repetitions for strengthening exercises)~* Two days / a week,The total duration of 5 weeks"
41142532|NCT06052943|BEHAVIORAL|Preschool Curriculum|Preschool age children learn about and try new foods.
41142533|NCT06052943|BEHAVIORAL|Cooking Matters|Nutrition education and hands-on cooking lessons for the whole family
41142534|NCT04487717|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
41142535|NCT06506279|DEVICE|CorTec Brain Interchange (BIC) System|Surgical implantation of the BIC System. This study's main objective is to implement and evaluate neuroplasticity-inducing stimulation. The stimulation methods for inducing neuroplasticity have been selected based on prior preclinical and intraoperative work that has shown promise in providing rehabilitative benefits for stroke patients.
41142536|NCT05709886|DEVICE|EUS-LA by LaserPro Diode Laser System|This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
41461489|NCT03818386|RADIATION|Whole Brain Radiation Therapy|30 Gy in 10 fractions of 3 Gy over 2-3 weeks
41461490|NCT02441985|DEVICE|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
40980185|NCT06057168|DRUG|Elucirem|Intravenous administration
40775523|NCT04212663|PROCEDURE|Achilles tendon lengthing|To lengthen the achilles tendon by using two incisions.
40775524|NCT04212663|PROCEDURE|Fascial release|To cut off the metatarsal fascia in the middle part.
40980186|NCT06057168|DRUG|Dotarem|Intravenous administration
40980187|NCT05320523|DEVICE|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.
40980188|NCT05320523|DEVICE|GPi stimulation|Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system
40980189|NCT05320523|DEVICE|NBM stimulation|Bilateral low-frequency neurostimulation of the NBM using a Vercise neurostimulation system
40980190|NCT05320523|DEVICE|Sham stimulation|Ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
41142537|NCT03405480|OTHER|Rehabilitation|Rehabilitation
41142538|NCT06562907|DRUG|GS-4571|Administered orally
41142539|NCT06562907|DRUG|Placebo|Administered orally
40980191|NCT03095391|DEVICE|VFI|The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
40980192|NCT03095391|DEVICE|Iohexol|Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
40980193|NCT00109889|PROCEDURE|magnetic resonance imaging|magnetic resonance imaging (MRI)
41142540|NCT06562907|DRUG|Omeprazole|Administered orally
41142541|NCT02690792|OTHER|NAFLD/NASH - Placebo|Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
41142542|NCT02690792|DIETARY_SUPPLEMENT|NAFLD/NASH - Vitamin E|Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
41142543|NCT04967014|DRUG|HIP2101|Test drug
41142544|NCT04967014|DRUG|RLD2101|Reference drug
41142545|NCT02399202|DRUG|osilodrostat|
41142546|NCT04938453|DRUG|nintedanib 25 mg|soft gelatin capsule
41142547|NCT04938453|DRUG|nintedanib 100 mg|soft gelatin capsule
41142548|NCT02349802|DRUG|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
41142549|NCT02349802|DRUG|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
41142550|NCT04721600|DEVICE|Evoke Radiofrequency Device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
41142551|NCT06051721|DRUG|CYB004|CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog.
41142552|NCT06051721|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
41302559|NCT01076842|DRUG|Exenatide-Bayetta|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
41461491|NCT02441985|DEVICE|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
41461492|NCT02441985|OTHER|Fahn-Tolosa-Marin Tremor Rating Scale (TRS)|All participants will receive a clinical assessment of tremor severity by using the TRS test.
41461493|NCT02441985|OTHER|"Timed Up & Go Test (TUG) test"|All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
41461494|NCT02441985|OTHER|10m walk test|All participants will receive a clinical assessment of walking speed by using the walk test.
40775525|NCT01395745|DRUG|blisibimod|blisibimod administered via subcutaneous injection every week for 52 weeks
40980194|NCT00109889|PROCEDURE|positron emission tomography|positron emission tomography (PET)
41142553|NCT02391766|BEHAVIORAL|empowerment|"The groups of 10 participants meet once a week for eight weeks. last for four hours~topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions."
41142554|NCT02391766|BEHAVIORAL|usual care|
41142555|NCT05167825|DRUG|Macitentan|Macitentan will be administered orally as a tablet.
41142556|NCT00337246|BIOLOGICAL|rituximab|
41142557|NCT00337246|DRUG|cyclophosphamide|
41142558|NCT00337246|DRUG|fludarabine phosphate|
41142559|NCT00337246|DRUG|mitoxantrone hydrochloride|
41302560|NCT01076842|DRUG|Insulin-Levemir and Exenatide-Bayetta|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
41461495|NCT02441985|OTHER|Tremor electrophysiology|All participant tremors will by analyzed using an EMG system
40775526|NCT01395745|DRUG|Placebo|Placebo will be administered weekly via subcutaneous injection for 52 weeks
41302561|NCT01076842|DEVICE|SenseWear Pro3® armband|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
41302562|NCT01076842|DEVICE|DexCom CGM|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
41302563|NCT05540613|BEHAVIORAL|Health Education|A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
41302564|NCT05540613|BEHAVIORAL|Conventional Exercise|A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.
41461496|NCT02441985|OTHER|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
41461497|NCT01055834|DRUG|Eszopiclone 3 mg|"Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting \>=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast \& the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration."
41461498|NCT01055834|DRUG|Eszopiclone 1 mg|"Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug."
41461499|NCT04883788|OTHER|Pandemic period|Perioperative care (nursing and physiotherapy) provided to patients treated with hip and knee replacement during the pandemic period
40775527|NCT06129955|DRUG|Pucotenlimab Combined With Lenvatinib|Patients treated by Pucotenlimab combined with Lenvatinib for 3 months before surgery
40775528|NCT04856280|BEHAVIORAL|Kinesiological taping|In KT Group, 6 sessions of KT were applied, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended.
41461500|NCT05752435|PROCEDURE|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS|comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts
41461501|NCT03436316|DRUG|AZD8154|SAD Part 1; 6 cohorts which receive single dosing. One cohort is invited back for large particle administration. Part 2; 1 cohort which receives IV dose and then inhaled administration of AZD8154. MAD Part 3; 3 cohorts will receive inhaled multiple dosing. Additional doses are provisional and could be adjusted based on the emerging data from the previous dose by the safety review committee (SRC).
41461502|NCT05485051|OTHER|2% chlorhexidine digluconate solution with surface-active agents|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
41461503|NCT05485051|OTHER|Usual Baths|Bathing will be performed at least daily using soap and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
40775529|NCT04856280|BEHAVIORAL|Aerobic exercise|In the AE group, walking and climbing stairs were given during the menstrual cycle, 3 days a week, 45 minutes.
40775530|NCT01427491|DEVICE|Aquacel® Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
40980195|NCT01731392|DIETARY_SUPPLEMENT|Milk with Bifidobacteria|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
41302565|NCT05540613|BEHAVIORAL|Tai Chi|A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
41302566|NCT06198621|DEVICE|cardiometry|cardiometry is noninvasive method, while swan ganz is invasive method in hemodynamic parameters assessment
41302567|NCT02898025|DEVICE|Active Interferential Current|Involves the application of medium frequency alternating currents
40775531|NCT01427491|DEVICE|Mepilex® Border Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
41302568|NCT02898025|DEVICE|Active Laser|Involves the application of low level laser over the knee
41302569|NCT02898025|DEVICE|Placebo Interferential Current|It is a sham interferential therapy
41302570|NCT02898025|DEVICE|Placebo Laser|It is a sham laser therapy
41302571|NCT04937478|OTHER|Observation|Only observational study, no intervention.
40980196|NCT01731392|DIETARY_SUPPLEMENT|Milk with non replicating lactobacilli|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
40980197|NCT01731392|DIETARY_SUPPLEMENT|placebo|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
41302572|NCT01829035|OTHER|Conventional Transarterial Chemoembolization (cTACE)|"Concurrent use of the following material/drug is defined as cTACE in this trial.~* Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~* Anti-tumor drug:~  1. Unapproved drug/embolization material from each regulatory agency should not be used.~ 2. To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed"
41302573|NCT04718987|RADIATION|Low dose rate (LDR) brachytherapy|Low dose rate (LDR) brachytherapy is a type of radiation treatment where doctor places the radioactive implants (seeds) inside patient's prostate gland and these seeds emits low dose radiation over a certain period of time. During low-dose-rate brachytherapy, a continuous low dose of radiation is released over time -from several hours to several days.
41302574|NCT05942651|DEVICE|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 4 ms intervals.|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
41302575|NCT05942651|DEVICE|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 100 ms intervals|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
40980198|NCT04897360|BEHAVIORAL|Increased breathing|hyperventilation to lower ETCO2
41302576|NCT01053546|BEHAVIORAL|exercise intervention|The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
40775532|NCT01343342|DIETARY_SUPPLEMENT|n-3 PUFA supplementation|3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
40775533|NCT02433938|PROCEDURE|Tibial nerve stimulation|patients underwent a three days postoperative transcutaneous tibial nerve stimulation
40980199|NCT04897360|OTHER|sharpened Romberg test (SRT)|Balance test conducted by standing with feet in front of each other, heel-to-toe in line while the right hand is on the left shoulder and the left hand is on the right shoulder.
41302577|NCT01053546|OTHER|questionnaire administration|Ancillary study
41302578|NCT01053546|PROCEDURE|quality-of-life assessment|Ancillary study
41302579|NCT02223221|PROCEDURE|IVF/ICSI|In vitro fertilization or intracytoplasmic sperm injection.
40775534|NCT02433938|PROCEDURE|Sham tibial nerve stimulation|patients did not undergo a postoperative transcutaneous tibial nerve stimulation
40980200|NCT01994460|DRUG|Linezolid|
40775535|NCT05532800|DRUG|JS002|JS002:150mg(1mL) Q2W PFS, Placebo: 1mL Q2W PFS.
40980201|NCT01994460|DRUG|Ethambutol|
40980202|NCT04410224|DRUG|ASN004|ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
40980203|NCT03695562|PROCEDURE|sequential drilling technique|Patient with vitamin D deficiency using sequential drilling technique
40980204|NCT03838822|DIETARY_SUPPLEMENT|Cofactors|Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
41302580|NCT02223221|GENETIC|PGS|Selection of embryos are based on SNP-array-based preimplantation genetic screening for the number of all chromosomes on the 5th day of IVF/ICSI.
41302581|NCT02223221|OTHER|Without PGS|Selection of embryos are based on morphology criteria on the 5th day of IVF/ICSI.
41302582|NCT00269191|DRUG|MK0663, etoricoxib / Duration of Treatment 12 Weeks|
41302583|NCT00269191|DRUG|Placebo or Ibuprofen / Duration of Treatment 12 Weeks|
40775536|NCT05532800|DRUG|Placebo|JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.
40980205|NCT03326258|DRUG|Glembatumumab Vedotin|Given IV
40980206|NCT03326258|BIOLOGICAL|Ipilimumab|Given IV
40980207|NCT03326258|OTHER|Laboratory Biomarker Analysis|Correlative studies
41302584|NCT03359005|DRUG|Vincristine|vincristine 1.5mg/m2 iv D1,D8
41302585|NCT03359005|DRUG|Temozolomide|Temozolomide 100mg/m2/d iv on days 1-5.
40980208|NCT03326258|BIOLOGICAL|Nivolumab|Given IV
40980209|NCT03326258|OTHER|Pharmacological Study|Correlative studies
40980210|NCT05491954|DEVICE|Dexcom G6|Continuous glucose monitoring
40980211|NCT02875483|OTHER|Expedited Scheduling|Patients are scheduled for tubal ligation surgery prior to discharge from the post-partum hospital service, with target date 4-8 weeks post-partum.
40980212|NCT02875483|OTHER|Standard Scheduling|Scheduling of tubal surgery occurs after completion of post-partum office visit
40980213|NCT04685915|DRUG|Ibrutinib|Capsule, taken by mouth once daily
40980214|NCT04685915|DRUG|Copanlisib|Intravenous Infusion
40980215|NCT04685915|DRUG|Acalabrutinib|Capsule, taken by mouth twice daily
40980216|NCT02231333|DRUG|S-adenosylmethionine (SAMe)|
40980217|NCT02231333|DRUG|pentoxiphylline (PTX)|
40980218|NCT05002855|OTHER|Enhanced Recovery After Surgery (ERAS)|Multidisciplinary approach to perioperative care.
40980219|NCT04610944|BEHAVIORAL|Changing Talk Online (CHATO)|Three, one-hour training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication.
40980220|NCT01829581|OTHER|no intervention, only descriptive data analysis|
40980221|NCT00005892|DRUG|cyclophosphamide|
41302586|NCT04381819|DIAGNOSTIC_TEST|SARS-CoV-2 PCR|SARS-CoV-2 E gene
41302587|NCT05462769|DEVICE|Percutaneous vascular closure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
40775537|NCT04608058|BEHAVIORAL|Digital storytelling training|"The digital content in this study is called Diabetes and Bumblebee. It features 35 minutes of animation that provides children with a brief description of the disease, its symptoms and complications, treatment methods, the type of insulin, how to preserve insulin, the importance of nutrition and exercise in treating diabetes as well as efficient communication and collaboration with parents and healthcare providers. Exciting and interactive animations were used to depict the daily life of a adolescence with diabetes."
41302588|NCT04152005|OTHER|Observation|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
41302589|NCT05080179|BEHAVIORAL|Self-Benefit/Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
40775538|NCT04608058|BEHAVIORAL|Routine training|The control group received the clinics' routine training include face to face class education.
40775539|NCT04647760|BEHAVIORAL|JOIN for ME|JOIN for ME is an empirically tested, effective weight management program for children ages 6-12 years.The curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are attended by the parent/caregiver and child, and occur at a location within their community setting (public housing or patient-centered medical home). Each session is 60 minutes and led by a certified Community Health Worker, with a private weigh-in for each dyad prior to the start of each session. Key behavioral targets include self-monitoring of dietary intake and physical activity, limiting LESS foods, limiting screen time, and weekly attendance. A family-based incentive structure is incorporated into the program such that parents/caregivers reinforce their children for achieving goals. Due to the COVID-19 pandemic, in-person sessions will be conducted virtually until it is safe to resume in-person group sessions.
40775540|NCT05892341|DEVICE|AQUACEL® Ag+ Extra™|Wound treatment with AQUACEL® Ag+ Extra™ dressing
40775541|NCT05892341|DEVICE|Cutimed® Sorbact®|Wound treatment with Cutimed® Sorbact® dressing
40775542|NCT02259595|DRUG|HPN-07|500-1,500 mg oral capsules administered in a single dose
40775543|NCT02259595|DRUG|NAC|1,200mg NAC administered via oral capsule in single dose
40775544|NCT02259595|DRUG|Placebo|placebo oral capsule
40775545|NCT04736355|DRUG|DAOIB|oral, for 24 weeks
40775546|NCT04736355|DRUG|Placebo|oral, for 24 weeks
40775547|NCT06528080|GENETIC|LY-M001|LY-M001 Injection by Single Intravenous Infusion
40775548|NCT00642291|DRUG|Emtricitabine|emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if \<30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if \>=7 to \<15kg; 10/2.5 mg/kg BID if \>=15 to \<=40 kg)
40980222|NCT00005892|PROCEDURE|Allogeneic Bone Marrow Transplantation|
40980223|NCT05685160|DIAGNOSTIC_TEST|MRI with contrast|MRI of the forefoot with contrast (Gadovist)
40980224|NCT05685160|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging of the forefoot
40980225|NCT03298594|DIAGNOSTIC_TEST|specific cervicograph|
40980226|NCT04087694|PROCEDURE|Microdecompression|comparative surgical treatment
40980227|NCT06369194|PROCEDURE|Colorectal Surgery|Postoperative Audit
40980228|NCT01378351|OTHER|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
40980229|NCT04035928|DEVICE|3D digital scanning for maxillofacial prosthetics|The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
40980230|NCT00500851|DEVICE|Electromagnetic imaging for jejunal tube placement (CORTRAK)|Jejunal feeding tubes are placed using electromagnetic imaging (CORTRAK)
40980231|NCT00500851|DEVICE|Endoscopy|Endoscopic placement of jejunal feeding tubes
40980232|NCT01563003|OTHER|Cognitive Behavioral Therapy|This condition involves 16 weekly CBT sessions.
40980233|NCT01563003|OTHER|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
40980234|NCT06096272|DEVICE|Augment Reality Exergames|Adaptive physical activity AR gaming modules were created in collaboration with physical therapists with expertise in CP and the Augment Therapy app development team. The program will consists of 5 games adapted for children with cerebral palsy.
41302590|NCT05080179|BEHAVIORAL|Self-Benefit/No Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. They will not read any information about the number of Pennsylvanians who downloaded the app."
41302591|NCT05080179|BEHAVIORAL|Other Benefit/Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
41302592|NCT05080179|BEHAVIORAL|Other Benefit/No Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They will not read any information about the number of Pennsylvanians who downloaded the app."
41302593|NCT03601416|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
40980235|NCT04506489|OTHER|Psychological investigation|Psychological tests, psychological interviews.
40980236|NCT02859675|OTHER|triangular test|metabolic state, impedance measurement, potential flavours evoked by sucrose,
40980237|NCT02859675|BIOLOGICAL|blood sampling|sampling of 2 mL
40980238|NCT02859675|OTHER|Questionnaires|Stunkard, PrefQuest
41302594|NCT03601416|DRUG|No Transplantation of Mesenchymal Stem Cell|Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
41461504|NCT05295524|OTHER|Kaftrio utilization in real life|daily utilization of PHEAL-CR-K application at home and VOC (volatile organic compound) measure of exhaled air for a group of the patients
40775549|NCT00642291|DRUG|Emtricitabine|emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
40775550|NCT02976805|DRUG|4L PegLyte + 15 mg bisacodyl|Randomized
40775551|NCT02976805|DRUG|6L PegLyte + 15 mg bisacodyl|Randomized
40775552|NCT04701554|OTHER|Qigong program|The intervention group received sixteen sessions lasting one hour with different techniques of diaphragmatic breathing, concentration techniques and exercises with smooth and coordinated musculoskeletal movements. The Qigong program was performed by a therapist with more than 10 years of experience.
41302595|NCT02085239|DRUG|Lidocaine Ropivacaine|"* 8-10 ml of Lidocaine given by subcutaneous injection~* 8-10 ml of Ropivacaine given by subcutaneous injection"
41302596|NCT02085239|DRUG|Lidocaine alone|
41461505|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (50 µg)|Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
40775553|NCT04701554|OTHER|Information on healthy lifestyles, physical exercise and dietary recommendations.|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
40775554|NCT01998477|BIOLOGICAL|TIVc|Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain \[A/H1N1-like, A/H3N2-like, and B-like\]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
40775555|NCT01998477|BIOLOGICAL|TIV|A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain \[A/ H1N1-like, A/H3N2-like, and B-like\]) IM injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere.
40775556|NCT01432444|DRUG|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
40775557|NCT05933811|PROCEDURE|exploratory laparoscopy|Laparoscopic exploration for impalpable maldescended testis in pediatric age group
40775558|NCT04717401|PROCEDURE|Strain-Counterstrain|Strain-counterstrain will be applied to four muscle which are . Tender point of each muscle will be identified then the muscle will be positioned passively in the most relaxed position which will be held for 90 sec. This procedure will repeated 3 times for each muscle
40775559|NCT04717401|PROCEDURE|Muscle Energy Technique|Muscle energy technique will be applied to four muscles which are quadratus Lumborum, iliacus, piriform and erector spinae. Each muscle will be positioned passively in stretched position the patient asked to push against the therapist isometrically while holding breath for 5-10sec. After exhalation, the muscle will be moved into a new barrier. This procedure will repeated 3 times for each muscle
40775560|NCT04585178|DEVICE|Biobeat patch|"The Biobeat device (BB-613WP) is a class IIa medical device and is a non-invasive patch used for monitoring vital signs in clinical and non-clinical settings. The sensor continuously records the photoplethysmographic waveform that allows the calculation of several physiological parameters: heart rate (HR), SPO2, systolic blood pressure (SBP) and change in SBP, diastolic blood pressure (DBP) and change in DBP, stroke volume (SV), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), and respiration rate (RR).~Translated with www.DeepL.com/Translator (free version)"
40775561|NCT04510207|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
40775562|NCT04510207|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP
40775563|NCT04510207|BIOLOGICAL|Placebo|The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
40775564|NCT04544280|DRUG|Xeomin Injectable Product|Intramuscular injection
40775565|NCT00543985|PROCEDURE|Stress Echocardiography|Echocardiography was performs prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
40775566|NCT02164409|PROCEDURE|Endoscopy tissue collection|The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
40775567|NCT03069716|DEVICE|Smartphone Text Messaging|A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
41302597|NCT04922892|PROCEDURE|Parathyroidectomy|Total Parathyroidectomy With Autotransplantation or Total Parathyroidectomy Alone
41461506|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (100 µg)|Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
41461507|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (200 µg)|Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
41461508|NCT03998592|OTHER|Placebo|Placebo without active component
41461509|NCT02832167|BIOLOGICAL|Nivolumab|Specified dose on specified days
41461510|NCT01853176|DRUG|Liposomal Injection Bupivacaine (Exparel)|
41461511|NCT01853176|DRUG|Standard bupivicaine|
40980239|NCT04650802|DEVICE|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
41302598|NCT05296850|OTHER|Manual Release|Individuals are placed in the prone position with their knees extended. The calcaneus is kept in eversion while maintaining talocrural dorsiflexion. As the toes are stretched in dorsiflexion, the therapist slides the big toe distally and proximally along the plantar fascia and flexor hallucis longus. Soft tissue mobilization depth will be applied according to the patient's tolerance and reactivity.
41461512|NCT04226339|PROCEDURE|total knee arthroplasty with a kinetic alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~it will be set to reproduce the preoperative constitutional deformity in varus or valgus as it was measured before surgery"
41461513|NCT04226339|PROCEDURE|total knee arthroplasty with a mechanical alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~It will be set to 180° as defined for a mechanical femorotibial alignment"
41461514|NCT00470691|PROCEDURE|plaster cast|complete circular plaster cast
41461515|NCT00470691|PROCEDURE|dorsal splint|dorsal plaster splint
41461516|NCT04212819|OTHER|Before Erythrocyte Suspension (ES)|ES transfusion needs of the patients were determined according to clinical signs and symptoms. Vital signs were closely monitored and recorded before, during and after transfusion. Infusion was performed slowly for the first 15 minutes in terms of allergic reaction, and then the transfusion rate was adjusted according to the patient's clinic.
40775568|NCT03069716|DEVICE|Fitbit Charge HR|The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
40775569|NCT02361892|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
40775570|NCT03864328|DRUG|RVT-1601|Inhaled RVT-1601 administered TID via eFlow nebulizer
40775571|NCT03864328|DRUG|Placebo|Inhaled Placebo administered TID via eFlow nebulizer
40775572|NCT01295489|OTHER|Laboratory Biomarker Analysis|Correlative studies
40775573|NCT04767321|DRUG|LTX-109 gel, 3% w/w|LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
40775574|NCT04767321|DRUG|Placebo|Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
40980240|NCT00091351|PROCEDURE|conventional surgery|
41461517|NCT04212819|OTHER|After Erythrocyte Suspension (ES)|Venous blood samples were obtained from patients who needed ES transfusion before transfusion. Control venous blood samples were obtained from the patients who did not develop any complications for 24 hours after starting of the transfusion and became hemodynamically stable.
40775575|NCT00775255|DRUG|clarithromycin 250 mg/5 mL powder for oral suspension|
40980241|NCT00091351|RADIATION|radiation therapy|
40980242|NCT06230081|DRUG|Ropivacain 5 mg/ml + Clonidine|Drug used in the block
40980243|NCT06085079|DRUG|Ixekizumab Prefilled Syringe|Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.
41461518|NCT03754387|DRUG|Ceftazidime|Patients choosing AT group were admitted to the hospital for observation and to receive intravenous antibiotics Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) was administered for 3 days.
41461519|NCT03754387|PROCEDURE|appendectomy|APPT group consisted of admission to the hospital with promptinitiation of intravenous antibiotics and appendectomy
41461520|NCT02654015|DEVICE|Apollo MIES|Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
41461521|NCT02654015|OTHER|Medical Management|Subjects will receive best medical management for intracranial hemorrhage
41461522|NCT04290494|DRUG|IV rtPA (intravenous recombinant plasminogen activator)|intravenous injection
41461523|NCT00004906|BIOLOGICAL|filgrastim|
41461524|NCT00004906|DRUG|anastrozole|
41461525|NCT00004906|DRUG|carboplatin|
41461526|NCT00004906|DRUG|cisplatin|
41461527|NCT00004906|DRUG|cyclophosphamide|
40775576|NCT05267782|DEVICE|Masimo's O3 Regional Oximetry|Correlation between new O3 regional oximetry monitoring, electroencephalography and somatosensory evoked potential in carotid endarterectomy and data collection during different stages of anaesthesia and correlation with new O3 regional oximetry
40775577|NCT00949533|DRUG|Oseltamivir|Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
40775578|NCT06171061|DRUG|Yangxinshi tablet|In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
41461528|NCT00004906|DRUG|docetaxel|
41461529|NCT00004906|DRUG|doxorubicin hydrochloride|
41461530|NCT00004906|DRUG|etoposide|
41461531|NCT00004906|DRUG|pamidronate disodium|
41461532|NCT00004906|DRUG|thiotepa|
41461533|NCT00004906|PROCEDURE|peripheral blood stem cell transplantation|
41461534|NCT03023709|BIOLOGICAL|Fluzone®|quadrivalent, inactivated influenza virus vaccine, intramuscular
41461535|NCT03023709|BIOLOGICAL|FluMist®|quadrivalent, live, attenuated influenza vaccine, intranasal spray
41461536|NCT06204016|DRUG|Estradiol Valerate|To elevate estradiol levels each woman will receive 12mg on two consecutive days (total 24mg) of estradiol valerate (Progynova21©)
41461537|NCT06204016|DRUG|Placebo|Placebo tablets will be administered as placebo-controlled condition (P-Tabletten White 7mm, Lichtenstein)
41461538|NCT02118025|PROCEDURE|Off-pump coronary artery bypass graft|Patients operated with the heart beating, without heart arrest.
41461539|NCT02118025|PROCEDURE|Mini extracorporeal circulation bypass|Patients operated with a modified extracorporeal circulation system
40980244|NCT05339087|DRUG|Riociguat Oral Tablet|Riociguat Oral Tablet (1 mg, 1.5 mg, 2.0 mg or 2.5 mg three times daily) Titration phase: dose will be individually adjusted in accordance with the in-label titration regimen. Dose adjustment will be performed every two weeks by phone taking the systemic blood pressure of the patient, the subjects and physicians' subjective estimation and occurrence of adverse reactions into account. At week 8 the maintenance dose will be established and continued for the rest of the study
40980245|NCT05339087|OTHER|Placebo|Sham titration and adjustment to maintenance dose will be performed according to individual tolerability as in the experimental arm.
40980246|NCT02654483|DRUG|VPD-737|VPD-737 inhibits the receptor neurokinin-1.
40775579|NCT06171061|OTHER|Basic medication|The control group will be given basic medication only. The treatment period is 24 weeks.
40980247|NCT02654483|OTHER|Placebo|Matching tablets to VPD-737 tablets without active drug
40980248|NCT03787953|DRUG|Anti-PD-1/PD-L1 antibodies|The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
40980249|NCT04542655|OTHER|Ergometer Cycling followed by treadmill running|The participants undergo ergometer cycling, treadmill running and rest.
40980250|NCT04542655|OTHER|Treadmill Running followed by ergometer cycling|The participants undergo treadmill running, ergometer cycling and rest.
40980251|NCT04542655|OTHER|Rest|The participants undergo ergometer cycling, treadmill running and rest.
40980252|NCT00627003|DRUG|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
40980253|NCT00627003|OTHER|Placebo|Placebo oral tablets administered daily for 5 weeks
40980254|NCT01779739|PROCEDURE|Perineorrhaphy|Procedure to build up the vaginal opening
40980255|NCT00597545|PROCEDURE|Carotid endarterectomy|When a shunt is inserted to increase blood flow to the brain
40980256|NCT00597545|DEVICE|Shunt|A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
40980257|NCT00877058|BEHAVIORAL|preventive home visit|
40980258|NCT00877058|BEHAVIORAL|senior meetings|
40980259|NCT04056676|PROCEDURE|Thoracic paravertebral block under ultrasound guidance|Ultrasound-guided thoracic paravertebral blocks in T2, T4 level
40980260|NCT04056676|PROCEDURE|Intraoperative modified PEC block|Pectoral nerve block by surgeon under direct vision after total mastectomy
40980261|NCT04056676|PROCEDURE|GA with ETT|General anesthesia with endotracheal intubation
40980262|NCT03336047|BEHAVIORAL|personal activity intelligence|"Participants randomized to the PAI intervention will receive a Mio Slice fitness bracelet and asked to install the Mio Pai 2.0 app on their smart phone. This tracks their fitness score based on the PAI algorithm where the goal is to maintain 100 PAI points a week. PAI is earned incrementally based on time spent in three different heart rate zones, low, medium and high intensity. PAI is recorded every day and added to the weekly total and the PAI earned on the same day the previous week is deleted (on Tuesday, the PAI earned the previous Tuesday will disappear).~Participants will be encouraged to maintain 100 PAI during the 8 weeks intervention by telephone messages (sms)."
40980263|NCT03336047|BEHAVIORAL|10,000 steps daily|Participants randomized to the 10,000 step intervention will receive a fit bit zip step counter and asked to obtain 10.000 steps per day. Participants will be encouraged to obtain 10.000 steps per day by telephone messages (sms).
40980264|NCT00518986|DRUG|armodafinil|200 mg/day
41461540|NCT03160079|DRUG|blinatumomab|"Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days"
40980265|NCT00518986|DRUG|placebo|placebo
40980266|NCT01918761|DRUG|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
41461541|NCT03160079|DRUG|pembrolizumab|"Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)"
40980267|NCT03874520|OTHER|Video triage|The operator will offer the parent calling regarding the sick child to assess the child on video, as compared to the current standard; on the telephone.
40980268|NCT01157949|DRUG|Thymoglobulin|Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
40980269|NCT04278079|PROCEDURE|Pars Plana Vitrectomy with Internal Limiting Membrane peel|Pars plana vitrectomy with staining and peeling of internal limiting membrane
40980270|NCT00851812|BEHAVIORAL|Exercise|Standard care monitoring
40980271|NCT00851812|BEHAVIORAL|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
40980272|NCT00047814|DRUG|FK788|
40980273|NCT01518166|DRUG|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
40980274|NCT01518166|DRUG|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
40980275|NCT01518166|DRUG|atorvastatin|One single dose of 40 mg. Tablet
40775580|NCT05214365|DEVICE|Pacemaker implantation and conventional cardiac pacing|Patients will have the pacemaker implanted in the electrophysiology laboratory. Electrode will be implanted (in the apical or septal portion) according to the criteria of the implanting physician.
40775581|NCT05214365|DEVICE|Conduction system pacing implant|Right ventricular lead was placed to get his bundle or left bundle branch.
40775582|NCT01880463|DRUG|Omega-3 fatty acids (fish oil)|
40775583|NCT01880463|DIETARY_SUPPLEMENT|Vitamin D3|
40775584|NCT01880463|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
40775585|NCT01880463|DRUG|Fish oil placebo|
40980276|NCT01518166|DRUG|lisinopril|One single dose of 20 mg. Tablet
40980277|NCT01518166|DRUG|griseofulvin|One single dose of 500 mg. Tablet
40980278|NCT01518166|DRUG|digoxin|One single dose of 1 mg. Tablet
40980279|NCT01088945|BEHAVIORAL|Enhanced Discharge process|Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
40775586|NCT01436227|OTHER|Laboratory Biomarker Analysis|Correlative studies
40775587|NCT01436227|DRUG|Pazopanib Hydrochloride|Given PO
41461542|NCT01980173|PROCEDURE|Routine care|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm of the study will continue to have routine care.
41461543|NCT01980173|DEVICE|Bakri balloon|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm will be treated with the immediate placement of a Bakri balloon, followed by routine care if necessary.
41461544|NCT00425009|DRUG|Berberine|
40775588|NCT06460272|OTHER|Medically Tailored Meals|Meals culturally tailored to provide essential nutrition
40775589|NCT02950259|DRUG|Cyclophosphamide|One dose of cyclophosphamide 300 mg/m2 IV infusion
40775590|NCT02950259|DRUG|Indomethacin|Indomethacin 25 mg three times a day for 21 days
40775591|NCT02950259|DRUG|Omeprazole|One tablet of omeprazole daily for 21 days
40775592|NCT02950259|DIETARY_SUPPLEMENT|Multivitamin|Daily multivitamin containing 15-30 mg of zinc for 21 days.
40775593|NCT01021800|BIOLOGICAL|MIS|Cell infusion
40775594|NCT02031614|PROCEDURE|Phlebotomy|Withdrawal of 500 mL of whole blood.
40775595|NCT01468545|OTHER|Iloprost (Ventavis inhaled, BAYQ6256)|An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
40775596|NCT01468545|OTHER|Iloprost (Ventavis inhaled, BAYQ6256)|No extra educational reinforcement.
40775597|NCT04744103|DRUG|TCA|Patients will receive a TCA peel as a treatment for their actinic cheilitis.
40775598|NCT04848194|PROCEDURE|skin biopsy and blood sampling|"* 4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.~* A blood sample"
40980280|NCT06332651|OTHER|Black beans|Black beans cooked and mashed and amino acid mixture as liquid drink to make methionine the limiting amino acid in the food consumed
40980281|NCT06332651|OTHER|Milk|Skimmed milk as liquid drink and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
40980282|NCT06332651|OTHER|Sorghum|Sorghum cooked and mashed and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
40980283|NCT04961645|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"TMS is a safe and noninvasive method for affecting brain function relying on the properties of electromagnetic induction. Action potentials are triggered in neurons, along with a subsequent period of deactivation. Normal ongoing brain activity is disrupted providing a way for investigators to produce a transient and reversible period of brain disruption.~Participants will be seated comfortably in a chair and asked to complete either a simple computer-based task or a simple behavioral task that will require them to walk around in a small room. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur. The entire visit will last about one and a half hours."
40980284|NCT03108833|DRUG|Recombinant Human Prourokinase|The drug is used for intravenous thrombolysis therapy
40980285|NCT03108833|DRUG|Alteplase|The drug is used for intravenous thrombolysis therapy
41461545|NCT00425009|DRUG|Metformin|
41461546|NCT05440305|PROCEDURE|surgery type/exstirpation/debulking|Evaluation of benefit according to surgery
41461547|NCT02314494|BEHAVIORAL|ProAsk|The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
41461548|NCT02922582|DRUG|DepoTXA|
41461549|NCT02922582|DRUG|Tranexamic Acid|
40775599|NCT01302886|DRUG|BHQ880|
40775600|NCT03719131|DRUG|Nivolumab|Receive standard of care nivolumab therapy
40775601|NCT03719131|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given IV or SC
40775602|NCT03719131|DRUG|Ipilimumab|Receive standard of care ipilimumab therapy
40775603|NCT02834364|DRUG|Encorafenib|450 mg p.o. once daily. One cycle is defined as 28 days
40775604|NCT02834364|DRUG|Binimetinib|45 mg p.o. twice daily. One cycle is defined as 28 days
40775605|NCT04035031|DRUG|Forxiga 10mg|Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)
40775606|NCT04035031|DRUG|Placebo|Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
40775607|NCT05288556|DEVICE|Placement of stoma site enteral feeding tube accessory|The study stoma site accessory will be attached at the stoma site during an enteral tube replacement procedure the patient is scheduled to have as a standard of care procedure. The study stoma site accessory is compatible with commercially available enteral nutrition feeding tubes ranging from size 16 to 20 French tubing that are adjustable to variable length.
40775608|NCT00841815|DRUG|Amlodipine Besylate|10 mg Tablet
40775609|NCT00841815|DRUG|Norvasc®|10 mg Tablet
40775610|NCT02946996|DRUG|Metformin|
40775611|NCT02946996|OTHER|OPC|OPC is a derivative of grape seed extract
40775612|NCT03950856|DRUG|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
40775613|NCT03950856|DRUG|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
40980286|NCT06395454|DIAGNOSTIC_TEST|Shorten antibiotics duration based on procalcitonin test levels|procalcitonin test will be taken on day 1 of recruitment as baseline, test done on day 5 will decide whether antibiotics will be withheld, followed by day 7 to determine rate of reinfection.
40980287|NCT00005622|DRUG|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
40980288|NCT00005622|RADIATION|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
41302599|NCT05296850|OTHER|Kinesio Taping|"In the first technique, an I tape will be applied on the plantar surface of the foot from the metatarsal heads to the popliteal fossa. First, the middle of the band is attached to the inferior of the calcaneus as the first anchor, then the ankle is dorsiflexed and the upper part of the band is applied with 15-25% tension until the popliteal fossa. The plantar fascia is placed in a stretched position by dorsiflexing the ankle and fingers, and the ends of the tape, which is divided into 4 parts, are applied separately to the metatarsal heads with 75-100% tension. In the second technique, the application is made with an I tape. The initial anchor starts from the dorsal aspect of the 5th metatarsal on the lateral aspect of the foot. Then, the tape passes to the medial side of the foot with 75-100% tension and is adhered to the medial side of the foot and ankle over the navicular. The end anchor is applied without tension."
41302600|NCT04937894|DRUG|Tigecycline|Efficacy and safety of Tigecycline
41302601|NCT03048721|PROCEDURE|Skin Tape Stripping|For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
41302602|NCT03048721|PROCEDURE|Punch Biopsy|For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
41302603|NCT02590016|DRUG|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
41302604|NCT06494904|DRUG|Buprenorphine|All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.
41302605|NCT05956249|OTHER|Online group therapy|Online group therapy for the treatment of depression, anxiety and improvement of emotional well-being.The intervention will be carried out in 6 groups of 6 participants.
40775614|NCT02903862|BEHAVIORAL|Mindoula|The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support \& assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
41302606|NCT05956249|OTHER|Control Group|Without intervention at the first moment, but the control group will receive the intervention after the reassessment of the scales by the scholarship holder was done.
41302607|NCT02069223|PROCEDURE|Gastrectomy|
41302608|NCT02069223|PROCEDURE|BPD-DS|
41461550|NCT02212236|OTHER|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
40775615|NCT02903862|DEVICE|DANA|DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
40775616|NCT05032378|BEHAVIORAL|Kinesthetic Awareness Training|One physical or occupational therapy session per week for 8 weeks during which the participant with disordered movement will attempt to perform desired movements while wearing the KAT device
40775617|NCT05032378|BEHAVIORAL|Provision of KAT-assisted physical or occupational therapy|Physical or occupational therapy professionals will provide one KAT-assisted therapy session per week for 8 weeks to one or more participants with movement disorder.
40775618|NCT02259114|DRUG|Birabresib|Birabresib 10, 20 and/or 40 mg oral capsules
40775619|NCT01967745|PROCEDURE|laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
40775620|NCT01967745|PROCEDURE|open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
40775621|NCT05896241|OTHER|non-interventional study|non-interventional study
40775622|NCT05990686|DRUG|Tramadol Hydrochloride|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started.~Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anaesthesia (induction agent will be Propofol 2mg/kg)"
40775623|NCT05990686|DRUG|Fentanyl injection|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started...Intravenous injection of 1microgram/kg fentanyl will be given to the patient followed by induction agents ( propofol 2mg/kg).~."
40775624|NCT00520338|DRUG|celecoxib|"1. placebo~2. celecoxib 400 mg oral single dose"
41461551|NCT00093730|DRUG|BMS-59926|
40775625|NCT02009826|RADIATION|[18F]-PBR111 Positron Emission Tomography (PET)|\[18F\]-PBR111 radioligand to assess binding to TSPO
40775626|NCT02009826|BEHAVIORAL|Cognitive and psychomotor tasks|Cognitive and psychomotor tasks on digitizing tablet
40775627|NCT02009826|BIOLOGICAL|Blood sampling|Blood sampling for peripheral inflammatory and neurotoxicity markers
41302609|NCT04748276|DRUG|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Protocol-approved antidepressant treatments (ADT) will be prescribed in accordance with standard of care, whenever possible following dosing recommendations within the Study Formulary and Prescribing Guidelines (Sertraline 100 mg/day; Citalopram 20 mg/day; Escitalopram 10 mg/day; Fluoxetine 20 mg/day; Paroxetine 20 mg/day; Duloxetine 60 mg/day; Buproprion 300 mg/day; Desvenlafaxine 50 mg/day; Venlafaxine 150 mg/day). ADTs may be up or down-tapered as necessary.
40775628|NCT04017858|BEHAVIORAL|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).|"Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis"
40775629|NCT04017858|BEHAVIORAL|Patients will be submitted to total knee replacement.|"Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively"
40775630|NCT04361279|DRUG|SIBP-02|Injection，100mg/10ml
40775631|NCT04361279|DRUG|Rituximab|Injection，100mg/10ml
40775632|NCT06186232|PROCEDURE|guided bone regeneration (GBR).|guided bone regeneration (GBR) using polymethylmethacrylate (PMMA) polymer as membrane.
40775633|NCT00062764|DRUG|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
40775634|NCT05266495|OTHER|Brolucizumab|There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.
40775635|NCT04809337|OTHER|Exercise|After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.
40775636|NCT06062693|DEVICE|smart sensor egg training|The portable hand trainer has three principal functionalities: (I) Grasping, (II) Pronosupination, and (III) wrist and finger extension. Different exercises can be done.
40775637|NCT02320188|OTHER|Eccentric exercise|This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.
40775638|NCT02320188|OTHER|Concentric exercise|The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
40775639|NCT04485702|DRUG|Midazolam injection|2mg IV
40775640|NCT04485702|DRUG|Ketamine Injectable Product|6mg IV
40775641|NCT04485702|DRUG|MELT-100|midazolam 3mg and ketamine 25mg SL tablet
40775642|NCT01728103|DEVICE|APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays|In Vitro Diagnostic Assays
40775643|NCT04694911|BEHAVIORAL|Focus Group|Participate in focus group
40775644|NCT04694911|OTHER|Interview|Complete cognitive interview
40775645|NCT04694911|OTHER|Research or Clinical Assessment Tool|Receive OOCAT
40775646|NCT03290027|DRUG|DFD-03|DFD-03 Lotion
40775647|NCT03290027|OTHER|Placebo Comparator|Vehicle (tazarotene 0%) Lotion
40775648|NCT06544460|PROCEDURE|Secondary cytoreduction|Repeated tumor cell reduction surgery for recurrent ovarian cancer patients
40775649|NCT06544460|DRUG|Hyperthermic intraperitoneal chemotherapy|Using the BR-TQR-I intraperitoneal hyperthermic perfusion chemotherapy instrument, after the surgical operation is completed, four drainage tubes are placed in the left and right upper abdomen and lower abdomen respectively. Connect all pipelines and preheat the instrument before starting treatment. The treatment temperature is controlled at 43 ℃± 0.1 ℃, the treatment time is 90 minutes, and the circulation pump flow rate is 400-600ml/min. Within 48 hours after the surgery, cisplatin 75mg/㎡ was added to 3000ml of physiological saline for intraperitoneal hot infusion. Through the comprehensive effects of circulation flushing, hyperthermia, chemotherapy, and thermochemotherapy sensitization, it kills and removes residual cancer cells or small lesions in the abdominal cavity.
40980289|NCT05855850|DEVICE|Brainsway H4-Coil Deep TMS System|Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H4-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
40980290|NCT05855850|DEVICE|Brainsway H7-Coil Deep TMS System|Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H7-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
40980291|NCT05991037|BIOLOGICAL|Blood sampling for psychoactive drugs dosage|4 blood samples for psychoactive drugs identification and dosage will be taken on arrival at the emergency room during fall management
40775650|NCT03573674|BEHAVIORAL|CE - Cognitive Ergonomics (KERGO)|"CE Cognitive ergonomics Intervention deals with themes such as disruptions, interruptions, information overload.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
40775651|NCT03573674|BEHAVIORAL|RS - Recovery Support (KUORMA)|"RS Recovery Support / Stress Management Intervention deals with themes such as workload management, recovery, work-family balance.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
40775652|NCT02256995|DEVICE|uChek|The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
41302610|NCT01574222|BIOLOGICAL|autologous dendritic cell adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
40775653|NCT03178409|PROCEDURE|Hepatectomy|Removal of a part of the liver
40980292|NCT05534386|BEHAVIORAL|Cancer survivorship care intervention|A one-off face-to-face assessment and personal advice by members of a multidisciplinary team
41302611|NCT05087628|BIOLOGICAL|PRV-3279|Bi-specific antibody-based molecule
41302612|NCT05087628|OTHER|Placebo|Placebo
41302613|NCT03546179|OTHER|tidal volume challenge test|Tidal volume (VT) will be increased from 6 to 8 ml/kg of for one minute and hemodynamic variables, including PVI with 8 ml/kg tidal volume ventilation (PVI8) will be recorded.
41302614|NCT03546179|OTHER|Volume loading|After these two baseline hemodynamic measurements, volume expansion will be performed for 10 min using an infusion of balanced crystalloid solution (6ml/kg of predicted body weight).
41302615|NCT06189001|DRUG|Oxytocin|Intravenous oxytocin 0.2 IU/min during experimental days
40775654|NCT03057704|DRUG|Lidocaine injection flushed|The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
40775655|NCT03057704|DRUG|Lidocaine injection tourniquet|Intravenous lidocaine: tourniquet
41302616|NCT06189001|OTHER|Placebo (saline)|Intravenous saline during experimental days
40775656|NCT05547672|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
41302617|NCT01243606|BEHAVIORAL|Single Diagnosis Treatment Protocol|SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
41302618|NCT01243606|BEHAVIORAL|Unified Protocol (UP)|The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
40775657|NCT04843280|PROCEDURE|FORCE therapeutics (physical therapy)|6 weeks of internet based physical therapy following arthroscopic knee surgery
40775658|NCT04843280|PROCEDURE|Traditional Outpatient Physical Therapy|6 weeks of outpatient physical therapy following arthroscopic knee surgery
40775659|NCT06249464|BEHAVIORAL|comprehensive rehabilitation|"All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
40980293|NCT05534386|BEHAVIORAL|Step-up targeted personalized intervention|To provide a more personalized intervention to the participants, but focusing more on symptom management and weight control.
41302619|NCT03403504|DRUG|Oxycodone Tamper Resistant|Orally administered Oxycodone Tamper Resistant 10mg
40980294|NCT05534386|BEHAVIORAL|First stage control intervention|A set of skill-based pamphlets will be given.
40980295|NCT05534386|BEHAVIORAL|Second stage control intervention|Those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlet
40980296|NCT01190878|DRUG|ISV-303|0.075% of bromfenac in DuraSite dosed QD
40980297|NCT01190878|DRUG|ISV-303|0.075% of bromfenac in DuraSite dosed BID
41302620|NCT03403504|DRUG|OXYCONTIN®|Orally administered OXYCONTIN® Tablet 10 mg
41302621|NCT02293954|PROCEDURE|radionuclide imaging|Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
41302622|NCT02293954|PROCEDURE|positron emission tomography|Undergo PET
41302623|NCT02293954|OTHER|laboratory biomarker analysis|Correlative studies
41302624|NCT02293954|OTHER|pharmacological study|Correlative studies
41302625|NCT02293954|DRUG|Cu 64 anti-CEA monoclonal antibody M5A IV|Cu 64 anti-CEA monoclonal antibody M5A IV
41302626|NCT05640713|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B Cell Malignancy .
41302627|NCT05640713|DRUG|Fludarabine Pill|Fludarabine is used for lymphodepletion.
41302628|NCT05640713|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
41302629|NCT05640713|DRUG|VP-16 Protocol|VP-16 is used for lymphodepletion.
41302630|NCT04673526|PROCEDURE|Laparoscopic intersphincteric resection|Laparoscopic intersphincteric resection for ultra low rectal cancer in elderly patients
41302631|NCT04673526|PROCEDURE|Laparoscopic abdomino-perineal procedures|Abdominoperineal resection + colostomy in left iliac fossa or perineum
40775660|NCT06249464|DRUG|Lidocaine hydrochloride|the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
40775661|NCT01216488|DRUG|Xylocaine|40 ml or 25 ml of Xylocaine injection
40775662|NCT05536791|DRUG|Dabigatran Etexilate (DE)|Dabigatran Etexilate (DE)
40775663|NCT04556253|DRUG|AK104|Subjects will receive AK104 by intravenous administration.
40980298|NCT01190878|DRUG|DuraSite Vehicle|Vehicle dosed BID
40980299|NCT01190878|DRUG|Xibrom™|0.09% bromfenac dosed BID
41142560|NCT00911638|BEHAVIORAL|Patient decision aid|"Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
41142561|NCT00911638|BEHAVIORAL|Usual care|"Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only"
41142562|NCT06505577|OTHER|No additional intervention|All patients are scheduled to undergo standard breast surgery as part of their routine clinical care. No additional interventions are administered specifically for this study.
41142563|NCT04566120|DRUG|cinnamon extract mouthwash|cinnamon extract mouthwash
41142564|NCT04566120|DRUG|chlorohexidine based mouthwash|chlorohexidine based mouthwash
41142565|NCT06360367|BEHAVIORAL|HI-FLY Curriculum|Participants receive the standard HI-FLY Curriculum over 6 weeks.
41142566|NCT06360367|BEHAVIORAL|HI-FLY Curriculum + PortionSize Ed app|Participants receive the standard HI-FLY Curriculum over 6 weeks and the PortionSize Ed mobile app.
41142567|NCT05888285|PROCEDURE|Erector spina plane block|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection
41142568|NCT05888285|PROCEDURE|Erector spina bale block and pulsed radiofrequency|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection and pulsed radiofrequency treatment
41142569|NCT01180959|DRUG|Bevacizumab|10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes
41302632|NCT00406640|DRUG|Desvenlafaxine succinate sustained-release (DVS SR)|flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
41142570|NCT01180959|DRUG|Erlotinib|150 mg by mouth once a day.
40980300|NCT03959566|DRUG|Sutezolid|Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.
40980301|NCT03959566|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.
41142571|NCT04191863|OTHER|Clinical, EEG and laboratory assessment at presentation|"* The patients' history, clinical, demographic, and laboratory data were acquired.~* The following tests and imaging studies are routinely done for epilepsy patients receiving valproate treatment and developed nocturnal enuresis, blood urea nitrogen (BUN), serum creatinine (Cr), urinary pH (before and after valproate therapy beginning and at enuresis onset), serum levels and therapeutic doses of valproate.~* Urinary tract ultrasonography (with full and void bladder).~* CT brain and EEG."
41142572|NCT04191863|DRUG|Valproate|valproate monotherapy
41142573|NCT02837419|BEHAVIORAL|Health related Quality of life EQ-5D|Quality of Care
41142574|NCT03206398|DEVICE|anti-gravity treadmill|anti-gravity treadmill for a total of 40 days in addition to physiotherapy
41302633|NCT00406640|DRUG|Escitalopram|Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
41302634|NCT00668434|DRUG|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
40980302|NCT03959566|DRUG|Midazolam oral solution|Midazolam will be administered as per probe drug use in a single dose of 2 mg at day -1 and day 14 to assess the potential of sutezolid for CYP 459 3A4 enzyme induction, as measured by its influence on the ratio of AUCs of the CYP 3A4 probe drug
40980303|NCT06140303|BIOLOGICAL|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
40980304|NCT06140303|OTHER|Control|"Standard care is defined in this protocol to include the following:~* Debridement~* Collagen dressing~* Local offloading~* Foam~* Multi-layer compression dressing~* Off-loading device such as a controlled ankle motion (CAM) boot"
40980305|NCT01060930|DRUG|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
41461552|NCT01085890|BEHAVIORAL|Motivational interviewing|The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
41461553|NCT00939523|DRUG|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
40980306|NCT02266745|DRUG|PT-112 Injection|
41302635|NCT00668434|DRUG|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
40980307|NCT00524368|DRUG|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
40980308|NCT00524368|DRUG|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
40980309|NCT05192551|OTHER|Bowel-prep (Plenvu as experimental arm)|In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine
40980310|NCT00363922|BEHAVIORAL|Rehabilitation in institution|Rehabilitation in institution for four weeks. Subjects follow standard rehabilitation in the center.
40980311|NCT00363922|BEHAVIORAL|Rehabilitation at home|Subjects get a written prescription of exercise training, diet, etc. to follow at home.
40980312|NCT00363922|BEHAVIORAL|Out-patient rehabilitation at the hospital|This intervention was removed. We never got time to randomize subjects into this category. We had planned to randomize patients from one hospital to either Rehabilitation in institution (rehab center) or rehabilitation at the hospital (out patient). And also patients from another hospital to either rehabilitation in institution (rehab centre) or rehabilitation at home. We have only managed to start the study in this second hospital so far (due to maternity leave and limited time to finish a PhD)
40980313|NCT05975515|PROCEDURE|Connective tissue graft /Bone graft/ Customized HA|Soft tissue management and augmentation
40980314|NCT04058145|DRUG|AMD3100|AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
41302636|NCT01985009|DEVICE|FibroScan® examination.|The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
41302637|NCT05130333|OTHER|No intervention|No intervention
41461554|NCT04006119|BIOLOGICAL|Ad-RTS-hIL-12|"* intratumoral injection of Ad-RTS-hIL-12~* 2.0 x 10\^11 viral particles (vp) per injection"
41461555|NCT04006119|DRUG|Veledimex|20mg/day 15 oral daily doses of veledimex
40980315|NCT04058145|DRUG|Pembrolizumab|"Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor."
40980316|NCT00061880|DRUG|forodesine hydrochloride|
40980317|NCT03059498|PROCEDURE|Unilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Unilateral. Using Bupivacaine
41461556|NCT04006119|DRUG|Cemiplimab-Rwlc|Infusion every 3 weeks (350mg)
41461557|NCT05913817|BIOLOGICAL|AVT02 (Alvotech Biosimilar to Adalimumab)|Phase IV Study
40980318|NCT03059498|PROCEDURE|Bilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Bilateral. Using Bupivacaine.
40980319|NCT03059498|DRUG|Bupivacaine|Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
40980320|NCT01919125|DRUG|IDX719|IDX719 supplied as 50 mg tablets.
41142575|NCT05615285|OTHER|PERCS Triage and Referral System|Participants will undergo an assessment of physical function and psychosocial wellbeing. Researchers will apply a triage algorithm, based on findings of assessment. Participants will be referred to one of three exercise-based rehabilitation pathways which will best meet their rehabilitation needs. Participants will be re-assessed after 12 weeks. System will be evaluated using RE-AIM framework.
41142576|NCT02418065|OTHER|training on ergonomic bicycle|
40775664|NCT05386966|OTHER|questionnaire|Patient demographic data ( age, gender, residence , work ,Level of education) .Detailed history about the trauma (type, site , manner , mechanism of injury , actual cause of assault , post traumatic period till arrival to hospital ) .Clinical assessment ( Rapid neurological assessment , assesment of Scalp injury ,Presence of other body trauma ,Degree of severity of head injury according to GCS , Radiological finding. Treatment (Conservative or operative intervention ) .Follow up and outcome at the time of discharge by using the GOS .Expected time for healing (\<20 day or \>20 day ).Expectance for permanent infirmity
40775665|NCT03434730|RADIATION|Total Body Irradiation|Participants will receive a total dose of 400 cGy on day -2 and day -1 as 2 fractions (200 cGy x 2). Participants receiving total body irradiation (TBI) are treated in a standing position, and the treatment takes about 20 to 30 minutes.
40775666|NCT03434730|DRUG|Cyclosporine|Dilute in D5W or NS to make a 2.5 mg/ ml solution. Infuse slowly over approximately 1-4 hours (intermittent infusion) or 24 hours for continuous infusion.
40775667|NCT03434730|DRUG|Mycophenolate Mofetil|A 1000 mg dose should be placed in 140 ml of D5W. Administer only with D5W, over at least 2 hours.
40775668|NCT03434730|DRUG|Tocilizumab|For participants \< 30kg, dilute with 50mL 0.9% sodium chloride. For participants ≥ 30kg, dilute to 100ml with 0.9% sodium chloride. Administer infusion over 60 minutes with infusion set.
40775669|NCT03434730|DRUG|Filgrastim|The single use prefilled syringes contain either 300 mcg or 480 mcg Filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. For the prevention/treatment of chemotherapy induced neutropenia, the dose of filgrastim is standardized per body weight: ≤ 60 kg = 300 mcg daily subcutaneously; \> 60 kg = 480 mcg subcutaneously daily.
40775670|NCT02445209|OTHER|EOX|combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
40775671|NCT02445209|OTHER|mDCF|combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
40775672|NCT04902872|DRUG|CBX-12|CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
40775673|NCT03278561|PROCEDURE|Sputum induction|Sputum induction according to the ERS protocol
40775674|NCT03278561|PROCEDURE|Blood sample|A blood sample of 100ml will be taken.
40775675|NCT04838067|DEVICE|Cefaly|Transcutaneous trigeminal nerve electrical neuromodulation
40775676|NCT04947189|DRUG|Seviteronel-D (Seivteronel in combination with dexamethasone)|Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
40775677|NCT04947189|DRUG|Docetaxel|Use of docetaxel chemotherapy for solid tumours
40775678|NCT06129747|RADIATION|Radiation Therapy|"Weeks 1, 2 and 3~* Weeks 1, 2 and 3 will include 5 days of treatment.~* One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes."
40775679|NCT01195597|DEVICE|E-Cigarette 7.2 mg nicotine|"Participants were given a free e-Cigarette kit containing two rechargeable batteries, a charger, and two atomizers and instructed on how to charge, activate and use the e-Cigarette. Key troubleshooting were addressed and phone numbers were supplied for both technical and medical assistance. A full 4-weeks supply of 7.2 mg nicotine cartridges (Original cartridges; Arbi Group Srl, Milano, Italy) was also provided and participants were trained on how to load them onto the e-Cigarette's atomizer"
41142577|NCT02418065|DRUG|Testosterone|
41142578|NCT02418065|DRUG|Oral nutritional supplementation|
41142579|NCT02418065|DRUG|n3 polyunsaturated fatty acid|
40980321|NCT03731780|OTHER|Personalized Treatment|Targeting individual caries risk factors
40980322|NCT03731780|OTHER|Chlorhexidine and Remineralization|chlorhexidine mouth wash and remineralizing agent
40980323|NCT03731780|OTHER|Control|Control is standard preventive measures (tooth brushing, fluoride tooth paste, interdental cleaning)
40980324|NCT01577823|DEVICE|Foley Catheter|
40980325|NCT03316131|DRUG|Verinurad|Randomized patients will receive orally once daily fixed dose of verinurad in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
40980326|NCT03316131|DRUG|Febuxostat|Randomized patients will receive orally once daily fixed dose of febuxostat in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
41142580|NCT04532814|OTHER|Exercise|Cycling 60% VO2 max
41142581|NCT05731440|DRUG|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan.
41302638|NCT05387915|RADIATION|Radiation Therapy|Undergo reduced dose radiation therapy
41142582|NCT00831194|BEHAVIORAL|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
40775680|NCT05944510|DRUG|Dextromethorphan|Dextromethorphan 30mg will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
40980327|NCT03316131|DRUG|Dapagliflozin|Randomized patients will receive orally once daily fixed dose of dapagliflozin in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
40980328|NCT03316131|OTHER|Dapagliflozin matched placebo|Randomized patients will receive orally once daily fixed dose of dapagliflozin matched placebo in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
40980329|NCT00454610|BEHAVIORAL|FLOW|
40980330|NCT00454610|BEHAVIORAL|SelfHelp|
40980331|NCT01781403|DRUG|Temozolomide|Preoperative chemoradiotherapy with fixed dose of capecitabine and temozolomide, the dose of temozolomide will be escalated for finding MTD and RD.
41142583|NCT05989308|BEHAVIORAL|Email|Email message sent to guardian with proxy information.
41142584|NCT05989308|BEHAVIORAL|Text|Text message sent to guardian with proxy information.
40980332|NCT05584176|DEVICE|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
40980333|NCT05584176|DEVICE|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
40980334|NCT00002245|DRUG|Abacavir sulfate|
41302639|NCT05629416|BEHAVIORAL|Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples|"1. Implement 'Ask the Specialist Plus', a structured program to promote anti-racism within Northern Territory (NT) hospitals by giving healthcare providers training in cultural safety.~2. Implement strategies to foster 'Clinical champions of cultural safety' through a social media chat platform and face to face meetings to discuss anti-racism practice, cultural safety and practical ways to deliver culturally safe care including interpreter use.~3. Support simplified and improved strategies for booking an interpreter to increase uptake.~4. Implement retention strategies to ensure interpreters receive workplace support.~5. Provide training in health terminology for interpreters.~6. Integrate interpreter supply and demand through efficiency and effectiveness strategies tailored to participating sites.~7. Implement continuous quality improvement cycles with senior managers, using findings from qualitative and quantitative data collection and evaluation."
41302640|NCT02667990|OTHER|orthopaedic stilettoe|stilettos with orthopaedic in-sole buildt into the shoe
41302641|NCT02667990|OTHER|standard stiletto|standard stiletto without insole
41302642|NCT02667990|OTHER|comfy trainer|comfy trainer
41302643|NCT02159391|BEHAVIORAL|Brief Motivational Interview|The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
41302644|NCT00019513|DRUG|fluorouracil|
41302645|NCT00019513|DRUG|gemcitabine hydrochloride|
41302646|NCT00019513|DRUG|leucovorin calcium|
41461558|NCT00381849|DRUG|Cystone|"Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg."
41302647|NCT01166412|DRUG|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|6.5mg patch daily for 11 weeks
41302648|NCT01166412|DRUG|levonorgestrel patch with BMI <32 kg/m2|6.5mg patch daily for 11 weeks
41302649|NCT01166412|DRUG|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|12.5mg patch daily for 11 weeks
41302650|NCT01166412|DRUG|levonorgestrel patch with BMI <32 kg/m2|12.5mg patch daily for 11 weeks
41302651|NCT02187094|DRUG|TC-6499|
41302652|NCT02187094|DRUG|Placebo|
41302653|NCT05948657|DIAGNOSTIC_TEST|PSMA-PET CT|Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.
40980335|NCT00002245|DRUG|Amprenavir|
40980336|NCT00002245|DRUG|Lamivudine|
40980337|NCT02365792|PROCEDURE|Clinical Decision Support Tool for Prehospital Care|"A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care."
41142585|NCT05989308|BEHAVIORAL|Patient Portal Message|Patient portal message (MyChart) to guardian with proxy information.
41302654|NCT00907881|DRUG|Sulfonylurea|The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
40775681|NCT05944510|DRUG|Placebo|Matched placebo will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
41302655|NCT02464787|DIETARY_SUPPLEMENT|LifePak Nano|Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
41142586|NCT04050683|PROCEDURE|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). Subjects with abnormal heart pressures during TIPS will have a right heart catheterization (RHC) to monitor heart function, blood flow, and pressures in and around the heart. The subject will be admitted to the Cardiovascular Intensive Care Unit and have a TTE all of which are standard of care. Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; TTEs; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. Diagnostic RHC will be done as needed per standard of care.
41302656|NCT03839147|BEHAVIORAL|Education and counseling|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale were applied to both groups by face to face interview during the day giving appointment for HSG. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher was repeated briefly on the morning of the HSG procedure and any questions of the patients were answered.
40775682|NCT04079660|DIAGNOSTIC_TEST|Capillary blood glucose blood draw|Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
40775683|NCT04881058|DEVICE|RF Non-Invasive Treatment|Self-controlled single-arm group using the PicoSure device.
40775684|NCT01238887|DIETARY_SUPPLEMENT|Microcrystalline Cellulose placebo pill|Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
40775685|NCT01238887|DIETARY_SUPPLEMENT|Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
40775686|NCT01238887|DIETARY_SUPPLEMENT|Garcinia Cambogia derived Hydroxycitric Acid|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
40775687|NCT04212494|PROCEDURE|Thrombus aspiration|Percutaneous Coronary Intervention with manual aspiration thrombectomy
41142587|NCT04050683|PROCEDURE|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|"Subject's with normal heart pressures who are having elective (planned in advance and not due to an emergency) TIPS due to refractory ascites (fluid build up in the belly that does not go away or comes back shortly after being removed). Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). The subject will be admitted to the hospital after TIPS for standard of care monitoring.~Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes."
41142588|NCT02793752|OTHER|Age|Maternal Age
41142589|NCT06139835|BIOLOGICAL|Tartarase|Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus
41142590|NCT06116656|DIAGNOSTIC_TEST|blood leucocyte transcriptomics|the analysis of the RNA transcripts produced by the genotype at a given time that provides a link between the genome, the proteome, and the cellular phenotype.
41142591|NCT03210025|DRUG|BF-Methyldopa 250mg Tablet|BF-Methyldopa 250mg Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
41142592|NCT03210025|DRUG|Metopa Tab 250mg|Metopa Tab 250mg is manufactured by APT
41142593|NCT02556697|DEVICE|Bronchoscopy with in vivo confocal endomicroscopy|A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
41302657|NCT02486510|DRUG|Maraviroc|"Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours"
41461559|NCT00381849|DRUG|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
40775688|NCT04212494|PROCEDURE|PCI Alone|Percutaneous Coronary Intervention without manual aspiration thrombectomy
40980338|NCT05039645|BEHAVIORAL|Patient specific, clinician determined Intervention|Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of \>2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment).
41302658|NCT02361762|BEHAVIORAL|Computerized executive control training|"Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.~Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.~A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks."
41302659|NCT02028104|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
41302660|NCT02954003|DEVICE|Endo Bypass System|Subject is implanted with the device for up to 3 years.
41302661|NCT03437772|BEHAVIORAL|Mindfulness Cognitive Behavioral Therapy program|16 simultaneous-but-separate therapy sessions for parents and children.
41302662|NCT05729217|OTHER|SBQ-LC survey|Symptom burden questionnaires of Long COVID
41302663|NCT01041690|DRUG|Bevacizumab|
41302664|NCT02397993|PROCEDURE|blood collection|blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA
41302665|NCT02397993|PROCEDURE|fine needle aspiration|During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas
41302666|NCT02397993|PROCEDURE|blood collection|blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
41302667|NCT05328921|DRUG|Antihypertensive Agents|Patients with narrow angle glaucoma and on systemic antihypertensive drugs.
41302668|NCT05328921|DRUG|Antihistaminics|Patients with narrow angle glaucoma and on systemic antihistaminic drugs.
41302669|NCT02231658|DRUG|Liraglutide|
41302670|NCT02231658|DRUG|Lixisenatide|
41142594|NCT00537914|DRUG|Omnitrope|All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
41142595|NCT01381341|DRUG|linifanib|QD on Day 1 of Periods 1 and 2
41142596|NCT01792505|BIOLOGICAL|Dendritic Cell Vaccine in combination with Imiquimod cream|After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
41142597|NCT05150652|DRUG|Anastrozole 1mg|Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.
41142598|NCT05150652|DRUG|Letrozole 2.5mg|Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.
41302671|NCT04234815|BEHAVIORAL|CETA Short Session (CSS)|CETA Short Session (CSS) is a brief, low-intensity psychosocial intervention incorporating foundational components of the Common Elements Treatment Approach (CETA). CETA is an 8-12 session, transdiagnostic psychotherapy for common mental disorders. CSS was designed to serve as both a prevention/support approach for a broader range of needs, as well as an engagement/outreach strategy to identify and refer individuals to treatment. CSS is delivered in a group format over approximately two hours and consists of: 1) Psychoeducation: instruction about the brain and brain functioning, including normalization of psychological responses to stress and a brief self-assessment; 2) Safety: screening and referral for individuals identified as at risk of harm to self or others; and 3) Cognitive coping: based on the cognitive triangle, participants practice identifying an unhelpful thought changing it to a more helpful alternative, and examining how these thoughts impact feelings and behaviors.
41302672|NCT04234815|BEHAVIORAL|Psychoeducation and Safety|This intervention is the same as CSS with the exception that the cognitive coping skill training is removed.
41302673|NCT03901612|DRUG|Ropivacaine 0.2%|Continuous post operative regional analgesia
41142599|NCT05150652|DRUG|Exemestane 25 mg|Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.
41142600|NCT05150652|DRUG|Tamoxifen|Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.
41142601|NCT03701334|DRUG|Ribociclib|Ribociclib orally taken at 400 mg on days 1 to 21 of a 28-day cycle
41142602|NCT03701334|OTHER|Endocrine Therapy|ET will be administered according to the local clinical guidelines and current local prescribing information
41142603|NCT06195332|PROCEDURE|open TAR|Participants will undergo open TAR repair according to the assigned treatment arm.
41142604|NCT06195332|PROCEDURE|endoscopic TAR|Participants will undergo endoscopic TAR repair according to the assigned treatment arm.
41142605|NCT02652845|BEHAVIORAL|Wellness Engagement Program|This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
41142606|NCT02344706|DEVICE|Registration of EEG|EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
41302674|NCT03901612|DRUG|saline 09%|Continuous post operative regional analgesia
41302675|NCT06198049|OTHER|Pilates Training|This group will receive Pilates training General rehabilitation exercises. Balance and strengthening exercises. Stretching exercises will be performed.Each exercises will be performed with ten repetition for three sessions per week
41461560|NCT05331625|BEHAVIORAL|Offering Additional Resources to Promote Symptom Management|Participants will be offered additional resources to promote symptom management.
41461561|NCT01958060|DRUG|BI 1034020|intravenous part
41461562|NCT01958060|DRUG|Placebo to BI 1034020|intravenous part
40980339|NCT00651573|PROCEDURE|Blood transfusion at hematocrit value less than 24%|transfusion
41302676|NCT06198049|OTHER|Balance Proprioception Exercises|This group will receive balance Proprioception exercises. The training program will consist of 14 basic exercises on and off the balance board, with variations on each exercise. Mat walking time per session increased from 6 to 12 min during the acclimation period of the first two sessions and progressed gradually but incrementally to a maximum of 20 min per session over the 12 ensuing sessions.
41302677|NCT01801137|DRUG|Everolimus (Afinitor®)|
41302678|NCT00719576|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|Implantation via mini-arthrotomy
41302679|NCT00719576|PROCEDURE|Microfracture|Microfracture performed by arthroscopic surgery
41302680|NCT06377800|OTHER|navicular mobilization along conventional therapy.|"In the prone position, when the foot is stabilized by a towel underneath, navicular mobilization is administered. The therapist's fixing hand wraps the calcaneus, grasps the talus bone, and fixes it.~By placing the thumb on the plantar surface of the foot and pushing with the thumb of the other hand in a dorsal direction, navicular mobilization is provided.~This dorsal glide will be given with 2 sets of 5 minutes. Each session will be of 30 minutes."
40980340|NCT00651573|PROCEDURE|Blood transfusion at hematocrit value less than 28%|transfusion
40980341|NCT04720846|OTHER|Matrix-based physical therapy|Matrix-based physical therapy will be physical therapy that is based on the matrix categorization of the patient (stiff vs. mobile hips, weak vs. strong hips) and involves instructions on the amount of time that should be spent doing stretching and strengthening therapy.
40980342|NCT04720846|OTHER|Standard-of-care physical therapy|Physical therapy that is being conducted as standard-of-care
40980343|NCT03158051|BEHAVIORAL|Home Blood Pressure Monitoring|Intervention arm participants will receive a home blood pressure monitor, home blood pressure log, and training on accurate home monitoring. They will be asked to share their home blood pressure readings during health coach telephone calls.
40980344|NCT03158051|BEHAVIORAL|Telephone Health Coaching|Intervention arm participants will receive a health coach phone call every 2 weeks for 6 months, for a total of 12 calls. During each call, the health coach will review and discuss home blood pressures and address barriers and concerns to hypertension management. During each telephone call, the coach will guide the participant on selecting health behavior goals. Intervention arm participants will also receive handouts about hypertension management during the study visits and after health coach calls.
41302681|NCT06377800|OTHER|conventional therapy|ultrasound therapy at 1.5 w/cm2 for 7 minutes in continuous mode at a 3MHz frequency. Stretching targets the medial arch and surrounding muscles like calf and tibialis posterior with exercises such as arch lift, heel raise, towel pickup, and toe lift. Additionally, strengthening exercises for intrinsic foot muscles like standing toe curls and towel toe curls are included. Ice pack application for 10 minutes follows
40980345|NCT05083104|DIAGNOSTIC_TEST|laboratory investigations on coagulation profiles|CBC ,PT ,aPTT ,Protein C .Protein S ,ATIII and vWF
40980346|NCT04696445|DRUG|Morphine & Oxycodone|Morphine and Oxycodone are used in daily practice as part of standard care. Morphine and Oxycodone will be acquired through the clinical pharmacy of St Antonius and administered according to the standard postoperative pain protocol.
41302682|NCT03126539|DRUG|Sulforaphane|Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.
41302683|NCT03126539|RADIATION|Narrow-band Ultraviolet B exposure|The investigators will use a Lumera ultraviolet B (UVB) light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).
41461563|NCT01910831|DRUG|DerMend Moisturizing Bruise Formula|DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
40980347|NCT01702454|BIOLOGICAL|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
41142607|NCT00063089|DRUG|S. aureus Immune Globulin Intravenous (Human) 5%|
41142608|NCT06344481|DEVICE|Surgical (Hyalex Cartilage Knee Implant)|Implantation of Hyalex Cartilage Knee Implant.
41142609|NCT06013124|OTHER|Work environment, well-being, customer satisfaction|Evaluation hospital work environment, staff well-being features and patients/caregivers satisfaction and perceived quality of care
41142610|NCT06061588|DEVICE|Virtual Reality|The use of virtual reality as an adjunct to routine treatment.
41142611|NCT05173766|OTHER|ergonomic principls|Ergonomic principles for posture correction in office for computer users.
41142612|NCT00430911|DRUG|Radiotherapy|
41142613|NCT04245722|DRUG|FT596|Experimental Interventional Therapy
41142614|NCT04245722|DRUG|Cyclophosphamide|Lympho-conditioning agent
41142615|NCT04245722|DRUG|Fludarabine|Lympho-conditioning agent
41142616|NCT04245722|DRUG|Rituximab|Monoclonal Antibody
41142617|NCT04245722|DRUG|Obinutuzumab|Monoclonal Antibody
41142618|NCT04245722|DRUG|Bendamustine|Conditioning agent
41142619|NCT03073902|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy
41142620|NCT06034444|OTHER|interRAI LTCF|Standardized evaluations (interRAI LTCF) will be introduced to selected nursing homes in Quebec.
41142621|NCT00861315|DRUG|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
41142622|NCT00861315|DRUG|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
41461564|NCT01910831|DRUG|Non-active placebo control|Non-active placebo control
41142623|NCT00861315|DRUG|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
40775689|NCT01086527|DRUG|10 mg tablet of montelukast (Singulair)|Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
40775690|NCT01799902|DRUG|Solifenacin|Oral
40775691|NCT04540367|DEVICE|Blood flow restriction therapy|The study group underwent the same exercises as the control group modified by the use of a tourniquet for blood flow restriction during those exercises.
40775692|NCT06518967|DIAGNOSTIC_TEST|analytical performance study|analytical performance study on left-over samples with the SiMoT IVD system for in vitro diagnostic tests
40775693|NCT01363102|PROCEDURE|SOMS|Apply a number to mobilization goal for patient
41142624|NCT00861315|DRUG|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
41302684|NCT03126539|PROCEDURE|4 mm skin punch biopsy|All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
41302685|NCT05940844|DRUG|OB-002|The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
41302686|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 1)|Single dose Norketotifen
41461565|NCT01691586|DEVICE|Remote patient monitoring|Remote monitoring of ICD and heart failure data
40775694|NCT00103844|DRUG|Dasatinib|Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
40775695|NCT00103844|DRUG|Imatinib|Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
40775696|NCT03822026|OTHER|Hyperventilation test|Increase of the alveolar ventilation by a stepwise increase in tidal volumes and respiratory rate until a reduction of end-tidal CO2 of 0.7 kPa is achieved
40775697|NCT02985723|DEVICE|AT LISA tri toric 939MP|
40775698|NCT04943861|BEHAVIORAL|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
40775699|NCT04943861|OTHER|Usual Care|There is no peer navigation within usual care.
40775700|NCT06451133|OTHER|Mean arterial blood pressure (MAP) goal of ≥65 mmHg|The treatment team will maintain MAP ≥65 mmHg for the first five days following injury.
40775701|NCT06451133|OTHER|Mean arterial blood pressure (MAP) goal of 85-90 mmHg|The treatment team will maintain MAP 85-90 mmHg for the first five days following injury.
41142625|NCT02917148|OTHER|Peripheral Venipuncture or Blood draw from Central Line|
41142626|NCT03279094|BIOLOGICAL|Hematopoietic stem cell transplantation|Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
41302687|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 2)|Single dose Norketotifen
41302688|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 3)|Single dose Norketotifen
41302689|NCT03712163|DRUG|Norketotifen Oral Capsule (Multiple Dose Cohort)|Multiple dose Norketotifen
40775702|NCT06451133|OTHER|Spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg|The treatment team will maintain SCPP ≥65 mmHg for the first five days following injury.
41142627|NCT04552457|BEHAVIORAL|No activity restrictions|"Patients in the No activity restrictions group will be allowed to return to their normal activity immediately."
41142628|NCT04552457|BEHAVIORAL|Activity restrictions|"Patients in the Activity restrictions group will not be allowed to perform strenuous exercise or lift anything greater than 10lbs. Strenuous exercise will be defined as is any activity that requires so much exertion that one cannot have a conversation comfortably while doing it."
41302690|NCT03712163|DRUG|Placebo Oral Capsule|Placebo
41302691|NCT00940342|DRUG|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
41302692|NCT00940342|DRUG|Rituximab|375 mg/m\^2 administered intravenously once weekly for four weeks
41302693|NCT00314756|DRUG|imiquimod|
41461566|NCT01691586|OTHER|In-Clinic check-ups|Calender-based In-Clinic ICD check-up
41461567|NCT03038763|OTHER|Eligibility Screening|Investigators will call eligible mothers to screen for the possibility that eligible mothers may have passed HCV on to adult children. Investigators will consent these mothers to contact the adult child(ren), as the child(ren) must be informed of the mother's HCV status, if not already known.
41461568|NCT03038763|DIAGNOSTIC_TEST|HCV test|Adult children will be invited to Penn or a Penn affiliate to have labwork, testing HCV antibody and HCV quant. If the quant comes back positive, investigators will also test genotype and fibrosure.
41461569|NCT04232540|DEVICE|MedViewer report|Results from the analysis of hair samples performed using the MedViewer
41461570|NCT05348395|OTHER|Experimental diet|Participants that successfully complete the run-in phase will participate in the experimental diet for 8 weeks of feeding. The Participants' adherence will be monitored using direct observation, written daily food diaries, and food waste inventory (i.e., participants are trained to estimate portion of uneaten foods). Participants will be asked to eat one meal onsite 2-3 weekdays (e.g., Monday, Wednesday, and Friday), at which time they will receive meals and snacks for the remainder of that day and enough until the next scheduled visit.
41461571|NCT04731324|DRUG|ZYIL1 capsule|NLRP3 inflammasome inhibitor
40775703|NCT04363346|DRUG|FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
40775704|NCT03408353|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40980348|NCT00719251|DEVICE|High voltage pulsed current|The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).
41302694|NCT00932529|DRUG|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
41302695|NCT00932529|DRUG|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
41302696|NCT00932529|DRUG|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
41302697|NCT00932529|DRUG|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
41302698|NCT04349306|DRUG|RASBURICASE SR29142|Pharmaceutical form:solution for infusion Route of administration: intravenous
41302699|NCT03951857|OTHER|Resistance exercise with a gym stick|Exercise intervention: The resistance exercise intervention is performed with a gym stick for 3 times a week for 12 weeks. Exercise load is gradually increased by the number of times the band is wound and the speed of motion by dividing into three stages in 1-4 weeks (1st stage), 5-8 weeks (2nd stage) and 9-12 weeks (3rd stage).
40775705|NCT03408353|PROCEDURE|Mammography|Undergo standard of care mammography
40775706|NCT03408353|OTHER|Questionnaire Administration|Complete questionnaires
40980349|NCT00719251|DEVICE|Low level laser|Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).
40980350|NCT00719251|OTHER|Standard nursing care|It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
40980351|NCT06362811|PROCEDURE|Sacral Erector Spinae Plane Block|Ultrasound-guided bilateral injection of 1ml/kg 0.25% bupivacaine into the plane underneath the erector spinae muscles over sacral crests. The needle is inserted with in-plane technique from cranial to caudal direction over S3-4.
41302700|NCT06514469|DRUG|Sufentanil intravenous administration followed consultation of remote physician|Intravenous administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
41302701|NCT06514469|DRUG|Sufentanil intravenous administration based on paramedic competency|Intravenous administration of sufentanil to patients with acute injury by paramedics based on their competencies
41302702|NCT03126929|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised and Glasgow Coma Scale|Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)
40980352|NCT00513474|DRUG|busulfan|Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
40980353|NCT00513474|DRUG|cyclophosphamide|Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
40980354|NCT00513474|DRUG|cyclosporin-A|Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
40980355|NCT00513474|DRUG|etoposide|Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
41302703|NCT00077337|DRUG|romidepsin|
41302704|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
41302705|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
41302706|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
41302707|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
41302708|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
41302709|NCT02197039|DRUG|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
41461572|NCT06504264|BEHAVIORAL|phonemic segmentation|during phonemic segmentation activities, articulatory gestures will be used while teaching letters and their sounds.
40775707|NCT00924092|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces Cerevisia|
40775708|NCT00924092|DRUG|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
40775709|NCT00057161|BEHAVIORAL|Coordinated Representative Payeeship with Case Management|
40775710|NCT06204484|OTHER|CAPEOX adjuvant therapy|In MRD-/+ standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.
40775711|NCT06204484|OTHER|deferred CAPEOX adjuvant therapy|In MRD-negative deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.
40775712|NCT06204484|OTHER|mFOLFOXIRI intensive adjuvant therapy|In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month mFOLFOXIRI intensive therapy, instead of the CAPEOX standard adjuvant therapy.
40775713|NCT04982796|DRUG|Psilocybin|See description of psilocybin-enhanced psychotherapy arm.
40980356|NCT00513474|DRUG|methotrexate|Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
41461573|NCT05542849|DRUG|Acarbose Tablets 50mg|"Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals."
40775714|NCT04982796|BEHAVIORAL|Treatment-as-usual|See description of treatment-as-usual arm.
40775715|NCT03224845|BEHAVIORAL|Cognitive behavioural skills training|The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
40775716|NCT06505460|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
40775717|NCT06565364|DIAGNOSTIC_TEST|"ZYMUTEST™ HIA immunoglobulin g ELISA (enzyme-linked immunosorbent assay )"|The enzyme-linked immunosorbent assay is an in vitro test done in the laboratory to detect specific antibodies against heparin/platelet factor-4 and protamine/heparin complexes.
40775718|NCT05119530|DIAGNOSTIC_TEST|AcuVid COVID-19 Rapid Antigen Saliva Test|The AcuVid COVID-19 Rapid Antigen Saliva Test is a lateral flow immunoassay to detect SARS-CoV-2 nucleocapsid antigens in human saliva specimens
40775719|NCT02001519|DRUG|AC4-CDDP4|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks
40775720|NCT01891955|BEHAVIORAL|Healthy diet A|"Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called healthy diet with grains and dairy). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
40775721|NCT01891955|BEHAVIORAL|Healthy diet B|"Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called healthy diet without grains and dairy). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
40775722|NCT05313490|DIETARY_SUPPLEMENT|Beetroot Juice|7 days of 140 mL per day of beetroot juice
40775723|NCT05313490|OTHER|Placebo Beetroot Juice|7 days of 140 mL per day of placebo beetroot juice
40775724|NCT05176067|RADIATION|Thoracic Three-dimensional Radiotherapy|Drug Therapy Combined With Thoracic Three-dimensional Radiotherapy
40775725|NCT00114348|PROCEDURE|R-Blocks|
40775726|NCT00114348|PROCEDURE|Protocol II-Ida|
40980357|NCT00513474|DRUG|rasburicase|Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
40980358|NCT00513474|DRUG|sirolimus|Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
40980359|NCT00513474|DRUG|tacrolimus|Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
41461574|NCT00676650|DRUG|Prednisone|5 mg BID, oral
41461575|NCT00676650|DRUG|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
41461576|NCT00676650|DRUG|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
41461577|NCT00676650|DRUG|Prednisone|5 mg BID, oral
41461578|NCT00881231|DRUG|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
40980360|NCT00513474|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40980361|NCT00513474|PROCEDURE|peripheral blood stem cell transplantation|
40980362|NCT00513474|RADIATION|total-body irradiation|Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
40980363|NCT00513474|DRUG|fludarabine|Fludarabine 40 mg/m\^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
40980364|NCT00513474|DRUG|allopurinol|Allopurinol per institutional guidelines
40980365|NCT00449540|DEVICE|Active Transcranial Magnetic Stimulation (TMS) Device|Transcranial Magnetic Stimulation Device treatment
41461579|NCT00881231|DRUG|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
41461580|NCT01041209|BEHAVIORAL|Strategy based on BPS guided antibiotic use|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
40980366|NCT00449540|DEVICE|Sham TMS Device|Simulated Sham treatment without TMS delivery
40980367|NCT03063554|PROCEDURE|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement;
40980368|NCT03063554|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement
40980369|NCT03774511|OTHER|High-Intensity Interval Exercise & Moderate Intensity Interval Exercise|Different Interval intensities Exercise
40980370|NCT06043076|DEVICE|TMS|Active iTBS will be applied using a butterfly figure-of-eight C-B60 coil connected to MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
40980371|NCT06043076|DEVICE|Sham|Sham iTBS will be applied using acoustic stimulation of a second coil behind the participant's head
40980372|NCT00273442|DRUG|timolol maleate|
40980373|NCT00273442|DRUG|dorzolamide/timolol maleate fixed combination|
40980374|NCT01550380|DRUG|BKM120|NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
40980375|NCT03758144|DRUG|Rifaximin 200 MG|patients with type 2 diabetes and gut dysbiosis will be given rifaximin
40980376|NCT03414723|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
40980377|NCT03414723|DRUG|Ramipril|"Pharmaceutical form: tablets~Route of administration: oral"
40980378|NCT03233906|DIETARY_SUPPLEMENT|Chia Seeds- Salvia Hispanica|Chia seed added-10% of kcals and a no-chia control diet. 10% will be calculated using the following formula: Harris-Benedict equation multiplied by the activity factor of 1.2, 1.375, and 1.55 depending on each participant's activity level based on the information provided on the initial screening form.
40980379|NCT00814398|PROCEDURE|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
40980380|NCT00814398|PROCEDURE|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
40980381|NCT00002067|DRUG|Megestrol acetate|
40980382|NCT03954951|OTHER|Multimodality behavioral strategy|"* On-line course on hypertension management based on the new ACC/AHA and ESC/ESH guidelines on hypertension management.~* Weekly performance feedback reports: will include percent of patients with uncontrolled hypertension and among this group percent of visits where no change in medication was made. It will also include a comparative assessment of the performance of the physicians compared with their colleagues in the province."
40980383|NCT03017950|DRUG|CKD-330|
40980384|NCT03017950|DRUG|D086|
40980385|NCT03017950|DRUG|CKD-330 + D086|
40980386|NCT00000210|DRUG|Buprenorphine|
40980387|NCT01017614|DRUG|Monofer|"* administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained~* administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained"
40980388|NCT01017614|DRUG|Iron Sulphate|200 mg daily
40980389|NCT02902965|DRUG|Ibrutinib|Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
40980390|NCT02902965|DRUG|Bortezomib|Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
40980391|NCT02902965|DRUG|Dexamethasone|"Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly~Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects \>75 years of age.~Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter."
40980392|NCT00081380|DRUG|Seroquel®, quetiapine fumarate (atypical antipsychotic)|
40980393|NCT00081380|DRUG|lithium (mood stabilizer)|
40980394|NCT00081380|DRUG|divalproex (mood stabilizer)|
40980395|NCT05038592|DRUG|Decitabine|Given IV
40980396|NCT05038592|BIOLOGICAL|Tagraxofusp-erzs|Given IV
40980397|NCT05230810|DRUG|Alpelisib|Orally twice a day
40980398|NCT05230810|DRUG|Tucatinib|Orally once a day
40980399|NCT05230810|DRUG|Fulvestrant|"500 mg intramuscularly into the buttocks slowly~\*Fulvestrant will be administered only in patients with HR+/HER2+ metastatic breast cancer"
40980400|NCT04946539|DIAGNOSTIC_TEST|Ultrasonography|Enthesitis assessment via ultrasonography
41142629|NCT04748705|DRUG|IMC-1|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
41142630|NCT04748705|DRUG|Placebo BID Tablet|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
41142631|NCT00835328|DRUG|Exendin (9-39)|A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
41142632|NCT00835328|DRUG|Vehicle|A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
40980401|NCT02835807|BEHAVIORAL|Health Chat including Indoor Tanning|Participants in the intervention join a private Facebook group to participate in the Health Chat program. The group is not viewable to the public, including other Facebook users. The content of Health Chat is designed primarily for mothers, the participants in the group. Posts will occur twice daily for 12 months for a total of 720 posts. Each group will be hosted by a moderator who is responsible for managing the intervention goals and mothers' engagement. Mothers likely will not continuously engage with a social media campaign that is limited only to indoor tanning. To engage mothers in the Health Chat program, content addressing several major health and wellness topics relevant to adolescent girls and their mothers will be posted.
40775727|NCT06030518|DIAGNOSTIC_TEST|Magnet Assisted Capsule Endoscopy|Procedures will be performed in the morning after an overnight fast. Patients wear a belt containing sensors and a data recorder. The patient will be asked to drink 500-1000ml (containing 80mg simethicone; volume depending on tolerance) immediately before swallowing the capsule. Gastric examination will proceed as previously described for a robot-controlled magnetic assisted capsule endoscopy. The whole procedure is anticipated to take 30-60 minutes. The patient will be discharged from hospital on completion of gastric examination but if clinically indicated will wear the belt for small bowel capsule study for eight hours to allow small bowel examination before detaching the equipment and returning it the following day. On completion of examination, the patient will be asked to complete a questionnaire about their capsule endoscopy experience. The full study (upper GI tract and small bowel) will then be downloaded onto the computer for formal reading and reporting.
40775728|NCT03144401|DRUG|Misoprostol|mesotac
40775729|NCT03144401|OTHER|Placebo|Placebo tablet identical to the misoprostol tablet but without the active ingredient
40775730|NCT00400101|BIOLOGICAL|Virosome-formulated synthetic peptides (malaria vaccine)|
40980402|NCT02835807|BEHAVIORAL|Health Chat excluding Indoor Tanning|In the comparison condition, 25% of the posts will be about prescription drug abuse and misuse. Prescription drug abuse was selected as control content because it is a) completely unrelated to tanning, and b) an emerging issue of great interest and relevance to young adults in east Tennessee. This 25% segment of posts is the only difference between the intervention and comparison conditions.
40775731|NCT06080555|DRUG|Ferric Carboxymaltose Injection|For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.
41461581|NCT01041209|BEHAVIORAL|Enforced Guidelines|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
40775732|NCT06080555|DRUG|Ferric Carboxymaltose Injection [Ferinject]|For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
40775733|NCT00967499|DRUG|Ondansetron|"Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.~Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting."
40775734|NCT00967499|DRUG|Palonosetron|"Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.~Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery."
40775735|NCT06503185|BEHAVIORAL|Prehabilitation|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
40775736|NCT04433182|DRUG|Copanlisib|"Induction phase: 6 cycles of Copa-RB every 28 days according to the following schedule~* Copanlisib (Copa): 60 mg/day i.v. on days 1,8,15~* Rituximab (R): 375 mg/sqm i.v. day 1\*~* Bendamustine (B): 90 mg/sqm i.v. days 1-2\*~note: during cycle 1 rituximab can be administered on day 2: in this case bendamustine will be administered on days 2-3; in the case of a frail patient or a patient with high tumor burden copanlisib could be administered on day 1, rituximab on day 2 and bendamustine on days 3-4, at physician discretion.~Maintenance phase: patients who reach at least SD after induction will receive a maintenance with copanlisib in monotherapy according to the following schedule:~• Copanlisib: 60 mg/day i.v. on days 1 and 15 in 28-day cycles for 1 year"
40980403|NCT02326376|DRUG|anakinra (Kineret)|
40980404|NCT03060239|OTHER|Near Infrared Spectroscopy|Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
40980405|NCT05398601|OTHER|MOBILIZATION with MOVEMENT|"They would be receiving conventional treatment as follow:~TENS (Transcutaneous electrical nerve stimulation) applied asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold - 10 mins Hot Pack - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive MWM techniques for Knee~1. Medial glide~2. Medial+ Internal rotation glide~3. Lateral Glide+ Internal Rotation glide~4. Anterior glide~5. Posterior glide"
41461582|NCT02895841|OTHER|SMART app wearable|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
41461583|NCT03110016|DEVICE|Smartphone Application|The participants use SPSRS to watch the motion picture for at least 10 min a day for 5 weeks.
40775737|NCT02094391|DRUG|Ipilimumab|Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
40775738|NCT02724202|DRUG|Curcumin|Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
40775739|NCT02724202|DRUG|5-flurorouracil|Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
40775740|NCT05876156|BEHAVIORAL|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
40775741|NCT05876156|BEHAVIORAL|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
40775742|NCT04506684|DEVICE|Investigational RAMware downloaded onto Reveal LINQ device|The study is utilizing an investigational RAMware, either LINQ HF or ALLEVIATE-HF, that will be downloaded onto the subject's market-released Medtronic Reveal LINQ ICM. The investigational RAMware enables the hardware to record and store additional sensor data from which a respiratory rate will be derived.
40775743|NCT06067984|DEVICE|Study App|An investigational prescription digital therapeutic in the form of a smartphone app.
40775744|NCT04858373|OTHER|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
41461584|NCT02310503|PROCEDURE|Mohs surgery|A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
40775745|NCT04858373|OTHER|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Greek emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
40775746|NCT04858373|OTHER|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Italian emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
40775747|NCT04858373|OTHER|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from whole wheat commercial bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
40775748|NCT06180837|BEHAVIORAL|Sleep Extension Intervention|Sleep extension-based intervention focused on increasing time spent in bed by 2 hours per night by directly scheduling assigned bed and waketimes based on participant's individual schedules. Participants will receive weekly sleep tips and counseling on improving their sleep duration.
40775749|NCT06092437|OTHER|Urine sodium guided diuretic algorithm|Loop diuretics are administered intravenously as soon as possible after diagnosis of ADHF and continued 3dd until recompensation. Spot urine sodium is measured 2 hours after administration of the first in-hospital IV diuretic dose and repeated until the target of 100mmol/L is reached in the first 72 hours of admission (after which, UrNa will be measured once daily). When target is not met, the next dosage of loop diuretic is doubled (max 3dd 250mg furosemide) and thereafter, other diuretics (thiazide, MRA) are added. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
40775750|NCT06092437|OTHER|Usual care|Treatment with IV loop diuretics left to the discretion of the treating physician. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
40775751|NCT00004157|BIOLOGICAL|filgrastim|
40775752|NCT00004157|BIOLOGICAL|recombinant interleukin-11|
40775753|NCT02757430|PROCEDURE|Cardiac Ablation|
40775754|NCT05830929|PROCEDURE|Ovarian tissue freezing and subsequent auto-transplantation after thawing|Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
40775755|NCT01958749|PROCEDURE|Fat graft with Platelet Rich Plasma|
41461585|NCT03318289|BEHAVIORAL|Ving Tsun|The VT training regimen is designed to improve reactive balance control, lower extremity muscle strength and balance confidence in the elderly. It comprises 9 VT sticking-hand drills that must be practised with a partner. Participants will be trained to respond rapidly to upper body perturbations and to maintain body balance. Those joined the VT training group will attend a one-hour supervised VT training session at an elderly community centre 2 times per week for 12 weeks.
40775756|NCT02803684|OTHER|MRI examination with tensor diffusion protocol acquisition. No injection needed.|standard MRI examination
41142633|NCT04506047|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
41142634|NCT01371227|DRUG|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
41142635|NCT05830422|OTHER|nothing|Follow-up observation was conducted without any intervention in an outpatient setting.
41142636|NCT01017159|DRUG|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
41142637|NCT01780272|OTHER|glucose clamp|Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
41142638|NCT00417885|DRUG|exemestane|25 mg, oral, daily dosing
40775757|NCT04580550|OTHER|Axial length variability|Biometry (axial length measurement)is performed using the IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) and Heidelberg Anterion (Heidelberg Engineering, Germany) pre and postoperatively.
40775758|NCT02510456|DEVICE|Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort|Subjects will have up to 9 DOSI scans at 6 different time points during the course of their neoadjuvant chemotherapy. The time course of chemotherapy may vary between 3-9 months depending on the type chemotherapy subjects receive. Depending on chemotherapy schedule, subjects may or may not be asked to participate in all the 6 measurement time points. The number of DOSI scans each subject requires will be decided during consent. Each DOSI scan will take about 30-60 minutes, although scans at infusion time point will take longer in total due to repeated or continuous measurements.
41142639|NCT00417885|DRUG|sunitinib malate|37.5 mg, oral, continuous dosing, daily
41142640|NCT06022198|PROCEDURE|Bronchoalveolar Lavage|Bronchoalveolar Lavage
41142641|NCT02169609|DRUG|Dinutuximab. Immunotherapy|"Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy."
40775759|NCT02510456|DEVICE|Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort|Subjects will have 1 DOSI scan at baseline. The DOSI scan will take about 30-60 minutes.
40775760|NCT05849558|DRUG|Ursoplus|Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)
40775761|NCT05849558|DRUG|UDCA 250mg|UDCA 250mg alone
40775762|NCT05849558|OTHER|Placebo|Placebo alone
40775763|NCT01482715|DRUG|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
40775764|NCT01891929|BEHAVIORAL|RECOS (COgnitive REmediation for Schizophrenia)|"Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.~After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
40775765|NCT01891929|BEHAVIORAL|TAU (Treatment As Usual)|"The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
40775766|NCT02602652|BIOLOGICAL|a live attenuated chimeric JE vaccine|"The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.~At the second visit (D28), blood samples were collected for evaluate the immunogenicity."
40775767|NCT00485173|DEVICE|INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate|All patients enrolled in this study will receive the investigational device.
40980406|NCT05398601|OTHER|Periosteal electrical dry needling|"They would be receiving conventional treatment as follow:~TENS (asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold) - 10 mins HOT PACK - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive periosteal electrical dry needling 4 point technique for Knee~Four sterile, single-use 30-gauge dry needles would be inserted into the following locations of the symptomatic knee(s) until they touch bone:~1. Medial femoral condyle~2. Lateral femoral condyle~3. Flare of the tibia~4. Head of the fibula Needles would be stimulated with 100 Hz for 30 minutes. The intensity of the stimulus would be adjusted so that it would be clearly felt but would not cause discomfort. The stimulus intensity would be adjusted periodically so that it is perceptible for the entire 30 minutes of PST."
40980407|NCT02060604|DRUG|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
40980408|NCT02060604|DRUG|Ranibizumab|3 monthly ranibizumab, then as needed
40980409|NCT01574326|DRUG|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
40980410|NCT01574326|DRUG|Sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
40980411|NCT04216017|DRUG|kenalog|Cortisone injection into shoulder
40980412|NCT04216017|DRUG|Lidocaine|Lidocaine injection into shoulder
40980413|NCT03407105|BIOLOGICAL|MDX-010|Specified dose on specified days
40980414|NCT00437099|DRUG|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
40980415|NCT00437099|DRUG|Placebo|Placebo
40980416|NCT03804879|DRUG|Nidufexor|50 mg (two 25 mg) LMB763 capsules for oral administration
40775768|NCT00178009|BEHAVIORAL|self-paced instruction|Patients and caregivers review a DVD as often as they wish on how to care for routine and emergency procedures associated with their artificial heart
40980417|NCT03804879|OTHER|Placebo|Placebo capsules for oral administration
41142642|NCT03853889|PROCEDURE|USG guided ONSD measurement preepidural|Measurement of the diameter of the optic nerve sheath preepidural and postepidural anesthesia
40775769|NCT05267496|DEVICE|oscillating positive expiratory pressure device|Patients randomized to the experimental arm of the study will receive an AEROBIKA oscillating positive expiratory pressure device in addition to the standard pulmonary rehabilitation program. The patient will receive instructions pertaining to the use of the device during the first evaluation visit to the rehabilitation service and this information will be reinforced at each follow-up visit. The patient will receive a log book in order to record date and time of use to assess treatment compliance and an instructions and maintenance booklet will be handed out to ensure adequate use of the device.
40980418|NCT03804879|DRUG|Standard of Care (SoC)|Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
40980419|NCT05830201|BEHAVIORAL|No Dog Present|Dog is not present during pin removal
40980420|NCT05830201|BEHAVIORAL|Dog is Present|Dog is present during pin removal
40980421|NCT00268996|DRUG|SB-480848|SB-480848 is available as enteric-coated, free-base micronized tablet
40980422|NCT00268996|DRUG|SB-480848 matching placebo|Placebo is available as enteric-coated, free-base micronized tablet
40980423|NCT00192829|PROCEDURE|Blood sample withdrawal|
40980424|NCT00073554|DRUG|Alfimeprase|
40980425|NCT04290689|DRUG|Botulinum Toxin-A injection|Botulinum Toxin-A injection to be administered by the surgeon to the subject's calf muscle as per normal clinical protocol to help improve muscle tone.
40980426|NCT04290689|PROCEDURE|Serial casting stretching|Stretching cast intervention to be carried out in clinic as per normal clinical protocol.
40980427|NCT02158104|PROCEDURE|Deep dry needling|
40980428|NCT01659463|OTHER|ICON|LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS
40980429|NCT01659463|BEHAVIORAL|instruction oral hygiene|Instructions diet and hygiene oral and topical fluoride
40775770|NCT05267496|PROCEDURE|Pulmonary rehabilitation|"Educational ventilatory techniques will be explained in order to re-educate respiratory muscles and increase patient awareness regarding the importance of complying with the exercise schedule to improve muscular strength. Including:~Pre-surgical rehabilitation~* Directed ventilation~* Physical conditioning Post-surgical rehabilitation~* Diaphragmatic mobilization~* Thoracic expansion through incentive flow spirometry"
40775771|NCT02001168|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, d1, 21 d as a cycle.
40775772|NCT02001168|DRUG|Docetaxel|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
40775773|NCT02001168|DRUG|rh-Endostatin|rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
40775774|NCT02001168|DRUG|Cis-platinum|Cis-platinum 60mg/m2, d1, 21 d as a cycle.
40775775|NCT03091855|OTHER|Questionnaire|Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
40775776|NCT03091855|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
40775777|NCT00893802|OTHER|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
40775778|NCT01511133|PROCEDURE|Stool sample|Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.
40775779|NCT01511133|PROCEDURE|Serum sample|Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
40980430|NCT05340608|OTHER|Smart, non-invasive shirt - Physiological parameters|Observation Group One and Control Group - Participants in these groups will be asked to wear a smart, non-invasive shirt while watching two different five-minute videos. One video will show relaxing images and will emit relaxing music (relaxing video). The second video will present impressive human body deformities accompanied by anxious music (disturbing video). Both videos will be presented with the participant in a sitting position. The duration of the entire session will be approximately 15 minutes. For the whole duration of the session, the smart shirt will collect data on participants' physiological parameters (electrocardiogram, heart rate, heart rate variability, respiration rate, minute ventilation, and body movement). Collected data will be used to develop an ad-hoc algorithm to anticipate the challenging behavior of participants with autism spectrum disorder based on physiological data collected by the smart shirt.
40980431|NCT05340608|OTHER|Smart, non-invasive shirt - Relation with challenging behaviors|Observation Group Two - Each participant in this group will be asked to wear the smart, non-invasive shirt for seven consecutive days during waking hours, performing his usual daily activities. During the same seven days, the caregivers who care for the participant will be asked to accurately report the participant's status in a behavioral diary. Each evening, the data collected by the smart shirt will be uploaded to an online cloud along with the behavioral diary of the day. Collected data will be used to develop an ad-hoc algorithm able to anticipate the challenging behavior of participants with autism spectrum disorder based on physiological data collected by the smart shirt.
40980432|NCT05340608|OTHER|Smart, non-invasive shirt - Proof of Concept|Proof of Concept - The participant with autism spectrum disorder enrolled in the proof-of-concept phase of this study will wear the smart, non-invasive shirt for seven days during all hours of attendance at the special school. At the end of the seven days, the healthcare professional and teacher who interacted with the developed system at the special school will participate in a focus group to analyze their experiences and opinions related to the system use.
40775780|NCT03834740|DRUG|Ribociclib|Ribociclib administered orally in 5 daily doses prior to resection
40775781|NCT03834740|DRUG|Everolimus|Everolimus administered orally in 5 daily doses prior to resection
40980433|NCT02396901|OTHER|Goal Direct Therapy|Goal Direct Therapy - in this group patients will receive the standard treatment according with institutional protocol.
40980434|NCT05820555|BEHAVIORAL|Timed evening technology and digital media use (tablet use)|timing of children's evening tablet device use relative to bedtime
40980435|NCT05820555|BEHAVIORAL|no technology and digital media use (screen media use)|no screen media use relative to bedtime (Tablets, computers, TV, moble devices, smart phone)
40980436|NCT06357598|DRUG|Tislelizumab|Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, neoadjuvant therapy : 2-4 cycles; Adjuvant therapy: 16cycles at most.
40980437|NCT06357598|DRUG|Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.
40980438|NCT06357598|DRUG|Carboplatin or Cisplatin|"Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 of each 21-day cycle for 2-4 cycles.~Cisplatin: 75 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles."
40980439|NCT06357598|PROCEDURE|Surgery|Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
40775782|NCT03714516|BEHAVIORAL|Psychological internet intervention|The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
40775783|NCT03990987|OTHER|time of receiving operation|patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance
40775784|NCT00890500|DRUG|Fludarabine|30mg/m2/day IV x 6 days
40775785|NCT00890500|DRUG|Melphalan|100 mg/m2/day IV x 1 day
40775786|NCT00890500|DRUG|Antithymocyte Globulin|1mg/kg/day x 4 days
40775787|NCT00890500|DRUG|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
40775788|NCT00890500|DRUG|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
40775789|NCT02526914|DRUG|Intranasal Oxytocin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
41142643|NCT04122976|DRUG|Darolutamide(Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
40775790|NCT02526914|DRUG|Intranasal vasopressin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
40775791|NCT02526914|DRUG|Intranasal placebo|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
40775792|NCT02657148|DRUG|Nexplanon (etonogestrel contraceptive implant)|Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
41302710|NCT02197039|PROCEDURE|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
41302711|NCT05498961|OTHER|Gallstone characteristics|stone size, number, the thickness
40775793|NCT02657148|DRUG|Standard postpartum contraceptive care|Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at \> 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time \> 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time \> 6 weeks after delivery.
40775794|NCT01138722|RADIATION|hypofractionated radiation therapy followed by surgery|hypofractionated radiation therapy followed by surgery
40775795|NCT02185183|DRUG|Alequel|Alequel
40775796|NCT01008826|DIETARY_SUPPLEMENT|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
40775797|NCT02906111|DRUG|estriol|"Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse"
40775798|NCT02906111|PROCEDURE|vaginal surgery|Control Group
40775799|NCT05024084|PROCEDURE|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Sevoflurane|Sevoflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
40775800|NCT05024084|PROCEDURE|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Desflurane|Desflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
40775801|NCT00003249|DRUG|carboxyamidotriazole|
41302712|NCT01675804|OTHER|Computerized cognitive rehabilitation|- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
40775802|NCT00003249|DRUG|chemotherapy|
40775803|NCT00003249|DRUG|ketoconazole|
40775804|NCT02073474|DRUG|Sativex®|Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
40775805|NCT05029388|OTHER|Aerobic Exercise|The participants will complete three training sessions per week over 10 weeks. The aerobic training program will last for one hour. The session will include a 10-minute warm-up period, followed by a 45-minute aerobic workout, wherein the participants can choose to use either a treadmill, a cycle ergometer, or a rowing ergometer. After the workout, a five-minute period of stretching will be provided for cooling down. The intensity during the workout will be set at 40%-55% of the individual's maximum heart rate.
40775806|NCT05029388|OTHER|High Intensity Interval Training|The intervention will be conducted over a period of 10 weeks, while the participants will complete three training sessions per week. The HIIT training program will last for 30 minutes. The session will include a 10-minute warm-up period, followed by a 15-minute HIIT workout, and a 5-minute period of stretching to cool down. The exercises will include repeated, high-intensity intermittent bursts of vigorous activity at maximal effort. The HIIT will mainly include bodyweight exercises (e.g., push-ups, squats, lunges) that disregards equipment usage. The intensity during the workout will be set to 85%-95% of the individual's maximum heart rate. A half-day training workshop will be provided to the personal trainer to ensure that he/she knows the exercises and can demonstrate them to the participants.
40775807|NCT06571344|DRUG|Cholecalciferol|"The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm."
40775808|NCT04609982|DEVICE|ear plugs|giving half of the patients ear plugs
40775809|NCT04546789|DRUG|M2951 (BTK inhibitor)|Participants will receive a single oral dose of M2951 (BTK inhibitor).
41142644|NCT01698567|DRUG|Antithrombin III|"ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)"
41142645|NCT01698567|DRUG|Placebo|placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
41142646|NCT04702594|BEHAVIORAL|Music therapy session via tools validated by MUSIC CARE|Use of the MUSICARE tool, a digital space allowing access to different validated methods of music therapy. Music listening times are offered to patients with cognitive impairment with psycho-behavioral symptoms. The sessions are individual or group performed by a psychomotor therapist in UHR and volunteer caregivers trained in SRH. The sessions last on average 20-30min.
41142647|NCT03763162|DRUG|Bortezomib|Given SC
41142648|NCT03763162|BIOLOGICAL|Daratumumab|Given IV
40775810|NCT03057184|BEHAVIORAL|Intervention|The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
40775811|NCT04633239|DRUG|Abemaciclib|Given PO
40775812|NCT04633239|PROCEDURE|Biopsy|Undergo tumor biopsy
40775813|NCT04633239|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40775814|NCT04633239|DRUG|Olaparib|Given PO
40775815|NCT05387746|BEHAVIORAL|Caring Science, Mindful Practice and Reiki Training|Participants will complete a) 4 week internet-based course on Caring Science Mindful Practice and b) 12 hour Reiki training. The participants will also complete online post-training survey with the same questions included in pre-training survey.
40775816|NCT04648020|DRUG|Clonidine HCl Mucoadhesive Buccal Tablet|100 μg of clonidine per tablet
40775817|NCT04648020|DRUG|Placebo Mucoadhesive Buccal Tablet|Placebo
40775818|NCT05245903|DEVICE|Emerald Device Monitoring|The study participants will have the Emerald device deployed in their home for up to 12 weeks as they participate in the parent study (ClinicalTrials.gov identifier NCT04430517). The device will be deployed in the bedroom of each subject to capture behavior continuously. The Emerald device is a radio-wave sensor that will use signal processing and machine learning algorithms to track the gait, movement, respiration, and sleep of these subjects via low-powered radio signals. Reflections of the radio signals are processed using algorithms to convert them into movement data, sleep stages, and key sleep parameters. These data will supplement bioenergetic, imaging, and biochemical data with digital biomarkers and phenotyping using this device.
40775819|NCT02824679|DRUG|hyoscine butylbromide|20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor
40775820|NCT02824679|DRUG|saline|0.9%normal saline
40980440|NCT03913793|OTHER|Exercise based-cardiac rehabilitation (EB-CR) program|The exercise group underwent an outpatient EB-CR program (phase II) according to the American College of Sports Medicine guidelines for exercise prescription for cardiac patients.\[19\] Sessions were 3 days/week for 8 weeks. The program included: (1) Warm up (10 minutes): stretching exercises. (2) Aerobic exercise training using treadmill (30 - 60 minutes/session): with target heart rate (HR) at 45 - 75% of HR reserve. The maximal HR (HR max) was derived from that obtained during exercise stress test (EST). Patients who had ischemic/arrhythmic manifestations during EST, exercise intensity was prescribed at a HR below the ischemic threshold (10 beats below). (3) Cool down (10 minutes): light intensity treadmill walking. Supervision was provided according to the risk status of each patient that was determined according to the American Association of cardiovascular and Pulmonary Rehabilitation criteria for risk stratification.
40980441|NCT00079118|DRUG|docetaxel|
40980442|NCT00079118|DRUG|irinotecan hydrochloride|
40980443|NCT03518385|DIAGNOSTIC_TEST|ultrasound,transvaginal scan|The presence of fluid in the uterine cavity during hormonal stimulation.
41302713|NCT01675804|DRUG|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
41302714|NCT01675804|OTHER|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
40980444|NCT03218007|BIOLOGICAL|blood samples|to evaluate expression and functionnaly activity of A2AR
41142649|NCT03763162|DRUG|Dexamethasone|Given IV or PO
41142650|NCT03763162|DRUG|Ixazomib|Given PO
41142651|NCT03763162|OTHER|Quality-of-Life Assessment|Ancillary studies
40775821|NCT06405750|PROCEDURE|left atrial appendage closure|systematic closure of the left atrial appendage in addition to the planned heart surgery
40775822|NCT03402841|DRUG|Olaparib|300 mg twice daily - oral
40775823|NCT01323608|DRUG|Vitamin D3|Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
40775824|NCT01323608|DRUG|Placebo|Placebo
40775825|NCT05213741|DEVICE|Autonomous navigation of a magnetic colonoscope|The proposed magnetic-assisted colonoscope system consists of an megnetic field nevigator, magnetic-assisted colonoscope, and image receiving decoder. All participants will receive the magnetic-assisted colonoscopic examination by using this proposed magnetic-assisted colonoscope system
40775826|NCT03730519|DEVICE|Baroreflex Activation Therapy with Barostim Neo|Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
41142652|NCT02363153|OTHER|Diet and Exercise|"Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.~Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates."
41142653|NCT00505427|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|
41142654|NCT02173990|DRUG|Aflibercept-FOLFIRI|"Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~* Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin\* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~* 5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~  * \*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²"
41142655|NCT00108407|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|
41142656|NCT00108407|BEHAVIORAL|Twelve Step Facilitation Therapy|
41142657|NCT02618876|DRUG|Nalbuphine plus Bupivacaine|Addition of caudal Nalbuphine to the standard Bupivacaine
41142658|NCT02618876|DRUG|Bupivacaine|Caudal Bupivacaine is the standard of care will be considered as a control
41142659|NCT02518399|OTHER|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
41302715|NCT04017988|DIETARY_SUPPLEMENT|Ethanol Extracts of Porphyra Tenera(PTE10)|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week
40775827|NCT04519970|BEHAVIORAL|Case Management|Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.
40775828|NCT00242606|DRUG|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
40775829|NCT00242606|DRUG|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
40775830|NCT06563947|BIOLOGICAL|Oral enterobacterium capsules|Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
40775831|NCT00499447|PROCEDURE|radiofrequency ablation|
40775832|NCT00499447|RADIATION|radiation therapy|
40775833|NCT03279952|DRUG|CNS Stimulant|Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
41142660|NCT02518399|OTHER|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
41302716|NCT04017988|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
40775834|NCT02229357|BIOLOGICAL|OrniFlu® inactivated vaccine|All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
40775835|NCT03524599|OTHER|Intervention municipality|In intervention municipalities, primary health care centres and the providers working within them will receive training and a range of community support mechanisms.
40775836|NCT05459662|DIETARY_SUPPLEMENT|oat based porridge|Consume one preparation per day, orally
40775837|NCT05459662|DIETARY_SUPPLEMENT|plant based preparation|Consume one preparation per day, orally
40775838|NCT06563622|PROCEDURE|Pericapsular Nerves Group Block|USG-guided single-shot PENG in a dose of 0.5 ml/kg of 0.25% bupivacaine per side.
40775839|NCT06563622|PROCEDURE|Caudal Epidural Block|USG-guided single-shot CEB in a dose of 0.5 mL/kg of 0.25% bupivacaine.
40775840|NCT05520684|DIAGNOSTIC_TEST|urine culture and urinalysis|urine culture and urinalysis
40775841|NCT04825743|DRUG|zalunfiban|zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
40775842|NCT04825743|DRUG|Placebo|A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.
40775843|NCT03552016|DRUG|Oral Riboflavin|The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
40775844|NCT00659022|PROCEDURE|immediate surgery (resection of primary colorectal tumor)|no neo-adjuvant treatment, immediate surgery
40775845|NCT00659022|DRUG|neo-adjuvant treatment with bevacizumab|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
40775846|NCT00659022|DRUG|neoadjuvant treatment with capecitabine and oxaliplatin|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
41142661|NCT00919815|DRUG|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
41142662|NCT00919815|DRUG|Prednisolone|prednisolone 40mg daily then reducing regimen over 24 weeks
41142663|NCT05197088|DRUG|Tamsulosin|1 week of tamsulosin
41142664|NCT00587756|PROCEDURE|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
41302717|NCT05323968|DIAGNOSTIC_TEST|Abdominal Ultrasonography|The result of the Abdominal Ultrasonography will be compared with that of the Abdominal Computerized Tomography
40775847|NCT00659022|DRUG|neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
40775848|NCT01138410|BIOLOGICAL|SCIB1|Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
40775849|NCT01047995|DRUG|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
40775850|NCT01047995|DRUG|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
40775851|NCT04193735|DIAGNOSTIC_TEST|MRI scans after a liquid meal|Participants will be scanned fasted, then receive a liquid meal, then be scanned every half hour, seven times
41142665|NCT03324048|OTHER|relaxation session|"During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.~Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y)."
41142666|NCT04753450|OTHER|No intervention|No intervention
41142667|NCT00383812|DRUG|Intravitreal Bevacizumab|
41142668|NCT03379597|DRUG|Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)|Bifico 840mg Bid
41142669|NCT03379597|DIETARY_SUPPLEMENT|Dietary fiber|dietary fiber compound powder 30g bid
40775852|NCT05904483|OTHER|PFA|PFA
41142670|NCT05794295|OTHER|Acoustic Stimulation (AS)|Acoustic Stimulation will be administered while participants have their sleep monitored.
41142671|NCT05794295|OTHER|SHAM Stimulation|No stimulation will be administered while participants have their sleep monitored.
40775853|NCT01003223|OTHER|Computer algorithm management of hyperphosphatemia|The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
40980445|NCT05851781|DRUG|Lacosamide tablet|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
40980446|NCT05851781|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
40980447|NCT04682067|BEHAVIORAL|Contingency Management|Escalating financial incentives contingent upon biochemical evidence of abstinence
40980448|NCT04682067|BEHAVIORAL|Usual Care smoking cessation|Usual care smoking cessation support
40980449|NCT04803097|DIAGNOSTIC_TEST||We took slit-lamp-adapted anterior segmental photography from pediatric cataract eyes at baseline，1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
40980450|NCT00512707|DRUG|Sildenafil citrate (open label)|On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
40980451|NCT00512707|DRUG|Testosterone gel|Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
40980452|NCT00512707|OTHER|Placebo gel|3 tubes of placebo gel equivalent to the amount of the testosterone gel will be applied during the placebo-controlled testosterone gel intervention for 16 weeks..
41302718|NCT05323968|DIAGNOSTIC_TEST|Abdominal Computerized Tomography|The result of the Abdominal Computerized Tomography will be compared with that of the Abdominal Ultrasonography
41461586|NCT00002633|DRUG|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
40980453|NCT04517253|DRUG|Baricitinib|Administered orally
40980454|NCT00799487|DRUG|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
40980455|NCT00799487|DRUG|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
40980456|NCT01980914|DEVICE|iPro2 glucose sensor attachment|At the same time the glucose sensor is started, a trained research nurse will connect the patient to an Icentia CardioSTAT, a continuous ambulatory ECG cardiac monitor.
40980457|NCT01214954|OTHER|Supervised progressive resistance training|Resistance training 2 times/week initiated within the first week after total hip replacement. The training is supervised by physiotherapists and individually progressed.
41142672|NCT01553617|DRUG|6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)|Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
40980458|NCT01214954|OTHER|Control group|Standard rehabilitation consisting of home-based exercises with 2 postoperative instructions by a physiotherapist.
40980459|NCT04593563|DRUG|Psilocybin|Single 5 capsule oral psilocybin dose: 25mg: 5 x 5 mg capsules.
40980460|NCT00812370|DRUG|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
40980461|NCT01110707|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day \[mg/day\]).
40980462|NCT01110707|DRUG|Recombinant human luteinizing hormone (r-hLH)|Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
41142673|NCT01553617|DRUG|Human serum albumin|Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
41461587|NCT00002633|DRUG|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
41461588|NCT00002633|DRUG|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
40980463|NCT04486781|DRUG|Pembrolizumab + sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
40980464|NCT05611879|DRUG|Tislelizumab|Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles
40980465|NCT05611879|DRUG|Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
40980466|NCT05611879|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.
41461589|NCT00002633|DRUG|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
40980467|NCT06261320|DRUG|Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate|4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.
40980468|NCT00790660|DRUG|ASP1941|Oral
41461590|NCT00002633|DRUG|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
40980469|NCT00790660|DRUG|Placebo|Oral
40980470|NCT02300584|BEHAVIORAL|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)
40980471|NCT02300584|BEHAVIORAL|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.
40980472|NCT02300584|OTHER|iPad|a tablet computer with an internet connection
41461591|NCT00002633|DRUG|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
41461592|NCT00002633|PROCEDURE|orchiectomy|Optional orchiectomy
41461593|NCT00002633|RADIATION|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
41461594|NCT04389645|DIAGNOSTIC_TEST|IP-10 in CDS protocol|Dynamic IP-10 measurements in hospitalized COVID-19 positive patients
41461595|NCT03316222|DRUG|GNS561|Escalating doses to be administered 3 times a week.
41461596|NCT04618172|OTHER|Exercise|30 minute long exercises twice a week
40980473|NCT06149507|DRUG|Acetaminophen|Prescribe the drug to the child
40980474|NCT06149507|DRUG|Ibuprofen|Prescribe the drug to the child
40980475|NCT05725811|OTHER|Dynamic foam rolling|The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
40980476|NCT03199586|DRUG|NP-G2-044|capsule
40980477|NCT05368974|DRUG|Direct Acting Antivirals|Direct-acting antiviral exposure during documented pregnancy
41142674|NCT03855384|DRUG|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|TQB2450 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
40980478|NCT00671502|DRUG|Carisoprodol SR|700 mg twice daily
40980479|NCT00671502|DRUG|Carisoprodol SR|500 mg twice daily
40980480|NCT00671502|DRUG|Placebo|Placebo tablet
41461597|NCT05426954|OTHER|Rehabilitation utilizing blood flow restrictive therapy|BFR therapy
40980481|NCT02014896|OTHER|Biomarker blood draw|Comparison of gene expression profiles using RNA isolated from whole blood.
40980482|NCT03587012|OTHER|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
40980483|NCT03587012|OTHER|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD with simultaneous transcranial alternating current stimulation (tACS)
40980484|NCT05249361|OTHER|no intervention|no intervention
41142675|NCT03855384|DRUG|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|placebo 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
41142676|NCT02384122|DRUG|Octreotide|Two injections of 20 mg will be given monthly.
41142677|NCT01557439|DRUG|Levocetirizine Dihydrochloride 5 mg Tablets|A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
41142678|NCT03950609|DRUG|Everolimus|Given PO
41142679|NCT03950609|DRUG|Lenvatinib|Given PO
41142680|NCT06133595|BEHAVIORAL|Behavioral: MiBridge|A series of five conversations over three weeks to help participants understand more about themselves and their willingness to change, and to help participants connect with the care they need and want.
41142681|NCT01474759|BEHAVIORAL|Advice on diet, physical activity, and behavior change|Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.
41142682|NCT01474759|BEHAVIORAL|Instruction in food portion size|Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.
40775854|NCT06442982|DEVICE|insole-type gait analyzer|Patients with subjective gait and balance disorders will wear insole-type gait analyzer and walk, then the collected data will be examined.
41461598|NCT02780063|OTHER|Lenstar Biometer|uses optical principles (laser interferometry) to measure axial length, measuring distance from the corneal apex to the retinal RPE. In addition to axial length, it also measures corneal thickness, anterior chamber depth, lens thickness, radii of curvature of flat and steep meridian, axis of flat meridian, white to white distance, and pupil diameter.
41461599|NCT03316976|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsule.
41461600|NCT03567460|BEHAVIORAL|Exercise|Across studies in adolescents in general population, 60 minutes of recommended daily exercise level is achieved, on average, within a total volume of 10,000-11,700 steps. The investigators will assess baseline physical activity quantitatively by using an accelerometer worn on the wrist during waking hours over a 7-day period. Each participant will be given a Garmin device to place on their wrist that will track their steps. Then patients will be asked to complete 10,000 steps daily for 6 months (acclimation over a week), which will be encouraged by daily text messages or e-mail, and weekly phone calls by the intervention team in addition to a Garmin and Facebook peer group.
40775855|NCT05192278|OTHER|erector spinae block|The patients will do the procedure under fluoroscopic guidance. The patients were placed in prone position. After the identification of the T4 transverse process, the targeted injection site was anesthetized with 3-4 ml of 2% lidocaine. A 25-gauge spinal needle was advanced until it contacted the transverse process at the T4 level. Next, a solution of 1mL of methylprednisolone 40mg/mL with 7 mL of 0.25% bupivacaine and 2mL of nonionic contrast in 10 ml saline 0.9% (group A) and in 20 ml saline 0.9% (group B) will injected. Then another photo will be taken with the fluoroscopy to determine the level of spread in each group. After finished, the patients will transfer to the post-operative care unit and will monitored for any complication for one hour.
40775856|NCT00416741|BEHAVIORAL|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting \[plasma flucose
40775857|NCT03580954|DEVICE|Transcranial Magnetic Stimulation|Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.
40775858|NCT05615064|OTHER|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players
40775859|NCT01734902|DRUG|Hyoscine butylbromide|sugar coated tablets for oral administration
40775860|NCT01734902|DRUG|Hyoscine butylbromide|drops for oral administration
40775861|NCT00038935|DRUG|ReFacto AF|
40775862|NCT06570122|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
40775863|NCT06570122|OTHER|Health warning leaflet|The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.
40775864|NCT06570122|BEHAVIORAL|AI-powered chatbot support|Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
40775865|NCT01390623|DRUG|Ceftriaxone|"Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.~The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria."
40775866|NCT01090947|DEVICE|ProtoCAD|Aquiring acoustic signals from heart patients.
40775867|NCT04750083|DRUG|HX008|HX008 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to 35 cycles
40775868|NCT04750083|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on Day 1 of Q3W for up to 35 cycles
40775869|NCT04750083|DRUG|pemetrexed|pemetrexed 500 mg/m\^2 IV on Day 1 of Q3W for up to 35 cycles
40775870|NCT04750083|DRUG|cisplatin/carboplatin|cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of Q3W for 4 cycles
40775871|NCT04052165|PROCEDURE|Glaucoma Implant|
40775872|NCT03808935|DRUG|Medical Cannabis|The experimental intervention will begin with two weeks of titration (100 mg to 200 mg of CBD per day), followed by four weeks of treatment (maximum 300 mg of CBD per day) and four weeks of maintenance (maximum 300 mg of CBD per day). A two week washout phase will slowly decrease the daily dose (200 mg to 100 mg of CBD per day). All daily doses are equally divided into a morning and evening dose.
40775873|NCT03808935|DRUG|Placebo|The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.
40775874|NCT05765721|BEHAVIORAL|FRAIL-SM Program|Patients in experimental group will receive a 8 week family-based frailty self-management program; patients in control group maintain their usual life activities.
40775875|NCT03864848|DEVICE|Mitral Touch Implant|The study population for this study will be comprised of patients who are to undergo cardiac surgery with a sternotomy (e.g. CABG) and who present moderate to severe ischemic or functional MR. In order to be considered eligible for the study, each patient must meet the conditions listed in the inclusion and none of the exclusion criteria.
40775876|NCT00809822|DRUG|NPB-01|Intravenous immunoglobulin
40775877|NCT00809822|DRUG|Placebo|Physiological saline
41142683|NCT01474759|OTHER|Provision of pre-portioned foods|Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.
41142684|NCT01474759|BEHAVIORAL|Advice on healthy eating for weight loss|Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
41142685|NCT00552461|DRUG|rituximab|IV, 1000 mg, two weeks, 2 times
41142686|NCT00644501|DRUG|DiaPep277|1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
41461601|NCT00000449|DRUG|naltrexone (Revia)|
41461602|NCT00000449|BEHAVIORAL|cognitive behavioral therapy|
41461603|NCT00000449|BEHAVIORAL|cue exposure treatment|
41142687|NCT04780685|BIOLOGICAL|hMSC|IV administration
41302719|NCT04800419|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a third generation cognitive behavioral approach which uses acceptance and mindfulness processes, and commitment and behavior change processes to produce psychological flexibility. ACT increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective-taking exercises while supporting cancer survivors in aligning behavior with their personal values. The objectives of the therapy are for client to learn to focus on behaviors and actions that are in line with their individual values - the things they care about most. ACT facilitates development and maintenance of health behavioral improvements by targeting internal barriers, such as emotional discomfort and self-defeating thoughts, and by fostering connection and commitment to personal values associated with self-management of positive health behaviors. ACT is useful in cancer patients, because it can help them to deal with the negative emotions caused by cancer instead of avoiding these.
40775878|NCT05399173|DEVICE|infrared (gallium aluminum arsenide laser)|Patient Position will be in supine \& prone position, the area of these points is resolved utilizing anatomical landmarks and an arrangement of length measurements whose units are in respect to the physical extents of the individual patient. Acupuncture points used to treat nighttime enuresis are situated in regions that coincide with innervation by spinal sacral segments S2 through to S4 and expressed in the treatment conventions. The points of BL 23, BL 28, BL 32, RN 3, RN 4, RN 6, RN 12 impact the spinal micturition centers and parasympathetic innervation to the urinary tract, while excitement on scalp acupoints of DU 20 and DU 14 change cerebrum function through inner temporal, thalamencephalon and prefrontal cortical frameworks. Excitation of acupoints UB 20, UB 13, SP 6, ST 36, KI 3 and LU 9 are considered to strengthen spleen, vital energy and blood which encourage standardized bladder capacity
40775879|NCT05399173|DRUG|medical treatment(desmopressin acetate)|participants will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) \& advice
41302720|NCT04800419|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|The term 'mindfulness' refers to mindful awareness as a way of being - a knowing and experiencing of feelings, thoughts, and perceptions as they arise and pass away each moment. It is a way of relating to all experiences in an open, receptive way, without judging experiences as good or bad (grasping at them or pushing them away). Mindfulness employed two styles of meditations: concentrative meditation involves intentionally focusing attention on a chosen object (e.g. the sensations of breathing) in a sustained way, while receptive meditation involves monitoring the content of experience (e.g. sensations, emotions, thoughts, sounds, etc.) in a non-reactive and non-judgmental way, from moment to moment, with the goal being to recognize the nature of emotional and cognitive patterns. Mindfulness-based stress reduction (MBSR) is an 8-week, standardized group intervention consisting of mindfulness meditation and gentle yoga that is designed to have applications for stress, pain, and illness
40775880|NCT02511106|DRUG|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
40775881|NCT02511106|DRUG|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
41461604|NCT05252234|OTHER|Observation of hemodynamic status and post operative pain|No intervention
40775882|NCT02511106|DRUG|Open-label AZD9291 80 mg/40 mg|Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
41142688|NCT02481011|DRUG|antithrombotic drugs|
41142689|NCT03799588|DEVICE|Biphasic Chest Cuirass|Patients will have a esophageal manometer placed after intubation and before initiation of negative pressure ventilation.
41142690|NCT04543669|BIOLOGICAL|Adacel®|Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
41302721|NCT00279968|DEVICE|ICD|
41302722|NCT01120093|DRUG|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
41302723|NCT01120093|DRUG|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
41302724|NCT01120093|DRUG|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
41142691|NCT04815135|OTHER|Observational study|Observational study, the study did not involve any interventions
41142692|NCT06413459|OTHER|Luminex; scRNAsec|Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses
41142693|NCT01870336|DEVICE|Combined treatment of medial knee osteoarthritis|
41142694|NCT03153475|DEVICE|ATTUNE Revision Knee System in Revision Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
41302725|NCT01120093|DRUG|Placebo|Placebo via inhalation in the morning and evening for 7 days
41461605|NCT03869424|OTHER|Active Placebo labelled as antidepessant|Participants receive an active nasal spray that is in fact a placebo.
41142695|NCT04221165|DRUG|Opioids|Opioids will be prescribed as per institutional standards.
41461606|NCT03373630|DEVICE|Midline catheter|The catheter will be inserted according to usual practices, after the enrollment of the patient in the study. The follow-up will last until the removal of the catheter, which will also be done according to usual practices. Following the removal, bacteriologic analyses will be performed in order to diagnose any prospective infection.
41142696|NCT04221165|DRUG|PAiN - multimodal analgesia|PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium
41142697|NCT05602961|DRUG|GLB-COV2-043|COVID-19 vaccine, administered as a booster
41142698|NCT05602961|DRUG|BNT162b2/COMIRNATY®|active control
41142699|NCT00611598|OTHER|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
40980485|NCT03785431|DEVICE|PCI with Phantom Bioresorbable Scaffold|Once baseline angiography is performed and all eligibility criteria are met, the patient is included in the study. The target lesion should be crossed with a standard coronary guidewire. Next, the NIRS/IVUS and OCT probe is inserted and a pullback is being performed to evaluate the lesion and vessel morphology. The predilatation with 1:1 non-compliant or semi-compliant balloon is mandatory. Thereafter the scaffold should be inserted and position across the target lesion. Lesions up to 14 mm should be covered with the 18 mm device, for lesions of 15-20 mm a 24 mm device should be used. The scaffold will be deployed with intent to achieve the inner diameter to the reference vessel ration of 1:1 using a single inflation. Post-dilatation using a non-compliant balloon should be performed to achieve complete scaffold apposition and reduce the residual angiographic stenosis below 20%. The final NIRS/IVUS and OCT of the target vessel should be performed.
41302726|NCT01120093|DRUG|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
41461607|NCT04345016|DEVICE|Once-daily remote foot temperature monitoring|Participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) which they used for one year or until dying, dropping out of the study, or disenrolling at a member of the health plan administering the study.
41302727|NCT04875975|DRUG|Rozanolixizumab|"* Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive rozanolixizumab in a pre-specified sequence during the Treatment Period."
41461608|NCT04221048|OTHER|Retrospective observational|Pregnancy scores will be based on information obtained from the relevant clinical letter and clinical notes
41461609|NCT02088333|BEHAVIORAL|mCRC intervention|a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
40775883|NCT01217034|DRUG|TACE with sorafenib|Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
40775884|NCT01217034|PROCEDURE|TACE alone|TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
40980486|NCT01970111|DRUG|KPS-0373, High dose|
40980487|NCT01970111|DRUG|KPS-0373, Low dose|
40980488|NCT01413191|BIOLOGICAL|Cixutumumab|10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks
40980489|NCT01413191|OTHER|Laboratory biomarker analysis|Correlative studies
40980490|NCT04120831|DRUG|Abatacept Injection|Drug
40980491|NCT01720992|OTHER|A theory-based action planning toolkit|The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
40775885|NCT03403686|BIOLOGICAL|blood draw|Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
40980492|NCT01365234|DEVICE|Pacing Lead|Implant and follow up of Model 20066 lead
41142700|NCT00611598|OTHER|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
41142701|NCT00798837|RADIATION|Intraprostatic maximal simultaneous boost|"Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~* The prescription dose will be 73.7 Gy in 28 fractions~* A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
41461610|NCT02088333|BEHAVIORAL|Healthy Lifestyles video|a brief video about healthy lifestyle habits displayed on a tablet device
40775886|NCT02935764|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
40775887|NCT02935764|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
40775888|NCT02935764|DRUG|Leucovorin|400mg/m2 iv gtt,d1
40775889|NCT02151240|DRUG|Foscarnet Sodium|
40775890|NCT02151240|DRUG|Acyclovir|
40775891|NCT01343472|BEHAVIORAL|WISP supervision|WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
40775892|NCT01343472|BEHAVIORAL|Parole-as-usual|Parolees are supervised under standard parole supervision practice in Washington State.
40775893|NCT01204788|PROCEDURE|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
40775894|NCT01204788|PROCEDURE|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
40980493|NCT02982850|DRUG|Dabigatran|
40980494|NCT02982850|DRUG|Acetylsalicylic acid|
40980495|NCT02982850|DRUG|Warfarin|
41461611|NCT03860025|OTHER|No intervention.|No intervention.
40980496|NCT04508868|BEHAVIORAL|Brief Behavioral Activation with Mental Imagery|"Session 1:~Provide psychoeducation about depression; Provide treatment rationale for BA; Provide rationale and instructions for activity log; Plan activities for coming week.~Session 2:~Review activity log; Discuss life goals and values; Plan activities aligned with life goals and values for coming week; Provide rationale for Mental Imagery (MI); Go through MI-exercise for one of the planned activities.~Session 3:~Review activity log; Troubleshoot any problems carrying out activities; Plan activities aligned with life goals and values for coming week; Go through MI-exercise for one of the planned activities.~Session 4:~Review activity log; Troubleshoot any problems carrying out activities; Review treatment; Stress the importance of continuing to engage in activities aligned with life goals and values; Referral to additional services if necessary."
40980497|NCT04508868|BEHAVIORAL|Minimal Attention Control Intervention|Weekly call with follow-up of psychiatric symptoms and assessment of suicide risk.
40980498|NCT00372125|DRUG|Norditropin SimpleXx|0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
40980499|NCT03091634|DRUG|xue-fu-zhu-yu capsule|participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
40980500|NCT03091634|DRUG|xue-fu-zhu-yu capsule simulated agent|participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks
40980501|NCT03484884|DIAGNOSTIC_TEST|Cerenkov luminescence imaging.|Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
40980502|NCT00940251|DRUG|Mersina|capsule, 3g/day, 3 months
40980503|NCT03527095|DRUG|FDL169|CFTR corrector
40980504|NCT05517928|DRUG|Omeprazole|40 MG oral capsules daily
40980505|NCT05517928|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Given as Culturelle Digestive Probiotic in the form of oral capsules daily
40980506|NCT05517928|DRUG|Placebo|Oral capsules daily that look exactly like the study drug, but contains to active ingredient
40980507|NCT00229099|DRUG|GerEPO|
40980508|NCT02429895|DRUG|ABT-122|Injection
40980509|NCT05695690|DEVICE|Ultrasonography|Comparing between value of ultrasound vs MRI in uterine fibroids
40980510|NCT00759863|BEHAVIORAL|Lifezig|Personalized Reminiscence Video
40980511|NCT05120297|DRUG|AK101|Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.
41142702|NCT06451107|OTHER|specific strength training with static neck stretching|The intervention will consist of specific strength training composed of 5 exercises performed with dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. In addition to the following static stretches: stretching towards lateral flexion of the upper part of the trapezius muscle, the scalene muscles, and the sternocleidomastoid muscle on both sides; extension of the extensor muscles; flexion of the flexor muscles; and contralateral flexion and rotation combined with scapular depression of the scalene muscles and elevation of the scapula on both sides, holding each stretch for 10 seconds. This sequence of stretches will constitute one set, with 6 sets performed with a 30-second rest between sets, lasting 8 minutes. Therefore, the intervention will have a total duration of 28 minutes per session, conducting 3 sessions per week.
41142703|NCT06451107|OTHER|Specific Strength Training|The intervention will consist of specific strength training comprised of 5 exercises using dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. Four sets will be performed, with a 1-minute rest between sets. Each exercise will be executed for 30 seconds, followed by a 25-second rest between exercises. Three 20-minute sessions will be conducted per week.
41142704|NCT04048226|DRUG|Placebos|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
41142705|NCT04048226|DRUG|Dexmedetomidine +Ketamine|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
41142706|NCT01875016|PROCEDURE|CRyo-Ablation to Treat HOCM.|CRyo-Ablation to Treat Patients With HOCM.
41142707|NCT03576118|DRUG|Deep neuromuscular block|Deep neuromuscular block using high dose rocuronium and 8 mmHg pneumoperitoneum
41142708|NCT03576118|DRUG|Moderate neuromuscular block|Moderate neuromuscular block using moderate dose rocuronium and 12-15 mmHg pneumoperitoneum
41142709|NCT00016042|BIOLOGICAL|lymphokine-activated killer cells|
41142710|NCT00016042|BIOLOGICAL|recombinant interferon alfa|
41142711|NCT00016042|BIOLOGICAL|sargramostim|
40980512|NCT05120297|DRUG|Placebo|Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.
40980513|NCT05792371|PROCEDURE|induced membrane technique|Masquelet technique, also called an induced membrane technique (IMT), was first introduced to treat critical size bone defect up to 25 cm in 1986 by Pr. Alain Charles Masquelet et al. IMT is a two-stage surgical operation that recently provides a more popular option for the treatment of critical size bone defect as well as fracture nonunion. Basically, first stage of IMT comprises the implantation of a polymethylmethacrylate (PMMA) cement spacer loaded with antibiotics into defect site. During 6 to 8 weeks, this spacer induces the formation and maturation of a thin layer called induced membrane surrounding it via a foreign body immune response. In stage II, the spacer is carefully removed while keeping induced membrane at the fracture site, autologous bone graft is then performed to provoke bone healing.
40980514|NCT05792371|PROCEDURE|Bone graft (Stage II of IMT)|Bone graft is only performed in this group to provoke bone healing, as same as demonstrated in the stage II of IMT.
40980515|NCT01922089|DRUG|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
41142712|NCT00016042|DRUG|fluorouracil|
41142713|NCT05786911|OTHER|nutritional score|correlation between a food habit and nutritional status score of the parturient and a postpartum fatigue (FSS) and pain (ENA) score
41142714|NCT03953300|BIOLOGICAL|Benralizumab|Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
41461612|NCT03729557|PROCEDURE|Nephrectomy|Unilateral nephrectomy
40775895|NCT06216977|OTHER|Clear Liquids|Participants will not take anything by mouth after midnight the day before surgery but will be given 12 ounce clear liquid (Sugar-free Gatorade) at bedside at the pre-operative holding area
40775896|NCT06216977|OTHER|Standard of Care|Participants will not take anything my mouth after midnight day before surgery
41142715|NCT03953300|BIOLOGICAL|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
41142716|NCT05579717|BEHAVIORAL|Equine Assisted Learning|EAL is an intervention in which mental health clinicians and equine specialists work together with clients to address a learning goal via unmounted interaction with a horse. It is 16 sessions in length, at a rate of two sessions per week.
40775897|NCT04843631|DRUG|BFI-751|Single use vial, solution
40775898|NCT04843631|DRUG|EU-STELARA®|Pre-filled syringe, solution
40775899|NCT04843631|DRUG|US-STELARA®|Pre-filled syringe, solution
40775900|NCT03841409|OTHER|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
40775901|NCT00267930|DRUG|Vernakalant (oral)|
40775902|NCT00267930|DRUG|Placebo comparator|
41302728|NCT04875975|DRUG|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive placebo in a pre-specified sequence during the Treatment Period."
40775904|NCT01164826|DRUG|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
40775905|NCT01164826|DRUG|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
40775906|NCT00924274|DIETARY_SUPPLEMENT|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
40775907|NCT00924274|DIETARY_SUPPLEMENT|sunflower oil|sunflower oil
40775908|NCT01357681|DRUG|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
40775909|NCT01357681|DRUG|Placebo|Placebo
40775910|NCT00626236|DRUG|SPN-810|capsule taken three times a day
40775911|NCT00626236|DRUG|SPN-810|capsule taken TID
40775912|NCT00626236|DRUG|SPN-810|capsule taken TID
40775913|NCT00626236|DRUG|SPN-810|capsule taken TID
40775914|NCT01090596|DRUG|Naproxen|500mg naproxen, twice daily for 7 days
40775915|NCT01090596|DRUG|Placebo|1 tab,twice a day for a seven days
40980516|NCT05199298|OTHER|"Mandala Activity-Based Breastfeeding Program"|Training modules for breastfeeding and Maternal -infant attachment will be implemented with pregnant women in the study group at 32-36 weeks of gestation. The training will be explained by the researchers by shooting a video. In addition, for each week, mandala drawings will be videotaped by the researcher who received mindfulness-based art therapy training and will be sent to the Whatsapp accounts of the pregnant women. t 36 weeks of gestation, the Prenatal Attachment Scale and Spielberger State Anxiety Inventories will be sent to mothers as Google forms. The mother will be called 24 hours after the birth and the situation of having a problem with breastfeeding will be determined. In the first week, in the first and second months after the birth, questionnaire forms and online questionnaires will be applied to the mothers, apart from the follow-up and counseling in the postpartum 2nd month, the posttests of the scales
40775916|NCT04179422|OTHER|anthropometric measurement|weight, height, BMI
41302729|NCT05549063|OTHER|Mobility and Stability Exercise|Mobility and stability exercises
41302730|NCT05549063|OTHER|Stretching Exercise|Balance and reaching exercise
41302731|NCT01793051|DRUG|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
41302732|NCT01793051|OTHER|Placebo|200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
41302733|NCT01793051|BEHAVIORAL|Questionnaires|Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
41302734|NCT00912158|OTHER|standard therapy (ST)|standard medical therapy
41302735|NCT00912158|DEVICE|CPAP|Non-invasive mechanical ventilation (CPAP)
41302736|NCT00912158|DEVICE|BIPAP|Non-invasive mechanical ventilation (BIPAP)
41302737|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
41302738|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
40980517|NCT03499223|DRUG|Ranibizumab 0.5mg|3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart
40980518|NCT03499223|DRUG|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
40980519|NCT03499223|DRUG|Sham injection|3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
40980520|NCT03042533|DEVICE|Conventional Compression|Method of Nail fitting
40980521|NCT03042533|DEVICE|Standard Backslapping|Method of Nail fitting
40980522|NCT03042533|DEVICE|Dynamic Locking with Backslapping|Method of Nail fitting
40980523|NCT05872646|DIAGNOSTIC_TEST|clinical assessment|clinical staging
40980524|NCT02012998|BIOLOGICAL|HBVAXPRO 5µg|0.5mL intramuscular injection
40980525|NCT03852940|OTHER|Parenteral nutrition|
40775917|NCT04179422|OTHER|nutritional questionnaire|24hs food recall, presence of feeding disorders
40775918|NCT05042687|DRUG|Tc99m sestamibi|Given by IV
40980526|NCT03852940|OTHER|Enteral Nutrition|
40980527|NCT03349112|BEHAVIORAL|4% Lidocaine Spray|2% Viscous Lidocaine is applied to the nares as standard of care. In this intervention, 4% lidocaine spray is applied additionally.
40980528|NCT03349112|BEHAVIORAL|2% Viscous Lidocaine|2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
41142717|NCT04893759|DRUG|Pelcitoclax|Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle
41142718|NCT06432036|PROCEDURE|Angiogram|Undergo angiogram
41142719|NCT06432036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41142720|NCT06432036|PROCEDURE|Computed Tomography|Undergo CT scan
41142721|NCT06432036|RADIATION|Radioembolization|Undergo radioembolization
41142722|NCT06432036|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
41142723|NCT06432036|OTHER|Survey Administration|Ancillary study
41142724|NCT06432036|RADIATION|Yttrium Y 90 Glass Microspheres|Given intra-arterially
41142725|NCT02626494|DRUG|N-Acetylcystein|n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
41142726|NCT02626494|DRUG|Placebo|14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
41142727|NCT03845088|PROCEDURE|temporomandibular jont reconstruction with costochondral transplantation|temporomandibular jont reconstruction with costochondral transplantation guided by virtual mandibular position
41142728|NCT04209322|PROCEDURE|pulsed Radiofrequency|Non-surgical treatment of lumbar disc herniation causing sciatica using pulsed radiofrequency (10 minutes) directed to the interested dorsal root ganglia (percutaneous technique); after radiofrequency application, using the same needle, steroid was administered (as per the control arm). The procedure was guided by CT imaging
40980529|NCT02969304|DRUG|dimethyl fumarate|"Off-Label Use: All participants \<18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants \>18 years of age with an MS diagnosis who are prescribed dimethyl fumarate"
40980530|NCT02670954|DRUG|Dexmedetomidine, tramadol and flurbiprofen|
40980531|NCT02670954|DRUG|tramadol and flurbiprofen|
40980532|NCT00242489|DRUG|MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)|
41461613|NCT04520061|BEHAVIORAL|Health Insurance Navigation Program|The program will be delivered via videoconferencing by a navigator over a 2-month period and will consist of 4 sessions. The navigation intervention sessions will be as follows: Session 1- Learning About Survivorship Healthcare Needs; Session 2- Learning About Your Plan in Relation to Policy; Session 3- Navigating One's Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs.
41461614|NCT02653235|BIOLOGICAL|Salmonella typhi vaccination|
41461615|NCT02653235|BIOLOGICAL|Placebo|
41461616|NCT00942734|DRUG|Erlotinib|One tablet (150 mg) by mouth every day of each 28 day study cycle.
41461617|NCT00942734|DRUG|RAD001|1 tablet (5 mg) by mouth every day of each 28 day study cycle.
41461618|NCT06317402|OTHER|malnutrition questionary|At the patient's bed, using a questionnaire, evaluators take anthropometric measurements (weight, height, muscle strength) and collect biological data (albumin, pre-albumin, CRP, if available in the medical record) to establish nutritional status according to HAS criteria for undernutrition 2019-2021 and 2003-2007.
41461619|NCT01015287|DRUG|Placebo|Administered once orally
41461620|NCT01015287|DRUG|Prasugrel|Administered orally
41461621|NCT04422652|DRUG|Bupropion|Bupropion is an anti-depressant medication.
40980533|NCT00242489|DRUG|Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks|
40980534|NCT04570150|DRUG|Sugammadex|Subjects who are randomized to into the sugammadex arm (Arm I) will receive sugammadex for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm II (neostigmine group).
40980535|NCT04570150|DRUG|Neostigmine|Subjects who are randomized into the neostigmine arm (Arm II) will receive neostigmine for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm I (sugammadex group).
40980536|NCT01945177|DEVICE|narrow band imaging|narrow band imaging
40980537|NCT01945177|DEVICE|white light endoscopy|white light endoscopy
40980538|NCT01845350|OTHER|M2 macrophage introduction|"* Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~* Intrathecal introduction of autologous M2 macrophages"
41302739|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
41302740|NCT01769690|OTHER|DBS stimulator setting alteration|"2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.~Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy"
41302741|NCT01769690|OTHER|virtual reality simulator|"This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test."
41461622|NCT04422652|BEHAVIORAL|Behavioral activation therapy|Brief behavioral activation treatments administered via video tele-conferencing.
41461623|NCT04422652|DRUG|Placebo|Double-blind placebo.
41461624|NCT04422652|OTHER|Clinical Management|Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.
41461625|NCT04809844|OTHER|Concurrent chemoradiation|concurrent Paclitaxel and radiation therapy after Adjuvant doxorubicin and Cyclophosphamide chemotherapy for stage ll or lll breast cancer .
40980539|NCT02826707|BEHAVIORAL|SPPAC intervention|A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
40980540|NCT00931814|OTHER|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
40980541|NCT05974033|COMBINATION_PRODUCT|Stenting plus medical therapy|Patients randomized to intervention group received the percutaneous transluminal balloon angioplasty with stenting within 5 days after randomization, and loading dose of aspirin and clopidogrel was allowed. Received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after procedure.
40980542|NCT05974033|DRUG|Medical therapy alone|Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.
40980543|NCT03017651|DIETARY_SUPPLEMENT|OM3-supplement 1|1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
40980544|NCT03017651|DIETARY_SUPPLEMENT|OM3-supplement 2|1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
40980545|NCT00060112|BIOLOGICAL|oblimersen sodium|Given IV
40980546|NCT00060112|DRUG|gemcitabine hydrochloride|Given IV
40980547|NCT00060112|OTHER|pharmacological study|Correlative studies
40980548|NCT00060112|OTHER|laboratory biomarker analysis|Correlative studies
40980549|NCT00442975|BIOLOGICAL|Fluarix|
41302742|NCT05347069|DRUG|Aspirin|Aspirin 100 mg/day
41302743|NCT05347069|DRUG|No aspirin|No aspirin administered
41461626|NCT05167149|PROCEDURE|Carbon nanoparticles|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to National Comprehensive Cancer Network (NCCN) guidelines, 1ml diluted ICG solution (25 mg /10 ml) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (2ml totally) with 1ml syringe. ICG should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection under the multimodel observation of fluorescence laparoscopy. Search the fluorescent labeled lymphatics from bilateral parametrium to iliac vessels. The diffusion of ICG is rapid , and it is easy to spread to the next stations lymph nodes. The first fluorescent labeled lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all fluorescent lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
40980550|NCT05747092|PROCEDURE|gingival graft|"investigators:~Donor site:~* tissue graft harvesting from the palate behind the palatal rugae .~* placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~* Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~* Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope"
40980551|NCT02786251|OTHER|Cold exposure|During cold exposure intervention, we will use an individualized cold exposure protocol above the individual shivering threshold of each participant using liquid condition garments and a temperature controlled room.
40980552|NCT02786251|OTHER|Exposure to thermoneutral conditions|For the thermoneutral conditions intervention, subjects will be exposed to thermoneutral conditions (\~26-28°C).
41461627|NCT05167149|PROCEDURE|Indocyanine green|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to NCCN guidelines, 0.5ml(25mg) carbon nanoparticle solution (the dose was from our retrospective study) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (1ml totally) with 1ml syringe. Carbon nanoparticle should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection. Search the black lymphatics from bilateral parametrium to iliac vessels. Because there is no fluorescence penetration as ICG, the black lymphatic vessels should be dissected carefully.The first black lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all black lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
41461628|NCT00559637|DRUG|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
41461629|NCT00642057|DRUG|tetrabenazine|25 mg titrated to optimal dose per patient
41461630|NCT00531128|BEHAVIORAL|High/Low Sitosterol|
41461631|NCT01424098|BEHAVIORAL|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
41461632|NCT05456022|DRUG|Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one|"Appearance (Color) Conforms Yellow Appearance (Form) Powder~1H NMR Spectrum Conforms to Structure Loss on Drying \< 4 % _ Purity (HPLC) \> 95 %"
41461633|NCT05456022|DRUG|Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)|Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
41461634|NCT05456022|DRUG|Doxorubicin chemotherapeutic drug as a positive control|Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
41461635|NCT00915434|DRUG|JNJ-31001074|
41461636|NCT04468282|DRUG|VGB-ST|Single oral administration of 500 mg VGB-ST
41461637|NCT05112991|DRUG|Envafolimab+Lenvatinib|"Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle."
40980553|NCT00622960|OTHER|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
40980554|NCT00622960|OTHER|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
40980555|NCT03012906|OTHER|the prevalence of ischemic events|
40980556|NCT05527392|BEHAVIORAL|Health Insurance Navigation Tools Program|The program will be delivered via videoconferencing by a navigator over approximately a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Section 1- Insurance Plan Basics; Section 2- Your Plan in Relation to Policy; Section 3- Navigating Your Plan and Overcoming Obstacles; Section 4- Managing Care Costs; 5-Understanding Your Medical Bills.
40980557|NCT04766801|PROCEDURE|Laparoscopic adjustable gastric banding|Weight-loss surgery, with the use of gastric banding
40980558|NCT05104164|OTHER|Self-myofascial release|At home, the patients performed a daily session, lasting 15 minutes each, over 8 weeks. Patients accessed an ad hoc mobile application designed by the Hemophilia Physiotherapy research group (He-Foam®). This app, accessible from any smartphone, made it possible to watch the videos with all the exercises included in the intervention. The seven exercises under the specific protocol for patients with hemophilic arthropathy were: Self-release of the plantar region of the foot with a foam ball; Release of the posterior region of the leg with the foam roller; Release of the anterior leg region with a foam roller; Release of the hamstrings region with a foam roller; Release of adductor muscles with a foam ball; Release of abductor muscles with a foam roller; Release of pelvic trochanteric muscles with a foam roller
41142729|NCT04209322|PROCEDURE|Transforaminal Epidural Steroid Injection|Percutaneous injection of steroid in the nerve root foramen. The procedure was guided by CT imaging
41461638|NCT05112991|DRUG|Envafolimab|Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
41461639|NCT02241798|OTHER|oxygen|O2 by nasal prongs
41461640|NCT02976064|BEHAVIORAL|PreHabilitation|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the anesthesiologist.~2. Case evaluation: Candidates will be assessed to identify the overall needs and perform a baseline evaluation.~3. Personalized Work plan definition: Personalization of the plan involves a calendar and planning of face to face visits and remote contacts; intensity of the supervised exercise training program; threshold of steps per day; nutritional intervention; psychological intervention; and integration of the intervention into the overall work plan.~4. Work plan execution \& 5-Follow-up+event handling: Involve the follow-up tasks, including non-scheduled interactions through the personal health folder (PHF)~6-Discharge: Patient will be discharged from prehabilitation and moved to rehabilitation."
41461641|NCT02976064|BEHAVIORAL|Rehabilitation in chronic stable patients in primary care|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the general practitioner.~2. Case evaluation: The primary care team will characterize the candidates, covering: i) patient requirements defining the work plan; ii) aerobic capacity and physical activity; iii) identification of factors modulating adherence.~3. Personalized work plan definition: The community-based intervention will include reassessment of the patient's work plan aiming at optimization of both pharmacological and non-pharmacological therapies. Consist of a motivational interview and a physical activity (PA) intervention (6-month duration) based on supervised endurance training, promotion of PA and empowerment for self-management using the PHF.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The patient will be discharged or moved to the PA service addressed to citizens at risk \& patients with mild disease."
41461642|NCT02976064|BEHAVIORAL|Rehabilitation in mild chronic patients and citizens at risk|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the GP.~2. Case evaluation: i) patient requirements defining the work plan; ii) aerobic capacity and PA; iii) identification of factors modulating adherence.~3. Personalized work plan definition: i) motivational interview; ii) training for the use of the PHF for self-management; and iii) assign one case manager for off-line remote surveillance. The following optional modules are envisaged: i) basic service (above); ii) endurance training programs; iii) community physical activity group sessions; and/or, iv) upgraded PA program including sensors and close off-line supervision.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The basic version of the promotion of PA program is conceived for a timeless duration. However, the different modules included in the service portfolio will have specific agendas and associated costs."
41461643|NCT01402128|DIETARY_SUPPLEMENT|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
41461644|NCT01402128|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
41461645|NCT01559558|PROCEDURE|vaginal packing|vaginal packing after urodynamic studies, and repeat urethral pressure profile
41461646|NCT02361736|DRUG|Hydroxyethyl Starch|6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
41461647|NCT02361736|DRUG|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
41461648|NCT03645876|DRUG|SHR-1210|200mg
41461649|NCT03645876|DRUG|BP102|7.5mg/kg
41461650|NCT03645876|DRUG|oxaliplatin|130mg/m2
41461651|NCT03645876|DRUG|capecitabine|1000mg/m2
41461652|NCT02756949|OTHER|Smartphone application|Laboratory result data will be presented in the app with simple explanations on every screen. English and Zulu languages will be offered in the same app and written at a grade 4 reading level (as per WHO guidelines on literacy). Laboratory results will be supplemented with informative and relevant information explaining the result that has been shown and the recommended action for the patient to take. Patients will also be able to view additional HIV-related information and a Frequently Asked Questions (FAQ) through the app.
41461653|NCT02756949|DEVICE|Smartphone|
41461654|NCT05600023|DRUG|Nitrofurantoin|Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions
40775919|NCT05014984|BEHAVIORAL|mental contrasting with implementation intentions|"To deliver MCII, Dr. Oettingen developed a step-wise procedure called WOOP (Wish, Outcome, Obstacle, Plan; Figure 1).36 In a quiet setting, patients identify an important wish (e.g., losing weight) and then name and vividly imagine the best outcome (e.g., feeling healthier). Next, they name a current internal obstacle (e.g., urge to eat when feeling stressed) and try to vividly imagine their experience when they encounter this obstacle. Finally, they address their obstacle with an if-then plan specifying when, where, and how to overcome it (e.g., If I have the urge to eat when feeling stressed, I will go for a walk) and then imagine themselves experiencing the obstacle and carrying out the action of surmounting it. To facilitate use of the WOOP technique, Dr. Oettingen developed a free, publicly available WOOP app"
41142730|NCT06557330|DRUG|Bendamustine|Bendamustine will be administered as 10 minute IV infusion at 90 mg/m2 (drug dose calculation is based on treatment day weight) on days 1 and 2 for 4-6 cycles (number of cycles determined per treatment design). Subjects will be dosed every 28 days. Ondansetron 16 mg IV is given as premedication per institutional guidelines. Dose modifications will be determined based on renal and hepatic function. Subjects should be carefully monitored for infusion reactions during Bendamustine administration. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Bendamustine may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment based on physician discretion.
41461655|NCT05600023|DRUG|Double Antibiotic|DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
41142731|NCT06557330|DRUG|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 (longer for the first dose) (drug dose calculation is based of treatment day weight) on day 1 for 4-6 cycles (number of cycles determined per treatment design). Infusion rate will be determined as per institutional standards. Subjects will be dosed every 28 days. Diphenhydramine 50 mg IV and acetaminophen 650 mg are required to be given to the subjects within 30 minutes prior to Rituximab dose. There are no dose modifications recommended with Rituximab. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Rituximab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
41461656|NCT06533644|DRUG|SV-102|SV-102 will be administered as an intratumoral infusion.
41461657|NCT02625506|DRUG|Levobupivacaine|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
40775920|NCT05014984|BEHAVIORAL|telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!|MOVE! is a national VA weight management and health promotion program to improve the quality of life of Veterans.6,75 This effective program encourages healthy eating behavior and increased physical activity. MOVE! will be delivered via telephone (16 sessions) by existing staff consistent with national MOVE! program guidelines. The program has 16 modules and will offered weekly, but Veterans will be able to make up sessions at their own pace if they miss one. MOVE! staff use the MOVE! facilitator guide that provides instruction on delivering the program via telephone. Update as of 11-2023, the New York Harbor VA paused their offering of telephone-delivered MOVE!. Participants in both arms are offered the in-person or video-delivered MOVE! program. For participants who do not want or are unable to attend group-based MOVE!, they are offered TeleMOVE!.
40775921|NCT05014984|BEHAVIORAL|Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All|All participants will receive handouts that they review with a lay educator on weight management, adapted from the educational materials developed for our FIReWoRk Study.Topics include losing weight at a healthy rate, setting a 6-month weight loss goal of 5-10%, limiting sugar-sweetened beverages and portion sizes, making better choices when eating at restaurants, self-monitoring diet and weight, and participating in at least moderate-intensity physical activities.
41461658|NCT02625506|DRUG|Levobupivacaine and Tramadol|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
41461659|NCT05995990|DEVICE|Raman Spectrometry|Laboratory technique of Raman Spectrometry
41461660|NCT03394716|RADIATION|Radiotherapy|standard radiotherapy treatment with 1-3 extra MRIs
41461661|NCT00244829|DRUG|imatinib mesylate|
41461662|NCT00244829|PROCEDURE|adjuvant therapy|
41461663|NCT05260008|DRUG|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
41461664|NCT05260008|DRUG|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
41461665|NCT05260008|DRUG|bupivacaine hydrochloride without epinephrine|bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
41461666|NCT02141048|BEHAVIORAL|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
41461667|NCT04374422|BEHAVIORAL|fsfi survey|sexual behavior Questionaire
41461668|NCT00345033|DRUG|Aripiprazole|15-mg dose once a day for 8 weeks
41461669|NCT00345033|DRUG|Placebo|1 tablet placebo dose once a day for 8 weeks
41461670|NCT06092827|BEHAVIORAL|Non weight-bearing physical activity program|12-week duration, 2 supervised trainings/week, 1 unsupervised home-based training/week Aerobic, resistance and flexibility exercises
41461671|NCT05472415|OTHER|cognicise|"a combination of cognition and exercise training"
41142732|NCT00376324|DRUG|Tigecycline|Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
41142733|NCT04024709|PROCEDURE|Gastric Peroral Endoscopic Myotomy|Creation by submucosal dissection of a tunnel in the gastric wall at the level of the antrum, then of a pyloric and antral myotomy, before closing the mucosal access by clips.
41142734|NCT05060406|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total
41461672|NCT05472415|DEVICE|arch support insoles|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
41142735|NCT02565225|BEHAVIORAL|RheumaLive App use|
41142736|NCT03447912|BEHAVIORAL|Intervention Condition|The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in public indoor and and outdoor spaces.
41142737|NCT02966197|PROCEDURE|prophylactic internal iliac artery balloon catheterization|Between June 2015 and August 2016
41142738|NCT02966197|DEVICE|Prophylactic internal iliac artery balloon|
41461673|NCT03814850|DEVICE|Standard Manual Aneroid Sphygmomanometer|Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
41461674|NCT00568711|DRUG|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
41461675|NCT00568711|DRUG|rifampin|a 5-day course of daily 600-mg doses of rifampin
41461676|NCT03492476|DEVICE|Circaid|"Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~* Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system"
41461677|NCT03492476|DEVICE|Short-stretching Bandage (Reference treatment)|"Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~* DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night"
40775922|NCT05014984|BEHAVIORAL|Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)|The lay educator will review and practice the WOOP technique based on protocols from prior studies.12 To probe Veterans' comprehension, the lay educator will ask for their four steps and ask about their WOOP use and experiences. If needed, the lay educator will help the Veteran to create a new WOOP for the next month and address any questions and concerns about using WOOP.
40775923|NCT02940548|DRUG|Nifedipine GITS|Nifedipine GITS 30\~60mg/day for 8 weeks
40775924|NCT02940548|DRUG|Amlodipine besylate|Amlodipine besylate 5\~10mg/day for 8 weeks
40775925|NCT01015950|DIETARY_SUPPLEMENT|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
40775926|NCT01015950|DIETARY_SUPPLEMENT|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available."
40775927|NCT01015950|DIETARY_SUPPLEMENT|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
40775928|NCT01015950|DIETARY_SUPPLEMENT|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
40775929|NCT02946203|OTHER|Barium Sulfate|Barium Sulfate Oral Contrast-VoLumen
40775930|NCT02946203|OTHER|Flavored beverage Oral Contrast|Flavored beverage for neutral abdominal/pelvic imaging
40775931|NCT01221116|DRUG|levosimendan|levosimendan 0.1 microgram/kg/min) for 24 hours
40775932|NCT06024031|DRUG|N-acetyl-L-cysteine|N-acetyl-L-cysteine (Yiweishi) capsules (Guangdong Renrenkang Pharmaceutical Industry) will be given orally 400mg three times a day from day 1 to day 28 after chemotherapy. In case of drug allergy such as nausea, vomiting, rash and bronchospasm, and disease relapse, to discontinue the drug immediately.
40775933|NCT04586933|DIETARY_SUPPLEMENT|Omega-3|It will be investigated whether diet optimization and supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used.
40775934|NCT04586933|DIETARY_SUPPLEMENT|Placebo (soya)|Placebo (soya)
40775935|NCT04586933|BEHAVIORAL|Dietary guidance|Dietary guidance
40775936|NCT03493139|BEHAVIORAL|Physical Activity Across the Curriculum|Activity breaks will be designed for delivery in the classroom without reconfiguration of the classroom space. Activities will emphasize whole body movements, using large muscle groups. Each break includes multiple activities. Each activity lasts about 2 minutes. There will be a total of about 20 minutes of physical activity done each school day.
40775937|NCT05241366|DEVICE|Transcranial Magnetic Stimulation|"The TMS group will be comprised of 10 patients, each subject will receive 12 sessions of low frequency (1 Hz) rTMS over the right dorsolateral prefrontal cortex with a total of 1500 pulses in each session. Each session will last approximately 30 minutes. There will be one session per day, five sessions per week. The total duration of the treatment will be four weeks.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
40775938|NCT05241366|DEVICE|Sham Transcranial Magnetic Stimulation coil|"Simulated TMS stimulation will be performed with a Sham TMS coil, which has a sound and scalp contact similar to those experienced during active stimulation. The duration of the treatment will be the same as in the experimental arm.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
40775939|NCT02974192|OTHER|Neopterin|Neopterin will be measured by using standard laboratory methods on the first day of admission.
40775940|NCT05021939|OTHER|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
40775941|NCT05021939|OTHER|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
40980559|NCT02467010|DRUG|Bortezomib|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
41142739|NCT02966197|RADIATION|Radiology operation|
40980560|NCT02467010|DRUG|Cyclophosphamide|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
41461678|NCT03803267|OTHER|Erector spinae plane block|For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.
40775942|NCT03733548|BEHAVIORAL|RELAX|Regulating Emotions Like An eXpert (RELAX) consists of 8 weekly, 90-minute sessions delivered (60 minutes of parents and adolescents meeting separately, 30 minutes of a combined meeting) in a group format. RELAX equips adolescents with emotion regulation and conflict management skills. This program includes a parent involvement component designed to help parents support adolescents' use of these skills. Each week skills will be discussed and practiced in group, and a skills rehearsal homework activity will be assigned. Following the program, an 8-week follow-up review session will be offered. Additionally, a single 60 minute focus group will be held following the review session to solicit parent and adolescent feedback on the intervention.
40775943|NCT04614324|DEVICE|RhinAer ARC Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG815), which is a cleared (FDA - K192471) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. RhinAer has CE Marking in EU. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy was cleared for use in the US (FDA - K162810) and has CE Marking in the EU (CE639608).
40775944|NCT01001689|BEHAVIORAL|Nutritional counseling + exercise groups|Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
40775945|NCT05521932|OTHER|endometrium collected|endometrium tissue collected following adhesiolysis surgery
40775946|NCT02119273|DRUG|Prednisone|See arm description
40775947|NCT02119273|DRUG|Placebo|See arm description
40775948|NCT00855361|DRUG|Rabeprazole sodium|One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
40775949|NCT03490565|BEHAVIORAL|Exercise training|Structured, supervised, high-intensity combined aerobic and resistance exercise. Based on patients' individual capacity (Wattmax and 1RM), a personalized exercise program will be prescribed. Following a 5 minutes warm up, the patients will perform 21 min of aerobic interval training on a stationary bicycle consisting of three 4 minute high intensity intervals (85-95% HRmax) with 3 minutes of active pause between each interval. The resistance training comprises 4 functional exercises by performed using bodyweight, elastic resistance bands or kettlebells followed by resistance exercises in machines for the major muscle groups: chest press, leg press, seated rows, and leg extension with 1 warm-up set followed by 3-4 sets of 8 to 12 repetitions.
40775950|NCT03324841|DIAGNOSTIC_TEST|Caris MI Profiling|Customized comprehensive biomarker testing
40775951|NCT00681070|OTHER|Arm 2: Absorbable sutures|use of absorbable catgut sutures in pediatric facial lacerations
40775952|NCT00681070|OTHER|Arm 1: non-absorbable sutures|Use of non-absorbing sutures
40775953|NCT04603183|DRUG|Abemaciclib|Patients will receive abemaciclib 150 mg orally twice daily (BID) (300 mg daily, administered as six 50 mg tablets) during each 28 day cycle combined with either letrozole or fulvestrant.
40775954|NCT04603183|DRUG|Paclitaxel|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
40775955|NCT04603183|DRUG|Letrozole|Patients will receive 2.5 mg letrozole, orally administered and taken daily during each 28-day cycle combined with abemaciclib.
40775956|NCT04603183|DRUG|Fulvestrant|Patients will receive 500 mg fulvestrant, by intramuscular \[IM\] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter combined with abemaciclib.
40775957|NCT01480687|DIETARY_SUPPLEMENT|DHA-EPA|1800 mg/day
40775958|NCT01480687|DRUG|Ciprofibrate|100 mg/day
40775959|NCT02146157|DIETARY_SUPPLEMENT|herb and mineral combination product|herb and mineral product containing cinnamon, turmeric and holy basil
40775960|NCT02146157|DIETARY_SUPPLEMENT|Placebo|Placebo of herb and mineral product containing cinnamon, turmeric and holy basil
40775961|NCT00009178|DRUG|Fluoxetine|
40775962|NCT00009178|BEHAVIORAL|Guided Self-Help|
40775963|NCT01533623|DEVICE|Mandibular Advancement Device|Nightly wearing time
40775964|NCT02259803|DRUG|Telmisartan/amlodipine fixed-dose combination (FDC) tablet|
40775965|NCT02259803|DRUG|Telmisartan|
40775966|NCT02259803|DRUG|Amlodipine|
40775967|NCT00019825|DRUG|decitabine|
40775968|NCT05006495|PROCEDURE|C3 laminectomy|C3 laminectomy preserving semispinalis cervicis inserted into the axis.
40775969|NCT05006495|PROCEDURE|C3 laminoplasty|Conventional C3-6 laminoplasty, resulting in injury of semispinalis cervicis.
40775970|NCT02260037|DRUG|Epinastine nasal|
40775971|NCT02260037|DRUG|Placebo|
40775972|NCT00776230|BIOLOGICAL|IC51|6 mcg im. at day 0 and day 28
40775973|NCT03830437|OTHER|Evaluation of newborn stress|Newborn stress will be evaluated by salivary cortisol levels at 48 hr of life. Saliva sample of the newborns will be collected in oral cavity at 48 hr of life. Samples collected will be storage at -80 C for up to 4 months and analysed by analysis laboratory of Poliambulanza Foundation.
40775974|NCT03830437|OTHER|Evaluation of body weight trend|Body weight trend between newborns subjected to double weighing or to body weight control will be carried out at 36 hr and 48 hr of life
40775975|NCT03454035|DRUG|Ulixertinib|Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
40775976|NCT03454035|DRUG|Palbociclib|Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
40775977|NCT03690245|PROCEDURE|Initiation of Resuscitation While Attached to the Cord|Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.
40775978|NCT03148002|DRUG|Current Bowel Protocol (senna/lactulose)|Stimulant and Osmotic Laxatives.
40775979|NCT03148002|DRUG|PEG Bowel Protocol (PEG/lactulose)|Osmotic Laxatives.
40775980|NCT04039243|BEHAVIORAL|Being Brave|Up to 12 weekly sessions
40775981|NCT04039243|OTHER|Parent Education|Parents receive educational materials about helping children overcome shyness and fear
40775982|NCT00822094|DRUG|CPX-351|
40775983|NCT00822094|DRUG|Intensive Salvage Therapy|
40775984|NCT04138056|BIOLOGICAL|RSVPreF3 formulation 3|One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
40775985|NCT04138056|BIOLOGICAL|RSVPreF3 formulation 2|One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
40980561|NCT02467010|DRUG|Dexamethasone|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
40980562|NCT00642941|DRUG|RG1507|Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
40980563|NCT05595356|DEVICE|transcranial direct current stimulation|"Session description: An electric current of 2mA will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. The anode will be placed over the left dorsolateral prefrontal cortex and the cathode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
40980564|NCT05595356|DEVICE|sham transcranial direct current stimulation|"Session description: Three ramps of 30 seconds of current will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
40980565|NCT05595356|DEVICE|run-in sham transcranial direct current stimulation|In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.
40980566|NCT05595356|BEHAVIORAL|Psychoeducation video|Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.
41142740|NCT06307574|BEHAVIORAL|bpMedManage|In this 16-week RCT, a total of 100 older adults with MCI will be recruited. There are two treatment arms, bpMedManage-S and bpMedManage-P with 50 participants in each arm. Participants randomized into the bpMEDManage-S intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. Participants in the bpMedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on the education portal. Both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. At the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. Immediate outcomes will be assessed 4 weeks after beginning of the intervention. Follow-up outcomes will be assessed 12 weeks after the beginning of the intervention.
41142741|NCT06463301|OTHER|Treadmill Training In CP child|"Treadmill training for children should be carefully tailored to their developmental level, physical ability, and specific therapeutic goals. Initial Sessions start with shorter sessions, around 5-10 minutes, especially for children with disabilities.~Progression will be made when the child becomes more accustomed to the treadmill. Aim for a total of 20-30 minutes per session, including breaks if necessary then then Start at a slow walking pace, approximately 0.5 to 1.0 miles per hour (mph) or 0.8 to 1.6 kilometers per hour (kph). Adjust the speed based on the child's comfort and ability to maintain a safe and effective walking pattern.~Older Children (8-12 years Begin with a walking pace of 1.0 to 1.5 mph (1.6 to 2.4 kph). Gradually increase the speed to a brisk walk or light jog, up to 2.0 to 3.0 mph (3.2 to 4.8 kph), depending on the child's progress and comfort level along with conventional physical therapy."
41142742|NCT06463301|OTHER|Conventional Physical Therapy|conventional physical therapy session would typically include gentle stretching, joint mobilization, range of motion exercises for both the upper and lower body, gait training, and standing frame activities. Each component is designed to improve various aspects of physical function, ensuring a comprehensive approach to rehabilitation
41142743|NCT04351243|DRUG|Gimsilumab|Gimsilumab is a fully human monoclonal antibody (mAb).
41142744|NCT04351243|DRUG|Placebo|Normal saline
41142745|NCT04021277|DRUG|20 uL/kg PS101|20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
41142746|NCT04021277|DRUG|40 uL/kg PS101|40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
41142747|NCT04021277|DEVICE|Ultrasound|Ultrasound activation and enhancement
41142748|NCT06586164|BEHAVIORAL|Targeted Cognitive Training|TCT is a computer-based cognitive training program in which participants train on progressively more difficult auditory processing exercises in order to improve speed, accuracy and fidelity of auditory information processing in order to generate gains in cognition and functioning.
41142749|NCT06022003|DRUG|AzaCITIDine Oral Tablet|AML study treatment
41142750|NCT06022003|DRUG|Xospata|R/R FLT3-mutated AML standard treatment
41142751|NCT01362309|DRUG|d-cycloserine.|50 mg administered on two occasions.
40775986|NCT04138056|BIOLOGICAL|Boostrix-ex-US|One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
41302744|NCT02742870|OTHER|Correlation of MRI results with clinical characteristics of the adnexal mass|"Quantitative analysis of the magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens), based on the ADC cartography.The post-processing will be realized with the Syngo Onco Care application of Siemens, that allows an histogram analysis of the ADC of all sections of the adnexal mass, as opposed to a section per section approach with the Region of Interest (ROI) method.~The results will be correlated with the clinical data regarding the adnexal mass: anatomo-pathology status (malignancy and aggressiveness of the tumor) and the gynecological follow-up."
41302745|NCT05113368|DRUG|Regorafenib|Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) \[3 weeks on/1 week off\] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
41302746|NCT05113368|DRUG|Fulvestrant|500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
41302747|NCT01887249|DRUG|Clarithromycin|
41302748|NCT01887249|DRUG|metronidazole|
41302749|NCT01887249|DRUG|esomeprazole|
41302750|NCT05764356|GENETIC|Detection of genotype and RNA profile in platelet and white blood cell|Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing
41302751|NCT05764356|OTHER|Indicators test related to coagulation function|Indicators test including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT), diluted TT (dTT), snake vein enzyme coagulation time (ECT), anti-XA or IIa activity, etc.
41302752|NCT05764356|OTHER|Indicators test related to platelet function|Indicators test related to platelet function. Platelet reactivity was measured by VASP. Platelet aggregation rate was measured by turbidimetric method. Platelet and fibrinolytic function were measured by thrombologram, etc.
41302753|NCT00256867|DRUG|GSK523338|
41302754|NCT05663359|PROCEDURE|EVLA 1940 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1940 nm
41302755|NCT05663359|PROCEDURE|EVLA 1470 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1470 nm
41302756|NCT00269074|DRUG|IDEA-070|
41302757|NCT05679687|DRUG|Treatment|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.
41302758|NCT05221645|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD 1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications because of its mechanism of action to bind the PD-1 receptor on the T cell.
41302759|NCT05221645|DRUG|Rituximab|Rituximab is a chimeric mouse/human monoclonal antibody that binds to CD20, on pre-B and mature B lymphocytes and eliminates these cells potentially via a number of different mechanisms. Anti-CD20 mAbs, like rituximab, are classified by their CD20-binding characteristics, ability to induce complement-dependent cytotoxicity (CDC), and immune effector cell effects.
41302760|NCT05221645|DRUG|Ifosfamide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
41302761|NCT05221645|DRUG|Carboplatin|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
41302762|NCT05221645|DRUG|Etoposide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
41302763|NCT04523441|OTHER|Focus group|Holding of a focus group by a sociologist
41302764|NCT04523441|OTHER|Semi-directive interview|Conducting a semi-directive interview by a sociologist after discharge from hospital
41302765|NCT03546387|OTHER|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|the WISC-V assessment produces a Full Scale IQ (FSIQ) used for primary power consideration in this study. The FSIQ is the most comprehensive global ability score on the WISC-V, and it has been conventionally reported and interpreted as an estimation of overall intellectual ability
40775987|NCT04138056|BIOLOGICAL|Boostrix-US|One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
40775988|NCT04138056|DRUG|Placebo|One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
41302766|NCT03546387|OTHER|California Verbal Learning Test, Children's Version|Used to assess verbal learning and memory in children and adolescents
41302767|NCT03546387|OTHER|Beery Developmental Test of Visual Motor Integration, 6th edition|Helps assess visual-motor skills in children and adults.
41302768|NCT03546387|OTHER|Grooved Pegboard Test|Measures dexterity
41302769|NCT03546387|OTHER|Behavior Assessment System for Children/Parent Report|The Behavior Assessment System for Children/Parent Report is a questionnaire that assesses the social-emotional and behavioral functioning (e.g., anxiety, depression, attention, hyperactivity, adaptability, leadership, social skills, etc.) in children between the ages of 2 and 22 years, and is available in English and Spanish.
40775989|NCT01527565|DRUG|biphasic insulin aspart 70|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
40980567|NCT05595356|BEHAVIORAL|Tutorial video|Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.
40980568|NCT05036434|DRUG|Pembrolizumab / Lenvatinib|Pembrolizumab Plus Lenvatinib administration.
41461679|NCT03803267|OTHER|Quadratus lumborum block|For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect
41461680|NCT03803267|DRUG|Propofol|Propofol (2 mg/kg)
41461681|NCT03803267|DRUG|Fentanyl NCS|Fentanyl (1µg/Kg)
41461682|NCT03803267|DRUG|Atracurium Injectable Product|atracurium (0.5mg/kg)
40980569|NCT01506427|RADIATION|[F-18] HX4|A single dose of 10 mCi, injected intravenously.
41461683|NCT03803267|OTHER|Endotracheal intubation|endotracheal intubation
41461684|NCT03803267|DRUG|Anesthesia Maintenance|Inhalational isoflurane in oxygen/air mixture
40980570|NCT05528679|DRUG|610 100mg|100mg administered subcutaneously Q4W
40980571|NCT05528679|DRUG|610 300mg|300mg administered subcutaneously Q4W
40980572|NCT05528679|DRUG|placebo|administered subcutaneously Q4W
40980573|NCT03643640|BEHAVIORAL|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
41461685|NCT03803267|DRUG|Muscle Relaxation|atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia
41461686|NCT04857593|BEHAVIORAL|Melodies for Mums|"Classes start with a chat between mothers and the artist. The singing session will include welcome songs, introducing the babies and mothers to one another, and then involve a range of singing and music activities. These will include learning songs from around the world, ranging from short vocal exercises that use motherese style noises and sound effects (including sound baths where the mothers sang a sustained note providing a relaxation technique), to simple lullabies that can be picked up very quickly and sung in basic harmonies or rounds, to longer or more complex songs that will be learnt gradually over the weeks. Instruments such as guitar and ukulele will also be used by the artist for a small number of songs. Mothers will also work to write some of their own songs over the weeks, developing lyrics together about their babies or experiences of motherhood and creating simple melodies. Classes will be led by workshop leaders trained by Breathe, with support of assistants."
41461687|NCT03732833|DRUG|MT10109L|MT10109L will be injected into either the LCL, or both the LCL and GL.
41461688|NCT03732833|DRUG|Placebo|Placebo will be injected into either the GL, or both the LCL and GL.
41461689|NCT06039774|DRUG|α-Mangostin Hydrogel Film With Chitosan Alginate Base|Patients will apply α-Mangostin Hydrogel Film With Chitosan Alginate Base once a day for 7 days
40980574|NCT03643640|OTHER|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
41461690|NCT06039774|DRUG|Placebo|Placebo
41302770|NCT01589068|DRUG|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
41461691|NCT02681588|PROCEDURE|Obstetric management|Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
40980575|NCT01529840|DRUG|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
40980576|NCT01529840|DRUG|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
41302771|NCT01589068|DRUG|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
40980577|NCT00549523|DRUG|Placebo|Capsules containing 0 mg bid (placebo)
40980578|NCT00549523|DRUG|Low Dose|Capsules containing 400 mg bid of L. frutescens.
40980579|NCT00549523|DRUG|Mid Dose|Capsules containing 800 mg bid of L. frutescens.
40980580|NCT00549523|DRUG|High Dose|Capsules containing 1200 mg bid of L. frutescens.
40775990|NCT01854684|DRUG|Temoporfin|Given IV
40980581|NCT05443932|DRUG|Dapagliflozin|10mg Dapagliflozin daily for 8 weeks
40775991|NCT01854684|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
40980582|NCT05443932|DRUG|Hydrochlorothiazide|50mg Hydrochlorothiazide daily for 8 weeks
40980583|NCT05554705|BEHAVIORAL|Intensive Lifestyle intervention|12 week therapeutic lifestyle change program
40980584|NCT03731988|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
40980585|NCT03731988|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 5.5% or 11% or 22% laser density with 350 µm ablation depth, level 1 coagulation and a single pulse
40980586|NCT03731988|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
40980587|NCT03731988|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
40980588|NCT03731988|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
40980589|NCT04630418|OTHER|NanoSilk Cosmo|Participant will receive 30 mL of NanoSilk Cosmo jar.
40980590|NCT05668455|DRUG|Hydrocortisone|1 drops 4 times a day
40980591|NCT05668455|DRUG|Dexamethasone|1 drops 4 times a day
40980592|NCT05668455|OTHER|Povidone|1 drops 4 times a day
40980593|NCT03409406|BEHAVIORAL|Caregiver Intervention|This intervention is a 3-month (or 12 weeks) sequenced mobile health intervention provided to the parent/caregiver to use at home with the child. It supplements the 30 minute speech and language therapy session provided to the child at the hospital once a month
40980594|NCT03409406|BEHAVIORAL|ST Intervention|This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
40980595|NCT04049123|DRUG|LY900014|Administered SC
41302772|NCT04969822|DEVICE|iDAScore®|A system that studies time lapse images obtained from the embryo culture system, Embryoscope, throughout the development to blastocyst. The system uses data acquired from a sequence of embryo images and has taught itself to identify the embryos with the highest likelihood of implanting and leading to fetal heart-beat detection.
41302773|NCT02425267|OTHER|Rehabilitation (Physiotherapy)|The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
41302774|NCT02013024|OTHER|cryopreservation technique|
41302775|NCT02767141|BEHAVIORAL|Coping Strategies|Coping strategies for households in the US with food insecurity
41302776|NCT02075762|PROCEDURE|Transbronchial biopsy|
41302777|NCT02075762|PROCEDURE|Cryoprobe biopsy|
41302778|NCT02075762|PROCEDURE|VATS biopsy|
41302779|NCT06554925|PROCEDURE|Cardiac surgery|The difference in males and females undergoing cardiac surgery of all types
41302780|NCT05046795|DRUG|Revefenacin 175 mcg in 3 ML Inhalation Solution|Revefenacin
41302781|NCT05046795|DRUG|Placebo inhalation solution QD|Placebo
41302782|NCT06514885|OTHER|SDF solution application|silver diamine fluoride (SDF) solution is highly effective in stopping and arresting the progress of decay in dental roots of older adults. The American Dental Association (ADA) has published a guideline based on the up-to-date evidence to support the use of SDF for managing tooth decay. As a non-invasive procedure, application of SDF is simple, quick, painless and non-aerosol generated.
41302783|NCT06514885|OTHER|Tonic water|Tonic water will be used as a placebo to mimic the SDF solution.
40980596|NCT04049123|DRUG|Insulin Lispro|Administered SC
40980597|NCT01379547|BEHAVIORAL|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
40980598|NCT01379547|BEHAVIORAL|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
41302784|NCT03093493|DIAGNOSTIC_TEST|Genotyping|Genotyping by next generation sequencing
41302785|NCT02577406|DRUG|AG-221|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
41302786|NCT02577406|OTHER|BSC|Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
41302787|NCT02577406|DRUG|Azacitidine|continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
40980599|NCT00102882|DRUG|fluticasone propionate/salmeterol|
40980600|NCT00102882|DRUG|salmeterol xinafoate|
40980601|NCT03706781|DRUG|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + mucus adhesive polymer|Test product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
40980602|NCT03706781|DRUG|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15%|Reference Product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
40980603|NCT01304745|BEHAVIORAL|Physical training in group|Physical training in group, 6-9 participants, two times av week (1.5 hours) over a period of 16 weeks, focusing on strength and endurance training including body awareness and relaxation.
40980604|NCT01304745|BEHAVIORAL|Educational and counseling in group|Educational and counseling groups with 6-9 participants, with seven group meetings 2.5 hours over a period of seven weeks. Each session starts with a (20 minutes) lecture were one out of seven different topics are presented (Fatigue, sexuality, coping and coping strategies, etc).
40980605|NCT03562104|OTHER|videofluoroscopy|Swallowing description in Minimally consciousness Patient
40980606|NCT03562104|OTHER|Wessex Head Injury Matrix scale|Wessex Head Injury Matrix scale in Minimally consciousness Patient
41302788|NCT02577406|DRUG|Low-dose cytarabine (LDAC)|continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
40980607|NCT03544502|DEVICE|CD player|CD player opened during anesthesia induction and continued until postoperative 15 minute
40980608|NCT03544502|DEVICE|CEL-480 Sound Level Meter Sonometre|Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.
40980609|NCT03544502|DEVICE|Earplug|the independent anesthesiologist placed earplug into the patients' ears during anesthesia induction and the ear plug were removed immediately before tracheal tube extubation.
40980610|NCT03544502|PROCEDURE|Ambient operating room noise|patients were exposed to the ambient operating room noise.
40980611|NCT02814513|DEVICE|ANDAGO|Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.
40980612|NCT02814513|DEVICE|ANDAGO|Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.
40980613|NCT02814513|DEVICE|ANDAGO|Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.
40980614|NCT02814513|DEVICE|ANDAGO|Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).
40980615|NCT02814513|DEVICE|ANDAGO|To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
40980616|NCT05417061|OTHER|Saliva and serum sampling|"Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes.~Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis."
40980617|NCT01096524|OTHER|Standard Physiotherapy|The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
40980618|NCT01096524|DEVICE|Kneehab|"NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.~Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes."
40980619|NCT01444326|OTHER|Dairy|"During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew)."
40980620|NCT04107233|BEHAVIORAL|Audit and Feedback|Charts for enrolled physicians will be audited and they will receive feedback, consisting of tailored reports and one-on-one meeting with colleague to review at baseline, 3 months and 6 months
40980621|NCT04925128|OTHER|Moderate Physical Activity + Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain Moderate physical activity on treadmill, brisk walk was performed 5 days a week for 30 minutes at 4 mph speed (3-6 METs) with warm up for a 5 minutes at low speed and then at the end speed was also decreased for a 5 minutes"
40980622|NCT04925128|OTHER|Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain"
40980623|NCT04316754|OTHER|music|"During angiography, the Intervention-1 group will listen to the music that the child wants to listen to. The Intervention-2 group will listen to the Arts of Fugue by Bach. No music will be played to the control group."
40980624|NCT02482623|BEHAVIORAL|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
40980625|NCT05745779|DIAGNOSTIC_TEST|HbA1c, Vitamin D, Vitamin B12|Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.
40980626|NCT02618889|BEHAVIORAL|CBT|All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
41302789|NCT02577406|DRUG|Intermediate-dose cytarabine (IDAC)|28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
41302790|NCT04676750|BEHAVIORAL|Mindfulness-Based Stress Reduction|yoga, meditation and psycho education
41302791|NCT06458140|PROCEDURE|Cardioneuroablation|Radiofrequency ablation of ganglionated plexi of the heart
41302792|NCT04841382|OTHER|Supporting information.|CardioSolv Software System is a software-based medical device meant which creates a patient-specific 3D heart model that provides physiologic information.
41302793|NCT03218423|DEVICE|Epi proColon|Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.
40980627|NCT02510859|OTHER|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
40980628|NCT05890807|DIAGNOSTIC_TEST|Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.|The diabetologist will take a photograph of the patient's oral cavity in the diabetology department.
40980629|NCT05420129|DEVICE|MAD Therapy|Participants will be treated with a Mandibular Advancement Device therapy
40980630|NCT05420129|DEVICE|CPAP Therapy|Participants will be treated with a Continuous Positive Airway Pressure therapy
40980631|NCT02635555|DRUG|Phenylephrine|100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
40980632|NCT04190615|DIAGNOSTIC_TEST|thromboelastometry test (TEM test)|TEM test from the whole blood sample
40980633|NCT02093832|OTHER|There are no specific Intervention|are no specific Intervention
40980634|NCT05319522|BEHAVIORAL|Acute Exercise|Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.
40980635|NCT01404845|DIETARY_SUPPLEMENT|Nutrof Total|Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
40980636|NCT01404845|DIETARY_SUPPLEMENT|food supplement without Lutein and Zeaxanthin|food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
40980637|NCT03593707|DRUG|Metformin|Metformin
40775992|NCT01854684|DRUG|Photodynamic Therapy|Undergo intraoperative PDT
40980638|NCT03593707|DRUG|PF-06865571|PF-06865571
40980639|NCT05971810|DIETARY_SUPPLEMENT|immunonutrition supplement of ORAL IMPACT™|For intervention group, patients will take immunonutrition supplement after recruitment until the day before surgery.
40980640|NCT05971810|OTHER|oral chlorhexidine decontamination|For intervention group, patients will use 0.12% chlorhexidine for oral rinse twice daily from the day before surgery until 3 days after surgery.
40980641|NCT02165020|DEVICE|Hyaluronic acid (Macrolane VRF 30®, Q-MED)|"One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.~The injection is performed under local anesthesia (with Lidocaine) and ultrasound guidance, using a 16 gauge needle."
41142752|NCT04927806|DEVICE|Silver Knight|"Silver Knight breathing systems are all validated for up to seven days use, and remain active, in unopened packaging, for up to five years. Silver Knight is proven to help reduce the incidence of MRSA infection and other organisms including:~* Staphyloccus epidermis~* Pseudomonas aeruginosa~* Klebsiella pneumoniae~* Acinetobacter calcoaceticus~* Escherichia coli"
41142753|NCT01995253|DEVICE|Energy expenditure estimation in controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
41142754|NCT01995253|DEVICE|Energy expenditure estimation in free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
41142755|NCT02090478|OTHER|Low sugar diet|All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
41142756|NCT02090478|OTHER|Sham diet manipulation|Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
41142757|NCT00915915|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
41142758|NCT00915915|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
41142759|NCT02607956|DRUG|DTG|50 mg tablets administered orally, once daily
41142760|NCT02607956|DRUG|F/TAF|200/25 mg tablets administered orally, once daily
41142761|NCT02607956|DRUG|B/F/TAF|50/200/25 milligrams (mg) FDC tablets administered orally, once daily
41142762|NCT02607956|DRUG|DTG Placebo|Tablets administered orally, once daily
41142763|NCT02607956|DRUG|F/TAF Placebo|Tablets administered orally, once daily
40775993|NCT01854684|OTHER|Laboratory Biomarker Analysis|Correlative studies
40775994|NCT01854684|OTHER|Pharmacological Study|Correlative studies
41142764|NCT02607956|DRUG|B/F/TAF Placebo|Tablets administered orally, once daily
41142765|NCT00046488|DRUG|IDEC-152|6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
41142766|NCT00388856|DRUG|Vitamin C 1000mg and E 400IU|
41142767|NCT05976672|OTHER|PRSS (Peer Recovery Support Specialist)|Upon receiving an alert through a study dashboard, the PRSS (who is blinded in not knowing whether the alert was caused by data anomaly or a random generation), the PRSS will be able to access identifiable contact details and contact the participant by phone and provide the necessary support assistance (e.g., locations of AA/NA meetings, sleep and/or relaxation techniques, etc).
40980642|NCT03566251|OTHER|Balance|Balance was assessed by Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Postural Stability (PS), Limits of Stability (LOS) and Modified Sensory Organization Tests (MSOT) were evaluated with this system. PS test assesses static balance during standing up by the ability to hold the center of gravity on the support surface. The test was performed on both feet and on the left and right foot separately. LOS test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces.
40980643|NCT03566251|OTHER|Functional mobility|Timed Up and Go (TUG) tests were used to evaluate functional mobility. The TUG measures the time it takes a subject to stand up from an armchair, walk a distance of 3 m, turn, walk back to the chair and sit down. Time was recorded in seconds with a stopwatch.
40980644|NCT03566251|OTHER|Core stability|Core endurance and core strength, which are two specific components of core stability, were evaluated separately. Trunk flexor, trunk extensor, right and left side bridge and prone bridge tests were applied to assess the endurance of the core muscles. Tests were terminated when the subjects said they could not continue the test or when the test position was broken. A stopwatch was used for the measurements and the results were recorded in seconds. The power of core muscles was evaluated with sit-ups and modified push-ups tests. It was recorded how many times the subject could do each test for 30 seconds. The tests were repeated twice and the best measurement score was recorded for use in the statistical analyses.
40980645|NCT03566251|OTHER|Trunk position sense|Trunk position sense was evaluated by the trunk reposition test with Dualer IQ digital inclinometer (J-TECH medical, Salt Lake City, UK, USA). Measurements were made in two levels: lumbosacral (LS) and thoracosacral (TS) regions. The testing took place while standing under three visual-surface conditions. Participants flexed the trunk approximately 30° in the sagittal plane, holding the position for a count of 3 seconds (position 1) and then participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position for a count of 3 seconds (position 2). The absolute difference in degrees between positions 1 and 2 was defined as the trunk reposition error (TRE) degree. Participants generated five scores for each visual-surface condition. For each condition, the highest and lowest scores were discarded and the mean of the remaining three scores represented the TRE score
40980646|NCT03864250|DRUG|Tacrolimus|The initial dose of TAC is 0.05-0.1 mg/kg/d, taking 2 hours before and after meals. The interval is strictly 12 hours. The blood concentration is measured after taking the drug. According to the concentration of blood drug valley, the dose of tacrolimus (blood concentration of ≤10ng/ml) is adjusted. If the blood drug concentration is low, the drug dose (≤0.1mg/kg/d) is increased accordingly. After 6 months of treatment, the drug is discontinued. The TAC dose is maintained at the original dose after 6 months of treatment with complete or partial remission of urinary protein until the end of the 48-week trial.
40980647|NCT03864250|DRUG|Prednisone|The initial dose of prednisone is 0.5 mg/kg/d orally (maximum dose 40 mg/d), and after 8-12 weeks, the dose was gradually reduced until discontinuation. TAC treatment is given at the same time (the treatment plan is the same as the experimental group).
40980648|NCT00344227|DRUG|Lucentis (Ranibizumab)|
40980649|NCT05714657|RADIATION|Shortened Course Adjuvant Radiotherapy Following TORS|Shortened Course Adjuvant Radiotherapy Following TORS
41302794|NCT06516510|DRUG|lutetium (177Lu) rhPSMA 10.1 and Pluvicto®|Radiopharmaceutical
41302795|NCT06555003|DRUG|Drug-Eluting Embolic Bead|A minimum of 2 sessions of DEBIRI treatment and 2-4 cycles of systemic chemotherapy are administered (based on tumor size, bilobar or unilobar involvement of the liver, treatment response rate, treatment tolerance, occurrence of side effects, and liver function). Prior to performing DEBIRI, initial angiography is done via the femoral or axillary artery to determine the anatomy of the right and left hepatic arteries as well as the arteries supplying the tumor. Subsequently, a vial of irinotecan (100 mg) eluted with a vial of beads(hepaSphere 25mg) is injected into the blood vessels feeding the tumor. The intervention will be repeated to deliver 200 mg of irinotecan intravascularly to the liver mass. A 14-day interval between the procedures is established to minimize side effects. Targeted therapy administration for each treatment group based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status as explained in control arm.
40980650|NCT04590261|OTHER|Blood sampling|Peripheral Blood sampling, 25 mL
40980651|NCT04590261|OTHER|Nasal Brushing|Nasal Brushing, facultative
41142768|NCT01928732|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
41302796|NCT06555003|DRUG|Chemotherapy drug|Control group will receive 2-4 cycles of systemic chemotherapy based on functional status of the patient, adverse event rate and treatment tolerance, tumor size and characteristics. Targeted therapy administration for each treatment group in based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status (e.g., administration of Pembrolizumab for patients with high rosatellite instability (MSI-H) or Bevacizumab for tumors harboring KRAS mutations). Due to the targeted nature of these therapies, they can not be administered to all participants of the trial, while It is not ethically justifiable to withhold targeted therapies from patients who are candidates for these treatments based on their tumor characteristics and deprive them of potentially life-extending options.
41302797|NCT02110810|DRUG|Indomethacin|Indomethacin suppository of 100 mg immediately afterwards while still under sedation
41302798|NCT02110810|DRUG|2.6-g suppository of glycerin|to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
40980652|NCT04669483|OTHER|evidence-based informed consent form|Evidence-based informed consent forms for total knee arthroplasty and related anesthesia procedures will be developed. The design of the evidence-based informed consent forms will be guided by an existing guideline on how to present evidence-based health information (guideline evidence-based health information) and nocebo research. The information will be presented in plain language. Benefits and harms of the procedures will be presented in absolute risk formats and in comparison with other interventions or placebo. Verbal presentations of risks lead to overestimations of risks and therefore, will not be applied exclusively. Gain and loss framing will be combined. To visualize important aspects, pictograms will be used. Information on uncertainty, missing or low quality evidence will be provided.
40980653|NCT05091099|DRUG|Alendronate|On time Zoledronate: Zoledronate would be given (one dose for one year) after the completiong of denosumab on time Alendronate and Zoledronate: Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).
40980654|NCT02050360|DRUG|Sildenafil 40 mg|
40980655|NCT02050360|DRUG|Sildenafil 80 mg|
40980656|NCT02050360|DRUG|Placebo|
40980657|NCT01109654|DRUG|Cetrorelix acetate and Follitropin alfa|Cetrorelix acetate given either as a single-dose regimen of 3 mg injection or as a multiple-dose regimen of 0.25 mg daily injection.Ovarian stimulation therapy with Follitropin alfa generally starts on cycle Day 2 or 3. The starting dose of Follitropin alfa is based on the Investigators' discretion
40980658|NCT04432857|DRUG|AN0025|oral administration
40980659|NCT04432857|DRUG|Pembrolizumab|Infusion
40980660|NCT00770289|OTHER|Cohort|Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
40980661|NCT02932033|PROCEDURE|Tack fixation of mesh|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization
40980662|NCT02932033|PROCEDURE|Synthetic glue fixation|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
40980663|NCT00045500|DRUG|7-hydroxystaurosporine|
40980664|NCT00045500|DRUG|prednisone|
40980665|NCT00075179|DRUG|Nesiritide (Natrecor)|Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.
40980666|NCT00075179|PROCEDURE|Right Heart Catheterization|Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
40980667|NCT06205004|OTHER|Questionnaires|In the present study, the investigators aim to investigate the prevalence and effects of IA on the psychosocial well-being among adults in Hong Kong by measuring the level of Internet use, depression, anxiety, sleep quality, QOL together with basic demographic data in the current situation of COVID with popularity of Metaverse.
40980668|NCT02315781|DEVICE|active tDCS|transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
40980669|NCT02315781|DEVICE|Sham tDCS|Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
41142769|NCT01928732|BEHAVIORAL|Prolonged Exposure (PE)|"PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure."
41142770|NCT01431157|PROCEDURE|Nocturnal nasal oxygen|Nasal oxygen at 2 l/min will be given at night
40980670|NCT03695107|DRUG|Nifedipine controlled released tablets|lower blood pressure
40980671|NCT01679977|DEVICE|Vibrational-proprioceptive Resistance Exercise Training|
40980672|NCT01679977|DEVICE|Neuromuscular Electrical Stimulation Training|
40980673|NCT00471744|DRUG|Treatment with levetiracetam or sulthiame over a six-month period.|
40980674|NCT02056782|DRUG|Dociparstat sodium|"The following induction regimen was administered:~* Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~* Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~* Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days."
40980675|NCT01829516|DRUG|Oxytocin|Intranasal oxytocin
40980676|NCT01829516|DRUG|Placebo|Intranasal placebo
40980677|NCT03153254|DEVICE|Test upper limb robot assisted therapy device|During 1 session of 1/2 hour.
40980678|NCT03153254|DEVICE|Training with new upper limb robot assisted therapy device|During 2 to 5 sessions of 1/2 hour.
40980679|NCT03535103|DRUG|Gonal-F®|A single Subcutaneous injection, 225IU
40980680|NCT03535103|DRUG|LM001|A single Subcutaneous injection, 225IU
40980681|NCT02622581|OTHER|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
40980682|NCT05081011|DEVICE|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily custom insulin titration instructions.
40980683|NCT05081011|DEVICE|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily generic insulin reminders.
40980684|NCT05974293|DRUG|Nabiximols|Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.
40980685|NCT05974293|DRUG|Placebo|The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.
40980686|NCT00166673|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|
40980687|NCT04742933|OTHER|There is no intervention in this observational trial|There is no intervention in this observational trial
40980688|NCT04541056|BEHAVIORAL|Goal Management Training (GMT)|The manual comprises an introduction to GMT for the survivors of ALL, and a detailed session structure incorporating cognitive and behavioral tasks. The GMT program involves teaching the participants about goals, attention slips and how to manage these, how to review and prioritize goals (e.g., Stop, Think, Organize, Plan), and how to keep goals in mind (e.g., using analogies such as the mental blackboard). Each session will follow the same general format; namely, facility-delivered presentations, flipchart discussions, group activities and homework.
40980689|NCT04541056|BEHAVIORAL|Brain Health Workshop (BHW)|BHW is a psycho-educative control condition, and is typically part of psycho-educative Acquired Brain Injury (ABI) rehabilitation programs, but adjusted for the ALL group of participants. The psycho-educative control condition BHW will be matched GMT for amount of training and therapist contact. Homework assignment and in-session tasks included readings, brain games, puzzles, and practical exercises such as logging sleep.
40980690|NCT00121550|DRUG|clarithromycin|
40980691|NCT02678845|OTHER|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
40980692|NCT03359447|DRUG|Weekly Ferrous Sulfate|Drops
40980693|NCT03359447|DRUG|Daily Ferrous Sulfate|Drops
40980694|NCT02036463|DRUG|Prednisone|
40980695|NCT02036463|DRUG|Placebo|
40980696|NCT04977908|DEVICE|CamAPS HX|Fully automated closed-loop system (CamAPS HX) with ultra-rapid Lispro insulin
40980697|NCT04977908|DEVICE|Standard insulin pump therapy with CGM|Participants usual insulin pump therapy with Dexcom G6 CGM
40980698|NCT02011737|DRUG|naftopidil 75mg|
40980699|NCT04376372|DIAGNOSTIC_TEST|Functional testing, Magnetic resonance imaging, Electromyography|Electromyography only for cases (F-Lefthanders), not for controls (TD-lefthanders)
40980700|NCT02337257|DRUG|Cholecalciferol|subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
40980701|NCT02337257|DRUG|Placebo|subjects will receive placebo one pill per day for 16 weeks
40980702|NCT00421538|DRUG|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
40980703|NCT00421538|DRUG|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
40980704|NCT05986162|DRUG|Itolizumab|Patients to be treated with Itolizumab.
40980705|NCT00940394|BEHAVIORAL|mutual support group|bi-weekly, 12-session, family-led mutual support group
40980706|NCT00940394|BEHAVIORAL|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
40980707|NCT00940394|OTHER|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
40980708|NCT06095427|BIOLOGICAL|LY06006 (Denosumab Biosimilar)|single dose of 60 mg LY006006 s.c.
40980709|NCT06095427|BIOLOGICAL|US-Prolia (Denosumab)|single dose of 60 mg US-Prolia s.c.
40980710|NCT06095427|BIOLOGICAL|EU-Prolia|single dose of 60 mg EU-Prolia s.c.
40980711|NCT01134978|BEHAVIORAL|Practice Order|"Blocked order - predictable~Random order - unpredictable"
40980712|NCT04960150|DEVICE|Press tack needle|"Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm"
40980713|NCT04960150|DEVICE|Plesterin|Plesterin
41142771|NCT01431157|OTHER|No nasal oxygen|Patients will have no intervention for sleep apnea
40980714|NCT04520932|PROCEDURE|Radiofrequency ablation|RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from Taewong®.
40980715|NCT02315170|DEVICE|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
40980716|NCT02315170|DEVICE|standard lid speculum|standard wire lid speculum
40980717|NCT04235049|DRUG|Glecaprevir/pibrentasvir|Treatment for HCV Infection
40980718|NCT01057550|PROCEDURE|Autologous fascial sling|Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
40980719|NCT01057550|PROCEDURE|TVT|Standard TVT as described by Ulmsten 1996
40980720|NCT01057550|PROCEDURE|Pelvicol|retropubic mid urethral sling made from Pelvicol
40980721|NCT02711540|PROCEDURE|Balloon Aortic Valvuloplasty|Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
40980722|NCT05741008|RADIATION|Target range|Compared with conventional radiotherapy, the target dose is unchanged and the CTV2 volume is reduced.
40980723|NCT04999150|PROCEDURE|Micro-Osteoperforations|"MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced \~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed. A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)"
41302799|NCT04628013|DEVICE|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied with a pair of 2x3 inch electrodes placed orthogonally to the knee joint line with one electrode on the medial and lateral sides of the knee. The device is a commercially available unit(Chattanooga Continuum, DJO Global, Vista CA) and the parameters of the NxES include: 400 μs biphasic square wave pulses delivered at 50-100 pulses/second, using a cycle time of 10-seconds on, with a 2-second ramp-up in intensity, followed by a 10-second off period. The current intensity will be dosed over the first 2-minutes of stimulation to find the sensory perception threshold and the threshold for the first perception of a sharp, prickly buzzing sensation that they would identify as painful. Next, the current intensity will gradually be increased until the participant reports a sharp or prickly buzzing sensation that achieves a pain rating of not more than a 5/10 using a numeric pain rating scale.
41461692|NCT00265785|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
40980724|NCT04999150|PROCEDURE|Corticotomy|"A full-thickness labial mucoperiosteal flap was reflected. Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed. The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex, until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed. A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)"
40980725|NCT05118828|BEHAVIORAL|Guided internet-based cognitive behavioural therapy|AS-iCBT offers guided CBT intervention for anxiety and depression, each consisting of 6 modules. It is recommended for clients to complete 1 module weekly. The structure and content of the programme modules follow evidence-based CBT principles, and comprises cognitive and behavioural components such as self-monitoring, gradual stimulus control, exposure, behavioural activation, and cognitive restructuring. It is recommended that therapist support is provided weekly during short sessions that focus on progress monitoring and feedback on completed work. Support sessions should last 15-20 minutes and are preferably delivered by phone or video conference.
40980726|NCT05118828|BEHAVIORAL|Treatment as usual in Prompt Mental Health Care (TAU-PMHC)|TAU-PMHC includes both low-intensity (guided self-help, group-based psychoeducation) and high-intensity CBT (F2F-CBT). The TAU-PMHC condition basically represents how PMHC services currently operates (i.e. a pragmatic stepped care model) and provides therapists with more flexibility to accommodate client needs and preferences.
40980727|NCT00514033|BIOLOGICAL|Poliomyelitis vaccine (inactivated) -PoliorixTM|Deep intramuscular injections for the primary vaccination and booster vaccination.
40980728|NCT06374706|BEHAVIORAL|Morning Walk training for stroke|Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Symmetrical Walking on the Ground.
40980729|NCT06374706|BEHAVIORAL|Morning Walk training for healthy|Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Asymmetrical Walking on the Ground.
40980730|NCT03402789|DRUG|Docosahexaenoic Acid|Docosahexaenoic acid 1,200mg daily plus 2 hours of eye patching daily
40980731|NCT03402789|DRUG|Placebo Oral Tablet|Placebo tablet daily plus 2 hours of eye patching daily
40980732|NCT00170716|DEVICE|Cortical Stimulation and rehabilitation|Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
40980733|NCT00170716|OTHER|Rehabilitation|Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
40980734|NCT03165279|PROCEDURE|Zenith Alpha Abdominal stentgraft|
40980735|NCT04895215|DRUG|AB-2004|Taken 3 times daily with food
40980736|NCT04895215|DRUG|Placebo|Take 3 times daily with food
40980737|NCT04699708|DEVICE|Carbon dioxide monitoring|Blinded recording of CO2 during preterm resuscitation.
40980738|NCT03940664|OTHER|immunohistochemistry on Formalin fixed and paraffin embedded blocks|
41302800|NCT04398017|PROCEDURE|Transesophageal echography|Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
41302801|NCT01293396|DRUG|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
40980739|NCT03443440|OTHER|Neurocognitive Testing|neurocognitive testing, computerized
40980740|NCT03064191|COMBINATION_PRODUCT|calcium hydroxide chlorhexidine combination|Endodontic intra-canal medicament used for decreasing postoperative signs ans symptoms
41302802|NCT01293396|DRUG|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
41302803|NCT01293396|DRUG|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
41302804|NCT00915005|RADIATION|Photon Therapy|Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
41302805|NCT00915005|RADIATION|Proton Therapy|"Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.~Each daily treatment should take about 20-30 minutes to complete."
41302806|NCT00915005|DRUG|Paclitaxel|50 mg/m2 by vein 1 time each week for 7 weeks.
41302807|NCT00915005|DRUG|Carboplatin|AUC 2 by vein 1 time each week for 7 weeks.
41302808|NCT02202096|OTHER|Patient education: One-on-one visit|The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
40980741|NCT03064191|OTHER|calcium hydroxide intra-canal medicament|Endodontic intra-canal medicament used for decreasing postoperative signs and symptoms.
40980742|NCT02111772|BIOLOGICAL|Rhinovirus|
41461693|NCT01307943|OTHER|Mindfulness-based stress reduction program|Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat
41461694|NCT01307943|OTHER|Usual care|The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
40980743|NCT03021265|DRUG|T80/A5/H12.5 FDC|Drug
40980744|NCT01430156|DRUG|Heme arginate (Normosang)|3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
40980745|NCT01430156|DRUG|0.9% sodium chloride|Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
40980746|NCT03504150|BEHAVIORAL|SPHERE|Comprehensive Internet-based CBT program with no human support
40980747|NCT03504150|BEHAVIORAL|PRISM|Brief Internet-based CBT program with no human support
40980754|NCT05395468|OTHER|photographs of each eye|All subjects included will take 5 photographs of each eye according to a standardised procedure in terms of distance, lighting and framing
40980755|NCT06181097|DEVICE|negative pressure wound therapy|The intervention group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The Smith \& Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility.
40980756|NCT06181097|OTHER|standard dressing|The standard dressing group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The same PICO dressing will be applied, but without the suction.
40980757|NCT03763123|DRUG|Sevacizumab|Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg，1mg/kg，1.5mg/kg and 2mg/kg
40980758|NCT03763123|DRUG|Paclitaxel|paclitaxel 80mg/m2 as a \> 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;
40980759|NCT03763123|DRUG|Topotecan|topotecan 4 mg/m2 as a \>30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;
40980760|NCT04489329|DEVICE|Ingestible Capsule|Participants will swallow capsule and undergo X-rays to establish transit
41461695|NCT00574769|DRUG|RAD001, Docetaxel, Bevacizumab|"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m\^2 every 21 days"
41461696|NCT05614115|DRUG|Empagliflozin|is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.
40980761|NCT04489329|DIETARY_SUPPLEMENT|Probiotic|Participants will swallow a probiotic capsule and the sample collection capsule at the same time to establish concentration of strain in small intestine.
40980762|NCT01502423|BIOLOGICAL|Adalimumab|Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
40980763|NCT01849224|OTHER|Pelvic and lower extremity exercise|
40980764|NCT03963791|OTHER|Eggshell powder gel|Eggshell powder gel produced from chicken eggs.
40980765|NCT03963791|OTHER|CPP-ACP crème|A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.
40980766|NCT06147310|PROCEDURE|Study Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Alveolar ridge preservation with blood platelet concentrate: heat-treated albumin (Alb-PRF) and advanced platelet-rich fibrin. The experimental site will be filled with A-PRF plugs/membranes until level flushed with the level of bone. An additional Alb-PRF membrane will be tucked and inserted below the buccal and oral flap. Surgical flaps will not be raised. Soft tissue will be tunnelled and undermined for insertion of the Alb-PRF membrane. The extraction site and membranes will be stabilized by cross-mattress sutures and allowed for secondary intention healing.
40980767|NCT06147310|PROCEDURE|Control Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Cross mattress suture will be applied and site allowed to heal naturally.
40980768|NCT03494309|PROCEDURE|Open Reduction & Internal Fixation|Patients underwent surgery and the fractures were reduced under direct vision followed by internal fixation with titanium plates and screws
40980769|NCT03494309|PROCEDURE|Closed Reduction & External Fixation|Patients underwent closed reduction of the fracture and external fixation by arch bars \& guided elastics
40980770|NCT00285597|DRUG|Ursodeoxycholic Acid|
40980771|NCT01662258|DEVICE|Point-of-Care diagnostic laboratory test|All POC tests are FDA-cleared.
40980772|NCT06154954|DIAGNOSTIC_TEST|Semen analysis|Semen analysis for extracellular matrix proteins analysis
40980773|NCT00842712|DRUG|Cilengitide|Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
40980774|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
41461697|NCT05614115|OTHER|Placebo|Placebo comparator
41461698|NCT00987480|DRUG|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
40775995|NCT04616898|DEVICE|Venus Bliss|The Venus Bliss™ system is an aesthetic medical device designed to non-invasively reduce subcutaneous adipose tissue of the abdominal area and flanks. It is intended for use in individuals with a Body Mass Index (BMI) of 30 or less. The device consists of an external treatment component and an internal control component. The treatment console is a 1060nm diode laser applicator and a radio frequency applicator. In addition, a Bliss Belt is provided with the system to properly secure one or more applicators to the patient's body during treatment. Finally, the touchscreen monitor is used by the clinician to control the setting display on the main console. It also keeps the clinician informed of the device's status and operating parameters.
40775996|NCT04908644|DRUG|MS-20 oral solution|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
40775997|NCT04908644|OTHER|Placebo|Placebo
40775998|NCT00630617|BEHAVIORAL|Diet, Physical activity, Physical inactivity|Community based participatory research design
40775999|NCT02646410|OTHER|FPD+NDOT|
40776000|NCT02646410|OTHER|FPD+DOT|
40776001|NCT02646410|OTHER|DDD+NDOT|Door to door delivery + non directly observed treatment
40776002|NCT02646410|OTHER|DDD+DOT|Door to door delivery + directly observed treatment
40776003|NCT04658485|DEVICE|Active tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1) with the cathode located over the right primary somatosensory cortex (S1).
40776004|NCT04658485|DEVICE|Sham tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide a sham stimulation with the anode place over the primary motor cortex (M1) and cathode located over the right primary somatosensory cortex (S1). The sham stimulation consists of 30 seconds of stimulation ramping up to a maximum of 2 mA, then 19 minutes of the device providing no stimulation and then ramping down from 2 mA intensity to 0 in the last 30 seconds. This configuration is designed to mimic the sensory experience of active tDCS.
40776005|NCT00226356|DRUG|Supplements of L-methionine, betaine and folate|
40776006|NCT06209866|DEVICE|PTA|Percutaneous Trans lumenal Angioplasty
40776007|NCT01346124|RADIATION|High Dose Intensity Modulated Proton Radiation|Radiation given once a day Monday-Friday
40776008|NCT05684302|OTHER|The free-toroidal design lenses|Participants were asked to wear the new design lenses (the free-toroidal design lenses) for 1 week
40776009|NCT04353687|DEVICE|Robotic-assisted inguinal hernia repair|Each surgeon will perform the robotic-assisted inguinal hernia procedure per their standard practice. Surgeon subjects will consent to prospectively provide selected procedure and case data.
40776010|NCT03616821|DRUG|Brazikumab|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
40776011|NCT03616821|DRUG|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
40776012|NCT00375258|DRUG|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
40776013|NCT00375258|DRUG|Sodium Chloride 0.9%|Visual matched placebo
40776014|NCT00420186|DRUG|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
40776015|NCT03485157|BIOLOGICAL|Micronized dHACM|Injection of 40 mg micronized dehydrated human amnion chorion membrane (dHACM) suspended in 1 mL 0.9% Sodium Chloride, USP
40776016|NCT03485157|DRUG|Saline|Injection of 1 mL 0.9% Sodium Chloride, USP
40776017|NCT04120207|BEHAVIORAL|Home-based Pilates|The Home-based Pilates group will complete two Pilates classes at home, twice weekly, for a period of eight weeks.
40776018|NCT04120207|OTHER|Delayed-start Pilates|The Delayed-start group will maintain their regular daily activities, and be provided with a copy of the Pilates DVD following the intervention, for their own use.
40776019|NCT05392816|OTHER|Single meal non-heme iron absorption|Two study groups, each designed as cross-over single-blinded iron isotope trials in apparent healthy Swedish women of the ages 18-45 years. Each participant serves as their own control. Meals are tagged with radiolabeled non-heme iron 55Fe and 59Fe.
40776020|NCT05521984|DRUG|Dapagliflozin|Commercially available
41461699|NCT00987480|DEVICE|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
40776021|NCT05521984|DRUG|Carmustine|Standard of care
40776022|NCT06320080|DRUG|TQB2223 injection|TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody.
40776023|NCT06320080|DRUG|Penpulimab Injection|Penpulimab Injection is an anti programmed death-1 (PD-1) antibody.
40776024|NCT02665260|DRUG|Cantharidin|cantharidin 0.7% topical liquid
40980775|NCT00842712|DRUG|Cetuximab|Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) as intravenous infusion over 2 hours on Day 1.
40980776|NCT00842712|DRUG|Cisplatin|Cisplatin (Cis) will be administered at a dose of 75 mg/m\^2 as intravenous infusion on Day 1.
40776025|NCT02665260|DRUG|Placebo|Placebo topical liquid
40776026|NCT02665260|DEVICE|Gauze occlusion bandage|Gauze occlusion bandage with adhesive tape
40776027|NCT05155111|DIAGNOSTIC_TEST|Telemedicine consult|A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy
40776028|NCT01151267|OTHER|Standard Anesthesia management for post surgical patients|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation \>97% and end tidal CO2 at 35-45mmHg.
40776029|NCT01151267|DEVICE|Hypercarbic Spontaneous Hyperpnoea|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
40776030|NCT02977078|BEHAVIORAL|Active feedback on monitored inhaler use|Feedback given on inhaler use by research nurse/ doctor based on mobile application feedback
40776031|NCT02977078|DEVICE|Inhaler casing|Monitors inhaler use
40776032|NCT02977078|DEVICE|Mobile application|Mobile application software linked to inhaler casing
40980777|NCT00842712|DRUG|Cisplatin|Cis will be administered at a dose of 80 mg/m\^2 as intravenous infusion on Day 1.
41461700|NCT03568604|DRUG|Prasterone|6.5 vaginal insert prasterone (dehydroepiandrosterone)
41142772|NCT05804734|DRUG|Vitamin K Antagonist - Drug|"Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~* For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~* For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment."
41142773|NCT03742622|BEHAVIORAL|CON . control condition without exercise / rest condition|CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
40980778|NCT00842712|DRUG|Gemcitabine|Gemcitabine (Gem) will be administered at a dose of 1250 mg/m\^2 as intravenous infusion on Days 1 and 8.
40980779|NCT00842712|DRUG|Vinorelbine|Vinorelbine (Vin) will be administered at a dose of 25 mg/m\^2 as intravenous infusion on Days 1 and 8.
40980780|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
40980781|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
40980782|NCT00842712|DRUG|Cetuximab|Cetuximab will be administered at a dose of 400 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m\^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
40980783|NCT00842712|DRUG|Chemotherapy|Cis 80 mg/m\^2 intravenous infusion on Day 1 + Vin 25 mg/m\^2 or Cis 75 mg/m\^2 intravenous infusion on Day 1 + Gem 1250 mg/m\^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
40980784|NCT01138631|DEVICE|Embryoscope|The embryoscope is an incubator with in-built photographic equipment
40980785|NCT00620828|OTHER|Placebo saline injection|20 cc of sterile, injectable saline
40980786|NCT00620828|DRUG|Ropivicaine 0.5%|Ropivicaine
40980787|NCT04231539|DRUG|Nicotine|Vape different flavor nicotine products
40980788|NCT04231539|DEVICE|Vaporizer Device|Take puffs from vaporizer filled with different flavors
40980789|NCT01503281|OTHER|Circuit training|Aerobic and resistance training exercises + Mediterranean diet
40980790|NCT04337606|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance; Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
40980791|NCT04337606|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
40980792|NCT04337606|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
40980793|NCT00656474|DRUG|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
40980794|NCT00656474|DRUG|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
40980795|NCT01010386|PROCEDURE|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
40980796|NCT01010386|PROCEDURE|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
40980797|NCT04889469|PROCEDURE|Breast reduction|Procedure to remove excess fat, tissue and skin from the breasts.
40980798|NCT02741882|OTHER|Questionary|Questionary with clinical, demographic and behavior outcomes at the pregnancy period
40980799|NCT04387851|BEHAVIORAL|Placebo induction|The placebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce placebo effects on somatosensory sensations.
40980800|NCT04387851|BEHAVIORAL|Control|Placebo and nocebo effects should be measured relative to a control group (between-subjects design). In the case of within-subjects designs, these will be included to the extent possible (in a separate analysis or descriptively depending on the number of results).
40980801|NCT04387851|BEHAVIORAL|Nocebo|The nocebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce nocebo effects on somatosensory sensations.
40980802|NCT00540514|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
40980803|NCT00540514|DRUG|Paclitaxel|Administered by intravenous infusion.
40980804|NCT00540514|DRUG|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
40980805|NCT02597348|PROCEDURE|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
40980806|NCT00511667|DRUG|MK0941|MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
40980807|NCT00511667|DRUG|Comparator: Placebo|Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
40980808|NCT00192842|DRUG|curcumin (+ gemcitabine)|
40980809|NCT00407823|PROCEDURE|Central venous oxygen saturation continuous monitoring|
40980810|NCT00965588|BIOLOGICAL|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
41302809|NCT02202096|OTHER|Discharge planning: Assessment of barriers to discharge|Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
41302810|NCT02202096|OTHER|Medication reconciliation: Patient medication review|The navigator will review the patient's medications with him/her prior to discharge.
40776033|NCT00523978|DEVICE|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
41302811|NCT02202096|OTHER|Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
41302812|NCT02202096|OTHER|Transition coach|The navigator will assist with coordination of care and tracking follow-up appointments and tests.
41302813|NCT02202096|OTHER|Patient-centered discharge instructions: Enhanced|Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
41302814|NCT02202096|OTHER|Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|"Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a walk-in basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline."
41302815|NCT02202096|OTHER|Timely follow-up: Barriers to clinic follow-up visits will be discussed|Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
41461701|NCT05055687|DRUG|FL058|2500mg、3000mg
40776034|NCT00523978|DRUG|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
41461702|NCT05055687|DRUG|Placebo|empty bottle
40776035|NCT00420706|DRUG|SCA-136|
40776036|NCT01871376|DRUG|Intravitreal aflibercept injection 2.0mg|Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
40776037|NCT05036135|DRUG|AV-101|AV-101 (imatinib) administered via dry powder inhalation
40776038|NCT05036135|DRUG|Placebo|Placebo administered via dry powder inhalation
40776039|NCT00006427|DRUG|Amitriptyline|
40776040|NCT03379974|DRUG|DDAVP Inhalant Product|For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
40776041|NCT03379974|BEHAVIORAL|Exercise Intervention|For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
40776042|NCT04470414|DIAGNOSTIC_TEST|IgG antibodies immunoassay|Assessment of IgG level will be done by quantitative assessment of IgG in the serum of recovered persons by Chemiluminescence Immunoassay (CLIA).
40776043|NCT03027596|PROCEDURE|Remote ischemic conditioning|
40776044|NCT06073522|OTHER|Artificial Intelligence for combining multi-domain data acquisition|Artificial Intelligence and machine learning techniques to combine data coming from multidomains data collection (such as clinical multiaxial assessments and questionnaires, Neuroimaging, Upper limb movement analysis during clinical assessment and daily life )
40776045|NCT02037529|DRUG|Eribulin Mesylate|Given IV
40776046|NCT02037529|OTHER|Laboratory Biomarker Analysis|Correlative studies
40776047|NCT02037529|DRUG|Paclitaxel|Given IV
40776048|NCT02037529|OTHER|Quality-of-Life Assessment|Ancillary studies
40776049|NCT03930953|DRUG|CC-99282|Specified dose on specified days
40776050|NCT03930953|DRUG|Rituximab|Specified dose on specified days
40776051|NCT03930953|DRUG|Obinutuzumab|Specified dose on specified days
40776052|NCT03930953|DRUG|Tafasitamab|Specified dose on specified days
41142774|NCT03742622|BEHAVIORAL|EX. Condition with an acute exercise set in the middle of the morning|EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals
41142775|NCT03742622|BEHAVIORAL|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
41461703|NCT05055687|DRUG|FL058|500mg、1000mg、2000mg
40776053|NCT03930953|DRUG|Valemetostat|Specified dose on specified days
41461704|NCT05055687|DRUG|Placebo|empty bottle
41461705|NCT02129062|DRUG|Ibrutinib|Given orally 560 mg daily (dispensed as 4 x 140-mg capsules)
41461706|NCT02129062|OTHER|Laboratory Biomarker Analysis|Correlative studies
40776054|NCT05026164|DIETARY_SUPPLEMENT|CHI-202|Blend of cannabinoids \& other ingredients
40776055|NCT05026164|DIETARY_SUPPLEMENT|CHI-101|Placebo
40776056|NCT04271293|DRUG|Edoxaban|Edoxaban will be administered via PEG in patients who are eligible for the anticoagulant treatment according to the current guidelines.
40776057|NCT02590107|DIETARY_SUPPLEMENT|Boost Plus|Receive nutritional supplementation twice daily to provide 28g of protein
40776058|NCT02590107|DIETARY_SUPPLEMENT|Pro-Stat 101|Receive nutritional supplementation twice daily to provide 30g of protein
40980811|NCT05838443|OTHER|Self-directed mindfulness utilizing a multi-sensor EEG-supported device with neurofeedback-assisted and technology-supported meditation|Neurofeedback-assisted, technology-supported mindfulness via EEG-supported device delivered individually without the need for a facilitator or travel to training site. The device allows noninvasive neural activity recording from frontal and posterior brain regions. A dedicated smartphone application uses the EEG data to provide real-time adaptive feedback-modulating natural sounds to prompt user awareness of mind-wandering and intentional return to present experience. A smartphone app will guide patients through attention and focus on breath exercises. Patients will hear their distracted mind as the wind. Wind becomes stronger if their mind wanders, prompting patient's awareness of their wandering mind and guiding the patient back to focusing on their breath without judgment of how they are doing. Patients will be asked to practice mindfulness using the device for 20 minutes per day for 4 sessions prior to surgery.
40980812|NCT05838443|OTHER|Provider-directed mindfulness|"Patients will receive mental health support by a licensed social work provider who is trained in mindfulness through four 20-minute telehealth sessions. Patients will be taught cognitive behavioral therapy (CBT) techniques to reduce pain catastrophizing and increase coping efficacy, the clinician will review patient's current sleep routine and teach concepts and strategies to improve sleep. Patients will be guided through mindfulness and meditation exercises to improve pain and mood coping. Mindfulness-based instructions takes patients through quieting their mind by focusing on breath, expanding focus (i.e., at the tip of their nose full flow of the breath), with emphasis on acknowledgement of arising thoughts/emotions without judgement or emotional reaction, and return attention back to breath sensation. Principles of CBT and mindfulness will be reiterated at subsequent sessions."
40980813|NCT05838443|OTHER|Conventional Care|Control group, as defined by our institution's standard preoperative care for given procedure, which does not include psychological preparation.
40980814|NCT00592839|DRUG|SCE-B|0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
40980815|NCT00592839|DRUG|Placebo|Matching placebo for 0.3 mg and 0.625 mg tablets
40980816|NCT00002222|DRUG|Valganciclovir|
40980817|NCT06163261|OTHER|Physical activity|The intervention group will receive an individualized and person-centred prescription of physical activity and exercise.
40980818|NCT02406976|OTHER|G1 -Exercise|"20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3."
40980819|NCT02406976|BEHAVIORAL|G2- Exercise and Lifestyle|"Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3."
40980820|NCT02406976|OTHER|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
40980821|NCT01988857|BIOLOGICAL|Boostrix™|Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
40980822|NCT05826886|BEHAVIORAL|Emotional Writing|Participants complete four 20-minute sessions of emotional writing (at home) on four consecutive days. Instructions are provided online before each writing session.
40980823|NCT03736317|DEVICE|sham TBS|Stimulate the dorsal lateral prefrontal cortex or medial prefrontal cortex for 2 weeks by sham Theta-burst stimulation (TBS), five times for a week with the sham coil.
41461707|NCT05107739|BIOLOGICAL|Drug Product De-TIL-0255|Autologous tumor-infiltrating lymphocytes
41461708|NCT01207492|DRUG|nilotinib|Taken orally twice daily
40980824|NCT03736317|DEVICE|real mPFC cTBS|Stimulate the medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
40980825|NCT03736317|DEVICE|real dlPFC iTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
41142776|NCT01911819|PROCEDURE|Sinus augmentation|
41461709|NCT05869916|BEHAVIORAL|psychological first aid|The effect of psychological first aid on earthquake victims was measured using the resilience scale and the secondary traumatic stress scale.
40776059|NCT02590107|DIETARY_SUPPLEMENT|Milkshake|Receive alternate nutritional supplementation once daily to provide 28g protein
41461710|NCT02725619|BEHAVIORAL|CBT|
40980826|NCT03736317|DEVICE|real dlPFC iTBS + real mPFC cTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
40980827|NCT06135987|DEVICE|TLC-NOSF dressings (D'URGOSTART PLUS® BORDER, URGOSTART PLUS® PAD and URGOSTART INTERFACE®)|Clinical evaluation of the dressing in the local treatment of chronic wounds (DFU and VLU)
40980828|NCT05451160|DEVICE|steep pulse therapy system|The steep pulse therapy system is produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation
40980829|NCT05451160|DEVICE|RF Ablation System|RF Ablation System
40980830|NCT01846611|DRUG|Trabectedin|1.1 mg/m\^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
40980831|NCT01846611|DRUG|DOXIL|30 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
40980832|NCT01846611|DRUG|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
40980833|NCT01846611|DRUG|DOXIL|50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
40980834|NCT01414075|DRUG|Roxadustat|Tiered, weight-based dosing per schedule specified in the arm.
40980835|NCT01414075|DRUG|Oral Iron|Administered per oral dose and schedule specified in the arm.
40980836|NCT01414075|DRUG|IV Iron|Administered per IV dose and schedule specified in the arm.
40980837|NCT01460420|DRUG|Bz (Bortezomib)|Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
40980838|NCT01460420|DRUG|Len (lenalidomide)|"Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified."
40980839|NCT02392247|DEVICE|Coagulation function|Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
40980840|NCT05756374|BEHAVIORAL|OUT to IN|OUT to IN comprises 20 body-oriented biweekly 40-minute sessions facilitated by a psychomotor therapist in a pedagogical partnership with the preschool teacher. Sessions are implemented outdoors. All sessions are framed in a context of freedom and self and mutual bodily resonance, according to the following structure: First, children are invited to engage in exercise play activities. Second, children engage in ludic relaxation proposals. Finally, children are asked to reflect on their bodily experiences and express themselves through different expressive mediators. Preschool teachers also participate in a 25-hour training focused on the underlying principles of OUT to In and participate in 20 body-oriented biweekly 20-minute relaxation sessions, facilitated by a psychomotor therapist.
41142777|NCT01911819|DRUG|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
40776060|NCT02590107|OTHER|daily food diaries|Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
41142778|NCT01911819|DRUG|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
41142779|NCT01911819|DRUG|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
40776061|NCT00435448|DRUG|Lonidamine|
40776062|NCT04155398|PROCEDURE|EUS elastography|A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
40776063|NCT02407119|DRUG|7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
40980841|NCT02545790|PROCEDURE|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
40980842|NCT02545790|BIOLOGICAL|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
40980843|NCT04907656|BEHAVIORAL|dCBT|As per arm of the same name
40980844|NCT03038334|DIETARY_SUPPLEMENT|Magnesium sulfate|Transdermal application of Magnesium sulfate 250mg every four hours per day for 90 days.
40980845|NCT03437720|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
40980846|NCT03437720|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
40980847|NCT05754515|PROCEDURE|target controlled infusion (TCI) group|"Patients in the TCI group will be anesthetized with propofol and remifentanil throughout the operation.~Patients included in the inhalation anesthesia group will be anesthetized with desflurane and remifentanil with a bispectral index of 40-60 throughout the operation."
41142780|NCT02625025|PROCEDURE|Low pression pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars."
40980848|NCT05390944|DRUG|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
40980849|NCT05390944|DRUG|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
40980850|NCT02987920|DRUG|Dextromethorphan|Additional medication to perioperative analgesic regimen in Group B
40980851|NCT02987920|DRUG|Placebo - Concentrate|Additional medication to perioperative analgesic regimen to Group A
40980852|NCT02987920|DRUG|Acetaminophen|Multimodal analgesic regimen to Group A and Group B
40980853|NCT02987920|DRUG|Oxycodone|Multimodal analgesic regimen to Group A and Group B
40980854|NCT02987920|DRUG|Celecoxib|Multimodal analgesic regimen to Group A and Group B
40980855|NCT02987920|DRUG|Pantoprazole|Multimodal analgesic regimen to Group A and Group B
41461711|NCT02725619|BEHAVIORAL|PST|
41461712|NCT01040273|DRUG|Bupivacaine|
41461713|NCT01040273|DRUG|Placebo|
40776064|NCT02407119|DRUG|Placebo, Omeprazole or Rabeprazole, Clarithromycin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
40776065|NCT00953628|DRUG|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
40776066|NCT00953628|DRUG|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
40776067|NCT03192436|DEVICE|Ultrasound|Low-intensity (Ispta \< 720 mW/cm2, Isppa \< 190 W/cm2) transcranial focused ultrasound
40776068|NCT01421056|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 24 weeks
40776069|NCT01421056|DRUG|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
40776070|NCT01421056|DRUG|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
40776071|NCT04474132|DEVICE|toxoplasma ICT IgG-IgM BK|a point-of-care device, using blood from finger stick to measure the presence or absence of anti Toxoplasma gondii antibody
40776072|NCT00371124|DRUG|Atropine Eye drops|
40776073|NCT01435343|DRUG|fludarabine|30 mg/m2/day intravenously on days 1 to 4
40776074|NCT01435343|DRUG|Idarubicin|10 mg/m2/day intravenously on days 1 to 3
40776075|NCT01435343|DRUG|cytarabine|2 g/m2/day intravenously on days 1 to 4
40776076|NCT01435343|DRUG|G-CSF|5 μg/kg/day subcutaneously from days 1 to 4
40776077|NCT01435343|DRUG|plerixafor|intravenously from days 1 to 4
40776078|NCT00064857|DRUG|Pycnogenol|
40776079|NCT05651828|DRUG|Vismodegib 150 MG Oral Capsule|Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
40776080|NCT00004264|DRUG|amifostine trihydrate|
40776081|NCT00004264|DRUG|cisplatin|
40776082|NCT00004264|DRUG|docetaxel|
40980856|NCT02987920|DRUG|Ketorolac|Multimodal analgesic regimen to Group A and Group B
40980857|NCT02987920|DRUG|Gabapentin|Multimodal analgesic regimen to Group A and Group B
40980858|NCT02987920|DRUG|Hydromorphone|Multimodal analgesic regimen to Group A and Group B
40980859|NCT01952431|DEVICE|Total Lung Capacity (TLC) testing|Comparison of TLC results
40776083|NCT05678140|DEVICE|soft tissue mobilization|soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
40776084|NCT05678140|OTHER|conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area
40980860|NCT05079295|PROCEDURE|CSDH evacuation|Burr hole for chronic subdural hematomas
40980861|NCT02502643|DRUG|OK-432 pleurodesis|1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
40980862|NCT02502643|DRUG|normal saline pleurodesis|Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
40980863|NCT06049745|DRUG|Misoprostol 400 Microgram Oral Tablet|S.L misoprostol 400 mcg
40776085|NCT04606927|OTHER|Natriuresis|Patients with insufficient decongestive response based on natriuresis (in the active arm) will be eligible for treatment adjustments according to the natriuresis guided treatment algorithm.
40980864|NCT03463343|OTHER|Cervical spine manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
41461714|NCT05562648|OTHER|Manual therapy techniques|"Myofascial trigger points are determined and the physiotherapist applies a light and continuous local pressure on them with his/her finger, usually not more than 30 seconds, until the moment of muscle relaxation, and as a result, the pain is expected to decrease to 0 (zero) and he withdraws his finger. He can do 3-5 repetitions until he sees relaxation in the muscle and reduction/disappearance of the pain.~Spinal mobilization is defined as low-speed, non-trust, passive movement within or at the limit of joint range of motion. Mobilization is low-speed, non-trust, passive joint movement.~MUSCLE ENERGY TECHNIQUES The muscle energy technique is a treatment technique that includes alternating periods of resistant muscle contractions and active-assist stretching, mostly used by osteopaths, physiotherapists, and chiropractors."
40776086|NCT00601744|BEHAVIORAL|Audio-Taped Interview|"Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration."
40776087|NCT00601744|BEHAVIORAL|Questionnaire|5-10 minute questionnaire to be completed after the interview.
40776088|NCT00027560|BIOLOGICAL|alemtuzumab|"Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.~Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours."
40980865|NCT03463343|OTHER|Cervical spine mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
40980866|NCT03463343|OTHER|Placebo intervention|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
40980867|NCT01499667|DRUG|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
40980868|NCT01499667|DRUG|Placebo|Matching placebo in capsules for oral administration once daily.
40980869|NCT00326989|PROCEDURE|intracoronary stem cell therapy|extracorporal shock waves prior to intracoronary cell therapy
40980870|NCT03772275|DIAGNOSTIC_TEST|New york Heart Association Class II-IV|"New york Heart Association Class II-IV  study of markers"
40980871|NCT03772275|DIAGNOSTIC_TEST|New york Heart Association Class I|New york Heart Association Class I
40980872|NCT04271891|DEVICE|WBPC|The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks.
40980873|NCT04271891|DEVICE|Without WBPC|Not treat with WBPC
40980874|NCT02577211|DIETARY_SUPPLEMENT|Hipocaloric enteral nutrition|15 kcal/Kg of body weight
40980875|NCT02577211|DIETARY_SUPPLEMENT|Normocaloric enteral nutrition|25 kcal/kg of body weight
40980876|NCT00102102|DRUG|[18F]SPA-RQ|
41142781|NCT02625025|PROCEDURE|Standard Pression Pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars."
41142782|NCT02625025|PROCEDURE|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
41142783|NCT03964272|DEVICE|Exablate Bilateral Subthalamotomy|Exablate bilateral treatment for Parkinson's Disease Motor Features
41142784|NCT00135278|PROCEDURE|CSF Drainage|See Detailed Description
41142785|NCT00135278|PROCEDURE|No CSF Drainage|See Detailed Description
41142786|NCT05860894|DEVICE|Implantable ECG holter device (Biomonitor3, Biotronik)|Subcutaneous implantation of ECG holder device to monitor ECG
41461715|NCT05562648|OTHER|Electrophysical agents|"TENS TENS is a low-frequency electrical current applied to the stimulation of sensory nerves, used for the inhibition of pain sensation. Pain inhibition of TENS is based on 3 basic mechanisms. These; gate control mechanism (segmental inhibition), release of endogenous opioids and reduction of excitability with repetitive stimulation (inhibition from pattern).~Ultrasound is an effective electrotherapy modality with a deep heating feature. In addition, it has been suggested that the analgesic effect of ultrasound occurs with the stimulation of sensory afferents and the activation of the gate control mechanism in the posterior horn of the spinal cord."
41461716|NCT04815460|BEHAVIORAL|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
40980877|NCT00492687|DRUG|carboplatin|
40980878|NCT00492687|DRUG|tamoxifen citrate|
40980879|NCT00492687|DRUG|temozolomide|
40980880|NCT00492687|PROCEDURE|adjuvant therapy|
40980881|NCT00492687|RADIATION|radiation therapy|
40980882|NCT00717340|DRUG|tivozanib (AV-951) + paclitaxel|"Tivozanib (AV-951):~Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.~Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.~Paclitaxel: Phase 1b study and Phase 2a study:~All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks)."
40980883|NCT03927664|OTHER|Radiological assessment|Radiological assessment of findings in the peritoneum, omentum, mesentery, ascites and other abdominal findings
40980884|NCT06409884|DEVICE|T-cell activation test using intracellular markers|A blood sample will be taken which is needed for the T-cell activation test (TAT). The TAT will than be performed by trained laboratory personnel.
41142787|NCT03928743|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
41461717|NCT04815460|BEHAVIORAL|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
41461718|NCT05941611|DEVICE|Powered toothbrush|Oral-B powered toothbrush
41461719|NCT02451644|DEVICE|pedometer|patient will cary pedometer
40776089|NCT00027560|DRUG|cyclosporine|Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.
40776090|NCT00027560|DRUG|fludarabine phosphate|Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.
40776091|NCT00027560|DRUG|melphalan|Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.
40776092|NCT00027560|PROCEDURE|allogeneic bone marrow transplantation|
40776093|NCT00027560|PROCEDURE|peripheral blood stem cell transplantation|
40776094|NCT00619866|DRUG|Elagolix|Elagolix tablets administered orally
40776095|NCT00619866|DRUG|placebo|Placebo tablet administered orally
40776096|NCT01656122|DRUG|abacavir|Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
40980885|NCT04208984|DEVICE|Study|After consent and assent the child and parent will be introduced the Lullabreath in pre-op. The purpose of Lullabreath will be explained and the Lullabreath will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the Lullabreath. The anesthesiologist will hook the device up to the anesthesia circuit and start the Lullabreath. The child will then undergo induction of anesthesia while playing the Lullabreath.
41142788|NCT03928743|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
41142789|NCT00838045|DEVICE|The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL|Surgery to implant the Bausch \& Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
41142790|NCT05871905|DRUG|TY-9591|C14 TY-9591
41142791|NCT00587405|PROCEDURE|cryotherapy|"The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy."
41142792|NCT00587405|PROCEDURE|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
41142793|NCT05245474|COMBINATION_PRODUCT|Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)|Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3
41142794|NCT03214614|DRUG|GLPG2451 multiple dose|GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
41461720|NCT04339634|OTHER|Simulation of Repurposed Drugs for COVID-19|This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.
41461721|NCT03239145|DRUG|Pembrolizumab|Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
41461722|NCT03239145|DRUG|Trebananib|AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
40776097|NCT01656122|DRUG|3TC|Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
40776098|NCT02648360|BEHAVIORAL|Text Messaging|The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
40776099|NCT02567903|DEVICE|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
40776100|NCT02567903|PROCEDURE|Knee arthroscopy|Knee arthroscopy
40776101|NCT05492266|DEVICE|Expiratory Muscle Strength Training|At visit 1, participants will be block randomized based on PWSS score (3-6 or 7+) to Expiratory Muscle Strength Training (EMST) for 6 to 8 weeks or no exercises. Participants in the EMST-150 group will perform 5 sets of 5 resistive expirations once a day with a 10-15 second rest between each repetition and a 1-2 minute rest between each set of 5 repetitions.
40776102|NCT05492266|DEVICE|Maintenance Training|"At visit 2, participants with improved (decreased) PWSS of 2 or more points, for whom the family and/or surgeon is not currently considering surgical intervention for VPI, will be further randomized to continue maintenance EMST exercises or no exercises for 6 months. Participants in the maintenance group will complete 3-5 sessions exercise sessions each week (rather than daily training), with 2 sets of 5 resistive expirations (rather than 5 sets)"
40776103|NCT00002366|DRUG|Ritonavir|
40776104|NCT00474903|DRUG|acetylsalicylic acid|Given orally
40776105|NCT00474903|DRUG|esomeprazole magnesium|Given orally
40776106|NCT00474903|OTHER|placebo|Given orally
41142795|NCT03214614|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
41142796|NCT03214614|DRUG|GLPG2451/GLPG2222 multiple dose|GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
41142797|NCT03214614|DRUG|Combined Placebo multiple dose|Combined Placebo, oral suspension, daily for 14 days
41142798|NCT01600196|PROCEDURE|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
41461723|NCT05121441|DRUG|ARD-101|Twice daily, oral administration
40776107|NCT06495606|DIAGNOSTIC_TEST|Voice sample; Recording with microphone + Questionnaire|Voice sample recording with microphone; afterwards digitalization and comparison between GERD and Non-GERD Group and also between GERD-Group before and after GERD treatment; searching for vocal biomarkers typical for GERD
40776108|NCT04885530|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
40776109|NCT04885530|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
40776110|NCT04885530|DRUG|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
40776111|NCT04885530|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
40776112|NCT04885530|DRUG|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
40776113|NCT04885530|DRUG|Metformin|Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
40776114|NCT03369158|PROCEDURE|patient specific pedicle screw positioning guide|
40776115|NCT03369158|PROCEDURE|Free hand technique pedicle screw positioning|
40776116|NCT03369158|DEVICE|MUST pedicle screw|
40776117|NCT04430998|DRUG|Zinc L-Carnosine|Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily
40776118|NCT04430998|DRUG|Chlorhexidine|Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily
40776119|NCT04430998|OTHER|Water|Rinse mouth with 10 ml of water, retain for 3 minutes, 3 times daily
41461724|NCT05121441|DRUG|Placebo|Twice daily, oral administration
41461725|NCT04409379|DIAGNOSTIC_TEST|Relative telomere length|Relative telomere length in peripheral blood cell
41461726|NCT04994938|OTHER|Diet Intervention|Participants will engage in discussions about healthy eating one time per week led by a trained peer leader for 12-weeks.
41461727|NCT04994938|OTHER|Exercise Intervention|Participants will participate in a group exercise session led by a trained peer leader 2-times per week for 12-weeks.
41461728|NCT05125809|BIOLOGICAL|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
41461729|NCT05125809|OTHER|Placebo|A 5% dextrose/glucose solution administered QM via IV infusion
41461730|NCT00403806|DRUG|dexamethasone|intravenous dexamethasone 0.05 mg per kg bodyweight
40776120|NCT04770207|DRUG|Injection of drug-eluting microspheres with multiple drugs into solid tumors|Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
40776121|NCT00309218|DRUG|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
40776122|NCT05849207|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
40776123|NCT06505226|BEHAVIORAL|in person meditation|in person guided meditation
40776124|NCT06505226|BEHAVIORAL|in person meditation using headphones|in person meditation using headphones
40776125|NCT06505226|BEHAVIORAL|virtual meditation|virtually guided meditation via Zoom
40776126|NCT06294587|PROCEDURE|FGG Before GBR|Free Gingival Graft before the guided bone regeneration,
40776127|NCT06294587|PROCEDURE|FGG after GBR|Free Gingival Graft after the guided bone regeneration,
40776128|NCT01020357|DRUG|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
40776129|NCT01020357|DRUG|placebo|normal saline
40776130|NCT00238394|DRUG|cediranib maleate|Given orally
40776131|NCT00238394|OTHER|laboratory biomarker analysis|Correlative studies
41142799|NCT03738826|BEHAVIORAL|Behavioral Intervention|Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.
41461731|NCT00403806|DRUG|Dexamethasone|Intravenous dexamethasone 0.15 mg per kg bodyweight
41461732|NCT00403806|DRUG|dexamethasone|Intravenous dexamethasone 0.5 mg per kg bodyweight
41461733|NCT00403806|DRUG|Saline|Intravenous saline
41461734|NCT00178724|OTHER|No Treatment Given|Intervention is not given.
41461735|NCT02005939|DIETARY_SUPPLEMENT|Pomegranate extract|All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
41461736|NCT02557217|DRUG|NP202|Active
41461737|NCT02557217|OTHER|Placebo|Placebo
41461738|NCT03845491|DEVICE|Mechanical Thrombectomy|Treatment of LVO with mechanical thrombectomy
40776132|NCT05096130|BEHAVIORAL|Lifestyle Medicine Strategies|"LM addresses health risk factors in primary, secondary, and tertiary prevention of developing disease rather than limiting resources and medical expenditures on acute care and reacting to illness, injury, and disease.~The intervention will target the four pillars of the LM approach including physical activity, diet, stress, and sleep. Certified in LM strategies professionals will consult participants from the LM group in a biweekly base in order to improve their lifestyle habits."
40776133|NCT03728803|DEVICE|Threshold IMT, Philips Respironics, Murrysville, PA, USA|Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
40776134|NCT05478876|RADIATION|carbon ion radiation therapy CIRT|"CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week.~The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable.~Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol."
40776135|NCT04694287|DIAGNOSTIC_TEST|Percutaneous DUS volume flow measurements|Volume flow measurements of the AFV will be obtained using intraprocedural DUS just prior to sheath insertion and at the end of the final balloon dilation, before sheath removal.
40776136|NCT05308810|PROCEDURE|Major Gynecologic- oncologic Surgery|Major Gynecologic-Oncologic surgery between january 2020 - january 2022
40776137|NCT04168502|DRUG|Glasdegib|After randomization patients in both arms will be randomized to maintenance with glasdegib vs clinical observation
40776138|NCT04168502|DRUG|Gemtuzumab Ozogamicin|Both arms, before randomization, will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine
40776139|NCT04803279|DEVICE|Collection of Pure tone thresholds from audiogram measured prior to fitting of Ponto 3 SuperPower|Unmasked and if available masked BC thresholds from audiogram obtained prior to Ponto 3 SuperPower were fitted.
40776140|NCT04803279|DEVICE|Collection of BC In-situ thresholds from BC In-situ audiogram measured during fitting of Ponto 3 SuperPower|BC In-situ thresholds will be collected from the BC In-situ audiogram obtained when Ponto 3 SuperPower were fitted
40776141|NCT04803279|DEVICE|Collection of Aided sound field thresholds measured with the Ponto 3 SuperPower|Sound field thresholds for frequencies 500Hz, 1kHz, 2 kHz, 3kHz and 4kHz will be collected from sound field audiogram obtained as follow-up after Ponto 3 SuperPower fitting, typically this is collected 3 months post fitting, alternatively from the fitting visit. Thresholds will be obtained aided, and when available unaided
40776142|NCT04803279|DEVICE|Collection of speech intelligibility scores|"Speech intelligibility is measured in a sound treated room using sentence tests. The sentence tests used at Norwich and Norfolk hospital is the BKB (Bamford-Kowal-Bench) and/or the The AB\[s\] Isophonemic Monosyllabic Word test (7).~The sentence tests are measured in quiet and/or with background speech-weighted noise."
40776143|NCT04803279|DEVICE|Skin reaction|Classification of skin reactions around skin penetrating implants will be made using the Holgers score. The Holgers classification is a scale from 0 to 4 that is used to grade skin reactions
40776144|NCT04803279|DEVICE|Collection of Glasgow Benefit Inventory|The Glasgow Benefit Inventory (GBI) contains 18 health status questions, which ask specific questions about how the health problem, in this study hearing loss, has affected their quality of life at the time the GBI is completed. In this study GBI has been collected on patients before intervention and 3 months after fitting of Ponto 3 SuperPower on abutment.
40776145|NCT04803279|DEVICE|Collection of power-on usage time with Ponto 3 SuperPower|Average power-on usage hours from Ponto 3 SuperPower will be collected.
40776146|NCT05730842|DRUG|EDG-5506 Tablet|Single Oral Dose - Tablet
40776147|NCT05730842|DRUG|Radiolabeled EDG-5506 Suspension|Single Oral Dose
41461739|NCT02166606|DEVICE|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
40776148|NCT05730842|DRUG|Radiolabeled EDG-5506 Intravenous|Single Intravenous Dose
41142800|NCT06460389|DIAGNOSTIC_TEST|Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
41142801|NCT00789971|DRUG|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
41142802|NCT00789971|DRUG|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
41461740|NCT04913545|DIAGNOSTIC_TEST|using salivary miRNA (412,512)|quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.
41461741|NCT03843125|DRUG|Baricitinib|Administered orally.
41302816|NCT02202096|OTHER|Timely PCP communication|The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
40776149|NCT03241056|BEHAVIORAL|CBT for Maladaptive Beliefs about Memory|The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
40776150|NCT03241056|OTHER|Treatment as Usual|Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
41302817|NCT02202096|OTHER|Follow-up telephone call|Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.
40776151|NCT05115266|BEHAVIORAL|Animal-assisted therapy (AAT|The activity program consists of 10 sessions with a duration of about 60 minutes. During the 10 sessions the animal is presented, in this case a dog. They caress it, dress it, educate it ...
41302818|NCT02202096|OTHER|Patient hotline: 24 hour follow-up following call to Ask My Nurse number|Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
40776152|NCT05115266|BEHAVIORAL|Usual treatment|receive usual treatment (group activities)
40776153|NCT00128999|PROCEDURE|Intensity-Modulated Radiation Therapy|
41302819|NCT06086639|OTHER|Online Occupational Therapy Group Training|In this study, a 4-week online occupational therapy group training was conducted by an occupational therapist specialized in the field of nutrition. The content of the training, which takes place one hour a week, is given below; Session-1 Defining the problem Understanding the causes Oral motor structures and anomalies Discussion Session-2 Feedback sharing The relationship between feeding and sensory integration Recognizing the symptoms of sensory integration Disorders Strategies for sensory integration disorders Discussion Session-3 Feedback sharing Parent behaviors and attitudes Behavioral strategies for feeding problems Discussion Session-4 Feedback sharing Self-compassion and self-regulation Cope with stress Discussion Review of outputs
41302820|NCT05579093|COMBINATION_PRODUCT|Cognitive test + Pupillary measure|"Patients will be put into a quiet room with a computer and a webcam for a five minute assessment with the NeuroTrack™ testing. Study personnel will stay in the room, and be available for answering questions about using the online testing tool.~After Neurotrack, pupillary responses will be recorded with the pupillometer with the PLR -3000TM. In brief, an eye cup attached to a pupillometer will be placed over one eye to allow measurement of the pupillary response to light. Once the eye cup is properly positioned, the reading takes approximately 5 seconds, after which time the eye cup will be removed. The reading will then be taken in the contralateral eye."
41302821|NCT01073345|PROCEDURE|Portal venous pressure|Portal venous pressure is measured by invasive means using an arterial canula
41302822|NCT01073345|PROCEDURE|Portal venous flow|Portal venous flow is measures using a noninvasive method (Doppler flow meter)
41302823|NCT01073345|PROCEDURE|Hepatic artery flow|Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)
40776154|NCT03318094|DRUG|Phentolamine|Intrabrachial phentolamine will be given on the blocked day
40776155|NCT03318094|OTHER|Saline|Intrabrachial saline will be given this day
40776156|NCT03318094|DRUG|Sodium Nitroprusside|Intrabrachial sodium nitroprusside will be given this day to compare with phentolamine
40776157|NCT01073293|BIOLOGICAL|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
40776158|NCT01073293|BIOLOGICAL|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
40776159|NCT01073293|BIOLOGICAL|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
41142803|NCT01297088|DRUG|BAY86-9596|One single dose administration of a diagnostic agent
41142804|NCT05905068|DRUG|RN0191 INJECTION|a sterile solution in each bottle for subcutaneous (SC) injection
41142805|NCT05832970|OTHER|Brief skin cooling|Brief skin cooling will be applied to the hand using the cold-bath immersion
41142806|NCT05169580|DRUG|FTX-6058 oral capsule(s)|Participants will receive FTX-6058
41302824|NCT03136081|DIAGNOSTIC_TEST|Candidiasis infection occurence|Candidiasis infection occurence
41302825|NCT00248313|DRUG|Rapamune®|
41302826|NCT02711761|DEVICE|central venous catheterization|"15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm."
41302827|NCT04426786|OTHER|Active exercise|Thrice-weekly supervised intense aerobic exercise classes on cycle ergometers, in groups, for six months. Percentage of VO2 max will be used to regulate exercise intensity, based on an initial aerobic exercise test.
40776160|NCT05788094|DRUG|Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)|"* Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
41142807|NCT00209885|DRUG|Gabapentin|
41142808|NCT00209885|DRUG|S-ketamine|
41142809|NCT00209885|DRUG|Lidocaine|
41142810|NCT00209885|DRUG|Droperidol|
40776161|NCT05788094|DRUG|Chloroquine plus Tafenoquine (450 mg adult dose)|"* Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
40776162|NCT05788094|DRUG|Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)|"* Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.)~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
40776163|NCT02367456|DRUG|PF-04449913 (Glasdegib)|Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
40776164|NCT02367456|DRUG|Azacitidine|75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
40776165|NCT04998513|DRUG|Medical Management Alone Arm|"The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group."
40776166|NCT04998513|PROCEDURE|Surgical Arm|"Surgical intervention consists of attempted incision and drainage of the abscess. Specific procedure steps and details are at the discretion of the treating surgeon. In general, incision and drainage consists of topical and submucosal local anesthetic followed by a mucosal incision along the palatoglossal arch and soft palate junction, and blunt dissection of the abscess cavity to evacuate pus. Some surgeons may first perform a needle aspiration. For purposes of the trial, positive aspiration of pus on needle aspiration must be followed by attempted incision and drainage. Failed needle aspiration or surgical drainage will be considered as a failed attempt at surgical intervention.~Patients randomized to receive surgical intervention will also receive medications as per the medical management arm."
40776167|NCT03956160|OTHER|A co-design phase aims to ensure the feasibility and relevance of the proposed intervention and evaluation.|"4 participatory co-design workshops lasting 4 hours each that will follow a user-centered design approach: identification of end-user needs, prototyping/development of the intervention (case-management procedures and platform), iterative improvement, end-user testing.~Based on the cognitive social theory underpinning the intervention, scientific literature, an overview of existing organizations and the results of the Stroke 69 and Arthur Tybra studies (patient needs following the acute phase), the advisory committee will:~* Define the case-manager's profile, and required knowledge and skills~* Identify the resources and tools to be proposed on the Internet platform~* Test the tools and content~* Refine the program evaluation criteria~* Test and validate the study procedures."
40776168|NCT01752049|DRUG|Topical timolol maleate|"* Topical timolol maleate 0.5% drops~* Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~* Study drops will be applied to 3 cutaneous telangiectasias per patient"
41142811|NCT03602053|BIOLOGICAL|ROTAVAC®|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
41142812|NCT03602053|BIOLOGICAL|ROTAVAC 5D|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
41142813|NCT03602053|BIOLOGICAL|Rotarix®|1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
41142814|NCT05285592|OTHER|Fecal Transplantation|Fecal Transplantation
41142815|NCT05285592|DRUG|Standard Medical Treatment|Standard Medical Treatment
41302828|NCT04426786|OTHER|Passive exercise|Thrice-weekly supervised passive exercise classes consisting of stretching and/or yoga, in groups, for six months.
41302829|NCT02539082|DEVICE|Regenseal|Regenseal, collagen, injection in the defect area
41302830|NCT02539082|DRUG|normal saline|placebo, normal saline, injection in the defect area
41461742|NCT03843125|DRUG|Placebo|Administered orally.
41461743|NCT03370510|DRUG|Oxytocin|Oxytocin nasal spray.
40776169|NCT01752049|DRUG|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.
41461744|NCT03370510|BEHAVIORAL|Pivotal Response Treatment|An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.
41461745|NCT03370510|DRUG|Placebo|Placebo nasal spray.
40776170|NCT04605250|OTHER|Respiratory variability before and after surgery|The procedure consist of measuring thoracic chest movement and then calculating the respiratory variability reflected by the coefficient of variation in patients undergoing a surgery. A first recording is done during preoxygenation period using as baseline for further comparisons. (T0, 10 min) The second recording is after extubation during the postoperative recovering period, 30 minutes after interruption of sedations. (T1, 20 min, SSPI ou SIPO) The third recording is before transferring back to classical hospitalization, 1h after T1 (20 min). A fourth recording will be realized 24h after surgery for patients hospitalized in the post operative intensive care unit (T3, 20 min) Optional recordings may be realized if the patient is developing a postoperative respiratory complication during his hospital stay. A follow up for maximum 7 days consisting in consulting the medical file will be realized.
40776171|NCT04781582|PROCEDURE|Lung volume reduction surgery|Surgical lung volume reduction
40776172|NCT04781582|PROCEDURE|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction by endobronchial valves
40776173|NCT02248571|DRUG|Bevacizumab|administered as combined therapy with Capecitabine
41302831|NCT05072548|BEHAVIORAL|The ABCs of SLEEPING|"The intervention is comprised of three components. The first is a sleep check-in which is a questionnaire that is evidence based and evaluates what areas of sleep parents can work on. The second component is the sleep report which summarizes to the parent what areas they're doing well in (i.e., within the ABCs of SLEEPING mnemonic described above) and what areas they can improve on. The third component of this intervention are the sleep tips which are sleep recommendations that are customized based on the identified areas of sleep the parents are suggested to work on."
41302832|NCT02763878|PROCEDURE|Uncut Roux-en-Y anastomosis|Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.
40776174|NCT02248571|DRUG|Capecitabine|administered as combined therapy with Bevacizumab
40776175|NCT02248571|DRUG|Everolimus|administered as combined therapy with Exemestane
41461746|NCT04139941|DIAGNOSTIC_TEST|Test for HCV antibodies with an RDT|Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
40776176|NCT02248571|DRUG|Exemestane|administered as combined therapy with Everolimus
40776177|NCT02248571|OTHER|Patient questionaires|Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
41461747|NCT03302949|DIETARY_SUPPLEMENT|Lacprodan® DI-8090|Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
41461748|NCT03315533|DRUG|Duloxetine 30 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
41461749|NCT03315533|DRUG|Duloxetine 60 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
41461750|NCT03315533|DRUG|Placebo Oral Tablet|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
40776178|NCT05210816|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
40776179|NCT04305210|DRUG|F-18 PMPBB3|In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
41461751|NCT01652638|DRUG|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
41461752|NCT04390230|PROCEDURE|Penile prostheses implantation|Penial implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France
40776180|NCT04305210|DRUG|18F-florbetapir|18F-florbetapir
40776181|NCT01901692|RADIATION|TACE+External beam RT|Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE
40776182|NCT01901692|DRUG|Sorafenib|Sorafenib 800 mg/day orally
40776183|NCT06387862|DRUG|Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Inhaled|Each patient will receive 12µg/kg of levosimendan by inhalation over 10 min. During 10h following inhaled dose, plasma concentrations will be measured.
40776184|NCT06387862|DRUG|Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Intravenous|Each patient will receive 12µg/kg of levosimendan by intravenous (IV) administration over 10 min and at the same timepoints plasma samples will be measured
40776185|NCT00024934|DRUG|B-Lymphocyte Stimulator (BLyS)|
40776186|NCT04116255|OTHER|Mandibular oral occlusal splint|The panoramic open-mouth and close-mouth radiographs of the first group(splint group) were taken, and intraoral and extraoral examinations were performed by an experienced dentist that also examined the radiographs. The upper jaw of the patients was measured with an alginate impression material, to obtain a hard plaster model. Then, using these models, a vacuum plate machine made a customized mandibular oral occlusal splint suitable for each patient's teeth. The suitability of the splints was checked and confirmed by the dentist on the first and seventh days of use. The patients were asked to use these splints at night (for at least six hours) throughout the study.
40980886|NCT04208984|OTHER|Music Video|After consent and assent the child and parent will be introduced to the game in pre-op. The purpose of the game will be explained and the game will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the game. The anesthesiologist will hook the device up to the anesthesia circuit and start the game. The child will then undergo induction of anesthesia while playing the game. The child can choose to watch one of two music videos (Frozen, Lion King)
41302833|NCT02763878|PROCEDURE|Billroth II anastomosis|Typical Billroth II anastomosis would be made after the Distal gastrectomy.
41302834|NCT03948659|PROCEDURE|Arterio ventricular coupling|We analyse ventriculo arterial coupling (VAC) among cirrhotic patients admitted in intensive care unit, with non-invasive echography method
41302835|NCT00028366|DRUG|Fosamprenavir|
41302836|NCT00028366|DRUG|Lopinavir/Ritonavir|
41302837|NCT00028366|DRUG|Ritonavir|
41302838|NCT00028366|DRUG|Tenofovir disoproxil fumarate|
41302839|NCT00161980|DRUG|Fibrin Sealant VH S/D|
41302840|NCT00161980|PROCEDURE|Surgical intervention alone without Fibrin Sealant VH S/D application|
41302841|NCT00045682|DRUG|Paclitaxel Poliglumex|Given IV
41302842|NCT00332514|BEHAVIORAL|telephone call by a pharmacist|
41302843|NCT00965705|BEHAVIORAL|Therapy|Individual Therapy and Group Therapy
41302844|NCT02564159|OTHER|Measure of quadriceps thickness with ultrasonography and albumin/prealbumin levels|"* Evaluation of quadriceps diameter on the anterior aspect of the thigh using the mid-distance between the anterior superior iliac spine and the upper pole of the patella ;~* Biospecimen collection: Blood samples (prealbumin levels, C-reactive protein, Interleukin-1, Interleukin-6, TNF-alpha and PATROL test™)collection of albumin and prealbumin levels"
41302845|NCT02399839|DRUG|lomitapide|As prescribed by Physician.
41302846|NCT04415489|DEVICE|Office hysteroscopy|Use of hysteroscopy in the clinical setting to directly visualize the cavity. If pathology amenable to immediate treatment is visualize, removal will be attempted by hysteroscopic graspers.
41302847|NCT01280890|BEHAVIORAL|Staff training using VIPS|Staff training using the VIPS framework
41302848|NCT01280890|BEHAVIORAL|Staff training using DCM|The staff will be supervised using Dementia Care Mapping
41302849|NCT01280890|BEHAVIORAL|Control group|Filmed traditional Lectures will be given to care staff
41302850|NCT05130164|RADIATION|CBCT|Cone beam computed tomographic images selected for age estimation
41302851|NCT03517683|OTHER|Low speed|Speed of intrathecal injection will be 1ml in 15 seconds
41302852|NCT03517683|OTHER|High speed|speed of intrathecal injection will be 1ml in 5 seconds
41302853|NCT03062319|DRUG|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban
41302854|NCT03062319|DRUG|Antiplatelet Drug|aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol
40980887|NCT01907880|DRUG|Pamidronate|90mg IV once every 4 weeks for 3 cycles
40980888|NCT01907880|DRUG|Zoledronic acid|4mg IV every 4 weeks for 3 cycles
41461753|NCT06464874|PROCEDURE|Conventional ESD|Conventional ESD is the most suitable method for total resection, especially for large lesions. This method can complete the resection of early gastrointestinal cancer and precancerous lesions, while maintaining the integrity of digestive tract anatomy and physiological function.The operation difficulty of this technique is high, the equipment requirements are high, the operation time is long, and the complication rate is closely related to the technical level of the operator.
40980889|NCT01907880|DRUG|placebo|
40980890|NCT02573727|DRUG|Nor adrenaline + albumin|
41461754|NCT06464874|PROCEDURE|Hybrid ESD|Hybrid ESD is a better choice, but only can remove the lesion in one piece, but also has a lower technical difficulty than conventional ESD
41461755|NCT00163969|DRUG|ketamine|
40980891|NCT02573727|DRUG|Terlipressin + albumin|
40980892|NCT05007964|DEVICE|Spatz4 Adjustable Balloon System|The Spatz4 Adjustable Balloon System is designed to assist weight loss by partially filling the stomach and inducing satiety. The intragastrical balloon is implanted endoscopically for up to 12 months.
41461756|NCT04789330|DRUG|Norepinephrine|Norepinephrine administered during anesthesia
41461757|NCT04789330|DRUG|Phenylephrine|Phenylephrine administered during anesthesia
41461758|NCT00344643|DEVICE|Silicone Hydrogel Soft Contact Lenses|
41461759|NCT02386761|DRUG|Single Ascending Dose (SAD)|
40980893|NCT02480842|OTHER|Alloplastic free ROM|
41461760|NCT02386761|DRUG|Multiple Ascending Dose (MAD)|
41461761|NCT04802564|OTHER|regular hand therapy|edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols
41461762|NCT00614276|BEHAVIORAL|Focus Group|To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.
41461763|NCT00614276|BEHAVIORAL|TENDRILS|Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.
41461764|NCT00614276|BEHAVIORAL|Questionnaires|The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.
40980894|NCT02480842|OTHER|Alloplastic limited ROM|
40980895|NCT02480842|OTHER|Oncoplastic free ROM|
40980896|NCT02480842|OTHER|Oncoplastic limited ROM|
40980897|NCT04007094|OTHER|ViviGen Cellular Bone Matrix|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10
40980898|NCT00168727|DRUG|ibritumomab tiuxetan (Zevalin®)|
40980899|NCT03256214|PROCEDURE|Closed suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.
40980900|NCT03256214|PROCEDURE|Open suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
40980901|NCT05725720|OTHER|Gut microbiome analysis|Characterization of the compositional and functional modifications of gut microbiome in patients affected by lymphoma undergoing therapy with CAR-T cells from baseline until the restaging after 18 months from the CAR-T cell infusion
40980902|NCT04462003|DRUG|Apixaban|10 mg/12 h for 1 week followed by 5 mg/12 h
40980903|NCT04462003|DRUG|Enoxaparin|1mg/Kg/sc/12h
40980904|NCT00728130|PROCEDURE|neck dissection of at least the ipsilateral sub-level 1B|neck dissection of at least the ipsilateral sub-level 1B
40980905|NCT00785395|DRUG|Oxytocin infusion|Up-down dosing determination
40980906|NCT01329731|DRUG|elmex® gelée|1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
40980907|NCT01329731|DRUG|negative control (placebo)|0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical
41461765|NCT00614276|BEHAVIORAL|Sexual Counseling Sessions|Attend 3 sexual counseling sessions at M. D. Anderson.
41461766|NCT02005562|DRUG|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (\*) height (h)/ liter(L).
41461767|NCT02005562|DRUG|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
41461768|NCT02005562|DRUG|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
41461769|NCT02005562|DRUG|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
41461770|NCT02005562|DRUG|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
41461771|NCT05063591|OTHER|Transfusion support|Patients will be offered symptom-driven transfusion support in addition to standard hospice care
41461772|NCT05198635|DEVICE|local cerebral oxygen saturation|minimum SctO2, SctO2 drop/rise defined by different thresholds, and area under/above the threshold
41302855|NCT02669797|BEHAVIORAL|In-home Visits and Food Preparation Activities|"Families will participate in eight in-home education activities. The visits will focus on family meal quality (dietary, interpersonal) and quantity (meal frequency) factors found in prior studies to be associated with child weight and weight-related behaviors. Eight of the visits (every other week) will be delivered by a CHW and will last 90 minutes. Additionally ,a family meal food preparation activity will occur to help support families in learning skills to increase family meal quality and quantity. On weeks opposite of the in-home education visits with a CHW, families will be given a Try it Yourself activity to reinforce the messages (e.g., use family meals as a family connection time) and skills (e.g., recipe that requires families to steam vegetables) taught by the CHW during the in-home education visits."
41461773|NCT05909241|DRUG|BA1202|"BA1202 will be administered intravenously (IV) once every 3 weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the duration of administration was no more than 2 years.~Part A: Patients will receive one of the following dosages of BA1202: 0.016mg, 0.08mg, 0.4mg, 1.6mg, 6.4mg, 19mg, 38mg, 56mg.~Part B: Based on the data of part A, one or two dose levels will be discussed for further evaluation in part B."
41302856|NCT02669797|BEHAVIORAL|Ecological Momentary Intervention|Parents will receive daily EMI messages regarding suggestions for increasing meal quality/quantity via a smartphone application, based on the stress level and source of stress they reported earlier in the day. Specifically, parents will receive two push notifications in the morning to report their stress level and type/source of stress (e.g., work, children, finances). Then, based on the reported stress level and source of stress, parents will be texted tips/ideas for carrying out a nutritionally and emotionally healthful family meal the same night, in the face of stress. If parents report no stress on their EMI measure earlier in the day, they will be provided with a menu of options regarding what type of meal tip they would prefer later in the day (e.g., recipe ideas, meal prep tips, mealtime conversation starters. Parents will be able to respond to the EMI messages indicating preferred tips so that EMI tips become more meaningful/relevant to the needs of each family.
41461774|NCT02874950|OTHER|office exercise training|The exercise group, did 6 months office exercise training.
41461775|NCT02874950|OTHER|ergonomic modification|The ergonomic modification group, followed 6 months modified office ergonomic modification.
41461776|NCT02874950|OTHER|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.
41461777|NCT02874950|OTHER|Control|Control group did not do any exercise and did not follow any ergonomic modification.
41461778|NCT03092167|OTHER|Physical exercises|Physical exercises
41461779|NCT04682587|DRUG|Axitinib|Inlyta, axitinib
41461780|NCT04682587|DRUG|Avelumab|Avelumab, Bavencio
41461781|NCT04682587|DRUG|Pembrolizumab|Pembrolizumab, Keytruda
41461782|NCT04499482|OTHER|Food|Soy-fiber containing food
41461783|NCT00635336|BIOLOGICAL|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
41461784|NCT00912522|DEVICE|TMS|TRANSCRANIAL MAGNETIC STIMULATION
40776187|NCT04116255|OTHER|Temporomandibular joint Exercises|This program was created by combining patient training and a home exercise program. The exercise program consisted of slow passive and active mouth opening and closing exercises, isometric masseter exercises, mouth stretching exercises, and resistant mouth opening and closing exercises. Each exercise set was administered twice a day, and each movement was undertaken for 10 seconds and repeated 15 times. The training was given by an experienced physical medicine and rehabilitation expert over approximately 45 minutes. The exercise program was demonstrated for the patients in front of a mirror, and each exercise was performed by a set of patients under the supervision of a doctor. A training document including the written exercise program was to the patients in the exercises group.
40776188|NCT02023437|DEVICE|Femtosecond laser cataract surgery|The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
40776189|NCT02023437|DEVICE|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
40776190|NCT05873088|DIAGNOSTIC_TEST|Isometric|Effects of Isometric Exercise in Female Patients With Osteoarthritis
40776191|NCT05873088|DIAGNOSTIC_TEST|Isotonic Exercise|Effects of Isotonic Exercise in Female Patients With Osteoarthritis
40776192|NCT06551649|OTHER|Venous blood draw and skin biopsy|The skin tissue will be used to isolate fibroblasts, which will then be reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs will be differentiated to develop patient-specific and control organoids. The blood samples will be used to isolate peripheral blood mononuclear cells (PBMC) to study the contribution of inflammation in the in vitro models developed.
40776193|NCT04961593|DRUG|Caspofungin|For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.
40776194|NCT01605994|DRUG|BMS-933043|
40776195|NCT01605994|DRUG|Placebo matching with BMS-933043|
40776196|NCT01605994|DRUG|Antacid Buffer Predose Solution|
40776197|NCT04440774|BIOLOGICAL|CHIK low dose|A single dose of 5x10\^9 vp ChAdOx1 Chik
40776198|NCT04440774|BIOLOGICAL|CHIK mid dose|A single dose of 2.5x10\^10 vp ChAdOx1 Chik
40776199|NCT04440774|BIOLOGICAL|CHIK high dose|A single dose of 5x10\^10 vp ChAdOx1 Chik
40776200|NCT04440774|BIOLOGICAL|ZIKA low dose|A single dose of 5x10\^9 vp ChAdOx1 Zika
40776201|NCT04440774|BIOLOGICAL|ZIKA mid dose|A single dose of 2.5x10\^10 vp ChAdOx1 Zika
40776202|NCT04440774|BIOLOGICAL|ZIKA high dose|A single dose of 5x10\^10 vp ChAdOx1 Zika
40776203|NCT04440774|BIOLOGICAL|Saline placebo|A single dose of isotonic saline solution (0.9%)
40776204|NCT02716441|DEVICE|Radio-opaque Tissue Markers|All participants will undergo implantation of radio-opaque tissue markers on their repaired rotator cuff at the time of surgery.
41461785|NCT02883439|DRUG|MP29-02|local nasal application
41461786|NCT02883439|DRUG|Fluticasone propionate|local nasal application
40776205|NCT06034340|DEVICE|LET Gel after STAR Particle Application (Right or Left Arm)|STAR particles are made of titanium dioxide, a widely used and safe ceramic material found in sunscreens, cosmetics, and paint. The particles vary in concentration and length in order to find the optimal concentration and length. Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying a STAR particle preparation to the volar surface of the antecubital fossa.
41461787|NCT02874196|PROCEDURE|Standard arthrography|
40776206|NCT06034340|OTHER|LET Gel Application without STAR Particle Application (Contralateral Arm)|Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying aloe gel (control condition) to the volar surface of the antecubital fossa of the contralateral arm to the one receiving the STAR particle preparation.
40776207|NCT02960737|DEVICE|Oral neuromuscular training using an oral device|The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
40776208|NCT01389687|BIOLOGICAL|Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
40980908|NCT00278655|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
41302857|NCT02669797|BEHAVIORAL|Feedback on Video-recorded Family Meals|Parents will video-record and upload via their cellphone one family meal every other week, which will be watched by intervention staff. Using Motivational Interviewing, CHWs will give specific feedback on how to adapt negative mealtime behaviors and provide reinforcement for positive behaviors seen in the videos, based on a validated interpersonal coding tool called the Iowa Family Interaction Rating Scales (IFIRS). Additionally, feedback will be given on the dietary healthfulness of the meal, based on a validated coding tool called the Healthfulness of Meal Index (HOM). After feedback, family members will be taught specific skills to improve their family meal processes and behaviors that vary from food preparation skills, to increasing healthful food options at meals, or role-playing family interactions to improve the emotional atmosphere at the meal. Families will also set SMART goals at each visit regarding family meal quality and quantity.
40776209|NCT00220090|DRUG|dexloxiglumide|
40776210|NCT04056247|OTHER|Plasma sample collection|Collect at least two plasma samples
40776211|NCT06565299|PROCEDURE|Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery about congenital heart defects with cardiopulmonary bypass
40980909|NCT04123054|DEVICE|Mobile App|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator.
41142816|NCT04543188|DRUG|PF-07284890|PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
40776212|NCT05155982|BIOLOGICAL|COVAC-1|Intramuscular vaccine against SARS-CoV-2
41461788|NCT02874196|PROCEDURE|Dual energy arthrography|
40776213|NCT05155982|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
41461789|NCT02874196|PROCEDURE|Arthro-tomosynthesis|
40776214|NCT03643081|DEVICE|"Use of the camera Fluobeam"|"Use of the camera Fluobeam to localize, visualize the parathyroid glands during a parathyroidectomy."
40980910|NCT04123054|DEVICE|Mobile App + Basal-Bolus Optimization Algorithm|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator. In addition, participants will receive weekly app notifications with personalized recommendations for insulin parameter adjustments made by the optimization algorithm.
40980911|NCT03043027|DRUG|liposomal bupivicaine|local anesthetic
40980912|NCT03043027|DRUG|Bupivacaine|local anesthetic
41142817|NCT04543188|DRUG|Binimetinib|Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
41461790|NCT02874196|PROCEDURE|Arthro-tomography|
41461791|NCT02874196|PROCEDURE|Surgery on painful prosthesis|Possibly performed during 6 months from arthrography
41461792|NCT03449225|OTHER|Computer-Aided Genetic Education Module|Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.
40776215|NCT00710099|DRUG|sildenafil|systemic absorption of sildenafil
40776216|NCT00710099|DRUG|nitroprussiate iontophoresis|nitroprussiate iontophoresis
40776217|NCT06173869|DRUG|FE 999049|FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.
40776218|NCT06173869|DRUG|GONAL-F|"GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days.~Coasting was not allowed."
40776219|NCT04426474|DRUG|LY3502970|Administered orally.
40776220|NCT04426474|DRUG|Placebo|Administered orally.
40776221|NCT04098588|BEHAVIORAL|BEAST|See Arm Description
40980913|NCT03043027|DRUG|Saline Solution|saline injection
40980914|NCT00860964|DRUG|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
41142818|NCT04543188|DRUG|Midazolam|Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15
41142819|NCT00891709|DRUG|LEO 29102|First-in-man. Healthy volunteers
41142820|NCT06432023|DIAGNOSTIC_TEST|Magnetic resonance imaging|Diagnostic and research scanning using magnetic resonance imaging.
41142821|NCT00004807|DRUG|dextromethorphan|
41142822|NCT00004807|DRUG|topiramate|
41142823|NCT00004807|DRUG|Donepezil|
41142824|NCT06560411|DEVICE|Non-Invasive Ventilation|Provide continuous or intermittent ventilatory support for the care of individuals who require mechanical ventilation
41461793|NCT04581122|PROCEDURE|Lymphadenectomy|Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group
41461794|NCT04282694|DIAGNOSTIC_TEST|Low-dose computed tomography (LDCT)|Early detection of lung cancer by LDCT and smoking cessation counselling
41461795|NCT04436419|DIETARY_SUPPLEMENT|Alpha lipoic acid (plus full hospitalization)|"Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:~Inclusion criteria: BMI\> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1\*04-03/06 polymorphisms; recent hospitalization (\<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.~Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.~Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals."
41461796|NCT04436419|DIETARY_SUPPLEMENT|Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)|Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.
41461797|NCT03168906|DRUG|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
41461798|NCT03168906|DRUG|Placebo|Saline bag
41461799|NCT01966809|DRUG|Photofrin photodynamic therapy.|"The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery."
41461800|NCT03482206|DEVICE|Automated extracranial internal carotid artery ultrasound sensor|The investigators' goal is to develop a wearable noninvasive, continuous, automated ultrasound sensor to accurately measure arterial blood flow volume outside of the head. Ultrasound uses sound waves to create a picture. In doing so, the investigators hope to detect CBF compromise early, preventing secondary injuries in TBI patients.
41461801|NCT01763255|BIOLOGICAL|stem cell intrathecal injection|Intrathecal injection of Bone marrow derived CD133 cells
40980915|NCT00860964|DRUG|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
40980916|NCT00740701|DEVICE|Cerebellar transcranial magnetic stimulation|single pulse TMS or repetitive TMS at 1 Hz frequency
41461802|NCT02004067|DRUG|Restasis|Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
40980917|NCT00938379|DRUG|20% deet insect repellent|skin-applied repellent lotion
41142825|NCT06318572|BEHAVIORAL|Psychological intervention|"Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will begin the program of psychological intervention. A first, session of psychoeducation will be performed, and thereafter sessions of psychotherapy will be performed at home during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days. A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months."
41302858|NCT02669797|BEHAVIORAL|Maintenance|After 16 weeks, EMI family meal tips for all arms will be reduced to only the days in which parent's report their highest stress levels. Stress profiles will be created for each parent in order to tailor the EMI family meals tips to days in which they experience their highest levels of stress. For example, during the 16-weeks of EMI, a parent may report their highest stress levels on Tuesdays and Thursdays. The stress profile that would be created for the parent during the maintenance phase would include receiving text messages only on Tuesdays and Thursdays. The parent would then receive these EMI family meal tips only on Tuesdays and Thursdays throughout the 8-week maintenance phase..
41461803|NCT02004067|DRUG|Refresh Endura|Refresh Endura is a topical lubricant produced by Allergan, Inc.
41461804|NCT01963455|BIOLOGICAL|paraurethral injection of MDCs|MDCs transplantation by paraurethral injection .
41461805|NCT03786354|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3DCRT
41461806|NCT03786354|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40980918|NCT00938379|DRUG|placebo control|Identical base formulation of lotion but without any deet active
40980919|NCT01488539|BEHAVIORAL|STAIR/NT treatment|STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.
40980920|NCT01488539|BEHAVIORAL|Treatment as Usual (TAU)|The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.
40980921|NCT03629067|DRUG|Treatment T|Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
40776222|NCT04098588|BEHAVIORAL|Descriptive Feedback|See Arm Description
40776223|NCT00000621|DRUG|all trans retinoic acid|
40776224|NCT00000621|DRUG|13 cis retinoic acid|
40776225|NCT00000621|DRUG|placebo|
40776226|NCT03766672|DIAGNOSTIC_TEST|Intervention Arm|The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
40776227|NCT04708847|DRUG|GYM329|GYM329 subcutaneous injection
40776228|NCT04708847|DRUG|Placebo|Placebo subcutaneous injection
40776229|NCT02115529|DRUG|Nabilone|Nabilone (0.5 mg) or placebo given preoperatively
40776230|NCT02115529|DRUG|Placebo|Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
40980922|NCT03629067|DRUG|Treatment R|Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
40776231|NCT01987414|BEHAVIORAL|occupational therapy task-oriented approach|It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.
40776232|NCT01987414|DEVICE|Forearm rotation orthosis|The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
40776233|NCT01987414|OTHER|No treatment|Participants will maintain their daily routines during the no treatment period.
40776234|NCT01960491|DEVICE|Device Closure of Atrial Septal Defect|"Device Closure of Atrial Septal Defect by Carag Bioresorbable Septal Occluder"
40776235|NCT03961126|DRUG|Injection of autologous fatty tissue associated with autologous platelet-rich plasma.|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
40776236|NCT03961126|DRUG|Corticosteroids (clobetasol 0.05%)|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
40776237|NCT00006021|DIETARY_SUPPLEMENT|ascorbic acid|
40980923|NCT05951504|DRUG|Methylprednisolone|Patients with an odontogenic cervicofacial infection were randomized between two intervention groups. Patients in one group were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Patients with an odontogenic cervicofacial infection in the other group were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
40980924|NCT01344161|DIETARY_SUPPLEMENT|Placebo|dosage form:lactose dosage: 25 micrograms frequency: every day duration: 12weeks
40980925|NCT01344161|DIETARY_SUPPLEMENT|vitamin D|dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
40980926|NCT02600949|DRUG|Imiquimod|Applied topically
40980927|NCT02600949|BIOLOGICAL|Pembrolizumab|Given IV
40980928|NCT02600949|BIOLOGICAL|Sotigalimab|Given IV
40980929|NCT02600949|BIOLOGICAL|Synthetic Tumor-Associated Peptide Vaccine Therapy|Given SC
40980930|NCT02600949|PROCEDURE|Computed Tomography|Undergo CT
40980931|NCT02600949|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40776238|NCT00006021|DRUG|arsenic trioxide|
40776239|NCT03326908|DEVICE|Spectral Domain Optical Coherence Tomography|Five SD-OCTs will be performed with various conditions of enlightenment.
40776240|NCT04310449|PROCEDURE|Connective tissue graft and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Connective tissue grafts from the hard palate will be placed at the implant sites in a supraperiosteal partial dissection prepared at the buccal aspect. Sutures will be used to stabilize the graft, followed by customized healing abutment. Flowable composite will be injected at the gingival margin level to adapt to the sandblasted abutment, taking the shape of the socket at the marginal gingiva. Buccal groove will be made after the polymerization of this material for easier application. The abutments will be removed for final configurations of the apical part mimicking the emergence profile of the extracted tooth and finishing with laboratory discs and burs. The custom healing screw will be screwed to the implant.
40776241|NCT04310449|PROCEDURE|Dual zone concept and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Followed by bone grafting following dual zone concept and customized healing abutment.
40776242|NCT03274778|DRUG|Ruxolitinib 20 MG|tablets
40776243|NCT02060981|BEHAVIORAL|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey.
40776244|NCT02060981|BEHAVIORAL|Interview Only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
40776245|NCT02060981|BEHAVIORAL|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension and to provide feedback regarding a new decision support tool for helping patients learn more about their medications.
40776246|NCT05450562|BIOLOGICAL|SAR444200|Sterile lyophilized powder for solution for infusion Route of administration: intravenous (IV) infusion
40776247|NCT05450562|BIOLOGICAL|Atezolizumab|concentrate for solution for infusion Route of administration: intravenous (IV) infusion
40776248|NCT03703557|DIAGNOSTIC_TEST|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.
40776249|NCT03703557|DIAGNOSTIC_TEST|Odour sampling|Analyzed by the dogs of Curie Institute at the training centers
40776250|NCT04772794|OTHER|fraction of inspired oxygen|after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
40980932|NCT04971473|BIOLOGICAL|rhTSH|Scanning was done 48 hours after the radioiodine administration. Each patient was scanned first following rhTSH and then scanned after thyroid hormone withdrawal.
40776251|NCT01636284|BIOLOGICAL|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
40776252|NCT00794430|DRUG|V3381|100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks
41461807|NCT03256994|DEVICE|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
40776253|NCT00794430|DRUG|Placebo|Capsule, bid, for 13 weeks
40776254|NCT02882347|DRUG|Somatostatin|
41302859|NCT06002282|BEHAVIORAL|Tailored messages|Messages will be individually tailored to parents' responses to a baseline survey (child gender, vaccination status) and real-time responses to interactive prompts about vaccine hesitancy determinants with links to additional information (e.g., CDC, NJ Department of Health) and community resources to overcome barriers.
41461808|NCT03256994|BEHAVIORAL|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT-FR will incorporate a quality-of-life questionnaire. CIRT-FR will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient
40776255|NCT02156947|PROCEDURE|Laparoscopic cholecystectomy|The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).
40776256|NCT01198665|DRUG|RAD001 (Everolimus)|Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks
40776257|NCT02225535|OTHER|NP face to face management of Chronic Low Back Pain|usual NP management of chronic low back disorder
40776258|NCT02225535|OTHER|PT face to face management of Chronic Low Back Pain|Includes manual therapy, education, exercise
40776259|NCT02225535|OTHER|Interprofessional Videoconferencing for Chronic Low Back Pain|Includes manual therapy, education, exercise.
40776260|NCT03986892|BEHAVIORAL|Physical Activity|Physical Activity
40776261|NCT05888064|DIAGNOSTIC_TEST|diffusion MRI sequences|Diffusion MRI sequences will be optimized to derive more accurate estimates of microstructure and microvasculature of tumour and healthy organs: multiple b-values will be acquired and advanced diffusivity models considered. MRI sequences to derive tumour hypoxia (i.e. indicative of radioresistance) will be also considered along with MR spectroscopy to evaluate tumour microenvironment.
40776262|NCT03637348|DEVICE|TrueTear|Ues of TrueTear neurostimulator
40980933|NCT05957484|DEVICE|Investigational brainstem neuromodulation device|This study device is non-invasive meaning it stays outside of the body. It stimulates activity in the brain through a headset with metallic earpieces that fit into the participant's ear canals. The device will be loaded with certain neurostimulation pattern, and the earpieces will provide the stimulation at the prescribed pattern.
40980934|NCT06387745|DEVICE|Hepatoscope|The Hepatoscope is a non-invasive external ultrasound imaging device, intended for general purpose pulse echo ultrasound imaging, and soft tissue elasticity imaging of the human body. In addition, the Hepatoscope provides measurements of shear wave speed and tissue stiffness, ultrasound beam attenuation and estimates of speed of sound, in internal structures of the body.
40980935|NCT04023786|PROCEDURE|PEEP-TEST|The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
40980936|NCT00345254|PROCEDURE|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
40980937|NCT02227589|BEHAVIORAL|MET/CBT-12|Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
40980938|NCT02227589|BEHAVIORAL|CBT-D|CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
41302860|NCT06002282|BEHAVIORAL|Standard messages|Generic reminder/recall HPV vaccination messages.
41302861|NCT04310163|OTHER|Natural history|Parent interview and video capture
41302862|NCT05787912|DEVICE|Photobiomodulation|The surgical sites were irradiated with a diode laser (980 nm, 0.2W) only.
41461809|NCT04190927|BIOLOGICAL|Compounded topical estradiol and compounded topical progesterone in a carrier cream|Apply topical compounded estradiol and progesterone in the amount prescribed twice daily for each day of the 28 day lunar or menstrual cycle. Repeat each cycle month. Make note of any AE's so that modifications in dosing can be made.
41302863|NCT05787912|OTHER|Hyaluronic acid after photobiomodulation|The surgical sites after gingivectomy were irradiated with a diode laser (980 nm, 0.2W) then covered by 2% Hyaluronic acid gel loaded in a special appliance for each patient.
40776263|NCT01461460|DRUG|TR-701 FA 1200 mg|6 tablet of T-701 FA
40776264|NCT01461460|DRUG|Moxifloxacin 400 mg|1 tablet 400 mg Moxifloxacin
40776265|NCT01461460|DRUG|TR-701 FA 200 mg plus Placebo|1 tablet of TR-701 FA with 5 tablet placebo
40776266|NCT01461460|DRUG|Placebo|6 placebo tablets
40776267|NCT01936831|DRUG|Isoniazid|INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.
40776268|NCT01936831|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6 was administered at \>= 25 mg daily and was obtained locally for use by study participants.
40776269|NCT03014804|BIOLOGICAL|autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Given ID
40776270|NCT03014804|OTHER|Laboratory Biomarker Analysis|Correlative studies
40980939|NCT02227589|OTHER|D-TAU|D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
40776271|NCT03014804|BIOLOGICAL|Nivolumab|Given IV
40980940|NCT04162015|DRUG|Nivolumab|nivolumab 360 mg
40980941|NCT04162015|DRUG|Pemetrexed|500 mg/m\^2
40980942|NCT04162015|DRUG|Cisplatin or Carboplatin|cisplatin 75 mg/m2 or carboplatin AUC=5
40980943|NCT05273138|OTHER|Blood sampling and skin biopsy|Blood sampling and skin biopsy
40980944|NCT06469970|DRUG|Glucose 30% Intravenous Solution|"Measurement of IDVG on admission, at 4 hours (H+4), and at 8, 16, 24, 48, 72 and 96 hours (H+8, H+16, H+24, H+48, H+72 and H+96) post-burn. The principle of this measurement consists of taking a reference blood glucose level measured on an arterial blood sample (arterial catheter) using a blood glucose meter. A bolus of 5g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection.~The intra-thoracic blood volume (ITBV) and extra-vascular lung water (EVLW) are measured using the PiCCO device as part of the usual management of burn patients."
40980945|NCT02415881|DRUG|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
40980946|NCT02415881|DEVICE|da Vinci Firefly|Da Vinci surgical robot with build-in fluorescence imaging option (Firefly technology)
40980947|NCT02415881|DEVICE|IMAGE1 + ICG Hopkins telescope and/or VITOM|IMAGE1 + ICG Hopkins telescope and/or VITOM -- Fluorescence camera allowing for imaging of IRDye800. Camera is suitable for open and laparoscopic surgery.
40980948|NCT00649701|BEHAVIORAL|Standard Text-Based Prevention Web Page|A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.
41461810|NCT05533151|DEVICE|Respiratory muscle training|All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.
40776272|NCT03014804|OTHER|Quality-of-Life Assessment|Ancillary studies
41302864|NCT04020484|BEHAVIORAL|Making Mindfulness Matter© (M3)|Making Mindfulness Matter© (M3) is an interactive online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3E is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.
41461811|NCT01220960|OTHER|art therapy|Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
41461812|NCT03563794|DRUG|CSII+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
40776273|NCT03014804|OTHER|Questionnaire Administration|Ancillary studies
40776274|NCT06328712|DRUG|EN001|"* Cohort 1: EN001 1.25×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals.~* Cohort 2: EN001 2.5×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals."
40776275|NCT01283672|OTHER|Controlled diet with whole grain barley, whole grain oats, or low grain diet|Participants will consume a standardized diet for 3 days prior to the treatment intervention meal. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. Participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
40980949|NCT00649701|BEHAVIORAL|The Morning After|A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.
40980950|NCT00649701|BEHAVIORAL|Talking About HIV|A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.
40980951|NCT00649701|BEHAVIORAL|Both Videos|Morning After and Talking About HIV videos
40980952|NCT02547610|DEVICE|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
40980953|NCT06207773|OTHER|Educator verbal feedback|the educator will hold one-on-one meetings with the students regarding their clinical internship for at least 20 minutes every week for a total of 6 weeks. Within the scope of this interview, the educator will give verbal feedback about the strengths and development aspects of the student's diagnosis, planning, implementation, evaluation stages and clinical skills in line with the nursing care plan. In addition, if there are clinical assignments (such as case analysis) given to the student, the educator will give feedback on this subject as well.
40980954|NCT01900327|RADIATION|External Beam Radiation|Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
40980955|NCT01900327|DRUG|Gemcitabine neoadjuvant|weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
40776276|NCT01831908|OTHER|Lifestyle counseling|People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
40776277|NCT05902897|DEVICE|Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis.|Heart Valve Replacement
40776278|NCT06042946|PROCEDURE|Microsurgical resection of ISCM|Microsurgical resection of ISCM defines the surgical removal of cancerous tumors that have spread to the spinal cord, using advanced microsurgical techniques and equipment like ultrasound, neuromonitoring, ultrasonic aspirator to prevent damage to the spinal cord.
40776279|NCT04719156|DRUG|Indocyanine green solution administered at 2.0mg/kg.|Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.
40776280|NCT04719156|DEVICE|Stryker SPY-PHI Imaging Device|The SPY-PHI system is used with the ICG dye to provide fluorescence images.
40776281|NCT06559332|DIAGNOSTIC_TEST|Risk-based CAD management|Patients will not undergo routine coronary angiography prior to TAVI. For patients without known atherosclerotic cardiovascular disease, a calcium score will be derived from the available routine CT and in case of a score \>100, statin treatment of at least moderate intensity is recommended.
40776282|NCT06559332|DIAGNOSTIC_TEST|Invasive coronary angiography|Routine invasive coronary angiography prior to TAVI. PCI recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.
40776283|NCT00900614|DRUG|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
40776284|NCT00158678|PROCEDURE|IMRT 75 Gy|50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
40776285|NCT00158678|PROCEDURE|Conventional radiotherapy 70 Gy|50 Gy in PTV1 and 20 Gy in PTV2
40776286|NCT00158678|DRUG|concomitant cisplatin|100 mg/m2 D1, D22, D43
40776287|NCT01040247|OTHER|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
40776288|NCT04373304|OTHER|low FODMAP diet|A diet specifically developed for the management of IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet. FODMAP is a collective term that includes fructose in excess of glucose, oligosaccharides including fructans/fructo-oligosaccharides (FOS), galacto-oligosaccharides, sugar polyols such as sorbitol and mannitol, and lactose. Controlled studies have established efficacy of the low FODMAP in managing IBS symptoms, but this diet is complex, associated with low calorie intake, and requires individualized explanation and follow-up by an experienced dietician.
40776289|NCT00383344|PROCEDURE|FDG PET/CT|
40776290|NCT04252664|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
40776291|NCT04252664|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
40776292|NCT05815888|DIAGNOSTIC_TEST|Lung Ultrasound Score|"one hemithorax is consisted of 6 scanning zones. Each of them are evaluated via ultrasonography in terms of presence of vertical B lines (\<4 B lines: 1 point; \>3 B lines or thick B lines: 2 points; marked disturbance in pleural line: 3 points). Higher scores reflect worse outcomes such as atelectasis and consolidation, and totally 12 zones are evaluated.~Three different time points are defined for LUS:~T1: 5 minutes after orotracheal intubation T2: At the end of surgery, before extubation T3: 30 minutes after extubation, in postanesthesia care unit.~DeltaT= T2LUS-T1LUS~Blood gas analysis will be evaluated hourly throughout the surgery"
40776293|NCT02693756|OTHER|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
40776294|NCT03396159|DIAGNOSTIC_TEST|mini fluid challenge|mini fluid challenge will be given to diagnose if patient is need fluid resuscitation or not
41461813|NCT03563794|DRUG|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
40776295|NCT03747692|PROCEDURE|study group|local anesthesia by mepicaine hydrochloride by intracervical local injection using 10 mm syringe.
40776296|NCT03747692|PROCEDURE|control group|each patient receives one tablet of NSAIDs (diclofenac sodium 50 mg) and 5ml of a placebo in form of normal saline are injected intracervical 5 minutes before the procedure using 10 mm syringe.
40776297|NCT05432973|PROCEDURE|Percutaneous Electrical Nerve Stimulation|In the PENS treatment, a biphasic continuous waveform current with a frequency of 2 Hz, a pulse width of 50 microseconds and an intensity that produces visible motor responses of the innervated muscles was used, below the patient's pain threshold. The NT6021 Percutaneous Neuromodulation equipment of the Nutek® brand distributed by Fisiolab Ibérica® was used. This equipment has the CE marking, which denotes compliance with the requirements of the legislation of Royal Decree 414/1996 of March 1, which regulates medical devices. B.O.E. of April 24, 1996
40776298|NCT05432973|PROCEDURE|Neurodynamic and manual therapy|"The manual therapy consisted of passive-assisted mobilization and massage therapy of the muscular and fascial tissue, beginning with the cervical area, kneading while asking the patient to rotate the neck and then in the same way along the muscles and soft tissues innervated by the target nerve.~Neurodynamic was performed in a passive-assisted manner, combining the patient's cervical mobilizations with the mobility of the upper limbs adapted to each case."
40776299|NCT05748769|BEHAVIORAL|Practice (UL)|Subjects performed RMs toward the units that were activated in the same order as the tested sequence 1-4-3-5-4-2, and with an activation duration and delay of 1 s. The practice included 16 blocks, each consisting of 30 RM with a 30 s pause after each block
40776300|NCT05748769|BEHAVIORAL|Observation (SO)|Subjects observed the illuminating switches while avoiding moving. The subjects observed RMs toward the units that were activated in the same order as the practiced sequence 1-4-3-5-4-2, also with an activation duration and delay of 1 s and 30 s pause after each block.
40776301|NCT05748769|BEHAVIORAL|Nature Observation (NO)|The video-clip consisted of a 16 min nature movie in cycles of one-minute observation and pausing 30 s, equivalent to the timing of RMs performed by groups UL and SO
40980956|NCT01900327|PROCEDURE|Surgery|Upfront pancreato-duodenectomy
40980957|NCT01900327|DRUG|Gemcitabine adjuvant|Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
40980958|NCT01502189|OTHER|Representational approach|The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
40980959|NCT02113605|OTHER|Cognitive behavior therapy|Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
40980960|NCT00955591|OTHER|Papanicolaou test|
40980961|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation B|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
40980962|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation C|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
40980963|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation A|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
40980964|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation D|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
40980965|NCT03958799|BIOLOGICAL|Licensed Tdap vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
40980966|NCT04304391|PROCEDURE|Resective Gingival Surgery|Gingivectomy and gingivoplasty:Resective gingival surgical procedured
40980967|NCT04566211|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
40980968|NCT04566211|DRUG|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
40980969|NCT02505230|BEHAVIORAL|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
40980970|NCT03342690|DRUG|Eplerenone|"In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions."
40980971|NCT01726153|BEHAVIORAL|Condom-HIM|The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
40980972|NCT06092749|OTHER|Transgrade technique (TG)|Transgrade (TG) Epidural Steroid Injection technique
40980973|NCT06092749|OTHER|Interlaminar technique (IL)|Interlaminar (IL) Epidural Steroid Injection technique
41302865|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement A|1, 2 or 4 capsules daily of oral supplement A for 3 days
40776302|NCT05923684|BEHAVIORAL|NLP-based Feedback|Audio recordings will be made using either digital recorders or telehealth platform-generated transcripts. Patient reports will include only the extracted sentences related to content areas. Physician reports will note the extracted statements across each content area, the quality scores for individual statements based on the pre-specified hierarchy, the statements that achieved the highest score across each content area, and feedback on what could be improved. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback. For physicians, the investigators will assess baseline quality of risk communication by pre-specified hierarchy, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.
40776303|NCT06532188|PROCEDURE|Hypno-ear-acupuncture|"5 acupuncture permanent needles on ear acupuncture points according to the National Acupuncture Detoxification Association (NADA) protocol, needle retention after 7 days standardized medical hypnosis:~* Induction of a trance~* suggestions for calm and good sleep"
41461814|NCT05740696|PROCEDURE|ALF|Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks
40776304|NCT06532188|PROCEDURE|Sham Hypno-ear-acupuncture|"5 acupuncture permanent needles on ear acupuncture points inserted at non-specific points on the backside of the outer ear, needle retention after 7 days standardized sham hypnosis~- story without trance induction and suggestions"
40776305|NCT02489279|BEHAVIORAL|Sustained Attention Control (SAC) Method|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
40980974|NCT05641207|DEVICE|RheOx™ with the RheOx™ Catheter treated in the trial|"Eligible patients be assigned two sessions of RheOx bronchial rheoplasty procedures~* Treatment 1 is for the treatment of right lung~* Treatment 2 is scheduled one month apart for left lung"
40980975|NCT03775057|OTHER|MyDoseCoach app|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
41302866|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement B|4 capsules daily of oral supplement B for 3 days
41302867|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement C|1,2 or 4 capsules daily of oral supplement C for 3 days
41461815|NCT05740696|PROCEDURE|SALF|The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks
41461816|NCT05740696|PROCEDURE|ACLF|On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
41461817|NCT04433494|DRUG|TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg|TY-302 is taken orally. Tamoxifen is taken orally.
40776306|NCT02489279|BEHAVIORAL|Scrabble|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
40776307|NCT06256055|BIOLOGICAL|UCMYM802 Injection|1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.
40776308|NCT03551093|DEVICE|ISS SPG stimulation|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).
40776309|NCT02297516|DRUG|Azzalure or Dysport|Glabellar lines
40776310|NCT02297516|DEVICE|Restylane or Emervel filler|Facial tissue augmentation
40980976|NCT04208620|DRUG|Placebo|Placebo administered subcutaneously
40980977|NCT04208620|DRUG|Cotadutide|Cotadutide administered subcutaneously
40980978|NCT03279328|DRUG|Topical Steroid Ointment|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
40980979|NCT03279328|OTHER|Vaseline|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
40980980|NCT03279328|DRUG|Skin Barrier Moisturier|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
40980981|NCT02103764|DRUG|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
40980982|NCT02103764|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
40980983|NCT02423577|DRUG|FF-3 dry powder|FF-3 dry powder administered by nasal inhalation
40980984|NCT02423577|DRUG|Placebo|Placebo dry powder administered by nasal inhalation
40980985|NCT00224315|DRUG|ziprasidone|
40980986|NCT00224315|DRUG|risperidone|
40980987|NCT03238508|PROCEDURE|Deferred stenting|Previously described
40980988|NCT02562794|BEHAVIORAL|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
40980989|NCT03704272|BEHAVIORAL|SunBrite|SunBrite is a family-empowered injury risk mitigation intervention with 3 core components: screening for the risk of supervisory neglect associated with traumatic injury in very young children; a brief behavioral intervention using motivational interviewing designed to provide feedback to the caregiver on supervisory risk and traumatic injury; and a referral to treatment for ongoing risks such as substance abuse, trauma or mental illness, requiring specific clinical interventions.
40980990|NCT01220622|DRUG|Nimodipine|Administration of nimodipine 30mg tid for 6 months
40980991|NCT01220622|DRUG|Placebo|Administration of placebo 30mg tid for 6 months
41302868|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement D|1 or 2 tablets daily of oral supplement D for 3 days
41302869|NCT03707652|DIETARY_SUPPLEMENT|Oral Supplement D in combination with oral supplement C|1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
41302870|NCT03914443|BIOLOGICAL|Nivolumab|240 mg or 360 mg
41302871|NCT03914443|DRUG|5-FU|750 or 800 mg\^2
41302872|NCT03914443|DRUG|CDDP|70 or 80 mg/m\^2
41302873|NCT03914443|DRUG|DTX|70 mg/m\^2
41302874|NCT03869957|DIETARY_SUPPLEMENT|Intervention group|0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days
41302875|NCT01926054|DRUG|Acthar gel|
41302876|NCT00571363|PROCEDURE|standard surgery|excision with 4 mm margins
41461818|NCT02559219|OTHER|Questionniares|
41461819|NCT01806311|DRUG|Candesartan32mg|
41142826|NCT06318572|BEHAVIORAL|Placebo|"Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will be instructed to take a capsule containing 0.5 g during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days, A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months."
41142827|NCT00652600|DRUG|Propranolol|ER Capsules, 160 mg, single-dose
41302877|NCT00571363|PROCEDURE|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
40776311|NCT02297516|DEVICE|Restylane Skinbooster|Facial skin rejuvenation
40776312|NCT00090376|DRUG|GPI 1485|
41142828|NCT00652600|DRUG|Inderal-LA|ER Capsules, 160 mg, single-dose
41142829|NCT01762397|DRUG|PMK-S005|
41142830|NCT06462989|DEVICE|ECHONEXT|ECHONEXT Artificial intelligence algorithm
41142831|NCT05274490|PROCEDURE|intubation and mechanical ventilation|patients who were in need were intubated and mechanically ventilated
41142832|NCT04842006|DRUG|Total neoadjuvant therapy (TNT)|Short radiotherapy (5X5 Gy) and capecitabine/oxaliplatin
41142833|NCT04842006|DIAGNOSTIC_TEST|Minimal residual disease (MRD)|Postoperative MRD on circulating cell-free DNA
41142834|NCT04842006|RADIATION|Long radiation therapy|Long-course 50.4 Gy radiation with capecitabine
41461820|NCT01806311|DRUG|Amlodipine10mg|
41461821|NCT06063590|BIOLOGICAL|StromaForte|100 millions allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
41461822|NCT01876953|DRUG|cytarabine|Given IV
41461823|NCT01876953|DRUG|idarubicin|Given IV
41461824|NCT01876953|DRUG|dasatinib|Given PO
41461825|NCT01876953|OTHER|laboratory biomarker analysis|Correlative studies
41461826|NCT00005668|DRUG|Itraconazole oral solution|
41461827|NCT04440150|PROCEDURE|Appendectomy|Open or Laparascopic Surgery
41461828|NCT00234780|PROCEDURE|pediatric nursing used in home to avoid hospitalization|
40980992|NCT04519151|DRUG|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
40980993|NCT04519151|DRUG|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
40980994|NCT01621620|DRUG|Yohimbine|
40980995|NCT05251909|BIOLOGICAL|Benralizumab|Benralizumab is a humanized, afucosylated, monoclonal antibody that binds specifically to the IL-5Rα on the target cell and thus directly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab has been widely approved for treatment of asthma.
40980996|NCT05251909|BIOLOGICAL|Placebo|Placebo will be injected as a comparator to injection with Benralizumab to examine effect on both the signs and symptoms of EG/EGE and the underlying eosinophilic inflammation, with dual primary outcome variables
40980997|NCT00237601|OTHER|obstetric care|
40980998|NCT01949051|DRUG|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
40980999|NCT01949051|DRUG|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
40981000|NCT02107027|DEVICE|nMARQ catheter|"In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted."
41302878|NCT01966562|BEHAVIORAL|WHOLE-BODY VIBRATION TRAINING|The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).
41302879|NCT01966562|BEHAVIORAL|MULTICOMPONENT TRAINING|This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
41302880|NCT01831557|OTHER|Blood samples will be taken for gene sequencing|
40776313|NCT00399529|BIOLOGICAL|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
40981001|NCT02107027|DEVICE|Navistar catheter|"In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted."
41142835|NCT05876286|OTHER|Neurological examinations|Neurological, neuropsychological, polysomnography examinations and multiple sleep latency test. The protocol is divided into three visits.
41302881|NCT01617681|DRUG|VAL489|Valsartan 3mg/kg oral solution
41302882|NCT01617681|DRUG|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
41302883|NCT05800444|DRUG|BAY3283142|Oral administration as tablet.
41302884|NCT05800444|OTHER|Placebo|Oral administration as tablet.
41302885|NCT02671890|DRUG|Chemotherapy|
40776314|NCT00399529|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
41142836|NCT00519844|DRUG|somatropin|
41142837|NCT06213298|DRUG|Kava|75 mg kavalactones
41142838|NCT06213298|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
41302886|NCT02671890|DRUG|Disulfiram|Given PO
41302887|NCT02671890|DRUG|Gemcitabine Hydrochloride|Given IV
41302888|NCT02671890|OTHER|Laboratory Biomarker Analysis|Correlative studies
41302889|NCT00251407|DRUG|Taxotere|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
41302890|NCT00251407|DRUG|Cisplatin|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
41302891|NCT00251407|DRUG|CPT-11|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
41302892|NCT04142307|DEVICE|Biofeedback Training|Microperimeter biofeedback training as described provides to the patient a variable frequency sound and a luminous stimulus that vary according to the eyes position, thus guides the oculomotor control and fixation stability accordingly.
40776315|NCT00399529|DRUG|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
40776316|NCT04629742|OTHER|Seawater Pizza|A seawater pizza administered to 12 healthy subjects
40776317|NCT04629742|OTHER|Standard pizza|A standard pizza administered to 12 healthy subjects
40776318|NCT02305992|PROCEDURE|Axillary Block with 0.5% Ropivicaine|Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.
40776319|NCT02305992|PROCEDURE|Stellate ganglion block with 0.2% Ropivicaine|A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
40776320|NCT02305992|PROCEDURE|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
40776321|NCT01048957|BEHAVIORAL|Real Time Feedback Training|
40776322|NCT00378092|DRUG|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
40776323|NCT00378092|DRUG|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
40776324|NCT00378092|DRUG|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
40776325|NCT05201807|DEVICE|Dailies Total 1 (DT1)|TEST Lens
40776326|NCT00002529|DRUG|cyclophosphamide|cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
40981002|NCT00064844|BEHAVIORAL|Cognitive Behavior Therapy for alcohol and smoking cessation|Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
41302893|NCT04142307|DEVICE|Sham - simulated BT|The simulated biofeedback training for Group B involves the following: each session includes presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button.
41302894|NCT01220648|DRUG|Nilotinib, interferon-alfa|
41302895|NCT01337531|DRUG|Gonal-F, Fostimon|dosage form
41302896|NCT01337531|DRUG|Gonal-F, Fostimon|injection, daily, 10-15 days
41302897|NCT01487668|BEHAVIORAL|Life Goals Collaborative Care|LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
41302898|NCT01269372|DEVICE|PillCam Colon 2|"Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon."
41302899|NCT01269372|DEVICE|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
41302900|NCT03442413|DRUG|2-[18F]-FA PET/CT|2-\[18F\]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.
40776327|NCT00002529|DRUG|doxorubicin hydrochloride|doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
40776328|NCT00002529|DRUG|epirubicin hydrochloride|epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
40776329|NCT00002529|DRUG|tamoxifen citrate|Tamoxifen 20 mg daily.
40776330|NCT00002529|DRUG|toremifene|Toremifene 60 mg daily.
40981003|NCT00064844|DRUG|Nicoderm CQ nicotine patch|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
40981004|NCT00064844|DRUG|Placebo gum|Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
40776331|NCT06486402|OTHER|participation rate|participation rate
40776332|NCT02101463|DEVICE|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
41142839|NCT04251325|OTHER|Basic Life Support Courses|4 hours basic life support courses for laypersons
41302901|NCT03442413|DRUG|I.V. Nicotine|Subjects in our study will receive intravenous nicotine at the adaptation session and each of the PET scans, close to the amount of nicotine absorbed from smoking 1/10 cigarette.
41302902|NCT02408796|DRUG|OTO-201|
40776333|NCT03006055|DEVICE|Circulating tumor cells|
40981005|NCT00064844|DRUG|Nicotine gum - Nicorette®|Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
40981006|NCT00775645|DIETARY_SUPPLEMENT|acetyl-L-carnitine hydrochloride|Given orally
40981007|NCT00775645|OTHER|placebo|Given orally
40981008|NCT05515757|BEHAVIORAL|Mobile-app based contingency management|We are adapting an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with stimulant use disorders requiring prolonged hospitalization. Participants will be enrolled into an 8-week mobile-app based contingency management intervention.
40981009|NCT03070574|DRUG|mesalamine 2400 MG (5-ASA)|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers, each 1200mg of IMP (= 2400 mg), every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
40981010|NCT03070574|DRUG|mesalamine 1200 MG|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (1200 mg/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
41302903|NCT03640806|OTHER|PHYSICAL ACTIVITY|3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
41302904|NCT02082314|PROCEDURE|RFA Vertebroplasty|
40981011|NCT03070574|OTHER|Placebo|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
40981012|NCT04496154|DIETARY_SUPPLEMENT|Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)|Triple Strength Omega-3 from Webber Naturals
40981013|NCT01176669|DRUG|Apatinib|Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
40981014|NCT01949350|DIETARY_SUPPLEMENT|Carbohydrate|Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.
40981015|NCT01949350|DIETARY_SUPPLEMENT|Carbohydrate protein|Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.
41302905|NCT01545908|OTHER|Fecal transplant|Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
41302906|NCT01545908|OTHER|Placebo enema|Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
41302907|NCT04292405|DEVICE|Wearable Cardioverter Defibrillator|Use of the Wearable Cardioverter Defibrillator and AUDICOR AM to evaluate accuracy of cardiac acoustic biomarker recordings.
41302908|NCT00004895|DRUG|octreotide acetate|
41302909|NCT01423617|DIETARY_SUPPLEMENT|Zenoctil|3 tablets 2 times daily
40776334|NCT03715790|BEHAVIORAL|EP referred group|Referred for sudden cardiac death (SCD) risk stratification and management
40776335|NCT03715790|BEHAVIORAL|Non-Referred group|Not referred for sudden cardiac death (SCD) risk stratification and management.
40981016|NCT01949350|DIETARY_SUPPLEMENT|Starved|Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
40981017|NCT05544331|BEHAVIORAL|Exercise group (written form)|The exercise program will be structUred with core stabilization exercises. Patients will be given the written form of exercises and will be applied as home exercises. Exercise progression will be provided by position changes.
40981018|NCT05544331|BEHAVIORAL|Exercise group (video based)|The exercise program will be structUred with core stabilization exercises. Patients will be given the exercise videos, which provide visual and auditory feedback, and will be applied as home exercises. Exercise progression will be provided by position changes.
41302910|NCT01423617|OTHER|Placebo|3 tablets 2 times daily
40776336|NCT06221007|PROCEDURE|Use of bone cement in otosclerosis surgery|Surgical technique; It involves separating the sclerosed stapes from the oval window and incus under an endoscope or microscope and replacing it with a Teflon piston, which is a middle ear prosthesis. In this way, a new connection between the incus and the oval window ensures the transmission of sound to the inner ear. Bone cement has long been used in primary and revision ossiculoplasty, including stapedotomy of the middle ear. During stapedotomy, the part of the Teflon piston that places the teflon piston on the incus is fixed with bone cement, aiming to keep the prosthesis in place for a long time and prophylactic treatment of incus necrosis.
40981019|NCT02093845|DEVICE|Biomatrix NeoFlex coronary stent|Percutaneous coronary intervention involving use of stent
40981020|NCT02093845|DEVICE|SYNERGY stent|Percutaneous coronary intervention involving use of stent
41302911|NCT02924506|DEVICE|Mobi-C prothesis|Mobi-C Prothesis, LDR Medical (company)
41302912|NCT02924506|DEVICE|ProDisc-C prothesis|ProDisc-C prothesis, Vivo Depuy Synthes (company)
41461829|NCT00223938|DRUG|Oral Iron|Oral Iron
41461830|NCT00223938|DRUG|sodium ferric gluconate|weekly intravenous injection Dose 1
41461831|NCT00223938|DRUG|sodium ferric gluconate|weekly intravenous injection Dose 2
41461832|NCT01421862|GENETIC|DNA methylation analysis|
40776337|NCT00677794|DRUG|Clear fluids|Clear fluids only after lunch.
41461833|NCT01421862|GENETIC|RNA analysis|
40981021|NCT01286012|DRUG|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
40981022|NCT01286012|DRUG|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
40981023|NCT01286012|DRUG|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
40981024|NCT01286012|DRUG|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
40981025|NCT05059067|DEVICE|Direct laryngoscopy for endotracheal intubation|Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation
40981026|NCT04803357|DEVICE|Continuous glucose monitor|We are offering you an opportunity to wear a medical device that monitors your blood sugars (glucose). This device is called a continuous glucose monitor (CGM). The CGM measures glucose levels through a tiny plastic filament that is inserted under the skin in your abdomen by a skin prick. Typically, you cannot feel this device once it is inserted.
41142840|NCT01921985|DRUG|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
41142841|NCT01921985|DRUG|Placebo|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
41142842|NCT01852175|DRUG|Prasugrel|Prasugrel 60mg loading dose and 10mg maintenance dose
41302913|NCT01517945|BEHAVIORAL|AIM materials and assessments|"Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10).~Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial.~Phase 3:~* Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS~* Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting~* Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30)~Phase 4:~* Part 1 of Phase 4 (complete) - dev of iThrive app for RCS~* Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely~* Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90)~For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over \< 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session."
41302914|NCT06273657|OTHER|Medisinstart|Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.
41302915|NCT03172611|OTHER|Dietary Intervention|Subjects consumed a defined, plant-based diet for 4-weeks. Emphasized were raw fruits and vegetables.
41302916|NCT02731703|DEVICE|Overdenture treatment|Conventional, FDA-approved prosthetics will be used in accordance with their labeling and pre-study prescribed standard treatment approach
41302917|NCT00362063|DRUG|growth hormone (Nutropin)|growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
41142843|NCT01852175|DRUG|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
41461834|NCT01421862|GENETIC|gene expression analysis|
41142844|NCT03441009|OTHER|Physio-/occupational therapy|Physio-/occupational therapy, ADL
41142845|NCT04387773|DRUG|GOCOVRI|"Participants will have gait and balance baseline assessment and then repeat assessment after being on full-dose of GOCOVRI for two weeks. The assessments will include measures of gait, balance and dyskinesia. Participants will also wear body-worn sensors (on wrist, feet and lumbar area) during daily-life for seven days to quantify mobility.~GOCOVRI will be started at 137mg/day for two weeks and then increased to 274mg/day for two weeks. Participants will repeat baseline assessments and then decrease to a dose of 137mg/day of GOCOVRI for one week, before stopping the medication completely.~All participants will receive GOCOVRI and they will know that they are on study drug. No placebo group."
41302918|NCT04005820|OTHER|Radiologic Centralized Review|The patient's imaging will be examined in one of the examination centers
41302919|NCT04005820|OTHER|Tissue sample (tumor, sung, urine)|all the samples will be made during the patients care
41302920|NCT02840487|BIOLOGICAL|VRC-ZKADNA085-00-VP|VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
40776338|NCT00677794|DRUG|Picosalax|Two sachets the evening prior to Video Capsule Endoscopy (VCE).
40776339|NCT00677794|DRUG|Polyethylene glycol|Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
40776340|NCT05188014|BEHAVIORAL|Luteal Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer during the last week of active pill consumption.
40776341|NCT05188014|BEHAVIORAL|Follicular Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer within 5 days of starting their menses.
41302921|NCT01369316|PROCEDURE|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
41142846|NCT03071523|PROCEDURE|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
41142847|NCT03071523|PROCEDURE|periosteal releasing incision|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
41302922|NCT01369316|PROCEDURE|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
41302923|NCT04716192|OTHER|Positional release technique|"Positional Release Technique The subject lies supine with therapist standing on the affected side; tender points are located along the upper fibres of the trapezius. Pressure will applied by pinching the muscle between the thumb and fingers. The subject's head is laterally flexed toward the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90° a slight flexion or extension is added to obtain fine-tune. The ideal position of comfort achieved is held for a period of 90 seconds and followed by a passive return of the body part to an anatomically neutral position continued for 5 minutes.~Mayofascial Release Technique Therapeutic Ultrasound"
41461835|NCT01421862|GENETIC|microarray analysis|
41461836|NCT01421862|GENETIC|mutation analysis|
41461837|NCT01421862|GENETIC|nucleic acid sequencing|
41461838|NCT01421862|OTHER|laboratory biomarker analysis|
41461839|NCT05971524|DIETARY_SUPPLEMENT|6-BT|2,4 or 8mg of 6-BT once daily for 4 weeks
41461840|NCT05971524|DIETARY_SUPPLEMENT|Placebo|A placebo capsule once daily for 4 weeks
41461841|NCT04334850|PROCEDURE|Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.
41461842|NCT04334850|OTHER|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
41461843|NCT00867919|BEHAVIORAL|Behavioral Family Treatment|"11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:~* parent-adolescent conflict~* adolescent development~* support and closeness~* behavioral activation~* response to adolescent negative affect~* relapse prevention~* suicide prevention, if necessary"
41461844|NCT00867919|OTHER|Community-based treatment as usual|Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
41461845|NCT05526924|RADIATION|Chemoradiation|A combination of chemotherapy and radiation given at the same time to treat cancer.
40981027|NCT01023750|DRUG|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
41461846|NCT05526924|DRUG|Pamiparib|An anti-cancer drug that targets specific cells to help fight cancer given by IV (through a needle inserted into a vein).
40776342|NCT04053387|DRUG|tapinarof cream, 1%|Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
40776343|NCT05790291|OTHER|Checklist|the experimental group will practice using the checklist
40981028|NCT00423150|DRUG|Temozolomide|Temozolomide capsules 150 mg/m\^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
40981029|NCT02500888|RADIATION|Radiosurgery|Only one radiation session of about 180 Gy in bilateral internal capsule.
40981030|NCT02998840|BIOLOGICAL|B244|odorless suspension
40981031|NCT02998840|BIOLOGICAL|Vehicle|odorless suspension
41142848|NCT04424745|OTHER|Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)|Participants will receive 10 sessions of computerised attention bias modification training with either real or sham tDCS. Participants will self-administer tDCS at home, with research supervision, and complete attention bias modification training on a laptop or desktop computer while receiving stimulation. Sessions will be completed week daily for 2-3 weeks.
41142849|NCT03039556|BEHAVIORAL|Normal Daily Steps|Complete normal daily ambulation for one week
41142850|NCT03039556|BEHAVIORAL|Step-Reduction|Reduce daily ambulation to fewer than 1000 steps per day for two weeks
41461847|NCT05526924|DRUG|Hydroxyurea|A chemotherapy drug given in pill form; used to treat leukemia and head and neck cancer.
41142851|NCT03039556|BEHAVIORAL|Return to Normal Daily Steps|Increase daily ambulation to 100% of normal daily step-count for two weeks
41142852|NCT06299748|BIOLOGICAL|Efgartigimod|Efgartigimod IV or SC
41302924|NCT04716192|OTHER|Myofascial release technique & Ultrasound|"Myofascial Release Technique~* Position of the patient - sitting comfortably with supported back, elbow flexed with forearm placed on a pillow. A low load, long duration stretch is applied along the lines of maximal fascial restrictions. The fascia is palpated and the pressure is applied directly to the skin, into the direction of restriction just until resistance (tissue barrier) is felt. The pressure will be applied for 90 to120 seconds. This procedure will carried out without sliding over the skin or forcing the tissue until the fascia complex starts to yield and a sensation of softening is achieved.~* Therapeutic ultrasound with the frequency of 3Mhz , with continuous mode and an intensity of 0.1-1.5 W/cm2 for a duration of 5 min will given with the patient position back rest."
41302925|NCT02114567|OTHER|PEEP titration|In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
41302926|NCT02274584|GENETIC|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
41461848|NCT05526924|DRUG|Fluorouracil (5FU)|A chemotherapy drug used to treat different types of cancer.
41461849|NCT05526924|DRUG|Tislelizumab|An anti-cancer drug.
41461850|NCT00684944|DRUG|TRx0014|Gelatin capsule, tid
40776344|NCT01878448|DRUG|Anlotinib|
40776345|NCT04165837|DRUG|FB-101|Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study
40776346|NCT04165837|DRUG|Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
40776347|NCT03401866|DIAGNOSTIC_TEST|DSC-MRI|"The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes."
40776348|NCT05973955|BEHAVIORAL|Insomnia Treatment|The Insomnia Treatment is a version of Cognitive Behavioral Therapy for Insomnia adapted to individuals with hazardous alcohol use. It consists of the standard features of this well-established insomnia treatment in addition to adaptations that focus on alcohol use behaviors and alcohol-related thoughts that may be sleep-interfering as well as the provision of alcohol education material.
40981032|NCT03778554|DRUG|Metoprolol Succinate|Eligible patients randomized to receive long-term therapy with oral beta-blockade
40981033|NCT03778554|DRUG|Bisoprolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
40981034|NCT03778554|DRUG|Carvedilol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
40981035|NCT03778554|DRUG|Nebivolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
40981036|NCT04615923|DRUG|Pridopidine|"Administration: Oral~Dose: 45mg twice daily"
40981037|NCT04615923|DRUG|Matching Placebo|"Administration: Oral~Dose: one capsule twice daily"
40981038|NCT05219084|DRUG|hip denervation|Lidocaine 2% 2ml was injected into each genicular nerve
40981039|NCT05219084|DRUG|intra-articular hydration|10 ml; of normal; saline were injected inside the hip joint
40981040|NCT05219084|DRUG|Combined group|hip denervation and intra-articular hydration were conducted together
41461851|NCT05336994|DIETARY_SUPPLEMENT|Multivitamin/mineral supplement A|Oral administration of Supplement A
41461852|NCT05336994|DIETARY_SUPPLEMENT|Multivitamin/mineral supplement B|Oral administration of Supplement B
41461853|NCT03867773|BEHAVIORAL|Time restricted feeding|TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)
40776349|NCT05973955|BEHAVIORAL|Education Control|The Education Control intervention is an educational control that provides psychoeducation related to both sleep and to alcohol use.
40776350|NCT05556902|DEVICE|Permanent Epidural Spinal Cord Stimulation|Permanent Spinal Cord Stimulation implanted in participants undergoing routine care for management of chronic neuropathic pain.
40981041|NCT05219084|DRUG|Control group|Normal; saline was injected subcutaneously
40776351|NCT00916227|DRUG|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
40776352|NCT03896191|PROCEDURE|Revision TKR surgery|This study will follow the cohort of patients who have an unstable primary TKR with which they are dissatisfied. They will be assessed before and after their revision TKR surgery.
40776353|NCT03896191|OTHER|No intervention.|This study will also make a case-control comparison between patients with a stable primary TKR and an unstable primary TKR.
40981042|NCT01250262|OTHER|normal medical care and follow up|physical activity/ nutrition guidelines will be provided and reviewed with the participant as part of standard care; telephone contact will be made weekly to encourage adherence to the health guidelines
40776354|NCT00006004|DRUG|carboplatin|
40776355|NCT00006004|DRUG|cisplatin|
40776356|NCT00006004|DRUG|gemcitabine hydrochloride|
40776357|NCT00006004|DRUG|paclitaxel|
40776358|NCT02305121|DEVICE|TFNA|All investigated procedures are part of the standard of care treatment. Only the parker mobility score is study-specific. All patients included are followed up from the time point of enrollment until three months after surgery
40776359|NCT06146816|DEVICE|photobiomodulation treatment in the infrared (IR) range.|The baseline treatment included 10 weekly 30 minutes long sessions of fIR treatment.
40776360|NCT06075784|OTHER|reiki|placebo reiki
40776361|NCT01741129|DEVICE|Nasal CPAP (SLE)|PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
40776362|NCT01741129|DEVICE|Nasal IMV (SLE)|PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
40776363|NCT00000222|DRUG|Buprenorphine|
40776364|NCT02164864|DRUG|Dabigatran Etexilate 110mg|Active treatment
40776365|NCT02164864|DRUG|Warfarin 3mg|Active comparator
40981043|NCT01250262|OTHER|Isolated Lumbar Resistance Exercise Program|lumbar extension, two set of 10-15 repetitions, once a week for two weeks; lumbar extension, one set of 10-15 repetitions, three times a week, week 3 to 4 months
40981044|NCT01250262|OTHER|Total Body Resistance Exercise Program|exercises: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl, one set of 10-12 repetitions, three time per week, week one to 4 months
40981045|NCT03724539|DEVICE|STRIPA intervention|"STRIPA is a Dutch software-based tool for the support of the pharmaceutical analysis by 1) taking into account the predictable adverse medication effects, 2) advising safe and appropriate therapy using established STOPP/START criteria, 3) interaction monitoring, and 4) appropriate dosing in accordance with renal function. It represents a highly efficient and user-friendly software engine, which is capable of individually screening the clinical status and pharmacological therapy of older patients with multimorbidity, which can define optimal drug therapy, and which can highlight the adverse drug reaction risk. A summary of these outputs will be used as STRIPA recommendations, which will, if applicable, be implemented by GPs and patients.~Prior to the STRIPA medication review, the necessary patient information will be loaded from the FIRE database that contains data from more than 300 Swiss GP practices."
41302927|NCT02566525|DEVICE|CytoSorb|Cytosorb device use during cardiopulmonary bypass
41302928|NCT05397886|DRUG|Remimazolam Besylate|Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.
40776366|NCT02164864|DRUG|Aspirin|Active comparator
40776367|NCT02164864|DRUG|Dabigatran Etexilate 150mg|Active treatment
40776368|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
40776369|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
40776370|NCT02164864|DRUG|Warfarin 5mg|Active comparator
40776371|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
40776372|NCT02164864|DRUG|Warfarin 1mg|Active comparator
40776373|NCT01349114|DRUG|aliskiren 300 mg once daily|aliskiren 300 mg daily
40981046|NCT03724539|OTHER|Sham intervention|Patients being assigned to the control arm will be treated in accordance with standard care. They will receive a sham intervention, which consists of a usual medication review by their GP and a shared decision making between patient and GP.
41302929|NCT05397886|DRUG|Flumazenil|Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
40776374|NCT01349114|DRUG|Placebo/sugar pill|Sugar pill/placebo
40776375|NCT02264366|BEHAVIORAL|Motivational Communication for Health Behavior management|"An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006)."
40776376|NCT05640089|OTHER|fMRI-based neurofeedback|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
40776377|NCT04304560|DRUG|Dapagliflozin 10 MG|inhibitor of sodium-glucose cotransporter 2
40776378|NCT04304560|DRUG|Placebo oral tablet|Similar Placebo oral tablet
40776379|NCT05586295|OTHER|Placebo|Microcrystalline α-cellulose, shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, sucrose, silica, talc, oxidized starch, gelatin, magnesium stearate, palm wax.
40776380|NCT05586295|OTHER|EX plus|Furanthiamine hydrochloride (vitamin B1), pyridoxine hydrochloride (vitamin B6), cyanocobalamin (vitamin B12), DL-alpha-tocopheryl acetate 50% (DL-alpha-tocopheryl acetate, sucrose, caprylic acid) Sodium alkenyl succinate starch, corn starch, water, sodium aluminosilicate), shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, γ-oryzanol (γ-oryzanol, rice bran powder ), sucrose, silica, inositol, taurine, talc, oxidized starch, gelatin, magnesium stearate, calcium panpolyate, microcrystalline α-cellulose, riboflavin (vitamin B2), palmar wax.
40776381|NCT03687281|OTHER|Survey|"The questionnaire consists of three parts:~* knowledge assessment;~* socio-demographic, medical and lifestyle data;~* use of Chemsex."
40981047|NCT06181201|PROCEDURE|Stool collection|"Stool collection is done with the Coll-off device (Zymo research, reference R1101-2-5) provided to the patient before and after the induction treatment and after the reference chemo-radiotherapy treatment (Cap50, Capecitabine). Collection must be carried out by the patient at home (collection using the Coll-off device and then transfer to a coproculture jar provided). The fresh sample is then picked up the same day by an approved transporter mandated by the promoter and will be stored at -20°C until the start of the analyses"
40776382|NCT02317627|DRUG|KD025|
40776383|NCT06459726|OTHER|shi style mobilization|Step 1 soothing tendon stepTherapist will aerate patient's neck 3 to 6 times.Step 2 moblization step Therapist will apply low velocity small amplitude oscillatory movement without thrust. Head will be in 45 degrees of flexion or extension. Repeat this for 3 to 6 times. Then distraction force is applied to the cervical. Step 3 dredging collateral step Therapist holds thenar and hypothenar muscles of patient's hand on affected side and gently shook the upper limb ebb and flow with small shaking and high frequency. Repeat the procedure 3 times 6 sesions over 2 weeks for 20minutes
40776384|NCT06459726|OTHER|SNAGS|Patient will receive sustained natural apophyseal glides as described by brian mulligan. Patient position will be upright sitting when therapist will apply a sustained passive assesory glide while patient moves actively through available physiological range of motion in the direction in which symptoms are produced. the headache SNAG technique will be performed with the patient sitting on a chair in the erect posture. The therapist will handle C2 spinous process with the middle phalanx of one hand. With the other hand, he will perform ventral gliding on C2 for 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Patient will be asked to report dizziness or any other symptom after procedure. If patient reports symptom then angle of application is changed to ensure symptom free treatment in all patientsNumber of repetitions are increased gradually from 6 to 10 and end physiological movement is maintained for 10second
40776385|NCT05775250|DRUG|giomer varnish|Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
40981048|NCT04246294|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP is golden standard treatment for moderate-to-severe sleep apnea with high compliance, effectiveness, and cost-effectiveness.~There will be no interference with standard care."
40981049|NCT04464915|OTHER|Isopropyl alcohol swab|Treatment will be administered by taking one deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes or every 20 minutes for a total of one hour.
40981050|NCT02228551|OTHER|Augmented renal clearance Point prevalence study|An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
40981051|NCT06474845|DEVICE|T-Control® catheter|Patients will be catheterized with T-Control® for 4 weeks
40981052|NCT06474845|DEVICE|Foley-type catheter|Patients will be catheterized with a conventional Foley-type catheter for 4 weeks
40981053|NCT02938871|DIETARY_SUPPLEMENT|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
40981054|NCT02938871|DIETARY_SUPPLEMENT|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
40981055|NCT00338689|DIETARY_SUPPLEMENT|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
40776386|NCT01051245|BEHAVIORAL|Case manager counseling|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
40981056|NCT01238679|DRUG|PF-04958242|Administered as specified in the treatment arm
40981057|NCT01238679|DRUG|Placebo|Administered as specified in the treatment arm
40981058|NCT01763216|OTHER|Road Tour|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
40776387|NCT01051245|OTHER|Usual care|Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
40776388|NCT05314660|DRUG|38 % silver diamine fluoride|Application of 38% SDF on carious dentine lesions.
41302930|NCT05397886|DRUG|Propofol|Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
41142853|NCT04607356|DEVICE|Blood Flow Restriction (BFR)|The Delphi Personalized Tourniquet System (PTS) will be utilized for the BFR exercises. The external constriction device will be applied to the proximal aspect of an individual's limb to restrict the flow of blood into and out of the extremity at 50% of usual flow. Subjects will perform a 30-15-15-15 repetition progression of 1-3 exercises as selected by the therapist. The Delphi PTS cuff is inflated at the start of the exercise and remains inflated throughout the exercise. Once the participant has completed an exercise, the cuff is deflated for 1 minute and the same cycle is performed for each subsequent exercise.
41142854|NCT04607356|OTHER|Evidence-informed care|Evidence-based resistive exercises, stretches, soft tissue mobilization and patient education for lateral epicondylalgia.
40776389|NCT05314660|PROCEDURE|Atraumatic restorative technique|Hand excavation of carious dentine followed by application of Glass ionomer
40776390|NCT05314660|PROCEDURE|Ultra conservative dentistry|Removal of soft dentine and enlarging of cavity to control bio film
41302931|NCT04813848|PROCEDURE|Application of varnish fluoride desensitizing agent on buccal surfaces of exposed dentin|"Varnish fluoride is a single dose transparent varnish with 5 % sodium fluoride (22.600 ppm fluoride) and 5 % calcium fluoride.~The application was performed according to the manufacturer's instructions. The varnish was applied on a clean and dry surface, then after 10-20 seconds to allow the fluoride varnish to be absorbed, was then dried with air."
40776391|NCT03005392|OTHER|exercise|"An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention)."
40776392|NCT05597384|PROCEDURE|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
40776393|NCT00788112|DRUG|vorinostat|
40776394|NCT00788112|GENETIC|protein expression analysis|
40776395|NCT00788112|OTHER|immunohistochemistry staining method|
41142855|NCT05576779|OTHER|Ofatunumab|All eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
41142856|NCT03071172|DRUG|Triptorelin for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
41302932|NCT04813848|PROCEDURE|Application of bonding agent desensitizing agent on buccal surfaces of exposed dentin|Bonding agent is a single dose dual curing universal adhesive and its application was performed according to the manufacturer's instruction for cases with hypersensitive tooth necks. The bonding was applied without etching, on a clean and dry surface. After 10 s any excess material was removed and then light cured for 30 s.
41302933|NCT04769635|DEVICE|CPAP therapy|All studied patients were received CPAP therapy with average cumulative adherence ⩾4 h/day of \>70% nights \[380\] obtained from device download with AHI\<5 /hr
41302934|NCT00837512|DEVICE|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
41302935|NCT00837512|DEVICE|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
41302936|NCT05853523|COMBINATION_PRODUCT|Gas ozone|The application of ozone was performed with the HealOzone System X4 (HealOzon, Kavo, Germany). The dentist adapted the silicon cup stricken on the cervical surface of the teeth. The pumping system created the vacuum and the machine applied high dosage of ozone, equal to 32 g/m3, for 30 second.
40776396|NCT00788112|OTHER|laboratory biomarker analysis|
40776397|NCT00788112|PROCEDURE|neoadjuvant therapy|
40776398|NCT00788112|PROCEDURE|therapeutic conventional surgery|
40776399|NCT01113684|DEVICE|Implantable pulse generator (deep brain stimulator)|This study evaluates the effects of subthalamic deep brain stimulation on central and peripheral nervous system activity in patients who have already had brain stimulators placed as a matter of routine clinical care.
40776400|NCT01475721|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
40776401|NCT01475721|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
40776402|NCT01475721|DRUG|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
41302937|NCT05853523|COMBINATION_PRODUCT|Diode laser and desensitized gel|"The dentist applied desensitized gel (JW-Desensitizing Gel, Heydent Gmbh, Germany) directly on the cervical zone of the teeth. Subsequently the irradiation was performed with Wiser III (Wiser, Doctor Smile, Italy) in the desensitizing assisted mode (preprogramed protocol). The protocol provides consecutively steps (not in contact) with 20 second of interval, 808 wavelength, and power incrementation, from 0,2 till 0,6 W. radiating the entire desensitize surface second using the black tip (400 micron). The procedure continued maintaining the tip of the laser on contact with the dentine surface making movement of lawn mowing (brushing technique) for 30 second. Then the surface was rinsed, and the irradiation applied again without the gel."
40776403|NCT01475721|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
40776404|NCT01475721|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
40776405|NCT01475721|DRUG|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
40776406|NCT01507740|DRUG|Avastin|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
40776407|NCT01507740|DRUG|Suntent|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
40776408|NCT01507740|DRUG|Nexavar|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
40776409|NCT02471144|BIOLOGICAL|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
40776410|NCT02471144|BIOLOGICAL|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
40776411|NCT02471144|BIOLOGICAL|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(\<25 kg, 25- \<50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
40776412|NCT02471144|BIOLOGICAL|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
40776413|NCT05358327|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
40776414|NCT00010478|PROCEDURE|Acupuncture|
40776415|NCT02232360|DRUG|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
40776416|NCT02232360|DRUG|Rosuvastatin alone|Rosuvastatin 10mg per day
40776417|NCT06179264|BEHAVIORAL|ACT Guide for Chronic Health Conditions|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. The current project is an online, self-guided, 6-session intervention based on ACT. The program is intended to help individuals with chronic health conditions improve their quality of life and mental health. Each session is expected to take about 30 minutes each, and the entire program will take 6 weeks to complete, as users will be encouraged to work on one session per week. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and chronic health condition specific vignettes, and apply ACT concepts to their own lives and situations related to their chronic health condition. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
40776418|NCT04183348|BEHAVIORAL|Training Protocol n°1 first at Visit 1, then, Training Protocol n°2 at Visit 2|"During Protocol 1 (visit 1), participants of Group A will perform auditory spatial localization tasks with sensory feedback and during Protocol 2 (visit 2), they will perform auditory tasks without any notion of spatial localization. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
40776419|NCT04183348|BEHAVIORAL|Training Protocol n°2 first at Visit 1, then, Training Protocol n°1 at Visit 2|"During Protocol 2 (visit 1), participants of Group B will perform auditory tasks without any notion of spatial localization and during Protocol 1 (visit 2), they will perform auditory spatial localization tasks with sensory feedback. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
40776420|NCT06387082|DRUG|HMPL-506|HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.
40776421|NCT02027792|OTHER|Cabbage leave wraps|
40776422|NCT02027792|DRUG|Diclofenac Gel|
40776423|NCT04573972|BEHAVIORAL|Social Incentive|Receiving half the monetary incentive conditional on meeting a step goal and half the monetary incentive conditional on walking together
40776424|NCT04573972|BEHAVIORAL|Standard Incentive|Receiving the full monetary incentive conditional on meeting a step goal and not conditional on walking together
40776425|NCT05946798|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
40776426|NCT05946798|DRUG|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
40776427|NCT01280331|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|Two Q8003 6 mg/4 mg IR Capsules q6h
40776428|NCT01280331|DRUG|Morphine sulfate|Two morphine sulfate 12 mg IR capsules q6h
40981059|NCT01763216|OTHER|Boatload of Crosswords|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
40981060|NCT01218204|DRUG|10mg atorvastatin|10mg
40981061|NCT01218204|DRUG|80mg atorvastatin|80mg
40981062|NCT01218204|DRUG|GSK1292263 Placebo|Placebo
40981063|NCT01218204|DRUG|100mg GSK1292263|100mg
40981064|NCT01218204|DRUG|300mg GSK1292263|300mg
40981065|NCT01218204|DRUG|800mg GSK1292263|800mg
40981066|NCT01218204|DRUG|10mg ezetimibe|10mg
40981067|NCT01218204|OTHER|Washout|No interventions - washout period
40981068|NCT04070950|OTHER|Questionnaires|Two self-questionnaires
40981069|NCT02064894|DRUG|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
40981070|NCT02064894|DRUG|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
40981071|NCT02064894|DRUG|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
40981072|NCT01149824|DRUG|Salvinorin A|
40981073|NCT01149824|DRUG|Placebo|
40981074|NCT01757054|DIETARY_SUPPLEMENT|ProNutrients Probiotic|Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
40776429|NCT01280331|DRUG|Oxycodone HCl|Two oxycodone HCl 8 mg IR Capsules q6h
40776430|NCT05428644|BEHAVIORAL|massage therapy|In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage and placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
40776431|NCT06154980|PROCEDURE|Preoperative Ultrasound TLIP|TLIP will be performed in preop with 20cc of 0.2% ropivacaine administered bilaterally, 40cc total. Blocks will be performed under ultrasound guidance with an in-plane technique.
40776432|NCT06154980|PROCEDURE|Intraoperative TLIP|TLIP will be performed intraoperatively with 20cc of 0.2% ropivacaine bilaterally, 40cc total. Blocks under direct surgical visualization.
40776433|NCT03186547|DRUG|Botulinum Toxin A Injection|adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
40776434|NCT03186547|PROCEDURE|Modified Lip Repositioning Surgery|the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
40776435|NCT00443742|PROCEDURE|Validation|
40776436|NCT02697357|BEHAVIORAL|Psychosocial Instruments|
40776437|NCT02697357|BEHAVIORAL|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|
40776438|NCT03859219|DRUG|Rozanolixizumab|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"
40776439|NCT03859219|DRUG|Placebo|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"
40776440|NCT05557708|DRUG|212-Lead Pentixather|Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.
40776441|NCT05557708|DIAGNOSTIC_TEST|203-Lead Pentixather SPECT/CT|Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.
40776442|NCT05303883|OTHER|Pediatric Constrained Induced Movement Therapy|Constraint of the child's less-impaired upper extremity for first 17 days of treatment. Children wear a removable, lightweight constraint for the first 17 of 20 therapy sessions.
40776443|NCT02786407|DRUG|Botulinum Toxin Type A for Injection|In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
40981075|NCT04962633|OTHER|Probiotic Pasta|Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
40981076|NCT04962633|OTHER|Control Pasta|Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
40981077|NCT00047840|DRUG|ZD6474|
40981078|NCT00047840|DRUG|Placebo|
40981079|NCT00047840|DRUG|Docetaxel|
40981080|NCT01533233|PROCEDURE|thoracoscopic lobectomy and mediastinal lymph node dissection|
41302938|NCT05662137|BEHAVIORAL|Emotions Recognition and Expression|Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.
41302939|NCT06242665|OTHER|Low UPF Meals (Study Provided)|Meals provided through delivery service
40776444|NCT02786407|DRUG|Placebo|In these studies,patients received placebo administered to 20 injection sites
40776445|NCT00137592|BEHAVIORAL|small media, group education (multicomponent)|
40981081|NCT05625009|PROCEDURE|Procedure/Surgery: Transversus Abdominis Plane Block (TAPB)|Patients received TAPB postoperatively
40981082|NCT05625009|PROCEDURE|Procedure/Surgery: Erector Spinae Plane Block (ESPB)|Patients received ESPB postoperatively
40981083|NCT06339723|BEHAVIORAL|Pecha Kucha|Pecha Kucha Method training was given
40981084|NCT02801240|OTHER|Nutrition support product|Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
41302940|NCT06242665|OTHER|Low UPF Nutritional Guidance|Self-guided instructions from study team.
41302941|NCT06242665|OTHER|Low UPF Snacks (Study Provided)|Low UPF snacks provided to participant
41302942|NCT05464446|DEVICE|Baseline Bubble Inclinometer, Baseline Digital İnclinometer and Hoggan microFET2 devices|Bubble inclinometer was used to measure lumbar lordosis angle, Digital inclinometer was used to measure pelvic inclination angle and Hoggan microFET2 was used for muscle strength measurement.
41461854|NCT05525702|DEVICE|Virtual Reality Treatment|Patients wear virtual reality head-mounted displays and experience immersive virtual environments.
41461855|NCT02773433|OTHER|Proportional Assist Ventilation|
41461856|NCT04255849|BIOLOGICAL|9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|Gardasil-9 HPV vaccine
40776446|NCT05657158|OTHER|Brolucizumab|Participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre were included
40776447|NCT04337047|OTHER|questionnaire assesment|questionnaire assesment
40776448|NCT02499887|DRUG|beclamethasone dipropionate|Inhaler
40776449|NCT02499887|DRUG|albuterol|Inhaler
40776450|NCT02499887|DRUG|Prednisone|Oral corticosteroid
40776451|NCT03429140|DRUG|Gel-One|an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
40776452|NCT03429140|OTHER|Saline Placebo|a placebo injection (saline, 3 mL) 1-2 weeks after ACL surgery
40981085|NCT03566927|COMBINATION_PRODUCT|FLEX Scoring Catheter with Lutonix DCB|Treatment by the FLEX Scoring Catheter, a plain balloon angioplasty, followed by a Lutonix DCB.
40981086|NCT03435744|DRUG|Simvastatin 20 mg|Simvastatin 20 mg added to TAU for 3 months.
40981087|NCT03435744|OTHER|Placebo Oral Tablet|Matched placebo added to TAU for 3 months
40981088|NCT05062681|DRUG|Dexamethasone|Patients will receive dexamethasone 8 mg q12hours
40776453|NCT01939145|DRUG|Normal saline|Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
41302943|NCT04544709|DRUG|Low back intradiscal injection of platelet rich plasma (PRP)|SOC Intradiscal Lumbar PRP Procedure : A small amount of blood is drawn from you, then it is spun in a centrifuge to obtain only the platelets and few other cells. After being spun the small amount of platelets will be injected into the specific disc that is believed to be causing pain in an attempt to help reduce inflammation and pain at the site. The injection will be done under fluoroscopic guidance (x-ray) that allows very careful and precise placement of the needle.
40776454|NCT01939145|DEVICE|Prontosan|Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
40776455|NCT02898948|BIOLOGICAL|Procalcitonin (PCT) as a diagnostic marker of bacterial infection|
40776456|NCT02612246|DRUG|GLPG1972 single ascending doses|single dose, oral solution
40776457|NCT02612246|DRUG|Placebo single dose|single dose, oral solution, matching placebo
40776458|NCT02612246|DRUG|GLPG1972 multiple ascending doses|multiple doses, daily for 14 days, oral solution
40776459|NCT02612246|DRUG|Placebo multiple doses|multiple doses, daily for 14 days, oral solution
40776460|NCT00498628|DRUG|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
40776461|NCT00498628|OTHER|Placebo|Placebo
40776462|NCT06424639|DRUG|Luspatercept|Luspatercept (dose of 1.0 mg/kg, subcutaneous injection every 3 weeks) Cyclosporine (3-5mg/kg/day)
40776463|NCT06424639|DRUG|cyclosporine|Cyclosporine (3-5mg/kg/day)
40776464|NCT02146378|DRUG|Vyndaqel|20mg/day
40776465|NCT04942002|DRUG|Methylprednisolone Acetate 40 MG/ML [Depo-Medrol]|Retrobulbar injection performed by care provider
41461857|NCT04255849|OTHER|Saline Placebo|Saline Placebo
40776466|NCT04942002|DRUG|Placebo Comparator: Standard treatment + placebo|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution by care provider
40776467|NCT06040788|PROCEDURE|immediate implant placement with customized healing abutment|immediate implant placement with customized healing abutment
40776468|NCT00928668|DRUG|Placebo|Placebo device for comparison
40981089|NCT05062681|DRUG|Methylprednisolone|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
40981090|NCT05522101|DEVICE|Mini-sized MCE|AKES-31SW capsule endoscopy（Mini-sized MCE), its diameter is 9.5mm, length is 24.5mm, weight is 3.0g, shooting frequency is 0.5-6fps, image resolution is 480\*480, working time is not less than 8 hours. Mini-sized MCE is 0.6 times of traditional MCE in volume and weight, which is the smallest capsule in clinical application
40981091|NCT05522101|DEVICE|Normal-sized MCE|Pillcam SB 3 capsule endoscopy（Normal-sized MCE), its diameter is 11.4mm, length is 26.2mm, weight is 3.0g, shooting frequency is 2-6fps, image resolution is 340\*340, working time is not less than 8 hours.
41461858|NCT05486338|DEVICE|Hybrid Argon Plasma Coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
40776469|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
40776470|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
40776471|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
40776472|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
40776473|NCT03243721|DIAGNOSTIC_TEST|7T MRI|A high field MRI that will take approximately one hour.
40776474|NCT03243721|DIAGNOSTIC_TEST|Neurocognitive testing|A series of tests to assess memory, verbal skills, and visuospatial skills.
40776475|NCT06227949|DRUG|Luveris|Patients will self-administer a subcutaneous injection of Luveris in addition to Gonal-F (FSH) daily until a pre-set criteria to trigger ovulation is reached.
40776476|NCT00365950|DRUG|Duration of anticoagulation|
40776477|NCT00365950|DRUG|Warfarin duration|
40776478|NCT03505333|PROCEDURE|conventional suture|we use Liga-sure device for hysterectomy
40776479|NCT02329808|PROCEDURE|blood drawing|The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
40776480|NCT05170685|BIOLOGICAL|Nivolumab plus Relatlimab FDC|
40776481|NCT06176547|DIAGNOSTIC_TEST|HbA1c|Blood glucose in last 3 months
40776482|NCT01085214|OTHER|Laboratory Biomarker Analysis|Correlative studies
40776483|NCT01085214|DRUG|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
40776484|NCT01914588|PROCEDURE|Telemonitoring|Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
40981092|NCT03037255|OTHER|long term conditions|Long term conditions including diabetes mellitus, chronic obstructive pulmonary disease or asthma, chronic heart failure, chronic renal failure, cerebrovascular disease or peripheral vascular disease.
40981093|NCT01622153|PROCEDURE|Formocresol application after pulpotomy preparation|1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
40981094|NCT01622153|PROCEDURE|GENTLEray 980 Soft Tissue diode laser|Application to pulp chamber until hemostasis achieved
40981095|NCT00314015|PROCEDURE|Evaluation of the success rate of implants|Evaluation of the success rate of implants will be followed.
40981096|NCT00314015|PROCEDURE|Questionnaires|Questionnaires will be used
40981097|NCT05087784|COMBINATION_PRODUCT|Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps|Patient-centered, technology-supported integrated survivorship- and care management
40776485|NCT01914588|OTHER|Standard care|"* Detailed instruction about medical therapy and lifestyle counseling~* Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~* Follow-up visits"
41302944|NCT02720016|BEHAVIORAL|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
41302945|NCT02720016|BEHAVIORAL|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
40776486|NCT04687930|DRUG|genicular nerve block|nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.
40776487|NCT04687930|DRUG|intra-articular steroid injection|Triamcinilone injection into the knee joint under ultrasound guidance.
40776488|NCT03256487|DRUG|Buprenorphine|buprenorphine 0.3mg IV
40776489|NCT03256487|DRUG|Morphine Sulfate|morphine 0.1 mg/kg IV (max 8mg per dose)
40776490|NCT04835129|DRUG|Isatuximab (for run-in portion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles.
40981098|NCT04993989|DRUG|Iberogast (STW5, BAY98-7411)|Survey without any intervention assigned in the study.
40981099|NCT02384707|OTHER|allegic food|"Reintroduction procedure for small doses :~* Administration of the first dose~* Clinical monitoring for 45 minutes~* Administration of the second dose"
40981100|NCT02384707|OTHER|Placebo|
41302946|NCT02720016|BEHAVIORAL|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
41302947|NCT04362904|OTHER|acupressure|
41302948|NCT04703660|PROCEDURE|cervical mobilization|3 types of cervical mobilization at the level of C 5- 6
41302949|NCT05224401|DRUG|Pivmecillinam and amoxicillin/clavulanic acid|1 tablet pivmecillinam 400 mg and 1 tablet Amoxicillin/clavulanic acid 875/125 mg, three times daily.
40776491|NCT04835129|DRUG|Isatuximab (for expansion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles.
40776492|NCT04835129|DRUG|Pomalidomide|4 mg PO days 1-21 of each cycle.
40981101|NCT03989557|DRUG|Aspirin and clopidogrel/Ticagrelor|The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
40981102|NCT03989557|DEVICE|Light transmittance aggregometry|point-of-care method to assess platelet function by light transmittance aggregometry.
40981103|NCT03989557|DRUG|Aspirin and clopidogrel/Ticagrelor|maintenance dose of aspirin, clopidogrel and ticagrelor.
40981104|NCT02433756|DEVICE|CRTD|
40981105|NCT04419454|DEVICE|BodyTite|retrospectively evaluate this novel treatment approach to improve the appearance of cellulite on the thighs and buttocks by tightening the SFS using RFAL.
40776493|NCT04835129|DRUG|Elotuzumab|10 mg/kg on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles.
40776494|NCT04835129|DRUG|Dexamethasone|40 mg (20 mg if \>75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
40776495|NCT02940925|OTHER|Drug: Taxol,cisplatin and capecitabine|Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
40776496|NCT02940925|OTHER|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
40776497|NCT06547736|DRUG|SHR-A2102 or/and HRS-4642|"Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
40776498|NCT06547736|DRUG|SHR-A1904 or/and HRS-4642|"Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
40981106|NCT05864508|DRUG|Oxytocin nasal spray|intranasal oxytocin treatment once a day during 6 weeks
40981107|NCT01969240|OTHER|Chest Pain Choice Decision Aid|The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the emergency department visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
40981108|NCT00119002|DRUG|dexamethasone|1mg/kg dexamethasone
40981109|NCT00119002|DRUG|Placebo|1mg/kg placebo
40981110|NCT00329654|PROCEDURE|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
41302950|NCT05224401|DRUG|Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility|Ciprofloxacin 500 mg twice daily, trimethoprim/sulfamethoxazole 800 mg/160 mg twice daily or ertapenem 1 g once daily.
41302951|NCT06369675|DRUG|MOB015B|Topical formulation
41302952|NCT06369675|DRUG|0.2% SLS|Positive control
41302953|NCT06369675|DRUG|0.9% Saline|Negative control
41302954|NCT06369675|DRUG|MOB015B vehicle|Topical formulation
41302955|NCT03637699|BEHAVIORAL|Positive Psychology|5-week positive psychology intervention
41461859|NCT00363857|DRUG|Ropinirole|
40776499|NCT06547736|DRUG|SHR-A1811 or/and HRS-4642|"Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
41461860|NCT02700971|PROCEDURE|Molecular Microscope Diagnostic system|Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
41302956|NCT05794932|DIAGNOSTIC_TEST|Stress test|"Diagnostic Test:~* Maximum effort test (CPET) on a cycloergometer~* Leg muscle strength assessment~* Leg muscle mass, composition and water compartments (segmental bioelectrical impedance)~* Spirometry, arterial blood gaz, NO/CO transfer"
41302957|NCT00683956|DEVICE|ReinLoop control software for patient-specific induction and maintenance of anesthesia|
41461861|NCT04952168|DRUG|Almonertinib|All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
41461862|NCT02037854|OTHER|Nutrient formulation|
41461863|NCT00001217|DRUG|pre-surgical chemotherapy|
41461864|NCT04943549|DRUG|Bupivacain|Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
41461865|NCT01285076|OTHER|Other: Retrospective chart review; one participant encounter visit.|Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
41461866|NCT00325312|DRUG|carbon dioxide, subcutaneous application|
41461867|NCT06347627|BEHAVIORAL|Group 1 (I x S x S x F)|Experimental message: Individual x Safety x Storytelling x Factual
41461868|NCT06347627|BEHAVIORAL|Group 2 (O x S x S x F)|Experimental message: Organization x Safety x Storytelling x Factual
41461869|NCT06347627|BEHAVIORAL|Group 3 (I x E x S x F)|Experimental message: Individual x Effectiveness x Storytelling x Factual
41461870|NCT06347627|BEHAVIORAL|Group 4 (O x E x S x F)|Experimental message: Organization x Effectiveness x Storytelling x Factual
41461871|NCT06347627|BEHAVIORAL|Group 5 (I x S x S x M)|Experimental message: Individual x Safety x Storytelling x Misinformation
41461872|NCT06347627|BEHAVIORAL|Group 6 (O x S x S x M)|Experimental message: Organization x Safety x Storytelling x Misinformation
41461873|NCT06347627|BEHAVIORAL|Group 7 (I x E x S x M)|Experimental message: Individual x Effectiveness x Storytelling x Misinformation
41461874|NCT06347627|BEHAVIORAL|Group 8 (O x E x S x M)|Experimental message: Organization x Effectiveness x Storytelling x Misinformation
41461875|NCT06347627|BEHAVIORAL|Group 9 (I x S x D x F)|Experimental message: Individual x Safety x Scientific data x Factual
41461876|NCT06347627|BEHAVIORAL|Group 10 (O x S x D x F)|Experimental message: Organization x Safety x Scientific data x Factual
41461877|NCT06347627|BEHAVIORAL|Group 11 (I x E x D x F)|Experimental message: Individual x Effectiveness x Scientific data x Factual
41461878|NCT06347627|BEHAVIORAL|Group 12 (O x E x D x F)|Experimental message: Organization x Effectiveness x Scientific data x Factual
40776500|NCT02327169|DRUG|MLN2480|MLN2480 tablets.
40776501|NCT02327169|DRUG|MLN0128|MLN0128 capsules.
40776502|NCT02327169|DRUG|Alisertib|Alisertib tablets.
41302958|NCT00683956|DRUG|Propofol|
41302959|NCT02938065|PROCEDURE|Ultrasound|Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
41302960|NCT02938065|OTHER|2% milk|16 participants will drink 10 ounces of 2% milk
41302961|NCT02938065|OTHER|apple juice|16 participants will drink 10 ounces of apple juice
40776503|NCT02327169|DRUG|Paclitaxel|Paclitaxel IV infusion.
40776504|NCT02327169|DRUG|Cetuximab|Cetuximab IV infusion.
40776505|NCT02327169|DRUG|Irinotecan|Irinotecan IV infusion.
40776506|NCT05486156|OTHER|A Time with e-Nature|"Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~1. Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~2. Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group."
40776507|NCT02470702|DRUG|Oritavancin|
41302962|NCT02938065|OTHER|ensure clear|16 participants will drink 10 ounces of ensure clear
41302963|NCT01507610|DRUG|Sumatriptan|To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
41302964|NCT03221322|BEHAVIORAL|Superlean|Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
41461879|NCT06347627|BEHAVIORAL|Group 13 (I x S x D x M)|Experimental message: Individual x Safety x Scientific data x Misinformation
41461880|NCT06347627|BEHAVIORAL|Group 14 (O x S x D x M)|Experimental message: Organization x Safety x Scientific data x Misinformation
41461881|NCT06347627|BEHAVIORAL|Group 15 (I x E x D x M)|Experimental message: Individual x Effectiveness x Scientific data x Misinformation
41142857|NCT03071172|DRUG|Recombinant Human Choriogonadotropin alfa Solution for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
40776508|NCT02470702|DRUG|Placebo (D5W)|
41142858|NCT03071172|DRUG|Progesterone Soft Capsules|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
41142859|NCT05172648|OTHER|oral spry|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength.
41142860|NCT05172648|OTHER|Cotton swab|Moisten the mouth with sterile distilled water with an oral cotton swab.
41142861|NCT00709787|OTHER|Usual Care|Normal care for hypertensive patients with risk factors for CHD
41142862|NCT02264444|OTHER|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
41142863|NCT04927949|DRUG|cangrelor perfusion during PCI|Cangrelor perfusion (started before PCI) with intravenous bolus of 30 microgram/kg, followed by a perfusion of 4 microgram/kg/min during 2 hours or until the end of the PCI if longer
41142864|NCT04927949|PROCEDURE|standard PCI|primary PCI without cangrelor
41142865|NCT03147222|BEHAVIORAL|Fracture Care at Home|This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
41142866|NCT00787176|DRUG|Group A Intravenous bolus of 1000 ml lactated ringers solution|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
41142867|NCT00787176|DRUG|Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
41142868|NCT00787176|DRUG|Group C 125 mL/hr of lactated ringers|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
41142869|NCT00787176|DRUG|Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
41142870|NCT01498614|BEHAVIORAL|Affect School and Basal body awareness|Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
41142871|NCT02379975|PROCEDURE|Non-surgical Periodontal Therapy|
41142872|NCT00010959|DRUG|Cimicifuga racemosa|
41142873|NCT00010959|DRUG|Trifolium pratense|
41142874|NCT03848741|BEHAVIORAL|Non-Exercise Control|Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
40776509|NCT02798341|OTHER|Biospecimen Collection|
40776510|NCT02996929|DEVICE|LC System|Subjects will undergo CIED lead extraction with the LC system
40776511|NCT05288192|DRUG|Suprachoroidal triamcinolone acetonide (SCTA) injection|Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.
40776512|NCT02972307|OTHER|wheelchair skills|the extent to which caregivers enhance the wheelchair skills of powered wheelchair users
41142875|NCT03848741|BEHAVIORAL|Resistance Exercise Training|Participants will complete a 12-week whole-body progressive resistance exercise training program.
41142876|NCT03848741|DIETARY_SUPPLEMENT|Placebo|Participants will be given placebo capsules to consume for 12-weeks.
41142877|NCT03848741|DIETARY_SUPPLEMENT|HMB+VitD|Participants will be given HMB+VitD capsules to consume for 12-weeks
41142878|NCT05334225|OTHER|Training Program|An in-person urethral catheterization training program that utilizes training videos (demonstrating procedures, providing examples of ordinary and difficult cases, utilizing animation techniques as well)
41142879|NCT01328756|DRUG|Lisdexamfetamine dimesylate|Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
41142880|NCT01854866|OTHER|Drug-packaging microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
41142881|NCT04634994|DRUG|[F-18]SDM-8|PET radiopharmaceutical. Subjects will undergo \[F-18\]SDM-8 PET Scanning to measure synaptic density.
41142882|NCT03305705|DRUG|Iron Carboxymaltose|Single intravenous infusion within 20 min
41142883|NCT03305705|DRUG|Sodium chloride 0.9%|Single intravenous infusion of 250 ml within 20 min
41142884|NCT04267952|BEHAVIORAL|Hand hygiene intervention program developed according to planned behavior theory|The perception of the importance of hand hygiene with expression of damages of microorganisms (stories about illnesses etc.). Visually assisted hand hygiene training experiments to ensure the visibility of microorganisms in the environment. Demonstration and application of the correct hand washing technique with music. All applications will take place in three lessons (120-minute).
41142885|NCT04267952|BEHAVIORAL|Classical hand hygiene education|expression of hand hygiene with verbal presentation method in a 40-minute lecture
41302965|NCT01759329|DIETARY_SUPPLEMENT|test coffee|test coffee with higher alkyl pyridine content
41302966|NCT01759329|DIETARY_SUPPLEMENT|control coffee|control coffee with regular alkyl pyridine content
41302967|NCT06182072|DRUG|ProAgio Dose Levels (DL) 1,2,3,4|ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
41302968|NCT06182072|DRUG|Gemcitabine, nab paclitaxel|ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
40776513|NCT05694247|DEVICE|CorNeat KPro|The optical component of the CorNeat KPro will be implanted into a circular disc of the cornea (as performed in standard penetrating keratoplasty surgery) and the skirt component will be embedded under a 360º conjunctival flap.
40776514|NCT01533415|DEVICE|CES treatment using Alpha-Stim technology|Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of \<1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
40776515|NCT01533415|DEVICE|Shame CES Treatment|Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
40981111|NCT00531817|DRUG|Tocilizumab|Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
40981112|NCT00531817|DRUG|Placebo|Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
40981113|NCT00531817|DRUG|Permitted DMARDs|As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
41302969|NCT05924906|DRUG|NB002|Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
41302970|NCT06271200|OTHER|Intermittent fasting and 10,000 steps per day|"Reduce calories intake and eat as 168 pattern, namely, eating foods for 8 hours while fast for 16 hours at daily basis plus walking more than 10,000 steps per day."
40776516|NCT02191618|DEVICE|WEB|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
40776517|NCT01459627|OTHER|6 months DAPT|Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.
40776518|NCT01459627|OTHER|12 months DAPT|Dual antiplatelet therapy will be continued till 12 months after enrollment in the study
40981114|NCT06505629|BEHAVIORAL|the online Paired Emotion Reading Intervention (PERI)|In the PERI, all children will receive three books about emotion knowledge. The paired reading groups will read and discuss these books over the next six weeks. Before starting the reading sessions, the paired groups will meet online via video to get to know each other and set reading goals. During the reading process, participants will check in daily with their reading progress. From the second week to the fifth week, participants will engage in weekly online discussions about the reading content. These discussions, led by the urban children, will follow a semi-structured discussion guide. The discussions aim to deepen the children's understanding of the book content and facilitate the application of emotion-related knowledge and emotion regulation strategies in their daily lives. The discussion sessions will be recorded and uploaded for regular review by the researchers.
40981115|NCT06505629|BEHAVIORAL|the online Paired General Reading Intervention (PGRI)|Apart from the differences in the reading materials and discussion topics, all other aspects are identical to the PERI group. In the online PGRI, children will read three books of their choice, and discussions will center around general reading experiences and feelings.
41461882|NCT06347627|BEHAVIORAL|Group 16 (O x E x D x M)|Experimental message: Organization x Effectiveness x Scientific data x Misinformation
40981116|NCT04233151|DRUG|QL1203|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
40776519|NCT03939390|DRUG|time of administration of Corifollitropin Alfa|The treatment will be identical in both arms. The difference between the arms is the moment of the Administration of Corifollitropin Alfa: follicular phase of the menstrual cycle (control group) vs. luteal phase of the menstrual cycle (study group).
40981117|NCT04233151|DRUG|Placebo|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
41142886|NCT01029639|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
41302971|NCT00845923|DRUG|Civamide Patch|Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
40776520|NCT00000600|DRUG|Vitamin E|
40981118|NCT04233151|DRUG|mFOLFOX6 regimen|The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m\^2 on Days 1 and 5-fluorouracil 400 mg/m\^2 IV bolus on day 1, then 1200 mg/m\^2/dx2days(total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.
41302972|NCT05131451|DIAGNOSTIC_TEST|Point of Care Autonomous AI diabetic retinopathy exam|Participants will get a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.
41302973|NCT00157092|DRUG|Aerosolized, Recombinant Alpha 1-Antitrypsin|
41302974|NCT04051021|BEHAVIORAL|Comfort Coach|A trained comfort coach will provide emotional and psychological interventions at six time points: preoperative clinic, day of surgery, extubation, chest tube removal, discharge, 30-day clinic follow-up, and 90-day post-discharge. Patients will also complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
41302975|NCT04051021|OTHER|Usual Care|Patients will complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
40776521|NCT00000600|DRUG|Vitamin C|
40981119|NCT00510133|BIOLOGICAL|GRNVAC1|Autologous dendritic cell vaccine
40981120|NCT01407640|PROCEDURE|Allergy tests|1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
41302976|NCT06492785|BIOLOGICAL|High Hyaluronic Acid concentrations (0.5 mg/ml)|Hyaluronic Acid(EmbryoGlue®)
41302977|NCT06492785|BIOLOGICAL|Low Hyaluronic Acid concentrations (0.125 mg/ml)|Hyaluronic Acid (G2 medium)
41302978|NCT00894413|DRUG|Tadalafil|20 mg once daily for 10 - 14 days
41302979|NCT00894413|OTHER|Placebo Pill|Placebo
41302980|NCT00501566|DRUG|satavaptan (SR121463B)|
41302981|NCT04462718|OTHER|Radiofrecuency|EXPERIMENTAL GROUP: After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.
41302982|NCT04462718|OTHER|Therapeutic Exercise|CONTROL GROUP: will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated at the end of that period and six moths later in order to have at least three timepoints to evaluate.
41302983|NCT02632110|DRUG|ALA|20% ALA applied to face prior to light treatment
41302984|NCT02632110|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face prior to light treatment
41302985|NCT02632110|DEVICE|IBL 10 mW|10 J/cm2 blue light delivered at 10 mW/cm2 for 16 minutes 40 seconds
41302986|NCT02632110|PROCEDURE|Microneedle lesion preparation|Microneedling of all visible/palpable AK lesions prior to solution application.
41302987|NCT02632110|DEVICE|IBL 20 mW|10 J/cm2 blue light delivered at 20 mW/cm2 for 8 minutes 20 seconds
41302988|NCT03136549|OTHER|Thermo-softening|The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
41302989|NCT03136549|OTHER|Room temperature|nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
41302990|NCT02939144|DIETARY_SUPPLEMENT|Liquorice|Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
40981121|NCT01541124|DRUG|Opioid|10 mg/pill, po, each 6h, during 6m
40981122|NCT02966587|BIOLOGICAL|Durvalumab|Given IV
41302991|NCT01519245|DRUG|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
41302992|NCT01519245|DRUG|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
41302993|NCT03294681|DEVICE|Objective measures with CSEP|Objective measures to be conducted with Custom SoundTM EP 5 software and the CP900 series sound processor in CI532 and CI512 Cochlear Implant recipients
41302994|NCT03499951|BEHAVIORAL|Wheelchair Skills Training - Remote|Individuals will receive wheelchair skills training remotely. They will be provided with the Wheelchair Skills Training Program to review (http://www.wheelchairskillsprogram.ca/eng/index.php), and then will be directed to use this information to perform the wheelchair skills. They will video the attempts, and will receive feedback on methods to improve their techniques.
40981123|NCT02966587|OTHER|Laboratory Biomarker Analysis|Correlative studies
41302995|NCT03499951|BEHAVIORAL|Wheelchair Skills Training - In Person|Individuals will receive wheelchair skills training in one-on-one sessions, taught by those who received the wheelchair skills training remotely.
41302996|NCT02648035|BIOLOGICAL|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
41302997|NCT06554834|PROCEDURE|CV4 + RR|Participants in this group will undergo three 30-minute sessions of osteopathic therapy. The intervention will involve a combination of the Fourth Ventricle Compression (CV4) technique and the Rib Raising (RR) technique. These sessions will be administered once per week over three consecutive weeks. The CV4 technique involves gentle compression of the occiput to influence cranial rhythmic impulses, while the RR technique involves mobilization of the rib cage to impact autonomic nervous system function.
40776522|NCT00529048|OTHER|Oral Glucose Tolerance Test|The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
40776523|NCT00529048|OTHER|Isoglycemic clamp|I.v. glucose infusion initiating the glucose responds curves from the OGTT
40776524|NCT00529048|OTHER|Gastric emptying rate|Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
40776525|NCT00114491|DRUG|Rosuvastatin|
40776526|NCT02415556|DRUG|Regular Human Insulin|Regular human insulin 40 IU daily over 24 weeks
40981124|NCT04298892|OTHER|clinical data and sample collection|Patients with hematologic malignancies and disorders will be asked to donate part of the samples collected as per clinical practice for the management of their disease for the aims of this study. In addition, patients will be asked to donate one oral swab sample, and urine samples. Collection of these additional samples is a non-invasive procedure with no associated risks for patients. Clinical data (demographics including ethnicity, stage of disease, concise treatment history, cytogenetic reports, and molecular data if available, as routinely performed during diagnosis procedures) will be collected.
41461883|NCT03845816|BEHAVIORAL|Self-Compassion Scale (SCS) questionnaire|all included patients with chronic pain will answer the Self-Compassion Scale (SCS) questionnaire
41461884|NCT04194216|DRUG|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."|Treatment Arm A
41461885|NCT04194216|DRUG|"Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days"|Treatment Arm B
41461886|NCT02279277|BEHAVIORAL|Supervised physical therapy program prior to total knee replacement surgery|
41461887|NCT05740748|DRUG|Tezepelumab|tezepelumab 210 mg sc q4wks for 20 weeks
41461888|NCT05740748|DRUG|Placebo|placebo sc q4wks for 20 weeks
41461889|NCT04099433|DIETARY_SUPPLEMENT|Vivomixx|Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
41461890|NCT04099433|OTHER|Placebo|Individuals in the placebo arm will undergo daily oral intake of placebo supplement
41461891|NCT03109041|DEVICE|CivaSheet|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
41461892|NCT04624594|OTHER|Artificial Intelligence Feedback|AI mobile application provides feedback to participants randomized to artificial intelligence group.
41461893|NCT04624594|OTHER|Physical Therapist Feedback|PT provides feedback to participants randomized to physical therapist group.
41461894|NCT04226586|DIETARY_SUPPLEMENT|Essential Amino Acid (EAA) group|Eligible children will be supplemented with Essential Amino Acids (EAA) for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
41461895|NCT04226586|DIETARY_SUPPLEMENT|Placebo|Eligible children will be supplemented with a placebo for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
41461896|NCT01200017|BIOLOGICAL|CD34+ enriched, T Cell Depleted donor stem cell product|stem cell transplant
41461897|NCT02957578|DEVICE|Solo TTD|Placement of tympanostomy tube with Solo TTD
40981125|NCT00758212|BIOLOGICAL|Mesotherapy|The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
40981126|NCT00459108|DRUG|dasatinib|Given orally
40981127|NCT01522989|DRUG|PD-0332991|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
40981128|NCT01522989|DRUG|5-FU|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
40981129|NCT01522989|DRUG|Oxaliplatin|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
41302998|NCT06554834|PROCEDURE|CV4|Participants in this group will receive three 30-minute sessions focusing solely on the Fourth Ventricle Compression (CV4) technique. The sessions will be conducted once per week for three consecutive weeks. The CV4 technique involves applying gentle pressure to the occiput with the goal of affecting cranial rhythmic impulses and promoting autonomic nervous system balance.
41302999|NCT06554834|DEVICE|sham ultrasound transducer|Participants in the placebo group will undergo three 30-minute sessions of a sham procedure using an ultrasound transducer. The transducer will be applied in a manner that mimics a therapeutic intervention, but without delivering any actual therapeutic effect. These sessions will also be conducted once per week for three consecutive weeks.
41461898|NCT05819437|OTHER|Balneotherapy program|"Whirlpool bath, bath with immersion showers, poultice application and underwater massage.~The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion.~The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes).~The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes.~The water used is a mixed sulphated Natural Mineral Water, collected by drilling the capuchins at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C."
41142887|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
41303000|NCT06554834|DEVICE|Ultrasound Transducer Sham Procedure|Participants in the placebo group will undergo three 30-minute sessions using an ultrasound transducer as part of a sham procedure. The transducer will be applied to the body in a manner that mimics a therapeutic intervention, but it will not deliver any actual therapeutic effect. This procedure is designed to simulate the experience of receiving treatment without providing the physiological benefits associated with active ultrasound therapy. The sessions will be conducted once per week over three consecutive weeks.
41461899|NCT02376257|DRUG|250 mg DCS|Drug
41461900|NCT02376257|DRUG|100 mg Modafinil|Drug
41461901|NCT02376257|DRUG|Placebo|Drug
40776527|NCT02415556|DRUG|Placebo|Intranasal sterile saline 40 IU daily over 24 weeks
40776528|NCT00332696|DRUG|Octreotide LAR|Octreotide long-acting release (LAR) 30 mg intramuscular injection.
40776529|NCT00332696|DRUG|Octreotide (Immediate release)|Immediate-release Octreotide supplied in 100 µg/mL ampules.
40776530|NCT00332696|DRUG|methylprednisolone|methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
41461902|NCT05312476|DRUG|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|"1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~2. Dose extension study:3 cases (1 dose group)."
40776531|NCT00332696|DRUG|Placebo|Physiologic saline solution
40776532|NCT01508364|DRUG|Sorafenib (Nexavar, BAY 43-9006)|Dosage according to label or at discretion of the attending physician
41461903|NCT05475548|DEVICE|powerscope|The PowerScope is the latest innovation in the treatment of Class II malocclusion which is a direct derivative of the Herbst Type II appliance. Dr. Andy Hayes worked in conjunction with American Orthodontics to develop PowerScope in 2016. This appliance supports intermaxillary wire-to-wire installation via a nut and hexagonal screw. A ball and socket joint is used to maximize lateral movement while improving patient comfort. The appliance is made up of a telescopic mechanism made up of an inner shaft/push rod, middle and outer tubing, and a spacer between the middle and outer tubing. A nickel-titanium (NiTi) spring provides a constant 260 g force. According to the present knowledge no studies regarding treatment outcomes of comprehensive fixed appliance treatment combined with the PowerScope in Class ΙII patients have been reported
41461904|NCT04305470|DRUG|Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)|One time oral dose on day of surgery (20 mg/kg bodyweight)
41461905|NCT01872715|DRUG|Oracea|
41461906|NCT05047718|BIOLOGICAL|COVID-19 vaccine Pfizer (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
41461907|NCT05047718|BIOLOGICAL|COVID-19 vaccine Pfizer (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
40776533|NCT01490021|PROCEDURE|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
40776534|NCT01490021|PROCEDURE|rTMS/Placebo TBS|rTMS/Placebo TBS
40776535|NCT06005402|BIOLOGICAL|CSX-1004|Recombinant human immunoglobulin G (IgG) 1λ monoclonal antibody specific for fentanyl and structurally related fentanyl analogs
41303001|NCT06554834|DEVICE|EEG/HRV/RSA (Electroencephalography, Heart Rate Variability, Respiratory Sinus Arrhythmia) Monitoring using Infiniti System|Participants in this study will undergo monitoring of Heart Rate Variability (HRV), and Respiratory Sinus Arrhythmia (RSA) using the Infiniti 8 measuring device. This system includes a ProComp Infiniti encoder, which is a versatile and advanced tool for capturing physiological signals, and the Biograph Infiniti software, which, along with the Physiology Suit, allows for detailed analysis and monitoring of autonomic nervous system function.
41461908|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
41461909|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
41461910|NCT03740191|OTHER|EPIC questionnaire|The EPIC questionnaire is used to evaluated the Quality of life of the patients including the sexual function.
41461911|NCT03740191|RADIATION|kV x-ray images|After the applied daily fraction, x-ray imaging will be repeated daily to assess for intra-fraction motion of the prostate.
40776536|NCT06005402|BIOLOGICAL|Placebo|Sterile saline for injection
40776537|NCT06564493|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
40776538|NCT06564493|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
40776539|NCT06564493|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
40776540|NCT06095960|BEHAVIORAL|Telehealth MOM|Patients will receive enhanced standard of care plus remote blood pressure monitoring, remote thermometer, and a 10- to 14-day post-partum telehealth visit.
40776541|NCT06095960|OTHER|Enhanced Standard of Care|Patients will receive enhanced standard of care which includes: education on symptoms and when to call their healthcare provider, comprehensive 6-week post-partum visit, and any healthcare deemed necessary by providers.
40776542|NCT02332811|DRUG|sevelamer carbonate 800mg|"Pharmaceutical form:tablet~Route of administration: oral"
40776543|NCT02332811|DRUG|sevelamer carbonate 2.4 g|"Pharmaceutical form:powder~Route of administration: oral"
40776544|NCT00760760|DRUG|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
40776545|NCT00760760|DRUG|control|equivalent amount of fat as butter
40776546|NCT04828954|OTHER|Immobilization for 2-weeks postoperative|Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks
40776547|NCT04828954|OTHER|Immobilization for 6-weeks postoperative|Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
40776548|NCT04908293|OTHER|Biorepair toothpaste|Use of New Biorepair Advanced Sensitive for home oral care.
40776549|NCT04908293|OTHER|Colgate toothpaste|Use of Colgate toothpaste for home oral care.
41303002|NCT01474746|DRUG|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
41303003|NCT01474746|DRUG|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
41303004|NCT03904446|DRUG|Methylergonovine|0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
40981130|NCT04809207|OTHER|CF Wellness Program Sessions|The intervention will last approximately 12 weeks. During this time, up to 9 coaching sessions will be delivered. Each will last approximately 45 - 60 minutes. Sessions will be delivered either by web-based video chat (e.g., Zoom) or by telephone. Sessions will cover content such as understanding the physiological, cognitive, affective, behavioral contributors to CF fatigue; understanding the role of physical activity/exercise and fatigue including the importance of balancing activity and rest periods; cognitive restructuring; addressing attention and interpretation processes contributing to fatigue; teaching techniques such as mindfulness meditation relaxation strategies, good sleep hygiene, and activity scheduling and behavioral activation; and engaging social support. Physical activity goals will be set each session. Participants will be encouraged to use the provided fitness tracker and to sync weekly prior the coaching session so that the results can inform session content.
40981131|NCT01414114|DRUG|Etelcalcetide|Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
40981132|NCT04850807|BEHAVIORAL|Music & Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences at times when behaviors are likely
41142888|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
41461912|NCT03740191|RADIATION|Conebeam CT|For the assessment of interfraction target and organs at risk movement. Conebeam CT as soon as it becomes available will be performed 5 x/week or at each day of proton therapy before treatment application.
41461913|NCT04416854|PROCEDURE|resection of primary tumor|resection of primary lesion with unresectablely metastatic colon cancer
41461914|NCT04416854|DRUG|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
41461915|NCT04416854|DRUG|mFOLFOX6|Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
41461916|NCT03727763|DRUG|Vemurafenib|960mg po bid
41461917|NCT03727763|DRUG|Cetuximab|500mg/m2 iv gtt (14 days per course)
41461918|NCT02342041|DRUG|SUVN-G3031|
41461919|NCT02342041|DRUG|Placebo|
41461920|NCT04335188|OTHER|Prospective oberservational registry|Non interventional study.
41461921|NCT03639220|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)
41461922|NCT01008709|DEVICE|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
41461923|NCT01008709|DEVICE|Aesculap U-clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
41461924|NCT00231582|DRUG|epirubicin|epirubicin
41461925|NCT00231582|PROCEDURE|high-dose and autologous stem cell transplantation|high-dose and autologous stem cell transplantation
41142889|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
41142890|NCT01537497|DRUG|Placebo|One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
41142891|NCT04671251|DRUG|AEVI-007|50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
41461926|NCT00231582|DRUG|paclitaxel|paclitaxel
41461927|NCT00231582|DRUG|etoposide|etoposide
41461928|NCT00231582|DRUG|ifosfamide|ifosfamide
41461929|NCT00231582|DRUG|carboplatin|carboplatin
41461930|NCT03996616|DEVICE|Head UP Position|"CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).~Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a \<10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput."
41461931|NCT03996616|DEVICE|Impedance Threshold Device|An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.
41461932|NCT03996616|DEVICE|New Automated CPR|Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).
41461933|NCT04158427|PROCEDURE|Faecal transplantation|Faecal transplantation from a healthy donor via colonoscopy
41461934|NCT04158427|PROCEDURE|Placebo faecal transplantation|Placebo faecal transplantation containing patient's own feces via colonoscopy
41461935|NCT04316325|DRUG|Medical abortion|Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
41461936|NCT03171194|DRUG|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
41142892|NCT04466735|DIETARY_SUPPLEMENT|Active group|2 x 12 g of EKS/day
40981133|NCT05560984|COMBINATION_PRODUCT|cervical internal os plasty|A long Allis forceps will be passed through the uterine incision and used to grasp the anterior lip of the cervix, pulling the cervix upwards into the uterine cavity. An assistant sometimes needs to elevate the cervix upwards from the vaginal aspect. The anterior lip of the cervix will be sutured to the anterior wall of the lower uterine segment using two or three simple interrupted absorbable stitches (Vicryl or Vicryl rapid no. 0). This aids to compress the bleeding sites of the placental bed and support the very thin lower uterine segment. If the placenta was implanted posteriorly and the bleeding areas will be mainly from the posterior wall of the uterus, the same procedure could be repeated using the posterior lip of the cervix. A Hegar dilator (size 12) will be inserted in a retrograde manner from the abdominal aspect toensure patency of the cervical canal .
40981134|NCT05778747|OTHER|Heart to Heart Yoga|The Heart to Heart Yoga intervention is a therapeutic and standardized form of yoga intervention that is adapted from MediYoga designed to fit the needs of patients with HF and family caregivers who have physical limitations and depressive symptoms and to fit cultural and social norms in Kentucky. The intervention will use a gradual, physical/ psychological yoga adaptation approach, and it will be delivered two times per week (40 -60 minutes per session) via videoconference technology for 12 weeks (total 24 sessions). Real-time, face-to-face, video conferencing technology is used.
40981135|NCT02138760|PROCEDURE|MRI UroNav fusion biopsy|
40981136|NCT03174236|DRUG|Ceftriaxone|Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
40981137|NCT03174236|DRUG|Benzyl penicillin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
40981138|NCT03174236|DRUG|Metronidazole|"The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials."
41303005|NCT03904446|DRUG|Normal Saline (placebo)|1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
41303006|NCT03832062|OTHER|Leftover surgical tissue homogenization|Leftover surgical tissue homogenization
41461937|NCT00731367|DEVICE|Aquacel Ag Gelled|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
41303007|NCT03811223|DRUG|Evolocumab Auto-Injector [Repatha]|Evolocumab 140 mg every 2 weeks for 12 weeks
41303008|NCT03811223|DRUG|Placebos|Placebo subcutaneous injection every 2 weeks for 12 weeks
40981139|NCT03174236|OTHER|Placebo|Suspension manufactured to match metronidazole
40981140|NCT03174236|DRUG|Gentamicin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
40981141|NCT01904682|DRUG|Oral rigosertib|Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
41142893|NCT04466735|DIETARY_SUPPLEMENT|Placebo group|Isocaloric placebo supplement with similar salt load but no EKS
41303009|NCT03277950|OTHER|Virtual reality with feedback|Individuals with stroke play game with correction of movement.
41303010|NCT03277950|OTHER|Virtual reality without feedback|Individuals with stroke play game without correction of movement.
41303011|NCT03277950|OTHER|Healthy|Healthy do not play game
41303012|NCT02714673|DRUG|anticoagulation|anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
41303013|NCT02196038|BEHAVIORAL|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
41303014|NCT02196038|BEHAVIORAL|Attention Control|Usual care with bi-weekly contact from study staff
40981142|NCT05575167|DRUG|Zoledronate or Alendronate|infusion (for zoledronate) or oral digestion (for alendronate)
41303015|NCT01967667|DIETARY_SUPPLEMENT|Liposomal glutathione|Escalating dose steps
41303016|NCT01967667|DIETARY_SUPPLEMENT|Placebo|escalating dose steps
41303017|NCT02750800|BIOLOGICAL|Adalimumab|Pre-filled syringe or pen, administered by subcutaneous injection
40981143|NCT02389010|BIOLOGICAL|Allogeneic cord blood platelet gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
40981144|NCT02389010|OTHER|Standard Local Medications-SLM|Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
41303018|NCT02750800|BEHAVIORAL|AbbVie Care 2.0|Supportive services provided to participants included reminder calls, emails, text messages, nursing services, dietician, and psychological support. An adalimumab starter pack, injection guide, digital and print educational materials were also provided.
41303019|NCT02577250|DRUG|Ketamine|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
41303020|NCT03382899|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus Pembrolizumab
41303021|NCT03382899|DRUG|Pembrolizumab|Pembrolizumab Alone
41303022|NCT02676310|DRUG|Bimatoprost|
41461938|NCT00731367|DEVICE|Aquacel Ag Adherent|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
40981145|NCT04350840|BEHAVIORAL|feedback|feedback of optical diagnosis performance per 3 month
40981146|NCT04396431|BEHAVIORAL|education|"The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy. The program was prepared by the researchers in consideration of the SunSmart Program implemented in Australia, the SunWise School Program developed by the United States Environmental Protection Agency. The program included various educational tools such as a sun protection story, activity book, PowerPoint presentations, cartoons, and puzzles.~Refresher training was conducted 15 days, 1 month, and 2 months after the initial training. Sun protection behavior and self-efficacy of the children were evaluated at the beginning of the study and six months after the program. As gifts to support their sun protection behavior, the children were given an FDA-approved sunscreen with 50+ SPF, a white cotton short-sleeved T-shirt as protective clothing, sunglasses with 100% UV protection, and a wide-brimmed hat."
41142894|NCT02464215|PROCEDURE|open surgery|Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.
41303023|NCT03100435|DEVICE|Er:YAG Laser|Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
41303024|NCT03100435|OTHER|Carbon Fiber Curette|Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
41303025|NCT00035425|DRUG|linezolid|600mg every 12 hours
41303026|NCT00035425|DRUG|vancomycin|1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
41303027|NCT03897920|OTHER|Doppler ultrasound assessment of renal arteria resistive index|A high frequency probe will be used together with the use of color or power Doppler to help vessel localization. As resistance to blood flow progressively increases from the hilar arteries toward the more peripheral parenchymal vessels, renal arteria resistive index (RRI) will be done at the level of the arcuate or interlobar arteries, adjacent to medullary pyramids. Measurements will be repeated in different parts of both organs (superior, median, and lower) when at least three reproducible waveforms have been obtained. An RRI will be calculated with the following formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and the mean value of three measurements at each kidney is usually considered. An RRI value 0.60 ± 0.01 (mean ± SD) is usually taken as normal with a value of 0.70 being considered the upper normal threshold
41303028|NCT04648423|DRUG|Sodium Oxybate|solution for oral administration
41303029|NCT04648423|DRUG|Placebo|solution for oral administration
41303030|NCT03080220|DEVICE|Astym|therapeutic massage instrument
40776550|NCT06281457|OTHER|Stimulus properties: task-defining feature|The feature used to determine which stimulus feature to attend to will be varied across trials using a letter cue (M = motion-attend, C = color-attend, F = fixation-attend)
40776551|NCT00909701|DIETARY_SUPPLEMENT|PreOP Booster|1 serving of 400 ml per study arm
40776552|NCT00909701|DIETARY_SUPPLEMENT|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
40776553|NCT04844333|OTHER|Extubation under deep anesthesia|When the patient in sedation or anesthesia state, no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 \< 45mmhg, regular waveform, stable circulation, the patient is in deep anesthesia state, and the endotracheal tube is removed.
40776554|NCT01920243|BEHAVIORAL|Health Mechanics Program|The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
40776555|NCT01202695|DRUG|AVP-21D9|intravenously, single dose
40776556|NCT01202695|DRUG|Placebo|Placebo comparator
40776557|NCT02683902|DEVICE|Active tDCS|The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.
40776558|NCT02683902|BEHAVIORAL|Hypocaloric diet|A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
40776559|NCT02683902|DEVICE|Sham tDCS|The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
40776560|NCT05819957|OTHER|Therapeutic Education Program (TEP)|the TEP lasts 12 months, being structured into 6 modules.
40776561|NCT03481439|OTHER|Collection of a Pharmaceutical intervention|collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort
40776562|NCT03271515|BIOLOGICAL|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
40981147|NCT03509025|DRUG|Jointstem|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
40981148|NCT00837304|DEVICE|PillCam Colon Capsule|PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
40981149|NCT00837304|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
40981150|NCT02759679|OTHER|Human breath samples|
41303031|NCT03080220|DEVICE|Stick|massage instrument
41303032|NCT03080220|DEVICE|Massage|massage instruments
41303033|NCT05058131|DIETARY_SUPPLEMENT|Dietary fibre|Dietary fibre as a powder, 24 g per day for 6 weeks
41303034|NCT05058131|DIETARY_SUPPLEMENT|Placebo compound|Maltodextrin powder, 24 g per day for 6 weeks
41303035|NCT02915406|DEVICE|CliniMACs|
41461939|NCT01086930|DEVICE|ReJoyce Workstation|The device has two parts. A muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff and an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. As well as a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association.
41461940|NCT01086930|OTHER|Standard Care|All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.
41303036|NCT06245018|BIOLOGICAL|iNK Injection|Subjects will receive about 4 cycles of iNK
41461941|NCT05098951|DEVICE|Acupuncture|Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
41461942|NCT05740553|DEVICE|ReTrieve Automated Stereognosis System|An automated tactile training system that may help patients recover lost tactile function after brain injury.
40776563|NCT04518137|DRUG|ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle|48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle
40776564|NCT01599286|DRUG|Carbaglu|"Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)~The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients \>15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste."
40981151|NCT04827550|OTHER|STUDY|Fibromyalgia Patient
40981152|NCT01834014|DRUG|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
41303037|NCT05217680|BIOLOGICAL|Bevacizumab|Administration of monthly intravitreal bevacizumab (4-12 injections)
41303038|NCT05217680|BIOLOGICAL|Lucentis®|Administration of monthly intravitreal ranibizumab (4-12 injections)
41303039|NCT04301882|DRUG|interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
41303040|NCT04301882|DRUG|direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
41303041|NCT00344617|DRUG|Bevacizumab (tradename: Avastin)|
41303042|NCT00326105|DRUG|Quetiapine fumarate|
41461943|NCT03518723|OTHER|Non-linear Periodized Resistance Training|8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session
40776565|NCT01599286|DRUG|Placebo|Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
40776566|NCT01570387|DRUG|Pomalidomide|Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle
40776567|NCT01570387|DRUG|Dexamethasone|10-20 mg on days 1, 8, 15, and 22
40776568|NCT01318681|DRUG|cetirizine 10 mg|cetirizine 10 mg over encapsulated
40776569|NCT01318681|DRUG|fluticasone furoate|nasal spray 25ug per dose
40776570|NCT01318681|DRUG|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
40776571|NCT01069757|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
40776572|NCT03931330|DEVICE|Percutaneous neurostimulation|Percutaneous neurostimulation using NSS-2 Bridge device
40776573|NCT02791243|DRUG|Finasteride 0.25%|Cutaneous solution of finasteride 0.25%
40776574|NCT02791243|DRUG|Placebo for Finasteride 0.25%|vehicle cutaneous solution of P-3074
40776575|NCT02791243|DRUG|Negative Control|0.9% aqueous NaCl
40776576|NCT01627886|DRUG|Ibandronate sodium|Ibandronate sodium Tablets 150 mg
40776577|NCT00861887|DRUG|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
40776578|NCT00861887|DRUG|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
40776579|NCT03419182|PROCEDURE|Open Reduction internal Fixation|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture.
41461944|NCT03518723|OTHER|Resistance training|8 week resistance training intervention, 3 sessions per week, 60 minutes per session
41461945|NCT00613041|PROCEDURE|CT Scan|All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
41461946|NCT04175860|BEHAVIORAL|The intervention with the patient (Chronic Patient Care Group and his family.)|"* Characterization: through the application of the characterization survey of the dyad (patient-caregiver),~* Evaluation of the competence to care at home: Application of the instrument 'competence to care at home, long and short version both the patient and the family caregiver.~* Risk assessment: this step is made based on the complexity of the treatment and the results of the evaluation the competence to care at home."
40776580|NCT03419182|PROCEDURE|Open Reduction Internal Fixation with Total Hip Arthroscopy|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture, and replaces the cartilage and bone of the greater trochanter with prosthetic components.
40776581|NCT04068922|BEHAVIORAL|Resilience Intervention|Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
40776582|NCT04069442|OTHER|This is a non-interventional study|This is a non-interventional study
40776583|NCT00711373|PROCEDURE|Allogeneic hand transplantation|Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
41303043|NCT02371759|DRUG|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
40776584|NCT00205959|DEVICE|Locking proximal humerus plate|
40776585|NCT00205959|DEVICE|Proximal Humerus Internal Locking System|
40776586|NCT00205959|DEVICE|Proximal Humerus Nail|
40776587|NCT03197519|BEHAVIORAL|TCApp|During these 12 weeks, in addition to TAU, the patient from the experimental group should use TCApp at least once a day, completing at least one self-record daily and/or contacting his/her therapist via chat when needed. The therapist responsible for the online monitoring should, at least once a week, connect to the online platform and perform the following actions: follow the patient's daily self-records, generate personalized reports or graphs and communicate with him/her via chat. After a 12-week period, patients from the experimental group and their therapists will stop using the TCApp application (they will be discharged).
41303044|NCT02371759|DRUG|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
41303045|NCT02371759|DRUG|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
41303046|NCT02371759|DRUG|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
41303047|NCT02149654|DEVICE|Engager Transcatheter Aortic Valve Implantation System|The Engager Transcatheter Aortic Valve Implantation System is indicated for use in patients with symptomatic severe aortic valve stenosis requiring aortic valve replacement and are at high or extreme risk for operative mortality or comorbidity judged by the heart team to pose an absolute or relative contraindication for conventional aortic valve replacement. The system is intended for use in patients with a life expectancy of at least one year following TAVI. The intended performance of the system is to provide relief of aortic valve obstruction without inducing significant regurgitation, thereby restoring effective hemodynamic function of the diseased aortic valve. The intended purpose of the system in this clinical study is in line with the intended purpose in the Instructions for Use.
40776588|NCT03197519|BEHAVIORAL|TAU|The TAU control group will receive treatment as usual, that is to say, the standard face-to-face CBT, offered by the different ED units in Spain.
40776589|NCT05858814|BIOLOGICAL|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
40776590|NCT00769054|DRUG|Ropivacaine|Local Infiltration Analgesia with 1 % Ropivacaine
40776591|NCT00769054|DRUG|Isotonic NaCl|Local Infiltration with NaCl
40776592|NCT06128057|OTHER|Blood products|Massive blood transfusion
40776593|NCT06565273|DRUG|FBL-MTX|Patients will be administered an initial dose of FBL-MTX by subcutaneous route. Subsequent doses will be titrated according to clinical response. Maximum dosage will be 2.5 mg, every 2 weeks.
40776594|NCT04047485|DIAGNOSTIC_TEST|Visual Acuity|During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)
40776595|NCT04047485|DIAGNOSTIC_TEST|CAM (Confusion Assesment Method)|"During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated."
40776596|NCT04047485|DIAGNOSTIC_TEST|CATQUEST 9-SF|The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
40776597|NCT04047485|DIAGNOSTIC_TEST|OCT|Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.
40776598|NCT04047485|DIAGNOSTIC_TEST|6CIT|This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
40776599|NCT04047485|DIAGNOSTIC_TEST|Barthel Index|To evaluate the everyday independence of the subject and it's trend durin the follow-up
40776600|NCT04047485|DIAGNOSTIC_TEST|Endothelial Microscopy - Cornea|Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
41461947|NCT06349096|DEVICE|Alma Harmony|The ClearLift is a class IIb medical device, High Power Q-switched (QS) 1064nm Nd:YAG laser module in the Harmony system. It has a targeted laser module for the non-invasive removal of various colored tattoos, as well as deep and superficial benign pigmented lesions, wrinkles, fine lines, and skin tightening.
40776601|NCT04740151|PROCEDURE|Best PEEP|In OLV, the investigator will perform a PEEP decremental titration trial, decreasing PEEP from 16 to 4 cmH2O (steps of 2-cmH2O, lasting 1 minute). At the end of every step driving pressure (Pplat-PEEP) will be calculated, and the PEEP corresponding to the lowest driving pressure + 2cmH2O will be set.
41303048|NCT05129813|BEHAVIORAL|Recovery Guide Counseling|Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling
41303049|NCT00333268|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
41461948|NCT03744286|DEVICE|Slip Training|-On a separate day (visit 2), using the identified optimal distance, a training session that involves 24 passes on the device where 1-2 planks move will be performed.
41461949|NCT03293771|OTHER|Focus group interviews|Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.
41461950|NCT03293771|DIAGNOSTIC_TEST|Questionnaire packet|Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.
40776602|NCT04740151|PROCEDURE|Standard PEEP|In OLV, a PEEP of 5 cm H2O will be set.
40776603|NCT05599724|OTHER|Biocollection|"For the FERTITHEQUE, will be collected:~* Clinical characteristics~* Biological characteristics measured as part of the usual follow-up~* consultation n°2 : DNA~* consultation n°2 : plasma~* consultation n°2 : serum~* consultation n°2 : vaginal microbiota~* consultation n°3 : follicular fluid (puncture fluid)~* consultation n°4 : plasma~* consultation n°4 : vaginal microbiota."
40776604|NCT00856557|BEHAVIORAL|Seminar and Practicum|A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
40981153|NCT01834014|DRUG|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
40981154|NCT01834014|DRUG|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
40981155|NCT01834014|DRUG|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
40981156|NCT01834014|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
41303050|NCT00333268|DRUG|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
41303051|NCT02000570|PROCEDURE|Sitting position (neurosurgery)|
41461951|NCT01650155|DRUG|BI 1005273 s.c.|injection
41461952|NCT01650155|DRUG|BI 105273 i.v. Placebo|infusion
40981157|NCT01834014|DRUG|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
40981158|NCT02953314|DRUG|TEZ|
40981159|NCT02953314|DRUG|TEZ/IVA|
40981160|NCT02953314|DRUG|IVA|
40981161|NCT03421821|DRUG|Ropivacaine|Subfascial injection OR extrafascial injection
41303052|NCT03794141|BEHAVIORAL|information on the risk gene status|information on risk gene status (APOE4 allele or not) was given before intervention
41303053|NCT03794141|BEHAVIORAL|life style advise|all test persons were given information on healthy diet and life style
41303054|NCT00698516|DRUG|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
41461953|NCT01650155|DRUG|BI 1005273 s.c. Placebo|injection
41303055|NCT04933279|DIETARY_SUPPLEMENT|iodine-containg spareribs soup|administrated a 150 ml - 200 ml of iodine-containg spareribs soup delivering ≈ 600 µg or 1200 µg iodine
40776605|NCT05552404|OTHER|conservative therapy|bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
40776606|NCT05552404|DRUG|Aminophylline|conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)
40776607|NCT05552404|PROCEDURE|trans nasal sphenopalatine ganglion block|conservative therapy plus sphenopalatine ganglion block SPGB using hollow cotton swab and lidocaine 2%
40776608|NCT04882943|OTHER|questionnaires|Quality of life questionnaires
40981162|NCT04874727|PROCEDURE|Mandible slacked and captured with Correct Plus™ Impression Material Superfast|In order to simulate the supine position, patients are placed in a supine position (180 degrees) in a dental exam chair, and asked to relax their lower jaw, allowing it to drop back, simulating their jaw falling back while sleeping. That bite is then captured with a Correct Plus™ Impression Material Superfast. Once the bite material hardens, it locks the bite in place. The patient then stands upright, and CBCT is taken standing while the jaw placement is still pseudo sleep-supine, supported by the bite material.
40981163|NCT00035620|DRUG|pegfilgrastim|pegfilgrastim
40981164|NCT00035620|DRUG|filgrastim|filgrastim
40981165|NCT04358133|DRUG|Chlorhydrate de morphine|The experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol
40981166|NCT04358133|DRUG|NaCl 0,9%,|The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm
40981167|NCT00211445|PROCEDURE|Photodynamic Therapy with Verteporfin|
40981168|NCT00211445|DRUG|verteporfin|
40981169|NCT04090840|BEHAVIORAL|Intermittent Fasting|Time restricted eating for 8 hours per day, with 16 hour fast. During the daily fast, patients are encouraged to drink water, black coffee, or green tea without sugar, cream, milk, or sweeteners.
41303056|NCT04933279|DIETARY_SUPPLEMENT|intrinsic iodine in natural kelp|administrated 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine). The natural kelp will be approximately produced in an experimental barn feeding supplementary iodine to reach a final iodine intake of ≈ 600 µg or 1200 µg. The iodine intake of natural kelp will be adjusted to the required dose by determing iodine content in the natural kelp.
41303057|NCT02404155|DRUG|Clozapine|
40776609|NCT01997164|DRUG|REGN910-3|
40776610|NCT01997164|DRUG|REGN910|
40776611|NCT01997164|DRUG|Intravitreal Aflibercept Injection (IAI)|
40776612|NCT02191163|DRUG|Antistax®|
40776613|NCT02191163|DRUG|Placebo|
40776614|NCT04190264|DEVICE|Thermal Rehabilitation Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
41303058|NCT00421343|DRUG|alendronate with cholecalciferol|alendronate 70mg /cholecalciferol 2800IU orally once weekly
41303059|NCT00421343|DRUG|calcium carbonate with cholecalciferol|calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
40776615|NCT04190264|OTHER|Cold Water Immersion|Whole-body immersion in cold water.
40776616|NCT04936555|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
41303060|NCT00421343|BEHAVIORAL|Falls prevention measures|personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
41303061|NCT01257126|DRUG|diclofenac potassium|
41303062|NCT01257126|DRUG|nimesulide|
41303063|NCT02258009|DRUG|Ranibizumab|0.5 mg intravitreal injections
41303064|NCT02258009|DRUG|Aflibercept|2 mg intravitreal injections
41303065|NCT00237796|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
41303066|NCT00237796|BEHAVIORAL|Goal Focused Supportive Contact (GFSC)|Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
41303067|NCT00216021|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
41303068|NCT00216021|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
41303069|NCT03548597|DEVICE|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
41461954|NCT01650155|DRUG|BI 1005273 i.v.|infusion
41461955|NCT05546099|BEHAVIORAL|Self-management of BP medications|Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist.
41461956|NCT05546099|BEHAVIORAL|Self-monitoring of home BP|Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.
40981170|NCT04358653|OTHER|fall prevention exercise program|The intervention protocol was starting with a 10 minute warm up (5 minutes circular walking combined with neck rotation in clockwise and counterclockwise fashion and 5 minutes upper and lower limp stretching exercises) and was followed by 30 minutes of exercises that were aiming to muscle strengthening, balance improvement and functionability enhancement. The muscle strengthening routine consisted of exercises both from standing and sitting position using an elastic band, heel and toe standing, upper limb strengthening using dumbbells. Balance training consisted of standing on one leg, shifting weight laterally from one foot to the other, staggered stance, side stepping. Functionalibility improvement was promoted through walking upstairs and downstairs, standing up from sitting to upright position. At the end a 5 minute cool down procedure was following consisting of circular walking, mild head movements and upper and lower body stretching.
40981171|NCT01645696|DEVICE|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
40981172|NCT01645696|DEVICE|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
40981173|NCT01645696|DEVICE|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
40776617|NCT00571714|DRUG|Peginterferon alpha-2a and ribavirin|Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
40776618|NCT00571714|DRUG|Peginterferon alpha-2a , ribavirin and betaine|Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
40776619|NCT03068000|BEHAVIORAL|Judo Training|Judo intervention is divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
40776620|NCT03068000|BEHAVIORAL|Ball Games|The Ball Games is divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
40981174|NCT06466122|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40981175|NCT06466122|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
40981176|NCT06466122|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
40981177|NCT06466122|PROCEDURE|Computed Tomography|Undergo CT
40981178|NCT06466122|DRUG|Pirtobrutinib|Given PO
40981179|NCT06466122|DRUG|Venetoclax|Given PO
40981180|NCT05133453|DRUG|Pirfenidone|drug intake three times daily for one year
40981181|NCT00662610|DRUG|naproxcinod 375 mg -750 mg -1125 mg bid|naproxcinod 375 mg -750 mg -1125 mg bid
41303070|NCT05686616|DRUG|Dapagliflozin Propanediol Hydrate 12.3 mg|Forxiga 10mg will be added on the conventional treatment for SGL2 inhibitor group.
41461957|NCT04532996|BEHAVIORAL|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in narrative coherence and affective dysregulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
40981182|NCT00662610|DRUG|naproxen 250 mg - 500mg -750 mg bid|naproxen 250 mg - 500mg -750 mg bid
40981183|NCT05443503|OTHER|Mobile health applications (mHealth apps) based intervention|Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH). Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track.
40981184|NCT05248412|OTHER|COVID-19 outbreaks|The intervention of the study is the COVID-19 outbreaks in Hong Kong. The pre-and post-COVID-19 outbreak periods will be defined as 1 January 2010 - 31 December 2019 and 1 January 2020 - 31 December 2024, respectively.
40981185|NCT01806948|DRUG|Ramosetron|
40981186|NCT01121887|BEHAVIORAL|Standard treatment|"Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
41303071|NCT05632458|DEVICE|Thrombectomy|Thrombectomy using double stent retriever vs thrombectomy using single stent retriever.
41303072|NCT06554938|DEVICE|water pik|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
41303073|NCT06554938|DEVICE|Super floss|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
41303074|NCT02795195|RADIATION|Carbon ion radiotherapy (CIRT)|Four dose levels (54GyE, 57GyE, 60GyE, 63GyE) are planned within the Phase I part. Daily fraction of 3 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., maximal tolerated dose, is determined or if the treatments to 63 GyE are safely delivered, the recommended dose (or 63 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the gross tumor volume plus 3\~5mm.
40981187|NCT01121887|BEHAVIORAL|Motivational Interviewing|"Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
40981188|NCT02328755|DRUG|peg-IFN-α|
40981189|NCT02328755|PROCEDURE|Hematopoietic Cell Transplant (HCT)|
40981190|NCT02328755|DRUG|Tacrolimus|Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.
40981191|NCT02328755|DRUG|Methotrexate|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
40981192|NCT06459908|OTHER|Robot Glove Hand Training|Robot Assisted group will perform hand exercises with the help of robotic glove assistance for 3 times per day/ 4 times per week, 45 minutes per session for 6 consecutive weeks. Total Number of Sessions will be 72 Hours.
40981193|NCT06459908|OTHER|Conventional Hand Rehabilitation Exercises|Conventional therapy group will perform hand exercises without the help of robotic gloves 3 times per day/ 4 times per week, 45 minute session for 6 consecutive weeks.Total number of sessions will be 72.
40981194|NCT01654731|DRUG|Bezafibrate|
40981195|NCT01654731|DRUG|placebo|
40981196|NCT02396433|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle.
40981197|NCT02396433|DRUG|Eribulin|Eribulin will be given on days 1 and 8 of each cycle.
40981198|NCT02396433|DRUG|E7449|E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
40981199|NCT00948623|BEHAVIORAL|physical activity counseling program|
41303075|NCT04883580|DEVICE|Navigation and Positioning System for Orthopedic Surgeries|"Experimental group: orthopedic surgery navigation system (Tuodao) assisted pedicle screw fixation~Control group: orthopedic surgery navigation system (tianzhihang) assisted pedicle screw fixation"
41303076|NCT04254289|BEHAVIORAL|Usual Care|Usual care
41303077|NCT04254289|BEHAVIORAL|Home-based exercise program|Home-based program determined by exercise physiologist
41303078|NCT03408574|DRUG|Nicotine patch, oral mecamylamine, placebo|Each participant randomly receives one active drug or placebo on each of three study days.
41303079|NCT03378011|OTHER|phototherapy|phototherapy either UVA1 or topical PUVA on acral vitiligo
41303080|NCT03924674|OTHER|Education, clinical decision support tools|"Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing"
41303081|NCT03174860|DRUG|Diclofenac Potassium 50mg Tab|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
41303082|NCT03174860|DRUG|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
41303083|NCT02318914|DRUG|gevokizumab|
41303084|NCT00004154|DRUG|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
41303085|NCT00004154|OTHER|Placebo|Two placebo capsules for 25 days of 28 day cycle.
41303086|NCT03311490|DEVICE|Spraino|"Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period."
41303087|NCT01515176|DRUG|Dinaciclib|Given IV
41303088|NCT01515176|OTHER|Laboratory Biomarker Analysis|Correlative studies
41142895|NCT02464215|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
41142896|NCT00923078|BEHAVIORAL|Auditory Cognitive Training|The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory. Training was administered in a supervised clinical laboratory setting at a frequency of five 60-minute sessions per week over 4 weeks.
41303089|NCT01515176|BIOLOGICAL|Ofatumumab|Given IV
41303090|NCT01515176|OTHER|Pharmacological Study|Correlative studies
41303091|NCT00556361|DRUG|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
41303092|NCT00556361|DRUG|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
41303093|NCT05445622|OTHER|learning spinal mobilization with a force sensor|Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.
40981200|NCT00948623|BEHAVIORAL|sham counseling program|
40776621|NCT05896748|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
40776622|NCT05896748|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
40776623|NCT04999410|BEHAVIORAL|High Intensity Interval Training|Interventions will contrast alternative training protocols
40776624|NCT00305396|DRUG|Sirolimus|
40776625|NCT00687076|DRUG|Ezetimibe|Daily dose of 10 mg of Ezetimibe
40776626|NCT00687076|DRUG|Niaspan|Daily dose of 1500 mg of Niaspan
40776627|NCT00687076|DRUG|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
40776628|NCT00687076|BEHAVIORAL|Standard care|Standard of medical care for PAD
40776629|NCT00687076|DRUG|Aspirin|Daily dose of 325 mg of aspirin
40776630|NCT00687076|DRUG|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
40981201|NCT01338493|PROCEDURE|lumbar spinal arthroplasty + Maverick™|All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
40981202|NCT03780907|DRUG|E2007|1 mg of E2007 was administered by mouth once daily.
40981203|NCT03780907|DRUG|E2007|2 mg of E2007 was administered by mouth once daily.
40981204|NCT03780907|DRUG|Placebo|Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
41142897|NCT00923078|BEHAVIORAL|Visual Cognitive Training|The program entails five computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and, following our laboratory procedures, calibration testing is repeated every 5th session. Exercises adapt in difficulty to individual performance, giving constant feedback about progress. Each of the five exercises focuses on a distinct process: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view. Training was administered in a supervised clinical laboratory setting at a frequency of five 40-minute sessions per week over 4 weeks.
41142898|NCT01274156|DEVICE|"MEDISPEC treatment probe"|300 shocks in 5 different anatomical locations of the penis.
40776631|NCT00687076|DRUG|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
40776632|NCT00687076|DRUG|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
40776633|NCT00687076|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
40776634|NCT01133847|DRUG|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
40776635|NCT01133847|BEHAVIORAL|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
40776636|NCT01133847|BEHAVIORAL|Parent Training|Nine sessions on parenting a child with ADHD
40776637|NCT01133847|DRUG|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
40776638|NCT01133847|DRUG|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
40776639|NCT01133847|DRUG|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
40776640|NCT01775540|DRUG|Systane Ultra|Artificial tear Eyedrop, 1 drop used QID for 4 weeks
40776641|NCT01775540|DRUG|Saline solution|Saline solution,1 drop used QID for 4 weeks
40776642|NCT01775540|DRUG|Maxidex|Eyedrop-1 drop QID for 4 weeks
40776643|NCT01910155|DRUG|Ciprofloxacin/Dexamethasone|
40776644|NCT01910155|DRUG|Ciprodex (R)|
40776645|NCT01910155|DRUG|Placebo|
40776646|NCT01617473|PROCEDURE|transplant with PBSCs|mobilized PBSCs for 2 consecutive days
40776647|NCT04843592|DEVICE|SOKARY Mobile|Effectiveness of using SOKARY Mobile Application on compliance of patient with Type II diabetes
40981205|NCT04388267|DRUG|Fluid challenge|"All patients who met the inclusion criteria will receive a standardised bolus of 250 ml of crystalloid in 5 minutes administered by hand with a 50 ml syringe.~During the study period, hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected for 20 minutes prior to the intervention (fluid challenge), during the fluid challenge and 25 minutes after completion.~The total duration of the intervention (fluid loading) is 5 min. The total duration of hemodynamic parameters recording is 60 min."
40776648|NCT01823055|PROCEDURE|Transvaginal suture capturing mesh device|The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
40981206|NCT04694144|DEVICE|telescoping intramedullary nail|All osteogenesis imperfecta patients with lower limb skeletal deformities corrected with multiple corrective osteotomies and insertion of two parts male and female segments of intramedullary telescoping nail
40981207|NCT03711045|BEHAVIORAL|eye-tracking|"After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded."
40981208|NCT05486858|OTHER|MSK ultrasonograpy|MSK ultrasonography was used to measure the thickness of diaphragm muscle in supine and sitting position and in a relaxed and in a contracted state.
41461958|NCT01269645|BEHAVIORAL|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
41461959|NCT01781312|DIETARY_SUPPLEMENT|ProTectis|
40981209|NCT05486858|OTHER|sitting Functional and Lateral Reach Test|Sitting reach tests were used to measure the stability limits of the trunk in different directions. Functional reach test is for testing the forward direction and lateral reach tests are for testing the right and the left directions.
40981210|NCT00083681|DRUG|Thalidomide|
40981211|NCT00083681|DRUG|Dexamethasone|
41461960|NCT01781312|DIETARY_SUPPLEMENT|Gastrus|
40776649|NCT04541667|OTHER|Air|Air will be used for luminal inflation.
40981212|NCT00083681|DRUG|Cytoxan|
40981213|NCT00083681|DRUG|Etoposide|
40981214|NCT00083681|DRUG|Cisplatin|
40981215|NCT00083681|DRUG|G-CSF|
40981216|NCT03641651|OTHER|Rehabilitation technology|"* Series of tailored rehabilitative training with the use of new technology which provide feedback and allow for a targeted and intensive and dense training.~* With supervision based on patients preconditions and therapy device (e.g. patient/ therapist ratio= 3/1).~* A training series lasts four weeks and comprises 3-5 training-days per week. Maximum training break of 7 days.~Five sessions of training with duration of 45 min per session, and up to four hours each day are foreseen.~* The training can take place in an outpatient or inpatient setting.~* Training will be organized in individual one-to-one or group session"
40981217|NCT03578289|BEHAVIORAL|Telemental Health - CBT|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
40981218|NCT00003623|DIETARY_SUPPLEMENT|multivitamin|
40981219|NCT00003623|OTHER|Placebo|
40981220|NCT00894322|DRUG|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
40981221|NCT00894322|DRUG|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
40981222|NCT00894322|OTHER|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
40981223|NCT04673331|OTHER|exercise capacity|3minute step test and 1minute sit to stand test used assessment of exercise capacity.
40981224|NCT00296894|DRUG|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
40981225|NCT00296894|DRUG|Placebo|Placebo
40981226|NCT06036667|PROCEDURE|"28Fr coaxial smart drain chest tube"|"To evaluate the efficacy of one 28Fr chest tube (coaxial smart drain versus standard chest tube according to local practice, types of drainage availability in each centre, surgeon's choice etc) after Uniportal- or Biportal-VATS upper lobectomies."
40981227|NCT00135720|DRUG|Enbrel (Etanercept)|
40981228|NCT05313074|BIOLOGICAL|CoronaVac vaccine|An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.
40981229|NCT01397032|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
40981230|NCT01397032|BEHAVIORAL|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
40981231|NCT04955522|DIAGNOSTIC_TEST|radiomics|Differential diagnosis of spinal myeloma and metastases by radiomics
40981232|NCT06343194|DEVICE|Bruxoff ®|Bruxoff ® is a holter that measures the masseter muscle contraction and heart rate.
41142899|NCT01274156|DEVICE|"MEDISPEC Sham Probe"|Sham probe applied same as treatment probe without energy
41142900|NCT01274156|DEVICE|"MEDISPEC Low intensity shock waves"|Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
41142901|NCT01274156|DEVICE|Sham|Probe does not deliver energy but creates same noise and sensation of active probe
40776650|NCT04541667|OTHER|Carbon Dioxide|Carbon dioxide will be used for luminal inflation.
41142902|NCT05228834|DRUG|Voxelotor Only Product in Oral Dose Form|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
41461961|NCT06241157|OTHER|Pediatric Quiz Game|"Investigator will start interacting with children upon their arrival and during their presence in the waiting room before entering the operating room. This will help to obtain better cooperation (frankl scale) and anxiety reductions (FIS and VPT) at different stages of the dental examination (e.g., entering the clinic, sitting on the dental chair, opening mouth, examination with mirror, probe, use of low-high-speed handpieces, ITR restoration). Pediatric Quiz is actually an ice-breaking quiz game developed for children, with the promise of a surprise gift at the end. It can be defined as asking children basic questions on colors, animals, fruits and/or cities depending on the age of the child among which the child would choose him/herself and answer the question easily."
41461962|NCT03407729|OTHER|Magnetic Resonance Imaging|MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.
41142903|NCT05228834|DRUG|Placebo|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
40776651|NCT02000102|DRUG|Intravitreal Injection of Aflibercept|
40776652|NCT05085132|BEHAVIORAL|MindFi app: Standard content|Digital wellness training in this study will be delivered via the MindFi app, designed by Jaedye Labs. Content includes learning, assesesment, and practice tracks A core component of the exercises in this app is mindfulness training; however, the app also incorporates other exercises drawn from positive psychology such as journaling and diaphragmatic breathing. The app goes beyond traditional guided meditation through content that reinforces the principles and attitudes taught during in-person training, and also seeks to maximize user experience by using interactive tasks and progress charts.
40776653|NCT05085132|BEHAVIORAL|Mindfi app: Standard content without practice|In this condition, participants will receive a version of the MindFi app that does NOT contain the practice tracks, only the learning and assessment tracks.
40776654|NCT06095895|OTHER|venipuncture|An additional measurement of exposure of mycophenolic acid and/or tacrolimus will be performed
41142904|NCT02125409|DRUG|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily for 7 days.
41142905|NCT02125409|PROCEDURE|Screening colonoscopy|
40776655|NCT05751577|PROCEDURE|TAVI WITHOUT ON-SITE SURGERY|After randomization, study TAVI operators of the participating center will schedule the patient for TAVI in their hospital without on-site surgery
41303094|NCT01662297|DRUG|Quetiapine|Quetiapine will be administered at a dosage prescribed by veterans' current providers for the treatment of insomnia.
41303095|NCT01662297|DRUG|Trazodone|Veterans willing to switch from quetiapine to trazodone for the treatment of insomnia will receive up to 400mg of trazodone daily.
41303096|NCT00386893|PROCEDURE|simultaneous EEG/fMRI|fMRI/EEG recordings
41303097|NCT00386893|DEVICE|fMRI|
41303098|NCT04980846|OTHER|Driving under the influence of alcohol with a driving simulator|"Participants will drive in three different states (sober, drunk above and below the legal limit) on designated circuits using a driving simulator. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target BrAC of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l BrAC) before the second driving session starts. Finally, the third driving session starts when the participants' BrAC drops to 0.15 mg/l. Heart rate, skin conductance, accelerometer, eye movement, radar, facial expression, and speech will be recorded by a smart-watch, an eye-tracker, microphones and an onboard camera, respectively.~Participants will be blinded to their alcohol levels during the study. They will have to rate their symptoms and their performance via questionnaires before and after each driving session. Further, capillary blood and oral fluid samples will be collected."
41303099|NCT03987620|DRUG|Ibrexafungerp|Ibrexafungerp 300mg BID for one day
41303100|NCT03987620|DRUG|Placebo|Matching Placebo
41303101|NCT03551301|OTHER|Transitional Case Management|"TCM program is a type of very flexible community treatment in terms of frequency and intensity of care. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialised in SUD treatment. The intervention begins during hospitalisation and lasts around 4 weeks after discharge from the hospital.~The main aim of this intervention is to accompany the patient in the difficult phase of transition between hospital and outpatient care and ensure their adherence to the treatment program. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs. Another important aim is to reduce the number of (unplanned) hospitalizations and emergency room visits."
41303102|NCT06266286|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more"
41303103|NCT06266286|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off
41303104|NCT00002058|DRUG|Clofazimine|
41303105|NCT03443726|PROCEDURE|Nerve block technique|Inferior alveolar nerve block with 1.8 cc of 4% articaine 1:100.000 epinephrine and 1.8 cc of the same anesthetic for the buccal nerve for third molar extraction.
41303106|NCT03443726|PROCEDURE|Infiltrative technique|Infiltrative anesthesia buccally between first and second mandibular molar with 3.6 cc of 4% articaine 1:100.000 epinephrine and 0.6 cc lingually to the third molar using the same anesthetic solution.
41303107|NCT03443726|DRUG|4% articaine 1:100.000 epinephrine|Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
41303108|NCT03443726|PROCEDURE|Third molar extraction|Third molar extraction under local anesthesia.
41303109|NCT00883558|DRUG|Insulin Lispro|
41303110|NCT00883558|DRUG|regular human insulin|
41303111|NCT00883558|DRUG|recombinant human hyaluronidase PH20|
41303112|NCT00883558|DRUG|Insulin glargine|
41303113|NCT00905879|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
41303114|NCT04162886|OTHER|Exercise|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
41303115|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
41303116|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
41303117|NCT00960440|DRUG|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
41303118|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
41303119|NCT00960440|DRUG|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
41303120|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
41303121|NCT00543751|DRUG|MK0767|
41303122|NCT03950570|DRUG|Abraxane|"The doses of ORIN1001 in both dose escalation and dose expansion will be 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600mg, 800 mg, 1,000 mg, 1,200 mg Weekly paclitaxel will be 80 mg/m2 given intravenously for the dose escalation and dose expansion phases.~cohorts as follows: 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1,000 mg, 1,300 mg and 1,500 mg administered for 21 days (one cycle)."
41303123|NCT05589116|OTHER|Online Compassionate Imagery Intervention|The intervention comprises 14 pre-recorded, 10-15 minute videos. Participants will be asked to watch one video per day over a two-week period. The videos initially focus on providing psychoeducation about what self-compassion is, before delivering a series of guided Compassion Focused Therapy (CFT) informed exercises to cultivate self-compassion. The first week of the intervention will teach key compassion skills, with the second week focusing on skill consolidation.
41303124|NCT05137509|DEVICE|Computerized Tomography|Using Computerized Tomography for diagnosis COVID -19 patients
41303125|NCT05005156|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)|All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.
41142906|NCT02291549|DRUG|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
41461963|NCT03407729|OTHER|Cognitive Performance Testing|For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots.
40776656|NCT05751577|PROCEDURE|TAVI WITH ON-SITE SURGERY|After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
40776657|NCT04275804|DEVICE|Low Magnitude High Frequence Vibration Platform|with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement \<0.1mm)
40776658|NCT04275804|OTHER|Conventional Dressing|Alternate Day Dressing
40776659|NCT04807738|DEVICE|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"The 110 outpatients will be randomized into groups: First arm, individual neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) in a real environment and the second arm, the same therapy in virtual reality environment. All participants will undergo 15 sessions, 60 minutes each, twice a week in a period of two months.~The therapy in a second, interventional group, uses virtual reality and new software that was developed specifically for inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). The software allows immediate feedback and moreover, movement is corrected by a present therapist. Evaluation of speed and performance quality might be extracted from the software of virtual reality."
40776660|NCT04807738|OTHER|"Neuroproprioceptive facilitation and inhibition"|The first arm of the study will consist of a physiotherapeutic approach based on neurophysiological principles using proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) approaches. MPAT makes use of particular motor patterns that evolve in postural control development. The repetition of activated programs, a set of stimuli, applied to change the posture with anatomical centration of the joint under various conditions in leading to better support of postural stabilization while seated, while getting up, stepping forward, and standing, in order to teach the patients to use the acquired motor skills automatically in daily life. PNF is a method used for learning effective movement patterns with high biomechanical effectiveness based on repetitive stimulation of cooperating alfa-motoneurons and proprioceptors in muscle, tendons and joint capsules. Therapy will be individualized and led in the standard face-to-face regiment.
40776661|NCT00133705|DRUG|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
40776662|NCT00133705|DRUG|Inert Capsule|sugar pill
40776663|NCT00691626|BEHAVIORAL|CBT for Insomnia plus Imagery Rehearsal|patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress
40776664|NCT00691626|BEHAVIORAL|CBT for Insomnia plus psychoeducation|patients receive standard CBT for insomnia combined with psychoeducation
40776665|NCT04976777|DEVICE|Updated DEX PS DDS Applicator|Intravitreal Administration
40776666|NCT04976777|DEVICE|Approved DEX PS DDS Applicator|Intravitreal administration
40776667|NCT04976777|DRUG|Dexamethasone|Dexamethasone 0.7 mg in a solid polymer drug delivery system
40776668|NCT03694028|OTHER|Limb Loading|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
40776669|NCT03694028|OTHER|Conventional Training|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
40776670|NCT05438147|OTHER|CT-100 DiNaMo|Active Treatment (Study App)
40776671|NCT05438147|OTHER|Care-as-Usual|Care-As-Usual control
40776672|NCT00158093|DRUG|Nebivolol|
40776673|NCT00158093|DRUG|Atenolol|
41142907|NCT02291549|DRUG|Mometasone furoate nasal spray|Mometasone furoate nasal spray (200mcg) once daily
41142908|NCT02291549|PROCEDURE|Sham|In-office bilateral sham procedure, consisting of advancement of a delivery system with the S8 Sinus Implant into the ethmoid sinuses followed by removal without deployment.
41303126|NCT04986969|BEHAVIORAL|Online cognitive behavioral therapy|online cognitive behavioral therapy delivered using one of two active methods
41303127|NCT05644665|DRUG|Ozanimod|Specified dose on specified days
41303128|NCT05644665|DRUG|Placebo|Specified dose on specified days
40776674|NCT00158093|DRUG|Moxifloxacin|
40776675|NCT01027676|DRUG|Study treatment|Gefitinib 250mg/QD plus vorinostat D1\~7 \& D15-21 / QD q 4weeks
40776676|NCT02017184|BIOLOGICAL|Noninvasive core temperature thermistor|
41142909|NCT06245902|DRUG|Naltrexone and Acetaminophen|Naltrexone plus acetaminophen
41142910|NCT06245902|DRUG|Naltrexone and Acetaminophen-High Dose|Naltrexon (high dose) plus acetaminophen
41142911|NCT06245902|DRUG|Naltrexone Alone (regular dose)|Naltrexone Alone plus Placebo
41142912|NCT06245902|DRUG|Acetaminophen Alone|Acetaminophen Alone plus Placebo
41142913|NCT06245902|DRUG|Matching Placebo|Two Placebo capsules
41461964|NCT06439394|DRUG|Optive MEGA-3 (OM3)|Eye Drops
41461965|NCT02199379|DRUG|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
41461966|NCT00831987|BIOLOGICAL|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
41461967|NCT00831987|BIOLOGICAL|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
41461968|NCT05509257|DRUG|Naltrexone|Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
40981233|NCT03709771|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Measurement|"Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.~Follow-up Visit (approx 1 month after starting treatment): Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure."
40981234|NCT01979484|DRUG|PPI-668 capsule|
40981235|NCT01979484|DRUG|PPI-668 tablet|
40981236|NCT04202991|OTHER|Exposure - pain|Groups are defined by their naturally occurring exposure to pain or not
40981237|NCT05721963|DIAGNOSTIC_TEST|No interventions.|No interventions.
40981238|NCT05573607|DIETARY_SUPPLEMENT|Placebo|Maltodextrin tablet
40981239|NCT05573607|DIETARY_SUPPLEMENT|Chromium|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
40981240|NCT02485301|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
40981241|NCT02485301|DRUG|Placebo|A single dose administrated intramuscular
40981242|NCT04246060|DRUG|Cysteamine Bitartrate|ERT
40981243|NCT00680043|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
40981244|NCT00680043|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
40981245|NCT00680043|DRUG|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
40981246|NCT03541824|BEHAVIORAL|Body Acceptance Program|The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
40981247|NCT03240250|PROCEDURE|VATS uni-portal lobectomy and lymphoadenectomy|VATS uni-portal lobectomy and lymphoadenectomy
40981248|NCT03240250|PROCEDURE|VATS three-portal lobectomy and lymphoadenectomy|VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
40981249|NCT00661622|DRUG|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
40981250|NCT00661622|PROCEDURE|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
40981251|NCT00147888|PROCEDURE|Acoustic rhinometry (procedure)|Acoustic rhinometry is a procedure that uses sound waves to measure the cross-sectional area and volume of the nasal cavity.
40981252|NCT03114813|DRUG|Carvedilol|Non-selective beta-blocker as per routine clinical care
40981253|NCT03114813|OTHER|MRI scan|One hour non-invasive MRI scan
40981254|NCT03114813|PROCEDURE|Hepatic Venous Pressure Gradient (HVPG)|Second HVPG to evaluate treatment response
40981255|NCT03232801|BEHAVIORAL|mindfulness-based multicomponent intervention|A group-based, multicomponent behavioral intervention rooted in mindfulness
40981256|NCT03232801|BEHAVIORAL|general health education group|A general health and aging education group
40981257|NCT04988724|BEHAVIORAL|Exercise training|Exercise training with aerobic and strength training, 30 min per session
40981258|NCT01862198|DEVICE|EUS-guided biliary drainage with a hybrid metallic stent|EUS-guided biliary drainage with a newly designed hybrid metallic stent
40981259|NCT05901779|DRUG|live combined Bifidobacteriun, Lactobacillus and Enterococcus capsules|Probiotics capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Each capsule contained\>10,000,000 colony-forming units (CFUs). This drug can treat endoxemia caused by imbalance of intestinal flora.
40981260|NCT01288469|DRUG|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
40981261|NCT01288469|DRUG|Placebo (for alirocumab)|One SC injection in the abdomen only.
40981262|NCT01288469|DRUG|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
41461969|NCT05509257|DRUG|Placebo|Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
40981263|NCT01288469|DRUG|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
40981264|NCT00970333|DRUG|[18F]-FEPPA|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) of \[18F\]-FEPPA followed by serial PET imaging
40981265|NCT05132920|DRUG|Dexamethasone|3 x 8 mg dexamethasone daily for days 1-7 and 1 x 8 mg dexamethasone daily for days 8-21
40981266|NCT05132920|DRUG|Placebo|3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21
40981267|NCT05567289|PROCEDURE|Blood sample collection|"Enrolled patients will undergo sequential blood collection beginning prior to conditioning, then on the day of transplant (day 0), followed by days 7, 14, 21, 28, 56 (2 months) and 90 (3 months) post-transplant.~Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.~The study will also collect an additional blood sample at the onset of treatment for aGvHD for those who receive systemic corticosteroids (PO or IV steroid equivalent to ≥0.5mg/kg prednisolone)."
40981268|NCT05567289|PROCEDURE|Bone marrow aspirate|Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.
40981269|NCT05945914|PROCEDURE|Oncoplastic Entirely Robot-Assisted Approach (OPERA)|Robotic-assisted surgery in both mastectomy and free DIEP flap harvest, so-called Oncoplastic Entirely Robot-Assisted Approach (OPERA).
40981270|NCT06264128|DEVICE|TPAP|"TPAP is a form of CPAP therapy where the therapy pressure is reduced from the beginning of inhalation through mid or later exhalation. The CPAP therapy pressure is only present at the end of the expiratory phase."
41461970|NCT06334562|DRUG|SUGAMMADEX SODIUM 100 Mg in 1 mL|The dose of Sugammadex Sodium 100 Mg in 1 mL is 2mg/kg
41303129|NCT06296628|DEVICE|Miraπ|"This device has tiny sensors that measure the movement of the healthy fingers and tiny motors that move the affected fingers of the patient.~The device is connected to a specially designed finger mechanism that moves the affected fingers of the patient. This opening mechanism is designed in a way that it prevents the fingers from being forced into any hurting position. If the patient moves the healthy fingers during training, also the fingers of the affected hand are moved by the device at the same time. This creates the effect of mirror therapy for the brain as the patient can see both hands moving."
41303130|NCT06296628|BEHAVIORAL|Mirror Therapy|Current standard of care using MT.
41303131|NCT05415540|OTHER|Questionnaires|Subjects included in the study will answer questionnaires
41461971|NCT06334562|DRUG|Neostigmine|Neostigmine is 50 μg/kg
41461972|NCT01763554|DRUG|Lu-177 DOTA-TATE|The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
41461973|NCT01514513|DRUG|Licefreee Spray|Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
41461974|NCT01514513|DRUG|1% permethrin creme rinse|Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
41461975|NCT00879684|BIOLOGICAL|CVX-060|Weekly, intravenous dose
41461976|NCT04346862|DRUG|Acetyl-L-carnitine hydrochloride 500mg|The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
41461977|NCT04346862|DRUG|Placebo|The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
41461978|NCT05327712|BEHAVIORAL|Control group|No outreach during the intervention period beyond an initial eligibility notice.
41461979|NCT05327712|BEHAVIORAL|Email only|Email reminders in addition to an initial eligibility notice.
41461980|NCT05327712|BEHAVIORAL|Phone only|Phone call offering enrollment assistance in addition to an initial eligibility notice.
41461981|NCT05327712|BEHAVIORAL|Phone and email|Phone call and email reminders in addition to an initial eligibility notice.
41461982|NCT03348527|DRUG|2-Hydroxyflutamide Depot|Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide
41461983|NCT01858922|DRUG|ABVE-PC|"Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 \& Day 2~Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8~Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 \& 8 (Max dose 2.8mg)~Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of \</=0.4mg/ml in NS on Day 1, 2 \& 3~Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable~Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1"
41461984|NCT01858922|DRUG|DECA|"Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine\*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide\*~\*Mix together in NS at an etoposide concentration of \</=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion."
41461985|NCT06449027|DRUG|T Leuprolide Injectable Emulsion|Arm 1 subjects were injected Leuprolide Injectable Emulsion 42mg every 24 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.
41461986|NCT06449027|DRUG|Leuprorelin Acetate Microspheres for Injection|Arm 2 subjects were injected Leuprorelin Acetate Microspheres for Injection 11.25mg every 12 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.
41461987|NCT05690035|DRUG|Tislelizumab & Fruquintinib|combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent
40981271|NCT06264128|DEVICE|CPAP|CPAP is a standard formal at home therapy for obstructive sleep apnea where a device attached via a facemask applies a constant pressure to a patient's lungs during sleep. It is the reference standard in this study.
41461988|NCT02978651|DRUG|Pitolisant (BF2.649)|
40776677|NCT05334238|DRUG|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
40981272|NCT01988259|PROCEDURE|Bilateral approach for Laminoplasty|Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis
40981273|NCT01988259|PROCEDURE|Unilateral approach for laminoplasty|Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.
41142914|NCT03788707|OTHER|Passive leg raising|After 30 seconds of lying flat, volunteers will have passive leg raising to 45 degrees. Expired CO2 will be measured via a face mask before and after leg raising.
41461989|NCT02978651|DRUG|Placebo Oral Tablet|
41461990|NCT02199119|BEHAVIORAL|Exercise|30 min of moderate exercise on a treadmill
41461991|NCT02199119|BEHAVIORAL|TV viewing|watching TV (animated children's programming) for 30 min
41461992|NCT02199119|BEHAVIORAL|Sitting quietly|Sitting quietly for 30 min
41461993|NCT00117182|DRUG|Dry powder mannitol|
41461994|NCT00117182|DRUG|Budesonide 400mcg administered via turbuhaler|
41461995|NCT00117182|DRUG|Ipratropium bromide 80mcg|
41461996|NCT00117182|DRUG|Salbutamol 400mcg|
41461997|NCT01104948|DRUG|DA-8031|
41461998|NCT01104948|DRUG|Placebo|
41461999|NCT05692791|DIAGNOSTIC_TEST|Two-point Discrimination Test|Two-point discrimination (2PD) is the ability to discern that two nearby objects touching the skin are truly two distinct points, not one. It is often tested with two sharp points during a neurological examination and is assumed to reflect how finely innervated an area of skin is.
40776678|NCT06563960|OTHER|carbonated water|Participants will drink carbonated water during videofluoroscopy.
40776679|NCT05799755|DRUG|Nintedanib|Nintedanib 150 mg BID
40776680|NCT05799755|DRUG|Placebo|Placebo comparator
40776681|NCT05799755|DRUG|Standard of Care|Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
40776682|NCT03695445|DRUG|Peripheral administration of Norepinephrine|Systematic follow-up of complications from peripheral administration of Norepinephrine
40981274|NCT01988259|PROCEDURE|Subperiosteal approach for foraminotomy|Unilateral subperiostal approach for single level foraminotomy
40981275|NCT01988259|PROCEDURE|Transmuscular approach for foraminotomy|Unilateral transmuscular approach for single level foraminotomy
40981276|NCT00846131|DRUG|Sorafenib|Randomized to Y-90 ± Sorafenib
40981277|NCT00846131|DRUG|Yttrium-90 (Y-90)|Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
40981278|NCT00864045|DRUG|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
41142915|NCT00722865|DRUG|Avastin|Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
41142916|NCT06257563|OTHER|Isle of TEND Intervention|"The Isle of TEND is an interactive videogame platform in which users navigate to different modules on a virtual island. The modules aim to create a pleasant, shared and error-free experience for persons with dementia and their caregivers."
41142917|NCT00015132|DRUG|Sertraline|
41142918|NCT05529485|PROCEDURE|Cataract surgery by phacoemulsification|Cataract surgery by phacoemulsification
41142919|NCT00071188|DRUG|ZD6474|
41142920|NCT00071188|DRUG|Paclitaxel|
41462000|NCT05692791|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament test|Semmes-Weinstein monofilament test is used to assess light touch sensations.
41462001|NCT02786927|DRUG|Placebo ELLIPTA device|Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
41462002|NCT02786927|DRUG|Placebo capsules for use in HANDIHALER device|Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
41462003|NCT02786927|OTHER|Inhaler Preference Questionnaire Version 1|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
41462004|NCT02786927|OTHER|Inhaler Preference Questionnaire Version 2|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
41462005|NCT00397696|DRUG|[123I] 5-IA|All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of \[123I\] 5-IA followed by SPECT imaging as described below. A second \[123I\] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial \[123I\] 5IA imaging session.
41462006|NCT01341405|DRUG|CG100649|once daily for 28 days
41462007|NCT01341405|DRUG|Celecoxib|capsule, celecoxib 200 mg, once daily for 28 days
41462008|NCT03008538|OTHER|MPM(Mineralized plasmatic matrix).|Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
41462009|NCT03008538|OTHER|Autogenous Bone Graft|Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
40776683|NCT02614820|PROCEDURE|Remote Ischemic Preconditioning Training Apparatus|
41142921|NCT00071188|DRUG|Carboplatin|
40776684|NCT01916031|BEHAVIORAL|Education|
40776685|NCT05779930|BIOLOGICAL|CD19 specific Chimeric Antigen Receptor T Cell|Infusion of CD19 CAR-T Cells manufactured on-site using the CliniMACS Prodigy
40776686|NCT04179344|OTHER|Integrated e-healthcare services (IeHS) web-based app|Each participant is asked to complete study tasks using the IeHS web-based app as a part of IeHS simulation. This activity is followed by user experience survey, and an in-depth interview to explore user satisfaction on the IeHS web-based app
40776687|NCT00478257|DEVICE|bright white light|Intervention: Bright white light administered for 30 minutes each morning
40776688|NCT00478257|DEVICE|comparator red light treatment|dim red light administered for 30 minutes every morning
40776689|NCT03598348|DRUG|Apatinib+Capecitabine|Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
40776690|NCT03598348|DRUG|Apatinib|Apatinib 250mg po Qd
40776691|NCT06349213|RADIATION|FDOPA injection before PET imaging|Fluorodopa labelled with fluorine 18 (physical half-life of 109.6 min) is used at a dosage of 1 to 2 MBq/kg in neuroimaging, depending on the sensitivity of the PET camera used. For these reasons, a dose of 2 MBq/kg will be administered slowly intravenously (approximately 1 minute for a maximum bolus of 10 mL). PET acquisitions will be performed at 90 minutes post-injection and will last 30 minutes. Participants will be asked to have fasted for at least 4 hours at the time of injection, with no restriction on fluid intake.
40776692|NCT06349213|BEHAVIORAL|Time perception tasks|The main tasks involves the comparison of duration to assess aging effects on the precision of temporal representations
41462010|NCT01367782|DEVICE|repetitive transcranial stimulation (r-TMS)|Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
40776693|NCT06349213|DEVICE|fMRI imaging|Imaging of brain structure during the completion of the time perception task
40776694|NCT06349213|DEVICE|EEG imaging|Recording of neural dynamics during the completion of the time perception task
41462011|NCT01367782|DEVICE|repetitive transcranial stimulation (r-TMS)|Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
41462012|NCT05578469|PROCEDURE|surgical treatment of Marfan Syndrome with subluxation lens|different surgical treatment of Marfan Syndrome with subluxation lens
41303132|NCT05863494|DEVICE|Transcranial Direct Current Stimulation (tDCS)|TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders. Although tDCS is not currently FDA-approved it is considered a non-significant-risk therapy with no record of serious adverse effects.
40776695|NCT06349213|BEHAVIORAL|3 year follow-up|Behavioral and EEG follow-up (for older adults only)
41462013|NCT01658358|DRUG|Lapatinib|"* dose level I, II 1000mg po daily~* dose level III, IV 1250mg po daily"
41462014|NCT01658358|DRUG|Lipo-Dox|at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
40776696|NCT06511583|PROCEDURE|Laryngotracheal Aspiration Procedure Using a Probe in the Emergency Department|For laryngotracheal aspiration using a blind probe, the patient will be positioned in a seated or semi-seated position; if this is not possible, the aspiration will be performed in a supine position. A soft, sterile catheter connected to the suction apparatus will be inserted into one nostril while keeping the patient\&#39;s head tilted back. When the tip of the catheter reaches the back of the pharynx, the patient will need to breathe to facilitate the insertion and allow the catheter to advance into the larynx and trachea. At this point, using negative suction pressure for a maximum of 3-5 seconds, the secretions will be aspirated. The aspiration will be repeated multiple times in cycles of 3-5 seconds.
40776697|NCT06511583|PROCEDURE|Aspiration Procedure Using Fibrobronchoscopy in the Emergency Department|"Equipment Setup:~A sterile bronchoscope will be connected to the suction apparatus.~Procedure:~The bronchoscope will be gently inserted through the patient\&#39;s nostril or mouth, advancing carefully through the pharynx and larynx into the trachea and bronchi.~The physician will visually inspect the airways through the bronchoscope. Using the bronchoscope's suction channel, secretions will be aspirated from the trachea and bronchi.~Suctioning will be performed intermittently to avoid hypoxia, with each suctioning cycle lasting no more than 3-5 seconds.~The procedure may be repeated as necessary to ensure thorough aspiration of secretions."
40776698|NCT03594708|DIETARY_SUPPLEMENT|Nutrition supplement|Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc
40776699|NCT03594708|DIETARY_SUPPLEMENT|Placebo supplement|rice starch, light olive oil, vegetable oil
40776700|NCT05743309|BEHAVIORAL|Video call sessions|Investigators made video call sessions with the participants.
41462015|NCT03311945|DRUG|Raltegravir|Raltegravir (1200 mg QD)
40776701|NCT03518021|DRUG|Naloxone, intranasal|"Active compound naloxone 14 mg/ml, (±10%). Nasal spray will be administered with one puff (100 microL ±10%) in one nostril (1.4 mg dose) using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
40776702|NCT03518021|DRUG|placebo, intranasal|"Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
40776703|NCT03518021|DRUG|Naloxone, intramuscular|Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM
40776704|NCT03518021|DRUG|placebo, intramuscular|Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
40776705|NCT01233544|PROCEDURE|SBRT or RFA|Patients are allocated to one of the two arms in a 1:1 randomization
40776706|NCT02889874|RADIATION|Omission of radiation therapy|Omission of radiation therapy (adjuvant endocrine therapy only).
40776707|NCT00573768|DRUG|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
40776708|NCT00573768|DRUG|Placebo|Vehicle 2 times daily
41462016|NCT03311945|DRUG|Lamivudine|Lamivudine (300 mg QD)
40776709|NCT00573768|DRUG|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
41462017|NCT02985749|DRUG|Intranasal Oxytocin|This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
41462018|NCT06206044|DRUG|Intrathecal 1.6 ml 0.75% bupivacaine in 8.25% dextrose combined with 15 mcg fentanyl and 150 mcg preservative-free morphine|Patients will receive standard intrathecal medications for urgent and scheduled cesarean delivery at the study site. All study subjects will receive bupivacaine, fentanyl, and morphine.
41462019|NCT05878899|DRUG|Enoxaparin|Prophylactic dose of enoxaparin once daily for 10 days after delivery.
41462020|NCT04339595|BIOLOGICAL|Tildrakizumab|Participants who have participated and completed the long-term extension phase of the reSURFACE 2 study (NCT01729754) and 12 weeks after the last Tildrakizumab dose will be included in the present study. Participants will not receive any study medication during the present study. Participants will remain in the study for 96 weeks or until they initiate any systemic therapy for psoriasis (including phototherapy), whichever occurs first.
41462021|NCT01686217|DRUG|ASP015K ER|oral extended release (ER) at three dosing levels
41462022|NCT01686217|DRUG|ASP015K IR|oral immediate release (IR)
41462023|NCT02405793|DRUG|Meloxicam Test Capsules|
41462024|NCT02405793|DRUG|Meloxicam Test Capsules|
41462025|NCT02405793|DRUG|Meloxicam Tablets|
41462026|NCT00753350|DEVICE|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
41462027|NCT03605992|OTHER|Home-based Rehab|This intervention will have the duration of 12 weeks, with a total of 60 sessions: 2 supervised and 58 at home (to complete five exercise's sessions for week).
40981279|NCT00864045|DRUG|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
40981280|NCT00006344|RADIATION|radiation therapy|
40776710|NCT00492453|PROCEDURE|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
40776711|NCT01793389|PROCEDURE|Subepithelial connective tissue graft|
40776712|NCT01793389|PROCEDURE|Platelet Rich Fibrin|
40776713|NCT03985202|OTHER|Structured exercise programme|9 week structured exercise programme. 3 sessions per week. (Intervention).The patient will be invited to the hospital for a 45-minute exercise counselling session, incorporating behaviour modification techniques. These behaviour modification techniques will be reinforced during the supervised exercise sessions. Participants will be offered 3 sessions of supervised aerobic interval exercise sessions per week on a cycle ergometer for 9 weeks.Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
40776714|NCT01741961|PROCEDURE|Ahmed valve|The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
41303133|NCT05863494|DEVICE|Transcranial Direct Current Stimulation (tDCS) sham|"TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders.~The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle."
41303134|NCT01264250|DRUG|AZD2927|Single dose of AZD2927
41303135|NCT01264250|DRUG|Placebo|Single dose of placebo
41303136|NCT01290484|DRUG|Sildenafil|Sildenafil oral tablet three times daily
41303137|NCT00307060|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks|
41303138|NCT00307060|DRUG|losartan / Duration of Treatment: 6 weeks|
41303139|NCT04951648|DRUG|Almonertinib|Almonertinib 165 mg，orally once a day Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
41303140|NCT04951648|DRUG|chemotherapy|Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
41303141|NCT02159963|OTHER|Supervised training|8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.
41462028|NCT03605992|OTHER|CentreRehab|This intervention will last 12 weeks, with a total of 60 sessions: 24 supervised and 36 at home (to complete five exercise's sessions for week).
40776715|NCT02157909|DEVICE|Lotrafilcon B sphere modified design contact lenses|
40776716|NCT02157909|DEVICE|Lotrafilcon B sphere contact lenses|
40776717|NCT02334657|OTHER|SF-36|postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
40776718|NCT01055028|DRUG|Bevacizumab|15 mg/kg, IV every 21 days x 6 cycles.
40776719|NCT01055028|DRUG|Paclitaxel|"Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle"
40776720|NCT02692573|OTHER|positioning|prone positioning for the initial 5 minutes of life
41303142|NCT02159963|OTHER|Unsupervised training|8 weeks home based high-intensity-interval cycle-training 3 times a week.
41303143|NCT02159963|OTHER|Optional training|8 weeks of optional home based, unsupervised training.
41303144|NCT02159963|OTHER|Control|8 weeks of control period. Participants are doing daily living.
41303145|NCT04140708|BEHAVIORAL|Exercise--Rock Steady Boxing class|Rock Steady Boxing is a class designed specifically for those with Parkinsonism and movement difficulty using explosive and fine tuned movements as well as cognitive learning skills.
41303146|NCT03960138|DEVICE|Intermittent Theta-burst stimulation (iTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
41303147|NCT03960138|DEVICE|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
41462029|NCT00464113|DRUG|XL228|1-hour IV infusion
41462030|NCT02913287|DIETARY_SUPPLEMENT|Aquamin/Aquamin MG|Marine-based nutraceutical
41462031|NCT02913287|OTHER|Maltodextrin Placebo|Maltodextrin Placebo
40776721|NCT02692573|OTHER|positioning|supine positioning for the initial 5 minutes of life
40776722|NCT03341936|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
40981281|NCT02622542|DEVICE|BMT+TEVAR|These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
40981282|NCT02622542|OTHER|BMT|Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
40981283|NCT02291874|DRUG|Ipragliflozin|oral
40981284|NCT01512082|DEVICE|Pulsed electromagnetic field devices|Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
40981285|NCT01512082|DEVICE|Pulsed electromagnetic field devices|Every persons received two sham pulsed electromagnetic field devices.
40776723|NCT03341936|DRUG|Lirilumab|Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
41303148|NCT02779192|DRUG|SPI-1005 200mg|Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
41303149|NCT02779192|DRUG|SPI-1005 400mg|Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
41303150|NCT02779192|DRUG|Placebo|Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
41462032|NCT03448692|DRUG|PF-06730512|Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.
41462033|NCT04274829|PROCEDURE|Thyroidecomt and lymphectomy|Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy
41462034|NCT01780467|BEHAVIORAL|Role of dopamine|
41462035|NCT05514340|DRUG|Normal Saline along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.
41462036|NCT05514340|DRUG|Sovateltide along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
41462037|NCT00943813|BEHAVIORAL|video-recording and completing a survey|"Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, I disagree completely  to 5, I agree completely ."
40776724|NCT05574881|DRUG|Dalpiciclib|150 mg qd
40776725|NCT05574881|DRUG|Fulvestrant|500mg d1, 15, 29, and then q4w
40776726|NCT05574881|DRUG|Pertuzumab|840mg q3w, and then 420 mg q3w
40776727|NCT05574881|DRUG|Trastuzumab|8 mg/kg q3w, and then 6 mg/kg q3w
40776728|NCT02838667|PROCEDURE|Standard of Care plus Nephrology Care|
40981286|NCT01549093|DRUG|Gemcitabine,Carboplatin,Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2\*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
40981287|NCT01549093|DRUG|Gemcitabine(G) Carboplatin(C) Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
40981288|NCT01549093|DRUG|Gemcitabine(G) Carboplatin(C)|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
40981289|NCT01857388|BEHAVIORAL|ParentCorps|
40981290|NCT05461794|DRUG|Sitravatinib|administered orally
40981291|NCT05461794|DRUG|Tislelizumab|administered intravenously
40981292|NCT05461794|DRUG|Docetaxel|administered intravenously
40981293|NCT05461794|DRUG|Irinotecan|administered intravenously
40981294|NCT02550145|DRUG|Exendin (9-39)|IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
41303151|NCT05962996|DEVICE|Pupillometry|Measurement of pain levels by pupillometry during the insertion of a deep venous catheter
41303152|NCT05369117|BEHAVIORAL|indocyanine green labeled fluorescent laparoscopy|indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery
41303153|NCT00086658|DRUG|mepolizumab|
40776729|NCT01786122|OTHER|Supervised Physical activity|Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
40776730|NCT01786122|BEHAVIORAL|education program on healthy habits|education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
40776731|NCT02298725|OTHER|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.
40981295|NCT02550145|OTHER|Placebo|IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
40981296|NCT05357274|DIAGNOSTIC_TEST|Diagnostic testing|Data will be uploaded to a server where algorithms will be deployed that incorporate features related to treatment use and variables of airflow will allocate the care pathway into one of the 4 pathways. Treatment will be directed by this using a validated automated decision support system
40981297|NCT05470426|OTHER|COVID-19 Omicron Recurrence|COVID-19 Omicron Recurrence
41142922|NCT00980538|DRUG|Etravirine|Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
41142923|NCT06185452|DRUG|Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as standard of care.
41303154|NCT01924910|DIETARY_SUPPLEMENT|250,000 IU cholecalciferol as single, oral dose|250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
40981298|NCT05490745|BEHAVIORAL|Skills4Parenting+|Skills4Parenting+ has 6-8 weekly individual online sessions (50 min) + 8-week follow-up. First, an assessment session of parents' positive parenting skills (PPS), based on mother/father-child interaction observation. The following sessions aim to (1) promote parental reflective functioning, enhancing parents' understanding of the child´s problems, and (2) activate PPS to solve the child's problems. Written registers of problematic situations - in which the problems of the child occur, are analyzed (i.e., child's and parents' behaviors, thoughts, and feelings) (intersession activity) - are reflected upon, to understand and solve through PPS. PPS implementations are analyzed to understand the changes in the child and parent. Future situations and activation of appropriate PPS are anticipated, to solve potential upcoming problems of the child's, related to adversity. When the therapeutic goals have not been fully achieved, two additional sessions (total of 8 instead of 6), are added.
40981299|NCT05490745|OTHER|Waiting-list (nocebo)|Participants wait to receive the psychological intervention (Skills4Parenting+) for eight weeks, after the assessment session.
40981300|NCT02653287|BEHAVIORAL|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary.
40981301|NCT02653287|OTHER|Control|The control group will receive four individual phone calls focusing on education for SLE disease management, as well as answering any questions the participants have about the study. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Each call will last about 10-15 minutes, and occur shortly after randomization, then at 1.5, 3, and 6 months.
40981302|NCT04075058|RADIATION|Hypofractionated Radiation therapy|
40981303|NCT00467259|DRUG|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
40981304|NCT00467259|DRUG|Placebo patch|placebo patch, changed twice a week for 52 weeks
40981305|NCT02552563|BEHAVIORAL|Dementia Care Management|The intervention involves two main components. The first component includes individualized dementia care management that involves regular and extended contact between the CG, care manager, and when appropriate, Veteran's primary care provider (PCP). The care manager monitors Veterans' symptoms via CG report, provides psychoeducation and support to CGs, influences adherence to guidelines by providing timely and tailored information to PCPs, and suggests appropriate care strategies and service referrals. The second major component is the Telehealth Education Program (TEP). For this pilot study, the program was modified for use with individual CGs and was formatted so that CGs could select from a menu of up to 7 modules covering various content areas evaluated during the course of the care management assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, long-term planning, etc.).
40981306|NCT00534274|OTHER|3'-deoxy-3'-[18F]fluorothymidine|
40981307|NCT01317082|DEVICE|Acupressure|P 6 Pressure Point
40981308|NCT01096225|BIOLOGICAL|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
40981309|NCT03372811|DRUG|TC cream|A well-characterized botanical drug for topical treatment of psoriasis vulgaris
40776732|NCT02298725|OTHER|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES What we eat in America report."
40776733|NCT03464773|OTHER|PIUO Pathway|See arm descriptions
40981310|NCT03372811|DRUG|Vehicle|Vehicle
40981311|NCT00002667|OTHER|cytology specimen collection procedure|
40981312|NCT00002667|OTHER|immunoenzyme technique|
40981313|NCT00002667|PROCEDURE|study of high risk factors|
40776734|NCT01447992|DEVICE|Portable artificial pancreas system with Control-To-Range|We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
40981314|NCT06037291|DIETARY_SUPPLEMENT|Coriander Seed Oil|The study foresees the intake of 1 capsule per day during 56 days
40981315|NCT06037291|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 56 days
40981316|NCT01438957|DRUG|Dexmedetomidine hydrochloride|Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
40981317|NCT01438957|DRUG|Placebo|
40981318|NCT03692364|DEVICE|Ceramic-on-ceramic uncemented hip arthroplasty|
40981319|NCT03692364|DEVICE|Metal-on-polyethylene uncemented total hip arthroplasty|
40981320|NCT01037647|OTHER|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
41142924|NCT06185452|DRUG|Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Out of Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as an optional therapy in HIV-Infected patients from Spain.
41303155|NCT01924910|DIETARY_SUPPLEMENT|Placebo|
41303156|NCT01465711|PROCEDURE|All abdominal surgical procedures|Laparotomy, Laparoscopy
40776735|NCT03372616|DIAGNOSTIC_TEST|Invasive left ventricular diastolic function assessment|Left ventricular (LV) polyethylene catheter was inserted into left ventricular to directly measure LV filling pressure.
40776736|NCT03372616|DIAGNOSTIC_TEST|Invasive aortic blood pressure measurement|Aortic blood pressure will be measured with polyethylene catheter in aortic root.
41303157|NCT01465711|PROCEDURE|Intubation|Ventilatory support
41303158|NCT01465711|RADIATION|Imaging|Abdominal ultrasound Computer Tomography Magnetic Resonance Imaging
41303159|NCT04645017|BEHAVIORAL|Intergenerational Music Program|Music activities will be lead by adolescent musicians for older adult participants.
41303160|NCT04486443|BEHAVIORAL|music therapy|patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist from the Conservatory Department in the Ege University, using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour.
40981321|NCT05157854|BEHAVIORAL|Active in My Home (AiMH)|"AiMH starts with two workshops for staff to introduce them to the intervention and the contributions expected from them. Their task is to participate in a couple of the sessions, inspire the course participant to stick to strategies developed during the sessions and support activity in general between the occupational therapy sessions.~AiMH consists of eight sessions, five individual ones and three in a group. Each session has a theme, such as: activity and health, and is built up with short lessons, using one's senses such as smell or touch, testing a simple activity, and setting goals for an activity one wants to test between sessions. The participants are given around 25 USD to try out that activity."
40776737|NCT03372616|DIAGNOSTIC_TEST|Non-Invasive left ventricular diastolic function assessment|Echocardiography will be performed in all participants to assess left ventricular diastolic function non-invasively.
41303161|NCT00916799|DEVICE|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
41303162|NCT04495361|OTHER|E-learning portal|An online learning portal for the identification and management of pneumonia in under five children
40981322|NCT06021782|OTHER|All subjects-Observation|The sonographer or study team member will scan the lateral vaginal walls (Left and right) directing the probe slightly caudad in direction of the ischial spine (IS). The IS is very echogenic and easily identifiable (bony landmark). Anatomically, the pudendal nerve courses underneath the IS and travels with the vascular bundle of the pudendal artery and pudendal vein. The artery and the vein will be identified using color flow Doppler at the time of the scan. These landmarks, IS, pudendal artery and vein will serve as the basis for the identification of the pudendal nerve.
41303163|NCT00398541|DRUG|losartan potassium (+) hydrochlorothiazide|losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
41303164|NCT00025532|OTHER|iodine I 131 monoclonal antibody CC49-deltaCH2|
41303165|NCT00506051|DRUG|ZD6474 (vandetanib) 100mg|once daily oral tablet
41303166|NCT00506051|DRUG|pemetrexed|intravenous infusion
41303167|NCT00506051|DRUG|ZD6474 (vandetanib) 300mg|
41303168|NCT00944606|DIETARY_SUPPLEMENT|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
41303169|NCT00944606|OTHER|Placebo candy|candy gum drops
41303170|NCT02046265|BEHAVIORAL|Step Up to Prevention|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
41303171|NCT02046265|BEHAVIORAL|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
41303172|NCT02046265|BEHAVIORAL|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
41303173|NCT02046265|BEHAVIORAL|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
41303174|NCT02661607|PROCEDURE|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
41303175|NCT02661607|DEVICE|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
41303176|NCT02661607|PROCEDURE|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
41303177|NCT04146272|DEVICE|Hearing Aid Mermaid Current|The current hearing aid used to treat hearing loss.
41303178|NCT04146272|DEVICE|Hearing Aid Mermaid New|The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.
41303179|NCT04146272|DEVICE|Power Hearing Aid Current|The current power hearing aid used to treat strong hearing loss.
41303180|NCT04146272|DEVICE|Power Hearing Aid New|The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
40776738|NCT03372616|DIAGNOSTIC_TEST|Non-Invasive aortic blood pressure measurement|Three devices (Sphygmocor \[AtCor Medical, Australia\], PulsePen \[DiaTecne SRL, Italy\], and Mobil-O-Graph \[IEM, Germany\] ) will be used to assess aortic blood pressure non-invasively when participants are undergoing invasive aortic blood pressure measurement.
41303181|NCT05281601|DRUG|AZD7442|"IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion."
40776739|NCT00651287|DRUG|quinapril 20 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
41303182|NCT04367025|DRUG|Camrelizumab|Camrelizumab: 200mg,iv drip for 1h,d1,q3w
41303183|NCT04367025|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
41303184|NCT04367025|DRUG|S1|S-1:40\~60mg Bid, d1\~14, q3w;
41303185|NCT00130299|BEHAVIORAL|low glycemic load diet|
41303186|NCT00130299|BEHAVIORAL|low fat diet|
41303187|NCT00601523|DRUG|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
41303188|NCT00601523|DRUG|Pramipexole|ER 0.375-4,5 mg
41303189|NCT05909566|OTHER|Clinical Decision Support (CDS)|Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.
41303190|NCT05909566|DEVICE|HHFNC Weaning|Wean patient off oxygen and flow as oxygenation and work of breathing improves.
41462038|NCT06358027|DIAGNOSTIC_TEST|lung ultrasound|The patients included in the study underwent lung imaging with lung ultrasound score twice, in the preoperative preparation room and in the postoperative recovery unit.Both lungs were determined as anterior and posterior axillary lines as anatomical markers and divided into a total of 12 regions, 4 in the anterior thoracic wall, 4 in the lateral wall, and 4 in the posterior region. In our study, we will use the modified LUS scoring, which has been shown to be more sensitive in the diagnosis of postoperative atelectasis in the recovery unit, based on existing literature reviews. The degree of the atelectasis will be determined according to do modified lung ultrasound score. Lung ultrasound score imaging of all patients was performed by the same anesthesiologist.
41462039|NCT05770804|BEHAVIORAL|Face to face education|Face-to-face training was provided and supported by booklets.
40776740|NCT00651287|DRUG|quinapril 20 mg plus hydrochlorothiazide 12.5 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
40776741|NCT00651287|DRUG|quinapril 40 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
40776742|NCT04503369|BEHAVIORAL|Non-technical skills|"Teamwork The work of the team consists of information exchange and coordination of all activities performed. In-team communication is always calm and assertive, and team members support each other.~Task management With the right planning and preparation of individual activities, the likelihood that all standards of care and best practices will be followed increases.~Situational awareness Situational awareness refers primarily to the collection of information, its understanding and, on that basis, prediction of direction into which the situation will develop. Maintaining situational awareness is crucial in order to move towards the right goal.~Decision-making With good situational awareness, one is able to keep in mind all information needed to make the correct decision at the right time. In some cases, it is advisable to consult with other team members or to verify their consent to the proposed procedure.~Communication Communication is a vital tool when working in a team."
40981323|NCT05394909|DRUG|Tocilizumab 162Mg/0.9Ml Autoinjector|Patients will receive high-dose pulse intravenous methylprednisolone (500 mg ) for 3 consecutive days (Day 0-1-2) and subsequently will be treated weekly with Tocilizumab 162 mg s.c. for 52-weeks and then following according to SOC
40981324|NCT03725696|DIAGNOSTIC_TEST|Semen Analysis|Sperm counts will be determined by semen analysis.
41303191|NCT04527016|PROCEDURE|Microbiota and eosinophils based therapy|"1. Blood eosinophils ≥3%+ mixed airway microbiota: 3 month course of FP 50 ug twice daily via spacer~2. Blood eosinophils\<3%+ Moraxella species\>40% in airway microbiota: Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~3. Blood eosinophils ≥3%+ Moraxella species\>40% in airway microbiota: 3 month course of FP 50 ug twice daily via spacer and Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~4. Blood eosinophils\<3%+ mixed airway microbiota: intermittent budesonide inhalation suspension (1mg twice daily) and terbutaline inhalation suspension for 7 days during wheeze episode.~The participants will be followed up for one year after the intervention."
41462040|NCT05126212|OTHER|User experience|User experience is assessed by validated scale
41462041|NCT03866928|DRUG|Stiripentol|1500 mg of stiripentol b.i.d.
41462042|NCT03976934|DRUG|Tamsulosin|administration of tamsulosin tablets
41462043|NCT03976934|DRUG|Placebo oral tablet|sugar pills
41462044|NCT01214239|DRUG|Placebo|once a day
41462045|NCT01214239|DRUG|Linagliptin|once a day
41462046|NCT05925725|DRUG|• harpagozid • boswellin = LOXACON|Exercise therapy
41462047|NCT06168903|PROCEDURE|Ultrasound guided EOI block|"Before receiving general anesthesia, patients will be randomly assigned to one of the two study groups: the EOI block group or the ESPB group.~Using Ultrasound (Siemens ACUSON X300 Ultrasound System), guided blocks will be administered immediately after the induction of anesthesia and prior to surgical incision by consultant anesthesiologists who have experience in regional anesthesia and are familiar with the EOI and ESPB blocks"
41462048|NCT04190706|OTHER|bioactive components fortified food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of fortified biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
41462049|NCT04190706|OTHER|control food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of standard biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
41462050|NCT05460962|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
41462051|NCT05460962|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
41462052|NCT04438044|DRUG|ICP-022|ICP-022 The drug product is a white, round, uncoated tablet
41462053|NCT05993754|OTHER|Non-pharmacological intervention|"The intervention consists of six main elements:~Correction of sensory deficits: Before surgery, the use of glasses, hearing aids and/or removable dental prostheses will be allowed, which will be removed before starting anesthesia in the emergency room. After surgery, they will be delivered back to the user.~Reorientation: In the postoperative period, the person will be informed where they are and the visit of the companion will be coordinated.~Early mobilization: A protocolized mobilization routine will be applied according to pain, state of consciousness, risk of thromboembolic disease and risk of falls.~Environmental management: You will be shown the time on a clock, it will reinforce the idea of the place where you are and that you can count on the team in case you need assistance.~Sleep protocol: The elderly person who does not want or cannot perform the mobilization routine, non-pharmacological sleep will be privileged.~Reduction of anticholinergic drugs"
41462054|NCT04136067|DRUG|NNC0268-0965|One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
41462055|NCT04136067|DRUG|insulin glargine|One daily dose of 3.0 nmol/kg administered s.c. for 6 days
41462056|NCT00691041|BEHAVIORAL|Unity in Diversity|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
41462057|NCT03563885|PROCEDURE|bariatric surgery|subjects already scheduled Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery
41462058|NCT04707846|DEVICE|Bright Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses are a commercially available device which have 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and typical irradiance (100% intensity) of approximately 250 µW/cm². AYO bright light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
41303192|NCT04527016|DRUG|Clinical guidelines based therapy|"The children will be treated as directed by their paediatrician ( The clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016).The treatment protocols include:~1. regular inhaled FP 50 ug twice daily via spacer for 3 months;~2. montelukast(4mg od for 3 months)~3. intermittent budesonide inhalation suspension (1mg twice daily for 7 days during wheeze episode).~The participants will be followed up for one year after the intervention."
41303193|NCT00488033|PROCEDURE|CT Angiography|If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
41303194|NCT00673998|DEVICE|Isokinetic Dynamometer (Biodex system III)|Biodex system III Isokinetic Dynamometer (Biodex Medical, Inc., Shirley, NY).
41303195|NCT06130657|PROCEDURE|Lateral Maxillary Sinus Floor Elevation using surgical guide|The surgical procedure begins with securing a prefabricated guide firmly to the surgical site. Implant positions are marked, and after guide removal, a crestal incision is made 1 mm palatal to the marked point, extending with sulcular and vertical incisions. A full-thickness mucoperiosteal flap is reflected to expose the maxillary sinus and alveolar crest. After readapting the surgical guide to the bone, implant positions are marked, and cutting edges are tracked. The lateral window is formed by extending and connecting mesial and distal borders, created using piezotome. The sinus membrane is carefully reflected and elevated with a surgical curette to avoid iatrogenic perforation. Implant fixtures are then placed using the identical surgical guide, followed by graft material placement beneath the elevated sinus membrane. If the bony plate is preserved, the lateral window is covered with the plate.
41303196|NCT06130657|PROCEDURE|Lateral Maxillary Sinus Floor Elevation without surgical guide|The sinus's lateral wall is exposed through a crestal incision and a mucoperiosteal flap. A bony window is created, and upon its removability, the sinus floor is carefully elevated using sinus elevation curettes, taking care to avoid membrane perforation. In cases of perforation, a resorbable collagen membrane is applied to cover the hole. Implant osteotomies are then completed following the standard sequential placement protocol. Graft material, mixed with normal saline, is gently packed into the sinus to fill the cavity with bone substitute material and achieve the desired bone height. Finally, a resorbable membrane is placed on the outer surface of the window, and the flap is sutured for primary closure.
41303197|NCT04230486|DEVICE|Cross-model Visual Auditory Rehabilitation|Subjects will put on a virtual reality rehabilitation system which will present sights and sounds.
40981325|NCT03725696|DIAGNOSTIC_TEST|Hormonal panel|Blood test for LH, FSH, testosterone, and estradiol
40981326|NCT03725696|PROCEDURE|RYGB Gastric Bypass|Roux-en-Y Gastric Bypass
40981327|NCT03725696|DIAGNOSTIC_TEST|IIEF Survey|International Index of Erectile Function is a validated 5-question survey examining sexual health in men
40981328|NCT04358666|PROCEDURE|surgery and focal radiosurgery of the surgical bed|hypofractionned radiosurgery of the lesion
40981329|NCT02751996|DRUG|SB 9200|SB 9200
40981330|NCT02751996|DRUG|Placebo|
40981331|NCT02751996|DRUG|Tenofovir|
40981332|NCT05424042|BEHAVIORAL|In-Person Caloric Restriction|20% CR delivered in-person by dietitian/coach
40981333|NCT05424042|BEHAVIORAL|Remote Caloric Restriction|20% reduction in caloric intake, meeting schedule, and physical activity goal delivered remotely.
41303198|NCT05196243|OTHER|Patients diagnosed as gastrointestinal mucosal lesions|Patients diagnosed as gastritis, gastric cancer, intestinal polyps and colorectal cancer
41303199|NCT02193269|DRUG|Sugar pill|you will receive 0.0 mg as a single daily dose for 4 days
41303200|NCT02193269|DRUG|Minocycline|you will receive 200 mg as a single daily dose for 4 days
41303201|NCT01529476|DRUG|Levofloxacin|levofloxacin 500 mg,QD,7\~10 days
41303202|NCT01529476|DRUG|Nemonoxacin|Nemonoxacin 500mg,QD,7\~10 days
41462059|NCT04707846|DEVICE|Dim Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses were made available to the research team by the vendor. The device has 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and reduced irradiance (1% intensity) of approximately 250 µW/cm². AYO dim light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
41462060|NCT04594720|OTHER|Identification group|papillary thyroid cancers (n=10) and benign thyroid tumors (n=10)
41462061|NCT04594720|OTHER|Validation group|papillary thyroid cancers (n=45) and benign thyroid tumors (n=35)
41462062|NCT04535193|DRUG|18F-mFBG for intravenous administration|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
40981334|NCT05424042|BEHAVIORAL|Time-restricted|8-hour TRE with ad libitum caloric intake. This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake.
40981335|NCT03612297|DIAGNOSTIC_TEST|Selective reporting of Antibiotic Susceptibility Tests|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
40981336|NCT01863212|PROCEDURE|Blood sampling for genetic analyse|Blood sampling are performed at the initiation visit in order to screen for allele variants
40981337|NCT01863212|BEHAVIORAL|Stroop test|Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.
40981338|NCT01863212|OTHER|fMRI|Functional Magnetic Resonance Imaging, performed to view brain activity
40981339|NCT01606345|DRUG|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
40981340|NCT03707327|OTHER|Game Ready|the participants remained for 20 minutes with intermittent compression therapy + cryotherapy
40981341|NCT03707327|OTHER|Ice pack|the participants remained for 20 minutes with cryotherapy with ice pack
41303203|NCT02069782|OTHER|Home visiting|Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
41303204|NCT04802876|DRUG|Spartalizumab|Spartalizumab (PDR001) 400mg will be given intravenously every 28 days
41303205|NCT04802876|DRUG|Tislelizumab|Tislelizumab 300mg will be given intravenously every 28 days
41303206|NCT05151341|DIAGNOSTIC_TEST|Urine collection (150ml)|Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)
41303207|NCT05151341|OTHER|Blood sample (20 ml)|"Blood sample will be tacken at inclusion, ONLY for case patients that agreed upon this. This sample will be addition to the collection for further research."
41303208|NCT03883022|DRUG|with U-VANCO (vancomycin hydrochloride)|1 gm or 2 gm mixed with autogenous cancellous bone graft
41303209|NCT03883022|DRUG|without U-VANCO (vancomycin hydrochloride)|no vancomycin added
41303210|NCT00121303|DRUG|cytarabine|
41303211|NCT00121303|DRUG|daunorubicin hydrochloride|
41303212|NCT00121303|DRUG|gemtuzumab ozogamicin|
41303213|NCT03064776|DEVICE|m-RESIST Patients|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
40981342|NCT05992610|OTHER|Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy|"Chemotherapy based on carboplatin 6 AUC + paclitaxel 75 mg/m2.~Radiotherapy:~D:1 - 2 x 0,5 Gy (first dose up to one hour after the end of the carboplatin infusion, second dose 3 to 6 hours later), D:2 - 2 x 0,5 Gy (interval between doses not less than 3 hours), D:8 and D:15 - 2 x 0,5 Gy (first dose up to one hour after the end of the chemotherapeutic infusion, second dose 3 to 6 hours later)."
40981343|NCT01569711|PROCEDURE|Deep brain stimulation of nucleus accumbens|"* Day0 : surgical placement of electrodes~* M1 : stimulation of nucleus accumbens~* M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)"
40981344|NCT03181204|PROCEDURE|Bronchial biopsy|The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.
40981345|NCT03181204|PROCEDURE|Skin biopsy|The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.
40981346|NCT03181204|PROCEDURE|Blood sample|The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
40981347|NCT03151460|DRUG|Dopamine Agent|"Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists."
41142925|NCT00916656|BIOLOGICAL|Fibrinogen Concentrate, Human (FCH)|"Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.~If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually."
41303214|NCT03064776|DEVICE|m-RESIST Caregivers|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
41303215|NCT04426123|DRUG|Botulinum toxin type A|Intramuscular injection with Botulinum toxin type A in m.masseter and m.temporalis.
41303216|NCT04426123|OTHER|saline solution|Intramuscular injection with NaCl in m.masseter and m.temporalis.
41303217|NCT02673593|DRUG|DS102|
41462063|NCT06021106|OTHER|Breathing exercise application with virtual reality glasses|In adapting breathing exercises to virtual reality glasses; The exercise video was first shot by the researcher in front of a green screen. Then, a 3D background design was made by a software developer, a 360-degree printout was taken, and it was converted into a form that can be viewed with glasses. The exercise video is prepared as 20 minutes. Exercises were performed at patients' homes through home visits. A total of 24 sessions of exercises were performed three days a week.
41462064|NCT06021106|OTHER|routine treatment and care|routine treatment and care
41462065|NCT00310115|BEHAVIORAL|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
40776743|NCT05129306|OTHER|Observational|In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.
41303218|NCT02673593|DRUG|Placebo|
41303219|NCT04534439|DRUG|APX-115|oral administration of APX-115 400mg capsule once daily for 12 weeks
41303220|NCT04534439|DRUG|Placebo|oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
41303221|NCT00745485|DRUG|zoledronic acid|
41303222|NCT04697472|DEVICE|LIFT System|The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.
41303223|NCT02634918|OTHER|ultrasound|ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
41303224|NCT04491786|DRUG|Gabapentin|Gabapentin plus nefopam
41462066|NCT00310115|BEHAVIORAL|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
41462067|NCT00310115|BEHAVIORAL|Counseling Intervention|2 in-person counseling sessions
41303225|NCT06417931|BEHAVIORAL|Patient education and counselling|The pharmacist intervention was aimed at identifying and addressing barriers to treatment adherence through tailored strategies
41303226|NCT02659111|OTHER|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
40776744|NCT02036346|DIETARY_SUPPLEMENT|Oral Ηydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.
40776745|NCT02036346|OTHER|Advise on calculated oral fluid requirements|
40776746|NCT02036346|OTHER|No nutritional advice will be given|
41303227|NCT02659111|OTHER|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
41462068|NCT05189691|BEHAVIORAL|walking exercise|Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. If they feel fatigue or palpitations during the day, they can do their exercises the next day. If there are complaints of shortness of breath/shortness of breath, chest pain, palpitation during walking, he should take a break from walking and rest. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.
41462069|NCT03468296|DRUG|Intravitreal Aflibercept Injection 2mg|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
40981348|NCT05333393|BEHAVIORAL|DİABOT (mobile application robot )|Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type 1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet.
40776747|NCT01685684|DRUG|Oxycodone DETERx|40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h
40776748|NCT01685684|DRUG|Placebo|Placebo, divided into 2 doses, q12h
40981349|NCT05278247|DIAGNOSTIC_TEST|NIRS|Performance of a NIRS to monitor abdominal tissue oxygen saturation in preterm infants
41303228|NCT00205725|DRUG|Ziprasidone, Olanzapine|
41303229|NCT01205672|DRUG|Metformin|850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
41303230|NCT04350658|PROCEDURE|Transcatheter aortic valve implantation required for symptomatic aortic stenosis|The procedure is performed via transfemoral or transcarotid access; Patients were confirmed to be eligible for TAVR by a multidisciplinary heart team including at least an interventional cardiologist, a cardiothoracic surgeon and an anesthetist. All TAVR implantation procedures were performed with the Edwards SAPIEN 3 THV or the MEDTRONIC CoreValve EVOLUT . For all patients, both vascular access and aortic valve were evaluated before the procedure by multislice computerized tomographic angiography (MSCT) of the entire aorta using vascular windows settings. The prosthesis and the vascular access were left to the discretion of the operating team. Transfemoral access was the first choice when possible. All TAVR procedures were performed in the same hybrid room (in Montpellier University Hospital), Most TAVR were performed under sedation or general anesthesia using mild low profile 14-16 French delivery systems and using percutaneous or surgical vascular access.
40776749|NCT05454865|DIETARY_SUPPLEMENT|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack PO bid for 2 treatment cycles (1 cycle = 3 weeks)
40776750|NCT05454865|DIETARY_SUPPLEMENT|Placebo|Placebo 1 1pack PO bid for 1 treatment cycle (1 cycle = 3 weeks) and followed by Jin Si Herbal Tea 1 pack PO bid for the 2nd treatment cycle
41303231|NCT05177952|OTHER|Blood Flow Restriction|Resistance training with BFR
40776751|NCT05383742|DRUG|Rifampicin (RIF)|Rifampicin 35 mg/kg
41303232|NCT05177952|OTHER|Standard of Care|Resistance Training with no BFR
41303233|NCT04683198|DRUG|camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
41303234|NCT04683198|DRUG|Apatinib Mesylate|Apatinib capsules 250 mg given orally , once daily in 21-day cycle and maintenance phase,until PD.
41303235|NCT04683198|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6).
41303236|NCT04683198|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6).
41303237|NCT02460926|PROCEDURE|Scaling & Root Planing|It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
41303238|NCT00000461|DRUG|pravastatin|
41303239|NCT00000461|DRUG|niacin|
41303240|NCT00000461|DRUG|cholestyramine|
41303241|NCT00000461|DRUG|gemfibrozil|
41303242|NCT00000461|DRUG|fatty acids, omega-3|
40776752|NCT05383742|DRUG|Isoniazid (INH)|Isoniazid 10 or15 mg/kg
40776753|NCT05383742|DRUG|Linezolid (LZD)|1200 mg
40776754|NCT05383742|DRUG|Pyrazinamide (PZA)|25 mg/kg
40776755|NCT05383742|DRUG|ethambutol (EMB)|20 mg/kg
40776756|NCT05383742|DRUG|Rifampicin|10 mg/kg
40776757|NCT05383742|DRUG|Isoniazid|5 mg/kg
40776758|NCT05648708|PROCEDURE|Combine Adductor Canal & Sciatic Nerve Block|The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia
40776759|NCT05648708|PROCEDURE|Combine Femoral & Sciatic Nerve Block|The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia
40776760|NCT05648708|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
40776761|NCT05648708|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
40981350|NCT00003204|DRUG|cyclophosphamide|Given IV
40776762|NCT05828108|DRUG|Bitopertin|Dose Escalation: Monthly (every 4 weeks) up to a maximum dose of 60 mg bitopertin (5 mg, 10mg, 20mg, 40mg, 60mg). At each monthly (4 week) interval, a complete blood count (CBC) with differential and a reticulocyte analysis (including reticulocyte hemoglobin) will be collected prior to taking the higher dose. If the absolute reticulocyte count (ARC) is 60,000 /microL or higher, the subject will hold at the current dose level (or return to that level if escalation has already occurred) for an additional 4 weeks. If, after 8 weeks at that dose, response criteria are met this will be considered the minimum effective dose (MED) and shall be the treatment dose throughout the remainder of the study unless modifications are indicated.
40776763|NCT00284128|DRUG|AVE7688|oral administration (capsules)
40776764|NCT00284128|DRUG|Losartan-potassium|oral administration (capsules)
40776765|NCT00793520|DRUG|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
41303243|NCT01152164|BEHAVIORAL|questionnaires|Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
41303244|NCT00151060|DRUG|Estramustine|
40776766|NCT00793520|DRUG|Placebo|Twice daily oral administration of placebo for 5 weeks.
40776767|NCT00793520|DRUG|Placebo|Twice daily oral administration of placebo for 5 weeks.
40776768|NCT00793520|DRUG|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
40776769|NCT04542928|BEHAVIORAL|nurse facilitated face care group|The experimental group is required to receive a nurse leading 50- minute face care group every two week
40776770|NCT06341335|DRUG|cadonilimab|iv, q3w
40776771|NCT06341335|DRUG|pulocimab|iv, q3w
40776772|NCT06341335|DRUG|paclitaxel|iv, q3w
40776773|NCT06341335|DRUG|placebo|iv, q3w
40776774|NCT01047540|DRUG|AIC316|Oral administration
40776775|NCT01047540|DRUG|AIC316|Oral administration
40776776|NCT01047540|DRUG|AIC316|Oral administration
40776777|NCT01047540|DRUG|AIC316|Oral administration
40776778|NCT01047540|DRUG|Placebo|Oral administration
40981351|NCT00003204|DRUG|fludarabine phosphate|Given IV
40981352|NCT00003204|DRUG|vincristine sulfate|Given IV
40981353|NCT00003204|DRUG|prednisone|Given PO
40981354|NCT00003204|BIOLOGICAL|rituximab|Given IV
40981355|NCT00003204|OTHER|laboratory biomarker analysis|Correlative studies
40981356|NCT00002942|PROCEDURE|autologous bone marrow transplantation|
40981357|NCT00002942|PROCEDURE|peripheral blood stem cell transplantation|
40981358|NCT04920604|OTHER|Face-to-face anesthesia consultation|The anesthesia consultation is carried out in person in accordance with the usual management.
40776779|NCT05618444|BEHAVIORAL|Automated Management (AM)|A tele-management intervention that will deliver two-way messages to participants via a bot - a computer program that simulates human activity. Programmed AM messages will address evidence based intervention components for positive airway pressure (PAP) adherence, including PAP use awareness (tele-monitoring), support and troubleshooting, education, and brief motivational messaging.
40981359|NCT04920604|OTHER|Remote anesthesia consultation|"Anesthesia consultation is carried out in teleconsultation via the Téléo web application (audio and video) at the patient's home on a computer or smartphone. This application allows sending and receiving documents identical to those during the face-to-face consultation."
40981360|NCT03219489|OTHER|Electronic medical record alert|"An electronic medical record alert will be inserted into the clinic's electronic medical records. The alert reads: Consider Progesterone 100-200 mg pv qhs \> or =16 weeks, if previous spontaneous PTB or current short cervix, and no allergies to peanuts or progesterone.~This alert will appear on the Ministry of Health-mandated Perinatal Records."
40981361|NCT05738161|DRUG|Magrolimab|Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma
40981362|NCT05738161|DRUG|Cisplatin|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
40981363|NCT05738161|DRUG|Gemcitabine|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
40981364|NCT02931487|BEHAVIORAL|Attentional Bias Modification|Computerized
40981365|NCT02931487|BEHAVIORAL|Sham Comparator|Computerized
40776780|NCT04749914|DRUG|Lasmiditan|Administered orally.
40776781|NCT04749914|DRUG|Dabigatran Etexilate|Administered orally.
40776782|NCT04749914|DRUG|Rosuvastatin|Administered orally.
40981366|NCT00751244|BEHAVIORAL|Trauma Affect Regulation: Guide for Education and Therapy|"Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy."
40981367|NCT00751244|BEHAVIORAL|Present Centered Therapy (PCT) - psychotherapy|"Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework."
40981368|NCT00751244|OTHER|"No-treatment waitlist group"|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
40981369|NCT04502953|PROCEDURE|Vertical plication|Vertical plication of the rectovaginal septum was done
41303245|NCT00151060|DRUG|Etoposide|
41303246|NCT00151060|DRUG|Paclitaxel|
40776783|NCT04856527|BEHAVIORAL|Physical therapist support|Participants will receive physical therapist support to reduce postural sway variability while completing an upper limb precision aiming task in virtual reality.
40981370|NCT04502953|PROCEDURE|Horizontal plication|Horizontal plication of the rectovaginal septum was done
40776784|NCT00158587|DRUG|primaquine|
40776785|NCT04862780|DRUG|BLU-945|Oral administration
40981371|NCT00054314|DRUG|ortataxel|
40981372|NCT04599712|DRUG|Amivantamab|Amivantamab will be administered intravenously at the recommended doses based on weight (1050 milligram \[mg\] or 1400 mg) once weekly for the first 4 week cycle (1 cycle equals to 28 days), then every 2 weeks thereafter.
40981373|NCT02867189|OTHER|atlas of micro-instrument|Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
40776786|NCT04862780|DRUG|osimertinib|Osimertinib tablets for oral administration
40776787|NCT02670473|DEVICE|fanfilcon A (test)|contact lens
40981374|NCT05630612|DRUG|Sparsentan|6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.
40981375|NCT04700618|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.
40981376|NCT03438175|BEHAVIORAL|Enhanced communication by brochure, website and posters|Several instruments to improve communication toward ICU patients' families were prepared for this study: a brochure of 12 pages, a website with 80 webpages, 8 posters for the waiting room, 1 sign for the ICU door. All these instruments are made to have more correct comprehension and to legitimize emotions of ICU patients' families.
40981377|NCT03598192|PROCEDURE|TAP|The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%
40981378|NCT03598192|PROCEDURE|PVB|The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%
40981379|NCT03598192|DRUG|Ropivacaine|Ropivacaine has been treated the both group
40981380|NCT03598192|DRUG|Sufentanil|Sufentanil has been included in Arm/Group Descriptions
40776788|NCT05699200|OTHER|Arterial Tonometry|We will measure arterial stiffness using arterial tonometry.
40981381|NCT05552768|PROCEDURE|Bone level-driven placement|The objective of this study will be to determine if implants placed according to the soft tissue-driving implant placement paradigm, i.e. 4 mm below the tissue margin will have different clinical performance as compared to the bone level-driven placement paradigm.
40981382|NCT05552768|PROCEDURE|Biological width-driven placement guidelines|Biological width-driven placement guidelines
40981383|NCT05030974|BIOLOGICAL|mRNA-1273|SARS-CoV-2 vaccination
40981384|NCT05030974|BIOLOGICAL|Ad26.COV2.S vaccine|SARS-CoV-2 vaccination
40981385|NCT05487781|COMBINATION_PRODUCT|Tirfostina/L-Carnitina|Estudio clínico fase 1 para describir la seguridad biológica y la farmacocinética de la tirfostina AG-17
40981386|NCT02186912|DEVICE|Nobel Active, Nobel Procera IBO|
40981387|NCT01584687|BIOLOGICAL|Omalizumab|The patients will receive Omalizumab according to their age and weight for 4 months.
40981388|NCT02375568|OTHER|103024-F|mesenchymal stem cell isolation
40981389|NCT05415085|PROCEDURE|Culprit-first PCI|PCI to the culprit artery prior to the demonstration of the whole coronary tree.
40776789|NCT05699200|DIAGNOSTIC_TEST|Echocardiogram|We will collect limited ultrasound images of the heart.
40776790|NCT05699200|DIAGNOSTIC_TEST|Carotid Ultrasounds|We will perform ultrasound imaging of the carotid artery.
40776791|NCT05699200|DIAGNOSTIC_TEST|Elastography|We will measure the elastic properties of the arteries using elastography.
40776792|NCT05699200|OTHER|Ankle-Brachial Index|We will measure the ankle-brachial index to assess peripheral artery blood flow.
40776793|NCT05699200|OTHER|Microneurography with sympathoexcitatory maneuvers|We will measure sympathetic nerve activity at rest and in response to isometric handgrip, mental stress test, cold pressor test, Valsalva maneuvers.
40776794|NCT01769027|DRUG|Sertraline+Antibiotic (penicillin/azithromycin)|"12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.~Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)"
40776795|NCT01769027|DRUG|Sertraline+placebo|12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
40776796|NCT01769027|BIOLOGICAL|IVIG|Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
40981390|NCT03824327|PROCEDURE|Blood Oxygen Level Dependent Imaging|Undergo BOLD fMRI
40981391|NCT03824327|DRUG|Papaverine Hydrochloride|Given IV
40981392|NCT03824327|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
40981393|NCT05053789|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
40981394|NCT05053789|DEVICE|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
40981395|NCT02388945|OTHER|APD|PDGO APD machines used in the PD patients for 8 weeks
40981396|NCT02388945|OTHER|CAPD|CAPD used in the PD Patients for 8 weeks
40981397|NCT03686371|PROCEDURE|posterior surgery for spinal arthrodesis|posterior surgery for spinal arthrodesis
41142926|NCT00916656|BIOLOGICAL|Cryoprecipitate|Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
40981398|NCT04752150|OTHER|Analgesia management; group ESPB and RIB|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
40981399|NCT04671225|BEHAVIORAL|Groups Psychoeducation|Manual-structured group psychoeducation with 8 sessions of 90 minutes over the course of 8 weeks (at one session per week). The manual is centred on behavioural principles from social education and self-regulation philosophies. All groups will have 6-8 participants and two health professionals to conduct the sessions; a psychiatric nurse and either a psychologist or a psychiatric resident. Patients will be offered to invite their relatives for 2-3 psychoeducation-days for relatives.
40981400|NCT04671225|BEHAVIORAL|Waiting-list|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
40981401|NCT03020680|DIETARY_SUPPLEMENT|Coenzyme Q10|To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
40981402|NCT03707314|PROCEDURE|Angiography with follow-on revascularisation if indicated|Angiography with follow-on revascularisation (if indicated)
40981403|NCT04534023|DRUG|Idebenone|trial group
40981404|NCT04534023|DRUG|Placebo|control group
40776797|NCT03314090|DRUG|Silicone Gels|silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
40981405|NCT02892760|DEVICE|C-Brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
40981406|NCT04090645|DEVICE|TheraSphere|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
40981407|NCT03386682|DEVICE|ESTYME® MATRIX Breast Implants|Breast implant surgery in breast reconstruction or breast augmentation
40981408|NCT02579850|DRUG|CHF 5993 + Ultibro matched placebo|Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
40981409|NCT02579850|DRUG|Ultibro + CHF 5993 matched placebo|Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
40981410|NCT02579850|PROCEDURE|Central spirometry|Central spirometry to assess forced expiratory volume at one second and forced vital capacity
40981411|NCT02579850|OTHER|COPD assessment test|COPD assessment test (CAT) at visit 1
40981412|NCT02579850|PROCEDURE|Local laboratory Assessments|ECG + Standard Haematology and Biochemistry
40981413|NCT02579850|OTHER|Saint George's Respiratory Questionnaire|Saint George's Respiratory Questionnaire
41142927|NCT06296875|DIETARY_SUPPLEMENT|Vegetable oil|mixed vegetable oil
41142928|NCT06296875|DIETARY_SUPPLEMENT|Krill oil|Krill oil
40981414|NCT02579850|OTHER|EXACT-pro questionnaire|daily from randomization (Visit 2) to end of study (Visit 7)
41303247|NCT01883323|DRUG|Cyclophosphamide|i.v., 60mg/kg per day for 2 days
41303248|NCT01883323|DRUG|Fludarabine|i.v., 25mg/m2 per day for 5 days
41303249|NCT01883323|BIOLOGICAL|Tumor-Infiltrating Lymphocytes|i.v., 1x10\^10 - 1.6x10\^11 cells
41303250|NCT01883323|BIOLOGICAL|Low-Dose Interleukin|i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
41303251|NCT02385825|BIOLOGICAL|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
41303252|NCT02892123|DRUG|ZW25 (Zanidatamab)|ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:
41303253|NCT02892123|DRUG|Paclitaxel|Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4
41303254|NCT02892123|DRUG|Capecitabine|Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
41303255|NCT02892123|DRUG|Vinorelbine|Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6
41303256|NCT02892123|DRUG|Tucatinib|Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7
41303257|NCT02892123|DRUG|Tucatinib|Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
41303258|NCT05913960|DEVICE|sham stimulation|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
41303259|NCT05913960|DEVICE|accelerated intermittent theta burst stimulation|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
41303260|NCT05913960|DEVICE|high frequency stimulation|"Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
41303261|NCT04088851|DRUG|On Metformin|Oral intake of Metformin (1 g / day) for 2 weeks
41303262|NCT04088851|DRUG|Off Metformin|No oral intake of Metformin (1 g / day) for 2 weeks
41303263|NCT05336526|DEVICE|ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants|Bilateral brest augmentation in primary intention
41303264|NCT01647594|BEHAVIORAL|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
41303265|NCT01647594|BEHAVIORAL|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
41303266|NCT03264508|BEHAVIORAL|Heat therapy|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.
41303267|NCT03264508|BEHAVIORAL|Thermoneutral water immersion|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature \>0.2°C.
41303268|NCT00626912|PROCEDURE|endovascular coil embolization|standard endovascular coil embolization with or without adjunct techniques
41303269|NCT04109625|DIAGNOSTIC_TEST|Demonstrator MAGIA|test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.
41303270|NCT02805868|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
41303271|NCT02805868|OTHER|Laboratory Biomarker Analysis|Correlative studies
41303272|NCT02805868|BIOLOGICAL|Siltuximab|Given IV
41303273|NCT06084390|OTHER|Interdisciplinary care + booster session (intervention)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden + one extra booster-session 3 months after the standard care rehabilitation. At the booster-session, the participant´s individual rehabilitation plan is followed-up and adjusted. This extra period also includes extended access to the team, meaning that the participants have the possibility to contact the team and, if needed, have digital or telephone contact.
40776798|NCT03985735|DRUG|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
41303274|NCT06084390|OTHER|Interdisciplinary care (control)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden.
41303275|NCT00323505|DRUG|Pegylated Interferon|
41303276|NCT00323505|DRUG|Interferon-alpha2a|
41303277|NCT03491722|OTHER|risk factors and revascularization procedures|arterial revascularizations needed since index procedure
41303278|NCT06342804|DRUG|4-MUST, 2 tablets, fasted|2 tablets (256 mg), fasted
41462070|NCT05917262|BEHAVIORAL|Mindfulness-based breathing|The 20-minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experiences in a non-judgmental fashion.
41462071|NCT05917262|BEHAVIORAL|HRV biofeedback|The 20-minute HRV biofeedback is based on the resonant frequency breathing with an external pacemaker. Generally, the breath rhythm is between 4.5 and 6.5 times per min.
41462072|NCT05917262|BEHAVIORAL|cognitive-behavioral pain psychoeducation|The 20-minute psychoeducation session is a supportive session where behavioral coping strategies for pain management are discussed.
41462073|NCT04709536|DRUG|IBI306|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
41462074|NCT04709536|DRUG|Placebo|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
41303279|NCT06342804|DRUG|4-MUST, 2 tablets, after meals|2 tablets (256 mg), after meals
41303280|NCT00922194|DRUG|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
41303281|NCT03742336|DRUG|PF-04965842|Single oral 200 mg dose of PF-04965842
40776799|NCT03498573|OTHER|tunneling surgical technique|sticky bone prepared by centrifuge patient blood and mixing with xinograft
40776800|NCT00000395|DRUG|Methotrexate|
40776801|NCT00000395|DIETARY_SUPPLEMENT|Folinic acid|
40776802|NCT00000395|DIETARY_SUPPLEMENT|Folic acid|
40981415|NCT06078761|BEHAVIORAL|Healthy Eating Active Lifestyle (HEAL) Program|Evidence-based lifestyle medicine program for cancer survivors
41303282|NCT03742336|DRUG|Dabigatran|Single 75 mg dose of dabigatran
41303283|NCT00632463|BIOLOGICAL|RI-001|Dose 1
41303284|NCT00632463|BIOLOGICAL|RI-001|Dose 2
41303285|NCT00632463|BIOLOGICAL|RI-001|Placebo
41303286|NCT02041546|DRUG|Lung lavage with surfactant|
41303287|NCT02041546|DRUG|Bolus surfactant|
41303288|NCT06448312|DRUG|SKB264|IV Infusion
41303289|NCT06448312|DRUG|Pembrolizumab|IV Infusion
41303290|NCT06410781|OTHER|Radial Extracorporeal Shockwave|Treatment procedure will be initiated by palpation to locate the painful area around the lateral femoral condyle and the lateral side of the thigh. The therapist uses the principle of clinical focusing where the patient guides the therapist to the most painful area. The area will be treated in a circumferential pattern, starting at the point of maximum pain. At each of the session a total of 4600 pulses will be applied. RESWT will start with 500 pulses at (2 Bar) with the frequency of 15 Hz to the lateral femoral condyle to adjust to treatment.An additional 2000 pulses will be applied at (2- 4 Bar), 15 Hz, depending on pain tolerance. in addition,stretching exercise, manual therapy, and ultrasound on the iliotibial band.
41303291|NCT06410781|OTHER|traditional therapy|the patients will receive traditional therapy in the form of stretching exercise, manual therapy and ultrasound on iliotibial band.
41303292|NCT03259334|DRUG|Ontamalimab|Participants will receive 1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
41303293|NCT03259334|OTHER|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
41462075|NCT01961245|DEVICE|nocturnal non-invasive ventilation|patients will undergo a non-invasive ventilation during the night
41462076|NCT02579005|BIOLOGICAL|Patients with a living donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.
41462077|NCT02579005|BIOLOGICAL|Patients with a UCB donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
41462078|NCT00660491|OTHER|exercise training|moderate intensity exercise group, and high intensity exercise group
41462079|NCT05275049|COMBINATION_PRODUCT|PT plus translingual stimulation device|PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
41462080|NCT05275049|COMBINATION_PRODUCT|PT plus translingual stimulation control device|Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
41462081|NCT06125756|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
41462082|NCT06125756|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
41462083|NCT06125756|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
40776803|NCT01451021|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
41462084|NCT02494505|DRUG|Mycophenolate Mofetil|2g/day per os
40776804|NCT05046314|BIOLOGICAL|TK216+Vincristin|TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m\^2 and 1.5mg/m\^2 from the second cycle，every 28 days is a study cycle.
40776805|NCT04505800|DIETARY_SUPPLEMENT|Tryptophan supplement|"* Pure L-tryptophan in capsules (500mg/capsule)~* 3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
40776806|NCT04505800|DIETARY_SUPPLEMENT|Maltose|Maltose
40776807|NCT03641196|DEVICE|Fixed appliance|Use of a cemented modified palatal Nance appliance presenting a bite-plane
40776808|NCT03641196|PROCEDURE|Composite bite plane|treatment with a composite build up in the palatal aspect of the upper central incisors.
40776809|NCT00317811|DIETARY_SUPPLEMENT|ascorbic acid|
40776810|NCT00317811|DRUG|bortezomib|
40776811|NCT00317811|DRUG|melphalan|
40776812|NCT00312286|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
41462085|NCT02494505|DRUG|placebo|
41462086|NCT05585489|OTHER|Gait training with musical cue|Entraînement de 20 minutes de marche à vitesse confortable sur un parcours ovale de 20 mètres au laboratoire ARM avec la technique d'indiçage musical personnalisé de la longueur de pas.
40776813|NCT00312286|DRUG|851B|851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
40776814|NCT00312286|DRUG|851B|851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
40776815|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, once a week for 1 cycle.
40776816|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, once a week for 2 cycles.
40776817|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
40776818|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
40776819|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, once a week for 1 cycle.
40776820|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, twice a week for 1 cycle.
40776821|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, once a week for 2 cycles.
40776822|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, twice a week for 2 cycles.
40981416|NCT02457910|OTHER|Biomarker Analysis|Correlative studies
40981417|NCT02457910|DRUG|Enzalutamide|Given PO
40981418|NCT02457910|OTHER|Pharmacological Study|Correlative studies
40981419|NCT02457910|DRUG|Taselisib|Given PO
40776823|NCT02190500|OTHER|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
40776824|NCT01526200|PROCEDURE|Contrast-enhanced intraoperative ultrasound|After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
40776825|NCT00213070|DRUG|Miglitol|
40776826|NCT03028701|DRUG|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
40776827|NCT03588754|DRUG|Propranolol|Propranolol Extended Release (160mg/day).
40776828|NCT03588754|DRUG|Placebo|Placebo pill administered orally.
40776829|NCT05858931|PROCEDURE|vaginal repair|vaginal repair
40776830|NCT05132972|BIOLOGICAL|Normoxic Allogenic UCMSC|Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition, administered through intravenousinfusion at dose 1x10\^6 cells MSC/kg body weight. The treatment will be administered three times, at three days intervals (day 0, day 3, and day 6)
40776831|NCT05132972|OTHER|Normal saline solution|Sterile saline solution and adminastered through intravenous infusion three times, at three day intervals (day 0, day 3, and day 6)
40776832|NCT06028750|PROCEDURE|Dynamic Computer Assisted Surgery|Surgical navigation system (X-Guide guided surgery system) Navigation system X-Guide
40776833|NCT06028750|PROCEDURE|Freehand|Freehand implant placement
40776834|NCT03150264|DEVICE|PCV-VG, PEEP5cmH₂O|This is an innovative ventilation mode developed in recent years. The preset tidal volume help the machine modify inspiratory pressures and compensate the decrease of lung compliance.
40776835|NCT03150264|DEVICE|PCV, PEEP5cmH₂O|This is a traditional ventilation mode used in obese patients in the past.
40776836|NCT02096107|DRUG|Everolimus|Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus
40776837|NCT02096107|OTHER|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
40776838|NCT05212207|OTHER|CGM, smartwatch, and electronic diary|Participants wear a CGM and a smartwatch while keeping an electronic diary with information such as meals, sleep, and activity.
40776839|NCT05901610|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
40776840|NCT05901610|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive past events.
40776841|NCT05901610|DEVICE|Low-intensity Focused Ultrasound|A transducer device will use focused ultrasound energy to neuromodulate the insular cortex. The participant's brain will be mapped based on information from the CT and MRI scans, and the transducer will deliver brief ultrasound pulses to the insular cortex.
40776842|NCT05901610|DEVICE|Sham Low-intensity Focused Ultrasound|All of the same actions done during LIFU will be performed, but the device will be inactive.
40776843|NCT05943262|DEVICE|mesoscale nonlinear optical microscope|The mesoscale nonlinear optical microscope based on the principles of nonlinear optics and computed-algorithms can acquire large-area image within few minutes.
40776844|NCT05204121|DRUG|Elpida|elsulfavirine, capsules
40776845|NCT04254406|OTHER|Descriptive study|Evaluation of routine treatment
40776846|NCT05900752|DIETARY_SUPPLEMENT|QiMeiYan Probiotics|consume one sachet of the assigned product, once a day after meals.
40776847|NCT05900752|DIETARY_SUPPLEMENT|Placebo product|consume one sachet of the assigned product, once a day after meals.
40776848|NCT05789251|DIAGNOSTIC_TEST|Standardized breakfast|Standardized breakfast to replace in fine oral induced hyperglycemia test
40776849|NCT06187389|OTHER|1 Grups|This methodological study was conducted using a cross-sectional observational approach at a leading teaching and research hospital. The study duration was from March to June 2023
40776850|NCT06267417|DEVICE|Laser therapy|- Laser will be applied with the specified wave length using Diode laser (Sirrolaser Blue ™, USA) device over 5 consecutive days from start of chemotherapy cycle beside the standard preventive protocol applied in the hospital
40776851|NCT06267417|DEVICE|Mock treatment|The exact repetition of the treatment modality but without any laser emission beside the standard preventive protocol applied in the hospital
40776852|NCT03782415|DRUG|MN-166|MN-166 is an anti-inflammatory/neuroprotective agent. MN-166 distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
40776853|NCT03782415|DRUG|Temozolomide|Temozolomide is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; and a first-line treatment for glioblastoma multiforme.
40776854|NCT00156195|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 months
40776855|NCT00156195|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 months
40776856|NCT01400711|OTHER|ERAS perioperative care|Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
40776857|NCT01400711|OTHER|Traditional|Nasogastric tube until bowel function, late oral eating, opioid analgesics.
40776858|NCT03601299|OTHER|Traditional food|Increasing traditional food consumption through Head start programs in Alaska
40776859|NCT05769114|PROCEDURE|Surgical stabilization|Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
40776860|NCT03544463|DEVICE|iNAP® Sleep Therapy System|The iNAP® provides a pressure gradient within the oral cavity, which pulls the tongue toward the upper palate and pulls the soft palate forward in a way that enhances the patency of the upper airway near the pharynx so that upper airway patency can be maintained to prevent sleep-disordered breathing.
40776861|NCT00744744|OTHER|informational intervention|Patient educational information
40776862|NCT00744744|OTHER|questionnaire administration|Survey
40981420|NCT03404791|DRUG|TAR-200|TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.
40981421|NCT00271050|OTHER|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
40981422|NCT04893603|DEVICE|Transcatheter Aortic Valve System|Procedure: Transcatheter aortic valve replacement
40981423|NCT02277301|BEHAVIORAL|Mellow Babies|Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
40981424|NCT00422175|DRUG|BAF 312|
40981425|NCT05548166|OTHER|Interview and scale development|Interview and scale development
40981426|NCT02634684|DRUG|Dextroamphetamine|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
40776863|NCT00744744|PROCEDURE|management of therapy complications|Survey
40776864|NCT00744744|PROCEDURE|psychosocial assessment and care|Survey
40776865|NCT00744744|PROCEDURE|quality-of-life assessment|Survey
40776866|NCT06131190|BEHAVIORAL|mindfulness training|it focuses on attention and has gained empirical support as a complementary or alternative intervention
40776867|NCT05057507|DIAGNOSTIC_TEST|Atrial cardiac magnetic resonance imaging|To include assessment of atrial size, shape, function, fibrosis and fat
40981427|NCT02634684|DRUG|Placebo|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
40981428|NCT01131923|DRUG|Amlodipine|Amlodipine Tablets, 10 mg
40981429|NCT02744391|DRUG|Levodopa|
40981430|NCT00260403|PROCEDURE|Photodynamic therapy versus Transpupillary thermotherapy|
40981431|NCT00002144|DRUG|Foscarnet sodium|
40981432|NCT00384995|DRUG|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
40981433|NCT00384995|DRUG|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
40981434|NCT06186011|PROCEDURE|Wire-guided surgery|If assigned to the WGS, the marking will be performed by the radiologist on the day prior to the intervention.
40981435|NCT06186011|PROCEDURE|Radioactive seed localization|If assigned to the RSL, the marking will be performed by the radiologist on the day prior to the intervention. The handling and traceability will be done by the nuclear medicine physician.
40981436|NCT06186011|PROCEDURE|Intraoperative ultrasound localization|If the patient is assigned to the Intraoperative ultrasound localization (IOUS), no further procedures will be necessary until surgery. Subsenquently, the primary surgery will be performed.
40981437|NCT05575011|DRUG|BIIB115|Administered as specified in the treatment arm
40981438|NCT05575011|DRUG|BIIB115-Matching Placebo|Administered as specified in the treatment arm
41462087|NCT03585309|PROCEDURE|The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts:|"Randomization Randomization will be conducted using computer generated table. Group A (48 CASES) without coagulation~Group A 6 89 92 35 1 15 21 16 60 49 53 91 34 5 94 64 88 58 7 33 8 75 29 56 10 23 37 19 32 71 55 84 36 77 50 2 46 70 82 9 51 54 72 18 25 31 14 63~Group B (48 CASES) with coagulation Group B 79 38 93 43 52 44 62 47 68 76 86 95 81 83 42 80 94 30 78 61 12 17 66 13 41 59 22 73 39 65 4 90 28 26 3 87 40 85 69 48 27 24 74 57 11 20 67 45~Allocation and concealment Nineteen six opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table then all envelopes will be closed and put in one box. When the first patient arrives the first envelope will be opened and the patient will be allocated according to the letter inside."
40776868|NCT05057507|DIAGNOSTIC_TEST|Atrial electro-anatomic mapping|To include assessment of atrial voltage and local activation time
40776869|NCT05057507|OTHER|Atrial fibrillation symptom questionnaire|To include assessment of atrial fibrillation symptoms and quality of life
40776870|NCT05057507|DIAGNOSTIC_TEST|Patch-based 2 week ambulatory monitor|To assess atrial fibrillation burden post-ablation
40776871|NCT06133023|PROCEDURE|Plastic stent|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed."
40776872|NCT06133023|PROCEDURE|LAMS|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed."
40981439|NCT03365739|DIETARY_SUPPLEMENT|Active Comparator 1|Mango (pulp/flesh) (500 g)
40981440|NCT03365739|DIETARY_SUPPLEMENT|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
40981441|NCT03365739|DIETARY_SUPPLEMENT|Control Comparator|Vitamin C (100 mg)
41142929|NCT01239641|PROCEDURE|High intensity focused ultrasound|The term 'high intensity focused ultrasound' means using ultrasound to causes coagulation necrosis to destroy the targeted tissue, in this case, uterine fibroids.
41462088|NCT04715139|DEVICE|Products listed in Group/Cohort Description|Depending on approved indication per product
40981442|NCT06076161|DIETARY_SUPPLEMENT|Spirulina supplementation and calorie restriction in obese men|The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction. The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.
40981443|NCT05744453|DIETARY_SUPPLEMENT|Olive Leaf Extract|experimental arm
40981444|NCT05744453|DIETARY_SUPPLEMENT|Cellulose|placebo comparator arm
40981445|NCT05911776|DRUG|Nasal packing Dexmedetomidine|patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
40981446|NCT05911776|DRUG|Intravenous Dexmedetomidine|patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
40981447|NCT02076880|OTHER|Caloric restriction|"Caloric restriction of 1000 kcal per day compared to the usual food intake.~* usual breakfast of the patient (possibly limited in quantity)~* midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened"
41303294|NCT01514188|DRUG|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
41303295|NCT01514188|DRUG|Doxorubicin|Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
41303296|NCT06462586|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
41303297|NCT06462586|DRUG|Placebo|Matching capsules administered orally, once daily
41303298|NCT00620321|DRUG|LY2181308 sodium|750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
41462089|NCT05005013|OTHER|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
41462090|NCT05005013|OTHER|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
41462091|NCT05005013|OTHER|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
41462092|NCT00963430|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
41462093|NCT01922960|OTHER|micro-imaging|micro-imaging
40981448|NCT02076880|OTHER|No caloric restriction|No change in eating habits to patients in this arm
40981449|NCT04833504|BIOLOGICAL|CD19 CAR-T Expressing IL7 and CCL19|A fourth generation CD19 targeting CAR-T expressing IL7 and CCL19
40981450|NCT05016973|DRUG|RC48-ADC|2.0mg/kg, Intravenous drip on days 1 every 21 days
40981451|NCT05016973|DRUG|Triplizumab|240mg, Intravenous drip on days 1 every 21 days
41303299|NCT00620321|DRUG|cytarabine|1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
41303300|NCT00620321|DRUG|idarubicin|12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
41462094|NCT04122027|OTHER|Cerebral oximeter|Near infra-red spectroscopy, NIRS
41462095|NCT03097939|DRUG|Ipilimumab|1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks
40981452|NCT05783115|PROCEDURE|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion|transverse bone transport with bone marrow cell transplantation
40981453|NCT05783115|PROCEDURE|Tibial Transportation|transverse bone transport
40981454|NCT03051607|DRUG|Tozadenant|1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
40981455|NCT03535870|DRUG|Fluticasone propionate/salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device
40981456|NCT03535870|DRUG|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
40981457|NCT03535870|DRUG|Placebo|placebo dry powder administered via the LOMI inhaler device
40981458|NCT02867787|DRUG|Botox arm|
41303301|NCT02602236|DEVICE|AOS-C2000-B|1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
41303302|NCT00343304|DEVICE|Robot|
41303303|NCT00343304|DEVICE|Ergometer|
41303304|NCT06150690|OTHER|No intervention|The participants did not receive any study-specific intervention
41303305|NCT06185218|OTHER|Intravesical Botulinum Toxin|Botulinum Toxin injections will be made into the bladder.
41303306|NCT04406246|DRUG|Nitazoxanide 500Mg Oral Tablet|Health workers affected by SARS-CoV-2 will receive the next doses of nitazoxanide: 500 mg every 6 hour for two days and then every 12 hours for four days.
41303307|NCT00124267|DRUG|Intrarectal quinine|
41303308|NCT00034970|BEHAVIORAL|Mindfulness-based at therapy|
41462096|NCT03097939|DRUG|Nivolumab|3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
41462097|NCT04674228|OTHER|Electronic Health Record Review|Review of medical records
41462098|NCT01346644|OTHER|Infant formula|Powder infant formula
41462099|NCT01346644|OTHER|Infant formula|Powder infant formula
41462100|NCT02246348|RADIATION|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
41462101|NCT05991362|DRUG|GFH312 100 mg|Participants receive single dose of GFH312 100 mg orally
41462102|NCT05991362|DRUG|GFH312 200 mg|Participants receive single dose of GFH312 200 mg orally
41462103|NCT05991362|DRUG|GFH312 120mg|Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days
41462104|NCT05991362|OTHER|Placebo|Participants receive placebo matching with GFH312
41462105|NCT00396955|DRUG|PLA-695|
41462106|NCT00287053|DRUG|divalproex sodium|Divalproex sodium vs. placebo
40981459|NCT00446290|DRUG|Docetaxel, Capecitabine and Oxaliplatin|
40776873|NCT02009566|RADIATION|Abdominal radiographs with microfabricated tags|Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
40981460|NCT05611203|PROCEDURE|An Oropharyngeal swab|An Oropharyngeal swab performed for diagnostic purposes
40981461|NCT03284164|DRUG|Tenofovir Exalidex (TXL)|Drug: Tenofovir Exalidex (TXL)
40981462|NCT00840554|OTHER|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
41303309|NCT03436446|OTHER|Interview|Interviews will be conducted with orthopedic patients to review the construction and phrasing of various social incentives aimed at promoting patient reported outcome collection amongst post-operative patients.
40981463|NCT00840554|OTHER|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
40981464|NCT02354079|GENETIC|hypobetalipoproteinemia genetic and genotypic screening|
40981465|NCT04111484|OTHER|Adrenomedullin|Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.
40981466|NCT04111484|OTHER|Saline|Placebo
41303310|NCT04611711|DRUG|decitabine＋ TQB2450 injection|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
40776874|NCT03849261|DRUG|CKD-387|Test drug
40776875|NCT03849261|DRUG|D635|Reference drug
40981467|NCT00536406|BEHAVIORAL|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
40981468|NCT00536406|BEHAVIORAL|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
40981469|NCT04178499|DIAGNOSTIC_TEST|cytokine analysis|analysis of intraocular cytokines
40981470|NCT01053728|DRUG|SAR161271|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
40981471|NCT01053728|DRUG|Insulin glargine HOE901|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
40981472|NCT00001929|DRUG|Eliprodil|
40981473|NCT01151644|BIOLOGICAL|Anti-pandemic H1N1 influenza vaccine|inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
41303311|NCT04611711|DRUG|decitabine＋ TQB2450 injection＋Anlotinib|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition. "
40981474|NCT01857232|DRUG|Ondansetron|5HT3-antagonist
40981475|NCT01857232|DRUG|Placebo|Comparator
40981476|NCT01857232|DRUG|Dexamethasone|Corticosteroid
40776876|NCT05781789|OTHER|Telehealth for preoperative evaluation|Conduct of preoperative evaluation remotely using Zoom application
40776877|NCT01738243|DRUG|Hyaluronic Acid Gel injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of Hyaluronic Acid Gel is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of Hyaluronic Acid Gel are injected with the end point being adequate lowering with improved symmetry.
40776878|NCT01738243|DRUG|Saline injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of saline is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of saline are injected with the end point being adequate lowering with improved symmetry.
40776879|NCT06091904|DRUG|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
40776880|NCT06091904|DRUG|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
40776881|NCT03226691|DRUG|Plerixafor|Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg
40981477|NCT01857232|DRUG|Fosaprepitant|NK1 antagonist
40981478|NCT01857232|DRUG|APD403 IV|Amisulpride IV 20 mg
40981479|NCT01857232|DRUG|APD403 oral|Amisulpride oral 10, 20 or 40 mg
40981480|NCT01172457|PROCEDURE|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
40981481|NCT01172457|PROCEDURE|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
40981482|NCT04890223|BEHAVIORAL|Brief MI intervention|Brief MI intervention
40981483|NCT04890223|BEHAVIORAL|Placebo intervention|Generic health advice consultations and self-help smoking cessation booklets
40981484|NCT01938378|BIOLOGICAL|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
40981485|NCT01536847|OTHER|Dietary Intervention|300 ml of liquid food product
40981486|NCT01536847|OTHER|Dietary Intervention|300 mL of liquid food product
40981487|NCT01536847|OTHER|Dietary Intervention|300 ml of liquid food product
40981488|NCT05314855|DEVICE|functional MRI|Subjects will undergo functional MRI at 4 time points in 24 hours.
40981489|NCT03183375|DRUG|Hydroxyurea|Hydroxyurea (starting from 10mg/kg/day with increasing dose by 2mg/kg/day until the desired response is achieved. The maximum dose given will be 20mg/kg/day)
40981490|NCT04220450|DIAGNOSTIC_TEST|T1 mapping on Cardiovascular Magnetic Resonance Studies|On clinically indicated Cardiovascular Magnetic Resonance Imaging Studies, native T1-times and extracellular volume will be determined
40981491|NCT05407467|DIETARY_SUPPLEMENT|Curcumin and virgin coconut oil extract (KurCo Smart)|we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result
40981492|NCT05464160|DEVICE|Focal Muscular Vibration using the EVM EVO medical device (Endomedica, Italy)|"FMV will be applied 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes."
40981493|NCT05464160|OTHER|Conventional Rehabilitation|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)
40981494|NCT05383768|OTHER|preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C|"Intervention 1: restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 2: Restoration with five time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 3: Restoration with ten time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020)."
40981495|NCT00844051|BIOLOGICAL|School-based influenza vaccination program|School-based influenza vaccination program
40981496|NCT01737151|RADIATION|stereotactic body radiation therapy|Undergo SBRT
40981497|NCT01737151|RADIATION|four fraction split-course SBRT|four fraction split-course SBRT
40981498|NCT01196923|DEVICE|Endoscopically Guided Ablation|Visually Guided Ablation using EAS-AC
41303312|NCT01989546|DRUG|BMN 673|Poly (ADP-ribose) polymerase (PARP) inhibitor; has been shown to cause single-agent synthetic lethality in breast cancer 1 and breast cancer 2 (BRCA1/2)- and phosphatase and tensin homolog (PTEN)-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in deoxyribonucleic acid (DNA) repair pathways.
41303313|NCT04591314|BEHAVIORAL|Neurofeedback|The intervention by neurofeedback (NF) will consist in providing the subjects with a feedback on their EEG Theta / Beta activity in real time Each subject will perform 8 sessions of neurofeedback (1h30 / session, 40 min of effective training by neurofeedback) at an average rate of 1 to 2 sessions per week.
41303314|NCT04635696|DRUG|Ethyl chloride|Pressurized vapocoolant developed for acute, mild pain relief.
40981499|NCT02415127|DRUG|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
41303315|NCT04635696|OTHER|Tissue culture grade water|Pressurized water mist
41303316|NCT02504476|DRUG|AMG 581|Active drug
41303317|NCT02504476|DRUG|Placebo|Placebo
41303318|NCT02504476|DRUG|Midazolam|Interaction
41303319|NCT03362346|DEVICE|intracranial pressure monitoring|The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.
41303320|NCT00138710|DRUG|Letrozole (Femara)|
40981500|NCT02415127|DRUG|Placebo|The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
40981501|NCT01132131|OTHER|Delegation form|The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.
40981502|NCT02626520|DRUG|Gemcitabine and nanoparticle albumin bound paclitaxel|Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
40981503|NCT02626520|DRUG|5-fluorouracil and irinotecan|FOLFIRI.3 given every 14 days x 4 cycles
40981504|NCT02626520|RADIATION|Preoperative chemoradiation|Pre-operative chemoradiation to 40 Gy in 20 fractions
40981505|NCT02626520|PROCEDURE|Definitive resection|Definitive surgical resection of primary tumor
41303321|NCT01670513|DRUG|IDP-118 Low Strength|8 weeks
40981506|NCT02160158|DRUG|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
40981507|NCT02160158|DRUG|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
40981508|NCT02160158|DRUG|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
40981509|NCT02160158|DRUG|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
40981510|NCT02160158|DRUG|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
40981511|NCT02160158|DRUG|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
40981512|NCT02160158|DRUG|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
41303322|NCT01670513|DRUG|IDP-118 High Strength|8 weeks
41303323|NCT02005601|DRUG|Placebo|Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
41303324|NCT02005601|DRUG|Duloxetine 60mg|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
41303325|NCT02402218|OTHER|Usual care plus peer-mentors|Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
41462107|NCT02633241|DRUG|Dexmedetomidine bolus and high infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 1mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
40776882|NCT05308121|OTHER|Evaluation of biomechanics and viscoelastic properties of Achilles tendon|The biomechanical and viscoelastic properties of the Achilles tendon will be measured in the side lying position. Measurements will be taken from two different points with the ankle in the neutral position.
40776883|NCT05308121|OTHER|Evaluation of foot characteristics|The mobility of foot, morphological changes of foot and foot posture will be evaluated
40776884|NCT01785030|DRUG|50% Nitrous oxide|
40776885|NCT02018211|OTHER|control|passive recovery following exercise test
40776886|NCT02018211|DEVICE|graduated compression socks|graduated compression socks worn after test exercise
40776887|NCT02018211|DEVICE|neuromuscular electrical stimulation device|neuromuscular electrical stimulation device worn after test exercise
40776888|NCT03848780|DRUG|Desflurane|
40776889|NCT05135728|BEHAVIORAL|Unstuck and On Target: Preschool|Unstuck \& On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.
40776890|NCT01209767|DEVICE|cryolipolysis|During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite
40776891|NCT01209767|PROCEDURE|Subcision|Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.
40776892|NCT01209767|OTHER|Control|
40776893|NCT02895217|OTHER|ergocycle|
41303326|NCT02402218|OTHER|Usual care plus incentives|Participants are given incentives after completing treatment goals.
41303327|NCT02402218|OTHER|Usual Care|Participants receive standard of care in the clinic from their health care team.
41303328|NCT02045277|DRUG|IDP-118 Lotion|Lotion
41303329|NCT02045277|DRUG|IDP-118 Monad HP Lotion|Active Comparator
41303330|NCT02045277|DRUG|IDP-118 Monad Taz Lotion|Active Comparator
41303331|NCT02045277|DRUG|IDP-118 Vehicle Lotion|Vehicle
41303332|NCT06071494|OTHER|Tropical fruits|papaya, mango, banana, orange
40776894|NCT04445103|DIAGNOSTIC_TEST|Assessment of cardiac function|Echocardiographic examination and assessment of cardiac biomakers
40776895|NCT05936333|PROCEDURE|Biological collection|up to 25 mL of blood collection for the adults and saliva collection for the minor at inclusion, and placenta collection at childbirth
40981513|NCT02160158|DRUG|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
41303333|NCT01395095|OTHER|rehabilitation+telephonic coaching|intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
41303334|NCT01395095|OTHER|OPTICARE-B|standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).
40776896|NCT06058091|DRUG|RY_SW01 cell injection|Administer basic treatment with an injection of RY_SW01 cell solution
40776897|NCT06058091|DRUG|Basic treatment|Basic treatment for SSc
40776898|NCT00016354|DRUG|benzoylphenylurea|
40776899|NCT02768207|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg tablets (three 20 mg tablet) orally OD for 21 consecutive days (Days 1 to 21), followed by a 7 day break (Days 22 to 28); in each 28-day cycle of treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
40776900|NCT02768207|DRUG|Vemurafenib|Participants will receive vemurafenib 960 mg tablets (four 240 mg tablet) orally BID from Day 1 to Day 28 of each 28-day cycle of the treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
40776901|NCT05805202|OTHER|Blood sampling and urine analysis|A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees
40981514|NCT02160158|DRUG|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
40981515|NCT02160158|DRUG|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
40981516|NCT02955485|OTHER|Patients do not undergo any type of interventions, but standard care if offered and accepted.|
40981517|NCT05467436|DRUG|Local anesthetics, IV sedation drugs and analgesics.|Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
40981518|NCT05406258|DEVICE|Modified Self-Catheterization Mirror|Following training, participants will have a modified mirror available for self-catheterization, as well as a standard, hospital-provided mirror. They will record the mirror used, position, and time for self-catheterization. They will also complete the System Usability Scale for each mirror related to self-operation and user satisfaction.
40981519|NCT00953446|PROCEDURE|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
40981520|NCT05109039|DIETARY_SUPPLEMENT|Creatine|Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days
40981521|NCT05109039|DIETARY_SUPPLEMENT|Placebo|Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days
40981522|NCT05641051|DRUG|Metoclopramide|Cases will receive 10 mg intravenous metoclopramide every 6 hours.
40981523|NCT05641051|DRUG|Placebo|Cases will receive the same volume of IV placebo / 6 hours.
40981524|NCT01806324|DRUG|HL040XC|single dose
40981525|NCT01806324|DRUG|Losartan + Atorvastatin|Single dose
40981526|NCT05971407|DEVICE|Remote Ischaemic Preconditioning|RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
40981527|NCT05971407|DEVICE|Sham Remote Ischaemic Preconditioning|Sham RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
40981530|NCT04282993|DEVICE|Wearable devices for identifying and measuring risk factors for ischemic stroke|Identifying and monitoring cerebrovascular risk factors using wearable devices
40981531|NCT04282993|OTHER|Standard of care monitoring|Periodical medical examinations
40981532|NCT03664557|DEVICE|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
41303335|NCT01395095|OTHER|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
41303336|NCT06108427|OTHER|Renin measurements|Use of plasma renin measurements to guide MRA dosing, aiming for plasma renin unsuppression
41303337|NCT01234402|BIOLOGICAL|Ramucirumab DP|"10 mg/kg I.V.~Day 1 of every-21-day cycle"
41303338|NCT01234402|BIOLOGICAL|IMC-18F1|"12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle"
41303339|NCT01234402|DRUG|Capecitabine|"1000 mg/m\^2 orally~Twice a day for 14 days"
41303340|NCT04594239|DEVICE|Belotero Balance (+) Lidocaine, needle|Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles
41303341|NCT04594239|DEVICE|Belotero Balance (+) Lidocaine, cannula|Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas
41303342|NCT04594239|DEVICE|Untreated-control / delayed-treatment, needle|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)
41303343|NCT04594239|DEVICE|Untreated-control / delayed-treatment, cannulas|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)
41303344|NCT01081873|DRUG|leuprolide (Lucrin/Lucrin-Tri-depot)|Subcutaneous or intramuscular administration for all participants
41303345|NCT03871140|OTHER|diagnosis|therre is no intervention diagnosis or treatment for patients
40981533|NCT00498602|BIOLOGICAL|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
40981534|NCT00498602|BIOLOGICAL|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
40981535|NCT00498602|OTHER|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
40981536|NCT00498602|BIOLOGICAL|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
40981537|NCT02441777|DEVICE|Polarization-Sensitive OFDI|OCT Imaging of the eye
41303346|NCT05434247|DEVICE|Needle choice|The type of needle use was the only intervention
41303347|NCT02388516|DIETARY_SUPPLEMENT|Vitamin D3|
41303348|NCT02388516|DIETARY_SUPPLEMENT|Placebo|
41462108|NCT02633241|DRUG|Dexmedetomidine bolus and low infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 0.5mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
41462109|NCT02633241|DRUG|Dexmedetomidine bolus only - Propofol|First, the investigators will begin by administering dexmedetomidine 1mcg/kg over 5 minutes. When this is completed, they will administer propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion which can also be titrated up or down to a maximum of 300mcg/kg/min to keep the blood pressure and heart rate within 30% of baseline levels.
41462110|NCT05402917|PROCEDURE|Erector Spinae Plane Block|Interfascial plane (area) blocks are blocks in which the local anesthetic agent is injected into the potential area between the two fasciae. The ESPB we used in our study is a member of interfascial plane blocks. The erector is applied between the spinal muscle and the transverse process, spreading the drug from the injection site to both cranial and caudal. Unlike other defined interfascial plane blocks, ESPB can show paraspinal block characteristics since the injection site is above the transverse process.
41462111|NCT04387201|DRUG|Cyanocobalamin|Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.
41462112|NCT04387201|DRUG|Dulaglutide|Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks
41462113|NCT04884724|OTHER|Adaptive Dance Exercise Program|It is planned to include balance, stabilization, mobility, speed and rhythm activities for the exercises applied in Cerebral Palsy rehabilitation and based on the principles of motor learning, and to apply the dance steps and figures to be applied with visual and auditory stimuli.
41462114|NCT06227754|PROCEDURE|Angiography-guided PCI group|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.
41462115|NCT06227754|PROCEDURE|Optical coherence tomography-guided PCI group|"\[Stent Optimization\]~1. Stent Expansion:~   Visually assess residual angiographic diameter stenosis \<10% AND~   ① In non-LM lesions: In-stent minimal lumen area (MSA) \>80% of the average reference lumen area OR \>4.5 mm2~   ② In LM lesion: MSA\>7 mm2 for distal LM and \>8 mm2 for proximal LM~2. Stent Apposition:~   No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and \< 1mm length) of the stent over its entire length against the vessel wall~3. Edge Dissection:~No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as \>60° of the circumference of the vessel at site of dissection and/or \>2 mm in length of dissection flap)"
41462116|NCT05179486|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, and blood
41462117|NCT05179486|OTHER|Questionnaire Administration|Complete questionnaire
41462118|NCT00503113|DRUG|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) injection every 3 months
41462119|NCT00503113|DRUG|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) infusion every 3 months
41462120|NCT00503113|DRUG|Alendronate|70mg per oral (po) weekly
41462121|NCT04370444|DEVICE|Phallus Length Reducer|Phallus Length Reducer
41462122|NCT04370444|OTHER|Self-assessment of dyspareunia|Use of a vaginal insert to self assess dyspareunia
41462123|NCT06148662|OTHER|No intervention (negative control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds."
41462124|NCT06148662|OTHER|Water (positive control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds. Then, participants will to rinse their mouth with tap water 60 seconds."
41462125|NCT06148662|DRUG|"Dental foam Biorepair PERIBIOMA"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam Biorepair PERIBIOMA to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
41462126|NCT06148662|DRUG|"Dental foam WATER:DENT"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam WATER:DENT to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
41462127|NCT06148662|DRUG|"Dental spray BUCCOTHERM"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental spray BUCCOTHERM to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
40776902|NCT06009302|PROCEDURE|US guided block of mandibular nerve|Extraoral ultrasound-guided block of the mandibular nerve will be performed in the examined group using an ultrasound device, using ropivacaine (0.75%, 2.5 mL).
40776903|NCT06009302|PROCEDURE|Intraoral block of lower alveolar nerve|Block of lower alveolar nerve will be applied intraoraly using articaine+adrenaline
40776904|NCT05470400|BIOLOGICAL|FP conjugate vaccine (25 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
40981538|NCT00534989|PROCEDURE|FDG PET|FDG PET
41142930|NCT06437158|DRUG|Bleomycin|To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
41462128|NCT01817595|OTHER|BG Star Meter (Conventional) Internet Blood Glucose Reporting|Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email
41462129|NCT01817595|OTHER|iBG Star (iphone) Internet Blood Glucose Method|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
41462130|NCT03052855|OTHER|Magnetic Resonance Imaging (MRI) and biological samples|Participants will have to do a MRI and biological samples.
41462131|NCT01937806|DRUG|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
41462132|NCT01937806|DRUG|tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
41462133|NCT03755739|DRUG|Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy|vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
41462134|NCT01401296|BEHAVIORAL|Deprexis|Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
41462135|NCT01401296|BEHAVIORAL|Wait-list|Behavioral: the wait-list group receives Deprexis after 8 weeks
41462136|NCT03358147|DRUG|GP MDI 28.8 μg|GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
41462137|NCT03358147|DRUG|GP MDI 14.4 μg|GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
41462138|NCT03358147|DRUG|GP MDI 7.2 μg|GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
41462139|NCT03358147|DRUG|Placebo MDI|Placebo taken as 2 inhalations BID
41462140|NCT03358147|DRUG|Spiriva Respimat 2.5 μg|Spiriva Respimat 2.5 μg QD (open-label)
41462141|NCT06070545|OTHER|Modified Supine Position|Among the patients in the control group, for whom consent was obtained, the standard clinical procedure including supine after percutaneous coronary intervention (0 degrees flat on the back) will be provided, and for the patients in the experimental group, care including the modified supine position will be provided. The modified supine position is a position in which patients lie on their back with the head of the bed elevated at a 20-degree angle, with a pillow between the soles of their feet and the end of the bed. Both study groups will be required to lie supine in bed for 6 hours and stay in bed for 12 hours before ambulation is allowed in order not to increase the risk of local bleeding, as required by the clinical procedure.
41462142|NCT00000953|DRUG|Sorivudine|
40981539|NCT04924647|DRUG|lenalidomide and dexamethasone|lenalidomide 25mg d1-21 and dexamethasone 20-40mg d1，8，15，22
41142931|NCT02841020|PROCEDURE|Additional biopsy|• Patients in the experimental group receive the additional biopsy for non-neoplastic disease during the same procedure before the biopsy of the renal mass (with potential for direct benefit to the patient by revealing non-neoplastic renal disease).
41142932|NCT04677595|DRUG|Capmatinib|400 mg of capmatinib tablets, administered orally twice daily
41142933|NCT00006079|DRUG|Eflornithine|Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
41142934|NCT00006079|OTHER|Placebo|Patients receive oral placebo daily for 28 days.
41142935|NCT01346722|OTHER|Diet-ZnBfR|zinc biofortified rice-based diet
41462143|NCT00000953|DRUG|Acyclovir|
41142936|NCT01346722|OTHER|Diet- CR|conventional rice-based diet
41142937|NCT01346722|OTHER|Diet-ZnBfR|zinc biofortified rice-based diet
41142938|NCT01346722|OTHER|CR + Zn|conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
41142939|NCT04968886|DIAGNOSTIC_TEST|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)
41462144|NCT05874648|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
41462145|NCT03346850|DEVICE|Nasogastric tube (NGT) feeding|A nasogastric tube goes from the nose to the stomach.
41462146|NCT03346850|DEVICE|Nasoduodenal tube (NDT) feeding|A nasoduodenal tube goes from the nose to the duodenum.
41462147|NCT00399724|DRUG|Insulin glargine|
41462148|NCT00290264|DRUG|Budesonide/formoterol|
41462149|NCT00235118|DEVICE|Cordis AAA Bilateral Device|
41462150|NCT00379509|DRUG|lapatinib ditosylate|Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
41462151|NCT00379509|GENETIC|TdT-mediated dUTP nick end labeling assay|Genetic analysis of tumor tissue
41462152|NCT00379509|GENETIC|gene expression analysis|Genetic analysis of tumor tissue.
41462153|NCT00379509|GENETIC|microarray analysis|Genetic analysis of tumor tissue.
41462154|NCT00379509|OTHER|immunohistochemistry staining method|Laboratory analysis of tumor tissue.
41462155|NCT00379509|PROCEDURE|biopsy|Serial biopsies by skin punch or core biopsy or fine needle aspiration.
41462156|NCT00379509|RADIATION|radiation therapy|Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
41462157|NCT06338423|DEVICE|vacuum mattress|vacuum mattresses used to better positioning of the patient
41462158|NCT06338423|OTHER|Standard Mattress|Standard Mattress
41462159|NCT01291095|DRUG|CISPLATIN|"IN CRT ARM:RADIATION ONE FRACTION PER DAY, ON FIVE CONSECUTIVE DAYS FROM MONDAY TO FRIDAY ALONG WITH INTRAVENOUS CISPLATIN 40mg/m2 WEEKLY FOR SEVEN DOSES.~IN AFRT ARM: PATIENTS WILL NOT RECEIVE ANY CHEMOTHERAPY WITH CISPLATIN"
40981540|NCT03921554|DRUG|Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
40981541|NCT04122898|OTHER|Pelvic Floor Muscle Training|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the gymnasts in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (inward lift of the pelvic floor assessed with suprapubic 2D ultrasound) and instructions on how to perform the training program. The athletes will be offered at least one individual follow-up session with the same physiotherapist during the intervention period. The program will consist of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The athletes will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 3 months and the exercises will take approximately 10 minutes per day to perform.
40981542|NCT03952000|BEHAVIORAL|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
40981543|NCT02889484|PROCEDURE|Lumbar disc hernia surgery|
40981544|NCT03655197|DRUG|Doxycycline|For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
40981545|NCT04233554|BEHAVIORAL|Patient Priorities Care|Patients will participate in a structured conversation in which the facilitator (i.e. social worker) helps patients identify their health goals, measurable, actionable, realistic outcomes (e.g. walk ½ mile daily). Both practice and patient level data will be collected.
40981546|NCT06295263|OTHER|Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers|Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups
40981547|NCT00619801|DRUG|Levocetirizine|Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
40981548|NCT00619801|DRUG|Placebo|Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
40981549|NCT00782145|OTHER|educational intervention|
40981550|NCT00782145|OTHER|informational intervention|
40981551|NCT00782145|OTHER|internet-based intervention|
40981552|NCT00782145|OTHER|questionnaire administration|
40981553|NCT00782145|OTHER|study of socioeconomic and demographic variables|
40981554|NCT00782145|OTHER|survey administration|
40981555|NCT00782145|PROCEDURE|psychosocial assessment and care|
40981556|NCT00782145|PROCEDURE|quality-of-life assessment|
40981557|NCT00782145|PROCEDURE|standard follow-up care|
40981558|NCT00159536|DRUG|Metformin|Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
40981559|NCT00159536|DRUG|Placebo|Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
40981560|NCT00681655|OTHER|Alcohol|Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).
40981561|NCT00681655|OTHER|Placebo|Placebo (saline vehicle) infused for 2.8 hour long session.
40981562|NCT00479661|DRUG|Dexmedetomidine|Continuous infusion
40981563|NCT00479661|DRUG|Propofol|Continuous infusion
40981564|NCT00869206|DRUG|zoledronic acid|Given IV
40776905|NCT05470400|BIOLOGICAL|FP conjugate vaccine (200 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
40981565|NCT06475950|OTHER|"Kid'EM app experimental group"|"In the Kid'EM app experimental group arm, only the application used differs. Visits are organized in the same way as in the controle app arm.~Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit~Children are included in the study by the investigator, formalized by signing a consent form.~Parents fill in questionnaires~Visit 2 (when 1st objective is set):~Telephone interview to assess performance and satisfaction levels after the first goal has been set.~Visit 3 (when setting the 2nd goal):~Telephone interview to assess performance and satisfaction levels after the second goal has been set.~Visit 4 (week 14 - end of study): Physical visit~The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input.~Visit 4 bis:~Telephone interview to assess performance and satisfaction levels after the work on the first two objectives.~Visit 5 (focus group, optional post-study visit)"
40981566|NCT06475950|OTHER|Kid'EM app control group|"Use of control application without guidance for goal setting~Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit~Children are included in the study by the investigator, formalized by signing a consent form.~Parents fill in questionnaires~Visit 2 (when 1st objective is set):~Telephone interview to assess performance and satisfaction levels after the first goal has been set.~Visit 3 (when setting the 2nd goal):~Telephone interview to assess performance and satisfaction levels after the second goal has been set.~Visit 4 (week 14 - end of study): Physical visit~The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input.~Visit 4 bis:~Telephone interview to assess performance and satisfaction levels after the work on the first two objectives.~Visit 5 (focus group, optional post-study visit)"
40981567|NCT02961751|DRUG|Ciprofloxacin|Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.
40981568|NCT01244906|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
40981569|NCT05513495|OTHER|The effect of drip versus intermittent feeding on splanchnic oxygenation|After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).
41303349|NCT05684120|BEHAVIORAL|Mood Lifters for Undergraduates|Participants will need to attend 14 hour-long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
41303350|NCT00830661|PROCEDURE|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
41462160|NCT01291095|RADIATION|EXTERNAL BEAM RADIOTHERAPY|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
41462161|NCT03711357|RADIATION|980 nm diode laser|980 nm high power diode laser device.
41462162|NCT03711357|OTHER|placebo|the diode laser fiber optic tip will be inserted in root canals, but will not be activated.
40981570|NCT01373801|DEVICE|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
40981571|NCT01373801|DEVICE|Control|Standard packing gauze roll bandage.
40981572|NCT02826031|DRUG|Sodium Hyaluronate Injection|
41142940|NCT06506552|PROCEDURE|IMA preserving|Performing left hemicolectomy, sigmoidectomy or rectal resection the IMA was preserved ligating the sigmoids arteries close to the colonic wall
41142941|NCT06506552|PROCEDURE|IMA sectioning|Performing left emicolectomy, sigmoidectomy or rectal resection the IMA is sectioned after the origin of left colic artery.
41142942|NCT04473937|RADIATION|Radiotherapy|Radiotherapy at pre-determined dose and schedule
41142943|NCT06385483|DRUG|Afatinib|Given PO
41142944|NCT06385483|PROCEDURE|Biopsy|Undergo biopsy
41303351|NCT00830661|PROCEDURE|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
41303352|NCT00377143|DRUG|Warfarin Dosing|
41303353|NCT03657914|PROCEDURE|Single-hole inflatable mediastinal mirror|The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
41462163|NCT04009876|DRUG|nal-IRI|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
41462164|NCT04009876|PROCEDURE|Surgical resection|Surgical resection of the tumour
41462165|NCT04009876|OTHER|Watch-and-wait|No surgery approach
41462166|NCT04009876|DRUG|5-FU/LV|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
41462167|NCT04009876|DRUG|Oxaliplatin|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
41462168|NCT06447285|DIAGNOSTIC_TEST|SensoDetect BERA technology|"All recruited participants are to be tested using SensoDetect's patented technology. All tests shall be performed in a quiet and darkened room. Participants will be asked to be comfortably seated in an armchair in a resting position (part 1 only). Surface electrodes will then be attached to the skin over the mastoid bones behind the left and right ear, with a ground electrode on one arm. Two reference electrodes will also be placed on the forehead. Before each test session, the procedure shall be fully explained to the test subject or parents.~The subjects will then be instructed to relax with their eyes closed and are permitted to fall asleep (with modifications in part 3). The test will require no active participation other than being subjected to sound stimulation. The subjects will be tested one at a time, and the duration of the testing procedure will be 15 min."
41462169|NCT05074706|BIOLOGICAL|IgG antibodies to Sars-Cov-2|Samples will be collected between 30 and 60 days after second vaccine dose.
41462170|NCT05074706|BIOLOGICAL|QuantiFERON SARS-CoV-2 test|Samples will be collected within 9 months after completion of the vaccination series
40981573|NCT02826031|DRUG|DICL-SR|
40981574|NCT03703765|DEVICE|lower limb volume estimation|"The 3D scanner system is a three-dimensional measurement system.~It allows to evaluate the volume of the lower limbs in order to quantify the evolution of the edema of the lower limbs in the venous pathology in pre and post therapeutic technique.~It is a non-invasive, easily accepted, non-invasive, non-invasive technique that minimizes discomfort."
40981575|NCT01640145|DIETARY_SUPPLEMENT|Protein|Whey protein intake
40981576|NCT01640145|OTHER|Exercise|Unilateral low intensity exercise
41142945|NCT06385483|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41142946|NCT06385483|PROCEDURE|Computed Tomography|Undergo CT scan
41142947|NCT06385483|PROCEDURE|Echocardiography|Undergo ECHO
41142948|NCT06385483|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41142949|NCT06385483|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
41142950|NCT01666821|OTHER|Follow-up observation|a epidemiologic survey of ocular diseases in an adult population (\>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
41142951|NCT00632736|DRUG|Ropinirole XL (formerly CR)|
41142952|NCT01945086|DRUG|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
41142953|NCT01945086|DRUG|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
41142954|NCT01945086|OTHER|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
41142955|NCT04645303|DRUG|hyaluronic acid (20 mg/2 mL)|A1-Pulley infiltration for trigger finger
41142956|NCT04645303|DRUG|Triamcinolone acetonide 10mg/ml|A1-Pulley infiltration for trigger finger
41462171|NCT00384592|DRUG|Esomeprazole|
41462172|NCT00384592|PROCEDURE|Physical exam|
41303354|NCT03816306|DRUG|LCZ 696|LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
41462173|NCT00384592|PROCEDURE|Pregnancy test if applicable|
41462174|NCT01634685|RADIATION|Radiation|Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
41462175|NCT01634685|DRUG|Bavituximab|Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
41462176|NCT01634685|DRUG|Capecitabine|capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
41462177|NCT03268096|DEVICE|Cerebral MRI and Optical Coherence Tomography|Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.
41462178|NCT04526080|DEVICE|TheraBionic Device|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 6-week treatment period will be considered a cycle of treatment. For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
40776906|NCT05470400|BIOLOGICAL|Trimer 6931 (100 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
40776907|NCT05470400|BIOLOGICAL|Trimer 6931 (200 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
40981577|NCT04537767|DRUG|Esmolol|The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
41142957|NCT00003049|DRUG|fluorouracil|
41142958|NCT00003049|DRUG|leucovorin calcium|
41142959|NCT00003049|PROCEDURE|conventional surgery|
41303355|NCT04283994|BEHAVIORAL|Survey-based Patient/Clinician Jumpstart|"The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The Jumpstart takes two forms. One is EHR-based and provides information to the clinician about prior advance care planning documentation derived from the EHR. The other is bi-directional and patient-specific (Survey-based Patient/Clinician Jumpstart Guide). It provides the same information as the EHR-based Clinician Jumpstart Guide but also includes information about patients' self-reported preferences for communication and care as well as primary barriers and facilitators to this communication. The Jumpstart Guides include tips to improve this communication for clinicians, patients and families."
41303356|NCT04283994|BEHAVIORAL|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page EHR-based Clinician Jumpstart Guide provides information to the clinician about prior advance care planning documentation derived from the EHR. The EHR-based Clinician Jumpstart Guide includes tips to improve goals-of-care communication.
41303357|NCT00409422|BEHAVIORAL|weight management program|
41303359|NCT00972244|DRUG|Dapagliflozin|once daily, 12 weeks
41303360|NCT00972244|DRUG|Placebo|once daily, 12 weeks
41303361|NCT02532634|DRUG|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
41462179|NCT04526080|DEVICE|Placebo Device|Subjects who are randomized to receive placebo, will receive the same instructions and a similar device. The placebo device will look and sound the same as the active device, but will not deliver the modulation frequencies. For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
41462180|NCT03231345|PROCEDURE|US guided IJ|IV catheter placement
41462181|NCT03231345|DEVICE|Ultrasound|Ultrasound-guided Internal Jugular vein
41462182|NCT02394288|PROCEDURE|Extremity orthopedic or trauma surgery|hip, leg, shoulder, arm
41462183|NCT04276012|OTHER|Multifactorial intervention|Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
40981578|NCT04537767|DRUG|Placebo|Placebo
41142960|NCT00003049|RADIATION|radiation therapy|
41142961|NCT01218048|DRUG|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
41142962|NCT01218048|PROCEDURE|Surgery|Surgery for tumor
41142963|NCT01218048|RADIATION|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
41142964|NCT01218048|DRUG|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
41462184|NCT03084458|BEHAVIORAL|Fitbit|The Fitbit device will allow experimental group participant access to their daily step count.
41462185|NCT03824834|DRUG|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions (three times per week for five weeks) on an electronically braked bike, supervised by a trained exercise specialist. Exercise sessions will be individualized based on participants' peak power output (60% PPO) determined from incremental exercise testing, and progressed to ensure the participant is exercising at a breathlessness intensity rating of between 3-5 Borg CR10 scale units and can complete at least 20-min of continuous cycling. Exercise duration will be increased in 5-min intervals up to 40-min. Thereafter, exercise intensity will be increased by 5-15% of baseline PPO.
41462186|NCT03824834|OTHER|Exercise training with placebo|Diluted simple syrup prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions as per the experimental group.
41462187|NCT02197416|DRUG|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
41462188|NCT03278158|DRUG|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
41462189|NCT03278158|DRUG|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
41462190|NCT03278158|DRUG|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet
40981579|NCT05016921|DEVICE|TcMS|Transcutaneous magnetic stimulation targeting the stellate ganglion
40981580|NCT01486914|DRUG|insulin aspart|Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
40981581|NCT01883843|DEVICE|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
40981582|NCT01883843|DEVICE|real tDCS + TOCT|Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
40981583|NCT00389363|DRUG|ALK HDM tablet|
40981584|NCT00711711|OTHER|Manual lymphatic drainage|Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery
41142965|NCT03067870|BIOLOGICAL|Stem Cell Transplantation|"* Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.~* Transplantation of autologous bone marrow derived stem cells in joints."
41303362|NCT02532634|DRUG|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
41462191|NCT03278158|DRUG|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
41462192|NCT03278158|DRUG|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
40981585|NCT00711711|OTHER|relaxation|Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
40981586|NCT05216328|DRUG|Macrogol Only Product in Oral Dose Form|Information already included in arm/group description.
40981587|NCT05216328|DRUG|Magnesium hydroxide 724mg|Information already included in arm/group description.
40981588|NCT01493206|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy
40981589|NCT03012425|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
40981590|NCT03012425|PROCEDURE|Acupuncture|
40981591|NCT03012425|BEHAVIORAL|questionnaires|
41142966|NCT05795283|DRUG|Citalopram i.v. and p.o|"Citalopram:~i.v.: 10 mg/die for day 1-7, 20 mg/die for day 8-14 p.o.: 20 mg/die for day 15-28"
41142967|NCT05795283|DRUG|Citalopram p.o|"Citalopram:~p.o: 10 mg/die for day 1-7, 20 mg/die for day 15-28"
41142968|NCT00584675|DEVICE|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
41142969|NCT02633228|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of Oculentis® MplusX® multifocal intraocular lenses with an addition of +2.0 D in the distance-dominant eye and +3.0 D in the fellow eye.
41462193|NCT00721916|DRUG|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
41462194|NCT00721916|DRUG|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
40981592|NCT03012425|OTHER|Diurnal Cortisol|saliva test
40981593|NCT01272414|DRUG|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
40981594|NCT01272414|DRUG|Saline injection|Injection of 0.4cc 0.9% normal saline
40981595|NCT01399138|DIETARY_SUPPLEMENT|Blueberry Powder|The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
40981596|NCT00353912|DRUG|valsartan + amlodipine|
40981597|NCT02269345|OTHER|Battlefield Acupuncture|Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
40981598|NCT02269345|OTHER|Standard Treatment|Standard Treatment alone.
41142970|NCT02580227|DRUG|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
41462195|NCT05828979|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
41462196|NCT02340624|BEHAVIORAL|Referral to SmokeFreeMoms, Quitline or Brief intervention|"1. SmokeFreeMom is a mobile text messaging service designed for pregnant women across the United States to help them quit smoking. The program provides 24/7 encouragement, advice, and tips to help pregnant women and mothers quit smoking and stay quit.~2. The 1-800 QuitLine provides smoking cessation services to Michigan residents who want to quit using tobacco. The Quit Line offers a personal health coach and participant toolkits to help tobacco users gain confidence and motivation they need to quit for good.~3. Computer-delivered 5As (CD-5As) brief intervention The software platform to be used for this study features an interactive three-dimensional narrator, clear and relevant graphics, and aura;Participants use headphones for privacy while working with the computer."
41462197|NCT00159419|DRUG|Alendronate|
41462198|NCT00159419|DRUG|Pamidronate|
41462199|NCT01175473|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
40776908|NCT05470400|BIOLOGICAL|Trimer 4571 (200 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
40776909|NCT05470400|BIOLOGICAL|Trimer 4571 (100 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
40776910|NCT01659502|DRUG|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
41142971|NCT02580227|OTHER|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
41462200|NCT01175473|DEVICE|Pen auto-injector|
41462201|NCT01175473|DRUG|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
41462202|NCT01175473|DEVICE|Pre-filled pen injector|
41462203|NCT01175473|DRUG|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
41462204|NCT02673086|OTHER|coracoid approach|Coracoid approach for ultrasound guided infraclavicular brachial plexus block
40776911|NCT06426979|DRUG|Methotrexate|Methotrexate 25 mg/ml was given as single-dose of intramuscular (IM) injection in a dose of 50 mg/m2.
41142972|NCT01196364|OTHER|Dietary Supplement: water with noncalorie sweetener|
41142973|NCT01196364|OTHER|Activity: With noncalorie sweetener or glucose|
41142974|NCT01890954|DEVICE|Diabetes Assistant (DiAs)|Diabetes Assistance (DiAs) is a software residing in a Smartphone that contains the algorithms to regulate and control insulin deliveries (insulin bolus for: Basal rate, meal insulin and correction bolus) with inputs glucose values from a CGM and outputs insulin infusion by an insulin pump
41142975|NCT04119700|PROCEDURE|Muco-muscular endorectal advancement flap after fistulectomy|After fistulectomy muco-muscular flap of the rectal wall will be mobilized. The muscular defect is sutured with separate interrupted sutures (Vicryl / Polysorb 2/0, 0/0, 3/0). The muco-muscular flap is fixed to the anoderm without tension by interrupted sutures (Vicryl / Polysorb 4/0). The wound of the perianal area is not sutured.
41142976|NCT04119700|PROCEDURE|Primary sphincter reconstruction after fistulectomy|Fistulectomy will be performed. The affected gland is visualized and removed. If there are secondary extensions, they are excised also. Sphincter defect with stitches (suture material Vicryl / Polysorb 2/0, 0/0, 3/0) with restoration of the anal canal profile (suturing of the anodermal-skin border). The skin is not suturing.
41142977|NCT04703114|DIAGNOSTIC_TEST|Blood count|Blood count at each visit
41462205|NCT02673086|OTHER|retroclavicular approach|retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
41462206|NCT01221649|DEVICE|ICD/CRT-D|BIOTRONIK ICD family Lumax 540 and its successors
41462207|NCT02890225|PROCEDURE|3 days after|in 3 days after RIRS.
41462208|NCT02890225|PROCEDURE|10days after|in10 days after RIRS.
41462209|NCT02890225|PROCEDURE|EPVL performed in30days after RIRS|Patients in Group C undergo EPVL in630days after RIRS.
40776912|NCT06426979|DRUG|Letrozole|FEMARA 2.5 mg tablets two tablets daily
40776913|NCT02112084|BEHAVIORAL|Individualized DPM|The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
40776914|NCT01059747|OTHER|no intervention applied|no intervention applied
40776915|NCT02081586|BEHAVIORAL|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
40776916|NCT02081586|DEVICE|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
41142978|NCT04703114|DIAGNOSTIC_TEST|Blood collection|Blood collection to understanding of the immunological profile at each visit
41142979|NCT04703114|DIAGNOSTIC_TEST|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR at day 8 and day 15
41142980|NCT04703114|DIAGNOSTIC_TEST|Saliva samples|Research of SARS-CoV-2 infection in saliva samples at each visit (excepted inclusion)
41142981|NCT04703114|DIAGNOSTIC_TEST|Faeces samples|Research of SARS-CoV-2 infection in faeces samples at day 3, day 15 and day 90
41142982|NCT04703114|GENETIC|Genetic blood collection|Collection to further research at each visit
41142983|NCT04703114|OTHER|Data collection|Demographics, symptoms, biological constants
41462210|NCT02818894|DRUG|Lidocaine|Spinal anesthesia administered prior to participant's THA
41303363|NCT03908138|DRUG|RDD|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
41303364|NCT03908138|DRUG|VDD|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
41462211|NCT02818894|DRUG|Bupivacaine|Spinal anesthesia administered prior to participant's THA
41462212|NCT03294317|DEVICE|His bundle pacing|Medtronic SelectSecure SureScan MRI model 3830 lead
41462213|NCT06449391|DEVICE|RAI|Immediate implantation
41462214|NCT02625311|PROCEDURE|surgery method using CR TKP|Operation through minimal invasive surgery or standard open surgery
41462215|NCT03755180|OTHER|Exercise Training|In exercise training, aerobic exercise and strengthening exercises, especially for gastrocnemius and tibialis anterior muscles, will be applied to the patients. In addition the exercise training, Compression Therapy is applied to patients.
41462216|NCT03755180|OTHER|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
41462217|NCT02414464|OTHER|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth."
41462218|NCT02414464|OTHER|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session."
41462219|NCT02414464|OTHER|20% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session."
41462220|NCT06383091|BEHAVIORAL|Anterior Neck Manual Therapy|Manual massage applied to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
41462221|NCT06383091|BEHAVIORAL|Pain Neuroscience Education|Description of how the pain system works from a neurobiological level, discussing the biopsychosocial model that influences pain.
41462222|NCT06383091|BEHAVIORAL|Neck Stretches|Bilateral cervical side bending, cervical extension and bilateral rotational neck stretches held for 20 seconds x3.
41462223|NCT06383091|BEHAVIORAL|Scar massage|Digital manipulation of the scar itself in circles.
41462224|NCT06383091|BEHAVIORAL|Voice Exercises|Stemple Voice Exercises
40776917|NCT02081586|OTHER|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
40981599|NCT04026867|OTHER|Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS), the most influential studies of HIV linkage-to-care to date.
40981600|NCT04026867|OTHER|Clinician Referral|"The Clinician Referral arm will serve as an active control and baseline standard of care."
41303365|NCT01351077|OTHER|CHICA DevScreen Module|This module assists in the diagnosis and management of developmental screening
40776918|NCT00708357|DRUG|NG-monomethyl-L-arginine|intravenous administration, bolus over 5 minutes, dosage 6mg/kg
40981601|NCT02793102|OTHER|Olfactory workshop|Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
40981602|NCT02793102|OTHER|Somesthesia workshop|Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
40981603|NCT02793102|OTHER|Auditory workshop|Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
41303366|NCT04666324|DRUG|Simethicone Solution|Oral daily treatment for four weeks
41303367|NCT04666324|DIETARY_SUPPLEMENT|Multilac Baby|Oral daily treatment for four weeks
41462225|NCT06383091|BEHAVIORAL|Placebo Anterior Neck Manual Therapy|Will apply extremely light manual contact to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
41462226|NCT06383091|BEHAVIORAL|Placebo Pain Neuroscience Education|Will discuss how pain will as a result of the surgical intervention.
41462227|NCT06383091|BEHAVIORAL|Placebo Neck Stretches|Will ask patient to look down as a neck stretch held for 20 seconds x3.
41462228|NCT00362505|DRUG|Clevudine|
41462229|NCT00905541|DRUG|simvastatin|40 mg/day
41462230|NCT00905541|DRUG|simvastatin|80 mg simvastatin acute-on-chronic
41462231|NCT01285505|DRUG|alprazolam commercial sublingual formulation|0.5 mg tablet, single dose
41462232|NCT01285505|DRUG|alprazolam test sublingual tablet|0.5 mg tablet, single dose
40981604|NCT05020990|DEVICE|Lens A (delefilcon A)|Daily disposable for one week
40981605|NCT05020990|DEVICE|Lens B (stenfilcon A)|Daily disposable for one week
40981606|NCT03267186|DRUG|Ibrutinib|Given PO
40981607|NCT03267186|OTHER|Laboratory Biomarker Analysis|Correlative studies
40981608|NCT02050074|DRUG|Colesevelam|
41303368|NCT03415477|DRUG|Denosumab (Xgeva)|Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle， perioperatively.
41303369|NCT02116660|DRUG|Raltegravir (MK-0518)|Raltegravir (MK-0518) 400 mg tablets
41303370|NCT02116660|DRUG|Nevirapine|Nevirapine (NVP) 200 mg tablets
41462233|NCT03012893|DEVICE|Ultrasound sagittal scan|Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
41142984|NCT03400748|DEVICE|RF Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
40776919|NCT06351514|DEVICE|Accelerated iTBS|Patients will be assigned to receive iTBS over the left dorsolateral prefrontal cortex or Frontal Medea with 5 sessions a day, every weekday for 1 week and total of 25 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 100%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions. All TBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.
40776920|NCT06032182|BEHAVIORAL|CRESTR Intervention|15 1-hour sessions of CRT + SRT
40981609|NCT02050074|DRUG|Metformin|
40981610|NCT02050074|OTHER|Placebo|
40981611|NCT00191555|DRUG|olanzapine|
41142985|NCT05809466|OTHER|Vegan diet|A self-composed 12 week fully plant-based diet
41142986|NCT05809466|OTHER|Resistance exercise|Biweekly resistance exercise for 12 weeks
41142987|NCT05809466|OTHER|Omnivorous diet|Habitual diet containing both animal- and plant-based food products
41142988|NCT05281809|DRUG|Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)|This protocol describes the use of an automated cell processor and culture system, the CliniMACS Prodigy device sold by Miltenyi Biotec, for the local manufacture of CAR T-cells targeting the CD19 antigen. The manufacturing process will use a lentiviral vector (CAR19) provided by Lentigen, a wholly owned subsidiary of Miltenyi Biotec, to transfect T-cells collected from eligible patients. Live cells will be harvested by the device after culture and infused intravenously to the patient from whom the cells were originally obtained.
41142989|NCT06299540|BEHAVIORAL|Individual Physical Activity Intervention (IPAI)|No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy.
41142990|NCT06299540|DRUG|Ibrutinib|No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.
41303371|NCT02116660|DRUG|Lamivudine|Lamivudine (3TC) 150 mg tablets
41303372|NCT02116660|DRUG|Tenofovir|Tenofovir disoproxil fumarate (TDF) 300 mg tablets
41303373|NCT02116660|DRUG|Emtricitabine|Emtricitabine (FTC) 200 mg tablets
41303374|NCT02116660|DRUG|Lopinavir|Lopinavir (LPV) 200 mg tablets
40776921|NCT06032182|BEHAVIORAL|CRESTR Control|15 1-hour sessions of SRT alone
40776922|NCT02735200|DRUG|Application of topical vitamin d3 (Top-D)|Topical Vitamin D3 will be applied on the skin, externally, 1 gram daily for 120 days
40776923|NCT02735200|OTHER|Application of Aloe vera gel|"aloe vera gel will be applied~Dosage: 1 gram Duration: 120 days Frequency: Daily"
41142991|NCT06534918|OTHER|Fitbit|Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
41142992|NCT06534918|BEHAVIORAL|Nutrition Course|The virtual, synchronous nutrition course will be a 30-60 minute group education class on nutrition information for cancer survivors. The class will be held once per week.
41142993|NCT06534918|BEHAVIORAL|Physical Activity Program|The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.
41303375|NCT02116660|DRUG|Ritonavir|Ritonavir (r) 100 mg tablets
41303376|NCT02116660|DRUG|Atazanavir|Atazanavir (ATV) 300 mg tablets
41303377|NCT02116660|DRUG|Darunavir|Darunavir (DAR) 400 mg tablets
40981612|NCT00191555|DRUG|haloperidol|
40981613|NCT04533347|DRUG|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
40981614|NCT04533347|DRUG|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
40776924|NCT02793960|DRUG|topical BPM31510 3.0% Cream|Application of drug to lesions of epidermolysis bullosa
40981615|NCT02793141|OTHER|No intervention|No intervention will be administered
40981616|NCT00074087|DRUG|pegylated liposomal doxorubicin hydrochloride|
40981617|NCT04859023|DIAGNOSTIC_TEST|saliva sample combined to an anterior nare self-swabbing (Self-samples)|Tested by antigenic test.
40981618|NCT04859023|DIAGNOSTIC_TEST|saliva sample (Self-sample)|Tested by RT-PCR.
41303378|NCT02996695|DRUG|Artesunate|Artesunate is a succinic ester of artemether.
41303379|NCT02996695|DRUG|Chloroquine|4-aminoquinolone, antimalarial agent for oral administration
41303380|NCT02996695|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
40981619|NCT04859023|OTHER|Survey of SARS-COV-19 knowledge|collection of : socio-professional characteristics, questions on health literacy on the transmission of the virus and barrier gestures, adherence to barrier gestures, isolation modalities in case of positivity, motivations for participating in this screening campaign.
40981620|NCT04859023|OTHER|Survey of acceptability of the different self-samples.|collection of : assessment and acceptability of the tolerance of self-samples.
40981621|NCT03600610|DEVICE|gadolinium-enhanced cardiac MRI|cardiac magnetic resonance imaging with gadolinium injection used T1-Mapping
40981622|NCT04576832|BEHAVIORAL|Mindfulness-Based Attention Training (MBAT) web-course|Pre-recorded weekly sessions for 4 weeks. Each session will consist of approximately 2 hours of video content per week and weekly mindfulness exercises. This video will include MBAT program lectures, pre-recorded testimony from military leaders, and teaching materials. The course will also include 15-min daily mindfulness practice drills.
40981623|NCT03194698|DEVICE|Intense Pulsed Light Treatment (IPL)|IPL is a high-intensity light source consisting of visible light in the wavelength range of 515-1200 nm, that is aimed at the eyes. Treatments are spaced four to six weeks apart for a total of 4 treatments.
40981624|NCT03194698|PROCEDURE|Meibomian Gland Expression|Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
41142994|NCT06534918|BEHAVIORAL|Weekly One on One Session with Registered Dietitian|Participants will be referred to weekly one on one sessions with a Registered Dietitian. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual.
41142995|NCT06534918|BEHAVIORAL|Weekly One on One Session with an Exercise Physiologist|Participants will be referred to weekly one on one sessions with an Exercise Physiologist. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual
41303381|NCT02996695|OTHER|Placebo|Placebo
41303382|NCT02196142|DRUG|Cortisol 20mg|Drug: Cortisol 20mg
40776925|NCT03842397|DEVICE|Kephalios Device 1|The Kephalios Device 1 is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of the Kephalios Device 1 is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
41303383|NCT02196142|DRUG|Placebo Mannitol|Drug: Placebo Mannitol
41303384|NCT00050349|DRUG|EPO906 epothilone B|
41303385|NCT05692193|BEHAVIORAL|pain education|Pain education was given to the experimental group for 20-30 minutes on the day of hospitalization.
41462234|NCT03012893|DEVICE|Ultrasound transverse scan|Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
41462235|NCT03012893|PROCEDURE|Fluoroscopic technique|C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
41462236|NCT04410705|OTHER|Extracorporeal shockwave theraphy for hamstring tendinopathy|For hamstring tendinopathy; a total of 2000 impulses will be done. We will apply twice a week and 5 times in total.
41462237|NCT04410705|OTHER|Extracorporeal shockwave theraphy for quadriceps tendinopathy|Energy flux density will be 0.58mJ/mm2 (2 bar) with 2000 impulses. We will perform twice a week, 5 times in total.
41462238|NCT04410705|OTHER|Extracorporeal shockwave theraphy for achilles tendinopathy|Each session consisted of 2400 impulses will be administered with an energy flux density ranged from 0.17 to 0.25 mJ/mm2 (1.7-2.5 bar). We will perform once a week, 3 times in total.
41462239|NCT04113616|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.
40776926|NCT05333926|DEVICE|MHNA-001|3-month digital therapy program designed to reduce the severity of IBS symptoms
40776927|NCT01450345|DRUG|Pregabalin|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
40776928|NCT06157073|DEVICE|Closed-loop ventilator|Fully automated closed-loop ventilator using the INTELLIVENT software
40981625|NCT06327867|DEVICE|Oro Tracheal Intubation by DL|DL
40981626|NCT06327867|DEVICE|Oro Tracheal Intubation by VL|VL
40981627|NCT03834701|DEVICE|EUS guided radiofrequency ablation|The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.
40981628|NCT04767204|BEHAVIORAL|peer co-delivered vocational rehabilitation service|The services provided by the trained peers in the work training or problem-solving group, which integrates into a supported employment services
40981629|NCT02105792|DRUG|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
40981630|NCT03006991|OTHER|therapeutic drug monitoring|dose of methotrexate can be adjusted by therapeutic drug monitoring.
40981631|NCT02557698|OTHER|Balneum oil bath|
40981632|NCT04987957|OTHER|Music Therapy|Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music
41142996|NCT06534918|BEHAVIORAL|Nutrition Prescription|The nutrition prescription pad serves as a quick checklist designed to assist participants in effectively monitoring their dietary habits. Participants randomized to intervention group will each receive a one-time nutrition prescription in person during their first intervention week.
41142997|NCT06534918|BEHAVIORAL|Physical Activity Prescription|The physical activity prescription pad serves as a quick checklist designed to assist participants in effectively monitoring their exercise routines. Participants randomized to intervention group will each receive a one-time physical prescription in person during their first intervention week.
40981633|NCT04718467|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|Three doses of Recombinant COVID-19 vaccine (Sf9 cells) (40μg) at the schedule of day 0, 21, 42.
40981634|NCT04718467|BIOLOGICAL|Placebo|Three doses of Placebo (1.0ml) at the schedule of day 0, 21, 42.
40981635|NCT00618059|DRUG|Pilocarpine|
40981636|NCT03314753|OTHER|No interventions - retrospective data collection|No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial
40981637|NCT05819515|PROCEDURE|Tunneled coronally advanced flap|Describes the flap design for both treatment arms
40981638|NCT05221814|DIAGNOSTIC_TEST|gross pathologic photo based deep learning model|Whether apply gross pathologic photo based deep learning model to predict pathologic subtype
40981639|NCT01712607|OTHER|Preoperative Warm-Up training|Preoperative Warm-Up training
41142998|NCT05186402|PROCEDURE|Total or subtotal gastrectomy|Gastric resection with digestive continuity according Roux or Bilroth
41303386|NCT03003143|DRUG|Vigabatrin 500 MG|
41462240|NCT04113616|DRUG|Cytarabine|Cytarabine is an anti-cancer chemotherapy drug taken via injection.
41462241|NCT04113616|DRUG|Decitabine|Decitabine is an anti-cancer chemotherapy drug taken via injection.
41462242|NCT01831986|DIETARY_SUPPLEMENT|Pregnenolone and L-Theanine|Pregnenolone (50 mg/day) with L-theanine (400 mg/day)
41462243|NCT01831986|OTHER|Placebo|Caps
41462244|NCT05598398|DEVICE|V.A.C.Ulta™ Negative Pressure Wound Therapy System|"The V.A.C.Ulta™ Negative Pressure Wound Therapy System is a 510(k) - cleared, Class II device (K100657) with the following indication for use: the V.A.C.Ulta™ Negative Pressure Wound Therapy System is an integrated wound management system that provides Negative Pressure Wound Therapy with an instillation option."
41462245|NCT05598398|OTHER|Standard of Care (Wet-to-dry dressings)|Wet-to-dry dressings
41462246|NCT04906941|DEVICE|MRI|"SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment.~\* Sense 2 \* 2: 9min33s"
41462247|NCT03937206|DIETARY_SUPPLEMENT|NutriterraTM|Nutriterra 1000mg
41462248|NCT03937206|DIETARY_SUPPLEMENT|Placebo|Corn Oil 1000mg
41462249|NCT01679431|DIAGNOSTIC_TEST|Doppler-echocardiography|
41462250|NCT01679431|RADIATION|Computed tomography|
41462251|NCT01679431|OTHER|Magnetic resonance imaging|
41462252|NCT01679431|BIOLOGICAL|Fasting blood sample|
41462253|NCT03769636|DEVICE|GaitUp Physilog 5|"The primary outcomes are measured by the Physilog 5 (physical activity) at four different periods (T1-T4). Physilog 5 is worn for 4 weeks in total.~The secondary outcomes are fatigue, measured by FSMC (fatigue scale for motor and cognitive functions questionnaire), self-rated health-related quality of life, measured by the EQ-5D (health-questionnaire) and self-rated walking capacity, measured by the MSWS-12 (Twelve Item MS Walking Scale)."
41462254|NCT04485806|OTHER|GPS/LM|Media microdroplet geometry (3D dishes) in combination with light mineral oil overlay
41462255|NCT04485806|OTHER|SPL/LM|Media microdroplet geometry (2D dishes) in combination with light mineral oil overlay
41462256|NCT04485806|OTHER|GPS/PO|Media microdroplet geometry (3D dishes) in combination with Paraffin oil overlay
41462257|NCT04485806|OTHER|SPL/PO|Media microdroplet geometry (2D dishes) in combination with paraffin oil overlay
40776929|NCT06157073|DEVICE|Open-loop ventilator|Conventional closed-loop ventilator with manual adjustments by the physician in charge
40981640|NCT03785665|DEVICE|MDI|Capsule MD1 (Motility dummy 1)
40981641|NCT05277701|DRUG|Lazertinib|Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
40981642|NCT03589443|DRUG|Multiplexed heptapeptides|Heptapeptides QRH and KSP
40981643|NCT06238401|DRUG|ACR246 for injection|80 mg/vial
40981644|NCT05898815|DIAGNOSTIC_TEST|Medical record collection|Medical record collection
41142999|NCT06315465|DIETARY_SUPPLEMENT|Modified Atkin's Diet with standard of care|children who have given their consent and are randomized into Group I arm receives Modified Atkins Diet along with standard of care after completion of baseline investigations. Modified Atkin's Diet will be started in ratio of 1:1 and compliance is monitored by urine ketones. Followup will be done telephonically to check for compliance , adverse events at every 4 week intervals till 24 weeks.
41462258|NCT02312037|BIOLOGICAL|Antibody Drug Conjugate Chemotherapeutic|"Three Treatment Regimens:~1. Mylotarg \<=9 mg/m2 as a single agent on Day 1 \& 14 of a 28-day cycle for a total of two cycles~2. Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen~3. Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL"
41462259|NCT00559598|GENETIC|proteomic profiling|
41462260|NCT00559598|OTHER|medical chart review|
41462261|NCT04735887|OTHER|SADL-eM|The SADL-eM includes three elements essential to the intervention, namely: knowledge, skills, and advice. The manual includes 92 A5 pages with six detailed sections: an Introduction and five chapters: (1) Rehabilitation team, (2) Activities of Daily Living, (3) Assistive devices, (4) Home environment adaptation, and (5) Knowledge guide. The SADL-eM uses text and illustrative pictures that are carefully selected for contextual relevance. The manual is simple, easy, and suitable for people with a non-medical background.
41462262|NCT02971813|BEHAVIORAL|Facebook|"1. Volunteers will be recruited during inpatient stay, or via phone call or in person after discharge and prior to beginning cardiac rehabilitation.~2. Participants will be given a baseline BREQ-3 survey and a PNSE scale.~3. Patients will be randomized to Facebook™ versus comparison groups using a blocked randomization.~4. The Facebook™ intervention will include peer support, education, provider support and text message prompts when new posts are added.~   1. Educational posts will cover topics that will cover healthcare information.~  2. Provider support will be posted much like the educational posts.~5. The data collection for this study will take place prior to beginning cardiac rehabilitation, at which time the participants will receive the BREQ-3 and PNSE surveys either in person or via email link.~6. Post-testing will include a BREQ-3 and PNSE surveys and count of the number of sessions completed in a 3 month period of time."
40981645|NCT04492995|DIAGNOSTIC_TEST|injection via TUMIR of the tracer [99mTc] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml)|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
40981646|NCT04492995|DIAGNOSTIC_TEST|injection via TUMIR of [99mTc] Tc-albumin nanocoloid (6mCi, 8ml).|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
40981647|NCT05423652|DEVICE|Lung point of care ultrasound|Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.
40981648|NCT05423652|OTHER|PRESUNA software|PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.
40981649|NCT04229615|DRUG|Fluzoparib; Apatinib|Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily
40981650|NCT04229615|DRUG|Fluzoparib|Fluzoparib Orally twice daily
40981651|NCT04229615|DRUG|Placebo|Placebo
40981652|NCT06061965|BEHAVIORAL|Web-based resilience-building intervention|There are 6 modules on the website. Participants will be encouraged to verbalize their impressions of the website prototype.
40981653|NCT02977689|DRUG|IDH305|study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
40981654|NCT05953246|BEHAVIORAL|Neutral labels|Participants view neutral labels (QR codes with and without neutral text) for menu items
40981655|NCT05953246|BEHAVIORAL|Numeric text-only sustainability labels|Participants view labels with numeric text depicting the greenhouse gas emissions associated with production of the menu item
40981656|NCT05953246|BEHAVIORAL|Endorsement text-only sustainability labels|Participants view labels using text to endorse menu items as having low environmental impact
40981657|NCT05953246|BEHAVIORAL|Endorsement icon-only sustainability labels|Participants view labels using icons to endorse menu items as having low environmental impact
40981658|NCT05953246|BEHAVIORAL|Endorsement text-plus-icon sustainability labels|Participants view labels using text and icons to endorse menu items as having low environmental impact
41143000|NCT06315465|OTHER|Standard of Care|Standard of care intervention plan will be devised for each subject which includes Behavioral therapy , Psychoeducation, Activity based interventions like attention enhancement exercises, self help skills, Occupational therapy, Pharmacotherapy, Sensory integration therapy. The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioral intervention to be provided to the child. Physical follow up will be done every 4 weekly till 24 weeks.
41462263|NCT01634854|DRUG|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
41462264|NCT01634854|DRUG|Intravenous Oxytocin|"Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
41462265|NCT04391517|DIAGNOSTIC_TEST|SpHb measurement|All included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
40981659|NCT00319644|DEVICE|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
40981660|NCT05548231|DRUG|LY3437943|Administered SC
40981661|NCT05548231|DRUG|Placebo|Administered SC
40981662|NCT05489809|PROCEDURE|Endotracheal extubation with suctioning|General anestheisa is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying suctioning.
40981663|NCT05489809|PROCEDURE|Endotracheal extubation with positive pressure|General anesthesia is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying positive pressure.
41143001|NCT04948866|BEHAVIORAL|ADRD-PC Program|Included in arm/group descriptions
41462266|NCT06188780|DIAGNOSTIC_TEST|urine/blood analysis with IA and LC-GCMS analysis|urine/blood analysis with IA and LC-GCMS analysis
41462267|NCT01861249|DRUG|SAR339658|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
41462268|NCT00493727|DRUG|N-acetylcysteine(Mucomyst)|
41462269|NCT05109520|DRUG|Insulin Glargine 300 UNT/ML [Toujeo]|Switch during standard routine care to Gla-300.
41462270|NCT05188417|DRUG|Tirofiban 0.05 MG/ML|intravenous injection of the drug according to different body weights and arms
40981664|NCT06117150|DEVICE|Drug-eluting Coronary Spur Stent System|All subjects enrolled will be treated with the Drug-eluting Coronary Spur Stent System.
40981665|NCT01516424|DRUG|Blonanserin|Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
40981666|NCT01516424|DRUG|Risperidone|Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
40981667|NCT02402439|DRUG|Islet cells|Transplantation of islets into the gastrointestinal submucosa
41143002|NCT05565898|DEVICE|positron emission tomography for exclusion of bone marrow infiltration in lymphoma|compare the diagnostic accuracy of PET/CT scan against Bone Marrow Biopsy in detection of bone marrow involvement for staging of lymphoma
41143003|NCT02926313|OTHER|Individualized Seating provision|Seating system selected and adjusted to meet individual needs.
41143004|NCT02064686|OTHER|Exhaled breath temperature|
41143005|NCT06469931|OTHER|range of motion exercises|In addition to range of motion exercises for wrist and hand and splinting, 3 sessions of ozone therapy will be applied once a week.
41143006|NCT06469931|DEVICE|Extracorporeal shock wave therapy|Patients in this group will receive ESWT once a week for 3 consecutive weeks in addition to range of motion exercises for wrist and hand and splinting.
41303387|NCT04077970|BIOLOGICAL|Intrauterine flushing of follicular fluid with granulosa cells|All patients in case and control groups will receive agonist and antagonist protocol. Ovarian stimulation will be carried out when pituitary desensitization is achieved and is continued until the day of hCG administration. COCs aspiration will be performed 34-36h after hCG injection. Clear Follicular Fluids (without blood cells) which contain COCs will be used. Endometrial flushing after oocyte retrieval with 2 ml of clear FF plus granulose cells will be performed by an IUI catheter. The control group included 70 women who would not have FF endometrial flushing. In both groups, embryo transfer will be carried out 2-3 days later. Luteal phase support will be started the day after ovum pick up by the vaginal administration of progesterone daily for 16 days and will continued for up to12 weeks if pregnancy occurred. Pregnancy was diagnosed by measurement of β-hCG level and later was confirmed by Transvaginal sonography.
40776930|NCT00633841|BIOLOGICAL|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
41303388|NCT05307822|OTHER|Non-combusted cigarette variant 42001401|Menthol flavor variant of a non-combusted cigarette (42001401)
41303389|NCT05307822|OTHER|Non-combusted cigarette variant 42001399|Menthol flavor variant of a non-combusted cigarette (42001399)
40776931|NCT03136055|DRUG|Pembrolizumab|Given Intravenously (IV)
40776932|NCT03136055|DRUG|Irinotecan|Given IV
40776933|NCT03136055|DRUG|Paclitaxel|Given IV
40776934|NCT05977296|DEVICE|CPAP|To use CPAP
40776935|NCT05503082|DRUG|Ubrogepant 50 MG [Ubrelvy]|Ubrogepant 50 MG \[Ubrelvy\]
40776936|NCT05503082|DRUG|Ubrogepant 100 MG [Ubrelvy]|Ubrogepant 100 MG \[Ubrelvy\]
40776937|NCT03064308|OTHER|Exercise Programme|Participants will complete the High-Intensity Functional Exercise (HIFE) programme. The programme improves lower-limb strength, balance and mobility and all the exercises can be performed by the individual at home and with minimal equipment.
40776938|NCT04250792|DRUG|Naltrexone Pill|role of low dose naltrexone in patients affected with psoriasis
40981668|NCT02402439|PROCEDURE|Islet transplantation into the gastrointestinal submucosa|Transplantation of islets into the gastrointestinal submucosa
40981669|NCT03930576|OTHER|Receipt of termination services outside of legal setting|This study uses variation in gestational age to examine the impact of receipt of legal termination services compared to denial and receipt outside legal settings and birth.
40981670|NCT06503419|OTHER|non-intervention|non-intervention
41303390|NCT05307822|OTHER|Non-combusted cigarette variant 40007386|Menthol flavor variant of a non-combusted cigarette (40007386)
41303391|NCT05307822|OTHER|Non-combusted cigarette variant 42001402|Non-Menthol flavor variant of a non-combusted cigarette (42001402)
40981671|NCT05276544|BEHAVIORAL|Dietary intervention|Dietary intervention: Preparation and follow-up of diet program.
41143007|NCT06469931|OTHER|ozone therapy|ozone therapy
41143008|NCT02495402|BEHAVIORAL|Motivational Interviewing|Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
41143009|NCT06012799|DIAGNOSTIC_TEST|continuous glucose monitoring|FreeStyle Libre Flash Glucose Monitoring System
41143010|NCT05771285|OTHER|Cold application|To evaluate the effect of cold application applied before subcutaneous low molecular weight heparin injection on post-injection pain, ecchymosis and hematoma formation.
41303392|NCT01823627|PROCEDURE|Spirometry with reversibility test|Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
40776939|NCT02796716|DEVICE|Testing on new technology called Accelerate ID/AST system|
40776940|NCT02647671|DRUG|Aquamin®|90 days of Aquamin
40776941|NCT02647671|DRUG|Calcium Carbonate|90 days of Calcium Carbonate
40776942|NCT02647671|DRUG|Placebo|90 days of placebo
40776943|NCT00929266|BIOLOGICAL|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
40776944|NCT01951391|OTHER|Control Hand Soap|Commercially available soap will be used to wash the subject's forearms
41462271|NCT05188417|DRUG|0.9% sodium chloride solution|intravenous injection of the drug according to different body weights and arms
41462272|NCT01094262|DRUG|Oxycodone CR (standard pain medication)|Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
41462273|NCT01094262|DRUG|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
41462274|NCT01094262|DRUG|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
41462275|NCT01094262|DRUG|Placebo|Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
41462276|NCT04685681|BEHAVIORAL|Hiking challenge|The main intervention of interest is the provision of free access to a local hiking challenge (which is provided following baseline assessments in the experimental group and after the conclusion of the study in the control group; $20 value). If participants choose to sign up for the free hiking challenge, they receive a list of local hikes/nature walks, accompanying maps, scavenger-hunt-like activities (finding a certain landmark on each hike), and the opportunity to earn prizes and engage with other hikers on social media.
40776945|NCT01951391|OTHER|Benzalkonium Chloride Soap|Commercially available soap containing benzalkonium chloride will be used to wash the subject's forearms
40776946|NCT01951391|OTHER|Triclocarban Soap|Commercially available soap containing triclocarban will be used to wash the subject's forearms
40776947|NCT05466305|DEVICE|Gold plated chrome cobalt alloy|Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
40776948|NCT00710619|DRUG|activated recombinant human factor VII|This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
41143011|NCT03941366|PROCEDURE|Standard of care chemotherapy with the change for avoidance of extensive surgery|All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.
40776949|NCT00710619|DRUG|Feiba VH|This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
40776950|NCT04149743|DIAGNOSTIC_TEST|Standard of Care with Hemotag|Comparison of outcomes
40776951|NCT01198626|DRUG|JNJ-32729463|150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
40776952|NCT01198626|DRUG|moxifloxacin|400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
40776953|NCT01198626|DRUG|JNJ-32729463 (Open-Label)|Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
40776954|NCT01280968|BIOLOGICAL|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
40776955|NCT01280968|BIOLOGICAL|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
40776956|NCT00133445|BIOLOGICAL|DTaP-Hep B-IPV Vaccine|U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
40776957|NCT00133445|BIOLOGICAL|Monovalent Hep B Vaccine|U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
41143012|NCT00002977|BIOLOGICAL|filgrastim|
41143013|NCT00002977|DRUG|melphalan|
41143014|NCT00002977|DRUG|thiotepa|
41143015|NCT00002977|PROCEDURE|peripheral blood stem cell transplantation|
41303393|NCT06074458|OTHER|Glucosano|Glucosano is a remote patient monitoring diabetes dashboard with a patient facing Smartphone application
41303394|NCT06074458|BEHAVIORAL|Community Health Worker diabetes technology coach|Community Health Workers will work with participants as a diabetes technology coach during scheduled and as needed visits
40776958|NCT00133445|DRUG|Placebo|Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
40776959|NCT05853965|DRUG|Belantamab mafodotin, Venetoclax|Belantamab mafodotin (IV) Venetoclax (PO)
41143016|NCT03897491|DRUG|5-aminolevulinic acid|5-aminolevulinic acid powder for oral solution
41143017|NCT04809701|PROCEDURE|Temporary implantation of defibrillation coils and pulse generator|Each subject will undergo temporary implantation of defibrillation coils and pulse generator according to the NV-ICD electrode configurations.
41143018|NCT04809701|PROCEDURE|Defibrillation following induction of VA (Configuration A first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration A. Then up to two defibrillation energies will be tested for Configuration B.
41303395|NCT01724736|DRUG|Placebo|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
41303396|NCT01724736|DRUG|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
41303397|NCT02411201|DRUG|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
41303398|NCT04297670|OTHER|Measurement of HPV types prevalence|Self collected genital samples to be tested for the presence of different HPV types.
41303399|NCT00006222|DRUG|cilengitide|
40981672|NCT03437525|BEHAVIORAL|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer coaches. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer coaches will provide education and support for insulin therapy to help reduce barriers around insulin use. Peer coaches will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer supporters and participants.
40981673|NCT00190996|DRUG|Duloxetine Hydrochloride|
40981674|NCT00190996|DRUG|placebo|
40981675|NCT05752201|BIOLOGICAL|Gamma Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
40981676|NCT05752201|BIOLOGICAL|Omicron Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
40981677|NCT05752201|BIOLOGICAL|Bivalent RBD-based ARVAC-CG vaccine|Vaccine containing 25 µg of gamma antigen + 25 µg of omicron antigen + Alum Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
40981678|NCT05752201|OTHER|Placebo (Alum)|Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection
40981679|NCT02436889|DRUG|Mirabegron|
40981680|NCT02436889|DRUG|Tolterodine Tartrate|
40981681|NCT04247581|DEVICE|1-lead ECG|"1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions."
40981682|NCT01101347|DEVICE|Aneurysm-Embolization System|
40981683|NCT04253145|DRUG|PM 01183|Lyophilisate for solution for infusion
40981684|NCT04253145|DRUG|Atezolizumab|Concentrate for solution for infusion
40981685|NCT00672789|BEHAVIORAL|Blood smear education|education at baseline and three month follow-up
40981686|NCT00672789|OTHER|standard education|standard education
40981687|NCT04822064|DRUG|Intranasal dexmedetomidine and ketamine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
40981688|NCT04822064|DRUG|Oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
40981689|NCT01717807|OTHER|C11-Erlotinib PET/CT|
40981690|NCT02263794|PROCEDURE|Conventional Bronchial Thermoplasty|Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
40981691|NCT02263794|PROCEDURE|Image Guided Bronchial Thermoplasty|Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
40981692|NCT04973124|DRUG|Dexmedetomidine|These participants will receive intraoperative dexmedetomidine.
41143019|NCT04809701|PROCEDURE|Defibrillation following induction of VA (Configuration B first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration B. Then up to two defibrillation energies will be tested for Configuration A.
41143020|NCT04809701|PROCEDURE|Removal of defibrillation coils and pulse generator|Defibrillation coils and pulse generator will be removed from the subject after the defibrillation tests are completed.
41143021|NCT01555892|BIOLOGICAL|EBV-specific T cells: A|Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
41462277|NCT04685681|OTHER|Activity list|The control group will receive a list of CDC-recommended activities following the baseline survey and will receive the hiking challenge as a delayed intervention following post-test.
41462278|NCT06347809|OTHER|Non-Interventional Study|Non-Interventional Study
40981693|NCT04973124|DRUG|Placebo|These participants will not receive intraoperative dexmedetomidine.
40981694|NCT06160154|OTHER|no intervention|all patients undergoing minimally invasive distal pancreatectomy, no intervention, no randomization
40981695|NCT00714454|OTHER|APS Topical Lotion|
40981696|NCT00714454|OTHER|Placebo|
40981697|NCT02701439|DEVICE|Small membrane filtration|"Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~* Abbreviated demographic and clinical evaluation~* TB history and evaluation~* Obtain three sputum samples - one early morning sample and two spot samples~* HIV testing (and CD4 if positive)~* Chest radiograph~* Small membrane filtration intervention will be administered to both arms"
40981698|NCT03590587|DRUG|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
40981699|NCT03590587|DEVICE|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
40981700|NCT03824912|DRUG|Ketoconazole Cream 2%|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
40981701|NCT03824912|DRUG|Ketoconazole Cream 2% (G&W Laboratories Inc.)|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
41143022|NCT01555892|BIOLOGICAL|EBV-specific T cells: B|Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
41143023|NCT01441336|PROCEDURE|Laparoscopic gastrectomy|Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
41462279|NCT03681587|OTHER|Control situation|"Standard breakfast usually offered monotonous control condition at the retirement home: the time of distribution, the duration of ingestion and the composition will be habitual. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone in the room or with others in the dining room."
40981702|NCT03824912|DRUG|Placebo|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
40981703|NCT02477254|BIOLOGICAL|Vaccination|A quadrivalent HPV vaccine
40981704|NCT04080297|DRUG|oral capsule of Q-122|
40981705|NCT01042327|DEVICE|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
40981706|NCT01042327|DEVICE|Fresenius FX100 dialyzer|
40981707|NCT06084403|DRUG|20 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine (Buvasin %5 flakon) 20ml will be injected here.
40981708|NCT06084403|DRUG|30 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 30ml will be injected here.
40981709|NCT06084403|DRUG|40 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 40ml will be injected here.
40981710|NCT03460483|OTHER|Genetic Counseling|Undergo genetic counseling
40981711|NCT03460483|OTHER|Genetic Testing|Undergo genetic testing
40981712|NCT03460483|OTHER|Laboratory Biomarker Analysis|Correlative studies
40981713|NCT03460483|PROCEDURE|Mutation Carrier Screening|Undergo tumor screening via next-generation sequencing
40981714|NCT00447642|DRUG|LX201|"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
40981715|NCT00447642|OTHER|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
40981716|NCT01093807|DRUG|Placebo|once daily for 10 weeks
40981717|NCT01093807|DRUG|Lercanidipine|10 mg once daily for 10 weeks
40981718|NCT01093807|DRUG|Lercanidipine|20 mg once daily for 10 weeks
40981719|NCT01093807|DRUG|Enalapril|10 mg once daily for 10 weeks
40981720|NCT01093807|DRUG|Enalapril|20 mg once daily for 10 weeks
41143024|NCT03982797|BIOLOGICAL|Instillation of IMUNO BCG Moreau RJ|Instillation in bladder will be done once per week during first six weeks after inclusion, and 3 instillations (one per week) on month three, another three on moth six and last three on month twelve .
41143025|NCT02382185|OTHER|Fluid optimisation|The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
41143026|NCT02382185|DRUG|Optimisation of blood pressure|Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
40981721|NCT01093807|DRUG|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
40981722|NCT01093807|DRUG|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
41143027|NCT02382185|DEVICE|Application of clearsight monitor|The clear sight monitor will be applied to measure stroke volume.
41143028|NCT04112563|PROCEDURE|exploration in white light (WLI)|Exploration of the right colon done in white light (WLI)
41143029|NCT04112563|PROCEDURE|Exploration in LCI|Exploration of the right colon in linked color imaging (LCI)
41143030|NCT00825318|PROCEDURE|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
41143031|NCT00823966|DRUG|Rescriptor|"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
40981723|NCT01093807|DRUG|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
40981724|NCT01093807|DRUG|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
40981725|NCT05299515|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately four weekly core sessions (approximately 30 minutes-1 hour) with two additional sessions to reinforce core content, and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to assist in their retention and persistence in methadone treatment and incorporating value-driven, substance-free, rewarding activities into their daily life."
40981726|NCT05543876|PROCEDURE|suturing procedure|Children presenting to the emergency department for suturing
41143032|NCT01533194|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
41143033|NCT01533194|BIOLOGICAL|Wild-type Reovirus|Given IV
41143034|NCT00546884|BEHAVIORAL|MI condition|Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
40981727|NCT03835585|DEVICE|Gun lock|A cable-style gun lock that can be applied to a wide variety of guns for safe storage. The application of this device to most firearms renders them impossible to use properly while the device is in place and locked.
40981728|NCT03835585|OTHER|Suicide Risk Assessment|Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
40981729|NCT03835585|BEHAVIORAL|Safety Planning|A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley \& Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.
40981730|NCT03835585|BEHAVIORAL|Lethal Means Counseling|A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
40981731|NCT04078061|BEHAVIORAL|MABA|Adaptive, modular, behavioral intervention.
40981732|NCT04078061|BEHAVIORAL|EIBI|Early Intensive Behavioral Intervention
40981733|NCT02988505|OTHER|Standard care|
40981734|NCT05615571|GENETIC|Establishment of mitochondrial markers|Establishment of mitochondrial markers from fibroblasts in culture, obtained from a skin biopsy. Establishment of yeast models to show biochemical mitochondrial alterations: introduction of missense variants in the pantothenate kinase yeast gene Cab1 whose deletion is lethal, followed by growth of mutant strains on fermentation and respiratory media.
40981735|NCT05615571|GENETIC|Sequencing tests|sequencing tests of a panel of 22 genes (9 already known and 13 new genes) using a dedicated custom capture and a medium throughput sequencing protocol.
41303400|NCT05437172|PROCEDURE|injectable platelet rich fibrin with demineralized dentin graft|after atraumatic extraction, collection of whole venous blood (9 ml) in sterile vacutainer tubes will be done without anticoagulant added, vacutainer tubes will be then placed in a centrifugal machine at 700 revolutions per minute (rpm) for 3 min with a tube filled with water to maintain the balance during the centrifuging process. ADDG particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze. Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.
41462280|NCT03681587|OTHER|Experimental situation|"Salty/sweet breakfast varied experimental situation: the time of distribution and the duration of mealtime will be open and the composition will be varied with sweet/savory foods. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone or in the room or with others in the dining room."
41462281|NCT02267408|OTHER|Warfarin adjustment using the Fearon algorithm|All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.
40776961|NCT00724763|DEVICE|acupuncture|to Liv 3 and PE 9.
40776962|NCT00724763|DEVICE|sham needle treatment|needle not in meridian area
40776963|NCT04507763|DRUG|Etanercept|Patients with ankylosing spondylitis as provided in real world practice
40776964|NCT00070304|BIOLOGICAL|filgrastim|Given by mouth or IV, 5 micrograms/kg/dose (up to 10 micrograms/kg/dose) daily starting on day 9 for a minimum of 7 days and until the ANC is greater to or equal to 1,500/uL.
40776965|NCT00070304|DRUG|gemcitabine hydrochloride|Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
40776966|NCT00070304|DRUG|vinorelbine tartrate|Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
40776967|NCT01014871|DRUG|Botulinum Toxin Type A - Azzalure|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
40776968|NCT01014871|DRUG|Botulinum Toxin Type A - Vistabel|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
40776969|NCT01197547|DEVICE|Genesys HTA|Genesys HTA Endometrial Ablation
40776970|NCT01853280|DRUG|L-methylfolate|15mg/day L-methylfolate.
40776971|NCT01853280|DRUG|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
40776972|NCT01853280|DRUG|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
40776973|NCT05755581|DRUG|Hormonal Antineoplastics|the Neoadjuvant endocrine therapy group will receive neoadjuvant hormonal therapy.
40776974|NCT05755581|DRUG|Chemotherapy drug|the Neoadjuvant chemotherapy group will receive neoadjuvant chemotherapy.
40776975|NCT04871620|DIAGNOSTIC_TEST|>15% SV increase during fluid challenge|The stroke volume will be measured before and after 15 minutes fluid challenge with crystalloids
40776976|NCT05815602|DRUG|Ebastine|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
40776977|NCT05815602|DRUG|Duspatalin|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
40981736|NCT02429518|DRUG|Miltefosine|
40981737|NCT05931159|OTHER|Abdominal Hypopressive Training|"Week 1 and 2 - Patient education , Hypopressive Maneuvers in Standing, Sitting and Supine 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week.~Week 3 and 4, Hypopressive breathing in with varying arm movements along with Week 1 and 2 protocols.~Week 5 to 8 - Hypopressive breathing in kneeling, Four-point kneeling and sitting, and supine positions with varying arm movements 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week."
40981738|NCT05931159|OTHER|Conventional Physical therapy for DrA|"Week 1 to 4, Draw-in maneuver in supine, Quadruped and Prone lying, Bent knee Fallouts and Curl ups. (8 to 12 repetitions x 3 sets, 2 days/week)~Week 5 to 8, Front and side planks added to week 1 to 4 exercises. (12 to 20 repetitions x e sets, 2 days/week)"
40981739|NCT04528849|DRUG|Gonadotropin dose increment timing|Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.
40981740|NCT01372280|DRUG|Reminyl|Galantamine Hydrobromide Tablets 4 mg
40981741|NCT03415750|DRUG|Everolimus|Conversion from Mycophenolate mofetil to Everolimus
40981742|NCT03415750|DRUG|Mycophenolate mofetil|Patients will remain in Tacrolimus + Mycophenolate mofetil
40981743|NCT03415750|DRUG|Tacrolimus|
40981744|NCT06477458|OTHER|Single inspiratory phase computed tomography.|Utilizing deep learning technology in conjunction with single inspiratory phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
40981745|NCT06477458|OTHER|Respiratory dual-phase computed tomography.|Utilizing deep learning technology in conjunction with respiratory dual-phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
40981746|NCT00232817|DRUG|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
40981747|NCT05558163|PROCEDURE|transverse scrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
40981748|NCT05558163|PROCEDURE|penoscrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
40981749|NCT05517889|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography is a non-invasive scanner which generates real-time in-vivo images of the skin and its adnexal structures. Images are generated by light-interferometry.
40981750|NCT00223951|DRUG|R89674 (generic name not yet established)|
40981751|NCT00463346|DRUG|Acamprosate|Acamprosate 1998 mg tid
40981752|NCT00463346|DRUG|Placebo|Placebo
40981753|NCT02630433|PROCEDURE|Index cholecystectomy|Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
40981754|NCT02630433|PROCEDURE|Scheduled cholecystectomy|Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
40981755|NCT01572454|DRUG|Dexmedetomidine infusion|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
40981756|NCT01572454|DRUG|Remifentanil infusion|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
41143035|NCT00546884|BEHAVIORAL|GI|The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
41143036|NCT00103857|DRUG|Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
41143037|NCT00103857|DRUG|Comparator: MK0431 100 mg q.d. (q.d. = once daily)|MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
40981757|NCT05615012|DRUG|BMS-986322|Specified dose on specified days
40981758|NCT05615012|DRUG|Rosuvastatin|Specified dose on specified days
40981759|NCT05615012|DRUG|Metformin|Specified dose on specified days
40981760|NCT05615012|DIETARY_SUPPLEMENT|Glucose|Specified dose on specified days
40981761|NCT05615012|DRUG|Methotrexate|Specified dose on specified days
40981762|NCT05615012|DRUG|Leucovorin|Specified dose on specified days
40981763|NCT03444519|DRUG|Mannitol|This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
40981764|NCT04053023|DRUG|GSK2330672 (linerixibat)|GSK2330672 is available as a tablet with unit dose strength of 45 mg.
40981765|NCT04053023|DRUG|Obeticholic acid|Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
40981766|NCT01453634|DRUG|Lunacalcipol 180|4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
40981767|NCT01453634|DRUG|Lunicalcipol 270|8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
40981768|NCT02331836|DEVICE|Arc Endocuff (AEC 110, 120, 130, 140)|
40981769|NCT02331836|DEVICE|Cap|Olympus Disposable distal attachment 15mm diameter, 4mm depth
40981770|NCT02331836|DEVICE|Standard colonoscope|
40981771|NCT04880512|DRUG|SYHX 1901 tablets|SYHX 1901, oral tablets, in fasted state
40981772|NCT04880512|DRUG|Placebo|Matching placebo, oral tablets, in fasted state
40981773|NCT02392741|OTHER|Physical exercise program|The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
41462282|NCT02267408|OTHER|Warfarin adjustment using standard dosing|Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
40776978|NCT00492557|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
40776979|NCT00492557|BIOLOGICAL|13vPnC + TIV|Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
40776980|NCT00054262|DRUG|T900607|
40776981|NCT02048007|DRUG|Azithromycin|Biannual mass oral azithromycin to children
40776982|NCT02048007|DRUG|Placebo|Biannual mass oral placebo to children
40776983|NCT01766687|DIETARY_SUPPLEMENT|Hydration|
40776984|NCT04734392|PROCEDURE|TAVR|TAVR implantation in cusp overlay technique
41143038|NCT00103857|DRUG|Comparator: Placebo (Phase A)/Metformin (Phase B)|During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
41143039|NCT00103857|DRUG|Comparator: Metformin 500 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
41143040|NCT00103857|DRUG|Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
41143041|NCT00103857|DRUG|Comparator: Metformin 1000 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
41143042|NCT06439277|DRUG|Tirzepatide|Administered SC
41143043|NCT06439277|DRUG|Placebo|Administered SC
41143044|NCT01990183|DEVICE|CareToy|Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home - session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.
41143045|NCT01990183|OTHER|Standard Care|Current care advices in the management of preterm infants in the first months of life
41143046|NCT00055068|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
41143047|NCT00055068|BEHAVIORAL|Relaxation Training|
41143048|NCT04312425|PROCEDURE|Modified rapid sequence induction|Modified RSI was put into use in day shift emergency surgery since March 1, 2018. In this scheme, dorsal elevated position and apneic oxygenation technic are applied. Positive pressure mask ventilation is avoided unless necessary. Sellick's technic is not used in this scheme.
41143049|NCT04312425|PROCEDURE|Classic rapid sequence induction|In classic RSI scheme, patients are in supine position during induction and intubation. Sellick's technic is applied after sedatives and muscle relaxant are given.
41143050|NCT02395692|OTHER|Treatment|Correlative studies
41143051|NCT02395692|DRUG|Methoxyamine|Given PO
41143052|NCT02395692|DRUG|Temozolomide|Given PO
41143053|NCT03853746|DRUG|Ocrelizumab|Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.
40981774|NCT05040841|BEHAVIORAL|M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result|"Standard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the Risk of Treatment Failure (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1."
40981775|NCT05040841|BEHAVIORAL|M2/PRM: Immediate outreach to subject after a missed pharmacy refill|The subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
40981776|NCT05040841|BEHAVIORAL|M3/EAM: Immediate outreach to subject after EAM-identified missed doses|The subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
40981777|NCT05040841|BEHAVIORAL|S1/Text: Weekly check-in texts|"Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent."
40981778|NCT05040841|BEHAVIORAL|S2/Peer: Enhanced peer group support|"Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks."
40981779|NCT04447261|DRUG|BI 1356225|BI 1356225
40981780|NCT04447261|DRUG|Placebo|Placebo
40981781|NCT02859207|DRUG|E2609|Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
40981782|NCT04741061|BIOLOGICAL|Sputnik Light|"Sputnik-Light vector vaccine:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 1011 particles per dose."
40981783|NCT04741061|OTHER|Placebo|Placebo
40981784|NCT03484481|DIETARY_SUPPLEMENT|Oral Nutritional Support; Nutrena|Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. \]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
40981785|NCT03484481|DIETARY_SUPPLEMENT|Intradialytic Parenteral Nutrition; Kabiven central|Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
41462283|NCT01274962|DRUG|FOLFOX|"* Oxaliplatin\* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~* Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes~* 5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~* 5-Fluorouracil\*\* 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~* Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days."
41462284|NCT01274962|RADIATION|high dose rate endorectal brachytherapy|High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
41462285|NCT05129189|DRUG|ASC22 group|The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
40981786|NCT00403442|DEVICE|Verteporfin Therapy/ Drug: Bevacizumab|
40981787|NCT04081311|DEVICE|comparing interdental floss to water flosser around dental implants|to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
41303401|NCT05437172|PROCEDURE|demineralized dentin graft|"after atraumatic extraction, ADDG particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze.~Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures."
41303402|NCT03929588|DEVICE|Hand-held device supported by a mobile application|Hand-held device supported by a mobile application to obtain refractive error of the eye.
41303403|NCT03929588|DEVICE|Phoropter|Manual refraction and ETDRS chart
41462286|NCT00777855|DRUG|warfarin plus rifampin|warfarin 7.5mg po x 1; rifampin 600mg IV x 1
41462287|NCT00777855|DRUG|warfarin|warfarin 7.5mg po x 1
40776985|NCT02806414|DRUG|Ivermectin|
40776986|NCT00645502|DRUG|risperidone|
40981788|NCT06038084|DRUG|Bronpass Tab.|Twice a day
40981789|NCT06038084|DRUG|Placebo of Erdos capsule|Three times a day (It is for the masking.)
40981790|NCT06038084|DRUG|Erdos capsule|Three times a day
40981791|NCT06038084|DRUG|Placebo of Bronpass Tab.|Twice a day (It is for the masking.)
41303404|NCT03929588|DEVICE|Autorefractor|Automated refraction
41303405|NCT04008433|DRUG|Lidocaine|Advanced intravenous injection of lidocaine before the propofol injection
41303406|NCT02466737|PROCEDURE|no axillary surgery versus SLNB|in cases with newly diagnosed breast cancer and clinically negative axillary status
41303407|NCT02466737|PROCEDURE|SLNB versus completion ALND|in cases with 1-3 macrometastases in sentinel lymph nodes
40981792|NCT02738151|DRUG|Insulin glargine, 300U/mL|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
40981793|NCT02738151|DRUG|Insulin degludec, 100 U/mL|"Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous"
40981794|NCT02738151|DRUG|Non-insulin anti-diabetic treatment|Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
40981795|NCT01692327|DIETARY_SUPPLEMENT|High fat meal|
40981796|NCT02548494|DRUG|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
40981797|NCT02548494|DRUG|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
40981798|NCT02548494|OTHER|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
40981799|NCT02548494|OTHER|Correction of Fluid Loss|"Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~* Administer 1-3 L during the first hour.~* Administer 1 L during the second hour.~* Administer 1 L during the following 2 hours~* Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings"
40981800|NCT00051402|DRUG|Isoflavones|
40981801|NCT03559465|PROCEDURE|skin biopsy|"A skin biopsy will be performed in 10 patients in the form of 2 punches of 5 mm in the injured area in aseptic condition with a Rodnan score.~In this study, 10 skin biopsies are needed, and will be performed on the first 10 patients accepting this biopsy."
41143054|NCT03032965|DRUG|Adenosine|"Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate."
40776987|NCT01152437|DRUG|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
40776988|NCT01152437|DRUG|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
40776989|NCT02030132|BEHAVIORAL|Feedback compared to 75th percentile|
40776990|NCT02030132|BEHAVIORAL|Forgiveness|
40981802|NCT03559465|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of B lymphocyte
40981803|NCT02601131|BIOLOGICAL|Platelet transfusion|
40981804|NCT03228589|DIETARY_SUPPLEMENT|probiotic strain|8 weeks of treatment with probiotic strain
40981805|NCT03228589|DIETARY_SUPPLEMENT|Placebo|8 weeks of treatment
40981806|NCT02653391|DRUG|Part A Elamipretide 1.0% Ophthalmic Solution|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.
40981807|NCT02653391|DRUG|Part B Elamipretide 3.0% Ophthalmic Solution|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.
40981808|NCT02653391|DRUG|Part A Placebo|Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
40981809|NCT02653391|DRUG|Part B Placebo|Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
40981810|NCT06474364|DRUG|Long-acting Cabotegravir injection|Cabotegravir is a potent integrase inhibitor that has been approved for use as PrEP.
40981811|NCT06474364|OTHER|SEARCH-YOUTH|It is a life stage informed HIV care model that dynamically supports adolescents and young adults living with HIV to achieve viral suppression and reduce depression through life event tailored solutions.
40981812|NCT05369455|PROCEDURE|erector spinae plane block|determine the efficacy and safety of ultra-sound guided erector spine plane block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
41143055|NCT03032965|DRUG|Isoproterenol|Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
41143056|NCT01234584|PROCEDURE|spk|implants using SPK Abutments
40776991|NCT02030132|BEHAVIORAL|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
41143057|NCT01234584|PROCEDURE|CPK Abutments|implants using CPK Abutments
41303408|NCT00052169|DRUG|ZD1839 in combination with docetaxel|Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
41303409|NCT03739463|DIETARY_SUPPLEMENT|MAG-DHA|375 MG of MAG-DHA per capsules, two capsules BID
40981813|NCT05369455|PROCEDURE|ultrasound guided caudal block|determine the efficacy and safety of ultra-sound guided caudal block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
40981814|NCT03273374|DEVICE|Intraoperative radiation therapy (IORT)|IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
40981815|NCT00643227|DRUG|clarithromycin extended release (ER)|7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
40981816|NCT00643227|DRUG|azithromycin SR|Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
40981817|NCT05519423|BEHAVIORAL|Physical Activity Incentive Program|Physical Activity Incentive (PAI) programs, which is a method used in preventive health services, are recommended by a number of public health institutions, including the World Health Organization, thanks to the universal access and high potential of health services. PAI is defined as offering verbal or written advice/guidance to encourage the individual to increase their current level of physical activity.
40981818|NCT01655550|OTHER|Withhold oral contrast|The intervention is to withhold oral contrast
40981819|NCT01021540|DRUG|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
40981820|NCT03741179|DRUG|ASA-withdrawn group|Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
41143058|NCT03946631|DIAGNOSTIC_TEST|2 hour glucose tolerance test using 75g glucose drink|intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
41143059|NCT04779463|DIAGNOSTIC_TEST|Parasternal intercostal muscles thickness ultrasound indicies|"Parasternal intercostal muscles thickness ultrasound indicies includes:~* Parasternal Intercostals Thickness Fraction.~* Parasternal Intercostals Thickness at the End of Inspiration.~* Parasternal Intercostals thickness at the End of Expiration."
41303410|NCT03739463|DIETARY_SUPPLEMENT|Oleic acid|375 MG of sunflower oil (oleic acid) per capsules, two capsules BID
41303411|NCT05920850|OTHER|Educational Video about LDCT lung cancer screening|A culturally tailored video that provides education about the process LDCT lung cancer screening
41303412|NCT05920850|OTHER|A culturally tailored shared decision-making tool|A culturally tailored shared decision-making tool that educates participants about the shared decision-making process
41303413|NCT05920850|OTHER|Flip chart|The use of a flip chart that reinforces the information provided in the video and shared decision-making tool
40776992|NCT02030132|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
40776993|NCT02692196|DEVICE|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|
40981821|NCT04223570|DEVICE|Portable Apple Smart Phone Protoporphyrin IX Spectrometer Camera|This is a portable device that uses a camera to non-invasively and efficiently measure the level of protoporphyrin IX in various areas skin. This camera will be used in all participants to measure the level of protoporphyrin IX in various areas of skin as detailed in the study description.
40981822|NCT02651727|DRUG|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
40981823|NCT02651727|DRUG|Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine|IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
40981824|NCT02651727|DRUG|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
40981825|NCT02045368|DRUG|IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
40981826|NCT00788151|BIOLOGICAL|CYD Dengue Vaccine Serotypes 1, 2, 3, and 4|0.5 mL, Subcutaneous (SC)
40981827|NCT00788151|BIOLOGICAL|Pneumococcal polysaccharide vaccine|0.5 mL, SC
40981828|NCT00126841|PROCEDURE|CT and MR fusion|
40981829|NCT02944474|DRUG|Lucerastat|Capsule for oral administration containing lucerastat
40981830|NCT02944474|DRUG|Placebo|Placebo capsules matching lucerastat capsules
40981831|NCT01387347|DRUG|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
40981832|NCT01387347|DRUG|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
41303414|NCT05920850|OTHER|Navigation support|Navigation support for participants who express interest in LDCT and quitting smoking.
41303415|NCT04558645|OTHER|Online Survey|Online surveys will be applied to all participants
41303416|NCT00403858|DRUG|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
41303417|NCT00403858|DRUG|Lactulose|
41303418|NCT02844101|DEVICE|GT3X Actigraph accelerometer.|
41303419|NCT06196476|BEHAVIORAL|Interactive digital-based educational program|"The Interactive digital-based educational program Sessions:~Session 1: The road start to green planet: Introductory to climate change concept Session 2: Towards Climate Change Literacy Modifications: remove the cover on illiteracy.~Session 3: Green scrubs and green environment: raising climate activities and environment self-efficacy Session 4: Strengthen resilience to overcome climate related anxiety Session 5: Sustaining phase: closing session"
41303420|NCT00524095|DRUG|azithromycin and fluticasone|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
41303421|NCT00524095|DRUG|fluticasone and azithromycin|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
40981833|NCT01313936|DRUG|Metaiodobenzylguanidine (MIBG)|Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
40981834|NCT06462807|BEHAVIORAL|ARC|ARC is an evidence-based intervention that uses three strategies (ARC principles, ARC component tools, and ARC mental models) to create organizational social contexts (OSCs) that support the implementation of interventions to improve patient outcomes.
40981835|NCT04719507|PROCEDURE|erector spinae block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 3 cm laterally to obtain the appropriate visualization. Under aseptic precautions, the needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine is administered in cephalad and caudal directions.
40981836|NCT04719507|PROCEDURE|thoracic paravertebral block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle is inserted cranial to caudal direction using in-plane approach . After confirming the displacement of pleura with 0.5-1 ml of local anesthetic (LA), 20 ml of 0.25% bupivacaine is administered for the block.
40981837|NCT04719507|DRUG|Pethidine Only Product in Parenteral Dose Form|pethidine (1 mg/kg ) once
40981838|NCT03326791|DRUG|Acetylsalicylic acid|Trombyl 160 mg once daily
40981839|NCT03326791|DRUG|Placebo Oral Tablet|Placebo one tablet daily
40981840|NCT03896776|BEHAVIORAL|Keep It Up! 3.0|KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions, totaling \~1 hour of main content, plus 2 booster sessions at 6- and 12-week follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.
40981841|NCT03876912|DRUG|GnRH antagonist|18F-PSMA 1007 PET/CT before, 3 weeks after ADT, at 1 year and at CRPC in 35 patients. 18F-FDG PET/CT in a subgroup of 20 patients before ADT.
40981842|NCT05187793|DRUG|Olokizumab|Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
40981843|NCT05187793|DRUG|Standard therapy|"Standard treatment including:~* Baricitinib, 4 mg, film coated tablets~* Favipiravir, 200 mg, film coated tablets~* Dexamethasone IV or IM OR Methylprednisolone IV"
40981844|NCT03914560|OTHER|Burn injury|minor burn injury
40981845|NCT00535223|BEHAVIORAL|Group Based Exposure Therapy|GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
40981846|NCT00535223|BEHAVIORAL|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus."
40981847|NCT03267498|DRUG|Nivolumab|Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.
40981848|NCT03267498|DRUG|Cisplatin|Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.
40981849|NCT03267498|RADIATION|Radiation Therapy|2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday
40981850|NCT05633524|OTHER|blood sample analysis|All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
40981851|NCT03917108|DEVICE|retraction cord|retraction cord ( Ultra dent sizes #0, #00, #000 ) is placed in the gingival sulcus using blunt instrument and using cotton roll isolation.
40981852|NCT03917108|DEVICE|subgingival clamp|subgingival clamp (KSK clamps W8A, #44, #42, #43) or (Brinker clamps B5, B6) is placed to retract the gingiva with rubber dam isolation
40981853|NCT06332846|OTHER|oral examination|The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in a day ight
40981854|NCT06332846|OTHER|oral examination|The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in the artificial lightning
40981855|NCT01991457|DRUG|Fludarabine|
40981856|NCT01991457|PROCEDURE|Total Body Irradiation|
40981857|NCT04565301|DRUG|Dexamethasone|adductor canal block
40981858|NCT04565301|DRUG|neostigmine|adductor canal block
40981859|NCT04565301|OTHER|NaCl solutions|adductor canal block
40981860|NCT02567942|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation
41303422|NCT03238144|OTHER|MRF scan|MRF with or without dynamic contrast-enhanced MRI scans.
40981861|NCT02567942|DRUG|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
40981862|NCT04646707|DRUG|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
40981863|NCT04646707|DRUG|Erector Spinae (ESP) Block with placebo|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
40981864|NCT03657758|DRUG|EPA and rosuvastatin|To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
40981865|NCT03657758|DRUG|High dose rosuvastatin|To take high dose rosuvastatin (10mg/day) for ９ months.
40981866|NCT03077750|DRUG|VBP-245 Topical Gel|Topical application BID
40981867|NCT03077750|DRUG|Vehicle|Vehicle Control With No Active Pharmaceutical Ingredients
40981868|NCT04756843|DEVICE|Quad-helix|Fixed orthodontic appliance
40981869|NCT00740142|DRUG|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
40981870|NCT00740142|DRUG|placebo and lactulose|placebo 3 times a day for 7 days
40981871|NCT03828357|OTHER|Study MRI scan|At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.
40981872|NCT06456151|DIAGNOSTIC_TEST|Invasive candidiasis test|The combination of acute phase marker monitoring and the T2Candida assay will be assessed.
41462288|NCT01475786|BIOLOGICAL|Low Dose: 16 mg Engensis (VM202)|"Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)"
40981873|NCT06456151|OTHER|Urine sample collection for future research|Patients will be asked to provide a urine sample for future research (urine biobank).
40981874|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis C antibody test|Qualitative point-of-care test for hepatitis C antibodies (saliva sample)
40981875|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis C RNA test|Hepatitis C Viral Load point-of-care test (fingerstick wholeblood sample)
40981876|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis B surface antibody test|Qualitative hepatitis B surface antibody point-of-care test (fingerstick wholeblood sample)
40981877|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis B surface antigen test|Qualitative hepatitis B surface antigen point-of-care test (fingerstick wholeblood sample)
40981878|NCT05839522|DIAGNOSTIC_TEST|Point-of-care HIV antibody test|Qualitative HIV antibody point-of-care test (saliva sample)
40981879|NCT05839522|BEHAVIORAL|Interview-style survey|Interview-style survey regarding demographics, risk behaviours, BBV testing and treatment history, and point-of-care testing acceptability
40981880|NCT04208399|DRUG|JNJ-56136379|JNJ-56136379 will be administered orally in fed condition.
40981881|NCT06030557|DRUG|Truvada|Participants will receive either Truvada or Descovy (based on prescription guidelines).
40981882|NCT02631954|DRUG|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
40981883|NCT02631954|DRUG|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
40981884|NCT01977508|DEVICE|ePTFE vascular access grafts|
40981885|NCT00989794|DEVICE|GelrinC|Applied once during surgery
40981886|NCT04012775|BIOLOGICAL|Insulin Humulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
40981887|NCT04012775|BIOLOGICAL|Insulin Rinsulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
40981888|NCT02305108|OTHER|fascial manipulation|"Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.~Specific points of fascial tissue will be treated with a deep friction to improve elasticity.~The number of point treated will be refered to a specific evaluation for each patient.~Fascial manipulation provide 3 session treatment (one treatment for week)."
40981889|NCT02305108|OTHER|standard treatment|"Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training."
40981890|NCT02547467|OTHER|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
40981891|NCT00002925|DRUG|ara-C|
40981892|NCT00002925|DRUG|Daunorubicin|
41462289|NCT01475786|BIOLOGICAL|High Dose: 32 mg Engensis (VM202)|"Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)"
40981893|NCT00002925|DRUG|Etoposide|
40981894|NCT00002925|DRUG|PSC-833|
40981895|NCT00002925|BIOLOGICAL|Aldesleukin|
40981896|NCT00825747|DEVICE|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
40981897|NCT04733092|DRUG|Lipiodol|Lipiodol in emulsion with contrast agent
40981898|NCT01751867|DRUG|Decitabine at 15 mg/m2|Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
40981899|NCT01751867|DRUG|Decitabine at 20 mg/m2|Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
40981900|NCT00396591|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
40981901|NCT04862364|OTHER|Endo Patients with Endometriosis Health Profile -30 (EHP-30) Test|The appointment of the patients consists of patients who were surgically diagnosed with Endometriosis in our clinic.
40981902|NCT06208228|DEVICE|Kinesiotaping|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
40981903|NCT02941965|PROCEDURE|ICSI without PGS|Selection of embryos are based on morphology criteria on the 5th day of ICSI.
40981904|NCT02941965|PROCEDURE|ICSI with PGS|PGS will be applied to selected embryos on the 5th day of ICSI.
40981905|NCT00254540|DRUG|SU011248 capsule|50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
41303423|NCT00235339|BEHAVIORAL|Exercise training|Standard exercise training at the hospital, two times per week for twelve weeks
41303424|NCT00235339|BEHAVIORAL|Exercise training|Interval exercise training with high intensity on treadmill. Subjects exercise two times per week for twelve weeks
41303425|NCT05304871|DRUG|Cefazolin|infusion
41303426|NCT05304871|OTHER|saline|infusion
40981906|NCT01408914|DRUG|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
40981907|NCT00525707|DRUG|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
40981908|NCT05058248|PROCEDURE|pudendal block|general anesthesia with an intravenous analgesic protocol then oral without anesthesia regional loco
40981909|NCT00208039|DRUG|Infasurf|Infasurf 3 cc/kg instilled via endotracheal tube, repeated 3 and 7 days later if infant stable and continues to meet criteria
40981910|NCT00138476|DRUG|Placebo|120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
40981911|NCT00138476|BIOLOGICAL|Norwalk Virus|Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.
40981912|NCT01698047|BEHAVIORAL|Resiliency Class|See Arm Description
40981913|NCT01698047|OTHER|Case Management|See Case Management description
40981914|NCT01891695|RADIATION|39.6 Gy radiation|
40981915|NCT05429190|RADIATION|Short MRI surveillance (SMS) protocol|Bi-annual, non-contrast agents, MRI screening consisting of Diffusion Weighted Imaging (b-values of 50 and 800 s/mm2), T2-weighted imaging and T1-weighted in- and out-of-phase imaging
40981916|NCT05429190|RADIATION|Bi-annual ultrasonography screening|Bi-annual ultrasonography for screening of HCC in high-risk patients
40981917|NCT02643082|DRUG|GFF MDI (PT003) 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate
40981918|NCT02643082|DRUG|Placebo MDI|Comparator: Placebo MDI which contains no active ingredients
40981919|NCT03704454|DIETARY_SUPPLEMENT|50 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
40981920|NCT03704454|DIETARY_SUPPLEMENT|100 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
40981921|NCT03704454|DIETARY_SUPPLEMENT|Placebo and then 50 mg PYC|4 weeks on placebo, then 4 weeks on PYC
40981922|NCT03704454|DIETARY_SUPPLEMENT|Placebo and then 100 mg PYC|4 weeks on placebo, then 4 weeks of PYC
40981923|NCT03406351|OTHER|Observational|Observational deep phenotyping physiological readouts
40981924|NCT00299013|DRUG|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
40981925|NCT00299013|DRUG|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
40981926|NCT00705081|DRUG|ezetimibe|10 mg once daily
40981927|NCT00705081|DRUG|statin|
40981928|NCT01929850|PROCEDURE|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
40981929|NCT01929850|BEHAVIORAL|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
40981930|NCT05879835|DEVICE|KiteLock 4% Sterile Catheter Lock Solution|KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.
40981931|NCT05879835|DEVICE|Heparin Lock Solution|Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.
40981932|NCT04867681|BEHAVIORAL|Psycho-education programme|4 individual sessions (S1, S2, S3, S4) of one hour each spread over 2 weeks, i.e. 2 sessions per week. S1 explains the different clinical signs and discusses the prognosis of the disease, S2 deals with the question of drug treatments, their different forms and their mechanisms of action. S3 discusses the evolution of the disease and the organisation of the care pathway. Finally, S4 looks at the aspects of quality of life, lifestyle and the fight against addictive co-morbidities, and concludes with a review of the patient's motivation and involvement in the subjects covered.
41303427|NCT03782818|DRUG|Olaparib|Olaparib up to 300 mg BID for 24 weeks
40981933|NCT03999450|BEHAVIORAL|brief motivational intervention (BMI)|The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.
41303428|NCT02532595|PROCEDURE|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
41303429|NCT02532595|PROCEDURE|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
41462290|NCT01475786|OTHER|Control- Placebo (normal saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
40981934|NCT03999450|BEHAVIORAL|cognitive behavioral therapy|This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
40981935|NCT06478160|DEVICE|Closed-Blood Sampling Devices|blood collection with Closed-Blood Sampling System (CBSD)
40981936|NCT06478160|OTHER|Waste discard volume|Blood collection without CBSD, usual practice, need to waste discard volume
40776994|NCT06205693|PROCEDURE|Fast Degradable, Biodegradable ARCHEMEDES stent|Fast Degradable, Biodegradable ARCHEMEDES stent. Placed in the pancreaticojejunostomy.
40776995|NCT01441960|DRUG|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
40981937|NCT03635957|BIOLOGICAL|Pegloticase|pegloticase administered intravenously (IV)
40981938|NCT03635957|DRUG|Methotrexate (MTX)|oral MTX
40776996|NCT01441960|DRUG|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
40776997|NCT00877656|BIOLOGICAL|HuMax-CD4|Active treatment
41462291|NCT01351363|DEVICE|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
40981939|NCT03635957|DRUG|Standard Gout Flare Prophylaxis|It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al.2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.
40776998|NCT03419494|DRUG|PLD|PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
40776999|NCT03419494|DRUG|DNR|DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
40777000|NCT03435380|BEHAVIORAL|Patient activation|Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.
40777001|NCT03435380|BEHAVIORAL|Primary care physician activation|Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.
40777002|NCT03435380|BEHAVIORAL|Control|Mailed educational materials.
40777003|NCT00185341|DRUG|CCR1-Antagonist (BAY86-5047, ZK811752)|Given orally in a dose of 600 mg three times daily over 12 weeks
40777004|NCT00185341|DRUG|Placebo|Placebo
40777005|NCT01651988|DRUG|Ketamina-Propofol Combination|"After randomization to the study group, the patients were given:~Procedures \< 10 minutes~1. Ketamine-Propofol Combination KETOFOL 1:1~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~2. Ketamine-Propofol Combination KETOFOL 1:2~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures \> 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min"
40777006|NCT05099263|DEVICE|Vivaer Arc Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal airway in a single study session.
40777007|NCT02874092|DRUG|Ticagrelor|
40777008|NCT02874092|DRUG|MTX therapy|
40777009|NCT02972645|DRUG|LY3305677|Administered SC
40981940|NCT03635957|DRUG|Infusion Reaction (IR) Prophylaxis|For IR prophylaxis, fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) will be taken the day before each infusion; fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) and acetaminophen (1000 mg orally) will be taken the morning of each infusion; and methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended) or hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.
40981941|NCT03635957|DIETARY_SUPPLEMENT|Folic Acid|Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.
41462292|NCT01351363|DEVICE|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
41462293|NCT04068987|DIAGNOSTIC_TEST|MRI parametric mapping|Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2\* mapping, ECV mapping) to determine the MR signal characteristics of the body
41462294|NCT05939102|COMBINATION_PRODUCT|v-prep combined with RMGIC for bracket bonding|prepare the tooth surface with the V-prep, then bond a bracket with the RMGIC
41462295|NCT05939102|COMBINATION_PRODUCT|Conventional bracket bonding technique|prepare the tooth with acid-etch, then bond a bracket using resin composite
40777010|NCT02972645|DRUG|Placebo|Administered SC
40981942|NCT01365325|OTHER|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
40981943|NCT01365325|OTHER|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
40981944|NCT04264598|BIOLOGICAL|sIPV|The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
40981945|NCT04264598|BIOLOGICAL|Commercialized sIPV|The commercialized sIPV was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.The antigen contents of type I, type II and type III polioviruses in the commercialized sIPV were 30 DU, 32 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
40981946|NCT04264598|BIOLOGICAL|Commercialized IPV|The commercialized Salk IPV was manufactured by Sanofi Pasteur S.A.The antigen contents of type I, type II and type III polioviruses in the commercialized IPV were 40 DU, 8 DU and 32 DU. The vaccine was in liquid form, 0.5 ml per dose.
40981947|NCT00269282|BEHAVIORAL|Self-Management Training|Asthma education and self-monitoring strategies
40981948|NCT00269282|BEHAVIORAL|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
40981949|NCT00745147|DRUG|Chinese herbal formula (CCH1)|initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
40981950|NCT00745147|DRUG|Duphalac|initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
41303430|NCT02030145|PROCEDURE|Compressive Thoracic Lymphatic Pump|This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
41303431|NCT02030145|PROCEDURE|Classic Thoracic Lymphatic Pump|This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
41303432|NCT02320799|BEHAVIORAL|interpersonal psychotherapy|Interpersonal psychotherapy is an evidence based, structured, brief psychotherapy which improves relationships in order to improve mood and reduce anxiety
40981951|NCT00630279|DRUG|Placebo|Placebo
40981952|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
40981953|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
40981954|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
40981955|NCT01892501|PROCEDURE|Guided punction of mediastinal lymphadenopathy by echoendoscopy|"EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken."
40981956|NCT01892501|DEVICE|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
40981957|NCT05525143|PROCEDURE|Pregnant women who have given birth vaginally or by cesarean section|Full-term pregnant women who have given birth vaginally or by cesarean section with PPH. Descriptive statistics and possible causal factors
40981958|NCT06321965|OTHER|evaluation of muscle function|Myogrip (≥ 6 years): precise dynamometric measurement of gripping force, measuring force in Newton up to 90kg with 0.01kg resolution. It's evaluated at D0, M6, M12, M18, and M24 Myopinch (≥ 6 years) : measure thumb-index force up to 15 kg with a resolution of 0.001 kg using a precision sensor equipped with two steel distance blades. It's evaluated at D0, M6, M12, M18, and M24
41303433|NCT02320799|BEHAVIORAL|treatment as usual|Clinic psychosocial treatment as usual
41303434|NCT01187901|DRUG|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
41303435|NCT01187901|DRUG|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
41303436|NCT01187901|DRUG|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
41303437|NCT01187901|DRUG|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
41303438|NCT05431413|DRUG|Control group: Fluoxetine and Placebo|Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.
41303439|NCT05431413|DRUG|Experimental group: Fluoxetine and ATP|Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.
40981959|NCT06321965|OTHER|First-line cognitive assessment|"Vineland-II (All patients) : is a scale for assessing adaptive behaviors. will be carried out during the telephone call at M1/V2.~All tests are evaluated at D0, and M18 :~Bayley-4 language part (\< 42 months) PVSE (≥ 4 years) CELF-5 (≥ 5 years) Conners-3 (≥ 6 years) AQ (≥ 4 years), EQ (≥ 11 years)~M-CHAT-R (\< 4 years) :~SRS-2 (≥ 2 years)"
41462296|NCT04997720|OTHER|Training|"Each course will consist of:~1. Initial evaluation~2. Theoretical tutorial~3. Training with exercises of increasing complexity.~4. Final evaluation."
41462297|NCT05455164|DIETARY_SUPPLEMENT|Isomalto Oligosaccharide|all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range)
41462298|NCT04411251|BEHAVIORAL|Nature-near integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
40777011|NCT05806216|DEVICE|EarliPoint Diagnosis|Diagnosis by the EarliPoint System: Evaluation for Autism Spectrum Disorder
40981960|NCT06321965|OTHER|second-line cognitive assessment|"In the event of positive cognitive screening at D0 or M18, a second-line cognitive assessment will be carried out at a subsequent visit. A list of tests is proposed below, but will be adapted according to the tests available at each center.~* EVALO BB (0-2 years) or EVALO (2-6 years) or full CELF-5 (5-18 years) following positive screening in the communication domain of first-line tests (Vineland II communication domain, Bayley 4, CELF-5 pragmatic profile)~* FEE and DSM-5 diagnostic criteria for ADHD (from age 6 only) following positive screening in the attention and executive functions domain of first-line tests (Conners 3, BRIEF)~* M-CHAT-R/F (\< 4 years) or SCQ (≥ 4 years) and ADOS-2 (≥ 12 years) following a positive screening in the area of social cognition and autistic traits on first-line tests (Vineland II, M-CHAT-R, SRS-2, EQ, AQ)."
40981961|NCT06321965|OTHER|Cardiac evaluation|"All tests are evaluated at D0, M12, and M24 :~Electrocardiogram (ECG) : This examination will be carried out in accordance with the 12 leads recording the following parameters: verification of sinus rhythm, P wave, PR interval, QRS complex (interval), ST segment, T wave, QT complex, heart rate.~Cardiac ultrasound: Non-invasive ultrasound will focus on the following parameters measured from 2-dimensional images, to look for cardiomyopathy and/or structural abnormality:~* end-diastolic/end-systolic diameter/left ventricular ejection fraction~* Septal wall thickness / left ventricular posterior wall~* Fractional shortening 24-hour Holter-ECG : This examination consists of a continuous test recording the heart rhythm for 24 hours."
41143060|NCT00785031|OTHER|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
41143061|NCT01151397|DRUG|Peg + Vitamin D + Ribavirin|Peg+ Vitamin D+ Ribavirin for 3 months
41143062|NCT01151397|DRUG|Peg + Ribavirin|Peg+ Ribavirin for 6 months
41143063|NCT06508762|DRUG|VX-993|Tablet and Suspension for Oral Administration.
41143064|NCT06201949|OTHER|Articaine infiltration technique|infiltration will be performed with articaine and epinephrine 1/100 000 (Artinibsa, Inibsa, Barcelona, Spain) for all patients on their second pri-mary molar. The needle tip was placed in the buccal vestibule and then directed to the apex of the tooth and about one-third to one-fourth of the cartridge will be slowly discharged
40777012|NCT05806216|BEHAVIORAL|Clinically Certain Expert Clinician Diagnosis (CC-ECD)|Diagnosis by an expert clinician using gold standard developmental assessment tools.
41303440|NCT05431413|DRUG|Control group: Fluoxetine and Phosphocreatine|Cap Fluoxetin 20mg OD for four weeks and injection Phosphocreatine 1g in NS BD for two weeks.
41303441|NCT02021058|OTHER|Experimental Formula|Experimental formula
41303442|NCT02021058|OTHER|Standard control formula|Standard Infant formula
41303443|NCT04015297|DIAGNOSTIC_TEST|raman analysis|negative or pozitive
41303444|NCT04623190|BEHAVIORAL|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
41462299|NCT04411251|BEHAVIORAL|Conventional integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
41462300|NCT00470860|BEHAVIORAL|Participation in LOFTS online tutorial|
41462301|NCT04726215|DRUG|[18F]F AraG|PET imaging agent specific to activated T cells
41462302|NCT00759616|DEVICE|Oxford Partial Knee|Oxford Partial Knee
40777013|NCT00066040|DRUG|Cervitec chlorhexidine varnish|
40777014|NCT00066040|DRUG|Duraphat fluoride varnish|
40777015|NCT00066040|DRUG|xylitol gum from Fennobon, Finland|
40777016|NCT00104884|DRUG|Depsipeptide|Given IV
40777017|NCT05106556|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, pursed lip breathing exercise, thoracic expansion exercises, upper and lower extremity exercises, stretching the pectoral muscles, posture exercises, walking training and teaching respiratory control.
40777018|NCT05106556|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure with the threshold loading method.
40777019|NCT04388826|DRUG|Veru-111|Respiratory Distress Syndrome, Adult
40777020|NCT01777061|DRUG|[11C]Acetate|intravenous injection of an average of 40 mCi of \[11C\]Acetate
40777021|NCT03254810|BIOLOGICAL|SYN060|a single subcutaneous 0.57 mg/kg dose of SYN060
40777022|NCT03254810|BIOLOGICAL|Adalimumab North American source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source
40777023|NCT03254810|BIOLOGICAL|Adalimumab European source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source
40777024|NCT05754866|PROCEDURE|Transbronchial lung cryobiopsy|Lung tissue was obtained by transbronchial lung cryobiopsy for subsequent pathology and clinical diagnosis.
40777025|NCT05754866|PROCEDURE|Transbronchial lung biopsy|Lung tissue was obtained by transbronchial lung biopsy for subsequent pathology and clinical diagnosis.
40777026|NCT05772871|DRUG|Huaiqihuang granule|Huaiqihuang Granule, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
40777027|NCT05772871|DRUG|Prednisone|Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again \[2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks\]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
40981962|NCT06321965|RADIATION|MRI|"Cerebral MRI : Performed at D0, only for patients with ASI type 1 ≥ 6 years, or younger patients for whom the investigator considers that the examination can be performed without sedation or general anesthesia. It will include sequences:~* 3D T1, gradient echo, 1.1 mm voxel, sagittal acquisition~* axial T2, spin-echo, slice thickness 4 mm~* 3D FLAIR, spin-echo, 1 mm voxel, sagittal acquisition Muscular MRI: performed at V1/J0, and V6/M24. The examination will include water-fat imaging (Dixon) in full-body, 3D mode, with proton density weighting and millimeter resolution."
40981963|NCT06321965|OTHER|Assessment of activity and muscle fatigue|"Syde® : evaluated at D0, M6, M12, M24. Patients aged 2 and over will receive the Syde® wearable device to collect their daily activities.~Muscular endurance tests (≥ 6 years) : evaluated at D0, M12, M24 ( only one of 3 tests based on motor function level) oESNHPT : In this test, patients are asked to walk a 10-meter path. oESBBT : In this test, patients have to move 10 blocks over a partition. oESWT: In this test, patients must repeatedly place and remove 9 sticks in 9 holes.~PedsQL Fatigue (≥ 2 years): evaluated at D0, M12, M24. Scale designed to measure fatigue in patients with acute and chronic conditions, as well as in healthy school and community populations.~Fatigue rating scale (≥ 6 years): evaluated at D0, M12, M24. The fatigue assessment scale has 11 numerical points ranging from 0 to 10. The patient is asked to give a rating that best reflects his or her perception of fatigue at that particular moment."
41143065|NCT06201949|OTHER|Articaine nerve block technique|this technique will be performed with articaine and epinephrine 1/100 000 for all patients on their second primary molar with conventional technique inferior alveolar nerve block. The thumb will be placed on the occlusal surface of intended side and protruded toward the inner oblique ridge of ramus and then placed in touch with retromolar pad. The syringe will be directed between the two mandibular primary molars of opposite side and the needle will be pushed forward until hitting the bone, then the injection will be slowly done. After three to five minutes, treatment will be started, after numbness in the lower lip is achieved
41143066|NCT04374981|DRUG|Celecoxib 100mg|Tablets
41143067|NCT04374981|DRUG|Montelukast 10mg|Tablets
41143068|NCT06478979|DEVICE|Neuclare|It is used to stimulate the brain for a certain period of time to assess gait improvement in patients with Idiopathic Normal Pressure Hydrocephalus (iNPH). In this clinical trial, it is used for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH).
41143069|NCT03403153|BEHAVIORAL|SAHP|"Aim 1: To obtain and incorporate expert clinician and Veteran feedback on credibility, acceptability, and satisfaction with the intervention to ensure Veteran-friendly intervention manual, materials, and processes. Aim 1 will be accomplished through two rounds of expert panel review of treatment/MIA manual and two rounds of pilot testing of the treatment for Veteran Feedback in 16 female and 16 male Veterans.~Aim 2: To evaluate feasibility of study recruitment, retention, assessment procedures and proposed methods of the intervention. Preliminary examination of whether the intervention results in improvements to parenting behaviors, parenting satisfaction and overall family functioning."
41303445|NCT04623190|BEHAVIORAL|PREVENT tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
41303446|NCT01151995|OTHER|Remote source document verification|Remote access to electronic medical records of the 5 participating sites
41462303|NCT03298516|DRUG|DCLL9718S|DCLL9718S will be administered as per the schedule specified in the respective arm.
41462304|NCT03298516|DRUG|Azacitidine|Azacitidine will be administered as per the schedule specified in the respective arm.
41462305|NCT00361387|DRUG|d-methylphenidate|oral dosing for 8 weeks then cross over to placebo in random order
41462306|NCT00176891|PROCEDURE|Stem Cell Transplant|enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
40777028|NCT05772871|DRUG|Levamisole placebo|Levamisole placebo, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
40777029|NCT05772871|DRUG|Levamisole|Levamisole, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
40981964|NCT06321965|OTHER|Assessment of bulbar function|"DDD-pNMD (≥ 2 years) : evaluated at D0, M6, M12, M18, and M24, is a list of 9 questions used by doctors to screen for dysphagia and dysarthria.~NdSSS (All Patients) : evaluated at D0, M6, M12, M18, and M24, is an 8-level scale for assessing swallowing.~TOMASS-c : (≥ 4 years of age, in patients able to eat solids safely, after assessment of the risk of a false route by the speech therapist): this is a score designed to assess mastication when eating a cracker. Age-dependent standards exist for different types of cracker.~- Fluid intake test (\> 110 cm, in patients able to drink a liquid safely, after assessment of the risk of a false route by the speech therapist): swallowing limit."
40981965|NCT06321965|OTHER|Evaluation of body composition and metabolism|"Food survey : The dietary survey questionnaire will be sent to parents at D0 and M18. Parents will be asked to complete it for 3 days before the M6 and M24.~Bioelectrical impedancemetry: Evaluated at M6 and M24. Renal ultrasound: Evaluated at M6, is a non-invasive examination that analyzes the appearance of the kidney and urinary tract.~Dual-energy X-ray absorptiometry (DXA) : Evaluated at M6, it measures body composition using spectral imaging, including fat mass, lean mass and bone mineral density.~Fibroscan : Evaluated at M6 and M24. This examination uses pulse elastography to measure liver elasticity, which provides information on the presence of hepatic fibrosis, and sound attenuation, which provides information on the presence of liver fat overload.~Indirect calorimetry : Evaluated at M6. This device enables precise measurement of Resting Energy Expenditure , Respiratory Quotient and metabolic substrate oxidation."
41143070|NCT03406390|PROCEDURE|Pterygium surgery|The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
41143071|NCT05082948|OTHER|Suture fixation of stent|Esophageal stent will be placed in the standard of care fashion by the endoscopists using standard gastroscopes. Covered self-expanding metal stent will be placed as per endoscopist preference. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.
41143072|NCT05082948|OTHER|Non suture|Standard placement of stent without suture fixation
41143073|NCT00113529|DRUG|Gefitinib + Sunitinib|Until disease progression or unacceptable toxicity.
41303447|NCT01151995|OTHER|On-site source document verification|Study monitor will perform on-site source document verification during routine visit to the five participating sites
40777030|NCT05772871|DRUG|Huaiqihuang Granule placebo|Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
40777031|NCT00462826|BIOLOGICAL|ziv-aflibercept|
40777032|NCT06546124|OTHER|Deep Fascia Dry needling Technique|"Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating subcutaneously to the deep fascia. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises."
40777033|NCT06546124|OTHER|Intramuscular Trigger Point Dry Needling Technique|"Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating through the deep fascia into the upper trapezius muscle. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises."
40777034|NCT00557440|DRUG|fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
41143074|NCT01237977|DRUG|Botulinum Toxin Type A(Meditoxin®)|single administration, Day 0, 20U
41143075|NCT01237977|DRUG|Botulinum Toxin Type A(Botox®)|single administration, Day 0, 20U
41143076|NCT05272254|DRUG|10% povidone iodine + FV|applied to children's teeth
41143077|NCT05272254|OTHER|Placebo +FV|applied to children's teeth
41143078|NCT00732498|DRUG|Methylprednisolone|250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
41143079|NCT00732498|DRUG|Etoposide|40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
41143080|NCT00732498|DRUG|Cytarabine|2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
41143081|NCT00732498|DRUG|Cisplatin|25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
41303448|NCT03570281|DRUG|Edoxaban|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
40981966|NCT06321965|OTHER|Questionnaires|"SMAIS : The questionnaire has been developed specifically for ASI. At D0, M6, M12, M18 and M24.~HUI2 : specializes in preference-based measures of health-related quality of life. At D0, M6, M12, M18 and M24.~Peds QL : is a modular instrument designed to measure health-related quality of life and disease-specific symptoms. At D0, M6, M12, M18 and M24.~Neuromuscular module : 17 disease-related items. It is evaluated at D0, M6, M12, M18 and M24.~Family impact module : It measures parents' reported physical, emotional, social and cognitive functioning, communication and concerns. At D0, M12, and M24.~ASI cost questionnaire: At visit 1 (D0): This questionnaire, completed by the parents, includes information on occupation, parents' working hours and any reduction in them due to the child's pathology, the number of working days missed by the parents or school days missed by the child, and disability-related costs."
40981967|NCT06321965|BIOLOGICAL|Biocollection|"A blood bio collection (optional) will be offered to patients at D0, M6 , M12, M18, M24.~Patients receiving intrathecal injections will also be offered the opportunity to participate in a CSF (cerebrospinal fluid) biocollection (optional)."
40981968|NCT06321965|OTHER|Skinfold measurement|The tricipital point should be marked on the posterior aspect of the arm, on the midline of the tricipital muscle, midway between the acromion and the radius. At D0, M6, M12, M18 and M24
40981969|NCT01316120|OTHER|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
40981970|NCT01316120|OTHER|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
40981971|NCT02848157|DRUG|Dexmedetomidine|Patients are put in lithotomy position. Two separate injection points are marked at 3 and 9 o'clock, about 2 to 2.5 cm from the center of anus. After aseptic preparation, a nerve stimulator needle advanced 1.5 to 3.5 cm perpendicular to the skin, and stimulation current is 2.5 to 5 mA. The unilateral contraction of anal sphincter means the inferior anal nerve stimulation. After reducing the current to 0.5 mA, the needle is then moved deeper until an up-and-down penile movement is observed. This is stimulation of the perineal branch of the pudendal nerve. Prepared drug (0.25% ropivacaine and 0.3 mcg/kg dexmedetomidine in the experimental group, and equivalent doses of ropivacaine and normal saline in the control group) is injected in half and half bilaterally.
40981972|NCT02848157|DRUG|plain ropivacaine|ropivacaine and normal saline equivalent doses of dexmedetomidine
40981973|NCT02848157|DRUG|Ropivacaine|
40981974|NCT04465851|DIETARY_SUPPLEMENT|Ferrous Sulphate 65 mg|"Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
40981975|NCT04465851|DIETARY_SUPPLEMENT|Curcumin|"HydroCurc™ 500 mg formulated curcumin~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
40981976|NCT04465851|OTHER|Placebo (Ferrous Sulphate)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
40981977|NCT04465851|OTHER|Placebo (Curcumin)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
40981978|NCT04465851|DIETARY_SUPPLEMENT|Ferrous Sulphate 18mg|"Oral ferrous salt supplement~Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
40981979|NCT05938543|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces an electrical current in neurons and allows for modulation of neural circuitry.~Other Name: iTBS"
40981980|NCT00469092|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
40981981|NCT00469092|DRUG|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
40981982|NCT00469092|DRUG|metformin|Tablets, 2550 mcg. Administered once daily.
40981983|NCT00469092|DRUG|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
40981984|NCT03251066|OTHER|Proponent Nasal Spray|The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
40981985|NCT05156320|DRUG|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.
40981986|NCT05156320|DRUG|Placebo|Placebo will be administered every 4 weeks by intravenous (IV) infusion.
40981987|NCT02728895|DRUG|Vedolizumab|Vedolizumab Injection.
40981988|NCT00215163|DRUG|Cognitive-behavioral therapy and paroxetine-CR|
41143082|NCT00732498|DRUG|Rituximab|250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.
41462307|NCT00176891|DRUG|Laronidase ERT|Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.
40981989|NCT04900194|BEHAVIORAL|mindfulness-based sexual counseling|Mindfulness-based sexual counseling was planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session lasted 30-40 minutes on average. The sessions were carried out individually by determining the appropriate days of pregnant women in the pregnancy class.In the study, the meditation techniques of the Mindfulness Therapy constituted the backbone/framework of the psychoeducation program. Body and breath, body scanning, mindfulness movement and three-minute respiration techniques were practiced during the psychoeducation program, practically every session in accordance with the researchers' directives.
40777035|NCT00557440|DRUG|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
40777036|NCT00557440|DRUG|placebo to indacaterol/mometasone|Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
40777037|NCT00557440|DRUG|placebo to fluticasone propionate/salmeterol|Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
40981990|NCT01001611|DRUG|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
40981991|NCT01001611|DRUG|Placebo|Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
40981992|NCT04079829|OTHER|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data|No interventions
40981993|NCT00112593|DRUG|fludarabine phosphate|Given IV
40981994|NCT00112593|RADIATION|total-body irradiation|Undergo TBI
40981995|NCT00112593|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow or peripheral blood stem cell transplantation
40981996|NCT00112593|DRUG|cyclosporine|Given IV or PO
40981997|NCT00112593|DRUG|mycophenolate mofetil|Given IV or PO
40981998|NCT00112593|OTHER|laboratory biomarker analysis|Correlative studies
40981999|NCT00003479|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with an ependymoma will receive Antineoplaston therapy (Atengenal + Astugenal).
40982000|NCT03657706|PROCEDURE|group A (Tunnel procedure with subepithelial connective tissue graft (sCTG)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
40982001|NCT03657706|PROCEDURE|group B (Tunnel procedure with modified free gingival graft (mFGG))|modified free gingival graft (autogenous graft) will be harvested from the palate and will be used with the prepared tunnel to be used in treating gingival recession
40982002|NCT04532866|BEHAVIORAL|Isolation and Confinement|Eight months of isolation and confinement in the spaceflight analog NEK in Moscow
40982003|NCT03971890|OTHER|Dance therapy|The experimental group will receive a dance treatment.This protocol will be administered at weekly sessions of 60 minutes with a period of 2 times / week with a total of 16 sessions, distributed over a 8-week period. They will be evaluated at baseline, after the end of the last treatment session.
40982004|NCT03971890|OTHER|Educational group|The control group will receive an educational intervention. They will be evaluated at baseline, after the end of the last treatment session.
40982005|NCT03253887|DRUG|Ethanol-lock|This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
40982006|NCT00811551|DEVICE|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
40982007|NCT06107712|OTHER|Online yoga exercise|"The basic yoga poses of Shivananda Yoga included in the online yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath.~In the scope of the study, the physiotherapist researcher who is a certified as the Shivananda Yoga instructor, performed the same yoga practice flow and steps in the both groups during six-week."
41143083|NCT00732498|DRUG|In-Zevalin|5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
41303449|NCT03570281|DRUG|Enoxaparin|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance \<30 mL/min), for 90 days.
41462308|NCT03269955|DRUG|Fibrinogen/thrombin-coated collagen patch|Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
41462309|NCT06134986|OTHER|Time restricted eating|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
40777038|NCT00784615|PROCEDURE|Blood samples, transvaginal ultrasound|Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
40777039|NCT00030264|DRUG|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
41143084|NCT00732498|DRUG|Y-Zevalin|Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from \>/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
41303450|NCT00426985|DRUG|Ketoprofen Topical Patch 20%|
41303451|NCT02422927|DIETARY_SUPPLEMENT|Nutraceutical Combination|red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
41303452|NCT02422927|OTHER|Standard of Care|low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
41303453|NCT02422927|OTHER|Placebo|placebo
41462310|NCT06134986|OTHER|Daily calorie restriction|25% energy restriction every day Diet counseling provided
40982008|NCT06107712|OTHER|Face-to-face yoga exercise|"The basic yoga poses of Shivananda Yoga included in the face-to-face yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath."
40777040|NCT00030264|DRUG|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
40982009|NCT02355353|OTHER|Experimental: imaging arm|DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
40777041|NCT01280942|BEHAVIORAL|EWS Nursing Alerts|An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.
40982010|NCT01822340|DRUG|HM10560A|Once weekly HM10560A
40982011|NCT01822340|DRUG|Genotropin|Once daily Genotropin
40982012|NCT02031731|DRUG|4 mg/kg Onartuzumab (MetMAb)|4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
40982013|NCT02031731|DRUG|15 mg/kg Onartuzumab (MetMAb)|15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
40982014|NCT02031731|DRUG|30 mg/kg Onartuzumab (MetMAb)|30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
40982015|NCT05212649|DIAGNOSTIC_TEST|cardiopulmonary exercise test|CPET was performed in this HF cohort within one month after being discharged and interpreted as previously described. Patients underwent an upright graded cycle ergometer exercise using a personalized ramp protocol or a motorized treadmill using a modified Bruce or Cornell protocol. Peak VO2 data measured by cycle ergometer were increased by 10% to allow a comparison between the two different procedures. Peak VO2 was defined as the highest 30-second average value obtained during exercise. Submaximal CPET variables such as ventilatory efficiency were calculated by the slope of VE versus VCO2 below the ventilatory compensatory point (VCP). If the slope of VE/VCO2 can't be calculated, we used the nadir of VE/VCO2, or the ratio of VE/VCO2 at the anaerobic threshold (AT) as the variable of ventilatory efficiency. The AT was determined by the V-slope method.
40777042|NCT01280942|DEVICE|Wireless Remote Sensor|A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
40777043|NCT04704193|OTHER|Survey of Decision Aid|The decision aid will be evaluated by a survey administered to those who have used the tool.
40777044|NCT05338138|DEVICE|ultrasound guided central venous catheter insertion|Prospective comparative randomized controlled clinical study.
40982016|NCT03965533|DRUG|GSK2831781|GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
40982017|NCT03965533|DRUG|Placebo|Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
40982018|NCT03453684|DRUG|Administration of Vancomycin|Intravenous Vancomycin Administration
41303454|NCT02796924|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
40777045|NCT01173744|DEVICE|Gamma-3 Nail|Gamma-3 Nail (stryker)
40777046|NCT01173744|DEVICE|DHS|DHS (Zimmer)
40777047|NCT00889005|OTHER|Telephone Based Cognitive Behavioral Therapy|Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
40777048|NCT01368094|PROCEDURE|Drain removal at D4|If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.
40982019|NCT06276439|PROCEDURE|Surgical removal of breast cancer and lymph nodes|The patients will undergo a surgical procedure to remove tumor tissue in the breast and its associated lymph nodes. No clinical decision is based on the imaging device tested.
40982020|NCT04279951|OTHER|Resistance exercise|High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
40982021|NCT04279951|DIETARY_SUPPLEMENT|Omega-3|1 gram of omega-3 per day for 20 weeks
40982022|NCT04279951|DIETARY_SUPPLEMENT|Placebo|1 gram of sunflower oleic oil per day for 20 weeks
40982023|NCT05339594|DEVICE|NeuraGen|NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
40982024|NCT05339594|DEVICE|NeuraGen 3D|NeuraGen 3D Nerve guide matrix is a resorbable implant for the repair of peripheral nerve gaps.
40777049|NCT01368094|PROCEDURE|Standard drain removal|If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.
40982025|NCT04567433|DRUG|Hydroxyethyl starch|Hydroxyethyl starch compared to 0.9% saline
40982026|NCT04567433|DRUG|Hydrocortisone|Hydrocortisone compared to Placebo
40982027|NCT04567433|PROCEDURE|Early Goal Directed Therapy|Early Goal Directed Therapy compared to Usual Care
40982028|NCT06014489|DRUG|azacitidine|during run-in and extention phase: from Cycle 1 until relapse
40982029|NCT06014489|DRUG|Venetoclax|during run-in and extention phase: from Cycle 1 until relapse
40982030|NCT06014489|DRUG|Cobicistat|"during run-in phase: from cycle 2 until relapse~during extension phase: from cycle 1 until relapse"
40982031|NCT01120301|DEVICE|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
40982032|NCT05944341|DRUG|articaine hydrochloride 4% with epinephrine 1:100 000|Local anesthetic agent
40982033|NCT05944341|DRUG|Lidocaine hydrochloride 2% with epinephrine 1:100 000|Local anesthetic agent
40982034|NCT01209364|DEVICE|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
40982035|NCT04489212|OTHER|Medical Chart Review|Review of medical chart
40982036|NCT04489212|OTHER|Patient Observation|Undergo observation
40982037|NCT04489212|OTHER|Quality-of-Life Assessment|Ancillary studies
40982038|NCT04489212|OTHER|Questionnaire Administration|Ancillary studies
40982039|NCT06439511|DEVICE|Darwin smartphone app|The participant must look into the smartphone camera with the Darwin app for about 30 seconds.
40982040|NCT06439511|DEVICE|Pulse oxymetry|Heart rate will be measured with pulsoe oximetry (gold standard)
40982041|NCT03627754|DRUG|Glasdegib 100 mg single oral dose|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.
40982042|NCT02835508|DRUG|JNJ-56021927 60 Milligram|JNJ-56021927 60 mg oral tablet.
40777050|NCT03243864|DRUG|Ceftazidime-avibactam|Patients will be started on 2.5 gm IV every 8 hours
40982043|NCT02835508|DRUG|JNJ-56021927 120 Milligram|JNJ-56021927 120 mg as 2 tablets of 60 mg.
40982044|NCT02835508|DRUG|JNJ-56021927 240 Milligram|JNJ-56021927 240 mg as 4 tablets of 60 mg.
41303455|NCT05058664|BEHAVIORAL|A-F texting component|Over the course of the 6-week intervention parents in the A-F condition will receive 1 message each day.
40982045|NCT04326907|PROCEDURE|Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy|Collection and injection of autologous adipose tissue in complex anal fistulas in one surgical step under locoregional or general anesthesia.
40982046|NCT00555750|DRUG|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
40982047|NCT00555750|DRUG|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
40982048|NCT00293254|DRUG|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
40982049|NCT00293254|DRUG|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
40982050|NCT03835611|OTHER|Game based treadmill Platform|"The protocol for the intervention group will be:~* Warm up exercised consisting of rhythmical large movements (10minutes)~* Dynamic standing balance training by playing commercial games with head rotations while standing on a compliant surface to increase balance demands. (10 Minutes)~* DT treadmill training, consisting of playing commercial computer games while walking on the treadmill at a self-selected comfortable speed. Participants will be allowed to take rest when required and total effective DT treadmill walking will be for 30minutes. Treadmill speed will be aimed to progress depending on participant performance and documented. An overhead safety harness will always be provided to participants while walking on the treadmill. (25minutes)"
40982051|NCT03835611|OTHER|Control Group|"* Warm-up exercise consisting of rhythmical large movements (10 minutes).~* Core standing balance exercises on a sponge surface (10 minutes).~* Treadmill walking for 20 minutes, which includes rests periods... An overhead safety harness will be provided to participants while walking on the treadmill~* Overground walking in an obstacle course. Participants will be instructed to walk along a curved path (marked by tape) and avoid obstacles placed randomly. The obstacle will be thin sponge pads with 10-12 inches in diameter (15minutes)."
40982052|NCT04053192|PROCEDURE|BAV|BAV
40982053|NCT04053192|PROCEDURE|BAV + TAVR|BAV + TAVR
40982054|NCT04053192|PROCEDURE|SAVR|Surgical aortic valve replacement (SAVR)
40982055|NCT00680667|BIOLOGICAL|Coriolus versicolor extract|Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
40982056|NCT01133301|DRUG|Naltrexone|50 mg/d Naltrexone will be administrated during three weeks.
40982057|NCT01133301|DRUG|Placebo|During 3 weeks of the study, Placebo will be administrated (daily)
40982058|NCT02375191|DRUG|fentanyl|
40982059|NCT02375191|DRUG|dexmedetomidine|
40982060|NCT02375191|DRUG|Ropivacaine|
40982061|NCT00050596|DRUG|MDX-010 / MDX-010 + Docetaxel|
40982062|NCT05451147|DRUG|Chhinnavahni Kashaya Vati along with Agnimantha Kwatha|Drug: Chhinnavahni Kashaya Vati Form : Tablet Dose: 1g TDS (2x500 mg), Before meals Mode of Administration: Oral Anupaan: 20 ml of Agnimantha Kwatha Duration: 3 Months
40982063|NCT05451147|DRUG|Metformin Hydrochloride|Drug: Metformin Form: Tablet Dose: 500mg BID/TDS, Before meals Mode of Administration: Oral Anupaan: Plain water Duration: 3 Months
40777051|NCT06392425|OTHER|caspase 3 and ADAM 17 biomarkers|Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
40982064|NCT05193656|DIAGNOSTIC_TEST|Al_bladder|Detection of bladder tumor with help of Artificial intelligence
40982065|NCT02614950|OTHER|Treatment interruption|
40982066|NCT03409172|OTHER|CTR|no counseling or nutritional therapy and no exercise
40982067|NCT03409172|OTHER|MICT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based moderate continuous intensity training (MICT).
40982068|NCT03409172|OTHER|HIIT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based high intensity interval training (HIIT)
40982069|NCT03357159|DRUG|Cyclophosphamide|In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg , the second phase will use the MTD cyclophosphamide dose identified in the first phase.
40982070|NCT03357159|DRUG|anti-human T-lymphocyte immunoglobulin (ATLG)|15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation
40982071|NCT02549183|DEVICE|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
40982072|NCT06033521|DRUG|Menopausal hormone therapy Intervention Type: Drug|Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
40982073|NCT01858090|DRUG|Control Group Chirocaine|Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
40982074|NCT01858090|DRUG|Group Fentanyl|
40982075|NCT01858090|DRUG|Group sufentanil|
40982076|NCT01858090|DRUG|Ephedrine|If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to \<100 mmHg, fluid loading and ephedrine (5 mg) were administered.
40982077|NCT01858090|DRUG|Atropine sulfate|A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
41303456|NCT05058664|BEHAVIORAL|P-F texting component|Over the course of the 6 week intervention, parents will receive between 1-2 messages, depending on randomization (in addition to A-F component messages)
41303457|NCT02540252|OTHER|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
41303458|NCT05263440|DEVICE|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
41303459|NCT03122028|DEVICE|LAA closure system|Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.
40777052|NCT02109276|DEVICE|Spheric Sensar(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
40777053|NCT02109276|DEVICE|Aspheric Tecnis(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
40777054|NCT01142180|PROCEDURE|TAE|The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
40777055|NCT01142180|PROCEDURE|No TAE|No TAE procedure will be performed after endoscopic treatment
40777056|NCT02421094|DRUG|GR-MD-02|GM-MD-02 active
40982078|NCT01858090|DRUG|Propofol|Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
40982079|NCT01858090|DRUG|Metoclopramide|Metoclopramide (10 mg IV) was administered for nausea
41303460|NCT01662700|DRUG|Artesunate|
41303461|NCT01662700|DRUG|Chloroquine|
41462311|NCT03179748|DRUG|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
40777057|NCT02421094|DRUG|Placebo|Placebo
40777058|NCT06189794|OTHER|Rosa damascena oil|Essential oils will used by inhalation
40777059|NCT01180127|DIETARY_SUPPLEMENT|Flavanol containing food product|12 weeks, 2X/day, 20g serving
40777060|NCT01180127|BEHAVIORAL|Aerobic training|4X/week, 1 hour/session at 75% maximum HR
40777061|NCT01180127|DIETARY_SUPPLEMENT|Food product lacking flavanol|20 g serving, 2X/day, food additive lacking flavonol
40982080|NCT01858090|DRUG|Diphenhydramine|for severe pruritus
40982081|NCT01858090|DRUG|pethidine hydrochloride|pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
40982082|NCT01858090|DRUG|Diclofenac sodium|as additional analgesic among cases in which VAS\>3(Postoperatively)
40982083|NCT04189211|DRUG|BAT8001|IV infusions.
40982084|NCT00391274|DRUG|pemetrexed|500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
40982085|NCT00391274|DRUG|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
40982086|NCT05195112|DRUG|MT921|Active ingredient
40982087|NCT05195112|DRUG|Placebo|Normal Saline
40982088|NCT06293807|DRUG|Xylocaine 2 % with 1:100,000 epinephrine|Local anesthetic used during dental procedures
40982089|NCT06293807|DRUG|Bupivicaine 0.5% with 1:200,000 epinephrine|Local anesthetic used during dental procedures
40982090|NCT06293807|OTHER|Placebo|0.9% Normal Saline solution used in place of local anesthetic
40982091|NCT05390879|OTHER|Meditation|After the circuit, a 6 minutes long meditation auto-guided video.
40982092|NCT05390879|OTHER|Control|After the circuit, a 6 minutes long emotionally neutral video.
40982093|NCT03398057|OTHER|Health education|SHEP included a comprehensive lecture about BC, with a generally deep focus on detection and screening tools, which were illustrated by a PowerPoint presentation with pictures and videos. The program also included a practical session about BSE (on breast silicon model). At the end of SHEP, a focused group discussion was conducted to answer participants' questions, and to discuss important barriers regarding BSE practice and visiting primary health care centers or clinics to undergo CBE and mammography. Different scientific and administrative solutions were discussed. SHEP materials were distributed as a hard copy (booklet) and in electronic format (CD) for all participants in the health education group at the end of training.
40982094|NCT03398057|OTHER|Control group|Placebo health education (pamphlets) will be applied to this group participants during study.
40982095|NCT05258890|OTHER|Social Network Group Counseling|Researchers will identify the influential network members based on their network position, driving distance from the patient, speaking frequency, and whether they have high blood pressure. The index patient and social network members will meet with the study nurse on weeks 2, 6, and 12 after initial enrollment. The study nurse will begin the social network counseling session in which she will provide counseling on teamwork and blood pressure control. The teamwork specific topics will include how networks can work together as a team, communication tips for engaging with one another, spreading positive messages, and establishing the roles and responsibilities of each network team member. The blood pressure control specific topics will include the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. Patient and social network members will receive text messages every week in the weeks between sessions.
40982096|NCT05258890|OTHER|Individual Counseling|The index patient will meet individually with the study nurse on weeks 2, 6, and 12 after initial enrollment. The nurse will provide counseling on the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. The patient will receive text messages every week in the weeks between sessions.
40982097|NCT05855031|DIAGNOSTIC_TEST|Transient Elastography|One transient elastography 1-2 weeks after randomization
40982098|NCT05346159|DIAGNOSTIC_TEST|the correlation between level of adrenal androgen and gender-typed behavior in Girls with TS|"Laboratory assessment Serum dehydroepiandrosterone sulfate (DHEAS), follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) will be measured using an enzyme mediated chemiluminescence for all participants Gender-typed behavior assessment~* Parents of girls aged two to six years will evaluate their children's gender-typed behavior using the Pre school Activities Inventory~* For girls above 6 years gender characteristics and gender role behavior will be evaluated using The Children's Sex Role Inventory (Child-adapted version of the original Bem Sex Role Inventory)~* For all participants a Parent-Report Gender Identity Questionnaire for Children will be used to evaluate gender role behavior"
40982099|NCT05328882|OTHER|Monitoring of paroxysmal atrial fibrillation recurrence after pulsed field catheter ablation|The implanted loop recorder will be interrogated to see how many patients had an early recurrence of AF (up to 3 months after the procedure). Then the late recurrence rate will be compared (3-12 months post-procedure) between groups with and without early recurrences.
41303462|NCT03007953|BEHAVIORAL|Palliative Care|Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
41303463|NCT04452591|BIOLOGICAL|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
41303464|NCT04452591|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
40777062|NCT01180127|BEHAVIORAL|Wait list control|12 week wait list control condition during which participants abstain from aerobic exercise
40982100|NCT03935191|DEVICE|Dexcom CGM System|Dexcom CGM System
40777063|NCT04326738|DRUG|Midazolam|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)
40982101|NCT05875090|DIAGNOSTIC_TEST|Glaucoma Screening|Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic
40982102|NCT00038207|DRUG|Liposomal Vincristine|Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
40982103|NCT02968745|OTHER|Observational study|Canadian Occupational Performance Measure (COPM) was applied to identify the main occupational performance problems
40982104|NCT05402592|DIETARY_SUPPLEMENT|Carbonhydrate rich drink|It will be prepared by adding 50 g of carbohydrates to 1200 ml of water in total and will be given to the patients the night before the surgery and the morning of the surgery.
40982105|NCT05402592|OTHER|Water|A total of 1200 ml of water will be given to the patients the night before and the morning of the surgery.
40982106|NCT00061698|BEHAVIORAL|Cognitive Behavior Therapy Child Only|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.
40982107|NCT00061698|BEHAVIORAL|CBT plus Parent Training|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
40982108|NCT04774107|DRUG|P1101 + Ribavirin|P1101 400 µg SC
40982109|NCT00003492|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
40982110|NCT05718258|DRUG|Venglustat (GZ402671)|"Pharmaceutical form: tablet~Route of administration: oral"
40982111|NCT04497506|BEHAVIORAL|Wise Intervention (Self-affirmation and Incremental theory of personality)|The intervention designed to promote prosocial behavior and reduce online risks is based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes two components: a self-affirmation activity and an ITP intervention. The SA component includes a list of values so that they could choose the two or three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component includes activities such as reading scientific information about social behavior and its role in people's well-being, the meaning and value of online risk behaviors through stories and videos of the experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change.
40982112|NCT04497506|BEHAVIORAL|Standard preventive intervention|It consists of an educational intervention that provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
40982113|NCT02371551|OTHER|Blood/urine sampling|Routine chemistry profile
40982114|NCT02371551|OTHER|Conventional routine CT examination|Standard diagnostic examination
41303465|NCT01139385|PROCEDURE|Harmonic scalpel|The Cholecystectomy is performed using only Harmonic Scalpel to mobilize the Cholecystis and to close the cystic duct and the cystic artery
40982115|NCT02371551|OTHER|Contrast-enhanced renal ultrasonography (CEUS)|Study-specific diagnostic examination
40982116|NCT02371551|OTHER|Functional MRI|Study-specific diagnostic examination
41303466|NCT01139385|PROCEDURE|Traditional|The cholecystectomy is performed using Harmonic Scalpel to mobilize the cholecystis and the cystic duct and the cystic artery are closed by titanium clips
40777064|NCT04326738|DRUG|normal saline|N group received corresponding intravenous normal saline of1ml·kg-1 .
40777065|NCT00437749|DRUG|CBT-1|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
40982117|NCT03395886|DRUG|Remifentanil|The noninvasive ventilation intolerated patients was sedated by remifentanil.
40982118|NCT03395886|DRUG|Dexmedetomidine|The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
40982119|NCT05830292|DEVICE|Diffuse reflectance spectroscopy (DRS) probe|The spectroscopic DRS probe, either sterilised or covered with a sterile probe cover, will be used on the tissue as part of the patient's operation, inside the body itself.
40982120|NCT03916757|BIOLOGICAL|V-Boost|Open label setting
40982121|NCT03779789|DRUG|Vortioxetine|"Antidepressant classified under the category other antidepressants according to the ATC/DDD index \[ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose\]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day)."
41303467|NCT01240122|DEVICE|Biotrue MPS|Multi-purpose contact lens care solution
40777066|NCT00437749|OTHER|Placebo|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
41303468|NCT01240122|DEVICE|Investigational MPS|Multi-purpose contact lens care solution
41303469|NCT01716468|OTHER|Ketogenic Diet|modified ketogenic diet
41303470|NCT01886131|OTHER|Synchronised video-polysomnography|"We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.~The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.~The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task."
41303471|NCT06053827|OTHER|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
40777067|NCT03796910|DRUG|SPR720 for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
41462312|NCT04197258|OTHER|Peer support|"The intervention studied is the psycho-social support by a peer-helper to the patients and their main informal caregiver during the return home following a stay in rehabilitation center for a stroke.~Peer support intervention will be based on evidence, Bandura's social learning and social support theory, and the results of our ongoing study of the needs of patients and their caregivers as a result of returning home (Stroke69). It will include a meeting before the discharge and a regular follow-up for 6 months (face-to-face meetings, virtual or by phone), adapted to the needs of the patient and his caregiver, taking into account the social environment and in connection with the devices existing sanitary and social."
41462313|NCT00001191|DRUG|Pantoprazole|
41462314|NCT00001191|DRUG|Omeprazole|
41462315|NCT06030115|OTHER|Exercise Component Of Cardiac Rehabilitation (Hybrid Model) Intensity Recovery Progression Protocol (IRPP)|Data collected on participants who completed the intensity recovery progression protocol program
41462316|NCT00662896|DRUG|naproxcinod 375 mg bid|naproxcinod 375 mg bid
40777068|NCT03796910|DRUG|Placebo for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
40777069|NCT03796910|DRUG|SPR720 for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
40982122|NCT03779789|DRUG|Sertraline|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day)."
41303472|NCT01603316|BEHAVIORAL|surveys|Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form. Need Assessment surveys will be administered via telephone or in person. The content of the needs assessment questionnaire has been informed by themes generated through IHCD's ongoing research and community outreach and service activities with the cancer patient population at our participating institutions. The survey will ask participants about the impact on their cancer care and their socioeconomic needs of the COVID-19 crisis.
41303473|NCT01603316|BEHAVIORAL|Focus groups|Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials, via mail, MSK Secure email, or in person and nutrition education sessions.
41462317|NCT00662896|DRUG|naproxcinod 750 mg bid|naproxcinod 750 mg bid
41462318|NCT00662896|DRUG|naproxen 250 mg bid|naproxen 250 mg bid
41462319|NCT00662896|DRUG|naproxen 500 mg bid|naproxen 500 mg bid
40982123|NCT03779789|DRUG|citalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day)."
40982124|NCT03779789|DRUG|Escitalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day)."
41462320|NCT00662896|DRUG|ibuprofen 600 mg tid|ibuprofen 600 mg tid
41462321|NCT00440115|BEHAVIORAL|High intensity disease management|Health education mailings, 6 motivation interviews/counseling
41462322|NCT00440115|BEHAVIORAL|Low intensity disease management|Health education mailings, one motivation interview/counseling
41462323|NCT00440115|BEHAVIORAL|Comparison group|Health education mailings
41462324|NCT00440115|DRUG|Bupropion|Buproprion or Nicotine Replacement Therapy
41462325|NCT00212654|DRUG|ONO-1101|
40777070|NCT03796910|DRUG|Placebo for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
40777071|NCT02826187|OTHER|Early complications data|"Early complications of interest are :~* New arthroplasty for any reason~* Related to the implant :~  * Wrong position of the implant~ * Early displacement of the implant~* Related to the intervention :~  * Hematoma~ * Dislocation (or not causing the resumption of joint replacement)~ * Deep vein thrombosis~ * Pulmonary embolism~ * Acute Infection"
40777072|NCT02826187|OTHER|Late stage complications data|"Late complications taken into account are:~* New arthroplasty for any reason~* Aseptic loosening~* Delayed hypersensitivity reaction type IV~* Solid Tumors~* Recurrent dislocation (causing or not the resumption of joint replacement)~* Allergic reactions of any kind~* Chronic infection"
40777073|NCT02826187|OTHER|Patient Satisfaction|Patient satisfaction evaluated by Womac reduced Score
40982125|NCT03779789|DRUG|Paroxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day)."
41462326|NCT06134440|DIETARY_SUPPLEMENT|Impact Oral®|All patients will follow low-fiber diet according to ERAS protocol during the study period. Patients assigned to the experimental arm will assume also Impact Oral®, an oral nutritional supplement with immune-nutrients (hyper-proteic formula), manufactured and commercialized by Nestlé Health Science S.p.a. It is a liquid drink packaged in a brick of 237 ml. Patients will assume Impact Oral® for 5 days before surgery and 5 day after surgery.
40777074|NCT02826187|OTHER|Efficacity|Efficacity as evaluated by Harris HIP score
40982126|NCT03779789|DRUG|Fluoxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day)."
40982127|NCT03779789|DRUG|Fluvoxamine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day)."
40982128|NCT05454956|DRUG|TP-03|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day in participants in the BID dosing arm and three times a day in participants in the TID dosing arm
40982129|NCT05454956|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered once a day in participants in the BID dosing arm to maintain masking between arms
40982130|NCT02986789|DEVICE|In vivo SpHb and PVi Monitoring|Pulse oximeter finger sensor that simultaneously monitors noninvasive hemoglobin (SpHb) and pleth variability index (PVi)
40777075|NCT02826187|OTHER|Radiographic evaluation|Bone reaction visible in radiography
40777076|NCT02299245|DRUG|rosuvastatin|different dose of rosuvastatin treatment
40777077|NCT03965845|DRUG|Telaglenestat (CB-839)|Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
40777078|NCT03965845|DRUG|Palbociclib Oral Capsule or Tablet [Ibrance]|Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.
40777079|NCT05754125|DIETARY_SUPPLEMENT|Di-Leucine Supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
40982131|NCT04122092|DIAGNOSTIC_TEST|The level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs
40777080|NCT05754125|DIETARY_SUPPLEMENT|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
40982132|NCT03087760|DRUG|Pembrolizumab|Concurrent Pembrolizumab after proton reirradiation
40777081|NCT05754125|DIETARY_SUPPLEMENT|Collagen Supplement|Participants will consume a amino acid supplement containing Collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
40777082|NCT01593540|DEVICE|metal-free interdental brush|one time per day
40982133|NCT03035708|DRUG|Varenicline|1 mg BID
40982134|NCT03035708|DRUG|Placebo oral capsule|1 mg BID
40982135|NCT01433601|BEHAVIORAL|Enhanced Treatment Support (ETS)|"An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup."
40982136|NCT00000976|DRUG|CD4-IgG|
40982137|NCT00000976|DRUG|Zidovudine|
40982138|NCT02348827|BEHAVIORAL|Family psychoeducation|
40982139|NCT02348827|BEHAVIORAL|Social support group|
40982140|NCT01119131|DRUG|Vitamin D3|Vitamin D3 at 10,000 IU a day
41462327|NCT02881359|DEVICE|LifeSeal® Kit|used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
40777083|NCT01593540|DEVICE|metal-core interdental brush|one time per day
40777084|NCT02157610|BEHAVIORAL|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
40777085|NCT02157610|DRUG|Nicotine Patch|Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke \>10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke \<10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.
40777086|NCT02157610|BEHAVIORAL|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
40777087|NCT02157610|PROCEDURE|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
40777088|NCT02157610|BEHAVIORAL|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
40777089|NCT02157610|DRUG|Nicotine lozenge|Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
40982141|NCT01119131|DIETARY_SUPPLEMENT|calcium|1000mg calcium daily
40982142|NCT01119131|OTHER|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
40982143|NCT05967611|DIAGNOSTIC_TEST|Trendelenburg hip abduction test|The Trendelenburg test performed at different hip flexion, extension, adduction and abduction angles.
40982144|NCT03645980|DRUG|DKN-01 300 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
40982145|NCT03645980|DRUG|DKN-01 600 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
40982146|NCT03645980|DRUG|Sorafenib|For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
41462328|NCT02742701|OTHER|diagnosis|Measurement of glycosuria
40777090|NCT02285881|BEHAVIORAL|Shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
40982147|NCT04843423|DRUG|Cariprazine|"At the screening visit, those who are eligible will enter an open-label trial with cariprazine in doses ranging from 1.5mg to 3 mg. The study will begin with a single week of cariprazine 1.5 mg oral tablets. After the first week the participants' dosage may be increased up to a maximum of 3 mg daily. This dose will remain fixed after 4 weeks of treatment until week 8, at which time the medication will be discontinued.~Because the drug is not yet available to market in Canada, participants will be dispensed the drug in appropriately labelled 7-day tablet containers with the appropriate dose, including 3 additional tablets to account for scheduling conflicts. Participants will be instructed to return the tablet containers at each Study Visit in order to assess drug compliance. They will then be newly dispensed the appropriate quantity according to their next scheduled study visit."
40982148|NCT01168531|DRUG|Pregabalin|pregabalin: 300 mg/day, po, from operative day until third postoperative day.
40982149|NCT01168531|DRUG|dexamethasone|Dexamethasone 16 mg, intravenous, before induction of anesthesia
40982150|NCT01168531|DRUG|placebo|vitamin B complex formula
40982151|NCT06135701|DIAGNOSTIC_TEST|One-legged knee-extensor exercise with Doppler measurements|Doppler ultrasound is used while participants exercise according to the one-legged knee-extensor exercise model
40982152|NCT01711177|DRUG|placebo|Placebo
40982153|NCT01711177|DRUG|travoprost|Travatan Z is administered to newly diagnosed glaucoma patient
40982154|NCT02367677|OTHER|Method comparison|
40982155|NCT02200445|DRUG|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
41462329|NCT02689817|DEVICE|Patch|A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
41462330|NCT03036592|BEHAVIORAL|Early OGTT|Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
40777091|NCT00664222|DRUG|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
40982156|NCT02533830|BIOLOGICAL|sugarless gum|"One Stick of Sugarless Gum (Samara for food \& Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
40982157|NCT02533830|OTHER|traditional management|Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
40982158|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|remifentanil 0 ng/ml
40982159|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
40982160|NCT01053611|DRUG|propofol + remifentanil 4 ng/ml|
40982161|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
41143085|NCT06131957|COMBINATION_PRODUCT|Fluoride varnish with SBGC|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA) mixed with 7.5% SBGC (Dencare (Chongqing) Oral Care Co., Ltd).
41143086|NCT06131957|DRUG|Fluoride varnish|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA)
41143087|NCT04007445|BEHAVIORAL|Formally Directed Group (Exercise Group)|This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
41462331|NCT03036592|BEHAVIORAL|Late OGTT|Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
41462332|NCT00002228|DRUG|Enfuvirtide|
40982162|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|
40982163|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
40982164|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
41462333|NCT03748095|DRUG|pipéracilline/tazobactam|There is not intervention description
41462334|NCT00096239|DRUG|CP-547,632|
40982165|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
40982166|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|
40982167|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
41462335|NCT05505825|DRUG|AK104 IV infusion；Chiauranib oral|AK104 IV infusion once every 3 weeks；Chiauranib once a day oral
41462336|NCT00526162|DEVICE|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
40982168|NCT01053611|DRUG|propofol + remifentanil 4 ng/ml|
40982169|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
40982170|NCT01264146|PROCEDURE|HBOT|Open reduction and internal fixation of calcaneal fracture + hyperbaric oxygen therapy 20 postoperative days (one time, 90 minutes a day)
40982171|NCT01264146|PROCEDURE|Placebo (Sham)|open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
40982172|NCT05325450|PROCEDURE|Program A|Presentation of the sentence to the implant alone
40982173|NCT05325450|PROCEDURE|Program B|Presentation of the sentence to the implanted ear, associated for the non-implanted ear
40982174|NCT05325450|PROCEDURE|Control|Presentation of the sentences alternately to the most recently implanted ear and both implanted ears at the same time
40982175|NCT05867472|DRUG|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
40982176|NCT05867472|DRUG|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
41462337|NCT04975724|DRUG|Liposom Forte|Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
40982177|NCT03280290|BIOLOGICAL|blood|assessment pre-donation of hematopoietic stem cells (blood sample)
40982178|NCT03638024|DIAGNOSTIC_TEST|Maternal plasma cell free fetal DNA levels|Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)
40777092|NCT06262542|OTHER|moxibustion and Chinese herbal medicine group|"Apply 15g of Chinese herbal powder (a mixture of scientific Chinese herbs: Jiseng Shenqi Pill, Xuanfu Daizheshi Tang, and Wendi Tang mixed in a 1:1:1 ratio, mixed with water to form a paste) to the Shénquè acupoint. Then, use 3g of 80:1 moxa wool placed in a moxibustion box for moxibustion on the lower abdomen (between the Guānyuán, Zhōngjí, and Shénquè acupoints) for 1 hour, once a day, six times a week, for a total of 12 sessions.~sham moxibustion and placebo herbal medicine group): Same acupoint frequency, but use 15g of flour instead of herbal paste and replace moxibustion with a heated nightlight for sham moxibustion."
40777093|NCT05136716|OTHER|Traditional Physical Therapy|Stretching for tight muscles, strengthening for weak muscles, postural reactions training, proprioceptive training, and walking training were all part of the neurodevelopmental treatment plan.
41462338|NCT04975724|DRUG|Citalopram|The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC
41462339|NCT04975724|OTHER|Placebo|Liposom Forte Placebo (2 ampoules of 2 ml solution for injection)
40777094|NCT05136716|DEVICE|Hyperbaric oxygen therapy|HBO2 therapy at a pressure of 1.7 atm For 60 minutes, participants breathed 100% O2.
40777095|NCT03747055|BEHAVIORAL|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
40777096|NCT03747055|BEHAVIORAL|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
40777097|NCT05417178|OTHER|myStrength Macropersonalization Enginge|An onboarding process that utilizes the PHQ-9, GAD-7, and WHO-5 that leads to a user of the digital program's clinical focus and primary, secondary, and tertiary intervention recommendations.
40777098|NCT06032611|DIAGNOSTIC_TEST|COGNUM_ALZVR|"Participants will complete a battery of tests/quizzes:~* cognitive tests~* medical questionnaire~* lifestyle/fragility questionnaire~* digital clock test~* fine motor skills tests They will also wear a connected watch for 7 days."
40777099|NCT04876911|BEHAVIORAL|Simulated Presence Therapy|A video recording of a loved one is played (via an iPad) prior to or during periods where a participant is presenting with stressed/distressed behaviours.
40777100|NCT00647647|DRUG|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
40777101|NCT00647647|DRUG|Lamisil® Tablets 250 mg|250mg, single dose fasting
40777102|NCT00085527|DRUG|depsipeptide|
40777103|NCT01505855|DRUG|23-valent polysaccharide pneumococcal vaccine|23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
40777104|NCT03780257|DRUG|QR-421a|RNA antisense oligonucleotide for intravitreal injection
40982179|NCT05390957|BEHAVIORAL|Acceptance Based Behavioural Therapy - Revised|The study intervention is a revised, updated version of a previously studied eight-module (8-week) online, acceptance-based behavioural therapy (ABBT) for chronic pain that was tailored specifically to a military, RCMP, and veteran population. The online treatment material is administered via the WebCAPSI Therapy program.
41303474|NCT02352051|DRUG|Atomoxetine|the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
40777105|NCT03780257|OTHER|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
40777106|NCT03891888|PROCEDURE|Intramedullary Bone Graft|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing), but will also have the reamings from the medullary canal preparation collected and packed into the exposed fracture cortex
40777107|NCT00360945|DRUG|cisplatin|
40777108|NCT00360945|DRUG|temozolomide|
40777109|NCT00360945|GENETIC|fluorescence in situ hybridization|
40777110|NCT00360945|GENETIC|loss of heterozygosity analysis|
40777111|NCT00360945|OTHER|immunohistochemistry staining method|
40777112|NCT00360945|OTHER|laboratory biomarker analysis|
40777113|NCT00360945|RADIATION|radiation therapy|
40777114|NCT00285779|DRUG|Etanercept|etanercept 50 mg twice weekly for 12 weeks
40777115|NCT00285779|DRUG|Placebo|
40777116|NCT05141695|DEVICE|therapeutic repetitive peripheral magnetic stimulation|Patients in the treatment group will receive peripheral magnetic stimulation therapy for the upper extremity arm/forearm spastic muscles on the hemiplegic side for a total of ten sessions once a day, five sessions a week, for two weeks, each session lasting ten minutes. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
40777117|NCT05141695|DEVICE|sham repetitive peripheral magnetic stimulation|rPMS will not be given to the sham group, the device will not be operated, the probe of the device will be positioned in the same way as the patients in the treatment group for ten minutes, and the sounds recorded during the operation of the device will be heard by the patients. Patients and evaluators will not know which group the patients are in. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
40982180|NCT05980650|OTHER|Reiki implication|Reiki will be implicate by researcher by putting hands on patient
40982181|NCT01320462|DRUG|Smoking cessation counselling group|The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
40982182|NCT01320462|OTHER|Control group:|Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
41462340|NCT02319850|RADIATION|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
40777118|NCT04696003|COMBINATION_PRODUCT|Continuous amnioinfusion with Amnion Flush Solution through the intraamniotic catheter|The amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intraamniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. and the amnioinfusion (about 100 ml/h, 2400 ml/day) with artificial amniotic fluid (Amnion Flush Solution, CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h under periodic ultrasound using the standard i.v. pump.
40777119|NCT02350452|PROCEDURE|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
40777120|NCT02350452|PROCEDURE|Bipolar coagulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
40777121|NCT00600340|BIOLOGICAL|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
40777122|NCT00600340|BIOLOGICAL|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
40777123|NCT03278522|DRUG|Ramosetron|Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
40777124|NCT04487509|OTHER|THROMBOLYSE|the treatment delivered to the emergency room, in particular the nature of the treatment for obstruction (primary angioplasty or thrombolysis)
40777125|NCT04994977|DRUG|Melphalan|Given at 0.5 mg/ml.
40777126|NCT04994977|DRUG|Carboplatin|Given at 5 mg/ml.
40777127|NCT04994977|DRUG|Topotecan|Given at 0.2 mg/ml.
40777128|NCT04076033|OTHER|functional compressive bandage|"The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers."
40777129|NCT02354521|OTHER|NO INTERVENTIONS|
40777130|NCT03035630|DRUG|Avelumab|Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle
40777131|NCT03035630|DRUG|Sunitinib|Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle
41303475|NCT02352051|DRUG|methylphenidate|the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
41462341|NCT02600208|BIOLOGICAL|CliniMACs|Depletion of Alpha Beta T cells in the PBSC graft
40982183|NCT03829150|DRUG|Dexlan|Dexlansoprazole MR 60 mg qd for 7 days
41462342|NCT05220046|DRUG|Psilocybin|Psilocybin, 25mg administered orally drug during an 8-hour monitored session with supportive pre- and post- session counseling
40777132|NCT03436667|DIAGNOSTIC_TEST|Spirometry|Lung volumes will be measured using spirometry.
40777133|NCT03436667|DIAGNOSTIC_TEST|Reaction Time|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
41462343|NCT04608682|DRUG|Sugammadex|The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.
40982184|NCT03829150|DRUG|Amoxicillin|Amoxicillin (Amolin) 1 g bid. for 7 days
41462344|NCT04608682|DRUG|Saline|The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
40777134|NCT05663684|DRUG|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
40777135|NCT05663684|DRUG|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
40777136|NCT02767076|PROCEDURE|conventional paramedian spinal anesthesia|land mark guided paramedian spinal anesthesia
40777137|NCT02767076|DEVICE|ultrasound guided paramedian spinal anesthesia|real time ultrasound guided paramedian spinal anesthesia
40777138|NCT05700409|BEHAVIORAL|Intensive lifestyle consultations|detailed above
40777139|NCT00223145|RADIATION|Radiotherapy 70 Gy|Radiotherapy to the prostate
40777140|NCT00223145|RADIATION|Radiotherapy 76 Gy|Radiotherapy to the prostate
40777141|NCT00223145|DRUG|Androgen blockade|Duration : 6 months
40777142|NCT00671086|DRUG|Ramelteon|Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
40777143|NCT00671086|DRUG|Ramelteon|Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
40777144|NCT04873908|OTHER|modified constraint-induced therapy|Patients received conventional rehabilitation and modified constraint-induced therapy schedule
40777145|NCT04873908|OTHER|Proprioceptive Training|Patients received conventional rehabilitation and Proprioceptive Training schedule
40777146|NCT04873908|OTHER|conventional rehabilitation|Patients received conventional rehabilitation schedule
40777147|NCT00718315|DRUG|erlotinib [Tarceva]|150mg po daily
40777148|NCT00718315|DRUG|fusidic acid [Verutex]|topical, daily for 30 days.
40777149|NCT00718315|DRUG|erythromycin [Eritex]|topical, daily for 30 days.
40982185|NCT03829150|DRUG|Clarithromycin 500mg|clarithromycin (Klaricid) 500 mg bid for 7 days
40982186|NCT03829150|DRUG|Metronidazole|Metronidazole (Flagyl) 500 mg bid daily for 7 days
40982187|NCT03649633|DRUG|Stress-dose Hydrocortisone plus Vitamin C|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
41462345|NCT06072924|BEHAVIORAL|Isotonic Endurance Exercise|Pressing tongue against a pressure sensor at the set number of repetitions per session (individualized per participant) 3 times per day
41462346|NCT06072924|BEHAVIORAL|Sham Exercise|Pressing tongue against pressure sensor at a low threshold (1-15kPa) 30x/day
41462347|NCT01802216|PROCEDURE|Scaling and root planing|non-surgical periodontal disease treatment
40777150|NCT00718315|DRUG|Fisiogel|topical, daily for 30 days
40777151|NCT02684461|DRUG|Pembrolizumab|"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."
40777152|NCT02356237|OTHER|No episiotomy|Avoidance of episiotomy
40982188|NCT03649633|DRUG|isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
40982189|NCT01229059|DIETARY_SUPPLEMENT|Lipovenös lipid infusion|Lipid enriched infusions will be applied for 2-6 hours.
40982190|NCT00301574|DRUG|galantamine|
40982191|NCT05642754|OTHER|Overall uncertainty language|Researchers are testing different forms of information about overall study uncertainty and margin of error around main result
40982192|NCT01166724|DRUG|Sirolimus|Tacrolimus to Sirolimus
40777153|NCT04541615|PROCEDURE|Online course with proficiency test|Participants will receive an online e-course with a proficiency test at the end. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
40777154|NCT04541615|PROCEDURE|Online course|Participants will receive an online e-course but are not required to pass the proficiency test. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
40777155|NCT04541615|PROCEDURE|Standard training group|After receiving a traditional lecture, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
40777156|NCT04541615|PROCEDURE|Apprenticeship group|Participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end. Participants will only receive papers on how the task will be performed and clinicians will help them with completion of the task.
40982193|NCT01166724|DRUG|Tacrolimus|dosage per trough level
40982194|NCT05421390|OTHER|Reduced fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. Skim milk, fat-free yogurt, and ≤22 % fat cheese
41143088|NCT04007445|OTHER|Self-Directed Group (Control Group)|This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
40982195|NCT05421390|OTHER|Regular fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. 3.25% fat milk, ≥2% fat yogurt, and ≥28% fat cheese
40982196|NCT03234192|PROCEDURE|Therapeutic ultra sound|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to therapeutic ultra sound treatment.
41462348|NCT01802216|DRUG|Minocycline|antibiotic microspheres
40777157|NCT06376955|OTHER|High intensity interval exercise|HIIT is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high intensity movements followed by short periods of lower intensity movements 2 times per week for 4 months.
40777158|NCT06376955|OTHER|Focused ultrasound|Focused ultrasound will be applied over the anterior abdominal, two sessions per week for 4 months, each session 40 minutes.
40777159|NCT05762432|DEVICE|Wound Dressing|RTD Wound Dressing that is being investigated
40982197|NCT03234192|PROCEDURE|Astym Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Astym Treatment.
40982198|NCT03234192|PROCEDURE|Graston Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Graston Treatment.
40982199|NCT05132829|DRUG|Azithromycin 1 gram IV|Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
40982200|NCT05132829|DRUG|Cefazolin and indomethacin|Perioperative standard of care with cefazolin and indomethacin
40982201|NCT00881712|RADIATION|PET positive nodal disease measuring 15 mm or greater|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.
40982202|NCT00881712|RADIATION|PET positive nodal disease measuring less than 15 mm|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.
40982203|NCT00881712|RADIATION|Patients considered resectable|Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.
40982204|NCT03072615|DIAGNOSTIC_TEST|Stiffness measurement|Transient Elastopgraphy (TE) or Shear-Wave-Elastography
40982205|NCT02187601|DEVICE|MPBA System|MPBA is the new generation Multi Purpose Breath Analyzer
40982206|NCT02187601|DEVICE|BreathID|BreathID is the name of the original Exalenz breath analyzer system
40982207|NCT04496544|OTHER|Retrospective data collection|No intervention; retrospective data collection
40982208|NCT00617045|DRUG|duloxetine|"Total treatment period is 12 weeks~30mg po qd times 1 week~60mg po qd times 11 weeks"
40982209|NCT02625259|DRUG|TAK-117|TAK-117 capsules
40982210|NCT02625259|DRUG|Lansoprazole|Lansoprazole capsules
40982211|NCT02625259|DRUG|TAK-117|TAK-117 tablets
40982212|NCT03232957|PROCEDURE|50 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 50 ug
40777160|NCT05762432|DEVICE|NHS Standard Dressing|This is the standard dressing used by NHS staff when currently dealing with a diabetic foot ulcer
40777161|NCT05126420|PROCEDURE|biopsy|biopsy to identify the lesion in the oral mucosa
40777162|NCT03056469|OTHER|Completion of patient-reported outcome (PRO) questionnaires|Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
40777163|NCT04017234|OTHER|frequency following response, eye exercise, and transcutaneous|frequency following response, eye exercise, and TENS for 3 times per week during 4 weeks
40777164|NCT00538850|DRUG|Fentanyl sublingual spray|In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
40777165|NCT00538850|DRUG|Placebo|Matching placebo to fentanyl sublingual spray.
40982213|NCT03232957|PROCEDURE|100 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 100 ug
40777166|NCT02154061|DRUG|IIV Flu Vaccine|This is an FDA approved and tested Inactivated Flu Vaccine.
40982214|NCT03232957|PROCEDURE|No IT morphine|Spinal block with bupivacaine and intrathecal morphine 0 ug
40982215|NCT03232957|DRUG|Morphine|intrathecal morphine
40777167|NCT02154061|DRUG|Metronidazole|This is a standard antibiotic
40777168|NCT02154061|DRUG|Neomycin|This is a standard antibiotic.
40777169|NCT02154061|DRUG|Vancomycin|This is a standard antibiotic.
40777170|NCT00251992|DRUG|Esomeprazole|
40777171|NCT04023487|BEHAVIORAL|Resilient, Empowered, Active Living-Telehealth (REAL-T)|REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
40777172|NCT05262569|OTHER|ileus|retrospectively allocation according to a postoperative outcome-ileus
40777173|NCT02806661|PROCEDURE|Vagus nerve-preserving Robot-assisted Gastrectomy|
40982216|NCT03232957|DRUG|Bupivacaine|0.5 isobaric bupivacaine
40982217|NCT03066271|OTHER|Exercise +|Usual care
40982218|NCT03066271|OTHER|Control +|Usual care
40982219|NCT06340828|OTHER|Washing Microbiota Transplantation|Fecal samples from healthy adults were collected and underwent multiple centrifugations and filtrations to obtain a bacterial solution, which was then transplanted into the duodenum of patients via a nasogastric tube.
40982220|NCT04299308|BEHAVIORAL|Aerobic Exercise|Participants will exercise for 15 minutes based on heart rate range. The study team will employ a stationary bike to maintain control over workload
40777174|NCT02806661|PROCEDURE|Conventional Robot-assisted Gastrectomy|
40982221|NCT02288559|OTHER|Sham|Sham injection will be administered as a matching intravitreal injection of lampalizumab.
40982222|NCT02288559|DRUG|Lampalizumab|10 mg dose of lampalizumab administered intravitreally
40777175|NCT06252233|BEHAVIORAL|patient- and physician-centered QoL monitoring|Electronic QoL monitoring including QoL diagnosis and therapy (pain therapy, psychotherapy, social support, nutrition, physiotherapy, fitness, respiratory counselling, palliative care). Patients and treating physicians have access to the results of their QoL monitoring and to a network of local healthcare providers.
40777176|NCT06252233|OTHER|Placebo|Electronic QoL monitoring without QoL diagnosis and therapy. Patients and treating physicians have no access to the results of their QoL monitoring. The therapist network is also available for control arm.
40777177|NCT03868501|BEHAVIORAL|n-back task|All participants will be asked to finish the 3-back task and the 1-back task. The 3-back task and the 1-back task will be carried out at intervals to avoid the influence between different tasks. The sequence of the 3-back task and the 1-back task will be counterbalanced across participants.
40777178|NCT06066086|PROCEDURE|A hinge flap will be performed to reinforce the buccal advancement flap to close the oroantral fistula at the most posterior area of the maxilla|The hinge flap is raised via circular incision around the oral side of the oroantral fistula then sutured with purse suture to close the sinus membrane perforation and it is used as an additional layer that reinforce the buccal advancement flap
40982223|NCT00470639|DEVICE|Transcranial Magnetic Stimulation|
40982224|NCT04535960|DRUG|Empagliflozin 25 MG + Liraglutide 1.8 MG|Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.
40982225|NCT04535960|DRUG|Liraglutide 1.8 MG + Empagliflozin 25 MG|Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.
40982226|NCT00819351|DRUG|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
40982227|NCT00819351|DRUG|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
40982228|NCT05400954|PROCEDURE|Breast reconstruction with silicone breast implant|(i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant.
41143089|NCT04256421|DRUG|Tiragolumab|Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.
41143090|NCT04256421|DRUG|Atezolizumab|Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.
41143091|NCT04256421|DRUG|Carboplatin|Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
40982229|NCT05400954|PROCEDURE|Breast conserving surgery/Mastectomy/Autologous reconstruction|(iv) simple mastectomy without reconstruction, (v) autologous reconstruction and (vi) breast conserving surgery,
40982230|NCT05400954|PROCEDURE|Breast Augmentation|(vii) cosmetic augmentation with silicone breast implants
40777179|NCT06066086|PROCEDURE|An anteriorly based palatal flap will be performed to close the oroantral fistula at the most posterior area of the maxilla|Two paralleling incisions will be performed on the palatal side of the fistula. The distance between the two incisions will be 2 to 3 mm greater than the width of the fistula. Then the two incisions will be connected together via a circular incision at the bony end of the hard palate. The flap reflection will be performed, and the greater palatine vessels will be legated and cauterized to allow lateral repositioning of the flap over the fistula. The flap will be sutured to the buccal tissues.
40982231|NCT01403714|PROCEDURE|Renal Artery Stenting|If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
41143092|NCT04256421|DRUG|Etoposide|Etoposide 100 mg/m\^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.
41143093|NCT04256421|DRUG|Placebo|Placebo administered by IV infusion on Day 1 of each 21-day cycle.
41143094|NCT00608959|DRUG|omiganan 1% gel|"Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).~In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site."
40777180|NCT02665091|BEHAVIORAL|Peer Education Program|
41143095|NCT00608959|DRUG|chlorhexidine 2% solution|"Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.~Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only."
40982232|NCT02989740|PROCEDURE|Optical Coherence Tomography|Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
40982233|NCT06185504|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows~1. The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~2. Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~3. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~4. Direct feeding training: with powdered milk, once a day, 5 days a week."
40982234|NCT06185504|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
41143096|NCT04392648|DRUG|TAK-573|TAK-573 intravenous infusion.
41303476|NCT02002442|OTHER|Mouthwash|An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
41303477|NCT02969343|BEHAVIORAL|Patient Safety health information technology|Patient safety technology toolkits on hospital care units
41143097|NCT04392648|DRUG|Pomalidomide|Pomalidomide capsules orally.
41303478|NCT02614872|DRUG|GLASSIA® and Institution standard of care (SOC)|Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)
41303479|NCT00170248|DEVICE|computer-based decision support for asthma management|The asthma management decision support system uses data from the patient problem and medication list to provide patient-specific management recommendations based on Canadian Consensus guidelines for asthma management. Web-enabled technology for asthma education nurses is used to collect home-monitoring information from patients between visits and feedback to primary care physicians in accordance with options selected by the physician for each patient.
40777181|NCT05077969|DRUG|Famotidine|80 mg tablet, QID for 14 days
41143098|NCT04392648|DRUG|Bortezomib|Bortezomib injection subcutaneously.
41143099|NCT04392648|DRUG|Cyclophosphamide|Cyclophosphamide tablets orally.
41143100|NCT04392648|DRUG|Dexamethasone|Dexamethasone tablets orally.
41303480|NCT05072769|DIETARY_SUPPLEMENT|Date Fruit|Within the first hour after birth, 100gr (5-6 pieces) dates will be eaten.
40777182|NCT05077969|DRUG|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
40777183|NCT05077969|DRUG|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
40777184|NCT06254625|OTHER|Fecal Microbiome|Fecal microbiome transplantation from a healthy donor.
40777185|NCT06254625|OTHER|Placebo|Place capsules
40777186|NCT01784029|DRUG|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
40777187|NCT05829837|OTHER|Ultrasonographic evaluation|Ultrasonographic evaluation for the thickness of piriformis muscle
40777188|NCT01681147|BEHAVIORAL|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
40777189|NCT01681147|BEHAVIORAL|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
40777190|NCT01999530|DRUG|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
40777191|NCT02148848|DRUG|Risedronate|Take risedronate 35 mg orally every week
41143101|NCT04937309|DEVICE|non invasive auricular vagal stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles
41462349|NCT01562132|DRUG|Flucytosine and fluconazole|Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
40777192|NCT02621892|DRUG|Tenapanor|
40777193|NCT02621892|DRUG|Placebo|
40777194|NCT03400423|DRUG|Caffeine|Oral administration of 1.2mg/kg of powdered caffeine with water.
40777195|NCT03400423|BEHAVIORAL|Moderate Intensity Exercise|Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)\*0.6.
41462350|NCT01562132|DRUG|Fluconazole|fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
40777196|NCT02323048|DRUG|methamphetamine|: Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
40777197|NCT02323048|DRUG|placebo|Placebo (sugar pill)
40777198|NCT05691920|PROCEDURE|Pectointercostal plane block and external oblique intercostal plane block|Patients will be subjected to bilateral external oblique intercostal plane and pectointercostal plane blocks
40777199|NCT05691920|PROCEDURE|Fentanyl infusion|Patients will be subjected to fentanyl infusion at a rate of 1μg/kg/h
40777200|NCT01994876|DEVICE|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
40777201|NCT01994876|DEVICE|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
41462351|NCT04475315|DEVICE|Papillary Muscle Sling|The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.
40777202|NCT05563948|DRUG|Cannabis|Vaporized cannabis will be administered 3x/day for 15 days.
40777203|NCT03085901|DEVICE|Precizon toric intraocular lens|Phacoemulsification and implantation of Precizon toric intraocular lens
40982235|NCT06185504|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
41143102|NCT04937309|DRUG|usual medical treatment|Standard anti emetic treatments to prevent emesis due to chemotherapy
41143103|NCT04937309|DEVICE|sham stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles, with a sham device
41462352|NCT04475315|PROCEDURE|CABG surgery|Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
41462353|NCT03460990|DRUG|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
41462354|NCT03460990|DRUG|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
41462355|NCT03460990|DRUG|IVA|Participants received IVA orally once daily in the evening.
41462356|NCT03460990|DRUG|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
41462357|NCT03460990|DRUG|Placebo|Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
41462358|NCT05089890|DEVICE|Sorbact® Compress|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Compress has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
40777204|NCT03085901|DEVICE|Tecnis toric intraocular lens|Phacoemulsification and implantation of Tecnis toric intraocular lens
40777205|NCT05162248|DIAGNOSTIC_TEST|Microsatellite instability analysis|Molecular analysis for Microsatellite Instability (MSI) status was performed using immunohistochemistry (IHC). IHC now recognized as an approved method to highly precision predict MSI in colorectal cancer.
40777206|NCT04269421|PROCEDURE|calcaneo-stop: arthrosis of the subtalar joint|arthrosis of the subtalar joint with a screw in the talus bone to stop pathological pronation of the heel
40777207|NCT01145950|DRUG|LBEC0101|Etanercept 25mg, single dose
40777208|NCT01145950|DRUG|Enbrel|Etanercept 25mg, single dose
40777209|NCT04745091|PROCEDURE|total mesorectal excision|excision of the rectum with complete excision of the mesorectum
40777210|NCT01198587|DRUG|Zinc Sulfate|"For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid."
40777211|NCT01198587|DRUG|Placebo oral capsule|Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
40777212|NCT03639402|BEHAVIORAL|Health education classes|Community empowerment through involvement of local mothers (peer mothers) for dissemination of education regarding health diet and physical activity to others eligible mothers in the community (fellow mothers).
40777213|NCT04612426|DEVICE|Brain-computer Interface-Pedaling Training System|The Brain-computer Interface-Pedaling Training System includes four parts: computer, monitor, EEG testing equipment and pedaling training equipment. The patient wears an EEG detection device, which calculates brain movement participation every 0.5 seconds. The system will provide real-time visual/auditory/somatosensory feedback to patients based on the results of participation, so that patients can participate in motor function training more attentively.
40777214|NCT04612426|DEVICE|Traditional Pedaling Training System|The patient will wear the same EEG equipment that will only collect data, but not guide training.
40777215|NCT04319276|DRUG|Gallium maltolate (500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
40777216|NCT04319276|DRUG|Gallium maltolate (1,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
41462359|NCT05089890|DEVICE|Sorbact® Gel Dressing|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Gel Dressing has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
41462360|NCT05089890|DEVICE|Sorbact® Ribbon Gauze|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Ribbon Gauze has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
40777217|NCT04319276|DRUG|Gallium maltolate (1,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
40777218|NCT04319276|DRUG|Gallium maltolate (2,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
40777219|NCT04319276|DRUG|Gallium maltolate (2,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
40777220|NCT04319276|DRUG|Gallium maltolate (recommended phase 2 dose)|The maximum-tolerated dose (recommended phase 2 dose).
40777221|NCT00906763|DIETARY_SUPPLEMENT|Chocolate|A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
40777222|NCT02101255|DEVICE|Curodont Repair|"Self-assembling peptide, biomimetic re-mineralisation~Application on Day 0 and Day 360"
40777223|NCT02101255|DEVICE|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
41462361|NCT00003700|BIOLOGICAL|G-CSF|Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC \> 5,000 uL after nadir: 7 day minimum for Courses I \& IV
40777224|NCT02748447|DEVICE|Automated FiO2 adjustment|AVEA ventilator according to SpO2 target range delivers an automated FiO2
40777225|NCT02541591|OTHER|Neuroprotective goal directed hemodynamic optimization|
41303481|NCT06555926|OTHER|Acupressure|The pregnant women will receive acupressure on the (Pc-6/Lung-7 )acupoints one minute for each point with 3 repetitions on both side( about 30minutes /session),2 times per week in addition to advices for 12 weeks.
41462362|NCT00003700|DRUG|asparaginase|6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I \& IV
41462363|NCT00003700|DRUG|cyclophosphamide|1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I \& IV (pts \< 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II \& V
41462364|NCT00003700|DRUG|cytarabine|2000 mg/sq m IV infusion over 3 hrs Days 1,2, \& 3: Courses II \& V
40777226|NCT02541591|OTHER|MAP > 65mmHg|MAP \> 65mmHg
40777227|NCT02702050|OTHER|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
40777228|NCT02702050|OTHER|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
40777229|NCT03081104|DEVICE|hystroscopy|The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
41462365|NCT00003700|DRUG|daunorubicin hydrochloride|80mg/sq m (pts\<60y/o)OR 60mg/sq m (pts =/\>60y/o) IV infusion over 5-10 min Days 1,2,\& 3: Courses I \& IV
41462366|NCT00003700|DRUG|leucovorin calcium|"Courses III \& VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX \<0.05 uM after ea IV dose"
41462367|NCT00003700|DRUG|mercaptopurine|60mg/sq m/d PO every day Course VII
41462368|NCT00003700|DRUG|methotrexate|15mg intrathecal Day 1 Courses II \& V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, \& 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III \& VI.
40777230|NCT03081104|DEVICE|ultrasound|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
40777231|NCT03081104|PROCEDURE|Aspiration|The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
40777232|NCT01246960|BIOLOGICAL|Ramucirumab|Administered intravenously
40777233|NCT01246960|DRUG|Placebo|Administered intravenously
40777234|NCT01246960|DRUG|Oxaliplatin|Administered intravenously
40982236|NCT04778579|DRUG|ARI-0001 cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
40777235|NCT01246960|DRUG|Leucovorin|Administered intravenously
40777236|NCT01246960|DRUG|5-Fluorouracil|Administered intravenously
40777237|NCT05539547|DEVICE|Neuromuscular Electrical Nerve Stimulation|"Application of NMES on quadriceps muscle groups bilaterally~Frequency: \>50Hz Pulse duration: 350 - 400µs Intensity: Maximal tolerance (visible quadriceps muscle contraction and/or maximally tolerated by the patient, eliciting a slight discomfort) Time: 30 minutes per session, 7 sessions per week Duty Cycle: 2s on / 18s off Duration: Until discharge to a maximum of 30 days"
40777238|NCT05539547|OTHER|Usual Physiotherapy treatment (Chest Physiotherapy and mobility)|Daily chest physiotherapy and mobility
40777239|NCT06167148|DEVICE|Biolase Epic X 940nm wavelength Diode laser|Participants were treated with Biolase Epic X 940nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (P3).
40777240|NCT06167148|DEVICE|Doctor smile simpler 980nm wavelength Diode laser|Participants were treated with doctor smile simpler 980nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (SP).
40777241|NCT04411992|DEVICE|Vibrating Device|The device used for the vibration application was produced to control pain and distract attention by providing vibration of 150 at 183 Hz (9000-11,000/min). The device is used again by being cleaned with 70% alcohol. The device was placed put 3 cm above the injection site. It should be ensured to completely contact with skin. Vibration was applied on the site for 3 minutes before injection
40777242|NCT04516278|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
40777243|NCT04544306|OTHER|Partial oral antimicrobial therapy|Switch intravenous antimicrobial therapy to oral after an initial period of 10 days to oral antimicrobial therapy. Antimicrobial choices will be guided by antimicrobial susceptibilities.
40777244|NCT02850341|DEVICE|Pedometer|Patients receive a pedometer with instructions how to raise their number of daily steps
40777245|NCT00251108|PROCEDURE|Cardiorespiratory fitness training|
40982237|NCT02657460|BIOLOGICAL|tumor derived microparticles|The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.
40982238|NCT02657460|DRUG|cisplatin|cisplatin is a traditional drug for lung cancer
40982239|NCT01096264|OTHER|SSI and SphygmoCor® evaluations|"* SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.~* SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived."
40982240|NCT00528385|DRUG|Spironolactone (Spironol) 25 mg|In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
40982241|NCT04700982|OTHER|Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and \> 3 months (Group 2).Clinical features and functional output will be then compared between the groups.
40982242|NCT05704608|OTHER|Aerobic training|Exercises on a treadmill at different speeds and inclination were performed.
40982243|NCT01182545|PROCEDURE|Ventilation|Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
40982244|NCT05625061|BEHAVIORAL|Core Behavioral Weight Loss (BWL) Intervention|"All participants receive a mobile behavioral weight loss intervention delivered through a study smartphone app with weekly behavioral lessons, food tracking log, weekly tailored feedback, and daily weight-related behavioral goals; a connected physical activity tracker and wireless scale. As micro-randomized trials are sequential, full factorial experiments, this core intervention component is combined with each of the 7 intervention messages (i.e., Behavior Change Technique (BCT) messages) to be tested repeatedly over time.~Participants will be evaluated at each of 3 decision points (morning, midday, evening) on each day of the study, and if eligible then micro-randomized, to receive or not receive, 1 of 7 types of daily intervention messages promoting achievement of proximal weight-related behavioral goals."
41462369|NCT00003700|DRUG|prednisone|60mg/sq m/day PO Days 1-21 (pts\<60y/o) OR Days 1-7 (pts \>/= 60y/o) Courses I \& IV and Days 1-5 of ea 4 cycle in Course VII
41462370|NCT00003700|DRUG|vincristine sulfate|2 mg total IV infusion Days 1,8,15,\& 22 Courses I \& IV and Days 1, 8, \& 15 Courses III \& VI, and Day 1 of ea 4 wk cycle in Course VII
40777246|NCT04329767|DEVICE|IRIS 1.0|Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans. It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
40777247|NCT01705392|DRUG|Bevacizumab|Bevacizumab 10 mg/kg q3w
40777248|NCT01705392|DRUG|Propranolol|Propranolol 80 mg x 1
41462371|NCT00003700|DRUG|Allopurinol|300mg PO q day Days 1-14 Course I
40777249|NCT01705392|DRUG|Enalapril|Enalapril 5 mg x 1
40777250|NCT01705392|DRUG|Dacarbazine|dacarbazine 1000 mg/m2 q3w
40777251|NCT05683366|DEVICE|No Intervention|There is no intervention in this study
40777252|NCT00502918|DEVICE|CLM - HA Continuous Monitoring System Heart Application|
40777253|NCT00484263|DRUG|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
40777254|NCT05213806|OTHER|Withholding feeds around transfusion|Withholding enteral feeds for preterm infants (\<30 weeks) around the time of blood transfusions to determine if any impact on the development and/or severity of Necrotizing Enterocolitis.
40777255|NCT05213806|OTHER|Continued feeds around transfusion|Continued enteral feeds
41462372|NCT03306927|DIETARY_SUPPLEMENT|Whole yellow pea chili|Chili containing whole yellow peas
40777256|NCT04542122|BEHAVIORAL|Choices and judgements|In the intervention arm, the participant is asked to answer clinical cases in a reverse order from the control group (control has to make moral choices then judge somebody else's choices ; intervention has to judge moral choices first, then make his own)
40777257|NCT04256447|DIAGNOSTIC_TEST|Urinary sodium concentrations|The urinary sodium excretion was measured using an immunochemical methodology
40982245|NCT05625061|BEHAVIORAL|Behavior Change Technique 1 Message (Action Planning)|Core BWL Intervention + Message in smartphone app prompts detailed planning of performance of one of the 3 target behaviors (daily weighing, active minutes, red food intake).
40982246|NCT05625061|BEHAVIORAL|Behavior Change Technique 2 Message (Discrepancy between Current Behavior and Goal)|Core BWL Intervention + Message in smartphone app provides feedback on each of the 3 target behaviors (daily weighing, active minutes, red food intake) in the form of information drawing attention to discrepancies between participants' current behavior and participants' daily goals.
40982247|NCT05625061|BEHAVIORAL|Behavior Change Technique 3 Message (Feedback on Outcome of Behavior)|Core BWL Intervention + Message in smartphone app provides participants with feedback on their weight change, relating it to their performance on one of the 3 target behaviors (daily weighing, active minutes, red food intake).
40982248|NCT05625061|BEHAVIORAL|Behavior Change Technique 4 Message (Social Support)|Core BWL Intervention + Message in smartphone app advises participants on eliciting the provision of social support from their existing network related to one of the 3 target behaviors (daily weighing, active minutes, red food intake).
40982249|NCT05625061|BEHAVIORAL|Behavior Change Technique 5 Message (Social Comparison)|Core BWL Intervention + Message in smartphone app systematically induces comparison of participants' behavioral performance with other participants, including general, upward (i.e., comparison to participants doing better: weighing more, engaging in more activity, staying within red food limits), and downward comparisons (to participants doing worse).
40982250|NCT05625061|BEHAVIORAL|Behavior Change Technique 6 Message (Social Reward)|Core BWL Intervention + Message in smartphone app reinforces participants' effort or progress in performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
40982251|NCT05625061|BEHAVIORAL|Behavior Change Technique 7 Message (Focus on Past Success)|Core BWL Intervention + Message in smartphone app advises participants to think about or list previous successes related to performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
40982252|NCT04995133|DRUG|Colistin|intravenous administration
40982253|NCT06263751|OTHER|Product prescription program- NutriConnect Credit|Patient is given $20 credit to their Schnucks (grocery) Rewards account every other week for F\&V shopping. The Rewards credit can be used either through the Schnucks App or in store.
40982254|NCT06263751|OTHER|Product prescription program- NutriConnect Delivery|Patient receives produce (F\&V) box (equivalent $20 value) delivered to home every other week. The items in the box will be pre-selected by Schnucks and the NutriConnect dieticians.
40982255|NCT04516590|OTHER||There was no intervention in this observational study
40982256|NCT05951010|DEVICE|Transcranial Direct Current Stimulation|Anodal stimulation was delivered by a battery-driven stimulator (Neuroelectrics, Barcellona, Spain) through a pair of saline-soaked surface sponge electrodes (7 x 5 cm2) producing a constant current of 2 mA for 20 min. The anode was placed 2 cm under the inion and the cathode was placed over the right deltoid muscle (CD-tDCS) or the spinal lumbar enlargement (2 cm under T11) as described by Benussi et al. (CS-tDCS). An electroconductive gel was applied to the electrodes to reduce contact impedance and the electrodes were held in place using elastic gauzes.
40982257|NCT00728780|DRUG|ABT-143|once
40982258|NCT00728780|DRUG|ABT-335 and rosuvastatin|once
40982259|NCT01045889|OTHER|Rituximab and CHOP regimen + PBSCT|
40982260|NCT05230225|BEHAVIORAL|Physician Notification Letter|Receiving the electronic Physician Notification Letter to highlight echocardiography results that are consistent with or may be consistent with severe AS and to be reminded of ACC/AHA Clinical Practice Guideline recommendations regarding the management of severe AS.
40982261|NCT03817385|DEVICE|repetitive TMS|rTMS x 10 times
40982262|NCT03817385|DEVICE|robotic GT|robotic gait training for 20 times
40982263|NCT02631850|BEHAVIORAL|Traditional CI Therapy|Intensive in-person therapy for upper extremity hemiparesis.
40982264|NCT02631850|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
40777258|NCT05540483|DRUG|Disitamab Vedotin combined with Zimberelizumab|Treatment regimen: Disitamab Vedotin , 2.5mg/kg, intravenously D1, once every 14 days (Q2W), combined with Zimberelizumab, 240mg, intravenously D1, once every 14 days (Q2W).
40982265|NCT02631850|BEHAVIORAL|Gaming CI Therapy with Additional Contact via Video Conference|Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
40982266|NCT02631850|BEHAVIORAL|Traditional Occupational Therapy/Physical Therapy|Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
40982267|NCT05486468|DRUG|Yutiq 0.18 MG Drug Implant|YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
40982268|NCT05486468|OTHER|Sham Injection|Sham injection
40982269|NCT04324554|DIAGNOSTIC_TEST|MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
40982270|NCT04670081|DRUG|Psilocybin|25 mg, p.o.
40777259|NCT02461186|DRUG|Arterolane maleate-piperaquine phosphate (Synriam)|
40777260|NCT02461186|DRUG|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
40777261|NCT00208130|DRUG|Topiramate|
40777262|NCT04926376|DEVICE|Eye90 Microspheres|Y90 glass microspheres
40777263|NCT00011544|PROCEDURE|Performance Measure|
40777264|NCT02128022|DRUG|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
40777265|NCT02128022|DRUG|Glibenclamide|Oral Glibenclamide 5mg
40982271|NCT04670081|DRUG|Psilocybin|5 mg, p.o.
41462373|NCT03306927|DIETARY_SUPPLEMENT|Split yellow pea chili|Chili containing split yellow peas
41462374|NCT03306927|DIETARY_SUPPLEMENT|Rice chili|Chili containing long grain white rice
41462375|NCT02176057|DRUG|Azithromycin|
41462376|NCT05284552|DRUG|Tinzaparin Injectable Solution|Subcutaneous injection
40982272|NCT04670081|DRUG|Nicotinamide|100 mg, p.o.
40982273|NCT04425265|PROCEDURE|Plasma radiofrequency ablation|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are completely removed through the bilateral nasal cavity. Then investigators use plasma radiofrequency ablation at low temperature to ablate the tumor tissue and normal tissue of the margin along the upper and lower surgical margin until no obvious tumor remained under the naked eye.
40982274|NCT04425265|PROCEDURE|Electrocautery block resection|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are continuously and completely removed through the bilateral nasal cavity. Then investigators separate the posterior part of the nasal cavity and the top wall of the nasopharynx along the bone of the nasopharyngeal fornix, cut the pharyngeal suture, and cut the two sides along the edge of the carina, and then merge along the anterior vertebral muscle surface to the midline incision. Along the the soft palate under the inferior margin, investigators horizontally cut the mucosa of the posterior wall of the nasopharynx, and completely frees the entire soft tissue of the posterior wall of the nasopharynx.
40982275|NCT00968994|DEVICE|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
40777266|NCT04311450|BEHAVIORAL|Behavioral Weight Loss (BWL) counseling|This therapy is a weekly treatment which focuses on making gradual and modest lifestyle changes with goals of establishing regular patterns of eating, setting weekly goals, decreasing caloric intake, developing coping skills, and increasing physical activity.
40777267|NCT01503320|DIETARY_SUPPLEMENT|Enteral glutamine|Dosage of glutamine: 0.57g/kg, \~ 30g/day= 3sachets
40777268|NCT01503320|DIETARY_SUPPLEMENT|Placebo|Similar appearing nutritional supplement without glutamine.
40777269|NCT04466839|OTHER|Questionnaire and interview|The questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).
40777270|NCT03381326|PROCEDURE|blood and FFPE sample collection|blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection
40777271|NCT00626080|DRUG|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
40777272|NCT00626080|DRUG|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
40777273|NCT02362685|DEVICE|functional test|subjects perform a metabolic exercise testing
40982276|NCT00968994|DEVICE|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
40982277|NCT00249444|DRUG|Mirtazapine|Mirtazapine
40982278|NCT00249444|DRUG|Placebo|placebo
40982279|NCT01847157|DEVICE|tDCS|"Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).~During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current."
40982280|NCT01847157|DRUG|Epidermis anesthesia|"15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
40777274|NCT02362685|GENETIC|matching genotype with phenotype|
40777275|NCT02604511|DRUG|Ibrutinib|
40777276|NCT05892107|PROCEDURE|Toy Group|After meeting the children in the toy group, the toy will be given to the children to play 1 minute before the procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
40777277|NCT05892107|PROCEDURE|Mask group with cartoon characters|The nurse who will open the vascular access with the children in the cartoon character mask group will meet the child 1 minute before the procedure with a cartoon character mask on his/her face.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
40982281|NCT01847157|DRUG|sham anesthesia|"15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
40982282|NCT01847157|OTHER|Repeated passive movement|"Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes."
41303482|NCT06555926|OTHER|advices for relieving carpal tunnel syndrome|"The pregnant women will receive advices for 12 weeks as follows:~* Avoid heavy lifting.~* Avoid repetitive tasks.~* Sit on chairs with armrests and elevate affected hand on the armrest~* Avoid sleeping on the side of the affected hand.~* Keep the wrist in a neutral (straight) position.~* Avoid positions of full flexion and extension.~* Reduce general swelling by:~  * eating less salty food .~ * elevating legs when sitting .~ * wearing compression garments.~* Apply cold water over the wrist."
40982283|NCT01847157|DEVICE|sham tDCS|The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
41303483|NCT00127062|OTHER|Oxford street|2 h walk around Oxford street
41462377|NCT02926053|PROCEDURE|Surgical removal of tumor tissue for T cell production|Surgical removal of \> 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
41143104|NCT04716517|OTHER|Alkasite bioactive restorative material.|"Alkasite restorative is a category of filling material, like compomer, and is essentially a subgroup~of the composite resin. Cention N is a urethane dimethacrylate (UDMA)-based, self-curing powder/liquid restorative with optional additional light curing. The liquid comprises of dimethacrylates and initiators, while the powder contains various glass fillers, initiators, and pigments. It is radio opaque and contains alkaline glass fillers capable of releasing fluoride, calcium, and hydroxide ions. Due to the sole use of cross-linking methacrylate monomers in combination with a stable, efficient self-cure initiator, Cention N displays a high polymer network density and degree of polymerization over the complete depth of the restoration."
41303484|NCT00127062|OTHER|Hyde park|2 h walk around Hyde park
41303485|NCT05473624|DRUG|HRS-1167|Participants will receive HRS-1167.
41303486|NCT03455478|DEVICE|spectacles|dispending spectacles for uncorrected refractive error
41462378|NCT02926053|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
41462379|NCT02926053|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
41462380|NCT02926053|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
41462381|NCT02926053|DRUG|Interleukin-2|Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
41462382|NCT01097551|DRUG|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
40982284|NCT03978429|OTHER|Community-based Pre-eclampsia/Eclampsia Detection and Management|Three Community Health Workers (CHWs) per health facility (cluster) will be equipped with android smartphones and blood pressure monitors. The CHWs will visit participant's home once per month until 6 weeks post-partum and complete a Case Report Form for signs and symptoms of pre-eclampsia and blood pressure. CHWs, Antenatal Care Nurses (ANC) at the woman's health facility and study coordinator will receive SMS message if the algorithm on our platform (informed by the Tanzanian Standard Treatment Guidelines (TSTG) deems she is at risk for pre-eclampsia. This message will indicate that the woman needs to be referred to her health facility if: participant has high blood pressure, a significant intrapatient rise in blood pressure or a combination of factors according to an algorithm. Woman's condition will be assessed and ANC will decide on the management, including rest at home with CHW monitoring. Women found to be at risk for pre-eclampsia will be visited twice monthly.
40982285|NCT03978429|OTHER|Strengthened Referral Network from Community to Referral hospital levels|ANC nurses and CHWs will play complementary roles in performing activities to meet key indicators and facilitate referrals. They will deliver a plan using the Pre-eclampsia application tool on their smart phone and then they can refer the pregnant woman for enrollment for facility care and track them as per key indicators. The key innovation is that the mHealth platform can detect increases in BP within each patient, and this ability to detect is brought down to the community level through CHWs. This will allow for earlier detection of PE as singular BPs. Nurses will receive protocolized instructions and education regarding when to refer a woman to a higher-level facility for further management. The program consists of SMS component delivered to provide information about participant's condition to relevant members of the referral pathway to enhance referrals and facilitate community level follow up.
40777278|NCT05892107|PROCEDURE|Control group|In the control group, the nurse who will open the vascular access will meet the child 1 minute before the procedure with a white mask on her/his face. Children in the control group will be subjected to routine procedures before blood collection.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
40777279|NCT00629928|DRUG|Esomeprazole|20mg oral capsule daily
40982286|NCT06120920|OTHER|Assigned Interventions|Conventional physical therapy consists of hot pack application and transcutaneous electric stimulation (TENS) and routine knee strengthening exercises in addition with core stability exercises in three sessions per week for 4 weeks. Core stability exercises include bent knee hollow hold, bridging, supine toe tap and knee strengthening exercises include knee flexion strengthening exercises and knee extension isometric exercises.
40982287|NCT06120920|OTHER|Conventional Physical Therapy and Routine Knee Exercises with Hip Strengthening Exercises.|Conventional physical therapy consists of hot pack application, Tens and routine knee exercise program same as group A and in addition with hip strengthening exercises. Hip strengthening exercises include hip flexion and extension strengthening exercises and hip internal rotation and external rotation and hip adduction and abduction strengthening exercises.C
40982288|NCT06404606|COMBINATION_PRODUCT|Black cumin and turmeric with Quantum Acoustic Waves (QAW)|Black cumin and turmeric are known to be helpful in reduction of inflammation of human body so it will be used in combination with Quantum Acoustic Waves (QAW) to determine effects on initial degenerative changes in osteoarthritis.
41143105|NCT04716517|OTHER|Resin Modified Glass Ionomer|The resin-modified glass ionomer materials are hybrid materials of traditional glass ionomer cement with a small addition of light-curing resin, and hence exhibit properties intermediate to the two, with some characteristics superior to conventional glass ionomer materials
40777280|NCT00629928|DRUG|Esomeprazole|40mg oral capsule daily
41462383|NCT01097551|DRUG|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
41462384|NCT01097551|DRUG|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
40982289|NCT01265732|DRUG|PF-04191834|single dose, 100mg, dispersion
41462385|NCT01097551|DEVICE|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
40777281|NCT00629928|DRUG|Placebo|
40777282|NCT00002193|DRUG|Amprenavir|
40982290|NCT01265732|DRUG|PF-04191834|single dose, 100mg, suspension
40982291|NCT01265732|DRUG|PF-04191834|single dose, 300mg, suspension
41143106|NCT02205255|DRUG|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
41143107|NCT02205255|DRUG|Placebo|
41143108|NCT00355784|OTHER|overfeeding|overfeeding 2000kcals/day above energy requirements for 14d
41462386|NCT02697617|DRUG|Pioglitazone|Pioglitazone
41462387|NCT02697617|DRUG|Placebo|Placebo
40777283|NCT04570384|DRUG|L-Citrulline|L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.
40982292|NCT04823039|OTHER|Blood sample taken|For patients with sepsis who require vaccination during hospitalization, we will analyze the immunogenicity of pneumococcal conjugate vaccine (PCV13) by taking blood samples
40982293|NCT03350633|DRUG|Tocilizumab Injection|Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.
40982294|NCT03350633|DRUG|Azathioprine|Azathioprine will be orally given at a dose of 2-3 mg/kg/d
40982295|NCT06220422|PROCEDURE|Standard Department procedure for managing direct-acting oral anticoagulants|Standard Department procedure for managing direct-acting oral anticoagulants (NACO \< 50 ng/mL) in the management of fractures before September 2021
40982296|NCT06220422|PROCEDURE|New Department procedure for managing direct-acting oral anticoagulants|New Department procedure for managing direct-acting oral anticoagulants (NACO \< 100 ng/mL) in the management of fractures after September 2021
40982297|NCT01471106|DRUG|Dasatinib|"Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day."
41303487|NCT01687738|OTHER|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
40982298|NCT03781609|BEHAVIORAL|Roller system group (RG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions on the roller system per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
41303488|NCT01687738|OTHER|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
41303489|NCT02738437|DEVICE|Kryptonite-bone cement|
41143109|NCT00355784|DRUG|growth hormone treatment|growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
41462388|NCT03646409|OTHER|Venous thromboembolic event, arterial thromboembolic event, bleeding events|Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
40777284|NCT04570384|DRUG|Placebo|Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
40777285|NCT02520778|DRUG|Navitoclax|Given PO
40777286|NCT02520778|DRUG|Osimertinib|Given PO
41143110|NCT04727099|DEVICE|PicoWay Laser System|The PicoWay® laser system is an alexandrite laser pumped, solid-state Neodymium:Yttruium Aluminum Garnet (Nd:YAG) laser emitting energy at user selectable wavelengths of 1064 nm, 532 nm, 785 nm or 730 nm, designed for the treatment of tattoo, benign pigmented lesions, acne scars, and wrinkles.
41303490|NCT04586894|DIAGNOSTIC_TEST|Cardiac MRI|Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy
41303491|NCT04586894|DEVICE|Smart cloth|A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.
41303492|NCT04586894|OTHER|Biobanking|Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.
41143111|NCT05702892|DIAGNOSTIC_TEST|ELISA|ELISA(enzyme-linked immunosorbent assay)
41143112|NCT04733573|DEVICE|Two different occlusal splints|Two different occlusal splints will be used for bruxism management, PPT would be evaluated twice - before and after 30 days of splint therapy using pressure algometer (FPX25, Wagner Instruments, US)
41143113|NCT01352026|DRUG|Metformin|
41143114|NCT04970472|BIOLOGICAL|collection of blood, urines, stool and tumor samples|blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.
41143115|NCT01662232|DIETARY_SUPPLEMENT|Green tea beverage|
40777287|NCT01832727|DRUG|Oprozomib|Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib. Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib. Both formulations were administered in a single dose on dosing days. The tablet formulation required multiple tablets to reach each dose on dosing days.
40982299|NCT03781609|BEHAVIORAL|Overground group (OG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions overground per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
40982300|NCT03781609|BEHAVIORAL|Placebo - Wheelchair skills group (WSG)|They will receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented.
40982301|NCT03621488|OTHER|Efficacy of Behavioral Self-Activation with virtual reality|Efficacy of Behavioral Self-Activation with virtual reality
40982302|NCT03621488|OTHER|Efficacy of Behavioral Self-Activation without virtual reality|Efficacy of Behavioral Self-Activation without virtual reality
40982303|NCT05713045|DIETARY_SUPPLEMENT|Konakion|Comparing 4 different regimen of Vitamin K administration in newborn
40982304|NCT01750242|DEVICE|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
40982305|NCT00939328|BIOLOGICAL|rituximab|
40982306|NCT00939328|DRUG|bendamustine hydrochloride|
40982307|NCT06064890|PROCEDURE|Intrathalamic AAV.PGRN administration|One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain
40982308|NCT06064890|GENETIC|Intrathalamic AVB-101|AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.
40982309|NCT00531050|DRUG|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
40982310|NCT00531050|DRUG|Placebo|Single dose indacaterol matching placebo via Concept 1 device
40982311|NCT00531050|DRUG|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
40982312|NCT01216527|PROCEDURE|Neo-adjuvant Chemoradiotherapy followed by Surgery|"1. Radiotherapy combined with concomitant chemotherapy:~   Radiotherapy Program:External radiation with a total dose of 40.0Gy is given in 20 fractions of 2.0Gy,5 fractions a week.~   neo-chemotherapy program: Vinorelbine 25mg/m2, IV (in the vein) on day 1 and day 8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle;or Cisplatin 25mg/m2,IV DRIP on day 1 to day 4 of each 21 day cycle.~   Number of cycles:two~2. surgery:Mckeown Modification Surgery and total two-field lymphadenectomy"
40982313|NCT01216527|PROCEDURE|surgery|two field lymphadenectomy
40982314|NCT03404557|OTHER|Proteomic analysis|Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
40982315|NCT05125978|DRUG|Canadá|Canadá association 1 tablet twice a day
40982316|NCT05125978|OTHER|Canadá placebo|Placebo of Canadá association 1 tablet twice a day
40982317|NCT05125978|DRUG|Dipyrone|Dipyrone 1 tablet twice a day
40982318|NCT05125978|OTHER|Dipyrone placebo|Placebo of dipyrone 1 tablet twice a day
41143116|NCT01662232|DIETARY_SUPPLEMENT|Green tea extract|
40982319|NCT05125978|DRUG|Tramadol hydrochloride|Tramadol 1 coated tablet twice a day
41143117|NCT01662232|DIETARY_SUPPLEMENT|EGCG|
41143118|NCT01662232|OTHER|Placebo|
41143119|NCT03761199|OTHER|whole body cryostimulation|In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.
41143120|NCT03898999|OTHER|Overall status|An assessment is made of the participants measuring both the joint range of the ankle and the balance and risk of falls.
41143121|NCT00211926|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single dose of vaccine containing 100 mcg of each serotype conjugate
40777288|NCT01832727|DRUG|Dexamethasone|Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
40982320|NCT05125978|OTHER|Tramadol hydrochloride placebo|Placebo of tramadol 1 coated tablet twice a day
40982321|NCT02454881|DRUG|Dexmedetomidine|
40982322|NCT02454881|DRUG|Oxycodone|
40982323|NCT06336915|BEHAVIORAL|Physician-Nurse Dyad Rounding|Collaborative Approach to Improve Unit-Level Metrics
40982324|NCT03441854|DEVICE|HFNC group|Application of HFNC oxygen delivery after extubation.
40982325|NCT01072812|DRUG|Posiphen® tartrate capsules|Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
40982326|NCT01685931|DRUG|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
40982327|NCT00909389|DRUG|Vytorin (R) (Ezetimibe + Simvastatin)|Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
40982328|NCT00756639|RADIATION|Prophylactic Cranial Irradiation (PCI)|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks.
40982329|NCT00756639|OTHER|Brain X-ray|On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
41462389|NCT05647291|DEVICE|extracorporeal Shock wave therapy|Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week, for two weeks, adding up to a total of 4 sessions.
40982330|NCT03303079|DRUG|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
40982331|NCT03303079|DRUG|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
40982332|NCT03303079|DRUG|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
40982333|NCT04464122|DRUG|Somatostatin analog; chemotherapy|According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
41462390|NCT05647291|DRUG|Corticosteroid injection|40mg/1ml methylprednisolone, two sessions once a week
40982334|NCT00168688|DIETARY_SUPPLEMENT|multi micronutrient supplement|
40982335|NCT00168688|DIETARY_SUPPLEMENT|MN1|Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg
40982336|NCT00168688|DIETARY_SUPPLEMENT|MN2|Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
41462391|NCT05647291|DEVICE|Kinesiotaping|The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends. Once a week, three times
41462392|NCT05857345|OTHER|Collection of breastmilk|Collection of breastmilk and other information about the participant
41462393|NCT00623558|DRUG|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
40982337|NCT00456131|BEHAVIORAL|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
40982338|NCT02733367|DRUG|Infacort®|Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
41143122|NCT00211926|BIOLOGICAL|placebo|single dose of placebo
41143123|NCT04814108|DRUG|ZN-c3|ZN-c3 is an investigational drug.
41143124|NCT04028518|DRUG|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time."
41143125|NCT04028518|DRUG|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time."
41143126|NCT04028518|DRUG|Alteplase for Injection|"Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h."
41143127|NCT02410109|BEHAVIORAL|SCRIPT integrated model|Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
41143128|NCT05123755|DRUG|AV-001 Injection|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
41143129|NCT05123755|DRUG|AV-001 Placebo Injection|D-PBS
41143130|NCT04704557|DEVICE|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
41143131|NCT06462248|DRUG|CUCART19|anti-CD19 chimeric antigen receptor modified T-cell (CAR-T)
41143132|NCT05661240|DEVICE|Tumor treating fields（EFE-P100）|Device: Tumor treating fields（EFE-P100） Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.
41143133|NCT05661240|DRUG|Docetaxel injection|Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.
41143134|NCT01420198|BEHAVIORAL|Lifestyle intervention|Increased physical activity and improved food habits
40982339|NCT00055263|DRUG|DN-101|
41143135|NCT04070937|DIAGNOSTIC_TEST|vestibular test 1|videonystagmography
41143136|NCT04070937|DIAGNOSTIC_TEST|vestibular test 2|video head impulse test
41143137|NCT04070937|DIAGNOSTIC_TEST|vestibular evoked myogenic potentials|vestibular evoked myogenic potentials to measure the function of otolith organs
41303493|NCT05087602|DRUG|Toripalimab and Anlotinib|Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
40777289|NCT00516282|DRUG|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
40777290|NCT00516282|DRUG|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
41143138|NCT04070937|DIAGNOSTIC_TEST|audiometry|tonal liminar audiometric thresholds
41143139|NCT04070937|DIAGNOSTIC_TEST|CT and MR imaging of temporal bone|Ct and MR imaging of temporal bone
41143140|NCT04070937|GENETIC|p.P51S mutation|analysis of presence of p.P51S mutation in COCH
41303494|NCT02583945|PROCEDURE|kidney treatment bundle (KDIGO)|Application of the measures of the kidney treatment bundle.
41143141|NCT03746015|BIOLOGICAL|TDV|TDV subcutaneous injection comprised of 1 molecularly characterized, attenuated dengue virus strain, and 3 chimeric dengue virus strains with potencies of not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) per dose of TDV-1, TDV-2, TDV-3, and TDV-4, respectively.
41303495|NCT01146067|DRUG|Rivastigmine|Rivastigmine capsules 1.5 mg
41303496|NCT02931695|OTHER|evaluation of QT interval duration|ECG to evaluation of QT interval duration
41462394|NCT00623558|DRUG|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
41462395|NCT00623558|DRUG|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
40982340|NCT05728307|DEVICE|neoGuard vital signs monitor|"The neoGuard device is a 4-in-1 wearable vital signs monitor developed by Neopenda, PBC (Chicago, Illinois). The system is designed to continuously measure temperature, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SpO2). It contains two non-invasive sensors: an optical reflectance pulse oximeter and a digital temperature sensor. These sensors measure signals from the surface of the patient's skin, and algorithms within the device calculate the pulse rate, respiratory rate, SpO2 and temperature.~The device is made of medical grade polyetherimide plastic and can be worn on the forehead through an adjustable band. The PR, RR, temperature and SpO2 data are collected, recorded and transmitted via Bluetooth Low Energy (BLE) to a tablet which can be placed within a range of 20-30 meter distance. The neoGuard technology has received CE mark certification and is also registered with the Kenya Pharmacy and Poisons Board (KPPB)."
40982341|NCT02625155|OTHER|Urine diagnostic testing as SOC, drug regimen changes per SOC|
40982342|NCT02625155|OTHER|Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results|
40982343|NCT00309842|BIOLOGICAL|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days.
40982344|NCT00309842|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW \> 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
40982345|NCT00309842|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \> 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
40982346|NCT00309842|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
41143142|NCT03949478|DRUG|Ibuprofen|Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
41462396|NCT05523960|PROCEDURE|No MBP|No mechanical bowel preparation before operation
40982347|NCT00309842|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).~Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day."
40982348|NCT00309842|PROCEDURE|umbilical cord blood transplantation|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
41143143|NCT03949478|DRUG|Nifedipine|Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
41143144|NCT03949478|DRUG|Placebo|Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.
41143145|NCT01336842|DRUG|Panobinostat, Cisplatin, Pemetrexed|"Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1."
41143146|NCT01049698|BEHAVIORAL|Resistance Training|3 d/wk resistance training
41462397|NCT01960608|OTHER|24_hours_urine_sodium|
41462398|NCT02630316|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
41462399|NCT02630316|DRUG|Placebo|Placebo administered four times daily
41462400|NCT00564343|OTHER|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
41462401|NCT01896492|DRUG|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
40777291|NCT04565730|OTHER|Grup I= General anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
40777292|NCT04565730|OTHER|Grup II= Spinal anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
40777293|NCT01862003|DRUG|AZD8931|160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
40777294|NCT01862003|DRUG|Irinotecan|180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
40777295|NCT01862003|DRUG|Folinic Acid|350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
40777296|NCT01862003|DRUG|Fluorouracil|400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
40777297|NCT01862003|DRUG|Fluorouracil|2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
40777298|NCT00930124|PROCEDURE|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
40777299|NCT00930124|PROCEDURE|Distraction osteogenesis|
40777300|NCT04242680|DEVICE|Brainstim DLPFC|"The active tRNS will be delivered to bilateral DLPFC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right DLPFC, F3 and F4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75 milliampere (mA) (100-500 Hz), the duration of stimulation will be 20 min."
40777301|NCT04242680|DEVICE|Brainstim PPC|"The active tRNS will be delivered to bilateral PPC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right PPC, P3 and P4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75mA (100-500 Hz), the duration of stimulation will be 20 min."
40777302|NCT04242680|DEVICE|Brainstim Sham|The same electrode placement will be used as in the stimulation conditions (Brainstim DLPFC or Brainstim PPC), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held five consecutive days for two weeks for a total of ten days.
40777303|NCT04242680|BEHAVIORAL|Cognitive Training|"A cognitive training (Vektor; Nemmi et al., 2016) will be adiministered concomitantly to Brainstim DLPFC, Brainstim PPC, Brainstim Sham for 20 min.~The training consisted of math exercises (number line, calculations) and math-related exercises (visuo-spatial working memory, mental rotation)."
40777304|NCT05963126|OTHER|No intervention.|No intervention.
40777305|NCT04713189|DRUG|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
40777306|NCT04713189|DRUG|Placebo|Participants in the stage Ⅰ were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence. I
40777307|NCT05294302|BEHAVIORAL|eSCCIP/eSCCIP-SP|eSCCIP/eSCCIP-SP is a psychosocial eHealth intervention for PCCC. It consists of four self-guided, web-based modules (including an introductory module) and three telehealth sessions with a study interventionist.
40777308|NCT05294302|BEHAVIORAL|Coping Space|Coping Space is a psychosocial informational website for PCCC.
41303497|NCT02931695|OTHER|circulating sex hormones levels sample|Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
40777309|NCT03944395|OTHER|Assisted Partner Notification Services|Three options for partner Notification services; contract referral, provider referral and dual referral
40777310|NCT00601341|OTHER|lumbosacral joint manipulation|lumbosacral joint manipulation
40777311|NCT00601341|OTHER|lumbar passive range of motion|lumbar passive range of motion
40777312|NCT00601341|OTHER|No active intervention|Lie on exam table for 3 minutes
40777313|NCT03532360|OTHER|Oral immunotherapy|Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic
40777314|NCT00360139|DEVICE|Sculptra Injection|
40777315|NCT03235050|DRUG|MEDI0382 low dose|Pharmaceutical form: solution Route of administration: subcutaneous
40777316|NCT03235050|DRUG|MEDI0382 mid dose|Pharmaceutical form: solution Route of administration: subcutaneous
40777317|NCT03235050|DRUG|MEDI0382 high dose|Pharmaceutical form: solution Route of administration: subcutaneous
40777318|NCT03235050|DRUG|Placebo|Pharmaceutical form: solution Route of administration: subcutaneous
40777319|NCT03235050|DRUG|Liraglutide|Pharmaceutical form: solution Route of administration: subcutaneous
41303498|NCT03342469|OTHER|Artificial Food Coloring|225mg mixed powdered Artificial Food Coloring (AFC)
41303499|NCT03342469|OTHER|Placebo|Placebo chocolate cookies
40777320|NCT03416816|DRUG|DSP-0337|DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.
40777321|NCT06461780|OTHER|Line-based questionnaire follow-up|The participant will use LINE group to report irAE severity, distress, financial toxicity and change trajectory of quality of life in one-year follow-up. If the severity grade of irAE reach the threshold and require referral, an alarm will appear to notify the research team to conduct and transfer to a clinical specialitst, or refer to the emergency room for treatment. Additionally, the Line group will also provide clinical relevant immunotherapy health education information currently and routinely used in study site. Patients can view it according to their interests, but the APP will not actively promote it.
40777322|NCT03093714|DRUG|FDL169|CFTR corrector
40777323|NCT03093714|DRUG|Placebo|Placebo for FDL169
40777324|NCT01990690|DRUG|anti oxidant omega 3|"Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks."
40777325|NCT03626766|BEHAVIORAL|Photo in Verification Alert|Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
40777326|NCT03626766|BEHAVIORAL|Photo in Banner|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.
40777327|NCT03626766|BEHAVIORAL|Photo in Banner and Verification Alert|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
40777328|NCT00842621|PROCEDURE|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
40777329|NCT00842621|OTHER|Laboratory Studies|"Blood for:~Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,~Serum for:~Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha~Plasma for:~Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1~Urine for:~Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin"
40777330|NCT03836404|DEVICE|Iliac crest reconstruction surgery|When autologous bone graft is needed for the treatment of non-unions or bone defects, is harvested from the pelvic iliac crest. Harvested tricortical graft blocks are used to facilitate fusion of joints (ie pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries and to fill in metaphyseal bone voids. The GreenBone device, with its inherent physical and biomimic properties, possesses similar structural properties to bone, thus, being the ideal material to be used for the treatment of the bone defect (3- 4cm) induced from the harvested tricortical iliac crest, restoring therefore the pelvic anatomy and minimising the risk of chronic pain, haematoma formation and herniation of the abdominal contents.
40777331|NCT03146260|PROCEDURE|Conventional TESE|usual procedure for sperm extraction
40777332|NCT03146260|PROCEDURE|Microdissection TESE|Procedure of extraction is performed under the operating microscope
40777333|NCT00344981|DRUG|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
40982349|NCT00309842|RADIATION|total-body irradiation|The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
41303500|NCT06425783|PROCEDURE|Warmed Blood Transfusion|"The erythrocyte suspension will be heated between 34-36 C⁰, which is the determined physiological temperature.~Before giving it to the baby, 2 ml of blood will be taken through a triple tap and its hematocrit and K value (blood gas) will be checked. It will be given to the baby after the temperature is checked with a body fluid thermometer and determined to be within the appropriate range and if hemolysis is not observed.~At the end of the standard transfusion period of 3 hours, all babies will be routinely checked for blood gases, HTC and K."
40982350|NCT05029674|DEVICE|Whoop|Wear WHOOP Strap, complete surveys
41303501|NCT04438889|OTHER|Non-interventional|Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.
41462402|NCT01425840|DRUG|Lidocaine|100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
41462403|NCT04129255|DRUG|Octreotide Acetate|administration every 28 days
40777334|NCT00344981|DRUG|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches \>400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
40777335|NCT01147302|BIOLOGICAL|Placebo|
40777336|NCT01147302|BIOLOGICAL|C1 Esterase Inhibitor (Human)|
40777337|NCT00422487|DRUG|MBX-2044|MBX-2044 1.5 mg one capsule daily for 14 days
41462404|NCT04661202|OTHER|multimodal exercise training|"A supervised moderate-intensity exercise training session, which will include aerobic exercise with a stationary exercise bike, resistance exercise using dumbbell, theraband band, or gym ball for each major muscle groups and core muscles (including pelvic floor muscle (PFM) training with biofeedback), and stretching exercise, twice a week for 8 weeks. All exercises will be individualized based on participant's heart rate reserve and Rate of Perceived Exertion (RPE). An oximeter and a sphygmomanometer will be used to monitor the heart rate, oxygen saturation and blood pressure of the participants to ensure safety.~A home exercise program will include a walking exercise for 30 minutes per day and a PFM training with the aim of completing 1\~3 sets of 8\~12 submaximal contraction of PFM by holding 6\~10 seconds with 12\~20 seconds of rest between each contraction, and it will end with 3 maximal PFM contractions by holding 1\~3 seconds 3\~6 seconds of rest between each contraction."
41462405|NCT00179933|BEHAVIORAL|Newborn Individualized Assessment Program|
41462406|NCT04119557|DRUG|Placebo|Administered SC
41462407|NCT04119557|DRUG|LY3471851|Administered SC
41462408|NCT01386125|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
41462409|NCT01386125|DRUG|Placebo for MFNS|Two sprays in each nostril BID for up to 16 weeks
41462410|NCT01781117|PROCEDURE|Holmium Laser Enucleation of the Prostate (HoLEP)|Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
40777338|NCT00422487|DRUG|MBX-2044|MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
40982351|NCT06268093|DRUG|Thalidomide|Thalidomide 50 - 200 mg once at nightime
40982352|NCT04814433|DRUG|Tranexamic acid|"FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.~Total dose of 500 mg (20 mL) total will be given."
41143147|NCT01049698|BEHAVIORAL|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
41143148|NCT02013804|DRUG|MEDI0680 (AMP-514)|Study has planned dose escalation cohorts
41143149|NCT00996164|DRUG|Flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
40982353|NCT04814433|DRUG|Aminocaproic acid|"FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.~Total of 1000 mg total will be given."
40982354|NCT04814433|DRUG|Recombinant Human Thrombin|"Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.~Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.~For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given"
40982355|NCT04814433|DRUG|Lidocaine Hydrochloride with Epinephrine|"Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.~Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given"
40982356|NCT04814433|DRUG|Bupivacaine Hydrochloride with Epinephrine|"Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.~Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given"
40982357|NCT06120231|DIAGNOSTIC_TEST|Pulse width modulation|Will be stimulating the pedicle screws utilizing three different pulse-width settings, 0.4 milliseconds, 0.2 milliseconds, and 0.05 milliseconds.
40982358|NCT04258345|OTHER|ASB Feeding Study|Participants will undergo a washout period and then scheduled for blood draw after which ASB feeding period will begin followed by a second blood draw.
40982359|NCT05047328|BIOLOGICAL|inolimomab|"1 or 2 Induction Phases at 0.3 mg/kg/day for adults or 0.4 mg/kd/day for children over 8 consecutive days If no complete response (CR) occurs after 8 days, a second induction phase is conducted until day 16 (even if CR is obtained before completion of the second induction phase).~Maintenance Phase: 0.4 mg/kg administered 3 times a week until Day 28 In case of a CR at day 9, the maintenance phase will start after day 9 and will be sustained until day 28.~In case of a CR, partial response (PR) or mixed response (MR) at day 17, the maintenance phase will start after day 17 and will be sustained until day 28.~Total duration of treatment is 28 ±2 days."
40982360|NCT03953573|OTHER|Survey|Survey completed at 1 day, 8 days 1 or 3 months post delivery
40982361|NCT05933512|BIOLOGICAL|SCTV01E-2|intramuscular injection
40982362|NCT05933512|BIOLOGICAL|SCTV01E|intramuscular injection
41143150|NCT00996164|DRUG|Placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
41143151|NCT06593210|BIOLOGICAL|Adjuvant, non-live RSV vaccine|One dose of arexvy vaccine to transplant recipients.
41143152|NCT04890626|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]|Main randomization
41143153|NCT04890626|DRUG|Baricitinib + dexamethasone|Rescue randomization
41303502|NCT01876732|DRUG|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
41303503|NCT00819624|OTHER|Interactive Voice Response System (IVRS)|Telephone based system
41143154|NCT04890626|DRUG|Dexamethasone|Rescue randomization
41303504|NCT00819624|OTHER|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
41303505|NCT02541838|OTHER|Muscle power|
41303506|NCT02541838|OTHER|balance perturbation|
41303507|NCT02541838|OTHER|aerobic exercise|
41303508|NCT05475821|DRUG|ABBV-990|Oral Tablet
41303509|NCT05475821|DRUG|Placebo for ABBV-990|Oral Tablet
41303510|NCT00021697|DRUG|AVP-923|
41303511|NCT06471465|DRUG|Bevacizumab|Drug: bevacizumab IV
41303512|NCT06471465|DRUG|Placebo|Drug: placebo IV
41303513|NCT06471465|DRUG|Prednisolone|Drug: corticosteroids IV
41303514|NCT03583762|DIAGNOSTIC_TEST|Mass spectrometry|Molecular diagnostic test for bacterial identification from bacterial colony
41303515|NCT03583762|DIAGNOSTIC_TEST|Microarray assay|Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
41462411|NCT01781117|DEVICE|Holmium laser enucleation system and morcellator|Holmium laser enucleation and morcellation
40777339|NCT00422487|DRUG|MBX-2044|MBX-2044 15 mg one capsule daily for 14 days
41303516|NCT05437224|DRUG|Ambrisentan|eligible subjects received 5 mg ambrisentan orally once daily for a 12-week primary evaluation period. Subjects then proceeded to a 12-week dose adjustment period during which dose titration to 10 mg was allowed.
41462412|NCT04537520|DEVICE|Kerecis Omega3 Wound|Treatment of the wound with Kerecis Omega3 Wounds matrices
41462413|NCT03365791|BIOLOGICAL|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
41462414|NCT03365791|BIOLOGICAL|LAG525|LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
41462415|NCT02833636|PROCEDURE|ACEF score|
41462416|NCT00249990|DRUG|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
40777340|NCT00422487|DRUG|MBX-2044|MBX-2044 30 mg two 15 mg capsules daily for 14 days
41462417|NCT00748137|DEVICE|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
40777341|NCT00422487|DRUG|MBX-2044|MBX-2044 60 mg one capsule daily for 14 days
40777342|NCT00422487|DRUG|MBX-2044|MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
40777343|NCT00422487|DRUG|Placebo for MBX-2044|Placebo Intervention
40777344|NCT00415090|DRUG|Nevirapine|Switch one of ARV drugs to Nevirapine
40777345|NCT02599116|OTHER|Bio-specimen collection|Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections
40777346|NCT02599116|OTHER|Questionnaire|Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
40777347|NCT02628535|BIOLOGICAL|MGD009|B7-H3 x CD3 DART protein
40777348|NCT01935453|BIOLOGICAL|Recombinant hGM-CSF Herpes Simplex Virus Injection|
40777349|NCT06467409|DRUG|Placebo|patient-controlled analgesia(PCA) administration
40777350|NCT06467409|DRUG|morphine hydrochloride injection|patient-controlled analgesia(PCA) administration
40777351|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
40777352|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
40777353|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
40777354|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
40777355|NCT00094276|BEHAVIORAL|Facilitated Asthma Communication Intervention (FACI)|A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
40777356|NCT00094276|BEHAVIORAL|Breathmobile intervention|A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
40982363|NCT03351179|COMBINATION_PRODUCT|clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes|The differences of data(clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were conducted. The differences between two groups were compared (clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were compared, and then found the risk factors. Following,the incidence of clinical outcomes and mortality were compared. Then, univariate logistic regression and multivariate logistic regression analysis adjusted for significant risk factors were performed to find out the independent predictive factors. Finally, the ROC was constructed, and the area was evaluated to assess the predicted probability of regression model.
40982364|NCT05874661|OTHER|External Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an external focus being thinking about a target or outcome in the environment.
40982365|NCT05874661|OTHER|Internal Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an internal focus being thinking about what one's body is doing.
41303517|NCT02007785|BEHAVIORAL|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
41462418|NCT00748137|OTHER|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
41462419|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
41462420|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
40777357|NCT01708044|DRUG|Pramlintide acetate|
40777358|NCT01708044|OTHER|Placebo|Placebo Comparator
40777359|NCT05628571|COMBINATION_PRODUCT|Zinc toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing amine-based zinc lactate (0.1%) and fluoride (1400 ppm F).
40777360|NCT05628571|COMBINATION_PRODUCT|Fluoride Toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing fluoride (1450 ppm F).
40777361|NCT02308514|DEVICE|cryostimulation|pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.
40777362|NCT02308514|OTHER|conservative care|manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
40777363|NCT05231863|DRUG|TKIs|tyrosine kinase inhibitors based therapy
40777364|NCT03134040|BEHAVIORAL|Incentives (Rebate)|
40777365|NCT03134040|BEHAVIORAL|Incentives (Donation)|
40777366|NCT03134040|BEHAVIORAL|Feedback|
40777367|NCT02102009|DIETARY_SUPPLEMENT|Complete enteral formula|"Product: Complete nutritional formula in powder enriched with key nutrients to be administered orally (200 ml of water per 57 g product).~Time of intervention: 3 months."
40777368|NCT02102009|OTHER|Dietary Advise|Patients will receive the usual dietary advise in these patients according hospital clinical practice .
40777369|NCT04635852|DRUG|Fentanyl|
40777370|NCT04635852|DRUG|Immediate release morphine|
40777371|NCT04676100|OTHER|Cardiac rehabilitation|"A CR program is defined as one that offers initial assessment, structured exercise (can be supervised or unsupervised) and at least one other strategy to control risk factors. The registry pertains to phase II CR.~Quality of care and patient outcomes are benchmarked with other countries anonymously, through 2 registry dashboards (real-time). The dashboards will also show change over time in 6-month increments; Sites will be encouraged to continue to provide data on new patients until all indicators show quality as possible.~Sites will be supported in quality improvement by the ICRR user sub-committee. High-performing programs will be recognized on ICRR's website and ICCPR's social media accounts. This mechanism may be used in future to support program accreditation."
40777372|NCT04902612|DEVICE|HM242-Solution|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
40777373|NCT04902612|DEVICE|Saline|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
40777374|NCT05157360|DRUG|HAT|hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT
40777375|NCT05157360|DRUG|Placebo|normal saline solution
40777376|NCT00410579|OTHER|Telephone interview|Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
40777377|NCT05023161|BIOLOGICAL|Blood samples|Performed a 10 ml blood sample in each of the 200 patients included.
40777378|NCT04436744|DRUG|Giredestrant|During the window-of-opportunity phase (first 2 weeks) giredestrant will be taken orally once per day (QD) as a single agent. During the neoadjuvant treatment phase, giredestrant will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
40777379|NCT04436744|DRUG|Anastrozole|During the window-of-opportunity phase (first 2 weeks), anastrozole 1 mg will be taken orally QD as a single agent. During the neoadjuvant treatment phase, anastrozole 1 mg will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
40777380|NCT04436744|DRUG|Palbociclib|During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.
40777381|NCT04436744|PROCEDURE|Surgery|Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.
40777382|NCT01331590|DRUG|G-CSF|
40777383|NCT01331590|DRUG|Ifosfamide|
40777384|NCT01331590|DRUG|Etoposide|
40777385|NCT01331590|DRUG|Dexamethasone|
40777386|NCT01331590|DRUG|Mesna|
40777387|NCT06537869|BEHAVIORAL|iCBT for depression|iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-12 weeks. Contact via email or telephone every week (therapist/nurse)
40777388|NCT01659060|OTHER|Flavanol-rich dark chocolate|The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
40777389|NCT01659060|OTHER|Placebo Chocolate|Placebo intervention
40777390|NCT00164580|BEHAVIORAL|Community-Level Intervention|
40777391|NCT03904485|RADIATION|cardiac magnetic resonance(CMR) T2 mapping|T2 value before transplant，3 month and 6month after transplant
40777392|NCT00914576|DRUG|Vitamin and mineral supplement|1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
40777393|NCT00914576|DRUG|Vitamin and mineral supplement|1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
40777394|NCT00914576|DRUG|Placebo|2 capsules/day for 14 days
40777395|NCT00914576|DRUG|100% Oxygen|breathing of 100% O2 for 30 minutes on both study days
40777396|NCT00914576|DRUG|Escherichia coli Endotoxin|Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
40777397|NCT03051191|DIAGNOSTIC_TEST|micro RNA|micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
40777398|NCT03767868|OTHER|color change in nail polish|The determination of color change in nail polish will be based on differences in skin temperature before and after the block.
40777399|NCT05632393|DRUG|Daridorexant|Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
40777400|NCT05120492|PROCEDURE|bariatric surgery followed by total knee replacement|The only intervention is the randomization of the priority of the 2 procedures.
40777401|NCT02704208|BEHAVIORAL|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
40777402|NCT02704208|BEHAVIORAL|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
40777403|NCT00006167|DRUG|oxandrolone|
40777404|NCT00006167|BEHAVIORAL|Progressive Resistance Training|
41303518|NCT00916500|DRUG|CONCURRENT CHEMORADIATION (CISPLATIN)|Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
41303519|NCT03779425|OTHER|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
41303520|NCT05259553|OTHER|Blood samples|"Peripheral blood sampling will be performed at different time points of the study, for a total volume of 20-40 mL:~* Sampling before MM treatment,~* Sampling during MM treatment (at 3 months post-initiation if no autograft or before autograft),~* Only for Patients treated with Apixaban or Eliquis®, 2 additional samplings during MM treatment for pharmacokinetics analysis."
40777405|NCT05017558|DIAGNOSTIC_TEST|point of care|"HIV-1 infected women will benefit from a viral load measurement by POC (Cepheid GenXpert HIV-1 viral load) at the time of delivery.~Newborns will benefit :~1. Antiretroviral preventive treatment differentiated according to their risk of infection in accordance with national recommendations:~   * High risk (maternal VL ≥1000 cp/ml): AZT/NVP for 12 weeks.~  * Low risk (maternal VL \<1000 cp/ml): NVP for 6 weeks.~2. virological screening for HIV by qualitative POC (Cepheid GenXpert HIV-1 qual) from birth (for high-risk newborns) at 6 weeks, at 9 months and at any time in the event of clinical manifestations suggestive of HIV infection.~3. In the event of a positive HIV test, the child will initiate immediately AZT/3TC/LPV/r~4. support from volunteers to improve retention in care, promotion of exclusive breastfeeding and family nutritional support"
40777406|NCT01677988|DRUG|Neo-adjuvant Chemotherapy|"1. Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~2. Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~   1. Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~  2. Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation."
40982366|NCT02053467|OTHER|Champlain BASE eConsult Service|After undergoing registration, which includes orientation and brief training on the use of the service, physicians randomized to intervention arm will be able to submit patient-specific clinical questions to specialists through a secure, web-based application. Specialists are asked to respond within 7 days and, for each eConsult, are able to: (1) provide a recommendation, (2) request more information, or (3) recommend a face-to-face referral. The communication between PCPs and specialists is iterative and the discussion can occur back and forth until, ultimately, the PCP closes the case.
40982367|NCT03386942|DRUG|Farletuzumab Ecteribulin|Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
40982368|NCT03582020|DIETARY_SUPPLEMENT|menu plans|menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
40982369|NCT04416464|OTHER|COVID-19 Pneumonia|Pneumonia due to proven or suspected SARS-Cov-2 infection
40982370|NCT02049307|DRUG|Losartan 100mg daily|
41143155|NCT01532609|BEHAVIORAL|MMT CARE|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
41143156|NCT05074212|OTHER|Factorial Assignment|At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).
41303521|NCT05013905|DRUG|PRA023 IV|PRA023 administered at timepoints as directed by the protocol
41303522|NCT05013905|DEVICE|Companion diagnostic (CDx)|CDx+ or CDx-
41303523|NCT05974735|BEHAVIORAL|Wellness trail|"Setting up wellness trails based on four distinct themes:~* Food, Nutrition and Micronutrition~* Physical activity~* Sleep~* Stress and well-being"
41303524|NCT05946135|DRUG|Lansoprazole|taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks
40982371|NCT02049307|DRUG|Matching placebo|
40982372|NCT00357487|DEVICE|peroperative scintillating probe|
40982373|NCT00357487|DEVICE|operative gamma camera|
40982374|NCT05133947|OTHER|Non interventional|Non interventional
40982375|NCT00971854|PROCEDURE|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
41143157|NCT06602479|DRUG|MEDI0618|MEDI0618 per protocol
41143158|NCT06602479|DRUG|Placebo|Volume-matched placebo for all arms
41143159|NCT05224388|DRUG|Enoxaparin|Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen
41143160|NCT05224388|DRUG|Heparin|Use of heparin in either prophylactic dose regimen or therapeutic dose regimen
41143161|NCT05141409|DEVICE|Artificial Intelligence|Artificial Intelligence
41143162|NCT02693665|BEHAVIORAL|FAmily CEntered Advance Care Planning for Teens with Cancer|3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
41143163|NCT00138814|PROCEDURE|Radiotherapy (boost versus no boost)|
41143164|NCT02199444|DRUG|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
41143165|NCT02199444|DRUG|Placebo|
41303525|NCT05946135|DRUG|Fexuprazan Hydrochloride|taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks
41303526|NCT00087737|DRUG|DVS-233 SR|
41303527|NCT00087737|DRUG|Venlafaxine ER|
41303528|NCT01379534|DRUG|TKI258|
41303529|NCT00511524|DRUG|GW842166X|GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
41462421|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
40777407|NCT01677988|RADIATION|Chemoradiation|"1. Chemoradiation may be administered at selected approved CTN sites.~2. Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~   1. Unresectable → Off study. Subsequent treatment per patient's primary MD.~  2. Resectable → Continue to Registration #3 for Surgical Resection"
40777408|NCT01677988|PROCEDURE|Surgical Resection|"1. Meets criteria for resectable\* →pancreaticoduodenectomy (POD)~2. At time of resection, snap frozen tumor specimen sent for correlative biomarker studies"
40777409|NCT01965847|BEHAVIORAL|Medication therapy management|
40777410|NCT06547320|BEHAVIORAL|Eat Less Intervention|A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the amount of food eaten.
40777411|NCT06547320|BEHAVIORAL|Eat Slower Intervention|A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the rate of eating.
40777412|NCT05595109|DRUG|Silymarin|"Silymarin administration prevent the neuro-degeneration through inhibiting the activation of microglia, silymarin attenuates the activation of glial cell activation in cellular models possibly through inhibition of inducible nitric oxide synthase (iNOS) production, also reported to protect both microglia and astroglia from oxidative insults induced by peroxide in ex vivo system .~It also significantly reduces doxorubicin-pro-oxidative activity and decreases histological changes in liver and heart tissue . The hepato-protective and cardio-protective effects of silymarin may be attributed to its antioxidant capacity, its ability to prevent lipid peroxidation and its ability to increase glutathione concentration.~silymarin was reported to improve cognitive impairment in mice."
40777413|NCT05595109|DRUG|Placebo|which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily.
40777414|NCT05059275|PROCEDURE|modified ostium obstruction surgery|An ostium at the end of the site where the nerve root enters the dural sac, from which CSF could flow continuously along the subarachnoid space, was identified An appropriate amount of autologous soft adipose tissue was removed under the skin of the incision or deep in the upper part of the buttock (Iliac spine incision, for less subcutaneous fat patients). It was then trimmed to resemble a gourd or dumbbell, with a relatively small middle section and two relatively large end sections. Trimmed graft was inserted into the neck of the sac and subarachnoid space below the dural sac so that it plugs the ostium inside and outside After filling the graft, Prolene 6-0 was used to continuously suture and close the ostium and dural sac starting from the lower part of the nerve root sheath and the ostium.The residual cyst cavity filled with autologous fat and gelatin sponge
40982376|NCT01203150|OTHER|Exercise|CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
41303530|NCT00511524|DRUG|[carbonyl-^11C]GW842166|\[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.
40777415|NCT00056823|DRUG|rhuFab V2 (ranibizumab)|
40982377|NCT03195543|DIAGNOSTIC_TEST|Platelet function analyzer-100|The PFA-100 system evaluates primary hemostasis in whole blood samples.
40982378|NCT03195543|DIAGNOSTIC_TEST|Light transmission aggregometry|Light transmission aggregometry is the gold standard method for assessing platelet function.
40982379|NCT03195543|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.
41462422|NCT02660541|DEVICE|Betafoam|Comparison between 2 medical devices
41462423|NCT02660541|DEVICE|Allevyn Silver Dressing|Comparison between 2 medical devices
40777416|NCT03289754|DEVICE|iPoly XE tibial insert with ConforMIS iTotal KRS|The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.
40982380|NCT03195543|DIAGNOSTIC_TEST|Endogenous thrombin potential|The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.
40982381|NCT05962970|DRUG|continuous adductor canal block (CACB) ropivacaine|The CACB group will receive an infusion of 0.2% ropivacaine 5mL/h
40982382|NCT05962970|DRUG|sham continuous adductor canal block - ShACB NaCl|sham continuous adductor canal block - ShACB and ShACB group will receive an infusion of NaCl 0.9% 5mL/h.
40982383|NCT03232281|DRUG|Triptorelin Pamoate PR 3-month|15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
40982384|NCT03232281|DRUG|Triptorelin Acetate PR 1-month|3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
40982385|NCT01712854|DRUG|Budesonide|budesonide 80 mcg
41143166|NCT01020578|OTHER|Plasma kinetic study|This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
41143167|NCT02451553|DRUG|Afatinib Dimaleate|Given PO
41143168|NCT02451553|DRUG|Capecitabine|Given PO
41143169|NCT02451553|OTHER|Laboratory Biomarker Analysis|Correlative studies
41143170|NCT05390710|COMBINATION_PRODUCT|LAE005 + Afuresertib + Nab-Paclitaxel|LAE005: 1200 mg IV Q3W, Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
41462424|NCT00000708|DRUG|Flucytosine|
41462425|NCT00000708|DRUG|Fluconazole|
41462426|NCT00000708|DRUG|Amphotericin B|
41462427|NCT04315272|DRUG|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
41462428|NCT04315272|DRUG|Placebo|Placebo
41462429|NCT02578745|DEVICE|Prophylactic NPWT (PICO system)|The PICO NPWT system is a small, lightweight (\~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
41462430|NCT02578745|OTHER|Standard Dressing|Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
41462431|NCT02004717|DRUG|DS-8895a|
40777417|NCT02635295|BEHAVIORAL|Mobile cooperation during the clinical practicum|"The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.~Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT."
40982386|NCT01712854|DRUG|Symbicort|A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
40982387|NCT05800795|DEVICE|Er: YAG laser|surface treatment with Er: YAG laser for heating abutments
40982388|NCT05800795|DEVICE|plasma spray|surface treatment with plasma spray for heating abutments
40982389|NCT02256228|DRUG|Ropivacaine|Active Group
40982390|NCT02256228|DRUG|Saline|Placebo Comparator
40982391|NCT03899142|BIOLOGICAL|a human hepatitis B immunoglobulin solution for injection for intramuscular administration|intramuscular administration
40982392|NCT06309212|OTHER|Observation|Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
40982393|NCT06219447|DEVICE|VRRS Home Tablet or Medico Amico Kids APP|Tele-rehabilitation (TR) permits intensive and personalized intervention monitored by clinicians in an ecological friendly, home setting. The VRRS Home Kit, comprising a tablet and peripheral devices, permits TR of cognitive, speech and motor functions. These peripherals such as sensors and balances allow motor rehabilitation across different body districts involved (upper and lower limbs, trunk). Touch screen activities, enables neuropsychological and speech therapy sessions. Medico Amico APP, offers a wide library of cognitive, language and motor exercises, stratified by difficulty levels, targeting specific functions. An avatar guides real-time movements, offering visual references. Adjustable parameters include duration, repetitions, difficulty, speed, movement amplitude. Both technologies facilitate TR sessions via a dedicated platform, that can occur in real-time, involving interaction with patients, or independently with continuous monitoring by clinical staff.
40982394|NCT04072211|BIOLOGICAL|Engerix-B|Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
40982395|NCT00866684|DRUG|Sirolimus|Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month
41303531|NCT02830841|DEVICE|remote ischemic preconditioning(RIPC)|After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.
41303532|NCT02830841|DEVICE|Sham RIPC|Only blood pressure cuff will be placed to the patient, but no inflation or deflation will be performed.
41462432|NCT04429867|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
41462433|NCT04429867|DRUG|Placebo|Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
40982396|NCT00866684|DRUG|Azathioprine|Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
40982397|NCT00866684|DRUG|Mycophenolate|Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
41462434|NCT04952467|DRUG|14C-XEN1101|Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101
41462435|NCT04436133|BIOLOGICAL|Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle
41462436|NCT04436133|BIOLOGICAL|9-valent HPV vaccine（Gardasil 9）|Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle
41462437|NCT03245333|DRUG|Recombinant Human Growth Hormone Injection|Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
40982398|NCT00866684|DRUG|Ciclosporin|Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
40982399|NCT00866684|DRUG|Tacrolimus|Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
40982400|NCT01132404|DRUG|Leuprorelin|Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
41143171|NCT05694286|PROCEDURE|Juvederm Volbella XC hyaluronic acid dermal filler injection|Infraorbital filler injection
41143172|NCT04299022|OTHER|Vivigen Cellular Bone Matrix|Allograft bone matrix
41143173|NCT02037009|OTHER|Health care organization (anesthetic surveillance)|
41143174|NCT01411605|BEHAVIORAL|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
41143175|NCT03366571|DRUG|Nucleos(t)ide Analogues|Entecavir 0.5mg daily, Lamivudine100mg qd daily, Adefovir Dipivoxil 10mg daily, telbivudine 600mg qd daily, their combination therapy, tenofovir 300mg qd daily.
41143176|NCT00403845|DRUG|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
41143177|NCT00403845|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
41462438|NCT03245333|DRUG|Recombinant Human Growth Hormone Injection|Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
41462439|NCT01952691|DEVICE|kinesiotaping|correction method was used to align hallux.
41462440|NCT04385745|PROCEDURE|Biodegradable Intramedullary Nailing (BIN)|Unstable forearm shaft fractures are treated by the study method (BIN) or the control method (ESIN).
41462441|NCT03790241|PROCEDURE|insertion of a catheter|Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins
41462442|NCT02404857|DEVICE|EEG based Brain Computer Interface|Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
41462443|NCT00271973|DRUG|Oxycodone|
41462444|NCT02594527|OTHER|Volunteer-led physical activity session|Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
41462445|NCT00096005|DRUG|tanespimycin|Given IV
41462446|NCT00096005|DRUG|bortezomib|Given IV
41462447|NCT00096005|OTHER|laboratory biomarker analysis|Correlative studies
41462448|NCT02571634|DRUG|Lazanda|Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
41462449|NCT02230267|OTHER|High intensity exercise and balance training|
41462450|NCT02230267|OTHER|Usual care arm exercise|
41462451|NCT06468514|OTHER|neural tensioning technique on radial nerve|the neural group tensioning technique: The test should be performed in approximately 10° of shoulder abduction. The examiner extends the elbow 2 seconds just to the range where the patient notices tension but no pain and then the elbow is flexed. Three sets of 6-8 swings are performed with 1 minute rest in between.
41462452|NCT06468514|OTHER|Sliding technique on radial nerve|The mobilization maneuver begins by identifying the first resistance and the range of extension associated with pain. Maintaining elbow extension within the elastic region of resistance free of pain and/or paresthesia the examiner increases elbow extension and simultaneously allows the wrist to extend as necessary for the radial nerve branches in the forearm to glide proximally. The physical therapist then flexes the wrist while allowing the elbow to flex to cause the radial nerve excursion distally in the forearm.
41462453|NCT02308696|BEHAVIORAL|Peer-to-Peer Support|All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.
41462454|NCT02308696|BEHAVIORAL|Standard Community Services|All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
41462455|NCT02747680|OTHER|hypoglycemia (low blood sugar) in MRI|hypoglycemia (low blood sugar) in MRI
41462456|NCT04096651|OTHER|gait recordings|gait recordings
41462457|NCT04096651|OTHER|brain magnetic resonance imaging|brain magnetic resonance imaging
41462458|NCT04096651|OTHER|oculomotor movement recordings|oculomotor movement recordings
41462459|NCT05397301|PROCEDURE|Controlled sedoanalgesia|Controlled sedoanalgesia was applied with Bispectral index and dexmedetomidine
41462460|NCT01259830|DRUG|Arcoxia®120 mg|Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
41303533|NCT03808623|DEVICE|MAC with NOVOCART Basic|"NOVOCART® Basic is a biphasic, collagen-based matrix to support the biological reconstruction of localized and full-thickness cartilage damages after treatment with bone marrow stimulation techniques (microfracture). The procedure is called matrix associated chondrogenesis (MAC). It is a single-step procedure.~NOVOCART® Basic is tailored to fit the prepared defect size and is inserted in the defect area after microfracture. The NOVOCART® Basic device component is fully resorbed over a period of a few months as new reparative cartilage tissue is generated and integrated with the surrounding host tissue."
41462461|NCT01259830|DRUG|P Tablet White Lichtenstein|P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
41462462|NCT01159899|PROCEDURE|Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis|Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure
41303534|NCT03463616|RADIATION|CT abdomen|CT scan of abdomen for metastasis staging of rectal cancer
41303535|NCT03463616|RADIATION|MRI abdomen|MRI of abdomen for metastasis staging of rectal cancer
41462463|NCT06428851|OTHER|Laser therapy|Shoulder girdle muscles were lasered for 5 minutes a day, 3 days a week, total of 4 weeks.
41462464|NCT06428851|OTHER|Neuromuscular electrical nerve stimulation|Neuromuscular electrical nerve stimulation was applied to the shoulder flexor and abductor muscles for 20 minutes a day 5 days a week, total of 4 weeks.
40777418|NCT00509288|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor|"Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.~A minimum of approximately 5 X 10\^8 cells will be given up to 3x10\^11 anti-MART-1 F5 TCR engineered TIL or PBL."
40777419|NCT00509288|DRUG|Cyclophosphamide|Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
41303536|NCT05641818|OTHER|Screening tool for vitamin D deficiency|(1) Determination of 25(OH) Vitamin D3 in human serum samples and (2) Question based screening tool with personal (age, gender,...), lifestyle (e.g. sun exposure, outdoor activity) and dietary factors that affect the status of vitamin D in the human body.
40777420|NCT00509288|DRUG|Fludarabine|Day -5 to 1: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
40777421|NCT00509288|BIOLOGICAL|Aldesleukin|Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e\^11 (with a minimum of 5x10e\^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
40777422|NCT00509288|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes|
40777423|NCT01195974|DRUG|YASMIN|YASMIN for 21 days
40982401|NCT01132404|DRUG|TAK-448|"Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months"
40982402|NCT04646798|OTHER|Hemiarthroplasty|standard surgical approaches to repair of fractured elbows
40982403|NCT04646798|OTHER|Total elbow arthroplasty|standard surgical approaches to repair of fractured elbows
41143178|NCT00403845|DRUG|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
41143179|NCT00576550|DRUG|Urea|Urea cream applied twice daily up to six months
41143180|NCT00576550|DRUG|betamethasone valerate|Application once daily for two weeks
41143181|NCT00576550|DRUG|betamethasone valerate|Application twice daily for two weeks
41143182|NCT00939211|DRUG|AZD9164|Solution for inhalation through nebulization, single dose
41303537|NCT02266901|PROCEDURE|endoscopic drainage|Endoscopic percutaneous access was obtained through surgical drains or after ultrasound-guided percutaneous drainage with a thin scope , and transluminal procedures with large scopes through the leak hole. All the procedures were performed under general anesthesia and carbon dioxide insufflation. Debridement was done by pus aspiration and irrigation.
41303538|NCT02410707|DRUG|Nitrous Oxide arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
41303539|NCT02410707|DRUG|Propofol|The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
41303540|NCT02410707|DRUG|Oxygen|If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
40982404|NCT04996888|DEVICE|AI based preoperative automatic reminder system|the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time. The system is an non-invasive AI system.
40982405|NCT02201186|OTHER|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
41143183|NCT00939211|DRUG|Tiotropium|Dry powder for inhalation, single dose
41143184|NCT00939211|DRUG|Placebo|Placebo
41143185|NCT06462378|RADIATION|Proton therapy|External beam proton therapy combined with standard cisplatin and brachytherapy
41143186|NCT04414865|DEVICE|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
41143187|NCT05568277|BEHAVIORAL|Education on preventive health behaviors based on Pender's Health Promotion Model|Pregnant women included in the study will be given education on preventive health behaviors based on Pender's Health Promotion Model on the prevention of gestational diabetes over the web (ZOOM/Teams etc.) every two weeks. Pregnant women's questions will be answered. At the end of each training, data will be collected from pregnant women and follow-up charts will be filled. The education booklet prepared by the researcher will be given to the pregnant women after the first education and will be sent to their e-mail addresses.
40777424|NCT01195974|DRUG|GSK2248761|200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
40777425|NCT01195974|OTHER|Placebo|Placebo taken on Days 1 - 10 or Days 12 - 21
40777426|NCT02446002|DRUG|Lofexidine + Naltrexone|Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
40777427|NCT01297855|DRUG|Colistin|Colistimethate Sodium dose 2.5-5mg/kg/day
40777428|NCT01297855|DRUG|Colistin plus Rifampicin|Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
40777429|NCT01188187|DRUG|Custirsen|
40777430|NCT01188187|DRUG|Docetaxel|
40777431|NCT01188187|DRUG|Prednisone|
40982406|NCT05109351|BEHAVIORAL|Participating to Boost Meal Participation|The Participating to Boost Meal Participation intervention consists of utilizing marketing and communication strategies to promote school meal participation in elementary school students.
40982407|NCT04918550|OTHER|no drug and device|there is no intervention
41143188|NCT04140526|DRUG|ONC-392|ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.
40777432|NCT01188187|DRUG|Dexamethasone|Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
40982408|NCT02306629|BIOLOGICAL|Epratuzumab sc|Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
41303541|NCT02804880|BEHAVIORAL|HAR|Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.
40777433|NCT01129206|DRUG|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
40777434|NCT01129206|DRUG|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
40982409|NCT02306629|BIOLOGICAL|Epratuzumab iv|Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
40982410|NCT04666233|PROCEDURE|Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection
40982411|NCT04666233|PROCEDURE|Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection
40777435|NCT01129206|RADIATION|fludeoxyglucose F 18|Correlative studies
40777436|NCT01129206|PROCEDURE|positron emission tomography|Correlative studies
40777437|NCT04476784|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
40777438|NCT04476784|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
40777439|NCT04476784|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
40777440|NCT02357303|DRUG|Simethicone|100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
40777441|NCT02357303|DRUG|Acetylcysteine|100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
40777442|NCT02357303|OTHER|Placebo|100mL of water
41143189|NCT04140526|DRUG|Pembrolizumab|Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).
41143190|NCT04140526|DRUG|Docetaxel|Docetaxel will be given intravenous (IV) infusion at 75 mg/m2, once every 21 days (Q3W).
41143191|NCT01962402|DRUG|lorcaserin|Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
41143192|NCT01962402|BEHAVIORAL|Intensive dietary counseling|All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.
41143193|NCT05005247|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
41143194|NCT03645213|DEVICE|Virtual Reality Box|Virtual Reality box, a head-mounted display with stereo earphones transmits the cartoon image onto screens in front of the child's eyes. It was showed on Samsung Galaxy Note5 phone and Samsung Gear VR box /SM-R323N.
41143195|NCT03645213|DEVICE|Tablet Computer|The tablet computer is a device that children watch on a 7-inch screen.
41143196|NCT05352854|DRUG|0.5% pilocarpine eye drops|Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
41143197|NCT01123200|DEVICE|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
41143198|NCT04115670|BEHAVIORAL|Group of educational intervention on the neurophysiology of pain and physical exercises|"The physiotherapist of the institution will execute the intervention on the group:~* 3 first pedagogical sessions on the neurophysiology of pain, distributed: 1 group session, 1 individual session at home, 1 in a personal interview format. These 3 sessions will last 2 weeks to be completed.~* Afterward, the protocol of physical exercise training will begin, supervised by the same physiotherapist who carried out the three initial sessions. There will be 15 sessions of specific and individualized physical exercise, in small groups of maximum 5 people. The duration of this part will be 10 weeks, so that from week 1 to 5 is 2 times per week, and from week 6 to 10 just 1 time per week."
41143199|NCT04115670|BEHAVIORAL|Control group|The control group will follow its normal course of activity
41143200|NCT00025376|DRUG|PS-341|
41143201|NCT00025376|PROCEDURE|Tumor Biopsy|
41143202|NCT06121778|OTHER|Home|There is no intervention but evaluations of elderly persons living at home will be conducted every three years and for the next 12 years. If some people leave the home, as far as possible, the reason will be asked.
41143203|NCT05557838|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
41143204|NCT05557838|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
41146967|NCT04121949|DEVICE|CADScor®System|The CADScor®System is a low cost, low resource-demanding, non-invasive, radiation-free device using highly advanced analysis of sounds originating from blood flow turbulence in the coronary circulation and myocardial motion. Heart sound recordings are obtained transcutaneously during a 3 minutes recording period with a microphone mounted at the IC4. A CAD-score on a scale from 0 to 99 is estimated immediately after the recording with a fully automated algorithm. The algorithm measures eight acoustic properties and the resulting acoustic score is combined with the clinical risk factors gender, age, and hypertension. The entire procedure lasts approximately 10 minutes.
40982412|NCT02233309|OTHER|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
40777443|NCT04890184|DIETARY_SUPPLEMENT|grape juice|grape juice
40777444|NCT04890184|OTHER|control|no intervention
40777445|NCT02437318|DRUG|Fulvestrant|
40777446|NCT02437318|DRUG|Alpelisib|
40982413|NCT03913650|PROCEDURE|0.25% bupivacaine|nerve block procedure will be decided by patients' will for post-op pain
40982414|NCT02298803|DEVICE|Holter and Glucose monitoring|"(i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.~(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities."
40982415|NCT05670366|DEVICE|Activity tracker and chest strap|During the study, the participants will be asked to wear a commercially-available activity tracker during day and night, and a chest strap during sport activities to collect data on physical activity (type, intensity and duration of activity).
40982416|NCT05670366|DEVICE|Diary app|During the study, the participants will be asked to log the ingestion of carbohydrates, periods and type of physical activity, feelings (e.g. sick, stress, ...) in a diary app.
40982417|NCT05635227|DRUG|Dexamethasone phosphate|See description of arms
41303542|NCT02804880|BEHAVIORAL|LTM|Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.
41303543|NCT02804880|BEHAVIORAL|AWARD|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.
41303544|NCT02804880|OTHER|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
41303545|NCT02804880|OTHER|A4 leaflet|The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
41303546|NCT02804880|BEHAVIORAL|Brief advice|Very brief, minimal and general smoking cessation advice
40777447|NCT02437318|DRUG|Alpelisib placebo|
40777448|NCT04629430|OTHER|Pre-biotic foods/drinks|2 servings per day
40777449|NCT01959685|DRUG|Androxal|125 mg Androxal, 250 mg Androxal separated by at least 7 days
40777450|NCT01959685|DRUG|Placebo|Placebo, single dose
40777451|NCT00406796|DRUG|Ranibizumab|0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
40777452|NCT06546332|DEVICE|KeriFuse®|The intramedullary arthrodesis Implant (KeriFuse®) is indicated for consolidation or bone fusion (arthrodesis) of degraded or arthritic distal interphalangeal (DIP) of hand digits or interphalangeal (IP) joint of the hand thumb.
40777453|NCT04494789|DRUG|Fludrocortisone Acetate|50mcg
40777454|NCT04494789|DRUG|Fludrocortisone Acetate|100mcg
40777455|NCT04494789|DRUG|Fludrocortisone Acetate|200mcg
40777456|NCT04494789|OTHER|Standard Therapy|NO Fludrocortisone
40777457|NCT05918848|DEVICE|Filme Gyno-V® Vaginal Ovules|Administration of tocopherol (Filme Gyno-V® Vaginal Ovules) for 14 days
40777458|NCT03972527|DEVICE|Photobiomodulation|Provide photobiomodulation therapy to subjects prior to each radiation therapy session.
40777459|NCT03972527|OTHER|Routine Oral Care and Analgesia|Standard oral care, oral hygiene and oral pain protocols
40982418|NCT05635227|DRUG|Isotonic sodium chloride (0.9%)|See description of arms
40982419|NCT05635227|DRUG|Olanzapine 10 MG|Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
40777460|NCT00448448|DEVICE|Brace|Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
40777461|NCT00448448|OTHER|Observation|Clinical, radiographic, and self-report follow-up every 6 months.
40777462|NCT02164110|BIOLOGICAL|Euvichol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
40777463|NCT02164110|BIOLOGICAL|Shanchol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
40982420|NCT05635227|DRUG|Placebo capsule|capsule identical to capsule containing olanzapine
40982421|NCT05635227|PROCEDURE|Flow-targeted hemodynamic management|See description of arms
40982422|NCT05635227|PROCEDURE|Pressure-targeted hemodynamic management|See description of arms
40982423|NCT05635227|PROCEDURE|Low tidal-volume ventilation|See description of arms
40982424|NCT05635227|PROCEDURE|No ventilation|See description of arms
40982425|NCT04416503|OTHER|Foot reflexology|Foot reflexology was performed for 12 week in the study group,whereas the control group continued their routine treatment and follow-up.
41303547|NCT02804880|OTHER|12-page booklet|12-page smoking cessation self-help booklet
41303548|NCT05006898|COMBINATION_PRODUCT|PBO to control presbyopia symptoms|Low dose PBO to control presbyopia symptoms
41303549|NCT04423926|DRUG|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
41303550|NCT04423926|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
41303551|NCT04423926|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 d1
41303552|NCT04423926|DRUG|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
41303553|NCT04423926|DRUG|Prednisolone|Prednisolone 60mg/m2 d1-5
41462465|NCT06428851|OTHER|Control|Classical physical therapy exercises were applied according to the patient's needs and neurologic level. These exercises are determined by the physiotherapist according to the functional status of the patient and consist of passive, passive assisted, active range of motion exercises, stretching and strengthening exercises, mobilization exercises 5 days a week for 1 hour, total of 4 weeks.
41462466|NCT03649945|DRUG|Docetaxel|75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
40777464|NCT02378480|DRUG|Omadacycline|Injection for IV dosing; Tablets for oral dosing
40777465|NCT02378480|DRUG|Linezolid|Infusion solution for IV dosing; Tablets for oral dosing
40777466|NCT03175029|DRUG|TAC-302|TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
41303554|NCT05980832|OTHER|Peer practitioner training - Peer Education Supported Psychosocial Skills Education|"Psychosocial skills training-practitioner training will be given to 4 patients diagnosed with chronic mental disorder by the research psychiatry nurse.~Educational content~1. Getting acquainted - briefing about the study~2. The Importance, Aims and Objectives of Psychosocial Skills Education~3. The importance of peer support~4. The importance, aims and objectives of peer education supported psychosocial skills training~5. Management of the meeting game, warm-up games and role plays~6. 1st and 2nd session peer education supported psychosocial skills training~7. 3rd and 4th session peer education supported psychosocial skills training~8. The last 5th and 6th sessions of peer education are supported by psychosocial skills training.~9. Key points and termination in group management. The training will be planned to last 10-13 hours in total. Trainer's booklet prepared by the researcher psychiatric nurse."
41462467|NCT03649945|DRUG|Nedaplatin|80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
40777467|NCT03175029|DRUG|Placebo|Placebo administered orally twice per day after meals, for 12 weeks.
40777468|NCT02348021|PROCEDURE|Percutaneous coronary intervention (PCI)|
40777469|NCT02348021|DRUG|Dual Anti Platelet Therapy|All patients will receive Dual Anti Platelet Therapy for one month
40777470|NCT06513247|DIAGNOSTIC_TEST|screening for Islet autoantibody|IAA, GADA, IA-2A, Zn-transporter 8 autoantibodies
40777471|NCT06513247|DIAGNOSTIC_TEST|HLA phenotype and genetic risk score|using DBS filter paper
40777472|NCT06529185|DEVICE|The BREATHER|The BREATHER is Light/Medium resistance inspiratory muscle trainer which has significance role in increasing inspiratory muscle strength and endurance which could result in a decreased sensation of dyspnea
40777473|NCT06529185|DRUG|pharmacological treatment|patient will receive the usually pharmacological treatment.
40777474|NCT04242147|DRUG|KD033 (SAR445710)|Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
40777475|NCT00433485|DRUG|sirolimus|
40777476|NCT00433485|GENETIC|comparative genomic hybridization|
40777477|NCT00433485|GENETIC|gene expression analysis|
40777478|NCT00433485|GENETIC|microarray analysis|
40777479|NCT00433485|GENETIC|protein expression analysis|
40777480|NCT00433485|GENETIC|proteomic profiling|
40777481|NCT00433485|OTHER|laboratory biomarker analysis|
40777482|NCT00433485|OTHER|mass spectrometry|
40777483|NCT00433485|PROCEDURE|biopsy|
40777484|NCT02893891|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
41462468|NCT03649945|DRUG|Endostar|7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles
41462469|NCT00722839|BIOLOGICAL|PADRE-CMV fusion peptide vaccine|Given subcutaneously
41462470|NCT00722839|BIOLOGICAL|tetanus-CMV fusion peptide vaccine|Given subcutaneously
40777485|NCT02893891|PROCEDURE|Laparoscopic gastric plication|Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
40777486|NCT02893891|PROCEDURE|Intragastric balloon|The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
40777487|NCT02893891|DEVICE|Intragastric balloon implantation|Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
40777488|NCT00416507|DRUG|fluorouracil|
40777489|NCT00416507|DRUG|gemcitabine hydrochloride|
40777490|NCT00416507|DRUG|liposomal cisplatin|
40777491|NCT03870048|DEVICE|transcranial direct current stimulation|A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
40777492|NCT00468247|DEVICE|Navigator|Navigator circulatory mgt system
40777493|NCT00468247|OTHER|Conventional care|Conventional haemodynamic care
40777494|NCT04240054|DRUG|Bortezomib|Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15
40777495|NCT04240054|DRUG|Isatuximab|Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22
40777496|NCT04240054|DRUG|Cyclophosphamide|Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15
40777497|NCT04240054|DRUG|Dexamethasone|Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23
40777498|NCT00906061|DRUG|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
40777499|NCT05482061|OTHER|visual analog scale (VAS).|The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
40777500|NCT00694863|DRUG|tetracosactide hexacetaat|Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
40777501|NCT00047034|DRUG|eribulin mesylate|Given IV
41462471|NCT00722839|DRUG|agatolimod sodium|Given subcutaneously
41462472|NCT03067935|DRUG|glembatumumab vedotin|
40777502|NCT00047034|OTHER|pharmacological study|Correlative studies
40777503|NCT00047034|OTHER|laboratory biomarker analysis|Correlative studies
40777504|NCT06034626|PROCEDURE|Intense pulsed light|Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.
40777505|NCT06034626|DRUG|0.3% hyaluronic acid eye drops|0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.
40777506|NCT01534559|OTHER|Medicines Management Outpatient service|New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
40982426|NCT05245747|DEVICE|Vitls Tego Device|The Tégo VSS Sensor is a battery-operated adhesive patch with integrated sensors and wireless transceiver which is worn on the upper body and records heart rate (HR), respiration rate, blood oxygen levels (SpO2), and body temperature. The Tégo VSS Sensor continuously gathers multiparameter physiological data from the person being monitored and then transmits the encrypted data via bi-directional communication to a third-party connectivity relay.
41462473|NCT00716625|DRUG|sunitinib malate|"SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
41462474|NCT01802645|DRUG|Cetuximab|
40982427|NCT00739544|OTHER|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
40982428|NCT06386133|DEVICE|MS Boost|remote monitoring digital tool based on functional tests (walking, dexterity, vision and cognition). These digital tests may be combined with a fatigue assessment via questionnaires and, if needed, a telerehabilitation program. This program includes an algorithm comprising fatigue management advice and/or physical activity recommendations personalised to the patients, aimed at improving fatigue-related symptoms. The patient can use the telerehabilitation program without supervision
40982429|NCT06386133|OTHER|Standard of care|General fatigue tips are given to patients who suffering from chronic fatigue such as stop smoking, eat a healthy diet...
40982430|NCT02543008|PROCEDURE|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
40982431|NCT02543008|PROCEDURE|Physical activity|Information already included in arm/group descriptions.
41146968|NCT05832320|DRUG|Etoposide|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
41146969|NCT05832320|DRUG|Daunorubicin|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
41462475|NCT01802645|DRUG|Bevacizumab|
41462476|NCT01802645|DRUG|Irinotecan|
41462477|NCT01802645|DRUG|Oxaliplatin|
40777507|NCT04618094|OTHER|bicycle ergometer training with different intensities|Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
40777508|NCT05159050|DRUG|Paclitaxel-loaded tumor penetrating microparticles|"Paclitaxel-loaded TPM, suspended in 0.5 L of 0.1% (w/v) polysorbate 80 in 0.9% sodium chloride is instilled into the peritoneal cavity over 3 to 5 minutes. Mixing of TPM is achieved by putting patient in 5 different positions for about 80 minutes.~Dose escalation, the starting dose of TPM is 50 mg/m\^2 paclitaxel-equivalents. Dose escalation will follow the Accelerated Titration Design. The dose levels to which patients will be assigned in sequential cohorts are listed below.~Dose escalation schedule of TPM, Dose Level 1\*: 50 mg/m\^2; Dose Level 2: 100 mg/m\^2; Dose Level 3: 135 mg/m\^2; Dose Level 4: 175 mg/m\^2; Dose Level 5: 200 mg/m\^2~\*Starting Dose"
40777509|NCT06546462|OTHER|Osteopathic Manipulative Treatment (OMT)|The active arm will receive osteopathic manipulative treatment which is a hands-on treatment modality use to treat a variety of health concerns.
40777510|NCT06546462|OTHER|Sham Light touch arm|Sham arm will receive a light touch sham treatment.
41462478|NCT01802645|DRUG|5-FU|
41462479|NCT01802645|DRUG|Folinic Acid|
41462480|NCT04021758|BEHAVIORAL|Peer to peer program intervention|Peer to peer suicide prevention program aimed at reducing suicide in a military population.
41462481|NCT04712916|BEHAVIORAL|Health education|Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.
41462482|NCT06260982|RADIATION|18-FDG-PET|18-FDG-PET and neuropsychological tests (language, memory, visuo-spatial tests, etc.).
41462483|NCT01664039|DRUG|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
41462484|NCT01664039|DRUG|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
41462485|NCT03528096|DEVICE|Somnomat B|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
41462486|NCT03528096|OTHER|Sound|Sound of the moving bed was recorded and played back during the baseline night.
40982432|NCT02543008|PROCEDURE|Placebo|Information already included in arm/group descriptions.
40982433|NCT02020395|DIETARY_SUPPLEMENT|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
40982434|NCT02020395|DIETARY_SUPPLEMENT|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
40982435|NCT05439512|PROCEDURE|transantral orbital floor reconstruction by titanium mesh|reconstruction of orbital floor fracture by patient specific titanium mesh
40982436|NCT02425150|PROCEDURE|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
40982437|NCT02425150|PROCEDURE|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
40982438|NCT04347239|DRUG|Placebos|Placebos
40982439|NCT04347239|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
40982440|NCT04761289|OTHER|Multimodal Exercise and Functional Rehabilitation Program|"1. Prescription of multimodal physical exercise.~2. Reeducation of Activities of Daily Living (ADL).~3. Prescription of support products and adaptations of the environment."
40982441|NCT00778089|DEVICE|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
40982442|NCT01431833|DRUG|TR-701 FA|Oral single dose 200 mg
40982443|NCT00251446|DRUG|Vinflunine|320 mg/m2 as a 20-minute IV infusion
40982444|NCT04067895|PROCEDURE|epiphysiodesis|All patients undergo surgical treatment of leg lengths discrepancies or primordial gigantism. Human bone graft screws will be used to stop the distraction of the growth plate.
40982445|NCT05555212|DRUG|QLH11811|"In Ia phase, subjects will first receive oral single dose of QLH11811, then will be observed for 7 days. If the drug is tolerated by the subjects, the subjects will continue to receive the oral repeat dose of QLH11811 for 21 consecutive days. Upon the completion of observation for DLT in the subjects (DLT observation period is the 28 days after the first dose), the subjects will continue to receive the repeat dose of QLH11811 in Cycle 2 and subsequent cycles. The dosing frequency in Cycle 2 and subsequent cycles is once daily, and each cycle has 3 weeks.~The RP2D of QLH11811 is determined on the basis of comprehensive evaluation of all safety and tolerability data and all available PK, PD and efficacy data during the dose escalation phase. In phase 1b, the cohort expansion study is carried out for all cohorts in China and the United States concurrently according to the determined RP2D."
40982446|NCT03683446|PROCEDURE|Laparoscopic rectal surgery|Minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon.
40982447|NCT03683446|PROCEDURE|Open rectal surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
40982448|NCT00818233|DEVICE|Dynamic contour tonometry|Observe variability of measurements by dynamic contour tonometry
40777511|NCT05504499|DEVICE|Interspinous Fusion|The intended study population are adults 18 years or older with symptomatic lumbar degenerative disc disease resulting in back pain with lower extremity symptoms and neurogenic claudication that improves with spinal flexion who are candidates for use of the Zip™ MIS Interspinous Fusion device when undergoing spinal fixation procedures.
40777512|NCT02876731|DEVICE|PET-CT|NaF PET-CT
40982449|NCT05691296|BEHAVIORAL|Home training|Letter Chart Accomodative Rock Training for 2 minutes each time
40982450|NCT05691296|BEHAVIORAL|School training|Letter Chart Accomodative Rock Training for 2 minutes each time
40982451|NCT04857515|DEVICE|Clickotine®|Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.
41462487|NCT02833831|DRUG|ALS-008176|Participants will receive a single dose of ALS-008176 orally.
41462488|NCT02833831|DRUG|Placebo|Matching Placebo will be administered.
41462489|NCT02833831|DRUG|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg.
41462490|NCT02153723|DRUG|Glatiramer Acetate|
40777513|NCT02876731|DEVICE|MRI|DWMRI
40777514|NCT05104827|OTHER|Complementary Integrative Medicine|30-minute individually tailored integrative medicine care, including acupuncture, acupressure, reflexology, movement therapies like QiGong or Feldenkrais as well as Anthroposophic Medicine and mind-body treatments.
40982452|NCT03102021|DRUG|erythropoietin|500 units/kg daily for 3 days at onset of acute kidney injury
40982453|NCT03102021|DRUG|saline|saline 10 ml for 3 days
41462491|NCT00954603|DRUG|quetiapine|25-100 mg
41462492|NCT00954603|DRUG|haloperidol|0.5-2 mg
41462493|NCT01390948|DRUG|Bevacizumab|10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
41462494|NCT01390948|RADIATION|Radiotherapy|Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
41462495|NCT01390948|DRUG|Temozolomide (TMZ)|75 milligrams per square meter (mg/m\^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m\^2/day) x 12 cycles, 1st cycle 150 mg/m\^2/days 1-5, escalated to 200 mg/m\^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
40777515|NCT02979587|DEVICE|Harmony TPV System|"The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame.~The Harmony TPV 25 and mTPV 25 (Model HTPV254952 and HTPV254252, respectively) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22 (Harmony TPV 25 Model HTPV254952 is not applicable for Continued Clinical Experience).~The Harmony Delivery System (DS) for the TPV 22, TPV 25, and mTPV 25 (NTPVDS0022 and HTPVDS0025) are all 25 Fr delivery systems using a coil loading catheter."
40777516|NCT02695654|DRUG|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
40777517|NCT02695654|DRUG|Clonidine|Clonidine 100 mcg
40777518|NCT02441218|DRUG|Ivabradine|2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
40777519|NCT02441218|DRUG|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
40777520|NCT03226041|DEVICE|transcutaneous monitor (TCM-4 monitor)|TCM-4 monitor, which had changed new electrode membrane and was calibrated by the same person(who had been trained systematically) before each placement. The electrode should be heated to 44℃, then fixed it to the anterior part of chest in the location of lateral position after remove grease by alcohol. The positon of electrode must be changed every 2 hours in order to avoid thermal injury, and should be calibrated again.
40777521|NCT01373281|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
40982454|NCT05817188|OTHER|No intervention|No intervention was applied
40982455|NCT01890850|OTHER|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
40982456|NCT04218227|BEHAVIORAL|Self-hypnosis/self-care group|Self-hypnosis/self-care
40982457|NCT04218227|BEHAVIORAL|Music/self-care|Music-therapy/self-care
40982458|NCT04218227|BEHAVIORAL|Self-care|Self-care
40982459|NCT04218227|BEHAVIORAL|Psycho-education|Psycho-education
40777522|NCT01373281|BIOLOGICAL|Placebo: Sodium chloride (NaCl) 0.9%|0.5 mL, Subcutaneous
40777523|NCT00637351|PROCEDURE|Blood sample|One blood sample will be collected at the time of screening for subjects
40777524|NCT00637351|PROCEDURE|Urine sample|One urine sample will be collected at the time of screening for subjects
40982460|NCT04218227|BEHAVIORAL|Self-hypnosis/self-care motivation|Motivation to learn self-hypnosis/self-care
40982461|NCT03272490|PROCEDURE|Medartis|Surgery using the medartis implant
40982462|NCT03272490|PROCEDURE|Synthes|Surgery using the Synthes implant
40982463|NCT01961323|DRUG|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP\<140 and DBP \<90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
40982464|NCT02956265|DEVICE|bimodal optical spectroscopy|an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra
40777525|NCT04595435|PROCEDURE|Lumpectomy|Removal of lump/tumor from breast utilizing an approach that saves as much breast as possible.
40777526|NCT04595435|RADIATION|Intraoperative Radiation Therapy|Delivery of low energy radiation therapy directly at surgical site, immediately removal of lump and tissue prior to final surgical closure
40982465|NCT04892888|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
40982466|NCT05766982|OTHER|Platelet Rich Plasma|Platelet rich plasma will be applied to assess rate of wound healing.
40982467|NCT05069454|BIOLOGICAL|COVID-19 vaccine Observation of individuals who receive the COVID-19 vaccine|To measure the effectiveness of COVID-19 vaccines against symptomatic laboratory-confirmed SARS-CoV-2 infection amongst hospital level health workers eligible for vaccination.
40982468|NCT02326753|DEVICE|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
40982469|NCT02326753|DEVICE|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
40982470|NCT02326753|DEVICE|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
40982471|NCT03480750|DRUG|trientine dihydrochloride|trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)
40982472|NCT03480750|DRUG|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 40mg/m2 IV D1
40982473|NCT03480750|DRUG|carboplatin|carboplatin AUC 4 IV D1
40982474|NCT02554812|DRUG|Avelumab|Anti-PD-L1 antibody
40777527|NCT05471921|BEHAVIORAL|SBIRT|SBIRT is an evidence-based treatment for unhealthy alcohol and other drugs (AOD) use in non-humanitarian settings and can efficiently provide individuals with an appropriate level of care based on their symptoms. Participants randomized to SBIRT will receive an on-the-spot alcohol brief intervention (CETA-BI) and be categorized as low or moderate/high severity using the AUDIT scale. Participants who are moderate/high severity will be connected to a counselor and will begin full CETA treatment. CETA is a transdiagnostic approach that combines motivational interviewing with cognitive behavioral therapy to assist clients in considering changing their rates of AOD use. The intervention lasts 30-40 minutes and consists of 6 components including 1) screening; 2) identifying the impacts of unhealthy AOD use; 3) talking about change/goal-setting; 4) understanding the primary reason for drinking; 5) skill-building; and 6) referral for services.
40777528|NCT05471921|BEHAVIORAL|Treatment as usual|Mantapala health workers and supervisors were trained in mental health gap action program-humanitarian intervention guide (mhGAP-HIG), which is a mental health service provision guide for use in humanitarian settings; this training was led by staff from United Nations High Commissioner for Refugees. This training did not include evidence-based psychological interventions (e.g., CETA). Participants randomized to TAU will be referred to the existing services that exist in the health clinic located in Mantapala refugee settlement. More specialized services are referred to the District Hospital in Nchelenge.
40777529|NCT02969135|BEHAVIORAL|Progressive early passive and active movement|Post-surgical physical therapy including active exercise
40777530|NCT02969135|BEHAVIORAL|Limited early passive movement|Post-surgical physical therapy including passive mobilisation
40777531|NCT01006148|BIOLOGICAL|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
40777532|NCT00754884|DRUG|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
40777533|NCT00754884|DRUG|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
40777534|NCT05890209|DEVICE|Continuous Glucose Monitoring device|A small wearable transdermal sensor that tracks glucose levels in interstitial fluid by taking measurements at regular and frequent intervals throughout the day and night.
40777535|NCT01202162|DRUG|Desflurane|Administratino of Desflurane
40777536|NCT01202162|DRUG|Administration of Sevoflurane|Administration of Sevoflurane
40777537|NCT05921344|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
40777538|NCT04597749|DIAGNOSTIC_TEST|PSG|In-lab sleep polysomnography test
40777539|NCT04597749|DIAGNOSTIC_TEST|Home Sleep Apnea Test with FDA cleared devices|In-lab HST test
40777540|NCT04597749|OTHER|Non-Contact Screening App|Non-Contact Sleep Apnea Screening Applications at bedside table to assess for sleep apnea.
40777541|NCT03537703|COMBINATION_PRODUCT|Active tDCS + Auditory Training|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
40777542|NCT03537703|COMBINATION_PRODUCT|Active tDCS + Control Condition|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The control condition will be subjects watching a silent movie for 20 min during active tDCS stimulation.
40777543|NCT03537703|COMBINATION_PRODUCT|Sham tDCS + Auditory Training|Sham tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 1 min with the current then slowly ramped down to 0 amps over the course of another minute. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
40982475|NCT02554812|DRUG|Utomilumab|Anti-4-1BB antibody
40777545|NCT05003414|DEVICE|GMK Sphere cementless Knee Replacement|Performance of Total Knee Arthroplasty (TKA) with GMK Sphere cementless Knee Replacement
40777546|NCT04910620|DRUG|Placebo|Placebo only
40777547|NCT04910620|DRUG|TCI378|TCI378 (Lactobacillus plantarum TCI378)
40777548|NCT04910620|DRUG|TCI507|TCI507 (Lactobacillus plantarum TCI507)
40777549|NCT02715284|BIOLOGICAL|Dostarlimab|Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
40777550|NCT02549066|PROCEDURE|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.
40982476|NCT02554812|DRUG|PF-04518600|OX40 Agonist
40982477|NCT02554812|DRUG|PD 0360324|Anti-M-CSF
40982478|NCT02554812|DRUG|CMP-001|TLR9 agonist
40982479|NCT03483883|DRUG|Avelumab|Avelumab IV 10 mg/kg every 2 weeks
40982480|NCT03483883|DRUG|Gemcitabine|Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks
40982481|NCT04493281|DRUG|MT-1186|Oral suspension
40982482|NCT04493281|DRUG|MCI-186|Intravenous formulation
40982483|NCT01169142|DIETARY_SUPPLEMENT|Vitamin D3|50,000 units of Vitamin D3 weekly
40982484|NCT01169142|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 units weekly
41146970|NCT04360928|DEVICE|Graymont X ERIS Knee Splint|Specific type of splint which utilizes an inflatable air pocket on the posterior aspect of the leg to provide a combination of bracing and splinting in full extension in the immediate postoperative period.
41146971|NCT04360928|DEVICE|Standard Hinge Knee Brace|Standard knee brace used postoperatively after ACL reconstruction.
40777551|NCT02549066|DRUG|Milrinone|"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.~Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) \< 12 %."
41462496|NCT05352438|OTHER|Manual Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Manual Therapy group received a manual therapy program applied as 2 sessions of 45 mins each week for 4 weeks (total 8 sessions) by an investigator. Soft tissue and joint mobilizations were applied to the TMJ and surrounding structures and to cervical segments, trigger point treatment was applied to trigger points, and myofascial loosening was performed. Patients were instructed to perform the exercises learned in the home exercise program in 3 sets of 10 repetitions every day."
41462497|NCT05352438|OTHER|Splint Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Splint Therapy group was given a static occlusal splint, and adjustments were made as necessary. All the patients in this group were instructed to use the splint when sleeping for a period of one month."
41462498|NCT05511441|PROCEDURE|Surgery Without Aspirin Withdraw|Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
41462499|NCT03930251|BEHAVIORAL|Clinic-Based Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led twice weekly by a clinician in small groups.
41462500|NCT03930251|BEHAVIORAL|Partial-Remote Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led once weekly by a clinician in small groups and clients gain additional practice by accessing clinician-assigned computer-based exercises independently.
41462501|NCT04909645|DIAGNOSTIC_TEST|Clearsight (finger cuff)|Clearsight (Edwards Lifesciences, Irvine, CA), a noninvasive technique, uses a finger cuff to measure blood pressure, cardiac output (CO) and cardiac index. Systemic vascular resistance (SVR) is calculated by the following equation: SVR=(Mean arterial pressure-Central venous pressure)\*80/CO.
41462502|NCT00971919|OTHER|questionnaire administration|
41462503|NCT00971919|PROCEDURE|assessment of therapy complications|
41462504|NCT00971919|PROCEDURE|psychosocial assessment and care|
41462505|NCT00971919|PROCEDURE|quality-of-life assessment|
41462506|NCT00002224|DRUG|Nelfinavir mesylate|
41462507|NCT00002224|DRUG|Stavudine|
41462508|NCT00002224|DRUG|Didanosine|
41462509|NCT04266431|BEHAVIORAL|EMPOWER|Behavioral weight loss intervention
41462510|NCT04912206|DIAGNOSTIC_TEST|Point-of-Care Ultrasound|Abdominal clinician-performed Ultrasound
41462511|NCT00820599|DEVICE|Sapien XT™ transcatheter heart valve and delivery system|
40777552|NCT03901430|BEHAVIORAL|Group navigation model|In a series of peer group sessions facilitated by Guadalupe Fuentes, a CHW who designed the model, we will create a culturally-appropriate, non-stigmatizing group intervention. The group process will allow participants to explore their own MEH, better understand the ways that mental health influences well-being and everyday dynamics of their lives, and to develop empowering knowledge and action plans through the support of other women.
40777553|NCT02348203|DRUG|Aspirin|Given PO
40982485|NCT01843751|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
40982486|NCT00222196|PROCEDURE|lifestyle, PTA|
40982487|NCT04563689|OTHER|CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|rinse 15 ml during 1 min during 5 days, twice daily
40982488|NCT04563689|OTHER|placebo rinse|destilled water rinse 15 ml during 1 min during 5 days, twice daily
40982489|NCT02673489|DRUG|DCV|
40982490|NCT02673489|DRUG|SOF|
40982491|NCT02673489|DRUG|RBV|
40982492|NCT05803811|DIETARY_SUPPLEMENT|Riboflavin|Colon delivered vitamin B2 (Riboflavin) for 12 weeks
41462512|NCT02288351|OTHER|Mix Nutrient Meal|Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
41462513|NCT02288351|OTHER|labs|Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
41462514|NCT02288351|OTHER|Biopsy|Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
41462515|NCT02288351|OTHER|Second Mix Nutrient Meal|2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
41462516|NCT02288351|OTHER|Second biopsy|. Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
40777554|NCT02348203|OTHER|Laboratory Biomarker Analysis|Correlative studies
41303555|NCT05980832|OTHER|Peer Education Supported Psychosocial Skills Education|"It is a psychosocial skills training that will be given to both experimental groups in 6 sessions within 6 weeks. 2 of the 4 peer trainers who received the practitioner training will conduct the training. During the training period, the research psychiatric nurse will support.~Session titles are as follows:~1. Session:Preparation Session~2. Session: Understanding Mental Disorders~3. Session: Developing Communication Skills~4. Session: Developing Emotion Recognition and Expression Skills~5. Session: Dealing with Daily Living Activities and Problems~6. Session: Understanding the Stigma Experience~The duration of each session is determined as 90 minutes. Taking into account the patient's opinions breaks not exceeding 15 minutes will be given as needed."
40777555|NCT02348203|OTHER|Placebo Administration|Given aspirin placebo PO
40777556|NCT02348203|OTHER|Placebo Administration|Given zileuton placebo PO
40777557|NCT02348203|DRUG|Zileuton|Given PO
40982493|NCT03219294|DRUG|Vecuronium 0.1 mg/kg|Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.
40982494|NCT03219294|DRUG|Vecuronium 0.2mg/kg|Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
40982495|NCT03415841|DEVICE|mHealth remote monitoring devices|"Blood Pressure and wearable vital signs monitor, Biovotion and Kardia mobile application"
40982496|NCT01092754|PROCEDURE|MRI|contrast enhanced MRI
40982497|NCT01092754|PROCEDURE|MRI|contrast enhanced MRI
40982498|NCT01092754|DRUG|Gadoversetamide|Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
40982499|NCT01432353|DRUG|DFRF4539A|multiple ascending doses
40982500|NCT04512209|PROCEDURE|MRI|"Patients will undergo an MR scan before undergoing cytoreductive surgery. If neoadjuvant chemotherapy is administered, an extra MR scan is planned before the start of the neoadjuvant chemotherapy.~During surgery, tissue samples will be taken for interstitial fluid pressure (IFP) measurement, immunohistochemistry (IHC) and characterization of biophysical properties (viscoelastic properties and hydraulic conductivity)."
40982501|NCT02963207|OTHER|Modified Sano's classification|Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.
40982502|NCT02963207|OTHER|NICE classification|Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.
40982503|NCT05706142|OTHER|Motor Imagery Education|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
40777558|NCT04337151|DEVICE|MAGEC Spine Rod|Magnetically controlled growing spine rod used for the surgical treatment of scoliosis.
40777559|NCT04337151|DIAGNOSTIC_TEST|Titanium blood test|A blood test captured to measure the level of titanium
40777560|NCT04946058|PROCEDURE|hyebrid Mathieu Urethroplasty|incision of the urethral plate during the procedure
40777561|NCT02796456|OTHER|blood sample|
40777562|NCT02133573|DRUG|Progesterone|Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.
40777563|NCT02133573|DRUG|Vaginal lubricant|Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
40777564|NCT02481557|DEVICE|Oxalate Salt Solution|Applied by dentist
40777565|NCT03195569|DRUG|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
40982504|NCT02776423|PROCEDURE|Bulkamid|The procedure was standardized, identical for all patients, and entirely performed in an outpatient setting. All injections were performed by a single urogynecologist. Before injection all patients received a single dose trimethoprim (Idotrim®, Orion Pharma). The patient was placed in a supine position and given intraurethral topical 2% lidocaine hydrochloride gel (Xylocain®, Astra Zeneca) for anesthetic. Using a video-urethroscope and a 23-gauge needle, polyacrylamide hydrogel deposits of 0.3-0.4 mL were injected at 12, 4 and 8 o´clock into the submucosa approximately 1 cm from the bladder neck. Patients were discharged after successful voiding.
40982505|NCT02738450|BIOLOGICAL|ACI-24 low dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
40982506|NCT02738450|BIOLOGICAL|ACI-24 high dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
40982507|NCT02738450|BIOLOGICAL|Placebo|Placebo is a standard PBS sterile solution administrated via s.c. injection.
40982508|NCT02742584|PROCEDURE|Cough Stress Test|Varying bladder volumes during cough stress test.
40982509|NCT03010163|OTHER|Health Fair|Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.
40777566|NCT03195569|DRUG|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
40777567|NCT03195569|DRUG|Paclitaxel|175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
40777568|NCT03195569|DRUG|Carboplatin|AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
40777569|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 alone|0.5 mL solution for injection x 2 (2 months interval)
40777570|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|0,5 mL suspension for injection x 2 (2 months interval)
40777571|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
40777572|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
40982510|NCT03010163|OTHER|Pedometer|The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.
40982511|NCT03010163|OTHER|Text Messaging|Daily healthy living advice and encouraging messages about walking through text messages
40982512|NCT03010163|OTHER|Social Network Support|Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities
40982513|NCT03652844|PROCEDURE|AAM|Subcutaneous injection procedure
41303556|NCT01840020|PROCEDURE|Gastric bypass|Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.
41303557|NCT01840020|PROCEDURE|gastric sleeve|Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
41303558|NCT02029404|PROCEDURE|Tibial nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
41303559|NCT02029404|PROCEDURE|Tibial peroneal nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
41303560|NCT05039580|DRUG|PD-1 monoclonal antibody|PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.
41303561|NCT01244542|OTHER|unpleasant stimuli|
41303562|NCT02592603|DEVICE|Endocuff-assisted Colonoscopy|Colonic examination with Endocuff-assisted Colonoscopy
41303563|NCT03381924|OTHER|Educational programme|In each session, neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
41303564|NCT03381924|OTHER|Routine clinical practice|Patients allocated to the control group will only receive the drugs used in the habitual clinical practice
41303565|NCT03442335|DIAGNOSTIC_TEST|Chromohysteroscopy|Standard hysteroscopy followed by injection of a dye, in this case iodine.
41303566|NCT03442335|DIAGNOSTIC_TEST|Endometrial biopsy (Pipelle)|A narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue.
41303567|NCT04901403|OTHER|Education|Parents will be provided with information about Earned Income Tax Credits and budgeting
41303568|NCT04901403|OTHER|Home visiting|Parents as Teachers home visiting program
41303569|NCT03184298|OTHER|Surveys|The purpose of the surveys is to collect quantitative data to determine the relative impact of the intervention program on participants' sexual behaviors and alcohol use.
41303570|NCT03184298|OTHER|Interviews|These Motivational Interviews aim to promote change in behavior through open-ended questions, affirmations, and reflections.
40982514|NCT02649907|DIETARY_SUPPLEMENT|nutritional stimulation via different testmeals|nutritional stimulation of hormonal response through different testmeals
41303571|NCT03184298|OTHER|Group Discussions|The purpose of the group workshop is to create discussions surrounding perceived and collective social norms found among male soldiers that have been connected to sexual aggression. These discussions are used to promote bystander intervention among participants and help identify the prosocial attitudes that may be more common than previously perceived.
41303572|NCT03147144|OTHER|Ultrasonographic imaging|Ultrasound pelvic scan
41303573|NCT01516164|DEVICE|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
41303574|NCT05356624|OTHER|Mulligan Mobilization|It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week
41303575|NCT05356624|OTHER|Soft Tissue Mobilization|in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.
40982515|NCT02649907|OTHER|Nutritional counseling|nutritional counseling for healthy eating behaviour
40982516|NCT02649907|DIETARY_SUPPLEMENT|formula diet|formula diet to help weight loss
40982517|NCT04791566|DRUG|Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
40982518|NCT04791566|DRUG|Physiologic saline|100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
40982519|NCT05457673|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
41462517|NCT02288351|DEVICE|PET/CT|Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
41462518|NCT03127306|DIAGNOSTIC_TEST|Assessment of Polish version of BPS|Validation of Polish Version of BPS.
41462519|NCT02528045|PROCEDURE|Vitrectomy with scleral shortening|
40777573|NCT03901586|OTHER|Satisfaction assessment|Patient will be asked to assess their satisfaction concerning the Richter procedure and its long term effect
40982520|NCT01504945|OTHER|RBC transfusion|1 bag of packed red blood cells
40982521|NCT01504945|OTHER|Normal saline infusion|500 mL of normal saline infusion
40982522|NCT06159712|OTHER|Blood samples|Extra blood samples
40982523|NCT03851042|DEVICE|Virtual Reality Head set in PACU|Use of VR headset to determine post op satisfaction in PACU, decreased pain reduction and opioid consumption
40982524|NCT03851042|OTHER|No intervention|Routine post laparoscopic hysterectomy management (no VR headset)
41143205|NCT01000935|OTHER|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
41143206|NCT01798537|DRUG|Neomycin Colistin Nystatin Vancomycin|All participating study arm patients will receive SDD from admission to discharge
41143207|NCT01271361|PROCEDURE|primary PCI with thrombectomy|thrombectomy is performed before implantation of a drug eluting stent
41143208|NCT01271361|PROCEDURE|primary PCI without thrombectomy|no thrombectomy is performed before the implantation of a drug eluting stent
41303576|NCT03709810|COMBINATION_PRODUCT|Marketed Denture Adhesive (Super Poligrip Max Seal)|The denture adhesive will be applied directly from the tubes. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.1 g for the maxillary and 0.6±0.1g for the mandibular dentures.
41303577|NCT03709810|OTHER|No Adhesive|No adhesive will be applied.
41303578|NCT04917835|DEVICE|PLADUO(PX1000)|Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.
41303579|NCT06085352|DRUG|TetraLens bandage contact lens|Methafilcon-A contact lens eluding tetracaine ophthalmic solution
41303580|NCT06085352|DEVICE|Control Acuvue Oasys Bandage contact Lens|Standard of care bandage contact lens
41303581|NCT00002157|DRUG|Thalidomide|
41303582|NCT06462417|DRUG|Arbidol|Arbidol Hydrochloride Tablets 0.2g/d for 2 weeks
41303583|NCT00012337|DRUG|gefitinib|
40777574|NCT03901586|OTHER|Quality of life|The Quality of life will be assessed with 3 questionnaires (I-Qol / PISQ-12/PFDI-20)
41143209|NCT02871726|DEVICE|TRUS-Robot|A robotic device used to hold and manipulate the ultrasound probe during a transrectal prostate biopsy.
41143210|NCT02871726|OTHER|TRUS biopsy|Uronav for prostate biopsy.
41143211|NCT02990494|BEHAVIORAL|STANDARD|Standard Internet-delivered behavioral weight loss
41143212|NCT02990494|BEHAVIORAL|PREVENT|enhanced standard Internet-delivered behavioral weight loss program
41143213|NCT02990494|BEHAVIORAL|PROMOTE|enhanced standard Internet-delivered behavioral weight loss program
41303584|NCT05699746|DRUG|Capecitabine tablets|Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.
41303585|NCT05699746|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
41303586|NCT00518219|DRUG|TW|TW,120mg/d
41303587|NCT06317272|OTHER|DIBH using ABC technique|Deep breath inspiration hold (DIBH) using Active Breathing Control (ABC) technique
41303588|NCT06317272|OTHER|DIBH using VC technique|Deep breath inspiration hold (DIBH) using Voluntary Coaching (VC) technique
41303589|NCT03243513|OTHER|Retrospective Chart Review|There is no intervention in this research. This research project is a retrospective chart review.
41303590|NCT05921006|DRUG|RJ4287|Oral，tablets，Once daily for 14 days
41303591|NCT05921006|DRUG|Placebo|Oral，tablets，Once daily daily for 14 days
41303592|NCT00002141|DRUG|Abacavir sulfate|
41303593|NCT01975766|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
41303594|NCT01975766|DEVICE|External beam radiation therapy|
41303595|NCT05302739|OTHER|Facial cooling|30 s of water mist sprayed onto the face during breaks in a simulated fencing competition
41303596|NCT02230124|DEVICE|MRE|
41303597|NCT02787993|BEHAVIORAL|Cognitive Behavioral Mult-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
41462520|NCT01876368|DRUG|LCZ696|
41462521|NCT01876368|DRUG|Olmesartan|
41462522|NCT01876368|DRUG|Placebo of LCZ696|
41462523|NCT01876368|DRUG|Placebo of Olmesartan|
41462524|NCT01611896|DIETARY_SUPPLEMENT|Selenium|100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
41462525|NCT01611896|OTHER|Placebo|Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
41462526|NCT05253430|PROCEDURE|Lymphadenectomy type|D1 vs D2 lymph node dissection
40982525|NCT05624203|DEVICE|Extracorporeal cardiac shock wave therapy(ECSW)|Extracorporeal cardiac shock wave therapy (CSWT) is a cutting-edge technology developed in the world for more than 20 years. It is mainly used in the treatment of refractory angina pectoris of coronary heart disease. The mechanism of extracorporeal cardiac shock wave therapy is mainly due to the small attenuation, small shear stress and strong penetration force of shock wave when propagating in human tissues. Shear stress and hole effect are generated in the focal area of shock wave, which leads to the repeated formation/rupture of microbubbles in tissue/cell microenvironment, resulting in various physical and biological effects. These physical mechanisms trigger a series of biological effects, such as promoting the expression of various intracellular cytokines and angiogenic factors, activating related signal transduction pathways, inhibiting apoptosis and oxidative stress, and finally increasing the number of new blood vessels in the treatment area and improving the ischemic state.
40982526|NCT06216145|OTHER|formative evaluation|"Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method"
40777575|NCT03901586|OTHER|Gynecological assessment|An optional gynecological consult is proposed to the patients to better estimate the gynecological long-term impact of the procedure
40777576|NCT01693367|DEVICE|DLS 5.0 (Dynamic locking screws)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
40777577|NCT01693367|DEVICE|SLS (Standard locking screw)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
40777578|NCT00582907|DRUG|Rilonacept|2.2 mg/kg/wk by subcutaneous injection, for 3 months
40777579|NCT00582907|DRUG|Placebo|placebo by subcutaneous injection weekly for 3 months
40777580|NCT04414787|BEHAVIORAL|PCplanner|PCplanner-augmented care. The PCplanner mobile app will allow patients / family members to report their needs in a platform viewable by ICU physicians. Should the needs not improve over time, the palliative care team will be activated to contribute to care.
40777581|NCT05671250|COMBINATION_PRODUCT|PRP gel and SOC-treatment|Platelet-lysate loaded sustained release thermo-gelling formulation
40777582|NCT05671250|COMBINATION_PRODUCT|EPO/ISDN/UFH cryogel dressing|Erythropoietin/Isosorbide dinitrate loaded cryogel scaffold
40777583|NCT05671250|PROCEDURE|Standard of Care|Sharp debridement, saline washing and regular saline dressing
40777584|NCT04290624|OTHER|Experimental Dentifrice: Stannous Fluoride|Participants will be instructed to dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion containing 0.454% w/w Stannous fluoride for 2 minutes twice daily (morning and evening) for 12 weeks.
40777585|NCT04290624|DEVICE|COREGA Denture Foaming Cleanser|Participant will clean their denture using 2 pumps of the denture cleansing foam and a denture cleaning brush for 90 timed seconds outside of the mouth twice daily (morning and evening) for 12 weeks.
40777586|NCT04290624|OTHER|Mouth rinse: Sodium Fluoride|Participants will take 10 ml of the mouth rinse containing 90 ppm sodium fluoride and swished around the mouth for 1 minute twice daily (morning and evening) for 12 weeks.
40777587|NCT02210676|OTHER|PROMIS Upper Extremity|
40982527|NCT03622307|DEVICE|Subcutaneous ICD Therapy Combined with VT Ablation|S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD
40982528|NCT06013540|COMBINATION_PRODUCT|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)
41303598|NCT00086957|BIOLOGICAL|trastuzumab|Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.
41303599|NCT00086957|DRUG|docetaxel|75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings
41303600|NCT00086957|DRUG|gefitinib|250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
40777588|NCT02210676|OTHER|Likert Pain Scale|
40777589|NCT02210676|OTHER|Mallet Finger Extensor Lag Measurement|
40777590|NCT04931576|PROCEDURE|no drainage tube applied|No drainage tube implacement after TOETVA
40777591|NCT00749346|DEVICE|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
40777592|NCT05910658|BEHAVIORAL|Competence in Romance and Understanding Sexual Health (CRUSH)|Manualized curriculum targeting sexual health and behavior in intimate relationships designed to meet the specific needs of autistic adults
40982529|NCT06013540|COMBINATION_PRODUCT|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)
40982530|NCT04106986|COMBINATION_PRODUCT|Pulsed electromagnetic field and Progressives resistance exercise|"The pulsed electromagnetic field treatment consist of 30 minutes pulsed electromagnetic field with 50 Hz pulses~The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
40982531|NCT04106986|OTHER|PRE|"The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
40777593|NCT01135966|BEHAVIORAL|Conventional resistance training program|Conventional resistance training program is followed.
40777594|NCT01135966|BEHAVIORAL|Whole body vibration resistance training program|WBV training on FITVIBE
40777595|NCT02041793|PROCEDURE|Laparoscopic cystogastrostomy|Patients undergo drainage of pseudocyst by laparoscopic technique
40777596|NCT02041793|PROCEDURE|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
40982532|NCT06398535|DEVICE|magenetic resonance and ultrasound|examination of patient using magentic resonace coil for imaging of knee and comapring the results obtaines by ultrasound examination using the ulatrsound tarsnsducer .
40982533|NCT03906903|DEVICE|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
40982534|NCT03906903|BEHAVIORAL|Cognitive Stimulation|Subjects will receive 30 sessions of 30 minutes with Cognitive Stimulation in three areas (attention, memory and executive functions), one each week.
41143214|NCT04222088|DRUG|Arthemeter-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
41143215|NCT04222088|DRUG|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)
41143216|NCT04222088|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
41143217|NCT03983642|DEVICE|Wii balance board|"Numerous video games exist to interact with the Wii Balance Board. One game that has been used in prior balance studies is Wii Fit.~On the first 4 weeks, balance training started with Soccer Heading game. The participants were asked to control their avatar by leaning to left or to the right in order to avoid the objects that were thrown towards them, and try to score the balls inside the net. The participants performed 3 sets of 5 rounds (2min each), totaling 30 min, and rested for 1 min between each set.~Table Tilt game continued for the remaining 4 weeks. Participants tried to enter balls into the holes by shifting their body weight on the balance board causing it to tilt in all directions. This game was divided into multiple levels of 30 seconds each, repeated over 30 min, with a one-minute rest interval between every 10 minutes of training. Moreover, 20 extra seconds were added each time a participant has won a level."
41143218|NCT04409392|OTHER|Prothestic joint infection due to Staphylococcus lugdunensis|description of prosthetic joint infection with Staphylococcus lugdunensis
41143219|NCT01156675|DEVICE|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
41143220|NCT01156675|DEVICE|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
41143221|NCT03471442|PROCEDURE|Paravertebral block|Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
40777597|NCT06113757|DEVICE|Signal Therapy provided by Dr.Biolyse device|Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. Electrical signal will be applied to the lung and upper leg area for 90 minutes in the morning, noon, and evening on the first 3 days, 60 minutes in the morning and evening on the 4th and 5th days, to the lung and upper leg area. During your first hospitalization, blood will be drawn from you daily for 5 days and evaluated in terms of various biochemical parameters and detailed molecular analyzes.
40777598|NCT06113757|OTHER|Liquid Support Treatment|The control group will only receive fluid therapy and will be monitored with the same blood parameters throughout the hospitalization.
40777599|NCT03190421|DIAGNOSTIC_TEST|Expanded Urinary Culture|involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.
40982535|NCT01650233|BEHAVIORAL|Mindfulness-based stress reduction|
40982536|NCT06472908|DRUG|Colchicine 0.5 mg|Colchicine 0.5 mg, one pill a day, oral intake
40982537|NCT06472908|DRUG|Colchicine 0.375 mg|Colchicine 0.375 mg, one pill a day, oral intake
40777600|NCT03190421|DIAGNOSTIC_TEST|Standard Urine Culture (SUC)|involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
40777601|NCT03140111|DEVICE|LAMELLEYE|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
40777602|NCT03140111|DEVICE|OPTIVE FUSION|Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.
40777603|NCT02177383|DIETARY_SUPPLEMENT|Docosahexaenoic acid diet supplementation|"Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
40982538|NCT06472908|DRUG|Placebo|Placebo, one pill a day, oral intake
40982539|NCT00489398|DRUG|epinastine HCL and olopatadine HCL|
40982540|NCT05864560|DEVICE|Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System|Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).
40982541|NCT00412854|BIOLOGICAL|Infanrix™/Hib|
40982542|NCT00412854|BIOLOGICAL|Infanrix|
40982543|NCT00412854|BIOLOGICAL|Hiberix|
40982544|NCT04734223|DIAGNOSTIC_TEST|Neuroimaging Findings in Patients With COVID-19|MR and BT Imaging
40982545|NCT02766062|OTHER|metabolic syndrome|metabolic syndrome
40982546|NCT04212247|BEHAVIORAL|Well-Being Therapy|Well-Being Therapy (WBT) is a short-term psychotherapeutic strategy, that emphasizes self-observation with the use of a structured diary, interaction between patients and therapists and homework. WBT was based on the model of psychological well-being that was originally developed by Jahoda in 1958 and further refined by Ryff in 2014. The standard number of sessions is 8. The initial phase is concerned with self-observation of psychological well-being. Then, the patient is encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of wellbeing. The final part involves cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
40982547|NCT04212247|BEHAVIORAL|Control condition|The control condition will include 8 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drug misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
40982548|NCT02101645|PROCEDURE|Periodical low intensity direct current (LIDC) stimulation of wound.|Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.
40982549|NCT02101645|PROCEDURE|Compression therapy of swollen limbs.|Compression bandage is used for reducing swelling of the limbs.
40982550|NCT01491503|DRUG|Levocetirizine|Levocetirizine dihydrochloride 5mg. PO. Single dose.
40982551|NCT01491503|DRUG|montelukast sodium|Montelukast sodium 10mg. PO. Single dose.
40982552|NCT01491503|DRUG|Montelukast & levocetirizine|Montelukast sodium 10mg \& levocetirizine dihydrochloride 5mg PO. Single dose.
40982553|NCT03274401|DEVICE|Zenicor intermittent ECG device|At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
40982554|NCT03274401|DEVICE|5 day ECG patch|Selection of device for monitoring clinicians' choice
40982555|NCT00704925|DRUG|3, 4 DAP|Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
40982556|NCT02894931|DIETARY_SUPPLEMENT|monosaccharides|The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
40982557|NCT02894931|DIETARY_SUPPLEMENT|Disaccharides|The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
40982558|NCT02894931|DIETARY_SUPPLEMENT|Amino acids|The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
41143222|NCT03471442|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
40982559|NCT02894931|DIETARY_SUPPLEMENT|Artificial Sweeteners|The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
40982560|NCT02894931|OTHER|Control- water|Chilled water flavored with lemon juice as control
40982561|NCT01148758|DRUG|RO5323441|cohorts receiving multiple doses iv
40982562|NCT04193657|OTHER|Daily and weekly triggered symptom monitoring|Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.
40982563|NCT06217289|OTHER|Observation|Observation and knowledgement on behavior of healthcare professional workers during hpreparation of oral solid pharmaceutical drug
41462527|NCT04915222|OTHER|Natural apophyseal glides|Patients received conventional therapy and NAGS with 2-3 hertz (less than 6 repetitions) in 3 sets for 3 weeks. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
40777604|NCT02177383|DIETARY_SUPPLEMENT|Placebo supplementation|"Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
40982564|NCT05726812|BEHAVIORAL|Plan My Life Together|A group training for adolescents with ADHD in which they learn to plan and organize. The training consists of 8 weekly sessions of 90 minutes for the adolescent and 2 parent sessions of 90 minutes.
41462528|NCT04915222|OTHER|Cervical manual traction|Patients received cervical manual traction (CMT) along with traditional therapy. Treatment frequency was 3 sessions per week for total three weeks duration. CMT applied was intermittent type traction.8 to 10 kg force was applied at an angle of 20 to 25 degree from horizontal. 5sets of cervical traction are performed. In every set traction is given for 1 minute with rest period of 20 seconds. The total time of traction session was 10 minute. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
40777605|NCT00271245|DIETARY_SUPPLEMENT|200 µg selenium as selenate|200 µg selenium as selenate
40777606|NCT00271245|DIETARY_SUPPLEMENT|400 µg selenium as selenate|400 µg selenium as selenate
40777607|NCT00271245|DIETARY_SUPPLEMENT|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
40777608|NCT00271245|DIETARY_SUPPLEMENT|Placebo|Placebo
40777609|NCT03526211|DEVICE|FES cycling|On the patient, three pairs of electrodes will be applied on tibial hamstring, quadriceps and gluteal muscles of each lower limb. Cycloergometer will be installed in passive mode. Then, optimal stimulation intensity for each muscle will be defined. During twenty minutes, neuromuscular electrical stimulation will generate a passive pedaling on cycloergometer.
40777610|NCT02862886|OTHER|myometrium biopsy|
40982565|NCT05070117|BEHAVIORAL|Exercise training|Study participants perform resistance/strength exercises 2-3 times per week for one hour, for one year.
41143223|NCT03471442|DRUG|General anesthetic|General anesthesia administered as per preference of intra-operative attending anesthesiologist
41143224|NCT03471442|DRUG|Opioids|Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
41143225|NCT03471442|DRUG|Anesthetics, Local|Weight-based dosing of this local anesthetic mixture.
41143226|NCT03837015|DRUG|Estring Vaginal Ring|Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days
41143227|NCT03837015|OTHER|RepHresh Pro-B|Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally
41143228|NCT01827748|DEVICE|Intraoperative Autorefractor IAR-1|This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position
41143229|NCT01827748|DEVICE|Hartmann-Shack Auto Refractor|Standard auto-refractor used with subject sitting upright in front of the instrument.
40777611|NCT02501447|BEHAVIORAL|Guided audio-visual relaxation|
40777612|NCT02143882|DRUG|Fluenz|Live attenuated influenza vaccine
40777613|NCT00833690|DRUG|Placebo|500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
40777614|NCT00833690|DRUG|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
40777615|NCT00833690|DRUG|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
40777616|NCT01923376|DRUG|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
40777617|NCT01923376|DRUG|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
41143230|NCT04249700|DEVICE|Curve Sauna Dome|All participants receive WBH for 80-110 minutes in an infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
40982566|NCT00237757|BEHAVIORAL|Information feedback|The experimental arm consisted of a six month staff training period. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing. The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes.
40982567|NCT00237757|BEHAVIORAL|Information feedback|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
40982568|NCT03569631|DRUG|BPN14770|25 mg BPN14770 capsules
40982569|NCT03569631|DRUG|Placebo|Placebo capsules to mimic 25 mg BPN14770 capsules
41303601|NCT04177056|RADIATION|SBRT|Patients will received a single fraction of 15-20 Gy to bone metastases causing pain. Planning and delivery will be conducted using a volumetric modulated arc therapy (VMAT) approach on the Varian TrueBeam platform. Patients will be CT simulated, with vac-lock immobilization. Use of 4-dimensional CT will be dependent on the area being treated. Daily image guidance will be performed using cone beam CT aligning to relevant bony anatomy.
40777618|NCT01435590|PROCEDURE|Curette v/s endocervical brush|
40777619|NCT01291589|BEHAVIORAL|Cognitive-behavioral therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors
41303602|NCT05794516|DRUG|ZB004|ZB004 single doses administered subcutaneously as solution
41462529|NCT05857917|DEVICE|Virtual Reality|Virtual reality in PD catheter insertion surgery in the pre- and intraoperative setting.
40777620|NCT05389072|DEVICE|control contact lens|control CRT lens
40777621|NCT04243148|COMBINATION_PRODUCT|Home exercise program for 12 months.|Physical exercise at home: At the beginning of the study, group sessions will be conducted with 5 patients of 1-hour duration, where they will be taught the individualized program according to their physical condition and they will be given the necessary material (pedaling, dumbbells and elastic bands) and paper support on the program, also using the Vivifrail method through infographics. The group session will be repeated every 3 months to check the compliance of the program by reviewing daily activity, evaluate possible problems and review the exercises. The program will consist of aerobic and anaerobic exercise by pedaling (cardiovascular resistance) and resistance exercises with dumbbells and elastic bands (muscular strength), flexibility training by stretching, and coordination and balance exercises. Patients will perform 3 sessions per week of 20-30 min. increasing progressively according to tolerance up to 45-60 min. each.
40982570|NCT02220933|DRUG|MD1003 100mg capsule|
40982571|NCT02220933|DRUG|Placebo|
40982572|NCT00044356|GENETIC|Allovectin-7®|
40982573|NCT02880189|DEVICE|Orbera Intragastric Balloon|The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
40982574|NCT02880189|PROCEDURE|Endoscopic Ultrasound Guided Core Liver Biopsy|
40982575|NCT05685082|BEHAVIORAL|Standardized patient simulation|The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual
40982576|NCT05685082|BEHAVIORAL|Manikin-based simulation|The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
40982577|NCT00128570|BEHAVIORAL|behavioral dietary intervention|
40982578|NCT00128570|OTHER|educational intervention|
40982579|NCT00128570|OTHER|internet-based intervention|
40982580|NCT00128570|OTHER|preventative dietary intervention|
40982581|NCT00128570|PROCEDURE|evaluation of cancer risk factors|
40982582|NCT01375985|DRUG|AVI-7100|Single intravenous administration
41303603|NCT05794516|DRUG|Placebo|Placebo single doses administered subcutaneously as solution
41303604|NCT01598727|DEVICE|Fluobeam(TM) Imaging System (Fluoptics)|Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
41462530|NCT03481517|DRUG|Bupivacaine|Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.
40982583|NCT01375985|DRUG|Placebo|Single intravenous administration
40982584|NCT00674661|DRUG|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
40982585|NCT00674661|DEVICE|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
40982586|NCT03966001|OTHER|Transvaginal sonography at six months after cesarean section|In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
40982587|NCT03966001|OTHER|Transvaginal sonography at twelve months after cesarean section|In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
40982588|NCT05931250|DEVICE|DC-Stimulator Plus (NeuroConn GmbH, Germany)|Transcranial alternating current stimulation
40982589|NCT05931250|DEVICE|Sooma direct current stimulator (Sooma, Finland)|Transcranial direct current stimulation
41303605|NCT05155696|DIETARY_SUPPLEMENT|Experimental: Kefir probiotic drink (supplied by Nourish)|125ml per day of dairy based probiotic drink (Kefir) containing ≥ 50billion colony forming units (CFU), supplied in plain packaging.
41462531|NCT04580186|PROCEDURE|bladder exstrophy repair|primary complete bladder exstrophy repair
41462532|NCT04326933|DRUG|Tyrosine kinase Inhibitors (Imatinib & Nilotinib)|Administration of tyrosine kinase inhibitors (Imatinib in a dose of 400mg/day \& Nilotinib in adose of 600mg/day)
40982590|NCT02838563|OTHER|SIWA|To investigate the scale reliability over time, SIWA are assessed twice, ten minutes apart. To investigate the validity of the tool, SIWA is correlated with another quality of life questionnaire (QoL-AD), a quality of health scale including an analog portion (EQ 5D), and a behavioral disorder scale (Neuropsychiatric Inventory, NPI).
40982591|NCT03018509|DRUG|JTE-451|Active drug tablets containing JTE-451
40982592|NCT03018509|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
40982593|NCT00898157|OTHER|laboratory biomarker analysis|
41303606|NCT05155696|DIETARY_SUPPLEMENT|Placebo comparator|125ml of non-fermented dairy based placebo (UHT milk) per day, supplied in plain packaging.
41462533|NCT06222606|PROCEDURE|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize parathyroid glands during surgery.
41462534|NCT06424691|DIETARY_SUPPLEMENT|Tailored Recommendations|Based on the microbiome analysis, participants will receive personalized action plans. These plans include dietary, lifestyle, and supplemental suggestions to improve their infant's gut health.
41462535|NCT06424691|BEHAVIORAL|Consult Call|Participants will have seven consult calls with a Gut Health Coach over the course of the study. These calls will provide guidance on the gut health reports, action plans, and any questions or concerns parents may have.
41462536|NCT06424691|BEHAVIORAL|Email Series|Parents will receive a series of educational emails covering topics such as the importance of gut health, breastfeeding benefits, the impact of C-section delivery on the microbiome, and tips for introducing solid foods.
40777622|NCT04243148|COMBINATION_PRODUCT|Multispecies probiotic: Vivomixx®|"Multispecies probiotic: Vivomixx® is a probiotic mixture of 8 bacterial strains:~Streptococcus thermophilus DSM 24731® / NCIMB 30438, Bifidobacterium breve DSM 24732® / NCIMB 30441, Bifidobacterium longum DSM 24736® / NCIMB 30435\*, Bifidobacterium infantis DSM 24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM 24735® / NCIMB 30442, Lactobacillus plantarum DSM 24730® / NCIMB 30437, Lactobacillus paracasei DSM 24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734® / NCIMB 30440\*\*~\* Re-classified as B. lactis \*\* Re-classified as L. helveticus The active agent will be supplied as an envelope of 4.4 g with a dose of 450x109 million live bacteria per envelope with maltose and silicon dioxide as excipients, administered 2 times/day throughout the study."
40777623|NCT04243148|COMBINATION_PRODUCT|Branched-chain amino acids (BCAA)|Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements (powder in 8:1:1 ratio in favor of L-leucine) 10 g 30-60 min. before the exercise session throughout the study, in order to enhance the effect of exercise on muscle mass and improve cognitive function. We have chosen this dose based on the literature data and the satisfactory results obtained with this dose in our previous study. BCAA supplements will be supplied by the Pharmacy Service of our center.
40777624|NCT04243148|COMBINATION_PRODUCT|No specific intervention.|Follow up as a clinical practice
40777625|NCT05069519|BEHAVIORAL|Personalized Smartwatch|"Participants will continue with standard care, but will receive a Fitbit and be encouraged to participate in at least 150 min. moderate-to-vigorous physical activity (5 sessions aerobic exercise, 30 min. per session; and 2 sessions of strength training) per week if their body condition allows throughout the intervention period. The previously established daily and weekly exercise prescription will be offered to participants based on their previous week Fitbit data.~PA improvements will be tailored over time based on each participant's previous week PA and they will be encouraged to increase PA by 5-10 min/week if possible depending on specific situations. Participants will save each workout and synchronize the Fitbit PA data to its app where they only share daily data and receive weekly personalized exercise prescriptions established in pilot studies."
40777626|NCT05069519|BEHAVIORAL|Facebook Health Education|Participants assigned to this condition will receive a Fitbit smartwatch, continue with standard care, but will receive health education tips developed in the investigators' previous studies from a private Facebook group in which only group members and researchers can access. Additionally, the investigators will track login counts, analyze their post activity and online sentiments via texting mining and natural language processing, and then offer weekly personalized feedback based on the data to facilitate social support
40777627|NCT03076684|OTHER|low-fructose diet|Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to \<5% of energy and keeping their weight stable.
40777628|NCT03076684|DRUG|Allopurinol|Subjects in the drug arm will take the drug allopurinol daily.
40982594|NCT05102383|DEVICE|Comfilcon A Toric contact lenses|Monthly replacement contact lenses
40982595|NCT05102383|DEVICE|Verofilcon A for Astigmatism Daily Disposable contact lenses|Daily disposable contact lenses
40982596|NCT00002433|DRUG|Interferon gamma-1b|
40982597|NCT02560584|DRUG|Hexaminolevulinate hydrochloride|Instillation in bladder
40982598|NCT02560584|DEVICE|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
40982599|NCT01285999|DEVICE|PROMUS Element Coronary Stent System|Everolimus-eluting Coronary Stent
40982600|NCT01285999|DEVICE|TAXUS Liberté Coronary Stent System|Paclitaxel-eluting Coronary Stent
40982601|NCT04557657|DRUG|Active bio Activa|Cement that release fluoride
40982602|NCT04557657|DRUG|Resin Cement|Resin Cement Convinonal
40982603|NCT00103142|BIOLOGICAL|falimarev|Given subcutaneously and intradermally
40982604|NCT00103142|BIOLOGICAL|inalimarev|Given subcutaneously and intradermally
41303607|NCT01808118|BIOLOGICAL|adalimumab|40 mg every other week
41303608|NCT01808118|BIOLOGICAL|Placebo|every other week
41303609|NCT03892785|DRUG|Prednisone treatment|tapering prednisone regimen
41462537|NCT04767087|DRUG|Honey|0.5 gm/Kg/day honey
40982605|NCT00103142|BIOLOGICAL|sargramostim|Given subcutaneously
40982606|NCT00103142|BIOLOGICAL|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
40982607|NCT04065906|BEHAVIORAL|NIRS neurofeedback|Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
40982608|NCT04065906|DRUG|Methylphenidate or Tomoxetine|Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
41303610|NCT03892785|DRUG|Tocilizumab treatment|Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)
41462538|NCT04767087|DRUG|Nigella sativa seed|40 mg/Kg/day
40777629|NCT05173090|DRUG|Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery|Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
40777630|NCT00006379|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
40982609|NCT01450839|DRUG|E2022|The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
41462539|NCT04767087|OTHER|Placebo|empty capsule with sugar water
40777631|NCT00006379|BIOLOGICAL|graft-versus-tumor induction therapy|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
40777632|NCT00006379|DRUG|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
40777633|NCT00006379|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
41462540|NCT05822726|DIAGNOSTIC_TEST|Prostate biopsy|"Targeted guided puncture biopsy guided by B-ultrasound will be performed (in addition to 12-needle system biopsy, if PSMA-PET/MRI or mpMRI indicates a positive lesion, puncture biopsy should be added at the lesion displayed on image, the 12-needle system biopsy+X scheme)."
41462541|NCT03495206|DRUG|Y-2(Edaravone And Borneol) Sublingual Tablet|Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
40777634|NCT00006379|PROCEDURE|peripheral blood stem cell transplantation|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
40777635|NCT05662657|DIAGNOSTIC_TEST|Diagnostic Test: PCL-S Questionnaire|PCL-S and HADS questionnaires
40777636|NCT02501421|BIOLOGICAL|tuberculosis vaccine|Live recombinant influenza vectored tuberculosis vaccine
40982610|NCT01450839|DRUG|Placebo|Matching Placebo tablets and tape
41462542|NCT06447441|OTHER|Placebo|Enteral supplementation of placebo in 3 consecutive days within 96 hours after ICU admission.
41462543|NCT06447441|OTHER|Cholecalciferol|Enteral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days within 96 hours after ICU admission
40982611|NCT00628992|OTHER|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
41143231|NCT03717207|OTHER|ecg Holter,|all patients before to perform an head up tilt test for syncope evaluation will be steadied by ecg Holter to assess heart rate, heart rate variability.
41462544|NCT04542915|OTHER|No intervention|No intervention.
40982612|NCT00628992|OTHER|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
40982613|NCT00628992|OTHER|Cycloergometer training|Muscular rehabilitation of the leg
41143232|NCT03717207|DIAGNOSTIC_TEST|cardiac scintigraphy|all patients before to perform an head up tilt test for syncope evaluation will receive a the 123I-MIBG, which is a norepinephrine analogous, to calculate the late heart-to-mediastinum ratio (H/Mlate) and washout rate (WR). Thus, we evaluated the H/Mlate as the index of global neuronal function due to norepinephrine uptake and the WR as the index of sympathetic tone.
40777637|NCT02501421|BIOLOGICAL|Placebo|Buffer
40777638|NCT01819740|OTHER|"determine the levels of the HEM substance in seminal plasma"|
40777639|NCT06264635|BIOLOGICAL|Platelet-Rich-Plasma|PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.
40777640|NCT06264635|OTHER|Saline|Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.
40777641|NCT04154722|DRUG|Meropenem Injection|inj meropenum for 10 days
40777642|NCT04154722|DRUG|Azithromycin Powder|syp azithromycin for10days
40777643|NCT03652155|PROCEDURE|Orthognathic surgery|Patient's pre and post operative hard and soft tissues will be evaluated retrospectively through the use of con-beam computed tomography imaging for hard tissue evaluation and 3DMd three dimensional photography for soft tissue imaging.
40777644|NCT01190319|OTHER|Strawberry Beverage|Beverage, daily for 8 weeks, 12g freeze-dried strawberry powder
40777645|NCT01190319|OTHER|Placebo|Placebo beverage, 8 weeks
41143233|NCT02070276|PROCEDURE|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
41462545|NCT04304339|OTHER|Hypercapnic respiratory failure|Patients with hypercapnic respiratory failure will be followed without any additional intervention
41462546|NCT01843309|DRUG|Spironolactone 100mg|
41462547|NCT01843309|DRUG|Spironolactone 200mg|
41462548|NCT01843309|DRUG|Placebo|
41462549|NCT02336906|DRUG|polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
41462550|NCT02336906|BEHAVIORAL|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
41462551|NCT02336906|BEHAVIORAL|Urotherapy|The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
40982614|NCT00628992|OTHER|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
40982615|NCT04434794|BIOLOGICAL|mesenchymal stem cells|autologous mesenchymal stem cells
40982616|NCT04434794|OTHER|standard treatment|standard treatment according to clinical protocols
40777646|NCT06317935|OTHER|ArmeoSenso|ArmeoSenso is an upper extremity virtual reality application with three motion sensors and one hand grip sensor. The device detects the person's body, arm, forearm and hand movements and displays the reflection of the movements on the screen. The application includes studies on upper extremity functions.
40777647|NCT06317935|OTHER|Traditional Rehabilitation|It includes traditional occupational therapy and physiotherapy approaches.
40777648|NCT05218707|OTHER|GUEDEL Airway|GUEDEL Airway of size '000,00,0,' and '1' will be used.
40982617|NCT01793675|PROCEDURE|transplant with haploidentical donor|patients with advanced MDS without identical sibling donor receive haploidentical transplant
40982618|NCT04688762|OTHER|e-consult application (tool)|A numeric application used as a support in consultation to explain the surgical management of the patient.
40982619|NCT05226325|DRUG|Dexmedetomidine|patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion
41462552|NCT05659238|BEHAVIORAL|the effect on language development & attention|Tv \& other electronic devices effects onn children's language development \& attention
41462553|NCT02393560|PROCEDURE|DECT scan|
40777649|NCT05548426|DRUG|Group B, Linezolid 10d|Oral Linezolid 600mg, taken twice a day for 10 days
40777650|NCT05548426|DRUG|Group A, Penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
40982620|NCT02417974|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
41462554|NCT01728740|DRUG|Acarbose/Metformin FDC (BAY81-9783)|Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
40777651|NCT02128737|BEHAVIORAL|Sleep|
40777652|NCT05472142|OTHER|UP FOR IT - practice facilitation|"Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The practice facilitation collaborative trains and supports clinical teams to use the Model for Improvement to make breakthrough improvements in diabetes care and DSMES utilization by recognizing barriers and changing clinical systems and care practices."
41462555|NCT01728740|DRUG|Acarbose (Glucobay, BAYG5421)|Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
40777653|NCT05472142|OTHER|UP FOR IT - health information technology|Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The health information technology component provides the scaffolding for quality improvement efforts by automating patient identification and enabling bi-directional referral communication between providers and diabetes self-management education and services (DSMES) programs.
40777654|NCT04345055|OTHER|Treatment of the lumbar fasciae|Treat the lumbar facial with a manual technique
40982621|NCT02677142|BEHAVIORAL|Structured social skills training program, SSIP|Detailed, session by session, in the manual written for this purpose. It addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion).
40982622|NCT02677142|BEHAVIORAL|CG - social skills activities|Sessions will not be designed around a specific social skill and activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
40982623|NCT05266742|OTHER|web based education|"An educative website was created for our study. The content of the website was accessible from www.diyabet.mumcu.net and the content of the website was brought together by scanning the literature. The content text was quoted from publicly available information and guides as ADA and IDF."
40982624|NCT06377254|BEHAVIORAL|Decreased Physical Activity|Physical activity levels will be decreased
40982625|NCT06377254|BEHAVIORAL|Increased Physical activity|Physical activity levels will be increased
40982626|NCT02201654|OTHER|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
41143234|NCT02070276|PROCEDURE|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
40777655|NCT04345055|OTHER|Placebo intervention|Introduce in a machine off
40777656|NCT00601731|BIOLOGICAL|MenACWY-CRM197|Blood test, 40-months and 60-months children
40777657|NCT00601731|BIOLOGICAL|Blood test|Blood test, 40-months and 60-months children
40777658|NCT00931281|DRUG|ABT-450|capsules, QD or BID, 14 days, ascending doses
40777659|NCT00931281|DRUG|ritonavir|capsules, QD or BID, 14 days, ascending doses
40777660|NCT00931281|DRUG|Placebo for ABT-450|capsule, QD or BID, 14 days
40777661|NCT00931281|DRUG|Placebo for ritonavir|capsule, QD or BID, 14 days
41462556|NCT01728740|DRUG|Metformin|Metformin 500mg, oral, single dose
41462557|NCT01222364|PROCEDURE|Standard Cord Clamping|Immediate clamping (\<5 seconds) of the umbilical cord after delivery.
41462558|NCT01222364|PROCEDURE|Delayed Cord Clamping|Clamping of the umbilical cord at 30-45 seconds after birth.
41462559|NCT03636087|PROCEDURE|Access cavity preparation|High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
41462560|NCT03636087|PROCEDURE|Working Length Determination|The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)
41462561|NCT03636087|PROCEDURE|Root canal instrumentation and chemo-mechanical preparation|Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)
41462562|NCT03636087|PROCEDURE|Root canal obturation|Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)
41303611|NCT03892785|DRUG|Methotrexate treatment|"Methotrexate subcutaneous from W0 to W51 (52 administrations).~* W0: 7.5 mg/week~* W1: 0.2 mg/Kg/week~* W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51"
41303612|NCT03892785|OTHER|Questionnaires|HAQ, SF-36, FACIT-fatigue
41303613|NCT03892785|BIOLOGICAL|Blood samples|Additionnal blood samples for immunomonitoring
40777662|NCT00127855|BIOLOGICAL|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
40777663|NCT00127855|BIOLOGICAL|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
41303614|NCT00258089|DRUG|Levofloxacin|
41303615|NCT06512818|DIETARY_SUPPLEMENT|Psiguavin|A purified guava extract will be used, enriched in psiguavin
41462563|NCT03636087|PROCEDURE|Coronal restoration build up|A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)
41462564|NCT03636087|OTHER|Changing gloves before obturation|The treating dentist will change gloves before obturation
40777664|NCT00127855|BIOLOGICAL|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
40777665|NCT00127855|BIOLOGICAL|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
40777666|NCT00127855|BIOLOGICAL|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
40777667|NCT00127855|BIOLOGICAL|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
40777668|NCT00127855|BIOLOGICAL|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
40777669|NCT04862494|OTHER|clinical surveillance|regular clinical follow up including chest X-rays, pulmonary investigations, etc...
40777670|NCT04862494|PROCEDURE|diaphragmatic plication|plication of a hemidiaphragm, performed via laparoscopy, thoracoscopy (including robot-assisted surgery), or classical thoracotomy
40777671|NCT00642486|OTHER|Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)|portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.
40777672|NCT00642486|OTHER|Standard polysomnography (PSG)|laboratory-based testing
40777673|NCT00475098|DRUG|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
41143235|NCT04087239|OTHER|HIV|
40777674|NCT03455686|OTHER|Hyperpolarized 129Xe MRI|Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.
40777675|NCT05464602|OTHER|Intervention group Lavender|This group received inhalation aromatherapy 2 drops of lavender oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
41143236|NCT05950841|DRUG|Low dose IHAT|Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)
41143237|NCT05950841|DRUG|High Dose IHAT|Twice daily dose of 1 capsule (100mg per capsule IHAT)
41143238|NCT05950841|DRUG|Carob flour|Twice daily dose of 1 capsule (carob flour)
41143239|NCT02400645|PROCEDURE|Pre-incisional wound infiltration|Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions
41462565|NCT03636087|OTHER|Disinfecting rubber dam|2.25% Sodium Hypochlorite solution will be used to disinfect the rubber dam surface
41462566|NCT03636087|OTHER|The use of new instruments at time of obturation|A new instrument's kit will be use at the time of obturation
40777676|NCT05464602|OTHER|Intervention group Geranium|This group received inhalation aromatherapy 2 drops of geranium oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
40777677|NCT06412887|DEVICE|Virtual reality headset|Meta-Quest 2 virtual reality headset was used in this study
40777678|NCT01574144|DEVICE|AVIVO™ PiiX Patch Monitor System|External monitoring for 30 days post-discharge.
40777679|NCT00152126|PROCEDURE|Stem Cell Transplantation|Autologous stem cell transplantation
40777680|NCT00152126|DRUG|Busulfan, Melphalan|Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
40777681|NCT00548535|PROCEDURE|Reliability of complication assessment|
40777682|NCT01849276|DRUG|metformin hydrochloride|Given orally
40777683|NCT01849276|DRUG|cytarabine|Given IV
40777684|NCT01849276|OTHER|laboratory biomarker analysis|Correlative studies
40777685|NCT04106245|BEHAVIORAL|Behavioral Intervention|Participate in PACK Health
40777686|NCT04106245|OTHER|Survey Administration|Complete survey
41143240|NCT02400645|PROCEDURE|Laparoscope to place TAP block with liposomal bupivacaine|Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%
41303616|NCT06512818|DRUG|Placebo|Capsules with the same characteristics that Psiguavin intervention but filled with a placebo compound
41462567|NCT03636087|RADIATION|Cone Beam Computed Tomography scanning (CBCT)|CBCT will be taken before treatment and one year after completion
41462568|NCT03636087|RADIATION|Radiographic imaging using periapical radiographs|Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
41462569|NCT01107028|OTHER|Standard pulmonary rehabilitation program|At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
41462570|NCT02403973|OTHER|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
41462571|NCT00668395|DRUG|Efavirenz|The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
41462572|NCT01570231|DEVICE|bilateral limb ischemic preconditioning (Doctormate, IPC-906X)|Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
40777687|NCT02499744|DEVICE|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
40982627|NCT05008250|DRUG|Tongmai Yangxin Pill (TMYXP)|"TMYXP is a Chinese patent medicine developed by many years of clinical practice experience. The ingredients of TMYXP are Radix Rehmanniae, Caulis Spatholobi, Polygonum Multiflorum, Colla Corii Asini, Ophiopogonis, Tortoise Shell (vinegar), Radix Codonopsis, Cassia Twig, Jujube, Schisandra Fruit, and Licorice Root. It has the effect of invigorating Qi, nourishing Yin, dredging the pulse, and relieving pain. It is used in treatment of Qi and Yin deficiency syndromes caused by coronary heart disease, angina pectoris, and arrhythmia.~Metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction."
40982628|NCT05008250|DRUG|metoprolol tartrate|metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
40982629|NCT05008250|DRUG|placebo|simulated pills
40982630|NCT00902369|DRUG|AK106-001616|Part1: Dose escalation Part2: Dose expansion
40982631|NCT00902369|DRUG|Placebo|
40982632|NCT00902369|DRUG|Active comparator|
41143241|NCT02400645|DRUG|Liposomal bupivacaine|Use of Liposomal bupivacaine in laparoscopic TAP block
41143242|NCT02400645|DRUG|Bupivacaine|20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.
41143243|NCT02400645|DRUG|Ketorolac|Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
41143244|NCT00091728|DRUG|Depo Medroxyprogesterone acetate|
41143245|NCT00091728|DRUG|Combined oral contraceptives|
41143246|NCT03874091|PROCEDURE|bilateral ESP block with 0,25% Bupivacaine+ Adrenaline|Regional anaesthesia technique performed under ultrasound guidance before surgery
41143247|NCT03874091|PROCEDURE|ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline|Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
41143248|NCT03874091|DRUG|Morphine PCA pump|Morphine given postoperatively.
41143249|NCT05823714|DRUG|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."
41143250|NCT04514094|DRUG|SDF|SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.
41143251|NCT04514094|PROCEDURE|ART|The ART technique involves caries excavation by hand instruments only with care to avoid pulp exposure. Such excavation is mainly from the periphery of the lesion to achieve a good seal of the restoration and minimize leakage. The tooth is then restored by glass ionomer cement.
41143252|NCT03821285|PROCEDURE|Pulmonary Rehabilitation|Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training
41143253|NCT02441829|DRUG|Eleclazine|Eleclazine tablets administered orally in morning with food
41143254|NCT00255749|BIOLOGICAL|epoetin alfa|
41143255|NCT04184271|DRUG|38% silver diamine fluoride|Topical application of SDF to teeth
41143256|NCT00245505|DRUG|Mesalazine (Mesalamine)|Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment
41143257|NCT02644941|BIOLOGICAL|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
41143258|NCT02644941|DEVICE|ePTFE graft|Surgical implantation of a commercially available ePTFE graft and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
40777688|NCT02499744|DEVICE|HHFNC|"For infants in the HHFNC-group who failHHFNC (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
40982633|NCT04565431|DRUG|Tysabri|Participants with RRMS who are planning to begin treatment with Tysabri will be compared to a group of healthy individuals who are matched for age, gender, and education.
40982634|NCT03666715|DRUG|Oral Antipsychotics (OAPs)|No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
40982635|NCT03666715|DRUG|Paliperidone Palmitate 1-Month Formulation (PP1M)|No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
40982636|NCT04245787|DRUG|Self assembling peptide with fluoride|peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
41143259|NCT05107453|DRUG|Levobupivacaine|"The Investigational Medical Product (IMP) is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.~The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery."
41143260|NCT04135872|OTHER|strengthened nuitritional treatment|improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L
41143261|NCT01948557|BEHAVIORAL|Infant feeding counselling and support|"Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.~Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice."
41143262|NCT05711589|PROCEDURE|CBA was performed under intracardiac echocardiography guidance without fluoroscopy|Zero-X group: Patients undergoing ICE-guided CBA
41143263|NCT05711589|PROCEDURE|cryoablation (CBA) was performed under fluoroscopic guidance|cryoablation (CBA) was performed under fluoroscopic guidance
41143264|NCT02010684|BEHAVIORAL|Empowerment and CBT Classes|"Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources."
41143265|NCT00237705|DRUG|metoclopramide|
41143266|NCT01377545|PROCEDURE|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
41143267|NCT01377545|PROCEDURE|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
41143268|NCT06115070|DRUG|Alteplase|intravenous alteplase(0.9 mg/kg;maximum dose, 90mg; 10% administered as a 1-minute bolus,the remaining infused over 1 hour)
41143269|NCT00375388|DRUG|Metformin on top of intensive insulin therapy|
41143270|NCT02206906|BEHAVIORAL|Incentive intervention model|All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
41143271|NCT00631202|DRUG|Epoetin alfa|Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
40777689|NCT03518151|OTHER|Product placement intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section and island in the first aisle; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
40777690|NCT03518151|OTHER|Sham comparator|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
40777691|NCT04714593|BIOLOGICAL|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
40777692|NCT01175122|BIOLOGICAL|H2N3 MO 2003/AA ca Vaccine|0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
40777693|NCT04415554|DIAGNOSTIC_TEST|echocardiography|echocardiography exam of the infant
40777694|NCT00335881|BIOLOGICAL|hepatitis B vaccine|
40777695|NCT06547606|OTHER|Usual Care|Participants in the control group will recieve usual care.
40777696|NCT03383666|DEVICE|PulseRider® Aneurysm Neck Reconstruction Device|Neck Reconstruction Device
40777697|NCT03986957|OTHER|No interventions|No interventions - observational study
40777698|NCT05809947|OTHER|Neuromuscular electrical stimulation|One bout of neuromuscular electrical stimulation in conjunction with forced lengthening contractions on one leg
40777699|NCT01561976|DRUG|Metformin hydrochloride prolonged release|1000mg in fasting state
40777700|NCT01561976|DRUG|metformin hydrochloride prolonged release|1000mg in fed state
40777701|NCT01561976|DRUG|Metformin hydrochloride sustained release/Glimepiride|1000/2mg in fed state
40777702|NCT00575666|DRUG|Insulin or Placebo|intranasal, 40IU, 4 times daily
40777703|NCT05731609|OTHER|Resistance Intensive Personal Training|Personalized power training program focused on participant goals.
40777704|NCT01647854|PROCEDURE|Teleconsultation|Teleconsultation in prehospital emergencies
40777705|NCT02519842|DRUG|Fosaprepitant|
40777706|NCT02519842|DRUG|Placebo for fosaprepitant|
40777707|NCT02519842|DRUG|Ondansetron|
40777708|NCT02519842|DRUG|Dexamethasone|
41143272|NCT02264847|DRUG|Human chorionic gonadotrophin|Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
40777709|NCT02519842|DRUG|5-HT3 antagonist|
40777710|NCT06331377|OTHER|Non-Interventional Study|Non-interventional study
40777711|NCT03212729|RADIATION|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.
40777712|NCT03212729|PROCEDURE|Conventional endodontic treatment|After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
40777713|NCT06490692|OTHER|Blood Flow Restriction Training|The affected limb will have a cuff placed proximally and inflated to occlude the blood flow by 40% attested using a golden standard vascular doppler after which the individuals will perform the strengthening program set forth by the physical therapist. This is preceded by other tennis elbow interventions such as ultrasound, stretching, and deep friction massage at the extensor origin.
40777714|NCT06490692|OTHER|Conventional Strength Training|The individuals in this group will undergo the same conventional physical therapy program as the other group including ultrasound, stretching, and deep friction massage. In addition, they will undergo the same strengthening program set forth by the physical therapist however with no blood flow restriction of any kind.
40777715|NCT02287610|DRUG|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
40777716|NCT04980248|BIOLOGICAL|ALXN1850|ALXN1850 will be administered as an IV infusion and via the SC route.
40777717|NCT02320656|OTHER|Blood sampling|Longitudinal (3 stages of the disease)
40777718|NCT02320656|OTHER|Bone marrow aspirate|Longitudinal (3 stages of the disease)
40777719|NCT02320656|OTHER|Skin biopsy|Single biopsy (optional)
40777720|NCT02320656|OTHER|Buccal swab|Single sampling.
40777721|NCT02071901|DRUG|eltrombopag olamine|Given PO
40777722|NCT05271357|PROCEDURE|Bilateral TMS|Stimulation begins with continuous TBS to the right dorsolateral prefrontal cortex (DLPFC) (120 seconds of uninterrupted bursts; 600 pulses per session) followed by intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds per hemisphere.
40777723|NCT05271357|PROCEDURE|Unilateral TMS|Stimulation involves only intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds.
40982637|NCT03341533|PROCEDURE|Ice packs plus usual post-op analgesia|A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.
40982638|NCT03341533|OTHER|Usual post-op analgesia|Standard post-operative analgesia orders will be followed.
40982639|NCT03701347|DEVICE|Reeve's model|Reeves, K. O., Young, A. E., \& Kaufman, R. H. (1999). A simple, inexpensive device for teaching the loop electrosurgical excision procedure. Obstetrics and Gynecology, 94(3), 474-5.
40982640|NCT03701347|DEVICE|Hefler's model|Hefler, L., Grimm, C., Kueronya, V., Tempfer, C., Reinthaller, A., \& Polterauer, S. (2012). A novel training model for the loop electrosurgical excision procedure: An innovative replica helped workshop participants improve their LEEP. American Journal of Obstetrics and Gynecology, 206(6)
40982641|NCT03701347|DEVICE|Ida's model|Reusable, portable and modular 3D printed simulator
40982642|NCT05107687|BEHAVIORAL|Smoking cessation|"Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.~Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.~The subject selects their preferred intervention."
40982643|NCT05126862|BEHAVIORAL|MindTrails|MindTrails is a web-based cognitive bias modification intervention. Training sessions are designed to encourage cognitive flexibility through repeated practice assigning benign resolutions to ambiguous, anxiety-provoking situations.
40982644|NCT05301426|OTHER|Stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
40982645|NCT05301426|OTHER|Neural slippage of the sciatic nerve.|Neurodynamic technique on the sciatic nerve.
40982646|NCT05301426|OTHER|Passive upper limb mobilisations.|Passive mobilisations performed on the upper limbs used as a placebo.
40982647|NCT02504008|DRUG|AXS-02 (oral zoledronate)|Once weekly for 6 weeks
40982648|NCT02504008|DRUG|Placebo|Once weekly for 6 weeks
41143273|NCT02264847|DRUG|clomiphene citrate alone|clomiphene citrate alone without hCG trigger
40982649|NCT04041804|PROCEDURE|semirapid maxillary expansion (SRME)|A Banded Hyrax is going to be used in order to provide an increase in the maxillary transverse dimension
40982650|NCT04466254|DRUG|CPGJ602|Q2W/QW iv
40982651|NCT04466254|DRUG|cetuximab|QW iv
40982652|NCT05160831|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cell injection is applied for treating knee OA patients.
41143274|NCT02009865|DRUG|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
41143275|NCT02009865|DRUG|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
41143276|NCT05501340|DRUG|Serplulimab|PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks
41143277|NCT05501340|DRUG|Molgramostim|200ug qd subcutaneous injection for 7 days
41143278|NCT05501340|RADIATION|Hypofractionated radiotherapy/Sterotactic body radiotherapy|8Gy\*3f
41143279|NCT05871502|DEVICE|Subcutaneous blood glucose monitoring device|After signing the informed consent and before the start of the endovascular procedure, a subcutaneous blood glucose monitoring device will be implanted, which will be removed on day 15 (or at hospital discharge if this takes place before 15 days). This device will be selected from those currently available on the market, with CE marking, and with previous studies documenting its safety and feasibility for radiological procedures.
41143280|NCT01217294|PROCEDURE|ultrasound guided fascia iliaca block|Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
41143281|NCT01217294|PROCEDURE|spinal morphine|Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
41143282|NCT02089425|DRUG|K-103-IP|
40982653|NCT03263442|DRUG|Thiamine|200 mg IV three times daily for seven days
40982654|NCT03263442|DRUG|Normal saline|Normal saline IV three times daily for seven days
40982655|NCT00998660|DEVICE|Activa RC|Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation
40982656|NCT01203046|DRUG|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
40982657|NCT01029574|OTHER|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
40982658|NCT03258190|DRUG|Lime Powder Regimen|LPR and placebo were randomly given to subjects for 6 months
41143283|NCT02089425|DRUG|Placebo|Placebo comparator
41146972|NCT01257724|OTHER|SHARE (Synthesized HIV/AIDS Research Evidence)|"SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~1. an online searchable database of HIV-relevant systematic reviews;~2. monthly email updates highlighting new reviews;~3. access to user-friendly summaries produced by us or by others (when available);~4. links to scientific abstracts;~5. peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~6. an interface for participants to leave comments in the records of systematic reviews in the database;~7. links to full-text articles (when publicly available); and~8. access to worksheets that help CBOs find and use research evidence"
41146973|NCT01740284|DRUG|Grazax + Aerius|
40777724|NCT04471311|PROCEDURE|Sub-lay mesh supported closure|A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above the arcuate line, posterior layer is reinforced suturing the peritoneum and the posterior rectus sheath; below the arcuate line, the posterior layer is reinforced suturing the peritoneum and the trasversalis fascia. Anterior layer is re-established suturing the anterior rectus sheath. A 3 cm BIO-A Mesh strip is sutureless placed between the posterior rectus sheath and the rectus muscle with an overlap of 1,5 cm at each side. In laparotomies \>20 cm two stripes of 15 cm each is designed. The midline anterior rectus sheath is closed using a running slowly absorbable suture , covering the mesh.
40777725|NCT04471311|DEVICE|BIO-A (GORE) mesh|3 cm BIO-A Mesh strip
40777726|NCT05829876|OTHER|High Frequency ECG Mapping|A high frequency ECG map will be performed to assess the optimum left ventricular pacing site.
40777727|NCT05829876|OTHER|Q-LV Measurement|Measurement of Q wave on 12 lead ECG to LV stimulus to assess optimum left ventricular pacing site.
40777728|NCT01726764|OTHER|St John's Wort|
40777729|NCT01726764|DRUG|Metformin|
40777730|NCT02474810|DRUG|Alteplase|Alteplase for CVC dysfunction.
40777731|NCT01126073|DRUG|Niacin/laropiprant|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
41303617|NCT05300100|BEHAVIORAL|sensorimotor activities|"The activities chosen involve either the whole body or specific parts such as the hand to grasp or perform graphic tests.~* Trial 1 : Straightening: passage from sitting to sitting.~* Trial 2 : Movement with difficulty of balance: heel-toe walking~* Trial 3 : Movement with difficulty of balance with a structured visual environment: heel-toe walk in a contrasting fabric decoration to increase the impact of visual flow~* Trial 4 : Move to a target, 5 m away~* Trial 5 : Graphics: drawing of a tree. This test requires spatial skills and the establishment of median space in written transcription.~* Trial 6 : Manual entry: collection of 12 small cubes arranged in an arc in front of the child using one hand, the choice of which will be left to the child.~All of these tests will be offered according to a so-called interlaced protocol, that is to say, each execution of an action will be followed by an action simulation, and this alternation will be repeated 5 times for each task. ."
40777732|NCT01126073|DRUG|Placebo|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
40777733|NCT05165472|OTHER|Quadri-pulse theta burst stimulation|High frequency transcranial quadri-pulse theta burst stimulation prior to hand motor function training
41303618|NCT02750813|DEVICE|Delefilcon A contact lenses|
41303619|NCT02750813|DEVICE|Senofilcon A contact lenses|
41303620|NCT02241395|BIOLOGICAL|Intrathecal autologous bone marrow mononuclear cell transplantation|
41462573|NCT03538795|COMBINATION_PRODUCT|iTBS&eCIMT|All will receive eCIMT+iTBS on an outpatient basis for 4 hours/day for 15 consecutive weekdays. eCIMT will include training of the more-affected arm following shaping principles, restraint of the less-affected arm, and the Transfer Package in combination with NDT techniques to reduce tone so that shaping of movement can be carried out. The Transfer Package is a set of behavioral techniques designed to transfer therapeutic gains from the treatment setting to everyday life. iTBS will be added to prime the areas of the brain that control movement of the more-affected arm so that the responsiveness of that tissue to motor training is enhanced. Treatment sessions will alternate between 10 minute periods of iTBS (which include time for set-up and transition) and 1-hour periods of eCIMT.
41462574|NCT03316040|BEHAVIORAL|JIC|"The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older."
41146974|NCT01740284|DRUG|Grazax + placebo|
41146975|NCT00988130|OTHER|laboratory biomarker analysis|
41146976|NCT00988130|OTHER|questionnaire administration|
41303621|NCT00860340|DRUG|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
41303622|NCT04385797|OTHER|Telephone interview|Sociodemographic data. Clinical data. PMCI/MD quality of life, cognition, depression, technophilia and perceived stress and caregiver quality of life and burden assessments.
41303623|NCT01463072|OTHER|Laboratory Biomarker Analysis|Correlative studies
41303624|NCT01463072|DRUG|Nab-paclitaxel|Given IV
41303625|NCT01463072|OTHER|Questionnaire Administration|Ancillary studies
41146977|NCT00988130|PROCEDURE|assessment of therapy complications|
41146978|NCT00988130|PROCEDURE|high-intensity focused ultrasound ablation|
41146979|NCT00988130|PROCEDURE|quality-of-life assessment|
41146980|NCT01767025|DRUG|Oxytocin|
41146981|NCT01767025|DRUG|Sea water|
41303626|NCT06359327|DIETARY_SUPPLEMENT|Placebo|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given placebo for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
41303627|NCT06359327|DIETARY_SUPPLEMENT|Pep19 2 mg|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 2 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
40777734|NCT06458556|DEVICE|Treatment with Morpheus|Radiofrequency device treatment
40777735|NCT00340054|OTHER|questionnaire administration|
40777736|NCT00340054|PROCEDURE|study of high risk factors|
40777737|NCT00121979|DRUG|Racivir, a non-nucleoside reverse transcriptase inhibitor|
40777738|NCT06059950|BEHAVIORAL|Mindfulness Flow Program|The mindfulness flow program (MFP) consisted of eleven 60-minute sessions via Zoom, with one session per week. Additionally, a 120-minute in-person sport-specific session were conducted.
40982659|NCT03446742|OTHER|Cardiovascular rehabilitation|The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
40982660|NCT04573907|DRUG|Drug Levothyroxine 100 mcg|Administration of a 600 mcg levothyroxine dose
40982661|NCT04573907|DRUG|Drug Eutirox 100 mcg|Administration of a 600 mcg levothyroxine dose
40982662|NCT02059460|DRUG|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
41143284|NCT06509594|OTHER|Protocol of Scapular Stabilization Exercises;|"Exercise for the middle trapezius and rhomboid muscles: Participants were instructed to stand with their arms hanging beside their bodies. Then, they were instructed to flex their elbows 90◦ holding an elastic band and performing an external rotation of the shoulder, pulling both scapula together. Subsequently, they returned to a neutral shoulder position with elbow flexion.~Exercise for the lower trapezius muscle: Participants were instructed to lie down in a prone position while holding an elastic band attached at one end under a mattress. They were then instructed to raise their shoulder 140◦.~Exercise for the serratus anterior muscle: Participants were instructed to stand and flex their elbows 90◦ while holding an elastic band fixed behind the participants. Next, they were instructed to move the arm forward with a protracted scapula."
41143285|NCT06509594|OTHER|Protocol of Muscle Energy technique;|"During upper trapezius stretching, the participants were in seated position by holding the chair with one arm, and laterally tilted the head to the opposite side with the other hand pushing the head to increase lateral stretch.~For pectoralis muscle stretch, participants were asked to stand in front of the Doorframe with elbow bent at 90 degree and was asked to lean forward without Taking a step forward. The stretch is felt across the anterior chest, which is held for 15-30 seconds with 2-3 repetitions. For levator scapulae stretch, the subjects were asked to take the seated position while holding the chair with one hand in order to maintain shoulder depression, then To flex and rotate neck to the opposite side by placing the other hand at the back of their head and to slowly pull it down toward the armpit."
41143286|NCT04674605|DEVICE|biomarkers|biomarkers
41143287|NCT00539955|BEHAVIORAL|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
41143288|NCT00539955|BEHAVIORAL|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
41143289|NCT02834559|DRUG|5-fluorouracil and low molecular weight heparin|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
41143290|NCT02834559|DRUG|Placebo|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
41143291|NCT05453435|DRUG|Entecavir|All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 6 months after completing CD20 monoclonal antibody therapy.
41143292|NCT00100009|DRUG|TAC-PF|
41143293|NCT00100009|DRUG|Triamcinolone Acetonide|
41143294|NCT02792738|BEHAVIORAL|hypnosis|
41143295|NCT03486756|BEHAVIORAL|Internet-CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
41143296|NCT04527679|DRUG|GC combined Lenvatinib|"1. GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~2. Lenvatinib (\<60kg: 8mg /d; ≥60kg, 12mg)."
41143297|NCT05020236|DRUG|Elranatamab|subcutaneous
40777739|NCT05557396|OTHER|Internal Tube Length Measurement Procedures for Nazogastric Tube|Different Internal Tube Length Measurement Procedures will used for the correct placement of nasogastric tube.
40777740|NCT04862754|OTHER|interval training exercise|interval training exercise
40777741|NCT03749239|DIETARY_SUPPLEMENT|Collagen protein|Collagen protein
40777742|NCT06564805|DRUG|Candida Albicans Antigen Injection|subcutaneous administration of Candida albicans antigen
40982663|NCT02059460|DRUG|placebo|
40982664|NCT05568147|DRUG|Aspirin tablet|When patients are randomized into the intervention group, they will receive aspirin at the dosage of 100mg orally once every day.
40982665|NCT05568147|DRUG|Placebo|When patients are randomized into the placebo group, they will receive placebo orally once a day.
40777743|NCT04466891|DRUG|ZW25 (Zanidatamab)|Administered intravenously
40777744|NCT03151655|BEHAVIORAL|MATTeRS Video|Narrative-based video intervention and accompanying workbook
40777745|NCT03151655|BEHAVIORAL|Didactic Video|Education only video
40777746|NCT00419744|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|
40982666|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
40982667|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (test)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
41303628|NCT06359327|DIETARY_SUPPLEMENT|Pep19 5 mg|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 5 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
41303629|NCT03992768|DEVICE|Hamamatsu NanoZoomer S360MD Digital Slide Scanner System|Detection of pathology features using whole slide imaging
41303630|NCT02898818|OTHER|vaginal and oral swab sample, questionnaire|vaginal and oral swab sample and questionnaire
40777747|NCT00419744|DRUG|Formoterol Turbuhaler|
41303631|NCT02898818|OTHER|papa smear|Papnicolaou Papa Smear test
41303632|NCT02050048|OTHER|Administration of Lactated Ringer's (LR) Solution|"Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~* initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~* LR fluid infusion during the procedure at 5 cc/kg/hr~* Post-procedure bolus of 20 cc/kg over 90 minutes"
41303633|NCT01412645|DIETARY_SUPPLEMENT|Resveratrol|"500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months"
41303634|NCT04739657|DEVICE|Insight Lifetech IVUS System|The Insight Lifetech IVUS System is intended for examination of coronary intravascular pathology only, including TrueVision IVUS diagnostic catheter and VivoHeart IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
41303635|NCT04739657|DEVICE|Boston Scientific IVUS System|The Boston Scientific IVUS System is intended for the examination of coronary intravascular pathology only, including Opticross IVUS diagnostic catheter and iLAB IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
41303636|NCT05951738|PROCEDURE|Blood and saliva collection|Blood and saliva samples from pregnant women; saliva samples from babies.
41303637|NCT05951738|BEHAVIORAL|Psychometric scales|A battery of psychometric scales and questionnaires.
41303638|NCT05951738|OTHER|Smartphone app|A smartphone application has been developed in the context of the study as a potential preventive and screening strategy.
41303639|NCT05978830|DEVICE|Transcranial ultrasound stimulation|In each active/sham-ultrasound stimulation experiment, subjects first underwent two baseline motor evoked potential (MEP) tests, with an interval of 15 minutes between the two baseline tests. After 15 minutes of true/pseudo-transcranial ultrasound stimulation, subjects immediately underwent a MEP test, and then 15 minutes later, subjects underwent another MEP test. The MEP was tested again 15 minutes later.
40777748|NCT03014466|BEHAVIORAL|Use of Video Projector|Bed mounted video projector that is used to play videos of the patient's choosing prior to induction of anesthesia
40777749|NCT03014466|BEHAVIORAL|Use of Video Tablet|7 inch video tablet that is used for displaying videos of the patient's choosing prior to induction of anesthesia
40777750|NCT02623244|PROCEDURE|Laparoscopic oophorocystectomy or oophorectomy|
40777751|NCT02136784|DRUG|morphine sulfate|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
41303640|NCT01241851|BEHAVIORAL|Aerobic exercise|
41303641|NCT01241851|BEHAVIORAL|Resistance exercise|
41303642|NCT03009331|PROCEDURE|Lungrecruitment manoeuver in prone position.|Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
41303643|NCT03009331|PROCEDURE|Lungrecruitment manoeuver in supine position.|Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
41303644|NCT04757779|DRUG|anlotinib hydrochloride combined with irinotecan or docetaxel|From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach.Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle),the dose of anlotinib can be adjusted as 12mg,10mg or 8mg according to adverse effects.On Day1 and Day8, subjects are required to inject irinotecan (65mg/m2)or docetaxel (60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
41303645|NCT04360187|DRUG|Crisaborole Ointment|Crisaborole ointment 2%
41303646|NCT04360187|DRUG|Crisaborole Placebo Vehicle|Placebo for crisaborole ointment
41303647|NCT01449591|DRUG|BFH772 1% ointment|
41303648|NCT01449591|DRUG|Vehicle ointment|
41303649|NCT01449591|DRUG|Noritate® 1% cream|
40777752|NCT02136784|DRUG|hydrocodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
40982668|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
40982669|NCT05741567|PROCEDURE|correction of anterior prolapse|percentage of failed prolapse correction
41303650|NCT01798134|DEVICE|TANDEM™|
41303651|NCT01087528|DEVICE|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
41303652|NCT06019000|COMBINATION_PRODUCT|CYR-064|CYR-064 is a nasal solution.
41303653|NCT02597023|DRUG|MitoQ|Mitoquinone pill, 20 mg/day
41303654|NCT02597023|DRUG|Placebo|Placebo pill with inert excipient, 1 time/day
41303655|NCT06175650|PROCEDURE|Cardiac surgery|Cardiac surgery of all types
41303656|NCT02362308|OTHER|Adrenalectomy|Adrenalectomy for treatment of primary aldosteronism, according to standard of care
41303657|NCT02362308|DRUG|mineralocorticoid receptor antagonist|Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
40777753|NCT02136784|DRUG|hydromorphone HCI|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
40982670|NCT03388060|PROCEDURE|Ultrasound guided SWL|Ultrasound guided SWL for radiolucent renal stone
40982671|NCT03388060|PROCEDURE|Dissolution therapy|Alkalinization dissolution therapy for radiolucent renal stone
40982672|NCT03388060|PROCEDURE|Combined ultrasound guided SWL and dissolution therapy|Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone
40982673|NCT05890040|OTHER|questionnaire|assessment of anxiety
40982674|NCT03352323|DRUG|Oxymetazoline|RLD
40982675|NCT05195463|OTHER|Exercise intervention|Women with diastasis recti abdominis will do core stabilization exercises for the transversus abdominis muscle with 10 repetitions 3 days a week for 8 weeks. The exercises include diaphragmatic breathing exercises, core stabilization exercises for the transversus abdominis muscle, and pelvic floor contractions
40982676|NCT05195463|OTHER|Exercise intervention by wearing abdominal corset|In this group, in addition to the first group, core stabilization exercises will be performed by wearing an abdominal corset. Participants will be asked to wear their corsets while performing their exercises.
40982677|NCT05195463|OTHER|Corset intervention|Participants included in this group will be required to wear only this corset all day (except for the bathroom) for 8 weeks.
40982678|NCT05856201|PROCEDURE|Laparoscopic cervicosacropexy|The first step consists of a supracervical hysterectomy with morcellation. Anterior and posterior dissection of the vesicovaginal and rectovaginal space. Placing a flexible blade or a Breisky blade in the vagina which is manipulated by the assistant in order to improve exposure of the tissue planes. The retroperitoneum will then be opened from sacral promontory to cervix with the incision just medial to the uterosacral ligament. A low-weight preshaped Y-shaped polypropylene mesh will be secured to the anterior and posterior vagina with four to six separated absorbable 2.0 polyglactin sutures and two nonabsorbable 2.0 prolene sutures can be placed at the level of the remaining cervix. The mesh will be attached to the sacral promontory using two or three nonabsorbable monofilament 2.0 prolene suture. The retroperitoneal space will be closed with continuous 2.0 polyglactin suture or barbed 2.0 absorbable suture material.
40982679|NCT05856201|PROCEDURE|Shull technique via V-NOTES|Using a cold-bladed scalpel, pericervical colpotomy and subsequent opening of the Douglas and vesico-uterine space is performed. The following step is forcipressure and section of uterosacral ligaments bilaterally with cold blade scissors and ligation in Polysorb 0. A v-PATH® wall retractor is placed, after insertion of three trocars. Total hysterectomy is then performed by standard V-NOTES technique. After transperitoneal visualization of the ureters bilaterally, the peritoneum is incised between the ureters and the uterosacral ligaments, which are thus bilaterally isolated, and three points in polydioxanone 2/0 are placed per side. The v-PATH wall retractor is then removed. Finally the suspension of the vaginal vault at the uterosacral ligaments is made according to Shull technique. Eventual fascial corrections of concomitant anterior or posterior defects will be associated if needed.
40982680|NCT03388333|PROCEDURE|Catheter Ablation|
40982681|NCT03134287|PROCEDURE|two-finger method, reverse sellick's method|Subjects received nasogastric tube placement by two-finger method; Subjects received nasogastric tube placement by reverse sellick's method
40982682|NCT03280914|DEVICE|Auto-CPAP|Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
40777754|NCT02136784|DRUG|oxycodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
40777755|NCT02136784|DRUG|buprenorphine|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
40777756|NCT02136784|DRUG|oral tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
40982683|NCT04899492|BEHAVIORAL|Motivational Interviewing (MI)|1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist
40982684|NCT04899492|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|6 Cognitive Behavioural Therapy (CBT) sessions should be performed after motivational interviewing up to 6 months by a psychotherapist
40982685|NCT04899492|BEHAVIORAL|Hypnotherapy|About 3 Hypnotherapy sessions should be performed after motivational interviewing up to 6 months by a hypnotherapist
40982686|NCT04899492|DRUG|Nicotine Replacement Therapy (NRT)|All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
40982687|NCT00704158|DRUG|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
40982688|NCT05576740|PROCEDURE|Determination of hormone level concentrations|Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.
40982689|NCT05576740|PROCEDURE|Jump height determination|by Chronojump contact mat, determine five types of jump in centimeters: Squat jump without additional weight, Squat jump with 50% of body weight, Countermovement jump, Abalakov jump, and Drop jump, during the early follicular phase, late follicular phase, and mid-luteal phase.
41462575|NCT02926755|PROCEDURE|Coronary Angiography|Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
41462576|NCT02336633|DIETARY_SUPPLEMENT|Resveratrol|2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
41462577|NCT02336633|OTHER|Placebo|
40777757|NCT02136784|DRUG|sublingual tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
40777758|NCT00151840|DRUG|IVIG-L|
40777759|NCT06544070|DEVICE|Entia Liberty System|Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
40777760|NCT01019265|DRUG|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
40777761|NCT00557193|DRUG|Asparaginase|Given IV, IM, or PO
40777762|NCT00557193|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40777763|NCT00557193|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40777764|NCT00557193|DRUG|Cyclophosphamide|Given IV
40777765|NCT00557193|DRUG|Cytarabine|Given IV or IT
40777766|NCT00557193|DRUG|Daunorubicin Hydrochloride|Given IV
41143298|NCT05020236|DRUG|Daratumumab|Daratumumab / hyaluronidase, subcutaneous
41143299|NCT05020236|DRUG|Pomalidomide|oral
41303658|NCT05276713|DRUG|Tucidinostat|Tucidinostat in combination with endocrine drugs
41303659|NCT01536977|OTHER|quality-of-life assessment|Ancillary studies
40777767|NCT00557193|DRUG|Dexamethasone|Given IV or PO
40777768|NCT00557193|PROCEDURE|Echocardiography|Undergo ECHO
40777769|NCT00557193|DRUG|Etoposide|Given IV
40777770|NCT00557193|BIOLOGICAL|Filgrastim|Given IV or SC
40777771|NCT00557193|OTHER|Laboratory Biomarker Analysis|Correlative studies
40777772|NCT00557193|DRUG|Lestaurtinib|Given PO
40777773|NCT00557193|DRUG|Leucovorin Calcium|Given IV
40777774|NCT00557193|DRUG|Mercaptopurine|Given PO
40777775|NCT00557193|DRUG|Methotrexate|Given IV, IT, or PO
41143300|NCT05020236|DRUG|Dexamethasone|oral
40777776|NCT00557193|DRUG|Methylprednisolone|Given IV
40777777|NCT00557193|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40777778|NCT00557193|DRUG|Pegaspargase|Given IM
40777779|NCT00557193|OTHER|Pharmacological Study|Correlative studies
40777780|NCT00557193|DRUG|Prednisone|Given PO
41143301|NCT03840447|BEHAVIORAL|Chronic Disease Self-Management programme|"The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens."
40777781|NCT00557193|DRUG|Therapeutic Hydrocortisone|Given IT
40777782|NCT00557193|DRUG|Vincristine Sulfate|Given IV
40777783|NCT05114928|PROCEDURE|Transepithelial Corneal Collagen Cross-linking|Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
40777784|NCT05114928|DIAGNOSTIC_TEST|Scheimpflug camera|Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
40777785|NCT00614224|BEHAVIORAL|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
40777786|NCT02468583|DRUG|FX006 32 mg|Experimental
40777787|NCT02468583|DRUG|TCA IR 40 mg|Comparator
40777788|NCT02406417|DEVICE|Investigation for pituitary dysfunction by blood tests.|Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
40777789|NCT02406417|DEVICE|Dynamic function tests and pituitary imaging|Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
41143302|NCT04078217|DEVICE|Jintronix|Participants will perform an exercise program at home through a telerehabilitation platform called Jintronix.
41143303|NCT04078217|OTHER|Booklet|Home-based exercise program using a paper booklet (not the technology).
41143304|NCT03392805|BEHAVIORAL|physical activity|beginning of regular physical activity under the supervision of a coach
41303660|NCT01536977|OTHER|questionnaire administration|Ancillary studies
41303661|NCT01536977|BEHAVIORAL|management of therapy complications|Undergo BBT-I
41303662|NCT01536977|BEHAVIORAL|cognitive assessment|Ancillary studies
41303663|NCT01536977|BEHAVIORAL|educational intervention|Undergo BBT-I
41462578|NCT06361472|OTHER|Standard Care|Standard Care includes exercises, mobilization, manual therapy, education, and Neck Wellness Home Care Guide (NWHCG). The rehabilitation program is based on current clinical practice guidelines aimed at reducing neck pain, improving range of motion, enhancing functionality, and promoting physical activity motivation. Each patient will receive active exercises and manual therapy techniques. Educational components will cover pain science, physical activity benefits, and return to normal activities , supplemented by a NWHCG. Treatment sessions will be conducted, featuring a one-to-one interaction between the participant and the physiotherapist. It will last 4 weeks, with two sessions per week, 45 minutes/session (8 treatment sessions).
40982690|NCT05576740|PROCEDURE|Grip strength determination|measuring of changes in muscle strength by handgrip dynamometer in the hand to be tested (handgrip test) during the early follicular phase, late follicular phase, and mid-luteal phase. Three attempts on each hand.
41462579|NCT06361472|BEHAVIORAL|Contextual Factors|Bundle of contextual factors divided into three categories: professional, treatment, and healthcare setting features. Regarding the professional contextual factors, they include reputation, appearance, and positive attitudes. The treatment contextual factors encompass positive attitudes, verbal communication, non-verbal communication, empathetic therapeutic alliance, therapeutic touch, and the use of a mirror to show the patient what is being performed. Finally, the healthcare setting contextual factors feature a comfortable setting, adequate environmental conditions, and appropriate design.
41462580|NCT00707187|DRUG|Cialis|35 pills of study medication (20 mg)
41462581|NCT04618939|BIOLOGICAL|BR-TD-1001|0.5 mL, IM
41462582|NCT04618939|BIOLOGICAL|Td-pur inj|0.5 mL, IM
41462583|NCT02402491|DRUG|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
41462584|NCT02402491|DRUG|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
41462585|NCT02402491|DRUG|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
41462586|NCT04729101|DRUG|Vonoprazan|Oral tablet
41462587|NCT04729101|DRUG|Lansoprazole|Oral capsule
41462588|NCT01886534|OTHER|Standardized Heart Failure Discharge Summary to Primary Care Physicians©|At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
41462589|NCT01886534|BEHAVIORAL|Standardized education sessions|Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
41462590|NCT01886534|OTHER|Heart Failure Diuretic Decision Support Tool for Patient Self Management©|Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
41462591|NCT01886534|OTHER|Digital talking scale|Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
41462592|NCT01886534|OTHER|Usual care|Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
41462593|NCT04848779|DRUG|Alglucosidase alfa GZ419829|"Pharmaceutical form: Lyophilized powder for solution~Route of administration: intravenous"
41462594|NCT00172016|DRUG|Zoledronic acid|
41462595|NCT00838981|DRUG|Modafinil|Modafinil is started at 200mg on the first day of week 1 (treatment phase) and increased to 400mg by the end of that week. Subjects will continue to receive 400mg/day for the remainder of the study.
41462596|NCT00838981|DRUG|Sugar Pill|placebo, sugar pill will mirror active drug
41462597|NCT00838981|BEHAVIORAL|Contingency Management|Subjects in the CM conditions will earn vouchers for providing cocaine-free urine specimens. Subjects will be informed of the urine test results when available and, for subjects in the CM condition, receive a voucher at that time if the sample is negative. Subjects in the CM condition earn a minimum of $3 for each urine sample they submit that is negative for cocaine. Voucher amounts will escalate by $1 per consecutive clean urine sample submitted up to a maximum of $15 per clean sample.
40982691|NCT05576740|PROCEDURE|Flexibility determination|measurement of changes in the range of motion of the hamstring musculature, by sit and reach test (cm), during the early follicular phase, late follicular phase, and mid-luteal phase. Three tries.
40982692|NCT05576740|PROCEDURE|Indirect maximum oxygen consumption determination|by the Course Navette test, the indirect oxygen consumption is calculated using the formula: VO2max = (6xFA) - 27,4 (FA = Speed of the last stage of the test completed. It takes place during the early follicular phase, late follicular phase, and mid-luteal phase.
40982693|NCT05576740|DEVICE|Sensory and pain threshold determination|by electrical muscle stimulator (Digitimer DS7A), during the early follicular phase, late follicular phase, and mid-luteal phase.
40982694|NCT05576740|OTHER|Physical and mental symptoms associated with the menstrual cycle|By The Daily Record of Severity of Problems (DRSP) questionnaire, during a full menstrual cycle.
41303664|NCT01124058|DRUG|warfarin|"Patients will be randomized to re-start warfarin at their maintenance dose or at a loading dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose)."
41462598|NCT00838981|DRUG|Methadone|Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
41462599|NCT00838981|BEHAVIORAL|cognitive behavioral treatment|All subjects will receive a manual-guided CBT treatment over the course of their 16-week participation. This manual-guided therapy promotes abstinence through a functional analysis of high-risk situations and coping skills training.
40777790|NCT06071676|OTHER|conventional impression group|Silicon impression material loaded on plastic tray and inserted inside the patient mouth
41303665|NCT01124058|DRUG|Warfarin|"Maintenance dose is the amount of warfarin that a patient required to maintain a therapeutic INR."
41462600|NCT00838981|BEHAVIORAL|Voucher Control|Subjects in the Yoked-Control condition (YC) will be paired with a CM subject. Subjects in the YC condition will be informed that they will receive vouchers according to an unpredictable schedule, and that they cannot control when they will receive these vouchers or how much they will be worth.
40777791|NCT06071676|OTHER|digital impression group|direct scanning was done using intraoral scanner to the female housing of the attachments on position
41462601|NCT00139438|BEHAVIORAL|Disease Management Assessment|
41462602|NCT01706263|DRUG|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
40777792|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
40777793|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
40777794|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
40777795|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)
41462603|NCT01706263|DRUG|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
40777796|NCT05310253|DRUG|Fludrocortisone|pill of fludrocortisone
40777797|NCT05310253|DRUG|Placebo|placebo pill
40777798|NCT05310253|BEHAVIORAL|Trier Social Stress Test (TSST)|psychosocial stress induction
40777799|NCT05310253|BEHAVIORAL|Placebo Trier Social Stress Test (P-TSST)|control condition
40777800|NCT02065219|DRUG|Bupivacaine|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
40777801|NCT02065219|DRUG|Placebo|10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
40777802|NCT01966627|OTHER|ogtt|oral glucose tolerance test
41462604|NCT01706263|DRUG|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
40777803|NCT01966627|OTHER|genotyping|genotyping to look for risk alleles
40777804|NCT01966627|OTHER|abdominal and liver magnetic resonance imaging|magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
40777805|NCT01966627|OTHER|stool sample|stool sample taken to investigate metabolites
40777806|NCT01966627|OTHER|liver biopsy|liver biopsy to examine for cellular change and steatosis
40777807|NCT02595515|OTHER|Chiropractic treatment|Procedure: chiropractic treatment.
40777808|NCT02595515|OTHER|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
41303666|NCT01513798|BEHAVIORAL|Modified paleolithic diet and exercise under observation|Modified paleolithic diet and exercise 3 session/week under observation
41462605|NCT01545739|DEVICE|Evia/Entovis HF-T pacemaker for CRT therapy|Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
40777809|NCT06047938|RADIATION|ultrasound on carotid|CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children\[11\]. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
41462606|NCT04053673|DRUG|RBN-2397|an oral PARP7 Inhibitor
41462607|NCT00705315|DRUG|Docetaxel|Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
40777812|NCT02998229|DEVICE|Artisse™ Intrasaccular Device|Intrasaccular Device
40777813|NCT02421757|DEVICE|Fischell Transcutaneous Magnetic Stimulation Pain Treatment Device|Transcutaneous Magnetic Stimulation
41462608|NCT00705315|DRUG|Epirubicin|Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
40777814|NCT02421757|DEVICE|Placebo|The placebo Transcutaneous device
40777815|NCT04225767|COMBINATION_PRODUCT|Calcium electroporation|Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.
40777816|NCT05636839|RADIATION|UVB treatment|UVB treatment 3 times per week for 10 weeks
40777817|NCT03914690|DRUG|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
40777818|NCT03914690|DRUG|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
40777819|NCT03048370|PROCEDURE|Left body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
40777820|NCT03048370|PROCEDURE|Right body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
41462609|NCT00705315|DRUG|Bevacizumab|Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
40777821|NCT03048370|PROCEDURE|Left warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
40777822|NCT03048370|PROCEDURE|Right warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
40777823|NCT03048370|PROCEDURE|Left cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
40777824|NCT03048370|PROCEDURE|Right cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
40777825|NCT00969423|DEVICE|5mm videoscope|use of 5mm videoscope
40777826|NCT00969423|DEVICE|10mm videoscope|use of 10mm videoscope
40777827|NCT01128478|PROCEDURE|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
40777828|NCT05903534|OTHER|Pediatric Endurance and Limb Strengthening Program (PEDALS) and Lower Limb Strength Training|Pediatric Endurance and Limb Strengthening Program (PEDALS) Group This will receive stationary cycling
40777829|NCT05903534|OTHER|Lower Limb Strength Training Group|Lower Limb Strength Training Group
41303667|NCT01513798|BEHAVIORAL|Modified paleolithic diet and general advice on exercise|Modified paleolithic diet and general advice on exercise
41303668|NCT00941616|BIOLOGICAL|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
40777830|NCT02822664|BEHAVIORAL|Pedophiles patients|cerebral MRI and/or cerebral PET imaging
40777831|NCT02822664|BEHAVIORAL|Healthy subjects|cerebral MRI and/or cerebral PET imaging
41303669|NCT00941616|BIOLOGICAL|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
41303670|NCT01863407|DRUG|DAM|composed of dexamethasone, allantoin and metronidazole
41303671|NCT01863407|DRUG|Normal Saline|Normal Saline 250ml
41303672|NCT02626819|BEHAVIORAL|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
41303673|NCT02626819|BEHAVIORAL|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
41303674|NCT04266860|OTHER|Experimental - Test Results and Education|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the DxTerity test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the DxTerity test at the clinically-appropriate point in each case."
41303675|NCT02344628|DRUG|Azithromycin|Comparison of two different dosing strategies for the treatment of yaws
40777832|NCT02822664|DEVICE|PET/MRI|
40777833|NCT03837509|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.
41462610|NCT03330132|BIOLOGICAL|Standard inactivated influenza vaccine (NH formulation)|0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
41462611|NCT03330132|BIOLOGICAL|MF 59 adjuvanted inactivated influenza vaccine (NH formulation)|0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
41462612|NCT03330132|BIOLOGICAL|High-dose inactivated influenza vaccine (NH formulation)|0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
41462613|NCT03330132|BIOLOGICAL|Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)|0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
41462614|NCT01126606|DRUG|Dermacid Silver (Lactic acid)|Liquid soap, daily use
41462615|NCT01126606|DRUG|Glycerine Vegetal Soap Granado Traditional|Vegetal soap, daily use
41462616|NCT01995331|DRUG|cyclophosphamide,cyclosporine A|"Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.~Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was \>1×109/L."
41462617|NCT03793296|DEVICE|Percutaneous Device Closure: Vascular plug|percutaneous transcatheter approach into cardiac valve
41462618|NCT02206009|DEVICE|Collagen Membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
40982695|NCT05576740|DEVICE|Daily activity|by accelerometer (GENEActiv) during a full menstrual cylcle: Wrist-worn device measuring accelerations as a measure of daily activity, in cpm, counts per minute.
40982696|NCT05576740|PROCEDURE|Biochemical parameters determination|Determination of concentration of iron (μg/dL), ferritin (ng/mL), and transferrin (mg/dL), during the early follicular phase, late follicular phase, and mid-luteal phase.
40982697|NCT05576740|PROCEDURE|Blood count determination|Determination of concentration of hemoglobin (g/dL), red blood cells (10\^6/μL), hematocrit (%), white blood cells (10\^3/μl), platelets (10\^3/μl), during the early follicular phase, late follicular phase, and mid-luteal phase.
40982698|NCT05576740|PROCEDURE|Body composition parameters determination|Determination of weight (kg), total body water (L), proteins (kg), minerals (kg), body fat mass (kg), body mass index (BMI) (kg/m2), basal metabolic rate (kcal) by Bioelectrical Impedance Analysis, during the early follicular phase, late follicular phase, and mid-luteal phase.
40982699|NCT05576740|PROCEDURE|Vital signs|Determination of blood pressure (mmHg) and heart rate (bpm) at baseline, one minute and three minutes after the Course Navette test
40982700|NCT05576740|OTHER|Checking for correct use of contraceptive methods|Pre-test questions about possible forgetfulness or mishandling of the method
40982701|NCT05576740|PROCEDURE|Urinary LH determination|Urine LH test strips are performed from day 8 of the cycle until positive.
40982702|NCT01336920|DRUG|carfilzomib|Given IV
40982703|NCT03186833|OTHER|no intervention|no intervention
41462619|NCT01520987|DRUG|BIA 9-1067|5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
41462620|NCT01520987|DRUG|Placebo|once-daily
40982704|NCT05047679|BEHAVIORAL|Perioperative Pain Neuroscience Education|Perioperative pain neuroscience education addresses modifiable preoperative risk factors, and in particular cognitive and emotional risk factors, such as fear of movement and pain catastrophizing (i.e., excessively negative orientation toward pain). This education is a cognitive-based therapeutic intervention which reconceptualizes pain, informs patients about what to expect from the evolution of their pain, de-emphasizes the patho-anatomical content and focuses on factors contributing to the development of pain. It explains this all within a biopsychosocial framework, which means that it aims to optimize patients' beliefs. Furthermore, it intends to reassure the patient about the decision to have surgery, to potentially decrease perioperative distress.
41143305|NCT01063465|DEVICE|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
41143306|NCT03720028|BEHAVIORAL|Observation|Describe communication and sensory profile using standardized tests and observations.
41143307|NCT03720028|BEHAVIORAL|Parental experiences|Survey parents' experiences with parent-child interaction and augmentative and alternative communication.
41303676|NCT04986579|DEVICE|Paxman Scalp Cooling System|Cap attached to coolant lines connected to a refrigeration unit placed on scalp
41303677|NCT04986579|DRUG|Eribulin|Intravenous Infusion
41303678|NCT04986579|DRUG|Sacituzumab govitecan|Intravenous Infusion
41303679|NCT04986579|DRUG|Trastuzumab deruxtecan|Intravenous Infusion
41303680|NCT05179031|DIETARY_SUPPLEMENT|First Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
41303681|NCT05179031|DIETARY_SUPPLEMENT|Second Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
41303682|NCT05179031|DIETARY_SUPPLEMENT|Third Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
41303683|NCT05179031|DIETARY_SUPPLEMENT|High protein tube feed|Nutritional product containing 25 g of available carbohydrates
41303684|NCT05179031|DIETARY_SUPPLEMENT|High-protein tube feed with additional amino acid|Nutritional product containing 25 g of available carbohydrates
41303685|NCT05179031|DIETARY_SUPPLEMENT|Oral Nutritional Supplement for diabetes patients|Nutritional product containing 25 g of available carbohydrates
41462621|NCT02413528|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
41462622|NCT02413528|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
41462623|NCT04395079|BIOLOGICAL|Durvalumab|Given IV
41462624|NCT04395079|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
41462625|NCT04395079|BIOLOGICAL|Tremelimumab|Given IV
41462626|NCT05705973|DEVICE|Ultimaster Nagomi™|The Ultimaster NagomiTM Sirolimus eluting coronary stent system with Rapid Exchange Balloon Delivery System consists of a balloon expandable intra-coronary L605 cobalt chromium (CoCr) stent with abluminal drug eluting coating, that consists of a blend of Sirolimus and Poly(D,L-lactide-co-caprolactone), pre-mounted onto a high pressure, semi-compliant balloon delivery catheter
41462627|NCT03208517|OTHER|Improving Wellbeing and Health for People with Dementia (WHELD) e-learning training programme|The e-learning WHELD intervention The optimised e-learning programme will consist of five 25-minute interactive online modules based on a recently completed RCT of an in person training programme (WHELD), combining the most effective elements of existing approaches to create a comprehensive but practical staff training intervention. Based on a factorial study and qualitative evaluation, WHELD combines: person-centred care, person-centred activities and interactions, and updated knowledge regarding optimal use of psychotropic medications.
41462628|NCT01609582|DRUG|TAK-875|TAK-875 tablets
40982705|NCT05047679|BEHAVIORAL|Perioperative Biomedical Education|Perioperative biomedical education will discuss the anatomy, physiology and biomechanics of the lumbar spine with the patient. Additionally, the content of this education includes the expected course of postoperative back and leg pain, as well as ergonomic advice on patient-specific daily activities. This education will be given within a biomedical framework, which means that it aims to explain the patients' complaints and recovery while focusing on anatomy and biomechanics, as opposed to patients' beliefs and cognitions.
40982706|NCT02014844|DRUG|250 mg/m2 aldoxorubicin|
40982707|NCT02014844|DRUG|350 mg/m2 aldoxorubicin|
41462629|NCT01609582|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
40982708|NCT03410940|DEVICE|CLS Brevius stem with Kinectiv technology|
40982709|NCT04076319|BEHAVIORAL|CAPABLE: Community Aging in Place-Advancing Better Living for Elders|"CAPABLE is a client-directed home-based intervention that consists of time-limited services from an occupational therapist, a nurse, and a handyman working collaboratively with the older adult client. In most cases, the OT makes 6 visits, the RN makes 4 visits, and a handyman makes 1 to 2 visits to make any modifications to a person's home during a 6-month period. The first visits for the OT and RN are usually 90 minutes each and the later ones are usually an hour each. Visits are spaced to enable older adults to practice new strategies learned in the previous visit. There should be a clear conclusion/graduation, with the older adult understanding how to use their new skills and apply them to future situations."
41143308|NCT05013398|BEHAVIORAL|The Together Webinar Programme|"The TTP-Webinar consists of six hour-long sessions. Each session focuses on psychoeducation and self-management strategies for supporting veteran mental health difficulties as well as self-management tools to enhance partners' own wellbeing.~The TTP-Webinar treatment protocol incorporates a range of techniques used in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), Compassion Focused Therapy (CFT), and Acceptance and Commitment Therapy (ACT)."
41143309|NCT02605876|DEVICE|Whole body vibration|
41143310|NCT02605876|DEVICE|Local muscle vibration|
41143311|NCT05776134|BIOLOGICAL|Brexucabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
41303686|NCT05179031|DIETARY_SUPPLEMENT|Oral Nutritional Supplement for diabetes patients (new formula)|Nutritional product containing 25 g of available carbohydrates
41462630|NCT00024258|DRUG|arsenic trioxide|
40777834|NCT03837509|BIOLOGICAL|Daratumumab SC|Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.
40777835|NCT03588702|DEVICE|RF and PEMF treatment|Treatment with Venus Legacy LB2 body applicator
41303687|NCT05179031|DIETARY_SUPPLEMENT|ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
41303688|NCT05179031|DIETARY_SUPPLEMENT|Plantbased ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
41303689|NCT01967420|BEHAVIORAL|Cognitive remediation|CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
41462631|NCT06389838|DEVICE|Kranus Mictera|An app-based digital therapy program aimed at multimodal self-treatment for incontinence. The app is certified class I medical device (MDR).
41462632|NCT03837405|BEHAVIORAL|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
41462633|NCT03837405|BEHAVIORAL|Mindfuless|Mindful eating app use plus group sessions to learn mindfulness
40982710|NCT01938599|DRUG|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
40982711|NCT01938599|DRUG|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
40982712|NCT03015012|GENETIC|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
41143312|NCT05603949|DEVICE|3D deep learning neural network system|With the consent of the patient, we will assist in the production of images of 3D defect blocks for free (3D deep learning neural network system (3D DNN) system process planning), complete the repair and reconstruction under the clinical routine surgery, and track the repair results after surgery. meet medical needs.
41303690|NCT01967420|BEHAVIORAL|Social cognition training|The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
41303691|NCT03681652|DRUG|Azathioprine|Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection
40982713|NCT03015012|OTHER|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
40982714|NCT01333059|DRUG|Midazolam|
40982715|NCT01333059|DRUG|Normal saline|
40982716|NCT01333059|DRUG|Fentanyl|
40982717|NCT04387175|DEVICE|Carriere Motion 3D Class III Appliance|The device made of stainless steel consists of a flexible bar with two pads at the end which are bonded bilaterally with composite resin to the lower second deciduous molar or the lower first permanent molar at the rear and the lower deciduous canine at the front. The base on the lower deciduous canine has a hook to which bilaterally elastic latex bands are connected with the vestibular tubes of the cemented bands on the upper deciduous second molars (Force 2 elastics ) or on the first permanent upper molars (Force 1 elastics), on whose palatine surface the a rapid maxillary expander is welded.
40982718|NCT04387175|DEVICE|Facial mask|The facial mask consists of a chin pad and frontal pad connected by a central steel bar. On the central bar there is a horizontal steel bar to which latex elastic bands are attached which develop 14 ounces of force. The elastics are connected to the rapid maxillary expander by means of two hooks welded on the bands of the second upper deciduous molars or the first upper permanent molars.
40982719|NCT03128333|OTHER|RunKeeper app + physiotherapy coaching|RunKeeper app for half a year to self-monitor leisure-time PA.
41303692|NCT03681652|DRUG|Anti-TNF Drug|Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
41303693|NCT01860053|BEHAVIORAL|behavioral intervention|This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
41303694|NCT02327286|BEHAVIORAL|Promote and support healthy behaviors|"* Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~* Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~* Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~* A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices."
41303695|NCT02191202|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
41303696|NCT05308225|BIOLOGICAL|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor
41303697|NCT00740779|DRUG|Silodosin 8 mg|Silodosin 8 mg daily
41303698|NCT00740779|DRUG|Placebo|Placebo
41303699|NCT00740779|DRUG|Silodosin 4 mg|Silodosin 4 mg daily
41303700|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 200 mL tap water via nasogastric tube|
41303701|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube|
41303702|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube|
41303703|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube|
41462634|NCT04056663|BEHAVIORAL|Health-Circuit mobile application|Health-Circuit as a collaborative tool between professionals and patient and professionals
41462635|NCT03045627|DRUG|AraC|ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
41462636|NCT03045627|DRUG|Aclarubicin|Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8
41462637|NCT03045627|DRUG|Peg-G-CSF|PEG-G-CSF 6mg subcutaneously on days 0.
40982720|NCT03128333|OTHER|Usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
40982721|NCT05417945|DEVICE|JensClip transcatheter valve repair system|"Transcatheter mitral valve repair system is derived from the Edge-to-Edge technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation."
41303704|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube|
41303705|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube|
41303706|NCT02473159|DRUG|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
41303707|NCT01165021|DRUG|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
41303708|NCT01165021|DRUG|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
41303709|NCT01165021|DRUG|Folic Acid|Administered orally.
41303710|NCT01165021|DRUG|Vitamin B12|Administered Intramuscular injection.
41303711|NCT01165021|DRUG|Dexamethasone|Administered orally.
41303712|NCT05056467|PROCEDURE|Induction of Labor|Induction of Labor at 39 weeks of gestation
41303713|NCT05610462|BEHAVIORAL|Guided Exercise Training Program|The guided exercise program training consists of: a video demonstration, an exercise training session or group session, a follow up home visit, and virtual check-ins. The exercises include treadmill, wall sits, straight leg raise, bicep curls, hand grips with dynamometer at 40% maximal voluntary contraction (MVC), and Stationary cycling at moderate intensity (100 Watts).
41462638|NCT03045627|DRUG|G-CSF|G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
41462639|NCT03776929|BEHAVIORAL|Dialectical Behavioral Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral therapy that focuses on the balance between change and acceptance. DBT skills include four modules: two that enforce acceptance-oriented skills, mindfulness and distress tolerance, and two that promote change-oriented skills, interpersonal effectiveness and emotional regulation.
41462640|NCT03993639|DRUG|Pegfilgrastim|Single dose of SC administration
40982722|NCT01437215|DEVICE|Ventana Fenestrated Stent Graft System|Endovascular repair of juxtarenal or pararenal aortic aneurysm
41462641|NCT01272024|BEHAVIORAL|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
41462642|NCT01272024|BEHAVIORAL|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
41462643|NCT04063670|OTHER|Video Intervention|Peri-operative video series focusing on expanded education and coping skills before and after scoliosis surgery for adolescent idiopathic scoliosis
41462644|NCT04063670|OTHER|Control|Routine, Standard-of-Care
41462645|NCT03455036|OTHER|Whole body vibration training|10 x 1 min whole body vibration exposure
41462646|NCT03632694|BEHAVIORAL|Health Coaching and Tech Support|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior."
41462647|NCT03632694|BEHAVIORAL|Tech Support Only|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching."
40982723|NCT04519125|DRUG|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
40982724|NCT04519125|OTHER|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
41303714|NCT05610462|BEHAVIORAL|Usual Care|Usual care consists of routine clinic visits and standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
41303715|NCT05293132|DRUG|Montelukast Sodium 10 mg|Film coated tablets containing 10 mg montelukast
41462648|NCT02684396|DRUG|TAK-648|TAK-648 Solution
41462649|NCT02684396|DRUG|TAK-648 Placebo|TAK-648 placebo-matching solution
41462650|NCT00451490|DRUG|Agomelatine|
41462651|NCT00451490|DRUG|Fluoxentine|
40982725|NCT00000233|DRUG|Buprenorphine|
40982726|NCT04588792|DRUG|Nebulized Furosemide|Furosemide administered by nebulization through the ventilator circuit
41462652|NCT02725411|DRUG|Celecoxib|Orally administered Celecoxib 100 mg twice daily for 56 weeks
41462653|NCT02725411|BIOLOGICAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
41462654|NCT02725411|BIOLOGICAL|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
40982727|NCT04588792|DRUG|Nebulized Saline|Saline administered by nebulization through the ventilator circuit
40982728|NCT05111158|DIAGNOSTIC_TEST|mfERG|mfERG was performed by RETI Scan (Roland consulting company) and software 6.16.3.10 according to the protocol of the International Society for Clinical Electrophysiology of Vision (ISCEV)
40982729|NCT05248945|DRUG|Evobrutinib|Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.
40982730|NCT05248945|DRUG|Carbamazepine|Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
40982731|NCT04896008|DRUG|Sotatercept|Sotatercept is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
40982732|NCT04896008|OTHER|Placebo|Placebo
40982733|NCT02188589|DEVICE|INEX nasal implant|Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)
40982734|NCT04629157|DEVICE|Innova Lateral Flow Device|The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.
40982735|NCT06112444|OTHER|scale|The scale of Short Western Ontario Rotator Cuff İndex
40982736|NCT00818662|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|400 mg/kg bodyweight every 2 weeks for 70 weeks
41303716|NCT05293132|DRUG|Co-Enzyme Q10|Capsules contain 210 mg Co-Enzyme Q10
41303717|NCT05293132|DRUG|Standard Treatment|Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
41462655|NCT02725411|DRUG|Placebo for celecoxib|Orally administered the placebo twice daily for 56 weeks
41462656|NCT02725411|BIOLOGICAL|Placebo for tanezumab|Subcutaneous injection of the placebo every 8 weeks for 56 weeks
41462657|NCT02677662|OTHER|Diesel Exhaust|Dilute diesel exhaust
41462658|NCT02677662|OTHER|Filtered air|Filtered air
41462659|NCT06080698|DRUG|Intravenous Antibiotics|Participants will continue to receive intravenous antibiotics until the completion of the treatment course
41462660|NCT06080698|DRUG|Oral Antibiotics|Participants will transition to oral antibiotics at the time of randomization and will continue oral antibiotics until the completion of the treatment course
41462661|NCT04646694|DRUG|Ketamine|The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.
41462662|NCT04646694|OTHER|Placebo|A placebo is given in this study to reduce the chances of believing that pain after surgery is getting better because one is receiving oral Ketamine
40777836|NCT05508347|DRUG|Nituzumab/placebo|"Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy"
40777837|NCT01604460|PROCEDURE|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
40777838|NCT01604460|PROCEDURE|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
40777839|NCT04136145|DRUG|Belimumab for IV|Belimumab will be available as white to off-white lyophilized cake at a unit dose strength of 400 mg to be reconstituted and diluted in normal saline to obtain 200 mg per dose.
40777840|NCT04136145|DRUG|Belimumab for SC|Belimumab will be available as clear to opalescent, colorless to pale yellow sterile solution at unit dose strength of 200 mg/milliliter (mg/mL) for SC injection in a single-use, prefilled syringe contained within an auto-injector device.
40777841|NCT02998190|DRUG|Single Ascending Doses of EB8018|
40777842|NCT02998190|DRUG|Single Ascending Doses of placebo|
40777843|NCT02998190|DRUG|Multiple Ascending Doses of EB8018|
40777844|NCT02998190|DRUG|Multiple Ascending Doses of placebo|
40777845|NCT02896205|DRUG|Mycophenolate mofetil|Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
40982737|NCT00818662|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|200 mg/kg bodyweight every 2 weeks for 70 weeks
40982738|NCT00818662|BIOLOGICAL|Placebo solution: Human Albumin 0.25% - 4 mL/kg|Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
40982739|NCT00818662|BIOLOGICAL|Placebo solution: Human Albumin 0.25% - 2 mL/kg|Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
40982740|NCT03649711|DRUG|Ticagrelor 90mg|Ticagrelor Pill
40982741|NCT03649711|DRUG|Clopidogrel 75mg|Clopidogrel Pill and a matching placebo to conceal frequency
40982742|NCT03649711|DRUG|Aspirin 81 mg|Aspirin Pill
41143313|NCT05917756|OTHER|Mobilization with Movement (MWM) and Tailored Therapeutic Exercise Program|The intervention consists of MWM techniques targeting the cervical and thoracic spine, and the first rib, applied by a certified physiotherapist for 8 weeks, 2 sessions per week, each session lasting 45 minutes. The intervention also includes a tailored therapeutic exercise program for the patients, comprising postural correction, stretching, and strengthening exercises. This intervention will be compared to conventional physiotherapy in the control group.
41303718|NCT05126823|BEHAVIORAL|Acceptance and commitment therapy + app|In the group ACT+app, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer and interleaved non-contact activities, which will serve as support for each of the modules. The non-contact activities will consist of assigning tasks, practices (mindfulness, breathing), reminder systems, recording, reinforcement and monitoring. Resources such as short texts, videos, audio files and recording systems will be used
41303719|NCT05126823|BEHAVIORAL|Acceptance and commitment therapy|In the group ACT, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer
41303720|NCT05569304|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty
41462663|NCT04560426|DEVICE|Intraoperative parathyroid gland auxiliary recognition system|The enrolled patients are grouped according to whether or not to use the intraoperative parathyroid auxiliary recognition system.
41462664|NCT02510872|OTHER|18F-FDG PET combined with CT with iodinated contrast injection|
41462665|NCT02510872|OTHER|18F-FDG PET combined with CT without injection|
41462666|NCT01143831|DIETARY_SUPPLEMENT|Vitamin K, 20mg|Subjects will take 20mg vitamin K by mouth in capsule form everyday for 14 continuous days.
41462667|NCT01263886|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
40777846|NCT02896205|DRUG|Placebo|Subjects will be given matching placebo for 6 months
40777847|NCT03582579|BEHAVIORAL|Training in Virtual Reality|Action Video Game Based Training in Virtual Reality
40777848|NCT03582579|BEHAVIORAL|Training on a computer screen|Action Video Game Based Training on a computer screen
40777849|NCT04841408|OTHER|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
40777850|NCT05978934|BEHAVIORAL|Static Lighting Condition (L1)|This indoor lighting condition keeps a constant brightness and correlated color temperature.
40777851|NCT05978934|BEHAVIORAL|Dynamic Lighting Condition (L2)|This indoor lighting condition has increased brightness and more blue correlated color temperature in the morning hours followed by decreased brightness and less blue correlated color temperature in the afternoon and evening hours.
40982743|NCT02532790|DRUG|Prednisone|1.5mg/kg/d
40982744|NCT02532790|DRUG|ACEI|0.2-0.3mg/kg/d
40982745|NCT01537510|BEHAVIORAL|STAR - Study of Technology to Accelerate Research|In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
41143314|NCT05917756|OTHER|Conventional Physiotherapy|Conventional physiotherapy, including manual therapy (soft tissue mobilization, joint mobilization, and nerve gliding techniques) for 8 weeks, 2 sessions per week, each session lasting 45 minutes, combined with a tailored therapeutic exercise program (including postural correction, stretching, and strengthening exercises).
41462668|NCT01263886|DRUG|placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
41462669|NCT03590834|BEHAVIORAL|Center-based Intervention|"1. Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~2. Staff training and technical assistance~3. Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~4. Health contests~5. Gross motor and physical activity program~6. Miranos! activity cards based on children storybooks"
40982746|NCT04101981|PROCEDURE|oocytes retrieval|The oocytes retrieval was performed after 34-36 hours from hCG administration . The collection of cumulus-oocyte complexes and FFs were performed via transvaginal ultrasound-guided aspiration with a needle of 18 gauge of diameter. The three major diameter follicles were identified by intraoperative ultrasound and FF of each follicle was collected in its own test tube.
40982747|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
40982748|NCT03138889|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
40982749|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
40982750|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
40982751|NCT03138889|DRUG|Cisplatin|Cisplatin will be dosed per the pharmacy manual
40982752|NCT03138889|DRUG|Carboplatin|Carboplatin will be dosed per the pharmacy manual
40982753|NCT03138889|DRUG|Nab paclitaxel|Nab-paclitaxel will be dosed per local practice and label
40982754|NCT03138889|DRUG|Paclitaxel|Paclitaxel will be dosed per local practice and label
40982755|NCT03138889|DRUG|Pemetrexed|Pemetrexed will be dosed per the pharmacy manual
40982756|NCT03138889|DRUG|Atezolizumab|Atezolizumab will be dosed per current label indication
40982757|NCT04400240|BEHAVIORAL|CALLS|The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.
40982758|NCT05217433|OTHER|Olive leaf extract|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
40982759|NCT05217433|OTHER|Placebo|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
41143315|NCT01517282|BIOLOGICAL|MOR103|Anti-GM-CSF monoclonal antibody
40982760|NCT01314833|DRUG|Docetaxel Cyclophosphamide|"Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC\*6"
41143316|NCT01517282|OTHER|Placebo|Placebo to anti-GM-CSF monoclonal antibody
41143317|NCT01821222|DEVICE|Wired mothers|"The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.~Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider."
41143318|NCT04728282|PROCEDURE|RTSA with subscapularis repair|Lateralized reverse total shoulder arthroplasty with repair of subscapularis
41143319|NCT04728282|PROCEDURE|RTSA without subscapularis repair|Lateralized reverse total shoulder arthroplasty without repair of subscapularis
41143320|NCT00021333|BIOLOGICAL|filgrastim|
41143321|NCT00021333|DRUG|cisplatin|
40777852|NCT05978934|BEHAVIORAL|Dynamic Lighting Condition (L3)|This exploratory indoor lighting condition matches the same pattern as L2 except the brightness in the morning hours is increased.
40982761|NCT01314833|DRUG|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|"1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF\*3-T\*3"
40982762|NCT01314833|DRUG|Epirubicin Cyclophosphamide Paclitaxel|"1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC\*4-P\*4"
40982763|NCT01862562|PROCEDURE|Open surgery|Conventional technique
40982764|NCT01862562|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
40982765|NCT01772706|PROCEDURE|low level laser therapy|
41143322|NCT00021333|DRUG|paclitaxel|
41143323|NCT00021333|RADIATION|radiation therapy|
41143324|NCT03948958|OTHER|Evaluation of the catheter function|Catheter function will be measured by the CINAS (Catheter injection and aspiration classification)
41143325|NCT03948958|OTHER|Catheter tip location, thrombus, sleeve and device damage visualization|Catheter tip location, thrombus, sleeve and device damage will be visualized by linogram
40777853|NCT06397092|PROCEDURE|transapical beating-heart septal myectomy|The patients with hypertrophic cardiomyopathy undergoing TA-BSM
40982766|NCT01772706|PROCEDURE|placebo (laser low level energy nonfunctional)|
40777854|NCT03669887|BEHAVIORAL|Lifestyle Modification Program|The intervention will consist of 5 individual face-to-face sessions at 2-weekly intervals with a dietitian with experience in lifestyle modification program, followed by monthly phone contact and smartphone text messages. All study participants in the intervention arm will also be arranged to meet with an exercise instructor at least once during the LMP on the same day as one of the dietitian appointment. Ongoing support from the exercise instructor will also be available by phone calls or emails.
40982767|NCT05893433|DEVICE|Bedside cycling|"participants receive daily cycling once the patient is relatively stable by weaning off the ventilator and off the require inotropic support and continued to the discharge from the hospital.~Duration progression if the following conditions are reached:~1. Initially increase the duration by up to15 min of low exercise time and then increase the intensity after the patient can complete 15- 20 min.~2. Complete 15min with a medially stable condition gradually until reaching 20 minutes besides the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment."
40982768|NCT05893433|OTHER|control|the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
40982769|NCT00460408|DRUG|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
40777855|NCT02829372|DRUG|CD3/HER2 bispecific monoclonal antibody|Increasing doses, IV on day 1 and 15 of each 28 day cycle
40777856|NCT05610735|DRUG|DOXIL|DOXIL will be administered IV as 40 mg/m2 IV every four weeks for 4 cycles or until disease progression and/or unacceptable toxicity, whichever comes first to a maximum of 10 cycles.
40777857|NCT05610735|DRUG|Withaferin A|Ashwagandha in the form of tablets will be administered orally on daily basis.
40777858|NCT05610735|DRUG|Ashwagandha|Administered orally on daily basis twice a day
40777859|NCT05610735|DRUG|Combination of ASWD and DOXIL|DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.
40982770|NCT05286307|DRUG|IPACK block|IPACK block with 20 mL of 0.25% Bupivacaine injected into the Interspace between the Popliteal Artery and Capsule of the Knee
40777860|NCT01530958|BEHAVIORAL|CKD Registry|"Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~* identify patients with CKD~* notify PCPs of a patients' CKD status~* provide PCP outreach with NKDEP guidelines and patient educational materials"
40777861|NCT01530958|BEHAVIORAL|ATSM + Health Coach|Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
40982771|NCT03898050|PROCEDURE|transcutaneous cardiac pacing|transcutaneous cardiac pacing
40982772|NCT00740844|DEVICE|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
40982773|NCT05833295|PROCEDURE|Downhill walking|Change in the H/M ratio after a downhill walk.
40982774|NCT05833295|PROCEDURE|Walking on flat ground|Change in the H/M ratio after a Walking on flat ground
40982775|NCT00553150|DRUG|everolimus|
40982776|NCT00553150|DRUG|temozolomide|
40982777|NCT00553150|RADIATION|radiation|
40777862|NCT01530958|BEHAVIORAL|Usual care|"Primary care providers will manage their patients with CKD per usual care.~Patients will receive usual care."
40777863|NCT03700125|PROCEDURE|ECMO resuscitation|Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest
40777864|NCT05687370|PROCEDURE|Modified dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using modified dynamic short-axis view.
40777865|NCT05687370|PROCEDURE|Long-axis technique|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
40777866|NCT05517408|DRUG|ciprofol|The first patient received Ciprofol 0.3mg/kg (actual body weight) at a rate of 1 mg/s. If the desired depth of sedation/anesthesia reached, then it was judged as negative, and the dose of Ciprofol in next patient would be decreased by one concentration gradient (the difference between two adjacent drugs was 1:1.1); If the desired sedation/anesthesia depth was not achieved, then it was judged as positive. And the dose of Ciprofol in next patient would be increased by one concentration gradient. Patients were enrolled consecutively until the trial was terminated at the eighth crossing point (positive to negative or negative to positive).
40777867|NCT03426527|DRUG|Levobupivacaine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine
40777868|NCT03426527|DRUG|Levobupivacaine-Dexmedetomidine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine in conjunction with dexmedetomidine
40777869|NCT03426527|OTHER|General Anaesthesia|Using propofol, fentanyl and atracurium
40777870|NCT03220009|PROCEDURE|Conventional Surgery|Undergo surgery
40777871|NCT03220009|BIOLOGICAL|Ipilimumab|Given IV
40777872|NCT03220009|OTHER|Laboratory Biomarker Analysis|Correlative studies
40777873|NCT03220009|BIOLOGICAL|Nivolumab|Given IV
40777874|NCT03220009|OTHER|Patient Observation|Undergo active surveillance
40777875|NCT03220009|RADIATION|Radiation Therapy|Undergo RT
40777876|NCT06074432|OTHER|Emergency Colorectal Resection|Patients underwent resection due to colorectal carcinoma in emergency surgery
40777877|NCT06418282|DEVICE|Dayspring|NPCD
40982778|NCT00022451|DRUG|tipifarnib|
40982779|NCT00815581|DEVICE|photorefraction,cycloautorefraction,cycloretinoscopy|
40982780|NCT00643032|PROCEDURE|Transcutaneous iliohypogastric|
40982781|NCT00643032|PROCEDURE|Perioperative administration near the nerve|
41303721|NCT01743339|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions
41303722|NCT01743339|BEHAVIORAL|Control|Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
41303723|NCT01739777|BIOLOGICAL|ucMSC|1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
41303724|NCT01739777|OTHER|Controls|Autologous Serum will administrated as placebo
41303725|NCT01665417|DRUG|Experimental|Icotinib: 125mg, oral administration, three times per day.
41303726|NCT01665417|DRUG|Chemotherapy|Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
41303727|NCT01665417|DRUG|Chemotherapy|Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
41303728|NCT06554470|DRUG|Systemic Methotrexate|Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
41303729|NCT06554470|DRUG|Local Methotrexate|Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).
41303730|NCT06364228|DRUG|Placebo|Placebo intranasal spray liquid administration. Oxytocin delivered 2 puffs to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).
41303731|NCT06364228|DRUG|Oxytocin Intranasal Spray 12 International Unit (12IU)|Oxytocin intranasal spray liquid administration. Subjects weighing \< 40 kg will receive 12 IU of oxytocin delivered as 1 puff (6 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).
41303732|NCT06364228|DRUG|Oxytocin Intranasal Spray 24 International Unit (24IU)|Oxytocin intranasal spray liquid administration. Subjects weighing \> 40 kg will receive 24 IU of oxytocin delivered as 2 puffs (12 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).
41303733|NCT06364228|PROCEDURE|Functional MRI|Functional MRI (fMRI) scan with affective Stroop and EmpaTom task (Empathy and Theory of Mind task). fMRI scan will administered pre and post-administration of oxytocin.
40777878|NCT04339036|DRUG|Capecitabine Oral Product|Capecitabine 750 mg/m2 twice daily orally for 14 days
40777879|NCT04339036|DRUG|Temozolomide Oral Product|temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles
40982782|NCT01648907|OTHER|Imaging exams|"Radiological examinations:~* Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front~* MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.~Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.~Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.~Biological tests :~* Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.~* Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.~* Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60."
40982783|NCT02947529|DRUG|Tranexamic Acid|intravenous dose
40982784|NCT02947529|OTHER|Placebo|intravenous dose
40982785|NCT02514447|DRUG|Trilaciclib|
40982786|NCT02514447|DRUG|Placebo|
40982787|NCT02514447|DRUG|Topotecan|
40982788|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
40982789|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
40982790|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
40982791|NCT04495842|OTHER|Essential Oil Blend|5 drops of on a tester strip
40982792|NCT04495842|OTHER|Control Blend|5 drops on a tester strip
40982793|NCT06101745|DRUG|Nizaracianine Triflutate|Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0, 2.5 or 5.0mg depending on trial phase.
40982794|NCT06101745|DRUG|Placebo Comparator|In Phase 3A only, 50 subjects will be randomly allocated to receive sugar placebo
41303734|NCT01925001|DRUG|MP4CO|43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution
41303735|NCT01925001|DRUG|Sodium chloride solution|Normal saline solution (0.9% Sodium Chloride Injection USP)
41303736|NCT01587872|PROCEDURE|Fujinon EC-450BI5 double-balloon colonoscope|Colonoscopy with the test instrument
41303737|NCT04691063|DRUG|SHR-1316; Carboplatin; Etoposide；Radiotherapy|SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）
41303738|NCT04691063|DRUG|Palcebo; Carboplatin; Etoposide；Radiotherapy|Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）
41303739|NCT02126644|DRUG|70% glycolic acid|
41303740|NCT03899194|DIETARY_SUPPLEMENT|fish oil capsules|fish oil capsules(1000mg，EPA 180mg；DHA 120mg)
41303741|NCT03899194|DRUG|escitalopram|escitalopram 10-20 mg/d
40982795|NCT00815009|BEHAVIORAL|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
40982796|NCT00815009|BEHAVIORAL|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
40982797|NCT00815009|BEHAVIORAL|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
40982798|NCT04645641|DEVICE|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
40982799|NCT00543348|PROCEDURE|CUTTING BALLOON ANGIOPLASTY|CUTTING BALLOON
40982800|NCT00543348|PROCEDURE|Balloon angioplasty|HIGH PRESSURE BALLOON
40982801|NCT01052051|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 2000 IU/daily
40982802|NCT01052051|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate 1500mg / daily
40777880|NCT04339036|COMBINATION_PRODUCT|transarterial radioembolization|Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4.
40982803|NCT06397352|OTHER|ShotBlocker®|All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors.It is positioned onto the skin before an injection is made. After positioning the ShotBlocker® and ensuring that the contacts were in contact with the children's skin, the injection was made through the central hole by the nurse. The ShotBlocker® was cleaned with 70% alcohol before use on another child.
40982804|NCT06397352|OTHER|Buzzy® Group|All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors. Vibrations started 30 seconds before the procedure and continued until it was completed. The device was cleaned with 70% alcohol before use on another child
40982805|NCT03065244|DRUG|IVIG|Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours
40982806|NCT03065244|DRUG|Infliximab|Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
40982807|NCT00806754|DRUG|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
40982808|NCT00806754|DRUG|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
40982809|NCT03573895|OTHER|Foam-Roller|Application of foam roller in the posterior part of thigh.
40982810|NCT03573895|OTHER|Neuromuscular stretching|Use of a neuromuscular stretching applied to the hamstring muscles
40982811|NCT03573895|OTHER|Pasive stretching|Use of a pasive stretching applied to the hamstring muscles
40982812|NCT02560233|OTHER|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
40982813|NCT02560233|OTHER|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
40777881|NCT06511063|DRUG|tenofovir disoproxil/emtricitabine|Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.
40982814|NCT04217746|DEVICE|High Flow Nasal Cannula|The HFNC group will receive heated and humidified oxygenated gas delivered at high flow.
40777882|NCT06511063|DRUG|Selzentry|Participants will take Selzentry for 90 days.
40777883|NCT06511063|DRUG|Placebo|Matching placebo.
40982815|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.1mg/kg|Remimazolam Tosilate for Injection 0.1mg/kg at induction
40982816|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.15mg/kg|Remimazolam Tosilate for Injection 0.15mg/kg at induction
40982817|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.2mg/kg|Remimazolam Tosilate for Injection 0.2mg/kg at induction
40982818|NCT04453033|DEVICE|Celeste Specialized Phototherapy Device|Ocular phototherapy light panel
40982819|NCT00284661|PROCEDURE|FAST FIX|Fast fix repair of a meniscal tear
40982820|NCT00284661|PROCEDURE|Meniscal suturing|standard suturing of meniscal tear
40982821|NCT02979847|PROCEDURE|hybrid approach|Before transseptal puncture, epicardial puncture is performed through subxyphoid approach. Atrial epicardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Endocardial potentials are also recorded in the same fashion. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
40982822|NCT02979847|PROCEDURE|conventional endocardial approach|Atrial endocardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
40982823|NCT03853395|DIAGNOSTIC_TEST|Tests for drug levels and anti-drug antibodies|Measurement of drug levels and anti-drug antibodies will be undertaken using commercially available enzyme-linked immunosorbent assays (ELISAs) and/or radioimmunoassays
40982824|NCT04108520|OTHER|Exercise|Exercise with respiratory training
40777884|NCT01995097|BEHAVIORAL|Scheduled Gradual Reduction Text Messages|
40982825|NCT01681732|OTHER|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
40982826|NCT01681732|OTHER|Control Standard Care|This is the standard care arm
40982827|NCT03794557|DRUG|Sterile Water Injection|Inhaled Sterile Water Injection
40777885|NCT01995097|BEHAVIORAL|Support Text Messages|
40777886|NCT02456129|DRUG|Vilaprisan (BAY1002670)|single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
40777887|NCT02456129|DRUG|[14C] Vilaprisan|an intravenous microtracer dose of \[14C\]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
40982828|NCT03794557|DRUG|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution
40982829|NCT03730493|BEHAVIORAL|Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
40982830|NCT06278857|DRUG|Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]|The dosing regimen follows standard clinical care protocol comprising of 4 cycles every 3-weeks, a rest period of 34 weeks followed by 3 cycles every 6 weekly for a total of 7 cycles.
40982831|NCT05886608|DEVICE|AI 500™ SINGLE-DOSE GEL|AI500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, intended to provide relief in cases of pain due to tension in muscles and adjacent tissues, to improve movement and function.
40982832|NCT02121288|DRUG|Ticagrelor|Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
40982833|NCT02121288|DRUG|clopidogrel|Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
40982834|NCT04517565|DIAGNOSTIC_TEST|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate presence, type and severity of brain abnormalities in enrolled subjects.
40982835|NCT04517565|BEHAVIORAL|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language and other neuro-cognitive functions potentially affected by Sturge-Weber syndrome.
41303742|NCT01685632|PROCEDURE|Surgery with IPCH|"surgical debulking and extensive tumoral resection after laparotomy under general anesthesia~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
41462670|NCT03590834|BEHAVIORAL|Home-based Intervention|"1. Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~2. Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~3. 16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~4. Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars"
40982836|NCT05928897|DRUG|Disitamab Vedotin combined with Sintilimab|Disitamab Vedotin combined with Sintilimab
40982837|NCT02680912|DEVICE|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
40982838|NCT02680912|DEVICE|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
40982839|NCT06420843|DIETARY_SUPPLEMENT|FOODMAP|Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) have been recently investigated in the management of functional gut symptoms in IBS.
41143326|NCT03948958|OTHER|Catheter-related colonization|TIVAD colonization will be investigated by microbiological culture of the tip and chamber content
41303743|NCT01685632|PROCEDURE|Without surgery and without IPCH|"The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
41303744|NCT02984826|OTHER|Strength training|The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
41462671|NCT03590834|BEHAVIORAL|Active Control|"Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention."
41462672|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
40777888|NCT02456129|OTHER|Itraconazole(ITZ)|Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
40777889|NCT06561802|DIAGNOSTIC_TEST|GCF and saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Also, 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips and put into propylene tube. Tubes were stored at -80ºC until the day of analysis.
40982840|NCT05529043|BEHAVIORAL|MINISTOP app|The MINISTOP app is a behavioural change program aiming to promote healthier diet and physical activity behaviours in pre-school children. The program consists of features such as information, monitoring and feedback (dietary variables, physical activity, and screen time) and it is built around 13 themes. The participants will have access to the app for 12-months.
40777890|NCT03489694|PROCEDURE|Skin test endpoint titration|An allergen that is suitable to cause skin reactions when introduced to the forearm through pricking will be administered in doubling concentrations.
40982841|NCT05529043|BEHAVIORAL|MINISTOP Plus Program|Consists of the MINISTOP app and the Community Group Mini. The Community Group Mini consists of group activities to promote physical activity for both children and parents. The Community Group Mini will meet once per week in different playgrounds and nature reserves and will be organized by a trained group leader.
40982842|NCT01693926|BEHAVIORAL|Acute physical activity intervention|25 min of physical activity. The placebo arm will have 25 min of reading.
40982843|NCT01693926|BEHAVIORAL|placebo|
40982844|NCT05188950|DEVICE|depression screening test App|The participants' use of the depression screening test App of 6 modules for 12 weeks, at least once a week, 20 minutes per once.
40982845|NCT03684954|OTHER|Prf|Take 10 cc blood from patient and gain prf
40982846|NCT02339740|DRUG|Arsenic Trioxide|Given IV
40982847|NCT02339740|DRUG|Cytarabine|Given IV
40982848|NCT02339740|DRUG|Dexamethasone|Given PO or IV
41303745|NCT02984826|OTHER|Ergonomic and posture|The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
41303746|NCT04523844|DRUG|Brinzolamide-brimonidine Fixed Combination|In case group one drop of a fixed combination of brinzolamide-brimonidine will be instilled two hours before the injection
41303747|NCT05572229|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
41303748|NCT05572229|DRUG|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
41303749|NCT05572229|DRUG|Lenalidomide|Lenalidomide will be administered orally
41303750|NCT02532361|DEVICE|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
41303751|NCT02532361|PROCEDURE|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
41303752|NCT05187806|BEHAVIORAL|motivational interview|After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions.The pretest and posttest Diabetes Self-Management Scale total scores and HbA1c values of the patients in the experimental and control groups were compared.
41303753|NCT01912768|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
41303754|NCT01912768|DEVICE|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
41303755|NCT01912768|DEVICE|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
41303756|NCT02932475|DRUG|Metformin|1000 mg twice a day
41303757|NCT02932475|DRUG|Placebo|Delivered to match active drug
41303758|NCT04357353|BIOLOGICAL|Platelet rich plasma|PRP will be used in the experimental arm.
40777891|NCT02460276|DRUG|Lenalidomide|
40982849|NCT02339740|DRUG|Idarubicin|Given IV
40982850|NCT02339740|OTHER|Laboratory Biomarker Analysis|Correlative studies
40982851|NCT02339740|DRUG|Mitoxantrone Hydrochloride|Given IV
40982852|NCT02339740|OTHER|Quality-of-Life Assessment|Ancillary studies
40982853|NCT02339740|OTHER|Questionnaire Administration|Ancillary studies
41303759|NCT04357353|OTHER|Placebo Sham Injection|sham injection
40777892|NCT02460276|DRUG|Ibrutinib|
40982854|NCT02339740|DRUG|Tretinoin|Given PO
40982855|NCT01453257|DRUG|Tailored Chemotherapy|"Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:~K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU"
41143327|NCT03948958|OTHER|patient-reported outcome measures (PROM) related to the presence of the TIVAD|PROM will evaluate patient's experiences regarding the TIVAD insertion, dwell time, and removal using the Leuven Patient Reported Experiences at Port removal (Leuven PREP) questionnaire.
41143328|NCT03948958|OTHER|Macroscopic evaluation of the port chamber and catheter|Macroscopic evaluation of the port chamber and catheter will be performed after port removal.
40982856|NCT05281445|BEHAVIORAL|Tic suppression task|Tic Suppression Task (TST, administered to Tourette syndrome participants only): At the beginning of the task, the child participant will be seated alone in front of a computer monitor with a countdown timer visible on the screen. For the first 10 minutes (baseline condition) they will be asked to tic freely and not to try to suppress their tics. For the second 10 minutes children will be asked to suppress their tics and will receive points for successful suppression. Participants will then be asked to sit alone in the room and tic freely for an additional 10-minutes.
41462673|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
41462674|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
41143329|NCT00703092|DRUG|Fiber-Stat|Liquid fiber supplement, 2 tablespoons twice daily.
41303760|NCT01240811|DRUG|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
41303761|NCT01240811|DRUG|Levonorgestrel IUD|
41303762|NCT01240811|DRUG|Copper T380A IUD|
41303763|NCT02889510|DRUG|liraglutide|7-week subcutaneous liraglutide once daily
41303764|NCT02889510|DRUG|placebo|7-week subcutaneous placebo once daily
41303765|NCT04729088|DRUG|Isosorbide mononitrate|Intra-anal application performed by the study physician of 2 g of the study drug
41303766|NCT04911270|DEVICE|Computer Decision Support Tool Intervention Group|Computer Decision Support Tool using Bayesian estimation to dose IV vancomycin in pediatric patients using AUC24/MIC
41303767|NCT04911270|OTHER|Matched Historical Controls|Vancomycin dosing based on standard hospital methods, with dose adjustments based on vancomycin trough targets
41303768|NCT05110183|DEVICE|electrical stimulation|A cochlear implant electrode will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software on a laptop computer will be used to control the delivery of a sequence of charge balanced current pules.
41303769|NCT05110183|OTHER|optical stimulation|Optical fibers will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software will be used to control the delivery of a sequence of charge balanced current pules.
41303770|NCT05110183|OTHER|combined optical and electrical stimulation|A short hybrid array consisting of optical sources and electrical contacts will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Biphasic electrical current pulse and optical pulse delivery will be controlled in amplitude and timing by a computer.
41303771|NCT05906134|PROCEDURE|Thoracic epidural catheter|The pain service and thoracic surgery attending physician will assess if the patient's pain is not well-controlled using the pain modality they are randomized to. If additional pain control is needed, this will be added as an adjunct to the study arm and will be noted in the data set. This will likely consist of a thoracic epidural catheter.
41462675|NCT03157869|DEVICE|Transcranial Direct Current Stimulation|Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
41462676|NCT03157869|OTHER|Simulated|Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
41462677|NCT04618419|DIAGNOSTIC_TEST|internal jugular vein distensibility index|It is a prospective observational clinical study to correlate hemodynamic monitoring between Electrical Cardiometry and internal jugular vein distensibility index by sonogram
41462678|NCT05488119|BEHAVIORAL|Intervention to increase diabetes technology uptake|The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment. I will recruit 20 families or providers to participate in the delivery of the pilot intervention designed in Phase 1 of the study via a stakeholder advisory board.
41462679|NCT01133236|DIETARY_SUPPLEMENT|Salt and fluid restriction|"I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.~II: Control Prescription without sodium and fluid restriction."
41303772|NCT05906134|PROCEDURE|Local intercostal nerve block|Patients receiving intercostal blocks will receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
41462680|NCT00749411|DRUG|Placebo|matching placebo
41462681|NCT00749411|DRUG|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
41462682|NCT03710096|DEVICE|macGrath|in the mac grath group we use the videolaryngoscope macGrath as first-line for the insertion of double lumen tube
41462683|NCT03710096|DEVICE|Macintosh's|in the macintosh group we use the laryngoscope with Macintosh's blade as first-line for the insertion of double lumen tube
41462684|NCT01611415|DRUG|Ipragliflozin|Oral
41462685|NCT01611415|DRUG|Furosemide|Oral
41462686|NCT04480372|DRUG|Gemcitabine|Gemcitabine is administered at the dose of 1000 mg/m2 intravenously (i.v.) on day 1 and day 8 of each cycle (every 3 weeks).
41462687|NCT04480372|DRUG|Atezolizumab|Atezolizumab is administered at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).
40982857|NCT05066373|DRUG|EDP1815 capsule A|EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
40982858|NCT05066373|DRUG|EDP1815 capsule B|EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
41462688|NCT00349401|DRUG|ketorolac|
41462689|NCT00349401|DRUG|morphine|
41462690|NCT04346563|OTHER|Kinesio tape, functional correction technique|According to Kinesio Taping, functional correction technique could use for correcting shoulder, scapular alignment and decrease pain.
41462691|NCT04346563|OTHER|Elastic band strengthening shoulder exercise|"The exercise in which both groups will receive Introduction of exercise with rubber bands (Elastic band) It is a home exercise (Home base exercise program) for patients to do with appropriate resistance. Which can be done at least 10 times and not more than 20 times continuously,will be asked to do all 3 positions.~1) Shoulder external rotation in shoulder abduction 90 degrees 2) Shoulder horizontal abduction in shoulder abduction 90 degrees 3) Seated bend row, which will be done 15 times, each hold for 10 seconds, do 3 sets, each set rest 2 minutes, 2 times a day ( Morning-evening) consecutively for 1 week"
40982859|NCT05066373|DRUG|EDP1815 tablet|EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA
40982860|NCT04914104|BEHAVIORAL|Mindfulness Training - Headspace App|The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
40982861|NCT02985164|RADIATION|PDSa|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSa1 (outside lead apron),PDSa2 (inside lead apron).
40982862|NCT02985164|RADIATION|PDSb|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSb1 (outside lead apron), PDSb2 (inside lead apron).
40982863|NCT02934906|PROCEDURE|Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion|Observational study.
40982864|NCT06215599|OTHER|Survey|The survey consisted of 14 questions that thoroughly examined the participants' knowledge levels of these conditions, as well as their indication preferences related to BAHIs.
40982865|NCT03623360|DIAGNOSTIC_TEST|Free breathing DCE-MRI|Free breathing DCE-MRI
40982866|NCT04130126|BEHAVIORAL|Taking cold showers|Showering behaviour
40982867|NCT01330485|BEHAVIORAL|Affect Regulation Training|The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
40982868|NCT01330485|BEHAVIORAL|Common Factor Control Condition|The CFC is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
40982869|NCT01107041|BEHAVIORAL|Mobilyze!|Mobilyze! delivers behavioral intervention for depression via a mobile phone, interactive website, and e-mail.
40982870|NCT00560079|DRUG|Allopurinol|Allopurinol 600mg/day bid for 28 days
40982871|NCT00560079|DRUG|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
40982872|NCT00560079|DRUG|Placebo|Placebo
40982873|NCT04372667|BEHAVIORAL|Community score card approach|"The CSC intervention is a participatory community approach. Health care workers (HCWs), PMTCT clients identified the issues that most impacted PMTCT service quality and uptake, and came together to implement actions for improvement. The core implementation strategy is using dialogue in a participatory forum that engages both service users and service providers. The CSC consists of five core phases, repeated on a regular basis (called rounds), for the life of the project. The five core phases include:~1. Phase I: Planning and preparation~2. Phase II: Conducting the Score Card with the community~3. Phase III: Conducting the Score Card with service providers~4. Phase IV: Interface meeting and action planning~5. Phase V: Action plan implementation and follow-up"
40982874|NCT04245696|DEVICE|Dermal Handpiece / SubQ Handpiece|Bipolar radiofrequency (RF) travels from the RF generator, through the electrodes and into the dermal layers beneath the surface of the skin. The microneedles of the Dermal and SubQ cartridges coupled with thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
41462692|NCT02625337|DRUG|Pembrolizumab|
40982875|NCT02137733|DRUG|Bisoprolol|
41462693|NCT02625337|DRUG|Dabrafenib|
41462694|NCT02625337|DRUG|Trametinib|
41462695|NCT02625337|PROCEDURE|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
41462696|NCT02625337|PROCEDURE|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
41462697|NCT03200535|OTHER|EHR gaps|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
40982876|NCT02137733|DRUG|Carvedilol|
40982877|NCT01654367|DRUG|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
41462698|NCT03200535|OTHER|Bulk outreach|A bulk letter or email will be sent
41462699|NCT03200535|OTHER|Dietician call|Patients will receive a personalized call by a registered dietitian
40982878|NCT02940847|PROCEDURE|medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique|It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
40982879|NCT02940847|PROCEDURE|medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique|Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
40982880|NCT00729989|PROCEDURE|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
41462700|NCT06193187|DRUG|Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg|Test (T)
41462701|NCT06193187|DRUG|Entresto 50 mg|Reference (R)
41462702|NCT04453969|OTHER|COVID-19|Exposure of interest for this observational study is current COVID-19 positive status or COVID-19 positive status during pregnancy
40982881|NCT04503759|OTHER|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
40982882|NCT04828447|DIETARY_SUPPLEMENT|Olive Oil|Subjects will be randomized to either high or low dose of olive oil and follow a whole food plant based diet.
40982883|NCT03642236|DRUG|Ibrutinib|Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
40982884|NCT01127412|BEHAVIORAL|Physical activity stimulating program|
40982885|NCT01902264|DRUG|EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)|One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
40982886|NCT00006488|DRUG|recombinant-methionyl human glial cell line-derived neurotrophic factor|
40982887|NCT03036761|PROCEDURE|Auriculotherapy|3 sessions of auriculotherapy at one month intervals.
40982888|NCT00611286|DRUG|clopidogrel treatment after bare metal stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
40982889|NCT00611286|DRUG|clopidogrel treatment after bare metal stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
40982890|NCT00611286|DRUG|clopidogrel after zotarolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
40982891|NCT00611286|DRUG|clopidogrel after paclitaxel-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
40982892|NCT00611286|DRUG|clopidogrel after everolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
40982893|NCT00611286|DRUG|clopidogrel after zotarolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
40982894|NCT00611286|DRUG|clopidogrel after paclitaxel-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
40982895|NCT00611286|DRUG|clopidogrel after everolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
40777893|NCT02460276|DRUG|Rituximab|
40777894|NCT06224023|DIAGNOSTIC_TEST|Determination of presepsin levels in ascites|A diagnostic paracentesis will be performed and presepsin level will be determined in ascites.
40777895|NCT02321475|DRUG|EGb761®|
40777896|NCT02183584|DRUG|Rifampicin|
40777897|NCT02183584|DRUG|Linagliptin|
40982896|NCT00224055|DRUG|Sodium Ferric Gluconate Complex in Sucrose Injection|Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
40982897|NCT00224055|DRUG|Ferrous sulfate tablets|ferrous sulfate, 325 mg oral, three times daily for 6 weeks
41143330|NCT00671853|DRUG|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
40777898|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel|
40777899|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
40777900|NCT00567554|DRUG|paclitaxel|
41143331|NCT00671853|DRUG|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
40777901|NCT00567554|DRUG|paclitaxel + everolimus (RAD001)|
40777902|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
40777903|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + lapatinib|
40777904|NCT03447392|BEHAVIORAL|Discharge Education of Chinese Medicine|Discharge Education of Integrated Traditional and Western Medicine
40777905|NCT03163511|COMBINATION_PRODUCT|VC-02 Combination Product|PEC-01 cells loaded into a Delivery Device
40777906|NCT04729790|DRUG|PRIM-DJ2727|oral FMT capsules
40777907|NCT03808571|OTHER|cord blood specimen during the delivery|The cord blood will be taken during the delivery of baby.
40777908|NCT00153660|DRUG|Celecoxib(drug)|Celecoxib 100 mg bd
40777909|NCT00153660|DRUG|Naproxen(drug)|Naproxen 500 mg bd
40777910|NCT04161664|DRUG|Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
40982898|NCT05704504|BEHAVIORAL|Group-based exercise intervention with EMA and personalized telephone support (SUP)|Participants in the SUP group will receive a 6-week group-based exercise intervention with EMA and personalized telephone support. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer and three 15-minute personalized telephone sessions delivered by research personnel. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and third group exercise sessions will include (1) reviewing exercise goals and EMA data, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
40982899|NCT05704504|BEHAVIORAL|Group-based exercise intervention (EXE)|Participants in the EXE group will receive a 6-week group-based exercise intervention. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer at the Chinese University of Hong Kong. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and the third group exercise sessions will include (1) reviewing exercise goals, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
40982900|NCT00300586|DRUG|observation|observation, second line chemotherapy if progression
40982901|NCT00300586|DRUG|gemcitabine|1250 mg/m² D1, D8 q21 days
40982902|NCT00300586|DRUG|erlotinib|150 mg daily
40982903|NCT03572140|DIAGNOSTIC_TEST|RAVS In relapsed and resistent cases|assessment of RAVS in relapsed and resistant cases after sofosbuvir plus daclatasvir regimen
40777911|NCT03969173|PROCEDURE|applying PEEP3|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
40982904|NCT01463319|OTHER|air insufflation|air insufflation during insertion phase colonoscopy
40982905|NCT01463319|OTHER|warm water irrigation|warm water irrigation during insertion phase colonoscopy
40982906|NCT02890589|DEVICE|SYNERGY stent|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
40982907|NCT02890589|DEVICE|ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
40982908|NCT03231033|DRUG|Pioglitazone|Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
40982909|NCT03752359|DIETARY_SUPPLEMENT|whey protein|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
40982910|NCT03752359|DIETARY_SUPPLEMENT|placebo|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
40982911|NCT00041327|BIOLOGICAL|filgrastim|5 ug/kg/d
41143332|NCT06192459|DEVICE|Modality physical therapy|Magnetotherapy, low-energy laser, electrotherapy, etc.
41143333|NCT06192459|OTHER|Combined therapy:|Muscle strength and joint mobility training, provided twice a week for a duration of three weeks (with assessment on the second session of the third week), totaling six rehabilitation sessions. Additionally, patients are required to engage in daily home-based rehabilitation. During the hospital-based training sessions, a therapist provides guidance and conducts the training. This process encompasses progressive muscle strength training, manual joint mobilization, and active and passive joint movement training to achieve effective rehabilitation outcomes. Each rehabilitation session in the hospital lasts approximately 30 minutes. For home-based training, patients must follow the therapist's instructions and complete 20-30 minutes of home rehabilitation every day. Modality physical therapy are are carry out as usual.
41143334|NCT00780078|PROCEDURE|extubation|extubation failure in patients intubated orotracheally
40777912|NCT03969173|PROCEDURE|applying PEEP6|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
41143335|NCT00038597|DRUG|SCH66336|
41143336|NCT00186563|PROCEDURE|Micro-plasmapheresis|
40777913|NCT03969173|PROCEDURE|applying PEEP9|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
40777914|NCT02789982|DRUG|β-adrenergic blocker propranolol|
40777915|NCT02789982|BEHAVIORAL|Treatment as usual|
40777916|NCT02865174|DRUG|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
40982912|NCT00041327|BIOLOGICAL|recombinant interferon alfa|9 mU subcutaneously per day for one year
40777917|NCT02865174|DRUG|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
40777918|NCT02865174|DRUG|Enoxaparin|Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
40982913|NCT00041327|DRUG|Etoposide|50 mg/m2/day continuous 96 hr infusion, days 1-4
40982914|NCT00041327|DRUG|cyclophosphamide|750 mg/m2 IV on day 5
40982915|NCT00041327|DRUG|doxorubicin hydrochloride|10 mg/m2/day as a continuous 96-hour infusion days 1-4
40982916|NCT00041327|DRUG|lamivudine|150 mg bid
40777919|NCT06096766|DIAGNOSTIC_TEST|blood test|Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.
41143337|NCT04529200|OTHER|electrotherapy treatment|physical therapy management like EMS IFT
41143338|NCT01322386|DRUG|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
41143339|NCT04126993|DRUG|Camrelizumab,|Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
40777920|NCT03735914|OTHER|MRI|Neuralgic patients for which a cryoneurolysis has been indicated, will passed an MRI befor and after the cryoneurolysis to check the presence of the nerve.
40777921|NCT04328389|BEHAVIORAL|electric toothbrush|Participants will be instructed to use their electric toothbrushes twice a day for controlling oral plaque
40777922|NCT04328389|PROCEDURE|Professional oral hygiene|Professional oral hygiene using ultrosound scaling and root planing
40777923|NCT04850326|DIETARY_SUPPLEMENT|AP green tea extract|single intake of AP green tea extract
40777924|NCT04313465|OTHER|Immediate discharge|Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid
40982917|NCT00041327|DRUG|prednisone|60 mg/m2 given orally days 1-5
40982918|NCT00041327|DRUG|vincristine sulfate|0.4 mg/m2/day as a 96-hour continuous infusion days 1-4
41143340|NCT04126993|DRUG|Apatinib|Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
41143341|NCT02312258|DRUG|Placebo|Ixazomib placebo-matching capsules.
41143342|NCT02312258|DRUG|Ixazomib|Ixazomib capsules.
41143343|NCT04202263|DRUG|Minocycline Topical|Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
41143344|NCT04202263|DRUG|Placebos|Placement of minocycline cream 0%
40777925|NCT04706988|OTHER|Treatment of asthma according to GINA guideline|Pharmacological treatment depending on level of control of asthma
40777926|NCT05871060|DIETARY_SUPPLEMENT|Whey Protein Concentrate|Whey protein concentrate consumed 30 minutes prior to breakfast and lunch meals
40777927|NCT05871060|DIETARY_SUPPLEMENT|Placebo|Flavoured water consumed 30 minutes prior to breakfast and lunch meals
40777928|NCT05871060|DIETARY_SUPPLEMENT|Whey hydrolysate|Whey hydrolysate consumed 30 minutes prior to breakfast and lunch meals
40777929|NCT04142489|OTHER|solar irradiation and biopsies|the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.
40777930|NCT02009579|DRUG|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
41143345|NCT00994708|DRUG|esomeprazole|
41143346|NCT03103945|DEVICE|CDS box connection of the Niobe™ Remote Magnetic Navigation System|For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
41143347|NCT03886207|OTHER|ginger powder footbath|38-40° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level, as practiced in anthroposophic medicine
41143348|NCT03886207|OTHER|warm water only footbath|38-40° C warm water footbath without any additive reaching up to mid-calf level
40982919|NCT00041327|DRUG|zidovudine|300 mg bid
40982920|NCT05520944|DRUG|ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray|Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.
40982921|NCT05000125|DIAGNOSTIC_TEST|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
40982922|NCT00003443|DRUG|bryostatin 1|
40982923|NCT04359108|DEVICE|Navigation System for Users of a Visual Prosthesis|We use common psychophysical judgments such as the following: discriminating between two alternatives by saying which is present in the field of view, touching a tablet computer to indicate the apparent location of a target in the frontal plane, and looking for targets by rotating the head and pointing when one is found. We will compare user performance using the Basic system with user performance using the Augmented and Augmented + Modal systems where contextual information associated with the task is conveyed to users via enhanced visual, auditory, and haptic modalities.
40982924|NCT04144556|OTHER|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
40982925|NCT04144556|OTHER|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
40982926|NCT01770379|BIOLOGICAL|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
40982927|NCT01770379|BIOLOGICAL|Placebo|
40982928|NCT00528333|DRUG|Lintuzumab (SGN-33)|600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
40982929|NCT00528333|DRUG|Low dose cytarabine|20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
40777931|NCT02009579|DRUG|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
40777932|NCT03888560|DEVICE|Micro-osteoperforations|MOPs will be performed using SIA Excalibur Mini-Implant with dimension 1.6 mm in width and length of 6 mm, screw 3 mm depth into buccal bone of intervention sites
40777933|NCT03381599|DRUG|Filgrastim Injection|Filgrastim of 10 ug/kg/day will be given for four serial days.
40982930|NCT00528333|DRUG|Placebo|IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
41143349|NCT05081778|BEHAVIORAL|Obese patient following a medical course|Questionnaires for the assessment of dissociative disorders in obese patients : DES scale of Carlson and Putman, SDQ-20 of Nijenhuis, comorbidities, Dutch Eating Behaviour Questionnaire (DEBQ), questionnaire of Rosenberg
41143350|NCT01020435|OTHER|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
41143351|NCT01020435|OTHER|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
41143352|NCT01513005|PROCEDURE|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~* position of 4 trocars and insertion of a nasogastric tube~* dissection and mobilization of the greater curvature of the stomach~* preparation of the stomach for division~* gastric partition~* extraction of the gastric remnant~* postoperative surveillance"
41143353|NCT03260452|PROCEDURE|Abdominal subcutaneous biopsies and Blood test|Abdominal subcutaneous biopsies and blood test for each volunteer.
41143354|NCT03451903|DRUG|Actilyse|Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
41143355|NCT03451903|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.
41143356|NCT02936609|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
41143357|NCT01451840|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
41143358|NCT01451840|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
41462703|NCT02711033|PROCEDURE|Laparoscopic-assisted total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.
40777934|NCT03179878|DRUG|Placebo|Placebo
40777935|NCT03179878|DRUG|SYNB1020|Investigational Product
40777936|NCT04284111|DEVICE|Orthokeratology lenses|Orthokeratology lenses
40982931|NCT02823288|OTHER|Sonke CHANGE intervention|"The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:~1. Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.~2. Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.~3. Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability."
40982932|NCT00376350|PROCEDURE|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
40982933|NCT00376350|PROCEDURE|Light Massage|light pressure massage of the low back.
40982934|NCT00376350|PROCEDURE|Pulsed Ultrasound|5 minutes pulsed ultrasound
40982935|NCT02062879|DRUG|Ketamine|Ketamine administered as patient-controlled analgesia.
40982936|NCT02062879|DRUG|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
40982937|NCT01037608|DRUG|Sativex(Registered Trademark)|
40982938|NCT01037608|DRUG|THC|
40982939|NCT03134989|DEVICE|Cochlear implant|Study involves measuring using Electrocochleography to measure the CM response in patients undergoing cochlear implant surgery
41143359|NCT03155035|DRUG|Albendazole|Albendazole 400 mg chewable tablets (200 mg each) Two tablets as a single dose recommended as ovicidal, larvicidal and vermicidal against all soil transmitted helminths
41462704|NCT02711033|PROCEDURE|Open total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
40777937|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
41303773|NCT05906134|PROCEDURE|Cryo-analgesia and intercostal nerve block|The cryo-ablation will occur 2 cm from the sympathetic chain 2 intercostal spaces above and 2 intercostal spaces below the access incision. The patient will also receive a total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
41303774|NCT05906134|PROCEDURE|Serratus plane catheter blocks and intercostal nerve blocks|A total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine will be administered. A total of 20 cc of the weight-based calculation will be reserved for the serratus plane catheter. The remaining local anesthetic will be divided into two-thirds for the chest and one-third for the abdomen. Patients with serratus plane catheters will have an ongoing infusion of 0.2% ropivacaine at 8 ml per hour. The serratus plane catheters will also receive a bolus of 20 ml of 0.25% bupivacaine with epinephrine on POD #1, 2, 3, 4, and 5 by the pain service.
41303775|NCT04419064|DIAGNOSTIC_TEST|Point of care ultrasound|Tracheal and lung ultrasonography
41303776|NCT06435195|PROCEDURE|Surgical Removal|Resection of pituitary pathologies.
41303777|NCT06435195|PROCEDURE|Biopsy|Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis
41303778|NCT03087825|PROCEDURE|preoxygenation without inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes
41303779|NCT03087825|PROCEDURE|preoxygenation with inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
41303780|NCT01868178|DEVICE|BIS and Spectral Entropy|The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
41303781|NCT03158688|DRUG|Dexamethasone|Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.
41303782|NCT03158688|DRUG|Daratumumab|Daratumumab was supplied as a concentrated solution for infusion in single-use vials.
41303783|NCT03158688|DRUG|Carfilzomib|"Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes.~Dose could be modified based on a \>20% change in body weight or toxicity."
41303784|NCT00308425|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS), valsartan|
41303785|NCT05635552|DIAGNOSTIC_TEST|Dynamic retinal vessel analysis (DVA)|DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.
41462705|NCT03480022|DRUG|Liraglutide Pen Injector [Saxenda]|daily sc injection of liraglutide with final dose of 3mg daily
40777938|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
41143360|NCT03155035|DIETARY_SUPPLEMENT|Calcium 400 mg + Vitamin D 2.5 mcg|2 chewable tablets provide recommended daily allowance for calcium and vitamin D
41143361|NCT06418919|PROCEDURE|Radiofrequency ablation treatment|RFA is used to ablate the entire thyroid gland
41303786|NCT05635552|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.
41303787|NCT05635552|DIAGNOSTIC_TEST|Biochemistry and immune phenotyping|Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.
41303788|NCT05635552|DIAGNOSTIC_TEST|Handgrip strength test|Measure the maximum isometric strength of the hand and forearm muscles and their fatiguability.
41303789|NCT05635552|DIAGNOSTIC_TEST|Questionnaires (Patient reported outcomes)|The questionnaires evaluate anxiety, depression, chronic fatigue, quality of life, and post-covid typical symptoms
41303790|NCT03901287|OTHER|dual energy CT scans|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
41303791|NCT02756390|BEHAVIORAL|CBTI-CS|CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.
41462706|NCT03480022|DRUG|Placebo Liraglutide Pen Injector|daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo
41462707|NCT01848717|DEVICE|MINTLIFT®|
41462708|NCT06177405|DRUG|genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors|drug therapy
41462709|NCT03293719|DEVICE|BPK-S Integration UC|Primary Knee Endoprosthesis
41462710|NCT02707887|BEHAVIORAL|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
41462711|NCT02707887|BEHAVIORAL|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
40777939|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
40777940|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
40777941|NCT03937479|DRUG|Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
40777942|NCT06116097|BEHAVIORAL|Nutrition education|Fifty participants took 6 physical nutrition education lectures and the other group (n=33) didn't have any nutrition education. Nutrition education was comprimised of 6 physical face to face 60 minutes sessions which was given every week in a school class. Each session was consisted of a different subject including energy metabolism in sport, energy balance, nutrition before and after training, low energy availability, macro and micronutrients, hydration and supplements. Participants also got written information as a printed booklet in order to be able to take notes under sessions and review after the sessions.
40777943|NCT03981874|OTHER|telephonic interview|Telephonic interview
40777944|NCT01484249|DEVICE|CE Pro System|The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
40777945|NCT01194037|DRUG|recombinant variant of interferon-alpha 2b|SC, Weekly
40777946|NCT01194037|DRUG|Peginterferon alfa-2a|SC Weekly
40777947|NCT05539326|OTHER|Performance Clinical Outcome Test|Patients will be asked to perform a fast 4-meter walk test (4mWT) and the Timed up and Go (TUG) test in the clinic during their post-operative follow-up visit. Both performance exams will be performed in a controlled environment within the physician's clinic.
40777948|NCT02490189|BEHAVIORAL|Mindfulness-based Intervention|Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.
40777949|NCT02490189|BEHAVIORAL|Cognitive Behavior Group Therapy|Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
40777950|NCT03038620|DRUG|Liraglutide|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
40777951|NCT03038620|DRUG|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
40777952|NCT04683705|DIAGNOSTIC_TEST|Ultrasound|"1. High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~2. High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~3. Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI)."
40777953|NCT02212860|RADIATION|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma
40777954|NCT01329133|PROCEDURE|Deep Brain Stimulation (DBS)|In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
40777955|NCT02900430|OTHER|Patients without antifungal prophylaxis|Epidemiology data: clinical and biological informations collecting
40777956|NCT02900430|DRUG|Patients with antifungal prophylaxis|Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
40777957|NCT01179373|DEVICE|TMS, H coil|TMS, H Coil, High/ Low Frequency
40777958|NCT01240057|PROCEDURE|fetal endoluminal tracheal occlusion|percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks
40777959|NCT01240057|OTHER|watchful waiting during pregnancy|pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
40982940|NCT02781051|BEHAVIORAL|Print-based education|All subjects will be given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors. Topics covered within the book include benefits of exercise in breast cancer survivors; recommendations on type, duration, frequency and intensity of exercise; goal-setting; and advice on overcoming barriers.
41462712|NCT02707887|BEHAVIORAL|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
40982941|NCT02781051|DEVICE|Fitbit|Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.
41143362|NCT01355809|DRUG|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
41462713|NCT04685850|OTHER|sequela evaluation|clinical and neurological examination, psychological evaluation (cognitive performance), an auditory, speech and visual assessment and an evaluation of the child's school performance
40982942|NCT02781051|BEHAVIORAL|Active Living counseling|The Active Living counseling program consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, and time management.
40982943|NCT02781051|OTHER|Facility Access|Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.).
40982944|NCT00505843|DRUG|MK0657|7mg MK0657 capsules
40982945|NCT00505843|DRUG|Comparator: Placebo (unspecified)|7mg MK0657 Pbo capsules
40982946|NCT00505843|DRUG|Comparator: levodopa|levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
40982947|NCT00505843|DRUG|Comparator: carbidopa|carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
40982948|NCT03194555|DRUG|Low-Dose Naltrexone and Acetaminophen Combination|Twice daily
40982949|NCT03194555|DRUG|Placebo|Twice daily
40982950|NCT02175498|DRUG|Homoeopathic medicines|4 pills once a week of the indicated Similimum
41143363|NCT01355809|DRUG|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
41143364|NCT01355809|DRUG|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
41143365|NCT04006015|OTHER|No intervention being delivered.|No interventions are being delivered.
41143366|NCT02805075|OTHER|Fructooligosaccharide|Given PO
41143367|NCT02805075|OTHER|Laboratory Biomarker Analysis|Correlative studies
41143368|NCT00004731|DRUG|Coenzyme Q10|
41143369|NCT01540019|DRUG|Paullinia cupana|50mg of Paullinia cupana as capsule, twice daily
41143370|NCT00147394|DRUG|Risperidone|
41143371|NCT04364399|BIOLOGICAL|Mumps vaccine|One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50
41143372|NCT04364399|BIOLOGICAL|measles, mumps and rubella combined vaccine, live|One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50
41143373|NCT00003240|DRUG|cisplatin|
41303792|NCT02756390|BEHAVIORAL|Sleep Hygiene|Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.
41303793|NCT02756390|BEHAVIORAL|CBTI-CS via Telehealth|The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.
41303794|NCT02462304|PROCEDURE|End-Point-Management grid laser|
40982951|NCT00569296|BIOLOGICAL|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
40982952|NCT00569296|BIOLOGICAL|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
40982953|NCT00569296|BIOLOGICAL|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
40982954|NCT02350725|DRUG|Furosemide injection solution for subcutaneous administration (80 mg)|
40982955|NCT02350725|DRUG|Oral Furosemide tablets (80 mg)|
40982956|NCT03486795|DEVICE|M1 stimulation|stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
40982957|NCT03486795|DEVICE|PMC stimulation|stimulating premotor cortex with anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
40982958|NCT03486795|DEVICE|Sham stimulation|sham stimulation over both primary motor cortex and premotor cortex
40982959|NCT01059786|DRUG|Pentostatin|28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
40982960|NCT01059786|DRUG|Rituximab|Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
40982961|NCT01059786|DRUG|Bendamustine|1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
40982962|NCT01059786|DRUG|Acetaminophen|Treatment of infusion-related symptoms with acetaminophen is recommended.
41143374|NCT00003240|DRUG|ifosfamide|
41143375|NCT00003240|DRUG|mitomycin C|
41143376|NCT00003240|DRUG|vinblastine sulfate|
41143377|NCT00003240|DRUG|vindesine|
41143378|NCT00003240|DRUG|vinorelbine tartrate|
41143379|NCT00003240|PROCEDURE|conventional surgery|
41143380|NCT00003240|RADIATION|radiation therapy|
41143381|NCT01090739|DEVICE|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
41143382|NCT01145326|DRUG|4% lidocaine gel application with sham microneedle device|Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
41143383|NCT01145326|DRUG|Microneedle-facilitated lidocaine application|Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
41143384|NCT04989023|OTHER|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.
41143385|NCT02548585|DRUG|MEDI0382|MEDI0382 administered subcutaneously.
41143386|NCT02548585|DRUG|Placebo|Placebo administered subcutaneously.
41143387|NCT02815800|DIETARY_SUPPLEMENT|ETHNODYNE VISIO|
41303795|NCT02462304|DRUG|ranibizumab|
41462714|NCT00187265|DEVICE|Cardiac Resynchronization Therapy|
41462715|NCT02805517|DEVICE|Percuvance™ Percutaneous Surgical System|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 12 mm trocars.
40982963|NCT01059786|DRUG|Diphenhydramine|Treatment of infusion-related symptoms with diphenhydramine is recommended.
40982964|NCT01059786|DRUG|Epinephrine|Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
40982965|NCT01059786|DRUG|Antihistamines|Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
40777960|NCT05032586|DEVICE|wearing virtual reality headsets|"When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
41303796|NCT02462304|DRUG|Bevacizumab|
40777961|NCT04567524|DRUG|LYN-005|LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
40982966|NCT01059786|DRUG|Corticosteroids|Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
40982967|NCT01059786|DRUG|Bronchodilators|Additional treatment with bronchodilators may be indicated.
40982968|NCT01059786|OTHER|Intravenous (IV) Saline|Additional treatment with intravenous (IV) saline may be indicated.
40982969|NCT05060159|OTHER|Hemofiltration|Postdilutional Hemofiltration
40982970|NCT00750711|PROCEDURE|Radiofrequency ablation for atrial flutter by catheters|
40982971|NCT04855097|DIAGNOSTIC_TEST|BVA-100|The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.
40982972|NCT00726804|DRUG|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
40982973|NCT02962804|DRUG|Nivolumab|240 mg per IV infusion over 60 minutes every 14 days (+/- 2 days) until disease progression or participant withdrawal from study
40982974|NCT02962804|RADIATION|Radiation|Radiation to at least 1 site (up to 3) of primary or metastasis, 5 fractions - delivered over 2 weeks, starting 1-3 days post-nivolumab administration. Recommended dose range is 6 Gy-12 Gy per fraction.
40982975|NCT02968927|DRUG|Everolimus 0.5 MG|
40982976|NCT02968927|DRUG|Auranofin 6 MG|
40982977|NCT02968927|DRUG|Vitamin D3|
40982978|NCT02968927|DRUG|CC-11050|
40982979|NCT02968927|DRUG|2HRbZE/4HRb|
41303797|NCT04183205|DIAGNOSTIC_TEST|LDAEP|This is an ERP task in which participants hear a series of tones ranging from 74dB to 104dB and electrophysiological activity is measured throughout. For each participant average P2 scores are derived for the 74dB tones, 84dB tones, 94dB tones, and 104dB tones. Then, LDAEP is defined as the slope of these average P2 scores.
41303798|NCT04183205|DRUG|Placebo|placebo pills of the same size, color and taste as the active drug will be administered
41303799|NCT04183205|DRUG|sertraline|Sertraline is an FDA approved SSRI for treatment of PTSD.
41303800|NCT03552549|BIOLOGICAL|PEG-Intron|Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.
41462716|NCT04504006|PROCEDURE|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
40777962|NCT05326737|OTHER|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
40777963|NCT05326737|OTHER|In hospital questionnaires|Patients are required to fill out the PCS questionnaire between on day -1 or +1.
40982980|NCT01949168|DRUG|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)|
40982981|NCT01949168|DRUG|Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection|
40982982|NCT01949168|DRUG|Rebetol® (ribavirin), 1000/1200mg by mouth daily|
40982983|NCT00410046|DRUG|Enbrel (etanercept)|Etanercept 50 mg SC injection once weekly
40982984|NCT01396707|DRUG|Herceptin+XELOX|"Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~* Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~* Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Oxaliplatin 130 mg/m2 i.v. on day 1"
40982985|NCT06209151|OTHER|monitor signs of infection|Prospective observational study of 1040 patients admitted to the ICU without any signs of infection. All patients were subjected to one or more of the most used procedures in ICU (Intubation \& mechanical ventilation, Central line insertion and Urinary catheterization) for at least 48 hours. Then, they were followed for any signs of infection either clinically or laboratorial.
40982986|NCT01408030|DRUG|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
41303801|NCT03552549|BIOLOGICAL|INTRON A|Interferon alfa-2b, recombinant for intravenous injection.
41303802|NCT00344149|DRUG|Rituximab (Mabthera)|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
40777964|NCT05326737|OTHER|Telephone contact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires DN4 and EQ5D5L.
41143388|NCT05065840|BEHAVIORAL|CDC 4 Pillars Program|The CDC's 4 Pillars Transformation Program (4 Pillars Program) is a robust and empirically supported strategic approach that promotes the uptake of adult vaccinations and addresses facilitators and barriers at the patient, provider, and clinic level. This multi-level, evidence-based intervention has been successfully utilized to increase HPV vaccination in the general population and is primed to be tested in the high-risk HIV population, particularly PLWH in the rural South. This proposal seeks to expand the success of the 4 Pillars Program and tailor, refine, and implement in the HIV positive population who are at extraordinarily high risk for HPV-related cancers and can obtain the most benefit from the vaccine.
40777965|NCT06326021|DRUG|autologous FL-33 CAR T therapy|Autologous FL-33 CAR T cells are infused intravenously.
40777966|NCT06326021|DRUG|prior-HSCT donor-derived FL-33 CAR T therapy|Prior-HSCT donor-derived FL-33 CAR T cells are infused intravenously.
40777967|NCT06204783|OTHER|Pressure volume (PV) loop measurement|Pressure volume (PV) loop measurement using a conductance catheter
40777968|NCT04857060|BEHAVIORAL|ACP Educator led, video assisted discussion|For hospitalized patients identified by a defined EHR algorithm, an ACP Educator will meet with the patient in the hospital to provide primary palliative care services such as goals-of-care conversations and clinician communication by leveraging certified video decision aids.
40777969|NCT03992950|OTHER|Maneuvers for occluding esophagus|Cricoid pressure: pressure on the cricoid ring Paratracheal pressure: pressure on the left paratracheal region below the cricoid level
40777970|NCT05664373|PROCEDURE|Coronally advanced flap and deepithelized free gingival graft|Free gingival grafts, de-epithelialized intraoraly or extraoraly in combination with coronally advanced flap will be used in the treatment of multiple gingival recessions.
40777971|NCT01988077|BIOLOGICAL|Adoptive cell transfer|Adoptive cell transfer
40777972|NCT01988077|DRUG|Ipilimumab 5 MG/ML Injection [Yervoy]|2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
40777973|NCT02912819|OTHER|Open-lung approach|Increase and decrease in airway pressure to open the lung and keep them opened.
40777974|NCT00670644|OTHER|questionnaire administration|Completed self-report form
40777975|NCT00670644|OTHER|survey administration|Completed self-report form-other
40777976|NCT00670644|PROCEDURE|quality-of-life assessment|Completed self-report form qol
40982987|NCT01408030|DRUG|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
41143389|NCT03436537|OTHER|Periodontal Aesthetic Perception Scale|Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
41143390|NCT00465114|PROCEDURE|Hemodynamic Monitoring|
40777977|NCT05801887|DEVICE|Extracorporeal shockwave device|"Extracorporeal shockwave device generates true shock waves which are characterized by a sudden rise in pressure followed by an exponential decay.~This is different from the commercially available shockwave devices in which they use piezoelectric based mechanisms which generate high frequency waves."
41143391|NCT04480957|BIOLOGICAL|ARCT-021 Dose 1|ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP)
41143392|NCT04480957|BIOLOGICAL|ARCT-021 Dose 2|ARCT-021 Dose 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
40777978|NCT05801887|DEVICE|No ESWT|the osteoblast like cells are not exposed to shockwaves
40777979|NCT04983043|DRUG|Low dose QiShen YiQi Dripping Pills 3 bags|Low dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 2 bags(0.52g dripping pills per bag) and QiShen YiQi Dripping Pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
40777980|NCT04983043|DRUG|High dose QiShen YiQi Dripping Pills 3 bags|High dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
40982988|NCT01408030|DRUG|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
40982989|NCT01408030|DRUG|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
40982990|NCT03206853|PROCEDURE|Hybrid Operating Techniques|It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
40982991|NCT04984993|DEVICE|MED3000 (Male)|Gel formulation
40982992|NCT04984993|DRUG|Tadalafil 5mg (Male)|Tablets
40982993|NCT04984993|DEVICE|MED3000 (Female)|Gel formulation
40982994|NCT04984993|DRUG|Tadalafil 5mg (Female)|Tablets
40982995|NCT04408482|DEVICE|Biliary cannulation|Cannulation of biliary duct by sphincterotome
40982996|NCT00022620|DRUG|paclitaxel|
40982997|NCT02596594|DEVICE|fetal nutrition port system|Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
40982998|NCT02260479|PROCEDURE|Preheated|Skin disinfection solution is preheated in a warming cupboard
40777981|NCT04983043|DRUG|QiShen YiQi Dripping Pills placebo 3 bags|QiShen YiQi Dripping Pills placebo contain QiShen YiQi Dripping Pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
41303803|NCT04013438|DRUG|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
41143393|NCT04480957|BIOLOGICAL|ARCT-021 Dose 3|ARCT-021 Dose 3 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
41303804|NCT04013438|DRUG|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
41303805|NCT03181165|BEHAVIORAL|Low-carbohydrate Therapeutic Nutrition|The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
41303806|NCT02548104|OTHER|ACB|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
41303807|NCT02548104|OTHER|ACB + iPACK|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
41303808|NCT02334332|OTHER|Educational Intervention|Receive educational brochure
41303809|NCT02334332|PROCEDURE|Standard Follow-Up Care|Receive standard post-operative care
41303810|NCT02334332|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
40777982|NCT03377660|OTHER|Clinical treatment|Patients undergo clinical treatment as indicated, they are studied before and after.
40777983|NCT02908711|DRUG|0.5% ropivacaine|Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
40777984|NCT00622726|DRUG|Bevacizumab|Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
40982999|NCT01124136|DEVICE|Neurostimulation + Medication Management (Standard of Care)|In addition to medication management, adding investigational implanted neurostimulator to heart
41143394|NCT04480957|BIOLOGICAL|ARCT-021 Dose 4|ARCT-021 Dose 4 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
41143395|NCT04480957|BIOLOGICAL|ARCT-021 Dose Regimen 1|ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
41143396|NCT04480957|BIOLOGICAL|ARCT-021 Dose Regimen 2|ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
41143397|NCT04480957|OTHER|Placebo|Sterile 0.9% saline
41303811|NCT00896987|DRUG|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg\~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
41303812|NCT00896987|DRUG|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg\~600 mg) and maintenance for 40 weeks (600 mg)
41303813|NCT01125176|DRUG|thalidomide|50 mg oral dosing every other day
40777985|NCT00622726|PROCEDURE|Conventional Laser for ROP|Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
40777986|NCT05799274|DRUG|RAD301 ([68Ga]-Trivehexin)|Whole body PET scan
40777987|NCT03963284|PROCEDURE|cardiac surgery|pediatric cardiac surgery with cardiopulmonary bypass
40777988|NCT03963284|DEVICE|NephroCheck test|Urine of the subjects undergoing cardiac surgery with CPB will be tested by NephroCheck test
40983000|NCT01124136|DRUG|Standard of Care (Control)|Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
40983001|NCT01867021|BIOLOGICAL|Fluvirin(TIVf)|
40983002|NCT01867021|BIOLOGICAL|Agriflu (TIV)|
40777989|NCT05796687|BEHAVIORAL|My Future Self|My Future Self is based upon the Theory of Possible Selves, which promotes the capacity of young people to construct goals for a successful adulthood. Youth who hold a balanced set of negative and positive images of their future have both a) a positive goal to strive for and b) awareness of the personally relevant consequences of not meeting that goal. My Future Self also includes two new supportive gaming elements that reinforce learning of relevant knowledge and skills as well as provide opportunities for youth to individually practice these skills in a personalized virtual environment. Gaming interventions using interactive technology can significantly increase self-reported abstinence and lower reports of diagnosed STD in young women, as well as reduce risky sex in high-risk young men who have sex with men. Youth will participate in these gaming elements on tablets provided by CHLA. My Future Self will be implemented as a ninety-minute small group 5-week program.
41143398|NCT05979766|OTHER|Manual lymphatic drainage versus marian clark drainage|Manual lymphatic drainage versus marian clark drainage
41143399|NCT01359059|DRUG|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
41143400|NCT01359059|DRUG|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
41143401|NCT05258929|OTHER|Data collection (Prior and planned treatments, allograft)|MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up
40777990|NCT04163757|DIETARY_SUPPLEMENT|crocin|2 tablets crocin per day
40777991|NCT04163757|DIETARY_SUPPLEMENT|placebo|2 tablets placebo per day
40777992|NCT00283192|DRUG|Sertraline|
41143402|NCT05755178|BEHAVIORAL|Music, feelings and relationships - music group for children at shelters|"A music group intervention, offered to children 3-10 years who live or have lived at a shelter.~6 group sessions with musicians and music therapist and a group of 4-8 children.~Focus on improving recognition and regulation of emotions, and on relational capacity with adults and peers."
41143403|NCT02629575|DEVICE|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
41143404|NCT03776565|OTHER|Ultrasound|Ultrasound of antrum of stomach
40777993|NCT04546100|OTHER|Maternal-Infant Exercise Program|"Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
40777994|NCT02518529|BIOLOGICAL|G17DT|
40777995|NCT06032130|OTHER|Clinical measurements|Optometric measurements
40777996|NCT06032130|OTHER|Oculomotor or perceptual therapy|Oculomotor or perceptual visual learning exercices
40777997|NCT02199041|DRUG|Cyclophosphamide|Given by intravenous infusion as part of the preparative regimen.
41143405|NCT02279732|BIOLOGICAL|Paclitaxel|
41143406|NCT02279732|BIOLOGICAL|Carboplatin|
41143407|NCT02279732|BIOLOGICAL|Ipilimumab|
41143408|NCT02279732|OTHER|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
41143409|NCT05516758|DRUG|Peresolimab|Administered subcutaneously (SC)
41143410|NCT05516758|DRUG|Placebo|Administered SC
41143411|NCT05864144|DRUG|SNS-101 (anti-VISTA)|SNS-101 IV every 21 days.
41143412|NCT05864144|DRUG|Cemiplimab|Cemiplimab IV every 21 days.
41143413|NCT00003634|BIOLOGICAL|oregovomab|
41303814|NCT01125176|DRUG|lenalidomide|varying oral doses every other day (max 25 mg/day)
41303815|NCT01125176|BIOLOGICAL|rituximab|375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
40777998|NCT02199041|DRUG|Thiotepa|Given by intravenous infusion as part of the preparative regimen.
40983003|NCT05783362|BEHAVIORAL|Conditioned Pain Modulation (CPM)|Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion. Conditioned pain modulation will be calculated as the average pain ratings of the second testing stimulus series minus the average pain ratings of the first testing stimulus series.
40983004|NCT02913547|DEVICE|Silk'n HST|Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
40777999|NCT02199041|DRUG|Fludarabine|Given by intravenous infusion as part of the preparative regimen.
40983005|NCT04021004|OTHER|Survey Questionnaire|Survey Questionnaire
40983006|NCT01430091|DRUG|Prasugrel (clinical formulation)|Administered orally
40983007|NCT01430091|DRUG|Prasugrel (Orally Disintegrating Tablet [ODT])|Administered orally
41143414|NCT00547326|PROCEDURE|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
40778000|NCT02199041|DRUG|Melphalan|Given by intravenous infusion as part of the preparative regimen.
40778001|NCT02199041|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
40778002|NCT02199041|BIOLOGICAL|G-CSF|Given either by intravenous infusion or subcutaneously daily until absolute neutrophil count (ANC) \>2000 for 3 consecutive days.
41143415|NCT00547326|PROCEDURE|Treatment with placebo|Treatment with placebo
41143416|NCT05214092|BEHAVIORAL|Speech sound stimulation|Participants will listen to repetitive speech sound stimuli, presented through headphones, which will induce a neural response (frequency-following response) to be measured via electroencephalography and pupillometry
41143417|NCT04704856|BEHAVIORAL|Supervised exercise|Supervised exercise during first 6 weeks of neoadjuvant chemotherapy.
41143418|NCT02290353|DEVICE|FEATHERS|"FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer \[2\]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants."
41143419|NCT05832489|DRUG|Placebo|"Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days."
41143420|NCT05832489|DRUG|Methylphenidate immediate release 25mg|"Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days."
40778003|NCT02199041|DRUG|Mycophenolate mofetil|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
40778004|NCT02199041|DRUG|Tacrolimus|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
40778005|NCT02199041|DRUG|Methylprednisolone|Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
40778006|NCT02199041|RADIATION|Total lymphoid irradiation|TLI will be administered in divided fractions given at a minimum of 6 hours apart.
40983008|NCT01759030|DRUG|Rituximab|Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
40983009|NCT06209645|DEVICE|tDCS (Transcranial Direct Current Stimulation)|The tDCS group will be treated with non-invasive motor cortex stimulation. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region. If pain is bilateral, the most painful region will be chosen to be treated.
41143421|NCT00599625|DRUG|Pravastatin|80mg administered daily for 6 consecutive weeks
41143422|NCT03989778|DRUG|Vitamin D|Vitamin D supplementation
41143423|NCT04316494|DRUG|Hydroxychloroquine|"White, round, film-coated tablets marked 'HCQ' on one side and 200' on the other side.~Excipients:~Lactose monohydrate Maize Starch Magnesium Stearate Polyvidone Opadry OY-L-28900"
41143424|NCT04316494|DRUG|Placebo|"Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate"
40778007|NCT02199041|BIOLOGICAL|Lymphocyte infusions|Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.
40778008|NCT02199041|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
40778009|NCT00907621|PROCEDURE|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
40778010|NCT05375630|DIETARY_SUPPLEMENT|Placebo|Placebo
40778011|NCT05375630|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2
40778012|NCT00772057|DRUG|Propranolol|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
40778013|NCT00772057|DRUG|Placebo|Placebo tablets given two times daily.
40778014|NCT02563015|DIETARY_SUPPLEMENT|cholecalciferol|liquid drops
40778015|NCT02563015|DIETARY_SUPPLEMENT|Reference 400|liquid drops
40778016|NCT03183310|DRUG|Chlorpromazine|an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
40778017|NCT03183310|DEVICE|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
40778018|NCT03183310|DRUG|Placebo - Concentrate|an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
40778019|NCT05802901|PROCEDURE|Spinal manipulation|Spinal manipulation of the lumbar spine only to be performed in the spinal manipulation arm/group.
40778020|NCT05802901|PROCEDURE|Dry needling|Dry needling of the lumbar erector spinae, multifidus, and gluteus medius on the symptomatic side performed in the dry needling arm/group.
40778021|NCT05802901|PROCEDURE|Spinal manipulation and dry needling|The spinal manipulation and dry needling arm/group receive both spinal manipulation and dry needling as outlined in the other groups.
40778022|NCT04339062|DRUG|Cemiplimab|Cemiplimab: via IV, flat predetermined dosage every 21 days.
40778023|NCT04339062|DRUG|Everolimus|Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
40778024|NCT04339062|DRUG|Sirolimus|Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
40778025|NCT04339062|DRUG|Prednisone|40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab
40778026|NCT00004466|DRUG|Atorvastatin|
40778027|NCT00004466|DRUG|Placebo|
40778028|NCT02884453|DRUG|ibrutinib|Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research \& Development, LLC and Pharmacyclics Inc.
40778029|NCT04120870|DRUG|Etomidate Injection 0.2 mg/kg|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
40778030|NCT04120870|DRUG|Ketamine injection 2 mg/kg|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
40778031|NCT05006066|OTHER|Temporal Summation|4 type of stimulations applied on the right arm
40778032|NCT00876447|BIOLOGICAL|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor \> 12 weeks as needed for up to 3 years.
40778033|NCT00876447|BIOLOGICAL|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor \> 12 weeks as needed for up to 3 years.
40778034|NCT03515421|DEVICE|Frazier 3 Verio|In vitro diagnostic device (IVDD)
40778035|NCT03515421|DEVICE|Frazier 3 UltraPlus|In vitro diagnostic device (IVDD)
40778036|NCT04204824|OTHER|Ultrasound and exercise|"The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home"
40778037|NCT00839969|PROCEDURE|Cystoscopy|Saline cystoscopy under general anaesthesia
40778038|NCT00839969|PROCEDURE|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
40778039|NCT05826509|OTHER|Surgery alone|Radical prostatectomy with lymph node dissection will be performed.
40778040|NCT05826509|DRUG|Peri-operative darolutamide + surgery.|"Darolutamide: 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg; for a total duration of 9 months. Darolutamide will start at day 1.~Surgery: radical prostatectomy with lymph node dissection will be performed after at least 3 months of darolutamide treatment."
40983010|NCT06209645|DEVICE|tACS (Transcranial Alternating Current Stimulation)|The tACS group will be treated with non-invasive motor cortex stimulation. The stimulation series comprises six sessions spaced 2 weeks apart, the first session being placebo. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Stimulation frequency will be set according to the dominant frequency recorded over the motor area. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region.
40778041|NCT03634956|DRUG|Group B. Sugammadex sodium-IONM|Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
40778042|NCT00251433|DRUG|lapatinib, docetaxel, trastuzumab|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
40983011|NCT05773287|BEHAVIORAL|Targeted Health Coaching Group|Participants in the THC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will partake in 6 virtual or in-person health coaching sessions lasting approximately 30-60 minutes in duration. These sessions will take place approximately every other week during the 3-month intervention period.
40778043|NCT04033458|DRUG|JNJ-64140284|Participants will receive JNJ-64140284 orally.
40983012|NCT05773287|BEHAVIORAL|Standard Care Group|Participants in the SC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will be provided with a single virtual or in-person education session, lasting approximately 30 minutes, at the beginning of the 3-month intervention period.
40983013|NCT03089606|DIAGNOSTIC_TEST|FDG PET/CT scan|18F-fluorodeoxy glucose (FDG) positron emission tomography (PET) with intravenous (IV) contrast images are obtained before and at the end study treatment (pembrolizumab infusion).
40983014|NCT03089606|DIAGNOSTIC_TEST|C11-AMT PET scan|11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) images are obtained before study treatment (pembrolizumab infusion).
40983015|NCT03089606|DRUG|Pembrolizumab|200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
40983016|NCT03089606|DIAGNOSTIC_TEST|CT scan|Computerized tomography (CT) images are taken without IV contrast before the treatment (pembrolizumab infusion) and with IV contrast 3 months after the treatment start.
40983017|NCT03731884|OTHER|Time from the onset of symptoms to PCI|Patients will be divided in two groups according to the time from the onset of symptoms to PCI
41143425|NCT01697982|BEHAVIORAL|Living with Hope Program|"The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
41143426|NCT01697982|BEHAVIORAL|LWH film|Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
41143427|NCT03530735|OTHER|Finger-prick Autologous Blood (FAB)|"Patients will be instructed to use FAB therapy by:~1. Hand hygiene with soap and water. Dry, then wipe their fingertip with an alcohol street before leaving to air dry.~2. Use a diabetic lancet to prick their cleaned fingertip.~3. Squeeze 5 drops of blood form their finger into 10ml of saline.~4. Gargle the blood-saline mixture for 5 minutes.~5. Swallow the blood-saline mixture.~6. Repeat this 4 times per day."
41143428|NCT05028257|BIOLOGICAL|COVID-19 Vaccines|Pursuit of vaccination in case of anaphylactic reaction
41303816|NCT04964219|DRUG|S-ketamine|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
41303817|NCT04964219|DRUG|Placebo|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
40778044|NCT02491879|DRUG|Ketoprofen|2.5% Ketoprofen gel with a 2 g local use
40778045|NCT02491879|OTHER|Placebo|Placebo gel with a 2 g local use
40778046|NCT00799565|GENETIC|catch of blood|"4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects"
40778047|NCT05120804|BEHAVIORAL|Standard behavioral treatment|Nutrition and physical activity education along with behavior modification techniques
40983018|NCT06441344|DRUG|Toripalimab plus Anlotinib|For patients who did not progress after standard chemotherapy, toripalimab plus anlotinib maintenance therapy was used
40983019|NCT06441344|DRUG|Toripalimab|For patients who did not progress after standard chemotherapy+toripalimab, toripalimab maintenance therapy was used
40983020|NCT04311996|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
40983021|NCT04311996|OTHER|TSST|Participants will, via an online session, complete the TSST which is a standardized speech \& math performance known to elicit a cortisol stress response.
40983022|NCT00158509|DRUG|Valacyclovir|
40983023|NCT01910610|BIOLOGICAL|FOLFIRI-cetuximab|
40983024|NCT01910610|BIOLOGICAL|mFOLFOX6-bevacizumab|
40983025|NCT01910610|BIOLOGICAL|OPTIMOX-bevacizumab|
40983026|NCT01910610|BIOLOGICAL|irinotecan-based chemo + bevacizumab|
40983027|NCT01910610|BIOLOGICAL|Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|
40983028|NCT01910610|BIOLOGICAL|XELOX + bevacizumab|
40983029|NCT04170257|DIAGNOSTIC_TEST|Endoscopic examination using white light, NBI and iodine staining|Participants' esophagus will be examined by three commonly used diagnostic techniques in the order of : 1. White light endoscopy (WLE); 2. Narrow Band Imaging (NBI) and 3. Iodine Staining Endoscopy (ISE) with 1.2% Lugol's iodine solution. The required observation time is no less than 1 minute for WLE and 2 minutes for NBI and ISE. Endoscopic images of each participant are routinely captured at every 5 centimeters in the esophagus, and information is recorded in detail for each focal lesion. Biopsies are taken from all visually abnormal areas found by any one of the three techniques, histopathologic diagnoses are rendered by two pathologists according to standard criteria and discrepancies are adjudicated by consultation. The recorded endoscopic images for each biopsied lesion are read by two trained researchers and the visualized feature of lesions are decomposed into several indicators (e.g. size, shape, color, and border of lesions) .
40983030|NCT01568931|DRUG|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
40983031|NCT01568931|DRUG|Saline|intracoronary, saline, bolus 1 cc
40983032|NCT06346990|OTHER|Holy Quran Recital|Holy Quran recital for four days. Typically, the second, third, fourth- and fifth-days following CABG. The daily sessions were done at 2 PM and 8 PM for 20 minutes each
40983033|NCT00306761|DEVICE|Dynamic Wheelchair Seating System|
40983034|NCT05770947|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy (CBT) is a psychological treatment or talk therapy that integrates how people think, feel, and behave to create new behavior patterns that improve thinking processes and reduce distress."
40983035|NCT05770947|BEHAVIORAL|Mindfulness|"Mindfulness is a psychological treatment or talk therapy that practices different coping skills to improve thinking processes and reduce distress."
40983036|NCT05678309|OTHER|Blood samples|"At inclusion :~* 52.5 ml of blood :~* 24 ml plasma~* 20 ml serum~* 6 ml DNA~* 2.5 ml RNA"
40983037|NCT05678309|OTHER|skin swab sample|At inclusion a skin swab sample will be collected
41143429|NCT05581394|DEVICE|BabySat V3|Evaluation of Accuracy of BabySat V3
40778048|NCT05120804|BEHAVIORAL|Standard behavioral treatment plus relationship skills training|Nutrition and physical activity education along with behavior modification techniques plus relationship skills training
40983038|NCT05678309|OTHER|skin biopsy sample|At inclusion a skin biopsy sample will be collected
40983039|NCT05678309|OTHER|Questionnaires|At inclusion, at 6 months and every year, the patient will respond to 5 questionnaires : Brest questionnaire, 5-D itch scale, Dermatology Life Quality Index, Itchy Quality of Life and Hospital Anxiety and Depression Scale
40983040|NCT01892202|OTHER|Cohort|
40983041|NCT06530342|OTHER|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in all athletes.
41143430|NCT02663297|DRUG|ATLCAR.CD30 cells|"Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2 (maximum dose 5x10\^7 cells)~Group Two, 1x10\^8 cells/m\^2 (maximum dose 2.5x10\^8 cells)~Group Three, 2x10\^8 cells/m\^2 (maximum dose 5x10\^8 cells)"
41143431|NCT01745835|DRUG|2L Coolprep®|\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
41143432|NCT01745835|DRUG|1L Coolprep® and Bisacodyl|"1. Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~   \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~2. Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) \* composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg"
41143433|NCT02480283|PROCEDURE|Bronchoscopy|Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
40983042|NCT00338702|PROCEDURE|Autologous Platelet Gel|
40983043|NCT06359782|DRUG|C1 Esterase Inhibitor Injection [Cinryze]|C1 Esterase Inhibitor Injection \[Cinryze\]
40983044|NCT06359782|DRUG|Placebo|Sodium Chloride /physiological saline (0.9%) in equal volume dosed intravenous
40983045|NCT01465087|OTHER|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
40983046|NCT01761656|DRUG|loading dose atorvastatin|For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
40983047|NCT01761656|DRUG|conventional dose atorvastatin|For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
40983048|NCT03931421|BIOLOGICAL|CAR-T treatment|a novel method for treatment of multiple myeloma, in which patients' T cells are engineered into B Cell Maturation Antigen（BMCA）-Targeted CAR-T cells to eliminate myeloma cells.
40983049|NCT06543069|DRUG|Sintilimab, Bevacizumab , Pemetrexed , Cisplatin|Sintilimab: 200mg, bevacizumab: 7.5mg/kg, pemetrexed: 500mg/m2, cisplatin: 75mg /m2, Q3w. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria. After 6 cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs.
41303818|NCT03591679|DRUG|Oxytocin|20 units by slow intravenous drip injection
41462717|NCT04522245|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss.|"The mobile cognitive behavior change program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.~There are 52 weeks of curriculum with 1-3 articles to read per day. Users are requested to perform weight logging once daily and food logging after each meal. Users are assigned human coaches and are able to interact with them via in-app messaging or phone communication. Users are also assigned to support groups via in-app messaging."
41462718|NCT04522245|OTHER|Matched Control|Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
41462719|NCT01115933|DEVICE|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
40983050|NCT04607850|BIOLOGICAL|ChAdOx1-HPV|Trial vaccine
40778049|NCT06150430|DEVICE|APO|"Subjects will take part in 14 experimental sessions: two baseline sessions (T1-T2), three familiarization sessions (F1-F3), six training sessions (E1-E6), two assessment sessions (one pre-training T3 and one post training T4) and one 2-month follow-up session (T5). Depending on the session, the subject will walk with and/or without the APO. During the assessment sessions (T3-T4), the subject will be evaluated through different standard tests (such as 10MWTs and 2mWTs) and instrumented gait analysis, with and without the APO.~The goal of each training session (E1-E6) will be to achieve a minimum of 30 minutes of overground walking assisted by the APO, leaving up to 15 minutes to rest if needed. Training sessions will occur 2-3 times a week for 2-3 weeks to complete the training protocol."
40778050|NCT00773188|DRUG|bevacizumab [Avastin]|7.5mg/kg iv or 15mg/kg iv every 3 weeks
40778051|NCT00773188|DRUG|cisplatin|75mg/m2 iv according to a standard chemotherapy treatment protocol
40778052|NCT00773188|DRUG|vinorelbine|15mg/m2 iv according to a standard chemotherapy treatment protocol
40778053|NCT04028830|OTHER|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
40778054|NCT04028830|OTHER|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
40778055|NCT05205837|DRUG|Letrozole 2.5mg, hCG|Drug -Treatment Intramuscular injektion - Treatment
40778056|NCT05205837|DRUG|Placebo|Drug - Placebo Intramuscular injektion - placebo
40778057|NCT03116126|DRUG|Guanfacine|2mg oral daily tablet
41143434|NCT02480283|RADIATION|Chest X-ray|To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
41462720|NCT04217538|OTHER|clinical exam|clinical oral examination
41143435|NCT02480283|PROCEDURE|Venipuncture|To collect blood cells and serum for analyses.
41303819|NCT03591679|PROCEDURE|bilateral uterine artery ligation|• The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
41303820|NCT05517603|DRUG|AJ201|Administered orally
41303821|NCT05517603|DRUG|Placebo|Administered orally
41303822|NCT04950582|DIAGNOSTIC_TEST|Spectral characteristics assessment|Urine sample analysis for evidence of urinary tract infection
41303823|NCT01969578|DRUG|bicalutamide + triptorelin|
41303824|NCT01969578|DRUG|Cisplatin + Doxorubicin|
41303825|NCT01969578|DRUG|Carboplatin + Paclitaxel|
41303826|NCT01250093|DEVICE|acupuncture|
41303827|NCT00043875|DRUG|lamotrigine|
41303828|NCT01670630|PROCEDURE|Sheathed speculum examination|
41303829|NCT01670630|PROCEDURE|Standard speculum examination|
41462721|NCT04245293|DEVICE|Ainara|Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
40778058|NCT03116126|DRUG|Placebo|inactive oral daily tablet
40778059|NCT06006104|DRUG|HRS-4357 injection|HRS-4357 injection
40778060|NCT03516721|OTHER|the prevalence of chronotropic incompetence CI during maximal cardiopulmonary exercise testing, CPET|
40983051|NCT04607850|BIOLOGICAL|MVA-HPV|Trial vaccine
40983052|NCT04607850|BIOLOGICAL|Placebo|Saline placebo vaccine
40983053|NCT04945902|BEHAVIORAL|Synchronous Intervention|Weekly one-hour support groups. These support groups will meet virtually using a restricted WebEx channel and will be recorded. In this support group, students will discuss the weekly activities and build connection and support with each other. This group will be led by advanced doctoral students in counseling psychology and overseen by a counseling psychology faculty member, who is also a licensed psychologist.
41143436|NCT02480283|PROCEDURE|Intravenous Catheter|To administer the appropriate medications for the bronchoscopy procedure.
41303830|NCT03471754|DEVICE|TESA-HB Transcranial Electronic Stimulation Device|Duration of treatment: 50 Minute Therapy sessions administered one time each day, for two 5-day cycles
41303831|NCT05901714|DRUG|Afimetoran|Specified dose on specified days
41303832|NCT05901714|DRUG|Phenytoin|Specified dose on specified days
41303833|NCT05901714|DRUG|Midazolam|Specified dose on specified days
41303834|NCT05858944|DRUG|Intensive Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
41303835|NCT05858944|DRUG|Standard Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
41462722|NCT04245293|DEVICE|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
41462723|NCT02822482|DRUG|Copanlisib|Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
40778061|NCT03748914|OTHER|Intervention Group|After delivery of the neonate via caesarean section the umbilical cord will be clamped within 30 seconds and cut long at least 30 cm by the obstetrician. The neonate is then placed under an overhead heater by the midwife. There, the umbilical cord must be untwisted and held in a vertical position. It is milked once by the neonatologist towards the baby at a speed of approximately 10 cm/s and then clamped 3 cm from the umbilicus by one member of the clinical team.
41462724|NCT02822482|DRUG|Cetuximab|Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
40983054|NCT04945902|BEHAVIORAL|Asynchronous Intervention|The asynchronous intervention will provide access to information and resources for mental health support via Brightspace. The intervention will be six weeks long and each week will have a topic. The weekly topics include: (1) identifying feelings; (2) biology of emotions; (3) mindfulness; (4) recognizing and responding to stress; (5) mental health stigma; and (6) self-care/self-advocacy. Each week, you will be required to complete four types of activities: education, reflective exercises, an activity, and a short assessment. All of these resources will be provided on Brightspace to be completed on your own time but the activities must be completed during the week they are assigned. You will not have to interact with other international students if you are in the asynchronous intervention group.
41303836|NCT06048055|OTHER|Transcutaneous auricular vagus nerve stimulation|Patients in this group will be treated with 12 sessions of transcutaneous auricular nerve stimulation, three sessions per week for four weeks. The stimulation of the left auricular branch of the vagus nerve will be performed by conventional transcutaneous electrical nerve stimulation (TENS) through a Gamna Duo 200 electrotherapy device with one channel and two electrodes (5mm diameter disposable adhesive stimulation electrodes). The TENS parameters will be used: 30 30-minute treatment time, a pulse width of 200 milliseconds, and a pulse frequency of 20 hertz. The intensity of stimulation will be individually adjusted according to the patient's perceptual threshold. The perceptual threshold (PT) is defined as the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. The stimulation intensity will be set at super-threshold levels, such as 200% of the patient's perceptual threshold.
41303837|NCT06048055|OTHER|selected physical therapy program|The selected physical therapy program session will be from 25 to 30 minutes, three sessions per week for four weeks. The program will be selected mainly for stretching for shortened upper limb muscles, strengthening for weak upper limb muscles, occupational therapy for hand, trunk, and pelvic control exercises, and gait training.
41462725|NCT00647894|DRUG|Alprazolam Extended-Release Tablets 1 mg|
41462726|NCT00647894|DRUG|Xanax XR Tablets 1 mg|
40778062|NCT03748914|OTHER|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
40778063|NCT03509402|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm)
40778064|NCT03509402|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal long implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
40778065|NCT04836533|OTHER|Experimental: Computerized Cognitive Training|Participants will complete 4 weeks of executive functioning / processing speed training through the BrainHQ platform on their personal computers.
41462727|NCT02776527|DRUG|Apatinib Mesylate Tablets|taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
41462728|NCT02710240|DRUG|Indocyanine Green (ICG)|
40778066|NCT04836533|DRUG|Experimental: Open-label antidepressant treatment|Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.
40983055|NCT00374790|DRUG|Ferrous sulfate|
40983056|NCT02753101|DRUG|[18F]-FTC-146|10 mCi± 1 mCi of \[18F\]FTC-146 intravenously
41462729|NCT02710240|RADIATION|Intraoperative near-infrared (NIR)|
41462730|NCT02879773|RADIATION|CTPVe|Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
40778067|NCT04836533|OTHER|Active Comparator: Solitaire Training|Participants will complete 4 weeks of Solitaire training through the BrainHQ platform on their personal computers.
40983057|NCT02345382|DRUG|Atuveciclib, BAY1143572|The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
40778068|NCT04836533|OTHER|Placebo Comparator: Placebo-controlled antidepressant treatment|Participants will be told they have a 50/50 chance of receiving a placebo or antidepressant.
40778069|NCT04755647|DRUG|Nitric Oxide-Releasing Solution|Active antimicrobial
40778070|NCT04755647|DRUG|Saline solution, hypotonic|Placebo
40778071|NCT04885959|BEHAVIORAL|Traditional Asian Diet|The personalized traditional Asian diet will be formulated based on dietary components of a typical Asian diet characterized by high intake of fruits and vegetables, whole grains, legumes, nuts, seeds, soy foods and herbs and spices; moderate intake of fish, poultry, eggs, healthy cooking oils, yogurt or functional foods and low intake of meats and sweets (Ismail et al., 2020). The diet design also considering the recommendation of personalized dietary approach by including the element of individual preferences, requirement, cultural preferences, affordability and foods availability to facilitate the adherence and response to the diet.
40983058|NCT04299204|PROCEDURE|Percutaneous nephrolitotomy|Pediatric PCNL
40983059|NCT02029950|DRUG|Cytarabine|Given IV
40778072|NCT04881760|DRUG|LY3437943|Administered SC
40778073|NCT04881760|DRUG|Placebo|Administered SC
40778074|NCT02181920|DRUG|Metamizole|
40778075|NCT02181920|DRUG|Diclofenac|
40778076|NCT02181920|DRUG|Diclofenac placebo|
40983060|NCT02029950|DRUG|Daunorubicin Hydrochloride|Given IV
40983061|NCT02029950|DRUG|Etoposide|Given IV
40983062|NCT02029950|DRUG|Idarubicin Hydrochloride|Given IV
40983063|NCT02029950|OTHER|Laboratory Biomarker Analysis|Correlative studies
40983064|NCT02029950|OTHER|Pharmacological Study|Correlative studies
40983065|NCT02029950|DRUG|Pomalidomide|Given PO
40983066|NCT04941235|DEVICE|ultrasound and nerve stimulator|nerve stimulator and ultrasound guided interscalene brachial plexus block
40983067|NCT04758754|OTHER|Training|8-weeks iso-volume active (SLKE) or passive static stretching training (PST) involving lower limb muscles
40983068|NCT04772755|DEVICE|Buzzy® and Electronic Game|Buzzy® was applied according to manufacturers directions and an electronic game was played. The participant was observed for 20 minutes post vaccination.
40983069|NCT05184920|OTHER|P1012919 nicotine pouch|P1012919, a nicotine pouch with 12 mg of nicotine
40983070|NCT05184920|OTHER|P1012915 nicotine pouch|P1012915, a nicotine pouch with 8 mg of nicotine
40983071|NCT05184920|OTHER|P1012914 nicotine pouch|P1012914, a nicotine pouch with 4 mg of nicotine
40983072|NCT05184920|OTHER|P1013315 nicotine pouch|P1013315, a nicotine pouch with 8 mg of nicotine
40983073|NCT05184920|OTHER|P1013119 nicotine pouch|P1013119, a nicotine pouch with 12 mg of nicotine
40983074|NCT05184920|OTHER|P1013218 nicotine pouch|P1013218, a nicotine pouch with 10 mg of nicotine
40983075|NCT05184920|OTHER|P1012818 nicotine pouch|P1012818, a nicotine pouch with 10 mg of nicotine
40983076|NCT05184920|OTHER|P1312915 nicotine pouch|P1312915, a nicotine pouch with 8 mg of nicotine
41462731|NCT02824185|DEVICE|PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)|A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
41462732|NCT01398787|DEVICE|Lotrafilcon B contact lens with color|Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel
40778077|NCT02181920|DRUG|Metamizole placebo|
40778078|NCT00183248|DRUG|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
40778079|NCT00183248|DRUG|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
40983077|NCT05184920|OTHER|P1312914 nicotine pouch|P1312914, a nicotine pouch with 4 mg of nicotine
40983078|NCT05184920|OTHER|P1313015 nicotine pouch|P1313015, a nicotine pouch with 8 mg of nicotine
41462733|NCT01398787|DEVICE|Phemfilcon A contact lens with color|Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
41462734|NCT02767934|OTHER|Laboratory Biomarker Analysis|Correlative studies
41462735|NCT02767934|BIOLOGICAL|Pembrolizumab|Given IV
41462736|NCT03285464|OTHER|Triplanar Rotary Resistance|Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
41462737|NCT06099964|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
40983079|NCT05184920|OTHER|P1313314 nicotine pouch|P1313314, a nicotine pouch with 4 mg of nicotine
40983080|NCT05184920|OTHER|P1312815 nicotine pouch|P1312815, a nicotine pouch with 8 mg of nicotine
40983081|NCT04715763|DRUG|Telmisartan Oral Product|Angiotensin Receptor Blocker (ARB) FDA approved for use in hypertension and for cardiovascular risk reduction
41462738|NCT06099964|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
40983082|NCT04715763|DRUG|Placebo|Gelatin capsules filled with an inactive ingredient
41462739|NCT05787392|BEHAVIORAL|Chamas cha MamaToto program|Chamas is a community health volunteer (CHV)-led group programme that engages women during pregnancy and the first 1000 days of their child's life. The strategy focuses on promoting maternal, newborn, and child health (MNCH) by providing health education, peer support, and opportunities to access financial capital, all while addressing inequities that perpetuate poor outcomes.
41462740|NCT04155827|OTHER|SIT|Sprint interval training of 4\*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.
41462741|NCT00402519|RADIATION|Accelerated partial breast irradiation|APBI with PDR and HDR brachytherapy
40983083|NCT06413342|DRUG|Sintilimab|Patients should receive their first dose of sintilimab within 42 days after completing the final radiotherapy session and continue treatment until disease progression, occurrence of intolerable toxicity, loss to follow-up, death, or as determined by the investigator, whichever comes first. The maximum duration of sintilimab treatment is 12 months (from the initiation of therapy). No other anti-tumor therapies are permitted during the treatment period.
41462742|NCT00402519|RADIATION|External beam whole breast irradiation|Standard Whole breast irradiation
41462743|NCT01738217|PROCEDURE|Fluobeam|
40983084|NCT00751647|OTHER|Physical Therapy|Treatment
40983085|NCT03933150|DEVICE|ultrasound guided caudal epidural injection|"A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.~B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor"
40983086|NCT04240925|DEVICE|NIMV with sigh breaths|Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( ≥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol
40983087|NCT04240925|DEVICE|Standard NIMV|Will be treated by standard NIMV with no sigh
40983088|NCT06053463|DEVICE|Daily disposable multifocal soft contact lens|Daily disposable multifocal soft contact lens that will be worn for 1 month.
40983089|NCT00187811|PROCEDURE|Delta amino leavulinic acid photodynamic therapy|
40983090|NCT00799604|DRUG|clevidipine|Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (\<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
40983091|NCT03387839|OTHER|Stress X-Ray|Antero-posterior stability of the knee measured with stress x-rays using the TELOS Stress device in 45° and 90° flexion
40983092|NCT03611790|DEVICE|NeVa VS|mechanical dilatation
40983093|NCT00633386|DRUG|Celecoxib|400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
40983094|NCT00633386|OTHER|Placebo|Matched placebo
40983095|NCT02967497|DRUG|YQ1|Oral administered powder
41143437|NCT03584282|BEHAVIORAL|Text Messaging|The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.
41462744|NCT00325104|PROCEDURE|Parathyroid hormone testing|
41462745|NCT00325104|PROCEDURE|Serum calcium testing|
40983096|NCT03255486|BIOLOGICAL|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
40983097|NCT00539331|DRUG|AZD2171|oral tablet
41462746|NCT03033134|DEVICE|BSJ003W|BSJ003W implant
41462747|NCT05467540|DEVICE|SPINERY|Radio-Frequency device designed for palliative treatments of patient with painful metastatic bone tumors involving vertebral bodies, sacrum, iliac crest and peri-acetabulum
41462748|NCT04282239|PROCEDURE|PECS2 block|Superficial peripheral nerve block placed at the interfascial plane between the pectoralis major and minor muscles and the plane between the pectoralis minor and serrates anterior muscles. Targeted nerves include the lateral and medial pectoral nerves in addition to the long thoracic nerve, thoracodorsal, and thoracic intercostal nerves from T2 to T6.
41462749|NCT04282239|DRUG|Ropivacaine 0.5% Injectable Solution|15 mL on each side of anterior chest for a total of 30mL
40983098|NCT00539331|DRUG|Paclitaxel|intravenous infusion
40983099|NCT00539331|DRUG|Carboplatin|intravenous injection
40983100|NCT02397759|OTHER|Blood draw and cerebrospinal fluid draw|
41462750|NCT04282239|DRUG|Lidocaine Epinephrine|10 mL on each side of anterior chest for a total of 20mL
41462751|NCT04282239|DRUG|Dexmedetomidine 0.004 MG/ML|10 mL
40778080|NCT00183248|DRUG|Sirolimus|Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
41462752|NCT03070015|BEHAVIORAL|Nutrisystem|The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI \> 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables \& no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch \& 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (\~50% kcal from carbohydrate,\~25% from protein,\~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.
41462753|NCT03070015|BEHAVIORAL|Self-Directed DASH|The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts \& sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day \& men ate 1500 kcal/day. Subjects with BMI \>40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
41462754|NCT03108820|BEHAVIORAL|TMH Intervention|Home visits and close interaction with injured patient to assure plan for care is being followed.
41462755|NCT03108820|OTHER|Usual Care|Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
41462756|NCT01863433|BIOLOGICAL|Trivalent Influenza Vaccine|
41462757|NCT03076749|OTHER|Creating models for the diagnosis of BL allergy|
41462758|NCT04082806|DRUG|GHB|50 mg/kg GHB at one experimental night
40778081|NCT00183248|DRUG|Tacrolimus|Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
40778082|NCT00183248|PROCEDURE|Donor bone marrow stem cell infusion|2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
40778083|NCT00183248|PROCEDURE|Kidney transplant|Occurs at study entry
40778084|NCT02346669|PROCEDURE|gastroscopy|as detailed in arm description
40778085|NCT02346669|DRUG|Fecal Microbiota Transplantation|as detailed in arm description
41143438|NCT03584282|BEHAVIORAL|Peer Navigation|The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
41462759|NCT04082806|DRUG|Trazodone|1.5 mg/kg trazodone at one experimental night
41462760|NCT04082806|DRUG|Placebos|placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
40778086|NCT02346669|OTHER|high fat low fiber diet|as detailed in arm description
40778087|NCT02346669|OTHER|sham diet|as detailed in arm description
40778088|NCT02346669|OTHER|low fat high fiber diet|as detailed in arm description
41143439|NCT05090566|DRUG|Elranatamab + Nirogacestat|BCMA-CD3 bispecific antibody + gamma secretase inhibitor
41143440|NCT05090566|DRUG|Elranatamab + lenalidomide + dexamethasone|BCMA-CD3 bispecific antibody + immunomodulatory
41143441|NCT02598388|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles).
40983101|NCT05342259|PROCEDURE|Caudal nerve block /neuroaxial|"Technique of the caudal block The patient was placed in lateral decubitus position for blind caudal epidural block. A line was drawn to connect the bilateral posterior superior iliac crests and used as one side of an equilateral triangle; then the location of the sacral hiatus was approximated by palpating the sacral cornua as 2 bony prominences, the sacral hiatus was identified as a dimple in between. A needle was inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone was contacted.~A subjective feeling of loss of resistance suggests piercing the sacral ligament.The whoosh test, performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of air, Palpating for subcutaneous bulging on rapid injection of 5 mL air or saline had a positive predictive value of 83% and a negative predictive value of 44%."
40983102|NCT05342259|PROCEDURE|Dorsal penile nerve block|"Technique of Dorsal penile nerve block:~Under aseptic technique and under ultrasound guidance. A 'hockey-stick' probe was used, covered by transparent sterile dressing. The probe was placed vertically over the pubic symphysis and the base of the penile shaft. With adjustment of the probe, a sagittal view of the penile shaft was produced. Scarpa's fascia was seen as a hyperechoic line superficial to the penile shaft. Under real-time guidance, the needle was inserted and advanced until its tip laid deep to Scarpa's fascia (i.e., within the subpubic space), where local anesthetic was deposited. The local anesthetic solution injected was 0.5% bupivacaine in a recommended volume. (2 ml up to 3 years and an additional 1 ml for each3 years up to maximum 6 ml)."
40983103|NCT05342259|PROCEDURE|Combined caudal and dorsal penile nerve block|Combined techniques of caudal and dorsal penile nerve block
40983104|NCT01133054|PROCEDURE|revascularization|surgery or stenting
41303838|NCT05756673|DRUG|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
41303839|NCT05756673|DRUG|LISTERINE ZERO Alcohol Mouthwash COOL MINT|Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.
40983105|NCT02289690|DRUG|Veliparib|Capsules administered orally twice a day according to the dosing schedule.
40983106|NCT02289690|DRUG|Carboplatin|Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.
40983107|NCT02289690|DRUG|Etoposide|Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².
41303840|NCT05756673|DRUG|LISTERINE COOL MINT Antiseptic Mouthwash|Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
41303841|NCT05756673|DEVICE|TePe Original Interdental Brush|Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.
41303842|NCT04126369|OTHER|mindfulness intervention|The mindfulness program is conducted in a group session of up to 10 people. Each session lasts 2 hours. A total of 12 sessions will be conducted by a practitioner who is specifically trained in this type of programme.
41303843|NCT04126369|OTHER|psycho educative programme|The psycho-educational control intervention will follow the same format and structure as the mindfulness meditation intervention in terms of group format, session duration and frequency. This is a therapeutic education programme developed for several years in the neurology department of the university hospital of Lyon and Grenoble. The program follows the repository recommended by the french league against epilepsy.
40778089|NCT05638074|PROCEDURE|Interlaminar Epidural Steroid Injection|"The patient will be placed in the prone position and cutaneous anesthesia is performed with 3 mL of 2% prilocaine using the sterile technique. After imaging the C7-T1 space with fluoroscopy, it will be entered from the right/left paramedian part of the C7-T1 space with an 18G Touhy needle, and the C-arm will be set in the contralateral oblique position for depth determination.~Under intermittent fluoroscopic imaging, the needle will be advanced, and access to the epidural space wiil be confirmed by the loss of resistance technique. Afterwards, the epidural spread will be controlled with a contrast agent, and a mixture of 10 mg dexamethasone, 1 mL 2% lidocaine hydrochloride, and 1 mL 0.9% saline will be applied to the epidural space. The patient will be discharged with recommendations after being kept under observation for 2 hours post-procedure. All injections will be performed by the same pain medicine specialist who has at least 5 years of experience."
40778090|NCT02071615|DRUG|Methylphenidate 20 mg tablet given once by mouth|3-arm, single-drug dosage comparison study
40778091|NCT02071615|DRUG|modafinil 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
40778092|NCT02071615|DRUG|caffein 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
40778093|NCT02071615|DRUG|placebo|
40778094|NCT04983784|BEHAVIORAL|walking|walking for 12 weeks at home
40778095|NCT04983784|OTHER|Routine care|Routine care
40778096|NCT03316430|OTHER|Podocyturia quantification|Podocyturia quantification at first planned prenatal care visit before 16 weeks of gestation
40778097|NCT03758183|PROCEDURE|total knee arthroplasty|
40778098|NCT04450732|DRUG|GQ1001|anti-HER2 antibody drug conjugate
40778099|NCT03070626|DIETARY_SUPPLEMENT|PreOp®|No preoperative drink.
40778100|NCT05665283|DRUG|Ensartinib Hydrochloride|oral ALK inhibitor
40778101|NCT05635006|OTHER||No special intervention, randomly classify the subjects
40778102|NCT05013554|DRUG|SAR443216 IV|Pharmaceutical form: Powder for solution; Route of administration: IV infusion
40778103|NCT05013554|DRUG|SAR443216 SC|Pharmaceutical form: Powder for solution; Route of administration: SC injection
40778104|NCT01704157|DEVICE|Cryo-Touch III|Study treatment at Day 0.
40778105|NCT04219410|PROCEDURE|Fully minimally invasive esophagectomy|Esophagectomy using a novel fully minimally invasive approach
40778106|NCT04047446|DRUG|Exparel 133 MG Per 10 ML Injection|10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
40778107|NCT04047446|DRUG|Dexamethasone|15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected
40778108|NCT00970398|OTHER|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
40778109|NCT00970398|OTHER|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
40778110|NCT01186861|DRUG|OSI-906|Tablet administered with food and with up to 200 mL of water
40983108|NCT02289690|DRUG|Placebo|Placebo to veliparib administered orally twice a day according to the dosing schedule.
40983109|NCT02168179|PROCEDURE|dermatologic complications management/prevention|Apply KeraStat Skin Therapy topically
40983110|NCT02168179|OTHER|questionnaire administration|Ancillary studies
41143442|NCT02598388|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL IM injection of (1x10\*8 infectious units).
40778111|NCT01186861|DRUG|erlotinib|Tablet administered at least 2 hours after food with up to 200 mL of water
40778112|NCT01186861|DRUG|placebo|Tablet administered at least 2 hours after food with up to 200 mL of water
40778113|NCT00272181|DRUG|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
41143443|NCT02598388|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9 percent (%) saline.
40778114|NCT01779414|OTHER|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
41143444|NCT03436563|BIOLOGICAL|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Given IV
40778115|NCT04636632|DRUG|fosaprepitant|fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
40778116|NCT04500145|RADIATION|SIB-IMRT|60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time
40778117|NCT04500145|RADIATION|routine IMRT|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
40778118|NCT02478151|DEVICE|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
40778119|NCT02428829|PROCEDURE|Attempt walking from 4 hours post operatively, on the day of their surgery.|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
40778120|NCT02428829|PROCEDURE|Control - standard treatment|standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
40778121|NCT02152748|GENETIC|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
40778122|NCT01966146|DEVICE|Echography GE Healthcare Vivid E9|Echography GE Healthcare Vivid E9
40778123|NCT00342134|PROCEDURE|Stem Cell Transplanataion|
40983111|NCT05354752|DRUG|VC005 tablets|VC005 groups repeat administration for 7 days
40983112|NCT05354752|DRUG|VC005 Placebo tablets|VC005 placebo groups repeat administration for 7 days
41143445|NCT01373723|OTHER|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
40778124|NCT05629988|DEVICE|IA with TheraSorb ® column|IA cycle is 5 days, repeat cycles will be given to responders at months 3 and 6
41303844|NCT01912729|BEHAVIORAL|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
41303845|NCT01912729|BEHAVIORAL|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
40778125|NCT00404807|DEVICE|CPAP(Continuous Positive Airway Pressure)|
41303846|NCT02344069|DRUG|Fibrinogen|Human fibrinogen concentrate as a injection
40778126|NCT02051426|OTHER|D-serine|single P.O. administration of D-serine (2.1g)
40778127|NCT02051426|OTHER|Placebo|single P.O. administration of Placebo
40778128|NCT03157947|BEHAVIORAL|Decision Aid Tool|Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.
40778129|NCT03157947|BEHAVIORAL|baseline survey|patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care
40983113|NCT01506167|DRUG|Bevacizumab|Bevacizumab was administered as part of standard first-line treatment
41303847|NCT02344069|DRUG|Placebo|Saline 0.9% as a injection
41303848|NCT01290172|DRUG|Administration of Somatostatin|"6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days."
41462761|NCT04993417|OTHER|Motor imagery technique along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. The patients were mentioned to play out the emotional facial appearances for non-verbal correspondence i-e pleasure, misery, interest, appall, dread, irritation and shock. Patients were then requestedto envision himself winking, for instance, envisioning himself in a wonderful and natural social setting, at that point the patient cognitively addresses, with his eyes shut, the movement of decaying the recognized central issues, without creating any specific movement.
41462762|NCT04993417|OTHER|Mime Therapy along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. Mime treatment incorporates self kneading of face and neck, breathing and relaxation works out, activities to synchronize the two sides and diminish synkinesis and for eye and lip closure per the myofascial way to deal with recovery, letter and word practices and expressive activities.
40778130|NCT03157947|BEHAVIORAL|follow-up surveys|at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
40983114|NCT01506167|DRUG|Capecitabine/Oxaliplatin|Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
40983115|NCT01506167|DRUG|Fluorouracil/Folinic Acid/Oxaliplatin|Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
41462763|NCT00401154|OTHER|Stationary Cycling|Use of a stationary bicycle for exercise
40778131|NCT00189423|DEVICE|Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)|"The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.~The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR."
40983116|NCT01506167|DRUG|Capecitabine|Capecitabine was administered along with bevacizumab as part of standard first-line treatment
40983117|NCT01506167|DRUG|Fluorouracil/Folinic Acid/Irinotecan|Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
40983118|NCT01506167|DRUG|Fluorouracil +/- Folinic Acid|Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
40983119|NCT01980992|DRUG|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
40983120|NCT01269060|PROCEDURE|Single Incision Laparoscopic Surgery|Single Incision Laparoscopic Sigmoidectomy
40983121|NCT04726423|OTHER|transcranial direct current stimulation|5 daily sessions of tDCS (2mA, 20 min) were recommended to all patients. Physical exercises were also done at the physiotherapy clinic. Physical exercises program was recommended to be continued at home after the week of physiotherapy visits.
40983122|NCT00772772|DRUG|Vitamin D3|2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
40983123|NCT00815945|DRUG|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
40983124|NCT00815945|DRUG|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
40983125|NCT05951868|BEHAVIORAL|Continuum of support on breastfeeding.|A continuous support program for women from antenatal period till 6 months after delivery to initiate early breastfeeding, exclusively breastfeeding for 6 month and to continue breastfeeding till 2 years and beyond.
41462764|NCT06502210|PROCEDURE|Personalized surgical therapy of neuroblastoma|If the size of the tumor tissue is too large, the doctor gives the patient chemotherapy and then performs surgery to remove the tumor. In this study, the genotypes of children with neuroblastoma are screened by using Deep Sequencing Technology and Third Generation Sequencing Technology, and the treatment will be performed according to different therapeutic modalities.
41462765|NCT03334149|OTHER|Self-Monitoring of Blood Pressure|"BUMP 1: Women randomised to the self-monitoring arm will be asked to measure blood pressures at least three times a week. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, and aided by the tele monitoring system.~BUMP 2: Women randomised to the self-monitoring arm will be asked to measure blood pressures daily. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, aided by a tele monitoring system."
41462766|NCT02528058|PROCEDURE|Vitrectomy with internal limiting membrane peeling|
40983126|NCT02496650|DRUG|Dexmedetomidine|DEX infusion in doses 0,2-1,4 μg/kg/hr
40983127|NCT03382938|DRUG|Dexmedetomidine|WOUND INFILTRATION IN CESAREAN SECTION
40983128|NCT03382938|DRUG|Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
40983129|NCT03382938|DRUG|Dexmedetomidine - Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
41462767|NCT02020109|RADIATION|splenic irradiation|
41462768|NCT01501110|DRUG|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
41462769|NCT04970862|PROCEDURE|reversion surgery|reversion surgery
41462770|NCT01719562|PROCEDURE|Magnetic resonance imaging|Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
40778132|NCT00189423|PROCEDURE|Standard cardiopulmonary resuscitation (S-CPR)|Conventional standard cardiopulmonary resuscitation (S-CPR)
40983130|NCT03382938|OTHER|0,9% saline|placebo WOUND INFILTRATION IN CESAREAN SECTION
40983131|NCT05605392|OTHER|Deinstitutionalization process|"Phase 1: Comprehensive geriatric assessment to evaluate who might be a candidate for deinstitutionalization.~Phase 2: Intervention:~1. Support plan: design a plan agreed upon with the participant to provide resources to the person's needs and which guarantees support during the transition and beyond.~2. Transition process: progressive withdrawal of support in the institution and implementation of support and adaptation in the community, with different types of accommodation depending on the needs and preferences of each participant. Coordination with primary care teams, social services, and other community resources.~3. Case follow-up and gradual withdrawal of the project team. If the process does not go as the person expects, or difficulties are encountered that cannot be resolved, the participant will have the option and choice, if desired, to return to the residence at any time during the process."
40983132|NCT04905446|OTHER|Deuterated nicotinamide (D4-NAM) IV infusion|Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. D4-NAM (in normal saline) will be infused via an indwelling catheter.The IV infusion will continue for 8 hrs.
40983133|NCT04905446|PROCEDURE|Skeletal muscle biopsy|Participants will have a muscle biopsy performed on the muscle in the thigh. We will collect a small sample of blood before the biopsy. This procedure is used to sample muscle cells from the right or left leg Vastus Lateralis (thigh) muscle.
40983134|NCT04905446|PROCEDURE|Skin tissue biopsy|This procedure is used to sample skin tissue from the upper thigh via a punch biopsy.
40983135|NCT01819077|PROCEDURE|TMMR|Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
40778133|NCT05939726|OTHER|Moisturising cream with vitamin E concentrate|The vitamin E moisturising cream contains 3% w/w of palm-oil-derived vitamin E concentrate, consisting of the following isomers: alpha-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. This formula provides a total of 1.2g tocotrienols per 100g product.
40778134|NCT05939726|OTHER|Moisturising cream without vitamin E concentrate|This moisturising cream is a similar moisturising cream but without the addition of the vitamin E concentrate
40778135|NCT05939726|OTHER|Urea cream|Urea cream (10%w/w) is used as the standard of care for PPE.
41462771|NCT01719562|OTHER|Physical Activity|Tailored aerobic exercise program onsite and at home.
41462772|NCT01719562|OTHER|Healthy Living|Healthy living presentations at a centralized meeting place and over the phone.
40778136|NCT00000628|DRUG|L-697,661|
40778137|NCT00000628|DRUG|Zidovudine|
40778138|NCT02791464|BEHAVIORAL|Transcendental Meditation program|a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
40778139|NCT02992730|BEHAVIORAL|No Intervention|No Intervention
40778140|NCT04312022|DIETARY_SUPPLEMENT|Berry extract|Berry extract supplement (hawthorn berry extract, tart cherry extract, bromelain)
40778141|NCT04312022|OTHER|Placebo|Placebo (flour capsule)
40778142|NCT04744584|OTHER|Medication reconciliation|MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.
40983136|NCT01671189|OTHER|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
40983137|NCT03747328|DRUG|ABI-009|nanoparticle albumin bound sirolimus
40983138|NCT02497950|DEVICE|HeartMate 3|Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
41143446|NCT03031353|DRUG|Misoprostol|Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage
41462773|NCT01719562|DEVICE|Cardiopulmonary Exercise Testing (CPET)|Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.
41462774|NCT01719562|OTHER|Questionnaire Administration|A self-administered 13-item scale to assess fatigue in participants
41462775|NCT05884970|DRUG|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
41462776|NCT05884970|DRUG|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
41462777|NCT05884970|DRUG|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
41462778|NCT05884970|DRUG|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
41462779|NCT00083694|DRUG|Thalidomide|
40778143|NCT04744584|OTHER|Medication reconciliation|After inclusion of the patient, the MR will be carried out retrospectively, that is to say that the information concerning the treatments taken by the patient at the time of the first assessment will be retrieved during the period of the first reassessment (therefore with a delay of 12 months depending on the deadline for the first assessment). All these discrepancies will be considered medication errors if the reason for the discrepancy was not entered in the patient's computerized medical record (IMR).
41143447|NCT03031353|DRUG|Placebos|placebos tablet will be given before elective Cesarean sections
40778144|NCT00402987|DRUG|Celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
40778145|NCT00402987|DRUG|Celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
40778146|NCT00402987|DRUG|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
40778147|NCT00402987|DRUG|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
40778148|NCT01696643|DRUG|CB-5945|
40778149|NCT01696643|DRUG|Placebo|
40778150|NCT02145936|OTHER|diet|Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
40778151|NCT03202394|DRUG|BIO-11006|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
40778152|NCT03202394|DRUG|Placebo|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
41143448|NCT00268697|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
41143449|NCT00268697|DRUG|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
41143450|NCT00268697|DRUG|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
41143451|NCT00275314|DRUG|Valganciclovir|
41143452|NCT01858909|DRUG|Melatonin|Administration via oral or via a nasogastric tube followed by 20mL saline
41462780|NCT03111667|BEHAVIORAL|Teen Marijuana Check Up|Two session Motivational Enhancement Therapy intervention. The first MET session relies on the use of motivational interviewing skills to hear the student's history and current concerns with marijuana. The second session involves the provision of a personalized feedback report based on the student's baseline assessment that reviews normative feedback on marijuana use, consequences experienced, money spent on marijuana, other drug and alcohol use, social supports for quitting and life goals.
41462781|NCT03111667|OTHER|Treatment as Usual|Referral to community resources
40778153|NCT02816814|OTHER|Diet rich in omega-3 fatty acids|A diet rich in omega-3 fatty acids (7g/die) will be administered for 4 months to overwieght women in menopause
41303849|NCT01290172|DRUG|Administration of placebo|"The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy."
41462782|NCT03111667|BEHAVIORAL|Gold Standard Coaching|Weekly coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in a group setting.
41462783|NCT03111667|BEHAVIORAL|As Needed Coaching|As needed coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in an individual setting.
41462784|NCT02613286|PROCEDURE|Extrafascial Hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
41462785|NCT02613286|PROCEDURE|Modified radical hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
40778154|NCT02816814|OTHER|Diet with extra virgin olive oil|A diet rich in EVO (25-30g/die) will be administered for 4 months to overwieght women in menopause
40778155|NCT01974284|DRUG|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
40778156|NCT00700206|DRUG|Ezatiostat Hydrochloride|"Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle."
40778157|NCT02008643|OTHER|filling questionnary to quality of life|filling questionnary to quality of life
40778158|NCT03727061|BIOLOGICAL|Nivolumab|Immunotherapy - Standard of care
40778159|NCT03727061|DRUG|Porfimer Sodium|Given IV
40778160|NCT03727061|PROCEDURE|Interstitial Illumination Photodynamic Therapy|Undergo I-PDT
40778161|NCT03727061|OTHER|Quality of Life Assessment|Ancillary Studies
40778162|NCT01726608|PROCEDURE|Comparison of active versus sham radiofrequency neurotomy with Simplicity III|
40778163|NCT03447873|DRUG|Continue with triple therapy|To continue with triple therapy
40778164|NCT03447873|DRUG|Switch to DTG + 3TC|Switch to dolutegravir + lamivudine once daily
40778165|NCT03447873|DRUG|Switch to DRV/cobicistat + 3TC|Switch to darunavir/cobicistat + lamivudine once daily
40778166|NCT01435161|DRUG|Nifedipine,|Nifedipine 30-60mg/day
40778167|NCT01435161|DRUG|Telmisartan|Telmisartan 80-160mg/day
41143453|NCT01102426|DRUG|Plitidepsin|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
41143454|NCT01102426|DRUG|Dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
40778168|NCT04820023|DRUG|BBT-176|BBT-176 given orally alone
40778169|NCT06487520|OTHER|group watching hot environment image|"In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Peaceful mountain snow image was shown. This image includes a cold winter day.~Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients."
40778170|NCT06487520|OTHER|group watching cold environment image|"In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Deep space relaxation image was shown. This image contains a hot environment image with explosions in space.Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients."
40778171|NCT00355043|DRUG|Zinc sulphate 20 mg|
40778172|NCT00508482|OTHER|deep needling|"Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks."
41303850|NCT01300897|PROCEDURE|Cortical Evoked Potentials|A probe with 2 ring electrodes is placed in the anorectum. A small amount of electric current is passed separately through the anal and rectal electrodes.. The cortical evoked potentials from the anal and rectal sites are measured.
41303851|NCT01300897|PROCEDURE|Transcranial motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the scalp at the anorectal site on each side, and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
41303852|NCT01300897|PROCEDURE|Translumbosacral motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the back at the lumbar plexus and sacral plexus levels and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
40778173|NCT00508482|DRUG|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
40778174|NCT00508482|OTHER|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
40778175|NCT04279743|DIETARY_SUPPLEMENT|omega-3 phospholipids|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening) (4 g/ day of phospholipids), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
40778176|NCT04279743|DIETARY_SUPPLEMENT|omega-3 Triglycerides|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
40778177|NCT02873728|PROCEDURE|Remote Ischemic Conditioning|Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
40778178|NCT02873728|OTHER|Control|Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
40778179|NCT00948350|PROCEDURE|awake intubation|two anesthesia techniques
40778180|NCT01621100|DRUG|OROS hydromorphone|Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
41462786|NCT01622660|DRUG|Gemcitabine|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
40778181|NCT03270995|BEHAVIORAL|Cognitive Existential Therapy Group 1|Six group sessions of two hour each using a cognitive-existential group approach
40778182|NCT03270995|BEHAVIORAL|Supportive Therapy Group 2|Six group session of two hour each using a supportive group approach.
40778183|NCT03739619|DRUG|Bendamustine|Given IV
40778184|NCT03739619|DRUG|Gemcitabine|Given IV
40778185|NCT03739619|BIOLOGICAL|Nivolumab|Given IV
40778186|NCT03283241|DEVICE|Zolidd One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
40778187|NCT03283241|DEVICE|One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
40778188|NCT06458569|OTHER|Rehabilitation|3-weeks rehabilitation in hospital
40778189|NCT04798677|DIETARY_SUPPLEMENT|ABBC1 Immunoessential|Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor
40778190|NCT04798677|DIETARY_SUPPLEMENT|Placebo|Powder for dissolution in water, excipents. Lemon flavor
40778191|NCT03297658|DEVICE|electro-acupuncture (EA)|stimulation of acupuncture points related to congenital heart surgery for comfort heart and renal health
40778192|NCT03297658|DEVICE|sham|Micro electrodes will be placed but there will be no stimulation
40778193|NCT05697705|OTHER|ChAdOx1 nCOV-19 vaccine (Vaxzeria)|Used as 2nd booster, 1st booster, or primary series
40778194|NCT05697705|OTHER|BNT162b2 (Pfizer)|Used as 2nd booster, 1st booster, or primary series.
40778195|NCT05697705|OTHER|Ad26.COV2.S (Janssen)|Used as 2nd booster, 1st booster, or primary series.
40778196|NCT05697705|OTHER|CoronaVac (Sinovac)|Used as 2nd booster, 1st booster, or primary series.
40778197|NCT00002930|PROCEDURE|positron emission tomography|
41303853|NCT03451864|PROCEDURE|Vaginal delivery|classic vaginal delivery
40778198|NCT00002930|RADIATION|fludeoxyglucose F 18|
40778199|NCT03625076|DRUG|Intra-articular Lidocaine|20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
40778200|NCT03625076|DRUG|Procedural Sedation with etomidate or propofol|Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
41303854|NCT03451864|PROCEDURE|Cesarean Section|routine lower segment cesarean scetion
41303855|NCT01366222|DIETARY_SUPPLEMENT|food concentrates: fruit, vegetable, fish oil and probiotics|comparison the effect of food concentrate
40983139|NCT01537744|DRUG|oral 5-azacitidine in combination with romidepsin|"DOSING REGIMEN(S):~Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)~Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15~Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15~Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15~Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15~Level 4d MTD 8mg/m2 days 8, 15, and 22~1. Each cycle will last 28 days.~2. Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.~3. On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.~4. Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene."
40983140|NCT05842603|BEHAVIORAL|Cardiac Lifestyle Program|12-week, tailored nutrition and physical activity program comprised of virtual and in-person classes.
40983141|NCT02100059|OTHER|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
40983142|NCT05176353|OTHER|VAP diagnostic stewardship bundle|Multifaceted VAP diagnostic stewardship bundle targeting the respiratory culture testing workflow through a custom order set within the institutional electronic medical record. Interventions will be made at the three levels of the diagnostic testing pathway (ordering, collection and reporting of test results). Full details available in detailed study description.
40983143|NCT00905554|PROCEDURE|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
40983144|NCT00905554|PROCEDURE|air insufflation|air insufflation during the insertion phase of colonoscopy
40778201|NCT01602484|DEVICE|Pre-prepared Splint Pack composed by Medline|Applying splint by using pre-prepared splint pack
40983145|NCT03681392|DIETARY_SUPPLEMENT|Dr. Pyke's Supplement for Stream (S4S)|Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3
40983146|NCT03630003|DEVICE|MOCS|"The device consists of a tablet computer that can produce visual and auditory components designed to improve subject knowledge about setting and communication, mounted on a table or at the side of the bed in a place that is visible to the subject.~The Arduino will be connected to switches/buttons and implemented in a 3D-printed platform."
40983147|NCT03630003|OTHER|Post-use interview|The Study team conducts an interview with participants to evaluate their experience with use of the MOCS device.
41303856|NCT01014637|DRUG|Amorolfine (Antifungal)|Treatment with Amorolfine for 36 weeks
41303857|NCT01014637|DRUG|RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)|Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
41303858|NCT04486924|DEVICE|Globe Mapping and Ablation System|Prospective, non-randomized, open-label clinical study.
41303859|NCT06050863|BIOLOGICAL|silk fibroin|silk fibroin extracted from bombyx mori silk worm is processed in laboratory to form silk fibroin films
41303860|NCT06050863|DRUG|Chlorhexidin|chlorhexidine is used
41303861|NCT06050863|BIOLOGICAL|combination of silk fibroin and chlorhexidine|combination of silk fibroin and chlorhexidine is used
40778202|NCT01602484|DEVICE|Bulk splint supplies|Applying splint by using the bulk splint supplies
40778203|NCT00619775|DEVICE|PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device|Carotid artery stenting with distal embolic protection.
40983148|NCT05378815|PROCEDURE|PRP injection|3 weekly intra-articular injections of 5mL PRP under ultrasound guidance
40983149|NCT05378815|PROCEDURE|Placebo injection|3 weekly intra-articular injections of 5mL NaCL under ultrasound guidance
41303862|NCT04640324|DRUG|Nutraceutical therapy|Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
41303863|NCT02219555|DRUG|Steroid Injection|volume and specific steroid drug will be based on the recommendation of the treating clinician
41303864|NCT02219555|PROCEDURE|Carpel Tunnel surgery|Standard of care carpel tunnel surgery
41303865|NCT04143542|PROCEDURE|trunk blocks|Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery
41303866|NCT03063775|DEVICE|BioOss® + Mucograft Seal®|Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
41303867|NCT03063775|OTHER|FGG + Bio-Oss®|Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
41303868|NCT03063775|OTHER|FGG + Gelatine sponge (Spongostan®)|Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
41303869|NCT03063775|DEVICE|Spongostan®+ Mucograft® Seal|Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
41303870|NCT02672319|PROCEDURE|EUS-guided glue injection|Experimental: EUS-guided glue injection Gastroesophageal varices \> 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
41303871|NCT03945045|PROCEDURE|Subclavian vein approach|Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
41303872|NCT03945045|PROCEDURE|internal jugular vein approach|internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
40778204|NCT05904717|DRUG|PXS-4728 (A)|Participants will receive once daily (QD) for period of 12 weeks
40778205|NCT05904717|DRUG|Matching Placebo (B)|Participants will receive once daily (QD) for period of 12 weeks
40778206|NCT02561962|DRUG|AMG 224|Administered as an IV infusion.
40778207|NCT06300775|DEVICE|modified hyrax|Appliance used for rapid maxillary expansion
40983150|NCT04801160|PROCEDURE|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
40983151|NCT04801160|PROCEDURE|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
40983152|NCT04232072|OTHER|Group ESPB|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
40983153|NCT04232072|OTHER|Group Ibuprofen|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period. In Group Ibuprofen, patients will be administered ibuprofen 800 mgr IV every 8 hours in the postoperative period.
40983154|NCT03963362|DRUG|GLA5PR tablet 75 mg|GLARS-NF3 tablet
40983155|NCT03963362|DRUG|GLA5PR tablet 150 mg|GLARS-NF3 tablet
40983156|NCT01649687|BIOLOGICAL|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10\^7 cells of allogeneic adipose-derived mesenchymal stem cells
40983157|NCT00748033|DEVICE|Reference catheter: LoFric PVC, Nelaton 40 cm, CH 12|The subjects were first catheterized with this reference catheter.
41303873|NCT04026438|DRUG|Potassium Phosphate Injection|One ml of the preparation contains 3 mmol of phosphorous which when equated with RDA 10ml ie 30 mmol of preparation will be supplemented. The preparation is given slowly, intravenously over 4 hours diluted in 500 ml normal saline
41303874|NCT02840058|OTHER|Biological samples|blood and tumor tissue samples
40983158|NCT00748033|DEVICE|LoFric POBE Hydro-Kit II, 5 seconds|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 5 seconds
40983159|NCT00748033|DEVICE|LoFric POBE Hydro-Kit II, 24 hours|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 24 hours
40983160|NCT02651298|DEVICE|Fractional Co2-laser|laser treatment
40983161|NCT03325361|OTHER|Tube drain insertion|A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
40983162|NCT02018588|DIETARY_SUPPLEMENT|tryptophan|graded levels of tryptophan will be given to each subject
40983163|NCT02529618|DEVICE|integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)|iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.
41303875|NCT02840058|DRUG|Anti PD1/PDL1 treatment|
41303876|NCT05932511|DRUG|30% ascorbic acid in DMSO|see above
41303877|NCT04182659|DEVICE|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
41303878|NCT04182659|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
41303879|NCT01537770|PROCEDURE|Percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
40778208|NCT06300775|DEVICE|quad helix|device use for slow maxillary expansion
40778209|NCT00615888|PROCEDURE|Fast track patient management|no bowel washout, patient controlled epidural anesthesia, early enteral feeding
40778210|NCT00615888|PROCEDURE|Traditional management|preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
40778211|NCT04927221|DRUG|DC371739 Tablets|Participants received one of 5 dose levels of DC371739 administered as single oral doses.
40778212|NCT04927221|DRUG|Placebo|Placebo orally administered as comparison
40778213|NCT06228950|BEHAVIORAL|Mindfulness-Based Stress Reduction|A therapeutic approach called mindfulness-based stress reduction, or MBSR, aims to reduce emotional and behavioral problems by fostering mindfulness, which is an impartial awareness of the present moment. MBSR will be an 8-week training course for students with visual impairment. MBSR training, translated and adapted in Urdu language that includes 8 audios and worksheets corresponding to each week. Worksheets to record home practice will be filled upon receiving oral feedback from the students with visual impairment. Face-to-face group-based sessions will be conducted weekly.
40778214|NCT03474276|DRUG|Azythromycin|Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days
40778215|NCT03474276|DIETARY_SUPPLEMENT|Inuline and fructo-oligosaccharides|Administration of inuline and fructo-oligosaccharides (Synergy1) 2g/day, mixed with the fortified blend flour given to the child through the whole intervention.
40778216|NCT03474276|DRUG|Albendazole|Administration of Albendazole at inclusion of the child : 200mgs, one administration
40983164|NCT02529618|DEVICE|Riddell High Impact Technology (HIT) System|The Riddell HIT system incorporates six acceleration sensors into standard football helmets worn during practice and game play. A computerized sideline system captures information on linear and rotational acceleration, as well as magnitude, duration, and location of impact for each player
40983165|NCT02529618|DEVICE|i1 Biometrics Vector Mouth Guard|The i1 Biometrics Vector Mouth Guard is an impact intelligence system that contains a collection of impact sensing mouth guards, housing accelerometer and gyroscope technology that allows real-time collection and storage of biomechanical impact data. Sensors in the mouth guard communicate directly with a sideline assessment base station and allows for immediate assessment and evaluation of hit exposure.
40778217|NCT03474276|DIETARY_SUPPLEMENT|Fortified blend flour|"Children from 6 to 11 months : 200 grams / day Children from 12 to 24 months : 300 grams / day~Compostion of the fortified blend flour per 100 grams : either :~Mil (whole grains): 58,56 g/100g, Soybeans (fat meal): 16,54g/100g Peanuts (roasted seeds): 8,75g/100g, Cane sugar: 7,35 g/100g Whole milk (Powder): 7,56g/100g, MSV MAM: 0,28g/100g, iodized salt :0,45g/100g, CaC03: 0,48g/100g,Amylase BAN: 0,03g/100g OR Corn (whole grains): 53,29g/100g, Soybeans (dry seeds): 17,82g/100g, Peanuts (roasted seeds): 9,00 g/100g, Cane sugar: 11,00 Whole milk (Powder): 5,00g/100g, Soybean Oil (Purified): 1,24g/100g, Peanut oil (Purified): 1,13g/100g, MSV MAM: 0,27g/100g, iodized salt: 0,53 g/100g, Ca3(PO4)2: 0,62g/100g, KCl: 0,09g/100g"
40983166|NCT05641233|RADIATION|Stereotactic radiotherapy|Preoperative radiotherapy delivered in a single fraction of 12 Gy focussed on 4cm pancreas at the intended (i.e. future) anastomotic site.
40983167|NCT03770442|DEVICE|Cycling with FES|As described already
40983168|NCT03770442|OTHER|Routine physiotherapy|As described already
40983169|NCT05518643|PROCEDURE|ERAS protocol|ERAS protocol as described above
40983170|NCT03666845|PROCEDURE|Sciatic nerve block|Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
40983171|NCT04915755|DRUG|Niraparib|Niraparib will be administered.
40983172|NCT04915755|DRUG|Placebo|Matching placebo will be administered
40983173|NCT05168267|BEHAVIORAL|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
40983174|NCT03618992|OTHER|Cholesterol-containing moisturizers|Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
40983175|NCT01120912|DRUG|Oshadi Oral Insulin|Oral insulin single administration
40983176|NCT03600974|PROCEDURE|Stretta|Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
40983177|NCT03600974|PROCEDURE|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
40983178|NCT03600974|DRUG|Probiotic Agent|Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
40983179|NCT03600974|DRUG|PPI|PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
41462787|NCT01622660|DRUG|Pazopanib|pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
41462788|NCT01022255|BIOLOGICAL|Autologous FL vaccine|1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
41462789|NCT03480685|DEVICE|IVUS and OCT Imaging|Use of an imaging catheter
40778218|NCT04652297|DRUG|HS-10356|Single dose of HS-10356
40778219|NCT04652297|DRUG|Placebo|Single dose of Placebo
40983180|NCT03600974|DRUG|Prokinetic Motility Agents|Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
40983181|NCT03600974|DRUG|Neuromodulators|Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
40983182|NCT00909116|PROCEDURE|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
40983183|NCT02734381|OTHER|Elderly patients|Elderly patients who visited the Emergency Department
40983184|NCT05485766|DRUG|Pembrolizumab|200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
40983185|NCT05485766|DRUG|Paclitaxel|80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
40983186|NCT05485766|DRUG|Carboplatin|Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
40983187|NCT05485766|DRUG|Olaparib|300 mg BID (twice daily) orally
40983188|NCT05485766|PROCEDURE|Definitive Surgery|Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.
40983189|NCT02174055|BEHAVIORAL|Patient Interviews|participate in a brief interview
41462790|NCT04201795|OTHER|Laser|laser with no emision will applied
41462791|NCT04201795|OTHER|pressure and traction tecnique|pressure and traction in plantar fascia with hands will be applied
41462792|NCT02077881|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
41462793|NCT02077881|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
40778220|NCT04652297|DRUG|HS-10356|Multiple doses of HS-10356
40778221|NCT04652297|DRUG|Placebo|Multiple doses of Placebo
40983190|NCT02174055|BEHAVIORAL|newly developed questionnaire|10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.
40983191|NCT02174055|BEHAVIORAL|Pilot Testing the Draft Measure|The draft measure (approximately 35 items, described above) will be administered to a large sample of older cancer patients (n=150) to generate data to evaluate preliminary psychometric properties (item properties including measures of central tendency, skewness/kurtosis, internal consistency, test/re-test reliability, and construct validity (i.e, convergent and discriminant).and known group differences) to further winnow the measure to include approximately 20 items.
40983192|NCT01966640|BIOLOGICAL|Basophil Activation Test|blood sample for Basophil Activation Test
40983193|NCT00151099|DRUG|high caloric drink with protein|
40983194|NCT05813795|DRUG|Ecnoglutide Low Dosage|Subcutaneous Injection
41303880|NCT01537770|PROCEDURE|Lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
41303881|NCT05554159|BEHAVIORAL|Standard Fitbit Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
40778222|NCT01463033|DRUG|Levetiracetam|55 mg/kg/day given in 2 divided doses 12 hours apart
40778223|NCT01224314|OTHER|Changing potassium concentration in dialysis fluids|The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
40983195|NCT05813795|DRUG|Ecnoglutide Medium Dosage|Subcutaneous Injection
40983196|NCT05813795|DRUG|Ecnoglutide High Dosage|Subcutaneous Injection
40983197|NCT05813795|DRUG|Placebo|Subcutaneous Injection with matched volume
40983198|NCT05837845|DRUG|MDMA|Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions
41303882|NCT05554159|BEHAVIORAL|Virtual Exercise Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
41303883|NCT04297384|OTHER|Informational Intervention|Receive standard chemotherapy educational materials
41303884|NCT04297384|OTHER|Informational Intervention|Receive personalized information about cancer, treatment, and side effects
41303885|NCT04297384|OTHER|Quality-of-Life Assessment|Ancillary studies
41303886|NCT04297384|OTHER|Survey Administration|Complete surveys
41303887|NCT03631862|DRUG|Apatinib|Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
41303888|NCT03631862|DRUG|CHOP Regimen|CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
41303889|NCT04680286|DRUG|Methadone Hydrochloride|Single dose, intravenous bolus, 0,1 mg/kg administered at induction of anesthesia.
40778224|NCT02741050|BEHAVIORAL|Tailored Physical Activity Intervention|The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
40778225|NCT02741050|BEHAVIORAL|Standard of Care|Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
40778226|NCT01591629|DRUG|Naloxone|Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
40778227|NCT01591629|DRUG|Delta-9-THC|Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
40778228|NCT01591629|DRUG|Placebo|Placebo
40778229|NCT02004626|DRUG|Collagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
40983199|NCT05837845|BEHAVIORAL|Cognitive Processing Therapy|Participants will receive 12-16 sessions of Cognitive Processing Therapy
40983200|NCT05837845|BEHAVIORAL|MDMA-assisted Therapy|Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.
40983201|NCT05985655|DRUG|GTAEXS617|GTAEXS617 tablets daily
40983202|NCT00759954|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
40983203|NCT00759954|DRUG|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
41303890|NCT04680286|OTHER|Placebo|Single dose, intravenous bolus. Administered as the experimental arm.
40983204|NCT00217139|DRUG|Celgosivir|
40983205|NCT01819402|DRUG|Pioglitazone vs Glimepiride|
40983206|NCT02097810|DRUG|Entrectinib|
40778230|NCT02004626|DRUG|Kollagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
40778231|NCT00730054|DRUG|Remifentanil+clonidine|iv Remifentanil+ iv clonidine
40983207|NCT04675203|PROCEDURE|Tooth extraction|Tooth extraction
40983208|NCT05347550|OTHER|Graduated Compression Stockings - Thromboembolic deterrent stockings|Centres randomised to the intervention arm will consist of participants receiving GCS.
40983209|NCT00361855|DRUG|NX-CP105|
40983210|NCT03118154|OTHER|Manual Physical Therapy|Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
41303891|NCT03563703|DEVICE|Ultrasound|Ultrasound allows viewing veins and surrounding anatomical structures, making it easier to perform the placement of a cannula into a peripherally located vein in real time. This process allows the cannulation of veins that are unable to be visualised or palpated.
41303892|NCT03563703|DEVICE|Near Infrared Light|Infrared technologies allows illuminating the vein with a near-infrared light, which is absorbed by blood and reflected by adjacent tissue.
41303893|NCT06282497|RADIATION|Optimised neck CTV|neck CTV delineation extends from the lateral process of C1
41303894|NCT06282497|RADIATION|standard neck CTV|neck CTV delineation extends from skull base
41303895|NCT04516018|OTHER|Cold exposure|Subjects will be exposed to shivering thermogenesis for at least 1 hour for 10 days
41303896|NCT01585961|DEVICE|Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)|Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.
41303897|NCT03491553|DRUG|Selgantolimod|Tablet(s) administered orally once weekly
40778232|NCT03229538|DRUG|Methylprednisolone|IV Steroid pre-operative and intra-operative
40778233|NCT03229538|DRUG|Isotonic saline|Isotonic saline pre-operative and intra-operative
40778234|NCT04670796|DRUG|HLX02|subject receive one dose of HLX02
40778235|NCT04670796|DRUG|EU-sourced Trastuzumab (Herceptin®)|subject receive one dose of EU-sourced Trastuzumab (Herceptin®)
40778236|NCT04670796|DRUG|US-licensed Trastuzumab (Herceptin®)|subject receive one dose of US-licensed Trastuzumab (Herceptin®)
40778237|NCT01365754|PROCEDURE|standard|fusion
40778238|NCT01365754|PROCEDURE|new|dynamic stabilization
40778239|NCT00540631|BIOLOGICAL|specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)|"Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued"
41143455|NCT02144883|BEHAVIORAL|Telephone counseling|Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
41143456|NCT02144883|BEHAVIORAL|Self-help materials|All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
41143457|NCT00603278|DRUG|GW685698X|GW685698X
41143458|NCT00603278|DRUG|placebo|placebo
41143459|NCT05050097|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
41143460|NCT05050097|DRUG|Carfilzomib|Carfilzomib will be administered as an IV infusion.
40778242|NCT03680521|DRUG|Sitravatinib|Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.
40778243|NCT03680521|DRUG|Nivolumab|Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.
41303898|NCT03491553|DRUG|Placebo|Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly
40778244|NCT00337168|DRUG|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
40778245|NCT00337168|DRUG|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
40778246|NCT00575224|DRUG|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
41143461|NCT05050097|DRUG|Daratumumab SC|Daratumumab will be administered subcutaneously.
41143462|NCT05050097|DRUG|Lenalidomide|Lenalidomide will be self-administered orally.
41143463|NCT05050097|DRUG|Pomalidomide|Pomalidomide will be self-administered orally.
41143464|NCT03779945|BIOLOGICAL|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
41462794|NCT02077881|DRUG|Indoximod|"Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth~Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity."
41462795|NCT01795235|DRUG|Saline|Saline s.c.
40983211|NCT05590754|DEVICE|Hyper-buoyancy Floatation (HBF)|Participants remained on a waterbed encased within a wooden frame partially (≈50%) filled with water super-saturated with magnesium sulphate at a temperature between 34-36°C regulated by an ultra-thin underbed heater. Participants remained supine and motionless when lay on the HBF except for temporary passive re-orientation to/and back from the prone position for vertebral compliance assessment
40983212|NCT05590754|DEVICE|Axial Load after 4h of HBF|Participants from observational sat upright in a chair without back support for 15 min before post testing (1G), whilst experimental group participants performed a 30s seated squat with 50% of their body weight (BW) before returning to the upright seated position.
40983213|NCT02161627|DEVICE|Saluda Medical External Trial System|
40983214|NCT02161627|DEVICE|Saluda Medical External Trial System|
40983215|NCT04679792|DIAGNOSTIC_TEST|Dynamic posturography|Balance evaluation
41462796|NCT01795235|DRUG|Glucagon|Glucagon s.c.
40983216|NCT04288648|DIAGNOSTIC_TEST|ultrasound examination|ultrasound examination of pelvic floor muscle will be conducted. In addition questionnaires regarding demographic characteristics and SUI will be performed.
41143465|NCT03779945|PROCEDURE|posteriolateral lumbar fusion only|performing posteriolateral lumbar fusion without using platelet rich plasma
41143466|NCT01575704|OTHER|Exercise|Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
41143467|NCT01575704|OTHER|Mental Training|Memorial/ mental training and relaxation, 5 times per week
41462797|NCT01795235|DRUG|Placebo|Sugar Pill
41462798|NCT01795235|DRUG|Atenolol|Beta-1 receptor antagonist
41462799|NCT03561987|PROCEDURE|Bariatric surgery|There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.
40983217|NCT00888251|OTHER|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
40983218|NCT06146426|DIETARY_SUPPLEMENT|Early diet resumption|Resuming oral diet at pace started from 2 hours after extubation from ventilator.
41143468|NCT04765046|DEVICE|Bispectral (BIS™) Complete Monitoring System|The BIS™ Complete Monitoring System is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS technology converts raw EEG data acquired from the frontal cortex into a single number to measure the level of consciousness, called the BIS index. A bilateral sensor is to be placed on the patient's forehead to collect the EEG signals and transmit them back to the system.
41143469|NCT05686967|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a biochemically modified form of ubiquinol
41143470|NCT05686967|DIETARY_SUPPLEMENT|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
41143471|NCT05686967|BEHAVIORAL|Aerobic exercise|Moderate intensity aerobic exercise on the treadmill
41143472|NCT05596916|OTHER|High frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 5 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
41143473|NCT05596916|OTHER|Low frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 3 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
41143474|NCT03064906|DEVICE|Insulet AP (artificial pancreas) System|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
41462800|NCT03064867|DRUG|Venetoclax|"Beginning with 400mg daily on days 1-10 of cycle 1-3~Phase I dose escalation scheme:~Dose Level -2 (DL-2): 100 mg daily, days 1-10, cycle 1-3~DL-1: 200 mg daily, days 1-10, cycle 1-3~DL1: 400 mg daily, days 1-10, cycle 1-3~DL2: 600 mg daily, days 1-10, cycle 1-3~DL3: 800 mg daily, days 1-10, cycle 1-3~Phase II: Given at a dose of 400mg daily for 5 days"
41462801|NCT03064867|DRUG|Rituximab|"Part of R-ICE treatment:~Rituximab: 375 mg/m\^2 intravenously (IV) on Day 1 of R-ICE every 21 days"
40983219|NCT03189758|OTHER|Observational Control Diet|Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
41143475|NCT01697605|DRUG|BGJ398|
41143476|NCT06604715|DRUG|JNJ-87562761|JNJ-87562761 will be administered.
41143477|NCT06168045|DIAGNOSTIC_TEST|Cerebral tissue oxygenation and blood pressure measurement|Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth
41143478|NCT02074384|DEVICE|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
41143479|NCT02074384|DEVICE|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
41143480|NCT02074384|OTHER|Clinician|Survey of clinicians after study visits
40983220|NCT03189758|OTHER|Controlled Dietary Sodium Restriction|Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
40983221|NCT06040554|OTHER|Elastic Band Resistance Exercises|8 Warm-Up Exercises followed by 10 Elastic Band Exercises followed by 8 Post-Workout Exercises.
41462802|NCT03064867|DRUG|Ifosfamide|"Part of R-ICE treatment:~Ifosfamide: 5,000 mg/m\^2 mixed together with mesna at a dose of 5,000 mg/m\^2 over 24 hours beginning on Day 2 and completing on Day 3 of each 21-day cycle"
41462803|NCT03064867|DRUG|Carboplatin|"Part of R-ICE treatment:~Carboplatin: At a dose corresponding to an AUC = 5 based on Cockcroft-Gault calculation of GFR using adjusted body weight. Carboplatin is given IV on the Day 2 of RICE of each 21 day cycle"
41462804|NCT03064867|DRUG|Etoposide|"Part of R-ICE treatment:~Etoposide: 100 mg/m2by IV daily on 3 consecutive days (Days 1-3) of each 21-day cycle"
41462805|NCT04095624|BEHAVIORAL|Spinal Fusion Preoperative Opioid Taper|Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.
40778247|NCT02661750|DRUG|Bowel Preparation|"Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy."
40778248|NCT03430167|OTHER|home therapy|Patients will be given a set of instructions for completing home therapy for range of motion and strengthening
40778249|NCT03430167|OTHER|formal therapy|Patients will be sent to physical therapist for formal treatment to regain range of motion and strengthening exercises
40778250|NCT01170663|BIOLOGICAL|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
40983222|NCT05356247|BEHAVIORAL|Lausanne Trialogue Play Brief|The brief treatment program will consist of an LTP family assessment with video feedback to caregivers to address family interaction patterns and child mental health. Families will participate in four sessions conducted online using the Zoom for Healthcare platform. In the first session, families will engage in a family assessment in different groupings that will be recoded on zoom and used later in the treatment. In the second session, taking place one week later, families will take part in a mini assessment to learn more about the difficulties of the child. In the third session, the clinical team will share videos of the family assessment to the parents and discuss the families strengths, concerns, and goals for moving forward. In the fourth session, taking place one month after the third session, families will participate in a check-in session, debriefing the family assessment.
41143481|NCT06165497|BEHAVIORAL|Meditation practices|Participants will listen to recordings of short meditation practices drawn from the Healthy Minds Program.
41462806|NCT04095624|OTHER|Non-taper Control|Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
41462807|NCT02845011|DEVICE|Audiovisual compression feedback|The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a handheld device consisting of three components. The rescuer-side has a red palm-sized push-button with a pictogram illustrating proper use. The center unit is composed of a stable plastic base containing an arrangement of springs, and the patient-side consists of liquid-absorbent polyurethane foam. Application of 400 ± 30 Newtons of force results in an audible click alerting the rescuer to cease compression, and an additional click on decompression alerts the rescuer to resume compression.
41462808|NCT02845011|OTHER|Standard Manual Chest Compression|Cardiopulmonary resuscitation according to published international guidelines.
40778251|NCT01170663|DRUG|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
40983223|NCT06201533|BEHAVIORAL|combined physical-cognitive exercise|A combined physical-cognitive exercise will be delivered in the form of exergame, where the participants move their body to interact with the game.
40983224|NCT01069107|OTHER|Cottage Hospital Care|Care at a cottage hospital compared with care at a general hospital
40983225|NCT00243581|BEHAVIORAL|Dean Ornish Heart Disease Reversing Program|
40983226|NCT02703389|BEHAVIORAL|Video|Animated video explaining acute otitis media and antimicrobial stewardship.
40983227|NCT02703389|BEHAVIORAL|Pamphlet|Contains same information as video.
40983228|NCT00749372|OTHER|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
40983229|NCT01170455|DEVICE|Macintosh laryngoscope|nasal intubation with macintosh laryngoscope after general anesthesia induction
40983230|NCT01170455|DEVICE|Blind Intubation Device|nasal intubation using Blind Intubation Device after general anesthesia induction
40983231|NCT05049876|OTHER|urine sample taken during consultations|urine sample taken during consultations
41143482|NCT06165497|OTHER|Internet-as-usual|Participants will be instructed to use the internet as they typically do.
41143483|NCT03019432|BEHAVIORAL|Observational clinical assessment|perception of verticality measures SVV and SPV; somatosensory assessment RASP
41143484|NCT03998956|PROCEDURE|CPVI|Circumferential PV isolation only
41143485|NCT03998956|PROCEDURE|CPVI+BOX|Circumferential PV and BOX isolation
41462809|NCT01706809|OTHER|blood sampels from vena rectalis superior and vena cubiti|
41462810|NCT00260793|DRUG|Ropinirole Hydrochloride|
41462811|NCT04593394|DIAGNOSTIC_TEST|Continous laryngoscopy exercise test|Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored
41462812|NCT04593394|DIAGNOSTIC_TEST|Overnight respiratory polygraphy|Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea
41462813|NCT00481026|DEVICE|transcranial direct current stimulation (tDCS)|tDCS
40778252|NCT01170663|DRUG|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
40778253|NCT05130073|PROCEDURE|Computed Tomography|Undergo PET/CT
40778254|NCT05130073|OTHER|Electronic Health Record Review|Review of medical records
40778255|NCT05130073|PROCEDURE|Follow-Up|Undergo follow-up
40778256|NCT05130073|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40778257|NCT00542178|DRUG|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
40778258|NCT00542178|DRUG|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
40778259|NCT00542178|DRUG|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
40778260|NCT00542178|DRUG|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
40778261|NCT00542178|DRUG|Fenofibrate|Blinded fenofibrate
40778262|NCT00542178|DRUG|Simvastatin|Simvastatin 20-40 mg/d
40778263|NCT00542178|DRUG|Placebo|Placebo
40778264|NCT00867334|DRUG|Imatinib mesylate and panitumumab|Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
40778265|NCT00867334|DRUG|Standard-of-care treatment with panitumumab|Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
40983232|NCT06087107|OTHER|High Intensity Spinal Decompression Exercises|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes with 8-10 repetitions of each exercise.
40983233|NCT06087107|OTHER|Eldoa|The duration of the intervention will be 4 weeks, 3 sessions a week, and a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes.
40983234|NCT00696176|DRUG|STAT 3 DECOY|single administration to a head and neck tumor
40983235|NCT06064474|BEHAVIORAL|High ventilation breathwork with retention (HVBR)|Intervention
40983236|NCT06064474|BEHAVIORAL|Placebo HVBR|Placebo
40983237|NCT05543122|DRUG|either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe|This is a cohort study of pharmacokinetics of drugs in milk. Participants in the group are those breastfeeding women on the listed drugs at steady state, who are prescribed these drugs for clinical reasons outside this study framework.
40983238|NCT04320381|BEHAVIORAL|Qualitative Interview|2 Semi-Structured Qualitative Interviews
40983239|NCT01525550|DRUG|sunitinib|Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
40983240|NCT06199531|GENETIC|GS-100|A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
40983241|NCT00372112|DRUG|GW642444|GW642444H
40983242|NCT00372112|OTHER|Placebo|Placebo administered twice daily
40983243|NCT02286505|DEVICE|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
40983244|NCT02286505|OTHER|Standard radiological assessment|Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
40983245|NCT05846906|DRUG|Sildenafil Citrate|oral sildenafil (Respatio® 20mg )
40983246|NCT05846906|DRUG|Clomiphene Citrate 50mg|used for ovionulation induct
40983247|NCT00830843|DRUG|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
40983248|NCT00830843|DRUG|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
40983249|NCT04843774|DRUG|SARS-COV-2 mRNA Vaccine|Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
41462814|NCT00481026|DEVICE|active tDCS|Active tDCS
40778266|NCT05159674|DEVICE|Dexmedetomidine+electroacupuncture compound anesthesia|Dexmedetomidine and acupuncture were given together to induce anesthesia
40778267|NCT02286063|DRUG|Ambulatory Oxygen|"The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm."
40778268|NCT00346723|BIOLOGICAL|Influvac® subunit influenza vaccine for i.m./deep s.c.injection|
40778269|NCT06289374|OTHER|Biosample collection|Collection of saliva, urine, blood, breath and quality of life questionnaires.
40778270|NCT04542681|DRUG|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo/normal saline
40778271|NCT04542681|DRUG|MANP - 1st Cycle|Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
40983250|NCT06160960|OTHER|OCT Scan, Video of pupil movement, video of toric lens|A picture of the central macular area is taken, video of pupil movment, video of toric lens rotation.
40983251|NCT01122706|OTHER|Taiji training|Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
41143486|NCT03998956|PROCEDURE|CPVI+BOX+SUB|Atrial substrate ablation apart from circumferential PV and BOX isolation
40778272|NCT04542681|DRUG|MANP - 2nd Cycle|Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
40778273|NCT01649193|OTHER|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
40778274|NCT02675400|DRUG|Vyvanse|Half of the participants (fathers) will be randomized to receive Vyvanse.
40778275|NCT02675400|BEHAVIORAL|Behavioral Parent Training|Half of the fathers will receive behavioral parent training.
40778276|NCT02675400|DRUG|Methylphenidate|If Vyvanse is not well tolerated, methylphenidate can be prescribed.
40778277|NCT02550002|DRUG|Aflibercept|Intravitreal injection
40778278|NCT04747301|DEVICE|Double-balloon catheter (UTAH CVX-RIPE) for cervical ripening|"Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA). The catheter will be inserted manually until the proximal balloon is in the cervical canal, the distal balloon should be intrauterine and in the extra-amniotic space. The intrauterine balloon is inflated with 40mL saline and retracted so that it rests against the internal oz. The proximal balloon should now be outside the external oz and is inflated with 20mL saline. If the balloons are correctly situated on both ends of the cervix, they can be inflated with up to 80mL saline each.~Cardiotocograph will be performed 30min, 2 hours after insertion and every 6 hours. The balloon is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another balloon is placed for a maximum of another 24 hours.~The patients will be examined in case of extremely painful or membranes ruptured."
40778279|NCT04747301|DRUG|Dinoprostone 10mg (Propess)|"Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).~A Propess vaginal system is inserted by a research doctors. As in the catheter procedure, Fetal Heart Rate is monitored 30min before and 2 hours after placement. Cardiotocograph and vaginal examination will be performed every 6 hours. The vaginal system is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another vaginal system is placed for a maximum of another 24 hours.~The patients will be examined in case of extreme pain or membranes ruptured."
40778280|NCT01252680|BIOLOGICAL|Healive+Healive|Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
40778281|NCT01252680|BIOLOGICAL|Healive+Havrix|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months
40778282|NCT01252680|BIOLOGICAL|Havrix+Havrix|Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
40778283|NCT01252680|BIOLOGICAL|Havrix+Healive|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
40778284|NCT03060837|DIAGNOSTIC_TEST|Preoperative Parameters|Preoperative Hmg and serum creatinine levels
40778285|NCT03060837|OTHER|Peroperative Parameters|Scope duration, perforation, hemorrhage, etc. complications
40778286|NCT03060837|OTHER|Postoperative Parameters|Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
40778287|NCT03060837|OTHER|Movement of kidney|Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
40778288|NCT03060837|PROCEDURE|single lung ventilation|Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied
40778289|NCT03060837|PROCEDURE|standard ventilation|Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
40778290|NCT05639959|DRUG|Mometasone Nasal 50 Mcg/Inh Nasal Spray|Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.
40778291|NCT05639959|DEVICE|Nasal spray|device can work properly for actuation during trials
40778292|NCT04348474|DRUG|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.
41462815|NCT01913717|RADIATION|External beam radiotherapy|The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
40778293|NCT04348474|DRUG|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
40778294|NCT04063813|BEHAVIORAL|Experimental: 40 minute up trial|
40778295|NCT04063813|BEHAVIORAL|Experimental: 40 minute down trial|
40778296|NCT04063813|BEHAVIORAL|Experimental: Two 20 minute up trials|
40778297|NCT04063813|BEHAVIORAL|Experimental: Two 20 min down trials|
40778298|NCT04063813|BEHAVIORAL|Active Comparator: Sedentary trial|
40778299|NCT00444106|DRUG|Artesunate-mefloquine|
40983252|NCT03792308|DRUG|SPR206|"SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13."
40778300|NCT00444106|DRUG|Atovaquone-proguanil|
40778301|NCT00444106|DRUG|Artemether-lumefantrine|
40778302|NCT02347605|DRUG|Nicotine lozenge 4 mg|
40778303|NCT02347605|DRUG|Placebo lozenge|
40778304|NCT06495957|OTHER|Electroacupuncture group|Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes.
40778305|NCT06495957|OTHER|Micro-acupuncture group|After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes. Electrical stimulation is applied briefly for the first 30 seconds.
40778306|NCT05453214|DRUG|Fludrocortisone Acetate 0.1 MG|Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.
41303899|NCT03491553|DRUG|Hepatitis B virus (HBV) OAV Therapy|"Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)"
40983253|NCT03792308|DRUG|Placebo|0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
40983254|NCT04411589|DEVICE|magnifying endoscopy with optical enhancement system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. After visualization in white light mode, the stomach was reinspected by using OE mode2. Then, in vivo diagnoses of lesions were made by using OE mode1 according to VS theory. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
40983255|NCT04411589|DEVICE|white light endoscopy system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
40983256|NCT02984189|OTHER|Inspiratory muscle training|The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
40983257|NCT01964703|DRUG|Rubus occidentalis extract|
41143487|NCT00078832|DRUG|anastrozole|aromatase inhibitor
41143488|NCT00078832|DRUG|placebo|Arimidex placebo
41303900|NCT05831670|DRUG|KSP-0243|Oral administration
40983258|NCT02356744|OTHER|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
41303901|NCT05831670|DRUG|Placebo|Oral administration
41303902|NCT04864912|OTHER|Questionnaires and survey|Questionnaires: Health Utilities Index Mark III, Chronic Otitis Media Outcome Test-15 and Speech, Spatial, and Qualities of Hearing Scale-12 Survey: Client Service Receipt Inventory (adapted version)
41303903|NCT03272945|PROCEDURE|Linked-color imaging|Linked-color imaging colonoscopy
41303904|NCT05954832|DIAGNOSTIC_TEST|Echocardiography|Echocardiography and Clearsight BP measurements before, immediately after anesthesia induction and after intubation (for 20 min)
41303905|NCT03679663|DEVICE|Ultrasound|Use of ultrasound to identify pre-puncture site
41303906|NCT05280041|BEHAVIORAL|SOLENA - Online self-help program for older adults who lost the partner|SOLENA follows the most relevant CBT elements of interventions for prolonged grief: 1) Exposure, e.g., telling the story of the loss; 2) cognitive reappraisal or restructuring of individual dysfunctional thoughts associated with the loss; 3) integration and restoration including self-care and social reengagement; and 4) behavioural activation. SOLENA's content is provided through a conversational virtual agent, Sol, who guides the user through the Study section the CBT intervention itself. In 10 study modules that address either the acceptance of the loss or the restoration and adaptation to a new life, SOLENA includes 1) readings, i.e., texts based about grief related topics that provide the background and rational for the module; and 2) exercises to encourage mourners to actively reflect on their grief and apply their new knowledge to their daily life and to practise the new routines regularly. SOLENA also provides users with the Notebook, Activities, and My Support sections.
41303907|NCT05807334|OTHER|DASH eating plan with eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to eat 2 whole eggs per day to supplement the DASH eating pattern.
41303908|NCT05807334|OTHER|DASH eating plan without eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to exclude eggs from their diet on a daily basis.
41303909|NCT01762540|DRUG|Glucocorticoids|Prednisolone 37.5 mg x1 for 5 days
41303910|NCT01762540|DRUG|Calcium Supplement|Placebo
40983259|NCT02245490|DRUG|Tamsulosin HCl controlled release capsules|
40983260|NCT02245490|DRUG|Matching placebo capsule|
40778307|NCT00003156|DRUG|topotecan hydrochloride|
40778308|NCT03503409|DRUG|AG-120|500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
40778309|NCT01658059|OTHER|Homeopathic remedy|drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
40778310|NCT01658059|OTHER|Placebo|drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
41143489|NCT04851197|OTHER|Flipped Learning Model|Students in the intervention group will be given training on testicular cancer and testicular self-examination in accordance with the Flipped Learning Model. The students in the control group will receive the same training with the traditional method. It was aimed to examine the effect of the training given with the Flipped Learning Model on the students' knowledge levels and health beliefs about testicular cancer and self-testicular examination.
40778311|NCT03282266|PROCEDURE|PADN|PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
40778312|NCT03282266|PROCEDURE|Sham operation|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
41303911|NCT03477565|DEVICE|Kinesio tape lymphatic drainage technique application|Kinesio Tex Tape strips are applied following Dr.Kase draining techinique. The choice of tape's length and strips' number is based on the area of breast edema and/or presence of seroma, which must be completely covered. The patch is cut into fan strips. The major base is positioned near the functioning lymph node stations closest to the edema and/or seroma area. The bases and the tails of the fan must be applied with zero tension, while for the central part is reached 15-25% of tension. The first application takes place on the 1st post-operative day, while the second is performed on the 7th post-operative day. In case the tape is detached from one application to another, it is necessary that the patient resume in the clinic for a new application to ensure continuity of the therapeutic effect; otherwise the patient is eliminated from the study. The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and counselin.
40778313|NCT02795039|DRUG|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
40778314|NCT02795039|DRUG|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
40778315|NCT05862688|OTHER|antimicrobial therapy|antimicrobial therapy
40778316|NCT00006384|BIOLOGICAL|recombinant interferon alfa|
40778317|NCT00006384|DRUG|semaxanib|
41143490|NCT03771300|BEHAVIORAL|Mindfulness|This program is structured around two central elements, mindfulness and compassion. The sessions combine theory and practice components, using a methodology which priorities the reflection and debate among the students. Regarding theory component, mindfulness and compassion concepts will be set out over the length of the program, in addition to others related to time management, stress, anxiety and the balance between personal life and academic/work life. The practical component of the program consists of mindfulness and self-compassion formal and informal practices under the guidance of a specialized instructor.
40778318|NCT04044157|OTHER|non-invasive measurement of cardiac output|cardiac output will be non-invasivaly measured by means of electrical cardiometry
40778319|NCT04844125|DRUG|SHR-1209|SHR-1209
40778320|NCT04844125|DRUG|SHR-1209 Placebo|SHR-1209 Placebo
40778321|NCT05420571|PROCEDURE|digital impression|3D printed models after digital impressions
41303912|NCT04615962|DRUG|Hydrocortisone Acetate 1% Cream|Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.
41303913|NCT04615962|DRUG|Mometasone Furoate|Mometasone is a medium-strength corticosteroid.
41303914|NCT04615962|DRUG|SNG100|A combination of low potency steroid and skin barrier repair agent
41303915|NCT04548089|BEHAVIORAL|Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)|Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.
41303916|NCT04208763|DRUG|Imipenem|Inj Imipenem 1gm i.v. TDS
40778322|NCT05420571|PROCEDURE|alginate impression|Alginate impressions after plaster model infusion to make models
40778323|NCT03688971|DRUG|Omiganan|Omiganan Topical Gel
40778324|NCT03688971|DRUG|Ketoconazole|Ketoconazole Cream
40778325|NCT03688971|DRUG|Placebo|Vehicle
40778326|NCT00806585|DRUG|MK-0736|
40778327|NCT00806585|DRUG|Comparator: Placebo|
40778328|NCT00806585|DRUG|Comparator: HCTZ|
40778329|NCT00116571|DRUG|Lemuteporfin for injection|
40778330|NCT00116571|DEVICE|Transurethral drug delivery system|
40778331|NCT00116571|DEVICE|Transurethral light delivery system|
40778332|NCT05035888|DRUG|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
40983261|NCT00207207|PROCEDURE|Alternate site blood glucose testing|
40983262|NCT06192186|DRUG|Adebrelimab combined with SOX regimen|Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
40983263|NCT06192186|DRUG|Placebo combined with SOX (S-1/oxaliplatin) regimen|Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles (stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging) → radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
40983264|NCT05891587|DRUG|Semaglutide|Semaglutide pen injector
40983265|NCT05891587|DRUG|Placebo|Saline solution
41303917|NCT04208763|DRUG|Tigecycline|Inj Tigecycline 100mg stat f/b 50mg i.v. OD
41303918|NCT04208763|DRUG|GMCSF|Inj GM-CSF 500mcg s.c. OD
41303919|NCT04208763|DRUG|Colistin|Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
41303920|NCT04904653|DEVICE|Hemopatch|"HEMOPATCH Sealing Hemostat (HEMOPATCH) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).~Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.~HEMOPATCH is supplied in the following 3 sizes:~* HEMOPATCH 27 x 27 mm~* HEMOPATCH 45 x 45 mm~* HEMOPATCH 45 x 90 mm"
40778333|NCT05035888|DRUG|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
40778334|NCT05617261|OTHER|Conscious sedation|Conscious sedation is a combination of medications to help you relax (a sedative, for example nitrous gas) and to block out pain (commonly known as freezing, for example lidocaine).
40778335|NCT06377501|OTHER|Whole-food, plant-based diet|Subjects will be instructed to adopt a whole-food, plant-based diet for 8 weeks. They will attend weekly group cooking classes led by a RD and receive weekly health coaching sessions.
40778336|NCT02665377|DRUG|ANP|
40778337|NCT02665377|DRUG|Placebo|
40778338|NCT02450825|PROCEDURE|Lung ultrasound examination on Day 1 and Day 2 to 4|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 and repeated on Day 2 to 4. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
41462816|NCT05414162|DIAGNOSTIC_TEST|Cardiac MRI|Hematooncology patients under CAR T-cell therapy will receive 3 MRI examinations: at baseline, within 2 weeks of start of CAR T-cell therapy, and at 6 months follow-up.
40778339|NCT02450825|PROCEDURE|Lung ultrasound examination on Day 1|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 only. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
40778340|NCT02450825|DEVICE|GE Vivid Ultrasound system|The GE Vivid ultrasound system will be used for all lung ultrasound examinations performed in this study.
40983266|NCT04954781|DRUG|Tislelizumab|Tislelizumab will be initiated on day 14 after the first TACE session. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
41143491|NCT03771300|BEHAVIORAL|Mindfulness condition complemented by VR|"The VR is comprised of a Samsung VR goggles, a Samsung Galaxy S6 phone and optional headphones.~In this condition, the instructor is the same as previously but the implementation of VR will be carried out by a psychologist specially trained for the application of these VR scenarios. Prior to the VR use, the psychologist will make sure about the participants´ health."
40778341|NCT05128747|OTHER|DASH diet|it will be face to face about the role of nutritional program to control dyslipidemia
40778342|NCT04733027|COMBINATION_PRODUCT|Dose escalation, first-in-human phase I clinical trial with an Expansion phase|PEP-010 will be administered on days 1, 2 and 3 every week, as a 3-hour intravenous infusion. Treatment will be administered until disease progression, unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Each cycle will be of 21 days duration.
40778343|NCT02525679|DRUG|BI 655130 (spesolimab)|
40778344|NCT02525679|DRUG|Placebo|
40778345|NCT01935388|OTHER|Common canister|Drug administration via a shared canister with a standardized cleaning protocol.
40778346|NCT03496116|OTHER|ECIG Session|Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.
40778347|NCT02464748|OTHER|TiM telehealth arm|
40778348|NCT00314977|DRUG|Doxorubicin|doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
40983267|NCT04954781|COMBINATION_PRODUCT|TACE|TACE is performed by using drug-eluting beads. TACE treatment starts on day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator's decision.
40983268|NCT05156879|DRUG|Aspirin|75mg, one time/day
40983269|NCT05156879|DRUG|Drospirenone ethinyl estradiol|1 table/day, 21 consecutive days, 28 days as a cycle of use
40983270|NCT00786487|DRUG|20% lipid infusion|1.5 ml/min for 6 hours
40983271|NCT00786487|DRUG|glycerol|glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
41303921|NCT04904653|OTHER|Control group|No sealant (liquid, gel or patch) + suction drain
41462817|NCT03657238|DRUG|RD01|single S.C. dose of RD01 for subjects in test group
41462818|NCT03657238|DRUG|Placebo|single S.C. dose of placebo for subjects in placebo group
41462819|NCT04065061|DIETARY_SUPPLEMENT|Erinacine A-enriched Hericium Erinaceus Mycelia|
41462820|NCT04065061|DIETARY_SUPPLEMENT|Placebo|Placebo supplement was given to the participants.
40778349|NCT00314977|DRUG|Cyclophosphamide|Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
40778350|NCT00314977|DRUG|Docetaxel|Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
40778351|NCT02835690|BIOLOGICAL|Pembrolizumab|IV infusion
40983272|NCT00271609|DRUG|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
40983273|NCT01356966|DRUG|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
40983274|NCT01356966|DRUG|Placebo|2 placebo pills PO BID for12 weeks
40983275|NCT01356966|DIETARY_SUPPLEMENT|Folate|Folate 1 mg daily for 12 weeks
40983276|NCT03838133|DRUG|TLC590|TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients
40983277|NCT03838133|DRUG|Naropin®|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
40983278|NCT03838133|DRUG|Normal Saline|Normal Saline (0.9% sodium chloride, 10ml)
40983279|NCT03838133|DRUG|Bupivacaine|Bupivacaine 50 mg (0.5%, 10 mL)
40983280|NCT02528643|DRUG|Enzalutamide|Oral capsule
40983281|NCT02528643|DRUG|Placebo|Oral capsule
40983282|NCT00243789|DRUG|Pentoxifylline|"Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, \<30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day."
40983283|NCT03454750|DRUG|177Lu-PSMA|177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks
40983284|NCT05814887|DEVICE|ReLink|Medical device
40983285|NCT04421729|BEHAVIORAL|Group sessions over 3 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 6 sessions.
40983286|NCT04421729|BEHAVIORAL|Group sessions over 6 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 3 sessions.
40983287|NCT00706407|DEVICE|Fully integrated Uro-NIRS:UDS|As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
40983288|NCT02428660|GENETIC|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
41462821|NCT02343354|BEHAVIORAL|Nutrition/physical activity intervention|Please see arm description
41462822|NCT01359748|DEVICE|Reference sphygmomanometer|\* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
41462823|NCT01359748|DEVICE|Sphygmomanometer under test|Electronic Oscillometric method.
40778352|NCT05074914|PROCEDURE|oesophagectomy|removal of oesophagus
40778353|NCT00902330|PROCEDURE|energy-based therapy|Given once a day for 18 weeks
40778354|NCT00902330|PROCEDURE|sham intervention|Given once a day for 18 weeks
40778355|NCT03497377|DRUG|18F-DCFPyL Injection|
40778356|NCT03497377|DRUG|18F-NaF|
40778357|NCT00414154|BEHAVIORAL|Group based multidisciplinary patient education programme|
40778358|NCT02982226|OTHER|ReNu Injection|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
40778359|NCT02982226|OTHER|Corticosteroid Injection|Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
40778360|NCT00160563|DRUG|LEVOCETIRIZINE|5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
40778361|NCT00160563|OTHER|Placebo|Oral drops, bid for 18 months
40778362|NCT03162432|DRUG|Vitamin D3|Oral Vitamin D3 therapy.
40778363|NCT05058326|DIAGNOSTIC_TEST|Portable endoanal manometry|Endoanal manometry values will be obtained using de Anopress® device. Fecal incontinence severity questionaries will be filled and collected.
40778364|NCT05058326|DIAGNOSTIC_TEST|Endoanal ultrasound|To assess the integrity of the anal canal.
40778365|NCT05058326|OTHER|Incontinence severity scale questionaires|Wexner and St. Mark's scales.
40778366|NCT04622592|BIOLOGICAL|Instramuscular vaccine|On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
40778367|NCT04636996|OTHER|artificial intelligence assisted follow-up|We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process
40778368|NCT06489015|DRUG|Recombinant Human Serum Albumin|Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.
40983289|NCT02428660|OTHER|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
40983290|NCT02428660|OTHER|MTM|Medication Therapy Management
40983291|NCT04051762|DEVICE|High flow nasal cannula vs. Nasal continuous positive airway pressure|High flow nasal cannula
41462824|NCT05868824|OTHER|Blood sample|A blood sample for assessing cytokines will be performed at baseline and at follow-up visit 3 months after initiation of treatment. The blood sample will be performed as part of blood tests done for standard AD follow up.
41462825|NCT03935841|DIETARY_SUPPLEMENT|3-OHB salt (NaCl)|36 gram 3-OHB salt diluted in 500 ml sterile water
40778369|NCT06348095|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
40778370|NCT06348095|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
40778371|NCT00384943|BEHAVIORAL|Moderate-intensity Exercise|
40778372|NCT03098095|BEHAVIORAL|Physical Activity|Moderate physical activity
40778373|NCT03673176|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|The prescribed dose will be 45 Gy in three fractions of 15 Gy, on each side that is treated.
40778374|NCT06064487|DIAGNOSTIC_TEST|renal cell arrest and damage biomarkers assessment|measurement of TIMP2 and IGFBP7, KIM-1
40778375|NCT04106778|DRUG|DMT310|Topical Powder
40778376|NCT04106778|DRUG|Placebo|Placebo Topical Powder
40778377|NCT00370292|DRUG|Pemetrexed - Before Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
40778378|NCT00370292|DRUG|Pemetrexed - After Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
40778379|NCT02042287|DEVICE|Vaginal lactic acid and glycogen gel|Medical device (registration number: 10-355-717, first licensed 12.08.2010)
40778380|NCT02042287|DRUG|Metronidazole|Oral antibiotic
40778381|NCT02373592|BEHAVIORAL|SMS and voice messaging|"This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
40778382|NCT02373592|DEVICE|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
40778383|NCT02266160|DRUG|EMLA cream 5%|"the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days."
40778384|NCT02266160|OTHER|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
40778385|NCT00256126|DRUG|Saizen|Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
40778386|NCT00256126|DRUG|Saizen|Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
40778387|NCT05716945|DRUG|Fluorometholone 0.1% Oph Susp|"Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.~Year 2: Half the patients in each study arm will use FML 0.1% daily."
40778388|NCT05716945|DRUG|Dexamethasone 0.1% ophthalmic suspension|Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
40778389|NCT05716945|OTHER|Stop steroids|Half the patients in each study arm will discontinue steroids.
40778390|NCT05221008|DRUG|SHR6508；Placebo|Group A:SHR6508 low dose
40778391|NCT05221008|DRUG|SHR6508；Placebo|Group B:SHR6508 medium dose
40778392|NCT05221008|DRUG|SHR6508；Placebo|Group C:SHR6508 high dose
40778393|NCT05221008|DRUG|SHR6508；Placebo|Group D:SHR6508 high dose(single dose)
40778394|NCT06278493|DRUG|AL2846 capsules|AL2846 is a multi -target receptor tyrosine kinase inhibitor.
40778395|NCT06278493|DRUG|Gemzar|It is a chemotherapeutic drug.
40778396|NCT05804721|DRUG|Apipe (Aripiprazole10 mg)|Test drug
40778397|NCT05804721|DRUG|Abilify (Aripiprazole10 mg)|Reference drug
40778398|NCT00154349|DRUG|Imatinib Mesylate|
40778399|NCT04549467|DRUG|Lamivudine 300 MG|Experimental arm
40778400|NCT04549467|DRUG|Emtricitabine / Tenofovir Disoproxil Pill|Active Comparator
40778401|NCT04015804|OTHER|Clinical database|Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe
40778402|NCT05748002|OTHER|Pentacam and Corvis ST|morphological and biomechanical parameters of corneal were obtain by Pentacam and Corvis ST
40778403|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2|
40778404|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2|
40778405|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2|
41303922|NCT05868941|DEVICE|Broncho Muco Cleaner|"The endotracheal tube will be passed with a bronchoscope. During the procedure, the product is connected to the oxygen jack in the hospital, inflated and deflated, turning the thickened goblet cell layer that causes sputum production to foamy liquid. For the procedure, it will be entered through the intubation tube with a fiberoptic bronchoscope, and the airways with a diameter of 3 to 8 mm, primarily the airways, and all the respiratory tract mucosa that can be reached will be treated with a balloon in a total of 3 sessions. For these procedures, balloons selected in accordance with the diameter of the bronchi will be used in the respiratory tract.~In patients who meet the patient selection criteria, intervention will be made with a balloon that inflates and deflates at the determined frequency and pressure from the subsegment level that can be reached with the bronchoscope to the inner surface of the airways proximally."
41303923|NCT02380430|OTHER|ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
41303924|NCT06103695|DRUG|Tapinarof|Add on Vtama (tapinarof) to biololgic therapy
41303925|NCT03566524|DIETARY_SUPPLEMENT|Citrulline|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
41303926|NCT03566524|DIETARY_SUPPLEMENT|Alanine|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
41303927|NCT01701583|DRUG|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
41303928|NCT06125054|DRUG|Ketamine|single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)
41303929|NCT06125054|DRUG|Placebo|single dose of placebo (0.9% saline solution i.v. over 40 minutes)
41303930|NCT06125054|BEHAVIORAL|real-time fMRI neurofeedback training|Real-time fMRI based neurofeedback over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on an experimental region. The training is repeated twice.
41462826|NCT03631173|PROCEDURE|Surgical og radiological intervention, antibiotics|Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
40778406|NCT02422979|COMBINATION_PRODUCT|PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
40778407|NCT02422979|COMBINATION_PRODUCT|PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
40778408|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
40778409|NCT05015231|DIAGNOSTIC_TEST|Echocardiography and MRI|Echocardiography and renal MRI before and after fistula closure
40778410|NCT05497375|DIAGNOSTIC_TEST|The amount of intraoperative bleeding|Total amount of intraoperative bleeding will be calculated in milliliters after the end of surgery.
40778411|NCT05497375|DIAGNOSTIC_TEST|Quality of the intraoperative surgical field|Quality of the intraoperative surgical field will be measured on a grade of 0-10 (0-1. no bleeding, 2-3. mild bleeding, 4-5. Mild to moderate bleeding, 6-7. moderate bleeding, 8-9. moderate to severe bleeding, 10. Severe bleeding)
40778412|NCT05497375|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon Satisfaction will be measured on a grade of 0-5 (1= very bad, 2= bad, 3= moderate, 4= good, 5= very good).
40778413|NCT05497375|DIAGNOSTIC_TEST|Heart rate|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
40778414|NCT05497375|DIAGNOSTIC_TEST|Mean arterial pressure|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
40778415|NCT05497375|DIAGNOSTIC_TEST|Peripheral oxygen saturation|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
40778416|NCT05349734|OTHER|overbody blanket|applying overbody blanket with forced-air blower set to 43℃
40778417|NCT05349734|OTHER|underbody blanket|applying underbody blanket with forced-air blower set to 43℃
40778418|NCT00961038|DRUG|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
40778419|NCT00961038|DRUG|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
40778420|NCT00961038|DRUG|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
40778421|NCT00734448|DIETARY_SUPPLEMENT|myo-inositol|2 g twice a day until delivery
40778422|NCT01276704|DRUG|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
40778423|NCT01276704|DRUG|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
40778424|NCT04785209|OTHER|Mean platelet volume, lymphocyte number, STEMI clinical risk scores|Lab parameters
40778425|NCT06113861|DIAGNOSTIC_TEST|Quantiferon Gold|Test for TB infection
40778426|NCT06113861|DIAGNOSTIC_TEST|HIV serology|Test for HIV infection
41303931|NCT06125054|BEHAVIORAL|sham real-time fMRI neurofeedback training|Sham real-time fMRI neurofeedback training over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on a control region. The training is repeated twice.
41303932|NCT03229915|BEHAVIORAL|cognitive processing therapy|Group therapy for PTSD patients
40778427|NCT06113861|DIAGNOSTIC_TEST|Respiratory secretion culture (sputum or gastric aspirate_|TB culture by MODS
41303933|NCT01548898|DEVICE|Nd-YAG laser|All patients received 5 sessions (4 weeks apart) of long pulsed nd-YAG laser assisted hair removal on the affected area, emitting 1064 nm, with a fluence of 35-45 J/cm2 and pulse duration 10-30 msec adjusted to skin type and hair thickness. Laser was applied to all papules and plaques.
41303934|NCT06331065|OTHER|Information session on mindfulness meditation and questionnaires|"The information session on mindfulness meditation is an information meeting on the PROMIND study opened to all hospital professionals from the 8 participating departments, i.e. the intervention and control groups.~During this information session, it is specified that it is desirable for the non-intervention groups to maintain their usual practice (or non-practice) during the study, without starting a new practice of mindfulness meditation.~Before this meeting, the baseline questionnaires are administered. Immediately after this time, the questionnaire on representations of mindfulness meditation is administered."
41462827|NCT03080376|OTHER|Web-based intervention with support|Web-based combined aerobics and muscular strength exercises.
40778428|NCT06113861|DIAGNOSTIC_TEST|Chest radiograph|Chest imaging test by traditional X ray
40778429|NCT06113861|DIAGNOSTIC_TEST|Lung ultrasound|Chest imaging test by ultrasound
40778430|NCT06113861|DIAGNOSTIC_TEST|cell free DNA test|Blood test for TB infection
40778431|NCT06529432|DRUG|Bupivacaine Liposome Injection|Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose
41462828|NCT03080376|OTHER|Web-based intervention without support|Web-based combined aerobics and muscular strength exercises.
41462829|NCT03080376|OTHER|Traditional intervention|3 months of Printed-based combined aerobics and muscular strength exercise intervention.
41462830|NCT00735930|DRUG|Alvocidib Hydrochloride|Given IV
41462831|NCT00735930|DRUG|Lenalidomide|Given PO
40983292|NCT01447524|BEHAVIORAL|Very Low Calorie Diet|Very Low Calorie Diet consisted of a 400 kcal/day diet, with percentage distribution of lipids, proteins and carbohydrates, according to Italian Standards of Care.
40778432|NCT06529432|DRUG|Bupivacaine Hydrochloride Injection|Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose
41462832|NCT00735930|OTHER|Pharmacological Study|Correlative studies
41462833|NCT00735930|OTHER|Laboratory Biomarker Analysis|Correlative studies
40778433|NCT05266547|DEVICE|OCT guided coronary intervention|patients were divided into two groups,on OCT guided coronary group and coronary angiography guided group
40778434|NCT05006664|DRUG|Adcetris 50 MG Injection|Treatment by study drug Brentuximab Vedotin (Adcetris) in combination with CHEP.
40778435|NCT05006664|DRUG|Endoxan|Treatment by study drug Cyclophosphamide (Endoxan) in combination.
40778436|NCT05006664|DRUG|Doxorubicin|Treatment by study drug Doxorubicin in combination.
40778437|NCT05006664|DRUG|Etoposide|Treatment by study drug Etoposide in combination.
40778438|NCT05006664|DRUG|Prednisone tablet|Treatment by study drug Prednisone in combination.
40778439|NCT03247829|DEVICE|Hemodynamic management using CardioMEMS HF System|Using the CardioMEMS HF System, clinicians will treat to target PA pressure ranges
40778440|NCT02681393|BEHAVIORAL|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
40778441|NCT02681393|BEHAVIORAL|Brochure|Participants will receive both the Aerobic Exercise After Stroke educational brochure.
40778442|NCT01595087|DRUG|Osteodex|Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
40778443|NCT04793516|OTHER|VR Therapy Game|Participants will complete 15 sessions of VR-based therapy modules developed for use in helping people with spatial neglect. These 15 sessions will be completed over 4-5 weeks.
40778444|NCT04700150|OTHER|Tai Chi 2 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
40778445|NCT04700150|OTHER|Tai Chi 4 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
40778446|NCT00163098|DRUG|UK-369,003|
40778447|NCT00529360|DRUG|Clofarabine|Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
40778448|NCT00529360|DRUG|Clofarabine|Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
40983293|NCT01366560|DRUG|Active|GSK962040 125mg
40983294|NCT01366560|DRUG|Placebo|Matching Placebo
41462834|NCT00032240|DEVICE|Shoe Insert|
41462835|NCT00006228|BIOLOGICAL|trastuzumab|Given IV
41462836|NCT00006228|BIOLOGICAL|aldesleukin|Given SC
40778449|NCT05613556|DEVICE|Orpyx SI® Sensory Insole System|Orpyx SI Sensory Insole System consists of Orpyx Custom Insoles and Orpyx Sensory Technology. The Orpyx Custom Insoles are precisely fabricated for an individual's feet. The Orpyx Sensory Technology, a powered limb overload warning technology, is compatible with the Orpyx Custom Insoles. It is intended for monitoring physiological parameters, such as plantar pressure, motion and temperature, and providing real-time cues for pressure offloading as the patient goes about their daily activities
41303935|NCT06331065|DEVICE|Mindfulness meditation experimentation, practice program, questionnaires, individual interview and focus group|"After randomization, a mindfulness meditation trial session is offered to all professionals in the intervention group follow by the questionnaire on representations of mindfulness meditation administration.~Then, interdepartmental focus groups is conducted with leaders. The following mindfulness meditation program consists of 10 1-hour sessions within 15 days, in groups of up to 15 professionals, conducted at the participants' place and time of work, by a certified mindfulness meditation trainer with a recommended daily practice of 10-20 minutes with the possibility of a longer duration, and an audio guidance tool adapted to the study.~After the program, and 3 months later, questionnaires are administered for both groups.~For the intervention group, individual interviews, and inter-departmental focus groups (leaders) are carried out at the end of the intervention, and intra-departmental focus groups are conducted 3 months after the end."
41303936|NCT02252874|BEHAVIORAL|Slow-paced action video game|20 hours slow-paced action video games
40778450|NCT02375074|BEHAVIORAL|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
40778451|NCT02375074|BEHAVIORAL|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
40778452|NCT03563482|DIAGNOSTIC_TEST|PET scan|Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment
40778453|NCT04769206|DRUG|Galantamine|4mg daily titrating up to 8mg twice a day
40778454|NCT04769206|DRUG|Placebo|1 pill a day for 4 weeks, 2 pills a day for 8 weeks
41462837|NCT00006228|OTHER|laboratory biomarker analysis|Correlative studies
41462838|NCT00006228|OTHER|pharmacological study|Correlative studies
41303937|NCT02252874|BEHAVIORAL|Fast-paced action video game|20 hours fast-paced action video games
41303938|NCT02252874|BEHAVIORAL|Control|20 hours leisure activities
41462839|NCT04347330|DRUG|Intensive BP Control|Participants in the Intensive group have a goal of home SBP \<120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.
41462840|NCT04347330|DRUG|Standard BP Control|Participants in the Standard group has a goal of home SBP \<135 mmHg. The same principle of BP treatment in the Intensive BP arm will be used for the Standard BP arm. Medications will not be provided by the CRAFT study.
41462841|NCT01579006|DRUG|Tocilizumab|
40778455|NCT02258802|BEHAVIORAL|Psychoeducational intervention|A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
40778456|NCT01767909|DRUG|Insulin (Humulin® R U-100)|20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
40983295|NCT00353561|DRUG|Boric|Gelatin capsules filled with 600 mg of boric acid
40983296|NCT00353561|DRUG|Fluconazole|150 mg oral fluconazole gives once in 14 days
41462842|NCT02169791|DRUG|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
41462843|NCT02247076|BEHAVIORAL|Grazing|
41462844|NCT02247076|BEHAVIORAL|Time-restricted feeding (early eating)|
41462845|NCT01204125|DRUG|paclitaxel|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
41462846|NCT01204125|DRUG|Iniparib (SAR2405550 -BSI-201)|"Pharmaceutical form : solution for infusion~Route of administration :Intravenous"
41462847|NCT03473067|BEHAVIORAL|Social Norms Marketing Campaign|This poster based marketing campaign is designed to correct inaccurate perceptions of norms regarding violence.
41462848|NCT03473067|OTHER|Capacity Building|Schools will participate in teacher training and parent training.
41462849|NCT05086770|DEVICE|Gelatin microsphere (Nexsphere™)|Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
41462850|NCT05086770|DEVICE|Embosphere|Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
41462851|NCT04914247|DRUG|Selexipag|
40778457|NCT01767909|DRUG|Placebo|Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
41303939|NCT04718181|DRUG|risdiplam|Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
41303940|NCT04718181|DRUG|omeprazole|Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
40778458|NCT02219152|DRUG|tranexamic acid|
40778459|NCT02219152|DRUG|saline|
41462852|NCT04721496|BEHAVIORAL|Power and Speed|"Analysis of the power and speed of execution in 6 conditions of increasing instability Situation 1 is stable and basic execution. Condition 6 is the most unstable.~The participants performed 2 series of 3 repetitions in each of the situations. All the exercises were executed on the same day."
41462853|NCT00006009|BIOLOGICAL|visilizumab|
41462854|NCT04878237|OTHER|Nasal Secretion Sampling|Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)
40778460|NCT05958602|BEHAVIORAL|Technology|See previous response.
41303941|NCT02329873|BEHAVIORAL|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
40778461|NCT05958602|BEHAVIORAL|Standard DSMES Only|See previous response.
40778462|NCT05958602|BEHAVIORAL|Traditional Recruitment Methods|See previous response.
40778463|NCT05958602|BEHAVIORAL|CHW-Led Recruitment Methods|See previous response.
40778464|NCT00221767|DEVICE|Brindley technique (bladder system)|Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
41303942|NCT02801097|DRUG|RRx-001|
41303943|NCT02801097|DRUG|Irinotecan|
41303944|NCT02083510|DRUG|Colchicine|
41303945|NCT04420481|DRUG|Somatropin|Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.
41303946|NCT04420481|DRUG|Placebo|Placebo
41303947|NCT06222372|DRUG|Rifampin|antibiotic
41303948|NCT01797198|DRUG|ASP3652|Oral
41303949|NCT01797198|DRUG|Gemfibrozil|Oral
41303950|NCT01797198|DRUG|Repaglinide|Oral
41303951|NCT02932722|OTHER|Control|Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
41303952|NCT02932722|DRUG|Propofol|Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
41303953|NCT02932722|DRUG|Sevoflurane|Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
41462855|NCT03109327|DIAGNOSTIC_TEST|Melanoma Detection System -MDS|Imaging of lesion using the MDS test.
41462856|NCT04030338|DRUG|18F-DCFPyL-iPSMA|Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
41462857|NCT04030338|DRUG|68Ga-HBED-iPSMA|Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
41303954|NCT03212404|DRUG|CK-301 (cosibelimab)|CK-301 will be administered in periods of 28-day cycles.
41462858|NCT04030338|DIAGNOSTIC_TEST|PET/CT scan|The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed
41462859|NCT05956756|BEHAVIORAL|Health and resiliency programming|Students will engage in resilience programming as part of their regular coursework including mindfulness training, lifestyle medicine interventions, and creating a coping plan.
40778465|NCT02651480|DIETARY_SUPPLEMENT|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
40778466|NCT02651480|DIETARY_SUPPLEMENT|Control Group|Unrestricted diet with no instruction.
40778467|NCT02089204|RADIATION|FMISO-PET/CT|Fluorine-18-labeled fluoromisonidazole PET/CT-guided dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
40778468|NCT02089204|RADIATION|FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
40983297|NCT02637700|DRUG|Intravenous Immunoglobulin|Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
40983298|NCT02637700|DRUG|Placebo|Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
40983299|NCT01863225|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
40778469|NCT02089204|RADIATION|contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
41143492|NCT03771300|BEHAVIORAL|Relaxation|This condition is based on the Progressive Muscle Relaxation.The relaxation program include training 16 muscle groups during the initial sessions, 7 muscle groups during the intermediate sessions, 4 muscle groups later and a only recall relaxation in the final session.This program is complemented with visualizations, as it was originally proposed by Jacobson (1938).
41143493|NCT05159427|DRUG|Glucotrol XL 5Mg Extended-Release Tablet|Participants are randomized to take one tablet of this study drug by mouth.
41143494|NCT05159427|DRUG|Glipizide ER 5 MG 24 HR Extended Release Oral Tablet|Participants are randomized to take one tablet of this study drug by mouth.
40983300|NCT01863225|DRUG|Rosuvastatin|20 mg daily, 28-42 days
40983301|NCT01863225|DRUG|Atorvastatin|40 mg daily, 28-42 days
40983302|NCT01863225|DRUG|Rosuvastatin|40 mg daily, 28-42 days
40983303|NCT01863225|DRUG|Atorvastatin|80 mg daily, 28-42 days
40983304|NCT00390533|DRUG|Saredutant|oral administration (capsules)
40983305|NCT00390533|DRUG|Placebo|oral administration (capsules)
40983306|NCT03740958|DRUG|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA
40983307|NCT03740958|DRUG|Argatroban|100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
41143495|NCT05159427|DRUG|Rifaximin 200Mg Tab|Participants will take one tablet of this study drug by mouth.
41143496|NCT05159427|DRUG|13C6-Glipizide|Participants will take 1 mg of this study drug dissolved in 40 ml glucose solution by mouth.
40778470|NCT03200002|DRUG|Cyclophosphamide|Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
40983308|NCT05324995|DRUG|Multimodal Drug|The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally
40983309|NCT05324995|DRUG|epinephrine|The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary
40983310|NCT05324995|DRUG|celecoxib|The third group administered celecoxib (200 mg) orally immediately before the surgery
41143497|NCT04214457|PROCEDURE|Biopsy and peripheral blood collection|"After obtaining informed consent, the samples (tumor tissue and peripheral blood) will be collected at the time of surgery, which the patient had already planned by medical indication according to the usual clinical practice. Part of the sample will be sent to histopathology for gold standard diagnosis while the rest of the sample will be sent to Igenomix for molecular analysis.~If samples are available from patients who underwent surgery prior to the study, after they sign the Informed Consent, the samples will be sent to Igenomix for molecular analysis and the results obtained by histopathology will be collected from the patient's medical record."
41143498|NCT01107509|DRUG|everolimus|10 mg/ day everolimus in the form of an oral tablet for 12 weeks leading up to nephrectomy (with a 1-week perioperative washout period) in patients with locally advanced disease and re-initiating the drug postoperatively in patients with metastatic disease for up to 24 months, or until disease progression. Dosage may be reduced at any point to 5 mg/ day in the event of any grade 3/ 4 toxicity.
41143499|NCT03492177|DRUG|selexipag (Uptravi)|Film-coated tablets for oral administration
41143500|NCT01470209|DRUG|BKM120|BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
40778471|NCT03200002|DRUG|Mycophenolate Mofetil|Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count \<1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count \<1000/mm3.
40778472|NCT06400498|BEHAVIORAL|Prompted Palliative Care Consult|When a patient is randomized to the Palliative Care Consultation Prompt Group, a clinical decision support tool in the electronic health record will inform the treating clinician of the patient's serious illness and the results of the Surprise Question and prompt the treating clinician to consider a palliative care consultation. If the treating clinician feels a palliative care consultation would be indicated for the patient, the clinical decision support tool will facilitate the placement of a palliative care consultation by the treating clinician. If the treating clinician feels that a palliative care consultation would not be indicated, then the clinical decision support will record a reason it is not indicated.
40778473|NCT01429688|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
40778474|NCT00399035|DRUG|Cediranib|oral tablet
40778475|NCT00399035|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
40778476|NCT00399035|DRUG|XELOX (Capecitabine and Oxaliplatin)|intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)
40778477|NCT00399035|DRUG|Cediranib Placebo|oral tablet
40778478|NCT06357104|DEVICE|electroencephalogram biofeedback|EB is conducted for 20 minutes per section with two sections per day in the primary efficacy endpoint.
40778479|NCT06357104|DEVICE|electrical brain stimulation|EBS is conducted for 20 minutes per section per day in the primary efficacy endpoint.
40778480|NCT06357104|DEVICE|ultra-low frequency transcranial magnetic stimulation|ULF-TMS is conducted mainly for the left side of the participant's brain for 20 minutes per section per day in the primary efficacy endpoint.
40778481|NCT06357104|DRUG|Sertraline Hydrochloride|Sertraline is taken in the morning for 150 mg per day.
40778482|NCT06357104|DRUG|Clonazepam|Clonazepam is taken in the morning for 1 mg per day.
40778483|NCT06357104|DRUG|Alprazolam|Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.
41462860|NCT03434691|DEVICE|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
41462861|NCT03434691|DRUG|remifentanyl|Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
40778484|NCT06357104|DRUG|Metoprolol|Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.
40778485|NCT06357104|DRUG|Olanzapine|Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.
40778486|NCT06357104|DRUG|Pravastatin Sodium 20 MG|Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.
40778487|NCT06357104|DRUG|Sacubitril Valsartan Sodium Hydrate|Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.
40778488|NCT01144000|DRUG|Daptomycin|10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
40778489|NCT03791879|DRUG|Caudal dexamedatomidine analgesia|"Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg."
40778490|NCT00940602|DRUG|Deferasirox|Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
40778491|NCT00940602|DRUG|Placebo|Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
40778492|NCT01171911|DRUG|Nicardipine , Esmolol|A loading dose of Nicardipine 10mg was at a bolus injected through vein , then continuous trans-venous titration at a speed 1ug/kg was kept. A loading dose of Esmolol 0.5mg/kg/min was at a bolus injected through vein , then continuous trans-venous titration at a speed 0.2mg/kg/min was kept.
40778493|NCT02916264|PROCEDURE|a scalp block|Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
40778494|NCT01900366|PROCEDURE|Fat Biopsy|Fat biopsy
40778495|NCT00281593|DRUG|Telmisartan|
40778496|NCT00281593|DRUG|Ramipril|
40778497|NCT04994223|DRUG|Rivaroxaban 10 MG Oral Tablet [Xarelto]|rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival
40778498|NCT04966325|DRUG|LC350189 200mg|Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
40778499|NCT04966325|DRUG|Placebo|Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
40778500|NCT04966325|DRUG|Moxifloxacin 400mg|Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
40778501|NCT04966325|DRUG|LC350189 600mg|Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
41303955|NCT02155296|BEHAVIORAL|Restorative Practices Intervention|"RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults-RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building-RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building-As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension."
40778502|NCT00659282|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
41303956|NCT02600325|DRUG|Grazoprevir/Elbasvir 100mg/50mg|Grazoprevir/Elbasvir 100mg/50mg
40778503|NCT01142440|BEHAVIORAL|behavioral intervention|"* Dietary instructions~* Oral hygiene instructions: GC plaque indicator kit~* Antibacterial therapy: medident sol. one week a month, for 6 months~* Fluorides: VOCO Profluorid varnish, once every 3 month~* Restoration~* Follow ups"
40778504|NCT00649350|DRUG|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fed
40778505|NCT00649350|DRUG|Glucophage XR 750 mg|750mg, single dose fed
40778506|NCT00991809|DRUG|Alfentanil|15 mcg/kg IM
40778507|NCT00991809|DRUG|Diphenhydramine|25 mg IM
40778508|NCT01593917|DEVICE|Trifecta™ Valve|Aortic valve replacement with the Trifecta™ aortic bioprosthesis.
40778509|NCT03526263|PROCEDURE|Gastric mucosal devitalization|During routine laparoscopic sleeve gastrectomy surgery, once the greater curvature of the stomach is excised as per normal surgical technique, the investigators will take the specimen out and perform an ablation ex-vivo, with the intention of performing selective mucosal devitalization. This specimen will then be transported to pathology lab for analysis.
41303957|NCT01592890|DRUG|RO4917523|\[14C\]-labeled RO4917523, single oral dose
41303958|NCT01592890|DRUG|RO4917523|\[13C\]-labeled RO4917523, single intravenous tracer dose
40778510|NCT05973643|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (bitemporal) or unilaterally (or fronto-temporal) on the frontotemporal region under anesthesia.~The stimulation dose is determined by titration method, during the first ECT session. An ECT cure corresponding from 12 to 20 sessions of ECT. Patients will receive 2 sessions a week.~Blood samples will be done during the anesthesia process."
40778511|NCT02008617|DRUG|Bupivacaine|30mL of Bupivicaine 0.20% with epinephrine 1:300,000
40778512|NCT02008617|DRUG|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
40778513|NCT06131788|BEHAVIORAL|Educational hand hygiene intervention|The intervention combines training in hand-washing with the supply of a single-use alcohol-based hand rub, called MONO-RUB
40778514|NCT01229124|GENETIC|RNA analysis|
40778515|NCT01229124|GENETIC|nucleic acid sequencing|
40778516|NCT01229124|GENETIC|reverse transcriptase-polymerase chain reaction|
40778517|NCT01229124|OTHER|laboratory biomarker analysis|
40778518|NCT06372795|OTHER|pure effortful swallowing|"The investigator instructed the patient to swallow forcefully while squeezing the tongue upward and backward in the direction of the soft palate based on the sounds of an electronic timer."
40778519|NCT06372795|OTHER|progressive resistance swallowing training|Patients in the test group, resistance swallowing exercise was performed by providing external resistance through Iowa Oral Performance Instrument (IOPI), and all other protocols were performed the same as those in the control group.
40778520|NCT04897945|BEHAVIORAL|Shared decision-making for diabetes prevention|Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
40778521|NCT01098422|DEVICE|Yttrium-90 Radioactive Resin Microspheres|An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
40778522|NCT05784181|DEVICE|bipolar transurethral resection and Laser enaculation by holmium: YAG laser|Laser enaculation by holmium: YAG laser
40778523|NCT03190122|PROCEDURE|surgical excision of the tumor|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. \[NCT ID not yet assigned\]
40778524|NCT03306550|DRUG|salvianolate injection|The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
40778525|NCT03306550|DRUG|Aspirin Tablet|Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
40778526|NCT03899350|OTHER|No intervention|No intervention
40778527|NCT03218969|DRUG|Ecopipam|oral drug in subjection currently experiencing dopamine agonist induced augmentation
41303959|NCT03016442|DEVICE|Cook Double Balloon Catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination.İt is placed for 12 hours
41303960|NCT03016442|DRUG|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
41303961|NCT01977053|OTHER|Clinical and psychosocial phone calls|"The standard medical supervision is defined as follows:~* Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.~* Nominative notebook containing details of chemotherapy administered and medical contacts.~* Consultations with psycho-oncologist or psychiatrist (if necessary).~The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported."
40778528|NCT03218969|DRUG|Placebo|matching placebo
40983311|NCT06137716|DEVICE|Training with a Robotic Hand Exoskeleton|The rehabilitation program extended over six consecutive weeks. Each therapy session, lasting 45 minutes, occurred four times per week, resulting in a total of 24 sessions. Within each session, a total of six exercises, consisting of three passive exercises and three bilateral exercises, were performed in an alternating manner. The exercises were executed in the following sequence: 1) Bilateral hand opening and closing; 2) Passive independent finger opening and closing; 3) Bilateral pinch; 4) Passive hand opening and closing; 5) Bilateral hand opening and closing based on a VR-based game involving squeezing an orange; 6) Passive pinch.
41143501|NCT01470209|DRUG|Everolimus|RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
41143502|NCT00221988|DRUG|Levetiracetam (Keppra)|
41143503|NCT00044759|DRUG|Piperacillin/Tazobactam (Tazocin)|
41143504|NCT04884256|DRUG|CBT-004|Dose response study
41143505|NCT04012359|DIAGNOSTIC_TEST|Lung ultrasound|Non-invasive external ultrasonography of the chest wall
41143506|NCT04012359|DIAGNOSTIC_TEST|Chest radiography|Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax
41143507|NCT04012359|DIAGNOSTIC_TEST|Pulmonary function tests|Pulmonary function evaluation as part of routine care for emphysematous patients
41143508|NCT04012359|OTHER|Clinical examination|Standard clinical examination performed by investigating physician
41143509|NCT02868086|DEVICE|OCT B-scans|
41143510|NCT02868086|DEVICE|OCT angiography|
41143511|NCT03063021|DRUG|N-Acetyl Cysteine (NAC)|Oral tablets of N-acetyl-cysteine
41143512|NCT05303324|DRUG|ALXN1840|Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.
41143513|NCT02912104|BIOLOGICAL|human amniotic epithelial cells (hAECs) transplantation|hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 3×10\^7 hAECs in 4.5ml is separately injected into ovarian tissue by bilateral ovarian artery infusion.
41143514|NCT01742585|DRUG|ASP1585|oral
40778529|NCT01459120|OTHER|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
40778530|NCT01459120|OTHER|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (Pitso)."
40778531|NCT06165055|DIAGNOSTIC_TEST|DNA Sample Collection + DNA genotyping|Volunteers' oral epithelial cell DNA will be collected using DNA swabs, followed by DNA isolation with the PureLink DNA Isolation Kit. The isolated DNA's quality will be assessed using the Invitrogen QUBIT 4 Fluorometer, and the samples will be stored at -20°C until analysis of specific genetic regions.
40778532|NCT05329220|BIOLOGICAL|ABNCoV2|ABNCoV2 100μg single dose
40778533|NCT05329220|BIOLOGICAL|Comirnaty|Comirnaty
40778534|NCT05663060|DRUG|Probiotic Formula|Probiotic Formula
40778535|NCT05427292|OTHER|serratus anterior block and PECs II block combination|The pre-surgery block will be applied. Sensorial block will be evaluated at the surgical incision site with the pinpirick test at 30 minutes after the block, and if the block is successful, surgery will begin.
40778536|NCT01079312|DEVICE|infusion pump|anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level
40778537|NCT01079312|DEVICE|infusion pump for patient-controlled sedation|self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
40778538|NCT01079312|DRUG|propofol|Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
40778539|NCT01079312|DRUG|fentanyl|Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
41143515|NCT01742585|DRUG|placebo|oral
41143516|NCT06258304|DRUG|GIGA-564|Administered by intravenous infusion
41143517|NCT06258304|DRUG|GIGA-564|Administered by intravenous infusion
41143518|NCT01366352|DRUG|MNTX tablet (Formulation 1)|
41143519|NCT01366352|DRUG|MNTX tablet (Formulation 2)|
41143520|NCT04014452|PROCEDURE|Microwave ablation|Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
41143521|NCT04014452|PROCEDURE|Radiofrequency ablation|Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
41143522|NCT03425175|OTHER|Audio-recoring|Recording of audio through microphone carried bu surgeon and assistant surgeon
41143523|NCT01027455|DEVICE|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
41143524|NCT01027455|PROCEDURE|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
41143525|NCT01027455|PROCEDURE|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
41303962|NCT03698604|PROCEDURE|Hysterectomy|Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
41303963|NCT01897415|BIOLOGICAL|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1|
41303964|NCT03121183|DEVICE|Laser sheath|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
40778540|NCT01079312|DRUG|sedative mixture|Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
40778541|NCT01079312|DRUG|remifentanil hydrochlorid|Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
40778542|NCT04626726|DRUG|CD19 CAR-T|CD19 CAR-T infusion for patients with CD19 positive tumor cells
40778543|NCT04626726|DRUG|CD22 CAR-T|CD22 CAR-T infusion for patients with CD22 positive tumor cells
40778544|NCT04626726|DRUG|CD19+CD22 CAR-T|CD19+CD22 CAR-T infusion for patients with CD19 positive and CD22 positive tumor cells
40778545|NCT04626726|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
40778546|NCT04626726|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
40778547|NCT01470157|DRUG|Ketamine|5mg/kg as oral suspension
40778548|NCT01470157|DRUG|Normal Saline|Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
40778549|NCT01729039|BEHAVIORAL|standard balance rehabilitation|All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
41303965|NCT03121183|BEHAVIORAL|Implantable Cardiac Device lead extraction|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
40778550|NCT01729039|BEHAVIORAL|gaze stability|Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
40778551|NCT01729039|BEHAVIORAL|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
40778552|NCT02194413|PROCEDURE|therapeutic touch|receiving healing touch
40778553|NCT02194413|OTHER|quality-of-life assessment|Ancillary studies
40778554|NCT02194413|OTHER|questionnaire administration|Ancillary studies
40778555|NCT02427490|BEHAVIORAL|Problem-Solving Intervention|The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.
40778556|NCT02427490|OTHER|Unenhanced Monitoring|Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
40778557|NCT01668680|DRUG|CAPECITABINE, CELECOXIB and METHOTREXATE|daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
40778558|NCT06102395|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, on day1 of Q3W, 2 cycle
40778559|NCT06102395|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, IV, day 1 of Q3W
40778560|NCT06102395|DRUG|Carboplatin|Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W
40778561|NCT06102395|DRUG|Nedaplatin|Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W
40778562|NCT06102395|DRUG|Nab paclitaxel|Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W
40778563|NCT06102395|DRUG|Docetaxel|Docetaxel 75 mg/m\^2, IV, day 1 of Q3W
40778564|NCT06102395|DRUG|Liposomal paclitaxel|Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W
40778565|NCT06102395|DRUG|Fluorouracil|Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W
40778566|NCT00107575|BEHAVIORAL|Standard treatment plus brief alcohol intervention|Standard smoking cessation treatment with nicotine patch plus a brief alcohol-focused intervention
40778567|NCT00107575|OTHER|Standard treatment (ST)|Behavioral smoking cessation counseling and nicotine patch.
40778568|NCT04750421|DEVICE|Transillumination Venolux®|Transillumination Venolux® method was used on the other half of the face before injections to visualize veins.
40778569|NCT02660229|DRUG|Oxycodone Hydrochloride|Oxycodone injection
40778570|NCT02660229|DRUG|Morphine Sulphate|Morphine sulphate injection
40778571|NCT02854163|DRUG|Secukinumab|All eligible patients registered into the study will receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months
40778572|NCT01211561|DRUG|Selenium, selenomethionine|Patients will receive one 200 ug pill of Selenomethionine
40778573|NCT01211561|DRUG|placebo|Patients will be given one 200 ug placebo pill each day for 6 months
40778574|NCT05768191|DRUG|premix insulin human isophane suspension and insulin human|Sequence (Premix first, then Humulin N + Humulin R): Subjects randomized to this sequence will receive premix insulin, twice per day for 16 weeks. After the first 16 weeks, subjects will cross over to the Humulin N plus Humulin R sequence for a further treatment of 16 weeks
40778575|NCT05768191|DRUG|Humulin N plus Humulin R|Sequence (Humulin N + Humulin R first, then Premix): Subjects randomized to this sequence will receive basal bolus insulin scheme with Humulin N (twice daily) and Humulin R (before meals) for 16 weeks. After the first 16 weeks, subjects will cross over to the Premix sequence for a further treatment of 16 weeks
40778576|NCT00897026|DRUG|cyclophosphamide|
40983312|NCT05603689|DIETARY_SUPPLEMENT|Isocaloric ketogenic diet|The ICKD definition was based on the works of Sansone (2018) and Trimboli (2020). We defined ICKD as a daily CHOs ingestion \< 30 to 50 g.d-1, without any limitation in fat consumption. Participants self-selected their own diet based on a list of advised and forbidden foods developed to fit the definition of ICKD. There were no instructions to limit calories.
40983313|NCT04299412|DEVICE|DPP Fever Panel II assay|Multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect (i) antigens produced by Dengue, Zika, Chikungunya, Malaria and Burkholderia and (ii) IgM directed against Dengue, Zika, Chikungunya, Leptospira, Rickettsia typhi and Orientia tsutsugamushi. The assay comes with a reader that provides results interpretation to the operator in a few seconds
40983314|NCT02855216|OTHER|Manual technique of sub-occipital inhibition|
40983315|NCT02855216|OTHER|Self-treatment by way of Occipivot®|
40983316|NCT05787691|OTHER|Individualised pain management|"TPS pain management consists in an evaluation by a pain physician, followed by specific measures for patients identified as having a particularly high risk of CPSP. The choice of these measures will be individualised according to specific risk factors and left to the discretion of the pain physician.~Potential measures: patient education, adjustment of analgesic therapy, referral to a psychiatrist or psychologist, cognitive behavioural therapy, hypnosis, use of locoregional analgesia for surgery, infusions of ketamine and/or lidocaine, introduction of gabapentins and/or antidepressants."
41143526|NCT04681209|BEHAVIORAL|DRT Condition|"Children were asked to provide five descriptors of two children who each engaged in defending behaviors. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what friendship heroes are like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity."
40983317|NCT04688307|BEHAVIORAL|Motivational interviewing|Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight
40983318|NCT00386776|OTHER|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
40983319|NCT04099927|DRUG|SHR0410|SHR0410 monotherapy,given intravenously
40983320|NCT06126133|DEVICE|Near Infrared Spectroscopy|Two NIRS probes will be attached to the extremity to be operated on and to the other lower extremity on the opposite side, at a level approximately coinciding with the midline above the quandriceps femoris muscle.
40983321|NCT01382056|OTHER|control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
40983322|NCT01382056|OTHER|Mixed bean (higher amount)|0.6 cup of mixed beans consumed 5 days per week for 8 weeks
40983323|NCT01382056|OTHER|Mixed beans (lower amount)|0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
40983324|NCT05076526|BIOLOGICAL|Hyaluronic acid (Synolis VA)|"Synolis VA harbours the following characteristics:~* NaHA (Sodium hyaluronate): 20mg/mL, biofermantative and pharmaceutical grade origin.~* Sorbitol: 40mg/mL~* Molecular weight of 2MDa, sterilized in moist heat"
40983325|NCT05076526|BIOLOGICAL|Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)|"The CM-PRP-HA tube is under vacuum containing the following:~* 2mL of hyaluronic acid gel in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride and water for injection). Not crosslinked Hyaluronic Acid (40mg per tube) is obtained from fermentation~* 3g of inert cell-selector gel~* 0.6mL of anticoagulant (sodium citrate 4%)"
40983326|NCT06505031|DRUG|TAK-861|Oral tablet.
40983327|NCT06505031|DRUG|Placebo|TAK-861-matching placebo tablet.
40983328|NCT03316664|BEHAVIORAL|Integrated Neurocognitive Therapy (INT)|Information already included in arm/group description.
40983329|NCT03316664|BEHAVIORAL|Integrated Psychological Therapy (IPT)|Information already included in arm/group description.
40983330|NCT03316664|OTHER|COGPACK|Information already included in arm/group description.
41303966|NCT06105879|DEVICE|covered or open skin|transcutaneous mesarument of covered or open skin area
40778577|NCT00897026|DRUG|doxorubicin hydrochloride|
40778578|NCT00897026|DRUG|paclitaxel|
40778579|NCT00897026|GENETIC|fluorescence in situ hybridization|
40778580|NCT00897026|OTHER|immunohistochemistry staining method|
40778581|NCT01969734|DEVICE|Zephyr endobronchial valve placement|
40983331|NCT03297996|DIAGNOSTIC_TEST|Mobio PowerSoil DNA Isolation Kit|16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence
40983332|NCT02244489|DRUG|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
40778582|NCT03412929|DEVICE|Honey Impregnated Dressing|The investigational product being examined contains 100% Manuka honey and is ideal for difficult to dress wounds. The dressing provides a moist wound environment to help promote autolytic debridement. The dressing is ideal for partial or full thickness wounds with moderate-to-heavy drainage.
40983333|NCT02244489|DRUG|Capecitabine|Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
40983334|NCT02244489|DRUG|Oxaliplatin|Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.
40983335|NCT04006197|OTHER|laryngostroboscopy and histoh-pathology|videolaryngoscopy and laryngostroboscoby will be performed .the latter will be pathological in case of highly reduced or abolished amplitudes of vocal fold vibration and if there is reduction of mucosal wave propagation.also direct microlaryngoscopy under general anathesia will be done and excesional biobsy will be taken followed by histopatholpgical examination .the histological finding will be catagorized into the following categories according to (WHO): squamous cell hyperplasia with non dysplasia,mild dysplasia,moderate dysplasia,sever dysplasia,carcinoma in situ and squamous cell carcinoma.
40983336|NCT05766644|OTHER|Education|An 8-week program providing educational materials via a mobile app for chronic kidney disease management. Materials consist of videos, card news, and live online seminars with a Q\&A session. Topics are on general disease information, nutrition, and exercise.
40983337|NCT03992820|DEVICE|TENS machine|"The trial group will have the TENS to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
41143527|NCT04681209|BEHAVIORAL|Empathy Condition|Children in the empathy-based condition were asked to provide five descriptors of how two children who were bullied would fee. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what being bullied feels like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity.
41143528|NCT05563987|BEHAVIORAL|ACT-DE|The acceptance and commitment therapy is a psychological component to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the hexagonal model of ACT, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
41143529|NCT05563987|BEHAVIORAL|DE|DE
41143530|NCT01264874|DRUG|Vitamin D3 ( Colecalciferol)|100000 IU every 50 days for 3 years
41143531|NCT01264874|OTHER|placebo|For 3 years IU every 50 days
41143532|NCT01075854|DRUG|Gonal-F (Follitropin alfa)|Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
41143533|NCT04281355|PROCEDURE|Omission of axillary lymph node dissection|Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B
41143534|NCT04281355|RADIATION|Omission of regional irradiation|Regional irradiation will be omitted in the interventional arm of Randomisation A.
41143535|NCT01565031|PROCEDURE|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
41143536|NCT05658900|OTHER|Enucleation with albumin PRF|"The protocol that will be used in the preparation of albumin PRF~1. A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube.~2. The venous blood sample will be centrifuged at 700 g for 8 minutes.~   \* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P~3. The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel.~4. Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes."
41143537|NCT05658900|OTHER|Enucleation without albumin PRF|"The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity.~The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone.~Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst."
41143538|NCT01794689|DRUG|Morphine|0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
41143539|NCT01794689|DRUG|Saline Placebo|Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
41303967|NCT00972400|GENETIC|protein analysis|
41303968|NCT00972400|OTHER|laboratory biomarker analysis|
41303969|NCT00972400|OTHER|mass spectrometry|
41303970|NCT00972400|OTHER|questionnaire administration|
40778583|NCT05511948|DRUG|DBI-102|Topical application on dorsal hand and upper volar arm
40778584|NCT05511948|DRUG|Vehicle gel|Inactive comparator
40778585|NCT05511948|DRUG|Hydroquinone Cream|4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
40778586|NCT05871957|DRUG|Vitamin D Drops|Supplement 2000IU of vitamin D, no matter the brand or manufacturer for 1 month.
41303971|NCT00972400|PROCEDURE|assessment of therapy complications|
40983338|NCT03992820|COMBINATION_PRODUCT|EMLA cream|"The control group will have EMLA applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution (this is already a procedure practised by many of the surgeons).~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
40983339|NCT02592785|DRUG|BAY1163877|"Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose."
41462862|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).
40983340|NCT00490854|DRUG|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
41462863|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose_06 Group and ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose_01 Group, ABCWY high doseS_02 Group and ABCWY high doseS_06 Group in study Phase II (Sourcing).
41462864|NCT04886154|COMBINATION_PRODUCT|Placebo|Placebo is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose_06 Group, ABCWY low dose_02 Group, ABCWY high dose_06 Group, ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding).
40983341|NCT00490854|DRUG|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
40983342|NCT01744990|OTHER|Oral food challenges to multiple nuts|
40983343|NCT04528654|OTHER|Mobile Health Application|The participants will be given instructions to use their smartphone or tablet to download the hypertension tracking app. They will follow the instructions provided within the app and use it to track their blood pressure over the next six months.
41462865|NCT04886154|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly in the deltoid region of the non-dominant arm, whenever it's possible, as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
41462866|NCT04886154|BIOLOGICAL|MenACWY vaccine|MenACWY vaccine is administered intramuscularly in the deltoid region of the dominant arm as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
41462867|NCT01655251|BEHAVIORAL|Intervention|
40983344|NCT01230268|OTHER|Mulberry fruit extract|1000 mg oral daily dose for 2 weeks
40983345|NCT05894421|DRUG|TQB2223 injection+ Penpulimab Injection|TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
40983346|NCT05108831|DEVICE|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
40983347|NCT02821182|RADIATION|stereotactic body radiotherapy|"In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated \>48h and \<96h."
40983348|NCT00344747|BEHAVIORAL|dietary, behavioral, physical activity|
40983349|NCT05142865|DRUG|Camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
40983350|NCT05142865|DRUG|Etoposide|100mg/m2 IV continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
40983351|NCT05142865|DRUG|Carboplatin|AUC 5 mg/mL/min IV on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6)
40983352|NCT05142865|DRUG|Cisplatin|25mg/m2，continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
41143540|NCT01794689|BEHAVIORAL|Forced Awakenings|Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.
41143541|NCT01794689|BEHAVIORAL|Uninterrupted Sleep|Participants will receive an 8 hour period of undisturbed sleep
41143542|NCT03220815|PROCEDURE|Drilling at low speed|
41143543|NCT03220815|PROCEDURE|Conventional drilling at high speed|
41303972|NCT00972400|PROCEDURE|cognitive assessment|
41303973|NCT00972400|PROCEDURE|quality-of-life assessment|
41303974|NCT00597935|PROCEDURE|SSLF|sacrospinous ligament fixation (SSLF)
41462868|NCT04646525|DIAGNOSTIC_TEST|Physical examination|Pediatric patients diagnosed with COVID-19 and who have had infection will be examined, adenoid and tonsillar tissues will be evaluated in terms of hypertrophy, chronic, or recurrent infection.
40778587|NCT01820000|PROCEDURE|Diffusion Weighted Imaging with MRI scans|Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
40778588|NCT04321408|DRUG|Ziconotide Injection|Intrathecal analgesia with Ziconotide
40778589|NCT04577781|DRUG|GLPG3970|GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
41462869|NCT01845753|OTHER|Observation|Observation
41462870|NCT05567627|BIOLOGICAL|Genetic: GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
41462871|NCT02995564|BEHAVIORAL|social skills therapy|Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
40983353|NCT05142865|DRUG|Apatinib|250 mg given orally, once daily in 21-day cycle
40983354|NCT05608109|BEHAVIORAL|Alcohol personalized normative feedback (APNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.
40983355|NCT05608109|BEHAVIORAL|Social media personalized normative feedback (SMPNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.
40983356|NCT00137423|DRUG|SU011248 (sunitinib)|37.5 mg/day, oral, continuous daily dosing
40983357|NCT00847704|DEVICE|Assisted movement and enhanced sensation|Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
40983358|NCT02605707|DRUG|Intravenous stem cell transplantation|Intravenous injection of autologous endothelial progenitor cells transplantation
40983359|NCT02324374|DEVICE|Endocystoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
40983360|NCT02324374|DEVICE|Endocytoscope|The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.
40983361|NCT00260494|OTHER|acupuncture|standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.
40983362|NCT00260494|OTHER|sham acupuncture|standardized sham acupuncture at same sites as acupuncture.
40983363|NCT04366076|DIAGNOSTIC_TEST|Fetal heart rate (FHR) monitoring through computerized cardiotocography (cCTG) analysis antepartum|The investigator conducted antepartum surveillance through computerized cardiotocography (cCTG) analysis antepartum. This is a non-invasive method to study fetal well being. For each patient, a cCTG was attended using a computerized cardiotocography machine. External cCTG was practised for no less than 20 min (max 60 min), two transducers were fixed on the maternal abdomen: one above the fetal heart level and the other at the uterine fundus
41143544|NCT04261309|OTHER|Usual care|Since this is an observational study there will be no interference with the care given by the primary healthcare providers. However, the usual care provided by these and other healthcare utilization used by the patients during follow-up will be recorded during the follow-ups.
41143545|NCT00380809|PROCEDURE|Rotational Atherectomy + PES|
41143546|NCT00380809|PROCEDURE|Standard Treatment (PES without Rotational Atherectomy)|
41462872|NCT04648007|DIAGNOSTIC_TEST|Kaihani Score|Assessment of neuromodulatory chemicals in peripheral blood plasma samples.
41462873|NCT04219358|DRUG|Vehicle Gel Base|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and water."
41462874|NCT04219358|DRUG|Imiquimod 5% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and free form imiquimod 5%."
41462875|NCT04219358|DRUG|Imiquimod 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquimod 0.05% free form."
40778590|NCT04577781|DRUG|Placebo|Placebo powder and solvent for oral solution to be reconstituted prior to use.
40778591|NCT00688714|DRUG|AZD6482|0,9-364,5 mg administrated through intravenous infusion over 3 hours
41143547|NCT05440240|PROCEDURE|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
41143548|NCT05440240|DRUG|Corticosteroid injection|Depo-Medrol
41143549|NCT05440240|OTHER|Saline injection|Isotonic saline
41143550|NCT00670852|PROCEDURE|X-rays and CT scan|CT Scan x-rays
40778592|NCT00688714|DRUG|Placebo|
40778593|NCT04517435|DRUG|ME-401|ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
40778594|NCT04517435|DRUG|Rituximab|"375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines."
41143551|NCT01631409|OTHER|Treatment of CHD risk factors|Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
41303975|NCT00597935|PROCEDURE|ULS|uterosacral vaginal vault ligament suspension (ULS)
41303976|NCT00597935|BEHAVIORAL|PMT|Pelvic muscle training and exercises (PMT)
41462876|NCT04219358|DRUG|Imiquimod nanoencapsulated 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquomod in a nanoencapsulated suspension at concentration of 0,05%"
41462877|NCT04219358|DRUG|Lip sunscreen 30 Sun Protector Factor (SPF)|Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
41462878|NCT04219358|DRUG|Dexpanthenol|"Apply dexpanthenol on the lip, two (2) times a day, once in the morning and once in the afternoon.~Reduces transepidermic water loss and maintaining the natural smoothness and elasticity of the skin. It accelerates the cell renewal, rebuilds damaged tissues and promote the normal keratinisation of the skin and hair."
41462879|NCT01530906|PROCEDURE|Repetitive transcranial Magnetic Stimulation (rTMS)|10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.
41462880|NCT01530906|PROCEDURE|Repetitive transcranial Magnetic Stimulation SHAM|Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
41462881|NCT04773509|PROCEDURE|Paravertebral block|Randomly selected patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides.
41462882|NCT06010576|PROCEDURE|EUS-guided rendezvous|A linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
41462883|NCT06010576|PROCEDURE|Early precut papillotomy group|The precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
40778595|NCT04517435|DRUG|Cyclophosphamide|750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
40778596|NCT04517435|DRUG|Doxorubicin|50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
40983364|NCT02394847|DRUG|propofol|
41143552|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
41143553|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
41143554|NCT01631409|PROCEDURE|PCA|Percutaneous coronary angioplasty
41143555|NCT01631409|PROCEDURE|CABG|Coronary artery bypass grafting
41143556|NCT01631409|DEVICE|Cardiospec|Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
41143557|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril|In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
41143558|NCT03033056|BEHAVIORAL|Test of fear conditioning|Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
40778597|NCT04517435|DRUG|Vincristine|1.4 mg/m2 (max 2 mg) IV Vincristine
40778598|NCT04517435|DRUG|Prednisone|100mg PO Prednisone Days 1-5 of 21-day cycle
40778599|NCT04382092|DIAGNOSTIC_TEST|FilmArray Pneumonia|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
40983365|NCT03181087|OTHER|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
40983366|NCT04906044|DRUG|Sintilimab|Sintilimab combined withTotal Neoadjuvant Treatment
40983367|NCT01586169|DRUG|triple co administration at once of the combination of Albendazole + ivermectin + azithromycin|Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once
40983368|NCT00732147|DRUG|Pramlintide acetate|120 micrograms given subcutaneously before each meal X 3.
40983369|NCT00732147|DRUG|Placebo|120 micrograms given subcutaneously before each meal x 3.
41143559|NCT04258891|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2004 in European, North American and South American centers, who have estimated glomerular filtration rate and proteinuria follow-up and data from protocol and for cause biopsies for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow-up, clinical, biological and histological data.
41143560|NCT04693598|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
41143561|NCT02058992|DRUG|Ramelteon|Ramelteon 8 mg tablets
41143562|NCT06147115|OTHER|Assessment tool to determine severity of GI bleeding|The Rockall score is a validated mortality risk assessment for patients admitted with upper GI bleeding.
41143563|NCT06088199|DRUG|Apremilast|Oral tablet
41143564|NCT02779972|OTHER|Echo stress test|Echo stress test
41143565|NCT03132571|DRUG|Naltrexone|37.mg oral capsule taken once daily for over the course of the study (16 weeks)
41143566|NCT03132571|DRUG|Bupropion|Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
41143567|NCT03132571|OTHER|Placebo|Oral placebo taken once daily for the course of the study (16 week)
41143568|NCT02166723|DEVICE|Cryoballoon Ablation|. The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon
41303977|NCT05160701|OTHER|Medherent|Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.
41462884|NCT02370836|OTHER|Education|One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
41462885|NCT02940522|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
41462886|NCT02940522|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
41462887|NCT04876937|DRUG|Dexmedetomidine|Dexmedetomidine is infused at a rate of 0.1-0.2 μg/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
41462888|NCT04876937|DRUG|Placebo (normal saline)|Placebo (normal saline) is infused at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
41462889|NCT05296941|PROCEDURE|Brush sampling|Brush sampling instead of surgical biopsy for control of reaccurance
41462890|NCT05953506|DRUG|HS-10506|HS-10506 will be administered orally once on Day 1.
41462891|NCT05953506|DRUG|HS-10506 Placebo|Matching placebo will be administered orally once on Day 1.
40778600|NCT00650507|PROCEDURE|Remote ischemic preconditioning (RIPC)|The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
40778601|NCT00650507|PROCEDURE|SHAM|For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
40778602|NCT04322461|DIETARY_SUPPLEMENT|Betaquik MCT supplement|50g/day divided in 3. Breakfast, lunch and dinner
40778603|NCT03164161|DEVICE|Cold pressor test|Described before.
40778604|NCT03164161|OTHER|β-endorphins evaluation in saliva|Described before.
40778605|NCT03164161|OTHER|β-endorphins evaluation in blood plasma|Described before.
40778606|NCT02115087|PROCEDURE|ultrasound guided rectus sheath block|the application of rectus sheath block with ultrasound guidance
40778607|NCT02115087|DRUG|Morphine|
40778608|NCT00366457|DRUG|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
40778609|NCT00366457|DRUG|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
40778610|NCT00366457|DRUG|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
40778611|NCT00499837|DRUG|Aerosolized, human, plasma-derived Alpha-1 Antitrypsin|
40778612|NCT02572531|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge three times daily for 2 weeks
40778613|NCT02572531|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge three times daily for 2 weeks
40778614|NCT03243084|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
40778615|NCT03243084|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
40778616|NCT01101529|DRUG|Aprepitant (Emend)|Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
40778617|NCT01101529|DRUG|Placebo|Placebo will be administered instead of Emend
40778618|NCT00558818|DRUG|Clevudine|clevudine 30 mg qd
40778619|NCT01395134|DEVICE|Neuromonitoring|Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
40778620|NCT06205121|DRUG|OATD-01|OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)
40778621|NCT06205121|DRUG|Placebo|Matching placebo tablets
40778622|NCT02589821|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
40778623|NCT02589821|OTHER|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
41462892|NCT04012216|DEVICE|Measure of mandibular movement using a mid-sagittal magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium)|A mid-sagittal MM magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium) measures the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and on the chin. Measurements last one night.
41462893|NCT04012216|DEVICE|Gold standard: polysomnography|Polysomnography will be performed according to the American Academy of Sleep Medicine Recommendations 2018
41462894|NCT01830309|DRUG|CJ-12420 200mg|"Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition~Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition"
41462895|NCT01619956|DEVICE|SLA dental implants|Dental implant with surface modification.
41462896|NCT01619956|PROCEDURE|Osteotome sinus floor elevation|"After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre."
41462897|NCT01619956|PROCEDURE|Bone grafting|the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
41462898|NCT05358808|DRUG|TCB008|TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
41462899|NCT05603936|OTHER|Questionnaire|"The original QOLISSY questionnaire was first developed in 2011, it is available as a patient reported and a parent reported instrument. It includes:~* QoLISSY questionnaire for children and adolescents (8-12, 13-18 yrs)~* QoLISSY questionnaire for parents of children with short stature (4-7, 8-12 and 13-18 yrs) The QoLISSY instrument can be used to assess the health-related quality of life in short stature youth regardless of its cause; however it was specifically developed for patients with GHD and ISS and their parents.The aim of the current study is the adaption, implementation and validation of the instrument for the investigation of the short stature specific quality of life (QoLISSY) for children (age 0-4 years) with achondroplasia (ACH), Small for Gestational Age (SGA) and Growth Hormone Deficiency (GHD) from a parental perspective."
41462900|NCT02078011|DEVICE|High Intensity Focused Ultrasound|The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
41462901|NCT03856034|DEVICE|Fetoscopy|Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).
41462902|NCT03167216|DRUG|Cromolyn Sodium|Mast cell stabilizer
41462903|NCT03167216|DRUG|Cetirizine Hydrochloride|Histamine receptor antagonist
41462904|NCT01598545|DRUG|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
41462905|NCT03205501|DRUG|IV-administation of EMI-137|Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
41462906|NCT03205501|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
40778624|NCT02971371|DEVICE|Lokomat|"Both the groups performed 40 45min Lokomat sessions, five times a week, between 9am and 11am. The RAGTand VR group received a visual feedback showing a VR run game where the patient had to collect or avoid objects, to motivate him/her to walk actively. Each avatar's leg movement corresponded to that performed by the patient. On the other hand, the RAGT without VR group was not provided an avatar, and a smile indicating the goodness of each leg movement. The biofeedback of the Lokomat gait orthosis is based on the interaction torques between the participant and the orthosis"
40778625|NCT00429988|GENETIC|fluorescence in situ hybridization|
40778626|NCT00429988|GENETIC|polymerase chain reaction|
41462907|NCT00020839|DRUG|temozolomide|
41462908|NCT00020839|RADIATION|radiation therapy|
40778627|NCT00429988|GENETIC|proteomic profiling|
40778628|NCT00429988|OTHER|cytology specimen collection procedure|
40778629|NCT00429988|OTHER|immunohistochemistry staining method|
40778630|NCT00429988|PROCEDURE|breast duct lavage|
40983370|NCT05156489|DEVICE|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28±4) and at visit 4 (day 56±4) into vestibule, following the IFU of the device.
41143569|NCT02166723|DEVICE|cryoballoon ablation|A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
41462909|NCT04491916|DRUG|irone sucrose|drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
41462910|NCT05002881|OTHER|Moringa oleifera (E-HS-01)|One capsule to be taken stat
41462911|NCT05002881|OTHER|Placebo|One capsule to be taken stat
40778631|NCT02134184|BIOLOGICAL|Fluzone® 2012-2013 Formula NDC No 498281-012-50|This vaccine is given intramuscularly
40778632|NCT05305924|DRUG|Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
40778633|NCT01186757|DRUG|PF-03715455|PF-03715455 1.6 mg BID
41143570|NCT03620474|DRUG|PRI-724|twice a week for 4 hours continuous intravenous administration of PRI-724
40778634|NCT01186757|DRUG|PF-03715455|PF-03715455 4mg BID
40778635|NCT01186757|DRUG|PF-03715455|PF-03715455 10 mg BID
40778636|NCT01186757|DRUG|Placebo|Placebo
40778637|NCT05363592|DRUG|CT-L01 12.5/500 mg|FDC tablet, 2 tablets at a time, oral administration
40778638|NCT05363592|DRUG|Alogliptin Benzoate 12.5 mg|Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration
40778639|NCT05363592|DRUG|Metformin HCl XR 500 mg|Metformin HCl XR 500 mg 2 tablets, at a time, oral administration
40778640|NCT01146145|DRUG|Ketamine|intravenous morphine titration combined to ketamine
40778641|NCT05294887|DRUG|Bisoprolol|beta-adrenergic receptor blocker
41303978|NCT04867135|DRUG|Amikacin Sulfate Injection|The dose and frequency of amikacin was defined by each hospital.
41303979|NCT02708043|OTHER|Flexible-Laryngeal Mask Airway|
40778642|NCT05294887|DRUG|Diltiazem|calcium channel blocker
41303980|NCT01255397|PROCEDURE|Male Infertility Protocol|"1. Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.~2. Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.~3. When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.~4. 35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.~   1. If the follicle has collapsed than IUI will be performed~  2. It the total motile sperm count is above 5 million sperm/ml then IUI will be done~  3. If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI~6) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple."
41462912|NCT04734782|DIAGNOSTIC_TEST|Determination of antibodies in maternal serum IgG for respiratory syncytial virus|By venipuncture, a blood sample will be taken and the levels of anti-RSV IgG antibodies will be processed in serum by commercial techniques.
41462913|NCT02749591|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
41462914|NCT02749591|OTHER|Robot-assisted therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
41462915|NCT02749591|OTHER|Mirror therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
40778643|NCT05294887|DRUG|Placebo|Placebo
41462916|NCT02749591|OTHER|Control intervention|After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
41462917|NCT00973089|OTHER|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
41462918|NCT03098628|BIOLOGICAL|PCV Vaccine|PCV vaccination
41462919|NCT02156154|DRUG|Intravenous Acetaminophen|
40778644|NCT03144167|OTHER|Analysis of spectroscopic biomarkers of proliferation for six-month survival|Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
40778645|NCT04626102|BEHAVIORAL|Healthy Eating Attitudes and Behaviours Group Program (Experimental Group Condition)|"The program has been developed by Clinical Psychologist Başak İnce and Psychiatrist Prof. Dr Başak Yücel. The session topics and contents of this program were based on the Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and 10-week online version of StudentBodies program designed by Saekow and her colleagues (2015). Program protocol was written based on Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and Fursland and her colleagues (2007)'s book titled Overcoming Disordered Eating.~This program aimed to inform participants about the causes and consequences of eating disorders, teach cognitive and behavioural techniques to change their unhealthy eating attitudes and behaviours, and provide support during their attitudinal and behavioural changes. Each week, participants were asked to complete homework activities which were related to topics covered in each session."
40778646|NCT04626102|BEHAVIORAL|Eating Disorders and Body Dissatisfaction: A Group Work (Active Control Group Condition)|"This single-session group program was designed as an active control group for the purpose of this study. The content of the program was prepared based on Stice and his colleagues (2013)'s four - sessions Body Project eating disorders prevention program. This single-session program aimed to inform participants about causes and consequences of eating disorders, and discuss thin ideal messages created by media and the negative impact of these messages on women's body images, and address possible ways of countering these messages. Detailed information regarding the covered topics and video presentations in the group session is provided below."
40778647|NCT04906694|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
40778648|NCT04906694|DRUG|Placebo|Diluent solution
40778649|NCT05881707|DRUG|CKD-828, D064, D702|QD, PO
40778650|NCT01868828|DRUG|PAD|Induction Therapy of PAD for 4 cycles.
40778651|NCT01868828|DRUG|VCD|Induction Therapy of VCD for 4 cycles.
41143571|NCT04434872|PROCEDURE|Colonoscopy|Fecal microbiota transplantation through colonoscopy
40778652|NCT01868828|OTHER|ASCT|Not suitable for transplant patients will continue accept treatment for 8 cycles.
40778653|NCT01501357|BEHAVIORAL|modified toothbrush with multilevel filaments|After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
40778654|NCT01501357|BEHAVIORAL|cross toothbrushing|Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
41143572|NCT04434872|PROCEDURE|Gastroscopy|Fecal microbiota transplantation through gastroscopy
41143573|NCT04434872|DRUG|Fecal Microbiota|
40778655|NCT03023345|DEVICE|Microwave trans rectal focal treatment|Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration
40778656|NCT00744861|DEVICE|Exospine sham|Inactive Exospine LIPUS device (dual transducers)
40778657|NCT00744861|DEVICE|Exospine|Active Exospine LIPUS device (dual transducers)
40778658|NCT00744861|DEVICE|Exogen 4000+|Active Exogen LIPUS device (single transducer)
40778659|NCT00744861|DEVICE|Exogen 4000+ sham|Inactive Exogen 4000+ LIPUS device (single transducer)
40778660|NCT00205127|PROCEDURE|Cardiac PET imaging- rest and pharmacological stress|
40778661|NCT00427037|DRUG|Cholecalciferol|50,000 IU weekly by mouth
40778662|NCT00427037|DRUG|Placebo|identical placebo pill orally by mouth
41143574|NCT04434872|PROCEDURE|Enema|Fecal microbiota transplantation through enema
41143575|NCT04330573|OTHER|No intervention. Observational study|Observational study
41143576|NCT05798598|OTHER|Scientific writing training course|Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.
40778663|NCT06122441|BEHAVIORAL|Complex lifestyle intervention|The complex lifestyle intervention comprise high-intensity aerobic and strength exercise, behavioral counselling based on Acceptance and Commitment Theory (ACT), and dietary counselling based on Norwegian nutritional guidelines. The different intervention elements are introduced step-wise to reduce initial overload. Participants are progressively transitioned over to the Tromsø municipality and local NGO's, who delivers activities harmonized with the intervention elements. Participants are at this stage also supported by an eTool which digitally reinforces the intervention through web-based information and videos.
40778664|NCT06122441|BEHAVIORAL|Physical activity monitoring and recommendations|Wrist-worn activity trackers that are worn throughout the trial, which monitors steps, activity intensity and energy expenditure. Access to Norwegian physical activity guidelines via the Directorate of Health.
40778665|NCT02442050|OTHER|del Nido solution|1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
40778666|NCT02442050|OTHER|Blood-based cardioplegia|An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
40778667|NCT02002325|DRUG|Tissue-type plasminogen activator (alteplase)|Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
40778668|NCT02002325|OTHER|Standard care|Standard treatment for acute stroke without intravenous alteplase.
40778669|NCT02939755|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
40778670|NCT02939755|BEHAVIORAL|Enhanced Usual Care|usual care from health providers
40778671|NCT03322904|DIAGNOSTIC_TEST|iris photography|"The LF (0.04-0.15 Hz) and HF (0.16-0.4 Hz) ratings were recorded for 24 hours (day and night average) by Holter recording system~Photographs of both irises of the healthy volunteers were taken . An image software program was used to draw circular limits over the iris exterior circle (IEC), coloretta circle (CC), and pupil circle (PC) on digital photographs. The areas between the circles were measured. The likelihood that the IRIS ratio was equal to the LF/HF ratio was calculated using the formula \[IEC-PC¬\] - \[CC-PC\] / \[CC-PC\]."
40778672|NCT04868292|DRUG|SPR206|Three 100 mg SPR206 intravenous doses administered every 8 hours
40778673|NCT05820503|PROCEDURE|Ultrasound-guided lower abdominis rectus sheath block|Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally
40778674|NCT05820503|PROCEDURE|Local anesthesia infiltration|Local anesthesia drugs were injected into the peri-umbilicus cord
41143577|NCT04150016|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
41143578|NCT00966706|DRUG|capecitabine|Given systemically
41143579|NCT00966706|DRUG|cisplatin|Given systemically
41143580|NCT00966706|DRUG|docetaxel|Given systemically
41143581|NCT00966706|DRUG|epirubicin hydrochloride|Given systemically
40778675|NCT04962516|DEVICE|single-use precision filtered infusion sets|single-use precision filter infusion set (Dalian JMS Medical Apparatus Co., Ltd.)
40778676|NCT04962516|DEVICE|single-use precision filter infusion set with needle|single-use precision filter infusion set with needle (Shandong Zhongbao Kang Medical Apparatus Co., Ltd.)
40778677|NCT06142591|DRUG|Oxycodone 10mg|10mg of oxycodone was added to Octenisept in the wound dressing.
40778678|NCT06142591|DRUG|Oxycodone 20mg|20mg of oxycodone was added to Octenisept in the wound dressing.
40778679|NCT04847687|DRUG|methylprednisolone|Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.
40778680|NCT01837355|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|
40778681|NCT01837355|DIETARY_SUPPLEMENT|Placebo|
40778682|NCT00841139|DRUG|Perhexiline|100mg o bd
40778683|NCT00841139|DRUG|Placebo|1 tablet bd
40778684|NCT05644873|DRUG|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
40778685|NCT05644873|DRUG|control group saline|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
40778686|NCT04501432|OTHER|No intervention|This study does not include an intervention
40778687|NCT04781491|BEHAVIORAL|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Forest Therapy means mindful visits in nature, actively perceiving the flora and fauna
40778688|NCT00380926|DRUG|polyunsatturated fatty acids (fish oil)|
40778689|NCT05181345|OTHER|Sleep recording (at home)|Before both heat exposures, the sleep-wake rhythm will be measured at home for 7 days using actigraphy and a sleep diary that will have been given to him/her during the inclusion visit.
40778690|NCT05181345|OTHER|Heat exposure|"The subjects will be exposed twice (2 different visits) to heat (45°C; 60-70% humidity rate) for 3 hours in a climate chamber.~The subjects will be equipped with various external sensors allowing the continuous recording of core temperature, mean skin temperature (9 skin measurement points), heart rate, cerebral electrical activity, cerebral oxygenation, skin vascular conductance (blood flow by laser-doppler), blood pressure and skin conductance.~Neurophysiological and cognitive exploration (NPCE) includes the Stroop test, the Psychomotor Vigilance Task (PVT) and the odd-ball test."
41143582|NCT00966706|DRUG|gemcitabine hydrochloride|Given systemically
41143583|NCT03442998|OTHER|Suburban walk|Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
41462920|NCT05105919|DRUG|Aspirin 80 mg EC Tab|Participants will receive a 7 day supply of Aspirin 80 mg EC Tab and will be instructed to take the drug at the same time every day for 7 days.
40778691|NCT05181345|OTHER|Normal sleep|"The night before one of the two heat exposures (first visit for the Normal sleep first group and second visit for the Reduced sleep first group), the participants will have a normal night at home. The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
40778692|NCT05181345|OTHER|Sleep restriction|"The night before one of the two heat exposures (first visit for the Reduced sleep first group and second visit for the Normal sleep first group), the participants' sleep will be restricted. The sleep restriction will correspond to a reduced sleep period with a bedtime of 3 hours (04:00 - 07:00). This night of sleep restriction will be carried out in a sleep apartment (at the lab). The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
40778693|NCT03204760|DRUG|Dexamethasone 8Mg Solution for Injection|Effect single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) in the treatment of mild to moderate acute asthma exacerbations in children
40778694|NCT03204760|DRUG|Prednisolone Oral, Per 5 Mg|Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
40778695|NCT04145596|DRUG|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
40778696|NCT03490994|DRUG|Rivaroxaban|Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months
40778697|NCT03490994|DRUG|Warfarin + LMWH|dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated
40778698|NCT05870345|DEVICE|Butterfly IQ|Butterfly IQ is a pocket sized ultrasound device. Each participant will undergo a ultrasound exam of both elbows using a pocket sized ultrasound device.
40778699|NCT00172809|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 135 ug/week for 24 weeks
40778700|NCT00172809|DRUG|Interferon alfa-2a|Interferon alfa-2a 3 MU tiw for 24 weeks
40778701|NCT06186609|DRUG|PD-1 inhibitor 200mg per three to four weeks, for one year|"PD-1 inhibitor delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.~Radiotherapy:56-60Gy/28-30 fraction."
40778702|NCT05666830|DEVICE|Lando® artificial dermal regeneration matrix|Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
40778703|NCT05839925|DIAGNOSTIC_TEST|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I and II|The presence of temporomandibular joint dysfunction was evaluated using the diagnostic criteria for temporomandibular disorders (DC/TMD).
40778704|NCT01428791|BEHAVIORAL|Generations older adult membership program|"Rush Generations is a membership program for older adults emphasizing chronic disease prevention and management through a wide range of health and aging-related programs. Participants assigned to the Generations intervention are actively encouraged to participate in activities, including:~• RUSH-based lectures by experts in the fields of health and aging providing practical information and resources on physical and mental health, functional status, and social support. • Individual and family consultations with social work staff. • Health fairs with a variety of assessment services and information about community-based social service and health agencies. • Assistance with referral to community programs such as physical activity, driver safety events, and mind-body connection workshops."
40778705|NCT01428791|BEHAVIORAL|BRIGHTEN Heart Virtual Team intervention|"BRIGHTEN Heart provides an interdisciplinary team evaluation of physical and mental health and on-going support for mental health \& health behavior change for 6 - 12 months, including:~• Comprehensive health risk assessment by a licensed social worker, including physical, mental, and functional status. • Virtual team case review and recommendations by interdisciplinary team including psychologist, social worker, occupational therapist, pharmacist, chaplain, dietitian, geriatric psychiatrist, and patient's primary care physician. • Development of Patient Centered Action Plan, in which the social worker assists the patient in prioritizing recommendations. • Monthly telephone calls by the social worker to support implementation of Action Plan and Case Management. • Evidence Based Psychotherapy, as needed, delivered by supervised geriatric psychology and social work fellows."
40778706|NCT02862574|DRUG|Andecaliximab|Administered via subcutaneous injection once weekly
40778707|NCT02862574|DRUG|Placebo|Administered via subcutaneous injection once weekly
40778708|NCT02862574|DRUG|Methotrexate|Administered orally weekly as part of the participant's current treatment regimen
41462921|NCT01733576|DEVICE|HD-tDCS|
41462922|NCT05735028|DRUG|Centipeda minima+PD-1/PD-L1 inhibitor|Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
40778709|NCT02862574|DRUG|TNF Inhibitor|An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
40778710|NCT03220438|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
40778711|NCT06127238|DRUG|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
40778712|NCT05931731|OTHER|Mechanical interference|The patients will receive mechanical interference treatment in the form of five techniques, including wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, the release of palmar hand fascia, gliding of the finger flexor tendons (using the oscillatory flexion-extension movement of the metacarpophalangeal joint) and release of the upper forearm muscle and fascia were applied. Manual techniques were performed total of 15 minutes in each session each technique included 3 sets for 3 minutes and conventional treatment
40778713|NCT05931731|OTHER|Neural mobilization|the patients will receive neurodynamic mobilizations, including sliding techniques and tensioning techniques which are thought to enhance ulnar nerve gliding and restore neural tissue mobility and conventional treatment
40778714|NCT05931731|OTHER|conventional treatment|the patients will receive therapeutic ultrasound (frequency of 1 MHz, intensity of 1 W/cm2, for 5 minutes), transcutaneous electrical nerve stimulation (TENS) (frequency of 80 Hz, pulse duration of 60 μs, at the level of comfortable tingling sensation, for 20 minutes) and therapeutic exercises.
40778715|NCT01761578|DEVICE|ART18Z Bioresorbable stent|The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
40778716|NCT01816984|DRUG|PI3K inhibitor BKM120|Given PO
41462923|NCT05735028|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor
40778717|NCT01816984|BIOLOGICAL|cetuximab|Given IV
40778718|NCT00451737|DEVICE|Isokinetic test|
40778719|NCT05381480|BEHAVIORAL|In-home Preventive Health Visits by Advanced Practice Nurse|Elements of Comprehensive Geriatric Assessment used as a preventive, health risk assessment, with recommendations tailored for health risks identified and offered to building tenants
40778720|NCT05381480|BEHAVIORAL|On-site Evidence-based Physical Activity, Health and Wellness Classes|Weekly calendar of health promotion and injury/illness prevention classes offered to building tenants.
40778721|NCT05393700|BEHAVIORAL|Action Observation Therapy|Action Observation Therapy implies the observation of video-clips representing motor tasks alone or followed by imagination and/or imitation of observed tasks.
41462924|NCT04949386|DRUG|S-1226 (8%)|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.
40778722|NCT01306292|DRUG|SonoVue|dose of 4.8 mL administered intravenously one time
40778723|NCT01306292|DRUG|Placebo|Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
40778724|NCT03593148|OTHER|Lifestyle|Lifestyle treatment
40778725|NCT02283034|DEVICE|The CPRmeter|Feedback device - 1
40778726|NCT02283034|DEVICE|The PocketCPR|Feedback device - 2
40778727|NCT02283034|DEVICE|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
40983371|NCT02499250|DEVICE|remote ischemic conditioning (TDFT-12-A2)|"The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd."
40983372|NCT02499250|DRUG|Optimal medical treatment|The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
40983373|NCT00876772|DRUG|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
40983374|NCT03729856|BEHAVIORAL|intervention|The adapted physical activity (APA) intervention is a theory-based physical activity (PA) promotion intervention. The APA model is comprised of 4 steps: 1) pre-participation evaluation of physiological, personal and environmental factors that influence PA adoption and maintenance; 2) application of individualised, evidence based strategies associated with increased PA participation tailored to the participant's motivational readiness; 3) development of structured exercise and/or lifestyle PA program; and 4) tailored relapse prevention strategies to maintain physical activity beyond the duration of the program. The intervention will be conducted in the participant's home environment.
40983375|NCT03729856|OTHER|B|Participants will undertake their usual activities during the baseline period. An extended pre-intervention time frame is needed to establish a stable control phase and enhance internal validity.
40983376|NCT03729856|OTHER|Follow-up|Participants will have no contact with intervention personnel during the 5 week follow-up, withdrawal period. The withdrawal phase enables initial assessment of physical activity behavior change.
40983377|NCT03396614|DIAGNOSTIC_TEST|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram
41303981|NCT02575079|DEVICE|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
41303982|NCT03463694|OTHER|Na Cl solution|\~2.6% NaCl solution prepared from sea salt
41462925|NCT04949386|OTHER|Placebo|Placebo will delivered by inhalation of saline (0.9% NaCl) and Medical grade air.
41462926|NCT02738216|BEHAVIORAL|Prenatal Yoga|As part of the yoga program, participants will be asked to go to one 75-minute prenatal yoga class each week for 9 weeks. The yoga classes will be designed to be safe for pregnant women. In addition to classes, the yoga teacher will ask them to practice yoga at home during the program. Each participant will be given a yoga mat and a prenatal yoga DVD to take home.
40778728|NCT02283034|DEVICE|The CPREazy|Feedback device - 3
41303983|NCT04438603|DRUG|Intervention for incipient patients at low risk of disease progression|Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of \< 130/80 mm Hg
41462927|NCT02738216|BEHAVIORAL|Mother Baby Wellness|This workshop is aimed at promoting moms' and babies' good health and will involve attending one 75-minute class each week for 9 weeks. Classes will cover topics such as: child development in the first year, child eating and sleeping in the first year, maintaining good health as a mom of an infant, and recent advances in women's healthcare. In addition to classes, participants will be given materials to review/ read at home.
41462928|NCT02382601|RADIATION|Ultrasound|With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
41462929|NCT02382601|RADIATION|MRI|Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
40778729|NCT02283034|DEVICE|The CPR PRO APP|Feedback device - 4
40778730|NCT02283034|DEVICE|The CardioPump|Feedback devices - 5
40778731|NCT02283034|DEVICE|Standard BLS|Chest compressions without CPR feedback device (manual resuscitation)
40778732|NCT01394159|PROCEDURE|22G ProCore biopsy needle|Tissue will be acquired with the 22G Procore biopsy needle and the sample will be compared to the sample obtained with the 22G standard FNA needle.
40778733|NCT01394159|PROCEDURE|22G standard FNA needle|Tissue will be acquired with the 22G standard FNA biopsy needle and the sample will be compared to the sample obtained with the 22G ProCore biopsy needle.
40778734|NCT05941286|DEVICE|CGM system with both glucose predictive alerts and threshold alerts on|the cloud-based real-time continuous glucose monitoring and management system with both glucose predictive alerts and threshold alerts on
40778735|NCT05941286|DEVICE|CGM system with only glucose threshold alerts on|the cloud-based real-time continuous glucose monitoring and management system with only glucose threshold alerts on
40778736|NCT05941286|DEVICE|CGM system with glucose alerts off|the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts off
40778737|NCT03942224|DRUG|Bortezomib|Given SC
40778738|NCT03942224|BIOLOGICAL|Daratumumab|Given IV
40983378|NCT03522974|DIETARY_SUPPLEMENT|Strawberry powder|Freeze dried strawberry powder
40983379|NCT03522974|DIETARY_SUPPLEMENT|Placebo powder|40 g/d placebo powder matched for taste and appearance
40983380|NCT00503009|DRUG|fluticasone propionate/salmeterol|comparator
40983381|NCT00503009|DRUG|fluticasone propionate|Comparator
40983382|NCT00503009|DRUG|placebo|Placebo
40983383|NCT01313767|DRUG|Botulinum toxin type A|Botulinum toxin type A
40983384|NCT01313767|DRUG|Botulinum Toxin type A|Botulinum Toxin type A
40983385|NCT05434182|PROCEDURE|Intradermal Suture|Skin closure with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
40983386|NCT05434182|PROCEDURE|Metallic Staples|Skin closure with metallic stapling using Visistat® (Weck®) 35W skin stapler.
40983387|NCT06297733|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the inventory and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
40983388|NCT06297733|OTHER|Validity|The inventory will be applied by face-to-face technique and convergent validity will be evaluated. Construct validity will be evaluated through exploratory and confirmatory factor analysis. Coefficients of fit will be calculated.
41462930|NCT02382601|PROCEDURE|Blood collection|The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
41462931|NCT02382601|BEHAVIORAL|Neurological Function Assessment|Neurological development tests including a Bayley exam, Mullen exam, Developmental Profile-3, Child Behavior Checklist, and Pediatric Stroke Outcome Measure (PSOM) will be performed.
41462932|NCT02382601|PROCEDURE|Placental Analysis|Placentas will undergo pathological evaluation for placental function.
41462933|NCT02382601|PROCEDURE|Measurement of body fat|The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
41462934|NCT02382601|RADIATION|Pediatric heart ultrasound|Children will have ultrasounds of their hearts during follow-up visits.
40983389|NCT06297733|OTHER|Reliability|The reliability of the items will be tested with Cronbach alpha. Test-retest reliability will be measured by ICC.
40983390|NCT01337947|DRUG|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
40983391|NCT06380842|OTHER|Necrotizing Pancreatitis patients' organ dysfunction progression|Study the dynamic nature of organ dysfunction
40983392|NCT01279551|DRUG|0.4% nitroglycerin ointment|Local endoanal application 2 times a day
40983393|NCT01279551|DRUG|lidocaine cloridrato 2.5% ointment|Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
40983394|NCT01547000|DRUG|placebo|Administered up to 8 weeks.
40983395|NCT01547000|DRUG|extended-release guanfacine (Intuniv)|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
41462935|NCT00416468|DRUG|Aliskiren|
40778739|NCT03942224|DRUG|Dexamethasone|Given IV and PO
40778740|NCT03942224|DRUG|Ixazomib|Given PO
40778741|NCT00265850|BIOLOGICAL|bevacizumab|Given IV
40778742|NCT00265850|BIOLOGICAL|cetuximab|Given IV
40778743|NCT00265850|DRUG|FOLFOX or|Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours
40778744|NCT00265850|DRUG|FOLFIRI|Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
40778745|NCT00473174|DRUG|Ramipril|Dosing on awakening versus bedtime
40778746|NCT00473174|DEVICE|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
40778747|NCT00618761|OTHER|hyperglycemic clamp test|hyperglycemic clamp test
40778748|NCT05282121|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
40983396|NCT03009435|OTHER|prophylactic manual rotation|
40983397|NCT03264495|OTHER|Weight the food served minus the left-overs|
40983398|NCT03827304|DEVICE|Virtual Reality Distraction from Burn Pain|Patients wore a VR headset while undergoing a burns dressing change
40983399|NCT00735592|OTHER|Observational|Retrospective data obtained from electronic files
40983400|NCT05570565|PROCEDURE|Erector spinae plane block|ultrasound guided injection of local anesthestics drugs (mixture of lidocaine and bupivacaine) in the Erector spinae plane which lies between the Erector spinae muscle and lumbar transverse process
40778749|NCT05282121|DRUG|Empagliflozin|Empagliflozin
40983401|NCT05570565|PROCEDURE|local field block|infiltration of local anesthestic drugs( mixture of lidocaine and bupivacaine) in the surgical field before surgical incision
40983402|NCT01051050|BEHAVIORAL|Mandatory use of surgery wiki|Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.
40983403|NCT01051050|BEHAVIORAL|Voluntary use of the surgery wiki|Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
40983404|NCT00412022|DRUG|tamoxifen|20 mg daily for 5 years
41462936|NCT00416468|DRUG|Valsartan|
40983405|NCT00412022|DRUG|triptorelin|Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55
40983406|NCT00412022|DRUG|letrozole|2.5 mg daily for 5 years
40983407|NCT00412022|DRUG|zoledronic acid|4 mg every 6 months
40983408|NCT06407544|PROCEDURE|peripheral nerve block|peripheral nerve block guided by ultra sound through Ultrasound-guided quadratus lumborum block versus FICB or fascia iliaca block
40983409|NCT06407544|DRUG|PCA device as rescue medication with IV morphine 1mg if VAS more than 4|PCA device as rescue medication with IV morphine 1mg if VAS more than 4 with a 10 min lock-out time
40983410|NCT02518828|OTHER|High SpO2|SpO2 range ≥96%
40983411|NCT02518828|OTHER|Low SpO2|SpO2 range 90-92%
40983412|NCT01084174|DRUG|Peanut powder|Delivered orally
40983413|NCT01084174|DRUG|Peanut extract|Delivered sublingually
40983414|NCT01084174|DRUG|Placebo extract|Delivered sublingually
40983415|NCT01084174|DRUG|Placebo powder|Delivered orally
40983416|NCT03394092|DIAGNOSTIC_TEST|Quantitative measurements the changes of IgG glycosylation|Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
41462937|NCT03941080|DIAGNOSTIC_TEST|fecal sample|patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.
41462938|NCT03941080|BEHAVIORAL|questionnaire|At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
40778750|NCT06362109|BEHAVIORAL|Routine rehabilitation|"Routine rehabilitation consists of:~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
40778751|NCT06362109|DEVICE|Intermittent Oro-esophageal Tube Feeding|The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
40983417|NCT03518073|DRUG|Zagotenemab|Administered IV
40983418|NCT03518073|DRUG|Placebo|Administered IV
40983419|NCT01519960|DRUG|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
41462939|NCT03941080|DIAGNOSTIC_TEST|Blood sample|4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.
41462940|NCT02910024|DEVICE|Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol|iTBS applied over ipsilesional M1
41462941|NCT02910024|DEVICE|Magstim Super Rapid2 System, sham-stimulation (in iTBS)|iTBS applied with tilted coil over parieto-occipital vertex
41462942|NCT02818296|BEHAVIORAL|Active IU CBM-I|
41303984|NCT04438603|DRUG|Intervention for patients at high risk of disease progression|"BP-lowering goal of \< 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:~1. If GFR\>60 ml/min/1.73m\^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.~2. If GFR is 30-60 ml/min/1.73m\^2, intravenous cyclophosphamide (CTX) 750 mg per month per m\^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks."
41462943|NCT02818296|BEHAVIORAL|Control CBM-I|
40778752|NCT00938301|DRUG|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
40778753|NCT00938301|DRUG|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
40778754|NCT04088292|DRUG|Alteplase 20 Mg Powder for Solution for Injection Vial|Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
40778755|NCT04088292|DEVICE|Ultrasound assisted Thrombolysis|Ultrasound assisted thrombolysis (USAT)
40778756|NCT03525509|DRUG|Methadone hydrochloride|Epidural bolus of 4mg of preservative free methadone hydrochloride (4mL of 1mg/mL solution)
40778757|NCT03525509|DRUG|Morphine Sulfate|Epidural bolus of 4mg of preservative free morphine sulfate (4mL of 1mg/mL solution)
40778758|NCT00002487|DRUG|dipyridamole|
40778759|NCT00002487|DRUG|methotrexate|
40778760|NCT04815863|DIAGNOSTIC_TEST|Assessment of somatic symptom disorder with SSS-CN|SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms
40778761|NCT04815863|DIAGNOSTIC_TEST|Assessment of depressive symptoms disorder with PHQ-9|PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms
41303985|NCT02338076|DRUG|Petrolatum application under occlusion|"Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)~1 well will be empty and the other well will contain petrolatum~Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch~1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)"
40778762|NCT04815863|DIAGNOSTIC_TEST|Assessment of anxiety disorder with GAD-7|GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder
40778763|NCT01101607|PROCEDURE|Distal Forearm Fracture Reduction|Fracture reduction
40778764|NCT02016521|OTHER|Cooling Fabric|Garment made of 100% nylon and consisting of long sleeved shirt and full trouser.
40778765|NCT02016521|OTHER|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser
40778766|NCT04497714|DIAGNOSTIC_TEST|Ultrasonic image collection|Ultrasonic image collection,consist of three static images and one dynamic image
40778767|NCT05469919|DRUG|Ceralasertib|Ceralasertib taken orally
40778768|NCT00786422|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
40778769|NCT04287972|PROCEDURE|DPC|The anterior fat pad is dissected until the left crura is visible, pars flaccida is open and the right crura exposed. Phreno-oesophageal ligament is sectioned starting from the right crura. Posterior and anterior vagal nerve are recognized before the oesophageal dissection. An intra-abdominal oesophagus lengths of 2 or 3 cm is obtained in order to reduce tension. Left and right crura are sutured with 2 or 3 non absorbable 2-0 stitches; an additional anterior stitch is posed if necessary to calibrate hiatus size without oesophageal deviation.
41303986|NCT03124615|DRUG|Enzalutamide|Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
40778770|NCT04287972|PROCEDURE|LSG|After omental section close to gastric insertion, gastric stapling is realised with triple line endo stapler (normally 5 or 6 re-loads). The gastrectomy begins 5-6 cm from the pylorus; gastric fundus is totally resected keeping a distance of 5-10 mm from oesophagus. Any bleeding on staple line is controlled with surgical clips or coagulator.
40778771|NCT03554655|DEVICE|Momentum app|The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
40778772|NCT05469178|DRUG|Bemcentinib|Bemcentinib capsules will be administered orally.
40778773|NCT05469178|DRUG|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as part of CIT every 3 weeks.
40778774|NCT05469178|DRUG|Pemetrexed|Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
40778775|NCT05469178|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks.
40778776|NCT00918619|DEVICE|Sangustop|Application of Sangustop haemostatic agent on resection area
40778777|NCT00918619|DRUG|Tachosil|Application of Tachosil fibrin sealant on resection area
41303987|NCT06036433|DEVICE|Infrared laser photobiomodulation device|904 super pulsed Infrared laser PBM therapy for the treatment of the signs and symptoms associated with Parkinson's, such as improved motor, non-motor and Quality of Life.
41303988|NCT06036433|DEVICE|Infrared & Red LED photobiomodulation device|Infrared \& red LED therapy for the treatment of the signs and symptoms associated with Parkinson's, such as motor, non-motor and Quality of Life.
41303989|NCT01601054|DEVICE|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
41303990|NCT02269111|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
41303991|NCT02269111|PROCEDURE|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
41303992|NCT02269111|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
41303993|NCT02269111|PROCEDURE|dynamic susceptibility contrast-enhanced magnetic resonance imaging|Undergo DSC-MRI
40983420|NCT01519960|DRUG|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
40983421|NCT02374554|DEVICE|Structured Light Plethysmography (Thora-3Di)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
40983422|NCT02374554|DEVICE|BCI Capnograph 9004 (Smiths Medical)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
41143584|NCT03442998|OTHER|Nature walk|Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
41462944|NCT05064267|DIAGNOSTIC_TEST|phlebotomy|phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.
41462945|NCT02063217|DRUG|Sodium Oxybate|Sodium oxybate h.s.
41462946|NCT02063217|BEHAVIORAL|Sleep deprivation|36hr sleep deprivation
41462947|NCT03321045|DRUG|[89Zr]-Df-Trastuzumab|\[89Zr\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.
41462948|NCT03321045|DIAGNOSTIC_TEST|PET/MRI Imaging|5-6 days post injection the patients will undergo PET/MRI imaging.
41462949|NCT03066934|OTHER|noninvasive ventilation respiratory support|
41462950|NCT04802213|OTHER|Rehabilitation exercise|Rehabilitation exercise use the methods that suggested by previous studies including finger wall climbing, pendulum exercise, and arms lifting.
41462951|NCT04802213|DEVICE|joint mobilization device treatment|The joint mobilization treatment used the mobilization device that developed in this research.It is a device developed by using the design of the vibration force generated by the vibration mechanism and the technologies to simulate the mobilization of the shoulder joint.When the subject uses the device, first sit on a seat that can be adjusted according to the user's body shape and buckle the shoulder fixation device. Then use the specially designed shoulder movement setting mechanism of the device to set the user's shoulder movement and movement angle.The next step is to set the direction and magnitude of the vibration force applied by the device to the shoulder joint in accordance with the joint mobilization technique (posterior, anterior, and inferior) that the therapist or user intends to perform to achieve the effect of simulating joint mobilization and increasing joint mobility.
41143585|NCT06226818|OTHER|completion of scales and questionnaires|"Patient questionnaires Abuse assessment Screen, Evaluation of the PCL-5 score, Measurement of insomnia severity indexes (ISI), quality of life scores (WHOQOL-BREF), anxiety and depression using the HAD scale (Hospital Anxiety and Depression), self-esteem score using the Rosenberg scale, feeling of security and well-being using five-point Likert scales.~Questionnaire on daily and occasional smoking, alcohol consumption using the Alcohol Use Disorders Identification Test-Concise (AUDIT-C), cannabis dependence using the Cannabis Abuse Screening Test (CAST) and use of other psychoactive substances."
41143586|NCT05990868|DRUG|Tylenol|Rectal tylenol will be placed at the time of oocyte retrieval
41143587|NCT05167578|BEHAVIORAL|Medication reconciliation|A pharmacist will go through all medicines physicians have prescribed, over-the-counter medicines (OTC) and food supplements one by one to assess the actual medicine used by the patient. If a pharmacist identifies medication discrepancies between physician's prescriptions and patient's self-reported use of medicine during the medication reconciliation, she/he will find out the patients' reasons for adjusting the medication.
41143588|NCT02091102|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
41143589|NCT02709200|DRUG|Dexmedetomidine|
41143590|NCT04292795|DEVICE|Therapeutic Ultrasound|The Intervention will be provided according to the set protocols used in previous literature.
41143591|NCT04292795|DEVICE|Short wave diathermy|The Intervention will be provided according to the set protocols used in previous literature.
41143592|NCT05898789|BEHAVIORAL|CaRE@Home intervention|participants randomized to the intervention arm will complete a virtual 8 week exercise and education program.
41143593|NCT06404736|DRUG|Bispecific antibody (bsAb) targeting PD-1 and CLTA-4|QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
41462952|NCT04802213|DEVICE|laser acupuncture device treatment|The laser acupuncture treatment use the laser acupuncture device that developed in this research. A gallium-aluminium-arsenide (GaAlAs, infrared laser) continuous wave diode laser device with a wavelength of 850nm (invisible), a power output of 100 mW, and a spot area of 0.07cm2 was used for laser acupuncture.When performing laser acupuncture treatment, the laser emitted by the device is irradiated on the selected acupuncture points .The acupuncture points (GB 21, LI 4, LI 11, LI 14, LI15, LI 16, SI 9, SI 10, SI 11, TE 14, and TE 15) were determined according to the literature regarding acupuncture application in shoulder pain based on traditional chinese acupuncture.
41462953|NCT06280417|DEVICE|Unreamed intramedullary tibial nail|Fixation of type IIIa tibial fractures by unreamed IMN
41462954|NCT01090817|DRUG|Mesenchymal stromal cells (MSC) for infusion|MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
40983423|NCT00198757|BEHAVIORAL|Medifast Plus for Diabetics Meal Replacement Supplements|
40983424|NCT00198757|BEHAVIORAL|Standard ADA recommended diet for type 2 diabetics|
41143594|NCT06404736|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
40778778|NCT00317837|PROCEDURE|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
40778779|NCT00317837|PROCEDURE|bipolar hemiarthroplasty|bipolar hemiarthroplasty
40778780|NCT00034814|DRUG|Talampanel|Non-enzyme-inducing TLP 35mg TID
40778781|NCT00034814|DRUG|Placebo|Enzyme-inducing placebo TID
40778782|NCT00034814|DRUG|Talampanel|Enzyme-inducing Talampanel 35 mg TID
40778783|NCT00034814|DRUG|Talampanel|Enzyme-inducing TLP 50mg TID
40778784|NCT00034814|DRUG|Placebo|Non-enzyme-inducing placebo TID
40778785|NCT00034814|DRUG|Talampanel|Non-enzyme-inducing TLP 25mg TID
40778786|NCT03639610|DRUG|Melflufen|Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.
40778787|NCT03639610|DRUG|Dexamethasone|Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged \<75 years. Dose of 20 mg for patients aged ≥75 years.
40778788|NCT06183398|OTHER|Skin prick test|Specific skin prick tests for 6 raw food: peach, apple, sesame, carrot, lemon and orange
40983425|NCT02212392|DRUG|Meropenem|inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
40983426|NCT02668133|DIETARY_SUPPLEMENT|the nutritional supplement to be used in this trial is a SQ-LNS|Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
40983427|NCT02668133|DIETARY_SUPPLEMENT|lipid-based nutrient supplement (SQ-LNS) with phytase|• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration \~500 FTU/20 g SQ-LNS) added during manufacturing
40983428|NCT02668133|DIETARY_SUPPLEMENT|0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc|delivered orally in sugar solution
40983429|NCT02668133|DIETARY_SUPPLEMENT|1 mg isotopically enriched 68Zn|administered intravenously
40778789|NCT00668629|DRUG|Lactic acid (Dermacid)|
40778790|NCT01447537|OTHER|Exercise + relaxation|Exercise + relaxation
40778791|NCT01447537|OTHER|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
40983430|NCT05965089|BIOLOGICAL|Placebo|Placebo
40983431|NCT05965089|BIOLOGICAL|AX-202|Humanized monoclonal antibody
41303994|NCT02642887|PROCEDURE|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
40778792|NCT01215851|DRUG|PA-824|200 mg tablet, once daily for 14 days
40983432|NCT01926314|DEVICE|PHENIX Neuromuscular Stimulation Therapy System device|
40983433|NCT01926314|OTHER|usual home care without device|
40983434|NCT06421779|BEHAVIORAL|Virtual reality (VR)|Children watch underwater experience video by wearing the virtual reality glass during the skin prick test.
40983435|NCT03337074|OTHER|Questionnaire, semen sample, fasting blood sample|Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.
40983436|NCT03337074|OTHER|Questionnaire|Participants are asked to complete a questionnaire.
40778793|NCT01215851|DRUG|Pyrazinamide|Dosed by Weight
40778794|NCT01215851|DRUG|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
40778795|NCT01215851|DRUG|Rifafour|Rifafour e-275
40778796|NCT01215851|DRUG|Moxifloxacin|moxifloxacin 400 mg
40778797|NCT02951260|DRUG|Metformin|17 days treatment with metformin
40778798|NCT02951260|OTHER|Placebo|17 days treatment with placebo
40778799|NCT01858727|OTHER|forced air warming group|30 minutes before the preoperative will use forced air warming
40778800|NCT01858727|OTHER|control group|do not heating group
40778801|NCT04487444|DRUG|Thymalfasin|Synthetic 28 amino acid peptide identical to naturally circulating compound
40778802|NCT03852030|BEHAVIORAL|Text or email message|Text or email messages sent to research participants
40778803|NCT03410654|DRUG|Tacrolimus, Extended Release, (Envarsus Xr)|After conversion of tacrolimus immediate release to tacrolimus extended release.
40778804|NCT01778413|DRUG|ATRIPLA|
40778805|NCT06156150|BIOLOGICAL|tumor vaccine|DC vaccine produced by the Team
40778806|NCT03053128|DEVICE|Cardiac shock wave therapy|Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
40778807|NCT03053128|OTHER|Sham cardiac shock wave (Control group)|Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
40778808|NCT02554955|DRUG|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
40778809|NCT02554955|DRUG|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
41303995|NCT02179515|BIOLOGICAL|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
41303996|NCT04511234|DEVICE|MagicTouch PTA sirolimus drug coated balloon (DCB)|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch PTA sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
41303997|NCT04511234|DEVICE|POBA standard balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
41303998|NCT03599141|BEHAVIORAL|Trust-building Self-management Together|Trust building plus depression self-management
41303999|NCT03599141|BEHAVIORAL|Depression Management|Traditional depression self-management
40983437|NCT03337074|OTHER|Questionnaire, fasting blood sample|Participants are asked to complete a questionnaire and provide a fasting blood sample.
40983438|NCT02810392|DRUG|Intranasal Insulin|Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.
40983439|NCT02810392|DRUG|Intranasal saline|Delivery is with the Vianase device, 0.5 cc of normal saline
40983440|NCT01897142|BIOLOGICAL|PF-05230907|0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
40983441|NCT01897142|DRUG|Placebo for PF-05230907|0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
40983442|NCT01897142|BIOLOGICAL|PF-05230907|0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
40983443|NCT01897142|DRUG|Placebo for PF-05230907|0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
40983444|NCT01897142|BIOLOGICAL|PF-05230907|1 micrograms per kilogram of PF-05230907, IV bolus, single dose
40983445|NCT01897142|DRUG|Placebo for PF-05230907|1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
40983446|NCT01897142|BIOLOGICAL|PF-05230907|2 micrograms per kilogram of PF-05230907, IV bolus, single dose
40983447|NCT01897142|DRUG|Placebo for PF-05230907|2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
40983448|NCT01897142|BIOLOGICAL|PF-05230907|3 micrograms per kilogram of PF-05230907, IV bolus, single dose
40983449|NCT01897142|DRUG|Placebo for PF-05230907|3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
40983450|NCT01897142|BIOLOGICAL|PF-05230907|5 micrograms per kilogram of PF-05230907, IV bolus, single dose
40983451|NCT01897142|DRUG|Placebo for PF-05230907|5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
40983452|NCT03026608|BEHAVIORAL|Veggie Van Program|This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
40983453|NCT06495164|DRUG|Palbociclib|CDK4/6 inhibitor
40983454|NCT06495164|DRUG|Aromatase inhibitor|Aromatase inhibitor
40983455|NCT06495164|DRUG|Ribociclib|CDK4/6 inhibitor
40983456|NCT06495164|DRUG|Abemaciclib|CDK4/6 inhibitor
40983457|NCT02248389|DEVICE|Sonatherm 600i ablation system|HIFU ablation of tumor.
40983458|NCT01566461|DEVICE|Drug-Coated Balloon (DCB)|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
40983459|NCT01566461|DEVICE|PTA Balloon: Balloon Angioplasty|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
40983460|NCT02111850|BIOLOGICAL|Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)|Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
40983461|NCT02111850|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.
40983462|NCT02111850|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.
40983463|NCT02111850|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
40983464|NCT03910608|DEVICE|MagPro X100 device (MagVenture, Farum, Denmark)|Each cPAS experimental session contained 100 pairs of stimuli at 0.2 Hz. The experimental conditions differed in the interstimulus interval of the paired pulses. DLPFC stimulation precedes IPL/MPFC stimulation by 10 ms (DLPFC+10) or by 4 ms (DLPFC+4), and IPL/MPFC stimulation precedes DLPFC stimulation by 4 ms (IPL/MPFC+4) or by 10 ms (IPL+10).
40983465|NCT06481514|OTHER|Interpretation of the CTG using FRI score|At each of the components of the score will be assigned a score of 1 if the variable evaluated is considered normal, 0 if classified as abnormal. To encourage a simplified clinical interpretation of the different scores obtained (score from 1 to 8) they will be classified into 3 risk categories: Score 5-8: green zone, Score 3-4: zone yellow, Score 1-2: red zone. An FRI of 1-2 (red zone) is to be considered as anomalous
40983466|NCT06481514|OTHER|Classic interpretation of the CTG|evaluate the CTG of group B patients according to the usual internal management protocols
40983467|NCT05398562|DIAGNOSTIC_TEST|Mycobacterial recombinant allergens 0.1 μg|solution for intradermal injection, 0.1 µg / 0.1 mL
40983468|NCT05398562|DIAGNOSTIC_TEST|Mycobacterial recombinant allergens 0.2 μg|solution for intradermal injection, 0.2 µg / 0.1 mL
40983469|NCT05398562|DIAGNOSTIC_TEST|Placebo|solution for intradermal injection
40778810|NCT02554955|DRUG|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
40983470|NCT03472027|BIOLOGICAL|BCD-145|Anti-CTLA-4 monoclonal antibody, IV infusion
40983471|NCT02299479|DEVICE|Dexcom G4 Platinum CGM|Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
40983472|NCT02299479|DEVICE|Activity monitor|Participants will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
40983473|NCT01243879|OTHER|Stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
40983474|NCT01243879|OTHER|No stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
40983475|NCT01290640|DEVICE|DePuy fixed-bearing Total Condylar III (TC3) TKA|
40983476|NCT01290640|DEVICE|DePuy PFC Rotating Platform TC3 TKA|
40983477|NCT01577056|DIETARY_SUPPLEMENT|Fish oil capsule|4g Omega capsule for 12 weeks
40983478|NCT01577056|DRUG|HMG Coenzyme reductase|All FH subjects are on standard statin treatment during study period
41304000|NCT04072146|DRUG|Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|Cross over bioavailability study
41304001|NCT04072146|DRUG|OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg|Cross over bioavailability study
40983479|NCT01973907|OTHER|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
40983480|NCT03892109|OTHER|No Cord impression material|the no cord self- retracting impression material placed directly in the tray
40983481|NCT03892109|DEVICE|cord|Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.
40983482|NCT03892109|OTHER|Gingitrac|packed into the sulcus
40983483|NCT03465241|DIAGNOSTIC_TEST|the ctDNA dynamic monitoring|To detect ctDNA in patients using the second generation of high-throughput gene sequencing (NGS)
40983484|NCT06541288|DIAGNOSTIC_TEST|AI Prediction Model|Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer. Further pelvic lymph node metastasis status was determined by artificial intelligence multimodal fusion prediction modeling
40983485|NCT06541288|DIAGNOSTIC_TEST|Conventional Imageing Assessment|Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer.Further pelvic MRI images are read by a specialized imaging physician to determine pelvic lymph node status.
40983486|NCT06518135|OTHER|SLNB group|After the completion of neoadjuvant therapy, axillary SLNB should be performed first before breast surgery; If the frozen pathology SLNs are negative, ALND will no longer be performed; If frozen pathological SLNs are positive, ALND should be performed directly; If frozen pathology is false negative.
40983487|NCT03566823|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
40983488|NCT03566823|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
41462955|NCT05378308|OTHER|Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)|Patients with AF or VTE; OAC treatment patterns according to patient demographics, clinical factors, risk stratification, geographic regions, local NOAC medical insurance policy and NOACs availability
40983489|NCT02302781|OTHER|Questionnaires|Several validated questionnaires, depending on moment in fertility work up or treatment.
40983490|NCT06288412|DRUG|Insulin icodec|Participants will receive insulin icodec subcutaneous (s.c.) once weekly.
40983491|NCT06288412|DRUG|Insulin degludec|Participants will receive insulin degludec s.c. once daily.
40983492|NCT01189214|DRUG|Memantine|Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
40983493|NCT02812147|DRUG|L-DOPS|Added as described in the Arm/Group Descriptions.
40983494|NCT02812147|DRUG|Placebo|Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
40983495|NCT03070379|PROCEDURE|Topical lidocaine pharyngeal anesthesia|Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
40983496|NCT05790629|PROCEDURE|endo-sequence putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
41304002|NCT05022771|DRUG|PMG1015 Dose 1|Dose level 1 of PMG1015
40983497|NCT05790629|PROCEDURE|neo-MTA putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
40983498|NCT02408458|DEVICE|MIROMESH®|
40983499|NCT03038958|DRUG|Isobaric 2-chloroprocaine|intrathecal injection of 50 mg isobaric 2-Chloroprocaine
40983500|NCT03038958|DRUG|Hyperbaric prilocaine|intrathecal injection of 50 mg hyperbaric prilocaine 2%
40983501|NCT02436356|DEVICE|Osteoprobe-Reference Point Indentation (RPI)|Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
40983502|NCT02436356|RADIATION|Dual-energy X-ray absorptiometry (DXA) Scans|Assessment of Fracture Risk
40983503|NCT02436356|RADIATION|MRI|Determines bound water and pore water of bone.
40983504|NCT01427894|OTHER|Maternal singing with Kangaroo Care|Maternal singing with Kangaroo Care
40983505|NCT02308410|PROCEDURE|Tourniquet application during surgery|Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
40983506|NCT02671994|OTHER|G8 screening|
40983507|NCT02671994|OTHER|Geriatric assessment|
40983508|NCT06235788|BEHAVIORAL|Experimental Group ICEMS verbal feedback with pause group|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down and reflecting for 22 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
40983509|NCT06235788|BEHAVIORAL|Experimental Group ICEMS audio feedback with pause and expert video|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down, turning their attention to a 9-second expert-level demonstration video, and reflecting for 13 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
40983510|NCT05039242|OTHER|Conventional Physical Therapy)|"Participants will receive a Hand exercise program including 8 different movements according to Flat 20 (flexion, extension, radial deviation of the fingers, dorsal flexion, palmar flexion, ulnar deviation of the fingers, and opposition and abduction of thumbs.~Repetitions include 5 times during each session, as given in the study. Balanced resistive hand exercise with use of physio hand ball squeezes including finger abduction and adduction exercises with MCP extended and gross grip.~Each contraction to be held for 3-5 seconds with a 20-second rest between contractions. Five repetitions of each resistive exercise will be done."
40983511|NCT05039242|OTHER|Kinesiotaping with I shaped application|Participants will receive Kinesiotape, by using I application technique from proximal to distal on dorsum of hand and forearm with less than 50% stretch of the subjects on both hands, once a week for a total time period of 4 weeks with 4 KT applications in total (19). Kinesiotape will be worn by the subjects for 3 days. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs.
40983512|NCT05039242|OTHER|Kinesiotaping with Fan-shaped Application|"Participants will receive exercise interventions as group A along with that the Kinesiotape will be applied, by using fan cut application technique on MCP joints involving extensor tendons of fingers on dorsal surface of both hands of subjects, once a week for a total time period of 4 weeks with 4 KT applications in total.~Kinesiotape will be worn by the subjects for 3 days. Less than 50% stretch with space correction technique. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs."
40983513|NCT02842918|PROCEDURE|Spinal Manual Therapy|
40983514|NCT02842918|PROCEDURE|Spinal Range of Motion|
41143595|NCT06404736|DRUG|Carboplatin|Carboplatin is a chemotherapy medication belonging to the platinum-based class of drugs, commonly used in the treatment of various cancers, including ovarian cancer, lung cancer, and bladder cancer. It functions by forming DNA adducts, disrupting DNA replication and transcription processes in cancer cells, ultimately leading to cell death. Despite its efficacy, carboplatin can cause side effects such as nausea, vomiting, and bone marrow suppression.
41143596|NCT03137732|DEVICE|Rectus Sheath Catheter|Insertion of rectus sheath catheter via either method
41143597|NCT06482528|OTHER|Motor Imagery|"After the measurement devices are connected to the individuals, they will be seated in a comfortable chair.~After the calibration of the devices, individuals will undergo a 2-minute relaxation session. During the relaxation session, individuals will be asked to focus on their breathing and relax as much as possible.~Then, heart rate variability, electrodermal activities and respiratory frequencies of the individuals will be measured in a sitting position for 5 minutes. In case of rest, after taking the variables, individuals will be kept to rest for 10 minutes.~After 10 minutes, the devices will be placed on the individuals again and a 2-minute relaxation session will be held.~Then, individuals will be asked to imagine running through kinesthetic imagery for 5 minutes.~Feedback will be given to individuals throughout the entire session. These feedbacks will be given verbally with an audio recording prepared by the physiotherapist."
41304003|NCT05022771|DRUG|PMG1015 Dose 2|Dose level 2 of PMG1015
40983515|NCT00225251|DRUG|bupropion XL|Antidepressant medication
40983516|NCT00225251|OTHER|Placebo|Placebo
40983517|NCT05919381|DRUG|Gentuximab Injection|Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
40983518|NCT05919381|DRUG|Gentuximab Injection Placebo|Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
40778811|NCT02975960|BIOLOGICAL|injection of autologous stromal vascular fraction|"1. Acquiring autologous stromal vascular fraction (SVF) from liposuction~2. purifying SVF from lipoaspirates and making syringe filled with SVF~3. SVF injection - Inject SVF on fingers subcutaneously."
40778812|NCT06518304|OTHER|GentleWave|GentleWave System employs a degassing process that removes dissolved gases from the solution. This optimization prevents the vapor-lock effect and ensures effective energy transmission through the root canal. As the solution enters the pulp chamber, hydrodynamic cavitation occurs, creating microbubbles that implode and generate sound waves across a broad frequency spectrum
40778813|NCT06518304|OTHER|Conventional Protocol|Delivers irrigants (NaOCl, EDTA) through a needle-syringe system, often fails to reach the entire working length. This inadequacy can result in residual bacteria and necrotic tissue, potentially compromising treatment efficacy and increasing the risk of treatment failure.
40778814|NCT00626041|OTHER|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
40778815|NCT00943644|DEVICE|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
40778816|NCT00943644|DEVICE|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
40778817|NCT02007629|DRUG|Riociguat (Adempas, BAY63-2521)|Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
40778818|NCT06005987|BEHAVIORAL|OneTouch Reveal application|Evaluate if compliance with glucose logging and percentage of in range glucoses changes with use of a mobile application instead of paper logging
40778819|NCT02563327|DRUG|Rifapentine|A rifamycin with activity against Mycobacterium tuberculosis
40778820|NCT02563327|DRUG|Moxifloxacin|A fluoroquinolone
40983519|NCT05653687|DEVICE|Intraoperative fluoroscopy|Fluoroscopy is a medical procedure that makes a real-time video of the movements inside a part of the body by passing x-rays through the body over a period of time.
40983520|NCT02723032|DEVICE|OxyFrame|Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
40983521|NCT04992455|OTHER|Older Patients Receiving Chemotherapy|No Intervention
40983522|NCT05003076|DRUG|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
40983523|NCT05003076|DRUG|Placebo|Participants will be given a placebo capsule that will only contain lactose.
40983524|NCT04838756|OTHER|AI screening modality|Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.
41462956|NCT03962868|PROCEDURE|Experimental procedure : ESD|ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (\<1.5%)
40983525|NCT04838756|OTHER|Conventional screening modality|Screen exams will be read by two radiologists without the support of AI.
40983526|NCT00108667|DRUG|IV Levodopa|
40983527|NCT00108667|DRUG|Talampanel|
40778821|NCT02563327|DRUG|Rifampin|A rifamycin with activity against Mycobacterium tuberculosis
40778822|NCT02563327|DRUG|Isoniazid|An anti-tuberculosis agent
40778823|NCT02563327|DRUG|Pyrazinamide|An anti-tuberculosis agent
40778824|NCT02563327|DRUG|Ethambutol|An anti-tuberculosis agent
40778825|NCT02563327|DIETARY_SUPPLEMENT|Pyridoxine|An essential vitamin
40778826|NCT06304155|DIAGNOSTIC_TEST|Diagnostic efficacy,SUV|"The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG and 18F-FAPI PET were calculated and compared to evaluate the diagnostic efficacy.~Standardized uptake value (SUV) of 18F-FDG and 18F-FAPI for each target lesion of subject or suspected primary tumor or/and metastasis."
40778827|NCT00066872|DRUG|imiquimod|
40778828|NCT00066872|PROCEDURE|conventional surgery|
40778829|NCT06220110|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
40778830|NCT06220110|DIETARY_SUPPLEMENT|Placebo|Capsules containing dextrose (1 capsule per day)
40983528|NCT02592174|OTHER|Health related quality of life and social and demographic informations|At the inclusion visit with a self-assessment questionnaire
40983529|NCT02592174|OTHER|Neurocognitive assessment|At the neurocognitive visit, with standard test as CONSTANCES cohort
40983530|NCT02592174|RADIATION|cerebral images sub-study|Standard magnetic resonance imaging
40983531|NCT02377466|DRUG|Retosiban IV infusion|Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
41304004|NCT05022771|DRUG|PMG1015 Dose 3|Dose level 3 of PMG1015
40778831|NCT04015388|DEVICE|iPro Continuous Glucose Monitoring|iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
40778832|NCT05784012|DRUG|Dostarlimab|Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.
40778833|NCT05784012|DRUG|Niraparib|Niraparib 200 or 300mg orally administered QD in neoadjuvant, concurrent with radiotherapy and adjuvant stage until completing week 48.
40778834|NCT05784012|DRUG|cisplatin plus radiotherapy|In the concurrent phase
40778835|NCT05784012|DRUG|Niraparib|Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).
40778836|NCT00673920|DRUG|Methotrexate|Oral or parenteral repeating dose
40778837|NCT00673920|DRUG|Ocrelizumab|"Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate."
40778838|NCT00673920|DRUG|Placebo|Intravenous repeating dose
40778839|NCT04270643|DIETARY_SUPPLEMENT|Vitamin D3|ATC code A11CC05 (cholecalciferol)
40778840|NCT04270643|DIETARY_SUPPLEMENT|Placebo|Ethyl oleate
40778841|NCT04049773|PROCEDURE|haemodialysis|haemodialysis, thrice weekly in-center
40778842|NCT03721250|OTHER|epidural|thoracic epidural analgesia
40778843|NCT05513963|BEHAVIORAL|Clairity|Treatment group participants will complete study session using the Clairity tool in between regularly scheduled therapy visits.
40778844|NCT03448328|DIETARY_SUPPLEMENT|NUTRALYS pea protein supplement|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
41462957|NCT03962868|PROCEDURE|Comparison procedure: WF-piece meal EMR|WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).
41462958|NCT00360490|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
41462959|NCT00360490|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
40778845|NCT03448328|DIETARY_SUPPLEMENT|Whey Protein|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
40778846|NCT03448328|DIETARY_SUPPLEMENT|Apple juice|1.2 calories per kilogram body weight before and after eccentric exercise, and each of 4 mornings of recovery
40778847|NCT00665834|DRUG|rosuvastatin|rosuvastatin 20 mg from day 0 to (maximum) day 6
40778848|NCT00665834|DRUG|placebo|placebo 20 mg from day 0 to (maximum) day 6
40778849|NCT00665834|DRUG|rosuvastatin|rosuvastatin 20 mg from discharge until the end of the study
40778850|NCT00665834|DRUG|atorvastatin|atorvastatin 80 mg from discharge until the end of the study
40778851|NCT01645176|DRUG|Hydroxychloroquine/Atorvastatin|Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
40778852|NCT00966459|PROCEDURE|Computed Tomography|1 low-dose CT is taken
40778853|NCT05410730|DRUG|SHR-1501|SHR-1501 single agent dose escalation will consist of 3 dose groups: 200 μ g、400 μ g and 600 μ g, and in combination of BCG. The administration method is intravesical instillation.
40778854|NCT01466088|DRUG|Donepezil|Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.
40778855|NCT01466088|DRUG|AZD3480|Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
40778856|NCT03342560|DEVICE|Sonographic SWE measurements with 4 different ultrasound systems|Sonographic Shear wave elastography will be performed to quantify liver fibrosis
40778857|NCT06528626|DIAGNOSTIC_TEST|rapid HIV and HCV serological tests|In the standard of care branch (SOC), the health personnel will ask people a series of questions to identify the HIV risk exposition, and also they will be provided pop-up computer alerts of HIV indicator conditions in the electronic medical record, moreover HIV and HCV serological tests will be carried out in the reference laboratory, while in the intervention branch in addition to the SOC, a SQ-R\&IC of HIV and HCV will be made available to the HC population, through a quick response (QR) code, as well as HIV and HCV RT.
40983532|NCT02377466|DRUG|Placebo IV infusion|0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
40983533|NCT02349581|PROCEDURE|PECS block|Ultrasound guided delivery of local anesthetic between the pectoral muscles
40983534|NCT02349581|DRUG|Bupivacaine|
40983535|NCT06507449|DEVICE|Lithotripsy|Calcified lesion preparation using lithotripsy before implantation of a drug-eluting stent
40983536|NCT06507449|DEVICE|Orbital atherectomy|Calcified lesion preparation using orbital atherectomy before implantation of a drug-eluting stent
40983537|NCT06507449|DEVICE|High-pressure non-compliant balloon|Calcified lesion preparation using high-pressure non-compliant balloon before implantation of a drug-eluting stent
40983538|NCT06507449|DEVICE|Optical coherence tomography|Optical coherence tomography assessment of coronary arteries.
41143598|NCT05901688|OTHER|Umbilical cord measurements & observations|"In the screening study of an unselected population at 20-22 weeks' and 35-37 weeks' gestation, women are offered an ultrasound scan as part of standard care and will be invited to take part in the study which will involve taking the following additional ultrasound measurements:~1. Umbilical cord coiling index (UCI)~2. Transverse diameter of umbilical cord (UC)~3. Transverse diameter of umbilical vein (UV) and artery (UA)~4. Umbilical vein (UV) Doppler flow characteristics~5. Presence of nuchal cord"
41462960|NCT01465568|DRUG|Denosumab|60mg subcutaneous injection 6 monthly for 2 doses
41462961|NCT01465568|DRUG|bisphosphonates|continue present bisphosphonate treatment
40778858|NCT02281045|DEVICE|EVODIAL dialyzer and Selectbag citrate|Evodial is a trademark of Hospal-Gambro.
40983539|NCT06507449|DEVICE|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function.
40983540|NCT02284711|DEVICE|Bipolar electric energy|Coagulation during salpingectomy using conventional bipolar electric energy
40983541|NCT02284711|DEVICE|ultrasound energy|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
40983542|NCT04040478|DEVICE|Transcutaneous monitoring|"Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery."
40983543|NCT02672423|DRUG|Abemaciclib Capsules (Reference Formulation)|Administered orally
40983544|NCT02672423|DRUG|Abemaciclib Tablet (Test Formulation)|Administered orally
40983545|NCT05683054|BIOLOGICAL|Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels|In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab (33% reduction). If patients still have a good clinical response and supratherapeutic adalimumab serum trough levels, will be further tapered to a dose regimen of 1 subcutaneous injection (40mg) every 4 weeks (50% dose reduction).
40983546|NCT05683054|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab
40983547|NCT05683054|OTHER|Dermatology Life Quality Index (DLQI)|The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
40983548|NCT05683054|OTHER|EQ-5D-5L questionnaire|The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.
40983549|NCT05683054|PROCEDURE|Dried blood spot sampling|A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
40983550|NCT01806753|PROCEDURE|Intermittent midazolam/propofol injection controlled by endoscopist|"In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.~First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.~When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).~If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected."
40983551|NCT01806753|PROCEDURE|Continuous propofol infusion with opioid administration|"In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.~First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.~Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.~When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.~If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min."
40983552|NCT03804944|RADIATION|Focal Radiation therapy|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
40983553|NCT03804944|DRUG|Pembrolizumab (200mg IV for 30 minutes|Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
40983554|NCT03804944|BIOLOGICAL|CDX-301|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
40983555|NCT05389150|DRUG|Fixed dose combination Pregabalin 150 mg / Tramadol 50 mg|Pregabalin/Tramadol (Laboratorios Silanes S.A. de C.V.), Pharmaceutical Form: Tablet Dosage: 150 mg / 50 mg Administration way: oral
40983556|NCT05389150|DRUG|Pregabalin 150mg|From Pfizer S.a. de C.V. Pharmaceutical Form: Capsule Dosage: 150 mg Administration way: oral
40983557|NCT05389150|DRUG|Tramadol 50 mg|From Grünenthal de México, S.A. de C.V. Pharmaceutical Form: Capsule Dosage: 50 mg Administration way: oral
40983558|NCT03715218|OTHER|Mothers Touch Program|Mothers Touch Program with bed rest, Relaxation program to reduce stress, massage for mother and infant, gently physical exercise and special dietary program each week.
40983559|NCT03715218|OTHER|Usual Care Program|Usual care group had advice, support and educational program delivered by midwife, or physicians.
40983560|NCT02056704|DEVICE|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
40983561|NCT05600491|DRUG|Temozolomide|Two weeks after surgery, temozolomide was administered orally at 200 mg·m-2 ·d -1 for 5 days. From day 29, patients were treated with a standard therapy regimen (Stupp).
40983562|NCT01610947|DRUG|Adalimumab, Etanercept, Golimumab or infliximab|Continuation of usual treatment with fixed intervals according to standard recommendations
40983563|NCT01610947|DRUG|Adalimumab, Etanercept, Golimumab or infliximab|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
40983564|NCT05048628|OTHER|Comparıson|"Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated."
41143599|NCT01135719|PROCEDURE|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
41143600|NCT06505356|PROCEDURE|Prostate biopsy|Transrectal prostate biopsy
41304005|NCT05022771|DRUG|PMG1015 Dose 4|Dose level 4 of PMG1015
41304006|NCT05022771|DRUG|PMG1015 Dose 5|Dose level 5 of PMG1015
41304007|NCT05022771|DRUG|PMG1015 Dose 6|Dose level 6 of PMG1015
41304008|NCT05022771|DRUG|Placebo|Placebo to match
41304009|NCT05022771|DRUG|PMG1015 Dose 7|Dose level 7 of PMG1015
41304010|NCT03727321|COMBINATION_PRODUCT|Fecal Microbial Transplant|Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
41462962|NCT06531915|DRUG|Ciprofol|Participants in the ciprofol group will be intravenously injected with 0.4 mg/kg of ciprofol (batch number H20200013, Haisike Pharmaceutical Co., Ltd., Liaoning, China) and sufentanil (0.2 μg/kg).
40778859|NCT02281045|DEVICE|Regional citrate anticoagulation|Regional citrate anticoagulation is performed according to local practice, using a calcium-containing dialysate
40778860|NCT01265485|DRUG|coated suppository|Dose escalating study
40983565|NCT05383547|DRUG|Bortezomib|Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.
40983566|NCT00795756|DRUG|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
40983567|NCT00795756|DRUG|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
40983568|NCT06258655|OTHER|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational program for the neonatal staff to improve their skills to collaborate with parents and provide support to parenting during an infant's hospitalization. First, experienced nurses and doctors from the units will undergo a 14-day to become unit mentors. Then these unit mentors will train other members of staff. The training of the units is based on bedside practices, a reflection of the practices, and the application of the knowledge in everyday work. Theoretical learning, preceding clinical bedside mentoring, will occur through an e-learning module. Staff members will spend about 4 working days in training alongside their routine work. The unit mentors will function as facilitators for the staff, and they have dedicated time for this. The content of the bedside practices is guided by a manual. The training team will provide frequent remote and contact support for the implementation."
40983569|NCT00763308|BEHAVIORAL|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
40983570|NCT00827879|BEHAVIORAL|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
40983571|NCT00827879|BEHAVIORAL|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
40983572|NCT00255047|BIOLOGICAL|DAPTACEL®. (DTaP), IPOL®., and ActHIB®.|0.5 mL, Intramuscular
40983573|NCT00255047|BIOLOGICAL|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
40983574|NCT00255047|BIOLOGICAL|DTaP-IPV and ActHIB®|0.5 mL, Intramuscular
40983575|NCT00255047|BIOLOGICAL|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
40983576|NCT04319120|OTHER|questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed. A dedicated telephone line and e-mail address will be used as a support if necessary (for questionnaires, emails or sending photos). The referring nurse and the clinical research assistant of the service will be in charge of centralizing the data collected.
40983577|NCT05611047|OTHER|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
40983578|NCT05611047|OTHER|Classical cognitive evaluation of several domains:|Information processing speed (IPS) Working memory (WM) Executive functions (EF) Episodic memory (EM) Premorbid intelligence quotient (IQ) Multidomain or complex task
40983579|NCT05611047|OTHER|Ecological evaluation|Virtual reality task : Urban DailyCog©
40983580|NCT05611047|BEHAVIORAL|Patent reported outcomes (PRO's)|"Patent reported outcomes (PRO's) : Beck Depression Inventory (BDI), European Quality of Life-5 Dimensions (EQ-5D-5L) for Health-Related Quality of Life (HRQOL), Multiple Sclerosis Impact Scale-29 Items (MSIS-29), French version of the Modified Fatigue Impact Scale (EMISEP) and State trait anxiety inventory (STAI).~Subjective cognitive deficits: Perceived Deficits Questionnaire (PDQ) and Cognitive Activities Questionnaire (DCAQ)"
40778861|NCT04824833|PROCEDURE|Serratus anterior plane block|local anesthetic application between serratus anterior muscle and 5th rib
40983581|NCT05611047|OTHER|Telerehabilitation : active procedure|The Cognitive rehabilitation (CR) consists of weekly 45 minutes online individual session with the unblinded Speech Therapist.
40983582|NCT05611047|OTHER|Telerehabilitation : comparator procedure|Once per week over a 12-week period completed by daily online exercises performed by the patient 4 days a week.
40983583|NCT02985307|BEHAVIORAL|Short Message Text Service|A service designed by professionals inside the National Health Service (NHS) to provide support and advice for participants to manage weight loss. It combines the expertise of the healthcare team and the convenience of the participant's own mobile phone to give prompts and advice to act on. It makes use of the familiar and convenient mobile phone text service 'SMS' to communicate directly with participants.
40983584|NCT02985307|BEHAVIORAL|Standard Weight Management Group|A standard Lothian NHS group programme facilitated by a Dietitian
40983585|NCT03533179|DRUG|Glucagon|"Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30."
40983586|NCT03533179|DRUG|Esmolol|Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or \>25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.
40983587|NCT03533179|DRUG|Physiologic saline - glucagon dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.
40983588|NCT03533179|DRUG|Physiologic saline - esmolol dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.
40983589|NCT01572909|DRUG|Bendavia (MTP-131)|0.05 mg/kg/hr
40983590|NCT01572909|DRUG|Placebo|Identically appearing placebo
40778862|NCT04987372|DRUG|Dexmedetomidine|The use of multimodal painkillers pre, per and postoperative
40778863|NCT01879007|DRUG|Factive® Tab / Factive IV|
40983591|NCT05335564|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression."
40983592|NCT00403663|DRUG|bupivacaine 0.75% with fentanyl and morphine|the following administered once, by spinal injection; 9-12 mg 0.75% hyperbaric bupivacaine 10 mcg fentanyl 100 mcg morphine
40983593|NCT01839773|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
40983594|NCT01839773|DRUG|Paclitaxel|Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
40983595|NCT00640445|BEHAVIORAL|Expressive Writing|In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
40983596|NCT00640445|BEHAVIORAL|Control Writing|Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
40983597|NCT06005844|DIAGNOSTIC_TEST|Cerebellar Cognitive-Affective Syndrome Scale|The CCASS will be administered by a neuropsychologist starting with version 1A. An alternative version (1B, 1C or 1D) will also be administered. An interval of approximately 30 minutes should be observed between the two administrations. In order to assess the inter-rater reliability of the scale, a second neuropsychologist will be present in the room and will independently evaluate (i.e., blind to his/her colleague's rating) patient's responses. The choice of alternative version (i.e., 1B, 1C, or 1D) will be randomized.
40983598|NCT04396990|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
40983599|NCT04396990|DRUG|Topical Prednisolone|Standard of care topical drop treatment
40983600|NCT01848002|DRUG|catridecacog|For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
40983601|NCT01848002|DRUG|placebo|For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
40983602|NCT02184182|PROCEDURE|VLS ablation/portal ligation/hepatectomy|"Step1:~* exploratory laparoscopy to exclude extrahepatic disease~* right portal vein ligation if surgically feasible~* RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~* radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight \> 0.5~- laparoscopic/laparotomic right trisectionectomy"
40983603|NCT00503308|PROCEDURE|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
40983604|NCT06290713|DRUG|Tadalafil|Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
40983605|NCT06290713|DRUG|Placebo|Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
40983606|NCT06290713|OTHER|Exercise Training|The home-based cycling exercise training program is designed to improve muscle strength and endurance. Participants will engage in individualized exercise sessions up to four times per week, lasting up to 40 minutes each. Live video and heart rate monitoring will ensure proper exercise performance and allow for adjustments to the program throughout the study. The participants will receive the exercise equipment for use at home.
41143601|NCT05624814|DEVICE|Spinal Cord Stimulation|Spinal Cord Stimulation consists of the transcutaneous or surgical implantation of different types of electrodes in the epidural space; electrodes are then connected to an Implanted Pulse Generator that generates stimulating currents.
41462963|NCT06531915|DRUG|Remimazolam|Participants in the remimazolam group will be intravenously injected with 0.1 mg/kg of remimazolam besylate (batch number HR7056, Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) and sufentanil (0.2 μg/kg).
40983607|NCT01942187|DRUG|Aripiprazole|Medication augmentation with Abilify (aripiprazole), in participants who have not responded to Selective Serotonin Reuptake Inhibitor (SSRI) treatment.
40983608|NCT01942187|DRUG|Bupropion|Medication augmentation with Wellbutrin (bupropion), in participants who have not responded to SSRI treatment.
40983609|NCT01942187|BEHAVIORAL|Problem Solving Therapy|Weekly specialized psychotherapy
40983610|NCT01326689|DRUG|KW-2246|Rescue medication at an optimal dose, which is determined by dose titration
40983611|NCT01326689|DRUG|Placebo|
40983612|NCT04217174|BEHAVIORAL|My Personal Health Guide|My Personal Health Guide is a theory-based mobile phone app that uses an Avatar as a personal health guide to increase patient knowledge of HIV disease and its complications and rationale for healthy behavior, increase self-efficacy and motivate participants to improve retention in care and medication adherence, and explain and illustrate behavioral skills related to retention in care, and adherence, with a result of improved behavior that leads to personal and population benefits through viral suppression and decreased risk of transmission, respectively. The relational aspect of the Avatar may be a powerful supplement to clinical care. The Avatar can encourage healthy behavior, acknowledge stigma and speak with empathy, audibly teach persons with low literacy, employ credible culturally appropriate phrasing, and invite the user to hear advice and motivational stories of other HIV-positive people and caregivers.
41143602|NCT05624814|OTHER|Standard therapies|Standard therapies for chronic low back pain are pharmacological, psychological, physical and occupational therapies or surgery.
41143603|NCT04728035|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection
41143604|NCT01697956|DRUG|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
41143605|NCT01697956|DRUG|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
41462964|NCT02962089|DIETARY_SUPPLEMENT|Branched chain amino acids (BCAA)|
40983613|NCT04217174|BEHAVIORAL|My Personal Food Guide|My Personal Food Guide is a mobile phone app that contains a talking realistic avatar who teaches about food safety, sugar content in selected foods, and some other food related information. The avatar motivates safe food behavior in order reduce the likelihood of food poisoning and promotes a healthy diet.
40778864|NCT01882816|RADIATION|IMRT|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC
40778865|NCT01882816|DEVICE|DWI MRI|The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.
40983614|NCT03304574|BEHAVIORAL|Integrated personalized feedback|Integrated personalized feedback about self-reported risk behaviors will be generated and shown to participants as they complete their baseline health risk assessment using the CheckED Yourself app. The integrated personalized feedback is based on motivational feedback strategies such as normative feedback (comparison to peer behaviors and age-based health guidelines), increasing knowledge regarding potential consequences of behaviors, and providing practical tips for changing behavior.
40983615|NCT00005972|DRUG|gemcitabine hydrochloride|
40983616|NCT00005972|DRUG|irinotecan hydrochloride|
40983617|NCT01901237|BEHAVIORAL|Hatha Yoga|This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
40983618|NCT00304499|DRUG|Oxybutynin|
40778866|NCT01882816|DRUG|Doxorubicin|Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
40778867|NCT01882816|OTHER|Modified Barium Swallow Impairment Profile (MBSImP)|The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.
40778868|NCT04585308|DEVICE|transShield Embolic Protection System|Used for embolic protection during TAVR.
40778869|NCT06398873|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300mg/2 weeks
40983619|NCT01150981|DRUG|Rosiglitazone|One 8mg capsule daily for 6 weeks.
40983620|NCT01150981|DRUG|Placebo|One capsule daily for 6 weeks.
40983621|NCT02175888|DIETARY_SUPPLEMENT|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days|
40983622|NCT02175888|DIETARY_SUPPLEMENT|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days|
40983623|NCT01306357|DRUG|Somatropin|4 mg or 10 mg delivered by needle-free device
40983624|NCT01221883|DRUG|Diazepam|Single dose 10mg Diazepam tablet
40778870|NCT00163644|PROCEDURE|aereobic plus resisted exercise|
40778871|NCT00163644|PROCEDURE|aerobic plus active exercise|
40778872|NCT00163644|OTHER|No formal exercise plus phone calls|
40983625|NCT03594292|DEVICE|FASTFORWARDTM Bunion|The participants will be assign to implantation of FASTFORWARDTM Bunion correction system surgery as a experimental group.
40983626|NCT03594292|PROCEDURE|Conventional surgery|The participants will assign to conventional surgery as a control group, the procedure is a standard treatment for the 1st metatarsal hallux valgus.
40778873|NCT02250248|BIOLOGICAL|AttraX Putty|
40778874|NCT02250248|OTHER|Iliac Crest Bone Graft (ICBG)|
40778875|NCT06465238|DRUG|SHR-A2009|Treatment group: Subjects will receive an intravenous infusion of SHR-A2009 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
40983627|NCT03209687|DRUG|human menopausal gonadotropin|Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
40983628|NCT04128384|DIAGNOSTIC_TEST|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR|For the purpose of obtaining intracardiac measurements, the quadripolar diagnostic catheter used as temporary pacemaker wire (5F, Woven, Boston Scientific) during TAVR was retracted from the apex and positioned at the His bundle to measure HV- and AH-intervals.
40983629|NCT05896527|DRUG|DC-806|DC-806 will be supplied as tablets to be administered orally.
41462965|NCT02962089|DIETARY_SUPPLEMENT|Placebo|
41462966|NCT04855591|DRUG|SHR-1703|SHR-1703 will be administered subcutaneously
41462967|NCT04855591|DRUG|Placebo|Placebo of SHR-1703 will be administered subcutaneously
41462968|NCT02064140|DRUG|Rocuronium|
41462969|NCT05337202|DEVICE|HeartSDK|The photoplethysmography (PPG) application enables patients to perform a finger tip heartbeat measurement and automatic analysis
41462970|NCT00033436|DIETARY_SUPPLEMENT|niacinamide|
40778876|NCT06465238|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
40983630|NCT05896527|OTHER|Placebo|Matching placebo will be supplied as tablets to be administered orally.
40983631|NCT03445572|OTHER|Best Practice|Receive standard supportive care
41143606|NCT02995447|OTHER|differences between surface and intracerebral EEG|No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
41143607|NCT00882050|DRUG|Exenatide 0.27 ng/kg/min|"Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.~* Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
41304011|NCT03727321|DIETARY_SUPPLEMENT|Fiber|A combination of soluble corn fiber (PROMITOR®: Tate\&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)
41304012|NCT03727321|DIETARY_SUPPLEMENT|Cellulose|Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
41304013|NCT02514460|DEVICE|plaque excision system|
41462971|NCT00033436|DRUG|carbogen|
41462972|NCT00033436|RADIATION|radiation therapy|
41462973|NCT00605176|DRUG|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
41304014|NCT02514460|DEVICE|Stent|
41304015|NCT00041613|GENETIC|INGN 201|
41462974|NCT00605176|DRUG|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
41462975|NCT00605176|DRUG|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
41462976|NCT03002792|PROCEDURE|general anesthesia|nitrous oxide, sevoflurane, propofol, cisatracurium, fentanyl for induction and maintenance with sevoflurane
41462977|NCT04874363|OTHER|no intervention|no intervention
40983632|NCT03445572|PROCEDURE|Meditation Therapy|Perform MSB
40983633|NCT03445572|PROCEDURE|Meditation Therapy|Perform IK meditation
40983634|NCT03445572|OTHER|Questionnaire Administration|Ancillary studies
40983635|NCT01477606|DRUG|Midostaurin|"Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year."
40983636|NCT01477606|DRUG|Cytarabine|"Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (\>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2)."
41304016|NCT01839188|BIOLOGICAL|PR5I|Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Hepatitis B \[HB; Recombinant DNA\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.
41304017|NCT01839188|BIOLOGICAL|Pediacel®|Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
41304018|NCT01839188|BIOLOGICAL|NeisVac-C®|Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
41462978|NCT02330016|DEVICE|Voluma XC|Voluma XC
40983637|NCT01477606|DRUG|Daunorubicin|"Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)"
40983638|NCT05070468|DRUG|Dexamethasone 0.5mg|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
40983639|NCT05070468|DRUG|Placebo|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
40983640|NCT01806831|DEVICE|"Biocellulose Mask, Farhorm®"|
40983641|NCT00825045|DRUG|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
41143608|NCT00882050|DRUG|Exenatide 0.41 ng/kg/min|"Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
40983642|NCT03138395|DIAGNOSTIC_TEST|droplet digital PCR|This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
40983643|NCT02237859|DRUG|Vancomycin|Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
40983644|NCT02237859|DIETARY_SUPPLEMENT|fruit juice/placebo|Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
40983645|NCT04212104|OTHER|watch a mukbang|watch the dim sum mukbang
40983646|NCT04212104|OTHER|watch a non-food video|watch the Big Bang Theory video
40983647|NCT05416320|DRUG|Calcipotriol|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
41143609|NCT00882050|DRUG|Placebo|"Intravenous Placebo of NSS infused at same rate as drug comparator. Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
41304019|NCT01839188|BIOLOGICAL|RotaTeq®|Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.
41304020|NCT01839188|BIOLOGICAL|Prevenar 13®|Pneumococcal polysaccharide conjugate vaccine \[PCV; 13-valent, adsorbed\]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
41304021|NCT00107770|DRUG|sodium phenylbutyrate|histone deacteylase inhibitor
41304022|NCT06031480|DRUG|Anlotinib and TQB2450|"Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent."
41304023|NCT05618457|DRUG|Aminoglycoside dose adjustment|Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC\~10 (8-12)
41304024|NCT00169494|BIOLOGICAL|HPV-16/18 L1/AS04|
40983648|NCT05416320|DRUG|Subject's already prescribed drug|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
41304025|NCT01142219|DRUG|L-arginine|L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
41304026|NCT01142219|DRUG|Placebo|Mannitol was administered orally at a dose of 01 g/kg/day for six months.
41304027|NCT06502353|DEVICE|BLOOM43|Heat preconditioning
41304028|NCT03285217|DIETARY_SUPPLEMENT|Ensure Plus Advance|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
40983649|NCT03412487|PROCEDURE|laparoscopy|under general anesthesia. CO2 pneumoperitoneum, the laparoscope inserted through the umbilicus and a thorough evaluation of the abdominal cavity and pelvis was performed. a grasper was inserted; the utero-ovarian ligament was stabilized with the round biopter will be introduced. The tip of the biopsy instrument was placed on an area of the ovary free of cysts; the hilar area was avoided because it is deficient in small follicles. After correct placement was verified, the inner protecting trocar was removed to expose the sharp leading edge of the round sheath. Gentle circular movements were made cutting through the ovarian cortex to produce a 5-mm disk of 2-3 mm in thickness.
40983650|NCT01170507|DRUG|vitamin D3 1000 IU orally daily for 5 months|
40983651|NCT01170507|DRUG|vitamin D3 3000 IU orally daily for 5 months|
40983652|NCT01170507|DRUG|vitamin D3 5000 IU orally daily for 5 months|
40778877|NCT06107530|OTHER|semi structured interview|Women fulfilling the inclusion / exclusion criteria will be asked to participate to a semi structured interview with a psychiatrist or a psychologist
40778878|NCT04681989|BEHAVIORAL|Moving On After Breast Cancer|"After the MOVE-ABC interventional group participant completes their baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~1. Instructions on how to use the physical therapy-based education materials by a research staff member~2. a range of motion wand~3. a small ball~4. MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment."
40778879|NCT04422496|DRUG|HEC96719|"single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study."
40983653|NCT01170507|DRUG|Placebo orally daily for 5 months|
40983654|NCT06017440|BEHAVIORAL|EXERCISE|Participants will receive at 08:00 am a calibrated breakfast of 500kcal. They should not perform physical exercise during the day. They will be asked at 11 a.m. to cycle for 30 minutes at 65% of the maximal capacities and their energy expenditure will be measured by indirect calorimetry. At 11 a.m., teenagers will receive a calibrated meal of 800 kcal respecting the nutritional recommendations for this age. Questionnaires on feelings of hunger will be distributed to them at regular intervals. They will also be asked to complete a 10-minute computer exercise to assess their relationship to food before and after lunch (LFPQ. Leeds Food Preference Questionnaire, Liking/ wanting). Finally, from 60 minutes after the midday test meal, teenagers will have access to an ad libitum buffet for one hour.
40983655|NCT06017440|BEHAVIORAL|CONTROL|Teenagers should not perform any physical activity during the day and they will be asked to stay at 11 a.m., for 30 minutes, resting in a semi-supine position.
40983656|NCT04813094|OTHER|Internet-Based integrated-management Program|The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Everyone have their own area to ensure the privacy of participants. The research nurse has sent messages every day to care about the participant's condition. In this area, when the participant have an emergency, it not only provided textual information, but also provided telephone coaching.
40983657|NCT04813094|OTHER|Control group|Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
40983658|NCT04824885|DEVICE|Chlorhydric acid based acid concentrate for bicarbonate hemodialysis (medical device)|usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months
40983659|NCT03888196|DIETARY_SUPPLEMENT|Panax Ginseng Supplementation|500 mg/day of Panax Ginseng
40983660|NCT03888196|DIETARY_SUPPLEMENT|Placebo Supplementation|500 mg/day of Cellulose
40983661|NCT00528398|DRUG|cytarabine|
40983662|NCT00528398|DRUG|idarubicin|
40983663|NCT03356951|PROCEDURE|TAR through anterior approach and subtalar fusion|Simultaneous total ankle replacement through anterior approach and subtalar fusion
40983664|NCT03356951|PROCEDURE|TAR through lateral approach and subtalar fusion|Simultaneous total ankle replacement through lateral approach and subtalar fusion
40983665|NCT00064376|DRUG|paricalcitol|
40983666|NCT01370174|OTHER|Physical Training Interventions|Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
41143610|NCT06123936|OTHER|Reminder|"At mid-campaign, GPs in the interventional arm will recall their patients to be vaccinated via the reminder module Eo software~* This recall will be carried out as follows: patients whose medical records include a number likely to receive telephone text messages will be recalled by this means Two generic messages that doctors can choose will be proposed by the call-back module integrated into the Eo medical software~* In addition, the recall module will offer to send a postal letter with the same content as the text message to patients who do not have a mobile phone number in the business software but do have a postal address~* The recall module will also provide the doctor with a list of patients who have neither a mobile phone number or a postal address, so that he can recall them to be vaccinated orally by landline telephone or in consultation when they next visit.~The type of recall and the date of it will be notified in the medical file of each patient."
41143611|NCT03119051|BEHAVIORAL|Online cognitive training|A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
40778880|NCT00827229|DEVICE|Labor Monitor|
40778881|NCT04857554|OTHER|Glucose as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
40983667|NCT02025244|PROCEDURE|Key Hole Biopsy ( KHB)|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
40983668|NCT02025244|PROCEDURE|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.
40983669|NCT01846507|DRUG|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
40983670|NCT04691284|OTHER|Blood, urine and stool sampling|Sampling of blood and urine for miR and chemokine detection. Sampling of stool for for microbiome studies.
40983671|NCT03933189|OTHER|Physical Therapy|Physical therapy modalities to treat chronic pain
40983672|NCT03936543|OTHER|Position change|Different position during central line catheterization
40983673|NCT03936543|OTHER|Conventional position|Conventional position during central line catheterization
40983674|NCT05277714|OTHER|Sham|The sham protocol will last 15 minutes per session, and during each session, the participants will receive the same instruction but will be shown a random signal, the goal being that the control strategy that the participant tries to implement is not correlated with the visual feedback provided by the gauge.
40983675|NCT05277714|OTHER|NF|"The neurofeedback protocol will be the same during the 8 sessions constituting the protocol and taking place over a period of 4 weeks (2 neurofeedback sessions per week, the first and the last one in an MRI context). It will last 15 minutes per session, and during each session, the patient will have to increase the brain activity of her dlPFC using a visual gauge representing the activity level of her own dlPFC. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
40983676|NCT04998747|DRUG|AMG 701|AMG 701 will be administered as SC or intravenous injection.
40983677|NCT04998747|DRUG|AMG 701|AMG 701 will be administered as SC injection.
41143612|NCT03119051|BEHAVIORAL|Cognitive training plus physical exercise|"Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.~Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction."
41143613|NCT04861259|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (\>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and every 4 weeks (Q4W) thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight \>= 40kg to \<100kg) or 1020 mg SC (for participants with body weight \>=100kg).
41143614|NCT01382706|DRUG|docetaxel|Given IV
41304029|NCT03285217|DIETARY_SUPPLEMENT|Ensure High Protein|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
41304030|NCT06329141|DRUG|Vutiglabridin|Once-daily oral administration
40983678|NCT01876342|PROCEDURE|open repair|2-0 sutures
40983679|NCT01876342|PROCEDURE|endoscopic TEP repair|mesh
41143615|NCT01382706|DRUG|lapatinib ditosylate|Given PO
41143616|NCT01382706|OTHER|immunohistochemistry staining method|Correlative studies
41143617|NCT01382706|GENETIC|fluorescence in situ hybridization|Correlative studies
41143618|NCT01382706|OTHER|laboratory biomarker analysis|Correlative studies
41304031|NCT06329141|DRUG|Placebo|Once-daily oral administration
41304032|NCT04567966|PROCEDURE|Split-block technique|Horizontal ridge augmentation using the split-block technique where a cortical bone plate harvested from the external oblique ridge was split in half and fixed at a distance from the atrophied ridge. Then autogenous bone chips were packed in the gap between the plate and the ridge.
41304033|NCT04567966|PROCEDURE|Cortico-cancellous block graft|Horizontal ridge augmentation using a cortico-cancellous block harvested from the chin of the mandible.
41304034|NCT01002534|DRUG|Vardenafil|Nasal instillation of Vardenafil
41143619|NCT00098735|DRUG|FTY720|
41143620|NCT06463509|OTHER|Establishment of an in-deepth tumor profiling platform|In-depth tumor profiling beyond genomics
41143621|NCT06103877|BIOLOGICAL|AZD1163|"In Part 1, Participants will receive AZD1163 through IV infusion or SC injection on Day 1.~In Part 2, participants will receive AZD1163 through SC injection on Days 1 and 15."
41143622|NCT06103877|OTHER|Placebo|"In Part 1, Participants will receive matching placebo through IV infusion or SC injection on Day 1.~In Part 2, participants will receive matching placebo through SC injection on Days 1 and 15."
41143623|NCT02854982|PROCEDURE|therapeutic management of the prostate Cancer as usual|
41143624|NCT04507347|DRUG|TRC041266|TRC041266 sachet 1500 mg strengths
40778882|NCT04857554|OTHER|White bread as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
40983680|NCT02461901|OTHER|Environmental sampling|Sampling of five sites in the patient's immediate environment for C. difficile spores
40983681|NCT02461901|OTHER|Skin swab sampling|Collection of swabs from three sites on the skin for C. difficile spores
40983682|NCT02461901|OTHER|Fecal sampling|Collection of fecal samples for C. difficile spores
40983683|NCT05908695|DRUG|GV-971|Administered PO
40983684|NCT05908695|DRUG|Placebo|Administered PO
40983685|NCT05513079|BEHAVIORAL|Positive Psychotherapy Based Counseling|The main purpose in Positive Psychotherapy is to develop the individual's main capacities. and to maintain balance in the four areas of life (body, success, relationships and future) in daily life. to help provide. The essence of Positive Psychotherapy is a five-step process: 1. Observation/distance phase, 2. Inventory phase, 3. Situational encouragement phase, 4. Verbalization phase, 5. Expanding the objectives phase. Shaping five-step model therapy It is a helpful guide.
40983686|NCT03792867|DRUG|Doxorubicin|Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
40983687|NCT03654651|DRUG|Peanut|Roasted, unsalted peanuts will be purchased from a local grocery store and provided to subjects to consume.
40778883|NCT04857554|OTHER|White bread with apricot jam|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread together with apricot jam along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
40778884|NCT04857554|OTHER|Cereal bar with cranberries|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from a cereal bar with cranberries along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
40778885|NCT04857554|OTHER|Cocoa drink|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from cocoa powder mixed with 500ml fat-free milk, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
40778886|NCT01680211|DIETARY_SUPPLEMENT|Salacia bark extract|
41304035|NCT01002534|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
41304036|NCT02046343|BEHAVIORAL|Health education|Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
41304037|NCT02046343|BEHAVIORAL|Telephone Counseling|Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.
41304038|NCT02046343|OTHER|Newsletter|Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.
41304039|NCT02046343|OTHER|Environmental Change|Create a site atmosphere that promotes PA and increases the number of PA program offerings.
41304040|NCT06347276|DEVICE|PFO occluder; ASD occluder|Transcatheter closure of atrial septal defect (ASD) and patent foramen ovale (PFO) All cases will be examined with DW-MRI preoperatively, and DW-MRI will be repeated 24 hours and 4 weeks after the transcatheter closure procedure.
41304041|NCT06101862|PROCEDURE|CCTA|Participants will be examined during admission.
41143625|NCT04507347|DRUG|Placebo|TRC041266 sachet 1500 mg matching placebo
40778887|NCT01680211|DIETARY_SUPPLEMENT|Salacia leaf extract|
40778888|NCT01680211|DIETARY_SUPPLEMENT|Sesame seed extract|
40778889|NCT01680211|BEHAVIORAL|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
40778890|NCT01680211|OTHER|Placebo|
41143626|NCT01998334|OTHER|CVVH 6h|CVVH 6h for first three days
41143627|NCT01998334|OTHER|CVVH 10h|CVVH 10h for first three days
40983688|NCT03654651|DRUG|High carbohydrate snack|Whole wheat crackers will be purchased from a local grocery store and provided to subjects to consume with a spread (e.g. cream cheese or margarine).
40983689|NCT00427466|DRUG|Pemetrexed|
41143628|NCT01998334|OTHER|CVVHDF 6h|CVVHDF 6h for first three days
41143629|NCT00753155|BEHAVIORAL|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
41143630|NCT00589628|DRUG|infliximab|5mg/kg/dose IV at 4 week intervals
41143631|NCT00589628|DRUG|infliximab|10mg/kg/dose IV at 4 week intervals
41304042|NCT06101862|PROCEDURE|Conventional ICA|Standard-of-care with conventional ICA.
41304043|NCT06101862|OTHER|Team-based interventional triage|If the CCTA suggests a potential requirement for revascularization, the CCTA will be discussed at a coronary CT-team conference to establish the treatment strategy and provide guidance for any necessary interventional procedure.
41304044|NCT02693483|DRUG|10% povidone iodine|Vaginal cleansing will be done with 3 gauze pieces soaked with 10% povidone iodine in a sterilized bowl and the scrub will be done from the vaginal apex to introitus with attention to the anterior, posterior and lateral vaginal wall
41304045|NCT05972135|DRUG|Teclistamab|Teclistamab will be administered subcutaneously at step-up doses on Day 1, Day 4 and Day 8, one week after first treatment dose and weekly thereafter. In participants who have a partial response (PR) or better after 6 months of therapy, dosing frequency may be reduced to every 2 weeks.
41304046|NCT05972135|DRUG|Talquetamab|Talquetamab will be administered subcutaneously at step-up doses on Day 1, Day 4, Day 8 and Day 15, one week after first treatment dose and every 2 weeks thereafter. In participants who have a very good partial response (VGPR) or better after Cycle 4, dosing frequency may be reduced to every 4 weeks
41143632|NCT05748808|BEHAVIORAL|Use of biofeedback and virtual reality in the treatment of aggressive outbursts|Participants are trained to identify their physiological response when they are relaxed and when an outburst is coming. They are treated with cognitive, behavioral and emotional self-regulation therapies for managing anger and learning positive coping skills. Biofeedback toghether with virtual reality help them to improve their recognition and control of emotions.
40778891|NCT05753176|BEHAVIORAL|Online 1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained facilitators (i.e., psychotherapists, social workers, nurses, and/or a psychiatrist) consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. Participants are also given a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
40778892|NCT00772759|DRUG|AZD3199 Turbuhaler®|240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
40778893|NCT00772759|DRUG|Placebo Turbuhaler®|single and multiple (o.d. for 12 days)
40778894|NCT00004103|DRUG|cisplatin|
40778895|NCT00004103|DRUG|floxuridine|
40778896|NCT00004103|DRUG|irinotecan hydrochloride|
40778897|NCT00004103|PROCEDURE|adjuvant therapy|
41143633|NCT03070301|DRUG|LEE011|LEE011 200 mg daily
41304047|NCT05972135|DRUG|Tocilizumab|Tocilizumab will be administered as a pretreatment medication in advance of administration of the first step-up dose of teclistamab or talquetamab on Cycle 1 Day 1.
41304048|NCT05903196|DEVICE|Mygen V-1000 RF system|The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation \& ablation of vessel, tissue \& bone
40778898|NCT00004103|PROCEDURE|conventional surgery|
41143634|NCT03070301|DRUG|everolimus|everolimus 5 mg daily or 2.5mg daily
41143635|NCT04362618|OTHER|Muscle Strengthening Training|Muscle strengthening training will take place for a period of 12 weeks, in which participants will have 36 exercise sessions (18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. Muscles of the leg (i.e. quadriceps, hip ab- and adductors) will be trained at 3 set of 10 repetitions at 80% of 1RM with the use of elastic bands. 1RM will be assessed at baseline and the exercise intensity will be progressively increased by 10% of 1RM every two sessions from 50 up to 70-80 % of 1RM. Every 6 sessions, the 1RM will be reassessed and the training resistances will be adapted.
40778899|NCT00004103|PROCEDURE|neoadjuvant therapy|
40778900|NCT00413114|DRUG|Obatoclax mesylate (GX15-070MS)|
40778901|NCT05253040|OTHER|KEEP Intervention|Educational intervention
40778902|NCT05253040|OTHER|control|booklet from Parkinson's UK
40778903|NCT02573064|DRUG|Colistin|
40778904|NCT02573064|DRUG|Tigecycline|
40778905|NCT02573064|DRUG|Vancomycin|
41462979|NCT02255487|DEVICE|IrriSept System|"The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.~Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation."
40778906|NCT01664624|DRUG|Roflumilast|Roflumilast tablets
40778907|NCT01664624|DRUG|Alogliptin|Alogliptin tablets
40778908|NCT01664624|DRUG|Exenatide|Exenatide solution
40778909|NCT01664624|DRUG|Placebo to roflumilast|Placebo-matching roflumilast tablets
40778910|NCT01664624|DRUG|Placebo to alogliptin|Placebo-matching alogliptin tablets
40778911|NCT00874601|DRUG|Diovan® (valsartan)|"The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded."
40778912|NCT04747262|BEHAVIORAL|SPACE|SPACE program, an evidence-based protocol that has been proven to be efficent in childhood anxiety disorders and OCD (Lebowitz, 2013; Lebowitz, Omer, Hermes \& Scahill, 2014)
40983690|NCT01705652|DRUG|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
40983691|NCT06405061|DRUG|Adebrelimab|Adebrelimab: 1200 mg, IV, q3w
40778913|NCT01006161|DRUG|SCH 527123|Low dose
40778914|NCT01006161|DRUG|SCH 527123|Medium dose
40778915|NCT01006161|DRUG|SCH 527123|High dose
40778916|NCT01006161|DRUG|SCH 527123|Placebo to match SCH 527123
40778917|NCT03982160|DRUG|L-Arginine|Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.
40778918|NCT03982160|OTHER|Placebo|Saline
40778919|NCT04089514|DRUG|Adalimumab|Administered as specified in the treatment arm
40778920|NCT01920490|DEVICE|GUILT-INCREASE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
40778921|NCT01920490|DEVICE|GUILT-STABILIZE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
40778922|NCT03217617|BIOLOGICAL|Direct intravenous injection of ivlv-X1 lentiviral vector|ivlv-X1 LV intravenous injection at a dose of \~1x10e9/kg body weight.
40778923|NCT05324241|DIETARY_SUPPLEMENT|Fat Microcapsules|Consumption of a drink that contains microencapsulated fat that will be released either in the stomach or in the distal small intestines.
40778924|NCT01093014|BEHAVIORAL|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
40778925|NCT01093014|BEHAVIORAL|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
40778926|NCT01093014|BEHAVIORAL|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
40778927|NCT04490278|OTHER|Medical Record Review - Inpatient Treatment|Patient characteristics, medical history, and information regarding their inpatient treatment from the electronic medical record
40983692|NCT00310583|DRUG|Pregabalin|
40983693|NCT00469989|PROCEDURE|Infection with hookworm larvae|
40778928|NCT04490278|OTHER|Online Questionnaires|Patients will complete online questionnaires related to their physical, cognitive and mental health function and inquire about current treatments. The multiprofessional CoV-PICS clinic practitioners will evaluate their responses and, combined with information obtained during their virtual visits, formulate a suggested treatment plan and needed referrals.
40778929|NCT03627052|DRUG|Itacitinib|In the double-blind period, itacitinib administered orally once or twice daily at the protocol-defined dose according to treatment group randomization. In the open-label extension, itacitinib administered at doses determined from the double-blind period.
40778930|NCT03627052|DRUG|Placebo|Placebo administered orally twice daily in the double-blind period.
40778931|NCT05237687|DRUG|Sirolimus|Patients will be randomly assigned to sirolimus or standard of care
41462980|NCT02255487|OTHER|No Intervention - Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) as surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
41462981|NCT06044727|PROCEDURE|Minimally invasive non surgical periodontal therapy|using Magnifying loupes
41462982|NCT06044727|PROCEDURE|Conventional subgingival instrumentation|Conventional subgingival instrumentation
40983694|NCT03793231|COMBINATION_PRODUCT|fungalAi platform technology|Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.
40983695|NCT01259323|BIOLOGICAL|REGN668|Dose 1: REGN668 or placebo
41462983|NCT02488824|PROCEDURE|Warm Temperature|Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
40778932|NCT03332030|DIAGNOSTIC_TEST|Collection of Stem Cells|One time collection of a 20 ml blood sample
40778933|NCT02877017|BEHAVIORAL|Family safety reporting intervention|family safety reporting intervention for families and providers
40983696|NCT01259323|BIOLOGICAL|REGN668|Dose 2: REGN668 or placebo
40983697|NCT01259323|BIOLOGICAL|REGN668|Dose 3: REGN668 or placebo
40983698|NCT03348956|DIAGNOSTIC_TEST|EPR Oximetry|Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
41143636|NCT04362618|BEHAVIORAL|Behavioral graded activity|Subjects will receive a behavioural treatment integrated within the concepts of operant conditioning with exercise therapy for a period of 12 weeks, in which the subjects will have maximum 36 BGA sessions (min. 13- max. 18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. The purpose of BGA is to increase the level of activities in a time-contingent manner and increase the level of physical activity in the subject's daily lives. BGA consists of 3 phases: pain education (phase 1), treatment phase in which subjects increase their level of activity gradually (phase 2) and integration of learned principles in daily live (phase 3).
41143637|NCT04047303|DRUG|CC-90010|CC-90010
41462984|NCT00929058|DRUG|Bevacizumab|Intra-arterial infusion during 6 minutes
40983699|NCT05264155|BEHAVIORAL|GameBus (mHealth app)|Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.
40983700|NCT02123745|DEVICE|The ivWatch Model 400|The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
40983701|NCT00934154|DRUG|Thalidomide|100 mg/day continuously for 12 months
40983702|NCT00934154|DRUG|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
40983703|NCT02442869|BEHAVIORAL|Stage 1 Treatment as usual (TAU)|4-8 weeks of the treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.
40983704|NCT02442869|BEHAVIORAL|Stage 1 CAMS|4-8 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
40983705|NCT02442869|BEHAVIORAL|Stage 2 CAMS|4-16 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
40983706|NCT02442869|BEHAVIORAL|Stage 2 Dialectical Behavioral Therapy (DBT)|4-16 weeks of Dialectical Behavioral Therapy (DBT)
40983707|NCT02314650|OTHER|acupoint stimulation|stimulation was given at acupoints
40983708|NCT02314650|OTHER|non-acupoint stimulation|stimulation was given at non-acupoints
40983709|NCT02314650|OTHER|electrodes attached|electrode were attached to skin
40983710|NCT03310554|PROCEDURE|26cm suspended overlength biliary stents|The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP
40983711|NCT03310554|PROCEDURE|30cm suspended overlength biliary stents|The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
40983712|NCT03310554|PROCEDURE|ordinary plastic biliary stents|The control group will be placed ordinary plastic biliary stents in bile duct in ERCP
40983713|NCT02143869|DEVICE|Bioelectrical Impedance Analysis|Measurements of body composition including fat mass, lean body mass, muscular mass, mineral mass, total body water, intra and extracellular water.
40983714|NCT04047433|GENETIC|screening for single nucleotide polymorphism|samples from both arms will be tested for a set of single nucleotide polymorphism
40983715|NCT04047433|GENETIC|whole exome sequencing|samples from arm #1 (women with external anal sphincter) will be tested for identifying specific genetic mutation
41143638|NCT00460434|DEVICE|TVT|Prophylactic TVT
41143639|NCT00460434|OTHER|Sham|Sham TVT
41462985|NCT03439995|OTHER|Open lung protective ventilation|Higher PEEP, lower tidal volume mechanical ventilation
41462986|NCT03439995|OTHER|Conventional ventilation|Lower PEEP, standard tidal volume mechanical ventilation
40983716|NCT03872219|COMBINATION_PRODUCT|Nature-based materials|In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
41143640|NCT02710669|DRUG|(R)-propafenone|
41143641|NCT02710669|DRUG|(S)-Propafenone|
41143642|NCT02710669|DRUG|Placebo|
41143643|NCT05792475|DIAGNOSTIC_TEST|Define Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software|TaiHao Breast Cancer Diagnostic Software independently define standard of truth (SOT) about108 cases.
41143644|NCT00941447|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
41462987|NCT01859026|DRUG|MEK162|Treatment as outlined in study arms.
41143645|NCT00941447|BEHAVIORAL|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
41462988|NCT01859026|DRUG|Erlotinib|Treatment as outlined in study arms.
41462989|NCT00080795|BIOLOGICAL|filgrastim|
41462990|NCT00080795|DRUG|cisplatin|
40983717|NCT03084874|BEHAVIORAL|Physical activity and sedentary behavior coaching program|The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
40983718|NCT03081507|BEHAVIORAL|SM-LHW|Will not receive additional follow-up from the LHW, but will be encouraged during the session to make an appointment with their provider to schedule a mammogram and Pap test, or to consult the MARHABA webpage for information on low-cost and culturally appropriate referral sources of screening. Individuals assigned to this arm who did not attend an educational seminar will be mailed a packet containing a palm card, brochure, and letter encouraging them to speak with their provider about breast and cervical cancer screening and/or going to the MARHABA webpage. LHWs will complete a follow-up survey with participants by phone or in-person at 4 months after baseline
40778934|NCT02213250|DRUG|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
40983719|NCT03081507|BEHAVIORAL|PN-LHW|PNLHW participants will receive three planned contacts with LHWs that focus on navigation for obtaining mammogram and/or Pap testing.The initial contact will be made by phone and will focus on motivating participants to make an appointment with their primary care provider and/or obstetrician/gynecologist (OB/GYN), as well as provide information on low-cost or free care if necessary. The second contact will discuss the process of going to the appointment and the third contact will focus on the process of obtaining and interpreting. The second and third contacts will be either made by phone or in-person, depending on participant needs.
40983720|NCT02062918|DEVICE|Abdominal belt|
40983721|NCT00588848|DEVICE|Autoadjusting CPAP (VPAP Auto)|An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
40983722|NCT00588848|DEVICE|CPAP|Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
40983723|NCT00607529|OTHER|hand-held POC creatinine analyzer-blood test|"This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the investigational hand-held creatinine analyzer using special test strips for the analysis."
40983724|NCT03106220|BEHAVIORAL|exercise|home exercise program
40983725|NCT03106220|OTHER|placebo|encourage walking and physical therapy per standard care.
40983726|NCT00755287|DRUG|insulin glargine|starting dose 10 IU daily
40983727|NCT00755287|DRUG|metformin|As prescribed
40983728|NCT00755287|DRUG|taspoglutide|10 mg once weekly
40983729|NCT00755287|DRUG|taspoglutide|20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
40983730|NCT03764137|DRUG|[89Zr]Panitumumab PET-MRI|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
40983731|NCT02786342|PROCEDURE|blood sample collection|
40983732|NCT00042770|OTHER|talc|Given intrapleurally
40983733|NCT00042770|PROCEDURE|dyspnea management|No talc
40983734|NCT05819554|PROCEDURE|Trans-sphenoidal surgery|Surgical removal of pituitary tumor by trans-sphenoidal approach
41143646|NCT00941447|BEHAVIORAL|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
41143647|NCT06340958|DRUG|CLE-100|1 tablet of CLE-100 administered once daily
41143648|NCT06340958|DRUG|Placebo|1 tablet of placebo administered once daily
41304049|NCT02817555|DRUG|Epoetin Alfa|"The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin \> 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
41462991|NCT00080795|DRUG|doxorubicin hydrochloride|
41462992|NCT00080795|DRUG|gemcitabine hydrochloride|
41462993|NCT00080795|DRUG|ifosfamide|
40983735|NCT03287505|DRUG|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.
40983736|NCT00292864|DRUG|SNS-032 Injection|
40983737|NCT06350292|BEHAVIORAL|SLEEP: COPE|Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
41143649|NCT05542004|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
41462994|NCT00080795|PROCEDURE|conventional surgery|
41462995|NCT00080795|PROCEDURE|neoadjuvant therapy|
41462996|NCT04692857|PROCEDURE|supra inguinal fascia iliaca block|injection of 30,40 or 50 ml of 0.2 ropivacaine .
41462997|NCT01474915|DRUG|Aprepitant|Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
41462998|NCT01474915|DRUG|Ondansetron|Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
41462999|NCT01474915|DRUG|Promethazine|Subject will receive 25 mg of Promethazine IV around anesthesia induction
41463000|NCT01474915|DRUG|Dexamethasone|Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
40983738|NCT00129454|BEHAVIORAL|Cognitive Behavioral Therapy|"The investigators adapted two previously validated CBT manuals for use in both Telephone and In-Person groups (the Personal Health Improvement Program and Dr. Charles Engel's group treatment for GWI). Treatment included the following standard components of CBT: Didactic or educational material about the causes of GWI and an explanation of how thinking can cause stress (ABC model); Assessment of psychological distress and behavioral problems that may be targets of therapeutic intervention (e.g. symptom-related anxiety); Assessment of thinking errors that lead to psychological distress and trigger behavioral problems (e.g. catastrophizing); Cognitive restructuring to teach disputing skills or how to correct thinking errors; Cognitive and behavioral homework assignments (e.g. written self-disclosure); Didactic homework assignments (e.g. listen to previous treatment session)."
40983739|NCT00129454|BEHAVIORAL|Cognitive Behavioral Therapy|This description is the same as the experimental treatment only disseminated in person rather than over the telephone.
40778935|NCT06192563|DRUG|Dupilumab|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
40983740|NCT00746642|DEVICE|Mellitor device for glucose measurement|"Glucose measurement using Mellitor device"
40983741|NCT02821481|DIETARY_SUPPLEMENT|Beta-alanine|
40778936|NCT06325787|PROCEDURE|thyroid lobectomy|thyroid lobectomy
40778937|NCT06325787|PROCEDURE|image-guided thermal ablation|radiofrequency ablation or microwave ablation or laser ablation
40983742|NCT02821481|DIETARY_SUPPLEMENT|Placebo|
40983743|NCT02821481|BEHAVIORAL|Muscular endurance exercise|
40983744|NCT03833973|BEHAVIORAL|Overtraining Monitoring|Athletes will be thoroughly monitored (i.e. training workload, match activities or event/race performance, markers of inflammation and oxidative stress as well as cell-free DNA) throughout the season in order to establish novel biomarkers that could function as either predictors or diagnostic tools of overtraining.
40983745|NCT03363204|DEVICE|BRUXENSE occlusal splint|Patients participating will put the BRUXENSE occlusal splint each night. During the night the device will collect data potentially related to bruxism. After each night the device will be cleaned with water and toothpaste and charged. This routine will be conducted over 10 consecutive nights.
40983746|NCT03036072|OTHER|Strict normothermia|
40983747|NCT03036072|DEVICE|Delayed Rewarming|Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
40983748|NCT04431648|DRUG|DEFINITY|MRI-guided ultrasound-stimulated microbubble-treatment
41304050|NCT02817555|DRUG|Darbepoetin alfa|"The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin \>150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
41304051|NCT05663996|OTHER|locally applied to the skin|Applying St John's wort oil locally on the knee three times a day for three weeks.
41304052|NCT05663996|OTHER|locally applied to the skin|Applying olive oil locally on the knee three times a day for three weeks.
41304053|NCT05841134|DRUG|Tislelizumab|"Neoadjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, D1, Q3W, a total of 4 cycles; Oxaliplatin 130mg/m2, intravenous infusion, D1, Q3W, 4 cycles in total; Capecitabine 1000mg/m2, orally twice in the morning and evening, D1-14, Q3W, 4 cycles in total;~Adjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, Q3W;~± Chemotherapy method (researcher judges whether to add chemotherapy according to the comprehensive condition of the patient); Until disease progression or unacceptable toxicity, the maximum treatment time is 12 months."
41304054|NCT04982432|DRUG|Orismilast|Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties
41143650|NCT00882323|DRUG|Cyclophosphamide, Fludarabine, Thymoglobulin|"cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)"
41143651|NCT02731950|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
41463001|NCT06409858|OTHER|Pilates|Twice-weekly mat Pilates class for 8 weeks, either in person or online (depending on participant availability)
41463002|NCT05824858|DRUG|LY3537982|Administered orally.
40983749|NCT04431648|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
40983750|NCT00975481|DRUG|dimebon|Oral tablet; 20 mg dimebon, single dose
40983751|NCT00975481|DRUG|dimebon|Oral tablet; 40 mg dimebon, single dose
41143652|NCT01393600|DRUG|NBI-98854|12.5 mg powder in bottle once daily for 14 days
41143653|NCT01393600|DRUG|NBI-98854|50 mg powder in bottle once daily for 14 days
41304055|NCT03531437|DRUG|1.5 mg estradiol and 2.5 mg nomegestrol acetate|
41304056|NCT03531437|DRUG|15 µg ethinylestradiol and 60 µg gestodene|
41304057|NCT06176963|COMBINATION_PRODUCT|SB11 PFS|SB11 provided in a pre-filled syringe (PFS) containing 0.5 mg ranibizumab in 0.05 mL for ITV injection
41304058|NCT03311607|DRUG|AmBisome|A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule
41463003|NCT06267183|DRUG|SV001|SV001 ： single-dose
41463004|NCT06267183|DRUG|Placebo|Placebo ： single-dose
41463005|NCT05750706|OTHER|observation of invasive fungal infections|observation of invasive fungal infections during chemotherapy
40983752|NCT00975481|DRUG|dimebon|Oral tablet; 60 mg dimebon, single dose
40983753|NCT00975481|DRUG|placebo|Oral tablet or capsule; placebo, single dose
40983754|NCT00975481|DRUG|alprazolam|Oral capsule; 1 mg alprazolam, single dose
40983755|NCT00975481|DRUG|alprazolam|Oral capsule; 3 mg alprazolam, single dose
40983756|NCT00927784|BIOLOGICAL|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
40983757|NCT00927784|DRUG|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
40983758|NCT01262950|OTHER|portable motion detector|
40983759|NCT01302587|DRUG|Albuterol|Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
40983760|NCT04617444|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
41143654|NCT01393600|DRUG|Placebo|Solution containing no active substance
41143655|NCT01217645|RADIATION|150 mg [14C] AZD6765|
41143656|NCT03773432|OTHER|Probe meal|The probe meal will be administered either in the afternoon (conventional schedule) or in the morning (unconventional schedule).
40983761|NCT04617444|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
40983762|NCT02312895|OTHER|Manual therapy|The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
40983763|NCT02312895|OTHER|Dry needling|Dry needling involves inserting a dry, mono-filament needle through the skin and into an area of symptomatic soft tissue. The two-inch needles will be placed segmentally and into the lower extremities following peripheral nerve patterning by the treating physical therapist. Following initial penetration into the skin over the tender area, the therapist carefully advances the needle into the tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the tender area identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the tissue for up to 5 minutes, removed, and appropriately disposed of.
40983764|NCT02312895|OTHER|Home Exercise Program|A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
40983765|NCT06203860|OTHER|Cardio-Metabolic Clinic|"The Cardio-Metabolic Clinic will adhere to a standardized evaluation and treatment program based on the latest treatment guidelines from the European Cardiovascular Society. The assessment will include the following points:~* Lipid management~* Blood pressure management~* Antithrombotic therapy~* Glycemic targets~* Prevention of diabetes-related complications~* Treatment of vascular disease affecting the lower extremities~* Evaluation of cardioprotective drugs~* Counseling on lifestyle factors, including diet, smoking, alcohol, and exercise~* Guidance on vaccinations"
40983766|NCT02348541|DEVICE|CollaGUARD|
41143657|NCT06092684|DRUG|BT-KTM-I|The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
40778938|NCT00003525|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41143658|NCT06092684|DRUG|Ketanest®S|The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
41143659|NCT05974631|BEHAVIORAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).
41143660|NCT05974631|BEHAVIORAL|Dialectical Behavior Therapy Prolonged Exposure protocol|DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).
41463006|NCT04817514|OTHER|Shoulder rehabilitation exercises and aerobic exercises|"SRG group: the group will only perform mobility and strengthening exercises involving the shoulder complex.~ARG group: The ARG group will perform the shoulder rehabilitation protocol presented above combined with the aerobic exercise program that will last 20 minutes per session at 40% of the reserve heart rate (HRC), progressing up to 40 minutes with a maximum of 60% of the HRC in the last two weeks, according to the recommendations for patients with type 2 DM proposed in the American College of Sports Medicine Guidelines."
41463007|NCT01263561|PROCEDURE|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
40778939|NCT05228418|DRUG|Naltrexone Pill|Naltrexone oral bridge to IM naltrexone maintenance therapy
40778940|NCT02143284|DEVICE|Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)|The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
40778941|NCT02040389|BEHAVIORAL|Picture book|Arm with showing and explaining for parents about perioperative typical surgery site/wound view by study's team
40778942|NCT02040389|BEHAVIORAL|Standard preoperative education|Arm with standard, verbal explaining for a parents about perioperative site/wound view
40983767|NCT03596528|PROCEDURE|Lung biopsy|Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
40983768|NCT01575496|DEVICE|BrainSTIM Transcranial Stimulator|Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
40983769|NCT01575496|DEVICE|BrainSTIM Transcranial Stimulator|Sham tDCS sessions will last 20 minutes.
40983770|NCT05599633|DIETARY_SUPPLEMENT|Sago starch drink|Sarawak sago starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
40983771|NCT05599633|DIETARY_SUPPLEMENT|Corn starch drink|Corn starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
40983772|NCT02441608|DEVICE|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
40983773|NCT03969394|DIAGNOSTIC_TEST|Medical imaging|Medical Imaging consisting of 1 MRI and 1 echocardiography at baseline
41463008|NCT01263561|PROCEDURE|trabeculectomy|trabeculectomy filtering surgery
40778943|NCT04734860|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
40983774|NCT03038633|OTHER|Novel Medical Food|This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
40983775|NCT06384716|OTHER|rehabilitation programme based on motor control of core muscles|The exercises performed during the intervention aim to improve the functionality of MS patients and to assess how this can improve pelvic floor health, quality of life, sexual health and urinary incontinence. A specific exercise programme has been designed and will be carried out by physiotherapists specialised in neurological physiotherapy for this purpose. The ultimate aim of the research is to be able to benefit other MS patients from our findings and to propose specific interventions in these areas. However, it is possible that no direct benefit will be obtained after the intervention. At the end of the research you will be informed, if you wish, about the main results and general conclusions of the study. The study does not pose any risk to your health as it is a non-invasive study and no harmful or deleterious action is incurred for the additional collection of the necessary records.
40983776|NCT03733691|DRUG|Ixazomib|3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles
40983777|NCT03733691|DRUG|Lenalidomide|Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.
40983778|NCT05473338|DIAGNOSTIC_TEST|Stool and blood samples|fecal microbiome and metabolomics, as well as metabolites in plasma
41143661|NCT05974631|BEHAVIORAL|Prolonged Exposure therapy|Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.
41143662|NCT05974631|BEHAVIORAL|Suicide risk management|Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.
41143663|NCT02172937|BIOLOGICAL|Decidual Stromal Cells thawed in plasma|
41143664|NCT02172937|BIOLOGICAL|Decidual Stromal Cells thawed in human albumin|
41304059|NCT05342129|OTHER|exercise bike|exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
41304060|NCT02739022|BEHAVIORAL|Early Psychological Support for the Critically Ill (EPSCI)|early psychological support based on positive therapeutic suggestion
41463009|NCT04647734|BEHAVIORAL|High intensity interval training|12 weeks of high intensity interval training on exercise bike for 38 minutes 3 times a week
41304061|NCT04070313|DRUG|S-1|Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
41304062|NCT05277155|DIETARY_SUPPLEMENT|BEJO Red Ginger Extract|"BEJO Red Ginger Extract ingredients:~* Zingiber officinale var. rubrum (Rhizome extract) 80 mg~* Foeniculi vulgare Fructus (Fennel) 25 mg~* Menthae arvensis Folium (Mint) 5 mg~* Piper retrofractum Fructus (Javanese long pepper) 12.5 mg~* Honey 7500 mg"
41463010|NCT04647734|BEHAVIORAL|Standard care|standard care after discharge from hospital (control group)
40778944|NCT04734860|DRUG|Placebo|Diluent solution
40778945|NCT04050384|DEVICE|Baby GentleStick|The Baby GentleStick is a handheld device that fits and provides vibration to an Owen Mumford Unistik3 Dual lancet. The gentle vibration occurs at 178 Hertz with a free-hanging 0.24 mm range of motion. The device may provide vibration alone and also allow for simultaneous vibration and deployment of the lancet.
41463011|NCT02495376|BEHAVIORAL|MBSR|Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
41143665|NCT03039322|DIAGNOSTIC_TEST|Serum Golgi Protein 73|Serum test
41143666|NCT05894551|OTHER|Evaluation of q angles different positions|Q angle evaluation in two different static postures (upright and supine position) and dynamic posture during the midstance phase of the gait
41463012|NCT02318550|OTHER|MRI Scan|"The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:~* Normal operating mode~* SAR ≤ 2.0 W/kg per patient."
41463013|NCT00124462|DEVICE|Realigning knee brace and custom orthodic|A valgus brace, customized functional orthotic for neutral foot position and motion control footwear
41463014|NCT00124462|DEVICE|Non realigning knee brace and flat orthodic|A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
41463015|NCT00230594|DRUG|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
41463016|NCT00230594|DRUG|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
41463017|NCT02226991|DRUG|Tipranavir|
41463018|NCT02226991|DRUG|Ritonavir|
41463019|NCT02226991|DRUG|Efavirenz|
41463020|NCT06249893|OTHER|Point-of-care vascular ultrasound|Point-of-care ultrasound will be used to image the femoral vessels and to perform a pulsed-wave doppler measurement of blood flow during chest compressions and during pauses for rhythm and manual pulse checks.
40983779|NCT05473338|OTHER|Physical examination|physical examination performed by a physician to confirm CRPS diagnosis and assess patient's eligibility to participate in the study. The exam will include skin temperature measured using a laser/infrared skin thermometry.
41463021|NCT01956565|OTHER|Inspiratory Muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
41463022|NCT04919590|BEHAVIORAL|This is Quitting|Text message-based intervention for quit vaping support.
40983780|NCT05473338|OTHER|Questionnaires|Questionnaires measuring pain level, sleep, mood and diet parameters.
40983781|NCT01248442|DRUG|Cholecalciferol|monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
40983782|NCT01248442|DRUG|Placebo|Matching Placebo
40983783|NCT00110825|BEHAVIORAL|Cognitive Behavior Therapy|extended treatment with cognitive behavior therapy
40983784|NCT05931354|OTHER|HPV test and Pap Smear|HPV test and Pap Smear
41463023|NCT04919590|OTHER|Assessment only control|Assessment only
41463024|NCT04919590|OTHER|Waitlist control|No contact until follow-up survey, waitlisted to receive intervention post study
41463025|NCT02197208|PROCEDURE|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
41463026|NCT02197208|PROCEDURE|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is \>/= 17 mm and the endometrium measures \>/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
41463027|NCT02197208|DEVICE|ultrasound|
41463028|NCT03620617|DIETARY_SUPPLEMENT|Raspberry supplement|During the 8-week protocol, participants will be invited either to consume 280g of frozen raspberries daily (morning and evening). The daily dose is equivalent to 2 cups of raspberries.
41463029|NCT05493358|PROCEDURE|Laparoscopic distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
41463030|NCT00297141|DRUG|Capecitabine|chemotherapy oral use
41463031|NCT00297141|DRUG|Oxaliplatin|chemotherapy intravenous use
41463032|NCT01061515|DRUG|Intraperitoneal Oxaliplatin|
41463033|NCT01061515|DRUG|Bevacizumab|
41463034|NCT01061515|DRUG|Capecitabine|
40778946|NCT01690754|OTHER|Interactive Reminders|Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
40983785|NCT06296108|OTHER|acute kidney injury|The incidence of acute kidney injury was determined in patients included to the study
40983786|NCT04966507|DRUG|Listerine Antiseptic Mouthwash Product|COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
40983787|NCT04966507|DRUG|Biotene Mouthwash|Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
40983788|NCT04860791|OTHER|questionnaires|Patients will complete the MSWDQ-23 in French, as well as the DEX, questionnaire for the evaluation of executive dysfunction in daily life, to evaluate their cognitive complaints and the SF36 questionnaire to evaluate their quality of life
40983789|NCT01719523|DRUG|EPI-743|
41463035|NCT01621906|DEVICE|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
41463036|NCT01621906|DEVICE|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
41463037|NCT04909112|OTHER|Evaluation of olfactory function|Evaluation of olfactory function using olfactory detection thresholds
41463038|NCT04909112|OTHER|Evaluation of taste function|Evaluation of taste function using taste detection thresholds
41463039|NCT04909112|OTHER|Evaluation of (intra-nasal and oral) trigeminal functions|Evaluation of (intra-nasal and oral) trigeminal, interacting with olfactory and taste pathways, using odor and taste stimuli.
41463040|NCT02132650|BEHAVIORAL|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
41463041|NCT02132650|BEHAVIORAL|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
40778947|NCT01378143|DRUG|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
40983790|NCT03757689|DRUG|Pembrolizumab|Pre-Surgery: Pembrolizumab, one 200mg dose; Post-Surgery: Pembrolizumab, 200 mg every 3 weeks.
40983791|NCT03757689|PROCEDURE|Wide Excision and Sentinel Lymph Node (SLN) Biopsy|Wide excision and SLN biopsy and pathologic assessment of tissue will be performed per standard of care.
40983792|NCT02645214|OTHER|Non-antiseptic scrubs|
40983793|NCT02645214|OTHER|Antiseptic scrubs|
40983794|NCT01484873|DRUG|Exenatide|Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
40983795|NCT02589951|OTHER|admission to non-psychiatric service|
40983796|NCT05829889|PROCEDURE|FFR-Guided PCI|Fractional Flow Reserve-Guided PCI
40983797|NCT05829889|PROCEDURE|Angiography-Guided PCI|Angiography-Guided PCI
40983798|NCT02066974|GENETIC|hepatoma requiring radiotherapy|hepatoma requiring radiotherapy
40983799|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - lowest ratio|the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
40983800|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - medium ratio|the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed
40983801|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - highest ratio|the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed
40983802|NCT01108601|DRUG|Ringer's Lactate (0.03% Ciprofloxacin)|For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
41143667|NCT05894551|OTHER|Physical examination|"With goniometric evaluations, the femoral anteversion angle will be measured. Pelvis width and thigh length will be measured with a tape measure. Quadriceps muscle strength, hamstring muscle strength, Hip abduction, adduction, internal and external rotation and extension muscle strength will be measured with hand-held dynamometer.~Joint mobility will be assessed with the Beighton score and foot posture will be evaluated with the foot posture index-6 (FPI-6)."
41143668|NCT05894551|OTHER|Functional mobility assessment|10-meter walking test will be conducted to understand functional mobility.
41143669|NCT01942772|DEVICE|Ankle-Foot Orthosis|
41143670|NCT01427816|DRUG|KCT-0809|
41143671|NCT01427816|DRUG|KCT-0809|
41143672|NCT01427816|DRUG|Placebo|
41143673|NCT03529435|BEHAVIORAL|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
41304063|NCT05277155|OTHER|Placebo|Placebo composition: Substance without active ingredient
41304064|NCT05769842|DRUG|propofol|Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1\~2mg/kg before extubation when the patient recovered spontaneously.
41463042|NCT02761603|BEHAVIORAL|Healthy Aging Practice-centered Instruction (HAPI)|"Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion."
41463043|NCT02761603|BEHAVIORAL|Tai Chi (CHI)|Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
40983803|NCT01842256|DRUG|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"* 3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)"
40983804|NCT01842256|DRUG|atorvastatin 40mg|"* 1 Tablet (atorvastatin 40mg),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)"
40983805|NCT03715166|DRUG|Bumetanide Oral Solution|Oral Solution dosed at 0.5mg/mL Taken twice daily
40983806|NCT03715166|DRUG|Placebo|Oral Solution Taken twice daily
40983807|NCT05589233|BIOLOGICAL|Vaccionation eighter started or full course|Vaccination against SARS-CoV-2 at any number of doses
40983808|NCT00876629|DEVICE|Pneumatic Driver|"Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.~The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed."
40983809|NCT05724069|DRUG|Velusetrag|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
40983810|NCT05724069|DRUG|Placebo|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
40983811|NCT03251079|DEVICE|Continuous glucose monitoring system|Implanted continuous glucose monitoring system
40983812|NCT02140788|DRUG|Metformin|
40983813|NCT02140788|DRUG|Fish Oil|
40983814|NCT05298332|DRUG|ATI-2173 50 mg|ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
40983815|NCT00994292|DRUG|YM150|oral
40983816|NCT00994292|DRUG|Placebo|oral
40983817|NCT06376110|DRUG|Topical Antioxidant Serum|An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.
40983818|NCT06376110|DEVICE|AviClear Laser|The AviClear (1726nm) laser is FDA-cleared for use on mild to severe inflammatory acne, with a recommended treatment course comprised of 3 laser procedures each one month apart.
40983819|NCT01019642|DRUG|cholecalciferol|4,000 IU per day during 6 months. Capsule form.
40983820|NCT01019642|DRUG|placebo|no active principles given.
40983821|NCT04659889|DIAGNOSTIC_TEST|Blood sampling (venesection)|"All study participants will have a single blood test to analyse the following parameters:~(i) Serum biochemistry, CRP, Thyroid function and liver enzymes (ii) FBC, d-Dimer, ESR, Blood film (iii) SARS-CoV2 antibody status and serum save (iv) Peripheral blood immunophenotyping."
40983822|NCT03631901|DRUG|oral melatonin|Both melatonin and diazepam were given only during the febrile illness.
40983823|NCT03631901|DRUG|oral diazepam|Both melatonin and diazepam were given only during the febrile illness.
40983824|NCT00240253|DRUG|pramlintide acetate|Clear, colorless, sterile solution for SC injection
40983825|NCT03863990|DRUG|PAH medication|Any PAH-targeted medication
40983826|NCT05514691|DIAGNOSTIC_TEST|iStatis COVID-19 Ag Rapid Test|SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
40983827|NCT05514691|DIAGNOSTIC_TEST|"COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (Labcorp)"|The Labcorp COVID-19 RT-PCR or EURORealTime SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
40983828|NCT04461015|DRUG|0.4mU Insulin followed by withdrawal period followed by 0.8mU study|Clamp study with insulin infused at 0.4 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.8 mU/Kg/min
40983829|NCT04461015|DRUG|0.8mU Insulin followed by withdrawal period followed by 0.4mU study|Clamp study with insulin infused at 0.8 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.4 mU/Kg/min
41143674|NCT03529435|BEHAVIORAL|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
41143675|NCT06335888|DRUG|AzaFol|AzaFol-PET/CT imaging
41143676|NCT06335888|DRUG|FDG|FDG-PET/CT imaging
41143677|NCT00874393|DRUG|Dopamine|Dopamine
41143678|NCT00874393|DRUG|Hydrocortisone|Hydrocortisone
40983830|NCT05278416|DEVICE|Lumoral treatment -device and Lumorinse tablets|Subjects will use Lumoral treatment -device and Lumorinse tablets daily as per protocol.
40983831|NCT02062034|DRUG|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
40983832|NCT02062034|DRUG|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
40983833|NCT02062034|DRUG|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
40983834|NCT00319917|DRUG|tacrolimus|oral
40983835|NCT00319917|DRUG|placebo|oral
41143679|NCT00874393|DRUG|Infusion Placebo|Dextrose (D5W)
41143680|NCT00874393|DRUG|Syringe Placebo|Normal saline
41143681|NCT00914056|DRUG|lactulose|withdrawal of lactulose
41143682|NCT04391439|DRUG|Intravenous Methylprednisolone|
41143683|NCT01918943|DEVICE|PLIF and Aspen (spinous process fixation device)|Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
40983836|NCT05328791|BEHAVIORAL|Dietary and mindfulness intervention|"Dietary intervention: Preparation and follow-up of diet program~Mindfulness intervention: Implementation of cognitive stress reduction program"
40983837|NCT01148121|OTHER|Skeletal Status Assessment of a Down Syndrome Population|The investigators hypothesize that the bone deficits seen in Down Syndrome patients are similar to the phenotype seen in the down syndrome mouse model (Ts65Dn).The bone turnover markers, CBC, and DXA scan results will be used to assess the skeletal status of the down syndrome patients. This data will form the basis to establish the Ts65Dn as a reasonable proxy for pathogenesis and treatment in humans.
41143684|NCT00438048|PROCEDURE|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
41143685|NCT00438048|DRUG|Artificial Saliva|5ml 3 times daily
41143686|NCT03166215|DRUG|TAK-935|TAK-935 tablets.
41143687|NCT03166215|DRUG|Placebo|TAK-935 placebo-matching tablets.
40983838|NCT02829281|DRUG|Botulinum Toxin Type A|Joint injection of Botulinum Toxin Type A
41463044|NCT06357156|RADIATION|CBCT|The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.
41463045|NCT01264835|DEVICE|Slotted Anoscope|SA411
40778948|NCT03478605|DRUG|Olanzapine|Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)
40778949|NCT03478605|DRUG|Aprepitant Pill|Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.
40778950|NCT03478605|DRUG|Ondansetron|Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)
40778951|NCT03478605|DRUG|Dexamethasone|Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
40778952|NCT01987076|DRUG|Prednisone|"Prednisone:~Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days."
40778953|NCT01987076|DRUG|Clobetasol|Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
40778954|NCT02114645|DRUG|Leuprolide acetate|in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
40778955|NCT02114645|DRUG|vaginal progesterone|crinone gel is applied till fetal heart beat is detected
40778956|NCT02114645|DRUG|4 mg oral estradiol valerate|estrofem is given twice a day
40778957|NCT00365807|BEHAVIORAL|Positively Fit|12-week group intervention for children with obesity and their parents/caregivers
40778958|NCT00365807|OTHER|Brief Family Intervention (Primarily education)|3 hours of contact with registered dietician for education and nutritional counseling.
40778959|NCT03655067|BEHAVIORAL|CATCH-IT|The CATCH-IT internet program consists of 14 modules and exercises and activities based on best practices components of depression prevention. They will be instructed to complete at least 2 modules a week, over a period of 6 weeks. This would require at least 40 minutes per week (approximately 20 minutes minimum per module).
40778960|NCT00651222|OTHER|No intervention was required|Death records were reviewed, therefore, there was no intervention
40778961|NCT03305484|OTHER|No intervention|No intervention, observation only
40983839|NCT02829281|DRUG|Triamcinolone hexacetonide|Joint injection of triamcinolone hexacetonide
40983840|NCT02829281|DRUG|Saline|Joint injection of Saline
40983841|NCT01594125|DRUG|Nintedanib high dose|twice daily oral dosing
41463046|NCT02773940|DEVICE|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during a patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
41463047|NCT05750953|BEHAVIORAL|eHealth@Hospital-2-Home|At hospital discharge, the intervention group will receive a wireless, portable personal computer system (i.e., IPAD) that includes the eHealth application MyDignio supplied by a certified m-Health company. MyDignio app is linked to monitoring devices by Bluetooth for each patient to daily and weekly measure clinical measures such as blood pressure, pulse, temperature, and weight, and self-reported symptoms and well-being, and daily report clinical measurements to the Nurse Navigators employed in the two hospitals. The patients will receive training from the nurses on how to log on and use the MyDignio app and the monitoring devices. Telephone contact details including information about how to access technical support will be provided to each study participant shortly following discharge.
41463048|NCT00040794|DRUG|paclitaxel|Given IV
41463049|NCT00040794|DRUG|carboplatin|Given IV
41463050|NCT00040794|DRUG|gefitinib|Given PO
41463051|NCT00040794|RADIATION|radiation therapy|Undergo radiotherapy
41463052|NCT00040794|OTHER|laboratory biomarker analysis|Optional correlative studies
41463053|NCT00250315|DRUG|Dobutamine|
40778962|NCT05809388|BEHAVIORAL|Parent training|"Parent Training program according to Ten steps of Barkley's program plus two additional follow-up sessions. This will be conducted by a trained psychologist; each session will last approximately 60 minutes and will includes exercises, discussions and role-playing."
40778963|NCT05809388|BEHAVIORAL|Virtual Reality-assisted PT sessions|"The experimental group will follow the same program of CG sample. Parent Training sessions will be conducted by a trained psychologist; each session will last approximately 60 minutes that include:~* 40 minutes of as usual PT session, with exercises, discussions and role-playing.~* 20 minutes of VR screen with which the parents may interact; VR screen will provides instructive, stimulating, interactive, and direct feedbacks exercises to enhance parenting strategies."
40778964|NCT01161771|PROCEDURE|Cataract Surgery and Limbal relaxing incision|Cataract extraction and limbal-relaxing incisions
40778965|NCT03064828|RADIATION|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA
40778966|NCT03064828|RADIATION|CT colonoscopy (low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
40778967|NCT05092750|DEVICE|FerroTraceTM|A magnetic
40778968|NCT05092750|DRUG|indocyanine green (ICG)|Given by SC injection
40778969|NCT00125788|DRUG|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
40983842|NCT01594125|DRUG|Nintedanib low dose|twice daily oral dosing
40983843|NCT01594125|DRUG|Nintedanib medium dose|twice daily oral dosing
40983844|NCT01594125|DRUG|Nintedanib medium dose|twice daily oral dosing
40983845|NCT01594125|DRUG|Nintedanib high dose|twice daily oral dosing
40983846|NCT00176826|PROCEDURE|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
41463054|NCT06246669|BEHAVIORAL|Treadmill Walking|A treadmill will be used for participant to walk on. The frequency of exercise will be 5 times per week until they report symptom-free. The intensity will be determined via random group allocation (RPE of 13 or 9). The type of exercise is treadmill walking. The time of the intervention will depend on the the time it takes an individual to reach a specific caloric expenditure as a function of their weight and treadmill incline. This is based on the most recent American Congress of Sports Medicine's guidelines for estimating gross energy expenditure during common physical activities.
41463055|NCT03619876|DRUG|Abatacept|125 MG/ML subcutaneous injections
41463056|NCT03619876|DRUG|Adalimumab|40 Mg/0.8 mL Subcutaneous Kit
41463057|NCT03760016|BEHAVIORAL|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
41463058|NCT03760016|BEHAVIORAL|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
40778970|NCT00125788|DRUG|Placebo|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
40778971|NCT04991220|PROCEDURE|Preoxygenation|Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
40983847|NCT00176826|DRUG|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
40983848|NCT06045026|OTHER|Stannous fluoride|Anti-sensitivity toothpaste containing 0.454% Stannous Fluoride
41463059|NCT00428155|DEVICE|closure device placement|
41463060|NCT05580588|DRUG|SPH4336|400 mg SPH4336 PO QD
41463061|NCT01560819|DRUG|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
41463062|NCT03485716|OTHER|running on a treadmill under normoxia or hypoxia|"* 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~* 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)"
40778972|NCT03070678|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
40778973|NCT03070678|DRUG|Mefenamic acid|"Pharmaceutical form: capsule~Route of administration: oral"
41463063|NCT02991560|OTHER|Strengthening exercises|The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.
40778974|NCT00508521|DEVICE|Functional Electrical Stimulation|commercially available surface electrical stimulator
40778975|NCT00508521|OTHER|Standard Care|Standard care as ordered by their physician and covered by their insurance company.
40983849|NCT06024057|DRUG|LX101|LX101 (Containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65 encoding human RPE65 gene).Specification: 0.2mL/bottle.Route of administration: subretinal injection, injection volume 0.3 mL/ eye
40983850|NCT03502226|BEHAVIORAL|Tailored feedback|"Electronic feedback based on participants stage of change which provided risk reduction behavior regarding their sexual health including use of condoms, contraceptions, and STI testing."
40983851|NCT00911495|DRUG|GMI-1070|Intravenous GMI-1070 given as two doses over the course of one day
40983852|NCT00323115|BIOLOGICAL|Autologous Dendritic Cell|Vaccine given by cervical lymph node injection 3 times every other week
40983853|NCT00323115|DRUG|Temozolomide|Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
40983854|NCT00323115|PROCEDURE|Radiotherapy|RT is standard of care (SOC) post surgery
40983855|NCT00323115|BIOLOGICAL|Dendritic Cell Vaccine|Vaccine given cervical lymphnode injection 3 times every other week
40983856|NCT05411679|DRUG|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
40983857|NCT05411679|DRUG|Olaparib tablets|Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor) Other names: Lynparza
40983858|NCT05089227|DRUG|"treatment intervention"|for a total of 12 weeks, prophylactic heparin therapy during hospitalization followed by prophylactic oral anticoagulation with apixaban
40983859|NCT05089227|DRUG|"treatment standard"|during hospitalization prophylactic heparin therapy followed by management without prophylactic anticoagulation.
40983860|NCT05089227|BIOLOGICAL|biological assessment|CBC, reticulocytes, haptoglobin, LDH, bilirubin
41463064|NCT02991560|OTHER|Intensive Physioytherapy|The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.
41463065|NCT02991560|DEVICE|Kinesio taping|Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis
41463066|NCT02991560|DEVICE|Athletic taping|By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
41463067|NCT01896505|DRUG|KCP-330|
41463068|NCT04743973|DEVICE|Muse S™ Headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
41463069|NCT03222037|DEVICE|senofilcon A|Acuvue Oasys 1-Day
41463070|NCT03222037|DEVICE|Control|Trial Frame with best spherocylindrical refraction (SCR)
41463071|NCT01984606|DRUG|Empagliflozin|Empagliflozin once daily
41463072|NCT01984606|DRUG|Placebo|Placebo matching empagliflozin
41463073|NCT01984606|DRUG|Sitagliptin|Sitagliptin once daily
41463074|NCT01984606|DRUG|Placebo|Placebo matching sitagliptin
41463075|NCT00214812|DRUG|HEC placebo gel|
40778976|NCT01346176|OTHER|Advance Directive Forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
40983861|NCT01778933|DRUG|EC17|
40983862|NCT02904512|DEVICE|Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
40983863|NCT02904512|OTHER|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
40983864|NCT05369845|OTHER|questionary|the patient will complete validated questionnaires, at three periods (at the time of the initiation of the CPAP, and during the 2 planned follow-up consultations: four months and at 1 year) The validated questionnaires are as follows: Illness Perception Questionnaire (IPQ-R), Beliefs about Medicines Questionnaire (BMQ), Morisky Medication Adherence Scale (MMAS), Hospital Anxiety and Depression Scale (HADS), Rollnick Scale.
41143688|NCT04887857|DRUG|CC-486|Specified dose on specified days
41143689|NCT04887857|DRUG|Venetoclax|Specified dose on specified days
41143690|NCT06284694|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|See experimental arm description
41143691|NCT02049684|PROCEDURE|Patch|
41463076|NCT05975112|DIAGNOSTIC_TEST|Coagulation tests (TEG, Levels of F1, F2, hs-D-dimer, Plasminogen, PAI 1+2), SpHb before discharge|Coagulation tests named earlier as well as SpHb
41463077|NCT03887598|DEVICE|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
41463078|NCT00249717|BEHAVIORAL|Contingency management|Receive rewards (prizes) abstinence and attendance
41463079|NCT04646824|DRUG|Almonertinib Pemetrexed/Cisplatin|Pemetrexed/Cisplatin Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
41463080|NCT02266940|DRUG|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
41463081|NCT02266940|DRUG|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
41463082|NCT05072119|DEVICE|Device implantation|Implantation of single chamber, dual chambers or triple chambers PM/ICD
41463083|NCT02276625|BIOLOGICAL|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
41463084|NCT00159172|DEVICE|Motor cortex stimulation|
41463085|NCT01182519|BEHAVIORAL|questionnaire, blood draw and urine sample|Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
40778977|NCT00285051|DRUG|inhaled delta-8-THC 300mcg or 600mcg per dose|"drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC"
40778978|NCT01658046|OTHER|Neuromuscular electrical stimulation|Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
40778979|NCT01658046|OTHER|Endurance training|Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
40778980|NCT01658046|OTHER|Quadriceps strength training|Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
40778981|NCT04816032|OTHER|Pennebaker's expressive writing intervention|It focuses on the emotional aspect of the written event
40778982|NCT04816032|OTHER|Neutral writing|Description of neutral topics with less emotional involvement
40778983|NCT01263119|DRUG|Warfarin|10-mg warfarin oral dose
40778984|NCT01263119|DRUG|LY2216684|18-mg LY2216684 oral dose
40983865|NCT01174927|DRUG|diacetylmorphine (DAM)|The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
40983866|NCT01174927|OTHER|Placebo|Saline
40983867|NCT01894854|PROCEDURE|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
41463086|NCT01388998|OTHER|Changes of difference in pulse pressure and plethysmography after applying various pressure levels on the caval vein|Following hepatic resection, a fitting area for pressure application on the caval vein will be identified by the attending surgeon. Baseline assessments of hemodynamic and heart-lung interaction parameters will be taken. Thereafter the surgeon will apply three different pressure levels (2 N, 5 N, 10 N) at random with a force gauge (Fa. ATP Messtechnik, Ettenheim, Germany). Assessment of the parameters will be performed after 2 minutes of pressure application by an investigator, unaware of the pressure applied. After each pressure application 5 minutes will be waited to assure hemodynamic recovery.
40778985|NCT03386162|DRUG|Alpelisib|fulvestrant (500 mg intramuscular \[as two 5 mL injections\] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
40778986|NCT03386162|DRUG|Chemotherapy|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
40778987|NCT03586973|DRUG|Cabozantinib|Cabozantinib tablet
40778988|NCT00335829|BIOLOGICAL|bevacizumab|
40778989|NCT00335829|DRUG|chemotherapy|
40778990|NCT00335829|DRUG|embolization therapy|
40778991|NCT00335829|PROCEDURE|hepatic artery infusion|
40983868|NCT03129243|DIAGNOSTIC_TEST|Sperm DNA integrity by flow cytometry|flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange. By using a flow cytometer 5.000-10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the World health organization analysis where only 1-300 cells are analyzed.
40983869|NCT01391390|DRUG|Melatonin|10mg/day, 12-week treatment
40983870|NCT01391390|DRUG|Placebo|10mg/day, 12-week treatment for TD
40983871|NCT03753347|BIOLOGICAL|2018-19 quadrivalent inactivated influenza vaccine|A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
40983872|NCT01190709|PROCEDURE|Dynamic Compression Plate|we made a longitudinal incision 1 cm lateral to the tibial crest, expose the fracture, and retract the muscles laterally. After determining the length of plate, we used bending instruments to contour the plate to the anatomy then threaded plate holders used to position the plate on the bone. After that we placed the drill guide at the edge of the dynamic compression unit (DCU) portion of the plate hole without applying pressure and tightening of the cortex screws results in dynamic compression. We verified the screw position with a guide wire before insertion and then inserted the locking screw.
40983873|NCT01190709|PROCEDURE|Unreamed intramedullary nailing|we inserted the nail, without reaming, across the fracture site, with particular attention being paid to the prevention of over distraction and the achievement of cortical contact of the fracture ends. An upper diameter limit of 10 mm and a nail measuring at least 2 mm less than the diameter measured at the isthmus of the tibia on anteroposterior and lateral radiographs were stipulated.
41463087|NCT03139240|DRUG|Oxycodone 10mg oral|Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
41463088|NCT03139240|OTHER|Placebo|Placebo given in addition to standard of care medications in women undergoing medical abortion
41463089|NCT03211455|DRUG|Lidocaine|intravenous lidocaine versus placebo
41463090|NCT03211455|DRUG|isotonic saline|intravenous isotonic saline
41463091|NCT00927251|DEVICE|Pacing Lead (Model 4296 LV Lead)|Implant and follow-up of study device
41463092|NCT02166853|DRUG|sevoflurane|Sedation with inhaled sevoflurane
41463093|NCT02166853|DRUG|midazolam|Sedation with intravenous midazolam
41463094|NCT04221594|PROCEDURE|Invasive Cardiac Catheterization (ICA)|Invasive functional measurements will be performed to assess the functional significance of specific lesions by means of FFR and CFR, and to test the presence of microvascular disease by means of IMR in all vessels for which the procedures are feasible. In summary, a 5- to 7-F guide catheter without side holes is used to engage the coronary artery and a pressure-temperature sensor-tipped guidewire introduced. The pressure sensor is positioned at the distal segment of a target vessel, and intracoronary nitroglycerine (100-200 mg) administered before each measurement. The best systolic and diastolic phase (located between 30-50%, and 60-75% of the cardiac cycle) will be selected for successive processing as it allows a relative motion free visualization of the main vessels and the myocardium.
41463095|NCT04221594|PROCEDURE|Coronary Computed Tomographic Angiogram (CCTA)|Fasting patients will undergo a test for coronary calcium by CT; calcium scoring analysis will be done post image data acquisition using the manufacturer's software. Nitroglycerine will be administered in all patients (sublingual administration prior to CCTA initiation). CT acquisitions will be prospectively ECG-gated (30-80% of the cardiac cycle). The acquisition begins with a scout scan to identify the borders of the heart to minimize the field of view and exposure to the patient. A bolus of 60 mL nonionic contrast agent is then injected followed by 60 mL of saline at a rate of 4 mL/s to enhance signal from coronary arteries and blood chambers. In case of irregular heart rate, beta-blockers can be provided to keep optimal heart rate \~65-70 bpm. Trans-axial images are reconstructed by means of a filtered back-projection algorithm.
41463096|NCT04221594|PROCEDURE|Dynamic Cardiac Positron Emission Tomography (dPET)|Patients will be asked to fast for 24 hours prior to the test. Before the resting perfusion phase, a single low-dose CT-based transmission scan is acquired for attenuation correction (AC) of all subsequent acquisitions. AC-CT images are automatically registered to the perfusion images, visually verified and manually corrected if necessary. Resting perfusion imaging started with the intravenous injection of a single bolus of 82Rb. Pharmacological stress imaging is obtained after adenosine infusion (140 μg/kg/min) through a peripheral vein, followed by a second dose of 82Rb. Image reconstruction is achieved by means of ordered subset expectation maximization (OSEM) iterative method. The hemodynamic responses to rest/stress tests are collected in terms of mean heart rate, mean blood systolic pressures and diastolic at rest and stress. Dynamic, gated and ungated trans-axial reconstructions are saved in DICOM format for further analysis and processing.
41463097|NCT00600873|DRUG|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
41463098|NCT01085669|DEVICE|Microbiological analysis of retained VEPTR Implants|Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
41463099|NCT00593827|DRUG|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m\^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
41463100|NCT00593827|DRUG|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
41463101|NCT01959802|PROCEDURE|Vitrectomy|
41463102|NCT06276296|DIAGNOSTIC_TEST|Holter EKG - 1 day before ablation|24 hours Holter EKG - 1 day before ablation
41304065|NCT05769842|DRUG|normal saline|Same dose as propofol.
41304066|NCT02660424|DRUG|VX-150|
41304067|NCT02660424|DRUG|Placebo|
41463103|NCT06276296|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation using radiofrequency ablation
41304068|NCT02460822|DEVICE|MyChemoCare iPad application|
41463104|NCT06276296|PROCEDURE|Pulsed field ablation|Pulmonary vein isolation using pulsed field ablation
41463105|NCT06276296|DIAGNOSTIC_TEST|Holter EKG - 1 month after ablation|24 hours Holter EKG 1 month after ablation
41463106|NCT03124303|PROCEDURE|High Density-Electroencephalogram|EEG is a safe non-invasive technology without complications that may be used to help diagnose delirium
41463107|NCT03124303|PROCEDURE|Magnetic Resonance Imaging|MRI scan of brain
41304069|NCT00055419|BIOLOGICAL|Cetuximab|400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
41304070|NCT03889093|OTHER|Yttrium-90|This is to evaluate the immunologic effects of yttrium 90.
41304071|NCT05536713|DEVICE|Guardant SHIELD blood-based colorectal cancer screening test|The Guardant SHIELD test combines a next-generation sequencing (NGS) based assay and a protein assay for the qualitative detection of colorectal cancer-derived tumor signal in the blood of patients at average risk for CRC. The Guardant SHIELD was developed at Guardant Health's clinical laboratory, a certified laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high-complexity clinical laboratory testing. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA); however, its performance has been established through a clinical trial, the ECLIPSE study (ClinicalTrials.gov Identifier: NCT04136002). The ECLIPSE clinical trial was a prospective, multi-site registration study and reached the targeted enrollment of 12,750 patients in December 2021.
40983874|NCT02484729|DRUG|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
40983875|NCT02484729|DRUG|Placebo, oral suspension|Matching placebo
41463108|NCT03969641|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
40778992|NCT03580044|COMBINATION_PRODUCT|ATM-AVI|ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
40778993|NCT03580044|DRUG|BAT|The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
40778994|NCT01502735|BIOLOGICAL|DENV-1 PIV, 2.5 µg|2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
40778995|NCT01502735|BIOLOGICAL|DENV-1 PIV, 5 µg|5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
40778996|NCT04062058|RADIATION|SIB-IMRT|45Gy in 25 fractions using intensity-modulated radiotherapy to the radiation target
40983876|NCT02484729|DRUG|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
40983877|NCT05017506|OTHER|A survey will be made.|A survey will be made.
40983878|NCT03259854|DEVICE|non invasive mechanical ventilation in pediatrics|use of non invasive mechanical ventilation in pediatrics after successful weaning from invasive mechanical ventilation
40983879|NCT03259854|DEVICE|oxygen mask|use of oxygen mask after successful weaning from invasive mechanical ventilation
40983880|NCT01647282|DRUG|locally-applied minocycline HCl (1 mg)|
40983881|NCT01647282|PROCEDURE|scaling and root planing (Sc/RP)|
40983882|NCT06371053|BEHAVIORAL|Community Intervention|"The intervention includes Cognitive Training: Activities targeting memory, attention, language, and executive functions to maintain cognitive abilities. This could involve cognitive games, memory exercises, and daily tasks.~Life Skills Training: Assistance in maintaining or relearning daily life skills such as personal hygiene, dressing, eating, and household chores. This could be through structured training programs and daily guidance.~Physical Exercise: Providing appropriate physical activities and exercises to maintain physical health and function, including walking, balance training, and light strength training.~Social Support: Organizing social activities and support groups to facilitate interaction and reduce social isolation and loneliness.~Emotional Support: Offering mental health support and psychosocial services to help individuals cope with emotional challenges such as anxiety and depression."
40983883|NCT02602860|RADIATION|[11C]UCB-J|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 20 mCi~* Route of Administration: iv"
41143692|NCT03473665|DRUG|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
41143693|NCT03473665|DRUG|Diclofenac|Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
41143694|NCT03473665|DRUG|Meloxicam|meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
41143695|NCT03473665|DRUG|Celecoxib|Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
41304072|NCT03734107|BEHAVIORAL|Plan, Reflect, and Engage with Providers for Diabetes Care|Behavioral intervention designed to improve health communication skills and readiness for adult diabetes care
41304073|NCT03271931|BEHAVIORAL|Active choice|EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
41463109|NCT03969641|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
41463110|NCT05310617|OTHER|Survey|Survey on the parental project and its realisation
41463111|NCT05164094|BIOLOGICAL|mRNA-1189|Sterile liquid for injection
41463112|NCT05164094|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
41463113|NCT02000115|DEVICE|Portico transcatheter aortic valve|St. Jude Medical transcatheter Portico aortic valve
41463114|NCT02000115|DEVICE|Commercially available transcatheter aortic valve|Commercially available transcatheter aortic valve
41463115|NCT06057506|DEVICE|Paranix® Shampoo|well established medical device for the treatment of head lice infestation (osmolone based)
40983884|NCT02602860|DRUG|Brivaracetam|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 10 mg/ml~* Route of Administration: iv"
40983885|NCT02602860|DRUG|Levetiracetam|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 100 mg/ml~* Route of Administration: iv"
40983886|NCT02602860|DRUG|Brivaracetam|"* Pharmaceutical form: Tablets for oral intake~* Concentration: 25 mg~* Route of Administration: oral"
40983887|NCT05965947|BEHAVIORAL|Medical Nutrition Therapy|One-on-one nutrition assessment, education, and counseling with a Registered Dietitian.
40983888|NCT05609045|BIOLOGICAL|Lyophilized COVID-19 mRNA Vaccine|RH109 is a mRNA-based vaccine encoding the N-Terminal Domain (NTD) - Receptor Binding Domain (RBD) derived from Spike (S) protein of SARS-CoV-2 Omicron variant.
40983889|NCT05609045|DRUG|Sodium chloride|0.9% sodium chloride
41143696|NCT01092715|PROCEDURE|Spinal mobilization|Non thrust mobilization to the cervical spine
41143697|NCT01092715|PROCEDURE|Massage|Sedative massage to cervical paraspinal muscles
41143698|NCT01092715|PROCEDURE|Neck exercises|Range of motion exercises to include foraminal opening
41143699|NCT01160159|OTHER|Tests|Arterial parameters
41143700|NCT01160159|OTHER|Healthy volunteers|Arterial parameters and blood test
40778997|NCT04062058|DRUG|S-1|40-60mg/m2(according to patient's body surface area), orally twice daily every weekday concurrently with radiotherapy treatment
40778998|NCT04062058|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
40778999|NCT04062058|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
40779000|NCT03555877|DRUG|Ribociclib|Ribociclib in addition to endocrine maintenance therapy. Endocrine therapy, at the discretion of the investigator, could have already been started up to 4 weeks before randomization but not later than with first dose of ribociclib.
40779001|NCT03555877|DRUG|Anastrozole|1mg once daily as indicated in the SmPC
40779002|NCT03555877|DRUG|Letrozole|2,5mg once daily as indicated in the SmPC
40779003|NCT03555877|DRUG|Exemestane|25mg once daily as indicated in the SmPC
40779004|NCT03555877|DRUG|Fulvestrant|(prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
41143701|NCT02813733|PROCEDURE|Thyroid surgery|Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
41143702|NCT05198557|DRUG|Inebilizumab|Participants will receive IV inebilizumab.
41143703|NCT05198557|DRUG|Placebo|Participants will receive IV placebo matched to inebilizumab.
41143704|NCT01654198|RADIATION|FDG-PET/CT scan|FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
41304074|NCT03271931|BEHAVIORAL|Passive choice|EHR passive alert to cardiologists about prescribing a statin
41304075|NCT01892033|BEHAVIORAL|Aerobic Exercise|12 weeks of brisk walking
41304076|NCT01790737|DRUG|Cyclophosphamide|
41304077|NCT01790737|DRUG|Filgrastim|
41304078|NCT05992480|BIOLOGICAL|rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)|It is an Ebola virus vaccine
41304079|NCT00804193|DRUG|Ciclopirox Olamine Topical Suspension|topical suspension
41304080|NCT00804193|DRUG|Ciclopirox Topical Suspension 0.77%-Reference Product|topical suspension
40779005|NCT03857776|OTHER|Open dialogue about complementary alternative medicine|1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care
40779006|NCT03857776|OTHER|Standard care|Standard care including referral to a homepage about CAM
40779007|NCT05457595|RADIATION|carbon ion radiation therapy|"CIRT: Planning Target Volume (PTV) will be delivered a total dose of 48-52.8 GyRBE in 12 fractions, 4 fractions per week. Treatment duration 3 weeks.~Treatment lasting more than 5 weeks or cases of treatment with less than 6 fractions in 14 consecutive days will not be accepted."
40779008|NCT02443935|DRUG|MGN1703|60 mg s.c. twice weekly for 4 weeks
40779009|NCT02443935|DRUG|MGN1703|60 mg s.c. twice weekly for 24 weeks
40779010|NCT03249402|DRUG|Ethinyl Estradiol + Levonorgestrel|Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
40779011|NCT03249402|DRUG|JNJ-42847922|Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
40779012|NCT02911727|PROCEDURE|Fast-track discharge|As described above
40779013|NCT06382844|DIAGNOSTIC_TEST|Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).|Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)
40779014|NCT03139448|DEVICE|Oxygen via nasal cannula|Oxygen will be supplied to the patient via nasal cannula according to the routine standard of care practice at Vanderbilt University Medical Center.
40779015|NCT03139448|DEVICE|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
40779016|NCT05639010|DEVICE|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
41143705|NCT02786277|OTHER|Alert|An alert informing the provider of the presence of acute kidney injury will be fired.
41143706|NCT05912998|PROCEDURE|cartilage regeneration technique|autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu
41143707|NCT02540915|OTHER|Standard of Care - Registry|Standard of Care - Registry
41143708|NCT00911391|DEVICE|Oesophageal Doppler|Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
41143709|NCT00911391|PROCEDURE|Intraoperative fluid restriction|Current best practice of avoiding fluid overload by intraoperative fluid restriction
41143710|NCT06498323|DRUG|tenecteplase|Intravenous thrombolytic agents administration
41143711|NCT03829566|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
41143712|NCT03829566|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
41143713|NCT03829566|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
41143714|NCT03829566|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
41143715|NCT03829566|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
41304081|NCT00804193|DRUG|Ciclopirox Olamine Topical Suspension-Placebo|topical suspension
41304082|NCT02432001|PROCEDURE|Image-Guided Biopsies|
41304083|NCT04182620|DEVICE|renal denervation|Renal denervation using the Paradise renal denervation system - a dedicated RDN catheter that delivers a circumferential ring of ablative ultrasound energy
41304084|NCT04182620|DEVICE|Catheter ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation
41304085|NCT01327040|OTHER|light exposure|12-hour light exposure of approximately 200 lux
41463116|NCT06057506|DEVICE|Paranix® Lotion|well established medical device for the treatment of head lice infestation (dimethicone based)
41463117|NCT01763658|DRUG|Antox tablets(Mepaco)|effect of antioxidant on disease outcome
40779017|NCT05639010|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
40779018|NCT06489002|OTHER|Implementation Support|Health centers receiving the intervention will have access to implementation support strategies designed to support adoption of social needs screenings and referrals to community organizations for patients with unmet social needs receiving care management. Implementation support will be provided by an OCHIN trainer, practice facilitators, workflow engineer, and analysts.
40779019|NCT05358002|PROCEDURE|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
40779020|NCT00320606|DRUG|Immunosuppression Withdrawal|Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
40779021|NCT00738296|DRUG|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
40779022|NCT00738296|DRUG|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
40779023|NCT00738296|DRUG|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
41463118|NCT01763658|OTHER|drug therapy for ITP|drugs will be selected according to ASH,2011 guidelines
41463119|NCT04544852|BEHAVIORAL|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test."
41463120|NCT04544852|BEHAVIORAL|Targeted intervention programme|The targeted intervention programme includes participants undergoing a structured educational program regarding colorectal cancer and the importance of screening in its prevention. The details will be explained to them using the pamphlet from MOH on Colorectal Cancer Screening. They will also be offered two FIT kits free of charge. Research team will educate participants on how to perform the FIT test. A detailed information guide on how to collect stool samples for FIT kit and how to return the completed FIT kit to the NUH Colorectal Centre will be given to them. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test.
41463121|NCT05642533|OTHER|No treatment given|No treatment given
41463122|NCT02853539|DRUG|Denosumab|Subcutaneous injection of Denosumab
41463123|NCT04323215|DEVICE|Support system|A support system named Provement will be used to provide behavioral treatment.
41463124|NCT06149091|DRUG|Tranexamic Acid；|Tranexamic acid (TXA) is an antifibrinolytic drug that competitively inhibits the activation of plasminogen. After its efficacy and safety were confirmed in several randomized controlled trials, both systemic and topical administration of TXA have been widely used for hemostasis in trauma and various surgical settings.
40779024|NCT03279653|PROCEDURE|SleeveGastrectomy|Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
40779025|NCT01917318|DRUG|Iloperidone|"Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)"
40779026|NCT01917318|DRUG|Placebo|During 8 weeks subjects will receive oral placebo
40779027|NCT02030626|DEVICE|active or placebo rTMS or active or placebo tDCS|
40779028|NCT02188966|DEVICE|Geographic Information System|"GIS data is delivered by SimaTech Enterprise System communicating via the mobile network and TETRA (in Denmark called SINE). It is developed as a Java Enterprise application and is executed on a JBOSS application platform"
40779029|NCT00926614|DRUG|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
40779030|NCT00926614|DRUG|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
40779031|NCT00992550|DRUG|Cigarette|
40779032|NCT00992550|DRUG|Hookah|
40779033|NCT00741377|DRUG|BHQ880|
40779034|NCT00741377|DRUG|Zoledronic acid|
40779035|NCT02348190|OTHER|Lipid/heparin|"32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs."
40779036|NCT01655277|PROCEDURE|Ultrasound Guided Adductor Canal Block|
41143716|NCT03829566|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
41143717|NCT03829566|BIOLOGICAL|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
41143718|NCT03829566|BIOLOGICAL|Autologous Stem Cells|Infusion of patient's own stem cells
41143719|NCT01745445|OTHER|concurrent chemo-radiotherapy arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
40779037|NCT01655277|PROCEDURE|Ultrasound Guided Femoral Nerve Block|
41143720|NCT00889473|DRUG|Larazotide acetate|gelatin capsule
41143721|NCT00889473|DRUG|Placebo|gelatin capsule
40779038|NCT06101810|BEHAVIORAL|COMET|information already included in arm/group descriptions.
40779039|NCT06101810|BEHAVIORAL|CBT|information already included in arm/group descriptions.
41463125|NCT06149091|DRUG|Adrenalin|In diagnostic bronchoscopy, one of the most commonly used topical hemostatic agent is epinephrine. The primary mechanism of epinephrine is vasoconstriction, leading to reduced blood flow and hemostasis.
41463126|NCT06149091|DRUG|Hemagglutinase|Thrombin injection (Batroxobin) is an enzymatic hemostatic agent refined from the venom of the Brazilian lancehead snake. It promotes clot formation at the bleeding site, characterized by rapid and effective hemostasis and high safety. It is now widely used for clinical prevention and treatment of perioperative bleeding and oozing. Multiple randomized controlled studies have evaluated the safety and efficacy of intravenous/topical application of thrombin in various trauma and surgical settings.
40779040|NCT04928378|OTHER|Descriptive retrospective study|characterization of the diagnosis, management and outcome of patients with osteoarticular infection due to MDR M. tuberculosis in France (MDR IOATB).
40983890|NCT03888547|OTHER|Occupational Therapy Health & Wellness Education|The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules. One of the investigators will lead each of these weekly modules under the direct supervision of the Principal Investigator. Investigators will be trained to provide the standardized educational module for each topic area and for using outcome measures. Each module will have an identified theme and information provided in each group will be education to topic, evidence based literature on intervention strategies, lifestyle, or environmental modifications that improve performance of daily activities that will last approximately 45 minutes. After, group sharing of ideas and individual identification of weekly goals for integration of 1-3 targeted interventions will occur and last approximately 30-45 minutes).
40983891|NCT05505903|DIAGNOSTIC_TEST|Temerature measurement|Temerature measurement on admission to WBN or NICU
40983892|NCT00881933|OTHER|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, \& -2) (if body weight \< 10 kg or if age \< 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, \& -8) total body irradiation (3G on days -1)
40983893|NCT02176850|DRUG|Micardis®|
40983894|NCT02888522|BIOLOGICAL|immunomodulation|Immunomodulation depending on chimerism
40983895|NCT01179945|OTHER|benzoate containing test drinks|"Subjects will consume 500ml of water with 0.5 grams of sodium benzoate, followed by a solution of 75g sugar in 500ml water with 0.5 grams sodium benzoate 3 hours later.~Each solution will be consumed over 5 minutes."
40983896|NCT01179945|OTHER|non sodium benzoate containing test drinks|"Subjects will consume 500ml of water followed by a solution of 75g sugar in 500ml water 3 hours later.~Each solution will be consumed over 5 minutes."
40983897|NCT04097093|OTHER|No intervention|No intervention
40983898|NCT00385242|PROCEDURE|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
40983899|NCT00385242|OTHER|PET imaging|PET viability imaging
40983900|NCT04814225|OTHER|Test Product 1|Pea Protein powder
40983901|NCT04814225|OTHER|Test Product 2|Pea \& Oat Protein Powder
40983902|NCT04814225|OTHER|Test Product 3|Oat Protein Powder
40983903|NCT04814225|OTHER|Comparator|Whey Protein Isolate
40983904|NCT05990543|DRUG|Nelmastobart and Capecitabine|"Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle.~Capecitabine is administered orally for two weeks followed by a one-week rest period"
40983905|NCT06422260|OTHER|Prosthesis superstructure|Prosthesis superstructure for 2 implant supported short span fixed bride constructed from different materials
40983906|NCT01565785|BEHAVIORAL|The FSM-DPI.|Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
40983907|NCT06226766|DRUG|JSKN033 Injection|JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.
41143722|NCT00889473|DIETARY_SUPPLEMENT|Gluten 900 mg|gelatin capsule
40983908|NCT03212612|DIAGNOSTIC_TEST|samples obtained by laparoscopy or punch biopsy for analysis by ELISA|Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
40983909|NCT03894579|BIOLOGICAL|Study Product: SNK01|SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
40983910|NCT04474067|OTHER|No intervention|This is an observational study, with no intervention.
40983911|NCT00415103|DRUG|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
40983912|NCT00415103|DRUG|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
40983913|NCT00415103|DRUG|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
41143723|NCT03270098|BEHAVIORAL|Aerobic Exercise|Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
40983914|NCT02278588|DRUG|Rasagiline|
40983915|NCT05662085|OTHER|No intervention|According to clinical practice.
40983916|NCT06412939|DEVICE|Agile Nail|Intramedullary implantation of the Agile intramedullary rigid nail in femur to provide bone fixation
41143724|NCT03270098|BEHAVIORAL|Stretching and Toning Exercise|Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
40779041|NCT04278404|DRUG|The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:|The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
40779042|NCT03836443|OTHER|"western diet meal"|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast."
40983917|NCT04905095|OTHER|EWS|Early Warning Score will be implemented in the computer system of the nursing station which belong to this intervention group. When the nurses enter the vital signs of the patients into the system, the EWS will be automatically calculated and an alarm will be displayed if an intervention is necessary, which is protocolized.
40983918|NCT04905095|OTHER|usual clinical care|Nurses perform their clinical monitoring activities as usual. EWS will not be implemented in their nursing station
41304086|NCT02191085|PROCEDURE|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the Fast Track clinic to assist with the assessment of patients who appear unwell. As in the Standard Management arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP."
41304087|NCT06382974|PROCEDURE|Cyst enucleation and bone grafting|cyst enucleation followed by bone grafting the residual bone defects using Atorvastatin combined with β-TCP.
41304088|NCT02335216|DEVICE|Implantation with the commercially available Axium neurostimulator|
41304089|NCT04792151|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C and UP-A) are transdiagnostic, behavioral interventions for youth with emotional disorders, including anxiety, depression, obsessive-compulsive disorders, and irritability.
41304090|NCT00109187|DRUG|Xolair (omalizumab)|
41304091|NCT04082364|BIOLOGICAL|margetuximab|margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
41304092|NCT04082364|BIOLOGICAL|Retifanlimab|Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.
41304093|NCT04082364|BIOLOGICAL|Tebotelimab|Tebotelimab: anti PD-1, anti-LAG3 bispecific DART (R) molecule 600 mg IV, Day 1 of each 3-week cycle.
41304094|NCT04082364|BIOLOGICAL|Trastuzumab|Anti-HER2 monoclonal antibody 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3-week cycle
41463127|NCT01198249|DRUG|multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide|amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
40779043|NCT02398331|OTHER|Standardised information and education on sexuality in women with spinal cord injury|"Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:~* Educational footage~* Clinical neurological examination with educational aim~* Structured consultation providing information on the physiology of sexual response in women with spinal cord injury"
40779044|NCT05117996|OTHER|capsule endoscopy|capsule endoscopy
40983919|NCT04723550|DEVICE|Hospital telemedicine management system|Patients upload data of blood glucose, diet and exercise. Then doctors guide patients' diet, exercise and medication adjustment through the telemedicine system.
41304095|NCT04082364|OTHER|Chemotherapy|"Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6~Chemotherapy~XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion~mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion."
41463128|NCT02435316|OTHER|Case vignette-based teaching of cell recognition|Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
41463129|NCT02435316|OTHER|Compare-contrast basic science teaching of cell recognition|The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
40779045|NCT05117996|OTHER|standard small bowel preparation|2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
40779046|NCT05117996|OTHER|Simplified small bowel preparation|Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
40779047|NCT00637910|DRUG|Erlotinib|Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
40779048|NCT00637910|DRUG|Docetaxel|Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). _Until disease progression or unacceptable toxicity develops
41463130|NCT02885428|DEVICE|echography|
41463131|NCT03111381|DRUG|Toradol|IV toradol
40983920|NCT04723550|OTHER|Usual care|Outpatient/telephone follow-up：continued care, as usual, from their primary care provider through out duration of action 6 months intervention period
40983921|NCT03222596|BEHAVIORAL|Exercise training|Exercise programme includes breathing and upper limbs exercises.
41304096|NCT06270940|PROCEDURE|Pulsed Radiofrequency (PRF) Treatment|PRF treatment maintains a temperature below 42°C and does not produce structural tissue damage around the needle. PRF exposure to the Dorsal Root Ganglion (DRG) induces c-Fos gene expression in the dorsal horn, which suggests a cellular response to the electric forces generated within the DRG. PRF has been found to relieve neuropathic pain by inducing long-term depression of synaptic transmission in the spinal cord, leading to a decrease in allodynia and hyperalgesia. It also modulates the inflammatory response in the injured area by decreasing the expression of pro-inflammatory cytokines, such as TNF-α, in the peripheral nerve and spinal cord, which is a major player in the development and maintenance of neuropathic pain. PRF is characterized by a 500 kHz current applied for 2 pulses per second, with each pulse lasting 20 milliseconds.
41304097|NCT02214186|OTHER|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
41304098|NCT04987060|DEVICE|Intrastromal Fresh Human Lenticule Implantation|The stromal pocket diameter was set 8.0 mm and cap thickness was set to 140 μm from corneal surface and a 2mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 2 mm superior incision. Incision position changed according to the position of the highest K values.
41304099|NCT00820703|DRUG|Nexagon®|
41304100|NCT00820703|DRUG|Nexagon® vehicle|
40983922|NCT04915833|DIAGNOSTIC_TEST|Standard high-definition colonoscopy|"Evaluation of the colonic mucosa with a high definition colonoscope (EPKi7010 video processor).~The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) only by one expert endoscopist, randomly assigned.~The number, location and polyps' features (Paris classification) will be recorded by the operator. If a polyp is detected, the endoscopist will remove the polyp endoscopically with a cold snare and forceps biopsy."
40983923|NCT04915833|DIAGNOSTIC_TEST|Colonoscopy with real-time AI assisted automated polyp detection|The same patient will be submitted to a second, same session, computed aided real-time colonoscopy using the DISCOVERY, AI assisted polyp detector. Colonoscopy will be performed by a same-level-of-expertise operator in comparison to the initial procedure. Any polyp or lesion detected with the AI system will be recorded and endoscopically removed and considered as a missed lesion from standard colonoscopy.
40983924|NCT00613938|DRUG|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
40983925|NCT00613938|DRUG|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
40983926|NCT00613938|DRUG|oxycodone|10mg capsule q4-6 hrs for 3 days
40983927|NCT00613938|DRUG|placebo|1 capsule q4-6 hrs for 3 days
40983928|NCT00637507|OTHER|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., \>10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 \>150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
40983929|NCT06122129|PROCEDURE|Flexible ureteroscope with ureteral access sheath|The flexible ureteroscope either directly or via an access sheath, depending on the size of the ureter, a 9.5/11.5 Fr or a 12 Fr access sheath will be used.
40983930|NCT06122129|PROCEDURE|Flexible ureteroscope without ureteral access sheath|Ureteroscopy will be carried out without a ureteral access sheath
40983931|NCT06493422|BEHAVIORAL|Reaching Movements|participants will perform a perceptual decision making task while moving their hand.
40983932|NCT02055014|DRUG|Liraglutide|
40983933|NCT02055014|DEVICE|Duodenal-jejunal bypass liner - Endobarrier device|
41304101|NCT00537550|DRUG|Vincristine|Steroids pre-treatment
41304102|NCT00537550|DRUG|Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy
40779049|NCT02095106|DEVICE|Waterproof Cast|
40983934|NCT04334291|COMBINATION_PRODUCT|Observational (registry)|Observational study.
40983935|NCT01614067|DRUG|Ganirelix acetate|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
41143725|NCT03576625|DIETARY_SUPPLEMENT|High Oleic Sunflower Oil|Consume oil smoothie (emulsified HOSO) with a meal once daily for 9 weeks
41304103|NCT03062904|DRUG|Inhaled Bronchodilators +/- Inhaled Methacholine|"1. Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer~2. Inhaled Methacholine based on international recommendations"
40983936|NCT03264209|BEHAVIORAL|Smart After-Care (Mobile health)|Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone. Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
40983937|NCT02180633|OTHER|Optical Coherence Tomography Scan|As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
40983938|NCT03331679|BEHAVIORAL|HIIT|2 Weeks of High Intensity Interval Training on a Cycle ergometer
40983939|NCT03658850|DRUG|Hydrochlorothiazide 50Mg|for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3
40983940|NCT03658850|DRUG|Placebos|for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
41143726|NCT03576625|DIETARY_SUPPLEMENT|Buglossoides Oil|Consume oil smoothie (emulsified Buglossoides oil) with a meal once daily for 9 weeks
41143727|NCT00595725|OTHER|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
41143728|NCT03636958|DRUG|Perampanel|Perampanel is an antiepileptic with a novel mechanism of action as it targets post-synaptic AMPA receptors. It has been shown to be effective as adjunctive therapy (dual therapy) for partial / focal epilepsy seizures and generalized in patients over 12 years of age.
41143729|NCT03636958|DRUG|conventional antiepileptic treatment|choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
41143730|NCT05293093|OTHER|Wheelchair Skills Training Program|a standardized training method for users of manual and powered wheelchairs and it combines evidence on motor-skills learning with evidence on how to perform specific wheelchair skills. A recent systematic review and meta-analysis provided evidence that WSTP is a safe and effective intervention that has a clinically meaningful effect on powered wheelchair skill capacity, in particular for new wheelchair users. The WSTP has shown to be effective in several wheelchair-dependent populations and promising to be used in people with complex movement disorders. Yet, adaptation to the specific needs and capabilities of individuals with complex movement disorders is necessary as it has not been assessed in this population. During the 4-week training phase, the participants will receive 3 training sessions per week of 45 minutes, including exercises as described in the Wheelchair Skill Training Program Version 5.1.2
41143731|NCT00266305|BEHAVIORAL|Fish oil (Dry n-3, BASF)|5 g/oil daily for the first four month of lactation
41143732|NCT02772510|DEVICE|Smart glove system with functional electrical stimulation|Game-based virtual reality rehabilitation system (Smart glove system) combined with functional electrical stimulation on distal upper extremity
41143733|NCT02772510|DEVICE|Functional electrical stimulation|Functional electrical stimulation on distal upper extremity
41143734|NCT05651802|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.
41304104|NCT02491658|BIOLOGICAL|UC-MSCs|Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
41304105|NCT02254668|OTHER|Protocol with Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
40779050|NCT02095106|DEVICE|Traditional cast|
40779051|NCT06527885|DRUG|Lurasidone|Patients treated with Lurasidone in according to routine clinical practice, in Italy
41143735|NCT05651802|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
40779052|NCT02499614|DRUG|Crizotinib|Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
40779053|NCT03586947|DRUG|Vitamin D3 400 UNT Oral Capsule|50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
41143736|NCT05651802|DRUG|Chemotherapy|Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
41143737|NCT02753075|DEVICE|Experimental Oral Rinse 1|Oral rinse containing 1.5% w/w KOX, 0ppm F, pH 4.5
41143738|NCT02753075|DEVICE|Experimental Oral Rinse 2|Oral rinse containing 2.0% w/w KOX, 45ppm F, pH 4.5
41143739|NCT02753075|OTHER|Placebo Oral Rinse|Oral rinse containing 0% w/w KOX 0ppm F, pH 4.5
41143740|NCT02753075|DRUG|Fluoride toothpaste|Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate
41143741|NCT02973035|DRUG|Amlodipine|
41143742|NCT02973035|DRUG|Valsartan|
41143743|NCT03840993|DRUG|MT-2990|over 16 weeks
41143744|NCT03840993|DRUG|Placebo|over 16 weeks
41143745|NCT05700656|DRUG|Galunisertib plus capecitabine|Combination therapy with galunisertib plus capecitabine
41143746|NCT03162835|OTHER|Pain Neuroscience Education|Children as well as their parents will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
41143747|NCT03602807|DEVICE|Extracorporeal Shockwave Therapy|"2 treatments a week for 3 weeks consisting of 3000 focused shockwaves of 4Hz and 0,20mJ/mm2 applied over the kidney allograft.~Treatment is performed using the STORZ DUOLITH® SD1 T-TOP F-SW ultra"
41143748|NCT02593552|DEVICE|DriveCam|Video event monitoring device
41143749|NCT06606769|OTHER|Exercise|supervised exercise training; twice a week for 12 months
41143750|NCT06102278|OTHER|Peritoneal Metastasis|Patients experiencing postoperative peritoneal metastasis
41143751|NCT00075699|DRUG|cisplatin|
41143752|NCT00075699|DRUG|mitomycin C|
41143753|NCT00075699|DRUG|vincristine sulfate|
41143754|NCT00075699|DRUG|vinorelbine tartrate|
41143755|NCT00075699|PROCEDURE|pain therapy|
41143756|NCT00075699|PROCEDURE|psychosocial assessment and care|
41143757|NCT00075699|PROCEDURE|quality-of-life assessment|
41143758|NCT00997152|DRUG|JTT-654|Tablets
41143759|NCT00997152|DRUG|JTT-654 Placebo|Tablets
41143760|NCT03748056|BEHAVIORAL|Targeted incentives|Participants receiving individually-targeted incentives will receive weekly coupons for healthier foods that are informed by their purchase history, responses to behavioral and health questions, food preferences, and need for improvement in different categories
41143761|NCT03748056|BEHAVIORAL|Nominal loyalty card discount and nutrition education|All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.
41143762|NCT05825105|BIOLOGICAL|Platelet-Rich Plasma|The PRP will be prepared using a single centrifugation process. Approximately 30 ml of peripheral blood will be drawn and collected into a vacutainer tubes with sodium citrate anticoagulant 0.129 mol/l (3.8%). The tubes will then be centrifuged at 900 RPM for 12 minutes at room temperature in a benchtop centrifuge. We will separate the lower third of the plasma fraction from all tubes with a syringe and needle, taking care to avoid the leukocyte layer. The PRP will be refrigerated at 4°C for no less than 1 hour. We will not use any exogenous factors to stimulate the platelet activation process. The periauricular skin surface will be disinfected with a povidone iodine solution, and an intra-articular local anesthetic with 1% lidocaine will be applied. A 21-gauge needle will be placed at the point of application. Finally, PRP will be injected into the joint, and the needle will be removed.
41143763|NCT01790100|DRUG|VX-135|12 weeks of VX-135
41143764|NCT01790100|DRUG|Ribavirin|12 weeks of ribavirin
41143765|NCT01964586|DRUG|Dexmedetomidine|2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
41143766|NCT01964586|DRUG|Lidocaine|10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
41143767|NCT01964586|DRUG|Adrenaline|12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
41143768|NCT05980078|OTHER|Interactive consent|They were randomized to complete an interactive consent.
41143769|NCT05980078|OTHER|Standard consent|They were randomized to complete a standard written consent.
41143770|NCT00545922|BEHAVIORAL|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
41143771|NCT00545922|BEHAVIORAL|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
40779054|NCT05364398|PROCEDURE|ACL reconstruction|Use of hamstring tendons graft to replace the torn ACL and being passed and fixed through the femoral and tibial sides
40779055|NCT04044794|BEHAVIORAL|Standard Care|Standard care includes standardized educational materials to promote self-management of body weight along with provision of $60 for participants to purchase supplies or equipment to facilitate weight management.
41143772|NCT03657641|BIOLOGICAL|Pembrolizumab|Given IV
41143773|NCT03657641|DRUG|Regorafenib|Given PO
41143774|NCT03043339|OTHER|Stool Specimen Collection|Participants will provide a stool sample at baseline (pre-operation) and 30 days after the transplant operation. Stool specimens will be self-collected by the participant.
41304106|NCT02254668|OTHER|Protocol with Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
40779056|NCT04044794|BEHAVIORAL|Daily Self-Weighing|Participants will receive a wireless digital scale and will be asked to keep the scale in their home, weigh daily at the same time, and view their weight trajectory on the scale's digital display.
40779057|NCT02234362|DRUG|vortioxetine|Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
40779058|NCT03659578|DRUG|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
40779059|NCT03659578|RADIATION|split-course radiotherapy|Patient was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break of four weeks. Patients without disease progression had a dose of 15 Gy in 5 fractions or 24 Gy in 6 fractions as a boost
40779060|NCT03659578|DRUG|thymosin alpha 1|subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
41304107|NCT03736746|BEHAVIORAL|Motivational Interviewing|An investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs)
40779061|NCT02563782|BIOLOGICAL|Sub-retinal transplantation of MA09-hRPE cells|transplantation
40779062|NCT02563782|DRUG|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
40779063|NCT02563782|DRUG|Placebo tacrolimus and mycophenolate mofetil|placebo
40779064|NCT02563782|PROCEDURE|Sham Surgery|Sham surgery
40779065|NCT03025126|OTHER|Multimedial Rehabilitation|
40779066|NCT03025126|OTHER|Usual care program|Usual care at home program according to healthcare professional's advice
40779067|NCT03461718|DRUG|Ketamine|Experimental arm for sedation.
40779068|NCT03461718|DRUG|Midazolam injection|Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
40779069|NCT03461718|DRUG|Fentanyl|Part of standard sedation regimen
40779070|NCT06368570|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery with neuraxial anesthetic
40779071|NCT02663154|DRUG|Aromatherapy inhaler|Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea
40779072|NCT02663154|DRUG|Saline inhaler|Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
40779073|NCT04397380|DEVICE|Thermography|Measure Temperature using Thermal Camera
40779074|NCT04397380|DEVICE|Tympanic Temperature|Measure Temperature using Tympanic Temperature
40779075|NCT05340413|DRUG|Olaparib|300mg twice daily
41143775|NCT03043339|OTHER|Anal Swab Sampling|Anal swabs will be collected prior to surgery (baseline) and at post-operation days 2, 15, and 30. Participants whose planned hospitalization duration is extended from the pre-surgical plan will have an additional, optional, anal swab collected 2 days prior to their anticipated hospital discharge date. Anal swabs will be collected by the study team, except for the standard of care post-operative appointment (30 days after the operation) for the living donors who will collect their own samples.
41143776|NCT03043339|OTHER|Short Diet Assessment (SDA)|The study coordinator will administer the Short Diet Assessment (SDA) to participants prior to surgery at baseline and post-operation days 2, 15, and 30. Participants whose planned hospital length of stay is extended from the pre-surgical plan will complete the questionnaire 2 days prior to their anticipated hospital discharge date.
41143777|NCT03043339|OTHER|NHANES Dietary Screener Questionnaire (DSQ)|The National Health and Nutrition Examination Survey (NHANES) 2009-2010 Dietary Screener Questionnaire will be completed on Post-Operative Day 2. The questionnaire asks about foods consumed during the past 30 days. There are 25 items on the questionnaire and additional questions may be asked depending on responses provided. The questionnaire will be self-administered or administered by a study team member.
40779076|NCT02100826|DRUG|Cephalexin|Administered orally.
40779077|NCT01061528|DRUG|Transdermal Nicotine|Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
40779078|NCT03531255|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
40779079|NCT01877174|DEVICE|MICHI(TM) NPS+f|Transcarotid delivery system for carotid stents with flow reversal
40779080|NCT01877174|PROCEDURE|transcarotid stenting|
40779081|NCT05107076|DIAGNOSTIC_TEST|2D Echocardiography with color Doppler assessment & Galactin-3 level in blood|"* Measurements will be~  1. Pulsed wave (PW) Doppler~ 2. E (early diastolic)/A (late diastolic) - Using PW Doppler~ 3. IVRT (isovolumic relaxation time)~ 4. Deceleration time (DT) - from the peak of E wave to baseline.~ 5. E/e'- PW tissue Doppler imaging (TDI)~ 6. Left atrial volume and left atrial volume index (LAVI)~* Peripheral blood samples will be obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level."
40779082|NCT00239915|DRUG|Pagoclone|
40779083|NCT01226108|DEVICE|Patch|"One patch per day, Duration: three weeks, Administration: behind the ear~--------------------------------------------------------------------------------"
40779084|NCT01912014|BEHAVIORAL|Psychosocial support and counselling|
40779085|NCT00946595|DRUG|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
40779086|NCT00946595|DRUG|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
40779087|NCT06338163|COMBINATION_PRODUCT|Polihexanide-based bundle|Pre- and intra-operative decontamination will be accomplished in the treatment (experimental) arm with Polihexanide-based products
40779088|NCT06338163|COMBINATION_PRODUCT|Standard bundle|Pre- and intra-operative decontamination will be accomplished in the control arm with normal soap/shampoo and saline solution
40779089|NCT00735657|DEVICE|needle|Peribulbar blockade with standard (25 mm) needle
40779090|NCT00735657|DEVICE|needle|Peribulbar blockade with short (12.5 mm) needle
40779091|NCT00735657|PROCEDURE|Pars Plana Vitrectomy|Peribulbar block
40779092|NCT01750853|DRUG|LY3045697|Administered orally
40779093|NCT01750853|DRUG|Placebo|Administered orally
40779094|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
40779095|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
40779096|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
40779097|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
41143778|NCT04224597|DIAGNOSTIC_TEST|ultrasonography|all participants will be determined by ultrasonography.
41143779|NCT04086342|DRUG|CHI-902|A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
41304108|NCT05273749|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
41304109|NCT05273749|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
41304110|NCT06288672|OTHER|True avoidance diet|Food patch test-directed avoidance diet for 16 weeks where participant avoids avoid eating the food(s) to which they are allergic
41304111|NCT06288672|OTHER|Sham avoidance diet|Avoidance diet for 16 weeks of randomly selected foods to which the patch testing did not show an allergy
41304112|NCT03357822|DRUG|Pegylated interferon|180ug Pegylated interferon is injected subcutaneously once a week
41463132|NCT05646537|BEHAVIORAL|Neuro-Linguistic Programming Techniques|"The new behavior creation technique of NLP is based on the argument that the imagination process and reality are recorded in the same way in the brain.~Using the Participant's eye movements and imagination . He will be asked to imagine himself while caring for the stoma. participient will then be asked to re-enact the process with the correct stages of stoma care and the jurals that must be adhered to in order to successfully care for it.~Questions will be asked about where he can find the support he needs to carry out this process successfully. At the end of this whole process, he will be expected to construct what life is like with a stoma.The technique will be applied to the patient once and will be instructed to remember this successful process every time he or she feels distressed about the stoma.~At the end of 6 months, the quality of life and compliance will be evaluated by asking the scale questions again."
41463133|NCT00243152|DRUG|Lamotrigine|: 25mg and 50mg tablets
41463134|NCT00243152|DRUG|Placebo (for Lamotrigine)|Sugar pill manufactured to mimic Lamotrigine tablets
40779098|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
40779099|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
40779100|NCT01058850|BIOLOGICAL|Rindopepimut|250 or 500 mcg; intradermal injection
40779101|NCT00529633|DRUG|Thalidomide|Thalidomide by mouth at night for a total of 24 weeks
40779102|NCT00529633|OTHER|Sugar pill|Placebo by mouth at night for a total of 24 weeks
40779103|NCT01071460|DEVICE|FlexStent Femoropopliteal Self-Expanding Stent System|"Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy~Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:~* Contralateral retrograde common femoral cross-over access or antegrade access~* Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion~* Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis~* Deployment of an appropriately sized FlexStent® to cover target lesion~* Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter~* Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications"
41143780|NCT04086342|DRUG|Placebo|Placebo is a vehicle oil that will match CHI-902.
41143781|NCT04201275|DRUG|HEC74647PA capsule|Capsule administered orally once daily
41304113|NCT03357822|DRUG|Entecavir|0.5mg entecavir is orally taken every day
41304114|NCT03357822|DRUG|Tenofovir disoproxil fumarate|300mg tenofovir is orally taken every day
41304115|NCT04180813|DRUG|Linagliptin|drug
41304116|NCT04180813|DRUG|Acarbose|drug
40779104|NCT05287750|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
40779105|NCT01042314|DRUG|Donepezil|Tablets, Oral, 5 mg, Once Daily, Days 1-28
40779106|NCT01042314|DRUG|BMS-708163|Capsule, Oral, 125 mg, Once Daily, Days 15-28
40779107|NCT05739448|OTHER|nutritional intervention|The nutritional intervention will be based on the following 4 elements: nutritional follow-up by a dietician, fortified meals, tender and juicy meat dishes and fish dishes
40779108|NCT05739448|OTHER|physical activity|The physical activity intervention will be based on the following 2 elements: Follow-up with a trainer for adapted exercise and physical exercise instruction sheets
41143782|NCT04201275|DRUG|placebo|HEC74647PA capsule matching placebo administered orally once daily
41143783|NCT00778609|DRUG|EV/DNG (Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
41143784|NCT00778609|DRUG|Encapsulated Microgynon + Placebo|Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
41304117|NCT05057273|DRUG|BT-11|Oral once daily tablet
41304118|NCT05057273|DRUG|Active comparator|Biologic
41304119|NCT05966909|DIAGNOSTIC_TEST|Doppler Ultrasound|Ultrasound diagnosi of asymptomatic and symptomatic upper extremities vein thrombosis
41304120|NCT05927727|DIAGNOSTIC_TEST|Ultrasound and biyopsy|Each participant has undergone to ultrasound and biopsy procedure if they have suspicious lymph node in axillar region
41304121|NCT03010995|DRUG|Prazosin|Prazosin will used to study the mechanism involved in nicotine induced acute cardiovascular changes
41304122|NCT05515601|DRUG|Mirikizumab|Administered SC.
41463135|NCT02329431|BEHAVIORAL|activation curriculum|psychosocial activation curriculum
41463136|NCT02329431|BEHAVIORAL|support group|parent directed support group
41463137|NCT05187741|DEVICE|mobile health (mHealth)|"A message will be sent on Monday and Friday at 9:00 am for 3 months, the first day they will receive a message focused on adherence and the second day a message focused on motivation. Subsequently, a message will be sent on Mondays for 3 more months.~Reminders for appointments with your treating physician will be sent during the entire intervention period (6 months)."
41463138|NCT03507686|DRUG|BIIB111|Administered as specified in the treatment arm.
41463139|NCT01345734|DRUG|liraglutide|Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
40779109|NCT02059421|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"- Therapy session administered by a clinical psychologist using web-based video conferencing software.~Therapy sessions will include:~* Sleep restriction therapy~* Stimulus control instructions~* Sleep hygiene education"
40779110|NCT02059421|OTHER|Johrei therapy|"* Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.~* Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.~* Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.~* Therapy will be administered without physical contact.~* During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient."
41463140|NCT02129517|OTHER|IMPACT intervention|Tailored, web-based educational short video clips
41463141|NCT02129517|OTHER|Online education materials|Online NCI-based educational materials
41463142|NCT02129517|OTHER|survey administration|Ancillary studies
41463143|NCT01776528|BIOLOGICAL|NGM282|
41463144|NCT01776528|BIOLOGICAL|Placebo|
41143785|NCT04443556|DRUG|Tramadol|Before the closure of the thoracotomy, the surgeon will place two catheters through a Tuohy needle into fascial planes for continue the RISS block. First catheter tip will be placed towards the interfascial planes between the rhomboid major and intercostal muscles and the second catheter tip will be placed in subserratus fascial plane. Continue local anesthetics will be injected through the catheters for 48 hours. Also an IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
41143786|NCT04443556|OTHER|IV PCA|An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
41143787|NCT04314102|OTHER|No intervention will be made.|No intervention will be made. Only checks will be made
41143788|NCT00065247|BEHAVIORAL|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project|
41463145|NCT04984187|OTHER|high intensity laser plus exercise|high intensity laser plus exercise
41463146|NCT04984187|DEVICE|high intensity laser only|high intensity laser only
41463147|NCT04984187|OTHER|exercise|exercise only
41463148|NCT01041235|DRUG|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
41463149|NCT00344045|DRUG|Paracetamol|IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours
41463150|NCT00344045|DRUG|Placebo|IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
41463151|NCT02816424|BEHAVIORAL|Teens Exploring and Managing Prevention Options (TEMPO)|
41463152|NCT03815409|OTHER|Treadmill with partial weight unload|10-minute treadmill walk with a support corresponding to 20% of his/her own weight, followed by a 5-minute rest and a second 10-minute session on the treadmill with a support corresponding to 10% of his/her own weight. In the initial treadmill session, the starting speed of the treadmill was set to 0.5 km/h, subsequent increments of 0.5 km/h per minute were added to reach the maximum speed that was comfortably tolerated by the patient. This latter was used for the entire training period.
41304123|NCT01058369|DRUG|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
41463153|NCT03815409|OTHER|Traditional PT rehabilitation treatment|Every 40-minute treatment session consisted in isotonic and isometric exercises for the major muscles of the limbs and trunk including cardiovascular warm-up exercises (5 minutes), muscle stretching exercises (10 minutes), muscle stretching exercises for functional purposes (10 minutes), balance training exercises (10 minutes), relaxation exercises (5 minutes)
41463154|NCT02051660|BEHAVIORAL|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
41463155|NCT02051660|BEHAVIORAL|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
41463156|NCT00027417|DRUG|Liothyronine sodium/triiodothyronine|
41463157|NCT00027417|PROCEDURE|Cardiopulmonary bypass and cardiac surgery|
41463158|NCT04025294|DEVICE|videogame|A videogame intervention that is interactive and engaging that teaches adolescents how to restructure negative automatic thoughts through an adapted thought record (a technique used in cognitive behavioral therapy to improve moods) by modeling how to do so and then empower them through real-life activities to improve their school climate. The videogame intervention is comprised of five mini-games, each containing a short narrative that models how to restructure negative automatic thoughts and navigate through challenging situations that often take place in school settings. The topics of each mini-game are informed by the constructs of school climate according to the National School Climate Center. Students using the videogame intervention will be prompted to think deeply and reflect on the narratives presented in each mini-game.
40779111|NCT03304366|DIAGNOSTIC_TEST|Pentacam (scheimpflug imaging)|Corneal changes including thickness, elevations....etc
40779112|NCT01464879|DRUG|Testosterone Gel (FE 999303)|
40779113|NCT01120405|DRUG|Xenon|
40779114|NCT01120405|DRUG|Sevoflurane|
40983941|NCT06087783|DIETARY_SUPPLEMENT|Experimental product - Fortifit® Powder|Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
41143789|NCT04150900|DRUG|Bavituximab|Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
41143790|NCT04150900|DRUG|Pembrolizumab|Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
41143791|NCT02591082|DEVICE|RenovoCath™ R120 Catheter|The RenovoCath™ RC120 Catheter will be used to isolate segments of arteries supplying blood to the pancreas. The two balloons on the catheter will be positioned and inflated to temporarily stop blood flow while medication is infused through the catheter between the balloons.
41143792|NCT03242863|OTHER|Food proportionality|Proportions of high and low energy dense foods manipulated
41143793|NCT01773707|DRUG|CTLA4-Ig (Abatacept)|Given as 30 minute IV infusion
41143794|NCT01773707|DRUG|Placebo|Saline given as 30 minute IV infusion
41143795|NCT00233545|DRUG|miltefosine|
41143796|NCT00233545|DRUG|antimony|
41304124|NCT01543490|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 2 weeks
41304125|NCT01543490|OTHER|Vehicle|Vehicle twice daily for 2 weeks
41304126|NCT03879668|DEVICE|eIPOS|Electronic version of IPOS
41304127|NCT04420455|DRUG|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
41304128|NCT02194400|BIOLOGICAL|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
41304129|NCT02242890|BEHAVIORAL|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
41304130|NCT00981383|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
41463159|NCT04025294|BEHAVIORAL|School Climate Assessment Survey|A school climate assessment survey will include items adapted from questions developed by the National School Climate Center. Items will assess various dimensions of school climate including safety, social media, relationships, support for learning, and environment.
41463160|NCT00003404|RADIATION|Adjuvant Radiotherapy|Adjuvant radiation therapy
41463161|NCT04946786|DIAGNOSTIC_TEST|Laboratory investigations, pelvi-abdominal US, fibroscan, and in body analysis|"1. Complete history taking.~2. Thorough clinical examination :Assessing for buffalo hump, double chin, acanthosis nigricans, skin tags or acrochordon and xanthelasma and anthropometric measurements as measuring height m, weight Kg, waist circumference (WC) Cm, hip circumference (HC) Cm.~3. Pelvi-abdominal ultrasound. 4. Fibroscan examination will be done for all subjects to assess steatosis by measuring the CAP score.~5. Body composition analysis: to detect water, muscle and fat percentage in the body.~6. Laboratory investigations:All samples wil be analyzed for fasting blood glucose (FBG), and post-prandial (2hrs after meals) blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein (VLDL-C), alkaline phosphatase (ALK), aspartate transaminase (AST),alanine transaminase (ALT).~• Fasting insulin levels will be measured using ELISA kits"
40779115|NCT05177250|DEVICE|HPLC|taking urine samples from participants and analyze these samples to detect bisphenol A and paraben
40779116|NCT05732038|BEHAVIORAL|Healthy Minds Program (HMP)|Participants assigned to the HMP group will be asked to complete a minimum of 10 minutes per day of meditation for 12 weeks. For the first four weeks, participants will listen to prescribed meditations that will teach them the foundations of mindfulness. During weeks 5-12, participants will have full access to the HMP meditation library.
40983942|NCT06087783|OTHER|Standard of care|Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement
40983943|NCT00004323|DRUG|anti-thymocyte globulin|
40983944|NCT00004323|DRUG|cyclophosphamide|
40983945|NCT00004323|DRUG|cyclosporine|
40983946|NCT00004323|DRUG|mesna|
40983947|NCT00004323|DRUG|methotrexate|
40983948|NCT00004323|DRUG|methylprednisolone|
40983949|NCT01509833|DRUG|rFSH|Administration of rFSH for ovarian stimulation.
40983950|NCT01509833|DRUG|hCG|Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
40983951|NCT01509833|DRUG|hCG|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
40983952|NCT05540301|OTHER|Modified sleeper stretching|Modified sleeper stretching was performed on shoulder joint to increase internal rotation range of motion.
40983953|NCT05540301|OTHER|Modified cross-body adduction stretch|Modified cross-body adduction stretching was performed on shoulder joint to increase internal rotation range of motion.
40983954|NCT01800864|OTHER|obesity|
40983955|NCT03027726|BEHAVIORAL|lifestyle and psycho-educational program|The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
40983956|NCT03027726|OTHER|Exercise plus lifestyle and psycho-educational program|The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
40983957|NCT04834427|DRUG|Conventional therapy + S (+)-Ketamine|"In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~1. Intravenous injection：Bolus intravenous injection before skin incision, the dose is 0.1\~0.25 mg/kg; Bolus intravenous injection (dose 0.1\~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1\~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02\~0.1 mg/kg/h for 24\~48 h.~2. Intramuscular injection：The dose is 2\~4 mg/kg."
40983958|NCT04834427|DRUG|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
40983959|NCT03440710|PROCEDURE|BET|Balloon Eustachian Tuboplasty
40983960|NCT01013701|DRUG|fluticasone furoate|nasal steroid spray
40983961|NCT01013701|OTHER|placebo|nasal steroid vehicle without drug
40983962|NCT04142554|DRUG|Parsaclisib|Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
40983963|NCT00457782|DRUG|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
40983964|NCT03909295|DRUG|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
40983965|NCT02913391|OTHER|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
40983966|NCT02913391|OTHER|control group (CG)|After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
41143797|NCT01042132|PROCEDURE|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
41143798|NCT01042132|PROCEDURE|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
41143799|NCT01379677|DRUG|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
41304131|NCT00981383|OTHER|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
40983967|NCT05481073|DEVICE|UV sensor|Use of UV sensor to be informed about the sun exposure daily through a mobile application
40983968|NCT04678154|DRUG|Standard of care|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
40983969|NCT04678154|DRUG|Vancomycin and Tobramycin|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
40983970|NCT06477614|BIOLOGICAL|DC cell Vaccine|Deliver DC cell vaccine into patients for anti-ancer therapy.
41143800|NCT01379677|DRUG|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
41143801|NCT01368549|OTHER|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
41304132|NCT04632095|PROCEDURE|Aortic valve replacement due to sternotomy|conventional surgery of aortic stenosis
41304133|NCT04632095|PROCEDURE|Aortic valve replacement due to parasternal right anterior mini-thoracotomy|surgery of aortic stenosis in minimally invasive technique
40983971|NCT04425707|DRUG|Ivermectin|use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt
41463162|NCT00096122|DRUG|cytarabine|Given IV
40779117|NCT05732038|BEHAVIORAL|Wellness App (WA)|"Participants in the WA group will listen to a minimum of 10 minutes per day of a caregiver specific educational podcast (including topics such as Caring for the Caregiver or Folate and Preventing Alzheimer's) delivered via a mobile app for the 12 weeks. The app contains one podcast per day for twelve weeks."
40779118|NCT03199833|DEVICE|RETRAINER-S2|"It consists of the execution of different exercises with the affected forearm-hand supported by the RETRAINER-S2 device. The subject is actively involved in the exercises and the system provides two types of support: wrist-fingers motion constraining and FES. The following exercises can be performed: controlled wrist flexion and wrist extension; controlled fingers flexion and extension; repeated grasping of an object; anterior reaching and grasping of an object; moving of objects on a plane or in space.~A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
41463163|NCT00096122|DRUG|idarubicin|Given IV
41463164|NCT00096122|DRUG|tipifarnib|Given orally
41463165|NCT03722108|COMBINATION_PRODUCT|Regorafenib and Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
40983972|NCT02389088|DRUG|Letrozole|In Phase II, letrozole, 5 mg/day, will be given for 14 days
40779119|NCT03199833|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy"
40779120|NCT02167711|DRUG|SIRT Yttrium-90|
40983973|NCT04389424|DRUG|Tamoxifen|Use of tamoxifen for breast cancer recurrence prevention
40983974|NCT04389424|DRUG|Exemestane|Use of exemestane for breast cancer recurrence prevention
40779121|NCT00286286|DEVICE|Intraperitoneal Aerosolization System, IntraMyst|
40779122|NCT04106505|BEHAVIORAL|Biofeedback training via app on smartphone|Biofeedback training as described in biofeedback arm.
40779123|NCT04106505|BEHAVIORAL|Sham-biofeedback training via app on smartphone|Sham-biofeedback training as described in sham-biofeedback arm.
40983975|NCT04389424|DRUG|Anastrozole|Use of anastrozole for breast cancer recurrence prevention
40983976|NCT04389424|DIAGNOSTIC_TEST|Basal|Initial diagnosis of breast cacner by biopsy or mastectomy
41143802|NCT03717233|DEVICE|Exoskeleton|Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
41143803|NCT05789134|OTHER|self-sampling kits for STI testing in the laboratory|Participants will receive the self-sampling kits and their submitted samples would be sent to laboratory for testing
40983977|NCT04389424|DIAGNOSTIC_TEST|Recurrence|Breast cancer recurrence under endocrine therapy
40983978|NCT03513302|DIETARY_SUPPLEMENT|placebo|2 x 70 mL concentrated beet root juice depleted of nitrate per day for 14 days.
40983979|NCT03513302|DIETARY_SUPPLEMENT|nitrate|2 x 70 mL concentrated beet root juice per day for 14 days.
41143804|NCT02734394|BEHAVIORAL|Exercise|Cardiovascular and resistance exercise training
41463166|NCT03722108|DRUG|Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
41463167|NCT02119962|BEHAVIORAL|Working memory training|
40983980|NCT00265954|BEHAVIORAL|internet, in-person and internet+in-person|All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
40983981|NCT00849810|DRUG|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
40983982|NCT00849810|DRUG|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
41143805|NCT01944774|DRUG|Nemonoxacin 500 mg|IV Infusion, once daily for 7\~14 days
41143806|NCT01944774|DRUG|Nemonoxacin 650 mg|IV Infusion, once daily for 7\~14 days
41143807|NCT01944774|DRUG|Moxifloxacin 400 mg|IV Infusion, once daily for 7\~14 days
41463168|NCT02119962|BEHAVIORAL|Placebo training|
41463169|NCT01418950|OTHER|Written information and verbal counseling|control group will only receive verbal counseling. Study group will receive written information before verbal counseling
41463170|NCT06466356|OTHER|Psychoeducational Course for Suicide Prevention|Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
40983983|NCT03578029|DRUG|RGN-137|It will be applied topically to the appropriate wound once a day for up to 84 days.
40983984|NCT03578029|DRUG|Placebo|It will be applied topically to the appropriate wound once a day for up to 84 days.
41143808|NCT00004171|DRUG|busulfan|
41143809|NCT00004171|DRUG|cyclophosphamide|
41143810|NCT00004171|PROCEDURE|peripheral blood stem cell transplantation|
41143811|NCT06173622|BEHAVIORAL|Fetal Positioning|In the study, venipuncture was applied to the intervention and control groups. While the procedure was performed by an experienced neonatal nurse, the neonates' pain score, crying duration and physiological parameters were monitored by another researcher (observer).
41143812|NCT03867396|DEVICE|CROS|Advanced Bionics CROS
41143813|NCT03867396|DEVICE|Hearing Aid|Advanced Bionics Naida hearing aid
41143814|NCT03867396|OTHER|Cochlear Implant Alone|No hearing device on contralateral ear
41463171|NCT06466356|OTHER|Individual therapy session|Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
40779124|NCT01689948|BEHAVIORAL|Home rehabilitation therapy|12 sessions of home rehabilitation therapy
40779125|NCT05447403|OTHER|Chewing gum combined with WeChat enhanced instructions|Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
40779126|NCT03430349|BIOLOGICAL|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~* Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
40983985|NCT04219332|DRUG|Subserosa injection of indocyanine green|After preoperative exploration, the indocyanine green powder (Dandong Yichuang Pharmaceutical Co) is dissolved in 0.5 mg/ml of sterile water and the prepared solution (1.5 ml for each point) is injected along the subserosal of the stomach at 6 specific points along the lesser and greater curvature of the stomach.
40983986|NCT04219332|DRUG|submucosal injection of indocyanine green|One day before surgery, 1.25 mg/ml indocyanine green (Dandong Yichuang Pharmaceutical Co) was prepared in sterile water and 0.5 ml of the solution was injected into the submucosal layer at 4 quadrants around the primary tumor, amounting to 2.5 mg of indocyanine green.
40983987|NCT00774150|BEHAVIORAL|Cognitive Behavioral Therapy|16 sessions of CBT
40983988|NCT00774150|BEHAVIORAL|Client Centered Therapy|16 sessions of CCT
40983989|NCT00412763|DRUG|Silymarin (Silybum marianum)|
40983990|NCT05863910|DRUG|Medical Cannabis|Any cannabis product that is available to participants through the Medical Cannabis Access Program is eligible to be included in this study.
40983991|NCT00050843|DRUG|thalidomide|
40983992|NCT01349803|DRUG|PT005 MDI|PT005 MDI administered as two puffs BID for 14 days
40983993|NCT01349803|DRUG|PT001 MDI|PT001 MDI administered as two puffs BID for 14 days
40983994|NCT01349803|DRUG|PT003 MDI|PT003 MDI administered as two puffs BID for 14 days
40983995|NCT01349803|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
40983996|NCT03615976|PROCEDURE|high tibial osteotomy with or without arthroscopic circumpatellar denervation with or without arthroscopic circumpatellar denervation|"Arthroscopy will be done in all cases before osteotomy to assess lat. Comp and grade of patellofemoral O.A Arthroscopic patellar denervation with vaper or diathermy will be done plus open wedge high tibial osteotomy in one group and other group OWHTO only will be done comparing the rustles of two groups to assess the efficacy of this procedure~followed by an average follow up to 12 months. And follow up( 6th weeks ,3rd month ,6th month , 12th month)~By clinical examinationan and x-ray and knee scores~1. Scoring of patellofemoral disorders( Kujala) score~2. Knee Injury and Osteoarthritis Outcome Score (KOOS)"
41143815|NCT05928494|OTHER|Scenario-based high-fidelity simulation method|Postpartum care applications were carried out with the high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the midwifery department to the students in the intervention group.
41143816|NCT04118998|BEHAVIORAL|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
41143817|NCT04118998|BEHAVIORAL|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
41143818|NCT05410717|BIOLOGICAL|Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells|"Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy."
41143819|NCT06452914|DEVICE|Semiconductor Embedded Therapeutic Socks|Semiconductor Embedded Therapeutic Socks
41143820|NCT06452914|DEVICE|Placebo Socks|Socks not containing the Semiconductor Embedded Therapeutic fabric
41143821|NCT01308099|DEVICE|Blood Pressure and Blood Flow|"A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.~The study lasts about 2 hours."
41143822|NCT05530239|OTHER|Blood sample collection|Blood sample collection
41463172|NCT06466356|OTHER|Treatment as usual|Treatment as usual (TAU) may include the use of psychotropic drugs, in and out-patient treatment, occupational therapy and other interventions the patients physician deem necessary.
40983997|NCT00561080|BIOLOGICAL|Zostavax|
40983998|NCT02659631|DRUG|PF-06671008|Dose Escalation Phase - Part 1
40983999|NCT02659631|DRUG|PF-06671008|Dose Expansion Phase - Part 2
40984000|NCT04540757|PROCEDURE|Surgery|Participants will be randomised to receive surgery as part of multi-modality treatment
41304134|NCT01572532|OTHER|Screening treatment and referral|"Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days."
41304135|NCT05017285|PROCEDURE|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum
41304136|NCT05017285|PROCEDURE|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
41463173|NCT04830241|DRUG|Antidepressant|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity
40779127|NCT03430349|BIOLOGICAL|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
40779128|NCT04264000|DRUG|platelet-rich plasma|Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
40779129|NCT04264000|DRUG|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
40779130|NCT02192957|DEVICE|Lifepak 20E Defibrillator, Licence No: 61944|"Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.~Ottawa AF Cardioversion"
41463174|NCT03417739|DRUG|BVD-523|ERK1 and ERK2 inhibitor
41463175|NCT03171324|DRUG|Iron Supplement|2 mg/kg/day elemental iron
40779131|NCT05702307|OTHER|Glucose as reference food|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40779132|NCT05702307|OTHER|Tagliatella control|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from tagliatella control, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40779133|NCT05702307|OTHER|5% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 5% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40779134|NCT05702307|OTHER|16% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40779135|NCT05702307|OTHER|16% sunflower penne|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower penne, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and samples from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40779136|NCT05702307|OTHER|16% sunflower fusilli|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower fusilli, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
41463176|NCT00466479|DRUG|brimonidine|
41463177|NCT00466479|PROCEDURE|laser trabeculoplasty|
41463178|NCT03846063|OTHER|Home-based rehabilitation program|The duration of the program is 12 weeks. Patients start the program within 7 days after of the surgery. Patients perform exercises independently at home using the tablet PC for instructions. The program includes strengthening and walking exercises based on increasing the muscle force, balance, and functionality. The exercises comprise movements that train abductors, flexors, and extensors of the affected hip. The content of the program is based on previous research and on guidelines from the American Association of Orthopaedic Surgeons. For the rest, the program is designed in line with the most recent guidelines from the Royal Dutch Society for Physical Therapy. Patients are asked to exercise at least 5 days a week, with rest days on Thursday and Sunday. Strengthening exercises will be performed 3 times a week. The instructions for the exercises will be provided by videos on the tablet PC, which patients have to imitate.
40779137|NCT04194424|OTHER|Multidisciplinary weight loss program|Diet and behavioral therapy,and supervised exercise sessions
40779138|NCT04194424|OTHER|Standard Care|General lifestyle tips
40779139|NCT04194424|DRUG|Metformin Hcl 850Mg Tab|1 tablet, twice daily
40779140|NCT01900665|DRUG|Solanezumab|Administered Intravenously (IV)
40984001|NCT04540757|PROCEDURE|No surgery|Participants will be randomised to receive no surgery as part of multi-modality treatment
40984002|NCT04265781|DRUG|BAY1817080|Three different doses over the course of study
40984003|NCT04265781|DRUG|Matching Placebo|Matching Placebo to BAY1817080
41304137|NCT00120120|DRUG|Lenalidomide (CC-5013)|Lenalidomide 2-5 mg capsules taken one time per day
40779141|NCT01900665|DRUG|Placebo|Administered IV
40984004|NCT01034462|DRUG|Levomilnacipran ER|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
40984005|NCT01034462|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
40984006|NCT01305850|DRUG|placebo|Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
40984007|NCT01305850|DRUG|Aliskiren|Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
40984008|NCT01305850|DRUG|Aliskiren plus Losartan|Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
40984009|NCT01305850|DRUG|Enalapril plus Losartan|Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
40984010|NCT02308254|DRUG|Lixisenatide|Abdominal administration
40984011|NCT02308254|DRUG|Placebo|Abdominal administration
40984012|NCT01905384|DEVICE|Covered Self-expanding metal biliary stents (C-SEMS)|Used for palliation of inoperable malignant distal bile duct obstruction.
40984013|NCT01905384|DEVICE|Uncovered Self-expanding metal biliary stents (U-SEMS)|Used for palliation of inoperable malignant distal bile duct obstructions.
40984014|NCT02671591|BEHAVIORAL|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
40984015|NCT02671591|BEHAVIORAL|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
40984016|NCT01951742|BIOLOGICAL|ANT-1401|Active
40984017|NCT01951742|BIOLOGICAL|Vehicle|Vehicle
40984018|NCT01585428|DRUG|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
41143823|NCT00942500|PROCEDURE|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade \<2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
41143824|NCT06505785|OTHER|The creative drama group|"10 weeks, once a week, each session will last approximately 2 hours and will be facilitated by a trained instructor in creative drama.~Sessions will include role-playing, improvisation, and scenario-based activities focusing on midwifery care situations, communication with patients, and empathy development."
41143825|NCT02935894|DRUG|Ibuprofen|400 mg ibuprofen given to inhibit cyclooxygenase metabolism
41143826|NCT02935894|OTHER|Physiological induction of sweating|15 minutes exercise at 60-80% oxygen consumption to induce sweating
40779142|NCT00893360|BIOLOGICAL|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
40779143|NCT00893360|BIOLOGICAL|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
40984019|NCT01585428|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
41143827|NCT02935894|DRUG|Pilocarpine|Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
40984020|NCT01585428|BIOLOGICAL|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
40984021|NCT01585428|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
40984022|NCT01729507|OTHER|tDCS|Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
40984023|NCT01729507|BEHAVIORAL|standardised behavioural therapy|"The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session."
40984024|NCT03762109|DRUG|Dantrolene|muscle relaxant
41143828|NCT02961283|DRUG|ASN003 ascending doses|
41143829|NCT02961283|DRUG|ASN003 MTD|The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
40779144|NCT00457392|DRUG|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
41463179|NCT04105634|DRUG|FNOS|The imaging drug used for this group is called 18F-NOS, it is an experimental imaging drug that has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
40779145|NCT00457392|DRUG|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
40779146|NCT00457392|DRUG|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
40779147|NCT00457392|DRUG|placebo|Placebo daily by oral capsules in a continuous regimen
40779148|NCT03464825|OTHER|Specific and progressive balance training|Specific and progressive balance training for the intervention group
40779149|NCT00716820|DRUG|SUNITINIB MALATE|"SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
40779150|NCT02394561|BIOLOGICAL|Secukinumab|Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
40779151|NCT05794607|OTHER|Rehabilitation group|The intervention group will be given strength training to improve muscle strength and flexibility, and aerobic exercise training to improve exercise capacity with function.
40779152|NCT05290532|OTHER|Individualized exercise training|The intervention will consist of a multicomponent exercise training program, which will composed of supervised progressive resistance exercise training, aerobic and anaerobic exercises. This training period consist on 2 training sessions of 40 minutes (Warm up 5´+ aerobic exercise 15´+ anaerobic exercise 15´+ stretching 5´)per week during 4 weeks after one week of discharge
40779153|NCT00173719|DEVICE|Standard cane|
40779154|NCT04846595|OTHER|self questionnaire|Evaluate the demographic variables and medical characteristics of people living with HIV in the Alpine Arc region
40984025|NCT03762109|DRUG|Placebo Oral Tablet|inactive pill
40779156|NCT03012750|DRUG|Indocyanine Green|Perioperative application of 0.1 mg ICG per kg Body weight
40779157|NCT06329219|DEVICE|water-filtered Infrared-A radiation|The water-filtered Infrared-A radiation device is designed for self-administered home treatments. The regimen prescribes 30-minute sessions, five times weekly, spanning 12 weeks.
41304138|NCT01742468|DIETARY_SUPPLEMENT|long-chain n-3 PUFA|Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder
40779158|NCT02004158|BEHAVIORAL|Positive psychology intervention|
40779159|NCT04573985|BEHAVIORAL|Serious game Eurekoi intervention|1 session in group using the serious game eurekoi
40779160|NCT03470025|OTHER|Psychological Intervention|"1. F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~2. TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~3. CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR."
40779161|NCT00871026|PROCEDURE|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
40779162|NCT00871026|PROCEDURE|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
40779163|NCT02234193|DEVICE|Micro biopsy|This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
40779164|NCT02234193|PROCEDURE|Lidocaine with epinephrine|The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
40779165|NCT06135584|DRUG|Pioglitazone metformin tablets|Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
40779166|NCT06135584|DRUG|Other drugs|Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
41304139|NCT01742468|DIETARY_SUPPLEMENT|sunflower oil|Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
41304140|NCT03407196|DRUG|Forxiga|Oral antidiabetics
40779167|NCT06135584|OTHER|Drug-free|Drug-free
40779168|NCT01646827|DRUG|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
40984026|NCT04478357|DRUG|4 mg Fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
41304141|NCT03758378|OTHER|Dietary intervention|Limiting dietary exposure to high intensity sweeteners and sugar alcohols; limiting eating out to a maximum of 2 days per week.
41143830|NCT01285882|OTHER|Representations|"1. A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.~2. To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :~   * 1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.~  * 2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.~3. Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation."
40779169|NCT01051661|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
40779170|NCT01051661|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
40779171|NCT01051661|BIOLOGICAL|Placebo|Intramuscular injection, one dose
40779172|NCT01471184|DEVICE|Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops|
40779173|NCT01471184|DEVICE|Placebo|Placebo Eye Drops/Nasal Spray
40779174|NCT02512692|DEVICE|SIR-Spheres microspheres (Yttrium-90 Microspheres)|On Day 3 or 4 of cycle 1 90Y TARE will be administered
40779175|NCT02512692|DRUG|Gemcitabine|On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
40779176|NCT02512692|DRUG|Cisplatin|On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
40779177|NCT00823173|BIOLOGICAL|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
40984027|NCT04478357|DRUG|4 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
40984028|NCT04478357|DRUG|8 mg fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
40984029|NCT04478357|DRUG|8 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
40779178|NCT01162759|BEHAVIORAL|Home Blood Pressure Monitoring|Home blood pressure readings are taken at least 3 times a week, uploaded to a Microsoft Health Vault account through American Heart Association Heart360 at least 1 time per week. Patients are followed by a clinical pharmacist, with physician oversight, who will make adjustments to antihypertensive medications or suggest additional medications using national JNC VII and KPCO hypertension guidelines.
40779179|NCT04653792|DRUG|Pregabalin 75mg|75 mg capsule
40779180|NCT04653792|DEVICE|Placebo|75 mg
40779181|NCT04582214|DEVICE|MetaNeb® System|The intervention device use in this study is The MetaNeb® System (Hill-Rom; St. Paul, MN). It is an FDA 510k cleared device (k124032), powered by compressed gas, that delivers oscillation and lung expansion (OLE) therapy using both continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP). The device also provides supplemental oxygen when used with compressed oxygen and can deliver aerosol therapy during CPEP and/or CHFO. The therapy is indicated for mobilization of secretions, lung expansion therapy and the treatment and prevention of pulmonary atelectasis. The device also provides supplemental oxygen when used with compressed oxygen.
40779182|NCT03281057|BEHAVIORAL|CRAFT|CRAFT is a counseling/therapist to concern significant others to get their loved one, with an alcohol use disorder, into treatment
41304142|NCT03329937|DRUG|Niraparib|Niraparib is a potent, orally active, highly selective poly adenosine diphosphate (\[ADP\]-ribose) polymerase 1 (PARP1) and PARP2 inhibitor. It will be supplied as 100 mg capsules and will be administered at starting dose of 200 mg PO daily throughout 28 days for 2 cycles (each cycle is 28 days), with the potential for an additional 4 cycles (maximum total of 6 cycles) at the assigned dose and schedule.
41304143|NCT05048823|OTHER|Visceral Osteopathic Techniques|Generalized Discharge Technique of the Peritoneum and Intestinal Wings, Mobilization of the Cecum, Technique for the Root of the Mesentery, Release of the D1-D2 Angle, Technique for the Sigmoid Colon
41304144|NCT05048823|OTHER|Simulated visceral techniques|Simulated visceral techniques in the region of the gastrointestinal system
40779183|NCT01359124|BEHAVIORAL|Exercise Cycle|Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.
40984030|NCT01529879|DEVICE|New Abutment Connection implant|New abutment connection implant
40984031|NCT01529879|DEVICE|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
40984032|NCT01797003|OTHER|High tibial osteotomy|
40984033|NCT03120819|BEHAVIORAL|Oncologist Recommendation|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist
40984034|NCT03120819|BEHAVIORAL|Oncologist Recommendation + DVD|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist and then be sent an instructional exercise DVD to follow at their home three times per week for eight weeks
40984035|NCT00841087|DRUG|insulin degludec|The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
40984036|NCT00841087|DRUG|insulin detemir|Injection subcutaneously at bedtime
40984037|NCT00841087|DRUG|insulin aspart|Injection subcutaneously immediately before each meal.
40984038|NCT01287897|DRUG|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
41304145|NCT03155191|BIOLOGICAL|TBI-1501|"Phase-I portion:~Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg).~Phase-II portion:~Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501."
40984039|NCT01287897|DRUG|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
40984040|NCT01287897|DRUG|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
40984041|NCT05361993|DRUG|Drug Aripiprazole|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
40984042|NCT05361993|DEVICE|biofeedback|Biofeedback therapy Biofeedback therapy, three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training（using the Infiniti3000A biofeedback system，Thought Technology Ltd.）.Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
40984043|NCT05821868|DEVICE|Dosivent|Dosivent® inhalation chamber is designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
40984044|NCT05821868|DEVICE|Aerochamber Plus Flow Vu|Aerochamber Plus Flow Vu® inhalation chamber is also designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
40984045|NCT01518010|BEHAVIORAL|Play game|Participants engage in non-game activity (establish baseline) 7 \* 1 hr weekly; play single-player game 7 \* 1 hr weekly; play multi-player game 7 \* 1 hr weekly.
40984046|NCT02760667|DRUG|Cisplatinum|Cisplatin 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
40984047|NCT02760667|DRUG|Docetaxel|Docetaxel 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
40984048|NCT02760667|DRUG|Carboplatin|Carboplatin AUC=5 every 3 weeks for a maximum of 3 cycles during the induction phase (if subject are unable to tolerate cisplatin)
40984049|NCT02760667|PROCEDURE|Transoral Robotic Assisted Surgery|TORS will be performed for the patients who responded to the induction treatment (80% reduction)
40984050|NCT03330522|OTHER|Love, Sex, & Choices video series|Love, Sex, and Choices was written and scripted by the study team and underwent pilot testing in the target population. The series was divided into 15-to-20 minute episodes that were streamed weekly. The principles of reducing HIV risk were communicated through the characters and high risk situations. The lead characters model how women become more powerful, meaning more aware of themselves as worthy of respect, making choices intentionally, feeling free to pursue their intentions, and involving themselves in creating change. This process leads to higher power sex scripts in the characters, meaning pursuing intentional choices and health promoting behaviors. The lead characters model open communication about HIV testing with a resistant partner, and initiating condom use.
40779184|NCT01359124|BEHAVIORAL|Land-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.
40984051|NCT03330522|OTHER|Messages in text|"The comparison group received 12 weekly HIV health promotion written messages over the smartphone. The messages were based on prevailing CDC recommendations and the theoretical framework. An example is: Sexual health means respecting your own rights and feelings. Feeling pressured to have sex means limiting your choices and your freedom to love safely. .... If he doesn't like you being you, it may be time to walk. Other messages provided instructions on the correct condom use and the importance of HIV testing. The 12 messages were reviewed by ten African American and Latina undergraduate nursing students for ease of comprehension."
40984052|NCT01067456|RADIATION|Comprehensive Cardiothoracic CT arm|Subjects in this arm will receive the comprehensive cardiothoracic CT to rule out aortic dissection/pulmonary embolism/acute coronary syndrome in a single scan.
40984053|NCT02699528|DRUG|methylphenidate|The drug will be prescribed as indicated for attention deficit disorder
40984054|NCT04855825|DEVICE|Robotic Exoskeleton Rehabilitation|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
40984055|NCT04855825|OTHER|Conventional Gait Therapy|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
40984056|NCT02442960|DRUG|Herbal treatment (SA100)|This treatment has been used extensively in traditional medicine practices for hundreds of years.
40984057|NCT05693675|DRUG|Postoperative methadone|Participants will receive intraoperative methadone (0.2 mg/kg ideal body weight intravenously but not exceeding 20mg) followed by oral/IV methadone postoperatively according to the following scheme: A) Opioid naïve patients will receive 5mg twice daily dosage of methadone on postoperative days 1 and 2 followed by 5 mg daily on postoperative days 3, 4, and 5. B) Patients taking opioids preoperatively will continue to receive their regular opioids and additionally receive 5 mg twice a day of methadone on postoperative days 1 and 2, followed by 5 mg per day on days 3, 4 and 5.
41304146|NCT03885739|OTHER|Continuous Pericapsular Nerve Group block|Continuous Pericapsular Nerve Group block to standardize the approach. Injections were performed using a curvilinear low-frequency ultrasound probe (3.5- to 5-MHz). The lateral border of iliopsoas tendon in an oblique axial plane at level of iliopectineal eminence provides target for needle placement. Toggling the transducer was necessary to optimize visualization of the iliopsoas tendon secondary to anisotropy. Injections were performed using an 18-gauge Tuohy needle under sterile conditions. Then, 10 mL 0.25% bupivacaine was administered and a 20-G polyamide catheter (connect to a filter) was advanced into the space. The end point of the catheter placement was the direct visualization of microbubbles in a peritendinous distribution using a bolus of agitated saline applied through threaded catheter connected to not purged filter. After catheter placement patients received a 0.1% bupivacaine continuous infusion at a constant rate.
41304147|NCT03032185|DEVICE|Transcutaneous Elevtrical Nerve Stimulation|
41304148|NCT06130696|OTHER|Clamshell exercises|Group A will receive treatment with Clamshell exercises Change sides and do 3 sets. Total of 6 session were given.
40779185|NCT01359124|BEHAVIORAL|Water-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
40779186|NCT00487916|DRUG|AMA1-C1/ISA 720|
40779187|NCT03819309|PROCEDURE|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
41463180|NCT04105634|DRUG|Florbetaben|The imaging drug used for this group is called Florbetaben, it is an FDA approved radioactive PET tracer used to image amyloid plaques in the body. Although not yet FDA approved for this purpose, it has already been used clinically to image amyloid in other parts of the body. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
41463181|NCT02349074|PROCEDURE|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
40779188|NCT03819309|PROCEDURE|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
40984058|NCT05693675|DRUG|Postoperative placebo|Participants will receive intraoperative methadone intravenously 0.2mg/kg followed by oral placebo postoperatively according to the following scheme: Opioid naïve patients and patients taking opioids preoperatively will receive placebo tablets twice daily on day 1 and day 2 and once daily day 3, 4 and 5. Patients taking preoperative opioids will be able to return to their baseline opioids immediately after surgery.
40984059|NCT05693675|DRUG|Rescue Analgesia|PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case. All patients receive IV intravenous patient-controlled analgesia and rescue opioids which is usual care for postoperative pain.
40984060|NCT01031940|DEVICE|macintosh laryngoscope|intubate with the macintosh laryngoscope
40984061|NCT01031940|DEVICE|C-MAC laryngoscope|intubate with the C-MAC laryngoscope
41463182|NCT00610506|DRUG|Escitalopram|Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
40984062|NCT01031940|DEVICE|Airtraq device|intubate with the Airtraq device
40984063|NCT05479955|OTHER|5 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. The women in this group received 5 minutes of skin-to-skin contact as a clinic routine.
40984064|NCT05479955|OTHER|60 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. In line with the recommendation of the World Health Organization, 60 minutes of skin-to-skin contact was applied to the women in this group.
40779189|NCT03168139|DRUG|Olaptesed pegol - Monotherapy|"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
40779190|NCT03168139|DRUG|Olaptesed pegol + Pembrolizumab - Combination Therapy|"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
40779191|NCT06423690|DEVICE|EAS1 System|tumor ablation system in IRE method
40984065|NCT02877823|BEHAVIORAL|Treatment|Healthy Lifestyle Education, bottled water, pedometer, family navigator service
40984066|NCT02877823|BEHAVIORAL|Control|Healthy Lifestyle Education
40984067|NCT02370979|BIOLOGICAL|Blood samples|
40984068|NCT03906045|DRUG|BGF-MDI|Budesonide, Glycopyrronium and Formoterol Fumarate.
40984069|NCT06188936|DEVICE|ExSeed®|"In work package 3, participants will use the provided ExSeed® device and associated app downloaded onto their smartphone to analyse a semen sample provided at home. The app gives a result of normal or below normal, as well as an exact value for sperm concentration, progressive motility, and total motile sperm count. The patient will send their semen analysis results from the smartphone to the research team via secure email."
40984070|NCT06188936|OTHER|Survey|Surveys will be completed on a hard copy or electronically.
40984071|NCT00773292|DRUG|ciclosporin|Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
40984072|NCT03163615|DRUG|Tibet Rhodiola Capsule|4 capsules, po, from admission up to 84 days
40984073|NCT03163615|DRUG|Placebo oral capsule|4 capsules, po, from admission up to 84 days
40984074|NCT03261947|DRUG|TAK-931|TAK-931 hard gelatin capsules
40984075|NCT05357950|DRUG|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
40984076|NCT05357950|DRUG|Placebo|Placebo matches active drug in size, color and taste
40984077|NCT00255827|BIOLOGICAL|HyperAcute-Pancreatic Cancer Vaccine|
40984078|NCT04109755|DRUG|Pembrolizumab|5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
40984079|NCT06120816|DRUG|Nitric Oxide|Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days. The intervention solution will be poured into their mouth from a medication cup containing 20 mL of the solution. Total exposure to study intervention will be a maximum of 63 treatments totaling 1,260 mL. All participants will be monitored for 7 days post-last treatment dose (to Day 28).
40984080|NCT02558712|OTHER|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
40984081|NCT00743327|DRUG|Pioglitazone|45mg capsule, once daily for 1 year
40984082|NCT00227162|BEHAVIORAL|Group 1|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
40984083|NCT00227162|BEHAVIORAL|Group 2|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
40984084|NCT00227162|BEHAVIORAL|Group 3|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
41143831|NCT00847977|DRUG|use of a non balced fluid and of a macromolecular fluid|Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes
40984085|NCT03644745|BEHAVIORAL|VM @ Home Usability|Our primary outcome measures will be use of the coaching system features, level of daily physical activity, mood, self-efficacy, and user satisfaction. Secondary outcomes that will inform our further development and be important outcomes in subsequent trials include user adherence to their coaching goals, physical function and level of socialization. For the pilot study, we plan to assess physical function and level of socialization at baseline and at the end of 3 months. For the other outcome measures, we will be able to integrate the data collection into the VM@Home platform and coaching process.
40984086|NCT01455142|DRUG|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
40984087|NCT04554329|PROCEDURE|bandage contact lens|bandage contact lens
40984088|NCT04239820|RADIATION|Imaging|MRI and TSPO-PET imaging at baseline and 18 months after baseline
40984089|NCT02689024|DRUG|Bupivacaine|Local anesthetic: amide group ATC code N01BB01
40984090|NCT02689024|DRUG|Acetaminophen|Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
40984091|NCT02689024|DRUG|Diclofenac|Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
40984092|NCT02689024|DRUG|Ibuprofen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
41143832|NCT00847977|DRUG|use of balanced crystalloids fluid and macromolecular fluid|Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
41143833|NCT03740386|DRUG|Phentolamine Mesylate 0.235 MG/ML [OraVerse]|compare effect of phentolamine mesylate in three arms
41143834|NCT06598891|PROCEDURE|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
41143835|NCT06598891|PROCEDURE|Paired associative stimulation|Use TMS combine ES to stimulate TA nerve and M1 cortical
41143836|NCT04664179|BIOLOGICAL|Dose Level 1A: 2 x 10^7 cells/m2|2 x 10\^7 cells/m2
41143837|NCT04664179|BIOLOGICAL|Dose Level 2A: 6 x 10^7 cells/m2|6 x 10\^7 cells/m2
41143838|NCT04664179|BIOLOGICAL|Dose Level 2B: 6 x 10^7 cells/m2|6 x 10\^7 cells/m2
41143839|NCT04664179|BIOLOGICAL|Dose Level 3B: 2 x 10^8 cells/m2|2 x 10\^8 cells/m2
41143840|NCT04664179|BIOLOGICAL|Dose Level 3A: 2 x 10^8 cells/m2|2 x 10\^8 cells/m2
41143841|NCT02416102|DRUG|Losartan 50 mg|50 mg Losartan taken orally once daily for 4 consecutive weeks.
41143842|NCT02416102|DRUG|Losartan 100 mg|50 mg Losartan taken orally twice daily for 4 consecutive weeks.
41143843|NCT02634593|BEHAVIORAL|Low glycemic load snacks|Intervention to replace standard night-time food and drinks with lower glycemic load options
41143844|NCT01864980|PROCEDURE|blood transfusion, intermittent Hbsatlab measurement|In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
41143845|NCT01864980|PROCEDURE|blood transfusion, based on continuous SpHb readings|RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
40984093|NCT02689024|DRUG|Naproxen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
40984094|NCT02689024|DRUG|Dipyrone|Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
40984095|NCT02689024|DRUG|Fentanyl|Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
40984096|NCT02689024|DRUG|Morphine|Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
40984097|NCT02689024|DRUG|Levobupivacaine|Local anesthetic: amide group ATC code N01BB10
40984098|NCT02689024|DRUG|Ropivacaine|Local anesthetic: amide group ATC code N01BB09
40984099|NCT00849381|BIOLOGICAL|GSK580299, GSK Biological's HPV vaccine|All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
40984100|NCT03540147|DEVICE|Hokanson Cuffs|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will be completed will be randomly assigned to the participant.
40984101|NCT03540147|DEVICE|BStrong Bands|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.
40984102|NCT05368350|DEVICE|Transcranial direct current stimulation|"Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds."
40984103|NCT02564042|DRUG|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
40984104|NCT02564042|DRUG|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
40984105|NCT02564042|DRUG|Vehicle cream|White to off-white vehicle cream base to be applied topically
40984106|NCT03032367|DRUG|bedaquiline|
40984107|NCT03877289|DRUG|Oxybutynin|Oxybutynin is a tertiary amine anticholinergic. It exerts both antispasmodic and antimuscarinic activity on smooth muscle. It also exerts analgesic and local anaesthetic effects.
41143846|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: caplet Route of administration: oral
40779192|NCT02411409|BEHAVIORAL|HealtheRx|The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
40779193|NCT04164381|DEVICE|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
40984108|NCT03877289|OTHER|"Orasweet Liquid Placebo"|A formulated Oxybutynin placebo that is nearly identical in appearance, volume, weight, taste, and smell.
40984109|NCT03877289|DRUG|Antibiotics|"All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician.~Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin."
40984110|NCT03367481|DEVICE|Toothbrush type|In this cross-over study, the participants will use either a soft brush (control) and the medium brush (test).
40984111|NCT05302154|BEHAVIORAL|Distraction by dentist|Basic behavior orientation techniques (tell-show-do) is applied by the dentist during the treatment.
40984112|NCT05302154|BEHAVIORAL|Distraction by cartoon movie|Children watch cartoons on a screen mounted dental unit during the treatment.
41143847|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
41143848|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
41143849|NCT05500872|OTHER|Cross-education and blood flow restriction training|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. During this training, a cuff will be worn from the upper part of the thigh muscles, as in the blood pressure devices, which will slow down the blood flow in the leg. The participant will be cross-educated with the cuff inflated to a safe pressure range that will not cause discomfort. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
41304149|NCT06130696|OTHER|Isometric and muscle strengthen exercise|"group B will receive simple exercises also with clamshell 10 to 20 times. Change sides and do 3 sets.~Total 6 session were given"
41304150|NCT03487380|PROCEDURE|Fecal sample collection|Fecal sample collection
41463183|NCT01762228|DEVICE|Transcutaneous electrical stimulation|Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
40779194|NCT03773809|OTHER|Vitamin D capsule|The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape \& appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3
40779195|NCT03773809|OTHER|placebo|oral administration of placebo
40779196|NCT01098747|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
40984113|NCT05302154|BEHAVIORAL|Distraction by virtual reality glasses|During the treatment visual and auditory stimuli provide information about treatment to the patient with the help of avatars (characters) and environmental elements placed within the VRG application. In a vivid dentist room, the explanatory introduction part takes place while the movies are watched in a fairy world or a futuristic world to separate the user from the actual location and context. The application was designed to function in such a way as not to require outside intervention. From start to finish, the application interacts with the user through gaze selection and head tracking mechanisms. The avatar characters provide information related to the dental treatment in a joyful manner. Gamification elements such as gaining stars and collecting rewards have been used to keep the patient engaged. Motion blur feature ensures the patient to keep head still as sudden movements are dangerous and undesired by the dentist during the treatment.
40984114|NCT05792631|DEVICE|Near infra red imaging|"The iTero Element 5D is an intra-oral scanner that incorporates near-infrared illumination capabilities used to provide a near-infrared image of the teeth enabling the detection of both occlusal and proximal caries, at the various stages, ranging from initial enamel caries to established caries reaching the DEJ.~Near-infrared Imaging (NIRI) is a nonionizing imaging technology that leverages differences in scattering and absorption of near-infrared light depending on the degree of tooth mineralization."
40984115|NCT04071496|OTHER|Blood samples|1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml
40984116|NCT01895660|BEHAVIORAL|Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation|Types of constraint and dosage amounts will be varied.
40984117|NCT01341964|DRUG|Clopidogrel|600mg (2 pills)
40984118|NCT01341964|DRUG|Aspirin|325mg (1 pill)
40984119|NCT01341964|DRUG|Aspirin|81mg (1 pill)
40984120|NCT05687422|PROCEDURE|100μm laser spot diameter micropulse laser|100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
40984121|NCT05687422|PROCEDURE|200μm laser spot diameter micropulse laser|200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
40984122|NCT04934345|DIAGNOSTIC_TEST|Fluid challenge|The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
41143850|NCT05500872|OTHER|Cross-education|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
41143851|NCT05797610|DRUG|RO7434656|RO7434656 will be administered subcutaneously per schedule as specified.
41143852|NCT05797610|DRUG|Placebo|Matching placebo will be administered subcutaneously per schedule as specified.
41143853|NCT06455605|DRUG|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
41143854|NCT06455605|DRUG|2141 V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
41143855|NCT00068809|PROCEDURE|Short Cycle Antiretroviral Therapy|
41143856|NCT00842959|DEVICE|Invent ZO|monofocal aspheric IOL for implantation into capsular bag
41143857|NCT00842959|DEVICE|XL Stabi ZO|monofocal aspheric IOL for implantation into capsular bag
41143858|NCT02109172|DRUG|TD-4208|
41143859|NCT02109172|DRUG|Placebo|
40984123|NCT04539847|DEVICE|High-end hearing aid|hearing aid with premium level of technology
40984124|NCT04539847|DEVICE|Basic hearing aid|hearing aid with basic level of technology
40984125|NCT01364662|DRUG|SPN-810|administered orally
41143860|NCT06226623|DIETARY_SUPPLEMENT|Coconut|Participants in the intervention group, unlike participants in the control group, were asked to consume 50 g of fresh coconut daily for four weeks.
41143861|NCT01302106|DRUG|Clofarabine plus low dose Ara-C|Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
41143862|NCT01079117|DRUG|Sevre-Long™|The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).
41143863|NCT01079117|DRUG|Slow release oral morphine|
41143864|NCT01079117|DRUG|Methadone|
41304151|NCT02772354|PROCEDURE|Radiofrequency catheter ablation|Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool
41463184|NCT01762228|DIETARY_SUPPLEMENT|TRPV1 agonist|Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
41463185|NCT04736862|DEVICE|Continuous non-invasive blood pressure monitoring|In patients randomized to the continuous monitoring group, continuous non-invasive finger-cuff blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
40779197|NCT01098747|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
40984126|NCT01364662|DRUG|Placebo|administered orally
40984127|NCT01409655|BEHAVIORAL|cognitive-behavioral therapy|. Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
40984128|NCT04975360|DIETARY_SUPPLEMENT|Caffeine|The 160 mg caffeine pulsatile-release formulation was manufactured using a drug layering process. Caffeine and the excipients are dispersed in the coating media and then sprayed onto inert microcrystalline cellulose spheres using a fluid bed through a Wurster tube with continuous inlet air that dries the liquid in the dispersion, to obtain various layers consisting of caffeine and release-controlling polymers. The applied release-controlling polymeric system is based on methacrylate copolymers, which control the release of caffeine in pH-dependent and pH-independent manner. The release mechanism of the polymeric system is mainly driven by the swellability and permeability of the copolymers. The final micropellets are then encapsulated into hydroxypropylmethylcellulose capsules.
40984129|NCT04975360|OTHER|Placebo|Identical hydroxypropylmethylcellulose capsules without containing caffeine micropellets.
40984130|NCT03886233|DRUG|Corticosteroid Series|immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
40984131|NCT04692428|PROCEDURE|Locoregional analgesia|the supra-inguinal fascia iliaca block versus the femoral nerve block
40984132|NCT02046356|PROCEDURE|MESS-RFA|
40984133|NCT03303378|DRUG|melatonin (Helsinn Chemical Co, Biasca, Switzerland)|"Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention)."
40984134|NCT03303378|DRUG|Placebos|The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
40984135|NCT00385879|BEHAVIORAL|Case management|
40984136|NCT03285620|DRUG|AL-034|Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2
40984137|NCT03285620|DRUG|Placebo|Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
40984138|NCT04415788|DEVICE|Test of Incremental Respiratory Endurance - IMT|The TIRE training regimen will involve the use of a tablet provided to assigned subjects with the training software installed and a PrO2® device through which they will train. The software allows subjects to track their inspiratory muscle performance via real-time graphic representations of their efforts as training progresses.
40984139|NCT04415788|DEVICE|Threshold - IMT|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
41143865|NCT01195402|PROCEDURE|pulmonary outpatient rehabilitation|Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
41143866|NCT02804074|OTHER|Optimization of antihypertensive treatment based on office BP|Optimization of antihypertensive treatment based on office BP
41143867|NCT02804074|OTHER|Optimization of antihypertensive treatment based on 24-hour ABPM|Optimization of antihypertensive treatment based on 24-hour ABPM
40779198|NCT01098747|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
40779199|NCT01098747|DRUG|Placebo|Single-dose of placebo
40779200|NCT05223673|BIOLOGICAL|Futuximab/modotuximab|Concentrate for solution for infusion, futuximab/modotuximab will be administered via IV route, once weekly of each cycle at 9 mg/kg/dose at Cycle 1 Day 1 and then at 6 mg/kg/dose. Each cycle is up to 28 days.
41143868|NCT03556059|OTHER|Role of EOSS|The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.
41143869|NCT04095897|PROCEDURE|Pecs II Block|Peripheral nerve block - Regional anesthesia : Pectoral Nerve block type 2
40984140|NCT04415788|DEVICE|Sham IMT (Low resistence)|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
40984141|NCT00708643|DEVICE|Habitual Silicone Hydrogel Contact Lens|contact lens
40984142|NCT00708643|DEVICE|narafilcon A|contact lens
40984143|NCT02921698|DEVICE|FRED®|Flow Re-Direction Endoluminal Device
40984144|NCT03676933|DRUG|DS107E|
40984145|NCT03676933|DRUG|Vehicle|
40984146|NCT03676933|DRUG|Hydrocortisone Butyrate 0.1% Cream|Steroid taken topically once a day
40984147|NCT01804374|DRUG|Sorafenib|Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
40779201|NCT05223673|DRUG|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally before futuximab/ modotuximab administration, twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
40779202|NCT05223673|DRUG|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
40779203|NCT04484857|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
40779204|NCT03949517|DRUG|68-Ga RM2|Radioactive agent
40779205|NCT03949517|DRUG|68-Ga PSMA11|Radioactive agent
40779206|NCT03949517|DEVICE|Investigational software and coils in PET/MR Scan|Investigational software and coils in PET/MR Scan by General Electric Healthcare
40984148|NCT01804374|DRUG|Everolimus|Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
40984149|NCT03914781|BEHAVIORAL|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
41304152|NCT02772354|DRUG|Metoprolol|"Antiarrhythmic therapy of premature ventricular complexes~Metoprolol 12-50 mg"
41304153|NCT02772354|DRUG|Verapamil|Verapamil 20-240 mg
40779207|NCT03949517|PROCEDURE|PET/MRI|Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan
41304154|NCT02772354|DEVICE|NAVI-STAR® RMT ThermoCool|
40779208|NCT04243486|DRUG|UHE-105|Topical shampoo containing active drug
40779209|NCT04243486|DRUG|Vehicle|Topical shampoo containing no active drug
41304155|NCT02596711|DRUG|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
40779210|NCT02847403|DRUG|Exenatide|Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
40779211|NCT02847403|OTHER|placebo|patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
40779212|NCT06120322|OTHER|Environmental factor monitoring; collection of blood, feces and urine. For UC: collection of 8 additional biopsies|During the routine surveillance according to the normal clinical practice, blood samples, feces and urines will be collected from UC patients and T1D patients (0, 6, and 12 months). Moreover, for UC patients during the surveillance sigmoidoscopy according to the normal clinical practice (or colonoscopy if the patient has more than 8 years; at the enrollment and after 12 months), colonic biopsies will be collected
41304156|NCT02596711|BEHAVIORAL|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
40779213|NCT02551588|PROCEDURE|Valvular aortic stenosis surgery|Dilatation of Valvular aortic stenosis
40779214|NCT03895073|OTHER|healthy volunteers|the questionnaire has been assessed by both groups, healthy and heart failure
40779215|NCT03433976|DRUG|spinal anesthesia|spinal anesthesia for planned cesarean sections
40779216|NCT04927702|DEVICE|Synthetic Hybrid-Scale Fiber Matrix|A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.
40779217|NCT04927702|DEVICE|Standard of Care|To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.
40779218|NCT04927702|DEVICE|Living Cellular Skin Substitute|An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.
40779219|NCT00561990|DRUG|Nimotuzumab|
40779220|NCT04009148|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
40779221|NCT02179034|DRUG|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
40779222|NCT02179034|OTHER|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
40779223|NCT02179034|OTHER|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
40779224|NCT06050980|DRUG|HSK40118|Oral administration, QD
41304157|NCT02596711|OTHER|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
41304158|NCT02596711|BEHAVIORAL|Health Education and Handouts|Participants receive general health education and handouts.
41304159|NCT02596711|BEHAVIORAL|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
41304160|NCT02596711|BEHAVIORAL|Counseling Sessions|Participants attend 3 counseling sessions during the study.
41304161|NCT00003019|DRUG|methotrexate|
41304162|NCT00003019|DRUG|vinblastine sulfate|
41304163|NCT05549141|OTHER|treadmill gait training with gait facilitators|6 sessions of 30 minutes each of treadmill gait training with functional electrical stimulation as a gait facilitator
41304164|NCT05549141|OTHER|treadmill gait training not-associated with gait facilitators|6 sessions of 30 minutes each of treadmill gait training
41304165|NCT03047863|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
40779225|NCT05064228|BEHAVIORAL|Mobile Rewarding Activity Centered Treatment (m-ReACT)|Participants will utilize m-ReACT for 12-weeks, reporting daily on substance-free activity engagement and enjoyment (EMA). m-ReACT will utilize these EMA reports to generate brief, automated, and personalized feedback about enjoyed categories of substance-free activities as well as make suggestions for increasing engagement in those rewarding, goal-oriented substance-free activities, and provide personalized suggestions of activities of interest.
40779226|NCT01084889|DEVICE|surgical mesh implantation (TiLOOP® Total 6)|The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The surgical mesh TiLOOP® Total 6 is placed transvaginal by the aid of TiLOOP® surgical instruments to place the mesh arms.
40779227|NCT03398330|DRUG|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fed state
40779228|NCT03398330|DRUG|OxyContin®|Orally taking OXYCONTIN® 40mg in fed state
40779229|NCT05010590|DRUG|Romosozumab|Monthly romosozumab
40779230|NCT05010590|DRUG|Denosumab|Every 6 months denosumab
40779231|NCT05140343|DIAGNOSTIC_TEST|KARDIA Mobile ECG Monitoring (KMCM)|The KMCM will be introduced to the patient of the KMCM arm in the outpatient clinic. The activation and configuration will be done together with the physician in the outpatient clinic (installation of the ECG app, enabling heart rate rhythm notification). Patients are requested to acquired ECGs twice weekly plus additional ECGs if symptomatic. In case of symptoms the patient is asked to generate an ECG and communicate the event timely to the investigator and to the treating physician by sending a report through the ECG app. An e-mail account created for the study will be checked at least once a day. The arrhythmia diagnosis will be performed by the clinician based on the ECG information, independently of the arrhythmia classification automatically performed by the device. In case of stronger symptoms of any kind at any time the patient is asked to request medical help regardless of the KMCM notifications. Change of management will be collected.
40779232|NCT03346993|DRUG|Bupivacaine Hydrochloride 5 MG/ML|Ultrasound guided infraclavicular brachial plexus block with warmed bupivacaine
40779233|NCT05406973|DEVICE|SBK microkeratome versus femtosecond laser in flap creation|prospective comparative non randomized interventional clinical study
40779234|NCT03071965|BIOLOGICAL|Ciliary neurotrophic factor (CNTF)|The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.
40779235|NCT03071965|PROCEDURE|Surgery|Surgery to implant device for NT-501
40779236|NCT03071965|PROCEDURE|Surgery|Sham surgery
40779237|NCT01342094|DRUG|DE-111 ophthalmic solution|
40779238|NCT01342094|DRUG|Timolol ophthalmic solution 0.5%|
40779239|NCT01342094|DRUG|Placebo ophthalmic solution|
40984150|NCT04566354|OTHER|Repeated 30-s sprint exercise|Analyze of Interleukin-6 concentration before and after repeated 30-s sprint exercise
40984151|NCT05571241|BEHAVIORAL|Fast rehabilitation program|1-2 weeks (first post-op visit): Long thumb spica splint removed; Staples/stitches removed; Short hand-based thumb spica fitted for the patient Start Active Range of Motion Exercises (AROM) for thumb Add active assisted rang of motion exercises (AAROM) if no significant progress 6 weeks: Gradually wean off of splint during the day; wear for protection and/or more strenuous daily activities 6-8 weeks: Passive Range of Motion Exercises (PROM) (ie. stretching), if needed - (ie. No significant changes in ROM of thumb) 8-10 weeks: Resisted exercises/activities without splint on
40984152|NCT04334408|DRUG|Fremanezumab|Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
40779240|NCT00030147|DRUG|Raloxifene|60 mg a day orally administered
40779241|NCT00030147|DRUG|Rimostil|1000 mg twice a day administered orally
40779242|NCT00030147|DRUG|Transdermal Estradiol|100 microgram per day transdermal estradiol
40779243|NCT00030147|DRUG|Placebo skin patch and placebo tablets|matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
40984153|NCT04334408|DRUG|Placebo|Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
40984154|NCT00350714|OTHER|MBT and BreathID|75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
41304166|NCT03047863|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
40779244|NCT03479983|DIETARY_SUPPLEMENT|AMX160|500 mg Phyllanthus emblica L. fresh fruit extract capsules
40779245|NCT03479983|DIETARY_SUPPLEMENT|Placebo|500 mg roasted rice powder in visually identical capsules
41304167|NCT02568033|DRUG|Pemetrexed|
41304168|NCT02568033|DRUG|Carboplatin|
41304169|NCT02568033|DRUG|Cisplatin|
40779246|NCT01402310|OTHER|Ultrasound and digital cervical examination|Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
40779247|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT"
40779248|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT"
40779249|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT"
40779250|NCT01564017|BIOLOGICAL|Allergovac depot|"depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT"
40984155|NCT01741701|DRUG|Oxaloacetate (OAA)|
40984156|NCT01741701|DRUG|Placebo|
40984157|NCT00982592|DRUG|oxaliplatin|Given IV
40984158|NCT00982592|DRUG|leucovorin calcium|Given IV
40984159|NCT00982592|DRUG|fluorouracil|Given IV
40984160|NCT00982592|OTHER|placebo|Given PO
40984161|NCT00982592|DRUG|vismodegib|Given PO
40984162|NCT00982592|OTHER|laboratory biomarker analysis|Correlative studies
40984163|NCT01998633|BIOLOGICAL|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~* Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~* Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~* Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~* Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~* Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
40984164|NCT02899910|BEHAVIORAL|Health education|Education on lifestyle changes for treatment of metabolic syndrome
40984165|NCT02899910|BEHAVIORAL|Yoga|Training in the practice of yoga for treatment of metabolic syndrome
40984166|NCT04602455|BEHAVIORAL|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a week webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
40984167|NCT06043089|DIETARY_SUPPLEMENT|Beetroot juice supplementation or placebo|Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
40984168|NCT00162656|DRUG|half cyclophosphamide|
40984169|NCT00162656|DRUG|without COPADM3|
40984170|NCT00162656|DRUG|mini CYVE, without 3 maintenance courses|
41143870|NCT06188949|DIETARY_SUPPLEMENT|Dolichos biflorus (Horsegram) seed extract|1 capsule twice a day (Before breakfast \& dinner)
41143871|NCT06188949|DIETARY_SUPPLEMENT|Carica papaya leaves extract|1 capsule twice a day (Before breakfast \& dinner)
41143872|NCT06188949|DIETARY_SUPPLEMENT|Placebo (MCC)|1 capsule twice a day (Before breakfast \& dinner)
41143873|NCT04607889|OTHER|Survey|Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.
40779251|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT"
40984171|NCT00162656|DRUG|LMB B|
40984172|NCT00162656|DRUG|LMB C|
40779252|NCT01564017|BIOLOGICAL|Allergovac depot|"Sterile suspension for subcutaneous injection.~Same number of administration as the active groups"
40984173|NCT03845907|DEVICE|Gen 1B|Diagnostic Ultrasound and Optoacoustic Imaging
40984174|NCT03845907|DEVICE|Gen 1|Diagnostic Ultrasound and Optoacoustic Imaging
40984175|NCT00321282|PROCEDURE|Atrial Fibrillation|
40984176|NCT00529542|DRUG|Lipitor|40mg caplets per day for six weeks
40984177|NCT00529542|DRUG|Placebo|1 placebo caplet per day for six weeks.
40984178|NCT00221754|DRUG|Pravastatin (drug)|
40984179|NCT05779761|BEHAVIORAL|Online, Self-Directed Attention Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
41304170|NCT02568033|DRUG|Docetaxel|
41304171|NCT02568033|DRUG|Paclitaxel|
40779253|NCT03198871|DRUG|Acetaminophen Injectable Product|The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
40779254|NCT03198871|DRUG|Sodium Chloride 0.9%, Intravenous|The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
41304172|NCT02568033|RADIATION|stereotactic radiosurgery|
41304173|NCT01551758|DRUG|FF/VI|FF/VI
41304174|NCT01551758|OTHER|Existing Maintenance Therapy|"Existing Maintenance Therapy:~* Long acting bronchodilator therapy alone~* ICS alone or in combination with a long acting bronchodilator~* Triple maintenance therapy"
41304175|NCT01580592|DRUG|Omalizumab|150mg, s.c., every 4 weeks
40984180|NCT05779761|BEHAVIORAL|Online, Self-Directed Attention & Reflective Thought Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention and reflective thinking skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
40984181|NCT05779761|BEHAVIORAL|Online, Self-Directed Health & Wellness Education Training with Coaching Support|The initial set of modules focus on psychoeducation about stress, the impact that stress has on one's life, and self-monitoring of stress. The next set of modules focus on sleep, time management, nutrition, and exercise. All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
40984182|NCT01075945|DRUG|Dihydroartemisinin- piperaquine|three tablets per day
40984183|NCT01075945|DRUG|artemether- lumefantrine|twenty tablet in eight doses
40984184|NCT01870960|OTHER|7 patients will be recuting to received EMDOGAIM in left side|
41143874|NCT02338505|DEVICE|Telelap ALF-X|"Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.~Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure."
41143875|NCT00130026|DRUG|Caffeine|500 mg IV
40984185|NCT01870960|OTHER|7 patients will be recuting to received EMDOGAIM in right side|
40984186|NCT00356369|BIOLOGICAL|meningococcal ACWY (vaccine)|One intramuscular dose.
40984187|NCT00356369|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose.
41143876|NCT04619823|OTHER|Blood sample collection|Blood sample collection Mosquito collection at home
41143877|NCT01720407|DRUG|Imiquimod cream + surgery|Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
41143878|NCT01720407|DRUG|Placebo + surgery|Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
41143879|NCT04379310|DRUG|ACE Inhibitors and Calcium Channel Blockers|effect of drugs on patients with covid-19 pneumonia
41146982|NCT04844294|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT is divided into three phrases. In phase I (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills such as relaxation and mindfulness. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
40779255|NCT02843633|DEVICE|BioFreedom™ Drug Coated Coronary Stent System|a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
40779256|NCT02843633|DRUG|Antiplatelet Drug|Dual antiplatelet therapy for one month followed by single antiplatelet therapy indefinitely. Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice
40984188|NCT06466109|BEHAVIORAL|social robot intervention|"In the first course, the patient and their parents interact with the social robot PARO for 30 minutes.~In the second course, the parent interacts with PARO individually for 10 minutes, then the parent and patient interact with PARO together for 10 minutes. At last, the patient interacts with PARO for 10 minutes.~In the third course, the parent interacts with PARO individually for 10 minutes, then the parent and patient interact with PARO together for 10 minutes. At last, the patient interacts with PARO for 10 minutes.~In the last course, the parent interacts with PARO individually for 10 minutes, and then the patient interacts with it. At last, they interact with PARO together for 10 minutes."
40779257|NCT03763747|DEVICE|Scoreflex NC Scoring PTCA catheter|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
40779258|NCT03144284|OTHER|Knowledge, attitude, and practice survey|A knowledge, attitude, and practice questionnaire is going to be distributed to dental interns.
40779259|NCT05486767|DIAGNOSTIC_TEST|Transient elastography|Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
40779260|NCT02736071|DRUG|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
40779261|NCT02736071|DRUG|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
40779262|NCT02736071|DRUG|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure
40779263|NCT02736071|DRUG|Placebo 2|Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
40779264|NCT01876498|PROCEDURE|Xiaflex surgery|Xiaflex surgery
40984189|NCT05516706|OTHER|Dynamic stretching|Participants in this group performed a 10 minutes warm-up followed by 15 minutes of dynamic stretching exercises which included arm cross-over, scapular scaption, upper body twist walking lunges, cat and cow pose, and rotator cuff movements.
41304176|NCT01580592|DRUG|Omalizumab|300mg, s.c., every 4 weeks
40779265|NCT00805389|BIOLOGICAL|Engerix-B™|2 doses intramuscular injections
40779266|NCT00805389|BIOLOGICAL|Fendrix™|2 doses intramuscular injections
40779267|NCT00805389|BIOLOGICAL|GSK Biologicals' Hepatitis B vaccines (GSK223192A)|2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
41463186|NCT04736862|DEVICE|Intermittent non-invasive blood pressure monitoring|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring using upper-arm cuff oscillometry will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous non-invasive finger-cuff blood pressure monitoring.
40779268|NCT00805389|BIOLOGICAL|HBsAg (Booster injection)|Single dose intramuscular injection
40779269|NCT00288145|BEHAVIORAL|WOW, Working On Wellness weight management|Treatment site, worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
40779270|NCT01968980|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
40779271|NCT01968980|OTHER|Placebo|subcutaneous injection every 2 weeks for 12 months
40779272|NCT00002322|DRUG|Atevirdine mesylate|
40779273|NCT00002322|DRUG|Zidovudine|
40779274|NCT02797821|DRUG|Asfotase alfa|
41304177|NCT01580592|DRUG|Placebo|Placebo, s.c., every 4 weeks
40779275|NCT02728024|OTHER|Missing items, Errors in Completion, Difficulties|
40779276|NCT05539482|BEHAVIORAL|Community-based Health Education based on core intervention package|"Community-based Health Education will potentially include the following three components:~1. A manual of emergency preparedness and self-protection against COVID-19 infection. The main content will include hand washing, mask wearing and social distancing guidelines.~2. Early testing. Participants will be trained on how to recognize the early symptoms of COVID-19 and appropriate practice to take in a response, and they will be provided with testing resources.~3. Knowledge of vaccines and their benefits and resources for vaccination.~Collaborators should design and implement health programs based on the core intervention package."
40779277|NCT05539482|BEHAVIORAL|Health Information Sharing Group|Collaborators are encouraged to collect and share health information to the participants. Shared information should be previewed by researchers.
40779278|NCT06098326|DRUG|cyclophosphamide, fludarabine, and antithymocyte globulin|"1. Cyclophosphamide 50 mg/kg/day i.v. daily on days -3 and -2 (for 2 days)~2. Fludarabine 30 mg/m2/day i.v. daily on days -7to -2 (for 6 days)~3. Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)"
40779279|NCT03849105|RADIATION|4-L-[131I]iodo-phenylalanine (131I-IPA)|"Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy"
40779280|NCT00362492|PROCEDURE|Bilateral ultrasound examination 7+/- 2 after surgery|
40984190|NCT05516706|OTHER|Plyometric push up|Participants in this group performed 10 minutes of warm-up followed by 15 minutes of plyometric push training which included one-arm push-ups and depth push up
41304178|NCT02311855|BIOLOGICAL|Influenza vaccine|"Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:~Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)~At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine."
41463187|NCT04955015|PROCEDURE|carotid endarterectomy|patients with carotid atherosclerosis refering to CEA
40984191|NCT00737620|PROCEDURE|Prosthetic AV graft implantation|Surgical arteriovenous fistula creation with standard or propaten graft
41304179|NCT00331370|BEHAVIORAL|GP training and Health Education|
41304180|NCT02434627|DRUG|Sodium Nitrate|Patients will be given sodium nitrate daily in the form of beetroot juice.
41304181|NCT02916498|DEVICE|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System|Spinal cord stimulation for the management of chronic neuropathic pain
40984192|NCT03434054|DRUG|Losartan|blood pressure medication
41304182|NCT04961372|OTHER|Survey|PHQ9 Depression Scale for evaluating depression, GAD7 Anxiety Score for evaluating anxiety, WSAS Score for evaluating Work and Social Adjustment
41304183|NCT02053220|BIOLOGICAL|Colo-Ad1|Oncolytic virus
41304184|NCT04022174|BEHAVIORAL|Moderate dosage training of action Observation and Motor imagery|Motor imagery and action observation of orofacial exercises with moderate dosage
41304185|NCT04022174|BEHAVIORAL|Intensive dosage training of action observation and motor imagery|Motor imagery and action observation of the orofacial exercises with intensive dosage
41463188|NCT02913755|BEHAVIORAL|Preparatory video|5 minute Preparatory video to increase motivation, awareness and engagement in ABI rehabilitation
40984193|NCT03434054|OTHER|Placebo|non-active sham intervention
40984194|NCT00939081|BEHAVIORAL|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
40984195|NCT00939081|BEHAVIORAL|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
40984196|NCT03277105|DRUG|Dara SC|Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
40984197|NCT03277105|DRUG|Dara IV|Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
40984198|NCT05955950|BEHAVIORAL|Gratitude list|Participants must to write 3-5 words a day for 14 days about aspects of their daily experience that they are grateful for.
40984199|NCT05955950|BEHAVIORAL|List of any event|Participants must to write 3-5 words a day for 14 days about events of your own choosing that impressed the participant during the day, whether positive or negative.
40984200|NCT04360954|DIAGNOSTIC_TEST|Diagnostic test|There is no intervention. This study will test deidentified archived biosamples.
40984201|NCT02987400|DRUG|Venetoclax|3 cycles followed by 9 cycles consolidation if not transplant eligible
40984202|NCT02987400|DRUG|Obinutuzumab|3 cycles followed by 9 cycles consolidation if not transplant eligible
40779281|NCT04782921|DEVICE|Xenogenic bone graft material|After access to the periodontal defect via straight incision in vestibulum, at the mucogingival border or short releasing incision on adjacent tooth, Gel 40 (a mixture of collagen gel and xenogenic bone particles) or Gen-Os (pure xenogenic bone particles) will be inserted.
40779282|NCT02847897|DEVICE|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
40779283|NCT05928988|DRUG|SHR8554；Itraconazole|Drug: SHR8554 Administered as specified in the treatment arm Drug: Itraconazole Administered as specified in the treatment arm
40779284|NCT01282541|DRUG|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
40779285|NCT01282541|DRUG|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
40779286|NCT02208219|BEHAVIORAL|Music-supported Therapy|A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
40779287|NCT02208219|BEHAVIORAL|home-based Music-supported Therapy|A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
40779288|NCT02208219|BEHAVIORAL|Conventional treatment|"This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:~* Passive mobilization: controlled manipulation of movements to release a joint.~* Stretch and progressive resistance training.~* Task-specific training: reaching and manipulation of different objects.~* Intense physical training: repetition of sequence of movements."
40779289|NCT02338388|PROCEDURE|cesarean section technique|Comparing three different types of suturing the uterus at Cesarea section
40779290|NCT05225909|DEVICE|Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope|ERCP Procedure will be done using aScope. We will assess the performance of the aScope.
40779291|NCT03291522|PROCEDURE|Ultrasound-guided rete testis flushing and aspiration|Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
40779292|NCT06497309|DEVICE|Treadmill training|Therapy with treadmill-based advanced technology device.
40779293|NCT06497309|DEVICE|Overground training|Therapy using an advanced technological device enables exercise on the ground.
40779294|NCT06497309|DEVICE|DIERS|The examination starts and ends with the DIERS motion analysis system, a light-optical scanning method based on VRS (Video Raster Stereography) and a sensor-equipped treadmill that allows the measurement of several parameters of gait and balancing ability.
40779295|NCT06497309|OTHER|Traditional physiotherapy assessments|Traditional physiotherapy assessment methods (Timed Up and Go, Berg Balance Test, 6-minute gait test, 10-metre gait test, Functional Independence Measure, Barthel) are used to assess gait pattern and self-sufficiency.
40779296|NCT01918189|BEHAVIORAL|behavioral pain self-management intervention Pain EASE|10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
40779297|NCT02536664|DRUG|Rituximab|
40779298|NCT01150292|DIETARY_SUPPLEMENT|First period DHA|400 mg DHA supplementation by day for 2 weeks during the first study period
40779299|NCT01150292|DIETARY_SUPPLEMENT|Second period DHA|400 mg DHA supplementation by day for 2 weeks during the second study period
40984203|NCT05202509|DRUG|Obicetrapib|10mg obicetrapib tablet
41143880|NCT01075672|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
40984204|NCT05202509|DRUG|Placebo|Placebo tablet to resemble obicetrapib
40779300|NCT04055974|BEHAVIORAL|Be a Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention targeting postpartum women. It consists of 5 weekly modules, each targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
40779301|NCT05691387|BEHAVIORAL|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
40779302|NCT05691387|BEHAVIORAL|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
40779303|NCT02268643|OTHER|ultrasound plus clinical breast examination|all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
40779304|NCT00068289|DRUG|bortezomib|
40779305|NCT04515888|OTHER|PFDI-20 / PFIQ-7 questionnaires|PFDI-20 / PFIQ-7 questionnaires (one shot)
40779306|NCT06292819|DEVICE|Bright light|Bright light will use a 5000-10,000 Lux LED light source. Exposure is for 60 minutes daily, between 7pm and 9pm.
40779307|NCT06292819|DEVICE|Near-infrared light|Near-infrared light will use a wavelength of 850nm and a dose range of 1 - 6.5 joules/cm2. It is fixed on the neck with a band, the light source contacts the back of the neck, and is used for 60 minutes before going to bed.
40779308|NCT06292819|DEVICE|Bright light+ near-infrared light|After using the bright light device, then use the near-infrared light device on the back of the neck before going to bed.
40779309|NCT03323957|DIAGNOSTIC_TEST|nutritional screening tool|screening of disease associated malnutrition in sick infants
40779310|NCT04682665|DRUG|Icosapent Ethyl Oral Capsule|Soft gelatin capsules containing 1g pure EPA-EE. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
40779311|NCT04682665|OTHER|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
40779312|NCT03099473|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
40779313|NCT03099473|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
40779314|NCT03099473|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
40779315|NCT02105129|DRUG|HMPL-523|HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
40779316|NCT02105129|DRUG|Placebo|Oral administration
40779317|NCT05598814|BIOLOGICAL|Mepolizumab Injection|All patients in both the intervention group and the control group will be treated with Mepolizumab injections every month.
40779318|NCT05598814|PROCEDURE|Functional Endoscopic Sinus Surgery (FESS).|The Functional Endoscopic Sinus Surgery will be performed 2 weeks after the first injection of Mepolizumab in the intervention group.
40779319|NCT00977210|DRUG|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
40984205|NCT05327686|BIOLOGICAL|Avelumab|Given IV
40984206|NCT05327686|DRUG|Axitinib|Given PO
40984207|NCT05327686|DRUG|Cabozantinib|Given PO
40984208|NCT05327686|BIOLOGICAL|Ipilimumab|Given IV
40984209|NCT05327686|DRUG|Lenvatinib|Given PO
40779320|NCT05782348|BEHAVIORAL|Cognitive behavioral intervention|A six-session CBI Intervention component will be used with the TEST GROUP I. This will examine a cognitive behavioral intervention designed to improve tooth brushing and oral hygiene. The components include oral health education, values-based activities, motivational interviewing, goal setting, problem solving skills, cognitive restructuring, verbal reinforcement and stress management.
40779321|NCT05782348|OTHER|Colgate smart toothbrush|A Colgate smart toothbrush that provides the user with details on toothbrushing habits and frequency
40779322|NCT02951780|DRUG|LY3185643|Administered SC
40779323|NCT02951780|DRUG|rGlucagon|Administered SC
40779324|NCT01132352|DRUG|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
40779325|NCT02224170|DRUG|Lidocaine|Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
40984210|NCT05327686|BIOLOGICAL|Nivolumab|Given IV
40984211|NCT05327686|BIOLOGICAL|Pembrolizumab|Given IV
40984212|NCT05327686|RADIATION|Stereotactic Ablative Radiotherapy|42 Gy in 3 fractions
40984213|NCT00001339|DRUG|doxorubicin, vincristine, and etoposide with mitotane|
41143881|NCT00312949|BEHAVIORAL|Interactive Website on management of schizophrenia|Participants in the web-user group will sit with a laptop computer, answer questions about themselves and their treatment, receive feedback on care that may be inconsistent with current recommendations, and receive suggestions on how to discuss this with their physicians.
40779326|NCT02224170|DRUG|Dexamethasone|Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
40779327|NCT01911351|DRUG|Nitrous Oxide|Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
40779328|NCT05123326|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM/ Sonoclot tests will be done in all patients at enrolment and after initiating anticoagulation in those who are eligible for the same.
40779329|NCT05123326|DIAGNOSTIC_TEST|Genetic tests for Thrombophilia|Tests for JAK2 mutation, CAL R mutation and Factor V Leiden mutation will be done.
40779330|NCT05123326|DIAGNOSTIC_TEST|ELISA tests/ Functional assays|Antithrombin III, Protein C, Protein S, Factor VIII, VWF using commercial assays
40779331|NCT04660734|PROCEDURE|Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.|Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach
40779332|NCT06186310|OTHER|Aquatic Therapy Group|After the initial evaluations, patients will be given aquatic exercises including personalized strengthening, balance and breathing exercises accompanied by a physiotherapist 3 days a week for total 5 weeks. At the same time, the exercises taught as a home program will be asked to be repeated every day for 5 weeks.
41143882|NCT00312949|BEHAVIORAL|Written materials and video on management of schizophrenia|Participants in the written materials/video group will be given the reading material and will watch a 20-minute video.
41143883|NCT00243568|DRUG|Vicriviroc|
41143884|NCT03028961|OTHER|Stanford Letter|Receive and complete the Stanford Letter
41143885|NCT03028961|OTHER|Interview|Undergo semi-structured, research staff-led interview
40779333|NCT06186310|OTHER|Conventional Physical Therapy Group|After the initial evaluations, patients in the control group will be taught passive, active, actively assisted or resistant upper and lower extremity exercises as a home program, appropriate to each patient's functional level and muscle strength. Subjects will be asked to perform the exercises every day for 5 weeks, not exceeding an average of 45 minutes, 5 to 10 repetitions of each exercise, depending on fatigue.
40779334|NCT05320978|DEVICE|Hand grip test, computed tomography|A hand grip test, abdominal computed tomography are performed before surgery.
40779335|NCT00624858|DRUG|naltrexone SR 32 mg/ bupropion SR 360 mg daily|"All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.~During the study, subjects will receive ancillary therapy including advice on diet and exercise"
40779336|NCT01073969|OTHER|wheat bran extract|Comparison of control cereal (containing no added wheat bran extract)to two test cereals containing different amounts of added wheat bran extract
40984214|NCT04841031|BEHAVIORAL|NET Treatment|Narrative Exposure Therapy (NET) aims to address PTSD symptoms among survivors of mass violence and torture (Onyut et al., 2004; Schauer, et al., 2005). Mainly, different from other psychosocial interventions which require the survivor to process a single traumatic event in his or her life at a given time, NET treatment recognizes that trauma survivors undergo multiple distressing events within their lifetime (Schauer et al., 2005). Focusing on the traumatic events, the patient constructs a chronological narrative of his or her life story and a coherent narrative is then structured with the assistance of the therapist. They received NET one to three months following their screening and randomization. The therapy involves 8 to 12 individual sessions of about 90 minutes each.
40779337|NCT01073969|OTHER|control wheat bran extract|Comparison of control cereal (containing no added wheat bran extract) to two test cereals containing different amounts of added wheat bran extract
40779338|NCT01615783|OTHER|Subjects with COPD|Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
40779339|NCT01615783|OTHER|Subjects without COPD|Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
40779340|NCT05572294|BEHAVIORAL|Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy|Sickle cell patients admitted with a vaso-occlusive pain crisis over a consecutive 12-week period will be offered participation in the study. After providing informed consent, participants will have access to 4 videos containing guided mindfulness meditation, breathing exercises, and gentle yoga therapy. The videos are 5-12 minutes long and taught by a physical therapist who is also certified in yoga therapy. Participants may turn off the video at any time. Participants will have access to the videos for the duration of their hospitalization, and they may watch the videos as many times as they desire.
40779341|NCT01468064|GENETIC|Autologous BMSCs transplantation|"The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
40779342|NCT01468064|GENETIC|Autologous EPCs transplantation|"The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
40779343|NCT01468064|GENETIC|IV infusion of placebo|IV infusion of saline plus 5% autologous serum.
40779344|NCT04870866|DRUG|Nicotinamide ribonucleoside|Two year intervention
40779345|NCT04627129|DRUG|SHR2554 and Itraconazole|Single dose of oral administration of SHR2554 and Multiple dose of oral of Itraconazole Capsules
40984215|NCT04841031|OTHER|Alternative Intervention|Individuals in control group received non-NET psychosocial support in the interim that is provided to SGBV survivors as part of the Great Lakes SGBV project and will then receive NET after endline data has been collected.
40984216|NCT00189657|PROCEDURE|5FU/LV Mayo Clinic or LV5FU2|
40984217|NCT00189657|PROCEDURE|LV5FU2 + irinotecan|
40984218|NCT01500629|DEVICE|C-1266-7|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.
40984219|NCT01500629|DEVICE|C-1266-6 (placebo)|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
40984220|NCT00052208|DRUG|gefitinib|Given PO
40984221|NCT00052208|RADIATION|radiation therapy|Undergo radiation therapy
40984222|NCT00052208|OTHER|laboratory biomarker analysis|Correlative studies
40984223|NCT02338531|DRUG|PF-03084014|
40984224|NCT02338531|PROCEDURE|Breast cancer surgery|
40984225|NCT03108027|DRUG|Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)|Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
40984226|NCT03108027|DRUG|Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)|QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
40984227|NCT03108027|DRUG|Treatment C: Placebo (morning dose) and placebo (evening dose)|Placebo (morning dose) and placebo (evening dose)
40984228|NCT03344432|DIAGNOSTIC_TEST|with intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
41143886|NCT03028961|OTHER|Questionnaire Administration|Ancillary studies
40984229|NCT03344432|DIAGNOSTIC_TEST|without intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
40984230|NCT03109587|DIETARY_SUPPLEMENT|Vivomixx|900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
41304186|NCT04022174|BIOLOGICAL|Intensive dosage orofacial exercises|Orofacial exercises with high intensity
40779346|NCT03938649|RADIATION|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy."
40779347|NCT03938649|DRUG|SBRT|RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
40779348|NCT04423432|OTHER|Lower Extremity Resistance Exercise Training|3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press (8-12 RM) leg extension (8-12 RM) Sit to stand squat (with weight) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)
40779349|NCT04423432|OTHER|Home Exercise Plan|"2 sets of 10 repetitions/day of~1. AROM isolated knee extension and knee flexion~2. Isometric isolated knee extension and knee flexion~3. Isometric terminal knee extension~4. Sit to stand squat~terminal extension as Home Exercise Program (HEP). (Iwamoto J et al, 2007)"
40984231|NCT03109587|DIETARY_SUPPLEMENT|Placebo|maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
41463189|NCT05215938|DIAGNOSTIC_TEST|MRI examination|"The magnetic resonance imaging session will be performed in a clinical 3T MRI scanner (GE healthcare). A commercial human intent non-diagnostic RF coil (PulseTeq) will be used for 23Na MRI.~The scanner, coils and sequences are regularly used in research projects and validated for the same safety requirements as routinely used in the clinic. Nevertheless, the complete MRI session will be performed in research mode to use the advanced options (limits the usage to non-diagnostic purposes).~Participants will be placed in a supine position with coils covering the area of interest (AOF).~MRI examination will be performed by trained personnel."
41463190|NCT01276496|DRUG|Cilengitide|Given IV
41463191|NCT01276496|OTHER|Laboratory Biomarker Analysis|Correlative studies
41463192|NCT01276496|DRUG|Paclitaxel|Given IV
41463193|NCT01276496|OTHER|Pharmacological Study|Correlative studies
40779350|NCT04423432|DEVICE|Electrotherapy + Heating|Iinterferential Current therapy (2P), in combination with heating pad for 20 minutes
40779351|NCT04423432|PROCEDURE|Joint Mobilization|"1. Tibio-femoral Anterior Glide~2. Tibio-femoral Posterior Glide~3. Patellofemoral Joint Mobilization"
40984232|NCT04991155|DRUG|BIA 5-1058|BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
40984233|NCT01406431|DRUG|Pitavastatin, Valsartan|Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
41463194|NCT01132261|OTHER|"brain preservation' diet"|dietetic evaluation and advice in small group for health diet
41463195|NCT04834895|OTHER|mhealth exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the M.ü Neck Exercises application according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
41463196|NCT04834895|OTHER|brochure exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the brochure according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
41463197|NCT05521022|DRUG|AT-02|AT-02 via IV infusion
41463198|NCT05521022|OTHER|AT-02 (Placebo)|Normal saline solution via IV infusion
41463199|NCT02259348|DRUG|Cyclophosphamide|Given intravenously (IV)
41463200|NCT02259348|DRUG|Fludarabine|Given IV
40779352|NCT04423432|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
40779353|NCT04423432|DIETARY_SUPPLEMENT|Glucoseamine/ Chondritin Sulfate Supplementation|Glucoseamine/ Chondritin Sulfate Supplementation (500mg+400mg/day)
40779354|NCT00338637|DEVICE|APOS shoe kit|
40779355|NCT00147329|DRUG|MM-093|
40779356|NCT02020161|DRUG|Atra|
40779357|NCT02020161|DRUG|Idarubicin|
40779358|NCT02020161|DRUG|methotrexate|
40779359|NCT01116284|PROCEDURE|Revision of gastric bypass|A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
40779360|NCT01874392|DRUG|Investigational inhaled insulin (Technosphere)|by MannKind Corp. IND 61,729
40779361|NCT01874392|DEVICE|Artificial Pancreas (AP) device (APS©)|"Device includes:~* OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.~* Dexcom® G4® CGM System (CGM) from Dexcom® Corp~* Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)"
40779362|NCT02326727|DRUG|Ropivacaine|Epidural analgesia
40779363|NCT02326727|DRUG|Fentanyl|General Anesthesia
40984234|NCT01406431|DRUG|Livalo® fixed combination drug|Livalo® fixed combination drug(1 tablet)
40984235|NCT06090279|DEVICE|OmniFlow Breathing Therapy BioFeeback System|FDA approved healthcare gaming system that is used for patients who have difficulty breathing and allows the patients to participate in breathing exercises for pulmonary rehab. Each game usage itself is expected to last 15-20 minutes.
40984236|NCT00432107|DRUG|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
40984237|NCT04904887|PROCEDURE|phacoemulsification|phacoemulsification with implantation of EYEHANCE IOL
40984238|NCT05395520|OTHER|Retrospective chart review|Retrospective chart review to be conducted at Methodist Charlton Medical Center (MCMC) in Dallas, TX. Adult patients who received vancomycin while inpatient at MCMC with at least one corresponding vancomycin trough level taken at steady state will be included. All vancomycin orders by providers are entered as pharmacy to dose; thus dosing and routine monitoring is conducted by pharmacists.
41463201|NCT02259348|BIOLOGICAL|G-CSF|Given IV or subcutaneously (SQ)
41463202|NCT02259348|BIOLOGICAL|Interleukin-2|Given SQ
41463203|NCT02259348|DRUG|Melphalan|Given IV
41463204|NCT02259348|DRUG|Thiotepa|Given IV
41463205|NCT02259348|DRUG|Rituximab|Given IV
41463206|NCT02259348|BIOLOGICAL|Natural killer cell therapy|Given IV
40779364|NCT02326727|DRUG|Propofol|General Anesthesia
40779365|NCT02326727|DRUG|Isoflurane|General Anesthesia
40779366|NCT02326727|DRUG|Nitrous Oxide|General Anesthesia
40779367|NCT02052973|OTHER|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
40779368|NCT01323192|DRUG|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
40779369|NCT01323192|DRUG|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
41463207|NCT02259348|BIOLOGICAL|T-cell depleted HPC transplant|T-cell depleted hematopoietic stem cells will be infused on day 0.
41463208|NCT02259348|BIOLOGICAL|CD45RA-depleted HPC transplant|CD45RA depleted stem cells will be infused on day 1.
41463209|NCT04411173|DIETARY_SUPPLEMENT|Whey Protein|Each condition (both rice and whey protein) match in color, flavor, and serving size.
41143887|NCT03028961|OTHER|CA Advance Health Care Directive Form|Receive and complete the CA Advance Health Care Directive Form
41143888|NCT03824743|DRUG|Lactate Ringer|Patients managed with Lactate Ringer and obstetric hemorrhage
41304187|NCT04022174|BEHAVIORAL|Moderate dosage orofacial exercises|Orofacial exercises with moderate intensity
41463210|NCT03607045|DEVICE|headless screw|headless screw group
41463211|NCT03065231|DEVICE|Extraventricular Drain|As mentioned above, intervention will take place to promote subarachnoid blood diversion from cerebrospinal fluid after ruptured intracranial aneurysm.
40779372|NCT01502384|OTHER|neurological examination|motor and cognitive functions
40779373|NCT02374229|PROCEDURE|Surgical ablation of ganglion plexus pulmonary artery.|Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.
40779374|NCT02374229|PROCEDURE|mitral valve surgery|The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
40779375|NCT00746811|DRUG|P-OM3|4 grams/day - 4 one gram capsules
40779376|NCT00746811|DRUG|Placebo|4 grams/day - 4 one gram capsules
40779377|NCT02805790|DRUG|Elamipretide|4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously
40779378|NCT02805790|DRUG|Placebo|4 weeks of treatment with placebo administered once daily subcutaneously
40779379|NCT01149746|DRUG|Tamsulosin|Test 0.4 mg Capsule
40779380|NCT01149746|DRUG|Tamsulosin|Reference Listed 0.4 mg Capsule
41143889|NCT03824743|DRUG|Plasma-lyte|Patients managed with Plasma-Lyte and obstetric hemorrhage
41143890|NCT06455072|DRUG|Nituzumab|EGFR monoclonal antibody
41463212|NCT03065231|DEVICE|Lumbar Drain|
41463213|NCT01352364|OTHER|physiotherapy intervention|a program of physical therapy intervention can match or improve motor skills in the deaf children
41463214|NCT04529876|DRUG|Tofacitinib|Tofacitinib claim is used as the reference group.
41463215|NCT04529876|DRUG|Abatacept|Abatacept claim is used as the exposure group.
41463216|NCT03701126|PROCEDURE|Transversus Abdominis Plane Block|ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
41463217|NCT03701126|PROCEDURE|Caudal Block|ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
41463218|NCT03701126|DRUG|Bupivacaine 0.25% Injectable Solution|Dose 1ml /kg of patient body weight
41463219|NCT03701126|DEVICE|Ultra-sound guidance|using superficial high frequency probe to guide regional anesthesia
41463220|NCT02057536|OTHER|Arm A Directed exercise program|
41463221|NCT02057536|OTHER|Observation|
41463222|NCT01658995|DRUG|Doxycycline|Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
41463223|NCT01658995|DRUG|Placebo|Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
40779381|NCT02228538|DEVICE|Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system \& off-the-shelf standard knee implant system from various manufacturers
41463224|NCT04329676|PROCEDURE|Deep Brain Stimulation|Patients with PD who are eligible to bilateral STN DBS surgery and chose to get directSTIM System implanted will be followed over a 6-month period to evaluate changes in their condition.
41463225|NCT02797379|OTHER|Psychoeducation|The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
40984239|NCT06219057|BEHAVIORAL|The Wise Adolescent|The program encompasses 20 individual weekly sessions manualized. Its main objective is to help adolescents to create affiliative feelings towards themselves and to develop a more compassionate inner voice. Sessions are organized across 6 main domains: (1) placing ourselves in the challenges of life: evolutionary roots of our mind, how social circumstances and life experiences shape us; the 3-affect regulation systems; (2) understanding difficulties: compassion focused therapy case formulation; (3) understanding compassion: the three flows of compassion, its three pillars (caring commitment, wisdom, strength and courage); (4) compassionate mind training: cultivating the compassion skills (compassionate attention, imagery, reasoning, and behavior); (5) working with difficulties: fears, blocks and resistances to compassion; multiple selves; shame and self-criticism; (6) sustaining a compassionate mind: reviewing the gains and relapse prevention.
40984240|NCT00202644|DRUG|Anagrelide|Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
40984241|NCT00202644|DRUG|Hydroxyurea|Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
40984242|NCT05888246|DIAGNOSTIC_TEST|Magnetocardiogram|Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.
41463226|NCT04200911|DRUG|Rapamune|Sirolimus 1mg capsules
41463227|NCT00348153|DRUG|Adalimumab|
40984243|NCT05505019|OTHER|Music listening|This intervention involves listening to participant-selected music that they have evaluated as rewarding/motivating. YouTube Music will be used to build both personalized music and podcast interventions.
40984244|NCT05505019|OTHER|Podcast listening|This intervention involves listening to participant-selected podcasts of neutral content. YouTube Music will be used to build both personalized music and podcast interventions.
40779382|NCT00043602|BEHAVIORAL|Standard interpersonal psychotherapy (IPT)|Participants will receive 12 sessions of IPT over 12 weeks.
40779383|NCT00043602|BEHAVIORAL|Clinician managed interpersonal psychotherapy (CM-IPT)|Participants will receive 12 sessions of CM-IPT over 1 year.
40984245|NCT04234282|PROCEDURE|Manual Physical Therapy|Orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment.
40984246|NCT04407000|DRUG|Test: Favipiravir 200 mg (LOQULAR)|Test Drug
40984247|NCT04407000|DRUG|Reference: Favipiravir 200 mg (Avigan)|Reference Drug
40984248|NCT04464343|OTHER|no intervention|This is an observation study, with no intervention
40984249|NCT00002546|DRUG|cisplatin|
40984250|NCT00002546|DRUG|ifosfamide|
41463228|NCT03164187|DRUG|Diabeton 60 MR|Administer Diabeton MR 60 mg 1/2 tablet. Increasing dosage of Diabeton MR 60 mg by ½ tablet is recommended if fasting glucose level exceeds 6 mmol/L.
41463229|NCT00183196|DRUG|Naltrexone|Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
41463230|NCT00183196|DRUG|Naltrexone plus Gabapentin|naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
41463231|NCT00183196|OTHER|Inactive Placebo|Placebo
41463232|NCT04977596|OTHER|No intervention|Retrospective study without intervention
41463233|NCT04920058|DEVICE|Continuous Glucose Monitor|Continuous glucose monitor - a device that monitors blood glucose levels in a continuous closed-loop manner. This can also refer to the process of continuous glucose monitoring
40779384|NCT02523950|PROCEDURE|Staged phacoemulsification and DMEK|"Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.~Stage 2. DMEK is performed secondarily according to the corneal status of patients."
40779385|NCT02523950|PROCEDURE|Combined phacoemulsification and DMEK|Routine phacoemulsification and DMEK are performed simultaneously.
40984251|NCT00002546|PROCEDURE|adjuvant therapy|
40984252|NCT00002546|RADIATION|radiation therapy|
41143891|NCT06455072|DRUG|Serplulimab|PD-1 (programmed death receptor 1) monoclonal antibody
41463234|NCT04920058|OTHER|<Active Comparator?>|\<describe, Comprehensive Wellness Program incorporating a low carbohydrate diet (\<50g/day) and associated education \>
41463235|NCT02440555|OTHER|fulfill the self-administered questionnaire|Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
41463236|NCT06163937|OTHER|Glucose as reference food|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40779386|NCT02523950|DEVICE|Intraocular lens (IOL) implantation|After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
40779387|NCT04031729|DRUG|Aspirin 81 mg|Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
40779388|NCT04031729|DRUG|Placebo oral tablet|Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
40779389|NCT06546527|DRUG|[177Lu]Lu-PSMA-137|\[177Lu\]Lu-PSMA-137 500 MBq;50% optimal dosing;100% optimal dosing
40779390|NCT03295344|OTHER|Diaphragm ultrasonography|"Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces~US mode:~2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data"
40779391|NCT03295344|OTHER|Tissue Doppler|Determine the threshold value for diaphragm mobility
40779392|NCT01942109|DRUG|Furosemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
40779393|NCT01942109|DRUG|Torasemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
40779394|NCT03292237|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
40779395|NCT00233532|DRUG|Trandolapril|0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
40779396|NCT04293198|DEVICE|KODEX-EPD System|The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 3D images of the human heart. The KODEX occlusion viewer provides an indication of the occlusion status of the PV during cryoballoon PVI procedure
40779397|NCT04293198|DEVICE|Fluoroscopy with contrast dye|Fluoroscopy with contrast dye is used to determine occlusion status during cryoballoon PVI procedures
40779398|NCT01706484|DRUG|BNO 1016|comparison of different dosages of drug and placebo
40779399|NCT05442736|DRUG|Ciprofloxacin|studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
40779400|NCT04527835|DIAGNOSTIC_TEST|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
40779401|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 1|Liposomal Mitoxantrone Hydrochloride 16 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
40779402|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 2|Liposomal Mitoxantrone Hydrochloride 18 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
40984253|NCT02245074|OTHER|Sputum induction|The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
40984254|NCT06314568|RADIATION|Radiochemotherapy plus interventional radiotherapy|All patients with vaginal cancer will undergo radiochemotherapy (45 Gy on pelvis and tumor in association with cisplatinum) plus interventional radiotherapy (28 Gy on residual disease) with exclusive intent
40984255|NCT02240199|DRUG|Intraoperative Intravenous Lidocaine Infusion|Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
40984256|NCT02240199|DRUG|Perioperative Pregabalin|Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
40984257|NCT02240199|DRUG|Perioperative Pregabalin Placebo|Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
41143892|NCT01163214|DRUG|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
40779403|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 3|Liposomal Mitoxantrone Hydrochloride 20 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
40779404|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 4|Liposomal Mitoxantrone Hydrochloride 22 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
40779405|NCT01880957|DRUG|Lithium|
40984258|NCT02240199|DRUG|Intraoperative Intravenous Lidocaine Placebo Infusion|Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
41143893|NCT01163214|DRUG|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
41463237|NCT06163937|OTHER|Orange juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from orange juice, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
41463238|NCT06163937|OTHER|Mixed fruit juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from mixed fruit juice (consisted of apple, orange, grape, and pomegranate), tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
40779406|NCT01880957|DRUG|Lamotrigine|
40984259|NCT02333695|DEVICE|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
41463239|NCT03417206|DRUG|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%
40984260|NCT04323280|DRUG|Dexamethasone therapy|Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months
40984261|NCT04323280|DRUG|NSAID therapy|NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
40984262|NCT00003903|PROCEDURE|management of therapy complications|
40984263|NCT03582072|BEHAVIORAL|letter from the CMO|informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.\*
40984264|NCT01230801|BIOLOGICAL|BMN 701|GILT-tagged recombinant human GAA
40984265|NCT06471569|BEHAVIORAL|Low/Mod|Aerobic exercise at 50% peak oxygen consumption expending approximately 1000 kilocalories per week equaling approximately 10 miles per week
41143894|NCT05851144|BEHAVIORAL|Bienestar/Neema Coordinated School Health Program (BN CSHP)|Bienestar/Neema Coordinated School Health Program (BN CSHP), a Texas Education Agency-approved school health curricula, is a multi-prong intervention
41143895|NCT01717625|DRUG|Montelukast|a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
41143896|NCT06017557|DIAGNOSTIC_TEST|Artificial Intelligence|With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, it would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumors can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.
41143897|NCT01528605|DIETARY_SUPPLEMENT|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
41143898|NCT01528605|DIETARY_SUPPLEMENT|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
41143899|NCT01528605|DIETARY_SUPPLEMENT|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
41463240|NCT03417206|DEVICE|pupillary dilatation reflex|PRD value will me measured before the start of FESS after 5 minutes of remifentanyl infusion, when PRD sensitivity \> 5% , infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5% and FESS will be started ; intraoperatively infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5%
41143900|NCT01528605|DIETARY_SUPPLEMENT|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
41463241|NCT06471179|DEVICE|Functional MRI|Functional Magnetic Resonance Imaging during rest for minutes and analysis of data obtained from resting fMRI
41463242|NCT03330860|OTHER|Twelve clips regarding maternal and neonatal health topics|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
41463243|NCT03330860|OTHER|Control Clip|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
40779407|NCT01690533|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Patients treated with Moxifloxacin in daily clinical practice
40984266|NCT06471569|BEHAVIORAL|High/Mod|Aerobic exercise at 50% peak oxygen consumption expending approximately 1600 kilocalories per week equaling approximately 16 miles per week
40984267|NCT06471569|BEHAVIORAL|High/Vig|Aerobic exercise at 75% peak oxygen consumption expending approximately 1600 kilocalories per week equaling approximately 16 miles per week
40984268|NCT03454581|PROCEDURE|Photobiomodulation|PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.
40984269|NCT03454581|PROCEDURE|Manual Therapy (MT)|Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .
40779408|NCT04496479|BIOLOGICAL|LYG-LIV0001|Allogenic hepatocytes suspended in a buffered cell preservation solution with increasing number of lymph nodes being transplanted for the dose escalation. Subjects will also receive immune suppression, including tacrolimus capsules to follow the dose prescribed by the investigator as well as a short course of prednisone.
41463244|NCT01107327|PROCEDURE|FDG-PET/CT|"The study is focused on two goals, both of which use a new imaging test called PET/CT. PET/CT combines a special radioactive scan with a CT scan. PET/CT is most commonly used in medical practice to evaluate cancer. Abnormal areas such as cancer light up on the PET/CT scan. However, many doctors, including us, have noticed that PET/CT also lights up in areas of blood clot formation as well. In this study, PET/CT will be used to evaluate the two goals of this project."
40779409|NCT04699344|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from morning urine will be analyzed by PROUD to determine the level of CNV.
40779410|NCT02673021|PROCEDURE|Microwave ablation|Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
40779411|NCT00545779|DRUG|Ibandronate|150 mg orally once monthly for 6 months
41463245|NCT06004934|DRUG|Avacopan|Administered orally.
40779412|NCT03501628|DIETARY_SUPPLEMENT|Placebo|Supplementation twice daily (1 serving dose per consumption) of maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
40779413|NCT03501628|DIETARY_SUPPLEMENT|L-leucine + maltodextrin|Supplementation twice daily (1 serving dose per consumption) of L-leucine + maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
40779414|NCT03501628|DIETARY_SUPPLEMENT|Whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
40779415|NCT03501628|DIETARY_SUPPLEMENT|Hydrolyzed whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of hydrolyzed whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
40779416|NCT03501628|DIETARY_SUPPLEMENT|Soy protein concentrate|Supplementation twice daily (1 serving dose per consumption) of soy protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
40984270|NCT01580189|DIETARY_SUPPLEMENT|Whey protein|18g protein, immediately after training, 9 weeks
40779417|NCT04539171|OTHER|Pain Neuroscience Education and Physical Exercise|Patients assigned to the experimental group perform a PNE program consisting of seven sessions, with therapeutic PE. PNE is a health education intervention aims to provide up-to-date information on neuroscience advances in the field of chronic pain.
40779418|NCT00706147|DRUG|Arimoclomol|Drug: Arimoclomol capsules given three times per day
40779419|NCT00706147|DRUG|Placebo|Drug: Placebo capsules given three times per day
40779420|NCT04384614|DIAGNOSTIC_TEST|Test PCR|Viral load (COVID+) testing by PCR
40779421|NCT04384614|GENETIC|TDR|IDR and blood sampling for testing DNA Cheque
40779422|NCT04384614|OTHER|Clinical Examination|COVID 19 symptoms and Physical Examination
40779423|NCT06142864|OTHER|Data collection|Data collection
40779424|NCT02118155|PROCEDURE|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
40779425|NCT04129307|BEHAVIORAL|Motor imagery|This group will perform motor imagery training in combination with physical practice on motor learning of different motor tasks.
40779426|NCT04129307|BEHAVIORAL|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group in combination with physical practice on motor learning of various motor tasks.
40779427|NCT04129307|BEHAVIORAL|Action observation|This group will perform action observation training in combination with physical practice on motor learning of various motor tasks.
40779428|NCT06345404|DRUG|Soquelitinib|Tablets
40779429|NCT06345404|DRUG|Placebo|Soquelitinib matching placebo tablets
40779430|NCT05993741|DEVICE|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
40779431|NCT01337570|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
40779432|NCT01337570|OTHER|Placebo|Vaginal Ring containing no drug substance
40779433|NCT01337570|DRUG|Dapivirine|
40779434|NCT01049373|DRUG|HDC|(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
40779435|NCT01049373|DRUG|Placebo solution|10 drops, t.i.d, 15 weeks
40779436|NCT06164158|OTHER|Procedural Videos|A randomized controlled trial was conducted at Pakistan Institute of Medical Sciences (PIMS) Islamabad between September 1, 2023 to November 30, 2023 under ethical approval from the Institutional ethical review board.
40779437|NCT06164158|OTHER|No procedural videos|No procedural videos
41143901|NCT01528605|DIETARY_SUPPLEMENT|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
41143902|NCT01528605|DIETARY_SUPPLEMENT|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
40779438|NCT03558217|DEVICE|Collared Femoral Implant|Corail collared femoral implant for total hip arthroplasty
41143903|NCT03066986|DRUG|Delta-inulin|Addition of adjuvant, delta-inulin to JJA VIT regime, to determine if this will allow lower doses and shorter regimes to promote protective responses, reducing costs and morbidity of JJA VIT.
40779439|NCT03558217|DEVICE|Collarless Femoral Implant|Corail collarless femoral implant for total hip arthroplasty
40779440|NCT00590967|RADIATION|IMRT extended field external beam radiation therapy|
40779441|NCT00590967|RADIATION|Brachytherapy|
40779442|NCT00590967|DRUG|Cisplatin|
40779443|NCT05318508|OTHER|Measurements of sagittal spinopelvic parameters|Sagittal spinopelvic parameters will be measured from lateral cervicothoracolumbar radiographs of patients with lower extremity amputation.
40779444|NCT01650402|OTHER|Anti-hypertensive therapy to SBP 130 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
40779445|NCT01650402|OTHER|Anti-hypertensive therapy to SBP 145 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
40779446|NCT00730886|DEVICE|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
40779447|NCT00730886|PROCEDURE|Myomectomy|Invasive surgical procedure for fibroid removal
40779448|NCT01788878|BEHAVIORAL|Questionnaires|"A first series of questionnaires will be given by the investigator at patients before treatment (inclusion visit) and then the questionnaires will be given at the follow-up visits planned at 6 months, 12 months and 18 months.~Medical data will be collected via the CRF."
40779449|NCT04429464|DEVICE|AcQBlate Force Sensing Ablation Catheter|Confirmation that the AcQBlate Force System is safe and effective for the treatment of atrial arrhythmias
40779450|NCT02538614|DRUG|Idelalisib|Tablets administered orally twice daily
40779451|NCT02538614|DRUG|BI 836826|Intravenous administration as a rate-controlled infusion
40779452|NCT06328842|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
41143904|NCT03066986|BIOLOGICAL|Dose finding comparison|"Define minimum effective maintenance dose (50mcg vs 25mcg). In real world sting challenges after 12 months of JJA VIT objective systemic reaction rates after 50 and 100 mcg maintenance doses respectively 14/130 and 12/126 subjects vs reaction rates to stings in similar subjects without JJA VIT 70-76%. Venom delivery in sting likely \<20mcg. Therefore minimum effective maintenance dose not yet defined."
41304188|NCT06250530|PROCEDURE|High tibial osteotomy using TOMOFIX|TOMOFIX: A guidepin is placed to determine the level and length of the osteotomy with an appropriate hinge position selected. The oscillating saw is then used along with osteotomes to complete the osteotomy under image intensifier guidance. This is opened to the desired width of correction with a trapezoidal gap noted when using laminar spreader in the posterior position to avoid slope change. The plate is then applied and secured as per manufacturers operative technique.
41463246|NCT04640194|PROCEDURE|Standard of care|Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.
40779453|NCT06328842|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
41463247|NCT04640194|DRUG|Alteplase low dose|0.3 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.02 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.3 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
41463248|NCT04640194|DRUG|Alteplase high dose|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
40779454|NCT03186339|PROCEDURE|TAVI|transfemoral transcatheter aortic valve implantation
40779455|NCT03186339|PROCEDURE|SAVR|isolated surgical valve replacement
40779456|NCT03186339|OTHER|MM|management of aortic stenosis by medical treatment only
40779457|NCT00279214|DRUG|drotrecogin alfa (activated)|
40779458|NCT02428426|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
40779459|NCT05452473|OTHER|CDSS-assisted upper GI endoscopy|Expert endoscopists perform screening upper gastrointestinal endoscopy while looking at the monitor (CDSS system: automatic detection or lesion classification function) and listening to the sound of the monitor next to the original endoscopy monitor system.
40779460|NCT05452473|OTHER|no intervention|Expert endoscopists perform routine screening upper gastrointestinal endoscopy without CDSS's help.
40779461|NCT03880357|DRUG|Betamethasone Scalp Suspension 0.064%;0.0005%|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
40779462|NCT03880357|DRUG|Taclonex®|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
40779463|NCT03880357|DRUG|Placebo topical suspension|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
40779464|NCT03893526|DRUG|Entresto|Single dose administration of entresto
40779465|NCT03893526|DRUG|Sitagliptin|Single dose administration of sitagliptin
40779466|NCT03893526|DRUG|Valsartan|single doses administration of valsartan
40779467|NCT03893526|DRUG|Placebo|placebo day
40779468|NCT05787015|BEHAVIORAL|Vaccine Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about vaccination rates and hesitant attitudes.
40779469|NCT05787015|BEHAVIORAL|Alcohol Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about alcohol use.
40779470|NCT05847634|DEVICE|Masimo O3 NIRS cerebral oximetry and SedLine processed EEG|Non-invasive neuromonitoring device for observational study
40779471|NCT04794933|OTHER|Conventional therapy|
40779472|NCT04794933|OTHER|CT+ PNF in extremity pattern|
40779473|NCT04794933|OTHER|CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns|
40779474|NCT05556434|DIAGNOSTIC_TEST|radiological evaluation|"All patients undergoing hepatectomy receive imaging evaluation and laboratory test before and after surgery to define clinical parameters.~diseases"
40779475|NCT04206761|DRUG|QVM149|QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication
40779476|NCT04206761|DRUG|High Dose Dual Therapy (ICS/LABA)|High dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) in any approved drug formulation and delivery device.
40779477|NCT03313973|PROCEDURE|with self stretching same muscle|with self stretching
40779478|NCT03313973|PROCEDURE|with self stretching of forearm muscles|without self stretching
40779479|NCT02930148|OTHER|PEGASO System (ICT based system/mHealth solution)|"Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians"
40779480|NCT01270529|OTHER|Increasing Physical activity|The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
40779481|NCT01340456|DRUG|Rifampicin treatment|induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
40779482|NCT05066412|OTHER|CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology|CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
40779483|NCT03920891|PROCEDURE|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
40779484|NCT03920891|PROCEDURE|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~3. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~4. Evaluated the procedure and radiofrequency ablation time.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
40779485|NCT01968343|BEHAVIORAL|Cognitive-behavioral therapy.|Subjects receive 22 sessions of cognitive-behavioral therapy.
40779486|NCT01968343|OTHER|Supportive therapy.|Subjects receive 22 sessions of supportive therapy.
40779487|NCT05678426|BEHAVIORAL|Smoking cessation|Smoking cessation encompasses three guided smoking cessation group therapy sessions (6-12 participants per session) followed by smoking cessation (occuring in the second session) for 6 months. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
40779488|NCT05678426|BEHAVIORAL|Intermittent fasting|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
40779489|NCT05678426|BEHAVIORAL|Intermittent fasting with ketogenic supplement|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive a ketogenic supplement, medium-chain triglyceride fiber, to use daily. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
40779490|NCT06392308|OTHER|none intervention|No interventions are administered to either group of patients.
40779491|NCT01066845|DRUG|tadalafil|prescribed in accordance with usual clinical practice
40779492|NCT05829174|BEHAVIORAL|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
40779493|NCT05829174|BEHAVIORAL|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
40779494|NCT05829174|BEHAVIORAL|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
40779495|NCT05829174|BEHAVIORAL|Behavioral module: Pomodoro Time Management Technique|Working in 25 minutes time intervals
40779496|NCT01010464|PROCEDURE|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
40779497|NCT05878574|DRUG|Low molecular weight heparin|Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy
40779498|NCT00980044|DRUG|Tramadol|Oral Medication
40779499|NCT00980044|DRUG|Placebo|Oral Medication
40779500|NCT02144467|DEVICE|MRI|fMRI, sMRI, ASL and DTI
40779501|NCT01603654|DRUG|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
40779502|NCT01603654|DRUG|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
40779503|NCT01601184|DRUG|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
40779504|NCT01601184|DRUG|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
40984271|NCT01580189|DIETARY_SUPPLEMENT|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
41143905|NCT01117285|OTHER|3-day post-graduate course|"A 3-day course in using the COTiD program in clinical practice. The 3 days are not provided uninterrupted but there are at least two weeks between each day to provide time to practice with the guideline (for discussion on the 2nd day).~The course consists of theory on the content of the guideline and its effectiveness, Practice parts of the guideline by rol playing, and discussing each others skills through watching video material."
40984272|NCT01580189|DIETARY_SUPPLEMENT|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
41304189|NCT06250530|PROCEDURE|High tibial osteotomy using BodyCAD|BodyCAD: The patient specific cutting block is applied to the proximal tibia and secured in placed. The osteotomy is then created with sequential drills and osteotome and opened to the predetermined correction as per the manufacturer's guidelines. The plate is applied and secured with the supplied screws.
41304190|NCT02166021|BIOLOGICAL|Mesenchymal stem cells|A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
41463249|NCT04815434|OTHER|Interview|Interviews will be conducted.
41463250|NCT06098313|DRUG|Cyclophosphamide|-Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 (for 2 days)
41463251|NCT03468712|PROCEDURE|Laparoscopic D2 distal gastrectomy|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
40779505|NCT04456907|OTHER|platelet rich plasma|Autologous platelet-rich plasma (PRP) was prepared using the RegenKit THT system (RegenLab SA, Le Mont-sur-Lausanne, Switzerland) following the manufacturer's instructions. Medical technicians, who had been well-trained by the manufacturer, were responsible for the process of PRP preparation. For each patient, 8-10 mL of venous blood was drawn and collected to the commercial RegnLab THT tube, which contained 1 mL sodium citrate. After single centrifugation at 3400 revolutions per minute (rpm) for 8 minutes, 4-5 mL of PRP was yielded with leukocytes maintained at physiological levels and red blood cells depleted. Then, the blood components were separated, with the platelet pellet resting on the separating gel. PRP for later application was obtained by re-suspending the platelet pellet in the plasma supernatant by gently inverting the unopened RegenKit THT tube 5 to 10 times.
40779506|NCT04456907|OTHER|saline injection|saline injection
40779507|NCT03926455|BIOLOGICAL|Typhax (investigational typhoid fever candidate vaccine)|
40779508|NCT03926455|BIOLOGICAL|Placebo|Placebo is administered to the control group on Day 0 and 28
40779509|NCT03926455|BIOLOGICAL|Active Comparator Typhim Vi|A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28
40779510|NCT06000930|DIAGNOSTIC_TEST|Troponin fragmentation|laboratory test from blood sample
40779511|NCT03443687|BEHAVIORAL|Pelvic Floor Physical Therapy|Pelvic floor exercises for 3 months under instruction of physical therapist
40779512|NCT03443687|DEVICE|Home Biofeedback|Pelvic floor exercises for 3 months using biofeedback device
40779513|NCT03210701|OTHER|A HIV POCT program adapted for & provided by community pharmacists|Using a Type II hybrid Implementation-Effectiveness study design investigators will assess the implementation and effectiveness of a multi-faceted, integrated, contextualized model of HIV POCT in pharmacies in urban and rural settings in NL and AB, Canada. This design will be flexible, responsive and capable of capturing changing elements at multiple points in time. A mixed methods approach will be used to assess Implementation and Effectiveness aims.
40779514|NCT01378195|BEHAVIORAL|CBT-based program for dementia caregivers|Participants will receive a CBT-based program \[Cognitive Behavioral Therapy\], containing videos, workbook, and website.
40779515|NCT01378195|BEHAVIORAL|Educational/Resources program|Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
40779516|NCT00461708|DRUG|Erlotinib|100 mg, PO, once per day
40779517|NCT00461708|DRUG|Gemcitabine|1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
41304191|NCT03165513|BEHAVIORAL|mhGAP-IG|psychosocial interventions
41304192|NCT01449357|DRUG|zalutumumab|IV infusion, 16mg/kg on weekly basis until DP
41304193|NCT05149794|OTHER|Calisthenic Exercises|Bunny Jumps, Bear Crawls, Bear Crawls, Bird Dog . these intervention were used
41304194|NCT00192335|BIOLOGICAL|CAIV-T|
41304195|NCT00192335|BIOLOGICAL|CAIVT|The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
41304196|NCT00192335|BIOLOGICAL|FluMist|The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
41304197|NCT05851508|DRUG|Methylprednisolon|Intratympanal injection with Methylprednisolon 62.5 mg/ ml
41304198|NCT05851508|DRUG|Placebo|Intratympanal injection with saline, natriumchloride 0.9%
41463252|NCT04846439|BIOLOGICAL|CAR-T infusion|Sequential infusion of CD19 and BCMA autologous chimeric antigen receptor T cells, the infusion dose was determined according to the body weight of the subject and the effective content of cell preparation.
41463253|NCT02814708|BIOLOGICAL|rTSST-1v|Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow-up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST-1 binding Ab titer of \< 20 to \> 40 or a 4-fold increase in TSST-1 binding Ab titer .
41463254|NCT05567016|OTHER|Active case detection using molecular testing (ACDm)|In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT.
41463255|NCT05567016|OTHER|Passive case detection using molecular testing (PCDm)|With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive.
41463256|NCT05567016|OTHER|Control (standard of care)|With fevers, participants will receive standard PCD using RDT with treatment using AL if positive.
41463257|NCT02121717|DRUG|Chiglitazar|Take orally
41463258|NCT02121717|DRUG|Placebo|Take orally
41463259|NCT04458467|DEVICE|Continuous Infusion|A continuous infusion of ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
40779518|NCT00713687|DRUG|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|"1. Photodynamic therapy (PDT) after successful drainage:~   Photosan® 2 mg/kg i.v. 48 hrs before laser activation~2. 9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~   * Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~  * Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~  * iteration every 14 days~  * afterwards 4 weeks intermission~3. Iteration of 1. and 2. in case of good compatibility"
40779519|NCT03276182|DEVICE|Lipiview 2|Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
40779520|NCT05181228|BEHAVIORAL|Web-Based Education Based on Family-Centered Empowerment Model|Parents in the intervention group will receive care for ten weeks using the family-centered empowerment model (FCEM). The first step (two weeks) is to increase knowledge. For this purpose, they will receive web-based training on cancer. The second step (four weeks) is to develop parents' self-efficacy and problem-solving skills. A web-based training and group meeting will be held to share information and experiences on the evaluation and control of the side effects of the treatment and to increase their self-efficacy in care. The third step (three week) was to increase self-esteem through participation in the training. At this stage, each participant will be asked to teach one of the family members responsible for the child's care what they have learned in the last two sessions. In the fourth step (one week), all participants in the intervention group will be evaluated by asking questions about the topics discussed in the second and third sessions and the overall content taught.
40779521|NCT00506142|DRUG|Marqibo® (vincristine sulfate liposomes injection)|"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."
40779522|NCT00261833|BIOLOGICAL|Alpha1-proteinase inhibitor|60 mg/kg body weight/week intravenous
40779523|NCT00261833|OTHER|Placebo|Lyophilized preparation: 60 mg/kg body weight/week intravenous
40779524|NCT01580228|DRUG|Dinaciclib|Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m\^2 on Day 1, 10 mg/m\^2 on Day 8, and 14 mg/m\^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
40779525|NCT01580228|DRUG|Ofatumumab|Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
40779526|NCT02636296|OTHER|Pilates|The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
40779527|NCT02636296|OTHER|Control|The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
40779528|NCT04477616|DRUG|Day 7 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
41463260|NCT04458467|DEVICE|Automated Intermittent Boluses|Administration of automated intermittent boluses of ropivacaine 0.2% (8 mL every 2 hr with 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room, but with a 5-hour delay for the first bolus (can be overridden by patients if they would like to initiate their perineural infusion earlier than 5 hours).
40779529|NCT04477616|DRUG|Day 3 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
41463261|NCT01195116|DRUG|Dexmedetomidine|1 mcg/kg/hour
40779530|NCT04108650|OTHER|Fit & Strong! group|Consistent with the original format of F\&S!, the classes met three times per week for 90 minutes each for 8 weeks (24 sessions in total). Each class session consisted of 60 minutes of exercise and 30 minutes of health education. The exercise protocol included 10 minutes of warm-up and cool-down exercises, 20 minutes of low-intensity aerobic exercises, and 20 minutes of lower extremity strengthening exercises. The health education program focused on symptom management and behavioral strategies to increase physical activity and commitment to lifestyle change.
40779531|NCT00698841|DRUG|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m\^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m\^2 over 60 minutes.
40779532|NCT05098392|BEHAVIORAL|Sibling-mediated intervention|Typically developing siblings will be trained to use an explicit instruction strategy (model-lead-test) and a checklist to self-monitor their teaching when working with their siblings with ASD on reading and social skills.
40779533|NCT00133133|DRUG|ALGRX 4975|
40779534|NCT01662206|DIETARY_SUPPLEMENT|Probiotic|2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
40779535|NCT01662206|DIETARY_SUPPLEMENT|Placebo|2 capsules daily containing 348.25 mg of potato starch
40779536|NCT04656587|DEVICE|Philips Respironics V60 Non-invasive ventilator, BPAP|Continuous albuterol will be administered through the BPAP circuit.
40779537|NCT04656587|OTHER|Standard Therapy|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
41304199|NCT05076851|OTHER|placebo|placebo+ADT（Androgen Deprivation Therapy） ，Route of placebo administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
41463262|NCT01195116|DRUG|Normal Saline|1mcg/kg/hr
41463263|NCT02128516|OTHER|oral powder in sachet|
41463264|NCT04501094|DRUG|Bintrafusp alfa (M7824)|1200 mg administered intravenous (IV) every two weeks
41463265|NCT05271227|OTHER|Transthoracic echocardiography and Carotid artery doppler (PHILIPS HD11 XE ultrasound device) before and after PLR test.|VTI-LVOT was measured by echo by placing the pulsed wave Doppler sample gate in the LVOT diameter in apical-5-chamber window. VTI-LVOT was obtained by manually tracing the Doppler velocity spectrum. LVOT velocity time integral was recorded before and after PLR test within 2 minutes. Carotid blood flow was measured by using two-dimensional image, the optimal image of the long-axis view was obtained at the common carotid artery. The sample volume was placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination,The angle correction cursor was placed parallel to the direction of blood flow. A PLR will be performed in 2 sequential steps, first step patient is seated in the semi recumbent position (45°) then using an automatic bed elevation technique, the lower limbs will be then raised to a 45° angle while the patient's trunk will be lowered in supine position. Thus, the angle between the trunk and the lower limbs will remain unchanged (135°).
41463266|NCT01787929|PROCEDURE|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
41463267|NCT00695383|BEHAVIORAL|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
41463268|NCT00695383|BEHAVIORAL|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
41463269|NCT05193422|DIAGNOSTIC_TEST|Spirometry - baseline|"Standard spirometry using a Micro5000 spirometer to determine baseline FEV1, FVC, FEV1/FVC, FEF25-75 and PEF.~Baseline spirometry will be performed before CPET in both study arms"
40779538|NCT04703140|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|2 nasopharyngeal swabs taken for PCR and COVIDISC
40779539|NCT04620161|DRUG|Pradigastat Tablets 20mg|20mg, once daily, oral administration
40779540|NCT04620161|DRUG|Pradigastat Tablets 40mg|40mg, once daily, oral administration
40779541|NCT04620161|DRUG|Pradigastat Tablets 20mg matching Placebo|once daily, oral administration
40779542|NCT04620161|DRUG|Pradigastat Tablets 40mg matching Placebo|once daily, oral administration
40779543|NCT06214403|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a defined microbial community derived from healthy donor stool. MET capsules are orally administered mixtures of pure cultures of human-derived bacterial strains.
40779544|NCT06214403|DRUG|Placebo|Microcrystalline Cellulose
40779545|NCT04707092|DRUG|Antibiotic|Antibiotic in case of now allergies will be Cefazolin at induction and Amoxicillin plus Clavulanic acid for the oral treatment week
40779546|NCT02449525|PROCEDURE|Perfusion of flaps by a special bypass system|Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
40779547|NCT05351528|OTHER|Questionnaire|Caregiver burden and healthy lifestyle behaviors were evaluated.
40779548|NCT02185300|DRUG|Dolutegravir Pediatric Granules|Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
41463270|NCT05193422|DIAGNOSTIC_TEST|Spirometry - post CPET|Standard spirometry using a Micro5000 spirometer to determine baseline % change in FEV1 after CPET and assess exercise-induced bronchoconstriction (defined as FEV1 decrease \>10% at 5 minutes after CPET) Post spirometry will be performed after CPET in both study arms
40984273|NCT03787628|DRUG|Cannabidiol (CBD) 600 mg|CBD (300 mg) will be administered orally twice daily in the morning and again in the afternoon. The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml od CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
40984274|NCT03787628|DRUG|Placebo|The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. Different amounts (numbers of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 28 days.
41463271|NCT05193422|DIAGNOSTIC_TEST|Nasal peak inspiratory flow - baseline|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured before CPET in both study arms"
40779549|NCT02185300|DRUG|Dolutegravir Dispersible Tablet|Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
40779550|NCT05807126|PROCEDURE|Biopsy|Undergo biopsies
40779551|NCT05807126|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40779552|NCT05807126|PROCEDURE|Computed Tomography|Undergo CT
40779553|NCT05807126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40779554|NCT05807126|BIOLOGICAL|Magrolimab|Given IV
40779555|NCT05807126|DRUG|Olaparib|Given PO
40779556|NCT01643057|DEVICE|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
40779557|NCT01802788|DEVICE|St Jude Medical Portico replacement aortic valve|
40779558|NCT01802788|PROCEDURE|Transcatheter Aortic Valve Implant|
40779559|NCT03807089|DEVICE|Conventional Pediatric Colonoscope|
40779560|NCT03807089|DEVICE|Short-Turn Radius Colonoscope|
40779561|NCT00108381|BEHAVIORAL|tailored cognitive behavior therapy|tailored psychological treatment
40779562|NCT00108381|BEHAVIORAL|standard care|standard psychological treatment
41463272|NCT05193422|DIAGNOSTIC_TEST|Nasal peak inspiratory flow - post CPET|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured after CPET in both study arms"
41463273|NCT05193422|DIAGNOSTIC_TEST|Oxygen saturation|Continuous monitoring of SpO2 using a Nonin 7500 pulse oximeter, in both study arms
40779563|NCT04651530|PROCEDURE|Phaco|phacoemulsification of cataract only
40779564|NCT04651530|PROCEDURE|Phaco+ECP|Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract
40779565|NCT04946604|BEHAVIORAL|Ashtangayoga|This is an active and intense type of yoga, focused on physical activity and breath control
40779566|NCT01101776|DRUG|Interferon beta-1a (Rebif)|Interferon beta-1a 44 micrograms (12 MIU) given three times per week (tiw) by subcutaneous injection (SCI). Dose to be reduced to 22 micrograms (6 MIU) tiw by SCI for subjects who cannot tolerate the higher dose.
40984275|NCT01912651|DRUG|cephalexin|This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
40984276|NCT02368431|DRUG|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
40984277|NCT02368431|DRUG|Placebo|Placebo
40779567|NCT05160389|DRUG|PBI-200|Single dose of PBI-200
40779568|NCT04769284|OTHER|Mental health student|"An ad-hoc questionnaire was designed that included sociodemographic variables related to the characteristics of the students. The variables sex, age, degree, employment situation, coexistence situation, economic situation, origin environment, country of origin, time of residence in the Spanish State were collected.~Personal variables:~* Gender stereotypes: Short version of the Bem Sex Rol Inventory (BRSI).~* International Physical Activity Questionnaire (IPAQ)~* Abbreviated Goldberg Anxiety Scale EADG~* Modified version of EPP-10 related to COVID-19 (EPP-10-C)"
40779569|NCT01938729|PROCEDURE|Liver resection and placement of hepatic artery infusion pump|
40779570|NCT01938729|DRUG|FLOXURIDINE|
40779571|NCT01938729|DRUG|DEXAMETHASONE|
40779572|NCT01938729|DRUG|GEMCITABINE|
40779573|NCT05682937|DEVICE|HFOV-sigh|HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5. No change in Hz, MAP, delta pressure, and increased FiO2 less than 0.1 occurred between intervention
40779574|NCT03352947|DRUG|Dabrafenib|150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm
40779575|NCT03352947|DRUG|Trametinib|Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm
40779576|NCT02987608|DEVICE|Power Up|Smartphone phone app
40779577|NCT00077974|DRUG|SU011248|50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
40779578|NCT05090618|GENETIC|DNA analysis|GWAS
40984278|NCT01752907|OTHER|General Education DVD|A general chemotherapy side effects education DVD
41463274|NCT05193422|DIAGNOSTIC_TEST|Heart Rate|Continuous monitoring of HR using a Nonin 7500 pulse oximeter, in both study arms
40779579|NCT00897884|DRUG|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
40779580|NCT04247438|OTHER|12h and 36h Biofilm formation on PMMA (Palapress®) dentures and samples worn by participants and brushing cycles needed to remove it.|"Capturing the clinical data for biofilm formation on PMMA dentures and samples worn by participants and the number of brushing cycles required to remove this biofilm.~Development of artificial denture biofilm substitute with similar mechanical properties to real denture biofilm."
40779581|NCT05472792|RADIATION|Accelerated Partial Breast Irradiation (APBI)|Radiation treatment delivered to the lumpectomy cavity.
40779582|NCT05472792|DRUG|tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene|Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.
40779583|NCT00831389|DEVICE|Closed Loop|Insulin pump controlled by closed loop unit and algorithm
40779584|NCT00147576|DRUG|CP-866,087|
40779585|NCT05775445|PROCEDURE|Blood draw|2 6ml blood tubes will be collected from patient
40984279|NCT01752907|OTHER|Bone Pain Education DVD|
40779586|NCT05443529|OTHER|Adaptive sports|Participation in community adaptive sports programs
40779587|NCT00454116|DRUG|Vandetanib|once daily oral tablet two doses
40779588|NCT00454116|DRUG|FOLFIRI|Intravenous infusion
40779589|NCT06029205|BEHAVIORAL|Conscious Awareness-Based Educatıon|The effect of Conscious Awareness-Based Education on nurses
40779590|NCT06029205|BEHAVIORAL|Stress coping training|The effect of stress coping training on nurses
40779591|NCT04462575|PROCEDURE|Onlay bone block covered using collagen membrane|The ratio is 40% of xenogenic bone particles (low resorption rate) to 60% of autogenous bone particles (contains viable cells) to be placed in recipient decorticated site and covered by onlay bone block..
40779592|NCT04462575|PROCEDURE|Onlay bone block without collagen membrane|Onlay bone block without collagen membrane
40984280|NCT02964962|DEVICE|29 mm LOTUS Edge™ Valve System|Transcatheter aortic valve replacement
40984281|NCT05130619|DIETARY_SUPPLEMENT|Ethanol|Crossover meal study
40984282|NCT03210376|DRUG|Deep Neuromuscular Blockade (NMB)|Deep Neuromuscular Blockade (NMB) given during surgery.
40779593|NCT03728933|DRUG|Rotigotine 1 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).
40779594|NCT03728933|DRUG|Rotigotine 2 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).
40779595|NCT03728933|DRUG|Placebo|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
40779596|NCT01983111|DRUG|buprenorphine|Dosage and administration: This one patch should be attached every 7 days.
40779597|NCT01983111|DRUG|tramadol/acetaminophen|"Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets."
40984283|NCT03210376|DRUG|Moderate Neuromuscular Blockade (NMB)|Moderate Neuromuscular Blockade (NMB) given during surgery.
41304200|NCT05076851|DRUG|Proxalutamide|Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
40779598|NCT02025790|PROCEDURE|Per Oral Endoscopic Myotomy (POEM)|"* Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).~* Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~* Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~* Long endoscopic myotomy is performed 10 cm proximal to GEJ extending~* Closure of mucosal entry: the mucosal incision is closed using hemostatic clips"
40779599|NCT02025790|PROCEDURE|Pneumatic Dilatation|Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
40779600|NCT01478932|BEHAVIORAL|diaphragmatic breathing retraining|In-person and written instructions will be given as to how to carry out the breathing retraining at home. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, progress and difficulties related to the breathing intervention will be discussed. A daily log to track performance of the intervention will be kept.
40779601|NCT01478932|BEHAVIORAL|Health Promotion|n-person instructions will be given about what the intervention includes. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, health promotion topics will be discussed (lipid profile, healthy eating to improve lipid profile, importance of regular doctor visits, cancer screening, and so forth).
40779602|NCT00619996|DRUG|Sorafenib (Nexavar)|"Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."
40779603|NCT00619996|DRUG|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
40779604|NCT00624845|DRUG|OMS103HP|Maximum 6 bags of OMS103HP irrigation solution
40779605|NCT00624845|DRUG|Vehicle|Maximum of 6 bags of vehicle irrigation solution
40779606|NCT04035889|DIETARY_SUPPLEMENT|Melatonin|Participants will start with 0.5 mg tablets of melatonin with the option of switching to an 'escalation dose' of 3 mg if no relief after 3 days.
40779607|NCT04035889|DIETARY_SUPPLEMENT|Placebo|Placebo
40984284|NCT03210376|DRUG|Sugammadex|4 mg/Kg, intravenously as a single bolus injection after surgery.
40984285|NCT03210376|DRUG|Neostigmine|70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
41304201|NCT02702908|OTHER||Historical Reference group.
41304202|NCT04253301|DEVICE|InnoVein Valve Treatment|Subjects will have the InnoVein Valve implanted
41463275|NCT05193422|DIAGNOSTIC_TEST|End-tidal CO2|Continuous monitoring of EtCO2 using a Microstream capnograph, in both study arms
41463276|NCT05193422|DIAGNOSTIC_TEST|Respiratory rate|Continuous monitoring of RR using a Microstream capnograph, in both study arms
41304203|NCT04753203|DRUG|Alpelisib plus Capecitabine combination|Adding Alpelisib to Capecitabine as a salvage regimen in mCRC with PIK3CA mutation
41304204|NCT04200716|BEHAVIORAL|Moderate intensity continuous training - session|Moderate exercise continuous exercise 30 minuts session
41463277|NCT05193422|DIAGNOSTIC_TEST|Temperature|Continuous monitoring of Temp in the face mask using a RHT03 sensor, only in the experimental study arm
41463278|NCT05193422|DIAGNOSTIC_TEST|Humidity|Continuous monitoring of Hum in the face mask using a RHT03 sensor, only in the experimental study arm
40779608|NCT03547427|OTHER|Basal insulin alone|A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
40779609|NCT03547427|OTHER|Basal pramlintide and reduced basal insulin|A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at \~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
40779610|NCT03547427|OTHER|CGM|Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
40779611|NCT03547427|OTHER|Acetaminophen test|Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
40779612|NCT03547427|OTHER|Insulin-induced hypoglycemia|During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
40779613|NCT03547427|OTHER|Exercise-induced hypoglycemia|During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
40779614|NCT04784156|PROCEDURE|Subtalar (Talocalcaneal) Arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
40779615|NCT04784156|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
40779616|NCT06282341|OTHER|Race: Simulated marathon|Participants will take part in a race: simulated marathon. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
40779617|NCT06282341|OTHER|Race: Simulated trail|Participants will take part in a race: simulated trail. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
40779618|NCT06282341|OTHER|Race: Trail in nature|Participants will take part in a race: trail in nature. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
40779619|NCT06373211|DRUG|Immunoglobulins IV (CLAYRIG)|"Patients will be treated with cycles of :~- Intravenous (IV) immunoglobulins: 2 g/kg per cycle, over 3 to 5 days (D1 to D3 or D5).~Cycles will be administered every 4 weeks for a total of 3 first cycles"
41304205|NCT04200716|BEHAVIORAL|High intensity interval training - session|The high intensity interval exercise sessions are isocaloric to the moderate intensity continuous exercise, therefore, the necessary exercise time equivalent to 30 minutes of the moderate exercise continuous exercise session was calculated.
41463279|NCT05193422|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|"CPET using an ULTIMA CPX device (MGC Diagnostics, Saint Paul, MI, USA) with an ergometric bike (eBike, GE Healthcare, Wauwatosa, WI, USA). Participants will be asked to exercise (steady pedaling at 60 rpm) at 30% of their predicted maximum workload (Wmax) for 4 minutes, at 50% of Wmax for 2 minutes and at 70% of Wmax for 1 minute. Wmax will be calculated as 3 Watts/kg.~CPET will be performed in both study arms"
40779620|NCT06373211|DRUG|Cyclophosphamide IV|"Patients will be treated with cycles of :~- Cyclophosphamide IV: 1 g on the first day (D1). Cycles will be administered every 4 weeks for a total of 6 cycles"
40779621|NCT06373211|DRUG|Methylprednisolone IV|"Patients will be treated with cycles of :~Methylprednisolone IV: 1 g/day for 3 days (D1 to D3). Cycles will be administered every 4 weeks for a total of 6 cycles"
40779622|NCT01990742|BEHAVIORAL|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
40779623|NCT02383160|DEVICE|Bioventus Exogen 4000: Low-intensity pulsed ultrasound|Active low-intensity pulsed ultrasound
40779624|NCT02383160|DEVICE|Sham device|Placebo device with no active therapy
40779625|NCT04358406|DRUG|Recombinant human plasma gelsolin (Rhu-pGSN)|Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses
40779626|NCT04358406|OTHER|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
40779627|NCT02347384|DEVICE|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head \& SL-TWIN Stem
40779628|NCT02347384|DEVICE|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head \& SL-PLUS Stem
40779629|NCT05187234|OTHER|Education|Experimental: intervention group Education and training booklet based on the Roy adaptation model was given to the patients. The training was repeated at the first welcome and after the first month.
40779630|NCT02995590|DRUG|Hyperpolarized He3|Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
40779631|NCT00501644|DRUG|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
40779632|NCT00501644|DRUG|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
40779633|NCT00501644|DRUG|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
40779634|NCT02947191|BIOLOGICAL|Collagen membrane + HUC-MSCs|After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
40779635|NCT02317692|BEHAVIORAL|Parent training|
40779636|NCT03641287|OTHER|Exercise Counseling|Meet with exercise physiology
40779637|NCT03641287|OTHER|Aerobic Exercise|Receive prescription for moderate aerobic exercise
41304206|NCT00088803|GENETIC|molecular genetic technique|
41304207|NCT00088803|GENETIC|polymerase chain reaction|
41304208|NCT00088803|GENETIC|polymorphism analysis|
41304209|NCT00127504|DRUG|Rifampin|
41304210|NCT00127504|DRUG|Azithromycin|
41304211|NCT01667575|DRUG|Esomeprazole|antisecretary drug of the quadruple therapy
41304212|NCT01667575|DRUG|Amoxicillin|antibiotic of the quadruple therapy
41304213|NCT01667575|DRUG|Clarithromycin|antibiotic of the quadruple therapy
40984286|NCT03210376|BEHAVIORAL|Pain Assessment|Pain assessment done at about 15, 45, and 90 minutes after surgery.
40779638|NCT03641287|OTHER|Physiological Support|Receive motivational support via telephone care
40779639|NCT03641287|OTHER|Quality-of-Life Assessment|Ancillary studies
40984287|NCT02697175|DEVICE|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
40984288|NCT02697175|OTHER|No Live Video-Colposcopy|The TV will be shut off during colposcopy
40779640|NCT03641287|OTHER|Questionnaire Administration|Ancillary studies
40779641|NCT03641287|OTHER|Best Practice|Undergo habitual level of physical activity
40779642|NCT03825627|DEVICE|Transcranial Direct Current Stimulation|"Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp at F3 (active electrode, 4.4×4.4cm) and on the contralateral supraorbital area (reference electrode, 5.1×10.2cm).~Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton, Alberta, Canada). For each stimulation, the direct current is initially increased in a ramp-like fashion over 10 s until reaching 2 milliampere (mA) and will be similarly decreased at the end of stimulation.~In the active tDCS condition, stimulation will be maintained for 20 min; in the sham condition, it will be turned off after 15 s of stimulation, with a ramp-up/down of 10 s (i.e., 35 s total)."
40779643|NCT03510273|DEVICE|Liger Medical Thermocoagulator|"Thermocoagulation treatment by Liger Medical device (US FDA 510K clearance received)"
40779644|NCT05176587|OTHER|Follow-up of patients undergoing bariatric surgery : integrated pathway|Integrated pathway : multidisciplinary, pre- and post-operative, care course for patients undergoing bariatric surgery
40779645|NCT05578014|PROCEDURE|Acupuncture|To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture the sham acupoint (EX-B2 T3 point) or Dazhui point.
40984289|NCT03414619|BEHAVIORAL|Cognitive Control Tasks and Script Driven Imagery|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors and anxiety/mood symptoms. They then will complete a battery of neuropsychological executive functioning tasks on the computer, each of which measures a different facet of cognitive control (i.e., response inhibition, cognitive flexibility, and attentional control). Finally, they will be guided through a standardized script-driven imagery paradigm that involves generating and listening to an individualized imaginal script associated with a moderately distressing intrusive thought. Self-report and psychophysiological data will be collected during this exercise.
40984290|NCT06494176|BEHAVIORAL|neVR Fear the Dentist|neVR Fear the DentistTM comprises two major evidence-based interventions. First is a self-administered eHealth app for CBT/ psychoeducation with exposure therapy - delivered via a mobile tablet - that can be completed anywhere. Second is a 1-hr virtual reality exposure treatment (VRET).
40984291|NCT03269942|PROCEDURE|Endovascular Flow-Diversion|Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.
40984292|NCT03269942|PROCEDURE|Cerebral Revascularization|Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
40984293|NCT06299033|DRUG|hNPC01|hNPC01, human forebrain neural progenitor cell product, intracerebral injection
40984294|NCT01095016|DRUG|Meptin swinghaler|"* Dose: 10ug/puff, 2 puffs daily~* Frequency: QD (total 20ug/day)~* Treatment duration: 2 days"
40984295|NCT01095016|DRUG|Berotec|"* Dose: 100ug/puff, 2 puffs daily~* Frequency: QD (total 200ug/day)~* Treatment duration: 2 days"
41143906|NCT01117285|OTHER|Combined implementation strategy|"The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.~OTs receive:~* 3-day post-graduate course~* 2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.~* Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.~* Discussion platform~* Web-based registration system: Provides guidance in using the COTiD program for every individual client.~* Regional meetings: successes and difficulties in using the COTiD are discussed.~Managers and physicians receive:~* Information on the COTiD program through a website and newsletters.~* Motivational reminders."
40779646|NCT02588885|BEHAVIORAL|Trauma-sensitive Care|"Psychological intervention~1. education~2. empowerment~3. desensitization~4. relaxation tools~Physical therapy intervention~1. techniques to address muscular tension~2. empowerment~3. comfort~4. encouragement of trauma-related coping skills"
40779647|NCT05370092|OTHER|Percutaneous needle electrolysis|Electrolysis is the process by which water (H2O) and sodium chloride (NaCl) molecules, which are present in the biological tissues and body compartments of our organism, are organically broken down into their constituent chemical elements, regrouping to create entirely new substances such as sodium hydroxide (NaOH), hydrogen gas (H2) and chlorine gas (Cl2). This process occurs thanks to the passage of a flow of direct electric current, also known as galvanic current, which is a totally athermal process. The passage of this current allows a local inflammatory response to occur (increase in lymphocytes and macrophages) as well as an increase in vasodilatation, inducing phagocytosis and biological stimulation of tendon repair.
40779648|NCT05370092|OTHER|Therapeutic exercise|The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase
40779649|NCT05370092|OTHER|Manual therapy|The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).
40984296|NCT06242249|BIOLOGICAL|Anti-BCMA CAR-NK|"Ten eligible patients with relapsed refractory multiple myeloma will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of BCMA CAR NK cells with close monitoring using one of the following dose levels:~* Dose Level 1: 1×10\^7/Kg~* Dose Level 2: 5×10\^7/Kg~* Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow IMWG guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease."
41304214|NCT01667575|DRUG|Bismuth Potassium Citrate|one of a component of a quadruple therapy
41463280|NCT05193422|DIAGNOSTIC_TEST|Discomfort level|"Discomfort assessment using a special scale graded from 1 to 10 (Fikenzer, 2020).~Both study arms, after CPET."
41463281|NCT00743860|DRUG|darapladib|experimental drug
40779650|NCT03399448|BIOLOGICAL|NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1|Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).
41304215|NCT01667575|OTHER|long duration (14 day)|
40779651|NCT03399448|DRUG|Cyclophosphamide|a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
40779652|NCT03399448|DRUG|Fludarabine|a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
41463282|NCT04606017|DRUG|Caltrate Pill|VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
41463283|NCT06394115|DEVICE|Ostomy pouch|Ostomy pouch coated with novel technology
40779653|NCT03399448|DEVICE|NY-ESO-1 expression testing|Testing to determine if NY-ESO-1 is expressed on tumor tissue.
40779654|NCT02345239|DRUG|Pantoprazole|proton pump inhibitor
40779655|NCT00534001|DRUG|bupropion hydrochloride|Given orally
40779656|NCT00534001|OTHER|placebo|Given orally
40779657|NCT00185094|DRUG|Olmesartan medoxomil|
40779658|NCT00185094|DRUG|Losartan potassium|
40779659|NCT00185094|DRUG|Atenolol|
40779660|NCT03838835|BEHAVIORAL|Augmented equine-facilitated CBT group program|Consists of CBT strategies including 1) providing psychoeducation about anxiety, 2) teaching coping strategies when anxious,and 3) identifying and addressing dysfunctional thoughts that maintain anxiety.
40779661|NCT03838835|BEHAVIORAL|TAU is equine-facilitated group therapy|TAU is equine-facilitated group therapy at GallopNYC, which consists of horseback riding and integrates strategies to support the development of cognitive, physical, emotional, and social skills.
40779662|NCT03838835|OTHER|WLC|WLC consists of youth who are not yet receiving any services at Gallop NYC.
40779663|NCT00901303|DRUG|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
40779664|NCT00176748|DRUG|AG 6013736|5 mg po bid
40779665|NCT03929692|BEHAVIORAL|Multi-layer health promotion program|
40779666|NCT03929692|OTHER|Standard health education|
40779667|NCT00271544|DEVICE|Pacing Lead|implant and follow-up of study device
40779668|NCT04562415|DEVICE|Active Repetitive Transcranial Magnetic Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and inhibitor rTMS was applied with a frequency of 1 Hz consisting of 1200 pulses for 20 minutes. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
40779669|NCT04562415|DEVICE|Active Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
40779670|NCT04562415|DEVICE|Sham Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and sham cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
40779671|NCT06486909|DIAGNOSTIC_TEST|Cerebrospinal Fluid (CSF) Sample|Samples for glucose in CSF will be taken upon EVD/LD placement until EVD/LD removal (within the first 14 days).
40779672|NCT06486909|DIAGNOSTIC_TEST|Blood Serum Sample|Samples for glucose in blood serum will be completed every day, for the first 14 days.
40779673|NCT04883268|OTHER|Expand Your Horizon|Expand Your Horizon is an online programme, comprising three 15min writing exercises delivered over the course of 1 week. In each writing exercise, participants are asked to describe the functions of their body, and why those are personally meaningful to them.
41304216|NCT01133210|DRUG|Maraviroc|dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
41304217|NCT01133210|OTHER|placebo|subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
41304218|NCT01889199|DRUG|Flutamide|Flutamide 125 mg orally each 28 day cycle for 6 cycles
41304219|NCT01889199|OTHER|Placebo|Placebo orally each 28 day cycle for 6 cycles
41304220|NCT02487628|DEVICE|HQ® Matrix Soft Tissue Mesh|
41304221|NCT02487628|DEVICE|ULTRAPRO® Partially Absorbable Lightweight Mesh|
41304222|NCT05795764|BEHAVIORAL|Crisis Response Planning|Crisis Response Planning (CRP) is a brief psychotherapeutic intervention.
41304223|NCT05795764|BEHAVIORAL|Treatment as Usual|Standard care provided for patients at risk for suicide
41463284|NCT01653795|DEVICE|LMA Unique: control device|LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
41463285|NCT01653795|DEVICE|LMA Supreme: comparison device|LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
41463286|NCT00011609|DEVICE|Robotic Arm|
40779674|NCT00844506|DRUG|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
40779675|NCT00844506|DRUG|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
40984297|NCT05319145|BEHAVIORAL|Intervention group|1) Multi-component exercise intervention program based on Vivifrail©. It consists of 1 daily-30 minutes session, twice a week, for 10 consecutive weeks supervised by an experienced exercise specialist. Exercises (resistance, gait retraining, balance training) are personalized depending on the person's functional capacity (evaluated by the SPPB and a walking speed test) and the risk of falling. Between sessions, individual, unsupervised training by the own patient, supported in the case by the caregiver, will be stimulated, through the recommendations of ViviFrail©. 2) Nutrition. Personalized recommendations according to nutritional and medical status (active oncologic treatment, remission, or palliative stage) will be offered according to the ESPEN recommendations for cancer patients, aimed at compensating for inadequate energy intake, improving patients' malnutrition risk stage (assessed by means of the MNA-SF).
40779676|NCT03119220|DEVICE|Fitbit One|Participants will receive a Fitbit device and a detailed user manual as well as diary materials to record daily steps taken, miles walked, and flight of stairs walked for a total of 12 weeks. An in-person follow-up meeting will be scheduled 7 days after the initial meeting to establish the baseline activity level of the participant and to determine the target number of daily steps for the subsequent 5 blocks of 2 weeks.
40984298|NCT05319145|OTHER|Control group|General recommendations (written and videos) will be offered.
40984299|NCT00596570|PROCEDURE|PCI|Percutaneous coronary interventiom
40984300|NCT04379882|DEVICE|Digital Sedation (Silva)|Use of Digital Sedation (virtual reality associated with psychological interventions) for preoperative anxiety management
40984301|NCT05034770|OTHER|major ozone autohemotherapy|This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.
40984302|NCT06130345|BIOLOGICAL|SPIKEVAX|Intramuscular injection
41143907|NCT03654482|DEVICE|SuperSeton|The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
40779677|NCT04272164|OTHER|technical taekwando training|Light jogging followed by star jump, Different running styles (forward, backward and sideways), Stretching exercises (Upper and lower Limb), Pushups and sit ups, Punches (single, double, triple, nonstop punches including speed and power, punches with forward and backward stepping), Kicks (rising kick, front kick, middle kick, drop kick ( in +out+center), Stances (walk stance, punching stance, front deep stance, kicking stance), Blockings (solar block, upper block and lower block), Self -defense (neck gripping, hand gripping, locking), Sand bag drills, Balance training 10 repeatitions of 1 set each, 3 days a week for 8 weeks
40779678|NCT04272164|OTHER|weighted rope jump training|Basic bounce step with both feet 2. Bell jump with both feet 3. Skier's jump 4. Right foot skipping 5. Left foot skipping, 6. Alternate foot step 7. Boxer shuffle 8. Side straddle 9. Scissors 10. Bonus jump with both feet After the preparatory weighted rope jump training (WRJT) for 1 week, subjects in experimental group followed jumping training by repetition method 3 days in a week for 8 weeks in addition to the routine taekwondo training program. 3 sets per week with 30 seconds training duration and 30 seconds rest duration. with progressive increase in the intensity and no. of sets.
40779679|NCT02712788|DRUG|Milrinone|
40779680|NCT02712788|DRUG|Placebo|
40779681|NCT00571883|OTHER|questionnaire administration|
40779682|NCT00571883|PROCEDURE|psychosocial assessment and care|
40779683|NCT00571883|PROCEDURE|quality-of-life assessment|
40779684|NCT00571883|PROCEDURE|regional lymph node dissection|
40779685|NCT00571883|PROCEDURE|therapeutic conventional surgery|
40779686|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
40779687|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
40779688|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.
40779689|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
40779690|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
40779691|NCT02444754|OTHER|Medical Chart Review|Obtain medical data
40779692|NCT02444754|OTHER|Questionnaire Administration|Complete demographics questionnaires
40779693|NCT02444754|OTHER|Survey Administration|Complete surveys
40779694|NCT05270993|BEHAVIORAL|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme where patients will receive 12 group-based sessions. Patients will also be given access to online educational resources. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
40779695|NCT05270993|BEHAVIORAL|I-CREST group|A 6-week home-based cardiac rehabilitation programme where participants will receive an I-CREST app (to deliver education, medication reminders, exercise and vital monitoring) and a wearable smartwatch device (to track physical activity). Participants will be remotely supervised by the cardiac rehabilitation team via an I-CREST web-portal. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
40779696|NCT01469247|RADIATION|Radiation Therapy|Starting Dose 24 Gy in 2 Gy fractions.
41143908|NCT04170634|OTHER|Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation|Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
41143909|NCT02367794|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
41143910|NCT02367794|DRUG|Carboplatin|Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
40779697|NCT04179617|OTHER|5% nicotine content JUUL pod|JUUL pods that contain 5% nicotine
40984303|NCT06215547|DEVICE|Enterra HDE|"Instructions for use Implanting physicians should have experience in the surgical and/or implantation techniques for the Enterra II system, operational and functional characteristics of the Enterra II system, 12 English 37800 2014-03 and experience in the continued management of patients by stimulation parameter adjustment. Physicians may contact Medtronic before prescribing or implanting an Enterra II system for the first time, and request a referral to a physician experienced in the use of the Enterra II system. Implanting physicians should be thoroughly familiar with all product labeling.~Cautions:~* When using sharp instruments near the neurostimulator, be extremely careful to avoid nicking or damaging the case, the insulation, or the connector block. Damaging the neurostimulator may require surgical replacement.~* Do not use saline or other ionic fluids at connections, which could result in a short circuit"
40779698|NCT04179617|OTHER|3% nicotine content JUUL pod|JUUL pods that contain 3% nicotine
40779699|NCT02691156|DIAGNOSTIC_TEST|Bilirubin Binding Capacity|Research laboratory assay of bilirubin binding capacity
40779700|NCT02691156|DIAGNOSTIC_TEST|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
40779701|NCT02691156|DIAGNOSTIC_TEST|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
40779702|NCT03984279|OTHER|Patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control|Not applicable, all patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control on a period of 1 year will be taken into account
40779703|NCT02803385|OTHER|Continous Epidural Analgesia|continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.
40779704|NCT02803385|OTHER|Patient Controlled Epidural Analgesia|patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour \& demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.
40779705|NCT03323164|DRUG|Timolol Maleate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
40779706|NCT03323164|DRUG|Brimonidine Tartrate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
40984304|NCT03604640|OTHER|Physical Training|Physical exercise program and health education
40984305|NCT04741074|DRUG|Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution|Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.
41143911|NCT02367794|DRUG|Nab-Paclitaxel|Nab-paclitaxel 100 milligrams per meter squared (mg/m\^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
41143912|NCT02367794|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m\^2 IV.
41143913|NCT02713776|DRUG|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
40779707|NCT00879489|BIOLOGICAL|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
40779708|NCT06333548|DIAGNOSTIC_TEST|Appropriate for gestational age , small for gestational age, large for gestational age, Baby of mother diagnosed with GDM|No intervention
40779709|NCT02466828|DRUG|Feraheme®|Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
40779710|NCT01493089|DRUG|Zegerid|20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
40779711|NCT01493089|DRUG|Losec|20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
40779712|NCT05321290|OTHER|Robotic Therapy Program|
40779713|NCT04373421|DRUG|Chlorhexidine Gluconate 0.12 % Mouthwash + benzydamine hydrochloride|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
40984306|NCT04741074|DRUG|Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution|Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.
40984307|NCT00299455|DRUG|amoxicillin-clavulanate|Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
41143914|NCT02713776|DRUG|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
40779714|NCT04373421|PROCEDURE|St. John's wort oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
40984308|NCT00299455|DRUG|Placebo|Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
40779715|NCT04373421|PROCEDURE|Virgin olive oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
40779716|NCT03999164|DRUG|[18F]DPA-714 Positron Emission Tomography Scan|All patients will undergo a \[18F\]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
40779717|NCT04753775|DRUG|Aloe vera gel|
40984309|NCT00914524|DRUG|olmesartan medoxomil|olmesartan medoxomil tablets, once daily
40984310|NCT01721421|OTHER|extended treatment time|patients receive extended dialysis treatment time time of 6 hours
40984311|NCT01721421|OTHER|Standard treatment time|
40984312|NCT05651633|DRUG|lidocaine hydrochloride 5mg/g|1-2 drops up to six times daily for a maximum of 7 days
41463287|NCT04633616|OTHER|Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.
40984313|NCT06067386|OTHER|Dissemination of a selective reporting for antibiotic susceptibility testing|For each E. coli positive urine culture analyzed by LabOuest, GPs will receive an antibiotic susceptibility testing report, with the list of antibiotics restricted according to four E. coli susceptibility profiles, with an emphasis on narrower-spectrum antibiotics. The selected antibiotic susceptibility testing was developed following a targeted literature review and consultation with a steering committee including GPs, biologists and infectiologists. At the GP's request, a full antibiogram can be provided.
41143915|NCT06602206|OTHER|Conventional Treatment|Hot pack,TENS, ultrasound and exercises
40779718|NCT06168240|OTHER|Manual lymphatic drainage. will be applied three days per week for four weeks.|Training will applied 3 days a week, for a total of 4 weeks.
40779719|NCT04722666|DRUG|MIJ821 Intravenous Injection|MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29
40779720|NCT04722666|DRUG|Placebo Intravenous Injection|40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29
40779721|NCT04256655|DRUG|cohort 1 0.225g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
40779722|NCT04256655|DRUG|Cohort 2 0.75g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
40779723|NCT04256655|DRUG|Cohort 3 2.25 g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
40779724|NCT03044145|BEHAVIORAL|The Cultural Formulation Interview-Engagement Aid|Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
40779725|NCT03044145|BEHAVIORAL|The Cultural Formulation Interview-Engagement Aid (Revised)|The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.
40779726|NCT03044145|BEHAVIORAL|Treatment as usual|Standard mental health treatment at FHMC
40779727|NCT04796584|OTHER|Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus|mRNA vaccination for SARS-CoV-2 is not provided by the study
40779728|NCT06527027|OTHER|Lymph node assessment according to RECIST 1.1 in CT|RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.
40779729|NCT06527027|OTHER|Lymph node assessment according to Node-RADS in CT|Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
40779730|NCT06527027|OTHER|Lymph node assessment according to LN-RADS in CT|"LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node"
40984314|NCT06067386|OTHER|Standard antibiotic susceptibility testing report|GPs will receive a standard antibiotic susceptibility testing report for each E. coli positive urine culture.
40779731|NCT06527027|OTHER|Lymph node assessment according to RECIST 1.1 in MRI|RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.
40984315|NCT01358591|DIETARY_SUPPLEMENT|High calcium milk|High calcium milk (9 mg/kgBM)
40984316|NCT01358591|DIETARY_SUPPLEMENT|Control|Regular Milk
40984317|NCT06189651|DEVICE|wrist splint|The same type of wrist splint to be used for at least 8 hours at night for 4 weeks, to be worn in a neutral position and in accordance with the wrist as described in previous studies to restrict movement in the wrist. Patients who did not sleep for 8 hours were asked to complete 8 hours of wrist splint use before going to sleep or after waking up.
41143916|NCT06602206|OTHER|shoulder mobilization|In the glenohumeral joint mobilization technique, distraction, anterior-posterior gliding, and inferior gliding movements will be applied.
41143917|NCT06602206|OTHER|neck mobilization|Bridge, lateral flexion movement combined with traction, anterior-posterior gliding with traction, and lateral gliding techniques will be applied in neck mobilization.
40779732|NCT06527027|OTHER|Lymph node assessment according to Node-RADS in MRI|Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
41304224|NCT02123160|BEHAVIORAL|Child Parent Psychotherapy (CPP)|Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
41304225|NCT02123160|BEHAVIORAL|Control (usual treatment)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
41304226|NCT02831634|PROCEDURE|Blood sampling|After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
41304227|NCT00374153|BEHAVIORAL|Feedback|Online personal feedback report
41304228|NCT00374153|BEHAVIORAL|Motivational Interview with Feedback|In-person Motivational Interview with personal feedback report
40779733|NCT06527027|OTHER|Lymph node assessment according to LN-RADS in MRI|"LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node"
40779734|NCT01985789|DRUG|Diphenhydramine|
40779735|NCT01985789|DRUG|cetirizine|
40779736|NCT01985789|DRUG|desloratadine|
40779737|NCT01985789|DRUG|placebo|
40779738|NCT00099021|DRUG|pioglitazone hydrochloride|Given PO
40779739|NCT04641091|DEVICE|Multispectral Optoacustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
40779740|NCT01195454|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: Lantus solution for injection~Route of administration: subcutaneous"
40779741|NCT01195454|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: New insulin glargine formulation solution for injection~Route of administration: subcutaneous"
41143918|NCT02221011|DEVICE|Shock wave|"Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases."
41143919|NCT02543307|PROCEDURE|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
41143920|NCT05777772|BEHAVIORAL|STOP Falls D Educational Intervention|This is one-arm, health-system embedded pragmatic pilot trial
41143921|NCT00924755|DEVICE|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
41304229|NCT00374153|BEHAVIORAL|Motivational Interview|In-person Motivational Interview only (without a personal feedback report)
41304230|NCT01673724|DRUG|pramipexole|pramipexole
41304231|NCT01673724|DRUG|Bromocriptine|bromocriptine
41304232|NCT03400696|BEHAVIORAL|Lower carbohydrate diet|Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity
40779742|NCT04033692|DEVICE|JuggerKnot Mini Soft Anchor|Patient who have been implanted with one or more JuggerKnot Mini Soft Anchor(s) who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc.
41304233|NCT03400696|BEHAVIORAL|Higher fiber diet|Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity
41304234|NCT03400696|BEHAVIORAL|Physical activity focused|Focused on aerobic and resistance exercise, while following dietary guidelines \<https://www.choosemyplate.gov\>
40779743|NCT00295789|DRUG|chemotherapy: Paclitaxel/Cisplatin|Drug: chemotherapy: Paclitaxel/Cisplatin
40779744|NCT00295789|DRUG|chemotherapy: Paclitaxel/Carboplatin|Drug: chemotherapy: Paclitaxel/Carboplatin
41304235|NCT06390579|OTHER|Deep learning algorithm applied on retrospectively collected color fundus photographs|Deep learning algorithm applied on retrospectively collected color fundus photographs
40779745|NCT06193707|OTHER|the Remote Intervention|Remote health intervention refers to the use of big data, artificial intelligence and 5G technology to provide healthcare services and interventions to individuals at a distance. This approach allows healthcare providers to deliver medical care, monitor patients' health, offer consultations, provide education, and offer support without the need for in-person interaction.
40779746|NCT06193707|OTHER|the Traditional Intervention|Ultrasound follow-up review is recommended. If there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
40779747|NCT03454789|DRUG|brachial plexus block for LB Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
40779748|NCT03454789|DRUG|brachial plexus block for BS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
40779749|NCT03454789|DRUG|brachial plexus block for LS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
40779750|NCT03454789|DRUG|brachial plexus block for BL Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
40779751|NCT01905540|DRUG|SSP-004184AQ|Magnesium salt
40779752|NCT01905540|DRUG|SSP-004184SS|Disodium salt
40779753|NCT00617864|DRUG|Human Albumin Infusion|Group will receive single infusion of albumin at the time of oocyte retrieval.
40779754|NCT00617864|DRUG|Saline Infusion|Group will receive single infusion of saline at the time of oocyte retrieval.
40779755|NCT02441894|DRUG|CABAZITAXEL XRP6258|Pharmaceutical form:solution Route of administration: intravenous
40779756|NCT02441894|DRUG|PEG-G-CSF|Pharmaceutical form:solution Route of administration: subcutaneous
40779757|NCT02441894|DRUG|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
41143922|NCT01850888|DRUG|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
41143923|NCT01850888|DRUG|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
41143924|NCT01850888|DRUG|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000).
41143925|NCT01850888|PROCEDURE|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum \> 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum \>2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
41304236|NCT00718419|DRUG|Enzastaurin|"Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg)~Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day).~Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression."
40779758|NCT02441894|DRUG|Dexchlorpheniramine or Diphenhydramine|Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
40779759|NCT02441894|DRUG|Ranitidine|Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
40779760|NCT02441894|DRUG|Metoclopramide, Granisetron, or Ondansetron|Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
41304237|NCT01563562|DRUG|Bardoxolone Methyl|Oral, Single dose
41304238|NCT05126524|OTHER|NO INTERVENTION|Observational study, no intervention performed
40779761|NCT02441894|DRUG|Dexamethasone|Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
40779762|NCT00214565|DRUG|Galida|
40779763|NCT04314622|DRUG|Supaglutide|Administered SC
40779764|NCT04314622|DRUG|Placebo|Administered SC
40779765|NCT02507986|DEVICE|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
40779766|NCT02507986|DEVICE|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
40779767|NCT06078566|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
41304239|NCT04060173|DRUG|ABP-671|ABP-671 is an investigational drug
41304240|NCT04060173|OTHER|Placebo|Matching placebo
40779768|NCT00876941|BEHAVIORAL|Standard Brief Intervention|"Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor."
41304241|NCT06224699|DRUG|Toothpaste Product|Use of toothpaste with or without sodium carbonate at 67%
41304242|NCT03611933|OTHER|position change applied at different times|Time 1 - in the first fifth minute after the procedure supine position in which the HOB was elevated 15° Time 2 - in the first hour low fowler's position were given in which the HOB was elevated 15-30° Time 3 - in the third hour semi high fowler's position were given in which the HOB was elevated 30-45° Time 4 - in the fourth hour left or right lateral position were given in which the HOB was elevated 15° Time 5 - in the fifth hour low fowler's position were given in which the HOB was elevated 15-30° Time 6 - in the sixth hour standard fowler's position were given in which the HOB was elevated 45-60°
40779769|NCT00876941|BEHAVIORAL|Enhanced Brief Intervention|"Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings."
40779770|NCT00876941|BEHAVIORAL|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
40779771|NCT05831943|DIAGNOSTIC_TEST|Contrast enhanced Kidney CT|"* Test group : Patient undergoing CT scan with 80kVP protocol and using low concentration intravascular contrast media ( Iobrix 270 mgl/MI , Taejoon pharm, Seoul, South Korea)~* Control group : Patient undergoing CT scan with 120kVP protocol and using high concentration intravascular contrast media ( Iobrix 320 mgl/MI , Taejoon pharm, Seoul, South Korea)"
40779772|NCT03147183|DRUG|Thymoglobulin|This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
40779773|NCT01597817|OTHER|chitosan coated textile|chitosan coated cotton long sleeved shirts and pants.
40779774|NCT01597817|OTHER|chitosan free cotton long sleeved t-shirts and pants.|chitosan free cotton long sleeved shirts and pants.
40779775|NCT00657267|DRUG|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
40779776|NCT06134882|BEHAVIORAL|Contingency management|Monetary incentives are delivered via reloadable debit card based on verified engagement in target behaviors, including drug abstinence, appointment attendance, and completion of self-paced cognitive behavior therapy modules.
40779777|NCT06134882|BEHAVIORAL|Cognitive-Behavior Therapy Modules|Self-paced cognitive-behavior therapy modules delivered via smartphone.
41304243|NCT03418402|DEVICE|Airseal®|Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.
41304244|NCT03418402|DEVICE|Standard insufflator|Standard insufflator
41304245|NCT00146393|BEHAVIORAL|People with Arthritis Can Exercise program|
41304246|NCT06133647|PROCEDURE|managing Male Breast Cancer Patients at Methodist Health System|To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).
41463288|NCT04633616|OTHER|Non-Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
41463289|NCT05624762|DEVICE|Low-Intensity Focused Ultrasound (LIFU)|LIFU device (LCA200; Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China).
41463290|NCT05624762|DEVICE|Sham Low-Intensity Focused Ultrasound|Sham Low-Intensity Focused Ultrasound
41463291|NCT02192294|DRUG|Oral Bosutinib|a single dose of 500 mg oral bosutinib
41463292|NCT02192294|DRUG|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
41463293|NCT04590781|BIOLOGICAL|XmAb18087|Monoclonal bispecific antibody
41463294|NCT04590781|DRUG|XmAb18087 ± Pembrolizumab|XmAb18087 ± Pembrolizumab
41463295|NCT04906096|DRUG|PAXALISIB|Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol
41463296|NCT00899535|GENETIC|DNA analysis|
41463297|NCT00899535|GENETIC|RNA analysis|
41463298|NCT00899535|GENETIC|microarray analysis|
41463299|NCT00899535|GENETIC|mutation analysis|
41463300|NCT00899535|GENETIC|polymorphism analysis|
41463301|NCT00999284|DRUG|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
41463302|NCT00999284|DRUG|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
41463303|NCT00999284|DRUG|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
41463304|NCT02724826|BEHAVIORAL|Qigong therapy|Medical qigong
40779778|NCT06134882|BEHAVIORAL|Peer Contingency Management (CM) Guide|Peer supports delivered via telehealth. Support is informed by the community reinforcement approach and includes motivational interviewing
40984318|NCT06189651|PROCEDURE|5% dextrose injection using USG-guided nerve hydrodissection method|2 ml each of 5% dextrose injection was administered once at the proximal wrist level above the median nerve separating the median nerve from the flexor retinaculum and below the median nerve separating the median nerve from the flexor tendons by nerve hydrodissection method in the transverse inplane plane under ultrasound guidance. After the application, the spread of the injectate was observed by looking longitudinally at the median nerve.
40984319|NCT05118074|DIAGNOSTIC_TEST|Creatinine, eGFR|Compare diagnostic tests to reference methods
40984320|NCT02260050|DRUG|WAL 801 CL dry syrup new formulation|
40984321|NCT02260050|DRUG|WAL 801 CL dry syrup conventional formulation|
40984322|NCT04446377|DRUG|Apilimod Dimesylate Capsule|LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
40984323|NCT04446377|OTHER|Placebo|Microcrystalline cellulose in Swedish orange, Size 0 capsules
41143926|NCT04755309|BEHAVIORAL|Rhythmic intervention|"The rhythmic intervention consists in an ecological and non-invasive intervention based on enriched auditory and musical active experience. It is based on the most recent scientific evidence in the field and provides exposure to and active synchronization with complex musical rhythms. It is thought to promote the infant's ability to recognize and process the complex rhythms of spoken language. Importantly, it taps into and empowers early auditory processing skills. The intervention includes several tasks described in the literature, for example tapping and bouncing at the beat of complex musical rhythms.~The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks."
41143927|NCT04755309|BEHAVIORAL|Passive auditory stimulation|The same auditory stimulation is provided to infants, but no active tasks are proposed. Children and caregiver are entertained with motor and cognitive tasks not related to the auditory stimuli presented. The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks.
41304247|NCT05742672|OTHER|ABDOMINAL MASSAGE APPLICATION|"* Experiment group twice a day in the morning and evening and 30 minutes after the feeding meal, for 15 minutes. For a period of time, effusion, petrissage, vibration massage movements will be applied by the researcher in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.- On the 3rd day (short term), 5th day (mid term) and 7th day (long term) to the massaged experimental group, the Constipation Severity Scale (CQS) and the Constipation Quality of Life Scale (QQQL) will be administered to determine the effect.~* Day 7 Rome Ш Constipation Diagnostic Criteria (Annex: 2) will be applied again and the patient's constipation status will be evaluated for the last time.~* Routine treatment and care practices in the clinic will continue."
41304248|NCT00551824|DRUG|Mitomycin C|Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
41304249|NCT04453839|DRUG|ZYESAMI (aviptadil acetate)|Patients will be treated with 12 hour infusions of ZYESAMI at ascending doses of 50/100/150 pmol/kg/hr on 3 or more successive days
41304250|NCT00482872|GENETIC|gene expression analysis|
41463305|NCT02724826|BEHAVIORAL|Exercise therapy|Regular exercise
41463306|NCT00533806|BEHAVIORAL|Cognitive Behavior Therapy|CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.
41304251|NCT00482872|GENETIC|mutation analysis|
41304252|NCT00482872|GENETIC|polymerase chain reaction|
41304253|NCT00482872|GENETIC|polymorphism analysis|
41304254|NCT00482872|OTHER|flow cytometry|
40984324|NCT02452346|DRUG|Tosedostat|120 mg PO once daily continuously for each 28 day treatment cycle
40984325|NCT01686633|DRUG|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
40984326|NCT01686633|DRUG|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
41304255|NCT00482872|OTHER|laboratory biomarker analysis|
41304256|NCT00358618|DRUG|Propofol|See Detailed Description.
41304257|NCT03633227|DRUG|Obeticholic Acid (OCA)|OCA will be administered per dose and schedule specified in the arm description.
41304258|NCT03633227|DRUG|Placebo|OCA matching placebo will be administered per the schedule specified in the arm description.
41304259|NCT03524833|DRUG|Metronidazole|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
41304260|NCT03524833|DRUG|Lansoprazole, Amoxicillin, Metronidazole|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
41304261|NCT02180503|DRUG|BI 1356 BS PIB - low dose|
40779779|NCT06134882|BEHAVIORAL|Drug testing|Self-performed salivary drug testing with incentives contingent upon proper completion of test procedures as confirmed by video.
41304262|NCT02180503|DRUG|BI 1356 BS tablet - low dose|
41304263|NCT02180503|DRUG|BI 1356 BS PIB - high dose|
41304264|NCT02180503|DRUG|BI 1356 BS tablet - high dose|
41463307|NCT00533806|BEHAVIORAL|Relaxation Therapy|Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
40984327|NCT01686633|DRUG|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
40984328|NCT02145364|DEVICE|Ultherapy® treatment|Microfocused ultrasound treatment
40984329|NCT00044395|DRUG|Ruboxistaurin mesylate|
40984330|NCT00252954|DRUG|Levetiracetam|Tablets 2000-3000 mg per day
40984331|NCT02877082|BIOLOGICAL|Thymoglobulin|Given IV
40984332|NCT02877082|DRUG|Bortezomib|Given IV
40984333|NCT02877082|DRUG|Tacrolimus|Given IV and PO
40984334|NCT05309564|DRUG|Botulinum toxin type A|Single intervention
41304265|NCT02180503|DRUG|BI 1356 BS tablet - high dose with food|
41304266|NCT02829177|DRUG|Allopurinol|
41304267|NCT02829177|DRUG|Placebo|
40984335|NCT02097407|DRUG|Group C : Saline + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment"
40984336|NCT02097407|DRUG|Group D : Dexmedetomidine + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment."
41304268|NCT01002859|DRUG|Sandimmum|Intravenous injection of cyclosporine
41304269|NCT01002859|DRUG|Placebo|Intravenous Injection of NaCl solution
41304270|NCT00870948|DRUG|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
41304271|NCT01201096|RADIATION|177Lutetium|two cycles of 177Lutetium radioreceptor therapy within two month
41304272|NCT01201096|PROCEDURE|Liver transplantation|about 9 month after finishing the receptor therapy liver transplantation takes place
41304273|NCT02709434|BEHAVIORAL|Psychoeducational programme|Activity diary analysis and a structured programme of intervention
41304274|NCT02709434|OTHER|Standard care|Usual IBD management
41304275|NCT02426411|DRUG|EMA401 200 mg|
41304276|NCT02426411|DRUG|EMA401 600 mg|
41304277|NCT02426411|DRUG|Placebo|
40779780|NCT06134882|BEHAVIORAL|Wellness modules|Basic health and wellness information delivered via self-paced learning modules.
41463308|NCT01020617|DIETARY_SUPPLEMENT|Ls-33|10\~10 CFU/day
41304278|NCT03350750|DEVICE|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
41304279|NCT02871180|DIETARY_SUPPLEMENT|Late night snack|The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
41304280|NCT02871180|OTHER|No late night snack|Patient consumed no nutrients at late night.
41304281|NCT06018467|DRUG|Dasatinib 100 Mg Oral Tablet|"Dasatinib tablets in blister packs of 10 tablets, from either: Sandoz, STADA Nordic, Zentiva or Bristol-Myers Squibb"
41304282|NCT06018467|DIETARY_SUPPLEMENT|Quercetin 1.250 mg (oral)|five 200mg Quercetin Phytosome capsules, from Thorne
41304283|NCT06018467|DIETARY_SUPPLEMENT|Nicotinamide Riboside 1g (oral)|four 250mg Nicotinamide Riboside Capsules, from Elysium Health
41304284|NCT00377624|DRUG|sodium hyaluronate|
41304285|NCT05224869|DEVICE|Medical Device Usage and Evaluation|Undergo hydrogel rectal spacer placement
41304286|NCT05224869|PROCEDURE|CT simulation|CT simulation of radiation treatment planning 2-7 days after hydrogel placement
41463309|NCT05652309|PROCEDURE|spinal block and obturator nerve block|spinal block and obturator nerve block
41304287|NCT05224869|PROCEDURE|Stereotactic body radiation therapy|SBRT in 5 fractions over 1 week, 7 days after CT simulation
41304288|NCT05224869|RADIATION|Brachytherapy|one month after completing SBRT
41304289|NCT05224869|PROCEDURE|Post-implant dosimetry scan|one month after brachytherapy
41304290|NCT06265077|DRUG|Placebo|Placebo
41304291|NCT06265077|DRUG|famotidine and loratadine|famotidine 20 mg once daily and loratadine 10 mg once daily
41304292|NCT01031524|BIOLOGICAL|PfCS102|Antigen of the sporozoite protein
41304293|NCT01031524|BIOLOGICAL|Montanide ISA 720|adjuvant alone
41304294|NCT04972032|DEVICE|Estrogen Intrauterine Stent System|A Estrogen Intrauterine Stent System（E-IUS）will be introduced post-operatively. The E-IUS will be removed 60 days after surgery with continuous dydrogesterone administration for 5 days at 20 mg/d, and routine management.
41463310|NCT01004445|DRUG|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
41463311|NCT01004445|DRUG|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
41304295|NCT04972032|DEVICE|Foley balloon combined with self-cross-link sodium hyaluronate gel|Foley balloon combined with self-crosslinking sodium hyaluronate gel will be introduced post-operatively，2 cycles of estrogen-progestin sequential therapy comprised of continuous estrogen and progestin added in the second half of the cycle or continuous estradiol valerate for 60 days, followed by dydrogesterone for 10 days
41304296|NCT01766336|DRUG|Group 1 ELND005|
41304297|NCT01766336|DRUG|Group 2 ELND005|
41304298|NCT01497314|OTHER|Low Lactose Infant Formula|Low Lactose Infant Formula
41463312|NCT01004445|DRUG|Placebo|Two aerosol treatments per day (one treatment every 12hr)
41463313|NCT01642563|PROCEDURE|Platelet transfusion|One dose of pathogen reduced platelets
41463314|NCT01642563|PROCEDURE|Platelet transfusion|One dose of standard platelets
41463315|NCT04536792|DRUG|AG-946|AG-946, oral encapsulated coated-granules or tablets.
41463316|NCT04536792|DRUG|AG-946 Matched Placebo|AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
41463317|NCT04602585|BEHAVIORAL|Psycho-education|Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
41463318|NCT04799223|OTHER|Four-foods eating guidelines|To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.
41463319|NCT04799223|OTHER|No designed-foods eating guidelines|To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.
41304299|NCT03737968|DRUG|Durvalumab|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
41463320|NCT03255044|DRUG|Atorvastatin|Atorvastatin administered as well as standard heart failure therapy
41463321|NCT03255044|DRUG|Rosuvastatin|Rosuvastatin administered as well as standard heart failure therapy
41463322|NCT03255044|OTHER|guideline directed therapy|standard heart failure therapy
41463323|NCT03467282|DIETARY_SUPPLEMENT|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
41463324|NCT03467282|DIETARY_SUPPLEMENT|Placebo|1g polydextrose/maltodextrin - twice day
41463325|NCT05135273|BIOLOGICAL|Pfs230D1-EPA/Matrix-M Vaccine|Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.
40779781|NCT06134882|BEHAVIORAL|Peer technical support|Peer support for promoting engagement and addressing technical issues delivered via a mobile digital platform.
40984337|NCT01494480|PROCEDURE|stem cell transplantation|after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
40984338|NCT04841902|OTHER|Life Style Intervention Manual (With Exercise Under Supervision)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. The exercise will be supervised will other two components will be home based.
40984339|NCT04841902|OTHER|General Advice|General advice to stay healthy and active
40984340|NCT04841902|OTHER|Life Style Intervention Manual (Home Based)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. All three components will be home based.
41143928|NCT03708744|DRUG|A: M207 3.8mg, 30 min, upper arm|A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
40984341|NCT04730245|DRUG|sodium phosphate enema, oral rifaximin and polyethylene glycol|Patients were hospitalized for 4-5 hours to receive two saline colon enemas with sodium phosphate Fleet®, 2 to 3 hours apart, appropriate hydration was provided during the procedure. If signs of fecal impaction were observed, the stools were removed manually prior to the first enema. Patients were discharged with oral treatment consistent with rifaximin 200 mg three times a day for 7 days and polyethylene glycol-3350, 17 gr per day in water for 10 days, but it was continued if necessary. Importantly, no modifications in time and dose of dopaminergic therapy or anti-dyskinetic medication (i.e. amantadine) were done at baseline or during the study
40984342|NCT01523574|DRUG|Vitamin E|Vitamin E 400mg PO orally
40984343|NCT01523574|DRUG|Placebo|Placebo, given orally
40984344|NCT03059654|PROCEDURE|tracheostomy|
40984345|NCT05076474|DRUG|Orlistat 60mg Cap|Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
40984346|NCT05205746|BIOLOGICAL|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
40984347|NCT05205746|BIOLOGICAL|Placebo|Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular
40984348|NCT01026792|DRUG|Temsirolimus|Given IV
40984349|NCT01026792|OTHER|Laboratory Biomarker Analysis|Correlative studies
40984350|NCT00005610|BIOLOGICAL|sargramostim|
41463326|NCT05135273|BIOLOGICAL|Verorab Rabies Vaccine|Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.
41143929|NCT03708744|DRUG|B: M207 3.8 mg, 30 min, thigh|B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
41143930|NCT03708744|DRUG|C: M207 3.8 mg, 1 hr, upper arm|C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
40779785|NCT02054637|DRUG|Lanreotide|
40779786|NCT02483364|OTHER|HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)|A single application in the context of a single surgical intervention.
40779787|NCT00138684|PROCEDURE|venesection|Venesection therapy is realised every 7 - 14 days until iron desaturation completion.
40984351|NCT01893710|PROCEDURE|biopsy sampling|"Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial."
40984352|NCT00159640|DRUG|PD-217,014|
40984353|NCT05688046|DRUG|Immune checkpoint inhibitors plus angiogenesis inhibitors|PD-(L)1-based therapy plus Bevacizumab or Anlotinib
40984354|NCT05688046|DRUG|Immune checkpoint inhibitors without angiogenesis inhibitors|PD-(L)1-based therapy
40984355|NCT01220947|DRUG|Copegus|Copegus 1000 mg or 1200 mg po daily for 24 weeks.
40984356|NCT01220947|DRUG|Danoprevir|Danoprevir 50 mg BID
40984357|NCT01220947|DRUG|Danoprevir|Danoprevir 100 mg BID
41143931|NCT03708744|DRUG|D:zolmitriptan nasal spray|D: 2.5 mg/0.1 mL intranasal zolmitriptan
41463327|NCT04934020|OTHER|Pre-pandemic stroke related metrics|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
41463328|NCT04934020|OTHER|Stroke related metrics during the pandemic|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
41463329|NCT04462744|OTHER|educational program|an oral health educational program regarding the emergency management of traumatic dental injuries.
41463330|NCT04515420|DRUG|noradrenaline|noradrenaline infusion
41304300|NCT03737968|DRUG|durvalumab + tremelimumab|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
41304301|NCT03398018|DRUG|repository corticotropin injection|80 units twice per week as a subcutaneous injection
41304302|NCT02032537|DRUG|Callmax cream application over affected skin|Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.
40779788|NCT03015493|OTHER|Neural mobilization combined with traction|Neural mobilization techniques combined with cervical traction for the cervical nerve roots
40779789|NCT03015493|OTHER|Traction|Traction techniques for the cervical spine
40779790|NCT00987350|DEVICE|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
40779791|NCT00987350|DEVICE|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
40779792|NCT00987350|BIOLOGICAL|Seasonal Trivalent Influenza Vaccine|Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
40779793|NCT00093509|DRUG|doxorubicin hydrochloride|To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
40779794|NCT00093509|DRUG|ifosfamide and mesna|2 gm / m2 ifosfamide mixed in 1000 cc D5W infused continuously over 24 hours daily for 6 days (144 hours); total ifosfamide dose 12 gm/ m2. For the day infusion only MESNA (sodium 2-mercapto-ethanesulphonate) is mixed with ifosfamide as above and given at 2.5 gm / m2 / 24 hours.
40779795|NCT00093509|PROCEDURE|hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator|Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90.
40779796|NCT00093509|RADIATION|radiation therapy|External beam megavoltage (≥ 4 MV) beams will be used at SSD, SAD ≥ 70 cm at a dose rate of \> 100 cGy/min. Fraction sizes of 180 cGy will be used 5 times per weeks in a continuous course. Total dose will be 45 Gy + 10%, consistent with sites being treated.
40779797|NCT04859192|OTHER|gamified flipped classroom|moodle will be gamified
40984358|NCT01220947|DRUG|Danoprevir|Danoprevir 200 mg BID
40984359|NCT01220947|DRUG|Pegasys|Pegasys 180 microgram sc qw
40984360|NCT01220947|DRUG|Ritonavir|Ritonavir 100 mg
40984361|NCT04405648|BEHAVIORAL|CVS GROUP|the students will respond to CVS-F3 questionnaire to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors.
40984362|NCT03256539|BEHAVIORAL|Sleep intervention|Behavioral sleep intervention program
41304303|NCT02032537|DRUG|Placebo|Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
41304304|NCT02990637|DIETARY_SUPPLEMENT|OLECOL|Olive leaf extract
41304305|NCT02990637|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
41304306|NCT04641364|DRUG|recombinant human albumin injection|single dose or multiple doses of intravenous infusion
41304307|NCT04641364|DRUG|Placebo|Single dose intravenous infusion of 0.9% sodium chloride injection
41304308|NCT04641364|DRUG|human albumin injection|multiple doses of intravenous infusion
41304309|NCT05990660|DEVICE|JuxtaFlow System|Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters
41304310|NCT01395589|DRUG|Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels \< 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
41304311|NCT00313599|DRUG|lapatinib|
41304312|NCT00313599|DRUG|paclitaxel|
41304313|NCT05073458|DRUG|parsaclisinib|parsaclisib will be administered QD orally
40984363|NCT03256539|BEHAVIORAL|Placebo intervention|Quasi-desensitization intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration)
40984364|NCT05040854|GENETIC|HLA-DQA1*05 and DRB1|All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1
40984365|NCT03556007|DRUG|LY3471851|LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
40984366|NCT03556007|DRUG|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
40984367|NCT01382979|BEHAVIORAL|AlcoholEdu for College|Online course for college freshmen.
40984368|NCT02685020|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
40984369|NCT02685020|BIOLOGICAL|Clade C gp140|The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
40779798|NCT01876381|DRUG|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
40779799|NCT04955548|PROCEDURE|arthroscopic micro-fracture with autologous adipose gel|Fully cut the adipose tissue taken out under the arthroscopy, transfer the cut adipose tissue to a syringe connected with a double pass, push back and forth through the syringe to physically emulsify the adipose, and centrifuge to obtain the autologous adipose gel, and inject it into the lesion
40779800|NCT04955548|PROCEDURE|arthroscopic micro-fracture|Surgeons routinely perform international standard micro-fracture surgery to repair cartilage damage
41304314|NCT05073458|DRUG|placebo|placebo will be administered QD orally follwed by Parsaclisinib in the open label period
40779801|NCT06222021|GENETIC|Genetic analysis of polymorphism of membrane receptors involved in lactate transport|The DNA extracted from the blood samples (through extractor MagCore) will then undergo gene sequencing by Sanger sequencing and/or Custom NGS (Next Generation Sequencing) panels and will be used to identify nucleotide variants within genes involved in lactate transport (MCT-1/4, GPR81).
41304315|NCT00704509|DRUG|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
41304316|NCT00704509|DRUG|Placebo|Encapsulated tablets, orally, 12 weeks
41304317|NCT00704509|DRUG|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
41304318|NCT04657016|DRUG|Tirzepatide|Administered SC
41463331|NCT03879486|OTHER|Intrarectal povidone-iodine cleansing plus formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy|The examiner will use a gauze soaked and saturated with iodopovidone and perform a mechanical friction motion on the anterior wall of the rectum, at least 5 times from one margin to another of the prostate laterally-laterally. A period of two (2) minutes shall be waited from the prophylactic cleaning of the rectum to the beginning of the biopsy. The examiner will use a technique of disinfecting the 10% formaldehyde biopsy needle without manual contact by soaking the distal 3 cm of the needle directly into a vial containing the bactericidal solution between obtaining the different fragments. An individual bottle will be used for each patient
41463332|NCT00089167|BIOLOGICAL|filgrastim|
41463333|NCT00089167|DRUG|dexamethasone|
41463334|NCT00089167|DRUG|melphalan|
41463335|NCT00089167|DRUG|thalidomide|
41463336|NCT02466087|DRUG|Mg Cl|Four supplements a day for 6 weeks.
40779802|NCT05201131|PROCEDURE|Rezum|Rezum
40779803|NCT00285571|BEHAVIORAL|Controlled Feeding Intervention|
40779804|NCT05512624|BEHAVIORAL|Common Elements Treatment Approach|"For treatment group participants, they will then have weekly meetings with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10 sessions. Both treatment and wait list participants will then complete the assessment instrument at 3 months and 6 months post-enrollment (each lasting no more than 1.5 hours). All total, it is expected that treatment group participants will have up to 13 meetings with a study team member or counselor over the course of their participation.~Wait list group participants will have 3 meetings with a study team member over the course of their participation. If the treatment is deemed to be effective these wait list participants will be the first adults to be offered the intervention after trial completion."
40779805|NCT04650581|DRUG|Ipatasertib|400 mg PO QD days 1-21 every 28 days
40984370|NCT02685020|DRUG|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
40984371|NCT04599920|DIETARY_SUPPLEMENT|Partial replacement of red meat with legume-based foods|560 g of cooked and boneless red meat is replaced with legume-based foods providing the equal amount of protein.
41304319|NCT04657016|OTHER|Placebo|Administered SC
41304320|NCT04699903|DIAGNOSTIC_TEST|POC SARS-Cov-2 IgG Antibody test|All patients will undergo a Point of care (POC) SARS-Cov-2 IgG Antibody test in fingerstick whole blood
41304321|NCT04097756|DRUG|LX-039 tablets|orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
41304322|NCT05420688|OTHER|Heart Failure Group|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
41304323|NCT02973529|DEVICE|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
41304324|NCT02973529|DEVICE|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
41304325|NCT03614442|OTHER|slopped shoulder implant|different implant design to enhance soft and hard tissue outcome
41304326|NCT04276220|DIAGNOSTIC_TEST|Tenosynovial biopsy|Tenosynovial biopsy taken from the wrist at the carpal tunnel release surgery.
41304327|NCT03174717|BEHAVIORAL|Music performance|residents of LTC will learn and perform songs with musicians from the community
41463337|NCT01801917|DRUG|Placebo|Matching placebo tablet for oral administration
41463338|NCT01801917|DRUG|BAF312|BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
41463339|NCT04299776|DEVICE|CirQPOD|CirQPOD is connected between the wye piece on ventilator/anesthesia machine tubing and the patient's airway and generates negative intrathoracic pressure during the expiratory phase of ventilation which has been shown to improve blood flow.
41463340|NCT04299776|DEVICE|Standard airway management|Standard airway management during surgery (PEEP of +5 cmH2O)
41463341|NCT03756701|BEHAVIORAL|Mind body skills|"2 hour skill sessions that focus on mindfulness: The topics for each session is based upon the Centers for Mind Body Medicine model. Both groups will follow this same weekly topic schedule.~1. Introduction and Drawings~2. Autogenic Training and Biofeedback~3. Guided Imagery~4. Meditation~5. Mobilizing, Transforming, and Celebrating Emotion~6. Genograms part 1~7. Genograms part 2~8. Mindful Eating and Healthy Nutrition~9. Spirituality~10. Closing Drawings and Ritual"
41304328|NCT04808154|DRUG|SNP-630|Subjects will receive one single dose of SNP-630 at Day 1. Blood and urine samples will be obtained to determine the PK of orally administered SNP-630.
41143932|NCT01482091|DRUG|Fentanyl Citrate|A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
41143933|NCT01482091|DRUG|Normal Saline|A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
41304329|NCT00125658|OTHER|Control|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
41304330|NCT00125658|OTHER|Experimental|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
41304331|NCT01821170|DRUG|Methylphenidate|Patient will take treatment during two months
41304332|NCT01821170|DEVICE|cognitive remediation|Patient will have 12 sessions during 6 to 8 weeks
41304333|NCT01821170|BEHAVIORAL|supportive psychotherapy|Patients will have 12 sessions during 6 to 8 weeks
41304334|NCT01821170|OTHER|neuropsychological tests|neuropsychological tests will assess attentional and executive performance
41304335|NCT04705558|OTHER|continuous moderate intensity aerobic training|continuous moderate intensity aerobic exercises with ketogenic diet group underwent supervised moderate-intensity exercised on a treadmill at 50%-70% of heart rate reserve for three month
40984372|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
41143934|NCT04059575|OTHER|Kinesio Taping (Performance Plus)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
40984373|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
41143935|NCT04059575|OTHER|Kinesio taping (Gold Tex)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
41143936|NCT03610685|DRUG|Prednisolone|Given daily for 2 weeks
41143937|NCT03610685|DRUG|Placebo oral capsule|Given daily for 2 weeks
41143938|NCT00274196|PROCEDURE|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
41143939|NCT00274196|PROCEDURE|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
41143940|NCT02978040|DRUG|Cangrelor|Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
40779806|NCT04650581|DRUG|Fulvestrant|500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles
40779807|NCT04650581|OTHER|Placebo|PO QD days 1-21 every 28 days
40779808|NCT02983409|RADIATION|Pstone|A adult patients who were diagnosed as urinary stone by the urinary CT
40779809|NCT02862119|PROCEDURE|FFR Treatment Arm|Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission
40779810|NCT02862119|OTHER|Conservative Treatment Arm|Initial Conservative management of non-culprit lesions during index hospital admission
40779811|NCT03189732|DRUG|Metformin Oral|
40779812|NCT03189732|DRUG|Metformin local in AT|
40779813|NCT03189732|OTHER|Exercise|
40779814|NCT03787654|DEVICE|electroacupuncture|"BL33 and BL35 are inserted by needles of 0.30×75mm size till a depth of 60\~70mm. SP6 is inserted by needle of 0.30×40mm size till a depth of 25-30mm. After manipulation and deqi sensation generation, the electrodes will be attached to the acupoints transversely with 20Hz continuous wave and an electricity current of 2mA-6.5mA at BL33 and BL35, and 1-3.5mA at SP6. The current is adjusted from zero to the degree where patients can tolerate.~Subjects receive 3 sessions per week（every other day ideally) for 12 weeks, 36 sessions in total."
40779815|NCT03787654|DEVICE|sham electroacupuncture|"In sham electroacupuncture group, sham acupoints 1 cun(≈15mm） horizontally outwardly lateral to BL33 and BL35, and 0.5 cun (≈10mm) horizontally behind SP6 are stimulated by needles of 0.30×40mm size. The needles are inserted to a depth of 2-3mm to stand still, without any manipulation and sensation of deqi. The electrodes will also be attached to needles with an electricity current of 0.1-0.3mA.~The sessions will be the same as the electroacupuncture group."
40779816|NCT03787654|DRUG|Solifenacin|Subjects take solifenacin 5-10mg per day for a succession of 36 weeks. The dose change is decided by doctors under a comprehensive consideration of side effects and Patient Global Symptom Control (PGSC), which is applied to evaluate the effectiveness of Solifenacin at the 4th, 8th, 12th and 24th week.The medicine can be discontinued at any time if the adverse effect is rather severe.
41304336|NCT04705558|OTHER|ketogenic diet|Ketogenic diet: a low carbohydrate high-fat diet consisted of the following nutrient conformation: 80% fat, 15% protein and 5% carbohydrates, entire daily intake was estimated to be 20-30 g of carbohydrates for three month.
41304337|NCT03696303|OTHER|Urinary antigen detection assay|Screening for Ag level in S. pneumoniae urinary antigen detection assay.
41304338|NCT02191423|DRUG|Oxytocin|administered pre-fMRI assessment
41304339|NCT02191423|DRUG|placebo|administered pre-fMRI assessment
40779817|NCT01991860|DRUG|APD421- Amisulpride for IV injection|APD421 ( Amisulpride) at 5mg given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
40779818|NCT01991860|DRUG|Placebo|Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
40779819|NCT00273884|DRUG|Amonafide L-Malate|
40779820|NCT00273884|DRUG|Cytarabine|
40779821|NCT04259593|OTHER|exercise training|
41304340|NCT02191423|BEHAVIORAL|Dyadic psychotherapy|
41304341|NCT04801537|OTHER|normal body temperature and warm extremities|environmental temperature is set according to the standard method to keep normal body temperature and warm extremities
41304342|NCT04801537|OTHER|normal body temperature and cold extremities|environmental temperature is set according to the standard method to keep normal body temperature, but cold extremities
41304343|NCT04840992|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation|Aerogen Solo
40779822|NCT06332586|BEHAVIORAL|Diversified teaching|Diversified teaching (read and jointly mark the key points of the triage diagnosis teaching manual and read the TMS online course at any time, 1 triage diagnosis seminar/quarter, interactive teaching) for triage diagnosis nurses
41304344|NCT04840992|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
41304345|NCT04840992|BIOLOGICAL|Placebo for Inhalation|Aerogen Solo
41304346|NCT04840992|BIOLOGICAL|Placebo|Intramuscular administration
41304347|NCT00856271|DRUG|olmesartan medoxomil|oral tablets, once daily for 8 weeks
41304348|NCT00856271|DRUG|losartan potassium|capsules, once daily for 8 weeks
41463342|NCT03285919|DEVICE|Balance Assessment Robot (BAR™)|"The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered."
40779823|NCT01170351|DRUG|Cyclosporine-A|Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
40779824|NCT03313934|COMBINATION_PRODUCT|Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)|The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.
41304349|NCT00657631|BEHAVIORAL|Acceptance and Commitment Therapy|"Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, \& Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl \& Wilson, 1999)."
41304350|NCT02256865|DRUG|Ketoconazole|Ketoconazole is taken 4 times a day
41304351|NCT02256865|DRUG|Hydrocortisone|Hydrocortisone is taken 3 times a day
40779825|NCT03313934|COMBINATION_PRODUCT|Hyaluronic Acid Filler and Saline|This intervention will use saline as a control to compare with PRF when mixed with hyaluronic acid fillers. Saline will dilute the HA filler in the same way PRF will, however saline as no growth factors or properties that will enhance treatment.
41463343|NCT00491257|BIOLOGICAL|Inactivated influenza vaccine (split virion) NH 2007-2008 formulation|0.5 mL, Intramuscular
41143941|NCT02978040|DRUG|Tirofiban|Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old) .
41143942|NCT02978040|DRUG|Prasugrel|In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
41143943|NCT03968276|OTHER|use of digital tablet|"At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.~In this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool."
41463344|NCT05645315|DRUG|TQB2618 injection and TQB2450 injection|TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
41463345|NCT01006954|DRUG|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
41463346|NCT01006954|DRUG|Flare up|Flare up protocol in poor responders for IVF/ICSI
41463347|NCT01380522|DRUG|Metronidazole|Capsules, single-dose, fed
41463348|NCT01380522|DRUG|Flagyl|Capsules, single-dose, fed
41463349|NCT03095755|OTHER|Ischemic Conditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
41463350|NCT03095755|OTHER|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
41463351|NCT05805527|DIAGNOSTIC_TEST|mobile health application named KANOPEE|Volunteers will undergo two clinical interviews, an in person clinician-led interview and a fully-automated interview administered via mobile phone
40779826|NCT01740687|DEVICE|ESS305 (Essure, BAY1454032)|Essure Permanent Birth Control
40779827|NCT01740687|PROCEDURE|NovaSure|Nova Sure Endometrial Ablation
40779828|NCT05201651|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.
40779829|NCT05201651|DIETARY_SUPPLEMENT|Maltodextrin Placebo|Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
40779830|NCT01940419|DRUG|Tranexamic Acid|1g Tranexamic acid iv administered over 10 minutes just before surgery
40779831|NCT01940419|DRUG|Placebo|10 ml sodium chloride iv administered over 10 minutes just before surgery
40779832|NCT02055508|BEHAVIORAL|Exercise Intervention|
41143944|NCT00104442|DRUG|Rivastigmine|
40779833|NCT02055508|OTHER|Care-Management-Phone-Calls|
40984374|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
40984375|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
40984376|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
40779834|NCT04552054|DEVICE|Mixed Reality+ 3D printing guided localization|Researchers project a three-dimensional reconstructed image of the patient's chest through MR glasses, then overlay the virtual chest with the actual chest. Finally, researchers put the three-dimensional printing navigational template on the surface of the body to guide for percutaneous lung puncture localization.
40779835|NCT04552054|DEVICE|Computerized Tomography guided localization|CT-guided percutaneous lung puncture staining marker localization.
40779836|NCT04750161|OTHER|No intervention|No intervention will be given to participants. It is purely observational.
40779837|NCT05244161|BEHAVIORAL|RMV-ECD|Combined radio messaging, video job aids (primarily for CHWs), Care for Childhood Development package
40779838|NCT00000276|DRUG|Bupropion|
40779839|NCT04958486|DRUG|5-Azacytidine and trastuzumab infusion|Patients will receive once weekly 10 mg intraventricular 5-Azacytidine infusions for six consecutive weeks followed by observation in the infusion suite for a minimum of 30 minutes and once weekly 21 mg intraventricular trastuzumab infusions for six consecutive weeks followed by observation for a minimum of 2 hour after each infusion for the first 2 infusions. During this monitoring period, temperature, blood pressure, heart rate, and oxygen saturation will be measured. Patients will also have a neurological examination performed to observe for neurological changes. All patients will undergo an MRI of the brain and total spine with and without gadolinium within 7 days after the final 5-AZA and trastuzumab infusion to determine treatment response and to assess for any signal changes in the brain or spine caused by the infusions and they will have a 30 day and a 90 day follow-up assessment by telephone or in person for assessment of outcome measures and safety
40779840|NCT00822380|DIETARY_SUPPLEMENT|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
40779841|NCT00822380|DIETARY_SUPPLEMENT|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
40779842|NCT00822380|DIETARY_SUPPLEMENT|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
40779843|NCT00822380|DIETARY_SUPPLEMENT|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
40779844|NCT00822380|DIETARY_SUPPLEMENT|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
40779845|NCT01889914|DRUG|2 different procedures of administration of insulin|Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
40779846|NCT05229016|BEHAVIORAL|Reflection on health-related experiences|This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
40779847|NCT04325308|PROCEDURE|Protein-enriched human milk diet|1.2 g of human-based protein will be added to each 100 ml of human milk administered
41463352|NCT03200145|OTHER|ACP intervention|"The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions:~1. - Attention to the person based on:~   * Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences.~  * Respect and acknowledge of the person.~  * Promotion of the autonomy.~  * Personalized treatment, with tailored attention and integrative cures~  * Protection of physical well-being, preventing damages and risks and promoting healthy habits.~  * Promotion of independence on daily activities.~  * Protection of privacy and personal matters~2. - Positive environment based on:~   * Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons.~  * Social relationships, with proximity and collaboration with families.~  * Friendly organization, with empathetic professionals empowering users."
40779848|NCT04325308|PROCEDURE|Usual human milk diet|Human-based protein will not be added to the human milk administered.
40779849|NCT00775658|DRUG|olopatadine|olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
40779850|NCT00775658|DRUG|placebo|placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
40779851|NCT03062943|DRUG|Nintedanib|
40779852|NCT03781414|BIOLOGICAL|CFZ533|Comparison with standard of care immunosuppression
40779853|NCT03781414|DRUG|Tacrolimus - MMF - corticosteroids|Standard of care immunosuppresive regimen
40779854|NCT05472493|BIOLOGICAL|[18-F]CETO|PET/CT will be performed; Non-contrast CT images will be acquired over the adrenals (slice width, \~3 mm). CETO (\~2.5 MBq/kg; up to 365 MBq +/- 20%) will be administered as a single dose intravenously and dynamic PET images will be acquired from \~0-90 minutes.
40779855|NCT04581811|OTHER|Prolonged Proned Positioning|Patients will be placed in the prone position for 24 hours followed by 8 hours supine for consecutive periods for the duration of the study period
40779856|NCT04581811|OTHER|Traditional Proning Arm|Patients will be placed in the prone position for 16 hours followed by 8 hours supine for consecutive periods for the duration of the study period
41463353|NCT03941795|BIOLOGICAL|JS001(Toripalimab Injection)|"Test Group:~Toripalimab (240 mg, IV, Q3W) + axitinib (5 mg/tablet, one tablet, twice a day, orally); axitinib is started on the second day of administration of toripalimab until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of toripalimab use of no more than 2 years."
40984377|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
40984378|NCT01529346|DRUG|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
41143945|NCT01634295|DRUG|CKD-828 2.5/40mg|"* Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."
41143946|NCT01634295|DRUG|CKD-828 5/40mg|"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."
41304352|NCT02256865|DRUG|Testosterone|Testosterone gel is applied once a day
40984379|NCT01529346|OTHER|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
41143947|NCT01634295|DRUG|CKD-828 5/80mg|"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~* With the others investigation product placebo 4 tabs QD 6 weeks."
41304353|NCT02256865|DRUG|Placebo for ketoconazole|Placebo for ketoconazole
41463354|NCT03941795|DRUG|Axitinib 1 MG [Inlyta]|Axitinib (5 mg/tablet) one tablet, twice a day, orally until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death
40984380|NCT01529346|OTHER|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
40984381|NCT01529346|OTHER|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
41143948|NCT01634295|DRUG|S-amlodipine 2.5mg|"* S-amlodipine 2.5mg QD 4 weeks~* With the others investigation product placebo 4 tabs QD 4 weeks."
41304354|NCT02256865|DRUG|Placebo for hydrocortisone|Placebo for hydrocortisone
40984382|NCT00602147|OTHER|laboratory biomarker analysis|Blood or cheek cells wil be collected.
40984383|NCT00244946|BIOLOGICAL|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
41143949|NCT01634295|DRUG|S-amlodipine 5mg|"* S-amlodipine 2.5mg QD 6weeks~* With the others investigation product placebo 4 tabs QD 6 weeks."
41143950|NCT00447356|DRUG|recombinant interferon alfa|
40984384|NCT00244946|DRUG|carmustine|
40984385|NCT00244946|DRUG|cytarabine|
40984386|NCT00244946|DRUG|etoposide|
40984387|NCT00244946|DRUG|melphalan|
40984388|NCT00244946|PROCEDURE|peripheral blood stem cell transplantation (PBSCT)|
41143951|NCT03401099|PROCEDURE|Radiofrequency ablation of CTI|Delivery of radiofrequency energy to the cavotricuspid isthmus (region of right atrial tissue between the tricuspid annulus and the inferior vena cava) until bidirectional block is achieved
41143952|NCT03401099|PROCEDURE|Cryoballoon PVI|Cryoballoon application to the pulmonary veins aiming for Pulmonary Vein Isolation
40779857|NCT01567722|GENETIC|DNA analysis|This sample will be used for germline DNA analysis.
40779858|NCT01567722|GENETIC|RNA analysis|RNA will be sheared, reverse transcribed, and sequenced to assess transcribed sequences.
40779859|NCT01567722|GENETIC|gene expression analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
40779860|NCT01567722|GENETIC|polymorphism analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
40779861|NCT01567722|OTHER|biologic sample preservation procedure|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
40779862|NCT01567722|OTHER|flow cytometry|Information will include HIV RNA load at time of malignancy diagnosis) and imaging tests, results of the diagnostic tumor biopsy and bone marrow biopsy, and results of flow cytometry, cytogenetics, and molecular studies.
40779863|NCT01567722|OTHER|medical chart review|Participants will be followed prospectively to record the types of treatment given, and treatment outcome and toxicity.
40779864|NCT00710593|BIOLOGICAL|HPV vaccine for strains -6, -11, -16, and -18|All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
40779865|NCT04968483|OTHER|Data collection|The general data, data of postoperative complications, data of nutritional assessment and nutritional support will be collected.
40779866|NCT04490798|PROCEDURE|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat the different painful syndromes. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation.
40779867|NCT01589614|DRUG|PH-797804|Tablet, 6mg, single
40779868|NCT01589614|DRUG|PH-797804 + erythromycin|PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
41304355|NCT02256865|DRUG|Placebo for testosterone|Placebo for testosterone
41304356|NCT01679080|DRUG|Zoledronic acid|antiresorptive and calcium and vitamin D
41304357|NCT01679080|DRUG|Teriparatide|anabolic and calcium and vitamin D
41304358|NCT01679080|OTHER|No active treatment|Calcium and vitamin D
41304359|NCT03297307|BEHAVIORAL|Presurgical Counseling|Children will attend the presurgical counseling visits with their mother
41304360|NCT05522335|BIOLOGICAL|BBV154(Intranasal) & covaxin|Intervention Covaxin
41304361|NCT03716232|DEVICE|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~- Stent will be extracted endoscopically after 6 months."
41304362|NCT03716232|DEVICE|Multiple plastic stents|"Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
41304363|NCT02897973|OTHER|Activity of daily living|walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
41304364|NCT03555903|OTHER|Endometriosis cohort|"The investigator record data on risks factors, symptoms (pain), quality of life (using standardized quality of life questionnaires), infertility history, and management of the disease with a 5-years follow up.~Different surgical procedures exist to treat DIE and are they are described in the database, to allow comparison."
41304365|NCT03218254|DRUG|Methylphenidate|Titration of MTP for treatment of fatigue
41304366|NCT03218254|DRUG|Placebo|Placebo
41304367|NCT02076256|BEHAVIORAL|The helping relationships intervention program|
41304368|NCT05768620|OTHER|CAVE|The training is designed to train spatial navigation and memory and in particular egocentric and allocentric processes
41304369|NCT05768620|OTHER|TAU|This is the usual care used to train visuospatial processes
41304370|NCT01115569|DRUG|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
41304371|NCT03141086|DRUG|LML134|LML134
41304372|NCT03141086|DRUG|Placebo|placebo
40779869|NCT04117633|DEVICE|Laparoscopy|Laparoscopic Procedures for Rectopexy
40779870|NCT04778202|DIAGNOSTIC_TEST|blood sample collection|blood sample collection by venipuncture four both groups and MRI for breast cancr patient group
40779871|NCT02434861|DRUG|Rolapitant|
40779872|NCT02434861|DRUG|Digoxin|P-gp substrate
40779873|NCT02434861|DRUG|Sulfasalazine|BCRP substrate
40779874|NCT02434861|DRUG|Cooperstown Cocktail|Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
40779875|NCT00127439|PROCEDURE|Manually Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
40779876|NCT00127439|OTHER|Robotic Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
40779877|NCT03563547|BEHAVIORAL|Dietary counseling (fat modifed diet)|Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
40779878|NCT03563547|BEHAVIORAL|Dietary Counseling (fat modified + soy enriched diet)|"Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
40779879|NCT04684589|DRUG|Tadalafil 20 MG|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
40779880|NCT04684589|DRUG|Placebo|Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
40779881|NCT05018364|DIAGNOSTIC_TEST|Serum erythropoietin level|Evaluate serum erythropoietin level in neonates exposed to hypoxia compared to control group
40779882|NCT01912235|OTHER|2-15N glutamine|Glutamine with N15 isotope tracer
40779883|NCT01912235|OTHER|15N2 arginine and 15N proline|Arginine and Proline isotope tracers
41143953|NCT04724252|DRUG|Gabapentin|Determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after surgery.
41463355|NCT03941795|OTHER|JS001 and Axitinib|"Control Group:~Toripalimab (240 mg, IV, Q3W) is administered on the first day until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of no more than 2 years"
41463356|NCT02870439|OTHER|Blood drawn|
41463357|NCT01261624|DRUG|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
41463358|NCT01015417|DRUG|Amoxicillin clavulanic acid|Postoperative administration of 2g, 3 times daily, since 5 days, of amoxicillin clavulanic acid (Augmentin or generic) oral form or parenteral form according to clinical patient and by the choice of medical teams
41463359|NCT01015417|OTHER|No medication|no postoperative antibiotics
41463360|NCT00578838|OTHER|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
41463361|NCT00578838|OTHER|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
40779884|NCT01912235|OTHER|1-13C glutamine|Glutamine carbon isotope tracer
40779885|NCT01663792|OTHER|Seaweed|Ten 500-mg capsules to be taken orally each day for 1 month
40779886|NCT01663792|OTHER|Placebo|Ten 500-mg capsules to be taken orally each day for 1 month
40779887|NCT01663792|OTHER|Placebo2|Ten 500-mg capsules to be taken orally each day for 1 month
40779888|NCT03719014|DEVICE|NovaCross|The NovaCross micro-catheter will be used during a standard of care Percutanous Coronary Intervention (PCI) on subjects diagnosed with at least one coronary chronic total occlusion (CTO), in order to assist the operator in guidewire stability and centralization.
40779889|NCT03789708|DIETARY_SUPPLEMENT|Gum Arabic|Instantly soluble granules of Gum Arabic; 100% Acacia Senegal
40779890|NCT03789708|OTHER|Placebo|Maltodextrin powder, easily soluble
40984389|NCT03791476|DRUG|rhC1INH|C1 esterase inhibitor
40984390|NCT03791476|OTHER|Saline Solution|saline solution
40984391|NCT03590145|DIAGNOSTIC_TEST|Clinical examination|Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
40779891|NCT06486883|DRUG|Trastuzumab deruxtecan (T-DXd, DS-8201a)|Patients will receive T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on Day 1 (D1) of each 21-day cycle. The initial dose will be administered as a 90-minute IV infusion.
40779892|NCT06486883|DRUG|CDK4/6i plus ET|Patients will receive physician's choice of CDK4/6 inhibitor (CDK4/6i) including palbociclib, ribociclib, and abemaciclib; physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane.
40779893|NCT01985230|DEVICE|ReActiv8 Implantable Stimulation System implanted and activated.|
40779894|NCT04052009|OTHER|Conventional gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
40779895|NCT04052009|OTHER|End-effector based gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
40779896|NCT04052009|OTHER|combined training (conventional and end-effector-based)|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
40779897|NCT02150707|DRUG|Dipeptidyl-Peptidase IV Inhibitors|Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
40984392|NCT00010075|DRUG|fluorouracil|
40984393|NCT00010075|DRUG|leucovorin calcium|
40984394|NCT00010075|DRUG|mitoxantrone hydrochloride|
40984395|NCT03394807|DRUG|Levobupivacaine|Levobupivacaine injection to Transversus abdominis plane and rectus sheath
40984396|NCT03394807|DRUG|Placebo|Saline injection to Transversus abdominis plane and rectus sheath
40984397|NCT03586856|DEVICE|Nasal mask interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
40984398|NCT03586856|DEVICE|Nasal prongs interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
40984399|NCT01575665|DEVICE|Partial Rebreathing Mask|Inducing normal CO2 for two hours a day for four weeks
41463362|NCT01275716|BEHAVIORAL|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications|Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
41463363|NCT03394833|OTHER|gelofusine|Preoperative colloid fluid bolus 6ml/kg ideal body weight
40984400|NCT06141590|DRUG|administration of UI068|Test
41463364|NCT05595122|DEVICE|EUS-CDS|EUS-CDS with FCSEMS through LAMS
41463365|NCT05002777|DRUG|rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
40779898|NCT02150707|DRUG|Glucagon-Like Peptide 1|Glucagon-Like Peptide 1 to treat hyperglycaemia
41463366|NCT02507817|OTHER|blood sample and tissue sample|"Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein"
40779899|NCT05994430|OTHER|End-of-life care awareness training in intensive care|End-of-life care awareness training in intensive care
40779900|NCT01564342|PROCEDURE|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
40779901|NCT02834455|DEVICE|Contrast-enhanced CT|50% of patients with unilateral pleural effusion will have performed a CE-CT
40779902|NCT02834455|DEVICE|PET-CT|50% of patients with unilateral pleural effusion will have performed a PET-CT
40779903|NCT00465673|DRUG|Liposomal Doxorubicin|40mg/m2 over 1 hour infusion for 21 days
40984401|NCT06141590|DRUG|administration of UIC202205, UIC202206|Reference
40984402|NCT04028596|DRUG|Paracetamol|once, 1000mg, 2 h before ECT session
40984403|NCT04028596|DRUG|Nimotop|once, 60mg, 2 h before ECT session
40779904|NCT03058133|OTHER|fMRI study|Functional brain activations of face-voice processing during a gender task
41143954|NCT04724252|OTHER|Placebo|Control Arm
41143955|NCT00455104|OTHER|No intervention|This is an observational, voluntary registry.
41143956|NCT06224244|RADIATION|Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 40 Gy
40984404|NCT00723892|BIOLOGICAL|Peginterferon alfa-2b (PegIntron)|Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg\^kg\^week
40984405|NCT00723892|DRUG|Rebetol (Ribavirin)|Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day
40984406|NCT00723892|BEHAVIORAL|Psychotherapy support program|Each site has implemented a psychotherapy support program.
40984407|NCT06137404|OTHER|Splint|Comparison of splints for trigger finger
40984408|NCT01074866|DEVICE|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally adjusted Ventilatory Assist
40984409|NCT03884218|OTHER|Infra red thermal imaging|thermal image using a non-touch, non-ionising, thermal camera system
41143957|NCT06224244|RADIATION|Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 43 Gy
41143958|NCT06277206|DIAGNOSTIC_TEST|18F-FAPI PET/CT|Enrolled patients underwent 18F-FAPI PET/CT at diagnosis. And preoperative 18F-FAPI PET/CT was completed in the patients met the criteria for conversion surgery after systemic treatment. The correlation between changes of parameters before and after treatment and pathologic response was analyzed.
41143959|NCT02053714|BEHAVIORAL|Diabetes self-management and education|
41143960|NCT00848952|OTHER|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
41143961|NCT02569294|BEHAVIORAL|Yoga intervention|Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.
41463367|NCT00465660|BEHAVIORAL|Progressive resistance training|
41463368|NCT00075686|BIOLOGICAL|cetuximab|Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles
41463369|NCT00075686|DRUG|gemcitabine hydrochloride|1000mg/m2 IV over 30 minutes
41463370|NCT06396637|DRUG|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride: 20mg/kg, qd
41463371|NCT05343273|DIAGNOSTIC_TEST|taking a blood sample|blood collection for routine biochemical analysis
41463372|NCT00461669|PROCEDURE|ultrasound examination of the hip|
41463373|NCT05531617|PROCEDURE|Intubation|Study groups Intubated with Macintosh or cmac video laryngoscopes
41463374|NCT00139932|DRUG|formoterol fumarate|
41463375|NCT02720549|PROCEDURE|remote ischemic postconditioning|Remote ischemic postconditioning post group will take a remote ischemic postconditioning with tourniquet in their lower extremity under thigh. The conditioning is 5 minutes of inflation, and 5 minutes of deflation, repeated 3 cycles.
41463376|NCT02720549|PROCEDURE|valvular surgery with bypass|valvular surgery with bypass
41463377|NCT00200317|BEHAVIORAL|Internet and print-based interventions|
40984410|NCT02902185|DRUG|ART plus Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
40984411|NCT02902185|DRUG|ART plus Placebo|Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
41304373|NCT03933917|PROCEDURE|Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
41304374|NCT05116540|BIOLOGICAL|HB-adMSCs|Autologous product
41304375|NCT05116540|DRUG|Placebo|Normal Saline
41463378|NCT05483270|BIOLOGICAL|the timing of embryo transfer in freeze-all cycles|"Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval."
40984412|NCT04667663|DRUG|Daratumumab|Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.
41304376|NCT00465153|DIETARY_SUPPLEMENT|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
41304377|NCT00465153|BEHAVIORAL|Resistance exercise training|Resistance training
41304378|NCT03572439|DIAGNOSTIC_TEST|Sensory block level check using ice|Patients are asked to report when the ice feels as cold as it does on the forehead.
41304379|NCT00003648|GENETIC|DNA stability analysis|
41304380|NCT00003648|GENETIC|gene rearrangement analysis|
41304381|NCT02856581|DRUG|Varenicline|Given PO
41304382|NCT02856581|DRUG|Placebo|Given PO
41304383|NCT02856581|OTHER|Tobacco Cessation Counseling|Complete counseling session
41463379|NCT04415047|DEVICE|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
41463380|NCT00792441|DEVICE|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
41463381|NCT05127135|BIOLOGICAL|ThisCART7 cells|0.5-6 x 10\^6 CAR T cells per kg body weight
41463382|NCT04245358|DEVICE|Ainara|1g of gel per administration
41463383|NCT05554965|DRUG|Propofol|Remifentanil maintenance analgesic dose was 1.2-9 μg/kg/h. If the CPOT score ≥3 at the time of maintenance administration, dose adjustment can be considered. Propofol was used for sedation at a loading dose of 0.5mg/kg and a maintenance dose of 1.5mg/kg/h.
40779905|NCT06513507|DIETARY_SUPPLEMENT|Cannabigerol (CBG)|The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
40779906|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
41143962|NCT02569294|BEHAVIORAL|Hypnosis intervention|Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.
41304384|NCT00174707|DRUG|epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
40779907|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
40779908|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
40779909|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
40779910|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
40779911|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
40779912|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
40779913|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
40779914|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
40984413|NCT04667663|DRUG|Cyclophosphamide|Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
40984414|NCT04667663|DRUG|Pomalidomide|Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.
41304385|NCT00174707|DRUG|epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
41304386|NCT00174707|DRUG|epidoxorubicine, docetaxel, cyclophosphamide|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
41304387|NCT03235544|DRUG|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food.
40984415|NCT04667663|DRUG|Dexamethasone|Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.
41304388|NCT02848300|DRUG|Bimatoprost 1% Formulation A|Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
41304389|NCT02848300|DRUG|Bimatoprost 1% Formulation B|Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
41304390|NCT01675011|DEVICE|Embozene® Microspheres|
41304391|NCT01675011|DEVICE|Embosphere®|
41304392|NCT06553196|BEHAVIORAL|MATAspire Web-app|Substance misuse prevention education and adaptive coping skills
41304393|NCT03862690|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
40984416|NCT03053414|DIETARY_SUPPLEMENT|Vitamin D (ergocalciferol and/ or cholecalciferol)|To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
40984417|NCT03654950|OTHER|No intervention|Interviews and questionnaires
40984418|NCT04379089|OTHER|Observational study only|No Intervention
41304394|NCT05160077|DIAGNOSTIC_TEST|Multispectral optoacoustic tomography (MSOT)|MSOT Acuity Echo, iThera medical, Munich
41463384|NCT05554965|DRUG|Remimazolam besylate|Remifentanil was administered at a maintenance dose of 1.2-9 μg/kg/h for analgesia. If CPOT score ≥3 during maintenance administration, dose adjustment could be considered. For sedation, remazolam besylate was given a load of 0.1-0.2mg/kg and a maintenance dose of 0.1-0.3mg/kg/h.
41304395|NCT05162950|DIAGNOSTIC_TEST|physical exercise as a standardized high intensity exercise test|High intensity exercise test, cycling, performed at the Karolinska University Hospital
41304396|NCT05162950|BEHAVIORAL|Stress vulnerability|Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire
40779915|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
41304397|NCT03651193|DIAGNOSTIC_TEST|Exon sequencing and Methylated sequencing|Exon sequencing and Methylated sequencing
40984419|NCT03866343|OTHER|Diet low or high in advanced glycation endproducts|All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.
40984420|NCT02087527|DRUG|Dexamethasone|IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours
41463385|NCT02676960|OTHER|MRI without sedation|
40779916|NCT01499537|DEVICE|biliary drainage|percutaneous transhepatic biliary drainage (PTBD)
40779917|NCT01499537|DEVICE|EUS guided biliary drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
40779918|NCT02576626|DRUG|indacaterol/glycopyrronium 110/50 Breezhaler®|
40984421|NCT02087527|DRUG|Normal Saline|IV normal saline every 6 hours for 48 hours
40984422|NCT02386904|DRUG|Phosphate Enema (Kleen® Enema)|120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
40984423|NCT00362908|BEHAVIORAL|Moderate Fat and Moderate Carbohydrate Diet|40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
40984424|NCT00362908|BEHAVIORAL|Low Fat and High Carbohydrate Diet|20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
40984425|NCT02350881|DEVICE|Primus FGTI (Flexible Great toe Implant)|Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.
40984426|NCT01472081|BIOLOGICAL|Nivolumab|
40984427|NCT01472081|BIOLOGICAL|Pazopanib|
41143963|NCT02569294|BEHAVIORAL|CBT intervention|CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
41143964|NCT04476524|OTHER|Quality improvement|All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.
41143965|NCT03410680|BEHAVIORAL|FUERTES|The intervention focuses on antiretroviral therapy habit-formation among MSM living with HIV
41143966|NCT03917186|DRUG|Sevoflurane|administration of sevoflurane
40779919|NCT02576626|DEVICE|Placebo by Breezhaler®|
40779920|NCT02576626|DRUG|ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation|
41143967|NCT03917186|DRUG|Desflurane|administration of Desflurane
41143968|NCT01754363|DEVICE|Attune Primary Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
41143969|NCT06411054|DEVICE|Acu-TENS|After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 4-12mA, and pulse width of 300µS will be delivered continually for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed).
41143970|NCT06411054|DEVICE|Sham acu-TENS|"After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair.~In the sham acu-TENS, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current. The pads will be stuck on the acupoints for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed)."
40984428|NCT01472081|DRUG|Sunitinib|
40984429|NCT01472081|BIOLOGICAL|Ipilimumab|
40984430|NCT01214161|DRUG|2% lidocaine gel|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
40984431|NCT01214161|OTHER|placebo|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control/placebo group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
40984432|NCT04018833|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|
40984433|NCT04018833|DRUG|Aflibercept 40 MG/ML Intraocular Solution [EYLEA]|
40984434|NCT06271941|PROCEDURE|Hybrid Argon Plasma Coagulation (h-APC)|The hybrid argon plasma coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows for the lifting of dysplastic epithelium, creating a cushion under the mucosa to facilitate the ablation of larger areas more thoroughly and with higher energy settings, while posing a low risk for side effects or complications.
40779921|NCT02576626|DEVICE|Placebo by nebulisation|
40779922|NCT01523938|BEHAVIORAL|Hypnotherapy|Pre- (one session) and postoperative (two sessions) Hypnotherapy
40779923|NCT05407701|DIETARY_SUPPLEMENT|Cranberry Juice|100% cranberry juice
40779924|NCT05407701|DIETARY_SUPPLEMENT|Placebo|Placebo juice
40779925|NCT04088903|DRUG|Daratumumab|\>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
40984435|NCT06271941|PROCEDURE|Snare tip soft coagulation (STSC)|The Snare tip soft coagulation (STSC) involves using a snare to remove polyps, while simultaneously applying soft coagulation to the surrounding tissue using a specialized tip on the snare.
40984436|NCT06323889|BEHAVIORAL|Modified Alternate Day Fasting|Participants are instructed to fast every other day.
40984437|NCT06323889|BEHAVIORAL|Time-Restricted Eating|Participants are instructed to limit food intake to two main meals consumed in maximum 8 hours per day
40984438|NCT06323889|BEHAVIORAL|Weight-loss counseling|Participants will receive nutrition counseling to structure their main meals according to the plate model for weight-loss and to reduce number of consumed plates.
40984439|NCT03988192|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
40984440|NCT04656145|DEVICE|3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing|On the day of the operation, after the procedure has concluded and the drains have been placed, the surgical drain site that has been randomized to be in the experimental group will receive the chlorhexidine gel dressing. The dressing will remain on the patient until the drain has been removed and the surgical site will be assessed for signs of infection.
40984441|NCT05612633|DRUG|zelavespib|Oral zelavespib 100 mg will be administered once daily
40984442|NCT00179400|DRUG|Pioglitazone 45 mg|
41143971|NCT04214093|DRUG|AZD0466|"In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort."
41143972|NCT01064778|OTHER|Low GI|Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
41143973|NCT01064778|OTHER|High GI|Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
41143974|NCT04516980|OTHER|Questionnaires administration|"Administration of Identification of Functional Ankle Instability (IdFAI) and the following assessment scales: Self-reported question assess the ankle instability as functional/stable or not functional/unstable, Foot and Ankle ability Measure Italian Version - Activity Daily Living (FAAM-I/ADL), Short-form 36-item Health Survey Italian Version (SF-36), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (VAS ankle instability).~After a week the participants will fill in the following questionnaires: Identification of Functional Ankle Instability (IdFAI), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (Vas ankle instability) with the additional question to measure the change in complaints."
41143975|NCT04693013|DEVICE|Virtual Reality for Anxiety Reduction|Virtual Reality for Anxiety Reduction during suturing of perineum
41143976|NCT03466645|DRUG|Vancomycin|The 1st group receives vancomycin an hour before craniotomy
41143977|NCT03466645|DRUG|Cefazolin|The 2nd group receives cefazolin an hour before craniotomy
41143978|NCT05055804|DEVICE|ELG|"The effectiveness of ELG to standardized blood test methods (fingerstick) and comparison to AlcNOW + (or equivalence) and of laboratory test results.~Human subject requirements during ELG study will not challenge diabetics or non-diabetics glycemic event. For example, diabetes type 1, the subject will not have to adjust their insulin or glucose. For type 2 diabetes, the subject will not have to adjust their oral hypoglycemic agent or glucose, as well."
41143979|NCT03571100|DRUG|Chlorhexidine|Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
41143980|NCT03571100|DRUG|Povidine-Iodine|Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
41143981|NCT04931498|OTHER|Questionnaire|Medical history, demographics and lifestyle factors will be assessed by the participant.
41463386|NCT06401941|PROCEDURE|Hyperbaric Oxygen Therapy|HBO session includes three 20-minute inhalations of pure oxygen in a hyperbaric chamber utilizing specially fitted face masks for each patient. The session is conducted as follows: 10 minutes compression of up to 2.5 atm (0.25 MPa), inhalation of 100% oxygen for 20 minutes, a 5-minute break in the chamber without the mask (oxygen concentration up to 23%, constant temperature (room) and humidity), again 20 minutes inhalation of 100% oxygen, another 5-minute break (the same condition), the last 20 minutes inhalation of 100% oxygen, and finally a 10-minute decompression. The total duration of the session was 90 minutes.
41463387|NCT05622994|DRUG|Rimonabant|Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
41463388|NCT01805635|OTHER|No intervention|No intervention
40984443|NCT00179400|DRUG|Placebo|
40984444|NCT05131074|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
40984445|NCT05131074|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
40984446|NCT02854735|OTHER|Imaging by CT and densitometry|Imaging by CT and densitometry, no intervention involved
41304398|NCT04118686|OTHER|CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)|CT program with Computerized cognitive training (CoRe) plus stimulation that modulates cortical activities by delivering strong magnetic pulses to the cortex through the scalp (rTMS) and weak electrical currents to the scalp to modulate neuronal transmembrane potential towards hyperpolarization or depolarization (tDCS).
41304399|NCT04118686|OTHER|CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)|CT program with Computerized cognitive training (CoRe) plus sham stimulation
41304400|NCT02912000|BEHAVIORAL|TEACH intervention|The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
41304401|NCT05884411|DEVICE|Left bundle branch area pacing|A cardiac pacing electrode is inserted into the left bundle branch area of the myocardium via a transvenous approach.
41304402|NCT05884411|DIAGNOSTIC_TEST|Cardiac MRI|A diagnostic imaging test using magnetic resonance imaging to evaluate cardiac function.
41304403|NCT00935142|DRUG|[18F]VM4-037|Bolus IV injection of \[18F\]VM4-037
41304404|NCT05874401|DRUG|Trilaciclib|Participants will receive intravenous trilaciclib infusion
41304405|NCT05874401|DRUG|Placebo|Participants will receive intravenous placebo infusion
41304406|NCT05874401|DRUG|Topotecan|Participants will receive intravenous topotecan infusion
41463389|NCT00277043|DRUG|paclitaxel, docetaxel, taxane|1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.
41463390|NCT00277043|DRUG|taxane|The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
41463391|NCT04000945|DEVICE|BTL-899|Treatment with BTL-899 device, 3 therapies
41463392|NCT04000945|DEVICE|Sham|Sham treatment with BTL-899 device, 3 visits
41463393|NCT02191124|DRUG|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
41463394|NCT02191124|DRUG|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
41463395|NCT00948909|DRUG|Placebo|Placebo intervention
41463396|NCT00948909|DRUG|ABT-126|Experimental intervention
41463397|NCT00948909|DRUG|donepezil|Active comparator intervention
41143982|NCT04931498|OTHER|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
41143983|NCT04931498|OTHER|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
41143984|NCT04931498|PROCEDURE|Venepuncture (GMPR)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key erythroid markers~* Proteomic analysis of isolated erythrocytes using mass spectrometry"
41143985|NCT04931498|PROCEDURE|Venepuncture (SWAP70)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key markers~* Fluorescence-Activated Cell Sorting (FACS) to assess B-cell receptor signalling and to isolate cell type-specific RNA for transcriptome analysis~* Immunoglobulin isotype titre analysis in plasma~* Isolation of monocytes for subsequent use in phagocytosis assays"
41143986|NCT02935673|DRUG|lumicitabine|Oral administration of lumicitabine as tablet.
41143987|NCT02935673|DRUG|Placebo|Oral administration of matching placebo.
41143988|NCT06311292|DEVICE|Volara System|Intrapulmonary percussive ventilation for mobilizing mucus.
41143989|NCT03800771|DEVICE|Cycléo BRAU|Practice dual-task tests.
41143990|NCT03800771|DEVICE|GAITRITE®|Routine practice dual-task tests.
41304407|NCT00366730|DRUG|Nitazoxanide|
41304408|NCT04898907|DRUG|ANG-3777 (Therapeutic Dose)|Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted
41304409|NCT04898907|DRUG|ANG-3777 (Supra-therapeutic Dose)|Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted
41304410|NCT04898907|DRUG|Placebo|Arms assigned to this intervention will receive normal saline, IV, Fasted
41304411|NCT04898907|DRUG|Moxifloxacin Hydrochloride|Arms assigned to this intervention will receive 400 mg, Oral, Fasted
41143991|NCT05978089|DRUG|Yangxinshi tablet|The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.
41143992|NCT05978089|DRUG|Yangxinshi tablet simulants|The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
41143993|NCT02268253|DRUG|SL-401|
41143994|NCT01420328|DRUG|Vytorin|Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks
41304412|NCT01839292|DEVICE|uncovered D-type stent insertion|
41304413|NCT01839292|DEVICE|double-layered ComVi stent insertion|
41304414|NCT01386710|DRUG|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
41463398|NCT05959616|BIOLOGICAL|Shigella sonnei 53G|Lyophilized S. sonnei 53G strain (Lot 1794)
41463399|NCT05959616|DRUG|Ciprofloxacin 500 mg|Ciprofloxacin (500 mg orally twice daily for three days),
41463400|NCT02518607|DRUG|MGB-BP-3|Treatment of CDI
41463401|NCT02518607|OTHER|Placebo|Placebo
41463402|NCT04975451|DRUG|Anlotinib|Anlotinib plus DCb
40984447|NCT03451344|OTHER|Integrated rehabilitation group|Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
40984448|NCT03451344|OTHER|Community-based rehabilitation group|Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
40984449|NCT00001889|PROCEDURE|Myocardial contrast echocardiography|
40984450|NCT00001889|PROCEDURE|Stress echocardiography with dobutamine|
40984451|NCT06177652|OTHER|Paravertebral Block|Ultrasound (US) -guided paravertebral block (PVB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the PVB group.
40984452|NCT06177652|OTHER|Serratus Plane Block|Ultrasound (US) -guided serratus plane block (SPB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the SPB group.
40984453|NCT05092685|GENETIC|AAVLK03hOTC|Peripheral intravenous infusion of AAVLK03hOTC.
40984454|NCT01248377|PROCEDURE|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
40984455|NCT06542120|DIAGNOSTIC_TEST|Heart Auscultation and Echocardiography|Heart auscultation will be done by pediatrician and echocardiography by echocardiologist
40984456|NCT06542120|DIAGNOSTIC_TEST|Chest Auscultation and Chest imaging examinations|Chest auscultation will be done by pediatrician and chest imaging examinations by radiologist
40984457|NCT06542120|DIAGNOSTIC_TEST|Abdominal Auscultation and Abdominal imaging examinations|Abdominal auscultation will be done by pediatrician and chest imaging examinations by radiologist
40984458|NCT05235074|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
40984459|NCT05366803|BEHAVIORAL|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
40984460|NCT04521075|BIOLOGICAL|Fecal Microbial Transplantation by capsules|"Cohorts A and B - Patients will receive 30 oral capsules per administration for two consecutive days (Days 1-2) Cohort C - Patients will receive FMT via colonscopy (Day 1), followed the day after by adnistration of 12 oral capsules (Day 2)~Combination cycles: 6 combined cycles Q2W of FMT maintenance followed by treatment with anti-PD1. Anti-PD-1 will be administered at least one day and up to 3 days after the FMT.~Maintenance of FMT by oral capsules: 12 capsules per administration. Anti PD-1 therapy: A dose of 240 mg Nivolumab will be administrated by intravenous infusion."
40984461|NCT06124612|DIAGNOSTIC_TEST|Thrombotic assessment|"GTT~The Global Thrombosis Test (GTT) (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~TEG Thromboelastography (TEG, Haemonetics Corporation, USA) is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Citrated plasma will be stored for subsequent evaluation of thrombosis and fibrinolysis markers (including but not restricted to D-dimer, PAI-1, hs-CRP, NETs)"
40984462|NCT01750099|PROCEDURE|Combined Spinal-epidural|See arm description
40984463|NCT01750099|PROCEDURE|Continuous Lumbar epidural|See arm description
41304415|NCT01386710|DRUG|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment~If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle"
41304416|NCT03196505|DRUG|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
41304417|NCT03196505|DRUG|Bupivacaine|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
41304418|NCT05828238|DRUG|[18F]SF-DEVD-2|Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2
41143995|NCT01420328|DRUG|Placebo|Placebo treatment for 6 weeks
41143996|NCT06280599|BEHAVIORAL|Transitional care model|In-hospital assessments, video-based stroke education, home visits, and weekly telephone follow-up
41143997|NCT00257894|DRUG|Baclofen|Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).
41143998|NCT00257894|DRUG|Placebo|Matched placebo capsules containing inert filler taken orally for a total of 12 days
41143999|NCT06201000|DRUG|SGLT2 inhibitors (Dapagliflozin and Empagliflozin)|10 mg of dapagliflozin or empagliflozin
41144000|NCT01079104|DEVICE|Hepa Wash|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
41144001|NCT01079104|PROCEDURE|Standard Medical Therapy|Standard of care treatment
41304419|NCT05828238|DRUG|[18F]-FDG|Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG
41304420|NCT03834129|DRUG|Dexmedetomidine|Two administrations, before anesthesia and during surgery, by intravenous infusion of dexmedetomidine 1 μg/kg in 250 ml of physiological serum for 30 minutes
40779926|NCT06118658|DRUG|tislelizumab|About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
40779927|NCT00854360|DRUG|Beclomethasone dipropionate HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
40779928|NCT00854360|DRUG|Placebo|HFA Vehicle Aerosol
40779929|NCT04767711|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri with cholecalciferol compared to cholecalciferol only.
40779930|NCT04767711|DRUG|Prednisolone|Oral glucocorticoid 25 mg daily for 7 days.
40779931|NCT06100757|DEVICE|Micra Transcatheter Pacing System (TPS°|Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months
40779932|NCT06100757|DEVICE|Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR|Implantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months
40779933|NCT04594746|DRUG|Amiodarone Hydrochloride|Amiodarone hydrochloride 2000 mg PO to be given as a 10-capsule dose pack and ingested in a single sitting with food
40779934|NCT04594746|DRUG|Placebo|Oral placebo to be given as a 10-capsule dose pack and ingested in a single sitting with food
40779935|NCT06410521|BEHAVIORAL|Exercise|Patients randomised to the intervention arm will undergo non-consecutive training sessions three times a week for a period of 12 weeks. The training session is divided into an aerobic and a resistance training component, with a 5-min warm-up (stretching exercises) and a 5-min cool-down (stretching and relaxing exercises). The cardiovascular component will comprise a progressive exercise duration from 30 to 40 minutes, an exercise intensity promoting moderate to severe claudication pain between 5-10 minutes, with rest time until the pain disappears, and a personalised load progression manipulated based on the claudication pain level, reaching a total of 50 minutes of walking per session. The resistance training component will comprise dynamic muscle contraction exercises (shoulders width squat, unilateral chair leg extension, and bilateral plantar flexion), with a load progression gradually increasing from one set of 10 repetitions to three sets of 15 repetitions.
40984464|NCT03945487|BIOLOGICAL|umbilical cord-derived mesenchymal stem cell|Taken a dose of 1.0\*10E6 UC-MSC/kg body weight intravenously three times at 3-week intervals, in addition to comprehensive treatment.
40984465|NCT03945487|OTHER|Comprehensive treatment|"1. All patients received anti-HBV treatment with NAs (entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)).~2. Strategies based on targeting abnormalities in gut-liver axis by antibiotic administration (i.e. rifaximin), improving the disturbed systemic circulatory function (i.e. longterm albumin administration), decreasing the inflammatory state (i.e. statins), and reducing portal hypertension (i.e. beta-blockers)."
41304421|NCT03834129|DRUG|sodium chloride 0.9%|Two administrations, before anesthesia and during surgery, by intravenous infusion of 250 ml of physiological serum for 30 minutes
41304422|NCT01333982|OTHER|Amoxycillin, Gentamicin|If referral fails, community management of neonatal sepsis according to clinical algorithm.
41304423|NCT01333982|OTHER|Counselling|counselling of management of neonatal sepsis in the community according to clinical algorithm.
41304424|NCT06439901|OTHER|Screening|A first step to identify and recruit people eligible for screening,
41304425|NCT06439901|OTHER|Inclusion|A second step for inclusion of participants, with an online self-questionnaire and information, and an inclusion visit to the health center,
41463403|NCT04383717|DRUG|Levamisole and isoprinosine|oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks
40984466|NCT04367688|DRUG|Tenofovir Disoproxil Fumarate 300 mg / emtricitabine 200 mg|daily use for PrEP
40984467|NCT02834208|OTHER|MRI (Magnetic resonance imaging)|
40984468|NCT02834208|GENETIC|Polymorphism (SNP in DNA)|
40984469|NCT02834208|GENETIC|quantitative measures of mRNA|
40984470|NCT02834208|OTHER|Neuropsychological assessment|
40984471|NCT01432860|BEHAVIORAL|In-person counseling|The design is a 3 \[in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care\] X 7 \[baseline, 4, 8, 12, 16, 20, and 24 month follow-up\] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
40984472|NCT01432860|BEHAVIORAL|Workbook|Participants will read a workbook and perform skills training exercises.
40984473|NCT01432860|BEHAVIORAL|Tablet Computer-Based Education|Participants will receive their education from an interactive app designed for a tablet computer.
40984474|NCT00166088|DIETARY_SUPPLEMENT|Mediterranean Diet|The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
40984475|NCT00166088|DIETARY_SUPPLEMENT|Mediterranean Dietary Supplement|The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
40984476|NCT02792556|DEVICE|Urine pregnancy test|Urine pregnancy test Check Top after transvaginal ultrasound
40984477|NCT02922608|OTHER|simulation practice|simulation session
40984478|NCT00094627|DRUG|gaboxadol|Duration of Treatment - 6 weeks
40984479|NCT00094627|DRUG|Comparator: placebo (unspecified)|Duration of Treatment - 6 weeks
40984480|NCT03523754|DRUG|Isosorbide Mononitrate 40 MG to study group|Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening \& induction of labor in study group
40984481|NCT02348606|DRUG|JZP-110|
40984482|NCT02348606|DRUG|Placebo oral tablet|
40984483|NCT04237090|DRUG|Diphenhydramine|Drug identification number : 02369567
40984484|NCT04237090|DRUG|Cetirizine|Drug identification number : 02231603
41304426|NCT06439901|OTHER|Chest CTscan and follow-up|A third step with an initial CTscan, with dual interpretation and appropriate management of participants, including follow-up care.
41463404|NCT04383717|DRUG|Azithromycin and hydroxychloroquine|oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily
40984485|NCT04237090|DRUG|Lactose pill|Natural product number : 00501190
40984486|NCT04237090|DRUG|Sodium chloride 0.9%|Drug identification number : 00037796
40984487|NCT04394104|OTHER|Survey|No intervention is being administered.
40984488|NCT05573945|BEHAVIORAL|Family Education and Active Listening|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator. In addition, weekly meetings of parent/s with a psychologist in a private location for an active listening counselling session.
41463405|NCT05730452|BEHAVIORAL|Risk-stratified discharge and post-discharge care|"Interventional intensity is based on predicted risk. Predicted risk based on previously developed prediction algorithms.~Low risk: receive discharge education and counselling only; Moderate risk: Discharge education and counselling + 1 post-discharge follow-up referral at day 7; High risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14); Very high risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14, D28)"
41463406|NCT06338631|OTHER|Diet|Pesonalized diet plan, devoloped according to Guidelines for dietary treatment of obesity, to be followed for a duration of 12 months
41463407|NCT00114595|DRUG|eicosapentaenoic acid|
40984489|NCT05573945|BEHAVIORAL|Family Education|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
40984490|NCT02033122|OTHER|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
40984491|NCT02033122|OTHER|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
40984492|NCT02537054|DRUG|Aflibercept|Intravitreal injection
40779936|NCT06410521|BEHAVIORAL|Usual care|Patients randomised to the active comparator arm will be advised about the importance of lifestyle modification (including general advice to increase walking but without specific recommendations about the exercise program) for a period of 12 weeks.
40984493|NCT03613012|DIAGNOSTIC_TEST|Pain index|Record the patients' EEG and extract pain index before and after pain treatments
40984494|NCT00765375|DRUG|Botulinum Neurotoxin Type A|1.5-3 units of Botox/lesion
40984495|NCT00765375|DRUG|Bacteriostatic saline|.1 cc bacteriostatic saline/lesion
40984496|NCT03447990|DRUG|MYK-491|Single Ascending Dose and Multiple Ascending Dose of MYK-491
40984497|NCT03447990|DRUG|Placebo|Single Ascending Dose and Multiple Ascending Dose of placebo
40984498|NCT04216654|DIAGNOSTIC_TEST|ELISA (enzyme-linked immunosorbent assay)|ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.
40984499|NCT05725954|BEHAVIORAL|GUT LINK SmartPath|A virtual care delivery and referral support tool for primary healthcare providers.
40984500|NCT00744627|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets.
40984501|NCT00744627|DRUG|Placebo|Vortioxetine placebo-matching capsules
40984502|NCT01622972|DRUG|Polyethyleneglycol|Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
40984503|NCT05421234|OTHER|diagnostic test and sperm analysis|"Diagnostic Test: 2x14 ml of peripheral blood collected in the tube with anticoagulant, for platelet isolation, respirometry mitochondrial analysis, antioxidants (coenzyme Q10, vitamin E, gamma-tocopherol, beta-carotene) and TBARS estimation.~Sperm analysis: standard spermiogram examination (volume, pH, number, motility and pathology) in the broker chamber, as well as extended examinations: mioxsys for redox potential, Vitalsperm (eosin-nigrosine staining) for sperm vitality and anti-sperm antibody (IgG) test."
40984504|NCT06241079|OTHER|non-intervention|non-intervention
41144002|NCT03975361|OTHER|Bliss-Believe|The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Only one sample of patients included in BLISS BELIEVE STUDY will be obtained during a standard of care visit. It will be 21ml of blood.
41144003|NCT05989386|PROCEDURE|0.9% saline solution|During emergency laparotomy, after the primary surgical procedure. the sheath will be sutured and the incision site will then be irrigated with three rounds of 1 liter of 0.9% saline solution, which will be completely aspirated before the closure of the incisional wound in experimental group.
40779937|NCT06410521|BEHAVIORAL|Home-based exercise|Patients who transitioned to the home-based exercise will undergo regular walking in or near the home at least three times week, with each walking taking approximately 30-40 minutes for a period of 12 weeks. The pace of intermittent walking will be self-selected in order to induce mild-to-moderate claudication pain between 5-10 minutes, with rest time until the pain disappears.
41144004|NCT05989386|PROCEDURE|Povidone-iodine Swab|No intra-operative wound lavage done, and wound would be cleaned with povidone doused swab.
41144005|NCT05037123|DRUG|Continuous ketamine infusion|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
41144006|NCT05037123|DRUG|Ketamine + Saline|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
41144007|NCT05037123|OTHER|Placebo|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
41304427|NCT03702582|DRUG|Rivaroxaban|Anticoagulant drug that works via direct inhibition of factor Xa. FDA approved for prophylaxis against stroke in non-valvular atrial fibrillation
41144008|NCT04095338|OTHER|traditional rehabilitation|Each session will include 50 minutes of traditional physical rehabilitation therapy
41304428|NCT03702582|DRUG|Warfarin|Anticoagulation drug that works via inhibition of vitamin K dependent clotting factors. FDA approved for prophylaxis against stroke in atrial fibrillation
41304429|NCT04561635|DIETARY_SUPPLEMENT|Multiple-micronutrients supplement|Multiple-micronutrients supplement with 15 micronutrients
41304430|NCT01073280|PROCEDURE|cerebral flexible endoscopy|The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
41304431|NCT05228444|BEHAVIORAL|CircadianCare|enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
41304432|NCT01613287|DEVICE|TheraSorb® - Ig flex|"TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.~5 treatments performed over 5 to 8 consecutive days."
41463408|NCT00939380|BEHAVIORAL|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
41463409|NCT00939380|OTHER|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
40779938|NCT03139058|OTHER|Evaluation of the hepatic fibrosis|Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)
40779939|NCT04622735|COMBINATION_PRODUCT|nefopam hydrochloride 30mg / paracetamol 500mg X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
41144009|NCT04095338|OTHER|virtual reality games intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Tymo system (Tyromotion, Austria), a wireless platform for the balance and the postural control training that simulates floor walking and stairs climbing. Tymo system is connected to a screen and provides virtual reality games, adaptable to the functional capacity of the patient. Through the games proposed, the physiotherapist will decide to work in a dimension (antero-posterior or medio-lateral dimension) or in two dimensions (combining the antero-posterior and medio-lateral movements).
41304433|NCT05457933|DRUG|Dapagliflozin|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
41304434|NCT05457933|DRUG|Glargine|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
41304435|NCT01806077|DRUG|PZ-128|Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
41304436|NCT01790893|DRUG|aflibercept|
41463410|NCT00939380|OTHER|DVD and pamphlet|"Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD."
41463411|NCT00939380|OTHER|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
41463412|NCT02293460|DRUG|I10E|"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days."
41463413|NCT05964673|DEVICE|bioptron light therapy|patients will receive patient education program and bioptron light therapy for four weeks
41144010|NCT04095338|OTHER|robotic treadmill intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Walker view (TecnoBody, Italy), a treadmill equipped with a sensorized belt with eight load cells and a 3D camera.to detect length, speed and symmetry of the pace and load, range of the trunk, hips and knees. Patients will be asked to walk at a comfortable speed, while the physiotherapist will be able to work on different parameters such as step length, load distribution, and step height. The setting will take place taking into account the clinical conditions of each patient, customizing the intervention. The Walker View will offer visual and auditory feedback to the patient, so as to correct gait in real time.
41144011|NCT05556200|DRUG|Anti-PD-1 monoclonal antibody|Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight \<50 kg)
41144012|NCT05556200|DRUG|VEGFR2 Tyrosine Kinase Inhibitor|Apatinib 250 mg, po, qd
41144013|NCT03326856|BIOLOGICAL|botulinum toxin, Type A|topical liniment
41144014|NCT03326856|BIOLOGICAL|Vehicle|Vehicle Formulation
40984505|NCT06399588|BEHAVIORAL|Intervention for Adolescent Tobacco Initiation Prevention (IATIP)|The IATIP is an evidence-based tobacco prevention program tailored for Bangladeshi adolescents, integrating Behavior Change Techniques, the Behavior Change Wheel, and the Theoretical Domains Framework. Utilizing the Arena Blended Connected (ABC) model ensures effective delivery. Six key learning types are integrated to optimize knowledge acquisition, concept exploration, collaboration, discussions, practical application, and skill development. The curriculum comprises three core components addressing adolescents' challenges: the information curriculum cultivates factual awareness, the social competence curriculum strengthens refusal skills and social competencies, and the social influence curriculum builds resilience against tobacco-promoting social influences.
40984506|NCT01792674|OTHER|In situ simulation|
40984507|NCT01792674|OTHER|Off site simulation|
40984508|NCT02318511|PROCEDURE|Knee injection|Injection into knee for the treatment of Osteoarthritis
40984509|NCT02318511|OTHER|ReNu amniotic allograft|
40984510|NCT02318511|DEVICE|placebo saline|
40984511|NCT02318511|DEVICE|Hyaluronic Acid|
40984512|NCT05318599|DEVICE|Lung auscultation|Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
40984513|NCT05318599|DEVICE|Lung ultrasound|Lung ultrasonography
40984514|NCT05318599|OTHER|Quality of Life's questionnaires|Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
40984515|NCT05318599|DIAGNOSTIC_TEST|Pulmonary functional tests|Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
40984516|NCT04392947|DEVICE|Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P
40984517|NCT04392947|DEVICE|Sham Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P without TMS being actively delivered
40984518|NCT00913003|DRUG|Lidocaine|Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
40984519|NCT00913003|DRUG|Placebo|Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
40984520|NCT02646280|OTHER|Massage therapy|Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
40984521|NCT02646280|OTHER|Neurocognitive rehabilitation|Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
41144015|NCT01535261|DRUG|Ranibizumab 0.5 mg/0.05 ml|Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
41144016|NCT01441596|DRUG|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
41144017|NCT01441596|DRUG|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
41144018|NCT01441596|DRUG|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
41144019|NCT01441596|DRUG|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
41463414|NCT02414763|BEHAVIORAL|Teachable Moment Brief Intervention|functional analysis, collaborative interpersonal style
40984522|NCT00916747|DRUG|Lonafarnib, Zoledronic Acid, and Pravastatin|"Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily."
40984523|NCT04483011|DIETARY_SUPPLEMENT|RiaGev|Dietary supplementation
40984524|NCT00003644|DRUG|carboplatin|
40984525|NCT00003644|DRUG|paclitaxel|
40984526|NCT00256373|PROCEDURE|Mod. functional restoration-Individ. dynamic back-muscle|
40984527|NCT06493396|DRUG|Opioid-free Analgesics|opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
41144020|NCT01558999|DRUG|High concentration SI-614|1 drop in each eye 4 times a day
41144021|NCT01558999|DRUG|Low concentration SI-614|1 drop in each eye 4 times a day
41144022|NCT01558999|DRUG|Vehicle|1 drop in each eye 4 times a day
41144023|NCT03883178|PROCEDURE|Minimal-invasive endoscopic transgluteal approach|Every patient, suffering from a pudendopathie or clunealgie, conform the Nantes criteria, and who are candidates for a surgical treatment through the transgluteal open approach, will be asked their permission to perform the procedure through a minimal-invasive endoscopic transgluteal approach.
41144024|NCT01490047|DRUG|Recombinant human TNF-α|Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
41144025|NCT01490047|DRUG|Liposomal doxorubicin|Infusion over 60 minutes
41463415|NCT02412137|OTHER|Counseled cohort|This group will be counseled after brace temperature/date/time data is logged at each visit.
40984528|NCT06493396|DRUG|Opioid group|Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
40984529|NCT01776775|DEVICE|Abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position."
40984530|NCT02939898|DRUG|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
40984531|NCT02939898|DRUG|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
40984532|NCT03274414|DRUG|Cisplatin|Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m\^2 (dose reductions after the first cycle allowed for toxicity)
40984533|NCT03274414|RADIATION|Adjuvant Proton Radiotherapy|"Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology."
40984534|NCT03274414|PROCEDURE|Endoscopic Resection|In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
41304437|NCT04148924|OTHER|Questionnaire|"Patients complete a questionnaire for assess their symptoms like anxiety and depression.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms~* HADS - A : Hospital Anxiety and Depression scale includes 2 subscales which assess anxiety (HADS-A) and depression (HADS-D)~* BEDS : Brief Edimburg depression Scale is s a relevant scale for assess depression in palliative care patients.~* Questions on the assessment, the treatment and difficulties in management of anxious and depressive symptoms.~The evaluation will be realized in the first days of hospitalization (72 hours)."
41304438|NCT04148924|OTHER|Medical staff questionnaire|"Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms"
41304439|NCT05948371|OTHER|High Intensity interval Training|"High Intensity interval Training~* Frequency: 3-5 day per week~* Intensity: 60 to 80% of HRR. If atrial fibrillation present use RPE of 11-14 on a 6-20 scale.~* Time: total 30 mint time.6 mint exercise with high intensity and 2 mints of low intensity for active recovery until 30 mints complete.~Type: walking and static cycling. Walking~* Frequency 3 -5 days per week Intensity : use RPE of 11-14.~* Time:30 mint total. 6 mint walk with high intensity and 2 mint walk with low intensity until 30mints completed."
41304440|NCT05948371|OTHER|Continuous Aerobic training|"Continuous Aerobic training~* Frequency : 3-5 days per week.~* Intensity:40-70% of HHR.~* Time : initial 5-10 then 10-15 until 30mints without rest interval~* Type : walking and static cycling."
41304441|NCT05257720|DIAGNOSTIC_TEST|GFAP, S100B|It is planned to measure serum GFAP and S100 B protein levels by ELISA method.
41304442|NCT00294008|DRUG|Risperdal Consta|flexible dosage for 24 months
41304443|NCT05645029|OTHER|glass ionomer-chlorhexidine|chlorhexidine will be added to glass ionomer
41304444|NCT05645029|OTHER|glass ionomer-titanium dioxide powder|titanium dioxide will be added to glass ionomer
41304445|NCT05645029|OTHER|glass ionomer|glass ionomer will be used without any additives
41304446|NCT05428072|OTHER|Sugar test|All participants will take two sugar tests ( sugar cocktail consisting of mannitol \& lactulose) subjects within 2-3 days of the initial sugar test.
41463416|NCT03698487|OTHER|Intervention|Pharmacist-led medication optimization intervention using an electronic tool (DBI Calculator©). The DBI Calculator is an electronic tool which calculates a score from the medication reconciliation list (medications taken prior to admission). It also creates a 'DBI report' which includes their full medication list, their DBI score, an explanation of the risks associated with their DBI score and highlighted medications which are contributing to their DBI score (that is, high risk medications which may be suitable for deprescribing).
41463417|NCT01843257|OTHER|Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
40984535|NCT03274414|DRUG|cisplatin and etoposide|If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
40984536|NCT01103284|DRUG|DiaPep277|1.0 mg dose in 0.5 mL of solution
41304447|NCT05428072|DRUG|Aspirin Challenge|All participants will take a sugar test after 2 doses of aspirin, 1.3 g each given at 12 \& 1 hour before the sugar drink.
41304448|NCT00003982|DRUG|sabarubicin|
41304449|NCT06198959|DEVICE|Adult blanket plus, MA2220 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Adult Blanket plus, MA2220 blanket connected to the Mistral Air, Blower. MA1200-PM system for 30 minutes.
40984537|NCT01103284|DRUG|Placebo|"40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"
40984538|NCT06376747|PROCEDURE|In line sampling|closed technique of sample collection
40984539|NCT06376747|PROCEDURE|Standard blood sampling technique|Blood draws using standard steps: blood withdrawal for catheter, decontamination (disposed),blood draw for laboratory analysis,catheter flush
40984540|NCT00867425|BEHAVIORAL|Virtual Lifestyle Management|"The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity)."
40984541|NCT01940679|DIETARY_SUPPLEMENT|encapsulated 600 mg EPA/DHA|encapsulated 600 mg EPA/DHA
41304450|NCT06198959|DEVICE|Premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.
41463418|NCT01843257|OTHER|Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
41463419|NCT04547933|DIAGNOSTIC_TEST|Bladder diary|A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.
41463420|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled Acetate|400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
41463421|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled propionate|340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
41463422|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled butyrate|990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
41463423|NCT01757379|DIETARY_SUPPLEMENT|Inulin|15 g of inulin dissolved in 200 ml of water
41463424|NCT01784016|RADIATION|[11C]-PHNO|\[11C\]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
41463425|NCT03096067|OTHER|Heavy slow resistance training|Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).
40984542|NCT03864211|PROCEDURE|Thermal ablation|Radiofrequency ablation or microwave ablation is performed under CT or ultrasound guidance for one to five target lesions.
40984543|NCT03864211|DRUG|Toripalimab|"Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation."
40984544|NCT02588833|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
41463426|NCT03096067|OTHER|Moderate slow resistance training|Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
40984545|NCT05767892|DRUG|YK-209A tablet|YK-029A 200 milligram (mg) , orally without food，once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
41144026|NCT01490047|DRUG|Caelyx|Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
41144027|NCT01490047|DRUG|Recombinant human TNF-α|Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
41144028|NCT03788278|DEVICE|BioBeat|The watch incorporates sensors, a battery, a software system, memory components, and a communications component. the watch will be worn 24 hours a day, 7 days a week.
41144029|NCT04007822|BEHAVIORAL|Pain Navigator Tool|The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
41144030|NCT00160758|PROCEDURE|retrieve massive allograft|Allograft constructs removed because of infection or cancer complications will be retained for biomechanical testing
41144031|NCT01128673|DEVICE|mRI|
41144032|NCT05109832|DRUG|14C-IMP4297|14C marked IMP4297
41144033|NCT03222232|BEHAVIORAL|catheter salvage|In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
41144034|NCT01795989|DEVICE|1.5T MRI Elbow Coil|Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
41144035|NCT03361202|OTHER|blood sampling|"* atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up~* control group:before coronary angiography and at hospital discharge."
41144036|NCT05722925|DRUG|Fluciclovine PET/CT|8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
41304451|NCT06198959|DEVICE|Blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 system.
41304452|NCT06198959|DEVICE|FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
41463427|NCT05683860|DRUG|WVE-004|WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection
41463428|NCT00916695|DEVICE|Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.|"Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.~Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique."
41463429|NCT00357539|DRUG|Azithromycin (T1225)|
41304453|NCT06198959|DEVICE|Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system.
41463430|NCT03723837|BIOLOGICAL|Inactivated Polio Vaccine (IPV)|Children receive one or two doses of IPV based on study arm they fall in
40984546|NCT05767892|DRUG|Pemetrexed+carboplatin/Cisplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
41304454|NCT05260931|DIAGNOSTIC_TEST|Fetal echocardiography|Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function. Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole. Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters. Atrial areas at maximum distension at end of systole. Atria and ventricle to-heart ratios calculated. Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV. MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV. Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated. Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
41304455|NCT01836575|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2 + Pretreatment \[dexamethasone + vitamin B12 + folic acid, as per pemetrexed label\] + Antiemetic therapy at investigator's discretion.
41304456|NCT01836575|DRUG|Carboplatin|Carboplatin \[Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle\].
41304457|NCT04811313|DRUG|Tranexamic acid|patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA
41304458|NCT04811313|PROCEDURE|caudal epidural block|regional anesthesia in orthopedic procedures are known to help reduction of intraoperative blood loss
41304459|NCT04811313|OTHER|Placebo|participants will receive standard care but neither TXA nor caudal epidural block
41304460|NCT01833767|DRUG|Cyclophosphamide and Interleukin 2|Cytoxan IV day 1, IL2 IV days 1-5
41304461|NCT05252884|DIAGNOSTIC_TEST|calcium correction according to PTH levels|A PTH blood test will be performed 4 hours post-thyroidectomy. If the PTH result is \>15 pg/mL, the patient will be discharged without calcium intake; if PTH \< 15 pg/mL, start a dose of 1200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days
41463431|NCT02079233|DRUG|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 7 consecutive days.
41463432|NCT04246281|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
41463433|NCT04246281|PROCEDURE|Standard interventional management of low back pain|Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
41463434|NCT04680780|OTHER|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 months
41463435|NCT04680780|OTHER|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.
41463436|NCT04680780|OTHER|Control|Patients are allowed to eat ad libitum, but will be advised that low salt intake (\< 5-7 g/day) and sufficient fluid intake (\>3 l/day) which is considered beneficial in ADPKD.
41304462|NCT05252884|DRUG|routine postoperative calcium and calcitriol|The patient will receive a dose of 1,200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days, starting on the same day as the intervention.
41304463|NCT00991380|BEHAVIORAL|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
41304464|NCT00991380|BEHAVIORAL|Usual Care|Control
41304465|NCT00746031|DRUG|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
41304466|NCT00746031|DRUG|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
41304467|NCT00145548|DEVICE|Intra Bronchial Valve|
41304468|NCT00961337|BIOLOGICAL|Trivalent inactivated influenza vaccine|one dose
41304469|NCT00808691|OTHER|Critical care|Standard care for each group of patients
40779940|NCT04622735|DRUG|Paracetamol 500 Mg Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
40779941|NCT04622735|DRUG|Nefopam HCl 30 MG Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
40779942|NCT04972279|BEHAVIORAL|Digital message (text + image)|"Messages can be up to 256 characters of text with an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
40984547|NCT01347450|DIETARY_SUPPLEMENT|Cocoa powder berverage, dark chocolate bar|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
40984548|NCT01347450|DIETARY_SUPPLEMENT|Placebo|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
40984549|NCT04329169|OTHER|Virtual Implant Planning|According to the virtual implant plan, a CAD/CAM tooth supported surgical guide will be fabricated to place the dental implant with a fully guided surgical protocol.The surgical guide will be manufactured from a photopolymer resin using a 3D printing machine. A hex- shaped metal sleeve will be inserted in the surgical guide with the flat surface located buccally so that it will help in orientation of the implant hex during the implant placement.
41144037|NCT06471153|BEHAVIORAL|Empowerment Program Based on BASNEF Model|Initially, the researcher established rapport with children of both groups and their gradians, screened them for the eligibility criteria, explained the aim of the study, the duration and nature of the training sessions, and obtained informed assent. The researcher established the session objectives and learning activities and prepared the learning materials. The researchers also prepared the learning environment. The Empowerment program is implemented in accordance with the BANCEF model for behavior transformation into four educational sessions. After the intervention, children's nail-biting knowledge, practice, attitude, and self-efficacy were reassessed.
41304470|NCT04894786|OTHER|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization (MIRM) Sleeper Stretch The therapist places a web of his one hand around patient's axilla and thumb of another hand in the bent elbow and the glide will be applied to the head of the humerus down in the glenoid fossa using thumb while stabilizing the scapula with another hand. Therapist will ensures that the other hand is stabilizing up and inwards. While this distraction is taking place the patient internally rotated his shoulder with the help of another hand, at the same time his affected upper arm will abduct by therapist abdomen distracting the head of the humerus laterally. The hand in axilla acts as a fulcrum. Mulligan MWM will be applied for 3 days alternate days by following the rule of 3
41463437|NCT00526435|BEHAVIORAL|Walk with Ease - Group|Participate in 6-week, 1 hour per week group assisted classes (with instructor).
40984552|NCT03240796|PROCEDURE|minimal invasive surgery and secondary IOL implantation|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
40984553|NCT03240796|PROCEDURE|traditional cataract surgery and secondary IOL implantation|"traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).~Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus."
40984554|NCT03985514|DRUG|Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).|Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.
40984555|NCT03985514|OTHER|Active observation|In-hospital observation without antibiotics
41304471|NCT04894786|OTHER|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique (PIRT) Sleeper Stretch The subject will be positioned supine on the treatment table with the shoulder and elbow, at 90 degree of abduction and flexion. The shoulder will be stabilized at the acromion process with one hand, and the other hand will be used to passively move the arm into internal rotation until the first barrier of motion will reached. The subject will be then instructed to perform a 5second isometric contraction of approximately 25% maximal effort in the direction of external rotation, against an opposing force provided at the distal forearm. Following the contraction, the subject will be instructed to internally rotate the arm toward the ground as a 30-second active assisted stretch will be applied. The subject will be instructed to relax, and a new movement barrier will then engage.
41304472|NCT02217319|DRUG|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
40779943|NCT05597176|OTHER|Spinal Cord Injury Exercise Group|Participants will have an initial accommodation period of 4 weeks, during which four 10-minute exercise bouts/day will be interspersed with 5 minutes of rest. The bouts will gradually increase until at least continuous 40-minute sessions. The remaining 12-week intervention will be set at 70% max heart rate for a total of 16 weeks.
40984556|NCT03338855|DRUG|Dapagliflozin|"The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2."
41463438|NCT00526435|BEHAVIORAL|Walk with Ease - Self|SUbject will receive the WWE workbook and follow it without group/instructor assistance.
40779944|NCT00003562|DRUG|carboplatin|
41463439|NCT02740907|PROCEDURE|premolar autotransplantation|Autogenous tooth transplantation of premolars to the anterior maxilla to stimulate bone and soft tissue growth.
41463440|NCT03296735|PROCEDURE|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
41463441|NCT03296735|PROCEDURE|Contralateral tilt|The operation table will be tilted 20 degrees left laterally.
40779945|NCT00003562|DRUG|docetaxel|
40779946|NCT03586960|DEVICE|Peak Force Measurement|Force will be measured at 5,10, and 30 minutes
40779947|NCT04757233|BEHAVIORAL|GlucoType|GlucoType is an mobile Health intervention for facilitating self-management in T2DM built for iPhone and Android smartphones. GlucoType includes a custom-built interface for low-burden capture of diet and blood glucose (BG) levels and relies on a commercial activity tracker, FitBit, for capture of sleep and physical activity. It then applies computational phenotyping techniques to identify patterns of associations between daily activities and changes in BG levels. GlucoType uses an expert system developed by our research team to translate identified phenotypes into automatically-generated personalized behavioral goals for improving glycemic control formulated in natural language.
40984557|NCT03033381|DEVICE|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for operated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
40984558|NCT03033381|DEVICE|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for nonoperated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
40984559|NCT00646529|DRUG|budesonide/formoterol (Symbicort)|
40984560|NCT00646529|DRUG|budesonide (Pulmicort)|
40984561|NCT01835067|DRUG|Ranibizumab|Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls
40984562|NCT01835067|DRUG|C3F8 Gas|Single intravitreal injection of 0.3 mls C3F8
41144038|NCT06471153|BEHAVIORAL|Routine Health Education|Children in the control group received routine health education about the problems of nail-biting and routine advice to quit nail-biting.
41144039|NCT01780428|DRUG|CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
41144040|NCT01780428|DRUG|Placebo|
41144041|NCT05809856|DEVICE|GrOwnValve - novel heart valve replacement approach|The autologous GrOwnValve is implanted into a stent before it is implanted via minimal-invasive transcatheter technique into the patients with high-grade pulmonary valve insufficiency and right ventricular dilatation. Control intervention/Reference test: Since the study is designed for investigating the safety of the procedure, there will not be a control group. However, the outcomes will be compared as a non-inferiority analysis with the standard of current medical care (Edwards SAPIEN 3 or Medtronic's Melody, both bioprosthetic transcatheter pulmonary valves).
41144042|NCT05666518|DRUG|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
41144043|NCT05666518|DRUG|Standard of care|Dosage at the discretion of the treating physician
41304473|NCT02217319|DRUG|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
41144044|NCT02152384|DRUG|Insulin Peglispro|Administered SC
41304474|NCT04056013|DEVICE|Vicryl Rapide absorbable suture|"In general, most laceration repair has been done with sutures on the surface of the skin that do not break down and fall off on their own, so after enough days have passed for the laceration to heal properly, the patient needs to return to the ED to have the sutures removed by cutting them off. These sutures are called nonabsorbable. Some newer sutures have been designed to slowly dissolve on their own and fall out over several days. These are called absorbable sutures. You do not normally need to return to the ED for removal as these should slowly dissolve and fall out on their own."
41304475|NCT05931523|BEHAVIORAL|Stress First Aid|The focus of the model is ongoing monitoring of stress in personnel, wide spread training to help personnel recognize peers or subordinates who may need additional assistance, a spectrum of one-on-one interventions, and the ability to provide personnel higher levels of care when indicated.
41304476|NCT00455260|DRUG|hGH-ViaDerm™ System (hGH or somatropin)|transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
41304477|NCT00455260|DEVICE|hGH-ViaDerm™ System|"The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).~The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system."
41304478|NCT01361009|DRUG|pramipexole|as prescibed by the investigator
41304479|NCT04220489|DRUG|Ketamine|Intraoperative ketamine and post operative 48 hour ketamine infusion with a standardized general anesthesia protocol.
41304480|NCT04220489|DRUG|Placebo Comparator|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure)
41463442|NCT02725164|DRUG|oxygen concentration|oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
40984563|NCT01835067|DRUG|tPA|Single intravitreal injection of 50 micrograms tPA in 0.05 mls
41144045|NCT02152384|DRUG|Insulin Lispro|Administered SC
41304481|NCT02324842|DRUG|Canagliflozin|Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
40984564|NCT05569200|DEVICE|Haifu Focused Ultrasound tumor therapeutic System|The device used in this trial will be Haifu Focused Ultrasound tumor therapeutic System. In Uterine benign tumor female, the investigators will observe the possibility of complication and tumor response of treatment.
40984565|NCT05013567|DRUG|Ibuprofen gel|Ibuprofen gel 5% topically four times a day
40984566|NCT05013567|OTHER|Placebo|Placebo gel topically four times a day
40984567|NCT00204607|BIOLOGICAL|mRNA|
40984568|NCT00204607|DRUG|GM-CSF s.c.|
40984569|NCT04945785|OTHER|No intervention|no intervention
40984570|NCT05363384|DRUG|CT-L01|FDC tablet, single dose, oral administration
40984571|NCT05363384|DRUG|Alogliptin Benzoate 25 mg|Alogliptin Benzoate 25 mg, oral administration
40984572|NCT05363384|DRUG|Metformin HCl XR 1,000 mg|Metformin HCl XR 1,000 mg, oral administration
40984573|NCT05325879|OTHER|VAGUS-NDT|Neurodynamic test for vagus nerve
40984574|NCT01638806|PROCEDURE|Group I: Primary PCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
40984575|NCT01012856|BEHAVIORAL|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
41304482|NCT02324842|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
40779948|NCT05738096|OTHER|TSEP + rhizotomy surgery|TGN patients recruited for this study will already be undergoing percutaneous rhizotomy surgery. TSEPs will be measured at baseline prior to surgery. During the rhizotomy procedure, an electrode or balloon is placed through a metal sheath to then damage the nerve. A stylet is introduced to clear tissue from the sheath in preparation for the electrode or balloon. Prior to the final insertion of the RF electrode where the gasserian ganglion will be damaged, we will place a standard stereotactic EEG electrode (SEEG). Following damaging the nerve (clinical procedure), we will record again to measure differences in the TSEPs following cell body damage. The Neuralynx system will be used to record the potentials at 40 KHz.
40779949|NCT05738096|OTHER|TSEPs recording only|TSEPS will also be recorded from healthy controls in a lab setting; all procedures for the healthy controls will be non-invasive.
40984576|NCT01012856|BEHAVIORAL|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
40984577|NCT04876443|DIAGNOSTIC_TEST|Study questionnaire|Study questionnaire related to drinking behaviour
40984578|NCT04063956|BEHAVIORAL|multi-domain internet-based adaptive training program|The training paradigms include a time perception task, visual search task, rapid serial presentation task, delayed match to sample task, paired-associate recall task, attention span task, digit span task, go-no go task, Stroop task, task switching, auditory span task and n-back working memory task. Each task has several difficulty levels. The tasks are grouped in different cognitive domains including: processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Participants in the cognitive training group will complete 40 min of training daily, 4 days a week for 12 weeks. When a high accuracy (80%) is achieved for each task, the level of difficulty will be upgraded for that task.
40984579|NCT04063956|BEHAVIORAL|active-control program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
40984580|NCT01572233|BEHAVIORAL|Personalized Physical Activity and Psycho-Education (PPAPE) Program|"1. Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection~2. The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment."
40984581|NCT05436951|BEHAVIORAL|Brief on-shift nap|The brief nap opportunity will allow for a 45-minute nap between the hours of 0200 and 0300 during the in-lab 12-hour simulated night shift.
40984582|NCT03472469|DRUG|Acetaminophen IV/PO|Acetaminophen 1g IV/PO every 6 hours
40984583|NCT03472469|DRUG|Acetaminophen PO|Acetaminophen 1g PO every 6 hours
40984584|NCT03472469|DRUG|Ketorolac|Ketorolac 30mg IV once
40984585|NCT03472469|DRUG|Celebrex|Celebrex 200mg PO every 12 hours
40984586|NCT03472469|DRUG|Naproxen|Naproxen 500mg PO every 12 hours
40984587|NCT03472469|DRUG|Tramadol|Tramadol 100mg PO every 6 hours
41463443|NCT02725164|DRUG|nitrous oxide concentration|nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
40984588|NCT03472469|DRUG|Pregabalin|Pregabalin 100mg PO every 8 hours
40984589|NCT03472469|DRUG|Gabapentin|Gabapentin 300mg PO every 8 hours
40984590|NCT03472469|DRUG|Lidocaine|Lidocaine patch every 12 hours
40984591|NCT03472469|DRUG|Opioids|Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)
40984592|NCT03472469|DRUG|Regional anesthesia|Regional anesthesia
40984593|NCT04566081|OTHER|iTALKbetter: deterministic|A word retrieval therapy application
40984594|NCT04566081|OTHER|iTALKbetter: reactive|A word retrieval therapy application
40984595|NCT00331279|DRUG|Oral Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
40984596|NCT00331279|DRUG|Placebo|Placebo pills in likeness of the cinnamon extract
40984597|NCT03946904|DEVICE|Er,Cr:YSGG Laser|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. one lesion was prepared with high power laser setting first to ablate the enamel, dentin, and caries. the other lesion was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
41304483|NCT03144583|BIOLOGICAL|Adult differentiated autologous T-cells|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
41304484|NCT05186883|BIOLOGICAL|Allogenic parathyroid cells|Allogenic parathyroid cells
41304485|NCT05186883|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
41463444|NCT02725164|DRUG|carbon dioxide concentration|carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation
41463445|NCT02725164|DRUG|sevoflurane concentration|sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
40984598|NCT02278250|DRUG|M4344 10 mg BIW|Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984599|NCT02278250|DRUG|M4344 20 mg BIW|Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40779950|NCT00822302|DRUG|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
40779951|NCT00822302|DRUG|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
40779952|NCT05822310|PROCEDURE|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points.
40779953|NCT05822310|PROCEDURE|intraairticular steroid injection|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The femoral neck was detected under ultrasonography and the joint capsule was entered with a 22G 9 cm spinal needle. Then, 5 cc bupivacaine and 5 mg betamethasone were given and the procedure was terminated.
40779954|NCT05822310|PROCEDURE|pericapsular nerve group (PENG) block|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The high-frequency linear ultrasonography probe was placed on the anterior superior iliacspina (ASIS). Later, the anterior inferior iliac spine (AIIS) was detected by descending caudally. Afterwards, the probe was brought to the oblique position and AIIS, iliopubikeminence, psoas muscle and tendon were seen. Using a 22G 90-mm Quinckespinal needle, the tendon of the iliopsoas muscle was entered in the lateral-medial direction in the in-plane plane and bone contact was achieved. After negative aspiration, 15 ml of 0.5% bupivacaine were administered by seeing the appropriate drug distribution.
40779955|NCT04944784|DRUG|Reldesemtiv|Reldesemtiv Oral Tablet
40779956|NCT04944784|DRUG|Placebo|Placebo Oral Tablet
40779957|NCT01387867|PROCEDURE|Strength training|Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
40984600|NCT02278250|DRUG|M4344 40 mg BIW|Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984601|NCT02278250|DRUG|M4344 80 mg BIW|Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
41144046|NCT02152384|DRUG|Insulin Glargine|Administered SC
41144047|NCT04502459|PROCEDURE|Tourniquet|A tourniquet is often used in total knee arthroplasty to achieve better visualization, reduce intra-operative bleeding and facilitate cement interdigitation
41144048|NCT04910711|DRUG|Dolutegravir|Dolutegravir-based antiretroviral therapy
40984602|NCT02278250|DRUG|M4344 160 mg BIW|Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
41463446|NCT04313426|OTHER|Integrative Yoga Therapy|Integrative Yoga Therapy included personalised yoga therapy sessions including their standard care, yoga movements, relaxation, meditation, breathing practices and yoga counselling sessions.
41463447|NCT00224484|BIOLOGICAL|GSK208141|3 intramuscular doses
41463448|NCT00224484|BIOLOGICAL|Havrix (investigational formulation)|3 intramuscular doses
41463449|NCT00224484|BIOLOGICAL|Placebo|3 intramuscular doses
41463450|NCT03673592|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
41463451|NCT00826137|DIETARY_SUPPLEMENT|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
40984603|NCT02278250|DRUG|M4344 300 mg BIW|Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984604|NCT02278250|DRUG|M4344 450 mg BIW|Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
41144049|NCT04910711|DRUG|Levonorgestrel implant|Women initiating the levonorgestrel implant
41144050|NCT04910711|DRUG|Depo medroxyprogesterone acetate injection|Women initiating the depo medroxyprogesterone acetate injection
41144051|NCT02467673|DRUG|Micronized estradiol + progesterone|Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
41304486|NCT02969434|OTHER|Sleep assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
41304487|NCT02728440|DRUG|human chorionic gonadotropin, human menopausal gonadotropin|drug for the treatment of male hypogonadism
41463452|NCT00826137|DIETARY_SUPPLEMENT|Placebo|Placebo is base powder of product with no oligosaccharides.
41463453|NCT04829448|DIETARY_SUPPLEMENT|Protein supplement|Protein supplement equivalent to Metagenics Ultrameal
40984605|NCT02278250|DRUG|M4344 700 mg BIW|Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984606|NCT02278250|DRUG|M4344 1050 mg BIW|Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984607|NCT02278250|DRUG|M4344 1200 mg BIW|Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984608|NCT02278250|DRUG|M4344 100 mg BID|Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984609|NCT02278250|DRUG|M4344 150 mg QD|Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984610|NCT02278250|DRUG|M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984611|NCT02278250|DRUG|M4344 350 mg QD|Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984612|NCT02278250|DRUG|M4344 400 mg|Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984613|NCT02278250|DRUG|M4344 500 mg|Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984614|NCT02278250|DRUG|Carboplatin|Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
40984615|NCT04913025|DRUG|Nivolumab|60-minute IV infusion, as a flat dose of 480mg
40984616|NCT04913025|DRUG|Pembrolizumab|60-minute IV infusion, as a flat dose of 400mg
40984617|NCT05372328|OTHER|Position of arm while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.
40984618|NCT04082325|DRUG|Lu AF88434|Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
40984619|NCT04082325|DRUG|Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
40984620|NCT04082325|DRUG|Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
40984621|NCT04082325|DRUG|Placebo|Placebo to Lu AF88434 oral solution, single dose
41463454|NCT02951195|DRUG|VX-152|Tablet for oral administration.
41463455|NCT02951195|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
40984622|NCT00119418|DRUG|TU 025 Keishi Bukuryo Gan|
40984623|NCT04345263|PROCEDURE|MTA pulpotomy|Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
40984624|NCT00913042|OTHER|sample blood|"* Early culture~* Bacterial DNA tests in blood"
40984625|NCT02734446|DRUG|Reuterin D3 drops|5 drops/day for 3 months
41463456|NCT02951195|DRUG|IVA|Tablet for oral administration.
41463457|NCT02951195|DRUG|Placebo|Placebo matched to VX-152.
40984626|NCT02734446|OTHER|Placebo|5 drops/day for 3 months
40984627|NCT01454947|BEHAVIORAL|Clinical Decision Support (CDS): Accountable Justifications|Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
40984628|NCT01454947|BEHAVIORAL|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
40984629|NCT01454947|BEHAVIORAL|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
40984630|NCT02601950|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
40984631|NCT03192943|DRUG|BMS-986205|Specified dose on specified days
41463458|NCT02951195|DRUG|Placebo|Placebo matched to VX-152/TEZ/IVA triple combination (TC).
41463459|NCT02845791|BEHAVIORAL|Interactive Lifestyle programme workshop|Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).
40984632|NCT03192943|BIOLOGICAL|Nivolumab|Specified dose on specified day
41304488|NCT02729558|RADIATION|local SRT|local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
40984633|NCT04117425|BIOLOGICAL|biological collection|"Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption."
40984634|NCT02568150|BIOLOGICAL|Single group, open-label|
40984635|NCT05212012|DRUG|Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)|Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)
40984636|NCT05095987|PROCEDURE|Laparoscopic Appendectomy|Laparoscopic Appendectomy for acute uncomplicated appendicitis in children
40984637|NCT01821521|DRUG|AGSPT_L20|
40984638|NCT01821521|DRUG|Pantoloc 40mg|
41463460|NCT03852524|DRUG|Methylnaltrexone|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
41463461|NCT03852524|OTHER|Placebo|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
41463462|NCT02938013|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]|antiviral therapy for HCV
40779958|NCT01387867|PROCEDURE|Nordic Walking|Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
40779959|NCT01387867|PROCEDURE|Unsupervised home based exercise|Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
40779960|NCT05558969|DRUG|pregnant women taking magnesium|The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
40779961|NCT05558969|DRUG|Placebo|Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
40779962|NCT03243461|DRUG|Temozolomide + Valproic Acid|Valproic acid additionally to simultaneous radiochemotherapy with temozolomide
40779963|NCT00000684|DRUG|Dextran sulfate|
40779964|NCT03245918|DRUG|Aprepitant Capsule 125 MG|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
40779965|NCT03245918|DRUG|Aprepitant oral suspension 20 mg/mL|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
40779966|NCT03170375|BEHAVIORAL|Performance of WHEELS-I in promoting DASH/SRD adoption|Participants will receive the WHEELS-I electronically-delivered tailored messaging intervention in addition to motivational interviewing-based counseling.
40779967|NCT03170375|BEHAVIORAL|Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors|Participants will be randomized to the sequence DASH/SRD-control diet or control diet-DASH/SRD, and consume the diets for 14 days each.
40779968|NCT04239248|DIETARY_SUPPLEMENT|Tasty&Healthy intervention group|"patients will receive dietary advice to exclude pro-inflammatory dietary components based on the book Tasty\&Healthy."
40779969|NCT04239248|DIETARY_SUPPLEMENT|EEN intervention group|Oral exclusive feeding of formulated food (EEN), using Modulen formula only, for 8 weeks in amount based on the Daily Recommendations Intake. Those not tolerating oral EEN can receive EEN via a nasogastric tube.
40779970|NCT03824951|BIOLOGICAL|Anti-CD19 iCAR NK Cells|Anti-CD19 iCAR NK Cells injection
40779971|NCT00313560|DRUG|erlotinib hydrochloride|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
40779972|NCT00399022|DRUG|Duloxetine|
40779973|NCT03991585|BEHAVIORAL|Musical Contour Regulation Facilitation (MCRF)|MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
40779974|NCT05193006|OTHER|No intervention|No intervention
40779975|NCT00491478|DRUG|sertraline|
40779976|NCT03339596|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.
40779977|NCT03339596|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
40779978|NCT05804929|OTHER|Observation without intervention|Observation of food intake, body composition, microbiota, genetics, metabolic rate, metabolomics.
40779979|NCT01092884|DIETARY_SUPPLEMENT|Polypodium leucotomos extract|240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
40779980|NCT01092884|OTHER|Placebo|This placebo capsule will be taken orally three times daily
40779981|NCT06272604|BEHAVIORAL|Personalized Exercise Rehabilitation|The experimental group will participate in a 12-week exercise intervention program, carefully transitioning from moderate-intensity interval training to high-intensity interval training. The progression of exercise intensity will be regularly adjusted based on each child's tolerance, ensuring a personalized approach to the regimen. The exercise program is structured into three phases: an adaptation phase, an intensification phase, and a consolidation phase. For each participant, the intensity of the exercises is calculated based on their reserve heart rate, allowing for a tailored and scientifically-grounded progression. This approach aims to optimize the exercise program's effectiveness while maintaining safety and adaptability to individual fitness levels and asthma conditions.
40779982|NCT04391712|DEVICE|MLS Laser|Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.
40779983|NCT04391712|OTHER|Regular Inpatient Medical Care|Regular inpatient medical care
40779984|NCT04284137|BEHAVIORAL|Modified FE-SaLiR|Participants will attend a 60-minute exercise program (modified Wu Qin Xi and Ba Duan Jin) in a non-clinical community setting twice a week and will perform the exercises at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
40779985|NCT04284137|BEHAVIORAL|Unmodified Chinese Medicine Exercise|Participants will attend a 60-minute exercise program (Wu Qin Xi and Ba Duan Jin published by the General Administration of Sport of China) in a non-clinical community setting twice a week and will be expected to practice exercise at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
40779986|NCT04284137|BEHAVIORAL|Active Control|Participants will attend a 60-minute health education program once a week.
40779987|NCT04627714|OTHER|Adapted Physical Activity|Intervention consists in 1h30/week of adapted fencing
40779988|NCT00197821|BIOLOGICAL|pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
40779989|NCT03625921|BEHAVIORAL|Powered device with physical therapy|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in a device-specific physical therapy (PT) program.
40779990|NCT03625921|BEHAVIORAL|Powered device with standard of practice|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in the current standard of practice training, which includes basic device education and prosthetic training.
40984639|NCT02567955|BIOLOGICAL|Immunogenicity two doses of Gardasil-9|Subjects will receive two standard doses of Gardasil-9 (0.5 ml)
41463463|NCT02938013|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|antiviral therapy for HCV
40984640|NCT02567955|BIOLOGICAL|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
40984641|NCT05237908|DEVICE|Transforaminal Lumbar Interbody Fusion|Interbody Fusion means the operative immobilization or ankylosis of two or more vertebrae by fusion of the vertebral bodies with a short bone graft or often with diskectomy or laminectomy. (From Blauvelt and Nelson, A Manual of Orthopaedic Terminology, 5th ed, p236; Dorland, 28th ed
40984642|NCT02178202|BEHAVIORAL|McKenzie exercise|First to sixth McKenzie exercises were performed for 5 times/week and 10 treatment sessions totally.
41463464|NCT05312255|BEHAVIORAL|Behavioral Intervention|Wear a FitBit device and receive prompts for 6 months
40779991|NCT00767026|BEHAVIORAL|COPE (Creating Opportunities for Parent Empowerment)|Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
40984643|NCT02178202|DEVICE|Harmonic technique|Lower limb suspension exercise was performed for 5 times/week and 10 treatment sessions totally
40984644|NCT00290368|PROCEDURE|Skin Prick Test|
40984645|NCT00290368|PROCEDURE|Nasal allergen challenge|
40984646|NCT00290368|PROCEDURE|Nasal filter paper placement|
40984647|NCT00290368|PROCEDURE|Nasal lavage|
40984648|NCT00290368|PROCEDURE|Nasal scrape|
40984649|NCT00290368|PROCEDURE|Nasal symptoms score|
41144052|NCT02467673|DRUG|Nanoparticulate estradiol + progesterone|Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
41144053|NCT06215326|BEHAVIORAL|moderate-intensity continuous training|Participants in MICT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a warm-up of 5 minutes at 50% at peak WR, the patient start exercising at 60%-70% peak WR for 30-40 minutes (four 5-8 minutes sets, with a 2-min rest in between), and then the patients cooled down for 5 minutes at 50% peak WR. Moderate-intensity exercise training intensity control at 55-74% HRmax or 40-69% VO2peak or PRE12-13 as recommended by guidelines.
41144054|NCT06215326|BEHAVIORAL|high-intensity interval training|Participants in HIIT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a 5-minute warm-up at 50% at peak WR, the patients complete 20 series of vigorous-intensity sprint (80%-100% peak WR for 30-60s) separated by a low-intensity recovery (30% peak WR or completely rest for 15s), and then the patients cooled down for 5 minutes at 50% peak WR. Participants will begin training at a relatively moderate intensity (60%-65% peak WR) for the first 3 sessions and gradually increase to the target intensity beginning on the 4th session. Intensity control of high-intensity exercise training at 75-90% HRmax or 70-85% VO2peak or PRE14-16 as recommended by guidelines.
40984650|NCT01657279|OTHER|Clinical scenarios|Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome \[i.e. from low (\<10%) to high (\>50%) expected risk death at 30 days\].
41144055|NCT04093115|DRUG|CX1106|administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
40984651|NCT00917709|OTHER|Imaging with IBVM|in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol
40984652|NCT00917709|OTHER|Imaging with DATSCAN|in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
40984653|NCT00917709|BEHAVIORAL|neuropsychological evaluation|neuropsychological evaluation using neuropsychological tests
40984654|NCT00702819|DRUG|Bevacizumab|Dosage of 0.75mg/0.03ml injectable, one time only.
40984655|NCT05434260|DEVICE|Surgiphor Irrigation Solution|use of Surgiphor wound irrigation solution during surgery
41144056|NCT05326685|OTHER|video with korotkoff sounds|The State-Trait Anxiety Inventory short version (STAIS-5, STAIT-5) and the student introduction form were applied at the beginning of the study. Then Intervention participants were shown and listened visual video with korotkoff sounds before blood presssure measurement. Afterwards, blood pressure was measured to the students 3 times and 3 measurements were recorded. After the application about 2 hours later, the students State Anxiety Inventory short version (STAIS-5) form was filled again by students.
41463465|NCT05312255|DRUG|Beta-Adrenergic Antagonist|Receive beta-blocker regimen as per SOC
41463466|NCT05312255|DRUG|Propranolol|Given PO
40984656|NCT05434260|DEVICE|Sterile saline|Use of sterile saline as a irrigation solution during surgery
40984657|NCT00337506|DRUG|Dexamethasone|
40984658|NCT00337506|DRUG|velcade|
40984659|NCT05682781|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Oral Nutritional Supplement
40984660|NCT05682781|OTHER|Dietary Counseling|Dietary Counseling
40984661|NCT02296268|BEHAVIORAL|Aerobic Exercise Screening and Prescription Clinic|Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
40984662|NCT00508625|DRUG|AMG 951 (rhApo2L/TRAIL)|AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
40984663|NCT00508625|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).
40984664|NCT00508625|DRUG|Carboplatin|Standard platinum based chemotherapy
40984665|NCT00508625|DRUG|Paclitaxel|Standard taxane chemotherapy
40984666|NCT00149084|DRUG|Lansoprazole, clarithromycin, amoxicillin|
40779992|NCT00767026|BEHAVIORAL|Standard education|This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
40779993|NCT05688085|DRUG|Irbesartan High/Amlodipine FDC|Irbesartan High/Amlodipine FDC
40984667|NCT04476433|OTHER|Ten Vida (10Vida)|10Vida is a psychoeducational and emotional programme for chronic illness in adolescents and their families.
41144057|NCT05513729|DRUG|Canagliflozin|According to the guideline of type 2 diabetes，canagliflozin will be given to 40 patients with type 2 diabetes combined with NAFLD as first-line choice if accompanied with indicators of high risk or established atherosclerotic cardiovascular disease, chronic kidney disease or heart failure, independently of HbA1c level. It can be also given to T2DM combined with NAFLD if their HbA1c above target.
40779994|NCT05688085|DRUG|Irbesartan High|Co-administration of Irbesartan High and Amlodipine
40779995|NCT05688085|DRUG|Amlodipine|Co-administration of Irbesartan High and Amlodipine
40779996|NCT02150239|PROCEDURE|operation|
40779997|NCT03279926|BEHAVIORAL|PLAY|Activity trackers + curriculum information
41144058|NCT05513729|DRUG|Pioglitazone|According to the newest guideline of Diabetes，pioglitazone will be given to 40 patients with T2DM combined with NAFLD if their HbA1c above target.
40779998|NCT03279926|BEHAVIORAL|PLAY Parents|Enhanced parental engagement
40779999|NCT03279926|BEHAVIORAL|PLAY Teachers|Enhanced teacher engagement with active living initiates for the teachers
40780000|NCT04814914|OTHER|KB109 + Self Supportive Care|KB109 is a novel glycan
40780001|NCT04814914|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
40780002|NCT04194450|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.
40780003|NCT04194450|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of taste-matched placebo prior to assessment of outcomes.
40780004|NCT03708367|DEVICE|LipiFlow Thermal Pulsation System|Treatment at preoperative visit for study group
40780005|NCT03708367|DEVICE|LipiFlow Thermal Pulsation System|Treatment at 3 month visit as the cross-over group
40780006|NCT03590886|OTHER|total response Group|biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
41304489|NCT03747835|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention involves collaboratively developing a list of food-related fears with the patient and planning treatment sessions in which the patient is exposed to the fear and inhibits safety behaviors. The explicit goal of these exposure sessions will be to violate the patient's expectation regarding the feared stimulus, rather than to reduce fear.
41304490|NCT03747835|BEHAVIORAL|Motivational Interviewing|"Motivational interviewing techniques including reflective listening to demonstrate empathy and understanding, asking questions to elicit change talk (speech that is pro-change), evaluating the decisional balance, and managing or rolling with resistance will be incorporated throughout the treatment sessions."
41304491|NCT01597557|DRUG|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
41304492|NCT01597557|OTHER|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
41304493|NCT03065712|DRUG|F-18 Fluoroestradiol|F-18 Fluoroestradiol will be administered for PET/CT scan.
41304494|NCT03065712|PROCEDURE|Computed Tomography|Undergo PET/CT
41304495|NCT03065712|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41304496|NCT03065712|OTHER|Laboratory Biomarker Analysis|Correlative studies
41304497|NCT01672996|DRUG|Ioforminol 160 mgI/mL|Given as s single administration to the subject
41304498|NCT01672996|DRUG|Ioforminol 200 mgI/mL|Given as a single administration to the subject
41304499|NCT01672996|DRUG|Iopamidol 300 mgI/mL|Given as a single administration to the subject
41304500|NCT01987349|BIOLOGICAL|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza vaccine (IIV3)
41304501|NCT01987349|BIOLOGICAL|FluMist® (intranasal)|Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)
41304502|NCT02477085|OTHER|all women with an induced labor|all women who have an induced labor
41304503|NCT03798912|COMBINATION_PRODUCT|RaniPill capsule containing octreotide|Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.
41304504|NCT00252122|DRUG|Ketamine|Ketamine. 0.2 mg/kg, intravenously
41463467|NCT05312255|OTHER|Quality-of-Life Assessment|Ancillary studies
41463468|NCT05312255|OTHER|Questionnaire Administration|Ancillary studies
41463469|NCT05312255|OTHER|Resistance Training|Undergo strength training for 6 months
40780007|NCT06018987|OTHER|No-Treatment Control|Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
40780008|NCT06018987|DEVICE|HAC 20L|Subdermal Injections
40780009|NCT03890510|OTHER|Ringer's Lactate solution|Patients in both groups will receive Ringer's lactate solution continuously during operation with different infusion volume.
41304505|NCT05872971|DEVICE|Dry Needling|Dry Needling: The technique will be used by a physiotherapist experienced in orthopedic conditions and with specific training in DN. The application will be through the deep technique, above 10mm deep, the therapist will score trigger points regions of the muscles of the posterolateral region of the hip with application duration of 30 to 60 seconds. Eight points of application will be standardized in the region of the muscles of the posterolateral region of the hip.
41304506|NCT05872971|DEVICE|Lasertherapy|Lasertherapy: The application of the Laser will be performed by a physiotherapist specialized in traumato-orthopedics. The equipment will be infrared laser (904 nm), by point technique. Eight points of application will be standardized in the region of muscles of the posterolateral region of the hip. The time, dose and amounts of application points will be guided according to the dosimetry criteria of the World Association for Photobiomodulation Therapy.
41304507|NCT00004013|BIOLOGICAL|trastuzumab|
41304508|NCT00004013|DRUG|paclitaxel|
41304509|NCT02993224|DRUG|Deferasirox dispersable tablet (DT)|"Deferasirox DT was provided as 125 mg, 250 mg, 500 mg dispersible tablets for oral use. The strengths provided in an individual country could differ and reflected the strengths available commercially in each country.~For iron chelation naive participants, the starting dose on Baseline Day 1 was 20 mg/kg/day in TDT and 10 mg/kg/day in NTDT.~For iron chelation (deferoxamine and/or deferiprone) pre-treated participants, the starting dose was equivalent to the dose of deferoxamine received (for participants pre-treated with deferoxamine) and based on their serum ferritin levels (for participants pre-treated with deferiprone).~Participants took deferasirox DT once daily for 24 weeks (core phase). The required number of deferasirox DT tablets were to be dispersed with gentle stirring in a glass of water."
41304510|NCT02993224|DRUG|Deferasirox film coated tablet (FCT)|"Deferasirox FCT was provided as 90 mg, 180 mg, 360 mg film coated tablets for oral use. The FCT starting dose on Week 25 was 14 mg/kg/day in TDT and 7 mg/kg/day in NTDT.~Participants took deferasirox FCT once daily for 24 weeks during the core phase and up to 48 weeks during the extension phase. For patients with difficulties in swallowing deferasirox FCT, it was allowed to crush the film-coated tablets and administer the study drug by sprinkling the full dose on soft food (like yogurt or apple puree)."
41304511|NCT00014664|BIOLOGICAL|apolizumab|
41463470|NCT05312255|OTHER|Short-Term Fasting|Participate in intermittent fasting
41463471|NCT01989299|DEVICE|ILR implantation|
41463472|NCT00069030|BIOLOGICAL|VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP|
41463473|NCT04601350|DRUG|remimazolam group was induced with remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia|remimazolam group was remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
41463474|NCT04601350|DRUG|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
41463475|NCT01374945|DEVICE|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
41463476|NCT04386109|OTHER|No intervention - exposure is to COVID-19|No intervention - exposure is to COVID-19
41463477|NCT03225352|DRUG|500 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 500mg
41463478|NCT03225352|DRUG|1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 1000mg
41463479|NCT03225352|DRUG|400 mg ibuprofen(Nurofen)|Single intake of 1 tablet, 400mg
41463480|NCT03225352|DRUG|400 mg ibuprofen (Dolormin Extra)|Single intake of 1 tablet, 400mg
41463481|NCT01266603|DRUG|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
41463482|NCT01266603|BIOLOGICAL|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
41463483|NCT01692886|BIOLOGICAL|7-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
41463484|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
41463485|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
41144059|NCT03665675|BIOLOGICAL|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given intravenously
41304512|NCT06006858|BIOLOGICAL|Moderna COVID-19 Vaccine|Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
41304513|NCT01242020|DRUG|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
41304514|NCT03916809|OTHER|EMST|Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.
41304515|NCT04848584|BIOLOGICAL|Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine|prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study
41304516|NCT04848584|BIOLOGICAL|BNT162b2 BA.4/5 bivalent|Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.
41463486|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
41463487|NCT01040793|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
41463488|NCT01040793|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
41463489|NCT01040793|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
40780010|NCT03890510|PROCEDURE|Spine surgery under general Anesthesia in the prone position|The surgery, general anesthesia, and the placement of the prone position will be performed according to the standard procedures.
41144060|NCT03665675|BIOLOGICAL|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given intravenously
41144061|NCT05771272|DIAGNOSTIC_TEST|Sit and Reach Test|To conduct the test, a box measuring 32 centimeters in height, 45 centimeters in width, and 35 cm in length, and the upper surface of the box was 15 cm longer than the area on which the feet rest. The participant is positioned on the ground with both legs fully extended, separated by shoulder width, and flat on the box. The participant positioned themselves with one hand on top of the other, knees fully extended, stretched as far forward as they could, sliding their hands across the ruler's top, and kept that posture for at least two seconds. The end location of the fingertips on or approaching the ruler was measured in centimeters to get the sit and reach score. Scores that are higher showed improved performance. The best result is recorded after the test was run three times.
41463490|NCT01040793|DRUG|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
41463491|NCT01040793|DRUG|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
41463492|NCT04148105|DRUG|Cilostazol 100 MG|The addition of 100 mg cilostazol, twice daily for 14 days, to the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
41463493|NCT04148105|OTHER|Placebo|The standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
41463494|NCT03693833|DRUG|Cannabidiol|Cannabidiol (CBD) tablets of 10mg each
41463495|NCT03693833|DRUG|Placebo Oral Tablet|Oral Placebo tablets of 10mg each
40780011|NCT03868410|DEVICE|New rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
40984668|NCT04020679|BEHAVIORAL|Goals of Care Initiative|Can-GUIDE will provide videos on a number of SDM topics including interviews with patients and clinicians discussing patient involvement in SDM and how goal conversations can inform the decision making process. Furthermore, there will be instructional videos on how to complete the Goal conversations sheet. Accompanying the videos will be interactive elements which will help users consider the types of questions that they wish to ask their clinical teams. The goal conversation sheet allows patients to list their goals and priorities that they wish to bring up in the consultation with their clinical teams. The Goals of Care (GOC) tool is a communication aid for clinicians to summarise goals of care discussions such as those facilitated by the goals conversation sheet. The completed tool will then be logged onto the Electronic Patient Record (EPR) and is then disseminated to other HCPs involved in the patients care.
40984669|NCT05736107|DRUG|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
40780012|NCT03868410|DEVICE|Conventional rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the ipsilesional primary motor cortex (iM1) before the start of each session. iM1 will be stimulated with high-frequency rTMS (5-Hz) using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
40984670|NCT05736107|OTHER|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
41304517|NCT04848584|BIOLOGICAL|XBB.1.5-adapted vaccinated|Vaccinated with XBB.1.5-adapted vaccine
41304518|NCT00422838|PROCEDURE|fine-needle aspiration biopsy|aspiration of intrahepatic cells
41304519|NCT03252496|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
41304520|NCT03252496|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
41304521|NCT03252496|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
41304522|NCT03252496|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
41304523|NCT03252496|RADIATION|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
41304524|NCT03252496|DRUG|250 mL Colloid over 5 minutes|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
41144062|NCT05771272|DIAGNOSTIC_TEST|Weight Bearing Lunge Test|To conduct the test, with a tape measure on the floor, measure the distance from the big toe's end to the wall. Participants make a lunging motion forward until their knee hit on the wall. The participant's foot is positioned on the floor with the big toe and heel line aligned on the tape measure. To determine how close to the wall a subject could touch the wall with their knee while still keeping their heel in contact. The tape measure is then used to calculate the distance from the big toe's tip to the wall in centimeters. Increasing the distance indicates that the participant has less ankle dorsiflexion range
41144063|NCT02791308|DRUG|Pimecrolimus Cream 1% (Valeant)|
41304525|NCT03252496|DRUG|250 mL Crystalloid over 5 minutes|Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
41304526|NCT03252496|DRUG|500 mL Crystalloid over 55 minutes|Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
41144064|NCT02791308|DRUG|Vehicle cream|
41144065|NCT02791308|DRUG|Pimecrolimus Cream, 1%|
41144066|NCT06385080|BIOLOGICAL|Amivantamab|Amivantamab will be administered subcutaneously.
40984671|NCT02415751|BEHAVIORAL|heart failure self-care education|It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
40984672|NCT05690555|OTHER|Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks and 6 weeks postoperatively. The following interventions will be performed:~3 weeks:~* Subjective assessment of bowel and bladder function~* Visual and external palpation and assessment of external pelvic floor region~* Intravaginal pelvic floor assessment~* Pelvic floor muscle dynamics and coordination assessment~* Instruction of pelvic floor coordination and lengthening~* Discussion of dilator program and progression~* Home program with instructions~  6 weeks:~* External scar assessment and treatment if tissue healing allows~* Instruction to patient of scar mobilizations~* Intravaginal pelvic floor assessment and treatment if indicated~* Review of pelvic floor lengthening and coordination~* Review and progression of dilator program if appropriate~* Assessment of current bowel/bladder symptoms; home program and instructions to address these symptoms"
40984673|NCT05690555|OTHER|No Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed:~Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function."
40984674|NCT05690555|OTHER|Preoperative PFPT and Postoperative PFPT|Preoperative Diaphragmatic breathing Discuss dilator positioning/introduce dilator program External pelvic floor assessment Teach pelvic floor coordination Current bowel/bladder symptoms; home program and instructions 3 weeks Assessment of bowel and bladder function Visual and external palpation and assessment of external pelvic floor region Intravaginal pelvic floor assessment Pelvic floor muscle dynamics and coordination assessment Instruction of pelvic floor coordination and lengthening Discussion of dilator program and progression Home program with instructions 6 weeks External scar assessment and treatment if tissue healing allows Instruction to patient of scar mobilizations Intravaginal pelvic floor assessment and treatment if indicated Review of pelvic floor lengthening and coordination Review and progression of dilator program if appropriate Current symptoms; home program and instructions
40984675|NCT05690555|OTHER|Cross-over Treatment|Any patients in the No PFPT arm who are determined to have pelvic floor dysfunction or symptoms that may benefit from PFPT referral, will be referred after the 12-week mark. Any patient in one of the PFPT arms who is determined to still need PFPT for persistent pelvic floor dysfunction or symptoms will be referred for continued care.
40984676|NCT03579589|DRUG|Sugammadex vs Neostigmine|Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.
40984677|NCT01401868|DRUG|ME-143|"experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
40984678|NCT05132504|DRUG|Pembrolizumab|Pembrolizumab will be initiated starting with the Cycle 2 Day 1 and will be administered every 6 weeks with a max amount of 9 cycles throughout the study.
41144067|NCT06385080|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered intravenously.
41144068|NCT06385080|DRUG|Paclitaxel|Paclitaxel will be administered intravenously.
41144069|NCT05067816|BEHAVIORAL|Med-South Lifestyle Program|The Med-South Lifestyle Program (MSLP) is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a southeastern US population and includes support for increased physical activity. To promote healthy dietary intake and increased physical activity, the intervention incorporates theory-based behavioral approaches targeting self-efficacy, self-regulation, and internal motivation. The MSLP is delivered in 4 monthly counseling sessions with 3 interim phone follow-up contacts. A maintenance phase lasting 6 months follows the 4-month MSLP and includes 2 phone contacts about 2 months apart. Participants are counseled individually, with 2 in-person counseling visits (at the 1st and 4th counseling visit) and 5 total phone contacts. Each participant is provided with program materials in a participant manual, a cookbook, and a local resource manual identifying community resources to support making targeted behavior changes.
41144070|NCT04864353|BEHAVIORAL|RestDep: Internet-delivered intervention targeting residual cognitive symptoms|The intervention is fully digital with weekly telephone guidance. Key intervention elements are 1) psychoeducation, 2) attention training, 3) strategy training. Cognitive domains as attention, memory and executive functions are covered and rumination.
41144071|NCT02408978|DRUG|OXP005|
41144072|NCT02408978|DRUG|Naproxen|
41144073|NCT03301597|BIOLOGICAL|NLA101|"NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use."
41144074|NCT03301597|DRUG|Standard of Care (SOC) chemotherapy|The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
41144075|NCT03149484|DEVICE|Personal remote microphone (RM) system|Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.
41144076|NCT03149484|OTHER|Subjective Questionnaire|These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
41304527|NCT03252496|DRUG|250 mL Colloid over 60 minutes|After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
40984679|NCT05132504|DRUG|Folfirinox|Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil) chemotherapy treatment. Each cycle is 14 days; a total of six cycles will be administered. Patients will receive growth factor support at the discretion of treating physician.
41463496|NCT03601494|OTHER|perineural injection of platelet-rich plasma|Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in-plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.
41463497|NCT03601494|DRUG|medical|vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
41463498|NCT01448148|OTHER|Cognitive intervention|Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
41463499|NCT01448148|OTHER|Psychosocial intervention|Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
40984680|NCT05692765|BEHAVIORAL|smartphone application to enhance fruit and vegetables intake among adolescents|"This randomized intervention study was conducted in an urban area of Jeddah, Saudi Arabia. We included 104 adolescents aged 13-18 years, who were randomized into intervention (n=55) or control (n=49) arms. We examined the effects of a smartphone application (My Plate) on fruit and vegetable intake over 6 weeks in the intervention group. Pre- and postintervention questionnaires were used in the intervention and control groups."
40984681|NCT06046339|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file.
40780013|NCT01362101|BEHAVIORAL|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|"60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~* Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~* Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol."
40780014|NCT01278264|DRUG|Ropivacaine 0.25%, 0.5 ml/kg|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
40780015|NCT01278264|DRUG|Ropivacaine 0.25%, 0.5 ml/kg|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
40984682|NCT01272609|DRUG|Timolol + LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
40984683|NCT01272609|DEVICE|LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
40984684|NCT02480543|DRUG|Misoprostol (cytotec)|
40984685|NCT05229120|BEHAVIORAL|Episodic Future Thinking|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
40984686|NCT02428946|DRUG|Bromocriptine|Investigating the randomized order for timing of bromocriptine administration
40984687|NCT05399381|DEVICE|Transcranial alternating current stimulation (tACS)|Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.
40984688|NCT02980887|OTHER|No Intervention|There is no intervention in this observational study
40984689|NCT04544098|DRUG|177Lu-DOTATATE|The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed for each patient: patients will receive two intra-arterial cycles of 7.4 GBq, unless toxicity occurs requiring dose modifications.
41304528|NCT03252496|DRUG|250 mL Crystalloid over 60 minutes|After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
41304529|NCT03252496|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
41463500|NCT00978887|OTHER|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
41463501|NCT00978887|OTHER|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
41463502|NCT02999698|OTHER|Observational|Observational
40984690|NCT05195827|DRUG|PRM-125|Antihypertensive
40984691|NCT02615587|DRUG|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
40984692|NCT03103386|DIETARY_SUPPLEMENT|intake of food product with a patented fermented rye bran|During the treatment period, participants will be provided 2 packages of puff（fermented rye bran）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
41304530|NCT03252496|DRUG|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
41304531|NCT02170805|DRUG|BIBR 1048 MS capsule formulation A|BIBR 1048 MS, formulation A 50 mg
41304532|NCT02170805|DRUG|BIBR 1048 MS capsule formulation B|BIBR 1048 MS, formulation B 50 mg
40984693|NCT03103386|DIETARY_SUPPLEMENT|intake of food product with common refined wheat|During the treatment period, participants will be provided 2 packages of puff （common refined wheat）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
41304533|NCT02170805|DRUG|BIBR 1048 MS powder plus solution|BIBR 1048 MS, powder plus solution 50 mg
40984694|NCT04181502|PROCEDURE|pneumatic tourniquet|a pneumatic tourniquet around 200 mmHg after venous chase of the lower limb, during 5 minutes then deflated. Repeated twice after general anaesthesia and prior to incision.
40984695|NCT04181502|OTHER|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
41144077|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 2 mg, Once daily, 14 days
41144078|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 12 mg, Once daily, 14 days
40984698|NCT05483179|DIAGNOSTIC_TEST|CPET|Cardiopulmonary exercise test
40984699|NCT03218033|BEHAVIORAL|Social Media|
41144079|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 25 mg, Once daily, 14 days
41304534|NCT02170805|DRUG|Pantoprazole|Pantoprazole 40 mg
41304535|NCT02234583|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
41304536|NCT01295112|DRUG|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
41304537|NCT01295112|DRUG|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
41304538|NCT00340314|PROCEDURE|Circumferential Pulmonary Vein Ablation|
40984700|NCT03121547|DRUG|Tapentadol 50 mg Oral Tablet|1 tablet administered
40984701|NCT03121547|DRUG|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|1 tablet administered
40984702|NCT03121547|DRUG|Placebo Oral Tablet|calcium tablet
40984703|NCT04864379|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01: 300 mcg per peptide
40984704|NCT04864379|OTHER|GM-CSF|GM-CSF: 40 mcg
40984705|NCT04864379|DRUG|PD-1|PD-1: 200mg administered by intravenous infusion every 2 weeks.
40984706|NCT04864379|PROCEDURE|RFA|Radiofrequency ablation surgery
41144080|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 15 mg, Once daily, 14 days
41144081|NCT01515202|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 14 days
41144082|NCT00749944|DRUG|varenicline|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
41144083|NCT00749944|DRUG|placebo|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
41304539|NCT00340314|DRUG|Antiarrhythmic Drug Therapy|
41304540|NCT04953949|DEVICE|NU-MAX®|Topical Hemostat
41304541|NCT01258348|DRUG|Drug: LY573636-sodium|"Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression."
40984707|NCT01058889|DEVICE|Telemedical device|Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
40984708|NCT02707250|DRUG|Placebo|Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
41304542|NCT01258348|DRUG|Sunitinib|"37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression."
41304543|NCT01101568|DRUG|Simvastatin|Simvastatin 40mg (single dose) on Days 1 and 10.
41304544|NCT01101568|DRUG|Rosuvastatin|Rosuvastatin 10mg (single dose) on Days 3 and 12.
41304545|NCT01101568|DRUG|GSK1292263|GSK1292263 300mg BID Days 6 to 14.
40780016|NCT05547113|DIAGNOSTIC_TEST|posturography|In our stabilometric laboratory we use for the posturography two Kistler stabilometric platforms (type 5619A, Switzerland) along with MARS software (version 5.0, Switzerland). We use the SYNAPSIS Subjective Vertical device (version 1.3.2, France) to examine the perception of the subjective visual vertical. The patients should also full fill 5 questionnaires to subjective evaluation of non-vestibular symptoms within ADL and QoL, namely for difficulties related to dizziness, tinnitus, orofacial function disorders and the occurrence of anxiety and depression. For this purpose we use Dizziness Handicap Inventory, Tinnitus Handicap Inventory, Facial Disability Index, Beck's Anxiety Inventory and Beck's Depression Inventory.
40780017|NCT03690778|DRUG|"Metformin and Rosuvastatin seperately"|"administration of Metformin and Rosuvastatin seperately"
40780018|NCT03690778|DRUG|JLP-1310|administration of JLP-1310
40780019|NCT01656161|DRUG|Triptorelin embonate 22.5 mg|
40780020|NCT01661283|DRUG|everolimus|10 mg tablet once daily
40780021|NCT01661283|DRUG|bevacizumab|10 mg/kg dose every 14 days
40780022|NCT03499756|BEHAVIORAL|Couple-based interpersonal psychotherapy|The contents include: (1) an overview of changes associated with the role transition of parenthood and an introduction to the coping skills relating to role transition and parenting; (2) discussing common postpartum and interpersonal difficulties, such as conflicts with partners or extended family, and teaching effective communication skills to resolve interpersonal conflicts and maintain a good interpersonal relationship; and (3) building family strengths and resources by enhancing family sense of coherence, such as reassessing the challenges of the new role, applying problem solving techniques to deal with role transition and interpersonal problems, and developing new social support.
40780023|NCT00399087|DRUG|Perifosine|Perifosine oral administration
40780024|NCT00399087|DRUG|Docetaxel|IV administration
40780025|NCT00399087|DRUG|Prednisone|Oral administration
40984709|NCT02707250|DRUG|Bupivacaine|Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
40984710|NCT02707250|DRUG|Pethidine|Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
40984711|NCT02707250|DRUG|Pethidine Local Infiltration (L.I)|Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
40984712|NCT05769790|DIAGNOSTIC_TEST|ddPCR|The search for cfDNA will be performed using assays available in the literature for the search for E. granulosus cfDNA developed for PCR analysis in biological samples, targeting EgG1 Hae III repeat region, cox1 and nad1 (Zhao et al 2021). Appropriate controls (synthetic sequences and Parasitic reference DNA, provided by the Echinococcosis Reference Center of the Istituto Superiore di Sanità, Rome) will be included in each experiment.
40984713|NCT05951790|DEVICE|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in
41144084|NCT04527965|OTHER|Customized diet to reduce liver fat|"Ad libitum diet high in plant-derived PUFA and lower in carbohydrates~Carbohydrates: 30 E% Fat: 50 E% (PUFA 10-15 E%) Protein: 20 E%~Key foods are provided"
41144085|NCT04527965|OTHER|Healthy Nordic diet|"Ad libitum diet, based on Nordic foods, high in carbohydrates (high fiber/low GI) and lower in fat~Carbohydrates: 50-55 E% Fat: 25-30 E% (PUFA 5-7.5 E%) Protein: 20 E%~Key foods are provided"
41144086|NCT04527965|OTHER|Control|"Ad libitum diet in accordance with the Nordic Nutrition Recommendations~Key foods are provided"
41304546|NCT05474690|DRUG|Docetaxel + Carboplatin + Trastuzumab + Pertuzumab|"Subjects who met the inclusion conditions were randomly divided into TCbHP group and ECHP-THP group according to 1:1.~Stratified at randomization by the following factors: T, N, HER2 expression (HER2 protein 3+ vs HER2 protein 2+ but FISH+), and hormone receptor status (HR positive vs HR negative).~TCbHP regimen drug dose: docetaxel 75 mg/m2 + carboplatin (AUC=6) + trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg) + pertuzumab Antibiotics (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle."
41304547|NCT05474690|DRUG|(Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)|Dosage of ECHP-THP regimen: epirubicin 90mg/m2+cyclophosphamide 600mg/m2 followed by docetaxel 90mg/m2, trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg /kg) + Pertuzumab (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle.
41463503|NCT04838379|DRUG|Dexmedetomidine|Ninety patients were randomized to receive ultrasound-guided RSB\&tap block After the induction of anesthesia and patient stabilization, the abdomen was sterilized and draped. Then, under complete aseptic conditions, ultrasound-guided Bilateral Rectus Sheath Block \& tap block was performed
40780026|NCT02542618|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|
40780027|NCT02542618|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
40780028|NCT01864434|DEVICE|Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
40984714|NCT05951790|DEVICE|Inspiratory Muscle Training (IMT) + Air Stacking|Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity
40984715|NCT02786316|OTHER|HIT program|HIT program for the rehabilitation of persons with NSCLBP
40984716|NCT02786316|OTHER|conventional rehabilitation program|a conventional rehabilitation program in persons with NSCLBP
40780029|NCT01864434|DEVICE|Zimmer PCR TKA|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
40780030|NCT03542617|DRUG|Dexamethasone|
40780031|NCT03542617|DRUG|Normal Saline Solution|
40780032|NCT00740181|DRUG|chemotherapy|
40780033|NCT05631444|BIOLOGICAL|Cell-based therapy|One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
40984717|NCT01334268|DEVICE|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
40984718|NCT01334268|DEVICE|Resolute Zotarolimus-Eluting Coronary Stent System|Resolute Zotarolimus-Eluting Coronary Stent System Implantation
40984719|NCT06209229|BIOLOGICAL|sodium nucleinate|"* Calcitriol- 5000 units in the morning before meals every other day 21 days and the next 3 weeks after the end of therapy.~* Magnesium (in the form of lactate dihydrate) 470 mg + pyridoxine (in the form of hydrochloride) 5 mg - take orally 3 tablets per meter square of body surface area, in the evening 2 hours before bedtime, 21 days and the next 3 weeks after the end of therapy.~* Quercetin from onion juice - take orally 1000 mg in the morning before meals, 21 days, as well as the next 3 weeks after the end of therapy.~* sodium oligodinucleatide orally at the rate of 2 tablets under the tongue per meter square of body surface, in the morning 15 minutes before meals every other day, a total of 5 times (1, 3, 5, 7 , 9 day from the beginning of therapy), then after 21 days to repeat the course for 3 months.~* Spray natirium nucleonate 4 doses in the morning on the hyoid, suck, do not swallow for 3-5 minutes, once every 4 days for 21 days."
40984720|NCT04669392|DRUG|70% Ethanol Alcohol|"Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time."
41144087|NCT05652452|OTHER|Neurodynamics|Subjects in the neurodynamic group performed the 'Seated Straight Leg Slider' (SSLS) (Fig.1). To execute this sliding technique, subjects assumed a seated slump position (thoracic and lumbar flexion) which they needed to maintain throughout the exercise. This SSLS consisted of alternating movements towards knee extension and ankle dorsiflexion (increase of neural tension) combined with cervical extension (decrease of neural tension) on one hand, and knee flexion and ankle plantar flexion (decrease neural tension) combined with cervical flexion (increase of neural tension) on the other. During this 6-week period, each subject in this neurodynamic slider group was instructed to perform 3 sets of 20 repetitions on a daily basis for 6 weeks.
41144088|NCT05652452|OTHER|Static stretch|Subjects in the control group were instructed to perform a standard standing static stretch with the heel of the dominant leg taking support on a chair. Then they had to move the pelvis into anteversion, simultaneously inducing a forward lean of the trunk, until the clear sensation of hamstring stretch was perceived at the posterior aspect of the thigh. Again, the execution of the exercise was thoroughly explained and evaluated by the researchers and subjects sent home with a comprehensive instruction guide and supporting pictures. Each subject was instructed to do 3 repetitions of 30 second static stretches on a daily basis during the 6-week intervention.
41144089|NCT02275351|DRUG|SM04554|Topical solution, applied once a day
41144090|NCT02275351|DRUG|Vehicle|Topical solution, applied once a day
41144091|NCT00272415|DRUG|INO-1001|Intravenous repeating dose
41144092|NCT00272415|DRUG|temozolomide|Oral repeating dose
41304548|NCT01631279|DRUG|PR610|Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
41304549|NCT00321100|DRUG|bevacizumab|Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
41304550|NCT00321100|DRUG|cetuximab|Cetuximab 400mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly each 21 day cycle
41304551|NCT00321100|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 IV day 1 every 21 days
40780034|NCT05857748|DRUG|lifitegrast|patient newly started on medication will be followed for 6 months
40780035|NCT01206127|OTHER|Postoperative positioning: Bed rest|Patients in this group should be lying down facing up 2 hours postoperatively
40780036|NCT01206127|OTHER|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperative
40780037|NCT03829592|DRUG|misoprostol in a neutral media|giving misoprostol in a neutral media
40780038|NCT03829592|DRUG|misoprostol in an acidic media|giving misoprostol in an acidic media
40780039|NCT03829592|DRUG|misoprostol in an alkaline media|giving misoprostol in an alkaline media
40780040|NCT01413815|DIETARY_SUPPLEMENT|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
40780041|NCT01413815|OTHER|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
41304552|NCT00321100|DRUG|Capecitabine|Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
41304553|NCT03192982|DEVICE|A-V impulse 6000 Series|foot pad and pump
41304554|NCT03192982|DEVICE|Standard treatment (compression)|Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
41304555|NCT06060275|DIAGNOSTIC_TEST|serum sample and nerve conduction study and cerebrospinal fluid study|serum sample and cerebrospinal fluid study to detect Neurofilament light chain Nerve conduction study
40984721|NCT01425957|PROCEDURE|Lumbar puncture|"All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).~Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36)."
40780042|NCT05987982|PROCEDURE|Oral exercises and oral hygiene|The patients will be required to perform oral exercises and maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
40780043|NCT05987982|PROCEDURE|Oral care|The patients will be required to maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
40984722|NCT01346839|BEHAVIORAL|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
40984723|NCT06455371|OTHER|Decision support tool|Patients in the intervention groups are given the option to use the decision support tool when adjusting the levothyroxine dose after total thyroidectomy. Levothyroxine therapy is not a part of the intervention, as all patients receive this therapy regardless of study participation.
40984724|NCT06403995|BEHAVIORAL|Self-referred, undirected Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
40984725|NCT06403995|BEHAVIORAL|Recommended, undirected Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
40984726|NCT06403995|BEHAVIORAL|Recommended, directed Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
40984727|NCT01821534|OTHER|No Intervention|No treatment (intervention) was administered.
40984728|NCT01000441|DRUG|infliximab, etanercept, adalimumab|
40984729|NCT01000441|DRUG|abatacept, rituximab or tocilizumab|
40984730|NCT04358575|DEVICE|Triathlon CS Knee System with all-polyethylene tibial components|Primary Total Knee Replacement
40780044|NCT03755193|DRUG|"SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug"|To examine the effects of SERM and ELD in osteoporosis patients
40984731|NCT04358575|DEVICE|Triathlon CS Knee System with metal-backed modular components|Primary Total Knee Replacement
40780045|NCT03755193|DRUG|"Bisphosphonates and ELD Edirol®Tablet 0.75ug"|To examine the effects of BP and ELD in osteoporosis patients
40780046|NCT03755193|DRUG|"ELD Edirol®Tablet 0.75ug"|To examine the effects of ELD in osteoporosis patients
40780047|NCT02481258|DRUG|Ataciguat (HMR1766)|
40780048|NCT02481258|OTHER|Placebo Comparator: Matching Placebo|
40780049|NCT01606579|DRUG|PRI-724|PRI-724
40780050|NCT01606579|DRUG|PRI-724|PRI-724 in combination with dasatinib
40780051|NCT01606579|DRUG|PRI-724|PRI-724 in combination with low dose ara-C therapy
40780052|NCT05233839|OTHER|Telerehabilitation|Application based video home exercise for the degenerative meniscus injury
40780053|NCT05233839|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the degenerative meniscus injury
40780054|NCT02096978|PROCEDURE|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
40780055|NCT02121093|PROCEDURE|vibration|
40780056|NCT04951349|DRUG|GX-03|Same dosage used in Bactroban Nasal studies.
40780057|NCT04951349|DRUG|Petrolatum ointment|Viscous ointment similar in form to study drug.
40780058|NCT01596114|OTHER|Stopping treatment with TKI|stopping until loss of MMR
40780059|NCT05101720|PROCEDURE|Ultrasound Guided Axillary Venous Access|Direct visualization of axillary vein will be obtained with ultrasound sterile linear probe.
40780060|NCT05101720|PROCEDURE|Fluoroscopy-Guided Axillary Venous Access|Fluoroscopic landmarks will be used and axillary venous puncture will be performed without ultrasound
40780061|NCT06148246|BEHAVIORAL|Family Fit Condition|Dyads in the Family Fit condition will use the Family Fit app and a Fitbit for 18 weeks, working to increase their moderate- to vigorous-intensity physical activity.
40780062|NCT06148246|BEHAVIORAL|Fitbit Only Condition|Dyads in the Fitbit only condition will use a Fitbit and the Fitbit app for 18 weeks, working to increase their moderate- to vigorous-intensity physical activity.
40780063|NCT01823289|DRUG|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
40780064|NCT06203834|DIETARY_SUPPLEMENT|I-Fiber Pearl|Eat 200g for once, and once a day.
40780065|NCT06203834|DIETARY_SUPPLEMENT|placebo|Eat 200g for once, and once a day.
40984732|NCT02248194|DEVICE|Tactile electrosurgical ablation probe|
40984733|NCT02248194|DEVICE|Hysteroscopic endometrial ablation|
40984734|NCT05520931|OTHER|Questionnaire and register-based data assessment|Primary data will be collected via a generic questionnaire from the two groups. Secondary data will consist of register-based socio-economic data and medical charts data collected from the Danish Health Data Authority and Denmark' Statistics.
41304556|NCT04527172|DIAGNOSTIC_TEST|neuromuscular ultrasound|ultrasound to visualize the peripheral nerves of lupus patients and to compare it with results of the raditional electrophysiological studies
40780066|NCT02497105|OTHER|Ketogenic Diet|Dietary
40780067|NCT01561911|DRUG|Chi Lob 7/4 (A chimeric monoclonal antibody)|3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
40780068|NCT03126487|PROCEDURE|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND GUIDED BY MRI AS THERMIC DESTRUCTION
40780069|NCT02070653|DRUG|Ticagrelor|
40780070|NCT02070653|DRUG|Placebo|
40780071|NCT02092714|OTHER|laboratory biomarker analysis|Correlative studies
40780072|NCT00690326|BEHAVIORAL|Behavioral change communication to promote physical activity|"treatment type: behavioral (lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
40780073|NCT00690326|BEHAVIORAL|Behavioral change communication to promote physical activity|"Arm B given placebo comparator ie pamphlet~Audiovisual module Physical activity frequency questionnaire"
40780074|NCT02104934|PROCEDURE|Adductor Canal Block|
40780075|NCT00151021|BEHAVIORAL|Tailored web-based walking program|
40780076|NCT01418456|DRUG|antibiotics|A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
40984735|NCT00810290|BEHAVIORAL|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
40984736|NCT03773705|PROCEDURE|Electrocautery versus scalpel|Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery
40780077|NCT02918448|OTHER|Training group|The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
40780078|NCT01720394|DEVICE|Cervical Ripening Balloon, Cook Medical Inc.|Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
40780079|NCT01720394|DRUG|Dinoprostone|Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
40780080|NCT02690142|DRUG|Placebo|Single dose i.v.
40780081|NCT02690142|DRUG|ABY-035 i.v.|Single dose i.v.
40780082|NCT02690142|DRUG|ABY-035 s.c.|Single dose s.c.
40780083|NCT03709966|DEVICE|Portable monitoring device|similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status
40780084|NCT03709966|BEHAVIORAL|Routine|Physical activity promotion supported by a kinesiologist
40780085|NCT01142570|OTHER|Caloric Support (Group 1)|Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).
40780086|NCT01142570|OTHER|Caloric Support (Group 2)|For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)
40984737|NCT05899309|DIAGNOSTIC_TEST|liver and spleen stiffness test and laboratory test|Diagnosis of cirrhosis can be based on liver biopsy,radiological ,clinical or liver stiffness measurement (LMS)
41304557|NCT04973033|DRUG|Tofacitinib|patients enrolled were prescribed tofacitinib 5mg twice a day orally.
41304558|NCT06092242|DRUG|Tas-102(Suyuan) combined with bevacizumab|Tas-102: po 35 mg/m2, bid, d1-5, d8-12, Q4 wks; bevacizumab: intravenous drip 5 mg/kg, D1, D15, Q4 wks.
41304559|NCT05255055|OTHER|Physical Therapy|A manual therapy protocol and a therapeutic exercise protocol
40780087|NCT01142570|DIETARY_SUPPLEMENT|Protein dose of 1.1 to 1.5 grams per kilogram weight.|Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.
40984738|NCT02792933|PROCEDURE|air in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be then withdrawn and the low resistance syringe filled with 3-5mL of air will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
40984739|NCT02792933|PROCEDURE|saline in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be withdrawn and the low resistance syringe filled with 3-5mL of saline solution will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
40984740|NCT04830020|DRUG|HMW-HA|Aerolized administration b.i.d.
40984741|NCT03959293|DRUG|Durvalumab|1500 mg by 1-hour IV infusion - Every 4 weeks
40984742|NCT03959293|DRUG|Tremelimumab|75 mg by 1-hour IV infusion - Every 4 weeks
40984743|NCT03959293|DRUG|FOLFIRI Protocol|"* Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
40984744|NCT02335489|DEVICE|Implantation with the commercially available Axium neurostimulator|
40984745|NCT06010940|DIETARY_SUPPLEMENT|Dietary supplement|nasogastric tube and oral care
40780088|NCT01142570|DIETARY_SUPPLEMENT|Protein at 1.1 grams per kilogram weight.|Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.
40780089|NCT01142570|DIETARY_SUPPLEMENT|protein at a dose of 1.5 grams per kilogram weight.|Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
40780090|NCT03678441|BEHAVIORAL|BrainCheck Cognitive Assessment|Receive BrainCheck cognitive assessment
40780091|NCT03678441|PROCEDURE|Cognitive Assessment|Receive pen and paper cognitive assessment
40780092|NCT06446570|DRUG|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
40780093|NCT04513782|DIAGNOSTIC_TEST|Audiological Assessments|Participants will all undergo routine audiological assessments. The results from these assessments will be evaluated in order to advance understanding of central hearing loss.
40780094|NCT03663192|DEVICE|strain echocardiography|strain echocardiography during septic shock
40780095|NCT05149729|PROCEDURE|Shortened hip arthroplasty|Crowe type 3 and 4 patients who underwent shortened hip prosthesis
40984746|NCT06010940|OTHER|Physical therapy|Designed physical therapy program consisting of neuromuscular electrical stimulation in addition to exercises for oropharyngeal muscles.
40984747|NCT02611778|BIOLOGICAL|ranibizumab|
40984748|NCT03443284|BEHAVIORAL|Health Partner|Health Partner is a combination of an iPhone or iPod Touch Operating System mobile application and a health care provider portal.
40984749|NCT03443284|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health \& Services.
40984750|NCT00549302|DRUG|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
40984751|NCT00549302|DRUG|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
40984752|NCT02843932|OTHER|functional brain MRI|functional imagery during motor-perception tasks
40984753|NCT06020365|OTHER|sequential fecal microbiota transplant combined with small intestinal fluid transplant|for eligible patients, the investigator use rifaximin, three times daily, 0.4 g each time, lasting 6 days followed by fecal microbiota transplant combined with small intestinal fluid transplant for 6 days. These procedures were repeated every 28 days.
40780096|NCT02202564|PROCEDURE|LT|Orthotopic LT
40780097|NCT02202564|DRUG|ADV-TK|
40780098|NCT02202564|DRUG|ganciclovir|
40780099|NCT03834896|OTHER|AYMES MADRID|AYMES MADRID is a gum-based commercial thickener, that can be utilised to modify fluid consistencies to Stage 1, 2 or 3 (as per the National Descriptors for Texture Modification) to enhance the safety of fluids in those with dysphagia.
40780100|NCT05185076|DEVICE|CureSight|watch CureSight treatment for 90 minutes per day, 5 days a week for 16 weeks
40780101|NCT02477748|DRUG|MDX|Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
40984754|NCT01974245|DRUG|Cholecalciferol|100,000 IU/week for 12 weeks
40984755|NCT01974245|DRUG|Placebo|100 drops/ week for 12 weeks
40984756|NCT06136702|BEHAVIORAL|Educational session|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.
40780102|NCT02477748|DRUG|Placebo|Tablet PO, taken once daily for 10 weeks.
41304560|NCT04776356|DEVICE|QuickFix Small Staple (Arthrex)|The Arthrex QuickFix Small Staple enables the surgeon to perform a wedge osteotomy of the first phalanx (Akin). The device is made of stainless steel and designed with barbed leg tips. The staple sizes are 8 and 10 mm wide with a 1 mm diameter.
40984757|NCT06136702|BEHAVIORAL|Self-sampling|Women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site, to measure the uptake of the self-sampling test (% of women who take the self-sample). Furthermore, two self-administrated questionnaires are applied to 1) assess attitudes regarding self-sampling (pre-intervention), and 2) assess users' experience regarding self-sampling (post-intervention). The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time. All women will be contacted 1-2 weeks after the self-sample taking to inform them on their test result.
40984758|NCT06136702|BEHAVIORAL|Follow-up assessment|To gauge the knowledge on cervical cancer screening after the educational session and to verify whether they got a pap smear, a 3-month follow-up is proposed for all women receiving an educational session (arm 1) and all women receiving an educational session and a self-sample (arm 2), because all women, whether or not invited for self-sampling, are provided information on where to get screened, although there is no formal referral to screening services.
40780103|NCT02434081|DRUG|Nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
40780104|NCT00071955|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
40780105|NCT00071955|BIOLOGICAL|sargramostim|
40984759|NCT00157950|BIOLOGICAL|Gardasil™|Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
41304561|NCT03783650|BEHAVIORAL|Control condition|Practices will submit control data and not receive centralized data feedback. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic.
40984760|NCT00157950|BIOLOGICAL|Placebo|Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
40984761|NCT04298554|OTHER|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration
40780106|NCT03888248|DEVICE|Whole-body vibration|Home-based whole-body vibration therapy by standing on Galileo Med 15 platform for 9 mins twice a day for 5 days per week
40780107|NCT03888248|OTHER|Muscle strengthening exercises|Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
40780108|NCT05222685|BEHAVIORAL|Better Together Physician Coaching|Professional group coaching for medical trainees. A 6 month, online, group, positive psychology based coaching program for wellness.
40780109|NCT04473560|DEVICE|Catheter-directed thrombectomy|Using common femoral venous access the pigtail diagnostic catheter will be placed into the main pulmonary artery and an initial pulmonary angiogram will be performed to demonstrate the location and extent of thrombi in pulmonary arteries. Then pulmonary arterial pressures will be measured. Subsequently an Indigo catheter (Penumbra, Alameda, California) will be placed and a direct-aspiration first-pass technique will be performed purposefully to attach a large thrombus to the catheter tip by suction and then pull it out through the sheath. The decision to terminate the intervention will be at operator's discretion after careful evaluation of hemodynamic parameters (restoration of the systolic blood pressure≥100 mmHg, heart rate \<100/min), improvement of arterial blood saturation≥ 92%, practicable clot burden reduction and total amount of aspirated blood (no more than 300 ml).
40780110|NCT02249078|DRUG|E6011|E6011 solution for injection
40780111|NCT02249078|DRUG|Placebo|Placebo 2-mL vial solution for injection
40780112|NCT04632017|DIAGNOSTIC_TEST|Computerized cardiotocography|To compare Dawes and Redman indices as determined by computer analysis of the fetal heart tracing
40780113|NCT01528579|OTHER|Neck Specific Exercises|2 times a week for 3 months followed by encourages to continue on their own
40780114|NCT01528579|BEHAVIORAL|Behavioral approach combined with neck specific exercises|Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
40780115|NCT01528579|OTHER|Prescribed Physical activity|Physical activity without neck specific exercises for 3 months
40780116|NCT00390377|PROCEDURE|Cutting scalp hair|
40780117|NCT00022438|BIOLOGICAL|aldesleukin|
40780118|NCT00022438|BIOLOGICAL|incomplete Freund's adjuvant|
40780119|NCT00022438|BIOLOGICAL|recombinant tyrosinase-related protein-2|
40984762|NCT04298554|OTHER|Hemp Oil|CBD PURE HEMP OIL
40984763|NCT05474742|OTHER|The Nori Health app|The Nori Health app consist of a chatbot that instantly answers questions about topics relevant to patients with IBD and 6-week education program. The chatbot is driven by artificial intelligence and armed with state of the art scientific literature to offer to the right information to the right person at the right time. The education program is offered during the first six weeks of use. The Nori Health app then actively offers information on four fixed topics and two topics to a participant's choosing (i.e. low energy, pain, stress, mental health, hydration, exercising). It is expected from participants that they respond to this by having approximately five chat conversations of five minutes per week. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention.
41304562|NCT03783650|BEHAVIORAL|QIC with PCP and without subspecialist|During this phase, practice will begin working on improving HTN practices within their clinic via a QIC, while the other cohort will act as a control (usual care) with data collection. They will attend an initial 1-day interactive video webinar learning session where they will learn QI methodology, enhance and practice QI skills, identify local 30-60 day aims to improve local HTN practices and increase their understanding of pediatric HTN. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic. They will participate in QI coaching, monthly video conferences, and monthly mini-root cause analyses (Mini-RCAs).
40780120|NCT00002325|DRUG|Fluconazole|
40984764|NCT02007018|DEVICE|Negative Pressure Wound Therapy|Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.
41304563|NCT03783650|BEHAVIORAL|QIC with Subspecialist|Practices will integrate their HTN subspecialist into the QIC and focus on issues at the boundary of PCP and subspecialty care (e.g. pre-referral work-up, communication across providers, and time for next available appointment).
41304564|NCT03783650|BEHAVIORAL|Hub and Spoke co-management|Practices will continue QIC components and implement a hub and spoke model, where the PCP diagnoses and provides definitive management for pediatric HTN with subspecialist support.
41304565|NCT03783650|BEHAVIORAL|Sustainability of changes|Practices will sustain their changes, illustrating the durability of these system changes even after QIC completion and without central feedback and regular meetings.
40984765|NCT02007018|OTHER|Usual Care of Surgical Wound|Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending \> 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
40984766|NCT05168410|OTHER|Alvarado Score|The Alvarado Score assesses patient symptoms to enable optimal triage and management of cases with suspected acute appendicitis.a
40984767|NCT01197053|BIOLOGICAL|Epicutaneous Immunotherapy|100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
40984768|NCT01197053|BIOLOGICAL|placebo of peanut|placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
41304566|NCT01660087|DEVICE|Biophotonic platform for VOC detection|Multiplex detection of VOCs with high sensitivity and specificity using a novel biophotonic device.
41304567|NCT01598584|DRUG|Mirtazapine plus gemcitabine|Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
40780121|NCT06255353|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
40780122|NCT06255353|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
40780123|NCT06255353|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
40780124|NCT00294034|DEVICE|Pacemaker|
40780125|NCT01854528|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
40780126|NCT01854528|DRUG|Ribavirin|Tablet
41304568|NCT01598584|DRUG|Gemcitabine, placebo|Gemcitabine 1.0g/m2,d1,d8,q3w placebo
41304569|NCT00436969|DEVICE|Orthovisc|Orthovisc injection
41304570|NCT00436969|DRUG|Control|Celestone (betamethasone sodium phosphate and acetate) - 2 mL
40780127|NCT01854528|DRUG|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
40780128|NCT01854528|DRUG|Telaprevir|Film-coated tablet
40780129|NCT00863161|DRUG|AZD3355|capsule, oral, single dose
40780130|NCT03733327|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
40780131|NCT03733327|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
40780132|NCT03733327|DRUG|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
40780133|NCT04237103|DRUG|Methotrexate|oral capsules taken once a week
40780134|NCT04237103|DRUG|Placebos|Administered identically to the experimental group
41304571|NCT02038296|PROCEDURE|transarterial chemoembolization|
41304572|NCT04068467|OTHER|Smartphone App|The application consists of content areas focused on mental health.
41304573|NCT04068467|OTHER|Waitlist Control|Waitlist control
41304574|NCT06455228|DEVICE|insert catheter|A fixed routine for pre-insertion cleaning and equipment was followed, including hand washing, placing the patient in a recumbent position, skin antisepsis, and preparation of the sterile field. Catheter insertion was performed by senior specialized nurses in the intravenous treatment room, which was a standardized setting for venipuncture.
40984769|NCT05106855|RADIATION|Low Laser Radiation|One group will receive laser application to check if there is acceleration of healing.
40984770|NCT05106855|OTHER|Changing the implant surface|Changing the treatment surface of the dental implant to see if osseointegration occurs more quickly.
41144093|NCT05223309|OTHER|Usinf thick loose sutures in seton techingues|"All patients were informed about doing fistulectomy and thick silk Seton suture placement for three months by excising the extrasphincteric part and putting the Seton suture to the intersphincteric part. Then, the second stage of operation includes the excision of the changing low type tract in which the silk Seton placed. We decrease the time of Seton placement in this study for three months to reduce the annoying symptoms of the patients. Therefore, the patient admitted to the operation theater after obtaining written consent. Most of the patients anesthetized by spinal anesthesia. In the operation theater, the patient assumed a lithotomy position~. After that, the injection of a solution, which is a mixture of methylene blue dye and hydrogen peroxide into the external opening of the fistula, was done to find the internal opening. The exit of color dye or bubbles achieved to localized of inner opening from it after using intraoperative proctoscopy examination."
40780135|NCT03700177|DRUG|Dexamethasone|modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.
40780136|NCT03700177|DRUG|Placebo|modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).
40780137|NCT03700177|DRUG|Ropivacaine Injection [Naropin]|30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
40780138|NCT00046072|DRUG|E5564|
40780139|NCT01465009|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
40780140|NCT01465009|DRUG|Paracetamol|Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
41304575|NCT03477526|PROCEDURE|Pulmonary rehabilitation program|3 weeks, ...
41304576|NCT00634959|DRUG|Maraviroc (UK-427,857)|150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
40780141|NCT01465009|DRUG|Placebo|Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
41304577|NCT00634959|DRUG|Maraviroc (UK-427,857)|100 mg oral tablet once daily while fasted on Days 1-10
41304578|NCT00634959|DRUG|Maraviroc (UK-427,857)|300 mg oral tablet once daily while fasted on Days 1-10
41304579|NCT00634959|DRUG|Maraviroc (UK-427,857)|150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
40780142|NCT03974516|DRUG|Careseng 1370|Careseng 1370 should be taken around 1 hour before meal.
40780143|NCT02148588|DRUG|Ultrasound-guided peripheral nerve block with 2% lidocaine|"Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)~Assessment of spontaneous and evoked pain responses~Completion of NPSI questionnaire~Mapping of the affected limb"
40780144|NCT00300378|DRUG|desvenlafaxine 50 mg|
40780145|NCT00300378|DRUG|desvenlafaxine 100 mg|
40780146|NCT01677260|DRUG|500 mg metformin hydrochloride extended release caplet (test drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
40780147|NCT01677260|DRUG|500 mg metformin hydrochloride prolonged release tablet (reference drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
40780148|NCT00859833|DRUG|Adenosine|Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
40984771|NCT05106855|RADIATION|Low Laser Radiation off|This group will receive laser application off.
40984772|NCT05106855|PROCEDURE|Implant placement immediately after tooth extraction|When the last alternative is tooth extraction, this will be done, and in the same surgical intervention the dental implant will be placed.
40984773|NCT05106855|PROCEDURE|Installing the dental crown with early loading|The installation of the dental crowns will be performed in a period of 6 to 8 weeks, after the dental implant has been installed.
40984774|NCT02078609|DRUG|LGH447|LGH447 in patients with AML or MDS
40984775|NCT02078609|DRUG|LGH447 + midostaurin|LGH447 + midostaurin in patients with AML
40984776|NCT02814123|OTHER|24-hour inpatient intervention|Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
40780149|NCT00859833|DRUG|Regadenoson|Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
40780150|NCT01155557|DEVICE|Specific Strength Training|10 weeks of progressive specific strength training for neck and shoulder muscles.
40780151|NCT01155557|BEHAVIORAL|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
40780152|NCT05040776|DRUG|EP-7041 Injection|EP-7041 infusion
40984777|NCT02234453|DEVICE|Minicare H-2000|Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
40984778|NCT04671550|DIAGNOSTIC_TEST|questionnaire|"Questionnaire on Driving performances and Visual Field"
40984779|NCT04620720|DRUG|capule gabapentin|neuropathic analgesic
41304580|NCT00634959|OTHER|Placebo|Matching placebo oral tablet on Days 1-10 (fed and fasted)
41463504|NCT06531876|DEVICE|Dreem 3S recording|Subjects in both Arms A and B will undergo at-home recording with the Dreem 3S EEG Headband to assess sleep. Subjects will undergo in-lab polysomnography and multiple sleep latency testing while also wearing the Dreem 3S EEG headband system. Arm B participants will be asked to withdraw from some or all of their Narcolepsy related medication therapy for roughly 19 days in order to assess the ability of the Dreem Headband System in characterizing sleep disturbances related to Narcolepsy.
40984780|NCT04963933|DEVICE|Nautilus endovascular device|Patients will be treated with the Nautilus Endovascular device followed by treatment follow up for up to 6 months
40984781|NCT03679650|DRUG|decitabine|Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.
40984782|NCT03679650|BIOLOGICAL|DC/AML fusion cells|An investigational agent that tries to help the immune system to recognize and fight against cancer cells
40984783|NCT01829750|GENETIC|Cardiac progenitor cell infusion|"(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group~(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1."
40984784|NCT00432471|PROCEDURE|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
40984785|NCT03249142|DRUG|ARM A Durvalumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : the tremelimumab 75 mg IV will be added to the durvalumab-chemotherapy combination at day 1 of cycle 2 before a salvage surgery. Durvalumab 1125 mg IV (with one cycle of tremelimumab 75 mg IV post S3) will be pursued in maintenance treatment, up to 1 year or until disease progression, unacceptable toxicity or patient withdrawn."
40984786|NCT03249142|DRUG|ARM B Durvalumab/Tremelimumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV + tremelimumab 75 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : patients will be treated according to investigator choice."
40984787|NCT04020393|PROCEDURE|SPGB|SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
40984788|NCT05343975|PROCEDURE|biopsy with audio-guided Meditation|biopsy with audio-guided Meditation
41144094|NCT03895567|DRUG|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)|"Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche)."
40984789|NCT03552146|DRUG|Propofol|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
41304581|NCT06331923|DEVICE|Continuous glucose monitoring (CGM) device|Continuous glucose monitoring (CGM) will be prescribed by the attending physician for at least 6 hours before surgery. The supervising nurse will educate the patient and their family on the correct wearing and connection of the CGM device. The calibration frequency and interval of glucose monitoring devices before and after surgery should be determined according to institutional treatment guidelines and the requirements of the monitoring device used. Intraoperative glucose calibration should be done immediately upon entering the operating room, immediately after skin incision, every 2 hours after skin incision, and at the end of wound closure. Glucose monitoring should be continued until the 7th day after surgery or discharge.
40984790|NCT03552146|DRUG|Dexmedetomidine|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
40984791|NCT04689295|OTHER|exercise programme 1|Schroth three dimensional scoliosis therapy method
40984792|NCT04689295|OTHER|exercise programme 2|Traditional scoliosis exercises
41144095|NCT03895567|DRUG|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule"
41144096|NCT03895567|DRUG|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet"
41144097|NCT04188353|DEVICE|Optic nerve sheath diameter measurement|ONSD measurements done at screening (T1), 30 minutes after mannitol infusion (T2), 60 minutes (T3) and 120 minutes (T4)
41144098|NCT04188353|DRUG|Mannitol|Mannitol at dose of 0.25 to 1 gm/kg over 20 minutes via a dedicated IV line
41144099|NCT01437540|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
41144100|NCT01437540|DRUG|Formoterol Fumarate|Inhaled formoterol fumarate 12 μg, twice per day
41144101|NCT06080945|OTHER|pharmacist-led patient-centered medication therapy management|The intervention group will receive a pharmacist-driven discharge counseling on budesonide, an inhaled glucocorticoid, from recruitment, until 12 months.
41144102|NCT01184027|BEHAVIORAL|nutrition /swallowing counseling|general nutrition and swalling information
41144103|NCT01184027|BEHAVIORAL|G-tube/swallowing intervention|Patient will have active swallowing intervention with an SLP
41144104|NCT01184027|BEHAVIORAL|nutrition /swallowing intervention|Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
41144105|NCT05415072|DRUG|DYP688|Single agent DYP688
41144106|NCT00079222|DRUG|itraconazole|
41144107|NCT00079222|DRUG|voriconazole|
41144108|NCT01985256|BIOLOGICAL|Toca 511|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.
41144109|NCT01985256|DRUG|Toca FC|
40780153|NCT02750969|DEVICE|Lidoderm patch (Lidocaine 5% patch)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
40780154|NCT02750969|OTHER|Tegaderm patch. (neutral patch, containing no drug)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
40780155|NCT02750969|PROCEDURE|blood test- serum lidocain levels|"each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.~the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests."
40780156|NCT02750969|OTHER|Hearing tests|each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
40984793|NCT05200533|OTHER|Task-sharing and shifting model between family physicians and physiotherapists|Medical consultations for acute low back pain patients are shifted from family physicians to physiotherapists.
40984794|NCT05200533|OTHER|Usual care|Medical consultations for acute low back pain patients are performed by family physicians
41304582|NCT05228730|BIOLOGICAL|Tozinameran - Standard dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A standard dose will be administered on day 0 of the study.
41304583|NCT05228730|BIOLOGICAL|Tozinameran - fractional dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.
40984795|NCT01794806|PROCEDURE|Tooth extraction and grafting with allograft|Alveolar ridge preservation using a bone grafting material (allograft) and a synthetic dPTFE (dense Polytetrafluoroethylene) barrier membrane
40984796|NCT01794806|PROCEDURE|Tooth extraction|Minimally traumatic single-rooted tooth extraction
40984797|NCT05774704|DRUG|Low curcumin group|One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.
40984798|NCT05774704|DRUG|High curcumin group|One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.
41144110|NCT04314206|DRUG|VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
41144111|NCT04314206|DRUG|Placebo for VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
40780157|NCT01295710|BIOLOGICAL|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
40780158|NCT01295710|BIOLOGICAL|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
40780159|NCT01892566|OTHER|mHealth Intervention|See arm description
40984799|NCT01953133|BEHAVIORAL|Couples Counselling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
40984800|NCT01947439|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent
40984801|NCT05791266|DEVICE|Sticker pads containing lavender and ylang ylang oil|Sticker pads , size 160 mm2, were produced by a certified ISO 9001 manufacturer and contained 0.3% lavender oil and 0.7% ylang ylang oil. The sticker pad was attached to the shirts of healthy volunteers for 2 hours. The outcomes were evaluated before, during and 30 minutes after removal of the pad.
41144112|NCT06481995|DRUG|Fibrogammin|Fibrogammin is administered according to the Summary of product characteristics (SmPC) after measured blood loss exceeds 700 ml and bleeding is ongoing
40780160|NCT02184533|DRUG|sodium selenite|Given PO
40780161|NCT02184533|RADIATION|radiation therapy|Undergo radiation therapy
40780162|NCT02184533|OTHER|laboratory biomarker analysis|Correlative studies
40780163|NCT02184533|OTHER|pharmacological study|Correlative studies
40780164|NCT02184533|OTHER|questionnaire administration|Ancillary studies
40780165|NCT01492088|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion
40780166|NCT04915716|OTHER|Peripheral blood glucose levels were monitored|Peripheral blood glucose levels were monitored
40780167|NCT03186638|DRUG|Ibuprofen|Given PO
40780168|NCT03186638|OTHER|Placebo|Given PO
41304584|NCT05228730|BIOLOGICAL|Elasomeran - standard dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study."
41304585|NCT05228730|BIOLOGICAL|Elasomeran - fractional dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study."
41304586|NCT00601588|DRUG|Sertraline|
41304587|NCT03696069|OTHER|Non-Interventional|Non-Interventional
41304588|NCT05380297|DEVICE|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
40780169|NCT03186638|OTHER|Questionnaire Administration|Ancillary studies
40780170|NCT06388252|PROCEDURE|Electrochemotherapy with Intratumoral Cysplatin|ECT will be performed directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
40984802|NCT05721989|DRUG|Ziltivekimab B|Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
41304589|NCT04921345|DRUG|Nemolizumab|Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.
41304590|NCT04921345|DRUG|Nemolizumab|Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
41304591|NCT04669678|DRUG|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.
41304592|NCT04669678|DRUG|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.
40780171|NCT06388252|PROCEDURE|Electrochemotherapy with Intravenous Bleomycin|ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
40780172|NCT01524406|DRUG|HPP593|Oral, twice a day.
40780173|NCT01524406|DRUG|Placebo|Oral, twice a day.
40780174|NCT05963438|PROCEDURE|anterior retraction|After placement of mini-implants and extraction of maxillary first premolar, retraction of anterior either simultaneously or separately depending on the allocated group will be done
40780175|NCT02896309|DIETARY_SUPPLEMENT|Sodium bicarbonate|
40780176|NCT02896309|DIETARY_SUPPLEMENT|Sodium chloride|
40780177|NCT05704153|DEVICE|Parasym 1Hz|Transcutaneous auricular vagus nerve stimulation of 1Hz
40780178|NCT05704153|DEVICE|Parasym 30Hz|Transcutaneous Auricular Vagus Nerve Stimulation of 30Hz
40780179|NCT05704153|DEVICE|Sham Intervention|Sham stimulation
40780180|NCT01697709|DRUG|Quetiapine|Quetiapine pharmacotherapy for cannabis dependence
40780181|NCT01697709|DRUG|Placebo|placebo capsules
40780182|NCT03464266|COMBINATION_PRODUCT|FTC/TDF and DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
40780183|NCT03464266|DRUG|FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
40780184|NCT03464266|DRUG|DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
40780185|NCT03464266|OTHER|Neither DMPA nor FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
40780186|NCT01205516|DRUG|Methadone|Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
40780187|NCT01205516|DRUG|Controlled Release Morphine|controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
40984803|NCT05721989|DRUG|Ziltivekimab D|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
40780188|NCT03906214|OTHER|Web-based Survey|"Participants will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and uneventful use of possibly risky medication. If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of Medications of Interest and report current or past use."
40780189|NCT02152189|OTHER|Screening for Fabry disease|
40780190|NCT03904147|DEVICE|TriClipTM Device|Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
40780191|NCT03257891|DRUG|Cabazitaxel|Cabazitaxel will be administered every 21 days
40780192|NCT02840630|OTHER|Tinned mackerel fish|Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
40780193|NCT03315585|DEVICE|steep pulse device|Applying the steep pulse to treat the patients with Prostate cancer
40780194|NCT00960089|DEVICE|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
41144113|NCT02301871|DEVICE|Dr. Gene's Health and Wellness|The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.
41304593|NCT04669678|DRUG|Sub-cutaneous medroxyprogesterone acetate (SC MPA)|SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.
41304594|NCT04669678|DEVICE|Non-hormonal intrauterine device (IUD)|The NOVA T-380 non-hormonal IUD consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in removal of the IUD. IUDs may be left in place for up to 5 years.
40780195|NCT03364504|OTHER|urine collection|3 urine collections during 24 hours
40780196|NCT02746315|DRUG|HS-20004|
40780197|NCT02746315|DRUG|Placebo|
40780198|NCT02433964|OTHER|Grupo LED|
41144114|NCT02301871|PROCEDURE|Muscle Energy Technique|MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
41144115|NCT02301871|PROCEDURE|Static stretching and Cervical non thrust manipulation|conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
41144116|NCT03733860|PROCEDURE|Cavernous tissue sparing penile prosthesis implantation|Beginning penile prosthesis implantation (Coloplast Titan USA) procedure after intracavenosal injection of PGE1 prostine.
41144117|NCT03733860|PROCEDURE|Conventional penile prosthesis implantation|Beginning penile implant procedure (Coloplast Titan USA) without prior intracavernosal injection of PGE1 prostine
41144118|NCT03733860|PROCEDURE|Intracavernosal injection of alprostadil|Intraoperative intracavernosal injection of alprostadil in the cavernous sparing group
41144119|NCT01887002|DRUG|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
41144120|NCT01887002|DRUG|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
40780199|NCT02433964|OTHER|Placebo|ledterapia off + price
40780200|NCT05542888|PROCEDURE|Sacroiliac joint mobilization|Sacroiliac joint mobilization will be performed with the patient in side lying position in which grade I,II pain relief mobilization will be given in PA direction.It will be given as 1 set of 30 oscillations per session, 3 times per week for 4 weeks.
40780201|NCT05542888|PROCEDURE|Standard therapy|Postural education, Hot pack, Antenatal exercises
40780202|NCT06400667|DEVICE|Upper limb Kinematic Assessment with Optoelectronic system|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks. During the data acquisition protocol, the subject perform five trial for each upper limb of a determinate functional task for each session. Every subject repeat this operations 2 times with 2 different operators.
40780203|NCT00749437|RADIATION|3-dimensional conformal accelerated partial breast irradiation|Accelerated partial breast irradiation following lumpectomy with placement of Acculoc fiducial markers.
40984804|NCT05721989|DRUG|Ziltivekimab C|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
40984805|NCT00240903|BIOLOGICAL|Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)|
40984806|NCT01548092|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
40984807|NCT02184689|DRUG|fexinidazole|
40984808|NCT04537507|PROCEDURE|Coronary angiography|
41144121|NCT01090258|DEVICE|Hamilton ventilator (G5 modify to S1) Automated settings|Automated settings (respiratory rate \[RR\], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
40780204|NCT03223675|RADIATION|hippocampal-sparing WBRT|
40780205|NCT00003287|DRUG|FOLFOX regimen|
40780206|NCT00003287|DRUG|fluorouracil|
40780207|NCT00003287|DRUG|leucovorin calcium|
40780208|NCT00003287|DRUG|oxaliplatin|
40780209|NCT05380687|DIAGNOSTIC_TEST|Inspiratory hold|A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of inspiration. It is used to asses expiratory force generation (maximal expiratory pressure, MEP) and frequently used in clinical practice.
40780210|NCT05380687|DIAGNOSTIC_TEST|Expiratory hold|A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of expiration. It is used to asses static PEEP and inspiratory force generation (maximal inspiratory pressure, MIP \& occlusion pressure, ∆Pocc) and is frequently used in clinical practice.
40780211|NCT05380687|DIAGNOSTIC_TEST|Ultrasound of respiratory muscles|Ultrasound of the diaphragm, parasternal intercostal muscle and internal oblique muscle will be performed during each block. Thickening fractions, calculated as thickness at end-inspiration minus thickness at end-expiration divided by thickness at end-expiration, are used to assess the contribution of the muscle to the tidal volume. A median over 5 breaths will be calculated.
40780212|NCT05380687|OTHER|PEEP 10|Positive End-Expiratory Pressure of 10cmH2O for 30 minutes
40780213|NCT05380687|OTHER|PEEP 5|Positive End-Expiratory Pressure of 5cmH2O for 30 minutes
40780214|NCT05380687|OTHER|PEEP 0|Positive End-Expiratory Pressure of 0cmH2O for 30 minutes
40780215|NCT01166035|DRUG|Lenalidomide|"Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.~Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy"
40780216|NCT01166035|DRUG|Cetuximab|"Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.~Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy"
40780217|NCT04015258|DIETARY_SUPPLEMENT|Blueberries|fresh spanish blueberries
40780218|NCT04015258|DIETARY_SUPPLEMENT|Blueberry powder|freeze-dried blueberry powder
40780219|NCT04015258|DIETARY_SUPPLEMENT|Blueberry components capsules|encapsulated blueberry components (microcrystalline cellulose powder in actual)
40780220|NCT01624753|DEVICE|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
40780221|NCT01746524|DEVICE|ATTUNE Primary Total Knee Arthroplasty|Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
40780222|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r PTCL and r/r CTCL
40780223|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r ATLL
40780224|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r PTCL
40780225|NCT04931381|OTHER|Chemotherapy guided by organoid drug sensitivity test|Chemotherapy guided by organoid will be given to advanced pancreatic cancer patients.
40780226|NCT01814982|DRUG|JNJ-17299425|JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
40780227|NCT01137890|DRUG|Zonisamide|Eight capsules administered daily in split doses at 22:00 and 09:00.
40780228|NCT01137890|DRUG|Placebo|capsules administered in split doses at 22:00 and 09:00.
40780229|NCT01137890|DRUG|Cocaine Hydrochloride|Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
40780230|NCT01137890|BEHAVIORAL|Neurocognitive and Performance Battery|Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
40780231|NCT01137890|BEHAVIORAL|Smoking Assessments|Participants answer questions about smoking and smoking behaviors are monitored.
40780232|NCT02230345|DIETARY_SUPPLEMENT|Probiotic yogurt|Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).
40780233|NCT02230345|DIETARY_SUPPLEMENT|Acidified milk|Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
40780234|NCT06456840|DIAGNOSTIC_TEST|ULTRASOUND|Measurements will be made in musculoskeletal system ultrasonography by an international Medicine and Rehabilitation assistant physician using images obtained with the Sonosite M-Turbo device using the ImageJ program. During the measurements, the patient and the patient will be face to face and the device will be placed postero-laterally. Five standard window spacings will be used for the shoulder attachment. These are: anterior transverse, anterior longitudinal, lateral longitudinal, lateral transverse, posterior transverse.
40780235|NCT03984825|DRUG|GSK3640254|GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.
40780236|NCT03984825|DRUG|Portia|Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.
40780237|NCT04897022|DRUG|Pembrolizumab|Fixed dose of pembrolizumab 200mg IV q3 weeks
40780238|NCT04897022|RADIATION|IMPRINT|The starting radiation dose will consist of 400cGy x5 fractions. Doses will be escalated by 100cGy per fraction (i.e. 400cGy, 500cGy, 600cGy) for a total of 3 dose levels. The MTD will be evaluated using a modified Continuous Reassessment Method. Dose limiting toxicities (DLTs) are defined as any treatment-related non-hematologic toxicity with a CTCAE v5 Grade ≥3 or grade ≥2 pneumonitis that requires use of steroids occurring after the start of IMPRINT through the first 3 months after the last fraction.
40984809|NCT04106921|OTHER|Universal Health Coverage Mode|"In the intervention arm, the CHW's household list will appear differently within the app in the following ways:~The CHW will be able to filter and order households by the date of the most recent home visit.~A color-coded visual icon will display the number of home visits in the past month for each household.~A red exclamation mark will be displayed for every household that has not reached 2 visits in the past month (default at the start of every month).~Text displayed below each household showing the date of last visit will turn red if more than 30 days have passed since last visit. When more than 60 days have passed since the most recent visit, the text displayed below each household showing the date of last visit will be changed to date of last visit is unknown in red.~The family profile will also contain the date of last visit, and the visits they have received in that month"
40984810|NCT03168308|DRUG|Sugammadex|Sugammadex 2 mg/kg
40984811|NCT03168308|DRUG|Neostigmine w/ Glycopyrrolate|Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
40984812|NCT04659967|BEHAVIORAL|Virtual Training|Participants will receive a virtual training that is tailored to age-related hearing loss, use of non-custom personal amplification devices, and communication strategies.
40984813|NCT05087095|BEHAVIORAL|CALM Intervention|"The CALM intervention includes 6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3 months. Participants will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~* Within one week before initiating the CALM intervention therapy~* Within one week after its completion,~* 3 months after the CALM intervention is complete~  * After each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components"
40984814|NCT01716598|DEVICE|IPS System|TLD Therapy will be achieved bronchoscopically.
40984815|NCT03648060|DEVICE|Digital kinematic biofeedback system|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
40984816|NCT03254927|DRUG|CDX-3379 and cetuximab|Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
40984817|NCT00807157|DIETARY_SUPPLEMENT|PROBIOSTICK® during 30 days|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
40984818|NCT00807157|DIETARY_SUPPLEMENT|Placebo during 30 days|Every morning subjects will consume a stick of placebo during 30 days
40780239|NCT00967616|DRUG|CS7017|CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
40984819|NCT03116607|OTHER|patient education/ recommendations to the health team|The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge that includes an analysis of the therapy indicated by the physician, evaluating the safer alternatives for the type of patient and the special conditions of their pathology, with emphasis on Assessments of effectiveness, safety and tolerability of medication, drug interactions, possible adverse events, dose adjustments as necessary according to patient conditions; Verification that the administration is optimal, including the choice of the best route for this and the time in which the drugs are infused to the patient.
40984820|NCT05054959|OTHER|consolidation chemotherapy|6 cycles CAPOX after chemoradiotherapy
40984821|NCT05054959|OTHER|induction chemotherapy|4 cycles CAPOX before and 2 cycles CAPOX after chemoradiotherapy
40984822|NCT02051829|OTHER|Comparison of the four screening score|Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
41144122|NCT01090258|OTHER|Hamilton ventilator (G5) protocolized settings|Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
40984823|NCT05023525|DRUG|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
40984824|NCT05023525|DRUG|Placebo, tablet|Matching placebo
41144123|NCT00255268|DRUG|Goserelin|
41144124|NCT00255268|DRUG|Bicalutamide|
41144125|NCT03105024|OTHER|Self-efficacy enhancement|specific instructions regarding the retrieval of mastery experiences during exposure will be given (e.g., pointing out discrepancies between expected negative consequences and actual outcome during exposure; focus on achievements)
41144126|NCT03105024|OTHER|Control intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (e.g., description of details regarding the virtual reality environment)
41144127|NCT04739306|BIOLOGICAL|CT-P42|2mg/0.05 mL by Intravitreal injection
40984825|NCT02561637|BEHAVIORAL|Case management|
40984826|NCT02561637|BEHAVIORAL|Control group|
40780240|NCT00967616|DRUG|irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)|"FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)"
40984827|NCT00862745|DRUG|Fesoterodine|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
40780241|NCT05287321|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg with Aspirin 100mg
40780242|NCT03620396|PROCEDURE|Scaling and root planing|After the serum collection is done from the patient for the assessment of trefoil factor 3, Non surgical periodontal therapy is carried out.
40780243|NCT01225952|DEVICE|Crystalens AO|Bausch \& Lomb model silicone multi-piece accommodating IOL.
40780244|NCT01225952|DEVICE|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
40780245|NCT01225952|DEVICE|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
40780246|NCT01541371|DRUG|Paliperidone ER|Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
40780247|NCT01657305|DRUG|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
40780248|NCT01657305|DEVICE|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
40780249|NCT03903783|OTHER|Cefotaxime|"Patients with C3G antibiotic therapy will receive cefotaxime. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
40780250|NCT03903783|OTHER|Ceftriaxone|"Patients with C3G antibiotic therapy will receive ceftriaxone. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
41144128|NCT04739306|BIOLOGICAL|Eylea|2mg/0.05 mL by Intravitreal injection
41144129|NCT05639556|DIAGNOSTIC_TEST|BMI and lean mass index from DXA|Estimate and compare correlation between lean mass index from DXA and BMI
41144130|NCT05639556|DIAGNOSTIC_TEST|Anthropometric Measurements|Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.
41144131|NCT05639556|DIAGNOSTIC_TEST|Hand-grip strength|A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.
41144132|NCT05639556|DIAGNOSTIC_TEST|Six-minute walk Test|This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.
41144133|NCT05639556|DIAGNOSTIC_TEST|Sit-to-Stand Test|This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.
41304595|NCT02833649|DEVICE|Toric Implantable collamer Lens|The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
41304596|NCT03272854|OTHER|No intervention performed, the study is observational|
41304597|NCT01176097|DRUG|AZD5658|oral suspension, escalating single doses
40780251|NCT05348421|PROCEDURE|FTPB|A 22-gauge needle will be advanced from anterior using an in-plane technique and passed through the posterior 'tail' of the transversus muscle. the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg will be injected to separate the transversalis fascia from the transversus muscle.
40780252|NCT05348421|PROCEDURE|PENG Block|A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly where the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg
41304598|NCT01176097|DRUG|Placebo|oral suspension,single doses
41304599|NCT06199440|DRUG|Group I|First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
41304600|NCT06199440|DRUG|Group II|Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.
41304601|NCT06199440|DRUG|Group III|"Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol."
41304602|NCT02403193|DRUG|PBF-509_80 mg|PBF-509: 80 mg, PO, twice daily (BID)
40780253|NCT01480102|DRUG|Group A-Paravertebral block|Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
40780254|NCT01480102|OTHER|Group B- No block|direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
40780255|NCT00753532|DIETARY_SUPPLEMENT|200mg of Palm vitamin E (tocotrienols) or placebo|Individuals randomized in the (MRI+ve) and (MRI -ve) cohort respectively. In the MRI(+ve) cohort, 62 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 59 were assigned to placebo, taken orally twice a day for a study period of two years. In the MRI(-ve) cohort, 63 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 57 consumed placebo, taken twice a day for a follow up period of 1 year.
40780256|NCT01343212|OTHER|stiffness measurement using ARFI|Stiffness measurement will be performed for HCC using ARFI technique.
40780257|NCT06513897|OTHER|Acupressure|Acupressure will be applied to the foreheads of the babies in this group starting two minutes before the heel prick. Acupressure application will be finished when heel prick blood collection is finished.
40780258|NCT06513897|OTHER|Father's Lap|Infants in this group will be placed on the father's lap two minutes before heel prick blood collection. They will remain on the father's lap during the heel prick procedure.
40780259|NCT04817150|PROCEDURE|Laparoscopic ventral mesh rectopexy|Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore
40780260|NCT05817461|DRUG|AZD0780 tablet|oral, fasted
41304603|NCT02403193|DRUG|PBF-509_160 mg|PBF-509: 160 mg, PO, twice daily (BID)
41304604|NCT02403193|DRUG|PBF-509_320 mg|PBF-509: 320 mg, PO, twice daily (BID)
41304605|NCT02403193|DRUG|PBF-509_640 mg|PBF-509: 640 mg, PO, twice daily (BID)
41304606|NCT02403193|DRUG|Combo PBF-509 (160 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
41304607|NCT02403193|DRUG|Combo PBF-509 (320 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
41304608|NCT02403193|DRUG|Combo PBF-509 (640 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
41304609|NCT02403193|DRUG|RP2D (PBF-509+PDR001)_immuno naïve|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
41304610|NCT02403193|DRUG|Experimental: RP2D (PBF-509+PDR001)_immuno treated|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
41304611|NCT00663728|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1 hour prior to sexual intercourse
41304612|NCT00663728|DRUG|Placebo|Matching placebo
41304613|NCT01555112|DRUG|Topical AS101|AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
41304614|NCT05111899|BEHAVIORAL|Newborn Health Education|Community influencers will receive training and give community education to women and their families regarding newborn health.
40780261|NCT05817461|DRUG|[14C]AZD0780 Solution for Infusion|intravenous
40780262|NCT05817461|DRUG|[14C]AZD0780 Oral Solution|oral, fasted
41304615|NCT01984541|BIOLOGICAL|Artemisia vulgaris|Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
41304616|NCT03526003|DIAGNOSTIC_TEST|Measurement of esophageal pressure|Measurement of esophageal pressure during posture changes and pneumoperotoneum
41304617|NCT04327817|DEVICE|Multifidus stimulator|"Patient eligible for the study and have provided consent will have a baseline PET scan. Multifidus ReActiv8 Stimulator will be inserted using standard treatment for lumbar pain at Barts Health NHS Hospitals.~All patients who receive the Reactiv8 system will continue to receive multifidus stimulation 20Hz for the next 6 months as per standard of care of multifidus stimulation; at the end of this period, the patients will undergo PET scanning and questionnaires. Thereafter, stimulation will continue and 3rd PET scan will be performed at 1year post implant."
40780263|NCT04046939|DRUG|Dexpramipexole|dexpramipexole twice daily oral dosing for up to 12 weeks
40780264|NCT04046939|DRUG|Placebo|placebo twice daily oral dosing for up to 12 weeks
40780265|NCT00565409|DRUG|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
40780266|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
40780267|NCT00565409|DRUG|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
40780268|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
40984828|NCT00862745|DRUG|Matching Placebo|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
40984829|NCT01601249|PROCEDURE|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
40984830|NCT02424747|OTHER|Acute Kidney Injury|"We will identify and observe exposure to Acute Kidney Injury during Intensive Care admission."
40984831|NCT06471595|BEHAVIORAL|Partnership for Improving Lifestyle Intervention (PILI) Lifestyle Program + Social Determinants of Health (SDOH) Component|The PILI Lifestyle Program (PLP) is an adapted 3-month behavioral lifestyle intervention focused on addressing and initiating weight loss in Native Hawaiians and Pacific Islanders (NHPIs). The PLP covers 8 lessons that offer empirically supported strategies (e.g., plate method, stimulus control) based on the social cognitive theory to improve healthy eating, physical activity, and time and stress management across the 3 months. In this study, the PLP will be enhanced with social determinants of health (SDOH) components that address challenges such as access to healthy foods, housing, and employment issues. There will be 4 SDOH activities relevant to participants' needs and lives. These activities will be delivered during the 3-month PLP.
40984832|NCT04751344|DRUG|Liposomal bupivacaine|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.
40984833|NCT04751344|DRUG|Bupivacaine HCl|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
40984834|NCT00875225|BEHAVIORAL|DVD|Control group will receive usual care DVD from health professionals
40984835|NCT00875225|BEHAVIORAL|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
40984836|NCT01820481|DRUG|WIN-901X dose level 1|100mg Bid, PO, 12weeks
40984837|NCT01820481|DRUG|WIN-901X dose level 2|200mg Bid, PO, 12weeks
40984838|NCT01820481|DRUG|WIN-901X dose level 3|300mg Bid, PO, 12weeks
40984839|NCT01820481|DRUG|Placebo|Bid, PO, 12weeks
41304618|NCT05954377|OTHER|Quarterly remote motivational interviews|Remote motivational interview will be in the form of quarterly telephone call (at 3, 6 and 9 months after the start of annual follow up; the patient is seen again at 12 months as part of the annual follow-up) and this for 4 years. It will be performed by medical staff trained in motivational interviewing and who have completed at least 40 hours training in therapeutic education
40780269|NCT00565409|DRUG|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
40780270|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
40780271|NCT02817178|OTHER|Additional biological samples|blood and tumor tissue samples
40780272|NCT04095052|DIETARY_SUPPLEMENT|Methyl Folate|1,000 mcg methyl folate and Microcrystalline Cellulose in a capsule
40780273|NCT04095052|DIETARY_SUPPLEMENT|Placebo|Microcrystalline Cellulose capsule
40780274|NCT00247546|BEHAVIORAL|Multifactorial prevention|
40780275|NCT03158831|DRUG|Placebo-Controlled Graded Drug Challenge|All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
40780276|NCT04476992|DRUG|Nitric Oxide-Sessions|Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).
40780277|NCT04476992|DRUG|Nitric Oxide-Continuous and Sessions|"Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).~The subjects assigned to the group NO High Concentration + Continuous Low Concentration will receive in adjunction a continuous dose of NO at 20 ppm."
40984840|NCT03293810|OTHER|Observational study|Post-Authorization Safety Study
40984841|NCT00528099|DRUG|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
40984842|NCT02464345|BEHAVIORAL|HAPIFED|HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).
40984843|NCT02464345|BEHAVIORAL|CBT-E|CBT-E therapy
40984844|NCT01045642|DRUG|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
41463505|NCT03731728|BEHAVIORAL|Group CBT|"All therapists will use a manualized Cognitive-Behavior Therapy (CBT) protocol with the same handouts and schedule developed based on the book Mind Over Mood. Group CBT will be provided to a group of maximum 10 participants. Each session will be 2 hours long and will be provided by certified therapists with special training to deliver group CBT. The structure of the session will be agenda setting, check-in, review of homework, new concepts/skills, homework assignment, and feedback."
40984845|NCT05356455|BEHAVIORAL|motivational interview technique|Difference between pre-test and post-test
41144134|NCT05639556|DIAGNOSTIC_TEST|Short physical performance battery (SPPB)|This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).
41144135|NCT05639556|DIAGNOSTIC_TEST|BIA Sub-study|A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).
40780278|NCT02403544|RADIATION|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
41144136|NCT05639556|DIAGNOSTIC_TEST|Accelerometry to assess physical activity|Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.
41144137|NCT05639556|OTHER|Gastrointestinal (GI) and nutrition questionnaires:|Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).
41144138|NCT05639556|OTHER|Psychosocial questionnaire: PHQ-8|This is an 8-item scale that measures depressive symptoms over the past two weeks.
41463506|NCT03731728|BEHAVIORAL|Group exercise|Participants enrolled in the group exercise plus TAU arm of the study will be wait-listed for TAU and will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks.
40780279|NCT02403544|DRUG|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
40780280|NCT02403544|DRUG|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
40780281|NCT05317130|OTHER|Athlete health monitoring|Observational study
40984846|NCT03071627|OTHER|New items with spin|Interpretation of news items with spin
40984847|NCT03071627|OTHER|New items without spin|Interpretation of news items without spin
40984848|NCT02169739|DEVICE|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
40984849|NCT00492115|DEVICE|Continuous positive airway pressure (CPAP)|therapeutic Continuous positive airway pressure (tCPAP) nightly for 6 weeks
40984850|NCT00492115|DEVICE|Placebo CPAP|Ineffective Continuous positive airway pressure (pCPAP) for 3 weeks followed by therapeutic CPAP for 3 weeks
40984851|NCT04447079|BEHAVIORAL|Assertive Community Treatment (ACT)|"Assertive Community Treatment (ACT) is part of a 6-month program ARFAs will undergo.~ACT teams will engage with ARFAs on a dedicated schedule. Each visit would last an average of 60 minutes. There will not be a re-arrangement of no-show visits. ACT teams will re-engage the ARFA over the phone to plan for the next visit as per the schedule.~In keeping with principles of ACT, ARFA's will be assertively sought out in the community and provided intensive engagement, with holistic and supportive care alongside a harm reduction approach. Care will also involve case management and involvement of SSA's.~Each interaction during the treatment period will focus on various aspects covering physical health, mental health, and addiction"
40780282|NCT02605902|BEHAVIORAL|(i)Comprehensive Behavioral Intervention for Tics|
40780283|NCT02605902|BEHAVIORAL|internet-delivered psychoeducation and relaxation training|
40780284|NCT00916448|DRUG|Atazanavir|capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
40780285|NCT00916448|DRUG|E. coli endotoxin|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
40984852|NCT06265740|OTHER|vaginal swab|Any pregnant woman attending the obstetrics department of Clermont-Ferrand University Hospital who requires a vaginal swab (VS) for her clinical situation (routine care) will be offered the study. If she accepts, the usual swab will be doubled and performed simultaneously in a single procedure using two swabs. The first swab will be sent to the laboratory and used for diagnosis. The second swab will be used for microbiota analysis.
41144139|NCT05639556|OTHER|Psychosocial questionnaire: GAD-7|This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.
41144140|NCT05639556|OTHER|Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)|This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.
41144141|NCT05639556|OTHER|Psychosocial questionnaire: CF Fatalism Scale|The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.
40780286|NCT03560492|OTHER|Exercises|5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.
40780287|NCT03560492|DEVICE|Posture garment|Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
40780288|NCT03904160|BEHAVIORAL|Weight management|Please see the arm descriptions.
40780289|NCT02814188|OTHER|Carbohydrate Beverage|750 ml of a 13.5% carbohydrate (sucrose) beverage
40780290|NCT02814188|OTHER|Placebo Beverage|750 ml of an artificially-sweetened beverage
40780291|NCT01317992|DRUG|Ibudilast|Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
41144142|NCT05639556|OTHER|Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)|The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.
41463507|NCT03201263|PROCEDURE|Sigh|Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation
41463508|NCT03201263|PROCEDURE|Standard of care|Standard of care
41463509|NCT04609397|DRUG|Hemay005|Hemay005 tables 60mg bid p.o;
41463510|NCT04609397|DRUG|Hemay005|Hemay005 tables 45mg bid p.o
40780292|NCT01317992|DRUG|Placebo|Placebo 4 capsules, orally, twice daily for 8 weeks.
40780293|NCT05059886|OTHER|completion of a questionnaire on the practice of sports and possible injuries|completion of a questionnaire on the practice of sports and possible injuries
40780294|NCT01627691|DEVICE|Lotus Valve System|"* bioprosthetic bovine pericardial aortic valve~* delivery system"
40780295|NCT00426803|DRUG|activated recombinant human factor VII|
41463511|NCT04609397|OTHER|Placebo|placebo to Hemay005 tables bid p.o
41463512|NCT06262139|DRUG|MT218 injection|a targeted magnetic resonance imaging contrast agent
40984853|NCT06430138|DIETARY_SUPPLEMENT|300ml Orange Juice|Acute intervention in populations with and without colon
41144143|NCT05639556|OTHER|12-month Questionnaire|A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.
41144144|NCT05639556|OTHER|Oral glucose tolerance testing (OGTT)|For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.
40780296|NCT01282073|DRUG|Mycophenolate mofetil, low dose steroid|"Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 \~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks"
40780297|NCT01282073|DRUG|Cyclosporin, low dose steroid|"Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks"
40780298|NCT03448211|DRUG|Para-toluenesulfonamide Injection (PTS)|Intratumoral injection
41144145|NCT05639556|DEVICE|Continuous glucose monitoring (CGM)|Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.
41144146|NCT05639556|DIAGNOSTIC_TEST|Chest CT scans (When available within the past 6 months in medical records)|Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.
41144147|NCT05639556|DIAGNOSTIC_TEST|Hologic Dual X-Ray Absorptiometry (DXA)|DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.
41144148|NCT05639556|DIAGNOSTIC_TEST|Ultrasound Sub-study of assessment of appendage muscles using ultrasound|A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.
41144149|NCT05639556|DIAGNOSTIC_TEST|Psychosocial questionnaire: Hunger Vital Sign questionnaire|Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.
41144150|NCT05639556|OTHER|Respiratory symptom questionnaire: CRISS|Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.
41144151|NCT05639556|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.
41144152|NCT05639556|OTHER|Psychosocial questionnaire: Additional Health Questionnaire|Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.
41144153|NCT01751295|DRUG|Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI|
41144154|NCT02097316|DEVICE|JewelPump|
41144155|NCT02097316|DEVICE|usual insulin pump|
41463513|NCT06444165|DRUG|Lebrikizumab Pen|Injected into a practice pad.
40780299|NCT01347814|DRUG|Domperidone 10mg|10mg domperidone tablet 30 minutes before a test-meal.
40780300|NCT01347814|DRUG|Placebo|Homeopathic (Sugar) pill-Placebo
40780301|NCT00818194|DRUG|extended release tacrolimus|oral
40780302|NCT00818194|DRUG|cyclosporine A microemulsion|oral
40780303|NCT01203007|DIETARY_SUPPLEMENT|Tailored diet|Tailored diet according to demonstrated food sensitivity, 6 months
40780304|NCT01203007|DIETARY_SUPPLEMENT|Low antigen content diet|Low-antigen content diet for one month
40780305|NCT02569853|DRUG|DFN-11|
40780306|NCT02569853|OTHER|Placebo|
40780307|NCT06151626|OTHER|virtual-reality based rhythmic skill training|Participants wear VR headsets and Oculus Touch controllers and undergo rhythm skill training for a total of 35 minutes.
40780308|NCT06151626|OTHER|rhythmic skill training with visual feedback|The rhythm skill training activities in this group are the same as the virtual reality-based system. Participants received 35 minutes of rhythm skill training presented through a computer interface
40780309|NCT06151626|OTHER|strengthening group|Participants receive an upper limb strengthening exercise program under the supervision of a therapist to ensure that the strengthening exercises are performed correctly. This includes: proprioceptive neuromuscular facilitation, resistance training, and tendon gliding exercises.
40984854|NCT06152757|BIOLOGICAL|First dose|1.0×10\^8cells,Intravenous infusion，1 subject is planned to be enrolled
40984855|NCT06152757|BIOLOGICAL|Second dose|3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
40984856|NCT06152757|BIOLOGICAL|The third dose|1.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
40984857|NCT06152757|BIOLOGICAL|The fourth dose|3.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
40984858|NCT00654160|DRUG|fluorouracil|
40984859|NCT00654160|DRUG|irinotecan hydrochloride|
40984860|NCT00654160|DRUG|leucovorin calcium|
40984861|NCT00654160|OTHER|pharmacogenomic studies|
40984862|NCT00654160|OTHER|pharmacological study|
40984863|NCT05332340|DRUG|BZ371A|Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
40780310|NCT06151626|OTHER|breathing and muscle relaxation exercises|5 minutes of breathing and muscle relaxation exercises
40780311|NCT01130792|DIETARY_SUPPLEMENT|Lactobacillus GG|10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks
40780312|NCT01130792|DIETARY_SUPPLEMENT|Inulin|Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
40780313|NCT01071161|DRUG|azithromycin|azithromycin, tablets, during 12 weeks, three times a week, 250mg
40780314|NCT01071161|DRUG|placebo|placebo
40984864|NCT02536352|DRUG|Prenatal vitamin-mineral containing 3 mg fluoride|Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
40984865|NCT02536352|DIETARY_SUPPLEMENT|Prenatal vitamin-mineral containing 0 mg fluoride|Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
40984866|NCT02022098|DRUG|Cisplatin|A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
40984867|NCT02022098|RADIATION|Radiotherapy|Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
41144156|NCT05007002|DEVICE|Robot-based therapy|Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)
41144157|NCT03991052|DEVICE|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically by the closed-loop system
41304619|NCT03697967|PROCEDURE|supine or prone position|"Before delivery, a sealed enveloppe is opened by the physician or nurse present at delivery. Immediately at birth the team in charge of delivery place the newborn in skin to skin contact on the mother's chest where he is dried. Umbilical cord clamping is delayed in both intervention arms to 1 minute after birth.~The newborn is placed in the prone or in the supine position depending on allocation. The nurse in charge of the newborn uses a stopwatch to check the time at which clamping was accomplished.~All subsequent nursery care are conducted according to hospital protocol."
41304620|NCT00109317|DRUG|Raptiva (efalizumab)|
40780315|NCT02966483|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
40780316|NCT02966483|PROCEDURE|LpTME|Conventional Laparoscopic Total Mesorectal Excision
40780317|NCT01871649|DRUG|golimumab|golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
40780318|NCT01871649|DRUG|methotrexate|Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
40780319|NCT03855904|DEVICE|TC-325|TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.
40780320|NCT01119638|DRUG|Escitalopram|Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
40780321|NCT01119638|DRUG|Risperidone|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
40780322|NCT03084848|OTHER|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
40780323|NCT03084848|OTHER|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
40780324|NCT04269954|DRUG|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin
40780325|NCT05089292|BEHAVIORAL|Narrative breast health education|Health education program utilizing narrative messages to promote breast cancer screening in Chinese immigrant women will be delivered in a group format in the community
40780326|NCT03322566|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
40780327|NCT03322566|DRUG|Epacadostat|Epacadostat administered orally twice daily.
40780328|NCT03322566|DRUG|Platinum-based chemotherapy|Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
40984868|NCT02022098|DRUG|Debio 1143|Debio 1143 solution
40984869|NCT02022098|DRUG|Placebo|Matching placebo solution
40984870|NCT02716103|OTHER|blood collection|
40984871|NCT02716103|OTHER|bone marrow collection|
40984872|NCT00003147|BIOLOGICAL|Ad5CMV-p53 gene|
40984873|NCT00616655|DRUG|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
40984874|NCT00616655|DRUG|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
40984875|NCT00616655|DRUG|Placebo|Placebo total daily dose 0.9 mg
40984876|NCT01462084|DEVICE|Adaptive servo-ventilation (ASV)|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
40984877|NCT01462084|DEVICE|Bi-Level PAP|Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
40984878|NCT00000901|DRUG|Indinavir sulfate|
40984879|NCT00000901|DRUG|Lamivudine|
40984880|NCT00000901|DRUG|Stavudine|
40984881|NCT04886050|DRUG|LC350189 Tablet|Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5
40984882|NCT04886050|DRUG|LC350189 Capsule|Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5
40984883|NCT00755157|DRUG|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
40984884|NCT00755157|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
40984885|NCT06056050|BIOLOGICAL|Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)|1 dose of Tdcp vaccine (0.5ml) on Day 0
40984886|NCT06056050|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）|1 dose of PPV23 vaccine (0.5ml) on Day 0
40984887|NCT06056050|BIOLOGICAL|Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)|1 dose of DT vaccine (0.5ml) on Day 0
41144158|NCT03991052|DEVICE|Control group|This system will recommend when patients need fluid or not and nurses will adjust vasopressor administration as usual (standard of care)
40780329|NCT03322566|DRUG|Placebo|Matching placebo administered orally twice daily.
40780330|NCT00744614|PROCEDURE|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
40780331|NCT06488755|DRUG|SIM0718 injection|"Dosage form: injection Specification: 300mg/2ml/bottle Dosage: A loading dose of 600 mg is injected subcutaneously on day 1, followed by 300 mg SIM0718 subcutaneously every two weeks.~Duration of medication: 52 weeks"
40780332|NCT06488755|DRUG|SIM0718 injection of placebo|"Dosage form: injection Specification: 2ml/bottle Dosage: 4ml subcutaneously on day 1, followed by 2ml of placebo subcutaneously every two weeks.~Duration of medication: 52 weeks"
40780333|NCT02957630|DRUG|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
40780334|NCT02957630|DRUG|30 mcg EE/150 mcg LNG|30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
40780335|NCT02957630|DRUG|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
40780336|NCT02514655|DEVICE|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
41144159|NCT00854594|BEHAVIORAL|Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)|The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
40780337|NCT02514655|OTHER|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
40780338|NCT01296308|OTHER|inpatient integrative treatment|two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
40780339|NCT04883138|DRUG|GIGA-2050|Recombinant Hyperimmune Polyclonal Antibody
40780340|NCT01301677|DRUG|Hydrocortisone|Hydrocortisone liquid formulation
41144160|NCT01501721|BEHAVIORAL|Exercise|Home-based exercise program
41144161|NCT01501721|BEHAVIORAL|Diet|Nutritional counseling aiming to reduce suggar intake
41144162|NCT04631874|DRUG|CDFF0318, Champix|CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
40780341|NCT01301677|DRUG|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
40780342|NCT01301677|DRUG|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
41463514|NCT03142620|DRUG|Esomeprazole|40mg twice daily
40780343|NCT06447909|BEHAVIORAL|Treatment App|"The behavioral treatment app content consists of tasks that caregivers can assign to their children in the app (e.g., finish homework, make bed, etc.). These tasks are completed offline, and then caregivers approve the child's completion of those tasks through the app, administering a token reward (coins) in-app. In the child version of the app, children take care of a virtual pet by feeding, cleaning, buying various accessories (using in-game coins), and exploring different lands with the virtual pet. The caregiver-assigned token coins can be used to redeem items needed to raise their pet, and access virtual lands. Caregivers can also choose to have their child redeem virtual tokens for real-life rewards. Ultimately, the app combines a video game with evidence-based principles to help children practice important tasks and behaviors as administered by caregivers."
40780344|NCT06447909|BEHAVIORAL|Sham app|As described above, the child will access a virtual pet that they can feed, clean and buy various accessories by redeeming virtual coins. They will not be able to explore different lands with that pet. Coins in the placebo version will be rewarded non-contingently. Additionally, children will not be able to redeem coins for real-life rewards as above in the treatment app. Caregivers will not need to review and approve tasks in order to redeem coins. The caregiver-version of the app will not contain the Assigned or Review tabs as assigned above, since the child will earn coins regardless of whether or not they complete tasks, so caregivers will not be able to review nor assign tasks. Instead, caregivers in this group will only have access to the guide tab which will contain helpful articles the parent can read about disruptive behavior problems in children.
40780345|NCT03744390|DRUG|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
40780346|NCT05101070|DRUG|S-531011|Administered by intravenous infusion
40780347|NCT05101070|DRUG|pembrolizumab|Administered by intravenous infusion
40780348|NCT00095550|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
40780349|NCT00095550|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 12 weeks.
40780350|NCT00095550|DRUG|HCTZ monotherapy|Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
41144163|NCT05112302|OTHER|Virtual reality|Use of virtual reality goggles during procedure
41144164|NCT02315209|DEVICE|UHS, UPP, Comfort Plug|only Repairs with 3D Devices (UPP,UHS,Comfort Plug)
41144165|NCT06284356|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
41144166|NCT04300270|DEVICE|Smartphone PPG recordings|Smartphone camera PPG recordings using a novel software application.
41144167|NCT04300270|DEVICE|Smartphone ECG|Smartphone connected one-lead ECG recordings.
41463515|NCT03142620|DRUG|Amoxicillin-Potassium Clavulanate Combination|1000mg twice daily
41463516|NCT03142620|DRUG|Clarithromycin|500mg twice daily
41463517|NCT03142620|DRUG|Vitamin D3|5000IU
41463518|NCT00877994|BEHAVIORAL|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
40984888|NCT02958150|DRUG|Dexmedetomidine|
40984889|NCT02958150|PROCEDURE|Standard Clinical Practice|
40984890|NCT01482247|DIETARY_SUPPLEMENT|L-Arginine|Dietary Supplement
40984891|NCT01482247|DIETARY_SUPPLEMENT|Placebo Supplement|Dietary Supplement
40984892|NCT04837157|DEVICE|Exoskeleton rehabilitation|The participants will perform physical therapy with the ATLSA2030 device, for 90 minutes per session.
40984893|NCT02953327|BIOLOGICAL|Bacille Calmette-Guerin|Vaccine against tuberculosis
40984894|NCT02953327|BIOLOGICAL|BCG solvent|Simple solvent
40984895|NCT02506140|DRUG|Ticagrelor and Acetylsalicylic acid|This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
40984896|NCT02506140|DRUG|Clopidogrel and Acetylsalicylic acid|This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
40984897|NCT04731987|BEHAVIORAL|Beverage consumption|"Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal."
40984898|NCT01110954|DRUG|PD L 506|Two different doses will be compared
40984899|NCT01881776|PROCEDURE|ISB|"In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter."
40984900|NCT03019302|DEVICE|Arrow PICC with Chloragard Technology|chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
40984901|NCT03690115|DRUG|Ponatinib 30 MG|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
40984902|NCT05527145|PROCEDURE|Minimally invasive surgery|Surgery with decompression. Central decompression of the stenotic segment with undercutting of the lateral recesses.
40984903|NCT05527145|PROCEDURE|Percutaneous Spacer|percutaneous image guided outpatient procedure that enables interspinous spacer insertion and fusion
40984904|NCT04203953|OTHER|Early mobilization program|Early mobilization will be defined as any active exercise where the patients could assist with the activity using their own muscle strength and control that occurred within the first 7 days of trauma ICU admission and will be intended to maintain or restore overall function as well as being scored using the ICU mobility scale.15 The ICU mobility scale includes rolling, bridging, sitting, standing and walking, and upper and lower limb flexion and extension. In-bed therapies will include active or active-assist range of motion, bridge exercise, quadriceps setting, straight leg raising, rolling exercises and facilitation.
40984905|NCT05175417|OTHER|MRI|3 tesla (T) MRI to provide higher resolution and quality brain images.
40984906|NCT03070392|BIOLOGICAL|IMCgp100|IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
40984907|NCT03070392|DRUG|Dacarbazine|Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
40780351|NCT04236999|BEHAVIORAL|Yo Sé Lo Que Quiero (YSLQQ)|"This program is organized in 12 sessions around three themes:~* Knowledge and attitudes (sessions 1, 3, 5 and 9): Students reflect on their knowledge of legal and illegal drugs, using critical thinking to obtain an objective assessment of this knowledge.~* Intrapersonal skills (sessions 4, 6, 8, 10. 11. and 12): Activities are carried out where students can put themselves in everyday situations and develop skills such as assertiveness, problem solving, among others.~* Interpersonal skills (sessions 2 and 7): Students are instructed to practice refusal skills, assertiveness, and analyze coping strategies."
40984908|NCT03070392|BIOLOGICAL|Ipilimumab|Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
40984909|NCT03070392|BIOLOGICAL|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
40984910|NCT06228547|OTHER|Questionnaire|Standardized questionnaire specifically made for the study. The interview lasts approximately 15 minutes. The form gathers baseline characteristics of the patients such as socio-demographic information, symptoms, lifestyle factors and gynecological history. The questionnaire focuses also on the manner in which the diagnosis was revealed to the patient and their experience of this disclosure. Lastly, the questionnaire includes items issued from French practice guidelines concerning etiological investigations, fertility assessment, osteoporotic and cardiovascular complications, HRT use, and residual symptoms
40984911|NCT00439426|DRUG|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
40984912|NCT00439426|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
40780352|NCT03055091|OTHER|Xylitol syrup|Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
40984913|NCT02145728|BEHAVIORAL|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
41144168|NCT03619044|OTHER|2 FES-PET Imaging will be performed:|"* before treatment initiation~* before treatment cycle 3 initiation"
41144169|NCT04936048|BEHAVIORAL|Music Therapy|Music therapy will use rhythmic cues, music instruments (piano, drums, djembe, xylophone, harmonica), songs, and stories accompanied by songs or musical instruments to target common goals.
41304621|NCT04190784|OTHER|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
41304622|NCT04190784|OTHER|Placebo stretching|The therapist maintains the same manual contact without stretching force.
41304623|NCT02988466|BIOLOGICAL|Haplo HCT <55 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion Day 0"
41304624|NCT02988466|BIOLOGICAL|Haplo HCT ≥55 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel): Dose reduction by 30%~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion"
41304625|NCT02988466|DRUG|GVHD Prophylaxis|"* Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)"
40780353|NCT03055091|OTHER|Placebo|Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
40780354|NCT05612230|OTHER|Data analysis|Data analysis is based on a single database from the National Health Medical Data (North Center).
40780355|NCT02259816|DRUG|Telmisartan|
41144170|NCT04936048|BEHAVIORAL|Play therapy|Play therapy is designed as a play-based active comparison condition to control for factors such as support, therapist attention, positive expectancies, and emotional engagement. It will use verbal interaction, toys (Lego, finger puppets, Play Doh, puzzles), and the same stories as in MT, but without a musical component, to target common goals.
41144171|NCT02744105|DIETARY_SUPPLEMENT|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
41304626|NCT02988466|BIOLOGICAL|Haplo HCT ≥55 and < 65 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* non-T-cell depleted donor bone marrow stem cells"
41304627|NCT02988466|BIOLOGICAL|Haplo HCT ≥65 and ≤75 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Total body irradiation (TBI)"
41304628|NCT06179550|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with NGT according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
41304629|NCT06179550|DEVICE|Intermittent Oro-esophageal Tube|The observation group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm (Appendix). However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
41304630|NCT01116219|BIOLOGICAL|bevacizumab, erlotinib|"* Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~* Erlotinib 150 mg p.o. daily until progression."
41304631|NCT01116219|DRUG|bevacizumab, pemetrexed, cisplatin|"Induction chemotherapy with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. and~* Cisplatin\* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
40780356|NCT02259816|DRUG|Amlodipine|
40780357|NCT04845256|DEVICE|SOMAVAC 100 Sustained Vacuum System|Evaluate performance of sustained vacuum system compared to manual suction bulbs
41304632|NCT03664193|RADIATION|SIBRT|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
40780358|NCT04924348|PROCEDURE|Experimental: WALANT procedure|"The WALANT technique, performed under ultrasound, includes two punctures.~* The first is a puncture through a medial approach above the wrist and includes two injections. A first subcutaneous injection reproducing a bar above the wrist flexion line, and a second injection above the median nerve. The volumes injected vary from 8 to 10 milliliters (ml).~* The second puncture is performed at the base of the palmar surface of the hand and consists of a 10 ml subcutaneous injection of the local anesthetic in order to take advantage of the vasoconstrictive effects of adrenaline, thus allowing the surgical procedure to be performed without a pneumatic tourniquet."
40780359|NCT04924348|PROCEDURE|Active Comparator: Axial ALR|The anesthetic protocol in the axillary block consists of performing a puncture, using a needle (50 mm 22G with a short bevel), under the armpit at the level of the axillary hollow after skin disinfection. This puncture, performed under ultrasound, allows the injection of the local anesthetic around the median, radial, ulnar and musculocutaneous nerves. The volume injected per nerve can vary from 5 to 8 ml depending on the visual appreciation during the injection.
40780360|NCT04924348|PROCEDURE|Active Comparator: Truncal ALR|The anesthetic protocol in truncal block consists in injecting the local anesthetic around the median and ulnar nerves by a puncture performed at the elbow or forearm (depending on the practitioner's experience). The volumes injected remain the same and the puncture is also performed under ultrasound guidance. Additional local anesthesia is administered by injecting an additional 5 ml above the wrist flexion line to block the sensory territory of the musculocutaneous nerve.
40984914|NCT02145728|BEHAVIORAL|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
40780361|NCT03768323|OTHER|1X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey
41144172|NCT04447586|OTHER|Pressure measurement during exhalation through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer|"Participants performed exhalation attempts through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer, following the instructions of Command A and B (A:please blow continuously so that you feel low resistance during exhalation and B:please blow continuously so that you feel moderate resistance during exhalation) in a specific order for each group. Every volunteer performed 3 attempts for each command.The outputs of the 3rd attempt were used to the study."
41304633|NCT02256332|DIETARY_SUPPLEMENT|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
41304634|NCT02256332|DIETARY_SUPPLEMENT|High dose plant based ingredient|Reference food with high dose of plant based ingredient
41304635|NCT02256332|DIETARY_SUPPLEMENT|Reference food format|Reference food without plant-based ingredient
41304636|NCT05913934|BEHAVIORAL|Gait analysis|Walk over 25 meters in a gym (GaitUp) Walk over 6 meters with footscan v9 in the office
41304637|NCT05553756|DIETARY_SUPPLEMENT|Maltodextrin|200 ml maltodextrin given 2 hours before cesarean section
41304638|NCT05785117|DEVICE|Vagal Stimulation|ear clips were placed in the ear region (auricular concha) at the stimulation site. The following stimulation settings were used: 1) density wave set to 20 Hz with a wave width of less than 1 ms; 2) intensity tuned to the patient's tolerance (4-6 mA)
41304639|NCT05785117|OTHER|Circuit training program|The training regimen included ten different forms of resistance and aerobic exercise that were done three times a week for four weeks. The resistance training program included push-ups, squats, crunches, lunges, and a superman exercise program that included light jumping, jogging on the spot, foot stomping, steps, and jumping jacks
41304640|NCT06262555|PROCEDURE|Transbronchial PDT peripheral lung tumor ablation|Transbronchial lung tumor ablation with Photodynamic therapy
40780362|NCT03768323|OTHER|2X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey
41304641|NCT05414708|BEHAVIORAL|Art Therapy|During the art research intervention session, the art therapist will walk you through the creation of various types of art and may spend time asking you about the artwork, how you are felling, as well as your past experiences.
40780363|NCT00467441|DRUG|VSF-173|
40984915|NCT02026908|DEVICE|Prostate Artery Embolization|Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
40780364|NCT01498861|DRUG|Ortho-Cyclen|Ortho-cyclen is an oral contraceptive.
40780365|NCT01498861|DRUG|Dolutegravir|Dolutegravir is an experimental HIV drug
40780366|NCT01498861|DRUG|Placebo|Placebo is a tablet with no drug in it
40780367|NCT04662164|DRUG|hepalatide|3 different dosage will be given sequentially to T2D patients
40780368|NCT01650454|OTHER|2 night polysomnography|Polysomnography
40984916|NCT01165554|DRUG|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
40780369|NCT01650454|OTHER|battery of neuropsychological tests|
40780370|NCT01650454|OTHER|virtual reality test|
40780371|NCT01650454|OTHER|subjective evaluation of sleep and somnolence|
40780372|NCT02072954|DRUG|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
40984917|NCT04137003|OTHER|Rouge et Or Program|It is a detailed, structured and precise training program. It is used from the third-month post ACL surgery to the sixth month.
40984918|NCT04137003|OTHER|CHU intervention guide|From the third month to the sixth month, it outlines the progression to have in the training without precise information on exercises, parameter or frequency.
40984919|NCT02526472|PROCEDURE|ET under transabdominal US guidance (UGET)|When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface
40984920|NCT02526472|PROCEDURE|ET after transvaginal US uterine measurement (mTVET)|When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
41144173|NCT04447586|OTHER|Pressure measurement during exhalation through an alternative PEP device/soft drink straw.|"Participants were requested to exhale as indicated by the right command (Command A or B), for 3 sets of 10 repetitions. This procedure included short breaks between sets."
41144174|NCT01521702|DRUG|Neoadjuvant chemotherapy|four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,
41144175|NCT01521702|PROCEDURE|surgery and Adjuvant chemotherapy|surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
41144176|NCT02930265|DRUG|Liraglutide|Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
41144177|NCT00211276|DRUG|ONTAK (denileukin diftitox)|
41144178|NCT03710850|DIETARY_SUPPLEMENT|Inulin|Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
41144179|NCT05396573|BIOLOGICAL|RQ3013|A single dose of 30 μg/0.15 mL, a single dose of 60 μg/0.3 mL
41144180|NCT05396573|BIOLOGICAL|Comirnaty|A single dose of 30 μg/0.3 mL
41304642|NCT04372576|DIAGNOSTIC_TEST|Assessment of ventilator-associated pneumonia criteria|Diagnosis of ventilator-associated pneumonia is based upon the routine daily clinical and laboratory parameters.
40780373|NCT02072954|DRUG|Asenapine Sublingual Tablets 10 mg|"Round, white to off-white sublingual tablets, with 10 on one side within a circle"
40780374|NCT01126957|DRUG|Ketamine|Ketamine was given as a 0.5mg / Kg bolus.
40780375|NCT01126957|DRUG|Placebo|Placebo given as an bolus to control group.
40780376|NCT01126957|DRUG|Fentanyl|Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
40780377|NCT01126957|DRUG|Propofol|Propofol given to both arms to maintain sedation throughout procedure.
40780378|NCT01397253|OTHER|Automated communication tools|"Automated communication tools will include:~* PCP notification of patient admission and location~* Data on medications begun on admission~* Automated alerts on changes in patient status and location while the patient is hospitalized~* Links to the EMR and to hospital physician contact information on all email alerts~* Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP~* Automatic reporting to PCPs of test results pending at discharge~* Electronic delivery of final discharge summaries"
40780379|NCT03296982|OTHER|Blood drawn by direct venipuncture|Subjects will have blood sampled (12 mL/sample) a total of 8 times by direct venipuncture. Samples will be spiked with predetermined concentrations of anticoagulants, or saline sham.
40780380|NCT03296982|DRUG|edoxaban|
40780381|NCT03296982|DRUG|Enoxaparin|
40780382|NCT03296982|DRUG|Saline sham|
40780383|NCT03377517|RADIATION|radiosurgical hypophysectomy|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
40780384|NCT04020640|OTHER|no intervention|Measure human intake using stable isotope technique
40780385|NCT03089814|PROCEDURE|ischemic conditioning|Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
40780386|NCT00151177|DEVICE|non-invasive continuous positive airway pressure ventilation|
40780387|NCT00151177|DEVICE|CPAP-treatment|night time CPAP-mask ventilation
40780388|NCT06079853|BEHAVIORAL|PureSomni Sleep Health Product Kit|PureSomni sleep health products offered: blue light blocking glasses, eye mask, nasal strips, white noise machine, lavender spray, herbal tea, ear plugs
40780389|NCT02004301|DRUG|Radiolabelled T4 Tablet|
40780390|NCT02004301|DRUG|Radiolabelled T6 Tablet|
40780391|NCT01307449|BIOLOGICAL|PNEUMOVAX|1 dose of PNEUMOVAX
40780392|NCT01307449|BIOLOGICAL|Prevnar|1 dose of Prevnar
40780393|NCT01983007|PROCEDURE|High-intensity exercise|Performance of high-intensity exercise
41144181|NCT00869609|BEHAVIORAL|GLB Traditional Maintenance (TM)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
41144182|NCT00869609|BEHAVIORAL|GLB-Carb-focused Maintenance (CF)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
41146983|NCT04844294|BEHAVIORAL|Present-Centered Therapy (PCT)|PCT includes (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions. PCT differs from BCBT in several key ways including less structure (i.e., patients are allowed to have more input into PCT session agendas) and no systematic training in behavioral or cognitive strategies for managing emotions and changing suicide-focused thoughts. PCT will be used as an active comparator because it is an empirically supported treatment for depression and PTSD that also reduces suicidal ideation (Bryan et al., 2016; Resick et al., 2017), but contains unique elements that distinguish the treatment from BCBT.
40780394|NCT01983007|PROCEDURE|Low-intensity exercise|Performance of low-intensity exercise
40780395|NCT00621283|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
40780396|NCT04250701|OTHER|Body Posture Assessment|Application of three evaluations above at a one time.
40780397|NCT03017001|DIETARY_SUPPLEMENT|CHO (carbohydrate)|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia
40780398|NCT03017001|DRUG|intravenous w-3 PUFA|Patients in this groups received during the operation (intraoperative) a dose of intravenous w3-PUFA
41304643|NCT03082495|BEHAVIORAL|Exercise|Supervised high-intensity interval training (HIIT) during NACRT followed by unsupervised moderate-to-vigorous intensity continuous exercise training after the completion of NACRT and before surgery
41304644|NCT04574284|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
40780399|NCT03017001|OTHER|CHO (carbohydrate) plus intravenous w3-PUFA|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia, plus an intravenous dose of w3-PUFA intraoperatively
40780400|NCT05325203|BIOLOGICAL|Ongericimab|Administered by subcutaneous injection
40780401|NCT05325203|DRUG|Placebo|Administered by subcutaneous injection
40780402|NCT02821325|OTHER|MRI|"Patients undergoing a total knee arthroplasty, will undergo additional MRI's. One MRI pre-operatively.~2nd MRI post-operatively on day 1. 3rd MRI post-operatively on day 2."
40780403|NCT01887717|DEVICE|TheraSphere®|Intrahepatic treatment of advanced hepatocellular carcinoma
40780404|NCT01887717|DRUG|Sorafenib|Standard of care therapy for treatment of advanced hepatocellular carcinoma
40780405|NCT00775957|PROCEDURE|FLT-PET scan|imaging scan
40780406|NCT00775957|PROCEDURE|FDG-PET scan|imaging scan
41304645|NCT04574284|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
41304646|NCT01689207|DRUG|Avibactam (AVI)|PART A: AVI IV infusion
41304647|NCT01689207|DRUG|Aztreonam (ATM)|PART A: ATM IV infusion
40780407|NCT03885700|BEHAVIORAL|Educational program for 2 months|"The intervention was suggested based on the recommendations for adolescents' healthy diet and physical activity, it was derived from the 2008 Physical Activity Guidelines for Americans and Dietary Guidelines for Americans, 2010 by the U.S. HHS, Physical activity guidelines for children and adolescents by CPS 2012. The Food Guide Pyramid by the USDA, Nutrition \&Healthy Eating by Mayo clinic \& CDC website. The program was modified according to the age of the child. This plan was typically pursued in a School-based Intervention to Promote Healthy Lifestyles in Sousse, Tunisia, by Harrabi et al. The 1st month covered the healthy diet \& the 2nd month covered the physical activity as follow:~* 1st \& 5th week: A 60-minutesession in health education.~* 2nd \& 6th week: Group counselling.~* 3rd \& 7th week: Students were divided into 8 groups \& each group was asked to make presentation about a task related to the topic.~* 4th \& 8th week: Discussing the presentation."
40780408|NCT04009980|OTHER|OMK2 group|topical administration of OMk2 ophthalmic solution for 36 months three times/day
40780409|NCT04009980|OTHER|Placebo group|topical administration of ophthalmic placebo solution for 36 months three times/day
40780410|NCT05151822|OTHER|Training session with the virtual reality mask|Patients will have a training session with the virtual reality mask, the day before surgery. The training consists in the realization, by the patient, of a series of language or neuropsychological tests and evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated)).
40780411|NCT05151822|OTHER|Monitoring of the device|In the operating room : installation and per-operative monitoring of the device. If the device was removed, the list of device side effects or surgery-related adverse events that was required discontinuation of the device will be established.
41304648|NCT01689207|DRUG|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
41304649|NCT01689207|DRUG|Placebo|PART A, PART B, PART C: matching placebo IV infusions
41304650|NCT03699787|OTHER|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
41463519|NCT00877994|BEHAVIORAL|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
40780412|NCT05151822|OTHER|Acceptability of the device|After the surgery: evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated))
40780413|NCT05151822|OTHER|Patient state of anxiety|Assessing patient's state of anxiety with the State-Trait Anxiety Inventory (STAI) after surgery.
40780414|NCT04623944|BIOLOGICAL|NKX101 - CAR NK cell therapy|NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
40780415|NCT03502681|DRUG|Eribulin Mesylate|"Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m\^2;~Dose level 0: 1.1 mg/m\^2;~Dose level +1: 1.4 mg/m\^2"
40780416|NCT03502681|DRUG|Avelumab|Days 1, 15 Avelumab (10mg/kg)
40780417|NCT04989361|PROCEDURE|Soluble Hyaluronic Acid Microneedle|The soluble hyaluronic acid microneedle eye mask is a nanometer-sized microneedle made of water-soluble hyaluronic acid, which can directly inject the active ingredients into the dermis, and after being absorbed and dissolved by the skin, it can achieve the purpose of improving the water content and elasticity of the skin.
40780418|NCT04989361|PROCEDURE|Non-fractional laser|he non-ablative fractional laser use 1565nm fiber laser, which acts on the target base in the dermis-water. The beam penetrates the epidermis and acts on the dermis. Using the principle of focal light and heat, the tissue cells are heated to initiate the repair process, which promotes increased collagen synthesis, thereby Achieve the effect of firming the skin and improving wrinkles.
40780419|NCT03548129|DRUG|phosphomycin|Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
40780420|NCT03548129|DRUG|Culture specific antibiotic therapy|Culture-specific antibiotic treatment for 5 days
40780421|NCT03548129|DIAGNOSTIC_TEST|Pre-treatment Urine Culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
40780422|NCT03548129|DIAGNOSTIC_TEST|Antimicrobial sensitivity testing|Susceptibility of urinary pathogens to various antimicrobials
40780423|NCT03548129|DIAGNOSTIC_TEST|Post-treatment urine culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
40780424|NCT02402595|DRUG|AVP-923|
40780425|NCT02402595|DRUG|AVP-786|
40780426|NCT02402595|DRUG|Itraconazole|
40780427|NCT00073125|DRUG|ABT-510/Thrombospondin-1 mimetic|
40780428|NCT04821167|PROCEDURE|laparoscopic orchiopexy for intra-canalicular testis|laparoscopic orchiolysis of abnormal fibrous attachments and then lap assisted transcrotal fixation of the testis in subdartos pouch for intra-canalicular testis
40780429|NCT01060943|DEVICE|KOKEN|"atelocollagen filler~1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year."
40780430|NCT01060943|DEVICE|Atelocollagen Filler|1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
40780431|NCT02639689|DEVICE|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
41304651|NCT04969640|OTHER|Optical coherence tomography|Anterior segment optical coherence tomography examination of corneas with infective keratitis
40780432|NCT05631847|PROCEDURE|Endovascular treatment|It is the emergency surgical removal of emboli which are blocking blood circulation. The strategies that were used for endovascular treatment included stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intraarterial thrombolysis (with alteplase), or combinations of these approaches that were left to the discretion of the treating team.
40780433|NCT05631847|DRUG|Intravenous thrombolysis (Alteplase)|Alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
41146984|NCT05365230|OTHER|On-demand personalized follow-up care|On-demand personalized follow-up care (on demand access to a WBCP nurse and an annual follow-up by telephone.
41304652|NCT05681741|PROCEDURE|current versus high pump flow|during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
41304653|NCT01103817|DIETARY_SUPPLEMENT|Vitamin D|"Dosing If the 25 OH Vitamin D level at Baseline/Screening is less than 20 nmol/L then the subject will receive 2000 IU daily.~If the 25 OH Vitamin D level at Baseline/Screening is between 20 and 37.5 nmol/L then the subject will receive 1000 IU daily."
41304654|NCT01158833|OTHER|classification of gait in diplegic children with CP|To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
41304655|NCT03866863|OTHER|Intrauterine growth restriction (IUGR)|Collection of number of patient's diagnosed with IUGR as defined in accordance with the consensus-based definition for early and late IUGR : birthweight \< 3rd centile using French AUDIPOG curves adjusted for term and sex or estimated fetal weight \< 10th centile combined with umbilical artery pulsatility index \> 95th centile or breakage of growth.
41304656|NCT00466128|DRUG|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
41304657|NCT06355557|OTHER|AI enabled ultrasound system for self-directed learning|use of the AI enabled ultrasound system for self-directed learning
41304658|NCT06355557|OTHER|Simulator for self-directed learning|use of the simulator for self-directed learning
40984921|NCT00380978|PROCEDURE|combined spinal epidural analgesia|Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
40780434|NCT03861338|DRUG|Sublocade|The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
40780435|NCT00145730|DRUG|Ibuprofen|
40780436|NCT00003888|DRUG|cisplatin|
40780437|NCT00003888|DRUG|docetaxel|
40780438|NCT00003888|DRUG|fluorouracil|
40780439|NCT00003888|RADIATION|radiation therapy|
40780440|NCT00216281|DRUG|Clozapine augmented with atomoxetine up to 40 mg or placebo|
40780441|NCT05821946|OTHER|Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections|Before discharge, individuals will be given a user name and password to enter the website by the researcher. The first access to the website will be made via the researcher's computer, and the website will be introduced. Individuals will be shown how to access the compatible website on Android and IOS phones and tablets by the researcher. Web-based multi-source training for individuals to prevent urinary tract infections will begin. The researcher will check the use of educational materials by individuals from the administrator's menu. To increase the effectiveness of the training, reminder, motivating, and supportive messages will be sent to the patients twice a week.
40780442|NCT00498212|BIOLOGICAL|1018 ISS-HBsAg-Single|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
40780443|NCT00498212|BIOLOGICAL|1018 ISS-HBsAg-Double|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
40780444|NCT05013814|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament test|Tactile function was evaluated mainly as tactile registration by using 20-item Semmes-Weinstein monofilament (SWM) kit. The monofilament was applied three times with a pseudorandom order to distal pad of the thumb, index, 4th and 5th digits (C6, C7 and C8 dermatomes). The lowest value of monofilament was recorded which the child was able to correctly identify at least one touch out of three
40780445|NCT05013814|DIAGNOSTIC_TEST|Box and Block Test|Box and Block Test (BBT) was used for dexterity assessment. The BBT measures unilateral gross manual dexterity. The child was asked to move, one by one, the maximum number of blocks from one compartment of a box to another of equal size within 60 seconds
40780446|NCT05013814|DIAGNOSTIC_TEST|9-Hole Peg Test|9-Hole Peg Test (9-HPT) is used to measure finger dexterity. Firstly, the child takes the pegs from a container, one by one, and place them in the holes on the board; then participant removes the pegs from the holes and replaces them back into the container. The total time taken to complete the test is recorded in seconds.
40780447|NCT05013814|DIAGNOSTIC_TEST|Duruöz Hand Index (DHI)|Duruöz Hand Index (DHI) is an 18-item self-report questionnaire regarding ability to carry out manual tasks. Individual items are scored on a 6-point Likert scale where 0=without difficulty and 5=impossible. The total score ranges from 0-90 with higher scores indicating poorer hand function.
40780448|NCT05013814|DIAGNOSTIC_TEST|Jamar hand dynamometer|Hand grip strength was measured by using Jamar hydraulic hand dynamometer. Measurement was done with the participant in sitting position and the elbow at 90 degrees of flexion. The force has most commonly been measured in kilograms according to the amount of static force that the hand can squeeze around the dynamometer.
40780449|NCT05013814|DIAGNOSTIC_TEST|Hydraulic pinch gauge|Hydraulic pinch gauge is used for evaluation of finger grip strength. The evaluation method was the same as Jamar hand dynamometer.
40780450|NCT02815163|OTHER|Empowerment education|"1. admission (1 hour)~   ▪partnership~2. 2 ds after THR (30-45min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~3. 2 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~4. 6 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~5. 10 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback"
41146985|NCT05365230|OTHER|Guideline-based follow-up care (standard of care)|Follow-up care based on current standard of care guidelines.
41146986|NCT05966545|PROCEDURE|pars plana vitrectomy and intraocular foreign body removal|removal of vitreous body and attachment to foreign body then extraction of foreign body
41304659|NCT06355557|OTHER|traditional with human instructors|Medical students who are randomised to this arm
41304660|NCT02249286|BEHAVIORAL|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area
41304661|NCT02249286|OTHER|no intervention|the control will only receive the agriculture extension and the existing health and nutrition education in the area
41304662|NCT01863849|BIOLOGICAL|Vaccination with Fluval AB suspension for injection|Single intramuscular injection with Fluval AB suspension for injection in both age groups
40780451|NCT03216798|OTHER|questionnaires survey|The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.
41146987|NCT05802498|DEVICE|IRMA|For patients in an advanced state of illness, advanced neuromotor rehabilitation treatment included 1) robot therapies, 2) specific water courses (e.g. walking pools, hydrokinesiotherapy pools, etc.), 3) advanced cognitive treatments (e.g. virtual reality courses); 4) augmentative immersive therapy in a virtual environment; 5) courses also dedicated to social reintegration and inclusive activities (theatre-therapy, art-therapy, dance-therapy, agro-therapy, etc.).
41304663|NCT05700175|DIAGNOSTIC_TEST|Transcriptomic, epigenetic and proteomic analysis|"Next-generation sequencing will be used to identify differences in expression of circulating transcripts (protein-coding and not) in patients affected by Marfan Syndrome (MFS), subdivided based on the presence or absence of thoracic aortic aneurysms (TAA) and indication of TAA-surgery (TAA_MFS_signature).~The obtained TAA_MFS_signature will be correlated to fundamental biological parameters by analysing:~Blood-levels of cytokines and chemokines relevant for inflammation. Transcriptomic and epigenetic (Cytosine methylation) changes in aortic aneurysms tissue by Next-generation sequencing.~Progression of biomarkers in surgical-patients before and at 6 and 12 months after surgery."
40780452|NCT04943237|DRUG|Anti-TNF agents|Group of patients using anti-TNF for the last 5 years.
40780453|NCT04943237|DRUG|Conventional therapy users for the last 5 years|Group of patients not using anti-TNF. Group of patients using conventional therapy (non -steroid anti-inflammatory drugs and/or salazopyrin) for the last 5 years
40780454|NCT00276419|DRUG|Diclofenac|Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
40780455|NCT00276419|DRUG|Placebo|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
40780456|NCT01039389|DRUG|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
40780457|NCT01039389|DRUG|Placebo|bid placebo
40780458|NCT02944890|DEVICE|Drug Eluting Balloon Catheters(RESTORE DEB）|
40780459|NCT02944890|DEVICE|Drug Eluting Balloon Catheters(SeQuent® Please）|
40780460|NCT03201120|BEHAVIORAL|Outdoor Sun Behavior|Participants will provide informed consent and complete a short background questionnaire about usual sun exposure and protection behaviors and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a computer monitor, keyboard and mouse setup. Each participant will view messages with different emotional appeals related to outdoor sun exposure (seeking shade, covering up, using sunscreen, and multiple behaviors). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
40780461|NCT03201120|BEHAVIORAL|Indoor Tanning Behavior|Upon arrival, participants will provide informed consent and complete a short background questionnaire about usual indoor tanning, sun exposure and protection behaviors, and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a typical computer monitor, keyboard and mouse setup. Each participant will view messages with each type of target behavior (freedom, health risk, appearance)). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
40780462|NCT02759445|OTHER|routine treatment|No intervention, only observation and describing
40780463|NCT03569189|OTHER|High Fat Diet|"Participants will consume a high fat diet for 7 days with 65% of energy from fat. The diet will also provide an energy excess at 150% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
40780464|NCT00001066|DRUG|Lamivudine|
40780465|NCT00001066|DRUG|Zidovudine|
40780466|NCT00001066|DRUG|Didanosine|
40780467|NCT00020254|BIOLOGICAL|aldesleukin|
40780468|NCT00020254|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|
40780469|NCT00020254|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
40780470|NCT00020254|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
40780471|NCT00020254|BIOLOGICAL|sargramostim|
40780472|NCT00020254|DRUG|nilutamide|
40780473|NCT02466919|DRUG|Pantoprazole|H. pylori eradication therapy
41304664|NCT01881594|PROCEDURE|Procedure/Surgery|daily stimulation of efferent loop prior to surgery (ileostomy closure)
41304665|NCT06276608|DIAGNOSTIC_TEST|Iron status|Iron status will be based on preoperative ferritin levels: a ferritin \< 10 mcg/L will be considered as iron deficiency, ferritin levels \> 10 mcg/L will be considered normal
41304666|NCT04348487|OTHER|Modified cephalica venous access|This modified technique prioritized the safety in TIVAPS by using several modified landmarks and techniques. The catheter was inserted through cephalic vein in deltopectoral groove regio and implanted the port in the anteromedial of thorax. Generally, the percutaneous and Seldinger technique was used to ensure safety and minimal tissue disruption. To connect the trimmed catheter to port pocket, the author anchored a special trocar from anteromedial of thorax to the deltopectoral groove for guidance.
41304667|NCT00398151|DRUG|MK0476, montelukast sodium / Duration of Treatment: 12 Weeks|
40780474|NCT02466919|DRUG|Amoxicillin|H. pylori eradication therapy
40780475|NCT02466919|DRUG|Metronidazole|H. pylori eradication therapy
40780476|NCT02466919|DRUG|Levofloxacin|H. pylori eradication therapy
40780477|NCT02466919|DRUG|Clarithromycin|H. pylori eradication therapy
40780478|NCT06026865|DIETARY_SUPPLEMENT|S-Adenosyl-L-methionine (SAMe)|S-adenosyl-L-methionine 1200 mg/daily as 2400mg S-Adenosyl-L-methionine disulfate tosylate
40780479|NCT06026865|OTHER|Placebo|Placebo of identical appearance, smell and taste, with the same schedule.
40780480|NCT02733757|DRUG|Clonidine|Clonidine 1 µg/kg plus 2% lidocaine
40780481|NCT03319576|OTHER|Feeding at 4 hours|Patients will be fed 4 hours after their gastrostomy tube placement procedure.
40780482|NCT00590317|DRUG|Prochlorperazine|Patients receiving Prochlorperazine
40780483|NCT00590317|DRUG|Ondansetron|Patients receiving Ondansetron
40780484|NCT05105321|DRUG|Berberine|The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily
40780485|NCT05105321|BEHAVIORAL|Healthy lifestyle intervention|"Healthy lifestyle intervention will be launched according to the Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019, including health lectures, health information promotion, health manual and so on."
40780486|NCT00943761|DRUG|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
40780487|NCT00943761|DRUG|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
40780488|NCT00943761|DRUG|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
40780489|NCT00943761|DRUG|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks
40780490|NCT00503984|DRUG|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
40780491|NCT00503984|DRUG|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
40780492|NCT00503984|DRUG|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
40780493|NCT00503984|GENETIC|GADD45α methylation and expression analysis|"Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so."
40780494|NCT00503984|DRUG|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
40780495|NCT00503984|DRUG|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
40780496|NCT03932409|DRUG|Pembrolizumab|"prior to VCB: 200mg IV given one week (7 days) before radiation~after VCB: 200mg IV on day 1 of a 21 day cycle prior to chemotherapy"
40780497|NCT03932409|RADIATION|Vaginal cuff brachytherapy (VCB)|Treatment should commence within 12 weeks of the surgery/hysterectomy
40780498|NCT03932409|DRUG|Paclitaxel|after VCB, Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
40780499|NCT03932409|DRUG|Carboplatin|after VCB, Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
40780500|NCT02639390|DEVICE|Robotic Therapy|Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.
40780501|NCT02639390|OTHER|Conventional Therapy|An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
40780502|NCT03655847|DRUG|Dexmedetomidine|Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
41304668|NCT02290535|PROCEDURE|patients|The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
41304669|NCT02290535|PROCEDURE|probands|Probands will receive the same treatment as patients, but without bronchospasmolysis.
41304670|NCT02347111|DRUG|Flecainide|flecainide up to 150mg twice daily for the control of atrial fibrillation
41304671|NCT02347111|DRUG|Sotalol|sotalol up to 120mg twice daily for the control of atrial fibrillation
40780503|NCT05770284|OTHER|12 weeks exercise|12 weeks exercise
40780504|NCT05770284|OTHER|Standard Medical Treatment|Standard Medical Treatment
40780505|NCT00497003|DRUG|Treatment with either metoprolol or carvedilol|
40780506|NCT02332928|DRUG|Melatonin|Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
40780507|NCT02332928|DRUG|Placebo|Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
40984922|NCT00380978|PROCEDURE|late analgesia (systemic)|Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
40984923|NCT03506607|OTHER|Exercise in hypoxia 1500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
41146988|NCT05823766|BEHAVIORAL|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
40780508|NCT04405817|DEVICE|ECMO|ECMO for circulatory and/or respiratory support
40780509|NCT00940550|DRUG|Prolonged-release melatonin|2 mg tablet, once.
40780510|NCT00940550|DRUG|Temazepam|20 mg capsule, once
40780511|NCT00940550|DRUG|Zolpidem|10 mg capsule, once
40780512|NCT00940550|DRUG|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
40780513|NCT04707079|DRUG|Duvelisib|Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
40780514|NCT03234634|PROCEDURE|endovascular thrombectomy|"Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral~1. Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.~2. Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well."
40780515|NCT03583229|DRUG|Aspirin 75mg|7 days treatment with 75 mg aspirin daily.
40780516|NCT03583229|OTHER|Extracorporeal photopheresis|4 x ECP treatments in 60 days.
40780517|NCT02151929|DEVICE|Bioresorbable vascular scaffold|stenting of an acute thrombotic lesion in patient within STEMI
40780518|NCT02151929|DEVICE|Everolimus eluting stent|stenting of an acute thrombotic lesion in patient within STEMI
40780519|NCT03344341|DRUG|Dapagliflozin|Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.
40780520|NCT03344341|DRUG|Acarbose|Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
40780521|NCT01643681|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
40780522|NCT01909544|OTHER|Fatiguing exercise|All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
40780523|NCT01428635|DRUG|Eltrombopag Olamine|Given PO
40780524|NCT02108288|DRUG|OPC-1085EL ophthalmic solution|
40780525|NCT02108288|DRUG|Carteolol long-acting ophthalmic solution|
40780526|NCT02108288|DRUG|Latanoprost ophthalmic solution|
40780527|NCT00660218|DRUG|paclitaxel poliglumex|Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
40780528|NCT00660218|BIOLOGICAL|cetuximab|400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
40780529|NCT00660218|RADIATION|radiation therapy (IMRT or 3D-CRT)|radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
40780530|NCT00241150|DRUG|VALSARTAN|
40780531|NCT02789852|DEVICE|Orthosis|use orthosis
41463520|NCT05721092|OTHER|Pre and Post Education on practice of pneumococcal vaccination|A cross-sectional study will be conducted among 25 diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
41463521|NCT04145245|DRUG|Levocarnitine|Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
40780532|NCT03436342|DRUG|68Ga-Pentixafor|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga-Pentixafor will be used to image lesions of MM and lymphoma by PET/CT.
40780533|NCT00922129|DRUG|Sirolimus (Rapamune)|Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
40780534|NCT00922129|DRUG|Cyclosporin (Neoral) or Tacrolimus (Prograf)|"Cyclosporin: 3-4 mg/kg, BID, PO, 24 months~Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months"
40780535|NCT02294032|DRUG|Immunosuppressive Agents|standard of care for patients post-transplant
40780536|NCT05894603|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir/ritonavir
40780537|NCT05894603|DRUG|Molnupiravir|Molnupiravir
40780538|NCT04815187|DRUG|Montelukast|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
40780539|NCT04815187|DRUG|Placebo|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
40984924|NCT03506607|OTHER|Exercise in hypoxia 2500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
41463522|NCT04458961|PROCEDURE|One-stage|A one-stage revision operation involves one operation to remove the joint, thoroughly cleaning the infected area and then implanting a new joint immediately.
40780540|NCT03621280|DRUG|Levoketoconazole|Levoketoconazole up to 1200 mg daily
40780541|NCT06203223|OTHER|Ova-max|use Ova-max 3 months prior to treatment initiation
40780542|NCT06203223|OTHER|placebo|use placebo 3 months prior to treatment initiation
40780543|NCT01082939|DRUG|Fludarabine|25 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
40780544|NCT01082939|DRUG|Cyclophosphamide|250 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
40984925|NCT03506607|OTHER|Exercise in normoxia|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
40984926|NCT05482763|DRUG|Terbinafine Topical Gel|Topical application of terbinafine
40984927|NCT05482763|DRUG|Itraconazole 200 mg|systemic itraconazole pulse therapy
40984928|NCT05482763|DRUG|Terbinafine 250 mg|systemic terbinafine
41463523|NCT04458961|PROCEDURE|Two-stage|A two-stage revision operation involves two operations: the joint is removed in one operation, a temporary spacer device is inserted, then the infection is treated with antibiotics, and then a new joint is implanted in a second operation.
40780545|NCT01082939|DRUG|Alemtuzumab|30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
40780546|NCT01082939|DRUG|Rituximab|"Cycle 1 (Week 1): 375 mg/m\^2/day IV on Day 2 over 4- 6 hours~Cycle 2 - 6 (Week 1): 500 mg/m\^2/day IV on Day 2 over 4- 6 hours"
40780547|NCT01221506|DRUG|Pazopanib|800 mg PO QD x 28 days
40780548|NCT01221506|DEVICE|DCE-MRI and Quantitative Doppler Ultrasound|Contrast-enhanced MRI
40780549|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
40780550|NCT00516724|DRUG|Carboplatin|intravenous injection
40780551|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
40780552|NCT00516724|DRUG|Paclitaxel|Intravenous injection
40780553|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
40780554|NCT00516724|DRUG|Paclitaxel + Carboplatin|Intravenous injection
40780555|NCT00646126|DRUG|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
40780556|NCT00646126|DRUG|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
40780557|NCT01352884|DRUG|AMP-224|Escalating doses of AMP-224
40780558|NCT01352884|DRUG|AMP-224|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
40780559|NCT03483389|DRUG|Alcohol, Ethyl|Randomized within-subjects design
40780560|NCT03483389|OTHER|Alcohol, Ethyl - placebo|Randomized within-subjects design
40780561|NCT00011583|DEVICE|Robot-assisted therapy|1 hour/day of mechanically-assisted upper limb therapy
40780562|NCT00011583|DEVICE|Traditional therapy|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
40780563|NCT01841996|DRUG|ME1111 solution|Once a day for 28 days
40780564|NCT01841996|DRUG|Vehicle Solution|Once a day for 28 days
40780565|NCT06033534|DEVICE|STIMULAN|"Procedures:~Surgical repair of the open fracture, as per standard-of-care guidelines. Insertion of the STIMULAN device at the site of the fracture. Standard post-operative care, including monitoring of inflammatory markers and clinical signs of infection."
40780566|NCT05173779|PROCEDURE|Left atrial isolation by catheter ablation|Procedure: Right pulmonary vein circumferential isolation + anterior left atrial line (superior mitral annulus to right superior pulmonary vein via the anterior wall) + para-septal line (para-septal mitral annulus to the right inferior pulmonary vein, including right atrial components-especially in and around the proximal coronary sinus) + posterior left atrial line (superior mitral annulus to right superior pulmonary vein via the posterior wall).
40780567|NCT03293121|BEHAVIORAL|Strength and Coordination Training|Perform training exercises 3/week. Weeks 1-2: general strength (isolated muscle groups) Weeks 3-4: running-specific strength (multi-joint, upright) Weeks 5-6: power/coordination I (low amplitude/intensity) Weeks 7-8: power/coordination II (higher amplitude/intensity) Weeks 9-16: Run training. Each training session will start with a 10 minute strength \& coordination warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
40780568|NCT03293121|BEHAVIORAL|Walking|Perform training exercises 3/week. Weeks 1-2: 30 minute walk Weeks 3-4: 35 minute walk Weeks 5-6: 40 minute walk Weeks 7-8: 45 minute walk Weeks 9-16: Run training. Each training session will start with a 10 minute walking warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
40780569|NCT02272127|DRUG|icotinib|
40780570|NCT05217173|OTHER|telerehabilitation|It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks
40780571|NCT00160953|PROCEDURE|Endorectal Coil Magnetic Resonance Images|
40780572|NCT06086964|OTHER|therapeutic diet.|gluten and casein free diet.
40780573|NCT06086964|OTHER|physiotherapy|specific physiotherapy developmental program according to the pre evaluation of gross motor status.
40780574|NCT06279611|DRUG|LY007|FC and LY007 infusion
40780575|NCT04400825|OTHER|Dry needling|Dry needling of the active MTrPs following the technique described by Hong et al (1994,1995)
40780576|NCT05441514|DRUG|Cobimetinib|Given PO
40780577|NCT05441514|DRUG|Enasidenib Mesylate|Given PO
40780578|NCT04201535|DIAGNOSTIC_TEST|Protein arrays on plasma samples|Protein arrays on plasma samples obtained from RA, OA patients and controls will be performed to identify a panel of acute phase proteins, cytokines and chemokines present at systemic levels and to highlight analogies and differences in the systemic protein profile.The synovial fluid will be used to identify through high-throughput MudPIT the proteins present in the synovial fluid of RA and OA patients.
40984929|NCT05482763|DRUG|Ciclopirox Topical Gel|Topical application of ciclopirox
40984930|NCT05482763|DRUG|Amorolfine 50 MG/ML|Topical application of amorolfine
40984931|NCT01778881|OTHER|Massage and stretching exercises|The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
40984932|NCT01778881|OTHER|Relaxation and imagination therapies|The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
40984933|NCT01778881|OTHER|Dental treatment|Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
40780579|NCT00845702|DRUG|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
40984934|NCT01778881|OTHER|Massage, exercises, relaxation and imagination therapies|The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
40984935|NCT05913180|DRUG|Ascorbic Acid 1000 MG|1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
40984936|NCT05913180|DRUG|Placebo|Placebo tablet daily starting day of elective gynecological surgery for 10 days
40984937|NCT00383149|DRUG|Ixabepilone|Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.
40984938|NCT00383149|DRUG|Cetuximab|Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.
40984939|NCT04919850|DIETARY_SUPPLEMENT|Saccharomyces boulardii and SOD|A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
40984940|NCT04919850|COMBINATION_PRODUCT|Placebo|A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
40984941|NCT00082355|DRUG|Alteplase (Activase, Genentech)|Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
40984942|NCT01910090|DRUG|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|MULTI-LAYER TABLET
40984943|NCT01910090|DRUG|ANTADYS® 100 mg, PEPCID® 20 mg|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
40780580|NCT00845702|OTHER|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
40780581|NCT05034328|DEVICE|Healsea® Children|Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed
40780582|NCT05034328|OTHER|Conventional therapies for common cold|Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics)
40780583|NCT06199414|DEVICE|Venous Closure|Vascular closure to achieve vascular hemostasis following femoral access with large bore sheaths in catheter ablation procedures
40780584|NCT00097279|DRUG|biphasic insulin aspart|
40780585|NCT00097279|DRUG|pioglitazone|
40780586|NCT00097279|DRUG|metformin|
40984944|NCT03807869|PROCEDURE|combined glaucoma surgery|phacoemulsification of cataract and I-stent by-pass implantation
40984945|NCT00087581|DRUG|Mycophenolate mofetil|Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m\^2 in pediatrics. In Groups A and B, subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. In Group C, subsequent doses are not to be adjusted, except in the case of unacceptable toxicity.
40984946|NCT00087581|DRUG|Cyclosporine|Cyclosporine will be given as 100-mg soft gelatin capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 125-165 ng/mL (reduced) or 250-270 ng/mL (full); Days 90 through end of study, 95-145 ng/mL (reduced) or 190-220 ng/mL (full).
40984947|NCT00087581|DRUG|Tacrolimus|Tacrolimus will be given as 1-mg and 5-mg capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL (reduced), 8-10 ng/mL (full); Days 90 through end of study, 3-5 ng/mL (reduced), 6-8 ng/mL (full).
40984948|NCT04900831|DIAGNOSTIC_TEST|Omnipolar Eletroanatomical mapping|Analyse intracardiac EGMs collected with the HD Grid catheter (Abbott, Chicago, IL) during routine Atrial Flutter ablation using the Omnipolar algorithm.
40984949|NCT03852641|OTHER|Length of feeding|Feeds will be given via nasogastric tube over 15-30 min versus 2 hr
41463524|NCT03609333|DEVICE|Multimodal Neuromonitoring|Application of multimodal neuromonitoring
41463525|NCT02987634|OTHER|PeriActive|mouthwash
41146989|NCT05823766|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
41146990|NCT05823766|BEHAVIORAL|Clinical Visit|Patients who screen positive for PTE will have an in-depth clinical visit
41463526|NCT03695809|BIOLOGICAL|G9a protein|To assess G9a protein expression on vulvar cancer
41463527|NCT00587249|BIOLOGICAL|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
41463528|NCT00587249|BIOLOGICAL|Alhydrogel|Aluminum hydroxide gel.
40780587|NCT06235580|OTHER|Biological Samples|"For patients, different types of banked frozen or fresh biological samples will be used in this research:~* Blood~* Skin biopsy or other tissues (liver, muscle, brain, lung...)~* Urine~* Saliva~* Cerebrospinal fluid~* Occasionally: operative leftovers (e.g. muscle, brain, lung tissue)~In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.~For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used."
40780588|NCT01164007|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
40780589|NCT01164007|DRUG|Dacarbazine|Dacarbazine will be given as 800 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 28-day cycle.
40780590|NCT00269581|OTHER|Educational CD-rom|Educational CD-Rom
40780591|NCT00269581|OTHER|Headstrong CD-rom|Headstrong CD-rom
41463529|NCT06009588|DEVICE|self-expandable valves|patients undergoing TAVR use self-expandable valves
40780592|NCT01392573|DRUG|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
40780593|NCT01392573|DRUG|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
40780594|NCT02803203|DRUG|osimertinib|
40780595|NCT02803203|DRUG|Bevacizumab|
40780596|NCT05423184|OTHER|Exercise Therapy For Lower Extremities|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg raise with theraband, squat, lunge walk and static balance exercises. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
40780597|NCT05423184|OTHER|Exercise Therapy For Myofascial Chains|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their structered exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg and arm raise with theraband, squat with arm participation using theraband, lunge walk with arm participation using theraband and static balance exercises with arm participation using theraband. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
40780598|NCT04621578|DEVICE|HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)|"Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point."
40780599|NCT04778150|DEVICE|VO 100 medical device from Mespere LifeSciences|The investigators want to show a positive relationship between SjvO2 and SvO2 in order to possibly use in the future SjvO2 measured by VO 100 as a noninvasive surrogate of SvO2 in patients undergoing liver transplantation surgery.
40984950|NCT02357901|DRUG|SUBOXONE|SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
41463530|NCT06009588|DEVICE|balloon-expandable valves|patients undergoing TAVR use balloon-expandable valves
41463531|NCT03782480|DRUG|Intrarosa|Prasterone intravaginal inserts
40780600|NCT00963872|DRUG|cyclophosphamide|50 mg/kg intravenously (IV) over 2 hours on Day -6.
40780601|NCT00963872|DRUG|fludarabine phosphate|40 mg/m\^2 over 1 hour on Days -6 through -2.
40780602|NCT00963872|RADIATION|Total body irradiation|200 cGy on Day -1
40780603|NCT00963872|BIOLOGICAL|Umbilical cord blood unit with C3a fragment|On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
40780604|NCT00963872|BIOLOGICAL|Unmanipulated UCB Unit|On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
40780605|NCT05475808|DEVICE|Static wrist splint treatment|Static wrist splint (volar wrist cock-up orthosis): It extends from the proximal of the metacarpophalangeal (MCP) joint to the distal 2/3 of the forearm, supports the wrist from the volar face. It stabilizes the wrist in 20-30 degrees of dorsiflexion and restricts wrist movements. It allows movement of the MCP joints. Patients will be asked to wear this splint continuously at night and for at least 4 hours during the day for 8 weeks.
40780606|NCT05475808|OTHER|Tendon and nerve gliding exercises|"Tendon and nerve gliding exercises will be applied 5 sessions a day for 8 weeks. Each session will hold 10 repetitions and approximately 7 seconds in each exercise position.~These exercises involve a sequence of finger movements (for tendon gliding) and wrist and fingers movements (for median nerve gliding)."
40984951|NCT02357901|DRUG|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.
41463532|NCT03782480|DRUG|Placebos|Placebo intravaginal inserts
41463533|NCT00212433|DRUG|Tagitol V, Lo So, Readi-Cat 2|
40984952|NCT02357901|DRUG|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
40984953|NCT03272607|OTHER|Deprescribing opportunities|An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
40984954|NCT04333784|OTHER|Exercise training|Exercise with blood flow restriction (with a pneumatic cuff).
40984955|NCT04010682|OTHER|urine sample collection|no drug/devise intervention. sample collection study only
41146991|NCT05823766|PROCEDURE|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
41146992|NCT05823766|PROCEDURE|EEG|An EEG will be performed on patients who screen positive for PTE at the clinical visit
41304672|NCT01321996|PROCEDURE|68Ga-DOTA-NOC PET/CT|procedure: PET/CT scan with 68Ga-DOTA-NOC
41463534|NCT05347394|DRUG|VX-708|Solution or suspension for oral administration.
41463535|NCT05347394|DRUG|Placebo|Placebo matched to VX-708 for oral administration.
41463536|NCT01632306|DRUG|LY2090314|LY2090314 administered IV
41463537|NCT01632306|DRUG|FOLFOX|FOLFOX administered IV
41463538|NCT01632306|DRUG|Gemcitabine|Gemcitabine administered IV
41463539|NCT01632306|DRUG|Nab-paclitaxel|Nab-paclitaxel administered IV
41463540|NCT05017649|BIOLOGICAL|Blood sample|Blood sampling.
41463541|NCT00820508|DRUG|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
41463542|NCT05308823|PROCEDURE|Stent|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent
40780607|NCT05475808|DRUG|Wrist local steroid injection|"Wrist local steroid injection:~After proper area cleaning with povidone solution, 1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from ulnar side of the wrist proximal crease under ultrasound guidance."
40780608|NCT05853354|BIOLOGICAL|Denosumab|Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
40780609|NCT02638909|DRUG|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
40780610|NCT00129857|DRUG|Dexanabinol|
40780611|NCT01252615|BEHAVIORAL|patient only|education, behavioral strategies, psychological interventions
40780612|NCT01252615|BEHAVIORAL|patient and partner intervention|education, psychological support, behavioral strategies
40780613|NCT00541112|BIOLOGICAL|cetuximab|
40780614|NCT00541112|DRUG|capecitabine|
40780615|NCT00541112|DRUG|fluorouracil|
40780616|NCT00541112|DRUG|leucovorin calcium|
40780617|NCT00541112|DRUG|oxaliplatin|
40780618|NCT00541112|PROCEDURE|adjuvant therapy|
40780619|NCT00541112|PROCEDURE|conventional surgery|
40780620|NCT00541112|PROCEDURE|neoadjuvant therapy|
40780621|NCT00541112|RADIATION|radiation therapy|
40780622|NCT01013571|DRUG|insulin glargine|pre-filled disposable pen, in package of 5.
40780623|NCT01013571|DRUG|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
40780624|NCT03722810|OTHER|Intervention|"The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher."
40780625|NCT03722810|OTHER|Sham comparator|In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
40780626|NCT05655767|OTHER|4D-flow MR & CT-scan|4D-flow MR and CT-scan after cardiac surgery (until 12 months afterwards), for the purpose of obtaining more precise data on (hemo)dynamic processes within the cardiovascular system, in combination with data extraction from the established biobank and databank (FIBAA-bank).
40780627|NCT01985022|BEHAVIORAL|Group-ESI|The Group-ESI intervention consists of weekly small group meetings where families receive information about social communication, emotional regulation, play development, and behavioral challenges in toddler playgroups in a relaxed, supportive, child-friendly setting that provides the opportunity to talk with a professional and meet other parents.
40780628|NCT01985022|BEHAVIORAL|Individual-ESI|The Individual-ESI intervention consists of twice-weekly home-based individualized coaching sessions. Parents learn how to support their child's communication, social, and play skills in everyday routines, activities, and places. Individual-ESI begins with an initial home visit, followed by a month of program planning, 6 months of intervention implementation, and 2 months of generalization. During generalization, the clinician meets with the family in a variety of community settings to teach the parent how to implement strategies in new settings.
40780629|NCT02235324|BIOLOGICAL|ziv-aflibercept|Given IV
40780630|NCT02235324|DRUG|leucovorin calcium|Given IV
40984956|NCT00129493|BEHAVIORAL|Group medical visits|Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
41146993|NCT05823766|BEHAVIORAL|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE
40780631|NCT02235324|DRUG|fluorouracil|Given IV
40780632|NCT02235324|OTHER|laboratory biomarker analysis|Correlative studies
40780633|NCT03111212|DRUG|Iloprost|Iloprost nebulized
40780634|NCT03111212|DRUG|control|sodium chloride 0,9% nebulized
40780635|NCT01486888|DRUG|biphasic human insulin 30|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
40780636|NCT04079738|DRUG|TAK-659|TAK-659
40780637|NCT04079738|DRUG|Ixazomib|Ixazomib
40780638|NCT02015247|PROCEDURE|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
40780639|NCT02550015|BEHAVIORAL|High intensity interval training|Uphill treadmill walking
40780640|NCT02550015|BEHAVIORAL|General information|Standard care
40780641|NCT00308334|DRUG|Domperidone|10 mg po TID X 14 days
40780642|NCT00308334|DRUG|Placebo- Sugar pill|placebo po TID x 14 days
40780643|NCT01906268|OTHER|Attentional Bias Modification Treatment (ABMT) - Active|"The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
40780644|NCT01906268|OTHER|Attentional Bias Modification Treatment - Placebo|"The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
40780645|NCT00090506|BEHAVIORAL|Yoga|
40780646|NCT00536289|DEVICE|Blunt needle|Blunt tipped suture needle
40780647|NCT00240877|BIOLOGICAL|AV024|0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
40780648|NCT00240877|OTHER|Placebo|Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
40984957|NCT03619187|DRUG|Ivabradine|Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
40984958|NCT04634747|DRUG|PVX-410|PVX-410 in combination with pembrolizumab and chemotherapy
40984959|NCT05897294|DRUG|Voriconazole Inhalation Powder|dry powder inhalation of voriconazole
40984960|NCT03448822|PROCEDURE|sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis
41304673|NCT06316791|BIOLOGICAL|single dose of CNCT19|Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously.
41304674|NCT02191917|PROCEDURE|Respiratory muscle strength measurements by different techniques.|
41304675|NCT00654511|DRUG|Fentanyl|Fentanyl 1mcg/kg, Intravenous (IV)
41304676|NCT00654511|DRUG|Fentanyl|Fentanyl 2mcg/kg, Intravenous (IV)
40984961|NCT03036787|BEHAVIORAL|family based intervention|behavioural advises to family for normal motor development
40984962|NCT05590065|DEVICE|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
41304677|NCT00654511|DRUG|Dexmedetomidine|Dexmedetomidine, 2mcg/kg, Intravenous (IV)
41304678|NCT00654511|DRUG|Dexmedetomidine|Dexmedetomidine, 4mcg/kg Intravenous (IV)
41304679|NCT00290576|DIETARY_SUPPLEMENT|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
41304680|NCT03828006|DIETARY_SUPPLEMENT|Red Rice Yeast|Participants will take one tablet per day of a dietary supplement based on red rice yeas for a period of six months
40780649|NCT06344637|DRUG|10 % lidocaine spray without adrenaline|Pateint with indication for manual vacuum aspiration aged between 20-60 years will received a standard injection of pethidine along with 1% lidocaine spray without adrenaline on cervical os to compare pain scores with placebo. Along with measuring side effects immediately and 30 minutes after receiving 1% lidocaine without adrenaline.
40780650|NCT06344637|OTHER|Placebo|4 puffs of normal saline apply on cervical os before manual vacuum aspiration
40780651|NCT03667105|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions.
40780652|NCT03667105|OTHER|MC|Xenogenous graft placed in the surgical site.
40780653|NCT03667105|OTHER|XDM|Xenogenous dermal collagen graft placed in the surgical site.
40780654|NCT04578626|DEVICE|dry needling|The use of filiform needles to stimulate muscles and connective tissues. The needle is inserted in a direction perpendicular to the skin, a local twitch response is looked for and, once found, the needle is kept in the muscle without moving for 10 seconds. No substances are injected.
40780655|NCT04982991|DRUG|RIPK1 inhibitor|Capsule Oral
40780656|NCT04999735|BEHAVIORAL|CHDR Monitoring Remotely (MORE)|CHDR MORE is a highly customizable platform which allows remote monitoring of patients and trial subjects, data ingestion, and data management. The current infrastructure includes an Android app to unobtrusively collect data from smartphone sensors, and a connection to the Withings Health online platform to collect wearable data. Data is stored on a secure server in a structured data scheme ensuring clear data management processes, forming a prerequisite for comprehensive data analysis. The Android app enables data collection from multiple smartphone sensors (e.g. location data, accelerometer and ambient light) as well as phone usage logs (e.g. app usage, calls and texts).
40780657|NCT04999735|BEHAVIORAL|Withings Steel HR|The Withings Steel HR is a commercially available smartwatch that combines various sensors to measure activity (steps, sleep, etc.) and heart rate (HR). HR is measured using a PPG (photoplethysmogram, i.e. optically obtained volumetric measurement) based on a commercially available sensor (AS7000) incorporating low-noise and high-sensitivity analogue circuitry. The manufacturer supplies the algorithm for converting the PPG signal into HR values. Data is transferred from the watch to the smartphone using the Withings Health Mate app from where it will be uploaded to the output server.
40780658|NCT04999735|BEHAVIORAL|Withings Body+ scale|Body composition (weight, BMI and Skeletal Muscle Mass) can be assessed with the Withings Body+ smart scale at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging.
40780659|NCT04999735|BEHAVIORAL|Withings Blood Pressure Monitor|Blood pressure can be assessed with the automated Withings Blood Pressure Monitor at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging
40780660|NCT05921110|PROCEDURE|Pericapsular nerve group block 0,25%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 20 ml volume."
40780661|NCT05921110|PROCEDURE|Pericapsular nerve group block 0,16%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,16% Bupivacaine will be used at 20 ml volume"
40984963|NCT02269020|PROCEDURE|Neck Dissection|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
40984964|NCT03630120|DRUG|Lenvatinib|"Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
40984965|NCT03630120|DRUG|Sorafenib|"Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
41304681|NCT03828006|OTHER|Placebo Group|Participants of this group will take one tablet of placebo per day for a period of six months
41304682|NCT02394444|OTHER|Triadic parent-infant Relationship Therapy (TRT)|22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
41304683|NCT06116461|DRUG|Nivolumab|Participants receive three reduced doses of 240 mg every four weeks
41304684|NCT06515769|DIAGNOSTIC_TEST|TERMOGRAPHY|Obtaining an image of the foot using a thermographic camera
41304685|NCT03355937|PROCEDURE|Sperm Chip|Sperm selection using by conventional or with sperm chip
41304686|NCT01666236|OTHER|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light \[wavelength of 689 nm\] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
41304687|NCT03201172|DEVICE|Primary Unicompartmental Knee Arthroplasty|Primary implantation of an unicompartmental knee implant
41304688|NCT01626183|GENETIC|RNA analysis|
40984966|NCT03630120|DRUG|Cabozantinib|"Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
40984967|NCT03630120|DRUG|Vandetanib|"Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
40780662|NCT06141928|OTHER|Functional recovery analysis|Functional recovery analysis with force evaluator \& tester
40780663|NCT03249194|DRUG|Direct acting Anti-Viral Therapy using Epclusa or Zepatier|All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
40780664|NCT02951130|DRUG|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo
40780665|NCT02951130|DRUG|Placebo (5% Dextrose)|The study intervention is an intravenous infusion of milrinone or placebo
40780666|NCT04400435|DEVICE|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
40780667|NCT06382051|DIAGNOSTIC_TEST|PEST Screening group|PEST Screening group
40780668|NCT05784857|OTHER|Touch Methods|"The Yakson touch method continue for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes). In this method, the palms of the practitioner and all fingers keep in close contact so that the babies don't feel pressure.~Gentle human touch refers to steady contact of the skin without caressing or massaging. While the practitioner place one hand on the crown of the preterm infant on the eyebrow line with the fingertip touch for 15 minutes, the other hand was place on the lower abdomen covering the waist and hip of the infants."
40780669|NCT04874519|BEHAVIORAL|Questionnaire|The questionnaire will be completed at the time of enrollment, every month, and at the end of study. Regardless of current interventions or lack of, assessments will be completed at enrollment and then monthly for a total of 18 months. In order to provide reasonable flexibility to participants, physicians, and study teams, the assessments can be completed within 30 days of the last assessment. The next month will be recalculated based on last reporting date.
40780670|NCT06206434|DIAGNOSTIC_TEST|Point of care ultrasonography|Transthoracic echocardiogrpahy followed spinal anesthesia and 5 ml/kg Ringers lactate fluid co-loading
40780671|NCT00668759|DRUG|Vernakalant Injection|10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
41146994|NCT02618109|BIOLOGICAL|Collection of blood samples|Collection of blood samples
41304689|NCT01626183|GENETIC|proteomic profiling|
41304690|NCT01626183|OTHER|laboratory biomarker analysis|
41304691|NCT00187239|DEVICE|Autointrinsic Conduction Search Algorithm|Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
41304692|NCT02437448|OTHER|No intervention|
41463543|NCT02539368|DRUG|CT-P13|biosimilar infliximab
41463544|NCT02539368|DRUG|Remicade|infliximab
40780672|NCT00668759|DRUG|Amiodarone Injection:|60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
40984968|NCT04463095|PROCEDURE|PER ORAL ENDOSCOPY MYOTOMY (POEM)|Peroral endoscopic myotomy (POEM)combines thelong-term efficacy of a myotomy with the benefits of an endoscopic, minimally invasive procedure.Other therapeutic options include endoscopic balloon dilatation and surgical myotomy. Endoscopic balloon dilatation is still widely performed because of its relative non-invasiveness and simplicity, but it has a relatively lower success rate and often requires multiple treatment sessions. Surgical myotomy has been thought to be the curative therapeutic choice for symptomatic achalasia. However, it requires skin incisions and additional anti-reflux surgical intervention.Unlike surgical myotomy, POEM preserves the anatomical integrity of the LES and possibly minimizes postoperative reflux.
40984969|NCT02983474|PROCEDURE|cholecystectomy|"Laparoscopic surgery~1. Reverse Trendelenburg position~2. Skin incision and trocar insertion~3. CO2 gas insufflation~4. Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction~6. Calot triangle exposure~7. Cystic artery and cystic duct isolation~8. Gallbladder bed dissection~9. Bleeding control~10. Gallbladder extraction~11. Trocar removal and wound closure~Open surgery~1. Supine position~2. Skin incision~3. Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction 6. Calot triangle exposure 7. Cystic artery and cystic duct isolation 8. Gallbladder bed dissection 9. Gallbladder extraction 10. Bleeding control 11. Wound closure"
40984970|NCT01654094|DEVICE|P6 Low Adherent Dressing|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
40984971|NCT01654094|OTHER|Standard of Care (SOC)|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
40984972|NCT01303887|DRUG|Rituximab|Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
40984973|NCT01303887|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
40984974|NCT01303887|DRUG|Vincristine|Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
40984975|NCT01303887|DRUG|Prednisolone|Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
40984976|NCT01303887|DRUG|Fludarabine|Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
40984977|NCT03727490|OTHER|Repair|The subscapularis will be repaired.
40984978|NCT03727490|OTHER|Standard Treatment|No repair will be performed
40984979|NCT04577118|DEVICE|iotaSOFT Insertion System|Enrolled subjects undergoing cochlear implant surgery will have the iotaSOFT Insertion System used by the surgeon to assist with implantation of the implant electrode array during the procedure.
40984980|NCT00330564|DRUG|SU011248|50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
40984981|NCT05126784|BIOLOGICAL|AVT03|AVT03 (biosimilar to denosumab) will be given as single subcutaneous injection
40984982|NCT05126784|BIOLOGICAL|Prolia|Prolia (denosumab) will be given as single subcutaneous injection
40984983|NCT04018950|DRUG|ETX2514|intravenous infusion
40984984|NCT04018950|DRUG|14C-ETX2514|intravenous infusion
40780673|NCT04919434|OTHER|IRECO|During 5 days, women included in the study will have to only use personal care product distributed by the research team.
40780674|NCT01561833|DRUG|Sorafenib|Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
40780675|NCT04156139|DEVICE|HFNC|The gas flow rate was set at 45\~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.
40984985|NCT06316141|OTHER|Aqua Jogging|This group performed aqua jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
40984986|NCT06316141|OTHER|Land based Jogging|This group performs land jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
40984987|NCT02632955|DRUG|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
40984988|NCT02632955|PROCEDURE|Regular angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
40780676|NCT04156139|DEVICE|NPPV|The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
40780677|NCT01987557|BEHAVIORAL|rate group|walking with a high cadence (steps per minute)
40780678|NCT01987557|BEHAVIORAL|magnitude treadmill group|
40780679|NCT01987557|BEHAVIORAL|regular treadmill walking|
40984989|NCT04810676|DRUG|CKD-501, D745, D150|QD, PO
40984990|NCT04810676|DRUG|CKD-383|QD, PO
40984991|NCT05792956|BEHAVIORAL|Using mobile app|Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
40984992|NCT03141242|BEHAVIORAL|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
40780680|NCT04256850|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Teaches acceptance, mindfulness, and values-based skills
40780681|NCT04256850|BEHAVIORAL|Self-Regulation (SR)|Teaches monitoring and reinforcement strategies designed to improve motivation and adherence to positive weight loss behavioral prescriptions.
40984993|NCT03141242|BEHAVIORAL|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
40984994|NCT02187484|DRUG|BIBR 277|
40984995|NCT04599894|DRUG|37.5mg Pregabalin + 75mg Pregabalin|37.5mg pregabalin preoperatively + 75mg pregabalin postoperatively
40984996|NCT04599894|DRUG|75mg Pregabalin|75mg pregabalin postoperatively
40984997|NCT00198965|BEHAVIORAL|dietary education|
40984998|NCT00198965|BEHAVIORAL|dietary education and provided full fat snack foods|
40984999|NCT00198965|BEHAVIORAL|dietary education and provided fat free snack foods|
40985000|NCT04988711|DIAGNOSTIC_TEST|Hb Oxymeter|Measurement of Hb Oximeter
40985001|NCT01477840|DRUG|Misoprostol|Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
40985002|NCT00867451|BEHAVIORAL|Sleep Intervention|A structured sleep protocol is taught to parents, use of a white noise generator
40985003|NCT00867451|DRUG|Melatonin|Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight \>40mg will be given 6 mg at bedtime for two weeks
40985004|NCT05598775|OTHER|Non Interventional long term safety follow up|Non Interventional long term safety follow up
40985005|NCT05652998|BIOLOGICAL|C. albicans antigen|a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.
40985006|NCT05652998|OTHER|autologous PRP|patients will receive intralesional autologous PRP injection every month until a complete clearance or for a maximum of 2 sessions. 20 cc blood will be collected under a complete aseptic condition in citrate tubes . The lower 2-4 cc of the plasma will be provided as PRP concentrate after centrifugation. 0.1 ml of PRP will be injected intralesional with an insulin syringe.
40985007|NCT05652998|OTHER|saline|patients will receive intralesional saline at a dose of 0.3ml into the largest wart at 2-week intervals until complete clearance is achieved or for a maximum of five treatment
40985008|NCT00332033|DRUG|Pirfenidone|
40985009|NCT00879281|BEHAVIORAL|Action plan|"Individualized written Action Plan to enhance self-management and early detection of an exacerbation."
40985010|NCT02153112|BIOLOGICAL|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
40985011|NCT02153112|BIOLOGICAL|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
40985012|NCT02153112|BIOLOGICAL|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
40985013|NCT02153112|BIOLOGICAL|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
40985014|NCT02153112|DRUG|Placebo|Placebo saline solution
40985015|NCT04207385|DIAGNOSTIC_TEST|pharmacogenomics|pharmacogenomics
40985016|NCT04207385|DIAGNOSTIC_TEST|pharmacogenomics & therapeutic drug monitoring|pharmacogenomics \& therapeutic drug monitoring
40985017|NCT04207385|DRUG|Venlafaxine|Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
40985018|NCT05332509|DEVICE|C-BRACE|The C-BRACE is a custom made Knee-Ankle-Foot-Orthosis with a microprocessor-controlled hydraulic knee-joint articulation. The C-BRACE technology offers to a patient with knee locking deficiencies the following advantages: approximation of the physiological gait pattern, stability while standing and walking, adaptation to various surfaces, inclines, gait situations and walking speeds.
40985019|NCT05332509|DEVICE|SCO|The SCO is a custom made Knee-Ankle-Foot-Orthosis with a knee-joint locked during stance phase and released during swing phase.
40985020|NCT01830582|PROCEDURE|Advanced MR Imaging|
40985021|NCT00427258|DRUG|MOA-728|
40985022|NCT00770796|DRUG|Atorvastatin|80 mg die
40985023|NCT00770796|DRUG|Placebo|
40985024|NCT03349749|DEVICE|LiDCOplus haemodynamic monitor|Patients in study group receive intravenous fluid bolus as part of standard fluid resuscitation. Fluid responsiveness (i.e. improvement in cardiac output) is estimated using both standard clinical parameters and by LiDCOplus haemodynamic monitor (with the clinician initially blinded to the latter) before a final decision about fluid responsiveness is made.
40985025|NCT05455788|DRUG|Aminoglycoside|injection of sewing ring of prosthetic valve with aminoglycoside
40985026|NCT02402543|DRUG|Gabapentin|
40985027|NCT02402543|DRUG|Ketamine|Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
40985028|NCT02402543|DRUG|Acetaminophen|
40985029|NCT02402543|DRUG|Dexamethasone|Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
40985030|NCT02402543|DRUG|Placebo|
40985031|NCT06294964|BEHAVIORAL|sleep education, behavioral education|Provide health education materials which covering sleep education, behavioral education, chronic diseases such as cardiovascular diseases. Topics touch on such as why you need healthy sleep? What methods can be used to regulate insomnia, and how to regulate sleep breathing problems? How do the elderly maintain a good sleep? What are the risk factors for cardiovascular and cerebrovascular diseases? How to reduce the risk of developing sleep disorders or chronic diseases through changing everyday life?
40985032|NCT00827983|DRUG|Progesterone|25 mg, s.c., once à day
40985033|NCT00827983|DRUG|Progesterone|90 mg, vaginally, once à day
40985034|NCT02662127|DEVICE|SIGVARIS® Class 2 - RAL: 23-32.|Below knee graduated elastic compression stocking
40985035|NCT05487638|OTHER|Nursing Education and Counseling Service Provided to Patients by Video Calling on the Phone|Nursing Education and Counseling Services were provided to the patients by video calling on the phone for the problems they may encounter in the postoperative period.
40985036|NCT01002950|DRUG|ACU-4429|ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
40985037|NCT01002950|DRUG|Matching placebo|Matching placebo tablets taken orally once daily for 90 days
40985038|NCT01326767|DRUG|Paclitaxel dosing according to SmPC|Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
40985039|NCT01326767|DRUG|Individualized pharmacokinetically driven paclitaxel dosing|Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
40985040|NCT04332354|OTHER|routine care. No intervention|no intervention
40985041|NCT04923087|DEVICE|Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements|"Validate the evaluation criteria Do you hear the biscuit crunch? and Is it a pleasure?"
40780682|NCT00865748|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
40985042|NCT04034173|DRUG|Panitumumab|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes."
40985043|NCT04034173|DRUG|Irinotecan|Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
40985044|NCT04034173|DRUG|Folinic acid|Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
40985045|NCT04034173|DRUG|5-FU|5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
40985046|NCT04976166|BEHAVIORAL|Education|More informed and detailed education
40985047|NCT04976166|BEHAVIORAL|Education|Shared decision making
40985048|NCT04976166|BEHAVIORAL|Education|education as usual
40985049|NCT00368654|DRUG|Methotrexate|Initial dose 5 mg, then 15 mg per week
40985050|NCT00368654|DRUG|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
41304693|NCT02884817|DRUG|Experimental: essential oils and ELA|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
40985051|NCT05312398|DRUG|Cetuximab|"I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter~II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line~THIRD LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
40985052|NCT05312398|DRUG|FOLFIRI|"I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter"
40985053|NCT05312398|DRUG|FOLFOX regimen|"II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line"
40985054|NCT05312398|DRUG|Irinotecan|"III LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
41304694|NCT02884817|OTHER|Placebo|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
41463545|NCT05380726|BEHAVIORAL|Patient education|The intervention received will be a specific patient education for each subject depending on the parameters assessed by the electronic wrist device in real-time. The recommendation are related to different educational topics as hygienic-dietary measures and sleep related habits, or physical activity.
41463546|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg|Administration: Inject intravenously single dose
41463547|NCT05276076|BIOLOGICAL|VM-001 3X10^6 cells/kg|Administration: Inject intravenously single dose
41463548|NCT05276076|BIOLOGICAL|VM-001 5X10^6 cells/kg|Administration: Inject intravenously single dose
40780683|NCT00865748|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
40985055|NCT00048607|DRUG|aprepitant|
40985056|NCT00048607|DRUG|Comparator: paroxetine HCL|
40985057|NCT00048607|DRUG|Comparator: Placebo (Unspecified)|
40985058|NCT04028076|BEHAVIORAL|Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence|An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
41463549|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg two dose|"Administration: Inject intravenously~1X10\^6 cells/kg per dose, two dose in total, weekly"
40985059|NCT03407378|DRUG|IPT803|Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
40985060|NCT03407378|GENETIC|Optional pharmacogenetic assessment|Blood sample of 3 milliliters for genotyping assessment (according to patient consent).
40985061|NCT03407378|OTHER|Questionnaires|Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)
40985062|NCT03407378|OTHER|Optional Blood-Oxygen-level Dependent functionalMRI|BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)
40985063|NCT03407378|OTHER|Motor Assessments before taking regular PD treatment|Regular PD treatment stopped 12 or 24 hours prior to Visits 2, 3 and 4 depending on the drug form (extended vs standard release). Motor assessments using UPDRS Part III are performed when patients are OFF regular PD treatment. Regular PD treatment is taken on site during the visit after the motor assessments are performed.
40985064|NCT03407378|OTHER|Motor Assessments on regular PD treatment|Regular PD treatment is not modified before the visits. The motor assessments using UPDRS Part III are performed while the patient is on regular PD treatment.
40985065|NCT00144976|DRUG|Tarceva|Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.
41144183|NCT01820702|OTHER|Defined Training Programme|A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at \~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against \~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
41144184|NCT00255242|DRUG|Simvastatin treatment for 28 days|40 mg / day
41146995|NCT04909099|OTHER|Standard treatment|"Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC).~The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness."
41463550|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg four dose|"Administration: Inject intravenously~1X10\^6 cells/kg per dose, four dose in total, weekly"
41463551|NCT02926170|DRUG|Rivaroxaban|Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
41463552|NCT02926170|DRUG|acenocumarol|Doses will be adjusted according to INR
41463553|NCT04423445|OTHER|Laser acupuncture combined with acupressure|Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. The de qi sensation appears to be an established intervention efficacy indicator during auricular acupressure. After five days, the seed was removed, and a new seed was taped on the other ear.
41463554|NCT02685696|DEVICE|Alexis O Retractor|A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.
41463555|NCT02685696|DEVICE|Metal Retractor|The traditional self-retaining metal Collins Caesarean Wound Retractor.
40985066|NCT01408979|DRUG|Magnesium sulfate 12 hours|Magnesium sulfate, 1g/h, (10% solution), for 12 hours
40985067|NCT01408979|DRUG|Magnesium sulfate 24 hours|Magnesium sulfate, 1g/h, (10% solution), for 24 hours
40985068|NCT02550366|DRUG|MRI Contrast|MRI Contrast
40985069|NCT02734979|DEVICE|Biobridge and lymph node transfer|Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
40985070|NCT02864251|BIOLOGICAL|Nivolumab|Specified dose on specified days
41146996|NCT02268526|BIOLOGICAL|CSJ148|CSJ148 IV q 4weeks
40985071|NCT02864251|BIOLOGICAL|Ipilimumab|Specified dose on specified days
40985072|NCT02864251|DRUG|Pemetrexed|Specified dose on specified days
40985073|NCT02864251|DRUG|Cisplatin|Specified dose on specified days
40985074|NCT02864251|DRUG|Carboplatin|Specified dose on specified days
40985075|NCT01647412|DRUG|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
40985076|NCT01647412|DIETARY_SUPPLEMENT|Nutraceutical Combination|
40985077|NCT01647412|OTHER|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
40985078|NCT01647412|OTHER|Placebo Growth Hormone|
40985079|NCT03582202|PROCEDURE|Nutritional assessment and therapy|Nutritional screening, nutritional plan, follow-up and instructions on discharge
40985080|NCT03582202|PROCEDURE|Standard care|Nutritional handling by nurse
40985081|NCT01040897|BEHAVIORAL|Health Communication and Obesity Prevention|Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
40985082|NCT01040897|BEHAVIORAL|Injury Prevention Arm|Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
41463556|NCT03129776|DRUG|Hyperpolarized 13C-Pyruvate|The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
40780684|NCT02740985|DRUG|AZD4635|AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
40780685|NCT02740985|DRUG|Durvalumab|Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
40780686|NCT02740985|DRUG|Abiraterone Acetate|"Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets."
41463557|NCT03129776|DRUG|18F-FDG|18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
40985083|NCT03584022|DEVICE|Biopsy + Nerve Repair|During the standard sural nerve biopsy procedure, a single-use, biodegradable implant designed to repair damaged peripheral nerves will be used to repair the nerve. The MCNS1 is a hollow nerve tube made of poly(caprolactone-fumarate) (PCLF), to connect severed nerve ends and promote the growth of regenerating axons.
40985084|NCT03584022|PROCEDURE|Biopsy Only|Standard sural nerve biopsy only, without nerve repair.
40985085|NCT03206645|DRUG|Unesbulin|Unesbulin will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.
40985086|NCT06459843|OTHER|pursed lip breathing techniques|Relax your neck and shoulder muscles. For the use of PLB exercise, the intervention will be given every day till the patient discharged from hospital. Patient will perform 5 sets. In each set, 10 times will be included. Then, instruct the patient to take deep breath through nose for two counts, and keep mouth closed. Inhale for 2 seconds. Now, ask the patient to purse the lips as if the patient was going to gently flicker the flame of candle. Now the patient will breathe out gently while counting for 4 seconds.
41146997|NCT02268526|DRUG|Placebo|Placebo IV q 4weeks
41463558|NCT02813382|DRUG|Bupivacaine|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
41463559|NCT02813382|DRUG|Prilocaine|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
41463560|NCT02813382|DRUG|Chloroprocaine|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
41463561|NCT06003816|BEHAVIORAL|Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) CATI|The CHoBI7 program is during group sessions by a health promoter to those residing in a ring around a cholera patient reinforced through weekly voice and text messages from the CHoBI7 mHealth program over 12 months on the recommended water, sanitation, and hygiene behaviors.
41146998|NCT04870905|DRUG|Tis-U-Sol|Tislelizumab 200mg will be given every 3 weeks for 12 cycles
40780687|NCT02740985|DRUG|Enzalutamide|"Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules."
40985087|NCT06459843|OTHER|coordinated breathing technique|Put one hand on your abdomen. Make your abdomen push out while you breathe in through your nose. Suck in your abdominal muscles. Breathe out using the pursed-lip technique. You should feel your abdomen go down. Repeat three times and rest for two minutes.
40985088|NCT00016146|BIOLOGICAL|GPI-0100|
40985089|NCT00016146|BIOLOGICAL|MUC-2-Globo H-KLH conjugate vaccine|
40985090|NCT00256945|PROCEDURE|dental restorative material surface preparation|
40985091|NCT03128112|OTHER|Exam room with poster|This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
40985092|NCT05545254|GENETIC|genetic testing|Two questionnaires were included in the link, one referring to the demographic information, and another one involving the health-promoting lifestyle. In the demographic information, the genetic test results were not requested to be written, but the participants need to answer whether they understand the results. The HPLP-Ⅱ is an scale instrument used to evaluate a person's health-promoting lifestyle behaviors, which contains 52 items and has been translated into Chinese in 1997. It contains 6 subscales: self-actualization, health responsibility, physical activity, nutrition, interpersonal relationships and stress management.
40780688|NCT02740985|DRUG|Oleclumab|Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.
40985093|NCT01808287|DEVICE|Edwards SAPIEN 3 Transcatheter Heart Valve|The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
40985094|NCT03695679|BEHAVIORAL|Interactive computer-based intervention|"There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~1. Perceived Susceptibility and Perceived Severity~2. Perceived Benefits and Perceived Barriers~3. Cue to Action~4. Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information."
40985095|NCT03913884|PROCEDURE|Concentrated growth factor|CGF fibrin matrix was placed in one socket which was randomly selected (test side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
41463562|NCT06003816|BEHAVIORAL|Standard message|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
40780689|NCT02740985|DRUG|Docetaxel|"Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice."
40985096|NCT03913884|OTHER|Non-Concentrated growth factor Group|To control group, extraction of the tooth on the opposite site was performed and the socket left to heal naturally. The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
40985097|NCT01189812|DRUG|Lithium Carbonate|300 mg one time per day for 4 weeks
40985098|NCT01189812|DRUG|Placebo|Take one time daily for 4 weeks
40985099|NCT01189812|DRUG|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
40985100|NCT01280214|DRUG|Triamcinolone|Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
40985101|NCT00455429|DRUG|Placebo|Matching placebo capsules to JNJ-26113100 (50 milligram \[mg\]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
41146999|NCT00540800|DRUG|docetaxel|given in combination with epirubicin or capecitabine
41147000|NCT00540800|DRUG|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
41147001|NCT00540800|DRUG|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
41147002|NCT00555620|DRUG|capecitabine|Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
41147003|NCT00555620|DRUG|oxaliplatin|Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
40985102|NCT00455429|DRUG|JNJ-26113100 (50 mg) once daily|JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
41304695|NCT02884817|OTHER|Water|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
41304696|NCT00767156|OTHER|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
40780690|NCT03868358|DEVICE|transcranial magnetic stimulation|"The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks"
40780691|NCT01402921|DEVICE|V0322 BC|"* Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~* The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~* 3 months duration daily treatment"
40780692|NCT05619237|DEVICE|NanoSALV Catalytic|NanoSALV Catalytic Antimicrobial Wound Dressing Gel is a Health Canada approved medical device for the management of Chronic Wounds.
40780693|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) \[Original\], single dose
40985103|NCT00455429|DRUG|JNJ-26113100 (100 mg) once daily|JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
41304697|NCT00767156|OTHER|Base cream|The subjects use the base cream on the face, twice per day
41304698|NCT00767156|DIETARY_SUPPLEMENT|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
41304699|NCT00767156|DIETARY_SUPPLEMENT|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
41304700|NCT06085846|DEVICE|Vivally® System Wearable, Non-Invasive Neuromodulation System, and Mobile Application|Vivally® System Wearable, Non-Invasive Neuromodulation System and Mobile Application to treat patients with the conditions of urinary incontinence and urinary urgency.
41304701|NCT03399175|DRUG|Early high-dose corticosteroid and immunosuppressive therapy|Early high-dose corticosteroid and immunosuppressive therapy
41304702|NCT01831934|BIOLOGICAL|Fluzone®|This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate
41304703|NCT05787834|OTHER|Best Practice|Receive usual care
41304704|NCT05787834|OTHER|Medical Device Usage and Evaluation|Wear accelerometer
41304705|NCT05787834|PROCEDURE|Respiratory Muscle Training|Undergo RMT
41304706|NCT05787834|OTHER|Survey Administration|Ancillary studies
41304707|NCT03392753|PROCEDURE|Mechanochemical ablation|Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)
41304708|NCT03392753|PROCEDURE|Cyanoacrylate adhesive|Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)
41304709|NCT04454996|DRUG|tong-jiang granules|This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
41304710|NCT04454996|DRUG|Chang 'an II Recipe|This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
41304711|NCT04454996|DRUG|The placebo of tong-jiang granules|This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
41304712|NCT04454996|DRUG|The placebo of Chang 'an II Recipe|This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
41304713|NCT00149656|DIETARY_SUPPLEMENT|Multivitamins|dietary supplement of multivitamins
41304714|NCT00149656|DIETARY_SUPPLEMENT|Selenium|dietary supplement of selenium only
41304715|NCT00149656|OTHER|Placebo|placebo pill
40985104|NCT00455429|DRUG|JNJ-26113100 (100 mg) twice daily|JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
40985105|NCT00455429|DRUG|JNJ-26113100 (250 mg) twice daily|JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
40985106|NCT02729974|PROCEDURE|ROTEM|rapid testing of blood clot formation
40985107|NCT02729974|PROCEDURE|standard treatment|visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
40985108|NCT01519453|BEHAVIORAL|Home Based Asthma Education|4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
41304716|NCT00916123|DRUG|Docetaxel|75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
41304717|NCT00916123|DRUG|Prednisone|10 mg per day starting on cycle 1, day 1
41304718|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
41304719|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
41304720|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
41304721|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
41304722|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
41304723|NCT01324583|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution~Route of administration: intravenous"
40985109|NCT05526612|OTHER|Group 1 Motor imagery and Bobath Therapeutic Approach (BTA+MI)|Motor imagery (MI) is the mental rehearsal of motor abilities to improve function. Without revealing any movement in the body, the representation of the movement is created in the mind, the person imagines that he/she is performing the movement. Eating activity will be applied in motor imagery. Individualized therapy sessions in the Bobath Therapeutic Approach will also be received by the Physiotherapist along with Motor imagery. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
40985110|NCT05526612|OTHER|Group 2 Motor imagery, Bobath Therapeutic Approach and Physical practice (BTA+MI+PP)|Individualized therapy sessions in the Bobath Therapeutic Approach with motor imagery will be performed by the physiotherapist, and in addition to these, 5 repetitions of the eating activity used in motor imagery will be practiced. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
40985111|NCT04060550|BIOLOGICAL|Xolair|This is in vitro mechanistic study. No drug will be given in vivo to patients.
40985112|NCT02546557|PROCEDURE|Coronary Artery Bypass Graft surgery|
40985113|NCT00653146|BEHAVIORAL|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
41147004|NCT00555620|DRUG|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
41147005|NCT00555620|DRUG|capecitabine|Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
41304724|NCT01324583|DRUG|prednisolone|"Pharmaceutical form:tablet~Route of administration: oral"
41463563|NCT04332211|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.
41463564|NCT04332211|DRUG|Pseudoephedrine 60 MG|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
41463565|NCT04332211|DRUG|Placebo oral tablet|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
41463566|NCT00133679|DRUG|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
41147006|NCT00555620|DRUG|cisplatin|Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
41147007|NCT00555620|DRUG|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
41304725|NCT01596842|DRUG|Omega-3 fatty acid ethylester 90|Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
41304726|NCT01596842|OTHER|Olive oil|Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
41304727|NCT01596842|OTHER|cholecalciferol|if baseline 25-hydroxyvitamin D levels are \< 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
41304728|NCT03560193|DRUG|2%Chlorhexidine-70%Isopropanol|2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
41304729|NCT03560193|DRUG|5%Povidone Iodine- 69%Ethanol|5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
41304730|NCT00672529|DIETARY_SUPPLEMENT|Orthomolecular Therapy or Placebo Comparator|"The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function."
41304731|NCT00958308|OTHER|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
41304732|NCT00958308|OTHER|Placebo|Placebo is devoid of microorganisms.
41304733|NCT01102153|DEVICE|Coolgard|invasive cooling via femoral ICY-catheter
41304734|NCT01102153|DEVICE|ArcticSun|non-invasive surface cooling by saline-cooled thermo-vest
41304735|NCT05149937|OTHER|interprofessional, person-centered care concept|interprofessional, person-centered care concept
41304736|NCT05329181|BEHAVIORAL|Integrated cognitive behavioral treatment|Integrated cognitive behavioral treatment adapted specifically for homeless individuals and developed to treat substance use and depressive symptoms simultaneously
40780694|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
41304737|NCT04086563|OTHER|Action observation|look at a clip of a hand doing neurodynamic exercises.
41304738|NCT04086563|OTHER|Mirror therapy|With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
41463567|NCT00133679|DRUG|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
41463568|NCT02569307|DRUG|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
41463569|NCT02569307|DRUG|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
41463570|NCT02569307|DRUG|Placebo|Placebo added to TAU
41463571|NCT02569307|DRUG|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
41463572|NCT01493596|DRUG|CPP-115|Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
41463573|NCT01493596|DRUG|Placebo|An equal volume of water mixed with juice will be administered.
41463574|NCT05810857|DIAGNOSTIC_TEST|Motor Relearning Program|patients will receive Motor Relearning Program including static and dynamic sitting and standing balance while static sitting balance
41463575|NCT05810857|DIAGNOSTIC_TEST|Mirror Therapy|"Mirror Therapy protocol. The baseline treatment will be weight bearing in standing which is extension of knee and weight bearing in standing on inclined"
41463576|NCT00067717|BEHAVIORAL|Distance healing|
41144185|NCT02469324|BEHAVIORAL|Cognitive Behavioral Therapy|The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.
41144186|NCT02469324|BEHAVIORAL|Compassionate Mind Training|see above
41144187|NCT02207140|DIETARY_SUPPLEMENT|HOWARU Restore|
41463577|NCT03441139|OTHER|Cryotherapy + Medical analgesics|"Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle.~Medical supportive care: Best analgesic therapy at investigator's discretion"
41463578|NCT03441139|DRUG|Medical Analgesics|Best analgesic therapy at investigator's discretion
41463579|NCT05079555|DEVICE|Robotic rehab|Patients using the robotic platform SWalker
41463580|NCT04310254|PROCEDURE|EDTA and CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with Qmix 2in1 solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
41463581|NCT04310254|PROCEDURE|EDTA Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with EDTA solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
41463582|NCT04310254|PROCEDURE|CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with CHX solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
41463583|NCT01504711|DRUG|fosaprepitant dimeglumine|Given IV
40985114|NCT00653146|BEHAVIORAL|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
41147008|NCT05129592|BEHAVIORAL|Coherent corrective messages|Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
41147009|NCT03071341|DRUG|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
41463584|NCT01995968|OTHER|Antenatal identification of fetal growth restriction|"FGR is considered as identified if:~* FGR was mentioned in medical charts~* OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)~* OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts~* OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)~* OR utero-placental Doppler ultrasound indicated for suspicion of growth failure"
41463585|NCT00564187|DRUG|Irbesartan|"Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
41463586|NCT00564187|DRUG|Irbesartan|"Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B"
41463587|NCT02240004|DEVICE|SUPRA HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen
41463588|NCT01546727|BEHAVIORAL|Behavioral Family Intervention|Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
40985115|NCT01404390|DRUG|BAY80-6946|0.4mg/ kg, iv, day 1,8 and 15, every 28 days
40985116|NCT01404390|DRUG|BAY80-6946|0.8mg/ kg, iv, day 1,8 and 15, every 28 days
40985117|NCT04938557|DEVICE|Automated closed-loop insulin delivery (AiD)|Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.
40985118|NCT04938557|DEVICE|A standard insulin delivery system|Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.
40985119|NCT06293885|DRUG|Dextrose 50|a solution of 50% glucose (D50) will be injected into your pleural space
40985120|NCT06293885|OTHER|Standard of Care - No Dextrose 50|Standard of Care
40985121|NCT04356274|OTHER|Participatory System Dynamics (PSD)|Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
41463589|NCT01546727|BEHAVIORAL|Motivational Interviewing|Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
41463590|NCT00263627|BIOLOGICAL|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
41463591|NCT00263627|OTHER|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
41463592|NCT01408888|BIOLOGICAL|LY2189265|Administered subcutaneously
41463593|NCT01408888|DRUG|Sitagliptin|Administered orally
41463594|NCT01744964|DRUG|Apomorphine|1.5 mg Apomorphine
41463595|NCT04256707|DRUG|Selinexor 100 mg|"100-mg 2 formulations:~* 5 × 20-mg tablets (Tablet A)~* 1 × 100-mg tablet (Tablet B)"
40780695|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
41463596|NCT04256707|DRUG|Docetaxel|75 mg/m\^2 IV
40780696|NCT01067807|DRUG|50 mg Proellex|50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
40780697|NCT03663855|DRUG|Tiopronin|Phase 1: No medication, Phase 2: 500mg PO daily x 7 days (total 500mg), Phase 3: 500mg PO BID x 7 days (total 1g), Phase 4: 1g PO BID x 7 days (total 2g)
40985122|NCT04356274|OTHER|Audit and Feedback (AF)|Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing clinical care team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
41463597|NCT04256707|DRUG|Pembrolizumab|200 mg IV
40985123|NCT05611034|DRUG|Oxaliplatin|Oxaliplatin infusion in single lung via IVLP technique
40985124|NCT00527007|OTHER|External cooling|External cooling
40985125|NCT06202391|PROCEDURE|Autogenic Inhibition-MET|Autogenic Inhibition-MET protocol: 3-5 repetitions of post isometric relaxation (PIR) (30- 50% isometric contraction of the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold. A total of 12 sessions, four times a week, for three consecutive weeks.
41147010|NCT00231166|DRUG|HCD122|
41304739|NCT04086563|OTHER|Neurodynamic exercises|active movement of the dominant hand. Do neurodynamic exercises.
41304740|NCT04086563|OTHER|Strength|Execute a short strength training for the dominant hand
41304741|NCT01523808|DRUG|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
41304742|NCT00470353|DIETARY_SUPPLEMENT|calcium carbonate|
41463598|NCT04256707|DRUG|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m\^2~* Leucovorin 400 mg/m\^2~* 5-FU 400 mg/m\^2 bolus~* 5-FU 2400 mg/m\^2 IV"
41463599|NCT04256707|DRUG|Selinexor 40 mg|- 2 × 20-mg tablets (Tablet A)
41463600|NCT04256707|DRUG|Selinexor 80 mg|- 4 × 20-mg tablets (Tablet A)
41463601|NCT04256707|DRUG|Selinexor 60 mg|- 3× 20-mg tablets (Tablet A)
41463602|NCT04093349|GENETIC|SPK-3006|adeno-associated viral (AAV) vector
40780698|NCT01404234|DRUG|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
40780699|NCT05951426|PROCEDURE|1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage|"1. removal of the uterus with both ovaries and fallopian tubes and pelvic lymph nodes~2. exploration of the uterine cavity and removal of the endometrium"
40780700|NCT02288130|DRUG|GnRHa|
40780701|NCT02288130|DRUG|Ulipristal|
40780702|NCT03564886|DRUG|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
40780703|NCT03564886|DRUG|Normal saline|Lactate Ringer's (LR, 273mOsm/L)
40985126|NCT06202391|PROCEDURE|Reciprocal Inhibition-MET protocol|Reciprocal Inhibition-MET protocol: 3-5 repetitions of Reciprocal Inhibition (RI) MET (30- 50% isometric contraction of the muscle opposite to the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold A total of 12 sessions, four times a week, for three consecutive weeks
41304743|NCT00470353|DIETARY_SUPPLEMENT|cholecalciferol|
41304744|NCT00470353|OTHER|immunohistochemistry staining method|
41304745|NCT00470353|OTHER|laboratory biomarker analysis|
41304746|NCT00470353|OTHER|pharmacological study|
41304747|NCT00470353|PROCEDURE|biopsy|
41304748|NCT01241669|DRUG|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
41304749|NCT01241669|DRUG|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
41463603|NCT01181531|DRUG|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
41463604|NCT01181531|DRUG|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
41463605|NCT01128868|DEVICE|Proximal femur locking plate|Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
41463606|NCT01128868|DEVICE|Intertrochanteric nail|Intertrochanteric nail (PFNA, TFN, GN)
41463607|NCT04552028|OTHER|Non invasive oxygenation|To determine if the SpO2 / FIO2 ratio has a correlation with PaO2 / FIO2 ratio to identify respiratory compromise in acute pancreatitis.
41463608|NCT02292550|DRUG|Ribociclib|CDK 4/6 inhibitor
41463609|NCT02292550|DRUG|Ceritinib|ALK inhibitor
41463610|NCT00930241|DRUG|Advagraf®|Advagraf® (one daily dose of Tacrolimus)
40780704|NCT06449560|OTHER|Practice Group|Participants in this group engage in the traditional core course (1-hour lecture on upper limb soft tissue differential diagnosis and assessment techniques. They have the opportunity to observe teacher demonstrations, and the course content and instructional demonstrations are consistent and delivered by the same therapist), followed by a 20-minute practical session where they pair up for mutual hands-on practice. The assessment of upper limb soft tissue operations takes approximately 4 minutes per session, allowing for approximately 5 practice sessions.
40985127|NCT05031533|RADIATION|Dose-Painting Radiation|"Radiation therapy:~1. Delineation of target area:~   The primary tumor is delineated into different target areas according to the anatomical position of the tumor, including the central area tumor GTV-Tcentral and GTV-Tperipheral.~2. Exposure dose:~1) GTV-Tcentral: 2.0～2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0～4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy"
40985128|NCT05553002|OTHER|Deneroll cervical extension traction|"Participants will lie flat on their back on the ground with their legs extended and arms by their sides. The denneroll will placed on the ground and positioned in the posterior aspect of the neck depending on the area to be addressed . The apex of the Denneroll orthotic will be placed in one of three regions based on lateral cervical radiographic displacements:~1. In the upper cervical region (C2-C4) region.~2. The apex of the Denneroll orthotic is placed in the mid-cervical region (C4-C6) region.~3. The apex of the Denneroll orthotic is placed in the upper thoracic lower-cervical region (C6-T1) region."
40985129|NCT05553002|OTHER|Traditional treatment|The participants will receive hot packs (15 minutes) and TENS therapy .During TENS application. Patients will be asked to adopt a prone position. The TENS therapy will be delivered at the lumbosacral region for 20 min. The frequency will set to 80 Hz and pulse width to 50 µs due to its analgesic effect . These conventional treatments will be repeated three times per week over the course of 10 weeks for 30 total sessions
40985130|NCT00602576|DRUG|sorafenib tosylate|Given orally
40985131|NCT00602576|DRUG|temozolomide|Given orally
41463611|NCT00930241|DRUG|Prograf®|Prograf® (two daily doses of Tacrolimus)
41463612|NCT06033313|BEHAVIORAL|Negatively Framed text messages|Negatively Framed text messages delivered to participants three times per week for 8 weeks.
41463613|NCT06033313|BEHAVIORAL|Positively Framed text messages|Positively Framed text messages delivered to participants three times per week for 8 weeks.
41463614|NCT04568161|PROCEDURE|Physical Characteristics|Body weight, height and waist circumference
41463615|NCT04568161|PROCEDURE|Muscular Sympathetic Nervous Activity|Microneurography technique.
41463616|NCT04568161|DIAGNOSTIC_TEST|Cardiac Function|Echocardiography.
41463617|NCT04568161|DIAGNOSTIC_TEST|Heart rate|Electrocardiography
41463618|NCT04568161|DIAGNOSTIC_TEST|Blood pressure|Non-invasive photoplethysmography.
41463619|NCT04568161|DIAGNOSTIC_TEST|Blood Assessments|Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.
41463620|NCT04568161|DIAGNOSTIC_TEST|Muscle blood flow|Venous occlusion plethysmography
41463621|NCT04568161|DIAGNOSTIC_TEST|Endothelium-dependent vascular function|Brachial ultrasound
41463622|NCT04568161|DIAGNOSTIC_TEST|Vascular intima-media thickness|Carotid ultrasound
41463623|NCT04568161|DIAGNOSTIC_TEST|Physical Capacity|Cardiopulmonary exercise test
41463624|NCT04568161|DRUG|Anthracycline & Cyclophosphamide treatment scheme|Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.
41463625|NCT03091257|DRUG|Dabrafenib|Administered Orally BID
41463626|NCT03091257|DRUG|Trametinib|Administered Orally once daily
41463627|NCT00200655|DRUG|Pravastatin|
41463628|NCT00200655|DRUG|Placebo|
41463629|NCT06616389|DRUG|ODX (Osteodex)|Multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX.
41463630|NCT02149394|OTHER|Ice popsicle|"Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort."
40780705|NCT06449560|OTHER|Video Feedback Group|Participants receive the traditional core course (as the same in the practice group) along with a 20-minute video feedback session. Initially, a therapist records students' assessment techniques in action, capturing the dynamic process on video. The recorded video is then played on a screen for both the course teacher and students to watch together. Participants can annotate specific actions during the viewing, and the course teacher facilitates a reflective discussion where participants observe and identify any issues or correct actions as expected. The teacher provides feedback on areas of improvement in the action process for further practice. The self-viewing of the recorded video serves as a valuable tool for enhancing the skill performance of physical therapy interns.
40780706|NCT03175107|DEVICE|Exergaming|
40780707|NCT02141321|DRUG|Misoprostol|
40780708|NCT02141321|DRUG|Placebo|
41304750|NCT04965766|DRUG|U3-1402|First infusion for 90 minutes and then infusion duration can be progressively decreased to 30 minutes if participant doesn't experience infusion related reactions (IRR)
41304751|NCT05034484|DRUG|ALPN-303|Multiple dose levels will be evaluated.
41304752|NCT05034484|DRUG|Placebo|Placebo will be administered
41304753|NCT01797276|DRUG|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day.
41304754|NCT02446054|DIETARY_SUPPLEMENT|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
40780709|NCT01907893|BEHAVIORAL|Trauma Collaborative Care Plus Treatment as Usual|
41304755|NCT01881035|PROCEDURE|Renal nerve denervation|Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
41304756|NCT00735124|DRUG|Gabapentin|1200 mg single dose gabapentin
41304757|NCT00735124|OTHER|placebo|Injection of placebo/sham
41304758|NCT01557608|PROCEDURE|Photon stimulation|The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
41304759|NCT01557608|PROCEDURE|Placebo treatment|"For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment."
41304760|NCT04207957|DRUG|Olorofim|150 mg
41304761|NCT03741582|OTHER|TransMiCable|"TransMiCable will have one service line 3.43 km-long with four stations (El Tunal , Juan Pablo II , Manitas , and Paraiso, see highlighted stops in Figure 2). El Tunal is the station that connects to the city's bus rapid transit system. The planned capacity of TransMiCable is 3,600 persons per hour in 163 cabins or gondolas. Each cabin fits ten passengers, with space for wheelchairs and bicycles and will be equipped with free Wi-Fi. The expected travel time reductions from each station to portal El Tunal, through the shortest pathway, are: 26 minutes saved from Juan Pablo II station-from 32 to 6 minutes; 31 minutes saved from Manitas station-from 38 to 7 minutes and 49 minutes saved from Paraiso station-from 62 to 13 minutes 22. In conjunction with TransMiCable, urban projects will be implemented including the construction of parks, outdoor gyms, sport courts, community centers for children and older adults, a market, an administrative, and a tourism offices."
41304762|NCT05803720|BEHAVIORAL|Provider Intervention on Addressing Intersectional Stigma and Medical Mistrust in Patients with HIV|The intervention will consist of psychoeducation and skills-building for HIV care providers to gain knowledge and skills needed to address intersectional stigma and medical mistrust with patients. The intervention will be online and conducted in groups.
41304763|NCT03323229|DIAGNOSTIC_TEST|Enhanced communications & ultrasound|Paramedics will perform standardised point-of-care ultrasound scan protocols (specific to the patient's symptom set) and record a short (\<1 minute) video summarising the patient's condition and current management. These will be transmitted via satellite to consultants at the receiving hospital before the ambulance leaves the incident scene. The emergency department consultants will provide support and advice on continuing patient management via standard ambulance communications systems while it is en route to the hospital.
41304764|NCT02353260|DEVICE|Ultrasound Hyperthermia|treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
41463631|NCT02149394|OTHER|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
41463632|NCT03604432|DEVICE|propylactic maze|Prophylactic limited left sided maze procedure for subjects in the treatment arm
40780710|NCT02988908|DRUG|Donepezil|"Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
40780711|NCT02988908|DRUG|Placebos|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
40780712|NCT00224393|DRUG|Enbrel|
40780713|NCT00003794|PROCEDURE|psychosocial assessment and care|
41304765|NCT02353260|DRUG|Docetaxel,Cisplatin,Fluorouracil|Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
41463633|NCT03666325|DRUG|Pembrolizumab|Pembrolizumab at 200 mg every 3 weeks for 9 weeks.
40985132|NCT05618964|OTHER|Deep Neck Flexors & Extensors exercises|"Deep neck flexor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck flexor muscle in supine Craniocervical flexion in supine~Deep Neck Extensor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck extensors in quadruped position Segmented extension movement with the head bent down onto their chest in a horizontal direction,"
40985133|NCT02939235|DRUG|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
40985134|NCT02939235|DRUG|Crushed ticagrelor, morphine,metoclopramide|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
40985135|NCT02935322|DRUG|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
40985136|NCT02935322|DRUG|0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
40985137|NCT02935322|DRUG|0.12% chlorhexidine|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
40985138|NCT02935322|OTHER|Placebo|"Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period."
41304766|NCT04296500|OTHER|Decision tree modeling|"A decision tree analysis was employed to explore the process of decision-making on types of pattern based on the existence or nonexistence of a symptom. At the end of tree presented is the proportion of patients who are categorised into each pattern.~In this study, the classification was performed by applying the classification and regression tree (CART) algorithm using Scikit-learn package of Python, which performs a division using the Gini coefficient or the decrement of dispersion. The Gini coefficient is one of the tools for measuring entropy or diversity in each node and it measures the decrement by comparing the information entropy before and after separation. To avoid overfitting, the maximum number of leaf nodes was limited to four and the pruning method which complied with the principle of minimum description length was applied."
40985139|NCT03946384|OTHER|data collection|data collection on the history of the disease, hemophilia
40985140|NCT04377477|RADIATION|Single fraction whole lung radiotherapy|Participants will undergo irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
40985141|NCT00494988|DRUG|insulin aspart|
40985142|NCT00494988|DRUG|insulin NPH|
40985143|NCT01482754|DRUG|Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)|Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
40985144|NCT02144441|DRUG|glargine and aspart|Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
40985145|NCT05808491|RADIATION|online resilience intervention|online resilience intervention were presented in four 60-minute sections, once a week for four weeks embracing four sections
41304767|NCT04425421|OTHER|OBSERVATIONAL|OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE
41304768|NCT03860311|DEVICE|Bladder Ultrasound|"Bladder fullness will be assessed upon enrollment and if not full, the patient will receive hydration, determined by treating physician, and the bladder ultrasound will be repeated every 30 minutes until the patient states that the bladder is full, or until bladder is deemed full based on a previously validated bladder fullness qualitative scale, at which point patients in this group will proceed to undergo pelvic ultrasound."
41304769|NCT03860311|OTHER|Standard of Care|Per institution protocol, patients in the standard of care group will have urethral (bladder) catheter placed immediately after the order for pelvic ultrasound and will undergo retrograde bladder filling as determined by the radiologist/ultrasonographer to the point necessary to fully visualize pelvic structures.
41304770|NCT01979796|DEVICE|Ecig 24 mg nicotine|Cigalike
41304771|NCT01979796|DEVICE|Ecig 0 mg nicotine|Cigalike
41304772|NCT01979796|DEVICE|Nicotine free inhalator|Plastic CIG a Like
41304773|NCT04946136|OTHER|Gait modification|Individualized gait modifications guided by real-time visual feedback of knee load
41304774|NCT02164513|DRUG|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
41304775|NCT02164513|DRUG|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
41304776|NCT02164513|DRUG|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
41304777|NCT06556056|OTHER|SesZen-Bio Serum|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liduid Frequency: Daily Night application. Route of administration: Topical"
40780714|NCT00003794|PROCEDURE|quality-of-life assessment|
40985146|NCT04940650|DIAGNOSTIC_TEST|exercise testing|To define the strenuous physical exercise in this study, each participant will be asked to perform two hours of high intensity (HIT)-effort during the endurance exercise of at least 6 to 7 hours. Therefore all participants will have exercise testing approximately 1 week before the physical exercise to set aerobic and anaerobic gas exchange thresholds, as well as VO2max.
40985147|NCT04940650|DIAGNOSTIC_TEST|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles at rest enabling comparisons with cardiac MRI and traditional echo measures.
40985148|NCT02178631|BEHAVIORAL|Deprexis|Online self-help
40985149|NCT02178631|OTHER|CAU|Care as usual
40985150|NCT03477227|DEVICE|Short stocking|Patients in the experimental group will be asked to wear new type of compression stockings for four weeks post-operatively
41304778|NCT06556056|OTHER|Minoxidil hair serum (1%)|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical"
41304779|NCT06556056|OTHER|Placebo|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical"
41463634|NCT03666325|DRUG|Cetuximab|In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
41463635|NCT04621656|COMBINATION_PRODUCT|January Mobile Application (Sugar AI)|Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.
40780715|NCT02384421|DEVICE|Adaptive DBS (Activa PC+S Neurostimulator)|
40780716|NCT02384421|DEVICE|Continuous DBS (Activa PC+S Neurostimulator)|
40780717|NCT06400784|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) will be added on top of conventional heart failure medications.
40780718|NCT03504228|DEVICE|Roadsaver|Dual layer micromesh Roadsaver carotid stent
40780719|NCT00560417|DRUG|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
40780720|NCT00560417|DRUG|Insulin Glargine|Administered subcutaneously once a day at bedtime
40780721|NCT01359956|DRUG|Dacarbazine|900 mg / m2 every 3 weeks
40780722|NCT01359956|DRUG|Fotemustine|100 mg / m2 every 3 weeks
40780723|NCT01359956|DRUG|Interferon Alfa-2b|5 M units every 3 weeks
40780724|NCT05745714|DRUG|Ruxolitinib|oral
40780725|NCT05745714|DRUG|Venetoclax|oral
40780726|NCT05745714|DRUG|Dexamethasone|oral/intravenous
40780727|NCT05745714|DRUG|Cyclophosphamide|intravenous
40985151|NCT03477227|DEVICE|Usual stocking|Patients in the control group will be asked to wear usual type of compression 2 class stockings for four weeks post-operatively
41463636|NCT01889472|DEVICE|Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy|
41463637|NCT02998606|DRUG|Naloxegol|MOVANTIK™ 25 mg, daily
41463638|NCT02998606|DRUG|Placebo Oral Capsule|Placebo 25 mg, daily
40780728|NCT05745714|DRUG|Cytarabine|intravenous
40780729|NCT05745714|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
40780730|NCT04167943|DRUG|Dual cured resin modified tricalcium silicate cement|A resin based, dual cured tricalcium silicate based cement
40780731|NCT01416350|DRUG|Azithromycin - 250 mg|Part A - A single azithromycin dose of 250 mg.
40780732|NCT01416350|DRUG|Azithromycin - 1000 mg|Part A - A single azithromycin dose of 1000 mg.
40780733|NCT01416350|DRUG|Azithromycin - 250 mg every other day for 3 weeks|Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
40780734|NCT02515318|OTHER|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
40780735|NCT02515318|DRUG|Medical standard treatment|"The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
40780736|NCT05489328|OTHER|Candidate-1|Biological
40780737|NCT05489328|OTHER|Candidate-2|Biological
41147011|NCT01525888|PROCEDURE|stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)|stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
40780738|NCT05489328|OTHER|Candidate-3|Biological
40780739|NCT05489328|OTHER|Candidate-4|Biological
40780740|NCT05489328|OTHER|Candidate-5|Biological
40780741|NCT05489328|OTHER|Candidate-6|Biological
40780742|NCT05489328|OTHER|Candidate Control|Biological
40780743|NCT05489328|BIOLOGICAL|13vPnC|13-valent pneumococcal conjugate vaccine
40780744|NCT05489328|BIOLOGICAL|PCV15|15-valent pneumococcal conjugate vaccine
41147012|NCT00903981|DRUG|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
41147013|NCT00903981|DRUG|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
41147014|NCT00903981|DRUG|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
40985152|NCT05877794|DEVICE|central venous catheter insertion|All patients were under trendlenburg position (10 degrees) and disinfected for CVC catheterization. After attaching 2 suture wings of 18G single catheter set to the insertion needle in the 7 Fr or 8 Fr central catheter set, check the IJV to be punctured with an ultrasonic probe. The IJV is punctured using a cross sectional image confirmed at the cricoid cartilage level. After confirming the needle tip on the ultrasound image and blood coming out, the guide wire is mounted on the IJV and then a CVC catheter (arrow international INC) ., USA) is inserted. All actions are performed by a specialist who has more than 30 CVC catheterization experiences using ultrasound, and the occurrence of side effects and the time from puncture to guide wire entry are recorded by another researcher. After the procedure, the researcher who directly performed the procedure records the difficulty or difference compared to when using a conventional needle that does not have a suture wing installed.
40780745|NCT05090787|DEVICE|Investigational mDCB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
40985153|NCT01358357|DRUG|Lurasidone|Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
40985154|NCT01358357|DRUG|Placebo|20-80 mg flexible dose
40985155|NCT04015245|DRUG|Stronger Neo-Minophagen C|intravenous injection after TACE
40985156|NCT00974909|DEVICE|Urgent PC neuromodulation system|Urgent PC neuromodulation system
40985157|NCT00974909|DEVICE|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
40985158|NCT03964155|BIOLOGICAL|Sample|After an exposure duration of at least 12 hours, a sample of directly-aspirated, undiluted pulmonary edema fluid will be collected concurrently with AnaConDa-S® filter collection.
41147015|NCT04176549|OTHER|Management of Ectopic Pregnancy|Expectant, Medical or Surgical management of Ectopic Pregnancy
41147016|NCT04176549|OTHER|Management of termination of pregnancy|Surgical termination of pregnancy
41304780|NCT04549597|DRUG|Tenapanor|Use of tenapanor
41304781|NCT00267280|DRUG|torcetrapib/atorvastatin|
41304782|NCT00267280|DRUG|simvastatin|
41304783|NCT03129581|BEHAVIORAL|Dietary Counseling|Counseling to only eat during a restricted amount of time.
41304784|NCT01099839|DRUG|ASP1941|oral
41304785|NCT01099839|DRUG|Miglitol|oral
41304786|NCT05537948|DRUG|Pitavastatin|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of Pitavastatin: Pitavastatin at visit 0 will be prescribed at a dose of 2 mg, after 1 month in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg.~The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with pitavastatin, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). There will be visits on the 7th, 9th and 12th months."
41463639|NCT03684889|BIOLOGICAL|SCRI-huCAR19v1|1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
41463640|NCT03684889|BIOLOGICAL|SCRI-huCAR19v2|Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
41463641|NCT01466036|DRUG|Cabozantinib|60 mg QD orally in cycles of 28 days
40780746|NCT05090787|DEVICE|Control DCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes
40780747|NCT06268470|DRUG|Desloratadine plus cilostazol and dipyridamole|Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
40780748|NCT06268470|DRUG|Desloratadine|Desloratadine 20 mg/day
40780749|NCT03060902|BEHAVIORAL|Dialectical Behavior Therapy Skills|DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
40780750|NCT02972996|OTHER|Blueberry|22 g freeze-dried whole blueberry powder
40780751|NCT02972996|OTHER|Placebo|22 g placebo blueberry powder
41147017|NCT04176549|OTHER|Elective management of gynaecology patients|Elective hysterectomy and salpingo-oophorectomy
41147018|NCT05254288|OTHER|Chlorhexidine|In-office and domiciliary use of chlorhexidine for 14 days.
41147019|NCT05254288|OTHER|Ozoral gels|In-office administration of Ozoral Pro and domiciliary use of Ozoral gel for 14 days.
41147020|NCT05257642|OTHER|REThink Game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
41147021|NCT01628939|OTHER|MRI of the lumbar spine|standard protocol, approximately 30 minutes
41147022|NCT01628939|OTHER|manual segmental examination of the lumbar facet joints|use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
41463642|NCT05770557|BEHAVIORAL|survey|administration of a survey among healthcare workers
40780752|NCT04240431|DIAGNOSTIC_TEST|Probing /irrigation of lacrimal passages|Probing of the lacrimal passage was done using #00 Bowman's lacrimal probe which can reveal any narrowing (resistance) or obstruction (soft stop) of the canaliculi during its advancement from punctum towards the lacrimal sac.
40985159|NCT06157723|OTHER|None (Observational study)|"Data related to the knee osteoarthritis will be extracted from patients' medical records:~The sociodemographic and clinical participants' characteristics: age, weight, height, duration of the condition, and occupational activity.~The healthcare costs: the number of visits in primary and specialized care, diagnostic tests, surgical interventions, and emergencies at both health centers and hospitals, physical rehabilitation and number of sessions.~Charlson Comorbidity Index (CCI). Pharmacotherapy (type of drug and dose). Work absences (temporary and permanent)."
40985160|NCT00375739|DRUG|PEP005|
40985161|NCT00864149|DRUG|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
40985162|NCT00864149|DRUG|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
40985163|NCT02320149|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day,
40985164|NCT02320149|DRUG|Placebo|Placebo-matching sarecycline tablets taken orally at the same time each day.
40985165|NCT04840238|DRUG|Cholecalciferol|30,000IU cholecalciferol
40985166|NCT04840238|DRUG|Placebo|Placebo tablets
40985167|NCT04343599|OTHER|Hypopressive exercises|The first two sessions will have as objective the correct and effective learning of the hypopressive technique. The rest of the sessions will be dedicated to the realization of an exercise protocol based on a progression of postures from standing to supine. Diaphragmatic apneas of approximately 7 seconds will be performed, alternating each apnea with three breaths.
40985168|NCT03109574|DEVICE|BioFlo DuraMax Chronic Hemodialysis Catheter|
40985169|NCT03109574|DEVICE|Standard of Care Catheter|
40985170|NCT04608851|DRUG|E. coli Nissle|1 ml of oral suspension containing 10 E8 CFU /ml of E. coli Nissle strain
40985171|NCT04608851|OTHER|Placebo control|1 ml oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g.
40985172|NCT02946645|DEVICE|Neuromuscular Bite (orthotic/sub-lingual)|Bite is a device which simulates a set of properly positioned teeth
40985173|NCT02946645|PROCEDURE|Mandibular Physiotherapy|"Mandibular Stabilisation Exercises~1. Place knuckle of index finger between top and bottom teeth.~2. Remove it, keeping the teeth separated one-knuckle apart.~3. Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above."
40985174|NCT02946645|OTHER|Placebo|No interventions.
40985175|NCT00132184|DRUG|Vitamin D|
40985176|NCT04846660|OTHER|Production pressure|Participant exposed to production pressure
40985177|NCT05920174|DEVICE|NEO|Subjects will be implanted with the NEO device.
40985178|NCT05153031|OTHER|lithiasic|Cholelithiasis is the presence of one or more calculi (gallstones) in the gallbladder.
41144188|NCT05951335|OTHER|m-Health Transition Care Program|The m-Health supportive care transition program is a routine support program for caregivers of TBI patients. This program consists of education and providing face-to-face information assisted by an android-based application that can access via a smartphone, skill demonstration, assessment of the readiness of hospital discharge, as well as weekly monitoring and follow-up after the patient is discharged from the hospital. This application provides education and information on TBI caregivers regarding (a) how to treat patients with TBI at home, which includes wound care and how to provide nutrition, (b) recognize signs of infection in wounds of craniotomy, (c) recognize emergencies in cases of TBI patients at home, (d) stress management, and (e) how to arrange a schedule for the care of patients with TBI at home. This program complements routine care, which consists of education about physical health, TBI medical problems, and how to treat TBI patients at home.
41144189|NCT00134056|DRUG|atrasentan hydrochloride|Given orally
41463643|NCT06467578|DEVICE|Breezing Portable Indirect Calorimeter|Indirect calorimeter with face mask and smartphone compatible application
40780753|NCT01018602|DRUG|vildagliptin|100 mg per day over 24 months
40780754|NCT01018602|DRUG|inactive pill|1 pill per day over 24 months
40780755|NCT00784121|DRUG|Lactic Acid|Lactic Acid (Dermacyd Breeze)
40780756|NCT01258673|DRUG|Fimasartan/HCTZ combination|Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
40985179|NCT05153031|PROCEDURE|Emergency surgery|Emergency cholecystectomy
40985180|NCT05153031|PROCEDURE|cholecystectomy|cholecystectomy
40985181|NCT04092101|OTHER|Cigarettes with varying nicotine content|1) Altering the nicotine content of the tobacco research cigarette
41144190|NCT00134056|DRUG|docetaxel|Docetaxel given IV and prednisone given orally
41144191|NCT00134056|DRUG|prednisone|Docetaxel given IV and prednisone given orally
41144192|NCT00134056|OTHER|placebo|Given orally
41144193|NCT02214095|DRUG|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
41144194|NCT02214095|DRUG|lactose capsules|
41144195|NCT02889900|DRUG|cediranib and olaparib|"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed"
41463644|NCT01863355|DRUG|B0 group: bolus 0.6mcg/kg without background infusion|
40780757|NCT01258673|DRUG|Fimasartan|Fimasartan 60mg, 120mg
40985182|NCT04092101|OTHER|E-Cigarettes|1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
40985183|NCT00805311|PROCEDURE|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
40985184|NCT00805311|DRUG|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
40985185|NCT04653805|OTHER|Current clinical practice in primary care of patients with type 2 diabetes mellitus|
40985186|NCT03992157|DEVICE|ECG telemetry|ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital
40985187|NCT04357392|DRUG|Prednisone|Prednisone 10mg, TID \* 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
40780758|NCT00998257|DRUG|EE20/DRSP (YAZ, BAY86-5300)|Patients under daily life treatment with YAZ according to local drug information.
40985188|NCT01586390|OTHER|Functional treatment for ankle sprain using ankle cast|Functional treatment for ankle sprain using ankle cast
40985189|NCT01586390|OTHER|Ankle sprain treated with removable ankle support|Ankle sprain functionally treated with removable and adjustable ankle support
40985190|NCT01655979|DIETARY_SUPPLEMENT|Whey Protein + Potassium bicarbonate|0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest
40985191|NCT01655979|OTHER|Control|Bed rest without dietary supplement
40985192|NCT02834533|DEVICE|Lokomat|Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
40985193|NCT00562939|BIOLOGICAL|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
40985194|NCT00562939|BIOLOGICAL|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
40985195|NCT00654173|DRUG|Rosuvastatin|
40985196|NCT00654173|DRUG|Simvastatin|
40985197|NCT00654173|DRUG|Atorvastatin|
40985198|NCT01505868|DRUG|Cabazitaxel|Given IV
40985199|NCT01505868|DRUG|Carboplatin|Given IV
40985200|NCT01505868|OTHER|Laboratory Biomarker Analysis|Correlative studies
41144196|NCT05429502|DRUG|Topotecan|Starting out dose of topotecan administered at standard dose given to neuroblastoma patients (0.75 mg/m2/day).
40985201|NCT03487861|DIAGNOSTIC_TEST|observational(urinary biomarker for kidney allograft fibrosis)|After an informed consent is obtained, urine specimens will be collected prospectively before kidney transplantation (if available) and 3rd and 7th day, 1st, 3rd, and 6th month post-transplant. About 35\~50ml of urine sample is collected from each patient. For each urine specimen, 0.5 ml of a protease inhibitor mixture (5mM 4-(2-animoethyl) benzensulfonyl fluoride hydrolchloride, 2 μM Leupeptin-hemisulfate, and 3.3 mM Sodium azide) is added. To remove urinary sediments including whole cells, large membrane particles, and other debris, urine specimens are centrifuged at a rate of 4000 rpm for 15 minutes at 4 ℃. An aliquot of supernatant is stored at -80 ℃ until use. Urinary biomarkers including transglutaminase 2 are quantified using ELISA or CBA. In addition, urinary exosomes are isolated and analyzed. When a for-cause biopsy is done for some patients, the correlation between biomarkers and pathologic diagnosis will be assessed.
40985202|NCT06391164|DRUG|XC243 25 mg|Patients will receive the Investigated Product (IP) once in the morning at least 30 minutes before eating for 7-10 days
40985203|NCT06391164|DRUG|XC243 50 mg|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
40985204|NCT06391164|DRUG|XC243 75 mg|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
40985205|NCT06391164|DRUG|Placebo|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
40985206|NCT05894733|OTHER|study group|Calling with phone frequently(15.th day, 1 month , 3 month, 6 month ) and face to face interwiew on first, 3 th and 6th month
40985207|NCT05894733|OTHER|control group|first and sixth month face to face interwiew
40985208|NCT05266755|OTHER|Fracture Territorial Liaison Service afert a Hip fracture|Give a diferent than the current one way of follow up to the patients with hip fracture
40985209|NCT00002733|BIOLOGICAL|aldesleukin|
40985210|NCT00002733|BIOLOGICAL|recombinant interferon alfa|
41463645|NCT01863355|DRUG|BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr|
41463646|NCT01863355|DRUG|BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr|
40985211|NCT00002733|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
40985212|NCT00002733|DRUG|cimetidine|
41463647|NCT00261417|DRUG|Tesaglitazar|
40780759|NCT00672997|DRUG|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
40780760|NCT00672997|DRUG|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
40780761|NCT05811325|OTHER|kinesiotaping without craniosacral therapy|The first treatment group will receive kinesio taping for 6 weeks atleast 4 times per week
40780762|NCT05811325|OTHER|kinesiotaping with craniosacral therapy|The second treatment group will receive kinesio taping with craniosacral therapy for 6 weeks atleast 4 times per week with each session lasting for 60 minutes
40780763|NCT00416117|PROCEDURE|Manual Physical Therapy and Exercise|
40780764|NCT00416117|PROCEDURE|Minimal Intervention|
40985213|NCT02278263|DRUG|Tranexamic Acid|Given intravenously or topically
40985214|NCT02278263|DRUG|Normal saline (0.9% NaCl)|Administered in all 3 groups
40985215|NCT02074787|DEVICE|Thermography|Standard thermographic images
40985216|NCT02074787|DEVICE|Laser Doppler|standard laser doppler analysis
40985217|NCT02074787|DEVICE|Spectrophotometric Intracutaneous analysis|standard SIA scope imaging
40985218|NCT05076747|BEHAVIORAL|Cardiovascular training|8 weeks of cardiovascular training
40985219|NCT05076747|BEHAVIORAL|Standard Therapy|8 weeks of Standard Therapy
41144197|NCT05429502|DRUG|Temozolomide|Starting out dose of temozolomide for first two cohorts for Phase 1-Part A: 150mg/m2/day. Starting out dose for subsequent cohorts in Phase 1-Part A will initiate at 100mg/m2/day and will be determined for Phase 1-Part B depending on safety outcome and for phase II.
41144198|NCT05429502|DRUG|Ribociclib|Ribociclib administered at the RP2D defined from Phase I-Part A.
41463648|NCT03973788|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|A single section of rTMS (2,000 pulses)
41463649|NCT01673841|PROCEDURE|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
41463650|NCT04570735|DIAGNOSTIC_TEST|MRI|MRI
41463651|NCT05547906|DRUG|ASCA101|IV infusion Twice a Week, 8 times per each Cycle
41304787|NCT05537948|DRUG|PCSK9 inhibitor|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of PCSK9 inhibitors:The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with a PCSK9 inhibitor, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). Pitavastatin will initially be prescribed at a dose of 2 mg, after 1 month. in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg. There will be visits on the 7th, 9th and 12th months."
41304788|NCT03879148|OTHER|Erector spinae plane block|Erector spinae plane block was performed to the patients under aseptic conditions
41304789|NCT05632575|BEHAVIORAL|Virtual Promotoras Program|"Participants will receive a unique participant code from the virtual promotoras (i.e., patient educators and navigators), to access the VIP mobile phone app intervention. This will give them access to the three main components of the VIP intervention:~1. Educational Modules (8 evidence-based educational modules made by the VPs),~2. Sexual and Reproductive Health Plan (SRHP): Quiz-style instrument to help the participant set goals for her sexual health and develop a set of questions to ask her provider.~3. Virtual Promotora's (VP) chat room.: Opportunity for participant to ask any questions that she may have about sexual health (SH) or sexual healthcare access (SHCA), refine her SRHP. The VP will also help her make her appointment for her clinical visit with one of the local free clinics which do not require insurance and are youth-friendly, and practice having the conversation that she wants to have with her clinical provider."
41304790|NCT00234858|DRUG|trandolapril/verapamil|2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
41304791|NCT00234858|DRUG|(Hyzaar) losartan/hydrochlorothiazide|50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
41463652|NCT06467097|RADIATION|SBRT(Stereotatic Body Radiation Therapy)|Patients will receive treatment for one to two weeks, one to five times per region.
41463653|NCT01501968|DRUG|Colistin|Colistimethate sodium 2.5-5mg/kg iv per day
41463654|NCT01501968|DRUG|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
40780765|NCT03823989|DRUG|Promitil|The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.
40780766|NCT03823989|RADIATION|EBR|A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
40780767|NCT01176617|DEVICE|Reveal XT implantable loop recorder|All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
40985220|NCT04260542|BEHAVIORAL|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
40985221|NCT04260542|BEHAVIORAL|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
40985222|NCT04260542|BEHAVIORAL|Ketogenic diet/ fasting|1 month of fasting-mimicking ketogenic diet and subsequent 2-days of refeeding. The subjects will be instructed by nutritional specialist to follow isocaloric ketogenic diet consisting of 6% carbohydrates, 17 % of proteins and 77% fat to cover individual energy demand. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
40985223|NCT04138329|PROCEDURE|Lichtenstein Technique|In this group was used the Lichtenstein technique for inguinal repair
41463655|NCT04612530|DEVICE|Irreversible Electroporation (IRE)|Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
40985224|NCT04138329|PROCEDURE|Onstep Technique|In this group was used the Onstep technique for inguinal repair
40985225|NCT06443840|DEVICE|AutonHome® device|The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.
41463656|NCT04612530|DRUG|Nivolumab|Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
40985226|NCT01011660|DRUG|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
40985227|NCT04463550|OTHER|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
40985228|NCT00213083|DRUG|Carraguard (PC-515)|
40985229|NCT02882854|DRUG|Guanfacine|Patients will receive 1 mg of guanfacine to take orally.
40780768|NCT01818687|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
40780769|NCT04863794|DRUG|RO7248824|A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
40780770|NCT04705805|BEHAVIORAL|Self-assessment of olfactory disorders through two questionnaires.|"* Assessment of sense of smell or loss of smell using an Analogue Visual Scale~* Carrying out the objective smell test (Sniffin' sticks test) (gold standard)~* Information from two self-questionnaires translated into French: a quality of life questionnaire (The Questionnaire Olfactory Disorders (QOD)) and a self-assessment questionnaire of his olfactory capacities (Self-Mini Olfactory Questionnaire (Self-MOQ))"
40985230|NCT02882854|DRUG|Placebo|Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
40985231|NCT03899584|DRUG|4-Aminopyridine|Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.
40985232|NCT03899584|DRUG|Placebo oral capsule|The placebo arm will include a placebo of microcrystalline cellulose.
40780771|NCT02076945|PROCEDURE|US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)|
40780772|NCT05554276|COMBINATION_PRODUCT|neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy|All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.
40985233|NCT01411696|DRUG|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
40780773|NCT02670902|BEHAVIORAL|Critical Time Intervention-Residential (CTI-R)|CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.
40780774|NCT02670902|BEHAVIORAL|Enhanced Usual Discharge Services-Residential|The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program plus enhanced transition services.
40985234|NCT01342146|DRUG|pegylated Somatropin|0.1 mg/kg/wk once a week for 25 weeks
40985235|NCT01342146|DRUG|pegylated Somatropin|0.2 mg/kg/wk once a week for 25 weeks
40985236|NCT01342146|DRUG|Jintropin AQ|0.25 mg/kg/wk, once a day for 25 weeks
41144199|NCT05746026|BEHAVIORAL|Psycho-educational Program|"This program consisted of five (5) sessions during two weeks.~* Session 1: introduction and basic information about Climate Change~* Session 2: causes and factors that contribute to climate change by humans and nature~* Session 3: explain climate change risks, describe and explain the impact of climate change on elder health and well-being.~* Session 4: teaching proper behaviors that contribute the most to climate-driving emissions.~* Session 5: learning how adapting and coping with climate change. Adaptation includes a range of coping actions that individuals may take, as well as psychological processes (e.g. emotion management, problem solving, and cognitive reframing responses) that influence reactions to (and preparations for) adverse impacts of climate change, including chronic environmental conditions and extreme events."
41144200|NCT02529176|BEHAVIORAL|Best-practice alert|The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
41144201|NCT06598774|OTHER|Assessment of head posture:|Head posture was assessed using photographic methods and craniovertebral angle
41144202|NCT06598774|OTHER|Assessment of Cervical Pain Pressure Threshold|The cervical PPTs were assessed using a mechanical pressure algometer (Baseline Force Gauge Model 12-0304; Baseline, NY, USA).
41144203|NCT06598774|OTHER|Assessment of general cervical mobility|Cervical mobility was assessed using the CROM (Cervical Range of Motion) deluxe device.
41144204|NCT06598774|OTHER|Assessment of upper cervical mobility|It will be assessed using the CROM device and the flexion-rotation test.
41144205|NCT06598774|OTHER|Assessment of Body Awareness|Body awareness will be assessed using a questionnaire designed to determine normal or abnormal sensitivity levels in body composition.
41144206|NCT02449902|DRUG|Estradiol|1 10 µg capsule inserted vaginally for 14 days.
41144207|NCT02449902|DRUG|placebo|1 placebo capsule inserted vaginally for 14 days.
41144208|NCT01613703|DRUG|ONO-2952|1 mg to 200 mg QD at a single descending dose
41144209|NCT04859465|DRUG|Abraxane combined with liposomal doxorubicin|Patients with advanced or unresectable angiogenic sarcoma who met the criteria of treatment failure received abraxane combined with liposomal doxorubicin regimen. Administration regimen: abraxane 220 mg / m2 D1 plus liposomal doxorubicin 35 mg / m2 D1, IV drip, 3 weeks as a cycle, until the disease progression or intolerable toxicity. Up to 8 cycles.
41463657|NCT04612530|DRUG|Toll-Like Receptor 9|Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.
40780775|NCT01259258|PROCEDURE|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
41463658|NCT05195177|DRUG|Anti-histamine cream 1 hour|At the start of session 1, one area of the middle forearms of the participant will be located (4x4cm). On the area, anti-histamine cream will be applied for approximately 1 hour.
40985237|NCT05003154|OTHER|Digitalized management|"In addition to conventional management, Patients also receive digitalized management, which provides personalized guidance in diet, excercise, prenatal visit, blood glucose monitoring,etc., from artificail intelliegence (AI) supevised by obstetricians, through a smartphone application and some werable devices (like sports bracelet).~The pivotal AI are based on clinical experience from obstetricians, therapeutic principle from official Guidelines and abundant data in previous work, and it will works under strict supervision."
40985238|NCT05762003|DRUG|interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab|Administered as part of routine clinical practice.
40985239|NCT04378140|OTHER|zirconia wing bridge|The zirconia wing bridge consists of an artificial tooth made out of zirconia and porcelain on the front side with two zirconia wings that are bonded (glued) onto the back of the two adjacent teeth in the patient's mouth.
40985240|NCT05829486|PROCEDURE|gastroscopy|anaesthetic management of ambulatory endoscopic procedures
40985241|NCT02389244|DRUG|Regorafenib|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily until progression or unacceptable toxicity
40985242|NCT02389244|DRUG|Placebo|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
40985243|NCT06287528|BIOLOGICAL|19-28z/IL-18 CAR T cells|19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL
40985244|NCT04923724|DEVICE|tourniquet|tourniquet is a device used during total knee surgery.
40985245|NCT04923724|DEVICE|No tourniquet|tourniquet is a device used during total knee surgery, this group does not get one
40985246|NCT05797155|BEHAVIORAL|CoQuit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips|CoQuit App (Cognitive Dissonance Based Smoking Cessation) Use of the CoQuit app, completion of cognitive dissonance activities, sharing of videos with online group, and providing support to other group members
40985247|NCT05797155|BEHAVIORAL|Tips for Smoking Cessation App|App containing daily tips for smoking cessation
40985248|NCT06120036|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion.
40985249|NCT06120036|DRUG|Asclera|Injection into the cutaneous Neurofibromas lesion.
41304792|NCT03268668|OTHER|Collection of thrombus that is responsible for stroke and blood sample|"A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria :~A) TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase \> 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis"
41304793|NCT00975195|DRUG|tiotropium inhalation|
41304794|NCT00975195|DRUG|salmeterol xinafoate|
41304795|NCT00975195|DRUG|fluticasone propionate|
41304796|NCT00975195|DRUG|placebo matched for fluticasone propionate|
41304797|NCT02380352|DRUG|Amoxicillin|
41304798|NCT02380352|DRUG|Placebo|Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
41304799|NCT05618899|OTHER|HIGH INTENSITY INTERVAL TRAINING|Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
41304800|NCT05618899|OTHER|MODERATE INTENSITY EXERCISE|moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
41304801|NCT02267863|DRUG|APTO-253|APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.
40780776|NCT01259258|PROCEDURE|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
40985250|NCT06153511|PROCEDURE|Robot assisted spinal transpedicular fixation|Surgical technique which joins two or more vetebrae with screws and rods to prevent any relative movement between them. It is a major surgery that usually lasts several hours and in which the patient is subjected to general anesthesia. The screws to be placed go through a narrow area of the vertebra known as the pedicle. Each patient will undergo a singular intervention.
40985251|NCT00732615|DRUG|Placebo|Placebo for subcutaneous injection
40985252|NCT00732615|DRUG|NPSP558|Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
40985253|NCT02456142|DRUG|caudal bupivacaine|
40985254|NCT02456142|DRUG|intravenous morphine|
40985255|NCT02190084|DEVICE|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
40985256|NCT01441310|PROCEDURE|Laparoscopic sentinel node navigation surgery|Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
41144210|NCT00916318|BEHAVIORAL|Obesity-Children|"(A) internet based information and communication tool Sundabarn.se(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group."
41144211|NCT00535626|DEVICE|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
41144212|NCT05509881|DEVICE|Continuous glucose monitoring (CGM)|"Patients in the CGM arm will undergo continuous real-time unblinded CGM using Dexcom CGM devices."
41304802|NCT00006360|DRUG|radioprotection|
41304803|NCT00006360|RADIATION|radiation therapy|
41304804|NCT04010786|DRUG|NNC0247-0829|Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.
40985257|NCT04768465|DRUG|Pyridostigmine, Prednisone, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Prednisone is administrated with an initial dose of 0.25mg/kg/d and started to tamper with the achievement of MMS or the presence of any intolerable side effects. The rate of tampering is considered by the physician, usually no more than 5mg/month. If the participants failed to maintain MMS, dose of prednisone should be increased 5mg/week to 0.25mg/kg/d and maintained until MMS reached again. After MMS sustained for 1 month, prednisone dose would be tapered again with 2.5mg/month. Calcium and potassium supplements and gastric mucosa protectors could be addressed to avoid any adverse effects of prednisone. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
40985258|NCT04768465|DRUG|Pyridostigmine, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
40985259|NCT05153512|PROCEDURE|MRI|Pelvic MRI without injection of contrast product and WITHOUT rectal or vaginal opacification
40985260|NCT00010374|DEVICE|NeuRx DPS|Laparoscopic implantation of diaphragm electrodes and subsequent pacing with the NeuRx DPS.
40985261|NCT03376854|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
40985262|NCT03376854|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
40985263|NCT03376854|DEVICE|Standard of Care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
40985264|NCT05779878|OTHER|Post Isometric Relaxation|Post-isometric relaxation (PIR) is a soft tissue stretching technique used by many health care professionals to lengthen both acute and chronic short muscles.
40985265|NCT05779878|OTHER|Myofascial arm pull technique|Myofascial therapy is described as the promotion of psychophysiological, neurological and structural adaptive capability as multiplexed via the myofascial system. Fascia covers all body structures, particularly muscles and their constituent myofibrils
40985266|NCT01390311|DRUG|Azacitidine|
40985267|NCT01390311|DRUG|Pre-DLI Salvage Chemotherapy|At the discretion of the treating physician
40985268|NCT01390311|BIOLOGICAL|Donor Leukocyte Infusion (DLI)|
40985269|NCT03736291|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
40985270|NCT05462587|DRUG|AVTX-803 (L-Fucose)|L-fucose crystalline powder
40985271|NCT03637972|OTHER|Ventilated cigarettes only|Participants given vouchers that are exchanged for ventilated cigarettes study cigarettes.
40985272|NCT03637972|OTHER|Unventilated cigarettes only|Participants given vouchers that are exchanged for unventilated cigarettes study cigarettes.
40985273|NCT03637972|OTHER|Access to Experimental Marketplace: Ventilated cigarettes + alternative nicotine delivery systems|Participants given vouchers that are exchanged for ventilated cigarettes + alternative nicotine delivery systems cigarettes.
40985274|NCT03637972|OTHER|Access to Experimental Marketplace: Unventilated cigarettes + ANDS|Participants given vouchers that are exchanged for unventilated cigarettes + ANDS.
40985275|NCT02047747|DRUG|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
40985276|NCT00532584|DRUG|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
40985277|NCT01730209|DRUG|Everolimus|Everolimus once daily titrated to trough levels of 5-10 ng/ml.
40985278|NCT01730209|DRUG|Placebo|
40985279|NCT05882799|PROCEDURE|Ultrasound-guided dry needling|Ultrasound-guided dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle while monitoring the needle's progress with real-time ultrasound imaging. In this technique, a trained practitioner visualizes the piriformis muscle and the surrounding structures using an ultrasound machine, and then inserts the needle through the skin and into the muscle tissue, guided by the ultrasound image.
41304805|NCT04010786|DRUG|Placebo (NNC0247-0829)|Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
41304806|NCT02227329|DRUG|Ethanol|Prophylactic ELT will be administered at the time when the HPN is not being infused.
40780777|NCT00003486|DRUG|antineoplaston A10|
40780778|NCT00003486|DRUG|antineoplaston AS2-1|
40780779|NCT00003486|PROCEDURE|alternative product therapy|
40780780|NCT00003486|PROCEDURE|biological therapy|
40780781|NCT00003486|PROCEDURE|biologically based therapies|
40780782|NCT00003486|PROCEDURE|cancer prevention intervention|
40780783|NCT00003486|PROCEDURE|complementary and alternative therapy|
40985280|NCT05882799|PROCEDURE|Blinded dry needling|Blinded dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle without using real-time imaging guidance. In this technique, the practitioner relies solely on their palpation skills to locate the trigger points of the piriformis muscle and inserts the needle through the skin and into the muscle tissue.
40985281|NCT00996047|GENETIC|cytogenetic analysis|
40985282|NCT00996047|GENETIC|fluorescence in situ hybridization|
40985283|NCT00878527|DEVICE|CircuLite Synergy Pocket Circulatory Assist Device|Goal of successful implantation and follow-up for at least three months
41144213|NCT05509881|DEVICE|Usual care (Self-monitored blood glucose)|Patients in the usual care arm will conduct self-monitored blood glucose at least 4 times/day.
41144214|NCT00259363|DRUG|Oxaliplatin|oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days
40985284|NCT04889339|DEVICE|Test brace versus control brace: Immediate correction|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
40985285|NCT04889339|DEVICE|Test brace versus control brace: Long-term correction|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
40985286|NCT00597766|DRUG|Lidocaine|One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
41144215|NCT04497818|OTHER|Cross Sectional study using scientifically validated psychometric Scales|Cross Sectional study using scientifically validated psychometric Scales (FEAR OF COVID-19, a 5 item Likert Scale \& Modified Dental Anxiety 5 item Likert Scale).
41144216|NCT03473652|OTHER|Adapted walking platform|The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.
41144217|NCT02110914|BEHAVIORAL|Coaching|"Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months."
41144218|NCT05333276|DRUG|TQB3602 Capsule + AK105 Injection|TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
41144219|NCT05177835|DRUG|ABX464|All subjects will receive ABX464 given at 25 mg QD.
41144220|NCT01458782|PROCEDURE|Treatment of cartilage defects in the knee|Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
41463659|NCT05195177|DRUG|Local anesthetic cream 1 hour|At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will be applied for approximately 1 hour.
41144221|NCT04527926|BEHAVIORAL|STEPuP Intervention|"Project STEPup has 4 components designed to address barriers to MAT and EBP adoption: 1) a hub and spoke remotely-supported provider education and training program, 2) addiction teleconsultation support, 3) case management and telepsychiatry support, and 4) a partnership with health system administrators and payers to address administrative and reimbursement related needs."
41144222|NCT04527926|BEHAVIORAL|Usual Care|Standard of Care
41144223|NCT02223078|BIOLOGICAL|G17DT|
41144224|NCT02223078|BIOLOGICAL|Placebo Comparator|
41144225|NCT02203513|DRUG|LY2606368|105 mg/m\^2 intravenous (IV) once every 14 days of a 28 day cycle
41144226|NCT01164319|PROCEDURE|Circumferential PVI and subcutaneous cardiac monitor implantation|"The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
41304807|NCT02227329|DRUG|Heparin Lock|3 mL of 100 U/ml heparin
41463660|NCT01411488|DEVICE|Fecal management system|rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
41304808|NCT02227329|DRUG|Normal Saline|
41304809|NCT05553431|DEVICE|Left bundle branch pacing|Left bundle branch pacing by a CRT device or dual-chamber pacemaker through the pacing lead at left bundle branch region
41304810|NCT00295698|DRUG|Diethylcarbamazine|
41304811|NCT02955654|BEHAVIORAL|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
41304812|NCT02955654|DRUG|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
41463661|NCT00603512|DRUG|Placebo|0 mg BID, 3 blinded tablets administered BID for 12 weeks
41463662|NCT00603512|DRUG|CP-690,550|10 mg BID, 3 blinded tablets administered BID for 12 weeks
41463663|NCT00603512|DRUG|CP-690,550|1 mg BID, 3 blinded tablets administered BID for 12 weeks
41463664|NCT00603512|DRUG|CP-690,550|3 mg BID, 3 blinded tablets administered BID for 12 weeks
41463665|NCT00603512|DRUG|CP-690,550|5 mg BID, 3 blinded tablets administered BID for 12 weeks
41463666|NCT05076682|DRUG|Choline|Choline 300mg tid or 500mg bid, p.o
41463667|NCT05076682|DRUG|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
41463668|NCT05076682|DRUG|Sodium Cromoglicate|Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
41463669|NCT05076682|DRUG|Efavirenz|Efavirenz 600mg qd, p.o
41463670|NCT03465150|OTHER|acne|Patient with acne
41463671|NCT05817006|OTHER|Device|research of the long-COVID-19 in the children
40985287|NCT00597766|DRUG|Triamcinolone + Lidocaine|Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
41144227|NCT06407141|BEHAVIORAL|transcranial pulse stimulation|Participants in the experimental arm will receive six sessions of Transcranial Pulse Stimulation (TPS) over a two-week period, using the NEUROLITH® TPS system (Storz Medical AG, Switzerland). Each session will involve delivering 6,000 ultrasound pulses at an energy level of 0.2-0.25 mJ/mm² and a frequency of 4-5 Hz, targeting specified brain regions based on MRI navigation.
41304813|NCT02955654|BEHAVIORAL|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
40985288|NCT00597766|DRUG|Triamcinolone + Lidocaine|Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
40985289|NCT00597766|DRUG|Triamcinolone + Lidocaine|High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
40780784|NCT00003486|PROCEDURE|differentiation therapy|
40985290|NCT05127447|DEVICE|ES application|Electrical stimulation (ES) application will be given to the ES group
40985291|NCT05127447|OTHER|Sham application|Only vacuum was applied and no current was given from the applied device
40985292|NCT05358171|OTHER|HIgh UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
40985293|NCT05358171|OTHER|No UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
41304814|NCT04335266|DRUG|SHR2554|SHR2554
41304815|NCT02836990|DEVICE|Prevena Incision Management System|A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
41304816|NCT02836990|DEVICE|Dermabond|A surgical skin adhesive used to prevent surgical wound infections
41304817|NCT00634244|DRUG|alvocidib|Given IV
41304818|NCT00634244|DRUG|mitoxantrone hydrochloride|Given IV
41304819|NCT00634244|DRUG|carboplatin|Given IV
40985294|NCT06054347|OTHER|VINELAND II|Standardised questionnaire filled by the investigator during an interview with the parents or with the patient himself if capable of it. Duration 1 hour to 1 hour and a half.
41144228|NCT06407141|BEHAVIORAL|Sham TMS|Participants in the sham control group will undergo six sessions over a two-week period, utilizing the same NEUROLITH® TPS system (Storz Medical AG, Switzerland) as used in the experimental group. The key difference lies in the standoff device attached to the handpiece: while the experimental arm uses a standoff filled with silicone oil to transmit ultrasound pulses, the sham group\&#39;s standoff is filled with air. This design ensures that the sham device replicates the appearance, feel, and sound of the active treatment without transmitting any therapeutic pulses, effectively maintaining the blinding aspect of the study.
41304820|NCT00634244|DRUG|cytarabine|Given IV
40780785|NCT04553757|OTHER|Survey Administration|Complete survey
40780786|NCT01832610|DEVICE|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
41144229|NCT00141271|DRUG|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
41144230|NCT00141271|DRUG|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
41144231|NCT00141271|DRUG|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
41144232|NCT02912338|BEHAVIORAL|Resistant Training|
41144233|NCT02912338|OTHER|Control Group|
41304821|NCT00634244|DRUG|sirolimus|Given PO
41304822|NCT00634244|DRUG|etoposide|Given IV
41304823|NCT00634244|DRUG|topotecan hydrochloride|Given IV
41304824|NCT04970771|BEHAVIORAL|Solving Wellness platform|Interactive wellness resources available include a wide range of curated content and resources including fitness and yoga classes, cooking classes, webinars on sleep and various mental health topics including resilience, stress management, relationships and mindfulness, and resources including e-books, videos and guided meditations. Online discussion groups will foster awareness for specific issues and allow casual discussion. A curated collection of links to additional resources including the Solving Healthcare podcast will also be provided.
41304825|NCT01532063|PROCEDURE|INTUBATION IN INTENSIVE CARE UNIT|Standard intubation procedure used in Intensive Care Unit
41304826|NCT00431847|PROCEDURE|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
40780787|NCT03326245|DRUG|Methylphenidate Pill|Oral methylphenidate (60 mg) given 30 minutes prior to bolus \[11C\]raclopride
40780788|NCT03326245|DRUG|Oral Placebo|Oral PL will be given 30 minutes prior to bolus \[11C\]raclopride injection
40780789|NCT03326245|DRUG|Intravenous Placebo|Intravenous Placebo given 30 minutes post bolus injection of \[11C\]raclopride.
40985295|NCT00195676|DRUG|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
41304827|NCT00431847|PROCEDURE|Standard Pain Management Protocol|Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
41304828|NCT00849264|DRUG|chemotherapy with endostar|15mg/d×14d
41304829|NCT00849264|DRUG|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
41304830|NCT00849264|DRUG|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
41304831|NCT00004735|BIOLOGICAL|Tetanus toxoid|
41304832|NCT00004735|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
40985296|NCT05077592|DRUG|10% Povidone Iodine|Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
41144234|NCT06106776|DRUG|Chimeric Antigen Receptor|This study will evaluate the incidence of cardiac dysfunction at 7 days and 1 month after chimeric antigen receptor-T cell infusion (tisagenlecleucel, axicabtagene ciloleucel e brexucabtagene autoleucel).
41144235|NCT05111340|BEHAVIORAL|Perioperative score|Creation and validation of a perioperative walk score. The patient has to answer different items.
40780790|NCT03326245|DRUG|Intravenous methylphenidate|Intravenous methylphenidate 0.25 mg/kg in 3ml sterile saline given 30 minutes post bolus injection of \[11C\]raclopride.
40780791|NCT00982384|OTHER|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
40780792|NCT00982384|OTHER|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
40780793|NCT01737892|DRUG|Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation|Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
40780794|NCT01737892|DRUG|Arm C-Epinephrine Inhalation Aerosol CFC|Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
40780795|NCT04470765|DEVICE|Zida|Transcutaneous Tibial Nerve Stimulation
40780796|NCT05905562|OTHER|core stabilization exercises|Core muscles activation exercises will be performed on patients to target the abdominals.
40780797|NCT05905562|OTHER|Spinal mobilization techniques|lumbar spine joint mobilization techniques will be performed to patient in prone lying.
40780798|NCT01872884|DRUG|Sevorane Remifentanil|Sevorane Remifentanil
41304833|NCT00400829|DRUG|eribulin mesylate|Given IV
41304834|NCT02510729|DEVICE|Neurostimulation|
40780799|NCT01872884|DRUG|Remifentanil|Remifentanil
41304835|NCT02510729|DEVICE|Sham stimulation|
40780800|NCT01563055|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
40780801|NCT01563055|DRUG|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
40780802|NCT03069378|DRUG|Talimogene Laherparepvec (T-VEC)|Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
40780803|NCT03069378|DRUG|Pembrolizumab|Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.
40780804|NCT02025374|DRUG|Hyperbaric levobupivacaine|
40780805|NCT02025374|DRUG|Hyperbaric bupivacaine % 0.5|
40780806|NCT05703230|OTHER|Structured preoperative multidisciplinary team meeting|"The intervention to be investigated is the introduction of a preoperative structured multidisciplinary team (sMDT) meeting for high risk noncardiac surgical patients, which is attended by at least the treating surgical specialist, an anesthesiologist and another medical consultant with expertise relevant for the patients comorbidities and preferences. In the preoperative sMDT meeting, at least the following questions will be discussed as recommended by the Dutch Perioperative Guideline:~* Is the proposed surgical intervention appropriate care for the patient?~* Is the risk/benefit ratio of the proposed surgical intervention acceptable for the patient?~* Should the patient's condition be optimized before undergoing the proposed surgical intervention?"
41304836|NCT02831075|BIOLOGICAL|Adipose-derived stem cell|stem cell acquisition, processing and reinfection, to evaluate the efficacy of adipose-derived stem cell.
40780807|NCT04221633|BEHAVIORAL|Enhancing Early Engagement (E3) webinar|Webinar-based training to provide information regarding evidence-based engagement strategies (e.g., motivational interviewing, McKay's engagement model), trauma, mental health screening, and identifying evidence-based mental health treatments for children.
40780808|NCT04221633|BEHAVIORAL|Consultation for E3 training|10 consultation calls with experts in engagement, child trauma, and mental health screening to support the webinar training
40780809|NCT00729950|BIOLOGICAL|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
40780810|NCT01143402|DRUG|Dacarbazine|Given IV
40780811|NCT01143402|OTHER|Laboratory Biomarker Analysis|Correlative studies
40780812|NCT01143402|OTHER|Quality-of-Life Assessment|Ancillary studies
40780813|NCT01143402|DRUG|Selumetinib|Given PO
40780814|NCT01143402|DRUG|Temozolomide|Given PO
41144236|NCT06600802|BIOLOGICAL|Blood samples|A total of 3 blood samples (2 tubes of 9mL each) are added. The first sample will be taken at the inclusion visit, the 2nd at the end of the 2nd treatment cycle and the last at the end of Lu-PSMA treatment.
41144237|NCT04416100|DIAGNOSTIC_TEST|Pulmonary function tests|Spirometry or plethysmography, measurement of diffusion capacity
41304837|NCT02831075|BIOLOGICAL|saline|
41304838|NCT02883582|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
41304839|NCT02883582|DEVICE|oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
40985297|NCT04818281|BIOLOGICAL|SARS-CoV-2 VLP Vaccine|VLP adjuvanted vaccine
41144238|NCT04416100|DIAGNOSTIC_TEST|Imaging|HRCT and echocardiography as scheduled within routine clinical examinations
41144239|NCT04416100|BIOLOGICAL|Blood sampling|Standard laboratory test as part of routine clinical examination and collection of peripheral blood for immunofibrotic phenotyping
40985298|NCT04818281|BIOLOGICAL|Placebo|0.9% NaCl
40985299|NCT05351242|OTHER|Thermotherapy/sauna bath|Thermotherapy/sauna bath
40985300|NCT02709031|DRUG|Cicletanine + magnesium|"Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,~Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses."
40985301|NCT02709031|DRUG|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,
40985302|NCT04946292|BEHAVIORAL|Theory-derived intervention|The intervention will be delivered through multimedia materials and group activities, as appropriate. Participants will spend approximately 30-45 minutes for the intervention. Intervention materials and activities will be carefully designed to address all the constructs/ domains of the selected theoretical model(s). The effectiveness of the interventions will be evaluated using behavioural outcomes (diet, brushing, flossing) and clinical outcomes (oral hygiene, caries and periodontal conditions).
41463672|NCT02735330|PROCEDURE|celiac plexus neurolysis using absolute alcohol|celiac plexus blockade with 40 ml of diluted absolute alcohol(50%) 20 ml on either side of celiac axis in a 4 quadrant fashion
40985303|NCT04946292|BEHAVIORAL|Conventional health education|The conventional health education will be delivered through an oral health talk and oral health booklet. Topics covered are: (i) common oral diseases and its consequences; (ii) common dental problems among older adults; (iii) importance of oral health measures (healthy diet, toothbrushing and dental flossing); and (iv) proper techniques for toothbrushing and dental flossing.
40985304|NCT00005010|DRUG|Irbesartan|
41144240|NCT03971539|DRUG|BI 894416|BI 894416 film-coated tablet.
40985305|NCT00005010|DRUG|Pravastatin|
40985306|NCT04040231|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.
40985307|NCT04040231|DRUG|Nivolumab|Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.
40985308|NCT04040231|BIOLOGICAL|Sargramostim|All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle
40985309|NCT05749575|DRUG|Chidamide Plus Toripalimab Plus Paclitaxel|Each participant receives chidamide plus toripalimab plus paclitaxel
41144241|NCT03971539|DRUG|Placebo|Placebo film-coated tablet matching BI 894416.
41144242|NCT04866563|DRUG|AX-8, Part 1 of the study|orally disintegrating tablets, BID
41144243|NCT04866563|DRUG|Placebo, Part 1 of the study|orally disintegrating tablets, BID
41144244|NCT04866563|DRUG|AX-8, Part 2 of the study|orally disintegrating tablets, TID
41144245|NCT04866563|DRUG|Placebo, Part 2 of the study|orally disintegrating tablets, TID
41144246|NCT03343041|DIETARY_SUPPLEMENT|low-carbohydrate nutrition|low-carbohydrate enteral nutrition
41144247|NCT03343041|DIETARY_SUPPLEMENT|Standard enteral nutrition|standard enteral nutrition
41147023|NCT02450786|DRUG|Donepezil|Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
41463673|NCT02735330|PROCEDURE|Placebo celiac plexus injection using saline|Placebo celiac plexus injection with 40 ml of saline 20 ml on either side of celiac axis in a 4 quadrant fashion for blinding
40985310|NCT00935844|DRUG|TAK-901|"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
40985311|NCT02724306|BEHAVIORAL|Active Lifestyle Programme|
40985312|NCT04135833|DRUG|BPI-7711|BPI-7711 60 mg
40985313|NCT04135833|DRUG|BPI-7711|BPI-7711 180 mg
40985314|NCT04135833|DRUG|Itraconazole|Itraconazole 200 mg
40985315|NCT04135833|DRUG|Rifampicin|Rifampicin 600 mg
40985316|NCT01524510|RADIATION|CT scan|low dose radiation scan without contrast without and with MRA
40985317|NCT01524510|DEVICE|Alice PDx polygraphy|Alice PDx polygraphy (Respironics)
40780815|NCT05617027|OTHER|actual transcranial direct current stimulation (tDCS)|"tDCS is a non-invasive brain stimulation technique that would influence the brain's pain control mechanisms.~The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA."
40985318|NCT02946047|DRUG|Ixazomib 1 MG|1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
40985319|NCT02946047|DRUG|Ixazomib 2 MG|2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
40985320|NCT02946047|DRUG|Ixazomib 3 MG|3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
40985321|NCT02946047|DRUG|Ixazomib 4 MG|4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
40985322|NCT03535350|DRUG|Ibrutinib|"Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.~November 2020:~420 mg of ibrutinib plus temozolomide and radiation was found to be safe - up to 36 participants can betreated at the expansion cohort in both arm 1 and arm 2."
40985323|NCT03535350|RADIATION|Radiation|2Gy x 30minutes for 6 weeks.
40985324|NCT03535350|DRUG|Temozolomide (TMZ)|Cycle 1 150mg/m2 and cycle 2-6 will be up to 200mg/m2.
40985325|NCT02084147|DEVICE|positron emission tomography|Undergo PET
40985326|NCT02084147|DEVICE|computed tomography|Undergo CT
40985327|NCT02084147|DEVICE|magnetic resonance imaging|Undergo MRI
40985328|NCT05114785|DIAGNOSTIC_TEST|Multi Parametric Cardiac Magnetic Resonance|Research based Cardiac MRI evaluation to determine cardiovascular haemodynamics
40985329|NCT02463474|BEHAVIORAL|mHealth Intervention|Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
40985330|NCT02308852|DEVICE|tDCS|
40985331|NCT01486628|DRUG|ND0612|levodopa and carbidopa solution for subcutaneous administration
40985332|NCT01486628|DRUG|Placebo|Saline solution for SC continuous administration
40985333|NCT03996954|DEVICE|Alivecor recording|Alivecor recording and ECG recording from the same patient in very close temporal proximity
40985334|NCT05569850|OTHER|Brushing|Brushing the teeth 2x a day for 4 weeks.
40985335|NCT03164928|DRUG|Denosumab|1mg/kg BW (up to a maximum of 60 mg) SC Q6M
40985336|NCT03164928|OTHER|Placebo|SC Q6M placebo
40985337|NCT06347666|BEHAVIORAL|Caregiver coaching|Speech language pathologists will meet with caregivers to talk through strategies to promote child development.
40985338|NCT00541034|BIOLOGICAL|rituximab|
40985339|NCT00541034|DRUG|cyclophosphamide|
40985340|NCT00541034|DRUG|pentostatin|
40985341|NCT03190161|BEHAVIORAL|Music session|Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level \<6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.
40985342|NCT04484233|DEVICE|iAnemia Decision Support System|iAnemia permits to display the appropriate guideline using several inputs about a patient: age, type and delay of the surgery, gender, hemoglobin level, and iron deficiency status.
40985343|NCT03907293|BEHAVIORAL|Exercise-based cardiac rehabilitation|Moderate intensity aerobic exercise, lifestyle advice, and psychological support.
40985344|NCT01973647|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Six weekly sessions of cognitive behavioral therapy for insomnia
40985345|NCT01973647|BEHAVIORAL|COPD Education|Six weekly sessions of COPD education
40985346|NCT01973647|BEHAVIORAL|Attention Control|Six weekly sessions of non-sleep, non-COPD health education
40985347|NCT05596591|DEVICE|Focused extracorporeal shockwave therapy|High energy level shockwaves (between 0.28-0.60 mJ/mm\^2) will be focused over the subchondral bone with the bone marrow lesion, previously localized on MRI.
40985348|NCT01354847|DEVICE|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
40985349|NCT05629390|DRUG|Lotilaner|Lotilaner Ophthalmic Solution
40985350|NCT05629390|DRUG|Vehicle Control|Vehicle of TP-03 ophthalmic solution
40985351|NCT02297269|DEVICE|laparoscopic surgery|the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
40985352|NCT02297269|DEVICE|open surgery|the method of surgery is conducted by surgical instruments to open the abdomen.
40985353|NCT00523250|DRUG|AR-102 0.003% Ophthalmic Solution|
40985354|NCT00523250|DRUG|AR-102 0.005% Ophthalmic Solution|
41463674|NCT02735330|PROCEDURE|Frey's procedure|Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
40985355|NCT00523250|DRUG|AR-102 0.01% Ophthalmic Solution|
40985356|NCT00523250|DRUG|AR-102 0.03% Ophthalmic Solution|
40985357|NCT00523250|DRUG|AR-102 Vehicle Ophthalmic Solution|
40985358|NCT05381467|PROCEDURE|immediate implant placement with The Dual-Zone Therapeutic Concept|After tooth removal, implant placement, bone grafting, and screw retained provisional restoration, the contour of the ridge can change. Using dual zone grafting was claimed to minimize contour change associated with immediate anterior implants. In this technique. The implant should be placed in an optimal 3 dimensional mode . Xenograft, will be used in the gap to graft the bone and tissue zones, . The graft material helps serve as a scaffold to maintain hard- and soft-tissue volume as well as blood clot for initial healing.
40985359|NCT05381467|PROCEDURE|Immediate implant placement with the bone shielding concept|After atraumatic tooth extraction using periotomes and luxators , socket curettage and cleaning simultaneously using an irrigation curette will be performed. Sulcular dissection of the attached tissue close to the socket orifice incisal and apically will be done using periotome to create a tunnel via the socket orifice. Dental implant will be placed. complete access of the labial plate of bone where all the regenerative materials will be performed to have the bone sheild delivered. A membrane will be inserted to the labial tunnel and tacked using 2 membrane tacks.
40985360|NCT06371404|DRUG|Bavarostat|Up to two injections of ≤ 5 mCi \[F18\] Bavarostat
41144248|NCT06412432|OTHER|Exercise training (ET1+ET2)|Exercise training will consist of continuous aerobic training of moderate intensity on cycle ergometer/treadmill, with a frequency of 2-3 weekly sessions lasting 12 weeks, with exercise intensity of VO2 peak of 40% gradually increasing up to 50-60% of VO2 peak based on individual tolerability and improvement; 55-65% of heart rate at peak; 40-59% of heart rate reserve; 4-6 Metabolic equivalents (METS); the duration of the session will gradually increase from 15-30 min to 45-60 min.
41463675|NCT04583150|PROCEDURE|Bariatric surgery|Bariatric surgery : sleeve gastrectomy or Roux-en-Y gastric bypass (RYGB)
41463676|NCT00162682|PROCEDURE|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
41144249|NCT06412432|BEHAVIORAL|Optimal Medical Therapy (No-ET)|Patients will be handled according to optimal medical therapy
41463677|NCT00162682|PROCEDURE|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
41463678|NCT01122589|BEHAVIORAL|Motivational Interviewing/CBT|6 sessions of in jail MI/CBT counseling will be administered.
41463679|NCT01122589|OTHER|CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)|a series of six weekly 30-45 minutes general wellness videos
40780816|NCT05617027|OTHER|placebo transcranial direct current stimulation (tDCS)|The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA for 30 secondes, and then 0 mA for the rest of the 20-minute session.
41144250|NCT02344602|DRUG|Febuxostat|Oral tablet, 80mg, OD, 8 weeks
41463680|NCT05038891|DIAGNOSTIC_TEST|Digital Cervical Exam|Standard Digital Cervical Exam by an experienced OB provider
41463681|NCT05038891|DIAGNOSTIC_TEST|Transperineal Ultrasound|Self-administered transperineal ultrasound after instruction by a health care professional
41463682|NCT05038891|DIAGNOSTIC_TEST|Transvaginal Ultrasound|Self-administered transvaginal ultrasound after instruction by a health care professional
41463683|NCT03762837|OTHER|Benigh gallbladder diseases|We aim to observe the relationship between the benigh gallbladder diseases and gallbladder cancer, and we will not take any actions to interrupt.
40985361|NCT00394628|DRUG|AQ4N|
40985362|NCT00394628|DRUG|Temozolomide|
41144251|NCT04751370|PROCEDURE|Computed Tomography|Undergo CT
41144252|NCT04751370|BIOLOGICAL|Ipilimumab|Given IV
41144253|NCT04751370|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41463684|NCT04592419|DRUG|KSI-301|Intravitreal Injection
41463685|NCT04592419|DRUG|Aflibercept|Intravitreal Injection
40780817|NCT06061692|DRUG|Tongxinluo Capsule|4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
40985363|NCT00394628|PROCEDURE|Radiotherapy|
40985364|NCT02802592|DRUG|Epogen|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
40985365|NCT02802592|DRUG|Normal Saline|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
40985366|NCT05216731|PROCEDURE|Femoro-popliteal bypass|Under general or local anesthesia: Use of the best vascular substitute (inverted saphenous vein or vascular prosthesis).
40985367|NCT05216731|PROCEDURE|Endovascular procedure|Under general anesthesia, local anesthesia or sedation: Performing a balloon angioplasty completed by preferred stent deployment or drug-coated balloon angioplasty.
41144254|NCT04751370|BIOLOGICAL|Nivolumab|Given IV
41144255|NCT04751370|RADIATION|Radiation Therapy|Undergo short-course radiation therapy
41144256|NCT04751370|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
41144257|NCT04751370|PROCEDURE|Total Mesorectal Excision|Undergo TME
41144258|NCT06171126|DIETARY_SUPPLEMENT|Faeces|Faeces from donor selected based on European guidelines, compared to own faeces (placebo)
41304840|NCT06317857|OTHER|Centio Forte|A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.
41304841|NCT03476785|BEHAVIORAL|High intensity exercise|Subjects will perform high intensity aerobic exercise in addition to moderate intensity sessions 4-5 times per week.
40985368|NCT06228040|OTHER|preanaesthetic teleconsultation|Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
40985369|NCT06228040|OTHER|preanaesthetic classical physical consultation|Pre-anaesthetic classical consultation before teleconsultation implementation
40985370|NCT05218473|DIAGNOSTIC_TEST|Prolonged ECG monitoring|Using 14-day continuous electrocardiography patch monitoring to increase the detection rate of paroxysmal atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation.
40985371|NCT05218473|DIAGNOSTIC_TEST|Conventional procedure group|Using serial 12-lead electrocardiograms once daily for five days or conventional 24-h Holter monitoring to detect new atrial fibrillation
40985372|NCT03609515|OTHER|Patient-controlled admission|The patients with a contract for patient-controlled admissions may refer themselves to short inpatient stays when they feel the need, without needing an approval from a clinician. They will be accepted for admission if a patient-controlled bed is available in the ward. Patient-controlled admissions are limited to a length of 5 days and at least three weeks between such stays.
40985373|NCT00674453|DRUG|Lasofoxifene|Oral tablet, 0.25 mg, daily, 2 years
40985374|NCT00674453|OTHER|Placebo|Matching placebo tablet given once daily for 2 years
40985375|NCT00891644|OTHER|Case Management|"Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.~Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts."
40985376|NCT00891644|OTHER|Snowball sampling|"Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.~When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.~Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care."
40985377|NCT00891644|OTHER|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
40985378|NCT06468631|BEHAVIORAL|Complex Nursing Intervention|"Training prepared as an expert opinion on patient handover, starting to use the standard patient handover form for each patient, ensuring standardization in handover and supporting this improvement work by managers were expressed as interventions.~Training offered; It includes the importance of patient handover, how to ensure standardization and why we should use the standard patient handover form."
40985379|NCT05855005|DEVICE|DTC Hearing Aids|DTC hearing aid programmed to the individual participant.
40985380|NCT05428488|DRUG|Abatacept (W12-W48)|"The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study."
40985381|NCT05428488|DRUG|TNF Inhibitor (W12-W48)|In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
40985382|NCT05428488|DRUG|TNF Inhibitor (W0-W12)|All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
41144259|NCT06440200|BEHAVIORAL|group gamed-based activity|Participants in interventional group will play the active-type software with Switch game console which develops by Nintendo company. Team building, cooperation, cohesion, sense of belonging and sense of achieving will be emphasized.
41147024|NCT03733756|PROCEDURE|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
41304842|NCT03476785|BEHAVIORAL|Yoga|Subjects will perform strength and flexibility exercises.
41304843|NCT04801342|RADIATION|Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Unilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
41304844|NCT04801342|RADIATION|Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Bilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
41304845|NCT04801342|DRUG|Memantine Hydrochloride|Start from day 1 of WBRT orally for 24 weeks and escalating doses over the first 4 weeks
41304846|NCT05041959|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours
41304847|NCT05041959|OTHER|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) in the day leading up to the scan and smoke one cigarette of their own brand immediately prior to scanning.
41304848|NCT05745402|BEHAVIORAL|Mobility Checkup for older adults|The Mobility Checkup (MC) for older adults is a 45-minute preventative physical therapy visit designed to maintain mobility during aging. It has two parts, measurement (25 minutes) and education (20 minutes). The 5 standardized measures of physical performance in the MC are Walking speed, single leg stance time (balance), Five rep sit to stand (muscular endurance, transitions), 6-meter walk test (general endurance), and Timed up from floor test (transitions). Participants are provided education structured into 4 elements. 1. They are told their performance scores 2. They are shown how their performance scores on each of the measures compare to age and sex-referenced normative values 3. They are provided information about what their performance predicts about their health 4. They are referred to an appropriate provider if there was a health or safety concern during their MC or they are educated to follow the recommendations for physical activity that are recommended by the CDC.
41304849|NCT04659226|GENETIC|Blood sampling for microRNA testing|Blood samples will be collected and analyzed for the microRNA profile by means of microfluidic cards
41304850|NCT03073681|DEVICE|Survey|Patients will complete a survey describing their satisfaction with vision after cataract surgery that was performed at least 2 months prior to study enrollment.
41304851|NCT02166593|DRUG|Pravastatin40mg/Fenofibrate160mg|Pravafenix(Pravastatin40mg/Fenofibrate160mg)
40780818|NCT01321814|BEHAVIORAL|Cognitive behavioural therapy|6 sessions by licensed psychologist, including psychoeducation, exposure therapy, applied relaxation and behavioral activation.
40780819|NCT03759496|BIOLOGICAL|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass
40985383|NCT03921086|DRUG|Antihypertensive medication according to the study's algorithm|"Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm."
41144260|NCT06501365|OTHER|Post Intensive Care Transitions Rehabilitation and Family Support (PIC-TRFS)|"PIC-TRFS is a complex dyadic intervention consisting of 4 essential elements:~1. rehabilitation;~2. health and symptom management;~3. social support;~4. healthcare coordination~It is delivered by an interventionist team via telehealth from the time of randomization at discharge until 6 months after discharge. This Team partners with survivors, families, and the usual care team to deliver the active ingredients of PIC-TRFS."
41304852|NCT02166593|DRUG|Atorvastatin Sodium 10mg|Lipitor 10mg(Atorvastatin Sodium)
40780820|NCT04457024|OTHER|classification statistics|Without any intervention
40780821|NCT04754464|DIETARY_SUPPLEMENT|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8-Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in water
40780822|NCT04754464|DIETARY_SUPPLEMENT|microcrystalline cellulose|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in water
40780823|NCT03820076|OTHER|AZT-04|Staphylococcus epidermidis
40780824|NCT02668666|DRUG|Palbociclib|Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
40780825|NCT02668666|DRUG|Tamoxifen|Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
40780826|NCT02330614|OTHER|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
41144261|NCT06501365|OTHER|Enhanced Usual Care Control|Dyads randomized to the Control group will receive: (1) the Run-In; (2) an informational brochure on the post-Intensive Care Syndrome; (3) ongoing assessments on the same schedule as the PIC-TRFS intervention; (4) referral for urgent emergent issues identified during the study
41144262|NCT04967677|DIAGNOSTIC_TEST|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|At first, each person will be asked to fill in the questionnaire. Than he/she will be tested by the Nine Hole Peg Test, Purdue Pegboard Test and the Box and Block Test according to the Czech version of extended manuals for those tests. Audio recording of verbal instructions will be used.
41144263|NCT01690000|DRUG|Melatonin|1 or 3 mg of melatonin PO each night for 12 months
41144264|NCT00409903|DRUG|Eprosartan|
41144265|NCT02718456|BEHAVIORAL|Expedited CD4 testing|
41144266|NCT02718456|BEHAVIORAL|Supplemental peer counseling|
40985384|NCT02977988|BEHAVIORAL|Mindfulness Meditation|MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
40985385|NCT02977988|BEHAVIORAL|Brain and Recovery (B&R)|B\&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B\&R group will receive didactic education on the neurobiology of addiction. B\&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
40985386|NCT06280573|COMBINATION_PRODUCT|Wim Hoff method|breathing exercises, cold exposure, and meditation
40985387|NCT06071442|DRUG|Vemircopan|Participants will receive oral tablets of Vemircopan.
40985388|NCT06071442|DRUG|Rosuvastatin|Participants will receive oral coated tablets of Rosuvastatin.
40985389|NCT06071442|DRUG|Metformin|Participants will receive oral film-coated tablets of Metformin.
40985390|NCT06071442|DRUG|Levonorgestrel / Ethinyl Estradiol|Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol.
40985391|NCT06071442|DRUG|Carbamazepine|Participants will receive oral chewable tablets of Carbamazepine.
40985392|NCT05476341|DRUG|Bevacizumab injection|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
41144267|NCT05242874|DRUG|Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen|Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4.
41144268|NCT05242874|DRUG|Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen|Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4. Dexamethasone 12 mg on Day 1, followed by 8 mg on Days 2 to 4.
41463686|NCT04592419|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
40985393|NCT05476341|DRUG|Bevacizumab injection（Avastin）|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
41144269|NCT00426218|DRUG|ACZ885|
41144270|NCT03697018|OTHER|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
40780827|NCT02330614|OTHER|Nothing - control group|Only NEO-FFI test , data used as control
40985394|NCT01403246|DRUG|Lenalidomide; Chlorambucil|MTD of lenalidomide given in combination with chlorambucil
41144271|NCT03956771|BEHAVIORAL|Real neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of the participant him/herself. Participants receive feedback of their own brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortical activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
41144272|NCT03956771|BEHAVIORAL|Sham neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of other participant. Participants receive feedback of other participant' brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortex activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
41304853|NCT03826355|PROCEDURE|CO2 (carbon dioxide) laser vaporisation|CO2 (carbon dioxide) laser is used to vaporise the inner wall of the endometrioma
41463687|NCT04479748|DRUG|Dexamethasone|Treatment of pain and inflammation following ophthalmic surgery
41304854|NCT03826355|PROCEDURE|Stripping technique|Identification of a cleavage plane and perform the cystectomy removing all the wall of the endometrioma from the healthy ovarian tissue
40780828|NCT05166668|DRUG|Letrozole 2.5mg tablet|letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response
40780829|NCT01418521|DRUG|Balanced hydroxyethyl starch solution|Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
40780830|NCT01418521|DRUG|Ringer- albumin|Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
41304855|NCT06522581|DRUG|Citicoline Sodium|one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth
41463688|NCT04479748|DRUG|Prednisolone Acetate 1% Oph Susp|Topical steroid
41463689|NCT01149434|DRUG|JI-101|JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
40780831|NCT01554748|PROCEDURE|Total joint arthroplasty|
40780832|NCT00639951|BIOLOGICAL|A|20 vials up front in a Single Dose of Antivipmyn
40780833|NCT00639951|BIOLOGICAL|Antivipmyn ®|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
41304856|NCT02362087|OTHER|Quality of life and brief pain inventory|blood collection and quality of life questionnaires and a pain medication diary
40780835|NCT06060873|OTHER|Non-Interventional Study|Non-interventional study
40780836|NCT02282748|OTHER|No intervention|
40780837|NCT04879407|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
40780838|NCT04879407|DRUG|Warfarin|Any warfarin dispensing claim is used as the reference group
40780839|NCT06159907|DIAGNOSTIC_TEST|the diagnostic and prognostic value of PET/MRI and PET/CT with 18F-FDG in patients presenting with gynecological tumors|"For the evaluation of patients affected by endometrial cancer, the correlations between semi-quantitative PET parameters (SUVmax, SUVmean, MTV and TLG calculated at different SUVmax thresholds) and histological data, such as for example myometrial invasion, will be investigated. lymph node invasion, tumor grade and type, risk level, probability of mutation of the p53 gene, etc.~In addition to traditional imaging parameters we will also investigate the usefulness of radiomic features, i.e. quantitative data extracted from PET images (PET/CT or PET/MRI), in predicting and explaining histological data"
40780840|NCT04608708|OTHER|The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions|lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.
40780841|NCT04191226|DIAGNOSTIC_TEST|Multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
40780842|NCT02757807|BEHAVIORAL|Utilization of Serenita for Relaxation|Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
40780843|NCT05415904|OTHER|HANTA-NE|Observational cohort study
40780844|NCT03322982|BEHAVIORAL|Low-fat diet|less than 20% calories from fat daily
40780845|NCT01901536|BEHAVIORAL|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
40780846|NCT01214837|BIOLOGICAL|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
40780847|NCT01214837|BIOLOGICAL|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
41463690|NCT01149434|DRUG|Everolimus|Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
41463691|NCT03103828|BEHAVIORAL|Computer-Tailored Intervention|CTI will receive telephone contact at three time points: baseline, two, and four months. Each contact consists of an integrated assessment and intervention feedback report, using an expert system. Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report.
41304857|NCT05185752|PROCEDURE|SIFP Block Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by SIFP block: lateral and anterior cutaneous branches of the 2nd-6th Intercostal Nerves.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
41304858|NCT05185752|PROCEDURE|PECS II block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by PECS-II: Lateral Pectoral Nerve and Medial Pectoral Nerve Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
41304859|NCT05185752|PROCEDURE|ESP block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by ESP Block: dorsal and ventral branch block of the spinal nerves; white and gray communicating branches of the sympathetic nerves that go to the thoracic sympathetic chain.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
41304860|NCT00077805|DRUG|Enoxaparin sodium|
41304861|NCT02426554|DIETARY_SUPPLEMENT|DDU-supplement|DDU: Vitamin D, DHA, Uridine
41304862|NCT02426554|DIETARY_SUPPLEMENT|Placebo supplement|
40780848|NCT01214837|BIOLOGICAL|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
40780849|NCT03424395|OTHER|Personalized dietary and wellness program|Single arm intervention containing three periods: (1) run-in (control), (2) personalized advice/counseling and meals, (3) personalized advice/counseling only
40780850|NCT00146744|BIOLOGICAL|Mtb72F/AS02A|
40780851|NCT03626233|OTHER|collect of placenta, blood and urinary samples at delivery|collect of placenta, blood and urinary samples at delivery
40780852|NCT04534673|DRUG|Lambda 180 mcg S.C|Prefilled injection syringe of 180 microgram Pegylated interferon lambda, administered on day 0 and if needed on day 7
40780853|NCT06047743|OTHER|Alternating unilateral Isometric Handgrip Exercise|Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.
40780854|NCT06047743|OTHER|Dominant knee extension Isometric Exercise|Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
40780855|NCT02976181|DEVICE|IPG|Patient might require IPG device to be implanted under standard of care
40780856|NCT04250545|DRUG|Sapanisertib|Given PO
40780857|NCT04250545|DRUG|Telaglenastat Hydrochloride|Given PO
40780858|NCT02167789|DEVICE|Paradym CRT 8770|
40780859|NCT05188989|DRUG|TPN171H 2.5mg group|TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
40780860|NCT05188989|DRUG|TPN171H 5mg group|TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
40780861|NCT05188989|DRUG|TPN171H 10mg group|TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse
40780862|NCT05188989|DRUG|Placebo group|Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse
40780863|NCT03716648|DIAGNOSTIC_TEST|DISE-assisted titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
40780864|NCT03716648|DIAGNOSTIC_TEST|PSG-guided titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
40780865|NCT03716648|DEVICE|subjective titration|Titration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness.
40780866|NCT02493764|DRUG|Imipenem|Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
40780867|NCT02493764|DRUG|Relebactam|Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
40780868|NCT02493764|DRUG|Cilastatin|Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
40780869|NCT02493764|DRUG|Piperacillin|Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
40985395|NCT06481969|PROCEDURE|Conventional IVF|Conventional In Vitro Fertilization (IVF) procedure and standard assisted reproductive treatments.
41463692|NCT03103828|BEHAVIORAL|Motivational Interviewing|MET will receive telephone contact at three time points: baseline, two, and four months. They will undergo the assessment as described above receive and they will receive a second a telephone contact within two weeks of the assessment, which will consist of an MET session. If the surrogate has been enrolled in the study, the MET will be conducted with both the Veteran and the surrogate in a dyadic telephone interview. The goal of the interview is to strengthen commitment to engage in ACP and promote self-efficacy. The interviewer will also help the Veteran to reflect on the pros and cons of ACP engagement as elicited in the assessment process, to understand how to build on ACP behaviors already engaged in, and, if appropriate, to help the Veteran create a change plan for further ACP engagement.
41463693|NCT03103828|BEHAVIORAL|Motivational Enhancement Therapy|Participants assigned to CTI+MET will receive the CTI intervention at baseline, two months, and four months as described above. with a follow-up MET session as described above occurring within two weeks of each contact.
40780870|NCT02493764|DRUG|Tazobactam|Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
40780871|NCT02493764|DRUG|Linezolid|Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
40780872|NCT00519727|DRUG|ISIS 325568|"4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride"
40780873|NCT06341894|DRUG|Dalpiciclib|CDK4/6 inhibitor dalpiciclib, 100mg orally qd
40780874|NCT06341894|DRUG|Endocrine therapy|Fulvestrant/AI
40780875|NCT04273269|GENETIC|LYS-GM101|LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection
40780876|NCT00871078|DEVICE|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
40780877|NCT00871078|DEVICE|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
40780878|NCT05795907|DRUG|SAR443820|Capsule / Oral
40780879|NCT05795907|DRUG|Placebo|Matching Capsule / Oral
40780880|NCT02862093|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
40780881|NCT05820035|DEVICE|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
40780882|NCT04116684|DEVICE|Withings Digital Blood Pressure Monitor|This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
40780883|NCT05568329|DEVICE|Hearing Aid Program|"Each subject will listen to recordings of music processed by seven different hearing aid brands set to the default Speech in Quiet program and the default Music program. Recordings (hearing aid brand x program x music sample) will be randomized from trial to trial."
40780884|NCT00883155|DRUG|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
40780885|NCT00883155|DRUG|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
40780886|NCT01172028|DRUG|Taxotere (Docetaxel)|Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.
40780887|NCT01172028|DRUG|Alimta (Pemetrexed)|ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
40780888|NCT06297148|OTHER|Self-management|"Patients will have 3-5 sessions with a physiotherapist that include individually tailored education, and address physical, cognitive, and behavioral factors deemed as relevant according to the participant's concerns and challenges. Important aspects in this are: problem-solving, decision-making, resource utilization, therapeutic alliance and taking action (The 5 core skills of self-management). SMART goals and an activity plan between sessions will be used as an exposure to maintain, change, or create health behavior.~Participants will have access to study material, including exercise alternatives and a podcast."
40780889|NCT06297148|OTHER|Usual care|Usual care at the department consists of general information about the condition and advice on pain management and exercise. For further treatment, patients are referred to primary care. Participation in the study will not affect how this is conducted.
40780890|NCT03732989|DEVICE|Interactive toy prototype|The interactive toy prototype takes the form of a hand-crafted plush toy, which was designed to support in-the-moment calming down strategies. The interaction relies on a number of sensors embedded in the 'creature' that register haptic interactions with the toy. In addition, a small vibration motor is used to indicate the creature's state by mimicking a frantic 'heartbeat'. If the creature is calming down in response to the child's touching of the sensors, the heartbeat slows down and eventually turns into happy purring (cf. paper linked below for more details about the design process).
40780891|NCT03732989|DEVICE|Non-interactive toy prototype|This toy is the same as the interactive one, but with the interactivity features (haptic feedback) turned off so that it looks and feels like a regular, hand-crafted plush toy.
41144273|NCT06476496|PROCEDURE|Acupuncture|A licensed acupuncturist will insert sterile disposable acupuncture needles in the selected body and ear acupoints aiming to alleviate long COVID related pain symptoms. Needles will be removed after 20 minutes of retention. After all the needles are removed, the acupuncturist will insert Pyonex press tack needles (0.3mm) in the participants' left ears and suggest the participants retain them in their ears for up to 5 days.
41147025|NCT03733756|PROCEDURE|POEM involving longitudinal muscle|participants are operated POEM involving both circular and longitudinal muscle
41304863|NCT04044534|DRUG|Intranasal insulin|Subjects in this arm will receive intranasal insulin (80 IU per day).
41304864|NCT04044534|DRUG|Placebo|Subjects in this arm will receive placebo.
41304865|NCT00313807|DRUG|Amino Acid|7% amino acid infusion
41304866|NCT00313807|DRUG|Placebo|0.9% Saline Infusion
41304867|NCT04332029|BEHAVIORAL|CBT + WGP + CM|The intervention will be implemented in 8-week group-based sessions and includes: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating, and 3) a Contingency Management procedure reinforcing smoking abstinence. This component will consist on providing vouchers to reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
41304868|NCT04332029|BEHAVIORAL|CBT + WGP|The intervention will be implemented in 8-week group-based sessions and will include only the first two components of the experimental intervention: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating.
41304869|NCT02260102|DRUG|Temocillin|Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations \[no change due to enrollment in the study\]).
41304870|NCT01119274|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
40780892|NCT00025415|DRUG|imatinib mesylate|Given orally
41304871|NCT01119274|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
41304872|NCT00909766|DRUG|BMS-830216|Capsules, Oral, 30 mg, once daily, 28 days
41304873|NCT00909766|DRUG|BMS-830216|Capsules, Oral, 100 mg, once daily, 28 days
41304874|NCT00909766|DRUG|BMS-830216|Capsules, oral, 300 mg, once daily, 28 days
41463694|NCT06086496|DEVICE|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
40780893|NCT00025415|OTHER|pharmacological study|Correlative studies
40780894|NCT01368614|DEVICE|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
40780895|NCT01368614|DEVICE|Respironics OnmiLab BiPAP S mode|Currently cleared Non-Invasive Ventilation (NIV) therapy modality
40780896|NCT01368614|DEVICE|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
40780897|NCT03767049|OTHER|Colection of clinical data|Colection of clinical data
40780898|NCT03913351|BEHAVIORAL|Lifestyle modification|The program consists of education on glycemic index, balanced diet, interpretation of food labels, food exchanges, healthy eating out techniques and healthy cooking methods.
40780899|NCT02665325|DRUG|TSH-suppressive therapy|Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
40780900|NCT01276626|DIETARY_SUPPLEMENT|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
40780901|NCT01276626|OTHER|Maltodextrin|Powder containing only maltodextrin
41147026|NCT02889172|BEHAVIORAL|Problem Solving Therapy|It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
41147027|NCT00003934|DRUG|tretinoin|Given orally
41147028|NCT00003934|DRUG|daunorubicin hydrochloride|Given IV
40780902|NCT03393104|BEHAVIORAL|Motor Control Exercise|Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.
40780903|NCT03393104|BEHAVIORAL|Patient Education|Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
40780904|NCT06019507|BIOLOGICAL|TCD601|Investigational Product
40780905|NCT06019507|BIOLOGICAL|Cyclophosphamide|Conditioning Regimen
40780906|NCT06019507|DRUG|TAC|Immunosuppression Therapy
40780907|NCT06019507|DRUG|MMF|Immunosuppression Therapy
40780908|NCT06019507|DRUG|Corticosteroids|Immunosuppression Therapy
40780909|NCT00216333|DRUG|combined fixed dose combination|
40780910|NCT00400686|BIOLOGICAL|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
41147029|NCT00003934|DRUG|cytarabine|Given IV
40780911|NCT03064932|OTHER|Controlled feeding diet|Average American diet with different levels of spices
40780912|NCT02782910|DEVICE|Smartphone-Based Ambulatory Assessment, Feedback via physician|Participants in the experimental condition SBAA+ will be contacted by their treating physician, once the predefined threshold for Smartphone activity is exceeded.
40780913|NCT02835469|DRUG|Menotrophin|
40780914|NCT01808378|DRUG|Expanded adipose-derived stem cells|Local injection of autologousadipose derived stem cells
40780915|NCT03946969|DRUG|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for two cycles.
40780916|NCT03946969|DRUG|Liposomal Paclitaxel + Cisplatin + S-1|Liposomal Paclitaxel (135mg/m2), ivd, d1 + Cisplatin (25mg/m2), ivd, d1-3 + S-1 capsule (40mg), po, d1-14, repeated every 3 weeks for two cycles.
40780917|NCT01987466|BIOLOGICAL|Serum NGAL level|Investigators will check the plasma NGAL level after 4 hour from resuscitation. The plasma NGAL level is measured in ng/mg
41147030|NCT00003934|DRUG|mercaptopurine|Given IV
41147031|NCT00003934|DRUG|methotrexate|Given IV
41147032|NCT00003934|DRUG|arsenic trioxide|Given IV
40985396|NCT06481969|PROCEDURE|Lower abdominal liposuction and preparation of SVF|After lower abdominal liposuction (the liposuction volume is about 100 ml), the preparation and quality inspection of SVF will be completed by a laboratory with good manufacturing practice-approved facilities immediately. The adipose tissue will be cut into pieces of about 1mm3, and the equal volume of 0.1% collagenase I will be added to digest the adipose tissue. The digestion will be terminated after 40 minutes, followed by isolation, filtration, centrifugation, resuspension and dilution to obtain the SVF suspension. The test items, including bacteria, fungi, viruses and endotoxin, will be tested, and the expression of SVF surface markers, including CD45, CD34, CD31, CD11b, CD44, CD73, CD105 and CD90, will be detected by flow cytometry to ensure the quality of the SVF suspension. After about 4 hours of quality control and detection, the SVF suspension will be transported to the operating room on ice in a sealed incubator.
40985397|NCT06481969|PROCEDURE|Ovarian injection|Under ultrasound guidance, the SVF suspension will be injected into patients' bilateral ovaries. SVF with a total amount of (1\~2)×107 cells from autologous fat tissue will be transplanted into each side of ovary. There are 3 injection points on each side of ovary, and 330±10μl SVF suspension will be administered at each point. The administration volume of each ovary will be 1ml in total. After injection, the patients will be required to lie flat for 2 hours to observe whether there would be adverse events.
40985398|NCT02223273|BEHAVIORAL|Multifaceted Strategy|"1. Simulation Based Team Training~2. Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions~3. Reminders -~4. Check lists - decision support algorithm~5. Distribution of educational materials: guidelines and recommendations for best practices"
40985399|NCT03020407|PROCEDURE|IVC Ultrasound-guided|IVC is identified in longitudinal section in the subcostal area of a patient using the curvilinear probe of standard ultrasound. The selected area of IVC diameter measurement is set at 2 centimeters distal to the confluence of hepatic vein by M-mode coupled by two-dimensional mode on frozen screen images using the Sonosite® X-porte.
40985400|NCT03020407|DRUG|Antibiotics|Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
40985401|NCT03020407|DRUG|Vasopressor|The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
41144274|NCT00488605|DRUG|Prednisone, Vinblastin, 6-mercaptopuroine|Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
41463695|NCT05377294|OTHER|Method of Levels therapy|MOL therapy aims to help people develop awareness of their personal goals so they can identify incompatibilities and find potential solutions. In MOL, the therapist uses a specific style to help people focus attention on the problem at hand, long enough to consider the issues from different perspectives, including reflection on the associated emotions. This process is usually very experiential and requires the client to be actively engaged in controlling the focus of the session and decision making.
41144275|NCT00488605|DRUG|Leucovorin, Methotrexate, Vinblastine, Prednisone|Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
41304875|NCT00909766|DRUG|BMS-830216|Capsules, oral, 600 mg, once daily 28 days
41304876|NCT00909766|DRUG|BMS-830216|Capsules, oral, 1200 mg, once daily, 28 days
41463696|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose in the fasting state.
41463697|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
40985402|NCT01570374|BEHAVIORAL|Internet-based cognitive behavioral therapy (iCBT)|9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
41304877|NCT00909766|DRUG|BMS-830216|Capsules, Oral, to be determined, once daily, 28 days
41304878|NCT00909766|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
41304879|NCT00788515|DRUG|Volinanserin (M100907)|2 mg tablets QD
41304880|NCT00788515|DRUG|Lormetazepam|1 mg tablets (overencapsulated) QD
41304881|NCT02778516|DIETARY_SUPPLEMENT|Sodium Restriction|
41463698|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.
41463699|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
41463700|NCT05367635|DRUG|SKB315 for injection|SKB315 for injection is an Antibody Drug Conjugates (ADC) drug targeting Claudin18.2. The strength of SKB315 is 200 mg/vial.
41463701|NCT06228248|OTHER|metagenomics|Feces used for metagenomic testing
41463702|NCT03180528|DRUG|Remetinostat|Applied topically under bandage occlusion
41463703|NCT00875082|DRUG|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
41463704|NCT00875082|DRUG|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
41463705|NCT02937506|DRUG|Propofol|The intervention is to use propofol as anesthesia during a colonoscopy.
41463706|NCT02937506|DRUG|Fentanyl Plus Midazolam|The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
41304882|NCT01443455|BEHAVIORAL|videodance|Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
40780918|NCT03242226|DEVICE|two spectacles|single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision
40780919|NCT03242226|DEVICE|single vision spectacles|Wear single vision spectacle only
40780920|NCT02908178|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
40780921|NCT03766984|DRUG|Diclofenac sodium 25 mg|Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
40780922|NCT03766984|DRUG|Tramadol hydrochloride 25 mg|Tramadol hydrochloride 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
40780923|NCT03766984|DRUG|Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg|Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)
40780924|NCT01510093|DRUG|Insulin Aspart 100 IE/ml|1.5 IE/hour/subject/visit. Each vist takes 10 hours
40780925|NCT00797719|OTHER|Pre-op RT +/- chemotherapy|Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
40780926|NCT03200470|OTHER|No intervention: sample collection study|Sample collection and collection of laboratory values
40780927|NCT04196530|DRUG|BDB001|BDB001 is an immunotherapy agent.
41144276|NCT00866541|DEVICE|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
41304883|NCT01443455|BEHAVIORAL|Brisk Walking|The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
40780928|NCT04196530|DRUG|Atezolizumab|Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
40780929|NCT03261830|DRUG|Cefazolin|Primary intervention
40780930|NCT03261830|DRUG|Clindamycin|For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.
40780931|NCT03261830|DRUG|Saline|Placebo Intervention
40780932|NCT05771532|BEHAVIORAL|Received the GS-SHEP|"The experimental group (n=33) received the GS-SHEP (a 10-15-minute individual sexual health education and a sexual health pamphlet). GS-SHEP effectiveness was examined using a self-report instrument to measure background information and three dependent variables: sexual knowledge, sexual attitudes, and sexual self-efficacy."
40780933|NCT01555060|DIETARY_SUPPLEMENT|ferrous gluconate|daily capsule of ferrous gluconate containing 38 mg of elemental iron
40780934|NCT04372303|BEHAVIORAL|Compassion Fatigue Resiliency Program (CFRP)|The purpose of Compassion Fatigue Resiliency Program (CFRP) is to provide oncology-hematology nurses with knowledge and skills that will increase their level of resilience by helping them recognize compassion fatigue, cope with its consequences and work effectively.
40985403|NCT01853046|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
40985404|NCT03472404|PROCEDURE|Internal Brace augmented ankle Ligament reconstruction|internal brace augmented ankle ligament reconstruction and an accelerated revalidation protocol.
40780937|NCT00639457|DRUG|Pioglitazone|Oral 30mg/day for 16 weeks
40780938|NCT00639457|BEHAVIORAL|Exercise training|Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks
40780939|NCT03522064|DRUG|Testosterone Enanthate 100 MG/ML Injectable Solution|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
40985405|NCT03472404|PROCEDURE|Brostrom-Gould ankle Ligament reconstruction|Brostrom-Gould and standard revalidation including 6 weeks immobilisation.
40985406|NCT01946425|BIOLOGICAL|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
40780940|NCT03522064|DRUG|Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
40780941|NCT00387088|DEVICE|Respimat|
40780942|NCT00387088|DRUG|Tiotropium|
40780943|NCT01093131|OTHER|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
41304884|NCT01443455|BEHAVIORAL|delayed entry control|"Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.~--------------------------------------------------------------------------------"
41304885|NCT00218036|DRUG|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
41144277|NCT06505525|PROCEDURE|Extra-articular reconstruction with the Anterolateral Ligament|Anatomical ACL reconstruction combined with extra-articular reconstruction with the Anterolateral Ligament
41144278|NCT02716272|DRUG|Nivolumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
41304886|NCT00218036|DRUG|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
41304887|NCT00218036|DRUG|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
41304888|NCT00218036|DRUG|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
41463707|NCT05696704|OTHER|Behavioral: Mindfulness Based Cognitive Therapy|Individual tele-therapy 12 to 16 weeks
41463708|NCT05696704|OTHER|Behavioral: Behavior Activation|Individual therapy 12 to 16 weeks
40780944|NCT01093131|DRUG|Oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
41144279|NCT02716272|DRUG|Nivolumab + Ipilimumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
41144280|NCT00458510|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
41304889|NCT00218036|DRUG|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
41304890|NCT00002288|DRUG|Zidovudine|
41463709|NCT03365063|OTHER|Active Knowledge Translation|"1. Integration of the KFRE in the CPCSSN DPT - The DPT will report the output from the KFRE for all patients with CKD Stages G3-G5 from the clinic sites. The risk output will include interpretation and automated categorized risk of progression to kidney failure, and will recommend actions based on the KFRE risk based care pathway.~2. Audit and Feedback - Providers at CPCSSN clinics receive sentinel feedback reports on a panel of chronic conditions and quality improvement targets. The investigators will add CKD to the feedback report for the intervention sites, and provide detailed feedback on the practices' risk profile.~3. Medical Detailing - The intervention CPCSSN clinics will receive a standardized presentation to clinic staff by the principal investigator, who will provide the evidence for the accuracy of the KFRE and guidance on implementation of a risk based treatment pathway, as well as describe the supporting visual aids."
40780945|NCT01093131|OTHER|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
40780946|NCT01093131|DRUG|Intravenous sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
40780947|NCT00237042|BEHAVIORAL|Self Management|Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.
40780948|NCT00237042|BEHAVIORAL|Targeted Self Management|Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.
40780949|NCT00237042|DRUG|20 mcg ethinyl estradiol and 100 mcg levonorgestrel|Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
40780950|NCT02412150|DRUG|Desflurane|Anesthesia is maintained with desflurane
40985407|NCT01946425|BIOLOGICAL|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
40985408|NCT03012958|OTHER|Lung clearance index (LCI)|LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
40985409|NCT03698747|DEVICE|McDESPOT|myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence
40985410|NCT02416440|OTHER|blood sample|blood sample
40985411|NCT05394987|DEVICE|Spectacles|"Prescription of refractive error correction in spectacles. Refractive error to be determined as part of standard optometric eye exam (performed by registered optometrist).~Guidelines for optical correction for the prescription of the study spectacles (based on Pediatric Eye Disease Investigator Group \[PEDIG\] amblyopia clinical trial protocols): Hypermetropia: not undercorrected by \>+1.50D spherical equivalent and the reduction in plus sphere must be identical between the two eyes. Anisometropia: full correction of the anisometropic difference. Astigmatism: cylinder power in each eye should be within ≤±0.50D of fully correcting the astigmatism for each eye. If cylinder power is ≥1.00D, the prescribed axis in both eyes should be within ≤±6 deg of the cycloplegic refraction axis.~Appropriate refractive error correction will be prescribed. Participants will be instructed to wear the optical correction full-time (i.e., \>50% of waking hours) for the duration of the study."
40985412|NCT06197815|BEHAVIORAL|The assistance type during ERCP|The senior trainer guides the trainees during ERCP procedure outside the operating room using communication equipment and the screen displaying an endoscopic view.
40985413|NCT06221514|OTHER|Core Strengthening Programs|"The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions."
40985414|NCT06221514|OTHER|Shoulder Strengthening Programs|"The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions."
40985415|NCT05872711|OTHER|Low carbohydrate diet|"In order to maintain equal intensity of treatment, each patient will get a cooking workshop and received a personalized diet regime at baseline, based on the randomly assigned diet. Format and quality of the materials are similar.~All diet plans are individualized and matched for energy intake personally . Participants will meet individually with the dietitian for diet instruction and support at week 1,2,4,7,10,12 and thereafter at 24 weeks for a total of seven frontal meetings. Twice during the first 12 weeks the dietician will conduct 10-15-minute motivational telephone calls with all the participants."
41463710|NCT04688372|OTHER|Surge Index|See study description above
40780951|NCT02412150|DRUG|Remifentanil|Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
40780952|NCT02412150|PROCEDURE|Thyroidectomy|The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
40780953|NCT02412150|OTHER|Vital signs|"Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.~And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed."
40985416|NCT05569187|DRUG|Ribociclib|Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
40780954|NCT02412150|BEHAVIORAL|Cough reflex|During recovery from anesthesia at operation room, cough reflex is measured and rated. \[Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)\]
40780955|NCT02412150|BEHAVIORAL|Ramsay Sedation Scale|"When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.~1. Awake Patient anxious and agitated or restless or both!~2. Patient cooperative, oriented and tranquil!~3. Patient responds to commands only!~4. Asleep A brisk response to a light glabellar tap or loud auditory stimulus!~5. A sluggish response to a light glabellar tap or loud auditory stimulus!~6. No response to a light glabellar tap or loud auditory stimulus"
40985417|NCT05633121|PROCEDURE|Rheopheresis|Technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications.
40985418|NCT05635240|OTHER|Interview / questionnaires|At each of the 4 visits, the participant will have to answer several questions regarding trauma-related data, employment and sport practice.
40985419|NCT06110429|DRUG|Lactate, Sodium|Isovolemic and osmotic infusion Comparison of osmotic agent
40985420|NCT06110429|DRUG|Hypertonic saline|Isovolemic and osmotic infusion Comparison of osmotic agent
40985421|NCT00220402|DRUG|SPM 907|
41463711|NCT05373667|PROCEDURE|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) - High Frequency at 10 kHz
40985422|NCT00373867|BEHAVIORAL|Standard physical therapy|Treatment-based classification physical therapy
40985423|NCT00373867|BEHAVIORAL|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
40985424|NCT00373867|OTHER|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
40985425|NCT05069766|OTHER|BioXmark™|During a scheduled outpatient gastroscopy, the tumor margins will be endoscopically marked by BioXmark™. BioXmark™ will be implanted at the most proximal margin of the tumor and 5 cm proximally of the tumor border.
40985426|NCT03498625|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy for CD patients in clinical remission
40985427|NCT04097808|DIETARY_SUPPLEMENT|collagen peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
41144281|NCT06493448|OTHER|observation|This is an observational study.
41463712|NCT03065699|DEVICE|DIALIVE Liver Dialysis Device|ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
40985428|NCT04443504|BEHAVIORAL|The Connected Family Series|The intervention is an online, self-paced post-adoption family intervention that occurs over a 4-week period to support adoptive families post-adoption.
40985429|NCT05149846|PROCEDURE|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
40985430|NCT05517382|OTHER|supportED|suicide prevention videogame
40985431|NCT05517382|OTHER|Control|non-health related videogame
40985432|NCT03686384|DRUG|SVT-15652|1 vial twice daily
40985433|NCT03686384|DRUG|Placebo|1 vial twice daily
40985434|NCT06209892|PROCEDURE|Extended anticoagulation|This study plan will extend the duration of rivaroxaban 20mg in the experimental group to 12 months. The regular anticoagulation group will take the drug for 6 months
40985435|NCT00421187|DRUG|Liposomal amphotericin B (AmBisome®)|
40985436|NCT00421187|DRUG|Liposomal amphotericin B (AmBisome®)|
40985437|NCT03967392|DRUG|Xylocaine|TREATMENT
40985438|NCT04416087|OTHER|Exercise|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
41144282|NCT03478306|DRUG|Melatonin 4 mg Tablet|Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
41144283|NCT05764395|DRUG|Rigosertib|Given by mouth
40780956|NCT02412150|OTHER|Extubation time and Recovery time|"The time from discontinuing anesthetic gas to endotracheal extubation is measured.~And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured."
40985439|NCT05109988|BEHAVIORAL|Breastfeeding telephone support|The intervention consists of four weekly 20-30 minutes telephone-administered counselling sessions on breastfeeding, delivered individually in the first month postpartum for mothers and fathers.
40985440|NCT05020392|DRUG|BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells|BTK inhibitor from enrollment to more than 90 days after CAR-T-CD19 infusion. Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
40985441|NCT05020392|DRUG|Fludarabine-based chemotherapy + CAR-T-CD19 Cells|Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
40985442|NCT02044744|BEHAVIORAL|Physical activity referral|Provision of a primary care referral to at least one community-based physical activity program that is a good match for the participant's needs and preferences and patient follow-up on enrollment.
41144284|NCT05764395|BIOLOGICAL|Pembrolizumab|Given by IV
41463713|NCT02415933|BEHAVIORAL|Trickle Up|"Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:~* Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;~* Provision of seed grants to assist in business start-ups through microfinance loans;~* One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;~* Trainings on financial planning and household livelihoods."
40780957|NCT02412150|BEHAVIORAL|Visual analogue scale|The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
40780958|NCT02412150|OTHER|Postoperative bleeding|The amount of postoperative bleeding which is collected in the barovac is measured.
40780959|NCT02412150|OTHER|Postoperative complications|Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
40985443|NCT05383560|BIOLOGICAL|mRNA-1273.214 Vaccine|Omicron Variant-Matched Vaccine
40985444|NCT05383560|BIOLOGICAL|MRNA-1273 Vaccine|Moderna's commercial COVID-19 Vaccine
41144285|NCT05764395|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40985445|NCT05383560|BIOLOGICAL|Placebo|Normal Saline for injection
40985446|NCT05383560|BIOLOGICAL|MRNA-1273.222 Vaccine|Moderna's commercial COVID-19 Vaccine
41144286|NCT05764395|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41144287|NCT05764395|PROCEDURE|Biopsy|Undergo tissue biopsy
41144288|NCT01759459|DRUG|Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
40780960|NCT02412150|OTHER|Time to remove drainage and duration of hospital staying|The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
40780961|NCT02412150|DRUG|Dexmedetomidine|Dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr) before end of surgery as experimental intervention
40780962|NCT02412150|DRUG|Normal saline|Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
40780963|NCT04858581|DIAGNOSTIC_TEST|Virological and serological tests|Survey, RT-PCR test and blood test
40780964|NCT01196195|DRUG|Kaletra dosed once daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
40780965|NCT01196195|DRUG|kaletra dosed twice daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
40780966|NCT01478984|PROCEDURE|One-Stage group|Patients randomized to One-Stage group were completely revascularizated in one time PCI,
40780967|NCT01478984|PROCEDURE|Multi-Staged group|patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
40780968|NCT06086743|OTHER|Experimental Group|This group will perform 10 minutes of same warm up exercises. After warm up participants will perform 4 resistance exercises with induced EMS. The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises. the intensity of EMS would be 100A and it would remain same throughout training session. The current administered would be galvanic current. Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
40780969|NCT06086743|OTHER|Control Group|Group B (Control group)will perform 10 minutes of same warm up exercises (Arm swings, jogging on the spot, Walks on treadmill). Group B will perform same 4 resistance exercises without EMS. These 4 exercises include Bicep curls, Triceps dips, Quadriceps chair and squats.The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises and the participants will be instructed, not to perform any kind of exercise during this period.Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
40780970|NCT05988918|DRUG|ESK981|160 mg, PO, Once daily 5 days on and 2 days off
40780971|NCT05698303|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
40780972|NCT02566863|DRUG|Dexmedetomidine|1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
40985447|NCT00726076|BEHAVIORAL|WebEase|"Computer-based epilepsy self-management program~The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment"
40985448|NCT00726076|BEHAVIORAL|WebEase|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
40985449|NCT04541576|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
41144289|NCT01759459|DRUG|Buffered Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
41144290|NCT01759459|DRUG|Bacteriostatic Normal Saline|The medication will be administered immediately prior to receiving peripheral IV catheter placement
41144291|NCT03385226|DRUG|Pembrolizumab|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.
41144292|NCT03385226|RADIATION|Radiotherapy|12Gy in 3 fractions
41144293|NCT02256553|BIOLOGICAL|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
41304891|NCT05381376|DIAGNOSTIC_TEST|Hysteroscopy|Hysteroscopy for CSGE, AFS, and endometrial receptivity assessment
40780973|NCT03968874|DEVICE|Light box therapy|The intervention is sitting in front of a lightbox for 1 hour in the morning upon waking up.
40780974|NCT03968874|DEVICE|Negative Ion Generator|The intervention is sitting in front of a modified negative ion generator for 1 hour in the morning upon waking up.
40780975|NCT00512564|OTHER|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
40780976|NCT04391920|DEVICE|CytoSorb 300 mL device|CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.
40780977|NCT04624984|DRUG|PD-1 inhibitor|PD-1 Inhibitor, intravenous drip, d1.
41144294|NCT02256553|BIOLOGICAL|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
41144295|NCT02256553|DRUG|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
41147033|NCT02707302|DEVICE|Iodophor-impregnated adhesive drapes group|Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.
41147034|NCT02707302|PROCEDURE|Iodophor-free adhesive drapes group|Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
41304892|NCT05381376|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography for Uterus size and endometrial thickness
40780978|NCT04624984|DRUG|PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome|PD-1 Inhibitor, intravenous drip, d1; Gemcitabine, 1000mg/m2, intravenous drip, d1,d8; Vinorelbine, 50mg/m2, PO, d1,d8; Doxorubicin Liposome, 30mg/m2, intravenous drip, d1;
40780979|NCT06131658|OTHER|Functional motor control excercise|This include functional motor control thrice a week for six weeks
40780980|NCT06131658|OTHER|convectional excercise|This include convectional exercise thrice a week for six weeks
40985450|NCT06366867|DEVICE|VibrantMinds|VibrantMindVibrantMinds offers five tablet games targeting cognitive stimulation in older adults: Whack-A-Mole, Word Search, Bejeweled, Mahjong Solitaire, Memory Game, and Glenrose Grocery Game (GGG). These games vary from nostalgic (e.g., Mahjong Solitaire) to leisure-oriented (e.g., Bejeweled), aiming to blend fun with cognitive exercises. Especially designed for ease of use, they cater to older individuals, including those with dementia, gradually increasing in difficulty to match player skill levels. The GGG stands out by integrating game design with everyday cognitive tasks, offering a practical simulation of grocery shopping. Developed with older adult input, VibrantMinds aims to enhance cognitive health in seniors through engaging, meaningful gameplay, supporting its clinical trial's focus on cognitive wellness in the aging.
41144296|NCT01872104|PROCEDURE|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
41304893|NCT01425073|OTHER|Discontinue TMP/SMZ prophylaxis|Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
41304894|NCT01880255|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
41304895|NCT02072317|DRUG|taxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
40780981|NCT04252209|OTHER|natural herbs of coconut, aloe vera, and pepperint|mixture of herbal oils of coconut, peppermint, aloe vera
40985451|NCT00390325|DRUG|Sorafenib Tosylate|Given PO
40780982|NCT04252209|OTHER|carboxy methyl cellulose|a moisturizing gel contained 3%carboxy methyl cellulose, 3% peppermint essential oil, 10% propylene glycol, 0.1% potassium sorbate, and water up to 100%.
40780983|NCT04162106|DEVICE|Smoke management during laparoscopic cholecystectomy using the Ultravision™ System|The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.
40780984|NCT04162106|DEVICE|Smoke management during laparoscopic cholecystectomy using the Airseal® iFS|The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.
40780985|NCT02300233|DRUG|Volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
40780986|NCT02300233|DRUG|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
40780987|NCT05170971|OTHER|fecal microbiota transplantation|The fecal bacteria were transplanted once every 5 days for a total of 4 times
41304896|NCT02072317|DRUG|taxol|taxol 135 mg/m2, every three weeks for a cycle
40780988|NCT04444089|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound with a curvilinear probe (DDED) is performed in all patients in a supine position on the lateral wall of the chest at approximately the level of the lower ribs using an ultrasound probe at a frequency of 4-12 MHz (AcusonX300, Siemens Korea, Seoul, South Korea). The mean number of B-lines detected on the ultrasound image and the percentage of patients who showed B-lines on their images were recorded. The mean of three measurements is used. Inter-observer variability is estimated to be 0.766 (95% confidence interval 0.675-0.847).
40780989|NCT01641484|PROCEDURE|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
40780990|NCT05187299|OTHER|observer tool|The observer tool is paper-based and is divided in columns (each column filled out for a dyad observed) with lines representing the above-described steps of learning and presented with visual incremental actions to be performed. The observer tool will only be used to reinforce learning and will not be used for summative evaluation. Instructors have already been involved in previous simulation studies performed in our center, and especially those in which an observer tool has been assessed (one study published, two manuscripts in preparation).
41304897|NCT05974085|DRUG|Selinexor+RCHOP|XPO-1 inhibitor selinexor in combination with RCHOP
41304898|NCT00883480|DRUG|Docetaxel|Docetaxel 75 mg/day 1 x 4 cycles
41304899|NCT00883480|DRUG|Cisplatin|Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
41463714|NCT02415933|BEHAVIORAL|Trickle Up Plus|"In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).~Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage)."
41304900|NCT00883480|DRUG|Gemcitabine|"Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles"
41304901|NCT00883480|DRUG|Erlotinib|Erlotinib 150 mg/day x 21 days
40780991|NCT05227976|BEHAVIORAL|Patient education (Theory)|"Theory/Lectures (1h/week)~Interventions given once weekly for 10 weeks."
40780992|NCT05227976|BEHAVIORAL|Physical training|"Physical training group (1 hour/week)~Interventions given once weekly for 10 weeks."
40780993|NCT05227976|BEHAVIORAL|Mindfulness and medical yoga in group|"Mindfulness/medical yoga in group (1hour/week)~Interventions given once weekly for 10 weeks."
40780994|NCT01078727|DEVICE|A custom-made constant temperature thermal stimulation system (FIRSTEK, Model-B401L, B-300, local company, Taiwan).|The subjects meeting our criteria will be randomly assigned to either the experimental group or the control group. First stage (3 months after onset), the subjects in the experimental group will receive an upper extremity Thermal Stimulation (TS) protocol for 30 minutes (3 times a week for 8 weeks). The subjects in the control group will receive a lower extremity TS protocol.
40780995|NCT00611390|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the larynx.
40780996|NCT00611390|DIETARY_SUPPLEMENT|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the larynx.
40780997|NCT04699721|DRUG|nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5|3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
40780998|NCT01193101|DRUG|LCZ696|LCZ696
40780999|NCT01193101|DRUG|Placebo|matching placebo to LCZ696
41304902|NCT05903300|OTHER|Surveys and Questionnaires|The intervention consists of completing the MIPIM-P, QuickDash, and Brief Pain Inventory questionnaires.
41304903|NCT06146712|OTHER|Asutra's 'Dream the night away' nighttime lotion|Product contains Water (Aqua), Magnesium Chloride, Dimethyl Sulfone (MSM), Prunus Amygdalus Dulcis (Sweet Almond) Oil, Butyrospermum Parkii (Shea Butter), Sodium Lactate, Cetearyl Alcohol, Glyceryl Stearate Citrate, Glycerin, Undecane, Cetyl Palmitate, Polyglyceryl-3 Diisostearate, Pentylene Glycol, Glyceryl Stearate, Magnesium Sulfate, Melatonin, Tridecane, Potassium Chloride, Sodium Chloride, Calcium Chloride, Tocopheryl Acetate, Xanthan Gum, Hydroxyacetophenone, Sodium Hydroxide, Cymbopogon Flexuosus (East-Indian Lemongrass) Oil, Citral, Geraniol, Linalool
41463715|NCT00731991|OTHER|ART|ART to the levator scapulae.
41463716|NCT00731991|OTHER|PNF|PNF to the levator scapulae.
41463717|NCT00731991|OTHER|No Treatment|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
41463718|NCT00110851|DRUG|rosiglitazone|
41463719|NCT00110851|DRUG|metformin|
41463720|NCT00110851|DRUG|PN2034|
40781000|NCT05378113|DRUG|Ondansetron|Ondansetron (Zofran) is a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist commonly used to treat postoperative nausea and vomiting.
40781001|NCT05378113|DRUG|Lidocaine|Lidocaine is a local anesthetic agent used intravenously prior to the propofol injection. Currently the standard of care to help decrease the severity of pain in the injection site, a common side effect of propofol.
40781002|NCT04257019|OTHER|Lavender oil|Inhalation of Lavender oil
40781003|NCT04257019|OTHER|Almond oil|Inhalation of Almond oil
40985452|NCT00462761|DRUG|AC220|Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
40985453|NCT04139187|OTHER|Combined training with power and strength exercises|"The training will be compose by power and strength exercises and divided in two days. One day with the exercises: vertical jumps, box jumps, sit-ups, back-extension and guided squat. The second with half squat jumps, high straight jumps, bounding jumps, drop jumps and sprint. Both days will be started with warm up on treadmill running lasting 5 minutes at 6.5-7.5 km/h.~The training protocol includes 20 sessions with 2 sessions per week during 10 weeks (2 weeks to adaptation and others 8 to training with progression of load after 4 weeks)."
40985454|NCT03863223|DRUG|Pyrotinib, Trastuzumab, Docetaxel|Pyrotinib 400mg orally daily until progressive disease
40781004|NCT04257019|OTHER|Water|Inhalation of water
40781005|NCT04383093|DRUG|Tadalafil 5mg|Combination therapy of daily tadalafil plus tamsulosin
40781006|NCT02606630|DRUG|ABT-555|ABT-555 will be administered on Visit 4 in Part 2 only
40985455|NCT03863223|DRUG|Placebo, Trastuzumab, Docetaxel|Placebo 400mg orally daily until progressive disease
41304904|NCT01294735|DRUG|MK-4827|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
40781007|NCT06315933|PROCEDURE|General anesthesia|General anesthesia inluding inhaled and intravenous
40985456|NCT06250985|OTHER|Timing of reimplantation|Patients will be rendomized 1:1 by computer to recieve either standart care or intervention prior to removal of infected system
40985457|NCT03140020|PROCEDURE|Clipping|During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.
40985458|NCT03140020|PROCEDURE|Coiling|Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
40985459|NCT02702505|BIOLOGICAL|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted
40781008|NCT04792385|DRUG|E4/DRSP 15/3 mg combined tablet|One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
40781009|NCT04800692|DRUG|Tetrahydrobiopterin 10 mg/kg|10mg/kg of Tetrahydrobiopterin daily.
40781010|NCT04800692|DRUG|Tetrahydrobiopterin 20 mg/kg|20mg/kg of Tetrahydrobiopterin daily.
40985460|NCT02702505|OTHER|ProRoot MTA|Control group
40985461|NCT00649623|DRUG|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fasting
41304905|NCT01294735|DRUG|Temozolomide|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
41304906|NCT04053088|DEVICE|INSPIRIS RESILIA Aortic Valve™|Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™
41304907|NCT02028546|PROCEDURE|bathing and moisturizer application|"regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.~regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))"
40781011|NCT04800692|DRUG|L-Ascorbate|3300 mg of l-ascorbate once daily
40781012|NCT04800692|DRUG|L-Arginine|3400mg of l-arginine once daily
40781013|NCT04052061|BIOLOGICAL|CD19 t-haNK|CD19 t-haNK Suspension for Infusion
40781014|NCT03124186|DEVICE|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
40781015|NCT03544450|BEHAVIORAL|Psychosocial counselling|"Individuals with psychological distress receive psychosocial counselling and enhanced usual care. The psychosocial the counselling process consists of: (i) introduction, explanation and rapport building; (ii) assessment of and understanding of the problem (including looking for positive assets); (iii) goal setting (asking the client what outcomes are preferred); (iv) problem management (exploring and identifying solutions, brainstorming, working with existing coping strategies, using social and cultural resources, and additional techniques such as relaxation and psycho-education); (v) implementation (making a plan of action and transition); and, finally, (vi) termination of counselling (including closing and follow-up). Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support)."
40985462|NCT00649623|DRUG|Benicar® Tablets 40 mg|40mg, single dose fasting
40985463|NCT03164200|OTHER|High fat breakfast|High fat breakfast
40985464|NCT03164200|OTHER|Higher carbohydrate breakfast|Higher carbohydrate breakfast
40985465|NCT04687033|DEVICE|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
40985466|NCT03456674|DEVICE|LaseMD System|A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.
40985467|NCT02910076|DRUG|Hydroxychloroquine|200 MG Plaquenil three times a day
41144297|NCT04418609|OTHER|further processing of health data|further processing of biological materials and health related personal data for research
40781016|NCT03544450|OTHER|Enhanced Usual Care|Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
40985468|NCT05503641|OTHER|Cognitive and psychomotor stimulation|"Each cognitive stimulation session aimed to maintain and/or improve cognition through memory, language, executive functions, attention, concentration, and perception activities. All the people in the two groups performed the same cognitive stimulation activities adapted to their cognitive and sensory abilities.~The psychomotricity sessions were aimed at maintaining and/or improving the motor, cognitive, social and affective functioning of the person through activities that work on postural tone, body scheme, laterality, fine and gross motor skills, balance, flexibility, among others, adding a cognitive component. All the psychomotricity activities were adapted to the motor and cognitive abilities of the users."
40985469|NCT03296657|DRUG|stannous fluoride|subjects will brush with paste twice daily for 2 weeks
40985470|NCT00708162|DRUG|Elvitegravir|Elvitegravir (EVG) tablet administered orally once daily with food
40985471|NCT00708162|DRUG|Raltegravir|Raltegravir tablet administered orally twice daily according to prescribing information
40985472|NCT00708162|DRUG|EVG placebo|Placebo to match elvitegravir administered orally once daily
41144298|NCT06339788|DRUG|HD-P023|Single dose administration of HD-P023
41144299|NCT06339788|DRUG|Teneligliptin|Single does administration of Teneligliptin and Empagliflozin High
41144300|NCT06339788|DRUG|Empagliflozin|Single does administration of Teneligliptin and Empagliflozin High
41144301|NCT04804371|DRUG|F18-FDG|Evaluate FDG uptake
40781017|NCT03692403|DRUG|Quinagolide 360 µg|Vaginal ring containing quinagolide 360 µg for daily releases
41144302|NCT05619991|OTHER|Group watching video|The video will include preparation for the surgery, the operating room environment and the post-operative process.
41144303|NCT05619991|OTHER|Scheduled training group|The scheduled training will include preparation for the surgery, the operating room environment and the post-operative process.
41144304|NCT04929509|OTHER|self-assembling peptide|each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators
41144305|NCT04929509|OTHER|nanosilver fluoride varnish|The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.
41144306|NCT04929509|OTHER|sodium fluoride varnish|5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.
41144307|NCT03455725|DEVICE|CardiAMP Cell Therapy System|The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.
41144308|NCT03455725|OTHER|Sham Treatment|Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
41144309|NCT05213585|DRUG|Ivermectin cream|Topical application of ivermectin cream to eyelashes of treatment eye.
41144310|NCT06237621|DEVICE|SnapshotNIR imaging|SnapshotNIR will be used for tissue oxygen-saturation imaging of all the subjects' foot along with standard of care procedures for PAD assessment.
41144311|NCT04760028|PROCEDURE|Adjusting the depth of anesthesia|After the main procedure, the depth of anesthesia can be adjusted as needed
41144312|NCT06542614|DRUG|TQH3906 capsules|To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.
41463721|NCT03754504|DIETARY_SUPPLEMENT|Cranberry powder|3 capsules /day of whole cranberry powder (500mg/each)
41463722|NCT03754504|DIETARY_SUPPLEMENT|Placebo|3 capsules/day of a placebo comparator
41463723|NCT06461377|DRUG|Glucagon-like peptide-1 receptor agonist：Semaglutide|The GLP-1RA intervention group was given subcutaneous injection of GLP-1RA for 3 months, while the control group was not given GLP-1RA intervention
41463724|NCT00497679|DRUG|AZD1152|7-day continuous intravenous infusion
40781018|NCT03692403|DRUG|Quinagolide 720 µg|Vaginal ring containing quinagolide 720 µg for daily releases
40781019|NCT03692403|DRUG|Quinagolide 1080 µg|Vaginal ring containing quinagolide 1080 µg for daily releases
40781020|NCT03692403|DRUG|Placebo|Matching placebo
40985473|NCT00708162|DRUG|RAL placebo|RAL placebo administered orally twice daily.
40985474|NCT00708162|DRUG|Background regimen|Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
41144313|NCT06542614|DRUG|Placebo of TQH3906 capsules|Placebo without drug substance.
41144314|NCT06520722|DIAGNOSTIC_TEST|Prolapse scoring system|"A FIXED APCD classification system :~A: Associated symptoms:~FIXED:~F: frequency I: infection X: sex problems E: everted mass(external protrusion of mass from the valva as PV lump sensation ,heaviness,itching and ulceration) D: digitation(patient need to digitate to complete the act of micturation or defecation)~APCD:~A: Dependent point on anterior wall. P: Dependent point on posterior wall. C: Cuff point either cervix or vault. Distance to hymen in centimeters (minus above or plus below) after pushing the opposite wall during maximal straining D: Dimensions; base diameter of vestibule/ perineal length.~The staging system will be interpreted as follows:~Normal:~A-3 P-3 C-8 D 2/2~Stages:~0: No prolapse.~A/P-2 OR C-7 to C-2 A,P or C-1 to +1 A,P or C ˃ +1~X component: (alone or with any stage):~Dimension disruption: ˃2 or \<2"
41144315|NCT04604899|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)
41144316|NCT04885140|BEHAVIORAL|Feedback-based health education|This study was approved by the Tianjin Hospital Ethics Committee, (2019082).The CONSORT 2010 statement: extension to cluster-randomised trials checklist.(Campbell et al., 2012) was used to guide reporting outcomes (File S1).Specific measures have been listed above.
41144317|NCT04885140|BEHAVIORAL|Routine health education|Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method.
41144318|NCT03368105|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy."
41144319|NCT03406507|BIOLOGICAL|Ravulizumab|Single intravenous (IV) loading dose on Day 1, followed by regular IV maintenance dosing beginning on Day 15, based on weight.
41144320|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
41144321|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
41304908|NCT03969043|OTHER|MRI|"The MRI examination will consist of a series of acquisition scans:~* Scanning Scan: for positioning the functional volume of interest.~* Task Scans: for exploring cerebral activation in emotional and action appraisal tasks during viewing high and low arousal stimuli and a localizer task .~* Anatomical MRI: for analyzing the functional images, and measuring volumes of gray and white substances.~* Resting state functional scan: for exploring cerebral activation during a rest activity.~* Diffusion Tension Imaging: for measuring structural connectivity.~* Perfusion imaging: scan for ensuring good perfusion conditions~All functional acquisitions will be performed in multi-slices in echoplanar mode using gradient echo sequences allowing the exploitation of the BOLD contrast."
41304909|NCT06088316|DRUG|group A : Amoxicillin Esomeprazole HDDT|"Group A - Amoxicillin 1gm 8 hourly after meal \& esomeprazole 40mg 8 hourly 30 minutes before meal for 14 days.~Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days."
41304910|NCT06088316|DRUG|group-B : Levofloxacin triple therapy|Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.
41304911|NCT03956953|DRUG|BMS-986165|Dose 1 or Dose 2 on Day 1, and from Days 5-19'
41304912|NCT03956953|OTHER|Placebo|Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
41304913|NCT05142332|OTHER|Covid-19 vaccine education materials|videos and flyers containing Covid-19 vaccine educational information
41304914|NCT02081339|DRUG|ranibizumab, aflibercept, pegaptanib, verteporphin|
41463725|NCT00875888|DEVICE|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
40781021|NCT00628381|DIETARY_SUPPLEMENT|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
40985475|NCT00227903|BEHAVIORAL|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
40985476|NCT00227903|BEHAVIORAL|Brief Advice|Advice and education
40985477|NCT02341807|BIOLOGICAL|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
40985478|NCT00425230|DRUG|Duloxetine|
40985479|NCT05297825|BEHAVIORAL|Vegan diet|Healthy vegan diet.
40985480|NCT05297825|BEHAVIORAL|Omnivore diet|Healthy omnivore diet.
40985481|NCT04695925|DRUG|Osimertinib 80 MG [Tagrisso]|osimertinib 80 mg po qd until disease progression
40985482|NCT04695925|DRUG|Pemetrexed 500 MG Injection|pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression
40985483|NCT04695925|DRUG|Carboplatin|carboplatin area under curve 5 intravenously every 3 weeks for four cycles
40985484|NCT03072628|OTHER|e-cig with nicotine|use an e-cig with nicotine for 30 minutes
40985485|NCT03072628|OTHER|e-cig without nicotine|use an e-cig without nicotine for 30 minutes
40985486|NCT03072628|OTHER|nicotine inhaler|use a nicotine inhaler for 30 minutes
41304915|NCT04087343|BEHAVIORAL|Meals plus exercise|Patients will receive 12 weeks of meals on wheels meal delivery consisting of 3 meals per day during the weekdays with 6 frozen meals to cover the weekends.They will also receive an exercise kit on the first visit by the meal delivery driver with 2 tennis balls,2 1-pound hand weights, and one towel.Every week,the driver will give them 3 exercises from the National Institute on Aging's Go4Life Workout-to-Go book,1 exercise from each of 3 categories:strength/endurance, balance, and flexibility. They will be asked to do the 3 exercises every day.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
40781022|NCT00628381|DIETARY_SUPPLEMENT|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
40781023|NCT03121521|DRUG|Melatonin 10 mg|melatonin 10mg daily p.o.
40781024|NCT03121521|DRUG|Placebo|Placebo 10mg daily p.o.
40781025|NCT06431880|OTHER|External oblique intercostal plane block|Patients will receive external oblique intercostal plane block
40781026|NCT06431880|OTHER|Thoracic paravertebral block|Patients will receive thoracic paravertebral block
40781027|NCT05747248|DEVICE|Ultrasonography|Tracheal, diaphragmatic and lung ultrasonography
40781028|NCT00691392|DRUG|Linezolid|Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated
40781029|NCT00691392|DRUG|Microcrystalline Methylcellulose - Placebo|The placebo will be over-encapsulated microcrystalline methylcellulose
40781030|NCT01489904|BIOLOGICAL|BOTULINUM NEUROTOXIN TYPE-A|Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
40781031|NCT02040714|PROCEDURE|Osteotomy + Long Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.
40781032|NCT02040714|PROCEDURE|Osteotomy + Short Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.
40781033|NCT02040714|PROCEDURE|Nonoperative Observation|Group will not undergo any surgical or invasive procedures during course of treatment.
41144322|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
41463726|NCT03027908|OTHER|Fluoride Toothpaste 1|Toothpaste containing 1450 ppm F as Sodium Fluoride
41463727|NCT03027908|OTHER|Fluoride Toothpaste 2|Toothpaste containing 1450 ppm F as Sodium Fluoride
41463728|NCT01332968|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
41463729|NCT01332968|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
40985487|NCT03072628|OTHER|sham control|use an empty e-cigarette for 30 minutes
40985488|NCT02630355|OTHER|Remote Ischaemic Preconditioning|Inflation of blood pressure cuff in lower limb
40781034|NCT02040714|PROCEDURE|Multiple Epiphyseal Drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
41144323|NCT01113593|DRUG|Foradil Aerolizer|Dry powder inhaler
41463730|NCT01332968|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
40781035|NCT03361878|DRUG|Metformin Hydrochloride|Single dose of 500mg oral metformin
40781036|NCT02996396|DEVICE|Nellix Endovascular Aneurysm Sealing System (Nellix®-System)|The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
40781037|NCT00060944|DRUG|Yondelis|1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.
40781038|NCT00060944|DRUG|Yondelis|0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
40781039|NCT00060944|DRUG|Dexamethasone|Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
40781040|NCT00060944|DRUG|Dexamethasone|Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
40781041|NCT05180968|DRUG|Nabilone 0.5 MG Oral Capsule|This intervention will consist of subjects receiving nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
40781042|NCT05180968|DRUG|Placebo Nabilone|This intervention will consist of subjects receiving placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
40781043|NCT03425955|DEVICE|SUNEKOS ® 200|"4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days. Two different injection techniques were carried out mono-laterally on the left or right face side randomly: interstitial fluid technique (IFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
40781044|NCT03425955|DEVICE|"SUNEKOS® 1200 and SUNEKOS® 200"|"5 micro-injection sessions (one of the product SUNEKOS® 1200 and four of SUNEKOS® 200. SUNEKOS® 1200 was injected bi-laterally on the face with cushion technique. 24 hours after the SUNEKOS® 1200 treatment, 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days were performed . SUNEKOS® 200 was injected with two different techniques, carried out mono-laterally on the left or right face side randomly: retrograde interstitial fluid technique (RIFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
40985489|NCT00753558|DRUG|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|"Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel."
40985490|NCT01141439|DRUG|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|Initiation of HFA-BDP (any dose) in steroid naive patients via MDI
40985491|NCT01141439|DRUG|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI
40985492|NCT01141439|DRUG|Fluticasone propionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI
41463731|NCT01332968|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
40985493|NCT01141439|DRUG|Beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
40985494|NCT01141439|DRUG|fluticasone propionate|Initiation of FP (any dose) via MDI in steroid naive patient
40985495|NCT01141439|DRUG|Chlorofluorocarbon beclomethasone dipropionate|Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
40985496|NCT05820308|BEHAVIORAL|Companion Dog Walking|Participants will be asked to walk their dog three times per week, for a minimum of 30 minutes each day of walking, over an 8-week period.
41144324|NCT01113593|DRUG|Foradil Aerolizer|Dry powder inhaler
41144325|NCT01389791|DRUG|magnesium sulfate|Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).
41144326|NCT01389791|DRUG|priming|Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
41144327|NCT01389791|DRUG|magnesium sulfate and priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
41144328|NCT04904354|DEVICE|AcQBlate® Force Sensing Ablation System|Catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein. Additional left and right atrial targets may be ablated as clinically indicated.
41144329|NCT02493556|DEVICE|LLLT before muscle damage|
41144330|NCT02493556|DEVICE|Placebo LLLT before muscle damage|
41144331|NCT02493556|DEVICE|LLLT after muscle damage|
41463732|NCT01332968|DRUG|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
40781045|NCT05313581|BEHAVIORAL|START NOW WebApp|"The WebApp is based on the existing manualized START NOW skills training. START NOW aims to improve emotion- and stress regulation, social competence, effective management of encountered problems/crises, subjective well-being and resilience through improving an individual's level of psychological flexibility. It primarily employs a cognitive behaviourally oriented group skills training with integrated components from Dialectical Behavioural Therapy (DBT), Acceptance and Commitment Therapy (ACT), trauma-informed care and Motivational Interview (MI) techniques.~During the training, participants will encounter different exercises to help them train their skills. There are several mindfulness exercises in the form of audio tracks, containing, e.g., instructions on a breathing exercise. The skills training phase takes place over a period of 9 weeks (sessions 1+2, 9+10 and 11+12 are double session)."
40985497|NCT05820308|BEHAVIORAL|Attention Control Group|Participants will be asked to read educational materials on dog health once per week, over an 8-week period.
40985498|NCT02904551|PROCEDURE|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
41144332|NCT02493556|DEVICE|Placebo LLLT after muscle damage|
40985499|NCT02904551|PROCEDURE|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
41144333|NCT05196256|PROCEDURE|Dural puncture|Dural puncture with a 25 Gauge needle without injection of local anesthetics into the dural space
41144334|NCT05196256|PROCEDURE|Combined spinal epidural analgesia|Standard epidural preceded by a dural puncture with a 25G sequential needle and intrathecal injection of 2.5 ug of Sufentanil and 2.5 mg of normobaric Levobupivacaine
41144335|NCT05196256|PROCEDURE|Epidural analgesia|Epidural analgesia
41144336|NCT05196256|DRUG|Sufentanyl/Levobupivacaine|Epidural analgesia
41144337|NCT03923556|DRUG|Sugammadex|Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation
41144338|NCT03923556|DRUG|Neostigmine|Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07 mg/kg) at the end of the surgery before tracheal extubation
41147035|NCT01825785|DRUG|Romosozumab|Administered by subcutaneous injection
41147036|NCT01825785|DRUG|Placebo|Administered by subcutaneous injection
41304916|NCT04087343|BEHAVIORAL|Meals only|Patients will receive 12 weeks of an enhanced meals on wheels (MOW) in-person meal delivery consisting of 3 meals per day (1 shelf-stable, 1 hot, and 1 frozen) during the weekdays (Monday through Friday) with 6 frozen meals at the end of the week to cover the weekends.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
41304917|NCT01419275|DRUG|Xenon contrast agent|
41304918|NCT01419275|DEVICE|Magnetic Resonance Imaging|Arterial spin label sequence for the purpose of measuring collateral flow
41304919|NCT05890287|DRUG|Chidamide|Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen
41304920|NCT03521687|DRUG|Apremilast|30 mg BID
41304921|NCT01518608|DRUG|Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)|"Induction dose(0µg/kg,10µg/kg,20µg/kg,30µg/kg,40µg/kg,50µg/Kg,and 60µg/kg) 12 patients in each dose group.~Pentothal 4mg/kg Rocuronium 0.6 mg/kg"
41304922|NCT02538588|DEVICE|Nebulizer 1|
41304923|NCT02538588|DEVICE|Nebulizer 2|
40781046|NCT01385579|OTHER|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
40781047|NCT01409096|DRUG|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
40985500|NCT00298220|BEHAVIORAL|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
40985501|NCT00298220|BEHAVIORAL|Dissemination guideline and patient information letters|
41144339|NCT05533034|OTHER|Rehabilitation|"* 1 supervised session of rehabilitation, including a cardiac stress test (to define maximal intensity for aerobic activities), aerobic activity with interval training of moderate and progressive intensity (walking), and respiratory exercise using a volumetric spirometer, and strengthening exercises for lower and upper limbs.~* 3 months of self-managed home exercises. Patients will be asked to use a tracker activity when performing home exercises to self-monitor cardiac frequency and to assess their adherence."
41144340|NCT04565288|DRUG|Atomoxetine|Participants randomized to receive the study medication, atomoxetine (brand name: Straterra) for 6-weeks (40 mg/day for 3 days then 80 mg/day thereafter). A comparator group will receive placebo (sugar pills).
41144341|NCT04565288|DRUG|Placebo|Matching placebo (sugar pill)
41144342|NCT02026583|DRUG|Simvastatin|
41144343|NCT00787475|OTHER|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
41144344|NCT00091572|DRUG|Temozolomide|"oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop."
41144345|NCT00091572|DRUG|Dacarbazine|intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
41144346|NCT05481008|DEVICE|transcatheter aortic valve implantation|All subjects undergo transcatheter aortic valve implantation because of symptomatic severe aortic valve stenosis. This is a routine medical procedure, not a study intervention.
41144347|NCT00163748|DRUG|gemcitabine, vinorelbine|
40781048|NCT01409096|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
41144348|NCT03040453|DEVICE|Microwave ablation|
41144349|NCT03040453|DEVICE|Irreversible electroporation|
41144350|NCT04255251|DRUG|Silver Diammine Fluoride|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
41144351|NCT04255251|DRUG|Fluoride Varnishes|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
41144352|NCT06329440|DIAGNOSTIC_TEST|Ultrasonographic measurement of diaphragm thickness|Lineer probe of the ultrasound machine will be placed sagitally on the level of 9th to 11th rib in order to observe diaphragmatic thickness change during a sniff. The thicknesses will be measured both in full expiration (Te) and full inspirium (Ti) in centimeters. The diaphragm thickness fraction will be calculated as follows: (Ti-Te)/Te
41144353|NCT04990037|DRUG|CAN04|Administered intravenously
41144354|NCT04990037|DRUG|FOLFIRINOX|Administered intravenously
41144355|NCT02677688|BIOLOGICAL|Autologous EBV specific CTL infusion|
41144356|NCT06207747|DIAGNOSTIC_TEST|additional PET/CT at 4 weeks, analysing using quantative analysis|Patient with metastatic melanoma will be monitored with additional PET/CT at 4 weeks, analysing using quantative analysis will be done.
41304924|NCT03200873|DEVICE|repetitive transcranial magnetic stimulation|Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.
40781049|NCT01668004|BIOLOGICAL|Golimumab|GLM 50 mg subcutaneously once monthly.
40781050|NCT05270525|DRUG|Ensifentrine|Ensifentrine twice daily administered with jet nebulizer for 8 weeks
40781051|NCT05270525|DRUG|Placebo|Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
40781052|NCT04891029|DIAGNOSTIC_TEST|DOvEEgene test|Women participating in the study will undergo a genomic uterine pap test, DOvEEgene test, for the screening of ovarian and endometrial cancers
40781053|NCT02408744|DRUG|Pirfenidone|Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
40985502|NCT00298220|BEHAVIORAL|Tailored educational training|for GP(T)s
40781054|NCT05477888|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,the Penn State Electronic Cigarette Dependence Index (PS-ECDI ).
40985503|NCT00298220|BEHAVIORAL|Tailored outreach based facilitator support|in the practices of the GPTs
40985504|NCT00298220|BEHAVIORAL|Facilitation of co-operation with local addiction services|
40781055|NCT01378117|DRUG|Sitagliptin|Sitagliptin 50-100mg po once daily
40781056|NCT01378117|DRUG|glargine|glargine once daily
40985505|NCT00298220|BEHAVIORAL|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
40985506|NCT00298220|BEHAVIORAL|Reminder-card for GP's desk|
40985507|NCT00298220|BEHAVIORAL|Personal feedback to patients|Patients receive advise based on their premeasurement answers
40985508|NCT06136923|DEVICE|CT-100-D-004-A|Attention Biases App CT-100-D-004-A Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
40985509|NCT06136923|DEVICE|CT-100-D-004-B|Attention Biases App CT-100-D-004-B Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
40985510|NCT06539559|DRUG|Eribulin|Based on the results of STUDY301 and STUDY304, eribulin showed outstanding therapeutic effect and tolerable adverse events in patients with metastatic breast cancer
40781057|NCT01378117|DRUG|lispro|lispro before meals
40781058|NCT03627702|RADIATION|Irradiated VIP (Visible Incoherent Polarized)|20 irradiations were performed twice a day. The exposure time was 10 minutes. Exposure was made at a distance of 10 cm.
40781059|NCT04097990|OTHER|blood sample|a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels
40781060|NCT06161584|DRUG|Pegcetacoplan|Administered intravitreally (IVT) in eyes with geographic atrophy (GA)
40781061|NCT00603681|DRUG|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
40781062|NCT00603681|DRUG|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
40781063|NCT06302023|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) 1000 mg|Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age
40985511|NCT06539559|DRUG|Bevacizumab|Study E2100, AVADO and RIBBON-1 found that in the first-line chemotherapy for advanced breast cancer, the addition of bevacizumab can significantly improve the efficacy of traditional chemotherapy drugs. Study RIBBON-2 and TANIA have confirmed the effectiveness of bevacizumab in the second and third line treatment of advanced HER2 negative breast cancer. Compared with chemotherapy alone, the addition of bevacizumab can prolong the PFS by 0.6 to 2.1 months.
40985512|NCT04572074|OTHER|Guided imagery|10 minutes of guided imagery experience
40985513|NCT04572074|OTHER|Virtual reality|10 minutes of virtual reality experience
40985514|NCT02612935|DEVICE|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
40985515|NCT00000633|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
40985516|NCT00000633|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
40985517|NCT03249233|DEVICE|ZenLens™|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
40985518|NCT03249233|DEVICE|Zen™ RC|The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
40985519|NCT02671279|DIETARY_SUPPLEMENT|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
40985520|NCT02118012|DRUG|Chlorcyclizine HCl|Chlorcyclizine HCl (75 mg twice daily)
40985521|NCT02118012|DRUG|Ribavirin|RBV was dosed via a weight-based regimen of 1000 mg daily\<75 kg and 1200 mg daily ≥75 kg.
41304925|NCT04480697|DRUG|HPG1860|6 subjects randomized to active compound and 2 subjects randomized to placebo
40781064|NCT04607343|DEVICE|Rehabilitation device based on electrical stimulation|Experimental tests with transcutaneous electrical stimulation at different intensities and at the points of the submandibular region previously explored will be conducted first of all on the five healthy volunteer subjects. During these tests, the neuromuscular thresholds of the upper airway, the most effective points of electrostimulation and the tolerance of intervention will be determined. The determination of the functional threshold will be made by clinical evaluation of the subject during stimulation.
40781065|NCT01752218|DEVICE|arcuate incision|
40781066|NCT05456048|DRUG|VAH regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
40781067|NCT05456048|DRUG|VEN+HMA regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
40781068|NCT05361460|OTHER|Cognitive decline|This is an observation study with the aim of explore patients' experiences of their early and late postoperative cognition after major orthopaedic surgery in relation to postoperative cognitive function assessed with validated neuropsychological tests, inflammatory signalling molecules and quality of postoperative recovery as well as to describe the relative's view of early postoperative cognition.
40781069|NCT04265794|BEHAVIORAL|H2GO!|Child participants will participate in a 6-week behavioral intervention consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. Each week consisted of a 1-hour health session and a 1-hour narrative session (delivered on separate days). Child participants will also receive reusable water bottles and a pictorial intervention booklet, which includes worksheets and parent-child take-home activities targeting attitudes, knowledge, and skills related to sugar-sweetened beverage and water consumption. Parent participants will be exposed to intervention messages (e.g., reduce SSB intake) through weekly parent-child take-home activities, child sharing of narratives produced, and a culminating open house event.
40781070|NCT03670160|DRUG|Phenobarbital|Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.
40781071|NCT03670160|DRUG|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
40781072|NCT00188214|PROCEDURE|contrast-enhanced dynamic CT perfusion study|contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
40781073|NCT00615576|DRUG|SB-656933|SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.
40781074|NCT00615576|DRUG|Placebo|A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
40781075|NCT03290352|OTHER|Questionnaire|Patients who enrolled in the study were asked to respond to the University of Washington Quality of Life Questionnaire one week before undergoing free flap reconstruction.
40781076|NCT06262438|DRUG|Quizartinib|"Quizartinib is a novel oral Class III receptor tyrosine kinase (RTK) inhibitor exhibiting highly potent and selective but reversible inhibition of FMS-like tyrosine kinase FLT3. The dose will be adjusted for the patient's body weight (BW) as measured at the start of each course. Quizartinib will be administered orally once daily and is taken for 14 consecutive days during induction and consolidation courses.~Induction course 1: Start on day 13; Induction course 2: Start on day 9; Consolidation course 1: Start on day 6; Consolidation courses 2 and 3 (only if no allo-SCT is done): Start on day 6.~Continuation courses 1-6: patients will receive quizartinib for six 28-day courses. For the first 15 days of course 1 a starting dose will be applicable. On course 1 Day 16, the dose will be increased if the average QTc of the triplicate Electrocardiograms is ≤450 msec on course 1 Day 15. Once the dose is increased, the patient may continue on this dose as long as dose reduction is not needed."
40781077|NCT06262438|DRUG|Etoposide|"Induction course 1: 150 mg/m2 once daily by Intravenous (IV) infusion over 2 hours (+/- 30 mins) on days 1-5 inclusive (total 5 doses).~Induction course 2: 150 mg/m2 once daily by IV infusion over 2 hours (+/- 30 mins) on days 6-8 inclusive (total 3 doses).~Consolidation course 2 (only if no allo-SCT is done): 100 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 1-5 inclusive (total 5 doses)."
40985522|NCT06297863|PROCEDURE|HEAD DOWN TILT -10° to -15°|"Head down tilt -10° to -15° (HDT15) is a positional therapy consisting of tilting the patient with the head -10° to -15° degrees below the rest of the body.~Application of HDT15 will not delay usual care. The standard in-hospital patient pathway, including transfer from neuroimaging room to the angiography suite and the required procedural steps of MT, will allow sufficient time for the application of HDT15. HDT15 duration is expected to be at least 30 minutes (estimated time 30 to 90 minutes), from start to the assessment of the primary efficacy endpoint.~The actual degree of HDT15 will be a range between -10° to -15°, depending on the angiographic system of each clinical site, but it will be maintained at -15° during the Emergency Room phase which is expected to account for \>50% of the total application time."
40985523|NCT05284669|OTHER|Experimental e-learning|Interactive lecture based on the guidelines for the management of LBP with a focus on self-management and patient's reassurance
40985524|NCT05284669|OTHER|Traditional e-learning|Traditional lecture based on the guidelines for the management of LBP with a focus on diagnostic triage and specific cause of LBP
40985525|NCT05164042|BIOLOGICAL|Allogeneic CD19 CAR-T cells|infusion of allogeneic CD19 CAR-T cells
40985526|NCT03032666|DRUG|sofosbuvir/velpatasvir|treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
40985527|NCT05243368|DIETARY_SUPPLEMENT|Personalized Nutritional Intervention|Those with malnutrition criteria will also receive a nutritional supplement (e.g. fortimel cubitan, advanced or extra, Nutricia) or another of similar composition, in case of intolerance to the first option. The aim will be to provide at least 50% of the recommended intakes for the main nutrients related to wound healing.
41304926|NCT00702052|DRUG|Everolimus|Everolimus tablets
41463733|NCT01332968|DRUG|Bendamustine|Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
41463734|NCT01332968|DRUG|Rituximab|Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.
41463735|NCT05675358|BEHAVIORAL|Virtual Reality|Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used in the study.
41463736|NCT02034448|PROCEDURE|Continuous Renal Replacement Therapy|
41463737|NCT05396417|PROCEDURE|cesarean delivery|Cesarean delivery under any form of anesthesia for any reason and for any indication
41463738|NCT04669457|DRUG|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
41463739|NCT04669457|DRUG|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
41463740|NCT04587245|OTHER|Online questionnaire and interviews|Online questionnaire, financial statements (one month per quarter in 2020) submitted electronically, interview with professional accounting firm and review of data and exit Interview
41463741|NCT04629339|DRUG|INCB086550|INCB086550 will be administered orally twice a day.
41463742|NCT04979923|DRUG|Lidocaine|Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
41463743|NCT04696757|DRUG|Capecitabine|Capecitabine without surgery
41463744|NCT04641403|PROCEDURE|The surgeon performed Laparoscopic-assisted TAP (LTAP) block|After the induction of anesthesia, the first port will be inserted through the umbilicus and a 12 mmHg pneumoperitoneum will establish as a standard. Under the direct view of the laparoscopic camera, the block will be performed by inserting a 22-G needle just above the iliac crest through the midclavicular line posteriorly into the triangle of Petit and then inserting the needle below the costal arch through the midclavicular line towards the anterior axillary line into the subcostal plane. The block needle will be advanced under direct view until the two pops were felt and the extraperitoneal space will reach without puncturing the parietal peritoneum, and pulling back the needle 0.5 cm, the area of the thin transversus abdominis muscle fibers wiil be infiltrated. In this area, the correct plane of the needle tip will confirm by observing Doyle's bulge and the spread of the local anesthetic.
41463745|NCT03102879|PROCEDURE|Regenerative Endodontic Procedure|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells.
41463746|NCT03102879|PROCEDURE|Conventional Root Canal Treatment|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.
40985528|NCT01906151|DEVICE|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
41463747|NCT02913131|DRUG|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
41463748|NCT02913131|DEVICE|MRI|MRI scan following the pyruvate (13c) injection
40781078|NCT06262438|DRUG|Dexrazoxane|"Induction course 1: 250 mg/m2 once daily by 15 mins IV infusion shortly before Mitoxantrone on day 6-10 inclusive (total 5 days), per investigator discretion and per institutional guidelines and availability.~Induction course 2: 600 mg/m2 once daily by 15 mins IV infusion shortly before daunorubicin on day 2,4,6 inclusive (total 3 does), per investigator discretion and per institutional guidelines and availability.~Consolidation course 1: 500 mg/m2 once daily by 15 mins IV infusion shortly before Mitoxantrone on 3-5 inclusive (total 3 does), per investigator discretion and per institutional guidelines and availability."
40781079|NCT06262438|DRUG|Mitoxantrone|"Induction course 1: 5 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 6-10 inclusive (total 5 doses). Please note that mitoxantrone and cytarabine should not be given concomitantly. Mitoxantrone should be completed before cytarabine is given.~Consolidation course 1: 10 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 3-5 inclusive (total 3 doses)."
40781080|NCT06262438|DRUG|Cytarabine|"Induction course 1: 200 mg/m2 once daily by IV infusion over 12 hours (+/- 1 hour) on days 6-12 inclusive (total 7 doses), following mitoxantrone. Induction course 2: 100 mg/m2 once daily by continuous IV infusion on days 1-2 inclusive. And 100 mg/m2 twice daily as a 30min (+/- 10 mins) IV infusion every 12 hours on days 3-8 inclusive (total 12 doses). Consolidation course 1: 1000 mg/m2 twice daily by IV infusion over 2 hours (+/- 30 min) every 12 hours on days 1-3 inclusive (total 6 doses).~Consolidation course 2 (only if no allo-SCT is done): 3000 mg/m2 twice daily by IV infusion over 2 hours (+/- 30 mins) every 12 hours on days 1-3 inclusive (total 6 doses).~Consolidation course 3 (only if no allo-SCT is done): 2000 mg/m2 once daily by IV infusion over 3 hours (+/- 1 hour) starting 4 hours after fludarabine on days 1-5 inclusive (total 5 doses), following fludarabine."
40781081|NCT06262438|DRUG|Methotrexate|"Induction course 1: Methotrexate (MTX) Intrathecal therapy (IT) prophylaxis is age-adjusted. If MTX is given at diagnosis omit IT therapy on day 6 unless in case of CNS involvement (CNS3). For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently. For children with CNS2, CSF must be investigated on day 22; if leukemic cells persist, treat as CNS3.~Induction course 2, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 1, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 2 and 3, Day 1 (only if no allo-SCT is done): MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently."
41463749|NCT02656251|DRUG|0.12% Clorhexidine with alcohol|Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
41463750|NCT02656251|DRUG|placebo|Use of placebo every 12 hours for 04 days
41463751|NCT02656251|DRUG|0.12% Clorhexidine without alcohol|Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
41144357|NCT05423171|OTHER|Intensive bimanual therapy|60-hour intensive therapy promoting the use of both hands (ex: bimanual activities, games,...)
41144358|NCT01707277|OTHER|Inspiratory muscle training|Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
41144359|NCT01707277|OTHER|Usual care|Usual pahramacological treatment
41304927|NCT06350227|COMBINATION_PRODUCT|the absorbable hemostat and suture|The hemostasis method of the experimental group is to use both the absorbable hemostat and suture.
41304928|NCT06350227|COMBINATION_PRODUCT|electrocoagulation and suture|The active comparator group is to use electrocoagulation and suture simultaneously to stop bleeding.
41304929|NCT06350227|OTHER|suture|The placebo comparator is to use suture alone for hemostasis.
41304930|NCT00789477|PROCEDURE|Laser Photocoagulation|laser every 16 weeks as needed
41304931|NCT00789477|DRUG|Intravitreal Aflibercept Injection|
40781082|NCT06262438|DRUG|Daunorubicin|Induction course 2: 60 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 2,4,6 inclusive (total 3 doses).
40781083|NCT06262438|DRUG|Fludarabine|Consolidation course 3 (only if no allo-SCT is done): 30 mg/m2 once daily by IV infusion over 30 mins (+/- 10 mins) on days 1-5 inclusive (total 5 doses).
40781084|NCT06262438|OTHER|allo-SCT|The SCT procedure is left to the discretion of the investigator and not part of this protocol.
40781085|NCT01152788|DRUG|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
40781086|NCT01152788|DRUG|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
40781087|NCT02024412|DRUG|monosialotetrahexosylganglioside Sodium|it is a component extract from pig's brain,shenjie is the brand name
40781088|NCT02024412|OTHER|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
41144360|NCT04830345|BIOLOGICAL|ATGC-100 100U|Clostridium botulinum toxin type A
41144361|NCT04830345|BIOLOGICAL|Botox 100U|Clostridium botulinum toxin type A
40781089|NCT02740465|BEHAVIORAL|Anxiety Inventory for Respiratory Disease (AIR)|An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
40781090|NCT02740465|BEHAVIORAL|Hospital Anxiety and Depression Scale (HADS)|The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
40781091|NCT05401981|OTHER|Story checklist|The story checklist consists of a couple of questions that gives the physician something to keep in mind while visiting the patients.
40781092|NCT01959529|DRUG|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
40781093|NCT01959529|DRUG|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
40781094|NCT03929003|BEHAVIORAL|Inspired|The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.
40781095|NCT06187857|BEHAVIORAL|Ecologically Oriented Neurorehabilitation of Memory (EON-Mem)|Feasibility study of a virtually-delivered adaptation of an ecologically oriented neurorehabilitation of memory (EON-Mem) in improving memory for healthy older adults
40781096|NCT02353962|OTHER|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. The intervention duration is three weeks. During this week the patients play daily a half hour on workdays. The treatening therapist will adjust the intensity according to the progress of the patient.
40781097|NCT02972229|RADIATION|10x(3-5) Gy IMRT|10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
40781098|NCT02972229|RADIATION|10x3 Gy IMRT|10x3 Gy IMRT on whole vertebral body for spinal metastases
40781099|NCT05083078|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
40781100|NCT05083078|DRUG|Risankizumab|Risankizumab will be administered subcutaneously.
40781101|NCT06464770|DRUG|Chlorhexidine Gluconate|Test Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at lower pressure (similar to a gentle wipe) for 30 seconds Control Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at higher pressure (similar to a massage) for 30 seconds
40781102|NCT05468502|DRUG|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
40781103|NCT01569412|BIOLOGICAL|Ertumaxomab|trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
41144362|NCT05520411|DIETARY_SUPPLEMENT|HUM Flatter Me|Proprietary Enzyme Blend: Protease 3.0 Protease 4.5 Protease 6.0 Neutral Bacterial Protease Peptidase Bromelain Papain Lipase Amylase Glucoamylase Alpha-galactosidase Invertase Diastase Hemicellulase + Cellulase Beta-Glucanase Phytase Lactase Ginger Root Fennel Seed Peppermint Leaf
41144363|NCT00648895|DRUG|Nebivolol|nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
41144364|NCT00648895|DRUG|Metoprolol ER (TM)|Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
41144365|NCT02684136|DRUG|suvorexant|suvorexant 20 mg taken before sleep
41144366|NCT02684136|DRUG|placebo|placebo taken before sleep
41304932|NCT04582734|BEHAVIORAL|Cognitive-behavioural therapy|Cognitive-behavioural therapy intervention
41463752|NCT05531604|BEHAVIORAL|appetitive conditioning|The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
41463753|NCT02221817|PROCEDURE|Trochanter bursa injections|
40985529|NCT01079091|DEVICE|ADVOS (Hepa Wash)|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
40985530|NCT01079091|PROCEDURE|Standard Medical Therapy|Standard of care treatment
40985531|NCT04484363|DRUG|Pevonedistat|Pevonedistat 20 milligram per square meter (mg/m\^2), intravenous infusion, on Days 1, 3, and 5 of repeated 28-day cycles.
40985532|NCT04484363|DRUG|Azacitidine|Azacitidine 75 mg/m\^2, intravenous or subcutaneous infusion, on Days 1 to 5, Days 8 and 9 of repeated 28-day cycles or Days 1 through 7 of repeated 28-day cycles.
40985533|NCT03989999|PROCEDURE|Transcranial Doppler (TCD)|"In the Emergency Department (ED):~After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 8 hours of the brain injury.~If TCD is normal (FVd\>25 cm/sec and PI \<1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (\< 4-6 hours after TBI), CT scan should not be controlled before patient discharge.~If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).~No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group."
40985534|NCT00816231|BEHAVIORAL|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
40985535|NCT00816231|OTHER|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
40781104|NCT00639288|OTHER|modified CPT-C|modified CPT-C
40985536|NCT00816231|OTHER|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
40985537|NCT02608749|BEHAVIORAL|Integrated care (IC)|Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
40985538|NCT02608749|BEHAVIORAL|Lower extremity exercise (LEE)|Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
40985539|NCT02608749|BEHAVIORAL|Home care (HC)|Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
40985540|NCT03326973|BEHAVIORAL|EuroQoL EQ-5D-3L|Overall QOL
40985541|NCT03326973|BEHAVIORAL|EORTC QLQ-C30|General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales
40985542|NCT03326973|OTHER|PRO-CTCAE|Additional potential immune-specific symptoms
40985543|NCT03326973|BEHAVIORAL|Fatigue severity score questionnaire|Fatigue severity
40985544|NCT03326973|BEHAVIORAL|The COST|Financial toxicity; satisfaction with ability to work
40985545|NCT03326973|BEHAVIORAL|Physician information|Details on outside health providers
40985546|NCT05941923|OTHER|respiratory critical care support|Patients in the intervention group will be received respiratory critical care support
40985547|NCT05885074|DRUG|Empagliflozin Arm|The subject will be randomized, in a double-blind manner to Empagliflozin 25mg once daily for a period of 12 months
41144367|NCT02472808|OTHER|cTBNA without ROSE|Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
41144368|NCT02472808|OTHER|cTBNA with ROSE|Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
41144369|NCT02472808|OTHER|EBUS-TBNA without ROSE|Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
41144370|NCT02472808|OTHER|EBUS-TBNA with ROSE|Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
41144371|NCT01757288|DRUG|NAB-PACLITAXEL|nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
41144372|NCT01757288|DRUG|PACLITAXEL|
41144373|NCT01757288|DRUG|NAB-PACLITAXEL|nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
40781105|NCT01882465|DEVICE|etafilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
40781106|NCT01882465|DEVICE|2-HEMA, EGDMA Non-ionic|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
40781107|NCT01882465|DEVICE|hefilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
40985548|NCT05885074|OTHER|Control Arm|The subject will be randomized, in a double-blind manner to receive placebo once daily for a period of 12 months
41144374|NCT02757456|BEHAVIORAL|Aerobic Exercise program|The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs. The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment. The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down. The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks. Blood pressure and heart continuous monitoring will be carried out during the exercise program. Exercise log sheets will be filled for each session for the 16 weeks.
41144375|NCT02757456|OTHER|Control|No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
41144376|NCT00363090|BIOLOGICAL|alemtuzumab|
40985549|NCT05885074|OTHER|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
41463754|NCT02221817|DEVICE|Ultrasound|
41463755|NCT02578641|BIOLOGICAL|autologous EBV specific Cytotoxic T cells|The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
41463756|NCT02578641|DRUG|combination IV gemcitabine and IV carboplatin (AUC2)|4 cycles for Arm A and 6 cycles for Arm B
41463757|NCT03434145|OTHER|ophthalmologic exams|ophthalmologic exams such as vision, intraocular pressure, axial length and optical coherence tomography
41463758|NCT01186016|BEHAVIORAL|Genetic Education Session|The intervention includes receiving education about genetics and smoking. The content is basic genetics and education about the multifactorial nature of smoking; research findings about genetic contributions to smoking, potential applications of this research for cessation treatment, and legal, ethical and social implications of future use of genotyping for cessation. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
41304933|NCT03894527|BEHAVIORAL|Single Bout of Exercise|An exercise condition, which will be walking at a moderate intensity (\~70% VO2peak). Time will vary based upon individual fitness levels to burn \~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.
41463759|NCT01186016|BEHAVIORAL|Nutrition Education Session|To control for an attention placebo effect, the control group will receive information about nutritional guidelines as established by the USDA and the FDA. The attention control group will be referred to as the Nutritional Education Session (NES) group. The content of NES sessions one and two are use of the USDA (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
41463760|NCT01891058|DEVICE|drug-shock vs shock only|procainamide followed by electrocardioversion if necessary vs cardioversion only.
41463761|NCT02215668|PROCEDURE|Physical exercise|Exercise muscle stretching and body warming.
41463762|NCT03447444|OTHER|music and physical activity|This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
41463763|NCT05103449|OTHER|Video Coaching|Video-based coaching sessions after salpingectomy 1 and 2
41463764|NCT04096339|OTHER|Colonoscopy followed by EGD|Colonoscopy is done first followed by EGD
40781108|NCT03239457|BIOLOGICAL|Heberprot P|75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.
40985550|NCT05885074|OTHER|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
40985551|NCT03709160|DRUG|Bumetanide 1 MG|all patients will be taking the treatment recommended by heart failure guidelines
40985552|NCT03649685|DEVICE|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
40985553|NCT03649685|DEVICE|shame rTMS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
41144377|NCT00363090|DRUG|cyclophosphamide|
41144378|NCT00363090|DRUG|doxorubicin hydrochloride|
41463765|NCT04096339|OTHER|EGD followed by Colonoscopy|Esophagoduodenoscopy (EGD) is done first followed by Colonoscopy
41463766|NCT01226524|DRUG|Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
41463767|NCT02603549|OTHER|Pituitary panel will be drawn pre-op and post-op for all patients.|
40781109|NCT01652781|DRUG|Azacitidine|5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
40781110|NCT00102661|DRUG|Campath-1H|15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
40985554|NCT00705107|BIOLOGICAL|PegIntron pen (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling.
40985555|NCT00705107|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
40985556|NCT01521455|DRUG|HCP0910|250/50, BID for 2 weeks
40985557|NCT01521455|DRUG|Seretide Diskus|250/50, BID for 2 weeks
40985558|NCT05951387|DRUG|dexmedetomidine plus ketamine|titrating the dose of dexmedetomidine mixed with ketamine (staring dose 0.5ug/kg/hr, 0.5mg/kg/hr respectively)to achieve full sedation
40985559|NCT05951387|DRUG|Dexmedetomidine|starting intravenous infusion with dexmedetomidine starting at dose 0.5ug/kg//hr and titrate the dose to achieve full sedation
40985560|NCT00574509|RADIATION|131Iodine-Anti-B1 Radioimmunotherapy|Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
41463768|NCT05386173|PROCEDURE|Fetal aortic balloon dilatation|Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.
41463769|NCT01160445|DRUG|Zanolimumab|14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.
41463770|NCT01160445|DRUG|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses.
41463771|NCT00137202|DRUG|Ondansetron (Zofran)|
41463772|NCT00137202|DRUG|Diphenhydramine (Benadryl)|
40985561|NCT00574509|DRUG|BEAM|Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran
41304934|NCT03894527|BEHAVIORAL|Control Condition|A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.
41304935|NCT03217578|OTHER|SMA Newborn Screening|
41304936|NCT03271385|DIAGNOSTIC_TEST|evaluated by the predetermined differentiating formula|After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
41304937|NCT05425238|OTHER|Blood flow restriction|"strengthening protocol but with Blood flow restriction technique~.Standard BFR Application: a standard pressure (used for all patients) for e.g. 180~mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.40% cuff pressure as percentage of LOP.(4) And performing BFR-RE with low load exercises. So 30% of 1 RPM would be enough 4 times a week for 6 week"
41304938|NCT05425238|OTHER|Conventional physical therapy|Resistance exercise 75 repetitions across four sets of exercises, with30 repetitions in the first set and 15 repetitions in each subsequent set. 4 times a week for 6
41304939|NCT03584854|DRUG|15-methyl prostaglandin F2α|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine."
41304940|NCT03584854|DRUG|Methylergonovine Maleate|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost."
41463773|NCT06183320|PROCEDURE|Restoration with Incremental Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, proximal wall will be completely restored with Vittra APS composite resin, using the triangular incremental traditional technique described for classe II restorations. Then, Opus Bulk Fill Flow APS will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
41463774|NCT06183320|PROCEDURE|Restoration with Bulk Fill Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, Opus Bulk Fill Flow APS resin will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
41463775|NCT00685750|PROCEDURE|Collection of tumor and blood samples|Samples will be collected before and after standard treatment
41463776|NCT05692154|DRUG|Fexofenadine|Fexofenadine oral tablet
40985562|NCT03348020|PROCEDURE|Blood Donation|Subjects will donate blood within \~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.
41304941|NCT00924976|BEHAVIORAL|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
41304942|NCT05545267|PROCEDURE|Angioplasties|Transluminal angioplastie
41463777|NCT05692154|DRUG|Placebo|Fexofenadine matching placebo oral tablet
40985563|NCT06221904|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
40985564|NCT00176007|PROCEDURE|Hypoxia|
40985565|NCT04834947|PROCEDURE|prone position|Choice of prone positioning a patient is at the discretion of the anesthesia physician.
41144379|NCT00363090|DRUG|prednisone|
41144380|NCT00363090|DRUG|vincristine sulfate|
41144381|NCT00363090|OTHER|flow cytometry|
41463778|NCT02754128|BEHAVIORAL|BeFAST|The motor learning (ML)-based gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined training/home imagery) will be five per week.
41463779|NCT02754128|BEHAVIORAL|BeSTRONG|The functional strength training program is designed to improve gait-related skills. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down. Children will be given a 3- to 5-min home program of strength exercises to practice on days when they do not have active training sessions. The total number of sessions (combined training/home program) will be five per week.
41463780|NCT05395494|DRUG|D-Cycloserine|"Daily oral D-cycloserine 100mg during TMS treatments (20 days).~Other Names:~Seromycin"
41463781|NCT05395494|DRUG|Placebo oral tablet|Daily oral placebo during the TMS treatments (20 days).
40781111|NCT05578066|OTHER|Developing teams of Local Leaders|A team of local leaders, consisting of 3-5 PHC providers and 1-2 users at each CESFAM will be developed in months 1-3 of the intervention.The teams will comprise some individuals who have provided critical support and input, including participating in the exploratory research phase and the Community-Based Participatory Research (CBPR) adaptation of the intervention framework for the Chilean context developed previously. The teams will assist with the data collection process throughout the study by encouraging colleagues to complete questionnaires and recruit users, as well as oversee and implement the intervention at their respective CESFAM. They will receive training to develop their skills as leaders and support the implementation process at their respective CESFAM.
40781112|NCT05578066|OTHER|Analysis of Internal Policies, Procedures and Protocols|This component involves evaluating CESFAM policies, procedures, and protocols using an anti-stigma/pro-recovery approach to identify strengths and areas for improvement in service delivery for individuals affected by MISUI. This will be completed using a policy analysis tool based on existing frameworks, such as the Health Equity Impact Assessment Tool (PHO \& OMHLTC, 2012) and the QualityRights Toolkit (WHO, 2012). At least 5 policies, procedures, or protocols to be analyzed will be selected by the local leaders at intervention CESFAM during months 3-6 of the intervention. Recommendations concerning health equity, prevention of stigma, and promotion of recoveryoriented practices for individuals with MISUI will be developed and shared following analysis. Each intervention CESFAM will be expected to implement at least one recommendation and make the necessary efforts to educate PHC providers about the policy change in months 7-18 of the intervention.
41463782|NCT05395494|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
41463783|NCT02358551|DEVICE|Placement of electrode lead through axillary vein puncture|
41463784|NCT02358551|DEVICE|Placement of electrode lead through subclavian vein puncture|
41463785|NCT00842816|DRUG|ST101|10 mg; administered once/day
41463786|NCT00842816|DRUG|ST101|60 mg; administered once/day
41463787|NCT00842816|DRUG|ST101|120 mg; administered once/day
41463788|NCT00842816|DRUG|Placebo|placebo tablets to match ST101 tablets
41463789|NCT04556734|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily
41463790|NCT04556734|DRUG|Etrasimod|Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily
41463791|NCT04556734|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily
41463792|NCT05736796|OTHER|Lumber strengthening exercises|Complex Training program to Achieve the normal postural. Lumber Extension Excersie will be done to prevent the lumber straighten.
41144382|NCT00363090|OTHER|pharmacological study|
41463793|NCT05736796|OTHER|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
41463794|NCT00125541|DRUG|C1 inhibitor concentrate (C1-esteraseremmer-N)|every 5-7 days
41463795|NCT01422928|PROCEDURE|Medical Acupuncture|"Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.~Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:~* GV.14~* LI.11 (bilateral)~* SP.6 (bilateral)~* SP.10 (bilateral)~* ST.36 (bilateral)~Additional points may be added based on the symptom concerns reported."
41144383|NCT00839085|DRUG|GSE|grape seed extract (100 mg/6h), PO
41144384|NCT00839085|DRUG|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
41463796|NCT03749915|DEVICE|Pain Ease Cold Spray|Pain Ease is a spray containing 1,1,1,3,3-Pentafluoropropane (HFC-245fa) and 1,1,1,2-Tetrafluoroethane (HFC-134a). It is a vapocoolant for use as a topical anesthetic.
41463797|NCT03749915|DRUG|Ametop|Tetracaine Hydrochloride Gel 4%
41463798|NCT02347319|DRUG|Pennel|Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
41463799|NCT02347319|DRUG|Legalon|Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
41463800|NCT02347319|DRUG|Placebo|Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
41463801|NCT06024382|OTHER|twin block|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
41463802|NCT06024382|OTHER|twin block combined with low level laser|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
41463803|NCT00111462|DRUG|Darbepoetin alfa|
41144385|NCT00861354|DEVICE|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
41463804|NCT01978691|DIETARY_SUPPLEMENT|Bifidobacterium animalis ssp. lactis 420|Studied as a probiotic bacteria
41463805|NCT01978691|DIETARY_SUPPLEMENT|Polydextrose|Studied as a prebiotic
41463806|NCT01978691|OTHER|Placebo|Control
41463807|NCT01427881|DRUG|cyclophosphamide|Given IV
41463808|NCT01427881|DRUG|cyclosporine|Given IV
41463809|NCT01427881|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
41304943|NCT02742649|DRUG|Fixed Combination|Continuous elution from the ocular insert.
41463810|NCT01427881|RADIATION|total-body irradiation|Undergo TBI
41463811|NCT01427881|DRUG|fludarabine phosphate|Given IV
41463812|NCT01427881|DRUG|busulfan|Given IV
41463813|NCT01427881|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
41463814|NCT01467596|DEVICE|Elderly population, Middle aged population|The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
41463815|NCT03504124|OTHER|Multicomponent intervention|An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
40985566|NCT01577329|BEHAVIORAL|Mindfulness meditation|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
41463816|NCT02104258|OTHER|Physiotherapy ASPETAR|Standardized physiotherapy protocol
41463817|NCT02104258|OTHER|Physiotherapy ASPETAR+|Standardized physiotherapy protocol including early lengthening exercises
41463818|NCT02823847|BEHAVIORAL|Screening Interview|Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.
40985567|NCT06313931|DEVICE|cognitive training via immersive virtual reality|20 minutes per session, twice a week for six weeks (totaling 12 sessions), using the cupboard task application.
41463819|NCT02823847|DEVICE|Carbon Monoxide Test|Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.
41463820|NCT02823847|BEHAVIORAL|Self-Help Materials|"Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline.~Participants with premalignant and malignant oral lesions \[PMOL\]) given printed materials and web-based programs for tobacco and alcohol cessation."
41463821|NCT02823847|PROCEDURE|Visual Oral Screening Examination|Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.
41463822|NCT02823847|PROCEDURE|Direct Fluorescent Oral Visualization Examination|Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.
40985568|NCT06313931|OTHER|cognitive training via paper and pencil|20 minutes per session, twice a week for six weeks (totaling 12 sessions), using cards.
40985569|NCT06313931|OTHER|motor stimulation|motor stimulation for 12 sessions (20 minutes per session)
40985570|NCT01851564|DEVICE|Self-expanding mesh-metal oesophageal stent (SEMS)|A removable stent designed for the treatment of bleeding oesophageal varices.
40985571|NCT01851564|OTHER|Standard Therapy|Standard Medical and Endoscopic Therapy
40985572|NCT05620550|PROCEDURE|ozonated oil|Post operative scar treatment with ozonated oil
40985573|NCT05620550|PROCEDURE|non ozonated oil|Post operative scar treatment with non ozonated oil
40985574|NCT00156533|DRUG|Zolpidem|10 mg of Zolpidem
40985575|NCT00156533|DRUG|Sugar Pill|
40985576|NCT01883830|DEVICE|gaming therapy (Xbox)|
40985577|NCT01883830|DEVICE|Dynamic balance platform (Biodex)|
40985578|NCT06155331|DRUG|Fenofibrate|It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).
40985579|NCT06155331|OTHER|Placebo|Placebo is made to look exactly like a real drug but is made of an inactive substance.
40985580|NCT06155331|DRUG|Doxorubicin|Anthracycline derived chemotherapy used in treatment of breast cancer
41304944|NCT02742649|DRUG|Bimatoprost|Continuous elution from the ocular insert. This is an active control arm.
40985581|NCT06155331|DRUG|Cyclophosphamide|Alkylating agent used in treatment of breast cancer
40985582|NCT01761838|OTHER|SMT for low back pain patients|High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
41144386|NCT04550455|DRUG|Cladribine Tablets|Cladribine tablets will be administered according the current package insert guidelines
41304945|NCT02742649|DRUG|Timolol|Continuous elution from the ocular insert. This is an active control arm.
41304946|NCT02742649|DEVICE|Placebo Segment|One segment of placebo (no drug product)
41304947|NCT02742649|DRUG|Timolol 0.5%|0.5% timolol drops twice daily.
41463823|NCT02823847|PROCEDURE|Oral Biopsy|Premalignant and malignant oral lesions \[PMOL\]) still present 2 weeks after oral exam are biopsied.
41463824|NCT03768817|OTHER|No Intervention|This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.
41463825|NCT04035954|OTHER|exercise|The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
41463826|NCT02595827|OTHER|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
41463827|NCT06232837|DEVICE|Direct laryngoscopy using Macintosh blade|Patients in operative room requiring direct laryngoscopy for endotracheal intubation
40781113|NCT05578066|OTHER|Raising Awareness|Various forms of media will be used to raise awareness about stigma related to MISUI among PHC providers and users. Local leaders at intervention CESFAM will determine the type of media they would like to use; this may include images, film, music, or a combination of media. The research team will work with local leaders to develop messaging to include in the media and assist with showcasing these pieces within each intervention CESFAM. This component will be implemented throughout the intervention (intervention months 1-18). Depending on the type of media, instances of use will be tracked accordingly. For example with posters, data on the number of posters posted at a CESFAM over what time period and an estimation of the number of PHC providers and users who have viewed the posters will be collected.
41463828|NCT02087917|DRUG|HS-25|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
41304948|NCT00041223|DIETARY_SUPPLEMENT|IH636 grape seed proanthocyanidin extract|
41304949|NCT00717262|DRUG|HQK-1001|HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
40985583|NCT01761838|OTHER|Pain induction (optional)|A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
40985584|NCT01761838|OTHER|Low back pain participants without SMT|No treatment
40985585|NCT05881603|OTHER|" VExUS score  (Venous Excess Ultrasound Score)"|" VExUS score  (Venous Excess Ultrasound Score)"
40985586|NCT00694213|BIOLOGICAL|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
40985587|NCT00694213|BIOLOGICAL|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
40985588|NCT00694213|BIOLOGICAL|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
41463829|NCT02087917|DRUG|Placebo|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
40985589|NCT00694213|BIOLOGICAL|PBS|IM, 1 mL, 2 injections, 0 and 21 days
40985590|NCT04771507|DRUG|Ibrutinib|Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.
40985591|NCT05383300|DRUG|Oxytocin nasal spray|Intranasal spray containing 40 IU of oxytocin
40985592|NCT05383300|OTHER|Placebo spray|Application of inert placebo, identical in odor, color, and droplet size except for absence of oxytocin
41144387|NCT02767037|DEVICE|Sudoscan and clinical assessment|The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.
41463830|NCT05788250|PROCEDURE|Subacromial spacer implantation|A biodegradable balloon implanted arthroscopically between the acromion and humeral head with tenotomy of long head of biceps.
41144388|NCT02767037|GENETIC|Skin biopsy|Evaluation of the denervation and synuclein deposition of skin biopsy
41144389|NCT02173457|DRUG|Chiglitazar|Take orally
41144390|NCT02173457|DRUG|Sitagliptin|Take orally
41144391|NCT00818519|DRUG|EE20/Drospirenone (YAZ, BAY86-5300)|20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
41144392|NCT00818519|DRUG|Placebo|Inert tablet
41304950|NCT00717262|DRUG|placebo|Matching placebo capsules administered once a day, orally, for 14 days.
41304951|NCT03472378|DRUG|DFN-15|Oral Solution of 4.8 mL containing 120 mg of DFN-15
41463831|NCT05788250|PROCEDURE|Rotator cuff repair|Rotator cuff repair with tenotomy of long head of biceps.
41144393|NCT01328223|RADIATION|sorafenib and radiotherapy for hepatocellular carcinoma|Concurrent and maintenance sorafenib 400mg twice daily
41144394|NCT00721097|OTHER|spirometry, and blood taken|each month during one year
41147037|NCT00668746|DRUG|Minocycline HCl microspheres|At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
41147038|NCT00227422|BIOLOGICAL|Mencevax ACWY|
41147039|NCT06381297|DIAGNOSTIC_TEST|Hearing test|Hearing and speech tests of MS group and control group in the presence and absence of noise will be evaluated. Suppression test will be performed with OAE test in the presence and absence of noise.
41304952|NCT03472378|OTHER|Placebo|Oral Solution of 4.8 mL containing 0 mg of DFN-15
41304953|NCT05673005|DEVICE|MED3000 topical gel|Topical gel that has been shown to improve erectile dysfunction when used as needed.
40781114|NCT05578066|OTHER|Innovative Contact-Based Education|Educational workshops will include anti-stigma and recovery principles, along with specific MISUI topics relevant to PHC providers. This will be determined by findings from the exploratory phase, current research, best practices, and the perspectives of local leaders. It may include (1) supporting CESFAM PHC providers in preventing stigma and promoting recovery in their practice and (2) enhancing the competencies of CESFAM PHC providers for discussing MISUI with their users, identifying MISUI signs and symptoms, and referring users to psychosocial centres for treatment. The key feature of these workshops is the contact-based educational element, where people with lived experience participate in developing and delivering the curriculum to CESFAM PHC providers. Four three-hour workshops will be held at each intervention CESFAM and will be facilitated by two academic/clinical trainers with expertise in stigma research and practice, and one person with lived experience.
40781115|NCT05578066|OTHER|Recovery-Based Arts|Local leaders at CESFAM will select one PHC provider member and recruit one artist to develop an arts curriculum and facilitate the art sessions. The facilitators will select an art form to use throughout the sessions, and in collaboration with local leaders they will determine themes related to MISUI to cover in each session (planning process will be completed in intervention months 7-8). Arts workshops will be held for 10 weeks, with each session lasting up to three hours (during intervention months 9-12). Ten users affected by MISUI and at least three CESFAM PHC providers will participate in the workshops each week. At the end of the 10-week program, each CESFAM will host an exhibition to showcase the artwork that has been produced (during intervention months 13-18). All PHC providers and users, as well as community members, will be invited to attend the exhibition. PHC providers and users will be invited to speak about their experiences learning and working together to create art.
40985593|NCT01518777|OTHER|Half-dose isotope for NuclearStressTest|Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
40985594|NCT04085133|DIAGNOSTIC_TEST|Gene Xpert Chest x ray and MSCT chest|Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis
41304954|NCT04629989|OTHER|Standard Oxygen Delivery System|The standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
40985595|NCT03474354|DEVICE|chemoembolization|correlation of necrosis with the deposition of beads
40985596|NCT04417881|OTHER|MEESSI score|MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.
40985597|NCT00183300|BEHAVIORAL|Prolonged Exposure Therapy|
40985598|NCT00148889|DEVICE|Deep brain stimulation (DBS)|Bilateral pallidal stimulation with an implanted DBS device
41304955|NCT04629989|OTHER|Double-Trunk Mask|The Double-Trunk Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
41304956|NCT04629989|OTHER|Surgical Mask|The Surgical Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
41304957|NCT06342726|DEVICE|PAX Warming Blanket|Electric resistive active external warming blanket
41304958|NCT06342726|DEVICE|Passive insulation|3-layered wrapping model
41304959|NCT01225640|DRUG|PNU-100480|600 mg twice daily (BID) for 14 days
41304960|NCT01225640|DRUG|PNU-100480|1200 mg once daily (QD) for 14 days
41304961|NCT01225640|DRUG|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
41304962|NCT01228071|DRUG|testosterone gel 2%|40 mg testosterone gel 2%
41304963|NCT02690233|PROCEDURE|Elective Surgery|Elective laparoscopic inguinal hernia repair
41304964|NCT01810198|PROCEDURE|Cardiac CT|Perform a non-invasive Cardiac CT Angiogram
41304965|NCT01810198|PROCEDURE|Invasive Coronary Angiography|Patient undergoes Invasive Coronary Angiography
41304966|NCT01524445|OTHER|bortezomib retreatment due to relapse|Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
41304967|NCT00810719|DRUG|Erlotinib|Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
40985599|NCT02474992|BEHAVIORAL|Microclinic|Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
41144395|NCT02474745|PROCEDURE|- Directed open-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
41144396|NCT02474745|PROCEDURE|Directed closed-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
41144397|NCT03267797|OTHER|Peripheral Blood Monouclear Cell|Blood samples (20 mL) were taken from individual patients at the time of ovulation induction. Then PBMC were isolated and cultured (20-30 million cells) 48 hour at the presence of hCG (10IU/ml daily). Afterward,15-20 million PBMCs in 500 microlitres PBS were injected into the uterine cavity two days before embryo transfer (ET) using ET catheter.
41304968|NCT00810719|DRUG|gemcitabine|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
41304969|NCT00175084|BEHAVIORAL|Comparison of dietary protein amino acid profile|Healthy adults over 50 years of age (men and postmenopausal women) will be assigned to one of two diets differing in lysine to arginine ration (0.7 vs. 1.4) for a 5 week period and then switched to the alternate diet, with a 2 to 4-week washout period, in a randomized crossover design. Blood samples will be collected three times in the fasted state and once 4-hours after the evening meal during the last week of each dietary period of measurement of concentration of plasma lipids, lipoproteins, apolipoproteins, arginine, C-reactive protein, nitrites/nitrates, homocysteine, lecithin-cholesterol acetyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and LDL-receptor messenger ribonucleic acid (mRNA) expression.A 24-hour urine sample will be collected at the end of each phase to measure F2-isoprostanes as an indicator of whole body oxidation.
41304970|NCT01332812|DRUG|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
41304971|NCT01332812|OTHER|control group|General anesthesia, without additional interventions
40985600|NCT01571414|DRUG|PA-824|200-mg tablets once a day
40985601|NCT01571414|DRUG|Efavirenz (EFV)|600-mg tablets once a day
40985602|NCT01571414|DRUG|Lopinavir/Ritonavir (LPV/r)|400-mg/100-mg tablets twice a day
41144398|NCT03267797|OTHER|Phosphate Baffer Saline|Only 500 microlitres PBS will be injected into the uterine cavity, instead of PBMCs, two days before embryo transfer (ET) using ET catheter.
41144399|NCT00637559|DRUG|Esomeprazole Magnesium|
41144400|NCT01853904|PROCEDURE|Bronchoscopy/ BAL with Channel Suction|The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
41144401|NCT01853904|PROCEDURE|Bronchoscopy/BAL with Syringe Suction|Syringe based suctioning will be performed with 20mL syringe.
41144402|NCT01543789|PROCEDURE|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity.
41144403|NCT01543789|PROCEDURE|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
41144404|NCT03370588|DRUG|dexmedetomidine|Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.
41144405|NCT03370588|DRUG|Normal saline|Group B: Saline infusion during same time period.
41144406|NCT05577182|DRUG|INCA32459-101|solution for infusion
41304972|NCT00559052|DRUG|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
41304973|NCT01963299|DRUG|5 ml Ropivacaine 10% + physiological saline|
41304974|NCT01963299|DRUG|5 ml Ropivacaine 10% + Clonidine 1 µg/kg|
40985603|NCT01571414|DRUG|Rifampin (RIF)|300-mg capsules once a day
40985604|NCT01068119|PROCEDURE|Same-day discharge|Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
40985605|NCT03984604|DRUG|CHI-921|a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form
40985606|NCT03984604|DRUG|Placebo|Placebo is a vehicle oil will match CHI-921
40985607|NCT02461108|BEHAVIORAL|Subsidy|Frame the price difference as a 10% subsidy on nutritious food items.
40985608|NCT02461108|BEHAVIORAL|Tax|Frame the price difference as a 10% tax on less nutritious food items.
40985609|NCT02461108|BEHAVIORAL|Tax and subsidy|Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
40781116|NCT01471964|DRUG|MLN8237 and Erlotinib|Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
40985610|NCT00449046|DRUG|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
40985611|NCT05494450|DEVICE|ExufiberAG+|confirm performance and safety of the Exufiber Ag+ dressing in medium to high exuding chronic wounds
40985612|NCT03869866|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
40985613|NCT01319903|BIOLOGICAL|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
40985614|NCT06131242|OTHER|It is an observational study|It is an observational study
41304975|NCT00433732|DRUG|sumatriptan|
41463832|NCT05478187|DEVICE|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
40781117|NCT06153056|DIAGNOSTIC_TEST|Bloed-, ontlasting- en speekselmonsters|"In addition, the blood collected (24 mL) will be used for the following analyses:~GLP-1, PYY, branched-chain amino acids, Adipokines, leptin, adiponectin Blood bile acid levels: total and detailed analyzed by HPLC MS/MS Serum microbiome profile Genome-wide association study.~The stool sample will be used to establish the :~Intestinal bile acid profile Intestinal microbiota profile Saliva sampling for oral microbiota profiling."
40781118|NCT04265131|OTHER|art therapy|Art therapy is a form of psychotherapy that uses creative methods of expression through art media, such as pencils, clay, paint etc.
40781119|NCT04899765|BIOLOGICAL|BCG vaccine|It is an attenuated live bacterial vaccine. This vaccine is a freeze-dried product that must be reconstituted.
40985615|NCT05884047|DEVICE|Virtual Glasses|"In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel \& Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel \& Relax is a Paris-Notre Dame museum tour video."
41304976|NCT00433732|DRUG|naproxen sodium|
40781120|NCT04899765|BIOLOGICAL|Measles vaccine|It is an attenuated live virus vaccine. This vaccine is a freeze-dried product that must be reconstituted.
40781121|NCT04899765|OTHER|Placebo|Saline
40781122|NCT03844308|BEHAVIORAL|Isha Kriya Meditation|Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.
40781123|NCT02175186|DRUG|ALBIS|
40781124|NCT02175186|DRUG|Placebo|
40781125|NCT04864691|BIOLOGICAL|endovascular recanalization|to recanalize the occlusion cerebral artery with intravascular intervention
40781126|NCT04140617|BEHAVIORAL|Exposure to aerosol of electronic cigarette|Exposure to aerosol of electronic cigarette (30 min)
40781127|NCT06135948|DRUG|Extra dose of L-thyroxine, 25 mcg during Ramadan|Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
40781128|NCT01114737|DRUG|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
40781129|NCT01114737|DRUG|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
40781130|NCT04252014|BEHAVIORAL|Hookah tobacco messages|Messages communicating the risks of hookah tobacco use in 4 thematic areas: health harms, addictiveness, social use, flavorings.
40781131|NCT05544253|PROCEDURE|mitomycin C-based hyperthermic intraperitoneal chemotherapy|The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group. All of them have received open liver resection and perfusion tubes had been set in the operation. For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC. Finally, place the HIPEC tubes. Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation. We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC. The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline. The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
40781132|NCT05726149|DEVICE|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
40781133|NCT05726149|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
40985616|NCT02964468|RADIATION|3DCRT treatment (sequential boost)|"Radiotherapy:~3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.~3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.~Chemotherapy:~According to routine clinical practice of the participating centers."
40781134|NCT05726149|DEVICE|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
40781135|NCT00473018|BEHAVIORAL|standard versus enhanced risk reduction counseling|
41304977|NCT03553329|DRUG|dabrafenib|Monthly biological assessment which included: blood count, a blood electrolytes, an creatininemia, a dosage of urea, a dosage of transaminases, of gammaGT, of phosphatases alkaline, of LDH and of albumin.
41304978|NCT04356755|DRUG|AdMSC|At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks
41463833|NCT05478187|OTHER|Traditional visual cues - Control group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
40781136|NCT01370187|DRUG|Montelukast|Montelukast 4mg daily for 2 months
40781137|NCT02263014|BEHAVIORAL|Questionnaires|Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
40781138|NCT05925348|DIAGNOSTIC_TEST|Patients with cardiopulmonary bypass|"Due to the observational design of the study, no study-specific interventions are performed.~Blood samples are measured to analyze blood-levels of endotoxin"
40781139|NCT04199585|DRUG|Lu AF95245|solution, single dose, orally
40781140|NCT04199585|DRUG|Lu AF95245 14C radiolabelled spiked dosage|solution, single dose, orally
40781141|NCT04199585|DRUG|Placebo|solution, single dose, orally
40781142|NCT03631264|DEVICE|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants to improve sucking and swallowing.
40781143|NCT02343302|DEVICE|Jackson-Pratt Drain|"A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain"
41144407|NCT06165133|OTHER|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP)|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP) through an accredited training programme prior to commencing participation in the study
41304979|NCT04356755|DRUG|Placebo|At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks
41463834|NCT04134637|DEVICE|ultrasound|in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.
40985617|NCT02964468|RADIATION|Dose Escalation Intensity Modulated Radiotherapy treatment|"Radiotherapy:~IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.~Chemotherapy:~According to routine clinical practice of the participating centers."
40985618|NCT03510520|DEVICE|Medium Cut-Off Haemodialysis|Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months
41144408|NCT06165133|OTHER|Mesh inguinal hernia repair performed by fully trained surgeons|Mesh inguinal hernia repair performed by fully trained surgeons, recognised by the Ghana College of Surgeons and Physicians and other recognised Surgical Colleges around the globe.
41144409|NCT06301945|DIAGNOSTIC_TEST|Artificial Intelligence Diagnostics|AI Diagnostics uses advanced algorithms for precise histological image analysis to help diagnose disease, including subtype.
41144410|NCT06301945|DIAGNOSTIC_TEST|Recurrence Prediction Tool|This AI tool evaluates thymic tumour data and other clinical data and calculates the risk of recurrence, with the aim of analysing whether there is an association with specific subtypes of thymic epithelial tumours and clinical data.
40985619|NCT03510520|DEVICE|On-Line Haemodiafiltration|Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)
40985620|NCT03735433|DRUG|162mg aspirin dose|2 pills of 81mg aspirin
40985621|NCT06420440|PROCEDURE|Hepatic arterial infusion chemotherapy|Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days)
40985622|NCT06420440|DRUG|Lenvatinib|Patients in the neoadjuvant therapy group received Lenvatinib before surgery(Len was started before HAIC treatment, discontinued during HAIC treatment, and discontinued approximately two weeks before surgery, Oral 8 mg or 12mg once a day depending body weight).
41144411|NCT03884478|BEHAVIORAL|Personalized Normative Feedback|Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
41144412|NCT04101188|OTHER|Moderate Potassium/Low Sodium Diet|Consumption of 10 days of a diet moderate in potassium and low in sodium.
41144413|NCT04101188|OTHER|Moderate Potassium/High Sodium Diet|Consumption of 10 days of a diet moderate in potassium and high in sodium.
41144414|NCT04101188|OTHER|High Potassium/High Sodium Diet|Consumption of 10 days of a diet high in potassium and high in sodium.
41144415|NCT00238745|DRUG|Bazedoxifene|
41144416|NCT00238745|DRUG|Placebo|
41463835|NCT04134637|DRUG|Bupivacaine Hydrochloride 5 MG/ML|twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
41144417|NCT05792176|BEHAVIORAL|Music Training Intervention|The Music Training Intervention (MTI) entails 12-weeks of online instruction to learn to play the ukulele. Participants will be taught the basic information on how to handle and hold the ukulele, musical chords, and popular songs. They will be instructed to play at least 30-minutes a day, five days a week.
41144418|NCT05792176|BEHAVIORAL|Music Listening|Participants randomized to this arm will be asked to listen to their preferred music for at least 30 minutes, 5 days a week. A member of our research team will call them every week to answer any questions they have about the ML protocol. They will be asked to record their experience in a practice log.
41144419|NCT01377844|DRUG|EGT0001442|
41463836|NCT00164372|BEHAVIORAL|Peer Education Intervention|
41463837|NCT01671592|BIOLOGICAL|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
40985623|NCT06420440|DRUG|Tislelizumab|Patients in the neoadjuvant therapy group received two cycles of Tislelizumab therapy before surgery (First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)
40985624|NCT06420440|PROCEDURE|Liver resection|Patients in the neoadjuvant therapy group were evaluated for tumor status and surgical safety after neoadjuvant therapy, and eligible patients subsequently underwent surgical resection. Patients in the direct surgery group underwent liver resection.
40985625|NCT06420440|DRUG|Tislelizumab|Given the high risk of postoperative recurrence, patients in both groups received adjuvant Tis therapy (every 21 days for 8 cycles) starting about one month after surgery.
41144420|NCT01377844|DRUG|Placebo|
41144421|NCT01176409|DRUG|Valacyclovir|Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
41144422|NCT01176409|DRUG|Placebo|Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
41144423|NCT04880031|DRUG|BOS-580|BOS-580 will be administered by subcutaneous injection
40781144|NCT02343302|DEVICE|Non-suctioning drainage|"A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain"
40781145|NCT06250764|DIAGNOSTIC_TEST|Clinical periodontal measuremenets|The periodontal assessment was performed by a single trained examiner (S.D.). A graded periodontal probe (Williams, Hu-Friedy, Chicago, IL, USA) was used to measure probing depth (PD) which was determined as the depth from the gingival margin to the bottom of the gingival sulcus/periodontal pocket, clinical attachment loss (CAL) which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording (+/-) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) in total except third molars G
40781146|NCT06250764|DIAGNOSTIC_TEST|ELISA test from gingival crevicular fluid (GCF)|GCF sampled from the buccal aspects of non-contiguous proximal regions in maxillary single-rooted teeth. In the periodontitis groups, fluid samples were taken from the two deepest pockets. In the gingivitis and periodontal healthy groups, fluid samples were obtained from areas with and without visible inflammation, respectively
40781147|NCT04167254|BEHAVIORAL|Sit Down and Play|Brief health care-based program that aims to promote key parenting behaviors that promote early childhood development
40781148|NCT03953807|DRUG|Dexamethasone Intravitreal Implant|Implant 700 μg
40781149|NCT03952208|OTHER|Neurocognitive Testing|A comprehensive assessment of neuropsychometric measures to evaluate cognitive functioning.
40781150|NCT02466724|DEVICE|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
40781151|NCT05291754|DEVICE|PEEK Cranioplasty|3D printed PEEK skull implant
40781152|NCT02890875|OTHER|Ethanol lock|
40781153|NCT02890875|OTHER|Heparin lock|
40781154|NCT05687227|BEHAVIORAL|Online education and counseling|Online education and counseling regarding gynecological examination
40781155|NCT01935947|DRUG|Azacitidine|Given SC
40781156|NCT01935947|DRUG|Azacitidine|Given PO
40781157|NCT01935947|DRUG|Docetaxel|Given IV
40781158|NCT01935947|DRUG|Entinostat|Given PO
40781159|NCT01935947|DRUG|Gemcitabine Hydrochloride|Given IV
40781160|NCT01935947|DRUG|Irinotecan Hydrochloride|Given IV
40781161|NCT01935947|OTHER|Laboratory Biomarker Analysis|Correlative studies
40781162|NCT01935947|DRUG|Pemetrexed Disodium|Given IV
40781163|NCT03132285|DEVICE|PrePex|Prepex is a non surgical male circumcision device
40781164|NCT04089020|BEHAVIORAL|Support for walking to school|5 modules that address psychosocial skills, with ongoing text messaging.
40781165|NCT04951531|PROCEDURE|BPTB double-bundle allograft|The patient underwent surgery of arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
40781166|NCT04951531|PROCEDURE|BPTB single-bundle allograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
40781167|NCT04951531|PROCEDURE|BPTB single-bundle autograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
40781168|NCT05070130|DEVICE|dPR and FFR|OpSens non-hyperemic dPR and/or OpSens FFR
40985626|NCT05643365|RADIATION|Radioactive Iodine therapy|All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.
41144424|NCT04880031|DRUG|Placebo|Placebo will be administered by subcutaneous injection
40781169|NCT05962944|DEVICE|Olympus Cellsens software|Olympus cellsens software will be used to visualise the cells and MS teams screen share will be used to send the live images in real time.
40781170|NCT01594242|DRUG|Bortezomib|
40781171|NCT03738917|DRUG|Dextromethorphan 15 milligrams|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
40781172|NCT03738917|DRUG|Ipratropium Bromide 20Micrograms Inhaler|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
40781173|NCT03738917|DIETARY_SUPPLEMENT|Honey 30 g (full tablespoon)|This study product will be provided free to the participants by the sponsor.
41144425|NCT04344236|DRUG|Saline oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
40781174|NCT03738917|OTHER|Usual clinical practice|Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.
40781175|NCT01310972|OTHER|Registry|Registry
40781176|NCT05989776|BEHAVIORAL|Informational brochure for patients and brief training for oncologists|For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.
40781177|NCT05908162|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils
40781178|NCT00419055|PROCEDURE|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
40781179|NCT02182518|DRUG|Epinastine|
40781180|NCT02182518|DRUG|Pseudoephedrine|
40781181|NCT02182518|DRUG|Placebo|Placebo during run-in period
40781182|NCT01911468|DRUG|metformin|
40781183|NCT01911468|DRUG|liraglutide|
40781184|NCT01911468|DRUG|metformin and liraglutide|
40781185|NCT05195203|DRUG|HS-10353|Single or multiple dose(s) of HS-10353
40781186|NCT05195203|DRUG|Placebo|Single or multiple dose(s) of placebo
40781187|NCT00427193|BEHAVIORAL|Caloric Restriction (CR)|Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
40781188|NCT00427193|BEHAVIORAL|Control|Participants continue their current diet for 24 months
40781189|NCT00003816|BIOLOGICAL|anti-thymocyte globulin|Given IV
40781190|NCT00003816|DRUG|busulfan|Given IV
40781191|NCT00003816|DRUG|carboplatin|Given IV
40781192|NCT00003816|DRUG|cyclophosphamide|Given IV
40781193|NCT00003816|DRUG|etoposide|Given IV
40781194|NCT00003816|DRUG|fludarabine phosphate|Given IV
40781195|NCT00003816|DRUG|melphalan|Given IV
41144426|NCT04344236|DRUG|0.5% Povidone/Iodine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
41144427|NCT04344236|DRUG|0.12% Chlorhexidine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
41144428|NCT04229940|PROCEDURE|Peritoneal bridging|The defect is covered by peritoneal bridging
41144429|NCT04229940|PROCEDURE|No peritoneal bridging|The defect is left without bridging
40781196|NCT00003816|DRUG|thiotepa|Given IV
41304980|NCT00675558|PROCEDURE|Initial Surgery|"NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.~MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.~All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) \& fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified."
41304981|NCT00675558|PROCEDURE|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
40781197|NCT00003816|RADIATION|total-body irradiation|Given twice daily for 3 days
40781198|NCT00193024|DRUG|Docetaxel|
40781199|NCT00193024|DRUG|Epirubicin|
40781200|NCT02659085|DRUG|Ketamine IV Infusion|Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
40781201|NCT02659085|PROCEDURE|ECT|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
40781202|NCT00790673|DRUG|CF 102|Oral capsules
40781203|NCT00790673|DRUG|Placebo|Matching placebo capsules
40781204|NCT01326442|OTHER|low glycemic diet|a low glycemic diet, calorie restricted with exercise sessions 3 times per week
40781205|NCT01326442|DIETARY_SUPPLEMENT|vitamin D omega-3|2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
40781206|NCT06306001|DRUG|Methylene Blue|Subjects in the intervention arm will receive a 1 mg/kg bolus of methylene blue over 30 minutes, followed by an infusion of 0.15 mg/kg/h. The infusion rate may be increased in steps of 0.15 mg/kg/h every 30 minutes until a maximum of 0.5 mg/kg/h.
40781207|NCT06306001|OTHER|Placebo|Subjects in the placebo arm will receive normal saline in the same volumetric dose as methylene blue in the intervention arm
40781208|NCT05281913|OTHER|Psychoeducational Game|Psychoeducational Game
40781209|NCT03005340|DRUG|Treatment B|Bazedoxifene 20 mg
40781210|NCT03005340|DRUG|Treatment C|Cholecalciferol granule 10 mg
40781211|NCT03005340|DRUG|Treatment BC|Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
40781212|NCT01071954|BIOLOGICAL|Romiplostim|Administered by subcutaneous injection once a week.
40781213|NCT04179110|DRUG|Pembrolizumab and Ramucirumab|Patients will receive Pembrolizumab 200 mg \& Ramucirumab 10 mg/kg every 3 weeks.
40781214|NCT05528575|DIETARY_SUPPLEMENT|Blueberry, cranberry, green tea extract, cocoa|tablet supplements, available readily.
40781215|NCT05528575|DIETARY_SUPPLEMENT|GOS, Inulin, RS2|Prebiotic combination, Inulin, GOS and RS2
40781216|NCT05528575|DIETARY_SUPPLEMENT|prebiotics and polyphenols|combination of the same prebiotics and polyphenols as above
40781217|NCT05528575|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin, 10g per day
40985627|NCT01291758|DIAGNOSTIC_TEST|Submaximal bicycle exercise stress tests performed 24 hr apart|Submaximal bicycle exercise stress tests were performed for 25 min at 70% predicted heart rate, then ramped up to 85% predicted heart rate. Subjects could stop when they felt they had reached their maximum effort if before reaching 85% predicted heart rate.
40985628|NCT01166178|DRUG|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
40985629|NCT01166178|DRUG|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
40985630|NCT01166178|DIETARY_SUPPLEMENT|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
40985631|NCT02498457|OTHER|low calcium dialysis|patients in this group will receive low calcium dialysis for 1 year.
40985632|NCT01516814|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
40985633|NCT01516814|DRUG|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
40985634|NCT01516814|DRUG|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
40985635|NCT05321732|DRUG|DWP16001|DWP16001 A mg
40985636|NCT05321732|DRUG|DWP202010|DWP202010 B mg
40985637|NCT05814939|DRUG|VC005 tablets|VC005 groups repeat administration for 12 weeks
40985638|NCT05814939|DRUG|Tofacitinib Citrate Tablets|Tofacitinib Citrate groups repeat administration for 12 weeks
40985639|NCT05814939|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
40781218|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (meta-cognitive imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of meta-cognitive imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
40985640|NCT05546047|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
40985641|NCT03861234|DRUG|BI 836880|Solution for Intravitreal (IVT) injection
40781219|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (Imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
40781220|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (promoting positive imagery de novo)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of promoting positive imagery de novo.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
40781221|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (visuospatial working memory tasks)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of visuospatial working memory tasks.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
40781222|NCT03508050|DEVICE|Clamping the Double Lumen Tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
40781223|NCT01138514|DRUG|Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)|Applied to the entire face twice daily for 10 weeks
40781224|NCT01138514|DRUG|Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)|Applied to the entire face twice daily for 10 weeks
40781225|NCT01138514|DRUG|Placebo|Placebo
40781226|NCT03690908|OTHER|no intervention (descriptive study)|no intervention (descriptive study)
40781227|NCT05805163|BEHAVIORAL|FABI tailored COVID-19 testing pamphlet|FABI adapted COVID-19 educational pamphlet
40781228|NCT05805163|BEHAVIORAL|Standard COVID-19 home-based test kit|Standard COVID-19 home-based test kit
40781229|NCT05815914|OTHER|app|The app will include a nutritional education programme through the APP throughout the study. At 2, 4, 6 and 8 months data will be collected through a telematics questionnaire
40781230|NCT05815914|OTHER|control group|Routine nutritional and dietary recommendations will be given.
40781231|NCT01979679|DRUG|Lurasidone 80 mg|
40781232|NCT01979679|DRUG|Lurasidone 120 mg|
40781233|NCT01979679|DRUG|Lurasidone 160 mg|
40781234|NCT03507582|OTHER|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
40781235|NCT03507582|OTHER|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
40781236|NCT03047135|DRUG|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
40781237|NCT01092221|DRUG|Allopurinol|Allopurinol 1 capsule 300 mg, BID
41304982|NCT04645472|DEVICE|CT-Ultrasound|For patients with kidney stones who are planning to undergo PCNL, perform a preoperative simulated CT-ultrasound fusion examination to further clarify the condition of the kidney stones and simulate and optimize the puncture route. Apply CT- Ultrasound fusion precise positioning to guide the intraoperative PCNL puncture process.
41304983|NCT06491953|DRUG|SGLT-2 inhibitors|SGLT-2 inhibitors use or not use； the duration of SGLT-2 inhibitors use
40781238|NCT01092221|DRUG|Placebo|Placebo 1 capsule, 300 mg, BID
40781239|NCT04268238|PROCEDURE|Hygiene Guidance|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate).
40781240|NCT04268238|PROCEDURE|Sealant Application|Permaseal (Ultradent) is an unloaded resin based on methacrylate and photopolymerizable. The teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal for 5 seconds to the tooth surface and light curing for 20 seconds. After that, it is necessary to evaluate occlusion.
40781241|NCT04268238|RADIATION|Low Level Laser Application|Volunteers will receive irradiation with AsGaAl laser, wavelength of 780nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, density of energy of 35 J/cm2 (considering a spot size of 0.028cm2 of this equipment), the dose will be 1 J per point. Irradiation will be performed at a cervical, an apical point, and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
40781242|NCT03940560|DEVICE|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
40781243|NCT00140140|DRUG|ABI-007|Weekly intravenous infusions over 30 minutes.
40781244|NCT00140140|DRUG|vinorelbine|Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
40781245|NCT00140140|DRUG|Trastuzumab|"Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor."
40781246|NCT00140140|BIOLOGICAL|G-CSF|"During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was \>20,000/mm\^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor."
40781247|NCT04985084|BEHAVIORAL|The intervention group|The intervention will last for four weeks and target six dietary behaviors related to gastric cancer. The intervention components include one session of face-to-face education prior to discharge and three sessions of telephone counselling after discharge. The face-to-face education will last for 20 to 30 minutes and each session of telephone counselling will last for 10 to 20 minutes. All the interventional sessions are individual based.
40781248|NCT04985084|OTHER|Usual care|General dietary advice provided as routine by the ward nurses before discharge from the hospital.
40781249|NCT06389214|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days
40781250|NCT06389214|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered six times over two consecutive days
41304984|NCT03754283|DEVICE|Indirect bonding|Indirect bonding is the technique where orthodontic appliances are first placed on a model of the patient and then transferred to the patient using some kinf of trays
41304985|NCT03162783|DRUG|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
41304986|NCT03162783|DRUG|ADX-102 Ophthalmic Solution (0.1%)|ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
41304987|NCT03162783|DRUG|ADX-102 Ophthalmic Lipid Solution (0.5%)|ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
41304988|NCT00461955|PROCEDURE|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
40781251|NCT02874729|PROCEDURE|Venesection|Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
40781252|NCT02874729|PROCEDURE|Urine collection|Urine will be collected in appropriate sterile holders provided.
40781253|NCT02874729|PROCEDURE|Sputum collection|Saliva will be collected in appropriate sterile holders provided.
40781254|NCT02874729|PROCEDURE|Bronchoalveolar lavage|Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
40781255|NCT04120129|DEVICE|TMS|Transcranial Magnetic Stimulation (TMS) is a noninvasive brain stimulation technique which produces short pulsatile magnetic fields (similar to that of an MRI) via two extracranial, figure 8-shaped electric coils which can induce a small, temporary, electric current in the brain currently approved and used for depression.
40781256|NCT04120129|DEVICE|sham TMS coil|The sham TMS does cause some stimulation to the participant so that the participants get the sensation of treatment without any cortical excitation that TMS delivers. The sensation experienced is similar to the muscle twitching or finger tapping experienced by TMS participants.
40781257|NCT04972253|DRUG|Infigratinib|Oral, dosage per protocol
40781258|NCT02063451|DIETARY_SUPPLEMENT|Very Low Calorie Diet (VLCD)|Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
40781259|NCT05292001|DRUG|Iron-Dextran Complex Injection [InFed]|single 1000mg dose
40781260|NCT05292001|OTHER|Saline Placebo|Normal saline
40781261|NCT05683379|DIAGNOSTIC_TEST|AAV8 DetectCDx|An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.
40781262|NCT06420206|OTHER|Standard of Care (Acute Cancer Care Center)|In Group 1, participants will receive the usual standard of care by an emergency care physician not trained in palliative care.
40781263|NCT06420206|OTHER|Standard of Care (Goals of Care)|In Group 2, participants will receive standard of care plus palliative care intervention by an emergency care physician trained in palliative care.
40781264|NCT01517984|DRUG|Tacrolimus (CNI) Withdrawal|"Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.~Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal."
40781265|NCT01517984|DRUG|Standard Immunosuppressive Therapy|Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
40781266|NCT01673126|DEVICE|Anodal tDCS|patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)
40781267|NCT01673126|DEVICE|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
40781268|NCT03571490|DRUG|Ropivacaine|Single shot of ropivacaine 0.325%
40781269|NCT03571490|DRUG|Saline|Single shot of saline 0.9%
40781270|NCT04661527|DRUG|Sarilumab|Treatment with Sarilumab 200 mg IV x 2 doses 24 hours apart for first 5 patients. If no severe AE and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg IV for the first dose and 200 mg or 400 mg IV for the second dose 24 hours later. Te second dose will be decided at the investigators discretion.
40781271|NCT03139461|OTHER|PT-REFER Capacity-building Toolkit|"1. Written guidelines for building partnerships with physical therapists. Information includes information on who to contact, how to contact them, and how to present information about the program (e.g., evidence base, program structure)~2. Support from Change Agent~3. Technical Assistance Calls"
40781272|NCT00688597|DRUG|Duvoglustat|Powder in a bottle for dissolution in water for oral administration
40781273|NCT01474109|DRUG|macitentan 3mg|macitentan 3mg tablet once daily
40781274|NCT01474109|DRUG|macitentan 10mg|macitentan 10mg tablet once daily
40781275|NCT01474109|DRUG|placebo|matching placebo once daily
41144430|NCT06222086|OTHER|Calisthenic exercise training with telerehabilitation|The training group will be given calisthenic exercise training 30-45 minutes a day, 3 days a week, via video conference, accompanied by a physiotherapist, for 6 weeks. The training workload of aerobic exercise training will be applied at 60-80% of peak heart rate, with dyspnea 3-4 points or fatigue 4-6 points according to the Modified Borg Scale (MBS). Blood sugar measurement will be taken before exercise training. People whose blood sugar result is \>300 mg/dL will not be allowed to exercise that day.
41144431|NCT06222086|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
41144432|NCT05248217|BEHAVIORAL|healthcare workers|healthcare
41144433|NCT01880359|DRUG|Cisplatin|
40781280|NCT05822414|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery
40781281|NCT01515371|DRUG|IncobotulinumtoxinA|"Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.~For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection."
40781282|NCT01515371|DRUG|Placebo Comparator|For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
40781283|NCT05857397|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
40781284|NCT01219257|BIOLOGICAL|Anti-TNF alpha therapy|All medical treatment will be standardizes following good medical practice
40985642|NCT01297140|BEHAVIORAL|questioning|Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
40985643|NCT04843644|DIETARY_SUPPLEMENT|honey|"Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
41144434|NCT01880359|RADIATION|Radiotherapy|
41144435|NCT01880359|DRUG|Placebo|
41144436|NCT01880359|DRUG|Nimorazole|
41144437|NCT00119782|BEHAVIORAL|Diet|A dietary intervention that will promote lower calorie intake
41144438|NCT00119782|BEHAVIORAL|Exercise|A physical activity intervention combining increased daily physical activity and regular, structured exercise
41144439|NCT00119782|BEHAVIORAL|Environment|Increase worksite access to both healthy foods and physical activity
41144440|NCT04718116|DRUG|Group tapentadol 50 mg|patients in group A will receive tapentadol 50 mg p.o 3 times daily for two days
41144441|NCT04718116|DRUG|group tapentadol 75 mg|patients in group B will receive tapentadol 75 mg p.o 3 times daily for two days
41144442|NCT04718116|DRUG|group tramadol 100 mg|patients in group C will receive tramadol 100 mg p.o 3 times daily for two days
41144443|NCT00780988|BIOLOGICAL|Autologous tumor cell + CpG vaccine|
41144444|NCT00780988|PROCEDURE|Autologous hematopoietic and immune cell rescue (transplantation)|
41144445|NCT06594497|OTHER|Conventional Physiotherapy|Conventional Physiotherapy
41144446|NCT06594497|OTHER|Conventional Physiotherapy + Kinesthetic motor imagery training|Conventional Physiotherapy + Kinesthetic motor imagery training
41144447|NCT01062165|DRUG|Caspofungin|Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
41144448|NCT01728090|OTHER|hand sanitizer|alcohol-based, hydroalcoholic gel
40781285|NCT03260712|DRUG|Pembrolizumab|The dose of pembrolizumab in this trial is 200 mg Q3W.
40781286|NCT03260712|DRUG|Cisplatin|25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
40985644|NCT04843644|DIETARY_SUPPLEMENT|propolis|"Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
40985645|NCT04843644|BEHAVIORAL|Control|usual care
40985646|NCT00519818|DRUG|Chronocort|Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
40985647|NCT00519818|DRUG|Cortef|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
40985648|NCT03659981|OTHER|MRI 7T|The imaging parameters will come from the 7 Tesla Siemens MRI
41144449|NCT04410445|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
41144450|NCT04410445|BIOLOGICAL|Nivolumab|Specified dose on specified days
41144451|NCT05692245|DRUG|Ondansetron|Administered Medication
41144452|NCT05692245|DRUG|Dexamethasone|Administered Medication
41144453|NCT04338568|DIAGNOSTIC_TEST|Lung ultrasound|The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.
41144454|NCT04471415|DRUG|DRP-104|"DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week"
41144455|NCT04471415|BIOLOGICAL|atezolizumab|atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.
41144456|NCT03335059|COMBINATION_PRODUCT|Synergo® RITE + MMC|Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC
41144457|NCT02571959|DRUG|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
41144458|NCT02571959|DRUG|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
41144459|NCT02536534|OTHER|Correlation assessment|
41144460|NCT01578304|DRUG|Imidafenacin|Tablet, 12 weeks twice daily
41144461|NCT01578304|DRUG|Fesoterodine|Tablet, 12 weeks once daily
41144462|NCT04636515|DRUG|F520|200mg，Q3W
40781287|NCT03260712|DRUG|Gemcitabine|1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
41304989|NCT00722553|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
41144463|NCT05588739|BEHAVIORAL|Cognitive Behavioral Therapy|The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
41144464|NCT00734253|DRUG|Pyridoxamine Dihydrochloride|150 mg capsules taken orally twice a day for 1-year.
41144465|NCT00734253|DRUG|Pyridoxamine Dihydrochloride|300 mg capsules taken twice a day for 1-year.
41144466|NCT00734253|DRUG|Placebo|Placebo capsules taken twice a day for 1-year
41304990|NCT00722553|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
41304991|NCT00722553|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
41304992|NCT06263634|OTHER|Hand exercises|30-45 minutes of home exercises consisting of stretching, mobility and strengthening
41304993|NCT01241513|DRUG|NAC|NAC provided to determine if beneficial at altitude
41304994|NCT01241513|DRUG|Placebo|Placebo
41463838|NCT06179563|OTHER|On-Demand Telemonitoring|Patients assigned to the on-demand intervention group do not have to use the app at set time intervals but will be asked to use the app at their own discretion, in case of symptoms. This implies that patients have full control over their monitoring activities. Patients have the option to reach out to the hospital whenever they feel the need.
41463839|NCT03787017|DRUG|FDC(MP-513 20mg/Metformin XR 1000mg)|
40781288|NCT04715035|OTHER|Physical therapy interventions|mobilization, stretch, education, eccentric exercises
40781289|NCT05656157|DEVICE|Medical device|Clinical decision support system
40781290|NCT05036343|DEVICE|InPen®|A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.
40781291|NCT02665910|DRUG|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
40781292|NCT02665910|DRUG|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
40781293|NCT00248924|BEHAVIORAL|Social Services|
40781294|NCT06389032|BEHAVIORAL|Peer Mentor Support and Caregiver Education|12- week modular curriculum with handbook (PDF and Website version), additional resources and weekly phone discussions with Lewy Body Dementia (LBD) peer mentor/mentee.
40781295|NCT06389032|BEHAVIORAL|Caregiver Education|12-weeks of receiving weekly curated list of Lewy Body Dementia (LBD) educational resources based on the weekly topics via email.
40781296|NCT02172794|DRUG|Tiotropium|
40781297|NCT02172794|DRUG|Placebo to tiotropium|
40781298|NCT02172794|DRUG|Salmeterol|
40781299|NCT02172794|DRUG|Placebo to salmeterol|
40781300|NCT01218269|DEVICE|nitinol u-clip|The U-clip is comprised of nitinol, an alloy of nickel and titanium.
40781301|NCT05964686|COMBINATION_PRODUCT|Conventional group (NaOCl/EDTA)|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
40781302|NCT05964686|COMBINATION_PRODUCT|Dual laser group (Er,Cr:YSGG/Diode):|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
40781303|NCT05964686|COMBINATION_PRODUCT|Combined group (EDTA/Diode):|17% EDTA was used to remove smear layer followed by diode laser for disinfection
41304996|NCT04906889|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia
41304997|NCT04906889|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
40781304|NCT02435654|DRUG|olanzapine|olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
40781305|NCT02870426|PROCEDURE|Frontal Craniotomy and retrieval of OBs|For Group 1A the craniotomy will occur during organ retrieval for transplantation under aseptic technique. For Group 1B it would occur as a separate surgical procedure prior to palliation under full asepsis.
40781306|NCT02870426|PROCEDURE|OB Retrieval During Anterior Cranial Surgery|Group 2: The patients routine anterior cranial surgery would proceed as planned without change to the surgical procedure. In the event that the ON had to be sacrificed for the purposes of surgery the OB of the concomitant nerve would be retrieved.
40985649|NCT05988411|DEVICE|Renal Denervation|Renal denervation using the Paradise renal denervation system - a dedicated Renal Denervation (RDN) catheter that delivers a circumferential ring of ablative ultrasound energy
40781307|NCT02145884|DRUG|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
40781308|NCT02805140|BEHAVIORAL|Virtual exercise|Using videoconferencing, mothers assigned to intervention arm will participate in daily (weekdays) virtual exercise sessions for 6 weeks with other mothers.
40781309|NCT02805140|BEHAVIORAL|Mobile apps|During virtual exercise sessions, mothers assigned to intervention arm will follow exercise routines using mobile exercise apps that are recommended by study staff.
40781310|NCT02805140|BEHAVIORAL|Exercise resources and information|For all mothers, the investigators will provide standard information on the benefits of exercise and link to existing public health resources on how to start and stay active.
40781311|NCT02266303|OTHER|Insulin Start-up Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are of the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
40781312|NCT01843530|DRUG|Berinert|
40781313|NCT01843530|DRUG|Clemastin|
40781314|NCT01843530|DRUG|Cortisone acetate|
40781315|NCT01843530|DRUG|NaCl|
40781316|NCT02569346|DRUG|Triumeq|Single-dose Triumeq as a whole tablet
40781317|NCT02569346|DRUG|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
40781318|NCT02569346|DRUG|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
41304998|NCT04906889|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
41304999|NCT01380106|DRUG|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
41305000|NCT01380106|DRUG|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
41463840|NCT03787017|DRUG|MP-513 20mg|
41463841|NCT03787017|DRUG|Metformin XR 1000mg|
41463842|NCT03267654|DRUG|gefitinib combined with chemotherapy|"Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit."
40781319|NCT04335071|DRUG|Tocilizumab (TCZ)|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
40781320|NCT04335071|DRUG|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
40781321|NCT05189678|OTHER|No intervention|No intervention
40781322|NCT02345733|OTHER|Ulcerative Colitis Diet|we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
40781323|NCT02345733|DRUG|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
40781324|NCT02457026|DRUG|Aflibercept|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
40781325|NCT02457026|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
40781326|NCT02457026|DRUG|Verteporfin|Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
40781327|NCT02553629|DRUG|Rocuronium|
40985650|NCT05988411|DEVICE|Catheter Ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation.
40781328|NCT05760274|DIAGNOSTIC_TEST|multichannel intraluminal impedance and pH monitoring (MII/pH)|A pH-MII probe is inserted nasally into the esophagus, and the position verified by chest radiograph. pH-MII data are evaluated using manufacturer's software, and each tracing is manually reviewed and validated.
40781329|NCT04708522|BEHAVIORAL|Breath Control - Equal Breathing Technique|The equal breathing (EB) exercise also known as square or box breathing will follow the four-part breathing cycle of inhalation, hold, exhalation, hold, repeat. Each part of the cycle will be a 4 second count repeated for 20 minutes.
40985651|NCT05125328|DRUG|Remifentanil|First start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An ANI lower than 30 and hyperdynamics (the increased heart rate and mean blood pressure up 20% of baseline or heart rate\>100bpm and arterial blood pressure\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.
41144467|NCT06604754|OTHER|Assigned Intervention for VR Training|In VR training patients use VR headsets to engage in virtual environments for 8 weeks where they perform exercises designed to enhance balance, coordination, and strength. Simultaneously, the VR platform incorporate pulmonary exercises that focus on improving breathing techniques, lung capacity, and overall respiratory health. Patients will engage in 3 sessions per week with total time duration of 45 to 60 minutes. VR-based training provides real-time feedback and adapts to the patient's progress, offering a comprehensive approach to rehabilitation that addresses both balance and pulmonary function in a motivating and controlled manner.
41144468|NCT06604754|OTHER|Assigned Intervention for Traditional Physical Therapy Training|In Traditional physical therapy balance training for patients with chronic obstructive pulmonary disease (COPD) involves exercises designed to improve stability, strength, and coordination for duration of 8 weeks. These exercises, such as static balance tasks, dynamic movement drills, and strength training, help address the balance deficits often seen in COPD patients due to muscle weakness and reduced physical activity. Additionally, pulmonary effects are managed through breathing exercises such as deep breathing and pursed lip breathing that enhance respiratory functions, improve lung capacity and efficiency.
41144469|NCT04430153|OTHER|"Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer"|Accelerometers on both patients' wrists will give insight into the daily life upper limb use.
41144470|NCT03555656|BEHAVIORAL|Repeated intervention|Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention
41144471|NCT03555656|BEHAVIORAL|Single session|Single 2-h group session educating patients at foot hygiene and ulcer prevention
41144472|NCT01049815|DRUG|sevelamer hydrochloride|800-3200 mg with each meal
41144473|NCT01049815|DRUG|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
41144474|NCT02282137|DRUG|68Ga-PSMA|Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
41144475|NCT05116306|DRUG|Hyaluronic acid|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with hyaluronic acid gel
41144476|NCT05116306|DRUG|Propylene glycol|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel
41144477|NCT04155372|PROCEDURE|Different Fluid Ingestion Rate|The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.
40781330|NCT04708522|BEHAVIORAL|Guided Mindfulness Exercise|The guided seated mindfulness (GSM) exercise will lead the participant through a 20 minute mindfulness meditation exercise using an audio recording.
40781331|NCT04708522|BEHAVIORAL|Control|The control intervention will utilize a sham exercise. The participant will be asked to rest in a comfortable seated position for the duration of the 20 minute session.
40781332|NCT03543124|DEVICE|cap|A commercially available transparent cap (Olympus) will be fitted to the end of the colonoscope.
40781333|NCT03543124|OTHER|Water|Using water instead air to help insertion
40985652|NCT04861155|DEVICE|SIVA-P3|Digital cough recording: Participants receive a small, wearable data recorder, wear it during waking hours and keep it on the nightstand during sleep for 7x24 hours. The data is sent to a smartphone application, where a cough detection algorithm converts it into time-stamped cough events. Participants respond to questions on their smartphone once a day for additional context data. The cough events and context data are sent to a secure online database for further evaluation. For the first 24 hours, segments of audio data are sent to be able to validate the performance of the cough detection algorithm. Afterwards, only cough events and context data are sent from the participant's smartphone.
41305001|NCT01094002|OTHER|Occupational therapy intervention|"Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.~Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.~Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities."
40781334|NCT04885101|PROCEDURE|LISWT Group|The treatment consists of a weekly session and 4,000 pulses will be emitted each of the eight sessions totaling 32,000 pulses with a frequency of 18Hz and 100mJ of energy.
40781335|NCT04885101|PROCEDURE|NARFT Group|The device used will be with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. Eight radio frequency sessions will be held with an interval of seven days between them.
40781336|NCT04885101|PROCEDURE|Sham Group|In the RNA group, radiofrequency will be applied, the device used will be the Nèartek Esthetic Ibramed - Tecarterapia e Radiofrequency Apparatus, with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. The radiofrequency will be applied with the patient in the supine position on both sides of the penis with an opposite dispersion plate against the radiofrequency emitter. To perform the procedure, the therapist will use a glove. Eight radio frequency sessions will be held with an interval of seven days between them.
40985653|NCT05821842|DEVICE|Sonu|Acoustic energy delivery
40985654|NCT05404373|OTHER|Normobaric Hyperoxia (NBO)|NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups
40985655|NCT05404373|OTHER|Low flow oxygen|immediately given oxygen inhalation at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
40985656|NCT00383279|OTHER|counseling intervention|
40985657|NCT00383279|OTHER|study of socioeconomic and demographic variables|
40985658|NCT01066247|DRUG|Morphine hydrochloride; Midazolam|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
40985659|NCT01066247|DRUG|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
40985660|NCT03208842|RADIATION|trans vaginal ultrasound|"trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity"
40985661|NCT02574130|DRUG|Amikacin|400 mg, nebulizer, every 12 hours, 10 days
40985662|NCT02574130|DRUG|Placebo|placebo 4 ml, nebulizer, every 12 hours, 10 days
40985663|NCT02839915|DRUG|Folinic Acid|Liquid levo-leucovorin via oral route. L-leucovorin is the active isomer.
40985664|NCT02839915|OTHER|Placebo|Inactive placebo comparator
40985665|NCT03686163|DRUG|Nerve Growth Factors|the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks
40985666|NCT03686163|DRUG|normal saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
40985667|NCT04210310|DRUG|Oxytocin|The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day
40985668|NCT04210310|OTHER|Placebo nasal spray|A placebo nasal spray, consisting of magnesium, chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both active drug and the placebo will appear identical in the glass bottles. The placebo will be administered in the same manner as the active study drug, with 1 puff in one nostril four times per day.
40985669|NCT03145025|DEVICE|Retisert|Intravitreal Implant
40985670|NCT03145025|DRUG|Fluocinolone Acetonide Intravitreal Implant|Intravitreal Implant
40985671|NCT05389345|BEHAVIORAL|Transcranial direct current stimulation|Participants will receive bilateral prefrontal anodal stimulation with cathode placed on the back of the upper neck. Transcranial direct current stimulation (tDCS) will be delivered by a research assistant under the supervision of a psychiatrist.
40781337|NCT05120050|DEVICE|ASP Health instrument|The instrument is an integrated device with a short processing time (measured in 2 to 3 minutes) that distributes cells from limited volume samples (measured in microliters). The process involves a novel aerosolization technique that transfers liquid sample to a glass slide via a burst of air. After the sample is deposited on the glass slide, the automated system uses an integrated heating strip to heat the specimen slide. This process is similar to using a hair dryer to dry the specimen slide in the current ROSE setting. After drying the slide, the system uses series of pumps to dispense microliters of stain reagent onto the slide to stain the cells. Currently, the system is configured to perform DiffQuik staining, which is commonly used in the ROSE process. In the future, the staining capability will be broadened to include other staining processes such as Rapid PAP, H\&E staining etc.
40781338|NCT05210725|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to acetylsalicylic acid (80-00mg once a day, standard care).
40781339|NCT02719392|DIETARY_SUPPLEMENT|N-acetylcysteine|NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.
40781340|NCT02719392|DRUG|Minocycline|Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
40781341|NCT02719392|OTHER|Placebo|The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
40781342|NCT01471613|PROCEDURE|Conventional Treatment|Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
40781343|NCT01471613|DRUG|Lithium Carbonate Tablet|250mg/tablet, administrated orally for 6 weeks.
40781344|NCT01471613|BIOLOGICAL|Cord Blood Cell|Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
40781345|NCT01471613|OTHER|Placebo|Placebo tablet, orally administration of placebo for 6 weeks
40985672|NCT05389345|BEHAVIORAL|Executive function training|The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.
40985673|NCT02059057|DEVICE|LVRC System|
40985674|NCT01805024|DRUG|Omigapil|Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
40985675|NCT00636909|DRUG|Cyclophosphamide|preparative cytoreduction
40985676|NCT00636909|DRUG|fludarabine|preparative cytoreduction
40985677|NCT00636909|DRUG|cyclosporine|immunosuppressive therapy
40985678|NCT00636909|DRUG|methotrexate|immunosuppressive therapy
40985679|NCT00636909|BIOLOGICAL|G-CSF|foster engraftment
41144478|NCT02704637|DEVICE|HS-1000|HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
40781346|NCT01192880|DRUG|Placebo|Participants will receive bitopertin matching placebo once daily for 56 weeks.
40781347|NCT01192880|DRUG|Bitopertin|Participants will receive 10 mg or 20 mg of bitopertin.
40781348|NCT01192880|DRUG|Antipsychotics|Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
40781349|NCT03156829|OTHER|Splint|Custom made splint
40781350|NCT03156829|DRUG|Betamethasone|Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml
40781351|NCT03156829|COMBINATION_PRODUCT|Splint + Cortico-steroid injection|Splint + Cortico-steroid injection given in combination
40781352|NCT05587491|DEVICE|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation
41305002|NCT05504148|DRUG|crocin|Take saffron total glucosides tablets for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day.
41305003|NCT05504148|DRUG|Placebo|Take placebo piece during for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day
40781353|NCT02514343|DRUG|Magnesium Sulfate|1ml of 10% magnesium sulfate with 1.5 ml of sterile water
40781354|NCT02514343|DRUG|Bupivacaine|1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
40781355|NCT03794973|BIOLOGICAL|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
40781356|NCT03794973|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
40781357|NCT00805584|DRUG|desloratadine|Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
40781358|NCT02935192|BIOLOGICAL|Vaccine|Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection
40781359|NCT02935192|OTHER|Placebo|Phosphate buffered saline, 0.5 mL by IM injection
40781360|NCT01578161|DRUG|Dexmedetomidine|There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
40781361|NCT01578161|DRUG|0.9% Normal Saline|Placebo,Normal saline 10ml ivs. for 10min.
40781362|NCT04907630|BEHAVIORAL|Antenatal Education|educational intervention
40781363|NCT00002414|DRUG|CPI-1189|
40985680|NCT03664947|OTHER|exercise|After the initial evaluations, a video-based gaming console exercise program will be implemented for 8 weeks, taking into account the possibility of accepting and participating in treatment with children. Exercises applied by a Nintendo Wii Fit Plus System. Evaluations will be repeated at the end of treatment.
40985681|NCT01254227|DRUG|Deferasirox and Deferoxamine|
41144479|NCT01554345|DRUG|vitamin E +Selenium|vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
41144480|NCT02779127|OTHER|Medical interrogatory|Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated
40781364|NCT05589987|DEVICE|power mobility|"Sessions of adjustment, adaptation and choice of the device for training will be carried out. Once the cars are fully adapted and conditioned to the environment and needs of the family and the child, the intervention will begin.~The study will take place in the child's natural environment for 12 weeks. Three 40-minute sessions per week will be held, each session includes: 1) configuration of the environment (families will be instructed by the therapists to adapt the environment to the child's situation and their conditions for driving the car): 5 min ; 2) natural play as a warm-up activity: 5 min; and 3) mobility and social training with cars: 30 min. The 30-minute driving session will involve participants learning cause and effect concepts by driving the toy car (press the button to move and release to stop). The therapist and caregivers will use verbal cues to encourage children to drive and explore the environment. All sessions will be video and audio recorded."
40781365|NCT04592809|DRUG|Ketamine Hydrochloride|infused over a 40 minute period
40781366|NCT04592809|DRUG|Midazolam Hydrochloride|infused over a 40 minute period
40781367|NCT03238989|OTHER|monitoring changes in clinical symptoms, pulmonary function, and chest radiography|For patients with interstitial lung disease, the investigators regularly monitor changes in clinical symptoms, pulmonary function, and chest radiography after basic questionnaire on symptoms, lifestyle, depression, and quality of life.
40781368|NCT01455480|DRUG|RPh201, botanical drug product|topical
40781369|NCT02947984|RADIATION|Standard Treatment|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
40781370|NCT02947984|RADIATION|Higher Dose|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
40781371|NCT02892240|OTHER|No intervention. Observational study|
40781372|NCT00413348|DRUG|Lactobacillus acidophilus NCFM|
41144481|NCT02779127|OTHER|Medical examination|Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation
41144482|NCT02779127|OTHER|Specific bioassay|Exhaled carbon monoxide measure and nicotine in the urine are evaluated
41144483|NCT02779127|OTHER|Endothelial function evaluation|Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation
40781373|NCT03082924|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
40781374|NCT03082924|DEVICE|Calibrated cycle ergometer|The most common device to perform cycle training is calibrated cycle ergometer.
40781375|NCT03082924|DEVICE|Threshold loading device|Threshold loading device is used to perform inspiratory muscle training.
40781376|NCT03082924|DEVICE|Calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
40985682|NCT05022784|DRUG|Nintedanib|Nintedanib
40985683|NCT00877877|PROCEDURE|Blood sampling|Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
40781377|NCT00353002|DRUG|Ametop (4% Amethocaine cream )|
40985684|NCT05402150|BEHAVIORAL|Behavioral Activation|"* instruction to create a list of individual positive activities.~* instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity."
40985685|NCT05402150|BEHAVIORAL|Mindulness and Gratitude|"* instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with these pleasant impressions of the situation they reflected upon~* instruction to do a gratitude exercise and name one or more things they are generally grateful for each day."
41144484|NCT02779127|OTHER|General bioassay|Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.
41144485|NCT04382053|DRUG|DFV890|DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.
41144486|NCT04382053|DRUG|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
40781378|NCT00353002|DRUG|Maxilene (4% Liposomal Lidocaine)|
40781379|NCT00000305|DRUG|Dextroamphetamine|
41305004|NCT01096446|DRUG|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
40781380|NCT01624714|DRUG|Alemtuzumab|alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
40781381|NCT01624714|DRUG|Alemtuzumab immunotherapy|Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
40781382|NCT03573492|OTHER|Education|Type of teaching being assigned to student arms
41305005|NCT02177851|DIETARY_SUPPLEMENT|Single oral iron dose of 120 mg per day for 3 consecutive days|
40781383|NCT05592301|DIAGNOSTIC_TEST|Diffusion-weighted Magnetic Resonance Imaging (DW-MRI)|The Diffusion-weighted Magnetic Resonance Imaging (DW-MRI) is used to diagnose perioperative stroke.
40781384|NCT05592301|DIAGNOSTIC_TEST|Transcranial Doppler (TCD)|Used to diagnose PFO
40781385|NCT05592301|DIAGNOSTIC_TEST|Transthoracic Echocardiogram (TTE)|Used to diagnose PFO.
40781386|NCT05833828|PROCEDURE|on-pump surgery|"the surgery will be performed on-pump"
40781387|NCT05833828|PROCEDURE|off-pump surgery|"the surgery will be performed off-pump"
40781388|NCT06467630|PROCEDURE|Preserving alveolar bone volume after tooth extraction|"* Visit 1: A periodontal or dental implant surgery is done aiming to preserve alveolar bone volume after extraction~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* V2bis (1 month +/- 1 week) - Early post-surgery follow-up~* Visit 3 (5 months ± 1 month) - Late post-surgery follow-up"
41305006|NCT02177851|DIETARY_SUPPLEMENT|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days|
41305007|NCT04542382|DRUG|Rosuvastatin|"Rosuvastatin will be administered as follows:~Day 1: single dose of 10 mg Rosuvastatin tablet."
41305008|NCT04542382|DRUG|Rosuvastatin (Inhibitor arm)|"Rosuvastatin will be administered as follows:~Day 8: single dose of 10 mg Rosuvastatin tablet."
41305009|NCT04542382|DRUG|Eltrombopag|"Eltrombopag will be administered as follows:~Day 8: single dose of 75 mg Eltrombopag tablet."
41305010|NCT03650452|DRUG|TAK-935|TAK-935 tablets or mini-tablets.
41305011|NCT03650452|DRUG|Placebo|TAK-935 placebo-matching tablets or mini-tablets.
41305012|NCT03950245|OTHER|Placebo|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.
41305013|NCT03950245|OTHER|GLP-1 antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.
41305014|NCT03950245|OTHER|GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.
41305015|NCT03950245|OTHER|GLP-1 and GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.
41305016|NCT02409784|DIETARY_SUPPLEMENT|Pre-KD|Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
41305017|NCT02409784|DIETARY_SUPPLEMENT|Post-KD|After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
41305018|NCT05655390|BEHAVIORAL|Safety Intervention Planning|The therapy is based on the iFightDepression platform implemented by the European Alliance against Depression. The aim of this specific therapy is to help individuals to acquire strategies to regulate emotions and learn to tolerate discomfort preventing the imminent risk for suicidal behavior. The safety planning intervention will be conducted by identifying warning signs and provide each individual with personal and individualized coping strategies and sources of support. Main skills to be acquired and integrated for the individual are as it follows: 1) Contingency plan by five steps (identification of warning signs; applying internal coping strategies; network as distraction; safe environment; reasons for living and contact professionals), 2) Mindfulness, 3) Discomfort tolerance, and 4) Regulating emotions.
41305019|NCT05304910|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
41305020|NCT05304910|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
41305021|NCT00064467|DRUG|Extended-release bupropion (HCl)|
41305022|NCT05362851|DRUG|YYC301-1 & YYC301-2 & YYC301-3|"YYC301-1: Subjects take the investigational products once a day~YYC301-2: Subjects take the investigational products once a day~YYC301-3: Subjects take the investigational products once a day"
41305023|NCT05362851|DRUG|YYC301 placebo & Celecoxib 200mg|comparator medication
41305024|NCT02411227|BEHAVIORAL|VR Driving|Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
41305025|NCT02353637|DIETARY_SUPPLEMENT|Partial Meal Replacements|The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
40781389|NCT06467630|PROCEDURE|Alveolar crest reconstruction|"* Visit 1: A periodontal or dental implant surgery is done aiming to alveolar crest reconstruction~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* Visit 3 (5 months ± 1 month) - Late post-surgery follow-up"
40781390|NCT06467630|PROCEDURE|Covering bone defects during immediate implant placement.|"* Visit 1: A periodontal or dental implant surgery is done aiming to cover bone defects during immediate implant placement.~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* Visit 3 (3 months ± 1 month) - Late post-surgery follow-up"
40781391|NCT04161209|DRUG|Citalopram|Single dose administration of citalopram (20mg)
40781392|NCT04161209|OTHER|Placebo|Lactose placebo tablet
40781393|NCT03130829|DIETARY_SUPPLEMENT|Oligo Fucoidan|Oral, twice daily
40781394|NCT03130829|DIETARY_SUPPLEMENT|Placebo|Oral, twice daily
40985686|NCT05402150|BEHAVIORAL|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
40985687|NCT00311623|DRUG|Rapamycin 3mg|Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
40985688|NCT00311623|DRUG|Rapamycin 6mg|Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
40985689|NCT00311623|PROCEDURE|Radical prostatectomy|Radical prostatectomy performed on Day 15
40985690|NCT05077709|DRUG|IO102-IO103 in combination with pembrolizumab|The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides
40985691|NCT01632969|BEHAVIORAL|The The Family Assessment of Treatment at the End of life (FATE ) survey|Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
40985692|NCT04097717|BEHAVIORAL|"My Decision tubal sterilization decision aid"|"The My Decision tubal sterilization decision aid is a web-based decision aid designed to help women make informed decisions about tubal sterilization."
40985693|NCT04097717|OTHER|Usual Care|Usual medical care will vary among participants.
40985694|NCT00988507|DRUG|Ferroquine (SSR97193)|"Pharmaceutical form: capsule~Route of administration: oral"
40985695|NCT00988507|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
40985696|NCT00988507|DRUG|artesunate|"Pharmaceutical form: tablets~Route of administration: oral"
40985697|NCT05585151|DRUG|Evolocumab 140 MG/ML|Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times
40985698|NCT05585151|DRUG|Intensive statin treatment|Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks
40985699|NCT00056407|DRUG|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
41305026|NCT05866835|OTHER|Manufacture of custom-made IOP|"Manufacture of custom-made unimaxillary and modified unimaxillary intra-oral protection (IOP) with vertical dimensions of 4 mm and 6 mm. 3D modeling of a IOP based on:~* digital recording of the maxillary and mandibular dental arches~* mandibular wedging performed with an inter-arch piece~* digital recording of the inter-arch position"
40781395|NCT01750125|DEVICE|measure ascending aortic blood flow with pulse wave Doppler|
40781396|NCT02268383|DRUG|Luspatercept|Luspatercept 1.0 mg/kg once every 3 weeks by subcutaneous injection.
40781397|NCT05634486|BEHAVIORAL|Multidisciplinary therapeutic approach (physiotherapy plus cognitive-behavioral therapy)|Patients randomly allocated to this arm of intervention will receive an ambulatory therapy regime of twelve 60-minute physiotherapy sessions plus four 60-minute psychotherapy sessions throughout one month of treatment
40985700|NCT00056407|DRUG|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
40985701|NCT00410553|DRUG|Eribulin Mesylate|Given IV
40985702|NCT00410553|DRUG|Gemcitabine Hydrochloride|Given IV
40985703|NCT01199289|DRUG|AMG 827|SC injection.
40985704|NCT01199289|DRUG|Placebo|SC injection.
40985705|NCT01641692|DRUG|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
40985706|NCT01641692|PROCEDURE|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
41144487|NCT05051488|PROCEDURE|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
40781398|NCT05634486|OTHER|Psychoeducation (Sham intervention)|Patients randomly allocated to this arm of intervention will receive an ambulatory regime of four 60-minute non-organized psychoeducational sessions throughout one month of treatment.
40781399|NCT01127620|DRUG|Bilastine|20 mg encapsulated tablets
40985707|NCT01641692|DRUG|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
40985708|NCT04745598|BEHAVIORAL|Control group: Dental Model|- Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.
41463843|NCT03267654|DRUG|gefitinib combined with apatinib|"gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death."
40985709|NCT04745598|BEHAVIORAL|Computer-assisted teaching format group|- Patients receive a Powerpoint presentation containing:
40985710|NCT04745598|BEHAVIORAL|Plaque-disclosing group|- Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums. With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth
41144488|NCT05051488|DEVICE|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
41144489|NCT06588894|BEHAVIORAL|Questionnaire and Physical Exam|Individuals motor imagery skills will be assessed using a mental chronometer and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using the Montreal Cognitive Assessment questionnaire.
41144490|NCT06588894|BEHAVIORAL|Motor Imagery Ability|Individuals motor imagery skills will be assessed using a mental stopwatch and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using theMontreal Cognitive Assessment questionnaire.
41144491|NCT04520321|DRUG|TTHX1114(NM141)|engineered FGF-1 delivered intracamerally
41144492|NCT04520321|OTHER|Vehicle (placebo)|Placebo
41463844|NCT03267654|DRUG|gefitinib single agent|Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
41463845|NCT03716323|DEVICE|immediate premolar implant with xenograft and allograft|"* A peritome will be used for atraumatic extraction of remaining roots.~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues.~* Copious normal saline irrigation and curettage will be performed.~* In the study group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with cortico-cancellous allograft (MinerOss®, BioHorizons, USA)~* In the control group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with anorganic bovine bone mineral xenograft (Bio-Oss®, Geistlich, USA)"
41144493|NCT03349476|DEVICE|MFAM|"Specifically, the mFAM Workstation accesses stored data of recorded electronic heart activity that has been obtained by conventional electrophysiological methods, using multi-electrode catheters placed in the heart (data inputs) for collection. Using proprietary software algorithms, the mFAM Workstation analyzes these data inputs and generates 3D anatomical structure.~mFAM improves on the FAM functionality by applying a model-based approach for reconstruction of left atrial chamber anatomy"
41144494|NCT05533788|DRUG|ABSK091 tablet|ABSK091 tablet which is being developed for the treatment of patients with advanced solid tumors
41144495|NCT00316121|DEVICE|HEALOS and Leopard Cage|Placement in interbody space
41144496|NCT00316121|DEVICE|Leopard Cage and Autograft|Placement in the interbody space
41463846|NCT01026857|DRUG|Propionyl-L-Carnitine|PLC colon release tablet 1 g/die for 4 weeks
41463847|NCT01026857|DRUG|Propionyl-L-Carnitine|PLC colon release tablet 2 g/die for 4 weeks
41463848|NCT01026857|DRUG|Placebo|Placebo PLC colon release tablet 2 g/die for 4 weeks
41463849|NCT01487499|DRUG|Cisplatin|40 mg in 40 mL of normal saline for each of 4 bronchoscopies
41463850|NCT06030544|DIETARY_SUPPLEMENT|OA-enriched functional olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a functional olive oil enriched in Oleanolic acid (equivalent dose 30 mg/day OA) Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494).
41463851|NCT06030544|DIETARY_SUPPLEMENT|commercial olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.
41463852|NCT03422224|DIAGNOSTIC_TEST|Mixed lymphocyte reaction|Assessment of alloreactive T cell repertoire
40781400|NCT01127620|DRUG|Cetirizine|10 mg encapsulated tablets
40781401|NCT01127620|DRUG|Placebo|encapsulated tablets
40781402|NCT02250417|OTHER|Wave sleep surface|The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.
40781403|NCT04949009|DRUG|Avatrombopag|Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.
40985711|NCT04745598|BEHAVIORAL|Intra-oral camera group|- An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
40985712|NCT05670990|OTHER|Equine assisted therapy|"A structured program that has been developed under several years at Humlamaden horse farm, for further information see under the description of the experimental group."
40985713|NCT00047021|BIOLOGICAL|sargramostim|Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.
40985714|NCT00047021|DRUG|cytarabine|high-dose cytarabine IV over 1 hour on days 1-5
41463853|NCT04863157|BEHAVIORAL|Survivor-SHIP|Parent/guardian education about healthy sleep practices to improve their child's sleep health.
41463854|NCT04560439|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo METFIT program
41463855|NCT02479477|OTHER|kinesio therapy|during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
41305027|NCT05866835|OTHER|Ventilation tests|"Realization of a ventilation test (VO2max) to determine the Maximum Aerobic Speed (MAS).~Measurement of ventilatory parameters without IOP and with each IOP :~* At rest, standing still.~* During a 4 minute run on a treadmill at 50% of MAS.~* During a 4-minute run on a treadmill, at a speed corresponding to 70% of MAS"
40985715|NCT00047021|DRUG|mitoxantrone hydrochloride|high-dose mitoxantrone IV over 15-30 minutes on day 5.
41463856|NCT02734524|BIOLOGICAL|NK cells|Natural killer cell infusion is an intervention between two arms. Dosage of infused cell \>1×10\^9，q28d\*4
40781404|NCT03895190|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
40985716|NCT01631877|DRUG|Enoxaparin with acenocoumarol|enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
40985717|NCT01631877|OTHER|placebo|injection placebo will be given for 5 days along with placebo tablets
40985718|NCT00988455|RADIATION|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
40985719|NCT03016247|BEHAVIORAL|TRUST Intervention|The TRUST intervention will be guided by Rotenberg's Framework of Interpersonal Trust 3. The TRUST group will meet with an interventionist trained in weight self-management for eight 90-minute weekly sessions. Each session will include adolescent/parent trust-building exercises (honesty, reliability, emotional connection), didactic content, experiential skills developing (nutrition label reading), behavior-change goal-setting, and problem-solving.
40985720|NCT03016247|BEHAVIORAL|Enhanced Usual Care|Single meeting with a Nutritionist for physical activity and eating counseling.
40985721|NCT03077802|OTHER|Modified Seldinger technique, Experienced group|This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
40985722|NCT03077802|OTHER|Seldinger technique, Experienced group|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
41144497|NCT03680781|DEVICE|Intermittent theta-burst stimulation (iTBS)|"Participants will receive iTBS to the left DLPFC or bilateral DLPFC, to the right and left DLPFC. The DLPFC will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device."
41305028|NCT05866835|OTHER|Evaluation of comfort level:|Collection from participants (self-questionnaire)
41305029|NCT02297334|DEVICE|CytoSorb device|In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
41305030|NCT05140005|DIAGNOSTIC_TEST|GlowTest COVID-19 Antigen Home Test|diagnostic testing for Covid 19
41305031|NCT00242385|BIOLOGICAL|Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
41144498|NCT06180109|DRUG|Empagliflozin film coated tablets|1 film coated tablet of 25 mg Empagliflozin
41144499|NCT06180109|DRUG|Jardiance film-coated tablets|1 film coated tablet of 25 mg Empagliflozin
41144500|NCT01753440|PROCEDURE|Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).|Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).
41305032|NCT00242385|BIOLOGICAL|Dose of 60 mg/kg alpha1-proteinase inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
41463857|NCT02734524|DRUG|Taxol|135-175mg/m2,q28d\*4
41463858|NCT02734524|DRUG|Carboplatin|AUC=5,q28d\*4
41463859|NCT05070962|OTHER|clinical population|or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.
41463860|NCT02443285|DRUG|Cefotaxime|Cefotaxime 2 gram every12 hours for 5 days
41463861|NCT02443285|DRUG|ceftriaxone|Ceftriaxone 2 gm every 24 hours for 5 days
41463862|NCT02277951|DEVICE|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
41463863|NCT02277951|DEVICE|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
41463864|NCT02277951|DEVICE|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
40781405|NCT03157050|OTHER|Intravenous iron therapy|each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses
41305033|NCT04798885|BEHAVIORAL|GAIN 2.0|1) three structured group sessions of two hours duration performed jointly by a neuropsychologist, an occupational therapist and a physiotherapist. Relatives are also invited. 2) Up to five weekly semi-structured individual sessions of 30 min. duration with an allocated therapist
40985723|NCT03077802|OTHER|Modified Seldinger technique, Inexperienced group|This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
41305034|NCT01134692|DRUG|Propranolol, Norfloxacin, VSL#3|Propranolol: as per heart rate titration Norfloxacin: 400mg BD
40781406|NCT03387956|DRUG|Intrathecal atropine|100ug intrathecal atropine will be injected with spinal anesthesia
40781407|NCT03387956|DRUG|dexamethasone|intravenous 8 mg dexamethasone (2ml).
40781408|NCT03674983|BEHAVIORAL|Conditional Economic Incentive (CEI)|"If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade A; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade B; and if he has taken PrEP pills only 2 times or less, he will receive a grade C. For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes."
40781409|NCT05412992|DRUG|DMTS Patch|DMTS applied before surgery and worn for 96 hours
40781410|NCT05412992|DRUG|Placebo Patch|Matching patches that have no active drug applied before surgery and worn for 96 hours
40781411|NCT05785208|DRUG|Osimertinib|Osimertinib will be administered at a dose of 80 mg daily until disease progression
40781412|NCT05065658|DRUG|Posaconazole|Intravenous posaconazole prophylaxis
41305035|NCT01649739|DRUG|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
41305036|NCT02557386|DRUG|Levobupivacaine 5 mL|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
41305037|NCT02557386|DRUG|Levobupivacaine 10 mL|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
41305038|NCT02557386|DRUG|Levobupivacaine 15 mL|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
41305039|NCT02557386|DRUG|Levobupivacaine 20 mL|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
41144501|NCT05986630|DEVICE|TEOSYAL® TPVM|"Injection of TEOSYAL® TPVM at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI."
41463865|NCT02277951|DEVICE|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
40781413|NCT00598507|DRUG|ZK-EPO|Participants were treated with 16 mg/m\^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
40781414|NCT06546085|BEHAVIORAL|Exercise|Supervised treadmill exercise at 85% VO2max, 3x/wk for 16 weeks. Exercise duration will be adjusted based on individual VO2-heart rate (HR) relationship so that \~400 kcals will be expended during each training session.
40781415|NCT00896012|PROCEDURE|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
41144502|NCT05986630|DEVICE|COMPARATOR|"Injection of a COMPARATOR at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI."
41144503|NCT04309578|DRUG|Trastuzumab, Capecitabine and Cisplatin|"* Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~* Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1"
41144504|NCT00096278|BIOLOGICAL|Bevacizumab|Given IV
41144505|NCT00096278|DRUG|Fluorouracil|Given IV
41144506|NCT00096278|DRUG|Leucovorin Calcium|Given IV
41144507|NCT00096278|DRUG|Oxaliplatin|Given IV
41305040|NCT02557386|DRUG|Levobupivacaine 25 mL|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
41305041|NCT02557386|DRUG|Levobupivacaine 30 mL|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
41305042|NCT03934892|DIAGNOSTIC_TEST|serum lactate|check lactate levels during cardiopulmonary bypass in adult cardiac operations
41305043|NCT03176277|DRUG|ONO-7475 3mg once daily|Part A initial dose level
41305044|NCT03176277|DRUG|ONO-7475 6mg once daily|Part A 2nd dose level
41305045|NCT03176277|DRUG|ONO-7475 10mg once daily|Part A 3rd dose level
41305046|NCT03176277|DRUG|ONO-7475 6mg + Venetoclax (70-400mg)|Part D ONO-7475 + Venetoclax Combination
41305047|NCT04836143|DRUG|Intravitreal anti-vascular endothelial growth factor injection|Intravitreal injection of either ranibizumab or aflibercept
41463866|NCT01477424|DRUG|PA21|The maximum dose of PA21 will be 15.0 g/day.
41463867|NCT01477424|DRUG|Warfarin|The maximum dosage of Warfarin will be 10 mg/day
41463868|NCT04287608|DRUG|dupilumab|No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.
40985724|NCT03077802|OTHER|Seldinger technique, Inexperienced group|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
41305048|NCT03494881|DRUG|Nucala|All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.
41305049|NCT00016874|DRUG|cisplatin|
41305050|NCT00016874|DRUG|paclitaxel|
41305051|NCT00016874|DRUG|triapine|
40985725|NCT03077802|OTHER|Long-axis technique|Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.
41144508|NCT02056379|DRUG|Budesonide|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.
41144509|NCT02056379|DRUG|Dexamethasone|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
41305052|NCT05966766|OTHER|Mozart selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections by Mozart of previously studied and shown to reduce anxiety.
41305053|NCT05966766|OTHER|Patient-preferred music selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections of patient choice.
40781416|NCT00896012|DRUG|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
40781417|NCT00896012|DRUG|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
40781418|NCT04258852|DRUG|Low strength nicotine e-liquid|Low strength nicotine e-liquid
40985726|NCT03077802|OTHER|Short-axis technique|Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.
40985727|NCT04427774|DRUG|Surufatinib plus Sintilimab|Surufatinib will be given orally. Sintilimab will be given intravenously
41144510|NCT03384342|DEVICE|Narrow-band UV-B therapy|"* Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.~* For a total period of 12 months, narrow-band UV-B therapy is performed once a month."
41305054|NCT00448253|BIOLOGICAL|NP-015|"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots."
41305055|NCT06553326|DEVICE|EndoStyle|The EndoStyle system is able to transform the style of the different video-processor images.
41305056|NCT06224894|OTHER|Music Therapy|Music Therapy
41305057|NCT06224894|OTHER|antiemetic treatment|antiemetic treatment
41305058|NCT04824196|OTHER|vestibular visual cues therapy|Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirrorAnterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear
41305059|NCT04824196|OTHER|propriocetion exercise|"1. Alternate knee flexion-extension with extended trunk posture using both hands for support.~2. Hip and knee flexion-extension with swiss ball between the back and wall.~3. Hip raises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises. then all exercise are perfomed on gym ball"
41305060|NCT01754220|DRUG|Montelukast|Montelukast is a leukotriene receptor antagonist
40781419|NCT04258852|DRUG|High strength nicotine e-liquid|High strength nicotine e-liquid
40985728|NCT03941431|DRUG|Jueyin granules|Jueyin granules p.o. once a day for 8 weeks.
40985729|NCT03941431|DEVICE|moving cupping therapy|Moving cupping therapy three times per week for 8 weeks.
40985730|NCT03941431|DEVICE|NB-UVB therapy|NB-UVB phototherapy three times per week for 8 weeks.
40985731|NCT03941431|DRUG|Jueyin placebo granules|Jueyin placebo granules p.o. once a day for 8 weeks.
41463869|NCT02460835|RADIATION|Adaptive Radiation Therapy|
40781420|NCT05348811|DRUG|HAIC combined with donafenib and sintilimab|"HAIC- GEMOX regimen, gemcitabine 1000 mg/m2, oxaliplatin 85mg/m2 (if the maximum tumor diameter \> 10cm, the dose is 130mg/m2), the first day of each cycle (D1), Q3W. The maximum of 6 times.~Sintilimab will be given on the first day of each cycle (D1). 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach (1 hour before or \> 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment until toxicity is intolerable, the investigator determines disease progression, death, informed consent is withdrawn, new antitumor therapy is initiated, or treatment is discontinued for any other reason specified in the protocol."
40781421|NCT02478489|DRUG|Oral naltrexone (PO-NTX)|oral naltrexone
40781422|NCT02478489|DRUG|Extended-release injectable naltrexone (XR-NTX)|injectable naltrexone
40781423|NCT00882089|DEVICE|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
40781424|NCT00198900|BEHAVIORAL|survey of information|
40781425|NCT02672995|RADIATION|Fractionated stereotactic radiosurgery|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5\~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5\~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break."
40781426|NCT02672995|DRUG|bevacizumab|"Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
40781427|NCT00372957|DRUG|GW823093 15mg|White opaque capsule containing 15mg of GW823093 as free base
40781428|NCT00372957|DRUG|GW823093 placebo capsule|Matching placebo of GW823093 capsule or 15mg capsule
40781429|NCT00372957|DRUG|GW823093 30mg|White opaque capsule containing 15mg of GW823093 as free base
40781430|NCT00406861|DRUG|montelukast in treatment of ENL reaction|
40781431|NCT03784248|OTHER|blood donation and isolation of leuco-platelet layers|patients donating blood. Blood bags will be treated and leuco-platelet coatings will be sent to Nice
40781432|NCT06007586|DRUG|Aprepitant Injection|Two antiemetic groups use placebo,Dexamethasone and Ondansetron, Three antiemetic groups use Aprepitant,Dexamethasone and Ondansetron.
40781433|NCT00872300|DRUG|PHA-739358|Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
41305061|NCT03165721|DRUG|SGI-110 (guadecitabine)|SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
41305062|NCT00486538|DRUG|ABT-869|One oral dose daily.
41305063|NCT03540134|DEVICE|Intracerebral Infusion of Autologous Cerebral Spinal Fluid|Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring
40781434|NCT01713439|BIOLOGICAL|Injection of allogeneic neuroblastoma cells|Patients will receive a fixed dose of IL-2 gene modified tumor cells (10\^7/kg, 10\^8 max) already shown to be safe from a previous protocol, and an escalating dose of Lptn transduced tumor cells, beginning at 10\^4/kg and rising to 10\^7/kg (10\^8 max). Patients will be assigned to an appropriate dose level for injection # 1. Injection #2 will contain 10 times more Lptn transduced cells than injection #1, until the max dose (10\^8) has been reached in the first injection. The dose of injections 3 through 8 will be the same as the dose of injection #2. Initial injection volumes will be \<1ml and should be injected in a single site. Only if these first patients show no undue local toxicity (including tumor cell growth) will multiple injection sites be used for subsequent high cell-dose studies.
40781435|NCT02984670|BEHAVIORAL|Cognitive Therapy|Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
40781436|NCT02984670|BEHAVIORAL|Behavior Therapy|Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
40781437|NCT02984670|BEHAVIORAL|Waitlist.|The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
40781438|NCT03152578|OTHER|BetaC + Capsaicin Topical Cream|BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.
40781439|NCT03152578|OTHER|BetaC Topical Cream|BetaC Topical Cream Cream applied to painful knee area 3 times per day.
40781440|NCT03152578|OTHER|Placebo Topical Cream|Placebo Cream applied to painful knee area 3 times per day.
40985732|NCT03941431|DEVICE|moving cupping placebo therapy|Moving cupping placebo therapy three times per week for 8 weeks.
40985733|NCT03941431|DEVICE|NB-UVB placebo phototherapy|NB-UVB placebo phototherapy three times per week for 8 weeks.
41305064|NCT05459389|OTHER|targeted antibiotics therapy|targeted antibiotics therapy guided by resistance genotyping (n=24)
40985734|NCT02905331|DRUG|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
41305065|NCT02128620|BEHAVIORAL|Game-Based Appointment System|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
41305066|NCT02275689|PROCEDURE|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
40985735|NCT02905331|DRUG|Placebo|Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
41144511|NCT02903602|BEHAVIORAL|Sharing Histories training method for CHW|Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.
41144512|NCT02903602|BEHAVIORAL|Standard training method for CHW|Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
40985736|NCT03705507|DRUG|Selumetinib|Selumetinib is a small molecule inhibitor of the MEK protein
41144513|NCT06313268|DRUG|Bevacizumab Biosimilar MB02|5 mg/kg to 15 mg/kg in combination with chemotherapy.
41305067|NCT02275689|PROCEDURE|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
41305068|NCT01643915|BEHAVIORAL|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
41305069|NCT01643915|BEHAVIORAL|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
41305070|NCT01643915|BEHAVIORAL|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
41305071|NCT04421196|OTHER|Exclusion of opioid analgesics|The intervention involves removing the option of patients having an opioid analgesic at any time point during the perioperative period.
41305072|NCT03235596|DEVICE|tDCS|cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2mA during 15 minutes
40985737|NCT03705507|DRUG|Dexamethasone|Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.
40985738|NCT01359449|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
40985739|NCT01359449|BIOLOGICAL|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
40985740|NCT03010254|DEVICE|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject
41144514|NCT06470308|OTHER|Medication Reviews and Deprescribing|Medication reviews will be conducted using validated tools such as the Beers Criteria and STOPP/START criteria. Then an educational intervention will be conducted to the General practitioners caring for patients of the intervention arm. The educational intervention will consist of training in how to conduct medication reviews using the mentioned tools and also training in validating deprescribing algorithms.
41463870|NCT05499416|DRUG|Bimekizumab|Self-administration of two (2-160 mg/mL \[1 mL\]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16
41463871|NCT00784030|OTHER|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
40781441|NCT04069988|BEHAVIORAL|Baduanjin program|This exercise program aimed to increase patient participation and control their metabolic parameters and body mass index through Baduanjin program. The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warmup, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
40781442|NCT03978845|DRUG|Lidocaine|Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.
40781443|NCT00886730|BEHAVIORAL|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
41144515|NCT03009123|OTHER|Erectile dysfunction|Patients with ED are considered belonging to the exposure group.
41144516|NCT03077958|PROCEDURE|Total Knee Replacement (2 different design)|Patients will randomely receive either Attune or PFC Sigma TKR
41144517|NCT01662713|DEVICE|OFDI|Imaging of skin
41144518|NCT03556332|DRUG|Carfilzomib|Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
41144519|NCT03556332|DRUG|Lenalidomide|Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
41144520|NCT03556332|DRUG|Dexamethasone|Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23
41144521|NCT03556332|DRUG|Daratumumab|"Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)~Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.~Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.~Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle."
41144522|NCT03556332|PROCEDURE|autologous hematopoietic cell transplantation|High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine \>2mg/dL, they will receive 140 mg/m2.
41305073|NCT05202093|DEVICE|Oclean electric toothbrush A|Use Oclean electric toothbrush to brush teeth twice a day for 8 weeks
41305074|NCT05202093|DEVICE|Oral B manual toothbrush|Use Oral B manual toothbrush to brush teeth twice a day for 8 weeks
41463872|NCT04038645|OTHER|Experimental group (laser)|"The patients will receive infrared LEDs in 6 points using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
40985741|NCT03010254|DEVICE|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
40985742|NCT03010254|PROCEDURE|Cataract surgery|IOL bilateral implantation
41305075|NCT05202093|DEVICE|Oclean electric toothbrush B|Use Oclean electric toothbrush B to brush teeth twice a day for 8 weeks
41305076|NCT00825383|OTHER|High Fiber and Moderate Fiber Diets|Dietary
40781444|NCT00886730|BEHAVIORAL|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
40781445|NCT00886730|BEHAVIORAL|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
40781446|NCT01977378|DRUG|Sustained-Release Desvenlafaxine Hydrochloride|
40781447|NCT01977378|DRUG|Sustained-Release Venlafaxine Hydrochloride|
40781448|NCT00674921|DRUG|cotrimoxazole|cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
40781449|NCT00674921|DRUG|Placebo|starch, magnesium stearate, sodium lauryl sulphate
40781450|NCT05887791|DIETARY_SUPPLEMENT|Collagen hydrolysate|Single dose
40781451|NCT05887791|OTHER|Placebo|Single dose
40985743|NCT06521359|DEVICE|flow cytometry|Two ml of peripheral venous blood samples will be collected in heparinized tubes from patients and controls for assessment of levels of TFH and TFReg cells by flow cytometry.
41144523|NCT06463314|DEVICE|INSTI Multiplex HIV/Syphilis Antibody Test|"The INSTI® Multiplex HIV-1/HIV-2 Syphilis Antibody Test (bioLytical Laboratories Inc., Richmond, BC), \[INSTI Multiplex Test\] is a single use, rapid, flow-through in vitro qualitative immunoassay for the detection of antibodies to HIV Type 1 and 2 and Treponema pallidum (Syphilis) in human fingerstick blood and serum. The test is intended to screen for HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and Syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than one minute. This test is licensed by Health Canada."
41305077|NCT00285298|DRUG|Pentoxifylline|
41305078|NCT00285298|DRUG|Placebo|
41305079|NCT05808348|OTHER|Scales and questionnaires|"We will ask participants about their age, gender, height, weight, education level, medical history, number of falls in the last 1 year, status and length of COVID-19-related hospitalizations, and whether they have gotten the COVID-19 vaccine. The participants will be interviewed in person as part of the evaluation process.~The Modified Baecke Physical Activity Questionnaire, the Fall Efficacy Scale-International, and the Numerical Pain Rating Scale will be used to assess the participants' levels of pain, fear of falling, and physical activity, respectively."
41305080|NCT05054673|OTHER|universal adhesive|PALFIQUE universal adhesive
41305081|NCT05054673|OTHER|universal adhesive|3M™ ESPE™ single bond Universal Adhesive
41463873|NCT04038645|OTHER|Control group (Placebo)|Patients will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days as well as the evaluation of serum CRP.
41463874|NCT04594798|DRUG|Polatuzumab vedotin|IV 1.8 mg/kg per cycle
41463875|NCT04594798|DRUG|Rituximab|IV 375 mg/m2 per cycle
41463876|NCT04594798|DRUG|Cyclophosphamide|IV 400 mg/m2 per cycle
41463877|NCT04594798|DRUG|Doxorubicin|IV 25 mg/m2 per cycle
40781452|NCT06405126|DIAGNOSTIC_TEST|Optiek predictive model|Patient data will be extracted to run the predictive model, which will estimate the probability of group 2 pulmonary hypertension. However the results of the model will have no diagnostic or therapeutic implications in this phase of the investigation.
40781453|NCT00006356|DRUG|carboplatin|
40781454|NCT00006356|DRUG|cisplatin|
40781455|NCT00006356|PROCEDURE|conventional surgery|
40781456|NCT04848402|DEVICE|On-Body Delivery System (OBDS)/Multiple Bolus Injector|Used to administer placebo SC.
40781457|NCT04848402|DEVICE|Single Auto Injector|Used to administer placebo SC.
40781458|NCT04848402|DRUG|Placebo|Administered SC.
40781459|NCT03929679|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
40781460|NCT03778801|DIAGNOSTIC_TEST|fibromyalgia syndrome and chronic neck pain|We assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.
40781461|NCT00015847|BIOLOGICAL|recombinant interferon alfa|IFN-α will be given at a dose ranging up to 5 MIU daily via subcutaneous injection.
40781462|NCT00015847|DRUG|imatinib mesylate|Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.
40781463|NCT02116179|BEHAVIORAL|DVD Intervention|Participants will be randomly assigned, with a baseline and 3 month follow up assessments
40781464|NCT02153489|DRUG|Aclidinium bromide|
40781465|NCT02153489|DRUG|Placebo|
40781466|NCT05595928|OTHER|position|To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.
40985744|NCT00366145|BIOLOGICAL|Prochymal®|2 infusions of 2 million cells/kg per week for 4 weeks
40985745|NCT00366145|DRUG|Placebo|2 infusions per week for 4 weeks
40985746|NCT00366145|DRUG|Standard of Care for GVHD|Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)
40781467|NCT01055145|DRUG|levofloxacin, moxifloxacin|Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
40781468|NCT05775900|DRUG|Cetuximab|Cetuximab will be given triweekly at a dose from 400mg/m2 to 700mg/m2.
40781469|NCT05775900|DRUG|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000mg/m2 BID po.)
40781470|NCT00708409|PROCEDURE|Cardiac valve surgery|Different autograft implantation techniques.
41305082|NCT01968096|DEVICE|home-based ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
41305083|NCT04987853|DIAGNOSTIC_TEST|Clinical and functional analysis|"General blood analysis - Complete blood count on an analyzer with differentiation of 5 classes of cells, the ratio of neutrophils to lymphocytes; Blood chemistry - ALT, AST, total bilirubin, direct, LDH, CRP, alpha-amylase, creatinine, urea, glucose, ferritin, glycosylated hemoglobin, vitamin 25 - OH vitamin D, vitamin B12; Coagulogram - D-dimers, fibrinogen, INR, APTT; Other - NT-pro BNP, Homocysteine, IL 6, Troponin, blood group determination; Linked immunosorbent assay - Determination of IgG and IgM antibodies to SARS-CoV-2 coronavirus (COVID-19) in blood serum, RBD; Functional diagnostics • ECG~* EchoCG + strain~* CT scan of the lungs~* Holter~* SMAD~* Kidney ultrasound~* Ultrasound~* Doppler ultrasonography of veins and arteries~* Chalder Scale, EQ Questionnaire"
40781471|NCT05434819|PROCEDURE|Surgical Atrial Fibrillation Ablation|Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed.
40781472|NCT02622789|OTHER|Pilates Exercises|Pilates method based stability exercise intervention
40781473|NCT01434004|BEHAVIORAL|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
40781474|NCT00358111|DEVICE|Luma Cervical Imaging System|Colposcopy using LUMA Cervical Imaging System
41305084|NCT04987853|DIAGNOSTIC_TEST|Neurological analysis|"Neurological examination with the isolation of neurological syndromes (motor, cognitive impairments, sleep disorders, asthenic-depressive syndromes, etc.).~2. Neuropsychological methods - research on the scales of anxiety and depression, MMSE, etc.~3. Instrumental method - EEG, polysonography, ultrasound of the neck vessels, CT perfusion.~4. Laboratory research methods:~1. The study of antibodies to some neurospecific antigens - myelin basic protein (MBP), neurospecific enolase (NSE).~2. Study of cellular immunity (CD3 +, CD4 +, CD8 +) and general indicators of humoral immunity (IgG, IgA, IgM, circulating immune complexes)."
41305085|NCT04987853|DIAGNOSTIC_TEST|Immunological analysis:|A comprehensive immunological analysis will be carried out to determine the level of the immune response. Calculation of the level of CD4 +, CD8 + and NK cells. The level of antibodies of the IgG and IgM classes to the proteins of the coronavirus S1, RBD and N was determined
41305086|NCT04987853|DIAGNOSTIC_TEST|Genetic analysis:|Isolation (extraction) of DNA will be performed from whole blood using commercial kits according to the manufacturer's instructions. To analyze a large number of genetic markers, it is planned to carry out genome-wide sequencing followed by analysis of genetic polymorphisms of candidate genes encoding coronavirus receptors and immunological factors.
41305087|NCT03055104|OTHER|management of severe malnutrition|multidisciplinary assessment; guideline for the management of severe malnutrition in PUTH
41305088|NCT04980924|OTHER|no intervention|no intervention
41305089|NCT00048594|DRUG|aprepitant|
41305090|NCT00048594|DRUG|Comparator: placebo (unspecified)|
41305091|NCT05918874|OTHER|Descriptive questionnaire|Questionnaires were administered to calculate whether the children were obese or not, to determine their asthma control levels, to determine their physical activity levels and to determine their leisure time activities.
41305092|NCT05864443|PROCEDURE|Severe complications following emergency surgery|The respondents are limited to surgeons who had previously experienced severe complications following emergency surgery as chief surgeons.
41305093|NCT02669550|DEVICE|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
41463878|NCT04594798|DRUG|Prednisone|PO 40 mg/m2 per cycle
41463879|NCT00006371|DRUG|aminoglutethimide|
41463880|NCT00006371|DRUG|ketoconazole|
40781475|NCT06010680|DRUG|[14C]SHR2554|Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.
40781476|NCT04887532|DRUG|HR19042 capsule|phase 1 :8mg; phase 2:12mg; phase 3:16mg
40781477|NCT05759780|DEVICE|Optical imaging of the tissues|OCT vibrography
40781478|NCT04108273|BEHAVIORAL|Organizational Skills Training|OST targets three core organizational skills domains - Tracking Assignments, Managing Materials and Time Management - in a program consisting of sessions over 12 weeks, each training lasting about 1 hour, and corresponding 30-60 minute weekly review sessions with the parent and the child, 2-3 days following each training session.
40781479|NCT00930449|OTHER|Cogmed Working Memory Training Program.|"This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.~Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day."
40781480|NCT00930449|OTHER|Academy of Math|"This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.~Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide."
40781481|NCT00930449|OTHER|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
41305094|NCT02669550|DEVICE|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
41305095|NCT03927248|DRUG|Nivolumab|See description in Arms/Groups section
41305096|NCT03762122|DRUG|Rogaratinib|Rogaratinib (BAY 1163877; Bayer) is an oral pan-kinase inhibitor, which selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4.
41305097|NCT06330948|DIETARY_SUPPLEMENT|SugarCut® Unripe Guava Fruit Extract|This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the SugarCut® Guava Extract group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
41305098|NCT06330948|DIETARY_SUPPLEMENT|Placebo group|This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the placebo group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
40781482|NCT03435068|DEVICE|Ceramic rotary bur|Gingivoplasties were performed with the same ceramic burs to easily provide a knife-edge appearance with ceramic rotary bur
40781483|NCT03435068|DEVICE|Diode laser|The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power were used in the study.
40781484|NCT03435068|DEVICE|Scalpel|Scalpel surgery were performed as control group (conventioanl group).
40781485|NCT02943694|DEVICE|TaTME with CS-Compact (GelPoint pathway)|Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
40781486|NCT01082848|DRUG|aripiprazole|10 mg QD during 26 weeks
40781487|NCT01082848|DRUG|placebo|QD during 26 weeks
40781488|NCT01679483|DRUG|FloSeal application|At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
40781489|NCT05162690|DRUG|Dapagliflozin 10 milligram|10mg per day of Dapagliflozin will be given to the patients
40781490|NCT05162690|OTHER|Placebo|Metformin DPP4 inhibitors
40781491|NCT03017443|BEHAVIORAL|Nutrisystem Turbo 10|Turbo10 plan provided approx. 1000 kcal/d for all subjects and included portion controlled foods/shakes for the first week (week 0). All food, except non-starchy vegetables and no-calorie beverages, was provided for the first week (week 0). Starting week 1, subjects followed the My Way plan intervention through week 16.
40781492|NCT03017443|BEHAVIORAL|Nutrisystem My Way|The Nutrisystem My Way plan provided 7 breakfasts, 6 lunches, 6 dinners, and 7 (women) or 14 (men) snacks/desserts as pre-packaged portion controlled foods every week. Subjects were instructed to prepare one lunch and one dinner on their own each week. General guidelines and recommendations were provided by Nutrisystem in order to allow subjects to self-select appropriate foods for these eating occasions that fit within the My Way plan guidelines (\~50% kcal from carbohydrate, \~25% from protein, \~25% from fat). Women were assigned to 1200 calories per day and men were assigned to 1500 calories per day. Nutrisystem packaged foods accounted for approximately 60% of daily calorie target; recommended grocery food additions (which subjects purchased on their own) accounted for the balance.
40985747|NCT04579692|DEVICE|ExAblate Transcranial treatment|Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.
41147040|NCT06381297|DIAGNOSTIC_TEST|Speech in noise discrimination test|Speech discrimination in noise (SDN) test will be performed in a quiet room in accordance with the Industrial Acoustic Company (IAC) standard using the Grason-Stadler GSI 61 Clinical Audiometer. After pure tone audiometry and speech tests, the GKAE test will be performed. The speech in noise discrimination test will be performed with a signal-to-noise (S/N) ratio of +10 dB. A word list at 50 dB SL will be presented to the tested ear using live sound, while simultaneously white noise at 40 dB SL will be presented to the test ear (Beattie et al. 1997). This will be done for both ears. The speech in noise discrimination test scores will be calculated as percentages (%) for both ears.
41305099|NCT00862966|OTHER|citrate|comparison of different catheter lock solutions
41305100|NCT00862966|OTHER|heparin|comparison of different lock solutions
40781493|NCT03017443|BEHAVIORAL|Nutrisystem DASH|The Nutrisystem DASH plan was a modification of the My Way plan designed to meet the nutrition profile of the DASH Diet, as described in NIH materials. Key nutritional targets included \< 30% fat (\< 7% saturated fat), \< 150 mg/d of cholesterol, and \< 2300 mg/d of sodium. Key dietary targets were consumption of 7-10 servings of fruit/vegetables/day, 2-3 servings of low-fat dairy/day, and 3 servings nuts/seeds/week. The Nutrisystem DASH plan included a subset of the Nutrisystem menu \[7 breakfasts, 6 lunches, 6 dinners, plus snacks as portion-controlled foods every week\], as well as modified guidelines for grocery additions, to achieve the nutrition targets of the DASH diet. Women consumed 1200 kcal/day and men consumed 1500 kcal/day.
40781494|NCT03017443|BEHAVIORAL|Dieting on Your Own (DIY) - DASH|The self-directed diet included publicly available information consistent with the Dietary Approaches to Stop Hypertension (DASH) diet instructing individuals to consume a reduced calorie diet to support self-directed weight loss efforts. Women were assigned to a 1200 calorie diet and men were assigned to a 1500 calorie diet. Information on the self-directed diet was provided at the beginning of the intervention (visit 2, week 0). Subjects randomized to this group did not receive additional dietary counseling throughout the study period.
40781495|NCT00882024|DRUG|Tranilast|150 mg tranilast tablets, bid, 12 weeks
40781496|NCT00882024|DRUG|Tranilast|75 mg tablets, bid, 12 weeks
40781497|NCT00882024|DRUG|Placebo|Placebo tablets, bid, 12 weeks
40781498|NCT05910944|PROCEDURE|Shunt surgery|Shunt surgery according to each local centers routine
41305101|NCT01144078|BEHAVIORAL|Traditional Intensity Exercise|The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
40985748|NCT02716064|BEHAVIORAL|TAP-CM Intervention|The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
40985749|NCT05481645|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.
40985750|NCT05481645|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
40781499|NCT00104702|PROCEDURE|adjuvant therapy|
41463881|NCT00006371|DRUG|therapeutic hydrocortisone|
41463882|NCT02631252|DRUG|Hydroxychloroquine|Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
41463883|NCT02631252|DRUG|Mitoxantrone|Dose: 10mg/m2 IVPB in 50ml NS
41463884|NCT02631252|DRUG|Etoposide|Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
40781500|NCT00104702|PROCEDURE|conventional surgery|
40781501|NCT00104702|RADIATION|radiation therapy|
40781502|NCT05595850|BEHAVIORAL|Mindfulness|Online non-meditation mindfulness program
40781503|NCT05595850|BEHAVIORAL|Mindful Learning|Online learning program
40781504|NCT02468830|DRUG|mirabegron|Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
40781505|NCT01031888|DRUG|Topical insulin eye drops|Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
40781506|NCT01031888|DRUG|Conventional postoperative eye drops|topical steroid, antibiotic and mydriatics
40781507|NCT02280993|DRUG|DHAP|DHAP
40781508|NCT02280993|DRUG|Brentuximab Vedotin|Brentuximab Vedotin
40781509|NCT02280993|OTHER|Autologous Peripheral Blood Stem Cell Transplantation|Autologous Peripheral Blood Stem Cell Transplantation
40781510|NCT05732064|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
40985751|NCT05481645|DRUG|Carboplatin Injection|Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.
40985752|NCT05481645|DRUG|Paclitaxel Injection|Paclitaxel is a diterpene alkaloid with anticancer activity
40985753|NCT05481645|DRUG|Doxorubicin Hydrochloride Injection|Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.
40985754|NCT05481645|DRUG|Gemcitabine Hydrochloride Injection|Gemcitabine is a cell cycle specific antimetabolic drug, which mainly acts on tumor cells at the DNA synthesis stage.
40985755|NCT05481645|DRUG|Docetaxel injection|Docetaxel is an anti-tumor drug of paclitaxel, which plays an anti-tumor role by interfering with the microtubule network necessary for cell Mitosis and interphase cell function.
41305102|NCT01144078|BEHAVIORAL|High Intensity Interval Exercise|The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
41305103|NCT05789004|PROCEDURE|Tooth Bleaching with Whiteness HP Automixx 35%|"* Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 35% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
41463885|NCT04172545|PROCEDURE|stapling|staples are fired through the gastric wall after waiting several seconds for compression without attention to blood pressure, fluids given or intra abdominal pressure, but these might have an impact on quality of stapling. therefore the conditions during stapling will be recorded during stapling.
41463886|NCT01006967|DEVICE|ActiveStep Treadmill|The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
41463887|NCT01006967|OTHER|Physical Therapy|Standard program of physical therapy for gait and balance
41463888|NCT04736394|DRUG|APL-1202|APL-1202 single-agent oral treatment
41463889|NCT04736394|DRUG|Epirubicin Hydrochloride|Epirubicin hydrochloride
41144524|NCT04528602|PROCEDURE|Control (Extended leg position) Group|"Common procedure steps -Legal representatives of the infants will sign an informed consent form. Materials (soap, napkin, non-sterile gloves, diaper, wet cotton towels for newborns, waste container, diaper change mat) will be prepared.~Hands will be washed and gloves will be worn. Tapes of the infant's dirty diaper will be opened.~For the Control Group~-The infant will be grasped on the legs, the legs will be given extension position and lifted up.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed. The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed.~The infant's legs will be given in extension position and a clean diaper will be placed under them.~Tapes of the clean diaper will be fastened. Hands will be washed after the procedure Data will be collected before, during, after and 3 minutes after application."
41463890|NCT06503003|DEVICE|Leonardo® Diode laser|The intervention involves non-ablative dual-wavelength diode laser therapy for treating Genitourinary Syndrome of Menopause (GSM). This includes three monthly sessions of the Leonardo® Diode laser (Biolitec®), with wavelengths of 980 nm and 1470 nm, delivering 8 pulses per centimeter along the vaginal canal, using local lidocaine gel as an anesthetic. Evaluations are conducted at baseline, 3 months, and 6 months post-treatment.
41463891|NCT04070079|DRUG|Tenofovir Alafenamide|TAF 25mg once daily orally, for 48 weeks
41463892|NCT02964390|PROCEDURE|Balloon Pulmonary Angioplasty|
41463893|NCT04546152|DEVICE|HYAPROF® SOFT and HYAPROF® BALANCE|Dermal filler injection to different facial areas
41463894|NCT05793632|DRUG|Quetiapine|The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
41463895|NCT03041532|PROCEDURE|Proximal retroflexion|The investigator explore twice right colon, first front view and second forward viewing or proximal retroflexion depends on randomization
41463896|NCT03041532|PROCEDURE|Frontal view|The investigator explore twice right colon with frontal viewing
41463897|NCT03930069|DRUG|Misoprostol|prostaglandin E1 analogue vaginally inserted two hours before hystertsopic myomectomy to evaluate intraoperative blood loss and operative time needed for completion of myomectomy
41463898|NCT03930069|DRUG|Vasopressin|one ampoule of vasopressin was diluted to 50 ml of normal saline, and 10 ml (4 units of vasopressin) was withdrawn in a syringe. Needle was inserted through the working channel of the hysteroscope until its tip was seen. The needle tip was pointed to the site of injection under hysteroscopic guidance during the whole injection technique. Aspiration was done first to avoid intravascular injection of vasopressin. The diluted solution was injected into the surface, especially to parts with dilated vasculature till they blanch.
41463899|NCT03356106|DEVICE|Continuous positive airway pressure (CPAP)|A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep
41463900|NCT03045133|DRUG|Methadone|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
41463901|NCT03045133|DRUG|Morphine|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
41463902|NCT05489796|DRUG|Fentanyl selector|Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
41463903|NCT05489796|DRUG|Fentanyl continuous|Continuous (2 ml/hr): fentanyl 700 mcg + N/S 86 ml = total 100 ml
41463904|NCT05489796|DRUG|Ketorolac continuous|Continuous (2 ml/hr): Ketorolac 180 mg + N/S 94 ml = total 100 ml
41463905|NCT00861549|DRUG|Phencynonate hydrochloride|2mg/tablet
41463906|NCT04775316|DEVICE|Leukomed T / Tplus skin sensitive treatment|Application of sterile wound dressing.
41463907|NCT04159194|OTHER|Control Diet|Players during the control trial will be instructed to maintain their normal food intake (\~55% CHO) and the type and amount of ingested food will be recorded.
41463908|NCT04159194|OTHER|Experimental Diet|The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
41463909|NCT01520545|DRUG|Gablofen® 3 mg/mL (baclofen injection)|This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
41463910|NCT01520545|DEVICE|SynchroMed® II Programmable Pump|Intrathecal programmable pump
41463911|NCT04590196|DRUG|Longvida curcumin|longvida curcumin verdure sciences formulation
40781511|NCT05732064|DRUG|Esketamine|Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
40781512|NCT05732064|DRUG|Normal saline|Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
40781513|NCT03361488|OTHER|Trained anesthesiogist|
40781514|NCT05384314|DEVICE|RespiraSense|The use of continuous electronic monitoring of respiratory rate
40781515|NCT02722408|DRUG|Gemcabene|300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
40781516|NCT06438991|OTHER|Adjustment of spinal cord stimulation parameters for voluntary motor control|All patients will receive a spinal cord stimulator and undergo adjustment of stimulation parameters for optimal voluntary lower extremity motor control during research visits. Muscle strength will be assessed with the stimulation turned on and off.
40781517|NCT00403156|DRUG|Imatinib Mesylate /Ranibizumab|
40781518|NCT05339529|DRUG|Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead.
40781519|NCT05339529|DRUG|Blank control|Blank control
40985756|NCT00473460|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
41463912|NCT04590196|OTHER|placebo|"Composition of Placebo :~95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide"
41463913|NCT02459886|DRUG|BIIB054|IV infusion
41463914|NCT02459886|DRUG|Placebo|IV infusion
41463915|NCT02351635|OTHER|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
41463916|NCT01080586|DRUG|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
41463917|NCT02912767|BEHAVIORAL|questionnaire|A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.
41463918|NCT01923818|DRUG|rivaroxaban|orally active direct factor Xa inhibitor
41463919|NCT01923818|DRUG|Aspirin|non-steroidal anti-inflammatory drugs
40781520|NCT02318017|DRUG|Methylphenidate|Before neurocognitive testing, Methylphenidate/Placebo will be given
40781521|NCT02318017|DRUG|Placebo|
40781522|NCT05227170|OTHER|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
40781523|NCT05227170|OTHER|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
40781524|NCT00451230|DRUG|cocaine|
40781525|NCT00451230|DRUG|hydrocortisone|
40985757|NCT00473460|DRUG|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
40985758|NCT04743427|OTHER|hot pack and exercises|20-minute hot pack,and three active exercises: (a) chin tucks in supine lying with the head in contact with the floor, (b) active Standing Shoulder pull back , and (c) scapular plane shoulder elevation. (3 sets of 10 repetitions for all the 3 exercises)
40985759|NCT04743427|DEVICE|body blade(BB)|The Body-blade (Classic, Mad Dogg Athletics, USA), an elastic pole exercise tool with 122 cm in length, 0.68 kg, 4.3 cm in width,based on oscillatory/vibration motions that have been used in training or rehabilitation.The body blade works by rapidly changing directions at a low-frequency rhythm of approximately 4.5 Hz (cycles per second )
40985760|NCT00743314|OTHER|screening questionnaire administration|
40985761|NCT00743314|PROCEDURE|computed tomography|
40985762|NCT00743314|PROCEDURE|lymphoscintigraphy|
40985763|NCT00743314|PROCEDURE|single photon emission computed tomography|
40985764|NCT00743314|RADIATION|intensity-modulated radiation therapy|
40985765|NCT00743314|RADIATION|technetium Tc 99m sulfur colloid|
41463920|NCT01923818|DRUG|placebo|
41463921|NCT04694703|DRUG|Covid-19 group|Routine COVID-19 treatment
41463922|NCT02248116|DRUG|Talsaclidine|
41463923|NCT02123732|DIETARY_SUPPLEMENT|DbXell|
41463924|NCT02123732|DIETARY_SUPPLEMENT|Placebo|
41305104|NCT05789004|PROCEDURE|Tooth Bleaching with Whiteness HP Automixx 6%|"* Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 6% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
41305105|NCT04574297|BEHAVIORAL|smoking and alcohol assumption|documenting the change of smoking and drinking status during the follow-up period
41305106|NCT04574297|DIAGNOSTIC_TEST|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
41305107|NCT03347331|DRUG|[18F]F13640|"Radiotracer injection and PET scan acquisition of 90 min:~\*150 Mbq + 1 MBq/Kg of \[18F\]F13640 at t=0 min~Arterial Blood Sampling during the 90min acquisition"
41305108|NCT03347331|DRUG|[18F]F13640|2 Radiotracer injections and PET scan acquisition of 90 min distant from 1 to 3 weeks: For each exam: 150 MBq + 1 MBq/kg of \[18F\]F13640 at t=0 min
41463925|NCT04681508|DIAGNOSTIC_TEST|Chest CT without contrast enhancement and chest X-ray|Chest CT without contrast enhancement and chest X-ray as supplement to diagnostic abdominal CT
41463926|NCT05525676|BEHAVIORAL|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
40985766|NCT00951808|BIOLOGICAL|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
40985767|NCT00951808|BEHAVIORAL|Standard care|Participants will receive standard care for ACS while in the hospital.
40985768|NCT02702440|OTHER|Liquid calories from sugars|
40985769|NCT01832870|DRUG|sipuleucel-T|
40985770|NCT01832870|DRUG|ipilimumab|
40985771|NCT04696939|DRUG|Atezolizumab|Atezolizumab intravenous infusion was administered at a dose of 1200mg on Day 1 of each 21-day cycle.
40985772|NCT04696939|DRUG|Carboplatin|Carboplatin intravenous infusion was administered at a dose of 75mg/m\^2 on Day 1 of each 21-day cycle.
40985773|NCT04696939|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Day 1 of every 3-day cycle.
40985774|NCT04051047|DRUG|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
40985775|NCT04051047|PROCEDURE|Tumor biopsy and blood draw|As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
40985776|NCT02933892|PROCEDURE|Cardiac Catheterization|Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.
40985777|NCT01953055|RADIATION|Stereotactic ablative radiotherapy|
41305109|NCT03108144|BEHAVIORAL|Brief alcohol intervention|The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
41305110|NCT01688167|BEHAVIORAL|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
40985778|NCT06053073|DEVICE|Cervical rippening at home|The experimental arm of the study will undergo cervical rippening at home between 6 and 8 hours and then will come back to the hospital to continue with the labor induction
40985779|NCT06053073|DEVICE|Cervical rippening in the hospital|The active comparator arm of the study will undergo cervical rippening in the hospital between 6 and 8 hours and then will remain there to continue with the labor induction
41305111|NCT01156038|DEVICE|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate reaction one day later(72 hrs after applying atopy patch test)
41305112|NCT02145156|BEHAVIORAL|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
41305113|NCT02145156|BEHAVIORAL|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
41305114|NCT02145156|BEHAVIORAL|Survey-only|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
41305115|NCT01276665|PROCEDURE|restrictive intraoperative fluid substitution|to analyze the impact of a restrictive volume regimen using advanced balanced electrolyte solution (which is by far more restrictive than the published data) combined with noradrenaline. We include only radical cystectomy and so nearly exclude surgical bias
41305116|NCT01276665|PROCEDURE|assessment of the pelvic venous pressure|A 20 G catheter will be introduced into a small collateral vein of the internal iliacal vein to monitor pelvic venous pressure
41305117|NCT05238948|DRUG|Midazolam|Substrate of CYP3A4
41305118|NCT05238948|DRUG|CKD-506|Perpetrator of CYP3A4
41305119|NCT01163162|DRUG|Paricalcitol|2 mcg oral Paricalcitol once per day for 7 days
41305120|NCT01473628|OTHER|Clinical Observation|Undergo observation
41305121|NCT01473628|RADIATION|Radiation Therapy|Undergo radiation therapy
41305122|NCT01473628|BIOLOGICAL|Rituximab|Given IV
41305123|NCT00871949|DRUG|PNU-100480|100 mg oral suspension given once
40985780|NCT04907539|DRUG|RXC004|"RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules."
40985781|NCT04907539|BIOLOGICAL|Nivolumab|Nivolumab will be administered via IV infusion, 480 mg q4w.
40985782|NCT04907539|BIOLOGICAL|Denosumab|"Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic"
41305124|NCT00871949|DRUG|PNU-100480|300 mg oral suspension given once
41305125|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
41305126|NCT00871949|DRUG|PNU-100480|300 mg oral suspension given once
41305127|NCT00871949|DRUG|PNU-100480|35 mg oral suspension given once
41305128|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
41305129|NCT00871949|DRUG|PNU-100480|100 mg oral suspension given once
41305130|NCT00871949|DRUG|PNU-100480|35 mg oral suspension given once
41305131|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
41305132|NCT00871949|DRUG|PNU-100480|1000 mg oral suspension given once
41305133|NCT00871949|DRUG|PNU-100480|1500 mg oral suspension given once
41305134|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
41305135|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
41305136|NCT00871949|DRUG|PNU-100480|1500 mg oral suspension given once
41305137|NCT00871949|DRUG|PNU-100480|600 mg oral suspension given once
41305138|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
41305139|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
41305140|NCT00871949|DRUG|PNU-100480|1000 mg oral suspension given once
41305141|NCT00871949|DRUG|PNU-100480|600 mg oral suspension given once
41305142|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
41305143|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
41305144|NCT00013624|DRUG|IV Levodopa|
41305145|NCT01615224|DRUG|misoprostol|repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
40985783|NCT00721773|DRUG|Benazepril|Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
40985784|NCT00721773|DRUG|Valsartan|Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
40781526|NCT05541848|OTHER|Cervical supervised exercises with laser-guided feedback (ELGF)|"Cervical supervised exercises with laser-guided feedback (ELGF) is defined as a procedure of proprioceptive training based on a type of therapeutic exercise that provides external feedback to exercise, achieving an improvement in range of motion and postural control in subjects with spinal pain. For the performance of the exercise program, Motion Guidance Clinician Kit (Motion Guidance LLC, Denver, CO, USA.) was used. The program consisted of 4 exercises, which progressed in difficulty according to the tolerance achieved over the course of the sessions: a) Maintaining the head position (cervical stabilisation); b) Cervical flexion-extension; c) Right-left rotations; d) Right-left lateral-flexions. Each exercise consisted of 4 series of 8 repetitions, except the first one, in which the head position is maintained by pointing the laser at the centre of the panel for 30 seconds (4 series). The average time to complete the entire program did not exceed 14 minutes."
40985785|NCT00721773|DRUG|Benazepril+Valsartan|Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
40985786|NCT00721773|DRUG|Control|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
40985787|NCT05844189|PROCEDURE|Physical therapy modalities on pelvic floor (manual therapy)|Intravaginal treatment (perineal massage)
41144525|NCT04528602|PROCEDURE|Experimental (Legs are flexed toward abdomen) Group|"Procedure steps for the Experimental Group~* Common procedure steps~* The infant will be grasped on the legs; the legs will be kept in the flexion position and approached toward the abdomen.~* The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~* The infant's feet will be freed.~* The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed and thrown into the medical waste bin.~* The infant's legs will be kept in the flexion position and a clean diaper will be placed under them. A bottom care plan will be applied in line with the treatment plan, if necessary.~* Tapes of the clean diaper will be fastened.~* Hands will be washed after the procedure.~* Data will be collected immediately before, during, immediately after and 3 minutes after the end of application."
41144526|NCT01543204|DRUG|Etanercept|Administered by subcutaneous injection
41144527|NCT04864106|DEVICE|Endoscopic Examination|Endoscopic airway grading using a rigid 75-degree angle laryngoscope.
41144528|NCT00490906|DRUG|Copaxone|20 mg, subcutaneous injections, taken daily
41144529|NCT00490906|DRUG|Interferon-beta 1a|30 mcg injected intramuscularly, once weekly
41144530|NCT00490906|DRUG|Interferon-beta 1b|.25 mg/day, taken every other day, subcutaneous injections
41305146|NCT03553433|DRUG|Apremilast 30mg|Anti-psoriatic drug
41305147|NCT03553433|DRUG|Placebo Oral Tablet|Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
41305148|NCT00563004|DIETARY_SUPPLEMENT|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
41305149|NCT00563004|DIETARY_SUPPLEMENT|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
40781527|NCT05541848|OTHER|Interferential current electro massage (ICE)|Interferential current electro-massage (ICE) is defined as a technique which combines simultaneously manual therapy (massage) and ICT. We used a current bipolar mode, using a carrier frequency of 4000 Hz at constant voltage and an amplitude-modulated frequency of 100 Hz (Sonopuls 692®; Enraf-Nonius BV, Rotterdam, The Netherlands), was administered. The intensity was set to provide a strong and comfortable tingling, without evoking muscle twitches even though a slight vibration (fasciculation) was allowed. The sequence combined (A) superficial stroke over the neck-shoulder for 30-45 seconds; (B) deep sliding movements, alone or (C) combined with shoulder drop, for 4-5 minutes; (D) bilateral kneading of the upper trapezius (4-5 minutes); (E) slight stretching of cervical muscles (upper trapezius, sternocleidomastoid, and levator scapulae); and repetition of step (A). The electro-massage protocol lasted 15 minutes.
40781528|NCT03423511|DEVICE|MiStent II coronary artery stent|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
40985788|NCT05844189|DEVICE|CRMRF|"CRMRF application on pelvic floor:~* Externally over the urogenital triangle of the patient,~* Intracavitary application (intravaginal)~* Externally over the urogenital triangle of the patient while the physical therapist performs the intracavitary manual therapy (intravaginal),~The device used is named Intradermik and it is the portable CRMRF device of the brand RÖS'S Estética SL.~It has these features:~* Frequency: 448kHz~* Capacitive power: 450 voltamperes~* Resistive power: 200 watts"
40985789|NCT05844189|DEVICE|Sham CRMRF|The physical therapist applies the same treatment as the Treatment Group but the device is switched off.
40781529|NCT03423511|DEVICE|Xience or Promus coronary artery stents|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
40781530|NCT02332473|DRUG|Ypeginterferon alfa-2b|
40781531|NCT02332473|DRUG|Granulocyte-macrophage colony stimulating factor|
40781532|NCT01853709|BEHAVIORAL|Education|
40781533|NCT01853709|OTHER|Fiber free diet|
40781534|NCT01853709|DIETARY_SUPPLEMENT|Adjuvants|
40781535|NCT01853709|DRUG|Polyethylene glycol (PEG)|
40781536|NCT01853709|DRUG|Bisacodyl|
40781537|NCT03366337|DRUG|Bardoxolone methyl capsules|Bardoxolone 5 mg capsules
40781538|NCT02138825|DRUG|Riociguat (Adempas, BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
40781539|NCT02138825|DRUG|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
40781540|NCT05504122|PROCEDURE|inguinal hernia repair|Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied
40781541|NCT00325143|BIOLOGICAL|DTPa-HBV-IPV/Hib|1 intramuscular injection (3rd study vaccine dose)
40781542|NCT00325143|BIOLOGICAL|DTPa-IPV/Hib vaccine|3 intramuscular injections (1st, 2nd and 4th vaccine dose)
41144531|NCT01735435|OTHER|Indirect Calorimetry|"The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.~IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes."
41144532|NCT01204879|BEHAVIORAL|Contingency Management|Participants earn the chance to win prizes for the targeted behavior.
41144533|NCT05756101|DEVICE|Research on the application of novel restraint devices in postoperative patient safety management in cardiac surgery|According to the individual characteristics of ICU patients and the needs of patients, a new type of restraint device was innovatively made and the effectiveness and safety of the new restraint device were studied, which provided clinical reference and theoretical basis for standardizing postoperative patient restraint.
40781543|NCT02812914|OTHER|Low-cost gas stove|Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas
40781544|NCT02812914|BEHAVIORAL|Peer education classes|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution
40781545|NCT02812914|BEHAVIORAL|Resource-intensive behavioral intervention approach|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution. Additionally, peer educators will visit each home after group classes to help the woman, and key decision-makers in her family, identify top priority strategies to reduce air pollution. Using a checklist, peer educators will observe whether household members are adhering to tailored strategies at subsequent home visits, and provide ongoing support to women and their families.
40781546|NCT05354219|OTHER|Imaging|Imaging with 3 iris cameras
41305150|NCT01260467|DRUG|memantine|10 milligrams orally twice a day
41305151|NCT00214851|DRUG|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
40781547|NCT03701243|PROCEDURE|mNT-BBAVF|Briefly, to construct an mNT-BBAVF, an incision is made on the ulnar side of the elbow. The brachial artery and basilic vein are then isolated, and a side-to-side anastomosis is performed without transposition of the basilic vein.
40781548|NCT03701243|PROCEDURE|RCAVF|Briefly, to construct a wrist RCAVF, an incision is made on the radial side of the wrist. The radial artery and cephalic vein are then isolated, and a end-to-side anastomosis is performed.
40781549|NCT04505761|DEVICE|Virtual Reality|Participants will use a Virtual Reality headset with a range of applications applicable for rehabilitation after COVID-19. Applications target physical, psychological, and cognitive rehabilitation. VR headset will be used for six weeks first at the physiotherapist's practice, and when possible, at home.
40781550|NCT00204529|DRUG|pegylated interferon-alpha-2a|
40781551|NCT00204529|DRUG|interferon-alpha-2a|
40781552|NCT03367884|PROCEDURE|Neck dissection followed by radiotherapy(50Gy) according to risk factors|Neck dissection followed by radiotherapy(50Gy) according to risk factors
40781553|NCT03367884|RADIATION|Definitive radiotherapy|Definitive radiotherapy (70Gy)
40781554|NCT03434834|DEVICE|optical coherence tomography|OCT measurements of 5 locations in the esophagus
40781555|NCT01459692|OTHER|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
40781556|NCT00633126|DRUG|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
40781557|NCT01544673|DRUG|linezolid|600 mg oral tablet twice daily for 4.5 days
40781558|NCT01544673|DRUG|Placebo|500 mg oral placebo twice daily for 4.5 days
40781559|NCT02842593|BEHAVIORAL|Lower-repetition, heavier-load|8-12 reps/set at \~80% 1 repetition maximum
40781560|NCT02842593|BEHAVIORAL|Higher-repetition, lighter-load|20-25 reps/set at \~30% 1 repetition maximum
40781561|NCT06452693|DRUG|TQA3038 injection/placebo|TQA3038 is a Anti-Hepatitis B virus (HBV) drugs.
40781562|NCT06452693|DRUG|Nucleotide drugs Control group|Nucleotide drugs are nucleoside reverse transcriptase inhibitors.
40781563|NCT03893981|OTHER|Proprioception and Balance Program|Balance Trainer device and playing ball in tandem position for using to improve balance, vibration and reposition exercises for using to improve proprioception. Progressive of training will increase after each 2 weeks.Patients will be taken to the treatment program 3 days in a week for 8 weeks.
40781564|NCT03893981|OTHER|Strengthening Program|Exercises which include open and closed kinetic chain exercise will be applied to strength knee and hip muscle. Progressive of training will increase after each 2 weeks. Patients will be taken to the treatment program 3 days in a week for 8 weeks.
40781565|NCT03483948|DRUG|HMPL-523|HMPL-523 tablet
40781566|NCT03483948|DRUG|Azacitidine|Azacitidine Injection
40781567|NCT01072526|DRUG|Euphrasia-based homeopathic therapy|ophthalmic solution; 1 drop both eyes twice daily
40781568|NCT01072526|DRUG|Cyclosporin solution|Cyclosporin solution; 1 drop both eyes twice daily
41144534|NCT00721734|DRUG|Carfilzomib|Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
40781569|NCT02169648|DRUG|ranibizumab|intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
40781570|NCT01344148|DRUG|INH RIF Rifb PZA EMB AZT 3TC D4T EFV|The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
40781571|NCT01932788|DRUG|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
40781572|NCT01932788|DRUG|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
40781573|NCT01068184|DRUG|AZD6553|Single or multiple oral dose
40781574|NCT01068184|DRUG|Placebo|single or multiple oral dose
40985790|NCT05533047|PROCEDURE|TURP|Bipolar and monopolar transurethral resection of the benign prostatic hyperplasia
41144535|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection and mapping.
41144536|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection and mapping.
41144537|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
41305152|NCT05263102|DEVICE|Vaginal Moisturizing Gel|All eligible subjects will received the Vaginal Moisturizing Gel twice per week, total in 8 weeks
41305153|NCT00007904|BIOLOGICAL|filgrastim|Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC \> 10,000/uL x1 day after the nadir cycles 1-3.
41305154|NCT00007904|DRUG|cyclophosphamide|cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
41305155|NCT00007904|DRUG|doxorubicin hydrochloride|Patients then receive doxorubicin IV on day 1.
41305156|NCT00007904|DRUG|paclitaxel|Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3
41463927|NCT05525676|BEHAVIORAL|Co-Located Collaborative Care (CCC)|"The investigators are using the Co-Located Collaborative Care model developed by the VA Center for Integrated Healthcare to deliver at all VAs. Although the CCC model is flexible and can range from 1-6 sessions, in this study the investigators standardize the model to three sessions for a clear comparison with BRC. Session 1 uses the CCC Functional Assessment/Initial Assessment protocol. Sessions 2 \& 3 use the CCC Follow-up protocol.~Session 1 (25-30 min)- Veteran completes a functional assessment of concerns (15 mins) and then develops a personalized action plan (10 minutes) Session 2 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan (20 minutes) Session 3 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan, including receiving referrals (20 minutes)"
41463928|NCT01053091|BEHAVIORAL|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
40781575|NCT05291533|OTHER|Virtual Reality (VR) Mindfulness Program|The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
40781576|NCT01356394|OTHER|dietary intervention|12-week calorie-restricted diet consisting of 50% carbohydrate, 20-25% protein, and 25-30% fat
40781577|NCT04480229|BEHAVIORAL|Telenursing and Counseling|After the first face-to-face training, counseling on the phone was conducted every week for four cycles of chemotherapy treatment. In total, six counseling sessions and four face-to-face training sessions were conducted for each patient.
40781578|NCT01816048|DRUG|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
40781579|NCT01816048|RADIATION|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
40781580|NCT01816048|PROCEDURE|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
40781581|NCT01816048|PROCEDURE|Computed Tomography|Undergo 18F NaF PET/CT scan
40985791|NCT04318990|PROCEDURE|Distal radial artery access|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
40985792|NCT04318990|PROCEDURE|Proximal radial artery surgery|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
41144538|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
41144539|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
41144540|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
41305157|NCT00007904|DRUG|tamoxifen citrate|tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed
40781582|NCT00551096|DRUG|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
40781583|NCT00551096|DRUG|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
40781584|NCT00551096|DRUG|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
40985793|NCT02570906|DEVICE|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
40985794|NCT04964154|BEHAVIORAL|Protect Your Elders Campaign|This is a behavioral intervention where participants will receive cultural appropriate educational information about COVID-19 testing and vaccination.
40985795|NCT05774158|OTHER|Physiotherapy assessment|Of the individuals included in the study; Information about age, height, body weight, type of congenital heart disease, surgical history, drug use, comorbid chronic disease, education level and occupation will be obtained. Functional Capacity, Peripheral Muscular Strength, Hand Grip Strength, Fatigue, Physical Activity Level, Quality of Life, Social Participation, Depression Anxiety Stress Level and Physical Activity Barriers will be evaluated
41305158|NCT00007904|PROCEDURE|adjuvant therapy|Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.
41305159|NCT00007904|RADIATION|radiation therapy|Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.
41305160|NCT04743245|DEVICE|TherOx DownStream System|SSO2 Therapy with Therox downstream System after Percutaneous Coronary Intervention (PCI)
41305161|NCT04743245|DEVICE|PCI|Standard Care of PCI
41305162|NCT03546725|DEVICE|Compression stocking|Compression stocking with length below the knee and a class two compression level (corresponding to 23-32 mmHg compression).
41463929|NCT04229290|DRUG|Dolutegravir|Switch of virally suppressed participants to Dolutegravir
41463930|NCT01937117|PROCEDURE|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
41463931|NCT01937117|DRUG|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
40781585|NCT03532022|DRUG|Chronocort®|Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
40985796|NCT05565846|COMBINATION_PRODUCT|NTX-001|One-time use surgical product of three solutions and a device
40985797|NCT01531374|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
40985798|NCT00320983|DRUG|Topotecan|Topotecan
40985799|NCT00320983|DRUG|Cisplatin|Cisplatin
40985800|NCT06502626|OTHER|Regular training|performed their routine programs
41463932|NCT01937117|DRUG|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
41463933|NCT04989569|DIETARY_SUPPLEMENT|Nutritional intervention|In the intervention group, the body composition data (of day 1, 3, 8) will be given to the dietitians for adjusting the diet formula. The diet formula will be adjusted on the discretion of the dietitian caring for the septic patients based on clinical judgement. The policy adopted by the dietary treatment guidelines for sepsis is to adjust the dietary concentration when there is too much extracellular water under the premise of gastrointestinal tolerance. When the skeletal muscle mass loss is too fast, the dietitians will increase the protein intake by 1.2g/kg of body weight. For patients with acute renal failure and excess extracellular water accumulation and muscle loss, the dietitians will adjust the protein, sodium, potassium, calcium and phosphorus content in the formula. The dietitians will give appropriate nutrition prescriptions based on clinical signs, disease diagnosis and biochemical values.
41463934|NCT01877694|DRUG|Auriclosene Solution 0.3%|Ophthalmic solution dispensed as drops onto the eye
40781586|NCT03532022|DRUG|Standard Care|The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
40781587|NCT05826587|BEHAVIORAL|Home-based, m-Health Delivered Physical Function Training|An individualized home exercise physical function training will be prescribed. This would include 5 balance training exercises and 1-2 upper and lower-body muscular conditioning exercises (i.e., wall push-up and chair stand) prescribed 3 days/week over the course of a 6-week period. Subjects will be assigned exercises from 1 of 3 different levels of exercise progression based on performance during the baseline muscular fitness assessment (functional chair stand and static chest throw).
40985801|NCT06502626|OTHER|Sprint Interval Training|Sprint interval training will be given for 4 weeks. Each week consisted of three training sessions, separated by at least one resting day. Participants will complete a 15-minutes warm up before training session. The Sprint interval training group consisted of 30 s sprints at near maximal effort, with three minutes of rest between each sprint. The training intensity of Sprint interval training sessions was evaluated subjectively during sessions. During the first week, the Sprint interval training group performed five sprints per session. The number of sprints then increased gradually, until a total of 10 sprints per session. When the number of sprints reached seven, subjects were given six minutes of rest midway through the training session
40985802|NCT03755687|OTHER|Art Therapy Intervention|Standardized mixed media art directives.
40985803|NCT01882621|DRUG|Monosialoganglioside(GM1)|80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
40985804|NCT01882621|DRUG|normal saline|80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
41463935|NCT01877694|DRUG|Auriclosene Vehicle|Ophthalmic Vehicle solution dispensed as drops onto the eye
40985805|NCT02085187|OTHER|Telemedicine training and counselling|"Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.~There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required."
40985806|NCT02175420|BIOLOGICAL|BCG|
40985807|NCT02175420|BIOLOGICAL|TFV|
40985808|NCT00064207|DRUG|gemcitabine hydrochloride|
40985809|NCT00064207|PROCEDURE|adjuvant therapy|
40985810|NCT00064207|RADIATION|radiation therapy|
40985811|NCT04983992|PROCEDURE|extracapsular release of lateral retinaculum|A new kind of surgery releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
40985812|NCT02550548|DRUG|GIP infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
40985813|NCT02550548|DRUG|GLP-1 infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
40781588|NCT05826587|BEHAVIORAL|Cardiac Rehabilitation & Exercise Prescription|Standard, clinically indicated cardiac rehabilitation and exercise program. Approximately 30 to 40 minutes of aerobic exercise within a prescribed rating of perceived exertion (RPE 11-14) and/or target heart rate and approximately 15 to 20 minutes of both upper and lower body resistance exercise up to three times per week for up to at least 12 weeks. In addition, subjects are provided with home exercise instructions, and will be expected to exercise for 30 to 60 minutes at home.
41463936|NCT04290234|OTHER|fMRI assessment of cognitive and reactive fear|An fMRI paradigm will be used to probe how childhood maltreatment may modulate the defensive survival circuitry that facilitates escape decisions when subjects encounter fast- or slow-attacking threats.
41463937|NCT02365909|DRUG|0.5% bupivacaine|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
41463938|NCT02365909|DRUG|normal saline|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
41463939|NCT06532435|DIETARY_SUPPLEMENT|DHA & ARA Candy|Parpicipants need to eat 1-2 candy daily, for 4 consective weeks
41463940|NCT00506116|BEHAVIORAL|Videotape, routine care, PME instruction|A 40 minute videotape about non-directed, spontaneous pushing and/or a videotape of antenatal perineal massage and pelvic muscle exerise (PME) at intake visit. The control women received routine care and PME instruction at intake visit.
41463941|NCT00506116|BEHAVIORAL|PME practice and record keeping (in diaries)|
41463942|NCT00506116|BEHAVIORAL|Non-directed or directed,spontaneous or sustained pushing|Non-directed, spontaneous pushing (experimental group) with perineal massage vs. directed, sustained pushing during delivery.
41463943|NCT00506116|PROCEDURE|Data collection|Baseline at 20 weeks gestation; longitudinal at 35 weeks gestation, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum
41463944|NCT05595616|DEVICE|Insertion of tracheal thermometer and pulmonary artery catheter|Endotracheal intubation of endotracheal tube with thermometer (Human Endotracheal Tube, Insung Medical Co., Korea) and insertion of Swan-Ganz catheter
41463945|NCT03310086|DEVICE|Traditional fixed appliance|aligning and leveling of lower anterior teeth using traditional fixed appliance.
41463946|NCT03310086|PROCEDURE|Corticision|Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
41463947|NCT00702793|DRUG|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
40781589|NCT05826587|OTHER|Connected mHealth mobile application|Mobile application that allows subjects to track their independent home exercise with the option of heart rate monitoring by connecting to an external heart rate monitoring device.
40781590|NCT02312648|OTHER|Interventional Group|Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
41463948|NCT02875028|DRUG|Vorapaxar|10mg-20mg vorapaxar to achieve \>80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition
41463949|NCT02875028|DRUG|Placebo|
41463950|NCT02875028|OTHER|LPS|2ng/kg Lipopolysaccharide as a bolus infusion
41463951|NCT05610007|DRUG|Prilocaine|Patients in the prilocaine group were given 50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume) before undergoing the cystoscopy procedure.
41463952|NCT00176358|DEVICE|PTCA and Stent Implantation|
40781591|NCT02312648|OTHER|Control group|The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
40781592|NCT03800550|DRUG|Bedaquiline|Bedaquiline tablet will be administered, orally.
40781593|NCT03800550|DRUG|Clarithromycin|Clarithromycin tablet will be administered, orally.
40781594|NCT04324281|OTHER|Investigation|cadaveric dissection
40781595|NCT06411301|DRUG|225Ac-DOTATATE|Two intravenous infusions every 6 weeks (Q6W)
40985814|NCT02550548|DRUG|Ex-9 infusion|Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
40985815|NCT04053959|DRUG|AI assisted insulin system|The patients receive the insulin regime set by AI assisted insulin titration system
41463953|NCT00176358|BEHAVIORAL|Exercise Training|
41463954|NCT00004188|BIOLOGICAL|filgrastim|Given IV
41463955|NCT00004188|DRUG|carboplatin|Given IV
41463956|NCT00004188|DRUG|cisplatin|Given IV
41463957|NCT00004188|DRUG|cyclophosphamide|Given IV
41463958|NCT00004188|DRUG|doxorubicin hydrochloride|Given IV
41463959|NCT00004188|DRUG|etoposide|Given IV
41463960|NCT00004188|DRUG|isotretinoin|Given IV
41463961|NCT00004188|DRUG|melphalan|Given IV
41463962|NCT00004188|DRUG|topotecan hydrochloride|Given IV
41463963|NCT00004188|DRUG|vincristine sulfate|Given IV
41463964|NCT00004188|PROCEDURE|autologous bone marrow transplantation|
41463965|NCT00004188|PROCEDURE|bone marrow ablation with stem cell support|
41463966|NCT00004188|PROCEDURE|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
41463967|NCT00004188|PROCEDURE|peripheral blood stem cell transplantation|
41463968|NCT00004188|RADIATION|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
41463969|NCT05384457|OTHER|High intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
41463970|NCT05384457|OTHER|Moderate intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
41463971|NCT01298609|DEVICE|Occipital Stimulation|Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
41463972|NCT02930668|DIETARY_SUPPLEMENT|Glucosanol 350mg|
41463973|NCT02930668|DIETARY_SUPPLEMENT|Glucosanol 500mg|
41463974|NCT02930668|DIETARY_SUPPLEMENT|Placebo|
41463975|NCT02026362|BIOLOGICAL|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .
41463976|NCT02026362|OTHER|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment|
41463977|NCT03883555|DEVICE|High flow nasal therapy (HFNT) : Optiflow™|"HFNT will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance"
41463978|NCT03883555|DEVICE|Non invasive ventilation (niv)|"NIV will be delivered through a face mask connected to a dedicated ventilator with pressure support applied in a noninvasive ventilation mode (Monnal T75, Airliquide Medical Systems, Antony, France).~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort."
41463979|NCT02396927|DEVICE|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
41463980|NCT02396927|DEVICE|2D HD laparoscopy|Placebo
41463981|NCT03730740|DRUG|Lenalidomide 25mg|Lenalidomide 25mg, day 1 - day 21 (1cycle=28days) for 2yeas
41463982|NCT05453409|OTHER|No intervention|No intervention
41463983|NCT02684331|OTHER|Cardiac Magnetic Resonance Imaging (CMR)|An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.
41463984|NCT02684331|OTHER|Echocardiography|Standard measurements and strain.
41463985|NCT02684331|OTHER|Bood samples|HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3
41463986|NCT03969108|DRUG|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
41463987|NCT05509959|BEHAVIORAL|Women SHINE|Minimum of nine weekly one-on-one peer navigation sessions and 7 weekly psychoeducation support group sessions.
40781596|NCT03941132|DRUG|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously."
41463988|NCT05509959|BEHAVIORAL|Control|Single group session and access to website
41463989|NCT05530850|BEHAVIORAL|Holistic Corrective Exercise Program|A holistic approach corrective exercise program including corrective exercises and postural perception training,
41463990|NCT05530850|OTHER|Thoracic exercise program|Thoracic region focused exercise program
41463991|NCT01029509|DRUG|OPB 31121|Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
41463992|NCT01999088|OTHER|Functional Meet|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
41463993|NCT01999088|OTHER|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
41463994|NCT03578809|BIOLOGICAL|MEDI6012|MEDI6012
41463995|NCT03578809|OTHER|Placebo|Placebo
41463996|NCT00264381|DRUG|Dalteparin sodium injection|Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
40781597|NCT03941132|DRUG|Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously."
41463997|NCT04319458|BEHAVIORAL|Fotonovela|Secret Feelings/Sentimientos Secretos
40781598|NCT00544206|OTHER|standard enteral feeding product|16 hrs daily x 5 days
40781599|NCT00544206|OTHER|Diabetes specific feeding product|16 hrs daily for 5 days
41463998|NCT04319458|BEHAVIORAL|Control|NIH Brochure: Depression: What You Need to Know
41463999|NCT05392569|OTHER|Deep Brain Stimulation|"In addition to standard micro electrode recordings, we propose to measure:~1. surface potentials at the scalp (EEG) evoked by stimulation at the DBS electrode site~2. micro electrode potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~3. local field potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~4. surface EMG in the first dorsal interosseus and gastrocnemius muscles during stimulation at the DBS electrode site."
41464000|NCT03452007|DEVICE|Epidural Stimulation|Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of \[5-6-5\]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
41464001|NCT02299687|DRUG|Omeprazole|
41464002|NCT05043857|RADIATION|Stereotactic Body Radiotherapy (SBRT)|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after tumor resection targeting 2 volumes~* CTV1 (clips+isotropic 5mm expansion, edited on anatomic barriers): receiving 40 Gy in 5 fractions of 8 Gy~* CTV2 (CTV1+ anisotropic 10-15 mm expansion including corresponding vessels, retroperitoneum posterior to the SMV/SMA or celiac axis, edited on anatomic barriers): receiving 30 Gy in 5 fractions of 6 Gy."
41464003|NCT02261220|BIOLOGICAL|MEDI4736|MEDI4736 is administered by IV infusion in combination with tremelimumab
41464004|NCT02261220|BIOLOGICAL|tremelimumab|Tremelimumab is administered by IV infusion in combination with MEDI4736
41464005|NCT01623804|DEVICE|low intensity, pulsed ultrasound|1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
41464006|NCT01623804|DEVICE|sham ultrasound|no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
41464007|NCT02269150|BIOLOGICAL|fecal microbiota transplantation (FMT)|
41144541|NCT00956527|BEHAVIORAL|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
41144542|NCT02659176|PROCEDURE|Transperineal repair with PIS|Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.
41144543|NCT02659176|PROCEDURE|Transperineal repair without PIS|Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
41464008|NCT02269150|OTHER|No fecal microbiota transplantation (FMT), routine management|
41464009|NCT02864524|OTHER|Manipulative and Massage Therapy|
41464010|NCT02864524|OTHER|Exercise Program|
41464011|NCT01341678|DRUG|Lanthanum Carbonate|Diet will be supplemented with 1000mg at each meal
41464012|NCT01341678|DIETARY_SUPPLEMENT|NeutraPhos|Diet will be supplemented with NeutraPhos
41464013|NCT01341678|OTHER|Diet Only|Diet containing 1500mg of phosphorus
41464014|NCT05099510|BIOLOGICAL|NatrunixTM|The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha). The entire XB2001 heavy and light chain sequences are identical to those found in naturally-occurring human IgG4-kappa, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual.
41464015|NCT05099510|BIOLOGICAL|Placebo|Placebo control for NatrunixTM subcutaneous injection.
41144544|NCT00488969|DRUG|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
41144545|NCT00488969|DRUG|Placebo|
41144546|NCT00992745|DRUG|123-I-MIP-1072|Single 10 mCi intravenous injection
41144547|NCT00992745|DRUG|111-In capromab pendetide|Single 5 mCi intravenous injection
41144548|NCT00992745|DRUG|123-I-MIP-1072|Single 5 mCi intravenous injection
41144549|NCT03264222|OTHER|Security screening procedure|Screening procedure with security device (model QPS 100)
41144550|NCT05463302|DEVICE|Active sleepgift blanket|Participants for group1 will be provided with real/active sleepgift blanket first for 10 consecutive nights and then cross over.
41144551|NCT05463302|DEVICE|Sham Sleepgift Blanket|Participants for group 2 will be provided with sham sleepgift blanket for 10 consecutive nights and then cross over.
41144552|NCT00059527|BEHAVIORAL|Healthy Youth Places: a behavior change model|
41144553|NCT01390753|DIETARY_SUPPLEMENT|Human donor milk|
41144554|NCT00213317|PROCEDURE|lombo-sacral magnetic stimulation|repetitive lombo-sacral nerve magnetic stimulation active and placebo performed during colonic recordings after bisacodyl instillation
41144555|NCT00457834|DEVICE|InSync III|Bi-ventricular pacing from leads in LV+RVA or LV+RVOT
40781600|NCT04281784|BEHAVIORAL|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page Jumpstart Guide provides information to the clinician about prior advance care planning documentation and code status derived from the EHR. The Jumpstart Guides includes tips to improve goals-of-care communication.
40781601|NCT03112876|OTHER|Skin Surface Lipid Collection and Skin Barrier Function|All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
40781602|NCT03040128|DRUG|Minocycline|high-dose, intravenous minocycline
40781603|NCT03040128|OTHER|normal saline infusion|
40781604|NCT01165034|OTHER|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
40781605|NCT03912363|OTHER|Rotating fluids protocol|"IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 100 mg/dL or less: IV fluids with 5% dextrose~* For blood glucose between 101-140 mg/dL: IV fluids without 5% dextrose~* For blood glucose \> 140 mg/dL on two consecutive occasions: insulin infusion protocol (Study arm 2)"
41144556|NCT01768572|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
41305163|NCT04060264|BIOLOGICAL|BCD-148|"Active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).~QW - once weekly"
41305164|NCT04060264|BIOLOGICAL|Soliris|"Active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period)."
41305165|NCT02586636|DRUG|Metformin|Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
41305166|NCT02586636|DRUG|Omeprazole|Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
41305167|NCT02586636|DRUG|Placebo|Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
41305168|NCT04069793|DEVICE|Commercially available device|A commercially available and registered with the FDA prosthesis equipped with a powered single-degree of freedom wrist and powered hand.
41305169|NCT04069793|DEVICE|Non FDA registered device|An experimental, non FDA registered prosthesis equipped with a multi function wrist and a powered hand.
41305170|NCT00748059|PROCEDURE|Standing or upright tilt|stand upright or tilt table test
41305171|NCT00748059|PROCEDURE|Microneurography|Recording from sympathetic nerve
41305172|NCT00748059|PROCEDURE|QSweat|quantitative sweat testing
41305173|NCT00748059|DEVICE|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
41305174|NCT00748059|DRUG|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|"IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect"
40781606|NCT03912363|OTHER|Insulin infusion protocol|"Regular insulin at 1 unit/ml AND IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 80 mg/dL: No insulin AND IV fluids with 5% dextrose~* For blood glucose 80-100 mg/dL: Insulin at 0.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 101-140 mg/dL: Insulin at 1.0 U/hr AND IV fluids with 5% dextrose~* For blood glucose 141-180 mg/dL: Insulin at 1.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 181-220 mg/dL: Insulin at 2.0 U/hr AND IV fluid without dextrose~* For blood glucose \> 220 mg/dL: Insulin at 2.5 U/hr AND IV fluids without dextrose"
40781607|NCT04679454|RADIATION|Phase I|To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
40781608|NCT04679454|RADIATION|Phase II|The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
40781609|NCT00165828|DRUG|Zonegran|Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
40781610|NCT02476448|DRUG|Normal saline|Used to distend the bladder for cystoscopic evaluation
40781611|NCT02476448|DRUG|Phenazopyridine|Administered orally preoperatively and assessed during cystoscopy
40781612|NCT02476448|DRUG|Dextrose 10%|Used to distend the bladder for cystoscopic evaluation
40781613|NCT02476448|DRUG|Sodium Fluorescein|Administered intravenously and assessed during cystoscopy
40781614|NCT03753048|PROCEDURE|Y-Graft|Y-Graft Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, the left internal thoracic artery is cut off distally and the right internal thoracic artery is cut off proximally and distally. Then they anastomose the following way. Left internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, distal part of the right internal thoracic artery should be anastomosed to the obtuse marginal artery. Finally, proximal part of the right internal thoracic artery is anastomosed to the left internal thoracic artery as Y-graft in the end to side fashion. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
40781615|NCT03753048|PROCEDURE|In-Situ|In-Situ Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, both internal thoracic arteries are cut off distally. Then they anastomose the following way. Right internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, left internal thoracic artery should be anastomosed to the obtuse marginal artery. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
40781616|NCT02093260|BIOLOGICAL|Vaccine|"Flubio (Influenza HA) Vaccine~The vaccine will be given intramuscularly."
40781617|NCT00002766|BIOLOGICAL|dactinomycin|
40781618|NCT00002766|BIOLOGICAL|sargramostim|
40781619|NCT00002766|DRUG|carmustine|
40781620|NCT00002766|DRUG|cyclophosphamide|
40781621|NCT00002766|DRUG|cytarabine|
41305175|NCT00748059|DRUG|clonidine,yohimbine,metoclopramide,alpha-methyldopa|"Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo"
41305176|NCT00748059|PROCEDURE|BodPod|Determination of body composition
41305177|NCT00748059|PROCEDURE|Eye exam|"Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~1. 0.5% proparacaine (Alcaine, Allergan, Inc)~2. Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~3. 0.5%, 1% tropicamide (Mydriacyl, Alcon)~4. Over-the-counter preservative-free artificial tears~5. 0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~6. 1% cyclopentolate hydrochloride (Alcon)"
40781622|NCT00002766|DRUG|daunorubicin hydrochloride|
40781623|NCT00002766|DRUG|doxorubicin hydrochloride|
40781624|NCT00002766|DRUG|etoposide|
40781625|NCT00002766|DRUG|mercaptopurine|
40781626|NCT00002766|DRUG|methotrexate|
40781627|NCT00002766|DRUG|mitoxantrone hydrochloride|
40781628|NCT00002766|DRUG|pegaspargase|
40781629|NCT00002766|DRUG|prednisone|
40781630|NCT00002766|DRUG|vincristine sulfate|
41144557|NCT01768572|DRUG|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
41305178|NCT00748059|PROCEDURE|Sleep study|Recording of sleep pattern overnight
41305179|NCT00748059|PROCEDURE|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
40781631|NCT00002766|RADIATION|radiation therapy|
40781632|NCT00613184|DEVICE|Nylon Flocked swab (Nasal secretion sampling)|Nasal Aspirate Nylon Flocked swab
40781633|NCT00613184|DEVICE|Nylon Flocked swab (Nasal secretion sampling)|Nylon flocked swab Nasal Wash
40781634|NCT03358030|DRUG|ISIS 416858|Subcutaneous injection
40781635|NCT03358030|DRUG|Placebo|Subcutaneous injection
40781636|NCT03324789|OTHER|Single Implant Partial Over-denture|Single Implant Retained Partial Over-denture will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
40781637|NCT03324789|OTHER|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
41144558|NCT01768572|DRUG|hydroxychloroquine|Dispensed according to local practice.
41144559|NCT01768572|DRUG|methotrexate|Dispensed according to local practice.
41464016|NCT03525340|BEHAVIORAL|Peer Navigation|Peer navigators help participants identify barriers that pose challenges to the participant's engagement in care and adherence and help develop an overall action plan for addressing these barriers by identifying specific changes that can be made/attempted to overcome an identified barrier. This may involve accompanying a participant to their social services/health appointments, or assisting a participant with disclosure of her HIV status to a family member or friend. The overall goal is to develop knowledge of social/HIV-related health services and good problem-solving skills in order to tackle multiple, potentially overlapping barriers. Over time, participants are encouraged to take increasing degrees of responsibility for identifying and implementing their own problem-solving strategies.
41464017|NCT03312894|DRUG|TAK-653|TAK-653 tablets
41464018|NCT03312894|DRUG|Placebo|Placebo-matching tablets
40781638|NCT00145626|DRUG|Chemotherapy and antibodies|Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
41305180|NCT00748059|PROCEDURE|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
41464019|NCT00070239|DRUG|alvocidib|Given IV
41464020|NCT00070239|OTHER|pharmacological study|Correlative studies
41464021|NCT00070239|RADIATION|fludeoxyglucose F 18|Correlative studies
40781639|NCT00145626|DEVICE|Miltenyi Biotec CliniMACS|Stem cell selection device
41464022|NCT00070239|OTHER|fluorine F 18 fluorothymidine|Correlative studies
41464023|NCT00070239|PROCEDURE|positron emission tomography|Correlative studies
41464024|NCT06422741|DIETARY_SUPPLEMENT|grape seed proanthocyanidin extract|250 mg of product presented in capsule form will be given.
41464025|NCT06422741|DIETARY_SUPPLEMENT|Placebo|165 mg of cellulose will be given presented in capsule form.
41464026|NCT02473237|DRUG|indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
41464027|NCT02473237|DRUG|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
41464028|NCT00411268|DRUG|OROS hydromorphone HCI SR (slow release)|
41464029|NCT00131716|DRUG|sulfadoxine-pyrimethamine|
41464030|NCT00460850|DRUG|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
41464031|NCT05629923|DRUG|tixagevimab-cilgavimab(AZD7442, AstraZeneca)|In the case of antibody level \<100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca).
41464032|NCT05665517|DEVICE|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q\&A) corpora were formed."
41464033|NCT04866017|DRUG|Tislelizumab|200 mg intravenously every three weeks
41464034|NCT04866017|DRUG|Durvalumab|10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)
41464035|NCT04866017|DRUG|Ociperlimab|900 milligrams (mg) intravenously every three weeks
41464036|NCT04866017|DRUG|Chemotherapy|"The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options:~* Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days.~* Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously.~* Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~* Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~The pemetrexed plus platinum regimen was only for participants with non-squamous histology."
41464037|NCT04866017|RADIATION|Radiotherapy|All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.
40781640|NCT00145626|PROCEDURE|Allogeneic stem cell transplantation|Allogeneic natural killer (NK)cell infusion
40985816|NCT04053959|DRUG|Physician based insulin regime|Patients receive the insulin regime recommended by physicians
40985817|NCT03184415|DRUG|DWC20155|tablet
40985818|NCT03184415|DRUG|DWC20156|tablet
40985819|NCT03184415|DRUG|placebo of DWC20155|tablet
40985820|NCT03184415|DRUG|placebo of DWC20156|tablet
40985821|NCT06155942|PROCEDURE|7 Tesla MRI|Patients will have a 7T MRI and questionnaires
40985822|NCT01725438|OTHER|sample blood|
40985823|NCT02715323|OTHER|Cross-sectional study|
41305181|NCT00748059|PROCEDURE|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
41305182|NCT00748059|PROCEDURE|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
41305183|NCT01579981|PROCEDURE|Roux-en-Y Gastric Bypass|On two separate experimental days before, 1 wk, and 3 months after RYGB, subjects are given a liquid meal test during Exendin 9-39 (900 pmol/min/kg)or saline infusion. The order of the infusions is randomized. At end of study day an ad libitum meal is served.
41305184|NCT03825276|DIETARY_SUPPLEMENT|Mango consumption|Daily consumption of 280 g of frozen mangos during 8 weeks. The daily dose in equivalent to a 2-cups serving.
41305185|NCT05176392|DEVICE|Active rTMS|Active rTMS will be given at the left dorsolateral prefrontal cortex with a double blind TMS coil.
40985824|NCT02507674|DEVICE|ultrasound|
40985825|NCT03857243|DEVICE|dual transcranial direct current stimulation|Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
40985826|NCT04262232|BEHAVIORAL|Adapted Ca-HELP for Geriatric Cancer Patients|Intervention group: This intervention will be informed by social-cognitive theory10-13 and modeled after the tailored education and coaching intervention (TEC) used for Ca-HELP previously and consists of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
40985827|NCT04415281|DEVICE|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
40985828|NCT04415281|DEVICE|sham THOR® laser system|sham THOR® laser system
40985829|NCT06120621|PROCEDURE|Arm 1 : VCST-phaco group , Arm 2 : phaco group.|Arm 1 : VCST-phaco group , Arm 2 : phaco group.
40985830|NCT00503087|PROCEDURE|Saline Injection|
40985831|NCT00503087|DEVICE|Pneumatic Skin Flattening (PSF)|
40985832|NCT04070391|DIETARY_SUPPLEMENT|vitamin B6|oral administration
40985833|NCT04070391|OTHER|control|oral administration
40985834|NCT00212732|DRUG|ONO-8025 (KRP-197)|
40985835|NCT02154581|DEVICE|SLActive implant|
40985836|NCT05878054|OTHER|Proactive, integrated and personalised care|During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.
40985837|NCT01269424|BIOLOGICAL|MGMTP140K-encoding retroviral vector|
40985838|NCT01269424|DRUG|O6-benzylguanine|
41144560|NCT01768572|DRUG|sulfasalazine|Dispensed according to local practice.
40985839|NCT01269424|DRUG|temozolomide|
40985840|NCT01269424|OTHER|laboratory biomarker analysis|
40985841|NCT01269424|PROCEDURE|autologous hematopoietic stem cell transplantation|
40985842|NCT01269424|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
40985843|NCT01269424|RADIATION|radiation therapy|
40985844|NCT05710549|DEVICE|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system (Geodesic Sensor Net, MegStim). An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek, Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touches the participant's scalp surface directly. Net application takes about 10 min to derive impedances to \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between 0.1-200 Hz. Vertex electrode Cz is used as an acquisition reference.
40985845|NCT05710549|DEVICE|Transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance.
40985846|NCT03966703|BEHAVIORAL|mixing analysing test|The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
40985847|NCT05789147|DEVICE|Active tVNS|It is a non-invasive transcutaneous electrical stimulation of the auricular branch of the vagus nerve which innervates the skin of the human ear. These nerve fibers project directly to the solitary tract nucleus (NTS) in the brain stem (6).
40985848|NCT05789147|DEVICE|Sham tVNS|Sham stimulation is obtained by placing the stimulation electrode at the level of the earlobe. The stimulation is therefore administered and perceived in an area not innervated by vagal fibers.
41144561|NCT01768572|DRUG|leflunomide|Dispensed according to local practice.
41144562|NCT01768572|DRUG|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
41144563|NCT01768572|DRUG|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
41305186|NCT05176392|BEHAVIORAL|Headache Management Therapy|Therapy will be provided on headache management.
41305187|NCT05176392|DEVICE|Sham rTMS|Sham rTMS will be given at the left dorsolateral prefrontal cortex. All parameters of the treatment will appear identical to the active treatment, with only the rTMS coil used to administer the treatment flipped 180 degrees to prevent stimulation.
41305188|NCT05176392|BEHAVIORAL|Headache Education Control|In the control, educational sessions on headaches will be provided.
41305189|NCT02200367|BEHAVIORAL|e-mental health collaborative programme|
41305190|NCT02200367|OTHER|Usual Care|
40781641|NCT01136369|DEVICE|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
40781642|NCT02455739|OTHER|chewing gum|postoperative gum chewing to improve gastrointestinal function
40781643|NCT00085748|DRUG|paliperidone ER|
40781644|NCT01497834|DRUG|BMS-790052 (Daclatasvir)|Tablets, Oral, 60mg, Once daily, 24 weeks
40781645|NCT01497834|DRUG|BMS-650032 (Asunaprevir)|Capsules, Oral, 100mg, Twice daily, 24 weeks
40781646|NCT02115321|DRUG|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
40781647|NCT02115321|DRUG|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
40781648|NCT02115321|DRUG|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
40781649|NCT04427293|DRUG|Lenvatinib|Lenvatinib 12mg daily for 7 days prior to surgery
40781650|NCT04427293|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on day 1
40781651|NCT05967754|DIAGNOSTIC_TEST|polysomnography|polysomnography and serum uric acid measurement
40781652|NCT04350684|DRUG|Umifenovir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
40781653|NCT04350684|DRUG|Interferon-β 1a|This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
40781654|NCT04350684|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
40781655|NCT04350684|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
40781656|NCT04350684|DRUG|Standards of Care|This Drug will be used in all arms as mandated by our governmental guidelines.
40781657|NCT04416243|BEHAVIORAL|Recumbent Stepping, High-Intensity Interval Training|"The intervention will involve 12 weeks of supervised, progressive (i.e., intensity increases after midpoint testing based on reassessment of aerobic fitness) HIIT sessions two to three times per week. HIIT exercise sessions will be manualized and led by exercise leaders. Secondary outcomes testing will occur at baseline (week 0), midpoint (following week 6 of training), and post-intervention (following week 12 of training).~The individual HIIT sessions will involve 10 cycles of 60s intervals at the wattage associated with 90% VO2peak followed by 60s of active recovery intervals at 15 watts, totaling 20 min in length. All exercise sessions will begin and end with a 5-minute warm-up and cool-down, respectively. Required power output for each interval of the exercise session will be individualized and completely automated. VO2peak from baseline and midpoint testing will be used to determine exercise intensity for weeks 1-6 and weeks 7-12, respectively."
41305191|NCT03668691|DEVICE|Robotic-arm assisted partial knee arthroplasty|Robotic-arm assisted medial unicompartmental knee arthroplasty, lateral unicompartmental knee arthroplasty, bicompartmental knee arthroplasty, patellofemoral knee arthroplasty implants. A robotic arm assisted unicompartmental or bicompartmental knee arthroplasty procedure to replace the medial or lateral and /or patellofemoral compartments of the knee.
40781658|NCT05511402|OTHER|Exercise training|People with Parkinson's Disease will be received a supervised physiotherapy and rehabilitation program.
40781659|NCT03136120|DRUG|Ipratropium Bromide|Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
40781660|NCT03136120|PROCEDURE|Flexible Bronchoscopy/Biopsy|After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
40781661|NCT05522686|OTHER|Patients in the Brochure Education Group|Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.
40781662|NCT05522686|OTHER|Patients in the Video Education Group|Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.
40985849|NCT03043989|DRUG|Docetaxel|6 infusions of Docetaxel with 18 doses clarithromycin
40781663|NCT05522686|OTHER|Patients in the Brochure-Supported Video Education Group|Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.
40781664|NCT05522686|OTHER|Control Group|Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
40781665|NCT04138095|DEVICE|Virtual Reality|Participants will have access to an Oculus Quest Virtual Reality Headset every second day as an alternative to opioids for pain management and benzodiazepines for anxiety management
40781666|NCT05575141|PROCEDURE|incisional hernia repair|Incisional hernia repair for the treatment of wide ventral incisional hernias.
40781667|NCT04326452|DEVICE|bidirectional oxygenation mouthpiece|Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.
40781668|NCT02559973|DRUG|RBP-6000|RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
40781669|NCT02559973|DRUG|SUBOXONE Sublingual Film|Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
40781670|NCT02603757|DIETARY_SUPPLEMENT|cholecalciferol|2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
40985850|NCT03043989|DRUG|Cabazitaxel|6 infusions of Cabazitaxel with 18 doses clarithromycin
40781671|NCT05499026|DRUG|Chenodeoxycholic Acid|Bile acid
40781672|NCT02343315|DEVICE|TENS|"Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.~* Equipment- TENS (CEFAR Basic TENS Machine)~* Electrodes- Four channel electrode to cover the site of pain~* Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.~* Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.~* Frequency- 5 Hertz~* Duration- 30 minutes"
40985851|NCT03043989|DRUG|Clarithromycin|18 doses of clarithromycin with either Docetaxel or Cabazitaxel
40985852|NCT01930747|DRUG|rocuronium|measure effect on laparoscopic workspace
40985853|NCT01930747|DRUG|Sevoflurane|1 MAC sevoflurane inhalation is given
40985854|NCT01930747|DRUG|remifentanyl|remifentanyl is given in infusion
40985855|NCT06404138|OTHER|The Geriatric Activation Program (GAPP) Home version|"The rehabilitation at home intervention consists of three 45 minutes session per week (total of 18 sessions) with a different focus for each session. The therapy is goal-oriented and includes functional exercises in the home where possible (e.g. transfers such as getting out of bed, walking to the toilet etc.). There are three sessions per week: 1 for training strength, 1 for training balance and 1 for speed, coordination and endurance. Each session will start with gait rehabilitation as a warming-up.~For each session, a set of exercises with varying levels of difficulty is available. As rehabilitation needs are diverse, the therapist is expected to choose the most appropriate exercise and the difficulty level of the exercise for the individual older person. This also includes scaling the exercises to the individual progression of the older person."
40985856|NCT06404138|OTHER|Standard of care|Standard of care, without any restrictions.
40985857|NCT01499550|DEVICE|humidified transnasal insufflation (TNI20oxy)|The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
40985858|NCT01499550|OTHER|overnight oxygen treatment with individual flow rate|The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
40985859|NCT05405192|DRUG|Dostarlimab|First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg.
40985860|NCT01537029|DRUG|Doxorubicin|Dosed by the patient's treating physician according to local standard of care.
40985861|NCT01537029|DRUG|Cyclophosphamide|dosage form: IV, Dosage, frequency, and duration: According to local standard of care
40985862|NCT05352893|DRUG|Imsidolimab high dose|intravenous
40985863|NCT05352893|DRUG|Imsidolimab low dose|intravenous
40781673|NCT02343315|OTHER|SMCE|"Six sessions of supervised Motor control exercises will be provided over the period of two weeks. Exercises will be provided in order to target the function of core muscles of the spine. Each participant in the SMCE group will be trained by a physical therapist to recruit the deep muscles of the spine and reduce the activity of superficial muscles.~Initially participants will be taught how to contract the transversus abdominis and multiﬁdus muscles in isolation from the more superﬁcial trunk muscles, but in conjunction with the pelvic ﬂoor muscles. Pressure biofeedback will be used in order to provide feedback about muscle recruitment to the participant. Exercises will be provided to the participants in the progressive manner. Later, movement of limbs will be incorporated with the contraction of the core muscles. Finally, these core muscle activation will be emphasized during the functional activities."
40781674|NCT02343315|OTHER|UHEP|"All the participants will receive the following treatments:~1. Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.~2. Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.~3. Participants will not be asked to not take the over the counter analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen)."
40781675|NCT00578097|BIOLOGICAL|Botulinum toxin type A|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
40781676|NCT00578097|DRUG|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
40781677|NCT05736393|DEVICE|Back Exosuit|The device is worn like a backpack. It weighs 6 pounds. Participants will be able to perform movements naturally in the device. A ribbon serves as an external muscle to reduce the load and effort during lifting. As participants bend forward, the device assists the participant by supporting some of their body weight by gently pulling back. As participants stand up, the device assists them by gently pulling their trunk upright. Participants will feel the level of assistance change slightly as they move faster or slower. Participants will use this device during 20-40 minutes of physical therapy exercises during 12 visits over 4-6 weeks. Once it is fit and adjusted to each participant's comfort, the physical therapist will control the level of assistance the device provides similarly to how they would adapt any given exercise. Participants may start with more assistance and wean down over the course of the study.
40985864|NCT05352893|OTHER|Placebo|intravenous
40985865|NCT00385996|DRUG|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
40985866|NCT05810792|DRUG|Histamine Dihydrochloride (HDC)|HDC is administrated in combination with IL-2 as peri- and post-operative treatment in patients undergoing surgery. 0.5 mg HDC is administered twice daily by subcutaneous injections 1 to 3 minutes after each IL-2 injection during three 3 week cycles, with 3-week resting periods inbetween. The first treatment cycle is initated 2 weeks prior to surgery, with an additional 2-3 days rest period during the surgical procedure, before the third treatment week is initiated.
40985867|NCT05810792|DRUG|Interleukin-2 (IL-2)|IL-2 is administrated in combination with HDC during three 3 week cycles as peri- and post-operative treatment in patients undergoing surgery. IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of histamine dihydrochloride; each dose of IL-2 is 16,400 IU/kg (1µg/kg).
41144564|NCT04651426|DEVICE|The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1|"The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1 which mechanism of action is through the ability of biominerals to reflect the far infrared radiation (FIR). Normally the human body temperature would dissipate regular far infrared radiations but, thanks to the FIT Therapy (Far Infrared Technology), these waves are reflected and allowed to reach deeper areas in the human body (wavelength spectrum is 4-21 µm with a denser concentration around 11 µm).~Every FIT device act as a mirror and they are able to induce an antalgic effect simply thanks to this biophysical process, therefore without releasing any active ingredient or creating a thermic shock.~The plasters are made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on. This particular mix in powder form is characterized by particles sizes above 100 nm."
41144565|NCT04644692|OTHER|Lung ultrasound|A lung ultrasound before and at the end of the stress test.
41144566|NCT05174871|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.
41144567|NCT05174871|BEHAVIORAL|TRF intervention|Food intake restricted to 8 hours per day during the window between 10h and 22h. Time restricted feeding will take place 6 days per week, with the seventh day unrestricted. The intervention will last for 2 months.
41144568|NCT01566552|DRUG|AMBISOME|SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
41144569|NCT04725032|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the propofol-based TIVA arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
41144570|NCT04725032|DRUG|Sevoflurane|Balanced general anesthesia with sevoflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
40985868|NCT03019107|DEVICE|Breath synchronized abdominal NMES|VentFree prototype (VF03) that delivers electrical stimulation pulses to the abdominal muscles during exhalation with a frequency of 30 Hz, a pulse width of 350 µs and 90% of the maximum current that the participant can tolerate. These stimulation parameters were selected to cause a tetanic (continuous) contraction of the abdominal muscles, without pain for the patient. Stimulation will be administered for 30 minutes 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
40781678|NCT04268914|DEVICE|Oculus Go VR|The Oculus Go is a standalone headset with built-in speakers that runs independently of a smartphone. Via the Oculus Go, participants will engage with BearBlast (developed by AppliedVR). Throughout the world, plush moles play the role of antagonist, standing in for the nuisance and distraction of pain. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. The VR HMD runs independently of a smartphone and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image.
40985869|NCT03019107|DEVICE|Sham breath synchronized abdominal NMES|Modified VentFree prototype (VF03) that delivers stimulation pulses to the abdominal muscles during exhalation with a frequency of 10 Hz, a pulse width of 100 µs and current set to 10 milliamp. These stimulation parameters were chosen to cause a twitch contraction of the abdominal wall muscles. Stimulation will be administered for 30 minutes, 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
40985870|NCT04375137|DIAGNOSTIC_TEST|Oxidative Stress ELISA Kit|Checking oxidative stress markers and redox system status
40985871|NCT00708539|DRUG|progesterone|90 mg, vaginal, once daily
40985872|NCT00708539|DRUG|Progesterone|200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
40985873|NCT01991067|BIOLOGICAL|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
40985874|NCT01169610|DRUG|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
40985875|NCT06249425|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
40985876|NCT06249425|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
40985877|NCT06249425|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
40985878|NCT03742154|DRUG|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
40985879|NCT00196560|DEVICE|Immobilization in External Rotation|
40985880|NCT04284618|DIAGNOSTIC_TEST|assessment of standardized and off axis view radiographs|Radiographic assessment of hallux valgus interphalangeus angles is performed on preoperative standing anteroposterior and on off axis view radiographs. These radiographs are taken by equalizing the hyperpronation of the greater toe.
40985881|NCT05922787|OTHER|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
40985882|NCT01727973|DRUG|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
40985883|NCT04349670|PROCEDURE|GPOEM - gastric per-oral endoscopic myotomy|Endoscopic section of the pyloric muscle with submucosal tunnel technique.
40985884|NCT04481633|DIAGNOSTIC_TEST|COVID 19 serology|Diagnosis of Covid-19 past infection will be made by serology
40985885|NCT04481633|OTHER|COVID 19 Self-Questionnaire|COVID 19 Self-Questionnaire
40985886|NCT03938584|DIETARY_SUPPLEMENT|Vitamin C|Just after induction of anesthesia in the OR, subjects will be administered a single intravenous (IV) dose of Vitamin C at 66mg/kg/hr for 2 hours during surgery. Post-operatively (beginning the morning after surgery) Vitamin C Treatment Group subjects will receive a 4 week prescription of oral, liquid Vitamin C, 500mg by mouth two times a day. These dosages are known to be safe and effective.89-91
40985887|NCT03938584|OTHER|Placebo|Subjects will receive IV placebo (normal saline) identically packaged. Post-operatively Placebo Control Treatment Group participants will receive a 4-week prescription of the aqueous solution base used for the treatment group without the active component (Vitamin C).
40985888|NCT05157490|BEHAVIORAL|Mindfulness training|Guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
41144571|NCT05652985|BEHAVIORAL|Inter-professional Collaboration Training|the participated nurses will receive session about Inter-professional Collaboration followed by activity which can boost Inter-professional Collaboration
40781679|NCT04268914|DEVICE|Mira Prism VR|The Mira Prism is a portable, augmented reality (AR) HMD powered by iPhone. When paired with the iPhone, the Mira Prism goggles can superimpose computer-generated images on the user's view of the real world. Unlike the full immersion of VR, AR allows users to view the outside world while interacting with digital content. In this study, the patient will interact with Magic Mallet (developed by Miney Moe) until falling asleep during the anesthesia induction process. Magic Mallet is a distraction game designed for pain management and communication during procedures. The game automatically adjusts cognitive load for optimal effect for users. Study team iPhones specifically loaded with Magic Mallet, and without cellular capability, will be used with the Mira Prism.
40781680|NCT06003439|BEHAVIORAL|Virtual Reality Program|Behavioral: Virtual Reality Program The VR Program will be pre-installed on Meta Quest 2 headsets, which will be donned by students as a class to experience the intervention for approximately the length of one school class period (approximately 30-40 minutes). Each participant will experience the program once a week for 3 weeks. Participants who missed a week will complete the program by the 4th or 5th week.
41144572|NCT05614141|DEVICE|Lokomat Augmented Performance Feedback|All participants will exercise with Lokomat Augmented Performance Feedback for six weeks. Augmented Performance Feedback has different virtual reality games.
41144573|NCT05614141|OTHER|Conventional Physiotherapy|Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
41305192|NCT06536335|DEVICE|Biomax Nuvola aligners|All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
41305193|NCT06536335|DEVICE|Biomax Nuvola aligners|All patients will be treated with Biomax Nuvola aligners built based on the individual atient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
40985889|NCT06275568|BEHAVIORAL|Usual Care Fresh Connect cardholder engagement|"Fresh Connect, a Food as Medicine product of the non-profit organization About Fresh, Inc., consists of a pre paid, programmable debit card, a cloud-based cardholder success platform, and an analytic engine designed to illuminate the healthcare value of improved food access and nutritional security.~This arm receives:~* About Fresh Food Rx debit card ($100 per month from enrollment until 2 months post-partum)~* Texts for all cardholders per month (1-2 outbound texts)~* Welcome call from About Fresh cardholder engagement team~* 1 text - notification that Fresh Connect funds have been reloaded~* As-needed program updates (e.g. new retailers), inactivity outreach~* Additional texts that would be ad hocs: texts with food experiences (cooking videos), produce how-tos, and fun engagement; and satisfaction surveys - e.g. feedback on the Fresh Connect program, feedback on retailers, satisfaction with cardholder success, etc."
40985890|NCT06275568|BEHAVIORAL|Enhanced engagement communication|Enhanced engagement involves additional outbound texts per month and additional ad hoc bi-monthly or quarterly texts, as well as tailored reminder text to use funds before the end of the month.
40985891|NCT01338831|DRUG|LFA102|
40985892|NCT02189473|RADIATION|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
41144574|NCT04184622|DRUG|Tirzepatide|Administered SC
41144575|NCT04184622|DRUG|Placebo|Administered SC
41305194|NCT02657668|BEHAVIORAL|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
41305195|NCT02488759|DRUG|Nivolumab|
41305196|NCT02488759|DRUG|Ipilimumab|
41305197|NCT02488759|DRUG|Relatlimab|
40781681|NCT06003439|BEHAVIORAL|VR Program|VR program participants will be able to download a mobile app that complements and reinforces the school-based VR session.
40985893|NCT02870660|OTHER|Registry|
40985894|NCT02769325|DRUG|Atropine|IV atropine 0.1%, 10 ml
40985895|NCT02769325|DRUG|Placebo|IV saline, 10 ml
40985896|NCT02769325|DRUG|Sevoflurane|All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
40985897|NCT02769325|DRUG|sugammadex|Patients will receive sugamadex for neuromuscular reversion, if necessary
40985898|NCT02769325|DRUG|Ketorolac|60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
40985899|NCT02769325|DRUG|Morphine PCA|Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
40985900|NCT02769325|DRUG|rocuronium|general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
40985901|NCT02769325|DRUG|propofol|for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
41144576|NCT04577599|OTHER|Mobile Low-dose Computed Tomography (LDCT) Screening|Low Dose CT Scan of the Chest
41144577|NCT04182217|OTHER|Epidemiological description|Description of the characteristics of Peritonitis in Haiti
41144578|NCT01085253|OTHER|3T and 7T MR imaging|all patients and controls will be explored using a 3T and 7T MR imaging
41144579|NCT04554615|DRUG|Insulin|insulin infusion to control postoperative hyperglycemia
40985902|NCT03885713|BIOLOGICAL|Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)) per clinical practice or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)) per clinical practice or tofacitinib (oral 5mg bid)
40985903|NCT03675802|DRUG|misoprostol|giving misoprostol to this group
40985904|NCT03675802|DRUG|dinoprostone|giving dinoprostine
40985905|NCT00023543|BEHAVIORAL|Diet, fat-restricted|Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.
40985906|NCT00023543|BEHAVIORAL|Exercise|Rigorous, stepped care approach to reach 150 min/week of physical activity.
40985907|NCT03625245|OTHER|Control Yogurt|125 g/day
40985908|NCT03625245|OTHER|Yogurt Variety 1|125 g/day
40985909|NCT03625245|OTHER|Yogurt Variety 2|125 g/day
40985910|NCT00571987|DEVICE|AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)|Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
40985911|NCT00968656|RADIATION|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
40985912|NCT00968656|OTHER|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
40985913|NCT00968656|OTHER|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
40985914|NCT00968656|OTHER|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
40985915|NCT00968656|DRUG|F-18-ISO|Patients receive F-18-ISO-1 i.v.
40985916|NCT03327298|PROCEDURE|pedicle screw fixation|One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
40985917|NCT04905173|OTHER|Squat-to-stand maneuver|Subjects will squat for 5 seconds and then stand. The squat-to-stand exercise will be done up to 10 times, and then immediately undergo echocardiographic imaging.
40985918|NCT04905173|DRUG|Amyl nitrite inhalation|Subjects will inhale amyl nitrite prior to undergoing echocardiographic imaging. This is administered according to current laboratory protocol and is part of standard of care. This is an FDA-regulated drug that will be used as a control and will not be studied experimentally.
40985919|NCT04905173|OTHER|Valsalva|Subjects will undergo echocardiographic imaging while performing the Valsalva maneuver. This is according to current laboratory protocol and is part of standard of care.
40985920|NCT02533037|OTHER|Traditional Instability Tools|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.
40985921|NCT02533037|OTHER|Ankle Destabilization Shoes|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
40985922|NCT06101199|OTHER|Acute Intermittent Hypercapnic Hypoxia|15 x \[1 min 9% O2, 4% CO2, and balance N2, followed by 1.5 min normoxia\];
40985923|NCT06101199|OTHER|Transcutaneous spinal cord stimulation|Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of \~25-35 mA and a pulse width of 400 µsec, using a biphasic symmetric waveform. Paired with Respiratory Resistance Training and Hand Grip Strength Training.
40985924|NCT06101199|OTHER|SHAM Acute Intermittent Hypercapnic Hypoxia|Normoxia for the amount of time AIHH is delivered.
40985925|NCT06101199|OTHER|SHAM Transcutaneous spinal cord stimulation|"Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of 0mA and a pulse width of 400 µsec,using a biphasic symmetric waveform.~Paired with Respiratory Resistance Training and Hand Grip Strength Training."
40985926|NCT02708147|OTHER|Physiotheraphy + Conventional treatment|The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
40985927|NCT02708147|OTHER|Conventional treatment|Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
40985928|NCT00000609|DRUG|amiodarone|
40985929|NCT00000609|DEVICE|defibrillators, implantable|
40985930|NCT05916729|DRUG|Miconazole|Protocol for active control groups includes use of Miconazole Oral gel for 14 days with frequency of four time per day.
40985931|NCT05916729|DIETARY_SUPPLEMENT|CandBerrol® lozenges|Protocol for experimental groups includes use of Miconazole Oral gel and CandBerrol® lozenges for 14 days with frequency of four time per day
40985932|NCT01362374|DRUG|5-FU|5-FU at a dose level of 400 mg/m\^2 as intravenous (IV) injection followed by a dose of 2400 mg/m\^2 as IV infusion over 46 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
40985933|NCT01362374|DRUG|Docetaxel|Docetaxel will be administered at dose level of 75 mg/m\^2 as IV infusion over 1 hr on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
40985934|NCT01362374|DRUG|Enzalutamide|Enzalutamide will be administered orally at a dose level of 160 mg once daily continuously as per schedule defined in respective arm until disease progression or unacceptable toxicity.
40985935|NCT01362374|DRUG|Ipatasertib|Ipatasertib will be administered orally (in escalating doses during Stage 1 followed by at a dose decided during Stage 1) as per schedule defined in the respective arms.
41305198|NCT02488759|DRUG|Daratumumab|
40985936|NCT01362374|DRUG|Leucovorin|Leucovorin at a dose level of 400 mg/m\^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
40985937|NCT01362374|DRUG|Oxaliplatin|Oxaliplatin at a dose level of 85 mg/m\^2 as IV infusion over 2 hours will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
40781682|NCT05699057|BEHAVIORAL|Suicide GROUP|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains. Finally, we will To document the prevalence of tendency to suicide among medical students in the Egyptian Universities and analyse associated risk factors and any correlated determents.
40781683|NCT05390788|OTHER|Application Of Neuromuscular Bands; Kinesio Taping|"Kinesio tape is a specialized elastic and adherent adhesive tape that mimics the elasticity of skeletal muscle, in that it can be extended up to 140% of its original length, before application to the skin, without allowing restrictions in the range of motion. of structures. Subsequently, it provides a tensile (shear) force on the skin, consisting of a fabric with special characteristics, such as air permeability and water resistance, and can be used for repeated days. Kinesio will be applied from a point 10 cm below the anterior superior iliac spine and divided in a Y shape above the patella, ending at the tibial tuberosity; from the upper third of the medial thigh to the medial border of the patella; from the greater trochanter of the femur, ending at the lateral margin of the patella."
40985938|NCT01362374|DRUG|Paclitaxel|Paclitaxel at a dose of 90 mg/m\^2 as IV infusion over 1 hr will be administered on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
40985939|NCT06242314|PROCEDURE|L_PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after L-PRF placing on palatal wounds
41305199|NCT06049290|DRUG|LBL-034 for Injection|Initial dose - MTD; Q2W; intravenous infusion
40985940|NCT06242314|PROCEDURE|A-PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after A-PRF placing on palatal wounds
40781684|NCT05722587|OTHER|Pain science education|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
40781685|NCT04025892|BEHAVIORAL|Daily weighing|Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
40781686|NCT00373542|DRUG|ropinirole CR-RLS|
40781687|NCT02003482|RADIATION|Postop IMRT for head/neck cancer|Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
40781688|NCT02003482|DEVICE|CT for Radiation Treatment Planning|Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
41305200|NCT02390635|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
41305201|NCT02390635|PROCEDURE|Diffusion Weighted Imaging|Undergo whole body PET/MRI
41305202|NCT02390635|RADIATION|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
41305203|NCT02390635|DRUG|Gadolinium|Given IV
41305204|NCT02390635|PROCEDURE|Magnetic Resonance Imaging|Undergo whole body PET/MRI
41305205|NCT02390635|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT and whole body PET/MRI
40985941|NCT06242314|PROCEDURE|Palatal stent|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after palatal stent placing on palatal wounds
40985942|NCT01838031|OTHER|thyroid screening|The thyroid function and antibody will be measured immediately. The subclinical hypothyroidism will be treated individually.
40985943|NCT05256160|OTHER|TMS Paired-Pulse assessment of cortical excitability|Using the paired-pulse TMS paradigm, intracortical inhibition and facilitation of cortical circuitry will be assessed by stimulating the motor cortex and using the electromyographic (EMG) response of a target muscle as readout. In such studies, a conditioning stimulus modulates the amplitude of the motor-evoked potential (MEP) produced by the test stimulus. Depending on the inter-stimulus interval, effects can be attributed to different aspects of cortical processing. Brief intervals (1-5 ms) will be used to assess short-interval intracortical inhibition (SICI) and short-interval intracortical facilitation (SICF), intermediate intervals (7-20 ms) to assess intracortical facilitation (ICF) and long intervals (50-200 ms) to assess long-interval intracortical inhibition (LICI).
41464038|NCT04018690|BEHAVIORAL|Patients will be submitted to needle lavage, followed by the injection of 3mL of hylan and 1 mL of ropivacaine|"Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
40985944|NCT05256160|OTHER|Autonomic activity|Autonomic function will be determined using continuously recorded EKG and used as covariates to investigate any systematic impact on cortical excitability measures collected with the paired-pulse protocols.
41144580|NCT06450340|BEHAVIORAL|Moderate-intensity aerobic exercise refers to rhythmic and long-lasting exercise with increased heart rate, slight sweating and slight wheezing.|Sessions lasted 60 minutes each and took place three times a week for 12 weeks for each of the study groups.
41144581|NCT06505382|DIAGNOSTIC_TEST|Ultrasound-guided percutaneous neuromodulation|Percutaneous ultrasound-guided neuromodulation of the saphenous nerve in subjects with patellofemoral pain to assess its positive effects on pain and functionality.
41305206|NCT02390635|PROCEDURE|Three-Dimensional Spoiled Gradient MRI|Undergo whole body PET/MRI
41305207|NCT04439838|DRUG|BI 1595043|BI 1595043
41305208|NCT04439838|DRUG|Placebo|Placebo
41305209|NCT03913624|OTHER|Neuromuscular electrical stimulation|
41305210|NCT00660036|DRUG|Gemtuzumab ozogamicin|On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m\^2, 6 mg/m\^2 or 9 mg/m\^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
41305211|NCT00660036|DRUG|Mitoxantrone|On Days 1-3 of an inpatient hospital stay: 10 mg/m\^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
41305212|NCT00660036|DRUG|Etoposide|On Days 1-5 of an inpatient hospital stay: 100 mg/m\^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
41305213|NCT00708604|PROCEDURE|Islet Transplantation|Islet Transplantation
41305214|NCT00708604|BIOLOGICAL|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
41305215|NCT03327181|DIETARY_SUPPLEMENT|short chain fatty acid tracers|stable tracer infusion of acetate, propionate, and butyrate
41305216|NCT01204658|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
40781689|NCT02221973|DIETARY_SUPPLEMENT|sterols and hawthorn powder|there are two dose level of sterols (1.2g/d; 1/8g/d)
40985945|NCT01743131|DRUG|Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
40985946|NCT01743131|DRUG|placebo|
40985947|NCT01312688|OTHER|Early Goal Directed Hemodynamic Therapy in Sepsis|Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
41144582|NCT02304445|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
41305217|NCT01204658|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
41305218|NCT01204658|BIOLOGICAL|Synflorix|Intramuscular injection
41305219|NCT01204658|BIOLOGICAL|Prevenar 13|Intramuscular injection
41305220|NCT01204658|BIOLOGICAL|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Intramuscular injection
41305221|NCT04463329|PROCEDURE|conventional two-operator versus single operator using Jedi grip axillary brachial plexus blockage|on goup C, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic. On Group J single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm.
41305222|NCT05897346|OTHER|'Learning while serving' training program|The training program will involve training workshops, hands-on sessions, and a smoker referral competition.
41305223|NCT05897346|OTHER|Usual care|A 3-hour training workshops in the control group are regarded as usual care since the training workshops are also conducted regularly to other secondary or tertiary schools.
41305224|NCT01550718|BEHAVIORAL|ESML-EX (Physical Activity Program)|ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
40985948|NCT04136054|BEHAVIORAL|Adjusted group CBT-i for Depression, Anxiety and PTSD|Adjusted group CBT-i for Depression, Anxiety and PTSD. CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. Adjustments include the relationship between sleep and the psychiatric conditions at hand and and working with motivational enhancement techniques to increase adherence to treatment.
40985949|NCT04136054|OTHER|Care as usual wait-list control group|Usual care at the clinic. This entails managing pharmacological treatment for the psychiatric problems and/or sleep problems. The clinic also provides different group treatments, such as mindfulness groups and CBT groups for symptoms of worry and depression, and individual therapy.
40985950|NCT05938751|BEHAVIORAL|TEAm_YOUNG ADULTS program|The TEAm_YOUNG ADULTS program is an intervention to develop self-determination in young adults with autism. It consists of 20 1.5h weekly sessions. The intervention is conducted by two facilitators with expertise in autism and self-determination promotion. Groups are formed by 4 to 6 participants. The program can be applied online or in person. The first five sessions address specific characteristics and support needs of people with autism. The next ten sessions are focused on the development of self-determination. The last five sessions are focused on working with others and the closure of the group. The individual goals of every participant are considered in the beginning of the group and a weekly follow-up of goals is conducted.
40985951|NCT02197806|DRUG|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
40985952|NCT02197806|DRUG|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
40985953|NCT02197806|DRUG|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
40985954|NCT00100815|BIOLOGICAL|bevacizumab|30-90 minutes on day 1, every 21 days up to 12 months.
40985955|NCT00100815|DRUG|capecitabine|twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
40985956|NCT00100815|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
41144583|NCT02304445|RADIATION|TACE+Stereotactic Body Radiotherapy|This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
40985957|NCT06356181|DEVICE|Respiratory Maximus Training Device|Those in the intervention group will wear the respiratory training device for 3 days per week of high-intensity functional training over 6-weeks.
41144584|NCT02830893|DEVICE|LARA|Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
41144585|NCT02830893|BEHAVIORAL|Standard|Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
41144586|NCT02207777|PROCEDURE|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose approximately 16-18% (with a range of 16-25%) of their body weight.
41144587|NCT02207777|BEHAVIORAL|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over approximately 6 months to lose approximately 16-18% (with a range of 16-25%) of their body weight.
41144588|NCT03742297|DRUG|Lenalidomide.|Lenalidomide
41144589|NCT03742297|DRUG|Carfilzomib|Carfilzomib
41305225|NCT01550718|BEHAVIORAL|ESML-Social (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session."
40985958|NCT06356181|DEVICE|No Respiratory Training Device|Those in the control group will train for 3 days per week of high-intensity functional training over 6-weeks.
41144590|NCT03742297|DRUG|Bortezomib|Bortezomib
41144591|NCT03742297|DRUG|Daratumumab|Daratumumab
41144592|NCT03742297|DRUG|Dexamethasone|Dexamethasone
41144593|NCT03742297|DRUG|Prednisone|Prednisone
41305226|NCT05603039|DRUG|QL1706|5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
41144594|NCT03742297|DRUG|Melphalan|Melphalan
41144595|NCT00977678|OTHER|open access gastroscopy|access to gastroscopy without preceding appointment
41144596|NCT00977678|OTHER|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
41144597|NCT04820088|OTHER|Computer based role play trianing|Participants will train with a computer-based role-play simulation. They will interact with a lifelike video character on screen. They will interact with the character in one of four scenarios (i.e., patient intake, traditional needs, high-risk needs,and social and physical transition). They will receive real-time and after-action feedback in a safe, non-stressful environment. Their usage of the system will be monitored and transcripts will be collected.
41144598|NCT02001467|OTHER|Simulation-based training|
41305227|NCT05603039|DRUG|QL1604|200mg#D1#Q3W IV
41305228|NCT05603039|DRUG|Bevacizumab|15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
41305229|NCT01905319|OTHER|Blood collecting for storage of samples|
41144599|NCT01159314|PROCEDURE|Baerveldt Device surgical Procedure|Implant surgery
41144600|NCT05128799|OTHER|3 Wishes Program (3WP)|"The 3 Wishes Program (3WP) is a palliative care intervention in which small wishes are implemented by healthcare workers (HCWs) in an effort to improve the EOL experience for dying patients and their families. Examples of wishes include playing the patient's favorite music, providing a non-hospital blanket, orchestrating a final date night, decorating a patient's room to reflect their identify, and providing grieving family members with keepsakes such as thumbprint keychains, framed EKG mementos, or word clouds."
41305230|NCT03605810|OTHER|No Intervention|This study is the development of algorithms/models to predict eGFR values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (AF, CAD, T2DM patients sub-populations).
40985959|NCT06476457|BEHAVIORAL|STAIR Coach|STAIR is a brief, low-intensity intervention targeting difficulties in affective and interpersonal regulation that tend to be a significant problem for those exposed to traumatic events.
40985960|NCT02040454|DRUG|Paclitaxel|
40985961|NCT02040454|PROCEDURE|Standard Therapy|
40985962|NCT02969512|OTHER|HIPPER|Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes.
40985963|NCT02969512|OTHER|OASIS Online Educational Webinars|2-hour online educational large group sessions
40985964|NCT00891722|OTHER|biologic sample preservation procedure|
40985965|NCT00891722|OTHER|laboratory biomarker analysis|
41144601|NCT03374722|DRUG|Opioids|Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
41144602|NCT06096727|BEHAVIORAL|Energize!|Energize! is 3 month online physical activity program which consists of weekly physical activity goals, video lessons, action planning, and homework.
41144603|NCT05665348|DRUG|Ipilimumab Injection|Administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm
41144604|NCT05665348|DRUG|Atezolizumab Injection|One of the standard treatment's product for HCC management
41305231|NCT03167086|BEHAVIORAL|"Empowered Relief (ER)"|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention to treat chronic pain.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the ER sessions.~Content of intervention: ER Participants have the 'ER Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device."
41305232|NCT03167086|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) \[1\& 2\], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner \[3\].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk \& Winter \[4\] for optional reading."
41464039|NCT04018690|BEHAVIORAL|Patients will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine,|"Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
40985966|NCT00891722|OTHER|questionnaire administration|
40985967|NCT06027853|DRUG|CLL1 CAR-NK cell injection|"Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent"
40985968|NCT02172742|DRUG|BIA 2-093|BIA 2-093 1200 mg once-daily
40985969|NCT02172742|DRUG|Placebo|matching placebo
40985970|NCT02172742|DRUG|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
40985971|NCT03973840|DRUG|Testosterone Undecanoate|dose was given orally and allowed to reach steady state
40985972|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine(non freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
40985973|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine(freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
41144605|NCT05665348|DRUG|Bevacizumab|One of the standard treatment's product for HCC management
41144606|NCT06225063|OTHER|Pilates|The application of pilates aims to correct real-time deviations observed in the body during movement, to maintain stability, to maintain stability, to gradually form proper sensorimotor ability and improve cervical dysfunction. Pilates is an important part but also a primary point in the stages of rehabilitation, since through it the execution of movement is encouraged earlier thus providing help for the later stages of rehabilitation. Pilates exercises concern movements at all levels of body movement and in various positions.
40985974|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
40985975|NCT06536803|OTHER|high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks|high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks
40985976|NCT06536803|OTHER|high-load strength training with routine physiotherapy|high load strength training with routine physiotherapy for 12 weeks
40985977|NCT01950845|DEVICE|Closed loop automated System (LIR®: learning intravenous resuscitator)|Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.
40985978|NCT01950845|DEVICE|manual current practice by anesthesiologist team|The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
40985979|NCT02404376|DRUG|Exenatide|Intravenous administration of Exenatide
41464040|NCT05766787|DEVICE|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
41464041|NCT05766787|DEVICE|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
41464042|NCT05766787|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
41464043|NCT00411333|DRUG|triamcinolone acetonide (Kenalog)|
41464044|NCT01513044|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
41464045|NCT01513044|DRUG|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
41464046|NCT01745094|DRUG|mirabegron|oral
41464047|NCT01745094|DRUG|solifenacin|oral
41464048|NCT06283121|BIOLOGICAL|BioTTT001 intraperitoneal infusion|Monotherapy lead-in phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3; Combination therapy phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3, 3 weeks per cycle
41464049|NCT06283121|DRUG|SOX regimen|Combination therapy phase: Oxaliplatin 130 mg，i.v., D1 and D3, 3 weeks per cycle; Tegafur 40\~60mg b.i.d. p.o. D1\~D14; 3 weeks per cycle
41464050|NCT06283121|DRUG|toripalimab|Combination therapy phase: toripalimab 160mg i.v. D1, 3 weeks per cycle.
41464051|NCT01745081|DRUG|20% mannitol bolus administration|
41464052|NCT01745081|DRUG|Hypertonic saline 3% bolus administration|
41464053|NCT04791371|BEHAVIORAL|Cardiovascular exercise|15 weeks of cardiovascular exercise 3x/week for 50 minutes/session
41464054|NCT04854408|OTHER|healthcare workers with the coronavac vaccine|Health workers who are vaccinated will fill in the 20-question survey electronically.
41464055|NCT04029454|BIOLOGICAL|birth dose vaccination against hepatitis B strategy|"Complex intervention targeting healthcare workers and involving:~* training on hepatitis B awareness and management~* training on EPI vaccination and cold chain~* training on the modalities for the birth dose administration~* the use of a monovalent unidose vaccine against Hepatitis B"
41464056|NCT01085578|DRUG|CG400549/placebo|Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
40985980|NCT02404376|OTHER|Remote Ischemic Conditioning (RIC)|Remote ischemic conditioning with a cuff in the arm
41464057|NCT01085578|DRUG|CG400549/placebo|Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
41464058|NCT01085578|DRUG|CG400549|Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
41464059|NCT06493279|DRUG|RJK002 Intrathecal injection|Eligible subjects will receive a single intrathecal administration of investigational product with dose 6E13 vg/person, 1.2E14 vg/person, and 2.4E14 vg/person sequentially.
41464060|NCT02462486|DRUG|Abicipar Pegol|Abicipar pegol intravitreal injection.
41464061|NCT02462486|DRUG|Ranibizumab|Ranibizumab intravitreal injection.
40985981|NCT02404376|DRUG|Placebo|Intrevenous administration of Placebo
40985982|NCT01643811|PROCEDURE|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
40985983|NCT01643811|PROCEDURE|Endoscopic submucosal dissection|endoscopic submucosal dissection
40985984|NCT00546845|DEVICE|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
41464062|NCT02462486|OTHER|Sham Procedure|Sham injection.
41464063|NCT02079363|OTHER|No interventions, this is an observational study|
41464064|NCT03417609|DEVICE|Tongue strength measurement|The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it.
41464065|NCT03417609|PROCEDURE|Blood sampling|Blood sampling
41464066|NCT03417609|DIAGNOSTIC_TEST|Mini Mental State Examination (MMSE)|Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items.
41464067|NCT03417609|DIAGNOSTIC_TEST|Minimal nutritional assessment (MNA-SF)|The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient.
41464068|NCT03417609|DIAGNOSTIC_TEST|Dual-energy x-ray absorptiometry (DEXA)|Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia.
41464069|NCT03417609|DEVICE|Dynamometer (Hand grip )|By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.
41464070|NCT03417609|DIAGNOSTIC_TEST|Walking speed|Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party.
41464071|NCT00070759|DRUG|Daclizumab|
41464072|NCT05762731|DIAGNOSTIC_TEST|Low dose CT thorax|A multi-detector row CT scanner with minimum section collimation of ≤1 mm and minimum number of data acquisition channels ≥ 16will be employed.
41464073|NCT05762731|DIAGNOSTIC_TEST|Low dose CT thorax|Control subjects will also proceed to CT thorax, and outcome measures be compared to subjects
40985985|NCT00546845|DEVICE|Use of self-expanding Expert stent|Nitinol stent
40985986|NCT04225351|PROCEDURE|MCAF+CM|CAF procedure + collagen matrix
40985987|NCT04225351|PROCEDURE|MCAT+CM|Tunnel procedure + collagen matrix
40985988|NCT02919501|DRUG|Vortioxetine (IV)|17 mg, solution for infusion, administered, over 2 hours as single dose
40985989|NCT02919501|OTHER|Placebo (IV)|Saline: isotonic sodium chloride, administered, over 2 hours as single dose
40985990|NCT02919501|DRUG|Vortioxetine (tablet)|10 mg, tablets, oral administration once daily for 15 days (open labelled)
40985991|NCT01714154|DRUG|danoprevir|100 mg orally every 12 hours
40985992|NCT01714154|DRUG|ritonavir|100 mg orally every 12 hours
40985993|NCT01714154|DRUG|setrobuvir|200 mg orally every 12 hours
40985994|NCT00003799|DRUG|fluorouracil|Given IV
40985995|NCT00003799|DRUG|oxaliplatin|Given IV
41305233|NCT03167086|BEHAVIORAL|Health Education (HE)|"Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention."
41305234|NCT04956822|OTHER|Basic information|Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.
41305235|NCT04956822|OTHER|Functional scores|depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores
41305236|NCT04956822|DEVICE|MINUX|MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.
40781690|NCT01593371|DRUG|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
40781691|NCT01593371|DRUG|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
40781692|NCT04242069|BEHAVIORAL|Healthy for my Baby|"Participants will start the preconception intervention by meeting with a health professional for a motivational interview session on healthy lifestyle habits. Following this interview, participants will have access to a mobile phone application that will allow them to track daily lifestyle modification goals. After a month, they will meet the health professional for a second motivational interview and review their progression. Participants will continue to make lifestyle changes through the preconception period by accomplishing smart goals followed daily in the mobile phone application.~If the woman becomes pregnant, the couple will participate in two more in-person motivational interviews, a month apart. The mobile application will be put in pregnancy mode, and participants will adapt their daily lifestyle goals for the pregnancy. Participants will continue to make lifestyle changes throughout pregnancy by accomplishing smart goals followed daily in the mobile phone application."
41305237|NCT04772664|DIETARY_SUPPLEMENT|Multispecies-Probiotic|Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.
40781693|NCT04242069|OTHER|Usual Care|"Participants in the control group will receive standard advice on healthy lifestyle habits as provided by their usual care provider. They will receive standard medical care in preconception and pregnancy.~To improve compliance with the study follow-up, participants in this group will have access to a simplified version of the mobile application that contains a fertility calendar and a research visit calendar. This version of the application does not include lifestyle goals or any information on healthy lifestyle habits."
40781694|NCT02022540|DRUG|PAN-90806 Ophthalmic Solution|
40781695|NCT02022540|DRUG|Lucentis|
40781696|NCT05271942|PROCEDURE|Tilt and Tumble|The Tilt and Tumble technique is used to remove the human lens.
40985996|NCT00003799|RADIATION|radiation therapy|Undergo radiotherapy
41305238|NCT04772664|DIETARY_SUPPLEMENT|Placebo Supplement|Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.
41305239|NCT05836532|PROCEDURE|Central edge-to-edge|Suture of free margins of the mitral leaflets in central position to restore coaptation
41305240|NCT00471393|DRUG|1.5% diclofenac in 45.5% DMSO (topical treatment)|
41305241|NCT00471393|DRUG|45.5% DMSO (topical placebo)|
41305242|NCT05226819|DRUG|PPI quadruple therapy|Among these outpatients, H. pylori-negative patients don't give any intervention. But H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed.
41305243|NCT02280681|OTHER|No intervention, only questionnaire|No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
40781697|NCT05271942|PROCEDURE|Divide and Conquer|The Divide and Conquer technique is used to remove the human lens.
40985997|NCT00003799|DRUG|leucovorin calcium|Given IV
40985998|NCT00003799|PROCEDURE|therapeutic conventional surgery|Undergo surgery
40985999|NCT04952142|OTHER|minimal water exchange|Use a new technique, minimal water exchange colonoscopy, which adds the infusion of modest amounts of water by constant pressure on the air-water valve button of the endoscope to achieve intubation.
40986000|NCT00340080|DRUG|Abacavir|
40986001|NCT04237441|OTHER|number of participants with surgical complications|observation before and after multidisplinary team conference (MDT) was implemented
41464074|NCT01026649|PROCEDURE|Central venous catheterization|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
41464075|NCT01026649|PROCEDURE|Central venous catheterization|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
41464076|NCT02966496|BIOLOGICAL|Acri.LISA366D multifocal aspheric IOLs|The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
41464077|NCT02966496|BIOLOGICAL|TecnisZ9001 multifocal aspheric IOLs|The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
40781698|NCT00770393|PROCEDURE|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
40781699|NCT00770393|PROCEDURE|Conventionnal chemotherapy|"Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion."
40781700|NCT04851964|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
40781701|NCT04851964|OTHER|Placebo|Placebo subcutaneous injection
40781702|NCT03827239|OTHER|Activity/Moderate Exercise|3-hour sedentary period with 3 minute activity breaks of moderate exercise every 30 minutes
40781703|NCT01076010|DRUG|Tivozanib|Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.
40781704|NCT01076010|DRUG|Sorafenib|Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
40781705|NCT04111471|DRUG|Prebiotics|Enrolled patients will receive 10 grams of inulin daily for 21 days
40781706|NCT04111471|DRUG|Placebos|Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days
40781707|NCT05298475|DRUG|Statin|Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
41144607|NCT06225063|OTHER|Cognitive Functional Therapy|Cognitive component: Educating patients about their perceptions of pain, explaining diagnosis and diagnostic findings, answering questions about their problem and symptoms, progressively challenge their customers in a non-judgmental way, education for multifactorial and biopsychosocial spectrum of pain, encouraging participants to movement and for active participation in daily activities, if receiving a self-management plan participation in activities with a degree of difficulty 2-3/10, tips for more effective sleep Specific functional training: Understanding pain modification through relaxation exercises, awareness and body control, modified body positions for better control of the cervical spine with parallel relaxation of the thoracic spine to participate in fearful or painful activities, engaging in movements of daily activities Lifestyle changes: Gradual increase in physical activity based on patient preferences, stress management and social interaction
41144608|NCT06600490|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
41144609|NCT03730688|DEVICE|Conventional compartment pressure measurement|Compartment pressure will be measured using the conventional compartment pressure measurement system.
40781708|NCT05298475|DRUG|PCSK9 inhibitor|1 injection of PCSK9 inhibitor once a month SC
40781709|NCT05298475|DRUG|PCSK9 inhibitor|1 injection of PCSK9 inhibitor twice a month SC
40781710|NCT04638478|OTHER|PRECODE-MRI|Patients with meningioma WHO I tumours treated with radiotherapy will be included, undergoing extensive cognitive testing combined with advanced brain MRI scans just before, 3 and 24 months after radiotherapy
41144610|NCT03730688|DEVICE|Experimental compartment pressure measurement|Compartment pressure will be measured using the newly-developed compartment pressure measurement system.
41144611|NCT04819204|DRUG|Cetrorelix Acetate|GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.
40781711|NCT04101773|PROCEDURE|RBL versus sutured mucopexy versus haemorrhoidectomy.|All 3 interventions are part of Dutch usual care, and serve as each other's control.
40781712|NCT04937725|DIAGNOSTIC_TEST|eye tracking|Eye tracker will be used to evaluate study parameters
40781713|NCT00796458|DRUG|docetaxel|Given IV
40781714|NCT00796458|DRUG|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
40781715|NCT01317303|PROCEDURE|cTBS-PAS25|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after
40781716|NCT01317303|PROCEDURE|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
40986002|NCT01831999|BEHAVIORAL|RecoveryTrack - Extended Care (RT-E)|Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
41144612|NCT04819204|DRUG|Testosterone gel|Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist
41144613|NCT03236727|DRUG|Dexmedetomidine|Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.
41144614|NCT04491370|DRUG|Polatuzumab vedotin|All patients will receive a myeloablative conditioning regimens (BEAM or CBV, as selected by the treating physician) followed by autologous stem cell transplant (ASCT). All patients on this study will receive an autologous stem cell transplant (ASCT) on Day 0 followed by supportive care including the drugs sargarmostim and filgrastim until blood counts are stable. If a complete, partial, or stable response is achieved following ASCT, the patient will receive an IV dose of Polatuzumab Vedotin once every 21 days until he/she receives 8 doses.
41305244|NCT03741894|DRUG|Iodoform|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.
41305245|NCT03741894|OTHER|Wound closure using sutures|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
41305246|NCT03741894|DRUG|Chlorhexidine|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
41464078|NCT06492408|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
40781717|NCT01317303|PROCEDURE|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
40986003|NCT00969176|DRUG|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
41305247|NCT06447025|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
41305248|NCT03060603|DRUG|Erythropoietin|Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
41305249|NCT00583323|DRUG|Lomotil|Orally 10ml of Lomotil
41305250|NCT00583323|OTHER|Normal saline|10 ml orally
41305251|NCT05489822|DEVICE|VERTICALE® Cervical System|"All measures and devices mentioned in the study protocol correspond to routine clinical practice with the exception of the following questionnaires:~NDI (Neck Disability Index) NRS (Numerical Rating Scale) neck pain (cervical spine) and NRS arm pain mJOA (modified Japanese Orthopaedic Association) Score"
41305252|NCT01948284|PROCEDURE|half-maximal pressure|the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).
41305253|NCT01948284|PROCEDURE|maximal pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
41305254|NCT01948284|DEVICE|Suction Unit|
41305255|NCT01577160|DRUG|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
41305256|NCT00002340|DRUG|Atovaquone|
41305257|NCT00002340|DRUG|Pentamidine isethionate|
41305258|NCT05832164|OTHER|Multifactorial intervention|"* Adherence to a Mediterranean diet.~* Progressive aerobic and anaerobic exercise program.~* Review of polypharmacy~* Group socialization activities"
41305259|NCT04604236|BEHAVIORAL|Mapping Enhanced Counseling|Practitioner-led, collaborative discussion with the youth and their caregiver on co-creating guide maps for decision making around starting treatment and continuing substance use that can help users organize information and think through a series of steps, questions, and behavior choices. encountered when attempting to initiate substance use treatment services. MEC is a communication and decision-making approach that uses graphic visualization tools to train individuals to monitor and control their decision making, improve judgment and behavioral choices (self-regulation), and improve communication and mutual understanding.
41464079|NCT00799708|DRUG|Comparator: placebo|placebo capsule once daily for 7 days.
41464080|NCT00799708|DRUG|Comparator: Estrace|Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
41464081|NCT02128009|OTHER|osteoporosis|
40781718|NCT01317303|PROCEDURE|iTBS|190 seconds of intermittent theta-burst stimulation
40781719|NCT05636202|OTHER|No intervention|There was no intervention in the retrospective study
40781720|NCT06487871|DIETARY_SUPPLEMENT|Fucoidan extracted from Undaria pinnatifida (UPF)|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
40781721|NCT06487871|DIETARY_SUPPLEMENT|Placebo|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
40781722|NCT06157034|OTHER|Placebo|Inert Material
40781723|NCT06157034|DIETARY_SUPPLEMENT|Zingier officinale powder|The raw form of Zingiber officinale will be grounded in powder by manual grinding and will be encapsulated.
40781724|NCT06157034|DIETARY_SUPPLEMENT|Carum carvi, L powder|The raw form of Carum carvi, L will be grounded in powder by manual grinding and will be encapsulated.
40781725|NCT06157034|DIETARY_SUPPLEMENT|Mentha spicata oil|Mentha spicata L will be extracted in the form of oil and will be encapsulated.
40781726|NCT03375099|BEHAVIORAL|Lethal Means Counseling|Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.
40781727|NCT03375099|BEHAVIORAL|Health and Stress Reduction|Single session motivational interviewing based interaction aimed to reduce vulnerability to negative outcomes across four domains: sleep, diet, exercise, and stress.
40781728|NCT02481414|BIOLOGICAL|PepCan|50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities
40781729|NCT02481414|BIOLOGICAL|Candin®|0.3 mL Candin® per dose administered intradermally in the extremities
40781730|NCT03263403|BIOLOGICAL|Ingovax ACWY|The pharmaceutical company in Bangladesh is now currently marketing meningococcal vaccine of Yuxi Walvax Biotechnology Co. Ltd which is filled finish by Incepta Vaccines Ltd. This fill finish meningococcal vaccine is already registered and licensed in Bangladesh. However, at present, no locally produced meningococcal vaccine is available in Bangladesh. Once this clinical trial is completed, it will then proceed for registration and licensure in Bangladesh. Ingovax ACWY is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis Group A, Group C, Group Y and Group W135. When reconstituted, the vaccine is a clear, colorless sterile solution for subcutaneous use.
40986004|NCT03519347|OTHER|Potassium Removal Maximization|This intervention will test whether prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia reduces the incidence of clinically significant arrhythmias compared to an approach minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
40986005|NCT03519347|OTHER|Potassium Gradient Minimization|This intervention will test whether minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients reduces the incidence of clinically significant arrhythmias compared to an approach prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
41305260|NCT04604236|BEHAVIORAL|Active Linkage|Practitioner-led, collaborative discussion with the youth and their caregiver on how to overcome barriers encountered when attempting to initiate substance use treatment services. Discussion focuses around the top barriers identified through assessment and identification of 1 or more treatment agency/options that fit the family's needs. Practitioner takes a more active role in addressing barriers to treatment by helping the family find ways to access resources for payment, childcare, or other needs, and actively linking them to the treatment provider (e.g., scheduling the initial appointment with family present).
41305261|NCT03957109|PROCEDURE|general anesthesia|
41305262|NCT05475262|DEVICE|Active white noise|Active white noise of 57 dB - 60 dB from 10 pm to 6 am
41305263|NCT05475262|DEVICE|Inactive white noise|Sham comparator - white noise machine played at lower decibel level not expected to impact sound level changes
41305264|NCT00849979|BEHAVIORAL|Questionnaire|Day 1 MDASI-GI Questionnaire
41305265|NCT00849979|OTHER|Interview|Open-ended, audiotaped interviews
40781731|NCT03263403|BIOLOGICAL|Quadri Meningo|Meningococcal polysaccharide vaccine Quadri Meningo vaccine manufactured by BiO-MeD Private Limited. Quadri Meningo \[Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined\] is a freeze-dried preparation of the Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y, and Group W-135. After reconstitution with diluent, the vaccine is a clear colourless liquid.
41305266|NCT03392155|BEHAVIORAL|Training & Nutrition|Exercise at moderate to high intensities and diet education/counseling
41305267|NCT06409078|DEVICE|repeated transcranial magnetic stimulation treatment group|Patients with irritable bowel syndrome received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 1 week.
41305268|NCT06409078|DRUG|Western medicine group|Patients with irritable bowel syndrome were given pivotal ammonium bromide tablets orally at 50 mg three times daily for seven days in the Western medicine group.
41305269|NCT01825590|OTHER|Dialysate and serum sodium concentration aligned|
41305270|NCT01742624|DRUG|Advagraf|oral
40781732|NCT03700229|DRUG|Bortezomib|Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses
40781733|NCT03700229|DRUG|Rituximab|rituximab intravenously 500 mg for one dose
40781734|NCT01871441|RADIATION|Total-body irradiation|Undergo TBI
40781735|NCT01871441|BIOLOGICAL|Donor lymphocytes infusion (DLI)|Undergo DLI
40781736|NCT01871441|DRUG|Cyclophosphamide|Given IV
40781737|NCT01871441|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo haploidentical allogeneic HSCT
40781738|NCT01871441|DRUG|Tacrolimus|Given IV
40781739|NCT01871441|DRUG|Mycophenolate mofetil|Given IV
40781740|NCT01737866|DRUG|AMG 423|omecamtiv mecarbil
40781741|NCT03368066|DRUG|Cosyntropin|Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
40781742|NCT04446481|DEVICE|Neurofeedback|Neurofeedback will be tested in both groups of Vets
40781743|NCT00644839|DRUG|CP-945,598|Administration of CP-945,598 alone in period 1
40781744|NCT00644839|DRUG|CP-945,598|Adminstration of CP-945,598 with omeprazole in period 2
40986006|NCT03519347|OTHER|Alkalosis Avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing alkalosis avoidance by use of lower dialysate HCO3 concentrations.
40986007|NCT03519347|OTHER|Acidosis avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing acidosis avoidance by use of higher dialysate HCO3 concentrations.
40986008|NCT03519347|DIAGNOSTIC_TEST|Point of Care Testing|POC testing will use the Abbott BLUE I-STAT CHEM8+ , a portable, handheld device that provides lab quality analysis within 2-3 minutes using a few drops of whole blood (≤100uL).
40986009|NCT03519347|DEVICE|Cardiac Monitor|Device is one-third of the size of a triple-A battery and is placed subcutaneously in the left chest during a brief procedure that can be done in-office under local anesthesia.
40986010|NCT00351260|PROCEDURE|Coronary Angioplasty|
40986011|NCT03564847|BEHAVIORAL|LTP Plus|"LTP+Dads is a 12 - session group integrated parenting intervention: i.e LTP (Learning through Play) which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment. In each stage, there are five areas of child development: sense of self, physical, relationships, understanding, and communication. All areas are written in simple, low-literacy language.~Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~Third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
41144615|NCT04553627|DEVICE|ZELTIQ thermoelectric device|This is a feasibility study to determine if cryolipolysis in this area produces a desirable lifted appearance to the buttocks. Typically, a lifted more youthful appearance is obtained through surgical means. Study participants will be recruited from the population of patients who have suitable, treatable subcutaneous fat on the medial infragluteal folds and desire a lifted appearance. Subjects will receive treatments with a cooled cup cryolipolysis applicator from the CoolAdvantage family of applicators (cooled cup vacuum applicator). Treatments will be performed with a treatment temperature of - 11°C for up to 35 minutes. Subjects will complete all study-required follow-up visits, including an 8-week follow-up which may include a second treatment session, as well as a 12-week post final treatment follow-up visit
41305271|NCT01742624|DRUG|Prograf|oral
41305272|NCT01742624|DRUG|Corticosteroid|oral
41305273|NCT01742624|DRUG|Mycophenolate mofetil|oral
41305274|NCT01847833|OTHER|MRI scan|
41305275|NCT03517748|DEVICE|DM05 eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
41305276|NCT03517748|DEVICE|Optive™ eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
40986012|NCT06144346|RADIATION|Stereotactic Ablative Radiation Therapy|SABR to all metastatic lesions
40986013|NCT06144346|PROCEDURE|Locoregional treatment|mastectomy or BCS for the primary tumor
40986014|NCT06144346|OTHER|Standard of Care|Systemic treatment and palliative treatment
40986015|NCT06018714|DRUG|Fruquintinib|"Drug:~Maintenance treatment regimen:~Fruquintinib 5 mg, qd, po, with three weeks of continuous treatment followed by one week of drug discontinuation. Each treatment cycle lasts four weeks. The treatment will be continued for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months.~Adverse drug reactions that occur during the trial will be graded according to the NCI CTCAE version 5.0 and dose adjustments will be made according to the corresponding rules."
40986016|NCT01857466|PROCEDURE|Floseal|
40986017|NCT01857466|PROCEDURE|Bipolar coagulation|
40986018|NCT01028365|OTHER|No intervention|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
41305277|NCT03233100|OTHER|FMT|fecal microbiota transplantation
41305278|NCT01855542|OTHER|0.9% normal saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
41305279|NCT01855542|OTHER|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
41305280|NCT04932525|PROCEDURE|Biopsy|Blood and tumor samples for Genetic Profiling research
40986019|NCT01622361|DRUG|Adriamycin+Cyclophosphamide>Docetaxel|"1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~   * Route: by slow intravenous bolus~  * Schedule: every 3weeks for 4 cycle~2. Docetaxel 75mg/m2~   * Route: intravenous as per local practice~  * Schedule: every 3weeks for 4 cycle"
40986020|NCT01622361|DRUG|GnRHa with Tamoxifen|"1. Goserelin(GnRHa) 3.6mg~   * Route: subcutaneously under the abdominal skin~  * Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~2. Tamoxifen 20mg/day~   * Route: Oral~  * Schedule: everyday"
41305281|NCT04719169|DIAGNOSTIC_TEST|Dynamic MRI enema|Dynamic MRI enema
41305282|NCT04719169|DIAGNOSTIC_TEST|Fluoroscopic enema|Fluoroscopic enema
41305283|NCT02635737|DEVICE|Sentimark|Placement of a metallic clip with paramagnetic properties for tumour localisation
41305284|NCT03194152|DIETARY_SUPPLEMENT|Peanut|Dietary Supplement: Peanut
41305285|NCT03194152|DIETARY_SUPPLEMENT|Control|Dietary Supplement: High carbohydrate snacks
41305286|NCT01252797|RADIATION|Stereotactic Radiosurgery (15 Gy)|"Group A will start at dose level II: 15 Gy~Group B will start at dose level I: 12 Gy"
41305287|NCT01252797|RADIATION|Stereotactic Radiosurgery (12 Gy)|Group B will start at Dose Level I: 12 Gy
41305288|NCT00320736|DRUG|galantamine|
41305289|NCT06553144|PROCEDURE|control|Canals were irrigated with only10 mL of 5% NaOCl
41305290|NCT06553144|PROCEDURE|methylene blue|0.1 mg/mL methylene blue solition delivered into the canal and irradiated with a 100mW diode laser at a wavelength of 660 nm
41305291|NCT06553144|PROCEDURE|erythrosine b|0.3 mg/mL eryrhtosine b solition delivered into the canal and irradiated with a 100mW diode laser at a wavelength of 660 nm
41305292|NCT06553144|PROCEDURE|curcumin|5.0 mg/mL curcumin solition delivered into the canal and irradiated with a 200mW diode laser at a wavelength of 450 nm
41305293|NCT03276936|DRUG|FMX103 1.5%|FMX103 1.5% minocycline foam
41305294|NCT02002806|OTHER|Alcohol Injection|Celiac plexus neurolysis by alcohol injection
41305295|NCT02002806|OTHER|Placebo Injection|
41305296|NCT01350349|BEHAVIORAL|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
41305297|NCT01350349|BEHAVIORAL|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
40781745|NCT04406987|PROCEDURE|decompression|surgical technique for neural decompression varied based on surgeon's preference, but always with preservation for spinous processes. Either open with or without microscope or using tubular retractors.
40781746|NCT04406987|PROCEDURE|fusion|fusion techniques consisted besides decompression of additional implantation of pedicle screws with rods, with or without intervertebral fusion and cage(s). Non-instrumented technique with allograft bone. Fusion technique on surgeon's discretion.
40781747|NCT00641264|DRUG|Omeprazole|
40781748|NCT00641264|BEHAVIORAL|Quality of Life questionnaire|
40986021|NCT01736150|DRUG|Placebo|"* Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals."
40986022|NCT01736150|DRUG|Sevelamer carbonate|"* Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals."
40986023|NCT01541969|DEVICE|CR Neuromodulation|"Ear level device which delivers patterned sound stimulation.~The experimental arm will use the device fitted according to audiologist training given by the manufacturer/funder. An individually specified sound stimulation algorithm is hypothesised to interrupt tinnitus generating activity in the brain. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks participants will be unblinded and continue with the same experimental intervention. In weeks 13-36 participants will be asked to wear the device every day for 4 hours, in continuous blocks of at least 1 hour."
40986024|NCT01541969|DEVICE|Tinnitus masking|The active comparator uses the same ear level device and also delivers patterned sound but the stimulus will be determined according to an algorithm predicted not to break up tinnitus generating activity in the brain. It may have a masking effect. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks, the participants will be unblinded and the device algorithm will be reprogrammed in the same way as the experimental intervention. In weeks 13-24 participants will be asked to wear the device for 6 hours per day, in continuous blocks of at least 1 hour. In weeks 25-36 they will be asked to continue using the device every day for 4 hours, in continuous blocks of at least 1 hour.
40986025|NCT02063854|DRUG|NE-58095 IR|NE-58095 IR tablets
40986026|NCT02063854|DRUG|NE-58095 IR Placebo|NE-58095 IR placebo-matching tablets
40986027|NCT02063854|DRUG|NE-58095 DR|NE-58095 DR tablets
40986028|NCT02063854|DRUG|NE-58095 DR Placebo|NE-58095 DR placebo-matching tablets
40986029|NCT01317745|OTHER|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
40986030|NCT01317745|DRUG|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
40986031|NCT01317745|BIOLOGICAL|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
40986032|NCT05139303|DEVICE|Orthoapnea NOA®|The efficacy of the appliance for the management of OSA will be stablished based on two criteria. Criterion I: \> 50% reduction of AHI/RDI. Criterion II: AHI/RDI \< 5 events/hour or \<15 events/hour with a significative reduction of OSA associates symptoms as defined before. Therapeutic failure will be established when at 100% of advancement of the device, there is less than 50% of reduction of the AHI/RDI with a residual AHI/RDI \>5 events/hour with OSA associates symptoms.
41305298|NCT02244723|OTHER|Lung ultrasound examination|Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia
41305299|NCT02310971|BIOLOGICAL|CVac|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
41464082|NCT01150006|OTHER|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
41464083|NCT02123524|DRUG|Rivaroxaban|
41464084|NCT02123524|DRUG|Placebo|
41464085|NCT00057967|BIOLOGICAL|alemtuzumab|Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
41464086|NCT03739216|DEVICE|ClariFix|The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
41464087|NCT01932190|PROCEDURE|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
40781749|NCT05964569|OTHER|model-guided optimization of treatment plan|original treatmant plans are optimized based on model-based NTCP
40781750|NCT05964569|OTHER|standard treatment plan, no optimization|original treatment plans are not optimized
40781751|NCT04314817|DRUG|Any drug used to treat Covid-19|lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
40781752|NCT01542970|DIETARY_SUPPLEMENT|Placebo|Olive oil
40781753|NCT01542970|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
41144616|NCT03927963|DRUG|Dexmedetomidine|Dexmedetomidine 0.7 ug/kg/h with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
41144617|NCT03927963|DRUG|Propofol|Effect site concentration of propofol 1.5 ng/ml with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
40986033|NCT04951245|PROCEDURE|UC group: ultrasound-assisted CNSs guided|1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast. The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla. During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used. Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle . A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters. Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region. Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
40986034|NCT04951245|PROCEDURE|GC group: CNSs plus ICG dual-tracer-guided|The preparation of CNSs mapping was identical to that of the UC group. 1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast. A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs. All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed. The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
40986035|NCT00004489|DRUG|alendronate sodium|
40986036|NCT00004489|DRUG|calcium carbonate|
40986037|NCT00004489|DRUG|cholecalciferol|
41305300|NCT03860545|DIAGNOSTIC_TEST|urine and blood analysis|concentration of ischemia modified albumin assessed in blood before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation; concentration of urinary excretion of brush-border enzymes of the proximal renal tubules assessed before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation, serum creatinine levels will be evaluated on the day of the operation and 24 h and 48 h postoperatively
41464088|NCT01932190|PROCEDURE|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary"
40781754|NCT01542970|DIETARY_SUPPLEMENT|Refined coconut and peanut oil without L. reuteri|2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
40986038|NCT02047357|OTHER|Learning Through Play Plus|Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
40986039|NCT05003453|DRUG|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
40986040|NCT05003453|DRUG|Placebo Comparator|A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
40986041|NCT00946959|PROCEDURE|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
41144618|NCT01223014|DRUG|AZD2423|AZD2423
41144619|NCT01277679|PROCEDURE|MRI|MRI of lungs to measure lung water content before and after passive leg raising (PLR)
41144620|NCT05307302|DIAGNOSTIC_TEST|Force Sense|A measure of proprioception, using a handheld dynamometer (MicroFET2-hoggan Health Industries Inc.), in a sitting position in a standardized position of the elbow joint of the dominant upper extremity (90 degree of flexion). Measurement of the elbow joint flexion force sense will be expressed as percentages. Each of the targeted trials will be calculated as a percentage of the maximum voluntary contraction (MVC) reference measure. The difference between the targeted and the actual percentage of MVC for each of the trials will be then calculated as a percentage of the targeted MVC, to reflect the proportion of error.
41144621|NCT05307302|DIAGNOSTIC_TEST|Joint Reproduction Sense|A measure of proprioception, using a smart phone goniometer (Android Clinometer) application, in a sitting position in a standardized position of the elbow joint of the dominant upper extremity. Measurement of the elbow joint position reproduction will be expressed as degrees of reproduced angle. Absolute Error (AE) score will be calculated by the absolute value of the difference in degrees of the angle reproduced after subtracting the angle targeted.
41144622|NCT05307302|DIAGNOSTIC_TEST|Seated Medicine Ball Throw|A measure of upper limb physical performance, using 2-kg medicine ball and a standardized protocol, throwing distance expressed in meters.
41144623|NCT05307302|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|A measure of upper limb physical performance, using body weight and a standardized protocol, touches between hands expressed in number of touches.
41144624|NCT05307302|DIAGNOSTIC_TEST|Passing Accuracy|A measure of the basketball passing skills, passing of The American Alliance for Health, Physical Education, Recreation and Dance (AAHPERD) test battery will be used in a standardized protocol. Accurate passes will be expressed in points.
41144625|NCT06204107|DRUG|CKD-379(Empagliflozin+sitagliptin+metformin) Test drug|oral, once
41144626|NCT06204107|DRUG|CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug|oral, once
40781755|NCT01542970|DIETARY_SUPPLEMENT|L. reuteri|The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
41144627|NCT00011102|BEHAVIORAL|Weight Gain Prevention for Women Project|
41305301|NCT02493426|DRUG|Intranasal Oxytocin|
41305302|NCT02493426|DRUG|Placebo|
41144628|NCT05278117|PROCEDURE|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh
41144629|NCT02376062|OTHER|Bundled Intervention|"The authors have designed continuing medical education curriculum to improve clinical capacity and competency about mental health for Nepali Primary Care Providers. Specifically:~* On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~* Weekly case conferences~* Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
41144630|NCT05022953|OTHER|Education, dijital storytelling|Digital story
41144631|NCT03110783|BIOLOGICAL|Bioseal|Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
41144632|NCT00000892|DRUG|Ritonavir|
41144633|NCT00000892|DRUG|Nelfinavir mesylate|
41144634|NCT00000892|DRUG|Levocarnitine|
41144635|NCT00000892|DRUG|Adefovir dipivoxil|
41144636|NCT00000892|DRUG|Saquinavir|
41144637|NCT00000892|DRUG|Delavirdine mesylate|
41144638|NCT02708498|BEHAVIORAL|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
41144639|NCT01605084|DRUG|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
41144640|NCT01605084|DRUG|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
41144641|NCT01605084|DRUG|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
41144642|NCT01605084|DRUG|Optimized NRTI backbone|"tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks~NRTI backbone are:~- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)~The following NRTI combinations are prohibited in this study:~* Didanosine + Stavudine~* Zidovudine + Stavudine~* Lamivudine + Emtricitabine"
41144643|NCT05647941|DIAGNOSTIC_TEST|Detection of levels of circulating EV-derived lncRNA-GC1|For patients with gastric cancer receiving neo-adjuvant chemotherapy, the dynamic changes of EV-derived lncRNA-GC1 was detected to identify whether is can serve as a monitoring biomarker for treatment response.
41144644|NCT01359163|DRUG|etynodiol diacetate|tablet, 0.5 mg, single dose
41144645|NCT01359163|DRUG|etynodiol diacetate|tablet, 0.5 mg, single dose
41144646|NCT03665714|OTHER|Impact Oral|Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
41144647|NCT03665714|OTHER|Enteral Nutrition Emulsion(TPF-T)|TPF-T
41144648|NCT01859689|RADIATION|brachytherapy|Undergo image-guided HDR brachytherapy
41144649|NCT01859689|RADIATION|image-guided radiation therapy|Undergo image-guided HDR brachytherapy
41144650|NCT01859689|OTHER|laboratory biomarker analysis|Correlative studies
41144651|NCT00677742|OTHER|enhanced initial supply of oral contraception|7 packs of pills, or 1 pack of pills and a prescription for 6 refills
41144652|NCT00677742|OTHER|conventional initial supply of oral contraception|3 packs of pills, or 1 pack of pills and a prescription for 2 refills
41144653|NCT05123118|BEHAVIORAL|Integrated intervention of smoking cessation and breastfeeding|The intervention group will receive an integrated intervention of smoking cessation and breastfeeding: education and counseling, monitoring and feedback, and contingent financial incentives.
41144654|NCT05123118|BEHAVIORAL|Attention placebo control|Participants in the control group will receive usual prenatal care from physicians, nurses, or social workers. They will receive best standard care on smoking cessation and breastfeeding, including referral to the New York State Smokers' Quitline and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).
41464089|NCT05594641|OTHER|Remote ischaemic preconditioning|A tourniquet will be applied to the right arm and it will be inflated (3 cycles, each lasting 5 minutes, at a pressure of 200 mmHg); each cycle is followed by 5 minutes of resting
41464090|NCT05594641|OTHER|Control|The tourniquet will be applied to the right arm but the cuff will be not inflated
41144655|NCT02865083|DEVICE|Traxi Pannus Retractor|traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.
41144656|NCT04400045|DRUG|Treosulfan|Treosulfan 21mg/m2 (days -6, -5, -4)
41144657|NCT04327349|BIOLOGICAL|Convalescent Plasma|Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU
41144658|NCT04372706|DRUG|RTX-240|Engineered red cells co-expressing 4-1BBL and IL-15TP
41144659|NCT04372706|DRUG|Pembrolizumab|Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody
41144660|NCT03677986|BEHAVIORAL|Video DOT+|Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.
41144661|NCT02832830|RADIATION|IMRT|Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis
41144662|NCT02832830|RADIATION|fractionated RT|external beam Radiotherapy of the involved spinal bone metastasis
40986042|NCT00795522|DRUG|Desloratadine|Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
40986043|NCT00517621|DRUG|Paclitaxel|
41144663|NCT02385539|DRUG|The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.|The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
41144664|NCT02226029|OTHER|Lipid emulsion|"2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~* Lipid emulsion 1: acid stable, particle size 0.6 µm~* Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~* 13C-markers will be mixed with emulsions"
41144665|NCT02821572|BIOLOGICAL|blood sample|
41144666|NCT02821572|PROCEDURE|spleen sample|
41144667|NCT00239642|DRUG|Venofer (iron sucrose injection)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
41144668|NCT00239642|DRUG|Venofer (iron sucrose injection)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
41144669|NCT00239642|DRUG|Venofer (iron sucrose injection)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
41144670|NCT02947880|DRUG|Bumetanide|For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
41144671|NCT02947880|DRUG|Placebo|For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
41144672|NCT05209256|DRUG|Chemotherapy|Patients in the alflutinib group received alflutinib (80 mg daily) until disease progression, unacceptable toxicity, or death.
41144673|NCT05209256|DRUG|Alflutinib plus chemotherapy|Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve \[AUC\] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
41144674|NCT03622905|DEVICE|DBS-f On|Deep Brain Stimulation of the fornix
41144675|NCT03622905|DEVICE|DBS Off|Deep Brain Stimulation of the fornix turned off
41144676|NCT05427942|DRUG|Adalimumab|Stable and treated for at least 3 months prior to inclusion either with an adalimumab biosimilar or originator adalimumab (40 mg dose injections only) and for whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
41144677|NCT00378456|DRUG|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
41144678|NCT00378456|DRUG|Folinic acid|
41144679|NCT00378456|DRUG|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
41144680|NCT00378456|DRUG|Placebo|
41144681|NCT00509314|BEHAVIORAL|melanocyte self-assembly and functional analysis|
41464091|NCT03431337|DRUG|Amoxicillin 875 mg|Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125
40986044|NCT00517621|DRUG|EPO|
40986045|NCT02128633|DRUG|placebo gel|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
40986046|NCT02128633|DRUG|5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
40986047|NCT02128633|DRUG|Fluoride neutral NaF gel 2 %|The product had similar appearance and viscosity than others.
40986048|NCT05545566|PROCEDURE|Thoracic ultrasound versus chest X-ray|"Perform un ultrasound test, in addition to Chest X-Ray (usual practice), few hours after the surgery (D0), the next day (D1) and 4 to 6 hours after drain removal.~The data are collected in the standardized protocol for the two type of imaging.~The thoracic ultrasound and the Chest X-Ray are performed, blindly each other, in the same position for the patient and the same suction level of drain."
40986049|NCT01982851|PROCEDURE|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
40986050|NCT01982851|PROCEDURE|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
41144682|NCT01706055|BIOLOGICAL|Interferon beta-1b (Betaseron, BAY86-5046)|Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
41144683|NCT01285167|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
41144684|NCT03029156|DEVICE|Aeroneb nebulizer|"The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.~The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium)."
41144685|NCT03029156|DEVICE|Small volume jet nebulizer|The bronchodilators will be administered via small volume jet nebulizer
41144686|NCT01287832|DRUG|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
41144687|NCT01287832|DRUG|Daptomycin|
41144688|NCT06264999|DEVICE|Journey II CR|Implantation of Journey II CR Crucite Retaining Knee
41144689|NCT06264999|DEVICE|Journey II XR|Implantation of Journey II XR Bi Cruciate Retaining Knee
41464092|NCT03431337|DIETARY_SUPPLEMENT|Placebo (lactase)|Placebo (in place of additional amoxicillin in experimental arm)
40986051|NCT03178773|BEHAVIORAL|TExT-MED|messages designed to inspire motivation and behavior change
40986052|NCT03178773|BEHAVIORAL|FANS|SMS delivered messages to family members to improve social support
40986053|NCT00378209|DRUG|Bortezomib|Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.
40986054|NCT00378209|DRUG|Lenalidomide|Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles
40986055|NCT00378209|DRUG|Dexamethasone|Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles
41144690|NCT00936065|DRUG|Etanercept|Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
41144691|NCT00936065|DRUG|Etanercept + Acitretin|Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
41144692|NCT00936065|DRUG|Acitretin|Acitretin at a dose of 10mg BID for 24 weeks
41144693|NCT01424345|DRUG|adjustment of immunosuppressant dosages|adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
41144694|NCT01424345|DRUG|adjustment of the dosages of immunosuppressants|adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
41144695|NCT01469884|DRUG|Everolimus|The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
41144696|NCT01469884|DRUG|Cyclosporine|Trough level should be between 100 and 200ng/ml.
41144697|NCT01469884|DRUG|Tacrolimus|Trough level should be between 5 and 10ng/ml.
41305303|NCT03284619|DEVICE|Magnetic resonance imager linear accelerator|The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
41305304|NCT05818293|DEVICE|radiofrquency device|• The radiofrequency system has been used for treatment of subcutaneous fat layers.
41305305|NCT06387888|OTHER|Listening to mother's voice|During the care, from the beginning to the end, mother's voice was played to the newborns. It took about 20 minutes. The mini Bluetooth speaker and the decibel meter were disinfected with the rapid surface disinfectant used in the clinic. The speaker was placed 30 cm away from the infant's ear and the sound level in the incubator was adjusted to be 50-60 dB by using a decibel meter (Official Gazette, 2018). Mother's voice was played from the beginning of the provision of care and continued for 15 minutes after the end of the provision of care. During the provision of care, COMFORTneo scores, pain scores, and vital signs were measured and recorded on the vital signs follow-up form.
41305306|NCT03397277|BEHAVIORAL|Safety behaviour promoting video|A 7 min. video which teaches 15 different safety behaviours to reduce violence or the effect of violence
41464093|NCT01341587|DEVICE|Telcare Blood Glucose Meter (BGM)|Cellular enabled glucometer
40986056|NCT02355119|DRUG|FOLFOXIRI|Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
40986057|NCT02355119|DRUG|Gemcitabine|
40986058|NCT02335099|DRUG|ticagrelor|ticagrelor 90 mg twice a day for 6 months
40986059|NCT02335099|DRUG|Placebo|1 pill twice a day for 6 months
40986060|NCT06219850|OTHER|No intervention|The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.
40986061|NCT03667560|PROCEDURE|Dermacell ADM without basement membrane|Patient will be implanted with Dermacell ADM.
40986062|NCT03667560|PROCEDURE|FlexHD|Patient will be implanted with FlexHD.
40986063|NCT01550796|BEHAVIORAL|Cognitive Training|250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
40986064|NCT00459173|DRUG|rimonabant (SR141716)|
40986065|NCT04506476|DEVICE|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
41144698|NCT00899795|GENETIC|cytogenetic analysis|
41144699|NCT00899795|GENETIC|fluorescence in situ hybridization|
41144700|NCT00899795|OTHER|flow cytometry|
41144701|NCT00899795|PROCEDURE|biopsy|
41144702|NCT03941977|DEVICE|Percutaneous introduction of cannula|An 8 gauge cannula is introduced at the site of the bone marrow lesion. The introduction of the cannula is guided by fluoroscopy.
41144703|NCT03941977|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI scans will be performed on a 1.5 T (Signa Excite HD, GE Healthcare, Waukesha, WI, USA) and a specific knee coil (HD TRKnee 8 Ch High Resolution Knee Array) will be used.
41144704|NCT03941977|BIOLOGICAL|Bone Grafting|A bone substitute consisting of calcium phosphate will be injected through the cannula, previously inserted, filling the area of the bone marrow lesion. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.
41144705|NCT00043459|DRUG|intravenous T900607-sodium|
41144706|NCT06502067|DRUG|Analgesia mangement group A,B|1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
41144707|NCT04403815|PROCEDURE|vascular access for coronary procedures|comparison of x-rays exposition of interventional cardiologist according to vascular access used
41144708|NCT04613947|BEHAVIORAL|Informed consent|The style of informing patients about the procedure they will undergo
41144709|NCT04613947|PROCEDURE|Third molar surgery|Surgical extraction of the third molar tooth
41144710|NCT00084825|DRUG|Docetaxel|30 mg/m\^2 IV on days 1, 8, 15, and 22 every 42 days
41144711|NCT00084825|DRUG|Imatinib mesylate|600 mg orally daily
40986066|NCT01927666|DIETARY_SUPPLEMENT|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
40986067|NCT03416257|OTHER|No intervention|
40986068|NCT00749918|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
40986069|NCT04119856|OTHER|Affiliation with the outgoing lung team|"The work of the outgoing lung team takes place in the patient's home and involves the following:~* The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.~* The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.~* The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.~* The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.~* The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call."
41144712|NCT03826056|BEHAVIORAL|Current standard discharge educational intervention|The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
40781756|NCT04306328|DEVICE|Neurostimulation|Implantation of 2 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
40986070|NCT02773355|DRUG|liraglutide 3.0 mg|Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
41144713|NCT03826056|BEHAVIORAL|Personalized discharge educational intervention|The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
41144714|NCT00860509|OTHER|Low Phytosterol and High Phytosterol Diets|Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
41144715|NCT05233904|DIAGNOSTIC_TEST|Diagnostic-CT-enabled Planning|Diagnostic-CT-enabled planning for patient receiving palliative radiation treatment to bone, soft tissue and lung disease
41144716|NCT05233904|DIAGNOSTIC_TEST|Standard of Care|Patients will be booked for CT simulation and treatment as per the local institution's standard practice
41144717|NCT00185692|PROCEDURE|non-myeloablative hematopoietic cell transplantation|TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
40781757|NCT05338450|DRUG|Clemastine Fumarate|4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)
41144718|NCT00185692|DRUG|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
41144719|NCT00185692|DRUG|Cyclosporine|6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
41144720|NCT00185692|DRUG|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
40986071|NCT02949492|DRUG|IL-2 (interleukin 2)|Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
40986072|NCT06542952|OTHER|seizure|epileptic children
40986073|NCT02743650|DIETARY_SUPPLEMENT|Sodium bicarbonate|The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.
40986074|NCT01895855|BIOLOGICAL|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 5x10\^8
41144721|NCT00185692|DRUG|G-CSF|16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
41144722|NCT00185692|DRUG|Solumedrol|1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
41144723|NCT00185692|DRUG|Acetaminophen|650 mg PO, 30 minutes prior to infusion Pain reliever
41144724|NCT00185692|DRUG|Diphenydramine|50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
41305307|NCT03397277|BEHAVIORAL|Control video|A 7 min. video which teaches women about safety regarding food, alcohol, smoking, medication and physical activity during pregnancy
41305308|NCT05158205|BEHAVIORAL|Yoga|12-week yoga intervention in which 60-minute classes are completed at Texas State University 3 times per week
40781758|NCT05338450|DRUG|Placebo|Placebo equivalent to experimental arm
40781759|NCT03649802|DIETARY_SUPPLEMENT|Low dose vitamin D3|Low dose arm-800 IU given daily
40781760|NCT03649802|DIETARY_SUPPLEMENT|High dose vitamin D3|High dose arm-5000 IU given daily
40781761|NCT01746290|OTHER|PulsePoint notification|When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
40781762|NCT03249363|PROCEDURE|Group A - Pulsed PVP-I Irrigation|
40781763|NCT01656577|DRUG|Pexacerfont|
40781764|NCT06258005|DIAGNOSTIC_TEST|PocDoc|PocDoc is a digital rapid 5-marker lipid test
40986075|NCT01895855|BIOLOGICAL|placebo|
40986076|NCT04931355|OTHER|Acupuncture|The Acupuncture intervention（Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi.） will start on the 5th day of menstruation cycle, which will be carried out 1 time per day, at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention.
40986077|NCT04931355|OTHER|Western medicine|Western medicine
40781765|NCT02663310|PROCEDURE|Surgery|Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.
40781766|NCT02663310|PROCEDURE|Rehabilitation|The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
40781767|NCT04971928|DRUG|GSK3228836|GSK3228836 will be administered
40986078|NCT02614430|OTHER|Vocational training|The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
40986079|NCT01404325|DRUG|standard therapy|centre specific CNI-based triple drug immunosuppression
40986080|NCT01404325|DRUG|Everolimus|quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
40986081|NCT04765579|BEHAVIORAL|visual analogy scala|We will investigate the effect of 4in1 block by questioning the vas score of the patients, its effect on quadriceps strength, and additional analgesia needs for 24 hours.
40986082|NCT02143440|BEHAVIORAL|The initial assessment of daily insulin dose.|
40986083|NCT05701774|DRUG|DCCR|Once daily oral administration
40986084|NCT04862845|DRUG|Duloxetine and Pregabalin|will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.
40986085|NCT04862845|DRUG|pregabalin|received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.
40986086|NCT04862845|DRUG|sham|received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
40986087|NCT00002233|DRUG|Indinavir sulfate|
41144725|NCT00185692|DRUG|Hydrocortisone|100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
41305309|NCT05158205|BEHAVIORAL|Slow, deep breathing|12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
41305310|NCT05158205|BEHAVIORAL|Control breathing|12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
41305311|NCT00638326|DRUG|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
40781768|NCT01573117|DEVICE|RhinoChill|Nasopharyngeal cooling with the RhinoChill device
40781769|NCT01573117|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
40781770|NCT05874089|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® 450 billions/sachets
40781771|NCT05874089|DIETARY_SUPPLEMENT|Placebo|Placebo sachets with maltose, cornstarch and dioxide
40781772|NCT03731403|OTHER|MI varnish|CPP- ACP with 5 % sodium fluoride GC
40781773|NCT03130686|DEVICE|OMRON blood pressure monitor HEM-9210T|To measure systolic blood pressure, diastolic blood pressure and pulse rate in patients.
40781774|NCT03206372|OTHER|Case group|Questionnaire to be completed, blood sample and possibly echo-doppler
40781775|NCT03206372|OTHER|Control group|Questionnaire to be completed, blood sample and possibly echo-doppler
40986088|NCT00002233|DRUG|Abacavir sulfate|
40986089|NCT00002233|DRUG|Amprenavir|
40986090|NCT00002233|DRUG|Lamivudine|
40986091|NCT04179695|OTHER|Consulting with PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months
40986092|NCT04179695|OTHER|Consulting without PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
40986093|NCT02208947|BEHAVIORAL|Consumer financial incentive|Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
40986094|NCT02208947|BEHAVIORAL|PREPARE|"PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library)."
40986095|NCT00485407|DRUG|Atomoxetine Hydrochloride|
41305312|NCT00638326|DRUG|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
41305313|NCT05183048|DRUG|[89Zr]Panitumumab Tracer|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
40781776|NCT00959907|DRUG|BOTULINUM TOXIN TYPE-A|"On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~* Dysport®: 4 units will be injected in the left or right forehead side.~* Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)"
40781777|NCT04316416|PROCEDURE|T7 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T7 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T7 spinous process.~After imaging of erector spina musceles and transvers process of 7 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
40986096|NCT04436185|BEHAVIORAL|Comparisons of procedural pain|This randomized experimental study with placebo and control groups
40781778|NCT04316416|PROCEDURE|T9 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T9 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T9 spinous process.~After imaging of erector spina musceles and transvers process of 9 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
40781779|NCT04316416|DRUG|control group|24 hours morphine consumption will be recorded using the patient controlled analgesia device with intravenous morphine.
40781780|NCT01171677|BEHAVIORAL|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
40781781|NCT02917005|DRUG|Palbociclib|CDK 4/6 inhibitor
40781782|NCT02917005|DRUG|Exemestane|Aromatase inhibitor
40781783|NCT02917005|DRUG|Goserelin|LHRH agonist
40781784|NCT01904721|DRUG|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
40781785|NCT01904721|DRUG|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
40781786|NCT01904721|DRUG|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
40781787|NCT01881789|DRUG|Oprozomib|Extended release (ER) tablets administered orally
40781788|NCT01881789|DRUG|Lenalidomide|Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.
40781789|NCT01881789|DRUG|Dexamethasone|Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.
40781790|NCT01881789|DRUG|Cyclophosphamide|Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
40781791|NCT04582591|DRUG|Cannabidiol 100 MG/ML|Patients receive cannabidiol before and after treatment with chemotherapy
40986097|NCT03512314|DRUG|Tadekinig alfa|Open label, 26 weeks on Tadekinig alfa treatment.
40986098|NCT02950454|OTHER|High intensity interval training|1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
40986099|NCT02950454|OTHER|Continuous moderate exercise|20 min at 60-70% heart rate max on cycle ergometer
40986100|NCT01859754|BIOLOGICAL|Octagam 5%|Intravenous immunoglobulin 5%
40986101|NCT01859754|BIOLOGICAL|Other marketed IVIG product|Any intravenous immunoglobulin marketed product approved for the treatment of PID
40986102|NCT01994629|BIOLOGICAL|MenACWY-CRM|MenACWY-CRM
40986103|NCT01994629|BIOLOGICAL|MenACWY-TT|MenACWY-TT
40986104|NCT04723381|OTHER|web based education|Expert support and consultancy were received for the design and preparation of the web page.
41305314|NCT01834924|OTHER|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
40986105|NCT04490720|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
40986106|NCT04490720|DIETARY_SUPPLEMENT|Buckwheat husk extract|consume 1 sachet per day for 2 months
40986107|NCT02598427|DRUG|Pertuzumab|Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
40986108|NCT02598427|DRUG|Trastuzumab|Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
40986109|NCT02310945|OTHER|Physiotherapy|Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
40986110|NCT04723940|DRUG|Bactrim|Bactrim will be given for 6 weeks to treat joint infection
40986111|NCT04723940|DRUG|Cefadroxil|Cefadroxil will be given for 6 weeks to treat joint infection
40781792|NCT04170920|DEVICE|LifeExtend-AI|"LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
40781793|NCT01010607|DEVICE|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
40781794|NCT01010607|DEVICE|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
40781795|NCT01010607|DEVICE|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
40781796|NCT01381770|BIOLOGICAL|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
40781797|NCT03493646|DRUG|Azacitidine|75mg/m2 per day for 7 days of each 28 day cycle. Cycles 1-6
40781798|NCT03493646|DRUG|CC-486|100 mg BID for the first 21 days of each 28-day treatment cycle (cycles 7-8). The dose should be increased from cycle 9 onwards to 150mg BID for the first 21 days of each 28-day treatment cycle (cycles 9-12) in the absence of Grade 3 or 4 AE. If 2 or more cycles are tolerated at this dose, further increments are permitted for patients with Stable Disease or if clinically indicated in consultation with the coordinating investigator as per the study dose modification schedule.
40781799|NCT06488664|BIOLOGICAL|GNR-068|GNR-068 was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 52.
40781800|NCT06488664|BIOLOGICAL|Stelara®|Stelara® was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg until week 52.
40781801|NCT03376516|DRUG|Wilate|von Willebrand factor / Factor VIII (plasma derived)
40781802|NCT00481936|DRUG|VB6-845|Intravenous infusion once weekly for 4 weeks
40781803|NCT03262961|DRUG|Sildenafil 20 MG|
40781804|NCT03262961|DRUG|Placebo Oral Tablet|
40781805|NCT06274658|BEHAVIORAL|High-intensity interval exercise|Three high-intensity exercise bouts, each at 100% of maximal power output for 20 seconds, interspersed with active recovery periods of 120 seconds at 10% of maximal power output.
40781806|NCT02253043|DEVICE|Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)|PINS Stimulator System
40781807|NCT04244734|OTHER|Usual care treatment|"All evaluations are the same in both groups:~Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
41305315|NCT04430049|PROCEDURE|Covid ICU containment measures|The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU
40986112|NCT04723940|DRUG|Doxycycline Hcl|Doxycycline HCl will given for 6 weeks to treat joint infection
40986113|NCT04723940|DRUG|Clindamycin|Clindamycin will given for 6 weeks to treat joint infection
40986114|NCT02296385|DIETARY_SUPPLEMENT|Triple Strength Fish Oil|Triple Strength Fish Oil
40986115|NCT05946850|PROCEDURE|Caudal analgesia|Caudal analgesia for chronic lumbosacral pain
40986116|NCT02662946|PROCEDURE|ICG- angiography|Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results
40986117|NCT02662946|PROCEDURE|No angiography|Extension of resection based on subjective measures
40986118|NCT03752112|DRUG|Cefixime|Cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection
41305316|NCT00002057|DRUG|Nystatin|
41144726|NCT02499497|DRUG|LY2452473|LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
41144727|NCT02499497|DRUG|Placebo|The participants will receive pills containing no active drug.
40986119|NCT03752112|DRUG|Benzathine penicillin 2.4 million units|Benzathine penicillin 2.4 million units: The investigators will include a contemporary arm of participants that will receive standard of care treatment with Benzathine penicillin 2.4 million units according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.This non-comparator arm of benzathine penicillin will be included to account for study population differences in terms of stage of disease, history of prior infection, experience of re-infection, experience of serofast state, or other co-factors that could impact serological response
40986120|NCT01918904|DRUG|Sodium thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
40986121|NCT01918904|DRUG|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
40986122|NCT03663725|DRUG|Intensified protocol|Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
40986123|NCT03663725|DRUG|Stupp protocol|RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
40986124|NCT05028439|DEVICE|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture. Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
40986125|NCT05028439|DRUG|Chemotherapy drug|Gemcitabine 1 000 mg/m2 intravenously on day 1，8; S-1 80 mg/m2 was taken orally twice for two weeks. The curative effect was evaluated comprehensively for each 2 cycles of chemotherapy
40986126|NCT00308503|DRUG|eplivanserin (SR46349)|oral administration
40986127|NCT00308503|DRUG|placebo|oral administration
40986128|NCT04750720|OTHER|Sampling by venipuncture (and eventually by nasopharyngeal swab)|"Biological samples :~* Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test~* PBMC (peripheral blood mononuclear cells)~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to SARS-CoV-2 infection~* Notion of hospitalization/ambulatory follow-up~Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)~* Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells"
40986129|NCT03444714|DRUG|RiMO-301|"Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection~Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks"
40986130|NCT03284996|DEVICE|Doppler ultrasonography|Examination of the whole cases \& controls by doppler ultrasound to measure renal resistive index.
40986131|NCT02069990|DRUG|Cholecalciferol|
41144728|NCT05511389|OTHER|Anterolateral electrode position|As described previously
41305317|NCT05740436|OTHER|Geriatric rehabilitation program based on CGA|Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.
40986132|NCT05300906|BEHAVIORAL|personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the personalized condition will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
41144729|NCT05511389|OTHER|Anteroposterior electrode position|As described previously
41144730|NCT05511389|OTHER|Manual pressure|Manual pressure applied to the anterior electrode
41144731|NCT04851288|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a biochemically modified form of ubiquinol
41144732|NCT04851288|DIETARY_SUPPLEMENT|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
41144733|NCT06299345|OTHER|Motor imagery training|MI for this study took the form of non-guided first-person mental practice. First-person imagery was explained to each participant where they imagined performing the target skill through their own eyes rather than if they were a bystander watching someone else do the task (third person).
41144734|NCT06299345|OTHER|NO motor imagery training|The participants performed the physical task only. It is a mirror tracing game that requires participants to trace a star shape viewed through a mirror, going as fast as possible while staying within the lines.
41147041|NCT06381297|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Scale|Translated into Turkish as the Montreal Cognitive Assessment Scale and abbreviated as MOBID, MOCA assesses attention, executive/managerial functions, memory, visual-spatial skills, language, abstract thinking and arithmetic. It is easy and practical to apply. The score that can be obtained varies between 0-30. The cut-off point for cognitive impairment is 21. Patients who perform below 21 points are considered to have cognitive impairment. Although it is not a battery used in the MS patient group, a study conducted on 39 MS patients and 20 healthy people showed that it can be used safely for screening purposes in patients with MS (Aksoy et al., 2013; Nasreddine et al., 2005; Selekler \& Cangoz, 2009).
41305318|NCT00002533|DRUG|fluconazole|
40986133|NCT05300906|BEHAVIORAL|non-personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the non-personalized condition will receive a random version of the intervention.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
40781808|NCT04244734|OTHER|New Treatment Protocol-MotoMED®|"Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
40781809|NCT03622047|DRUG|Dexmedetomidine ropivacaine|Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
40781810|NCT03622047|DRUG|No analgesia labor|No analgesia labor control group
40781811|NCT05124730|DRUG|Metformin 500mg prolonged release tablets (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
40986134|NCT00956904|DEVICE|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
40986135|NCT02450110|DEVICE|Spinal cord stimulation|
40781812|NCT05124730|DRUG|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of Reference (R) Product was administered orally with 240 mL of water.
40781813|NCT01651468|DIETARY_SUPPLEMENT|HEMOFIX|unique complex herbal mixture
40781814|NCT02055846|PROCEDURE|Realisation of blood sample, urinary sample and tumor biopsy|
40781815|NCT05544487|PROCEDURE|Colorectal Anastomosis|Differences in intra-operative techniques and surgeon grades
40781816|NCT04804124|BEHAVIORAL|Regularized Sleep Schedule|Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
40781817|NCT00716274|DRUG|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
40781818|NCT00716274|DRUG|Placebo|oral, daily, for 16 weeks
41305319|NCT00002533|RADIATION|radiation therapy|
40986136|NCT00438087|DRUG|methylprednisolone|methylprednisolone administrated intra and post operatively
41144735|NCT03615547|DRUG|Clomifene Citrate|"After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day."
41144736|NCT03615547|OTHER|Placebo|The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
41305320|NCT04331873|DIAGNOSTIC_TEST|Ultrasound|An ultrasound will be obtained prior to obtaining the standard contrast injection to determine if this imaging modality is equivocal.
41305321|NCT01528800|DRUG|Vitamin K1|10mg orally three times a week for 12 months
40986137|NCT06005922|OTHER|physiotherapy|ultrasound hotpack electrotherapy joint range of motion exercises isometric neck exercises stretching exercises
41305322|NCT01528800|DRUG|Microcrystalline Methylcellulose|10mg orally three times a week for 12 months
40781819|NCT04858399|DIAGNOSTIC_TEST|Evaluation|To examine the differences in respiratory functions, orofacial muscle tone changes, anxiety/ depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
40986138|NCT06005922|OTHER|TMJ exercises|tongue relaxation position TMJ isometric strengthening exercises Posture exercises Isometric neck extension in neutral position back extension Strengthening the abdominal muscles Supine dorsal stretch pectoral stretch
40986139|NCT03531307|OTHER|Data correlation|Correlation between lactate levels and Ki-67 index
40986140|NCT03191760|BEHAVIORAL|Behavioral Activation|Participants will be asked to attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, to be held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills.
40986141|NCT03204305|DRUG|11C-OMAR|11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.
40986142|NCT03204305|DRUG|Cannabis|Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
40986143|NCT03896555|DEVICE|ExacTrac position verification|Repeated measurement of patient head position with ExacTrac X-ray Monitoring
40986144|NCT03514784|DRUG|BB-12 with LGG (Higher Dose)|BB-12 with LGG - Higher Dose (10 billion CFUs)
40986145|NCT03514784|DRUG|Placebo|Maltodextrin
40986146|NCT03514784|DRUG|BB-12 with LGG (Lower Dose)|BB-12 with LGG - Lower Dose (1 billion CFUs)
40986147|NCT02632539|PROCEDURE|Manual air-impingement operation|A method which we invented to clear subglottic secretion
40986148|NCT02632539|PROCEDURE|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
41144737|NCT04017598|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg elemental iron as ferrous sulfate
41144738|NCT04017598|DIETARY_SUPPLEMENT|Ferrous Bisglycinate|18 mg elemental iron as ferrous bisglycinate
41305323|NCT04804722|DEVICE|18F-FDG PET-CT (fluorodesoxyglucose positron emission tomography)|18F-FDG PET-CT exams during 30 minutes with injection of radiopharmaceutical product
41305324|NCT01104584|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
41305325|NCT03734081|DEVICE|ODC system (type 1 capsule)|ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
41464094|NCT05196815|OTHER|Ultrasound|Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan
40781820|NCT00361712|PROCEDURE|Preemptive epidural analgesia|Parturients will receive early epidural analgesia before onset of painful contractions as oppose to standard of care in which parturients receive epidural analgesia with onset of painful contractions.
40986149|NCT05204654|OTHER|In-office fabricated appliance|A 0.022 Slot MBT™ second molar mini tube that has been modified to have a 2 mm length will be placed on the maxillary first molar and a 0.018 slot MBT™ maxillary canine bracket will be placed on the maxillary canine, with a 0.016x0.022 stainless-steel wire spanning from the maxillary first molar to the maxillary canine. A bayonet bend will be placed mesial to the molar tube. A curve will be bent into the wire, so that the wire is able to passively rest on the buccal surface of the maxillary canine. A stainless-steel closed coil will span the molar to canine and lay flush to the mesial portion of the molar tube and the distal portion of the canine bracket. The wire will be cinched mesial to the maxillary canine tie-wing and also 2-3 mm distal to the maxillary first molar to ensure that the molar can rotate during treatment, if needed. A stainless-steel tie will be used to secure the wire into the canine bracket. AP correction will be completed following CMA protocol
41305326|NCT03734081|DEVICE|ODC system (type 2 capsule)|ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
40986150|NCT05204654|DEVICE|Carriere Motion Appliance|A bar spanning from the maxillary first molar to canine with a ball and socket joint at the molar and a canine pad at the canine. A slight bend is present between the molar and canine bracket. The ball and socket is designed to allow the molar to rotate to -15 degrees along it's longitudinal axis. The appliance claims that it allows for Class II correction with minimal secondary tooth movements when used with mandibular anchorage.
40986151|NCT03689803|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy.
40986152|NCT03689803|PROCEDURE|gastric bypass|gastric bypass
40986153|NCT00280956|DRUG|natalizumab|
40986154|NCT01873001|DRUG|Pioglitazone HCl|15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration
40986155|NCT01873001|DRUG|Abiraterone acetate|1000 mg tablets administered by mouth on Day 8
40986156|NCT03407768|BEHAVIORAL|Individualized interventions|"A participant will be able to select one or more (or no intervention) based on her preferences.~Individualized exercise program Yoga and mindfulness Massage therapy Acupuncture Others: Women who are not interested in any above intervention but like to explore other interventions will be offered material pertinent to their choice of complimentary techniques."
40986157|NCT02133027|PROCEDURE|Rouviere's sulcus|Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
40986158|NCT02133027|DEVICE|surgical instruments|surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
40986159|NCT01909154|BIOLOGICAL|Mesenchymal stromal cell therapy|Stem cells administration locally
41305327|NCT04870554|BEHAVIORAL|Enteric feeding|All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.
41305328|NCT01810042|DRUG|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
40781821|NCT00361712|DRUG|Standard of care|Epidural analgesia with parturients with cervical dilatation and painful labor (VAS \>5)
40986160|NCT00378274|BEHAVIORAL|Observation|
40986161|NCT01457066|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
40986162|NCT01219920|DRUG|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
40986163|NCT01219920|DRUG|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
40986164|NCT03009565|OTHER|coronary artery disease|
40986165|NCT05581537|OTHER|Systematic Desensitization|"Systematic desensitization: 2 techniques~1. Jacobson's technique (progressive muscle relaxation):~   It involves tensing and releasing muscles that progress through the body throughout focusing on mental relaxation throughout releasing muscle tension~2. Guided imagery (vividly imagining):~It includes 2 types of imagery training/mental practice (MP) which includes visual imagery is based on the sensory (visual) perception of the imagined movement and Kinesthetic imagery is based on sensory-motor information (proprioceptive). MP will be conducted in a quiet room, where each patient will be given detailed instructions to perform both visual and kinesthetic practice"
40986166|NCT01558752|DEVICE|Total hip replacement with titanium shell and CORAIL stem|Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).
40986167|NCT01558752|DEVICE|Total hip replacement with Modular Titanium Femoral Stem|Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).
40986168|NCT00608231|DRUG|Dexmedetomidine Hydrochloride Infusion|Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
40986169|NCT00608231|DRUG|Normal Saline|Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
40986170|NCT01066754|DRUG|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
40986171|NCT01912846|BEHAVIORAL|Interactive advance care planning|"The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.~Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.~Facilitating EOL care discussions throughout the dying process.~A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP."
40986172|NCT01912846|BEHAVIORAL|Attention usual care|a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..
41144739|NCT04017598|DIETARY_SUPPLEMENT|Placebo of microcrystalline cellulose|placebo
41305329|NCT03572270|DIAGNOSTIC_TEST|AMH test|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
41305330|NCT03572270|DIAGNOSTIC_TEST|pelvic ultrasound|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
41305331|NCT04064320|BEHAVIORAL|Lullaby intervention|Listening to lullabies, and accompanied by lullabies touching their abdomen and think about their babies of hospitalized women with high-risk pregnancy
41464095|NCT05196815|PROCEDURE|Catheters|During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).
41464096|NCT05196815|PROCEDURE|Soft study wire|Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.
41464097|NCT05196815|RADIATION|X-ray|Participants will have chests x-ray when the soft study wire is inserted.
40781822|NCT01074931|DRUG|Lopinavir/ritonavir (Kaletra)|"Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study."
40986173|NCT04342845|BEHAVIORAL|Experimental: Motivational interviewing Placebo Comparator: Traditional lectures|Patients in the intervention group (n=117) received a four-session patient empowerment program in small groups over one month by trained nurses and doctors. he control group received traditional lectures that consisted solely of conveying healthcare information to patients.
40986174|NCT00001482|DRUG|Lamotrigine (Lamictal® (Registered Trademark)|
40986175|NCT00001482|DRUG|Gabapentin (Neurontin® (Registered Trademark))|
40986176|NCT02806310|OTHER|Blood draw|blood sampling for biomarker levels
40986177|NCT03793582|DIAGNOSTIC_TEST|ApneaLink Type III portable sleep study|Type III portable sleep study
40986178|NCT01879241|DRUG|Rasagiline|
40986179|NCT01879241|DRUG|Placebo|a sugar pill manufactured to mimic Rasagiline 1 mg tablet
40986180|NCT01980875|DRUG|Idelalisib|150 mg tablet administered orally twice daily
41305332|NCT00543829|DRUG|doxorubicin, docetaxel, tamoxifen|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
41305333|NCT00543829|DRUG|doxorubicin, docetaxel|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
40986181|NCT01980875|DRUG|Chlorambucil|2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
40781823|NCT04996329|OTHER|early health warning intervention|early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
40986182|NCT01980875|DRUG|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
40986183|NCT05874856|DIAGNOSTIC_TEST|Heart rate variability, blood pressure and pulse wave velocity|Resting HRV in supine and standing position, blood pressure and pulse wave velocity in supine position at first and last week of inpatient treatment
41305334|NCT05923489|DIAGNOSTIC_TEST|Routine Angiography Follow-up|Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.
41305335|NCT05923489|DIAGNOSTIC_TEST|Routine Clinical Follow-up|Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
40986184|NCT05874856|DIAGNOSTIC_TEST|Assessment of cognitive function, balance, strength and cardiorespiratory fitness|"THINC-it test for cognitive function; One-leg Standing test for balance assessment; 10-time chair rise test and hand grip test for strength assessment; Åstrand-Ryhming Test for cardiorespiratory fitness.~All assessments will be performed at first and last week of inpatient treatment."
40986185|NCT05874856|BEHAVIORAL|Monitoring of physical activity and sleep|GENEActiv accelerometer will be worn on the wrist daily during 8-week inpatient treatment.
40986186|NCT05874856|BEHAVIORAL|Monitoring of self-rated exhaustion, mood and tension|Using the customized PsyMate app.
40986187|NCT03163550|DRUG|ACHN-383|Oral dose
41144740|NCT06461949|DRUG|Dupilumab|Dupilumab (Dupixent) is a human monoclonal antibody administered via subcutaneous injection to treat various conditions such as Chronic Rhinosinusitis with Nasal Polyps, Asthma and Eosinophilic Esophagitis.
40781824|NCT00144326|DRUG|Tiotropium Bromide|
40986188|NCT03163550|DRUG|ACHN-789|Oral dose
40986189|NCT03163550|DRUG|Placebo|Oral dose
40986190|NCT04751396|OTHER|Best Practice|Receive standard educational information
40986191|NCT04751396|OTHER|Educational Intervention|Navigate educational tool
40986192|NCT04751396|OTHER|Interview|Participate in interview
40986193|NCT04751396|OTHER|Questionnaire Administration|Complete questionnaire
40986194|NCT04751396|OTHER|Survey Administration|Complete surveys
40986195|NCT02653807|OTHER|mobilization with movement|manual therapy intervention
41144741|NCT04187378|DEVICE|Surgical Underbody Blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
41144742|NCT04187378|DEVICE|Surgical access blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
41144743|NCT03370094|DIAGNOSTIC_TEST|Audio-video-streaming of suspected stroke symptoms and signs|The diagnosis based on the patient evaluation by end-to-end encrypted real-time video will be compared to the gold standard, consisting of an in-person neurological examination by a stroke specialist in patients with suspected acute stroke.
41144744|NCT04759378|DIAGNOSTIC_TEST|Upper endoscopy, esophageal manometry, 24-hour pH monitoring|upper endoscopy determines if there are structural abnormalities in upper Git. esophageal manometry determines if there are motility disorders. 24-hour pH monitoring determines if acid reflux is present or not, and specifies its rate and duration.
41144745|NCT03849300|OTHER|Aquatic walking exercise program group 1|12 week aquatic walking exercise program
41144746|NCT03849300|OTHER|Aquatic walking exercise program group 2|12 week aquatic walking exercise program
41144747|NCT03849300|OTHER|Land-based walking exercise group|12 week land-based walking exercise program
41144748|NCT00383500|DEVICE|Flexitouch|A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
41144749|NCT00383500|DEVICE|Class 1 compression garment|Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
41144750|NCT00383994|DRUG|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
41144751|NCT00383994|DRUG|Rituximab|375 mg/m\^2 by vein followed by 1000 mg/m\^2 weekly for 3 weeks for a total of 4 doses.
41144752|NCT00383994|BIOLOGICAL|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
41144753|NCT01554332|DEVICE|Motor Cortex Stimulation using SJM EonC Stimulator|Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
41144754|NCT02491645|OTHER|Sensory interventions|"1. Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.~2. Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.~3. Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.~4. Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.~5. Auditory stimulation : Sound familiarisation and music time will be done."
41144755|NCT01794351|DIETARY_SUPPLEMENT|Trans-resveratrol|In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
41144756|NCT01794351|OTHER|Placebo|In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
41305336|NCT01542476|DRUG|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
40781825|NCT00144326|DRUG|Placebo|
40781826|NCT00371371|PROCEDURE|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
40781827|NCT00371371|PROCEDURE|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
40781828|NCT00371371|PROCEDURE|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
40781829|NCT01599884|DRUG|N-acetylcysteine|1800 mg twice daily for 8 weeks
40781830|NCT01599884|DRUG|Oral acetylcysteine|Identical placebo pills twice daily for 8 weeks
40781831|NCT03343561|BEHAVIORAL|Nutrition Advice|Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.
40781832|NCT01286597|DIETARY_SUPPLEMENT|dietary restriction|restrict intake of lactose
41144757|NCT02790645|OTHER|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
41144758|NCT02790645|OTHER|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
41144759|NCT02790645|OTHER|Group 1b.Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
41144760|NCT02790645|OTHER|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .
41305337|NCT05241015|OTHER|Control Group|Treatment protocol; It will be applied to improve posture, strengthen muscles, eliminate shortness, increase flexibility, balance/coordination, sit up/stand up and in-bed mobilization, and improve gait. Before taking the treatment, a general evaluation will be made and as a result of this evaluation, muscle shortness, loss of strength, postural disorders and the activities and positions they have the most difficulty in daily life will be determined. Treatment programs will be shaped according to the problems determined in line with the evaluations made.
40781833|NCT05544084|BEHAVIORAL|Patient Navigator Approach|Patient navigators in collaboration with community health workers will work with women eligible for cervical cancer screening to overcome intrapersonal and community level barriers to screening in order to engage early with the health system for cervical cancer screening and follow-up of positive screens. Their support can help patients get the cancer screenings and follow-up care they need, while addressing prevalent gender inequities and community-level stigma associated with cancer within the Senegal context.
40781834|NCT02114177|DRUG|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
41144761|NCT04023266|DRUG|Intravenous N-Acetylcysteine|Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
41144762|NCT01174472|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of the novel paclitaxel eluting balloons
41144763|NCT01174472|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of conventional angioplasty balloons
40986196|NCT02653807|OTHER|osteopathic mobilization|manual therapy intervention
40986197|NCT03325075|BIOLOGICAL|VAL-181388|Escalating dose levels
40986198|NCT03325075|OTHER|Placebo|Saline
40986199|NCT02692599|BIOLOGICAL|investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
40986200|NCT02692599|BIOLOGICAL|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
40986201|NCT04831203|DIETARY_SUPPLEMENT|An egg-protein hydrolysate (NWT-03)|As described in the experimental arm
40986202|NCT04831203|DIETARY_SUPPLEMENT|Placebo|As described in the Control arm
40986203|NCT05542264|DRUG|SEP-363856|SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.
40986204|NCT05542264|DRUG|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
40986205|NCT01479153|PROCEDURE|Randomization of the site for catheterization|Ultra-sound guided insertion strongly recommended
40986206|NCT05745558|BEHAVIORAL|Prehabilitation|"The prehabilitation program consists of 4 components:~1. Fitness training led by a physiotherapist. The patients will receive personalized training schedules to perform at home. The training sessions focus on improving aerobic fitness (biking or walking) and muscle strength (specific exercises for the different patient groups) and respiratory exercises aimed to relax.~2. Nutritional counseling led by a dietician. All patients will be offered an intake with a dietician (60 min) to discuss current eating habits and give personalized advices. Based on indication, patients will receive follow-up consults.~3. Smoking cessation counseling led by a trained social worker. For patients that are currently smoking, a social worker will offer counseling sessions to coach the patient in the process of smoking cessation.~4. Psychosocial counseling led by a psychologist. All patients will be offered counselling by a psychologist."
40986207|NCT02276729|OTHER|Mirror Box Therapy|Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
40986208|NCT01541774|DEVICE|Phoenix Atherectomy System|Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
40986209|NCT00695396|DRUG|Placebo|Matching volume 2 mLfor 48 weeks
40986210|NCT00695396|DRUG|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
40986211|NCT00695396|DRUG|Placebo|Matching volume 1 mL for 48 weeks
40986212|NCT00695396|DRUG|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
40986213|NCT02771158|DRUG|Midodrine|midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
40986214|NCT02771158|DRUG|placebo|placebo will be administered to double blind the study
40986215|NCT02850393|OTHER|Functional magnetic resonance imaging|
40986216|NCT02850393|BEHAVIORAL|behavioral measures|
40986217|NCT02850393|OTHER|physiological measurements|
40986218|NCT03849833|DIETARY_SUPPLEMENT|cholecalciferol, Vitamin D3|Vitamin D3 as dietary supplement
41144764|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
40781835|NCT02114177|DRUG|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
40781836|NCT02114177|DRUG|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
40781837|NCT02114177|DRUG|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
40781838|NCT03100266|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamonosus GG
40781839|NCT03100266|OTHER|Inactive capsules|Placebo
40781840|NCT04920318|COMBINATION_PRODUCT|tDCS + language therapy|In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
40781841|NCT04920318|COMBINATION_PRODUCT|sham TDCS + language therapy|sham control will be applied with language therapy to the same regions as active TDCS.
40781842|NCT04232852|DIETARY_SUPPLEMENT|Probiotic mix|The probiotic mix will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule.
40781843|NCT04232852|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive an identical capsule of maltodextrin.
40781844|NCT02098135|DEVICE|ArmeoSenso|Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
40781845|NCT01846026|DRUG|Vitamin D|compare how vitamin D influences the course of ulcerative colitis versus placebo
40781846|NCT01846026|DRUG|placebo|
40781847|NCT05786287|BIOLOGICAL|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
40781848|NCT05786287|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
40781849|NCT02125955|DIETARY_SUPPLEMENT|Prebiotic fiber|Dissolved in water.
40781850|NCT02125955|DIETARY_SUPPLEMENT|Placebo|Dissolved in water
40781851|NCT01306747|BEHAVIORAL|The Stanford Chronic Pain Self-Management Programme|The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
40781852|NCT01370148|DRUG|conivaptan hydrochloride|Intravenous
40781853|NCT04327440|BIOLOGICAL|RTS,S/AS01 malaria vaccine|Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.
40781854|NCT04327440|OTHER|PBO bed nets|PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
40781855|NCT05503329|DIAGNOSTIC_TEST|arterial lactate level|an arterial lactate level measured from arterial sample from STEMI patients
40781856|NCT00658268|DRUG|Clodronate|60 mg/ml, 10 ml, single dose mixed in bone graft at operation
40781857|NCT00658268|DRUG|Placebo|10 ml, single dose mixed in bone graft at operation
40781858|NCT03768427|COMBINATION_PRODUCT|EZ 10 mg/Ator 10 mg|FDC of EZ10 mg/Ator 10mg
40986219|NCT05492331|OTHER|Music Therapy|Patient preferred artist or music genre to be playing from an iPad
40986220|NCT01755884|DIETARY_SUPPLEMENT|Wheat oral immunotherapy|Cooked spaghetti
40986221|NCT03946033|DIAGNOSTIC_TEST|Immunoscore Colon Test|Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.
41144765|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
40781859|NCT03768427|COMBINATION_PRODUCT|EZ 10 mg/Ator 20 mg|FDC of EZ10 mg/Ator 20mg
40781860|NCT03768427|DRUG|Atorvastatin|Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
40781861|NCT03768427|DRUG|Placebo for FDC EZ/Ator|A single placebo tablet administered orally QD for 84 days
40781862|NCT03768427|DRUG|Placebo for atorvastatin|Two placebo tablets matching atorvastatin administered orally QD for 84 days
40781863|NCT03481348|DEVICE|Pharyngeal Electrical Stimulation|Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.
41144766|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
41464098|NCT05196815|DRUG|Dobutamine|Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
41464099|NCT00152906|PROCEDURE|Stereotactic radiotherapy (SRT) or highly conformal (CRT)|SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
41464100|NCT03662724|DRUG|Venetoclax|Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
41464101|NCT01203917|DRUG|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
41464102|NCT04649697|DRUG|Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer.
41464103|NCT04649697|DRUG|Nanoparticulated Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer will be used in nanotechnology.
40781864|NCT01758029|DRUG|testosterone undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
40781865|NCT00984503|DRUG|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
40781866|NCT00984503|DRUG|Placebo|Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
41464104|NCT04649697|DRUG|Clobetasol Propionate|A corticosteroid drug used as a gold standard for treatment of methotrexate induced oral ulceration.
41464105|NCT01463709|DEVICE|PulseCure pulse generator and Derm-pulse electrode|"PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.~NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure"
41464106|NCT01487434|BEHAVIORAL|Check & Connect|Structured mentoring and case management
40781867|NCT00984503|DRUG|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
40781868|NCT00984503|DRUG|Placebo|Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
41464107|NCT03241316|BEHAVIORAL|Observational study of behaviour|As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
40986222|NCT01669733|OTHER|Music|Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
40986223|NCT01669733|OTHER|Standard of Care|The control group subjects will receive standard anesthesia, nursing and surgical care.
40986224|NCT05252000|DEVICE|mechanical debridement|subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque
40986225|NCT05252000|DEVICE|adjunctive aPDT|Antimicrobial photodynamic therapy will be done at tooth sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. After 3 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the tooth using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
40986226|NCT05252000|DEVICE|sham aPDT|subjects will receive saline and non-light emitting laser on the tooth
40986227|NCT05925023|DRUG|Sirolimus|Oral administration, 1-3 mg/d, sirolimus plasma concentration: 4-15 ng/mL
41464108|NCT01947686|DEVICE|Robotically guided patellofemoral UKA isolated patellofemoral implants|A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
40781869|NCT02328872|DEVICE|Molecular testing for HPV|Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
41464109|NCT02427399|OTHER|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
41464110|NCT02427399|OTHER|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
41464111|NCT02427399|OTHER|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
41464112|NCT02427399|OTHER|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
41464113|NCT00930033|PROCEDURE|Nephrectomy|Current surgery
41464114|NCT00930033|OTHER|Sunitinib alone|Sunitinib alone without nephrectomy
41464115|NCT03566407|PROCEDURE|Colonoscopy|Colonoscopy will be required for all subjects at 6 months - Visit 3.
41305338|NCT05241015|OTHER|Exercises Group|In addition to the standard physiotherapy program, sensorimotor training including the cervical region will be given to the this group. Deep cervical flexor and extensor muscles, which provide stability in the cervical region, will be trained. A Pressure Biofeedback Device will be used to train the deep cervical flexors. Both positional and kinesthetic sensory training will be provided by maintaining the stability of the cervical region by means of the laser kit that provides visual feedback.Additionally, oculomotor exercises will be given.
40986228|NCT05538754|DEVICE|EVO ICL|The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
40986229|NCT01394679|DRUG|(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)|One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
40986230|NCT01394679|DRUG|18 F FDG followed by PET/CT imaging|Single injection of 18 F FDG range of 10-20 mCi
40986231|NCT06018259|PROCEDURE|healthy volunteers blood sampling|One blood sample will be taken from healthy volunteers in order to isolate PBMC and to assess the effect of the lipid of interest on them PBMC will be activated in vitro (e.g. using LPS or PHA) in the presence or absence of the lipid of interest.
40986232|NCT01682902|DRUG|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
40986233|NCT01682902|DRUG|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
40986234|NCT01682902|DRUG|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
40986235|NCT05087147|DEVICE|0.7 mm stainless steel orthodontic wire|0.7 mm stainless steel orthodontic wire
40986236|NCT05087147|DEVICE|Banded space maintainer|band and loop space maintainer
40986237|NCT00937872|DRUG|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
40986238|NCT00937872|DRUG|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
40986239|NCT05982509|DEVICE|EasyDew Regen MD Cream|For the study group, I received the prescription Easy Dew Regen MD Cream from Picosure Laser Apply an appropriate amount twice a day (morning and evening) to the skin of the area so that it can be absorbed well do. The control group is the non-chalant group. However, for one month after the procedure, it is not a medical device The normal moisturizer you use at home is available, and the area where you have undergone laser treatment Apply it twice a day (morning and evening) to the skin so that it can be absorbed well.
40986240|NCT04101903|DIAGNOSTIC_TEST|The 6-week Hip Checklist|Comprehensive 9-item structured guide to aid in correct diagnosis of developmental dysplasia of the hip.
40986241|NCT05643768|BEHAVIORAL|Inspiratory muscle strength training (IMST)|30 breaths/day, 5 days/week, 6 weeks
40986242|NCT05487495|BIOLOGICAL|CD5 CAR T (CT125B)|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
40986243|NCT01396460|OTHER|breakfast (a chicken sandwich with juice)|patients received a breakfast after de initial measurement
41144767|NCT00674609|DRUG|Placebo|Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
41305339|NCT00137852|DRUG|Cisplatin|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
41305340|NCT00137852|DRUG|Irinotecan|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
41305341|NCT00137852|DRUG|Celecoxib|Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
41464116|NCT02075840|DRUG|Alectinib|Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
40986244|NCT01349790|DRUG|NewGam|NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
40986245|NCT02808026|DRUG|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast
40986246|NCT04039412|DRUG|Hybrid regimen|two-step (dual-quadruple) treatment
40986247|NCT04039412|DRUG|Reverse hybrid regimen|one-step two-phase (quadruple-dual) treatment
40986248|NCT04039412|DRUG|Levofloxacin quadruple regimen|non-Clarithromycin non-Bismuth quadruple therapy
40986249|NCT00372931|DRUG|AL-37807|
40986250|NCT00006903|DRUG|Fulvestrant|Given intramuscularly
40986251|NCT05851950|OTHER|group rumination focused cognitive behavioural therapy|Psychotherapy
40986252|NCT05851950|OTHER|Treatment as usual|opus treatment
40986253|NCT05673044|PROCEDURE|modified Studer ileal neobladder|orthotopic ileal neobladders
40986254|NCT01496547|DRUG|intensive chemo - RIC preparation|The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
40986255|NCT03573479|OTHER|PICU Liber8 Bundle|Bundle of elements for quality improvement
40986256|NCT02689401|DRUG|Ferumoxytol|
41305342|NCT00137852|PROCEDURE|Radiation Therapy|5 days a week for 5-6 weeks
41305343|NCT00137852|PROCEDURE|Esophagectomy|Within 4-8 weeks of chemoradiation therapy
41305344|NCT06255470|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment involves the removal of microbial dental plaque and calculus by mechanical debridement using manual and ultrasonic instruments. Motivating and educating patients about oral hygiene procedures is another important part of the treatment. The aim is to stop the progression of the disease and to prevent the occurrence of active clinical inflammation.
41464117|NCT02075840|DRUG|Crizotinib|Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
41464118|NCT01669824|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
40781870|NCT02328872|DEVICE|Liquid Based Cytology|The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
41305345|NCT03554005|DRUG|PEG Interferon Alfa-2b|Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
41305346|NCT03554005|DRUG|Acetaminophen|Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
41305347|NCT04939077|BIOLOGICAL|Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|In CABG with hUC-MSC treatment group, 1×10\^7 Human Umbilical Cord Mesenchymal Stem Cells were injected at the edge of the myocardial infarction area at 20 points at the same time in CABG
40986257|NCT02689401|DEVICE|MRI 3T scanner|
40986258|NCT04758819|PROCEDURE|Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB)|In vitro Fertilization by ICSI then embryo culture until Day 5/6; all blastocysts with morphological scores compatible with TE biopsy and vitrification will be submitted to Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB) and vitrified.
40986259|NCT00276159|DRUG|852A|Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
40986260|NCT00422591|DRUG|Cytarabine|1.5 g/m2 IV over 24 hours daily on day 1-4 (age \<60 years) or days 1-3 (age \> 60 years).
40986261|NCT00422591|DRUG|Idarubicin|12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
41305348|NCT06016608|DIAGNOSTIC_TEST|Magnetic Resonance Angiography, Ocular OCTA, CT Angiography|Magnetic Resonance Angiography of intracranial artery, carotid artery, renal artery and lower extremity artery, CT angiography of coronary artery or intracranial artery
41464119|NCT03799822|DRUG|Rivaroxaban 10 MG Oral Tablet|replacement of warfarin by rivaroxaban
41464120|NCT03799822|DIETARY_SUPPLEMENT|MK-7 2000µg thrice weekly|dietary supplement of vitamin K2 MK-7 2000µg thrice weekly
40781871|NCT05619393|DEVICE|Mobilie Bi-planar X-ray Imaging system|on the Mobilie Bi-planar X-ray Imaging system, images are acquired for three movements: walking, downhill walking, and squat
40781872|NCT01767896|BIOLOGICAL|ASP7374|subcutaneous (sc)
41464121|NCT03799822|DRUG|Vitamin K Antagonist - Drug|treatment with a vitamin K antagonist
41464122|NCT04747132|OTHER|Telegeriatric intervention|Individualized, comprehensive and specialized counseling for older adults through the Internet
41464123|NCT04282655|OTHER|Treatment Guardian Milk Warmer (Medela TM)|Infants were randomized to receive prepared syringes of breast milk via the continuous milk warmer (treatment arm)
41464124|NCT04282655|OTHER|Control|Standard warming procedure of breast milk in syringe prior to feeding.
41464125|NCT00709514|DRUG|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
41464126|NCT00709514|DRUG|Placebo|Placebo
40781873|NCT01767896|BIOLOGICAL|approved egg-derived TIV|subcutaneous (sc)
40986262|NCT05044754|PROCEDURE|Local treatment of the prostate (SCAP or HIFU)|Once the local involvement of the recurrent prostate cancer is confirmed, patient will undergo local treatment of the prostate (SCAP or HIFU)
40986263|NCT05576493|PROCEDURE|phaco+MP-TSCPC|The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.
40986264|NCT05576493|PROCEDURE|phaco+TSCPC|The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.
40986265|NCT05576493|PROCEDURE|phaco+endocyclophotocoagulation|phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction
41305349|NCT02349334|DEVICE|Percutaneous Tibial Nerve Stimulation|
41305350|NCT05822908|DRUG|VO659|VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
41305351|NCT05128253|OTHER|High fat meal in a subset of patients with NAFL or NASH|In a subset of NAFL (n=11) and NASH (n=11) patients venous blood samples will also be taken 2 (T0+2h), 4 (T0+4h) and 6 (T0+6h) hours after consumption of a high fat meal.
41305352|NCT05596968|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
41305353|NCT02795351|DRUG|Sildenafil|Single oral administration of active or placebo one week apart
41305354|NCT02795351|DRUG|Placebo|
41305355|NCT06420765|DRUG|VX-150|Suspension for oral administration.
41464127|NCT03490409|DEVICE|Thigh compression stocking|Thigh compression stocking
41144768|NCT00674609|DRUG|Sativex®|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
41305356|NCT06420765|DRUG|VX-548|Solution or suspension for oral administration.
41305357|NCT06420765|DRUG|Placebo|Suspension for oral administration.
41305358|NCT01469013|DRUG|Placebo|
40986266|NCT05576493|PROCEDURE|phaco GSL|phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.
40986267|NCT04517214|DRUG|Toripalimab|PD-1 inhibitor
40986268|NCT04517214|RADIATION|IMRT to the nasopharynx and neck|IMRT to the nasopharynx and neck
40986269|NCT04517214|DRUG|Gemcitabine and Cisplatin Chemotherapy|Systemic chemotherapy
40986270|NCT04517214|DRUG|Adjuvant chemotherapy with Capecitabine|Adjuvant chemotherapy after radiation
41144769|NCT00674609|DRUG|THC Alone|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
41144770|NCT06193915|DEVICE|Ultrasound guided hematoma block.|Patients with a dislocated fracture of the distal radius will receive ultrasound guided hematoma block with 10mL lidocaine 2% to get real-time guidance of the given anesthesia into the fracture site before closed reduction of a distal radius fracture.
41144771|NCT06193915|PROCEDURE|Blind hematoma block|Patients with a distal radius fracture will receive standard treatment; hematoma block with 10mL 2% lidocaine performed with palpation of the fracture site (blind hematoma block) before closed reduction of dislocated distal radius fractures.
41144772|NCT05536440|DRUG|PF-07261271|IV or SC
41144773|NCT05536440|DRUG|Placebo|IV or SC
41144774|NCT02919059|DRUG|Dapagliflozin 10 mg|"Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
41305359|NCT01469013|DRUG|Baricitinib|
40986271|NCT04853927|DRUG|Proxalutamide|Proxalutamide 300mg q.d suspension
41305360|NCT01469013|DRUG|Baricitinib|
41305361|NCT01469013|DRUG|Baricitinib|
41305362|NCT01469013|DRUG|Methotrexate|Administered orally as background therapy
41305363|NCT02641236|DRUG|Vancomycin-polymyxin B|
41305364|NCT02668107|OTHER|Hammock positioning|Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
41305365|NCT00089843|DRUG|Testosterone|Testosterone patch 150mcg daily
41305366|NCT00089843|DRUG|Actonel (risedronate)|Actonel (risedronate) 35mg PO one time weekly
40986272|NCT04853927|DRUG|Placebo|Proxalutamide 300mg q.d placebo
41305367|NCT00089843|DRUG|Placebo Actonel (risedronate)|Placebo tablet identical in appearance to active Actonel (risedronate) tablet
41305368|NCT00089843|DRUG|Placebo testosterone|Placebo patch identical in appearance to testosterone patch
41305369|NCT04191577|DRUG|CVN424 Low Dose|CVN424
41305370|NCT04191577|DRUG|CVN424 High Dose|CVN424
41305371|NCT04191577|DRUG|Placebo|Placebo
40986273|NCT06441175|OTHER|Intubation device order|"D-V group: the group that performs direct laryngoscopy first and then videolaryngoscopy.~V-D group: the group that performs video laryngoscopy first and then directlaryngoscopy."
40986274|NCT02003612|OTHER|Not applicable - observational study|No intervention exists as this is a retrospective observational study
40986275|NCT05931939|PROCEDURE|Ileal Interposition|Bariatric surgery by laparoscopic Ileal Interposition
41305372|NCT05722236|BEHAVIORAL|IBD Strong Peer2Peer|Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.
41305373|NCT05722236|OTHER|Waitlist control|Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.
41305374|NCT04817085|DEVICE|Visant Medical Canalicular Plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
41305375|NCT04817085|DEVICE|Commercially available canalicular plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
41305376|NCT02306187|DRUG|Edirol|Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
41305377|NCT03301766|DRUG|lidocaine 5% patch|transdermal patch
40986276|NCT05931939|PROCEDURE|Traditional surgical technique|Bariatric surgery by laparoscopic traditional technique
41305378|NCT03301766|DRUG|standard therapy|Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
41305379|NCT03301766|DRUG|Non-medicated patch|non-medicated patch
41305380|NCT02934048|OTHER|7-day triple regimen guided by AST|Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
41464128|NCT06353308|BEHAVIORAL|Sexual Violence Prevention|The intervention included a game, five short videos, two posters, and five online quizzes, which were provided with a frequency of two posts per week and a final real-time online workshop. Materials included content on the spectrum of gender and sexual identities and orientations, gender and sexual roles, consent and communication, body positivity and self-acceptance, sexual pleasure and desire, as well as risky sexual behavior associated with dating app use and the legal issues and risks of sexual assault, such as precautionary steps and available resources.
40986277|NCT06021015|DEVICE|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
40986278|NCT06021015|DEVICE|Irinotecan and HepaSphere Microspheres|Irinotecan and HepaSphere Microspheres
40986279|NCT00665847|DRUG|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
40986280|NCT00665847|DRUG|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir \[LPV\], darunavir \[DRV\], atazanavir \[ATV\] or saquinavir \[SQV\]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N\[t\]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
40986281|NCT03760120|DEVICE|PEP-MASK|
40986282|NCT06461533|DRUG|Susoctocog Alfa (Genetical Recombination)|Susoctocog Alfa (Genetical Recombination), Intravenous injection
40986283|NCT02913079|BEHAVIORAL|Sit-stand desk|
40986284|NCT02913079|BEHAVIORAL|Sitting desk|
40986285|NCT03627689|OTHER|Active air purifier in respiratory allergies/asthma|Continuous use of air purifier to improve allergies and asthma control
40986286|NCT03627689|OTHER|Sham air purifier|control arm
40986287|NCT02045706|OTHER|Community Health Worker Trainings|
40986288|NCT04057014|DRUG|Amoxicillin|Antibiotic given at different dosages and durations.
40986289|NCT04057014|PROCEDURE|Tooth extraction|Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
40986290|NCT04661007|DRUG|tafasitamab|tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.
40986291|NCT04661007|DRUG|lenalidomide|lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.
40986292|NCT04661007|DRUG|parsaclisib|parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
40986293|NCT04661007|DRUG|R-CHOP|R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.
41305381|NCT02934048|OTHER|10-day triple regimen guided by AST|Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
41305382|NCT02934048|OTHER|14-day triple regimen guided by AST|Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
41305383|NCT00610935|DRUG|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
41305384|NCT00610935|DRUG|Placebo|Single intramuscular injection
41305385|NCT06424873|RADIATION|PET/CT with FDG or FES|The study consists of an additional 50 minutes of imaging during the radiotracer's uptake phase prior to their clinical scan (standard of care).
41305386|NCT05070273|DIAGNOSTIC_TEST|Hypoglossal nerve conduction study|"NCS of nervus hypoglossus (evaluation of M-response parameters) was carried out using a 4-channel electromyographic machine. The stimulation will be carried out from three points:~1. angle of the lower jaw (proximal point),~2. the area of the carotid triangle (distal point),~3. directly from the electrode of St. Mark when it is localized on the muscles of the tongue.~The initial stimulation parameters: strength of an electric current 20 mA, stimulus duration 0.2 ms, and frequency 1 Hz. To achieve supramaximal stimulation, the stimulation strength will be increased with a step of 1-2 mA to a maximum of 35 mA, the duration of the stimulus will be increased to 0.3 ms."
41305387|NCT05070273|DIAGNOSTIC_TEST|Transcranial magnetic stimulation of hypoglossal nerve|"TMS will be carried out using a Magstim 200 magnetic stimulator connected with a BiStim module (Magstim Co. Ltd., Whitland, Wales, UK). The generated magnetic pulses will be delivered by the coil 65 mm in diameter tangentially located relative to the scalp in the F7 projection - T3 and F8-T4 (according to the international scheme 10-20). The area of cortical stimulation will be localized by supplying single pulses with gradual increase, with a coil displacement with a step of 1 cm, until the contraction of the facial muscles will be obtained, followed by the determination of the MEP threshold value. Analysis of conduction by cortical-lingual pathway will be performed at TMS with magnetic stimulus intensity 20-30% above the MEP threshold."
40986294|NCT05870709|OTHER|sacubitril/valsartan|There is no treatment allocation. Patients with a first ambulatory sacubitril/valsartan prescription who are interested in study participation will be enrolled.
40986295|NCT00555607|DRUG|prednisolone|Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
40986296|NCT01372501|DEVICE|Endobarrier Liner|Medical device placed endoscopically in the duodenum
40986297|NCT02725242|DRUG|Budesonide/formoterol (160/4.5 μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
40986298|NCT02725242|DRUG|Budesonide (400μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
40986299|NCT01798472|PROCEDURE|cemented hemiarthroplasty|Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
41144775|NCT02919059|DRUG|Glimepiride 4 mg|"Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
40986300|NCT01798472|PROCEDURE|reverse hybrid total hip arthroplasty|Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
41144776|NCT04800263|DRUG|SHR-1905|SHR-1905 will be injected subcutaneously
41464129|NCT06353308|BEHAVIORAL|Sexual health intervention|This general online sexual health education consisted of online videos, quizzes and game that covered a wide range of diverse topics on love, sex and relationships such as healthy and respectful relationships, body self-esteem, sexual identity and orientation, sexual rights and decision making, in addition to the conventional focus on sexual dysfunction and disease aversion.
41464130|NCT02798328|DEVICE|TEG6s DOAC Cartridge|Testing subjects for presence of DOAC
41464131|NCT00781430|DRUG|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
41144777|NCT04800263|DRUG|Placebo|Placebo will be injected subcutaneously
41144778|NCT02547974|BIOLOGICAL|Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
41144779|NCT02547974|BIOLOGICAL|Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
41144780|NCT02547974|BIOLOGICAL|Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
41144781|NCT02547974|DRUG|Placebo|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
41144782|NCT06473194|PROCEDURE|general anesthesia drug (like Propofol, esmeron, and ketamin, .effects of pneumoperitoneum|this research will involve the selection of elective cases with ASA class I or II and assessment of patients with respiratory cardiovascular parameters and hematology perioperative
41144783|NCT02370953|DEVICE|VERION for toric IOL alignment|The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
41305388|NCT02125006|BEHAVIORAL|Mindfulness-Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
41305389|NCT06177054|BEHAVIORAL|Rotation guided by ultrasound|Instruction to avoid areas with hyperechogenicity - after two weeks observation
41305390|NCT05610774|DRUG|Dexmedetomidine|pre-eclamptic Patients will receive a loading dose of iv dexmedetomidine (0.5 ug/kg) diluted in 50 ml saline and given over 10 min, followed by a maintenance infusion of (0.2 ug/kg/h) diluted in 200 ml saline till The sedation scores on the Richmond Agitation and Sedation Scale was -2 to +1 (lightly sedated to restless).
41305391|NCT05610774|DRUG|Saline|pre-eclamptic patients will receive 50 ml saline loading for 10 min followed by 200 ml saline infusion
41305392|NCT00226681|BEHAVIORAL|Nursing Telephone Support Protocol|
41305393|NCT00226681|BEHAVIORAL|Usual Care|
41305394|NCT05478343|BIOLOGICAL|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
41305395|NCT02427256|DEVICE|Topcon Specular Microscope SP-1P|
41305396|NCT02427256|DEVICE|Konan Specular Microscope CELLCHEK XL|
41305397|NCT00038688|BEHAVIORAL|Peer HIV Education Program|
41464132|NCT03761056|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
41464133|NCT03761056|DRUG|Fludarabine|Administered according to package insert
41464134|NCT03761056|DRUG|Cyclophosphamide|Administered according to package insert
41464135|NCT02427087|BEHAVIORAL|Continuous Aerobic Training twice|Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet
40986301|NCT01798472|PROCEDURE|cemented total hip arthroplasty|Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
41144784|NCT02370953|PROCEDURE|Conventional, manual ink-marking for toric IOL alignment|Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
41144785|NCT02512315|DRUG|Docetaxel (DOC)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.
41144786|NCT02512315|DRUG|Cisplatin (DDP)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.
41305398|NCT04226859|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
41305399|NCT05977517|BEHAVIORAL|Sleep and well-being tracking|This study will track sleep, learning and wellbeing of 500 freshmen under free-living conditions for 20 weeks
41305400|NCT01153763|DRUG|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
41305401|NCT00809172|DRUG|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
41305402|NCT00809172|DRUG|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
41305403|NCT02288767|DEVICE|Conventional arterial blood pressure monitoring|
40986302|NCT01798472|PROCEDURE|uncemented hemiarthroplasty|"Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel."
40986303|NCT00003010|DRUG|marimastat|
40986304|NCT01968668|DRUG|BAY94-8862|1.25 mg BAY94-8862 tablet once daily in the morning
40986305|NCT01968668|DRUG|BAY94-8862|2.5 mg BAY94-8862 tablet once daily in the morning
40986306|NCT01968668|DRUG|BAY94-8862|5 mg BAY94-8862 tablet once daily in the morning
40986307|NCT01968668|DRUG|BAY94-8862|7.5 mg BAY94-8862 tablet once daily in the morning
40986308|NCT01968668|DRUG|BAY94-8862|10 mg BAY94-8862 tablet once daily in the morning
40986309|NCT01968668|DRUG|Placebo|Placebo tablet once daily in the morning
40986310|NCT01968668|DRUG|BAY 94-8862|15 mg BAY 94-8862 tablet once daily in the morning
40986311|NCT01968668|DRUG|BAY 94-8862|20 mg BAY 94-8862 tablet once daily in the morning
40986312|NCT00989339|DRUG|Twenty-four Hour TPN and Saline Infusion|Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
41144787|NCT02512315|RADIATION|Concurrent chemoradiation (CCRT)|"The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly."
41144788|NCT03363100|BEHAVIORAL|Digital health Partnership program|The program pairs patients with their own certified diabetes educator coach who will guide the patient through a personalized program that leverages a proven educational curriculum combined with proven patient engagement methods.
40986313|NCT01452607|DRUG|SPI-1005|200 mg Ebselen oral capsules (SPI-1005), single dose
40986314|NCT01452607|DRUG|Placebo|0 mg Ebselen oral capsules (SPI-1000), single dose
40986315|NCT04016246|DRUG|Propofol-Lipuro|sedation of babies \< 32wGA with propofol / placebo before a LISA Procedure
40986316|NCT04016246|DRUG|Placebos|injected to babies \< 32wGA with propofol / placebo before a LISA Procedure
40986317|NCT04487639|DIAGNOSTIC_TEST|SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics|a nasopharyngeal swab for SARS-CoV-2 research by RT- qPCR will be performed on the day of semen collection. On the same day, serological tests will be carried out, and 30 to 50 days after, according to HAS specifications with methods validated by the National Reference Center
40986318|NCT00725556|OTHER|Speech Therapy|Speech Therapy
40986319|NCT03925740|DRUG|MI Varnish|Application of MI varnish material versus the standard 1.23% APF.
40986320|NCT03925740|DRUG|PreviDent Varnish|Application of PreviDent Varnish material versus the standard 1.23% APF.
40986321|NCT03925740|DRUG|1.23% APF|Standard 1.23% APF application
40986322|NCT02316041|PROCEDURE|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
40986323|NCT02316041|DEVICE|ReLEx® (SMILE)|
40986324|NCT06447727|DRUG|SIRT with Yttrium-90 Microspheres|Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection
40986325|NCT06447727|DRUG|FOLFIRI and Bevacizumab|FOLFIRI and Bevacizumab
40986326|NCT03892590|BIOLOGICAL|Gut microbiota|Status of microbiota
40986327|NCT01106898|DRUG|cyclophosphamide|Given IV
40986328|NCT01106898|DRUG|paclitaxel|Given IV
40986329|NCT01106898|BIOLOGICAL|trastuzumab|Given IV
41144789|NCT03323502|BEHAVIORAL|ACP Specialist Program|New structured role with responsibility for ACP
41144790|NCT06008665|OTHER|Action Observation Therapy and Otago Exercises|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs.~Training Frequency and Guidance: Exercises conducted three times a week,Guidance provided by a therapist.~Training Session Duration: Each session lasts for 35-40 minutes. Warm-up and Cool-down:5-minute warm-up before each session and 5-minute cool-down after each session."
41144791|NCT06008665|OTHER|Otago Exercises|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs."
41144792|NCT00301054|DRUG|Ferrous sulphate|
41144793|NCT00301054|DRUG|Sulphadoxine-Pyrimethamine|
41305404|NCT02288767|DEVICE|Stroke volume variation monitoring with arterial blood pressure monitoring|
40986330|NCT01106898|OTHER|laboratory biomarker analysis|Correlative studies
40986331|NCT04881708|DEVICE|Remote Monitoring|Subjects assigned to the Remote Care group will receive education from a clinical nurse from Mayo Clinic's Department of Connected Care on use of the equipment as part of Remote Monitoring. The equipment will be shipped along with instructions and Welcome Letter describing the Mayo Clinic Remote Patient Monitoring program. The Remote Patient Monitoring kit includes a digital tablet, a blood pressure cuff, a thermometer, a pulse oximeter, and a weight scale. Subjects will be contacted by phone at the end of the study to be instructed how to return the kit by mail.
40986332|NCT02093481|OTHER|Test meal|
41305405|NCT00003750|BIOLOGICAL|hu14.18-IL2 fusion protein|
41305406|NCT02227017|DRUG|TPV capsule|
41305407|NCT02227017|DRUG|TPV solution|
41305408|NCT02227017|DRUG|RTV capsule|
41305409|NCT02227017|DRUG|RTV solution|
41305410|NCT02227017|OTHER|standard meal|
41464136|NCT02427087|BEHAVIORAL|Healthy Diet|Diet group (21) Recommendation for healthy diet.
41464137|NCT03826394|BEHAVIORAL|Exercise Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be exercise specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
40986333|NCT02093481|OTHER|Reference|
40986334|NCT02093481|OTHER|Priming|The reference or test meal was eaten 3 days prior to measurements of variables.
40986335|NCT02093481|OTHER|No priming|The reference or test meal was eaten 1 days prior to measurements of variables.
40986336|NCT05282173|BEHAVIORAL|Siyakhana CHW Training|Please see arm description.
40986337|NCT02391155|PROCEDURE|single lumen needle in oocyte retrieval|single lumen needle use during oocyte retrieval
40986338|NCT02391155|PROCEDURE|double lumen needle in oocyte retrieval|after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
40986339|NCT00343200|DRUG|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
40986340|NCT00343200|DRUG|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
40986341|NCT03282188|BIOLOGICAL|Reolysin|Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
41144794|NCT02162927|DIETARY_SUPPLEMENT|Dietary Nitrate|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
41144795|NCT02162927|DIETARY_SUPPLEMENT|Potassium Chloride (placebo)|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
41147042|NCT06381297|DIAGNOSTIC_TEST|Symbol Number Modalities Test (SDMT)|Attention, visuospatial information processing speed and working memory are assessed. It is one of the subtests of the Short Repeatable Neuropsychological Battery developed to assess cognitive functions in MS (Smith, 1973).
41305411|NCT03979105|DRUG|Ketamine|Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison
41305412|NCT02040194|DRUG|AM-101|AM-101 gel for intratympanic injection
41305413|NCT02040194|DRUG|Placebo|Placebo gel for intratympanic injection
41305414|NCT05867316|BEHAVIORAL|Unified Protocol|Unified Protocol based treatment, modified for use in brief treatment on inpatient units
41305415|NCT01248624|BEHAVIORAL|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
41305416|NCT05868213|DRUG|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
41305417|NCT05535127|DIAGNOSTIC_TEST|"Palpation with  laryngeal handshake technique"|Information alredy included
41305418|NCT05535127|DIAGNOSTIC_TEST|Palpation strategy plus sequential ultrasound|Information alredy included
41144796|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
41144797|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
41144798|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing \<30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
41144799|NCT00811239|DRUG|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
41305419|NCT05535127|DIAGNOSTIC_TEST|Identification of the cricothyroid membrane with routine ultrasound|Information alredy included
41305420|NCT06269341|OTHER|No intervention|No intervention
41305421|NCT05930392|PROCEDURE|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
41305422|NCT05930392|PROCEDURE|Conventional surgical depigmentation|GINGIVAL DEPIGMENTATION USING CONVENTIONAL SURGICAL TECHNIQUE
41305423|NCT02593747|DRUG|Loratadine oral solution|Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
41305424|NCT02593747|DRUG|Loratadine (Claritin peach syrup)|Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
41305425|NCT06373614|OTHER|foot massage|Interventions are to be performed in the evening before bedtime for 4 consecutive days.
41305426|NCT06373614|OTHER|bed bath|Interventions are to be performed in the evening before bedtime for 4 consecutive days.
41305427|NCT01512641|OTHER|Primary stage|Kiddie-Schedule for Affective Disorders and Schizophrenia
41305428|NCT01512641|OTHER|Secondary stage|children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
41305429|NCT03355599|OTHER|3d camera|3 D camera and associated software that introduces measurement and monitoring of wounds as a specific intervention
40781874|NCT06020521|OTHER|Three spectrometry differents technics|"Collection of expired air as follows:~* For online mass spectrometry techniques (PTR-MS and SICRIT)~* For offline mass spectrometry (GCxGC-MS)~Performing volatolome analyses:~* By PTR-TOF-MS (Ionicon) and SICRIT-HRMS (SICRIT module (Plasmion) coupled to a Q-exactive instrument (Thermofisher)) for online analyzes~* By two-dimensional gas chromatography coupled with mass spectrometry (Pegasus BT-4D, Leco) for the desorption tubes."
40781875|NCT03534388|OTHER|Sodium Hypochlorite Cleanser|Cleansing with CLn BodyWash
40781876|NCT04486040|PROCEDURE|Drainage|Use of the suction drainage after hip revision arthroplasty
40781877|NCT04486040|PROCEDURE|No-drainage|Patients without drainage after surgery
40781878|NCT02063256|DIETARY_SUPPLEMENT|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
40781879|NCT02063256|OTHER|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
40781880|NCT05247203|BIOLOGICAL|Telitacicept|subcutaneous injection
40781881|NCT05247203|DRUG|standard therapy|A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
40781882|NCT05309044|BEHAVIORAL|Planetary Health Diet Group|This group includes a diet proportional to the EAT-Lancet reference diet (2500 kcal), with a caloric intake of 1200 to 1800 kcal, in addition to a behavioral change protocol during the time of the study (4 months).
40781883|NCT05309044|OTHER|Low-fat diet group|This group includes a low-fat, low-calorie diet (1200-1800 kcal), in addition to a behavioral change protocol
40781884|NCT05309044|OTHER|Waiting list group|This group will only receive digital information with recommendations on healthy eating. When the study has finished, this group will receive a behavioral change protocol with a low-fat, low-calorie diet.
40781886|NCT01822925|DRUG|DA-9801 300mg|300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.
40781887|NCT01822925|DRUG|DA-9801 600mg|600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.
40781888|NCT01822925|DRUG|DA-9801 900mg|900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.
40781889|NCT01822925|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
40781890|NCT00317265|PROCEDURE|Coronary bypass surgery|
41305430|NCT02536170|DRUG|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
41305431|NCT02536170|DRUG|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
40986342|NCT03282188|DRUG|GM-CSF|GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
41144800|NCT00811239|OTHER|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
41144801|NCT05779254|DRUG|Neomycin Sulfate|Postoperative day-1 Oral Antibiotic Prophylaxis + patients get po. 3x1000mg Neomycin sulfate and 3x500 mg Metronidazole
41144802|NCT03563989|DEVICE|Implantation of Stent (PCI)|Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent
41144803|NCT03400059|DEVICE|Chordate System S211 in treatment mode|Chordate System S211 in treatment mode
41144804|NCT03400059|DEVICE|Chordate System S211 in placebo mode|Chordate System S211 in placebo mode
41144805|NCT04891497|DRUG|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
40986343|NCT00140569|PROCEDURE|CHVP + interferon|
40986344|NCT00140569|DRUG|fludarabine|
40986345|NCT00140569|PROCEDURE|CHOP + TBI and autotransplant|
41305432|NCT02536170|OTHER|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
41305433|NCT05233696|DRUG|Nab-paclitaxel|All patients are encouraged to receive nab-paclitaxel 100 mg/m2 IV D1 and D8 every 21 days (in combination with pembrolizumab) for at least 4-6 cycles per institutional standards and treating physicians' recommendations.
40986346|NCT00448474|BEHAVIORAL|Mailed Arthritis Self-Management Education|
40986347|NCT05178966|BEHAVIORAL|Bp OneDay psychoeducation program|"The BP One-Day Psychoeducation program is based on a single day of psychoeducation . This program was carried out by members of the bipolar expert center network in various hospitals of the network and included :~* Representation of BD~* Definition, diagnosis and awareness of the disorder~* Depressive, hypo / manic symptoms~* Vulnerability to BD causes of BD, risk factors for relapses~* Drug treatments, drug compliance and non-drug treatments~* Early detection of prodromal signs~* Communication techniques~Each BP One-Day psychoeducation session welcomes an average of ten participants (5 patients / 5 caregivers). At the end of the day, participants receive a booklet containing the main information of the day.~BP One-Day program is delivered by a nurse and a psychologist specialized in both BD and therapy group facilitation. A specialized psychiatrist intervenes in the section Medication treatments and medication adherence for a period of approximately one hour."
40986348|NCT03324854|PROCEDURE|Rives technique|Open ventral hernia repair followed by the placement of the mesh.
40986349|NCT03324854|PROCEDURE|Drainage|Placement of active-close drainage in surgical site.
41144806|NCT04891497|DRUG|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
41144807|NCT03823703|DRUG|Miricorilant|Tablets taken orally
41305434|NCT05233696|DRUG|Paclitaxel|Paclitaxel can be substituted for nab-paclitaxel at the discretion of the treating physician 80 mg/m2 IV D1 and D8 every 21 days.
40986350|NCT03324854|DRUG|Prophylactic|Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
40986351|NCT01843764|DEVICE|HRP2 and LDH based rapid diagnostic tests for P.falciparum|
41144808|NCT03823703|DRUG|Placebo|Placebo tablets
41305435|NCT05233696|RADIATION|Radiation Therapy|The treating radiation oncologist will select 1-4 sites of metastatic disease to target with radiation. All sites of disease may be targeted with radiation. Sites of metastatic disease planned to be biopsied should not be radiated.
41305436|NCT05233696|DRUG|Pembrolizumab|Patients will receive pembrolizumab 200 mg D1 every 21 days.
41305437|NCT01599754|DRUG|Axitinib|Axitinib 5 mg twice daily
41305438|NCT01599754|DRUG|Placebo|Placebo twice daily
41144809|NCT01578629|OTHER|Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin|Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
41144810|NCT01578629|OTHER|Placebo vehicle control|vehicle control compared to Vitamin E TCT pills
41144811|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 7 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age
41144812|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 8 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age
41144813|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 10 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age
41144814|NCT02643368|BIOLOGICAL|IPV at 6 weeks of age|Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
41144815|NCT01115309|DEVICE|XprESS Balloon Device|Sinus dilation completed with the XprESS Balloon Device with or without additional endoscopic sinus surgery procedures (dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia).
41144816|NCT03150004|DRUG|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|"Subjects will be started on CLAG-M regimen, which consists of the following:~* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 2 gm/m\^2 IV over four hours on days 1-5~* Mitoxantrone 10 mg/m\^2 IV on days 1-3;~* G-CSF at a dose of 300 μg on days 0-5."
41144817|NCT03150004|DRUG|Cladribine and Cytarabine (CLLDAC) Regimen|"* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 20 mg/m\^2 subcutaneous injection on days 1-10;"
41305439|NCT05687695|OTHER|backward walking program|six weeks of backward walking program at self selected speed for 30 minutes 3 times per week
41305440|NCT05687695|OTHER|core training|six weeks of core training program including curl up, lateral plank on both sides, bird dog exercises done 3 times per week
41305441|NCT00758914|DIETARY_SUPPLEMENT|Vitamin E|200 IU alpha-tocopherol or placebo for 1 year.
41305442|NCT06549023|PROCEDURE|Single-session panretinal PRP (SS-PRP)|Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit.
40781891|NCT04343092|DRUG|Ivermectin (IVM)|Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly
40986352|NCT00484211|DRUG|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
40986353|NCT03300479|DRUG|Clevidipine|Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
40986354|NCT03300479|DRUG|Urapidil|We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
40986355|NCT05775315|OTHER|Action Observation Therapy|"Exercises of AO protocol MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
41144818|NCT05587907|DEVICE|FitLight Trainer|Evaluation of the reaction time before and after special training program using visual stimuli.
41305443|NCT06549023|PROCEDURE|Multiple-session panretinal PRP (MS-PRP)|Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.
41305444|NCT02680223|DEVICE|Precision tinted lenses|Tinted lens for patient with reading difficulty or visual stress
41144819|NCT01809444|DRUG|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
41144820|NCT01809444|DRUG|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
41144821|NCT06171685|DRUG|Teclistamab|Comparing treatment regimens
41144822|NCT06171685|DRUG|Investigational Agent|Comparing Treatment Regimens
41144823|NCT02282215|BIOLOGICAL|CLT-008|Single intravenous infusion
41144824|NCT02282215|BIOLOGICAL|G-CSF|Daily subcutaneous injections
41144825|NCT05190289|OTHER|Pre-existing degenerative factors of paraspinal muscles and bone mass|Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass
41144826|NCT03075475|BEHAVIORAL|Common Elements Treatment Approach|The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
41305445|NCT02680223|DEVICE|Non-beneficial tinted lenses|Tinted lenses that are unlikely to help reading difficulty or visual stress
40781892|NCT04324892|DRUG|Treat to target|All patient will received protocolized treatment with an aim to achieve SDAI remission
41305446|NCT03059810|DEVICE|etafilcon A|Investigational Contact Lens
40781893|NCT04127318|BEHAVIORAL|Pedaling Group|Participants will pedal at low-moderate intensity using a stationary pedal ergometer concurrent to their immunotherapy infusion (30 minutes).
41305447|NCT01192217|PROCEDURE|Modified thoracoscopic technique|Two-port thoracoscopic technique
41305448|NCT01192217|PROCEDURE|Axillary mini-thoracotomy|Axillary mini-thoracotomy
40986356|NCT05775315|OTHER|Action Observation Therapy along with visual feedback|"Exercises of AO protocol in front of a mirror MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
40986357|NCT03028831|DIETARY_SUPPLEMENT|70g of fully digestible starch amylopectin corn starch|Fully digestible amylopectin corn starch
40986358|NCT03028831|DIETARY_SUPPLEMENT|Resistant starch|70g high-amylose maize starch
40986359|NCT06495346|OTHER|self-questionnaires exploring|At each stage, subjects are asked to fill in self-questionnaires exploring the quality of their sleep, their potential distressing symptoms, their psychological state and the quality of their life at that moment. They complete the self-questionnaires at t
40986360|NCT02432534|DRUG|Atorvastatin|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
40986361|NCT02432534|OTHER|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
40986362|NCT04576611|OTHER|face-to-face protocol|The intervention is based on education (on pain neurophysiology and healthy lifestyle habits) and physical exercise (strength, flexibility, joint mobility and self-massage).
40986363|NCT04576611|OTHER|self-managed protocol|Subjects of this group receive the same intervention content as the other experimental group, but through a mobile application.
40986364|NCT05666258|DIAGNOSTIC_TEST|GEP|GEP before surgery to determine need for neoadjuvant chemotherapy
40986365|NCT00298545|DRUG|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
40986366|NCT00298545|DRUG|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
40986367|NCT01981291|PROCEDURE|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
40986368|NCT01981291|PROCEDURE|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
40986369|NCT01981291|PROCEDURE|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
40986370|NCT01981291|PROCEDURE|Patient-controlled postoperative analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
40986371|NCT01981291|DRUG|Mepivacaine|Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
40986372|NCT04774874|DRUG|Topical formulation|Topical administration on the scalp once daily for 16 weeks
40986373|NCT00374881|DRUG|Morphine|Morphine
40986374|NCT00374881|DRUG|Morphine|Morphine low dose
40986375|NCT00374881|DRUG|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
40986376|NCT00374881|DRUG|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
40986377|NCT00374881|DRUG|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
41144827|NCT06152497|DRUG|Placebo|Oral placebo
40986378|NCT05068557|DIETARY_SUPPLEMENT|Dietary plan along with fish oil capsules (3 capsules daily. Containing EPA+DHA: 1.8 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: EPA+DHA: 1.8 g.
40986379|NCT05068557|DIETARY_SUPPLEMENT|Dietary plan along with chia/linseed oil capsules (3 capsules daily. Containing ALA 1.6 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: ALA 1.6 g).
40986380|NCT06346873|DEVICE|JOGO|AI driven mobile app and wearable sensors to provide virtual treatments
40986381|NCT02615054|DEVICE|2D Echocardiogram|All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
41144828|NCT06152497|DRUG|H1 blockade: Telfast: 180mg Fexofenadine|H1 blockade: oral blockade with 180mg Fexofenadine
41144829|NCT06152497|BEHAVIORAL|Resistance training|Resistance training: lower body exercise
41147043|NCT00765791|PROCEDURE|Selective Neck Dissection Excluding Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is not dissected.
41147044|NCT00765791|PROCEDURE|Selective Neck Dissection Including Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is also dissected.
41147045|NCT02523417|PROCEDURE|interventional therapy|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
41147046|NCT04711018|DIAGNOSTIC_TEST|Laryngoscopy|The laryngoscopy is performed with the help of an appropriate size Macintosh blade. The patient's head is held in the sniffing position. External manipulation is not used for improving the view in this investigation.
41144830|NCT04255004|DEVICE|Pall Celeris System, point of care device for human cell therapy|Concentration of PB-MNCs autologous cell therapy was produced by a filtration-based point-of-care device. All the procedures were performed in operatory room with anaesthesiologic support (propofol and/or peripheral block). Blood withdrawal (120 ml) was collected through a peripheral venous access. Blood was loaded, and gravity filtration was allowed to proceed until the upstream side of the filter had no remaining blood; filtration last about 10 minutes. During filtration, MNCs were captured in the filter while plasma, platelets (PLTs) and red blood cells (RBCs) were not retained. Immediately concentrate solution is injected in the perilesional area and intramuscular in the foot and the leg (0.2-0.3cc in boluses) below the knee, at intervals of 1-2 cm and to a mean depth of 1.5-2 cm, using a 21G needle. This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
40986382|NCT02615054|DEVICE|Cardiopulmonary exercise testing and post-CPET cardiac function|To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
40986383|NCT05959330|OTHER|Neural Tension Technique(ulnar, median, radial)|Neural Tension Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
40986384|NCT05959330|OTHER|Neural Slider Technique (ulnar, median, radial)|Neural Slider Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
40986385|NCT05959330|OTHER|Neural Tension Technique and Neural Sliding Technique(ulnar, median, radial)|Neural Tension and Sliding Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
40986386|NCT06333769|RADIATION|Short-course Radiotherapy|Rectal lesions + metastatic lymph nodes, DT: GTV-P 30Gy/5Fx. Pelvic lymphatic drainage area, DT: CTV-P 22.5Gy/5Fx.
41144831|NCT03612102|BEHAVIORAL|Intensive Group Behavioral Treatment (IGBT)|IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
40986387|NCT06333769|DRUG|Tislelizumab|Tislelizumab：200mg，d1，q3w，2 cycles.
40986388|NCT06333769|DRUG|capecitabine|capecitabine：1000mg/m2， d1-14，2 cycles.
40986389|NCT06333769|DRUG|Oxaliplatin|oxaliplatin：130mg/m2 d1，q3w, 2 cycles
40986390|NCT05487482|OTHER|Ageing Safe from the Risk (ASRi) Model of safety culture|For the intervention groups, planning will be done to provide education and training. Families will be given modules on Safety Culture in the Elderly. Materials provided about the safety of the elderly include changes in the elderly, the concept of safety in the elderly, the type of danger to the elderly, how to prevent harm in the elderly, the first handling in case of accidents, and the role of the family in the efforts of elderly safety. The material will be delivered by experts in elderly health and patient safety (professionals from health centers, social services, and academics). In addition to education and training, families will also receive home visits to check and monitoring the condition of the elderly at home related to adverse events and the home environment. Measuring will be done every 4 weeks by using a monitoring book.
40986391|NCT04836728|BIOLOGICAL|CIK cell injection|CIK cells, more than 1x10\^10 (10 billion ), intravenous infusion,d14; Q3W.
41305449|NCT03132805|BEHAVIORAL|PATHS to PAX|A universal classroom-based preventive intervention designed to prevent aggression.
41305450|NCT03132805|BEHAVIORAL|PATHS to PAX and the Incredible Years|A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
41305451|NCT01477892|DRUG|low dose remifentanil|non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
41305452|NCT04541212|DIAGNOSTIC_TEST|Cardiac Imaging|Cardiac Imaging: echography, ECG, MRI Blood tests: Lipid profile, hs-CRP, metabolic markers, HDL functionality, pharmacogenetic testing (optional), hematocrit, pregnancy test
41305453|NCT04541212|OTHER|Data Collection|Collection of retrospective data
41305454|NCT01620632|PROCEDURE|Laparoscopy assisted ERCP|Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
41305455|NCT05256056|DRUG|Bupivacain|efficacy of bupivacaine in different volumes
41305456|NCT01757639|BIOLOGICAL|Ipilimumab|Given IV
40781894|NCT01993082|BEHAVIORAL|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
40781895|NCT06338111|DIAGNOSTIC_TEST|ELISA Sepsis Biomarkers dosage|Observational
40986392|NCT04836728|DRUG|Sintilimab Injection|Sintilimab Injection intravenous infusion 200mg d1
40986393|NCT04836728|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d2
40986394|NCT04836728|DRUG|Albumin paclitaxel|Albumin paclitaxel intravenous infusion 260mg/m2 d2
40986395|NCT04836728|DRUG|Carboplatin|Carboplatin intravenous infusion AUC5 d2
40986396|NCT02371109|OTHER|selftaken versus clinically taken swabs|
40781896|NCT05203380|DRUG|dupilumab|Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)
40781897|NCT03401203|PROCEDURE|Rotational atherectomy followed by balloon angioplasty|Percutaneous coronary intervention
40781898|NCT03401203|PROCEDURE|Balloon angioplasty|Percutaneous coronary intervention
40781899|NCT01739894|DRUG|IP Paclitaxel|Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
40986397|NCT04371887|OTHER|Local Tailoring|"The guided local tailoring approach will employ a standard structured process, including (1) convening a project team, (2) conducting a local diagnostic process to identify likely barriers using provider/patient survey and interviews with providers/administrators, (3) selecting from a pre-developed menu of implementation strategies categorized by core function (form and function menu), and (4) deploying the selected strategies in collaboration with local implementation and improvement consultants."
40986398|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the upper arm
40986399|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the lower abdomen
40986400|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the thigh
40781900|NCT00640003|DRUG|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
40781901|NCT00640003|DRUG|Placebo|placebo drug
40986401|NCT01722240|DRUG|Liraglutide 1.8mg|
40986402|NCT01722240|DRUG|Placebo|
40781902|NCT00735150|BEHAVIORAL|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
40781903|NCT05123014|OTHER|relex smile|In OCT, firstly, the thickness of the adenoviral subepithelial infiltration in the cornea is calculated in microns, and extraction is performed accordingly with Small Incision Lenticule Extraction( SMILE )and fresh lenticule implanted stromal in the same volume.
40781904|NCT03928925|OTHER|Bougie|disposable tracheal tube introducer of approximately 70 cm in length
40781905|NCT03928925|OTHER|Endotracheal Tube with Stylet|endotracheal tube preloaded with a removable, malleable stylet
40781906|NCT05846893|DEVICE|SeQuent® Please NEO drug-coated balloon catheter|Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries
40781907|NCT05846893|DEVICE|Current-generation drug-eluting stent|Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries
40986403|NCT01738854|PROCEDURE|intracuff pressure by cuff pressure manometer|36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
40986404|NCT04597307|COMBINATION_PRODUCT|IN.PACT™ Admiral™ Drug Coated Balloon (DCB)|For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.
40986405|NCT04262505|BEHAVIORAL|Mediterranean Diet Group|Participants will be advised to follow a traditional Mediterranean diet
40986406|NCT04262505|BEHAVIORAL|Healthy Eating Group|Participants will be advised to follow the Healthy Eating Guidelines in Ireland
40986407|NCT06200233|DRUG|Rivoceranib|700mg once daily
40986408|NCT02036502|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
40986409|NCT02036502|DRUG|Lenalidomide|Oral capsule
40986410|NCT02036502|DRUG|Dexamethasone|Oral tablet IV infusion
40986411|NCT02036502|DRUG|Carfilzomib|IV infusion
40986412|NCT02654535|OTHER|Dietary tree nuts & peanuts|An intervention in which tree nuts and/or peanuts are included in the diet
40986413|NCT04602182|PROCEDURE|music therapy intervention|Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
40986414|NCT06522048|OTHER|Observational studies do not require intervention|This is an observational retrospective study and does not require any intervention.
40986415|NCT04635215|DEVICE|Sensura Mio Bodyfit technology ostomy pouches|The use of medical devices, the ostomy pouches from Sensura Mio Bodyfit technology range, will be studied from inclusion visit (less than one month after the beginning of use) and during 3 months.
41144832|NCT04148794|BEHAVIORAL|echo-assisted advanced life support|"Integrated point-of-care ultrasound skill in to the setting of resuscitation, and critical condition patients.~Educate the participants to use these protocols and monitoring if there were improvement of patient's outcomes"
41144833|NCT04755907|PROCEDURE|surgical resection|Surgical resection will be performed for locoregional lesions or liver metastases.
41305457|NCT01757639|OTHER|Laboratory Biomarker Analysis|Correlative studies
41144834|NCT04755907|OTHER|adjuvant chemotherapy|Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
41144835|NCT04755907|OTHER|neoadjuvant therapy|Regimens of neoadjuvant chemotherapy are directed by clinical guidance and experience.
41144836|NCT00795639|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
41144837|NCT00795639|DRUG|Placebo|Sitaxsentan Placebo = 1 tablet administered orally, once daily
41305458|NCT03364426|OTHER|No intervention|No intervention - this is was an observational, cross-sectional study to identify potential risk factors associated with stunting
41144838|NCT03555617|DRUG|TD-1473|oral capsule/tablet, QD
41144839|NCT03555617|DRUG|Itraconazole|oral solution, QD
41144840|NCT06475326|DRUG|Adebrelimab|Adebrelimab ,20mg/Kg per time, Q4W
41144841|NCT06475326|DRUG|Oxaliplatin 100 MG|Oxaliplatin: 60mg/m2, Q2W
41144842|NCT06475326|DRUG|Irinotecan liposome|Irinotecan Liposome: 50mg/m2, Q2W
41144843|NCT06475326|DRUG|Calcium Folinate|Calcium Folinate: 400mg/m2, Q2W
41144844|NCT06475326|DRUG|Fluorouracil|Fluorouracil: 2400mg/m2, Q2W
41144845|NCT02797899|DEVICE|Platelet Rich Fibrin|Native growth factors
41144846|NCT02499991|BEHAVIORAL|memory|keep track of social events in diary for memory recall. Used by treatment group
41305459|NCT04229589|OTHER|Clinic follow-up|Patients are regularly evaluated to asses the occurrence of syncopal relapses
40781908|NCT03381989|DEVICE|ASHI_INTECC Astato XS 20 0.014 guidewire|A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
40781909|NCT03155139|DIAGNOSTIC_TEST|Aldosterone/renin ratio (ARR) testing|Plasma aldosterone concentration tests, Direct renin concentration tests
40986416|NCT01243970|DRUG|Phenylephrine|"Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg \*~\* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg."
40986417|NCT01243970|DRUG|Ephedrine|"Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. \*~\* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg."
41305460|NCT01986634|PROCEDURE|Laser Treatment|Patient will have split face laser resurfacing as per standard of care. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
41464138|NCT03826394|BEHAVIORAL|Dietary Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be diet specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
40781910|NCT03155139|DIAGNOSTIC_TEST|Confirmatory tests|Captopril challenge test, Saline infusion test
40781911|NCT06026124|BEHAVIORAL|Retrieval-based word learning|"Learning sessions: Children will practice novel nouns in the context of a story book on Day 1. They will learn 4 words in each of the two conditions. Study only condition: they will simply hear the information (word \& meaning) as part of the story. Spaced retrieval condition: they will initially hear the information and be asked to retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening words. After each retrieval attempt, they will hear the target information again. In the study only practice condition, children will simply continue to hear the information. This practice schedule is repeated the next day (Day 2) using the same story book.~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word and meaning twice. One week after Day 1, this recall test is completed again. The child will also complete a recognition test: the child will hear a novel noun and point to its referent in an array of 3."
41305461|NCT05641792|DEVICE|CGM (Dexcom G6)|Dexcom G6 system consists of a transmitter and sensor that measure interstitial glycaemia every 5 minutes. Measurements are transmitted via Bluetooth to a compatible device, that uploads the data on a virtual drive. This allows for remote real-time glycaemia monitoring on another device.
41305462|NCT00038701|DRUG|TNP-470|
41305463|NCT05908344|DEVICE|Activated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system capable of producing a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect. The field potentials generated by the pad are hypothesized to have benefit for sleep.
40781912|NCT00905229|DRUG|Phytonadione|2.5 mg po
40781913|NCT00905229|DRUG|Phytonadione|0.5 mg IV
40781914|NCT06448975|PROCEDURE|Deep cervical Lymphovenous Bypass|Deep cervical lymph-vein bypass surgery, connecting deep cervical lymph input vein vessel
40781915|NCT04772209|DRUG|Sodium bicarbonate|Dialysis catheter lumen will be filled (locked) by sodium bicarbonate solution. The amount of solution depends on the diameter and length and will be in accordance with the manufacturer's specifications.
40781916|NCT04772209|DRUG|Heparin|Dialysis catheter lumen will be filled (locked) by classic heparin. The amount of pure heparin depends on the diameter and length and will be in accordance with the manufacturer's specifications.
40781917|NCT00148356|DEVICE|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
40781918|NCT00148356|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
40781919|NCT05170386|OTHER|Cognitive training Therapy|"Cognitive training Therapy include: Writing the reminiscences~• Solving a table• Writing a letter making a calendar and writing a note about the daily activities on it Facing patients' fears instead of avoiding them.Using role-playing to prepare for potentially problematic interactions with others.Learning to calm one's mind and relax one's body."
40781920|NCT05170386|OTHER|instructive conventional treatment|instructive conventional treatment breathing relaxation exercise inform of diaphragmatic breathing Practice sleep hygiene such as keeping a regular sleep schedule. Get regular exercise. Minimize noise. Minimize light. Manage the temperature so that you're comfortable.
40781921|NCT00318929|DRUG|Divalproex Sodium Extended-Release Tablets|Once a day dosing
40781922|NCT04804527|OTHER|Intensified physiotherapy|Physiotherapy x2
41464139|NCT02868996|DRUG|Recombinant human tissue kallikrein|Intravenous DM199
40781923|NCT04804527|OTHER|Usual care physiotherapy|Physiotherapy x1
40781924|NCT03561155|DEVICE|Robot assisted treatment (Amadeo®)|"The protocol will consist of exercises as follows:~passive modality , passive/plus modality , assisted therapy and Balloon."
40781925|NCT03561155|OTHER|Conventional treatment|"The protocol will consist of exercises as follow:~upper limb mobilization, facilitation of movements and active tasks. The exercises will be focused on improving muscle strength, finger extension and flexion and motor control"
40781926|NCT02751944|DIETARY_SUPPLEMENT|NEM|Dietary supplement for the support of joint health.
40986418|NCT06267950|BEHAVIORAL|systematic therapy|Both groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
40986419|NCT06267950|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
41144847|NCT05747872|BEHAVIORAL|Buerger Allen Exercises|"These exercises are specific exercises aimed at improving circulation in the feet and legs.~While doing the exercises, first of all;~1. The legs are raised at an angle of 45 degrees and supported in this position for 1-3 minutes until the skin turns white.~2. Sit on the edge of the bed and let your legs hang down (make sure there is no pressure behind the knees). In this position, move your foot left and right and up and down for 3 minutes.~3. Lie on your back for 5 minutes keeping your legs warm with a blanket.~Performing all three of these exercises in sequence means 1 session. Exercises are done 2 times a day, at least 3 sessions each time."
41144848|NCT06093451|DRUG|Dexmedetomidine|Moderate agitation: 120 mcg Severe agitation: 180 mcg
41144849|NCT06093451|DRUG|Lorazepam 2 MG/ML|2 mg
41144850|NCT01313988|DIETARY_SUPPLEMENT|Plant sterols and fish oil|4 weeks intervention, 3 times daily
41144851|NCT01313988|DIETARY_SUPPLEMENT|Plant sterols|4 weeks intervention, 3 times daily
41144852|NCT01313988|DIETARY_SUPPLEMENT|Placebo|4 weeks, 3 times daily
41144853|NCT05220813|DRUG|Lidocaine|local infiltration by lidocaine in the surgical site
41144854|NCT05220813|DRUG|Bupivacain|44patients will receive bupivacaine in ilioinguinal \& iliohypogastric nerve blocks
41144855|NCT00158847|DRUG|fluticasone 500 mcg|
41464140|NCT04645940|DRUG|fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole|"fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
40781927|NCT02751944|DIETARY_SUPPLEMENT|Placebo|Placebo
40781928|NCT05439733|OTHER|Questionnaire completion|Women will be asked to complete questionnaires 6 weeks after delivery
40781929|NCT05431647|OTHER|Sensory integration therapy|The individuals were divided into two as randomized controlled. Both physiotherapy and sensory integration therapy were applied to the intervention group. Each treatment was applied as 2 sessions per week, 2 days a week for 8 weeks. In the control group, only physiotherapy treatment was applied for 8 weeks, 2 days a week, 2 sessions per week.
40781930|NCT00579644|DRUG|Combination of Minocycline and MTX or MTX alone|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
41144856|NCT00158847|DRUG|fluticasone 500 mcg + salmeterol 50 mcg|
41144857|NCT01406899|BEHAVIORAL|Computer Based Treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
41305464|NCT05908344|DEVICE|Deactivated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system that produces a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
41305465|NCT05949099|DRUG|Nirogacestat|Nirogacestat 150 mg by mouth twice-daily continuously for Cycles 1 through 3. Treatment with nirogacestat may continue via this study protocol for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, start of new anticancer therapy, or Subject Study Completion or Termination occurs.
41305466|NCT05949099|PROCEDURE|Cryoablation|Cryoablation procedure (single session) of one tumor mass between Cycles 3 and 4 of nirogacestat treatment
41305467|NCT05901038|DEVICE|Wearing heart rate monitors|Participants will use 2 consumer wearable heart rate monitors: Polar H10 chest strap and Fitbit Inspire 2 fitness tracker.
41305468|NCT00071201|DRUG|Adefovir Dipivoxil for oral suspension, 2 mg/mL|
41305469|NCT03430687|OTHER|Laboratory Biomarker Analysis|Correlative studies
40781931|NCT00579644|DRUG|methotrexate|"Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study."
40781932|NCT06361134|BEHAVIORAL|SAFE Early İntervention|As part of the intervention, sensory-based intervention was applied in an enriched environment. In the home setting, physiotherapists collaborated with the family to advance the intervention. The intervention was revised by making monthly home visits to infants with a corrected age of 42 weeks.
40781933|NCT06361134|BEHAVIORAL|NDT based therapy|Neuromotor evaluations of the babies were performed in a clinical setting. The rehabilitation program to be implemented was given to the family as a booklet. The programs of the children examined in the clinic every month were revised.
41305470|NCT03430687|BIOLOGICAL|Talimogene Laherparepvec|Given intravesically
41305471|NCT04649203|DRUG|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.
40781934|NCT05907811|PROCEDURE|Neuromuscular blocker usage|The patients were followed up, the total amount of muscle relaxant used was determined, intraoperative effects and postoperative analgesic usage
40781935|NCT04027647|DRUG|Dacomitinib|30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.
40781936|NCT03988426|BIOLOGICAL|Octanorm|Octanorm
40781937|NCT03680807|DIAGNOSTIC_TEST|Muscle function test|Power and strength tests of the knee-extensor muscles, handgrip strength, functional capacity tests
40781938|NCT01877304|DEVICE|AKITA|
40781939|NCT05253404|DEVICE|Ambu® AuraOnce™ Disposable Laryngeal Mask|Switching endotracheal tube to laryngeal mask at sevoflurane 2.63-2.97%, Removing endotracheal tube when spontaneously generating tidal volume of \>4ml/kg, EtCO2\<45mmHg, Train of four ratio \>70-90%.
40781940|NCT01336816|OTHER|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
40781941|NCT01336816|OTHER|Placebo Wintergreen|Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
40781942|NCT04435743|DRUG|Lenalidomide|"Lenalidomide is given as any following dosage:~1. 25mg, PO QD, Day 1-10 in every 21 days for 6 cycles;~2. 15mg, PO QD, Day 1-14 in every 21 days for 6 cycles;~3. 25mg, PO QD, Day 1-10 in every 21 days for 1 year;~4. 25mg, PO QD, Day 1-21 in every 28 days for 1 year;~5. 25mg, PO QD, Day 1-10 in every 28 days for 12 cycles;~6. 20mg, PO QD, Day 1-21 in every 28 days for 12 cycles."
40781943|NCT02107612|DEVICE|Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture|
40781944|NCT02107612|OTHER|Denture|
40781945|NCT02475421|BIOLOGICAL|Glucagon|One hour glucagon-clamp followed by one hour of blood sampling
40781946|NCT02990650|BEHAVIORAL|Balance Task Training with therapist guarding support|"Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The therapist will provide guarding support"
40781947|NCT02990650|BEHAVIORAL|Balance task training with robotic guarding support|"Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot"
40781948|NCT02990650|BEHAVIORAL|Challneged balance task training with robotic guarding support|"Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot"
40781949|NCT01480167|DEVICE|Vertebral Augmentation (STABILIT)|Vertebral Augmentation with the STABILIT Vertebral Augmentation System
40781950|NCT01480167|OTHER|Non-operative Management|Conservative Care
41305472|NCT04649203|DRUG|Placebo|The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
41305473|NCT02099916|DRUG|gonadotropins plus DHEA|Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
41305474|NCT02099916|DRUG|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
41305475|NCT04730986|BEHAVIORAL|ED GOAL Nursing|A brief (\<7minutes) interview by an emergency department nurse to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
41305476|NCT03057834|BEHAVIORAL|Pelvic floor muscle exercise|Standardized pelvic floor muscle exercise regimen
41305477|NCT00926796|DRUG|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 gm dose.
41464141|NCT04645940|DRUG|fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole|"fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
41464142|NCT05491512|DIAGNOSTIC_TEST|18 F-FMISO PET/CT|The 18F-FMISO PET/CT Scan Protocol consists first of an IV bolus injection of approximately 5-10 mCi of the radiotracer. At between 150-180 mins post injection, 18F-FMISO images will be acquired.
40781951|NCT01684670|BEHAVIORAL|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
40781952|NCT00725088|BEHAVIORAL|Exercise training|Exercise training
40781953|NCT04016857|PROCEDURE|RIPC|4 cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of arm cuff
41464143|NCT05491512|RADIATION|Radiation|Total Radiation Dose (over 3 weeks) 30Gy\*\* in 2 Gy per fraction
40781954|NCT04016857|PROCEDURE|Control|deflated cuff placed on the left arm for 40 min
41305478|NCT00926796|DRUG|Gentamicin|Fixed dose of 240 mg intramuscular one time for patients \>45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
41464144|NCT05491512|DRUG|Cisplatin|Concurrent chemotherapy (2 cycles) will be given. At the start of week 1 of radiation, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2 ), typically on days 1 and 2, or as a single dose, typically on day 1.
41464145|NCT05491512|DRUG|Carboplatin|"If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).~(Cohort B to start carboplatin (AUC 1.5) and paclitaxel 45 mg/m2 at the start of RT)"
40781955|NCT01926743|PROCEDURE|Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy|0.75mg of ICG injection around tumor each four direction by endoscopy on one or two days before surgery. NIR fluorescence imaging application during laparoscopic or robotic gastrectomy
40781956|NCT02194114|OTHER|Protein Diet|Protein diets fed for 17-19 days to each patient in random order: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
40781957|NCT04712747|PROCEDURE|Ophthalmological examinations|"* OCT (Optical Coherence Tomography): posterior pole OCT B scan , optic nerve and posterior pole OCT Angiography~* Adaptive optics (AO) : Image acquisition on the vessels at the exit of the optic nerve before the first upper temporal bifurcation OD or OG and evaluation of the photoreceptor mosaic. Adaptive optics may require dilatation of the pupil with a drop of tropicamide in the eye examined a few minutes before the examination.~* Color retinophotography~* Measurement of intraocular pressure~Patients with stroke : At the inclusion visit and 3 months after their stroke Control group : At the inclusion visit."
40781958|NCT04712747|PROCEDURE|Blood pressure measurement at rest|At the inclusion visit
40781959|NCT01029535|DEVICE|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
40781960|NCT02379052|DRUG|Dupilumab|
41305479|NCT00926796|DRUG|Gemifloxacin|One 320 mg tablet administered orally.
40781961|NCT02379052|DRUG|Placebo|
40781962|NCT02329743|DRUG|RX-10045|topical therapy
40781963|NCT00281424|DEVICE|pedometer|gave pedometer and info
40781964|NCT01220661|DRUG|Cefotetan|preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)
40781965|NCT06089993|OTHER|Exercise|"The total volume of exercise is 40 repetitions of each of the 4 exercises. The participant is instructed to perform a maximum of 10 repetitions each set, with 1'30'' rest between sets and between exercises. The researcher provides instructions and verbal encouragement. The total duration of the exercise bout is between 1 hour and 1 hour and 15 minutes.~Part 1: Before and after the exercise condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
40781966|NCT06089993|OTHER|Rest|"The participant remains in sedentary activities such as reading or using a laptop.~Part 1: Before and after the rest condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
40986420|NCT06267950|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
40986421|NCT00298181|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
40986422|NCT04225728|DRUG|Iron Sucrose IV|"Intervention will consisted of the administration for the IV route.~-The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14."
41305480|NCT03246217|BEHAVIORAL|Therapeutic Instrumental Music Performance|Participants will play a variety of instruments (acoustic and electronic) to facilitate retraining of everyday functional movements.
41305481|NCT03246217|BEHAVIORAL|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
41305482|NCT03246217|BEHAVIORAL|Therapeutic Performance with Motor Imagery|Participants will engage in motor imagery of previously practised movements.
40781967|NCT01812057|DRUG|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
40781968|NCT01812057|DRUG|Placebo|Sodium Chloride 0.9% -5 ml
41305483|NCT01438567|DRUG|oxycodone/naloxone prolonged release (OXN PR) tablets|Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
41305484|NCT01438567|DRUG|oxycodone prolonged release (OxyPR) tablets|Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
41464146|NCT05491512|DRUG|5-fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
41305485|NCT00347854|OTHER|Systane Free lubricant eye drops|
41305486|NCT00347854|OTHER|Visine Tears Lubricant Eye Drops|
41305487|NCT00347854|OTHER|Refresh Liquigel Lubricant Eye Drops|
41305488|NCT00347854|OTHER|Refresh Plus Lubricant Eye Drops|
41305489|NCT01150994|BEHAVIORAL|Safety Assessment and Follow-up Telephone Intervention (SAFTI).|Mental health evaluation in ED, followed by Post-ED counseling
41305490|NCT03984318|PROCEDURE|Blood sample|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
41305491|NCT04194658|DRUG|Letrozole 2.5mg|Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
41305492|NCT06042751|BEHAVIORAL|Exercise Therapy|Six online consultations will take place on the basis of the sports medicine assessment every two weeks, resulting in 300 min in 3 months. For the home-based implementation, participants receive wearables with which the activity and training data are collected. In conjunction with feedback, the goal is to ensure that the interventions lead to improvements in self-control, reduced resilience, and fatigue without overwhelming participants with volume or intensity. Due to the expected large differences in personal performance, determined in the initial assessment, the exercise plan is individually designed and regularly adjusted. This includes control of everyday activity as well as moderate endurance and strengthening exercises totalling up to 30min daily. The individual training intensity is below the aerobic lactate threshold so that overload is avoided. The average training heart rate is planned to be in the range between 50 and 70% of the maximum heart rate.
41305493|NCT06042751|BEHAVIORAL|Psychotherapy|Six online consultations will take place based on the psychosocial assessment and the initial psychosomatic interview every two weeks, resulting in 300 min in 3 months. A structured, telemedicine-supported, modularized, brief psychosomatic intervention is planned with a focus on psychoeducational elements, promotion of self-management, improvement of illness acceptance, modification of self-monitoring, and learning to cope with altered performance levels. The six modularized telemedical sessions taking into account the specific deficits identified in the psychosomatic evaluation. Within the sessions, starting points are identified with the patients, which the patients can work on independently between the sessions.
41305494|NCT01121159|PROCEDURE|orbital fracture repair|All patients will receive orbital fracture repair with one of the 4 specified implants
41305495|NCT02307344|DIETARY_SUPPLEMENT|Nigella Sativa|
41305496|NCT02307344|DIETARY_SUPPLEMENT|Placebo|Capsules that contain a placebo but look like the Nigella Sativa capsules
41305497|NCT05427071|DEVICE|Magnetic seed localization|Magnetic seed guided localization
41305498|NCT05078333|OTHER|dry needle|dry needling (on 3 trigger points on the bilateral trapezius muscle) will applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
41464147|NCT05685017|DIAGNOSTIC_TEST|Nur Aisiyah Widjaja|Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation
41464148|NCT04861740|OTHER|Autism ALERT|Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
41464149|NCT04861740|OTHER|Screening Intervention|Autism screening intervention only.
41464150|NCT03770793|PROCEDURE|Lung-sono guided|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, alveolar recruitment is performed to the non-surgical side of lung under examination with ultrasound just after anesthesia induction.~During the gradual increment in the pressure of recruitment, the anesthesiologist can find the opening pressure that means the minimal pressure at which observed atelectasis starts to disappear.~Then, alveolar recruitment is performed with the opening pressure until the atelectasis is not visible."
41305499|NCT05078333|DEVICE|high intensity laser therapy|High intensity laser therapy (HILT), one of the physical therapy methods, was approved by the FDA in 2002. Its beneficial and versatile effect has been proven in the treatment of many musculoskeletal diseases. In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
41305500|NCT00409604|DEVICE|Temporary RV VVI pacing|temporary pacing at the onset of revascularisation
41305501|NCT04836455|BEHAVIORAL|The FDA's The REal Cost vaping prevention ads - Health harms theme|Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about the health harms of vaping will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
41305502|NCT04836455|BEHAVIORAL|The FDA's The Real Cost vaping prevention ads - Addiction theme|Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about vaping addiction will be shown to participants at week 0, 1, and 2. Ads will be shown in a random order.
41305503|NCT04836455|BEHAVIORAL|Neutral vaping ads|Three neutral (i.e., purely informational and without graphics) vaping video ads developed by the Investigators will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
41305504|NCT01401816|OTHER|Text Message|Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
41464151|NCT01978873|DRUG|Cabazitaxel + Androgen deprivation therapy|Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
40781969|NCT03274765|DIAGNOSTIC_TEST|Dosage of oestradiol|"The study is based on a concept using capillary blood tests using lateral flow by migration on membrane similarly to a pregnancy test, patented by a french company (NGBiotech).~This study is therefore a feasibility study of a rapid test for oestradiol dosage during monitoring of ovarian stimulation."
40781970|NCT05198401|OTHER|covid-19|viral infection
40781971|NCT00727116|BEHAVIORAL|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
40986423|NCT04225728|DRUG|Ferric polymaltose hydroxide complex IM|Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
40986424|NCT04225728|OTHER|Saline solution|100 ml i.v. of normal saline administered at Day 0 and at day 14.
40986425|NCT01968590|DRUG|Cholecalciferol|DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose. Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
40986426|NCT01660607|BIOLOGICAL|Conventional T cells (Tcon) and Regulatory T cells (Treg)|A baseline cell dose of conventional T cells of 1x10\^6/kg will be used with escalation to the maximum tolerated dose up to 1x10\^7/kg
40986427|NCT05701410|DIAGNOSTIC_TEST|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin amyloidosis.
41144858|NCT03843333|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|TJQMBB is an evidence-based, Centers for Disease Control and Prevention (CDC)-recommended, group falls prevention program based in Tai Chi that has been shown to reduce falls risk, improve physical function, and improve cognition. The program is delivered in 1-hour sessions twice weekly over 24 weeks, with the first 12 weeks spent learning the basic Tai Ji Quan forms and the second 12 weeks focused on variations in practice that progressively increase physical and cognitive demands. A physical therapist at Dartmouth is an authorized TJQMBB trainer and will train the CHWs to deliver the intervention and provide remote supervision monthly.
41144859|NCT03843333|BEHAVIORAL|Behavioral Activation|BA is a brief intervention for depressive symptoms that focuses on engagement in positively-reinforcing activities and decreasing activity avoidance. CHWs will be trained by Dartmouth psychologists to deliver a brief behavioral activation program to encourage participants to increase their involvement in meaningful activities. BA will be delivered in one-hour sessions in the home every other week for 12 weeks. Supervision will be provided remotely on a weekly basis.
41144860|NCT03843333|OTHER|Resource Navigation|CHWs will assess participants' unmet psychosocial needs and assist them in identifying and connecting them with resources to address these needs.Types of assistance may include identifying transportation services, assisting with applications for benefits, linking participants to Meals on Wheels and other local food resources, and connecting participants to community programs for older adults. We expect that participant needs and services delivered will vary and acknowledge that this intervention component will not be standardized due to the nature of this work.
41305505|NCT01343134|DEVICE|Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)|Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
41305506|NCT03433287|DIAGNOSTIC_TEST|18F-NaF-PET/MRI|PET/MRI scan after injection of 18F-labelled sodium fluoride
41464152|NCT01978873|DRUG|Androgen deprivation therapy|LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
40986428|NCT01735643|DEVICE|interactive videogame Wii Fit Plus|Use of the interactive videogame Wii Fit Plus für 12 weeks.
40986429|NCT01735643|OTHER|waiting|waiting for 12 weeks
41464153|NCT06353412|PROCEDURE|Lumbar puncture|Medical treatment Lumbar puncture Theco peritoneal shunt
40986430|NCT03297385|DRUG|Enzalutamide|Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
40986431|NCT02484742|BEHAVIORAL|Insomnia symptom induction|Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
40986432|NCT05700981|DIAGNOSTIC_TEST|colon capsule endoscopy|Patient allocated for the intervention arm will have a CCE using the PillCam Colon 2 (Medtronic, Minneapolis, Minnesota, USA). Upon inclusion and allocation to the intervention arm patients are contacted by a dedicated CCE nurse. The course of the CCE procedure and preparations are explained thoroughly. In case of additional questions patients can contact the nurses by telephone during office hours (Monday-Friday, 8am-3pm). Before the CCE participants will have to undergo a bowel preparation procedure. The bowel preparation kit will be distributed by mail and is to be completed at home, beginning 72 hours before the CCE. The kit contains polyethylene glycol (PEG) sachets (Movicol, Norgine Danmark A/S, Herlev, Denmark), PEG solutions (MoviPrep, Norgine Danmark A/S, Herlev Denmark) and instructions on how to properly perform the preparation procedures.
40781972|NCT00727116|BEHAVIORAL|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
40781973|NCT02805452|DRUG|Succinate of Solifenacin|
41464154|NCT01309724|OTHER|USCOM-guided fluid administration|Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
40986433|NCT02248350|BEHAVIORAL|Supervised and Home Based Exercise|Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
40986434|NCT02248350|BEHAVIORAL|Stretching Control Group|Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
40986435|NCT01361464|DRUG|Tipifarnib|Given PO
40986436|NCT01361464|OTHER|Laboratory Biomarker Analysis|Correlative studies
41464155|NCT01367938|DEVICE|OMNI Apex Ultracongruent Knee Device|
41464156|NCT01449409|OTHER|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
41464157|NCT02805309|BEHAVIORAL|Exercise|Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.
40781974|NCT02805452|DRUG|Placebo of Succinate of Solifenacin|
40781975|NCT00329030|DRUG|Autologous transplantation using rituxan/BEAM|Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
40986437|NCT06249412|DEVICE|MI-E with PEP function activated during the pause|PEP function will be activated during the pause when using the EOVE-70. The PEP function in cmH2O will start at 8 cmH2O; the PEP setting can be decreased or increased at the discretion of the practitioner to optimize. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
40986438|NCT06249412|DEVICE|MI-E without PEP function activated during the pause|The PEP function will not be activated during the pause when using the EOVE-70. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
40986439|NCT02126956|DRUG|ACT-128800|ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
40781976|NCT00329030|DRUG|Autologous transplantation using Bexxar/BEAM|Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
41464158|NCT02805309|BEHAVIORAL|Cognitive behavioral interventions|The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.
40781977|NCT02612493|OTHER|Obese patients with type I diabetes|Postsurgical follow - up in obese patients with type I diabetes
40781978|NCT06251414|BEHAVIORAL|Exercise Intervention|Blood Flow Restriction (BFR) training, also known as occlusion training or restricted blood flow training, involves applying external pressure to a limb using inflatable cuffs or elastic bands. This pressure partially restricts arterial blood flow while occluding venous blood flow in the pressured limb. The goal is to increase muscle strength and size by creating metabolic stress and promoting physiological adaptations, such as muscle hypertrophy, with lighter loads than traditional resistance training.
40781979|NCT06251414|BEHAVIORAL|Instrument-Assisted Soft Tissue Mobilization|Instrument-Assisted Soft Tissue Mobilization (IASTM) is a therapeutic technique that involves the use of specially designed tools or instruments to apply controlled mechanical pressure to soft tissues in the body. These tools are typically made of stainless steel or other materials and have various shapes and edges. The primary aim of IASTM is to address musculoskeletal conditions by breaking down scar tissue, fascial restrictions, and adhesions in the soft tissues. Practitioners use the instruments to detect and treat areas of tissue dysfunction, promoting improved range of motion, reduced pain, and enhanced functional mobility.
40781980|NCT06251414|BEHAVIORAL|Tuinal|Tuinal, also known as Tui Na or Chinese therapeutic massage, is a traditional Chinese medicine (TCM) healing technique that involves manual manipulation of the body's soft tissues, including muscles and tendons. It is a form of bodywork that aims to balance the flow of vital energy (Qi) within the body and promote overall well-being. Tuina techniques may include kneading, rolling, pressing, and brushing, and they are applied to specific acupressure points or along the body's meridians. Tuina is used to address various health concerns, alleviate pain, improve circulation, and enhance the body's natural healing processes, making it an integral part of traditional Chinese medicine.
40781981|NCT02474979|DEVICE|CBPM-system|The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.
40781982|NCT02474979|OTHER|Control|
41464159|NCT02805309|BEHAVIORAL|Attention control education program|A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
40781983|NCT04068805|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
40781984|NCT02398812|OTHER|Medication assessment and treatment plan based on it|"Intervention~* Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.~* Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician."
40781985|NCT00401076|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
40781986|NCT04487405|DEVICE|OVAnex|OVAnex is a multivarite index assay assessing ovarian cancer risk
40781987|NCT03445312|BEHAVIORAL|not processing urine cultures|microbiology lab will not process culture unless called
40781988|NCT02296476|DRUG|Birabresib|Administered orally in a fasted state once daily.
40781989|NCT01644643|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
40781990|NCT01644643|DRUG|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
40781991|NCT01644643|DRUG|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
40781992|NCT05562505|OTHER|Venovenous ECMO|ECMO therapy for patients with hypoxic respiratory failure.
41464160|NCT02726386|DRUG|ND0612|ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
41464161|NCT04178382|DIAGNOSTIC_TEST|PCR-CRISPR／Cas12a detection|Evaluate whether the combination of PCR and CRISPR/Cas12a detection of alveolar lavage fluid changes the choice of early antibiotics in patients with pneumonia in artificial airways, and whether it changes the prognosis compared with traditional pathogenic microbial detection techniques.
40986440|NCT01109251|PROCEDURE|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
41464162|NCT00919334|DEVICE|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
40781993|NCT03237806|DRUG|Deep sedated|Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
41464163|NCT00111137|DRUG|rHuEPO|rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
41464164|NCT00111137|DRUG|Darbepoetin alfa|4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
40781994|NCT03237806|DRUG|Light sedated|Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
40986441|NCT01109251|PROCEDURE|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
40986442|NCT03442621|DRUG|Relacorilant Fasted|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10.5 h fast
41464165|NCT05218109|DEVICE|tVNS|transcutaneous vagus nerve stimulation
41464166|NCT05218109|BEHAVIORAL|Mindfulness|Brightmind mobile mindfulness application
41464167|NCT05218109|DEVICE|sham tVNS|sham transcutaneous vagus nerve stimulation
40781995|NCT01744015|BEHAVIORAL|Patient Decision Making tool|The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
40781996|NCT01744015|OTHER|Standard of care|A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
40781997|NCT00832013|DRUG|Propofol|See detailed description
40986443|NCT03442621|DRUG|Relacorilant with a high fat breakfast|Relacorilant presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a high fat breakfast
40986444|NCT03442621|DRUG|Relacorilant with a moderate breakfast|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a moderate breakfast
40986445|NCT03930043|DIAGNOSTIC_TEST|Metagenomic shotgun sequencing|preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen
41464168|NCT05218109|OTHER|Number Puzzle|Control number puzzle task delivered via mobile device
40781998|NCT00832013|DRUG|Propofol|See detailed description
40986446|NCT03130842|DRUG|Sublingual alprazolam|Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
40781999|NCT03470350|DRUG|Galunisertib|treatment with capecitabine and galunisertib
40782000|NCT03674892|DEVICE|TrueTear™ intranasal neurostimulator (ITN)|Subject will place the tips of the ITN into both nostrils simultaneously. Subject will be asked to apply it for 3 minutes \[could be modified if need be\], daily.
40986447|NCT03130842|DRUG|Oral midazolam|Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
40986448|NCT02478801|DIETARY_SUPPLEMENT|amino acids intake|amino acids intakes will be varied at 0.2-2.8 g/kg/day
40782001|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|50 mg twice-daily (BID)
40782002|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|150 mg quaque die (QD)
40782003|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|200 mg quaque die (QD)
41305507|NCT01986569|DRUG|[18F]fluoroestradiol (FES)|\[18F\]FES PET/CT will be performed 90 min (± 10 min) after administration of \[18F\]FES. Patients will undergo core needle biopsy or surgery within 15 days after \[18F\]FES PET; or patients will undergo core needle biopsy within 30 days before \[18F\]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
41305508|NCT01383395|DRUG|simvastatin/cilostazol|
41305509|NCT03847155|DRUG|Nicotine patch|The patients will receive a nicotine patch for the period of a maximum of 7 days.
41305510|NCT03847155|OTHER|Placebo patch|The patients will receive a placebo patch for the period of a maximum of 7 days.
41305511|NCT02028429|DRUG|Sildenafil.|Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
41305512|NCT02353351|DEVICE|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
41464169|NCT02861651|OTHER|DNA sequencing|
40782004|NCT01444105|DEVICE|iStent|Implantation of two iStent devices
40782005|NCT01444105|OTHER|SLT|Laser treatment
41464170|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
41464171|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
41464172|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
40782006|NCT03545672|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
40986449|NCT04576130|DEVICE|Implantable cardioverter defibrillator|Implantation of an ICD for secondary prevention
40986450|NCT04450147|BEHAVIORAL|Tai Chi/Qigong vs. Walking/Stretching|Both interventions can be thought of as a form of movement and exercise.
40986451|NCT01818154|OTHER|LED phototherapy|
40986452|NCT01818154|OTHER|narrowband UVB phototherapy|
40986453|NCT03711487|DRUG|Foeniculum Vulgare Seed Ironing|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
40986454|NCT00999791|DRUG|Bevacizumab|
40986455|NCT00999791|DRUG|Diclofenac|
40986456|NCT01456104|BIOLOGICAL|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
40986457|NCT03113019|BIOLOGICAL|Immunotherapy based on dendritic cells|Intravenous injection of cells
40986458|NCT01522755|DEVICE|Pacing system implant with the CapsureFix MRI pacing lead model 5086|Pacing system implant with the CapsureFix MRI pacing lead model 5086
41464173|NCT04973800|DRUG|Simvastatin 20mg|Simvastatin 20mg ON PO for 28-30 days
41464174|NCT04973800|DRUG|Placebo|Sucrose placebo ON PO for 28-30 days
41464175|NCT01068704|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, \~ 12 months depending on response
41305513|NCT00429065|DRUG|Rituximab|
41305514|NCT04547738|DRUG|TB treatment according to national guidelines|National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis
41305515|NCT00798213|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
41305516|NCT00798213|DRUG|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
41305517|NCT00040833|PROCEDURE|complementary or alternative medicine procedure|
41305518|NCT00040833|PROCEDURE|pain therapy|
40782007|NCT03421184|OTHER|blood sample|25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
41305519|NCT00406952|PROCEDURE|electronic diary|
41305520|NCT00406952|DRUG|Sertraline|
41305521|NCT00406952|DRUG|Placebo|
40782008|NCT03421184|OTHER|urine sample|10 ml
41305522|NCT00406952|PROCEDURE|voice acoustics|
40782009|NCT03421184|OTHER|food questionnaire|dietary habit enquiry and a 48h dietary
41305523|NCT01028651|DRUG|Treprostinil|"Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.~Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min."
41305524|NCT00000271|DRUG|Desipramine|Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
41305525|NCT00000271|DRUG|Placebo|Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
41305526|NCT06504173|PROCEDURE|diced cartilage|In reconstructions using DC management of IMVES, the surgical nurse processed the removed cartilage into DC using a dermatome blade. Cartilage pieces of approximately 0,5-1 mm were used. After microvascular anastomosis (coupler device for venous anastomosis; Synovis MCA, Birmingham AL, USA), all DC was placed back into the rib removal zone using a blunt dissector. The vessels were embedded and stabilized in cartilage paste according to the desired orientation.
41305527|NCT06484530|DRUG|N acetyl cysteine|1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.
40782010|NCT03421184|OTHER|hair|lock of hair
40782011|NCT05780879|DRUG|Venetoclax|Venetoclax administered orally once daily on days 3-16.
40782012|NCT05780879|DRUG|FLAG or CLAG Protocol|FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days with daily subcutaneous injections of G-CSF until count recovery. Tbo-filgrastim will be administered as follows: WBC count \>50,000 - 5mcg/kg; WBC count \<50,000 - hold Tbo-filgrastim. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
40782013|NCT05129956|DEVICE|"Covidien Emprint Ablation System with Thermosphere Technology"|The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes
41305528|NCT05379426|OTHER|Impact COVID-19 pandemic|Battery of screening tests and the semi-structured interview focusing on the difficulties experienced by the older adult during the pandemic period.
41305529|NCT04363086|BEHAVIORAL|iFightDepression online self-help tool|Computerized cognitive behavior therapy
41305530|NCT04363086|BEHAVIORAL|Treatment as Usual|TAU
41464176|NCT01068704|DRUG|Lapatinib|Tablets, Oral, 1500 mg, once daily, \~ 12 months depending on response
41464177|NCT01068704|DRUG|Letrozole|Tablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response
41464178|NCT06282406|OTHER|Transcutaneous Electrical Stimulation|Electrical pulse trains applied to the skin overlying putative sites of auricular vagal innervation.
41464179|NCT06282406|OTHER|Sham|Electrodes placed on the skin overlying putative sites of auricular vagal innervation but no current administered.
40782014|NCT02196753|OTHER|PET CT|"All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient's weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.~In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV\> 40% of the background."
41305531|NCT04363086|BEHAVIORAL|phone call|phone call
41305532|NCT03027804|PROCEDURE|Ross Operation|Replacement of the aortic valve by means of pulmonary artery autograft
41305533|NCT03021798|OTHER|No Drug and no aspecific intervention|No intervention
41305534|NCT04211610|DIAGNOSTIC_TEST|Blood and urine sampling|"* Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin."
41305535|NCT02370849|DRUG|nimotuzumab|nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
41305536|NCT02370849|DRUG|cisplatin|cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
41305537|NCT02370849|DRUG|S-1|S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
41305538|NCT00188877|PROCEDURE|intensity modulated radiation therapy|
41305539|NCT00188877|DRUG|cisplatinium and fluorouracil - standard treatment|
41305540|NCT00538980|DRUG|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
41464180|NCT05795296|DRUG|Fruquintinib|Fruquintinib: 5mg po, d1-d14, q3w
41464181|NCT05795296|DRUG|Sintilimab|Sintilimab: 200mg ivgtt, d1, q3w
40782015|NCT02107885|DRUG|DS-1971|6 subjects in each group will receive DS-1971.
40782016|NCT02107885|DRUG|placebo|2 subjects in each group will receive placebo.
40986459|NCT02587065|DRUG|peginterferon beta-1a|125 mcg administered subcutaneously (SC) every 2 weeks.
41305541|NCT03823417|DRUG|Tranexamic Acid|Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
41464182|NCT06112054|DEVICE|Clotild Smart Guidewire System (CSGS)|In the current study, a commercially available CE marked guidewire will be used to direct a catheter through blood vessels while the Clotild® Smart Guidewire (study device) will only be used to perform electrophysiological measurements (via its sensors) in the blood vessels during peripheral endovascular procedures. It is thus designed for use as an adjunct to conventional angiographic procedure
41464183|NCT02208973|DRUG|PBF-680|5, 10, 20, 40 and 60 mg of PBF-680
41144861|NCT03843333|OTHER|Enhanced Usual Care|Comparison participants will receive a detailed resource guide on community supports for older adults. The research team will facilitate referrals to local resources (e.g. the Dartmouth Aging Resource Center) if desired by participants. Data from research assessments of cognition, depressive symptoms, mobility, and functional status will be provided to the primary care team for follow-up and intervention as needed.
41144862|NCT01714479|OTHER|Leucine-enriched nutritional supplement|A protein and carbohydrate supplement with high levels of leucine
41144863|NCT01714479|OTHER|Placebo|
41305542|NCT03823417|DRUG|Normal saline|Normal saline infusion
41305543|NCT05804305|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue
40782017|NCT00778427|DRUG|metformin hydrochloride 1000 mg tablets|
40986460|NCT05330455|DRUG|GSK3965193|GSK3965193 will be administered
41305544|NCT05804305|DRUG|Placebo|Placebo contained substance that has no therapeutic value.
41305545|NCT02715960|DRUG|Acitretin Capsules|During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
41305546|NCT03857763|COMBINATION_PRODUCT|Apatinib,Paclitaxel,Cisplatin,RT|Apatinib Mesylate Tablets 250mg qd p.o. d1-35; Paclitaxel：50mg/m2 iv d1，8，15，22，29; Cisplatin: 30mg/m2 iv d1，8，15，22，29; RT：41.4Gy/23f , 1.8Gy/f，5 f/w
40782018|NCT04551300|DRUG|VS-505|4 dosages of experimental drug
40782019|NCT04551300|DRUG|Sevelamer Carbonate|Active Comparator
41305547|NCT01175278|PROCEDURE|Vertebral Augmentation with Balloon Kyphoplasty|Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
41464184|NCT02208973|DRUG|Placebo|placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
41464185|NCT01337596|DRUG|LY2951742|Administered subcutaneously
41464186|NCT01337596|DRUG|Placebo|Administered subcutaneously
41464187|NCT00374166|DRUG|SSR149415|Oral administration (capsules of 50 and 100 mg)
41464188|NCT00374166|DRUG|Placebo|Oral administration (capsules)
41464189|NCT00374166|DRUG|Paroxetine|Oral administration (capsules)
41464190|NCT04805385|DIETARY_SUPPLEMENT|PS128|Each PS128 capsule contained \>1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
41464191|NCT03853096|DRUG|Cefazolin|Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.
40782020|NCT04254146|OTHER|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
40782021|NCT01426061|OTHER|Reflexology plus conventional treatment|Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
40986461|NCT05330455|DRUG|Placebo to match GSK3965193|Placebo to match GSK3965193 will be administered
41464192|NCT02528409|DRUG|Vortioxetine|Medication currently approved for major depression.
41464193|NCT02528409|DRUG|Placebo|
40782022|NCT01426061|OTHER|Homeopathy plus conventional treatment|Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
40986462|NCT05330455|DRUG|Bepirovirsen|Bepirovirsen will be administered
41144864|NCT05324748|DRUG|Methylprednisolone|Injection with prednisolon
41144865|NCT05324748|DRUG|Saline solution|0,9%
41144866|NCT02700009|BEHAVIORAL|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
41144867|NCT02700009|OTHER|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
41144868|NCT05689177|BIOLOGICAL|Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)|Booster dose administration
41144869|NCT05702190|DRUG|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
41144870|NCT05702190|DRUG|Placebo|Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
41144871|NCT00000250|DRUG|0% N2O|Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
41144872|NCT00000250|DRUG|40% N2O|Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
41144873|NCT00853957|DRUG|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
40782023|NCT01426061|OTHER|Conventional treatment|Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
40782024|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
40782025|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
40782026|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
40782027|NCT00149786|BEHAVIORAL|Family Based Therapy|Family therapy will be given for a total of 24 hours over the course of 12 months.
40782028|NCT00149786|BEHAVIORAL|Ego-Oriented Individual Psychotherapy|Individual therapy will be given for a total of 24 hours over the course of 12 months.
40782029|NCT04229888|DEVICE|LipiFlow|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
40782030|NCT04229888|DEVICE|Light Based (Sham) Treatment|A light based (sham) treatment will be used to compare effectiveness to the LipiFlow treatment.
40782031|NCT00641693|DRUG|Budesonide|16mg Nasal Spray
40782032|NCT00641693|DRUG|Budesonide|32mg Nasal Spray
40782033|NCT00641693|DRUG|Budesonide|64mg Nasal Spray
40782034|NCT00641693|DRUG|Placebo|
40986463|NCT06241339|OTHER|Mat Pilates|"Mat Pilates training will last 12 weeks, with three weekly trial sessions being held at 48-72h intervals. Each session will last approximately 60 minutes, including: 5 minutes of warm-up (light calisthenic exercises for the shoulder and pelvic girdles); 50 minutes of Mat Pilates exercises; 5 min back to calm.~Upon arriving at the training site, volunteers will rest for 10 minutes in a sitting position, after which BP measurements will be taken and HR at rest. Throughout consecutive training sessions, participants will perform Pilates method exercises with a progressively greater degree of difficulty and complexity, following the official recommendations for prescription of resistance exercise for individuals with BP elevated and post-stroke. The exercises will be performed in single sets of 10 repetitions. Groups will be advised to maintain daily activities without physical exercise during the 12-week period."
40986464|NCT02657382|BEHAVIORAL|Heart Rate Variability (HRV) Biofeedback (BF)|Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.
41305548|NCT01175278|OTHER|Non-surgical Treatment|Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
41464194|NCT01004510|DRUG|zoledronic acid|Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
40986465|NCT02657382|OTHER|Mental Stress Protocol|Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
40986466|NCT04177342|DRUG|Fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
40986467|NCT04177342|DRUG|Oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
40986468|NCT05337007|OTHER|high protein diet|48 hours intervention with a 'high protein' ad libitum diet (30 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
40986469|NCT05337007|OTHER|moderate protein diet|48 hours intervention with a 'moderate protein' ad libitum diet (13 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
40986470|NCT01928329|DRUG|Exenatide (Bydureon®)|
40986471|NCT01928329|DRUG|Placebo|
40782035|NCT02918526|DEVICE|airway management|airway management with Laryngeal Mask or Oro Tracheal Intubation
40782036|NCT04096417|DRUG|Pemigatinib|Given PO
41144874|NCT00853957|DRUG|Amlodipine|Amlodipine 5 mg titrated to 10mg
41144875|NCT02174315|BEHAVIORAL|Contingency Management|
40782037|NCT04096417|OTHER|Quality-of-Life Assessment|Ancillary studies
40782038|NCT06118645|DRUG|cadonilimab combined +paclitaxel (albumin-bound)|"1. In the safe induction phase6 subjects will receive cadonilimab (10mg/kg, Q3W, intravenous infusion, up to 2 years) and paclitaxel (albumin-bound type)(125 mg/m2,Days1, 8,Q3w, intravenous infusion, up to 8 cycles).~2. If the safety and tolerability are good, and the initial efficacy signal is observed, the extended enrollment phase will enter the extended enrollment phase of drug administration and the safety introduction phase"
40782039|NCT06000592|DEVICE|Digitimer|transcutaneous spinal cord stimulation for blood pressure control following spinal cord injury.
40782040|NCT04616937|DIETARY_SUPPLEMENT|GOS|Prebiotic
40782041|NCT04616937|DIETARY_SUPPLEMENT|Placebo|Placebo
40782042|NCT02750514|BIOLOGICAL|Nivolumab|Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
40782043|NCT02750514|DRUG|Dasatinib|
40782044|NCT02750514|BIOLOGICAL|Relatlimab|
40782045|NCT02750514|BIOLOGICAL|Ipilimumab|
40986472|NCT00584142|BEHAVIORAL|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
41464195|NCT00982228|DRUG|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
40782046|NCT02750514|DRUG|BMS-986205|Specified dose on specified days
40782047|NCT04575519|DRUG|Control group|placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
40782048|NCT04575519|DRUG|ASA group|Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
40782049|NCT04575519|DRUG|IBU group|Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
40782050|NCT04575519|DRUG|SoC TB|Standard of Care Tuberculosis treatment
40782051|NCT06097403|DIAGNOSTIC_TEST|Covid 19 swap|diagnostic tool
40782052|NCT03703388|DIETARY_SUPPLEMENT|Arctigenin|Arctigenin capsule
40782053|NCT04976023|DRUG|Yupingfeng Powder granules|14.5 5 g twice daily for 8 weeks
40782054|NCT04976023|OTHER|Placebo|14.5 5 g twice daily for 8 weeks
40782055|NCT00995852|DEVICE|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
40782056|NCT00995852|DEVICE|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
40782057|NCT02710539|DRUG|perindopril, indapamide , amlodipine|Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
40782058|NCT02710539|DRUG|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
40782059|NCT05801913|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
40782060|NCT05801913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40986473|NCT03340025|DEVICE|PICO Single Use Negative Pressure Wound Therapy System|Class II negative pressure wound therapy powered suction pump
41464196|NCT00982228|DRUG|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
41464197|NCT00982228|DRUG|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
41464198|NCT03527680|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|daily one capsule containing 1.6\*107 CFU of Lactobacillus Rhamnosus prepared by Tabriz Nutrition Research Center from yogurt and cheese of different farms located in the suburbs Heris, after meal for 28 days
40782061|NCT05801913|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40782062|NCT05801913|PROCEDURE|Computed Tomography|Undergo CT
40782063|NCT05801913|PROCEDURE|Leukapheresis|Undergo leukapheresis per SOC
40782064|NCT05801913|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion chemotherapy per SOC
40782065|NCT05801913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40782066|NCT05801913|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
40782067|NCT05801913|PROCEDURE|Positron Emission Tomography|Undergo PET
40782068|NCT05801913|PROCEDURE|X-Ray Imaging|Undergo x-ray
40986474|NCT03340025|DEVICE|xeroform gauze|traditional surgical dressing of xeroform gauze and padding
40986475|NCT03358901|DRUG|YC-6|
40986476|NCT03358901|DRUG|Vehicle|
40986477|NCT00671307|DRUG|rhu-pGelsolin|IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
40986478|NCT00671307|DRUG|Placebo|Vehicle control given as IV infusion over 1 hour
40986479|NCT06066645|DRUG|Travoprost Intraocular Implant|anchored intracameral implant containing travoprost in subjects who successfully received iStent infinite
40782069|NCT01426802|DRUG|vildagliptin|Drug 50mg vildagliptin bid
40782070|NCT04001400|DRUG|Rabeprazole 20mg bid|Rabeprazole 20mg tablet b.i.d.
40782071|NCT04001400|DRUG|Rabeprazole 20mg qd|Rabeprazole 20mg tablet q.d.
40986480|NCT06066645|OTHER|Sham procedure|Sham procedure (to mimic placement of travoprost intraocular implant) in subjects who successfully received iStent infinite
40986481|NCT06066645|DEVICE|iStent infinite|Successful iStent infinite surgery
40986482|NCT03641144|DEVICE|Navigation laser|Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.
40986483|NCT03641144|DEVICE|Traditional laser|Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
41464199|NCT03527680|DRUG|Placebo - Cap|daily one capsule of placebo
40782072|NCT04147273|DEVICE|Determination of postprandial glucose response by continuous glucose measurement after consuming different carbohydrate containing foods|"One day prior to the study beginning, participants were equipped with a CGM system (FreeStyle Libre®, Abbott Diabetes Care, Alameda, CA, USA). This CGM system provides glucose recordings every 15 min over a period of 14 days. The glucose data were downloaded manually by a scan with a handheld device.~On the second day of the study, participants consumed portions of these three test products containing 50 g of available carbohydrate on 3 separate days without a washout period. The products were tested in random order at the same time of the morning after a 10 h overnight fast. Venous blood samples were collected at 0, 15, 30, 45, 60, 75, 90, 105 and 120 min postprandial by inserting an intravenous cannula into a forearm vein. Capillary blood samples were obtained through finger pricking. Blood glucose levels in these samples were measured with a high quality SMBG system (ContourXT/Contour next, Ascensia Diabetes Care, Leverkusen, Deutschland, Germany)."
40782073|NCT01227785|DEVICE|INCEPTA ICD or CRT-D|
40782074|NCT00166127|DRUG|Levosimendan|
40986484|NCT04057079|COMBINATION_PRODUCT|Anugel, Hydrogel sponge|A calibrated sponge impregnated with hydrogel is inserted to the rectum post hemoroidectomy.
40986485|NCT04057079|COMBINATION_PRODUCT|Gelatine Sponge|A gelatine sponge is inserted in to the rectum pos hemoroidectomy.
40986486|NCT01207765|DRUG|indium-111-ibritumomab tiuxetan|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
40986487|NCT01207765|DRUG|90Y Zevalin|Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
40986488|NCT01879501|BEHAVIORAL|Low Vision Self-Management Program|The program has been describe above.
40986489|NCT02746874|PROCEDURE|Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
40986490|NCT02746874|PROCEDURE|Simulated Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
40986491|NCT04826770|DRUG|BNT162b2|vaccination against COVID-19
41305549|NCT01833273|DRUG|PolyMVA|Subjects will take 8 tsp/day of PolyMVA over a 26 week period while receiving standard of care from his/her neuro-oncologist. Subjects will begin taking the study compound after maximal surgical resection of the tumor and receiving an initial treatment of radiation therapy. Subjects will not take study compound on days when they receive chemotherapy.
40986492|NCT04826770|DRUG|AZD 1222|vaccination against COVID-19
41144876|NCT01736722|DEVICE|Visualase®|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
41305550|NCT06101173|BIOLOGICAL|Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
41305551|NCT06101173|BIOLOGICAL|Inactivated poliomyelitis vaccine (IPOL)|1 dose of IPOL vaccine (0.5ml) on Visit 1
41305552|NCT06101173|BIOLOGICAL|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
40986493|NCT04826770|DRUG|mRNA-1273|vaccination against COVID-19
41305553|NCT06101173|BIOLOGICAL|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
41305554|NCT06101173|BIOLOGICAL|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
41305555|NCT06101173|BIOLOGICAL|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
41305556|NCT00138151|BIOLOGICAL|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
41464200|NCT05832424|BEHAVIORAL|UPLIFT program|The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
40986494|NCT00002490|BIOLOGICAL|BCG vaccine|
40986495|NCT00002490|DRUG|mitomycin C|
41305557|NCT00138151|DRUG|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
41305558|NCT00138151|DRUG|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
41305559|NCT00219336|BEHAVIORAL|Self-guided Motivational Intervention|Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.
41305560|NCT00219336|BEHAVIORAL|Informational Only|Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
41305561|NCT00846079|DEVICE|Regadenoson (Lexiscan) [muti-detector computed tomography]|Regadenason, typical dosing
40986496|NCT00002490|RADIATION|radiation therapy|
40986497|NCT04275440|BEHAVIORAL|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
40986498|NCT04275440|BEHAVIORAL|Caloric restriction|"1. In the first two weeks, participants would reduce their daily energy intake to 100% -110% of his or her basal metabolic energy under instruction, and stick to it till the end of the intervention.~2. According to the dietary recommendation proposed by Chinese government, participants are required to take in cereals, vegetables, fruits, meat and eggs, while minimize the consumption of sugar-sweeten beverages.~3. Participants are instructed to arrange their three meals according to the recommended energy distribution (3:4:3)."
41305562|NCT02401750|DRUG|Oxycodone Naltrexone (a)|
41305563|NCT02401750|DRUG|Oxycodone Naltrexone (b)|
41305564|NCT02401750|DRUG|Placebo|Matches both experimental drugs
41305565|NCT00455247|DRUG|Glutamine|
41305566|NCT05420272|BEHAVIORAL|Trunk performance and endurance lower extremity biomechanic|Trunk performance and endurance lower extremity biomechanic
40782075|NCT03321071|BEHAVIORAL|Healthy Summer Learners|"Physical Activity Component. The physical activity component of Healthy Summer Learners is designed to engage children in moderate-to-vigorous physical activity (MVPA) for at least 50% of the time. With 3 hours each day dedicated to physical activity, this translates into children accumulating 90 minutes of MVPA daily. This is 30 minutes above the 60 minutes of MVPA each day recommended by the Physical Activity Guidelines for Americans.~Nutrition Component. The nutrition component of Healthy Summer Learners is designed to provide healthy snacks and meals and nutrition education via standardized pre-existing curricula.~Food/Beverage Guidelines. Meals will follow the USDA Nutrition Standards for the National School Lunch and School Breakfast Programs.~Academic Component. The academic component will consist of existing, effective academic programs focused on Math and Reading."
40782076|NCT03321071|BEHAVIORAL|21st Century Summer Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
41144877|NCT02836184|DRUG|Nicotinic Acids|Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.
41144878|NCT02836184|DRUG|Calcium Carbonate|Calcium Carbonate 500mg per oral, twice a day
41144879|NCT00267865|DRUG|Methotrexate|6000 mg/m\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
41144880|NCT00267865|DRUG|Rituximab|375 mg/m\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate
41144881|NCT00267865|DRUG|Leucovorin|Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
41144882|NCT00794274|DRUG|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
41144883|NCT06245317|DEVICE|Mechanical Ventilation Mode|Each arm will have a different ventilation mode according to the allocation.
41144884|NCT03237026|OTHER|No intervention required|No intervention required
41144885|NCT03807934|OTHER|Stimulation via Soterix Medical or Neuroelectrics noninvasive brain stimulation systems|Active (at or below 2mA) versus sham (at or below 0.5mA) stimulation targeting brain regions engaged during verbal and/or spatial perceptual and cognitive processing. Brain stimulation devices are not currently regulated by the United States Food and Drug Administration. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
41144886|NCT01848132|DRUG|Bortezomib|Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
41144887|NCT01848132|DRUG|Rituximab|Rituximab: intravenous, 375 mg/m2, day 1
41144888|NCT01848132|DRUG|Cyclophosphamide|Cyclophosphamide: intravenous, 750 mg/m2, day 1
41144889|NCT01848132|DRUG|Doxorubicin|Adriamycin:intravenous, 50 mg/m2, day 1
40986499|NCT06069960|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
40986500|NCT06133192|DRUG|Uvadex|Uvadex use for ECP
40986501|NCT06133192|DRUG|Steroids|steroids 2 mg/kg/d
40986502|NCT05245760|DRUG|Intravenous Tislelizumab|Participants will receive 200mg, every three weeks for up to 51 weeks
40986503|NCT05245760|DRUG|Chemotherapy|Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
40986504|NCT05245760|RADIATION|Fractionated radiation|Concurrent with chemo, x5 weeks
40986505|NCT05245760|PROCEDURE|Esophagectomy|Surgical resection of cancer after chemoradiation therapy when no disease progression found.
40986506|NCT00488345|DRUG|Tygacil|
41144890|NCT01848132|DRUG|Prednisone|Prednisone: oral, 100 mg, days 1-5
41144891|NCT01848132|DRUG|Vincristine|Vincristine: intravenous, 1,4 mg/m2, day 1
41144892|NCT05920538|DRUG|Nicardipine|Subcutaneous infiltrate drug at puncture site by ultrasound-guided
41144893|NCT05920538|OTHER|Normal saline|Subcutaneous infiltrate NSS at puncture site by ultrasound-guided
41144894|NCT01150305|BIOLOGICAL|blood sample|Peripheral whole blood sample, 5 ml
41144895|NCT04883515|DIETARY_SUPPLEMENT|Oral glutamine supplementation|patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks
41144896|NCT04883515|DIETARY_SUPPLEMENT|Oral protein powder supplementation|patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks
41144897|NCT04883515|PROCEDURE|Insulin-resistance evaluation|Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
41144898|NCT04883515|PROCEDURE|Functional intestinal disorders evaluation|Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
40782077|NCT04392973|COMBINATION_PRODUCT|Favipiravir and Hydroxychloroquine|"Route of Administration: Oral (or through Nasogastric tube)~Dose:~Favipiravir: Administer 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (total days of therapy is 10 days or till hospital discharge)~Hydroxychloroquine (400mg) twice daily on day 1; for days 2-5 (200mg) twice daily."
40782078|NCT01404650|DRUG|AUY922|AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
40782079|NCT05477654|DIAGNOSTIC_TEST|Extensive motor-cognitive testing protocol|Screening of their functional performance while monitoring brain and muscle activity
40782080|NCT00110214|DRUG|docetaxel|Given IV
40782081|NCT00110214|OTHER|placebo|Given IV
40782082|NCT00110214|DRUG|prednisone|Given orally
40782083|NCT00110214|BIOLOGICAL|bevacizumab|Given IV
40782084|NCT00110214|OTHER|laboratory biomarker analysis|Correlative studies
40782085|NCT05158413|DIETARY_SUPPLEMENT|High dose|Patients will receive a high dose of sesame paste or flour (1200 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
40782086|NCT05158413|DIETARY_SUPPLEMENT|Low dose|Patients will receive a low dose of sesame paste or flour (300 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
40986507|NCT00826800|DRUG|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
40986508|NCT00946426|OTHER|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
40782087|NCT04941690|OTHER|A questionnaire method was used.|The questionnaire included general population information, International Index of Sexual Function-5 (IIEF-5), Premature Ejaculation Diagnostic Tool (PEDT), General Anxiety Disorder-7 and CPSI.
40782088|NCT01641575|DRUG|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
41305567|NCT01252134|DEVICE|Biotrue multipurpose solution|Contact lens care solution
40986509|NCT01967212|DEVICE|Game-based swallow biofeedback|"The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator."
40986510|NCT01967212|BEHAVIORAL|Swallow training without biofeedback|"The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Mendelsohn's maneuver and effortful swallow without biofeedback 30 min."
40986511|NCT04728581|DRUG|Mirtazapine|Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.
40986512|NCT04728581|DRUG|Quetiapine|Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.
40986513|NCT04728581|DRUG|Placebo|a gelatinous capsule without an active ingredient
41305568|NCT01252134|DEVICE|Sauflon Synergi multipurpose solution|Contact lens care solution
40782089|NCT01861665|DRUG|Marcaine- 0.25%|Marcaine 0.25% administered pre-incision.
40782090|NCT01861665|DRUG|Marcaine 0.25%.|Marcaine 0.25% administered post-incision.
40782091|NCT02901886|BEHAVIORAL|Intensive smoking cessation intervention|The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
40782092|NCT04278703|DRUG|Oxycodone|Patients will be given a prescription for 15 opioid tablets for post-operative pain
40782093|NCT04278703|DRUG|Oxycodone|Patients will be given a prescription for 25 opioid tablets for post-operative pain
40782094|NCT04278703|DRUG|oxycodone|Patients will be given a prescription for 35 opioid tablets for post-operative pain
40782095|NCT01352429|RADIATION|Proton Therapy|
40782096|NCT01352429|RADIATION|IMRT|
40782097|NCT03912870|OTHER|Value of Flow Cytometry in Infectious Point of Care|"To validate the diagnostic orientation properties of two new biomarkers (CD64, CD169) for patients with infectious syndromes arriving in emergency departments. This prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (Pr Morange laboratory) without modifying the usual diagnostic and therapeutic procedures. The results of these assays will be compared with the diagnoses made at the end of treatment in order to determine their sensitivity and specificity.~This study is the preliminary study, necessary to determine the detection characteristics of these biomarkers."
40782098|NCT01141530|OTHER|No intervention|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
40782099|NCT05081921|DRUG|MesoCellA-Ortho administration|"Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups."
41144899|NCT02979678|OTHER|Questionnaire|The questionnaire should be updated with respect to wording, terminology.
41305569|NCT01252134|DEVICE|OTE Elements multipurpose solution|Contact lens care solution
41305570|NCT01252134|DEVICE|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
41305571|NCT04404595|BIOLOGICAL|CT041|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
41305572|NCT00046319|DRUG|BSF 208075|
40782100|NCT05081921|DRUG|HA administration|"Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups."
40986514|NCT00810407|DRUG|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily."
40986515|NCT02299986|OTHER|Ultrasound measurement|Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
41144900|NCT02848586|OTHER|ECIGS|15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.
40986516|NCT03092531|BEHAVIORAL|Positive STEPS|Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.
41144901|NCT02848586|BEHAVIORAL|mobile contingency management (mCM)|"mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study."
41144902|NCT02848586|OTHER|Usual brand|"The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study."
41144903|NCT00705172|DRUG|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
41305573|NCT02253706|DEVICE|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.
41305574|NCT02253706|DEVICE|low flow nasal oxygen supplementation|Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
41305575|NCT04006899|DEVICE|Bioelectrical Impedance Monitor|Subjects had been under the test of three commercially available devices and the device that the investigators had developed.
41305576|NCT03013322|DRUG|Physostigmine|
41305577|NCT03013322|DRUG|Isotonic Saline|
41305578|NCT02857907|OTHER|Blood sample|A blood sample is performed one year after kidney transplantation.
41305579|NCT05999474|DRUG|Topical tioconazole|Laser
41305580|NCT04379934|DIETARY_SUPPLEMENT|3-hydroxybuturate|3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model
41305581|NCT02218658|DRUG|WE941 OD tablets|
41305582|NCT02218658|DRUG|Brotizolam|
41305583|NCT00411788|DRUG|Rapamycin|oral rapamycin 6 mg daily
41305584|NCT00411788|DRUG|Trastuzumab|Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
41305585|NCT00002333|DRUG|Saquinavir|
41305586|NCT00002333|DRUG|Zalcitabine|
41305587|NCT05888428|DEVICE|MyoTrain|MyoTrain is a virtual prosthesis control training system. From a hardware perspective it consists of an Apple iPad tablet computer and an eight-channel EMG armband, based on the Element electrode platform, which interfaces with the tablet via Bluetooth™. From a software perspective, MyoTrain was developed in the cross-platform Unity 4.0 game development environment.
41305588|NCT05888428|BEHAVIORAL|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
41305589|NCT02150187|DIETARY_SUPPLEMENT|HCap Formula|Pill should be taken every other day during the treatment phase.
41305590|NCT02150187|DIETARY_SUPPLEMENT|Placebo|Similar pills without active ingredients
41305591|NCT05337813|DEVICE|"Storz Medical Extracoporeeal Shock Wave Therapy System"|A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)
41305592|NCT05110040|DRUG|immunosuppressive agent|patients with TAO recruited in this study will administrated with immunosuppressive agent per day
41305593|NCT04158024|OTHER|Erector Spinae Plane Block|The ESPB is a fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
41305594|NCT01936285|DRUG|Colchicine 2 mg loading dose; 0.5 mg bid for 5 days|
41305595|NCT01936285|DRUG|Placebo|
40782101|NCT00442702|DRUG|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
40782102|NCT00442702|DRUG|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
40782103|NCT04739943|DEVICE|Mobile Monitoring Device|App for self monitoring device for respiratory symptoms
40782104|NCT06087380|PROCEDURE|auricular acupressure|Auricular pressure The experimental group commenced auricular acupressure intervention post-surgery. Questionnaire assessments and heart rate variability measurements were conducted in the experimental group on the first, second, third, and fourth days before discharge.
40782105|NCT06087380|OTHER|standard ward care|standard ward care
40782106|NCT03679390|DRUG|Ketamine|With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.
41305596|NCT04346069|OTHER|PCIT (parent child interaction therapy)|Parent child interaction therapy is a treatment strategy that nurture parent child relationship and teach effective parenting strategies to decrease child non compliance behavior (BodifordMcNeil; Hembree-Kigin, 2010).Parent-Child Interaction Therapy (PCIT; Eyberg; Robinson, 1982 ; Zisser; Eyberg, 2008 ) is a manualized parent training intervention that has received substantial empirical support in the treatment of disruptive behavior across multiple reviews (e.g., Brestan; Eyberg, 1998 ; Gallagher, 2003 ; Thomas \&amp; Zimmer-Gembeck, 2007 ). PCIT established strong relation among parenting, social learning, and attachment theories and proceeds.
40986517|NCT00481195|DRUG|Armodafinil|Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day \[2 tablets\]) was allowed. The dosage could not be increased after it was decreased.
41144904|NCT04995497|DRUG|Intravenous Administration of Lidocaine Post Cardiac Surgery|Lidocaine will be administered via intravenously. Initial dose will be at 2 mg/kg ideal body weight followed by dosing at 2 mg/kg/hr for 48 hours
41305597|NCT03363048|BEHAVIORAL|Restricted|Certain foods and beverages are not allowed to be purchased with food benefit dollars.
40782107|NCT05156411|OTHER|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied
40782108|NCT00511758|PROCEDURE|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
41144905|NCT04995497|DRUG|Administration of Lidocaine Post Cardiac Surgery via ESP Catheter|Lidocaine will be administered via ESP catheter. Initial dose will be at 2 mg/kg ideal body weight split between two catheters followed by dosing at 2 mg/kg/hr for 48 hours
41144906|NCT04167852|BEHAVIORAL|Daily text message|Patients will receive a daily text message stating how many days they have until or since their surgery.
41144907|NCT04167852|BEHAVIORAL|Mindfulness intervention|Patients will receive a link to mindfulness meditation intervention for ten minutes.
41305598|NCT03363048|BEHAVIORAL|Restriction plus Incentive|Certain foods and beverages are not allowed to be purchased with food benefit dollars; 30% of the total dollars spent toward the purchase of certain foods result are added to their food benefit dollars.
41305599|NCT05326750|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
41305600|NCT04247750|DRUG|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
41305601|NCT02108951|DRUG|Nilotinib|Nilotinib 150mg hard gelatin capsules taken orally
41464201|NCT05395767|PROCEDURE|Endoscopic Anterior Cruciate Ligament reconstruction using living donor hamstring allograft from a parent donor|The Parent donor will undergo hamstring tendon graft harvest under general anaesthesia in a routine fashion in one theatre. The Graft material will be transported thorough to the adjacent theatre, where the child will be anaesthetised and undergoing arthroscopy of their injured knee in preparation for receiving the graft. ACL reconstruction Surgery will be undertaken in the child recipient as per the Surgeons usual technique, +/- meniscus repair +/- lateral tenodesis as required.
41144908|NCT02255006|DEVICE|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
41305602|NCT00103194|DRUG|lapatinib ditosylate|Given PO
41305603|NCT00103194|OTHER|laboratory biomarker analysis|Correlative studies
41305604|NCT01152008|OTHER|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
41305605|NCT01521234|BEHAVIORAL|Feedback of daily walking activity|Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
40782109|NCT04670861|PROCEDURE|Upper extremity Biodex balance training|"The person assumes the prone plank posture with both hands poisoned in the area assigned for foot placement on the tilting balance platform. Using the four keypads, the person's left hand, left wrist, right hand and right wrist positions are entered into the system using the midline of the hand and the platform grid as reference points. The dot that appears on the position patient screen represents the person's segmental center of gravity.~During each trial test, the person should shift his weight to move the cursor from the center along a target path and back as quickly and with a little deviation as possible. The same process is repeated for each of the targets. Target paths activate in a random order."
40782110|NCT03433547|PROCEDURE|Buckle|Surgical procedures of macular buckling
40782111|NCT03433547|PROCEDURE|Vitrectomy|Surgical procedures of small gauge vitrectomy
40782112|NCT03433547|OTHER|Limbal paracentesis|Drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis
40986518|NCT00481195|DRUG|Placebo|Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
40986519|NCT05052385|DRUG|Ruxolitinib|As per treating physician's decision - non interventional study
40986520|NCT05052385|DEVICE|Extracorporeal photopheresis|As per treating physician's decision - non interventional study
40782113|NCT03433547|OTHER|Gas injection|Inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous cavity through pars plana.
40782114|NCT03433547|OTHER|Peeling internal limiting membrane|Peeling internal limiting membrane with forceps
40986521|NCT05052385|DRUG|Ibrutinib|As per treating physician's decision - non interventional study
40986522|NCT05227794|BEHAVIORAL|Compassion Cultivation Training (CCT)|CCT is a secular, empirically supported 8-week program that integrates meditation practices, interactive discussions, and educational lectures to improve self-compassion and other-oriented compassion, emotion and stress management, and happiness and well-being. It includes a weekly 2-hour educational lecture with discussion and in-class exercises, a recommendation of 15-30 minutes of daily meditation, and real-world assignments to practice compassion. The program is taught by a certified instructor with more than 5 years experience.
41144909|NCT02255006|DEVICE|Sham acupuncture|"For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.~Volunteers undergo FMD measurement and acupuncture like above methods."
41144910|NCT02255006|DRUG|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
41144911|NCT02255006|DRUG|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
40782115|NCT03433547|OTHER|Gas tamponade|Filling the vitreous cavity with gas (C3F8, 14%)
40782116|NCT00203190|DRUG|Topiramate|
40782117|NCT00082121|DRUG|TP10|
40782118|NCT06161480|DEVICE|Weighted Blanket|Weighted Blanket is an occupational therapy modality which has been associated with significant increases in grounding, orientation to reality, soothing, and quality of life.
40782119|NCT02392988|OTHER|acupuncture treatment|acupuncture treatment
40782120|NCT02392988|OTHER|Placebo Comparator|Placebo Comparator
40782123|NCT02031406|OTHER|Post-discharge counseling on medication adherence & literacy|
40782124|NCT00002143|DRUG|Acitretin|
40782125|NCT05690425|DRUG|BC3402 Injection|Subjects will receive BC3402 as a single agent via intravenous infusion once every 3-weeks (Q3W),the dose of BC3402 was calculated according to the dose group and body weight of the subjects.
40986523|NCT05227794|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|MBSR is among the most studied mindfulness-based interventions in the literature and is a secular, 8-week psycho-educational group-based intervention. The program structure (slightly modified to match CCT) includes a weekly 2-hour class, a prescription of 15-30-minutes of daily mindfulness practice, and a one-day optional retreat (6 hours) between week six and seven. The program is taught by a certified instructor with more than 5 years experience.
40986524|NCT05412654|DIETARY_SUPPLEMENT|High potassium water|High potassium water Potassium 6.2 mg/100ml
40986525|NCT05412654|DIETARY_SUPPLEMENT|Control low potassium water|Control water Potassium 0.2 mg/100ml
40986526|NCT02677922|DRUG|AG-120|Specified dose on specified days
40782126|NCT01305187|DEVICE|Hyaluronic Acid Filler|The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
40782127|NCT04302116|DRUG|Combination therapy with vigabatrin and prednisolone|High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
40782128|NCT04302116|DRUG|Vigabatrin Tablets|Vigabatrin (50-150 mg/kg/day) twice daily for 4 months
40782129|NCT03758807|OTHER|Manual Therapy with Traditional Biomechanical Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (AP) Pressure with a traditional biomechanical or anatomic explanation of the technique..
40986527|NCT02677922|DRUG|Azacitidine|Specified dose on specified days
40782130|NCT03758807|OTHER|Manual Therapy with Neuroplastiicity Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (PA) Pressure with a neuroplastic explanation of the technique.
40782131|NCT00076440|DRUG|Leuprolide acetate|
40986528|NCT02677922|DRUG|AG-221|Specified dose on specified days
40986529|NCT02252198|OTHER|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2\*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
40986530|NCT01035203|BEHAVIORAL|Exercise|Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
40986531|NCT01035203|BEHAVIORAL|Cognitive behavioural therapy|Teaching of techniques to reduce fatigue and to improve stamina
40986532|NCT00431210|BIOLOGICAL|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
40986533|NCT00776347|DRUG|Donepezil|Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
40986534|NCT00776347|DRUG|Donepezil|
40986535|NCT06268561|OTHER|Visual acuity analysis|Collection of information on visual acuity from the medical file concerning the surgery
40986536|NCT06268561|OTHER|Intraocular pressure analysis|Collection of information on intraocular pressure from the medical file concerning the surgery
40986537|NCT06268561|OTHER|Analysis of optical coherence tomography (OCT) images|Collection and analysis of optical coherence tomography (OCT) images of the medical file concerning the surgery
40986538|NCT06268561|OTHER|Analysis of retinograms|Collection and analysis of retinography images of the medical file concerning the surgery
40986539|NCT02445482|PROCEDURE|Biopsy|archival tissue or fresh biospsy
40986540|NCT04674384|DIETARY_SUPPLEMENT|Optifast meal replacement shakes|Optifast® is provided as 53g sachet. Each sachet replaces one meal. It is available in 5 flavours: vanilla, strawberry, chocolate and coffee shakes and vegetable soup.
40986541|NCT04002531|OTHER|General and Neurological examination|Information about your general health, neurological symptoms and current medications with be collected
41144912|NCT01261793|DRUG|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
40782132|NCT00120133|DRUG|Atorvastatin|
40782133|NCT01932684|OTHER|Breath-Stacking|We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
40986542|NCT04002531|OTHER|Vital signs|Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
40986543|NCT04002531|PROCEDURE|12 lead electrocardiogram|A non-invasive test that measures the electrical activity of the heart
40986544|NCT04002531|PROCEDURE|Echocardiogram|A non-invasive sonogram of the heart
40986545|NCT04002531|PROCEDURE|Blood draw|Blood will be drawn to evaluate general health and renal function (kidney health)
40986546|NCT04002531|PROCEDURE|Urine collection|Urine will be collection to evaluate renal function (kidney health)
40986547|NCT04002531|PROCEDURE|2-hour Holter Monitor|A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
40986548|NCT04002531|OTHER|Brief Pain Inventory questionnaire|A questionnaire about daily pain
40986549|NCT04002531|OTHER|Quality of Life questionnaire|A questionnaire about the impact of disease on their activities of daily living and quality of life
41144913|NCT01261793|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
41144914|NCT01261793|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
41144915|NCT01923935|DRUG|BUSULFEX®|BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6\~day-4)
41305606|NCT00787696|BEHAVIORAL|Cognitive-behavioral HIV/STD risk reduction|18 60-minute group sessions plus 1 individual health and safety planning session
40986550|NCT01729754|DRUG|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
40986551|NCT01729754|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.
40986552|NCT01729754|DRUG|Tildrakizumab Placebo|Matching placebo to tildrakizumab administered SC
40986553|NCT01729754|DRUG|Etanercept Placebo|Matching placebo to etanercept administered SC
40986554|NCT01729754|DRUG|Etanercept 50 mg|Etanercept 50 mg administered SC
40986555|NCT00713154|DRUG|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
40986556|NCT00713154|DRUG|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
40986557|NCT05482633|OTHER|Inspiratory muscle training (IMT)|Treatment group will perform IMT every day for eight weeks. Initial load is going to be set as the 60% of maximal inspiratory pressure (PImax) and is going to be increased by %10 of the initial load every two weeks.
40986558|NCT00645073|DRUG|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
40986559|NCT00645073|DRUG|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
40986560|NCT01940809|DRUG|Dabrafenib|Given PO
40986561|NCT01940809|BIOLOGICAL|Ipilimumab|Given IV
40986562|NCT01940809|OTHER|Laboratory Biomarker Analysis|Correlative studies
40986563|NCT01940809|BIOLOGICAL|Nivolumab|Given IV
40986564|NCT01940809|DRUG|Trametinib|Given PO
40986565|NCT04665284|DRUG|Empagliflozin|Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs
41144916|NCT01923935|DRUG|Alkeran®|Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3\~day-2)
41305607|NCT02287012|OTHER|Time/Motion evaluation of actual apheresis|The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
41305608|NCT00003636|DRUG|carboplatin|
40986566|NCT04665284|DRUG|Usual care group|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
40986567|NCT03659591|BEHAVIORAL|Cognitive Behaviour Therapy|CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group
40986568|NCT03659591|BEHAVIORAL|Adaptive Psychological Training|APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group
41144917|NCT04694053|PROCEDURE|surgical debridement|The surgical team performed an extended surgical debridement to healthy tissue of external genital, as well as perineal, perianal, and infrapubic regions.
40986569|NCT06320795|DEVICE|SOUNDI|Continuous monitoring of vital signs for diagnosis and follow-up of sleep-disordered breathing in adults.
40986570|NCT03282942|OTHER|Strength training group|"Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.~The following exercises will compose the strength training protocol:~* Squatting~* Leg press~* Knee Extension~* Knee Flexion~* Supine Challenge~* High Pull~* Elbow flexion~* Extension of elbows~* Development~* Abdominal"
40986571|NCT03282942|OTHER|Aerobic Training Group|Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
40986572|NCT05502328|DIETARY_SUPPLEMENT|Energy Study Product Usage|Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
40986573|NCT06244225|DRUG|Donafenib； Sintilimab； HAIC|"Drug: Sintilimab Q3W 200mg IV d1, Q3W~Drug: Donafenib 200 mg BID d1-21, Q3W~other: HAIC Q3W Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h."
40986574|NCT02743806|DRUG|Vedolizumab|Vedolizumab IV infusion
40986575|NCT03577743|DRUG|Bevacizumab|-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
40986576|NCT02066740|DEVICE|EverFlex™ stent with Entrust™ delivery system|
40986577|NCT02307955|DEVICE|firefly|
40986578|NCT02307955|OTHER|Standard of care|
41144918|NCT04823156|DIETARY_SUPPLEMENT|Calcium|Daily calcium food supplement.
41305609|NCT00003636|DRUG|cisplatin|
40782134|NCT01932684|OTHER|Incentive spirometry|We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
40782135|NCT01932684|DEVICE|5000 Voldyne ® Sherwood Medical, USA|
40782136|NCT01932684|DEVICE|Silicone face mask|
40782137|NCT00089492|DRUG|Optimized Background ARVs|As prescribed
40986579|NCT00403793|DRUG|etonogestrel with testosterone undecanoate|42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
40986580|NCT00403793|DRUG|Placebo|42 or 44 weeks with placebo implant and placebo injections
40986581|NCT01682590|PROCEDURE|Renal Remplacement Therapy|"Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output \> 1000ml/24 hr or \>2000ml/24hr with diuretics), RRT is not mandatory."
40986582|NCT03589950|DRUG|anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
40986583|NCT03589950|DRUG|chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
40986584|NCT00697203|DRUG|Placebo|po daily for 12 weeks
40986585|NCT00697203|DRUG|Pravastatin|40mg po daily for 12 weeks
40986586|NCT00697203|DRUG|Dalcetrapib|300mg po daily for 12 weeks
40986587|NCT00697203|DRUG|Dalcetrapib|600mg po daily for 12 weeks
40986588|NCT00697203|DRUG|Dalcetrapib|900mg po daily for 12 weeks
40986589|NCT02965274|DRUG|Torrent's Fluoxetine Tablets|
41144919|NCT05601167|DRUG|nirmatrelvir/ritonavir|Tablets 300/100mg, 2 times a day with 12 ±2 hours interval for 5 days
41144920|NCT05601167|DRUG|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines' validated at the time of the study
41144921|NCT00065663|GENETIC|GAM501|
41144922|NCT05387629|BEHAVIORAL|Education|Nursing students will be trained through social media.
40986590|NCT02965274|DRUG|Warner Chilcott LLC's Sarafem Tablet|
40986591|NCT00255450|DRUG|ferumoxytol or placebo|
40986592|NCT05098925|OTHER|Biological testing|Blood sampling, microcapillary sampling, temperature monitoring, saliva testing, EHI questionnaire
40986593|NCT05592782|BEHAVIORAL|Virtual Reality Based Mindfulness meditation|Participants will undergo a guided VR meditation using a commercial VR application. The meditation will last approximately 15 minutes. Prior to starting and on upon completion of each VR meditation session, participants' state pain, anxiety, depression, and stress will be assessed. For each participant enrolled, baseline and monthly assessments using the DASS-21 and PPI-SFI3a will be performed for three consecutive months.
40986594|NCT04826705|DEVICE|Drug-coated Balloon|To observe the effectiveness and safety of the drug-coated balloon in the treatment of lower extremity arteriosclerosis obliterans of the femoral popliteal artery segment.
41144923|NCT03635801|DEVICE|MyoVista 12 lead Electrocardiogram (ECG)|MyoVista 12 Lead Electrocardiogram (ECG)
41144924|NCT00761332|DRUG|teriparatide|treatment will be prescribed according to usual standard of care
41144925|NCT00761332|DRUG|antiresorptives|treatment will be prescribed according to usual standard of care
41144926|NCT04436965|OTHER|Standardized nutrition therapy|Standardized nutrition therapy with ONS, nasal feeding tube, PEG or parenteral nutrition
41144927|NCT04436965|DRUG|Cisplatin|Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
41144928|NCT04436965|RADIATION|Intensity Modulated Radiation Therapy|Patients in both arms received Intensity Modulated Radiation Therapy:All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose was 70-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-70 Gy to PTVnd (Planning target volume of the cervical lymph node),60- 64Gy to PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
41144929|NCT00796575|DRUG|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
40782138|NCT00089492|DRUG|enfuvirtide [Fuzeon]|180mg sc once daily for 48 weeks
40782139|NCT00089492|DRUG|enfuvirtide [Fuzeon]|90mg sc bid for 48 weeks
40782140|NCT04349683|DRUG|Jinshuibao|6 capsules at a time, 3 times a day (tid).
40782141|NCT04349683|DRUG|Placebo|6 capsules at a time, 3 times a day (tid).
40782142|NCT02252315|OTHER|Educational Brochure|Participants will receive written education materials about mild traumatic brain injury.
40782143|NCT02252315|OTHER|Verbal education module|A structured in-person education module about mild traumatic brain injury.
40782144|NCT02505425|BEHAVIORAL|Behavioral Support|"ENABLE CHF-PC includes:~1. In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~2. Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines."
40782145|NCT02505425|BEHAVIORAL|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
40782146|NCT02227303|BEHAVIORAL|lifestyle modification instructional and motivational sessions|
40986595|NCT01721642|DEVICE|Apica Cardiovascular ASC Access, Stability and Closure Device|Access, stabilisation and closure of trans-apical approach for TAVI
40986596|NCT02747706|BEHAVIORAL|Parent-to-parent mentoring|phone, SMS/text, and smartphone-based support
40986597|NCT02736409|DRUG|Oral Budesonide Suspension (OBS)|OBS 2mg twice daily
40986598|NCT02736409|DRUG|Placebo|Matching Placebo dose
40986599|NCT00003150|BIOLOGICAL|rituximab|
40986600|NCT00003150|DRUG|CHOP regimen|
40986601|NCT00003150|DRUG|cyclophosphamide|
40986602|NCT00003150|DRUG|doxorubicin hydrochloride|
40986603|NCT00003150|DRUG|prednisone|
40986604|NCT00003150|DRUG|vincristine sulfate|
40986605|NCT05376696|BEHAVIORAL|Set For Variability|This intervention will focus on training students to use a sound variation of grapheme correspondence rule in order to read an irregular spelling word correctly.
40986606|NCT05376696|BEHAVIORAL|Current Best Practices|This active control intervention will focus on training students to use grapheme-phoneme correspondence rules and sight words in the absence of set-for-variability component
40986607|NCT02721927|OTHER|Syrian Refugees|Adult Syrian patients who visited the Emergency Department
40986608|NCT00605670|BEHAVIORAL|questionnaires|patients will fill out two questionnaires post surgery
40986609|NCT00605670|BEHAVIORAL|questionnaires|Patient will fill out questionnaire before and 3 to 6 months after treatment.
40782147|NCT06049914|BEHAVIORAL|Experimental group|"1. Exercise interventions~   * Measuring blood pressure and weight: before starting exercise~  * Flexibility exercises: 5-10 minutes of stretching~  * Strength exercises: Consists of 4 upper body exercises (Biceps Curl, Dips, Front raise, Chest press) and 5 lower body exercises (Leg lateral rotation, Leg extension, Hip abduction, Squat, Heel raise). The intensity of the band starts according to the subject's muscle strength.~  * Aerobic exercise: 5 times a week, home-based, 30 minutes or more each time~2. Nutritional interventions~   * Well nourished: Overall diet check and correction~  * at risk: Correction of diet and intake of up to 2 packs of supplemental protein products per day~  * Malnourished: Correction of diet and intake of up to 3 packs of supplemental protein products per day~  * Nutrition counseling is provided at the beginning of the intervention and high-protein diet composition education is provided~  * Confirm compliance and provide feedback once every 2 weeks"
40782148|NCT05194150|DEVICE|non-diffractive monofocal IOL|Rayone EMV
40986610|NCT04712773|DEVICE|PMD-200 monitor|Patient is connected to non-invasive PMD-200 monitor, measuring Nociception Level
40986611|NCT04712773|DEVICE|Surgical Pleth Index monitor|Patient is connected to non-invasive monitor measuring Surgical Pleth Index
40986612|NCT02468869|BEHAVIORAL|"Communication skills training empathy skills"|
40986613|NCT02468869|BEHAVIORAL|"Communication skills training information structuring skills"|
40986614|NCT04532957|DRUG|KBP-7072|QD oral capsules
40986615|NCT04532957|DRUG|Placebo|matching placebo capsules
40986616|NCT02414334|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|
40986617|NCT00403247|DIETARY_SUPPLEMENT|Capsule with folate, Vitamin B12 & pyridoxine|
40986618|NCT00403247|OTHER|placebo|placebo capsule
40986619|NCT04264637|DRUG|Azelastine hydrochloride (BAYR9258)|Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration.
40986620|NCT04264637|DRUG|Placebo|Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.
40986621|NCT03597958|GENETIC|Next generation sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
41144930|NCT00796575|DRUG|placebo tablets|placebo tablets matching active
41144931|NCT00796575|DRUG|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
41144932|NCT00796575|DRUG|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
40986622|NCT00568750|DRUG|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
40986623|NCT05453344|DEVICE|DexCom one|Provision of DexCom One for glucose monitoring
40986624|NCT02507583|DRUG|IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|
40986625|NCT00004984|DRUG|Parenteral Insulin|Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.
40986626|NCT00004984|OTHER|Close Observation|Study visits every 6 months including an oral glucose tolerance test
40986627|NCT00004984|DRUG|Oral Insulin|Capsules oral insulin, 7.5 mg of recombinant human insulin crystals
40986628|NCT00004984|DRUG|Placebo|Placebo for oral insulin
40986629|NCT00324324|DRUG|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
40986630|NCT00324324|DRUG|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
40986631|NCT04890639|PROCEDURE|Acute Intermittent Hypoxia|Four hypoxia sessions, consisting of 15 cycles of hypoxia (21%, 17%, 13% or 9% O2), each of which lasts up to 60 seconds, interspersed with up to 90-second normoxic episodes.
40986632|NCT03893422|OTHER|WB-010|Medical food formulation
40986633|NCT03893422|OTHER|WB-011|WB-011 medical food product
40986634|NCT03893422|OTHER|Placebo|Placebo Capsules identical to those containing WB-010 and WB-011.
40986635|NCT00758030|DRUG|Paliperidone ER OROS|
40986636|NCT00434655|PROCEDURE|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
41144933|NCT01778803|DRUG|defactinib|
41144934|NCT01778803|DRUG|Paclitaxel|
41305610|NCT00003636|PROCEDURE|conventional surgery|
41305611|NCT00003636|PROCEDURE|neoadjuvant therapy|
40986637|NCT06406192|DIAGNOSTIC_TEST|Height, Weight, and Blood Pressure Measurement Procedures Improvement|"In the intervention group, the investigators improve the process of measuring blood pressure, height, and weight, requiring timely recording of these measurements. The intervention includes:~i. Enlisting the assistance of nurses and volunteers to improve the accessibility of measurement environments and provide guidance on instrument operation.~ii. Using paper reminders at check-in stations to prompt patients to complete blood pressure and weight recordings before entering examination rooms; providing paper for recording if patients forget their health insurance cards.~iii. Providing alcohol and hand wipes outside examination rooms for disinfecting measurement instruments.~iv. Promoting the recording mode outside the check-in station.~v. Ensuring that physicians or nurses in examination rooms accurately record measurements in the medical order system.~vi. Encouraging patients to ask physicians during consultations, Is my blood pressure and weight okay?"
40986638|NCT01341262|DRUG|Thalidomide|"* INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-120 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 200 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 200 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200"
40986639|NCT01341262|DRUG|Dexamethasone|"* INDUCTION THERAPY: 40 mg/d days 1-4, 9-12 and 17-20 (cycles 1 and 3, 30 days each); 40 mg/d days 1-4 (cycles 2 and 4, 30 days each)~* AFTER PBSC COLLECTION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
40986640|NCT01341262|DRUG|Zoledronic acid|"* INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)~* AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
40986641|NCT01341262|DRUG|Cyclophosphamide|Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
41305612|NCT02902016|DRUG|GED|Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
41464202|NCT05900323|COMBINATION_PRODUCT|enteral nutrition guidelines|The nurses will be educated about the enteral nutrition guidelines. Then they will apply these guidelines on the participants during enteral nutrition procedure. After conducting the guidelines, the researcher will assess the effect of the guidelines on patients' outcomes.
41464203|NCT04556916|DIAGNOSTIC_TEST|Blood sample|"Per patient 49 ml of peripheral blood sample :~* 21ml divided into 3 TransFix or EDTA 7ml tubes will be sent to Hamburg for subsequent CTCapture analysis;~* 28ml divided into 4 EDTA 7ml tubes will be sent to Montpellier for subsequent EPIDROP analysis (21 ml), PHI analysis (7 ml) and plasma isolation."
40986642|NCT01341262|DRUG|Melphalan|Melphalan 200 mg/sqm on day -1 for first and second ASCT
40986643|NCT05239273|OTHER|Complex Decongestive Therapy|Phase 1 of CDT will be applied. This application consists of manual lymph drainage, skin care, compression bandage and exercises.
40986644|NCT05239273|OTHER|Control|No intervention
40986645|NCT04767854|BEHAVIORAL|OA school|Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
41144935|NCT06351800|BEHAVIORAL|Predictplusprevent intervention|The intervention is based on validated risk algorithms to predict depression and anxiety and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps participants to develop their own personalized plans to prevent (PPP) depression and/or anxiety; 3) eight intervention modules (the core of the system) including activities to prevent depression and anxiety, to be proposed and monitoring by the DSS. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6, 9 and 12 months.
41464204|NCT00153257|DEVICE|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
41464205|NCT00067132|PROCEDURE|Juven (nutritional), HMB (nutritional)|
40986646|NCT04767854|OTHER|Virtual Training mobile health application|Individually tailored home exercise programs delivered through a mobile health application
41144936|NCT06351800|OTHER|Psychoeducational intervention|To know the level of risk of experiencing depression and/or anxiety in the next 12 months. In addition, participants assigned to this intervention will have free access to the 24 self-help pamphlets for preventing depression and anxiety.
41144937|NCT05362279|OTHER|Training|"One month after the pre-test, the post-test will be administered to the nurses who will be in the control group.~Nurses who will be in the experimental group will be given training after the pre-test. A post-test will be administered one month after the training."
41464206|NCT02178124|DRUG|Donepezil|
41464207|NCT02178124|DRUG|placebo|
40782149|NCT05194150|DEVICE|standard EDOF IOL|Acrysof IQ Vivity
40986647|NCT04767854|OTHER|Usual care|Individually tailored exercise programs conducted in weekly supervised individual or group sessions
40986648|NCT05063747|OTHER|No intervention.|Observational study. No intervention.
40986649|NCT01012518|DEVICE|Standard PCT|The standard technique, performed without video guidance
40986650|NCT01012518|DEVICE|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
41464208|NCT00604916|OTHER|standardized oral care protocol - electronic toothbrush|a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
41464209|NCT00604916|OTHER|mimic protocol|a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
41464210|NCT00164918|DEVICE|nasogastric tube|
41464211|NCT01396694|OTHER|Questionnaire|Questionnaire
41464212|NCT03281096|DRUG|Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
41464213|NCT03281096|DRUG|Placebo|pill manufactured to mmic Berberine hydrochloride 100mg tablet
41464214|NCT01069796|DRUG|Paclitaxel|80 mg/m² weekly
41464215|NCT01069796|DRUG|Bevacizumab|10 mg/kg d1 d15
41464216|NCT01069796|DRUG|Capecitabine|800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3
40986651|NCT05217420|BEHAVIORAL|Moving Well|Experimental arm
41305613|NCT04967508|DRUG|Stelara® (Ustekinumab)|Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.
40986652|NCT05217420|BEHAVIORAL|Staying Well|Active comparator arm
40986653|NCT04954547|BEHAVIORAL|Subsidy Treatment|Participants will be awarded $50 for reaching the PBF goal at the end of 12 weeks. Regardless of goal-attainment, participants will be reimbursed 50% of approved health-improving expenses up to a cap of $300 in the 12 weeks. The subsidy is voluntary and flexible, with no direct intervention from researchers - participants will submit receipts and simply be reimbursed at the end of the experiment (subject to approval from the research team).
40986654|NCT04954547|BEHAVIORAL|Cash Treatment|Participants will be awarded $350 for reaching the PBF goal at the end of 12 weeks.
40986655|NCT06201117|BEHAVIORAL|Preparatory information for ICU stay|Preparatory information for ICU stay after cardiac surgery via 12-minute digital media
41144938|NCT02028390|DEVICE|Scout takes visual and thermal images of external wounds|All images are taken after the wound has acclimated.
41144939|NCT02028390|DEVICE|ImageReview's visual perimeter trace of the external wound|Trace is drawn by the study staff using the ImageReview software.
41464217|NCT00846898|DIETARY_SUPPLEMENT|cinnamon 2g per day for 12 weeks|Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
41464218|NCT01958515|OTHER|research blood draw and tissue biopsy|research blood draw and tissue biopsy
41144940|NCT02028390|DEVICE|ImageReview's External Wound Trace Overlay|Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.
41144941|NCT02028390|DEVICE|ImageReview's unaffected reference area selected|Study Staff select an unaffected reference area of an adjacent body surface.
41144942|NCT02028390|DEVICE|Adjacent tissue trace of the wound trace overlay|Study staff select an adjacent tissue trace of the wound trace overlay
41144943|NCT00610194|DRUG|RDEA119|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
41144944|NCT06523686|PROCEDURE|Guided bone regeneration|Compare the linear and volumetric bone width changes, clinically and radiographically, between two different bone graft combinations (autogenous-xenogeneic and allogeneic-xenogeneic) covered with a cross-linked collagen membrane in a horizontal GBR.
41144945|NCT04415580|OTHER|Vestibular Rehabilitation (VR)|"VR consisted of two types of exercises, i.e., those for gaze stability and those for postural stability~* Gaze stability exercises The patients will perform the exercises while holding their gaze on a firm target (VORx1) during active horizontal and vertical head movements (one minute for each axis).~* Postural stability exercises March in Place Each patient will ask to get on a foam cushion of 10 cm in height and then will blindfold. Treadmill Training As preparation for training, all subjects underwent a 1-minute walk on treadmill with open eyes using preferred walking speed. Immediately after preparation, patients will blindfold and will ask to walk on treadmill without support of hands for 4 minutes.~When patients made the mistake of changing direction, the physiotherapist help them to keep the right position using verbal cues (e.g., you are turning left or right)."
41144946|NCT04415580|OTHER|Conventional Neurorehabilitation|muscles stretching, active and assisted limbs mobilization, four limbs coordination exercises, balance training on instable platform and gait training
41144947|NCT03733574|DRUG|LY03005|Drug: LY03005 80 mg, oral tablets, single dose
41144948|NCT03733574|DRUG|Pristiq|Drug: Pristiq 50 mg, oral tablets, single dose
41144949|NCT03867656|OTHER|GLP-2|GLP-2 injection
40986656|NCT06201117|BEHAVIORAL|Usual information|Preoperative information that is given to patients before having cardiac surgery
40986657|NCT00707707|DRUG|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
40986658|NCT00707707|DRUG|Paclitaxel|Intravenous infusion over 1 hour
40986659|NCT00469560|DRUG|Deferasirox|
40986660|NCT02985229|DRUG|Mifepristone|The option of home or clinic administration of 200 mg oral mifepristone
41305614|NCT04967508|DRUG|SB17 (Proposed Ustekinumab Biosimilar)|"Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.~Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection."
41305615|NCT04906655|DRUG|Glycopyrronium 2.4 % Medicated Cloth|The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.
40986661|NCT02985229|DRUG|Misoprostol|800 μg buccal misoprostol through 70 days LMP following administration of mifepristone
40986662|NCT05403138|DRUG|Daratumumab|Induction Phase: (8mg/kg) via intravenous (IV) evey 2 weeks for two cycles. Maintenance Phase: (4mg/kg) IV every 4 weeks.
40986663|NCT05403138|DRUG|Placebo|Induction Phase: matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles; Maintenance Phase: matching placebo (4mg/kg) IV every 4 weeks.
40986664|NCT01864733|OTHER|Physical rehabilitation (exercise).|
40986665|NCT01581307|DRUG|FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)|The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
41144950|NCT03867656|OTHER|GIP|GIP injection
41144951|NCT03867656|OTHER|Placebo|Placebo injection
41144952|NCT04945044|DEVICE|Computed adenoma detection system (CADe)|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps
40782150|NCT03940716|BEHAVIORAL|IntERact|"This intervention integrates motivational interviewing, cognitive behavioral skills therapy, and care management into a single behavioral counseling intervention delivered by a therapist. The intervention is delivered either in the emergency department or remotely over the subsequent 5 weeks for a total of six therapy sessions (\~30 min each). A smartphone app is also loaded on the participant's phone and delivers additional behavioral intervention content, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact encouragement, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
40782151|NCT02969070|DIETARY_SUPPLEMENT|LopiGLIK™ therapy|4 weeks of LopiGLIK™ therapy 1 capsule/day
41464219|NCT03481855|DEVICE|Lower-body-low-pressure chamber|The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.
40782152|NCT02969070|DIETARY_SUPPLEMENT|Armolipid Plus® therapy|4 weeks of Armolipid Plus® therapy 1 capsule/day
40782153|NCT00920556|DRUG|5.0g SRT501|5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
40782154|NCT00920556|DRUG|Bortezomib|Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
40782155|NCT03423121|DRUG|Tauroursodeoxycholic Acid|Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.
40782156|NCT03423121|DRUG|Placebo oral capsule|Participants will be given four capsules of the placebo twice daily.
40782157|NCT05759208|DRUG|OK-101|Ophthalmic Solution
41464220|NCT01456260|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
41464221|NCT01456260|DRUG|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
40782158|NCT05759208|DRUG|Placebo|Placebo
40782159|NCT05106348|DIAGNOSTIC_TEST|Aerobic Fitness Test|aerobic fitness test to assess wheelchair rugby players capacity
40782160|NCT05285228|BEHAVIORAL|effect of choice on cooperation (pseudoalternative)|For the test group, before the standard check-up starts, the participant is given the choice of selecting the taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint), which will be applied at the end of the visit. Post-placement instructions provided by the manufacturer will be given to the caregiver and the child and questionnaires will be handed out.
40782161|NCT05285228|BEHAVIORAL|given fluoride varnish (control)|For the control group the participant is provided with a given taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint) according to the randomization list.
41144953|NCT04945044|BEHAVIORAL|Control group (regular colonoscopy)|It is exclusively the endoscopist in charge of the detection of the polyps (usual practice)
41144954|NCT03507452|DRUG|BAY2287411|"Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days)."
41144955|NCT03507452|DRUG|BAY2287411|"Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation."
41144956|NCT01569399|OTHER|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
41144957|NCT06500403|DIAGNOSTIC_TEST|liver and stiffness measurement|liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension
41144958|NCT05473468|DRUG|Famitinib|a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)
41305616|NCT00603980|DRUG|Inhaled placebo + oral placebo|Inhaled Staccato placebo + oral placebo
41144959|NCT06021002|DRUG|R848|Nasal R848 administration
41144960|NCT06021002|DRUG|Saline|Nasal saline administration
41144961|NCT05861232|BEHAVIORAL|Behavioral|fear and anxiety during inhalation therapy
41305617|NCT00603980|DRUG|Inhaled alprazolam 0.5 mg|Inhaled Staccato alprazolam 0.5 mg + oral placebo
41305618|NCT00603980|DRUG|Inhaled alprazolam 1 mg|Inhaled Staccato alprazolam 1 mg + oral placebo
41464222|NCT01456260|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
41464223|NCT01456260|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
40986666|NCT01581307|DEVICE|TheraSpheres|TheraSpheres are a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver. TheraSpheres have restricted approval from the United States Food and Drug Administration (FDA) for the treatment of hepatocellular liver cancer; but has not yet been approved for the treatment of pancreatic cancer that has spread to the liver.
41464224|NCT01456260|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
41464225|NCT01456260|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
41305619|NCT00603980|DRUG|Inhaled alprazolam 2 mg|Inhaled Staccato alprazolam 2 mg + oral placebo
41305620|NCT00603980|DRUG|Oral alprazolam 1 mg|Oral alprazolam 1 mg + Inhaled placebo
41305621|NCT00603980|DRUG|Oral alprazolam 2 mg|Oral alprazolam 2 mg + Inhaled placebo
41464226|NCT04325854|PROCEDURE|I and II level ART procedure|I level: Intrauterine insemination II level: Invitro fertilization technique; Intracytoplasmic sperm injection; Embryo transfer
41464227|NCT06533072|OTHER|The group receiving infrared LED therapy|Patients in this group are the ones who will be exposed to IR LED light therapy, three times in total
41464228|NCT06401954|DEVICE|High-intensity focused electromagnetic therapy|"High-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is set to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks"
40986667|NCT00130221|DRUG|2% chlorhexidine gluconate impregnated cloth|
41305622|NCT00603980|DRUG|Oral alprazolam 4 m|Oral alprazolam 4 mg + Inhaled placebo
41305623|NCT00603980|DRUG|Oral alprazolam 2 mg qualifying session|Qualifying session (2 mg oral alprazolam)
41464229|NCT06401954|BEHAVIORAL|Foot core training|"Foot core training will consist of 4 exercises with 10 repetitions per set and 3 sets per session for each exercise.~Twice a week for a total of six weeks."
41464230|NCT06401954|DEVICE|Sham high-intensity focused electromagnetic therapy|"Sham high-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is unable to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks"
41464231|NCT04815109|OTHER|Encephalography measurement|Encephalography measurement and partially aggravated sedation.
41464232|NCT05065541|DRUG|CC-97489|Specified dose on specified days
41305624|NCT00603980|DRUG|Oral placebo qualifying session|Qualifying control session (oral placebo)
41305625|NCT06550141|DRUG|Emapalumab|An interferon gamma (IFNγ) blocking antibody
41464233|NCT05065541|DRUG|[18F]T-401|Specified dose on specified days
41464234|NCT05065541|DRUG|[11C]MK-3168|Specified dose on specified days
41464235|NCT01540292|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
41464236|NCT00355524|DRUG|TMC114|TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
41464237|NCT00355524|DRUG|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
41464238|NCT03686215|COMBINATION_PRODUCT|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
41305626|NCT06550141|DRUG|Cyclophosphamide|Alkylating agent
41305627|NCT06550141|DRUG|Fludarabine Phosphate|Purine antagonist antimetabolite
41305628|NCT06550141|DRUG|Axicabtagene Ciloleucel|Autologous treatment
41305629|NCT02162485|DRUG|Salmeterol/fluticasone Easyhaler|
41305630|NCT02162485|DRUG|Salmeterol/fluticasone Easyhaler with charcoal|
41305631|NCT02162485|DRUG|Seretide Diskus|
41464239|NCT00367016|DRUG|Omalizumab|Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
41464240|NCT00367016|DRUG|Placebo|Placebo, given by subcutaneous injection.
41464241|NCT03793530|OTHER|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
41464242|NCT03793530|OTHER|Transforaminal lumbar interbody fusion with local bone graft|Transforaminal lumbar interbody fusion with local bone graft
41464243|NCT00441961|DRUG|methotrexate|methotrexate
41464244|NCT02503813|PROCEDURE|venous blood gas|Venous blood gas will be measured at the time of arterial blood gas measurement.
41464245|NCT00894517|BIOLOGICAL|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
41464246|NCT00894517|DRUG|Placebo (saline)|Saline injected into the prostate on Day 1.
41464247|NCT01192399|BIOLOGICAL|Eculizumab|
41464248|NCT05281172|BEHAVIORAL|Guided Self-Change therapy (GSC)|The GSC program follows a motivational cognitive-behavioral approach designed to minimize resistance in drug behavior changes, prevent relapse risk, and increase motivation to quit. The GSC consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
41464249|NCT05281172|BEHAVIORAL|Psychoeducation program about healthy habits|The psychoeducational program will include talks about healthy habits such as physical activity, relaxation, and sleep hygiene. This intervention consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
41305632|NCT02162485|DRUG|Seretide Diskus with charcoal|
41305633|NCT05607290|BEHAVIORAL|Cognitive-Behavioral Treatment|12 sessions of Cognitive-Behavioral Treatment for Alcohol Use Disorder
41305634|NCT02392039|DRUG|Pegfilgrastim|6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
41305635|NCT02392039|DRUG|Loratadine|"Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
41305636|NCT02392039|OTHER|Placebo|"Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
40986668|NCT00130221|OTHER|Daily bathing with Bar soap|bathed daily with bar soap (Dial Corp., Scottsdale, AZ), warm water, and cotton washcloths.
41464250|NCT06411392|RADIATION|Stereotactic Antiarrhythmic Radiotherapy|Patients with ventricular tachycardia will undergo cardiac stereotactic antiarrhythmic radiotherapy with a single fraction of 25 Gy to the arrhythmia substrate, as determined by electrophysiological cardiac mapping.
41464251|NCT00400582|DRUG|Candesartan up to 32 mg daily|Candesartan 4 to 32 mg daily
41464252|NCT02073006|DIETARY_SUPPLEMENT|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
41464253|NCT00585312|DRUG|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
41464254|NCT00585312|DRUG|Placebo|Masked, placebo comparator
40986669|NCT05160454|DEVICE|near infrared spectroscopy|evaluate cerebral blood flow with and without breatholding
40986670|NCT00167882|DRUG|5-aminosalicylate (Pentasa, Ferring)|
40986671|NCT05001074|DRUG|Extended release tacrolimus|de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
40986672|NCT05001074|DRUG|Immediate release tacrolimus|de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
40986673|NCT01687959|OTHER|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
40986674|NCT01979809|BEHAVIORAL|MENU GenY|Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.
41305637|NCT02392039|BEHAVIORAL|Questionnaires|Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
41305638|NCT03116399|BEHAVIORAL|PRISM 2.0 Condition|Access to the PRISM 2.0 program
41305639|NCT03116399|BEHAVIORAL|Tablet Condition|Access to the tablet
40986675|NCT01170754|DRUG|PEG-3350 and Gatorade|255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
40986676|NCT01170754|DRUG|Golytely 4 liters|Golytely 4 liters
41305640|NCT05178953|DRUG|Zinc Sulfate 220 mg Capsules|Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
41305641|NCT05178953|DRUG|Pentoxifylline|Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
41305642|NCT03007745|DEVICE|autoadjusting continuous positive airway pressure|Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
41305643|NCT06381518|OTHER|Switch to SC CT-P13.|all patients in the study will switch from IFX to SC CT-P13
41305644|NCT03065504|DIETARY_SUPPLEMENT|Turmeric|
40986677|NCT02127242|PROCEDURE|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
40986678|NCT03770390|PROCEDURE|Surgical correction of pectus excavatum|Surgical correction of pectus excavatum
40986679|NCT00690092|BIOLOGICAL|Spherule-derived coccidioidin|1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
40986680|NCT03486132|PROCEDURE|repair of episiotomy|Different techniques for repair of episiotomy incsicion
40782162|NCT01923883|PROCEDURE|EUS-FNA|EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
40986681|NCT03022565|DRUG|Vorinostat|Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.
40986682|NCT02760446|BEHAVIORAL|CAM-ICU.fr|Neuropsychological testing
40986683|NCT03794414|PROCEDURE|PEEP challenge|apply PEEP 10 mmHg in one-lung ventilating patients.
41144964|NCT02581826|DRUG|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
41144965|NCT02581826|DRUG|Placebo|No column specified.
41144966|NCT00728325|BEHAVIORAL|Supported Employment (SE)|SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
41305645|NCT03065504|DIETARY_SUPPLEMENT|Turmeric-containing combination tablet|
41305646|NCT03065504|DIETARY_SUPPLEMENT|Placebo tablets|
41305647|NCT00003243|BIOLOGICAL|aldesleukin|
41305648|NCT00003243|BIOLOGICAL|filgrastim|
40782163|NCT01923883|DEVICE|Echoendoscope Olympus GF-UCT240|
40782164|NCT04753489|DRUG|Rivaroxaban film-coated tablet 10 mg|Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of rivaroxaban.
40782165|NCT04753489|DRUG|Xarelto® film-coated tablet 10 mg|Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 10 mg of rivaroxaban.
40782166|NCT00587041|DIETARY_SUPPLEMENT|Oxadrop|Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
40986684|NCT04974112|OTHER|Apply SGA and NRS2002|Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information
40986685|NCT01589445|DRUG|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
40986686|NCT01589445|DRUG|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
40986687|NCT01917201|PROCEDURE|IVUS-guided group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used."
41305649|NCT00003243|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41305650|NCT00003243|DRUG|cyclophosphamide|
41305651|NCT00003243|DRUG|etoposide|
41305652|NCT00003243|DRUG|pegylated liposomal doxorubicin hydrochloride|
41305653|NCT02537314|DRUG|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
41305654|NCT02537314|OTHER|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
41305655|NCT01735747|RADIATION|Radiotherapy|WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
40986688|NCT01917201|PROCEDURE|Non-IVUS group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used."
40986689|NCT05302544|OTHER|Mixed Reality training|Mixed Reality training: Mixed Reality game with appearance of virtual balloons in the game area that the subject must find and pierce with finger
40986690|NCT05302544|OTHER|motor activities|motor activities usually performed
40986691|NCT03744923|PROCEDURE|transmuscular QL block|"Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate)."
41144967|NCT00728325|BEHAVIORAL|Standard Vocational Rehabilitation (VRP)|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
41144968|NCT00992693|DRUG|Ribavirin (Virazole) Injection|"The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60."
41144969|NCT05749562|DEVICE|Cheneau-Toulouse-Munster brace|Full length, orthogonal anteroposterior and lateral X-rays will be taken with the Cheneau-Toulouse-Munster brace.
41144970|NCT03694145|OTHER|In-Person Eye Examination|Dilated in-person eye examination by a board-certified ophthalmologist or retinal fellow.
41144971|NCT02952170|OTHER|MRI|MRI to assess hepatic steatosis
41144972|NCT00860301|OTHER|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
40782167|NCT00587041|DIETARY_SUPPLEMENT|Agri-King Synbiotic (AKSB)|AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
40782168|NCT00587041|OTHER|Placebo|1 placebo packet daily and 1 placebo capsule twice daily
40782169|NCT04692389|DEVICE|Jalosome soothing gel|This study has not got other intervention
40782170|NCT02950337|RADIATION|Group 1: Peripherally Located Tumors|Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
40782171|NCT02950337|RADIATION|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
40986692|NCT03744923|PROCEDURE|Transversus Abdominus Plane block|"Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning."
40986693|NCT05230537|DRUG|Iptacopan (LNP023)|oral capsules
41305656|NCT01735747|DRUG|nedaplatin|nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
41305657|NCT01735747|DRUG|vincristine|vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
40782172|NCT02950337|RADIATION|Group 3: Centrally Located Tumors|Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
40782173|NCT03181191|OTHER|Oral glucose tolerance test|Oral glucose tolerance test and biopsies
40782174|NCT00100802|OTHER|Laboratory Biomarker Analysis|Correlative studies
40986694|NCT05230537|DRUG|Placebo|oral capsules
40782175|NCT00100802|DRUG|Lomustine|Given PO
40782176|NCT00100802|RADIATION|Radiation Therapy|Undergo radiation therapy
40782177|NCT00100802|DRUG|Temozolomide|Given PO
41464255|NCT04553835|BEHAVIORAL|Rhythmic auditory stimulation (RAS) for schizophrenia patients|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday."
40782178|NCT04663074|DIAGNOSTIC_TEST|IVUS control|Intravascular Control of the bridging stentgrafts during branched EVAR
40782179|NCT00741078|DRUG|statin, amlodipine|
40782180|NCT05344534|BEHAVIORAL|Leadership and Organizational Change for Implementation|LOCI is data driven leadership development and coaching for clinic managers and working with agency executives and middle managers to foster a strategic implementation climate
40782181|NCT05660603|OTHER|control|patients will receive standard general anesthesia
40782182|NCT05660603|PROCEDURE|LSP|patients will receive standard general anesthesia followed by ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of bupivacaine 0.25%.
40782183|NCT05660603|PROCEDURE|CP|patients will receive standard general anesthesia followed by ultrasound-guided circum-psoas blocks with 40 ml of bupivacaine 0.25%.
40782184|NCT05660603|DEVICE|Ultrasound|ultrasound
40782185|NCT06240650|DEVICE|modified Health- Dx™ (mHDx) study capsule|The Study mHDx capsule has a mechanism that allows the mHDx to remain resident in the stomach for no more than six (6) hours. After this residency period, the Study mHDx will disassemble and pass safely through the subject's gastrointestinal system.
40782186|NCT06240650|DEVICE|modified Health- Dx™ (mHDx) control capsule|The Control mHDX capsule does not have a functional residency mechanism so it will disassemble once safely through the esophagus (within 10 minutes) and will then pass safely through the subject's gastrointestinal system.
40782187|NCT06544044|BEHAVIORAL|Brief Mindfulness' Self compassion|session includes mindfulness exercises like breath awareness and body scans, self-compassion practices like self-kindness meditations, and emotional regulation strategies such as cognitive reappraisal and response modulation. Discussions focus on applying mindfulness and self-compassion to manage difficult emotions, improve interpersonal interactions, and reduce aggression. Home practice assignments encourage students to integrate mindfulness and self-compassion into their daily lives. The program curriculum is based on existing evidence-based interventions, including mindfulness-based stress reduction for teens.
40782188|NCT03396887|OTHER|U Control Drink Smartphone Application|The smartphone application comprises five recovery focused features: supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, craving management and gamification.
40986695|NCT03997149|BEHAVIORAL|Acute Laboratory Stressor|The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.
40986696|NCT03997149|BEHAVIORAL|Low affect video|The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
40986697|NCT03787251|DRUG|Apatinib|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
40986698|NCT03787251|DRUG|The chemotherapeutic drug chosen by the investigator.|"The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice."
40986699|NCT01526616|DRUG|Metformin|Metformin 850 mg twice a day for six months
40986700|NCT01526616|DRUG|Metformin plus Spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
40986701|NCT02029833|OTHER|Regular Canola Oil|
40986702|NCT02029833|OTHER|High Oleic Canola Oil|
40986703|NCT02029833|OTHER|Western Type Diet - Common Dietary Oils|
40782189|NCT03396887|OTHER|Control group|The control group will receive treatment as usual.
40782190|NCT04024826|BEHAVIORAL|EFP|This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.
40782191|NCT04024826|BEHAVIORAL|LFP|This group will perform the Resistance training intervention on day 11 of the menstrual cycle, which corresponds to the mid of late follicular phase.
40782192|NCT04024826|BEHAVIORAL|ELP|This group will perform the Resistance training intervention on the day 18 of the menstrual cycle, which corresponds to the mid of early luteal phase
40782193|NCT04024826|BEHAVIORAL|LLP|This group will perform the Resistance training intervention on day 21 of the menstrual cycle, which corresponds to the mid of late luteal phase
40782194|NCT05430061|DIETARY_SUPPLEMENT|slowly digestible carbohydrate|carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
40782195|NCT01047189|DRUG|clindamycin phosphate 1.2% and tretinoin 0.025%|applied once daily for 12 weeks
40782196|NCT01047189|DRUG|clindamycin 1% gel|Topical clindamycin applied each morning for 12 weeks
40782197|NCT01047189|DRUG|tretinoin 0.025% cream|Tretinoin 0.025% cream each evening for 12 weeks
40782198|NCT00899912|GENETIC|microarray analysis|
40782199|NCT00899912|OTHER|diagnostic laboratory biomarker analysis|
40782200|NCT01067430|DRUG|Etoricoxib|Film coated tablet, 90 mg taken once a day for 14 days
40782201|NCT01067430|DRUG|Diclofenac|Enteric coated tablet 50 mg given three times a day for 14 days
41144973|NCT00943371|DRUG|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
40986704|NCT06516887|DRUG|bemcentinib|Bemcentinib has been investigated in a phase I/II clinical trials for solid tumors. Phase I and II clinical studies of BGB324 are ongoing in non-small cell carcinoma, in which combinations with other agents such as Phase I study of docetaxel (NCT02922777), erlotinib (NCT02424617), and pembrolizumab (NCT03184571) are also being investigated. In a phase I dose escalation study of bemcentinib in combination with docetaxel study, patients with treatment naïve, advanced lung adenocarcinoma receive docetaxel 75 mg/m2 given IV every 21 days in combination with bemcentinib. Bemcentinib dose will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
40986705|NCT06516887|DRUG|pacritinib|For use in clinical studies as an oral agent, pacritinib is supplied as size #0 hard gelatin capsules with gray bodies and scarlet caps. Capsules contain 100 mg pacritinib (free base) and the following inactive ingredients: microcrystalline cellulose NF, polyethylene glycol 8000 NF, and magnesium stearate NF. The capsule gelatin is bovine derived. Pharmacies at investigational sites will receive subject-specific bottles containing 120 capsules packaged in 200 mL high-density polyethylene bottles with child-resistant closures.
40986706|NCT05924750|DRUG|BL-M11D1|Administration by intravenous infusion
40986707|NCT05289414|DEVICE|Radiofrequency|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency treatment
40986708|NCT05289414|PROCEDURE|Greater occipital nerve block|patients with diagnosis of cervicogenic headache will be subjected to Greater occipital nerve block
40986709|NCT00487851|PROCEDURE|surgery|hepaticojejunostomy and gastroenterostomy
40986710|NCT00487851|PROCEDURE|endoscopic strategy|Stent insertion
40986711|NCT02150954|DRUG|pitocin|
40986712|NCT00604331|DRUG|Pyruvate|sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
40986713|NCT03722550|OTHER|Starter Infant Formula, Follow-up Formula, and Growing-up Milk Supplemented With a Blend of Five Human Milk Oligosaccharides|Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
40986714|NCT03722550|OTHER|Breast-feeding|Exclusive Breast-feeding up to 4 months of age
41144974|NCT00943371|DRUG|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
41144975|NCT01765023|DRUG|Period I : atorvastatin, Period II : atorvastatin and metformin|
41144976|NCT01765023|DRUG|Period I : metformin, Period II : atorvastatin and metformin|
41144977|NCT06160375|DIAGNOSTIC_TEST|pain assessment after video assisted thoracoscopic lung surgeries|a scalp needle with an extended tube will be inserted into the paravertebral space at the T4 level under thoracoscopic direct vision before closing the chest. One centimeter adjacent to the vertebrae will be inserted vertically 0.5 cm under the parietal pleura with the needle, and 20 ml 0.25% bupivacaine will be injected then the field will be observed for 5 min to make sure that there is no hemorrhage or hematoma.
41144978|NCT01043614|BEHAVIORAL|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
40782202|NCT01728142|DEVICE|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
40782203|NCT01728142|OTHER|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
40782204|NCT04486690|DRUG|Ketofol (propofol to ketamine ratio 1:1)|"* Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min"
40782205|NCT04486690|DRUG|propofol|"Propofol infusion, 25-150 mcg/kg/min.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min."
40782206|NCT06489366|DEVICE|Thulium Fiber laser (TFL) lithotripsy|Patients with proximal ureteral stones undergoing ureteroscopic lithotripsy using thulium laser lithotripsy.
41144979|NCT01838707|DRUG|0.125% Bupivacaine HCL @ 4-5 ml/h|
41144980|NCT01838707|DRUG|0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h|
40782207|NCT06489366|DEVICE|Ho: YAG lithotripsy|Ho:YAG laser lithotripsy was used in patients with proximal ureteral stones undergoing ureteroscopic lithotripsy.
40986715|NCT03722550|OTHER|Standard Starter Infant Formula, Follow-up Formula, and Growing-up Milk|Standard Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
40986716|NCT01673451|DRUG|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
41144981|NCT01838707|DRUG|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h|
41144982|NCT03686917|OTHER|CHAT-P|Survey
41144983|NCT06005116|RADIATION|[68Ga]-NOTA-SGC8|Participants will be irrigated with \[68Ga\]-NOTA-SGC8 intravesically, with 0.05mCi/kg per person per time according to body weight, no more than 5mCi. The participants will be instructed to urinate cleanly before irrigation, and then irrigated \[68Ga\]-NOTA-SGC8 into the bladder via catheter for 30 minutes to make full contact between the injection and tumor. After 30 minutes, the injection will be withdrawn and 300ml normal saline will be injected into the bladder to maintain the shape of the bladder.
41144984|NCT00416442|DRUG|RSV604|
41144985|NCT01074281|DRUG|Enalapril maleate (10 mg) + nitrendipine (20 mg)|The drug was administered as per the Summary of Product Characteristics (SPC)
41144986|NCT00600366|DRUG|biphasic insulin aspart|
41144987|NCT06337045|BEHAVIORAL|Complex prevention and rehabilitation intervention|The complex intervention started and ended with individual consultations with health professionals and furthermore included physical exercise, smoking cessation, alcohol treatment, dietary interventions, AF specific patient education, MediYoga, and/or psychosocial support.
41144988|NCT06387940|OTHER|nEB Diet, followed for 36 hours|nEB diet first, then LC25 and LCEB in random order with a 5 days washout between each diet
40782208|NCT06451588|DRUG|FMT|Active FMT
40782209|NCT06451588|DRUG|Placebo|The placebo treatment will be prepared based on the patients' fecal samples (autologous).
41464256|NCT04553835|BEHAVIORAL|No RAS for schizophrenia patients|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
41464257|NCT04553835|BEHAVIORAL|RAS for at-risk individuals|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day."
41464258|NCT04553835|BEHAVIORAL|No RAS for at-risk individuals|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
41464259|NCT00324896|DRUG|eszopiclone|eszopiclone
41464260|NCT00324896|OTHER|placebo|matching placebo administered at night
41464261|NCT02369549|DRUG|Micro-particle Curcumin|as described in Arm
41305658|NCT01735747|DRUG|Temozolomide|Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
41464262|NCT02369549|DRUG|Placebo|Looks, smells, tastes and feels exactly like the Curcumin capsules.
40986717|NCT01673451|DRUG|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
40986718|NCT02788968|OTHER|MRI|"Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI"
40986719|NCT02983331|PROCEDURE|complications during procedure|patients may have anesthesia related complications during procedure
41144989|NCT06387940|OTHER|LC25 Diet, followed for 36 hours|LC25 diet first, then nEB and LCEB in random order with a 5 days washout between each diet
41144990|NCT06387940|OTHER|LCEB Diet, followed for 36 hours|LCEB diet first, then LC25 and nEB in random order with a 5 days washout between each diet
41144991|NCT06443736|PROCEDURE|Standardized perineal massage|Patients in this arm will be educated in the perineal massage proposed by the authors; the training will be performed during a group session, (organized bimonthly) conducted by obstetrical staff specialists, in the presence of the principal investigator and/or co-authors. In these sessions, a brief lecture on aspects of primary prevention related to pelvic floor structures (healthy diet, body weight control, moderate physical activity avoiding excessive exertion, posture control, therapy minctional education) and then screened an explanatory video regarding the three-step perineal massage proposed by the authors. The adequately prepared patient should then apply such perineal massage at home from the 34th gestational week until delivery according to the procedural methods provided.
41144992|NCT06443736|BEHAVIORAL|Primary prevention|Patients in this arm will be offered a group meeting in which aspects of primary prevention related to the structures of the pelvic floor (healthy diet, body weight control, moderate physical activity avoiding exertion excessive exertion, posture control, micturition educational therapy); participation in this meeting will be on a voluntary basis, and patients randomized to that group will have free choice in educating the pelvic floor pelvic floor in pregnancy.
41305659|NCT00678275|DRUG|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
41305660|NCT00678275|DRUG|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen WITHOUT ATG when randomised Arm B
41305661|NCT02544971|BEHAVIORAL|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
41464263|NCT04751630|OTHER|Therapeutic Exercise|Online and structured exercise therapeutic program based on flexibility, strength, balance and aerobic exercises. The program have been supervised by an expert on the field and it participants will perform it under the supervision of an expert physiotherapist.
40782210|NCT03041220|PROCEDURE|cesarean section|obese patients (BMI of 30 or greater) who have had a cesarean section
40986720|NCT02862613|PROCEDURE|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
40986721|NCT02862613|BIOLOGICAL|Precision Cells|DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
40986722|NCT04458233|PROCEDURE|long axis FNA method|"). A long-axis view (i.e., a longitudinal image of the needle) is obtained by placing the US probe in a parallel position relative to the course of the needle. Short-axis and long-axis views can be used for both US assistance and guidance of FNA procedure. Correspondingly, approaching the nodule with the needle from the lateral or frontal aspect results in either a long axis or short axis view of the needle on the US screen"
40782211|NCT03662282|DRUG|Omegaven|Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury
40782212|NCT05945888|DRUG|BI 3000202|BI 3000202
40782213|NCT05945888|DRUG|Placebo matching BI 3000202|Placebo matching BI 3000202
40986723|NCT00473642|DRUG|Ranibizumab|intravitreal administered ranibizumab 0.5 mg in 0.05 mL
41144993|NCT03242239|BIOLOGICAL|ALT02|
41144994|NCT03242239|BIOLOGICAL|EU-licensed Herceptin|
41305662|NCT02544971|OTHER|Control|Treatment as usual
41305663|NCT04156750|DRUG|LY3556050|Administered orally.
41305664|NCT04156750|DRUG|Placebo|Administered orally.
41305665|NCT04156750|DRUG|Iohexol|Administered IV.
41305666|NCT04156750|DRUG|Metformin|Administered orally.
40782214|NCT03666390|DRUG|Ketamine|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
40782215|NCT03666390|DRUG|Midazolam|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
40782216|NCT03693495|DIAGNOSTIC_TEST|ellume·lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic participants. The sample type used is a throat swab.
40782217|NCT03693495|DIAGNOSTIC_TEST|Bacterial Culture|Pharyngeal swab is collected from participant and this specimen is inoculated into 5% sheep blood agar plates. Beta-haemolytic colonies are isolated, followed by latex agglutination test.
40782218|NCT03693495|DIAGNOSTIC_TEST|Polymerase Chain Reaction (PCR)|Polymerase Chain Reaction (PCR) is a molecular diagnostic technique for the detection and identification of Group A Streptococcus, both for clinical samples and isolates. Polymerase Chain Reaction (PCR) allows template bacterial RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
40782219|NCT04747288|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine pattern diagnosis.
40986724|NCT00473642|DRUG|Verteporfin|Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
40986725|NCT00473642|DRUG|Verteporfin|Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
40986726|NCT05715008|OTHER|Kefir|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
40986727|NCT05715008|OTHER|Placebo|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
40986728|NCT00842686|DRUG|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
40986729|NCT06520930|BEHAVIORAL|breathing exercise therapy|Description: The breathing exercises to be applied were taught to each pregnant woman face to face with one-on-one training. The taught practice was then repeated by the pregnant woman and the researcher together. In the next step, pregnant women were asked to perform the application themselves. In this way, it was determined whether individual breathing exercise practices were performed correctly and effectively. After the one-on-one training was completed, the pregnant women were divided into groups of maximum six people and breathing exercise exercises were performed 7 days a week, once a day and once a week face-to-face for 8 weeks. Each session lasted approximately 45 minutes. For 8 weeks, a short reminder message was sent to pregnant women every morning to ensure that they did not interrupt their daily breathing exercise practices, and they were called in the evening to check whether they had performed the application correctly and whether they had any problems.
40986730|NCT03045081|BEHAVIORAL|PainTracker Self-Manager|Interactive web-based educational and assessment program supported by a nurse care manager
40986731|NCT06493695|BEHAVIORAL|Both EGChat and CES intervention|"1. A exercise-promoting chatbot called EGChat, integrated into an established online health promotion platform.~2. Intervention of CES (Cranial Electrotherapy Stimulation) at Home"
40986732|NCT06493695|OTHER|Exercise Chatbot|Exercise Chatbot
40986733|NCT06493695|DEVICE|CES (Cranial Electrotherapy Stimulation)|Intervention of CES (Cranial Electrotherapy Stimulation)
40986734|NCT01738763|DIETARY_SUPPLEMENT|Pinitol|Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
40986735|NCT06176573|PROCEDURE|Chlorhexidine|Pre-operative and post-operative vaginal cleansing.
41464264|NCT04309994|OTHER|Myocardial protection system (MPS)|cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
41464265|NCT04309994|OTHER|Cardioplexol|cardioplegia solution
40986736|NCT03318250|DEVICE|Dorsal Root Ganglion Stimulation|During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
40986737|NCT00131833|BIOLOGICAL|Typhoid Vi vaccine|
40986738|NCT00131833|BIOLOGICAL|Meningococcal A (control)|
40986739|NCT04019314|PROCEDURE|Blood Collection|Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.
40782220|NCT04747288|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine tongue diagnosis.
40782221|NCT04747288|DIAGNOSTIC_TEST|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
40782222|NCT04747288|DIAGNOSTIC_TEST|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
40986740|NCT04019314|PROCEDURE|Blood Volume Analysis|A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
40986741|NCT01287689|OTHER|Immunoglobulin G (IgG)|Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
40986742|NCT04659850|OTHER|low fat, low AGE milkshake|low fat, low AGE milkshake given after an overnight fast
40986743|NCT04659850|OTHER|low fat, high AGE milkshake|low fat, high AGE milkshake given after an overnight fast
40782223|NCT04747288|DIAGNOSTIC_TEST|Ocular Surface Diseast Index (OSDI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Ocular Surface Diseast Index (OSDI).
40782224|NCT04747288|DIAGNOSTIC_TEST|EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
40782225|NCT04747288|DIAGNOSTIC_TEST|36-Item Short Form Survey (SF-36)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the 36-Item Short Form Survey (SF-36).
40782226|NCT03589274|BEHAVIORAL|I-FS-CBT|12 manual-guided sessions of I-FS-CBT
40782227|NCT03589274|BEHAVIORAL|G-FS-CBT|12 manual-guided sessions of G-FS-CBT
40782228|NCT05767281|BEHAVIORAL|prevention program|introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
40782229|NCT06544915|DIETARY_SUPPLEMENT|Synbiotic, Probiotic, Placebo|Use of dietary supplements to improve gut microbiome and cardiometabolic health
40782230|NCT00656682|BEHAVIORAL|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian
40782231|NCT00656682|BEHAVIORAL|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
40782232|NCT01822665|DRUG|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
40782233|NCT01822665|DRUG|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
40782234|NCT01822665|OTHER|Placebo|Placebo tablets
40782235|NCT00570843|DRUG|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
40782236|NCT00570843|DRUG|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
40986744|NCT04659850|OTHER|high fat, low AGE|high fat, low AGE milkshake given after an overnight fast
40986745|NCT04659850|OTHER|high fat, high AGE milkshake|high fat, high AGE milkshake given after an overnight fast
40986746|NCT03296254|BEHAVIORAL|Sitting Mindfulness Exercises.|5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation
40986747|NCT03296254|BEHAVIORAL|Body Mindfulness Exercises|5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
40986748|NCT04962009|COMBINATION_PRODUCT|Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug|Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
40986749|NCT02042248|BIOLOGICAL|AGS-004|All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
40986750|NCT06077292|BEHAVIORAL|15% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 15% less potent than baseline
40986751|NCT06077292|BEHAVIORAL|35% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 35% less potent than baseline
40986752|NCT01089959|DRUG|Esomeprazole|40 mg daily for 7 days
41144995|NCT03242239|BIOLOGICAL|US-licensed Herceptin|
40782237|NCT05948189|OTHER|exercise program|The participants of the intervention group received back health education (Back School) in the classroom. After the education program, they participated in exercise training for six weeks (one day a week).
40782238|NCT02830243|DRUG|Sevoflurane|End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
40782239|NCT02830243|DRUG|Desflurane|End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
40782240|NCT00307957|DEVICE|Pillar Palatal Implants|
40782241|NCT03213509|OTHER|Interview (Social and Verbal Autopsy)|Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
40986753|NCT01089959|DRUG|esomeprazole|40 mg. daily, oral medication, once daily for 7 days.
40986754|NCT03929718|DRUG|Spironolactone|receive spironolactone treatment after CTI ablation
40986755|NCT03929718|DRUG|No Spironolactone|no spironolactone treatment
40986756|NCT04682184|DRUG|Propranolol|Administered orally.
40986757|NCT04682184|DRUG|Pseudoephedrine|Administered orally.
40986758|NCT04682184|DEVICE|Wearable Biosensor Patch Device|Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.
41144996|NCT02082639|BIOLOGICAL|Cervarix™|2 doses intramuscularly in the deltoid muscle of the non-dominant arm
41144997|NCT02082639|BIOLOGICAL|Havrix|2 doses intramuscularly in the deltoid muscle of the dominant arm
40782242|NCT02462226|BEHAVIORAL|The-Optimal-Lymph-Flow|"The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI."
40782243|NCT02462226|BEHAVIORAL|Arm Precaution|"The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb."
40782244|NCT00198679|DRUG|Chlorhexidine|
40782245|NCT05110326|OTHER|ERGON Technique|"* Hot pack for 15 minutes.~* Patient position: Prone with knee flexion approximately 45◦.~* Position of therapist: Standing at the affected side of patient.~* Technique:Massage cream will be applied on the hamstring and overactive or short muscle fibres that are restricted.The instrument will be applied parallel to the muscle fibers, both in a distal to proximal and them proximal to distal direction as needed.Then gentle massage stroking from the origin to the insertion will be performed using the instrument. Instrument Assisted Soft Tissue Mobilization(IASTM) will be applied for 5 minutes.~* Strengthening exercises for quadriceps and hamstring will then be performed.~* Isometrics exercises of Quadriceps: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Isometrics exercises Hamstrings: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Wall sits: For 10 seconds, 5 sets."
40782246|NCT05110326|OTHER|Proprioceptive Neuromuscular Facilitation (PNF) stretching|"* The patient will be laid down prone and moist heat will be given for 15 minutes prior to stretching the hamstrings.~* Then patient will be lying supine with hip in 90⁰ of flexion. Patient's knee will be extended until a very mild stretching sensation is felt in hamstring muscles.~* Then patient will be asked to flex the knee against the resistance applied by hand of therapist.~* The patient will be asked to use a force of around 50% of maximal strength and an isometric form of contraction will be gained in the hamstring muscles. The patient will hold the contraction for 8 seconds and then the therapist command to relax the hamstring muscle.~* Immediately after the muscle relaxation the therapist further stretches the hamstring muscles up to a point where the subject reported a mild to moderate stretching sensation without any pain and will be held for 30 seconds.~* The procedure will be repeated 3 times in every session.~Strengthening Exercises:~* Same as ERGON Group"
40782247|NCT03703050|DRUG|Nivolumab cohort 1|Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
40782248|NCT03703050|DRUG|Nivolumab cohort 2|Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
40782249|NCT02382588|DRUG|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
40782250|NCT02382588|DRUG|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
40782251|NCT00743470|DRUG|lopinavir/ritonavir|lopinavir/ritonavir tablet; see arm for intervention description
40782252|NCT00743470|DRUG|rifabutin|rifabutin capsule; see arms for intervention description
40782253|NCT06088329|BEHAVIORAL|Mindful Walking for Adults with Chronic Pain|Participants identified with chronic pain will complete 6 sessions of mindfulness based walking exercises.
40986759|NCT03487757|OTHER|Core Stabilization Exercises|Jeffrey's core stabilization exercise training protocol will be performed to the training group. This protocol includes exercises progressing gradually from level 1 to level 3. Level 1; static contraction training on a stable surface, level 2; dynamic training on a stable surface, level 3; dynamic and resistant training on an unstable surface.
40986760|NCT03487757|OTHER|No Intervention|Since no training is given to the control group during the study period, it is ethically necessary to give the same training to the control group if the benefit is achieved when the study is completed.
40986761|NCT00453544|OTHER|Enhanced Consent Procedure|This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved
40986762|NCT00453544|OTHER|Routine Consent Procedure|This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
40986763|NCT05350150|DEVICE|Auricular Vagal Nerve Stimulation|The Parasym device will be placed on the patient's left tragus to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve.
40986764|NCT04953221|DRUG|YJ001|Skin spray
40986765|NCT02150096|OTHER|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
41305667|NCT01397071|OTHER|Avocado|Fresh Avocado
41305668|NCT01598857|DRUG|Blisibimod|
41305669|NCT01598857|DRUG|Placebo|
41305670|NCT05583006|DRUG|tenofovir alafenamide (TAF)|TAF switch therapy in CHB patients who are unsatisfied to ETV therapy.
41305671|NCT03777579|DRUG|JS001，an engineered anti-PD-1 antibody|JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
41305672|NCT03777579|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.
41464266|NCT04456933|PROCEDURE|Extracorporeal left hemicolectomy anastomosis|"Standard surgical technique protocolized in the unit for laparoscopic surgery of the left colon, sigma and high rectum for the last 10 years.~After sectioning the distal colon using a mechanical stapler (60mm blue load), a pfannestiel-type suprapubic accessory incision is made, with externalization of the tumor under wound protection with a ringed retraction device. Both the resection of the left mesocolon or mesosigma, and the placement of the head of the circular stapler are performed extracorporeally by proximal section of the colon with a pursetring® self-suturing device, removal of the piece, placement of the head, and reconnection of the pneumoperitoneum for colorectal anastomosis with Circular Stapler Curved B. Braun®"
40782254|NCT01374425|DRUG|5-Fluorouracil|5-Fluorouracil 400 milligrams per meter-squared (mg/m\^2) by IV bolus and subsequent 2400 mg/m\^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
40986766|NCT02150096|OTHER|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
41144998|NCT06226441|PROCEDURE|Continuous Renal Replacement Therapy|CRRT
41305673|NCT03777579|DRUG|Placebo|Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
41305674|NCT04065477|BEHAVIORAL|computer-based cognitive rehabilitation (CBCR)|Program designed to improve strategic cognitive domains (e.g., complex attention, working memory)
41305675|NCT00008294|DRUG|FOLFOX regimen|
41305676|NCT00008294|DRUG|dexamethasone|
41305677|NCT00008294|DRUG|floxuridine|
41305678|NCT00008294|DRUG|fluorouracil|
41305679|NCT00008294|DRUG|leucovorin calcium|
41305680|NCT00008294|DRUG|oxaliplatin|
41305681|NCT01835496|DRUG|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
41305682|NCT00880672|DRUG|dutasteride|5mg, oral, daily, 2-4 weeks
41305683|NCT00118027|DRUG|sulphadoxine-pyrimethamine intermittent preventive treatment|
41305684|NCT01720615|DRUG|Propofol / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
41305685|NCT01720615|DRUG|Sevoflurane / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
40782255|NCT01374425|DRUG|Bevacizumab|Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
40782256|NCT01374425|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
40782257|NCT01374425|DRUG|Leucovorin|Leucovorin 400 mg/m\^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
40782258|NCT01374425|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
40986767|NCT02150096|OTHER|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
40986768|NCT04215380|DIETARY_SUPPLEMENT|Acacia Senegal extract|Oral Digestion of Gum Arabic dissolved in 200 ml of water to be consumed early morning in daily basis for 12 weeks
40986769|NCT04215380|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
40986770|NCT01618409|BEHAVIORAL|PictureRx card|An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
41144999|NCT03927118|PROCEDURE|intravitreal dexamethasone implant application|Peripapillary RNFL thickness measurements and colored fundus photographs were compared before and 6 months after intravitreal DEX implant injection. The cup-to-disc ratios of fundus photographs were calculated using the Image-J program.
41145000|NCT05000359|BEHAVIORAL|text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
41145001|NCT01308879|BEHAVIORAL|Contextualized Feedback Systems (CFS)tm|After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.
41145002|NCT02771561|PROCEDURE|Patent Foramen Ovale Closure|Transoesophageal guided percutaneous patent foramen ovale closure using Gore™ septal occluder device
41145003|NCT00559572|BEHAVIORAL|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
41145004|NCT00559572|OTHER|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
41145005|NCT03726502|PROCEDURE|ureteroscopy with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
41305686|NCT02523326|DEVICE|saliva samples obtained with mouthwash|saliva samples obtained with mouthwash
41305687|NCT04178681|OTHER|100% vegetable blend|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.
41305688|NCT04178681|OTHER|100% AMF|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.
41305689|NCT04178681|OTHER|100% cream|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
41305690|NCT03393364|DRUG|Oxycodone|Patients receive oxycodone for pain control after outpatient urologic surgery.
41305691|NCT03393364|DRUG|Ketorolac|Patients receive ketorolac for pain control after outpatient urologic surgery
41145006|NCT03726502|PROCEDURE|ureteroscopy alone|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
40986771|NCT05291247|DEVICE|Peripheral lithotripsy system (Shockwave Medical)|The combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device for calcified femoropopliteal disease.
40986772|NCT00993291|PROCEDURE|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
40986773|NCT00993291|PROCEDURE|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
40986774|NCT01770548|GENETIC|analysis of the glutamate synapse in autism|Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism
40986775|NCT01770548|GENETIC|DNA collection|DNA collection
41305692|NCT00305006|PROCEDURE|Constraint-Induced Movement Therapy (CIMT)|90 hours
41464267|NCT04456933|PROCEDURE|Intracorporeal left hemicolectomy anastomosis|"o Intracorporeal resection of the left mesocolon~The mesocolon resection will be performed totally intracorporeally to its proximal end. The distal colon section will be performed using a mechanical stapler (blue charge 60mm)~o Preparation of Intracorporeal Anastomosis~The anastomosis will be performed in a mechanical end-to-end manner using a Circular Stapler Curved B. Braun®.~The Insertion of the stapler head into the proximal colon will be placed intracorporeally with an incision distal to the staple section. Once the head has been exteriorized at the terminal end of the proximal colon, a circular purse-type suture with prolene 2.0 will be made.~Once the mechanical colorectal anastomosis is performed, 4-6 stitches of anastomotic reinforcement with silk 2.0 will be placed.~The extraction of the piece will be carried out with endobag protection and with an accessory incision (pfannestiel or other location depending on the patient)"
41464268|NCT03548662|BIOLOGICAL|Platelet-Rich Plasma|Platelet-Rich Plasma prepared by RegenKit® PRP, Regenlab SA
41464269|NCT03548662|DRUG|Hyaluronic Acid|Hyruan Plus Inj. produced by LG Life Sciences, Ltd.
41464270|NCT03548662|OTHER|Exercise|passive range of motion (PROM) exercise, active-assisted range of motion (AAROM) exercise, active range of motion (AROM) exercise, rotator cuff strengthening exercise, and peri-scapular muscle strengthening exercise
41464271|NCT06036108|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered at least 10 hours of fasting. In Period 2, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal.
41464272|NCT06036108|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal. In Period 2, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered following at least 10 hours of fasting.
40782259|NCT01374425|DRUG|Capecitabine|Capecitabine 850 or 1000 mg/m\^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
40782260|NCT00712517|DRUG|propofol|propofol anesthesia 3-5mg/kg
40986776|NCT01770548|OTHER|Auditory evoked potentials|auditory evoked potentials
40986777|NCT03271112|OTHER|Exercise program|Measurement of physical performance before and after the 12 wks-exercice program
40986778|NCT01797692|OTHER|geriatric assessment|A single geriatric assessment with a geriatrician was proposed to patients and to control population.
41305693|NCT00305006|PROCEDURE|Hand-Arm Bimanual Intensive Therapy (HABIT)|90 hours
41305694|NCT03100942|DRUG|Lanraplenib|1 x 30 mg tablet administered orally once daily
41305695|NCT03100942|DRUG|Filgotinib|1 x 200 mg tablet administered orally once daily
41305696|NCT03100942|DRUG|Tirabrutinib|1 x 40 mg tablet administered orally once daily
41305697|NCT03100942|DRUG|Lanraplenib placebo|1 x tablet administered orally once daily
41305698|NCT03100942|DRUG|Filgotinib placebo|1 x tablet administered orally once daily
41305699|NCT03100942|DRUG|Tirabrutinib placebo|1 x tablet administered orally once daily
41305700|NCT00527111|DRUG|Cetuximab|
41464273|NCT03768349|DRUG|Ga-68 PSMA11|Ga-68 PSMA11 PET/CT for detection of tumor location
41464274|NCT03768349|DRUG|F-18 PSMA 1007|F-18 PSMA 1007 PET/CT for detection of tumor location
40986779|NCT06167044|OTHER|thoracic mobilization|Thoracic mobilization will be performed for the thoracic spine mobilization group, thoracic mobilization therapy will be performed for five minutes.
41145007|NCT03726502|PROCEDURE|without safety guide-wire|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
41145008|NCT03726502|PROCEDURE|with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
41145009|NCT01115153|OTHER|prophylaxis|single doses of antibiotics before surgery in patients with gangrenous appendicitis Metronidazole 500 mg IV + amikacin 1 gr IV
41145010|NCT01115153|OTHER|therapy|antibiotic treatment (5 days) therapy in patients with gangrenous appendicitis metronidazole 500 mg IV three times a day + amikacin 1 gr IV per day
41145011|NCT05214248|OTHER|a multimedia admission orientation|A short video based on self-drawing characters and figures with Chinese dubbing and background light music, explaining the NICU environment, health care workers, and tests and examination that are essential for an infant admitted to this NICU of Cathay Hospital in Taipei, R.O.C.
40986780|NCT03538158|BEHAVIORAL|Intervention Condition|Participants will have access to Fittle Senior which will provide guided exercises and social support from other participants of the study.
41305701|NCT00527111|DRUG|5-fluorouracil|
41305702|NCT00527111|RADIATION|Pelvic irradiation|
41305703|NCT03127215|DRUG|Olaparib|Olaparib 150 mg tablet
41305704|NCT03127215|DRUG|Physician's choice|treatment according to current guidelines
41305705|NCT03127215|DRUG|Trabectedin|Trabectedin 1.1mg/m² infusional solution
41305706|NCT02249234|DRUG|Botox|
41305707|NCT02249234|DRUG|Placebo|
41305708|NCT01608789|DEVICE|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
41464275|NCT03884725|DRUG|Fibrinogen Concentrate|Fibrinogen Concentrate is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given Fibrinogen Concentrate at an individually determined dose based on FIBTEM MCF and body weight as follows: (15 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[mm\*kg/g\] = gram fibrinogen to be dosed as Fibrinogen Concentrate. Fibrinogen Concentrate is to be infused over 1 to 2 minutes. After Fibrinogen Concentrate infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
41464276|NCT03884725|OTHER|control|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF). 0.9% saline is to be infused over 1 to 2 minutes. After 0.9% saline infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
41464277|NCT04234555|DIAGNOSTIC_TEST|Corticomotor excitability to the pelvic floor muscles|Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.
41464278|NCT04234555|DIAGNOSTIC_TEST|Pelvic floor muscle response to pressure applied at the vulvar vestibule|Electromyography will be used to determine whether the pelvic floor muscles (PFMs) respond to pressure applied to the vulvar vestibule as anticipatory (i.e. PFMs are active before the pressure is applied) and as behavioural (i.e. PFMs are active after the pressure is applied) responses. The amplitude of the EMG responses will also be recorded.
41464279|NCT04234555|DIAGNOSTIC_TEST|Pressure pain threshold (PPS)|A custom vulvalgesiometer will be used to determine the mean pressure at which participants first report pain at the posterior vaginal fourchette.
41464280|NCT04234555|DIAGNOSTIC_TEST|Temporal summation of pain|A custom vulvalgesiometer will be used to apply the same pressure (rated as 4/10 duiring PPS testing as described above) to the vulvar vestibule across 10 repetitions. The difference in pain rated on the tenth application and that rated on the first application will be the outcome.
41464281|NCT04234555|DIAGNOSTIC_TEST|Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)|Electromyography will be used to measure the mean smoothed, rectified activation amplitude across 1 second of complete rest, across three maximal effort PFM contractions, and across three attempts at a bearing down maneuver.
41464282|NCT02310763|BIOLOGICAL|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
40782261|NCT00712517|DRUG|sevoflurane|sevoflurane anesthesia
40986781|NCT03538158|BEHAVIORAL|Control Condition|Participants will have a paper booklet with suggested exercises that they may choose to complete for the duration of the study.
41305709|NCT02683915|PROCEDURE|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
41305710|NCT04042610|BEHAVIORAL|Electronic Prompt for Interrupting Sitting Time|An electronic prompt via the IOS application Stand-Up will be given through the Amazfit BIP device to interrupt sitting time every hour during the office workers workday. The office worker will engage in 2 minutes of physical activity with each prompt.
41464283|NCT02310763|DRUG|Placebo|
41464284|NCT02107222|DEVICE|CO2-Removal (PALP-Device/MaquetCP)|extracorporeal circuit to remove CO2 out of the blood
41464285|NCT04476186|DRUG|Acyclovir|oral syrp
41464286|NCT04476186|DRUG|KOH 10 %|solution for local application
41464287|NCT05714241|OTHER|Data extraction|"After routine coronary function testing using a diagnostic pressure-temperature sensor guidewire in order to assess Coronary Flow Reserve (CFR) and the Index of Microvascular Resistance (IMR); and/or the acetylcholine (Ach) provocative test to assess the presence of coronary vasomotion disorders, patients will be stratified, accordingly to coronary function testing and Ach provocative test, in four groups/endotypes:~1. MVA (evidence of CMD defined as any of abnormal CFR \[\<2.0\], IMR \[≥25\], or microvascular spasm);~2. VSA (CFR ≥2.0, IMR \<25 and epicardial spasm);~3. both MVA and VSA (evidence of CMD and epicardial spasm);~4. none/non-cardiac chest pain (CFR ≥2.0 and IMR \<25 and neither microvascular nor epicardial spasm)."
40986782|NCT03761147|OTHER|Paula exercises|structured exercises aimed to stimulate ring muscles
40986783|NCT02297828|DEVICE|Boussignac CPAP|Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
40986784|NCT02297828|DEVICE|Venturi face mask|Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
40986785|NCT01887574|OTHER|questionnaire|questionnaires given to all patients to assess risk factors and quality of life
40986786|NCT05998200|OTHER|Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA|Participants will used the serum twice daily for 8 weeks
40782262|NCT01263327|BIOLOGICAL|HPV 16/18|Participants would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
40782263|NCT02982629|BEHAVIORAL|Reminder letter Intervention|Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
40782264|NCT06230809|BEHAVIORAL|Web-based self-help|Web-based self-help with 5 modules, lasting 5 weeks.
40986787|NCT05892042|DRUG|Rivaroxaban 15 MG [Xarelto]|Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.
40986788|NCT01028339|DRUG|Hypertonic saline|2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
40986789|NCT01028339|DRUG|Mannitol|Mannitol
40986790|NCT00003055|DRUG|cisplatin|
40986791|NCT00003055|DRUG|irinotecan hydrochloride|
41305711|NCT06018584|OTHER|Tooth extraction|Tooth extractions were performed by a single physician. Topical anesthesia (Xylo-caine, Astra, Södertalje, Switzerland) was applied to the dried mucosa in the area to be lo-calized with the help of an ear stick for 1 minute. Posterior-superior-alveolar nerve block anesthesia and palatal anesthesia were applied for the upper primary molars; Inferi-or-alveolar nerve block anesthesia and lingual anesthesia (Ultracain, Aventis Pharma, Is-tanbul, Turkey) were applied for the lower primary molars. After anesthesia control was achieved, a randomly selected tooth was extracted. Tooth extraction on the other side was performed two weeks later. During the shootings, attention was paid to the traumatic ap-proach. After the control of bleeding was achieved, data were recorded for each group.
41305712|NCT00786838|DRUG|Trabectedin|Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
41305713|NCT00786838|DRUG|Placebo|Participants will receive 3-hour placebo intravenous infusion on Day 1.
41464288|NCT05714241|OTHER|Blood sampling|At the time of this coronary angiography, arterial blood samples through the radial sheath will be collected. If collected at the time of any follow-up visit, venous blood samples will be collected by venipuncture with the same modalities to obtain whole blood, serum and plasma samples after centrifugation.
41464289|NCT05714241|OTHER|Clinical Follow-up|"All patients will undergo a final follow-up visit at 12 months from the date of enrollment.~During the visit, the incidence of MACE in the past months will be investigated, the Seattle Angina Questionnaire (SAQ) will be administered and the SAQ summary score will be collected."
41464290|NCT00458159|DRUG|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, \& 50mg, taken once daily, orally.
40782265|NCT04656405|OTHER|Online real-time quality measurement and feedback video-based CPR training|"Participants in the online real-time quality measurement and feedback video-based CPR training program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. The study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) are provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing and collect real-time performance data using the QCPR mannequin device. Using this information, the instructor will provide real-time online feedback to participants."
40782266|NCT04656405|OTHER|Online real-time feedback video-based CPR training without quality measurement|"Participants in the online real-time feedback video-based CPR training without quality measurement program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. When study participants access the online training center, study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) is provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing. The instructor will provide real-time online feedback to participants."
40782267|NCT04656405|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) device are provided to measure and give feedback on the participants CPR performance."
40782268|NCT01242514|DRUG|Fostamatinib|Fostamatinib 100mg twice daily
40782269|NCT01242514|DRUG|Fostamatinib|Fostamatinib 150mg once daily
40782270|NCT01242514|DRUG|Fostamatinib|Fostamatinib 100mg once daily
40782271|NCT02793661|DEVICE|RenalGuard|Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
40782272|NCT02793661|OTHER|Control|Hydration protocol following ESC Guidelines 2014
40782273|NCT01792167|BEHAVIORAL|Second Step Curriculum|social emotional learning program for 6th-8th graders. 15 50 minutes lessons in 6th grade, 13 50 minute lessons in 7th and 8th grade. covers empathy, perspective taking, anger management, impulse control, problem-solving, alcohol and drug prevention, sexual harassment, prejudice, bully prevention, bystander intervention
40782274|NCT01603017|DEVICE|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
40782275|NCT01603017|DEVICE|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
40986792|NCT01485640|DRUG|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
41145012|NCT05223725|BIOLOGICAL|AdKCNH2-G628S|adenovirus containing the transgene KCNH2-G628S
40782276|NCT02468024|PROCEDURE|Lung Surgery|Sublobar Lung Resection
40782277|NCT02468024|RADIATION|Radiation therapy|Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
40782278|NCT00458549|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
40782279|NCT00458549|PROCEDURE|biopsy|
40782280|NCT02588014|OTHER|Magnetoencephalography|Magnetoencephalography is a non-invasive technique for investigating human brain activity. It allows the measurement of ongoing brain activity on a millisecond-by-millisecond basis, and it shows where in the brain activity is produced.
41145013|NCT00773344|DRUG|Tanespimycin|"Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT~This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)"
41145014|NCT05581004|DRUG|RO7502175|RO7502175 will be administered as per the schedules specified in the respective arms.
41145015|NCT05581004|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
41145016|NCT00529529|DRUG|Indacaterol 300 μg|Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
40986793|NCT03459742|BEHAVIORAL|Gamification strategy|"The intervention is a gamification strategy, including game elements such as points, levels and rewards. Points are scored by completion of healthy challenges, i.e. a healthy snacks challenge, a steps challenge and activity challenge. Intervention takes place for 8 months from Mar to Nov. There will be three levels. Level 1 at baseline, level 2 expected at month 4 by 100% of participants and level 3 expected in month 8 by 70% of participants. A new cycle will start in 2019.~Rewards include an initial reward (Starting Kit), a structural reward and an activity reward. The Starting Kit is a box with souvenirs, information for students and teachers. A structural reward, at level 2, will be achieved collectively by all participating classes in one school. It consists of school infrastructure improvements to promote a healthy nutrition and PA (eg. climbing wall, shared bicycles, sports equipment). An activity reward (AR), when reaching level 3, consists of a fun and healthy activity."
40986794|NCT03775980|DEVICE|Emprint Microwave Ablation System|Microwave Ablation of colorectal liver metastases
40986795|NCT01589744|DEVICE|Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)|The haemostatic intra-uterine suction-cup is introduced in uterus and a depressure in this device is applied. This medical device is used for 5 minutes at maximum.
40986796|NCT03474120|PROCEDURE|IVF treatment|Relationship between IVF treatment outcome and genotypes in POI//DOR/ovarian dysgenesis patients
40986797|NCT00039754|DRUG|Holmium-166-DOTMP|
40986798|NCT01137045|BIOLOGICAL|SPEEDA and TRCS SPEEDA|"For modified TRC-ID regimen,0.1 ml of SPEEDA, TRCS SPEEDA or VERORAB will be given at each of two sites,intradermally on upper arms on days 0,3,7 and 28.~For ESSEN regimen, 1 vial of SPEEDA will be given intramuscularly at upper arm on days 0,3,7,14 and 28.~For ERIG,it would be given in a single dose 40 IU/Kg at the same time as the first dose of vaccine. ERIG will be infiltrated around and into all wounds as recommended by WHO for patients in group IV and injected intramuscular at each of both gluteal areas for participants in group III,V,VI"
40986799|NCT02338960|DRUG|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
40986800|NCT02338960|DRUG|Placebo|Placebo
40986801|NCT04798547|PROCEDURE|Short Myotomy|Evaluation of short length myotomy
40986802|NCT04798547|PROCEDURE|Standard Length Myotomy|Standard Length Myotomy
40986803|NCT00547742|PROCEDURE|PET/CT Scan|
40986804|NCT00547742|PROCEDURE|phlebotomy|
41464291|NCT00443482|DRUG|formoterol|
40986805|NCT05938933|BEHAVIORAL|PHP|personalized health planning (PHP)
40986806|NCT05938933|BEHAVIORAL|SMA|shared medical appointments (SMAs)
40986807|NCT02736045|DEVICE|emWave|Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
40986808|NCT01382017|DRUG|Lacosamide|Lacosamide 200 or 400 mg
40986809|NCT01382017|DRUG|Placebo|Placebo
40986810|NCT01382017|DRUG|Carbamazepine|Carbamazepine 600 mg
41464292|NCT05598034|DEVICE|Left DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.
40782281|NCT05836636|OTHER|Torque teno virus DNA measurement|Torque teno virus DNA level will be obtained from all study subjects upon recruitment, when subjects are admitted and when subjects undergo kidney allograft biopsies.
41464293|NCT05598034|DEVICE|Right DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.
41464294|NCT05598034|BEHAVIORAL|Cognitive task|Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS
41464295|NCT01324856|PROCEDURE|Pancreatico gastro anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
41464296|NCT01324856|PROCEDURE|Pancreaticojejuno anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
40986811|NCT02211001|OTHER|Pilates Group|The exercises were applied once a week during eight weeks.
40986812|NCT02211001|OTHER|Segmented Dynamic Exercises Group|The exercises were applied once a week during eight weeks. once a week for eight weeks.
40986813|NCT02211001|OTHER|Global Postural Reeducation|The exercises were applied once a week during eight weeks.
40986814|NCT03315208|BEHAVIORAL|Unified Protocol (UP)|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based psychological intervention designed to be applied across anxiety, depressive, and other disorders in which emotion dysregulation is central. The UP targets shared temperamental vulnerabilities to emotional disorders through emotion-focused CBT strategies.
41464297|NCT00198354|DRUG|gemcitabine + cisplatine|gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
41464298|NCT00198354|DRUG|Paclitaxel + Carboplatine|paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
41305714|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
41305715|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
41464299|NCT03722862|DIETARY_SUPPLEMENT|Low fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 3 gram doses
41464300|NCT03722862|DIETARY_SUPPLEMENT|Placebo|Participants will receive the placebo/dextrose.
41464301|NCT03722862|DIETARY_SUPPLEMENT|High fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 6 gram doses
41464302|NCT02041858|OTHER|Altered Alarm Settings|An altered set of alarm parameter settings
41464303|NCT00003822|DRUG|apomine|
41464304|NCT03113435|OTHER|Oxygen consumption optimization|hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
41145017|NCT00529529|DRUG|Salmeterol 50 μg|Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
41145018|NCT00529529|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
41464305|NCT03203642|DRUG|Tesevatinib|Pharmaceutical form: Tablet; Route of administration: orally
41464306|NCT03203642|DRUG|Placebo|Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
41464307|NCT02413424|DIETARY_SUPPLEMENT|Sucralose|60 ml of 2mM sucralose
41464308|NCT02413424|OTHER|Water|60 ml of water
40986815|NCT03315208|OTHER|Treatment as Usual (TAU)|Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
40986816|NCT00530933|PROCEDURE|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
40986817|NCT00530933|PROCEDURE|Transcutaneous tibial nerve stimulation|30 minutes once weekly
40986818|NCT00530933|PROCEDURE|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
40986819|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
41464309|NCT02413424|DIETARY_SUPPLEMENT|glucose load|
41464310|NCT05681416|DIAGNOSTIC_TEST|Panel sequencing, whole exome sequencing, whole genome sequencing|Besides the mutation positive men (group 2), all will receive multigene panel analysis in a patient care setting and if negative, whole exome sequencing (WES), whole genome sequencing and transcriptome analyses. In PCA-affected men (group 3), additional mutational analysis will be performed on formalin-fixed paraffin embedded (FFPE) - and fresh frozen (FF) tumor tissue from biobanked radical prostatectomy specimens using FFPE panel analysis (like TruSightOncology 500) or WES if FF samples are available.
41464311|NCT03426540|DRUG|Conbercept|Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
41464312|NCT01544517|DRUG|Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)|amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
41464313|NCT00206180|DRUG|esomeprazole magnesium (oral medication)|
40986820|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
40986821|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
40986822|NCT01405963|DRUG|Placebo|Administered in a 1-hour intravenous infusion
40986823|NCT01405963|BIOLOGICAL|Tezepelumab|Administered in a 1-hour intravenous infusion
40986824|NCT04600674|PROCEDURE|Delayed cord clamping|DCC performed at 60 sec after birth
40986825|NCT04600674|PROCEDURE|Early cord clamping|ECC performed at 15 sec after birth
40986826|NCT02412566|DRUG|SMOFlipid|Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
40782282|NCT02383316|OTHER|Oral Glucose tolerance test|Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
40782283|NCT05233514|OTHER|Aerobic exercise in addition to Metformin treatment|The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.
40986827|NCT03178747|DIAGNOSTIC_TEST|Methylene blue|working solution methylene blue
40986828|NCT03178747|DIAGNOSTIC_TEST|Giemsa stain|working solution Giemsa stain (Wolbach's modification)
40986829|NCT04389567|DRUG|Famotidine|Use of oral Famotidine.
40986830|NCT04651088|DRUG|Potassium citrate|Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
40986831|NCT04651088|DRUG|Sodium bicarbonate|650mg tabs. Take 3 tabs twice daily.
40986832|NCT04651088|DIETARY_SUPPLEMENT|Litholyte|One packet is taken with 170ml of water. Two packets daily.
40986833|NCT04651088|DIETARY_SUPPLEMENT|Crystal Lite|The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
40986834|NCT04651088|DRUG|Potassium Bicarbonate|20 mEq tablets, one tablet twice daily
40986835|NCT01192282|PROCEDURE|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
40986836|NCT04368819|DRUG|Allopurinol 300 MG|Allopurinol 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
41145019|NCT00529529|DRUG|Placebo to salmeterol|Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
41145020|NCT02168855|DRUG|active nicotine gum|2 mg, standard over-the-counter nicotine replacement therapy gum
41464314|NCT00359671|DRUG|MK6592|MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
40986837|NCT04368819|DRUG|Placebo oral tablet|Placebo 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
40986838|NCT06313970|DRUG|QL1706|QL1706 5mg/kg，IV，D1, Q3W
40986839|NCT06313970|DRUG|Nab-paclitaxel|Nab-paclitaxel, 125mg/m2，IV，D1、8, Q3W
40986840|NCT06313970|DRUG|Gemcitabine|gemcitabine，1000mg/m2，IV，D1、8；Q3W.
40986841|NCT06313970|DRUG|Bevacizumab|bevacizumab, 7.5mg/kg，IV，D1；Q3W.
40986842|NCT05880810|DEVICE|Continuous Glucose Monitor Dexcom G6 PRO|Connected to a smart phone that transmits continuous glucose monitoring data in real time to Advanced Care at Home Command Center for monitoring.
40986843|NCT04983576|PROCEDURE|spinal fusion|patients undergoing spinal fusion
41464315|NCT00359671|DRUG|comparator: docetaxel|docetaxel, delivered as a standard IV infusion.
41464316|NCT05445570|DIAGNOSTIC_TEST|Non-Interventional|This is an observational, non interventional study
40782284|NCT02315092|DEVICE|Fluorescence Imaging|Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
40782285|NCT01900886|OTHER|Peginterferon alfa-2a|Treatment as usual clinical practice
40782286|NCT01900886|DRUG|Ribavirin|Treatment as usual clinical practice
40782287|NCT01027429|DRUG|procaine penicillin and gentamicin|procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
40782288|NCT01027429|DRUG|amoxicillin and gentamicin|oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
40782289|NCT01027429|DRUG|procaine penicillin, gentamicin, amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
40782290|NCT03925987|BEHAVIORAL|Exposure therapy|10 weekly sessions of group-based exposure therapy
40782291|NCT05361265|OTHER|fetal movement counting|pregnant women were trained about fetal movements and fetal movement counting was taught. Pregnant women were asked to perform ten fetal movements by counting once a day. In the application of the study, it was ensured that the pregnant women in the experimental group performed fetal movement counting for at least four to six weeks. In this context, pregnant women were called every week to monitor and to motivate them to continue the counting.
40782292|NCT01370876|DRUG|Oxaliplatin|Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
40782293|NCT04005300|DIETARY_SUPPLEMENT|standard enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d
40986844|NCT05035628|OTHER|Cardiopulmonary exercise training|"Participants will follow a 2-month exercise training program, thrice-weekly trainings. The training sessions will start with a 5-min warmup, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with respiratory exercises and cool down period (10 min). Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test.~A certified kinesiologist will supervise trainings. Heart rate, oxygen saturation and rating of perceived exertion (Borg Scale, 6-20) will be measured during training sessions."
40986845|NCT00084981|DRUG|decitabine|Given IV
40986846|NCT00084981|DRUG|valproic acid|Given PO
40986847|NCT00084981|OTHER|pharmacological study|Correlative studies
40986848|NCT00084981|OTHER|laboratory biomarker analysis|Correlative studies
41145021|NCT02168855|BEHAVIORAL|Standard behavioral therapy|Standard behavioral therapy for smoking cessation
41145022|NCT06332885|DEVICE|Zephyr Endobronchial Valve|Zephyr Valve provides an alternative technique to achieve bronchoscopic lung volume reduction (BLVR) using a minimally invasive approach. Zephyr Valve is a tiny unidirectional valve. During BLVR, multiple valves are placed to occlude a hyperinflated lobe of the lungs, allowing air to escape while blocking airflow into the treated lobe. This is intended to result in a reduction in lung volume and hyperinflation in the targeted area. Consequently, the remaining lobes can expand more fully, the overall lung works more efficiently, with resultant improvement in overall lung function in patients with hyperinflation associated with severe emphysema.
40986849|NCT05594914|DRUG|AK104|AK104 plus TC regimen(paclitaxel liposome , carboplatin), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 plus TC regimen is combined with radiotherapy for 2 cycles.
40986850|NCT04262843|DRUG|Cyclophosphamide|Given IV
40986851|NCT04262843|DRUG|Fludarabine|Given IV
41145023|NCT00553813|DRUG|TPI 287|Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.
41464317|NCT03710707|DRUG|DNL201|Oral repeating dose
41464318|NCT03710707|DRUG|Placebo|Oral repeating dose
41464319|NCT00220727|DRUG|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
41464320|NCT00354562|DRUG|ABT-751|200mg ABT-751 daily for 14 days every 21 days
41464321|NCT00354562|DRUG|Placebo|Placebo daily for 14 days every 21 days
40782294|NCT04005300|DIETARY_SUPPLEMENT|restricted enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
40986852|NCT04262843|DRUG|Fludarabine Phosphate|Given IV
40986853|NCT04262843|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|Growth factor therapy
40986854|NCT04262843|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
40986855|NCT04262843|PROCEDURE|Intensity-Modulated Radiation Therapy|Undergo TMLI
40986856|NCT04262843|DRUG|Mycophenolate Mofetil|Immunosuppressive therapy
41145024|NCT01233245|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
41145025|NCT02745509|OTHER|Extensive Intraoperative Peritoneal Lavage|Extensive Intraoperative Peritoneal Lavage
41145026|NCT03684499|OTHER|fluid supplementation|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.
41305716|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
41464322|NCT00354562|DRUG|Docetaxel|Standard Docetaxel every 21 days
41464323|NCT04015960|OTHER|no intervention|qualitative research and patient reported outcome measure (PROm) development
40782295|NCT00069641|BIOLOGICAL|Iduronate-2-sulfatase enzyme replacement therapy|Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
40782296|NCT00069641|BIOLOGICAL|iduronate-2-sulfatase enzyme replacement therapy|Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
41145027|NCT03684499|OTHER|breast feeding|The subjects will be divided into two equal groups Study group and control group by randomization . The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.(Bandyopadhyay et al, 2017)
41145028|NCT00490113|DRUG|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
41464324|NCT00673764|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
40782297|NCT00069641|BIOLOGICAL|Placebo|Patients will receive weekly infusions of placebo.
40782298|NCT01931917|BEHAVIORAL|Incredible Years Parents and Babies Program|4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
40782299|NCT01931917|BEHAVIORAL|Usual Care|4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
40986857|NCT04262843|DRUG|Tacrolimus|Immunosuppressive therapy
40986858|NCT00070187|BIOLOGICAL|aldesleukin|Given IV
40986859|NCT00070187|BIOLOGICAL|filgrastim|Given IV
40986860|NCT00070187|BIOLOGICAL|recombinant interferon gamma|Given IV
40986861|NCT00070187|DRUG|carmustine|Given IV
40986862|NCT00070187|DRUG|cyclosporine|Given IV
40986863|NCT00070187|DRUG|cytarabine|Given IV
40986864|NCT00070187|DRUG|etoposide|Given IV
40986865|NCT00070187|DRUG|melphalan|Given IV
40986866|NCT00070187|PROCEDURE|autologous bone marrow transplantation|
40986867|NCT00070187|PROCEDURE|bone marrow ablation with stem cell support|
41464325|NCT00673764|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
41464326|NCT05597839|DRUG|DF9001|Immunotherapy agent targeting NK cells.
41464327|NCT05597839|DRUG|pembrolizumab|Anti-PD-1 immunotherapy agent
41464328|NCT05597839|DRUG|KEYTRUDA®|Anti-PD-1 immunotherapy agent
41464329|NCT01571817|BIOLOGICAL|Isolated Human Pancreatic Islets|
40986868|NCT00070187|PROCEDURE|peripheral blood stem cell transplantation|
40986869|NCT05966324|DRUG|baxdrostat|Baxdrostat is an aldosterone synthase inhibitor
40986870|NCT03797209|DEVICE|EUS-guided fistulization AXIOS|By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.
40986871|NCT03667365|PROCEDURE|aortic valve replacement|aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
40986872|NCT03667365|OTHER|strict clinical surveillance|strict clinical surveillance strategy
40986873|NCT06365268|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns a period of three years maximum.
40986874|NCT02496832|DRUG|18F-Fluoroazomycin arabinoside|
41145029|NCT01779089|DRUG|Minocycline 100 mg po bid for 6 months|Minocycline 100 mg po bid or placebo for 6 months
41145030|NCT01779089|DRUG|placebo|
41145031|NCT04102605|DEVICE|Nunap Vision|Participants receive visual perceptual training using the Nunap Vision software
41145032|NCT04102605|DEVICE|Nunap Vision-C|Participants receive sham training using the Nunap Vision-C software
41145033|NCT03583034|PROCEDURE|Holmium laser enucleation of the prostate (HoLEP)|Surgery for benign prostatic hyperplasia
41464330|NCT03735706|RADIATION|Radiation dose reduction|The radiation dose is is different between groups
41464331|NCT03735706|OTHER|Contrast media volume reduction|Contrast media volume is different between groups
40986875|NCT05530174|OTHER|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
40986876|NCT01924312|BEHAVIORAL|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
40986877|NCT05847231|BEHAVIORAL|Perceived Stress, Mandala application|Mandala
40986878|NCT03724851|DRUG|TEW-7197|"Vactosertib will be administered orally without regard to meals for 5 days per week (5D/W) at the same time in the morning (QD), at the same time in the morning and evening (BID) approximately 12 hours apart.~Pembrolizumab will be administered as a dose of 200 mg using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible."
41464332|NCT03735706|RADIATION|Unenhanced slice|One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
41464333|NCT03735706|DIAGNOSTIC_TEST|Weight|A weighing scale is used to measure a patients body weight right before the scan.
41464334|NCT02537509|DRUG|Cholecalciferol|
40782300|NCT02828384|OTHER|low fodmap diet|dietary teaching
40986879|NCT03781128|DRUG|Lysergic Acid Diethylamide|100 µg, per os, 3 times within 3 weeks
41145034|NCT05675748|DRUG|Azvudine|Azvudine tablets are taken orally 5mg daily for a maximum of 14 days
41464335|NCT02537509|DRUG|Placebo of cholecalciferol|
41464336|NCT02695927|DEVICE|Computer rehabilitation glasses|
40782301|NCT02828384|DIETARY_SUPPLEMENT|Psyllium|7.1g of psyllium daily
40782302|NCT00002217|DRUG|Lamivudine/Zidovudine|
40782303|NCT00002217|DRUG|Abacavir sulfate|
40782304|NCT00002217|DRUG|Amprenavir|
40782305|NCT01999192|DRUG|Tregalizumab|humanized anti-CD4 mAb
40782306|NCT01999192|DRUG|Placebo|identical end formulation buffer
40782307|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic CGRP|Immunoassay kit for the evaluation of CGRP in blood
40782308|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic SP|Immunoassay kit for the evaluation of SP in blood
40782309|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic enkephalins|Immunoassay kit for the evaluation of enkephalins in blood
40782310|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic VIP|Immunoassay kit for the evaluation of VIP in blood
40782311|NCT05958914|DIAGNOSTIC_TEST|Dosage of CGRP in follicolar fluid|Immunoassay kit for the evaluation of CGRP in follicolar fluid
40782312|NCT05958914|DIAGNOSTIC_TEST|Dosage of SP in follicolar fluid|Immunoassay kit for the evaluation of SP in follicolar fluid
40782313|NCT05958914|DIAGNOSTIC_TEST|Dosage of enkephalins in follicolar fluid|Immunoassay kit for the evaluation of enkephalins in follicolar fluid
40782314|NCT05958914|DIAGNOSTIC_TEST|Dosage of VIP in follicolar fluid|Immunoassay kit for the evaluation of VIP in follicolar fluid
40782315|NCT04812327|DIAGNOSTIC_TEST|BD Veritor Plus System for Rapid Detection of SARS CoV-2|Nasal Sawb for the conduct of the Veritor Antigen Test
40782316|NCT04812327|DIAGNOSTIC_TEST|rt-PCR|Nasopharyngeal Swab for the conduct of a rt-PCR
40782317|NCT04812327|DIAGNOSTIC_TEST|viral culture|Nasopharyngeal Swab for the conduct of viral culture
40782318|NCT04065321|PROCEDURE|PET-CT examination|All patients in the control group will undergo PET-CT examination after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years.
40782319|NCT04065321|PROCEDURE|Peripheral blood detection|All patients in the trial group will be followed up after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years. Peripheral blood will be collected for detection of circulating tumor cells at each follow-up. If circulating tumor cells are abnormal (number of circulating tumor cells ≥ 2 or CD133 ≥ 1), PET-CT will be performed immediately.
40782320|NCT02366325|DRUG|EPO-018B|
40782321|NCT00057564|DRUG|A (Thalidomide + Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
40782322|NCT00057564|DRUG|B (Placebo + Dexamethasone)|Placebo + Dexamethasone 40mg
40782323|NCT05330871|BIOLOGICAL|1 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
41145035|NCT03060525|BEHAVIORAL|Deaf Weight Wise 2.0|"Deaf Weight Wise 2.0 is a group or individual intervention lead by trained, American Sign Language fluent Deaf counselors, who utilize an existing evidence-based curriculum that emphasizes healthy eating, exercise, and lifestyle components. It is a behavior change intervention that uses motivational interviewing techniques to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The Curriculum includes group exercise activities (Do It!), experiential learning activities (Try It! such as learning how to read a nutrition label or modify a recipe to make it healthier), and group activities related to food preparation or sampling healthy foods (Taste It!). Self-monitoring using daily food diaries and weekly weigh-ins is also a key component. The intervention also includes a 6-month follow up and maintenance phase."
41145036|NCT05771402|DRUG|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
41305717|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
41464337|NCT05147740|DRUG|B/F/TAF|50/200/25 mg fixed-dose combination administered orally once daily without regard to food.
41464338|NCT02889302|DRUG|KPS-0373|24 weeks
40782324|NCT05330871|BIOLOGICAL|2 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
41464339|NCT02889302|DRUG|Placebo|24 weeks
40782325|NCT05330871|BIOLOGICAL|3 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
40782326|NCT05330871|BIOLOGICAL|4 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
41464340|NCT04569461|DRUG|pembrolizumab|200 mg of Pembrolizumab (KEYTRUDA) will be given by IV every 3 weeks for 5 cycles, a total of 15 weeks of treatment.
41145037|NCT05771402|DRUG|NAs|Once/day, 1 capsule/time, oral
41145038|NCT05771402|DRUG|Peg-IFNα|Once/week, 180μg/time, subcutaneous injection
40782327|NCT05330871|BIOLOGICAL|5 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
40782328|NCT05330871|BIOLOGICAL|6 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
40782329|NCT05330871|BIOLOGICAL|7 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
40782330|NCT05330871|BIOLOGICAL|8 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
40782331|NCT05330871|BIOLOGICAL|9 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
40782332|NCT05330871|BIOLOGICAL|10 Intramuscular injection for booster groups|1 dose 0.5ml
40782333|NCT05330871|BIOLOGICAL|11 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
40782334|NCT05330871|BIOLOGICAL|12 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
40782335|NCT05330871|BIOLOGICAL|13 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
40782336|NCT05330871|BIOLOGICAL|14 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
40782337|NCT05330871|BIOLOGICAL|15 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
40986880|NCT03781128|DRUG|Placebo|placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
40986881|NCT03993431|DRUG|Bio-active cement|A cement used for crown cementation, specially recommended for pediatric esthetic crowns
40986882|NCT03993431|DRUG|Packable glass ionomer|Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
41145039|NCT04255823|OTHER|General practitioner and Patient receive informations related to PPI deprescribing.|"General practitioner will receive a sensibilization and an algorithm related to PPI deprescribing.~Their patients will receive any informations (patient information material on PPI deprescribing)"
40782338|NCT05330871|BIOLOGICAL|16 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
40782339|NCT05330871|BIOLOGICAL|17 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
40782340|NCT05330871|BIOLOGICAL|18 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
40782341|NCT05330871|BIOLOGICAL|19 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
40782342|NCT05330871|BIOLOGICAL|20 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
40782343|NCT05330871|BIOLOGICAL|21 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
40782344|NCT05330871|BIOLOGICAL|22 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
40782345|NCT05330871|BIOLOGICAL|23 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
40986883|NCT03529240|DEVICE|Kinesiology Taping|Kinesiology taping (KT) which was developed by Dr. Kenzo Kase, is a new application of elastic and adhesive taping. KT is applied by specialized physiotherapists and physicians. This type of taping is a very frequently used technique to accelerate recovery after musculoskeletal injuries. Also, this technique is usually used as an alternative to athletic taping to support fascias, muscles, and joints for many purpose such as positioning, inhibition, and fascilitation
40986884|NCT06317155|OTHER|Occupational therapy|Occupation Therapy, specifically interoception informed interventions which aim to improve sensory integration and emotional regulation. Additionally, occupational therapy models which focus on augmenting well-being and functionality, facilitating participation and engagement within communities, and promoting involvement in meaningful activity.
40986885|NCT05023187|BEHAVIORAL|SCOT|"A 8-week social and cognitive online training to improve both cognitive and social functioning, which includes 2 sessions (\~45 minutes each) of individual cognitive training through the BrainHQ© program 2020 (BrainHQ© Posit Science) and a psycho-educational group session for each week (24 sessions in total).~In the experimental intervention, all activities are focused on enhancing executive functions (working memory, processing speed, inhibitory control etc.) and social cognition abilities (identifying/recognizing facial expressions, styles attribution, drawing conclusions etc.)."
41145040|NCT04255823|OTHER|Only General practitioner receive informations related to PPI deprescribing.|"General practitioner will receive the sensibilization and an algorithm related to PPI deprescribing.~Their patients will not receive any informations."
41145041|NCT00253552|BIOLOGICAL|filgrastim|
41145042|NCT00253552|DRUG|busulfan|
41145043|NCT00253552|DRUG|cyclophosphamide|
41145044|NCT00253552|DRUG|cyclosporine|
41145045|NCT00253552|DRUG|etoposide|
40782346|NCT05330871|BIOLOGICAL|24 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
40782347|NCT01227057|BEHAVIORAL|Cognitive Rehabilitation and Exposure Therapy for Compulsive Hoarding|The intervention includes cognitive remediation for deficits in executive functioning and exposure therapy for discarding/acquiring.
40782348|NCT01227057|BEHAVIORAL|Case Management|Case management
40782349|NCT05713461|BEHAVIORAL|exercise training program|"Adapted Interval Training Intervention, three days a week, 10 weeks.~Warm-up 10': Joint mobility and cardiovascular activation~Main part:~Resistance training circuit for strengthening the main muscle groups.~Cool down Flexibility and CORE"
40782350|NCT05713461|BEHAVIORAL|Feeding training|Two workshops on healthy eating habits (Week 1 and week 5). Food Frequency Questionnaires (weekly). Feedback weekly. Mediterranean Diet Adherence Screener (MEDAS). The dietary intervention will be based on the nutritional recommendations based on the Mediterranean diet, according to the evidence from the PREDIMED trial.
41145046|NCT00253552|DRUG|methotrexate|
41145047|NCT00253552|PROCEDURE|allogeneic bone marrow transplantation|
40782351|NCT00202696|DRUG|nalmefene|Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
41145048|NCT00253552|RADIATION|radiation therapy|
41145049|NCT04114279|PROCEDURE|Performance of laparoscopic duodenal atresia repair|completion of laparoscopic duodenal atresia repair in a surgical simulator
41145050|NCT03068741|DRUG|Comparison 1: Prehospital Ceftriaxone|Paramedics will administer 1g of intramuscular ceftriaxone.
41145051|NCT03068741|DRUG|Comparison 1: Placebo|Paramedics will administer an identical volume of reconstituted intramuscular placebo.
41145052|NCT03068741|DRUG|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
41145053|NCT03068741|DRUG|Comparison 2: Conservative fluids|Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is \<90mmHg and continued until systolic blood pressure is \>=100mmHg.
41145054|NCT00742560|BIOLOGICAL|elotuzumab|Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
40782352|NCT00202696|OTHER|Placebo|Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
40782353|NCT05352802|BEHAVIORAL|Multimodal prehabilitation program|Multimodal prehabilitation programs have adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.
40782354|NCT05352802|BEHAVIORAL|ERAS protocol|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
40782355|NCT03347630|DIAGNOSTIC_TEST|MRI|Thoraco-abominal MRI
40782356|NCT02078869|DRUG|Progesterone in oil|Daily administration of 50 mg of IM Progesterone
40782357|NCT02078869|DRUG|vaginal progesterone suppositories|Vaginal Promterium 200 mg , 3 times a day
40986886|NCT05023187|BEHAVIORAL|CON|"A 8-week active control intervention consisting of 2 sessions (\~45 minutes each) of cognitive stimulation exercises and a group session for each week (24 sessions in total) during which the various cognitive domains are deepened and the exercises carried out during the week are reviewed all together.~The online control intervention has been specifically designed to increase the cognitive involvement of the subjects and to replicate the condition of exposure to social dynamics."
40986887|NCT01111149|OTHER|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
40782358|NCT03944850|BEHAVIORAL|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions. A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body. Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal. Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
41464341|NCT04569461|RADIATION|Stereotactic body radiation therapy|SBRT will begin on week 7 of the study. The radiation will be given every other day in 5 fractions of 6 Gy for a total of 30 Gy of radiation exposure.
40986888|NCT01111149|DRUG|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
40986889|NCT01111149|DRUG|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
40986890|NCT01065233|GENETIC|DNA extraction|DNA extraction of blood sample for DNAship analysis
40986891|NCT05838885|DRUG|YPEG-rhGH|YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks
40986892|NCT05838885|DRUG|YPEG-rhGH|YPEG-rhGH, 280μg/kg, s.c., once a week, for 52 weeks
40782359|NCT00565565|DRUG|BAY60-4552|Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
40986893|NCT05838885|DRUG|rhGH|rhGH, 245μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
40986894|NCT05838885|DRUG|rhGH|rhGH, 470μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
40986895|NCT01012687|DRUG|perindopril erbumine|8 mg tablet
40986896|NCT02658357|DRUG|Risperidone Implant|
41145055|NCT00742560|DRUG|lenalidomide|Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
40782360|NCT00087217|DRUG|tanespimycin|Given IV
40782361|NCT00087217|DRUG|paclitaxel|Given IV
40782362|NCT00087217|OTHER|laboratory biomarker analysis|Correlative studies
40782363|NCT00087217|OTHER|pharmacological study|Correlative studies
40782364|NCT02092181|DRUG|Mirabegron|25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
40782365|NCT02092181|DRUG|Placebo|Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
40782366|NCT02170064|DRUG|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
40782367|NCT02869724|OTHER|Weekly divided delivery|
40782368|NCT02869724|OTHER|Monthly divided delivery|
40782369|NCT03997864|DRUG|Prazosin|"Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks."
40782370|NCT03997864|DRUG|Placebos|Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
40782371|NCT04330976|BEHAVIORAL|Nutrition and physical activity intervention|Messages sent on nutrition and physical activity in pregnancy
40782372|NCT04330976|BEHAVIORAL|Control|Messages sent on general health during pregnancy
40986897|NCT00775970|BEHAVIORAL|walking activity|
40986898|NCT03305198|BIOLOGICAL|Capillary blood sampling from the earlobe|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
41145056|NCT00742560|DRUG|dexamethasone oral|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
41145057|NCT00742560|DRUG|dexamethasone injection|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
40986899|NCT00509782|DRUG|ZIO-101|Starting Dose 78 mg/m\^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
40986900|NCT05237583|BEHAVIORAL|Prehabilitation|All participants will be offered a multimodal prehabilitation program. This program will include an individualized and supervised aerobic and resistance exercise training program, nutritional optimization, and psychological support. The program will last 6 months or until liver transplantation, whichever comes first.
40986901|NCT01558388|DRUG|Lactobacillus acidophilus|Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
40986902|NCT01558388|DRUG|Placebo|One vaginal tablet daily for 10 days.
40986903|NCT01227772|BIOLOGICAL|OTSGC-A24|OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
41145058|NCT01237600|PROCEDURE|Cultivated limbal transplantation|Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
41145059|NCT01182272|DRUG|sorafenib tosylate|
41145060|NCT01182272|OTHER|laboratory biomarker analysis|
41145061|NCT01182272|PROCEDURE|neoadjuvant therapy|
41145062|NCT01182272|PROCEDURE|therapeutic conventional surgery|
41145063|NCT03100851|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|a bottle of 100 mililiter probiotic dairy beverage containing 10\^8 CFU Lactobacillus casei strain Shirota every day after lunch.
41145064|NCT01383590|BIOLOGICAL|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart.
41145065|NCT05711433|PROCEDURE|pancreatic surgery|pancreaticoduodenectomy and distal pancreatectomy
41305718|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
41305719|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
41464342|NCT04569461|DRUG|Short-term androgen deprivation therapy|Short-term ADT will last for five months. It will consist of treatment with a 1 month dose beginning on Day 0 of the study. Then it will continue with either a single 4 month dose on week 5, or 4 additional 1 month doses, depending on patient and physician preference.
41464343|NCT04569461|PROCEDURE|Radical Prostatectomy|Radical prostatectomy surgery will be performed between week 17 and week 20 of the study, as scheduling permits.
41464344|NCT01247844|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
40782373|NCT00008086|DIETARY_SUPPLEMENT|calcitriol|
40782374|NCT00008086|DRUG|carboplatin|
40782375|NCT02243358|DRUG|Folfox6|
40782376|NCT02243358|DRUG|Gemcitabine|
40782377|NCT02243358|RADIATION|Radiation Therapy|
40782378|NCT02243358|PROCEDURE|Pancreaticoduodenectomy with retroperitoneal lymphadenectomy|
41464345|NCT04888533|OTHER|EHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment Tool|EHSSA will be used to evaluate every patient for suicide risk.
40782379|NCT02239926|DRUG|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
40782380|NCT02239926|DRUG|Placebo|
40782381|NCT00560300|DRUG|1 alpha D2|Vitamin D sterol
40782382|NCT00560300|DRUG|1,25 dihydroxy vitamin D3|Active vitamin D sterol
40782383|NCT00560300|DRUG|Sevelamer HCl|Phosphate binder
40782384|NCT00560300|DRUG|Calcium Carbonate|Phosphate binder
40782385|NCT01870869|DEVICE|Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection|Surgical implant
40782386|NCT01529229|DRUG|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
40782387|NCT01529229|DRUG|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
40782388|NCT05781581|OTHER|no intervention|no intervention
40782389|NCT02485015|BIOLOGICAL|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
41305720|NCT04514237|DRUG|BOS172767 enantiomer E1 or E2|Oral tablets
41305721|NCT04514237|DRUG|Placebo|Oral tablets
41305722|NCT02949115|DIETARY_SUPPLEMENT|70 mL red beetroot juice|1x daily intake of 70 mL red beetroot juice
41305723|NCT02949115|DIETARY_SUPPLEMENT|70 mL red beetroot juice without nitrate|1x daily intake of 70 mL red beetroot juice without nitrate
41305724|NCT02949115|DIETARY_SUPPLEMENT|70 mL placebo drink plus potassium nitrate|1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
41305725|NCT02949115|DIETARY_SUPPLEMENT|70 mL placebo drink|1x daily intake of 70 mL placebo control drink
41305726|NCT03910933|OTHER|elearning patient information|The videos will standardize patient teaching about anticoagulants, warfarin, INR testing, and warfarin safety for Patient Self-Testing, and Patient Self-Management. eKITE, will provide a user-friendly interface to provide health education about anticoagulation. eKITE will teach concepts to the patient, facilitate sustained patient knowledge (6 month evaluation), reduce stress associated with learning, actively engage patients in their anticoagulant management (preference, satisfaction and knowledge).
41305727|NCT03022305|BEHAVIORAL|Group one - standard therapy|Group two - standard physical therapy treatment for shoulder and hip maladjustment.
41305728|NCT03022305|BEHAVIORAL|Group two - neuromuscular therapy|Use of physical therapy treatment for shoulder and hip maladjustment.
41305729|NCT00580177|PROCEDURE|Lichtenstein mesh|The different techniques are compared and evaluated according to primary and secondary objectives.
41305730|NCT00580177|PROCEDURE|PerFix Plug®|The different techniques are compared and evaluated according to primary and secondary objectives.
41305731|NCT00580177|PROCEDURE|Prolene® Hernia System|The different techniques are compared and evaluated according to primary and secondary objectives.
41305732|NCT02020031|DRUG|Vancomycin|
41305733|NCT03225781|DEVICE|Electrochemotherapy with Bleomycin|Application of Reversible Electroporation (Electrochemotherapy) with Bleomycin
41305734|NCT02858609|OTHER|Nasopharyngeal Swab|
40782390|NCT02485015|DRUG|Apatinib|Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
41305735|NCT06316622|DEVICE|ultrasound|measured by ultrasound
41464346|NCT01142661|DRUG|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m\^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
41464347|NCT04651920|GENETIC|Evaluation of homologous recombination deficiency score|Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
40782391|NCT02814058|DRUG|zolpidem hemitartarate 1.75 mg - Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
40782392|NCT02814058|DRUG|zolpidem hemitartarate 1.75 mg - Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
40782393|NCT04101097|OTHER||
40782394|NCT03789292|BIOLOGICAL|CT-P17 SC|Subcutaneous injection of Adalimumab 40mg every two weeks
40782395|NCT03789292|BIOLOGICAL|Humira SC|Subcutaneous injection of Adalimumab 40mg every two weeks
40782396|NCT04271800|BIOLOGICAL|CD19 CAR-T cells|A single infusion of CD19-CAR-T cells will be administered intravenously.
40782397|NCT04381247|DIAGNOSTIC_TEST|Molecular diagnostics in HAP and VAP|Airway samples will be analyzed both by standard and molecular based microbiological analysis.
40986904|NCT04317456|DEVICE|Hearing Aids and Hearing Implants|Hearing Aids and Hearing Implants (age at first fitting and implantation and aided audibility)
41145066|NCT04243772|OTHER|Data extraction|Data extraction from medical files
40782398|NCT05215002|OTHER|Telephone Call|Patient will be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
40782399|NCT05215002|OTHER|No telephone call|Patient will not be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
40782400|NCT03406403|DEVICE|Laryngeal mask airway|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
40782401|NCT03406403|DRUG|Magensium sulphate|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
40986905|NCT04317456|BEHAVIORAL|Family Centred Early Intervention|Family Centred Early Intervention
41145067|NCT04184349|DRUG|LA group|In the LA group, only the local anesthetic infiltration will be performed by injecting the numbing medicine ropivacaine into the surgical site.
41145068|NCT04184349|DRUG|B Group|In the B Group,pectoral (PECS) and transversus thoracic plane(TTP) blocks will be performed by injecting the numbing medicine ropivacaine near the nerves.
41145069|NCT03717558|DRUG|ivermectin T1|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
41145070|NCT03717558|DRUG|ivermectin T2|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
41145071|NCT03717558|DRUG|ivermectin T3|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
41145072|NCT03243838|DRUG|Apatinib|All enrolled patients were administered oral apatinib at a dose of 250 mg once daily and intravenously docetaxel (100 mg/m2) every three weeks for four cycles, followed by epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2) every three weeks for four cycles. All the treatments were continued until disease progression, patient withdrawal, or unacceptable toxic effects.
41145073|NCT01641848|DEVICE|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
41145074|NCT02256826|DRUG|BILR 355 BS|
41305736|NCT00968253|DRUG|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
40782402|NCT03406403|OTHER|Control group (closure of anesthetics)|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
40782403|NCT00678704|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 10 mg tablet prior to intercourse on demand
40782404|NCT00678704|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 20 mg tablet prior to intercourse on demand
41305737|NCT00968253|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
41464348|NCT02001155|PROCEDURE|Water Drinking Test|The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
40782405|NCT00678704|DRUG|Placebo|Placebo tablet prior to intercourse on demand
40782406|NCT06547762|OTHER|Hybrid approach (in-person and remote) to pediatric rehabilitation: A look beyond the COVID-19 crisis|Hybrid rehabilitation. Out patients will receive one day a week of remote therapy and the remaining (1-4 days) in person at rehabilitation hospital
40986906|NCT03773887|OTHER|collection of liver biopsies collection of blood samples|blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies
40986907|NCT06496139|BEHAVIORAL|Therapist-guided internet-delivered cognitive behavioural therapy|The intervention consists of 8 weeks of therapist-guided self-help ICBT.
40986908|NCT01977170|BIOLOGICAL|Hib/PRP-T vaccine|Hib liquid vaccine
41305738|NCT00968253|DRUG|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
41305739|NCT00968253|DRUG|Doxorubicin|50 mg/m\^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
41305740|NCT00968253|DRUG|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
41305741|NCT00968253|DRUG|Mesna|600 mg/m\^2 IV continuous infusion daily for 24 hours days 1-3.
41305742|NCT00968253|DRUG|Methotrexate|200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 IV over 22 hours day 1.
41305743|NCT00968253|DRUG|Ara-C (Cytarabine)|3 gm/m\^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
41305744|NCT00968253|DRUG|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
41305745|NCT00968253|DRUG|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
41305746|NCT05126368|OTHER|Cataract surgery|During cataract surgery the Eyhance toric II intraocular lens will be implanted in one eye of the patient
40986909|NCT02699554|PROCEDURE|Single-event multilevel surgery|
40986910|NCT06388863|DRUG|Healthy donor-derived FMT capsule|Participants will be treated with healthy donor-derived fecal microbiota transplantation in the form of oral capsules.
40986911|NCT06388863|DRUG|Placebo capsule|Capsules whose appearance and smell are identical as FMT capsules but contain milk powder
40986912|NCT05718895|DRUG|ATG-022|"Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design."
40986913|NCT04890366|DRUG|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
40986914|NCT05502900|DRUG|Melatonin|White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
40986915|NCT05016557|DIETARY_SUPPLEMENT|Protein ingestion|Bolus ingestion of 25g protein
40986916|NCT03211949|PROCEDURE|axillary block|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
40986917|NCT03211949|DRUG|Scandicaine|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
40986918|NCT01826487|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
40986919|NCT01826487|DRUG|Placebo|Placebo will be administered as per the schedule specified in the arm.
40986920|NCT00537381|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.
40986921|NCT00537381|DRUG|Prednisone|Prednisone 5 mg orally twice daily.
40986922|NCT00537381|BIOLOGICAL|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
41145075|NCT02256826|DRUG|Ritonavir (RTV)|NORVIR®
41145076|NCT02256826|DRUG|Kaletra®|(lopinavir (LPV) and ritonavir (RTV))
41145077|NCT05305300|BIOLOGICAL|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A|receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.
41305747|NCT00736710|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
41305748|NCT00736710|PROCEDURE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
41305749|NCT03661827|DIAGNOSTIC_TEST|Stress Cardiac MRI|Dobutamine and adenosine stress MRI
40782407|NCT05909137|RADIATION|IMRT+adjuvant immunotherapy|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT and the control group with CTV-delineated IMRT using a random number table.
40986923|NCT00537381|DRUG|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
40986924|NCT01649531|PROCEDURE|1 Implant|
41145078|NCT05305300|BIOLOGICAL|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B|receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
41145079|NCT00895076|DRUG|dexamethasone|iontophoretic patch and injection
41145080|NCT05272202|DRUG|Propofol|STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).
40782408|NCT02267434|BIOLOGICAL|Low dose AFFITOPE® PD03A + Adjuvant|s.c. injection
40782409|NCT02267434|BIOLOGICAL|High dose AFFITOPE® PD03A + Adjuvant|s.c. injection
40782410|NCT02267434|BIOLOGICAL|Adjuvant without active component|s.c. injection
40986925|NCT01649531|PROCEDURE|2 Implants|
40986926|NCT04275791|OTHER|Triage|Experimental : Trauma patient orientation in a structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
40986927|NCT02258230|DEVICE|3D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
40986928|NCT02258230|DEVICE|2D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
40986929|NCT01410045|PROCEDURE|Ovariectomy|Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
40986930|NCT06398054|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg tablet
40986931|NCT06398054|DRUG|Hyoscine N-Butil Bromide|Hyoscine N-Butil Bromide 10 mg two tablets
40986932|NCT06398054|DRUG|placebo|Two tablets
40986933|NCT01002469|OTHER|sodium [1-13C] acetate|
40782411|NCT01979614|DRUG|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
40782412|NCT01979614|OTHER|Placebo|5% v/v glucose solution
40782413|NCT02261961|BIOLOGICAL|TDAP|Both arms will receive the tetanus, diptheria, and pertussis vaccination after two weeks of treatment with supplement or placebo
40782414|NCT02261961|OTHER|Acute Resistance Exercise|Both arms will receive a single bout of resistance exercise twice, before and after two weeks of treatment with supplement or placebo, and be evaluated for the response within blood and muscle
40782415|NCT02261961|OTHER|Resistance Exercise Training|Both arms will receive 36 sessions of progressive high-intensity resistance exercise training (thigh muscle) over the course of approximately 12 weeks.
40782416|NCT02261961|OTHER|Post-training Follow-up|Both arms will continue to receive treatment with supplement or placebo for approximately 26 weeks after completion of the exercise training. During this time subjects will not be allowed to perform resistance exercise.
40782417|NCT02261961|DIETARY_SUPPLEMENT|Nutritional Supplement (Muscle Armor)|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
40782418|NCT02261961|DIETARY_SUPPLEMENT|Placebo (Kool-Aid)|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
40782419|NCT06094504|OTHER|Spectral Lighting|Spectral room lighting containing violet and blue wavelengths of light capable of stimulating non-visual opsins including OPN5 and OPN3.
40782420|NCT05379699|OTHER|TOR-BSST© eLearning Training|An online self-directed training program for TOR-BSST© dysphagia screeners.
40782421|NCT05379699|OTHER|Standard TOR-BSST© Training|Standard 4-hour in-person TOR-BSST© screener training conducted by a Speech-Language Pathologist.
40782422|NCT00959426|DRUG|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
40782423|NCT00959426|DRUG|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
40782424|NCT00530881|DRUG|PHX1149|
40782425|NCT02964377|DRUG|(+)- Epicatechin|
40782426|NCT00564109|PROCEDURE|retrospective Observation|retrospective Observation
40782427|NCT01527630|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
40986934|NCT01865539|DEVICE|Custom Foot Orthotic|Custom foot orthotic with custom design pads
40986935|NCT01865539|DEVICE|Sham Orthotic|Leather insert without the custom design pads
40986936|NCT02709161|BEHAVIORAL|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
40986937|NCT02709161|BEHAVIORAL|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
40986938|NCT04518514|DEVICE|TAPE-Software|Telemedical Risk Assessment and Preoperative Evaluation prior to anaesthesia via personal computer
40986939|NCT06427811|DRUG|Asciminib|Film-coated tablets with 40 mg dose strength taken orally
40986940|NCT06427018|OTHER|No intervention.|Observational study with no intervention.
40986941|NCT00130416|BEHAVIORAL|E-mail coaching to improve patient communication with doctor|
40986942|NCT03434847|OTHER|Education|Participants who receive perioperative educational to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes.
40986943|NCT01144442|DRUG|Hyperthermic intraperitoneal chemotherapy with Carboplatin|Carboplatin at a dose of 1000mg/m\^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
40986944|NCT01144442|OTHER|Isotonic saline (perfusate)|The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.
40986945|NCT01144442|PROCEDURE|Surgery|"The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.~If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach."
40986946|NCT01144442|DRUG|Carboplatin|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
40986947|NCT01144442|DRUG|Paclitaxel|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
40986948|NCT00304564|BEHAVIORAL|Music Listening|subjects listen to music
40986949|NCT00123591|DRUG|activated recombinant human factor VII|
40986950|NCT02221284|DRUG|Alogliptin|Alogliptin tablets
40986951|NCT01693575|DEVICE|Pupil expansion with APX 100 device|Patients with small pupils (\<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
40986952|NCT03370354|BEHAVIORAL|Observational|Ask patients about sleep quality and identify reasons of troubled sleeping patterns in the units.
41145081|NCT05272202|DEVICE|Median nerve stimulation|The right-hand median nerve will be stimulated in the same way as for measurement with a conduction velocity or for an evoked potential. Two stimulation electrodes will be placed on the right-hand wrist according to the standards.The stimulation is transcutaneous and painless using the specific Micromed device Sd Ltm Stim Energy (Micromed, Mˆacon, France). The stimulus intensity will range between 3 and 14 mA. The stimulation duration will be 100 ms with a frequency of 0.1 Hz.
41145082|NCT05272202|DEVICE|EEG measurements|Changes in ERD and ERS patterns during median nerve stimulation according to the various propofol concentrations will be continuously monitored by an EEG amplifier. EEG signals will be acquired using the OpenViBE platform with a Biosemi Active Two 64-channel EEG system, arranged in the Biosemi's ABC system covering the entire scalp at 2048 Hz. Among all recorded sites, some of the electrodes will be localized around the primary motor cortex, the motor cortex, the somatosensory cortex, and the occipital cortex.
41464349|NCT01557062|OTHER|Polysomnography|The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
40986953|NCT02838680|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
40986954|NCT06537154|PROCEDURE|Active Surveillance|Participant found to have a cCR will be randomized to either standard of care or investigational active surveillance.
40986955|NCT06537154|PROCEDURE|Control arm - Definitive bladder treatment|Standard of care, consisting of radical cystectomy or chemo-radiation of the bladder
40986956|NCT05943145|OTHER|Group Dance and Movement Training|Dance movement-based sessions including personalized tasks and imagery, mirroring, and inscription, plus warm-up and cool down practices to ensure physical safety
40986957|NCT00058604|BIOLOGICAL|Intravenous injection of EBV specific CTLs|Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
40986958|NCT00622479|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib will be administered at 400mg BID for a 28 day cycle.
40986959|NCT04777708|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given by intratumoral injection
40986960|NCT04777708|BIOLOGICAL|Pembrolizumab|Given IV
40986961|NCT04422054|PROCEDURE|Open Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent open surgical repair.
40986962|NCT04422054|PROCEDURE|Endovascular Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent endovascular repair.
40986963|NCT01518920|DRUG|PF-04958242|PF-04958242 0.35 mg oral solution
40986964|NCT01518920|DRUG|PF-04958242|PF-04958242 0.27 mg oral solution
40782428|NCT06345885|BIOLOGICAL|HPV vaccine|Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months
40782429|NCT05242289|DEVICE|CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
40782430|NCT00111072|DRUG|dexamethasone 0.01% solution|
40782431|NCT06250829|OTHER|Observational|Observational study of body composition, cytokine profile, immune status, ctDNA, serial radiology.
40782432|NCT02447185|DRUG|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
40782433|NCT02447185|DRUG|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
40782434|NCT04089410|DEVICE|Hyperthermic Fitness Treatment (HFT)|The Hyperthermic Fitness Treatment uses Alfa Basic capsule, an ergonomic camera in which a participant may take a lying position and undergo hyperthermia procedures (infrared heating with intracapsule temperature increase up to 80 degrees C◦), the head being outside the camera blown by cool air with a built-in ventilator. HFT is comparable to dry sauna bathing. Core body temperatures will be raised to 37.5-38.5°C◦. Recommended duration of one HFT session is 40 min. All the HFT group participants while undergoing sessions in the Cocoon will be dressed in bathing suits.
40782435|NCT04089410|DEVICE|Placebo Hyperthermic Fitness Treatment|Attenuated heating with less heat set (20-30 degrees C◦). This results in no increase of core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual HFT, and will be in the capsule for the same period of time.
40782436|NCT04089410|OTHER|Physical Examination|"Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand."
40782437|NCT04089410|OTHER|Assessment of Cardiorespiratory Fitness|An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.
40782438|NCT04089410|OTHER|Autonomic Balance, Orthostatic and Hypoxic tolerance|"1. Evaluation of Autonomic balance is assesed using Heart Rate Variability (HRV) analysis. The HRV test relies on a 5-min RR interval (time in milliseconds between two R waves of the electrocardiogram complex) recorded at rest for 5 min supine (SU) followed of 5 min resting time. Measurement of the interval duration between two R waves of the cardiac electrical activity are performed with a HR monitor.~2. Orthostatic tolerance is assessed after ANS balance assessment by HRV analysis to continue RR intervals registration for 3 min after participant was asked to stand up taking a vertical position near the couch.~3. The individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (HT) - breathing through a facial mask by a gas mixture with 11% of O2, with minute-by-minute monitoring of HR and hemoglobin saturation by oxygen (SaO2). Arterial blood pressure is recorded before and after HT."
40782439|NCT04089410|OTHER|Psychological Testing|"1. Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36), which is a self-completed quantity of health-related QoL.~2. Participants are asked to complete the Pittsburgh Sleep Quality Index (PSQI), a retrospective self-report measure assessing their quality of sleep during the last three weeks preceding the study.~3. Anxiety level is estimated by using State and Trait Anxiety Scales (SA and TA) developed by Ch. Spielberger~4. Subjective Ratings of Thermosensation and Pain.Participants rate their comfort, thermosensation, and pain by fixing results in visual-analogous scale (VAS) while passing each of HFT treatment."
40782440|NCT04089410|OTHER|Measurement of Blood Markers|Periferal venous blood (10 ml) sumples of the fastest (overnight fast) study subjects are withdrawn by a qualified laboratory technician via aseptic technique from the antecubital vein in the sitting position, using sterile needles and are collected. Serum BDNF, HGH, HSPs (60, 70, 90) concentrations are determined.
41464350|NCT01557062|OTHER|Teperature measure|Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
40782441|NCT03567694|DRUG|HA115|Test Drug
40782442|NCT03567694|DRUG|Placebo|Placebo
40986965|NCT01518920|DRUG|Placebo|Placebo oral solution
40986966|NCT00121420|DRUG|Motexafin gadolinium|
41145083|NCT00584909|DRUG|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
41145084|NCT03455751|GENETIC|PGx-guided post-operative pain management|Post-operative pain management as indicated by pharmacogenomic testing results.
41464351|NCT01557062|OTHER|Fibromyalgia Impact questionary|The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
41464352|NCT04066257|DRUG|Tegoprazan|Tegoprazan 50 mg tablet
41464353|NCT04066257|DRUG|Metronidazole|Metronidazole 250 mg tablet
40782443|NCT00781547|DRUG|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
40782444|NCT03070093|DRUG|gilteritinib|oral
40782445|NCT02972710|OTHER|Supine thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
40782446|NCT02972710|OTHER|Seated thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
40782447|NCT01143220|OTHER|No specific interventions|Observational investigation, only procedures according to local hospital standard.
40986967|NCT05298280|DEVICE|Pendulum appliance|In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires. The 0.032-inch TMA wires were activated 45 degrees to produce a force of 200-250g per side. On average, intraoral reactivation of the distalizing springs was performed twice during the procedure. When a super Class I molar relationship was obtained, pendulum was replaced by a Nance holding arch. The average treatment duration was 8 months followed by bracket conventional therapy.
40986968|NCT05298280|DEVICE|clear aligners|The standardized orthodontic intervention was represented by the maxillary molar distalization protocol proposed by Align Technology: it was planned in order to obtain a sequential distalization on the upper arch, and the staging was set at 0.25 mm per aligner. During sequential distalization aligners are set up to distalize one tooth at a time. The attachments were engineered by Align Technology to achieve predictable tooth movements. Each couple of aligners was worn for 7 days.
41464354|NCT04066257|DRUG|Tetracycline|Tetracycline hydrochloride 250 mg capsule
40782448|NCT01385150|GENETIC|mutation analysis|
40782449|NCT01385150|GENETIC|protein analysis|
40782450|NCT01385150|OTHER|laboratory biomarker analysis|
40782451|NCT01385150|OTHER|liquid chromatography|
40782452|NCT01385150|OTHER|mass spectrometry|
40782453|NCT01783444|DRUG|Capecitabine|Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
40782454|NCT01783444|DRUG|Exemestane|Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
40782455|NCT01783444|DRUG|Everolimus|Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
40782456|NCT04335968|DRUG|Melatonin 4 mg|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery.
40782457|NCT04335968|DRUG|Placebo oral tablet|placebo of this drug with the same schedule, during the same period of time.
40986969|NCT04263207|OTHER|No intervention|No intervention
41464355|NCT04066257|DRUG|Bismuth|Tripotassium bismuth dicitrate 300 mg tablet
41464356|NCT04174573|OTHER|GTO|"1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)"
41145085|NCT02791685|BEHAVIORAL|MULTIFIT Cardiac Rehabilitation|MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
41145086|NCT02791685|BEHAVIORAL|Movn Pulmonary Rehabilitation|Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
41145087|NCT02791685|BEHAVIORAL|Standard of Care Cardiac Rehabilitation|Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
41145088|NCT05187520|DEVICE|Patient-controlled epidural analgesia (PCEA)|Epidural analgesia is a technique of neuraxial block by placement of a 20G polyether epidural catheter into the epidural lumen and fixed at the desired depth, and analgesic effect is usually achieved by administration of mixture of local anesthetics and opioids using a programmed pump.
41145089|NCT05187520|DRUG|Naldebain®|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
41145090|NCT02107235|DRUG|oral rigosertib|
41145091|NCT02107235|DRUG|cisplatin|
41145092|NCT02107235|RADIATION|Radiotherapy|
40782458|NCT00374647|DRUG|mycophenolate mofetil|
40782459|NCT00374647|DRUG|sirolimus|
40782460|NCT04591119|PROCEDURE|Transversus Thoracic Muscle Plane Block|40 ml %0.375 bupivacaine divided into 4 equal doses will be injected by the surgeon between internal intercostal muscle and transversus thoracis muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space
40782461|NCT04591119|PROCEDURE|Parasternal Intercostal Plane Block|40 ml %0.375 bupivacaine injection will be performed by ultrasound guidance after completion of surgery between pectoralis major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally by anesthesiologist.
40782462|NCT01106989|DRUG|Heated lidocaine/tetracaine patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
40782463|NCT01306695|BEHAVIORAL|New York University Caregiver Intervention (NYUCI)|"The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
40782464|NCT01306695|OTHER|Community Health Worker (CHW) Case Management|The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
40782465|NCT00050804|DRUG|sertraline|
40782466|NCT06488924|DRUG|JR-446|IV infusion
40782467|NCT02018120|PROCEDURE|connective tissue graft|
40782468|NCT02018120|PROCEDURE|platelet rich fibrin|
40782469|NCT00976456|DRUG|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
40782470|NCT00976456|DRUG|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
40782471|NCT04617080|PROCEDURE|SUPRACOR Regular|SUPRACOR algorithm with regular (100%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
40782472|NCT04617080|PROCEDURE|SUPRACOR Strong|SUPRACOR algorithm with strong (130%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
40782473|NCT05971095|DEVICE|Percutaneous neuromodulation using the EPTE® Bipolar System device|"The two stimulation protocols will be applied consecutively. Firstly, the high-frequency protocol (HFS) will be applied in order to produce potentiation of the non-nociceptive pathway, using the pulsed square waveform and 5 bursts of stimulation lasting 5 seconds at a frequency of 100 Hz separated by 55 s interval between bursts. Adjustments to amplitude and pulse width are made until the patient experiences paresthesias at a perceptible but not painful intensity, and the intensity will be set 200 μA above the detection threshold for each subject.~In order to depress the nociceptive pathway, the low-frequency protocol (LFS) with stimulation at 2 Hz for 16 min with an intensity of 1000μA will subsequently be switched to. To ensure the recruitment of higher threshold type C nociceptive fibers, the intensity level will be programmed at the pain threshold for each subject."
40782474|NCT00284635|PROCEDURE|Fast track vs conventional|
40782475|NCT01740869|OTHER|Stem cells|
40782476|NCT01781338|OTHER|Induction therapy|The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
40782477|NCT06280248|PROCEDURE|Endoscopic ultrasound guided cystogastrostomy of symptomatic pancreatic pseudocyst|"The technical success rates, clinical success rates, and potential complications of the different endoscopic ultrasound-guided techniques for the best drainage of pancreatic fluid collections (PFCs) as regard type, caliber, and number of plastic stents and the ideal timing for stent removal will be assessed.~Also compare early vs. late intervention for complete endoscopic necrosectomy of walled off pancreatic necrosis (WOPN ) as regard to technical success rates, clinical success rates, potential complications, and the number of sessions needed will be done.~In order to evaluate total resolution or a reduction in cyst diameters with clinically significant improvement in symptoms, patients will be monitored for one month and six months following the insertion of the stent."
40782478|NCT01442987|DRUG|Irbesartan/Atorvastatin A|once daily, P.O. 8week
40782479|NCT01442987|DRUG|Irbesartan|once daily, P.O. 8week
40782480|NCT01442987|DRUG|Atorvastatin A|once daily, P.O. 8week
40782481|NCT01442987|DRUG|Placebo|once daily, P.O. 8week
40782482|NCT01442987|DRUG|Irbesartan/Atorvastatin B|once daily, P.O. 8week
40782483|NCT01442987|DRUG|Atorvastatin B|once daily, P.O. 8week
41145093|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
40782484|NCT06264609|DRUG|Alendronate|Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months.
40782485|NCT06264609|DRUG|Teriparatide|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months.
40782486|NCT06264609|DRUG|Alendronate|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continue on Alendronate for 12 months.
40782487|NCT01402960|DEVICE|High Definition Transcranial Direct Current Stimulation (HD-tDCS)|"Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~* For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~* For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~* For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)"
41145094|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
41145095|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
41145096|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
40782488|NCT02234765|OTHER|Primary Care-based management|Patients will be diagnosed and follow-up in Primary Care.
40782489|NCT02234765|OTHER|Standard management|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
40782490|NCT04102007|DRUG|Risankizumab|Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
40782491|NCT01406600|DRUG|recombinant hCG (Ovidrel®)|Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.
40782492|NCT06022094|OTHER|2 months of reduced carb menus|Participants will eat a reduced carb menu for 2 months
40782493|NCT00196209|PROCEDURE|catheter ablation|catheter ablation to treat persistent atrial fibrillation
40782494|NCT00196209|PROCEDURE|external electric cardioversion|external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
40782495|NCT03302767|OTHER|Psychological and Social Consultation|Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
40782496|NCT02989181|DEVICE|Continues Positive Airway Pressure (CPAP)|Mask with positive airway pressure during exhalation which maintains the airway open
40782497|NCT03855943|BEHAVIORAL|Personalized Computer Program|Training with a personalized computerized inhibitory training program
40782498|NCT03855943|BEHAVIORAL|CBT|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
40782499|NCT04067232|DIAGNOSTIC_TEST|4D-CT-scan|Both forearms of the subjects with posttraumatic forearm impairment are scanned with a 4D-CT scanning technique, during forearm rotation.
40782500|NCT01731561|DRUG|Rituximab (Arm B)|Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are \> to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
40782501|NCT01731561|DRUG|Rituximab (Arm A)|Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
40782502|NCT04278248|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine|1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.
40782503|NCT02878876|DIETARY_SUPPLEMENT|Oral consumption of milk with sequence A1-A2|Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
40782504|NCT02878876|DIETARY_SUPPLEMENT|Oral consumption of milk with sequence A2-A1|Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
40782505|NCT02189889|DRUG|EPO|The treatment group will receive up to three doses of EPO 300U/kg. The first dose of study medication will be administered up to 28 days before the day of surgery and the second will be administered 1-7 days before the day of surgery. These first two doses will be given at least 7 days apart. A third dose may be administered two days following surgery. All 3 doses will be administered per surveillance strategy guidelines.
40782506|NCT02189889|DRUG|Feraheme|Supplementation with Feraheme, 510mg delivered as an IV infusion, will be given following the first two preoperative doses of EPO.
40782507|NCT01631968|PROCEDURE|Cement without antibiotic.|
40782508|NCT01631968|PROCEDURE|Cement with erytromycin and colistin.|
40782509|NCT02710188|DRUG|HTL0009936 modified release|HTL0009936 modified release
40782510|NCT02710188|DRUG|HTL0009936 immediate release|HTL0009936 immediate release
40782511|NCT03545048|OTHER|Internet based exercises|Exercises for knee OA (online- digital health)
40782512|NCT03722979|PROCEDURE|Cardiac surgery|The study will enroll patients having a planned cardiac surgery under extracorporeal circulation (CEC)
41145097|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
40782513|NCT04284709|OTHER|cognitive-physical training|combined physical and cognitive training
40782514|NCT02655887|DEVICE|VENOVO™ Venous Stent|VENOVO™ Venous stent placement
40782515|NCT00960544|DRUG|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
40782516|NCT04366856|BEHAVIORAL|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
40782517|NCT04366856|BEHAVIORAL|2: No instruction regarding positioning|group with no instruction regarding positioning (control group)
40782518|NCT02363530|DEVICE|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
41145098|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
41145099|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
41145100|NCT01428622|DRUG|Olodaterol|aqueous solution
41145101|NCT01428622|DRUG|Olodaterol|aqueous solution
41145102|NCT01428622|DRUG|Olodaterol|aqueous solution
40986970|NCT05587205|BIOLOGICAL|EO2002|Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
40986971|NCT05587205|OTHER|Sham injection|Sham injection
40986972|NCT01172847|DRUG|oseltamivir [Tamiflu]|multiple oral doses
40986973|NCT01172847|DRUG|rimantadine|multiple oral doses
40986974|NCT01475331|DRUG|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
40986975|NCT01475331|DRUG|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
40986976|NCT01475331|DRUG|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
40986977|NCT00914355|RADIATION|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
40986978|NCT05089682|DEVICE|DBS Stimulation during sleep|Open and closed-loop electrical modulation triggered and based on ongoing sleep staging by researcher as well as automated closed-loop algorithm for stimulation.
40986979|NCT01351844|BEHAVIORAL|Education and exercise intervention|An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
40986980|NCT01351844|BEHAVIORAL|Education and General Exercise|A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
40986981|NCT01411709|DRUG|Vitano|two 200mg tablets per day for 14 days
40986982|NCT06301711|BEHAVIORAL|Rehabilitation therapy|"The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
41145103|NCT01428622|DRUG|Olodaterol|aqueous solution
41464357|NCT04174573|OTHER|GT-tDCS|"1. Group therapy~   1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. tDCS Left anodal and right cathodal tDCS : Anode- F3, Cathode- Right Supra orbital area, Intensity- 2mA, Duration- 30 minutes, once in a week for 6 weeks"
41464358|NCT06435832|DRUG|Absorbable Gelatin|After tooth extraction, only saline irrigation was applied and a absorbable gelatin sponge was placed in the socket.
41464359|NCT06435832|DRUG|Chlorhexidine|After tooth extraction, after irrigation with saline, 2% chlorhexidine gel was absorbed into gelatin sponges and placed into the socket.
40986983|NCT06301711|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41464360|NCT06435832|DRUG|Tranexamic acid|Tranexamic acid 50mg/ml for injection after saline irrigation after tooth extraction solution into gelatin sponges was applied to the socket after it was cured.
40782519|NCT02363530|DEVICE|BSS|Balanced Salt Solution including normal saline and glucose
40986984|NCT06301711|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41145104|NCT01428622|DRUG|Olodaterol|aqueous solution
41145105|NCT01428622|DRUG|Olodaterol|aqueous solution
41145106|NCT01428622|DRUG|Olodaterol|aqueous solution
41145107|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
41145108|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
40782520|NCT01060787|PROCEDURE|Fluocinolone Acetonide 0.59 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
40782521|NCT01060787|PROCEDURE|Fluocinolone Acetonide 2.1 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
40782522|NCT03346525|DRUG|intramuscular benzathine penicillin G (BPG) prophylaxis|Intramuscular BPG prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days.
41145109|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
41145110|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
41145111|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
41145112|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
41145113|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
41145114|NCT01428622|DRUG|BI54903|ethanolic solution
41145115|NCT01428622|DRUG|BI54903|ethanolic solution
40782523|NCT00414375|PROCEDURE|Operation on Admission|Laparoscopic appendectomy on admission
40782524|NCT00414375|PROCEDURE|Drainage and Interval Appendectomy|drainage with interval appendectomy
40782525|NCT05739266|BEHAVIORAL|3 minutes step test|3 minutes step test- Stair hight:20 cm, Pace: 96 steps per minute
40782526|NCT03672149|DRUG|Cefazolin|Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion
41145116|NCT01428622|DRUG|BI54903|ethanolic solution
41145117|NCT01428622|DRUG|BI54903|ethanolic solution
41145118|NCT01428622|DRUG|BI54903|ethanolic solution
41145119|NCT01428622|DRUG|BI54903|ethanolic solution
40782527|NCT06353477|DRUG|EPs® 7630|EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \&gt;12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.
40782528|NCT03118336|DRUG|Empagliflozin 10Mg Tab|1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
40782529|NCT02953184|DRUG|Pegylated Liposomal Doxorubicin|35mg/m2 iv drop during the first 4 cycles every three week
40782530|NCT02953184|DRUG|Cyclophosphamide|600mg/m2 IV drop during the first 4 cycles every three week
40782531|NCT02953184|DRUG|Taxotere|100mg/m2 IV drop during the last 4 cycles every three week
40782532|NCT02953184|DRUG|Dexrazoxane (DZR)|DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
40782533|NCT02953184|DRUG|vitamin B|Vitamin B will be administrated for protecting HFS in PLD group
40782534|NCT02953184|DRUG|Doxorubicin|60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
41145120|NCT01428622|DRUG|BI54903|ethanolic solution
41145121|NCT00279409|DRUG|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
41145122|NCT00279409|DRUG|Sugar pill|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
41145123|NCT01737398|DRUG|Inotersen|
41145124|NCT01737398|DRUG|Placebo|
41145125|NCT02299011|DEVICE|Orsiro drug eluting stent|Orsiro Hybrid drug eluting stent
41145126|NCT02299011|DRUG|Biomatrix drug eluting stent|Biomatrix Flex drug eluting stent
41145127|NCT04004832|DIAGNOSTIC_TEST|there is not any intervention procedure|there is not any intervention procedure
41145128|NCT06186063|OTHER|Pramlintide|At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.
41145129|NCT06186063|OTHER|Placebo (saline) infusion|At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.
40782535|NCT02953184|PROCEDURE|Breast Conserved Surgery|Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
40782536|NCT02953184|PROCEDURE|Modified Radical Mastectomy|Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy
40782537|NCT02953184|PROCEDURE|Sentinel Lymph Node Biopsy（SLNB）|Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
40782538|NCT01876212|BIOLOGICAL|DC vaccine|
40782539|NCT01876212|DRUG|Dasatinib|
40782540|NCT00499525|DRUG|paclitaxel|given IV
40782541|NCT00499525|DRUG|sorafenib tosylate|given orallly
41305750|NCT04236206|BEHAVIORAL|Mobile Phone Short Message Service|"SMS content will be adopted from the validated Arabic national and international diabetes educational materials (Centers for Disease Control (CDC), 2018; Diabetes Australia, 2004; Diabetes Queensland, 2012; Utah Diabetes Control Program, 2005).~* The mobile phone SMSs will be pre-tested for clarity on a sample of 10 patients similar to the study population and their comments on the SMSs wording will be used to modify them to ensure acceptance.~* The SMS will be sent to participants using the internet, open-source software for bulk messages and a local telephone network provider.~* Patients will be encouraged to send messages/call the researcher for any queries encountered."
40782542|NCT00499525|OTHER|placebo|given orally
40782543|NCT02273089|DEVICE|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
40782544|NCT00664950|DEVICE|sliding hip screw|surgical repair of hip fracture using conventional sliding hip screw
40782545|NCT00664950|DEVICE|IntertAn IM nail|interTAN IM nail
40782546|NCT02455167|DRUG|Simeprivir (SMV)|Experimental Single arm study. All participants will get the same treatment.
41145130|NCT00452894|DRUG|varenicline tartrate|
41145131|NCT00832650|DRUG|fesoterodine fumarate|8 mg OD for 14 days
41305751|NCT00711269|DRUG|SM-13496 (lurasidone HCl)|Lurasidone HCl: 40 mg/day
41145132|NCT00832650|DRUG|placebo|OD for 14 days
41145133|NCT00832650|DRUG|solifenacin|10 mg OD for 14 days
41305752|NCT00711269|DRUG|SM-13496 (lurasidone HCl)|Lurasidone HCl: 80 mg/day
41305753|NCT00711269|DRUG|Placebo|
41305754|NCT00711269|DRUG|Risperidone|
41305755|NCT06312449|OTHER|The side-lying position with the peanut ball during the second stage of labor.|"The usage of the peanut ball is divided into two stages:~Stage one: The parturient assumes a side-lying position with the bed elevated to a 30-degree angle. The peanut ball is placed between the legs, allowing for leg separation. The parturient can choose to lie on either the left or right side according to preference.~Stage two: When the fetal presenting part reaches 1 centimeter below the ischial spine (+1 Station), still in a side-lying position with the bed elevated to a 30-degree angle, the parturient has the option to switch sides. The peanut ball is then positioned between the legs with the knees bent together, for pushing"
41305756|NCT06312449|OTHER|During the second stage, the patient is placed in a lateral position|The parturient assumes a side-lying position with the bed elevated to a 30-degree angle. The parturient can choose to lie on either the left or right side according to preference.When the fetal presenting part reaches 1 centimeter below the ischial spine (+1 Station), still in a side-lying position with the bed elevated to a 30-degree angle, the parturient has the option to switch sides, for pushing
40782547|NCT02455167|DRUG|Sofosbuvir (SOF)|Experimental Single arm study. All participants will get the same treatment.
40782548|NCT02455167|DRUG|Ribavirin (RBV)|Experimental Single arm study. All participants will get the same treatment.
40782549|NCT04628130|OTHER|Yoga Therapy|Yoga based self managed practices personalised to chronic pain patients
40782550|NCT03021096|OTHER|Surveys|The study is just using validated surveys to assess pain and mood states after surgery
40782551|NCT02512380|DRUG|Docetaxel;oxaliplatin;s1|Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
40782552|NCT02512380|DRUG|oxaliplatin;s1|oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
40782553|NCT00202579|DRUG|Ivabradine|
40782554|NCT00888147|DIETARY_SUPPLEMENT|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
40782555|NCT02985411|BEHAVIORAL|Immediate Gardening Intervention|Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,
40782556|NCT02985411|OTHER|Delayed Gardening Intervention|Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
40782558|NCT01358162|OTHER|Placebo|Placebo given orally, daily for 14 consecutive days
41145134|NCT05868382|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
41145135|NCT05868382|BIOLOGICAL|mRNA-1010.4|Sterile liquid for injection
41145136|NCT05868382|BIOLOGICAL|mRNA-1010.6|Sterile liquid for injection
41145137|NCT01430416|DRUG|AEB071|
41145138|NCT00001806|OTHER|Genetic Education and Counseling|Group Education and Counseling
41145139|NCT00001806|OTHER|Genetic Education and Counseling|Individual Education and Counlseing
41145140|NCT00361088|DRUG|PS-341|Phase I and II: 1.3mg/m2 iv days 1,4,8,11
41145141|NCT00361088|DRUG|R11577|"Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.~Phase II: Maximum Tolerated Dose (MTD)"
40986985|NCT03836547|BEHAVIORAL|Coaching and Weight Loss for patients with dyspnea|Patients with lung disease and a BMI of 35 or greater who suffer from shortness of breath will be invited to participate in a study involving a commercial weight loss application with health coaching. The patients will subscribe on their own to the weight loss application. The patients will be provided with a blue tooth scale so that they may weigh themselves weekly. A health coach will call them weekly for 8 weeks.
40986986|NCT03836547|BEHAVIORAL|Active Control|Participants will receive usual care for 12 weeks followed by the active intervention.
40986987|NCT05451862|DEVICE|Holmium-166 treatment|Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.
40986988|NCT05451862|DEVICE|Holmium-166 work-up|Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.
40986989|NCT03439670|DRUG|Vamorolone|Oral administration of 2.0 mg/kg/day for the duration of the study.
40986990|NCT03439670|DRUG|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
40782559|NCT01358162|DRUG|SQ109|A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
40782560|NCT00968409|RADIATION|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
40782561|NCT00968409|OTHER|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
40782562|NCT00968409|OTHER|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
40986991|NCT03439670|OTHER|Placebo|Oral administration of placebo daily for 24 weeks.
40986992|NCT03439670|DRUG|Vamorolone|Oral administration of 6.0 mg/kg/day for the duration of the study.
40986993|NCT03439670|DRUG|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
40986994|NCT03439670|OTHER|Placebo|Oral administration of placebo daily for 24 weeks.
40986995|NCT03439670|DRUG|Vamorolone|Oral administration of 2.0 mg/kg/day for 20 weeks.
40986996|NCT03439670|DRUG|Vamorolone|Oral administration of 6.0 mg/kg/day for 20 weeks.
40986997|NCT01563718|DRUG|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
40986998|NCT00824044|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
40986999|NCT00824044|DRUG|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
40987000|NCT05193864|DEVICE|Device: JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
40987001|NCT02068586|DRUG|Sunitinib|Given PO
40987002|NCT02068586|DRUG|Valproic Acid|Given PO
40987003|NCT02068586|DRUG|Sunitinib Malate|Given PO
40987004|NCT02068586|DRUG|Sunitinib Malate + Valproic Acid|Given PO
40782563|NCT00968409|DRUG|F18-FFNP|injection of F18-FFNP
40782564|NCT01816295|DRUG|Testosterone Solution|Administered topically to axillae.
40782565|NCT01816295|DRUG|Placebo Solution|Administered topically to axillae.
40782566|NCT00105664|PROCEDURE|Collaborative care model|
40782567|NCT00105664|PROCEDURE|Group interventions|
40782568|NCT00105664|PROCEDURE|Facilitated consultation|
40782569|NCT01678521|PROCEDURE|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
40782570|NCT04073056|DRUG|Bupivacaine|Bupivacaine Hcl 0.25% Inj
40782571|NCT03581175|PROCEDURE|Colonoscopy|
40782572|NCT03581175|DRUG|Bowel cleansing regimen|
40782573|NCT01686113|OTHER|NEFA|
40782574|NCT01686113|OTHER|Sucrose|
40782575|NCT04411303|BEHAVIORAL|Step length biofeedback|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
40782576|NCT04411303|BEHAVIORAL|Propulsive force biofeedback|Participants will be provided with real-time visual feedback of anterior-posterior ground reaction forces of the paretic limb during stance phase on a screen in front of a treadmill.
40987005|NCT02969824|BEHAVIORAL|Supervised Aerobic Exercise|The AE protocol will consist of eight sessions that proceed in a stepwise fashion in terms of duration and intensity over 11 days. Exercise will be performed on the Velotron Pro stationary cycle ergometer (RacerMate Inc., WA, USA), which will be digitally connected to a heart rate monitor and programmed to monitor the wattage of the bike based on the participant's heart rate. Exercise duration (15min-20min) and intensity (60%-75% max HR) will increase over the intervention period. For the remotely supervised sessions, exercise intensities and heart rate will be monitored via FitBit.
40987006|NCT00090311|DRUG|quetiapine fumarate|
40987007|NCT00015301|DRUG|Methylphenidate|
40987008|NCT00798044|BEHAVIORAL|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
40987009|NCT00798044|BEHAVIORAL|Patient Feedback|Weekly feedback reports provided to counselors
40987010|NCT04267991|DRUG|Tacrolimus ointment|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
40987011|NCT04267991|PROCEDURE|phototherapeutic keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
40987012|NCT00947479|OTHER|continuous positive airway pressure (CPAP)|After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
40987013|NCT05309109|OTHER|Hemodialysis sessions|Patients will receive thrice weekly 4 hours hemodialysis sessions during 12 months.
40987014|NCT00322842|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
40987015|NCT01683955|DRUG|Tranexamic acid|Topical tranexamic acid (2g/100mL 0.9% saline)
40987016|NCT01683955|DRUG|Placebo|100mL 0.9% sterile saline
40987017|NCT03054545|DRUG|Iguratimod|Iguratimod 25mg twice a day, oral administrated.
41305757|NCT05388708|DEVICE|ECMO support|ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.
41464361|NCT02857647|BEHAVIORAL|An information video|Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
41464362|NCT05333315|DIETARY_SUPPLEMENT|IP1|"IP1: 2 softchews 3 times a day before meals with 1-2 glasses of water for eight weeks.~OTHER: Placebo"
41464363|NCT05333315|DIETARY_SUPPLEMENT|IP2|"IP2: One bag per day mixed in 200 mL of cold water or tea and consumed immediately, on an empty stomach, half an hour before breakfast for eight weeks.~OTHER: Placebo"
40782577|NCT04411303|BEHAVIORAL|Interlimb asymmetry biofeedback|Participants will be provided with visual feedback of stride-by-stride values of their interlimb asymmetry on a screen in front of a treadmill.
40782578|NCT04411303|BEHAVIORAL|Aerobic intensity-based walking|Participants will walk at three different aerobic intensities. Aerobic intensity will be set based on target heart rate zones calculated with the Karvonen Formula. For low intensity, participants will walk at 30-40% intensity. In moderate intensity conditions, participants will walk at a 50-60% intensity level. In vigorous intensity conditions, participants will walk at an 70-80% intensity level. Aerobic intensity will be manipulated by changing walking speed.
40782579|NCT01310010|DRUG|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
40782580|NCT04616248|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IT
40782581|NCT04616248|DRUG|Poly ICLC|Given IT
40782582|NCT04616248|RADIATION|Radiation Therapy|Undergo radiation therapy
40782583|NCT04616248|BIOLOGICAL|Recombinant Flt3 Ligand|Given IT
40782584|NCT04616248|DRUG|Pembrolizumab|Given IV
40782585|NCT04616248|DRUG|Tocilizumab|Given SC
40782586|NCT01923636|OTHER|detection of CMV|Clinical, radiological and laboratory (virological and immunological) standardized reports
40782587|NCT01128569|DRUG|Fluticasone Furoate|FF
40782588|NCT01128569|DRUG|FF/Vilanterol (VI; GW642444M)|FF/VI
40782589|NCT01128569|DRUG|Placebo|Placebo Inhaler
40782590|NCT03363178|BIOLOGICAL|GC3107|BCG Vaccine, 0.1mL
40782591|NCT03820011|OTHER|PEM+|PEM+ is a five-step recursive process (i.e., the caregiver can repeat the five-step process to create as many intervention plans for their child as needed, relative to the number of activities in which change is desired based on the YC-PEM e-PRO, and it offers tiered support to the user during completion (tier 1: frequently asked questions available in the application, tier 2: support provided by email, tier 3: support provided by phone).
40782592|NCT05850767|OTHER|Sleep deprivation|Participants will stay fully awake for 24 hours
40782593|NCT01228214|DRUG|Placebo|Placebo 5mg/daily for 12 months
40782594|NCT01228214|DRUG|amiloride|5mg/daily for 12 months
40782595|NCT05081830|BEHAVIORAL|Transdiagnostic online intervention|Based on the theoretical proposal of Barlow et al. (2011) a treatment applicable to all anxiety and mood disorders (unipolar depression) will be implemented. The unified protocol incorporates proven emotion-focused psychological techniques (Ellard et al., 2010). The main components are: (1) motivation for change, understanding emotions, and recognition and observation of emotional response; (2) learn to observe experiences, evaluate and reevaluate thoughts; (3) what is emotional avoidance, emotion and behavior, and awareness and tolerance of physical sensations; (4) emotional exposure to physical sensations and situations and achievements, maintenance and prevention of relapses.
40987018|NCT00450333|DRUG|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
40987019|NCT00450333|DRUG|Dynepo|subcutaneous, QW for 24 weeks
40987020|NCT00450333|DRUG|Dynepo|subcutaneous, QW for 24 weeks
40987021|NCT00450333|DRUG|Dynepo|subcutaneous, Q2W for 24 weeks
40782596|NCT05081830|BEHAVIORAL|TCC online intervention|This program incorporates psychological techniques under the cognitive-behavioral model that have demonstrated their effectiveness in online mode (De la Rosa, 2019; Flores et al., 2014). The main components are: (1) psychoeducation, (2) cognitive restructuring, (3) identification and expression of emotions, (4) assertiveness training and (5) problem solving, and (6) relapse prevention. The order of application of each technique is established by the advisor derived from the formulation of treatment of each case to solve the problems raised, under supervision.
40782598|NCT03419429|DRUG|Simvastatin|Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.
40782599|NCT03419429|OTHER|EDTA|EDTA is a demineralizing agent used for root surface conditioning.
40782600|NCT03419429|DEVICE|Occlusive membrane|Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.
40782601|NCT03419429|DEVICE|Modified perforated membrane|Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration
40782602|NCT06085547|BEHAVIORAL|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include rural-targeted information
40782603|NCT06085547|BEHAVIORAL|Rural-Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a two and a half minute video based messaging adjunct meant to enact a rural-targeted framing of health information presented to White rural individuals.
40782604|NCT01951053|DRUG|JNJ-40411813|Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.
40782605|NCT01951053|DRUG|Placebo|Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.
40782606|NCT01951053|DRUG|Citalopram|Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.
40782607|NCT05746988|OTHER|Mouthwash gargling|15 - 20 ml of mouthwash to be gargled vigorously for 30 to 60 seconds daily (morning and night) as an adjunct to regular toothbrushing, and before and/or immediately after sexual activities.
40782608|NCT03431454|PROCEDURE|trained to do the pencil push-ups procedure|15 minutes per day, five days a week
40782609|NCT03431454|PROCEDURE|using a major amblyoscope twice weekly with additional home orthoptic therapy|60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed.
40782610|NCT03431454|PROCEDURE|using three diopter over-minus lenses and a base out prism|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
40782611|NCT05955339|OTHER|NOTES|The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
40782612|NCT05955339|OTHER|AUDIO|The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.
40782613|NCT05702814|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
40782614|NCT06213272|BEHAVIORAL|Phono-Motor Therapy|The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) \& vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
40782615|NCT06213272|BEHAVIORAL|Aerobic Exercise Training (AET)|Stationary ergometer cycling at 60% heart rate range for 20 minutes, plus 5 minutes of warm up and cool down.
40782616|NCT06213272|BEHAVIORAL|Stretching|Light stretching activities targeting the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
40782617|NCT02147821|PROCEDURE|No Pleural Chest Tube|
40782618|NCT05017623|DRUG|YH003|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
40782619|NCT04198883|COMBINATION_PRODUCT|Protheracytes|Intramyocardiac (LV) injection of stem cells with a dedicated catheter
40782620|NCT01126190|BIOLOGICAL|Neugranin|Neugranin will be administered per dose and schedule specified in the arm description.
41464364|NCT05333315|DIETARY_SUPPLEMENT|IP3|"IP3: One bag per day in the morning, dissolved in a glass of warm water and three capsules per day with a glass of water or tea (one capsule at breakfast, one at lunch and one at dinner) for eight weeks.~OTHER:Placebo"
40782621|NCT01126190|BIOLOGICAL|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
40782622|NCT01126190|DRUG|Chemotherapy|The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination
40782623|NCT03026244|DIETARY_SUPPLEMENT|Milk protein, prebiotics, vitamin D|3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
40782624|NCT03026244|DIETARY_SUPPLEMENT|Placebo product|3 periods of 3 weeks placebo product
41464365|NCT05333315|DIETARY_SUPPLEMENT|IP4|"IP4: Twice a day 20 mL half an hour before breakfast and half an hour before dinner for eight weeks.~OTHER:Placebo"
41464366|NCT05333315|DIETARY_SUPPLEMENT|IP5|"IP5: Formula 1: One capsule per day at breakfast with a glass of water for eight weeks and Formula 2: Two capsules a day at breakfast and at dinner with a glass of water for eight weeks.~OTHER:Placebo"
41464367|NCT05201638|DRUG|IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
40782625|NCT02314442|DRUG|ALN-PCSSC|Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
41464368|NCT05201638|DRUG|Placebo matching IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
41464369|NCT00756717|DRUG|MK-0752|Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
40782626|NCT02314442|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
40987022|NCT00829543|PROCEDURE|guide-free sacroiliac corticosteroid injection|guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
40987023|NCT02930551|DRUG|Lidocaine|
40987024|NCT02930551|DRUG|Isotonic Saline|
40987025|NCT01161914|DRUG|Cerezyme®|administered by IV infusion for a dose of 60 U/kg
41464370|NCT05054049|DEVICE|Interventional Diagnostic Device Arm|Point of care testing venous blood diagnostic device.
41464371|NCT05054049|OTHER|Usual care|Usual care provided to patient without use of point of care testing device
41464372|NCT05049668|DRUG|ATGAM plus CsA with or without Eltrombopag|Standard treatment with or without Eltrombopag
41464373|NCT02828566|DRUG|IN ketamine|Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
41464374|NCT02828566|DRUG|IV ketamine|Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
41464375|NCT02828566|DRUG|IN saline 0.9%|Intranasal 0.9% normal saline
41464376|NCT02828566|DRUG|IV saline 0.9%|Intravenous 0.9% normal saline
40987026|NCT01161914|DRUG|ISU302|administered by IV infusion for a dose of 60 U/kg
40987027|NCT01613625|PROCEDURE|Elastography|
40987028|NCT01251549|DEVICE|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device
40987029|NCT00195182|BEHAVIORAL|Self affirmation and positive affect induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
41305758|NCT05388708|OTHER|PROSpect protocolized therapies|"PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure.~The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure \<28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 \< 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine."
40987030|NCT02201706|PROCEDURE|Multi-electrocoagulation retinectomy|"a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina.~All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.~Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process."
40987031|NCT00082654|PROCEDURE|psychosocial assessment and care|
41305759|NCT01737840|DRUG|Pantoprazole|33 patients
41305760|NCT01737840|DRUG|Ranitidine|33 patients
41305761|NCT05813327|DRUG|ADI PEG20|ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m\^2 via intramuscular injection into either the deltoid or gluteal muscle.
41305762|NCT05813327|DRUG|Ifosfamide|Ifosfamide will be administered intravenously per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
41305763|NCT05813327|RADIATION|Radiotherapy|Radiotherapy will begin on C2D1 and will continue as per institutional practice.
41305764|NCT05813327|DRUG|Mesna|Mesna will be administered for supportive care either intravenously or by mouth per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
41305765|NCT04123756|BEHAVIORAL|standardized exercise therapy for knee OA patients|Standardized exercise therapy for 6-8 weeks (two times per week).
41305766|NCT05877885|BEHAVIORAL|Targeted Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
41305767|NCT05877885|BEHAVIORAL|General Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
41305768|NCT06047093|PROCEDURE|Investigation of the intrahepatic compartment using the fine needle aspiration (FNA) technique|"The FNA will be performed at the Croix Rousse digestive pathology day hospital of the Hospices Civils de Lyon by a doctor from the hepatology department who has been trained to perform FNA.~After echography, a subcutaneous anesthesia with LIDOCAÏNE is administered. Two FNA passages will be performed for virological and immunological analyses. The patient will be monitored in the supine position for 1 hour after the procedure.~A single FNA will be performed during the study."
40987032|NCT01394523|DRUG|Bupivacaine|0.25% or 0.5%
40987033|NCT05181423|OTHER|Biomarkers|Different serum and radiological biomarkers neonates undergoing abdominal surgery.
40987034|NCT03045887|DRUG|GSK2292767 50 μg|GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
40987035|NCT03045887|DRUG|GSK2292767 500 μg|GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
40987036|NCT03045887|DRUG|Placebo|Lactose as powder for inhalation
41145142|NCT03779776|OTHER|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at 1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
41145143|NCT03779776|OTHER|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
41145144|NCT06470685|BEHAVIORAL|Qualitative Research Interviews|Research Interviews
41145145|NCT01999335|DRUG|Oprozomib|Extended release (ER) tablets administered orally
41145146|NCT01999335|DRUG|Pomalidomide|Capsules for oral administration
41145147|NCT01999335|DRUG|Dexamethasone|Tablets for oral administration
41145148|NCT06585124|DIAGNOSTIC_TEST|Flow Cytometry|Study of t cell population in flow cytometry
41145149|NCT02915003|BEHAVIORAL|E-health website|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
41145150|NCT05941988|PROCEDURE|pre grafting partial maxillary expansion with post grafting expansion|pre grafting partial maxillary expansion then anterior iliac grafting followed by 2 months period for consolidation then post grafting expansion till full arch alignment
41145151|NCT02327975|OTHER|Training group|"The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).~During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax."
40987037|NCT01996826|DRUG|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
40987038|NCT01996826|DRUG|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
41145152|NCT02327975|OTHER|Mobile group|The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
40987039|NCT01688258|PROCEDURE|Diagnostic swab|
40987040|NCT01365507|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
40987041|NCT01436981|PROCEDURE|CABG|Preparation of artery mammaria interna
40987042|NCT00616681|DRUG|Oxcarbazepine|
40987043|NCT04234035|BEHAVIORAL|Decision Aid|Decision aid to facilitated shared decision-making
41145153|NCT02327975|OTHER|Control group|No received intervention.
41464377|NCT01992341|DRUG|AMG 386|Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
40987044|NCT04234035|OTHER|Standardized Educational Material (informational pamphlet)|Pamphlet with information about kidney stones
40987045|NCT03674242|DRUG|eryaspase (L-asparaginase encapsulated in red blood cells)|IV infusion 100 U/kg
40987046|NCT03674242|DRUG|Gemcitabine|IV infusion 1000 mg/m2
41145154|NCT02470312|PROCEDURE|CRT implantation|It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
41145155|NCT02470312|DEVICE|MediGuide|
41145156|NCT02470312|PROCEDURE|EP|
41145157|NCT03430362|DRUG|Hyoscine N Butylbromide|7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
41145158|NCT03430362|DRUG|Normal Saline 0.9%|Group B, will receive 2 ml of normal saline single intravenous dose
41145159|NCT04580732|DEVICE|MiniStim PNS|MiniStim PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
41145160|NCT06500910|OTHER|Physical Exercise|10 weeks of child-friendly physical exercise program
41145161|NCT02820909|PROCEDURE|venous and arterial catheter set-up using ultrasound guidance|The insertion of the venous and arterial catheter will be done using ultrasound guidance. Vein and artery will be identified in cross section. In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.
41145162|NCT02820909|PROCEDURE|Anatomical guidance.|"In the anatomical group, catheter will be inserted using, as it is currently done in intensive care unit, anatomic landmarks. If catheterization according to the anatomic method is considered too difficult (\> 3 punctures), a conversion to ultrasound guidance will be done.~In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit."
41145163|NCT04070521|OTHER|Observational EEG Monitoring|Subjects will be monitored with electroencephalogram (EEG) after arriving to the Emergency Department with suspected overdose
41145164|NCT02060175|DEVICE|Cilotax drug-eluting stents implantation|
41145165|NCT02060175|DEVICE|DESyne drug-eluting stents implantation|
41145166|NCT02183402|DRUG|Digoxin|
41145167|NCT02183402|DRUG|BI 1356|
41145168|NCT06345092|DRUG|Vitamin C|addition of vitamin C to IPRF
41145169|NCT06345092|OTHER|Injectable platelet rich fibrin|injection of IPRF alone
41145170|NCT02474004|PROCEDURE|medial meniscal surgery|one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis \& knee scores 6 mo after the procedures
41145171|NCT05049174|BEHAVIORAL|Nuse-led interview and referral to municipal healthy life-centres|Usual care treatment and written information to patients and general practitionnaires about smoking cessation and the municipal healthy life-centres
41145172|NCT02644980|DRUG|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
41145173|NCT02644980|DRUG|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
41145174|NCT02644980|DEVICE|Bispectral Index Monitor|BIS monitored from beginning of anesthesia induction to the end of the surgery.
41145175|NCT02644980|DRUG|Induction of anesthesia|Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5\~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
41145176|NCT02644980|DRUG|Maintenance of anesthesia|After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
41145177|NCT02644980|OTHER|Tracheal Intubation|After the induction of anesthesia, Tracheal intubation is performed.
41145178|NCT04460937|DRUG|Adavosertib|Given PO
41145179|NCT04460937|RADIATION|Radiation Therapy|Undergo radiation therapy
41464378|NCT01992341|DRUG|Paclitaxel|Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.
41464379|NCT00120315|DRUG|esomeprazole|esomeprazole, original Nexium, 40 mg pills Up to once a day
41464380|NCT00120315|PROCEDURE|Helicobacter pylori c-13 breath test|Breath test done at entry to find Helicobacter pylori
41464381|NCT05268419|DRUG|Ethanol|Inhalation of 35%-ethanol spray
40987047|NCT03674242|DRUG|Carboplatin|IV infusion AUC2
40987048|NCT02443012|DRUG|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
40987049|NCT02443012|PROCEDURE|Laser|Grid/Focal Laser Photocoagulation
40987050|NCT01154218|DRUG|crizotinib|"Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC"
40987051|NCT02951156|BIOLOGICAL|Avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
40987052|NCT02951156|BIOLOGICAL|Utomilumab|Investigational, fully human IgG2 CD 137/4-1BB agonist
40987053|NCT02951156|BIOLOGICAL|Rituximab|CD20-directed cytolytic antibody
40987054|NCT02951156|OTHER|Azacitidine|Antimetabolite antineoplastic agent and demethylation agent.
40987055|NCT02951156|DRUG|Bendamustine|Alkylating drug
40987056|NCT02951156|DRUG|Gemcitabine|Nucleoside analogue
40987057|NCT02951156|DRUG|Oxaliplatin|Platinum-based drug
40987058|NCT05544786|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
41464382|NCT05268419|DRUG|Water Distilled|Inhalation of water distilled spray
41464383|NCT00859040|DRUG|SOM230C|Injection in the buttocks every 28 days
41464384|NCT00083434|DRUG|Epoetin alfa|
40987059|NCT05544786|DRUG|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition
40987060|NCT05544786|DRUG|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
40987061|NCT05544786|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
40987062|NCT05544786|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
40987063|NCT03238638|DRUG|Pembrolizumab|Both cohorts will receive pembrolizumab at a flat dose of 200mg every 3 weeks.
41145180|NCT04151147|PROCEDURE|Concentrated Growth Factor (Test group)|The patients' blood was collected in 9 ml glass tubes and immediately centrifuged to prevent coagulation in special centrifuge device. The CGF program was set up as follows: accelerated for 30 seconds so as to reach 2700 rpm, rotated for 2 minutes, then reduced to 2400 rpm, then rotated again for 4 minutes and accelerated to 2700 rpm, rotated for 4 minutes, then accelerated to 3000 rpm for 3 minutes, and decelerated for 36 seconds to stop. The middle layer in the tube was separated by the ''Buffy coat'' containing the CGFs fibrin gel using forceps and scissor. Then, this fibrin gel was inserted in the extraction cavity.
41145181|NCT04151147|PROCEDURE|Non-Concentrated Growth Factor (Control group)|Third molar extraction was performed under local anesthesia. Following the extraction, the socket was sutured and natural healing process was observed. This side was considered as a control group.
41145182|NCT00222209|BEHAVIORAL|Experimental heat pain model|
41145183|NCT00603018|DRUG|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
41145184|NCT02865109|DRUG|Nusinersen|Administered by intrathecal injection
41145185|NCT01630239|PROCEDURE|Laser ablation|Laser ablation of hepatic tumors
41464385|NCT02690051|DEVICE|BeSmooth peripheral stent|patients treated with the BeSmooth Peripheral Stent System
41464386|NCT03964363|BEHAVIORAL|Unsupervised home-based physical prehabilitation|Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
40987064|NCT03238638|DRUG|epacadostat|Both cohorts will receive epacadostat. Patients in cohort 1 will take 300mg of epacadostat by mouth twice per day. Cohort 2 will take 300mg of epacadostat every 6 weeks.
40987065|NCT01278485|DRUG|Sulphonylurea|SU administered according to usual practice.
40987066|NCT01278485|DRUG|Metformn|Metformin administered according to usual practice.
41145186|NCT02558907|OTHER|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
41145187|NCT04265417|PROCEDURE|Robotic Assisted Rectal Cancer Resection Alone|participants in this group underwent robotic assisted rectal cancer resection alone, the specimens were extracted through the incision on the abdominal wall.
41145188|NCT04265417|PROCEDURE|Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction|participants in this group underwent robotic rectal cancer resection，the specimens were extractd through anus and vagina.
41145189|NCT03431649|DRUG|Beraprost Sodium|1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
41145190|NCT03431649|DRUG|Sildenafil Citrate|0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
41145191|NCT03153566|BIOLOGICAL|tuberculin|inject the mother wart with .3 ml tuberculin vaccine every 2 weeks
41145192|NCT03153566|DEVICE|cryotherapy|10 sec 1 cycle into all genital warts
41145193|NCT03072745|DIAGNOSTIC_TEST|Neuropsychological assessment|Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
41464387|NCT04623528|DIAGNOSTIC_TEST|T1 and T2 relaxometry of the liver parenchyma|Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
41464388|NCT02272309|PROCEDURE|EEG and EP measurement|
41464389|NCT00932217|DRUG|filgrastim|subcutaneous filgrastim administration
41464390|NCT00932217|DRUG|lenograstim|subcutaneous lenograstim administration
41464391|NCT02913820|OTHER|snowfall > 5cm/day|the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
41464392|NCT04188808|OTHER|Bypass surgery|All patients scheduled for elective surgery of PAA and PAD.
41464393|NCT02289820|BIOLOGICAL|MEDI7510|RSV sF antigen plus adjuvant
41464394|NCT02289820|BIOLOGICAL|IIV|Marketed Inactivated Influenza Vaccine
40987067|NCT02426892|BIOLOGICAL|ISA 101|100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
40987068|NCT02426892|DRUG|Nivolumab|3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
40987069|NCT02921776|OTHER|Aim 1 - VidaTalk - post-extubation|"Observation of task completion will be made while patients complete a series of messages using the VidaTalk app:~* Tell me you are tired~* Tell me you are having pain~* Rate this pain~* Tell me there is pain in your back~* Tell me your pain is sharp~* Ask to see the doctor~* Write your favorite color by drawing with your finger~* Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task.~Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak.~Group 1 only:~Patients will be asked about their preferences for customizing the VidaTalk app."
40987070|NCT02921776|OTHER|Aim 2 - VidaTalk - intubated|Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).
41145194|NCT05085678|DEVICE|Co'moon (online website to support women with AET)|"The tool contains three parts:~1. e-learning based on the brochure on adjuvant endocrine therapy (AET) in the University Hospital Leuven,~2. serious game where patients are confronted with scenes of their daily life and motivational guidelines to stimulate their self-management,~3. a patient-reported-outcome questionnaire (PROMs), reported in the patient medical file.~The tool is designed to stimulate patients self-management of their menopausal AET-related complaints and to discuss them with their health care professionals ."
41145195|NCT03490188|BEHAVIORAL|Discharge Mentoring|Phone Conversations on the importance of complying to discharge instructions delivered before discharge
41145196|NCT05993247|COMBINATION_PRODUCT|Probiotics capsule|Subjects will take a probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) three times a day for 8 weeks in combination with NSAIDs
41145197|NCT05993247|COMBINATION_PRODUCT|Placebo capsule|Subjects will take a placebo capsule identical in shape and size to probiotics capsule three times a day for 8 weeks in combination with NSAIDs
41145198|NCT04054856|DEVICE|Body Sensor Network|"The Integrated Posture and Activity NEtwork by Medit Aachen (IPANEMA) Body Sensor Network (BSN) is a wireless sensor network with several sensor nodes. A sensor node consists of a base unit equipped with different sensor modalities: Acceleration sensor, Rotation rate sensor, Air pressure sensor, Photoplethysmography (PPG, optional), Galvanic Skin Response (GSR, optional) measurement. The sensor data is transmitted via a wireless 433/868 MHz ISM band radio link to the central radio node. From there, the data is transferred via a Bluetooth connection to a laptop or PC for processing. Three sensors are attached 1) to the wrist with a flexible Velcro strap, 2) hung around the neck on a specially designed collar and 3) worn loosely in the trouser pocket without further fixation or at the belt. The respective sensors are located in a closed, ergonomically shaped housing (size 70x40x20mm\^3, approx. 35g) and have no electrically conductive contact to the skin surface of the test person."
41145199|NCT02074709|DRUG|Plain bupivacaine|"Intraoperative: TAP block with plain bupivacaine + Acetaminophen 1000 mg IV + Ketorolac 30 mg IV .~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h,prn"
41145200|NCT02074709|DRUG|Liposomal bupivacaine|"Group intraoperative: Wound infiltration with liposomal bupivacaine (Exparel) + IV acetaminophen 1000 mg IV + Ketorolac 30 mg IV~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
41145201|NCT01558765|OTHER|Integrated rehabilitation|Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
41145202|NCT00307489|DRUG|tenofovir DF|300 mg tablet, once daily (QD)
41145203|NCT00307489|DRUG|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
41145204|NCT04680559|BEHAVIORAL|MCBI|The topics covered in the sessions are: Week 1: Introduction to mindfulness and attention to breathing. Week 2. Open awareness of bodily sensations. Week 3: Work with thoughts, introductory theory and practice in attention to sounds. Week 4: Working with thoughts, advanced theory and practice in mental landscape. Week 5: Introductory theory and practice in labeling emotions. Session 6: Advanced theory in working with emotions and practice in difficult emotions. Week 7: Introductory theory on self-compassion and compassion. Practice in self-compassion. Week 8: Practice in compassion and active compassion (acts of kindness and shared humanity).
41145205|NCT04680559|BEHAVIORAL|Active Comparator|Free observation of the psychotherapist's own feelings, thoughts, distractions, biases and behavior in general for 8 weeks. Observations of these variables are recorded during psychotherapy sessions with patients participating in the research.
41145206|NCT01033123|DRUG|BSI-201|IV infusion, 5.6 mg/kg
40782629|NCT03849209|DEVICE|Stylet slow-pull technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
40987071|NCT02921776|DEVICE|Aim 3 - VidaTalk tablet app|Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
40987072|NCT02921776|OTHER|Aim 3 - attention-control with non-VidaTalk tablet|Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
40987073|NCT00844363|PROCEDURE|NB-UVB|UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
40987074|NCT05966168|DEVICE|Medtronic Micra AV Device|Participants will already be planned to have a Micra AV 2.0 device implanted. Participants will then undergo treadmill exercise testing and wear a Holter monitor to determine the effectiveness of the Micra AV 2.0 device during exercise or elevated heart rates.
40987075|NCT00827970|BEHAVIORAL|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
40987076|NCT01337219|DRUG|Tobramycin|
40987077|NCT04102215|DEVICE|HEARO|Robotic system for otological procedures
40987078|NCT04102215|DEVICE|OTOPLAN|Otological surgical planning software
40987079|NCT01947920|DRUG|Tramadol HCl, 50 mg|50-mg overencapsulated tablet for oral administration
40987080|NCT01947920|DRUG|Placebo|Size-matching capsules containing an appropriate inactive excipient
40987081|NCT01675128|DRUG|ISIS 183750|
40987082|NCT01675128|DRUG|Irinotecan|
40987083|NCT00887354|DRUG|Teriparatide|Administered subcutaneously
40987084|NCT00887354|DRUG|Risedronate|Administered orally
40987085|NCT00887354|DRUG|Placebo|"Weekly: Administered orally~Daily: Administered subcutaneously"
40987086|NCT00887354|DIETARY_SUPPLEMENT|Calcium|Approximately 500 to 1000 mg/day administered orally throughout study.
40987087|NCT00887354|DIETARY_SUPPLEMENT|Vitamin D|Approximately 800 International Units per day (IU/day) administered orally throughout study.
41145207|NCT03272815|DEVICE|Percussion Device (PD)|A laboratory prototype of the Percussion Device (PD) has been designed and built; laboratory data collection software, signal analysis and classification algorithms have been developed. It has been designed to detect a pneumothorax.
41145208|NCT03272815|DEVICE|Ultrasound (US)|The SonoSite hand help portable ultrasound device.
41145209|NCT05636306|DRUG|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
41145210|NCT05636306|DRUG|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
41145211|NCT03747575|DRUG|MSTT1041A|Participants will receive subcutaneous (SC) MSTT1041A
41145212|NCT03747575|DRUG|Placebo|Participants will receive SC placebo
41145213|NCT02288572|DIETARY_SUPPLEMENT|Lactobacillus plantarum PCS 26|Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.
41145214|NCT02288572|DIETARY_SUPPLEMENT|Placebo|Taking dietary supplement on a daily basis for 3 months.
40987088|NCT02068443|DRUG|Alogliptin|Alogliptin tablets
40987089|NCT02068443|DRUG|Metformin hydrochloride|Metformin hydrochloride tablets
40987090|NCT02068443|DRUG|Metformin hydrochloride Placebo|Metformin hydrochloride placebo-matching tablets
40987091|NCT03375801|OTHER|Decision Aid|This will be an online tool giving evidence based information and explanation on their options.
40987092|NCT03945396|DRUG|Homeopathic Medication|A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
40987093|NCT03945396|OTHER|Multidisciplinary intervention (Exercise program, diet, motivational support)|"Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight."
40987094|NCT03945396|DRUG|Homeopathic placebo|A 30 ml bottle of 30% alcohol-distilled water.
40987095|NCT04698733|DEVICE|BEST™ HVPC microcurrent electrical stimulation Pro-Sport Ultra® device|"Participants will receive two (2) 20-minute treatments a week on nonconsecutive days for 6 weeks in the clinic. At the end of 6 weeks, participants will have a 6-week pause in treatment.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
40987096|NCT03902535|OTHER|Comprehensive Geriatric Assessment|Complete comprehensive geriatric assessment
40987097|NCT03902535|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
40987098|NCT03902535|OTHER|Questionnaire Administration|Complete questionnaires
40987099|NCT00206947|DRUG|donepezil (5-10 mg/day)|Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment
40987100|NCT00206947|DRUG|Placebo|Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
40987101|NCT03999190|DRUG|NPA radiotracer|"\[11C\]NPA radiotracer, 2 injection per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
41145215|NCT02481934|PROCEDURE|NKAE cells infusion|Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
41145216|NCT02481934|DRUG|Lenalidomide|Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
40782630|NCT03849209|DEVICE|Standard suction technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed using a 10-mL suction syringe.
40782631|NCT03960047|BEHAVIORAL|Virtual Reality Training|This group gets trained to cross streets using virtual reality
40782632|NCT03960047|BEHAVIORAL|Streetside Training|This group is trained to cross streets based on streetside experiences
40782633|NCT01344343|OTHER|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
40782634|NCT05236166|DRUG|Rapid withdrawal of antiepileptic|"Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
40782635|NCT05236166|DRUG|Slow withdrawal of antiepileptic|"Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
40782636|NCT06431425|BEHAVIORAL|eCG Family Clinic|The DNA-poli is an online tool which is designed as an addition to the current genetic counseling method to make the process more efficient and to increase the uptake without compromising counseling quality. Probands can invite their at-risk family members by entering their email addresses. The family members are invited to the DNA-poli via which they can get all the information needed to make a well-considered decision about genetic testing. The information is provided in different formats, for example via a virtual assistant and via videos, which they can evaluate at their own pace, and which can be reread or rewatched. Afterwards they can request an appointment with a health care professional and make a definite decision about genetic testing.
40782637|NCT05882396|OTHER|Rood's approach|Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.
40782638|NCT05882396|OTHER|Traditional physical therapy program|Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
40782639|NCT04340518|DEVICE|Scleral lens|Scleral contact lenses, manufactured in rigid gas permeable fluorosilicone acrylate polymers and treated with plasma treatment prior to use.
40782640|NCT02818517|OTHER|ACE inhibitors|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
40782641|NCT02818517|OTHER|beta blockers|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
40782642|NCT01049087|RADIATION|Plasma volume determination (99mTc-albumin)|The test is performed using 5MBq technetium-labeled albumin (99mTc-albumin-Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
40782643|NCT01049087|RADIATION|Plasma volume determination (125I-albumin)|The test is performed using 0.2MBq 125iodine-labeled albumin (125I-albumin) with several postinjection samples for accurate zero-time extrapolation.
40782644|NCT02028845|DEVICE|Biliary cannulation with loop guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
40782645|NCT02028845|DEVICE|Biliary cannulation with straight guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
40782646|NCT05981326|PROCEDURE|Biopsy|biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment
40782647|NCT05981326|PROCEDURE|Blood samples|Centralized blood samples will be performed at inclusion + evaluation visits
40782648|NCT05981326|BEHAVIORAL|Questionnaires|Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion
40782649|NCT03322163|OTHER|Exposure is maternal iodine|The exposure is preconception maternal iodine status There is no intervention in this observational study
41305769|NCT06047093|BIOLOGICAL|Creation of a serum biobank|42ml blood sample for study of circulating peripheral blood mononuclear cells (PBMC) and new circulating hepatitis B markers. These samples will enable us to gain a better understanding of peripheral immune responses and to correlate intrahepatic virological data with new serum markers of HBV.
40782650|NCT00444314|DRUG|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
40782651|NCT00444314|DRUG|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
40782652|NCT02405299|OTHER|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
40782653|NCT02549079|OTHER|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
40782654|NCT04357899|DRUG|thrombolysis therapy|
40782655|NCT04357899|PROCEDURE|endovascular therapy|
40782656|NCT04357899|PROCEDURE|decompressive surgery|
40782657|NCT04357899|DIAGNOSTIC_TEST|multimodal imaging in acute ischemic stroke|
40782658|NCT04357899|PROCEDURE|transfer of acute stroke patients to tertiary stroke centers|
40782659|NCT04357899|DRUG|initiation of antiplatelets, oral anticoagulation and lipid lowering drugs for secondary prevention|
40782660|NCT02539550|DRUG|Placebo|Placebo
40782661|NCT02539550|DRUG|PF-06266047|PF-06266047
40782662|NCT05104060|PROCEDURE|pectoralis minor intervention group|The subjects in pectoralis minor group will received manual therapy for pectoralis minor by physical therapist, the technique including stretch and soft tissue mobilization. The subjects asked to perform the scapular control exercise and shoulder strength exercise.Subjects will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.
41145217|NCT02481934|DRUG|Bortezomib|Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
40782663|NCT05104060|PROCEDURE|shoulder strengthening group|The subjects in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
40782664|NCT04228458|DEVICE|Thermal Imaging|Testing the effectiveness of using a Thermal Imaging camera in participants with Juvenile Arthritis.
40782665|NCT03720366|DRUG|enasidenib|enasidenib
40782666|NCT03720366|DRUG|Arm 1 probes|caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole
40782667|NCT03720366|DRUG|Arm 2 Probes|digoxin and rosuvastatin
40782668|NCT03720366|DRUG|Arm 3 probes|pioglitazone
40782669|NCT00265915|BIOLOGICAL|rituximab|
40782670|NCT00265915|BIOLOGICAL|sargramostim|
40987102|NCT03999190|DRUG|Raclopride radiotracer|"\[11C\]raclopride radiotracer, 2 injections per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
40987103|NCT03999190|DRUG|Dextroamphetamine|Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
40987104|NCT00391989|DRUG|Dasatinib|
40987105|NCT04249037|DRUG|bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)|A 30 day supply of Bictegravir 50mg/Emtricitabine 200mg/Tenofovir Alafenamide 25mg will be provided to the rapid start arm.
40987106|NCT04249037|DRUG|Standard initiation of antiretroviral therapy (ART)|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
40987107|NCT02859779|BEHAVIORAL|education programs|Four audio-recorded discussion groups will be organized in each of the 10 clinical settings
41145218|NCT02416297|PROCEDURE|Micro-osteoperforation|Flapless cortical perforations will be made 8 months minimum after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, 3 micro osteoperforations will be done with manual instrument, between apex to the contour of free gum between the canine and second pre-molar. Perforations near each tooth will have 6-8 mm depth
41145219|NCT03001141|OTHER|Observational|Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.
40782671|NCT04255914|PROCEDURE|Periodontal plastic surgery procedure and orthodontic treatment|subepithelial connective tissue graft and orthodontic tooth levelling and alignment
40782672|NCT04255914|PROCEDURE|Periodontal plastic surgery procedure|subepithelial connective tissue graft procedure
40782673|NCT03643835|DEVICE|Thermal Rehab Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
40782674|NCT03643835|OTHER|Forearm Ice Towels|Towels that are wetted with ice water and wrapped around participants forearms (length of arm from wrist to elbow)
40987108|NCT05042947|DEVICE|double-loop clips|a new ligation method using the double-loop clips (D-L clips) technique
40987109|NCT05042947|DEVICE|Titanium Clip|the Titanium Clip
40987110|NCT01619683|DRUG|enclomiphene citrate|12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
40987111|NCT01619683|DRUG|Placebo|1 placebo capsule per day, oral
41145220|NCT00323778|DRUG|Hyalgan|
41145221|NCT04794465|DIAGNOSTIC_TEST|Colorectal cancer screening|Patients with IBP diagnosed during the colorectal cancer screening
41145222|NCT06085859|DEVICE|Routine nasal catheter group|The anaesthesia provider supplied oxygen via a nasal cannula at an oxygen flow rate of 8 Litres/minute supplied from an oxygen flowmeter as described in the guide
41145223|NCT06085859|DEVICE|Mask group|The study team applied the mask with a head strap to ensure a proper seal,simultaneously ensuring the same oxygen flow rate as the control group
41145224|NCT03556267|DEVICE|spinal needle|It is a spinal needle with 'QUINCKE' Bevel. It is inserted in the lumbar region at the inter-space L4-L5, L4-L3 ,or L3-L2 lumber spaces, while the patient is put in the sitting position then CSF sample is taken then 2.5 ml of a local anesthetic(0.5 ml of 25 ug fentanyl and 2 ml of 8 mg heavy bupivacaine) is given intrathecal then the needle is withdrawn.
41464395|NCT03772756|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.
41464396|NCT03772756|RADIATION|chemoradiotherapy|Receive chemoradiotherapy
40987112|NCT01433679|BEHAVIORAL|Zamzee Intervention|The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
40987113|NCT01802723|DRUG|Drug: salmeterol xinafoate|
40987114|NCT01802723|DRUG|Drug: Placebo|
40987115|NCT01552252|DIETARY_SUPPLEMENT|apple juice|unaltered(0% POs-Ca) commercially available apple juice
40987116|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 0.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
40987117|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 1% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
40987118|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 1.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
40987119|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 2% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
41145225|NCT05280509|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
41145226|NCT05280509|DRUG|Ruxolitinib|Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
41145227|NCT06501508|DEVICE|Stratafix Symmetric|Use of Stratafix Symmetric for primary fascial closure
41464397|NCT03114358|OTHER|Early Carbapenem de-escalation|The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
41464398|NCT04674709|DRUG|Oleander 4X - single|Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
41464399|NCT04674709|DRUG|Oleander 4X - double|Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
41464400|NCT04674709|DRUG|Oleander 4X - quadruple|Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
41464401|NCT04674709|DRUG|Placebo|The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
40782675|NCT02005744|DRUG|CKD-501|CKD-501 0.5mg, PO(per oral), once
41145228|NCT03143036|DRUG|Daratumumab, thalidomide and dexamethasone|"Patients will be treated with with the following schedule. IV daratumumab 16mg/kg body weight weekly for weeks 1-8 followed by daratumumab 16mg/kg body weight once every 2 weeks from weeks 9 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; PO thalidomide 100mg daily for 1 year and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients \>75 years old) once weekly for 1 year (13 cycles, each cycle is 4 weeks). After 1 year, patient only continue on daratumumab until progression~Patients will be assessed every 28 days (+/-10 days)."
40987120|NCT06449313|DRUG|Cemiplimab-Rwlc|350 mg every 3 weeks, intravenously, on day 1 of a 21 day cycle for 4 cycles, then every 3 weeks after surgery for 1 year.
40987121|NCT02069366|DRUG|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive dronabinol.
40987122|NCT02069366|DRUG|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive placebo.
41145229|NCT05438745|OTHER|Copenhagen Burnout Inventry|Questionnaire
41145230|NCT05780957|OTHER|MCED|multi-cancer early detection (MCED) test
41145231|NCT01432223|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 q3w
41145232|NCT00027209|DRUG|prempro|
41464402|NCT02476331|BEHAVIORAL|Working memory training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
41464403|NCT02224053|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
41464404|NCT02224053|DRUG|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
41464405|NCT02224053|DRUG|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
41464406|NCT02224053|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
41464407|NCT01866176|DEVICE|Stabilizing Knee Brace|Brace with no valgus action
41464408|NCT01866176|DEVICE|Valgus Knee Brace|Valgus brace with traditional three point bending system
41464409|NCT01866176|DEVICE|New Knee Brace|Brace with new mechanism to decrease the knee loading.
41464410|NCT01849458|DEVICE|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
41464411|NCT05167617|DRUG|Vit D|Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
41464412|NCT05791734|OTHER|assessing preoperative skin cleanliness|2 skin swabs on surgical incision sites and direct skin visual observation by a nurse
41464413|NCT01267916|DEVICE|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
40782676|NCT05677880|OTHER|Study Procedures|"Participants will experience~* Neurocognitive Tests and Self-Report Measures~* Clinical Interviews~* Neurological Exam~* MRI screening at baseline, 18 months, 36 months~* Fasted Blood draw"
40782677|NCT02178800|DRUG|GSK1265744 Tablets|30-mg tablets, taken orally
40782678|NCT02178800|DRUG|Injectable GSK1265744|"Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections~Cohort 2: 600-mg injection, administered as one IM gluteal injection"
40782679|NCT02178800|DRUG|Placebo for GSK1265744 Tablets|Taken orally
41305770|NCT06047093|OTHER|FNA feasibility and acceptability questionnaire|An FNA feasibility and acceptability questionnaire carried out at inclusion (V1) and at V2 after the FNA has been performed.
41305771|NCT01532700|DRUG|Ofatumumab with GSK2110183|"* GSK2110183 125mg OD continuously~* Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"
41305772|NCT03916250|DRUG|PF-06700841 cream|PF-06700841 will be applied topically
41305773|NCT03916250|DRUG|White petrolatum|White petrolatum will be applied topically
41305774|NCT02960932|DEVICE|ultrasound scanner|Ultrasound scanner used to the SSI technical reproducibility.
40782680|NCT02178800|DRUG|Injectable Placebo for GSK1265744|"Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections~Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection"
40782681|NCT05178186|PROCEDURE|Thyroidectomy|Surgery for thyroid carcinoma
41145233|NCT04923685|OTHER|Trier Social Stress Test|The TSST is a standardized test to induce acute psychological stress in humans. Participants will abstain from caffeine for 12 hours and nicotine for 2 hours prior to the test. An IV butterfly catheter will be placed in an arm vein and flushed with saline. Participants will rest for 15 minutes. A 10ml baseline blood sample will be drawn. They will perform the TSST task and then have 10ml of blood drawn at 0, 15, 30, 60, and 90 minutes post-TSST.
41145234|NCT03669419|DIAGNOSTIC_TEST|QoR 9 Questionnaire|The QoR-9 as established patient-centred outcome measure, which is validated in German language, is surveyed preoperatively, as well as on postoperative day 1 and 3 after non-cardiac surgery. Postoperative complications are evaluated using the Clavien-Dindo Score. A follow-up is intended after 6 months. Preoperative risk is estimated using the ASA (American Society of Anesthesiologists) and the POSPOM (Preoperative Score to predict postoperative mortality) score.
41145235|NCT00579020|DRUG|Moxifloxacin/dexamethasone phosphate ophthalmic solution|
41305775|NCT04282226|DEVICE|active transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical stimulator.
41305776|NCT04282226|DEVICE|sham transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
41464414|NCT01267916|DEVICE|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
41464415|NCT01267916|DEVICE|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
41464416|NCT01267916|DEVICE|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
41464417|NCT01267916|DEVICE|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
41464418|NCT01267916|DEVICE|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
41464419|NCT04273087|OTHER|Observation|Clinical signs and symptoms
41464420|NCT00793234|DRUG|TB-402|TB-402 administered as single bolus 18-24 post total knee replacement surgery.
41464421|NCT00793234|DRUG|Enoxaparin|Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
41464422|NCT00807209|DRUG|Low Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
41464423|NCT00807209|DRUG|High Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
41464424|NCT00807209|DRUG|Placebo|Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
41464425|NCT00807209|DRUG|Fentanyl via PCA|Fentanyl via PCA
40782682|NCT00986882|DRUG|SAF312A|
40782683|NCT00986882|DRUG|Placebo|
40782684|NCT00986882|DRUG|Ibuprofen|
40782685|NCT05456529|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
40782686|NCT03091361|OTHER|imaging, no intervention|no intervention
41145236|NCT00579020|DRUG|Moxifloxacin ophthalmic solution 0.5%|
41145237|NCT00579020|DRUG|Dexamethasone phosphate solution, 0.1%|
41145238|NCT02464072|PROCEDURE|Subtotal Parathyroidectomy|Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.
41464426|NCT00807209|DRUG|Bupivacaine via epidural|Bupivacaine via epidural
40782687|NCT04008914|OTHER|retrospective observation|Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
40782688|NCT06033625|PROCEDURE|CEMENTLESS TOTAL KNEE REPLACEMENT|CEMENTLESS CRUCIATE RETAINING BICOMPARTMENTAL TOTAL KNEE REPLACEMENT
41145239|NCT02464072|PROCEDURE|Total Parathyroidectomy + 45 autografts|Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
41305777|NCT02149836|DRUG|ezogabine|"Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue"
41145240|NCT02464072|PROCEDURE|Total Parathyroidectomy + 90 autografts|Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.
41145241|NCT05931224|DRUG|D064, D702, placebo of D660|Experimental Group Subjects assigned to this group are treated with D064, D702, placebo of D660
41145242|NCT05931224|DRUG|D660, placebo of D064, placebo of D702|Experimental Group Subjects assigned to this group are treated with D660, placebo of D064, placebo of D702
41305778|NCT02487849|PROCEDURE|HIPEC|secondary cytoreductive operation
41305779|NCT02487849|DRUG|Carboplatin|Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
41145243|NCT04526171|BEHAVIORAL|Vaparshun|Participants in the intervention clusters were encouraged to improve their existing toilets.
41145244|NCT00441168|DRUG|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
41145245|NCT00441168|DRUG|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
41145246|NCT00441168|DRUG|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
41145247|NCT00441168|DRUG|vincristine|vincristine: 0.4mg IV push on days 1 to 4
41305780|NCT00734773|BIOLOGICAL|Rituximab|Infusion will be given at week 2, week 4, week 6 and week 8. Infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
41305781|NCT00734773|DRUG|Cytarabine|Administered by IV over 3 hours at a dose of 3 g/m2/day for 2 days given at week 17 and week 21.
41305782|NCT00734773|DRUG|Methotrexate|Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
41305783|NCT00734773|DRUG|Motexafin gadolinium|"* Administered to the first five patients enrolled on trial, MGd will be given at 5 mg/kg q day x2 doses (completed on 2 consecutive days 1 to 2 weeks prior to day of cycle 1) to be followed by a non-infused MRI (without contrast) 1-5 hours after 2nd MGd dose (to evaluate for MGd tumor selective uptake).~* For induction chemotherapy, MGd 10 mg/kg will be given intravenously on day 8 of each cycle. MGd will be given immediately after Rituxan.~* During radiation therapy, MGd will be administered at 5 mg/kg 2-5 hours prior to WBRT, daily for the first 10 days (fractions) and then every other day of radiation thereafter."
40782689|NCT04256187|OTHER|Qualitative interview|Qualitative interviews to sample the patient's feelings, experiences and thoughts risen by the treatments in the program.
40782690|NCT05962021|DRUG|Toripalimab plus Chemotherapy|Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.
41145248|NCT04558021|DRUG|Niclosamide suspension|200mg/10ml
41145249|NCT04558021|OTHER|Placebo|10ml placebo(absent of niclosamide)
41145250|NCT01024023|DEVICE|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
41145251|NCT04247256|DRUG|FOLFIRI Protocol|FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly
41145252|NCT04247256|DRUG|SCO-101|Investigational Medicinal Product, oral tablet administered on day 1 to 6 (both days included) of a 14 day period. repeated bi-weekly
41145253|NCT04097314|DRUG|Zibotentan|10mg OD Zibotentan
41145254|NCT04097314|DRUG|Placebo oral tablet|Placebo
41145255|NCT04493307|DIAGNOSTIC_TEST|Phlebotomy|Serial assessment of hemostasis by blood and urine collection
41145256|NCT01171950|DEVICE|CentriMag Ventricular Assist System|All patients will be treated with the CentriMag device for up to 30 days.
41145257|NCT05945979|DIETARY_SUPPLEMENT|A power supplement with biotin|A power dietary supplement containing aminoacids and vitamins
41145258|NCT02162823|PROCEDURE|Pancreatic Surgery|Surgical removal of the pancreatic tumour (cancer) in the intervention group
41145259|NCT01653392|BIOLOGICAL|Observational Intervention|This is an observational study, therefore no interventions are specified.
41145260|NCT00101296|DRUG|tipifarnib|Given orally
41145261|NCT00101296|OTHER|pharmacological study|Correlative studies
41145262|NCT00101296|OTHER|laboratory biomarker analysis|Correlative studies
41305784|NCT00734773|DRUG|Procarbazine hydrochloride|Taken orally, 100 mg/m2 days 1-7 of the 1st, 3rd, and 5th cycles of induction therapy.
41305785|NCT00734773|DRUG|Vincristine sulfate|Administered by IV at a dose of 1.4mg per meter squared on weeks 1, 3, 5, 7 and 9.
41305786|NCT00734773|RADIATION|Radiation therapy|Given at weeks 11 through 16.
40782691|NCT01805284|DRUG|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
41145263|NCT04034732|BEHAVIORAL|Mindfulness-based Relapses Prevention (MBRP)|"Manualized MBRP program is used with a central theme in each session, with meditation practices and relapse prevention exercises and discussions. Themes include the concept of automatic pilot and its relationship to addiction relapse, recognizing thoughts and emotions in relation to triggers of relapse, integrating mindfulness practices into daily activities, practicing mindfulness in high risk situations and the role of thoughts and emotions in relapse. Include daily homework exercises that consist of awareness exercises directed at increasing non-judgmental awareness of bodily sensations, thoughts and feelings, together with exercises designed to integrate awareness skills into daily life. Include training in mindfulness through body scan, sitting meditation, and mindful stretching exercises, to cultivate awareness during simple stretching movement."
41145264|NCT04034732|BEHAVIORAL|Usual Care Control|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
41145265|NCT00547885|DRUG|Dihydrocodeine|"Group 1: 2\* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3\* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4\* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4\*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6\*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8\*30 mg dihydrocodeine short acting"
41145266|NCT06049719|OTHER|NIH Task Force's Recommended Multidimensional Minimal Dataset|Questionnaire
41145267|NCT01581333|DRUG|Empirical antimicrobial treatment discontinuation|Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
41145268|NCT01581333|DRUG|Standard empirical antimicrobial treatment discontinuation|"The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3."
41145269|NCT02655900|OTHER|Pelvic Floor Ultrasound|Transperineal Ultrasound (3D TPUS) and Endovaginal Ultrasound (3D EVUS)
41145270|NCT03769090|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
41145271|NCT03769090|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
41305787|NCT04837534|BEHAVIORAL|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
41305788|NCT04837534|BEHAVIORAL|SMS and phone call reminder group|In this group after the children have been examined, treatment plan, and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol.
41305789|NCT04263337|DRUG|[11C] PiB|Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
41305790|NCT04263337|DRUG|[18F] PBR111|Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
41305791|NCT04263337|DRUG|[18F] Flortaucipir|Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
41305792|NCT01470573|PROCEDURE|biological replacement corneal surface|the expanded tissue will be applied to patient to replace the damaged ocular surface
41305793|NCT04698590|DEVICE|Wavefront Guided Scleral Lenses|Custom wavefront guided, higher order aberration correcting scleral lenses
41305794|NCT04698590|DEVICE|Traditional Scleral Lenses|Traditional scleral lenses
41305795|NCT03239756|BIOLOGICAL|TK006|Subcutaneous injection
41305796|NCT01458444|DEVICE|Non invasive ventilation (VNI)|BIPAP® vision
41305797|NCT01458444|DEVICE|Non invasive ventilation|OPTIFLOW system
41305798|NCT03535233|DRUG|Triamcinolone Acetonide|
41305799|NCT03535233|DRUG|Minoxidil 5 % Topical Spray|
41305800|NCT03535233|DRUG|clobetasol propionate|
40987123|NCT05771233|OTHER|Prevention|"First, an anamnesis is performed to collect information on illnesses, previous and current injuries, medication, sports practice outside of dance, diet, sleep hours and, where appropriate, information on menstruation.~Subsequently, an individual pre-intervention assessment of each participant is carried out, where personal data is collected, motor, elasticity and flexibility, muscle strength and stability tests are performed.~After the initial assessment, group sessions are stablished, divided by classes according to the type of specialty of 6th grade dance. The first session is focused on teaching the different exercises and the importance of muscle strengthening, the subsequent sessions are focused on the correction of the exercises, the resolution of doubts and the incorporation of progressions regarding strength and stabilization.~At the end of the intervention, each participant is re-evaluated and results are compared."
41305801|NCT01745393|BEHAVIORAL|Clinic Quality Improvement + Behavioral Counseling|
41305802|NCT01745393|BEHAVIORAL|Clinic Quality Improvement + Attention Control|
41464427|NCT04232527|DIAGNOSTIC_TEST|Y Balance Test|The footballer will place one foot on the stationary platform of the test set during the test so that the top of the sneaker does not exceed the starting line. The second foot, or the tip of the foot, will push the movable part of the platform down the measuring tube, which is marked by half-inch intervals. Any lifting of the standing leg on the heel, on the toes or loss of balance will be considered a mistake and the attempt will be repeated. Mobility will be tested through 3 trial and 3 valid measurements of the lower limbs in the anterior, posteromedial, and posterolateral directions. The arms should rest on the hips.
41464428|NCT04232527|DIAGNOSTIC_TEST|Sit and Reach Test|This test involves sitting on the floor with your legs stretched straight forward. Shoes should be removed. The feet themselves are set straight against the box. Both knees must be stretched. With the palms facing down and the palms side-by-side or side-by-side, the subject approaches the measurement line as far as possible. It is important to keep your hands in the same position level, not that one reaches further than the other. Once the subject has reached the maximum distance, hold this position for one to two seconds and record the distance.
41464429|NCT04232527|DIAGNOSTIC_TEST|"Maximum Legs Abduction Test"|Seated legs abduction is a test to assess the flexibility of the groin region. Respondent without the shoe sits with its back and head resting against the wall. As a sign, the subject extends the legs (stretches) to the maximum extent. During the test, the legs should not be bent at the knee joint.
41464430|NCT04232527|DIAGNOSTIC_TEST|"S_RAG (reactive agility) Test"|The test consist of fast-moving forward, and a change of direction conditioned by visual stimuli.
41464431|NCT04232527|DIAGNOSTIC_TEST|S_CODS (change of direction speed) Test|S_CODS (change of direction speed) is a test that allows athletes to outperform their opponents in situations where they can pre-define a movement pattern.
41464432|NCT00307970|DRUG|HFA FP MDI|
41464433|NCT00307970|DEVICE|conventional chamber/mask; anti-static chamber/mask|
41464434|NCT05934357|OTHER|Fiber|The intervention treatment will contain fiber.
41464435|NCT05934357|OTHER|Control|The control treatment will contain corn meal.
41464436|NCT02083172|DEVICE|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
41464437|NCT04205838|BIOLOGICAL|Anakinra|Given SC
41464438|NCT04205838|BIOLOGICAL|Axicabtagene Ciloleucel|Given via infusion
40987124|NCT03893604|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2) 2mA or sham
40987125|NCT06093009|PROCEDURE|pancreatectomy|
41305803|NCT01276457|DRUG|Everolimus 0.25 and 0.75 mg tablets|The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
41305804|NCT01276457|DRUG|Cyclosporine very low dose (150-300 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
41464439|NCT04205838|DRUG|Cyclophosphamide|Given via infusion
41464440|NCT04205838|DRUG|Fludarabine|Given via infusion
41464441|NCT04205838|DRUG|Fludarabine Phosphate|Given via infusion
40987126|NCT02120950|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea is administered as an intravitreal injection
41464442|NCT01737255|OTHER|Whole body MRI|Individuals will undergo whole body and brain MRI
40987127|NCT02120950|OTHER|Visudyne|Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
40987128|NCT06120556|DRUG|GLP-1 receptor agonist|Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.
41305805|NCT01276457|DRUG|Cyclosporine low dose (350-500 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
41305806|NCT01935687|DEVICE|Using of instrumented wheel|Using of instrumented wheel
41305807|NCT01935687|DEVICE|Using of ergometer roller|Using of ergometer roller
41464443|NCT01737255|OTHER|Psychological questionnaires|All recruits will complete questionnaires at 6 time points to assess psychological impact
41464444|NCT02887924|DEVICE|Neopuff; Fisher and Paykel, Auckland, New Zealand|Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
41464445|NCT00496067|DEVICE|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
41464446|NCT03856606|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
40987129|NCT06218355|OTHER|Intensive Education|Intervention will consist of virtual education and communication through scheduled push notifications
40987130|NCT06218355|OTHER|Enhanced Virtual Care|"Intervention will utilize a telehealth model consisting of pull approach of patient engagement."
40987131|NCT06160973|OTHER|Feed the Household|Medically tailored meals will be provided for the enrolled individual, with additional meals provided as needed for others living the same household
40987132|NCT06160973|OTHER|Dedicated Driver|Medically tailored meals will be delivered each week by a driver who is an employee of Community Servings
40987133|NCT06160973|OTHER|Feed the Individual|Medically tailored meals will be provided for the enrolled individual
40987134|NCT06160973|OTHER|Commercial Shipper|Meals will be delivered by a commercial shipping organization
40987135|NCT06473259|DRUG|Docetaxel|6 courses of docetaxel 75 mg/sqm iv
40987136|NCT06473259|DRUG|Apalutamide Oral Tablet|240 mg /daily orally
40987137|NCT06473259|DRUG|Enzalutamide Oral Tablet|600 mg /daily orally
40987138|NCT06473259|DRUG|Abiraterone acetate tablets|1000 mg /daily orally
40987139|NCT06473259|DRUG|Darolutamide Oral Tablet|600 mg/daily orally
40987140|NCT06473259|RADIATION|radiotherapy|radical radiotherapy on primary tumor
40987141|NCT06473259|DRUG|Triptorelin|3,75 mg im/4 w
40782692|NCT03737552|OTHER|Polysomnography|Polysomnography Is considered as the gold standard of sleep assessment. It combines a number of measures of body function during sleep, including measurement of brain activity(electroencephalography),eye movements(electrooculography ),muscle activity (electromyography),heart rhythm(electrocardiography).
40782693|NCT06159257|DIAGNOSTIC_TEST|Blood test|"Whenever possible, samples will be collected by the nurse in the patient's home, according to the study visit schedule. However, if this is not possible, patients will be asked to come in for sample collection at another mutually convenient time at the CERBA ALLIANCE LABORATORY closest to the patient's address.~Venous blood will be drawn on each visit."
40782694|NCT04249401|DRUG|Rivaroxaban (Xarelto)|NOAC, reduced dose
40782695|NCT04249401|DRUG|Apixaban|NOAC, reduced dose
40987142|NCT02663609|OTHER|No intervention|No treatment (intervention) was administered.
40987143|NCT00687765|DRUG|bsi-201 plus temozolomide|BSI-201 given iv. 2x weekly, temozolomide given orally
40782696|NCT04249401|DRUG|Dabigatran|NOAC, reduced dose
40782697|NCT04249401|DRUG|Warfarin|VKA
40782698|NCT03606291|RADIATION|isotoxic hypofractionation|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
40782699|NCT02714660|OTHER|none, observational study|
40782700|NCT00210444|BIOLOGICAL|Botulinum toxin type A|
40987144|NCT00829374|DRUG|Dimebon|5 mg orally three times daily
40987145|NCT00829374|DRUG|Dimebon|20 mg orally three times daily
40987146|NCT00829374|DRUG|Placebo comparator|Placebo orally three times daily
40987147|NCT02617511|DIETARY_SUPPLEMENT|Omega-3 Supplementation|
40987148|NCT02617511|DIETARY_SUPPLEMENT|Placebo|
40987149|NCT01229423|DRUG|bimatoprost 0.03%|One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
40987150|NCT01837979|PROCEDURE|cell-free fetal DNA|cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
40987151|NCT01402674|DRUG|Abrupt cessation of phentermine pharmacotherapy|Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
40987152|NCT00712829|DRUG|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
40987153|NCT00712829|DRUG|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
40782701|NCT01638507|DEVICE|Resolute Integrity Stent|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
40782702|NCT02522039|DRUG|Latanoprost|1 drop of latanoprost was given to study eye after washout period of 1 week between drugs
40782703|NCT02522039|DRUG|Timolol|1 drop of timolol was given to study eye after washout period of 1 week between drugs
40782704|NCT02522039|DRUG|Dorzolamide|1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs
40782705|NCT02771405|DRUG|Sofosbuvir|Sofosbuvir 400 mg orally once daily
40782706|NCT02771405|DRUG|Ribavirin|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
40987154|NCT01589757|OTHER|Standard Care|Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
40987155|NCT01589757|OTHER|Low GI diet|"Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate."
40987156|NCT04728061|DRUG|Gen1E-1124|Intravenously-infused Gen1E-1124 in vehicle.
40987157|NCT04728061|DRUG|Placebo|Intravenously-infused vehicle.
40987158|NCT04324060|DRUG|Danazol + rhTPO (recombinant human thrombopoietin injection)|subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased \>50×10e9/L, total course is 6 months
40987159|NCT04324060|DRUG|Danazol + sodium chloride|Danazol 0.2g tid po+ control (sodium chloride)
40987160|NCT06397898|OTHER|Educational video|Viewing an educational video before Novasure treatment
40987161|NCT04718142|DEVICE|vNEP|Apply vNEP therapy to the anterior surface of the throat with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O and vNEP devices of varying shapes and sizes.
41145272|NCT03769090|DRUG|Albuterol sulfate metered-dose inhaler 180 μg|Albuterol sulfate inhalation aerosol
41145273|NCT02400398|OTHER|Tube feeding|Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
41145274|NCT03790098|BEHAVIORAL|Restorative-Flow Yoga|Restorative yoga consists of a series of gentle poses, supported by props, with an emphasis on breathing and relaxing; as opposed to stretching or contracting muscles, it is designed to support muscles. Flow yoga consists of a series of linked poses synchronized with the breath.
41145275|NCT03961178|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cytology of lower genital tract
41145276|NCT03961178|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cytology of lower genital tract
40782707|NCT02771405|DRUG|Simeprevir|Simeprevir 150 mg orally once daily
41464447|NCT03856606|BEHAVIORAL|Prolonged sitting with interval exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo a prolonged sit which with will be broken up every hour on the hour by a small bout of interval exercise. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
41145277|NCT05431426|DRUG|CH6001|CHF6001 will be administered using the NEXThaler® DPI device
41145278|NCT00160537|DRUG|Levocetirizine|
41464448|NCT01463891|DRUG|Eribulin Mesylate|The usual adult dose of eribulin mesylate is 1.4 mg/m\^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
41464449|NCT03968926|OTHER|Arterial pressure management during circulatory support by VA-ECMO|Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)
40782708|NCT02771405|DRUG|daclatasvir|Daclatasvir 60 mg orally once daily
40782709|NCT02771405|DRUG|Ledipasvir|Ledipasvir 90 mg orally once daily
40782710|NCT02916316|DRUG|R-CHOP with doxorubicin|Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
40782711|NCT01727388|PROCEDURE|lateral decubitus|
40782712|NCT01727388|PROCEDURE|supine decubitus|
40782713|NCT03732469|DRUG|Acetaminophen|Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.
40987162|NCT03021239|PROCEDURE|Echo Guided Testing|
40987163|NCT03021239|PROCEDURE|Hemodynamic-Echo Ramp Testing -|
40987164|NCT02232633|DRUG|BBI503|
40987165|NCT05113615|DRUG|Tiotropium Bromide|respimat inhaler 2.5mcg/puff
40987166|NCT05113615|DRUG|Matching placebo|matching placebo Respimat inhaler
40782714|NCT03732469|DRUG|Fentanyl|Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
41145279|NCT06585163|DRUG|Hydrocodone Bitartrate|Hydrocodone bitartrate oral suspension
41145280|NCT06585163|DRUG|Doxapram Hydrochloride|Doxapram hydrocholoride oral suspension
41145281|NCT01637194|DRUG|everolimus|Given PO
41145282|NCT01637194|BIOLOGICAL|cetuximab|Given IV
41145283|NCT01637194|OTHER|pharmacological study|Correlative studies
41145284|NCT01637194|OTHER|laboratory biomarker analysis|Correlative studies
41145285|NCT05497804|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
41145286|NCT05497804|DRUG|Carfilzomib|Given IV
41145287|NCT05497804|PROCEDURE|Computed Tomography|Undergo CT
41145288|NCT05497804|BIOLOGICAL|Daratumumab|Given SC
40782715|NCT03732469|DRUG|Propofol|Weight-based IV Propofol as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
40987167|NCT00301444|DEVICE|mirror-box treatment|
40987168|NCT00301444|BEHAVIORAL|Mental visualization|
40987169|NCT01455337|DRUG|pentoxifylline|400mg tid
40987170|NCT01455337|DRUG|Prednisolone|40mg qd
40987171|NCT04351087|DEVICE|Platelet Rich Plasma|"Platelet rich plasma: 157cc of whole blood will be collected, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.~Microfragmented adipose tissue: Adipose will be aspirated from the subcutaneous tissue of the buttock or abdomen, processed, and injected into the knee joint under sterile technique using ultrasound-guidance."
40987172|NCT05536258|OTHER|Fluid|The investigators will titrate fluid administration to maintain a RI \> 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI \> 90 over at least 85% of the intraoperative period.
41145289|NCT05497804|DRUG|Dexamethasone|Given IV/PO
41145290|NCT05497804|DRUG|Lenalidomide|Given PO
41145291|NCT05497804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41145292|NCT05497804|PROCEDURE|Positron Emission Tomography|Undergo PET
41145293|NCT05497804|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
41145294|NCT04223674|DIAGNOSTIC_TEST|Serological screen and treat|Multi-antigen sero-diagnostic test for measurement of P. vivax antibodies in plasma from finger stick as a means to detect hypnozoite carriers for treatment
41145295|NCT05758532|BIOLOGICAL|Measles-Mumps-Rubella vaccine (MMR)|0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh
41305808|NCT03092869|OTHER|Feet and Ankle Mobilization|A set of manual therapy mobilization in feet and ankle joints
41464450|NCT05045612|OTHER|Stop antibiotic therapy|Stop antibiotic therapy instituted by the admitting physician
41464451|NCT01446224|DRUG|Pazopanib|Patients treated with pazopanib
40782716|NCT02234726|BEHAVIORAL|Early Childhood Development Program|"A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
40782717|NCT02301897|DRUG|Telapristone Acetate|Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
40987173|NCT00706979|OTHER|Practice Quit Attempt plus nicotine lozenge|nicotine lozenge, 2 mg or 4 mg
40987174|NCT00706979|BEHAVIORAL|Practice Quit Attempt only|Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
40987175|NCT03702946|OTHER|oxytocin in abdominal myomectomy|Women were divided into two groups randomly. In the study group 30 Units of oxytocin in 1000 ml normal saline were given during surgery, at the rate of 15units/hour. In control group, pure normal saline was given
40987176|NCT03956745|BEHAVIORAL|sleep-wake timing|Study participants will have one inverted day when they are scheduled to sleep \~12h opposite their usual sleep time.
40987177|NCT03956745|BEHAVIORAL|constant routine|Study participants will spend \~28-50 hours awake, inactive, sitting in bed, in constant lighting and temperature.
40987178|NCT05251545|OTHER|Pulmonary vein isolation|Comparison of power levels in catheter ablation in regard of single procedure success rate (freedom of any atrial arrhythmia with a duration of more than 30 sec. 45 Watts versus standard power levels (30 Watts).
40782718|NCT02301897|DRUG|Placebo|Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
40987179|NCT03253107|DRUG|Chemotherapy|"Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin"
40987180|NCT00624052|DRUG|fixed-dose combination of telmisartan 40mg+amlodipine 10mg|
40987181|NCT00624052|DRUG|fixed-dose combination of telmisartan 80mg+amlodipine10mg|
40987182|NCT02360592|DRUG|Entecavir|In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
40987183|NCT02360592|DRUG|Interferon alfa-2b|In arm 2 and 3, interferon alfa-2b is used for 48 weeks
40987184|NCT02360592|DRUG|Interleukin 2|In arm 3, Interleukin 2 is used for 12 weeks
40987185|NCT02360592|DRUG|Hepatitis B Vaccine|In arm 3, Hepatitis B Vaccine is used for 48 weeks
40987186|NCT00803868|DRUG|varenicline|up to 1mg po bid for 9 weeks
40987187|NCT00803868|DRUG|placebo|placebo matching study drug up to 1mg po bid
40987188|NCT01096810|DRUG|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
40987189|NCT01564121|DRUG|acid Zoledronic|Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
40987190|NCT01782859|DRUG|Prednisone|
40987191|NCT01782859|DRUG|Hydrocortisone|
41464452|NCT01446224|DRUG|Other anti-VEGFs|Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
41464453|NCT03077009|DRUG|Hyaluronic Acid|Ultrasound guided injection for plantaris friction syndrome
40987192|NCT01782859|DRUG|Placebo (for Prednisone)|
40987193|NCT04888156|OTHER|Unchanged treatment|Treatment is the same pre- and post self-tonometry
40987194|NCT04888156|OTHER|Changed treatment|Treatment is changed post self-tonometry
40987195|NCT01517269|BEHAVIORAL|Parent education with human patient simulator|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
40987196|NCT01517269|BEHAVIORAL|Standard care|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
40987197|NCT00134251|DRUG|SLV308|
40987198|NCT01136850|DRUG|chloroquine, sulphadoxine pyrimethamine, LLIN|"\> 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~\< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~Given at enrolment, 14-26 weeks gestation, by mouth."
40987199|NCT01136850|DRUG|azithromycin, sulphadoxine pyrimethamine, LLIN|"sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation."
40987200|NCT00541073|DIETARY_SUPPLEMENT|vitamin B12|
40987201|NCT00541073|DRUG|cisplatin|
41464454|NCT01256697|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil|9-cis Rich Powder
41305809|NCT03092869|OTHER|Proprioceptive Training|A set of proprioceptive exercises oriented to improve balance abilities
40782719|NCT03097289|DEVICE|Trima Accel system|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
40782720|NCT00300014|PROCEDURE|Intravitreal triamcinolone injection|
40782721|NCT00300014|PROCEDURE|Air-fluid exchange|
40987202|NCT00541073|DRUG|pemetrexed disodium|
40987203|NCT00541073|GENETIC|gene expression analysis|
40987204|NCT00541073|OTHER|laboratory biomarker analysis|
40987205|NCT00541073|OTHER|pharmacological study|
40987206|NCT00783445|BEHAVIORAL|Community-Based Exercise Program (C-FIT)|Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.
40987207|NCT00783445|BEHAVIORAL|Self-Help Exercise Program (HOME)|After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
41305810|NCT00408421|DRUG|Duloxetine|
41305811|NCT00408421|DRUG|placebo|
41305812|NCT04414657|OTHER|blood sampling for biobank|blood sampling for biobank
41305813|NCT02273440|DRUG|BIIL 284 BS|
41305814|NCT02273440|DRUG|Theophylline|
41305815|NCT02273440|DRUG|Placebo|
41305816|NCT00002663|BIOLOGICAL|Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
41305817|NCT00372190|DEVICE|Tensionfree vaginal mesh kit (Prolift)|Insertion of a tension free vaginal mesh using a Prolift mesh kit
41305818|NCT00372190|PROCEDURE|classic vaginal prolapse surgery (fascia plication)|classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
41305819|NCT05390450|DEVICE|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block. Prior to Popliteal plexus block, the proximal end of the adductor canal will be identified. The transducer will be slid distally along the femoral artery until the artery deviated away from the sartorius muscle in the distal part of the adductor canal towards the adductor hiatus. The nerve block needle will be inserted from the anterolateral end of the transducer and advanced in-plane through the medial vastus muscle. The endpoint of injection will be inside the distal end of the adductor canal close to the adductor hiatus. The injection will be adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle. The Popliteal plexus block will be carried out with 10 mL of local anesthetic mixture, containing 50 mg of bupivacaine and 0.05 mg of epinephrine.
41464455|NCT01256697|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawill|9-cis Rich Powder
41464456|NCT01256697|OTHER|Sugar pill|Sugar pill
41464457|NCT01195220|BEHAVIORAL|HIV testing|This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test
40987208|NCT06122701|DIETARY_SUPPLEMENT|Thiamin|"A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration."
40987209|NCT04994990|DRUG|OnabotulinumtoxinA Standard Dose|Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
40987210|NCT04994990|DRUG|OnabotulinumtoxinA Half Standard Dose|Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
40987211|NCT00226954|DRUG|zoledronic acid|
40987212|NCT01053819|DRUG|etanercept|Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
40987213|NCT02976623|OTHER|metric-based feedback training|Structured feedback; a trained investigator will give feedback according to a set of metrics and errors previously developed and validated. Trainees will undergo deliberate practice on the volunteer until they demonstrate adequate and objective performance as assessed by the set of metrics and errors provided.
40987214|NCT04660448|DIAGNOSTIC_TEST|Bedside lung ultrasound examination|Lung ultrasound exploring 12 areas (6 in each lung) at 12 +/- 6 hours and at 48-72 hours from PICU admission. Clinical and analytical data collection coinciding with ultrasound imaging and during follow-up while admitted to PICU.
40987215|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 10 mg, once daily
40987216|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 30 mg, once daily
40987217|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 100 mg, once daily
41145296|NCT05064475|DIAGNOSTIC_TEST|PET/CT|Patients with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients will underwent 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT. The final diagnosis of relapse will be derived from histopathological sampling As much as possible or radiological follow up for at least 6 months will be compared with PET/CT results.
41145297|NCT04617145|OTHER|Aerobic exercise|resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.
41145298|NCT03118609|OTHER|Understanding Needs Survey|"2-hour Focus Group~Mailed or E-mailed Survey"
41145299|NCT03539237|OTHER|Video demonstration of physical activity intensity levels|In the video demonstration, an approximately 50 year old male explains 1) light-intensity, 2) moderate-intensity, and 3) vigorous-intensity physical activity referring to differences in heart rate, breathing frequency and capability to talk normally. Simultaneously, on a treadmill he demonstrates the body signs of the three intensity levels. He gives examples and points out that there are individual differences in the intensity evaluation of comparable activities.
41145300|NCT01248663|PROCEDURE|antecolic reconstruction|see study arm description
41145301|NCT01248663|PROCEDURE|retrocolic reconstruction|see study arm description
41145302|NCT02349815|DRUG|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Women use Levonorgestrel (Jaydess, BAY86-5028) .
41145303|NCT05344742|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle)
40987218|NCT01142700|DRUG|Placebo|Capsule, Oral, 0 mg, once daily
40987219|NCT01142700|DRUG|Peginterferon Alpha-2a|Syringe, subcutaneous 180 mcg/0.5 mL, weekly
41145304|NCT05344742|DRUG|Capecitabine|The fixed dose of oral capecitabine will be administered 1000mg/m\^2, twice daily, from day 1 to day 14.
41145305|NCT05344742|DRUG|Albumin-paclitaxel|The fixed dose of albumin-paclitaxel will be set as 260 mg/m\^2, once every three weeks.
41145306|NCT02637999|DRUG|PEG IFN alfa-2a|
41145307|NCT02637999|DRUG|Myrcludex B|
40987220|NCT01142700|DRUG|Ribavirin|Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
40782722|NCT06101303|OTHER|Psychophysical assessment|"Thermal stimuli: The Thermal Sensory Analyzer will be used to deliver heat and cold stimuli. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water bath or an electronic electronic temperature-controlled water bath. Participants will be free to pull out of the water bath at any time.~Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer. These devices have a round probe that allows quantifying the amount of pressure that is being applied by real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.~Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture."
40782723|NCT06101303|BEHAVIORAL|Psychophysical assessments of experimental pain|"Pain ratings- Pain intensity and pain unpleasantness ratings will be assessed~Pain thresholds to heat, cold and/or pressure will be tested and participants will be instructed to press a button the first moment they feel pain.~Temporal summation- participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli.~Conditioned pain modulation (CPM) efficiency - CPM testing includes the application of a test stimulus without conditioning (heat or pressure stimuli) and a subsequent application of the same test stimulus together with a conditioning stimulus (cold stimulus).~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). During the OA paradigm, real time pain intensity ratings will be obtained~Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold water bath. Tolerance will be defined by the time of hand/foot withdrawal."
40782724|NCT06101303|DIAGNOSTIC_TEST|Blood, urine and saliva samples|Blood (approximately 2 tablespoons), urine and saliva samples will be collected and sent to ZRT Laboratory, LabCorp, or internal Washington University lab for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone). Additional samples will be stored in a biobank for future processing.
40987221|NCT01080690|PROCEDURE|EGD|In this arm EGD will be performed before EUS.
40987222|NCT01080690|PROCEDURE|EUS|In this arm EUS will be performed before EGD.
40987223|NCT05436847|OTHER|Proprioceptive Training|Proprioceptive Training using increased joint to joint approximation through ankle weights and joint splints.
40987224|NCT05436847|OTHER|Routine Physical Therapy|Neurodevelopmental treatment- age appropriate
40987225|NCT01228357|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
40987226|NCT01228357|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
40987227|NCT06210854|DRUG|pBI-11|HPV16/18 vaccine
40987228|NCT04355325|DEVICE|modified monolithic zirconia crowns|outcomes and complications of implant restoration
40987229|NCT04355325|DEVICE|Metal Ceramic crowns|outcomes and complications of implant restoration
40987230|NCT04725760|DEVICE|BrainPort Vision Pro|"Ten hours of training over 3 to 5 days, followed by autonomous use of the device.~It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months."
40987231|NCT06101667|DRUG|Best medical management|Best medical management included assessment of vital signs and neurological deficits,airway protection respiratory support,circulation;blood pressure monitoring;nutritional support;complication control;symptomatic treatment;laboratory and imaging examinations;etiological analysis and evaluation; anti platelet（e.g. aspirin,adenosine diphosphate (ADP) receptor inhibitors,Adenosine reuptake inhibitors,Glycoprotein platelet inhibitors）；anticoagulation(e.g. warfarin, rivaroxaban,dabigatran,apixaban,edoxaban)；lipid lowering(e.g. Statins,Fibrates）；control of blood pressure(e.g. Thiazide diuretics,Potassium-sparing,Loop diuretic,Beta-blockers,Angiotensin II receptor blockers,Calcium channel blockers,Alpha blockers,Central alpha-2 receptor agonists);control of blood glucose(e.g. SULFONYLUREAS (SFUs),GLINIDES,BIGUANIDES,ALPHA-GLUCOSIDASE INHIBITORS: STARCH BLOCKERS,THIAZOLIDINEDIONES,GLP-1 ANALOGS,DPP-4 INHIBITORS,SGLT2 inhibitors); control of other risk factors
40987232|NCT06101667|PROCEDURE|Endovascular treatment|The strategies that were used for endovascular treatment included :stent retrievers (e.g., Solitaire® \[Medtronic, USA\], Trevo® \[Stryker, USA\], EMBOTRAP® \[Johnson \& Johnson, USA\], Captor® \[HeartCare, China\] and other stent-retriever systems) thromboaspiration (e.g., Penumbra® \[Penumbra, USA\], Afentta® \[HeMo, China\] and other aspiration systems)) balloon angioplasty (e.g., Gateway® \[Stryker, USA\], Neuro RX® \[SinoMed, China\], FocuStar® \[HeMo, China\] and other intracranial balloon catheter systems) stent deployment (e.g., Wingspan® \[Stryker, USA\], Apollo® \[MircoPort, China\], Enterprise® \[Johnson \& Johnson, USA\], Neuroform EZ® \[Stryker, USA\] and other Intracranial stent systems)) intraarterial thrombolysis (with alteplase or urokinase) combinations of above approaches that were left to the discretion of the treating team
41145308|NCT06019715|BEHAVIORAL|Postpartum Remote Physical Activity Intervention|Includes 8 remote health coaching session to promote physical activity, use of a Fitbit device, and use of a home based blood pressure monitor.
41145309|NCT01483131|OTHER|Exercise training|12 weeks of resistance training twice a week.
41145310|NCT01483131|OTHER|Resistance training with vascular occlusion|12 weeks of resistance training with vascular occlusion twice a week
41145311|NCT04782570|DEVICE|Verum TMS|Intensity of 100% of the resting motor threshold with iTBS. 600 stimuli applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s.
40987233|NCT05421728|BEHAVIORAL|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
41145312|NCT04782570|DEVICE|Sham TMS|Sham stimulation with same protocol, but without magnetic stimulation
41145313|NCT02765347|DRUG|Metformin|For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
41145314|NCT02765347|DRUG|Insulin|For arm 2, just accept insulin for 24 weeks
41464458|NCT01195220|BEHAVIORAL|STI/HIV-T|This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.
40782725|NCT06101303|PROCEDURE|Biopsy and surgery-related data.|During the surgery, biopsies will be collected from the endometriosis lesions as well as from a healthy peritoneum. If there are no endometriosis lesions, biopsies will be taken of two common locations where endometriosis lesion grows (the infra-ovarian fossa). The lesions will be characterized based on their appearance and invasiveness of the lesions (i.e., powder-burn lesions, nonclassical red or white lesions, and superficially or deeply infiltrating (\>5mm) lesions). In addition, surgery-related data such as the incision size, type of anesthesia, pain ratings after the surgery, analgesic medication after the surgery, and side effects will be documented. Blood, saliva, urine, and samples will be collected for hormonal analyses or stored in a Biobank for future analyses.
40782726|NCT01241630|PROCEDURE|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
40782727|NCT00741169|DRUG|TMC435350|200 mg taken by mouth once daily for 7 days
40782728|NCT00741169|DRUG|Rifampin|600 mg taken by mouth once daily for 7 days
40782729|NCT00741169|DRUG|TMC435350+rifampin|The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
40782730|NCT04461353|DRUG|Aerolized Hydroxychloroquine Sulfate|sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.
40782731|NCT04461353|OTHER|Placebo|The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.
40987234|NCT05421728|BEHAVIORAL|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
40987235|NCT03784885|BIOLOGICAL|AD07010|A protein based adjuvant
40987236|NCT03784885|BIOLOGICAL|Inactivated trivalent influenza vaccine|Inactivated trivalent seasonal influenza vaccine
40987237|NCT04892043|BIOLOGICAL|SQZ-AAC-HPV|Activating antigen carriers (AACs) cell therapy; therapeutic vaccine engineered from red blood cells manufactured with immunogenic epitopes of HPV16
40987238|NCT04892043|DRUG|Ipilimumab|Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
40987239|NCT04892043|DRUG|Nivolumab|Programmed cell death 1 (PD-1) blocking antibody
40987240|NCT04269980|OTHER|MAP|MAP
40987241|NCT02569216|DEVICE|Electrical Inhibition (EI)|constant direct current 1-20mA transvaginal 10 second bursts only when needed
40987242|NCT00411645|DRUG|maribavir|100 mg twice daily for up to 12 weeks
40987243|NCT00411645|OTHER|placebo|twice daily for up to 12 weeks
40987244|NCT06019637|OTHER|Onasemnogene Abeparvovec|Retrospective and prospective observational study. There is no treatment allocation.
40987245|NCT00457600|PROCEDURE|patient-driven health IT product|
40987246|NCT02608554|BEHAVIORAL|Taichi|The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
40987247|NCT02608554|BEHAVIORAL|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
40987248|NCT05365633|BEHAVIORAL|Empowerment activity-enhanced tobacco cessation assistance|Participants will receive standard Tobacco Treatment Research Program (TTRP) tobacco cessation assistance either remotely or in-person: 6 weekly counseling sessions and 12 weeks of combination NRT (nicotine patches + nicotine gum or lozenges). During the 6 weeks of counseling, participants will also engage in at least 4 'empowerment activities' (i.e., SGM social change mobilization and community-building activities48) for a total of at least 8 hours. Activities will be tailored to each participant's comfort level and provide COVID-19 risk-reduction options (e.g., remote or masked outdoor activities). Examples are: (i) running tobacco-free Pride events that occur in Jun and Oct in OK; (ii) organizing a virtual SGM town hall to inform the OK State Plan on Aging; (iii) SGM-relevant legislative phone banking (e.g., regarding transgender student participation in school athletics); and (iv) follow-up surveying of Freedom OK's name and gender marker change clinic72 participants.
40987249|NCT02723084|DRUG|ABT-493/ABT-530|Co-formulated tablet
40987250|NCT02723084|DRUG|sofosbuvir (SOF)|Tablet
40987251|NCT02723084|DRUG|ribavirin (RBV)|Capsule
40987252|NCT04803669|PROCEDURE|Intrument-assisted soft tissue mobilization technique|This technique; It is applied with the help of a tool made of stainless steel. The instrument is rubbed on the skin at an angle of about 30 degrees, creating a massage-like effect on the soft tissue (2 sessions per week and 5 minutes per session, 8 sessions in total for 4 weeks).
40987253|NCT04803669|PROCEDURE|Conventional Treatment|Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.
41145315|NCT02884622|OTHER|nasal epithelial|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
40782732|NCT04556344|BEHAVIORAL|Emotional skills|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
40987254|NCT04778189|DRUG|Placebo|while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes, after spinal anesthesia
41145316|NCT02884622|OTHER|Blood sampling|CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
40987255|NCT04778189|DRUG|i.v dexmethasone|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia
40987256|NCT00560950|BIOLOGICAL|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
40987257|NCT03755986|DEVICE|ATOMO Diagnostic Test|The ATOMO diagnostic test device is the only intervention used in this study.
40987258|NCT04699409|OTHER|stroke educational campaign: FAST|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
41145317|NCT03563170|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
41145318|NCT03563170|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins
40987259|NCT04699409|OTHER|stroke educational campaign: STROKE 112|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
40987260|NCT05162547|DEVICE|NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay|The NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay (IUO) is a multiplexed, in vitro real-time Polymerase Chain Reaction assay, diagnostic test intended for the simultaneous qualitative detection and differentiation of Influenza A virus (Flu A), Influenza B virus (Flu B), Respiratory Syncytial Virus (RSV) and SARS-CoV-2 RNA
40987261|NCT04156776|OTHER|Muscle Energy Technique|Muscle energy technique was repeated 4 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.
40987262|NCT04156776|OTHER|Active Isolated Stretching|"The patient was asked to sit in an upright seated position and flex his/her knees 12 to 18 inches. Patient was asked to tuck the chin, exhale, and firmly contract the abdominal muscles as he/she curls their body forward. He/she was also guided not to bounce or make rapid movements at the end range of the active motion. Then, he was asked to move back to the starting position and repeat the same procedure for 8 to 10 times. Stretch on the end range was not more than 2 seconds.~This technique was repeated 10 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session."
40987263|NCT04156776|OTHER|Conventional Treatment|Conventional physical therapy treatment includes the application of moist heating pad for 30 minutes on lower back/ lumbar region prior to the intervention to both groups.
40987264|NCT02382679|DIETARY_SUPPLEMENT|Experimental: Vitamin Mixture|Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
40987265|NCT02382679|DIETARY_SUPPLEMENT|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
40987266|NCT01909596|DEVICE|Neutral customized foot orthoses|Foot orthoses with arch support and without lateral inclination
40987267|NCT01909596|DEVICE|6° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 6°
40987268|NCT01909596|DEVICE|10° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 10°
40987269|NCT02461355|BEHAVIORAL|Aphasia therapy|Aphasia therapy using a computerized scripting program
41145319|NCT03563170|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
41145320|NCT03563170|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
41145321|NCT03563170|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
41145322|NCT03563170|DRUG|Cyclophosphamide|anhydrous
40782733|NCT04556344|BEHAVIORAL|Short free talk and relaxation|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
40987270|NCT02461355|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
40987271|NCT02461355|DEVICE|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
40987272|NCT03873389|DRUG|Ocrelizumab|Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
40987273|NCT01864447|BEHAVIORAL|VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)|
40987274|NCT03438812|DIETARY_SUPPLEMENT|dehydroepiandrosterone (DHEA)|Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.
40987275|NCT00445159|DRUG|UT-15C SR (treprostinil diethanolamine) 1mg oral tablets|
40987276|NCT04935112|DRUG|Sitravatinib|100 mg sitravatinib on Day 1
40987277|NCT04935112|DRUG|Pantoprazole|40 mg QD on Day 1 to Day 7 of Period 2 in Group 1
40987278|NCT04935112|DRUG|Famotidine|40 mg PO 2 hrs after sitravatinib in Period 2 of Group 2
40987279|NCT04460820|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2,IV on Day 1 of each cycle
40987280|NCT05742438|DRUG|Lidocaine IV|Continuous intravenous infusion of lidocaine
41145323|NCT03563170|DRUG|5-Fluorouracil|5-FU; Fluorouracil
41145324|NCT03563170|DRUG|Leucovorin|Leucovorin calcium salt
41145325|NCT03563170|DRUG|nab-Paclitaxel|ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
41145326|NCT03563170|DRUG|Sorafenib|NEXAVAR® tablets, for oral use
41145327|NCT03563170|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
41145328|NCT03563170|BIOLOGICAL|Aldoxorubicin hydrochloride|HCl
41145329|NCT03563170|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
41145330|NCT03563170|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
41145331|NCT03563170|BIOLOGICAL|GI-6207|CEA yeast vaccine
41145332|NCT03563170|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
41145333|NCT03563170|DRUG|Cetuximab|ERBITUX® injection, for IV infusion)
41145334|NCT03563170|BIOLOGICAL|N-803|Recombinant human super agonist IL-15 complex \[also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex\]
41145335|NCT02518802|DRUG|Gefitinib|Gefitinib 250mg per day for 2 years.
41145336|NCT02518802|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
40987281|NCT05742438|DRUG|Dexmedetomidine IV|Continuous intravenous infusion of dexmedetomidine
40782734|NCT02160288|DRUG|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
40782735|NCT02160288|DRUG|Normal Saline|Dispensed in a 5 cc syringe
40987282|NCT05742438|DRUG|intrathecal morphine|intrathecal morphine injection
40987283|NCT03343808|PROCEDURE|cooled radiofrequency ablation of genicular nerves|Cooled RF consists of creating an injury in the nerve trough a high frequency flow. Unlike conventional RF, in cooled RF through a closed circuit where intravenous flows, we can create an injury for a longer period of time, at a lower temperature (standard RFA 90º C, cooled RFA 60º C) and within an area 8 times larger. As the lesion is spherical, and larger (about 10-12 mm in diameter), the chances of neurolysis of the nerve increase.
40987284|NCT06442514|BEHAVIORAL|PASS-IVR|An intervention that includes a proactive telehealth intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain, and nightly Interactive Voice Response (IVR) calls to report smoking status, pain, and pedometer-measured step counts, which the clinician will use to provide individualized feedback.
40987285|NCT06442514|OTHER|Treatment as Usual|Referral to the local smoking cessation VA clinic.
40987286|NCT01622699|DEVICE|Transcutaneous Bilirubinometer|If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.
40987287|NCT01622699|OTHER|visual assessment of neonatal jaundice|To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
40987288|NCT00999557|DRUG|bimatoprost ophthalmic solution|Applied topically
40987289|NCT00999557|DRUG|placebo|Applied topically
40987290|NCT05705986|OTHER|Blood Draw|Single blood draw
40987291|NCT01428453|DRUG|250mg rilapladib|Experimental Drug
40987292|NCT01428453|DRUG|placebo|Placebo comparator
40987293|NCT00656409|DRUG|Conjugated pneumococcal vaccine (Prevenar)|
40987294|NCT05138575|DRUG|Empagliflozin + Potassium Chloride|"Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control."
40987295|NCT05138575|DRUG|Empagliflozin + Potassium Nitrate|Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.
41464459|NCT01195220|BEHAVIORAL|STI/HIV-Plus|This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
40987296|NCT05138575|DRUG|Potassium Chloride + Placebo for Empagliflozin|Active control.
40782736|NCT02781441|BEHAVIORAL|Question prompt list (QPL)|
40782737|NCT02781441|BEHAVIORAL|Education brochure of Groupe Français des Myélodysplasies|
40782738|NCT00546481|DRUG|methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]|0.6 micrograms/kg every 2 weeks
40782739|NCT00546481|DRUG|Epoetin|As prescribed, iv, 3 times weekly
40782740|NCT05489471|OTHER|Artificial intelligence review|The AI looks for ten different abnormalities on each chest X-ray and produces a heat map and percentage confidence score if it detects an abnormality.
40782741|NCT02091076|DEVICE|Silk fibroin with bioactive coating layer dressing|
40782742|NCT02091076|DEVICE|Bactigras wound dressing|
40782743|NCT03294005|DIAGNOSTIC_TEST|Thyroid ultrasonography|Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients.
40987297|NCT06430203|BEHAVIORAL|Peer mentoring|Indigenous young adult peer mentors who will develop and deliver the program based on needs and wants of our participants. The program will be built on their experience and ideas. They will be empowered to guide the program in the direction they see best for their communities.
40987298|NCT02968563|DRUG|Tirabrutinib|Tablets administered orally
40987299|NCT02968563|DRUG|Idelalisib|Tablets administered orally
40987300|NCT02968563|DRUG|Obinutuzumab|Administered intravenously
41145337|NCT04977089|DIAGNOSTIC_TEST|lipid profile test .|Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
41464460|NCT01908205|DRUG|Intranasal Oxytocin|
41464461|NCT01908205|DRUG|Placebo|
40782744|NCT05809089|DEVICE|High flow nasal cannula (HFNC)|"High-flow nasal cannula device was utilized. Humidifier temperature was set at 37°C via large-bore bi-nasal prongs, and inspired oxygen (FiO2) was adjusted to maintain oxygen saturation by pulse oximetry (SpO2) ≥ 90%.The flow was initially set at 10 L/min and titrated upward in 5 L/min steps until patients experienced discomfort.~Patient will be evaluated every 8 hours and discontinued the device for eating, drinking and coughing up secretion and returned back to the device for 72 hours."
40782745|NCT05809089|DEVICE|Noninvasive ventilation (NIV)|Patients initiated NIV; Inspiratory positive airway pressure (IPAP) was initiated at 10-12 cmH2O, and expiratory positive airway pressure (EPAP) started at 4-5 cmH2O. FIO2 was adjusted to maintain SpO2 ≥ 90%. The same protocol as done in HFNC, patient will be evaluated every 8 hours and discontinued the device and returned back to the device for re- evaluation within 72 hours
40782746|NCT03007771|DEVICE|Magnetic Resonance-guided High-Intensity Focused Ultrasound|-Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
40782747|NCT04201639|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
40987301|NCT04804943|DEVICE|NOA-001|NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
40782748|NCT03767881|DEVICE|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
40782749|NCT00001034|DRUG|Ganciclovir|
40782750|NCT05152511|COMBINATION_PRODUCT|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy is a specially designed cabinet for infants and neonates with a barometric pressure equal to 760 mmHg for 20 minutes daily, then gradually increase up to one hour daily for 5 days per week (fig. 1). The chamber was kept warm. The babies were fed before entering the chamber and if signs of hunger appear during therapy. The baby was continuously monitored with pulse oximeter. Older children are managed in the conventional Hyperbaric oxygen chamber with the same regimen.
40782751|NCT01041261|DIETARY_SUPPLEMENT|BariatrX Essentials 360 Treatment|Medical food
40782752|NCT01468480|DRUG|Pro Root MTA|application of MTA in second group and 24 hour interval before restoration
40987302|NCT02494427|DEVICE|CAD/CAM manufactured fixed unitary dental prostheses|
40987303|NCT02494427|DEVICE|Conventionally manufactured unitary dental prostheses|
40987304|NCT03720496|BIOLOGICAL|CD19-TriCAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.1-1 x 10\^6 CAR+ T cells/kg body weight.
40987305|NCT00271089|PROCEDURE|PBSC Collection|
40987306|NCT00271089|PROCEDURE|Bone Marrow Harvest|
40987307|NCT00271089|DEVICE|CliniMacs Cell Selection System|
40782753|NCT01468480|DRUG|Pro Root MTA- single visit|application of MTA in third group and 15 minute interval before restoration
40782754|NCT01468480|DRUG|MultiCal|application of Multical in forth group as a pulp dressing agent
40782755|NCT01468480|DRUG|Dycal|application of Dycal in first group as a pulp dressing agent
40782756|NCT04655157|DRUG|encorafenib|A small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.
40782757|NCT04655157|DRUG|nivolumab|A programmed death receptor-1 (PD-1) blocking monoclonal antibody that works by helping the immune system to slow or stop the growth of cancer cells.
40782758|NCT04655157|DRUG|ipilimumab|A monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
40987308|NCT00441844|DRUG|Simvastatin|
41145338|NCT05681390|DRUG|Tislelizumab|Tislelizumab 200mg iv drip, d1, Q3W;Anlotinib tablet : 10mg, PO, QD; Chemotherapy: selected by investigator following CSCO or NCCN pancreatic adenocarcinoma guideline; Tislelizumab and Anlotinib continue unless disease progression or intolerance to toxicity, chemotherapy continue upto 8 cycles unless disease progression or intolerance to toxicity
40782759|NCT04655157|DRUG|binimetinib|A small molecule, selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
40782760|NCT02196532|DEVICE|Device: Optical coherence tomography|
40782761|NCT01115907|DEVICE|Freedom SOLO Stentless Heart Valve|Freedom SOLO Stentless Heart Valve
40782762|NCT03842735|OTHER|exercise and rehabilitation counselling|The intervention consists in a standardized physical exercise (PE) and rehabilitation counselling indications (RCI). PE is done 5 days/week (2 days in autonomy by the patient with parents support and 3 days supervised). Each session lasts 30 minutes and this is supervised by one therapist for all patients. Patients are enrolled in an EP composed by three different types of exercises, each carried out for 10 minutes per session: muscle strength exercises for upper and lower extremities preceded by warming up, aerobic exercises and stretching. The kind of exercise is differentiated by age range (children, 5-12 years and adolescents, 13-18 years).
40987309|NCT01039233|DRUG|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
41464462|NCT01370239|BIOLOGICAL|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
41464463|NCT04604210|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.
40987310|NCT01646515|DRUG|Placebo|"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"
40987311|NCT01646515|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
40987312|NCT00003901|OTHER|immunohistochemistry staining method|
40987313|NCT00003901|PROCEDURE|biopsy|
40987314|NCT00003901|PROCEDURE|surgery|
40987315|NCT02539277|DRUG|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
40987316|NCT02539277|DRUG|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
40987317|NCT02539277|DRUG|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
40987318|NCT02539277|DRUG|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
40987319|NCT04672447|DIETARY_SUPPLEMENT|L-Citrulline|Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
40987320|NCT04672447|DIETARY_SUPPLEMENT|L-Citrulline|Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
40987321|NCT04672447|DIETARY_SUPPLEMENT|Placebo|Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
40987322|NCT04672447|DIETARY_SUPPLEMENT|Glutathione|Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
40987323|NCT02002364|PROCEDURE|tracheal intubation|
40987324|NCT01275833|DEVICE|Cardiac resynchronization therapy-defibrillator|Device programming that modifies AV timing
40987325|NCT00009854|DRUG|carmustine in ethanol|
40987326|NCT00009854|PROCEDURE|conventional surgery|
40987327|NCT01466348|DRUG|Paracetamol and Caffeine|Paracetamol 1000 mg and caffeine 130 mg
40987328|NCT01466348|DRUG|Paracetamol|Paracetamol 1000 mg
40987329|NCT01107587|BIOLOGICAL|GSK Biologicals' human rotavirus vaccine 444563|Oral, two doses.
41305820|NCT05390450|DEVICE|Ultrasound-Guided Fascia Iliaca block|Patients will be placed in a supine position, and the skin will be cleaned aseptically. The inguinal ligament from the anterior superior iliac spine to the pubic tubercle will be drawn on the skin and divided into 3 parts. The injection point was 1 cm caudally from the point where the lateral and middle part of the inguinal ligament met. The skin and deep tissues were infiltrated with 1% lidocaine. A 18G nerve block needle will be inserted into the skin perpendicularly until the first (fascia lata) and second loss of resistance (fascia iliaca) will be felt. Following aspiration to exclude intravascular injection, 40 mL of 0.25% bupivacaine (1-1.5 mg/kg), which will be prepared under aseptic conditions, and then injected. Sensorial block will be evaluated using the pinprick test 20 minutes after injection for areas of the thigh innervated by the femoral, lateral cutaneous and obturator nerves.
41464464|NCT00380588|DRUG|gemcitabine|1000 milligrams per square meter (mg/m2), intravenous (IV)
40987330|NCT01107587|BIOLOGICAL|Placebo|Oral, two doses.
40987331|NCT06036342|DIAGNOSTIC_TEST|MobiCARE test|7-days continuous electrocardiography monitoring using MobiCARE device
40987332|NCT02081144|OTHER|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of \~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
40987333|NCT02081144|DRUG|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
41305821|NCT04261634|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
41305822|NCT04261634|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
40987334|NCT02081144|DRUG|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
40987335|NCT02081144|BEHAVIORAL|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
40987336|NCT05503147|DRUG|Sativex|Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
40987337|NCT03362073|DRUG|Ketamine|"Application of ketamine using continuous intravenous infusion method during 5 days~* Ketamine 100mg/2ml + 5% Dextrose water or Normal saline 98 ml mixed fluid~* Dose schedule: 0.05mg/kg/hr -\> 0.10mg/kg/hr -\> ... -\> 0.5mg/kg/hr (increase dose at a rate of 0.05mg/kg/hr every 8 hours)"
41464465|NCT00380588|DRUG|cisplatin|25 milligrams per square meter (mg/m2), intravenous (IV)
41464466|NCT02583308|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
41464467|NCT02583308|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
40987338|NCT06057792|DEVICE|negative pulsed pressure AeroFlow system|"For the application of pulsatile negative pressure, the AeroFlow® equipment will be used, carried out by one of the researchers participating in the project.The application will be carried out addressing the structure of interest (scar), following the protocol established by INDIBA to release adhesions between the different depth planes. The work will consist of an application of pulsed negative pressure using suction cups, which will work automatically at a frequency and intensity tolerable by the patient.~Treatment protocol in 2 phases Total application time 15min~1. Static cup: preparation: Prepare the tissue surrounding the scar. 5min~2. Dynamic Cup: work: Lock the tissue around the scar and the scar itself.10min Suction mode: continuous with continuous sliding of the cup The number of treatment sessions will consist of a total of 6 sessions, so there will be two sessions over 3 weeks."
40987339|NCT02881242|OTHER|Laboratory Biomarker Analysis|Correlative studies
40987340|NCT02881242|OTHER|Quality-of-Life Assessment|Ancillary studies
40987341|NCT02881242|DRUG|Trametinib|Given PO
40987342|NCT05560997|DIAGNOSTIC_TEST|10-year ASCVD risk estimation|High CVD risk was defined as a history of CVD or a 10-year ASCVD risk ≥10%. The 10-year ASCVD risk estimation was carried out according to 2016 Chinese guidelines for the management of dyslipidemia in adults.
40987343|NCT04089059|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)"
40987344|NCT01685996|DRUG|zonisamide|In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
40987345|NCT01685996|DRUG|placebo|
40987346|NCT04759703|DRUG|Pramipexole|0.25 mg pramipexole tablets
40987347|NCT04759703|DRUG|Placebo|Matching placebo tablets
40987348|NCT06105151|DRUG|VV119(SAD)|VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;
40987349|NCT06105151|DRUG|VV119 Placebo(SAD)|VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 3 mg Group:2 subjects will receive VV119 Placebo 3 mg, orally; VV119 4.5 mg Group:2 subjects will receive VV119 Placebo 4.5 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;
40987350|NCT06105151|DRUG|VV119(FE)|A：4 mg VV119, following an overnight fast of at least 10 hours for Period 1; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 2; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 3; B: 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1; 4 mg VV119, following an overnight fast of at least 10 hours for Period 2; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 3; C: 4mg VV119, administered 30 minutes after the start of a standard meal for Period 1; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2;4 mg VV119, following an overnight fast of at least 10 hours for Period 3.
40987351|NCT05483855|OTHER|Objective 1 Only: Telehealth Satisfaction Survey|Participants must complete a telehealth satisfaction survey rating their standard of care telehealth visit on a scale of 1 to 10, with 1 denoting low satisfaction and 10 denoting high satisfaction.
40987352|NCT05483855|OTHER|Objective 2 Only: ArthritisPower Joint Assessment|RA patients must complete a self-assessment examination of their joints using the ArthritisPower app prior to their in-office visit, where a repeat joint assessment is performed by participating physician.
41145339|NCT05982756|DRUG|DAG pre-excitation regimen with Bortezomib|Bortezomib+DAG pre-excitation regimen: Bortezomib (specification 3.5mg, intravenous injection, 4 times a course of treatment, 1.3mg/m2, d1, 4, 8, 11; doxorubicin liposome injection 5 mg/ m2, intravenous infusion, once every other day, 5 times in total; cytarabine 10 mg/m2 every 12 hours, subcutaneous injection, d1-14; G-CSF 200 μg/m2 daily, subcutaneous injection, d1-14 Days, WBC \>10×109/L during chemotherapy, postpone the use until it falls below this value;
41145340|NCT05029271|DEVICE|InPen with Guardian 4 System|Subjects will receive the InPen™ and InPen™ Diabetes Management App combined with the Guardian™ 4 system.
41305823|NCT03445052|BEHAVIORAL|XPAND|The intervention is personalised to the psychosocial factors influencing poor photoprotection for each person. These factors could include beliefs that reduce motivation to protect as well as factors that prevent intentions being translated into action. The facilitator will use behaviour change techniques to target the factor most important for each person. Standardised content related to habit formation will be received. The intervention will be delivered via 7 1:1 sessions with a facilitator (psychologists or clinical nurse specialist). Sessions 1 (1.5 hours maximum) and 6 (45 minutes) will be delivered face to face in the home of the participant and the remaining sessions will be conducted via telephone calls or skype sessions.
40782763|NCT03842735|BEHAVIORAL|rehabilitation counselling|RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
40782764|NCT04017130|DRUG|MT-0169|MT-0169 intravenous infusion.
40782765|NCT04681144|DRUG|Radium-223-dichloride (Xofigo, BAY88-8223)|Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice
40782766|NCT03199183|RADIATION|PET-CT|PET-CT will be proceed on the basis of clinical status and aspiration of individual patient. The imaging results will be analysed by professional radiologists.
40782767|NCT03199183|OTHER|laboratory biomarker analysis|Screening of potential biomarkers related to Takayasu arteritis and verification tests will be operated.
40782768|NCT03199183|GENETIC|genetic sequencing|Genetic sequencing results will be analysed to identify susceptible alleles or single nucleotide polymorphisms of Takayasu arteritis.
40782769|NCT03997032|DIETARY_SUPPLEMENT|Ocufolin|Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
40782770|NCT03225482|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training|ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
40782771|NCT03225482|BEHAVIORAL|Goal-focused Supportive Contact|SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
40782772|NCT02286895|BIOLOGICAL|pentavalent rotavirus vaccine (PRV)|Each two-ml dose contains 5 live human-bovine reassortant rotaviruses with a minimum of 2.0 - 2.8 x 106 infectious units (IU) per reassortant, depending on the serotype, and not greater than 116 x 106 IU per aggregate dose. Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq contains no preservatives. RotaTeq is a pale yellow clear liquid that may have a pink tint. This vaccine was administered orally.
40782773|NCT02286895|BIOLOGICAL|measles vaccine (MV)|A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
40987353|NCT06199102|DIETARY_SUPPLEMENT|cholecalciferol/ Devikap|Infants in the monitored group will receive an initial dose of 1000 IU of vit D. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). At 28±2 days of age, blood samples will be obtained for 25(OH)D concentration measurement, followed by measurements every 4 weeks and/or 35±1 weeks of PCA. In the monitored group, vit D doses will be appropriately modified, based on 25(OH)D levels, using the scheme described in the Polish recommendation. The intake from the diet will be calculated from the second month of life.
41305824|NCT02800564|BEHAVIORAL|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
41305825|NCT02800564|BEHAVIORAL|Passive mass media approach|These communities will be exposed to twice weekly radio programming for up to 18 months only.
41305826|NCT02537301|OTHER|joining in the platform|The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
41305830|NCT04076150|DEVICE|Transcatheter Aortic Valve (TAV) Implantation With The Optimum TAV System|Treating patients with severe symptomatic aortic stenosis via transcatheter aortic valve implantation by implanting the Optimum TAV inside the native diseased valve via a the Precision Catheter. The Optimum TAV and Precision Catheter together are the Optimum TAV System.
41305831|NCT04829383|DRUG|Atezolizumab|1,200 mg
41305832|NCT04829383|DRUG|Bevacizumab|15 mg/kg
41464468|NCT05191511|RADIATION|Far- infrared|safety of far- infrared
40782774|NCT02286895|BIOLOGICAL|yellow fever vaccine (YFV)|A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
40987354|NCT06199102|DIETARY_SUPPLEMENT|cholecalciferol/ Devikap|Infants in the controlled group will receive 250 IU for very low birth weight infants and 500 IU for infants weighing above 1000 g. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). Infants assigned to the standard therapy group will undergo the same blood sample collection procedure as the monitored group, but without any alterations in their dosing regimen.
40782775|NCT02286895|BIOLOGICAL|meningitis conjugate vaccine (PsA-TT-5μg)|A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
40987355|NCT03229824|DEVICE|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
40987356|NCT04023448|PROCEDURE|transverse coloplasty pouch|a transverse coloplasty pouch was performed before end to end colon-rectum (or anal canal) anastomosis
40987357|NCT02551731|DRUG|Cannabidiol Oral Solution|20 or 40 mg/kg/day BID
40987358|NCT06226233|OTHER|Juniver program|The Juniver program is a self-help intervention for eating disorders delivered digitally, through an iPhone app. It features three components: an evidence-based curriculum, interactive tools, and moderated peer support groups.
40987359|NCT05225142|PROCEDURE|Modified minimally invasive surgery|Surgical intervention alone
40987360|NCT05225142|PROCEDURE|Modified minimally invasive surgery with enamel matrix derivative|Surgical intervention with local application of regenerative biomaterial
40987361|NCT05225142|PROCEDURE|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Surgical intervention with local application of regenerative biomaterial and bone replacement graft
40987362|NCT04896320|DRUG|Tucatinib|Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
40987363|NCT02418923|OTHER|Procedure: Blood specimen collection|Blood specimen collection
40987364|NCT05931679|DEVICE|VR Headset|A VR headset will be used for participants in the Interactive VR and 360 degree video groups.
41145341|NCT05959837|OTHER|Adaptive Rowing Exercise|Participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity.
41145342|NCT03597997|DRUG|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%.
41305833|NCT04746612|DRUG|HH30134|HH30134 administered orally on a continuous once daily(QD) in patients with advanced solid tumors
41305834|NCT00932152|DRUG|fulvestrant (Faslodex)|Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
41305835|NCT00932152|DRUG|anastrozole (Arimidex)|Anastrozole (Arimidex) 1 mg orally QD
41305836|NCT00932152|DRUG|Bevacizumab (Avastin)|Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
40987365|NCT05931679|OTHER|Traditional Theatre-based simulation|Traditional theatre-based simulation sessions require the physical presence of interdisciplinary groups of learners caring for a physical mannequin-based patient, where social distancing is challenging.
40987366|NCT01948128|DRUG|Vitamin D3|Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.
40987367|NCT01948128|OTHER|Placebo|Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
40987368|NCT02141282|DRUG|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.
40987369|NCT00103181|RADIATION|3-dimensional conformal accelerated partial breast irradiation|
40987370|NCT00103181|RADIATION|brachytherapy|
40987371|NCT00103181|RADIATION|whole breast irradiation|Patients undergo radiation therapy once daily (days 1-5) for up to 7 weeks
40987372|NCT00103181|RADIATION|MammoSite or other single-entry intracavitary device|
40987373|NCT01881230|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
40782776|NCT03186768|BEHAVIORAL|Soap on a rope hall pass intervention|School health and nutrition coordinators will be trained on how to make and utilize the soap on a rope hall pass to improve hand washing behavior in schools.
40987374|NCT01881230|DRUG|Carboplatin|Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
40987375|NCT01881230|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
41145343|NCT03597997|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
41145344|NCT00604344|DRUG|insulin detemir|
41145345|NCT00604344|DRUG|insulin NPH|
41145346|NCT03639194|DRUG|ABBV-011|Intravenous
41145347|NCT03639194|DRUG|Budigalimab|Intravenous
41145348|NCT00729170|DIETARY_SUPPLEMENT|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
41145349|NCT05256355|OTHER|musculoskeletal ultrasound|The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.
41145350|NCT05408156|OTHER|Insoles|semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)
41145351|NCT03873038|DRUG|MK-2060|"Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22."
41145352|NCT03873038|DRUG|Placebo|Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
41145353|NCT01236144|DRUG|Plerixafor|Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1\&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.
41145354|NCT01236144|DRUG|AC220|Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1\&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.
41145355|NCT01236144|DRUG|Ganetespib|Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
41145356|NCT00782353|DRUG|ANA598 200 mg bid or placebo|ANA598 200 mg bid or placebo
41145357|NCT00782353|DRUG|ANA598 400 mg bid or placebo|ANA598 400 mg bid or placebo
41145358|NCT00782353|DRUG|ANA598 800 mg bid or placebo|ANA598 800 mg bid or placebo
41145359|NCT03062488|DRUG|IV acetaminophen|multi-modal analgesia with IV acetaminophen
41464469|NCT03092596|BEHAVIORAL|Patient-administered screening tool|screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST
40782777|NCT04104347|OTHER|Metacognitive training (MCT)|Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz \& Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.
40987376|NCT02432846|BIOLOGICAL|Intuvax (INN: ilixadencel)|Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.
40987377|NCT02432846|DRUG|Sunitinib|Cytostatic/cytotoxic drug: protein kinase inhibitor .
40987378|NCT02959047|DRUG|Alirocumab|150mg SQ every 2 weeks
40987379|NCT02959047|DRUG|Matching placebo|SQ every 2 weeks
41145360|NCT03062488|DRUG|Fentanyl|single modal analgesia
41464470|NCT03092596|BEHAVIORAL|Patient health navigator-administered screening tool|patient health navigator-administered screener
40987380|NCT01166763|DRUG|vitamin D3|oral capsules, 10,000 IU per week for 6 months
40987381|NCT05233618|DRUG|Tagraxofusp|inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
41145361|NCT03062488|DRUG|PO acetaminophen|multi-modal analgesia with PO acetaminophen
41145362|NCT01017055|OTHER|Voice and Swallowing evaluations|Fiberoptic exam to evaluate vocal cord and swallowing function
41145363|NCT04182451|DEVICE|Meso Wound Matrix|"Subjects who meet eligibility criteria will receive standard of care and Meso Wound Matrix.~The standard of care therapy in this study is offloading of the DFU, appropriate sharp or surgical debridement, and aggressive infection management with the use of appropriate dressings. Total contact casting or fixed ankle walker will be used for off-loading. Wound Matrix is an acellular scaffold to reinforce and repair soft tissue defects. Subjects may receive up to eight applications of Meso Wound Matrix. Subjects whose study ulcer does not heal after eight applications will receive only SOC treatment for 4 additional weeks."
41145364|NCT06277011|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
41145365|NCT01234025|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
41464471|NCT03092596|BEHAVIORAL|Patient health navigator-assisted linkage to treatment|patient health navigator-assisted linkage to substance abuse treatment
40782778|NCT04104347|OTHER|Support group|Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
40987382|NCT00575913|DRUG|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
40987383|NCT06135233|OTHER|No intervention|all patients undergoing minimally invasive pancreatic surgery, no intervention, no randomization
40987384|NCT01874847|DIETARY_SUPPLEMENT|Melatonin|Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
40987385|NCT01874847|DIETARY_SUPPLEMENT|Sugar pill|Sugar pill will be given, one capsule, once at night, for 28 days
41145366|NCT01234025|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
41145367|NCT01234025|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
41145368|NCT01234025|DRUG|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
41145369|NCT01234025|DRUG|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
41145370|NCT01204775|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
41145371|NCT01204775|DRUG|Placebo (Saxagliptin)|Tablets, Oral, Once daily, 1-16 weeks
41145372|NCT01204775|DRUG|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
41145373|NCT01204775|DRUG|Placebo (Metformin)|Tablets, Oral, Once daily, 1-16 weeks
41145374|NCT01204775|DRUG|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
41464472|NCT01483625|DRUG|tiotropium|18mcg
41464473|NCT01483625|DRUG|Placebo|placebo
41464474|NCT04201028|BEHAVIORAL|Video Conferencing Health Coaching with devices|Devices
41464475|NCT04201028|BEHAVIORAL|Video Conferencing Health Coaching with no devices|No Devices
41464476|NCT04987749|DEVICE|intermittent theta burst stimulation|stimulatory protocol
41464477|NCT06223633|DEVICE|PK Papyrus Covered Coronary Stent System|PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
40782779|NCT00686673|BEHAVIORAL|Providing tailored message on disclosing terminal illness|an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
41145375|NCT05749315|OTHER|Play Based Therapy|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
40782780|NCT00686673|BEHAVIORAL|Providing non-tailored message on pain control|an attention control group that receives non-tailored video and manual on pain control
40782781|NCT06194305|OTHER|CBIT|Participants will receive 8 sessions delivered weekly over 10 weeks. All sessions will be video recorded. CBIT components are: 1) Psychoeducation about tics, 2) Functional interventions, 3) Competing response (CR) training, 4) Social support: supportive people (e.g., parent, teacher) , 5) Motivational enhancements, 6) Homework: is assigned each session and typically involves self-monitoring and CR practice. Participants will complete a brief daily homework tracking log in REDCap.
40782782|NCT05385211|OTHER|Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency|Blood samplings; Glucose monitoring; CFTR variants
40782783|NCT04409834|DRUG|Unfractionated Heparin IV|Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an aPTT of 1.5-2.5 times the control as per institutional therapeutic target for treatment of VTE
40782784|NCT04409834|DRUG|Enoxaparin 1 mg/kg|Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours
40782785|NCT04409834|DRUG|Clopidogrel|Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days
40782786|NCT04409834|DRUG|Unfractionated heparin SC|Heparin 5,000 units administered subcutaneous three times daily
40782787|NCT04409834|DRUG|Enoxaparin 40 mg SC|Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl\<30 ml/min)
40782788|NCT05480007|DRUG|sitagliptin and metformin|sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)
40782789|NCT05480007|DRUG|Sitagliptin|sitagliptin treatment (100mg per day)
40782790|NCT05480007|DRUG|Metformin|metformin group who received metformin (500mg three times per day)
40782791|NCT06545032|PROCEDURE|lumbar fusion|Minimal Invasive Transforaminal Lumbar Interbody Fusion
40782792|NCT01453166|OTHER|Brazilian heart-prevent meal|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
41145376|NCT05749315|OTHER|Functional Communication Training|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
41145377|NCT04807452|OTHER|Strength and balance training|Passive ROM to possible level of knee (flexion and extension), ankle (dorsiflexion and plantar flexion), forefoot (inversion and eversion) and toe (flexion and extension, adduction and abduction) joints.Resisted flexion and extension of knee, dorsiflexion and planter flexion of ankle, inversion and eversion of foot, flexion/extension, and abduction/adduction of toe with help of thera-band.The exercise prescription for strength training was made at approximately 50% of the estimated 1-RM. Exercise progression was achieved by instructing participants to increase the weight lifted in a specific exercise when they could perform 2 sets of 10-12 repetitions without maximal exertion on 2 consecutive training days. On basis of Borg Rating of Perceived Exertion of 10 to 13.Tandem leg stance for first 2 weeks and then it was progressed to Single leg stance toe and heel stance.For dynamic balance:backward walk Tandem walk and sideways walk.
41145378|NCT04807452|OTHER|Aerobics training|"After the baseline assessment, the participant in the Group B received Aerobic exercise with routine medical care.~All patients were followed for 3 days a week for 8 weeks treatment. Control Group received aerobic training. Control group received stretching exercise for 10 minutes and then treadmill walk for 10 minutes and then stationary bicycle for 10 minutes, and steppers for 10 minutes and 5 minute cool down ."
41145379|NCT06091709|OTHER|Multimodal Exercises and Education delivered through tele rehabilitation|Participants will follow the MEET-R that will include stretching, strengthening and core stabilization exercises, and education material pertaining to the proper posture during work.
41145380|NCT06091709|OTHER|Selafcare|The control group is allowed to opt for self-care management of back pain in the form of medications, rest, conventional physiotherapy, and a home exercise plan. They are also allowed to change their self-care management during the study period; information about the use of the alternative management will be recorded. The information on self-care management will be gathered after 6 weeks at the end of the intervention
41145381|NCT03735368|DRUG|Dexmedetomidine Injection|Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion
41145382|NCT03735368|DRUG|Placebo oral capsule|placebo oral capsules
40782793|NCT01453166|OTHER|Heart prevent control meal weekly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
40782794|NCT01453166|OTHER|Heart prevent control Meal monthly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
40987386|NCT06214650|OTHER|Radiofrequency|"Experimental group will receive the common exercise program associated with a radiofrequency treatment using INDIBA® (INDIBA Activ 7, Barcelona, INDIBA S.A.) at a frequency of 448 hertz. It will use the capacitive electrode as a method of preparation and vascularization of the superficial tissues and immediately, within the same session, the resistive electrode to stimulate deep tissues. This treatment is based on the protocols established by INDIBA® S.A.~It will consist of one weekly diathermy session of thirty minutes during ten weeks. The use of diathermy will not be interrupted throughout the session.~The common exercise program consist in a ten abdominal exercises (including recti abdominis, transversus and obliques). It will practised at home only just three days at week."
40987387|NCT06214650|OTHER|Control|Control group will receive a weekly INDIBA® session in the abdominal area with the same protocol as the experimental group in athermic mode (placebo treatment) and the common exercise program. The session will last thirty minutes and will be carried out by the research physiotherapist during ten weeks.
40987388|NCT02393547|DRUG|Varenicline|All subjects receive Varenicline
40987389|NCT02393547|DRUG|Lorcaserin|All subjects receive Lorcaserin
40987390|NCT00955942|DIETARY_SUPPLEMENT|flaxseed|Given orally
40987391|NCT00955942|OTHER|placebo|Given orally
40987392|NCT00003573|BIOLOGICAL|filgrastim|
40987393|NCT00003573|DRUG|cisplatin|
40987394|NCT00003573|DRUG|cyclophosphamide|
40987395|NCT00003573|DRUG|etoposide|
40782795|NCT01855386|OTHER|Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
40782796|NCT01855386|OTHER|Controls without Gestational Diabetes|Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
40782797|NCT01709357|OTHER|Muscle energy technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.
40782798|NCT01709357|OTHER|Passive stretching technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.
40782799|NCT01709357|OTHER|Ischemic compression technique|"The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was moderate but bearable, a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to no pain and 10 do unbearable pain). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds."
40782800|NCT01709357|OTHER|Sham technique|The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
40782801|NCT03563092|PROCEDURE|Laparoscopic Inguinal Hernia (TEP/TAPP) Surgery|Standardized minimally invasive approach to inguinal hernia repair
40987396|NCT00003573|DRUG|vincristine sulfate|
40782802|NCT00220506|DRUG|Provigil|
40782803|NCT03388372|BIOLOGICAL|Nimotuzumab|Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times.
40987397|NCT00003573|RADIATION|radiation therapy|
40987398|NCT06084546|DEVICE|geko™ X-W3|The geko™ X-W3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ W3 device and the new geko™ XW-3 device is the adhesive used to attach each device to the skin.
40987399|NCT04256785|DIETARY_SUPPLEMENT|VSL#3|sachets containing probiotic
40987400|NCT04256785|DIETARY_SUPPLEMENT|Placebo|sachets containing placebo
40987401|NCT02391103|DEVICE|Compex 3 Professional (CefarCompex Medical AB) stimulator|NMES
40987402|NCT02391103|DEVICE|sham-stimulation|no electricity applied
41145383|NCT03735368|DRUG|Pregabalin Oral Capsule|150 mg pregabalin Oral Capsule
41145384|NCT03735368|DRUG|topical anesthesia|topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops
41464478|NCT02070549|DRUG|Trametinib|Given PO
41464479|NCT02381197|DEVICE|Congo Red Dot test|The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
41464480|NCT01104571|BIOLOGICAL|trastuzumab|Trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery
40987403|NCT02409459|DRUG|Injectafer|
40987404|NCT02409459|DRUG|Placebo|Normal saline solution
40987405|NCT01498718|BIOLOGICAL|DNA vaccine|VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
40987406|NCT01498718|BIOLOGICAL|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
40987407|NCT02283047|BEHAVIORAL|DIET|Lifestyle intervention through hypocaloric diet
40987408|NCT02283047|BEHAVIORAL|DIET & MODERATE CONTINUOUS TRAINING|Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).
40987409|NCT02283047|BEHAVIORAL|DIET & HIGH VOLUME HIIT|Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).
40987410|NCT02283047|BEHAVIORAL|DIET & LOW VOLUME HIIT|Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
40987411|NCT03345589|DRUG|18-22mg/kg/d Ursodeoxycholic|18-22mg/kg/d Ursodeoxycholic
41305837|NCT00932152|DRUG|Best supportive care|Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
40987412|NCT03345589|DRUG|13-15mg/kg/d Ursodeoxycholic|13-15mg/kg/d Ursodeoxycholic
40987413|NCT02675413|DRUG|Dimethyl Fumarate|Open-label
41305838|NCT00533637|DRUG|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
41464481|NCT01104571|DRUG|lapatinib ditosylate|"Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.~Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery."
41464482|NCT01104571|OTHER|laboratory biomarker analysis|
41464483|NCT01104571|PROCEDURE|adjuvant therapy|
40987414|NCT03930706|OTHER|Longer administration of estradiol (Progynova®)|All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
40987415|NCT04309656|DRUG|Pretomanid|"1. Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~2. Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~3. Treatment C (test) = single 50-mg dispersible tablet, orally administered.~4. Treatment D (test) = single 10-mg dispersible tablet, orally administered."
40987416|NCT02276872|DRUG|oral treprostinil|
40987417|NCT04903249|BEHAVIORAL|Core Exercise Promotion Intervention|"Participants are instructed to increase weekly time spent exercising to \>90 minutes over 12 weeks. Exercise will be defined as activities that use large muscle groups, increase heart rate and breathing rate, and are performed intentionally for the purpose of exercise (as opposed to physical activities of daily living, e.g., housework). Participants complete a videoconferencing visit with the study team and are given task and safety related information pertaining to exercise for survivors of cancer. Participants engage in exercise-related goal-setting and action planning and are provided activity trackers to monitor their activity levels over the 12-week study period."
40987418|NCT05835609|DRUG|PM534|PM534 drug product is provided as a powder for concentrate for solution for infusion, is a sterile, preservative-free, lyophilized white cake in a single-dose vial for reconstitution prior to intravenous infusion.
41305839|NCT00533637|DRUG|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
41305840|NCT00533637|DRUG|Placebo|Citrate buffer with preservatives
41305841|NCT02391090|DEVICE|hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
41305842|NCT02391090|DEVICE|sham hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
41464484|NCT01104571|PROCEDURE|neoadjuvant therapy|
40987419|NCT02364544|BEHAVIORAL|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
41305843|NCT02391090|PROCEDURE|Pulse oximetry|Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.
41305844|NCT02391090|OTHER|Asthma and Quality of Life Questionnaires|Before every session in the hypoxic chamber as well as on the day after the last session will be completed.
41305845|NCT02391090|PROCEDURE|Lung function testing|On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.
41305846|NCT02391090|PROCEDURE|Blood taking|On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.
40987420|NCT02364544|BEHAVIORAL|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
40987421|NCT02364544|BEHAVIORAL|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
41464485|NCT01104571|PROCEDURE|therapeutic conventional surgery|therapeutic conventional surgery
41464486|NCT05947084|OTHER|Infant Formula|Growth Monitoring Study of Infant Formula fed to Healthy Term Infants over a 16 week period
41464487|NCT00002616|BIOLOGICAL|aldesleukin|
41464488|NCT00002616|BIOLOGICAL|filgrastim|
41464489|NCT00002616|DRUG|carboplatin|
41464490|NCT00002616|DRUG|cyclophosphamide|
41464491|NCT00002616|DRUG|thiotepa|
41464492|NCT00002616|PROCEDURE|peripheral blood stem cell transplantation|
40782804|NCT03388372|DRUG|Temozolomide|Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle.
40782805|NCT03388372|RADIATION|Radiotherapy|Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks.
41305847|NCT02391090|PROCEDURE|FeNO measurement|Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.
41305848|NCT03897673|DIETARY_SUPPLEMENT|Early Iron|iron syrup for the first three months (84 days) and placebo syrup for the fourth month
40782806|NCT03576235|DRUG|PG102P|Daily dose of 1.5g
40987422|NCT02364544|BEHAVIORAL|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
40987423|NCT02364544|OTHER|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
40987424|NCT02418507|DIETARY_SUPPLEMENT|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
40987425|NCT02418507|OTHER|Placebo|The placebo is administered to randomized healthy participants
40987426|NCT01894789|DRUG|Ticagrelor|Blinded administration of ticagrelor for 10 days
41305849|NCT03897673|DIETARY_SUPPLEMENT|Delayed Iron|placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
40987427|NCT01894789|DRUG|Clopidogrel|Blinded administration of clopidogrel and placebo for 10 days
40987428|NCT05602987|PROCEDURE|enema|receiving enema at the night before anal surgery
40987429|NCT05602987|PROCEDURE|no enema|no enema before anal surgery
40987430|NCT02872493|PROCEDURE|Small bowel length measurement|The total length of the small bowel with be measured at the time of the bariatric surgical operation.
40987431|NCT03238404|PROCEDURE|NAC group|NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.
40987432|NCT03238404|PROCEDURE|Surgery alone group|Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
40987433|NCT02046460|DRUG|Acetylsalicylic acid|Acetylsalicylic acid, 300mg o.p.d.
41305850|NCT01434472|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
40782807|NCT03576235|DRUG|Placebo|Daily dose of placebo
40987434|NCT02046460|DRUG|Vitamin K antagonist|Vitamin K-antagonists, target INR 2.0-3.0
40987435|NCT04961554|OTHER|loco-regional anesthesia|demonstrate that the mouth opening (measured in millimeters) of a patient treated for mandibular surgery with a very limited opening (defined by a threshold less than 20mm, not allowing the passage of a video laryngoscope blade per route buccal) is more important after locoregional anesthesia of the V3 than before anesthesia.
40987436|NCT02626637|OTHER|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
40987437|NCT01067014|DEVICE|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
40987438|NCT02089633|BIOLOGICAL|PACOX|Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
40987439|NCT01986660|DRUG|Ibuprofen Cream (SST-0225)|
40987440|NCT04157608|DEVICE|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
40987441|NCT04157608|DEVICE|Energy-Harvesting Mesofluidic Impulse Prosthesis|e-MIP is an experimental lower limb ankle-foot prosthesis.
40987442|NCT03063658|DRUG|Paracetamol|The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
40987443|NCT03063658|DRUG|Ibuprofen 800 mg|The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
41305851|NCT01434472|DRUG|Cyclosporine|Given PO
41305852|NCT01434472|DRUG|Fludarabine Phosphate|Given IV
41305853|NCT01434472|RADIATION|Indium In-111 Ibritumomab Tiuxetan|Given IV
41305854|NCT01434472|DRUG|Mycophenolate Mofetil|Given PO
41305855|NCT01434472|OTHER|Pharmacological Study|Correlative studies
41305856|NCT01434472|BIOLOGICAL|Rituximab|Given IV prior to yttrium Y 90 ibritumomab tiuxetan
41305857|NCT01434472|RADIATION|Total-Body Irradiation|Undergo TBI
41305858|NCT01434472|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
41305859|NCT01434472|DRUG|Fludarabine|Given IV
40987444|NCT03628755|BEHAVIORAL|Digital Manipulation of Thyroid cartilage|"Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60."
40987445|NCT03628755|BEHAVIORAL|Fluency Shaping Therapy|FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
40987446|NCT03628755|BEHAVIORAL|combination Group|combination group intervention of DMT + FST
40987447|NCT06242587|DEVICE|Pericoccygeal nerve block|The coccygeal corneas are visualised with a linear probe under ultrasound guidance. The pericoccygeal nerves are located medial to the cornu and a combination of local anaesthetic and dexamethasone is injected.
40987448|NCT06242587|PROCEDURE|Impar ganglion block|The sacrum is visualised with fluoroscopy. A needle is inserted through the sacrococcygeal junction. The optimal image is obtained by administering contrast material. A combination of local anaesthetic and dexamethasone is injected.
40987449|NCT03780868|PROCEDURE|external dacryocystorhinostomy|external DCR under general anesthesia with standard sterilization procedures.
40987450|NCT03780868|PROCEDURE|canalicular silicone intubation with MMC|canalicular silicone intubation with MMC under general anesthesia with standard sterilization procedures.
40987451|NCT00233896|DRUG|Oral beclomethasone dipropionate (drug)|
40987452|NCT05264545|DEVICE|PrimeTaper EV|The PrimeTaper EV Implant is a screw shaped dental implant with a defined surface achieved through grit blasting, followed by a process involving a treatment in diluted hydrofluoric acid. There is a conical connection between the implants and the abutments for a tight and stable connection.
40987453|NCT01271660|DRUG|Pregabalin|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
40987454|NCT01271660|DRUG|Placebo|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
40987455|NCT01481233|DRUG|Colchicine|Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
40987456|NCT02680743|OTHER|Education of parents to pursue prompt hearing screening.|Parents of patients will be counseled on the risks of hearing loss with a positive screen.
40987457|NCT01619345|DRUG|semaglutide|Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
40987458|NCT04056442|DRUG|Cannabidiol , synthetic form|Cannabidiol ( synthetic form)
41145385|NCT06374407|BEHAVIORAL|Dietary intervention based on the MIND diet|A 12-week pilot randomized controlled trial (RCT) involving N=126 obese participants (1:1 gender ratio) to assess protocol feasibility, including recruitment, retention, compliance, physical examinations, and gut sample collection. Sample size, calculated by a statistician, expects a 5% body weight change at follow-up (std. dev. 10%). We chose a 12-week duration for this pilot study to allow sufficient time to observe significant changes in both body weight and mental health.
41145386|NCT02219529|DEVICE|MCE|
41145387|NCT02219529|DEVICE|Standard gastroscopy|
40782808|NCT00490581|OTHER|case management and supportive housing|patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
40782809|NCT05293340|DIETARY_SUPPLEMENT|Avocado Vouchers|Food as Medicine to demonstrate clinically meaningful benefits for underserved communities. Avocados are fruits with fats, fiber, micronutrients, and bioactive phytochemicals.
40782810|NCT00613106|DRUG|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
40782811|NCT00613106|DRUG|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
40782812|NCT00508092|PROCEDURE|local anesthetic administration|"Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight"
40987459|NCT04056442|DRUG|Placebo|Olive Oil Solution, 5%
40987460|NCT04882228|DRUG|Entelon Tab.150mg|twice daily for 8 weeks
40987461|NCT04882228|DRUG|Venitol Tab.|twice daily for 8 weeks
40987462|NCT04882228|DRUG|Placebo of Venitol Tab.|twice daily for 8 weeks (with Entelon Tab.150mg. It is for the masking.)
40987463|NCT04882228|DRUG|Placebo of Entelon Tab.150mg|twice daily for 8 weeks(with Venitol Tab. It is for the masking.)
40987464|NCT03821298|OTHER|Standard of Care Hand Therapy|8 sessions 2 times a week for 4 weeks
40987465|NCT04937296|BEHAVIORAL|Physical activity|Participants will be asked to perform resistance exercises 3-times a week on alternating days for 12 weeks. Exercises will be performed with a TheraBand and will include the squat, lunge, press-up, cross body reach, reverse fly, lateral raise, biceps curl, triceps extension, frontal raise and bridge. In addition to the resistance exercises, the participants will perform aerobic exercise. They will be asked to download a specific exercise app to record the number of steps on day 1 of the intervention and participants who do not possess the required phone technology will be provided with a pedometer. They then will be asked to add 2000 steps on to their daily steps; this amount will then become their daily step goal. Once they have reached this goal on 4 out of 5 days, they will be asked to increase their new step step goal by an extra 500 per day.
40987466|NCT04937296|OTHER|Usual care|Usual care.
40987467|NCT06489652|DRUG|89Zr-Oxine-RY_SW01 Cell Injection|Biodistribution and metabolic kinetic characterization of zirconium-labeled cells in vivo for the treatment of systemic sclerosis by intravenous infusion of 89Zr-Oxine-RY_SW01 cells injection
41145388|NCT00003697|DRUG|vadimezan|
41145389|NCT01405508|DRUG|Brivaracetam tablets|100 mg, intake twice daily (BID) for 7 days during Run-In Period
41145390|NCT01405508|DRUG|Brivaracetam bolus|10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period
41305860|NCT02581319|PROCEDURE|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
40782813|NCT03551782|DRUG|Cetrelimab 480 mg|Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
40782814|NCT03551782|DRUG|Apalutamide 240 mg|Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.
40782815|NCT05485558|DRUG|N-acetyl cysteine|10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
40782816|NCT05485558|DRUG|Placebo|15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
40987468|NCT03301142|PROCEDURE|Laser|The patients will be submitted to application of the Erbium Laser: YAG(yttrium aluminium garnet) 2940nm, SMOOTH mode developed by FOTONA.The vaginal canal will be accessed using a specific speculum. The 90 degree laser tip shall be used to perform 4 applications to the anterior and lateral vaginal wall at each of the 5 clock points (9,10:30,12,1:30,3 'o´-clock´), commencing at the back of the vagina, retracting in increments of 0.5cm, where 4 shots are made at each interval up to a distance 1cm short of the external opening of the urethra. After completion of this stage, the 90 degree tip shall be switched for the 360 degree tip, whereupon 4 additional applications shall be performed with 4 shots every 0.5 cm along the vaginal trajectory outlined above.
41145391|NCT01405508|DRUG|Brivaracetam infusion|10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period
41145392|NCT01405508|OTHER|Placebo|100 mg twice daily (BID) for 7 days during Run-In Period
41305861|NCT05426707|DEVICE|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
41305862|NCT05426707|DEVICE|Sham-RIC|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
40782817|NCT05485558|DRUG|NAc|40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
40782818|NCT00099255|DRUG|SGN-30|
40782819|NCT04270422|OTHER|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial approach
40782820|NCT04270422|OTHER|Usual physiotherapy|Usual evidence based physiotherapy
41145393|NCT05293379|OTHER|Connected teleconsultation booth|15-minutes assessment in a connected teleconsultation booth.
41305863|NCT04286412|BIOLOGICAL|Nonacog alfa|Nonacog alfa is indicated in India for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
41305864|NCT00454064|BEHAVIORAL|cognitive-behavioral treatment|
40782821|NCT02544854|DRUG|Propofol|"Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~1. First 15 minutes: 15 mg/kg/min~2. 16 to 30 minutes: 13 mg/kg/min~3. 31 to 60 minutes: 11 mg/kg/min~4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~1. 5, 15 and 25 minutes of starting infusion,~2. 1, 3, 5, 7, 9 and 12 minutes of bolus and,~3. 5, 25, 60 and 120 minutes of infusion ended."
40782822|NCT03763578|OTHER|Licorice|Natural herbal product
40782823|NCT02230982|DRUG|nintedanib|soft gelatin capsule
41145394|NCT05771545|OTHER|Telepsychiatry|Instead of coming to the hospital physically, the attending psychiatrist will evaluate the patient via a video-link.
41145395|NCT06212180|DEVICE|mask|patients will be their own comparator. Patients will try both mask for 10 min and then decide which mask they want for the rest of the ventilation
41145396|NCT06232941|PROCEDURE|Full pulpotomy procedure|vital pulp therapy for molars with irreversible pulpitis instead of doing root canal treatment
41145397|NCT06081972|DIETARY_SUPPLEMENT|Maltodextrin|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing placebo powder with a breakfast item on a daily basis.
41145398|NCT06081972|DIETARY_SUPPLEMENT|Chicory RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing chicory RG-I with a breakfast item on a daily basis.
41145399|NCT06081972|DIETARY_SUPPLEMENT|Carrot RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing carrot RG-I with a breakfast item on a daily basis.
41145400|NCT00005867|BIOLOGICAL|bleomycin sulfate|
41145401|NCT00005867|DRUG|CHOP regimen|
41145402|NCT00005867|DRUG|cyclophosphamide|
41145403|NCT00005867|DRUG|doxorubicin hydrochloride|
41145404|NCT00005867|DRUG|etoposide|
41145405|NCT00005867|DRUG|mitoxantrone hydrochloride|
40987469|NCT03301142|PROCEDURE|kinesiotherapy|"Patients will be guided by the physiotherapist to perform exercises to strengthen the pelvic floor muscles at home on a daily basis in the supine position with an empty bladder. It will be performed 10 repetitions of five-second contractions, the 15 three-second contractions; 20 two seconds contractions; 20 contractions of a second; 5 repetitions of strong contractions while coughing; 10 repetitions of exercise bridge associated with pelvic floor contraction and relaxation up in descending.The level of difficulty in performing the exercises will be determined in accordance with the adopted position. In .changes position should be held every four sessions."
41145406|NCT00005867|DRUG|prednisolone|
41145407|NCT00005867|DRUG|vincristine sulfate|
41145408|NCT02896673|PROCEDURE|ventilatory conditions and measures with scanner and EIT|"Different ventilatory conditions are studied and measures are acquired with scanner and EIT~Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)~Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV~Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time~Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds~Time E: return to adjustment period A"
41145409|NCT01358201|DRUG|vINCRISTINE|
41145410|NCT01358201|DRUG|Dexamethasone|
41145411|NCT01358201|DRUG|Methotrexate|
41145412|NCT01358201|DRUG|Cytosine arabinoside|
41145413|NCT04512456|BEHAVIORAL|Exercise training|Exercise training performed during 12 weeks, 3 sessions per week of 60 minutes of strength and aerobic exercises.
41145414|NCT02334202|BEHAVIORAL|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
41305865|NCT00941954|BEHAVIORAL|Structured Education|The intervention group will be offered a group-based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self-efficacy, barriers to physical activity and self-regulatory skills based on pedometer use. The programme will employ a person-centred approach to patient education that is based on self-management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5-10 participants by two trained educators and is 3.5 hours long. Brief follow-up counselling will be offered once every 6 months.
41305866|NCT00941954|BEHAVIORAL|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
41305867|NCT01597427|DRUG|Clonidine|Administration of 2 μg/kg of intravenous clonidine
41305868|NCT01597427|DRUG|Placebo|Injection of placebo solution.
41305869|NCT04856436|DRUG|Benzodiazepine|Exposure to benzodiazepine during early pregnancy
41464493|NCT01291641|DRUG|HMG-CoA Reductase Inhibitor|"During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor"
41464494|NCT01291641|DRUG|Probucol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)"
41464495|NCT01291641|DRUG|Cilostazol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route"
41464496|NCT03944161|DIETARY_SUPPLEMENT|Oral nutrition supplement|Hypercaloric and high protein supplement
41464497|NCT03944161|OTHER|Nutritional advice|Advice given by the clinician
41464498|NCT00493064|DRUG|Nicotinic acid|topical eye drops
41464499|NCT00493064|DRUG|Prednisolone acetate|topical eye drops
41464500|NCT03915561|DRUG|Parecoxib Injectable Product|Dynastat (parecoxib sodium) is rapidly converted to valdecoxib following injection and reduces the production of prostaglandins that are important mediators of pain and inflammation. After intravenous injection with 40mg Dynastat, the onset of analgesia was 7-14 minutes and reached a peak effect within 2 hours. After a single dose, the duration of analgesia was dose and clinical pain model dependent and ranged from 6 to greater than 24 hours and maximal daily dose of Dynastat is 80mg. According to recommendation of acute postoperative pain management and product information, the timing of first injection will be at 10 minutes before anesthetic induction, and second injection will be 6 to 12 hours after first injection.
41464501|NCT03915561|DRUG|Normal saline|Placebo group (0.9% saline, group S) will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice.
41464502|NCT00365690|BEHAVIORAL|Telephone-administered coping improvement therapy|Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
41464503|NCT00365690|BEHAVIORAL|Telephone-administered supportive-expressive therapy|Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
40987470|NCT04730830|OTHER|Questionnaire|Patients completing emergence assessment questionnaires at the time of the first dressing placement, as well as at the scheduled weekly placement. As part of a planned repair, the emergence will be assessed at most once a week, preferably at the beginning of the week by the patient. In any other case of dressing change, an emergence assessment will be requested.
40987471|NCT04853979|OTHER|PRONE POSITION|Any combination of prone or side position for 3 hours, 3 times a day for 3 days
41305870|NCT06554392|DIAGNOSTIC_TEST|Blood sample|Blood sample from each subject to detect Glutathione Peroxidase 4.
41305871|NCT02077075|BEHAVIORAL|Web-based weight loss program|A 4-week web-based wellness program.
40987472|NCT02039674|BIOLOGICAL|Pembrolizumab|IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy
40987473|NCT02039674|DRUG|Paclitaxel|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
40987474|NCT02039674|DRUG|Carboplatin|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
40987475|NCT02039674|BIOLOGICAL|Bevacizumab|IV on Day 1 of each 3-week cycle
40987476|NCT02039674|DRUG|Pemetrexed|IV on Day 1 of each 3-week cycle
40987477|NCT02039674|BIOLOGICAL|Ipilimumab|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
40987478|NCT02039674|DRUG|Erlotinib|Orally tablet once daily
40987479|NCT02039674|DRUG|Gefitinib|Oral tablet once daily
41305872|NCT02077075|BEHAVIORAL|On-line health coaching|A 4-week web-based wellness program with weekly personalized on-line health coaching.
41305873|NCT04045613|DRUG|Derazantinib 300 mg once daily monotherapy|Derazantinib was administered orally at a dose of 300 mg once daily
41305874|NCT04045613|DRUG|Derazantinib 200 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
41305875|NCT04045613|DRUG|Derazantinib 300 mg once daily+ atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
41305876|NCT04045613|DRUG|Derazantinib 200 mg twice daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks
40987480|NCT06493708|OTHER|Trauma focused psychotherapy: EMDR|14 sessions of psychotherapy with EMDR will be carried out with patients. One session per week, lasting 90 minutes. The first two sessions will be used for the description of the EMDR method and for stabilization, then there will be treatment sessions.
40782824|NCT05251649|DEVICE|tACS combined with 40 Hz sound stimulation|"The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).~Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). Sound stimulation was turned on simultaneously at the beginning of tACS. The duration of sound stimulation was set to 5 min stimulation, 5 min rest, 5 min stimulation, 1 min rest, and continued stimulation until the end of electrical stimulation while sound stimulation was turned off."
40987481|NCT06113432|DIAGNOSTIC_TEST|Arterial blood gases|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio
40987482|NCT06113432|DIAGNOSTIC_TEST|Respiratory rate (RR)|Measurement of respiratory rate by waveform analysis using a ventilator
40987483|NCT06113432|DIAGNOSTIC_TEST|Pulseoximeter|Peripheral capillary oxygen saturation (SpO2) measurement and the ROX-index calculation (SpO2/FiO2/RR)
41145415|NCT02334202|OTHER|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence."
40782825|NCT05251649|DEVICE|Transcranial alternating current stimulation|The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).
40782826|NCT05251649|DEVICE|40 Hz sound stimulation|Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). The duration of the sound stimulation was set to stimulate for 5 min, rest for 5 min, stimulate for 5 min, rest for 1 min, and last for a total of 20 min. 15 sessions of 20 min were performed over a period of 3 weeks (21 days).
40782827|NCT00078221|DEVICE|Rheopheresis blood filtration|
40782828|NCT05746390|BEHAVIORAL|Home Alone|See Home Alone description.
40782829|NCT03898284|DIAGNOSTIC_TEST|Impulse Oscillometry|Impulse Oscillometry will be performed in addition to usual care
40782830|NCT05814471|DEVICE|Cable fastening system and 3d printed straps|The participants will wear a Odra knee brace held in place with by a cable fastening system and 3d printed straps for 2 weeks.
40782831|NCT05814471|DEVICE|Velcro straps system|The participants will wear a Odra knee brace held in place with by a velcro straps system for 2 weeks.
40782832|NCT06154616|DIETARY_SUPPLEMENT|Control Product|Lactose-free skimmed milk
40782833|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 250|Lactose-free skimmed milk enriched with 250 mg aswaghanda
40782834|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 250 + TRP|Lactose-free skimmed milk enriched with 250 mg aswaghanda and tryptophan
40782835|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 600|Lactose-free skimmed milk enriched with 600 mg aswaghanda
40987484|NCT06113432|DIAGNOSTIC_TEST|Assessment of accessory respiratory muscles work|Patrick score calculation. Score: 0. No visible tonic or phasic use of neck muscles. 1. Neck muscles taut but with no respiratory modulation (i.e., tonic activity). 2. Mild respiratory modulation in neck muscle contraction. 3. Moderate phasic activity (no supraclavicular or intercostal indrawing). 4. Vigorous phasic activity with indrawing. 5. Vigorous phasic activity with abdominal paradox.
40987485|NCT06113432|DIAGNOSTIC_TEST|Esophageal pressure measurement|Esophageal pressure measurement on inspiration and expiration with calculation of delta esophageal pressure, transpulmonary pressure and delta transpulmonary pressure
40782836|NCT00660803|DRUG|Fulvestrant|
40987486|NCT06113432|DIAGNOSTIC_TEST|Discomfort Visual Analog Scale (VAS)|From 1 to 10 points, where 1 point - maximal discomfort, 10 points - minimal discomfort.
40987487|NCT06113432|DIAGNOSTIC_TEST|Noninvasive blood pressure|Noninvasive blood pressure
40987488|NCT06113432|DIAGNOSTIC_TEST|Heart rate|Heart rate calculation using electrocardiogram monitoring
40782837|NCT06323070|OTHER|Low-fat cookies|To determine the effects of low-fat cookie consumption on physiological indicators of wellness regarding sexual, skin, and gut health
40987489|NCT02335164|BIOLOGICAL|recombinant influenza hemagglutinin|recombinant influenza hemagglutinin
40987490|NCT02335164|BIOLOGICAL|Advax1|Delta inulin adjuvant formulation 1
40987491|NCT02335164|BIOLOGICAL|Advax2|Delta inulin adjuvant formulation 2
40987492|NCT02081079|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
40987493|NCT06231212|DRUG|ECa 233|Intervention groups are separated into group A and group B. Group A takes capsules containing 250 mg of ECa 233 and group B takes capsules containing 500 mg of ECa 233.
40987494|NCT06231212|DRUG|Ibuprofen|Ibuprofen group was given capsules containing 200 mg of ibuprofen
40987495|NCT06231212|OTHER|Placebo|Placebo-controlled group received capsules containing 250 mg of lactose
40987496|NCT04244279|OTHER|Ergonomic workshop|Participants will participate in a single meeting workshop regarding ergonomic principles in baby care.
40987497|NCT04244279|OTHER|Brochure|Participant will receive a brochure summarizing the main contents of the workshop.
41145416|NCT03438968|BEHAVIORAL|Exercise training|Cardiac Rehabilitation exercise training
40782838|NCT06323070|OTHER|Watermelon|To determine the effects of watermelon consumption on physiological indicators of wellness regarding sexual, skin, and gut health
40782839|NCT01308840|DRUG|Panitumumab|Day 1 and 15 = 6 mg/kg IV
40782840|NCT01308840|DRUG|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
40782841|NCT01308840|DRUG|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
40782842|NCT01623063|PROCEDURE|Hysteroscopy|hysteroscopy with guided biopsies
41305877|NCT04045613|DRUG|Derazantinib 300 mg once daily monotherapy (QD)|Derazantinib was administered orally at a dose of 300 mg once daily
40782843|NCT02150161|DRUG|Lidocaine/ ketamine|
40782844|NCT02150161|DRUG|Fentanyl|
40782845|NCT05109741|BEHAVIORAL|Internet-based Psychodynamic Therapy|Internet-based Psychodynamic Therapy based on the SUBGAP model developed by Farrell Silverberg
40782846|NCT05109741|BEHAVIORAL|Internet-based Behavioral Activation|Internet-based Behavioral Activation based on the BATD-R model developed by Carl Lejuez and others.
41305878|NCT04045613|DRUG|Derazantinib 300 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
40782848|NCT03156114|DRUG|BI 754111|Day 1 of 3 week cycle
40782849|NCT03156114|DRUG|BI 754091|Day 1 of 3 week cycle
40782850|NCT02412670|DRUG|Methotrexate|Given IV
40782851|NCT02412670|DRUG|Vinblastine|Given IV
40782852|NCT02412670|DRUG|Doxorubicin|Given IV
40782853|NCT02412670|DRUG|Cisplatin|Given IV
40782854|NCT02412670|DRUG|Gemcitabine|Given IV
40782855|NCT02412670|DRUG|Carboplatin|Given IV
40782856|NCT02412670|DRUG|Pegfilgrastim|Administered subcutaneously
40782857|NCT02412670|PROCEDURE|Nephroureterectomy|Undergo nephroureterectomy and lymph node dissection
40782858|NCT05081362|OTHER|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity during ten minutes in rest and ten minutes in orthostatic position
40782859|NCT01989429|DRUG|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
40782860|NCT05579652|DIAGNOSTIC_TEST|Abdominal tension measurement|A tensiometer scale will be used to measure the tension needed to pull each side of the abdominal wall to midline
40782861|NCT01943760|DRUG|tramadol|The volume of the solution was adequate to maintain the concentration of 2% tramadol
40987498|NCT04244279|OTHER|Videos|During the next three months after the beginning of the research, they will receive videos that will be a reminder of the principles learned in the workshop.
40987499|NCT00680745|DRUG|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
40987500|NCT00680745|DRUG|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
41305879|NCT04045613|DRUG|Derazantinib 200 mg twice daily monotherapy|Derazantinib was administered orally at a dose of 200 mg twice daily
41305880|NCT01345123|BEHAVIORAL|Provision of condition specific shared decision making (SDM) aids only|Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
41305881|NCT01345123|BEHAVIORAL|Telephonic outreach and support by Health Coach|Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
41305882|NCT04740268|DEVICE|Straberi|"The patient's entire face will be treated with the Straberi microneedling devise.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
41305883|NCT05298033|DRUG|Crisaborole 2 % Topical Ointment|Twice daily crisaborole 2% topical ointment
41305884|NCT05298033|DRUG|PF-07038124 0.01% topical ointment|Twice daily PF-07038124 0.01% topical ointment
40782862|NCT01943760|DRUG|0.9% saline|
40987501|NCT00680745|DRUG|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
40987502|NCT00680745|DRUG|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
40987503|NCT00680745|DRUG|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
40987504|NCT04711473|BEHAVIORAL|Colonoscopy Only|Mailed letter asking participants to complete CRC screening by colonoscopy
40987505|NCT04711473|BEHAVIORAL|Choice|Mailed letter and FIT test asking participants to complete CRC screening by their choice of either colonoscopy or mailed FIT
40987506|NCT04711473|BEHAVIORAL|FIT Only|Mailed letter and FIT test asking participants to complete CRC screening by mailed FIT
40987507|NCT00730912|DRUG|loratadine|Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
40987508|NCT00730912|DRUG|loratadine|loratadine 10 mg tablet once daily for 4 weeks
40987509|NCT00730912|DRUG|loratadine|loratadine 10 mg tablet once daily for 4 weeks
40987510|NCT00826020|DRUG|Omegaven™|10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
40987511|NCT05554757|DEVICE|conventional rubber dam system|rubber dam is a protective sheet with a hole that a dental professional positions over a tooth during an endodontic procedureEndodontists . This allows to isolate the treatment area with a dental clamp around the tooth. The dental sheet is placed around the in the Dental Rubber Dams and then a u-shaped device is hooked around. This isolates the single tooth where dental treatment will be conducted.
40987512|NCT05554757|DEVICE|OPTRADAM|OptraDam Plus is a three-dimensional rubber dam that is flexible and has an anatomical shape, automatically stretched in an oral direction, an automatic hold of the device in the oral cavity is ensured.
40987513|NCT02232542|DRUG|Duloxetine - low dose|
40987514|NCT02232542|DRUG|Duloxetine - high dose|
40987515|NCT02232542|DRUG|Placebo|
40987516|NCT00055081|BEHAVIORAL|Critical Time Intervention|
40987517|NCT01172184|PROCEDURE|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
40987518|NCT00384722|DEVICE|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
40987519|NCT05589207|DIAGNOSTIC_TEST|Vascular wall invaded|Inferior vena cava vascular wall is invaded according to pathologic examination on the postoperative tumor thrombus/ vascular wall specimen.
40987520|NCT06135155|DRUG|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
40987521|NCT06135155|DRUG|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
41305885|NCT05298033|DEVICE|NBUVB phototherapy|Home narrow band UVB phototherapy exposure sessions 3 times per week
40782863|NCT04488133|DRUG|Nusinersen|Administered as specified in the treatment arm.
40987522|NCT04833621|DEVICE|NMES GROUP|The effects of NMES and muscle strengthening and standard physiotherapy exercises on the development of ICU-AW were observed
40987523|NCT04830787|OTHER|no intervention|there is no intervention, we just chose patients diagnosed with hypertrophic cardiomyopathy and underwent CAG, and patients without hypertrophic cardiomyopathy as control ,the two groups are matched with age, gender and hypertension.
41305886|NCT05298033|DEVICE|Sham phototherapy|Non-NBUVB visible light radiation exposure sessions 3 times per week
40987524|NCT00099385|BEHAVIORAL|Social Development Instruction|Weekly instruction during regular classroom time by classroom teacher using PATHS (Greenberg \& Kusche) curriculum.
40987525|NCT00966173|DEVICE|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
40987526|NCT04482842|DEVICE|Gene detection (CYP2C9*3, VKORC1)|Warfarin is administered at the recommended dose by detecting CYP2C9\*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.
41305887|NCT05298033|DRUG|Vehicle|Twice daily vehicle ointment
41305888|NCT03419767|DRUG|Melatonin|Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
40782864|NCT04541485|DRUG|DWRX2003|Intramuscularly injection at pre-defined injection sites
40782865|NCT04541485|DRUG|Placebo|Intramuscularly injection at pre-defined injection sites
40782866|NCT00403130|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
41305889|NCT03419767|OTHER|blank|Patients under carotid revascularization surgery without taking melatonin
41305890|NCT02027116|BIOLOGICAL|VGX-6150|Plasmid DNA delivered via IM injection with electroporation
40782867|NCT00403130|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
40782868|NCT00403130|DRUG|Bevacizumab|Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
40987527|NCT04482842|DRUG|Warfarin Sodium|Warfarin is administered at a gene-guided dose or at a regular dose.
40987528|NCT02024867|DRUG|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
40987529|NCT01665066|OTHER|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
40987530|NCT01665066|OTHER|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
40987531|NCT01665066|OTHER|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
40987532|NCT01665066|OTHER|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
40987533|NCT01665066|OTHER|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
40987534|NCT01073709|DRUG|Acetaminophen|
40987535|NCT03366376|RADIATION|WBRT with hippocampus-sparing and SIB|"Radiotherapy could be delivered in 5, 8, or 10 fractions according to participating investigator's choice. The prescribed doses are as below;~Fractions 5fxs 8fxs 10fxs Whole brain 20 Gy 24 Gy 25 Gy Gross tumor 30 Gy 40 Gy 40 Gy"
40987536|NCT05871268|OTHER|Physician Awareness|The patients' pre-visit Control Preference Scale response are shared with their physician.
41305891|NCT04985799|DEVICE|Gynecare TVT Exact Continence System|Participants will have placement of Gynecare TVT Exact sling.
41305892|NCT04985799|DEVICE|Neomedic KIM (Knotless Incontinence Mesh)|Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling
41305893|NCT04058262|OTHER|Meditation presential|Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.
40782869|NCT04167527|DEVICE|Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device|"Treatment initiation is defined as the date and time of arterial puncture. Femoral artery puncture will occur within 45 minutes of randomization and no longer than 90 minutes after the completion of the qualifying imaging. It must occur before 8 hours since the subject was last known well.The initial procedure will be performed using only the EmboTrap II Retriever for the first two passes, and a third pass is encouraged. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two hours of arterial access.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
41145417|NCT02769754|DEVICE|Hemopatch|Hemopatch will be apply once the standard surgical hemostasis is achieved.
40782870|NCT04167527|COMBINATION_PRODUCT|Initial medical management (iMM)|"Patients will receive standard medical therapy based on current AHA guidelines. For patients who are treated with intravenous tissue plasminogen activator (rtPA), the sites' post-rtPA protocol will be followed. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
40782871|NCT00152438|DRUG|Oral Micronized Progesterone (Prometrium®)|300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
40782872|NCT00152438|OTHER|Placebo|3 identical placebo pills daily, no active ingredient.
40782873|NCT05532969|OTHER|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
40782874|NCT00382174|DRUG|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
40782875|NCT00382174|DRUG|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
40782876|NCT05498584|BEHAVIORAL|exercise based cardiac rehabilitation|The types of exercise are treadmill walking/walking-jogging/jogging, ergometer cycling, stair climbing, or elliptical machine training. The training intensity is gradually increased fortnightly to reach the targeted Borg's rate of perceived exertion (RPE) of 12-14. The training duration is 40 minutes, which included 5-10 minutes of warm-up and cool-down exercises. The training frequency is three sessions per week, with 36 sessions concluding a complete course.
40782877|NCT04573855|BIOLOGICAL|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
40782878|NCT06157021|PROCEDURE|Rotary pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using (Fanta AF baby\* rotary files and Endo Radar\* rotary device).
40782879|NCT06157021|PROCEDURE|Manual pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using Manual H files, Mani\*)
40987537|NCT05871268|OTHER|Usual Care|The patients' pre-visit Control Preference Scale response are not shared with their physician.
40987538|NCT01549392|DEVICE|DECT|DECT at tumor progression and 3 months later
40987539|NCT01549392|DEVICE|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
40987540|NCT00788892|DRUG|CPX-351|
40782880|NCT05221892|DRUG|Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin|Tablets to be taken 30 minutes before each of 4 trips.
40987541|NCT00788892|DRUG|Cytarabine|
40987542|NCT00788892|DRUG|Daunorubicin|
40782881|NCT05221892|DRUG|Ginger|Tablets to be taken 30 minutes before each of 4 trips.
41145418|NCT02769754|OTHER|Control|No additional treatment will be applied after performing the usual surgical hemostasis.
41145419|NCT04395196|DIETARY_SUPPLEMENT|Choline bitartrate|Provided in beverage form
40782882|NCT02382354|DRUG|remifentanil|The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
40987543|NCT03756688|DEVICE|RestoreX PTT - 6 months|Penile traction therapy in straight position for all 6 months.
40987544|NCT03756688|DEVICE|RestoreX PTT - 3 months|Penile traction therapy in straight position for first phase (3 months)
40987545|NCT05397054|BEHAVIORAL|Education|- Education: Education about risk of high sodium intake, type of sodium, nutrition ingredients
40987546|NCT05397054|BEHAVIORAL|Reformulation|- Reformulation: Dietary recommendation in low sodium intake
40987547|NCT05397054|BEHAVIORAL|Environmental change|- Environmental change: Encourage about low sodium intake in community
40987548|NCT05397054|DEVICE|Salt meter|- Used salt meter: at least 3 times/wk
40987549|NCT05397054|BEHAVIORAL|standard treatment|standard treatment
41145420|NCT04395196|DIETARY_SUPPLEMENT|Placebo|Provided in beverage form
41145421|NCT02529735|OTHER|efficiency study|Blood pressure values measured for comparative lower limb and arm
41145422|NCT01555879|DRUG|Abatacept|As prescribed by a doctor for patient medical care.
41145423|NCT04999722|BEHAVIORAL|Traditional mode of management|Traditional model management of Diabetes Mellitus patients
41145424|NCT04999722|BEHAVIORAL|Mobile APP management|Management of diabetic patients with mobile phone APP
41145425|NCT03358485|DRUG|Aolanti Weikang tablets|Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).
41145426|NCT03358485|OTHER|Placebo|Placebo
40782883|NCT02382354|DEVICE|i-gel|I-gel insertion was inserted 5 min after anesthesia induction
40782884|NCT02382354|DEVICE|laryngeal mask airway|laryngeal mask airway insertion was inserted 5 min after anesthesia induction
40782885|NCT02382354|DRUG|propofol|Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
40782886|NCT00402129|PROCEDURE|1064nm Nd:YAG laser at 12 J/cm2, 20 ms and 10mm spot size.|
40782887|NCT01732536|DRUG|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
40782888|NCT01732536|PROCEDURE|Sham procedure|In-office bilateral sham procedure
40782889|NCT01732536|DRUG|Mometasone furoate nasal spray|Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
40782890|NCT02189109|DRUG|NVX-108|0.2% emulsion administered i.v.
40782891|NCT05584579|PROCEDURE|laparoscopic surgery|laparoscopic surgery
40782892|NCT01758094|DRUG|Sustanon 250 mg ampule (Testosterone esters)|Drug used for treatment of hypogonadism
40782893|NCT03971929|DRUG|SHR0532|once daily(QD) for 4weeks
41305894|NCT04058262|OTHER|Reiki|Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.
40782894|NCT03971929|DRUG|SHR placebo|once daily(QD) for 4weeks
40782895|NCT03971929|DRUG|Hydrochlorothiazide 25 mg|once daily(QD) for 4weeks
40782896|NCT00079313|DRUG|Imatinib|
40782897|NCT03840213|BEHAVIORAL|Filling a questionnaire and interviewDescription|"The questionnaire focuses on the dietary practices of patients treated with chemotherapy. It consists of 35 questions, completing an average of 20 minutes.~Interviews will be conducted with patients who have changed their diet since the beginning of their treatment in order to further develop the results of the quantitative survey."
40782898|NCT00002429|DRUG|Lamivudine/Zidovudine|
40782899|NCT00002429|DRUG|Nelfinavir mesylate|
40782900|NCT00002429|DRUG|Stavudine|
40782901|NCT00002429|DRUG|Didanosine|
40782902|NCT02299310|DRUG|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
40782903|NCT02299310|DRUG|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
40782904|NCT06152341|DEVICE|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
41305895|NCT04058262|OTHER|Meditation (app)|Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.
40782905|NCT04286178|DIETARY_SUPPLEMENT|creatine monohydrate|Creatine will be taken at a dose of 150mg/kg/day of creatine base divided into 2 daily doses up to 39.7kg in body weight, after which dosing will be based on body surface area (BSA) at 4.69g/m2/day. Creatine will be administered orally as a chewable tablet provided by BioTechUSA™. Tablets are 2g and contain 0.9g of creatine monohydrate which is equivalent to 0.8g of creatine base.
40782906|NCT04286178|DIETARY_SUPPLEMENT|ubiquinol|Coenzyme Q10 (CoQ10, ubiquinol) will be taken at a dose of 10mg/kg/day divided into 2 daily doses with a daily maximum of 500mg. CoQ10 will be administered orally in 50mg softgels containing 50mg of ubiquinol (Active Q®), provided by Tishcon Corporation.
40782907|NCT04286178|DIETARY_SUPPLEMENT|glucose tablet|Creatine placebo will be in the form of a glucose tablet with identical appearance and taste to the active supplement. The number of tablets/day will be determined based on the dose of creatine required for each patient.
40782908|NCT04286178|DIETARY_SUPPLEMENT|gel capsule|Ubiquinol placebo will be in the form of a gel capsule with identical appearance to the active supplement. The number of capsules/day will be determined based on the dose of ubiquinol required for each patient.
40782909|NCT04286178|BEHAVIORAL|Exercise|"Participants will be coached to hit 12,000 steps or 60 active minutes per day as logged by a FitBit (FitBit calculates active minutes as activities equivalent to moderate-to-vigorous physical activity (MVPA) done continuously for at least 10 minutes)"
40987550|NCT04025307|DRUG|bacTRL-IL-12|bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
41305896|NCT04058262|OTHER|round of conversation|The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
40782910|NCT02982330|BEHAVIORAL|Low Carbohydrate Breakfast|A low carbohydrate breakfast containing \<10% carbohydrate, \~75% fat, and 15% protein. Matched for calories to the active comparator arm.
40782911|NCT02982330|BEHAVIORAL|Guidelines Breakfast|A low fat breakfast containing \~55% carbohydrate, \<30% fat, and 15% protein. Matched for calories to the experimental arm.
40782912|NCT02117102|OTHER|Bladder and lumbar stimulation technic|
40987551|NCT05715073|DIETARY_SUPPLEMENT|TeaCrine and Caffeine|Participants will take Teacrine and caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
40987552|NCT05715073|DIETARY_SUPPLEMENT|Caffeine|Participants will take caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
40782913|NCT04225858|PROCEDURE|Omission of sentinel lymph node biopsy|No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
40782914|NCT04832347|OTHER|Exercise|Exercise Group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
40782915|NCT04832347|OTHER|Vagus Nerve Stimulation|Vagus therapy will be applied for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
40782916|NCT05900076|DIAGNOSTIC_TEST|Curettage for the evacuation of the product of conception|The product of conception taken during the intervention will be recovered at Day 1
40782917|NCT00187109|DRUG|Recombinant Human Thrombopoietin|
40782918|NCT02701764|DRUG|Pregabalin|
40782919|NCT02701764|DRUG|Placebo|
40782920|NCT01736917|DRUG|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
40782921|NCT01736917|DRUG|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
40782922|NCT01736917|DRUG|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
40782923|NCT00240851|DRUG|acetaminophen extended release|
40782924|NCT04756830|BIOLOGICAL|Adsorbed COVID-19 (inactivated) Vaccine|Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
40782925|NCT03540680|OTHER|Blood punction|"For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood."
40782926|NCT05287243|OTHER|inspiratory muscle training|Participants will complete inspiratory muscle training daily in their homes for 12 weeks. The dosage will depend on their initial maximum pressure. At the end of the 12 week intensive period, participants will reduce the inspiratory resistance by a third and continue a maintenance training for an additional 12 weeks.
40782927|NCT00724100|DRUG|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
40782928|NCT04211363|DRUG|Roflumilast 0.3% cream|Roflumilast 0.3% cream for topical application.
40782929|NCT04211363|DRUG|Vehicle Cream|Vehicle cream for topical application.
40987553|NCT05715073|OTHER|Placebo|Participants will take the placebo cellulose pill and than an hour later perform an intense interval exercise protocol followed by cognitive tests.
40987554|NCT03852550|OTHER|e-health application|In the first part of this study, an e-health application (MyREADY Transition\[TM\] BBD App) was developed, targeting the needs of youth with BBD during their transition and transfer from pediatric to adult health care. Program development centered on three core foci of health care transition planning: education, empowerment, and navigation. The intervention has an emphasis on the process of transition in which youth and young adults learn information and develop skills in order to eventually assume maximal responsibility for self-management of their conditions (e.g., learning how to speak directly with health providers) while also providing information to prepare youth for the event of the transfer from pediatric to adult health care.
41305897|NCT04680663|DIAGNOSTIC_TEST|Peripheral Perfusion index|Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue
41305898|NCT04680663|DIAGNOSTIC_TEST|serum lactate level|Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values
41305899|NCT01959386|DRUG|Trastuzumab|Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.
40782930|NCT01577602|OTHER|Printed medication list|Provide a list of patient's current medication list as noted in the EMR
40782931|NCT01577602|OTHER|Open ended question|medical assistants begin medication reconciliation with a scripted open ended question.
40782932|NCT01577602|OTHER|Combined intervention|Combines the printed medication list with the open ended question
40782933|NCT02598141|BIOLOGICAL|Biological sampling grinding|One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
40782934|NCT02598141|BIOLOGICAL|Biological sampling with standard procedures|One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
40782935|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
40782936|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
41145427|NCT01543945|DRUG|Dexamethasone|4 mg iv before induction for high and extremely high risk
41145428|NCT01543945|DRUG|Ondansetron|4 mg iv before ended surgery 30 min
41145429|NCT01543945|DRUG|Dimenhydrinate|1 mg/kg iv before ended surgery 30 min
40782937|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
40782938|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
40782939|NCT01425814|DRUG|Reference|Dry powder inhalation (capsule),single dose
40782940|NCT01425814|DRUG|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
40782941|NCT03549962|PROCEDURE|TKA|Total Knee Arthroplasty
40782942|NCT06032039|DRUG|Triamcinolone|Standard treatment for osteoarthritis knee pain
40782943|NCT06032039|OTHER|Platelet Rich Plasma|Alternative treatment for osteoarthritis knee pain
40782944|NCT05239078|DRUG|local anaesthetic injection|Inferior alveolar nerve block
40782945|NCT02024854|BEHAVIORAL|skin-to-skin|
40782946|NCT02024854|BEHAVIORAL|standard care|
40782947|NCT02873078|BEHAVIORAL|Internet-delivered Cognitive behavior therapy|The treatment is delivered via an online platform and is based on interventions for adults, adolescents and children tested in previous trials. Therapists are CBT-psychologists och students in clinical psychology under supervision.
40782948|NCT03076606|DIAGNOSTIC_TEST|ophthalmologist examination|ophthalmologist examination after geriatric consultation
40782949|NCT05691933|PROCEDURE|Block group|Patient will be subjected to bilateral external oblique intercostal plane block
40782950|NCT05691933|PROCEDURE|Morphine infusion|Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
41305900|NCT03928834|BEHAVIORAL|Adapted Nzira Itsva|Adolescents will be provided an enhanced adherence package consisting of VL testing using DBS, including the NI intervention and low-cost genotyping and drug resistance monitoring. Participants receiving the intervention will have their first session after recruitment and enrollment, and will schedule up to 4 additional booster sessions at a time convenient for them spaced approximately 1 month apart. This may be modified after the formative assessment.
41305901|NCT02270892|DEVICE|Ulthera treatment|Focused ultrasound energy delivered below the surface of the skin
40782951|NCT04624100|PROCEDURE|Hernia repair|Primary or mesh repair of primary ventral or incisional hernia
40782952|NCT04266522|OTHER|Informational Intervention|Receive printed materials
40782953|NCT04266522|OTHER|Counseling|Receive direct physicist interactions to describe the technical aspects of the treatment
40782954|NCT04266522|OTHER|Questionnaire Administration|Ancillary studies
40782955|NCT00405288|DRUG|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
40782956|NCT05125744|DIAGNOSTIC_TEST|Assisted Ventilation|patients will be invasively ventilated in assisted mode. In all enrolled patients ventilated in assisted mode. Diaphragmatic activity will be evaluated through ultrasound (primary end point) and electrical activity of the diaphragm (optional) at stepwise decreasing of PEEP level. Also, the activity of remaining respiratory muscles will be assessed through sonography at the same levels of PEEP (secondary end point).
40782957|NCT06084364|DRUG|Injection of triamcinolone acetonide into the CMC-1 joint|intraarticular injection with triamcinolone acetonide
40782958|NCT06084364|BEHAVIORAL|Multimodal Occupational therapy for CMC-1 joint OA|Patient education, instructions about hand exercises, orthosis and training
40782959|NCT06084364|DRUG|Placebo|Intraarticular injection with saline
40782960|NCT02053844|OTHER|lottery for tool users to win a $500 prize|Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
40782961|NCT02053844|OTHER|enhanced promotion of the tool to employers and members|Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
41464504|NCT00365690|BEHAVIORAL|Individual therapy|Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
41464505|NCT01275976|DRUG|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
40782962|NCT04209556|DRUG|PF-06826647 100 mg QD|Investigational Product
40782963|NCT04209556|DRUG|PF-06826647 300 mg QD|Investigational Product
40782964|NCT04209556|DRUG|PF-06826647 600 mg QD|Investigational Product
40782965|NCT04209556|DRUG|Placebo|Matched Placebo
40782966|NCT04209556|DRUG|PF-6826647 400 mg QD|Investigational Product
40782967|NCT06461039|DRUG|NNC0487-0111 A|NNC0487-0111 A will be administered subcutaneously.
40782968|NCT06461039|DRUG|NNC0487-0111 C|NNC0487-0111 C will be taken orally.
40782969|NCT06461039|DRUG|Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)|Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) will be taken orally.
40782970|NCT06461039|DRUG|Acetaminophen - 500 mg/15 ml|Acetaminophen - 500 mg/15 ml will be taken orally.
40782971|NCT00003109|DRUG|irinotecan hydrochloride|
40782972|NCT00003109|DRUG|raltitrexed|
41464506|NCT01275976|OTHER|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
41464507|NCT04912856|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
41464508|NCT04912856|DRUG|Placebo|Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
41464509|NCT03354208|OTHER|blood sampling|small volume blood sampling, according to local laws, is not categorized as intervention (observational study)
40782973|NCT00408980|BEHAVIORAL|Fat and calorie controlled diet|
40782974|NCT01329861|BEHAVIORAL|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
40782975|NCT03931187|BEHAVIORAL|Cognitive progressive muscular relaxation therapy|This therapy combines cognitive psychotherapy and progressive muscular relaxation, intervened 6 times with 1-1.5 hour each time. The whole therapy will last round 28-30 days during IVF-ET.
40782976|NCT03192098|DEVICE|Savary bougie dilation|Patients will be dilated with the use of the Savary bougienage device
40782977|NCT05261659|BEHAVIORAL|Exposure Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.
40782978|NCT05261659|BEHAVIORAL|Exposure Therapy|These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
40782979|NCT04255771|DRUG|Gemcitabine|Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
40782980|NCT04255771|DRUG|Placebos|Use a placebo as a comparison
40782981|NCT01203709|DRUG|low dose combination of MMF and Tac|mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
40782982|NCT00875914|PROCEDURE|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
40782983|NCT01472731|OTHER|89Zr-GC1008|radioactive labeled GC1008, intravenous use, 37 MBq total
40782984|NCT01472731|DRUG|GC1008|5 mg/kg intravenous use
40782985|NCT04592406|OTHER|CVP screening|An appropriate dual screening process including both renal and cardiac parameters to minimize the risks of post-contrast renal adverse outcomes and of prophylactic hydration in eGFR\<30mL/min/1.73m2 patients.
40782986|NCT04201704|OTHER|Balanced crystalloid solution volume administration|Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.
40782987|NCT04201704|OTHER|Packed Erythrocytes Units, Blood Product Unit volume|For patients designated as Bleeding, where hemoglobin \<7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
40782988|NCT04201704|OTHER|Plasma volume|For patients designated as Bleeding, where International Normalized Ratio (INR) \> 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
40782989|NCT04201704|OTHER|Platelets volume|For patients designated as Bleeding, where platelets \< 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
40782990|NCT03156218|DRUG|Modulation of FiO2|Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
40782991|NCT01555866|DRUG|isavuconazole|IV
40782992|NCT05471986|DEVICE|Color Fundus Photography/Non-Mydriatic Opthalmic Cameras|Subjects will have underwent Fundus Photography using FDA approved non-mydriatic fundus cameras compatible with EyeCheckup which are either TOPCON NW400, CANNON CR2, CANNON CR2 Plus or OPTOMED AURORA IQ
40782993|NCT01099488|PROCEDURE|Blood withdrawal|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received GSK2231392A vaccine, were enrolled for blood withdrawal, at each study visit: Day 0, Day 14 and Day 180, to support the development of CD8+ T cell immunological detection assays.
40782994|NCT01847755|DRUG|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
40782995|NCT03487016|DRUG|Gemcitabine|Arm A
40782996|NCT03487016|DRUG|Nab-paclitaxel|Arm A
41305902|NCT03955887|BIOLOGICAL|bronchoalveolar lavage fluid (BAL)|Recovery of a 10 mL volume of BAL fluid, performed as part of patient care
40782997|NCT03487016|DRUG|5-FU|Arm B Arm C
40782998|NCT03487016|DRUG|Irinotecan Liposomal Injection|Arm B Arm C
40782999|NCT03487016|DRUG|Oxaliplatin|Arm C
40783000|NCT02113319|DRUG|dasatinib|dasatinib 50 mg and 20 mg During one year
40783001|NCT02213029|DRUG|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or \>150mg
40783002|NCT02213029|DRUG|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
41305903|NCT03955887|BIOLOGICAL|Venous blood|Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care
41305904|NCT04288804|DEVICE|Smartphone microphone sensor|The volunteer will record themselves sustaining the short a vowel sound for 10 seconds.
40783003|NCT02213029|DRUG|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
40783004|NCT02213029|DRUG|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson
40987555|NCT02945033|DRUG|aspirin intake|Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
40987556|NCT02945033|DRUG|placebo intake|Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
40987557|NCT02945033|PROCEDURE|Surgical resection of colonic adenocarcinoma stage III or II high risk|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
40987558|NCT02945033|BIOLOGICAL|Molecular analysis of exon 9 and 20 of PI3K|Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
40987559|NCT02945033|BIOLOGICAL|blood intake|Blood intake will be done every 6 months to evaluate patient compliance to treatment
40783005|NCT01424800|DEVICE|A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.|When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
40783006|NCT00049543|DRUG|gefitinib|Given PO
40783007|NCT00049543|OTHER|placebo|Given PO
40783008|NCT00049543|OTHER|laboratory biomarker analysis|Correlative studies
40783009|NCT03198156|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
40783010|NCT03198156|DEVICE|Sham stimulation|Sham stimulation
40783011|NCT05003193|DEVICE|pedometer|2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
40783012|NCT00529672|PROCEDURE|crossectomy and short stripping|under spinal or complete anaesthesia
40783013|NCT00529672|PROCEDURE|ultrasound guided sclerotherapy with foam|1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein\>
40783014|NCT00529672|PROCEDURE|endovenous laser therapy|940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
40783015|NCT02007304|BEHAVIORAL|Eccentric exercise training|12 weeks of lower leg eccentric training
40987560|NCT05587400|BEHAVIORAL|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
40987561|NCT05587400|DRUG|dobutamine test|infusion dobutamine
40783016|NCT03089060|DEVICE|Silicone Finger cap|Treatment with silicone finger cap
40783017|NCT03089060|DEVICE|Film Dressing|Treatment with conventional film dressing
40783018|NCT01281111|DRUG|Dimethyl Fumarate (BG00012)|
40783019|NCT01281111|DRUG|Aspirin|
40783020|NCT01281111|DRUG|BG00012 matching placebo|
40783021|NCT01281111|DRUG|ASA matching placebo|
40783022|NCT03166748|COMBINATION_PRODUCT|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
40783023|NCT02747147|DEVICE|TIVA blood collection device|the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe
40783024|NCT02097784|PROCEDURE|Echocardiography|
40783025|NCT00002219|DRUG|Nelfinavir mesylate|
40783026|NCT00002219|DRUG|Levocarnitine|
40783027|NCT00002219|DRUG|Adefovir dipivoxil|
40783028|NCT02612311|BIOLOGICAL|Obinutuzumab|Obinutuzumab: IV infusion
40783029|NCT02612311|BIOLOGICAL|Ublituximab|Ublituximab: IV infusion
40783030|NCT02612311|DRUG|TGR-1202|TGR-1202: Oral daily dose
40783031|NCT02612311|DRUG|Chlorambucil|Chlorambucil: Oral dose
41305905|NCT04288804|DEVICE|Smartphone accelerometer sensor|The volunteer's smartphone's accelerometer will record accelerometer data (positions on the x, y, and z axes) while the volunteer maintains 4 positions, each for 10 seconds.
41305906|NCT01325480|DEVICE|Cardiac Pacing|
41305907|NCT01841424|BEHAVIORAL|Dietary counseling. Maintain a food diary.|The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
40783032|NCT05641610|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose levels are as follows: 2.0×10\^12vg/kg, 5.0×10\^12vg/kg, 1.0×10\^13vg/kg.
40783033|NCT03555058|OTHER|Treatment escalation|Treatment escalation per TDM and physician's decision.
40783034|NCT03781674|DRUG|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 18-22 weeks gestational age
40783035|NCT03781674|DRUG|progesterone 200mg|Women received vaginal progesterone suppositories in a dose of 200 mg daily beginning at 18-22 weeks gestational age
40783036|NCT03781674|DRUG|placebo to progesterone 200mg|Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
40783037|NCT03781674|DRUG|placebo to progesterone 400mg|Women received placebo to vaginal progesterone 400 mg suppositories in a dose of (4 tablets) daily beginning at 18-22 weeks gestational age
40783038|NCT00525421|DRUG|Curcuminoids|Curcuminoids tablets 2000mg three times per day for 12 days
40783039|NCT00525421|DRUG|Placebo|
40783040|NCT02799589|DRUG|Remifentanil|1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
40783041|NCT02799589|DRUG|Dexmedetomidine|1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
40783042|NCT02799589|DRUG|Ropivacaine|Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
40783043|NCT01865487|BIOLOGICAL|H56ug/IC31nmol|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
40783044|NCT01865487|BIOLOGICAL|Placebo|Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
40783045|NCT01597739|DRUG|JNJ-40346527|Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
40783046|NCT01597739|DRUG|Placebo|Form=capsule; route=oral use; twice daily.
40783047|NCT00196040|DEVICE|PFX Closure System|
40783048|NCT05271006|BEHAVIORAL|Exercise|The mHealth platform to be used by the exercise group is Down Dog, which has a suite of apps for yoga, HIIT, barre, and running workouts. Down Dog has agreed to provide free memberships for one year to all participants in the study. To ensure participant de-identification on the Down Dog platform, each participant will receive a Participant ID which will be pre-registered by the study coordinator on the Down Dog platform. Randomized participants will be provided instructions for downloading the apps onto their phone or a link to the website to be used on their computer. Following randomization, participants in the exercise group will be asked to engage in physical activity (using any if the Down Dog apps), 4 days a week for 20 minutes a day for 12 weeks.
41305908|NCT02358330|OTHER|EHR Enhanced Clinic Intervention|The clinics assigned to the experimental condition will have EHR enhancements introduced.
41305909|NCT06305104|BIOLOGICAL|2.5μg/ml EEC|0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
41305910|NCT06305104|BIOLOGICAL|5μg/ml EEC|0.1ml, one time, containing high dose 5μg/ml of active ingredients
40783049|NCT01463527|DEVICE|Nellcor NPB-70 Capnograph|Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
40783050|NCT05192421|BEHAVIORAL|Wellness Education|Receive wellness education through a weekly email and web portal content.
40783051|NCT05192421|BEHAVIORAL|Exercise Videos|Receive pre-recorded exercise videos through a weekly email and web portal content.
40783052|NCT05192421|BEHAVIORAL|Livestream Classes|Receive 3 videoconference group exercise classes per week for 8 weeks.
40783053|NCT02823002|PROCEDURE|Slow, Room Temperature Injection|The room temperature local anesthetic agent will be administered by slow infiltration.
40783054|NCT02823002|PROCEDURE|Rapid, Room Temperature Injection|The room temperature local anesthetic agent will be administered by rapid infiltration.
40783055|NCT02823002|PROCEDURE|Slow, Warm Temperature Injection|The warmed local anesthetic agent will be administered by slow infiltration.
40783056|NCT02823002|PROCEDURE|Rapid, Warm Temperature Injection|The warmed local anesthetic agent will be administered by rapid infiltration.
40783057|NCT02823002|PROCEDURE|Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
40783058|NCT02823002|PROCEDURE|Non-Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
40783059|NCT02823002|DRUG|Lidocaine|Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
40783060|NCT02823002|DRUG|Buffer|Sodium Bicarbonate
40783061|NCT04618588|PROCEDURE|Low Window Sinus Lift technique|"Preoperative CBCT of surgical site and Fabrication CAD/CAM surgical stent, Sinus elevation using Low Window Sinus Lift technique, Implant, bone graft and membrane placement"
41305911|NCT06305104|BIOLOGICAL|5 unit（U） EC|0.1 ml , one time, containing 5U of active ingredients
41305912|NCT00435032|PROCEDURE|early appendectomy|Appendectomy within 24 hours of admission
41305913|NCT00435032|PROCEDURE|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
40783062|NCT03835078|DEVICE|methafilcon A contact lenses|Bilateral daily wear of methafilcon A contact lenses
40783063|NCT03835078|DEVICE|fanfilcon A contact lenses|Bilateral daily wear of fanfilcon A contact lenses
40783064|NCT04936191|DEVICE|DynamX Bioadaptor|Patients received percutaneous coronary intervention in a similar way to a traditional DES. Patients first receive radial artery or femoral artery cannulation with anticoagulation during the intervention. All coronary angiograms are carefully measured by at least 2 orthographic views and performed under the same standard conditions. After adequate predilatation of the target lesion, the coronary stenting will be performed. All patients will receive a loading dose of acetylsalicylic acid and a P2Y12 inhibitor pre-procedure followed by dual antiplatelet therapy for at least 6 months.
40783065|NCT04333615|BEHAVIORAL|Exercise|Three conditions will be tested: self-selected exercise, walking with pain exercise, and control session.
40783066|NCT05443828|OTHER|Breakfast Control Meal|The participants consumed extruded puff with added vitacel (cellulose) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
40783067|NCT05443828|OTHER|Breakfast Test Meal|The participants consumed bread with added arabynoxylans (AX) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
40783068|NCT05443828|OTHER|Breakfast Test Meal|The participants consumed extruded puff with added wheat bran as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
40783069|NCT04834921|DEVICE|Ultraflux® EMiC®2|Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout
40783070|NCT03961308|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
40783071|NCT01777477|DRUG|Chloroquine|Addition of Chloroquine to Gemcitabine
40783072|NCT01777477|DRUG|Gemcitabine|
40987562|NCT05587400|DRUG|inhaled nitric oxide|nitric oxide inhalation
41305914|NCT00256048|PROCEDURE|Nasojejunal feeding|
41305915|NCT03169452|DEVICE|Non-invasive mechanical ventilator|mechanical assisted breaths without the placement of an artificial way
41305916|NCT06239909|OTHER|24-h pad-weight test|The patients will be asked to perform the 24-h pad-weight test
41305917|NCT06239909|OTHER|Patient Global Impression - Improvement Questionnaire|The patient-reported outcome, as measured by PGI-I (Patient Global Impression - Improvement Questionnaire)
41305918|NCT05046834|OTHER|cold application|Oral paracetamol 10 mg/kg, which is administered as standard 60 minutes before the procedure, will be given to patients who have decided to remove the chest tube by the physician and comply with the limitations of the study. After that, initial pain severity and vital signs of the patient will be recorded using FLACC 15 minutes before the start of the chest tube removal process (1.MEASURE). After this measurement, the cold gel package will be wrapped in gauze and placed directly on the skin, covering the area around the chest tube with a radius of about 5 cm. The cold gel package will remain on the skin surface for about 20 minutes. After 15 minutes, the cold package will be removed and the chest tube will be removed by the doctor.
41305919|NCT05046834|OTHER|cold application until 13.6 C|After measurements, the cold gel package, which rotates with one end open and forms a circle, will be wrapped in gauze and placed directly on the skin in a radius of about 5 cm, covering around the chest tube. 10 of the app. After the minute, the skin temperature will be measured with an infrared thermometer if the heat falls below 13.6 o C, the process will be terminated. If the skin temperature does not fall below 13.6 0 C, the application will continue, the application will be terminated when the heat falls below the specified temperature. After the cold package is removed, the chest tube will be removed by the doctor.
41305920|NCT02426372|BIOLOGICAL|QBECO SSI|QBECO Site Specific Immunomodulators
40783075|NCT03340714|DEVICE|Monitoring Device|Wear ADAMM
40783076|NCT00946933|DIETARY_SUPPLEMENT|NH4Cl (ammonium chloride)|0.2 g/kg/day of NH4Cl (ammonium chloride)
41145430|NCT03605745|DEVICE|Prostatic Vapor Ablation|"Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.~Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response."
41305921|NCT04747548|BEHAVIORAL|Kurbo Only|Kurbo is a structured behavioral weight management program for youth that focuses on diet, physical activity and mindset skills and is based on the traffic light diet developed at Stanford University. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories consumed. Foods are categorized into the colors of a traffic light signal based on their nutritional and caloric content, such that youth are encouraged to eat more of green and yellow foods, and less of red foods. Participants will log their daily food intake and self-monitor dietary and physical activity behaviors, incorporating behavior substitution and habit formation. Participants will also have 15 minute weekly individualized coaching sessions.
41464510|NCT03244605|OTHER|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training include aerobic exercise training (using cycle ergometer for 7-14 times at all, once a day, 15-20 min/time and using treadmill for 7-14 times at all, once a day, 15-20 min/time according to the patient's endurance) and Liu Zi Jue lung exercises, which strengthen the lung function of the human body in Chinese traditional health culture, five times a week, 15 min/time.
41305922|NCT04747548|BEHAVIORAL|Kurbo + PolyRules!|In addition to Kurbo, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
41464511|NCT03244605|OTHER|Rehabilitation Education|General health education
40783077|NCT00946933|DIETARY_SUPPLEMENT|placebo|0.025 g/kg/day of NaCl (sodium chloride)
40783078|NCT01357343|OTHER|Chiropractic|Spinal manipulation and active and passive therapy.
41145431|NCT05992584|DRUG|Lenvatinib, sintilimab plus SIRT|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
41145432|NCT02066454|DRUG|Apixaban|2.5mg x 2 per day during 6 months
41145433|NCT06198452|PROCEDURE|Vision Improvement|Laser Vision Improvement for Patients with Age-Related Macular Degeneration
41145434|NCT01086514|PROCEDURE|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
41145435|NCT06162611|DRUG|Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg|Single pill of oral levonorgestrel 1.5mg X 1 dose (e.g. Plan B) same day as contraceptive implant insertion
41464512|NCT03244605|DRUG|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
41464513|NCT03244605|DRUG|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
41464514|NCT04830982|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
41464515|NCT04830982|OTHER|Placebo|Placebo added to one liter of cardioplegia
40783079|NCT01357343|OTHER|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
40783080|NCT06546475|DRUG|N-Acetylcysteine|regular dose or high dose add-on
40783081|NCT04672135|DRUG|REM0046127|Oral solution: 100 mg/mL REM0046127
40783082|NCT04672135|DRUG|Placebo|Oral solution with 0 mg/mL REM0046127
40783083|NCT01096602|BIOLOGICAL|DC AML Vaccine|Group 1: 2-3 doses of the vaccine at 4 week intervals
40783084|NCT04574336|PROCEDURE|Surgical treatment|We anticipate that surgical treatment will include plate osteosynthesis (MIPO and ORIF), intramedullary nailing (antegrade and retrograde) and external fixation. Plate and nail types, screw configuration and surgical approaches will be decided by the surgeon. The procedure will be conducted or supervised by a senior consultant.
41145436|NCT06162611|DEVICE|Etonogestrel implant with oral placebo|Single pill of placebo same day as contraceptive implant insertion
41145437|NCT02418819|DRUG|PF-06412562 3mg BID|PF-06412562
41145438|NCT02418819|DRUG|PF-06412562 9mg BID|PF-06412562
41145439|NCT02418819|DRUG|PF-06412562 45mg BID|PF-06412562
41145440|NCT02418819|OTHER|Placebo|Placebo
41145441|NCT04884282|DRUG|Tedopi|TEDOPI is a T-specific immunotherapy was designed to induce cytotoxic T-lymphocytes against five five tumor associated antigens (ie CEA, p53, HER-2/neu, MAGE2 and MAGE3)
41145442|NCT04884282|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. Nivolumab is produced from cell culture using a CHO cell line.
41145443|NCT04884282|DRUG|Docetaxel|Docetaxel is a cytotoxic microtubule inhibiting antineoplastic agent in the taxane class. Docetaxel monotherapy is indicated for locally advanced or metastatic NSCLC after failure of prior platinum- based chemotherapy.
41145444|NCT05644067|BIOLOGICAL|SumayaVac-1(SUM-101)|One immunization every 4 weeks for 3 months (total 3 immunizations)
41145445|NCT05644067|BIOLOGICAL|Verorab|One immunization every 4 weeks for 3 months (total 3 immunizations)
41145446|NCT02085824|DRUG|Enoxaparin|
41145447|NCT02085824|DRUG|rivaroxaban|
41145448|NCT02085824|DRUG|dabigatran|
41145449|NCT02660086|BEHAVIORAL|Personalized nutrition feedback|Automated personalized nutrition feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
41145450|NCT04743999|OTHER|Quality of life questionnaire|We will evaluate patients' quality of life with a series of questionnaires at baseline, 3, 6, 12, and 24 months after surgical staging. These are prospectively validated questionnaires and include FACT-G (physical and functional well-being sections), FACT-En (additional concerns section), FACT/GOG-NTX-4 (additional concerns section), and FACT-C (items C3 and C5).These sections will be combined into one single form for ease of completion for the patients (a total of 36 items).
41145451|NCT01846156|DRUG|MgSO4|A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
41145452|NCT05243602|DRUG|Switch to B/F/TAF|This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
41145453|NCT05243602|DRUG|Continue current regimen|Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
41145454|NCT01279447|DRUG|0.25% Bupivacaine|10cc, single dose, US guided injection
41145455|NCT01279447|DRUG|Normal Saline|10cc, single dose, US guided injection
41145456|NCT02838888|DEVICE|Automatic polyp detection software|A computer program for the detection of colonic polyps will be used during colonoscopy
41145457|NCT04964037|OTHER|No intervention|No intervention
41145458|NCT00976053|PROCEDURE|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
41145459|NCT05374967|BEHAVIORAL|Lifestyle intervention: Live with IBD|"A digital lifestyle intervention divided into two phases:~1. An intensive phase lasting six months~2. a facultative phase lasting six months~During the Intensive Phase, participants will receive regular counseling by a nutritionist and a lifestyle coach in groups of 25 people. Participants will also follow five online meetings focusing on either nutrition, exercise, sleep, and stress. In addition, participants will have 24/7 access to an online platform that contains additional information, challenges, recipes, and peer-support groups. Finally, during the facultative phase, participants can attend smaller group sessions for additional counseling by a nutritionist or a lifestyle coach; these sessions will be organized every six to 12 weeks."
41145460|NCT05374967|OTHER|Control group|The standard of care for patients with IBD suffering from chronic fatigue.
41145461|NCT03458416|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
41145462|NCT00589745|OTHER|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
41145463|NCT01241994|OTHER|AASD dialysis technique|
41145464|NCT03778606|DIETARY_SUPPLEMENT|Potato starch|Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.
41145465|NCT01894620|DEVICE|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
41145466|NCT01894620|DEVICE|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
41145467|NCT02398539|DRUG|Silver Nitrate|Silver Nitrate Sticks
41145468|NCT02398539|DRUG|Triamcinolone|0.5% cream
41145469|NCT05710627|DEVICE|TENEX|Use of TENEX device for sectioning of the gluteus medius and ITB tendons.
41145470|NCT01952002|OTHER|Inspiratory Muscle Training|Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
41145471|NCT03689452|DEVICE|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is defined as an autologous concentration of human platelets that is 3 to 5 times greater than physiologic concentration of platelets in whole blood. Using the Eclipse PRP system, the participants PRP will be attained. The PRP will then be used as described in the arm/group description section.
41145472|NCT03689452|DRUG|Normal saline|Preservative-free normal saline will be used as described in arm/group description section.
41145473|NCT00513123|PROCEDURE|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
41464516|NCT01410760|OTHER|Perfusion CT scan|Patients in this imaging substudy of the FOXFIRE clinical trial will undergo a perfusion CT prior to FOXFIRE protocol therapy( Ox/MDG chemo alone for 12 cycles in arm A or OX+MDG chemo for 12 cycles with Yttrium 90 SIRshpheres liver radioembolisaton in arm B cycle 2) on Day 1/2 cycle 2, Day 1/2 cycle 3 and Day 1/2 cycle 5 chemotherapy.
41464517|NCT01324544|DRUG|Buprenorphine IV|Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
41464518|NCT06083987|BEHAVIORAL|Intersectionality and Identity|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of intersectionality and identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
40783085|NCT04574336|DEVICE|Non-surgical treatment|Non-surgical treatment will include sugar tong, splint, plaster splints, hanging casts, or functional bracing as the Sarmiento brace and will be worn until a surgeon removes it. If the surgeon deems it appropriate, participants will be offered to undergo early secondary surgery with a surgical procedure of their choice. The participants will be recorded and the reason will be noted. We anticipate the surgical procedures will be similar to the previous mentioned and perhaps with the addition of bone graft.
40783086|NCT04002375|OTHER|pectouteropexy|The surgical procedure was initiated after adhesiolysis had been performed by opening the peritoneal layer along the round ligament toward the pelvic side wall. Preparation started at the right external iliac vein and was performed in the medial and caudal direction. A segment of area approximately 3- 4 cm2 of the right lateral part of the iliopectineal ligament (Cooper ligament) adjacent to the insertion of the iliopsoas muscle was exposed.The peritoneum of the bladder was dissected, and the anterior parts of the distal uterus were prepared for mesh fixation. The uterus was elevated to the intended tension-free position using the transvaginal probe (POP-Q level 0-1). The mesh was fixed anteriorly to the cervix using four polyester permanent sutures (Ethibond Excel®; Ethicon). Finally, the mesh was covered with peritoneum using a continuous monofilament absorbable suture (Maxon™; Medtronic).
40783087|NCT00191711|DRUG|Gemcitabine|
40783088|NCT00157118|DRUG|Protein C Concentrate (Human) Vapor Heated|
40783089|NCT00105534|DRUG|AzaSite|"1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days."
41145474|NCT01748851|DRUG|XELOX|capecitabine 1000mg/m2 bid po D1-D14
41145475|NCT01748851|DRUG|FOLFOX|5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
41145476|NCT05064566|DEVICE|caries assessment|clinical visual examination (ICDAS II), digital io radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), and micro-CT images.
41145477|NCT02612285|DRUG|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
41145478|NCT04520620|DRUG|Lovenox 40 MG in 0.4 mL Prefilled Syringe|"Patients with a high thrombotic risk:~In patients with a BMI included between \< 30 kg/m² and \> 30 kg/m² without added thrombotic risk factor:~* Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization~* if weight \> 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization~Patients with a very high thrombotic risk:~In patients with a BMI \> 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen \> 8 g/L or D-Dimer \> 3 μg/ml or 3000 ng/ml)~\* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours"
41145479|NCT04520620|DEVICE|Ultrasound of the lower limbs|A 4-point compression ultrasound will be performed. In case of suspicion, an angiologist will perform to check the absence of legs thrombosis.
41145480|NCT04323514|DIETARY_SUPPLEMENT|Vitamin C|10 gr of vitamin C intravenously in addition to conventional therapy.
41145481|NCT02301286|DRUG|Acetylsalicylic acid|
41145482|NCT02301286|DRUG|Placebo Acetylsalicylic acid|
41145483|NCT01034774|DRUG|ACHN-490 Injection|ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
41145484|NCT01034774|DRUG|Placebo (normal saline)|Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
41145485|NCT03603275|DRUG|New FVIII products|Kovaltry or Jivi prescribed by the treating Physician
41305923|NCT01597622|DRUG|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
41305924|NCT02315937|PROCEDURE|transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography
41305925|NCT05050721|OTHER|CT imaging|clinical, radiological and biochemical parameters associated with disease progression
40783090|NCT00105534|OTHER|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
40783091|NCT05952050|DRUG|Dexmedetomidine|Different Administration Routes of Dexmedetomidine
40783092|NCT06056180|OTHER|Balance Training|Participants will be given static and dynamic balance training with a balance platform game console (20 minutes) containing interactive video games based virtual reality for a total of 6 weeks.
40783093|NCT06056180|OTHER|Motor İmagery Training|For motor imagery training, two visualization scenarios will be created: anterior and posterior motor imagery. One of the visualization scenarios appropriate to each individual's needs will be used. Participants will be asked to perform kinesthetic or visual motor imagery in accordance with the scenario they listened to (10 minutes).
40783094|NCT06056180|OTHER|Action Observation Training|Action observation training will be done using video modeling method. The video content will include Nintendo Wii games in which the games that the person will play in that session are played by someone else and successful scores are achieved (10 minutes).
41305926|NCT03355287|OTHER|Traditionally Threshed Teff (TTT)|The intervention will take place for 7 months in Debre Zeit where the the arm will be fed injera based on teff that are threshed traditionally
41305927|NCT03355287|OTHER|Lab Threshed Teff (LTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher.
41305928|NCT03355287|OTHER|Fortified Lab Threshed Teff (FTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher. In addition, they will receive Ferrous sulfate drops
41305929|NCT02654704|BIOLOGICAL|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
41305930|NCT01693458|BEHAVIORAL|Appreciative Inquiry Change Agents (CA) program (NAMWEZA)|The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
41305931|NCT04786873|DRUG|Macimorelin|Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.
41464519|NCT06083987|BEHAVIORAL|Confidentiality|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on Confidentiality for caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
40783095|NCT04494048|OTHER|Endoscopic Bariatric Therapies|Participation in this study will allow for data collection through medical chart review for at least 6 standard of care visits up to 1 year after consenting to participate in this registry study. The exposure of interest is total body weight loss, safety and efficacy
41305932|NCT04786873|DIAGNOSTIC_TEST|Arginine|For the arginine GHST, R-Gene® 10 from Pfizer will be provided as labelled investigational medicinal product (IMP). After an overnight fast, soluble arginine hydrochloride (0.5 g/kg) will be given i.v. as an infusion with an infusion duration of 30 min.
41305933|NCT04786873|DIAGNOSTIC_TEST|Clonidine|"For the clonidine GHST, CATAPRESAN® 75 tablets (Boehringer Ingelheim) will be provided as labelled IMP. Each tablet contains 75 ug clonidine hydrochloride. The tablets will be provided in boxes containing 10 tablets. The target dose is 0.15 mg/m2 body surface with a dose range of 0.08 - 0.15 mg/m2. Maximum dose will be 0.25 mg.~After an overnight fast, clonidine (0.15 mg/m2 body surface) will be given orally."
40783096|NCT04561856|DRUG|Dexamethasone|Intravenous 4mg
41305934|NCT02853734|OTHER|SEVERE PERIODONTITIS|Patients exhibiting moderate to severe periodontitis
41305935|NCT02853734|OTHER|NO PERIODONTITIS|Patients without existing periodontitis or exhibiting mild periodontitis
41305936|NCT03003780|BEHAVIORAL|Mindful Steps|Integrated website, activity tracker, and mind-body training
41305937|NCT00978809|OTHER|Epley maneuver|
41305938|NCT00978809|OTHER|Semont maneuver|
40783097|NCT04561856|DRUG|Dexamethasone|Perineural 4mg
40783098|NCT04561856|DRUG|Placebo|Normal Saline 2ml
40783099|NCT03825744|DRUG|Hetrombopag Olamine+Standard Therapy|once daily
40783100|NCT03825744|DRUG|Placebo+Standard Therapy|once daily
40783101|NCT00005935|DRUG|Mycophenolate mofetil|
40783102|NCT00005935|DRUG|Cyclosporine|
40783103|NCT01015521|DRUG|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
40783104|NCT05419752|DRUG|bioceramic sealer|bioceramic based obturating sealer
40783105|NCT05419752|DRUG|MTA|MTA based obturating sealer
40783106|NCT05419752|DRUG|resin sealer|resin based obturating sealer
40783107|NCT01918137|DIETARY_SUPPLEMENT|chocolate bar|
40783108|NCT01918137|DIETARY_SUPPLEMENT|Porridge|
40783109|NCT06274983|DEVICE|IVR platform trial|8 DMD patients from Sheffield Children's Hospital and 8 DMD patients from Leeds Teaching Hospital to trial the IVR platform. Patients will receive device training and then use the VR device at home for 12 weeks. Physiotherapists will conduct pre (visit 1) and post (visit 2) assessments to assess changes using a Goniometer (measures ankle range of movement), PEDSQL quality of life data, GAD-7 anxiety questions and the NorthStar Ambulatory Assessment.
40783110|NCT02066649|DRUG|Carvedilol|Administering carvedilol to patients diagnosed with large varices on endoscopy
40783111|NCT02066649|PROCEDURE|Variceal band ligation|Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
40783112|NCT03037970|DRUG|RhPDGF-BB|One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.
40783113|NCT03037970|OTHER|Placebo|Collagen Wound Dressing wetted with buffer.
40783114|NCT01183351|BEHAVIORAL|Psychosocial intervention|Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
40783115|NCT06277440|OTHER|cognitive training|cognitive training, 15 min, three times per week, for 12 weeks
40783116|NCT06277440|OTHER|active control|Traditional rehabilitation programs
40783117|NCT02636647|BIOLOGICAL|Fecal transplant|
40783118|NCT03467516|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
40783119|NCT02479191|DEVICE|Ovation Abdominal Stent Graft Platform|
40783120|NCT05589909|DIAGNOSTIC_TEST|IL27, PCT, CRP, Blood culture|magnetic bead multiplex platform
40783121|NCT03159182|DEVICE|Pressure garment and silicone insert|Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.
40783122|NCT03159182|DEVICE|Pressure garment|Custom made fabric pressure garment
40783123|NCT06484582|OTHER|workers|This study will be conducted as a face-to-face survey. Surveys will be created with Google Forms and will be filled out by the physiotherapist according to the participant's response.
40783124|NCT02932826|BIOLOGICAL|Umbilical Cord Blood Regulatory T cells Therapy|Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml NS
40783125|NCT02932826|DRUG|Insulin|Treated according to routine clinical practice at the discretion of the treating physician
40783126|NCT01445847|DRUG|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
40783127|NCT01445847|OTHER|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
40783128|NCT06351618|OTHER|No intervention will be conducted.|No intervention will be conducted.
40783129|NCT01814956|DRUG|Lipoplus 20%|Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
40783130|NCT01814956|DRUG|Lipofundin N 20%|Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
40783131|NCT02620163|DRUG|telmisartan/amlodipine 40/5mg|
40783132|NCT02620163|DRUG|YH22162 40/5/12.5 mg|
40783133|NCT02620163|DRUG|telmisartan/amlodipine 80/5mg|
40783134|NCT02620163|DRUG|YH22162 80/5/25 mg|
41305939|NCT03223324|DEVICE|abdominal fetal/maternal monitor|A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
41305940|NCT02734719|DEVICE|Bonestim|Bonestim is the multipad electrical stimulation device.
41305941|NCT01924546|OTHER|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
40783135|NCT02620163|DRUG|telmisartan/amlodipine 40/5mg placebo|
40783136|NCT02620163|DRUG|YH22162 40/5/12.5 mg placebo|
40783137|NCT02620163|DRUG|telmisartan/amlodipine 80/5mg placebo|
40783138|NCT02620163|DRUG|YH22162 80/5/25 mg placebo|
40783139|NCT02832414|BEHAVIORAL|Intensive weight loss program|behavioral and dietary supplement
40783140|NCT05181488|RADIATION|intraoperative radiotherapy, IORT|A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.
40783141|NCT03268564|BEHAVIORAL|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~1. Viewing a promotion video and a demonstration video~2. Brief motivational interviewing through telephone~3. Visiting the HIVST-online webpage~4. Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~1. Viewing a promotion video and a demonstration video~2. Visiting the HIVST-online webpage~3. Receiving a free self-testing kit and follow-up reminders"
40783142|NCT04734314|OTHER|conventional physical therapy|conventional physical therapy in the form of transcutaneous electrical stimulation (TENS) for 20 min and hot pack for 10 min Each patient received 12 sessions three session per week.
41305942|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing Contour® Next One|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
41305943|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing Accu-Chek® Aviva Connect|
41305944|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing FreeStyle Freedom Lite|
41305945|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing OneTouch® Verio|
40987563|NCT06246318|OTHER|virtual reality|The virtual reality protocol here is based on perceptual-motor activities, supported by Nintendo Wii resources. The user will be able to control a game character in a virtual environment using a remote control with a motion sensor. Wii Fit Plus requires the use of the Wii Balance Board that the player stands on during gameplay. The Wii Balance Board is not a wobbly balance board, but is able to detect and track the user's center of balance, a feature used extensively in the game. Wii Fit Plus includes more than 40 activities including yoga, strength training, aerobics and balance games. During the virtual reality application, different games will be preferred in each session depending on the duration of the games. Virtual reality application will be carried out in a corner prepared for virtual reality application in the room where the conventional occupational therapy session is held. Families have the right to observe and attend all sessions whenever they wish.
41305946|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing GlucoMen® areo|
41305947|NCT01918098|DRUG|Oxycodone/naloxone prolonged release tablets|
41305948|NCT00943293|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
41464520|NCT06083987|BEHAVIORAL|Educating Your Community|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of the education of family and friends about identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
41464521|NCT06083987|BEHAVIORAL|How to find Affirming Caregivers|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of finding affirming caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
41464522|NCT06083987|BEHAVIORAL|Control Group - No Interventions|Control Group - Will be given no interventions
41464523|NCT03110796|DEVICE|Dressing with LU3103209 - Dose 1|Dressing with LU3103209 - Dose 1
41464524|NCT03110796|DEVICE|Dressing with LU3103209 - Dose 2|Dressing with LU3103209 - Dose 2
40783143|NCT04734314|OTHER|vojta therapy|"Vojta Dynamic Neuromuscular Stabilization (DNS) is a therapy used to manage neurological and musculoskeletal conditions each patient in the study group (group B) was instructed to lie prone on an examination table with the participant's shoulders abducted, elbows flexed approximately 80-90°, and the forearms hanging off the edge of the table. Pressure-like stimulation of the calcaneus and ASIS were performed in the postural position named by Vojta as reflex creeping.~Each patient received 12 sessions three session per week."
41145486|NCT06031493|COMBINATION_PRODUCT|Multimodal intervention on sexual dysfunction and quality-of-life|Multimodal intervention includes education on healthy habits, the prevention of vaginal dysfunction using vaginal moisturizers and topical estrogens, and a systematic evaluation of the need of hormone replacement therapy.
40783144|NCT01883921|OTHER|Immunoglobulin Therapy|
40783145|NCT02645864|DRUG|Apatinib|250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
40783146|NCT02645864|DRUG|Irinotecan|150mg/m\^2 i.v. q2w
41305949|NCT00943293|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
41305950|NCT00943293|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
41305951|NCT01786616|DRUG|Formoterol|
41305952|NCT02814968|DRUG|Enzalutamide|
41305953|NCT02814968|DEVICE|18-FDG PET/CT|
41305954|NCT02814968|DEVICE|Whole body MRI|
41464525|NCT03110796|DEVICE|Dressing without LU3103209|Dressing without LU3103209
41305955|NCT02814968|DEVICE|Bone scan|
41305956|NCT01073956|PROCEDURE|Medium-wave 448 kHz therapy|0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
41305957|NCT01073956|PROCEDURE|Ultrasonic therapy|Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
41305958|NCT01073956|PROCEDURE|Inactive electrotherapy|Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
41464526|NCT04217148|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
41464527|NCT04217148|DRUG|ATRA|ATRA, po,10mg bid, for 12 weeks
40783147|NCT04773665|BIOLOGICAL|VBI-2902a|VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
40783148|NCT04773665|BIOLOGICAL|Placebo|0.9% sodium chloride
40783149|NCT04773665|BIOLOGICAL|VBI-2905a|VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
40783150|NCT02573948|OTHER|no intervention is assessed|
40783151|NCT04410159|DRUG|Povidone-Iodine|Gargle
41305959|NCT05673863|BEHAVIORAL|Psychological Resilience Program|The psychological resilience program was applied to the children in the intervention group twice a week for a total of 5 weeks. Each session consisted of 90 minutes of structured practice. The application is carried out using narrative therapy, cognitive behavioral therapy, psychodrama and analogy techniques, self-assessment and didactic teaching techniques. In addition, participants were engaged in self-regulation exercises and positive imagery activities. Each session includes practices on empathy, stress management, resilience, realistic and unrealistic thinking, optimism and pessimism, autonomy and humor related to resilience.
40783152|NCT04410159|DRUG|Essential oils|Gargle
40783153|NCT04410159|OTHER|Tap water|Gargle
40783154|NCT05050903|OTHER|Rhinovirus infection|Inoculation with rhinovirus-16
40783155|NCT02217969|BEHAVIORAL|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
40783156|NCT03921905|DIAGNOSTIC_TEST|ABI measurement|ABI measurement wil be done with an automatic device to diagnose PAD in patients with CAD
40783157|NCT05566704|DEVICE|Modulus ALIF System|The Modulus ALIF System is designed to address lumbar pathologies utilizing interbody placement through an anterior or anterolateral surgical approach. The Modulus ALIF System is an interfixated interbody system available in various shapes and sizes to suit the individual pathology and anatomical conditions of the patient.
40783158|NCT00185887|DRUG|Terbutaline|Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
41305960|NCT01803399|DRUG|GSK1322322 1200 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
40783159|NCT05455892|OTHER|Clinical data collection during hospitalization in short geriatric units.|Retrospective clinical data collection, at time of infection and 10 days later. Correlation between mortality and gravity. Identification of predictive mortality factors such as frailty, preexisting comorbidities, complications and treatments. Description of medical prescription evolutions.
40783160|NCT02045602|GENETIC|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
40783161|NCT02045602|DRUG|Gemcitabine|1000 mg/m2 intravenous administration
40783162|NCT02045602|DRUG|Abraxane®|125 mg/m2 intravenous administration
41305961|NCT01803399|DRUG|GSK1322322 3000 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
40783163|NCT04549480|DRUG|Bosutinib capsule|100 mg dose of bosutinib pediatric capsule
40783164|NCT04549480|DRUG|Bosutinib tablet|100 mg dose of bosutinib tablet
40783165|NCT02128087|BEHAVIORAL|Two-way SMS intervention|"Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond well or press 2 or write 'Unwell in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds unwell then the study coordinator will follow up with a call within 24 hours."
40783166|NCT02128087|BEHAVIORAL|One-way SMS intervention group|Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
40783167|NCT04908150|OTHER|Core training|A total of 12 sessions were carried out, which lasted for 4 weeks, with a frequency of 3 sessions/ week. The duration of each session was 11 minutes 30 seconds. The working time of each exercise was 30 seconds with a 5 seconds rest between exercises, meaning that each exercise cycle lasted for 2.50 seconds. Three exercise cycles were performed with a 90 seconds rest between each one of them
41305962|NCT01803399|DRUG|Placebo|Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
41464528|NCT03091868|DRUG|Placebo oral capsule|Matching placebo capsules. Oral administration.
41464529|NCT03091868|DRUG|Sinemet® 100/25|Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.
41464530|NCT03091868|DRUG|Comtan®|Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.
40783168|NCT04464551|DRUG|[14C]D-0316 suspension|Before administration, the drug preparation was placed at room temperature, and 40ml drinking water was added into each bottle to prepare suspension for the subjects to take. 40ml pure water was injected again. After washing the container, the subjects took orally. Repeat the previous step, and then used 160ml purified water. After the administration container was moistened for several times, the subjects took all the moistening lotion. Pay attention not to splash the liquid during mixing outside the bottle
40783169|NCT03429088|BEHAVIORAL|Motivational interviewing telephone counseling|
40783170|NCT05236036|DRUG|Mycophenolate Mofetil|Given PO
40783171|NCT05236036|OTHER|Quality-of-Life Assessment|Ancillary studies
40783172|NCT05236036|RADIATION|Radiation Therapy|Receive radiation therapy
40783173|NCT05236036|DRUG|Temozolomide|Given Orally (PO)
40783174|NCT03757429|OTHER|RS-virus infection|The intervention consists of lower respiratory tract infection due to RS-virus
41305963|NCT01803399|DRUG|Moxifloxacin|Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
41305964|NCT03176940|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
41464531|NCT03091868|DRUG|BIA 6-512 25 mg|BIA 6-512 capsules strengths 25 mg. Oral administration.
41464532|NCT03091868|DRUG|BIA 6-512 100 mg|BIA 6-512 capsules strengths 100 mg. Oral administration.
41464533|NCT00736398|PROCEDURE|Spinal fusion|Spinal fusion
41464534|NCT05103917|DRUG|X4P-001|CXCR4 inhibitor
40783175|NCT03333603|DRUG|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
40783176|NCT01480778|DRUG|LNG+EE2|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
40783177|NCT01480778|DRUG|Nordette|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
40783178|NCT00328172|DRUG|Placebo|Placebo matching BI 1356
41305965|NCT06203730|BEHAVIORAL|dyadic psychological intervention strategy|an intervention strategy for both patients and caregivers that combines psychotherapy techniques and health management
40783179|NCT00328172|DRUG|BI 1356 dose 3 once daily|BI 1356 dose 3 once daily
40783180|NCT00328172|DRUG|BI 1356 dose 2 once daily|BI 1356 dose 2 once daily
40783181|NCT00328172|DRUG|BI 1356 dose 1 once daily|BI 1356 dose 1 once daily
40783182|NCT00328172|DRUG|Metformin|Metformin
40783183|NCT01293812|DRUG|88% sucrose po solution|"88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
40783184|NCT01293812|DRUG|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
40783185|NCT02914938|DRUG|ME-401|60 mg
40783186|NCT02914938|DRUG|Rituximab|IV infusion 375 mg/m2
40987564|NCT06246318|OTHER|conventional occupational therapy|"Sensory integration and gross motor training approaches will be used in the conventional occupational therapy program. A manualized protocol based on Ayres sensory integration principles will be followed (Schaaf et al., 2012). The intervention will be carried out by a licensed occupational therapist trained in sensory integration.~This approach suggests that if a child engages in individually adapted sensorimotor activities, the nervous system is better able to modulate, organize, and integrate sensory information and is also more likely to use sensory information in adaptive ways (Ayres, 1972). Components of the intervention include a sensory-rich, playful, child-centered approach, providing a decision challenge, and facilitating increasingly complex adaptive behaviors by engaging the child in individually tailored, developmentally appropriate play interactions"
40987565|NCT05318183|OTHER|Whole Wheat Bread|Standardized whole wheat bread (128 g daily)
40987566|NCT05318183|OTHER|White Bread (control)|Standardized white bread (128 g daily)
41305966|NCT05340257|DRUG|Augmentin ES|Amoxicillin and clavulanic acid in fixed dose combination will be administered
41305967|NCT05449613|DRUG|acupoint application|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
41305968|NCT05449613|OTHER|placebo|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
40783187|NCT02914938|DRUG|Zanubrutinib|80 and 160 mg bid
40783188|NCT01371058|DRUG|high maintenance clopidogrel|clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
40783189|NCT01371058|DRUG|routine dual antiplatelet|clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
40783190|NCT01371058|DRUG|policosanol plus dual antiplatelet|aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
40783191|NCT04637529|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuvix®
40783192|NCT04637529|DRUG|Ibuvix® - ibuprofen|Ibuvix® + placebo of S(+) - Ibuprofen
40783193|NCT02772029|DRUG|Apatinib Mesylate Tablets|Apatinib 750 mg is administered orally daily, until disease progression or untolerable toxicity.
40783194|NCT06053528|DRUG|Antibiotic|Effect if treatment
40783195|NCT00175279|BEHAVIORAL|Opinion leader generated and endorsed evidence summaries|
40783196|NCT02209467|OTHER|Group balance training|Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
40783197|NCT03528317|OTHER|Alternate day fasting|Alternate day fasting with a high protein diet
40783198|NCT02006186|BEHAVIORAL|Bicycle Train|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
40783199|NCT06047132|DIAGNOSTIC_TEST|Salivaru biomarkers|C-reactive protein (CRP), triggering receptor expressed on myeloid cells-1 (TREM-1), interleukin (IL)-1beta, metalloproteinase (MMP)-8, IL-10, IL-6, monocyte chemoattractant protein-1 (MCP-1), Macrophage Inflammatory Protein-1 Alpha (MIP-1), interferon-gamma (IFN-gamma), osteoprotegerine (OPG), Receptor activator of nuclear factor kappa B ligand (RANKL), Tumor Necrosis Factor-Alpha (TNF-alpha)
40783200|NCT01482858|DIETARY_SUPPLEMENT|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
40783201|NCT01482858|OTHER|Placebo|Gelatin capsules, each containing 500 mg \[comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose\] for oral use as placebo
40783202|NCT00765219|BEHAVIORAL|CBT|10-12 weekly sessions of CBT in person or over the telephone.
40783203|NCT00765219|OTHER|Usual Care|Treatment as usual provided by participants' physician(s)
40783204|NCT00685061|DRUG|Thymoglobulin|Induction
40783205|NCT00685061|DRUG|Campath-1H|Induction
41305969|NCT03154632|DEVICE|Ultrasound Therapy|Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
40783206|NCT00685061|DRUG|Daclizumab|Induction
40783207|NCT06226961|DEVICE|cupping|The dynamic cupping will be performed for ten minutes, at a slow pace, and consisted of applying a small amount of massage cream (ATL®) over the entire shoulder (to obtain the ideal sliding surface for cupping application), insufflation of the suction cup, with two pumps, and sliding it in the direction of the muscle fibers around the shoulder and also in the transversal direction.
40783208|NCT03704493|DIAGNOSTIC_TEST|Video Group|A video of a group of five amateur runners running along woods and fields. The group was filmed from behind to give the patient the impression of running within the group.
40783209|NCT00346619|DRUG|Nelfinavir|
40783210|NCT00038844|DRUG|Campath-1 H (Alemtuzumab)|Starting Dose of 15 mg by vein daily, 3 days in a row.
40783211|NCT00038844|DRUG|Fludarabine|30 mg/m2 by vein daily, 3 days in a row.
40783212|NCT00038844|DRUG|Cyclophosphamide|1 gm/m2 by vein daily, 3 days in a row.
40783213|NCT00038844|DRUG|Rituximab|375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
40783214|NCT02045784|DIETARY_SUPPLEMENT|Infant formula|To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.
40783215|NCT02045784|OTHER|Breast milk|Unlimited breast feeding
40783216|NCT00533429|DRUG|enzastaurin|1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression
40783217|NCT00533429|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
41305970|NCT03154632|DEVICE|Digital Capacitive Diathermy Therapy|"The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second."
40783218|NCT00533429|DRUG|carboplatin|Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
40783219|NCT00533429|DRUG|bevacizumab|15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
40783220|NCT00533429|DRUG|Placebo|oral, daily
40783221|NCT03793621|DRUG|BI 730357|single rising oral dose
40783222|NCT03793621|DRUG|Placebo|single rising oral dose
40783223|NCT03703505|DRUG|AG-348|120 milligrams (mg) oral capsule, single dose, contains 100 microcuries (μCi) of radio labelled \[14C\]AG-348.
41305971|NCT03191656|DEVICE|IASD Implant|Implantation of the IASD device using trans-septal puncture and the IASD system
41305972|NCT02241044|DEVICE|Argon plasma coagulation|Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
41145487|NCT04706442|OTHER|Supportive Parenting Application|The Supportive Parenting Application is a theory-based perinatal educational intervention for couples administered through a mobile application. The mobile app consist of knowledge-based content, informational videos and audio, discussion forum, chat groups with peer volunteers, and an experts advice section
41145488|NCT01245998|DRUG|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
41145489|NCT01245998|DRUG|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
41145490|NCT03230981|DEVICE|Optical imaging of the cornea in healthy subjects|OCT vibrography and Brillouin microscopy
41145491|NCT06509269|PROCEDURE|intraoral scanning|Intraoral Scanning of edentulous Jaw
41145492|NCT06509269|PROCEDURE|Desktop scanning|Desktop scanning of definitive impression
41145493|NCT01699178|DRUG|Oral testosterone undecanoate|Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
40783224|NCT03703505|DRUG|[13C6]AG-348|IV microdose of approximately 100 micrograms (mcg), single dose.
40783225|NCT00067561|DRUG|Alosetron|
40783226|NCT01033929|BIOLOGICAL|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
40783227|NCT03265184|DIETARY_SUPPLEMENT|green coffee extract|Patients in treatment group take 400 mg GCE supplements twice a day for tow month
40783228|NCT01957865|DEVICE|Fixed SMS, real-time monitoring|SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
40783229|NCT01957865|DEVICE|Triggered SMS, real-time monitoring|SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
40783230|NCT06487000|DRUG|EC-18|oral administration, QD
40783231|NCT06487000|DRUG|Placebo EC-18|oral administration, QD
40987567|NCT03322254|OTHER|respiratory pathogen panel|lab testing for respiratory pathogens
40783233|NCT02731287|DRUG|Timolol|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
40783234|NCT02731287|DRUG|Placebo|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
40783235|NCT03631693|PROCEDURE|Simplified papilla preservation flap|The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.
40987568|NCT02133950|PROCEDURE|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
41145494|NCT01699178|DRUG|Transdermal testosterone gel (AndroGel)|Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
41305973|NCT02241044|DEVICE|Distilled water|Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
41305974|NCT00330655|DRUG|memantine|
41305975|NCT02325635|OTHER|Educational Training|Intervention/Training offered to endoscopists only.
41464535|NCT03604549|DRUG|Lipiodol UF|Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter
40783236|NCT03631693|PROCEDURE|Resective periodontal flap with osseous recontouring|The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
40783237|NCT00445094|DRUG|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
41305976|NCT04599205|DRUG|Tranexamic acid|fractional co2 laser, microneedling and topical tranexamic acid gel
40783238|NCT00445094|DRUG|Comparator: amikacin / Duration of Treatment: 3 Days|
41305977|NCT02496637|BEHAVIORAL|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
41305978|NCT02496637|BEHAVIORAL|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
41305979|NCT02850887|OTHER|general endotracheal anesthesia|sedation with the use of endotracheal intubation
41305980|NCT02850887|OTHER|deep sedation without endotracheal intubation|deep sedation without endotracheal airway management.
40783239|NCT00445094|DRUG|Comparator: tazocin / Duration of Treatment: 3 Days|
40783240|NCT00445094|DRUG|Comparator: vancomycin / Duration of Treatment: 3 Days|
40783241|NCT00678522|DRUG|Atorvastatin|80 mg atorvastatin daily on two following days
41305981|NCT00207103|DRUG|Brivanib|Tablets, Oral, 180 mg, once daily, until disease progression
41305982|NCT00207103|DRUG|Brivanib|Tablets, Oral, 320 mg, once daily, until disease progression
41305983|NCT00207103|DRUG|Brivanib|Tablets, Oral, 600 mg, once daily, until disease progression
40783242|NCT00098995|DRUG|cisplatin|
40783243|NCT00098995|DRUG|tirapazamine|
40783244|NCT00098995|RADIATION|brachytherapy|
40783245|NCT00098995|RADIATION|radiation therapy|
40987569|NCT02133950|PROCEDURE|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
40987570|NCT00664742|DRUG|Fluvastatin XL®|Fluvastatin extended release 80 mg
41305984|NCT00207103|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression
41305985|NCT00207103|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
41305986|NCT00207103|DRUG|Brivanab|Tablets, Oral, 1000 mg, once daily, until disease progression
40987571|NCT04212260|BEHAVIORAL|Oropharyngeal exercises|Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.
40987572|NCT04212260|BEHAVIORAL|Sham control|Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.
41145495|NCT03503188|DEVICE|Littmann ®|electronic stethoscope
41305987|NCT05737173|DRUG|Leukocyte-rich platelet-rich plasma|Intra-articular knee injection
41305988|NCT05737173|DRUG|Leukocyte-poor platelet-rich plasma|Intra-articular knee injection
41305989|NCT05737173|DRUG|Corticosteroid|Intra-articular knee injection
41305990|NCT00678509|BIOLOGICAL|TTK peptide mixed with Montanide ISA 51|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
41464536|NCT03604549|DRUG|Saline|Up to 10cc of saline will be infused via intrauterine catheter
41464537|NCT01195155|DIETARY_SUPPLEMENT|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
41464538|NCT05178576|DRUG|Gevokizumab|120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)
41464539|NCT05178576|DIAGNOSTIC_TEST|Signatera test|ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.
40783246|NCT01345448|DRUG|Brimonidine|0.1% Brimonidine Lotion, dosed once.
40783247|NCT01345448|DRUG|Placebo Lotion|Placebo Lotion dosed once.
40783248|NCT02951507|OTHER|O T unilateral attachment|O T unilateral attachment system
40783249|NCT02951507|OTHER|New design of extracoronal attachment system|O T unilateral attachment
40783250|NCT03111316|DRUG|Cervidil 10 MG Vaginal Insert|Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
41305991|NCT00004285|DEVICE|Standard dose, low flux hemodialysis|
41305992|NCT00004285|DEVICE|Standard dose, high flux hemodialysis|
41305993|NCT00004285|DEVICE|High dose, low flux hemodialysis|
41305994|NCT00004285|DEVICE|High dose, high flux hemodialysis|
41305995|NCT01407497|BIOLOGICAL|DNA HIVIS and MVA-CMDR|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
41305996|NCT01407497|BIOLOGICAL|DNA HIVIS and MVA-CMDR|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
41305997|NCT01407497|BIOLOGICAL|Saline solution|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
41305998|NCT01407497|BIOLOGICAL|Saline solution|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
41464540|NCT00000243|DRUG|Buprenorphine|
41464541|NCT05222360|OTHER|Education|3 educational sessions about body image and nutrition
40783251|NCT03111316|DEVICE|Foley Catheter|The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
40783252|NCT02167321|DRUG|Arm A : standard neoadjuvant chemoradiotherapy group|radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
40783253|NCT02167321|DRUG|Arm B : adjuvant FOLFOX group|FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
40783254|NCT04715126|OTHER|Oxyjun|One capsule to be taken after breakfast with water.
40783255|NCT04715126|OTHER|Placebo|One capsule to be taken after breakfast with water.
40783256|NCT02637986|DIETARY_SUPPLEMENT|Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14|2 capsules will be given per day
41305999|NCT05688579|DRUG|Mineralocorticoid Receptor Antagonists(MRAs)|Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
41306000|NCT05688579|OTHER|Blank control|Participants will be treated with the original antihypertensive drugs for 48 months.
41306001|NCT06210191|PROCEDURE|Intramedullary headless screw fixation|fixation of fractures of metacarpals and phalanges by intramedullary headless screws
41306002|NCT01994226|DRUG|Low-dose colchicine|"Route of Administration: Tablet - Oral Use~Dose: 500 mcg (one tablet) every eight hours for four days"
41306003|NCT01994226|DRUG|Naproxen 750 mg/250 mg|"Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days"
41306004|NCT01680094|DRUG|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
41306005|NCT04264767|PROCEDURE|Blood collection|Peripheral blood collection via routine venipuncture
41464542|NCT01030094|DRUG|Topiramate|This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
41464543|NCT01030094|DRUG|Carbamazepine|This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
40783257|NCT02637986|OTHER|Placebo - capsule with no active ingredient|2 capsules will be given per day
40783258|NCT02013609|DRUG|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
40783259|NCT06134817|DEVICE|Embozene Color-Advanced Microspheres.|"Embozene Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer. The microspheres are intended to occlude vasculature for the purpose of blocking blood flow to a target tissue.~In the study, the abnormal vessels will be embolized with 100 μm Embozene Microspheres solution under direct fluoroscopic visualization to prevent reflux and non-target embolization. Multiple geniculate arteries may be embolized until neovascularity is no longer seen."
40783260|NCT03669796|DIETARY_SUPPLEMENT|Marine protein hydrolysate (mph)|Marine (Cod) protein hydrolysate
40783261|NCT03669796|DIETARY_SUPPLEMENT|Control|Maltodextrin/Casein
40783262|NCT06298227|OTHER|Postoperative analgesia management with Paracerol® and IV PCA with Talinat®|In the postoperative period, 1 g of acetaminophen (Paracerol®) will be administered intravenously to patients every 8 hours. Patients in all groups will have IV patient-controlled analgesia (PCA- CADD-Solis®) containing 10 mcg/ml fentanyl ( Talinat®). 10 mcg bolus without infusion dose, 20-minute lock time will be the protocol. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®) will be administered as a rescue analgesic.
40783263|NCT06298227|OTHER|Erector spinae plane block|The block will be applied while the patient is in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed longitudinally 4 cm lateral to the T11 transverse process. The erector spinae muscle and the hyperechoic transverse process will be visualized. Using the in-plane technique, the 100 mm block needle (Stimuplex 360®) will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block location. Once the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
40987573|NCT06526637|OTHER|Paper Package|Paper based (as per current practice at Central and North West London (CNWL) NHS Foundation Trust) version of Palliate.
40987574|NCT06526637|OTHER|V1 + Preparation Sheet|Paper based version of Palliate plus a preparation sheet, that provides visual cues as to what equipment is required for the preparation and administration of the medications.
40987575|NCT06526637|OTHER|V2 + Video Training|Hybrid - paper based materials, preparation sheet, and video instructions available via an interactive portable document format (PDF) version of the training materials.
40987576|NCT04469114|DRUG|Tofacitinib 10 mg|Tofacitinib 10mg administered orally twice daily for 14 days or until hospital discharge
40987577|NCT04469114|DRUG|Placebo|Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
41306006|NCT05000814|DEVICE|DLT|VDLT versus the use of DLT with fiberoptic bronchoscope
41464544|NCT01030094|DRUG|Valproic acid|This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
41464545|NCT01030094|DRUG|Normal control|This is an observational study. Healthy female participants will be observed in Normal control group.
41464546|NCT02596633|BEHAVIORAL|Telephone-support Acceptance and Commitment Therapy (ACT)|Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
41464547|NCT01241682|BIOLOGICAL|DC + CTX|3x 50x10e6 DC + cyclophosphamide
41464548|NCT02024594|DRUG|Nitrous Oxide-Oxygen conscious sedation|
41464549|NCT02024594|BEHAVIORAL|cognitive-behavioral therapy|
41464550|NCT04161573|BEHAVIORAL|Watching ironic stories|All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.
41464551|NCT05746117|DEVICE|Aktiia Device|The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.
41464552|NCT05746117|DEVICE|Upper arm cuff|A standard upper arm oscillometric cuff that can be used to take blood pressure at home.
41464553|NCT01110317|DRUG|paliperidone palmitate 100 mg|Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
40783264|NCT06298227|OTHER|Quadratus lumborum plane block|QLB will be performed with the patient in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed at the level of the 12th rib, just above the iliac crest, in the parasagittal oblique plane, at the L1-L2 level. After the quadratus lumborum, erector spinae, and psoas major muscles are visualized, a 100 mm block needle (Stimuplex 360®) will be advanced in-plane anteriorly to QL, and the needle tip will be brought between the QL and PM muscles (Anterior QLB). The location will be confirmed by hydraulic dissection with 5 ml saline injection. After the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
40783265|NCT00314613|DRUG|Antipsychotic/Risperidone Consta|
40783266|NCT02286609|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
40783267|NCT02790502|DEVICE|Food Photography Application©|Group testing RFPM as method of recording plate waste
40783268|NCT06546891|BEHAVIORAL|Adaptive Rowing|12 supervised and coached sessions of 10-20 minutes of moderate to vigorous exercise using an adaptive rower.
40783269|NCT02359903|DRUG|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
40783270|NCT02359903|DRUG|Infliximab (Remicade)|
40783271|NCT06467682|OTHER|tele-exercise|The 12-week tele-exercise program will be performed and supported via the USTEP digital platform, with each patient taking part in 3 training sessions per week with a 60-min duration period per training session. There will be personalized training sessions: i) warm-up and warm-down, ii) aerobic exercise, and iii) strength exercises. All tele-exercise program participants, will use wearable-based tracking to assessment the cardio-oxygenation.
40783272|NCT04280575|PROCEDURE|Percutaneous coronary intervention|Coronary artery stenting for stable angina
40783273|NCT03140618|OTHER|The light and environment project in psychiatric inpatient care|"Complete rebuilding of a hospital ward.~The ward layout is remodeled and different devices and services are installed such as light, sound, and color settings, increased opportunities for physical activity, social harmony, privacy, peace, and quiet. A comfort room and a activity room will be built."
40783274|NCT01606150|DRUG|1% lidocaine|0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
40783275|NCT01606150|DRUG|topical lidocaine|1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
40783276|NCT05700825|BEHAVIORAL|Expiratory Muscle Strength Training + Cough Skill Training|"Expiratory Muscle Strength Training (EMST). EMST is a widely used and efficacious treatment approach that uses a calibrated device with a one-way, spring-loaded pressure relief valve to mechanically overload the expiratory and submental muscles.~Cough Skill Training (CST) involves a digital peak flow meter device which measures PEFR (peak expiratory flow rate) in liters/second and allows patients to receive immediate biofeedback."
40783277|NCT01077063|PROCEDURE|paracentesis|surgical drainage of malignant ascites
40783278|NCT01077063|DEVICE|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
40783279|NCT03775993|DRUG|Human growth hormone|Administration of growth hormone
40783280|NCT03775993|OTHER|Placebo|Administration of placebo
40783281|NCT03522402|DRUG|Sevoflurane|38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
40783282|NCT04676906|DRUG|NNC0113-6861|Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861
40783283|NCT04676906|DRUG|NNC0113-6860|Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860
40783284|NCT04676906|DRUG|NNC0113-6891|Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891
40783285|NCT03768037|DRUG|Anlotinib plus Pemetrexed|"Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.~Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects"
41464554|NCT03147833|DIETARY_SUPPLEMENT|Sport beverages Protein|Beverage ingested before each night sleep during the intervention
41464555|NCT03147833|DIETARY_SUPPLEMENT|Sport beverages Carbohydrate|Beverage ingested before each night sleep during the intervention
40783286|NCT03768037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
40783287|NCT01451411|DRUG|Conivaptan hydrochloride|Intravenous
40783288|NCT01451411|DRUG|Placebo|Intravenous
40783289|NCT05067868|BIOLOGICAL|Replagal|Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.
40783290|NCT04946630|DEVICE|PreciseInhale|Three different settings of the medical device PreciseInhale will be used in the study; PreciseInhale Whole Lung Exposure, PreciseInhale Bronchial Bolus/Breath hold Exposure and PreciseInhale Alveolar Bolus/Breath hold Exposure.
40783291|NCT04946630|OTHER|Seretide Evohaler forte|Single dose of Seretide Evohaler forte (fluticasone propionate/salmeterol 250 µg/25 µg) administered according to SmPc or via the PreciseInhale system.
40783292|NCT04038073|DIAGNOSTIC_TEST|Antistreptolysin O Test|Test to evaluate of any histories of streptococcal infections
40783293|NCT04038073|DIAGNOSTIC_TEST|Anti-Deoxyribonuclease B|Test to evaluate of any histories of streptococcal infections
40783294|NCT04038073|DIAGNOSTIC_TEST|TLR, MyD88, IRAK-4 polymorphism|Test to evaluate of the frequency and types of genetic alterations of innate immunity
40987578|NCT02755324|BIOLOGICAL|male Schistosoma mansoni cercariae|Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
40987579|NCT01761110|BEHAVIORAL|Community-based buprenorphine treatment (CBBT) intervention|Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
41145496|NCT01989845|DRUG|Rivaroxaban|Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
41464556|NCT05746052|PROCEDURE|Punch insturment|surgical and dermatological tool used mainly for skin biopsy and therapeutic skin disorders
41464557|NCT01681862|BEHAVIORAL|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
41464558|NCT05918341|DRUG|Piracetam|Subtherapeutic dose of piracetam (once-weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg)
41464559|NCT01185860|DRUG|danoprevir|oral doses
40783295|NCT04038073|DIAGNOSTIC_TEST|Anti-Basal Ganglia Antibody|Test to evaluate the autoimmune component
40783296|NCT00314457|DRUG|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
40783297|NCT04419246|OTHER|interscalene block|ultrasound guided ultrasound guided interscalene block 30 minutes before operation. 30 minutes before operation.
40783298|NCT04419246|DRUG|tranexamic acid|10 mg/kg intravenous tranexamic acid 10 minutes before the incision.
40783299|NCT04419246|OTHER|general anesthesia|general anesthesia will be applied in accordance with standard procedures
40783300|NCT02832570|DRUG|Sildenafil 100mg single oral dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
40987580|NCT02677987|DEVICE|Intervention systematic light exposure|Bright light using Litebook device.
40987581|NCT02677987|DEVICE|Comparison systematic light exposure|Dim light using modified Litebook device.
41145497|NCT01118156|OTHER|Education|75-minute training teaching utilization of new standardized suicide nomenclature
41145498|NCT05310292|BIOLOGICAL|Oral glucose tolerance test|Consumption of 75 grams of glucose, diluted in water, added 1,5 g of acetaminophen.
41145499|NCT05310292|BIOLOGICAL|Mixed meal test|Consumption of a standardized liquid meal, with caloric and dietary content equal to a standard meal.
41464560|NCT01185860|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly
41464561|NCT01185860|DRUG|placebo|oral doses
41464562|NCT01185860|DRUG|ribavirin|1000-1200mg/day po
41464563|NCT01185860|DRUG|ritonavir|oral doses
41464564|NCT00003707|DRUG|gemcitabine hydrochloride|
41464565|NCT00003707|DRUG|tipifarnib|
41464566|NCT01083862|BEHAVIORAL|Educational Intervention - Text plus DVD/VHS|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level."
40783301|NCT02832570|DRUG|Placebo, Oral intake single dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
40783302|NCT05018494|OTHER|experimental treatment|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
40783303|NCT05018494|OTHER|common treatment|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
40783304|NCT06254066|DRUG|Adebrelimab plus Fluzoparib|Adebrelimab combined with Fluzoparib in HRD-positive HR +/HER2- advanced breast cancer
40783305|NCT03101800|DRUG|Azathioprine and Allopurinol|Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
40783306|NCT03101800|DRUG|Azathioprine|Standard weight based azathioprine dosage
40783307|NCT01769924|OTHER|Nephrectomy|Nephrectomy for the purposes of living kidney donation
41306007|NCT00986258|DRUG|Tapentadol Prolonged Release|"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~* if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~* if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~* if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached."
41306008|NCT01027208|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m²
40783308|NCT05309525|DRUG|Collagenase Clostridium Histolyticum-Aaes|subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
40783309|NCT05309525|DRUG|Lysteda 650 MG Oral Tablet|Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
40783310|NCT02441842|DRUG|atenolol|administered 60 minutes pre procedure
40783311|NCT02441842|DRUG|lisinopril|administered 60 minutes pre procedure
40783312|NCT02441842|OTHER|glucose|administered 60 minutes pre procedure
40783313|NCT02835586|DRUG|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
40783314|NCT00928343|DRUG|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
40783315|NCT00928343|DRUG|Placebo|Matching subcutaneous or oral placebo
40783316|NCT04410861|PROCEDURE|Micropulse laser photostimulation|In this treatment invisible, non-damaging laser shots are delivered to the affected area which are believed to lead to absorption of accumulated retinal fluid. Contact lens will be used along with topical anesthesia.Following the procedure eye will be washed with balanced salt solution.
40783317|NCT04795401|DEVICE|FRAME FR IFU|The surgeon will use the medical device FRAME to perform the plication procedure. The device will be selected and implanted according to the product IFU.
40783318|NCT04584047|PROCEDURE|Cell-based non-invasive prenatal testing|Blood sampling.
41145500|NCT04065685|OTHER|serious game named Go Wish|"The nurse led intervention Go Wish is composed of 36 cards presenting statements of personal needs, values, and beliefs about end-of-life care. The aim is to decide about what to put into the patient's file as care options and the subsequent appointments to name a potential surrogate or to elaborate ADs.~Patient and relative (if participating) will meet their nurse twice:~Session 1: patient the cards in three piles and to rank the ten most important. Session 2 without relative: the nurse reiterates the wishes of care and treatments previously expressed and links them to the state of health and symptoms of the patient and the current treatments and their possible evolution.~Session 2 with a relative: the relative sort the cards based on his/her beliefs about the patient's expectation.~Session 3 with a relative: the nurse bring together the patient and his/her relative to discuss the priorities selected independently, identify, and explore the similarities and differences."
41145501|NCT04065685|OTHER|usual care|Standardized information on anticipated directives (ADs): the imad nurse are trained to promote AD to clients to help nurses to describe and explain ADs, to identify and to mobilize the required interview condition to promote ADs to clients to facilitate and initiate discussion on ADs
41145502|NCT06483698|OTHER|Sublobar resection|Sublobar resection is a series of surgical approaches for lung cancer.
41145503|NCT06483698|OTHER|Lobectomy|Lobectomy is the surgical approach for lung cancer.
41145504|NCT01341106|DRUG|Treatment with entecavir(Baraclude®)|Patient will be daily treated with 1 tablet of entecavir per oral
41145505|NCT06383507|DRUG|CHT101|After lymphodepletion with Fludarabine and Cyclophosphamide, CD70 UCAR T cells were transfused intravenously.
41145506|NCT00549666|DRUG|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
41145507|NCT00549666|DRUG|Placebo 40 mg|Placebo 40 mg once daily during treatment period
41145508|NCT00549666|DRUG|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
41145509|NCT01394406|DRUG|Ketamine|ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)
40783319|NCT01313507|BIOLOGICAL|NewGam|The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
40783320|NCT03537443|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|Prenatal and postpartum supplementation with vitamin D3 and/or placebo.
40783321|NCT01182350|DRUG|Bevacizumab|
40783322|NCT01182350|DRUG|Erlotinib|
40783323|NCT01182350|DRUG|Temozolomide|•
40783324|NCT01182350|RADIATION|Radiation|
40783325|NCT06011083|DRUG|Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm|using topical ointment containing calcipotriol and betamethasone dipropionate for plaque psoriasis.
40783326|NCT06011083|DEVICE|Fractional carbon dioxide (CO2) laser|fractional CO2 laser sessions once per month for 3 months over a similar psoriatic plaque
40783327|NCT01384318|OTHER|Manometer|Measuring cuff pressure
41145510|NCT01394406|DRUG|Saline|equal volume of normal saline mixed to intravenous patient controlled analgesia device
41145511|NCT05667909|DRUG|Rituximab|375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.
40783328|NCT05874726|DIAGNOSTIC_TEST|Blood Collection|Blood collection via venipuncture
40783329|NCT05874726|DIAGNOSTIC_TEST|Urine Collection|Free catch urine sample collection
41306009|NCT01999634|DEVICE|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
41306010|NCT00827996|DRUG|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
41306011|NCT00420394|PROCEDURE|Chemotherapy|
40783330|NCT05874726|DIAGNOSTIC_TEST|Tissue Sample Collection|Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned.
41306012|NCT00420394|PROCEDURE|surgery|
41306013|NCT00420394|PROCEDURE|radiotherapy|
41464567|NCT01083862|BEHAVIORAL|Educational Intervention - Text Only|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level."
41306014|NCT01795222|DRUG|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
41306015|NCT01795222|DRUG|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
41306016|NCT04823208|DRUG|LY3437943|Administered SC
41306017|NCT04823208|DRUG|Placebo|Administered SC
41306018|NCT00490373|DRUG|pemetrexed|
41464568|NCT04881513|DIAGNOSTIC_TEST|Narrow Band Imaging|Testing the taste buds structure (blood vessels morphology- classified to 5 types) and the number of taste buds per 20mm2, by Narrow Band Imaging technique before and after the operation (one and six months)
41464569|NCT04881513|DIAGNOSTIC_TEST|Tongue sensitivity testing|testing the tongue sensitivity change prior to surgery and after (1 and 6 months) the surgery with two point discrimination test in mm.
41464570|NCT04881513|OTHER|Qualitiy of life|Testing the patients quality of life before and after (one and six months) the stapes surgery by SF 36 questionnaire
40783331|NCT01074125|DRUG|ferric citrate|1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
41306019|NCT01938781|DRUG|entecavir|antiviral therapy
41306020|NCT01938781|DRUG|Peg-IFN|antiviral and antifibrosis therapy
41306021|NCT02215421|BEHAVIORAL|Mommio|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
41306022|NCT06072001|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
41306023|NCT06072001|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
41306024|NCT03775018|PROCEDURE|Transversus abdominis plane blockade|Patients will undergo Transversus abdominis plane blockade with Bupivacaine 0.25% 30ml, applied in the plane between the internal oblique muscle and the trasnversus abdominis. The injection will be performed laterally to the port-sites, bilaterally at the same levels.
41306025|NCT03775018|DRUG|Intravenous analgesia|Acetaminophen 1g/6h iv will be administered
41464571|NCT04881513|DIAGNOSTIC_TEST|Threshold change|Measuring the intraoperative chorda tympani stimulation threshold change at the beginning and at the end of the procedure- surgery
41464572|NCT04881513|DIAGNOSTIC_TEST|Taste|Taste is measured by applying taste strips (sweet, sour, salty, bitter) in 4 concentrations prior to, 1 and 6 months after surgery.
41464573|NCT04533906|DEVICE|Coldamaris lozenges|sucking carageenan containing lozenge
40987582|NCT04380259|BEHAVIORAL|Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)|"MBTR-R is a mindfulness-based group intervention of nine 2.5-hour weekly sessions. MBTR-R format and structure parallel MBSR (mindfulness-based stress reduction) and MBCT (mindfulness-based cognitive therapy). MBTR-R includes systematic training in formal and informal mindfulness practices with trauma-sensitive adaptations and home practice. Trauma-sensitive adaptations include a safe place practice, psychoeducation about posttraumatic stress, stress reactivity, as well as self-compassion practices to cope with fear, self-judgement, guilt and shame. Socio-cultural adaptations include real-time linguistic translation of each session by a cultural mediator from the refugee community and use of socio-culturally specific metaphors. MBTR-R groups were conducted for men and women separately and delivered in an accessible, safe space in the local refugee community. Group meetings included a shared meal of traditional Eritrean food and female participants were offered free child care."
40987583|NCT06538337|RADIATION|External beam Radiotherapy|Five fractions of radiation therapy using adaptive planning and CT or MRI guidance (6 Gy per fraction) delivered once every other day excluding weekends and holidays
40987584|NCT00913367|DRUG|glimepiride + insulin glargine (Amaryl + Lantus)|"* Amaryl® 4 mg at breakfast + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
40987585|NCT00913367|DRUG|glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)|"* Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
40987586|NCT02249533|OTHER|Spot Light Concussion App|Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
41145512|NCT06189898|DIAGNOSTIC_TEST|Re Staging FDG-PET|Additional interim FDG-PET during week four of preoperative or definitive chemoradiation for esophageal carcinomas. Evaluation of standardized uptake ratio (SUR) and increased uptake of non tumor affected esophagus (Delta NTO).
41306026|NCT01104259|DRUG|veliparib|Given PO
40987587|NCT00150839|DRUG|Mirtazapine|Patients receive mirtazapine 45mg and placebo.
40987588|NCT00150839|DRUG|Venlafaxine|Patients receive mirtazapine 45mg and venlafaxine 300mg.
41306027|NCT01104259|DRUG|cisplatin|Given IV
41306028|NCT01104259|DRUG|vinorelbine tartrate|Given IV
40783332|NCT02814656|DRUG|AZD8871|Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
40783333|NCT02814656|DRUG|Placebo|Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
40783334|NCT00002907|DRUG|bryostatin 1|
40783335|NCT05975125|DRUG|Vitamin C 500 MG Oral Tablet|compare between Vitamin C with iron supplement and iron supplement alone in prevention of anemia in pregnancy.
40783336|NCT05268757|BEHAVIORAL|Oral hygiene discontinuation|Oral hygiene discontinuation for 14 days followed by 14 days of regular oral care
41145513|NCT02407288|DEVICE|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
41145514|NCT02407288|DEVICE|Sham tDCS|
41145515|NCT00933634|PROCEDURE|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
41145516|NCT00933634|DRUG|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
41145517|NCT05390515|DRUG|Tildrakizumab Prefilled Syringe|IL-23 inhibitor
41145518|NCT05971615|OTHER|peripheral venous blood gases|peripheral venous blood gases
41145519|NCT05725447|OTHER|Validity and reliability study|Face-to-face questionnaire study
41306029|NCT01104259|OTHER|laboratory biomarker analysis|Correlative studies
41306030|NCT01104259|OTHER|pharmacological study|Correlative studies
41306031|NCT02773238|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
41306032|NCT02773238|PROCEDURE|Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA
41306033|NCT02773238|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
41306034|NCT02773238|OTHER|Laboratory Biomarker Analysis|Correlative studies
41306035|NCT02773238|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
41306036|NCT02773238|RADIATION|Radiation Therapy|Undergo functional avoidance radiation therapy
41306037|NCT02773238|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
41306038|NCT02773238|RADIATION|Technetium Tc-99m Albumin Aggregated|Undergo Tc-99m MAA SPECT/CT
41306039|NCT02773238|RADIATION|Technetium Tc-99m Sulfur Colloid|Undergo Tc-99m sulfur colloid
40783337|NCT04442893|BEHAVIORAL|Rumination-Focused Cognitive Behaviour Therapy|Rumination-Focused Cognitive Behavioural Therapy(RFCBT) is based on a differentiation between functional and dysfunctional styles of perseverative thinking with the helpful style characterized as a concrete, process-focused and specific style of thinking and the idea that rumination is a habit maintained by negative reinforcement. In line with the theoretical assumptions, RFCBT combines strategies from behavioral activation with strategies to foster concrete, process-focused and specific thinking.
40783338|NCT04442893|OTHER|Health Education programme|Health education programme would be any planned activity or set of activities aimed at increasing health literacy and developing life skills conducing to health (e.g. decision making, problem solving, critical thinking, interpersonal skills, stress management, coping with emotions).
40783339|NCT05016089|OTHER|The 16-style simplified Pilates exercise programme|The 16-style simplified Pilates exercise programme was developed by a group of experienced Pilates and rehabilitation experts from our completed pilot work.
40783340|NCT02172014|DRUG|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
40987589|NCT05891899|OTHER|observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
40987590|NCT04500834|BIOLOGICAL|Metal Panel T.R.U.E. Test|Diagnostic patch test
40987591|NCT01069146|PROCEDURE|Mild therapeutic hypothermia induction|Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
40987592|NCT01907672|PROCEDURE|Rapid Diagnostic Test|Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
40987593|NCT03247075|BEHAVIORAL|Cognitive Behavior Therapy|Guided Internet-delivered CBT includes exposure training, coping techniques and cognitive components, intended to reduce social anxiety symptoms
40987594|NCT03247075|BEHAVIORAL|Support and Counseling|Guided Internet-delivered support and counseling includes educative material about social anxiety and health related issues such as physical activity, nutritious diet, sleep habits etc.
40987595|NCT02904473|OTHER|GROWell|The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
40987596|NCT00982709|BEHAVIORAL|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
41306040|NCT02302794|PROCEDURE|open surgery|Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.
41306041|NCT02302794|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
40783341|NCT02172014|DRUG|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
40783342|NCT02236676|BEHAVIORAL|Nap after rehearsal trials|Behavioral
40783343|NCT04470024|DRUG|INCAGN01876|agonistic antihuman GITR mAb
41145520|NCT03810300|OTHER|Cash transfer|1500 taka ($18.75) per household distributed monthly
41145521|NCT03810300|OTHER|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
41145522|NCT03810300|OTHER|Food and cash transfer|15 kg of rice, 1 kg of lentils, and 1 kg of micronutrient-fortified cooking oil, and 750 taka cash per household, distributed monthly
41306042|NCT03689725|OTHER|Music|Music created by A. Vollenweider at least 5 times per week from 33 weeks of gestational age until term-equivalent age
41306043|NCT04441203|DEVICE|CardioMems|novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System
41306044|NCT03179514|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
40783344|NCT04470024|DRUG|INCMGA00012|humanized, hinge-stabilized, IgG4κ mAb that recognized human PD-1
40783345|NCT04470024|BIOLOGICAL|DPV-001|autophagosome cancer vaccine
40783346|NCT06353503|PROCEDURE|autologous bone marrow aspirate concentrate|local knee joint injection of autologous bone marrow
40783347|NCT03475602|DIAGNOSTIC_TEST|PLA2R|Determination of serum concentration of anti PLA2R antibody
40783348|NCT03475602|DIAGNOSTIC_TEST|TSHD7A|Determination of serum concentration of anti TSHD7A antibody
41145523|NCT03810300|BEHAVIORAL|Nutrition behavior Communication Change (BCC)|Weekly, group-based, one-hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings
41145524|NCT03810300|OTHER|Control|No transfer, no behavior change communication
41145525|NCT00473031|BEHAVIORAL|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
41145526|NCT00473031|BEHAVIORAL|Caloric restriction; normal protein|Weight loss with recommended level of protein (18%)intake
41145527|NCT00473031|BEHAVIORAL|Counseling|Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
41306045|NCT03179514|DRUG|Lipid Regulating Drugs|Mainly including statins
41306046|NCT03179514|DRUG|Coronary Vasodilator|Mainly including nitrates
41306047|NCT03179514|DRUG|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
41306048|NCT05790811|OTHER|Physician-oriented Video|previously validated Hand and Wrist Examination Video by NEJM designed for usage by a physician in diagnosing common hand and wrist diagnoses
41306049|NCT05790811|OTHER|Patient-oriented video|"The previously validated Hand and Wrist Examination Video by NEJM was modified via the TogoTiki application and approved by a patient advisory council."
40783349|NCT06424223|PROCEDURE|Horizontal Ridge augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel. A pouch is create between the bone and the matrix and the Biphasic Calcium Phosphate is inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
40783350|NCT01154452|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
40783351|NCT01154452|OTHER|Laboratory Biomarker Analysis|Correlative studies
40783352|NCT01154452|OTHER|Pharmacological Study|Correlative studies
40987597|NCT05212714|DEVICE|taVNS|The non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) device that will be used in this study is a wearable TENS unit called the Vorso STIM100 System. The Vorso system consists of a wearable, external stimulator, a neural interface ear piece, and an arm band designed to be safe for human contact. The external stimulator generates electrical pulses that are transcutaneously delivered to the auricular branch of the vagus nerve through the ear canal. The ear piece contains 4 electrodes that carry current from the external stimulator to the auricular branch of vagus nerve. The external stimulator connects to a flexible arm band that attaches to the upper arm for ease of use during each stimulation session. The type of stimulation (including shape, frequency, pulse width, amplitude, total charge, and energy delivered) is comparable to the levels applied by commercially available TENS stimulators. The sham control group will not receive any stimulation.
40987598|NCT04200456|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
40987599|NCT04200456|OTHER|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
40987600|NCT05196841|BEHAVIORAL|Anastatica Hierochuntica|During the sampling process, the researcher inquired through women who apply for pregnancy follow-up and contacted the mothers who had some inclusion criteria. Also, the researcher outlined the research plan and objectives. The participants were assessed based on the eligibility criteria and, if they were eligible and willing to participate in the study.
40987601|NCT00277433|OTHER|Buccal Swab|collection of buccal swab
40987602|NCT00003752|DRUG|bexarotene|
40987603|NCT06051188|DEVICE|Flow-controlled ventilation|Flow-controlled ventilation (FCV)
41306050|NCT04251208|OTHER|Observational Study|No intervention will be administered.
40783353|NCT01154452|DRUG|Vismodegib|Given PO
40783354|NCT04160104|OTHER|Questionnaire|Patients were asked to complete a questionnaire before colonoscopy. Bowel preparation was subsequently assessed by single endoscopist in each center using Boston bowel preparation quality score (BBPS). Both univariate and multivariate logistic regression models were used to identify high-risk factors associated with IBP and a predicting model with the bowel preparation score (BPS) was developed in the training cohort.
40783355|NCT04160104|OTHER|Questionnair|Patients were asked to complete a questionnaire before colonoscopy. The predicting modle established by the training cohort will be used to assessing the preparation of validation cohort. The result will compared with endoscopists assessment of preparation.
40783356|NCT04907071|DEVICE|Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)|The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
41306051|NCT06457984|DIETARY_SUPPLEMENT|Selenium nutritional supplementation|Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.
41464574|NCT03711396|BEHAVIORAL|Advance Care Planning Group Visits|Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.
40987604|NCT02703909|DRUG|Rocuronium|Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
40987605|NCT02703909|DEVICE|Insufflation pressure|The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
40987606|NCT03857984|OTHER|Blood sampling|blood sample before and after a single HD
41145528|NCT06399198|PROCEDURE|Free gingival graft|After adequate local anesthesia is achieved, a horizontal incision will be placed at mucogingival junction level to prepare the recipient bed. A split-thickness flap will be raised without disturbing the periosteum. A free gingival graft will be obtained from the palate. The graft will be shaped and sutured to the recipient surface.
41145529|NCT03315195|DIETARY_SUPPLEMENT|Oral nutritional supplement (ONS)|ONS supplement by 500 kcal/day for 14 days
41306052|NCT03699631|DRUG|Tacrolimus|Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.
41306053|NCT03699631|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
40783357|NCT04709003|DIAGNOSTIC_TEST|Serologic test|A blood test to check antibodies type and amount
40783358|NCT04709003|DIAGNOSTIC_TEST|Respiratory swabs|PCR test to Covid-19
40783359|NCT02015039|DRUG|BoNT Injections|
40987607|NCT04990414|OTHER|Cognitive Behavioural Therapy|Sessions 1-4 were focused on engagement, assessment of presenting problems, identification of treatment goals and normalization/ psychoeducation. Sessions 5- 14, focused on techniques to manage dissociative responses and/or increase perceived controllability of dissociation. Although further work on dissociation and/or trauma was encouraged, the targets for intervention in subsequent sessions (15-22) and the strategies selected depended on individual formulation of clients' difficulties and negotiation with the client. This could include re-appraisals on negative beliefs about dissociative experiences, cognitive and/or behavioural change strategies targeting core appraisals of voices leading to related distress, trauma-related techniques (e.g., imagery techniques,), or consolidation of a developmental/longitudinal psychological formulation of the client's difficulties. The final two sessions focused on plans for relapse prevention and maintenance of gains.
40987608|NCT00014677|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
40987609|NCT00014677|PROCEDURE|conventional surgery|
40987610|NCT04123847|OTHER|Standing and Stepping|Participants will have at least 80 sessions of stand and step training with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill.
41145530|NCT01092585|DRUG|Tesetaxel|"Tesetaxel capsules will be administered orally once every 21 days until the patient meets a withdrawal criterion or initiates nonstudy therapy for melanoma. The duration of protocol therapy will not exceed 12 months.~In Cycle 1, a flat dose of 40 mg will be administered to patients of relatively normal weight. For patients who weigh at least 25% below their ideal body weight, a flat dose of 35 mg will be administered. For patients who weigh at least 25% above their ideal body weight, a flat dose of 45 mg will be administered. Dose escalation by 5 mg in Cycle 2 and an additional 5 mg in Cycle 3 is permitted provided protocol-specified criteria are met."
41145531|NCT03726528|DIAGNOSTIC_TEST|Measurements of left ventricular pressure and volume|Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.
41145532|NCT00634348|DRUG|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
41145533|NCT00634348|DRUG|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
41145534|NCT04014686|OTHER|No exercise intervention group|no exercise intervention
41145535|NCT04014686|BEHAVIORAL|Resistance band exercise intervention group|Resistance band exercise training intervention (12 weeks, 3x per week, for 60 minutes per day)
41145536|NCT01147757|DRUG|remifentanil|During surgery, 3 different dose of remifentanil or placebo was infused.
41145537|NCT00554905|PROCEDURE|Radiofrequency ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
41145538|NCT00554905|PROCEDURE|TACE|TACE first, then RFA within 2 weeks
41145539|NCT01410721|BEHAVIORAL|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
41145540|NCT01410721|BEHAVIORAL|Cognitive Rehabilitation Control Intervention|Baseline training and follow-up at two months and four months.
41145541|NCT01996514|DIETARY_SUPPLEMENT|Glucose with water|Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
40783360|NCT02015039|PROCEDURE|Occupational Therapy|
41145542|NCT01996514|DIETARY_SUPPLEMENT|non-caloric sweetener with water|0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
41145543|NCT01996514|BEHAVIORAL|TV program with non-food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
41145544|NCT01996514|BEHAVIORAL|TV program with food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
40783361|NCT01576783|DRUG|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
40783362|NCT01576783|DIETARY_SUPPLEMENT|Placebo|400 mg corn oil per day for 6 months
40783363|NCT02903290|OTHER|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait|
40783364|NCT02903290|OTHER|walking track GAITRite,manual dynamometer, and treadmill|
40783365|NCT03828760|BEHAVIORAL|Music listening|Patients will be asked to either use their personal phones to listen to preferred music which is already on their device, or if they do not have a phone or other personal device capable of playing music of their choice, we will use a device (e.g. iPod) to load music of their choice. While in the waiting room, participants will listen to music through headphones/earphones, however they will need to remove their headphones/earphones during the initial consultation with the family physician (explaining risks, etc.), and resume listening to music through the phone speakers once in the examination room as patients will need to be able to hear instructions from the physician during the procedure.
40987611|NCT04123847|DEVICE|Standing, Stepping and Voluntary Movement with spinal cord Epidural Stimulation|Participants will be have at least 80 sessions of stand and step training with epidural stimulation, with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill. Voluntary movement with epidural stimulation will be completed in the supine or seated position.
40987612|NCT05757661|OTHER|Focal Vibration|"A single 30-minute focal vibration procedure will be performed on both quadriceps with the V-Plus Wintecare® machine.~Three channels will be used on the muscle bellies of the rectus anterior, vastus internus and vastus externus. The positioning of the vibration heads will be done with straps designed by the manufacturer to keep the vibration focus stable on the muscle belly.~The configuration of the vibration program will be in an automatic mode of 10 seconds of vibration and 3 seconds of rest to avoid the coupling of the mechanoreceptors. The frequency used will be between 60 Hz to 150 Hz with a power of 80%."
41306054|NCT03699631|DRUG|Tocilizumab|Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
41464575|NCT05831735|BEHAVIORAL|Physical activity|"The 6-month APA program is supervised via the videoconference platform and/or carried out independently based on a personalized written program that is updated weekly. The program is based on structured sessions alternating 3 types of PA: aerobic sessions, stretching sessions and muscle strengthening sessions (to be practiced following the teacher's oral or written instructions).~The sessions last from 20 minutes to 1 hour and are of low to moderate intensity depending on the initial level of fitness. The sessions are structured, adapted and progressive. During the sessions, the exercises are adapted according to the means and materials available to the patients at home or in their immediate environment.~The patients will be progressively led to practice in an autonomous way (i.e., without supervision) but following an adapted, personalized and structured program. These PA sessions can be declared afterwards to the PA teacher,(duration and the exercises actually performed)."
41464576|NCT05831735|BEHAVIORAL|Physical activity and education|"In addition to the intervention in physical activity, the people participating in this program will benefit from 6 months of educational activity (EA). The EA program includes 6 sessions scheduled according to the patients' availability in groups and by videoconference.~Following their entry into the study and their allocation to the programs (1 month maximum), the patients will be invited to a first individual EA session, in order to establish an educational diagnosis (1 hour). This session will allow for an assessment of their needs and the presentation of the workshops. Then, between the second and the sixth month following randomization, patients will benefit from 5 collective EA sessions per group of 6 patients maximum (1h30 to 2h). These sessions will be about PA, nutrition, pain management. An individual session will be held at the end of the intervention and will allow for an educational assessment."
41145545|NCT03136588|DEVICE|Feedback using ICT based monitoring system|In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
41306055|NCT03886701|DRUG|Doravirine (DOR)|Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
41464577|NCT03525249|DIETARY_SUPPLEMENT|nutraceutical|Subjects will consume a capsule for eight weeks
41464578|NCT01065389|BEHAVIORAL|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
41464579|NCT01065389|BEHAVIORAL|Unstructured Nonprogressive resistance exercise|Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
41464580|NCT03092414|PROCEDURE|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
41145546|NCT06420752|DEVICE|Calf Plantar flexion|Daily passive calf stretching
41145547|NCT06420752|DIETARY_SUPPLEMENT|Dietary nitrate|Weekday 140 ml dietary nitrate consumption two hours prior to passive stretching
41145548|NCT02578004|OTHER|biochemical and molecular analysis|
41145549|NCT05582434|DRUG|Adapalene Gel|Single topical treatment arm topical to be applied daily to area affected
40783366|NCT06101368|BEHAVIORAL|Phsical Activity|Combined Aerobic and Resistance Training
40783367|NCT06101368|DRUG|Medication|The drug will maintain their usual activity level, foot care, diet, and blood glucose diary on a regular basis. Continue the prescribed medication
41145550|NCT05582434|DRUG|Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel|Two topical treatments will be dispensed and instructions to apply daily to affected area
41145551|NCT05582434|DRUG|adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.|Three topical treatments will be dispensed and instructions to apply daily to affected area arm.
41145552|NCT02185586|PROCEDURE|laparoscopic cholecystectomy|
41145553|NCT00539604|PROCEDURE|MDCT and Coronary Angiography|
41145554|NCT02954276|DRUG|Omexa Sublingual Sumatriptan tablet|75 mg
41145555|NCT02954276|DRUG|Imitrex Oral Product|100 mg
41306056|NCT03886701|DRUG|Rifapentine (RPT)|Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
41306057|NCT03886701|DRUG|Isoniazid (INH)|Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
40987613|NCT05757661|OTHER|Sham Group|The same procedure of the intervention group will be performed but without the focal vibration head contacting the skin (sham). A sufficient space will be left between the head and the headgear so that the vibration does not touch the skin.
41464581|NCT03092414|PROCEDURE|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
40783368|NCT06399107|GENETIC|Drug Product is administered by IV infusion following myeloablative conditioning with busulfan|An autologous CD34+ cell-enriched population from patients with sickle cell disease (SCD), which includes hematopoietic stem cells (HSCs) that have been transduced with the BAH243 lentiviral vector (LVV) carrying the βA-T87Q-globin gene, is preserved in a cryopreservation solution.
40987614|NCT03610022|DRUG|Treatment with vismodegib|Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
40987615|NCT01893073|BEHAVIORAL|Mindful walking program|
40987616|NCT03890549|DIAGNOSTIC_TEST|SnoreLab (smart phone application for snoring recording)|The investigators selected 3 appropriate downloadable smart phone applications for snoring recording and make validation with the golden standard of polysomnography.
40987617|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with rhubarb root|TeTrimTeas welsh Herbal tea with green tea and rhubarb root
40987618|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with senna|TeTrimTeas welsh Herbal tea with green tea and senna
40987619|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with green tea|TeTrimTeas welsh Herbal tea with green tea
40987620|NCT03016286|OTHER|vibration|Whole body vibration at 25Hz frequency
40987621|NCT00755131|OTHER|Exercise-based Cardiac Rehabilitation program|Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
40987622|NCT05766475|BEHAVIORAL|ROSE Program: In Person|In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.
40987623|NCT05766475|BEHAVIORAL|ROSE Program: Virtual|Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.
41464582|NCT01463982|DRUG|Oratecan and Capecitabine|"Oratecan in combination with Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14"
40987624|NCT03721315|BEHAVIORAL|Intervention|"The health literacy enhancement will comprise of the following:~* Practical day to day information to help manage the disease~* Benefits of medication and adherence~* Tips to improve managing shortness of breath~* Proper use of inhalers (if applicable)~* Managing daily activities"
40987625|NCT05387655|BIOLOGICAL|BCG|BCG vaccination
41464583|NCT02361957|DIETARY_SUPPLEMENT|Ecologic 825|Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
40987626|NCT05387655|BIOLOGICAL|Placebo vaccine|Placebo vaccination
40987627|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 1
40987628|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 2
41145556|NCT05045456|DEVICE|Cardiologs Platform|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
41464584|NCT02361957|DIETARY_SUPPLEMENT|Placebo|Placebo
41306058|NCT03614091|PROCEDURE|Erector spinae plane block|20 ml Bupivacaine 0.5% below erector spinae muscle groups
41464585|NCT00898820|GENETIC|gene expression analysis|
40987629|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 3
40987630|NCT02692781|DRUG|MOD-6031|
40987631|NCT02692781|OTHER|Placebo control|
40987632|NCT01018368|DRUG|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
40987633|NCT01018368|DRUG|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
41306059|NCT03614091|PROCEDURE|Paravertebral plane block|20 ml Bupivacaine 0.5% between pleura and costotransverse ligament
41306060|NCT02242825|DRUG|Micardis®|
41306061|NCT02242825|DRUG|MicardisPlus®|
41464586|NCT00898820|GENETIC|polymorphism analysis|
41464587|NCT00898820|GENETIC|protein expression analysis|
41464588|NCT01485471|DEVICE|Diffuse optical spectroscopy imaging|ear exam imaging
41464589|NCT01950676|DEVICE|Smart phone application|The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
41464590|NCT04093154|DEVICE|wearing the virtual headset|watching the application by wearing virtual glasses to the child/adolescent
41464591|NCT00260273|BEHAVIORAL|Cognitive Behaviour Therapy|therapy
41464592|NCT03992651|DEVICE|Measurements of capnia and tissue oxygenation by optical transcutaneous sensors|Capnia and tissue oxygenation will be measured by optical transcutaneous sensors
41464593|NCT00409461|DRUG|ATG-Sirolimus-Tacrolimus|
40783369|NCT05810519|BEHAVIORAL|Active break with the proposed lumbar and hip extension exercises|Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting. In the experimental intervention, the exercise program include exercises and will be based on patient education. The participants will also explain the importance of regular training and receive a booklet with photographed and described exercises.
41145557|NCT03448302|RADIATION|Computed tomography perfusion|Pre-contrast images will be obtained to identify the colorectal tumor location. Then Fifty milliliters of iopromide (Ultravist ) will be injected intra-venously at rate of 5 milliliter per second via an automatic pump injector for computed tomography perfusion scans. Computed tomography perfusion scans will be performed at the mid-portion of the tumor for 60seconds beginning 5 seconds after contrast injection. Then arterial input will be defined by using the mouse to place a circular region of interest and the tumor region of interest will be placed on the most enhanced area of the tumor. Tumor blood flow, blood volume, mean transient time \& permeability surface measurements will be obtained.
41145558|NCT02364674|RADIATION|High Resolution Computed Tomography scan|"a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
41145559|NCT03903185|DRUG|Ledipasvir / Sofosbuvir Oral Product|45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food
40783370|NCT05810519|BEHAVIORAL|Self-care recommendations|Participants assigned to the control group will receive an educational self-care book containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. The control group will perform their regular baseline activities.
40987634|NCT05481515|DEVICE|Pulse oximetry|Pulse oximeters will be evaluated against routine arterial blood gas measurements
40987635|NCT05481515|DEVICE|Spectrophotometry|Spectrophotometry will be used to measure skin tone
40987636|NCT05426226|DEVICE|laser acupuncture|using laser acupuncture device on sleep acupoints during sleep
40987637|NCT05426226|DEVICE|sham device|using sham device on sleep acupoints during sleep
40987638|NCT03968302|DRUG|ARM A Triple therapy for helicobacter pylori|The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
40987639|NCT03968302|DRUG|ARM B Quadruple therapy for helicobacter pylori|Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
41145560|NCT05075135|DEVICE|Swibrace 3D-splint|"The Swibrace 3D splint is a custom-made splint. For scanning of the forearms, the investigators will use the scanner HandySCAN300 and the therewith delivered software VXElements, the latter being necessary to create an accurate scan on the computer.~Printing of the splint will be done by Materialise, Belgium."
41464594|NCT01348204|OTHER|quercetin|health food supplement
40987640|NCT02182531|DRUG|Epinastine|
40987641|NCT02182531|DRUG|Pseudoephedrine|
40987642|NCT02182531|DRUG|Epinastine + Pseudoephedrine combination|
41145561|NCT05075135|DEVICE|Plaster cast|The conservative gold standard treatment of distal radius and scaphoid fractures is applying a plaster cast. Therefore, patients in the control group follow standard therapy procedures.
41145562|NCT02289885|DEVICE|SonoScape|Ultrasonography device
41145563|NCT05630794|PROCEDURE|Biopsy|Undergo biopsy
40987643|NCT00437554|DRUG|Glimepiride|
40987644|NCT03633487|DRUG|Mucinex®|Mucinex® 1200 mg ER Bi-Layer tablet
40987645|NCT00396045|DRUG|Revlimid (CC-5013)|
40987646|NCT04571580|DRUG|Normal Saline|intracoronary infusion with normal saline
40987647|NCT04571580|DRUG|Reteplase Injection 9mg|low-dose intracoronary fibrinolytic therapy with reteplase 9mg
40987648|NCT04571580|DRUG|Reteplase Injection 18mg|low-dose intracoronary fibrinolytic therapy with reteplase 18mg
40987649|NCT05240560|DRUG|BP1.3656|Histamine H3 receptor antagonist/inverse agonist
40987650|NCT02576288|DRUG|Sitagliptin|anti-inflammatory properties
40987651|NCT02576288|DRUG|Placebo|No anti-inflammatory properties
40987652|NCT02975219|DRUG|Bevacizumab-800CW|4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
41145564|NCT05630794|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41145565|NCT05630794|PROCEDURE|Colonoscopy|Undergo colonoscopy
41464595|NCT03853369|DRUG|Nifekalant hydrochloride|Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride.
40987653|NCT01319812|DEVICE|Astron Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.
40987654|NCT01319812|DEVICE|Pulsar Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
41145566|NCT05630794|DRUG|Dordaviprone|Given PO
41145567|NCT05630794|OTHER|Questionnaire Administration|Complete questionnaire
41145568|NCT05630794|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
41145569|NCT00407732|BEHAVIORAL|psychosocial intervention|motivational enhancing case management intervention
40783371|NCT05654584|PROCEDURE|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery will be performed by a single surgeon.
40783372|NCT02827721|DEVICE|impulse oscillometry|
40783373|NCT02827721|DEVICE|multiple breath washout test|
40783374|NCT02827721|DEVICE|body plethysmography|
40783375|NCT04509258|DRUG|N-acetyl cysteine|a drug which can have an off label use as an antidot for aluminium phosphide poisoning in addition to sodium bicarbonate and ondansetron as standard of care
40783376|NCT04509258|DIETARY_SUPPLEMENT|acetyl L-carnitine|Naturallu occuring amino acid derivative which can be taken as a dietary supplement involves in mitochondrial function and energy production and is suggested to have a role in lowering organ damage resulting from aluminium phosphide poisonong in addition to sodium bicarbonate and ondansetron as standard of care
40783377|NCT04509258|DRUG|medicated paraffin oil|refined mixture of liquid hydrocarbons which used as laxative and is suggested to reduce absorption of aluminium phosphide if taken within two hours of administration of the toxin in addition to sodium bicarbonate and ondansetron as standard of care
40783378|NCT04509258|DRUG|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
40783379|NCT02545439|DRUG|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
40987655|NCT05903885|OTHER|On-site Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home based Fecal Immunochemical Test (FIT) kit directly at the DMV site by the research staff.
40987656|NCT05903885|OTHER|Onsite with social media advertising Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home-based Fecal Immunochemical Test (FIT) kits directly at the DMV location through face-to-face contact, supplemented by exposure to targeted social media advertisements.
40783380|NCT02213614|DIETARY_SUPPLEMENT|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
40783381|NCT02213614|DIETARY_SUPPLEMENT|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
41306062|NCT05574764|BEHAVIORAL|Cultivating Awareness and Resilience in Education (CARE)|CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.
40987657|NCT01420445|DRUG|YHD001 dose level 1|three times daily / 7 days
40987658|NCT01420445|DRUG|YHD001 dose level 2|three times daily / 7 days
40987659|NCT01420445|DRUG|Pelargonium sidoides extract|6-9mL three times daily / 7 days
40987660|NCT01420445|DRUG|placebo|three times daily / 7 days
40987661|NCT02661542|DRUG|FF-10502-01|
40783382|NCT02213614|OTHER|natural spring water|A group will drink natural spring water for 4 months
40783383|NCT06160323|PROCEDURE|EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis|"The EUS scope was first inserted into the stomach, and the coeliac trunk was visualized by scanning from the lesser curve of the gastric body. After visualization, the scope was rotated clockwise, enabling visualization and identification of the left adrenal gland. The coeliac ganglia are often seen to the left of the coeliac artery, between the aorta and the left adrenal gland, at the level between the coeliac artery and the left adrenal artery. They are also visualized cephalad to the coeliac artery in some cases. Hypoechoic nodular structures linked by hypoechoic threads residing in the periphery of this region were defined as the coeliac ganglia . A 19G or 22G needle was used for puncture of the CGN. After confirming the lack of backflow of blood with aspiration, a mixture of 5ml of 0.25-0.5% bupivacaine and 5ml absolute alcohol was injected.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed."
40783384|NCT01070342|DEVICE|Spacelabs 90217|Comparison of the two ways to measure blood pressure: using the ambulatory blood pressure device (Spacelabs 90217) versus the standard method of measuring blood pressure is done by using a stethoscope and a blood pressure cuff.
40987662|NCT06456060|DRUG|Alvogyl|Alvogyl soaked in a sterile gauze will be applied to cover the socket.
40987663|NCT06456060|DRUG|Honey|Honey soaked in a sterile gauze will be applied to cover the socket.
40987664|NCT03897179|DEVICE|INVSENSOR00032 and INVSENSOR00033|Investigational pulse oximeter device
40987665|NCT02566083|DEVICE|non-toric intraocular lens|TECNIS One-piece Monofocal Model ZCB00
40987666|NCT02566083|DEVICE|toric intraocular lens|TECNIS One-piece Toric Models ZCT300 or ZCT400
40987667|NCT03184350|RADIATION|Adjuvant pelvic proton radiation|Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation
40987668|NCT02850315|DEVICE|optimal coherence tomography|
40987669|NCT06340646|OTHER|Return of Genetic Results: Biomarker information from cancer cells|Participants will receive a novel return of results report that is tailored to their choices.
40987670|NCT06340646|OTHER|Return of Genetic Results: Inherited mutations related to cancer|Participants will receive a novel return of results report that is tailored to their choices.
40987671|NCT06340646|OTHER|Return of Genetic Results: Inherited mutations related to other medical issues|Participants will receive a novel return of results report that is tailored to their choices.
40987672|NCT03173599|DRUG|PNA 40mg|The beginning dose is 40mg.
40987673|NCT03173599|DRUG|PNA 80mg|The single dose is 80mg.
40987674|NCT03173599|DRUG|PNA 160mg|The single dose is 160mg.
40987675|NCT03173599|DRUG|PNA 240mg|The single dose is 240mg.
40987676|NCT03173599|DRUG|PNA 360mg|The single dose is 360mg.
40987677|NCT03173599|DRUG|PNA 480mg|The single dose is 480mg.
41306063|NCT01053845|OTHER|Neuropathic pain|to study the working of down inhibitor bundle at patients suffering of neuropathic pain
41306064|NCT02600026|DEVICE|DriveCam|Video event monitoring device
41306065|NCT02600026|BEHAVIORAL|Feedback|Video feedback intervention
41306066|NCT01236612|DRUG|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
40783385|NCT01135225|DEVICE|PROMUS(TM) Element (TM) Stent System|The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
40783386|NCT01135225|DEVICE|Evolution Stent System|The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
40783387|NCT02095756|OTHER|755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)|
40783388|NCT02095756|OTHER|Lytera Skin Brightening System (Non-hydroquinone topical therapy)|
40783389|NCT06201728|OTHER|Follow-up in a flare-up clinic|Follow-up in the clinic based on the time frame specified above. Additional interventions during the clinic visit, other than specified above, includes: An overview by a pulmonologist of new exacerbations, systemic steroid use, or other hospitalizations, active medications and compliance to treatment, inhaler using technique, possible medication side-effects, and the asthma control test (ACT) score. The physician will provide information on smoking cessation when relevant and pulmonary rehabilitation. In addition, decision on change of treatment and further evaluations outside of the clinic, including initiation of biologic treatment.
40783390|NCT04077177|BEHAVIORAL|Male Athlete Body Project|Participants who meet eligibility criteria and consent to the study will be randomized to one of two conditions: intervention condition (i.e., Male Athlete Body Project) or an assessment only control condition. The intervention groups will take place at IIT. Participants who accept randomization to condition will complete baseline questionnaires after randomization (immediately prior to Session 1 in the intervention condition and after being randomized to the assessment only control condition). Questionnaires will be repeated immediately post-intervention (intervention condition)/after a 3-week interval (control). All participants will be asked to complete the questionnaires again, 4 weeks after the previous round of questionnaires. The 3, 80-minute group sessions will be separated by 1 week.
40783391|NCT00602693|BIOLOGICAL|umbilical cord blood transplantation|Infusion of umbilical cord blood
40783392|NCT00602693|DRUG|Allopurinol|Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
40783393|NCT00602693|DRUG|fludarabine phosphate|40 mg/m\^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
40783394|NCT00602693|DRUG|Cyclophosphamide|50 mg/kg intravenous over 2 hours on Day -6
40783395|NCT00602693|RADIATION|Total body irradiation|200 cGy on Day -1
40783396|NCT00602693|BIOLOGICAL|Treg infusion|Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10\^5 Treg/kg.
40783397|NCT00602693|DRUG|Sirolimus|Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
40783398|NCT04927676|DIAGNOSTIC_TEST|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, a hormone status is determined.
40783399|NCT00921050|DRUG|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
40783400|NCT00921050|DRUG|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
40783401|NCT02359656|PROCEDURE|surgical treatment|C1-C1 arthrodesis
40783402|NCT02359656|OTHER|non operative treatment for odontoid non unions|specific non operative treatment protocol
40783403|NCT01643460|PROCEDURE|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size \& amount of fluid aspirated from the cyst.
40783404|NCT04602091|OTHER|no intervention|no intervention
40783405|NCT01299389|DRUG|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
40783406|NCT01299389|DRUG|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
40987678|NCT03173599|DRUG|PNA Placebo|The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
40987679|NCT06237595|DEVICE|Vagus nerve stimulation|Electrical stimulation of the vagus nerve.
40987680|NCT06237595|DRUG|Medical treatment|Medical treatment for fibromyalgia patients
40987681|NCT06237595|COMBINATION_PRODUCT|Combined vagus nerve stimulation and medical treatment|Combination of the two interventions
40987682|NCT01709851|DEVICE|Vascular microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
40987683|NCT01709851|DEVICE|Vascular and subcutaneous microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
40987684|NCT03922451|DRUG|piperacillin-tazobactam|Administered for infection treatment or prophylaxis per hospital protocol
40987685|NCT03922451|DRUG|Cefazolin|Administered for infection treatment or prophylaxis per hospital protocol
40987686|NCT04979169|BEHAVIORAL|Text Messaging|A series of theory-informed text messages encouraging them to contact their primary care provider and the UR LCS Program's Patient Navigator to coordinate screening, along with contact information to do so.
40987687|NCT01348347|DRUG|Volasertib, low dose, d1q3w|Patient to receive low dose of Volasertib IV
40987688|NCT01348347|DRUG|Volasertib, middle dose, d1q3w|Patient to receive middle dose of Volasertib IV
40987689|NCT01348347|DRUG|Volasertib, high dose, d1q3w|Patient to receive high dose of Volasertib IV
40783407|NCT03940079|DEVICE|computer-based cognitive game (including 3 training tasks)|"First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor."
40783408|NCT06370390|BEHAVIORAL|swallowing function training|"The group rehabilitation program comprised daily 60-minute sessions, five times per week for a duration of 4 weeks.~The group rehabilitation program included: Rehabilitation oral and facial exercises, Game-based surface electromyographic biofeedback training, Participants experience sharing, Individual direct feeding training"
40783409|NCT01552837|DRUG|Seroquel|for 4 weeks, 300 - 800 mg per day in 2 doses
40783410|NCT04382443|DRUG|Colchicine|At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.
40783411|NCT06212193|DEVICE|Trillium™|Trillium™ Stent Graft for Cross-Caval Tricuspid Valve Replacement
40783412|NCT04780139|DIAGNOSTIC_TEST|Ultrasonographic Evaluation of Internal Jugular Vein Cross Sectional Area|Measuring the internal jugular vein cross section area and relate this to the incidence of hypotension after spinal anesthesia.
40783413|NCT02515344|OTHER|Providing a list of patients not compliant with CRC sreening|GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
40783414|NCT02515344|OTHER|Providing general information about CRC sreening|
40783415|NCT02850588|PROCEDURE|Transcarotid artery revascularization|Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement
40987690|NCT05023265|RADIATION|Stereotactic body radiotherapy|SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.
40783416|NCT02850588|PROCEDURE|Carotid endarterectomy|Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
40783417|NCT02361671|OTHER|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
41145570|NCT01562275|DRUG|Ipatasertib|multiple doses
41145571|NCT01562275|DRUG|Cobimetinib|multiple doses
40987691|NCT01256554|PROCEDURE|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation.
40987692|NCT01256554|BEHAVIORAL|Questionnaires|Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
40987693|NCT06287333|DIAGNOSTIC_TEST|Polysomnography in routine care|Children performed a polysomnography in routine clinical care
40987694|NCT02340598|OTHER|cold vest|The lowering of body temperature increases basal metabolic rate
40987695|NCT03721276|BEHAVIORAL|EQuIP (Empowering Queer Identities in Psychotherapy)|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
40987696|NCT01304966|PROCEDURE|biopsy|excisional biopsy
40987697|NCT05364723|OTHER||no intervention
40987698|NCT01710956|RADIATION|Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy|Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
40987699|NCT03532919|DIAGNOSTIC_TEST|Serum Tropinin|Blodsamples will be taken 4 times from preoperatively to 2 Days postoperatively
41145572|NCT02443532|BEHAVIORAL|Structured group education|The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
41145573|NCT02443532|BEHAVIORAL|Individual education|Usual care (individual consultations as routinely performed)
41306067|NCT01236612|BIOLOGICAL|Immunization|Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
41306068|NCT01236612|BIOLOGICAL|Plasmodium falciparum Bloodstage challenge|Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
41306069|NCT01236612|BIOLOGICAL|Plasmodium falciparum mosquito challenge|Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
41306070|NCT01236612|DRUG|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
41306071|NCT04709991|PROCEDURE|Endovascular procedure|Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.
41306072|NCT00465491|DRUG|picoplatin|IV picoplatin 150mg/m2 q3wk
41306073|NCT00465491|OTHER|best supportive care|best supportive care
41145574|NCT00236470|DRUG|risperidone|
41145575|NCT04623996|DRUG|TP-0184|Oral dose
41306074|NCT00859781|DRUG|177Lu-J591|177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
41306075|NCT00859781|DRUG|Ketoconazole|Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
41306076|NCT00859781|DRUG|Hydrocortisone|Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
41306077|NCT00859781|DRUG|111In-J591|111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
41306078|NCT05556824|DRUG|MHS-1031|Study medication will be supplied as a syrup in individual sachets containing 1g (1.5 mL) of MHS-1031. Subjects will be randomized in 2:1 fashion to either study drug (2) or placebo (1)
40987700|NCT02607891|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
41306079|NCT05556824|OTHER|Placebo|Matching placebo is an oral solution formulated to have a degree of sweetness and acidity similar to the study medication and will be provided in equivalent sachets containing 1.5g (1.5 mL) of the oral placebo solution.
41306080|NCT04913714|BEHAVIORAL|3-month radio intervention on infant vaccination|Radio intervention comprising 10-minute drama, 10-minute discussion of the drama by trained health extension workers and 30-minute phone-in from listeners
41306081|NCT06442852|OTHER|exposure|The observed exposure factor was the expression level of synaptic associated mirna in the serum of patients with Alzheimer's disease and healthy volunteers
41306082|NCT03270696|DRUG|administration of propofol and rocuronium|compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
41306083|NCT00209599|DRUG|fospropofol disodium|
41306084|NCT03161938|DRUG|Dexamethasone|intravenous
41306085|NCT01746732|DRUG|Ortho-Cyclen|Oral administration
41306086|NCT01746732|DRUG|Evacetrapib|Oral administration
41306087|NCT04319562|PROCEDURE|needle-embedding therapy|"First group is comprised of Xinshu (BL15), Ganshu (BL18), Juque (CV14) bilaterally, and Xin and Gan of auricular point on the left ear. Second group includes Shentang (BL44), Hunmen (BL47), Jiuwei (RN15) bilaterally, and Xin and Gan of auricular point on the right side.~After skin cleansing with a 75% alcohol swab, intradermal thumbtack needle will be quickly inserted into the skin and embedded at acupoints mentioned above bilaterally. The needles will remain in the acupoints for 3 days and they will be removed by the therapists at next visit. This also can ensure better implementation of the blind method.Participants are required to receive this treatment twice a week. The specification of the needle used in the back shu point is φ9mm 0.20×1.5mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan), that in the auricular point is φ9mm 0.20×0.6mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan)."
41306088|NCT04319562|DEVICE|shame needle-embedding therapy|The acupoint selection in this group is the same as in the needle-embedding therapy group, except that the shame intradermal needles will be used. After skin cleansing with a 75% alcohol swab, the shame intradermal needles，instead of insert into the skin, it can only stick on the surface of the skin. It also will be removed by the therapists after 3 days. This takes place twice a week. The specification of the shame needle is the same as above.
41464596|NCT04636450|PROCEDURE|Rotatory technique pulpectomy|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system or a Kedo-S system.
41464597|NCT04636450|PROCEDURE|Manual pulpectomy|Primary mandibular molars treated with a manual pulpectomy and a K-file system or a Kedo-SH system.
41464598|NCT01155102|DRUG|Anastrozole|1 mg tablet
41464599|NCT02051595|OTHER|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
41464600|NCT04769115|DEVICE|Alert for temperature delta|If alert for potential complications refer to appropriate specialist
41464601|NCT04094740|DEVICE|Jet Injector without A Needle|Patients in the experimental group will use a needle - free jet injector to inject insulin, which delivers insulin at a high velocity into subcutaneous tissue and dispenses insulin over a larger area than a syringe.
41464602|NCT00252447|PROCEDURE|Pre-Operative Conformal Radiotherapy|
41464603|NCT06502990|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
40783418|NCT02289469|OTHER|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
40987701|NCT02607891|DRUG|Placebo|Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
41306089|NCT01388582|DEVICE|LNG-IUS|10 women will receive the LNG-IUS during breastfeeding
41306090|NCT01388582|DEVICE|Implanon|60 mcg/day contraceptive implant
40987702|NCT05854589|DRUG|Sodium Chloride Granules|Sodium Chloride crystals
40987703|NCT05854589|OTHER|Water|Plain distilled water
41306091|NCT01388582|DRUG|30 mcg EE and 150 LNG oral contraceptive (Microvlar)|10 women will receive oral contraceptive during breastfeeding
41306092|NCT01388582|DEVICE|TCu380A copper-intrauterine device|Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
41464604|NCT05393349|BEHAVIORAL|Empowering the patient and caregiver for early and safe discharge of patients with geriatric hip fractures|Orthopaedic surgeon, geriatrician, physiotherapists, occupational therapists, and nurses will make videos (each 3-5 minutes long) which are available to the patients and caregivers during both the hospitalization period and after discharge. They will complement the therapists' training sessions and allow revision of the contents by the patients and caregivers anytime. The patients and caregivers will be asked to complete an assessment after they view the videos to reinforce the knowledge they learn in the videos. Caregivers can be patient's relatives, friends or domestic helper who can commit to visiting the patient at least two days per week during the early discharge period.
41464605|NCT06198647|PROCEDURE|Tui-na massage|Using Tui-na massage for the back muscles
41464606|NCT06198647|PROCEDURE|positional release technique|using positional release manual technique to relax the back muscles
40987704|NCT05045976|OTHER|Web-based interactive self-management support program|The intervention group will receive a 60-90 minute introduction to the web-based interactive self-management support program. They will be instructed to do the weekly online self-assessment on symptoms, emotion, and health behaviors and how to use the web-based program to manage their health by applying self-manage skills and behavior change techniques. The contents of the interactive colorectal cancer self-management website include the following five main components: Health Support Station, Knowledge Supply Station, Sharing Stories, My Dear Friend, and Asking a Nurse.
40783419|NCT04607629|BIOLOGICAL|Genolar® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
40783420|NCT04607629|BIOLOGICAL|Xolair® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
40987705|NCT04729569|PROCEDURE|Feather edge finish line preparation|Tooth preparation with feather edge finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
40783421|NCT05272189|BEHAVIORAL|Simulated Second Reader AI|In this experiment, in some conditions, the participant makes their decision in the presence of information about a simulated artificial intelligence decision.
40783422|NCT05272189|BEHAVIORAL|Target Prevalence|The frequency with which targets are presented varies from 10% to 90%
40987706|NCT04729569|PROCEDURE|Deep chamfer finish line preparation|Tooth preparation with deep chamfer finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
40987707|NCT04508192|OTHER|Exercise|Both interventions are simple strength exercises without technical equipment
41145576|NCT00166075|PROCEDURE|Computer screen with community resource printout|Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
41145577|NCT03249272|DRUG|Regadenoson|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
41306093|NCT01388582|DEVICE|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
41306094|NCT04227249|PROCEDURE|no lymph node dissection|do not undergo lymph node dissection
41306095|NCT04511637|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|15 mg as 1 x 15 mg orally disintegrating tablet (ODT)
41306096|NCT04511637|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|15 mg as 1 x 15 mg film-coated tablet
41306097|NCT03706534|DEVICE|Ultrasound Image review with CADe|This software is a computer-aided detection (CADe) software application, designed to assist radiologist to analyze breast ultrasound images. S-Detect automatically segments and classifies shape, orientation, margin, lesion boundary, echo pattern, and posterior feature characteristics of user-selected region of interest. The device uses deep learning methods to perform tissue segmentation and classification of images.
40783423|NCT01144143|DRUG|Infliximab|the study drug will be injected into the joint through a needle
40987708|NCT02152579|DRUG|Isosorbide-5-mononitrate|Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
40987709|NCT06186531|DIETARY_SUPPLEMENT|PhytoSERM|PhytoSERM, a formulated dietary supplement, will be an ovalized tablet measuring 8.51 mm x 15.49 mm. Each pill will contain a white PEG coating and an equal mixture of, daidzein, genistein, and S-equol.
40783424|NCT01144143|DRUG|Placebo|the placebo will be injected into the joint through a needle
40783425|NCT01144143|DRUG|Standard of Care: Methylprednisolone acetate|Methylprednisolone acetate will be injected into the joint through a needle
41306098|NCT03706534|DEVICE|Ultrasound Image review with CADx|This software is also a computer-assisted diagnostic(CADx) software application, designed to assist a medical doctor in determining diagnosis by presenting whether a lesion is malignant in a breast ultrasound image obtained from an ultrasound imaging device.
40783426|NCT03910621|DRUG|Miglustat|capsule, oral use
40783427|NCT01217411|DRUG|Gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
40783428|NCT01217411|RADIATION|Whole-brain radiation therapy (WBRT)|Undergo WBRT
40783429|NCT01217411|RADIATION|Stereotactic radiosurgery (SRS)|Undergo SRS
40783430|NCT01217411|PROCEDURE|Cognitive assessment|Ancillary studies
40783431|NCT01217411|OTHER|Laboratory biomarker analysis|Correlative studies
40783432|NCT05987124|DRUG|Defibrotide|HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought(Maximum of 4 dose levels). Defibrotide will be administered in D5W or 0.9% NaCl via IV infusion over 2 hours q6 hours.
40783433|NCT01248793|DRUG|Placebo|Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
40987710|NCT06186531|DRUG|Placebo|Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.
40987711|NCT05581758|DRUG|AMG 510|Oral Tablet
41464607|NCT01405469|OTHER|Peroral Endoscopic Myotomy|A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
40783434|NCT01248793|DRUG|Golimumab|Golimumab 50 mg SC injection every 4 weeks for 48 weeks
40783435|NCT01248793|DRUG|Golimumab (placebo group)|Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
40783436|NCT01038505|DRUG|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
40783437|NCT00646386|DRUG|adalimumab|40 mg eow Week 0 - Week 24
40783438|NCT00646386|DRUG|placebo for adalimumab|40 mg eow Week 0 - Week 24
40783439|NCT03569943|DEVICE|Robot Based Transtympanic drain placement|Placement of a transtympanic drain with a robot based device assistance called RobOtol
40783440|NCT03121144|DEVICE|Masimo Centroid System|Noninvasive positional monitoring device
40783441|NCT05641402|OTHER|Text messages|Text messages based on behaviour change techniques
40783442|NCT03383042|DRUG|Cohort 1 (JP-1366 A mg)|Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
40783443|NCT03383042|DRUG|Cohort 2 (JP-1366 B mg)|Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
40783444|NCT03383042|DRUG|Cohort 3 (JP-1366 C mg)|Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
40783445|NCT03383042|DRUG|Cohort 4 (JP-1366 D mg)|Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
40987712|NCT00654407|DRUG|Rosuvastatin|
40987713|NCT00654407|DRUG|Atorvastatin|
40987714|NCT00654407|DRUG|Simvastatin|
40987715|NCT04002596|DEVICE|ExAblate Neuro Thalamotomy Treatment|Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
40987716|NCT01927406|DRUG|Prostaglandin Analog|The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
40987717|NCT01927406|DRUG|Timolol|Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
40987718|NCT04188522|DIAGNOSTIC_TEST|Magnetoencephalography (MEG)|Participants will undergo MEG at the University of Maryland (College Park) to measure cerebral activity while performing a visual naming task. The Montreal Cognitive Assessment (MOCA) will also be administered.
40987719|NCT00909779|DRUG|Arformoterol|Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
41306099|NCT03706534|DEVICE|Ultrasound Image manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored.
41306100|NCT03706534|PROCEDURE|Biopsy|Suspicious lesions found on breast ultrasound are then followed either by ultrasound guided biopsy or ultrasound imaging every 6 months for two years. For those who undergo biopsy, ultrasound provides images which are used to localize the lesion and guide the placement of the biopsy needle. The sample is sent to pathology for diagnosis, while the ultrasound guidance images are stored. For those who have imaging follow-up, ultrasound images of the breast mass are obtained, digitally stored and interpreted by the radiologist typically using BIRADS scheme.
41306101|NCT02834052|DRUG|pembrolizumab|200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
41306102|NCT02834052|DRUG|Poly-ICLC|"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18"
41306103|NCT00548080|DRUG|MK0991, caspofungin acetate / Duration of Treatment:|
41464608|NCT01817686|OTHER|Comfort Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
40783446|NCT03383042|DRUG|Cohort 5 (JP-1366 E mg)|Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
40783447|NCT03383042|DRUG|Cohort 6 (JP-1366 F mg)|Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
40783448|NCT03383042|DRUG|Cohort 7 (JP-1366 G mg)|Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
40783449|NCT03383042|DRUG|Cohort 8 (JP-1366 H mg)|Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
40783450|NCT03383042|DRUG|Cohort 9 (JP-1366 I mg)|Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
40987720|NCT00909779|DRUG|Placebo|Placebo inhalation solution, twice daily (BID) for a duration of one year.
40987721|NCT00000278|DRUG|Disulfiram|
40987722|NCT04448405|BEHAVIORAL|Questionnaire for evaluation of confinement on deviant sexual fantasies|Questionnaire for evaluation of confinement on deviant sexual fantasies. Population already followed for deviant fantasies
40987723|NCT05750355|DRUG|TPN171H 10 mg Group|6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
41306104|NCT04129749|PROCEDURE|Real-Time Analysis Interactive Lab|The Real-Time Analysis Interactive Lab uses an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment is projected on a 180 ° screen. This equipment allows patients to walk spontaneously or at prescribed speeds to a standstill in a virtual and secure virtual reality environment.
41306105|NCT03927937|PROCEDURE|AUTOTRANSPLANTATION TOOTH|Tooth with imposible prognosis is replace with a healthy tooth from the same patient.
40783451|NCT06230484|DEVICE|Invisalign first palatal expander|Most recently, a new design of a removable expander by Align was brought to our attention. In this prospective clinical study, the investigators will compare the patient-reported treatment outcomes and the dental-skeletal treatment effects on palatal dimensions. With this study, the investigators will have a better understanding of this newly developed appliance and its application in early orthodontic treatment.
40783452|NCT06230484|DEVICE|Conventional rapid maxillary expansion|Malocclusions with narrow upper arches are usually treated in the mixed dentition with a traditional bonded maxillary expander.
41306106|NCT00819208|BEHAVIORAL|exercise intervention|3 phases Phase 1: Intensive intervention for 6 months Phase 2: Reduced intervention for months 6-12 Phase 3: Minimal intervention for months 12-36
41306107|NCT00819208|OTHER|counseling intervention|Achieving an increase in PA from baseline of ≥ 10 MET hours/week will require a significant amount of behavioural support. The intervention will comprise a 36-month individualized PA and behavioural support program with a PAC. This will include a personalized PA prescription which takes into account the baseline fitness test results, PA history, performance status and patient's personal PA preferences and any barriers to activity. Most patients are likely to choose a walking program however any PA of at least moderate intensity level is acceptable.
41306108|NCT00819208|OTHER|educational intervention|Once at the beginning of the program
40783453|NCT02878395|PROCEDURE|Ileocolic resection|
40783454|NCT02367963|BEHAVIORAL|Training period|Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
40783455|NCT02367963|BEHAVIORAL|Peer-group|The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
40987724|NCT05750355|DRUG|TPN171H 30 mg Group|6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
40987725|NCT05750355|DRUG|TPN171H 40 mg Group|6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
40987726|NCT05750355|DRUG|TPN171H 50 mg Group|6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
40987727|NCT06415409|OTHER|Water|Plain water
40987728|NCT06415409|OTHER|Gatorade|Sport Drink Gatorade
40987729|NCT06415409|OTHER|BodyArmor|Sport Drink BodyArmor
40783456|NCT05610644|OTHER|isocaloric, isonitrogenous meals|Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.
40783457|NCT05936424|OTHER|Unilateral Resistance Exercise Leg|One will perform unilateral resistance exercise
40987730|NCT06415409|OTHER|GoodSport|Sport Drink GoodSport
40783458|NCT05936424|OTHER|Non-Exercise Control Leg|One leg will serve as a non-exercise control
40783459|NCT01459809|DRUG|GLIMEPIRIDE|"Pharmaceutical form: oral~Route of administration: oral"
40783460|NCT01459809|DRUG|METFORMIN|"Pharmaceutical form: oral~Route of administration: oral"
40783461|NCT03961061|BEHAVIORAL|Brenner mFIT (standard care)|Families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and PA specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, PA, and parenting. Specialized visits with the PA specialist or dietician are scheduled as pertinent issues arise. Motivational interviewing, modified by Brenner FIT for use with families, is the key to treatment; family counselors are trained in cognitive behavioral therapy, parenting support/mindfulness, and employ these approaches to assist families in developing healthy habits.
40987731|NCT03575312|DRUG|Enrofloxacin|dermal application, inhalation rsp. oral administration of Enrofloxacin
40987732|NCT03508817|DRUG|Atropine Sulfate 0.01% Eye Drops|atropine eye drop in study eye once nightly for two years.
41145578|NCT03249272|DRUG|Adenosine|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
41145579|NCT01077440|GENETIC|DNA analysis|DNA analysis will be performed on samples collected.
41145580|NCT01077440|GENETIC|polymerase chain reaction|A polymerase chain reaction (PCR) assessment will be done on the samples collected.
41306109|NCT00819208|OTHER|laboratory biomarker analysis|Every 12 months
41306110|NCT00819208|OTHER|questionnaire administration|Every 6 months
41306111|NCT00819208|OTHER|study of socioeconomic and demographic variables|Every 6 months
41306112|NCT00819208|PROCEDURE|fatigue assessment and management|Every 6 months
41306113|NCT00819208|PROCEDURE|quality-of-life assessment|Every 6 months
41306114|NCT00819208|OTHER|Educational Intervention|For Arm 2 just once at beginning of program.
41306115|NCT00819208|OTHER|Fitness testing|Objective fitness testing for both arms
41306116|NCT00076219|PROCEDURE|renal replacement therapy|renal replacement therapy
41306117|NCT03504774|DRUG|Cashew or Shrimp Oral Immunotherapy|All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
41306118|NCT06247059|DEVICE|Box Fan|Classrooms assigned to this arm will be equipped with 2 - 8 box fans each with a single minimum efficiency reporting value-14 (MERV-14) filter sufficient to increase effective air changes per hour to 12 based on the clean air delivery rate measured in cubic feet per minute of the box fan + filter \* 60 divided by the room volume.
41306119|NCT06247059|DEVICE|UV Germicidal Irradiation Lamp Unit|Classrooms assigned to this arm will be equipped with one or two 222nm wavelength light ultraviolet germicidal irradiation lamp units (number of units per classroom based on room volume).
41306120|NCT06247059|DEVICE|Combined: Box Fan and UV Germicidal Irradiation Lamp Units|Classrooms assigned to this arm will be equipped with both box fans and UV germicidal irradiation lamp units.
41306121|NCT00997048|PROCEDURE|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
40783462|NCT03961061|BEHAVIORAL|Brenner mFIT (standard care plus mobile health components)|"Brenner mFIT includes all components of the standard Brenner FIT program in addition to six mobile health components.~The six mHealth components that will be used in addition to standard Brenner Families in Training program include-~1. a mobile-enabled website,~2. diet and physical activity tracking apps and physical activity tracker~3. tailored self-monitoring feedback~4. caregiver podcasts~5. animated videos for adolescent patients~6. social support via social media."
40987733|NCT04111679|OTHER|Music|Participant selected music, applied using noise cancelling headphones
40987734|NCT01481142|DEVICE|(GMA) Adsorptive Apheresis|Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
41145581|NCT01077440|OTHER|flow cytometry|Flow cytometry will be done on the samples collected.
41145582|NCT01077440|OTHER|laboratory biomarker analysis|Laboratory biomarker analysis will be performed on the samples collected.
41145583|NCT03835819|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
41145584|NCT03835819|DRUG|IMGN853|Mirvetuximab soravtansine is an antibody-drug conjugate.
41145585|NCT00856453|BEHAVIORAL|Home yoga practice|training for and tracking of patient's practice of yoga at home
41145586|NCT00856453|BEHAVIORAL|yoga classes|organized out of home classes for yoga
41145587|NCT01430299|DEVICE|Demineralized Bone Matrix|Accell Evo3 in posteriolateral fusion (prospective cohort)
41306122|NCT00997048|PROCEDURE|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
41306123|NCT04652336|PROCEDURE|laparoscopic sleeve gastrectomy|Comparator arm - will receive standard laparoscopic sleeve gastrectomy
41306124|NCT04652336|PROCEDURE|ligamentum teres cardiopexy with sleeve gastrectomy|experimental arm - Ligamentum teres will be divided from umbilicus to up to umbilical fissure. The ligament will then be wrapped around lower esophagus and sutured.
41306125|NCT01620385|DEVICE|ciPDA|The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
41306126|NCT06113185|OTHER|survey|Demographic and clinical information of the participants will be recorded using a standardized form. The cognitive status of the patient will be evaluated according to the answers to the questions asked to the patient during the questioning of demographic data and reading and signing the consent form. The participants will be asked to complete a series of questionnaires to assess pain intensity and characteristics, pain-related functional disability, and pain-related fear-avoidance behavior. To record the presence and severity of pain behaviors exhibited during physical performance tests, patients will be asked to complete 5 functional tests (repetitive trunk flexion, repetitive sit-to-stand, timed get-up-and-go test, reach with load, 50-step walk test) and observers will simultaneously complete the Pain Behavior Scale. Each participant will be asked to attend two testing sessions separated by one week and occurring before the start of treatment.
41306127|NCT02268201|DRUG|Advagraf|oral
40783463|NCT05761821|DEVICE|Leadless pacemaker|All enrolled patients were implanted with leadless pacemaker.
41306128|NCT02268201|DRUG|Prograf|oral
41306129|NCT00287326|DRUG|Bupivacaine, Clonidine, Morphine|
41306130|NCT04460690|DEVICE|Rapid Onsite COVID-19 Detection|saliva assay test for high concentrations of SARS-CoV-2
41306131|NCT06518512|DEVICE|Automated Vision Assessment and Impairment Detection through Gaze Analysis (AVIGA) system|"AVIGA is an automated method and system for vision assessment of a subject. The method includes the following: determining a set of test patterns for the subject based on a preliminary assessment of an eye of the subject; displaying the set of test patterns sequentially to the subject; collecting data on the subject's gaze in response to each test pattern displayed; and correlating central vision function of the subjects to the collected gaze data.~Subjects perform the AVIGA test monocularly and pursue a pre-determined target moving in a customized waveform across the computer screen. The trail of the gaze points generated by the subject following the target is simultaneously recorded and stored.~1. Static Fixation Evaluation (SFE)~2. Static Perimetry Assessment (SPA)~3. Static Perimetry Sensitivity Assessment (SPSA)~4. Pursuit"
41464609|NCT01817686|OTHER|Life Extension Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
41464610|NCT01817686|OTHER|Standard Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
41464611|NCT05694260|DRUG|Bempedoic acid|Once daily oral dosing with oral tablets or oral suspension.
41464612|NCT02588196|DRUG|Dexamethasone acetate|
41464613|NCT06504303|DEVICE|3D-printed socket|During the shape-capturing in-patient appointment, participants will be measured for the prosthetic device through (1) manual casting using Plaster of Paris bandages and (2) scanning using a 3D scanner. The clinician will manually modify the positive plaster cast and digitally modify the scanned impression using OMEGA software. The manually-modified positive cast will be digitized by scanning the cast, then 3D-printed. The digitally-modified socket file will also be 3D printed. The research investigator will make a de-identified mark on each socket to differentiate between the two sockets after 3D printing, and will record the order in which the sockets are fit to the patient.
41464614|NCT00263887|DRUG|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
40783464|NCT01016132|DEVICE|lotrafilcon A contact lens|Investigational silicone hydrogel, single-vision, soft contact lens worn for four weeks at least as often as and on the same basis as participant's habitual lenses, as prescribed by participant's eye care practitioner -- ie., on a daily wear, flex wear, or extended wear basis.
40987735|NCT01561820|BEHAVIORAL|5-month aerobic exercise intervention|The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5\[HRmax-HRrest\]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
40987736|NCT03689998|DEVICE|immediate implant placement|immediate implant placement in freshly extraction socket
40783465|NCT05956002|DRUG|Estraimod Immediate Release (IR)|an immediate release tablet
40987737|NCT03689998|DRUG|Melatonin|topical application of melatonin
40783466|NCT05956002|DRUG|Etrasimod Mini Tab in water|very small tablet mixed in water
40783467|NCT05956002|DRUG|Etrasimod Mini Tab in chocolate pudding|very small tablet mixed in chocolate pudding
40783468|NCT05956002|DRUG|Etrasimod Mini Tab in yogurt|Very small tablet mixed in yogurt
40783469|NCT05956002|DRUG|Etrasimod Mini Tab in applesauce|Very small tablet mixed in applesauce
40783470|NCT04236089|DEVICE|robotic hand|mirror therapy with robotic hand
40783471|NCT03667404|DIETARY_SUPPLEMENT|Resistant maltodextrin|Resistant maltodextrin powder
40783472|NCT03667404|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin powder
40783473|NCT05465525|PROCEDURE|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
41145588|NCT01430299|DEVICE|rh-BMP2|rh-BMP2 in posterolateral fusion (retrospective cohort)
40783474|NCT05465525|PROCEDURE|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
40987738|NCT02473354|DRUG|Remifentanil|The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air \[21% Oxygen\]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
40783475|NCT05465525|OTHER|No Block|The patients will receive general anesthesia.
40987739|NCT02473354|DRUG|Oxygen|Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
40987740|NCT02473354|DRUG|Carbon dioxide|Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
41145589|NCT03122444|DRUG|Imipramine|Imipramine will be given daily for 21-30 days.
41145590|NCT06211751|DRUG|TQB3909 tablets|TQB3909 is a protein inhibitor.
41145591|NCT06211751|DRUG|TQB3702 tablets|TQB3702 is a kinase inhibitor.
40783476|NCT03759990|DEVICE|lean|Videolaryngoscope used in intubation
40783477|NCT03759990|DEVICE|obese|Videolaryngoscope used in intubation
40783478|NCT03951285|DIETARY_SUPPLEMENT|NR in BMI-discordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
40783479|NCT03951285|DIETARY_SUPPLEMENT|NR in BMI-concordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
40783480|NCT02434211|OTHER|Questionnaire and focus group|
40987741|NCT04552392|OTHER|No intervention|No intervention
40987742|NCT03571074|OTHER|Oxygenation|Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
40987743|NCT05161598|DRUG|Teclistamab|Teclistamab will be administered subcutaneously (SC).
40987744|NCT02588170|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
41145592|NCT05183802|DRUG|Setmelanotide, administered subcutaneously [SC], once daily.|Dosing based on age, and titrated from starting dose to target dose.
41464615|NCT00263887|DRUG|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
41464616|NCT01024777|DRUG|Cholecalciferol|Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
41464617|NCT01024777|DRUG|Cholecalciferol|Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
41464618|NCT03941834|DRUG|Rimegepant|BHV3000 (rimegepant) 75mg tablet
40783481|NCT06387069|DRUG|HMPL-306 Regimen|Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.
40783482|NCT06387069|DRUG|Salvage Chemotherapy Regimen|"Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:~* MEC regimen: etoposide injection 100 mg/m2, cytarabine injection 1000 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).~* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4).~* LoDAC: cytarabine injection 20 mg q12h SC or IV for 10 consecutive days (Days 1-10).~* Azacitidine: azacitidine injection 75 mg/m2 QD SC or IV for 7 consecutive days (Days 1-7)."
40783483|NCT00770302|DRUG|Saxagliptin|Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days
40783484|NCT03973957|DEVICE|Indwelling pleural catheter placement|Indwelling pleural catheter placement by interventional pulmonologist
40783485|NCT03973957|DRUG|Fentanyl Citrate|Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
40783486|NCT03973957|DRUG|Talc Slurry|Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
40783487|NCT03973957|DEVICE|Drainage collection bag|Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
40783488|NCT03313414|DRUG|Sofosbuvir/Velpatasvir Treatment for 14 days|14 day therapy with Sofosbuvir/Velpatasvir
41306132|NCT02259036|OTHER|Ecological Momentary Treatment Enhancement|Participants will be given a pre-programmed smartphone on which they will enter their responses to a series of questions about moods and daily experiences using an app developed for this study. The child will receive an electronic notification message once per day and will be prompted through a series of questions about what he/she is doing, who he/she is with, how he/she is feeling, worries or stressful events, and how he/she coped with these events. It should take the child approximately 5 minutes each time to complete the questions. Participant data will be sent to study therapists to be reviewed weekly. The therapist will integrate this information into treatment and provide customized feedback to the patient.
41464619|NCT03941834|DRUG|Placebo|Placebo
41306133|NCT00579124|DEVICE|CliniMACs|T and B Cell depletion
41306134|NCT00462696|DRUG|docetaxel|
41306135|NCT00462696|DRUG|epirubicin hydrochloride|
41306136|NCT00462696|PROCEDURE|conventional surgery|
41464620|NCT05539534|BEHAVIORAL|Training on suicide prevention|Suicide prevention training in Flanders is organised by the Centre for the Prevention of Suicide and the suicide prevention workers of the Centra for Mental Health Care. These trainings are announced via the website zelfmoord1813.be/vormingen or are organized on demand. When a participant registers, they will be invited to participate in the study one week before the training.
41464621|NCT00193973|DRUG|Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C|Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
40783489|NCT03830580|OTHER|Positive stimulation (singing)|A nurse or assistant trained in singing with an operal singer sings a lullaby She sits next to the incubator and sings from the time the sucrose is administered (2 minutes before the fundus exams is performed) until the end of the examination - taking into account the child's reaction
40783490|NCT00956293|DRUG|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
40783491|NCT00956293|DRUG|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
41306137|NCT00462696|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
41306138|NCT00462696|PROCEDURE|neoadjuvant therapy|
41464622|NCT00193973|RADIATION|Radiation Therapy|Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
41464623|NCT04073134|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
41306139|NCT00462696|PROCEDURE|radiomammography|
41306140|NCT01515306|BIOLOGICAL|ramucirumab (IMC-1121B)|ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
41306141|NCT01515306|DRUG|paclitaxel|paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
40783492|NCT00956293|DRUG|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
40783493|NCT00956293|DRUG|Cyclosporin A (CsA)|Dosage was based according to blood level
40783494|NCT00956293|DRUG|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
40783495|NCT01497197|DRUG|GONAL-f®|GONAL f® 300 international units \[IU\] per day as subcutaneous injection using liquid pen.
40783496|NCT01497197|DRUG|Luveris®|Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
40783497|NCT01497197|BIOLOGICAL|Recombinant human chorionic gonadotropin (r-hCG)|A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
40783498|NCT00290810|BIOLOGICAL|bevacizumab|Given IV
40783499|NCT03612024|BEHAVIORAL|questionnaire|a standardized questionnaire was sent to all participants
40783500|NCT04462601|OTHER|Biomarker detection|Quantification of serum markers of intestinal permeability and bacterial and fungal translocation
40783501|NCT03653182|DIAGNOSTIC_TEST|Pulse, tongue image, and voice sound|They are four diagnosis methods of TCM
41464624|NCT04073134|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
41464625|NCT04351230|DRUG|Abemaciclib|Given IV
40783502|NCT05821660|OTHER|Five-day hypocaloric and ketogenic programme|Dietary intervention
40783503|NCT02455869|DRUG|SRP and Placebo gel|After SRP, placebo gel was delivered subgingivally into the pocket
40783504|NCT02455869|DRUG|SRP and Atorvastatin|After SRP, Atorvastatin gel was delivered subgingivally into the pocket
40783505|NCT02455869|DRUG|SRP and Alendronate|After SRP, Alendronate gel was delivered subgingivally into the pocket
40783506|NCT04787003|DRUG|oncolytic virus (OVV-01) injection|intratumoral injection of OVV-01 with or without immune checkpoint inhibitors
40783507|NCT05285579|BIOLOGICAL|Blood collection|Systematic extra blood sampling at inclusion, 6 weeks after inclusion and in case of progression of the cancer
40783508|NCT05285579|OTHER|Tumour samples|reuse of tumour tissue collect in usual patient care
40987745|NCT02588170|OTHER|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
40987746|NCT02045797|DRUG|GSK2140944 Lyophile|GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
40987747|NCT02045797|DRUG|GSK2140944 Capsules|GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
40987748|NCT03737747|PROCEDURE|induced hypothermia|
40987749|NCT03301038|DRUG|Rifampin|Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
40987750|NCT04278547|DIAGNOSTIC_TEST|ELISPOT IFN-γ assay|"ELISPOT IFN-γ diagnostic test: Evaluation of specific cellular immune response against the IE-1 antigen and the CMV pp65, using the technique ELISPOT IFN-γ and individualize the preventive strategy according to the result. In patients with a ELISPOT of low risk will be made advance therapy (preemptive therapy) guided by PCR of CMV In patients with a high risk ELISPOT, universal prophylaxis with valganciclovir will be performed oral (900 mg / 24h) or intravenous ganciclovir (5-10 mg / Kd / day) in case the oral route is not available."
40987751|NCT00656344|OTHER|Cognitive behavioral treatment enhanced by virtual reality|A cognitive behavioral protocol with cognitive and behavioral techniques will be used to treat symptoms. The exposure part of the treatment will be enhanced with the use of a virtual environment.
41464626|NCT04351230|BIOLOGICAL|Trastuzumab Emtansine|Given PO
41464627|NCT05735158|BIOLOGICAL|KB105|Replication-defective, non-integrating HSV-1 vector expressing TGM1 formulated as a topical gel
41464628|NCT05735158|OTHER|Placebo|Visually matched excipient gel
41464629|NCT01505361|BIOLOGICAL|Lactobacillus salivarius PS2|9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth
40783509|NCT00521677|PROCEDURE|Sage oral care|Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
40783510|NCT00521677|PROCEDURE|Traditional oral care|Cleaning of oral cavity with menthol solution, TID
40783511|NCT06350422|OTHER|Head-Down tilt Bed Rest test|All of the volunteers underwent 60 days of the Head-Down tilt Bed Rest test.
40987752|NCT02416258|DRUG|LP0113 aerosol spray|
40987753|NCT02416258|DRUG|Aerosol spray vehicle|
40987754|NCT02416258|DRUG|LEO 90100 aerosol foam|
40987755|NCT02416258|DRUG|Betamethasone dipropionate aerosol spray|
40987756|NCT02416258|DRUG|Calcipotriol aerosol spray|
40987757|NCT02416258|DRUG|Daivobet® gel|
40987758|NCT04165512|COMBINATION_PRODUCT|bupivacaine and triamcinolone|a mixture of 4 mL 0.5% bupivacaine (marcaine) and 1 mL 40 mg triamcinolone (kenacort-a)
40987759|NCT05202743|OTHER|Observational for ALS patients|Open to ALS patients interested in mindfulness training.
41464630|NCT01505361|BIOLOGICAL|Excipient (milk powder)|100 mg/once a day from 30 week of pregnancy until birth
41464631|NCT05496673|DIAGNOSTIC_TEST|Pastorex Latex Agglutination Test|Rapid diagnosis of bacterial meningitis
41464632|NCT05496673|DIAGNOSTIC_TEST|Biofire PCR for meningitis|Rapid diagnosis of multiple forms of meningitis
41464633|NCT05496673|DIAGNOSTIC_TEST|Immy CrAg Lateral Flow Assay|Rapid diagnosis of cryptococcal meningitis
41464634|NCT04412486|BIOLOGICAL|COVID Convalescent Plasma|One unit of COVID Convalescent Plasma transfused on Day 0
41464635|NCT03066791|DIETARY_SUPPLEMENT|Turmeric tablets|
41145593|NCT00572494|DEVICE|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
41306142|NCT05436197|BEHAVIORAL|PLAYshop Program|The intervention includes: 1. Educational Training - the 60 min virtual/hybrid workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be provided with physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
41306143|NCT00664092|OTHER|Residential|living in a democratic, resident-run setting
41306144|NCT00664092|OTHER|Residential|Professionally-run substance abuse recovery setting
41306145|NCT03055403|DRUG|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
41306146|NCT03055403|DRUG|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
41306147|NCT06033339|OTHER|Blood sampling|Collection of 10 ml of blood on EDTA tubes per patient. Once collected, the blood tubes will be transported within 24 hours to the IRB (Biotherapy Research Institute) of Montpellier University Hospital, where the monocytes will be isolated by magnetic sorting on the basis of expression of surface marker CD14+, after a preliminary step of Ficoll. Monocytes will then be frozen in nitrogen at -196°C until use (biobank).Gain-of-function experiments will then be performed on monocytes by transfecting them with the microRNA of interest or control. The expression of the pyrin protein and its phosphorylation rate will be evaluated after induction by immunoprecipitation experiments followed by western blot. The activity of the pyrin inflammasome will also be studied by looking at pyroptosis and toxicity rate using LDH test. All these experiments will be carried out in the absence and in the presence of the microRNA in order to study its role in the pathophysiology of FMF.
40987760|NCT05830487|BEHAVIORAL|Low AGE diet with reduced energy and fat|This group will be given a low AGE diet with reduced energy and fat,.
40987761|NCT05830487|BEHAVIORAL|Energy and fat-reduced normal diet|This group will be given a diet with reduced energy and fat, and AGE levels will not be interfered with
40987762|NCT01226446|DRUG|vitamin D|Vitamin D on top of the standard treatment
40987763|NCT03169582|DRUG|Avanafil|Drug administration (Avanafil)
40987764|NCT03169582|DRUG|Sildenafil|Drug administration (Sildenafil)
40987765|NCT01053364|DEVICE|NL-Prow interspinous spacer implant|Interspinous spacer implant
40987766|NCT03493009|DEVICE|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
40987767|NCT00774319|RADIATION|conventional radiotherapy with 'high' dose cisplatin|"radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.~100 mg/m2 cisplatin iv on day 1, 22 and 43"
40987768|NCT00774319|RADIATION|accelerated radiotherapy with 'low' dose cisplatin|Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
40987769|NCT00231335|DRUG|escitalopram|
40987770|NCT03432741|DRUG|Belinostat|Given intralesionally
40987771|NCT03432741|DRUG|Carfilzomib|Given intralesionally
40987772|NCT03432741|DRUG|Copanlisib Hydrochloride|Given intralesionally
40987773|NCT03432741|BIOLOGICAL|Daratumumab|Given intralesionally
40987774|NCT03432741|DRUG|Fludeoxyglucose F-18|Undergo FDG-PET
40987775|NCT03432741|DRUG|Gemcitabine Hydrochloride|Given intralesionally
40987776|NCT03432741|OTHER|Laboratory Biomarker Analysis|Correlative studies
40987777|NCT03432741|BIOLOGICAL|Nivolumab|Given intralesionally
40987778|NCT03432741|BIOLOGICAL|Obinutuzumab|Given intralesionally
40987779|NCT03432741|BIOLOGICAL|Pembrolizumab|Given intralesionally
40987780|NCT03432741|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
40987781|NCT03432741|BIOLOGICAL|Rituximab|Given intralesionally
40987782|NCT03432741|DRUG|Romidepsin|Given intralesionally
40987783|NCT03432741|OTHER|Saline|Given intralesionally
40987784|NCT03432741|BIOLOGICAL|Trastuzumab|Given intralesionally
40987785|NCT06376682|PROCEDURE|CT-guided bone percutaneous procedure|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures (thermal ablation, bone consolidation, biopsy procedures).
40987786|NCT03394482|DRUG|Lu AF35700 5 mg clinical formulation|Lu AF35700 tablets 5 mg oral single dose
40987787|NCT03394482|DRUG|Lu AF35700 5 mg commercial formulation|Lu AF35700 tablets 5 mg oral single dose
40987788|NCT03394482|DRUG|Lu AF35700 10 mg clinical formulation|Lu AF35700 tablets 10 mg oral single dose
40987789|NCT03394482|DRUG|Lu AF35700 10 mg commercial formulation|Lu AF35700 tablets 10 mg oral single dose
40987790|NCT03394482|DRUG|Lu AF35700 20 mg clinical formulation|Lu AF35700 tablets 20 mg oral single dose
40987791|NCT03394482|DRUG|Lu AF35700 20 mg commercial formulation|Lu AF35700 tablets 20 mg oral single dose
40987792|NCT01037387|DRUG|Control|Current treatment according to the ATS/ERS guidelines
40987793|NCT01037387|DEVICE|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
41464636|NCT03066791|DIETARY_SUPPLEMENT|Curcumin and Bioperine tablets|
40987794|NCT02154191|PROCEDURE|Surgical Intervention|The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
40987795|NCT02929823|DRUG|High Dose SJP-0035 Ophthalmic Solution|0.001% SJP-0035 Ophthalmic Solution
40987796|NCT02929823|DRUG|Low Dose SJP-0035 Ophthalmic Solution|0.0002% SJP-0035 Ophthalmic Solution
40987797|NCT02929823|DRUG|Vehicle of SJP-0035 Ophthalmic solution|0% SJP-0035 Ophthalmic Solution
40987798|NCT05250037|PROCEDURE|Home spirometry|Undergo spirometry measurements
40987799|NCT05250037|PROCEDURE|Biospecimen Collection|Undergo nasal and/or oral swabs, and blood collection
40987800|NCT05250037|OTHER|Questionnaire Administration|Complete questionnaires
40987801|NCT04739631|OTHER|acupuncture|use disposable sterile needles to insert to the acupuncture point
40987802|NCT04739631|OTHER|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture(superficial needling) at non- acupoints.
40987803|NCT02855437|DEVICE|IVR (Phone call)|IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
40987804|NCT02855437|DEVICE|RheumPro (Smartphone application)|"RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm."
40987805|NCT02556333|DRUG|FTC/TAF|Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
40987806|NCT04474860|DIAGNOSTIC_TEST|gene sequencing|Gene fragment analysis, Sanger sequencing method and/or high-throughput whole-genome sequencing will be performed to find the pathogenic gene and mutation site of MH in Chinese population.
40987807|NCT04192877|DIAGNOSTIC_TEST|Vagus Nerve Neurodynamic test|The VN-NDT has been developed starting from the VN morphology selecting the physiological movements that induce the greater mechanical tension on the nerve. The subjects will be assessed supine on an examination table with assessors standing at the cranial short side of the table. Upper cervical flexion and contralateral lateral flexion had been selected for loading the intracranial portion. The ipsilateral neck rotation had been selected for loading the cervical tract. Keeping the subject's head in the final movements combination gentle movements of the upper abdomen caudally and cranially had been selected for loading the thoracic tract and used as discrimination maneuver. The test will be declared positive (indicating abnormal responses) if symptoms will be felt in anatomical regions other than the neck on the same side of the test and discrimination maneuvers changed the subject's symptoms indicating a neurogenic source, otherwise it will be declared negative.
40987808|NCT05224674|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
40987809|NCT03716882|DEVICE|Song Meter (SM)4|Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights. This record will take place at 15 days of life, 1 and half months, 2 and half months and 3 and half months.
41306148|NCT06376214|DRUG|Dratumumab / Hyaluronidase Injection [Darzalex Faspro]|Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.
41306149|NCT06376214|DRUG|Pomalidomide 4 MG|Patients received oral pomalidomide on days 1-21 of a 28-days cycle from cycle 1 to 6.
41306150|NCT06376214|PROCEDURE|autologous stem cell transplantation (ASCT)|"The ASCT protocol included mobilisation with colony-stimulating factor alone and conditioning with high-dose melphalan140-200 mg/m2~."
41306151|NCT05169307|DRUG|CPX-351|This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.
41306152|NCT05365620|DEVICE|Mechanical In-Line Inexsufflation|In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.
41464637|NCT03066791|DIETARY_SUPPLEMENT|Placebo tablets|
41464638|NCT01917084|OTHER|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
41464639|NCT04502849|PROCEDURE|Bypass surgery|Creating a bypass with graft or vein.
41464640|NCT04502849|PROCEDURE|Endovascular angioplasty/stenting|Performing an angioplasty with or without stenting in stenosis.
41464641|NCT04502849|PROCEDURE|Hybrid surgery|Performing an angioplasty with or without stenting in stenosis and creating a bypass with graft or vein.
41464642|NCT04502849|DRUG|Vitamin E|100 mg Vitamin E per os 1 per day (1 month).
41464643|NCT04502849|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound of lower limbs arteries.
41464644|NCT04502849|DIAGNOSTIC_TEST|Blood sampling|Blood sampling for apoptosis and endothelial dysfunction markers.
41464645|NCT04502849|DIAGNOSTIC_TEST|Arterial wall sampling|Arterial wall sampling for apoptosis markers.
41464646|NCT03496987|DEVICE|Vacuum Bottle Drainage|Patients undergo drainage via vacuum bottles
41464647|NCT00384124|DRUG|Imiquimod|Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
41464648|NCT00670033|DRUG|Travoprost ophthalmic solution (new formulation)|
41464649|NCT00670033|DRUG|Travoprost ophthalmic solution, 0.004%|
41464650|NCT00670033|DRUG|Vehicle|Inactive ingredients used as a placebo
41464651|NCT01166815|DIETARY_SUPPLEMENT|Zinc sulphate|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
41464652|NCT01166815|OTHER|Placebo|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
41464653|NCT04181164|OTHER|Microindentation|Microindentation is a new technology directly measuring bone strength by a minimal invasive technique.
41464654|NCT04181164|OTHER|High resolution peripheral quantitative computed tomography (HRpQCT)|HRpQCT scan can assess the cross-sectional geometry of the bone and is an appropriate investigation to evaluate bone quality.
40987810|NCT05985850|DRUG|Aurora 1:1 Drops (Indica)|Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.
40987811|NCT05985850|DRUG|Placebo|Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).
40987812|NCT03395912|DRUG|Intervention|After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
40987813|NCT00941018|DRUG|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
41464655|NCT04181164|BIOLOGICAL|Biochemical analysis of different bone markers.|Measurement of different bone markers by biochemical analysis of blood samples.
41464656|NCT05582109|DRUG|Envafolimab, Lenvatinib Combined With TACE|PD-L1 inhibitor
40987814|NCT03479307|DRUG|Bilastine Ophthalmic Solution 0.6%|1 drop in each eye at 2 separate times during an 8 day period.
40987815|NCT03479307|DRUG|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|1 drop in each eye at 2 separate times during an 8 day period.
40987816|NCT03479307|DRUG|Vehicle of Bilastine Ophthalmic Solution|1 drop in each eye at 2 separate times during an 8 day period.
40987817|NCT01266460|BIOLOGICAL|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
40987818|NCT01266460|OTHER|Laboratory Biomarker Analysis|Correlative studies
40987819|NCT02123355|DRUG|Induction of anesthesia|Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
41464657|NCT00428818|DRUG|trimethoprim-sulfamethoxazole or doxycycline|
41464658|NCT04568577|OTHER|Tape with tension|The elastic bandage will be applied with a voltage increase controlled weekly, for five weeks. Each week, 5% of tension will be added to the application. In the first week the application will be tension-free.
41464659|NCT04568577|OTHER|Tape without tension|Bandaging applications will be weekly, for five weeks, without tensioning the tape.
41464660|NCT04387617|DRUG|Cannabidiol|The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.
41464661|NCT04387617|DRUG|Placebo|The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
40987820|NCT02123355|PROCEDURE|Intubation|After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35\~40 mmHg，pulse oxygen saturation is more than 95%.
40987821|NCT02123355|DRUG|Sevoflurane, remifentanil ,vecuronium|Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
40987822|NCT02123355|DRUG|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
40987823|NCT02123355|DRUG|Placebo|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
41464662|NCT02040519|BEHAVIORAL|Filling out voiding diaries.|
41464663|NCT00091286|BIOLOGICAL|HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine|
41464664|NCT03476681|DRUG|NEO-201 in combination with pembrolizumab|NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
41464665|NCT00040690|BIOLOGICAL|filgrastim|
41464666|NCT00040690|DRUG|cyclophosphamide|
41464667|NCT00040690|DRUG|cytarabine|
41464668|NCT00040690|DRUG|doxorubicin hydrochloride|
41464669|NCT00040690|DRUG|etoposide|
41464670|NCT00040690|DRUG|ifosfamide|
41464671|NCT00040690|DRUG|leucovorin calcium|
41464672|NCT00040690|DRUG|methotrexate|
41464673|NCT00040690|DRUG|vincristine sulfate|
41464674|NCT00040690|RADIATION|radiation therapy|
41464675|NCT01100450|BEHAVIORAL|Progressive Resistance Training|12-week progressive resistance training (PRT) exercise program
41464676|NCT01572519|DRUG|Phase 1, Cohort 1|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
41464677|NCT01572519|DRUG|Phase 1, Cohort 2|Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
41464678|NCT01572519|DRUG|Phase 1, Cohort 3|Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
41306153|NCT05365620|PROCEDURE|catheter suction|catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.
41306154|NCT01389648|OTHER|Pre Operative|Pre operative chest physiotherapy treatment
41306155|NCT02522962|BEHAVIORAL|GroupCoreSIT|"Each group session lasts for 60 minutes. The physiotherapist will chose from an exercises bank of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training."
41306156|NCT02522962|BEHAVIORAL|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
41306157|NCT04875039|DRUG|Dexamethasone|dexamethasone 2 mg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
41306158|NCT04875039|DRUG|Dexmedetomidine-Dexamethasone|A mixture of dexamethasone 2mg with dexmedetomidine 50mcg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
41306159|NCT02280291|DRUG|Ankle SSB|general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
41464679|NCT01572519|DRUG|Phase 1, Cohort 4|Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
41464680|NCT01572519|DRUG|Phase 2|JNJ-40346527 at the recommended dose determined in Phase 1
41464681|NCT00988468|PROCEDURE|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
41464682|NCT00988468|BEHAVIORAL|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
40987824|NCT04011501|PROCEDURE|Continuous Erector spinae block|Erector spine block and catheter placement will be performed for continuous analgesia prior to the surgical procedure.A initial bolus of 20 ml of Levobupivacaine 0.25% will be administered. Subsequently a 22G catheter will be introduced. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
40987825|NCT02956486|DRUG|Elenbecestat|Oral tablet.
40987826|NCT02956486|DRUG|Placebo|Oral tablet.
40987827|NCT05814575|BEHAVIORAL|NEXUS intervention|During the fetal ultrasound protocol, the NEXUS intervention is added for the component of 'attachment promotion' as it is a natural extension to share with the pregnant person the behavioral and social strengths of their unborn child. As the participant observes the fetus on the monitor (a second external monitor is set up for easy viewing by the mother), she may also feel fetal movement simultaneously in the womb (after 23 weeks gestation), creating a visual and sensory link between the mother and fetus. A trained nurse or ultrasonographer shares observations of fetal behavior with the mother and others if present. The nurse is also trained in motivational interviewing techniques to use the strengths of the mother and those attributed to her fetus to explore readiness to change and other motivational factors that may be barriers to health promotion.
40987828|NCT05814575|BEHAVIORAL|Standardized Non-Medical fetal ultrasound|A standardized protocol using non-diagnostic fetal ultrasound that includes basic maternal-fetal health assessment by a trained nurse, fetal neurobehavioral assessment, measures of fetal growth, and pictures \& videos given to parents.
40987829|NCT02094261|DRUG|AZD9291|Once daily tablet 80 mg
40987830|NCT02533947|BEHAVIORAL|Exercise|The intervention consists of an individually tailored supervised exercise program with aerobic, strength and coordinative components.
40987831|NCT02533947|BEHAVIORAL|Control|A waitlist control group will get the intervention after 7 month of treatment as usual.
40987832|NCT04698720|BEHAVIORAL|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot).The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds.The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
41464683|NCT00988468|BEHAVIORAL|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
41464684|NCT01029392|DRUG|Vitamin D|2000iu once a day
41464685|NCT05884255|DRUG|Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide|Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide
41464686|NCT05884255|DRUG|long-acting Octreotide.|High-dose long-acting Octreotide.
41464687|NCT01288391|DRUG|NNC 0128-0000-2011|Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
41464688|NCT01288391|DRUG|NNC 0128-0000-2011|Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
41464689|NCT03710616|PROCEDURE|Surgeries|Surgical operations plus systematic lymphadenectomies
41464690|NCT03542734|OTHER|multimodal magnetic resonance imaging|multimodal magnetic resonance imaging included T1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI
41464691|NCT06275178|PROCEDURE|Medical thoracoscopy|The included particpants are the patients with unexplained pleural effusion who underwent thoracoscopic or video-assisted thoracoscopic biopsy.
41464692|NCT00005887|DRUG|efaproxiral|
41464693|NCT00005887|RADIATION|radiation therapy|
40783512|NCT03949023|PROCEDURE|Standard of Care Cerebral Angiogram Group|"Subjects will undergo the standard of care cerebral angiogram and any intervention(s) (when applicable) that were discussed with their provider, following the standard procedural protocol for the procedure at WFBMC. There are no additional interventions or changes to the planned intervention(s) that will take place by agreeing to participate in the study.~The data collected from this procedure, following the standard of care protocol, will include the following: force of injection of contrast material for each angiographic run (peak pressure associated with injection, duration of peak, and area under pressure curve), volume of contrast utilized, images from the procedure, measurements of vessel diameter at defined distances from the catheter tip utilizing the images, catheter type, any additional device(s) (when applicable) utilized during the procedure, and if spasmolytic agents are utilized (including dose and time of administration)."
40783513|NCT02749747|DRUG|Sulpiride use|50mg sulpiride once a day use for 60 days
40783514|NCT02749747|DRUG|Placebo|50mg placebo once a day use for 60 days
40783515|NCT03729843|RADIATION|CBCT and intraoral digital radiography|Simulated periodontal bone defects will be measured by 2 techniques: group I detected and measured using CBCT and group II intraoral digital radiography and all the measurements will be compared with the gold standard real measurements on the dry jaws
41464694|NCT02360306|PROCEDURE|Endobronchial Ultrasound|Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
41464695|NCT01588548|DRUG|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
40783516|NCT03262805|DIETARY_SUPPLEMENT|Lanconone|. Lanconone® is a joint pain supplement containing natural herbs such as Shyonak, Ashwagandha, Shunthi, Guggul, Chopchini, Rasna and Shallaki in therapeutic quantities and documented in the ancient scriptures as pain relievers.
40783517|NCT03262805|OTHER|Placebo|Microcrystalline cellulose
40783518|NCT03092479|BEHAVIORAL|Behavioral Intervention|Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
40783519|NCT04794348|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Autologous units of fresh frozen plasma collected from the subject by plasmapheresis
40783520|NCT04794348|BIOLOGICAL|Freeze Dried Plasma (FDP)|Autologous units of freeze dried plasma manufactured from plasma collected from the subject by plasmapheresis
40783521|NCT04502862|DRUG|SAR231893|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
41145594|NCT00572494|DEVICE|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of \>50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
41145595|NCT04093050|DRUG|Vasostrict Injectable Product|Vasostrict® (vasopressin injection, USP)
41145596|NCT04862507|OTHER|Telephone call on day 90|telephone call on day 90 to assess the primary outcome (mRs 90)
41464696|NCT00455962|DRUG|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
40783522|NCT04502862|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
41145597|NCT04862507|DIAGNOSTIC_TEST|Quantification of lesion water uptake by CT densitometry|Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
41147047|NCT01141985|DEVICE|LenSx Laser modified disposable contact lens|Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
41464697|NCT00455962|DRUG|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
41464698|NCT00948337|BEHAVIORAL|Brochure of Secondary Cancer Screening|One kind of printed educational material
41464699|NCT06157853|PROCEDURE|Radiofrequency Microneedling|A fractional bipolar radiofrequency microneedling device will be performed at Visit 2, after the 7-day washout period. Subjects were numbed 45 minutes prior to RF microneedling with topical numbing Benzocaine 20%/Lidocaine 6%/tetracaine 4%. Bony areas, periorbital, forehead, and chin were treated with 15 watts at a 2 mm needle depth on cycle mode. All subjects received 20 watts at 3 mm depth on cycle mode on soft tissue, neck, and cheeks.
40783523|NCT00766519|OTHER|volume optimization|"Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~  + systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is \> 10%"
40783524|NCT00766519|OTHER|standard volume administration|"Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV"
40783525|NCT04280003|OTHER|Alogenic adipose tissue-derived stem cells|Concentration of the cells: 10 million cells / ml
40783526|NCT04280003|DRUG|Placebo solution|Placebo intravenous solution, same appearance stem cells solution
40783527|NCT00005852|BIOLOGICAL|anti-thymocyte globulin|
40783528|NCT00005852|BIOLOGICAL|filgrastim|
40783529|NCT00005852|BIOLOGICAL|muromonab-CD3|
40783530|NCT00005852|DRUG|cyclophosphamide|
40783531|NCT00005852|DRUG|cyclosporine|
41306160|NCT02280291|DRUG|Ankle OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
41306161|NCT02280291|DRUG|DR SSB|general anesthesia/sedationwith a single shot; general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
40783532|NCT00005852|DRUG|methylprednisolone|
41145598|NCT05188248|DEVICE|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
41306162|NCT02280291|DRUG|DR OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
41464700|NCT06157853|OTHER|Facial Cleanser|Facial cleanser to be used by subjects twice-daily. This product was used during the entire 14-day study (7-day washout period and 7-day post-procedure timeline).
41464701|NCT06157853|OTHER|Facial Moisturizer|Bland moisturizer to be used by subjects twice daily during the 7-day washout period. Use 1 to 2 pumps and place all over face and avoid the eye area.
41464702|NCT06157853|OTHER|Sunscreen|Bland sunscreen to be used by subjects after cleansing and the facial moisturizer during the 7-day washout period. Bland sunscreen to be used by subjects after cleansing and after the active post-procedure cream and comparator anhydrous cream. Use the provided sunscreen and reapply as needed throughout the day and per recommendation of the FDA, every 2 hours.
41464703|NCT00650273|DRUG|Azithromycin Tablets 600 mg|600mg, single dose fasting
40783533|NCT00005852|PROCEDURE|allogeneic bone marrow transplantation|
41145599|NCT03398902|BEHAVIORAL|Sleep extension|Based on CBTI principles, the instructor will prescribe bed times and wake times each week to allow for gradual increases in sleep opportunity.
41145600|NCT03398902|OTHER|Habitual sleep|The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
41145601|NCT02759406|DEVICE|coronary stent|
41145602|NCT05863585|DRUG|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)|100µg
41145603|NCT00629447|DRUG|Innohep|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
41145604|NCT05444374|DRUG|Serplulimab|Recombinant anti-PD-1 humanized monoclonal antibody injection
41145605|NCT05444374|DRUG|Bevacizumab|Humanized anti-VEGF monoclonal antibody injection
41145606|NCT02936401|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
41145607|NCT01748058|BEHAVIORAL|Exercise based on active video gaming|
41464704|NCT00650273|DRUG|Zithromax® Tablets 600 mg|600mg, single dose fasting
40783534|NCT03816189|DIAGNOSTIC_TEST|Blood test|Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing
40783535|NCT03816189|DIAGNOSTIC_TEST|Skin biopsies|In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)
40783536|NCT02684968|PROCEDURE|Colorectal surgery|
40783537|NCT03776630|OTHER|Blood sample|"Two blood samples (2 tubes of 4 ml for each blood sample) will be collected per patient during the study period for EC and OC. One blood sample will be collected for control population. The first sample will be collected prior to any treatment for EC, OC, and control population.~For EC, the second collection will be done one month post-surgery. For OC, the second collection will be done 6 to 9 months after the initial diagnosis, in most cases at the completion of adjuvant chemotherapy. For control population, there will be no second sample."
40783538|NCT04754763|DRUG|Dentin-Bonding Agents|3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.
40783539|NCT04754763|DRUG|Propolis|Propolis was obtained from Margalla hills, Islamabad by NARC (National Agriculture Research Council, Islamabad). Plant source origin is Acacia modesta and Apis mellifera bees collect it. The 30% ethanolic extract of propolis from raw propolis was obtained in Pakistan Council of Scientific \& Industrial Research (PCSIR) by dissolving the propolis in 95% ethanol and straining out the precipitate
41145608|NCT03200509|OTHER|Physical Activity Intervention|Participants will receive a group exercise program, health coaching sessions and an activity monitor.
41145609|NCT03200509|OTHER|Control group|Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
41306163|NCT06441812|DRUG|SHR-1703 Injection|SHR-1703 Injection
40783540|NCT05221866|BEHAVIORAL|Empowering patient to steer their pain management after surgery|Prior to discharge from the hospital, patients will be approached regarding interest in the study with an introductory letter that describes the content and purpose of the study. Following informed consent, patients will be randomized to receive the consumer health informatics app (UControlPain) versus provision of an app with only data collection function (no educational components) in an intent-to-treat design. Randomization will be implemented via REDCap by the study coordinators so that all investigators will remain blind to group assignment. Further, information on which type of app was installed will not be shared with providers or patients.
40783541|NCT05221866|BEHAVIORAL|Provider-facing prescription aid|Providers will be given information to inform a patient-centered post-discharge pain management plan.
40783542|NCT05372393|PROCEDURE|Local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. The care provider pinches from the area of median nerve blockade prior to performing local anaesthesia. All the anaesthetic solution is injected locally. Additional anaesthetic solution can be injected locally if necessary.
40783543|NCT05372393|PROCEDURE|Distal median nerve block with local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. Half of the anaesthetic solution is injected into the median nerve area 5-7 cm proximally from the distal wrist crease. The other half is injected locally. Additional anaesthetic solution can be injected locally if necessary.
40783544|NCT05690828|BEHAVIORAL|Cognitive remediation|The cognitive remediation programme shall be run either in video workshops or face to face workshops and in home sessions via a web app. The programme will run for 4 months during which there will be 3 different evaluations. A first evaluation after randomisation, a second evaluation 4 months after inclusion (corresponding to the end of the programme), and a third evaluation 8 months after inclusion for the experimental group (4 months after the end of the programme). The face to face workshops will take 8 to 10 participants and will be led by a neuropsychologist.
40783545|NCT05009095|DEVICE|The Listening Program® with bone conduction headphones|The Listening Program method of Music-Based Auditory Stimulation is enhanced with the addition of bone conduction technology with the ABT Bone Conduction System. Bone Conduction combines the experience of listening to music through modified headphones adding subtle, synchronized acoustic vibration of the skin and skeletal system, engaging the whole body and brain in the listening process. This multi-sensory approach accelerates and expands the benefits of The Listening Program.
40783546|NCT05118113|PROCEDURE|Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers|Mobilisation of hematopoietic stem cells by injection of filgrastim (authorized auxiliary medicinal product) for 4 consecutive days and leukapheresis on Day 5
40783547|NCT02755961|BEHAVIORAL|Dietary education|
40783548|NCT02755961|BEHAVIORAL|Education on phosphate binder use|
40783549|NCT01061385|DEVICE|ReShape Intragastric Balloon|Placement of ReShape Medical Intragastric Balloon for twenty four weeks
40783550|NCT01061385|OTHER|Control Arm|Behavioral Modification (Diet and exercise counseling) alone
40783551|NCT03783780|DEVICE|INVSENSOR00031|Noninvasive pulse oximeter sensor
40783552|NCT00006132|DRUG|acyclovir|
40783553|NCT01267474|OTHER|Nutritional education|"A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.~All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.~Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.~All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts."
40783554|NCT01267474|OTHER|Control|The control group received only three one-hour general sessions on health issues.
40783555|NCT00607802|BIOLOGICAL|leukocyte therapy|
40783556|NCT00607802|GENETIC|polymerase chain reaction|
40783557|NCT01889394|PROCEDURE|secondary wound healing|secondary wound healing
40987833|NCT04698720|BEHAVIORAL|Hypnosis with Guided Imagery|"In the beginning of the first session we apply the Eye-Roll Test for Hypnotizability of Herbert Spiegel. Each session follows the Hypnotic Protocol with the following steps:Pre-talk/Absortion/Ratification/Aliciation/Dissociation/Awakening.~The four sessions train the participants in visual, auditory and kinesthetic perception on ulcer healing. The protocol also promotes medical treatment acceptance."
41145610|NCT05851521|DEVICE|Temporary prostatic stent (Exime®)|Placement of temporary prostatic stent (Exime®) following the procedure described in the product information
41145611|NCT05851521|DEVICE|Indwelling catheter|Placement of indwelling catheter
41145612|NCT01653509|DEVICE|Acyclovir patch|Patch containing acyclovir
41145613|NCT01653509|DEVICE|Placebo patch|Patch without acyclovir
40783558|NCT01889394|PROCEDURE|primary wound closure using a limberg flap|primary wound closure using a limberg flap
40783559|NCT04618029|OTHER|Home Modification|"Home Modification Intervention~Floor~Provide recommendations to:~* Fix the back of the rugs and mats with adhesive/heavy duty tape~* Buy non-slip mats~* Tie all cables with a proper cable tie~Lighting~Provide recommendations to:~* Buy a torch light~* To replace worn light bulbs~* Buy a light switch~Bathroom~Provide recommendations to:~* Buy a non-slip mat~* Install a grab rail~* Buy a commode chair for showering~Stairways~Provide recommendations to:~• Fix an adhesive tape for stair contrast"
41147048|NCT04515745|BEHAVIORAL|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
41147049|NCT04515745|BEHAVIORAL|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
41306164|NCT04345991|DRUG|Transfusion of COVID-19 convalescent plasma|Two convalescent plasma units of 200 to 220 ml each will be transfused i.v. as early as possible and no later than 10 days after onset of clinical symptoms. In the absence of acute unforeseen adverse events in the first 3 patients, an additional 2 plasma units of 200/220 ml each will be transfused 24 hours after first 2 units: a total of 4 units / patient
41306165|NCT00334932|DRUG|bortezomib|
41306166|NCT00334932|DRUG|melphalan|
40783560|NCT04618029|OTHER|Education|"Techniques Description Energy Conservation~* Take your time~* Go to the toilet more often, so you don't have to rush~* Use a nearby toilet: commode, different bathroom~* Prepare ahead (e.g., toilet paper near, other items for toileting, etc.)~* Adjust equipment before changing position~* Avoid transfers when tired~* Ask for help if you feel sick or especially tired~* Allow time for eyes to adjust to change in lighting~Task Simplification~* Plan and organise workspaces to eliminate unnecessary steps, save time, energy and reduce fatigue.~* Prioritise and plan activities, alternating between active and quiet jobs and include rest periods.~Ergonomics~* Proper positioning while doing tasks~* Safe mobility around the home"
40783561|NCT05564637|DRUG|Treprostinil|30mcg (5 breaths) of inhaled treprostinil will be administered during the RHC procedure and patients will be initiated on outpatient inhaled treprostinil therapy for 3-months with gradual up titration to target dose as per standard clinical practice.
40783562|NCT05564637|DIAGNOSTIC_TEST|Right Heart Catheterization (RHC) while exercising|A procedure to measure how well or poorly your heart is pumping and to measure the pressures in the heart and lungs. A catheter will be inserted into a vein and artery in order to take the measurements and this will be conducted while exercising on a supine cycle ergometer. Various measurements will be taken during periods of rest and exercise.
40783563|NCT05564637|DIAGNOSTIC_TEST|Optional Muscle Biopsy|A sample of muscle tissue will be collected and analyzed for the ability of the cells to utilize oxygen.
41306167|NCT00334932|DRUG|pegylated liposomal doxorubicin hydrochloride|
41306168|NCT04644289|DRUG|olaparib|Olaparib tablets are administrated orally 300 mg twice daily.
41306169|NCT04644289|DRUG|durvalumab|Durvalumab is administered 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle) .
41306170|NCT05430451|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
41306171|NCT05430451|BEHAVIORAL|Referral card|The content consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information, and strong supporting messages or slogans.
41306172|NCT05430451|BEHAVIORAL|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
40783564|NCT05061888|OTHER|Smart Intervention for Food Waste Management and Replacing current diet with Fruits and Vegetables|Will receive a Smart Intervention on Food Waste Management and replacing less healthy foods with fruits and vegetables.
40783565|NCT05061888|OTHER|Smart Intervention for Stress Managment|Will receive a Smart Intervention on stress management practices and strategies.
40783566|NCT02007941|DRUG|CKD-501|From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
40783567|NCT06146647|BEHAVIORAL|Positive body image TV show|This is a 15 minute (approximately) show that has positive body image content embedded in the storyline. It also showcases a diverse range of body sizes in the casting.
40783568|NCT06146647|BEHAVIORAL|Positive body image music video|This is a positive body image song with strong visual representation of diverse body sizes in the music video.
40783569|NCT06146647|BEHAVIORAL|Active control TV show about a visit to the dentist|14 minute tv show following a tv character as he visits the dentist.
40783570|NCT06146647|BEHAVIORAL|Active control music video about brushing teeth|Music video of a tv character singing about brushing teeth
40783571|NCT00988793|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy
40783572|NCT00988793|PROCEDURE|Open distal pancreatectomy|Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
40783573|NCT02373904|DEVICE|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
40783574|NCT03345277|OTHER|Continuous Temperature monitoring|Residents in a long term care facility will wear a thermometer continuously for 3 months, measuring their body temperature
40783575|NCT04572334|OTHER|Auto and Subjective Refraction|All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
40783576|NCT01103856|BEHAVIORAL|Patient Mentor Intervention|The first session includes an exploration of needs, barriers, and facilitators to HIV care. HIV educational materials are introduced to identify areas of need. Mentors will address concerns and possible barriers to care using their own experiences. Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal. The second session will reinforce the first session. Mentors will call the patient 5 times over the 10 weeks after discharge. These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.
40783577|NCT01103856|BEHAVIORAL|HIV transmission risk reduction|The control intervention is a modification of the project RESPECT intervention. We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention. These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy. The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes. The counselors will call the patient 5 times in the 10 weeks after discharge. These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
40783578|NCT03652714|PROCEDURE|Ganglion sphenopalatine block with local anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL.
40783579|NCT03652714|PROCEDURE|Ganglion sphenopalatine block with placebo|Block performed with bilaterally inserted q-tips with isotone NaCl
40783580|NCT04580914|DEVICE|Treatment with IntellaNav StablePoint Ablation Catheter|Patients will be treated with an ablation catheter
40783581|NCT04283188|BEHAVIORAL|Dialectical behavioral therapy|Participants will be provided with the option to continue treatment with their study therapist. For those who elect to continue with DBT sessions, they will discuss frequency of sessions with their therapist, in addition to selecting type of sessions (individual and/or family skills). Participants who elect not to continue with DBT sessions at the time of enrollment will retain the option of being able to request additional sessions at any point during the 12-month study. Irrespective of participation in additional DBT sessions, all participants will be asked to complete follow-up interviews and questionnaires.
40783582|NCT04184479|BEHAVIORAL|LEVAmethod by Bertz et al|Ordinary treatment
40783583|NCT00328029|DRUG|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
40783584|NCT00328029|PROCEDURE|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
40783585|NCT00328029|PROCEDURE|pharmacokinetics, done during the treatment|"12 blood collections :~* after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.~* 3 hours after 2nd taken of Busulfan~* 3 hours after 3rd taken of Busulfan~* 3 hours after 4th taken of Busulfan~* 3 hours after 5th taken of Busulfan~* 3 hours after 6th taken of Busulfan."
40783586|NCT03099122|BIOLOGICAL|Rabbit Anti-thymocyte Immunoglobulin|"Pharmaceutical form: creamy-white powder~Route of administration: intravenous"
40783587|NCT03099122|DRUG|Tacrolimus|"Pharmaceutical form: tablet~Route of administration: oral"
40783588|NCT03099122|DRUG|Methylprednisolone|"Pharmaceutical form: powder~Route of administration: intravenous"
40783589|NCT03099122|DRUG|Mycophenolate mofetil|"Pharmaceutical form: capsule~Route of administration: oral"
40783590|NCT03099122|DRUG|Mycophenolate Na|"Pharmaceutical form: capsule~Route of administration: oral"
40783591|NCT03099122|DRUG|prednisone|"Pharmaceutical form: tablet~Route of administration: oral"
40783592|NCT03509961|DIAGNOSTIC_TEST|NGS-MRD|Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.
40783593|NCT03509961|DRUG|Myeloablative allogeneic HCT with a non-TBI conditioning regimen|"Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant"
40783594|NCT02807701|PROCEDURE|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy~1. dissection~2. reconstruction"
40783595|NCT02807701|PROCEDURE|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
41464705|NCT01847365|DEVICE|Transcorneal electrical stimulation|Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
40783596|NCT04042805|BIOLOGICAL|Sintilimab|200mg intravenously every 3 weeks
41464706|NCT05308368|DEVICE|Ultrasound Imaging|We will collect ultrasound images during the grasping motion for both groups
40783597|NCT04042805|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
40783598|NCT00948077|DRUG|Rifater and EMB|"The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---\> Treatment B (6th day) ; Treatment B (5th day) ---\> Treatment A (6th day)"
40783599|NCT05805137|DEVICE|WoundWatch wound management system|eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch wound management system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
40783600|NCT01709526|BEHAVIORAL|Improvement after psychiatric inpatient treatment|Cognition, psychosocial functioning
40783601|NCT04937192|OTHER|No intervention|No intervention
40783602|NCT03709901|OTHER|Active Allograft|Injection of viable allograft into the nucleus pulposus of the degenerated disc
40783603|NCT03709901|OTHER|Placebo|Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
40783604|NCT01419119|DRUG|Cholecalciferol high dose at Vitamin D deficiency|10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
40783605|NCT01419119|DRUG|Cholecalciferol median dose at Vitamin D insufficiency|2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
40783606|NCT01419119|DRUG|Cholecalciferol low dose at Vitamin D deficiency|2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
40783607|NCT01419119|DRUG|Cholecalciferol median dose at sufficient Vitamin D level|2000 IU daily i.e. 3 drops orally once daily for 12 weeks
40783608|NCT01231789|PROCEDURE|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
40783609|NCT01231789|PROCEDURE|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
40783610|NCT00352300|PROCEDURE|Adjuvant Therapy|
40783611|NCT00352300|DRUG|Carboplatin|Given IV
40783612|NCT00352300|DRUG|Paclitaxel|Given IV
40783613|NCT00352300|BIOLOGICAL|Pegfilgrastim|Given IV
40783614|NCT01855893|OTHER|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
41147050|NCT01588379|BEHAVIORAL|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
41147051|NCT01588379|BEHAVIORAL|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
41147052|NCT01588379|OTHER|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
40783615|NCT01855893|OTHER|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
40783616|NCT01135472|DRUG|Esomeprazole Magnesium|NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
40783617|NCT00714948|DRUG|gemcitabine and cisplatin plus sorafenib|Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) \> 2.1), after consultation with the Principal Investigator.
41464707|NCT05308368|DEVICE|Electromyography|We will collect electromyography (EMG) signals of both the flexor and extensor muscles of the wrist during the grasping motion for both groups
41464708|NCT05308368|DEVICE|Inertial Measurement Units (IMU)|We will use data from the ultrasound images and EMG to develop a tremor model. The model will be validated in comparison to joint angle measurements from an Inertial Measurement Unit (IMU) collected during the grasping motion
41464709|NCT05308368|DEVICE|Functional Electrical Stimulation (FES)|We will use the develop closed-loop control methods for tremor suppression using information from the ultrasound-image based tremor models. FES will be used to provide stimulation that will help with tremor suppression
41464710|NCT02678871|DEVICE|Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
41306173|NCT05430451|BEHAVIORAL|Simple physical exercise training|The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises, and c) resistance exercises. Participants will receive handgrips and elastic bands, and trained smoking cessation ambassadors will demonstrate and encourage the use of handgrip and elastic bands onsite with an instruction leaflet.
41306174|NCT05430451|BEHAVIORAL|Simple physical exercises with instant messaging support|During the 3-month instant messaging support, smoking cessation counselors will deliver regular messages to encourage the practices of simple physical exercise, provide strategies for managing craving and withdrawal symptoms, and provide information on smoking-related knowledge and available smoking cessation services. Our trained smoking cessation counselors will also provide real-time support upon participants' inquiries.
41306175|NCT05430451|BEHAVIORAL|SMS|SMS on follow-up survey reminders
41464711|NCT02678871|DEVICE|WATCHMAN|LAA closure with the WATCHMAN device
41464712|NCT04674982|DEVICE|a vibrating device|vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz)
41464713|NCT02820740|DEVICE|NeuroBlate System|Laser Interstitial Thermal Therapy
41464714|NCT03934060|OTHER|Exercise|specific strength training
41464715|NCT00026923|PROCEDURE|Laparoscopic surgery|
41464716|NCT05358353|DEVICE|Bare Temporary Spur Stent System|Treatment of qualifying infrapopliteal arteries with the Bare Temporary Spur Stent System, in subjects with critical limb ischemia.
40783618|NCT05007548|DRUG|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
40783619|NCT03108521|DRUG|Sitagliptin|100mg.QD for 3 months
40783620|NCT04303975|OTHER|clinical measurements|Only clinical parameters were recorded, no intervention was made.
41464717|NCT01514123|DRUG|VGX-100|VGX-100 will be administered by IV infusion once every week
41464718|NCT01514123|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion once every 2 weeks
41464719|NCT05484791|OTHER|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization(LRSM) technique during two sessions per week. The LRSM technique is applied while patients are lying on their side. The uppermost hip and knee are placed in 90 degree flexion, this is to assist rotational stress, and the lower leg is placed in extension. The lower shoulder is strongly pulled; thus, the upper shoulder is positioned toward the posterior and the pelvis moves anteriorly. The clinician stands in front of the patient. They stabilize the upper shoulder with one hand, and place the palm of the other hand behind the hard part of the ilium wing, with forearm horizontal and fingers turned toward the clinician. A rotational force is applied with pressure in the horizontal direction by pulling the hand on the ilium toward the clinician. In this position, 30 slow repeated movements are performed. The same practice is performed on both sides
41464720|NCT04759079|DEVICE|Acupuncture Needles|Acupuncture Needles placement at the PC6 in association to anti-emetic medication
41464721|NCT04759079|DRUG|Antiemetic Drug|Administration of Anti-emetic medication without acupuncture
41464722|NCT01625117|BEHAVIORAL|A variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
41464723|NCT00726895|DRUG|Quinine Sulfate Capsules 324 mg|1 x 324 mg capsule
40783621|NCT06000670|PROCEDURE|stromal vascular fraction injection in the osteoarthritic knee|stromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee.
40783622|NCT02770066|DEVICE|Percutaneous transluminal renal angioplasty|"Angioplasty plus stenting (angioplasty in patients with fibromuscular dysplasia)~Adjuvant therapy in atherosclerotic renal artery stenosis - at the discretion of the treating physician~* Antiplatelet therapy (usually standard)~* Cholesterol-lowering drugs (usually standard)~* Antihypertensive treatment with angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker (normally not contraindicated)~* Smoking cessation, diet and physical activity (usually standard)"
40783623|NCT04592341|DRUG|Gantenerumab|Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.
40783624|NCT03091088|OTHER|walking at an intense pace|Participants walk 6 kilometers in 1 hour at least 3 times per week
41464724|NCT00726895|DRUG|Quinine Sulfate Capsules 324 mg|2 x 324 mg capsules
41464725|NCT00786630|BEHAVIORAL|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
41464726|NCT00786630|BEHAVIORAL|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
41464727|NCT06199960|OTHER|Doustim protocol|In Duostim group, the follicular stimulation will be started with a ﬁxed dose of 150 IU of rFSH and HMG 75 IU for 4 days. Daily administration of a GnRH antagonist will be started when the leading follicle are 13-14mm in diameter and continue until the day of the trigger of the ovulation. Five days after the ﬁrst oocyte retrieval second gonadotropin stimulation will be started identical to the ﬁrst one..
40987834|NCT04698720|BEHAVIORAL|Neutral Guided Imagery|This placebo consists of neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends, and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, positive or negative, which occurred before patient has the current DFU. Then, the patient is asked about a number of questions regarding the chosen episode in order to promote a more detailed reconstruction of the event. The patient is asked to imagine according to the instructions given by the Psychologist. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered regarding each of the questions.
40783625|NCT03091088|OTHER|osteoporosis specific-oriented training|1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)
40783626|NCT01102595|DRUG|Temozolomide|"* Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~* Temozolomide 75 mg/m2/d x 42-49 days~* Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
40783627|NCT01102595|DRUG|Bevacizumab|"* 2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.~* Bevacizumab 10 mg/kg every 15 days, three dosis."
40783628|NCT01102595|RADIATION|Standard radiation therapy|42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
40783629|NCT01444781|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
40783630|NCT01444781|BIOLOGICAL|DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
40783631|NCT01444781|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine|0.5 mL (each), Intramuscular each into the right and left deltoid muscle
40783632|NCT05246527|BEHAVIORAL|Physical Exercise|30 min of cycling on an ergometer, moderate or high intensity
40783633|NCT05246527|BEHAVIORAL|Control Intervention|30 min of watching a movie
40783634|NCT02962921|DRUG|Insulin LISPRO intravenous loading|intravenous infusion of insulin Lispro.
40783635|NCT04794738|DRUG|SHR8554|SHR8554 Injection; high dose
40783636|NCT04794738|DRUG|SHR8554|SHR8554 Injection; low dose
40987835|NCT06486090|BEHAVIORAL|#Utviklingsklar|The intervention consists of 1) an e-learning course, 2) a workshop to create plans and practices for injury-prevention, 3) a mid-season meeting
40987836|NCT01883414|DEVICE|Ultherapy™|All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
40987837|NCT05523661|DRUG|Dasatinib plus anti-CD19/CD22 CAR-T cells|Dasatinib plus VP chemotherapy was administrated to newly diagnosed Ph-positive patients aged 55-70 years old,if hCR was achieved,autolymphocyte was collected,and anti-CD19/CD22 CAR-T cells infusion was administrated to patients followed by Fludarabine and Cyclophosphamide therapy
40987838|NCT04055142|PROCEDURE|electrocoagulation|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)
40987839|NCT04055142|DRUG|cidofovir 1% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)
40987840|NCT04055142|DRUG|sinecatechins 10% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
40987841|NCT04208594|DRUG|Ivabradine|comparing between both drugs for the effect of hypotensive anesthesia
41306176|NCT03161639|OTHER|Pulpectomies|Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
41464728|NCT05478928|OTHER|Dynamic dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point. A movement with the needle will be done at 1 Hz for 120 seconds.
40987842|NCT04208594|DRUG|Propranolol|comparing between both drugs for the effect of hypotensive anesthesia
41306177|NCT05092737|PROCEDURE|Prone positioning|Prone position during invasive mechanical ventilation
41306178|NCT04369430|DRUG|AKST4290|Oral AKST4290
41306179|NCT04369430|DRUG|Placebo|Oral Placebo
41306180|NCT02754934|OTHER|Cervical range of motion|Patients will fill out the Neck Disability Index, Visual Analogue Pain Rating Scale and the Self-administered Neck range of motion questionnaire.
41306181|NCT03141060|DRUG|Delamanid|Administered orally; dosing will be based on participants' age and weight.
40783637|NCT04794738|DRUG|Saline Solution|Saline Solution
40783638|NCT04794738|DRUG|Morphine|Morphine
40783639|NCT05221619|DRUG|Nipocalimab|Depending on the dose received at their last administration in the MOM-M281-006 (NCT04119050) study, participants will continue to receive either nipocalimab dose-1 every 2 weeks (Q2W) or nipocalimab dose-2 every 4 weeks (Q4W) by intravenous (IV) infusion.
40783640|NCT00643942|OTHER|No intervention required|
40783641|NCT05577026|BEHAVIORAL|Educational intervention and prescription feedback|Brief educational intervention and patient and provider materials regarding prescription of opioids. Subsequent feedback on clinic prescription of opioids over 12 months.
40783642|NCT05577026|BEHAVIORAL|General information on treatment guidelines|Written information on guidelines and recommendations regarding prescription of opioids.
41464729|NCT05478928|DEVICE|Fixed dose dynamic MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. A movement with the needle will be done at 1 Hz with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
40987843|NCT00157703|DRUG|G207|1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
40783643|NCT01663311|DEVICE|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
40783644|NCT01663311|DEVICE|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
40783645|NCT05295628|DEVICE|"EMBLOK™ Embolic Protection System (EMBLOK EPS)"|The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
40783646|NCT05295628|DEVICE|SENTINEL™ Cerebral Protection System|The SENTINEL CPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
40987844|NCT04835025|DRUG|PD-1/PD-L1 inhibitor|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
40987845|NCT01590238|BIOLOGICAL|PRFM treatment|Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
40987846|NCT00326950|DRUG|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
41464730|NCT05478928|OTHER|Static Dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point for 120 seconds.
40783647|NCT04479592|OTHER|Particle counter|Particle counter to measure the aerosol generated
40783648|NCT02654496|OTHER|Meal challenge|Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
40783649|NCT01044030|DRUG|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
40783650|NCT01044030|DRUG|Placebo|7.5 mL by mouth three times daily
40783651|NCT01820806|DRUG|100 mg dose of [14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion
40783652|NCT06413732|OTHER|Conventional physiotherapy|Conventional physiotherapy was applied for approximately 1 hour, 5 days a week.
40783653|NCT06375083|BEHAVIORAL|Cognitive Behavioral Therapy|The computerized Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) course is comprised of 12 online sessions and is augmented by use of a companion workbook. The computerized Cognitive Behavioral Therapy for Depression (cCBT-D) course is comprised of 12 online sessions.
40783654|NCT03986125|BEHAVIORAL|Emotional Awareness & Expression Therapy|emotion-focused
40987847|NCT04426331|BEHAVIORAL|Voucher Without Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital. The voucher included the patient's name, the screener's name, and an expiration date 90 days from the date of screening.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. So, with this voucher, both the exam and the glasses will be completely free."
40987848|NCT04426331|BEHAVIORAL|Voucher With Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital, which would normally cost $250. The voucher included the patient's name, the screener's name, an expiration date 90 days from the date of screening, and a statement about the $250 voucher value.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. These services normally cost about $250, but with this voucher, both the exam and the glasses will be completely free."
40987849|NCT04458545|DRUG|Placebo|Intranasal placebo 0mg
40987850|NCT04458545|DRUG|Oxy 25 mg|Intranasal oxycodone 25mg
40987851|NCT04458545|DRUG|OXY 50 mg|Intranasal oxycodone 50mg
40987852|NCT04458545|DRUG|OXY 100 mg|Intranasal oxycodone 100mg
40987853|NCT04458545|DRUG|Heroin|Intranasal heroin 100mg
40783655|NCT03986125|BEHAVIORAL|Mindfulness Meditation Training|meditation training and practice
40783656|NCT04650295|OTHER|Household Remedy|If the participant experiences a muscle cramp one tablespoon (one sip) of the household product will be taken. The treatment phase of the study will be for 28 days.
40783657|NCT04650295|OTHER|Tap water|If the participant experiences a muscle cramp one tablespoon (one sip) of tap water will be taken. The treatment phase of the study will be for 28 days.
41306182|NCT03141060|DRUG|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
40783658|NCT01246882|BEHAVIORAL|Augmented activity feedback|Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
41464731|NCT05478928|DEVICE|Fixed dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
40783659|NCT01246882|BEHAVIORAL|Speed-only feedback|Feedback about walking speed will be provided 3 times per week.
40783660|NCT05865951|OTHER|Isometric Exercises|Isometric (same length) strengthening exercises of the neck muscles will be performed.
40783661|NCT05865951|OTHER|Isotonic Exercises|Isotonic strengthening exercises for the neck muscles will be performed.
40783662|NCT03248323|RADIATION|dyna-pbv|
40783663|NCT01485848|DRUG|EP-100|Pharmaceutical form:Solution Route of administration: Intravenous
40783664|NCT01485848|DRUG|Paclitaxel|Pharmaceutical form:Solution Route of administration: Intravenous
40783665|NCT05545748|BEHAVIORAL|Zero (0) Tolerance Program (SToP)|"1. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.~2. Giving reminder objects (Magnet, sticker): For example; at the entrance door of the house: 0 TOLERANCE magnet to cigarettes; No smoking in my home label.~3. Informative materials (information notes and brochures): Brochures on the harms of second-hand smoking (SHS) and third-hand smoking (THS), the diseases they cause, and how to protect them~4. Informative telephone text messages: Reminder phone messages related to SHS and THS"
40783666|NCT05545748|BEHAVIORAL|Exposure Feedback Group|1. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.
40783667|NCT01309789|DRUG|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)
40783668|NCT01309789|DRUG|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 3-8)
40783669|NCT01309789|DRUG|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)
40783670|NCT01309789|DRUG|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)
40987854|NCT00954902|DIETARY_SUPPLEMENT|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
40987855|NCT00954902|BEHAVIORAL|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
40987856|NCT00954902|OTHER|Placebo antioxidant concentrate|Placebo capsules
40987857|NCT02848183|DRUG|Cytarabine|
40783671|NCT01309789|DRUG|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 1-6)
41464732|NCT05478928|DEVICE|Algorithm-based dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically, at 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed. Treatment will finish when the patient does not refer any discomfort for a period longer than 60 seconds. Total dose in mC will be registered.
40783672|NCT01309789|DRUG|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 3-8)
41464733|NCT05478928|OTHER|Placebo|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly up to 3 mm deep into the upper trapezius trigger point for 120 seconds.
40783673|NCT01309789|DRUG|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 1-6)
40783674|NCT01309789|DRUG|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
40783675|NCT01309789|DRUG|vincristine|1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
40783676|NCT05960357|OTHER|To inform|It includes providing all necessary information about the fetus to the pregnant woman by using the ultrasound monitor during the detailed ultrasound.
40783677|NCT05669222|DIAGNOSTIC_TEST|FAST Technique|The next-generation QFR (μQFR) introduces a more intelligent algorithm and supports single-projection rapid calculation with a diagnostic accuracy of 93.0% compared with FFR; Computational RWS technique facilitates the assessment of lesion vulnerability.
40783678|NCT05669222|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.
40783679|NCT00598819|DEVICE|CDI 1000 COM|CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
40783680|NCT03814135|DRUG|Hipnos 3|1 tablet, oral, once a day.
40783681|NCT03814135|DRUG|Hipnos 5|1 tablet, oral, once a day.
40783682|NCT03814135|OTHER|Hipnos 5 Placebo|1 tablet, oral, once a day.
40783683|NCT03814135|OTHER|Hipnos 3 Placebo|1 tablet, oral, once a day.
40783684|NCT06167486|DRUG|SG2918|The SG2918 will be administrated by intravenous infusion every 3 weeks
40783685|NCT00765414|BIOLOGICAL|Myozyme|30 mg/kg qow f and 40 mg/kg qow
40783686|NCT06065124|PROCEDURE|Bariatric surgery strategy|Bariatric surgery including an intensive pre- and postoperative treatment scheme
40783687|NCT04294355|DEVICE|Artificial intelligence-Assisted colonoscopy|Artificial intelligence-Assisted colonoscopy for detection of colonic polyp
40783688|NCT04294355|PROCEDURE|Conventional colonoscopy|Conventional colonoscopy
40783689|NCT05857566|DRUG|RDX-002|A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
40783690|NCT02750930|DRUG|Albiglutide|Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
40783691|NCT02750930|DEVICE|Auto-injector|The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
40783692|NCT06174207|OTHER|Oxygen|Standard supplemental Oxygen therapy (5l/min) will be applied with an oxygen concentrator via nasal cannula.
40783693|NCT05768594|OTHER|Blood sample|After blood sampling, patients will undergo a Color Doppler Echocardiogram, a non-invasive method
40783694|NCT04084041|DEVICE|Simeox|Airway clearance device
40783695|NCT04084041|OTHER|CCPT|Conventional chest physiotherapy
40783696|NCT01082302|DRUG|Polyphenon E (Veregen) 15% ointment|3 times daily application on genital and perianal warts over 7 days
40783697|NCT01082302|OTHER|Green Tea Beverage with defined catechin content|3 times daily oral intake over 7 days
40783698|NCT04364087|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test with 75 g glucose (75 g OGTT) will be performed to those with normal fasting glucose and HbA1C levels. Women will be recommended to have normal diet for 3 days and overnight fasting for at least 8 hours. The blood withdrawal will be performed twice: (i) fasting and (2i) 2 hours after solution administration. The volume of blood for each test is 2 ml. Impaired glucose tolerance will be diagnosed when two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol/l) (American Diabetes Association, 2018).
40783699|NCT00281970|DRUG|cisplatin|
40783700|NCT00281970|DRUG|docetaxel|
40783701|NCT00281970|PROCEDURE|adjuvant therapy|
40783702|NCT01924780|DEVICE|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
40783703|NCT01924780|DEVICE|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
40783704|NCT01924780|DEVICE|NEMOS Device sham stimulation 10 minutes|
40783705|NCT00001937|DRUG|FK463|
40783706|NCT00001937|DRUG|Fluconazole|
40783707|NCT06005909|OTHER|Cawthorne-Cooksey Exercises|"A- Head and Eye Movements While Lying and Sitting:~1. While keeping your head still, look up and then down again.~2. Look from side to side while keeping your head still.~3. Extend your hand at arm's length, draw your fingers towards your nose while focusing your eyes on your fingers.~4. With eyes open, slowly turn your head from side to side.~5. Turn your head from side to side quickly.~6. With eyes open, slowly move your head up and down.~7. Move your head up and down quickly.~8. Repeat items 4,5,6 and 7 with your eyes closed.~B-Head and Body Movements While Sitting:~1. Place an object on the floor in front of your feet, reach out to pick it up, then upright return to your position. Looking down while picking up the item, then Remind you to look up when trying to fix it.~2. Lean forward and move the object forward and back under your knees. C- Standing Exercises~1-Get from a sitting position to a standing position and sit down again. 2-Repeat this with your eyes closed."
40783708|NCT06005909|OTHER|Mechanical Hippotherapy Exercises|"From the patient on the mechanical hippotherapy device;~* Maintaining trunk balance while raising both hands above head,~* Maintaining trunk balance while opening the arms next to the trunk,~* Maintaining trunk balance while extending the arms back and forth with successive movements,~* Maintaining trunk balance with hands clasped behind the waist,~* The arms are open to both sides, while transferring the weight ball from one hand to the other, it is requested to maintain the body balance."
40783709|NCT01926132|DRUG|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
40783710|NCT01926132|DRUG|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
40783711|NCT04461496|PROCEDURE|Hybrid revascularization|The first stage is performed femoral-popliteal bypass surgery above the fissure of the knee joint according to conventional technology. Conduit is at the discretion of the operating surgeon. Intraoperatively bolus is administered sol. heparin 5000 IU. The second step is the puncture of the selected CFA with a retrograde installation of the introducer sheath. The iliac segment is recanalized with angioplasty and stent implantation in the affected area
40783712|NCT04461496|PROCEDURE|Full metall Jacket|The first step is the puncture contralateral CFA with a retrograde installation of the introducer. Intraoperatively bolus is administered sol. heparin 5000 IU. A conductor is placed in the contralateral iliac artery along the conductor. A stent is implanted in the iliac artery lesion. The second stage is the recanalization of the femoral-popliteal segment with angioplasty and stent implantation in the affected area.
40783713|NCT02764411|DRUG|Brimonidine 0.33% gel|Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
40783714|NCT03852784|OTHER|Bone and joint infection with Streptococcus peumoniae|description of the osteoarticular infection with Streptococcus peumoniae
40783715|NCT02160821|PROCEDURE|Caudal Epidural|Ultrasound Guided Caudal Block
40783716|NCT02160821|PROCEDURE|Transversus Abdominis Plane Block|Ultrasound Guided Transversus Abdominis Plane Block
40783717|NCT04186585|DRUG|BP-C2|Oral daily intake
40783718|NCT01440361|DRUG|Belimumab|10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
40783719|NCT01440361|DRUG|Normal saline placebo|Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
40783720|NCT03586271|PROCEDURE|trifocal lens|phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation
40783721|NCT03586271|PROCEDURE|bifocal lens 1|phacoemusification +bifocal lens(Diff-aay) implantation
40783722|NCT03586271|PROCEDURE|bifocal lens 2|phacoemusification +bifocal lens (ReSTOR +3.0D) implantation
40783723|NCT03586271|PROCEDURE|bifocal lens 3|phacoemusification +bifocal lens (ReSTOR +2.5D) implantation
40783724|NCT03861182|BIOLOGICAL|Biological functionalization of the prosthetic materials by PRF|The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.
40783725|NCT00641108|DRUG|ADAM SPECT plus Cognitive Therapy|
40783726|NCT00641108|DRUG|ADAM SPECT plus No Therapy|
40987858|NCT02848183|DRUG|Idarubicin|
40987859|NCT02848183|DRUG|Mitoxantrone|
41145614|NCT02619578|OTHER|TEAS|According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
41145615|NCT02619578|OTHER|Con|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
41145616|NCT02619578|DRUG|propofol, remifentanil, vecuronium|Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
41145617|NCT02619578|OTHER|mechanical ventilation|Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
41145618|NCT01900015|DRUG|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
41464734|NCT01223209|DRUG|LTX-315|0.25-2.0 mg/ML, maximum 5 injections during 36 days.
40783727|NCT01179230|OTHER|SPECT imaging|Dipyridamole stress testing 0.57 mg/kg
40783728|NCT01179230|OTHER|PET imaging|Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
40987860|NCT02848183|DRUG|Etoposide|
40987861|NCT02848183|PROCEDURE|Hematopoietic stem cell transplantation|
40987862|NCT02970409|DEVICE|saline|catheter lock using saline
41145619|NCT01900015|DRUG|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
41145620|NCT05049265|BIOLOGICAL|JS007|JS007 only
41145621|NCT00021996|DRUG|valdecoxib|
41145622|NCT06296784|OTHER|e-health psychoeducation|e-health psychoeducation intervention provides information about BD clinical condition and symptoms, as well as identifying effective coping strategies to manage symptoms and the dysregulation of biological rhythms. The content covered the impact of the pandemic and its related restrictions on mental health, particularly on anxiety and depressive symptoms. The intervention comprised one session per week for two months, and each session lasted approximately an hour and a half. It was conducted by healthcare professionals.
41147053|NCT03059147|DRUG|SF1126|SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops.
41464735|NCT02896543|OTHER|measurement|Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
41464736|NCT04210349|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
40987863|NCT02970409|DEVICE|Heparin|catheter lock using Heparin
40987864|NCT00376909|OTHER|educational intervention|
40987865|NCT00376909|OTHER|study of socioeconomic and demographic variables|
40987866|NCT02146547|DRUG|Aripiprazole|Administration in once-a-day schedule without regard to meals.
40987867|NCT02146547|DRUG|Aripiprazole depot|Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.
40987868|NCT02146547|DRUG|Paliperidone|Administration once a day orally standardised in relation to food intake.
40783729|NCT02779868|DIETARY_SUPPLEMENT|Omega-3|patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.
40987869|NCT02146547|DRUG|Paliperidone palmitate|In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
40987870|NCT02502539|PROCEDURE|Controlled physical activity|
40987871|NCT01430390|BIOLOGICAL|Biological/Genetically Modified T cells|Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells. A fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose allowing for multiple infusions and potential for multiple patient treatments per cell line generated will be used for all patients on this trial. Cohorts will be determined separately but cohort 3 will not begin to accrue until cohort 2 has treated three (3) patients without a DLT. Each patient is eligible for up to three (3) infusions.
40987872|NCT01430390|DRUG|Cyclophosphamide-based chemotherapy|Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
40987873|NCT05608044|DRUG|Botensilimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
40987874|NCT05608044|DRUG|Balstilimab|An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody.
40987875|NCT05608044|DRUG|Standard of Care|Regorafenib or trifluridine and tipiracil.
40987876|NCT00567892|DEVICE|rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
40987877|NCT05202418|BEHAVIORAL|Biofeedback Enhanced Treatment|The intervention involves biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. Participants will complete questionnaires before and after each session to measure autonomic reactivity, lifetime stress, depression, anxiety in response to stress induction, and coping strategies.
41145623|NCT02163499|DRUG|Sodium Zirconium Cyclosilicate|Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
41145624|NCT06293794|OTHER|Personalized Clinical Decision Support (CDS)|The personalized CDS intervention evaluates clinician past prescribing patterns to determine whether prescribing misconceptions might exist and then conditionally present information to address those misconceptions. This is done through a nudge in the electronic health record that addresses common prescribing misconceptions for heart failure.
41145625|NCT06293794|OTHER|Traditional Clinical Decision Support (CDS)|The traditional CDS is the usual care intervention, which is patient-specific but are not clinician-specific.
41145626|NCT04998825|DIETARY_SUPPLEMENT|Proteoglycan F|Salmon proteoglycan (Proteoglycan F) was extracted from salmon (Oncorhynchus keta) nasal cartilage. Salmon cartilage PG (Proteoglycan F) was manufactured in the form of a hard capsule by Ichimaru Pharcos, Co., Ltd. (at 318-1 Asagi, Motosu-shi, Gifu 501-0475 Japan) and consisted of 50 mg proteoglycan.
40783730|NCT02779868|DIETARY_SUPPLEMENT|Olive oil|patients included in this group will take 4 capsules per day of olive oil.
40987878|NCT01263301|DEVICE|carotid duplex|Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
41145627|NCT04998825|OTHER|Placebo product|The placebo capsule contained only dextrin powder (Ichimaru Pharcos, Co., Ltd.).
41147054|NCT03059147|DRUG|Nivolumab|Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. It will be administered at 240 mg IV every 2 weeks until progression or unacceptable toxicity develops.
40783731|NCT02131766|DEVICE|DiAs|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
40987879|NCT03134560|DEVICE|Vein Display Instrument|
41464737|NCT04210349|BIOLOGICAL|Trivalent Influenza Vaccine 1 SP Shz TIV1|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
41464738|NCT04210349|BIOLOGICAL|Trivalent Influenza Vaccine 2 SP Shz TIV2|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
41464739|NCT01857973|DEVICE|Hybrid Closed Loop|The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
41464740|NCT01134991|DRUG|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
41464741|NCT03690089|DRUG|Atropine Sulfate|Atropine sulfate 0.01% eye drops which consist of 10mls of a clear colourless solution of atropine sulfate 0.01% w/v and benzalkonium chloride 0.01% w/v in sterile water.
40783732|NCT02131766|OTHER|Sensor Augmented Pump Therapy|Insulin pump plus CGM.
40783733|NCT02598037|DIETARY_SUPPLEMENT|Test meal|The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
40987880|NCT05096845|BIOLOGICAL|Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|"Appearance: creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5mL) /vial Vaccination route: intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg Immunization schedule: two doses, one each on Day 0 and 21 (+7 days), respectively.~Storage condition: store at 2\~8°C protected from light Expiry date: 24 months after production date"
40987881|NCT05096845|OTHER|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
40987882|NCT04098224|DEVICE|smART+ System|Utilizing the smART+ System to provide feeding optimization to the patient
40987883|NCT03585179|DRUG|Oral Tranexamic Acid|Participants will take a pill of 250 mg bid for 12 weeks
40987884|NCT03585179|DRUG|5% topical tranexamic acid|Participants will apply a layer of gel on the affected skin bid for 12 weeks
41147055|NCT00074932|BIOLOGICAL|Myozyme|20 mg/kg
41464742|NCT03690089|OTHER|Placebo|Placebo eye drops which consist of 10mls of a clear colourless solution of benzalkonium chloride 0.01% w/v in sterile water.
41464743|NCT04286295|DRUG|Cytisine|Cytisine is a plant-based smoking cessation medication. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support.
41464744|NCT04286295|DRUG|Nicoderm C-Q Transdermal Product|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
41464745|NCT04286295|DRUG|Nicorette Lozenge Product|Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
41464746|NCT02702869|PROCEDURE|cleft lip repair|
40783734|NCT01043718|BEHAVIORAL|More-Intensive|The online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program. The program will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs. The program curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives.
40783735|NCT01043718|BEHAVIORAL|Less-Intensive|The participants will be provided with the information to access the online Diabetes Prevention Program (DPP) intervention materials. Following the original DPP trial, all DPP materials were placed online for the public to access. This group will receive a lifestyle counseling session and tools to facilitate their intervention.
40783736|NCT02622191|DEVICE|Spectral domain Optical Coherence Tomography|Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).
40783737|NCT01105663|OTHER|Pharmacokinetic Sampling and pharmacogenetic analysis|Pharmacogenetic and pharmacokinetic samples will be obtained from a peripheral catheter, central catheter, or venipuncture coordinated with scheduled phlebotomies. Pharmacokinetic and pharmacogenetic analyses will be performed. Pharmacodynamic data will be collected.
40783738|NCT00905190|DRUG|Ondansetron|24 mg one time
40987885|NCT03585179|DRUG|4% hydroquinone|Participants will apply a layer of cream on the affected skin once at night
41145628|NCT01659697|BEHAVIORAL|intensive lifestyle counseling|Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
40987886|NCT00261677|DRUG|epoetin alfa|
40987887|NCT04349488|DEVICE|Anodal Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
40987888|NCT04336982|DRUG|CC-90009|Injection
41145630|NCT02888353|DEVICE|Device: MRI|Perform MRI in patients with cardiac devices
41145631|NCT06593275|PROCEDURE|Protection of the palatal donor area with flowable resin|Use of fluid resin for protection of the palatal donor area to assess postoperative pain generated during14 days
41145632|NCT06593275|PROCEDURE|Protection of the palatal donor area with a self-adhesive dressing|Use of a self-adhesive dressing for protection of the palatal donor area to evaluate postoperative pain generated for 14 days
41145633|NCT04251845|DIETARY_SUPPLEMENT|topical melatonin|Topical melatonin at 3% concentration with dosage of 15 mg once daily will be applied on the lesion for 6 weeks followed by a follow up of 3 months
41145634|NCT04251845|OTHER|PLACEBO|Topical application of placebo once daily for 6 weeks with a follow up for 3 months
41145635|NCT00116233|DEVICE|REPEL-CV|
41306183|NCT02018952|OTHER|Ultrasonography assessment|"All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).~Day 0 :~* Information of patient and no opposition getting~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day 4 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day15 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~M3 :~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~* Functional outcome"
41464747|NCT02702869|PROCEDURE|cleft palate repair|
40783739|NCT05068349|DRUG|Butylphthalide|Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
40987889|NCT04336982|DRUG|Venetoclax|Tablet
40987890|NCT04336982|DRUG|Azacitidine|Injection
40987891|NCT04336982|DRUG|Gilteritinib|Tablet
41145636|NCT03037827|PROCEDURE|Endovenous laser ablation (EVLA)|Endovenous laser ablation with laser wavelength 1470 nm and radial laser fiber
41145637|NCT03037827|DEVICE|Laser|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
41145638|NCT02181179|BEHAVIORAL|Yoga|The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
41145639|NCT04814719|DRUG|Pentosan Polysulphate Sodium|Subcutaneous Injection (100mg/ml)
41145640|NCT04814719|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
41464748|NCT02702869|PROCEDURE|oronasal fistula repair|
41464749|NCT02702869|PROCEDURE|pharyngoplasty|
41464750|NCT02702869|PROCEDURE|gingivoperiosteoplasty|
41464751|NCT02702869|PROCEDURE|LeFort-1 maxillary repositioning|
41464752|NCT02702869|PROCEDURE|rhinoplasty|
41464753|NCT02702869|PROCEDURE|myringotomy and tympanostomy tube placement|
41464754|NCT02702869|OTHER|speech therapy|
41464755|NCT02702869|PROCEDURE|orthodontia|
41464756|NCT02702869|PROCEDURE|presurgical orthopedics|
41464757|NCT02702869|DEVICE|sound amplification for hearing|
41464758|NCT00240617|DRUG|sumatriptan succinate/naproxen sodium|comparator
40987892|NCT05052099|DRUG|mFOLFOX6, Atezolizumab and Bevacizumab|"All study medication is administered by intravenous (IV) infusion on Day 1 of each 14-day cycle:~• mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form \[levo leucovorin\]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2~combined with~* Atezolizumab 840 mg and~* Bevacizumab 10 mg/kg"
40987893|NCT04226274|DRUG|REN001|Once daily for 12 weeks
40987894|NCT06069687|BIOLOGICAL|MELPIDA|A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg
40987895|NCT04790760|DIETARY_SUPPLEMENT|Supplement Consumption|Participants will consume one 500 mg cinnamon capsule and one 300 mg aloe vera capsule twice per day for weeks 3-6.
40987896|NCT04790760|DEVICE|Continuous Glucose Monitors|Participants will wear a CGM on the back of their left and right arm for weeks 1-6.
40987897|NCT02046109|PROCEDURE|Repair|
40987898|NCT02046109|PROCEDURE|Replace|
40987899|NCT03945474|OTHER|Sham|See description in sham arm.
40987900|NCT03945474|OTHER|Osteopathic Manipulation, OMT|See description in OMT arm
40987901|NCT03975855|DEVICE|NeoNavia® Biopsy System|Biopsy of axillary lymph node using the NeoNavia Biopsy System. The investigator shall obtain as many/large samples as judged adequate and sufficient for diagnosis.
40987902|NCT01525043|DRUG|Naproxen|Naproxen 500mg BID for the first 2 weeks
40987903|NCT01525043|DRUG|Synera patch twice daily|1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
40987904|NCT01525043|DRUG|Synera patch for 12hrs/day|1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
41306184|NCT01806246|BEHAVIORAL|integrative rehabilitation program|
40987905|NCT01525043|DRUG|Naproxen|500mg bid
40987906|NCT01525043|DRUG|Synera|Topical appication of single patch to elbow for 12hrs/day
40987907|NCT01525043|DRUG|Synera|Single patch applied to elbow for 4hrs/twice daily
40987908|NCT02355691|DEVICE|PREVENA|The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
40987909|NCT00494832|DRUG|Dexmedetomidine|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
40987910|NCT00494832|DRUG|Normal Saline|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
40987911|NCT06300242|BEHAVIORAL|Reminders|Reminders
40987912|NCT06300242|BEHAVIORAL|Financial Incentive|$50 financial incentive for getting vaccinated within 1-week
40987913|NCT06300242|OTHER|Placebo|No special messages or incentives
40987914|NCT06002347|BEHAVIORAL|STAC Parent Module for Middle School|"The STAC Parent Module is a 30-minute pre-recorded online presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies parents can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
40987915|NCT04352114|DRUG|LY3461767 - SC|Administered SC.
40987916|NCT04352114|DRUG|LY3461767 - IV|Administered IV.
40987917|NCT04352114|DRUG|Placebo - SC|Administered SC.
40987918|NCT03892460|DEVICE|neuromuscular electrical stimulation|bilateral quadriceps exercise with neuromuscular electrical stimulation
40987919|NCT00152750|DRUG|APO-clonidine|
40987920|NCT00822068|DEVICE|anodal tDCS|anodal transcranial direct current stimulation
41306185|NCT02804412|OTHER|Control group|This is the control group with 14 h treatment over 10 workdays.
41306186|NCT02804412|OTHER|CIAT-group|Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
41306187|NCT02804412|OTHER|communication treatment group (CTG)|Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
41306188|NCT06257238|DEVICE|Fully immersive Head-Mounted Display Virtual Reality|patients are asked to wear the Oculus Quest VR on their heads and to hold the hand controllers by their hands and start the game exercises (Dance loop, Tennis ball and Boxing) with 10 min. for each game with 1 min. rest in between, plus the traditional PT program:(Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
41306189|NCT06257238|BEHAVIORAL|Traditional Physical Therapy Program|patients are treated with Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles, 2 sessions per week for 2 months.
41306190|NCT00219765|DRUG|Imatinib mesylate 600 mg|
40987921|NCT00822068|DEVICE|cathodal tDCS|cathodal transcranial direct current stimulation
40987922|NCT00822068|DEVICE|sham stimulation|sham stimulation
40987923|NCT03963115|DRUG|Epinephrine or normal saline|epinephreine or normal saline coated syringe before drawing allergen for injection.
40987924|NCT00589914|DRUG|RISPERDAL CONSTA|RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
40987925|NCT00589914|DRUG|Paliperidone palmitate|PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
40987926|NCT04375189|OTHER|High Risk Clinic|"Subgroup of primary care clinic where patients have longer time slots, supervision by one longitudinal attending, bedside presentations"
40987927|NCT01684631|DEVICE|Total Hip arthroplasty|
40987928|NCT03130166|PROCEDURE|Intracorporeal anastomosis|Use of intracorporeal anastomosis technique
40987929|NCT03130166|PROCEDURE|Extracorporeal anastomosis|Use of the conventional extracorporeal anastomosis technique
40987930|NCT05501184|OTHER|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
41306191|NCT00219765|DRUG|Cytarabine|
40987931|NCT05501184|OTHER|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
40987932|NCT04898257|DIETARY_SUPPLEMENT|Multistrain probiotic|After completion of screening phase, during baseline visit, eligible patients will be assigned to Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day on an empty stomach (30 minutes before breakfast and 30 minutes before dinner).
40987933|NCT05025111|DEVICE|Entia Liberty|Home monitoring device
40987934|NCT01788670|DIETARY_SUPPLEMENT|Ethanol|
40987935|NCT01788670|OTHER|Water|
40987936|NCT04829565|DRUG|Botulinum toxin|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of botulinum toxin 50 IU
40987937|NCT04829565|DRUG|Placebo|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of placebo
40987938|NCT04432051|BEHAVIORAL|mechanical ventilator settings and position|Mechanical ventilation settings and patient position will be re-evaluated
40987939|NCT03287804|BIOLOGICAL|AUTO2|"AUTO2 (APRIL CAR T Cells) Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells.~Following Phase 2 dose determination patients will be treated with selected dose of APRIL CAR T Cells"
41145641|NCT05839743|OTHER|Aerobic Exercise|The aerobic exercise program will be specially prepared for the participants and will aim to rhythmically exercise large muscle groups. The exercise will be performed twice a week for 6 weeks at 50-75% of maximum heart rate for 20-50 minutes per session. Each exercise will last 30-60 minutes in total, after adding 5 minutes of warm-up and 5 minutes of cool-down before and after the exercise. The participant's pulse will be monitored continuously during the exercise.
41145642|NCT05839743|OTHER|Balance Exercise|Balance exercises belonging to the Otago Exercise Program and other balance exercises used in the elderly will be prepared specifically for the participant and will be applied 2 days a week for 6 weeks in combination. Before and after the exercise, a 5-minute warm-up and 5-minute cool-down exercise will be performed.
41145643|NCT05839743|OTHER|Combined Exercise|In the combined exercise program, first balance exercises and then aerobic exercise program will be applied 2 days a week for 6 weeks.
41145644|NCT01619007|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
41145645|NCT01619007|DRUG|Standard of care|Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
41306192|NCT00219765|DRUG|Daunorubicine|
41306193|NCT04059445|DEVICE|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Regenerative therapy with biphasic calcium phosphate + collagen membrane.
41464759|NCT00240617|DRUG|placebo|placebo to match
41464760|NCT02872350|DEVICE|Abdominal ultrasound|Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
41464761|NCT05120791|DIETARY_SUPPLEMENT|Placebo vegetable bouillon|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
40783740|NCT03006588|PROCEDURE|EUS-FNA for RPLN in NPC patients|An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
40987940|NCT06117384|GENETIC|Biomolecular profiling|Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.
40987941|NCT01882374|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
40987942|NCT02796040|DEVICE|MRI|
40987943|NCT01371474|DRUG|Paroxetine|
40987944|NCT06094673|OTHER|No intervention|No intervention
41464762|NCT05120791|DIETARY_SUPPLEMENT|microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
40987945|NCT03495323|DRUG|LY3300054|LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (
40987946|NCT03495323|DRUG|Prexasertib|Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death
40987947|NCT04300595|PROCEDURE|Combination of General anesthesia and local anesthesia in dacryocystorhinostomy surgery|"all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).~In both groups, general anesthesia was induced with 2 mg/kg propofol and tracheal intubation was facilitated by 0.1 mg/kg cisatracurium. All patients underwent mechanical ventilation with 100% oxygen. Anesthesia was maintained with isoflurane, and muscle relaxation was provided by an injection of cisatracurium 0.02 mg/kg every 20 minutes."
40987948|NCT05029986|BEHAVIORAL|Socialization phase|Control condition: does not involve speech-related exercises
40987949|NCT05029986|BEHAVIORAL|Speech breathing intervention|Experimental condition: involves speech-related exercises
40987950|NCT06308120|DEVICE|Ion Endoluminal System|Participants in the test arm will undergo a diagnostic bronchoscopy with ION™ Endoluminal System.
40987951|NCT06308120|DEVICE|superDimension Navigation System and Accessories|Participants in the control arm will undergo a diagnostic bronchoscopy with superDimension Navigation System and Accessories.
40987952|NCT04615663|BEHAVIORAL|Score SMI|the investigator will complete the SMI score
40987953|NCT00518323|DRUG|Paliperidone ER|3 mg or 6 mg tablet once daily for 6 weeks
40987954|NCT00518323|DRUG|Placebo|Once daily for 6 weeks
40987955|NCT00518323|DRUG|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
40987956|NCT00518323|DRUG|Paliperidone ER|6 mg or 12 mg tablet once daily for 6 weeks
41464763|NCT05120791|DIETARY_SUPPLEMENT|From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
40783741|NCT06324032|PROCEDURE|EUS Elastography (EUS-E)|All procedures will be performed with Olympus echoendoscopes (Olympus Europa SE \& CO. KG, Hamburg, Germany) or Pentax echoendoscopes in combination with dedicated elastography software
40783742|NCT00527618|DRUG|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
40783743|NCT00527618|DRUG|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
41464764|NCT05120791|DIETARY_SUPPLEMENT|A combination of the vegetable bouillon, the microalgae and the beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
41464765|NCT01618487|PROCEDURE|Arthroscopic tenotomy|This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
41464766|NCT01618487|PROCEDURE|Open tenotomy|This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
41464767|NCT01618487|PROCEDURE|Debridement and repair|This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
40783744|NCT02229617|DRUG|Subcutaneous testosterone|
40783745|NCT03833141|OTHER|Survey Administration|Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.
40783746|NCT03041935|PROCEDURE|Ilioinguinal/iliohypogastric nerve block|See arm description
40783747|NCT03041935|PROCEDURE|Caudal-epidural nerve block|See arm description
40783748|NCT03041935|DRUG|Acetaminophen|See arm description
40987957|NCT00455364|DRUG|Voriconazole|
40987958|NCT02632552|BEHAVIORAL|Technology-assisted care transition intervention|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
40987959|NCT02632552|BEHAVIORAL|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
40987960|NCT04658095|DEVICE|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy using the OMNI Surgical System
41145646|NCT03095261|BEHAVIORAL|Web-based exercise diary|All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.
41464768|NCT05180591|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
40987961|NCT04658095|DEVICE|iStent inject|Ab-interno implantation of iStent inject (2 microstents)
40987962|NCT04658095|DEVICE|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System
41464769|NCT05180591|BIOLOGICAL|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
41464770|NCT06130969|OTHER|Cervical Retraction Exercise|Participants will hold cervical retraction for 10 s up to 10 times. A break of 5 s will be provided per one movement and 30 s per one set. A total of three sets will be conducted. Therefore, the total exercise time will be \<10 mints.
41464771|NCT06130969|OTHER|Diaphragmatic Breathing|The diaphragmatic exercise will be performed in a supine position with 40° trunk flexion while holding 2.5 kg on the abdomen in the first 5 sessions and then 5 kg in the second 5 sessions. Participants will perform 3 sets with 10 repetitions at a ratio of one second of inspiration to two seconds of expiration, three sets of 15 repetitions at a ratio of two seconds of inspiration to four seconds of expiration, and three sets of 20 repetitions at a ratio of three seconds of inspiration to six seconds of expiration. The rest between rests will be 60 s.
40783749|NCT03041935|DRUG|Sevoflurane|See arm description
40783750|NCT03041935|DRUG|Remifentanil|See arm description
40783751|NCT03041935|DRUG|Propofol|See arm description
40783752|NCT03041935|DRUG|Morphine|See arm description
40783753|NCT03041935|DRUG|Ondansetron|See arm description
40783754|NCT03041935|DRUG|Dexamethasone|See arm description
40783755|NCT03041935|DRUG|Ketorolac|See arm description
40783756|NCT03041935|DRUG|Ropivacaine|See arm description
40783757|NCT00655837|DRUG|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
40783758|NCT00655837|DRUG|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
40987963|NCT02207790|DRUG|E2609|
40987964|NCT02207790|DRUG|Placebo|E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
41464772|NCT06130969|OTHER|Baseline Treatment|"Hot fomentation will be given by applying cervical hot pack over the area in prone lying position for 10 mints and Isometric neck strengthening exercises (10 repetitions, each 5-second hold, 1 set) (20). • Nerve Stimulation (TENS) on the painful regions around the neck for 15 minutes with a TENS device. TENS parameters will be 150 μs square pulses with a frequency of 80 Hz.~The intensity of the current will be adjusted to produce no contraction.~• Posture education to keep upright posture during sitting."
41464773|NCT02185963|DRUG|Rosuvastatin|Rosuvastatin 20mg once a daily for 12 weeks
41464774|NCT04581876|DRUG|raltitrexed for injection|Patients receive raltitrexed 2mg/m2 (iv, 15min) on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
41464775|NCT04581876|DRUG|nab-paclitaxel|Patients receive nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
41464776|NCT03776578|PROCEDURE|swallow fuction and swallow training|nasogastric tube dependence rate
40783759|NCT00655837|DRUG|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
40783760|NCT02469220|DIETARY_SUPPLEMENT|Low FODMAP|Blinded food supplements containing only items with a low content of FODMAPs
40987965|NCT06071091|DEVICE|Intracranial stenting|"In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible.~Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication."
41145647|NCT03095261|DEVICE|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.
41145648|NCT03095261|BEHAVIORAL|Virtual Reward|"Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months."
41306194|NCT04059445|DRUG|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
41464777|NCT01644149|DEVICE|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
41464778|NCT01644149|DEVICE|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
41306195|NCT04355312|DIAGNOSTIC_TEST|Use of Indocyanine Green in laparoscopic ovarian cystectomy|"During intraperitoneal cystectomy or Plasmajet destruction of the cyst, as a benign organic cyst requiring surgical treatment, peroperatively, at the end of the cystectomy procedure, injection by the anesthetist on a peripheral venous route of a bolus of Indocyanine green diluted 0.2mg / kg. Installation of the SPIES camera system (KARL STORZ GmbH \& Co.KG, Tuttlingen, Germany).~Evaluation of the degree of fluorescence at the location of cystectomy or destruction of the cyst.~A fluorescence score between 0 and 4 (on the model of a Likert scale) will be used for the evaluation of fluorescence.~A second reading of the Likert scale results will be carried out by a second inspector so that the score is as objective as possible. Then, second evaluation technique realized by the METAMORPH software, which will assign a raw and objective score according to the fluorescence visualized."
41464779|NCT01644149|BIOLOGICAL|2011-2012 Fluzone trivalent inactivated influenza vaccine|
40783761|NCT02469220|DIETARY_SUPPLEMENT|Standardized FODMAP|Blinded food supplements containing FODMAPs
40783762|NCT01587248|DEVICE|Harmonic|Dissection with harmonic scalpel
40783763|NCT01587248|PROCEDURE|electrocautery|Dissection in modified radical mastectomy
40783764|NCT02833883|DRUG|Enzalutamide|
41464780|NCT01451996|DRUG|Claritin|Subject will be given 10mg Claritin tablet.
41464781|NCT04227041|DRUG|Pyrotinib in combination with capecitabine|Pyrotinib in combination with capecitabine
40783765|NCT02833883|DRUG|CC-115|
40783766|NCT02319486|DRUG|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
40783767|NCT02319486|DRUG|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
41306196|NCT00263302|DRUG|dexamethasone|
41464782|NCT03169621|PROCEDURE|Endometrial Biopsy and endometrial fluid collection|"On day 5 of the Hormonal Replacement Therapy (after 5 days of progesterone administration), the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.~The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE."
40783768|NCT05655975|PROCEDURE|upper gi endoscopy|In all patients undergoing RYGB gastric bypass, an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
40783769|NCT01250054|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
41464783|NCT03964441|BIOLOGICAL|Invasive fetal sampling, blood sampling of mother and father|to perform an exome sequencing analysis in trio
41464784|NCT03964441|BIOLOGICAL|blood sampling from the mother to recover the circulating cell free fetal DNA|to perform a sequencing analysis of the genome of circulating free fetal DNA
41464785|NCT03964441|OTHER|Parent interviews (optional organizational study)|Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results
40783770|NCT01250054|DEVICE|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
40783771|NCT05792748|PROCEDURE|Pulp hemostasis with a dry cotton pellet|Application of a dry cotton pellet, then the chamber was filled with ZOE directly over the pulp
40783772|NCT05792748|PROCEDURE|Pulp hemostasis with a wet cotton pellet impregnated with FS|Application of a a wet cotton pellet impregnated with FS, then the chamber was filled with ZOE directly over the pulp
40987966|NCT06071091|OTHER|Optimal medical care, without additional endovascular procedures|"The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts.~In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion.~The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list):~* Nursing~* Nursing care~* Symptomatic treatments: analgesics for example~* Systematic clinical monitoring and control imaging if necessary~* Rehabilitation if necessary)"
40987967|NCT01700855|PROCEDURE|non-electroacupuncture|The same procedure as electroacupuncture except stimulation
40783773|NCT05792748|PROCEDURE|Stainless steel crown|Stainless steel crown placed as a final restoration
40783774|NCT01248325|DRUG|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
40783775|NCT01248325|DRUG|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
40783776|NCT06048211|OTHER|Stool color scale|observationnal trial about the use of the stool color scale by the health professionnals
40783777|NCT01342926|DRUG|GSK933776|GSK933776
40783778|NCT01342926|DRUG|Placebo|Placebo
40987968|NCT01700855|PROCEDURE|Electroacupuncture|"Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3\~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate."
40783779|NCT00527228|DRUG|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
40783780|NCT00527228|DRUG|placebo|
40987969|NCT01986855|DRUG|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
40987970|NCT01986855|DRUG|Placebo 5 mg|Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
40987971|NCT01986855|DRUG|Ertugliflozin 10 mg|Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
40987972|NCT01986855|DRUG|Placebo 10 mg|Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
40987973|NCT03273192|DRUG|Adalimumab|A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
40987974|NCT06320145|DEVICE|Cryotherapy|This device used at the first, second and third day of period to decrease pain for 20 min at first, second and third day
40987975|NCT06320145|OTHER|core stability exercises|core stability exercises
40987976|NCT05865899|PROCEDURE|valgus producing medial opening wedge high tibial osteotomy|Valgus producing Opening wedge high tibial osteotomy will be performed through a medial incision at the proximal tibia and stabilized with a plate and screws. Hardware will be removed within 10-12 months to avoid soft tissue irritation.
40987977|NCT00303498|DRUG|Sitexsentin sodium|sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
40987978|NCT00303498|DRUG|Placebo|placebo identical to the study drug in description, dose and duration
40987979|NCT05823623|DRUG|Inetetamab|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
40987980|NCT05823623|DRUG|Pyrotinib|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
40987981|NCT05823623|DRUG|Oral Vinorelbine Tartrate|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
40987982|NCT03104114|BEHAVIORAL|pharmacist-intervention|A clinical pharmacist provides patients with motivational counseling regarding their cancer treatments. Patients will be asked to complete three different surveys throughout the study; surveys focus on social support systems and both provider- and pharmacist-patient relationships
40987983|NCT03104114|BEHAVIORAL|Historical control|Patients that did not receive in-person motivational counseling support from a clinical pharmacist prior and during treatment
40783781|NCT02913963|DEVICE|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
40783782|NCT02913963|DEVICE|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
40783783|NCT00327912|PROCEDURE|Laparoscopic Biliopancreatic diversion with Duodenal switch|
40783784|NCT00327912|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
40783785|NCT02373618|OTHER|DN and conventional PT|Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.
40987984|NCT02259361|DRUG|Sustained-release oral dalfampridine|One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
40987985|NCT02259361|DRUG|Placebo|Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
41145649|NCT03095261|BEHAVIORAL|Financial Incentive|"Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months."
41145650|NCT01299324|DEVICE|BMAC infusion|Infusion of 60 mL of Bone Marrow Aspirate Concentrate
41306197|NCT00488618|DRUG|Cariprazine (RGH-188)|Cariprazine 3 mg - 12 mg oral administration, once per day.
41306198|NCT00488618|DRUG|Placebo|Dose-matched placebo oral administration, once per day.
40987986|NCT06112951|PROCEDURE|Extracorporeal Photopheresis|Patients randomized into the interventional group will receive ECP. ECP will be started within one week after randomization. Initially a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.
17045547|NCT06361849|DEVICE|Trocar Placement Assist Device (TPAD)|The TPAD is an experimental device used to assist with placement of Veress needle and trocar during laparoscopic surgery.
40987987|NCT00907985|DRUG|Placebo|Single dose of placebo will be provided.
40987988|NCT00907985|DRUG|Vofopitant|Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
40987989|NCT00907985|DRUG|Lamotrigine|Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
40987990|NCT03887000|OTHER|magnesium|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
40987991|NCT03887000|OTHER|placebo|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
40987992|NCT05488691|BEHAVIORAL|EMDR|The first session consists of recording the patient's history. In the second session the therapist evaluates the presence of coping mechanisms of the patient and, if necessary, suggests extra coping techniques. The following sessions are devoted to the reprocessing process. During these sessions, a target memory is identified and processed using EMDR. After a total of 8-10 sessions, it is expected that the patient will have achieved physiological reconciliation, relieved distress, and the ability to reformulate negative beliefs.
40987993|NCT05488691|BEHAVIORAL|TAU|treatment as usual for substance use disorders
40987994|NCT01093547|PROCEDURE|Blood samples|Samples taken monthly
40987995|NCT01093547|PROCEDURE|Measure of peritoneal ultrafiltrates|Measured by the investigators intermittently and by the patients themselves on a monthly basis
41145651|NCT04117386|DIAGNOSTIC_TEST|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong)|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) for swab sample collected from pterygium and normal conjunctiva and also for urine collected in Colli-PeeTM device (Novosanis, Belgium)
41145652|NCT04117386|DIAGNOSTIC_TEST|Bio-Plex® 200 system (Bio- Rad, Hercules, CA)|Bioplex was use for measure cytokine IL-6, IL-18 and VEGF from tears collected from Schirmer strip
41145653|NCT03981549|BIOLOGICAL|Autologous Bone Marrow CD34+ Stem Cells|Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
41145654|NCT03981549|BIOLOGICAL|Sham Therapy|Sham bone marrow aspiration procedure that penetrates the skin, but does penetrate the bone followed by sham intravitreal injection without penetration of the eye
40783786|NCT02373618|OTHER|Conventional PT|Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
40987996|NCT00807807|DIETARY_SUPPLEMENT|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
40987997|NCT00807807|DRUG|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
40987998|NCT05710107|OTHER|PENG + LFC Block|Subjects assigned to this group will receive PENG + LFC Block
40987999|NCT05710107|OTHER|QL Block|Subjects randomized to this group will receive a QL Block
40988000|NCT00483379|BIOLOGICAL|alglucosidase alfa|intravenous infusion
40988001|NCT04964128|DEVICE|MiniMed™ 780G insulin pump with Klue Health app utilizing meal gesture micro insulin dosing (meal gesture dosing)|The AHCL system with Meal Gesture Dosing evaluated in this study includes a commercial/CE-Marked insulin pump with investigational software, and the Klue Health mobile app with investigational software (installed on Apple Watch) for meal gesture detection and micro dosing.
40988002|NCT03564145|DRUG|S5G4T-1|Once a day topical cream
40988003|NCT00524550|DIETARY_SUPPLEMENT|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
40988004|NCT04597996|OTHER|web based education for students|"Web-based education will include modules on the following subjects;~* Mental health literacy knowledge level~* Improving help-seeking behavior~* Avoiding self-stigmatization in seeking psychological help"
40783787|NCT03820830|DRUG|Palbociclib 125mg|Palbociclib 125 mg oral tablet taken daily for 3 years from randomization
40988005|NCT02440477|OTHER|clinical shoulder tests|Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
41306199|NCT03121872|PROCEDURE|Root Coverage Surgery with T-PRF|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
40988006|NCT02015650|DRUG|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
40988007|NCT02015650|DRUG|Mitomycin-C/ 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
41306200|NCT03121872|PROCEDURE|Root Coverage Surgery with CTG|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
41306201|NCT06217458|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|The CEM performance protocol involves the intravenous administration of non-ionic, low-osmolarity iodinated contrast medium using an automatic syringe that delivers the required bolus of contrast medium at a dose of 1.5 ml/kg body weight at a rate of 3 ml/s without compressing the breast. After a two-minute pause, necessary to allow the breast parenchyma to absorb (stain) the contrast agent, the patient is positioned for the mammogram and the breast is compressed. First the symptomatic and then the non-symptomatic breast is imaged in two or a total of four standard projections: craniocaudal (CC) and oblique mediolateral (MLO) projections of the breast. The delayed CC and MLO projections of the symptomatic breast are taken within eight minutes of the start of the examination. The delayed mammograms are used to assess the dynamics of the contrast uptake of the lesion and are compared to the same parameters of the breast MRI. The time required to perform the CEM is 8-10 minutes.
41306202|NCT00498108|DRUG|Rotigotine|
41306203|NCT05253313|OTHER|MRI scan|Patients will be randomized to a pre-operative scan or not. The MRI scan will evaluate the local extent of the tumor and especially focus on identifying possible liver metastases unseen on the CT-scan.
41306204|NCT02782663|DRUG|ABT-494|Tablet: Oral
41306205|NCT04387058|DEVICE|TIPS|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is an interventional radiology method that creates an anastomosis between the portal venous network and the hepatic venous network.
41306206|NCT02626104|DIETARY_SUPPLEMENT|Bovine lactoferrin|The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.
41306207|NCT02626104|DIETARY_SUPPLEMENT|Maltodextrin|The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
41306208|NCT03347604|DIAGNOSTIC_TEST|Supine spirometry, MIPs and MEPs|We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
41306209|NCT04371731|OTHER|Care4todayheart failure platform|Platform allowing patients to enter information about their health at home, namely weight and BP and medications
41306210|NCT00267332|DRUG|Modafinil|
41306211|NCT00516269|DRUG|Methylphenidate|18 mg by mouth daily for 2 weeks
41306212|NCT00516269|DRUG|Placebo|Capsule by mouth daily for 2 weeks
41306213|NCT04567602|DRUG|PAH medication|There will be no specific interventions.
41306214|NCT03123354|DEVICE|O3 regional oximeter sensor|Noninvasive sensor that is placed on the forehead for measurement of oxygenation in the area under the sensor
41306215|NCT04355156|DRUG|Axitinib|"* All patients randomised to this arm will receive 3mg BD, and increased at 2 weeks to 5mg BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)~* At 8 weeks, after tumour CT RECIST assessments, responders will continue monotherapy. In non-responders, those with disease progression, monotherapy can be continued if patient chooses to continue and if tolerated"
40783788|NCT03820830|DRUG|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
41306216|NCT04355156|DRUG|Placebo|"* All patients receiving placebo will receive tablets to take BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)"
41306217|NCT03182205|OTHER|IME|The IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets. Inspiratory load will be set at 40% of maximum static inspiratory pressure. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a clip nasal.
40988008|NCT01656590|OTHER|High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding|"1. High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age \& gender~2. 500 cc Formula - Nutren Replete with Fiber overnight \[8 hours\] via gastrostomy tube~3. Conditioning Exercise once daily"
40988009|NCT04997993|DRUG|Leflunomide|Leflunomide, 20-50mg PO daily
40988010|NCT01364207|OTHER|Caffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
40988011|NCT01364207|OTHER|Decaffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
40988012|NCT06410118|BEHAVIORAL|DreamChanger+IRT|Families will receive the DreamChanger remote along with 3 instructional videos for parents, explaining how to present the remote to children, and how to rehearse alternative dream imagery using the DreamChanger remote.
40988013|NCT05217329|OTHER|smart phone App rehabilitation|stroke subjects use smart phone to complete therapeutic tasks 5 min/session total 8 sessions/day with affected arm or bilateral arm movement for 6 weeks
40988014|NCT05217329|OTHER|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program for 6 weeks(30min/day)
41147056|NCT05804552|DEVICE|Dorsal genital nerve stimulation|Two types of stimulation electrodes will be used: UCon Patch Electrodes (InnoCon Medical ApS, Denmark) and ValuTrodes/EconoStim Electrodes (5x5 cm, Axelgaard Manufacturing Co. Ltd., United States). The UCon Patch Electrode acts as a cathode and will be placed on the clitoris. The ValuTrode/EconoStim acts as an anode and will be placed on the lower abdomen. The continuous stimulation consists of a train of single pulses provided continuously with a frequency of 20 Hz and a pulse duration of 200 μs. The burst stimulus pattern consists of a train of bursts. The length of the train is 10 s and will consist of 20-30 bursts/s. One burst consists of 5 identical square pulses (monophasic). The inter-pulse interval is 4 ms (time between the onset of 2 consecutive pulses) while a pulse duration of 200 μs will be used.
41306218|NCT03182205|OTHER|Sham IME|The Sham IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets, but without a load generating resistance. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a nasal clip.
41306219|NCT04035135|DRUG|ANX005|investigational drug
41306220|NCT04035135|DRUG|Intravenous immunoglobulin|investigational drug
40783789|NCT04155476|DRUG|Nitroglycerin Topical Product|application of NG topical to dorsals pedis and posterior tibial arteries.
40783790|NCT00411424|DRUG|ASK8007|IV
40783791|NCT00411424|DRUG|Placebo|IV
40988015|NCT04317911|OTHER|Catheter Ablation|Patients with preserved ejection fraction presenting for catheter ablation via of atrial fibrillation are included in this study and prospectively observed regarding arrhythmia-related, functional and biomarker-associated outcomes.
40988016|NCT02063490|BEHAVIORAL|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
40988017|NCT01392976|DRUG|CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
40988018|NCT01392976|DRUG|CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
40988019|NCT06182826|PROCEDURE|Core Stability protocol|5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Curl Up Side Planks Bird Dog Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
40988020|NCT06182826|PROCEDURE|Routine exercise therapy|5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
40988021|NCT01715311|DRUG|Indacaterol|Indacaterol once daily via single-dose dry powder inhaler
41306221|NCT00257387|DRUG|Cyclosporine|
41306222|NCT06007482|DRUG|ES009|ES009 is administered via intravenous infusion, once every 21 days.
40988022|NCT01715311|DRUG|Placebo to tiotropium|Placebo to tiotropium capsules for inhalation once daily
40988023|NCT01715311|DRUG|Tiotropium|Tiotropium capsules for inhalation once daily
40988024|NCT01715311|DRUG|Placebo to indacaterol|Placebo to indacaterol capsules for inhalation once daily
40988025|NCT03192592|OTHER|Body moisturizer|Daily body moisturizer application for skin protection and barrier.
40988026|NCT03022344|RADIATION|Cardiac CT|
40988027|NCT00002631|DRUG|chemotherapy|
40988028|NCT00002631|DRUG|cisplatin|
40988029|NCT00002631|DRUG|fluorouracil|
40988030|NCT00002631|RADIATION|low-LET electron therapy|
40988031|NCT00002631|RADIATION|low-LET photon therapy|
40988032|NCT02591147|DEVICE|Silver Diamine Fluoride 38%|Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
40988033|NCT02591147|DEVICE|Group 2 (Placebo)|Group 2 (Placebo) subjects will receive application of sterile water (placebo) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
40988034|NCT04554277|BIOLOGICAL|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
40988035|NCT04769310|DEVICE|Cardiac and Brain MRI|"A CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner will be used. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
40988036|NCT05248841|DRUG|HEC-Glargine|Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
40988037|NCT05248841|DRUG|US-Lantus|Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
41145655|NCT04389086|DRUG|Combination drug|"Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles.~If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI."
41145656|NCT04389086|RADIATION|Chemoradiotherapy|"Concomitant chemotherapy agent: capecitabine~Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy."
41145657|NCT04389086|PROCEDURE|Surgery locally recurrent rectal cancer|"Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.~Intraoperative radiotherapy is optional."
41145658|NCT05458544|DRUG|[177Lu]Ludotadipep 3.7 GBq|"Phase 1:~Patients will receive a single dose of 3.7 GBq of \[177Lu\]Ludotadipep~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 3.7 GBq~* Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (4 to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"
41145659|NCT04914520|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
41145660|NCT04914520|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
41306223|NCT02580487|PROCEDURE|appendicectomy|Appendix was removed either laparoscopically or open surgery
41306224|NCT01849835|PROCEDURE|trans-rectal to perform the prostate biopsy|the puncture points are at the rectal
41306225|NCT01849835|PROCEDURE|trans-perineal to perform the prostate biopsy|the puncture points are at the perineal
41306226|NCT01202227|DRUG|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
40988038|NCT05423028|PROCEDURE|Ultrasound-guided nerve hydrodissection|Peri- median nerve injection for hydrorelease and decompression
40988039|NCT06001554|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
40988040|NCT05744947|OTHER|Data collection|"Specific Readapt -DISCO complementary questionnaire rehabilitation"
40988041|NCT03104595|DRUG|EC-18|oral administration
40988042|NCT06065033|BEHAVIORAL|Exercise|"Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR).~* Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions.~* Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~* Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2.~* Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance."
40988043|NCT02211573|OTHER|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
40783792|NCT03488329|DIETARY_SUPPLEMENT|Individual nutritional therapy|"Guidance from a clinical dietician.~Individual nutrition plan~A package containing foods and drinks, which will cover their nutritional needs the first day after discharge.~A goodiebag containing samples on protein-rich milk-based drinks.~Telephone follow-up after 4 and 30 days and the possibility to call the dietician in case of questions about nutrition."
40783793|NCT01727934|DRUG|Miravirsen sodium|Subcutaneous injection
40783794|NCT04275076|PROCEDURE|Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia|comparison between 2 energy sources of enucleation in management of benign prostatic hyperplasia, holmium laser versus bipolar energy source in trans-urethral enucleation of the prostate
40783795|NCT03152123|DRUG|Pitolisant|Pitolisant 40 mg or 240 mg (tablets over-capsuled)
40783796|NCT03152123|DRUG|Placebos|tablets over-capsuled
40783797|NCT03152123|DRUG|Phentermine|Phentermine 60 mg (capsule over-capsuled)
40783798|NCT05144828|DEVICE|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYOS-L cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
40783799|NCT05144828|DRUG|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
40783800|NCT03256721|DRUG|Apatinib/docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
40783801|NCT03256721|DRUG|docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
40783802|NCT01647698|BEHAVIORAL|Adaptive working memory training task|"The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
40783803|NCT01647698|BEHAVIORAL|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
40988044|NCT05098860|OTHER|Home Exercise Program|Educational training program includes active stretching, strengthening, and stabilization exercises of head and neck muscles as well as relaxation and breathing exercises.
40988045|NCT05098860|OTHER|Manual Therapy Combined with Home Exercise Program|Manual Therapy program includes soft tissue and joint mobilizations of the cervical vertebrae, scapula and thoracic vertebrae.
40988046|NCT05098860|OTHER|Tele-rehabilitation Assisted Program|Tele-rehabilitation assisted program will be given in the on-line environment. Patients will apply active cervical and thoracic region mobilizations called self-mobilization.
41147057|NCT02611193|PROCEDURE|Manipulative treatment|Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
40783804|NCT01647698|BEHAVIORAL|No training|No training during the experiment.
40783805|NCT03848455|DIAGNOSTIC_TEST|genetic diagnosis|The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.
40783806|NCT02965066|DEVICE|Coloplast Test Catheter|Newly developed intermittent catheter
40783807|NCT02965066|DEVICE|Coloplast Speedicath|Marketed Coloplast Speedicath catheter
40783808|NCT04301648|OTHER|STAR Nurse|"This intervention will consist in that the nurse who is in the hemodynamic nurse's office will do the STAR Nurse's tasks and competences.~Although the intervention will be detailed through phase 1 (integrative review) and 2 (Delphy methodology).~It is expected that the main STAR nurse's competencies and tasks in the nurse's office will be:~1. To guarantee a comprehensive evaluation and appropriate triage to candidates for an interventional procedure of structural heart disease, coordinating the request for complementary tests and previous visits.~2. Make education to the patient and family.~3. Make communication bridge with cardiologists.~4. Establish specific patient-centered care processes.~5. Promote continuity of care after discharge, follow up after discharge, and reevaluate quality of life and fragility."
40783809|NCT04301648|OTHER|Common Practice|Common practice will consist in that the nurse who is in the hemodynamic nurse's office will do her usual task that is exclusively health education.
40988047|NCT01270711|DRUG|Study Drug|non interventional study - usage as per usual care
40988048|NCT05275764|PROCEDURE|primary or secondary intraocular lens implantation surgery|primary or secondary intraocular lens implantation surgery
41147058|NCT02611193|PROCEDURE|Simulated manipulative treatment|Simulated Manipulative Treatment
41306227|NCT01341431|DRUG|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
41464786|NCT03964441|OTHER|parent questionnaire (optional organizational study)|To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results
41464787|NCT03964441|OTHER|professional interviews (optional organizational study)|interview to understand how the decision is formed
41464788|NCT03964441|OTHER|Focus group for professionals (optional organizational study)|interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.
41464789|NCT04231409|DEVICE|Boston Scientific Spectra WaveWriter SCS System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
41464790|NCT01148524|BIOLOGICAL|No Vaccine|
41464791|NCT01148524|BIOLOGICAL|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
41464792|NCT00669435|DRUG|Losartan + Simvastatin|"tablets; 50, 100 mg; od; 12 months~tablets; 20 mg; od; 6 months"
41464793|NCT00669435|DRUG|Amlodipine + Simvastatin|"tablets; 5, 10 mg; od; 12 months~tablets; 20 mg; od; 6 months"
41464794|NCT03888534|DRUG|Ixazomib|Ixazomib intravenous injection in combination with reduction chemotherapy.
41464795|NCT02520453|DRUG|Durvalumab|
41464796|NCT02520453|DRUG|Placebo|
41464797|NCT05700396|BEHAVIORAL|Breast Cancer Survivor Education Program|Weekly sessions via Zoom platform with study staff.
41464798|NCT04374799|DRUG|Heparin|two doses of heparin
41464799|NCT04374799|DRUG|Placebos|placebo
40783810|NCT02543775|PROCEDURE|Preoperative and intraoperative SLN Mapping|"Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section."
40783811|NCT03166930|BEHAVIORAL|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
41464800|NCT05678517|DRUG|Anti-VEGF|intravitreal ranibizumab or intravitreal aflibercept
41464801|NCT06191159|DEVICE|Scalpel and standard electrocautery or PEAK PlasmaBlade|Scalpel followed by completion of surgery with standard electrocautery or PEAK PlasmaBlade.
41464802|NCT06191159|DEVICE|PEAK PlasmaBlade|PEAK PlasmaBlade for entire surgery.
41464803|NCT06191159|DEVICE|Standard Electrocautery|Standard Electrocautery for entire surgery.
41464804|NCT01531504|DEVICE|ViKY UP|laparoscopic-assisted hysterectomy procedure
41464805|NCT03458143|DRUG|Ketamine 150 ng/ml|conscious sedation in TCI-mode
41145661|NCT05586763|DRUG|Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)|Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication, post medication at 30 and 60 mins posts anti-vertigo medication and at time of disposition. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.
41464806|NCT03458143|DRUG|Remifentanil|conscious sedation in TCI-mode
41464807|NCT03458143|PROCEDURE|Oocyte retrieval|Oocyte retrieval for In Vitro Fertilization
41145662|NCT02893618|DRUG|Diazoxide choline controlled-release tablet|QD tablet formulation of choline salt of diazoxide
41145663|NCT03493906|OTHER|Patient Ambassador Support|Patient Ambassador Support, with former patient treated for acute leukaemia being ambassadors for newly diagnosed patients for a period of 12 weeks.
41306228|NCT02390336|OTHER|Real mobilization-with-movement (MWM)|For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
41306229|NCT02390336|OTHER|Sham mobilization-with-movement (MWM)|In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
41464808|NCT03458143|DRUG|Ketamine 200 ng/ml|conscious sedation in TCI-mode
41464809|NCT03230123|DIETARY_SUPPLEMENT|Green banana biomass|Green banana biomass will be suplemented to diet as 4.5 g per day.
41464810|NCT03384433|BIOLOGICAL|exosome|allogenic mesenchymal stem cells derived exosome enriched by miR-124
41464811|NCT04522999|DEVICE|Photobiomodulation|The Valeda™ Light Delivery System
41464812|NCT04372134|DEVICE|repetitive transcranial magnetic stimulation therapy|A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (\>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
41464813|NCT04420624|DRUG|Colchicine|1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month
41464814|NCT00039910|DRUG|(PN-152,243)/ PN-196,444|
40783812|NCT03166930|BEHAVIORAL|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management from the manual.
40783813|NCT00998010|DRUG|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
40783814|NCT02100293|DRUG|magnesium sulfate 30 mg/kg|Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
40783815|NCT02100293|DRUG|saline|Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
41306230|NCT05164861|DIETARY_SUPPLEMENT|kombucha-based beverage|"kombucha-based beverage: drinking water, black tea, kombucha, inulin, vitamins (B1, B2, B6, niacin, folic acid). Nutritional value in 100 ml: carbohydrates - 2.57 g (including sucrose - 0.22 g, glucose - 1.32 g, fructose - 1.03 g), inulin - 1.15 g (46%\*), vitamin B1 - 0.4 mg (29%\*), B2 - 0.21 mg (13%\*), B6 - 0.48 mg (24%\*), niacin - 2.74 mg (15%\*), folic acid - 24.0 mcg (12%\*). Energy value/Caloric content - 54 kilojoules/13 kcal (\* - % of the recommended daily allowance, according to the Technical regulations of the Customs Union #022/2011). Flavours, identical by nutrient's content and nutrients density: black currant berries \& juniper berries, or strawberries \& lime leaves, or passion fruit \& mango.~Portion's volume - 220 ml. Daily intake: 1 portion"
41306231|NCT00882102|DRUG|Decitabine|Decitabine 20 mg/m\^2 IV over 1-1/2 hours daily for 5 days.
41306232|NCT00882102|DRUG|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m\^2 IV on day 5.
41306233|NCT04213287|DRUG|Dexketoprofen Trometamol|Drug: Dexketoprofen Trometamol oral tablet
41306234|NCT04213287|OTHER|spinal anesthesia|Drug: heavy bupivacaine 2,5 ml 0,5%
41306235|NCT04213287|OTHER|IPACK|Drug: bupivacaine 20 ml 0,025%
41306236|NCT04213287|OTHER|PAI|Drug: bupivacaine 30 ml 0,025%
41306237|NCT04213287|OTHER|Adductor canal block|Drug: bupivacaine 20 ml 0,025%
41306238|NCT02520622|BEHAVIORAL|Digital photographs loaded onto a mobile device|
41306239|NCT02520622|BEHAVIORAL|Skin exam reminders|
41306240|NCT02520622|BEHAVIORAL|Social support network|
41306241|NCT04322630|OTHER|Change in Soluble MER Concentration|Measuring change in soluble MER Concentration post compared to pre bypass for each patient.
41464815|NCT03577886|DRUG|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.
41464816|NCT03577886|DRUG|Placebo|Phosphate Buffer Diluent oral solution
41464817|NCT03023189|DRUG|Tranexamic acid|"At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.~Total dose : 4 g of TA"
41464818|NCT03023189|DRUG|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
41464819|NCT06467201|DRUG|KSHN001126 150mg|6 subjects will receive single oral dose of 150mg
41464820|NCT06467201|DRUG|KSHN001126 300mg|6 subjects will receive single oral dose of 300mg
41464821|NCT06467201|DRUG|KSHN001126 600mg|6 subjects will receive single oral dose of 600mg
41464822|NCT02642523|DRUG|Nesiritide|Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
41464823|NCT02642523|DRUG|Insulin|The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
41464824|NCT02642523|OTHER|Saline|Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
40783816|NCT04799002|DRUG|Topotecan|Topotecan intraocular injection for chemotherapy in retinoblastoma
40783817|NCT04799002|DRUG|Melphalan|Melphalan intraocular injection for chemotherapy in retinoblastoma
40783818|NCT05265546|DRUG|Psilocybin|The effects of different doses of psilocybin (0 - 14 mg) will be compared.
40783819|NCT02122380|DRUG|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
41306242|NCT00173251|PROCEDURE|obtain surgical specimen for analysis|
41306243|NCT02620462|DEVICE|Wearable sensor-based exercise training|The device provides real-time visual feedback of joint movement during balance exercise
41306244|NCT05775406|DRUG|KT-253|KT-253 will be administered intravenously per the defined protocol frequency and dose level.
41306245|NCT05279833|DRUG|dronedarone|Pharmaceutical form is tablet and route of administration is oral
41306246|NCT05279833|DRUG|sotalol|Pharmaceutical form is tablet and route of administration is oral
41306247|NCT01318473|DEVICE|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
41306248|NCT05888467|OTHER|supervised infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.
41306249|NCT05888467|OTHER|supervised non-infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.
41306250|NCT05888467|OTHER|Control group|Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.
41306251|NCT04382859|PROCEDURE|Transversus abdominis plane (TAP) block with liposomal bupivacaine|Transversus abdominis plane (TAP) blocks are safe and effective procedures for the provision of postoperative pain management following abdominal procedures (3) and have been widely used across specialties with reduction in postoperative pain and narcotic use (4-7).
41464825|NCT01047033|BEHAVIORAL|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
41464826|NCT01047033|OTHER|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
41464827|NCT06070805|OTHER|depression|The score of Hamilton Rating Scale for Depression (HAMD) is ≥8
41464828|NCT00022555|DRUG|bryostatin 1|Given IV
41464829|NCT00022555|DRUG|vincristine sulfate|Given IV
40783820|NCT02122380|DRUG|Placebo|1 placebo pill by mouth per day for 30 days
40783821|NCT00352859|DRUG|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
40783822|NCT00352859|DRUG|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
40783823|NCT03856866|DRUG|Hydroxychloroquine|Hydroxychloroquine: 4mg/kg/day, divided bid.
41464830|NCT01469741|BEHAVIORAL|Prospective Memory Strategy|Prospective memory is central to performance in everyday life as it serves to bind together goal-directed actions and enables people to carry out their plans and wishes meaningfully and appropriately. Everyday prospective memory tasks include remembering to run errands, keep appointments, and turn off the stove after using it.
41464831|NCT06494098|PROCEDURE|Nasoalveolar Molding|presurgical orthopedics
41464832|NCT06494098|DIAGNOSTIC_TEST|Addition silicone impression|diagnostic impression for maxillary arch and nose
41464833|NCT04703855|DEVICE|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
41464834|NCT05904262|OTHER|Foot Sole Sensation Evaluation|Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
41464835|NCT03860337|DIETARY_SUPPLEMENT|Alginate Sausage|Alginate sausage
41464836|NCT03860337|OTHER|Control Sausage|Control Sausage
41464837|NCT06321354|DRUG|The diprospan plus ropivacaine group|The local infiltration solution containing 0.5ml diprospan and 15mg of 1% ropivacaine. The total volume is 30 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
41464838|NCT06321354|DRUG|The ropivacaine group|The local infiltration solution containing 15mg of 1% ropivacaine. The total volume is 30 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
41464839|NCT02760355|DRUG|Ledipasvir 90 mg/Sofosbuvir 400 mg|Oral administration on one fixed dose combination tablet for 12 weeks
40783824|NCT03856866|DRUG|Placebo|Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
41306252|NCT05799443|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
41306253|NCT05799443|DRUG|Irinotecan Hydrochloride|Irinotecan will be administered on day 1 of each cycle at 180 mg/m2 once every 14 days.
41306254|NCT05799443|DRUG|cetuximab|cetuximab will be administered on day 1 of each cycle at 500 mg/m2 once every 14 days.
40783825|NCT02246010|DIETARY_SUPPLEMENT|Lactose- free milk|Lactose- free milk
40783826|NCT00182143|DRUG|LMWH (Fragmin, dalteparin)|Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose
40783827|NCT00182143|DRUG|Unfractionated Heparin|5000 IU BID
40783828|NCT02588157|DEVICE|Macintosh|Direct laryngoscopy
40783829|NCT02588157|DEVICE|Glidescope|Glidescope videolaryngoscope
40783830|NCT02588157|DEVICE|McGrath MAC X-Blade|McGrath MAC X-Blade videolaryngoscope
40783831|NCT00538057|DRUG|GW685698X & GW642444M|study drug
41147059|NCT01742832|DRUG|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
41306255|NCT05799443|RADIATION|SBRT|8-10Gy×5F，QOD
41464840|NCT02760355|DRUG|Ribavirin|Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients \<75 Kg of body weight, or 1,200 mg in two administrations for those \>75 Kg) for 12 weeks.
41464841|NCT01526135|DRUG|mFolfirinox|"mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
41464842|NCT01526135|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
41464843|NCT06321471|DEVICE|AeviceMD|AeviceMD is a remote patient monitoring system consisting of a wearable stethoscope, silicone patches, a docking station, and a mobile application.
41464844|NCT03902301|DIETARY_SUPPLEMENT|Lactobacillus group|Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).
41464845|NCT03902301|DIETARY_SUPPLEMENT|Dietary group|Nutritional intervention focused on the treatment of insulin resistance (35 subjects).
41464846|NCT02748655|OTHER|Alkaline ionized water|
41464847|NCT02748655|OTHER|Tap water|
41464848|NCT03700645|DRUG|Allopurinol|Allopurinol
41464849|NCT01176981|DRUG|High Dose Methotrexate|"Methotrexate will be given by IV at a dose of 12 gram/m2/dose.~The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days)."
41464850|NCT02809768|DRUG|Avatrombopag|
40783832|NCT03764111|DEVICE|Large Mobile Ultrasound System|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the large mobile ultrasound system.
40783833|NCT03764111|DEVICE|Handheld Ultrasound Machine|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the handheld device.
40783834|NCT05947006|OTHER|Standard care|Patients in this arm will receive the standard care stablished in the emergency room after a febrile seizure, consisting of a medical assessment of the child, followed by 6 hours of supervision of the child and his parent in the waiting room, a reassessment of the child by the doctor, and finally they can return home
40783835|NCT05947006|OTHER|CONSULFE consultation|In addition to the standard care, patients in this arm will receive a consultation managed by the pediatric nurse (CONSULFE) during the 6 hour supervision time in the waiting room
40783836|NCT01302002|DRUG|Metformin Pre-Surgery|500 mg tablet, taken twice a day for 3 weeks
41306256|NCT03437538|DEVICE|MCO-HD|Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
41306257|NCT03437538|DEVICE|High-flux HDF|Measurements will be done during a single hemodiafiltration session with standard high-flux filter
41306258|NCT03241758|DIAGNOSTIC_TEST|Doppler ultrasound|Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
41306259|NCT04698213|DRUG|Axitinib Oral Tablet|"Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect."
41306260|NCT04698213|DRUG|Avelumab|Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
41306261|NCT01834144|OTHER|Exercise Training|
41306262|NCT04684550|DRUG|Stabilized hypochlorous acid|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
41464851|NCT02809768|DRUG|Fluconazole|
41464852|NCT02809768|DRUG|Itraconazole|
41464853|NCT02809768|DRUG|Rifampin|
41464854|NCT03911739|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
41464855|NCT03911739|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
40783837|NCT00003614|DRUG|estramustine phosphate sodium|
40783838|NCT00003614|DRUG|paclitaxel|
40783839|NCT00812955|DRUG|ABT-143|Once daily for 8 weeks
40783840|NCT00812955|DRUG|simvastatin|Once daily for 8 weeks simvastatin capsules 40 mg
40988049|NCT01062282|DRUG|Iloprost (Ventavis BAYQ6256)|Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
40988050|NCT04919954|DRUG|Tebipenem Pivoxil Hydrobromide|Tebipenem 300 mg or 600 mg will be administered orally every 8 hours for total of 3 to 7 doses
41306263|NCT04684550|DRUG|Placebo|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
41464856|NCT03885869|OTHER|Ankle Joint Position Sensation Evaluation|In this test, individuals are placed in the supine position with their eyes closed for prevent visual cues; measurements are performed with the plex of the goniometer, 1.5 cm below the lateral malleol, the fixed arm parallel to the long axis of the fibula and the movable arm parallel to the long axis of the 5th metatarsal. Desired target angles were defined as 10 ° dorsi flexion, 10 ° plantar flexion and 20 ° plantar flexion. Individuals are instructed to focus on the position of the ankle joints in space for 5 s by bringing the feet in neutral position to the target position by the researcher. This procedure is repeated 3 times and the patient is expected to learn this position. The target angle is then asked to repeat in the testing phase. The measurement is repeated 3 times for each target angle. As a result criterion; By recording the absolute value of the deviation amounts from the target angles; The averages of the deviations during the 3 repetitions are averaged.
41464857|NCT03885869|OTHER|Knee Joint Position Sensation Evaluation|Bilateral knee joint position sensation will be evaluated in the literature with an analogue inclinometer(BASELINE®),which is a valid and reliable method for measuring joint position sensations.Measurements were planned to made in the sitting position,with the eyes of the individual closed and the joint to be evaluated bare,without any socks or shoes worn,fixing the inclinometer with a strap to the lower leg perpendicular to the knee flexion axis.In this measurement,the knees of the participants are passively shifted from the initial (90°flexion)position to the 30°flexion position,at this point 5 sec is waited and after they are told to keep this angle in mind,the starting position is returned.This procedure is repeated 3 times and the patient is expected to learn this position.After the individuals are rested for 5 s,they are asked to actively perform the target angle again.The same procedure was planned to be repeated 3 times for each angle at 45° and 60° knee flexion target angles.
41464858|NCT03885869|OTHER|The Evaluation of Plantar Sensation|"In the plantar sensory evaluation of the participants, Semmes-Wenstein Monofilament, which is frequently used in the literature and to be a reliable method in the diagnosis of neuropathy, was aimed to be tested by touching 7 regions on the foot base .~In this evaluation, the individual is in the supine position, the physiotherapist is at the foot end of the patient; monofilament should be applied 90⁰ to the surface.~The filament thickness which is the first feeling of the individual is recorded by being asked whether the individual is feeling. The 3 most commonly used monofilaments for patients with diabetic neuropathy are 4.17, 5.07 and 6.10 monofilaments. The highest monofilament value is the hardest and most difficult bending monofilament."
41464859|NCT03885869|OTHER|The Evaluation of Balance|In order to evaluate the static and dynamic balances of the participants, determination of open and closed postural oscillations and stability limits were planned with Prokin branded isokinetic balance system.
41306264|NCT02481037|OTHER|Primary care clinical pathway|Installing a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate the use of best-evidence by practitioners.
40988051|NCT05373329|DEVICE|Sanvello (app)|Sanvello is a commercially available mobile app designed to teach users strategies to manage their stress, anxiety, and depression. Users can choose which tools they want to use. The strategies are digital implementations of existing practices in psychology such as thought records, mindfulness meditation \& relaxation exercises, and behavioral activation.
41306265|NCT02481037|OTHER|Asthma education|Physicians will receive web-based education through an interactive learning module regarding best management for childhood asthma and use of the primary care clinical pathway. Chronic disease management (CDM) health professionals in practices will attend asthma education sessions delivered by an asthma educator. This training will be then used by the CDM professional to provide targeted and timely asthma education to parents and children with asthma.
41306266|NCT02481037|OTHER|EMR embedded dashboard|An EMR embedded dashboard will deliver real-time feedback to clinicians.
41306267|NCT00414310|DRUG|Decitabine|20 mg/m\^2 IV over 1 hour daily for 5 days.
41306268|NCT00414310|DRUG|Valproic Acid|50 mg/kg orally daily for 7 days
41306269|NCT03555851|DRUG|Cyclophosphamide|Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
41306270|NCT03555851|OTHER|Specimen collection|Buccal swabs will be obtained from donors for pharmacogenomics.
41306271|NCT00678587|DRUG|Eltrombopag|75 mg, once daily, oral
41306272|NCT00678587|DRUG|Placebo|placebo, once daily, oral
41306273|NCT01912937|DEVICE|Angioplasty treatment with the CVI Drug-coated Balloon (DCB)|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
40988052|NCT06366321|OTHER|relining technique|construction of complete denture by flasking and casting the relining impression
41306274|NCT04500314|DEVICE|whole body vibration device|20 patients will receive vibration training on vibration platform (Power Plate International, Irvine, California, USA) at a frequency of 25-30 Hz and amplitude of 3-5mm, plus traditional physical therapy program 3 sessions per week for total period of 8 weeks. The total duration of the WBV training stimulus will 10 min in first week and progress gradually to 25 min in the 8th week with regular increase by 5 minutes after each 2 successive weeks
40988053|NCT06366321|OTHER|CAD/CAM milling technique|construction of complete denture by milling of the scanned relining impression
41145664|NCT01801202|DEVICE|LightSheer Duet HS handpiece|The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
41147060|NCT01742832|DRUG|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
40988054|NCT05301296|DIAGNOSTIC_TEST|Clinical examination of the breast for early detection of Cancer|Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
40988055|NCT00499018|DRUG|Rituximab|375 mg/m2 day 1
41464860|NCT03885869|OTHER|Evaluation of Dual Task Performance|"In order to evaluate double task performances, it is planned to evaluate 1 dynamic and 1 static 2 different performances, including Time Up and Go Test (TUG) and single leg standing time. For each performance; the single task, the motor second task and cognitive seconder tasks separately, and again for each application to be performed in such a way that two trials, the average time was planned to record. Motor and cognitive tasks for each test are planned as described below.~Motor Task (TUG): Carrying cup full of water on tray. Cognitive Task (TUG): Counting the days of the week backwards from the current day Motor Task (Single Leg Standing Time): Hand-Over ball transfer Cognitive Task (Single Leg Standing Time): Counting backward month names from the current month"
41464861|NCT03885869|OTHER|General Evaluation Form|A form, which is prepared by us, including demographic information and physical characteristics of the individuals.
41306275|NCT04500314|OTHER|routine physical therapy treatment|The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation
41464862|NCT01948401|DRUG|LABA|long-acting beta-agonist treatment
41464863|NCT01948401|DRUG|corticosteroids|chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
41464864|NCT01948401|DRUG|prednisolone|additional 0.5 mg/kg orally for 7 days
41464865|NCT01132417|DRUG|In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
40988056|NCT00499018|DRUG|Ciclofosfamide|1200 mg/m2 day 1
40988057|NCT00499018|DRUG|Doxorubicina|70 mg/m2 day 1
40988058|NCT00499018|DRUG|Vincristina|1,4 mg/m2 (max 2 mg) day 1
40988059|NCT00499018|DRUG|Prednisone|100 mg day g 1-5
40988060|NCT00499018|DRUG|Pegfilgrastim|6 mg day +1
40988061|NCT00499018|DRUG|Mitoxantrone|8 mg/m2/days 1-3
40988062|NCT00499018|DRUG|ARA-C|2000 mg/m2/12h day 1 - 3
41306276|NCT00000539|DRUG|niacin|
41306277|NCT00000539|DRUG|pravastatin|
41306278|NCT00000539|DRUG|beta-carotene|
41306279|NCT00000539|DRUG|vitamin E|
41306280|NCT00000539|BEHAVIORAL|dietary supplements|
41306281|NCT00000539|DRUG|vitamin C|
41306282|NCT00000539|DRUG|warfarin|
41306283|NCT02262039|DEVICE|Valveless recirculating insufflation (VTI)|10 mmHg target pressure
41306284|NCT02262039|DEVICE|Conventional pressure|15 mmHg target pressure
41306285|NCT02202031|BEHAVIORAL|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
41306286|NCT02202031|BEHAVIORAL|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
41306287|NCT01432197|OTHER|ADL intervention|1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
40988063|NCT00499018|DRUG|Lenograstim|5 μg/Kg/days +2
40988064|NCT00499018|DRUG|BCNU|300 mg/m2 day -7
40988065|NCT00499018|DRUG|ARA-C|200 mg/m2/12 days -6,-5,-4,-3
40988066|NCT00499018|DRUG|VP-16|100 mg/m2/12h days -6,-5,-4,-3
40988067|NCT00499018|PROCEDURE|ASCT|PBSC Reinfusion
40988068|NCT00499018|DRUG|Ciclofosfamide|750 mg/m2 day 1
40988069|NCT00499018|DRUG|Doxorubicina|50 mg/m2 day 1
40988070|NCT00499018|DRUG|Vincristina|1,4 mg/m2 (max 2 mg) day 1
41306288|NCT05728970|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 Ag Ultra|The LumiraDx SARS-CoV-2 Ag Ultra Test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal swab samples collected from symptomatic individuals within the first twelve days of symptom onset suspected of COVID-19 by their healthcare provider.
41306289|NCT05728970|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
41306290|NCT01683071|DRUG|Placebo|Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
41306291|NCT01683071|DRUG|EXPAREL 67 mg|5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
41306292|NCT01683071|DRUG|EXPAREL 133 mg|10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
41306293|NCT01683071|DRUG|EXPAREL 266 mg|20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty
41306294|NCT04062851|OTHER|No Gastric residual volume monitoring|Gastric residual volumes will not be monitored
41145665|NCT03936725|OTHER|1 year phone call : data collection|"Included patients are contacted by telephone at 12 months after discharge. The investigators explain to the patient that this call is in the same context as a regular follow-up rehabilitation consultation and that the data collected will also be part of a study to evaluate and improve the program in which they participated. The interview will be transcribed in writing in their computerized and secure medical file. During this 20-minute telephone conversation, the patient answers a number of questions via a standardized questionnaire, in order to gather the various criteria for judgment.~If patients do not answer the first call, a phone message will be left and they will be contacted again up to 2 times. Patients who do not respond to 3 calls will be considered lost to follow-up."
41464866|NCT03890562|OTHER|Auricular acupressure|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
41464867|NCT06128187|OTHER|Control Group|Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of virtual reality training will be given.
41464868|NCT06128187|OTHER|Study Group|Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of dual-task training will be given
41464869|NCT05140317|PROCEDURE|Transcatheter heart valve implantation with or withour predilatatation|long term up to 5 years echographic and clinical follow up
40988071|NCT05566990|BIOLOGICAL|LIV-GAMMA SN Inj.10%|LIV-GAMMA SN Inj. 10% is administered intravenously at a dose of 1 g/kg daily for 2 consecutive days to patients with primary immune thrombocytopenia.
41145666|NCT00950235|BEHAVIORAL|Weight Management|Two individual counseling session on nutrition and once weekly group sessions including use of food diaries for the remaining weeks of their pregnancy
41306295|NCT05820256|DIETARY_SUPPLEMENT|Milk Protein Isolate (MPI)|Study participants will consume two smoothies per day containing a milk protein isolate (MPI) for 31 days.
41306296|NCT05820256|DIETARY_SUPPLEMENT|Soy Protein Isolate (SPI)|Study participants will consume two smoothies per day containing a soy protein isolate (SPI) for 31 days.
40988072|NCT03914040|OTHER|IPSE program|"1. Pre-immersion preparation. A self-study course will be offered about lifestyle modification. Some readings will be suggested to introduce students to the concepts of health promotion and prevention of metabolic syndrome.~2. Immersion. Four different learning methods will be provided: I) four hours of didactic lectures followed by group discussion, II) four hours per student of role playing, III) 30' per students of standardized patient experiences and IV) 30' per students of a new immersive advanced simulation learning environment (e-REAL). Four case-studies will be used to create scenarious, including woman with menopause weight gain, obese young adult, obese child and adult with unhealthy behaviours."
40988073|NCT00146146|DRUG|testosterone undecanoate alone|1000 mg/12 weeks
41306297|NCT02464397|DEVICE|Stent|In the study, either OPTIMAX or SYNERGY stent will be implanted in coronary artery lesion
41306298|NCT02963714|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
41306299|NCT02963714|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
41306300|NCT04548687|PROCEDURE|carbon dioxide insufflation|Carbon dioxide insufflation at a rate of 5 l / min. through the Redon drainage during cardiac surgery (minimally invasive or repeated) during cardiopulmonary bypass
41306301|NCT04548687|PROCEDURE|No carbon dioxide insufflation|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
41306302|NCT01586156|DRUG|Carvedilol|Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.
41306303|NCT01586156|DRUG|placebo|Placebo will be taken twice daily for 6 months
41306304|NCT03209180|DRUG|CarVeDilol-SR (Slow Release)|patients will receive slow-release carvedilol (SR) once daily
41306305|NCT03209180|DRUG|Carvedilol IR (Immediate Release)|patients will receive immediate release carvedilol (IR) twice daily
41306306|NCT02251054|OTHER|Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.
40988074|NCT00146146|DRUG|testosterone undecanoate plus letrozole|TU 1000 mg/12 weeks Letrozole 2.5 mg/day
40988075|NCT00146146|DRUG|testosterone undecanoate plus dutasteride|TU 1000 mg/12weeks Dutasteride 0.5 mg/day
40988076|NCT05461651|PROCEDURE|Knee arthroplasty|total or unilateral knee arthroplasty
41464870|NCT01304186|BEHAVIORAL|Tailored Information|The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.
41464871|NCT06366282|BEHAVIORAL|Caregiver Counseling for Childhood Traumatic Injury|Caregiver intervention will be provided by the counseling team that includes components of trauma narrative, psychoeducation, coping strategies, and resilience-building using, for burn patients.
41306307|NCT02251054|OTHER|No Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
41306308|NCT06440369|OTHER|Training group|"The patient will perform an intermittent exercise which consists of nine 5-minute cycles with a succession of work (top: 1 minute; bottom: 4 minutes). The high-intensity work phase will be adjusted so as to achieve a target Heart Rate (HR) corresponding to resting HR + 80% reserve HR (reserve HR = (200 - age) - resting HR). The low-intensity work phase will be adjusted to achieve a target maximum HR corresponding to resting HR + 60% reserve HR. In total duration, the exercise presents a submaximal intensity, commonly used in exercise rehabilitation studies carried out with various pathologies. It is an intensity capable of promoting benefits on the cardiovascular aspect without representing a severe intensity for the patient.~In order to adapt the training and guarantee patient safety, the first exercise session will be carried out with an alternation between a high-intensity work phase of resting HR + 70% reserve HR and a work phase. at low intensity of resting HR + 50% reserve HR."
41306309|NCT06440369|OTHER|Physical activity orientation group|Every week, for around ten minutes, patients in the AP orientation group will be contacted by telephone. The main objective of this exchange is to provide targeted advice on physical activity, its role, its objectives as well as its different ways of carrying it out. The second objective is to provide each week a personalized objective for each patient which can evolve over the weeks to increase levels of physical activity as far as possible. During each call, the evaluator will practice reflective listening, ask open-ended questions to facilitate the exchange, value and summarize the patient.
41306310|NCT02433288|OTHER|Smart phone based patient support tool|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
41306311|NCT02433288|OTHER|Control application: only for data collection|the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
41306312|NCT01912430|BEHAVIORAL|ICC (Integrated Care Coaching) Intervention Group|
41306313|NCT05021536|OTHER|Placebo|Matching Placebo Comparator
41306314|NCT05021536|DRUG|AMX0035|Proprietary formulation of taurursodiol and sodium phenylbutyrate
41306315|NCT05624684|DIAGNOSTIC_TEST|Multiplex respiratory PCR|The BIOFIRE® FILMARRAY® Pneumonia plus Panel
41464872|NCT06366282|BEHAVIORAL|Standard of Care for Childhood Traumatic Injury|Control group receives the current standard of care provided by the counseling team
41464873|NCT03769831|DRUG|SHR2285|Ascending dose oral adminstration
41145667|NCT00950235|OTHER|Usual Care|Standard nutrition counseling from Health Plan
41145668|NCT05926557|PROCEDURE|Spermidine gel|First step: Non-surgical mechanical debridement (NSMD) Second step: application of spermidine gel
40988077|NCT06437899|DRUG|intravesical botulinum toxin A injection unter local anaesthesia|"Arm1: Botulinum toxin A injection under local anesthesia according to standard protocol:~Retrograde filling of the empty urinary bladder with a 1:1 mixture of 50 ml lidocaine 1% mixed with 50 ml sodium bicarbonate 8.4%, leave the local anesthetic mixture in the bladder for 15 minutes.~Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10 ml NaCl 0.9% into the detrusor at 10 points using a rigid 70 degree cystoscope~Arm 2: botulinum toxin A injection in sedoanalgesia according to the anesthesia standard protocol:~Intravenous administration of remifentanil (0.05-0.15µg/kg/min) and propofol. Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10ml NaCl 0.9% into the detrusor."
41145669|NCT05926557|PROCEDURE|NSMD|Only mechanical debridement with curettes and scaler peek tips
41145670|NCT01458288|DRUG|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
41306316|NCT03387904|DRUG|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
41306317|NCT03387904|DRUG|Irinotecan|Irinotecan Day 1,8 ivgtt
41306318|NCT00390000|DRUG|vatalanib|Given orally
41306319|NCT00390000|DRUG|pemetrexed disodium|Given IV
41306320|NCT00390000|OTHER|pharmacological study|Correlative study
41306321|NCT00390000|PROCEDURE|ultrasound imaging|Correlative study
41464874|NCT03769831|DRUG|Placebo|Ascending dose oral adminstration
41464875|NCT00297245|DRUG|cognitive function|
41464876|NCT00080431|DRUG|Daclizumab|
40988078|NCT04568057|DEVICE|NIR Transcranial phototherapy device|1068 nm NIR helmet
40988079|NCT04568057|DEVICE|Placebo Transcranial Device|The placebo device looks like the active device.
41145671|NCT01448993|DRUG|Azithromycin|Taking 250mg azithromycin 3 times per week in alternate days.
41145672|NCT01448993|DRUG|Placebo|
41145673|NCT05090904|DRUG|Brensocatib|Oral tablet
41145674|NCT05090904|DRUG|Placebo|Oral tablet
41145675|NCT01928888|DRUG|Talcid (Hydrotalcite, BAY4516H)|2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
41306322|NCT02529761|DRUG|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
41464877|NCT03996837|OTHER|Intra uterine infusion of platelet rich plasma|Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
41464878|NCT01057173|PROCEDURE|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
41464879|NCT01057173|PROCEDURE|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
40988080|NCT03401983|OTHER|Pelvic Floor Muscle Training and Abdominal Training|Pelvic Floor Muscle Training + Abdominal Training program was used in the study. The follow-up measurements of the PFMT+AT group were obtained in the 0th, 4th, and 8th weeks.
40988081|NCT03401983|OTHER|Pelvic Floor Muscle Training|Pelvic Floor Muscle Training program was used in the study. The follow-up measurements of the PFMT group were obtained in the 0th, 4th, and 8th weeks.
40988082|NCT02109614|DRUG|Extended release Niacin|Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
40988083|NCT02109614|DRUG|Placebo Comparator|Placebo Comparator arm will be taking 1500mg of the placebo daily
40988084|NCT03642210|COMBINATION_PRODUCT|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system
40988085|NCT04922983|DRUG|Botulinum toxin type A|A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).
41145676|NCT01928888|DRUG|Famotidine|2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
41145677|NCT01928888|DRUG|Placebo|2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
41145678|NCT01479842|DRUG|BTK inhibitor PCI-32765|Given PO
41145679|NCT01479842|BIOLOGICAL|rituximab|Given IV
41145680|NCT01479842|DRUG|bendamustine hydrochloride|Given IV
41145681|NCT01479842|OTHER|pharmacogenomic studies|Correlative studies
41145682|NCT01479842|OTHER|pharmacological study|Correlative studies
41145683|NCT01479842|OTHER|laboratory biomarker analysis|Correlative studies
41145684|NCT00042939|BIOLOGICAL|cetuximab|Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.
41306323|NCT02529761|PROCEDURE|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
41306324|NCT03856086|BEHAVIORAL|Baseline questionnaire|Baseline questionnaire on the day of the patient's surgery.
41306325|NCT03856086|BEHAVIORAL|NCCN Problem List|NCCN Distress Thermometer
41306326|NCT03856086|BEHAVIORAL|FACT-GP|Greater overall quality of life
41306327|NCT03856086|BEHAVIORAL|HADS|Lower anxiety and depression
41306328|NCT03856086|BEHAVIORAL|CSS-CG|web-based CSS-CG
41306329|NCT00901537|DRUG|Azacitidine and Cisplatin|We plan to give azacitidine daily as subcutaneous injection at escalated doses (37, 60, 75, 85, 100 and 110 mg/m2) for 5 days from day 1 to day 5, and give cisplatin 75 mg/m2 as intravenous injection on day 8, every 4 weeks as a cycle.
41306330|NCT04119726|BEHAVIORAL|Usual Text Messages|Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.
41306331|NCT04119726|BEHAVIORAL|Personalized reminders|Personal information, life behavior and risk factors will be registered when patients are enrolled. According to the baseline information, personalized knowledge will be sent to patients in the intervention group. Besides, patients will receive drug information and regular medication adherence reminders daily according to patients' baseline prescription drugs and modifications.
41464880|NCT05179161|DEVICE|Prone crawl positioning|Breast cancer patients are placed in a prone position with the ipsilateral arm besides the body rather than extended besides the head on a dedicated couch that provides the required support for maintaining this position.
41464881|NCT06163417|PROCEDURE|laparoscopic|laparoscopic
41464882|NCT03936894|DRUG|Canakinumab Injection [Ilaris]|Subject receives subcutaneous injection of canakinumab 2 mg/ kg or 4 mg/kg
41464883|NCT01012141|DIETARY_SUPPLEMENT|phytochemical|
41464884|NCT01012141|DRUG|Docetaxel|
41464885|NCT06398418|DRUG|R-5780|Probiotic
41464886|NCT06207292|RADIATION|Stereotactic Ablative Radiotherapy|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be chosen based on the target to be treated and its proximity to organs at risk(s):~Lung-peripheral 33-45 Gy/ 3 fractions~Lung-central/ultra-central 35-60 Gy/5 fractions~Mediastinal/supraclavicular node 35-45 Gy/5 fractions~Liver 45-54 Gy/3 fractions; 50-65 Gy/5 fractions~Bone non-spine 30-36 Gy/3 fractions; 35-50 Gy/5 fractions~Bone spine 30-33 Gy/3 fractions (SIB); 35-40 Gy/ 5 fractions (SIB)~Abdominal-pelvic node 33-39 Gy/ 3 fractions; 35-50 Gy/5 fractions~Adrenal gland 30-42 Gy/3 fractions; 35-50 Gy/5 fractions"
41464887|NCT02930135|PROCEDURE|Indirect pulp capping|Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
41464888|NCT04485507|OTHER|Nature-VR|Viewing 360 degree nature pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
41464889|NCT04485507|OTHER|Urban-VR|Viewing 360 degree urban pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
41464890|NCT00078741|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
41464891|NCT05066568|DEVICE|Active Tracranial Direct Current Stimulation|Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Stimulation time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.
41464892|NCT05066568|OTHER|Hypnotic analgesia suggestion|The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
41464893|NCT05066568|BEHAVIORAL|Rest|The patient is asked to remain seated still for 20 minutes.
41464894|NCT05066568|OTHER|Active tDCS + Hypnotic analgesia suggestion|"Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Intervention time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.~The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance."
41464895|NCT05066568|OTHER|Sham tDCS + Hypnotic analgesia suggestion|Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 0mA Intervention time: 20 min The current is turned off after 30 seconds. The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
41464896|NCT04738838|DRUG|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
40988086|NCT04922983|BEHAVIORAL|Isometric Yoga-like exercise|Extended torso and legs held diagonally by one straight arm, back against wall if necessary
40988087|NCT04922983|BEHAVIORAL|Placebo|Used as placebo
40988088|NCT03021850|PROCEDURE|Flexibility training with or without different thermal modalities|Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
40988089|NCT02268786|OTHER|Preimplantation Genetic Screening by NGS|The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
41145685|NCT00042939|DRUG|docetaxel|Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
41145686|NCT00042939|DRUG|irinotecan hydrochloride|After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
41147061|NCT03109210|BEHAVIORAL|Online Cognitive Behavioral Therapy (OCBT)|Cognitive behavioral therapy delivered via commercial online software.
41464897|NCT04738838|DRUG|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
41464898|NCT05240092|BEHAVIORAL|Haptonomy|Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
41464899|NCT02656654|OTHER|Whole-body compression|
41464900|NCT04445701|DRUG|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
41464901|NCT04445701|DRUG|AO-176 + Dex|Humanized mAb targeting CD47 plus dexamethasone
41464902|NCT04445701|DRUG|AO-176 + Dex + Bort|Humanized mAb targeting CD47 plus dexamethasone plus bortezomib
41464903|NCT00704496|DRUG|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
41464904|NCT05820919|BEHAVIORAL|LOCK Sleep Program|The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).
40783841|NCT02340884|BEHAVIORAL|Promoting Resilience In Stress Management (PRISM)|"The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding."
40783842|NCT03845829|PROCEDURE|In situ laser assisted fenestration|In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
40988090|NCT06279377|OTHER|Stabilization Exercises|"* Stabilizer Pressure Biofeedback device will be used in deep neck flexors training. Once the starting level is determined, training will be carried out with 2 mmHg pressure increases until the target value is 30 mmHg.~* During the exercises performed with the elastic resistance band, the patient will be asked to move the band with his hands (neck extension, right-left lateral flexion).~* During the exercises with the elastic ball, you will be asked to press your head on the ball at 90 degree angles (in 4 positions).~* Exercises will be performed in 10 repetitions by maintaining muscle contraction for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the color of the elastic resistance band or the level of the exercise will be changed and continued."
40988091|NCT06279377|OTHER|Standard Exercises|"* Cervical flexion, extension, lateral flexion and rotation movements will be performed within the scope of the warm-up and cool-down program. Cervical movements will be limited to approximately 30 degrees in the early period.~* As posture exercises, you will be asked to do scapular retraction and turning your shoulders forward and backward. In addition to these movements, pectoral stretching, anterior and posterior capsule stretching exercises will be performed.~* Elastic resistance bands will be used during neck exercises. Patients will be asked to perform cervical flexion, extension and right-left lateral flexion movements against the fixed band.~* Patients will be asked to continue each exercise for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the elastic resistance band color will be changed and the exercise will progress."
40988092|NCT06072950|OTHER|Usual care|Patients received usual care
41464905|NCT05820919|OTHER|No intervention (control period/baseline data collection)|Each NH serves as its own control. During the control period, baseline data will be collected.
41464906|NCT02324231|OTHER|39.0°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
41464907|NCT02324231|OTHER|38.5°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
41464908|NCT01031992|DRUG|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
41464909|NCT01031992|DRUG|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
40783843|NCT05589454|DRUG|Atorvastatin Calcium tablets 80mg|Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
40783844|NCT05589454|DRUG|Atorvastatin Calcium tablets 20mg|Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
40783845|NCT03059784|OTHER|APP-based multifaceted management|Patients after PCI will be regularly given education materials, medication reminders, life-style behaviors instruction through APP. Cardiologists can interact with patients on advice provision and clinical support after discharge through APP.
40783846|NCT04532515|DEVICE|Seal-G Surgical Sealant|"Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
40783847|NCT04532515|DEVICE|Seal-G MIST System|"Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
41306332|NCT04119726|BEHAVIORAL|Internet-based counselling|"The internet-based counselling is the key module of social media in the intervention group. The consultation content mainly includes the feedback of coronary heart disease secondary prevention drug compliance, the feedback of risk factor level control, the feedback of life and behaviour habits, the feedback of adverse events, the feedback of health education knowledge improvement, the reminders of data upload, behaviour change, and health education learning.~When the patient has questions or discomfort during the medication, they can consult the applet and the applet will perform internet-based answers on the large database built by cardiologists. Meanwhile, social media will upload the question of consultation and report to the doctor according to individual differences in disease. If the patient is not satisfied with the auto-response, the patient can further consult his doctor and the doctor's response will be collected to improve the auto-response database"
41306333|NCT04304755|DRUG|Zoledronic Acid 5 MG in 5 ML Injection|Zoledronic acid
41306334|NCT04304755|DRUG|Placebos|NaCl 0.9%
41306335|NCT03215264|DRUG|hydroxychloroquine|600-1200mg daily
41306336|NCT03215264|DRUG|entinostat|3-5mg weekly
41306337|NCT03215264|DRUG|regorafenib|160mg daily
40783848|NCT02837718|PROCEDURE|bupivakain % 0,5|Bupivacaine 0,5% The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
41147062|NCT03109210|BEHAVIORAL|Therapist-directed Cognitive Behavioral Therapy (TCBT)|Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
41147063|NCT03436797|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
41306338|NCT01540461|DRUG|Brivanib|Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
41306339|NCT03766334|DIETARY_SUPPLEMENT|Highland Barley Diet|Highland Barley Diet(20g, thrice-daily)
41306340|NCT05428748|OTHER|1 serving of test product|Participants will consume 1 serving/day of the test product for 28 days
41306341|NCT05428748|OTHER|2 servings of test product|Participants will consume 2 servings/day of the test product for 28 days
41306342|NCT05428748|OTHER|3 servings of test product|Participants will consume 3 servings/day of the test product for 28 days
41306343|NCT05428748|OTHER|Placebo|Participants will consume 1 serving/day of the placebo for 28 days
41306344|NCT04929340|OTHER|Probiotic bacteria|The children are randomly allocated to a test or a control group with aid of computer-generated numbers at the time of consent. After the treatment, children in the test group are given 5 drops per day containing probiotic bacteria (Lactobacillus reuteri Protectis DSM 17938, Biogaia AB, Sweden) before bedtime. One dose consists of a minimum of 100 million live bacteria. Children in control group are given 5 drops per day (containing no bacteria).
41306345|NCT04929340|OTHER|Placebo|Children in control group are given 5 drops per day (containing no bacteria).
41306346|NCT00615290|DRUG|tipranavir|
41306347|NCT00005117|DRUG|pravastatin|
41306348|NCT00307593|DRUG|Infliximab|Infliximab
41306349|NCT00307593|DRUG|Rituximab|Rituximab
41306350|NCT06553456|DRUG|Recombinant Human Serum Albumin|The experimental drug was administered at a dose of 20 g/ day for 7 days.
41306351|NCT06553456|DRUG|Human Serum Albumin|The positive control drug was administered at a dose of 20 g/ day for 7 days.
41306352|NCT00771407|DEVICE|Strattice Reconstructive Matrix|Strattice will be placed as a fascial inlay to support stoma sites
41306353|NCT00771407|OTHER|Standard ostomy creation|Ostomy will be created as routinely performed
41147064|NCT06510946|BEHAVIORAL|(Health education program) To increase therapeutic adherence in patients with secondary prevention for cardiovascular disease|"The intervention involves a comprehensive health education program based on the Chronic Care Model to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The program includes the following components:~Health Education Sessions: Education on the importance of adherence, understanding the disease, side effects of medications, and their management. It addresses personal beliefs and concerns.~Mobile Phone Reminders: Use of alarms and the ti.care® app to remind patients to take their medications.~Medication Verification: Ensuring that the medications and dosages taken match the prescriptions.~Personalized Dosing Systems (PDS): Helping manage medication intake.~Additional Health Advice: Control of other cardiovascular risk factors and benefits of the Mediterranean diet."
41147065|NCT02851394|DRUG|Levobupivacaine|
40783849|NCT00363584|DRUG|capecitabine|
40783850|NCT00363584|OTHER|clinical observation|
40783851|NCT00363584|PROCEDURE|adjuvant therapy|
40988093|NCT00405587|DRUG|PLX4032|Oral capsules administered BID
40988094|NCT00100126|DRUG|Amoxicillin Pulsatile Release Multiparticluate Sprinkle|
40988095|NCT03688750|OTHER|no intervention|
40988096|NCT04358848|DEVICE|X-PLO2R|Portable Oxygen Concentrator (POC)
41147066|NCT02851394|DRUG|levobupivacaine|
41147067|NCT02851394|DRUG|tramadol|
41147068|NCT04578691|DEVICE|"Anatase Spine Surgery Navigation System"|using navigation system in pedicle screw placement in spine surgery
41147069|NCT04578691|DEVICE|Medtronic Stealthstation S7 Treatment Guidance System|using navigation system in pedicle screw placement in spine surgery
40783852|NCT03537638|BEHAVIORAL|Multicomponent intervention|Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
40783853|NCT03129542|DRUG|Midodrine Hydrochloride 10 milligrams|Three doses taken every 8 hours.
40783854|NCT03129542|DRUG|Placebo capsule|Three doses taken every 8 hours.
40783855|NCT04818905|DIETARY_SUPPLEMENT|Helichrysum italicum infusion|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
40783856|NCT04818905|OTHER|Hot water|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
40783857|NCT00748631|DEVICE|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
40783858|NCT03131908|DRUG|GSK2636771|"Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.~Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I."
40783859|NCT03131908|DRUG|Pembrolizumab|Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.
40783860|NCT02162706|OTHER|Non intervention study|
40783861|NCT01335126|OTHER|Emulsion type artificial tear|2 types of artificial tears
40783862|NCT01493414|DRUG|INC424|All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
40783863|NCT03817489|BEHAVIORAL|Baduanjin qigong|The intervention consists of eight sequential forms of movements which is practiced with guidance on rhythmic breathing and mindful awareness. Each cycle of the eight movements requires 10 to 15 minutes for completion. Four cycles will be practiced in each session with short breaks arranged between them.
40783864|NCT03817489|BEHAVIORAL|Mindfulness meditation|The intervention is developed based on the core components of the established Mindfulness-Based Stress Reduction and the Mindful Self-Compassion program with adaptation for local practice. The focus of the group is to nurture mindful awareness, acceptance, and self-compassion. The group sessions are composed of a combination of mindfulness-based practice, relaxation, and yoga exercise. The basic philosophy of this intervention is the emphasis of the nurturing of self-kindness attitude, and non-attachment attitude towards inter-personal connectedness and letting go of self-criticism, need for control, and defensive separation in times of adversity. Short breaks will be arranged between each practice.
40783865|NCT00392093|DRUG|Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d|
40783866|NCT05341947|BIOLOGICAL|Activated T cells|Activated T cells (ATC) administered intravenously at one timepoint
40783867|NCT04500457|BEHAVIORAL|Exposure-based Treatment for Perfectionism (ETP)|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
40783868|NCT03495401|DIETARY_SUPPLEMENT|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
40783869|NCT03495401|DIETARY_SUPPLEMENT|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
40783870|NCT06191484|BEHAVIORAL|WELL Behavioral Probe|Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.
40783871|NCT03054714|DEVICE|catheter replacement|catheter removal and delayed replacement, versus exchange over a guidewire
40783872|NCT01343888|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
40783873|NCT01343888|DRUG|BI 201335|BI 201335 once daily high dose
40783874|NCT01343888|DRUG|BI 201335|BI 201335 once daily low dose
40783875|NCT01343888|DRUG|Placebo|
40783876|NCT04841993|DRUG|Cannabis decoction|A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
40783877|NCT04841993|DRUG|Cannabis oil|A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.
40783878|NCT04841993|DRUG|Vaporized cannabis|100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
41147070|NCT03020914|DEVICE|Audiovisual Distraction|watching a movie using video glasses and headphones
40988097|NCT01082965|DRUG|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
41306354|NCT01982604|DRUG|TI-Inhalation Powder A|Inhaled Insulin
40988098|NCT01082965|DRUG|Placebo|matching placebo
40988099|NCT00774228|DEVICE|I-ZIP Ocular Bandage|
40988100|NCT00774228|DEVICE|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
41147071|NCT04196517|OTHER|Educational Tool, PALS|The Patient Activated Learning System is a free, health education platform.
41306355|NCT01982604|DRUG|TI-Inhalation Powder B|Inhaled Insulin
40988101|NCT01382446|DRUG|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
40988102|NCT01382446|OTHER|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
40988103|NCT05494242|OTHER|Surgical intervention|Pars-plana vitrectomy.
40988104|NCT05331287|OTHER|Head position|Influence of different head position on nasal endotracheal intubation
40988105|NCT03989908|OTHER|Microfludic noodle|In this intervention arm, subjects will be served with noodles made using microfludic technology.
40988106|NCT03989908|OTHER|Control noodle|In this intervention arm, subjects will be served with normal noodle.
40988107|NCT02420054|BEHAVIORAL|Intermittent fasting|Alternate day fasting (ADF) (water permitted) for 3 weeks with double energy intake every other day. Followed by ADF for 3 weeks with ad libitum diet on eating days.
40988108|NCT02420054|OTHER|Time control|Time control period with no change in eating habits.
41145687|NCT03209336|RADIATION|Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）|We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
40783879|NCT00827957|DEVICE|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
40783880|NCT00827957|DEVICE|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
40783881|NCT02431156|OTHER|Assessment of visual capacity|"Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC"
41145688|NCT06088082|DRUG|Bupivacaine Hydrochloride|Patients will be randomly assigned to receive a TAP and PRS blocks with 34 mL of 0.25% bupivacaine (study group) or standard hospital analgesia protocol (control group).
41464910|NCT02093923|DRUG|DX-2930|Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
40783882|NCT04877860|OTHER|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Finally, patients will have access to the PaiNEd system before the start of the program (to prepare them for treatment sessions) and during the development of the treatment program in which they will introduce their pain levels and their characteristics and also receive a series of educational advice and recommendations for its improvement."
40988109|NCT05749445|DRUG|Nirmatrelvir-Ritonavir|Nirmatrelvir-Ritonavir
40988110|NCT00300859|BEHAVIORAL|brief motivational intervention|
40988111|NCT02164747|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
40988112|NCT05846061|OTHER|Prevalence study population|No intervention
40988113|NCT05359666|DEVICE|Irrisept|"Irrisept® is a manual, self-contained irrigation device designed for wound cleansing and irrigation. The solution is 0.05% Chlorhexidine Gluconate (CHG) in sterile water for irrigation, USP (99.95%). Irrisept contents include the solution, a 450 mL bottle, and the Irriprobe applicator. Irrisept is a manual, self-contained irrigation device that can produce 7-8 psi of pressure for effective wound cleansing and irrigation. The user squeezes the bottle to create streams of solution and directs the fluid from the applicator onto a wound. The mechanical action of the streams of fluid being applied over a wound removes particulates and debris.~Subjects randomized to Irrisept on study protocol IRR-CT-901-2013-01 used the device, per the provided Instructions for Use. Those randomized to SoC received routine care, per the discretion of the investigator, and in accordance with the institution's guidelines."
40988114|NCT05359666|DEVICE|Standard of Care|"Subjects randomized to SoC on study protocol IRR-CT-901-2013-01 used any SoC type, per the investigator's discretion. SoC types were not standardized. Sites recorded SoC information as free text. The following were recorded as SoC types: Saline (recorded as normal, warm and/or sterile saline or saline solution); Sodium Chloride (recorded as sodium chloride (NACL) or NACL 0.9%); SoC; Irrisept (recorded as normal saline \& Irrisept and Irrisept); Chloraprep; Gentamicin \& saline; unknown; and none."
40988115|NCT04442204|OTHER|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health
41145689|NCT02313194|DEVICE|Epidural Stimulation|Determine if epidural stimulation can improve motor function
41145690|NCT02313194|DRUG|Buspirone|Determine if the pharmacological agent in combination with the stimulator can improve motor function.
41145691|NCT00905255|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
41145692|NCT00905255|DEVICE|Pen auto-injector|
41145693|NCT04249115|DEVICE|Nano-Pulse Stimulation (NPS)|Electrical pulses (nanosecond duration) applied directly to target SK lesions using sterile single-patient use treatment tips with microneedles.
41464911|NCT02093923|DRUG|Placebo|Participants will receive matching placebo subcutaneously.
41464912|NCT04752319|DEVICE|BreEStim|BreEStim will be applied for 10 to 20 minutes per session for multiple sessions
41306356|NCT04336397|DIAGNOSTIC_TEST|multi-target stool DNA test|Cluster randomized trial of high and medium intensity outreach with MT-sDNA compared with usual care
41306357|NCT04408859|DRUG|Neoadjuvant Chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
41306358|NCT00793702|BIOLOGICAL|rdESAT-6 + rCFP-10|rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
41306359|NCT01023399|DRUG|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
41306360|NCT05118204|DRUG|BUP microdose induction|"Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).~Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours"
41306361|NCT05118204|DRUG|TAU|2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours
40783883|NCT04877860|OTHER|Multimodal rehabilitation program + traditional biomedical information|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Patients will receive a dossier with traditional biomedical recommendations on pain management and disability associated with the side effects of cancer treatment."
40783884|NCT04877860|OTHER|Control group|Waiting list of patients who have agreed to participate in the study. They will receive an information dossier with recommendations on pain control and improvement of dysfunction (similar to what was worked on in the experimental group). These recommendations will be distributed at the beginning of the study (initial assessment) and they will be summoned at 8 weeks for the next collection of variables. All patients will be invited to participate in the experimental phase at the end of the control phase.
40783885|NCT04446403|PROCEDURE|Suprascapular Nerve Block|The patient will be put in sitting down position with upper limbs pending beside the body then a high-frequency linear ultrasound probe will be positioned transversely above the spine of the scapula. The suprascapular nerve often appears as hypereccoic structure at the suprascapular notch. A 20-gauge spinal needle will be advanced in-plane from medial to lateral 10mL of bupivacaine 0.25% into the suprascapular notch deep to the superior transverse scapular ligament (STSL) and adjacent to the suprascapular artery (SSA) .
40783886|NCT04446403|PROCEDURE|Axillary Nerve Block|Patient will be put in sitting position, with the shoulder in full adduction. linear transducer (8-14 MHz) will be positioned in the short axis orientation at the neck of humerous to identify the axillary artery about 1 to 3 cm from the skin surface.The artery is the most reliable landmark, then a 21-gauge 90 mm needle will be advanced in-plane and 10 mL of bupivacaine 0.25% will be injected adjacent to the artery.
40783887|NCT04446403|PROCEDURE|posterior cord block|Patient will be put in supine position with head turned away from side that will be blocked with the arm abducted 90 and flexed at the elbow then linear transducer (8-14 MHz) will be positioned in short-axis just medial to coracoid process.Once the artery will be identified, an attempt will be made to identify the hyperechoic cords of the brachial plexus and their corresponding positions relative to the artery, although these may not always be identifiable. The needle will be inserted in plane from the cephalad end of the probe. 10 mL bupivacaine 0.25% will be injected at the posterior cord.
40783888|NCT04446403|PROCEDURE|General anesthesia|General anaesthesia will be induced after giving nerve block in a standardized way with propofol 1.5-2.5mg/kg, fentanyl 2-3 µ/kg and atracurium 0.5mg/kg. maintenance of anaesthesia with isoflurane and atracurium 0.1mg/kg/20min.
40783889|NCT01428310|DIETARY_SUPPLEMENT|Anatabloc(TM)|one dissolvable bit, one time, after a period of abstinence from smoking
40783890|NCT01428310|DIETARY_SUPPLEMENT|CigRx(R)|one dissolvable bit, one time, after a period of abstinence from smoking
40783891|NCT06167226|DRUG|Personalized Ayurveda treatment protocol|The treating physician decided and advised personalized Ayurveda treatment protocol based on disease and patient's condition
40783892|NCT04931238|DRUG|JS016|Single Intravenous Injection of JS016 with a dose of 50mg/kg
40783893|NCT02327767|DEVICE|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
41147072|NCT04196517|OTHER|WebMD|WebMD is a widely used educational platform for health information.
41306362|NCT05118204|BEHAVIORAL|Linkage to outpatient BUP treatment|Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center
41306363|NCT01524172|BEHAVIORAL|Yoga Based Psychotherapy Group|YBPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).
41306364|NCT01524172|BEHAVIORAL|Standard Mental Health Treatment|Trauma and evidence informed therapy
41306365|NCT01771718|DEVICE|MPTflex-multiphoton microscopy-based tomograph.|non-invasive optical biopsy
41306366|NCT03226080|DRUG|Rocuronium|The neuromuscular blockade group will receive intravenous rocuronium
41306367|NCT03226080|DRUG|Sugammadex|The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
41306368|NCT03226080|DRUG|Normal saline|Normal saline will be administered as a placebo in equal volume for the placebo group
41464913|NCT04752319|DEVICE|EStim|EStim will be applied for 10 to 20 minutes per session for multiple sessions
41306369|NCT02787434|OTHER|Prostate Cancer Screening Decision Aid|All patients recruited to the study will receive the PCSPrep decision aid. There is only 'study arm.' The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test. Individuals will see the survey questions on screen and will hear accompanying audio through headsets. Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
41306370|NCT06520176|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
41306371|NCT06520176|DRUG|Cytarabine|Day 1\~Day 2: 200g/m\^2, q12h
41306372|NCT06520176|DRUG|Pegfilgrastim|Day 6: 6mg
41306373|NCT06520176|DRUG|Cyclophosphamide|Day 1\~Day 2: 1～2g/m\^2
40783894|NCT00873925|BIOLOGICAL|Autologous UCB|Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
40783895|NCT00873925|DIETARY_SUPPLEMENT|Omega 3 FA|Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
40783896|NCT00873925|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
40783897|NCT01394380|OTHER|artificially sweetened sodas|subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
40988116|NCT03366402|DIAGNOSTIC_TEST|RT-PCR H1N1|At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
40988117|NCT05681455|DEVICE|Neuromodulation NESA NXSIGNAL® device|"Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®.~The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire.~The directional electrode will be placed in the cervical area at the superficial level between C6 and C7."
40988118|NCT04110093|DRUG|Regorafenib and PD-1 inhibitor|All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
40988119|NCT03076957|DRUG|CKD-516 Tablet|CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
40988120|NCT00242957|BEHAVIORAL|Intervention with Microfinance for AIDS and Gender Equity|
41145694|NCT02287948|DEVICE|Nintendo Wii Fit Balance Board|"Clinical and instrumental evaluations carry out on the same day.~1) Instrumental evaluations~All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:~* Open eyes, monopodalic balance for 20 seconds~* Closed eyes, monopodalic balance for 20 seconds~* Open eyes, balance on both feet for 60 seconds~* Closed eyes, balance on both feet for 60 seconds~During trials subjects can leave arms in the most comfortable position they prefere~Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials."
41145695|NCT01241448|DRUG|LY2409021|Administered Orally
41145696|NCT01241448|DRUG|Placebo|Administered Orally
41145697|NCT01992497|DIETARY_SUPPLEMENT|Probiotic|
41306374|NCT06520176|DRUG|G-CSF|Subcutaneous injection at dose 5ug/kg, from day 6 until the end of mobilization.
41306375|NCT06520176|DRUG|G-CSF|Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
41306376|NCT03951961|DRUG|Midostaurin|50mg Midostaurin bid for 12 months
40783898|NCT03053778|OTHER|Early follow-up|Early follow-up until 4 weeks after discharge
40783899|NCT01100112|DRUG|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
40783900|NCT00477815|BIOLOGICAL|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
40783901|NCT00477815|DRUG|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
40783902|NCT00477815|BIOLOGICAL|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
40783903|NCT00477815|BIOLOGICAL|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
40783904|NCT00477815|RADIATION|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
41145698|NCT02691702|DRUG|BIIB118|Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
41145699|NCT02691702|DRUG|Melatonin|Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
41145700|NCT03234478|OTHER|cognitive assessments|Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
40783905|NCT00477815|BIOLOGICAL|111In Zevalin|5.0 mCi by IV
40783906|NCT04764526|OTHER|Protein-enriched ice cream|Offering two protein-enriched ice creams
40988121|NCT05119283|OTHER|Scraping and straightening of the crown and root and rinsing with mouthwashes|Patients will answer a questionnaire about their socioeconomic conditions, and soon after undergoing the examination for bleeding, probing, clinical attachment level, probing depth and plaque index for initial clinical evaluation. Basic periodontal treatment will be carried out with the same operator (blind to the treatments performed), with complete removal of plaque and calculi, prophylaxis with pumice and prophylactic paste and oral hygiene instructions. After basic periodontal treatment, patients will be randomly divided based on a draw with closed, opaque and non-translucent envelopes, into 3 groups according to the supporting treatments: G1 - patients who will receive mouthwashes with saline solution; G2 - patients who will be rinsed with 0.12% chlorhexidine and G3 - patients who will be treated with PHTALOX®.
40988122|NCT01599871|DRUG|theophylline|theophylline 100 mg, twice at day
40988123|NCT01599871|OTHER|placebo|Placebo
40988124|NCT04407312|DRUG|Cilostazol Tablets|Cilostazol-SR, capsule, 200mg, once daily, 30 days.
40988125|NCT04407312|DRUG|placebo|Placebo, tablet, 200mg, once daily, 30 days.
40988126|NCT04407312|DRUG|Aspirin|Astrix, capsule,100mg, once daily, 30 days.
40988127|NCT04407312|DRUG|Clopidogrel|Plavix, tablet, 75mg, once daily, 30 days.
40988128|NCT02493608|DEVICE|scalpel|used to cut the abdominal wall.
40988129|NCT02493608|DEVICE|Diathermy|Diathermy used to cut , coagulate the tissue
40988130|NCT03864471|OTHER|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
40988131|NCT03864471|OTHER|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
40988132|NCT03098537|DRUG|enteral nutrition + proton pump inhibitor|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
40988133|NCT03098537|OTHER|enteral nutrition only|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
40988134|NCT01710033|DRUG|Placebo|Placebo tables twice daily (BID) for 28 days
40988135|NCT01710033|DRUG|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
40988136|NCT01710033|DRUG|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
40988137|NCT01710033|DRUG|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
40988138|NCT01554423|OTHER|Testing and Counseling|Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
40988139|NCT01554423|BEHAVIORAL|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
40988140|NCT01554423|BEHAVIORAL|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
40988141|NCT02710045|BIOLOGICAL|Measles Vaccine at 9 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
40988142|NCT02710045|BIOLOGICAL|DTP Vaccine at 9 months of age|Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age
40988143|NCT02710045|BIOLOGICAL|Measles Vaccine at 18 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
40988144|NCT01678092|BIOLOGICAL|omalizumab|
40988145|NCT03826979|OTHER|Pliates method treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
40988146|NCT04826146|DEVICE|Validation of qCON versus BIS|Correlation between qCON and BIS values (main outcome) and qNOX and MOAA/S scale are determined
40988147|NCT02116400|OTHER|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
40783907|NCT06187324|DIAGNOSTIC_TEST|biomarkers|by th use of perio paper GCF was collected and Biomarkers level was estimated
40783908|NCT05685784|DEVICE|Bytelfies kit - sensor dot|"Participants will be asked to undergo a standard of care gait analysis and PSG whilst simultaneously wearing sensor dots.~GAIT: sensor dots will be placed in the neck, on the chest and one on both ankles.~PSG: sensor dots will be placed on the forehead, chin, chest, abdomen, both legs(tibialis anterior) and an SpO2 device will be placed on the finger middle finger of the non-dominant hand"
40783909|NCT00577278|BIOLOGICAL|rituximab|Given IV
40988148|NCT02116400|OTHER|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
40988149|NCT02116400|BIOLOGICAL|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
40988150|NCT05434520|PROCEDURE|Preoperative biliary drainage (ERC og PTC-aided)|Placement of biliary stent (plastic, covered SEMS, uncovered SEMS) endoscopic by ERC or placement of plastic catheter by PTC
40988151|NCT05851430|DEVICE|PEF ablation|Pulsed Electric Field (PEF) Ablation per institutional standard of care
40988152|NCT06146933|DIAGNOSTIC_TEST|Glucometer Test|blood glucose measurement using finger tip capillary blood using BGM
40988153|NCT06146933|DIAGNOSTIC_TEST|Refernce Measurement|blood glucose measurement using finger tip capillary blood using reference method
40988154|NCT04052048|DIAGNOSTIC_TEST|Subtraction Normalized Expression of Phagocytes Blood Test|Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness
40988155|NCT03124914|OTHER|Neuromuscular tests|Neuromuscular tests
41145701|NCT05773599|OTHER|laughter yoga|A pre-test will be applied to evaluate sleep quality and life satisfaction. Laughter yoga will be applied one day apart to the experimental group with a low sleep quality score. After dasa, sleep quality and life satisfaction will be evaluated again with
41145702|NCT04429672|BEHAVIORAL|The Right to your Sexual Health|which is of a socio-educational type and is made up of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Behavior and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of opening, development and closing phase
41306377|NCT01762657|DRUG|Oral Cyclosporine and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
40783910|NCT00577278|DRUG|fludarabine phosphate|Given IV
40988156|NCT03407573|BIOLOGICAL|Administration of Red Cell|Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.
40988157|NCT03774953|DIETARY_SUPPLEMENT|Protein and vitamin supplementation|The intervention group will receive 1.5 g protein/kilo/day during hospitalization and a standard dose of 27 g protein/day in 60 days after discharged together with a daily dose of vitamin/mineral supplement
40988158|NCT03577704|DRUG|HLX07+Gemcitabine+Cisplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.~HLX07, IV, weekly."
40783911|NCT00577278|DRUG|melphalan|Given IV
40783912|NCT00577278|DRUG|sirolimus|Given PO
40988159|NCT03577704|DRUG|HLX07+Paclitaxel+Carboplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.~HLX07, IV, weekly."
40988160|NCT03577704|DRUG|HLX07+mFOLFOX6|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly."
40988161|NCT04061811|DIAGNOSTIC_TEST|Diagnostic biomarker study|Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.
40988162|NCT02891460|DEVICE|40 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
40783913|NCT00577278|DRUG|tacrolimus|Given PO or IV
40783914|NCT00577278|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo APBSCT
40783915|NCT00577278|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
40783916|NCT00577278|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
40988163|NCT02891460|DEVICE|80 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
41145703|NCT04429672|BEHAVIORAL|Friendly sexual health services and reproductive for adolescents|consists of six sessions (one a week) lasting 50 minutes each, using illustrative material through official flipcharts of the secretary of health on reproductive health, sexually transmitted diseases and sexual violence
40783917|NCT00577278|OTHER|laboratory biomarker analysis|Correlative Studies
40783918|NCT03218917|DRUG|Brensocatib 10 mg|Administered once per day for 24 weeks
40988164|NCT00031889|DRUG|Exemestane|Exemestane
40988165|NCT00031889|DRUG|Exemestane+bicalutamide|Exemestane as in arm I and oral bicalutamide once daily
40988166|NCT03986320|DEVICE|Keeogo™ Dermoskeleton|This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
40988167|NCT06161220|DRUG|Carbidopa capsule|Dose: 4x 100 mg
40988168|NCT06161220|DRUG|Moxifloxacin Tablets, USP|Dose: 400 mg
41464914|NCT02000323|OTHER|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day.~nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day"
40783919|NCT03218917|DRUG|Brensocatib 25 mg|Administered once per day for 24 weeks
40988169|NCT06161220|DRUG|Placebo|Placebo capsules matching the carbidopa capsules
41145704|NCT06607315|OTHER|physical properties of soft tissue|Using the Myoton Pro device, the physical properties such as elasticity and viscosity of the Achilles tendon, patellar tendon, gastrocnemius, quadriceps, and hamstring muscles will be measured.
41145705|NCT06607315|OTHER|Analysis of Running Form|High-speed camera systems will be used to analyze biomechanical parameters in detail, such as angular movements of the lower extremity joints (tibia, ankle, knee, hip), step length, and ground contact time during running. These analyses will allow us to objectively characterize different running forms.
40783920|NCT03218917|DRUG|Placebo|Administered once per day for 24 weeks
40783921|NCT02030821|DRUG|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
40783922|NCT02030821|DRUG|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
41145706|NCT06503991|BEHAVIORAL|Community Health Worker (CHW)-delivered Hypertension Management Pilot (CHAMP)|Clinic-based hypertension educational intervention delivered by a Community Health Worker.
41306378|NCT01762657|DRUG|Placebos|Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
41306379|NCT02526927|DEVICE|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
41306380|NCT02526927|DEVICE|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (\< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
41306381|NCT02526927|OTHER|Blood samples|
41306382|NCT04388280|DIAGNOSTIC_TEST|Echocardiography|Functional assessment of coronary artery disease
41306383|NCT04388280|DIAGNOSTIC_TEST|CT angiography|Anatomical assessment of coronary artery disease
41464915|NCT02000323|OTHER|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~* The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~* After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure \<20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~* Patients are targeted to receive calories for 25 kcal/kg/day."
41464916|NCT05607433|DEVICE|cook ®Airway Exchanger Catheter|A tube exchanger is a small calibre , flexible tube used to guide endotracheal intubation through a supraglottic device.
41464917|NCT00282581|BIOLOGICAL|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
41464918|NCT00843089|OTHER|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
41145707|NCT06503991|BEHAVIORAL|Control of Blood Pressure and Risk Attenuation (COBRA)|Multi-component counseling program addressing patient education, provider training, coordination of care, and subsidizing care costs.
41306384|NCT06165484|PROCEDURE|laparoscopy and hysteroscopy|laparoscopy and hysteroscopy for patient with failed IVF
41464919|NCT02497079|DEVICE|Nested PCR for formalin-fixed tissues|For nested PCR, formalin-fixed paraffin-embedded tissues were incubated in 1 mL of xylene at 60°C for 30 min and then centrifuged for 10 min. Paraffin and the supernatant were removed from the samples after centrifugation. The same procedures were repeated until deparaffinization was complete. After adding 1 mL of alcohol, the samples were centrifuged for 5 min, and the supernatant was removed. The sample was then air-dried as a pellet. DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
41306385|NCT00551720|BEHAVIORAL|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
41306386|NCT00551720|BEHAVIORAL|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
41306387|NCT00316303|DRUG|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
41306388|NCT00316303|BEHAVIORAL|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
41306389|NCT06361329|DRUG|Homoharringtonine|Intravenous infusion
41306390|NCT06361329|DRUG|venetoclax|Orally by mouth
41306391|NCT06361329|DRUG|Cytarabine|subcutaneous injection or Intravenous infusion
41306392|NCT06361329|DRUG|G-CSF|subcutaneous injection
41306393|NCT06361329|DRUG|Vindesine|Intravenous infusion
41306394|NCT06361329|DRUG|Daunorubicin|Intravenous infusion
41306395|NCT06361329|DRUG|cyclophosphamide|Intravenous infusion
41306396|NCT06361329|DRUG|Dexamethasone|Intravenous infusion or orally
41306397|NCT06361329|DRUG|L-ASP|subcutaneous injection
41306398|NCT06376474|DRUG|Hemay005|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
41306399|NCT03076047|DEVICE|end-tidal CO2 (ETCO2) monitoring|monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2, Capnostream, and Massimo
41306400|NCT01096849|DRUG|levofloxacin|
41306401|NCT01096849|DRUG|plazomicin|
41464920|NCT02497079|DEVICE|Nested PCR for fresh tissues|For nested PCR with specimens in sterile saline, DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
41145708|NCT03647800|BIOLOGICAL|APVO436|APVO436
41145709|NCT01508117|DRUG|Axitinib|5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
41306402|NCT01096849|DRUG|placebo|
41306403|NCT00322595|DRUG|Quetiapine fumarate|
41306404|NCT00322595|DRUG|Paroxetine|
40988170|NCT06067542|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
40988171|NCT05348161|PROCEDURE|Samples including blood and tissue collection|Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.
40783923|NCT05031143|DRUG|Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease|Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
40783924|NCT05098314|OTHER|Personalized interventions regarding the Cicat-Occitanie network|"First of all, healthcare professionals from EHPAD in the intervention arm were invited by email to answer a closed questionnaire. It was built by the authors, on Google forms, and consisted of 11 questions divided into 2 sections.~Section 1 collected data about the participants. In section 2, they were asked to score from 0 to 4 (ranging from not at all to a lot ) the various obstacles to teleconsultations reported by the literature."
40783925|NCT04781530|DEVICE|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus): Nasopharyngeal swab
40988172|NCT05348161|PROCEDURE|CTC detection|Peripheral blood collected from patients will be administrated to CTC detection.
40988173|NCT05348161|PROCEDURE|ctDNA detection|DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.
40988174|NCT05348161|PROCEDURE|10×genomics single cell RNA sequence|Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.
40988175|NCT05348161|PROCEDURE|Whole exon sequence|DNA will be extracted from patients' tissue and administrated to whole exon sequence.
40988176|NCT05348161|PROCEDURE|Proteomics detection|Peripheral blood collected from patients will be administrated to proximity extension assay .
40988177|NCT04608786|DRUG|ZKAB001 5mg/kg|ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
40988178|NCT04608786|DRUG|Capecitabine|Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
41306405|NCT02730507|DEVICE|Surgery with patient-specific rod|Bras A: PSRs must be used with the appropriate instrumentation designed by the same manufacturer. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation must be the same (except the use of standard straight rod) in both groups. The surgical method to implement the PSR will be the same as the one to implement the conventional rod. Except for the bending procedure (patient specific rod or conventional rod with perioperative manual bending), the characteristics of implantable devices (biomaterial and diameter of the rod, design, type of screw, etc.) will be the same in each center.
41306406|NCT02730507|DEVICE|Conventional straight rod|Bras B: The control group is composed of patients operated with standard straight rods, which are bent in the operating room by the surgeon. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation used in the control group must be the same (except the use of PSRs) than the experimental group.
41306407|NCT01853111|BIOLOGICAL|Interleukin-2|
40783926|NCT02986074|DEVICE|Paresthesia mapping lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
40783927|NCT02986074|DEVICE|Anatomical midline lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
40783928|NCT02886130|DIETARY_SUPPLEMENT|Placebo|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
40783929|NCT02886130|DIETARY_SUPPLEMENT|Experimental|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
40783930|NCT01056614|DRUG|fludarabine phosphate|Given IV
41306408|NCT03803852|DEVICE|Intraocular Lens Implantation|"Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impressinto the capsular bag using an injector, after removing of the human cristalline lens.~Implantation of the Alcon Clareon toric and Rayner RayOne EMV toric IOL on the axis according to the steep meridian of the cornea"
41306409|NCT06231199|OTHER|gastrocnemius release|The patient will be prone to lying and the therapist will stand at the side of the patient's leg. The therapist uses both hands in cross-hand pattern (Figure 10a and 10b). Myofascial Release will be performed for 20 repetitions, then gastrocnemius release by foam roller;This involved long sitting, with the affected leg will be extended on the foam roller and foot relaxed. The non-affected leg will be flexed at knee so that the foot will be rested on the floor. The participants will be instructed to use their arms and non_affected foot to propel their body back and forth from the popliteal fossa to Achilles tendon in continuous motion. then patients perform plantar fascia realise from standing by foam roller
41306410|NCT06231199|OTHER|conventional treatment|the patients will receive conventional treatment in the form of ultrasound therapy (continuous mode/1MHZ) followed by plantar fascia stretch and inctruction
41306411|NCT00198445|DRUG|Bromfenac|One drop in study eye every 12 hours for 14 days
41306412|NCT00198445|DRUG|Placebo|One drop in study eye every 12 hours for 14 days
41306413|NCT03969797|DEVICE|RADIAQBIO Heart Guardian HR-501|Arm one offers ECG data and electric shocks recorded during AED operation.
41306414|NCT03766087|PROCEDURE|decompressive craniectomy|decompressive craniectomy is decompression at the supratentorial level that is achieved by removing part of the skull and by making an opening, in the dura mater (with or without plastic surgery), without compromising the venous sinus.
41306415|NCT03185455|OTHER|Remote (text based) surveillance|Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
41306416|NCT02528097|DRUG|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
40783931|NCT01056614|DRUG|busulfan|Given IV
40783932|NCT01056614|BIOLOGICAL|anti-thymocyte globulin|Given IV
40783933|NCT01056614|DRUG|tacrolimus|Given IV and orally
40783934|NCT01056614|DRUG|methotrexate|Given IV
40783935|NCT01056614|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
40783936|NCT01056614|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
41306417|NCT02528097|DRUG|Experimental|25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr \> 1.0 or BUN or Cr \> baseline)
41306418|NCT04789642|OTHER|blood pressure measurement whatsapp educational program|educational
41306419|NCT04811521|BEHAVIORAL|Primary care follow-up|Those randomized to primary care and enhanced primary care coordination will receive the minimal intensity treatment that includes: (1) assistance in identifying a primary care provider for participants who do not have one, (2) sharing results of diagnostic testing (including anxiety screening) with the primary care provider (results sent via EMR note, mailed letter, or delivered by participant at appointment); and (3) an educational brochure on anxiety and treatment.
41306420|NCT04811521|BEHAVIORAL|Online Self-Administered Anxiety Management Program plus Peer Support Guidance|Individuals randomized to the online Cognitive Behavioral Therapy (CBT) + peer support guidance arm will receive access to six online, evidence-based CBT modules in the This Way Up Generalized Anxiety Course to be completed weekly or bi-monthly. Individuals who screen positive on the PHQ panic measure will complete 2 additional panic-specific homework assignments applying exposure therapy to panic (in addition to Generalized Anxiety Disorder) experiences aligned with content from the This Way Up Panic Course.
40783937|NCT01056614|OTHER|laboratory biomarker analysis|Correlative studies
40783938|NCT01889992|RADIATION|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short \& long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 \>/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
40988179|NCT00734279|DRUG|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
40988180|NCT00734279|DRUG|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
40988181|NCT00734279|DRUG|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
41145710|NCT01508117|RADIATION|Radiation Therapy|45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
40783939|NCT01889992|PROCEDURE|Coronary angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
40783940|NCT01889992|OTHER|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
40783941|NCT01889992|DRUG|M-TOR Immunosuppression|"Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels."
40783942|NCT01889992|PROCEDURE|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
41306421|NCT04811521|BEHAVIORAL|Therapist-Administered Cognitive Behavioral Therapy|Individuals randomized to therapist-led CBT via telehealth will receive 8 one-hour sessions over the course of 8 to 10 weeks via telehealth (HIPAA compliant software such as Zoom Health or AmWell) or telephone. Therapists will be master's-degreed or eligible clinicians trained in CBT by our study psychologist. Therapists will follow a manualized protocol for delivering CBT for anxiety, specifically, with a primary focus on anxiety and worry management. Individuals who screen positive on the PHQ panic measure will have training in exposure therapy added to CBT. Although many CBT trials have a standard length of 12 sessions, brief CBT lasting 4-8 sessions is equally efficacious.
41306422|NCT05905211|OTHER|Observational Tests|The Berg Balance Scale was used to evaluate the balance levels, the Timed Up and Go Test was used to evaluate the functional mobility levels, and the Functional Independence Scale was used to evaluate the activities of daily living. The World Health Organization Quality of Life Instrument-Older Adults Module (WHOQOL-OLD) was used to evaluate the quality of life, the Fear of COVID-19 Scale was used to evaluate the COVID-19 fear levels, the Geriatric Depression Scale was used to evaluate the symptoms of depression.
41464921|NCT02497079|DEVICE|Real-time PCR for fresh tissues|For real-time PCR, specimens in sterile saline were filtered and 1 mL of phosphate based saline was added. After centrifugation for 3 min, the supernatant was removed. Next, 50 μL of extraction buffer was added to the sample, and the sample was heated at 100°C for 20 min. After centrifugation for 3 min, the supernatant was used in PCR. Real-time PCR was performed using the AdvanSure TB/NTM real-time PCR kit. Three channels were used in the real-time PCR reaction (Mycobacterium tuberculosis complex, mycobacteria, and internal control). Signals for FAM, HEX, and Cy5 were measured in each channel. Mycobacterium tuberculosis was considered present if the cycle threshold of rpoB was less than 35 on each signal and greater than or equivalent to that of IS6110.
41464922|NCT04659486|BEHAVIORAL|Home-based exercise training|Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
41464923|NCT04138784|OTHER|Individualized comprehensive rehabilitation program|The program general contents were pain education, joint protection techniques, general care lifestyle habits, which were complemented by a problem-based session. The program plan was designed to fit patients' goals, priorities, and lifestyles after an initial interview.
41145711|NCT01933776|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
41145712|NCT01933776|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
41145713|NCT03474978|DEVICE|Peripherally Inserted Central Venous Cather (PICC)|Location of the PICC insertion will be randomized and compared
41147073|NCT03470701|OTHER|Mailed Urinalysis Smartphone Kit|Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.
41147074|NCT01434355|OTHER|Laboratory Biomarker Analysis|Correlative studies
40783943|NCT01889992|GENETIC|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
40783944|NCT01889992|OTHER|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
40783945|NCT06322667|OTHER|No Intervention|This is a non-interventional study.
41147075|NCT01434355|OTHER|Questionnaire Administration|Ancillary studies
40783946|NCT00477984|DRUG|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
40783947|NCT01711528|DRUG|Bortezomib|Given SC
40783948|NCT01711528|DRUG|Dexamethasone|Given PO
40783949|NCT01711528|DRUG|Dinaciclib|Given IV
41464924|NCT04138784|OTHER|Aquatic training|Patients received a 45 min-water exercise program which included balance and proprioception activities, isometric exercise, flexibility exercises, core stabilization exercises and aerobic/endurance exercises. All sessions were developed in groups and addressed by a qualified professional.
41464925|NCT01352052|OTHER|interdisciplinary rehabilitation|A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
40783950|NCT01711528|OTHER|Laboratory Biomarker Analysis|Correlative studies
40783951|NCT02916485|DEVICE|Bioresorbable scaffold|Percutaneous coronary intervention (PCI)
40783952|NCT03085680|DRUG|Curcumin|Participants will be given curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
40783953|NCT03085680|DRUG|microcrystalline cellulose|Participants will be instructed to consume two capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
40783954|NCT02320864|PROCEDURE|Total knee replacement surgery|The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
40783955|NCT04645173|DEVICE|CIED envelope|Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.
40988182|NCT00734279|DRUG|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
40988183|NCT03143569|DEVICE|aPTT guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
40988184|NCT03143569|DEVICE|Anti-factor Xa guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
41306423|NCT01240044|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
41464926|NCT01659034|DRUG|Thienopyridine for 3 months|
41464927|NCT05274191|DRUG|Pyrotinib Maleate|Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;
41464928|NCT05274191|OTHER|standard regimen|standard regimen
41464929|NCT03124134|DEVICE|Gelesis200|Encapsulated hydrogel
41464930|NCT03124134|OTHER|Water, only (placebo)|300 mL of water
41464931|NCT04475250|DEVICE|Tetragraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
41464932|NCT00003467|DRUG|carmustine|
40988185|NCT03854617|DRUG|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
40988186|NCT03854617|DRUG|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period
40988187|NCT00811473|DRUG|Quetiapine XR|Oral treatment with 150 up to 300 mg/day once daily in the evening
40988188|NCT00811473|DRUG|Placebo|Oral treatment once daily in the evening
40988189|NCT03541018|PROCEDURE|Type of repositional maneuvre|Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
40988190|NCT05793320|PROCEDURE|Carpal Tunnel Release Surgery|Carpal tunnel release surgery used to take a biopsy to diagnose amyloidosis and determine whether or not carpal tunnel syndrome can predict who's at risk for having amyloidosis.
41464933|NCT00003467|DRUG|polifeprosan 20 with carmustine implant|
41464934|NCT00003467|PROCEDURE|surgical procedure|
41464935|NCT06380257|OTHER|Observational study methods|Neuroimaging, body compostion, laboratory tests and psychiatric interview in study and in control groups.
41464936|NCT05344287|OTHER|Typical American Diet|Participants self-reported adherence to a typical American diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
40783956|NCT00713011|DRUG|Adalat XL|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
40783957|NCT00713011|DRUG|Tiazac XC|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
40783958|NCT04149496|COMBINATION_PRODUCT|in vitro maturation of oocytes|Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
41464937|NCT05344287|OTHER|Plant-Based Diet|Participants self-reported adherence to a 100% plant-based diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
40988191|NCT00388635|DRUG|Velcade|Phase I: Velcade, 1.0mg/m2-1.3mg/m2 in escalating doses every 6 weeks for 4 cycles Pase II: Velcade at optimal doses, twice a week (days 1, 4, 8, 11, 22, 25, 28 and 32) follow a rest period for 10 days (days 33 to 42)
41464938|NCT04709224|DRUG|Lumateperone Long-Acting Injectable|Lumateperone Long-Acting Injectable
41145714|NCT05308342|PROCEDURE|transplantation of human UC-MSCs into ovaries of POI patients|UC-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the China Food and Drug Administration) are injected into the ovary of patients under transvaginal ultrasonographic (TVUS)-guidance. A total number of 10×106 cells, 5×106 for unilateral ovarian injection) is immediately preserved and transferred for direct injection. After vaginal sterilization, TVUS-guided transplantation is performed by two senior-level medical physicians, using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcare Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The UC-MSC solution is injected into the ovary by using 21-G PTC needles (Hakko Medical Co, Japan) under TVUS guidance.
41145715|NCT05308342|DRUG|hormone replacement treatment|Routine estrogen progesterone replacement periodic therapy
41145716|NCT04898582|OTHER|Mineral 89 Probiotic Fractions|The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions
41145717|NCT01529853|DRUG|SAR156597|"Pharmaceutical form: solution~Route of administration: subcutaneous"
40783959|NCT06041321|DEVICE|Reparel Sleeve|For the purpose of this study, the Reparel Sleeve will be evaluated against a placebo sleeve of similar feel, texture, and look. The indication is that due to its technology, the Reparel sleeve will allow for the ability to reflect energy using a blend of semi-conductors grounded to nanoparticles interwoven between fibers of the sleeve. Thermal energy is then absorbed from the patient thus activating electrons on the nanoparticles and releasing photonic energy directed at tissues within the surrounding area7. This photostimulation is expected to alleviate pain and inflammation while promoting wound healing as well as tissue regeneration.
41306424|NCT01240044|PROCEDURE|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
41145718|NCT01529853|DRUG|Placebo (for SAR156597)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41145719|NCT05555199|RADIATION|99mTc-nanocolloid|Injection of 99mTc-nanocolloid when lung cancer is diagnosed during a navigation bronchoscopy, followed by one or two SPECT/CT-scans.
41145720|NCT05555199|DRUG|ICG|If patient undergoes surgery to treat the lung cancer, ICG will be injected and retrieved fluorescent lymph nodes will undergo additional pathological assessment.
41145721|NCT01259219|DRUG|Mycobutin|"Indication and Usage:~Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.~Dosage and Directions for use:~Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.~Identification:~Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder."
41306425|NCT02653105|BIOLOGICAL|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
41306426|NCT01073527|DRUG|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
40783960|NCT06041321|DEVICE|Placebo Sleeve|Generic sleeve used as a placebo. This placebo will have a similar feel, texture, and look with no additional technology.
40783961|NCT01263457|DEVICE|Easypod|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod
41306427|NCT01073527|DRUG|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
40783962|NCT06165991|DRUG|Liposomal bupivacaine, Bupivacaine|"1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA"
40783963|NCT03224039|DRUG|Sufentanil|Intranasal for one dose (experimental)
40783964|NCT03224039|DRUG|Normal saline|Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
40783965|NCT03224039|DRUG|Morphine|intravenous push for one dose (active comparator)
40783966|NCT01654939|DRUG|Rifaximin|All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
40783967|NCT03109405|DEVICE|Stimulation-assisted venous access|Stimulation-assisted venous access
40783968|NCT03109405|OTHER|20 guage cannula for IV, tourniquet optional|Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
40783969|NCT01677871|DRUG|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
41145722|NCT01301183|DRUG|RhIGF-1 with transdermal 17-beta estradiol|"RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D."
41145723|NCT01301183|DRUG|Placebo and transdermal 17-beta estradiol|Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
41145724|NCT02659059|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
41145725|NCT02659059|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
41145726|NCT02659059|DRUG|Platinum Doublet Chemotherapy|
41145727|NCT04392856|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
41145728|NCT04392856|BEHAVIORAL|Same than experimental condition (UP), after it finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
41145729|NCT03188887|DRUG|corticotherapy|3 IV pulses steroids followed by oral steroids for 4 months
41145730|NCT03188887|DRUG|Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)|treatment with Renin angiotensin system (RAS) blockade or SGLT2i
41145731|NCT01823458|BEHAVIORAL|Lottery Insurance|
41145732|NCT01823458|BEHAVIORAL|Standard Lottery|
41145733|NCT05487937|OTHER|Use of Toleriane Ultra to relieve face allergic skin|The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
41145734|NCT00000497|BEHAVIORAL|diet, sodium-restricted|
41145735|NCT00000497|BEHAVIORAL|diet, reducing|
41145736|NCT04421534|DRUG|Lactoferrin|adding lactoferrin to standard of care treatment regimens
41145737|NCT04995601|DEVICE|RF Health MAC|The RF Health MAC is a novel device that is applied to the lower legs of patients that provides intermittent active compressions to the calf muscles which results in increased blood flow in the veins, moving blood towards the direction of the heart and reducing the risk of clot formation.
41145738|NCT04780906|OTHER|Wrist taping|Wrist taping as used as standard in CrossFit practice
41145739|NCT04278690|OTHER|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent. Instruction sheets include optimized instructions (mL-only, doses appropriately rounded, visuals of recommended tool (e.g. 1-mL syringe best for doses of \<1 mL), explicit frequency information (e.g. 'morning and night' instead of '2x/day') reinforced by pictograms (e.g. sun/moon icons)). For each medication, staff will: 1) review the dose (refer to the pictographic dose diagram, which illustrates optimal dosing tool filled to correct amount), 2) demonstrate the dose using optimal dosing tool, 3) ask parent to 'teachback'/'showback' dose (e.g. parent shows provider how much they would give by pulling back plunger on syringe to right level), 4) provide optimal dosing tool for the parent to take home. We anticipate this process will take \~5-10 minutes.
41145740|NCT04278690|OTHER|HELPix+Tech|After parent receives usual care and HELPix , trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app. For each medicine: A. Dosing module with optimized instructions (c/w HELPix); parent teachback/showback of dose B. Frequency module supports simplified, explicit intervals (e.g. 'morning and night'), parent chooses convenient times (text reminders sent based on preferences). Time for TECH depends on # medicines and parent baseline knowledge; structured protocol used to see # teachback rounds needed .
41145741|NCT00825513|DEVICE|Akreos Toric IOL|Lens implant following cataract surgery
41145742|NCT00825513|DEVICE|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)|Lens implant following cataract surgery
41145743|NCT02301299|BEHAVIORAL|Community-based Stroke Awareness Program|A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
40783970|NCT01677871|DRUG|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
40783971|NCT01677871|DRUG|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
40783972|NCT01677871|DRUG|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
40783973|NCT00678730|DRUG|delta 9 tetrahydrocannabinol|0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
40783974|NCT00003929|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
40783975|NCT00003929|DRUG|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
40783976|NCT00003929|DRUG|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
40783977|NCT00003929|RADIATION|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
40783978|NCT00403325|DRUG|rhuFab V2 [ranibizumab] ( Lucentis )|
40783979|NCT06521216|DRUG|Ferrous sulfate|all patients will receive 200 mg elemental iron (ferrous sulphate)
40783980|NCT02271893|DRUG|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
40783981|NCT04197284|DEVICE|Biofeedback, Myomed 632|"Biofeedback is a mind-body technique that involves using visual or auditory feedback to gain control over involuntary bodily functions.~Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses."
40783982|NCT04197284|DEVICE|device for electrical stimulation, BTL 4000 Smart|Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses. Electrodes, controlled by a unit, are placed on the skin over a predetermined area. Electrical current is then sent from the unit to the electrodes and delivered into the muscle causing a contraction.
41464939|NCT05796518|OTHER|PREVENT Cardiovascular Health Assessment Tool|Participants will access a heart health information visualization tool online using a personal device or a study tablet computer using their e-mail address to log-in. Investigators will review participant lab results specifically related to their cardiovascular health (e.g. blood pressure, cholesterol) in order to personalize the heart health tool for participants. A brief survey before and after use of the tool will also be completed by participants.
40783983|NCT04197284|OTHER|kinesitherapy|isometric exercise of the quadriceps muscle
40783984|NCT03980639|DRUG|patient treated with DMARD|Case report of cancer overall
41464940|NCT05796518|OTHER|Survey|A brief survey before and after use of the tool will also be completed by participants.
41464941|NCT05796518|OTHER|Interview Regarding Heart Health|Participants will be asked questions related to their heart health.
41464942|NCT04541680|DRUG|Nintedanib 150 MG [Ofev]|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
41464943|NCT04541680|OTHER|Placebo|Placebo
41464944|NCT03990480|DRUG|valsartan (160 mg/d)|Group I treated with valsartan (160 mg/d, n = 100)
40783985|NCT05910515|OTHER|Debriefing|Structured debriefing in non-technical skills. (This is an educational study)
40783986|NCT02801786|DRUG|Placebo|The arm will be composed of 03 women who used placebo capsules and gel.
40783987|NCT02801786|DRUG|Lidocaine|The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.
40783988|NCT02801786|DRUG|Tamoxifen|The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.
40783989|NCT03930589|PROCEDURE|Remote Ischemic conditioning|BP cuff inflation for 5 min and deflation for 5 mins with 4 cycles
40783990|NCT03930589|OTHER|Standard of care|Standard of care
40783991|NCT05977998|DRUG|Paclitaxel|Given by IP (Intraperitoneal injection)
40783992|NCT05977998|DRUG|Dexamethasone|Given by IV (vein)
40783993|NCT05977998|DRUG|Diphenhydramine|Given by IV (vein)
40783994|NCT05977998|DRUG|Famotidine|Given by IV (vein)
40988192|NCT00388635|DRUG|Melphalan|Melfalán 9mg/m2 days 1 to 4, V.O, follow by a rest period of 38 days in phse I and II
40988193|NCT00388635|DRUG|Prednisone|Prednisone 60mg/m2 v.o days 1 to 4 follows by a rest period of 38 days (phase I and II)
40988194|NCT01764009|BIOLOGICAL|naked DNA coding for protein AMEP|injections 28days interval of 3 increasing doses of plasmid with electrotransfer
40988195|NCT03893812|DEVICE|MRI|diffusion weighted MR
40988196|NCT03893812|DEVICE|Ultrasound|Color Doppler ultrasound
40988197|NCT01747941|DRUG|PF-06305591|single dose, solution
40988198|NCT01747941|DRUG|Placebo|matching placebo
40988199|NCT01747941|DRUG|PF-06305591|single dose, solution
40988200|NCT01747941|DRUG|Placebo|matching placebo
40988201|NCT01747941|DRUG|PF-06305591|single dose, solution
40988202|NCT01747941|DRUG|Placebo|matching placebo
40988203|NCT00000381|DRUG|Fluoxetine|
40988204|NCT02758015|OTHER|Standardized Meal|
40988205|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 1500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
40988206|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 3000mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
40988207|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 4500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
40988208|NCT02166554|OTHER|Saline|On the day of initial surgery
40988209|NCT02166554|DEVICE|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
40988210|NCT05886218|DEVICE|Quantitative Neuromuscular Function Monitoring|Quantitative electromyographic (EMG) monitoring
41464945|NCT03990480|DRUG|amlodipine (10 mg/d).|Group II amlodipine (10 mg/d, n = 100).
41464946|NCT02026479|DRUG|Dexamethasone Phosphate|5mg; postauricular injection
41464947|NCT02026479|DRUG|Dexamethasone Phosphate|10mg; postauricular injection
41464948|NCT02026479|DRUG|Ginaton|40mg/pill, 3times/day,oral
41464949|NCT01287455|DRUG|"Vitamin D3 as BABY D3"|drops, 70 drops (= 14000 units), once weekly for 6 weeks
41464950|NCT01287455|OTHER|placebo|drops, 70 placebo drops, once weekly for 6 weeks
40783995|NCT02906410|OTHER|Item-Level Calorie information|Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
40783996|NCT02906410|OTHER|Meal-Level Calorie information|"Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen."
40988211|NCT02555332|OTHER|75g oral glucose tolerance test (OGTT)|All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
41145744|NCT04315545|DIAGNOSTIC_TEST|meal tolerance test|In addition to the standard oral glucose tolerance (which is normally performed between 24-28 weeks of pregnancy), is used to test the metabolic resilience capacity of glucose, we will provide our participants with a different diagnostic tool named 'meal tolerance test' in an earlier stage of pregnancy (12-16 weeks), mid pregnancy (24-28 weeks) and 3 months postpartum.
41464951|NCT02476305|DEVICE|"cryoprobes"|Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
41464952|NCT03380416|OTHER|Portfolio Diet|Medium-term (8 weeks ) nutritional intervention
41147076|NCT03426709|BEHAVIORAL|Low intensity Internet-delivered psychotherapy|The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
41306428|NCT04284956|PROCEDURE|Proximal and distal segment of saphenous vein harvested by No-Touch technique|two longitudinal incisions are made on the thigh and shank from unilateral lower limb (for harvesting of proximal segment of saphenous vein, incision is started from about 3 or 4cms inferolateral to the pubic tubercle and then extended downward). As previous reported. the adventitia and perivascular tissue are carefully kept intact to avoid damage. Then a margin of about 5 mm from both sides of the vein is created to include the fat pedicle using electrocautery, and all visible side branches are ligated with 4-0 silk or by metal clipping (branches are divided at the pedicle margin rather than the vein trunk). The saphenous vein is then separated from its bed using scissors and electrocautery, together with surrounding tissue.
41306429|NCT03647371|PROCEDURE|Macintosh laryngoscopy|intubation with MAcintosh laryngoscopy after anesthetic induction
41464953|NCT03380416|OTHER|MUFA Diet|Medium-term (8 weeks ) nutritional intervention used as control
41464954|NCT02681406|BEHAVIORAL|ACHESS|Smartphone based additions focused application, encouraging social support
41464955|NCT02681406|BEHAVIORAL|TMC|Brief telephone monitoring and counseling
41306430|NCT03647371|PROCEDURE|McGrath MAC video laryngoscopy|intubation with McGrath MAC videolaryngoscopy after anesthetic induction
41464956|NCT04917627|DRUG|Vancomycin|one vial of vancomycin (1000 mg ) powder form.
41464957|NCT04522804|DRUG|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
41464958|NCT03803254|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
41464959|NCT03803254|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
41464960|NCT03803254|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
41464961|NCT03803254|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
41464962|NCT05381896|OTHER|Conventional Scoliosis Exercise Program|Program will include breathing exercises, spinal stabilization and strengthening exercises, posture exercises and stretching execises.
41464963|NCT05381896|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
41464964|NCT01989676|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
40988212|NCT02608268|DRUG|MBG453|Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
40988213|NCT02608268|DRUG|PDR001|Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
40988214|NCT02608268|DRUG|Decitabine|commercially available chemotherapy
40988215|NCT03318354|DRUG|Torrent's Olmesartan Medoxomil Tablets 40 mg|
40988216|NCT03318354|DRUG|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
40988217|NCT01817933|BEHAVIORAL|physical therapy|
41464965|NCT01989676|DRUG|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
41464966|NCT01989676|BIOLOGICAL|Herceptin®|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
40783997|NCT00226005|DRUG|PTK787/ZK222584|One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
40783998|NCT03719807|OTHER|Rehabilitation protocol|A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.
40988218|NCT04289246|DEVICE|Medication Ambient Display (MAD)|"MAD was implemented for Android tablets to provide the following external cues:~* Abstract and stylized representations of medication adherence. The MAD shows a virtual birdcage, which has the aim of raising elders' consciousness about how they have to take responsibility for caring for their health, in a way similar to willingly caring for a pet. Each day, a newborn pet grows to represent medication compliance. By touching any point on the parakeet's virtual cage, the MAD presents information on the participants' daily medication compliance.~* Auditory and visual reminders. The parakeet provides auditory reminders (a parakeet whistle) and pictograms to inform the medication to take.~After participants take their medication, they move the MAD closer to the pill container to indicate that the medication was taken. This functionality was implemented through Near Field Communication (NFC) technology. Afterward, the parakeet acknowledges that the medication was registered as taken."
40988219|NCT04146025|BEHAVIORAL|Nature Coach Intervention|"1. Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~2. Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~3. Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
40988220|NCT03012347|DRUG|BAY987517|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
40988221|NCT03012347|DRUG|BullFrog Gel Sunscreen Land Sport SPF-50|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
40988222|NCT03800927|DEVICE|Long duration ultrasound|Low-intensity long duration ultrasound treatment
40988223|NCT02204787|DEVICE|transcranial direct current stimulation|
40988224|NCT01633892|PROCEDURE|Fat Grafting|
40988225|NCT02974296|DEVICE|transcranial magnetic stimulation|non invasive brain stimulation approach
40988226|NCT03229668|DRUG|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
40988227|NCT03229668|DRUG|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
40988228|NCT03229668|DRUG|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
40988229|NCT06519188|OTHER|Nebulization application with 5 ml isotonic sodium chloride|Nebulization application with 5 ml isotonic sodium chloride in the morning and evening for two months.
40988230|NCT01818076|DRUG|Botulinum Toxin Type A|Botulinum toxin type A, Dose A applied to the lateral canthal area
40783999|NCT03719807|OTHER|Usual Care|No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
40784000|NCT00049361|DRUG|temozolomide|
40784001|NCT00049361|DRUG|thalidomide|
40988231|NCT04623918|OTHER|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
40988232|NCT04623918|OTHER|Control rice|Control rice (C4), identical in appearance
40988233|NCT04716387|OTHER|Standard LLIN|Long-lasting insecticidal net containing alphacypermethrin, a pyrethroid insecticide, and manufactured by Shobikaa Impex Private Limited.
40988234|NCT04716387|OTHER|Piperonyl butoxide ITN|Insecticide treated net containing permethrin, a pyrethroid, and piperonyl butoxide, an insecticide synergist, manufactured by Sumitomo Chemical.
40988235|NCT04716387|OTHER|Pyriproxyfen ITN|Insecticide treated net containing alpha-cypermethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, manufactured by Disease Control Technologies.
40784002|NCT00049361|RADIATION|radiation therapy|
40784003|NCT00894387|DRUG|Aliskiren|Aliskiren 150 mg and Aliskiren 300 mg
40784004|NCT00894387|DRUG|Placebo|Placebo
40988236|NCT04716387|OTHER|Chlorfenapyr ITN|Insecticide-treated nets containing two active ingredients: alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide, manufactured by BASF.
40988237|NCT01754844|DRUG|AZD7624|Single dose inhaled IMP via a nebulizer
40988238|NCT01754844|DRUG|Placebo to match|Single dose inhaled Placebo via a nebulizer
41306431|NCT04393636|OTHER|Digital cardiac Counseling|"* Screening for reduced physical fitness and digital counseling.~* Screening for smoking and digital counseling.~* Screening for malnutrition and obesity and digital counseling.~* Screening for anxiety and depression and digital counseling.~* Screening for elevated pulmonary risk score and digital counseling."
41306432|NCT02283606|DEVICE|Accuvix SnonAce UGEO|vaginal ultrasonography
40988239|NCT01748981|OTHER|Physical training|"Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls"
40988240|NCT01748981|OTHER|As usual|Controls, not training
40988241|NCT05316389|PROCEDURE|Breast reconstruction|Muscle sparing Latissimus Dorsi Flap or prothesis
40988242|NCT05548842|DIETARY_SUPPLEMENT|The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill|The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill 1,000 mg/day for 4 weeks
40988243|NCT05548842|DIETARY_SUPPLEMENT|Placebo group|Placebo 1,000 mg/day for 4 weeks
40988244|NCT02542878|DEVICE|Foam roller|A bout of 60 seconds of myofascial release with foam roller
40988245|NCT05461677|DEVICE|SAIRE smart walker|Participants will walk along the 10-meter walkway 5 times using the SAIRE smart walker
40988246|NCT05461677|DEVICE|Standard 4-wheeled walker|Participants will walk along the 10-meter walkway 5 times using a standard 4-wheeled walker
40988247|NCT05461677|OTHER|No walking aid|Participants will walk along the 10-meter walkway 5 times without using a walking aid
40988248|NCT03475381|DRUG|Ivacaftor+lumacaftor|1 year follow-up after initiation of ivacaftor+lumacaftor
40988249|NCT00914862|DRUG|Ramelteon|Ramelteon tablets, orally for one day only.
40988250|NCT04325958|DRUG|Cannabis|750mg cigarette of plant material
40988251|NCT04325958|DRUG|Placebos|750mg cigarette of plant material
41145745|NCT03662737|DIAGNOSTIC_TEST|Visuomotor adaptation task|We will measure performance of the subjects of each group on the visuomotor adaptation task, especially in the rotation condition, in which a perturbation will be induced between the anticipated location of the hand and the provided visual feedback, and in the washout condition, in which the rotation will be removed. We expect that subjects with cannabis use disorder will not show the expected implicit motor adaptation to the perturbation and consequently no deterioration of performance on the task, due to cannabis-induced cerebellar damage. In other words, we want to show that this visuomotor task is a cheap and quick biomarker of cerebellar dysfunction in chronic cannabis users.
41306433|NCT02555644|DRUG|Prexasertib|Administered IV
41306434|NCT02555644|DRUG|Cisplatin|Administered IV
41306435|NCT02555644|DRUG|Cetuximab|Administered IV
40988252|NCT05104034|BEHAVIORAL|Osteoporosis screening and treatment as needed|All residents underwent screening using the Fracture Risk Assessment Tool (FRAX) and Mobile dual-energy X-ray absorptiometry (DXA) (Horizon Wi, Hologic Inc., Bedford, MA). Our study nurses actively assisted osteoporosis treatment if indicated.
40988253|NCT05104034|BEHAVIORAL|Sarcopenia|Sarcopenia assessment adhered to the 2019 Consensus Update on Sarcopenia Diagnosis and Treatment by the Asian Working Group for Sarcopenia guideline. Following screening, individuals identified with sarcopenia underwent tailored interventions involving exercise and nutrition as deemed necessary.
40988254|NCT05104034|BEHAVIORAL|Exercise|TheraBand (resistance band) was utilized as the exercise tool within the community. T
40988255|NCT05104034|DIETARY_SUPPLEMENT|Nutrition|Nutrition Nutritional education programs aim to increase protein food serving and the choice of those with insufficient dietary intake. Protein supplement was added if indicated.
40988256|NCT05104034|BEHAVIORAL|Pharmaceutical care|We collected drug information of the elderly. Detailed and real-time prescription drug information was retrieved from the National Health Insurance PharmaCloud System. A pharmaceutical care team performed patient-centered drug review and discussion every three to six months.
40988257|NCT06323460|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40988258|NCT06323460|DRUG|Carboplatin|Given IV
40988259|NCT06323460|DRUG|Cisplatin|Given IV
40988260|NCT06323460|PROCEDURE|Computed Tomography|Undergo PET/CT
40988261|NCT06323460|RADIATION|External Beam Radiation Therapy|Undergo external beam radiotherapy
40988262|NCT06323460|DRUG|Paclitaxel|Given IV
41464967|NCT01989676|DRUG|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
40784005|NCT05837533|OTHER|Communication model|During the medical consultation of each patient assigned to the intervention group, the oncologist will use the systematic communication model for patients with metastatic breast cancer. For this, the oncologist will follow the conversation guide for patients with metastatic breast cancer, which will allow directing the conversation towards information about the patient's diagnosis, treatment and prognosis. The guide consists of a series of steps and questions to be asked to the patient in order to explore her understanding of her disease and her information preferences, as well as to facilitate the oncologist providing said information to the patient. The responses to each item in the guide will be electronically documented by the oncologist.
40988263|NCT06323460|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40988264|NCT06323460|OTHER|Questionnaire Administration|Ancillary studies
40988265|NCT04489576|PROCEDURE|Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)|Hair will be treated with 2 different types of keratin in groups 1 \& 2. All steps of keratin application will be done in group 3 without keratin application as a control group.
41306436|NCT02555644|RADIATION|Intensity Modulated Radiation Therapy|
40988266|NCT04243187|OTHER|Chilean Native Beans|"In each visit the participant would have to:~1. Fill a survey of gastrointestinal symptoms and basal bowel movements (THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS))~2. Fill a survey of food consumption~3. Bean plate intake~4. Expired hydrogen test, which consists of exhaling air in a syringe every 20 minutes for 12 times (4 hours in total). During this time the participant can do quiet activities (not physical activity).~5. Fill surveys of gastrointestinal symptoms (online or on paper), during the hydrogen test, at 12 and 24 hours (3 times). During this time (1 day before and 2 days later) the participant cannot eat other bloating foods (legumes, cauliflower, broccoli, lettuce, cabbage, artichokes, onions, topinambur and others described in the food survey)."
40988267|NCT04906551|DEVICE|laser Doppler|A direct measure of blood flow
40988268|NCT02401880|DRUG|Linagliptin|22 subjects will receive Linagliptin for 30 days
40988269|NCT02401880|OTHER|Placebo|22 subjects will receive Placebo for 30 days
40988270|NCT02401880|DRUG|Empagliflozin|44 subjects will receive Empagliflozin for 60 days
40988271|NCT02099097|OTHER|web-based video game (Quit IT)|
41145746|NCT03479502|DRUG|Methylprednisolone Injectable Product|3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
41145747|NCT03479502|DRUG|Doxycycline Injection|3 intra-articular injections of Doxycycline Injection spaced every two weeks
41145748|NCT00739024|DRUG|Ramelteon|8 mg tablet, oral, once daily
41306437|NCT01272297|DEVICE|LI-ESWT|Low intensity shock wave treatment - 12 sessions
41306438|NCT06467643|PROCEDURE|non-instrumented root canal treatment with passive ultrasonic activation of heated sodium hypochlorite|Root canals were irrigated with room temperature 5.25% sodium hypochlorite which was activated ultrasonically for 30 seconds and then intra-canal heated using a heat carrier to a temperature fixed at 150 degree celsius. Three consecutive cycles of PAU and intra-canal heating of sodium hypochlorite were performed. After the first and the last cycle, root canals were irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) and kept in the canal for 60 seconds and then flushed out with 5 mL of saline. Root canals of this group were kept un-instrumented.
40784006|NCT00776789|OTHER|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
41145749|NCT00739024|DRUG|Placebo|Placebo tablet, oral, once daily
40784007|NCT00776789|OTHER|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
40784008|NCT01247623|BIOLOGICAL|GV1001|
40784009|NCT01873105|OTHER|Health Team Educational Intervention|AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
40988272|NCT02099097|BEHAVIORAL|Questionnaires|In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
40988273|NCT02099097|OTHER|Salvia sample|The investigators will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
40988274|NCT00660530|DRUG|Lanthanum Carbonate Chewable Product|Lanthanum carbonate 1 g to be chewed, three times daily with meals
41145750|NCT03840278|DEVICE|Bihormonal iLet Bionic Pancreas|Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon
41306439|NCT06467643|PROCEDURE|conventional root canal treatment with passive ultrasonic activation of heated sodium hypochlorite|Root canals were convetionally prepared using Reciproc Blue rotary files according to the manufacturer's instructions. Once the instrumentation was done, the canal was irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) kept for 60 seconds and then flushed with 5 mL of saline. NaOCl was placed in the canal and PUA followed by intracanal heating was performed three times as described for group 1 (IHAN).
41306440|NCT01609803|OTHER|laboratory biomarker analysis|Correlative studies
41306441|NCT05818527|DEVICE|Acceledent vibrating device|used to accelerated the movement of teeth during orthodontic treatment
41306442|NCT06043206|PROCEDURE|Bariatric Surgery|Bariatric Surgery
41306443|NCT01560728|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Individual psychotherapeutic approach occurring once per week for 12 to 20 weeks
41306444|NCT02290886|OTHER|Intravenous administration of placebo|
41306445|NCT02290886|DRUG|Intravenous administration of 1 million of MSC|
41306446|NCT02290886|DRUG|Intravenous administration of 2 million of MSC|
41306447|NCT02290886|DRUG|Intravenous administration of 4 million of MSC|
41306448|NCT04398992|OTHER|observation|Data were collected by a designed form. Statistic software was used to analyze clinical data.
40784010|NCT04859998|BEHAVIORAL|dog-assisted therapy|It will consist of 20 sessions conducted twice a week in the facilities of the association. It will involve different activities and physical exercises facilitated by the dogs. The program will be conducted in two associations (12 participants in each one, 6 belonging to the experimental and 6 belonging to the control group in each association) and in groups of three participants.
40784011|NCT00928967|DRUG|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
40784012|NCT05604261|DRUG|Anaprazole sodium 40 mg|Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
40784013|NCT05604261|DRUG|Anaprazole sodium 60 mg|Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
40784014|NCT05604261|DRUG|Rabeprazole sodium 20 mg|Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
40988275|NCT00660530|DRUG|Lanthanum carbonate crushed powder|Lanthanum carbonate (Fosrenol) 1 g crushed into a fine powder, three times daily with meal
41145751|NCT03840278|DEVICE|Insulin-only Bionic Pancreas|Insulin-only iLet Bionic Pancreas using just insulin
41145752|NCT03840278|DRUG|Dasiglucagon|Experimental stable glucagon for use in the iLet Bionic Pancreas
41145753|NCT03918733|PROCEDURE|surgical treatment|surgical treatment will be done of failed root canal treated teeth
41145754|NCT03918733|PROCEDURE|Non surgical retreatment|Non surgical retreatment will be done.
41145755|NCT02079402|DRUG|Isotonic crystalloids|
41145756|NCT04873544|PROCEDURE|ERAS protocols for TKA|ERAS protocols for TKA
41145757|NCT03928821|BIOLOGICAL|PGT121|20 mg/kg administered intravenously
41145758|NCT03928821|BIOLOGICAL|PGDM1400|20 mg/kg administered intravenously
41145759|NCT03928821|BIOLOGICAL|10-1074|20 mg/kg administered intravenously
41145760|NCT03928821|BIOLOGICAL|VRC07-523LS|20 mg/kg administered intravenously
41306449|NCT00964548|DRUG|Dantrolene|1.25 mg/kg IV once over 60 min
41306450|NCT00964548|DRUG|Dantrolene|2.5 mg/kg IV once over 60 min
41306451|NCT04748224|DRUG|Bupivacaine 0.25% Injectable Solution|a local anesthetic drug
41306452|NCT04748224|DRUG|bupivacaine plus dexmedetomidine|bupivacaine is a local anesthetic drug plus dexmedetomidine is a new generation highly selective α2-adrenergic receptor (α2-AR) agonist that is associated with sedative and analgesic sparing effects
41306453|NCT05485272|OTHER|Silver Diamine Fluoride combined with Potassium Iodide.|Riva Star, Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia.
41306454|NCT05485272|OTHER|Silver Diamine Fluoride.|A clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride.
41306455|NCT05485272|OTHER|High-Viscosity Glass Ionomer.|A Glass Hybrid material.
40988276|NCT03668938|OTHER|Occupational Therapy|The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.
40784015|NCT01166347|DEVICE|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
40784016|NCT01166347|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
40784017|NCT03345303|DRUG|Bortezomib|Bortezomib Injectable Solution
40784018|NCT04960124|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
40988277|NCT03668938|OTHER|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
40988278|NCT02596581|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
40988279|NCT04599374|OTHER|no intervention|This study collected data only without any intervention.
40988280|NCT02391740|OTHER|Questionnaire|
41464968|NCT04318431|DIAGNOSTIC_TEST|Data collection and rhinopharyngeal swab|Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology
40784019|NCT05710250|BEHAVIORAL|6-week MBSR program|"Participants will follow a 6-week program of mindfulness meditation. MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 6 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
40988281|NCT05317533|PROCEDURE|cardiac catheterization via distal radial artery|cardiac catheterization via distal radial artery
40988282|NCT06127992|DEVICE|Cold stimulation tests / critical temperature threshold|ICT was performed following a standard protocol. Briefly, a melting ice cube in thin plastic bag was placed on the volar surface of the patient forearm for 5 min, with macroscopic assessment of the test site 10 min later. TempTest® CSTs were done with TempTest® 4.0 (Courage \& Khazaka, Cologne, Germany), which has a single Peltier element (length: 350 mm, width: 2 mm) that provides a continuous temperature gradient from 4°C to 44°C. The use of TempTest® allows for reproducible and standardized cold (and heat) provocation tests and the identification of CTTs. TempTest® CST results were also assessed 10 min after the end of cold exposure.
41464969|NCT00810706|DRUG|exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years.
41464970|NCT00248937|BEHAVIORAL|Positive affect and self-affect induction|
41464971|NCT04162587|OTHER|Carotid duplex+/- MRA neck|Carotid duplex and or MRA neck
41145761|NCT03362853|DRUG|Nemonoxacin 500Mg Capsule|Receive a single dose in a fasting state
41306456|NCT03793478|DRUG|Quizartinib|"Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28"
40988283|NCT01840709|BEHAVIORAL|Psychotherapy|Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
40988284|NCT00598247|DRUG|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
40988285|NCT01254526|DRUG|GDC-0980|Oral repeating dose
40988286|NCT01254526|DRUG|bevacizumab|Intravenous repeating dose
40988287|NCT01254526|DRUG|paclitaxel|Intravenous repeating dose
40988288|NCT05025189|OTHER|Table Grape Powder|Freeze Dried Whole Table Grape Powder
41464972|NCT04162587|OTHER|brain MRA+/-CT angio on carotid and brain|brain MRA and or CT angiography on carotid and brain
40988289|NCT05025189|OTHER|Beige Diet|Low Fiber, low polyphenol Diet
40988290|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
40988291|NCT03762148|DIETARY_SUPPLEMENT|ferrous sulphate|nutritional iron (14 mg) supplement in form of ferrous sulphate
40988292|NCT03762148|DIETARY_SUPPLEMENT|ferric pyrophosphate|nutritional iron (14 mg) supplement in form of ferric pyrophosphate
40988293|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 3.5 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)
40988294|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 7 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)
40988295|NCT03762148|DIETARY_SUPPLEMENT|ferrous sulphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)
40988296|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C
40988297|NCT03762148|DIETARY_SUPPLEMENT|ferric pyrophosphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)
40988298|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 7 g GOS + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C
41145762|NCT03362853|DRUG|Moxifloxacin 400Mg Tablet|Receive a single dose in a fasting state
41464973|NCT04162587|OTHER|MRI brain|MRI brain with diffusion to detect asymptomatic stroke
41464974|NCT04162587|OTHER|DSA (digital subtraction angiography)|DSA (digital subtraction angiography) in some cases to confirm diagnosis.
41145763|NCT03362853|DRUG|Nemonoxacin 750Mg Capsule|Receive a single dose in a fasting state
41145764|NCT03362853|DRUG|Placebo oral capsule|Receive a single dose in a fasting state
41306457|NCT03793478|DRUG|Fludarabine|30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
41306458|NCT03793478|DRUG|Cytarabine|"2000 mg/m\^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m\^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m\^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18"
41464975|NCT00676494|DEVICE|Pathway PV Atherectomy System|The Pathway PV Atherectomy System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic debris and thrombus in lower limb peripheral vasculature during percutaneous interventional procedures.
41464976|NCT04047953|DRUG|Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1|Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40\~60mg，bid, d1-14( BSA\<1.25m2，40mg；1.25m2≤BSA≤1.5m2，50mg；BSA\>1.5m2，60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\\PR\\SD and decided by the investigator to continue the treatment for two cycles or directly.
41464977|NCT00090116|DRUG|Neramexane|
41464978|NCT04100096|DRUG|Brexpiprazole|Tablet
41464979|NCT04100096|OTHER|Placebo|Tablet
41464980|NCT04543331|DRUG|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
41464981|NCT03011060|PROCEDURE|Neo-adjuvant Chemotherapy|A preoperative chemotherapy based on anthracyclines and taxanes.
41464982|NCT03011060|DRUG|Capecitabine|Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
41464983|NCT00813345|OTHER|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
41464984|NCT00813345|OTHER|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
41464985|NCT00269334|DRUG|Using Citalopram(drug) or Paroxetine(drug)|
40988299|NCT03808051|PROCEDURE|Physiological-based cord clamping|See Arm description.
40988300|NCT03808051|PROCEDURE|Time-based cord clamping|See Arm description.
41145765|NCT03108222|OTHER|Phosphorus Absorption Test|Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
41145766|NCT00833599|DRUG|NIRFLI with ICG|We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
41464986|NCT01636817|DRUG|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
41464987|NCT01636817|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
40988301|NCT01057420|DRUG|oxygen inhalation|Inhalation of 80% oxygen via face mask
41145767|NCT02259959|DRUG|Single rising doses of BI 1744 CL, solution for oral inhalation|
41306459|NCT03793478|DRUG|Intrathecal (IT) triple chemotherapy prophylaxis|IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
41306460|NCT03793478|DRUG|Etoposide|"Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m\^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5"
41464988|NCT02438540|DRUG|metformin|metformin tablet 500 mg
41464989|NCT02438540|OTHER|acupuncture|Electro body acupuncture and auricular acupuncture
40988302|NCT00832585|DRUG|Alefacept|Alefacept 15mg IM every week for 12 weeks
40988303|NCT04814420|DEVICE|Delayed enhancement magnetic resonance imaging (DE-MRI)|The patient will be injected with late gadolinium enhancement (0.01 mmol/kg standard dosage), which is a contrast agent used in clinical practice in MRI imaging studies. The contrast agent is used to enhance specific regions/tissues on MRI and, in this study, will allow the investigators to identify fibrotic tissue within the heart. The patient then undergoes the MRI sequence, which lasts approximately 20-25 minutes. Images will be reviewed for quality by trained technicians. This will be repeated after 6 months.
41306461|NCT03828084|DRUG|Decitabine|Combination drugs containing decitabine and tetrahydrouridine
40988304|NCT04573595|DEVICE|Blood Pressure Measurement|The purpose of this study is to provide supporting documentation for Noninvasive blood pressure measurement accuracy claims for Fresenius 5008S BPM Module and Cuffs on the intended population(s). The same arm sequential method with dual observer auscultation will be used to collect data.
40988305|NCT05153954|OTHER|Quantitative Indocyanine Green Fluorescence Angiography|Quantitative analyse of ICG around the proximal/oral part of the anastomosis pre-formation of the primary anasomosis
41306462|NCT00399984|BEHAVIORAL|Asthma Education Program|interactive seminars regarding daily inhaled corticosteroids
41306463|NCT04236479|BIOLOGICAL|BM-MSC|Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
41306464|NCT04435262|OTHER|Remote Monitoring|Remote Monitoring Follow-up
41464990|NCT00671567|DRUG|Ramelteon|Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
41464991|NCT00671567|DRUG|Ramelteon|Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
41464992|NCT00671567|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
41145768|NCT02259959|DRUG|Tiotropium, fixed dose, solution for oral inhalation|
40988306|NCT01894581|DIETARY_SUPPLEMENT|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
40784020|NCT05710250|BEHAVIORAL|6-week muscular relaxation program|"Control group : This group will follow a 6-week program of progressive muscle relaxation training in order to learn achieving a deep relaxation of the body through voluntary tensing and relaxing muscles. It proceeds by the individual sequentially tensing and then releasing specific groups of muscles throughout the body, and noticing how tension feels relative to relaxation.~The accomplishment of physical relaxation promotes mental calmness in a parallel manner. This program is based on the work of Bernstein and Borkovec and Jacobson, and will be structured in 6-week group with weekly two and half hours sessions and out-of-session assignments for at-home practice (30-min daily)."
41306465|NCT02623036|DRUG|Equivalent dose enalapril|Chronotherapy with enalapril.
40784021|NCT01234493|PROCEDURE|fixation|Syndesmosis fixation with one 3.5mm fully threaded three cortical screw
40784022|NCT01234493|PROCEDURE|no fixation|No syndesmosis fixation.
40784023|NCT01186250|DRUG|Pioglitazone|15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
40784024|NCT01186250|DRUG|Placebo|placebo taken daily for one year
41145769|NCT02259959|DRUG|Placebo|
41145770|NCT06500117|OTHER|eMind application|learning phase accompanied by application for 8 weeks, then independent practical application phases
41306466|NCT02623036|DRUG|Equivalent dose lisinopril|Chronotherapy with lisinopril
41306467|NCT00375882|PROCEDURE|hypothermia|
41306468|NCT00375882|PROCEDURE|cochlear implantation with mild hypothermia|
41306469|NCT00127556|PROCEDURE|Label applied to blood bag|
41306470|NCT01613014|DRUG|ABT-436|Target dose - 400mg BID
40784025|NCT00750230|DIETARY_SUPPLEMENT|NEM|see Treatment Arm
40784026|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected intravenously with a dose of 0.3μg/kg, 1μg/kg, 3μg/kg, 6μg/kg, 12μg/kg, 24μg/kg, 36μg/kg, 48μg/kg or 64μg/kg until disease progresses or unacceptable tolerability occurs;
40784027|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected intravenously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
40784028|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected subcutaneously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
40784029|NCT04414293|RADIATION|Lung Low Dose Radiation|The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
40784030|NCT06078826|OTHER|passive music therapy|30 minutes before tracheal aspiration to intubated patients connected to mechanical ventilator treated in the 3rd step intensive care unit. and music between 60-74 dB will be played via headphones and MP3 player during aspiration (Şahin, 2018). This music is a 30-minute Hüseyni makam mp3 music recording . Hüseyni makam is effective in the morning and at dawn, and its effect is high between morning and noon. For this reason, passive music therapy practice in the research will be done by the researcher in the morning and afternoon. This maqam has beauty, benevolence, silence, comfort, a sense of peace and a refreshing feature. It has positive effects on the liver, heart, internal organs and spirit and unites with nature.
41145771|NCT06500117|OTHER|questionnaires|"Visual Analogue Scale VAS (craving) and Mobile Application Rating Scale MARS-F"
41145772|NCT06500117|OTHER|focus groupe|Patients who so wish will be able to give us more detailed feedback on the application. The focus groups will be carried out between visit 3 and visit 4.
41145773|NCT01895868|OTHER|Simulation-based ultrasound training|
41145774|NCT04279054|DRUG|Morphine Sulfate 150 mcg|Use of 150mcg of morphine sulfate for neuraxial block (dosing difference)
41145775|NCT04279054|DRUG|Morphine Sulfate 50mcg|Use of 50mcg of morphine sulfate for neuraxial block (dosing difference)
41306471|NCT01613014|DRUG|Matched Placebo - Sugar Pill|Target Dose - 2 pills BID
41306472|NCT03648476|BEHAVIORAL|ICAN|A 6-week group therapy sessions once a week for 90-120 minutes.
41306473|NCT06367868|PROCEDURE|After 5 ml CSF Drainage|Optic Nerve Sheath Diameter and Intracranial Pressure measurements will be after 5 ml CSF drainage
41306474|NCT05208424|DIAGNOSTIC_TEST|Coronary angiography|Invasive coronary angiography
41306475|NCT04358042|OTHER|Brief Psychiatric Rating Scale|The Abbreviated Psychiatric Rating Scale is a clinical scale for measuring symptomatic change in psychiatric inpatients for various conditions. It includes an accurate and complete description of the major characteristic symptoms. It is based both on patient responses and on observations made during the interview by the clinician. The usual reference period is the last two weeks.
41306476|NCT04358042|OTHER|Depression, Anxiety and Stress Scale|"evaluation of 3 dimensions of psychological distress: depression, anxiety and stress. The scale consists of 21 items and the patient is instructed to choose for each item the one that best corresponds to his or her experience over the past week, on a scale of 0 (does not apply to me at all) to 3 (applies entirely to me, or the vast majority of the time). A score is calculated for each dimension according to a predefined rating."
40988307|NCT01894581|DRUG|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
40988308|NCT00507754|OTHER|T-SPOT TB test|Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
40988309|NCT03346499|BIOLOGICAL|NK cells and IL-2|Natural Killer Cells
40988310|NCT04171687|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg tablet
40988311|NCT04171687|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
40988312|NCT04171687|DRUG|RAPA113|RAPA113 tablet
40988313|NCT06203847|DRUG|Combination group|Combination of epinephrine (Adrenaline® 1mg/vial) every 3 minutes, vasopressin (Pitressin® 20Unints/vial) every 3 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)
40988314|NCT06203847|DRUG|Standard group|standard doses of epinephrine (Adrenaline® 1mg/vial) every 3 minutes
40988315|NCT05294172|DRUG|KL-A167|KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.
40988316|NCT05294172|DRUG|Gemcitabine|4-6 cycles for combined therapy
41464993|NCT04750668|OTHER|Multisensory Balance Training|Multisensory Balance training includes 30 minutes per day, 5 days a week for 4 weeks, using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system, postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
41464994|NCT06291090|BEHAVIORAL|OUD treatment intervention|Participants received education on the diagnosis and management of OUD, have access to protocols to walk them through assessment of OUD using Diagnostic and Statistical Manual, fifth Edition (DSM)-5, COWS score to calculate severity of opioid withdrawal, buprenorphine or methadone initiation with pre-populated orders, and clickable links for OUD treatment referral post discharge.
41464995|NCT00480324|BIOLOGICAL|Rotarix|Two-dose oral vaccination.
41464996|NCT00480324|BIOLOGICAL|Placebo|Two-dose oral administration.
41464997|NCT02725424|DRUG|S-1|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
41464998|NCT02725424|DRUG|Trastuzumab|Her-2 positive patients with SOXT Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Trastuzumab: 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1 Every 3 weeks.
40988317|NCT05294172|DRUG|Cisplatin|4-6 cycles for combined therapy.
40988318|NCT05294172|DRUG|Placebo|4-6 cycles for combined therapy.Placebo maintenance.
40988319|NCT01798199|OTHER|The training by Verve System|
40988320|NCT03125070|OTHER|Best Practice and Internet site with links to existing resources|Receive usual care
40988321|NCT03125070|OTHER|Internet, Mobile app and Telehealth Intervention|Receive INSPIRE and survivorship care plan
40988322|NCT03125070|OTHER|Survey Administration|Ancillary studies
40988323|NCT01356745|DRUG|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
40988324|NCT01356745|DRUG|medical air|inhalation gas for inhalation use
40988325|NCT03900767|OTHER|Electronic Health Record intervention|AAC
41145776|NCT05852509|BEHAVIORAL|TPA4You|TPA4You integrates technology components in the form of video-conferencing (e.g., Zoom) with a health coach, wearable sensor (e.g., Fitbit), and personalized text messaging into a package to (a) tailor physical activity (PA) prescriptions based on the family care partners of persons with heart failure (HF-FCP)'s feedback and individual wearable sensor data, (b) provide tailored PA coaching sessions using video-conferencing, and (c) motivate daily exercise using text messages.
41464999|NCT02725424|DRUG|Oxaliplatin|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
40988326|NCT03900767|BEHAVIORAL|Smoking Cessation Intervention|Receive standard Utah Quitline treatment
40988327|NCT03900767|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
40988328|NCT03900767|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls
40988329|NCT00565968|DRUG|melphalan|
40988330|NCT00565968|DRUG|sorafenib tosylate|
40988331|NCT00565968|GENETIC|gene expression analysis|
40988332|NCT00565968|GENETIC|protein expression analysis|
40988333|NCT00565968|GENETIC|western blotting|
40988334|NCT00565968|OTHER|pharmacological study|
40988335|NCT03559322|DEVICE|iNAP® Lite Sleep Therapy System|Class II intraoral devices for snoring and/or obstructive sleep apnea
40988336|NCT06187610|BEHAVIORAL|Digital education|Patients assigned to the experimental group will learn about symptom self-management in a digital learning environment.
40988337|NCT00480272|DRUG|adalimumab, plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
40988338|NCT00480272|DRUG|adalimumab plus placebo|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
41465000|NCT02725424|DRUG|Docetaxel|Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks
41145777|NCT05852509|BEHAVIORAL|Attention control group|Participants will be given booklets, provided by the NIA, AHA, and National Alliance for Caregiving, that include content about self-care for FCPs' health and well-being, but not specific to PA or exercise. Participants will receive text messages every other day to encourage them to wear the Fitbit device, and to provide friendly greetings and reminders of upcoming survey data collection.
41306477|NCT04358042|OTHER|Impact of Event Scale-Revised|is a 22-item self-questionnaire that measures perceived stress in reference to a traumatic event during the previous 7 days. Each item is rated on a scale ranging from 0 (not at all) to 4 (extremely) and 3 sub-scores of post-traumatic symptoms are calculated: Revivification, Avoidance, Psychophysiological Activation, as well as a total score of severity of the state of stress. Acute Stress Disorder (ASD) and Post-Traumatic Stress Disorder (PTSD) share the same symptoms, the former lasting between 3 days and one month, while the latter is diagnosed when symptoms persist beyond one month. Since the exposure to the stressful event will have occurred less than a month ago, this questionnaire here will help identify a state of acute stress. A total R-ESI score equal to or greater than 33 suggests a significant level of symptoms
41306478|NCT04358042|OTHER|Connor-Davidson Resilience Scale 10 items (CD-RISC 10)|"Self-questionnaire composed of 10 items, evaluating the resilience capacities of patients. Resilience may act as a moderator against the symptoms of PTSD. This instrument uses a 5-point Likert-type response scale ranging from 0 Not true at all to 4 True most of the time."
40784031|NCT06078826|OTHER|foot massage|Massage will be applied by the researcher in the research. Towel, sponge, etc. under the foot to be worked on. The foot will be held at a 45 degree angle While applying, 1-2 drops of liquid Vaseline will be used to moisten the hand. A total of 30 minutes of foot massage will be made for each individual, 15 minutes per foot. Foot massage will start 30 minutes before the start of aspiration and massage will continue throughout the aspiration period. Since the speed of the massage movements and the number of repetitions should be at the normal frequency, the massage will be done at a speed that does not disturb the individual, has a non-stimulating and calming effect and does not tire the practitioner. In the massage, efflorescence (stroking), petrissage and friction (circular rubbing) movements that support circulation and relax the tissues will be used. Evaluations will be made before the foot massage, at the end of the foot massage and 30 minutes after the foot massage.
40784032|NCT02928861|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
40784033|NCT02404714|DEVICE|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
40784034|NCT01490034|BEHAVIORAL|Metabolic effects of consuming energy dense beverages|Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
41145778|NCT01116700|DRUG|Dexmedetomidine|Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
41145779|NCT04058847|OTHER|Your Heart Forecast|1 year follow up with Your Heart Forecast and a follow-up email every 2 weeks.
41145780|NCT05088733|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
41306479|NCT03278080|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
41306480|NCT03278080|OTHER|Car-following test|Driving with simulator program for DCV measurement
41306481|NCT03278080|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
41306482|NCT02805556|DRUG|BMS-663068|Single oral dose of BMS-663068
41306483|NCT02805556|DRUG|BMS-626529|Single intravenous dose of \[13C\]BMS 626529
41306484|NCT06553339|DRUG|Oral HS-10516|Oral HIF-2α inhibitor
41306485|NCT04536740|DEVICE|PDT treatment device|All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
41465001|NCT03297151|DIETARY_SUPPLEMENT|CONTROL|"Food grade mixture of non-essential amino acids in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10955"
41465002|NCT03297151|DIETARY_SUPPLEMENT|Whey Protein Concentrate|"Whey protein concentrate in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Trade name of product is Carbelac80 Instant Product Reference Number 10431"
41465003|NCT03297151|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|"Whey protein concentrate hydrolysate (degree of hydrolysate 27%) in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10468"
41465004|NCT02927834|DRUG|6 day Prednisone|6 day prednisone burst
41465005|NCT02927834|DRUG|Augmentin|Antibiotic augmentin for 3 weeks
41465006|NCT02927834|DRUG|21 day Prednisone|21 day prednisone burst
40784035|NCT01490034|BEHAVIORAL|energy dense solid food|Effects of consuming energy dense solid food for two weeks on physiological responses
40784036|NCT01490034|BEHAVIORAL|Energy dilute beverages|Effects of consuming energy dilute beverages for two weeks on physiological responses.
40784037|NCT01490034|BEHAVIORAL|Energy dilute solid food|Effects of consuming energy dilute solid food for two weeks on physiological responses
40988339|NCT06054087|PROCEDURE|Basal therapy+EA|"1. Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.~2. Main acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). Supporting acupoints: for pain in the upper limbs, add Baxie, Quchi (LI11), Shousanli (LI10), Hegu (LI4), and Ashixue; for pain in the lower limbs, add Bafeng, Neiting (ST44),Kunlun (BL60). Operation: Acupuncture needles of size 25\*40mm will be used. The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject."
40988340|NCT06054087|OTHER|Basal therapy|Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.
40988341|NCT01669915|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
41465007|NCT00519506|OTHER|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
41465008|NCT06374654|OTHER|Home-based Exercise Protocol|The home-based eccentric exercise protocol is a do-as-tolerated variation on the protocol described by Alfredson et al. in 1998. The protocol includes doing a series of heel raises, twice daily. No equipment is necessary. Patients will be given handouts and video links that depict and describe the exercises and their prescribed frequency.
40784038|NCT06451354|OTHER|Erector spinae plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided erector spinae plane block after spinal anesthesia and at the end of surgery. The erector spinae plane block will be performed by using bupivacaine 0.25% (20 ml in each side). Erector spinae plane block will be performed at the level of T9.
41145781|NCT05088733|OTHER|Routine medical care|Routine medical care
41465009|NCT06374654|OTHER|Formal Physical Therapy|Patients will be given a prescription for physical therapy consisting of 1-2 sessions per week for 6 weeks, with a renewal for another 6 weeks to be executed at the physical therapists' discretion. If an in-person visit is necessary for the renewal, or is requested by the physical therapist, the patient will be seen again in the office. Each patient will be given a release form to provide to his or her physical therapist. The release form will request a written record of all the treatment methods used by the physical therapist. Physical therapists who participate in the care of patients in this study will treat each patient using any and all methods that their professional experience deems clinically necessary.
41465010|NCT03847974|DRUG|LIB003|300 mg SC Q4W
41465011|NCT03359720|OTHER|no intervention survey|survey
41465012|NCT03785769|PROCEDURE|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by washing and drying the cavity with cotton balls; and fill with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
41465013|NCT03785769|PROCEDURE|HVGIC restoration with non pre-etching|Restoration with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
41465014|NCT01123291|PROCEDURE|follow-up coronary angiography|follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
40784039|NCT06451354|OTHER|Posterior Quadratus lumborum plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided quadratus lumborum plane block after spinal anesthesia at the end of surgery. The quadratus lumborum plane block will be performed by using bupivacaine 0.25% (20 ml in each side).
40784040|NCT06451354|OTHER|Lateral Transversus abdominis plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided transversus abdominis plane block after spinal anesthesia at the end of surgery. The transversus abdominis plane block will be performed by using bupivacaine 0.25% (20 ml in each side) to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest.
40988342|NCT01669915|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
40988343|NCT01669915|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
40988344|NCT01669915|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
41145782|NCT02594267|DRUG|Pralatrexate Injection|"Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone"
41145783|NCT03417375|PROCEDURE|Bilateral Sinus Augmentation|Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
41145784|NCT03751761|DRUG|durvalumab, tremelimumab, paclitaxel|Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
41465015|NCT01123291|PROCEDURE|Clinical follow-up|no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
41465016|NCT01189682|PROCEDURE|Tegaderm, Tegaderm HP, Tegaderm CHG|dressings on catheters
40988345|NCT04919577|DIAGNOSTIC_TEST|X-ray|We defined RSS as (1) the presence of symptoms such as nausea, vomiting, or abdominal fullness, (2) refasting after liquid or semi-liquid diets, (3) imaging methods (X-ray, CT, upper gastroenterography) confirmed without mechanical obstruction. All three conditions must be met at the same time and should occur within 30 days after operation.
41465017|NCT05310708|DIAGNOSTIC_TEST|Polysomnography|Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
41465018|NCT01734694|DRUG|Vancomycin|"Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;~Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;"
41465019|NCT01734694|DRUG|Ceftaroline|"Dose based on package insert labeling~CrCL \> 50 mL/min: 600 mg IV q12h~CrCL 31-50 mL/min: 400 mg q12h~CrCL 15-30 mL/min: 300 mg q12h~CrCL \< 15mL/min: 200 mg q12h;"
40988346|NCT03103919|DEVICE|Kinesia-ONE™|Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
40988347|NCT03103919|DEVICE|Kinesia-360™|Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
40988348|NCT03103919|DRUG|Rotigotine|All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
40988349|NCT02220582|OTHER|MRI|Magnetic Resonance Imaging
40988350|NCT05623267|DRUG|Sugemalimab|Recombinant anti-PD-L1 fully human monoclonal antibody
40988351|NCT05623267|DRUG|Placebo|Placebo of Sugemalimab
40988352|NCT00606476|DRUG|Bapineuzumab (AAB-001)|IV q13w
40988353|NCT03593265|OTHER|MUNIX|Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
40988354|NCT05847075|OTHER|Heat Therapy|Participants in the HT group will undertake whole body heat treatment according to previous methods. Participants will be housed in an environmental chamber initially set at 55.0oC on three non-consecutive days of the week during 12 weeks. Each session will last 60 min.
41145785|NCT02889809|DRUG|Fluticasone furoate|Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
41465020|NCT01734694|DRUG|Daptomycin|"Dose based on renal function and literature dosing recommendations~CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h~CrCL \< 30 mL/min: 6 - 10 mg/kg IV q48h"
41465021|NCT01734694|DRUG|Linezolid|600 mg IV/PO q12h
41465022|NCT02722616|DEVICE|Ultrasound scan of the pancreas|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery.
40784041|NCT01162551|DRUG|Sirolimus and Methotrexate|"Single Arm Efficacy Trial:~Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days."
41145786|NCT02889809|DRUG|Placebo|Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
41145787|NCT02889809|DRUG|Montelukast|Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (\>=6 year old subjects)
41145788|NCT02889809|DRUG|Short Acting Beta 2 Agonist|Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
40784042|NCT06482775|DRUG|dexmedetomidine|The dosing and administration will be implemented according to an algorithm based on pain scoring results
40784043|NCT05257382|PROCEDURE|ENB followed by trans-bronchial biopsy and trans-bronchial cryobiopsy|After having performed the ENB procedure to reach the identified lung lesion, biopsies will be performed (six forceps trans-bronchial biopsies and one trans-bronchial lung cryobiopsy)
40784044|NCT00001561|DRUG|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
40784045|NCT00001561|DRUG|GM-CSF|
40784046|NCT02524561|DRUG|CEE pill|Conjugated equine estrogens 0.45 mg/day
40784047|NCT02524561|DRUG|Estradiol patch|Climara 50 mcg/day
41306486|NCT05868876|DRUG|AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion|AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
40784048|NCT02524561|DRUG|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
41145789|NCT00396409|DRUG|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
41145790|NCT00396409|DRUG|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
41145791|NCT00396409|DRUG|Placebo|Placebo given during the 2006 core study
41145792|NCT01844063|GENETIC|Conventional plus BM-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
41145793|NCT01844063|GENETIC|Conventional plus UC-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
41465023|NCT02722616|DEVICE|Ultrasound scan of the Liver|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
40988355|NCT05847075|OTHER|StrengthTraining|Participants will perform supervised exercise in a gym on three non-consecutive days of the week. Each session will last \~60 min and will consist of a warm up, the resistance training and a cool down. All sessions will be conducted by qualified sport and exercise scientists for 12 weeks.
40988356|NCT05847075|OTHER|Sedentary Control|Participants will not receive any intervention during 12 weeks.
40988357|NCT06196333|DEVICE|Non-contact specular microscopy|using specular microscope to do morphological examination of corneal endothelial cells
40988358|NCT01754233|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser for epidermal and dermal pigmented lesions
40988359|NCT00350636|DRUG|Oxybutynin topical gel|1 application daily to skin for 12 weeks
40988360|NCT00350636|OTHER|Placebo topical gel|1 application daily to skin for 12 weeks
40988361|NCT05969288|OTHER|Behavioral survey|"Behavioral survey by administering a short self-administered questionnaire (read more in the Detailed description section)."
40988362|NCT04602832|OTHER|Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19|ENHANCE is a 12-session program designed to help improve subjective well-being, especially through the challenges of a pandemic. The ENHANCE program introduces and teaches people about the evidence-based principles and skills that have been shown across decades of research to improve overall health and well-being.
40988363|NCT03014323|DRUG|Galantamine|Galantamine 4 mg twice a day for 4 weeks
40988364|NCT03014323|DRUG|Placebo|Placebo 1 capsule twice a day for 4 weeks
40988365|NCT00696852|BEHAVIORAL|Mindfulness Meditation|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
40988366|NCT00696852|BEHAVIORAL|Yoga|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
40988367|NCT00696852|BEHAVIORAL|Exercise, Relaxation, and Health Education|The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
40988368|NCT01156311|DRUG|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
40784049|NCT02524561|OTHER|Placebo tablet|Placebo tablet
40784050|NCT02524561|OTHER|Placebo patch|placebo patch
40988369|NCT00413192|DRUG|E7389|1.4 mg/m\^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
40988370|NCT00487747|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
41306487|NCT02132234|DRUG|Etanercept|biological treatment according to rheumatologic indication
40988371|NCT02278107|DEVICE|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
40988372|NCT02278107|DEVICE|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
40988373|NCT03008083|DRUG|3 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
40988374|NCT03008083|DRUG|12 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
41306488|NCT02132234|DRUG|Adalimumab|biological treatment according to rheumatologic indication
41306489|NCT02132234|DRUG|Certolizumab|biological treatment according to rheumatologic indication
41306490|NCT02132234|DRUG|Infliximab|biological treatment according to rheumatologic indication
41306491|NCT02421328|DEVICE|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
41306492|NCT02421328|DEVICE|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
41306493|NCT05505565|DEVICE|Abbott Freestyle Libre 2|Subjects will be educated on use of Abbott Freestyle Libre 2 and educated on how daily activities impact glucose.
41306494|NCT05505565|OTHER|Standard physical activity and nutritional counseling for prediabetes management|Subjects will be advised on recommendations for nutrition and activity goals for preventing progression of prediabetes.
41306495|NCT05120622|DRUG|Tremelimumab|"Tremelimumab 25 mg / 50 mg / 75 mg local cystoscopic injection into bladder wall at or adjacent to site of prior tumour resection (dose divided into 4 injection sites), administered 6 and 3 weeks before radical cystectomy.~Durvalumab 1500mg via IV infusion administered 6 and 3 weeks before radical cystectomy."
41306496|NCT06502756|DEVICE|SOBER, mobile Application providing digital CBT|SOBER is a software application (Android) that delivers cognitive behavioral therapy (CBT) in a structured and interactive manner. It analyzes patterns in participants\&#39; lifestyles to identify problematic behaviors related to their alcohol consumption. By providing tailored guidance and support, the app aims to help individuals make sustainable changes, ultimately reducing hazardous drinking. This approach combines the principles of CBT with the convenience and accessibility of digital technology, offering a personalized experience to support the reduction of alcohol consumption.
41306497|NCT03227562|DRUG|RisperiDONE 0.5 MG|To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
40784051|NCT02524561|OTHER|Placebo progesterone|placebo progesterone
40784052|NCT05641935|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
40784053|NCT05641935|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
40784054|NCT05641935|PROCEDURE|Computed Tomography|Undergo CT
41145794|NCT01844063|DRUG|Conventional treatment|"Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma."
40784055|NCT05641935|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40784056|NCT05641935|OTHER|Electronic Health Record Review|Review electronic medical record
40784057|NCT01657370|DRUG|MK-1602|"Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
40784058|NCT01657370|DRUG|Placebo|"Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
40784059|NCT01657370|DRUG|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded."
40784060|NCT03271866|DRUG|metformin|metformin 1500mg per day
40784061|NCT06301503|DRUG|USG Guided Combined LPB-SNB with Isobaric Bupivacaine|Local anesthetic infiltration of 2% lidocaine (3ml) along with injection anaesthetic agent consisting of isobaric bupivacaine 0.25% (20 ml)
41465024|NCT02722616|DRUG|Reference ultrasound|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
41465025|NCT02902133|DRUG|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 5 days
40784062|NCT06301503|DRUG|Control|Local anesthetic infiltration of 2% lidocaine (3ml)
40784063|NCT02756403|DRUG|Azithromycin|500 mg
41465026|NCT01610024|DIETARY_SUPPLEMENT|Beetroot Juice|Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
41465027|NCT01652586|DRUG|dexmedetomidine-remifentanil|
40784064|NCT02756403|DRUG|Doxycycline|200 mg
40784065|NCT02756403|DRUG|Metronidazole|500 mg
40784066|NCT02756403|DRUG|Placebo|Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
40784067|NCT02171143|DRUG|ASP2409|intravenous (IV)
40784068|NCT02171143|DRUG|Placebo|intravenous (IV)
41465028|NCT01652586|DRUG|midazolam-remifentanil|
40784069|NCT05992129|OTHER|foot exercise|These are foot and ankle muscle strengthening exercises described and evaluated by the literature
40784070|NCT03251521|OTHER|pain rating during injection with botulinum toxin|The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection
40784071|NCT00698828|DRUG|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
40784072|NCT00698828|DRUG|SUN11031 20 μg/kg|Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
40784073|NCT00698828|DRUG|SUN11031 40 μg/kg|Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
40988375|NCT03844360|DRUG|Bortezomib|bortezomib was administered follow the doctor's advice.
40988376|NCT03844360|DRUG|Eltrombopag|eltrombopag was administered follow the doctor's advice.
40784074|NCT05232656|BEHAVIORAL|Pre-Discharge Checklist and Patient Safety Dashboard|Pre-discharge preparation checklist for patients to assess discharge readiness. Patient safety dashboard for clinicians to proactively identify at-risk patients.
40784075|NCT04347421|DIETARY_SUPPLEMENT|Krill oil group|This group takes 500 mg/day Krill oil for 12 weeks.
40784076|NCT04347421|DIETARY_SUPPLEMENT|Placebo group|This group takes 500 mg/day Placebo for 12 weeks.
40784077|NCT04883255|DRUG|10 mg Δ9-tetrahydrocannabinol (THC)|5-day course of orally-administered THC (dronabinol), 10 mg
40784078|NCT04883255|DRUG|600 mg cannabidiol (CBD)|5-day course of orally-administered CBD, 600 mg
40784079|NCT04883255|DRUG|Placebo|5-day course of orally-administered placebo
40784080|NCT05160948|OTHER|Informational Report|All EcoMAPPE participants and their caregivers will be invited to complete a questionnaire to assess their understanding of air pollution and attitudes and beliefs about science and research before and after receiving their individual study air pollution monitoring results collected as part of their participation in EcoMAPPE.
40784081|NCT01757665|DEVICE|Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M|Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
40988377|NCT03844360|DRUG|Imatinib|imatinib was administered follow the doctor's advice.
41465029|NCT04467099|OTHER|Foot Exam Follow-Up|All participants will have a clinical assessment of their surgery foot by the study doctor.
40784082|NCT02393859|DRUG|Blinatumomab|15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
40784083|NCT02393859|DRUG|Dexamethasone|10 mg/m\^2/day intravenous (IV) on Days 1-6
40988378|NCT03844360|DRUG|dasatinib|dasatinib was administered follow the doctor's advice.
41145795|NCT06181019|DRUG|50 mg of mirabegron|Patients in the control group were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks.
41145796|NCT06181019|COMBINATION_PRODUCT|acupuncture combined with mirabegron.|Patients in the treatment group were treated with acupuncture combined with mirabegron.
40784084|NCT02393859|DRUG|Vincrisitne|1.5 mg/m\^2/day IV on Days 1 and 6
40784085|NCT02393859|DRUG|Daunorubicin|30 mg/m\^2 IV over 24 hours on Day 5
40784086|NCT02393859|DRUG|Methotrexate|1 g/m\^2 IV over 36 hours on Day 1
40784087|NCT02393859|DRUG|Ifosfamide|800 mg/m\^2 IV for 1 hour on Days 2-4
40784088|NCT02393859|DRUG|PEG-asparaginase|1000 U/m\^2 IV for 2 hours or intramuscularly (IM) on Day 6
40784089|NCT02393859|DRUG|Erwinia-asparaginase|In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
40784090|NCT00066690|DRUG|Exemestane|Exemestane 25mg orally daily for 5 years plus ovarian function suppression
40784091|NCT00066690|OTHER|Laboratory Biomarker Analysis|Correlative studies
40784092|NCT00066690|PROCEDURE|Oophorectomy|Undergo bilateral surgical oophorectomy
40784093|NCT00066690|OTHER|Quality-of-Life Assessment|Ancillary studies
40784094|NCT00066690|RADIATION|Radiation Therapy|Undergo ovarian irradiation
40784095|NCT00066690|DRUG|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
40784096|NCT00066690|DRUG|Triptorelin|3.75 mg by im injection q28 days for 5 years
40784097|NCT00005989|DRUG|tipifarnib|
40784098|NCT05733689|DEVICE|ctDNA Blood Test|Blood will be collected for ctDNA testing
40784099|NCT05733689|COMBINATION_PRODUCT|FLOT|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Docetaxel 50 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 2600 mg/m2 continuous infusion over 24 hours daily on Day 1 Every 14 Days"
40784100|NCT05733689|COMBINATION_PRODUCT|FOLFOX|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
40784101|NCT05733689|COMBINATION_PRODUCT|FOLFIRI|"* Irinotecan 180 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
41465030|NCT04467099|RADIATION|X-ray|Standard x-ray of the foot.
40784102|NCT05733689|COMBINATION_PRODUCT|FOLFIRINOX|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Irinotecan 150 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 days"
40784103|NCT05733689|COMBINATION_PRODUCT|PACLITAXEL with or without CARBOPLATIN|"* Paclitaxel 200 mg/m2 IV on Day 1~* Carboplatin AUC 5 IV on day 1 Every 21 Days~OR~- Paclitaxel 80mg/m2 IV on Days 1,8,15 Every 28 Days"
40784104|NCT05733689|COMBINATION_PRODUCT|DOCETAXEL and IRINOTECAN (alone or combined)|"* Docetaxel 35 mg/m2 IV on Days 1 and 8~* Irinotecan 50 mg/m2 IV on Days 1 and 8 Every 21 Days~* Docetaxel 75 mg/m2 IV on Day 1 Every 21 Days~* Docetaxel 150 mg/m2 IV on Day 1 Every 14 Days"
40784105|NCT05733689|DRUG|NIVOLUMAB (alone or when added to a regimen above)|"* 240 mg IV on Day 1 every 14 days, or~* 360 mg IV on Day 1 every 21 days, or~* 480 mg IV on Day 1 every 28 days"
40784106|NCT05733689|DRUG|PEMBROLIZUMAB (alone or when added to a regimen above)|"* 200 mg IV on Day 1 every 21 days, or~* 400 mg IV on Day 1 every 42 days"
40784107|NCT00097630|PROCEDURE|SAT: Spontaneous Awakening Trial|
40784108|NCT00097630|PROCEDURE|SBT: Spontaneous Breathing Trial|
41465031|NCT04467099|OTHER|Questionnaire|All participants will complete a questionnaire.
40784109|NCT00299364|DRUG|Black Cohosh (iCR) or tibolone|
40784110|NCT04061109|DRUG|Recombinant Human Coagulation FVIII|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
40784111|NCT00947128|DRUG|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
40784112|NCT00947128|DRUG|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
40784113|NCT05142306|BIOLOGICAL|COVID-HIG|Anti-SARS-CoV-2 Immunoglobulin (Human) \[COVID-HIG\] is a purified liquid immunoglobulin G (IgG) preparation
40784114|NCT03888014|DEVICE|GLOW800|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
40784115|NCT03888014|DRUG|indocyanine green (ICG)|This is a standard medication which can be given IV during a surgery to better visualize blood vessels under the microscope
40784116|NCT01057628|DRUG|ipragliflozin|oral
40784117|NCT01057628|DRUG|placebo|oral
40784118|NCT05548764|PROCEDURE|Prevention Bundles for SSIs|10 preoperative, intraoperative and postoperative bundles that aim to decrease SSIs rate after their implementation in patients that underwent abdominal surgery.
40784119|NCT00112892|DIETARY_SUPPLEMENT|selenium|
40784120|NCT00112892|DRUG|irinotecan hydrochloride|
40784121|NCT00755170|DRUG|Vinorelbine|Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
40784122|NCT00755170|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
40784123|NCT00736983|DRUG|adalimumab|24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
40784124|NCT00736983|DRUG|ciprofloxacin|12 weeks; daily 2 x 500mg
40784125|NCT03174327|DIAGNOSTIC_TEST|Hepatic Transplantation|Systematic long-term monitoring of liver transplant patients includes an annual consultation and more comprehensive follow-up at one year, 5 years and 10 years of transplantation during which patients are hospitalized in day hospital hepatology and have a clinical examination Complete, biological assessment, Fibroscan® graft elastography measurement, hepatic Doppler ultrasound and liver biopsy. Measurement of liver stiffness by SuperSonic® will be added during ultrasound.
40784126|NCT00286650|PROCEDURE|3rd molar teeth extraction|
40784127|NCT04716894|DRUG|BI 474121|BI 474121 oral solution
40784128|NCT04716894|DRUG|Itraconazole|Itraconazole oral solution
40784129|NCT03906643|DRUG|HS-201|HS-201 will be administered intravenously as a single dose
40784130|NCT01173679|DRUG|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
41465032|NCT06031220|OTHER|deep breathing exercise inform of diaphragmatic and costal breathing|deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks,
40784131|NCT01173679|DRUG|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
40784132|NCT01173679|DRUG|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
40784133|NCT00741065|PROCEDURE|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
40784134|NCT01100281|BEHAVIORAL|Neuropsychological examination|Examination including especially concept formation
40784135|NCT01100281|OTHER|MRI|MRI performed in T1-weighted three dimensional sequence
40784136|NCT04778592|DRUG|ETX-018810|Study Drug
40784137|NCT04778592|DRUG|Placebo|Placebo
40784138|NCT00692003|DRUG|Zonisamide|"25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg; \>= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
40784139|NCT00692003|DRUG|Placebo|"25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg Zonisamide Placebo; \>= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
40784140|NCT05748821|DEVICE|Delfi Personal Tourniquet Systems|Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
40784141|NCT05117814|DRUG|Zanubrutinib|as long as 24 months or consolidated with ASCT or WBRT after achieving PR or CR
40784142|NCT04630483|OTHER|INHA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
40784143|NCT04630483|OTHER|TIVA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
40784144|NCT06179979|DIAGNOSTIC_TEST|PET/CT with 11C-PiB|Subjects considered suitable will undergo a clinical and neuropsychological evaluation and a PET/CT study with intravenous administration of 11C-PIB.
40784145|NCT04719221|DRUG|Evolocumab|The maximum dose of combined cholesterol therapy (Statin + Ezetimibe) is prescribed for 2 months, and a cholesterol test is performed in an outpatient clinic to ensure that LDL-Cholesterol \<70mg/dL is met. Patients who do not meet the criteria are randomized to maintain current treatment or receive additional Evolocumab according to randomization.
40784146|NCT04719221|DEVICE|NIRS IVUS|near-infrared spectroscopy
40784147|NCT01697111|DRUG|EE20/DRSP(BAY86-5300)|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
40784148|NCT01697111|DRUG|Placebo|One tablet (no active ingredient) / day and one tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day, for the first 24 weeks and the later 28 weeks, respectively
40784149|NCT01697111|DRUG|Dienogest|Dienogest 1mg twice a day (bid)
40784150|NCT03613064|OTHER|Socially Enhanced Transitional Care Intervention|Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.
40784151|NCT05187260|DRUG|Nusinersen|SPINRAZA® (nusinersen) prescribed as part of standard of care
40784152|NCT03083782|DRUG|Apixaban alone|A single dose of 10 mg apixaban administered orally at 0H on Day 1.
40784153|NCT03083782|DRUG|Cyclosporine|Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
40784154|NCT03083782|DRUG|Tacrolimus|Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
40784155|NCT03083782|DRUG|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
40784156|NCT03083782|DRUG|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
40784157|NCT03925363|DEVICE|Physical activity mobile-application|The active group will be given the feedback app and the control group the blind app
40784158|NCT04781816|DRUG|SAR443122|Pharmaceutical form: Capsule Route of administration: Oral
40784159|NCT04781816|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
40784160|NCT02448355|DEVICE|OCT swept source DRI-Atlantis, Topcon|3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
40784161|NCT02864264|DRUG|BMS-986184|
40784162|NCT02864264|DRUG|Placebo matching BMS-986184|
40784163|NCT05791214|OTHER|score|Creation and validation of new nurse' score in ICU
40988379|NCT03844360|DRUG|Pegaspargase|pegaspargase was administered follow the doctor's advice.
40988380|NCT03844360|DRUG|Anti-Infective Drugs|anti-infective drugs was administered follow the doctor's advice.
40988381|NCT03844360|DRUG|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor|pegaspargase was administered follow the doctor's advice.
40784164|NCT05738330|BEHAVIORAL|Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD)|Dialysis clinics randomized to the SMaRRT-HD group will use the SMaRRT-HD system to capture patient-reported symptoms and support clinician follow-up. The online system includes the patient symptom ePROM surveys, clinician real-time email alerts, clinician guidances for symptom management, and patient-facing symptom reports as well as an administrative dashboard supporting management of trial participants at clinics using SMaRRT-HD. Designated clinic personnel (i.e., patient care technicians and nurses) will receive training on how to use the system to administer the symptom ePROM surveys to patients on tablet computers. Designated clinic nurses and medical providers will receive training on how to access guidances for symptom management and patient-facing symptom reports in the SMaRRT-HD system. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.
40784165|NCT05738330|BEHAVIORAL|Usual Care|Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
40988382|NCT03071978|DEVICE|CRT with LV-only pacing / bi-ventricular pacing|LV-fusion pacing group received cardiac resynchronization therapy with adaptive algorithm and disabled RV pacing. While BV pacing group received conventional cardiac resynchronization therapy without adaptive algorithm.
40988383|NCT03164096|DRUG|Bupivacaine Hydrochloride|intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
41145797|NCT04454125|BEHAVIORAL|AQI intervention|The intervention arm will receive AQI education, an asthma action plan containing AQI information and recommendations, and will be required to demonstrate ability to check AQI (either via airnow.gov website or downloaded AirNow smartphone app).
41145798|NCT04454125|OTHER|Routine care|The routine care arm will be provided with general AQI education and an asthma action plan not containing AQI information.
40988384|NCT02135146|DRUG|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
40988385|NCT02135146|DRUG|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
40988386|NCT00136305|BEHAVIORAL|Pictorial asthma action plan|
40988387|NCT00136305|BEHAVIORAL|Written asthma action plan|
40988388|NCT04341142|DIAGNOSTIC_TEST|Serological tests will be applied on patients blood sampling|Application of tests on patients' serum
40988389|NCT01963403|DRUG|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
40988390|NCT01963403|DRUG|Placebo|1 pill per day; daily during study participation (up to 84 days)
40988391|NCT02402309|DRUG|Active topical NS2 1% dermatologic cream|
40988392|NCT02402309|DRUG|Vehicle placebo 0.0% NS2 dermatologic cream|
40988393|NCT01811173|OTHER|Nurse-physician comprehensive care|"Components of the intervention include:~1. Complete assessment of the patient's and family's needs conducted by the nurse.~2. Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.~3. Multimorbid care plan integrating all care aspects.~4. Action Plan for patients, supporting self management~5. Proactive monitoring according to the plan."
41145799|NCT04433247|BEHAVIORAL|Peer Led Group Intervention|Four week dissonance-based program wherein women with body image concerns complete verbal, written, and behavioral activities. The program consist of four 60-minute sessions.
41145800|NCT03508830|DRUG|Liposomal bupivacaine|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
41145801|NCT03508830|DRUG|Bupivacaine Injection|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
40784166|NCT03874767|BEHAVIORAL|Patient Mobility|A team of two mobility technicians will switch between two units on a monthly basis. The unit staffed by the mobility technician will be referred to as the intervention unit, while the other will be referred to as the control unit. One unit will start as the control unit and will switch to being the intervention unit after one month. Similarly, the other unit will start as the intervention unit and will switch to becoming the control unit after one month. All patients present on a unit during the intervention period will be provided mobility technician support according to standardized clinical guidelines that have been developed by the care team and described below. Patients who are present on a unit at the time of cross-over will not be included in the analysis, but will either no longer receive mobility technician support (if crossing from intervention to control) or will start to receive mobility technician support (if switching from control to intervention).
40784167|NCT04494685|DEVICE|Intervention group (Robotic rehabilitation)|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland). The training protocol has a progression of the board inclination up to 90º associated with flexion/extension movements of the knees and hips, with time evolution of up to 40 minutes. Such equipment is associated with electrostimulation of the quadriceps, hamstrings, sural triceps and anterior tibialis.
40988394|NCT05543941|DEVICE|XPERIENCE Advanced Surgical Irrigation|The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.
40784168|NCT04494685|OTHER|Control group (Conventional physiotherapy)|Knee and hip flexion and extension movements, hip adduction, and abduction, respecting the articular physiology of each joint. Weight transfer will also be performed in the sitting and standing position, mini squat, and gait training. All exercises will have a total of 10 repetitions in three sets. In the end, stretching of the upper and lower limbs will be performed.
40784169|NCT05123300|DIAGNOSTIC_TEST|18F-PSMA-1007|18F-PSMA-1007 is a tracer for a PET/CT. Prostate cancer often has marked uptake of PSMA, hence PSMA-PET/CT is in the guidelines in the European Union for detecting relapse. But we will use it for staging primary prostate cancer.
40784170|NCT01530373|DRUG|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
40784171|NCT01530373|DRUG|Clonidine|oral clonidine 0.1 mg daily for 3 weeks
40784172|NCT05833711|DRUG|Froniglutide|SC Weekly Injection
40784173|NCT05833711|DRUG|Placebo|SC Weekly Injection
40784174|NCT03154021|COMBINATION_PRODUCT|Next Science OTC Oral Rinse with Essential Oils|This group will receive Next Science Oral Rinse with Essential Oils and the other half will be give OTC Oral Rinse Control
40784175|NCT03154021|COMBINATION_PRODUCT|OTC Oral Rinse Control|This group will receive OTC Oral Rinse Control
40784176|NCT04255615|OTHER|AI to analyze 3 D ultrasound|AI to assess 3 D ultrasound to assess antral follicle count
40784177|NCT02725333|PROCEDURE|Shoulder Stabilization|Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
40784178|NCT03753022|OTHER|Group G5|Submitted to peep 5
40784179|NCT03753022|OTHER|Group G10|Submitted to peep 10
40784180|NCT03753022|OTHER|Group G15|Submitted to peep 15
40784181|NCT03807583|DRUG|Aminoven 10%|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care."
40784182|NCT03807583|DIETARY_SUPPLEMENT|RENORAL|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care."
40784183|NCT02633735|OTHER|Appy CDS|See description under arm/group section
40784184|NCT05245539|DRUG|CVL-231|CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.
40784185|NCT04960670|OTHER|Evaluation of microbiome and maternal/infant lifestyle|Identification of the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with adiposity rebound vs children with early adiposity rebound.
40784186|NCT01819272|DRUG|Met DR|metformin delayed-release tablets
40784187|NCT01819272|DRUG|Met XR|metformin extended-release tablets
40784188|NCT01819272|DRUG|Placebo|placebo delayed-release tablets
40784189|NCT05595746|PROCEDURE|dental implant placement|In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.
40784190|NCT02350218|DRUG|Eglandin|Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
40784191|NCT01466465|DRUG|Cholecalciferol|given orally, once daily, before grass pollen season
40784192|NCT01466465|OTHER|middle-chain fatty acids (carrier)|given orally, once daily, before grass pollen season
40784193|NCT04849637|DRUG|Virgin Coconut Oil|Oral supplementation of virgin coconut oil to COVID-19 patients
40784194|NCT02652221|DEVICE|Acoustic Radiation Force Imaging|ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
40784195|NCT05446714|DEVICE|CH 4 band|expansion of maxilla and observation improvement of the air way
40784196|NCT05446714|DEVICE|HH 2 bands|expansion of maxilla and observation improvement of the air way
40784197|NCT05446714|DEVICE|MSE 2 bands and 4|expansion of maxilla and observation improvement of the air way
40784198|NCT02797314|OTHER|Bone biopsies|Bone biopsies
40784199|NCT02920320|OTHER|Internet-based self-help program|
40784200|NCT03961802|OTHER|sessions of shoulder rehabilitation|3 sessions of shoulder rehabilitation per week for 3 months (36 sessions)
40784201|NCT05746858|OTHER|no intervention (observational study)|No intervention (observational study)
40784202|NCT03787329|OTHER|Core decompression surgery with bone marrow concentration|Core decompression surgery with bone marrow concentration
40784203|NCT03787329|OTHER|Core decompression surgery|Core decompression surgery only
40784204|NCT01088503|DRUG|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
40784205|NCT00098800|DRUG|fenretinide|
40784206|NCT04049500|OTHER|Digital Diabetes Prevention Program (dDPP)|dDPP tool suite to integrate with the EHR and clinical workflows
40784207|NCT05391230|OTHER|Permethrin-treated lesu|0.5% permethrin soaked baby wraps (lesus)
40784208|NCT05391230|OTHER|Untreated lesu|Water soaked baby wraps (lesus)
40784209|NCT01226303|DRUG|ATRA|see the protocol
40784210|NCT01226303|DRUG|ATRA + IDA|see the protocol
40784211|NCT01176760|DRUG|Dipeptidyl peptidase 4 (DPP 4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
40784212|NCT01176760|OTHER|oral glucose|50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
41145802|NCT02142478|BEHAVIORAL|Adapted Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week. In February 2012, Centre A introduced some changes to the EFH scheme as follows:~* Pre-scheme meeting with a health trainer to help the patient decide if EFH is for them.~* Participants offered specially tailored group classes (exclusive to EFH participants, e.g. low-impact circuits, Zumba) as well as access to the main gym.~* Opportunities to attend daily.~Although subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members) is also available, this option is not openly advertised on the adapted scheme."
40784213|NCT00101348|DRUG|erlotinib hydrochloride|Given orally
40784214|NCT00101348|BIOLOGICAL|cetuximab|Given IV
40784215|NCT00101348|BIOLOGICAL|bevacizumab|Given IV
40784216|NCT00101348|OTHER|laboratory biomarker analysis|Correlative studies
40784217|NCT05895994|DRUG|RD13-02 cell infusion|CAR-T cells
40784218|NCT03515161|DEVICE|closed-loop|Vasopressor admnistration in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of vasopressor the patient receives using feedback from standard operating room monitors.
40784219|NCT01269684|DRUG|Everolimus|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
40784220|NCT04445948|DRUG|Esomeprazole 40 milligrams Oral Tablet|Proton Pump inhibitor
40784221|NCT04445948|DRUG|Amoxicillin 1000 milligrams tablets|Penicillin derivative antibiotic
40784222|NCT04445948|DRUG|Clarithromycin 500 milligrams Tablets|Macrolide antibiotic
40784223|NCT04445948|DRUG|MetroNIDAZOLE 500 milligrams Oral Tablet|Antiprotozoal
40784224|NCT04445948|DRUG|Lactoferrin Bovine sachets 200 milligrams|a protein found naturally in milk from humans and cows
40784225|NCT03092310|DEVICE|Artificial Pancreas Device|Artificial Pancreas Device
40784226|NCT05045716|DRUG|Lecanemab|Lecanemab IV infusion.
40784227|NCT05045716|DRUG|Lecanemab|Lecanemab SC injection.
40784228|NCT04855175|DEVICE|Synthetic Bone Allograft (ClearFit)|Patients in this arm will receive ClearFit (synthetic bone allograft)
40784229|NCT04855175|OTHER|Autograft|Patients in this arm will use patient's own bone
40784230|NCT04518657|BEHAVIORAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
40784231|NCT04518657|BEHAVIORAL|Wellness for MS (WellMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing wellness in people with MS.
40784232|NCT03210857|OTHER|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
40784233|NCT04653974|BEHAVIORAL|Needle-free injection|"This study was performed among children aged 4-11 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 70 patients were evaluated in accordance with the exclusion criteria and 56 children (31 girls and 25 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the Wong-Baker Pain Scale at three time points: immediately after injection (Pain 1), during treatment (Pain 2), and at the end of the treatment (Pain 3)."
40784234|NCT06310382|DRUG|GH55|GH55 capsule is a novel small molecule, highly selective dual-mechanism ERK1/2 inhibitor developed by Suzhou Genhouse Bio. Co., Ltd. This product can be used to treat cancers caused by abnormal activation of the MAPK pathway (mutational activation of RAS/RAF/MEK) by targeted inhibition of ERK1/2.
40784235|NCT04485845|DRUG|Vildagliptin|to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
40784236|NCT04485845|DRUG|Captopril Tablets|used to treat hypertension in metabolic syndrome patients and as a renal protector
40784237|NCT04485845|DRUG|MetFORMIN 500 Mg Oral Tablet|antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
40784238|NCT00293163|DEVICE|Hylaform, Hylaform Plus (hylan B gel)|
40784239|NCT00224965|BEHAVIORAL|Behavior Therapy|
40784240|NCT02205320|BIOLOGICAL|DRL_PG|
40784241|NCT02205320|BIOLOGICAL|Pegfilgrastim Form A|
40784242|NCT02205320|BIOLOGICAL|Pegfilgrastim Form B|
40784243|NCT02761642|DRUG|Epoetin Beta|All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
40784244|NCT00509327|DRUG|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
40784245|NCT00509327|DRUG|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
40784246|NCT00956761|BIOLOGICAL|Seasonal Influenza Vaccine (MF59C.1)|1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
40784247|NCT04790786|BIOLOGICAL|Lilly Bamlanivimab|Administration of Lilly Bamlanivimab to COVID positive patients
40784248|NCT04790786|BIOLOGICAL|Regeneron Casirivimab + Imdevimab|Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients
40784249|NCT04790786|BIOLOGICAL|Lilly Bamlanivimab + Etesevimab|Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients
40784250|NCT04790786|BIOLOGICAL|Sotrovimab|Administration of Sotrovimab to COVID positive patients
40784251|NCT04790786|BIOLOGICAL|Bebtelovimab|Administration of Bebtelovimab to COVID positive patients
40784252|NCT02487953|DRUG|Nicotine patch|21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
40784253|NCT02487953|OTHER|ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
40784254|NCT02487953|OTHER|Placebo patch|21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
41306498|NCT05974540|DIAGNOSTIC_TEST|Determination of cricothyroid membrane|"After the patient's head is extended, the pediatric surgeon will be asked to mark the cricothyroid membrane with a pencil using traditional inspection and palpation methods. Then, the cricothyroid membrane will be determined by the Anesthesiology and Reanimation specialist by USG method and the difference will be determined. Demographic and morphometric characteristics of the patients will be recorded. In addition, the length of the cricothyroid membrane, the distance between the cricoid cartilage and the skin, the distance between the cricoid cartilage and the 2nd tracheal ring will be measured by USG.~Mallampati classes of patients with intubation, Cormack-Lehane (CL) glottic appearance grades, Likert scale with intubation difficulties (1: very easy, 2: easy, 3: medium, 4: difficult) will also be recorded."
41306499|NCT02417870|BIOLOGICAL|aldesleukin|
41306500|NCT01667068|OTHER|Comprehensive non invasive cardiovascular examination|"* Anamnesis with the participian~* File recherche,Physical examination~* Documentation of the carciovascular and antiretroviral medical therapy~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* Measuring of the arterial media thickness~* Exercise Montreal Cognitive Assesment test~* Exercise the Grooved Pegboard test~* Blood collection~* Questionnaire to quality of life and health economics"
40784255|NCT02487953|OTHER|Placebo ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
41306501|NCT04870112|DRUG|Durvalumab|Anti-PD-L1 antibody
41306502|NCT04870112|DRUG|Cisplatin|Chemotherapy
41306503|NCT04870112|DRUG|Carboplatin|Chemotherapy
40784256|NCT02341066|DEVICE|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
40784257|NCT03995160|PROCEDURE|Use of closed suction drainage following total knee arthroplasty|Use of closed suction drainage following total knee arthroplasty
40784258|NCT03995160|PROCEDURE|Abstain of using a closed suction drainage|Abstain of using a closed suction drainage following total knee arthroplasty
40784259|NCT04222530|DIAGNOSTIC_TEST|Linear EUS first|Linear endoscopic ultrasonography followed by magnifying narrow band endoscopy are used to determine the depth of invasion of early rectal cancer.
40784260|NCT04222530|DIAGNOSTIC_TEST|ME-NBI first|Magnifying narrow band endoscopy followed by linear endoscopic ultrasonography are used to determine the depth of invasion of early rectal cancer.
40784261|NCT04180111|DEVICE|CATS Tonometer|CATS Tonometer Prism
40784262|NCT05689879|DRUG|STOP arm|TNF-alpha antagonists withdrawal
40784263|NCT02121509|DRUG|Linagliptin|1 x Linagliptin tablet
40784264|NCT02121509|DRUG|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
40784265|NCT02121509|DRUG|Metformin ER|3 x Metformin ER tablets
40784266|NCT00557037|DRUG|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
40784267|NCT00041028|DRUG|EF5|
40784268|NCT00041028|OTHER|flow cytometry|
40784269|NCT00041028|OTHER|immunohistochemistry staining method|
40784270|NCT03502564|BEHAVIORAL|CBT for ED|Cognitive behavior therapy (CBT) for eating disorders (ED) is a 16-session individual therapy protocol which will focus on maintaining improvements in eating following intensive treatment, as well as addressing overconcern with weight/shape. Interventions will be adopted from the Enhanced CBT for ED manual.
40784271|NCT03502564|BEHAVIORAL|Concurrent CBT for ED and PTSD|The concurrent ED and PTSD intervention will consist of 16 sessions of CBT for both PTSD and for ED (ED interventions described above). CBT for PTSD will be based on interventions in the Cognitive Processing Therapy (CPT) manual.
40784272|NCT04970069|OTHER|Video on analgesic education|A four minute video informing the patient about opioids.
40784273|NCT04970069|OTHER|Video on general perioperative education|A four minute video informing the patient about general perioperative process.
40784274|NCT04685213|DEVICE|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
40784275|NCT04685213|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
40784276|NCT01567033|BEHAVIORAL|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
40784277|NCT04218812|DIAGNOSTIC_TEST|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT
40784278|NCT04218812|DIAGNOSTIC_TEST|Automated electrical source imaging (ESI)|"The automated source imaging consists of 2 phases~1. Automated detection of EDs~2. Source imaging of each spike cluster and seizure onset epoch."
40784279|NCT04330209|OTHER|weight loss diets|The ketogenic diet group were instructed to consume \<35g of carbohydrates per day, and \<10% of total calories were from saturated fats. Daily protein intake was set at 1.2g/kg bodyweight for females, and 1.5g/kg bodyweight for males. The low-GI nutrigenetic diet group had individualised dietary instructions based on their genetic results
41306504|NCT04870112|DRUG|Etoposide|Chemotherapy
40784280|NCT04945486|OTHER|Peer-mentor intervention|Peer-mentor support for up to 6 months
40784281|NCT01809665|DEVICE|ICD/CRT-P therapy|
40784282|NCT01809665|OTHER|MRI|
40784283|NCT02347592|DEVICE|Self-locating Catheter|Procedure/Surgery necessary if obstruction occurs
40784284|NCT02347592|DEVICE|straight Tenckhoff|Procedure/Surgery necessary if obstruction occurs
40784285|NCT02953912|PROCEDURE|Reciproc single-file|The Reciproc is a single-file nickel-titanium systems , made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue
40784286|NCT02953912|PROCEDURE|One Shape single-file|One Shape is one of the few single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue.In addition to , the electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
40784287|NCT03261895|BEHAVIORAL|Nurse-led Integrative health and wellness programme|Participants in the intervention group will go through a eight-session structured education programme. The education programme was designed by incorporating the evidences of diabetes care from the western medicine and the philosophy of traditional Chinese medicine.
40784288|NCT03568812|DRUG|Rillus®|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
40784289|NCT03568812|OTHER|Placebo|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
40784290|NCT03520309|PROCEDURE|Dental treatment|Treatment of all dental restorations of the children according to the diagnosis criteria
40784291|NCT04317144|BEHAVIORAL|Web-based follow-up programme.|Participants who are randomized to the intervention-group will have access to web-based follow-up for one year. The programme includes short films of equipment used in intensive care e.g. ventilator, suction-device. Continous renal replacement therapy , central vein catheter among other things. About 15 short films with icu-staff talking and show how the equipment works and alarm sounds. The intervention also includes lectures about how the ICU works and what problems a critically ill patient can suffer from post-icu. There is a built-in conversation tool in the programme that can be used both by the participant and the staff who works with the follow-up programme. Questionnaires is sent out 2,6 and 12 month post-icu. The questions include PTSD, Depression, QoL and physical activity. At the end of the study, participants are sent a questionnaire asking for their experience using the web-based follow up programme.
41306505|NCT03793816|DEVICE|BiZactTM Open Sealer/Divider|The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.
40784292|NCT04317144|BEHAVIORAL|No follow-up|"Participants randomized to no follow-up receive e-questionnaires 2, 6 and 12 months post-ICU care. The questions are the same as in web-based follow-up intervention group and include PTSD, Depression, QoL and physical activity."
40784293|NCT03769350|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
40784294|NCT03423602|DEVICE|PerQseal®|Large hole closure system
41306506|NCT02811536|DEVICE|optical coherence tomography angiography|Imaging with optical coherence tomography angiography
41465033|NCT05976854|OTHER|Pain neuroscience education|The patients in the intervention group will receive, in addition to the prenatal educational content, the 12 Pain neuroscience education lessons in audiovisual format. Each lesson will last between 10-15 minutes. The contents of PNE will be an adaptation, focused on the context of a pregnant woman, of the Butler \& Moseley postulates. These contents have already been previously adapted according to the nature of the patients' pain, both in chronic pain and in acute pain. In summary, the participants will receive a detailed explanation about the biopsychosocial component of pain through the use of diagrams, metaphors and practical examples. In turn, the objectives of this program could be summarized as: (1) Reformulate erroneous beliefs about pain, (2) Inform about the biology and protective nature of pain and (3) Provide techniques to reduce kinesiophobia and, consequently, promote physical activity, with the beneficial effect it entails for patients with pain.
41465034|NCT03878264|DRUG|CORT118335 Oral|CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
41465035|NCT03878264|DRUG|14C-CORT118335 intravenous|14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C
40784295|NCT02765048|BEHAVIORAL|GAIN Program|Receives GAIN, a 10-session program that incorporates cognitive behavioral therapy skills in a group format to address symptoms of trauma such as PTSD and depression related to histories of child maltreatment. GAIN includes the following elements: 1) assertive communication skills and relationship boundaries, 2) understanding the connection between feelings, thoughts, and behaviors, 3) increased personal confidence, 4) how to have healthy relationships and personal safety, and 5) how to cope with stress and anxiety.
41306507|NCT01758393|DRUG|Prednisone|
40784296|NCT04841954|DIAGNOSTIC_TEST|hemp prick-test|hemp seed and flower prick-test
40784297|NCT00219089|DRUG|aliskiren|
40784298|NCT03172143|PROCEDURE|Mesenteric Sparing Ileocolic Resection|In this resection, the mesentery will be spared, or left in situ during resection.
40784299|NCT03172143|PROCEDURE|High Ligation Ileocolic Resection|"In this resection, a high ligation is performed, where the feeding vessel is taken at its origin in order to take sufficient mesentery and lymph nodes with the colon specimen."
40784300|NCT05523284|DIAGNOSTIC_TEST|SonoPODography|SonoPODography (SPG) is a novel ultrasound-guided technique whereby saline is injected through the cervix and flushed into the POD, creating an acoustic window for diagnosing superficial endometriosis.
40784301|NCT05914194|DRUG|NLS-2|Participants will receive NLS-2 tablets orally.
40784302|NCT05914194|DRUG|Placebo|Participants will receive NLS-2 matching placebo tablets orally.
40784303|NCT03559270|DRUG|Baricitinib|Administered orally
41306508|NCT01934192|DRUG|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
41306509|NCT01934192|DRUG|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
41306510|NCT01934192|DRUG|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
41306511|NCT01934192|DRUG|Placebo IV|Placebo will be administered IV every 6 hours
41306512|NCT03628508|OTHER|Exercise|Comprehensive exercise program including strengthening, stretching, gait modification etc.
41306513|NCT04926194|BIOLOGICAL|Decidual stromal cells (DSC)|DSCs are isolated from donated human placenta and have been shown to have anti-inflammatory effects.
41306514|NCT06346457|DRUG|Tamoxifen|Tamoxifen is 20 mg once daily for two to three weeks.
41306515|NCT06346457|DRUG|Letrozole|Letrozole (Aromatase inhibitor) is 2,5 mg once daily for two to three weeks.
41306516|NCT06346457|DRUG|Letrozole + GnRH|When they take Letrozole + GnRh, the GnRh is an injection once a month.
41306517|NCT04022811|DRUG|0.1% bromfenac|the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
41306518|NCT06101394|DRUG|Cetuximab-IRDye800|Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab-IRDye800 over 30 minutes to 1 hour.
41306519|NCT01426425|DEVICE|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
41306520|NCT02917187|DRUG|BIIB074|Administered as specified in the treatment arm
41465036|NCT03878264|DRUG|14C-CORT118335 oral|14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
41465037|NCT00602615|DRUG|Torsemide|
41465038|NCT01628549|DRUG|50 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
41465039|NCT01628549|DRUG|Placebo|Dose-matched Placebo capsule administered as an oral capsule(s) once daily
41465040|NCT01628549|DRUG|100 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
41306521|NCT02917187|DRUG|Placebo|Matched placebo
41306522|NCT04669314|PROCEDURE|Liver resection or enucleation for liver hemangioma|Operations in which the hemangioma is selectively removed from the liver parenchyma border are named enucleation, and the operations in which the hemangioma is removed anatomically or non-anatomically with some liver parenchyma surrounding it are named liver resection
41306523|NCT01188382|PROCEDURE|CSF dynamic investigation|
41306524|NCT03420716|DIETARY_SUPPLEMENT|yogurt|
41306525|NCT01189435|DRUG|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
40784304|NCT04482725|OTHER|Trial product 1|Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL
40988395|NCT05543941|DEVICE|Dilute Betadine|The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.
40988396|NCT04400786|PROCEDURE|intermittent treatment|According to the feeling of pain, the on-demand treatment group is prescribed with or without Imrecoxib (100mg/tablet, 100mg.prn.po), but the maximal dose does not exceed 100 mg per time, twice (morning and evening) per day. The duration lasted for 24 weeks.
40784305|NCT04482725|OTHER|Trial product 2|Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL
40988397|NCT04400786|PROCEDURE|continuous treatment|The continuous treatment group is prescribed Imrecoxib (100mg.bid.po) regardless of the pain in the treatment course for 24 weeks.
40988398|NCT03605303|DEVICE|Test/Control|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
40988399|NCT03605303|DEVICE|Control/Test|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
40988400|NCT05214482|DRUG|AK112|IV infusion,Specified dose on specified days
40988401|NCT05214482|DRUG|AK117|IV infusion,Specified dose on specified days
41306526|NCT05959772|RADIATION|Photobiomodulation|"Light-Aid equipment from Bright Photomedicine-Brasil will be used, with an 850 nm Arsenide, Gallium and Aluminum (AsGaAl) LED. Exposure time between 4 and 9 minutes; radiant exposure of approximately 41mW/cm2; with 8 clusters in each session. Two tapes containing four clusters each will be arranged, and each cluster contains 25 led's adding up to a total of one hundred (100) led's arranged in each on the tape"
41306527|NCT00808327|DRUG|Bupivacaine|A single, 15mg, intrathecal dose of bupivacaine.
41306528|NCT00808327|DRUG|Bupivacaine, fentanyl|A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
41306529|NCT02576964|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
41306530|NCT02576964|DRUG|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
41306531|NCT02837692|DRUG|JNJ-42847922 10 milligram (mg)|JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
41306532|NCT02837692|DRUG|JNJ-42847922 20 mg|JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
40988402|NCT05214482|DRUG|Chemotherapy|IV infusion,Specified dose on specified days
41306533|NCT02837692|DRUG|JNJ-42847922 40 mg|JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.
41306534|NCT02837692|DRUG|JNJ-42847922 60 or 80 mg|JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
40784306|NCT04482725|OTHER|Trial product 3|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL
40784307|NCT04482725|OTHER|Trial product 4|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL
40988403|NCT01438918|DRUG|SD-6010|200 mg tablets once a day for 2 years
40988404|NCT01438918|DRUG|SD-6010|50 mg tablets once a day for 2 years
40988405|NCT01438918|DRUG|Placebo|Placebo tablets once a day for 2 years
40988406|NCT00212030|DRUG|nicorandil|(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
40988407|NCT00212030|DRUG|placebo|Control
41306535|NCT06257706|BIOLOGICAL|Vedolizumab|All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.
41306536|NCT04158713|DRUG|Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine|Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
41306537|NCT02973841|DEVICE|Sono-ease device|insertion of US guided IJV using sono-ease device
41306538|NCT00000309|DRUG|Risperidone|
40988408|NCT06320730|OTHER|Observational study, records of blood glucose level after reperfusion|Analyzes blood glucose level after reperfusion by dividing it into two groups: those with blood glucose levels between 110 and 180 and those with blood glucose levels below 110 or above 180.
40988409|NCT00495170|DRUG|Carboplatin|2 area under curve (AUC) by vein Weekly
40988410|NCT00495170|RADIATION|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
40988411|NCT00495170|DRUG|Paclitaxel|50 mg/m\^2 by vein Weekly
40988412|NCT02177045|DRUG|Sonovue, Bracco|Intravenous injection
40988413|NCT00417807|DRUG|Imatinib mesilate|
41306539|NCT03136185|DRUG|Bomedemstat|Oral (capsule) administration according to dose allocation.
41306540|NCT04940871|DRUG|Favipiravir HU 200 mg hard capsules|Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules
41306541|NCT04940871|DRUG|Placebo HU|Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules
41306542|NCT05705570|DRUG|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
41306543|NCT05705570|DRUG|Fludarabine|Fludarabine 25mg/m\^2 IV on days -5 to -3
41306544|NCT05705570|BIOLOGICAL|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0"|"Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
41465041|NCT05327439|OTHER|Nicotine (electronic cigarette)|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at in-person and phone assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose one of two e-liquid flavors (tobacco, menthol) at baseline.
40988414|NCT00670865|OTHER|Electronic discharge summary system|The customized electronic discharge summary program will be used to generate patient discharge summaries.
40988415|NCT00966602|DRUG|VX-809|VX-809 capsule, once daily for 14 days
40988416|NCT00966602|DRUG|VX-770|VX-770 tablet, once every 12 hours for 14 days
40988417|NCT00966602|DRUG|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
40988418|NCT00966602|DRUG|Placebo|Matching Placebo
40988419|NCT02181439|DEVICE|(LLLT Low Level Laser Therapy) SiroLaser advance|Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
40988420|NCT05175690|DIAGNOSTIC_TEST|Diagnostic Software as Medical Device|"AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses.~The AudibleHealth Dx is a cloud-based AI/ML (locked ML) diagnostic software as medical device (Dx SaMD) with a mobile app based graphical user interface (GUI) designed to operate with COTS Android Operating System (OS) and Apple OS based mobile devices. The AudibleHealth Dx system uses a forced cough vocalization (FCV) signal data signature (SDS) to diagnose COVID-19 illness in ambulatory adults. Results are sent to ordering physicians, State Health Departments, and participants using Health Level 7 (HL7) compliant communication protocols."
40988421|NCT04859751|DRUG|VB4-845 Injection|Intravesical administration of VB4-845 Injection.
41145803|NCT02142478|BEHAVIORAL|Standard Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week.~The scheme includes exclusive EFH gym sessions (i.e. includes EFH participants only) on two to three days of the week, plus subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members)."
41145804|NCT04567745|DIAGNOSTIC_TEST|Retinal fundus photography|Fundus photographs
41306545|NCT05837026|BEHAVIORAL|Enhanced Outreach Intervention (EOI) plus Care as Usual (CAU)|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~Outreach (via phone or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if the participant has suicidal thoughts, and (c) discuss plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals provide to patients who present with suicidal thoughts."
41306546|NCT05837026|OTHER|Care as Usual (CAU)|Participants will receive standard care that hospitals provide to patients who present with suicidal thoughts.
41306547|NCT05560841|DEVICE|topical treatment|Topical application of Nailner brush 2in1 for toenail onychomycosis
41306548|NCT05295368|OTHER|Multicomponent intervention|Intervention includes four components 1) training nurses as health coaches for motivational conversation and CKD specific lifestyle counseling on diet and exercise, using hybrid follow-up approach of in-person, telephone, and secure video sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
41306549|NCT02862821|OTHER|HR-EEG|
40988422|NCT02803151|RADIATION|Stereotactic ablative radiotherapy|SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
41145805|NCT04508829|DRUG|Anti-EGFR monoclonal antibody|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy in locally advanced oropharyngeal carcinoma with induced chemotherapy resistance. The specific treatment description is included in arm description.
41145806|NCT04816435|DIAGNOSTIC_TEST|Ultrasound test|Ultrasound evaluation of airway
40784308|NCT04482725|OTHER|Trial product 5|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL
40784309|NCT04482725|OTHER|Trial product 6|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL
40784310|NCT04482725|OTHER|Trial product 7|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL
40784311|NCT04482725|OTHER|Trial product 8|Buffering agent: Disodium hydrogen phosphate dihydrate 5.34 mg/mL Isotonic agent: NaCl 6.72 mg/mL
40784312|NCT04482725|OTHER|Trial product 9|Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL
40784313|NCT04482725|OTHER|Trial product 10|Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
40784314|NCT04482725|OTHER|Trial product 10|Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
40784315|NCT04482725|OTHER|Trial product 12|Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
40784316|NCT05964894|OTHER|ergonomic training|ergonomic education \& exercise training
40784317|NCT03535987|DEVICE|myocardial PET imaging|using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen-deprivation therapy with external beam radiation therapy
41465042|NCT05327439|OTHER|Nicotine (nicotine pouch)|Participants will be provided with 4mg nicotine pouches for 8 weeks and encouraged at in-person and phone assessments to use the nicotine pouches any time they would normally smoke. Participants will be able to choose one of two nicotine pouch flavors (tobacco, mint) at baseline.
41465043|NCT03195673|DRUG|Terazosin|TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
40784318|NCT03751397|OTHER|blood test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein, beta-2 microglobulin, uromodulin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
40784319|NCT03751397|OTHER|urine test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein beta-2 microglobulin, uromodulin, albumin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
40784320|NCT00039013|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
40784321|NCT00039013|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
40784322|NCT00039013|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
40784323|NCT00039013|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
40784324|NCT02197572|DRUG|Sapanisertib|Sapanisertib capsules.
40784325|NCT01510873|OTHER|HRQOL evaluation|"Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start."
41465044|NCT03195673|PROCEDURE|Carotid artery stenting|Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.
41465045|NCT02821949|BIOLOGICAL|PCT dosage|When connecting chemotherapy products, a PCT dosage will be made. The results of dosage won't be communicated to the clinician responsible for the patient. Patient's care will then be identical to any other chemotherapy treated patient
41465046|NCT04973813|BEHAVIORAL|Guideline + Active Choice + action&coping planning (GA+)|Web-based intervention consisting of information and assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning
40784326|NCT03507127|DRUG|Varenicline|Standard dosing: 0.5 mg/day on days 1-3, 0.5 mg twice daily (morning, evening) on days 4-7, then 1 mg twice daily to the end of the medication period.
41465047|NCT04973813|BEHAVIORAL|Guideline + Active Choice (GA)|Web-based intervention consisting of information and several assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
40784327|NCT03507127|DRUG|Placebo|Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
40784328|NCT02603679|DRUG|Paclitaxel|Any brand of paclitaxel may be used, excluding nab-paclitaxel
40784329|NCT02603679|DRUG|Tamoxifen + Palbociclib|Any brand of tamoxifen may be used
40784330|NCT02603679|DRUG|Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
40784331|NCT02603679|DRUG|Goserelin + Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
41465048|NCT04973813|BEHAVIORAL|Guideline + information (GI)|Web-based information about the national physical activity guideline, pros and cons of physical activity, and possible barriers to physical activity.
41465049|NCT04973813|BEHAVIORAL|Guideline (G)|Web-based information about the national physical activity guideline.
41465050|NCT04271072|OTHER|No intervention|No intervention
40784332|NCT00051077|DRUG|Adefovir dipivoxil|
40784333|NCT00051077|DRUG|Peginterferon-alfa-2A|
40784334|NCT00051077|DRUG|Ribavirin|
40784335|NCT00051077|PROCEDURE|Liver Biopsy|
40784336|NCT01852643|PROCEDURE|Spreader graft|Spreader graft technique is performed by a group of expert surgeons.
40784337|NCT01852643|PROCEDURE|Lateral crural overlay|Lateral crural overlay technique is performed by a group of expert surgeons.
41465051|NCT05562453|DEVICE|FlowOx 2.0|Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.
41465052|NCT05562453|DEVICE|FlowOx2.0 (Sham)|Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.
41465053|NCT05712317|BEHAVIORAL|Exergame Intervention|8-week exergame-based intervention 3x per week
41465054|NCT05712317|BEHAVIORAL|Moderate-intensity endurance exercise|8-week moderate-intensity endurance exercise 3x per week
41465055|NCT01401335|BEHAVIORAL|Questionnaires|questionnaires at entry, month 4, 8 and 12
41465056|NCT00558623|DIETARY_SUPPLEMENT|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
41465057|NCT03788369|PROCEDURE|Hybrid Coronary Revascularization|Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.
41465058|NCT01445860|DRUG|Simvastatin/PF-03882845|Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
40784338|NCT00578032|BEHAVIORAL|Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment|All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
40784339|NCT04734457|DRUG|Levothyroxin|We assess the effect of early diagnosis of CH by neonatal screening and start of treatment on the final height of the patients
40784340|NCT05538130|DRUG|PF-07799544|Tablet
40784341|NCT05538130|DRUG|PF-07799933|Tablet
40784342|NCT05538130|DRUG|encorafenib|Capsule
40784343|NCT05781243|DRUG|Lactated Ringer Solution|Patients in the LR (Lactated Ringer solution) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
40784344|NCT05781243|DRUG|Normal saline|Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
40784345|NCT05429619|OTHER|PeerOnCall|A mobile health peer-to-peer support platform that consists of two inter-connected apps: PeerOnCall and PeerOnCall Support. The apps were co-designed by and for the public safety community in Canada, with customized content for correctional workers, emergency communicators, firefighters, paramedics and police.
40784346|NCT04925141|DRUG|Dasatinib Tablets|Tyrosine Kinase Inhibitor (TKI)
41306550|NCT01593683|BEHAVIORAL|Psychological education program for nurses|Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
41306551|NCT05474508|OTHER|Diaphragmatic breathing|Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.
41306552|NCT05474508|OTHER|Aerobic exercises|Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks.
41306553|NCT01781429|DRUG|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
41306554|NCT04758273|BIOLOGICAL|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
41306555|NCT04758273|BIOLOGICAL|high dosage inactivated SARS-CoV-2 vaccine|high dosage
41306556|NCT04758273|BIOLOGICAL|Placebo|placebo
41306557|NCT03017924|DEVICE|Q collar|q-collar concussion prevention device
41306558|NCT03169829|DIETARY_SUPPLEMENT|Standard Diet|"Adapted from National Kidney Foundation guidelines for HD1~* Animal only Protein~* Refined only Grains~* Limit Dairy~* Low-k only"
40784347|NCT00707993|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.
40784348|NCT00707993|DRUG|Glipizide|Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
41306559|NCT03169829|DIETARY_SUPPLEMENT|Low-k|"•¼ Animal, ¾ Plant Proteins~•½ Refined, ½ Whole Grain~* Limit Dairy, provide Soymilk Dairy~* Low-k only Fruit and Vegetables"
41306560|NCT03169829|DIETARY_SUPPLEMENT|Standard|"•¼ Animal, ¾ Plant Proteins~* Refined, ½ Whole Grain~  •Limit Dairy, provide Soymilk Dairy~* Low-k, Fruit and Vegetables~* High-k Fruit and Vegetables"
41306561|NCT01769417|DRUG|Placebo|Placebo
41465059|NCT00943865|BEHAVIORAL|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
41306562|NCT01769417|DRUG|MEDI4893|Human immunoglobulin G1 kappa monoclonal antibody
40784349|NCT03941847|OTHER|music|listening music
41465060|NCT00943865|BEHAVIORAL|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
41465061|NCT00943865|BEHAVIORAL|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
41465062|NCT00943865|BEHAVIORAL|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
40784350|NCT01667341|BIOLOGICAL|GEN-003 with Matrix M-2|IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
40784351|NCT01667341|BIOLOGICAL|GEN-003|IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).
40784352|NCT01667341|BIOLOGICAL|Placebo|IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
40784353|NCT01983592|OTHER|Homeopathic medicine|Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.
40784354|NCT01983592|OTHER|Unmedicated lactose/sucrose globule|
40784355|NCT06176209|DIAGNOSTIC_TEST|screening tool with biomarkers for prediction of chronic post traumatic neck pain|Diagnostic screening with biomarkers for prediction of chronic post traumatic neck pain
40784356|NCT01500317|DRUG|Tapentadol|Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.
40784357|NCT01500317|DRUG|Oxycodone|Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.
40784358|NCT01500317|DRUG|Placebo|Subjects received placebo three times per day (tid) for 48 hours.
40784359|NCT01929200|DRUG|1-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
40988423|NCT02505620|PROCEDURE|Treatment of OSAS with CPAP mask|Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
40988424|NCT02505620|PROCEDURE|Surgical Treatment with multilevel operation|Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
40988425|NCT06408623|DRUG|chidamide combined with Sintilimab and bevacizumab|chidamide combined with Sintilimab and bevacizumab
41306563|NCT05194293|BIOLOGICAL|Durvalumab|Given IV
41306564|NCT05194293|DRUG|Regorafenib|Given PO
41306565|NCT02915367|BEHAVIORAL|SMS Reminders|Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
40784360|NCT01929200|DRUG|2-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
41306566|NCT03417180|DRUG|Remifentanil|a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
41306567|NCT03417180|DEVICE|surgical pleth index|every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
41465063|NCT00943865|BEHAVIORAL|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
41465064|NCT03627598|DEVICE|HFNC|patients will receive high flow warmed air with low inspired fraction of oxygen between non invasive ventilation sessions
40784361|NCT02431325|DRUG|Teduglutide|
40784362|NCT02431325|DRUG|Placebo|
40784363|NCT01952938|PROCEDURE|LINK SL versus EnduRo|
40988426|NCT01284920|DRUG|MDV3100|oral
40988427|NCT04611750|DRUG|AD036|AD036 will be given for 14 days
40988428|NCT04611750|DRUG|Placebo|Placebo will be given for 14 days
40988429|NCT04585022|DEVICE|Magnum, Zimmer Biomet, Warsaw, IN|
40784364|NCT01554098|PROCEDURE|Strategy : Supine first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
40988430|NCT04585022|DEVICE|Recap, Zimmer Biomet, Warsaw, IN|
40988431|NCT01857349|OTHER|Chlora Prep|Surgical Scrub skin preparation
40988432|NCT01857349|OTHER|Dura Prep|Surgical Scrub skin preparation
40988433|NCT06163846|DIAGNOSTIC_TEST|Assess the role of baseline image mining, ctDNA data and their combination in patient staging and risk stratification|Assess the combination of baseline and follow-up image mining, together with ctDNA, in predicting disease relapse and progression.
41306568|NCT05313932|OTHER|Sleep deprivation|Participants wake after six hours so that they are deprived of 2 hours of sleep
41306569|NCT00532948|DRUG|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
41306570|NCT04182997|DRUG|Dexamethasone|Patients included in the treatment group will have their surgical site lavaged with dexamethasone at the end of their surgery.
41306571|NCT04182997|DRUG|saline 0.9%|Patients included in the placebo group will have their surgical site lavaged with sterile saline at the end of their surgery.
41306572|NCT03765541|DRUG|Dexamethasone|"In combination with intensive chemotherapy amsacrine-cytarabine:~* Induction (1 cycle): 10 mg/12h from Day 1 to Day 3 of cycle (2 infusions/24h, slow IV \[10 minutes\])~* Consolidation (3 cycles): 10 mg/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[10 minutes\])~In combination with azacitidine:~* Cycle 1: 20 mg/24h from Day 1 to Day 3 of cycle (1 infusion/24h, slow IV \[10 minutes\]).~* Subsequent cycles: 20 mg/24h on Day 1 of each cycle (1 infusion/24h, slow IV \[10minutes\])."
40784365|NCT01554098|PROCEDURE|Strategy : dynamic first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
40784366|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
40784367|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
40784368|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
40784369|NCT03698279|BIOLOGICAL|Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
40784370|NCT03698279|BIOLOGICAL|FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
40784371|NCT03601390|DEVICE|PET/CT and EBV DNA|PET/CT and EBV DNA will be proformed after the IMRT treatment
40784372|NCT06006871|BEHAVIORAL|The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game|Patients are pharmacologically stable and receive a cognitive intervention with our videogame twice a week in the hospital (10 sessions) and twice a week in their home with a computer video game (other 10 sessions).
40784373|NCT06006871|DRUG|Usual treatment for ADHD|All patients continue with their stable pharmacological treatment and do not receive any additional cognitive intervention.
40784374|NCT02987582|BEHAVIORAL|Emotion-focused mindfulness group|Intervention The group will run for 8-weeks. Each group session is 2 and a half hours. Half way through the intervention there will be a 5 hour retreat on the weekend. A typical group format includes 20-40 minutes of meditation, followed by 10 minutes of independent journaling. Then group members will have time to report on recollections from meditation and facilitators will provide feedback. There is a break and the second part of the group focuses on a didactic teaching topic. Topics change each week; groups will run between October 2016 and June 2018.
40784375|NCT00981721|DRUG|cediranib (RECENTIN TM, AZD2171)|20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8
40784376|NCT06373003|OTHER|Diagnostic accuracy|To assess the diagnostic accuracy of non-criteria aPL (anti-vimentin/cardiolipin and anti-phosphatidylserine/prothrombin) in identifying APS in patients with thrombosis/ recurrent adverse pregnancy outcomes
40784377|NCT02058979|DRUG|BOLUS INFUSION (Ancef)|Bolus Infusion of antibiotics
40784378|NCT02058979|DRUG|CONTINUOUS INFUSION (Ancef)|Continuous Infusion of ANCEF with infusion pump
40784379|NCT02001129|BEHAVIORAL|Automated Telephone System|Participants receive automated reminder phone calls.
40784380|NCT02001129|BEHAVIORAL|Personalized Telephone Call|Participants receive reminder phone calls by study staff.
40784381|NCT02001129|BEHAVIORAL|Usual Care|Participants receive a standard reminder letter in the mail.
40784382|NCT04170088|DRUG|Tranexamic Acid|Tranexamic acid intradermal injections were used for treatment of melasma
40784383|NCT04170088|DRUG|0.9% Normal Saline|Normal saline used for comparision of efficacy of tranexamic acid
40784384|NCT04203589|BEHAVIORAL|The Explorer Baby Early Intervention Program|Centered based intervention, once or twice a month, 6 months follow up
40784385|NCT04203589|OTHER|Neurodevelopmental Therapy|Centered based intervention, once or twice a month, 6 months follow up
40784386|NCT01296503|DRUG|Thalidomide plus dexamethasone|"D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
40784387|NCT01296503|DRUG|Dexamethasone|dexamethasone alone 40 mg/day for 4 days every 28 days
40784388|NCT00672594|DRUG|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
40784389|NCT05164471|GENETIC|verbrinacogene setparvovec|FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B
40784390|NCT04635137|PROCEDURE|Ablation and Cementoplasty|Percutaneous thermal ablation with subsequent cementoplasty in a single procedure
40784391|NCT04863430|DRUG|Apatinib|500mg oral qd
40784392|NCT04863430|DRUG|Oxaliplatin|130mg/m\^2 administered as IV infusion on Days 1 of each 21-day cycle
40784393|NCT04863430|DRUG|S1|According to body surface area,(\<1.5m\^2) 40mg or (≥1.5m\^2)50mg bid oral on Day 1-14 of each 21-day cycle
40784394|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir|Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
40784395|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
40784396|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
40784397|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
40784398|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
40784399|NCT01444911|DEVICE|Vaginal Renewal Program|The Vaginal Renewal™ Program (VRP) consists of instructions on the use of a vibrating vaginal wand along with a particular water based lubricant.
40784400|NCT01444911|DEVICE|Vaginal Dilator|Still vaginal dilator with lubricant.
40784401|NCT06058962|DRUG|Suramin Sodium|Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
40784402|NCT02464982|PROCEDURE|Tattoo|tattoo device with EC standards, and sterile single-use only needle
41306573|NCT03765541|DRUG|Amsacrine|"* Induction (1 cycle): 200 mg/m2/24h from Day 1 to Day 3 of cycle (slow IV \[3 hours\])~* Consolidation (3 cycles): 200 mg/m2/24h on Day 1 of each cycle (slow IV \[3 hours\])"
41306574|NCT03765541|DRUG|Cytarabine|"Patients \< 60 years of age:~* Induction (1 cycle): 3 g/m2/12h from Day 1 to Day 4 of cycle (2 infusions/24h, slow IV \[2 hours\])~* Consolidation (3 cycles): 3 g/m2/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[2 hours\]) Note: If the investigators believe that there is an undue risk for the safety of a patient under 60 years of age with comorbidity in receiving a dose level of 3 g/m2/12h, the dose may be reduced to 1 g/m2/12h"
41306575|NCT03765541|DRUG|Azacitidine|75 mg/m2/24h from Day 1 to Day 7 of each cycle \[or from Day 1 to Day 5 and from Day 8 to Day 9 of each cycle\] (SC)
41306576|NCT05323903|OTHER|Telesimulation|Telesimulation is an application that is a teaching process by which telecommunication and healthcare simulation resources are used to provide education, training and assessment to learners at an off-site location. In this study, simulation was recorded and this was shared with the students through means of telecommunication.
41306577|NCT05323903|OTHER|Kahoot Game|Kahoot is a game-based learning platform, used as educational technology in schools and other educational institutions.
41306578|NCT06478758|DRUG|Ibuprofen 400 mg|The ibuprofen group (n=36) was administered 800 mg of ibuprofen . All procedures were performed with the same team. During surgery, a 20% increase in the participant's heart rate and mean arterial pressure remifentanil infusion was administered. During the postoperative period, all participants continued to receive acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4. In the recovery room, the participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
40784403|NCT00953706|DRUG|Ivacaftor|Tablet
40784404|NCT00953706|DRUG|Placebo|Tablet
40784405|NCT03577899|BIOLOGICAL|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
40784406|NCT03577899|BIOLOGICAL|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
40988434|NCT03417453|DEVICE|Eye Drop Dispenser TYPE Opticare|"Subject will apply normal saline eye drops to them-self with various eye drop dispensers.~Assessment of ease of use will be conducted by questioners."
40988435|NCT03417453|DEVICE|Eye Drop Dispenser Autodrop|Eye Drop Dispenser Autodrop
40784407|NCT03577899|BIOLOGICAL|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
40784408|NCT01653444|DRUG|GC1119|biweekly, IV infusion
40988436|NCT02436551|OTHER|Observation|
40988437|NCT06450626|OTHER|Listening Music Intervention|Participants will listen to a music playlist while vitals are monitored, along with completing a pre- and post-assessment survey (both of which are the Edmonton Symptom Assessment Scale). Participants will also be asked a set of qualitative questions about their overall experience with the music therapy session.
40988438|NCT04032041|DEVICE|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
40784409|NCT02700672|OTHER|Observational study|Observational study: kinematic variables, falls and executive function were analyzed
40784410|NCT02576873|OTHER|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
40784411|NCT01312480|OTHER|5A's Model|"The smoking cessation intervention is based on the 5A's model, which includes the following elements:~1. Ask if the patient smokes.~2. Advise every patient to quit.~3. Assess readiness to quit.~4. Assist in quitting and finding services.~5. Arrange for cessation services and follow-up."
40784412|NCT01312480|OTHER|Media Use Assessment|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
40784413|NCT02217618|DRUG|LY2409021|
40784414|NCT06054399|OTHER|educational program|Education resources in Spanish through social media directed to the targeted audience mentioned above. There will be at least three interventions along the study, one for each pregnancy trimester, including topics such as: Migraine criteria, management strategies, risks of medication overuse, alarm symptoms, etc. These educational interventions will be conducted by trained health care professionals, mainly using audio-visual media.
40784415|NCT03940807|DRUG|11.25mg GnRH agonist|"Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
40784416|NCT03940807|DRUG|0.1 mg GnRH agonist|"Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
40784417|NCT03940807|DRUG|25 µg transdermal oestradiol|Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
40784418|NCT04326790|DRUG|Colchicine|Low-dose colchicine treatment, 0.5 mg bid
40988439|NCT04382833|OTHER|HOT APPLICATION|HOT APPLICATION
40988440|NCT04382833|OTHER|MASSAGE|
40988441|NCT03876431|DEVICE|Easy-Flex|The Easy-Flex device will be used to increase knee flexion and extension ROM.
41145807|NCT04002856|DEVICE|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride
40988442|NCT03876431|OTHER|Exercise|After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
41145808|NCT00328120|DRUG|Fulvestrant|500 mg intramuscular injection
41145809|NCT00376935|DRUG|Palifermin|Keratinocyte growth factor administered via injection
41306579|NCT06478758|DRUG|Acetaminophen 100 MG/ML|The investigators administered 1000 mg of acetaminophen to the participants in Group A. A 20% increase in the participant's heart rate and mean arterial pressure was evaluated as pain and remifentanil infusion was administered. All participants continued to receive the routine application of acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4, postoperatively.In the recovery room, participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
41306580|NCT04612062|DRUG|CEE321|CEE321 administered to all subjects
41145810|NCT00376935|DRUG|Palifermin placebo|Keratinocyte growth factor placebo administered via injection
41145811|NCT04315428|BEHAVIORAL|swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
41306581|NCT03516019|OTHER|personalized notices|The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.
41306582|NCT03516019|OTHER|standard notices|The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.
41306583|NCT03516019|OTHER|am notices|notifications sent at 7 am.
41306584|NCT03516019|OTHER|pm notices|notifications sent at 7 pm.
41306585|NCT03516019|OTHER|weekday notices|notifications sent on Wednesday
41306586|NCT03516019|OTHER|weekend notices|notifications sent on Saturday
41306587|NCT04982120|DEVICE|Repris Needle|Injection of Botox
41306588|NCT01638000|DRUG|Mirabegron|oral tablet
41306589|NCT01638000|DRUG|Solifenacin succinate|oral tablet
41306590|NCT03665376|DIETARY_SUPPLEMENT|Carbohydrate drink load|Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
41306591|NCT03665376|COMBINATION_PRODUCT|Enhanced Recovery After Surgery (ERAS)|The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
41306592|NCT00410501|DRUG|Indacaterol (QAB149)|
40784419|NCT04326790|DRUG|Standard treatment|Standard treatment
40784420|NCT01885988|DRUG|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
40784421|NCT01885988|DRUG|Sugar Pill|Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
40784422|NCT04660760|DRUG|Paclitaxel|Given IV
40784423|NCT04660760|OTHER|Quality-of-Life Assessment|Complete questionnaires
41306593|NCT02011126|DRUG|Imetelstat Sodium|Given IV
41306594|NCT02011126|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41306595|NCT03644940|DIAGNOSTIC_TEST|CustomSight|Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
41306596|NCT03326219|PROCEDURE|Clarivein|The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
41306597|NCT01740440|DEVICE|BMR Face|BMR Face used in accordance with manufacturer IFU
41306598|NCT01675531|DRUG|Targin|Single arm for Targin
41306599|NCT04043182|PROCEDURE|ultrassound|The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.
40784424|NCT04660760|BIOLOGICAL|Ramucirumab|Given IV
40784425|NCT04660760|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
40784426|NCT04276025|OTHER|Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
40784427|NCT02613195|DRUG|Hydrogen-Rich Celsior Solution|Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
40784428|NCT03381118|DRUG|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2
40784429|NCT03381118|DRUG|Nivolumab|Nivolumab 40 mg IV infusion on D+5
40784430|NCT03381118|DRUG|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3
41306600|NCT01003561|PROCEDURE|spinal anesthesia for surgery|spinal anesthesia (T10) for elective TURP surgery
41306601|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (Low Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 2 consecutive minutes for each side, only once for the experiment duration.
41465065|NCT03627598|DEVICE|standard|patients will receive low flow oxygen therapy at 1 to 4 liters per minute
41465066|NCT01739413|PROCEDURE|Anesthesia|Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
40784431|NCT03381118|DRUG|Nivolumab|Nivolumab 40 mg IV infusion on D+1
40784432|NCT03381118|BIOLOGICAL|G-CSF mobilized HLA-haploidentical donor PBSC|G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0
40784433|NCT06543485|PROCEDURE|intramedullary screw fixation of metacarpal fractures|intramedullary screw fixation of metacarpal fractures through limited open approach
40784434|NCT05788445|DEVICE|nrTMS treatment|Using the nrTMS treatment coli to stimulation with high frequency
40784435|NCT05788445|DEVICE|nrTMS sham|Using the nrTMS sham coli to stimulation with high frequency
41465067|NCT05577494|OTHER|Questionnaire online|"Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual."
41465068|NCT02363439|DRUG|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly|IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
40784436|NCT03609424|DRUG|PDR001, Imatinib|"-Phase Ib part~: The standard 3+3 dose escalation scheme will be applied. DLTs will be evaluated during the first cycle (4 weeks).~PDR001 400mg, every 4 weeks, IV~Imatinib dose level -1 : 200mg, PO, QD Imatinib dose level 1 : 300mg, PO, QD Imatinib dose level 2 : 400mg, PO, QD~-Phase II part~* Recommended dose defined in phase Ib part will be tested"
40784437|NCT03423407|DEVICE|Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|FDA approved scanner
40784438|NCT01497756|DEVICE|CAPP use|Any abdominal pelvic pressure
40988443|NCT01629368|DRUG|Carbamazepine|Multiple doses of carbamazepine
41306602|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (Intermediate Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 3 sessions of 2 minutes, with 2 minutes of rest for each side. stimulation will be provided only once for the experiment duration.
41306603|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (High Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 8 consecutive minutes for each side, only once for the experiment duration.
41306604|NCT06381648|DIAGNOSTIC_TEST|LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)|A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)
41306605|NCT00623454|BEHAVIORAL|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
41306606|NCT03088293|DRUG|Infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
41306607|NCT03088293|DRUG|Cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
41306608|NCT01496430|DRUG|Placebo|
41306609|NCT01496430|DRUG|Azilsartan medoxomil|
40784439|NCT03538093|OTHER|Experimental: Local Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus a. activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase:4th-6th week: hot compress + electrotherapy IFT (fr: 4kHz, AMF 100Hz, modulation 20Hz, 20 mins), stabilizer training. Hamstring, quadriceps, gluteus maximus and psoas stretching, stationary bicycle without load. 7th-9th week: stabilizer training elevating a leg, stationary bicycle low load. 10th-12th week: 1kg to elevated leg on stabilizer training, stationary bicycle moderate load."
40988444|NCT01629368|DRUG|RO4917523|Single dose of RO4917523
41306610|NCT01496430|DRUG|Azilsartan medoxomil|
41465069|NCT01086228|DEVICE|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
40988445|NCT03287440|BEHAVIORAL|COPD Wellness|This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.
41465070|NCT00458445|DRUG|SPD465|
41465071|NCT00458445|OTHER|Placebo|Placebo is a material that may look similar to SPD465, however, contains no active drug.
40784440|NCT03538093|OTHER|Experimental: Global Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: add obliques cross exercises in supine with contralateral leg, lumbopelvic bridge exercises, sitting on the edge of the bed. Day 3: add bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase: physiotherapy: 4th-6th week: hot compress + electrotherapy IFT, lumbopelvic bridge exercises, obliques cross exercises. Hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, stationary bicycle low load. 10th-12th week: physiotherapy, side plank, unilateral bridge, stationary bicycle moderate load."
41145812|NCT04315428|BEHAVIORAL|no swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
41306611|NCT06518109|OTHER|Zarit Caregiver Burden Scale|The Zarit Caregiver Burden Scale (ZCBS) is a widely used instrument for assessing the burden experienced by caregivers of individuals requiring long-term care. It consists of 22 items and the total score ranges from 0 to 88 (low/no burden to severe burden)
41306612|NCT03765801|DRUG|GRTA9906 60 mg PR tablet|GRTA9906 60 mg PR tablet
41306613|NCT03765801|DRUG|GRTA9906 60 mg IR capsule|GRTA9906 60 mg IR capsule
41306614|NCT03173820|GENETIC|Genotype guided|Tacrolimus will be prescribed depend on CYP3A5 genotype. CYP3A5\*1/\*1 patients will receive tacrolimus 0.125 mg/kg/day. CYP3A5\*1/\*3 patients will receive tacrolimus 0.1 mg/kg/day. CYP3A5\*3/\*3 patients will received tacrolimus 0.08 mg/kg/day. Tacrolimus target level for this phase will be 5-8 ng/ml.
41306615|NCT03173820|GENETIC|Conventional|Tacrolimus will be prescribed 0.1 mg/kg /day for all patients to achieve tacrolimus level 5-8 ng/ml.
41306616|NCT00042354|DRUG|clofarabine (IV formulation)|
41306617|NCT01740037|OTHER|Specialized outpatient AF Clinic|
41306618|NCT01740037|OTHER|Usual Care|
41465072|NCT03594825|DRUG|Valsartan|Different time of taking medicine
41465073|NCT02246764|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
41465074|NCT02246764|DRUG|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
41145813|NCT05588661|OTHER|Perturbation Exercises|"Perturbation exercises will be performed 3 times in a week for 6 weeks for 10-15 minutes per session with baseline treatment for total 30 minutes.~Total 18 sessions will be given to the patients."
41145814|NCT05588661|OTHER|Whole Body Vibration|"It will be performed 3 times in a week for 10-15 minutes per session with baseline treatment for total 30 mints.~Total 18 sessions will be given for 6 weeks"
41145815|NCT01299441|DEVICE|ECOM ETT|Intubation with ECOM endotracheal tube (ETT)
41145816|NCT05760417|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
41145817|NCT01851694|DRUG|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
41306619|NCT01477151|DRUG|Volatile anesthetic|"The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration."
41306620|NCT02775552|BEHAVIORAL|A&T community-based interventions|"1. Interpersonal communication delivered by health workers and community volunteers at the health post and during home visits to:~   - Increase mothers' knowledge about adequate child feeding practices~2. Interpersonal communication delivered by agricultural extension workers to:~   - Increase fathers' knowledge about nutrition-sensitive agriculture and child feeding~3. Community mobilization activities to:~   * Raise awareness of child feeding practices among community members, and increase support to mothers (enhanced community conversations)~  * Increase mothers' knowledge about preparation of complementary foods (cooking demonstrations)~  * Raise awareness of adequate child feeding during fasting among family and community members (church sermons)~4. Enhanced training of government health and agricultural extension workers in infant and young child feeding to:~   * Improve their ability to provide timely and appropriate information and support to mothers and families"
41465075|NCT02246764|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
41465076|NCT02246764|OTHER|Placebo|1 drop QD, AM, OU
41465077|NCT01333917|DRUG|Curcumin C3 tablet|4 grams Curcumin C3 tablet daily x30 days
41465078|NCT02023996|RADIATION|89Zr-DFO-trastuzumab|
41145818|NCT01851694|DRUG|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
41465079|NCT02023996|DEVICE|PET imaging|
41465080|NCT05152615|DIETARY_SUPPLEMENT|Short Chain Fatty Acids (SCFA) Dietary Supplement|Butryate 1000 mg three times daily will be used in this study.
41465081|NCT03642067|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
41306621|NCT02775552|BEHAVIORAL|Mass media|Radio campaign - radio drama series, spots, and jingles
41306622|NCT06092138|DEVICE|Wearable Device|Whether to use wearable devices.
41306623|NCT05151770|OTHER|Measure of glycemia levels and comparison to algorithm predictions|The study aims to evaluate the efficacy of a new algorithm in predicting the evolution of glycemia levels after a full meal. Glycemia levels measured during and after a full meal will be compared to the values predicted by the algorithm. Composition of the meals will also be collected.
41306624|NCT06186882|BEHAVIORAL|Action Video-Game|Thanks to their specific characteristics (presentation of multiple peripheral, rapidly moving, spatio-temporally unpredictable stimuli), Action Video-Games improve reading skills through their effects on the Magnocellular-Dorsal stream. Training will consist of 20 days of Action Video-Games sessions of 1 hour each, three times per week.
41306625|NCT01668563|PROCEDURE|surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
41306626|NCT01668563|PROCEDURE|Endovascular management|Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
41306627|NCT00813514|GENETIC|VEGF genotyping|blood sample for gene analysis
41306628|NCT00631488|DRUG|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
41306629|NCT00631488|DRUG|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
41306630|NCT00631488|DRUG|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
41306631|NCT00631488|DRUG|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
41306632|NCT00631488|DRUG|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
41306633|NCT00631488|DRUG|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
41306634|NCT01228266|BIOLOGICAL|autologous mesenchymal stem cells|A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
41306635|NCT03541512|BEHAVIORAL|Mindfulness + Education|"Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
41306636|NCT03541512|BEHAVIORAL|Education|"Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
41306637|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
41306638|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
41306639|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
41306640|NCT03435991|OTHER|Validation Experience Sampling Method 'Uromate'|In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.
41306641|NCT04527562|DRUG|Colchicine|Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
41306642|NCT04527562|DRUG|Placebo|Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
41465082|NCT03642067|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
41465083|NCT03642067|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
41465084|NCT03642067|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
41465085|NCT02909517|OTHER|cSLO imaging|
41465086|NCT02970045|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, and other biological samples
41465087|NCT02970045|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
41465088|NCT02970045|OTHER|Medical Chart Review|Review of medical chart
41465089|NCT02970045|OTHER|Quality-of-Life Assessment|Ancillary studies
41465090|NCT02970045|OTHER|Questionnaire Administration|Ancillary studies
41465091|NCT02569281|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
41145819|NCT05986799|DIETARY_SUPPLEMENT|Amway Herbal Drink|1 sachet per time, 3 times daily, for 3 months period.
41145820|NCT05986799|DIETARY_SUPPLEMENT|Placebo Drink|1 sachet per time, 3 times daily, for 3 months period.
40988446|NCT03287440|BEHAVIORAL|Health Advocate|The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
41145821|NCT00253851|DRUG|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
41145822|NCT05316649|OTHER|Measurement of external blood loss|Measurement of external blood loss
41145823|NCT05316649|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|Serum Hemoglobin concentration
41145824|NCT01215253|DRUG|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
41145825|NCT05730192|DEVICE|CADDIE|A colonoscopy is an examination of the bowels using a colonoscope, or a thin, flexible tube with a light and camera. It can help identify issues like colorectal cancer, polyps, and ulcers.
41145826|NCT02817685|OTHER|3 months|
41145827|NCT02817685|OTHER|6 months|
41145828|NCT02817685|OTHER|3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI|
41145829|NCT05264506|DRUG|NOMAC-E2 COC|"Dosage Formulation: Film-coated Tablet Unit Dose Strength: Nomegestrol acetate (NOMAC) 2.5 mg and estradiol (E2) 1.5 mg; Each blister strip contains 28 tablets: 24 tablets with the active drug (number 1 to 24) and 4 tablets with placebo (number 25 to 28).~Dosing Instructions: oral. Take 1 tablet daily at about the same time as directed."
41145830|NCT05591456|RADIATION|adjuvant radiotherapy|Treatment schedule and delivery The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
41465092|NCT02569281|OTHER|Eccentric exercise|An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
41465093|NCT00655317|OTHER|Acupuncture|Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
41465094|NCT00655317|OTHER|Sham acupuncture|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
41465095|NCT03864458|DRUG|KHK7791|oral administration
40988447|NCT04320485|DIAGNOSTIC_TEST|Active Anthrax Detect™ Plus (AAD Plus)|A lateral flow immunoassay rapid test (AAD Plus) for early and presumptive diagnosis of inhalational anthrax.
40988448|NCT05880927|DRUG|Pyrotinib|Patients receive pyrotinib 400mg/day for half or one year
40988449|NCT03889821|BEHAVIORAL|Parent-implemented Early Start Denver Model|The Parent-implemented Early Start Denver Model (P-ESDM; Rogers et al., 2012) consists of 12 consecutive sessions, each session approximately 1 hour long, that promote parental ability to support and interact with their young children with autism spectrum disorder (ASD). Intervention sessions are conducted in the clinic setting by therapists trained to fidelity by ESDM-certified parent trainers. The manualized intervention has a detailed parent-training curriculum, a specific coaching intervention method, and a therapist fidelity measure. Therapists introduce skills through descriptions, interaction, modeling, coaching, and feedback.
41145831|NCT00003732|DRUG|carboplatin|
41145832|NCT00003732|DRUG|paclitaxel|
41145833|NCT00003732|DRUG|topotecan hydrochloride|
41306643|NCT04111887|BEHAVIORAL|Group-based therapy|College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
41465096|NCT03864458|DRUG|Placebo|oral administration
41465097|NCT02966340|DRUG|Prazosin|2mg Prazosin
41145834|NCT04455542|OTHER|LMND-ALS|in line with LMND -ALS inclusion criteria, and CMAP amplitude of peripheral motor nerves (CMAP amplitude of the 10 peripheral motor nerves with the most obvious CMAP amplitude decline was selected as the CMAP amplitude for grouping of the patients) was less than the median of CMAP amplitude of LMND -ALS group.
41145835|NCT04455542|OTHER|UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
41306644|NCT04341675|DRUG|Sirolimus|Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.
41306645|NCT04341675|DRUG|Placebo|Matching placebo
41306646|NCT05055115|PROCEDURE|Balloon Eustachian Tuboplasty|Balloon Eustachian Tuboplasty of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
41465098|NCT02966340|DRUG|Placebo|Placebo
40784441|NCT03538093|OTHER|Experimental: Mixed Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus abdominis activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~4th-6th week: hot compress + electrotherapy IFT, stabilizer training, hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, change stationary bicycle load to low load. 10th-12th week: physiotherapy, advanced global exercise (side plank), unilateral bridge,stationary bicycle moderate load."
40784442|NCT03392181|DRUG|18F-DCFPyL|To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
40784443|NCT03271775|OTHER|physical therapy program (group)|Exercises group transmitted by physical therapist (Up to four participant in each group).
41145836|NCT04455542|OTHER|FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy.
40784444|NCT03271775|OTHER|physical therapy program (computerized exercises)|Remote exercises program accompanied by a physical therapist guidance
40784445|NCT05626933|PROCEDURE|Buccinator myomucosal flap with Furlow palatoplasty|Anatomical restoration concept using Buccinator myomucosal flap with Furlow palatoplasty is an effective technique for lengthening the palate and improving speech outcomes
40988450|NCT03889821|BEHAVIORAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) protocol is derived from the work by Dykens et al. (2014), which is based on the stress reduction and relaxation program (Kabat-Zinn, 1982, 1990). In this study, it is offered as 6 weekly sessions that run concurrent with the P-ESDM intervention. Participants work one-on-one with a therapist for instruction and practice in mindfulness skills as well as discussions of stress, coping, and homework assignments.
40988451|NCT00676299|DRUG|JNJ-26483327|
41145837|NCT04367948|DIAGNOSTIC_TEST|18F-FDG and 68Ga-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
41145838|NCT04367948|DIAGNOSTIC_TEST|18F-FDG and 18F-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
41145839|NCT03460132|DEVICE|Tomas® Anchorage System - DENTAURUM|self drilling, bone inserted, screw like device used for anchorage preparation during orthodontic treatment.
41145840|NCT00800917|DRUG|Temsirolimus|25 mg weekly IV
41145841|NCT00800917|DRUG|Bevacizumab|10 mg/kg every 2 weeks
41145842|NCT06157840|DEVICE|mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity
41145843|NCT06157840|DEVICE|Simplified mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will receive a simplified version of the app with sleep hygiene instructions and will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.
41145844|NCT04203368|DRUG|adenosine|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
41145845|NCT04203368|DRUG|verapamil|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
41145846|NCT02181881|BEHAVIORAL|DuoPACT|Intervention sessions are administered weekly by a counselor.
41145847|NCT02181881|BEHAVIORAL|Life Steps|Intervention sessions are administered weekly by a counselor.
41306647|NCT06261099|OTHER|control + working group|Upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group using the telerehabilitation method, which was applied to in 5 sessions per week for 6 weeks.
41306648|NCT06363045|DEVICE|NIDEK TONOREF III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
41306649|NCT06363045|DEVICE|Haag-Streit, PERKINS HAND-HELD APPLANATION TONOMETER|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
41465099|NCT02802215|DRUG|metformin|Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.
41465100|NCT02802215|DRUG|placebo (folic acid )|500 micro gram of folic acid every 8 hrs
41465101|NCT00006331|PROCEDURE|renal transplant|
40784446|NCT06487780|BEHAVIORAL|Lifestyle-focused Occupational Therapy Intervention|The proposed intervention, led by trained occupational therapists, will focus on establishing sustainable self-care routines. It will consist of approximately 12 biweekly sessions, each lasting about an hour on average. Therapists will customize session timing and duration based on participant needs.
40784447|NCT06487780|OTHER|Education|Participants in the education group will receive standardized education materials on diabetic foot ulcers (DFUs), foot care, and offloading treatment to prevent foot ulcer recurrence.
40784448|NCT02752347|DEVICE|Surface EMG device|measuring the muscles activity using surface EMG device
40784449|NCT00586157|DRUG|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
40784450|NCT00586157|DRUG|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
40784451|NCT04123730|OTHER|Fixed-dose compared to variable oxygen flow supplementation during walking|"At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT"
40784452|NCT02589288|PROCEDURE|Continuous Infusion of ropivacaine 0.2%|Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
40784453|NCT02589288|PROCEDURE|Automatic Intermittent Bolus of ropivacaine 0.2%|Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
40988452|NCT01428180|DRUG|Indomethacin|3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
40988453|NCT01428180|PROCEDURE|Surgical Ligation|In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
40988454|NCT01428180|DRUG|Ibuprofen|3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
40988455|NCT01477060|DRUG|Lapatinib|1250 mg/ die, os
40988456|NCT01477060|DRUG|Metformin|1500 mg/die, os
40988457|NCT01640483|OTHER|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
40988458|NCT02424929|PROCEDURE|Sedation|Propofol anesthesia administered during entire surgery.
40784454|NCT03766061|PROCEDURE|Onlay mesh Hernioplasty|Patients with paraumblical hernia are treated with onlay mesh hernioplasty in which mesh is placed on anterior rectus sheath
40784455|NCT03766061|PROCEDURE|Sublay Mesh Hernioplasty|Patients with paraumblical hernia are treated with sublay mesh hernioplasty in which mesh is placed in retromuscular space
40784456|NCT02782442|BEHAVIORAL|Structured Cognitive Training & PRIME|The treatment condition-- 30-35 hours of CT over 16 weeks (\~2 hours per week) is a structured program of 20 hours of auditory processing exercises followed by 10 hours of social cognition exercises, combined with the personalized PRIME coaching application
40784457|NCT02782442|BEHAVIORAL|Computer Games Control & PRIME|Computer games control condition which comes in the official PositScience wrapper. 30-35 hours of games over 16 weeks (\~2 hours per week), combined with the personalized PRIME coaching application.
40784458|NCT00022178|DRUG|cisplatin|
40784459|NCT00022178|DRUG|cyclophosphamide|
40784460|NCT00022178|DRUG|doxorubicin hydrochloride|
40784461|NCT00022178|DRUG|epirubicin hydrochloride|
40988459|NCT02424929|PROCEDURE|Original Surgery|No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
40784462|NCT00022178|DRUG|fluorouracil|
40988460|NCT05595681|DRUG|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The investigational product is a C2C_ASC cell product (Cell2Cure®, Cell2Cure ApS, Denmark).~C2C_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The exipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
40988461|NCT03274531|BEHAVIORAL|Referral of hypertensive patients to the attending physician|Immediate referral to the treating physician in case of elevated automated office blood pressure measurements
40988462|NCT02859051|DEVICE|Humanoid Robot MEDi|Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
40988463|NCT05283798|DEVICE|IUD|Postpartum intra-caesarean section insertion of copper T380 versus multiload 375
40988464|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
41465102|NCT04767958|DIAGNOSTIC_TEST|Spartan COVID-19 Platform|Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform
40784463|NCT00022178|DRUG|vincristine sulfate|
40784464|NCT00159926|PROCEDURE|Cell saver|Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass
40784465|NCT00159926|PROCEDURE|No cell saver|Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
40784466|NCT05710952|DEVICE|Review by Modjaw|A review by Modjaw's will be done before the braces treatment and after.
40784467|NCT02133469|BIOLOGICAL|PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)|injection 0.5 mL, single dose
40784468|NCT02133469|BIOLOGICAL|Hib Vaccine|Single Dose
40784469|NCT06007417|DRUG|GenSci004|GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)
40784470|NCT06007417|DRUG|Genotropin|Genotropin
40784471|NCT03889652|DIAGNOSTIC_TEST|Oct scans|Oct scans to assess thickness of RNFL and GCC before and after cataract extraction surgery in both groups
40784472|NCT01912573|DRUG|Intranasal (IN) naloxone|
40784473|NCT01912573|DRUG|Intravenous (IV) naloxone|
40784474|NCT01912573|DRUG|Intramuscular (IM) naloxone|
40784475|NCT01912573|DRUG|Intraosseus (IO) naloxone|
40784476|NCT04955184|DEVICE|non-invasive monitoring|non-invasive measurements of cardiac output
40784477|NCT03390725|BEHAVIORAL|A Healthy School Start Plus intervention|Intervention for prevention of childhood overweight and obesity in disadvantaged areas through parental support in the school setting
40784478|NCT01012284|DRUG|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
40784479|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.05 mg/kg once daily oral liquid dose
40784480|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.20 mg/kg once daily oral liquid dose
40784481|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.40 mg/kg once daily oral liquid dose
40784482|NCT00547963|BEHAVIORAL|brief counseling|baseline assessment + two 40 minute sessions of brief counseling
40784483|NCT01127919|BEHAVIORAL|Aerobic Exercise Training|40 minutes, 3 times a week for 35 weeks.
40784484|NCT01127919|OTHER|Cognitive Component|Provide general information about health and fitness
40784485|NCT01148667|DIETARY_SUPPLEMENT|Casein hydrolysate added with LGG|Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.
40784486|NCT01148667|DIETARY_SUPPLEMENT|Infants drink casein hydrolysate without LGG|Infants drink extensively hydrolysed casein formula without added LGG
40784487|NCT02835144|OTHER|TIQAAM_therapy|The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.
40784488|NCT02835144|OTHER|Psychoeducation|This intervention is a psychoeducation module pertaining to substance use disorders.
40784489|NCT01083602|DRUG|panobinostat|PAN 20 mg PO given TIW, weeks 1\&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1\&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1\&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
40784490|NCT01083602|DRUG|bortezomib|
40784491|NCT01083602|DRUG|dexamethasone|
40784492|NCT05231824|BEHAVIORAL|Standard Behavioral Weight Loss Treatment|Behavioral weight loss treatment is the current gold standard treatment for obesity.
40784493|NCT05231824|BEHAVIORAL|AI-optimized Behavioral Weight Loss Treatment|AI-optimized Behavioral Weight Loss Treatment will continuously vary intensity (automated text message, videoconference group, individual coaching call) and coach type (paraprofessional or MS-level expert) based on continuously-monitored participant digital data.
40784494|NCT02529683|DRUG|Nuvaring|contraceptive vaginal ring with ethinyl estradiol and etonogestrel
40784495|NCT00374114|PROCEDURE|cervical conization|
40784496|NCT00374114|PROCEDURE|ultrasonic surgical aspiration of the cervix|
40784497|NCT01478022|DRUG|Isosorbide Dinitrate|Isosorbide Dinitrate 10 mgx2, daily, capsules
40784498|NCT01478022|DRUG|Ibuprofen|Ibuprofen 200 mg daily, capsules
40784499|NCT01478022|OTHER|Ibuprofen and Isosorbide Dinitrate combination|Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
40784500|NCT00605059|DRUG|[123I]AV94|Evaluation of \[123I\] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
40784501|NCT03030456|DEVICE|Power Plate®|Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
40784502|NCT01465841|DEVICE|PC 400 coils (Penumbra )|The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in ± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.
40784503|NCT03391999|OTHER|A questionnaire; CHU9D|Measuring Health Related Quality of Life
40784504|NCT01900067|DEVICE|BARRIER® EasyWarm Active Self-Warming Blanket|
40784505|NCT01045369|DRUG|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
40784506|NCT03769688|DRUG|Cervicovaginal secretions|Same as arm descriptions
40784507|NCT03769688|DRUG|Metronidazole gel|5 day course of vaginal MetroGel will be used prior to VMT intervention.
40784508|NCT03769688|DIAGNOSTIC_TEST|Screening tests|Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.
40784509|NCT03769688|BEHAVIORAL|Activities restriction|Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.
40784510|NCT03769688|OTHER|Sterile Saline placebo|This will be administered as a placebo in place of cervicovaginal secretions
40784511|NCT01897532|DRUG|Placebo|placebo matching tablets
41145848|NCT05512988|BIOLOGICAL|UC-MSC|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per trial group for the entire duration of the course, with a total dose of 2×10\^6/Kg/person."
40784512|NCT01897532|DRUG|Linagliptin|
41306650|NCT06363045|DEVICE|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
40784513|NCT00278161|BIOLOGICAL|Pegfilgrastim|6 mg SQ 24-48 hours after last dose of cyclophosphamide.
40784514|NCT00278161|BIOLOGICAL|Rituximab|375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52.
40784515|NCT00278161|DRUG|Cyclophosphamide|50 mg/kg/day on Days 15, 16, 17, and 18.
40784516|NCT04817202|DRUG|hzVSF-v13 (intravenous, single dose)|Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)
40784517|NCT04817202|DRUG|hzVSF-v13 (subcutaneous, single dose)|Dosage form: 100mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
40784518|NCT04817202|DRUG|hzVSF-v13 (intravenous, multiple dose)|Dosage form: 100mg / 400mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
40784519|NCT04817202|DRUG|Placebo (intravenous, single dose)|Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1 (single administration)
40784520|NCT04817202|DRUG|Placebo (subcutaneous, single dose)|Dosage form: 0.9% NaCl Solution Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
40784521|NCT04817202|DRUG|Placebo (intravenous, multiple dose)|Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
40784522|NCT06375525|DEVICE|Janssen's icon Application (App)|
40784523|NCT06354673|PROCEDURE|Stellate ganglion block|Sympathectomy by using combination of regional nerve block and systemic drugs
40784524|NCT06354673|DRUG|Dexmedetomidine|intravenous Dexmedetomidine infusion
40784525|NCT06354673|DRUG|Ketamine|intravenous ketamine infusion
40784526|NCT02746302|DRUG|HS-20004|
40784527|NCT02746302|DRUG|Placebo|
40784528|NCT04861714|DEVICE|Regeneten|Augmentation of standard subscapularis repair with regeneten patch
40784529|NCT04861714|PROCEDURE|Standard repair|Standard subscapularis repair
40784530|NCT02297412|DRUG|Minocycline Hydrochloride|Given PO
40784531|NCT02297412|OTHER|Placebo|Given PO
40784532|NCT02297412|OTHER|Quality-of-Life Assessment|Ancillary studies
40784533|NCT02297412|OTHER|Questionnaire Administration|Ancillary studies
40784534|NCT01749527|BEHAVIORAL|minimal activity|Pad test with minimal activity
40784535|NCT03895294|OTHER|Health care under the strategic purchase-Clinical pathway|1) purchase of DAA by the MoHSP; 2) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in internal medicine, hepatology or Infectious disease; 3) daily supervised drug administration by a nurse or weekly treatment dispensing by pharmacist; 4) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, week of the end of treatment (8, 12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support. In case of identifying any Drug-related Problem, the respective pharmaceutical intervention was made.
40988465|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
40988466|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
40988467|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
40988468|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
40988469|NCT03580850|OTHER|No intervention in this restrospective study|This study is an obervational study
40988470|NCT02410382|DRUG|Dexamethasone|oral dexamethasone 4 mg bid for 14 days
40988471|NCT02410382|DRUG|Placebo|oral placebo
40988472|NCT05306301|DRUG|Ponatinib|Ponatinib is a novel, synthetic, orally-active TKI discovered using a computational and structure based drug design approach. Ponatinib was specifically designed to inhibit all clinically relevant variants of BCR-ABL1, including the T315I mutant (15-17). In vitro assays have demonstrated that Ponatinib potently inhibits the kinase enzymatic activity of the T315I ABL kinase domain, as well as that of the native (unmutated) enzyme. In leukemia cell lines expressing these BCR-ABL1 variants, Ponatinib potently inhibited BCR-ABL1 signaling, leading to the reduction of cellular proliferation and induction of apoptosis. Ponatinib also inhibits the proliferation of cell lines expressing other major clinically-observed Imatinib-resistant mutants of BCR-ABL1.
40988473|NCT02522286|BEHAVIORAL|Ask 3 Questions|"Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare."
41145849|NCT05512988|BIOLOGICAL|Saline solution|"Usage: The saline solution in this study is used intravenously in the elbow.~Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per person for the entire duration of the course"
41145850|NCT05658809|PROCEDURE|thyroidectomy|Patients will be divided into 2 groups group will be treated with total thyroidectomy and the other group will be treated with hemithyroidectomy
41145851|NCT01648075|DIETARY_SUPPLEMENT|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
41145852|NCT04054245|DRUG|LOXL2 Inhibitor PAT-1251|Given PO
41145853|NCT04054245|OTHER|Quality-of-Life Assessment|Ancillary studies
41306651|NCT02666092|OTHER|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
41145854|NCT04054245|OTHER|Questionnaire Administration|Ancillary studies
40988474|NCT02522286|BEHAVIORAL|Open Communication|"Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow."
40988475|NCT05502055|OTHER|Individual interviews|One on One interviews by Zoom video conferencing, \< 2 hours in duration
40988476|NCT05502055|OTHER|Focus Groups|Focus Groups discussions by Zoom video conferencing, \< 2 hours in duration
40988477|NCT05502055|OTHER|National Survey|Survey conducted online and distributed nationally
41145855|NCT02933645|DRUG|Actrapid|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
41306652|NCT02666092|BIOLOGICAL|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
41306653|NCT01245426|DRUG|GW870086 2mg|oral inhalation
41306654|NCT01245426|DRUG|GW870086 4mg|oral inhalation
40988478|NCT02294344|OTHER|DFPP&CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35\~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented."
41145856|NCT02933645|DRUG|Placebo|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
41145857|NCT02933645|RADIATION|[18F]-FDG PET-CT|All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq \[18F\]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
41145858|NCT02933645|DRUG|Hyperinsulinemic euglycemic clamp|All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
41145859|NCT00006229|DRUG|carboplatin|
41145860|NCT00006229|DRUG|paclitaxel|
41306655|NCT01245426|DRUG|GW870086 Placebo|oral inhalation
41306656|NCT01245426|DRUG|GW870086 1mg|oral inhalation
41306657|NCT01245426|DRUG|GW870086 3mg|oral inhalation
41306658|NCT04515875|BEHAVIORAL|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
41465103|NCT02964650|DEVICE|Personalised rate-response settings|Rate response range fixed to limits suggested by force-frequency curve
41465104|NCT04542694|DRUG|Favipiravir|200 mg coated tablets
41465105|NCT04542694|DRUG|Standard of care|"Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc."
41145861|NCT00006229|DRUG|rebimastat|
41145862|NCT01463397|DRUG|SAR292833|"Pharmaceutical form: capsule~Route of administration: oral"
41145863|NCT01463397|DRUG|placebo|"Pharmaceutical form:capsule~Route of administration: oral"
41145864|NCT02655536|DRUG|Bevacizumab plus erlotinib|Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of every 3 weeks cycle by IV infusion erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
41145865|NCT02655536|DRUG|Erlotinib|erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
41145866|NCT01803828|DRUG|Tadalafil|20 mg/die (1 capsule)
40988479|NCT02294344|DRUG|CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count \<3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count \<3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study."
41306659|NCT04515875|BEHAVIORAL|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
40988480|NCT05719805|DRUG|Mavacamten|Specified dose on specified days
40988481|NCT00678119|BIOLOGICAL|AGS-003|Dendritic cell Immunotherapeutic
40988482|NCT00678119|DRUG|Sunitinib|An approved drug for the treatment of RCC
40988483|NCT04011527|PROCEDURE|Rotational Atherectomy in Coronary Lesion/s|
41145867|NCT01803828|DRUG|Placebo|Placebo 20 mg/die (1 capsule)
41145868|NCT03404440|OTHER|L.Reuteri|
41145869|NCT05248672|DRUG|CT1812|Study Drug
40784536|NCT03895294|OTHER|Usual care process prior strategic purchase-clinical pathway|1) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in hepatology; 3) weekly treatment dispensing by pharmacist; 4) patient use; 5) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, 8, week of the end of treatment (12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support). In case of identifying any Drug-related problem, the respective pharmaceutical intervention was made.
40784537|NCT05167812|OTHER|Observation of pregnancies after intake|Monitoring pregnancies after intake at a dedicated recurrent pregnancy loss clinic to predict pregnancy success chances in couples with recurrent pregnancy loss
40784538|NCT03767543|DRUG|INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
40784539|NCT04115462|DRUG|Morphine|A 20 mg tablet of morphine
40784540|NCT04115462|DRUG|Placebo oral tablet|Matching tablet of placebo
40784541|NCT04115462|DRUG|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
40784542|NCT04115462|DRUG|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
40784543|NCT04115462|DRUG|isotonic saline|A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
40988484|NCT04510779|DEVICE|Apple Watch|Apple Watch is a smartwatch developed by Apple Inc. The heart rate variability function will be used.
40988485|NCT02848014|BEHAVIORAL|Writing task|
41145870|NCT00393185|BIOLOGICAL|Non-myeloablative Hematopoietic Stem Cell Transplantation|autologous Hematopoietic Stem Cell Transplantation
41145871|NCT00338325|BEHAVIORAL|Reading program|Reading of children's story/picture books preoperatively
41145872|NCT02691884|PROCEDURE|maternal abdominal pressure|The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
41306660|NCT03518099|BIOLOGICAL|blood sampling|Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
41306661|NCT03439748|BEHAVIORAL|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
41306662|NCT03439748|BEHAVIORAL|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
40784544|NCT04115462|DRUG|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the mandibular area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
40784545|NCT04115462|DRUG|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
41145873|NCT02442102|BEHAVIORAL|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
41145874|NCT00583349|DRUG|Paclitaxel, nanoparticle albumin-bound|Intravesically administered, dose escalation, 6 weekly instillations
41145875|NCT04203225|DRUG|LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel|Topical anesthetic
41145876|NCT06063915|DEVICE|Isoinertial training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using isoinertial machines
41145877|NCT06063915|OTHER|Strength Training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using classic exercises
41145878|NCT04768491|DRUG|Dacomitinib|effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
41145879|NCT05726994|BIOLOGICAL|exhaled breath collection|Fasting children will be asked to breathe normally through a mouthpiece for the collection and analysis of exhaled breath.
41145880|NCT05726994|OTHER|Data collection|Clinical data will be collected in order to seek correlations with the exhaled breath profile.
41145881|NCT05692414|DIETARY_SUPPLEMENT|Preoperative carbohydrate drink|Allocation will be performed using an alternating weeks scheme. Patients undergoing surgery in the first week will be included in the control group and follow a conventional fasting protocol. However, patients undergoing surgery the following week will be included in the intervention group and take 800 ml of CHO drink on the day before surgery and 400 ml on the surgery day no later than 6 hours before the procedure.
41145882|NCT06277245|DRUG|LNK01001|Capsule; Oral
41145883|NCT06277245|DRUG|Placebo|Capsule; Oral
41145884|NCT03703999|DEVICE|Type 1 diabetic patients freestyle libre|patients selected to use freestyle libre
41145885|NCT00005713|BEHAVIORAL|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
41145886|NCT05099068|BIOLOGICAL|Blood and tumor samples|Longitudinal molecular profiling of tumor and liquid biopsies.
41145887|NCT01906385|DRUG|Rhenium Liposome Treatment|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
41145888|NCT05770206|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Subjects in the experimental group will receive treatment by using Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd., flow rate: 3L/min) combined with conventional basic supportive treatment (symptomatic support treatment determined by the investigator based on the condition of the subjects);
41145889|NCT05770206|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|subjects in the control group will receive treatment by using Medical Molecular Sieve Oxygen Generator (manufactured by Shanghai Ouliang Medical Devices Co., Ltd., flow rate: 3L/min, provided by the sponsor) combined with conventional basic supportive treatment (same with that in the test group).
41145890|NCT01727076|OTHER|Laboratory Biomarker Analysis|Correlative studies
41145891|NCT01727076|OTHER|Pharmacological Study|Correlative studies
41145892|NCT01727076|BIOLOGICAL|Recombinant Human Interleukin-15|Given SC
41145893|NCT02951702|DRUG|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"
41145894|NCT02595788|OTHER|Change from supine to prone position|Change from supine to prone position
41306663|NCT03685799|DIAGNOSTIC_TEST|Pathological revision|Pathological revision
40784546|NCT02656667|DEVICE|neuromuscular electrical stimulation|quadriceps strenghthening with neuromuscular electrical stimulation (medical device)
40988486|NCT03806959|OTHER|Pan Capsule and colonoscopy in patients with IBS|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only Usual biological tests (CBC, CRP, TSH, anti-transglutaminase antibodies) and measurement of fecal calprotectin.
41465106|NCT03934827|DRUG|MRx0518 Capsules|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
41465107|NCT03934827|DRUG|MRx0518/placebo Capsules|MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
41465108|NCT00575380|DRUG|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days.
41465109|NCT00575380|DRUG|Vigamox Eye Drops|One drop three times a day for seven days
41465110|NCT04936594|DEVICE|iTBS|1800 pulses of iTBS
40784547|NCT02656667|DEVICE|cycle ergometer training|quadriceps strenghthening with cycle ergometer training
40784548|NCT02656667|OTHER|Conventional pulmonary rehabilitation|excercise training on treadmill
40988487|NCT05373420|OTHER|Education level|Educational level was classified using the International Standard Classification of Education (ISCED) : ISCED0 (less than primary education), ISCED1 (primary education), ISCED2 (lower secondary school), ISCED3 (upper secondary school), ISCED4 (post-secondary non tertiary education), ISCED5 (short-cycle tertiary education), ISCED6 (bachelor's or equivalent level), ISCED7 (master's or equivalent level), ISCED8 (doctoral or equivalent level). We merged these different categories into three main education level : low (ISCED0 to ISCED2), middle (ISCED3 to ISCED4) and high (ISCED5 to ISCED 8). This information is provided by STATBEL.
40988488|NCT05373420|OTHER|Household net income|Income information is available as deciles of the net income of the whole household. This indicator is further categorized into low income (deciles 1 to 4), middle income (deciles 5 to 7), and high income (deciles 8 to 10). This information is provided by STATBEL.
40784549|NCT02472249|RADIATION|CT perfusion|Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
40784550|NCT02472249|DRUG|Norepinephrine intra-arteriel/hepatic|A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds..
40784551|NCT01287494|DRUG|Sertraline|dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
40784552|NCT02649764|DRUG|Cytarabine|Given IV
40784553|NCT02649764|DRUG|Fludarabine Phosphate|Given IV
40784554|NCT02649764|OTHER|Laboratory Biomarker Analysis|Correlative studies
40988489|NCT05373420|OTHER|Gender|Male or female. This variable is obtained from the Belgian national registry.
41306664|NCT01294891|OTHER|Imaging|Contrast ultrasound perfusion imaging and complete echocardiography
40784555|NCT02649764|DRUG|Prexasertib|Given IV
40784556|NCT03730584|DRUG|Ropivacaine|"Ampoules of ROPIVACAINE 2mg / ml will be used by local cutaneous application in soft application with device of hand shower on the painful wounds without exceeding the dose of 1mg / kg per bath."
40988490|NCT05373420|OTHER|Migration background|Migration background is based on the first nationality and the parents' country of origin. This variable distinguishes between native-born individuals, second-generation migrants, first-generation European migrants, and first-generation non-European migrants. This information is provided by STATBEL.
41306665|NCT00002250|DRUG|CD4-IgG|
41306666|NCT02697461|OTHER|Intrinsic Foot Strengthening|"Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises."
41306667|NCT02697461|OTHER|Joint Mobilization|Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
40784557|NCT03730584|BIOLOGICAL|Blood test|Blood test during the first bath with Ropivacaine for Titration of Ropivacaine
40784558|NCT03374020|DEVICE|Notal OCT|Imaging using Notal OCT
40784559|NCT02739958|DRUG|Propofol group|Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
40784560|NCT02739958|DRUG|Isoflurane group|Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
41306668|NCT00456963|BEHAVIORAL|Diet|total fat \< 5%, saturated fat \< 10%, vegetables, fruit
41306669|NCT00456963|BEHAVIORAL|Moderate exercise|30 min at least 5 times/week
41306670|NCT00456963|DRUG|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
40988491|NCT05373420|OTHER|Household type|Household type provides a partial picture of the social environment and is distinguished between one person, couples, couples with children, single parents, other, collectivity (prison, nursing homes, religious community, etc.). This information is provided by STATBEL.
40988492|NCT05373420|OTHER|Health literacy|Having a health care degree is used as a proxy for health literacy and is provided by CoBRHA. The scientific and medical background can lead to more preventive and responsible behaviors towards infectious diseases. Moreover, being a health professional can lead to the need to protect patients and themselves against infections, without necessarily having very advanced knowledge of infectious diseases and vaccines.
40988493|NCT04098107|DEVICE|Throwing Device|The Innovative Design Labs ( IDL) PhySens will be used to monitor the physical motions of subjects during standard sports-related actions (e.g. throwing a baseball). For this test, the PhySens Carrier will be attached via clothing rivets to a fabric sleeve or strap made of compliant materials commonly used in clothing and wearable products (e.g. nylon, spandex, neoprene).
40988494|NCT05939375|BEHAVIORAL|FCC educational training|An educational training, grounded in six weeks of nurse-centered interactions, was implemented.
40988495|NCT02254928|DRUG|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
40988496|NCT04213365|OTHER|Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
40988497|NCT05829330|OTHER|Outpatient|Outpatient Initiation of noninvasive mechanical ventilation
40988498|NCT05829330|OTHER|Hospitalization|Initiation of non-invasive mechanical ventilation during hospitalization
40988499|NCT02885961|DRUG|Dabigatran|Anti-coagulant
40988500|NCT02885961|RADIATION|FDG PET scan|Scan using PET combined with a high resolution CT scan (HRCT)
40988501|NCT02144233|PROCEDURE|Occlusal adjustment|"The first step consists of the elimination of premature tooth contacts during retruded jaw closure.~The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)"
41145895|NCT06505005|DEVICE|Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT) Other Names:|Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT)
40784561|NCT05505461|DRUG|neoadjuvant Radiation plus SOX and PD-1 antibody|"Patients will be given the perioperative treatment as below once recruited:~First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.~The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.~SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery."
40988502|NCT02144233|PROCEDURE|Placebo occlusal adjustment|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
41145896|NCT06505005|DEVICE|Sham Patch without haptic vibrotactile trigger technology (VTT)|Sham Patch without haptic vibrotactile trigger technology (VTT)
41145897|NCT00083473|DRUG|Pivanex|
41145898|NCT02270125|PROCEDURE|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
41145899|NCT02137603|OTHER|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
41145900|NCT05206552|OTHER|Questionnaire|Maternal - Infant bonding questionnaire. EPDS - Postpartum depression questionnaire
41145901|NCT01326624|DEVICE|wearable defibrillator (LifeVest)|LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
40988503|NCT05109507|BEHAVIORAL|Visitor Mindset|Single-session, self-guided intervention
41145902|NCT02747056|OTHER|clinical, psychological and neuropsychological assessment|the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept
41145903|NCT02747056|OTHER|Autobiographical memories Assessment|The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.
41145904|NCT02747056|OTHER|Autobiographical memories assessment characteristics|During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
40784562|NCT02553187|DRUG|Kanglaite Injection|"200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks)."
40988504|NCT05109507|BEHAVIORAL|Relaxing with Nature|Single-session, self-guided intervention
40988505|NCT01984008|DRUG|Picosulfate sodium, magnesium oxide, citric acid|
40988506|NCT01650207|PROCEDURE|acupuncture|"All participants were received regular rehabilitation program, and received different interventions.~treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks"
41145905|NCT00004080|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
41145906|NCT00004080|PROCEDURE|conventional surgery|
41306671|NCT00456963|DRUG|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
40988507|NCT01650207|PROCEDURE|TENS|
40988508|NCT01650207|PROCEDURE|sham acupuncture|
40988509|NCT03159481|BEHAVIORAL|Usual Care + Health Promotion Intervention|Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
41306672|NCT00456963|DRUG|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
41306673|NCT05158309|OTHER|8% Capsaicin patch|Cutaneous pain was induced using a (5x10 cm) 8% topical capsaicin patch (transdermal patch, 'Qutenza', Astellas) on the volar part of the dominant right forearm (5 cm from the wrist) of each participant.
40988510|NCT03136003|DRUG|DDAVP|The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
40784563|NCT06179680|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|"MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition."
41145907|NCT02365402|DRUG|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
41145908|NCT01050699|DRUG|Dexmedetomidine|Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
41306674|NCT05158309|OTHER|placebo patch|A transparent patch with no formulation or effect but the same size of the capsaicin patch was applied to the same location.
41306675|NCT02476981|DRUG|Remifentanil|Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
41306676|NCT02476981|DRUG|Dexmedetomidine|Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
41306677|NCT02476981|DRUG|midazolam|All patients were premedicated with midazolam 0.02 mg/kg before induction.
40784564|NCT05042206|BIOLOGICAL|Cellgram-CKD|Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease
40784565|NCT03076281|DRUG|Metformin Hydrochloride|Given orally
41145909|NCT01050699|DRUG|Midazolam and Fentanyl|"Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)"
41145910|NCT00559195|BIOLOGICAL|epoetin beta|
41145911|NCT00559195|PROCEDURE|quality-of-life assessment|
40784566|NCT03076281|DRUG|Doxycycline|Given orally
40784567|NCT03076281|DRUG|Metformin +Doxycycline|Given orally
41145912|NCT04802967|DRUG|Ketoprofen Lysine Salt combined with Gabapentin|KLS-GABA (80 mg-34 mg) in Part A and KLS-GABA (40 mg-17 mg or 80 mg-34 mg or 160 mg-68 mg) in Part B
41145913|NCT04802967|DRUG|Ketoprofen Lysine Salt|KLS (80 mg) alone in each treatment period in Part A and KLS alone (40 mg, 80 mg, or 160 mg) in Part B
41145914|NCT04802967|DRUG|Gabapentin|300 mg
41145915|NCT04802967|OTHER|Placebo|2 capsules to maintain the blind
41145916|NCT00002045|DRUG|Zidovudine|
41306678|NCT02476981|DRUG|propofol|All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
41306679|NCT02476981|DRUG|ephedrine|Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
40784568|NCT00487981|DEVICE|Precision Spinal Cord Stimulation|Stimulation on throughout the study once device is implanted
40784569|NCT03160625|DEVICE|Rate Adaptive Pacing|Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
40784570|NCT02999607|OTHER|transcranial direct current stimulation|0.5 mA, 1mA, 2mA for 10 minutes each
40784571|NCT05753514|OTHER|ESWT|ESWT
40784572|NCT00788814|BEHAVIORAL|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
40784573|NCT06017492|BEHAVIORAL|video assisted discharge teaching|Patients will be educated using the video assisted discharge teaching. The educational content will be in English and will focus on the following topics: surgical process, medication use complication after surgery, pain management, wound care, nutrition, self-care after, surgery, home care after surgery and situations to refer to a physician.
40988511|NCT03136003|BEHAVIORAL|Exercise|The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
40988512|NCT04765150|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
41306680|NCT04829955|OTHER|Eccentric manual resistance training|Eccentric bodyweight resistance training
40784574|NCT00696878|DRUG|Corifollitropin alfa|Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
40784575|NCT00696878|BIOLOGICAL|FSH|FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
40784576|NCT00696878|BIOLOGICAL|GnRH antagonist|GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
40784577|NCT00696878|BIOLOGICAL|(rec)hCG|(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
40784578|NCT00696878|DRUG|Progesterone|Progesterone administered vaginally at a dose of at least 600 mg/day.
40784579|NCT03376932|DRUG|FF/UMEC/VI|FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
40784580|NCT03376932|DRUG|FP/SAL|FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.
40784581|NCT03376932|DRUG|Tiotropium|TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.
40784582|NCT03376932|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
40784583|NCT03376932|DEVICE|ELLIPTA DPI|The ELLIPTA device will be used to administer FF/UMEC/VI once daily. The ELLIPTA DPI is a molded plastic two-sided inhaler that can hold two individual blister strips, which contain powder formulation for oral inhalation.
40784584|NCT03376932|DEVICE|DISKUS DPI|The DISKUS device will be used to administer FP/SAL twice daily. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FP/SAL for oral inhalation.
40784585|NCT03376932|DEVICE|RESPIMAT inhaler|The RESPIMAT inhaler will be used to administer TIO once daily. The RESPIMAT inhaler has a solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminum cylinder.
40988513|NCT04765150|OTHER|Electronic Health Record Review|Medical charts are reviewed
40988514|NCT03025867|DRUG|Niraparib|
40988515|NCT01857934|DRUG|cyclophosphamide|Given intravenously (IV)
40988516|NCT01857934|DRUG|topotecan|Given IV
40988517|NCT01857934|BIOLOGICAL|hu14.18K322A|Given IV
40988518|NCT01857934|PROCEDURE|peripheral blood stem cell harvest|Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
40988519|NCT01857934|PROCEDURE|surgical resection|The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
40988520|NCT01857934|DRUG|cisplatin|Given IV
40988521|NCT01857934|DRUG|etoposide|Given IV
41306681|NCT04829955|OTHER|Concentric manual resistance resistance training|Concentric bodyweight resistance training
41465111|NCT04936594|DEVICE|TMS|MagVenture MagPro x100 device. This will be used as the comparator.
40988522|NCT01857934|DRUG|doxorubicin|Given IV
41147077|NCT02531061|DEVICE|HR-pQCT|"The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes."
41465112|NCT02569541|DRUG|sodium fusidate|
41465113|NCT00458289|DRUG|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
41465114|NCT02148354|BEHAVIORAL|Smiling is Fun|"Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else...?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress."
41465115|NCT05116137|BEHAVIORAL|Circuit-based resistance exercise (CRT)|CRT is a common training method used to foster aerobic fitness, muscular endurance and strength, as well as neuromuscular adaptations in one workout. CRT is comprised of several sets of different exercises with little rest in between each set.
41465116|NCT01903564|DEVICE|magnetocardiography|recording of magnetic heart activity
41465117|NCT01903564|DEVICE|postnatal ECG|postnatal ECG
40784586|NCT03376932|DEVICE|Metered Dose Inhaler|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
40988523|NCT01857934|DRUG|vincristine|Given IV
40988524|NCT01857934|DRUG|busulfan|Given IV
40988525|NCT01857934|DRUG|melphalan|Given IV
40988526|NCT01857934|BIOLOGICAL|peripheral blood stem cell transplantation|Transplantation of previously harvested peripheral blood stem cells.
40988527|NCT01857934|BIOLOGICAL|natural killer cell infusion|Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
40988528|NCT01857934|RADIATION|radiation therapy|Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
40988529|NCT01857934|BIOLOGICAL|GM-CSF|Given subcutaneously (SQ)
40988530|NCT01857934|BIOLOGICAL|G-CSF|Given subcutaneously (SQ)
40988531|NCT01857934|DRUG|mesna|Given IV
40988532|NCT01857934|DRUG|levetiracetam|Given IV
40988533|NCT01857934|BIOLOGICAL|interleukin-2|Given by continuous infusion during MRD maintenance, and SQ during induction.
40988534|NCT01857934|DRUG|Isotretinoin|Given orally (PO)
40988535|NCT01857934|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
40988536|NCT03094845|BIOLOGICAL|Placebo solution|15 injections over 7 weeks
40988537|NCT03094845|BIOLOGICAL|hdmASIT+TM|15 injections over 7 weeks
40988538|NCT05970757|DIAGNOSTIC_TEST|Extended MRI|Extension of the brain tumor MRI-protocol
40988539|NCT00741039|BIOLOGICAL|inactivated influenza vaccine and the 23- valent pneumococcal vaccine|Patients \>65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
40988540|NCT00741039|BIOLOGICAL|inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)|MSKCC employee volunteer controls \> or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
41465118|NCT01903564|DEVICE|fetal echocardiography|fetal echocardiography
41465119|NCT00142116|DRUG|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
41465120|NCT00142116|DRUG|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
41465121|NCT02194140|OTHER|oral iodinated contrast material|diluted in water
41465122|NCT02272894|PROCEDURE|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
41465123|NCT03209024|OTHER|Handwritten logbook recording of home blood pressure readings|Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
41465124|NCT03209024|DEVICE|Smartphone assisted wireless recording of home blood pressure readings|Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
41465125|NCT02682108|DEVICE|Diffusion-weighted magnetic resonance imaging (DW-MRI)|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
41465126|NCT03355352|DRUG|Sufentanil|Sufentail sublingual 15ug nanopills
41465127|NCT06216860|BEHAVIORAL|Laughter Yoga|In Laughter Yoga Practice; each session will last approximately 30 - 45 minutes and will consist of four parts. These parts are: warm-up exercises, deep breathing exercises, childlike games and laughter exercises.
41465128|NCT02594813|PROCEDURE|Biopsy, cold or hot snare polypectomy, or EMR|
41465129|NCT00804245|PROCEDURE|needle biopsy|Biopsy of positive findings found on CT scan
41465130|NCT00804245|DRUG|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
41465131|NCT02851732|BEHAVIORAL|Quality Improvement Intervention|The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports
41465132|NCT00136890|PROCEDURE|PET Imaging|Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
41465133|NCT00347906|PROCEDURE|laser treatment|
41465134|NCT05540678|DIETARY_SUPPLEMENT|FibreGum|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
41465135|NCT05540678|DIETARY_SUPPLEMENT|Placebo|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
41465136|NCT00826345|OTHER|Acupuncture / Moxibustion|"Acupuncture/Moxibustion points will be administered per point prescription.~- Active"
40988541|NCT03418298|BEHAVIORAL|Prehabilitation group|Subjects will performed an internet-based exercise program before surgery
41147078|NCT03352570|DEVICE|COLOVAC|The intervention consists in the placement of the Colovac device, during the colorectal surgery, Once the colorectal anastomosis has been completed as per standard care and the water-thightness of the anastomosis has been verified.
41465137|NCT00826345|OTHER|Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion - Not active
41465138|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
41465139|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
41465140|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
41465141|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
41465142|NCT00131482|DRUG|Placebo|Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
40784587|NCT03376932|DEVICE|Connected Inhaler System|The CIS will consist of a sensor, which clips on to the ELLIPTA DPI. This will inform subject's if/when they have taken their medication that is in the ELLIPTA inhaler. The sensor will measure when the ELLIPTA inhaler mouth piece cover is fully opened and closed and this data can be fed back, via the app on a mobile device to the subject. The sensors, app, and provider portal that provide data are subsequently described as the CIS.
41145917|NCT06213363|DRUG|TCR1672 tablet|All potential participants proceed to the screening period (7-14 days) after voluntarily signing the informed consent form, and the investigators conduct eligibility assessment for the participants as per the inclusion and exclusion criteria. 72patients with RCC are planned to be enrolled in this study. All participants will firstly be randomized at a ratio of 1:1:1 to receive one of the three oral doses of three times a day TCR1672 (20mg, 40mg, 60mg). Then patients will further be randomized to two treatment sequences, Dosing Sequence 1 and Dosing Sequence 2. Participants in Dosing Sequence 1 will be given TCR1672 Tablets for 1 weeks, followed by a 1-week washout period, and then crossover to 1-week placebo treatment. Participants in Dosing Sequence 2 will be firstly administered 1-week placebo treatment, followed by a 1-week washout period, and then crossover to TCR1672 tablets for 1-week treatment.
41145918|NCT00882375|DRUG|Nicotine|Nicotine administered using novel NRT user instructions
41145919|NCT00882375|DRUG|Placebo|Placebo administered using novel NRT user instructions
41147079|NCT04992884|DEVICE|Gastric Alimetry|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
41465143|NCT06059417|OTHER|2x2 inch piece of 3M microfoam adhesive|"A 2x2 inch piece of 3M microfoam adhesive will be applied to the medial aspect of the subject's upper arm.~The adhesive will remain in place for 48 hours at which time an investigator will remove the adhesive and assess the study area. A numerical value will be assigned based on the Cutaneous Irritancy Scoring System (CISS). The study site will be compared to the contra-lateral upper extremity at the end of the 48 hour period."
41465144|NCT04469725|DRUG|KN046|KN046 5 milligram per kilogram, every 2 weeks
40988542|NCT01696994|OTHER|Laboratory Biomarker Analysis|Correlative studies
40988543|NCT01696994|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
40988544|NCT01696994|PROCEDURE|Ultrasound Imaging|Undergo TVU
40988545|NCT04291391|OTHER|North American-type diet|All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)
40988546|NCT02136576|DEVICE|Sensodyne|Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
41145920|NCT05567302|OTHER|Manual therapy|"In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~A rotational maneuver will be performed from the posterior side of the articular pillar part of the superior vertebra, on the opposite side of the side where the movement restriction is present."
41145921|NCT05567302|OTHER|myofascial release|The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
41145922|NCT05356065|OTHER|survey administration|Outcome Measures
41145923|NCT05000593|OTHER|normal saline|Intra-articular injection of normal saline
41145924|NCT05000593|OTHER|Cord Blood Mononuclear Cells (UCB-MNCs)|Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)
41145925|NCT04945616|DRUG|Aspirin、clopidogrel、placebo or SHR2285|groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；
41145926|NCT04945616|DRUG|Aspirin、clopidogrel、placebo or SHR2285|groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)
41465145|NCT03143517|DIAGNOSTIC_TEST|Stool collection|Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.
40784588|NCT02606318|OTHER|Adjusted the challenge-skill balance|In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
40784589|NCT02606318|OTHER|Non-adjusted the challenge-skill balance|The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
40784590|NCT05960838|DEVICE|Ultrasling® Quadrant|Immobilization with the Ultrasling® Quadrant (DJO Global Switzerland Sàrl, Ecublens, Switzerland) shoulder brace after surgical treatment
40784591|NCT05960838|DEVICE|Bledsoe ARC®|Immobilization with the Bledsoe ARC® (Breg Inc., Carlsbad, CA USA) brace after surgical treatment
40784592|NCT00484783|PROCEDURE|Natural Orifice Transluminal Endoscopic Surgery (NOTES)|Patients will have the standard laparoscopic procedure and the NOTES procedure will be added. The surgical procedure will require two operating teams: one led by a laparoscopic surgeon, the other by an endoscopic surgeon. During the usual course of the surgery, the flexible endoscope will be passed through the mouth urethra top gain access to the peritoneal cavity.
40784593|NCT00484783|PROCEDURE|Natural Orifice Translumenal Endoscopic Surgery (NOTES)|chart review of historical data from control group
40784594|NCT01416961|RADIATION|Radiation Therapy|Concurrent chemo and photon radiation therapy will start within 7 days of completing neutron therapy. There will be a Day 1 of neutron therapy and a Day 1 of concurrent therapy.Photon radiation therapy will begin within 24 hours of the first cycle of chemotherapy and will be delivered 5 days per week, one fraction per day, in 1.8 Gy per fraction. High LET radiotherapy will be delivered in 1 NGy per fraction five days per week. High LET radiotherapy will be delivered first followed by combined chemoradiotherapy.
40784595|NCT01416961|DRUG|Chemotherapy - Squamous Cell Histologies|Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33
40784596|NCT01416961|DRUG|Chemotherapy - NSCLC other than squamous cell|Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43
40784597|NCT01207206|DRUG|oral ketamine|"The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).~The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception"
40988547|NCT02136576|DEVICE|Crest Cavity Protection & MI Paste Plus|Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
40988548|NCT02136576|DEVICE|Clinpro 5000|Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
41147080|NCT02104375|DIETARY_SUPPLEMENT|L-citrulline|2 weeks of L-citrulline supplementation (6g/day).
41465146|NCT00603395|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
41465147|NCT00022841|DRUG|Pamidronate|
41465148|NCT05028634|BIOLOGICAL|Tetanus, diphtheria, and acellular pertussis vaccine|Tdap
41465149|NCT05028634|BIOLOGICAL|Pneumococcal polysaccharide vaccine|PPSV23
41465150|NCT05028634|BIOLOGICAL|Seasonal influenza vaccine|Seasonal influenza vaccine
41306682|NCT04105556|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.
41465151|NCT00197080|DRUG|Ropinirole Extended Release (XR)|
41465152|NCT01287715|DRUG|etanercept|Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
41465153|NCT01287715|DRUG|etanercept|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
41465154|NCT03029117|PROCEDURE|correction of rheumatic valve lesions|
41465155|NCT05703841|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
41465156|NCT05001191|OTHER|Gentle Human Touch|Gentle human touch, which has a pain and stress-reducing effect, is a sensitive tactile stimulus applied to the skin, without caress or massage, which provides a kind of relaxation.
40784598|NCT02742129|DRUG|Nebulized Sodium Nitrite|Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
40784599|NCT02742129|DRUG|Placebo|Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
40784600|NCT01897493|DRUG|Evacetrapib|Administered orally
40784601|NCT01897493|DRUG|Digoxin|Administered orally
40784602|NCT03829111|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
40784603|NCT03829111|BIOLOGICAL|Ipilimumab|Given IV
40784604|NCT03829111|BIOLOGICAL|Nivolumab|Given IV
40784605|NCT03495934|DRUG|pracinostat|\[14C\]-pracinostat
40784606|NCT00901225|DRUG|G-CSF plus Plerixafor|"On Day 5 of G-CSF mobilization,~1. if the patient's peripheral CD34+ cell count is \< 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~2. if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is \< 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected."
40784607|NCT03480984|OTHER|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
40784608|NCT03480984|OTHER|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
40784609|NCT05962255|DRUG|Furosemide intravenous infusion|"At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics."
40784610|NCT05962255|DRUG|Continous intravenous infusion of 0.9% Sodium Chloride solution|Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h
40784611|NCT05962255|DRUG|Continous intravenous infusion of 5% Glucose solution|Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
40784612|NCT03010943|DEVICE|Virtual reality headset|Feasibility and tolerance
40784613|NCT01249001|DRUG|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
40784614|NCT01249001|DRUG|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
40988549|NCT05647473|BEHAVIORAL|Routine treatment|Participants will be educated on ways to avoid induced hypotensive states, such as avoiding prolonged standing, standing after exercise, being nervous, eating several carbohydrate-rich foods, drinking alcohol, and being in a warm environment (such as a sauna). Participants will be encouraged in a comfortable home environment, such as a sit-down bath. If there are no contraindications, they are advised to increase their salt intake to approximately 10 grams per day and adjust their fluid intake to 2-3 liters per day. They will also be encouraged to perform lower-body strength training and moderate, non-strenuous activities. Seriously ill patients will be proposed to raise the head of their bed during sleep, wear tight clothing, eat small meals, and reduce alcohol intake.Concomitant treatment with cholinesterase inhibitors, memantine, or both was allowed.
41306683|NCT02205827|OTHER|Single-arm|collection of blood for assessment of whole blood clotting time
41306684|NCT04332640|DEVICE|VERITAS Vision System|The investigators or designees will perform routine small-incision cataract surgery via phacoemulsification and use the VERITAS Vision system. The Investigator or designee will then complete a questionnaire regarding the clinical use of the VERITAS Vision system. The system log files automatically generated by the VERITAS Vision system after completion of each surgery will be collected.
41465157|NCT01362296|DRUG|GSK1120212|Oral once daily
41465158|NCT01362296|DRUG|docetaxel|IV once every 3 weeks
41465159|NCT04172324|DEVICE|HIBBOT|Hibbot is an assistive mechanical device, lightweight and portable. The mechanism of the Hibbot manages to control all degrees of freedom (3x rotation and 3x translation) at the level of the pelvis and lower trunk. The goal is to maximize a child's own muscle activity and postural control while giving as minimal support as needed.
41465160|NCT04172324|OTHER|Standard Care|Standard care involves the standard physiotherapy the child would get during clinical care.
41465161|NCT05536531|DEVICE|Neuromuscular electrical stimulation (NMES)|Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
40784615|NCT01641107|DRUG|Ponatinib|"Treatment:~Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion."
40784616|NCT02425397|GENETIC|Genetic study|study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.
40784617|NCT02425397|GENETIC|Genetic study MT-RN1|study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
40784618|NCT01151657|DIETARY_SUPPLEMENT|Probiotics|Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
40784619|NCT01151657|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing maltodextrin
40784620|NCT00819429|DIETARY_SUPPLEMENT|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
40784621|NCT00819429|BEHAVIORAL|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
40784622|NCT00819429|OTHER|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
40784623|NCT05562115|OTHER|Tear collection|Collection of tears by Schirmer strip (2 to 4 mm).
40784624|NCT05354024|BIOLOGICAL|NDV-HXP-S 10μg|NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)
40784625|NCT05354024|BIOLOGICAL|BNT162b2 30μg|Vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), 1 dose (booster)
40784626|NCT05775211|BIOLOGICAL|Intrauterine administration of PBMC immunomodulated with IFNt|Standard density gradient centrifugation will be performed to obtain autologous PBMC from patients' peripheral blood (9 ml). Isolated cells will be suspended in RPMI 1640 supplemented with 10% HSA (human serum albumin) and incubated in the presence of 500 IU/ml IFNt for 24 h at 37˚C. The cultured cell suspension will be introduced into the uterine cavity via a catheter.
40784627|NCT00114725|PROCEDURE|Laser-assisted intracytoplasmic sperm injection|
40784628|NCT00244192|DRUG|infliximab (Remicade)|
40988550|NCT05647473|DRUG|add-on low dose Astragalus|Participants received an additional 10g of astragalus per day.
40988551|NCT05647473|DRUG|add-on high dose Astragalus|Participants received an additional 20g of astragalus per day.
40988552|NCT01210365|DRUG|Diurisa®|Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
40988553|NCT01210365|DRUG|Lasix ®|One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
40784629|NCT02826616|DRUG|Trimetazidine|Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
40988554|NCT01768351|DRUG|Paricalcitol|Zemplar cp 1 mcg/day per os
40988555|NCT01768351|DRUG|Calcitriol|Rocaltrol cp 0,5 mcg every other day per os
40988556|NCT04315337|BEHAVIORAL|Virtual Kitchen Training|VR Training will include repeated practice of a single, everyday task in a non-immersive VR context (e.g., VR Breakfast) using a laptop with a touch-screen interface for four days over the course of one week.
40988557|NCT03559140|PROCEDURE|Applied saline solution at 2.5 oC (Cryotherapy group)|Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
41145927|NCT04945616|DRUG|Aspirin、ticagrelor、placebo or SHR2285|groupC： Aspirin + ticagrelor + placebo or SHR2285
41145928|NCT05134922|DRUG|Gedatolisib|Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.
41145929|NCT02525497|DEVICE|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h
41145930|NCT02525497|DEVICE|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h
41145931|NCT02135445|DRUG|TAK-385|TAK-385 tablet
41145932|NCT02135445|DRUG|Degarelix|Degarelix injection
41145933|NCT05718492|PROCEDURE|digital subtraction angiography.|Each patient received an artery catheter procedure guided by digital subtraction angiography.
40784630|NCT02834819|DRUG|3% Nebulized Hypertonic Saline|
40988558|NCT03559140|PROCEDURE|Applied saline solution at 8oC (Cryotherapy )|Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
40784631|NCT03988946|DEVICE|Transcatheter Mitral Valve Replacement via Transseptal Access|The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
40784632|NCT02452073|OTHER|Thyroid function tests|
40988559|NCT03559140|PROCEDURE|Applied saline solution at room temperature (No cryotherapy)|Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
40988560|NCT05601986|OTHER|Physiotherapy and Rehabilitation Program|"The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board."
40988561|NCT05601986|OTHER|Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program|The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.
40988562|NCT06253611|DRUG|Nivolumab|Nivolumab 240 mg IV; every 2 weeks
41145934|NCT05718492|DRUG|FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )|Hepatic artery infusion chemotherapy. The FOLFOX (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) regimen was sequentially infused through the catheter every cycle (3 weeks).
41145935|NCT06361056|BEHAVIORAL|Survey|All participants will complete a brief questionnaire.
41145936|NCT06361056|BEHAVIORAL|mHealth app|Eighty Black women with newly diagnosed breast cancer (inclusive of all stages) and who have access to a mobile device or computer will be recruited to the study intervention.
40784633|NCT01850953|DRUG|Varenicline|This is an approved smoking cessation medication.
40784634|NCT01850953|DRUG|Placebo|
40784635|NCT00089622|DRUG|Intravenous Levodopa|
40784636|NCT00089622|DRUG|Lisuride Transdermal System|
40784637|NCT02184676|BIOLOGICAL|Analysis of early immune modifications|"* blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)~* cord blood sampling~* stool sampling in mothers and newborns at birth (day 7)~* blood and stool sampling in children at the age of 8, 18, 30 and 42 months"
40988563|NCT06253611|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks
40988564|NCT06253611|BIOLOGICAL|EXL01|Orally 1 capsule/day, starting on day 1 of each FOLFOX/nivolumab treatment.
40988565|NCT05280067|DEVICE|ZetaFuse™ Bone Graft|The ZetaFuse™ Bone Graft will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.
40988566|NCT02071888|DRUG|CB-839|Glutaminase inhibitor
40988567|NCT02071888|DRUG|CB-839 and low dose dexamethasone|CB-839 and low dose dexamethasone
41145937|NCT05726097|DRUG|polyethylene glycol|colonic preparation
41145938|NCT05726097|DRUG|sodium phosphate|colonic preparation
41145939|NCT05726097|DRUG|polyethylene glycol + ascorbic acid|colonic preparation
41145940|NCT05726097|DRUG|gastrografin|colonic preparation
41145941|NCT05726097|DRUG|magnesiumoxid + sodium picosulfate|colonic preparation
41145942|NCT05726097|DRUG|prucalopride|colonic preparation
41306685|NCT01425190|DRUG|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
40784638|NCT02184676|OTHER|Collection of clinical and socio-demographic data|"1. Questionnaire filled in by clinicians at enrollment and at birth~2. Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42"
41145943|NCT06348160|BEHAVIORAL|iHERO Toolkit Resource|iHERO Toolkit consists of micro-videos and supplemental online resources. Participants will have access to the toolkit housed on pathfactory for 30 days.
41306686|NCT00259220|DRUG|erythomycin|erythomycin
41465162|NCT05121168|DRUG|Active bupivacaine 0.25% via an erector spinae plane perineural catheter|Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
41465163|NCT05121168|DRUG|Placebo normal saline via an erector spinae plane perineural catheter|Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
41306687|NCT00259220|PROCEDURE|gastric lavage alone|gastric lavage alone
41306688|NCT00259220|PROCEDURE|erythromycine and gastric lavage|erythromycine and gastric lavage
41465164|NCT03683329|OTHER|Antibiotic de-escalation|"All the therapeutic protocols made the object of a consensus between the different partners of the study.~Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation."
41465165|NCT03683329|OTHER|Standard treatment|Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
41465166|NCT05191745|DRUG|Parasternal blocks|Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg
41306689|NCT04484818|DRUG|Darolutamide|Given PO
41306690|NCT04484818|DRUG|Goserelin Acetate|Given via injection
41306691|NCT04484818|DRUG|Leuprolide Acetate|Given IV
41306692|NCT04484818|DRUG|Placebo Administration|Given PO
41306693|NCT04484818|OTHER|Quality-of-Life Assessment|Ancillary studies
41306694|NCT04484818|DRUG|Triptorelin|Given via injection
41306695|NCT02332356|DRUG|azathioprine or adalimumab and infliximab|
41306696|NCT00678106|DRUG|Dalbavancin|Subjects weighing \> 60 Kg: 1 gram IV single dose Subjects weighing \< 60 Kg: 15 mg/Kg IV
41306697|NCT03016299|PROCEDURE|microfracture techniques|Drill will be performed in 3 contiguous areas. First Area by Nailing, Second by KW drilling and 3rd area drilled by regular drill obtaining a triangle with the three drilled epicenters.
41306698|NCT06254105|OTHER|HANDY programme|The manualised HANDY program includes descriptions of procedures related to the GP's evaluation of the client's need for referral to occupational therapy, procedures for referral from the GP to community-based occupational therapy, the group-based occupational therapy programme, and recommendations related to collaboration and communication between GP and occupational therapist.
41306699|NCT04517617|OTHER|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.he perinatal period.
41306700|NCT00861484|DRUG|GSK958108|Coated Tablets 1 mg
41306701|NCT00861484|DRUG|Placebo|Coated tablets
41306702|NCT01922427|DRUG|RNS60|
41306703|NCT06177782|DEVICE|Tooth modified scan bodies|Tooth modified scan bodies are used during scanning for full arch implant cases.
40988568|NCT02071888|DRUG|CB-839, pomalidomide, and low dose dexamethasone|CB-839, pomalidomide, and low dose dexamethasone
40988569|NCT04327232|DRUG|Spironolactone 25mg|Mineralocorticoid Receptor Antagonists
40988570|NCT04327232|DRUG|Placebo oral tablet|Placebo
40988571|NCT03724409|DRUG|[90]Y-DOTATOC|Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.
40988572|NCT01980355|DRUG|Tranexamic Acid|
40988573|NCT01980355|OTHER|Placebo|
40988574|NCT02225756|DRUG|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
40784639|NCT03348293|PROCEDURE|3D printing|Scope of tumor resection was simulated according to the MR imaging data. After meticulous design, we created the personalized porous biodegradable scaffold and printed by 3D printer, using porous PCL biomaterials. During operation, the biodegradable scaffold was implanted into the defective cavity after tumor resection.
40988575|NCT02225756|DRUG|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
40988576|NCT02225756|DRUG|Placebo|Oral administration for a short time of placebo
40988577|NCT02081690|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily
40988578|NCT02373020|OTHER|colonoscopic biopsies|
40988579|NCT03554226|BEHAVIORAL|NeuroPsychiatric Inventory Clinician (NPI-C)|All scales that will be administered to the patient during this study, (ADL, MMSE, QoL-AD, NPI and CMAI), are the subject of recommendations for the management of patients with AD (HAS 2009, HAS 2011)
40988580|NCT03342547|PROCEDURE|Duodenal biopsy|Two duodenal biopsy samples will be collected from each participant
40988581|NCT03342547|PROCEDURE|Saliva|Saliva (1-2 mL) will be collected from each participant for secretor status testing
40988582|NCT02130661|DRUG|Rilapladib 25 mg|White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
40988583|NCT02130661|DRUG|Rilapladib 250 mg|White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
41306704|NCT06177782|DEVICE|Conventional scan bodies|Conventional scan bodies will be used for scanning the full arch implant cases.
41306705|NCT04004624|DEVICE|Ablation|Cardiac Ablation
40988584|NCT02130661|DRUG|Itraconazole|100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
40988585|NCT01185119|DRUG|native glp-1 (7-36)|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
40988586|NCT01148602|OTHER|LED stopwatch-clock timers|"We will attach a large, in-your-face red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation."
40988587|NCT05771207|DIETARY_SUPPLEMENT|soy protein|The intervention is made up of soy protein supplements (30g/d) and dietary pattern modification.
40988588|NCT05771207|DIETARY_SUPPLEMENT|whey protein|The intervention is made up of whey protein supplements (30g/d) and dietary pattern modification.
40988589|NCT05771207|DIETARY_SUPPLEMENT|placebo|The intervention is made up of maltodextrin (30g/d) and dietary pattern modification.
40988590|NCT04698031|DRUG|Clopidogrel treatment|After randomization, patients will receive clopidogrel 75 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
40988591|NCT04698031|DRUG|Aspirin treatment|After randomization, patients will receive Aspirin 325 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
40988592|NCT02173912|DRUG|Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
40988593|NCT02173912|DRUG|CJ-30059 (Test)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
40988594|NCT05259007|DIETARY_SUPPLEMENT|propolis solved in lactic acid solvent|propolis given as a dietary supplement which was solved in a lactic acid solvent.
40988595|NCT05259007|DRUG|Amoxicillin-Clarithromycin-Lansoprazole|H pylori eradication treatment
40988596|NCT05259007|OTHER|IV saline 0.9%|Physiological serum solution is given as a placebo
40988597|NCT05259007|OTHER|Lactic acid|given to determine if the improvement of the symptoms are due to propolis or the solvent
40988598|NCT03540966|COMBINATION_PRODUCT|CapulinTM|a kind of camouflage agent
41306706|NCT02123563|OTHER|Ultrason Essential oils rinse|Test treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a commercially available non-prescription essential-oils solution (20mL, 30 seconds for each rinse) for 3 months. This solution is composed of eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%, zinc chloride and sodium fluoride 0.0221%.
41465167|NCT05191745|DRUG|Standard of care|All standard management of postoperative pain, as per local protocols
41465168|NCT01689155|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
41465169|NCT03566238|DRUG|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).
41465170|NCT03566238|DRUG|Placebo|Placebo identical in appearance to active drug (A4250).
40784640|NCT03763630|DRUG|House dust-mite SLIT|received 2000 standard treatment units of glycerinated HDM allergen extract (ALK-AbellÓ) per day. Normal saline was administered to the placebo group. 11 µg of HDM allergen (equal parts of Dermatophagoides pteronyssinus and Dermatophagoides farinae) administered twice daily as oral drops.
40784641|NCT03763630|DRUG|Normal saline|Normal saline administered in same frequency and manner as intervention
40784642|NCT00800800|DRUG|Rosuvastatin|40 mg, oral, single dose
41306707|NCT02123563|OTHER|Ultrason Placebo rinse|Comparative treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a placebo solution (20mL, 30 seconds for each rinse) for 3 months.
40784643|NCT00800800|DRUG|Placebo|oral, single dose
40784644|NCT04464239|DRUG|TS-142|TS-142 tablets
40784645|NCT04464239|DRUG|TS-142 Placebo|TS-142 matching placebo tablets
40784646|NCT03564873|DRUG|Omacetaxine|Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
40988599|NCT03540966|OTHER|Chinese version of the vitiligo life quality index, VLQI-C|a questionaire designed for patients with vitiligo
40988600|NCT00945139|DRUG|Doxil|Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
40988601|NCT00945139|DRUG|Avastin|First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
40784647|NCT03564873|DRUG|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
40988602|NCT03023969|DRUG|ozone oxygen mixture|receive 10 ml of ozone oxygen mixture under variable dosing
40988603|NCT02482103|PROCEDURE|Renal denervation|Catheter based renal nerve ablation
40988604|NCT02225522|OTHER|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
40988605|NCT05660564|PROCEDURE|DIGU Dorsal inlay preputial graft urethroplasty|"Using a scalpel, a midline incision is made from the meatus to the end of the plate .~The edge of the distal glans should not be incised to avoid meatal stenosis. The depth of this relaxing incision depends on the plate's width and depth, but in all cases, it extends down to the corpora cavernosa. Degloving of the penile skin to the penoscrotal junction If a minimal chord is present, it should be corrected.~From the inner prepuce, a free graft was measured, harvested, defatted, and stitched to the UP. With interrupted 6/0 polyglactin sutures running from the old meatus to the tip of the glans, the graft was secured to the medial edges of the incised plate. Depending on the location of the meatus, the characteristics of the UP, and the depth of the midline incision, the graft width and length varied in each case."
41306708|NCT02632708|DRUG|AG-120|
41306709|NCT02632708|DRUG|AG-221|
41306710|NCT02632708|DRUG|cytarabine|
41306711|NCT02632708|DRUG|daunorubicin|
41306712|NCT02632708|DRUG|idarubicin|
41306713|NCT02632708|DRUG|mitoxantrone|
41306714|NCT02632708|DRUG|etoposide|
40784648|NCT03564873|DRUG|Omacetaxine|Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
40988606|NCT04853745|DEVICE|AIR-FLOW® Master Piezon|AIR-FLOW® Master Piezon is intended for use in the cleaning and polishing of teeth by the projection of water,air, and dental powders onto the tooth surface. The device removes dental plaque, soft deposits, and surface stains from pits, grooves, interproximal spaces, or smooth surfaces of teeth. This air polishing device was used for all powder instrumentations.
40988607|NCT00402961|OTHER|Acupuncture|Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.
41306715|NCT05059652|DEVICE|Ischemic Preconditioning|The Ischemic Preconditioning (IPC) is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff.
41306716|NCT04497662|DRUG|KPL-404|humanized IgG4 monoclonal antibody
41306717|NCT04497662|OTHER|Matching Placebo|Placebo
40988608|NCT00402961|OTHER|Sham Acupuncture|Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
40988609|NCT05955118|DEVICE|Hydrus Microstent|Hydrus Microstent placed at the time of cataract surgery
40988610|NCT01114165|OTHER|Detection of microbial DNA in blood by SeptiFast Test|The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
40988611|NCT01114165|OTHER|Pathogen detection by blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
40988612|NCT04800211|OTHER|Experimental: Test Product 1|Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)
40988613|NCT04800211|OTHER|Experimental: Test Product 2|Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)
40988614|NCT03205059|BEHAVIORAL|LST MS curriculum+ Bullying/Cyberbulling serious game|The prevention materials for middle school bullying and cyberbullying will (1) utilize both interactive classroom sessions and serious/educational games (digital games used to educate in an entertaining format); (2) positively change social norms surrounding bullying and cyberbulling; (3) challenge positive expectancies about bullying and cyberbullying; (4) enhance protective factors by building social, self-regulation, and relationship skills throughout the interactive learning and behavioral rehearsal; and (5) include booster sessions.
40988615|NCT03205059|BEHAVIORAL|LST MS curriculum|The evidence-based LifeSkills Training program has been successfully used as a universal, school-based substance abuse and violence prevention program for middle school youth. The goals of the LST program are to teach youth the personal self-management skills, social skills, and other life skills needed to successfully resist drug and alcohol use, navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
40988616|NCT05196009|BEHAVIORAL|mHealth peer navigation and social support|Peer navigation, asynchronous support via SMS, Motivational Interviewing, virtual social support group focused on mental health and substance use, linkage and follow-up
40988617|NCT05950789|OTHER|Virtual reality application|"During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.~With virtual reality glasses, patients watch three-dimensional video nature images, which we determined according to the patient's preference, accompanied by music. They put on the virtual reality glasses before the process started and removed them after the process was over."
40988618|NCT06154447|DRUG|VX-828|Suspension for Oral Administration
40988619|NCT06154447|DRUG|Placebo|Suspension for Oral Administration
40988620|NCT06154447|DRUG|Itraconazole|Solution for Oral Administration
40988621|NCT06154447|DRUG|Midazolam|Syrup for Oral Administration
40988622|NCT03163082|OTHER|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
41465171|NCT00785096|OTHER|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
40784649|NCT03564873|DRUG|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
40988623|NCT03163082|BEHAVIORAL|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
40988624|NCT03163082|OTHER|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
40988625|NCT03163082|OTHER|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
40988626|NCT03302013|PROCEDURE|Vanguard XP Bi-cruciate Retaining Knee Replacement System|Newer design of knee replacement retaining the Anterior Cruciate Ligament as well as the Posterior Cruciate Ligament.
40988627|NCT03302013|PROCEDURE|Vanguard CR Single Cruciate Retaining Knee System|Current 'gold standard' for total knee replacement which retains Posterior Cruciate Ligament but sacrifices the Anterior Cruciate Ligament, instead providing artificial support.
40988628|NCT00874354|DRUG|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
40988629|NCT02732483|DRUG|Endo-Clot(TM)|The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
41465172|NCT04306172|OTHER|An US Readmission Risk Prediction Model|Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.
41465173|NCT04306172|OTHER|LACE+ score|The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.
41465174|NCT04306172|OTHER|SQLAPE model|The readmission risk model (Striving for Quality Level and analyzing of patient expenditures), is a computerized validated algorithm and was developed in 2002 to identify potentially avoidable readmissions.
40784650|NCT02375100|PROCEDURE|Spinal Anesthesia|All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
41465175|NCT05416749|DRUG|8MW2311|All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
41465176|NCT05614219|OTHER|Biochemistry interpretive comment on elevated LDL-C levels|The interpretive comment on LDL-C will encourage for excluding secondary dyslipidemia (measuring Hba1C, TSH and checking current drugs and talk about diet). If secondary dyslipidemia ca be excluded we encourage to referral to lipid clinic. Familial hypercholesterolemia should be suspected if LDL-C \> 4 mmol/L in persons under the age of 40, or LDL-C \> 5 mmol/L in persons over the age of 40. The biochemistry interpretive comment will thus be released to the referring physician if the blood sample meet the criteria above. We advice that in pregnant women to control elevated LDL-C after childbirth.
40784651|NCT02375100|PROCEDURE|Transversus Abdominis Plane Block|Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance
40988630|NCT02195076|OTHER|non-invasive detection of cancer odor|The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
40988631|NCT05584150|OTHER|Deep Cleansing Gel|daily use
40988632|NCT03241355|DIETARY_SUPPLEMENT|prebiotic inulin-type fructan|
40988633|NCT03241355|DIETARY_SUPPLEMENT|Placebo maltodextrin|
40988634|NCT01517009|DRUG|Docetaxel|60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
40988635|NCT01517009|DRUG|cisplatin|60 mg/m2, one gift every three weeks, in total 4 gift
40988636|NCT01517009|DRUG|Capecitabine|1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
40988637|NCT01517009|PROCEDURE|D1extra-resection|An extended lymphadenectomy compared to a D1 resection for gastric cancer
40988638|NCT01092182|DRUG|EPOCH-R|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
41306721|NCT03505567|DEVICE|KOWA OCT Bi-µ|Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.
41306722|NCT03505567|DEVICE|Optovue iVue 100|U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100
41306723|NCT03696758|PROCEDURE|Pulmonary Function Testing|Subjects will undergo spirometry, Plethysmography, and diffusion capacity.
41306724|NCT03696758|PROCEDURE|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
41465177|NCT00664287|DRUG|niacin (+) laropiprant|Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
41465178|NCT00664287|DRUG|placebo (unspecified)|Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
41465179|NCT04099641|DRUG|Bavituximab|Bavituximab IV infusion
41465180|NCT04099641|DRUG|Pembrolizumab Injection|Pembrolizumab IV Infusion
40784652|NCT02375100|PROCEDURE|Ilioinguinal Nerve Block|Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance
40988639|NCT01092182|DRUG|EPOCH-RR|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 3 cycles
40988640|NCT01742507|DEVICE|Resolute Integrity Stent|Resolute Integrity Stent
41306725|NCT03696758|PROCEDURE|Cardiac Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
41306726|NCT03696758|DRUG|Metoprolol|Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.
41306727|NCT03696758|DRUG|Sildenafil|Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
40784653|NCT02375100|DRUG|Bupivacaine %0.5 (hyperbaric)|
40784654|NCT02375100|DRUG|Bupivacaine %0.25 (isobaric)|
40988641|NCT01742507|DEVICE|Biomatrix stent|Biomatrix stent
40988642|NCT01797289|OTHER|Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer|
40988643|NCT03694860|OTHER|questionnaire|Members of European society of anaesthesiology care will obtain an electronic survey considering their clinical practice in RSI
40988644|NCT06528704|DEVICE|Ventilation feedback device|Device showing delivered ventilation frequency and volume.
40988645|NCT00623727|BIOLOGICAL|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
40988646|NCT00623727|BIOLOGICAL|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
40988647|NCT03586388|OTHER|Oral immunotherapy protocol|"In hospital setting: three increasing doses every 30 minutes of 1ml, 5ml and 10ml of cow milk (CM). Oral food challenge (OFC) stopped at 10ml even if no clinical reactions occurred.~At home: every child will take the dose tolerated in hospital, starting the day after the OFC, for 3-4 weeks.Once reached the dose of 40ml of CM without reactions for at least 2 weeks, families increment the dose of 5 ml every week, till the tolerance of 50 ml, then of 10 ml every week, till the tolerance of 100ml and then, of 10 ml every 3 days till the tolerance of 150 ml of milk."
40988648|NCT01952756|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
40988649|NCT01952756|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
40988650|NCT00690014|DRUG|probenecid|500 mg q 6 hrs
41145944|NCT05143580|BEHAVIORAL|Cognitive therapy|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education.~* Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~* Use gamification to evaluate: pain relief skills, lung expansion skills."
40988651|NCT01224847|DRUG|Tetracaine|1 gtt
40988652|NCT01224847|DRUG|Cocaine|1 gtt
40988653|NCT01224847|DRUG|Lidocaine|Lidocaine soaked pledget
40988654|NCT01772303|DRUG|HO/03/03 10-40 µg|HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
40988655|NCT05590689|DRUG|Gliolan|A repetitive dose of Gliolan will be administrated in combination with radiotherapy (radiodynamic therapy)
40988656|NCT05590689|RADIATION|Radiodynamic therapy|Radiotherapy will be performed in combination with Gliolan administration
40988657|NCT00878709|DRUG|neratinib|
40988658|NCT00878709|OTHER|placebo|
40988659|NCT02155140|DIETARY_SUPPLEMENT|Jejunal feeding|A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
40988660|NCT04175769|DIETARY_SUPPLEMENT|Nutritional supplement|Subjects will orally consume two gelatin capsules of nutritional supplement (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
40988661|NCT04175769|OTHER|Placebo|Subjects will orally consume two gelatin capsules of placebo (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
40988662|NCT01271920|DRUG|AUY922|
40988663|NCT01271920|DRUG|Trastuzumab|
40988664|NCT01291056|OTHER|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
41145945|NCT05143580|BEHAVIORAL|Routine care|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education."
41145946|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
40988665|NCT01291056|DRUG|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
40988666|NCT04919356|GENETIC|G2019S LRRK2|No cost genetic testing for G2019S LRRK2
40988667|NCT00507442|DRUG|VELCADE (bortezomib)|bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
40988668|NCT00507442|DRUG|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
40988669|NCT00507442|DRUG|cyclophosphamide|cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
40988670|NCT00507442|DRUG|Revlimid (lenalidomide)|"lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)"
40988671|NCT02937779|DRUG|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
41145947|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 1.1|Participants will use their Radicle Relaxation Active Study Product 1.1 as directed for a period of 6 weeks.
41145948|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
41145949|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 2.1|Participants will use their Radicle Relaxation Active Study Product 2.1 as directed for a period of 6 weeks.
41145950|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
40988672|NCT02937779|DEVICE|Rapid tests HBe Ag|For all HBs Ag positive women
40988673|NCT00813085|OTHER|Electronic disease management decision support|A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
40988674|NCT03389009|DIAGNOSTIC_TEST|Ultrasound Biomicroscopy of anterior segment of the eye|5150 Vumax (Sonomed, USA) under standard illumination
40988675|NCT04007523|BEHAVIORAL|Family Support System|Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.
40988676|NCT04007523|BEHAVIORAL|HELP Support System|A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.
40988677|NCT04103762|PROCEDURE|laparoscopic cholecystectomy|laparoscopic cholecystectomy
40988678|NCT04103762|DIAGNOSTIC_TEST|systematic intraoperative cholangiography|systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)
40988679|NCT05014750|OTHER|None intervention|There is no intervention included in this study.
40988680|NCT03068247|DRUG|Duloxetine|10 week treatment
40988681|NCT03068247|DRUG|Placebo|10 week treatment
40988682|NCT02558257|BEHAVIORAL|Survey|Participants complete palliative care survey within 1 week +/- 4 days of initial consultation via phone survey conducted by Research nurse/assistant.
41145951|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 3.1|Participants will use their Radicle Relaxation Active Study Product 3.1 as directed for a period of 6 weeks.
41147081|NCT05835856|DEVICE|Virtual coach with NAO robot|The coaching device used is the softbank NAO 5 and NAO 6 humanoid interactive mobile robot. These robot platform allows multimodal natural language interaction and robot autonomous movement.
41147082|NCT05835856|DEVICE|Virtual coach with Google Nest Hub (2e generation) group|The coaching device used is Google Nest Hub (2e generation). This is a connected speaker enriched with a 7-chip touch screen. It has a loudspeaker and 3 microphones, making interaction possible.
41465181|NCT03933267|OTHER|Cervical sensorimotor control training exercises|"Cervical sensory motor training exercises consisting of cervical position sense and cervical movement sense exercises with 3 levels of difficulty and 5 repetitions \* 3 sets for each exercise will be given. Some exercises are:~Head relocation with laser feedback:~head relocation to neutral and predetermined position with eyes opened (in horizontal / vertical direction) (5 reps x 3 sets) Head relocation to neutral, predetermined and to specific targets with eyes opened (in diagonal directions) (5 reps x 3 sets) Head relocation to neutral and predetermined position with eyes closed (in all directions)(5 reps x 3 sets) In addition to it conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility."
41465182|NCT03933267|OTHER|Conventional Exercises|conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility exercises will be given to patients.
41465183|NCT01947309|DRUG|Revlimid (lenalidomide)|Revlimid (lenalidomide) as prescribed in usual clinical practice
41465184|NCT00235417|PROCEDURE|Bone marrow transplantation|
41465185|NCT05380219|OTHER|dual task strength training|strength training and dual task
40988683|NCT00625859|DRUG|GSK189075|GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
40988684|NCT00625859|DRUG|Bupropion|Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
40988685|NCT00625859|DRUG|Placebo|Placebo tablets will be given to subjects.
40988686|NCT03580317|OTHER|EA+ Carbamazepine|"Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily."
40988687|NCT03580317|OTHER|EA+Placebo|In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
40988688|NCT03580317|OTHER|sham EA+Carbamazepine|"Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part."
40988689|NCT03580317|OTHER|sham EA+Placebo|The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
40988690|NCT04176900|OTHER|Ingeo Biopolymer (PLA)|Biopolymer used for 3D-printing of rigid bolus
40988691|NCT04176900|OTHER|Ecoflex 030|Polymer used for the 3D-printed flexible bolus
40988692|NCT02555033|OTHER|Resistance training|traditional resistance training
40988693|NCT02555033|OTHER|Instability resistance training|training under unstable conditions
40784655|NCT02375100|DEVICE|25G Quincke needle|
40784656|NCT02375100|DEVICE|Echogenic Needle with 30° bevel|
40988694|NCT02258126|OTHER|Multidisciplinary intervention program|"Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months."
41306728|NCT04181320|DEVICE|Venous Leg Ulcer Standard of Care with Granulox|Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
41306729|NCT01415037|PROCEDURE|annular array ultrasound exam|For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
41306730|NCT01372111|DRUG|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
41306731|NCT01372111|RADIATION|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
41306732|NCT05877534|OTHER|Individual tailored exercise|A 16 week period of progressive exercise, supervised by a physiotherapist once a week.
41306733|NCT04314167|DRUG|Lowering cholesterol concentrations by PCSK-9 inhibitor|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
41306734|NCT04689750|DIAGNOSTIC_TEST|Next generation sequencing|"Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.~Gene mutations and pathogenic gene fusion will be determined in the peripheral blood and/or marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing."
41306735|NCT01540916|OTHER|Increase minute ventilation|Respiratory rate will be increase in order to have a 30% increase of minute ventilation
41306736|NCT01540916|OTHER|Decrease minute ventilation|Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
41306737|NCT03792776|OTHER|cuff inflation with air|Endotracheal tube cuff inflation with air
41306738|NCT03792776|DRUG|cuff inflation with lidocaine 1%|Endotracheal tube cuff inflation with lidocaine 1%
41306739|NCT03792776|DRUG|cuff inflation with lidocaine 2%|Endotracheal tube cuff inflation with lidocaine 2%
41465186|NCT03370822|DEVICE|MONICA AN24 device|Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)
40988695|NCT02493673|DEVICE|Continuous positive airway pressure device|(ResMed Spirit S8)
41145952|NCT02861716|DRUG|Bupivacaine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds."
41145953|NCT02861716|DRUG|Fentanyl|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
41306740|NCT03792776|OTHER|Induction of anesthesia|The induction of anesthesia will be made following a preoxygenation with a facial mask with 100% Oxygen. It consists on the intravenous injection of Sufentanil 5 mcg or Fentanyl 50mcg, Lidocaine 1mg/Kg, Propofol 2.5mg/kg, Rocuronium 0.6mg/kg or Cisatracurium 0.15mg/kg.
41306741|NCT03792776|OTHER|Maintenance of anesthesia|Maintenance of anesthesia will be done by sevoflurane + nitrous oxide, and reinjections of morphinomimetics and curare will be made as needed (the total doses will be noted at the end of the intervention).
40988696|NCT05505357|PROCEDURE|Breast surgery omission|For patients who are expected to achieve pathologic complete response after neoadjuvant chemotherapy based on MRI findings, vacuum-assisted biopsy will be performed on the main primary lesion marked with a clip. In case of pCR on vacuum-assisted biopsy specimen, breast surgery will be omitted.
41306742|NCT03792776|OTHER|Endotracheal intubation|The intubation is made by a N° 7.5 tube in men and a N° 7 tube in women. Cuff inflation will be done upon placement of the endotracheal tube. The cuff's pressure will be monitored at several intervals of the intervention and kept \< or = 20 centimeter of water (cmH2O).
41306743|NCT03792776|OTHER|Systematic post-operative analgesia|All patients will receive Paracetamol every 6 hours for the first 24 hours after the end of surgery.
41306744|NCT01009801|DRUG|doxorubicin-eluting beads|Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
41306745|NCT01009801|DRUG|everolimus|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
41306746|NCT01009801|OTHER|placebo|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
41306747|NCT00162396|DRUG|Albuterol|
41306748|NCT06523452|OTHER|Laser Speckle Imaging|At least three scans (four for skin sparing mastectomy) will be performed on participants randomised to the LSI Assisted Group. Further scans may be taken at the discretion of the surgeon.
41306749|NCT05763160|DRUG|RZL-012|Ready to use drug product for injection into the subcutaneous fat
41306750|NCT00757770|BIOLOGICAL|Rotarix|Two oral doses.
41306751|NCT00757770|BIOLOGICAL|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
41306752|NCT02776657|OTHER|Magnetic Resonance Imaging|Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
41306753|NCT02776657|DEVICE|Optical Coherence Tomography|Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
41306754|NCT02776657|PROCEDURE|Invasive Coronary Angiography|This will be performed as part of usual care and does not constitute part of the research project.
41306755|NCT00683241|BIOLOGICAL|DCVac-L|Subjects will receive three doses of intradermal vaccination with \~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28
41306756|NCT00676273|DEVICE|TVT-Obturator (TVT-O)|sub urethral sling
41306757|NCT00676273|DEVICE|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
41306758|NCT02001116|OTHER|Quality Improvement intervention|"1. Training for local trainers and medical staff on the National Adaptation of the WHO guidelines Pocket Book of Hospital Care for Children.~2. Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care"
41306759|NCT03265509|DIETARY_SUPPLEMENT|glutamine supplementation|30 g/day glutamine supplementation for three months
41306760|NCT03265509|DIETARY_SUPPLEMENT|fantomalt supplementation|30 g/day fantomalt supplementation for three months
41306761|NCT05390814|DRUG|PET-MRI|\[18F\]-Fludarabine imaging in the diagnostic workup of primary central nervous system lymphomas: a PET-MRI pilot study
41306762|NCT04310215|BIOLOGICAL|CARTISTEM®|"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture~2. Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)"
41306763|NCT04310215|PROCEDURE|Microfracture|"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture"
41306764|NCT05717452|DIETARY_SUPPLEMENT|Blueberry drink|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder mixed with 250 ml water.
41306765|NCT05717452|DIETARY_SUPPLEMENT|Placebo drink|22 g placebo powder matched for macronutrients, color, and flavor mixed with 250 ml water.
41465187|NCT00781079|BEHAVIORAL|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
41465188|NCT00522990|DRUG|AT9283|Three weekly intravenous administration of AT9283
41465189|NCT01953172|DIETARY_SUPPLEMENT|AMP-886|AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
41465190|NCT01953172|OTHER|Placebo|Placebo
41465191|NCT03248986|OTHER|Dry needling|Dry needling of the spastic muscles of the affected arm through DNHS®.
40784657|NCT02375100|DRUG|Acetaminophen|Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
40784658|NCT02375100|DRUG|Tramadol|Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
40784659|NCT05994768|OTHER|18F-FDG PET/CT|Patients who underwent an 18F-FDG PET/CT examination and a labeled leukocyte scintigraphy before and after antibiotic therapy in the case of management of an EO.
40784660|NCT02399644|BEHAVIORAL|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
40784661|NCT02399644|OTHER|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
40784662|NCT05353413|DEVICE|Neuroimaging|Magnetic resonance diffusion tensor imaging of the brain
40784663|NCT05353413|DIAGNOSTIC_TEST|VEP - visual evoked potential|Electrophysiology of the visual pathway.
40784664|NCT05353413|DIAGNOSTIC_TEST|Ophthalmology examination.|Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)
40784665|NCT04326062|OTHER|Main Study|The pharmacist will participate in the management of repeat prescribing and undertake medication reviews (which will address high risk prescribing and potentially inappropriate prescribing, deprescribing and cost-effective and generic prescribing) with adult patients. Pharmacists will also provide prescribing advice regarding the use of preferred drugs, undertake clinical audits, join practice team meetings and facilitate practice-based education. Throughout the six-month intervention period, anonymised practice-level medication (e.g. medication changes) and cost data will be collected.
40784666|NCT04326062|OTHER|PROM Study|For this, a sub-set of patients (n=200) aged ≥65 years on ≥10 repeat medicines will be recruited and invited to a medication review with the pharmacist. PROMs and healthcare utilisation data will be collected using patient questionnaires and a six-week follow-up review with these patients will also be conducted.
40784667|NCT03264144|BEHAVIORAL|Social norms campaign|Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
40784668|NCT00051714|BEHAVIORAL|Family-Based Preventive Intervention|
40784669|NCT02136914|DRUG|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
40784670|NCT02136914|OTHER|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
40784671|NCT01752803|DIETARY_SUPPLEMENT|Probiotic|mix probiotic
40784672|NCT01752803|DIETARY_SUPPLEMENT|Placebo|placebo
40784673|NCT00133627|DRUG|Ketotifen|
40784674|NCT01911455|DRUG|acamprosate|
40784675|NCT01911455|DRUG|Placebo|
41147083|NCT05835856|DEVICE|Virtual coach with Gatebox device|The coaching device used is the Gatebox, a hologram like device which the user can interact. There are internal sensors such as a camera and a microphone allow the user to converse with the projected character. It connects to the Internet via a wireless LAN. With infrared rays and Bluetooth, it can also be connected to household appliances and other devices.
41465192|NCT03078257|DRUG|tirofiban in PV|"a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day."
41465193|NCT03078257|DRUG|tirofiban in IC|"a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
40784676|NCT02303262|DRUG|Mocetinostat|Mocetinostat is taken orally at 70 mg/dose, 3 days per week, during cycle 1. Dose is increased to 90 mg starting at cycle 2.
40784677|NCT02303262|DRUG|Gemcitabine|Gemcitabine is administered via intravenous infusion at 1,000 mg/m2 at a rate of approximately 10 mg/m2/minute, on days 5 and 12 of every cycle.
40784678|NCT05771129|DEVICE|Pulse electric field ablation system developed by Zhouling (Shanghai) Medical Appliance Co., Ltd.|Pulsed electric field ablation instrument is a therapeutic instrument based on the irreversible electroporation (IRE) mechanism. The high frequency short duration energy is delivered via a disposable pulse ablation catheter through the bronchoscope and act on the bronchial mucosa, through which goblet cell hyperplasia and airway mucus secretion will be alleviated. The entire treatment consists of two procedure sessions that will be performed one month apart. The first treatment procedure consists of a baseline biopsy of the airway mucosa followed by the treatment of the right lung. The second procedure consists of a biopsy of the treated airway, followed by the left-side treatment. A third bronchoscopy will be performed three months following the first treatment and mucosa-biopsy will be conducted to evaluate the histopathological change in mucus producing cells after treatment. Subjects will also be required to fill questionnaire and complete several examinations during follow-up.
40784679|NCT01642550|DRUG|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
40784680|NCT01642550|DRUG|Placebo|
40784681|NCT04811690|BEHAVIORAL|front-of-package modification|testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks
40784682|NCT02162654|PROCEDURE|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
40784683|NCT02162654|PROCEDURE|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
40784684|NCT01014702|DEVICE|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
41306766|NCT03759457|DEVICE|High Flow Nasal Cannula (AIRVO2)|High-flow nasal cannula (HFNC) delivers oxygen flows of up to 60 L/min. The gas source (air/oxygen blender, ventilator, or turbine flow-generator) is connected via an active heated humidifier to a nasal cannula and allows FiO2 adjustment independently from the flow
41465194|NCT03078257|DRUG|antiplatelet thrombolysin|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
41465195|NCT03078257|DRUG|placebo|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
41465196|NCT03078257|DRUG|Clopidogrel|loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
41465197|NCT03078257|DRUG|Aspirin|loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
41465198|NCT03078257|DRUG|Clopidogrel|loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
40784685|NCT01014702|DEVICE|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
40784686|NCT01354093|DRUG|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
40784687|NCT01354093|DRUG|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
40784688|NCT01416025|DRUG|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
40784689|NCT06237634|OTHER|splint and exercise and advices|A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.
40784690|NCT06237634|OTHER|Triamsinolon Asetonid ozone|40 mg (1 ml) of triamcinolone acetonide was injected to the median nerve's around at wrist level under ultrasound guidance.
40988697|NCT02092662|OTHER|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
41145954|NCT02861716|DRUG|Dexmedetomidine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
41145955|NCT01979211|DRUG|Cetuximab|400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
41145956|NCT01979211|RADIATION|Radiation Therapy|Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
41306767|NCT02736292|BEHAVIORAL|Mindfulness Practices for Healthcare Professionals|
41306768|NCT06280261|OTHER|parenting stress index, Zarit burden scale, Rosenberg self esteem scale, stait trait anxiety inventory, struggles and difficulties questionnaire|Scales and questionnaires
41306769|NCT01218932|DRUG|A|Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
41306770|NCT01218932|DRUG|B|Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
41306771|NCT02336594|DRUG|RDEA3170 10 mg|
41306772|NCT02336594|DRUG|RDEA3170 2.5 mg|
41306773|NCT00059722|DRUG|ZD6474|
41306774|NCT00059722|DRUG|Placebo|
41306775|NCT00059722|DRUG|ZD1839|
41306776|NCT04288726|BIOLOGICAL|CD30.CAR-EBVST cells|"The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 108 cells/m2 and we did not reach an MTD. We will be splitting the total dose between 2 infusions three days apart to improve tumor exposure to CAR-T cells.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Days 0 and 3 ±1 of study, patients will receive half their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL."
41306777|NCT00086710|DRUG|Fuzeon|
41306778|NCT02755844|DRUG|Olaparib|"Olaparib tablet dose will be dose-escalated on 4 dose levels , guided by a continual reassessment method (CRM).~One cycle will be 28 days (4 weeks) in duration, except for cycle 1 which will be 6 weeks."
41306779|NCT02755844|DRUG|metformin|From week 3 metformin will be gradually escalated from 500 mg/day to 1500 mg/day with weekly 500 mg dose escalation levels
41465199|NCT00673192|PROCEDURE|peripheral blood isolation|to isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
41465200|NCT05947097|DRUG|HSK21542 Injection|1ug/kg bolus for 2min±5s
41465201|NCT04302337|PROCEDURE|Curettage adenoidectomy with transoral endoscopic ablation|Transoral endoscopic examination of nasopharynx at the end of cold curettage adenoidectomy, and, if found, ablation of residual tissue.
41465202|NCT04302337|PROCEDURE|Conventional cold curettage adenoidectomy|Conventional cold curettage adenoidectomy without endoscopic examination for residual tissue.
41465203|NCT04763473|DIETARY_SUPPLEMENT|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
41465204|NCT04763473|DIETARY_SUPPLEMENT|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
40784691|NCT06237634|OTHER|ozone|In addition to the treatment and recommendations given to the first group, the affected side was injected with ultrasound-guided 3 cc ozone (O2-O3) into the wrist with a concentration of 10 micrograms/ml.
40988698|NCT02092662|OTHER|Healthy controls|no treatment
41145957|NCT01461967|DRUG|Placebo|Single ascending doses
41145958|NCT01461967|DRUG|RO5508887|Single ascending doses
41465205|NCT00843830|RADIATION|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
41145959|NCT01461967|DRUG|RO5508887|Single doses
41145960|NCT00801528|DRUG|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
41145961|NCT00001848|DRUG|Raloxifene|
41306780|NCT02755844|DRUG|metronomic cyclophosphamide|from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
41465206|NCT00843830|BIOLOGICAL|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
41465207|NCT05420116|BEHAVIORAL|Cerdanya on Fitness|The intervention lasts 9 months. The participants will carry out group activities and will be followed individually by the different interdisciplinary professionals. Goals will be set for each visit. Before and after the training there will be an assessment of physical exercise, nutritional and positive mental health habits.
40784692|NCT02012803|PROCEDURE|End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture|Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.
40784693|NCT02012803|OTHER|Conservative treatment of achilles tendon rupture|Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
41145962|NCT02269072|DRUG|Testosterone|Testosterone cream applied daily for two weeks
41145963|NCT02269072|DRUG|Nesiritide|Administered IV once during the study
41465208|NCT02301533|BEHAVIORAL|Shikamana Intervention|See arm description
41465209|NCT02301533|BEHAVIORAL|Standard Care|See arm description
41465210|NCT06532409|DRUG|Amoxicillin/CA|Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
41145964|NCT02269072|DRUG|Leuprolide|Administered twice during the study by injection
41145965|NCT02269072|DRUG|Anastrozole|Daily pill for 8 weeks
41145966|NCT02269072|DRUG|Placebo|Inert cream otherwise identical to testosterone cream applied daily for two weeks
41145967|NCT02879669|BIOLOGICAL|ONCOS-102|
41145968|NCT02879669|DRUG|Pemetrexed/cisplatin (carboplatin)|
41145969|NCT02879669|DRUG|Cyclophosphamide|
41145970|NCT05530434|OTHER|transpulmonary pressure guided positive end expiratory pressure|Positive end expiratory pressure will be titrated to achieve a transpulmonary pressure of 0-2 cm H2O
41145971|NCT05530434|OTHER|standard positive end expiratory pressure|Positive end expiratory pressure will be set to a standard 5-8 cm H2O by the clinician for spontaneous breathing trials
41306781|NCT00525148|DRUG|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
41306782|NCT04778267|DRUG|Bupivacaine Hydrochloride|We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
41306783|NCT04778267|DRUG|Dexamethasone phosphate|used as additive to bupivacaine
41465211|NCT06532409|DRUG|IV ceftriaxone|Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
41465212|NCT04592653|BIOLOGICAL|Nemvaleukin alfa|IV infusion over 30 minutes
41306784|NCT00943319|DRUG|Busulfan|Daily intravenous dosing to target AVC
40784694|NCT05362994|DEVICE|Selution SLR™ sirolimus-eluting balloon|If the residual stenosis is ≤30% after initial plain old balloon angioplasty, the investigators will perform angioplasty with the Selution SLR catheter, inflated at nominal pressure for at least 120 seconds. After dilatation of the entire target-lesion, biplane angiograms and IVUS imaging will be obtained. Technical success is defined as residual diameter stenosis ≤30% and adequate distal run-off. Bail-out stenting will be performed if residual stenosis is \>30%, either after plain old balloon angioplasty or angioplasty with Selution SLR. For lesions with residual stenosis \>30% but not suitable for stenting, repeat angioplasty will be performed for at most twice.
41465213|NCT04592653|BIOLOGICAL|Pembrolizumab|IV infusion over 30 minutes
40988699|NCT05061979|DRUG|BAY1747846|Solution for intravenous (IV) injection, single dose
40988700|NCT02824250|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction (MBSR) is an 8-week classroom based program of mindfulness meditation and gentle yoga.
40988701|NCT01967251|DRUG|Udenafil|Udenafil tablets
40988702|NCT01967251|DRUG|Placebo|Udenafil placebo-matching tablets
40988703|NCT01948817|DRUG|Deferasirox|Deferasirox 20mg/kg taken BID
40988704|NCT05721833|DEVICE|Non-invasive high-frequency oscillatory|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
40988705|NCT05721833|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation.
41145972|NCT00647374|OTHER|this is an observational study|
41145973|NCT03205345|DRUG|Emricasan (25 mg)|25 mg emricasan
41145974|NCT03205345|DRUG|Emricasan (5 mg)|5 mg emricasan
41145975|NCT03205345|DRUG|Placebo|Matching Placebo
41145976|NCT02335242|DRUG|Sildenafil 20 mg tablets|
41145977|NCT02335242|OTHER|Placebo tablets (resembling Revatio)|
41145978|NCT01292499|BEHAVIORAL|Psychotherapy|10 sessions (50 min)
41145979|NCT01292499|BEHAVIORAL|Psychoeducation|7 sessions + 7 phone calls
41145980|NCT01292499|BEHAVIORAL|Psychoeducation and psychotherapy|Psychoeducation + psychotherapy
41145981|NCT06197100|OTHER|Supportive care training|The program includes breastfeeding teaching, baby massage, managing gas issues (shaking, white noise), and nutrition for mothers.
41145982|NCT06197100|OTHER|control grups|Mothers in this group will be given an educational brochure containing information about colic.
41306785|NCT00943319|DRUG|Fludarabine|Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.
41306786|NCT00943319|DRUG|Campath|All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).
41306787|NCT00943319|PROCEDURE|Stem Cell Transplant|Infusion of bone marrow and donors(related/ unrelated).
41465214|NCT01011556|DRUG|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
41465215|NCT01011556|DRUG|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
41465216|NCT00802373|DRUG|Solifenacin succinate|oral
41465217|NCT00802373|DRUG|Tolterodine|Oral
41465218|NCT04771247|PROCEDURE|Cardia Band Ligation|Patients will undergo cardia band ligation at the level of the GEJ.
41465219|NCT05796596|BEHAVIORAL|Experimental: Virtual Reality (VR) distraction|Children in the VR distraction group will begin interacting with the virtual environment (VE) 2 minutes prior to the skin prick test and will continue playing throughout. The VR environment is a game in which the child draw a 360 degree image.
41465220|NCT05796596|BEHAVIORAL|Active Comparator: Distraction by the book|In the book distraction group, the child will be invited to find and count animals in various landscapes. The book will be given 2 minutes prior to the skin prick test and continued reading throughout.
41465221|NCT03801317|DIETARY_SUPPLEMENT|BC/ egg|4.3 egg powder + 5.7 g bovine colostrum
41465222|NCT03801317|DIETARY_SUPPLEMENT|Control|15 grams corn-soya blend
41465223|NCT03801317|DIETARY_SUPPLEMENT|multiple micronutrient|multiple micronutrient sprinkle powder
41465224|NCT04712084|PROCEDURE|Positive pressure|Inspiratory support of 8 cmH2O was applied associated with PEEP at 6 cmH2O. After extubation, same support was applied by facemask for 3 minutes
41465225|NCT05659329|DEVICE|Simplex HV|Simplex HV bone cement is a fast-setting acrylic resin for use in bone surgery. Mixing the two separate sterile components produces a ductile bone cement which, after hardening, fixes the implant and transfers stresses produced during movement evenly to the bone.
41465226|NCT05596292|DEVICE|Immersive Virtual Reality glasses|The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.
41465227|NCT05596292|OTHER|early mobilization protocol|Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
41465228|NCT05568316|DIETARY_SUPPLEMENT|Preoperative Immunonutrition|"Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
41465229|NCT05568316|DIETARY_SUPPLEMENT|Perioperative Immunonutrition|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
41465230|NCT00059709|PROCEDURE|Mediated Negotiation Training|
40784695|NCT05362994|DEVICE|Plain old balloon angioplasty|The investigators routinely start with a balloon catheter with a diameter ≥0.5 mm smaller than the reference vessel and ended with a balloon catheter with the size approximately equal to the reference vessel diameter. Three minutes after balloon predilation, the investigators will obtain an angiogram. If the residual stenosis is ≤30%, no further intervention will be performed in the plain old balloon (POB) group.
40784696|NCT01634230|DRUG|OCR-002|daily dose: 10 g infused over 24 hours
40988706|NCT01046682|DRUG|Salsalate|Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
40784697|NCT06488274|DIETARY_SUPPLEMENT|New infant formula|The new formula will be given to infants during the 4-month study period.
40784698|NCT05439980|OTHER|Knowledge questionnaire|Completion of a questionnaire at baseline
40784699|NCT05439980|OTHER|Focus groups|structured interviews
40784700|NCT05587673|DRUG|Methylprednisolone|High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.
40988707|NCT01062555|DRUG|Cyclosporine & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
40988708|NCT01062555|DRUG|Prograf & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
40988709|NCT01062555|DRUG|Low Dose CNI (Cyclosporine or FK) and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
41145983|NCT01029418|DRUG|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
41465231|NCT04986124|OTHER|treatment as usual|No inervention. Treatment regime remains unchanged.
41306788|NCT04413435|OTHER|File Scanning|The patients' epidemiological, clinical, laboratory, and radiological characteristics and treatment and outcomes data will accessed from Hospital Data Management System (HDMS) of Konya Training and Research Hospital and Public Health Management System (PHMS) of Ministry of Health.
41306789|NCT01975779|DRUG|Cohort A1: Lu AE58054 or placebo|One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
40988710|NCT01062555|DRUG|Rapamune and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
40988711|NCT00893750|BEHAVIORAL|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
40988712|NCT00893750|BEHAVIORAL|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
40988713|NCT00893750|BEHAVIORAL|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
40988714|NCT05270655|OTHER|Cognitive-behavioural intervention|Participants in the experimental group will receive five sessions of cognitive-behavioural intervention. Each session will be conducted face-to-face for 30-35 minutes a week and supplemented by home-based practices. The first session is an introductory to cognitive-behavioural intervention, the second session includes identifying, evaluating and challenging maladaptive thoughts, beliefs and behaviour, the third session includes behavioural activation, the fourth session is deep breathing, and the last session includes treatment evaluation and relapse prevention. The interventions will be delivered before chemotherapy sessions to avoid fatigue and to increase the patient's engagement with the interventions. To establish a strong therapeutic alliance and enhance intervention delivery and family support, parents will be invited to attend the introduction of the first session and the summary of each session (the last five minutes).
40988715|NCT05747729|DRUG|Surufatinib and Serplulimab|"Surufatinib: Safety lead-in : Oral, QD, starting dose 250 mg, adjusted according to DLT. Dose expansion: administration according to the dose determined in the safety lead-in phase.~Serplulimab: 300 mg intravenous infusion on day 1, repeated every 3 weeks."
40988716|NCT03902912|DRUG|Prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
41145984|NCT00039052|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
41145985|NCT04626128|DRUG|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI)
41306790|NCT01975779|DRUG|Cohort A2: Lu AE58054 or placebo|One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
41145986|NCT04626128|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
41306791|NCT01975779|DRUG|Cohort B1: Lu AE58054|Two single oral doses 60 mg with \>=7 days washout.
41306792|NCT04279912|DEVICE|Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis|The intervention is MRIgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
41306793|NCT02007330|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.
41306794|NCT02007330|DRUG|Normal saline infusion|In group C, the patients receive same volume of normal saline
41465232|NCT03031834|DRUG|Quinapril|
41465233|NCT04908280|DRUG|Ruxolitinib|1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.
41465234|NCT01790230|DEVICE|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
41465235|NCT02209116|OTHER|Qb Test|Given to all participants but the results will be open or blind depending on arm allocation
41465236|NCT01137734|DEVICE|Adjustable Annuloplasty Ring with option to adjust off pump.|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty repair, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.
41465237|NCT01137734|DEVICE|Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)|Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
41465238|NCT03901157|DIETARY_SUPPLEMENT|Yogurt A: Active|Free fat yogurt containing oil-filled alginate gels
41465239|NCT03901157|DIETARY_SUPPLEMENT|Yogurt B: Control|Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels
41465240|NCT04628845|DEVICE|Endo-perio therapy with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
41465241|NCT04628845|DEVICE|Endo-perio therapy without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals
40784701|NCT02388880|DEVICE|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
40784702|NCT02234349|PROCEDURE|pancreas kidney transplantation|
40784703|NCT02234349|PROCEDURE|kidney transplantation|
40784704|NCT03012334|DRUG|Lasmiditan|Dose is based on treatment sequence in 5-way crossover
40784705|NCT03012334|DRUG|Alprazolam|Active comparator based on treatment sequence in 5-way crossover
40784706|NCT03012334|OTHER|Placebo|Placebo comparator based on treatment sequence in 5-way crossover
40784707|NCT04230967|BEHAVIORAL|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit Inspire devices will be set to this goal and notifications will be given on the device for the participants meeting their goals
40784708|NCT04230967|BEHAVIORAL|Routine Care|No encouragement to ambulate will be provided to subjects. Their movement will be recorded
40784709|NCT01707537|BIOLOGICAL|Euvichol|1.5mL/vial, 1vial at 2-week intervals twice
40784710|NCT00003616|DRUG|irinotecan hydrochloride|
40784711|NCT04389073|DRUG|Vinorelbine 40mg|Two tablets per day, three times a week. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
40784712|NCT04389073|BIOLOGICAL|Toripalimab 240mg|Toripalimab 240 MG IV infusion every 3 weeks. Toripalimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
40784713|NCT04389073|BIOLOGICAL|Bevacizumab 5 mg/kg|Bevacizumab 5 mg/kg IV infusion every 3 weeks. Bevacizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
40784714|NCT04389073|DRUG|Cyclophosphamide 50 mg|50 mg per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
40784715|NCT04389073|DRUG|Capecitabine 500Mg Oral Tablet|500mg three times a day. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
40988717|NCT06389747|OTHER|BFR technique|For BFR application, Airbands brand, wireless, automatic training cuffs will be used. During application, it will be ensured that the device module faces forward and the cuff will be fixed in the correct position by wrapping the band around the metal ring. There will be a space between the skin and the cuff that can fit two fingers. The cuff will then be paired via Bluetooth with the Airbands app installed on the phone. BFR cuffs will be placed proximal to the biceps brachii muscle and pressure will be applied. The cuff will be inflated to automatically detect limb pressure. BFR application with 80% pressure to one group of participants and 20% pressure to the other group will be applied simultaneously with the exercise.
41465242|NCT02769650|PROCEDURE|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
41465243|NCT02769650|DRUG|Optimal medicamentous treatment|
41465244|NCT02769650|PROCEDURE|Stress-MRI|A standard stress-MRI test with adenosine
41465245|NCT04884594|DRUG|AAV8-hCocH|2e12 vg/kg single infusion intravenous
40988718|NCT01003509|PROCEDURE|modified shouldice and double|one arm modified shouldice, other one is double repair
41465246|NCT04884594|DRUG|AAV8-hCocH|6e12 vg/kg single infusion intravenous
41465247|NCT04884594|DRUG|AAV8-hCocH|4e12 vg/kg single infusion intravenous
40988719|NCT02591355|DEVICE|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
40988720|NCT02591355|DEVICE|Saline solution injection|Placebo is a saline solution
41306795|NCT04737031|OTHER|Clinician Nudge|"Investigators will use the Best Practice Alert functionality within the EMR as the conduit to the point of decision-making. Epic currently fires a BPA for each new patient presenting to ACC within the Medical Assistant check-in and vital sign workflow, requiring that medical assistants assess tobacco use status within the past 30 days and satisfy the alert with one of three possible answers. Upon opening the Epic Order tab at a patient's next visit after the screening encounter, clinicians will receive the implementation strategy, placed directly over the order interface. The clinician will be required to acknowledge or opt-out when presented with the order. Opting-out will require clinicians to acknowledge a reason for opt-out using a checklist or free text."
41465248|NCT00537017|DRUG|Preladenant|5 mg BID capsules
40988721|NCT05471479|DRUG|Activated Charcoal|Activated charcoal administered as per Clinical Toxicology Recommendations Collaborative or as per current practices
40988722|NCT03134027|PROCEDURE|Bone marrow biopsy|Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.
40988723|NCT03134027|PROCEDURE|Tumor biopsy|Subjects will undergo a tumor biopsy to obtain tissue for generation of a PDX.
40988724|NCT06536777|OTHER|Plyometric Exercises|This include Plyometric Training for 8 weeks
40988725|NCT06536777|OTHER|Blood Flow Restriction Training|This include Blood Flow Restriction Training for 8 weeks
41465249|NCT00537017|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
41465250|NCT00537017|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
41465251|NCT05831579|RADIATION|Proton GRID Radiotherapy|The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.
41465252|NCT00277030|DRUG|Surfactant|
41465253|NCT00277030|DEVICE|Nasal CPAP|
40988726|NCT00333866|DRUG|pregabalin|600mg/day
40988727|NCT00333866|DRUG|pregabalin|450mg/day
40988728|NCT00333866|DRUG|pregabalin|300mg/day
40988729|NCT00333866|DRUG|placebo|placebo
40988730|NCT01831154|DRUG|Tight Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
40988731|NCT01831154|DRUG|Conventional Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
40988732|NCT01831154|DRUG|Standard Glycemic|Insulin was Regular Insulin administered intravenous bolus.
40988733|NCT05837416|DRUG|blue®m Gel|Oxygen will be released after application Oxygen Releasing Oral Gel (blue®m gel) creating a partially high oxygen pressure (pO2), which aids in restoring the micro-environment for a healthy oral cavity
40988734|NCT05837416|DRUG|NBF GINGIVAL GEL®|Anti-oxidant gel (Nano-emulsion complex propolis and vitamin C - NBF GINGIVAL GEL®) is a nano bio fusion gel containing propolis, nano vitamin C, E and herb extract
40784716|NCT04389073|DRUG|Cisplatin|Cisplatin 50mg/m2 IV infusion every 3 weeks. Cisplatin will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
40784717|NCT03279107|OTHER|Soluble corn fiber|soluble corn fiber
40784718|NCT03279107|OTHER|maltodextrin|maltodextrin
40784719|NCT00017043|DRUG|ixabepilone|
40784720|NCT03048435|OTHER|EORTC QLQ CX-24|Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
40784721|NCT03048435|OTHER|Physician Feedback Form|This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.
40784722|NCT00830050|DRUG|Naproxen|500 mg BID 7 days
40784723|NCT00830050|DRUG|Placebo|BID 7 days
41306796|NCT04737031|OTHER|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status (at the screening encounter). In all cases, the message will include information specific to the upcoming appointment with the oncology clinician.
41306797|NCT02756650|DRUG|Canakinumab|150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)
41306798|NCT05052801|DRUG|Bemarituzumab|Intravenous (IV) infusion
41306799|NCT05052801|DRUG|mFOLFOX6|mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.
41306800|NCT05052801|DRUG|Placebo|IV infusion
41306801|NCT00376597|OTHER|quality of life assessment|Ancillary studies
41465254|NCT04554147|BEHAVIORAL|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
40784724|NCT00693888|BEHAVIORAL|advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)|initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
40784725|NCT03586518|DIAGNOSTIC_TEST|Cardiac MRI scan|"A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany).~This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping."
40988735|NCT05837416|DRUG|COE-PAK™|It is non eugenol periodontal dressing. It is supplied in two tubes, the contents of which are mixed immediately before use. One tube contains zinc oxide, oil, a gum, and lorothidol. The other tube contains liquid coconut fatty acids thickened with colophony resin and chlorothymol
40784726|NCT03586518|DIAGNOSTIC_TEST|Echocardiogram|Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.
40784727|NCT03586518|PROCEDURE|Cardiac explantation|A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.
40784728|NCT03586518|DIAGNOSTIC_TEST|48-Hour continuous cardiac monitoring|Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.
41306802|NCT00376597|OTHER|educational intervention|Receive lymphedema educational materials
41306803|NCT00376597|PROCEDURE|Physical therapy|Complete physical therapy-focused intervention
41306804|NCT01605565|PROCEDURE|A nasal brushing|A nasal brushing in every nostril
41306805|NCT03803540|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via duodenal infusion
41465255|NCT01997723|DEVICE|Portable monitoring|A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.
41465256|NCT01997723|OTHER|Polysomnography|One attended diagnostic sleep study.
41465257|NCT01997723|DEVICE|Home portable monitoring|Portable monitoring with WP200 device - applied by participants once at home.
41465258|NCT01997723|DEVICE|Laboratory portable monitoring|Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
41465259|NCT06202534|OTHER||radiotherapy
41465260|NCT05648110|BIOLOGICAL|AZD5156 (Parent study Sentinel Safety Cohort)|"600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL~3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1"
41465261|NCT05648110|BIOLOGICAL|Placebo (Parent study Sentinel Safety Cohort)|single dose of Placebo (3 mL + 2 mL) IM
41465262|NCT05648110|BIOLOGICAL|EVUSHELD™ (Parent study Main Cohort)|"600 mg EVUSHELD™/AZD7442 consisting of 300 mg AZD1061 and 300 mg AZD8895, both at 100 mg/mL~2 IM injections (thigh) of 3 mL each IM on Visit 1 Day 1 and on Visit 5 Day 181"
41465263|NCT05648110|BIOLOGICAL|AZD3152 (Parent study Main Cohort)|"300 mg AZD3152 at 150 mg/mL~1 IM injection (thigh) of 2 mL of AZD3152 on Visit 1 Day 1 and on Visit 5 Day 181"
41465264|NCT05648110|BIOLOGICAL|Placebo (Parent study Main Cohort)|Single doses of 0.9% sodium chloride 2 mL IM for injection on Visit 1 Day 1 and Visit 5 Day 181
41465265|NCT05648110|BIOLOGICAL|AZD3152 (Sub-study)|Single dose of 1200 mg IV at Visit 1 Day 1
41465266|NCT05648110|BIOLOGICAL|AZD7442 - EVUSHELD™ (Sub-study)|Single dose 300 mg IM administered on Visit 1 Day 1
41465267|NCT05648110|BIOLOGICAL|AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152|Single dose of AZD7442 (EVUSHELD™) 300 mg IM
41465268|NCT03747653|DRUG|ADVATE|Patients will be administered a single dose of ADVATE.
41465269|NCT03747653|DRUG|FRSW107|Patients will be administered a single dose of FRSW107 for Injection.
40988736|NCT01830660|DRUG|Hetrombopag Olamine Tablets|
41145987|NCT06585735|DIETARY_SUPPLEMENT|Proteolytic enzyme fortified protein supplement|Group I receive Enzotein 15 gms (proteolytic enzyme with 70000 Hb unit tyrosine (HUT) fortified with 15 gms of whey protein), given for 6 weeks. Enzotein will be provided by (Mylin Biotech India Ltd.)
40988737|NCT01830660|DRUG|placebo|
41145988|NCT00009763|BIOLOGICAL|filgrastim|
41145989|NCT00009763|BIOLOGICAL|monoclonal antibody m170|
41145990|NCT00009763|DRUG|cyclosporine|
41145991|NCT00009763|DRUG|paclitaxel|
41145992|NCT00009763|PROCEDURE|peripheral blood stem cell transplantation|
41145993|NCT00009763|RADIATION|yttrium Y 90 monoclonal antibody m170|
41145994|NCT04468737|BEHAVIORAL|Bowel preparation|Observe patients who undergo bowel preparation by enema or irrigation
41145995|NCT01426217|DEVICE|Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt|Implementation of passive bundle which includes HubScrub and DocIt device into the operating room environment.
41145996|NCT01592422|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
41145997|NCT01592422|OTHER|Best Supportive Care|Best Supportive Care in the absence of disease progression
41145998|NCT01743807|DRUG|GNKG168|GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.
41145999|NCT05812209|PROCEDURE|Stellate Ganglion Block|Ultrasound guided block of the Stellate Ganglion with local anesthetics.
41146000|NCT02167230|PROCEDURE|Jailed-balloon technique|A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
41146001|NCT02167230|PROCEDURE|Jailed-wire technique|A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
41146002|NCT00071929|DRUG|oxaliplatin|
41146003|NCT02512107|DIETARY_SUPPLEMENT|Juice Plus+|Dried fruit and vegetable juice capsule.
41146004|NCT02512107|OTHER|Placebo|Placebo capsule
41465270|NCT05141786|DRUG|MRG002|Administrated intravenously
41465271|NCT01235715|DRUG|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
41465272|NCT06326645|DRUG|Crofelemer Oral Product|Crofelemer powder for solution (50g and 100g) or Crofelemer Powder for Oral Solution (100 mg/mL or 30 mg/mL vials for reconstitution and oral dosing)
41465273|NCT02172196|DRUG|BI 10773|
40784729|NCT03586518|DIAGNOSTIC_TEST|Blood samples|Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
40784730|NCT03348124|BEHAVIORAL|"Children - what does it involve?"|"Thirteen educational lessons based on the conversational material Toolkit will be delivered in the classroom at school, two lessons per theme. The themes consists of: 1) a card game: What i wish 2) Time 3) Money 4) Skills 5) Relations 6) Housing. The material is prepared and same for all schools. This intervention will be given 1-2 lessons per week over a period of 8-14 weeks. During this period the students also care for the RCB simulator during three days and nights, but with a break for day care for the simulator which was between 7 am and 5 pm when the students were in school. All students will practice handling the simulator to be familiar with all types of needs: to rock, change diaper, feed and burp and were taught the skills of head support, techniques to avoid rough handling."
40784731|NCT03215043|DIETARY_SUPPLEMENT|Eriocitrin|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
40784732|NCT03215043|OTHER|Placebo|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
40784733|NCT04163939|OTHER|Vista Therapy Collar|The patient will wear the cervical collar
40784734|NCT04163939|OTHER|Placebo|The patient will not wear the cervical collar
40784735|NCT03420144|DRUG|Standard Medical Therapy|Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
40784736|NCT03420144|DRUG|Growth Hormone|GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.
40784737|NCT01413438|PROCEDURE|Craniotomy|
40988738|NCT03294733|PROCEDURE|Ultrasound|This ultrasound machine is owned by the department of orthopaedic surgery and is capable of up to 15 MHz image definition with its linear transducer
41306806|NCT02588846|DEVICE|Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'|This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
40784738|NCT04442568|OTHER|ERAS|early mobilisation, early oral intake, early discharge
40988739|NCT04515342|DIAGNOSTIC_TEST|DXA|Each participant will undergo one DXA scan
40988740|NCT04515342|OTHER|Muscle strength and function assessment|Each patient will have their muscle strength and function assessed with the measurements of handgrip strength, 10 m gait speed and a 30 s sit-to-stand test. They will also fill out a questionnaire assessing Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls (SARC-F questionnaire).
40988741|NCT04515342|OTHER|Blood samples|Each patient will undergo a physical examination and also deliver blood samples.
40988742|NCT00279890|DRUG|Topical SR-01|
40988743|NCT03553407|DEVICE|Low Level Laser - Pulse|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
40988744|NCT03553407|DEVICE|Low Level Laser - continuous|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
41146005|NCT01484015|DRUG|cefepime hydrochloride|Given IV
41146006|NCT00312546|DRUG|Enfuvirtide|90 mg subcutaneously twice daily
41146007|NCT00312546|DRUG|Valproic acid|500 to 750 mg, taken orally twice daily
41146008|NCT04127695|DRUG|ABBV-0805|ABBV-0805 administered by IV infusion.
41306807|NCT05339438|RADIATION|functional MRI|Functional MRI scanning (around 1h30 min): SMS + multi-band (with FPVS paradigms for both)
41306808|NCT01921257|DRUG|Cat-PAD|
41306809|NCT01921257|DRUG|Placebo|
41465274|NCT02172196|DRUG|Sitagliptin|
40784739|NCT05150678|PROCEDURE|removal of ceserean section scar|we will remove the previous scar in group A
40784740|NCT05150678|PROCEDURE|non removal of cesearean section scar|we will open in the previous cesearean scar in group B
40988745|NCT03553407|DEVICE|Low Level Laser - placebo|placebo will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
40988746|NCT04145999|PROCEDURE|PRP application|The study participant will receive topical anesthesia with lidocaine ointment (50mg/g). After 5 minutes the face will be cleaned with 0.5% alcohol chlorhexidine solution. The newly obtained platelet-rich plasma activated with 10% calcium chloride packed in a 5mL syringe will be applied to the face using a 30G needle in the frontal, lateral periorbital, nasogenian sulcus, bilateral malar region and an infra-auricular point. 0.1ml per cm2 will be injected, totaling 43 points. Only one application of PRP will be performed at the defined points.
41146009|NCT04127695|DRUG|Placebo ABBV-0805|Placebo ABBV-0805 administered by IV infusion.
41146010|NCT05884671|DRUG|Sulpiride 400 MG|All participants will receive one single dose of 400mg sulpiride. None of the participants will receive repeated doses. In order for the fMRI data acquisition to coincide with the time-window of maximal drug effects represented by a combination of plasma kinetics and physiological effects we will administer the drug 90 minutes prior to fMRI data acquisition.
41146011|NCT05884671|DRUG|Placebo|All participants will receive placebo during one of the sessions.
41146012|NCT05146479|PROCEDURE|Fluoride varnish and pit and fissure sealants onto first permanent molars|Quarterly application of fluoride varnish. Application of pit and fissure sealant, and replacements if necessary.
41306810|NCT01743963|BEHAVIORAL|Decision support|Clinical pharmacists mediated computerized decision support
41306811|NCT01743963|BEHAVIORAL|Usual Care|clinicians typical apporach for GID monitering
41306812|NCT01711320|DRUG|Placebo|
41465275|NCT06398834|DRUG|Esketamine|In the esketamine combined with butorphanol group (Group BK), patients received an intraoperative intravenous infusion of esketamine (0.3 mg/kg/h) followed by postoperative patient-controlled intravenous analgesia (PCIA) (esketamine 1.5 mg/kg + butorphanol 0.15 mg/kg + azasetron 20 mg).
41465276|NCT06398834|DRUG|Butorphanol|In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.
40784741|NCT00268281|DEVICE|Left Ventricular Capture Management Software|
40784742|NCT02562781|DRUG|Oxygen|Oxygen in sufficient quantity to maintain SpO2 \> 98%
40784743|NCT02562781|OTHER|Air|Supplemental Oxygen in sufficient quantity to maintain SpO2 \> 90%
40784744|NCT00757068|BEHAVIORAL|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
41465277|NCT02251977|DRUG|GM1|GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
40988747|NCT04145999|OTHER|Placebo PRP application|Blood collection will be performed normally, the time between collection and application of saline will be the same as the PRP protocol, but in this case, the blood will be discarded, only a sample to quantify the number of platelets will be sent for analysis.
40988748|NCT04145999|RADIATION|Photobiomodulation|Photobiomodulation will be applied with a Cosmedical LED face mask (São Paulo, Brazil) containing 92 red LEDs. The applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP or placebo.
40988749|NCT04145999|OTHER|Placebo Photobiomodulation|Participants will not be aware of whether or not they have received the PBM application as they will be using eye protection and the researcher will position the equipment at the irradiation locations on all participants. The characteristic sound of the device will be triggered by recording in the placebos groups for the PBM. The placebo applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP.
40988750|NCT05554198|BEHAVIORAL|Attend Behavior Parent Training|Attend Behavior is a Parent Training intervention available in application form for smartphones or online. Attend Behavior consists of 12 instructional modules and it is recommended that parents complete one module a week in addition to practicing the techniques taught in that course. Each learning module typically around 30 minutes to complete and includes an introductory video to give parents an overview of the different features of the application. At the start of the intervention, parents will take an assessment that will provide information for the program to create individualized goals, plans, reinforcement agents, and even daily schedules. A HIPPA compliant clinician portal within the application allows the clinician to have real time access to monitor the parent learning progress, tracked behaviors, parental notes, and message with the parent.
40988751|NCT01982747|DRUG|MGN-Placebo|
40988752|NCT01982747|DRUG|Placebo-MGN|
40988753|NCT02051946|DEVICE|Retroject Device|
41306813|NCT01711320|DRUG|Omeprazole|
41306814|NCT02423434|OTHER|Exposure: Corneal nerve fibre morphology by the CCM Procedure|"CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.~In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed."
41306815|NCT00904826|DRUG|Eculizumab|"The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.~The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months."
41306816|NCT04175704|DRUG|UB-221|Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
40988754|NCT02051946|DRUG|ethacrynic acid injection|
41306817|NCT03799718|BIOLOGICAL|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
41306818|NCT00394290|DEVICE|Continuous Positive Pressure|Nighttime continuous positive pressure device, to be used every day
40988755|NCT02051946|DRUG|balanced salt solution|
40988756|NCT03832621|DRUG|Temozolomide|temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks
40988757|NCT03832621|DRUG|Nivolumab|nivolumab 480 mg i.v. every 4 weeks
40988758|NCT03832621|DRUG|Ipilimumab|low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
40988759|NCT01951157|DRUG|Docetaxel|Powder for solution for infusion
40988760|NCT01951157|DRUG|Gemcitabine|Powder for solution for infusion
40988761|NCT01951157|DRUG|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
40988762|NCT02782533|DEVICE|Deep Brain Stimulation V3|
41306819|NCT05493371|DRUG|Empagliflozin 10 MG|10 mg once daily empagliflozin oral tablets for 12 weeks
41306820|NCT00114283|DRUG|lapatinib ditosylate|Given PO
41306821|NCT00114283|OTHER|laboratory biomarker analysis|Correlative studies
41306822|NCT01370096|DRUG|Vasopressin infusion|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure.
41465278|NCT02251977|DRUG|placebo|Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
40988763|NCT03669692|BEHAVIORAL|Caloric Restriction|Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.
40988764|NCT03669692|BEHAVIORAL|Control|Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
41146013|NCT06501521|DIAGNOSTIC_TEST|Diagnostic test|No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.
41146014|NCT05967377|DRUG|Sorafenib - Period 1|Sorafenib (Nexavar®) Tablet, 200 mg
41146015|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 1|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
41146016|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 1|XS005 Sorafenib Tablet A, 100 mg
41146017|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 2|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
40988765|NCT06478537|DRUG|Hetrombopag Olamine|"Treatment period: 24-week Hetrombopag (2.5mg/d\~7.5mg/d) treatment.~* Two consecutive visits with PLT\>600 × 10\^9/L: daily dose reduction of 2.5mg; If the lowest dose has been used, extend the dosing interval.~* Two consecutive visits with PLT\<300 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached.~* Two consecutive visits with PLT\<50 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached; If PLT is still\<50 × 10\^9/L with7.5mg/d × 28d, the patient will be withdrawn.~Drug discontinuation period：8-week Hetrombopag (2.5mg/d\~7.5mg/d) reduction. Hetrombopag reduces by 2.5mg every 2 weeks, and after reducing to the minimum dose of 2.5mg/d x 2 weeks, it is changed to 2.5mg once every other day (Qod) treatment, with a maximum reduction time of 8 weeks. If the PLT during two consecutive visits is less than 30 × 10\^9/L, the patient will be withdrawn."
40988766|NCT06478537|DRUG|Aspirin|Aspirin 100mg, qd
40988767|NCT03042247|DIAGNOSTIC_TEST|FDG PET/TC and FDG PET/MRI|Combined assessment with FDG PET/TC and PET/MRI
40784745|NCT00757068|BEHAVIORAL|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
40988768|NCT00228917|BIOLOGICAL|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
40988769|NCT00228917|BIOLOGICAL|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
40988770|NCT00228917|BIOLOGICAL|Mencevax-ACWY|Meningococcal Serogroups A, C, W-135 and Y Vaccine
40784746|NCT06320704|DEVICE|Digital occlusal adjustment using Occulosense digital device|Digital occlusal adjustment of mandibular complete denture using Occulosense digital device
41146018|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 2|XS005 Sorafenib Tablet A, 100 mg
40784747|NCT01736033|DRUG|Tamsulosin|1 tablet(0.2mg) orally q.d.
40784748|NCT01736033|DRUG|Finasteride|1 tablet(5mg) orally q.d.
41146019|NCT05967377|DRUG|Sorafenib - Period 2|Sorafenib (Nexavar®) Tablet, 200 mg
41146020|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 3|XS005 Sorafenib Tablet A, 100 mg
41146021|NCT05967377|DRUG|Sorafenib - Period 3|Sorafenib (Nexavar®) Tablet, 200 mg
40784749|NCT01736033|DRUG|Placebo|1 tablet(0.2mg) orally q.d.
40988771|NCT00294073|PROCEDURE|Fascia Iliaca Block|
41146022|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 3|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
41146023|NCT06055478|PROCEDURE|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block|"Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using ropivacaine or saline.~Low fixed dose patient controlled analgesia (PCA) were done in the two group."
41146024|NCT05655689|DRUG|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
41146025|NCT05655689|DRUG|Ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
41146026|NCT05655689|DRUG|Gentamicin 1.4% + vancomycin 5%|In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
41146027|NCT05655689|DRUG|Natamycin 5% Oph Susp|In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
40784750|NCT02418520|DEVICE|Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
40784751|NCT04596722|DIETARY_SUPPLEMENT|Pomella|"Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size 1 capsules packed in white color HDPE bottle of 30 counts"
40784752|NCT04596722|OTHER|Placebo|"White/white HPMC size 1 capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts"
40784753|NCT04702607|PROCEDURE|contrast enhanced 4DCT|Functional Lung Imaging with DECT and 4DCT
40784754|NCT03654144|DRUG|Dienogest|oral tablets
40784755|NCT03654144|DRUG|Combined Oral Contraceptive|oral tablets
40988772|NCT00294073|PROCEDURE|Femoral Block (with stimulating catheter)|
40988773|NCT00294073|PROCEDURE|Femoral Block (without stimulating catheter)|
40988774|NCT02090647|BEHAVIORAL|aesthetic outcome|
40988775|NCT05133219|OTHER|Occupational Therapy|Occupational therapy is the only profession that helps people across the lifespan to do the things they want and need to do through the therapeutic use of daily activities (occupations). Occupational therapy practitioners enable people of all ages to live life to its fullest by helping them promote health, and prevent-or live better with-injury, illness, or disability.
40988776|NCT04782089|DRUG|Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors|Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable
40988777|NCT00778011|DRUG|Ondansetron|dosage
40988778|NCT00778011|DRUG|Ondansetron|4 mg
40988779|NCT00778011|DRUG|Metoclopramide|10 mg IV
40988780|NCT05958355|OTHER|Functional postural control training|All participants will receive functional postural control training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
40988781|NCT05958355|OTHER|Treadmill training|All participants will receive treadmill training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
41146028|NCT05655689|DRUG|Voriconazole 1%|In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
41146029|NCT05655689|DRUG|Natamycin 5% + voriconazole 1%|In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
41146030|NCT05655689|DRUG|Natamycin 5%+ ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
40988782|NCT04208204|OTHER|somatocognitive physiotherapy|Somatocognitive physiotherapy (SCT) is a multimodal physical therapy approach that has been developed in an attempt at alleviating the burden of longstanding pain. The main foci of SCT include: (1) bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension in different situations; (2) education about the vulvodynia and factors influencing pain experience; (3) coping with emotions and thoughts related to bodily experiences; and (4) structured homework assignments promoting application of the learned techniques in daily situation and gradual exposure to activities associated with pain. An important goal of SCT is to facilitate integration of new bodily habits into the patient's daily activities. The most important learning process thus occurs in the space between the treatment sessions. The therapeutic techniques are to be rehearsed in everyday situations.
40784756|NCT04636307|OTHER|Biomarkers|To identify biomarkers obtained using non-invasive procedures that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in NPDR.
40988783|NCT03160534|OTHER|preoperative exercise|Each intervention session contains a stretching part and aerobic training
40988784|NCT05855668|BEHAVIORAL|CBT|12 weeks of group CBT for AUD or CUD
40988785|NCT01094691|PROCEDURE|Renal Allograft Biopsy|A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
40988786|NCT01819454|DEVICE|pH monitoring (Restech)|"see in detail description of the study part of the protocol"
40988787|NCT03019939|DRUG|Isavuconazole|Given PO or IV
40988788|NCT02636868|DRUG|Lucinactant delivered via investigational delivery device|Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)
40988789|NCT02636868|DRUG|nCPAP|Nasal CPAP
40988790|NCT02395900|DIETARY_SUPPLEMENT|Flaxseed|
40988791|NCT02395900|OTHER|control|
40988792|NCT03695510|DRUG|Afatinib Oral Tablet|40mg oral, daily, continuously
40988793|NCT03695510|DRUG|Pembrolizumab Injection|200mg, intra-venous injection, every 3 weeks, for 35 cycles
40988794|NCT03255382|DRUG|Fumaderm|Fumaderm tablet administered orally
40988795|NCT03255382|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
40988796|NCT06403735|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
41465279|NCT02251977|DRUG|mFOLFOX6 or XELOX|"mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient."
40988797|NCT04779489|RADIATION|personalized ultrafractionated stereotactic ablative radiotherapy|next-generation stereotactic ablative radiotherapy to bladder and enlarged lymph nodes
40988798|NCT02059850|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
40988799|NCT02059850|DRUG|Cyclophosphamide|Given IV
40988800|NCT02059850|OTHER|Laboratory Biomarker Analysis|Correlative studies
41146031|NCT05655689|DRUG|Voriconazole 1% + ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
41146032|NCT02450747|DEVICE|etafilcon A MULTIFOCAL|Subjects will wear the test lens for four weeks.
41146033|NCT03576378|DRUG|BrentuximabVedotin (BV)|All patients will be treated with 6 cycles of BV-EPEM
41146034|NCT02646878|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.
41146035|NCT00038376|DRUG|Isotretinoin (Accutane)|0.5 mg/k (1.0 mg/k total) by mouth twice a day
41146036|NCT00038376|DRUG|Interferon Alpha|Starting dose of 3 MU injected under skin once a day for 12 weeks.
41465280|NCT03145324|OTHER|Collection of vaccine histories|
40988801|NCT03444922|OTHER|Placebo|Ingestion of Placebo
40988802|NCT03444922|OTHER|BPA 4 ug/kg BW|Oral BPA ingestion of 4 ug/kg BW
40784757|NCT04032821|DRUG|Alkotinib（300mg)|1. First empty stomach, after the meal.2. After eating first, after fasting.
40988803|NCT03444922|OTHER|BPA 50 ug/kg BW|Oral BPA ingestion of 50 ug/kg BW
40988804|NCT05824533|DEVICE|onlay patella button|Total knee arthroplasty (TKA) with a patella onlay button placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
41146037|NCT01964547|DRUG|Sativex|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
41146038|NCT01964547|DRUG|Placebo|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
40988805|NCT05824533|PROCEDURE|Conventional procedure; NO onlay patella button|Total knee arthroplasty (TKA) placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
41465281|NCT01974076|DEVICE|Active tDCS + CBT|
41465282|NCT01974076|DEVICE|Sham tDCS + CBT|
41465283|NCT05476133|OTHER|Executive functions training-elementary and Promoting executive function in in the classroom|evidence based practice that target executive function skills in early elementary years.
41465284|NCT00089076|BIOLOGICAL|ipilimumab|Given IV
40784758|NCT01069913|DRUG|BG00012|"Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation."
40784759|NCT00437398|BIOLOGICAL|Islet Transplant|Purified pancreatic islets
40784760|NCT02669498|PROCEDURE|Routine fallopian tube removal|Fallopian tubes are removed by dissection of the Mesosalpinx.
40988806|NCT02519530|BEHAVIORAL|Teen Outreach Program|The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
40988807|NCT00536107|DRUG|Gefitinib|250 mg oral
41146039|NCT05860218|OTHER|advices|"The following advice will be given to the patients :~1. Walking as flexibly (normally) as possible~2. Advise when lifting ;~   * avoid twisting and bending.~  * for heavy objects use thighs with a vertical back.~  * at other times, use the back and flex it.~3. Heat application for 20 mins twice /day .~4. Avoid sitting or standing for prolonged period and change position every 15 mins.~5. Sitting: Sit with a back support~6. Driving: Use a back support (lumbar roll) at the curve of your back.~7. Sleeping and lying down: Select a firm mattress and box spring set that does not sag. If necessary, place a board under your mattress. You can also place the mattress on the floor temporarily if necessary."
41146040|NCT05860218|OTHER|exercises plus advices|"In addition to the same advice of group A, a suggested functional exercise will be performed for this group.~1. Sidestepping against band resistance:~2. The quadriped opposite arm leg aganist resistance .~3. Squat row on a balance board with band resistance:~4. Front raise single leg support with band resistance:~5. The Advanced Prone Bridge:~6. Side sliding on a fitter board (lateral lunge with band):"
41146041|NCT01373359|DRUG|Misoprostol|400 µg sublingual misoprostol
41146042|NCT01373359|DRUG|Oxytocin|10 IU IM
41146043|NCT03562117|DRUG|Gepotidacin|It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
41146044|NCT00223769|DRUG|Oxandrolone|
41306823|NCT01370096|DRUG|Vasopressin infusion and epoprostenol inhalation|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure. If the target 20% increase in SBP is not achieved with vasopressin titration, the infusion will remain at 0.002U/kg/min. After a period of ten minutes of drug exposure to allow for patient equilibration, subjects will receive nebulized prostacyclin at a dose of 50ng/kg/min for 15 minutes via Aeroneb into the endotracheal tube.
41306824|NCT02432287|DRUG|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
41146045|NCT02175017|DRUG|ONO-4538|
41146046|NCT03958305|PROCEDURE|RADICAL HYSTERECTOMY|Radical hysterectomy is an operation done to treat some cancers of the cervix. The surgeon takes out the uterus and the ligaments (tissue fibers) that hold it in place. The cervix and an inch or 2 of the vagina around the cervix are also removed.
41146047|NCT03114592|OTHER|mHealth tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol)."
41146048|NCT03638700|DEVICE|VisiGlide™ angled tip|Arm A: Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
41465285|NCT00089076|OTHER|laboratory biomarker analysis|Correlative studies
41465286|NCT03592329|BEHAVIORAL|Stress Reduction Training A|"twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions"
41465287|NCT03592329|DEVICE|active tVNS|non-painful electrical stimulation of the auricle
41465288|NCT03592329|BEHAVIORAL|Stress Reduction Training B|"twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions"
41465289|NCT03592329|DEVICE|sham tVNS|sham stimulation
41465290|NCT04149535|DEVICE|Sentinel® Cerebral Protection System|cerebral embolic protection system
41465291|NCT06465147|BIOLOGICAL|SCRI-CAR19v3|Single infusion of SCRI-CAR19v3
41465292|NCT00260689|BIOLOGICAL|Anti-thymocyte globulin (rabbit)|
41465293|NCT00260689|BIOLOGICAL|Anti-thymocyte globulin (horse)|
41465294|NCT00260689|DRUG|Cyclosporine|
41465295|NCT00260689|DRUG|Alemtuzumab|
41465296|NCT06073886|DEVICE|Active cTBS|600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
40988808|NCT00536107|PROCEDURE|CT or MRI|performed at screening and every 6 weeks
40988809|NCT00536107|DRUG|Docetaxel|60mg/m2 intravenous infusion
41146049|NCT03638700|DEVICE|VisiGlide2™ angled tip|Arm B: Primary use of VisiGlide2™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (straight tip) resp. to VisiGlide™ (tip according to the examiner)
41146050|NCT03638700|DEVICE|VisiGlide™ straight tip|Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
41146051|NCT03638700|DEVICE|VisiGlide2™ straight tip|Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)
40784761|NCT03401437|BEHAVIORAL|SF-36|Evaluation of the quality of life with an auto-questionnaire validated, with 8 dimensions: physical activity ; limitations due to physical condition; physical pain; perceived health; vitality; life and relationship with others; limitations due to physical condition; psychic health as well as the assessment of perceived health compared to a year ago. Evaluation done pre-operatively, at M1 and M3
40784762|NCT03401437|BEHAVIORAL|HAD|Evaluation of anxiety and depression with a scale validated with 14 items assess between 0 and 3. Evaluation done pre-operatively and at M3.
40988810|NCT00002091|DRUG|Pentoxifylline|
40988811|NCT05304156|OTHER|Biobanking blood and bone marrow specimens|"Interventions, procedures added for research purposes :~Blood Samples :~* Peripheral blood (20mL EDTA) (at Screening, pre-ICT Day 1, Day1 H8, Day 2, Day 3, Day 4 and Day of EOI evaluation~Bone Marrow samples :~* Biopsy at Screening and at EOI Evaluation~* Additional volume (2mL EDTA) on the Screening,2 and EOI Evaluation aspirations for single-cell analyses.~* Aspiration at D8 for Smears and 2 mL EDTA for single-cell analyses (instead of D15 standard care)."
40988812|NCT02373787|DEVICE|creos xenoprotect|Implant placement with simultaneous bone augmentation
40988813|NCT02373787|DEVICE|Bio-Gide|resorbable collagen membrane
40988814|NCT01288794|DRUG|Diuretics plus human albumin|The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
40988815|NCT01288794|DRUG|Diuretics (standard medical treatment)|The patients will receive standard medical treatment (diuretics)
40988816|NCT05487326|PROCEDURE|Erector spinae plane block|fascial plane injection guided by ultrasound guidance
40988817|NCT05487326|PROCEDURE|cervical epidural injection|cervical epidural injection by fluoroscopy
41146052|NCT00454545|DRUG|Atorvastatin|
41146053|NCT00042510|BIOLOGICAL|Treatment group|
41306825|NCT02432287|DRUG|Placebo|there is no other name we used for the placebo
41146054|NCT05722821|OTHER|Hypopressive intervention|"Hypopressive abdominal gymnastics is based on a basic level hypopressive exercise program that will be:~* A duration of 12 weeks with a frequency of 2 sessions a week and lasting 45 minutes each. Hypopressive abdominal exercises will be performed individually adapted to the capacity of the participant.~* There will be an initial anatomical training of the muscles involved in carrying out the exercise and practice in the respiratory technique for a duration of 15 minutes. Afterwards, hypopressive exercises will begin for 20-30 minutes, changing positions if possible."
41146055|NCT02676778|DRUG|E7777|
41146056|NCT04123119|BIOLOGICAL|Rotavirus vaccine|An exploratory and observational cohort study following infants receiving two standard doses of live, attenuated, oral Rotarix™ administered at 6 \& 10 weeks.
41465297|NCT06073886|DEVICE|Inactive/Sham cTBS|600 inactive, or sham, cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
41465298|NCT06073886|BEHAVIORAL|Imaginal exposure|Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
41465299|NCT00378027|DRUG|Fondaparinux|Administer Fondaparinux Risk Stratify
41465300|NCT03069677|OTHER|music|patients in this group will receive research-selected music after the golden moment has been completed between the patient, provider, and nursing staff
41465301|NCT03069677|DRUG|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
41465302|NCT05276687|DRUG|Betadine|Wound irrigation
41465303|NCT05276687|DRUG|Vancomycin|instillation in the wound
41465304|NCT04386317|DRUG|Terazosin|Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.
41146057|NCT00649402|DRUG|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
41306826|NCT01606592|BEHAVIORAL|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
41306827|NCT01606592|BEHAVIORAL|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
41306828|NCT01606592|OTHER|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
41465305|NCT00565513|PROCEDURE|blood test|cord blood and maternal milk test
41306829|NCT00208312|DRUG|Regadenoson|0.4 mg, bolus intravenous injection
41306830|NCT00208312|DRUG|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
41306831|NCT03503149|OTHER|no intervention|observational study
41306832|NCT01096771|DRUG|ClinOleic 20%|96 hour continuous infusion.
41306833|NCT01096771|DRUG|Intralipid 20%|96 hour continuous infusion.
41146058|NCT00649402|DRUG|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
41146059|NCT01668992|BEHAVIORAL|Family intervention|12-week parenting skills program for Burmese migrant and displaced children and families.
41146060|NCT06267326|PROCEDURE|debridment|resection of dead bone
41146061|NCT02604199|DRUG|ARC-520 Injection|ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
41146062|NCT02604199|OTHER|placebo|Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
41146063|NCT02604199|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
41146064|NCT02604199|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
41306834|NCT03412318|DEVICE|Twisted file|Use of twisted file during cleaning and shaping of root canals
41306835|NCT03412318|DEVICE|Mpro|Use of Mpro during cleaning and shaping of root canals
41306836|NCT05678413|PROCEDURE|DVIU with paclitaxel injection|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
41306837|NCT05678413|PROCEDURE|DVIU|DVIU
40784763|NCT03401437|OTHER|ANSM|Additional information requested by the ANSM (french National Agency for Medicines and Health Products Safety) following a materiovigilance report. Evaluation done pre-operatively and at M3.
40784764|NCT01309061|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml
40784765|NCT02474121|DEVICE|Bone marrow concentration device|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
40784766|NCT01400009|DRUG|Vitamin D (Cholecalciferol )|10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
40784767|NCT01400009|DRUG|Placebo|Standard Placebo made of Lactose 100 mg
40784768|NCT00549159|DEVICE|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
40784769|NCT00549159|DEVICE|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
40784770|NCT01291966|BEHAVIORAL|Motivational interview|
40784771|NCT05778695|DIETARY_SUPPLEMENT|Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate|Ketone ester (KE) dietary supplement (KetoneAid)
40784772|NCT03212352|DRUG|Mifepristone|Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.
40784773|NCT03212352|DRUG|Misoprostol|Regular treatment with Misoprostol 800 mcg.
40784774|NCT02711501|PROCEDURE|Laser-assisted surgery.|laser-assisted surgery
40784775|NCT02711501|PROCEDURE|conventional surgery by blade|conventional surgery
40784776|NCT00652275|BIOLOGICAL|MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP|189 children will receive 3 doses of experimental vaccine
40784777|NCT00652275|BIOLOGICAL|Verorab vaccine|189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
40784778|NCT01331759|DEVICE|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
40988818|NCT06455397|BEHAVIORAL|The Building Emotional Awareness and Mental Health (BEAM) Program|"The BEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving maternal mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy, and the Unified Protocol.~Program delivery will be facilitated through a mobile application. The BEAM program uses a stepped care model to address the pressing need for accessible and effective mental health interventions. Stepped care is a framework that provides mental health services in a tiered manner, ensuring that participants receive appropriate levels of support based on the severity of needs. At the heart of this model are BEAM peer coaches, who will have the most direct contact with participants. Peer coaches are trained to escalate concerns to the program clinical team as required."
40988819|NCT01593423|BEHAVIORAL|plant-based Homestead Food Production|The village model farm will be provided with the necessary inputs to establish their farm including saplings seeds etc.
40988820|NCT01593423|BEHAVIORAL|Homestead Food Production plus small pond aquaculture|In the case of the aquaculture arm a pond will be dug if there is not an existing pond and fingerlings and brood stocks will be provided. Hatcheries will be established if there is not one within a reasonable distance of the farms.
40988821|NCT01593423|BEHAVIORAL|a comparison group|No intervention.
40784779|NCT01158859|DRUG|Pregabalin|Preoperative administration of pregabalin vs placebo 1 hour before surgery
40784780|NCT01971684|DRUG|Second Line ITP agents|The treating physicians will select the second line agent and clinical data will be collected.
40784781|NCT02108886|DRUG|Montelukast|10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
40988822|NCT04760912|DRUG|Rocuronium|Rocuronium used for neuromuscular blokade during anesthesia and anesthesia without rocuronium
40988823|NCT04760912|PROCEDURE|General anesthesia for surgery|General anesthesia with standard anesthetic monitoring,
41306838|NCT03700476|DRUG|Sintilimab|Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
41306839|NCT03700476|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
41306840|NCT03700476|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
41306841|NCT03700476|RADIATION|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
40784782|NCT02108886|DRUG|Placebo|empty capsule filled with sugar
40784783|NCT02108886|OTHER|urine and vaginal secretions sampling|Urine and vaginal secretions sampling, once a week in both groups
40784784|NCT03704350|DIETARY_SUPPLEMENT|controlled diet|Participants will consume a diet that is controlled in its daily contents of oxalate, calcium, vitamin C and sodium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements (vitamins, calcium or other minerals, herbal supplements, nutritional aids), to exercise strenuously, or to consume food or drink that is not provided to them as part of the controlled diet.
40784785|NCT04039529|DEVICE|SCENERGY-guided Biopsy|Use of SCENERGY during a lung, liver or kidney biopsy
41306842|NCT03466489|DEVICE|Floraseal|FloraSeal is a cyanoacrylate-based sealant used in the prevention of surgical site infections.
41306843|NCT00440427|DRUG|Desvenlafaxine Sustained Release (DVS SR)|
41306844|NCT04374110|OTHER|Clinical data|Clinical characteristics from medical records
41465306|NCT05531851|OTHER|Instrument Assisted Soft Tissue Mobilization|"For IASTM treatment, IASTM soft tissue mobilization blade to apply the treatment used. It is a stainless steel shaped metal tool with beveled edges. The researcher, with a 30° angled tool, at a speed of 120 BPM, in the direction of the fibers of the m.biceps brachii muscle.~He applied it with a light pressure by intervening with his weight. Researcher during treatment used a metronome to ensure consistent speed and adjusted the instrument angle before each subject's treatment.~calibrated with a protractor. The application took 8 minutes and the instrument was comfortable on the skin."
40784786|NCT00532844|DRUG|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
40784787|NCT00532844|DRUG|Sapropterin Dihydrochloride and Vitamin C|Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
40784788|NCT00034021|DRUG|Ginkgo Biloba|
41146065|NCT02604199|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
41146066|NCT00993434|BEHAVIORAL|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
41146067|NCT00993434|BEHAVIORAL|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
41306845|NCT03266484|DIETARY_SUPPLEMENT|Probiotic Mixture|The probiotic supplement contains 8 different strains of bacteria and participants will be dosed in two dosages per a total of 40 billion bacteria daily.
40784789|NCT00034021|BEHAVIORAL|Sex Therapy (genital focus)|
40784790|NCT06218810|DRUG|Cadonilimab + bevacizumab + FOLFOX|Cadonilimab + bevacizumab + FOLFOX
40784791|NCT06026150|OTHER|Ultrasound scanning of inguinal area for femoral nerve and artery|ultrasound scanning of inguinal region is done in femoral fracture patient to identify femoral artery and nerve
41146068|NCT00538499|DRUG|Fentanyl citrate|
41146069|NCT00538499|DRUG|Bupivacaine hydrocloride|
41146070|NCT00538499|PROCEDURE|videothoracoscopy|
41146071|NCT04878809|OTHER|Escola L'Horitzó|Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .
41146072|NCT04878809|OTHER|Escola John Talabot|John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
41146073|NCT02992496|DRUG|Ketamine|1mg/kg, 6 applications over 2 weeks
41146074|NCT02992496|DRUG|Midazolam Hydrochloride|0.03mg/kg, 6 applications over 2 weeks
41146075|NCT00321555|DRUG|Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
41146076|NCT05629806|DRUG|Metformin plus pioglitazone|After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
41306846|NCT03266484|DIETARY_SUPPLEMENT|Placebo|A placebo which is identical to the probiotic mixture. Participants will be dosed in two dosages daily.
41306847|NCT00337376|DRUG|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
40784792|NCT03151031|PROCEDURE|Cryotherapy|The cooling procedure for the knee joint will be initiated by using a cryopack or cold-pack. On completion of the initial SEBT, the participant will lie supine and the investigator will apply the cryotherapy for 10 minutes. After the 10 minute period of cryotherapy, the cryopack will be removed, and the participants will perform SEBT for the second time.
41146077|NCT05629806|DRUG|Acarbose|After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
41146078|NCT03248076|DRUG|Fentanyl Citrate|1γ/Kg fentanyl
41146079|NCT04471298|DRUG|Qishenyiqi dripping pills, 6 bags|28 consecutive days
41306848|NCT00337376|DRUG|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
40784793|NCT01630317|PROCEDURE|Peripheral line|Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
41306849|NCT00146705|PROCEDURE|blood samples are taken once|
41306850|NCT06555705|OTHER|Placebo|The control group will be given placebo for 3 months
41306851|NCT06555705|DIETARY_SUPPLEMENT|Omega 3|The interventional group will be given omega 3 for 3 months
41306852|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
41306853|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
41306854|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
41306855|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
41306856|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
41306857|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate placebo + metformin 850 mg bid (F0-M1700)
41146080|NCT04471298|DRUG|Qishenyiqi dripping pills, 9 bags|28 consecutive days
41146081|NCT04471298|DRUG|Qishenyiqi dripping pills, 12 bags|28 consecutive days
41146082|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 6 bags|28 consecutive days
41146083|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 9 bags|28 consecutive days
41146084|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 12 bags|28 consecutive days
41465307|NCT03847194|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
40784794|NCT01630317|PROCEDURE|Central line vein|Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
40988824|NCT05034107|OTHER|Aromatherapy|Approximately 6-7 drops of Ylang-ylang essential oil will be diffused in a common area estimated to be about 300 square feet with temperature of around 25 - 26 degree Celsius and humidity of 50% - 60%. Water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases.
41146085|NCT05877365|DIETARY_SUPPLEMENT|Standard Process 21-Day Purification Program|Purification, also known as detoxification, may help remove natural toxins from the body, while maintaining a healthy weight. The toxin load humans are exposed to daily may take a toll on physical and emotional well-being. Internally, human bodies produce waste byproducts because of normal metabolic function. Although the body is designed to rid itself of these toxins naturally, it can become overburdened. Purification may offer the body additional support to expel these toxins and manage weight, which is important to maintaining health and vitality.
41146086|NCT03892265|OTHER|Observational Study|No intervention is included in this observational study.
41146087|NCT03000829|OTHER|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
40784795|NCT03087175|DEVICE|MGuard stent|MGuard micronet mesh-covered stent in treatment of STE and NSTE-ACS
40784796|NCT03087175|DEVICE|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent in treatment of STE and NSTE-ACS For example, Resolute Onyx
40784797|NCT06480201|DRUG|Ketamine|Ketamine infusion amount is dictated by BMI, sex, and age.
40988825|NCT03066674|OTHER|McKenzie group|Mobilization for lumbar spine,TENS,Exercises,Postural education ,Home exercises program.
40988826|NCT03066674|OTHER|Control group|TENS,Exercises,Postural education ,Home exercises program.
41146088|NCT03000829|OTHER|"Simulated observation by ICU physician"|Display of silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site cardiac arrest team will be told that an intensive care physician is observing the mock code.
41146089|NCT00703365|DRUG|Sorafenib and Gemcitabine|Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
41306858|NCT00703755|DRUG|Placebo|Placebo
41306859|NCT04261387|DRUG|LUT014 Gel|Topical application qd for 28 days
41306860|NCT04261387|DRUG|Placebo for LUT014 Gel|Matching placebo for qd topical application for 28 days
41306861|NCT05529940|DRUG|Folfirinox|The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
41306862|NCT03442829|BEHAVIORAL|Sweet food consumption|Sweet food consumption at breakfast
41306863|NCT03442829|BEHAVIORAL|Non-sweet food consumption|Non-sweet food consumption at breakfast
41306864|NCT04634773|RADIATION|Low-dose CT|"A low-dose, or quantitative (q) CT scan will be performed on the shoulder. This CT scan will be done to assess the bony structure of the shoulder, as well as bone strength, which can influence the health of the cartilage.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
41306865|NCT04634773|OTHER|T1Rho MRI|"A T1Rho MRI will be performed on the shoulder. This imaging technique uses a special sequence and will be used to assess the muscles and tendons around the shoulder.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
41306866|NCT04634773|OTHER|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
41306867|NCT00875784|DRUG|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
41306868|NCT00875784|DRUG|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
41306869|NCT00875784|DRUG|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
41465308|NCT02212106|BIOLOGICAL|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
41465309|NCT02212106|BIOLOGICAL|Comparator Quadrivalent Influenza Virus Vaccine|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
41306870|NCT00875784|DRUG|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
41306871|NCT02343536|DRUG|Oral Azacitidine|
41306872|NCT02343536|DRUG|Rituximab|
41465310|NCT00823381|DIETARY_SUPPLEMENT|resveratrol|one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
41306873|NCT02343536|DRUG|cyclophosphamide|
41465311|NCT00823381|OTHER|placebo|one placebo pill taken once a day with breakfast
41465312|NCT00823381|BEHAVIORAL|Calorie Restriction|supervised calorie restriction diet: 30% reduction in caloric intake
40784798|NCT06480201|OTHER|Saline|Saline infusion amount is dictated by BMI, sex, and age.
41465313|NCT03514355|BEHAVIORAL|Mindfulness-Based Stress Reduction|8 weekly 2.5 h sessions plus one day of practice
41465314|NCT05363579|OTHER|Physiotherapy|Physiotherapy can be defined as a treatment method that focuses on the science of movement and helps people to restore, maintain and maximize their physical strength, function, motion and overall well-being by addressing the underlying physical issues.
41465315|NCT05363579|OTHER|Tuina therapy|Tuina is mainly applied to the meridians or acupoints by manipulation techniques such as pushing, grasping, pressing and rubbing of the soft tissues or muscles of the body. It is reported to improve circulation and the qi in the body.
40784799|NCT01441388|DRUG|Crizotinib plus VEGF inhibitor combinations|Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
40784800|NCT01441388|DRUG|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
40988827|NCT02475551|DRUG|IdeS|Intravenous infusion
41465316|NCT05363579|OTHER|Physio and Tuina therapy|Physiotherapy mixed with Tuina
41465317|NCT04550741|OTHER|telerehabilitation|After obtaining consent, the volunteers will be included in the study at the start of the 4th week and randomized into two arms: Experimental and Control group
41465318|NCT05061914|PROCEDURE|pericardial effusion drainage|tamponading pericardial effusion is a life threatenning condition , pericardiocentesis is performed for patients who are vitally unstable and with a massive amount of effusion to prevent cardiac tamponade, Surgical drainage of pericardial effusion was classically conducted by either open thoracotomy or subxiphoid pericardiectomy. Thoracoscopy has established itself as an alternative to open thoracotomy for the management of many pericardial, pleural and pulmonary disorders
41465319|NCT06535035|DEVICE|laser therapy After implant surgery, laser therapy (LLLT) was applied|After implant surgery, laser therapy (LLLT) was applied a single session with an EPIC X Biolase diode laser (BIOLASE, Inc., USA)
41465320|NCT06535035|DEVICE|SHAM|After implant surgery, After implant surgery, laser therapy (LLLT) was applied in the same manner but without activating it
41465321|NCT00006124|DRUG|celecoxib|Given orally
40784801|NCT01441388|DRUG|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
40784802|NCT01441388|DRUG|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
40784803|NCT01441388|DRUG|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
41306874|NCT02343536|DRUG|Vincristine|
41306875|NCT02343536|DRUG|Prednisone|
41306876|NCT02631135|DRUG|Remifentanil|In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
41465322|NCT00006124|DRUG|placebo|Given orally
41465323|NCT04012931|DRUG|Rilpivirine|Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
40784804|NCT01441388|DRUG|Crizotinib plus bevacizumab|Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
40784805|NCT01441388|DRUG|Crizotinib plus sorafenib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
40784806|NCT01381367|BIOLOGICAL|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
40988828|NCT04395209|OTHER|assesment|muscle strength assessment in stroke individuals
40988829|NCT03103997|PROCEDURE|EUS-guided liver biopsy|EUS-guided liver biopsy using needles with various preparations
41306877|NCT02631135|DRUG|Propofol|BIS values were arranged 40-60 until the end of operation
41306878|NCT02631135|DRUG|Dexmedetomidine|0.5 microgram/kg infusion, no changes
41306879|NCT02631135|DRUG|Rocuronium|0.5 mg/kg iv for intubation, no changes
41306880|NCT00002118|DRUG|Zalcitabine|
41306881|NCT06267092|OTHER|No treatment given|Participants will not get any medicine during this study.
41306882|NCT06267092|DRUG|Cagrilintide and Semaglutide|Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.
41306883|NCT06267092|DRUG|Placebo|Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
41306884|NCT06534424|OTHER|Best Practice|Receive standard care
41306885|NCT06534424|PROCEDURE|Biospecimen Collection|Undergo collection of blood or mouthwash sample
41306886|NCT06534424|OTHER|Counseling|Receive tailored counseling
41306887|NCT06534424|PROCEDURE|Discussion|Participate in phone discussion
41306888|NCT06534424|PROCEDURE|Genotyping|Undergo genotyping
41306889|NCT06534424|PROCEDURE|Molecular Risk Assessment|Undergo enhanced risk assessment
41465324|NCT04012931|DRUG|ARV Background Regimen|The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine \[AZT\], abacavir \[ABC\], tenofovir alafenamide \[TAF\], or tenofovir disoproxil fumarate \[TDF\] in combination with emtricitabine \[FTC\] or lamivudine \[3TC\]), whichever are approved and marketed or considered local standard of care for children aged between 2 and \< 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir \[DTG\] or raltegravir) can also be administered in combination with RPV, as appropriate.
41465325|NCT01920750|BIOLOGICAL|MLCwA|Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
41465326|NCT01920750|BIOLOGICAL|MLSA-LAM|Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
41465327|NCT01920750|OTHER|Mock Antigen|Physiological saline
41465328|NCT02418624|DRUG|carboplatin, olaparib|2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
41465329|NCT00109850|BIOLOGICAL|cetuximab|400mg/m\^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m\^2 maintenance dose, IV over 60 min, Days 8 \& 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
41465330|NCT00109850|DRUG|cisplatin|30mg/m\^2, bolus intravenous (IV), on Days 1 \& 8 of each cycle.
40784807|NCT01381367|DRUG|Normal Saline|normal saline, 0.5ml given subcutaneously
40784808|NCT04133168|DEVICE|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~* POLARx™ or POLARx™ FIT Cryoablation Catheter~* POLARMAP™ Catheter~* POLARSHEATH™~* SMARTFREEZE™ Console~* Diaphragm Movement Sensor (DMS)~* Related Accessories"
40784809|NCT04256525|DRUG|Rivaroxaban 10mg|10mg orally per day
41306890|NCT06534424|OTHER|Questionnaire Administration|Ancillary studies
41306891|NCT01326052|PROCEDURE|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
41306892|NCT01326052|PROCEDURE|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
41306893|NCT05051865|DRUG|camrelizumab|camrelizumab combined with SHR1020 for advanced melanoma
41306894|NCT05051865|DRUG|SHR1020|camrelizumab combined with SHR1020 for advanced melanoma
41306895|NCT03965663|DEVICE|Vibro-tactile Feedback|The device measures the force between the prosthetic food and the ground. With this signals, vibratators are triggered. The vibrators are housed by the prosthetic socket and stimulate the stump.
41306896|NCT00427583|DRUG|imatinib mesylate|
41306897|NCT02801162|DEVICE|conventional ABG analyser|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
41306898|NCT02801162|DEVICE|Proxima 3®|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
41306899|NCT02433379|DEVICE|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
41306900|NCT04619875|OTHER|KB5|KB5, a novel glycan, is a Kaleido laboratory code for KB174
41306901|NCT04619875|OTHER|SG1|SG1 is a novel glycan
41306902|NCT04619875|OTHER|Lactulose|Lactulose is a synthetic dissacharide
41306903|NCT00101803|DRUG|vildagliptin|
41306904|NCT00115349|DRUG|Deferoxamine|Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
41306905|NCT00115349|DRUG|Deferiprone (L1)|The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
41465331|NCT00109850|DRUG|irinotecan hydrochloride|65mg/m\^2, intravenous (IV) over 30 min, on Days 1 \& 8 of each cycle.
41465332|NCT00109850|RADIATION|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
41465333|NCT00942812|OTHER|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
41465334|NCT00942812|OTHER|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
41465335|NCT06535711|RADIATION|Acute CT|Acute CT (a CT within 24 h)
41465336|NCT06535711|RADIATION|Deferred CT|Deferred CT (a CT within 3-4 weeks)
40784810|NCT04256525|DRUG|Aspirin 100mg|100mg orally per day
40784811|NCT04256525|DRUG|low molecule heparin|0.4ml per day subcutaneous injection
40784812|NCT00140023|DRUG|Azithromycin microspheres 2.0 single dose|
41306906|NCT00308438|DRUG|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
41306907|NCT02514928|PROCEDURE|resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
41306908|NCT02514928|PROCEDURE|standard pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
41306909|NCT03705962|DRUG|Tobramycin|
41306910|NCT03705962|OTHER|Placebo: normal saline|
41306911|NCT00603434|DRUG|OROS-MPH|18 mg bid on days 1 and 2
41306912|NCT00603434|DRUG|OROS-MPH|27mg bid on days 3 and 4
41306913|NCT00603434|DRUG|OROS-MPH|35 mg bid on days 5-9
41465337|NCT05608252|DRUG|VS-6766|Taken Orally
41465338|NCT05608252|DRUG|Abemaciclib|Taken Orally
41465339|NCT05608252|DRUG|Fulvestrant|Administered by intramuscular injection
41465340|NCT02562287|DRUG|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
41465341|NCT02562287|DRUG|Risperidone|Risperidone, in a flexible dosage
41465342|NCT02562287|DRUG|Olanzapine|Olanzapine, flexible dosage
41465343|NCT02562287|DRUG|Quetiapine|Quetiapine, flexible dosage
40784813|NCT04187131|BEHAVIORAL|augmented reality|The participants will be wearing an EEG cap and Augmented Reality headset (AR-based EEG-guided system) for 10 sessions with a licensed occupational therapist, provided in addition to usual rehabilitation care (either in inpatient rehabilitation or at home). These sessions will focus on activities of daily living that the participants want to practice. All sessions will last approximately 1 hour. These sessions will be scheduled around the existing therapy schedule to cause the least amount of interference with planned clinical activities.
40784814|NCT06414044|DRUG|Atogepant 60 mg|Patients using atogepant 60 mg tablet daily as migraine prevention
40988830|NCT05220163|DIAGNOSTIC_TEST|CAD|It is an artificial intelligence (AI) system for detection of TB on CXR images. The system input is a frontal CXR, and the outputs are 1) a heatmap indicating suspicious regions on the image; and 2) a score (0-100) which implies the likelihood that the x-ray image shows TB.
40988831|NCT05220163|DIAGNOSTIC_TEST|Xpert|A novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at POC in a mobile van.
40988832|NCT03970733|BIOLOGICAL|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
41146090|NCT05910788|DEVICE|high flow nasal cannula|"The purpose of this intervention is clarify the benefit with the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications.~is to clarify whether there is benefit from the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications."
41146091|NCT01417923|DRUG|vitamin D|P.O.4000 units Vit D per day for 6 weeks
41146092|NCT00785798|DRUG|Vorinostat|200mg to 400 mg twice daily on days 1-7
40988833|NCT03970733|BIOLOGICAL|Placebo|PBS (Phosphate Buffered Saline)
41146093|NCT00785798|DRUG|Pegylated Liposomal Doxorubicin (PLD), Doxil|IV 30mg/m2 on day 3 of a 21-day cycle
41146094|NCT01956396|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
41306914|NCT01085305|BEHAVIORAL|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
41306915|NCT01085305|BEHAVIORAL|TAU|Usual treatment for behavioral disorders
41306916|NCT02108600|DRUG|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
41306917|NCT00751530|DRUG|raltegravir|New combination ART incorporating raltegravir with other ARVs.
41306918|NCT05910294|OTHER|questionnaires|Vaginal Assessment Scale (VAS) \& Vulvar Assessment Scale (VuAS) Breast survivorship Tool (MSK Engage Symptom Assessment) Female Sexual Function Index (FSFI) Sexual Activity Questionnaire (SAQ) Female Sexual Distress Scale Revised (FSDS-R) Menopausal Symptom Check List (MSCL) Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF) Weekly Non-Hormonal Moisturizer Diary
41306919|NCT05910294|OTHER|moisturizers|Patients will be provided a list of recommended moisturizers by the female sexual medicine and women's health program (FSMWHP), but will purchase the moisturizers themselves at their local pharmacy.
41306920|NCT05910294|OTHER|moisturizers|potential vaginal moisturizers include Hyalogyn, Replens, Liquibeads, or Vitamin E capsules
41306921|NCT01016106|GENETIC|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
41306922|NCT04070768|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 3mg/m\^2, Days 1,4,7
41465344|NCT02009709|DRUG|Riboflavin 0.1% ophthalmic solution|Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
41306923|NCT04070768|DRUG|Venetoclax|Venetoclax, 100,200,400, or 600mg Daily Dose
40988834|NCT04713774|DEVICE|High-resolution peripheral quantitative CT scanner (HRpQCT)|HR-pQCT images of the distal radius and distal tibia (non-dominant, non-fractured limb) will be obtained using the XtremeCT device with standard protocols. HR-pQCT images wil be analysed with standard software and extended cortical measures software. This software identifies the periosteal and endosteal boundaries, enabling assessment of cortical micro- structural bone properties, including apparent cortical thickness (Ct.Th, mm), cortical tissue mineral density (TMD, mgHA/cm3) and cortical porosity (Ct.Po, %).
40988835|NCT01974583|PROCEDURE|regrafted with thin split-thickness skin graft|Group A (the treatment group) were regrafted with thin split-thickness skin graft
40988836|NCT01974583|PROCEDURE|covered with the occlusive hydrocellular dressing|group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith \& Nephew)
40988837|NCT01974583|PROCEDURE|covered with paraffin gauze|Group C covered with paraffin gauze
40988838|NCT05194618|DIETARY_SUPPLEMENT|Valerian - lavender|1 tablet per day, half hour before bedtime, day 1 to day 28
40988839|NCT05194618|DIETARY_SUPPLEMENT|Placebo|1 tablet per day, half hour before bedtime, day 1 to day 28
40784815|NCT05973162|OTHER|Virtual Realty Training|"They would be receiving treatment as follow:~Virtual Reality is a technology that aims to completely immerse the user inside the computer generated world, giving the impression to the user that they have stepped inside the synthetic world. RA mobile phone , head mounted display (HMD) will be used and videos of patient's interest will be played on phone which will create a 3D world around the patient.~And while watching conventional physical therapy will be performed side by side.~Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
40784816|NCT05973162|OTHER|Transverse friction massage (TFM)|"They would be receiving treatment as follow:~Transverse friction massage (Soft tissue mobilization technique) on the surrounding burn region for 5-10min in intervals. Frequency: 3 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 10 mins Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
40784817|NCT04256239|BEHAVIORAL|Dignity Therapy|Intervention aimed at enhancing patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress
40988840|NCT02227342|BIOLOGICAL|Fecal Microbiota Transplant|serial FMT
40988841|NCT02074631|DRUG|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
40988842|NCT02074631|DRUG|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
40988843|NCT03357692|PROCEDURE|all on four implant rehabilitation|implant insertion after piezoelectric site preparation for trans-sinusal implants
40988844|NCT04706195|BEHAVIORAL|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
40988845|NCT00212823|DRUG|almotriptan malate|
40988846|NCT00727753|DRUG|Ranibizumab|ranibizumab (0.5 mg) will be injected intraocular
40988847|NCT00727753|DRUG|Bevacizumab|Bevacizumab (1.25 mg) will be injected intraocular
41306924|NCT00736086|DEVICE|Vessel Closure (StarClose™)|
41306925|NCT01683110|DRUG|cabozantinib|
40988848|NCT00727753|OTHER|No treatment|No treatment
40988849|NCT04726345|DRUG|Fexofenadine Hcl 180Mg Tab|Fexofenadine 180mg tablet to be taken orally once a day until stent removal.
41306926|NCT02046031|DRUG|Ginkgolides Meglumine Injection|25 mg, ivdrip, once.
41465345|NCT02009709|DEVICE|CCL-VARIO UV lamp|Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes
41465346|NCT02009709|DEVICE|CCL-VARIO at 18 mW/cm2|Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
41465347|NCT05434351|OTHER|vaginal dehydroepiandrosterone|the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated
41465348|NCT00179673|DRUG|Lenalidomide|Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
40988850|NCT04726345|DRUG|Placebo|Placebo tablet to be taken orally once a day until stent removal.
40988851|NCT01793727|DEVICE|Glidescope videolaryngoscope|
40988852|NCT01571258|BEHAVIORAL|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
40988853|NCT03599050|BEHAVIORAL|Audiotaped Counseling Session|Patients and nurses will complete audio taped counseling session at least 3 months following the baseline visit. Patients will rate quality of nurse communication skills
40784818|NCT04441697|DIAGNOSTIC_TEST|Multiple sleep latency tests|The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.
40988854|NCT02034786|PROCEDURE|Adipose tissue collection|"Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia."
40988855|NCT02034786|BIOLOGICAL|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
40988856|NCT02034786|PROCEDURE|Transdermal injection|Transdermal injection of hyaluronic acid only.
40988857|NCT00415909|DRUG|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
40988858|NCT00415909|DRUG|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
41146095|NCT00334438|BIOLOGICAL|rituximab|250mg/m2, IV, Days 1 and 8
41146096|NCT00334438|DRUG|bortezomib|dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
41146097|NCT00334438|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8
41146098|NCT00334438|RADIATION|Indium 111 ibritumomab tiuxetan|5cmCi; IV day 1
41146099|NCT00564447|DRUG|Azithromycin|azithromycin topical solution 1% given as a single drop in a single eye
41306927|NCT05630404|DRUG|Surgical ESPB|"In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
41306928|NCT05630404|DRUG|US guided ESPB|"US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
41306929|NCT00121069|DRUG|Escitalopram|
41306930|NCT03375905|DEVICE|cNEP|subjects with OSA will be treated with the cNEP device with the goal of reducing the number of apneas and hypopneas
41146100|NCT00564447|DRUG|Moxifloxacin|Moxifloxacin topical solution given as a single drop in a single eye
41465349|NCT00979212|DRUG|panitumumab|Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
41146101|NCT01461434|DEVICE|Medtronic Reveal XT implantable loop recorder|subcutaneous implantation
41146102|NCT02158845|DRUG|LNG-IUS: levonorgestrel intrauterine system|LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
41146103|NCT02158845|DRUG|GnRHa: leuprolide|3.75 mg leuprolide injected intramuscularly on a monthly basis
41146104|NCT02896556|DEVICE|Resin infiltrate|A resin that used for micro-invasive treatment of enamel-restricted, non-cavitated caries or hypo/demineralized smooth enamel surfaces.
41146105|NCT04523909|DIAGNOSTIC_TEST|Trajectory of neuroinflammatory proteins in CSF and blood|Kinetics of neuroinflammatory markers in CSF and blood
40784819|NCT03319641|DIAGNOSTIC_TEST|PSMA-PET/CT scan|perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC
40784820|NCT04188132|OTHER|EEG -BCI based Feedback for rehabilitation|Subjects will undergo EEG based BCI as feedback for rehabilitation
40784821|NCT02734329|PROCEDURE|conventional laparoscopic partial nephrectomy|renal artery will be clamped during surgery.
40784822|NCT02734329|PROCEDURE|zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)|
40784823|NCT04144777|DIETARY_SUPPLEMENT|Solarplast|Subjects will take one capsule of Solarplast (100mg) daily for 45 days.
40784824|NCT00239603|DEVICE|OV-Watch|
40988859|NCT05447754|OTHER|Combined RAGT and TBT|Combined RAGT and TBT: Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
40988860|NCT05447754|OTHER|balance exercises|TBT
40988861|NCT02659709|DEVICE|Interest in medical education through social media|Measuring interest in social media technology designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
40988862|NCT05267652|OTHER|Preoxygenation with Non-Invasive Positive Pressure Ventilation|The delivery of oxygen and ventilation by non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
40988863|NCT05267652|OTHER|Facemask Oxygen|The delivery of supplemental oxygen via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
40988864|NCT02193373|OTHER|Osteopathic Manual Medicine|Osteopathic Manual Medicine
40988865|NCT02193373|OTHER|Sham|Osteopathic Manual Medicine
40988866|NCT02621242|PROCEDURE|Upper endoscopy|Upper endoscopy with biopsies
40988867|NCT02621242|PROCEDURE|Anoscopy|Anoscopy with biopsies
40988868|NCT02621242|DRUG|Truvada|Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
41465350|NCT00979212|DRUG|carboplatin|Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
40784825|NCT05525962|BEHAVIORAL|questionnaries, scales, cognitive tests|"A first interview is planned with a psycholgist in the weeks following the minor arrival in the structure (M0)~* M0: cognitive test, psychiatric classification and psychologic assessments~* M12 and M24: psychiatric classification and psychologic assessments"
40784826|NCT04940728|OTHER|Creative thinking techniques intervention program|The intervention program based on creative thinking techniques was designed to consist of four stages: preparation, theoretical briefing, skill development and evaluation. In the first stage of the program, acquaintance and information meeting, in the second stage, the theoretical part lasts for two weeks, in the third stage, various creative thinking techniques are applied for four weeks to gain creative thinking skills.
40988869|NCT06527131|DEVICE|pulsed electromagnetic field therapy|PEMF is regarded as an efficient physical therapy method that has been utilized clinically to treat a variety of orthopedic conditions, including delayed union and nonunion of fractures. According to studies, PEMF has been authorized for its biological effects, which include the mineralization of bone matrix, osteogenic differentiation of mesenchymal stem cells, and osteoblast proliferation
40988870|NCT06527131|DEVICE|Transcutanous electrical nerve stimulation|Electrical stimulation consider a safe and cost-effective method for pain management. It has no side effects and few contraindication in addition to no drug interaction . According to studies ,electrical stimulation decreases pain through reducing central transmission of pain signals because of nociceptive inhibition at the presynaptic level in the dorsal horn.
40988871|NCT06527131|DRUG|Vancomycin|medical antibiotics
40988872|NCT03885141|DRUG|Zolpidem|Zolpidem or Placebo if there is a wake up during the night
40988873|NCT05371574|DRUG|clonidine group|Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision
40988874|NCT02986568|PROCEDURE|Cervical cancer|"If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles), then perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above.~If tumor size \< 5cm, perform Fusion Total mesometrial resection (TMMR)~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
41146106|NCT05236218|OTHER|Discrete Choice Experiment (DCE) Patients DCE Questionnaire|Discrete Choice Experiment (DCE) Patients
41146107|NCT05236218|OTHER|Semi-Structured Interview Patients Interview|First version of questionnaire (readability/comprehension check)
41146108|NCT05329142|DIAGNOSTIC_TEST|Surplus sample toxicology analysis|Anonymised surplus blood sample will be analysed for drugs and their metabolites by way of Mass Spectrometry and LGC Group, Cambridge.
41146109|NCT04583293|OTHER|No intervention|This study does not involve any intervention or new treatment.
41146110|NCT02080143|DEVICE|Thermal Adhesion Patch|
41146111|NCT02080143|DEVICE|Thermal Adhesion Patch|
41146112|NCT04907344|DRUG|Camrelizumab|IV infusion
41146113|NCT04907344|DRUG|Nab-Paclitaxel|IV infusion
41146114|NCT04907344|DRUG|Carboplatin|IV infusion
41146115|NCT04464499|DIAGNOSTIC_TEST|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings BPM Core and ECG signal for the reference 12-lead ECG
41465351|NCT00979212|DRUG|paclitaxel|Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
40988875|NCT02986568|PROCEDURE|Uterine cancer|"Perform Fusion Peritoneal mesometrial resection (PMMR).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
40988876|NCT02986568|PROCEDURE|Cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy. Patients with primary disease will be treated with adjvuant chemotherapy. In case of recurrent disease, bevacizumab, paclitaxel, and cisplaitn will be administered regardless of the pathologic report (bevacizumab 15mg/kg on day 1, paclitaxel 135mg/m2 on day 1, and cisplatin 50mg/m2 on day 2, of each 21 day cycle).~If not, no adjuvant therapy."
40988877|NCT02986568|PROCEDURE|Non-cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, appropriate adjuvant chemotherapy will be administered depending on the tumor type."
40988878|NCT04087252|BIOLOGICAL|tumor neoantigen|tumor neoantigens
40988879|NCT03002012|DRUG|Sertraline|sertraline 400mg/day
40784827|NCT04670809|DRUG|Clevidipine Butyrate Injection|Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
40988880|NCT03002012|DRUG|Placebo Oral Tablet|matched placebo tablet
40988881|NCT03002012|DRUG|Fluconazole|Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
41306931|NCT04451655|DRUG|Continuous insulin infusion|This study aims to explore the hypothesis that diabetic patients undergoing coronary artery bypass graft (CABG) surgery receiving intravenous continuous insulin infusion (CII) for tight glycemic control (110-149 mg/dl) protocol during the intraoperative period would have improved intraoperative glycemic stability, efficacy and consistency compared to patients receiving conventional glycemic control (150-180 mg/dl) protocol during the intraoperative period
41306932|NCT05280431|DEVICE|AGREE exoskeleton|"Upper limb exoskeleton with four actuated degrees of freedom (shoulder horizontal adduction/abduction, shoulder flexion/extension, humeral rotation, elbow flexion/extension), and one passive degree of freedom (wrist pronation/supination), implementing different rehabilitative strategies.~The intervention consists of the execution of different exercises with the affected arm supported by the AGREE device. The subject is actively involved in the exercises and the system provides different kinds of assistance that can be tailored according to the patient's status.~The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects (on a plane or in the space)~* exergames.~A subset of exercises is defined based on the patient's capability."
40784828|NCT04670809|DRUG|Ncardipine Hydrochloride Injection|Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
40784829|NCT05749640|OTHER|Precontoured sectional matrix EZ COAT|All teeth will be treated with (Palodent ® plus sectional matrix system) (sectional matrix, biting ring, plastic diamond wedge)
40784830|NCT05749640|OTHER|PerForm™|Treated with (PerForm™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
40784831|NCT05749640|OTHER|AdDent Trimax™|Treated with (AdDent Trimax™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
41465352|NCT00979212|PROCEDURE|surgery|A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
41465353|NCT03788135|BEHAVIORAL|cooling|the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.
41465354|NCT05302219|OTHER|Respiratory rate|The participant alternates respiratory rates of 30, 15 and 7.5 breaths/min. Breathe each frequency for 2 minutes with a one-minute break.
40784832|NCT05749640|OTHER|Contact Pro™|Treated with (Contact Pro™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
40784833|NCT01173510|DRUG|Raltegravir plus Truvada|Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily
40784834|NCT01173510|DRUG|Atripla|Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
41465355|NCT05302219|OTHER|Tidal volume|The participant alternates tidal volumes of approx. 2, 1 and 0.5 litres. Breathe each tidal volume for 2 minutes with a one-minute break.
40784835|NCT02039011|DRUG|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
40988882|NCT00941044|DEVICE|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
40988883|NCT05953454|OTHER|Pain neuroscience Education|A pain neuroscience education session geared towards fear-avoidance beliefs
40988884|NCT01334723|DRUG|Adherent with 5-alpha-reductase inhibitor (5ARI) therapy|Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
40988885|NCT01334723|DRUG|Non-adherent to 5ARI therapy|Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
40988886|NCT01782807|PROCEDURE|Salpingectomy or Fimbriectomy|
41465356|NCT05302219|OTHER|Apnea|The participant simulates three apneic pauses lasting 1 minute with a two-minute break.
41465357|NCT04851067|OTHER|Dry Needling and Therapeutic Exercises (DNTEx)|Already included in arm/group descriptions.
41146116|NCT04153994|PROCEDURE|Erector Spinae Plane Blockade|The ESPB is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
40784836|NCT02039011|DRUG|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
40784837|NCT04388007|OTHER|Thoracic spinal manipulation|High velocity, low amplitude force manipulation
40784838|NCT02524249|DRUG|Caffeine|
40784839|NCT02524249|DRUG|Placebo (dextrose)|
40784840|NCT02385006|BIOLOGICAL|Blood sample|
40784841|NCT04926116|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
41306933|NCT05280431|DEVICE|FEXO exoskeleton|After patient's preparation (tDCS and FES) the FEXO assessment is conducted. The subject performs FEXO assessment games. This stage is also used to calibrate the reach and grasp movement intention EEG patterns. The movement is recorded using internal kinematic sensors; therefore, these measures can be extracted for both reaching and lifting movements. Trunk forward bending is measured to avoid compensatory movements when doing reaching assessment. The clinician then reviews the plan for today's session: game selection, number of repetitions and assistance levels. The patient gets ready to play the games and the clinician starts the first activity of the active stage of FEXO therapy. The patient plays the game and sees his own results. The clinician monitors patient activity, assistance levels, effort and signs of discomfort. The patient plays the next game and sees his own results, and the clinician checks the patient's progress with the results overview.
40784842|NCT04926116|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
40784843|NCT01175343|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
40784844|NCT01175343|OTHER|Laboratory Biomarker Analysis|Correlative studies
41146117|NCT01929616|DRUG|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
41146118|NCT04454723|PROCEDURE|Blood and/or platelet transfusion|The transfused patients will receive one unit each of blood and/or platelet transfusions once a week based on CTCAE symptom grade 2 or greater of anemia and/or thrombocytopenia.
41465358|NCT04851067|OTHER|Manual Therapy and Therapeutic Exercises (MTTEx)|Already included in arm/group descriptions.
41465359|NCT03668951|DRUG|Dexmedetomidine buccal|DEX 2 mcg/kg buccal
41465360|NCT03668951|DRUG|Dexmedetomidine Intranasal|DEX 3 mcg/kg intranasal
40784845|NCT00794092|DRUG|Sinerem administration|Single dose
40784846|NCT00947219|DEVICE|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
40784847|NCT00947219|DEVICE|Control device|Device is used 3 times a week on non-consecutive days
40784848|NCT04593121|DRUG|BIIB107|Administered as specified in the treatment arm.
41465361|NCT03668951|DRUG|Dexmedetomidine Intranasal|DEX 4 mcg/kg intranasal
41465362|NCT05715307|OTHER|Intensive training for endocrinologists in T2DM management|"One-week intensive experiential training for endocrinologists includes a 1-week hospitalization experience at Ruijin Hospital, involving health examinations, results interpretation, and integrated training courses for T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and participate in regular training sessions, including experience-sharing meetings."
40988887|NCT05667038|DRUG|Probiotic|"The probiotics sachet contains a granular powder with 6 microorganism strains (30 × 109 CFU/gram): Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, and Bifidobacterium longum BCMC®02120.~The drug is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length."
41465363|NCT05715307|OTHER|Regular training for endocrinologists in T2DM management|"Regular training and communication are implemented by Ruijin Hospital under the guidance of T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and receive regular routine training."
41465364|NCT04511611|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|10 mg as 1 x 10 mg orally disintegrating tablet (ODT)
40988888|NCT05667038|DIETARY_SUPPLEMENT|Placebo|"Placebo:~Subjects in the placebo group will receive the placebo consisting of only the carrier of the probiotic product, that is maize starch and maltodextrins.~The sachet is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length."
40988889|NCT06368960|RADIATION|Radiotherapy|Radiation： Hypofractionated radiotherapy
40988890|NCT06368960|DRUG|BM201 injection|BM201 injection：Dose escalation：24mg to 240mg
40988891|NCT03309358|DRUG|Inhaled SNSP113|A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
41465365|NCT04511611|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|10 mg as 1 x 10 mg film-coated tablet
41465366|NCT04164030|BEHAVIORAL|Education and Exercise Program for Adults with Type 2 Diabetes|Eating Smart and Being Active program
41465367|NCT04164030|BEHAVIORAL|Nutrition Education plus Occupational Therapy plus Yoga|multimodal interdisciplinary approach
41465368|NCT05058768|DIAGNOSTIC_TEST|The lungs causes and extrapulmonary factors|Acute lung injury due to internal and external pulmonary causes can be used as intervention items in this study, and intervention items can be excluded according to inclusion criteria and exclusion criteria.
41465369|NCT01999894|DRUG|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
40988892|NCT03309358|DRUG|Inhaled Placebo|A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
40988893|NCT05828199|DRUG|Ketamine Hydrochloride|Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.
40988894|NCT05828199|DRUG|Dexmedetomidine|bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr
40988895|NCT00805623|DIETARY_SUPPLEMENT|sucrose|1 cc of sucrose 33.5% with or without pacifier
40988896|NCT04183920|OTHER|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
40988897|NCT04183920|OTHER|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
40988898|NCT03287167|DRUG|1 month DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.
40988899|NCT03287167|DRUG|6 months DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
40988900|NCT05196542|PROCEDURE|patients with apical prolapse who will do Sacro hysteropexy using mersilene tape|comparison between standard poly prolene mesh and the poly ester mersilene tape in Sacro hysteropexy surgical procedure
41146119|NCT04454723|PROCEDURE|Complete blood count (CBC) collection|CBC will be collected from patients weekly while on this protocol.
41465370|NCT05120817|BEHAVIORAL|"Personal intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the personal benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
41465371|NCT05120817|BEHAVIORAL|"Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
41465372|NCT05120817|BEHAVIORAL|"Personal + Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about both personal and social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
41465373|NCT06369610|DRUG|Abiraterone Acetate|Given abiraterone acetate
41465374|NCT06369610|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41465375|NCT06369610|PROCEDURE|Computed Tomography|Undergo CT
41465376|NCT06369610|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given SC or IM
41465377|NCT06369610|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41465378|NCT06369610|PROCEDURE|Positron Emission Tomography|Undergo PET
41465379|NCT06369610|OTHER|Questionnaire Administration|Ancillary studies
41465380|NCT06369610|RADIATION|Radiation Therapy|Undergo radiation therapy
41465381|NCT00964873|DRUG|STA-9090 (ganetespib)|Chemotherapy agent
41465382|NCT01835535|DEVICE|TIVUS|
41465383|NCT01218035|DRUG|zoledronic acid|The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
40784849|NCT04593121|DRUG|Placebo|Administered as specified in the treatment arm.
40784850|NCT01255280|BEHAVIORAL|Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
40784851|NCT01255280|BEHAVIORAL|Information, Motivation, Behavioral skills change approach to sexual risk reduction|The comparison condition will only receive the two IMB risk reduction sessions.
40784852|NCT02622269|DEVICE|Patient-regulated compression device|Compression of the abdomen with a patient-regulated compression device
41146120|NCT00681135|DEVICE|sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)|toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
41146121|NCT00681135|DEVICE|manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)|toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets
41146122|NCT00681135|DEVICE|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
41146123|NCT00681135|DEVICE|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
41146124|NCT04515576|DRUG|LY3493269|Administered SC
41306934|NCT05280431|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Occupational therapy exercises~* Constraint-induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training"
41306935|NCT02115815|BIOLOGICAL|Placebo|Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
41306936|NCT02115815|BIOLOGICAL|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
40784853|NCT02622269|DEVICE|Standard compression device|Compression of the abdomen with the standard compression device
40784854|NCT05951166|DEVICE|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure
40784855|NCT00287924|DRUG|methotrexate|
40784856|NCT00287924|PROCEDURE|adjuvant therapy|
40784857|NCT01585727|PROCEDURE|TME|Total mesorectal excision
40784858|NCT01585727|PROCEDURE|TME|Total mesorectal excision
41306937|NCT02115815|BIOLOGICAL|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
41306938|NCT02115815|BIOLOGICAL|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
41306939|NCT02115815|BIOLOGICAL|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
41306940|NCT02115815|BIOLOGICAL|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
41306941|NCT02115815|BIOLOGICAL|MEDI7510 (80 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
41306942|NCT03989219|PROCEDURE|plasma cfDNA methylation|plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
40784859|NCT01585727|PROCEDURE|Neuromonitoring|Intraoperative neuromonitoring of pelvic autonomic nerves.
40988901|NCT03727503|OTHER|PPV from the capstesia|we will challenge the application by doing 2 maneuvers: the first one is to increase the PEEP level from 5 to 15 cmH2O and the second one is the infusion of a mini-fluid challenge (100 ml) followed by the other 400 ml.
40988902|NCT00144209|DRUG|pramipexole|
40988903|NCT00144209|DRUG|levodopa in combination with benserazide|
41146125|NCT04515576|DRUG|Dulaglutide|Administered SC
41306943|NCT03411213|DEVICE|diffuse optical tomography|Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.
41306944|NCT02623634|BEHAVIORAL|Position, waveform|different positions and waveform
41306945|NCT00828087|DRUG|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
41306946|NCT00828087|DEVICE|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
41146126|NCT04515576|DRUG|Placebo|Administered SC
41146127|NCT00694902|DRUG|GSK610677|GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
41146128|NCT00694902|DRUG|Placebo|Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
41146129|NCT03624114|PROCEDURE|comparison of data from MRI with data from CT compared with intraoperative data from endoscopic pituitary adenoma surgery|A comparison of MRI with CT of the skull base or paranasal sinuses and intraoperative Video documentation of the anatomical site will be used.
41306947|NCT04655950|OTHER|protocols and practices for the immobilization of vertebral osteomyelitis in different French hospitals and bone and joint infections Centers|"Evaluation of the frequency of neurological complications in a large prospective cohort, and to identify clinical and imaging risk factors for neurological complications.~We search for association between type and duration of spine immobilization and neurological status at the end of follow-up"
40784860|NCT05570032|DEVICE|Virtual Reality Training|In intervention the participants took part in the VR training. The X-BOX 360 (Augmented virtual reality) device was used. The participants were guided about the virtual reality training including Kinect sports gamming (Trail 1. badminton, beach volley ball, Soccer goal keeping). Each training was performed for 15 minutes with 5 minutes break time. The whole training was performed for 8 weeks. After eight weeks final assessment was done through outcome measuring tools (TUG test, MAS scale, forward stepping test and Functional reach test).
40988904|NCT01184625|OTHER|Physical Exercise|12 weeks of physical exercise.
40988905|NCT05659810|DRUG|Gabapentin 300mg|Preoperative gabapentin before spinal anesthesia
40988906|NCT05266092|OTHER|Observational study|Observational study
40988907|NCT01010906|DRUG|Vaniprevir 300 mg|single dose administration of 300 mg oral tablet
40988908|NCT01010906|DRUG|Vaniprevir 200 mg|single dose administration of 200 mg oral tablet
40988909|NCT04167007|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days
40988910|NCT04167007|DRUG|FOLFOX|Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
40988911|NCT03551912|PROCEDURE|Surgery|All patients coming for elective surgery
40988912|NCT03713203|DEVICE|pagetex PDT|2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
41306948|NCT00535015|DRUG|Betamarc|2 tabs BID
41306949|NCT04860284|DRUG|Hydroxychloroquine tablets|Hydroxychloroquine tablets 400mg given orally 12 hourly on day 1 and 200mg 12 hourly on day 2 to 5
40988913|NCT06278246|RADIATION|PET Scan|PET scan using the novel \[11C\]MK-6884 tracer to measure M4R during the antipsychotic-free state
40988914|NCT03573947|DRUG|Nivolumab|360 mg intravenously every 3 weeks
41306950|NCT05747131|BEHAVIORAL|Emotion Detectives In-Out|Emotion Detectives In-Out is a blended cognitive-behavioral intervention for children with emotional disorders aged between 7 to 12 years and their parents. It contains group sessions, online self-guided sessions and videoconference sessions. The groups will consist of about 5 to 7 children. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists with specific training in the program. The online sessions were developed by the research team and are completely self-guided. These sessions last approximately 45 minutes. Parents will be asked to participate in 2 face-to-face sessions, 4 videoconference sessions and 10 self-guided online sessions. It is a transdiagnostic and emotion-focused manualized cognitive-behavioral therapy designed to help children reduce the intensity and frequency of strong and aversive emotional experiences and to help parents reduce parental emotional behaviors.
40988915|NCT03573947|DRUG|Ipilimumab|1 mg/kg intravenously over 30 minutes
40988916|NCT03573947|DRUG|Paclitaxel|80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
40988917|NCT05827926|BIOLOGICAL|Influenza Vaccine 1|quadrivalent seasonal influenza vaccine
40988918|NCT05827926|BIOLOGICAL|mRNA-1083.1|Sterile liquid for injection
40784861|NCT00382226|DRUG|Azopt|
40988919|NCT05827926|BIOLOGICAL|mRNA-1083.2|Sterile liquid for injection
40988920|NCT05827926|BIOLOGICAL|mRNA-1083.3|Sterile liquid for injection
40988921|NCT05827926|BIOLOGICAL|Investigational Influenza Vaccine 1|Sterile liquid for injection
40988922|NCT05827926|BIOLOGICAL|Investigational COVID-19 Vaccine 1|Sterile liquid for injection
40988923|NCT05827926|BIOLOGICAL|COVID-19 Vaccine 1|Sterile liquid for injection
40988924|NCT05827926|BIOLOGICAL|Investigational Influenza Vaccine 2|Sterile liquid for injection
40988925|NCT05827926|BIOLOGICAL|Influenza Vaccine 2|quadrivalent seasonal influenza vaccine
40988926|NCT05827926|BIOLOGICAL|mRNA-1083|Sterile liquid for injection
41306951|NCT05747131|BEHAVIORAL|Coping Cat|Coping Cat is a cognitive behavioral therapy for children with anxiety aged between 7 to 13 years. Coping Cat consists of 16 weekly group sessions with the children (5 to 7 children per group) and 2 sessions with the parents. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists.
40784862|NCT01830985|DRUG|VX-509|VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
40784863|NCT00246363|DRUG|Silymarin|Silymarin (milk thistle)
40784864|NCT00246363|DRUG|Placebo|Placebo
40784865|NCT05407103|OTHER|Cold Acupressure|For the cold acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the cold acupressure pouches were kept in a freezer for 40 minutes.
40784866|NCT05407103|OTHER|Warm Acupressure|For the warm acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the warm acupressure pouches were heated in a microwave at 600 W for one minute.
40988927|NCT05827926|BIOLOGICAL|Investigational COVID-19 Vaccine 2|Sterile liquid for injection
41306952|NCT05271084|DRUG|Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg|Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties
41306953|NCT05271084|DRUG|Citalopram (tablet) 20 mg + Placebo (tablet)|Selective serotonin reuptake inhibitor (SSRI) + placebo
40784867|NCT02875470|DEVICE|Intensiv Perio Set|Diamond burs for root planing
40784868|NCT02875470|DEVICE|Gracey curette|
40784869|NCT05261828|BEHAVIORAL|Education and rehabilitation associated with personalized follow-up|short multidisciplinary program including education and rehabilitation and a personalized follow-up for patients with subacute and chronic low back pain
40784870|NCT05261828|BEHAVIORAL|Reassuring messages and advices|Reassuring messages and advices in agreement with current recommendations
41306954|NCT00138034|PROCEDURE|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
40784871|NCT03192137|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
41306955|NCT06121063|COMBINATION_PRODUCT|CCT-102 A and CCT-102 B|2 day oral regimen
41465384|NCT03427476|DRUG|CTT1057|"Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging."
40784872|NCT03192137|OTHER|Vehicle|Vehicle twice daily for 16 days
40784873|NCT00175929|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
40988928|NCT05827926|BIOLOGICAL|COVID-19 Vaccine 2|Sterile liquid for injection
40988929|NCT05751967|DRUG|Placebo Combined With Ursodeoxycholic Acid|1 tablet/ day
40988930|NCT05751967|DRUG|Fenofibrate Combined With Ursodeoxycholic Acid|200 mg/day
40988931|NCT04490161|OTHER|intravenous reinstallation of cerebrospinal fluid|10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
41306956|NCT02160379|OTHER|standard test meal|
41306957|NCT05638906|DEVICE|MINT|Mechanical rotation of the Surgical Device is achieved by the rotating system (i.e., Activation Device), which is comprised of: (1) Controller which dictates the activation pulse duration, the rotations per minute (RPM) and the forwards and backwards movement of the micro trephine; (2) Motor; and (3) Footswitch.
41306958|NCT02165657|DEVICE|Excimer laser treatment|Excimer laser irradiation twice a week for up to 20 treatments.
41306959|NCT00771030|BIOLOGICAL|Brodalumab|Solution for subcutaneous or intravenous administration
41306960|NCT00771030|OTHER|Placebo|Solution for subcutaneous or intravenous administration
41465385|NCT00996424|DRUG|Acetylcysteine|Inhalation with N-Acetylcysteine
41465386|NCT00996424|DRUG|normal saline|Inhalation with normal saline solution
41465387|NCT02519543|DRUG|Placebo|Placebo to be given twice daily, once with breakfast and once with supper
41465388|NCT02519543|DRUG|Metformin|Active experimental drug to be given twice a day, 1000 mg with breakfast and 1000 mg with supper
41146130|NCT06375317|DRUG|PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets|"PD-L1 injection: 20 mg/kg, administered every 3 weeks (Q3W).~Regorafenib: 80 mg, orally, once daily (qd), continuously for 14 days per cycle, followed by a 7-day rest period, administered every 3 weeks (Q3W).~FOLFOX regimen: Oxaliplatin 85 mg/m2, Calcium folinate 400 mg/m2, Fluorouracil 400 mg/m2 as an IV bolus, followed by Fluorouracil 1200 mg/m2 infusion over 23 hours, administered every 3 weeks (Q3W) for a total of 6 cycles.~The above doses are recommended doses."
41146131|NCT02649478|DRUG|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
40784874|NCT00175929|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
40988932|NCT04061096|DIAGNOSTIC_TEST|Evaluation of cold test|Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
40988933|NCT04061096|DIAGNOSTIC_TEST|Evaluation of electrical pulp test|Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
40988934|NCT04061096|DIAGNOSTIC_TEST|Evaluation of pain during the treatment|Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
41146132|NCT02649478|DRUG|Placebo|
40988935|NCT02202642|PROCEDURE|collagenase|Cultured limbal stem cells transplantation
41146133|NCT02649478|DRUG|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
41146134|NCT02017509|PROCEDURE|Diagnostic Biopsy and Surgical Procedure|A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.
41146135|NCT02017509|PROCEDURE|Intravoxel incoherent motion MRI (IVIM)|At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
41146136|NCT02017509|PROCEDURE|Dynamic Contrast Enhanced MRI (DCE-MRI)|Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.
41146137|NCT02017509|GENETIC|RNA gene expression analysis|RNA will be collected from biopsy and surgical tissue for gene expression analysis.
40784875|NCT00175929|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
40784876|NCT03440866|DRUG|Administration of drugs concomitantly.|Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.
40784877|NCT02254291|DRUG|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
40784878|NCT02254291|DRUG|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
40784879|NCT02254291|DRUG|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
40988936|NCT05336474|DIAGNOSTIC_TEST|Ultrasonographic upper airway measurements|Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge
40784880|NCT04470388|DRUG|EDP-514|Oral Capsule
40784881|NCT04470388|DRUG|Placebo|Placebo to match EDP-514
40784882|NCT05193149|BEHAVIORAL|Inspiratory muscle training|Training of respiratory muscles
40784883|NCT05193149|BEHAVIORAL|Exercise training|Supervised aerobic exercise intervention
40784884|NCT01941602|DRUG|prophylactic enoxaparin|enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
40988937|NCT03254186|DRUG|Propranolol Hydrochloride|Propranolol is started 10 mg tablet twice per day per oral, two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks, then will remain on a stable dose for six weeks.
41146138|NCT03696563|DEVICE|Automated oxygen administration - FreeO2|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration of oxygen flow every second to reach the SpO2 target. The SpO2 target will be set at 90% in COPD patients and 94% in trauma patients.
41465389|NCT01636934|DRUG|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
40784885|NCT01941602|PROCEDURE|non-prophylactic|no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
40784886|NCT00459940|DRUG|Pioglitazone|
40784887|NCT05435248|DRUG|HS-10375|HS-10375 will be administered orally once daily in a continuous regimen
40988938|NCT03254186|DRUG|Placebo Oral Tablet|Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
40988939|NCT02069743|OTHER|ePAL Mobile Application|A mobile application designed to help cancer patients better self-manage cancer pain.
40988940|NCT05759442|DRUG|Metformin Hydrochloride (HCL)|Tab Metformin HCL 500mg twice per day aimed at improving glycemic indices in Prediabetics
40988941|NCT05759442|DIETARY_SUPPLEMENT|Apple cider vinegar|Apple cider vinegar aimed at improving glycemic indices in Prediabetics
40988942|NCT03234751|DRUG|Continous IV infusion of Nesiritide|Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
41465390|NCT01636934|OTHER|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
41465391|NCT01636934|BEHAVIORAL|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
40988943|NCT03234751|DRUG|Hyperinsulinemic euglycemic clamp|48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
41465392|NCT02277262|DEVICE|Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention|The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
41465393|NCT02277262|PROCEDURE|Direct suture of the anterior abdominal wall fascia|Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
41465394|NCT00005087|BIOLOGICAL|filgrastim|
41465395|NCT00005087|DRUG|cisplatin|
41465396|NCT00005087|DRUG|paclitaxel|
40988944|NCT03234751|DRUG|Placebo|48 hours of placebo.
40988945|NCT01930851|PROCEDURE|Gastric bypass operation|
40988946|NCT05279820|PROCEDURE|Partial pulpotomy|Partial pulp tissue amputation
40988947|NCT05279820|PROCEDURE|Full Pulpotomy|Full Pulpotomy
40988948|NCT00049101|DRUG|erlotinib hydrochloride|
40988949|NCT00049101|DRUG|fluorouracil|
40988950|NCT00049101|DRUG|leucovorin calcium|
40988951|NCT00049101|DRUG|oxaliplatin|
40988952|NCT03731520|DIAGNOSTIC_TEST|Assessing exercise behavior|11-point Numeric Analogue Scale (NRS) for satisfaction of exercising, Exercise Stages of Change Scale-Short Form (ESCS), Exercise Self-Efficacy Scale (ESES), and Decisional Balance Scale (DBS) for exercise behaviour will be inquired for the patients with JIA.
41146139|NCT03696563|OTHER|Standard administration of oxygen flow|The flow of oxygen will be administered according to the usual protocol during the transport and until transfer to the emergency departement.
40784888|NCT06016322|DIETARY_SUPPLEMENT|Dried Chicory Root|"Subjects will receive 1 sachet of 10g WholeFiberTM for the first 2 weeks (equals 8.5 g fiber), and 2 sachets of 10g WholeFiberTM per day for the last two weeks (equals 17 g fiber).~WholeFiberTM is a fiber-rich dried vegetable made from the chicory root that contains four types of prebiotic fibers (inulin, pectin, cellulose, hemi-cellulose)."
40988953|NCT06423144|PROCEDURE|TACE/HAIC|TACE/HAIC were performed within 1 month prior/after the first PD-1/PD-L 1 inhibitor/antiangiogenic drug treatment;
40988954|NCT06423144|DRUG|PD-1/PD-L1 inhibits and anti-angiogenic agents|Agents were administrated based on the instructions recommended
40988955|NCT06115408|DRUG|Dienogest 2 MG|Clinical trial
40988956|NCT06115408|DRUG|N-acetyl cysteine|Clinical trial
40988957|NCT04690543|PROCEDURE|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
41306961|NCT03764215|DRUG|Nilotinib 150 MG|10 participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If this dose is tolerated another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
41306962|NCT05212168|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
41306963|NCT05212168|OTHER|Placebo Tablets|Oral tablets similar in appearance and number to active vaccine tablets
40988958|NCT04690543|PROCEDURE|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
40988959|NCT00475176|DRUG|Peginterferon alfa-2a|
40988960|NCT00475176|DRUG|Ribavirin|
40988961|NCT00475176|DRUG|S-adenosyl methionine for Chronic Liver Disease|
40988962|NCT03064217|PROCEDURE|CLP and 12 weeks waiting|Restorative treatments will be initiated 12 weeks after clinical crown lengthenings (CLPs).
40988963|NCT03064217|PROCEDURE|Digital impression taken at surgery|The final impression will be made at surgery.
40988964|NCT03961607|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
41306964|NCT05212168|BIOLOGICAL|Norovirus GI.1 Norwalk Virus Inoculum|Norwalk Virus Inoculum Lot 01-09NV
41465397|NCT00005087|PROCEDURE|conventional surgery|
41465398|NCT00005087|RADIATION|radiation therapy|
40988965|NCT04372680|DIAGNOSTIC_TEST|CTUS examination|fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
40988966|NCT03904433|OTHER|Coconut oil|Coconut oil given in coffee with cream
40988967|NCT03904433|DIETARY_SUPPLEMENT|Caprylic acid|Caprylic acid given in coffee with cream
41146140|NCT06360120|DRUG|Atorvastatin 40 Mg Oral Tablet|The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
41146141|NCT06360120|DRUG|Rosuvastatin 20mg|The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
41146142|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19
41146143|NCT04324606|BIOLOGICAL|MenACWY|Standard single dose of MenACWY vaccine delivered intramuscularly
41146144|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 full boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10\^10vp of ChAdOx1 nCoV-19
41146145|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 half boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 2.5x10\^10vp of ChAdOx1 nCoV-19
41146146|NCT04324606|BIOLOGICAL|MenACWY boost|A standard dose of MenACWY followed by a boost dose of MenACWY
41146147|NCT04324606|DRUG|Paracetamol|1g every 6 hours for 24 hours
41146148|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp)
41146149|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)|A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of 5x10\^10vp of ChAdOx1 nCoV-19
41146150|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)|A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of MenACWY, then a boost 4-12 weeks later
41146151|NCT05244954|DRUG|Dihydroartemisinin-Piperaquine|Treatment of females less than 10 years old and all males in Arm 2 and those who test positive in Arm 1.
41306965|NCT06519006|PROCEDURE|Pelvic floor exercise|Exercises aimed at this issue consist of identification and isolated contraction of the pelvic floor muscles as well as their activation during complex movements and daily activities. During the engagement of the pelvic floor muscles, the correct engagement of the respiratory activity is important. Within the exercise units, exercises are used from sphincter contraction, through the gradual activation of individual pelvic floor layers in various ways, to their complex involvement in movement activities. Exercises are practiced repeatedly, at different frequencies and intensities that gradually increase, 4-5 times per day.
41306966|NCT02052843|BEHAVIORAL|Steps to Success|
40784889|NCT00395473|DRUG|MK0653, ezetimibe / Duration of Treatment: 6 Weeks|
40784890|NCT03266029|DEVICE|Cordio App|
40988968|NCT03904433|OTHER|Sunflower oil|Sunflower oil given in coffee with cream
40988969|NCT03904433|OTHER|Glucose|Glucose dissolved in water
40988970|NCT02347267|BEHAVIORAL|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
40988971|NCT02347267|BEHAVIORAL|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
40988972|NCT04371679|OTHER|No interventions planned|No interventions planned. Observational.
40988973|NCT04349618|OTHER|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
40988974|NCT04349618|OTHER|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
40988975|NCT04568590|BEHAVIORAL|educational intervention|If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average \> 3), they will be given the informational handout along with a brief script.
40988976|NCT05023226|PROCEDURE|RM|RM refers to that under FiO2=100% oxygen concentration and fixed inspiratory pressure (15cmH2O), the PEEP starts from 10 cmH2O and increases at a pressure of 5 cmH2O every minute until the Peak inspiratory Pressure(PIP) reaches 55cmH2O, and the level was fixed to 40 seconds in each increment. Then, the ventilator was transferred to PEEP-titration phase, the PEEP was adjusted to 25 cm H2O, and it was reduced by increments of 5 cm H2O each time. The each increment was fixed to 5 minutes till the end-maneuver PEEP.
41146152|NCT05244954|DRUG|Chloroquine|Treatment of females 10 years old and older in Arm 2 and those who test positive in Arm 1.
41146153|NCT03498456|DRUG|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
41146154|NCT03498456|DRUG|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
41146155|NCT00857077|DRUG|Sulfadoxine-pyrimethamine|
41146156|NCT00857077|DRUG|Placebo|
41146157|NCT00409747|DRUG|Minocycline|
41146158|NCT03988309|DIAGNOSTIC_TEST|Cxbladder|"The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Not low risk patients will be evaluated as per standard of care."
41465399|NCT05683691|DEVICE|Vanquish System|Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.
41465400|NCT02302716|DRUG|LY2963016|Administered SC
41465401|NCT02302716|DRUG|LANTUS®|Administered SC
41465402|NCT02302716|DRUG|Oral Antihyperglycemic Medication|Administered as per standard-of-care.
41465403|NCT04759534|BIOLOGICAL|protein convertase subtilisin/kexin type 9 inhibitor|IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W
41465404|NCT02807441|DRUG|Acetylsalicylic acid|Patients will receive different doses of aspirin perioperatively to assess bleeding association.
40988977|NCT05023226|PROCEDURE|LPVS|LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight \[PBW\]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
40988978|NCT03542344|DRUG|BI 1015550|Single rising oral dose
40988979|NCT03542344|DRUG|Placebo|Single rising oral dose
40988980|NCT00323518|DRUG|velafermin|administered intravenously as 100mL single dose over 15 minutes on day 1
40988981|NCT00323518|DRUG|placebo|administered intravenously as 100mL single dose over 15 minutes on day 1
40988982|NCT04062838|DRUG|Dextrose 50|As above
41465405|NCT02658019|DRUG|Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
41465406|NCT02806609|OTHER|Cold water immersion, with 10 degrees, for 10 minutes|cold water immersion
41465407|NCT02806609|OTHER|immersion in water at room temperature|immersion in water at room temperature
41465408|NCT02806609|OTHER|active recovery - running|active recovery
41146159|NCT05168345|OTHER|Course and web information|"The interventional phase of the study will be conducted on IBD patients only. Patients will undergo two interventional periods which will include:~1. Self-selected information from the internet - patients will be asked to independently search the web for information regarding the categories of information which are discussed in the online course.~2. An online, interactive IBD course. Lectures will be passed by the multidisciplinary team of the IBD Center which includes IBD gastroenterologists, an IBD nurse, an IBD dietitian, and a social worker."
41146160|NCT01858649|PROCEDURE|Metastases resection|Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
41306967|NCT02052843|BEHAVIORAL|Traditional Healthy Families|
41306968|NCT01401010|DRUG|Doripenem|500 mg every 8 hours
41306969|NCT01401010|DRUG|doripenem|1000 mg every 8 hours
41306970|NCT04315376|BEHAVIORAL|Exercise-Diet Intervention|The participants who performed exercise-diet intervention performed an Astrand-rhyming test before and after the exercise program intervention. Participants followed a progressive exercise-program during four months according to initial physical fitness. The main exercises consisted of improving aerobic, speed and resistance performance. During all single sessions, breathlessness and fatigue were measured using 0 to10 Borg scale. A personal trainer certified by American College of Sports Medicine (ACSM) supervised three sessions per week, the other two unsupervised training days the subjects were given the detailed training program to do in house/park. And also, this group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
41306971|NCT04315376|BEHAVIORAL|Diet Intervention|This group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
41306972|NCT03334669|BEHAVIORAL|Parents Connect for Healthy Living (PConnect)|Parents Connect for Healthy Living (PConnect) parent curriculum: This 10-week program (20 hours total) engages Head Start parents in a wide range of topics related to health and empowerment and is designed to foster a safe, open forum through which parents can connect with other parents and mobilize resources to support their family's health; NOTE: The PConnect program was not implemented in 2019-2020 due to the coronavirus pandemic. In 2020-2021, PConnect was implemented virtually; these are pilot data and not part of the main trial.
40784891|NCT05579210|BEHAVIORAL|Online relapse prevention therapy|Participants in the e-RPT group will receive 10 weekly predesigned online modules. The content of this program will involve interactive therapy modules based on the principles of. On average each module consists of 30 slides and should take approximately 45 minutes to complete. At the end of each module, participants will be assigned homework to be completed and submitted to their respective therapists up to 48 hours before their next weekly session. The therapists will develop personalized feedback by using session-specific therapy feedback templates. These templates ensure that feedback is also more standardized and structured between different patients and therapists. In previous studies, therapists have been able to effectively use these templates to prepare feedback in approximately 15-20 minutes. The contents of each session are outlined on the detailed description section.
40988983|NCT03043625|OTHER|Visceral manipulation|Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
40988984|NCT03043625|OTHER|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
40988985|NCT01739582|DRUG|Androxal|
40988986|NCT03265249|DEVICE|BRIDGE device|an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
40988987|NCT00108160|DRUG|Mupirocin Ointment [Treatment]|The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
40988988|NCT00108160|DRUG|Polyethylene Glycol Ointment [Placebo]|The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
40988989|NCT02794103|DEVICE|Virtual Reality Distraction|VR prototype developed by the SAT will be used as the experimental intervention. It has a wide screen installed at the end of the hydrotherapy tank offering a 150-degree field view, on which appears a game allowing the child to have the immersive entertainment experience without the need to wear a helmet or 3D glasses. The child or a proxy, depending on age and burn site, will have the opportunity to interact with the game. The interactive component is not mandatory for the immersive and distractive experiences provided by the prototype. Video games tailored to the child's age and injury, different from the commercially available ones, will be adapted to each age-group of children recruited with control over the speed of movement to avoid motion sickness.
40988990|NCT06215404|OTHER|Liberal group|Fluid challage to keep stroke volume variation \< 10%
40988991|NCT06215404|OTHER|restrictive group|Fluid challage to keep stroke volume variation \< 18%
40988992|NCT05774587|BEHAVIORAL|mHealth control group|Cardiac rehab control group
40988993|NCT05774587|BEHAVIORAL|mHealth technology assisted exercise counselling (mHealth)|Exercise and counselling through mHealth technology
40988994|NCT03359642|OTHER|blood sample|14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
40988995|NCT03359642|OTHER|stool samples|Study of the fecal microbiota
40988996|NCT03359642|OTHER|food questionnaire|food questionnaire on the seven days before the collection
40988997|NCT03359642|OTHER|colonoscopy|Only for patients with ulcerative colitis (in routine care)
40988998|NCT03359642|OTHER|VOCs profile|Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry
40988999|NCT04295512|BEHAVIORAL|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based executive functioning treatment that targets flexibility, goal-setting and planning through a cognitive behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. UOT will be adapted for use in mental health service settings. Mental health therapists will be trained in UOT and deliver to youth and caregivers.
40989000|NCT01067222|DRUG|BF2.649|BF2.649 oral capsules at 10 or 20 or 40 mg per day
40989001|NCT01067222|DRUG|Modafinil|Modafinil oral capsules at 100 or 200 or 400 mg per day
40989002|NCT01067222|DRUG|Placebo|Placebo oral capsules, 4 capsules per day
41146161|NCT01858649|DRUG|Bevacizumab|Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
41146162|NCT01858649|DRUG|5 FU|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
41146163|NCT01858649|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
41146164|NCT01858649|DRUG|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
41465409|NCT02806609|OTHER|rest in the chair|rest in the chair
41146165|NCT05408845|DRUG|Docetaxel|Given IV
41146166|NCT05408845|OTHER|Questionnaire Administration|Ancillary studies
41465410|NCT02285933|OTHER|virtual reality training|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.
40989003|NCT03994692|DEVICE|PEEK eminoplasty|making obstacle at eminence using patient specefic PEEK device
41146167|NCT05408845|BIOLOGICAL|Trastuzumab|Given IV
41146168|NCT05408845|BIOLOGICAL|Trastuzumab Emtansine|Given IV
41146169|NCT03159494|OTHER|High-Intensity Training|"8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed"
41146170|NCT05177029|DRUG|Lu AG06466|Lu AG06466 will be administered per schedule specified in the arm.
40989004|NCT03994692|PROCEDURE|autogenous onlay grafting eminoplasty|making obstacle at eminence using chin graft
41146171|NCT05177029|DRUG|Placebo|Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
41146172|NCT04412174|BIOLOGICAL|GC022F|GC022F is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The dosage ranges from 3×10\^5 to 1×10\^6 CAR+T/Kg.
40989005|NCT06437028|OTHER|Multilayer perinatal tissue allograft|The multilayer perinatal tissue allograft is an amnion - amnion allograft
40989006|NCT06437028|OTHER|Full thickness perinatal tissue allograft|The full thickness perinatal tissue allograft is an amnion - intermediate layer - amnion allograft
40989007|NCT06437028|OTHER|Standard of care|Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading.
41146173|NCT02406859|BEHAVIORAL|Bowel Biofeedback|Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.
41146174|NCT02406859|BEHAVIORAL|Anorectal Manometry|Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
41146175|NCT03853525|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
40989008|NCT02411292|DRUG|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
40989009|NCT03396588|DRUG|Clonidine|1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
40989010|NCT03396588|DRUG|Morphine|Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
40989011|NCT00945009|BIOLOGICAL|Dactinomycin|Given IV
40989012|NCT00945009|DRUG|Doxorubicin Hydrochloride|Given IV
40989013|NCT00945009|RADIATION|Radiation Therapy|Undergo radiation therapy
40989014|NCT00945009|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
40989015|NCT00945009|DRUG|Vincristine Sulfate|Given IV
41146176|NCT03853525|OTHER|Semisolid vaseline|Product is applied to one side of the inguinal region.
41146177|NCT06449599|DEVICE|ultrasound|local anesthesia 400 mg prilocaine (priloc 2%, 20 ml, Vemilac,Türkiye) to surgical field and additionally ultrasound-guided rhomboid intercostal plane block 0,25% bupivacaine 20 ml (Buvasin 0,5%, 20 ml, Vemilac, Türkiye) will be applied to the patients who will be inserted implantable cardioverter defibrillator.
41146178|NCT06449599|PROCEDURE|parenteral local anesthesia|only local anesthesia 400 mg prilocaine (priloc 2%, 20 ml, Vemilac,Türkiye) to surgical field will be applied to the patients who will be inserted implantable cardioverter defibrillator.
41146179|NCT02473549|DEVICE|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
41146180|NCT02473549|DEVICE|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
41146181|NCT02473549|DEVICE|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
41146182|NCT02473549|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
41146183|NCT03798132|DIAGNOSTIC_TEST|laparoscopy|evaluation of peritoneal carcinomatosis by laparoscopy
41146184|NCT03593590|DRUG|Ocrelizumab|Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
41146185|NCT04306081|DRUG|Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
41465411|NCT02285933|OTHER|control|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
40989016|NCT03809507|OTHER|Qualtrics survey questions|"Qualtrics Survey:~For each of the scenarios, practitioners will be asked whether opioids are prescribed or not, and the type(s) of other analgesic medications that would be prescribed, the strength in mg, and the number of doses for each medication"
40989017|NCT02255500|DRUG|Bupivacaine FNB|A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.
40989018|NCT02255500|DRUG|EXPAREL Infiltration|A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
40989019|NCT01127308|DRUG|Ertugliflozin|Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of \[14C\]ertugliflozin
40989020|NCT01950923|DRUG|sildenafil citrate|Given PO
40989021|NCT01950923|OTHER|placebo|Given PO
41146186|NCT04306081|OTHER|Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen
40989022|NCT01950923|PROCEDURE|therapeutic conventional surgery|Undergo standard robotic partial nephrectomy
40989023|NCT00048295|DRUG|Alicaforsen|
40989024|NCT05023746|DIAGNOSTIC_TEST|Genetron lung cancer panel|Follows the principle of synchronous blinding. The enrolled cases are coded, and the enrolled samples are detected with Genetron lung cancer panel and comparison methods. The detection results are compared, and the samples that are inconsistent with the detection results of similar products on the market are reviewed by the the Sanger sequencing method, when the site detection results compared with Sanger sequencing method are inconsistent, Sanger's detection results are recognized. The results were determined independently according to the cutoff values or interpretation requirements provided by each method, and relevant statistics were used to evaluate clinical application performance of Genetron lung cancer panel.
40989025|NCT05024500|OTHER|ARDSNet table|The setting of the lowest PEEP level and FiO2 match stated by the table to achieve a goal oxygenation.
40989026|NCT05024500|OTHER|Driving Pressure|The setting of the lowest PEEP level by the lowest correspondent driving pressure, which is defined by the difference of plateau pressure, after a modified alveolar recruitment maneuver.
40989027|NCT05024500|OTHER|Electrical Impedance Tomography|The setting of the PEEP level above the intersection of the curves representing relative alveolar overdistention and collapse, after a modified alveolar recruitment maneuver.
40784892|NCT05579210|BEHAVIORAL|Face to face relapse prevention therapy|Participants in the face-to-face intervention will meet with their therapist weekly through Microsoft Teams (video conference). During these 1-hour sessions, therapists will follow the same 10-week structure and content as e-RPT. Though compared to e-RPT, in face-to-face sessions, the homework will be reviewed with the participant, during the session, providing the appropriate feedback. Then the therapists will prepare a weekly patient report of each session for the principal investigator. At the end of each session, participants will receive the same homework as the e-RPT condition which they will receive feedback on during the following face-to-face session. Following the 10-week face-to-face intervention, participants will have the opportunity to join the e-RPT program.
40784893|NCT01913327|DRUG|Aripiprazole|
40784894|NCT01913327|DRUG|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
40784895|NCT01913327|DRUG|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
40784896|NCT00641732|DRUG|TAK-442|TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
40784897|NCT00641732|DRUG|TAK-442|TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
40784898|NCT00641732|DRUG|TAK-442|TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
40784899|NCT00641732|DRUG|TAK-442|TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
40784900|NCT00641732|DRUG|TAK-442|TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
40784901|NCT00641732|DRUG|TAK-442|TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
40784902|NCT00641732|DRUG|Enoxaparin|Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
40784903|NCT01160809|OTHER|Mosquito repellent|Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs
40989028|NCT01091389|PROCEDURE|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
40989029|NCT02496247|OTHER|Canned Herring|Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child).
40989030|NCT03006744|BEHAVIORAL|Phonological awareness training|Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
40989031|NCT03006744|BEHAVIORAL|Reading enjoyment training|Training on how to make reading enjoyable for children.
40989032|NCT03504696|OTHER|Non-interventional|Non-interventional
40784904|NCT00569933|BEHAVIORAL|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
40784905|NCT05035238|BIOLOGICAL|Triple dose vaccination by inactivated Covid19 vaccine|triple dose intramuscular vaccine on Day 0, Day 28, and Day 120.
40989033|NCT00271947|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after conditioning regimen
40989034|NCT00352846|DRUG|Zoledronic Acid|4 mg/m\^2 by vein over 30 Minutes at baseline and 6 months.
40784906|NCT03454230|PROCEDURE|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
40784907|NCT05930080|DRUG|SKCPT|the randomly assigned subjects took the study drug for 12 weeks
40989035|NCT00352846|DRUG|Vitamin D|400 mg by mouth daily
40989036|NCT00352846|DRUG|Calcium Carbonate|1200 mg by mouth daily
40989037|NCT03311659|BIOLOGICAL|Boostrix|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
40784908|NCT05930080|DRUG|Celebrex|the randomly assigned subjects took the study drug for 12 weeks
40784909|NCT01298336|DRUG|Clarithromycin|500 mg twice a day seven days a week
40784910|NCT01298336|DRUG|Moxifloxacin|400 mg per day seven days a week
40784911|NCT02057926|DRUG|The effect of tetracycline in degradation and permeability of collagen membranes.|
40784912|NCT03197610|PROCEDURE|enamel matrix derivatives|enamel matrix derivatives and subepithelial connective tissue grafts
40784913|NCT00005903|DRUG|GDNF & Synchro Med Infusion System|
40989038|NCT03678532|DRUG|Midazolam|
40989039|NCT00910312|DEVICE|Ice-Sense|Ice-Sense Cryoprobe
41146187|NCT04930263|BEHAVIORAL|Aerobic exercise|The intervention was 24 weeks walking exercise program. Participants exercised frequency at 5 sessions a week for 30 minutes per section with moderate-intensity and wearable device assisted. Each session consisted of a 5 minutes warm-up, moderate-intensity walking exercises and 5 minutes cool-down. The program included individualized education, telephone and social media counselling, and booklet guidance
41146188|NCT04930263|BEHAVIORAL|control group|control group received routine care and a manual on healthy living
40784914|NCT01527994|DRUG|Aprepitant|Aprepitant 125 mg oral tablets
40784915|NCT01527994|DRUG|Placebo pill|Placebo oral pill- inactive compound
40784916|NCT03332121|BIOLOGICAL|B001|4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
40784917|NCT02481193|DRUG|Cisatracurium|Different doses of cisatracurium pretreatment
40784918|NCT03280368|OTHER|Bloodtest|
40784919|NCT03280368|OTHER|Questionnaires|
40784920|NCT06360419|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
40989040|NCT06162442|DRUG|Preservative-free sterile ophthalmic solution, with 0.3% propylene glycol and 0.4% polyethylene glycol (400)|"The procedures during the study consist of ophthalmological activities and attention to the participating subject with a diagnosis of DED and who starts using a specified ocular lubricant, free of preservatives. The ophthalmologist will notify the subject of the wash out, which will consist of suspending the usual treatment medication for 7 days, to then start with the lubricant Glicolub Ultra®, with a dosage of 1 drop every 6 hours in both eyes. Self-assessment questionnaires will be delivered for their respective completion. An assessment will be made by the comprehensive ophthalmologist in all clinical tests for dry eye with a mild to moderate diagnosis, under compliance with the TOSF DEWS II criteria and study inclusion criteria."
41146189|NCT05483556|DEVICE|Real tDCS|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the left inferior frontal gyrus during speech therapy.
41146190|NCT05483556|DEVICE|Sham tDCS|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the left inferior frontal gyrus during speech therapy.
41146191|NCT05333757|OTHER|Questionnaire|Adults with spinal deformities were asked to complete two questionnaires assessing quality of life
40989041|NCT03543592|DIAGNOSTIC_TEST|3 dimensional ultrasonography and Doppler|Three-Dimensional images will be recorded. The volumes will be generated by the automatic rotation of the mechanical transducer 360 degrees. Visualization of the endometrium and myometrium in the three planes will be done to detect endometrial cavity and any lesions. The power Doppler gate will be activated for blood flow mapping of the endometrium and endometrial-myometrial interface (sub-endometrial area). The pulsed Doppler sample volume will be activated to obtain a flow velocity waveform (FVW). Vascularization index (VI), flow index (FI) and vascularization-flow index (VFI) will be automatically calculated from three consecutive FVWs.
40989042|NCT00501293|DRUG|Methylphenidate Transdermal System|One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
40989043|NCT01467947|BIOLOGICAL|Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection|Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
40989044|NCT05603559|DRUG|1.1 GBq (30 mCi) of 177Lu-P17-087|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
40989045|NCT05603559|DRUG|1.1 GBq (30 mCi) of 177Lu-P17-088|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
40989046|NCT06082882|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include a \~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).
40989047|NCT06082882|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
40989048|NCT00491387|DRUG|Metoprolol Succinate|Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
40989049|NCT02400879|DRUG|Remifentanil|administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
41465412|NCT03656263|DIAGNOSTIC_TEST|Doppler assessment of portal vein flow|Doppler assessment of portal vein flow using peri-operative trans-esophageal echography before and after cardiopulmonary bypass.
41146192|NCT00741923|OTHER|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
41146193|NCT02669056|OTHER|5-HT measurement|
41146194|NCT02669056|OTHER|cerebral MRI|
41146195|NCT02669056|OTHER|Video recording|
41146196|NCT02669056|OTHER|EEG|
41146197|NCT02669056|OTHER|growth curves|
41146198|NCT02669056|OTHER|ASQ questionnaire|
41146199|NCT05778799|OTHER|Balance test|10 second left- or right-leg stance with eyes open, and single 10 second left- or right-leg stance with eyes closed
41146200|NCT02875444|OTHER|Angio-CT|
41146201|NCT05651035|OTHER|oral feeding|"In experimental group infants: Preterms in this group will be breastfed by their own mother.~In control group infants: Preterms in this group will be fed by the researcher by putting the baby's own mother's milk in the bottle. During feeding, the preterm will be placed on the lap by the researcher in a standing position on the same mother's breast, and will be given a raised side-lying position. In this position, the preterm's head and body will be elevated 45-60 degrees with the help of a small pillow. While the researcher will support the preterm's head, neck and shoulder with one hand, he will control the bottle with the other hand. By touching the preterm's nipple to the preterm's lips, the preterm will be prepared for feeding, and the bottle will be placed in the baby's mouth with the mouth opening and the tongue lowering. During feeding, stimulating movements such as pushing the bottle back and forth in the mouth, which will lead the newborn to suck faster, will not be made."
41146202|NCT00731692|DRUG|FTY720|Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
41146203|NCT00731692|DRUG|Placebo|Matching placebo capsules were administered orally once daily
41306973|NCT03334669|BEHAVIORAL|Enhanced Nutrition Support|Enhanced Nutrition Support: Existing nutrition resources within Head Start (e.g., Biannual child health letters) are expanded and improved to ensure parents are aware of their child's weight status and are linked with age-appropriate weight management services if their child has overweight or obesity. NOTE: Enhanced nutrition support was not implemented in spring 2020 due to the pandemic. In 2020-2021, it was moved to a virtual format in what will be a pilot virtual trial.
40989050|NCT02400879|DRUG|sevoflurane and sufentanil|administering sevoflurane and sufentanil for anesthesia maintenance
40989051|NCT00456547|PROCEDURE|Blood Draw|Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
40989052|NCT04879004|DRUG|Ropivacaine injection|Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.
41146204|NCT04280978|DIAGNOSTIC_TEST|ABI ABC|"The assessor will administer ABaCo test through a computer device and she will marked the responses on a paper sheet. Video recordings are needed only to allow an impartial scoring. In fact, an external trained judge will do the scoring.~Furthermore the linguistic abilities will be assessed through the administration of some subtests of the Italian battery BVL 4-12. In particular, the researcher will administer the following subtests: naming, lexical comprehension and grammatical comprehension.~Moreover, some neuropsychological abilities will be analysed using the test BVN 5-11. In addition, the theory of mind and the non-verbal IQ will be assessed.~The Socio-Economic-Status of the family involved in the research will also be investigated, considering its importance on the rehabilitation outcomes."
41146205|NCT02649725|BEHAVIORAL|patient's satisfaction|Questionnaire based measurement.
41146206|NCT06200909|OTHER|Mindfulness Meditation|8-week mindfulness meditation program, based on Kabat-Zinn's MBSR program and modified for caregivers. The intervention will be led by MBSR-trained facilitators.
41146207|NCT06200909|OTHER|Psychoeducation|"A lecture-style program based on the 10 KeysTM to Healthy Aging Course, an evidence-based program for older adults. The program will be delivered by a facilitator experienced in delivering similar content."
41146208|NCT06200909|OTHER|Wait list control|Participants will receive two hours of respite from their caregiving responsibilities per week, for eight weeks. They will be given the opportunity to participate in either the MM or the PSY condition following completion of testing.
41146209|NCT01404702|DRUG|Zoledronic Acid|4 mg/m2/dose given iv on day 0 of every 28 day cycle
41146210|NCT01404702|BIOLOGICAL|Aldesleukin|"Dose Level 1: 3 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle~Dose Level 2: 6 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle"
41146211|NCT01315418|OTHER|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
41146212|NCT01315418|OTHER|2-Non fermented dairy product (control)|
41146213|NCT06053983|DEVICE|Turbox CRP kit|Quantitative estimation of hs-CRP will be conducted at the beginning of the study and after the treatment period using the Turbox CRP kit, which employs turbidimetry as the method of measurement.
41146214|NCT06053983|DRUG|rosuvastatin 20 mg,|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
41146215|NCT06053983|DRUG|atorvastatin 40 mg|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
41306974|NCT03334669|BEHAVIORAL|Media Resources|Media Resources: Print and online resources that employ consistent messaging to reach parents and ensure that behavior change messages are accessible to families. NOTE: Due to the pandemic, media resources were not shared in spring 2020. They were implemented in virtual format in 2020-2021 in a pilot virtual trial.
40989053|NCT05990101|BEHAVIORAL|Awake prone position (APP)|Awake prone position for 4 or more hours per day for the first 72 hours following randomisation.
40989054|NCT01225575|DRUG|co.don chondrosphere®|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect"
41146216|NCT05301725|OTHER|PPI regimen|All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
41306975|NCT05667727|DRUG|nebulized epinephrine|we are using 1:1000 epinephrine into nebulization form
41306976|NCT05667727|DRUG|Salbutamol|Patient will receive salbutamol as 4th nebulization.
41306977|NCT02778750|PROCEDURE|Two-Bronchoscope Technique|Used to validate the use of sputum to sample the lower airway microbiome
40989055|NCT06245590|DRUG|Albumin|20 grams/ week Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90).
40989056|NCT06245590|DRUG|Midodrine|Midodrine
40989057|NCT06245590|OTHER|Standard of Care|Standard of Care
41306978|NCT04910724|OTHER|Energy Deficit|A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
40989058|NCT00868075|PROCEDURE|Chest physiotherapy|Twice daily for 8 weeks
40989059|NCT00868075|PROCEDURE|Chest Physiotherapy + Exercise Program|Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
40989060|NCT02641769|BIOLOGICAL|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
40989061|NCT02159690|DRUG|Enzalutamide|160mg
41306979|NCT01094717|DRUG|Acitretin 25Mg Oral Capsule|Acitretin 25 mg oral daily for 12 weeks
41306980|NCT01094717|DEVICE|Excimer laser|Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.
40989062|NCT02159690|DRUG|Abiraterone acetate|1000mg
41465413|NCT03001024|BEHAVIORAL|Implementation of WayToServe Español|Following baseline assessment and randomization to experimental condition, premises assigned to the intervention condition will be contacted and recruited to the trial. Managers will provide a list of all servers. All servers will be registered by project staff on the WTS-E website and provided a unique identification code, which will track their use of the training and associate it with the premise. Servers will complete a profile on the program during their first login. Servers will be asked to complete the training within four weeks from initial registration; email and text reminders will be sent to those who do not login within one week of initial registration.
40989063|NCT02159690|DRUG|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
41465414|NCT03001024|BEHAVIORAL|Usual and Customary RBS Training|The premises randomized to the UC training condition will be, in effect, blind to the investigation. Server training is mandatory for all servers in New Mexico. Server training is voluntary in Texas but heavily incentivized by TABC's Safe Harbor clause. Under this clause, liquor licensees are held harmless for any service infractions if all servers are trained and certified by an approved RBS trainer; instead, the server is cited for the infraction.
40784921|NCT06360419|DRUG|Placebo|Placebo tablets, taken once daily
40784922|NCT06462404|DRUG|E2086|E2086 oral tablets.
40784923|NCT06462404|DRUG|E2086 Placebo|E2086 matching placebo tablet.
40784924|NCT06462404|DRUG|Active Comparator|Active comparator oral tablets.
40784925|NCT06462404|DRUG|Active Comparator Placebo|Active comparator matching placebo tablet.
40989064|NCT02159690|DRUG|Dutasteride|0.5mg
40989065|NCT02159690|DRUG|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
41146217|NCT05301725|OTHER|P-CAB regimen|All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
41146218|NCT05656937|PROCEDURE|internal jugular venous cannulation|internal jugular venous cannulation
41146219|NCT03512041|BEHAVIORAL|RLIC - 5 cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
41146220|NCT03512041|BEHAVIORAL|RLIC - 4 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
40784926|NCT03979300|OTHER|Learning process during role play on psychiatric interview|"Methodology: Mixed method study with:~* Quantitative features:~  * Self-reported questionnaries :  Learning Effectiveness Inventory Scale  (18)~ * Sociodemographical data and others questions~* Qualitative : Grounded Theory~  * Video-record of simulation and audio-record and briefing and debriefing, quoted with conversational analysis~ * Semi-structured interview of learners and teachers"
40784927|NCT02220634|DRUG|Regadenoson|Injection for intravenous administration
40784928|NCT01322256|PROCEDURE|Bone scintigraphy|Bone scintigraphy of the affected area
40784929|NCT01322256|PROCEDURE|Leukoscan|Scintigraphy with labeled neutrophils
40784930|NCT01322256|PROCEDURE|PET / CT|PET / CT of the affected area
40784931|NCT01322256|PROCEDURE|Bone biopsy|A bone biopsy is performed during pre-inclusion work up.
40784932|NCT01322256|BIOLOGICAL|Bloodwork|CRP and procalcitonin are measured in the pre-inclusion work up.
40784933|NCT03765125|DIETARY_SUPPLEMENT|collagen peptide test|Collagen peptides from bovine skin with an average molecular weight of approx. 2,000 g/mol. Average particle size is about 150 μm.
40784934|NCT03765125|DIETARY_SUPPLEMENT|collagen peptide placebo|collagen peptide placebo
40784935|NCT02043990|DEVICE|Noninvasive NAVA ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
40784936|NCT00820547|BIOLOGICAL|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
40784937|NCT00820547|DRUG|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
40784938|NCT00820547|DRUG|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
40784939|NCT00820547|DRUG|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
40989066|NCT02385084|DRUG|LY2409021|Administered orally
40989067|NCT00981955|DIETARY_SUPPLEMENT|Caffeine and L-theanine|Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
40989068|NCT05738941|PROCEDURE|radiofrequency ablation|17-G length-adjustable electrode (RITA RF Electrode;) a 200-W RF generator is going to be used,under CT fluoroscopic guidance. The type of the electrode and the length of the active tip will be selected according to the size, location, and shape of the tumor, as well as the operator preference.ablation will be performed with 100 W energy for 30 seconds. The number of electrodes placed, ablation time per electrode, total ablation time, and total energy delivered to targets, as well as the temperature of the lesions, will be recorded. For lesions less than 3 cm, surgery was performed with one electrode , and for lesions of 3 cm or more, two or more electrodes were used . The procedure may be followed by injection of bone cement through the same working cannula, and a long working time will be delivered (STABILIT, Merit Medical Systems, Inc.) for the optimal filling of the bone lesion
40989069|NCT05738941|PROCEDURE|angioembolization|"Use a 4- or 5-French diagnostic catheter for the initial angiogram and either continue to use this catheter for embolization where the feeding vessel is large or add a standard 2.3- to 2.5-French microcatheter as a coaxial technique .~- Injection of embolizing material in the feeding vessels using gel foam , PVA or histoacryl according to the nature of the bony lesion"
41146221|NCT03512041|BEHAVIORAL|RLIC - 3 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
41465415|NCT02812654|DRUG|Doxorubicin|Doxorubicin 75mg/m2 (cycle 1,2 and 3)
41465416|NCT02812654|DRUG|Ifosfamide|Ifosfamide 9 g/m2 (cycle 1 and 3)
41465417|NCT02812654|RADIATION|radiotherapy|radiotherapy: 25 Gy / 5 x 500 cGy/day
40989070|NCT03360370|OTHER|Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)|"This questionnaire screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.~It takes about 15-20 minutes. Data are collecting and a scoring by a professional is provided. Follow-up action is taken for children at risk. Medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders among neonatal data, characteristics of congenital heart disease and first surgery, and other comorbidities."
41146222|NCT03512041|BEHAVIORAL|Sham conditioning|Sham conditioning is achieved as listed in the arm/group descriptions. Sham conditioning is performed on visits 1-7, which occur on consecutive weekdays.
41306981|NCT01094717|DRUG|Tazarotene 0.1% Gel,Top|Topical tazarotene 0.1% gel was applied daily to active lesions.
40989071|NCT00483808|DEVICE|Ardian Symplicity™ Catheter|Renal denervation using the Symplicity Catheter
40989072|NCT01199744|DRUG|zanamivir|zanamivir
40989073|NCT05237479|PROCEDURE|Suprainguinal fascia ilica block|Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory \& motor distribution of the LFCN, FN, \& ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory \& motor distribution of LFCN, FN, \& ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory \& motor distribution of LFCN, FN, \& ON \& adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
40989074|NCT05237479|OTHER|Placebo|The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
41306982|NCT01094717|DEVICE|Sham excimer laser|Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
41306983|NCT03135587|PROCEDURE|Loading level|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
41465418|NCT04980495|BIOLOGICAL|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a continuous treatment regimen
41465419|NCT04980495|BIOLOGICAL|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a cyclic treatment regimen
40784940|NCT00820547|DRUG|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
41306984|NCT03029650|DRUG|Transderm Scop®|TDDS dosage is 1.5 mg/72 hrs
40989075|NCT05380973|OTHER|Short fiber resin composite|resin composite reinforced with short glass fibers
40989076|NCT05380973|OTHER|Polyethylene ribbon fiber|resin composite reinforced with polyethylene ribbon fiber
40989077|NCT02192918|BEHAVIORAL|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
41306985|NCT03029650|DRUG|Intravenous scopolamine hydrobromide|0.4 mg via intravenous injection
41306986|NCT04243135|DEVICE|ESWT|Extracorporeal shock wave therapy
41306987|NCT05902507|DIAGNOSTIC_TEST|Magnetic Resonance Imaging Simulation|Radiographic Image Simulation
41306988|NCT04686006|DRUG|Potassium Iodide|
40784941|NCT05714007|DRUG|Ferric derisomaltose|Single intravenous dose ferric derisomaltose
40784942|NCT05714007|DRUG|Ferrous succinate|Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
40784943|NCT04321616|DRUG|Hydroxychloroquine|Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
40784944|NCT04321616|DRUG|Remdesivir|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
41146223|NCT03512041|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
41146224|NCT03512041|BEHAVIORAL|Arm training|All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
41146225|NCT03512041|BEHAVIORAL|Sequence production training|All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
41306989|NCT00790738|DRUG|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
41306990|NCT00790738|DRUG|placebo|placebo
41465420|NCT05467982|BEHAVIORAL|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness. Subsample of 75 will also receive COVID-specific Integrated Illness Management and Recovery module.
40784945|NCT04321616|OTHER|(Standard of Care) SoC|The standard of care will be supplied to all patients not receiving a drug intervention.
40784946|NCT05093972|DRUG|Ulonivirine|Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
40784947|NCT02793583|BIOLOGICAL|Ublituximab|
40784948|NCT02793583|DRUG|Umbralisib|
40784949|NCT02793583|BIOLOGICAL|Bendamustine|
41465421|NCT05467982|BEHAVIORAL|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
41306991|NCT01469494|PROCEDURE|DIEP flap breast reconstruction|DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
40989078|NCT02192918|BEHAVIORAL|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
41465422|NCT03345758|OTHER|outcome|telephone to patients to finish SF-36 (the MOS item short from health survey,SF-36)，EQ-5D(EuroQol-5 Dimensions,EQ-5D)， AMT-4（Abbreviated Mental Test-4,AMT-4）and MMSE（Mini-mental State Examination,MMSE） to make assessments of their physical and mental health, cognitive function and social adaptation after discharge
41465423|NCT00964353|DRUG|Warfarin|Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
41465424|NCT04249596|DRUG|Tianeptine Sodium|At baseline, and following 8 weeks of treatment with tianeptine(12.5 mg, 3x daily), participants will be assessed in a number of procedures to evaluate their emotional and physical pain state and pain stimulus response and the relationship of such states/responses to endogenous opioid signaling. To further assess emotional pain, participants will also undergo fMRI while performing a validated social rejection and social acceptance paradigm known to induce endogenous opioid release in control subjects and blunted release in MDD. Examining both rejection and acceptance is important because the MOR system regulates both social distress and social reward in animals and humans, and tianeptine may also act on abnormal MOR-mediated responses to social acceptance in MDD. Likewise, a second fMRI scan will be used to explore physical pain response using an established thermal pain sensitivity task. The protocol at Stanford University will not include pain testing or imaging studies.
40989079|NCT02192918|BEHAVIORAL|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
40989080|NCT03556189|DEVICE|Case management|Case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
40989081|NCT00961844|BIOLOGICAL|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
40989082|NCT00961844|DRUG|Temozolomide|
40989083|NCT05805982|BEHAVIORAL|Educational Video|Pre-recorded educational video including hereditary cancer information, genetic cancer testing candidates, types of testing, type of results, benefits and risks, recommendations according to results, inheritance and common questions.
40989084|NCT05805982|BEHAVIORAL|In person genetic cancer counseling|"Includes:~Family history of cancer (3-generation family tree) Personal Cancer Risk Assessment Education on inheritance and expression of disease Types of tests Preparation on possible outcomes according to results Obtaining consent for test Opportunity to solve doubts"
40989085|NCT05972265|BEHAVIORAL|Moderate Intensity Exercise (one day)|Participants will engage in 40 minutes of cycling at 70-75% maximum heart rate (MHR).
40989086|NCT05972265|BEHAVIORAL|Placebo - Light Intensity Exercise (one day)|Control participants will engage in 40 minutes cycling at 40-50% maximum heart rate (MHR).
40989087|NCT05972265|BEHAVIORAL|Moderate Intensity Exercise (9 wks)|Participants will be asked to engage in moderate-intensity activity four days each week, 40 minutes each time, and will wear an activity monitoring device to assess their fidelity to the intervention.
40989088|NCT05972265|OTHER|Day 1 Assessments|Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), Life Events Checklist (LEC-5), and neuropsychological testing: approximately 1.50 hours
40989089|NCT05972265|OTHER|Symptom Measures and Neuropsychological Tests|Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), and neuropsychological testing: approximately 1.25 hours
40989090|NCT05972265|OTHER|Day 36 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
40989091|NCT05972265|OTHER|Day 57 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
40989092|NCT05972265|OTHER|Day 78 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
40989093|NCT06200727|PROCEDURE|PRF membrane tamponade surgery in macular hole|A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.
40989094|NCT06200727|PROCEDURE|ILM peeling in macular hole|The treatment of the macular hole was ILM peeling.
40989095|NCT06200727|PROCEDURE|PRF membrane grafting in pterygium|Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.
40989096|NCT06200727|PROCEDURE|Autologous conjunctival transplantation in pterygium|Used of autologous conjunctiva to cover exposed sclera after pterygium excision
40989097|NCT06200727|PROCEDURE|autologous PRF membrane grafting in trabeculectomy for glaucoma|Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.
40989098|NCT06200727|PROCEDURE|Amniotic membrane in trabeculectomy for glaucoma|Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.
40989099|NCT06200727|PROCEDURE|PRF membrane grafting incorneal ulcer|After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing
40989100|NCT06200727|PROCEDURE|Amniotic membrane in corneal ulcer|After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing
40989101|NCT02087475|DRUG|Irinotecan|
40989102|NCT02087475|DRUG|5-fluorouracil|
40989103|NCT02087475|RADIATION|Local radiotherapy|
40989104|NCT02087475|PROCEDURE|R0 resection|
40989105|NCT02938689|OTHER|Exercise|
40989106|NCT00939809|BIOLOGICAL|Urokinase-Derived Peptide A6|Given SC
40989107|NCT00939809|OTHER|Laboratory Biomarker Analysis|Correlative studies
40989108|NCT05103215|DRUG|Lidocaine HCl 2%|Intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
40989109|NCT05103215|DRUG|Normal saline|Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
40989110|NCT05218018|DIETARY_SUPPLEMENT|Lipid drink|100 mls of heavy cream
40989111|NCT05982054|PROCEDURE|core decompression with local bone marrow mononuclear cells injection|under local anesthesia ,anterior approach, with ultrasound and fluoroscopy guide
40989112|NCT01514760|OTHER|Mobile-based Asthma Action Plan|"The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly."
40989113|NCT03688477|DEVICE|iovera°|iovera° is minimally-invasive procedure using cold to target sensory nerve tissue and provide temporary pain relief through cryoneurolysis. The iovera° device uses well-established principles of cryobiology to temporarily deactivate sensory nerves that contribute to pain
40989114|NCT04382573|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
40989115|NCT04971733|DRUG|E2814|E2814 intravenous infusion.
40989116|NCT04949165|DIETARY_SUPPLEMENT|Iron Supplementation|low dose ferrous sulphate (65mg elemental iron) supplements
40989117|NCT04124289|OTHER|Pain measurement using 3 scales|Patients will assess their pain after surgery using three different pain scales.
40989118|NCT03011307|DRUG|Oxytocin|spinal injection of oxytocin
40989119|NCT03011307|DRUG|Placebo|spinal injection of placebo
40989120|NCT03767920|DRUG|bupivacaine|TAP block with 20 ml of 0.25% bupivacaine bilaterally
40989121|NCT03767920|DRUG|dexamethasone|TAP block with 4 mg dexamethasone bilaterally
40989122|NCT03767920|DRUG|placebo to dexamethasone|TAP block with 4 mg placebo to dexamethasone bilaterally
40989123|NCT01661192|DRUG|AAT( Alpha 1 Antitrypsin)|
40989124|NCT01001507|PROCEDURE|Integrated family planning/HIV care and treatment services|Family planning services will be provided during the patient's HIV care visit.
40989125|NCT03221920|OTHER|Very Low Carbohydrate Diet|1 : 4 ratio of carbohydrate to fat of the total daily calories intake
40989126|NCT02662881|DEVICE|PerFuse Percutaneous Decompression System|Core decompression with PerFuse
40989127|NCT02662881|DEVICE|BioCUE Platelet Concentration System|PRP injection through the PerFuse cannula into core decompression site
40989128|NCT06135727|DEVICE|Maestro2 OCT|3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)
40989129|NCT03345667|DRUG|lucentis|Use of lucentis and other anti-vegf in patients with diabetic retinopathy
40989130|NCT01369576|DRUG|Placebo|3.75-7.5mg 14 doses 4 weeks
40989131|NCT01369576|DRUG|Zopiclone|3.75-7.5mg 14 doses 4 weeks
41146226|NCT03062124|PROCEDURE|SpyGlass pancreatoscopy|During the SpyGlass pancreatoscopy procedure visually guided biopsies and flushing liquid are collected from the pancreatic duct
40989132|NCT02829463|RADIATION|Magnetic resonance imaging|3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
40989133|NCT01627054|DRUG|AT7519M|Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
40989134|NCT00034333|DRUG|MTC-DOX for Injection|
40989135|NCT00511615|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|Tissue sample removed from cervix using LEEP and contrast agent.
40989136|NCT00002627|BIOLOGICAL|filgrastim|
40989137|NCT00002627|DRUG|carboplatin|
40989138|NCT00002627|DRUG|cyclophosphamide|
40989139|NCT00002627|DRUG|mesna|
40989140|NCT00002627|DRUG|paclitaxel|
40989141|NCT00002627|PROCEDURE|peripheral blood stem cell transplantation|
40989142|NCT05887687|DRUG|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
40989143|NCT04319042|PROCEDURE|Immediate Loading|The implant receives an artificial tooth the same day as it is placed.
40989144|NCT04319042|PROCEDURE|Early Loading|The implant receives an artificial tooth 4 weeks after placement.
41465425|NCT02872051|BEHAVIORAL|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment"
40784950|NCT06123611|BEHAVIORAL|Adopting Comprehensive Training for FireArm Safety in Trauma centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
41306992|NCT01469494|PROCEDURE|SIEA flap breast reconstruction|"The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.~The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast."
41465426|NCT02872051|OTHER|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
40784951|NCT04708262|OTHER|Cognitive Analytic Therapy for Containing Self-Harm in Young People|The intervention will run over five sessions, each lasting around 30 - 40 minutes. Researchers will follow the CATCH-Y manualised treatment guide. CATCH-Y is a brief, five session psychological intervention based upon CAT principles and designed to help young people who have self-injured.
40989145|NCT05533450|DEVICE|Multi-focal rigid scleral contact lens|True scleral lenses rest on the sclera and do not touch the cornea and limbus, leaving a clear area between the contact lens and the cornea.
40989146|NCT05533450|DEVICE|Rigid gas permeable contact lens|"RGP contact lens is designed from a special rigid hydrophobic material. Patients wear RGP contact lens to form a contact lens-tear-cornea system to correct irregular astigmatism, reduce aberrations, provide good visual quality, and control the development of the disease through mild shaping effect."
40989147|NCT03518333|DEVICE|Injection of adipose derived cells into penis|Injection of Icellator-derived cells
40989148|NCT04057404|DEVICE|Alivecor Heart Monitor|
40989149|NCT05562973|DRUG|Psilocybin|Participants will receive three psilocybin sessions, at least two weeks apart.
40989150|NCT02756884|BIOLOGICAL|LoFU and aADSC|Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.
40989151|NCT02756884|BIOLOGICAL|adipose derived stem cells|control arm will only received the adipose derived stem cells.
40989152|NCT03047642|DIAGNOSTIC_TEST|Biomarker assay|There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients
40989153|NCT03911414|DRUG|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
40989154|NCT03911414|DRUG|Open-label Treatment with N-acetylcysteine|Open-label Treatment with N-acetylcysteine
40989155|NCT05849181|DEVICE|Moona Device|Moona Device pillow pad
40989156|NCT05849181|DEVICE|Inactive Moona Device|Inactive Moona Device pillow pad
40989157|NCT01975909|DEVICE|Transcranial Magnetic Stimulation|0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
40989158|NCT06172764|DIETARY_SUPPLEMENT|Vitamin D supplements along with behavioral modification|"Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
40784952|NCT02961036|OTHER|Group 1 information|Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
40784953|NCT02961036|OTHER|Group 2 information|Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
40784954|NCT02961036|OTHER|Group 3 information|Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
40784955|NCT02961036|OTHER|Group 4 information|Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
40989159|NCT06172764|COMBINATION_PRODUCT|Topical fluoride application and Vitamin D supplements along with behavioral modification|"Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
41146227|NCT04425252|DRUG|Brequinar|DHODH inhibitor, 100 mg daily x 5 days
40989160|NCT06172764|PROCEDURE|Topical fluoride application along with behavioral modification|"Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
41146228|NCT04425252|OTHER|Standard of Care|Standard of Care per institutional guidelines for COVID-19 patients
41146229|NCT01330953|DRUG|Placebo|Single intravenous placebo dose.
41146230|NCT01330953|DRUG|LY2928057|Single intravenous dose.
41146231|NCT02848898|DEVICE|Equistasi|
41146232|NCT02848898|OTHER|Placebo|
41146233|NCT05728372|DRUG|Copper Cu 64-DOTA-pembrolizumab|Given IV
41146234|NCT05728372|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40784956|NCT02961036|OTHER|Group 5 no information|Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
40989161|NCT02316067|OTHER|Rehabilitation|The CHORDATA® Method (16 sessions; 50 minutes each; twice a week) consisted of three exercises: (1) anterior pendulum, with the patient seated on a chair, upper limb suspended by springs and straps, and actively moving the trunk forward; (2) posterior pendulum exercise, on a similar position as exercise (1) but now moving the trunk backwards and recruiting the abdominal wall muscles during a posterior pelvic tilt motion; and (3) stand-up and sit-down exercise, patient with knees fixed anteriorly, initiating the standing-up movement by pulling back and down the springs, trying to maintain the standing position for as long as possible, balancing the trunk and transferring the supporting force from the upper limbs to the lower limbs.
40989162|NCT01042704|DRUG|Bendamustine|Bendamustine is given intravenously (into a vein or IV infusion) on days 1 and 2 of each cycle. Each bendamustine infusion will take 60 minutes
40989163|NCT01042704|DRUG|Lenalidomide|Lenalidomide is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
40989164|NCT01042704|DRUG|Dexamethasone|Dexamethasone is taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
40784957|NCT02961036|OTHER|Group A Reminder|One survey reminder at 14 days
40784958|NCT02961036|OTHER|Group B Reminders|Two survey reminders one at 14 days and one at 28 days
40784959|NCT02132286|DRUG|Quetiapine XR (extended release)|Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
40784960|NCT01504295|DRUG|Metadoxine|Improve Liver Function and Reduce ALcohol Use
40989165|NCT01042704|DRUG|Aspirin|All patients will receive enteric coated aspirin, 325 mg, QD while on study. If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.
40989166|NCT01042704|DRUG|Prophylaxis|All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
41146235|NCT05728372|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41146236|NCT05803122|OTHER|Uniform Data Set (UDS) neuropsychological battery|Uniform Data Set (UDS) neuropsychological battery was administered to patients with Mild Cognitive Impairment (MCI) and patients with Alzheimer's Disease
41146237|NCT02287571|DEVICE|Derotation splint|This group is the actual intervention group.
41146238|NCT02287571|DEVICE|elastic bandage|This group is the routine treatment (control) valid in the clinical practice.
41146239|NCT05935982|BEHAVIORAL|Virtual reality exercise|During school special physical education, participants will be asked to exercise using a virtual reality exercise headset, that will be adapted for arm use. Participants will asked to be seated during gameplay. Heart rate will be monitored and recorded during exercise.
40784961|NCT02957513|BEHAVIORAL|Text Messaging (TM)|As specified in the arm description above
40784962|NCT02957513|BEHAVIORAL|Health Coaching (HC)|As specified in the arm description above
41146240|NCT04267549|DRUG|sintilimab|a checkpoint inhibitor via blocking PD-1 (programmed cell death-1) site of signaling.
41146241|NCT04267549|DRUG|apatinib|a multi-target anti-angiogenic tyrosine kinase inhibitor (TKI)
41146242|NCT04267549|DRUG|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).
41146243|NCT04267549|DRUG|Nab paclitaxel|Nab paclitaxel is a albumin-bound well tolerated paclitaxel than traditional paclitaxel
41146244|NCT00903214|DRUG|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
41146245|NCT00903214|GENETIC|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
41146246|NCT00903214|PROCEDURE|axillary lymph node biopsy|
41146247|NCT00903214|PROCEDURE|digital image analysis|
41146248|NCT00903214|PROCEDURE|needle biopsy|
41146249|NCT00903214|PROCEDURE|sentinel lymph node biopsy|
41146250|NCT00903214|PROCEDURE|therapeutic conventional surgery|
41465427|NCT03408431|DEVICE|Ambu® AuraGain™|Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.
40784963|NCT02957513|BEHAVIORAL|Enhanced Usual Care (EC)|As specified in the arm description above
41146251|NCT00596960|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.
41146252|NCT00596960|BEHAVIORAL|Health education|Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
41146253|NCT05449145|DIETARY_SUPPLEMENT|Vitamin D|1st week: Vitamin D 82285.71 IU per day (total dose: 576000IU per week); 2th to 4th week: Vitamin D 41142.86 IU per day (total dose: 288000IU per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
41146254|NCT05449145|DIETARY_SUPPLEMENT|Non-Vitamin D|1st week: 95% MCT oil 5.71 ml per day (total dose: 40 ml per week); 2th to 4th week: 95% MCT oil 2.86 ml per day (total dose: 20 ml per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
41146255|NCT01607697|BEHAVIORAL|Mindfulness Training|Mindfulness Training
41146256|NCT02936258|PROCEDURE|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
41146257|NCT02936258|PROCEDURE|MRI|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
41306993|NCT05171231|DEVICE|HEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MD|"HEMOCOLLAGENE® is an absorbable, sterile and hemostatic sponge, composed of type I undenatured, native and lyophilized bovine collagen (0.027 g per sponge).~HEMOCOLLAGENE® will be inserted into oral sites (mainly the alveoli dental) after post-extraction or post-invasive dental surgical procedure, in case of bleeding not controled by usual hemostatic method. HEMOCOLLAGENE® will be let in place and will undergo a complete and natural absorption after several weeks."
40989167|NCT01042704|DRUG|Antibiotic|PCP antibiotic prophylaxis with a Bactrim will be recommended. In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.
40989168|NCT01042704|OTHER|Biweekly Follow Up|Vital signs (heart rate, breathing rate, blood pressure, and temperature) will be measured, and Blood tests to check CBC, Calcium, Electrolytes, serum, creatinine, and BUN. This follow up will take place at the Hillman Cancer Center, or whichever cancer center in which the subject is treated.
40989169|NCT01042704|OTHER|Cyclical Follow Up|At the beginning of each treatment cycle subjects will undergo a Physical exam, a Performance status check, Recording of any new symptoms or side effects and any new medications, Blood tests (including blood chemistry, organ function and indicators of disease), Urine test, and pregnancy test (if applicable).
40989170|NCT01042704|OTHER|Restaging|Every other cycle subjects' disease will be restaged. This will be accomplished by their treatment physician. Re-staging procedures includes a regular office visit, x-ray, and a bone marrow biopsy. Subjects will spend approximately 4 hours at the Hillman Cancer Center or the UPMC Cancer Center location where they are being treated for this re-staging.
40989171|NCT01042704|OTHER|Post-Treatment Follow Up|"After subjects stop receiving the study drugs, they will be followed every 3 months for the first two years, every 6 months for years 2-5, and annually thereafter. The following procedures, which are considered routine for their cancer care, will be done as part of this follow-up:~* Physical exam~* Performance status (check of ability to perform daily functions)~* Recording of any new symptoms and any new medications being taken~* Blood tests to check blood counts (numbers of red and white blood cells and platelets), blood chemistry (to check organ function), and indicators of disease (immunoglobulins)~* Urine test (24hr urine)~* Women who are able to have children will have a pregnancy test (4 weeks after their last dose of lenalidomide).~* A check of the status of disease (includes bone marrow biopsy, skeletal survey, and blood and urine tests). Bone marrow biopsy will be done at the end of treatment, if subjects have a complete response, and their disease gets worse."
40989172|NCT02389998|OTHER|Placebo Suspension|The study is divided into three phases: 1 one-week baseline assessment followed by 2 three-week study phases (phase A and phase B). Phase A will require subjects to take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary. In phase B subjects will not take the placebo. After 3 weeks in initial phase (either Phase A or B), subjects will switch to the alternate phase and continue the study for another 3 weeks. Hyoscyamine is available as a rescue medication during Phase A and Phase B. Half of the subjects will be randomized to begin with Phase A and half will be randomized to begin with Phase B.
40989173|NCT02389998|DRUG|Hyoscyamine|While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
40989174|NCT00072618|DRUG|Exisulind|
40989175|NCT01135758|DRUG|Ketamine|Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
41306994|NCT05008913|DRUG|[14C]Adavosertib|Patients will receive a single administration of \[14C\]Adavosertib as an oral solution on Day 1.
41306995|NCT05491057|DRUG|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
41306996|NCT04145830|DEVICE|Ultrasound Cyclo Plasty (UCP)|Cyclocoagulation using High Intensity Focused Ultrasound
41306997|NCT04622787|OTHER|Knowledge translation|"A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).~The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.~Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.~Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings."
41146258|NCT02936258|PROCEDURE|MRI Targeted Biopsy|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
41146259|NCT05836753|DRUG|Sarecycline Tablet|Each tablet contained 100 mg of Sarecycline.
41146260|NCT05836753|DRUG|Placebo tablets of Sarecycline tablets|Each tablet contained 0 mg of Sarecycline.
41146261|NCT03535545|DRUG|[68Ga]CBP8|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
41146262|NCT03535545|DIAGNOSTIC_TEST|PET Imaging|All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.
41146263|NCT06441214|DRUG|Zanubrutinib|Patients will be treated with Zanubrutinib as per routine clinical practice.
41146264|NCT05114499|DRUG|Donepezil|Donepezil 5mg qd
41146265|NCT05114499|DRUG|GV-971|GV-971 450mg bid
41146266|NCT01680315|BEHAVIORAL|low calorie yogurt|all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
40784964|NCT04815798|COMBINATION_PRODUCT|Bacteriophage-loaded Microcapsule Spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.
40784965|NCT04815798|COMBINATION_PRODUCT|Placebo|Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.
40989176|NCT06496503|BEHAVIORAL|Physical activity Protocol|The children included in the experimental group will undergo 12 weeks of physical activity sessions, and it is mandatory that all children complete a minimum of two weekly sessions of physical activity for 50-60 minutes. The activities will consist of content such as motor and cognitive games, sports, dance, and gymnastics. The intensity of the sessions will be checked using accelerometry. The physical activity protocol is adapted from a previously described protocol (CMSP, 2021; Klem, Filha, Monteiro, 2017; Mazzoccante et al.; 2020; Paiano, 2019; Rodrigues, 2018; Rosini et al., 2014). Acceptance of the exercise program in the pediatric population has been previously observed in a pilot study.
40989177|NCT00974012|DRUG|Divalproex Sodium|500 mg ER Tablet
40989178|NCT00974012|DRUG|Depakote®|500 mg ER Tablet
40989179|NCT03978585|DEVICE|high tone external muscle stimulation|Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
40989180|NCT03978585|DEVICE|transcutaneous electrical nerve stimulation (TENS) therapy|Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
40989181|NCT01454869|DRUG|standard care|Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
40989182|NCT01454869|DRUG|Heparin|Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
40989183|NCT04092790|DEVICE|Virtual Gate Device (VGD)|A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
40989184|NCT00768300|DRUG|Ambrisentan|Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
40989185|NCT00768300|DRUG|Placebo|Placebo to match ambrisentan was administered orally once daily.
41146267|NCT01680315|BEHAVIORAL|high calorie yogurt|all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
41146268|NCT03252210|PROCEDURE|Preoperative Stereoscopic Localization|1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
40784966|NCT04815798|PROCEDURE|Standard of Care|Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
40989186|NCT01761214|DRUG|Fluroquinolones|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
40989187|NCT01761214|DRUG|Beta-lactamase inhibitor|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
40989188|NCT05028179|DIAGNOSTIC_TEST|EchoGo|EchoGo Pro is an software Medical Device which is able to assess Stress Echocardiograms and provide a binary classification of risk of CAD
40989189|NCT01528956|GENETIC|DNA methylation analysis|
40989190|NCT01528956|GENETIC|RNA analysis|
40989191|NCT01528956|GENETIC|gene expression analysis|
40989192|NCT01528956|GENETIC|nucleic acid sequencing|
40989193|NCT01528956|GENETIC|polymorphism analysis|
40989194|NCT00525733|DRUG|darunavir 800 mg|darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
41146269|NCT05467267|PROCEDURE|TURBT|Patients with known bladder tumor undergoing TURBT - A biopsy from the tumor tissue will be taken. Peri operation a urine sample will be taken.
41146270|NCT02212626|DEVICE|Rotarex S|
41146271|NCT02413645|BIOLOGICAL|TriMix_100|100 μg of TriMix in
41146272|NCT02413645|BIOLOGICAL|TriMix_300|300 μg of TriMix in
41306998|NCT05463874|BEHAVIORAL|Mindful Self-Compassion Program|The intervention consists of 8 sessions, one per week for 8 weeks, that last 1 hour and 30 minutes each. These sessions will cover a variety of mindfulness and self-compassion practices, such as dealing with difficult emotions and developing a kind inner voice.
41306999|NCT02529241|DRUG|Group 1:LCB01-0371|"1. Period:LCB01-0371 Tablet 400 mg~2. Period: LCB01-0371 Tablet 400 mg"
41307000|NCT02529241|DRUG|Group 2:LCB01-0371|"1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg"
40989195|NCT00525733|DRUG|FTC 200 mg/TDF 300mg|Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
40989196|NCT00525733|DRUG|Maraviroc|Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
40989197|NCT00525733|DRUG|Raltegravir|Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
40989198|NCT00525733|DRUG|Ritonavir 100 mg|one tablet of ritonavir is taken with darunavir daily
41146273|NCT02413645|BIOLOGICAL|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)
41307001|NCT04436627|DEVICE|Amadeo-assisted training-1|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes active assistive training mode, followed by 20 minutes RT functional games (grasp and release) and 20 minutes RT finger coordination training.
41307002|NCT04436627|DEVICE|Amadeo-assisted training-2|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 10 minutes continuous passive motion mode followed by 20 minutes active assistive training mode, and 30 minutes RT functional games (grasp and release).
41307003|NCT04436627|DEVICE|Amadeo-assisted training-3|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes continuous passive motion mode followed by 20 minutes active assistive training mode. After 40 minutes of RT, 20 minutes functional tasks without robot.
40989199|NCT03337100|BEHAVIORAL|Co-Dispensing|"Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use."
40989200|NCT01014520|DRUG|Gabapentin , Amitriptyline|"Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery"
40989201|NCT01524848|DRUG|Pazopanib|Two (2) tablets of 400 mg given once daily continuously
40989202|NCT03006159|DRUG|SHR0534|
40989203|NCT03006159|DRUG|Placebo|
40989204|NCT05200520|BEHAVIORAL|Appetite Self-Regulation Intervention|The intervention will consist of content from Appetite Awareness Training (AAT), a cognitive-behavioral intervention to promote intuitive eating and the Diabetes Prevention Program (DPP)20, a behavioral lifestyle intervention. The goal of AAT is to enable participants to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants to reduce binge and overeating. Participants are taught to respond to external cues to eat (e.g., social gatherings), self-monitor the participant's adherence to biological signals of hunger and satiety, and to develop appropriate coping skills to manage urges to eat when not physically hungry.
40989205|NCT03972280|BIOLOGICAL|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody|Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion
41146274|NCT02413645|BIOLOGICAL|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)
41146275|NCT02413645|BIOLOGICAL|1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)|1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
41307004|NCT02338791|DEVICE|Manual Mobilization|Stabilization of the glenoid fossa with movement of the humerus using varying degrees of force as applied by a physical therapist. Subject is positioned with the shoulder in 55 degrees of abduction and 30 degrees of horizontal adduction. Manual force is applied by a physical therapist on the proximal humeral head moving the humeral head posterior, inferior or lateral (distraction). An ultrasound transducer placed over the anterior shoulder joint provides imaging of the humeral head and the glenoid fossa. This manual intervention is repeated three times in each direction on each arm.
40989206|NCT00299260|BIOLOGICAL|CMV gB vaccine|20 micrograms
40989207|NCT00299260|DRUG|Placebo|normal saline
40989208|NCT02741700|BEHAVIORAL|Gout Storytelling Video Intervention|The investigators developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management, which were narrated by several Veterans with gout. One of the veterans also presented a PowerPoint on gout and its management. The intervention was shown to the participants on a touchscreen computer or the desktop screen at the baseline study visit. Subsequently, they were provided with DVD with similar intervention to watch at home.
41146276|NCT01399905|DRUG|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
41146277|NCT00647465|DRUG|vaccine|IFNalpha 2b
41146278|NCT00647465|DRUG|Placebo|Placebo
41146279|NCT02521337|OTHER|observation|observation
41146280|NCT02506322|BEHAVIORAL|SEKT - Cognitive-Behavioral-Emotional|"This Bipolar Disorder specific psychotherapy has 4 modules:~1. psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation~2. Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance~3. dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods~4. behavior changes, (social, problem solving) skill training, communication skills, crisis management"
41307005|NCT01871896|DEVICE|Endoscopic Suturing to Create Early Satiety|Evaluating the efficacy of endoscopic suturing for weight loss.
41307006|NCT01996137|DEVICE|VASST II treadmill|Supervised treadmill training under physiotherapist
41307007|NCT03333057|DRUG|NOV03|Perfluorohexyloctane
41307008|NCT03333057|DRUG|Placebo|Saline solution (0.9% sodium chloride solution)
41307009|NCT00176670|DRUG|midazolam or GameBoy or parental presence|
41307010|NCT01975233|DEVICE|WEB Aneurysm Embolization System|WEB Aneurysm Embolization System
40784967|NCT03351946|PROCEDURE|ZEEP|Zero positive end-expiratory pressure (ZEEP) during emergence preoxygenation and awakening.
40784968|NCT03351946|PROCEDURE|PEEP|Positive end-expiratory pressure remains during emergence preoxygenation and awakening and until the study subject is extubated.
40989209|NCT06536751|RADIATION|Photobiomodulation|LED photobiomodulation therapy, once a week, for 08 consecutive weeks in the same day of the institution's standard physiotherapy session that the patient already uses regularly (not linked to the study). PBM will be transcutaneously, punctual application of the LED in the medial and lateral gastrocnemius muscles of the right lower limb, in contact mode, 3J/cm2, with a 850nm wavelenght.
40989210|NCT06536751|OTHER|Institution's Standard Physiotherapy|Physiotherapy treatment on the University, occur 2 therapeutic days per week, for 08 consecutive weeks (one of them in the same day of the PBM session). It consists of the use of motor physiotherapy, posture guidelines, stretching, positioning, joint range gain, ergonomics, sensory stimulation and proprioception, motor strengthening, tonus adjustment, functional training of upper and lower limbs, guidelines for the use of orthoses, stands, parapodium, parallel bars or wheelchair when needed. These are 45-minute sessions conducted by a physiotherapist.
40989211|NCT06536751|RADIATION|Photobiomodulation Placebo|The same procedures of PBM group but device will be turned off
40989212|NCT01180673|BEHAVIORAL|MINT-TLC|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
40989213|NCT01180673|BEHAVIORAL|Control Condition|"Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants."
40989214|NCT04787029|DEVICE|Medical compression stocking (medical device name: mediven Harmony 734 (compression class1 AG armsleeve or with wide(735))|Compression stockings worn on the arm or partial swelling of the hand after trauma or surgery.
40989215|NCT02809690|DEVICE|CAT|Undergo 18F-FMAU PET/CT
40989216|NCT02809690|DRUG|18F-FMAU|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
40989217|NCT02809690|OTHER|Laboratory Biomarker Analysis|Correlative studies
40989218|NCT02809690|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
40989219|NCT02809690|DEVICE|Positron Emission Tomography|Undergo 18F-FMAU PET/CT
40989220|NCT02809690|DEVICE|Ultrasound|Undergo TRUS-guided biopsy
40989221|NCT00019396|DRUG|flt3 ligand|
41307011|NCT04682834|DRUG|Sulopenem Etzadroxil/Probenecid|Individual Patients
41307012|NCT00186745|DRUG|Tinzaparin|Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
41307013|NCT05745324|PROCEDURE|Scaling and root planing|SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth
41465428|NCT03408431|PROCEDURE|neck extension|Patients' neck will be maximally extended (\~60°) during blind intubation.
40784969|NCT05884372|DRUG|Eldecalcitol|the same as arm descriptions.
41307014|NCT03589105|DRUG|Ocrelizumab 300 mg|Two doses of 300 mg infusion administered 14 days apart.
41465429|NCT05366231|DRUG|Kesuting syrup|"Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
41465430|NCT05366231|DRUG|LianHuaQingWen Granules|"Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
40784970|NCT05884372|DRUG|Native Vitamin D|the same as arm descriptions.
40784971|NCT05884372|DRUG|Denosumab|the same as arm descriptions.
40784972|NCT05884372|DRUG|Calcium|the same as arm descriptions.
40784973|NCT03222674|BIOLOGICAL|Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells|Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
40989222|NCT00019396|DRUG|gp100 antigen|
40989223|NCT00019396|DRUG|MART-1 antigen|
40989224|NCT00019396|DRUG|Montanide ISA-51|
40989225|NCT00019396|DRUG|tyrosinase peptide|
40989226|NCT05241522|DIAGNOSTIC_TEST|Tc-99m-Tilmanocept|Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.
40989227|NCT05899608|BIOLOGICAL|Ivonescimab Injection|Subject will receive ivonescimab and chemotherapy as an IV injection
40989228|NCT05899608|BIOLOGICAL|Pembrolizumab Injection|Subject will receive pembrolizumab and chemotherapy as an IV injection
40989229|NCT04052269|DRUG|Sildenafil 100mg|study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
40989230|NCT03352986|BIOLOGICAL|biological analysis|biological analysis will be performed in the 6 groups of patients
40989231|NCT03352986|OTHER|peripheral arterial tonometry|peripheral arterial tonometry will be performed in the 6 groups of patients
41307015|NCT03589105|DRUG|Ocrelizumab 600 mg|A single does of 600 mg infusion administered 24 weeks after the initial dose.
40784974|NCT02705092|OTHER|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
40784975|NCT02705092|OTHER|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
40784976|NCT01899430|DRUG|liraglutide|
40784977|NCT01899430|DRUG|metformin|
40784978|NCT01760577|DRUG|Botulinum Toxin A (Allergan, Inc, Irvine CA)|patients received intraarticular injections by the same experienced physician using aseptic procedures.
40784979|NCT01760577|DRUG|Hyalgan (Hyalgan, Fidia , Italy)|The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
40784980|NCT04923243|PROCEDURE|hip/knee replacement|hip/knee replacement
40784981|NCT02745873|DRUG|Ascorbic Acid|Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
40784982|NCT06086054|BEHAVIORAL|Navigation and EMR referral to childcare facility|See arm description
40784983|NCT04420676|DIETARY_SUPPLEMENT|Omnibiotic AAD|Bacterial strains in Omni-Biotic® 10 AAD are Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 which are embedded in a matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate
40784984|NCT04420676|DIETARY_SUPPLEMENT|Placebo|matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate.
40784985|NCT03500211|DRUG|Lidoderm 5 % Topical Patch|Lidocaine patch after cesarean section delivery.
40784986|NCT03500211|OTHER|Sham Topical Patch|Sham patch after cesarean section delivery.
40784987|NCT06021132|DEVICE|cochlear implant|Insertion of a electrode into the cochlear with the aim of providing deaf and severe hearing handicapped with the ability to hear speech.
40784988|NCT05289752|PROCEDURE|dental implants in the mandible|placement of two interforaminal dental implants in the canine region in the mandible
40784989|NCT05289752|DEVICE|locator attachment and overdenture|placement of locator attachment and insertion of mandibular overdenture
40784990|NCT03517670|OTHER|Rhythmic tolerance|Rhythmic intolerance is defined by the occurrence of arrhythmia prompting the initiation of an antiarrhythmic medication and the need to decrease or even to stop the infusion of milrinone
40784991|NCT03517670|OTHER|Hematological tolerance|Hematological tolerance will be considered good if milrinone infusion was not interrupted owing to the occurrence of thrombocytopenia
40784992|NCT03517670|OTHER|Milrinone efficiency on cerebral vasospasm|It will be assessed using ultrasound measurements of middle cerebral arteries velocities. A decrease of at least 20% of the mean velocity or of the Lindegaard index will be considered as a significant positive effect of the treatment (including milrinone).
40784993|NCT03517670|OTHER|Milrinone efficiency using the modified Rankin scale|Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to perform all usual activities, despite certain symptoms, 2= Slight disability. Able to take care of his own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderate severe disability. Unable to meet their own physical needs without help and unable to walk without help, 5 Severe disability. Needs constant care and attention, bedridden, incontinent, 6 = Death.
40784994|NCT06350448|DRUG|Washed Microbiota Transplantation|Washed microbiota suspension (5U) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5U, three times.
40784995|NCT01688297|BIOLOGICAL|VXA-A1.1 Oral Vaccine|One or two doses of replication incompetent adenovirus oral tablet vaccine
40784996|NCT01688297|BIOLOGICAL|VXA Placebo Tablet|Off-white tablets similarly formulated to the active drug product tablets.
40784997|NCT06185426|DRUG|Methyprednisolon and low level laser theraphy|All rats will be anesthetized with ketamine hydrochloride at a dose of 50 mg/kg (i.p) (Ketalar ®, Eczacıbaşı Parke-Davis, İstanbul, Türkiye) and Xylazine HCl (Alfazyne ®, Alfasan International B.V. Woerden, Hollanda) at a dose of 10 mg/kg (intraperitoneal). A right postauricular incision will made under general anesthesia, and an external trunk of the facial nerve will be found. In the DCG and other experimental groups, the facial nerve was dissected, and it will be clamped with an average force of 150 g for about 1 minute. Afterward, the surgical area will be sutured in all rats in the DCG, L, S, and LSG groups. At the end of the 4 weeks of study, tissue samples will be taken from the facial nerve trunk in the control and experimental groups with a second surgical procedure preserved in formalin solution and sent for histopathological and biochemical examination.
41465431|NCT02449616|DRUG|MST-188|Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
41465432|NCT02129309|PROCEDURE|Forearm plethysmography|Dose response study
40784998|NCT04281498|DRUG|Ruxolitinib|Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count
40784999|NCT04281498|DRUG|Enasidenib|50mg -100mg daily
40785000|NCT05834049|BEHAVIORAL|Virtual Parental Presence on Induction of Anesthesia|Apple Inc's FaceTime™ video application will be used when the child is taken to the operating room
40785001|NCT05834049|BEHAVIORAL|Midazolam|Preoperative midazolam (0.5 mg/kg of oral midazolam with a maximum dose of 20mg) will be given unless medically contraindicated.
40785002|NCT06091358|DEVICE|PrO2|"The intervention arm will receive a handheld PrO2 device and will participate in two unsupervised sessions and one supervised via Microsoft teams sessions per week.~Participants will complete 3 sessions per week, for 4 weeks. Each session will include 6 x 6 inspirations at 80% of MIP. MIP will be measured on the supervised session day each week."
40989232|NCT02085785|BEHAVIORAL|Coached group|Participants randomized to the coached arm will receive 1) education and self-monitoring materials \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], 2) a home visit by an exercise specialist, and 3) 11 telephone calls (over a 20-week period) by a health coach who will utilize motivational interviewing techniques to help the participant set eating and activity goals and trouble shoot problems when they occur
41307016|NCT03018626|DRUG|Rituximab|rituximab (375 mg/m2) given intravenously (IV) on day 0
41307017|NCT03018626|DRUG|Etoposide|Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
41465433|NCT02129309|PROCEDURE|Haemodynamic studies|Dose response study
41465434|NCT03164109|DRUG|GC4419 IV|50mg infused IV over 15 minutes
40785003|NCT04884607|OTHER|subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes|"* Evaluation of electrocardiogram measurement from external auditory canal electrodes: Participants are required to attach specially designed external auditory canal electrodes to their both ears to record electrocardiogram. Both electrocardiogram from the precordium and the ear would be simultaneously recorded and compared.~* Evaluation of low-level autonomic nerve stimulation using external auditory canal: Using the electrodes described above, Arnold's nerve will be stimulated with low-level electric impulses using TENS device. During and after the stimulation, heart rate variability will be measured to investigate the impact of nerve stimulation on autonomic function modulation on the heart."
40989233|NCT02085785|BEHAVIORAL|Self-directed control group|Participants randomized to the self-directed control arm will receive the same educational and self-monitoring materials as the coached group \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
40989234|NCT02085785|OTHER|Screened only|Screened only - No intervention -- individuals who are contacted and/or screened for eligibility
41146281|NCT02506322|BEHAVIORAL|FEST - Clinical Supportive Educational|This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
41146282|NCT03810911|DRUG|Darbepoetin|Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.
40989235|NCT00000954|DRUG|Bleomycin sulfate|
40785006|NCT04076332|OTHER|Decision aid|Decision aid is a tool that helps patients become involved in decision making on choosing treatment plans. Decision aid provides information about the options and outcomes, and by clarifying personal values.
40989236|NCT00000954|DRUG|Vincristine sulfate|
40989237|NCT00000954|DRUG|Doxorubicin hydrochloride|
40989238|NCT00000954|DRUG|Zalcitabine|
41146283|NCT01752816|BEHAVIORAL|exercise training|
41146284|NCT02568202|OTHER|No treatment given|"This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.~There will be no treatment."
41146285|NCT01219751|DRUG|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
40989239|NCT00000954|DRUG|Didanosine|
40989240|NCT02301273|OTHER|Usual Physiotherapy|o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
41146286|NCT02151994|DRUG|BIA 5-1058|oral administration
41307018|NCT03018626|DRUG|Doxorubicin|Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
41307019|NCT03018626|DRUG|Vincristine|Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
41307020|NCT03018626|DRUG|Cyclophosphamide|Cyclophosphamide(750 mg/m2)/dayg IV on days 5
41307021|NCT03018626|DRUG|Prednisone|prednisone (100 mg) given orally bid on days 1 through to 5.
41307022|NCT03018626|DRUG|Doxorubicin|Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
41307023|NCT03018626|DRUG|Cyclophosphamide|Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
40989241|NCT02301273|OTHER|Enhanced Physiotherapy|o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (\>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
40989242|NCT03447509|DEVICE|iTMS|Small magnetic pulse will be given to the brain in a non invasive manner.
40989243|NCT03447509|OTHER|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
41146287|NCT02151994|DRUG|Placebo|oral administration
41146288|NCT02292056|BEHAVIORAL|1-on-1 counseling|"1. Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method~2. Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.~3. Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.~4. 10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.~5. Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.~6. Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling"
41146289|NCT01962376|DRUG|Oxaliplatin;Capecitabine|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
41146290|NCT01962376|DRUG|Oxaliplatin;Capecitabine;Bevacizumab|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
41146291|NCT01212809|DEVICE|Juvéderm Ultra|Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
41146292|NCT01212809|DEVICE|Cosmoderm 1|Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
41307024|NCT03018626|DRUG|Vindesine|Vindesine (2 mg/m2) given on days 1 and 5
41307025|NCT03018626|DRUG|Bleomycin|Bleomycin (10 mg) given IV on days 1 and 5
41307026|NCT05647902|DIAGNOSTIC_TEST|Serum samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum samples will be collected from both groups for biochemical analysis.
41307027|NCT05685641|DIAGNOSTIC_TEST|Histoplasma Urine Antigen Lateral Flow Antigen test|Lateral Flow Antigen test for urine samples to detect Histoplasma capsulatum disseminated disease
41307028|NCT05685641|DIAGNOSTIC_TEST|Cryptococcal Lateral Flow Antigen test|Lateral Flow Antigen test for serum or cerebrospinal fluid samples to detect Cryptococcus sp meningitis or disseminated disease
41307029|NCT05685641|DIAGNOSTIC_TEST|Tuberculosis-lipoarabinomannan Lateral Flow Antigen test|Lateral Flow Antigen test for serum samples to detect Mycobacterium tuberculosus disease
41307030|NCT00032968|DRUG|Buprenorphine/naloxone|
41146293|NCT04177849|PROCEDURE|ACDF|A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.
41146294|NCT04177849|PROCEDURE|PF|A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
41146295|NCT01107171|DRUG|Tang-min-ling pills low dosage|low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
41146296|NCT01107171|DRUG|Tang-min-ling pills high dosage|high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
40989244|NCT03447509|DEVICE|Sham iTMS|Sham or fake stimulation will be given to the brain in a non invasive manner.
40989245|NCT03447509|OTHER|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
41146297|NCT01107171|DRUG|Placebo|Tang-min-Ling pills analogue 6g,tid,po
41146298|NCT02703519|PROCEDURE|resection of uterine scar tissue|resection of uterine scar tissue of a previous cesarean section during a second cesarean section
41146299|NCT04156685|DRUG|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
41146300|NCT04156685|DRUG|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
40989246|NCT03164343|DEVICE|Pain Neuroscience Education for children|Children and their parent will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
40989247|NCT05353127|DIAGNOSTIC_TEST|CPET/Cardiopulmonary Exercise Test|During CPET, a patient exercises against a progressively increasing work rate until volitional exhaustion, while breath-by-breath respiratory gasses are analyzed.
40989248|NCT00374725|BEHAVIORAL|Administration of probiotic (L. rhamnosus and L. acidophilus)|
40989249|NCT00525174|DEVICE|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
40989250|NCT00525174|DEVICE|Patching|2 hours daily patching of the sound eye
40989251|NCT00525174|PROCEDURE|Near activities|one hour near visual activities
41146301|NCT04156685|DRUG|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
41146302|NCT04156685|DRUG|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
41146303|NCT00006214|DRUG|flutamide|
41146304|NCT00006214|OTHER|placebo|
41307031|NCT04716166|OTHER|Volume-oriented incentive spirometry|3 sets of 5 repeated deep breaths using volume oriented incentive spirometry 3 times a day for 2 days
40989252|NCT02404285|DRUG|Next Science Acne Gel|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
40989253|NCT02404285|DRUG|Vehicle|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
41146305|NCT00641797|DRUG|Meclizine|medication administration 25mg PO one time
41146306|NCT00641797|OTHER|Epley Maneuver|Patient has vestibular rehabilitation utilizing the Epley Maneuver.
41146307|NCT00641797|DRUG|Lorazepam|Lorazepam 1 - 5mg PO/IV prn
41307032|NCT04716166|OTHER|Flow-oriented incentive spirometry|3 sets of 5 repeated deep breaths using flow oriented incentive spirometry 3 times a day for 2 days
40989254|NCT00017992|DRUG|Lopinavir/Ritonavir|
40989255|NCT00017992|DRUG|Emtricitabine|
40989256|NCT00017992|DRUG|Stavudine|
40989257|NCT02255721|BEHAVIORAL|SHIP (Sleep Health in Preschoolers)|SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
41146308|NCT00641797|DRUG|Diphenhydramine|25 - 50mg PO/IV once prn
41146309|NCT00641797|DRUG|Ondansetron|Ondansetron 4 - 8 mg PO/IV prn
41146310|NCT03019809|BIOLOGICAL|G-CSF for Conditioning before HSCT.|Mobilization of hematopoietic stem (HSC) into circulation
41146311|NCT03019809|BIOLOGICAL|Plerixafor for Conditioning before HSCT.|Directed inhibition of CXC chemokine receptor type 4 (CXCR4) for opening enough BM niches for adequate donor HSC engraftment.
41146312|NCT06421376|DRUG|Cardonilizumab|Two cycles of Inductive therapy： nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles
41146313|NCT06421376|RADIATION|Chemoradiotherapy ±immunotherapy|"Chemoradiotherapy ± immunotherapy：~* PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ②nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ③Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles"
41307033|NCT02426060|DRUG|Imrecoxib|
41307034|NCT02426060|DRUG|Warfarin|
41465435|NCT03164109|DRUG|Placebo|Infused IV over 15 minutes
41465436|NCT03164109|DRUG|Oral moxifloxacin|400 mg tablet orally with 250 mL room temperature water
41307035|NCT05820100|OTHER|Observational|"The goal of this observational study is to assess the reliability and validity of the multi-luminance Y-Mobility Test (MLYMT) and multi-luminance shape description test (MLSDT) for evaluation of subjects with severe vision impairment due to RP.~Normally sighted subjects will provide a control group. The MLYMT consists of two LED panels, one of which is illuminated at multiple luminance levels, positioned at the end of Y-configuration. Seven obstacles are placed ahead of the panels, which the test subject should detect and avoid before reaching and touching the lit panel."
41465437|NCT02919189|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
41465438|NCT00490932|DRUG|Hypo-osmolar ORS|
41465439|NCT03749733|DRUG|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)|Marketed Drug
41465440|NCT03749733|DRUG|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)|Investigational Medicinal Product
41465441|NCT05063539|DRUG|LY3372689|given orally
41465442|NCT05063539|DRUG|LY3372689|given orally
41465443|NCT05063539|DRUG|Placebo|given orally
41465444|NCT04902911|DEVICE|COVID-19 SARS-CoV IgG/IgM antibody rapid test|Needle stick point of care and 3mL vial of blood will be collected and tested for individual without history of COVID-19 and immunization as well as a second group composed of individuals with history of COVID-19
41465445|NCT00245817|BEHAVIORAL|HINCAB|Psycho-educative intervention performed 2 and 4 weeks after surgery
41465446|NCT04281524|DRUG|CSL312|CSL312 administered as an IV infusion
41465447|NCT04281524|DRUG|Placebo|Solution of 70% 0.9% saline / 30% CSL312 diluent
41465448|NCT05507320|BEHAVIORAL|Mechanisms of action perception and execution|Study the mechanisms of action perception and execution
40989258|NCT02255721|BEHAVIORAL|SHIP Control Arm|Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
40989259|NCT02101047|DRUG|Phenylephrine|
40989260|NCT05308745|DIETARY_SUPPLEMENT|Yakult®|Fermented milk drink containing over 6.5×10\^9 CFUs of L. casei Shirota/65 ml
40989261|NCT05308745|DIETARY_SUPPLEMENT|Placebo|Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product
41307036|NCT04344405|DRUG|Vitamin D|vitamin D supplementation
41307037|NCT04344405|DRUG|Steroid Drug|control
41307038|NCT02467803|OTHER|Scapula mobilization|
41465449|NCT00055549|DRUG|Dextromethorphan|
41465450|NCT00055549|DRUG|Lorazepam|
41307039|NCT02467803|OTHER|Shoulder ROM exercises|
41465451|NCT02993419|DRUG|Bacillus licheniformis Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
41465452|NCT02993419|OTHER|placebo Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of placebo drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
41465453|NCT05864924|BIOLOGICAL|Cohort A: 3.0x10^6 CAR-T cells/kg|Intravenous infusion
41465454|NCT05864924|BIOLOGICAL|Cohort B: 9.0x10^6CAR-T cells/kg|Intravenous infusion
41465455|NCT05864924|BIOLOGICAL|Cohort C:1.5x10^7 CAR-T cells /kg|Intravenous infusion
41465456|NCT00959569|DRUG|Esmolol|esmolol (1-3 mg/kg) during cardiac surgery
40989262|NCT01907503|PROCEDURE|Evaluation of the balance of force platform|
40989263|NCT02423538|DRUG|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
40989264|NCT02423538|DRUG|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
40989265|NCT00310128|DRUG|cisplatin|
40989266|NCT00310128|DRUG|cytarabine|
40989267|NCT00310128|DRUG|etoposide|
40989268|NCT00310128|DRUG|methylprednisolone|
40989269|NCT00310128|DRUG|rituximab|
40989270|NCT00310128|DRUG|yttrium Y 90 ibritumomab tiuxetan|
40989271|NCT00310128|PROCEDURE|antibody therapy|
40989272|NCT00310128|PROCEDURE|biological therapy|
40989273|NCT00310128|PROCEDURE|chemotherapy|
41465457|NCT00959569|DRUG|Placebo|normosaline (same ml of the study drug)
41465458|NCT01785615|DRUG|Atorvastatin|80mg
41465459|NCT01785615|OTHER|Placebo|80mg
41465460|NCT02004691|DRUG|placebo (saline)|"Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion"
41465461|NCT02004691|DRUG|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants.~Route of administration: intravenous infusion"
41465462|NCT01010035|OTHER|Plasma kinetic study|this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
41465463|NCT01011335|BIOLOGICAL|Monovalent rAT|10, 25, 50 or 100 μg
41465464|NCT01011335|BIOLOGICAL|Monovalent rLukS-PV|10, 25, 50 or 100 μg
41465465|NCT01011335|BIOLOGICAL|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
41465466|NCT01011335|BIOLOGICAL|Placebo with adjuvant|Placebo with adjuvant
41465467|NCT01011335|BIOLOGICAL|Placebo|Placebo saline
41465468|NCT02361814|PROCEDURE|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
41465469|NCT02102269|DEVICE|actimove sling|
41465470|NCT02102269|DEVICE|shoulderlift|
41307040|NCT03514758|PROCEDURE|several virtual 3-D complex audio environments|The focus is a comparison of four virtual 3-D complex audio environments with regard to the sensitivity of hearing aid algorithms.
41146314|NCT06421376|PROCEDURE|Radical surgery|Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.
41307041|NCT01380158|DEVICE|Cup pessary (Bioteque America, Inc)|Placement of cup pessary in the vagina after randomization
41307042|NCT02583802|DRUG|Ear pills|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
41307043|NCT02583802|DRUG|Shengmai capsule|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
41307044|NCT01480206|OTHER|Endovascular Aortic Repair (EVAR)|Use of 3D interventional imaging tools in endovascular procedures in the surgical environment
40989274|NCT00310128|PROCEDURE|monoclonal antibody therapy|
40989275|NCT00310128|PROCEDURE|radiation therapy|
41307045|NCT03785496|DRUG|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
41307046|NCT06060223|OTHER|Teach Back Method|"Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the Heart Failure Training Guide in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary."
40989276|NCT00310128|PROCEDURE|radioimmunotherapy|
41146315|NCT01843920|DRUG|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
40785007|NCT01029912|DEVICE|Electrical stimulator|"6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
40785008|NCT02673944|DEVICE|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
40989277|NCT00310128|PROCEDURE|radioisotope therapy|
40989278|NCT03895281|DIAGNOSTIC_TEST|FilmArray Meningitis/Encephalitis (ME) Panel|The FilmArray ME pouch is a closed system disposable that houses all the chemistry required to isolate, amplify and detect nucleic acid from multiple meningitis and encephalitis pathogens within a single CSF specimen obtained from a lumbar puncture. The rigid plastic component (fitment) of the FilmArray ME pouch contains reagents in freeze-dried form. The flexible plastic portion of the pouch is divided into discrete segments (blisters) where the required chemical processes are carried out. The user of the FilmArray ME Panel loads the sample into the FilmArray ME pouch, places the pouch into the FilmArray instrument/Module, and starts the run. All other operations are automated.
40989279|NCT04251221|DRUG|Oral Alcohol Challenge|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08
40989280|NCT00944450|DRUG|Sitagliptin phosphate anhydrous formulation|Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
40989281|NCT00944450|DRUG|Comparator: sitagliptin phosphate monohydrate form|Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.
40989282|NCT03849404|BIOLOGICAL|Adalimumab|Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48
40989283|NCT01471379|DRUG|Milnacipran|50mg Milnacipran PO, BID, for 6 weeks.
40989284|NCT01471379|DRUG|Milnacipran|Milnacipran, 100mg PO, BID, for six weeks
41146316|NCT01843920|DRUG|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
41146317|NCT05722756|OTHER|craniosacral therapy|subtle form of applied touch, type of osteopathy
41146318|NCT05828654|BEHAVIORAL|Focus Group Discussions and Semi-structured Interviews|Community representatives will be asked to participate in either 1:1 semi-structured interviews with a research staff member or to engage in focus group discussions with other community members. These interviews and discussions will gather broad perspectives on resource and training needs for community lay navigators and inform the adaptation of existing Peer Connect training materials
41307047|NCT00069576|BEHAVIORAL|nutritional counseling|
41307048|NCT00069576|BEHAVIORAL|self blood glucose monitoring|
41307049|NCT04007666|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms.
40785009|NCT05206903|OTHER|Questionnaires|Questionnaires about pandemia process
40785010|NCT04824014|DIAGNOSTIC_TEST|4FMFES-PET|Intravenous 4FMFES injection, followed with PET imaging
40785011|NCT02838641|DEVICE|GeneXpert|Real time integrated and automated nucleic acid amplification test for detection of TB
40785012|NCT03420937|DRUG|Sugammadex|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
40785013|NCT03420937|DRUG|Neostigmine, Atropin Biotika|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
40989285|NCT01471379|DRUG|Milnacipran|Milnacipran, 50mg PO BID for 12 weeks
40989286|NCT01471379|DRUG|Placebo|Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
40989287|NCT06200077|PROCEDURE|Modified Ridge-Splitting|Unlike the conventional ridge-splitting where bone grafting is done in the same visit after ridge splitting, modified ridge splitting involves splitting the ridge only at the first visit, then bone grafting is done either alone afterwards in the second visit (Modified 3-Staged Ridge-Splitting Group) and dental implants will be placed in the third visit, or, as in the Modified 2-Staged Ridge-Splitting Group, bone grafting and dental implants placement will be done in the second visit.
40989288|NCT01675687|BEHAVIORAL|Follow Up Support|inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training
40989289|NCT04086290|PROCEDURE|RARP|Radical prostatectomy + extended pelvic lymph node dissection
41307050|NCT04007666|BEHAVIORAL|Control Group|Coping-focused treatment drawn from material already offered in selected facilities.
41307051|NCT03608553|DEVICE|MR Guided Focused Ultrasound|Blood Brain Barrier Disruption using FUS
41307052|NCT02678234|DRUG|Paracetamol, phenylephrine HCl, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
41307053|NCT04484779|DEVICE|IIM System|IIM System
41307054|NCT04484779|DRUG|Insulin Lispro and/or Insulin Glargine|Administered subcutaneously (SC)
40785014|NCT02563730|PROCEDURE|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
40785015|NCT04164069|BIOLOGICAL|Bevacizumab|Given IV
40785016|NCT04164069|DRUG|Dasatinib|Given PO
40785017|NCT04164069|DRUG|Fluorouracil|Given IV
40989290|NCT04086290|RADIATION|SBRT|Stereotactic body radiotherapy to osseous lesions
40989291|NCT04086290|DRUG|ADT|six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
40989292|NCT01295515|DRUG|Pegylated Interferon Alpha 2b (PEGINTRON)|pegylated preparation of interferon alpha 2b
41146319|NCT05828654|BEHAVIORAL|Training community lay navigators|Lay navigators identified from among the recruited community representatives will be trained either in-person or virtually by research staff members in motivational interviewing and other strategies to provide psychosocial support to older socially disadvantaged adults with cancer. For community lay navigators and inform the adaptation of existing Peer Connect training materials.
41146320|NCT02092909|DRUG|IMO-8400|IMO-8400 at escalating dose levels by subcutaneous injection
41146321|NCT04362722|DRUG|L19IL2 +L19TNF|Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (\~1.08 mg) and 200 µg L19TNF.
41146322|NCT03639545|DRUG|Empagliflozin 25mg|The patients receive empagliflozin (25 mg daily) for 12 weeks.
41146323|NCT03639545|DRUG|Metformin|The patients receive metformin (2000 mg daily) for 12 weeks.
41146324|NCT03639545|DRUG|Empagliflozin/Metformin|The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
41146325|NCT03639545|DRUG|Placebos|The patients receive for 12 weeks.
41146326|NCT04127513|DRUG|Ammonium Lactate|12% ammonium lactate moisturizing cream
41146327|NCT04127513|DRUG|Urea|10% urea moisturizing cream
40785018|NCT04164069|DRUG|Leucovorin|Given IV
41146328|NCT05234476|BEHAVIORAL|Behavioral Activation plus Savoring|Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.
41146329|NCT05234476|BEHAVIORAL|Empathic Listening|Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.
41146330|NCT04019301|OTHER|Baduanjin Qigong, Community-based|The Community-based Qigong group, will attend one 75 minute long Qigong class per week for 12 weeks. Additionally, participants practice Qigong at home for 20 minutes a day, 3 days a week. Printed materials will be provided to guide home practice.
41146331|NCT04019301|OTHER|Baduanjin Qigong, Internet-based|The Internet-guided Qigong group will be given a computer tablet to access online Qigong classes. All participants assigned to this group will be provided with a tutorial to use the Qigong program by the research coordinator. Participants will be asked to follow a 40 minute long Qigong class twice a week for 12 weeks, and to practice an additional 20 minutes a day, 3 days a week. All sessions will be completed at home.
41146332|NCT02913898|BEHAVIORAL|IBLT|Information bias learning task-- a computer based task in which positive information is more useful when learning how best to complete it
41146333|NCT02913898|BEHAVIORAL|IBLT control|A control version of the IBLT task-- a computer based task in which both positive and negative information is useful when learning how to complete it
41146334|NCT03988855|DRUG|DNV3837|Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total maximum daily dose of 120 mg DNV3837. Infusions will be administered once daily for 10 consecutive days.
41146335|NCT00881972|BEHAVIORAL|Exercise|walking/running/cycling
41146336|NCT04464148|DRUG|Pregnenolone 250 mg|Pregnenolone 250 mg capsule BID (500 mg QD total)
41146337|NCT04464148|DRUG|Pregnenolone 400 mg|Pregnenolone 400 mg capsule BID (800 mg QD total)
41146338|NCT03423992|BIOLOGICAL|chimeric antigen receptor T cells|chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively
41307055|NCT04576637|PROCEDURE|Neurophysiological monitoring during intubation|In the operating room patients will be connected to the anesthesia monitor and an IV line as standard clinical practice. Participants will receive oxygen and an IV infusion of 1-3 ng/ml remifentanil via TCI infusion pump to achieve mild sedation. Patients will then be connected to the neurophysiological electrodes to monitor for EEG, EMG, SSEP and MEP signals. After preparing the videolaryngoscope, anesthesia induction will be achieved with the use of IV ketamine 2mg/kg. Then the anesthesiologist will perform a clinical and ECG reading assessment to ensure that the patient is anesthetized and will be able to titrate more ketamine as needed to achieve hypnosis. A biteblock will be located to prevent teeth damage. A neurophysiological baseline recordings will then be performed by a neurophysiologist. The videolaryngoscope will then be inserted, during which a second neurophysiological testing will be performed to ensure the patients safety. Then mechanical ventilation will be initiated.
41307056|NCT01636024|DRUG|AZD7594|Suspension inhaled via Spira nebuliser
40785019|NCT04164069|DRUG|Leucovorin Calcium|Given IV
40785020|NCT04164069|DRUG|Oxaliplatin|Given IV
40785021|NCT04164069|OTHER|Quality-of-Life Assessment|Ancillary studies
40785022|NCT01562886|DRUG|Rilpivirine|Rilpivirine 26mg
40785023|NCT03412825|DIETARY_SUPPLEMENT|Egg supplementation|Participants will required to consume 2 eggs per day, 5 days a week (a total of 10 eggs per week).
41465471|NCT03597724|OTHER|Questionnaire composed of 13 choice questions.|In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
40785024|NCT01999933|RADIATION|Radiation|Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
40785025|NCT01999933|DRUG|cisplatin（DDP） weekly|concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
40785026|NCT01999933|DRUG|docetaxel plus cisplatin|concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
40785027|NCT01999933|DRUG|docetaxel plus cisplatin|adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
40785028|NCT01732614|PROCEDURE|Topcon Endpoint Management laser|
40785029|NCT01213082|DRUG|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
41465472|NCT06096350|DEVICE|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
41465473|NCT06096350|DIAGNOSTIC_TEST|hematochemical analysis|Blood samples of patients will be collected from patients in the early morning (7:30-9:00 a.m.) after an overnight fast at T0 and at T1. Sera samples will be separated by centrifugation (3,000 rpm, 10 min, and 4 °C), divided into 0.5 mL aliquots, and rapidly stored at -80 °C. Subjects' and reference samples were thawed just before the diagnostic test.
41465474|NCT06096350|DEVICE|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1), muscular force with hand grip
40785030|NCT01213082|DRUG|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
40785031|NCT01213082|DRUG|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
40785032|NCT05576025|OTHER|Lifestyle intervention (cold exposure)|Participants will undergo two cold exposures with different shivering intensities. Mild shivering is defined as energy expenditure increased by 1.5-fold compared to the resting metabolic rate. Moderate shivering is 2.5-fold increase in metabolic rate.
40785033|NCT05230576|DIAGNOSTIC_TEST|Deep learning training cohort|train the deep learning model
41465475|NCT06096350|DIAGNOSTIC_TEST|nutritional assessment, MNA,|nutritional status assessment will be performed by: body mass index measurements, (height and weight measurements at T0 and at T1); a Mini Nutritional Assessment survey will be administered to patients at admission; a food questionnaire will be administered to patients during from T0 to T1.
41465476|NCT06096350|DIAGNOSTIC_TEST|stool sampling|stool will be collected at T0 and at T1
41465477|NCT06096350|DIAGNOSTIC_TEST|urine sampling|the first morning urine will be collected at T0 and at T1
41465478|NCT06096350|DEVICE|indirect calorimetry analysis|indirect calorimetry analysis with K5 (COSMED, Italy) during six minute walk test or timed up and go test.
41465479|NCT01767727|PROCEDURE|Soft tissue coverage|The dorsal homodigital island flaps are used for soft tissue coverage of multiple finger defects
41465480|NCT06471478|COMBINATION_PRODUCT|intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion|patients received intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion for decresing donor specific antibodies.
41465481|NCT02937363|DIETARY_SUPPLEMENT|Alpha-lipoic acid|A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
41465482|NCT02937363|OTHER|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
40785034|NCT05230576|DIAGNOSTIC_TEST|Deep learning validation cohort|evaluate the model
40785035|NCT05508828|PROCEDURE|Percutaneous Continuous Irrigation assisted Vacuum Drainage Combined With Transgastric Necrosectomy|All patients with SAP were given contrast enhanced CT scan within 48 hours after admission to identify the location and range of the necrosis. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. Subsequently, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. The procedure was repeated until all loosely adherent necrotic material were cleared and replaced by granulation tissue. Percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.
40785036|NCT01051037|RADIATION|Stereotactic Body Radiation|3 fraction of stereotactic body radiation therapy within 10 days.
41307057|NCT01636024|DRUG|Placebo to match|Matching placebo inhaled via Spira nebuliser
40785037|NCT01051037|RADIATION|Radiofrequency Ablation|Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
40785038|NCT00119197|BIOLOGICAL|killed whole cell oral cholera vaccine|"Bivalent oral killed cholera vaccine: each dose of this vaccine contains:~* Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells~* Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells~* Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells~* Inactivated V.Cholerae O139 - 50.109 cells~each 1.5 mL dose given orally, two doses given 14 days apart"
40785039|NCT00119197|BIOLOGICAL|Heat Killed E. coli|"Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.~Each 1.5 mL dose given orally, two doses given 14 days apart"
40785040|NCT04274595|DRUG|Generic antiretroviral|200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days
40785041|NCT01334554|DRUG|Sildenafil|20 mg three times a day.
40785042|NCT01334554|DRUG|Placebo|No active drug
40989293|NCT04954612|OTHER|Questionnaire study (Cross-sectional analytical clinical research)|Questionnaire study (Cross-sectional analytical clinical research)
40989294|NCT05874076|BEHAVIORAL|Physiotherapy|Physiotherapy
40785043|NCT00818493|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, ascending flexible dose, every 4 to 6 hours
40785044|NCT00818493|DRUG|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
40785045|NCT00818493|DRUG|Percocet (oxycodone and acetaminophen)|One or two 5mg/325 mg tablets every 4 to 6 hours
41465483|NCT03342235|PROCEDURE|Photorefractive Keratectomy (PRK)|Subjects randomized to refractive surgery will be referred to one of six study surgical centers (surgical centers are listed in Appendix B) to have photorefractive keratectomy (PRK) in the affected eye within 60 days after randomization.
40989295|NCT00183092|DRUG|Quinacrine|100mg by mouth three times a day
40989296|NCT00183092|DRUG|Placebo|100mg by mouth three times a day
40989297|NCT06541015|DEVICE|InTENSity 10 TENS Stimulator|InTENSity 10 TENS stimulator is a portable electrotherapy device featuring Transcutaneous Electrical Nerve Stimulation (TENS) therapeutic device. The stimulator sends a gentle electrical current to underlying nerves and muscle group via electrodes applied on the skin. The parameters of device are controlled by the buttons.
40989298|NCT02911181|OTHER|BIVA measurement|
40989299|NCT05864300|BEHAVIORAL|Neurocheck frequency|Randomized to hourly or every-other-hour examinations
40989300|NCT00302874|BEHAVIORAL|Implementation of a protocol for treatment of hyperglycemia|
40989301|NCT00785109|DIETARY_SUPPLEMENT|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
41465484|NCT03342235|OTHER|Patching 2 hours per day|Patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able.
41465485|NCT03342235|DEVICE|Excimer Laser System|Excimer Laser System for use in photorefractive keratectomy.
41465486|NCT01632163|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
41465487|NCT01632163|DRUG|Placebo|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
41465488|NCT04356807|PROCEDURE|Reflex Locomotion Therapy|The exercises corresponding to the motor complexes of the 1st phase of the rolling reflex and the original creeping reflex were performed, dedicating one minute to each side and performing two repetitions in each session.
41465489|NCT04356807|PROCEDURE|Passive Joint Mobilizations|Passive Joint Mobilizations with articular pressure described by Moyer-Mileur, et al. 1995 and modified by Vignochi, et al. 2008
41307058|NCT03136757|OTHER|Transcriptomic analysis of GVHD biopsies|"The transcriptomic analysis of GVHD biopsies aims at:~* to demonstrate an evocative or even specific molecular profile, making the diagnosis of GVHD easier~* to identify new intracellular signaling pathways that could lead to new therapeutic"
41465490|NCT04356807|PROCEDURE|Massage|Soft massage with soft pressures in limbs, tactile stimulation and no motion.
41465491|NCT06024967|DRUG|PEG-somatropin|PEG-somatropin
41465492|NCT03267927|DEVICE|Rapid palatal expansion|Fixation of rapid palatal expansion from day 0 to day 60
41465493|NCT03267927|DEVICE|MGA™ system|Use of a mandibular advancement Appliance during the night from day 60 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
40785046|NCT00369837|DRUG|clevidipine|Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
40785047|NCT02572375|DRUG|Codeine Phosphate/Guaifenesin ER Tablet|Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
40785048|NCT02572375|DRUG|Codeine Phosphate/Guaifenesin IR Tablet|Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
40785049|NCT01847443|DRUG|Nicotine (2 mg)|2 mg nicotine gum in two formulations
40785050|NCT01847443|DRUG|Nicotine (4 mg)|4 mg nicotine gum in two formulations
40785051|NCT01201551|DRUG|Brimonidine|Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
40785052|NCT01201551|DRUG|Latanoprost|Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
40785053|NCT01201551|DRUG|Placebo|Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
40785054|NCT02592421|DRUG|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
40989302|NCT00278083|DRUG|Study drug administration|
41465494|NCT03267927|DEVICE|Yoobreath™ system|Use of a device allowing sleep in a semi-seated position during the night from day 15 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
40785055|NCT02592421|DRUG|Placebo|Placebo Comparator
40989303|NCT00278083|PROCEDURE|Tuberculin intradermal skin test|
40989304|NCT00278083|PROCEDURE|Lung function test for FEV1|
41465495|NCT02248714|DIETARY_SUPPLEMENT|Glucerna SR|Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
41465496|NCT04559750|BEHAVIORAL|Internet delivered behavior therapy (I-BT)|10 weeks of I-BT
40989305|NCT00278083|PROCEDURE|Asthma symptom scores diary|
40989306|NCT00278083|PROCEDURE|Quality of life diary|
40989307|NCT00278083|PROCEDURE|Breath nitric oxide|
40989308|NCT00278083|PROCEDURE|Breath condensate|
40989309|NCT00278083|PROCEDURE|Sputum induction|
40989310|NCT00278083|PROCEDURE|Blood sampling|
40989311|NCT00278083|PROCEDURE|Urinalysis|
40989312|NCT05757531|DRUG|[¹⁴C]-LY3437943|Administered SC.
40989313|NCT01421758|BEHAVIORAL|online social network enrollment plus education and self monitoring|Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
40989314|NCT01421758|BEHAVIORAL|Web education control|Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
40989315|NCT03822208|BIOLOGICAL|AL003|"Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort"
40989316|NCT03822208|OTHER|Saline Solution|Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo
40989317|NCT06297109|DEVICE|Patient-specific implants|Application of patient-specific implants for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
40989318|NCT06297109|DEVICE|Conventional mini-plates|Application of conventional mini-plates for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
40989319|NCT01828047|DEVICE|orthogonal polarization spectral (OPS) imaging|orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces
40989320|NCT00897247|GENETIC|microarray analysis|
40989321|NCT00897247|GENETIC|protein expression analysis|
40989322|NCT00897247|GENETIC|proteomic profiling|
40989323|NCT00897247|OTHER|laboratory biomarker analysis|
40989324|NCT00293644|DRUG|Diclectin®|Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
40989325|NCT00128947|DRUG|Mycophenolic Acid|
40989326|NCT00128947|DRUG|Mycophenolate 7-O-Phenolic Glucuronide|
40989327|NCT04759209|DIAGNOSTIC_TEST|Biopsies|
40989328|NCT02988791|DIETARY_SUPPLEMENT|probiotic (BIfidobacterium, BB-12®)|probiotic (Bifidobacterium, BB-12®)
40989329|NCT02988791|DIETARY_SUPPLEMENT|Placebo|Placebo
41465497|NCT03877926|BIOLOGICAL|AV7909|AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.
40989330|NCT01992861|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
40989331|NCT01992861|PROCEDURE|Diffusion Weighted Imaging|Undergo DW MRI
40989332|NCT01992861|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
40989333|NCT01992861|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
40989334|NCT01992861|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
40989335|NCT01992861|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
40989336|NCT01701843|DRUG|Cromoglicate|Twice daily topical treatment for 14 days
40989337|NCT01701843|DRUG|Placebo|Twice daily topical treatment for 14 days
40989338|NCT00963287|DRUG|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
40989339|NCT01531712|DRUG|Gemcitabine|1000mg/m2 / / 40mg/m2
40989340|NCT01531712|RADIATION|Radiotherapy|50.4 Gy
41465498|NCT03877926|BIOLOGICAL|BioThrax|BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.
41465499|NCT05123781|DRUG|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the test product was administered orally with 240 ml of water
40785056|NCT03122938|DIETARY_SUPPLEMENT|lactoferrin-supplemented formula|Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
40989341|NCT01531712|DRUG|Tarceva|100mg/day
40989342|NCT01531712|DRUG|Oxaliplatin|100mg/m2 (only in QT)
40989343|NCT02116244|DRUG|Civamide Nasal Spray|
40989344|NCT03139149|PROCEDURE|Adhesiolysis|"Method of video laparoscopic operation:~* Open access in the left upper quadrant of the anterior abdominal wall,~* Installation of trocars, depending on the prevalence of the adhesion process~* Assessment of the peritoneal adhesion index~* Detection of the asleep gut~* Detection of obstacle area~* Removing the obstacle without trying to completely eliminate the adhesion process in the abdominal cavity~If there is no possibility to eliminate the cause of intestinal obstruction laparoscopically laparotomy is performed."
40989345|NCT03139149|RADIATION|X-ray diagnostics|X-ray of the thoracic (1) and abdomen (2-5 times) with water soluble contrast.
40989346|NCT03139149|RADIATION|Computer tomography|Computer tomography of abdomen with iv contrast
40989347|NCT03139149|PROCEDURE|Ultrasound|Ultrasound of the abdomen (2 times)
40989348|NCT03139149|OTHER|General and biochemical blood test|General blood test and biochemical blood test 2 times a day
40989349|NCT02884596|DRUG|selective serotonin reuptake inhibitor|Taking any type of SSRI medicaments
40989350|NCT03899376|RADIATION|Volumetric modulated arc therapy|VMAT therapy focuses on reducing the dose radiation in adjacent organs at risk
40989351|NCT03899376|RADIATION|conventional radiotherapy|Radiotherapy focus on pelvis area
40989352|NCT04309643|DRUG|CTP-543|Investigational Drug
40989353|NCT04309643|DRUG|Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)|Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
40989354|NCT04267133|DIAGNOSTIC_TEST|Facial video of detection of cardiac disease|This project proposes to evaluate a non-contact video recording technology to detect the presence of AF. The technology extracts a pulsatile signal by measuring the subtle variations in skin color of a patient's face (flushing) due to the variations of blood volume underneath the skin. The technology uses a standard web camera. This technique is videoplethysmography (VPG).
40989355|NCT01953341|DRUG|AMG 333|Oral administration available in varying dose strength.
40989356|NCT01953341|DRUG|Placebo|Placebo containing no active drug
40989357|NCT02282670|DRUG|DA-5204|
40989358|NCT02282670|DRUG|Stillen tab.|
40989359|NCT02307357|BEHAVIORAL|physical fitness tests|the subjects will perform 6 different tests to evaluate their physical fitness
40785057|NCT03122938|DIETARY_SUPPLEMENT|formula without lactoferrin supplementation|Subjects consume formula without lactoferrin supplementation (\<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
40785058|NCT03984721|DIAGNOSTIC_TEST|Amyloidosis typing using mass spectrometry-based proteomics|Amyloidosis typing using nanoLC-MS/MS method
40785059|NCT00948688|RADIATION|Radiation therapy|Once per day, 5 days a week for 6 weeks
40989360|NCT03103607|DIAGNOSTIC_TEST|Ophthalmological evaluation|exophthalmometry, evaluation of the Clinical Activity Score (CAS), assessment of diplopia, measurement of visual acuity, assessment of the corneal status; examination of the fundi
41465500|NCT05123781|DRUG|Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orally with 240 ml of water
40989361|NCT03103607|DIAGNOSTIC_TEST|Questionnaire|Patients were asked to fill a questionnaire on self-perception related to GO with the following questions: i) are your eyes identical to the way they were before GO appeared?; ii) are your eyes normal? iii) do you have any limitations in daily activities related to your eyes?; iv) do you have any limitations in social life related to your eyes?
40989362|NCT02775734|DRUG|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
40989363|NCT02775734|DRUG|Clomiphene citrate|Clomiphene citrate + Laparoscopic ovarian drilling
40989364|NCT02004028|DRUG|VS-6063|
40989365|NCT02982967|OTHER|Physical Activity|Recreational Physical Activity (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
41307059|NCT03005977|PROCEDURE|Urodynamics|UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.
41465501|NCT01594034|PROCEDURE|expired air|collection of expired air from ventilator
41465502|NCT00333853|DEVICE|OneTouch(r) UltraSmart(r)|
41465503|NCT02633878|DRUG|Chinese Herbal Medicine plus Oral Micronized Progesterone|Chinese Herbal Medicine (1 pack 2 times a day) + Oral Micronized Progesterone (100 mg three times a day)
40785060|NCT00948688|DRUG|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
40785061|NCT00948688|DRUG|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
40785062|NCT03161210|OTHER|Dextrose Prolotherapy|Dextrose is a solution, mixture of dextrose and water.
40989366|NCT00644280|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
40989367|NCT04996849|OTHER|Data Capture|Data collected
40989368|NCT04996849|OTHER|Questionnaire Administration|Ancillary studies
40989369|NCT05584644|DRUG|Palbociclib plus hormonal treatment - first line treatment|Palbociclib plus hormonal treatment
41465504|NCT02633878|DRUG|Chinese Herbal Medicine plus Oral Micronized Progesterone Placebo|Chinese Herbal Medicine (1 pack 2 times a day) + Oral Micronized Progesterone Placebo (100 mg three times a day)
40785063|NCT03161210|OTHER|Local Anaesthesia|A local anaesthetic is a medication that causes reversible absence of pain sensation
40785064|NCT03161210|OTHER|Saline|Saline is a control group
40785065|NCT04796038|DEVICE|Balloon dilatation|Patient will be treated with balloon dilatation either stand-alone (POBA) or followed by stent implantation.
41465505|NCT02633878|DRUG|Chinese Herbal Medicine Placebo plus Oral Micronized Progesterone|Chinese Herbal Medicine Placebo (1 pack 2 times a day) + Oral Micronized Progesterone (100 mg three times a day)
41465506|NCT02633878|DRUG|Chinese Herbal Medicine Placebo plus Oral Micronized Progesterone Placebo|Chinese Herbal Medicine Placebo (1 pack 2 times a day) + Oral Micronized Progesterone Placebo (100 mg three times a day)
40785066|NCT01949129|DRUG|VP16|60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
40785067|NCT01949129|RADIATION|TBI|2 x 2Gy/day , 3 days (total 12Gy)
40785068|NCT01949129|DRUG|Thiotepa|2x5 mg/kg BW, 1 day
40785069|NCT01949129|DRUG|Treosulfan|14g/m² BS, 3 days
40785070|NCT01949129|DRUG|Fludarabine|30 mg/m² BS, 5 days
40785071|NCT01949129|DRUG|Busulfan|iV, dosage according therapeutic drug monitoring, 4 days
40785072|NCT01949129|DRUG|ATG Thymoglobulin|MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
40785073|NCT01949129|DRUG|Cyclophosphamide|as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
40785074|NCT01949129|DRUG|Grafalon|MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
40989370|NCT05584644|DRUG|Palbociclib plus hormonal treatment - second line treatment|Palbociclib plus hormonal treatment
40989371|NCT00845169|PROCEDURE|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
40989372|NCT00775931|PROCEDURE|umbilical cord blood transplantation|Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
40989373|NCT00775931|DRUG|Campath-1H|Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
40989374|NCT00775931|RADIATION|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
40989375|NCT00775931|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
40989376|NCT00775931|DRUG|Busulfan|patients\<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
40989377|NCT00775931|DRUG|Fludarabine monophosphate|Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
40989378|NCT00775931|PROCEDURE|marrow graft transplantation|Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
40989379|NCT00853723|DRUG|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
40989380|NCT00853723|DRUG|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
40989381|NCT00853723|DRUG|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
40989382|NCT02007876|BEHAVIORAL|Mobility and Activity Training|"Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.~Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2."
40989383|NCT00703612|PROCEDURE|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
40989384|NCT02635828|DRUG|Palonosetron 0.075 mg IV|At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
40989385|NCT02635828|DRUG|Dexamethasone 10 mg IV|At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
40785075|NCT04691921|BEHAVIORAL|Current clinical practices of participating physicians|Current clinical practice of participating physicians on choice of pharmacological agents for clinical management of Severe COVID-19
40785076|NCT02112643|DRUG|Sodium selenate|A 100 microgram pill will be orally administered twice a day for 6 months.
40785077|NCT02112643|DIETARY_SUPPLEMENT|Sugar pill|The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
40785078|NCT03314610|OTHER|Gait speed|No intervention, only propose water and wait for need to void
40785079|NCT03914989|OTHER|olfactory enrichment (essential oils)|Participants will be exposed to either a higher or lower concentration of essential oils nightly for two hours as they are going to sleep, using a nebulizing fragrance diffuser, rotating through seven different scents, one per night.
40785080|NCT05196750|OTHER|Behavioural questionnaires and assessments on mother and child|Questionnaires include, but not limited to, State Trait Anxiety Inventory, Beck Depression Inventory, LYNDON Maternal Health and Well Being, Facial Imitation Task, Deferred Imitation, Habituation, Relational Binding, Behavioural Observation, Mirror Self Recognition, Standardized Assessment and Experimental Task, Snack and Sticker Delay, Implicit Attitude Test
40785081|NCT05752656|OTHER|Clinical examinations|Clinical examinations and administration of clinical scales
40785082|NCT05772325|OTHER|Individually tailored diet counseling|Participants in the intervention group will receive a 60 min individually tailored heart-friendly diet consultation by a dietitian
40785083|NCT05772325|OTHER|The brief standardized 4-minute heart healthy dietary advice|The brief standardized 4-minute heart healthy dietary advice will be provided by an experienced cardiologist or rheumatologists
40785084|NCT01903005|DRUG|Higher bioavailability BNX sublingual tablets|Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
40785085|NCT04552002|DIETARY_SUPPLEMENT|Synbiotic group|Probiotics and prebiotics
40989386|NCT02635828|DRUG|Promethazine 25 mg IV|At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
41307060|NCT05311280|OTHER|high intensity interval training plus myotherapy|"High intensity interval training (HIIT) has been proved its same effect on lower down body fat as moderate intensity continuous training (MICT). In addition, HIIT has the additional benefit of being a time-efficient program which can increase exercise adherence and the participants were more likely to intend to continue. Previous two studies show that HIIT could improve the severity of OSA in both obese adults and obese children.~Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas."
41307061|NCT05311280|OTHER|home exercise plus myotherapy|Home exercise: ambulation by patients themselves Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas.
41307062|NCT06430047|DRUG|EsoDuo® Tablet|QD, PO
41307063|NCT00884182|BIOLOGICAL|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
41307064|NCT04628403|OTHER|massage|clinical interventions, of mechanophysiological origin for the treatment of symptoms corresponding to DOMS, after exercise
40989387|NCT05404919|DRUG|Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide|Anti-hepatitis B medications
40989388|NCT03811431|PROCEDURE|Contrast enhanced ultrasound guided liver biopsy|Conventional liver biopsy
41307065|NCT04628403|DEVICE|lasertherapy|lasertherapy
41307066|NCT04628403|DEVICE|shock waves|shock waves
41307067|NCT06454604|BEHAVIORAL|Meta Quest 3 VR Headset with noise cancelling headphones|Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.
41307068|NCT05740449|DRUG|Decitabine|intravenous
41307069|NCT05740449|DRUG|Venetoclax|oral
40785086|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product A
40785087|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product B
41146339|NCT04577391|OTHER|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the involved side's use, and unimanual gross and fine motor activities were practiced with the more affected hand. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to the deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating).
40785088|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product C
40785089|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Spiriva 18 Mcg/capsule inhaled via HandiHaler
40785090|NCT02332187|DEVICE|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
40785091|NCT02332187|DEVICE|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
40785092|NCT00917319|OTHER|Bundling Infection Control Interventions|identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
41307070|NCT05740449|DRUG|Navitoclax|oral
41307071|NCT05740449|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
41307072|NCT02351245|OTHER|observation|
41307073|NCT03836976|OTHER|Auditory gamma sensory stimulation|"Gamma-conditioning stimulation will be~administered in 2 blocks of 3 min each. During each block, participants will be presented with a continuous~tone at the CF (500 or 1200 Hz) that will be amplitude modulated at 40 H"
41307074|NCT04426825|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
41307075|NCT04426825|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
41307076|NCT03657368|PROCEDURE|Low tidal Volume|Tidal volume = 6 ml/kg predicted body weight
41307077|NCT03657368|PROCEDURE|High tidal Volume|Tidal volume = 10 ml/kg predicted body weight
41465507|NCT00049296|DRUG|docetaxel|"Patients receive docetaxel IV over 30 minutes once weekly. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
40785093|NCT02112305|DRUG|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) NB on three occasional at 20 minutes interval
40785094|NCT02112305|DRUG|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
40785095|NCT02070497|OTHER|case management|case management group will accept the case manager's service; the control group will just accept the routine care
41307078|NCT03657368|PROCEDURE|Low PEEP|PEEP = 5 cm H2O
41307079|NCT03657368|PROCEDURE|High PEEP|PEEP = 8 cm H2O
40785096|NCT05486390|BEHAVIORAL|Nudge, health coaching and shared decision-making|"The EMPOWER app aims to nudge the participant towards successful self-management of their diabetes condition by encouraging and reinforcing positive lifestyle behaviors in 3 main aspects - diet, physical activity, medication adherence. Notifications included content based on behavioural change technique including feedback on performance, positive reinforcement, and prompts to self-monitor. Each notification focused on a single behaviour (physical activity, medication adherence or diet).~The participants in the intervention group will also interact with health coach throughout the study duration. In this study, the health coach will be responsible for the following roles :~1. Goal setting and action plan~2. After-visit summary~A report card summarizing the lifestyle behaviour, goals will be made available to facilitate shared decision making."
40785097|NCT00050583|BEHAVIORAL|Cognitive Behavioral Therapy|Ten Weekly Sessions of Manualized CBT
40989389|NCT04335279|OTHER|SPIN-CHAT Program|Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.
40785098|NCT00050583|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
40785099|NCT05157087|DRUG|Omalizumab|"Omalizumab use was analyzed in two categories. First, initiators were defined as individuals with ≥ 1 omalizumab prescription. Responders were defined as individuals with at least 4 administrations of omalizumab."
40785100|NCT00305448|DRUG|Fulvestrant|250 intramuscular injection
40785101|NCT00305448|DRUG|Fulvestrant|500 mg intramuscular injection
40989390|NCT04521465|DEVICE|NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)|Eye drops
40989391|NCT04959942|OTHER|scapular stabilization exercise|In the supine position, the subject will instruct to take a deep breath to relax the body. In croock-lying position, the subject will raise his dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. In the quadruped position, the subject lifts up his arms alternatively with shoulder abduction and 120 ° flexion. In a sitting position with 90° knee flexion on a stool or bed without back support, the subject held a pair of dumbbells (2 kg) in each hand and laterally lifted them up while maintaining the height of scapulae below 80°. Each stage will instruct to be held for 10 seconds before returning to the starting position and three laps of 10 repetitions with a 30-second break in between will perform. In the sitting position, a mirror will place in front of the patient. The subject will instruct to check and correct his posture by him
40989392|NCT04959942|OTHER|postural correction exercise|The program consisted of two strengthening (deep cervical flexors and scapular retractors) and two stretchings: cervical extensors (sub-occipital muscles) and pectoral muscles). The program was based on a program by Harman and Kendall.
40989393|NCT04959942|OTHER|advice|all subjects will be instructed to maintain normal alignment of the cervical vertebry
40989394|NCT05654155|OTHER|auricular acupressure|Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
40989395|NCT01109199|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
40989396|NCT01109199|DIETARY_SUPPLEMENT|Rice flour|The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
40989397|NCT03836196|RADIATION|LDR Brachytherapy and External Beam Radiation Therapy|Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
41307080|NCT05431140|DEVICE|CloudCare|Only eligible subjects to whom CloudCare is introduced as part of their new standard care will be enrolled. Participants will not be subjected to extra procedures on top of their standard of care, except that they will be asked to fill out short questionnaires about their treatment satisfaction and the emotional burden caused by diabetes, which are not standard in the participating study locations.
40785102|NCT04095065|BEHAVIORAL|itMatters|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking.
40989398|NCT05337215|BEHAVIORAL|kangaroo father care|The effect of postpartum kangaroo father care on paternal attachment
40989399|NCT02447081|DEVICE|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
40989400|NCT04814758|DIAGNOSTIC_TEST|MRI DWI sequence (ADC values)|Initially and after pre-operative chemotherapy To evaluate the differences in ADC values according to the malignancy degree of nephroblastoma in children
40989401|NCT06363006|DRUG|TKI+Cardunilimab|Cardonilizumab 6mg/kg, IV, Q2W + lenvatinib 8mg (body weight \< 60kg) or 12mg(body weight ≥60kg) PO, QD, / Sorafenib 400mg, PO, BID/ Regorafenib 160mg, PO, QD/ Donafenib 200mg, PO, BID。 omniscience
40989402|NCT04460547|DRUG|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion to COVID-19 infected patients.
40989403|NCT04460547|DRUG|Hydroxychloroquine|Hydroxychloroquine administration to COVID-19 infected patients.
41307081|NCT00741143|OTHER|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
41307082|NCT03090620|DRUG|Physostigmine|Administration of physostigmine bolus followed by an infusion
40785103|NCT04095065|BEHAVIORAL|itMatters and itMatters Sexual Violence Prevention|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
41465508|NCT00049296|DRUG|thalidomide|"Patients receive oral thalidomide twice daily. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
41146340|NCT04577391|OTHER|Bimanual Training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
41146341|NCT03761979|DIETARY_SUPPLEMENT|Strontium L-lactate|The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.
41146342|NCT03306329|DRUG|DNS-7801 (low-dose)|DNS-7801 (low-dose) tablets administered once daily.
41146343|NCT03306329|DRUG|DNS-7801 (high dose)|DNS-7801 (high dose) tablets administered once daily.
41146344|NCT03306329|DRUG|Placebo|Placebo tablets administered once daily
41146345|NCT01429168|DRUG|Etoricoxib|One 60-mg tablet orally daily
41146346|NCT01429168|DRUG|Placebo for etoricoxib|One 60-mg tablet orally daily
41146347|NCT06261515|PROCEDURE|Active periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets; periodontal surgery if needed (residual probing pocket depths ≥ 6 mm).
41146348|NCT02935478|DEVICE|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embosphere Microspheres beads) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry
41146349|NCT00111865|BEHAVIORAL|Aerobic Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
41146350|NCT05776056|DRUG|Methylphenidate|Methylphenidate 10mg will be taken twice daily.
41307083|NCT03090620|DRUG|Lorazepam|Administration of lorazepam bolus followed by normal saline infusion
41307084|NCT06254352|DIAGNOSTIC_TEST|scoring system|Clinical Risk Scores in Prediction of Outcome of Acute Upper Gastrointestinal Bleeding in Non Cirrhotic Patients.
41465509|NCT02751216|OTHER|EEG recording + pain protocol|
41146351|NCT05776056|DRUG|Placebo|An inactive pill (placebo) will be taken twice daily.
41146352|NCT02640326|OTHER|No Foley Urinary Catheter|No Foley urinary catheter will be put in place during the operation
41146353|NCT02640326|OTHER|Standard of care Foley urinary catheter insertion|A Foley urinary catheter will be put in place during the operation
41146354|NCT04062279|DIAGNOSTIC_TEST|serum alpha synuclein autoantibodies, motor and non motor scales|measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment
41146355|NCT05612113|BEHAVIORAL|Live Supervision + Session Goal Formulation|"Read under Arms"
41307085|NCT00348634|DRUG|Tegaserod|
41465510|NCT02111434|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
41465511|NCT00460109|BIOLOGICAL|denileukin diftitox|
41146356|NCT05612113|OTHER|Session Goal Formulation|"Read under Arms"
41146357|NCT02033343|RADIATION|Prostate cancer radiotherapy using real-time tracking|Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
41146358|NCT01317914|OTHER|Dietary instruction|Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
41307086|NCT05989490|OTHER|Static stretching|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort and to the point of pain.
41307087|NCT06447116|DEVICE|CGuard Prime™ Carotid Stent System|CGuard Prime™ Carotid Stent System
41307088|NCT02686606|DIETARY_SUPPLEMENT|Vital 1.5|Oral nutritional supplement
41307089|NCT02686606|DIETARY_SUPPLEMENT|Ensure Plus|Oral nutritional supplement
41465512|NCT00460109|BIOLOGICAL|rituximab|
41465513|NCT05958381|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
41465514|NCT05958381|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
41465515|NCT03537911|BEHAVIORAL|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
41465516|NCT03818295|DRUG|[14C]-praliciguat|10 mg praliciguat containing approximately 500 μCi of \[14C\]-praliciguat
40989404|NCT04460547|DRUG|DAS181|DAS181 administration to COVID-19 infected patients.
40989405|NCT04460547|DRUG|Ivermectin|Ivermectin administration to COVID-19 infected patients.
41307090|NCT05803889|OTHER|Cardiac evaluation|In order to obtain information on the body composition of the patients, a body composition measurement will be performed. A resting cardiac echocardiography will be performed to record myocardial deformations in a non-vulnerable way. A non-invasive evaluation of arterial function will be performed by ultrasound on the femoral artery during a standardized passive movement of the leg. An assessment of myocardial deformations will also be performed under submaximal exercise conditions (at a target heart rate of 120 beats per minute, low to moderate exercise intensity). All of these measurements will be performed during evaluation 1 and reproduced in the same way during the 4 other sessions planned during (evaluation 2, 3 and 4) and after the treatment (evaluation 5).
40989406|NCT04460547|DRUG|Interferon Beta-1A|Interferon Beta-1A administration to COVID-19 infected patients.
40989407|NCT06431854|BEHAVIORAL|ED-MINERVA Program|ED-MINERVA Program aims to improve ED symptoms and related difficulties of the patient and provide tools to enhance the family's management (nutritionally, emotionally, and behaviorally) in their natural environment. The treatment consists of four phases with a gradually decreasing therapeutic intensity, ranging from total hospitalization, family treatment apartment, to home treatment and subsequent linkage with specialized local facilities. The ED-MINERVA program uses various aspects of family-based treatment, cognitive behavioral therapy, dialectical behavioral therapy, and systemic family therapy.
41146359|NCT06518811|OTHER|Video-Based Exercise Programme|The asynchronous video-based telerehabilitation programme had a duration of eight weeks. The participants were instructed to perform the exercises on a regular basis, three days a week, with a time interval of 24 hours between each session. The exercises were to be performed using the instructional videos and recorded in the exercise diaries provided. The participants were used exercise balls and resistance bands distributed by the researchers according to exercise programme.
41307091|NCT05803889|OTHER|Cardiac evaluation|The same measurements as the EC + Tax group will be performed but only once, at the end of the treatment.
41307092|NCT01750398|DRUG|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
41465517|NCT01109017|DRUG|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
40785104|NCT04095065|BEHAVIORAL|itMatters Well-being and itMatters Sexual Violence Prevention|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
40785105|NCT04095065|BEHAVIORAL|itMatters Well-being|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
41146360|NCT00001998|DRUG|Nystatin|
41465518|NCT00557245|DRUG|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
40785106|NCT01093313|BEHAVIORAL|Cognitive therapy|
40785107|NCT01093313|BEHAVIORAL|attention training|
40989408|NCT03439020|PROCEDURE|Plastic stent anchoring|Insert an additional plastic stent to anchor the fully covered self expandable metal stent.
41146361|NCT02011789|DIETARY_SUPPLEMENT|Citrus Limonoid Beverage|The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
41146362|NCT02011789|DIETARY_SUPPLEMENT|Placebo beverage|The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
41307093|NCT01750398|DRUG|Goserelin|"Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist."
41465519|NCT00557245|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
41465520|NCT00557245|DRUG|Placebo|Placebo TDF \& Placebo FTC/TDF, 1 tablet each daily.
41465521|NCT03945058|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks
41465522|NCT03945058|DEVICE|SHAM|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
40989409|NCT03439020|PROCEDURE|FCSEMS|Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
40989410|NCT03816085|OTHER|Shoes|Shoes with different heel heights
40989411|NCT00293696|DRUG|bicalutamide (Casodex), goserelin (Zoladex)|
40785108|NCT00733486|DEVICE|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
40989412|NCT05516342|BEHAVIORAL|LEAD IT! Programming|LEAD IT! is an intervention that enables persons with dementia to lead activities for their peers. The activities take place on tablets.
41307094|NCT01750398|DRUG|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
41307095|NCT02640846|DRUG|Norepinephrine|Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
40785109|NCT00180037|DRUG|Coenzyme Q10 Nanodispersion (Nanoquinone)|
40785110|NCT00180037|DRUG|Placebo|
40785111|NCT01836289|DRUG|High-dose Cyclophosphamide|
40785112|NCT02971319|DEVICE|Tc-99M-Tetrofosmin SPECT|
40785113|NCT02971319|DEVICE|F-18 FDG PET|
40785114|NCT06351826|OTHER|ELLASI|A structured intervention for polytrauma patients
40785115|NCT06351826|OTHER|Standard|Unstructured interventions that are given in everyday practice (standard intervention)
40785116|NCT01745588|DRUG|Pomalidomide|
40785117|NCT01745588|PROCEDURE|stem cell|
40785118|NCT01745588|DRUG|Dexamethasone|
40785119|NCT01745588|DRUG|Clarithromycin|
40785120|NCT01716364|BIOLOGICAL|Anti-LeY- scFv-CD28-ζ vector,.|
40989413|NCT01312818|DRUG|Bortezomib|1.3 mg/m\^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
40989414|NCT01312818|DRUG|Vorinostat|180 mg/m\^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
40989415|NCT01312818|DRUG|Dexamethasone|6 mg/m\^2 by mouth (PO) divided twice a day (BID) on days 4-15.
40989416|NCT01312818|DRUG|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
40989417|NCT01312818|DRUG|Imatinib mesylate|"For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for \>18 years on Days 1-16."
40989418|NCT05254457|BIOLOGICAL|EN3835|Treatment or retreatment with up to two doses of EN3835
40989419|NCT03980457|DEVICE|Indego Exoskeleton|Powered generated orthosis
40989420|NCT03980457|OTHER|Standard Rehabilitation|Standard Rehabilitation
40989421|NCT01239706|DRUG|NTx 265|10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
41307096|NCT02640846|DRUG|Milrinone|Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
40785121|NCT05572879|BIOLOGICAL|EuCorVac-19|COVID-19 vaccine
40785122|NCT05572879|BIOLOGICAL|ChAdOx1 nCoV-19|COVID-19 vaccine
40989422|NCT04385823|DEVICE|patients receiving nasal high flow|patients admitted to the ICU for Covid-19-related acute hypoxemic respiratory failure treated with nasal high flow
40989423|NCT01374087|DRUG|Triptorelin 22.5 mg|Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
40989424|NCT01374087|RADIATION|Brachytherapy|Brachytherapy: Low or high dose rate.
41307097|NCT02640846|DRUG|Levosimendan|Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
41307098|NCT05806047|DRUG|chidamide combined with fulvestrant|chidamide combined with fulvestrant
41307099|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (3mg/kg IV)|3/1 (6/2 if DLT)
41307100|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (10mg/kg IV)|3/1 (6/2 if DLT)
41307101|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (30mg/kg IV)|3/1 (6/2 if DLT)
41307102|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)|3/1 (6/2 if DLT)
41307103|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)|3/1 (6/2 if DLT);
40785123|NCT01244711|DRUG|quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
40785124|NCT06270238|DEVICE|High-Frequency1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
40785125|NCT06270238|DEVICE|cTBS1|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
40785126|NCT06270238|DEVICE|High-Frequency2|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral premotor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
41307104|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)|3/1 (6/2 if DLT)
41307105|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)|3 (max 9)
40785127|NCT06270238|DEVICE|cTBS2|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
40785128|NCT06270238|DEVICE|High-Frequency3|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
40785129|NCT06270238|DEVICE|cTBS3|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
40785130|NCT04838184|DEVICE|Dental Implants (Straumann Roxolid® / SLActive®)|"In this study the 4 mm implants will be inserted in the area surrounding 36/46. The implant diameters will be defined based on the patient's situation.~In the interforaminal region, two implants of conventional length with a minimum of 10 mm will be inserted. The implant diameter and the length will be defined based on the patient's situation."
40785131|NCT05043948|DIAGNOSTIC_TEST|Blood samples|for evaluation of the genome-wide association study
40785132|NCT04418895|OTHER|Chemoradiation|Subjects will receive neoadjuvant chemoradiation per standard of care. This is typically comprised of radiotherapy of 5040 cGy (centigray) with concurrent capecitabine 825 mg/m2 by mouth (po) two times daily (bid) (typically rounded to the nearest 500 mg dose) or infusional 5-fluorouracil (5FU). However, dosing and administration are at the discretion of the treating medical and radiation oncologist.
40785133|NCT04418895|RADIATION|short course radiation therapy|An acceptable alternative approach is short-course radiation therapy per standard of care, which is typically comprised of radiotherapy of 25 Gy (gray) in 5 fractions, with surgery within 1 week of completion of therapy or delayed for 6-8 weeks. Selection of the optimal radiation therapy approach is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist. However, generally, short-course radiation therapy is not recommended for low-lying tumors less than 5 centimeters (cm) from the anal verge.
40989425|NCT03348345|BEHAVIORAL|Eat Breathe Thrive|Eat Breathe Thrive (EBT) program which was designed to increase positive body image, awareness, self-regulation, and mindful eating habits. This program aims to achieve these things through psychoeducation of cultural influences of beauty standards, the basic neuropsychological systems in the body and how they affect eating habits, creating a community within the group members for support, and finally through the practice of yoga.
40989426|NCT05575063|DEVICE|Investigational Healon Endocoat|Ophthalmic Viscoelastic device
40989427|NCT05575063|DEVICE|Control Healon EndoCoat|Ophthalmic Viscoelastic device
40989428|NCT03204981|DEVICE|Intramural Needle Ablation|The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.
41146363|NCT04099576|OTHER|physiotherapy and education|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program. In addition to physiotherapy, therapeutic neuroscience education were applied to experimental group. One-to-one speech sessions focusing on pain neurophysiology were organized twice a week for three weeks. Each session lasted 40 minutes. The Therapeutic neuroscience education program included nociception, ion channel neurophysiology, central and peripheral sensitization, methods to help reduce sensitization, neuroplasticity, psychosocial factors involved in the transition from acute pain to chronic pain and behavioral, cognitive responses to pain.
41146364|NCT04099576|OTHER|Physiotherapy alone|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program.
40785134|NCT04418895|DRUG|mFOLFOX6|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
40785135|NCT04418895|DRUG|CAPOX|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
40989429|NCT03204981|PROCEDURE|Ablation|standard ablation
41146365|NCT05398484|DRUG|Psilocybin 25 mgs|One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.
41146366|NCT05398484|DRUG|Niacin 100mg|One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.
41146367|NCT05398484|BEHAVIORAL|Psychotherapy|The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
41146368|NCT00157209|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
41146369|NCT00157209|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
41307106|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121 (MTD IV)|3 (max 9)
40785136|NCT04418895|DRUG|fluoropyrimidine +/- oxaliplatin|possible adjuvant chemotherapy regimen. Subjects who do not receive preoperative mFOLFOX6 or CAPOX typically receive postoperative adjuvant chemotherapy with a fluoropyrimidine +/- oxaliplatin for an additional 16-18 weeks of therapy, if permitted based on recovery after surgical resection and post-surgical performance status. This treatment is at the discretion of the treating medical oncologist. Subjects will remain on study regardless of postoperative therapy administration or duration.
40785137|NCT00419692|DRUG|Ropinirole|Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.
40785138|NCT03960879|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
40785139|NCT03960879|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cervical cytology
40989430|NCT02424383|DEVICE|PTA (Lutonix® 035 DCB Catheter)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The Lutonix® DCB through the blood vessel to the narrowed area to be treated."
40989431|NCT05735392|OTHER|Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.|Both blood and tissues will be obtained duringT-DM1 treatment of enrolled patients at the participating Sites at the study specific timelines.
40989432|NCT04927390|DRUG|Mycophenolate Mofetil 500mg|Mycophenolate Mofetil oral tablet twice daily for up to 96 weeks
40989433|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Cathodal stimulation|Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
40989434|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Anodal stimulation|Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
41146370|NCT00157209|OTHER|Best Supportive Care (BSC)|The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
41307107|NCT02724774|BEHAVIORAL|Promoting First Relationships®|"PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting."
41465523|NCT01620281|DEVICE|no!no!Back|Self treatments daily for 3 weeks, in up to three 10-minutes sessions
40785140|NCT03960879|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
40785141|NCT00495703|BEHAVIORAL|Exercise|6-months of regular aerobic exercise
40785142|NCT00495703|BEHAVIORAL|Usual Care|6-months of behavioral strategies to aid memory/cognition
40785143|NCT00436436|DRUG|O6-benzylguanine|
40785144|NCT00436436|DRUG|temozolomide|
40785145|NCT01550601|PROCEDURE|bariatric surgery|The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
40989435|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Sham stimulation|Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
40989436|NCT00040937|BIOLOGICAL|filgrastim|PBSC collection: 10 mcg/kg SQ days 1-10
40989437|NCT00040937|BIOLOGICAL|sargramostim|"PBSC collection: 500 mcg/m2 SQ day 1 through last apheresis~1st and 2nd trans: 500 mcg SC or IV days 6-WBC recovery"
40989438|NCT00040937|DRUG|cyclophosphamide|PBSC collection: 1 mg/m2 IV over 45-60 mins day 0
40989439|NCT00040937|DRUG|dexamethasone|40 mg/d PO days 1-4, 9-12, 17-20
40989440|NCT00040937|DRUG|melphalan|"1. st trans: 140 mg/m2 IV over 20 mins day -1~2. nd trans: 200mg/m2 IV over 20 mins day -1"
40989441|NCT00040937|DRUG|prednisone|maint: 50 mg/d PO every other day until progression
40989442|NCT00040937|DRUG|thalidomide|ind: 50 mg increased by 50 mg every week to max 400 mg PO qhs for 35 days maint: 50 mg/d increased by 50 mg every week to 200 mg PO daily until progression
40989443|NCT00040937|PROCEDURE|peripheral blood stem cell transplantation|2-4 x 10\^6/kg IV day 0
40989444|NCT05190380|OTHER|HIGH INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
41146371|NCT00390806|DRUG|HYCAMTIN, oral capsules|topotecan oral capsules 1.1 mg/m2
41146372|NCT00390806|RADIATION|Radiation|Whole brain radiation
40785146|NCT01848093|OTHER|sputum collection|collecting of spontaneous sputum from the patient
40989445|NCT05190380|OTHER|LOW INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
40989446|NCT02197507|DEVICE|Digitized sensor|Measure of grip strength of the dominant hand
41307108|NCT05796453|DEVICE|Clareon Vivity IOL - Non Toric|Spherical extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
41307109|NCT05796453|DEVICE|Clareon Vivity IOL - Toric|Toric extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
41307110|NCT05796453|DEVICE|Clareon PanOptix Trifocal IOL - Non Toric|Spherical trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
41307111|NCT05796453|DEVICE|Clareon PanOptix Trifocal IOL - Toric|Toric trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
40989447|NCT00091273|BIOLOGICAL|incomplete Freund's adjuvant|
40989448|NCT00091273|BIOLOGICAL|ovarian cancer peptide vaccine|
41146373|NCT02788708|DRUG|Lenvatinib Mesylate|Given PO
41307112|NCT06323915|DEVICE|intraocular lens implantation in cataract surgery|Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
40785147|NCT04568603|DRUG|Islatravir|ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
40785148|NCT04005586|DEVICE|Light Delivery Device (LDD)|Study eye will undergo Light delivery Device treatments
40785149|NCT01948479|DEVICE|Optimised instant offloading insole|
40785150|NCT04677998|PROCEDURE|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 3-6 months and 5 years, depending on severity of polyposis and performed endoscopic interventions.
40989449|NCT00091273|BIOLOGICAL|sargramostim|
40989450|NCT00091273|BIOLOGICAL|tetanus toxoid helper peptide|
40989451|NCT00091273|PROCEDURE|adjuvant therapy|
41146374|NCT02788708|DRUG|Paclitaxel|Given IV
41146375|NCT02788708|OTHER|Pharmacological Study|Correlative studies
41307113|NCT02340819|DRUG|Teduglutide|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
41307114|NCT02774226|DRUG|Tetrahydrobiopterin (BH4)|12 week intervention
41307115|NCT02774226|DIETARY_SUPPLEMENT|Antioxidant Cocktail|12 week intervention
41307116|NCT00119301|DRUG|leucovorin calcium|
41307117|NCT00119301|DRUG|methotrexate|
41307118|NCT00119301|DRUG|trimetrexate glucuronate|
41307119|NCT04972344|DIAGNOSTIC_TEST|Ionized magnesium|Assessment of ionized magnesium level
41307120|NCT05822895|DEVICE|CADe enabled programme (GI Genius)|CADe enabled programme (GI Genius)
41146376|NCT04889820|DRUG|Neoadjuvant chemotherapy|In this study, patients with obstructive colon cancer will be divided into two groups; in the control group, curative surgery will be performed within 2 weeks after successful SEMS placement, and in the experimental group, 3 cycles of neoadjuvant chemotherapy will be administered into patients who undergo successful SEMS placement and then curative surgery will be performed after neoadjuvnat chemotherapy. After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
41307121|NCT05291949|DEVICE|ATLASense RAPHAEL PolyMonitor|All patients will be monitored using the ATLASense RAPHAEL PolyMonitor during their surgery.
41307122|NCT01686022|OTHER|Immunoblot|serum specific IgE binds to grass extract by immunoblot
41307123|NCT01175967|OTHER|Palliative Performance Scale version 2 (PPSv2)|PPSv2 is arrayed on a scaled from 10 (bedbound) to 100 (full ambulation) at 10 points increment. It will be administered beginning at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
41307124|NCT01175967|OTHER|McCorkle Symptom Distress Scale (SDS)|A 13-item scale of SDS is used to indicate the degree of distress for a given symptom on a 5 point Likert Scale, ranging from 1 (least amount of distress) to 5 (extreme distress). This will be administered at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
41307125|NCT01175967|OTHER|Geriatric Assessment|This will evaluate the subject's overall geriatric status. The first part will be filled out by the study team and the second half of the assessment will be populated with information provided by the subject. This will be completed at baseline, 2 weeks post-surgery and 14-21 days after completing cycle 3 and cycle 6.
41307126|NCT01175967|OTHER|Medical Records Abstraction|Data collected from medical records will include information on surgical complications and chemotherapy toxicities, dose reductions, and any change in choice of chemotherapy drug. This will occur continuously throughout the study.
41307127|NCT01463904|PROCEDURE|SADI-S 250|Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
41307128|NCT01661361|PROCEDURE|blood levels|
41307129|NCT04664595|DRUG|Propofol Fresenius|final dose of Propofol (mcg/kg) to reach the target effect-site concentration
41307130|NCT04392102|DRUG|ZL-2306(Niraparib）|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
41307131|NCT02968043|OTHER|physiotherapeutic scoliosis specific exercises|Physiotherapeutic scoliosis specific exercises (PSSE) is recommended as a first step in the treatment of AIS to halt curve progression by SOSORT guidelines. The PSSE program will be personalized according to the subject's curves characteristics. The program includes patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living. A physiatrist will give a detailed explanation of the aims, importance, methods, and procedure of an intervention to patients and their parents. Each subject will receive guidance from multiple physiotherapists to ensure that the treatment effects are the result of the protocol and not any particular physiotherapists.
41307132|NCT02968043|OTHER|generalised physiotherapy exercises|Generalised physiotherapy exercises includes stretching and strengthening activities. Little evidence is in favor of generalised physiotherapy exercises. Each subject will receive guidance from multiple physiotherapists.
41307133|NCT01251276|BIOLOGICAL|Modified Process Hepatitis B Vaccine|Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
41307134|NCT04591912|BEHAVIORAL|mind. body. voice|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
41307135|NCT00024076|PROCEDURE|radiofrequency ablation|
41307136|NCT02150473|DRUG|Adalimumab|adalimumab 40 mg every other week in combination with MTX for 24 weeks
41307137|NCT02150473|DRUG|Placebo|Placebo the same amount as adalimumab
41307138|NCT02592629|DRUG|lidocaine|used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
41307139|NCT02592629|DRUG|ethyl chloride|topical spray
41307140|NCT02592629|DRUG|Kenalog|used with lidocaine in shoulder injection
41307141|NCT03840668|DEVICE|USB Eye Mask|To evaluate the acceptance of the USB eye mask via questionnaire and also to monitor the use of USB eye mask over a period of 2 months.
41307142|NCT02143362|DRUG|Anesthesia induction,propofol, remifentanil ,cisatracurium|"1. Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.~2. Intermittent injection cisatracurium (0.15mg/kg).~3. A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60."
41307143|NCT02143362|DRUG|Anesthesia maintenance , propofol,remifentanil,cisatracurium|"1. Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~2. Target Controlled Infusion remifentanil , targeted plasma concentrations are 3\~6ng/ml ,maintain heart rate to 60\~100 beats per minute and mean blood pressure to 70\~105 mmHg.~3. Intermittent injection cisatracurium (0.05mg/kg)."
41307144|NCT02143362|PROCEDURE|Awaken test|"1. Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.~2. In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .~3. Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.~4. Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .~5. Patients will receive initial anesthesia after finish awaken test."
41465524|NCT00209547|DRUG|fospropofol disodium|
41307145|NCT02939924|DEVICE|Kanshas DCB|The appropriate Kanshas DCB size is selected after review of the patient's baseline angiogram and determination of the reference vessel diameter and lesion length. The balloons is sized to ensure the full length of the lesion is treated. The initial inflation of the study device should be approximately 1 minute for optimal drug release. In order to optimize lesion dilatation, longer inflation times are possible at the discretion of the operator.
41465525|NCT02458391|OTHER|Standard of care complete decongestive therapy|Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
41465526|NCT04934995|OTHER|Blood Pressure Cuff|"After obtaining consent and confirming eligibility, Blood Pressure cuffs will be used as specified below:~Cuff size: large BP cuffs will be the default size for both arm and ankle measurements, but can be changed as clinically indicated based on circumferences of limbs Cuff location: BP cuffs will be placed on the contralateral arm to the main peripheral IV following standard procedures. Left ankle cuff will be placed underneath intermittent pneumatic compression cuffs Ankle blood pressure monitor screen will be covered. Thus, anesthesia providers will not be able to make any clinical decisions based on ankle blood pressures but arm blood pressure (standard) instead."
41465527|NCT02223286|DIAGNOSTIC_TEST|Corus CAD|Age/Sex/Gene Expression Score
41465528|NCT02988271|OTHER|Interview|Participate in interview
41465529|NCT02988271|PROCEDURE|Meditation Therapy|Complete meditation therapy
41465530|NCT02988271|PROCEDURE|Quality-of-Life Assessment|Complete questionnaires
41465531|NCT02988271|PROCEDURE|Supportive Care|Receive supportive care
41465532|NCT02688387|DRUG|FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose|The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
41465533|NCT02688387|DRUG|Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)|Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.
41465534|NCT00683787|DRUG|docetaxel|Given IV once every 3 weeks
41465535|NCT00683787|DRUG|vandetanib|Oral vandetanib once daily
41465536|NCT03561922|DEVICE|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
41465537|NCT05226741|DEVICE|Head protection device|The participants are fitted with a form of head protection over the craniectomy and provide feedback on design, use, and comfort
41465538|NCT02045355|OTHER|Fish intervention|The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.
41465539|NCT04083443|OTHER|Additional blood sampling|Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
41465540|NCT01398839|DEVICE|VEGA UV-A Illumination System|Only subjects assigned to the treatment group will receive treatment with the UV Light
41465541|NCT01398839|DRUG|Riboflavin|Both treatment and sham groups will receive riboflavin
41465542|NCT05537467|OTHER|Music|Patients randomized to the music group will listen to upbeat music using headphones.
41465543|NCT01657526|BIOLOGICAL|GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)|Administered intramuscularly (IM) in the deltoid region of non-dominant arm
41465544|NCT01657526|BIOLOGICAL|GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)|2 doses administered IM in the deltoid region of non-dominant arm
41465545|NCT01657526|BIOLOGICAL|Saline placebo|2 doses administered IM in the deltoid region of non-dominant arm
41465546|NCT04973098|BIOLOGICAL|CT0181 Cells|5 dose levels each with or without lymphocyte clearance were tentatively determined.
41465547|NCT01257191|DRUG|Carbon Black|source: commercial
41465548|NCT01257191|DRUG|Diesel Exhaust Particles|source: diesel engine
41465549|NCT01257191|DRUG|Fine Concentrated Ambient Particles|source: concentrated ambient air
41307146|NCT01725152|DRUG|Ganaxolone|oral suspension, given in 3 divided doses
41307147|NCT01725152|DRUG|Placebo|oral suspension, given in 3 divided doses
41307148|NCT03168256|DRUG|CF101 2mg|CF101 tablets, 2mg BID for 16 weeks
41307149|NCT03168256|DRUG|CF101 3mg|CF101 tablets, 3mg BID for 16 weeks
41465550|NCT01257191|DRUG|Ultrafine Concentrated Ambient Particles|source: concentrated ambient air
41465551|NCT01257191|DRUG|Saline|Saline solution
41465552|NCT04731493|OTHER|Therapeutic Education Program|"* needs assessment~* educational group workshop~* specialized workshops by age group: child / adolescent / transition / adult / entourage / separated parents and in parallel~* socio-administrative workshop~* individual summary (accompanied or not by his entourage / family)~* satisfaction questionnaire"
41465553|NCT00032916|DRUG|NS2359|
41465554|NCT04091763|DRUG|Polidocanol Injectable Foam|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
41465555|NCT04091763|DEVICE|Rubber band ligation|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
40785151|NCT01060254|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
40785152|NCT01060254|DRUG|JNJ-42160443|Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
40785153|NCT05775302|OTHER|IASTM of Gastrocnemius + Conventional therapy|The SWEEP technique will be performed downwards from the popliteal region to the Achilles tendon for 60 seconds, 30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
40785154|NCT05775302|OTHER|IASTM of AchillesTendon + Conventional Therapy|Participants will receive a maximum of 60 seconds\<30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
40785155|NCT04063917|DEVICE|ZENS|ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.
40785156|NCT00066326|DRUG|imatinib mesylate|
40785157|NCT00066326|DRUG|tanespimycin|
40785158|NCT05174585|BIOLOGICAL|JAB-BX102 (anti-CD73 monoclonal antibody)|Administered by intravenous infusion (IV)
40785159|NCT05174585|BIOLOGICAL|pembrolizumab (anti-PD-1 monoclonal antibody)|Administered by intravenous infusion (IV)
40785160|NCT03420742|DRUG|Midazolam|Midazolam syrup.
40785161|NCT03420742|DRUG|Brigatinib|Brigatinib tablets.
40785162|NCT03479489|OTHER|Human dehydrated amnion chorion allograft|Closed hemorrhoidectomy patched with dehydrated human amnion chorion allograft
40785163|NCT03068897|DRUG|Metaxalone|Metaxalone 400-800mg
40785164|NCT03068897|DRUG|Tizanidine|Tizanidine 2-4mg
40989452|NCT06208059|OTHER|manual acupuncture|In manual acupuncture, the scalp motor area on the lesion side will be needled and left in place for 30 minutes after obtaining qi. During the needle retention, the needles will be twisted intermittently for 2 minutes twice, at a frequency of approximately 200 r/min.
41146377|NCT04889820|DRUG|Adjuvant chemotherapy|After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
41146378|NCT04889820|PROCEDURE|Curative resection|After successful SEMS placement, curate resection will be performed for all enrolled patients regardless of neoadjuvant chemotherapy.
41146379|NCT04992494|BEHAVIORAL|MBCT-Telephone|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via telephone by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
41146380|NCT04992494|BEHAVIORAL|MBCT-Video|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via WebEx video-conferencing by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
41146381|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
41146382|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
41146383|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
41146384|NCT00234832|DRUG|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
40785165|NCT03068897|DRUG|Baclofen|Baclofen 10-20mg
40785166|NCT03068897|DRUG|Ibuprofen 600 mg|Ibuprofen
40785167|NCT03068897|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
40785168|NCT01107067|DRUG|Sustanon|250 mg/21 days
40785169|NCT01749488|OTHER|Designated dietitian for the ward|This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
40785170|NCT05217966|RADIATION|Radiation: Single Pre-Operative Radiation Therapy|Ablative preoperative partial breast radiation therapy
40785171|NCT01452477|DRUG|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
40785172|NCT01452477|DRUG|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
40785173|NCT06104137|OTHER|course (MOOC) patient education|this is a massive open online course created by us for patient education. Patients will be given a login and password to access the MOOC from their own computer. The MOOC has 3.5 hours of content and patients will be given 3 weeks to complete.
40989453|NCT06208059|OTHER|electroacupuncture|In electroacupuncture, the scalp motor area will be needled, and after obtaining qi, the treatment will involve applying electroacupuncture stimulation using a continuous wave with a frequency of 2 Hz. The intensity of the stimulation will be adjusted based on the patient's tolerance, and each treatment session will last for 30 minutes.
41465556|NCT03432091|DRUG|melatonin|Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders
40989454|NCT03420651|OTHER|Peak Expiratory Flow Rate (PEFR)|PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
40989455|NCT03420651|OTHER|Standard Clinical Judgement|Providers will use physical exam and standard clinical judgement to guide management.
41465557|NCT01557686|BEHAVIORAL|Health counseling and exercise|The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.
40989456|NCT02143609|DRUG|oxygen|Nocturnal nasal oxygen during stay at 2048 m
40989457|NCT02143609|DRUG|sham oxygen (room air)|Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
40989458|NCT06419387|DEVICE|Self-Therapy Mobile App|Self-Therapy Mobile App includes videos and guidelines for applying EMDR Flash Technique
40989459|NCT06419387|OTHER|Psycho-education Videos|Psycho-education Videos include guidelines for increasing emotion regulation skills.
40989460|NCT01076881|BEHAVIORAL|exercise training|
40989461|NCT04220008|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
40989462|NCT04220008|DRUG|Busulfan|Given IV
40989463|NCT04220008|DRUG|Clofarabine|Given IV
40989464|NCT04220008|DRUG|Cyclophosphamide|Given IV
40989465|NCT04220008|DRUG|Gemcitabine|Given IV
40989466|NCT04220008|DRUG|Mycophenolate Mofetil|Given IV
40989467|NCT04220008|BIOLOGICAL|Rituximab|Given IV
40989468|NCT04220008|DRUG|Tacrolimus|Given IV
40989469|NCT04220008|DRUG|Vorinostat|Given PO
40989470|NCT00410644|DRUG|OROS Hydromorphone HCI|
40989471|NCT01601782|PROCEDURE|Ultrasound Scan|Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
41146385|NCT00234832|DRUG|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
41146386|NCT00234832|DRUG|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
41146387|NCT03932253|OTHER|FCN-159|Administered orally once a day
40785174|NCT06104137|OTHER|standard patient consent process|standard consenting and shared decision making in the clinic
40785175|NCT06282861|DRUG|Trelegy Ellipta 100/62.5/25Mcg Inh 30D|Product to be used according to specifications. 1 inhalation daily for 12 months
40785176|NCT06282861|DRUG|Brimica|As per product specifications
40989472|NCT01601782|DEVICE|Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).|The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
40989473|NCT05714956|BEHAVIORAL|Mothers and Babies Online (eMB)|"This study's intervention is called Mothers and Babies Online or eMB, which consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention."
40989474|NCT03625791|BIOLOGICAL|blood sample|1 tube with 4 ml of blood per patient
41146388|NCT00233142|BEHAVIORAL|Expressive writing|Writing as therapeutic intervention
41146389|NCT00233142|BEHAVIORAL|Neutral writing|Non-expressive writing
40989475|NCT03099876|PROCEDURE|treatment period|7 days treatment or 10 days treatment
41146390|NCT03277391|PROCEDURE|Serratus anterior plane block|SPB realized under ultrasound guidance. Infiltration of local anesthetic (bolus then infusion through a multi-holed catheter) is realized under the serratus anterior muscle at a level situated around the 5th to 6th intercostal space on the anterior axillary lign, in order to anesthetize the cutaneous lateral branches of the intercostal nerves, with a first ropivacaine 0,375% bolus (0,4ml/kg), followed by an infusion of ropivacaine 0,2% at a 10ml/hr rate, through a multi-holed catheter, for a duration of 24 hours.
41465558|NCT00249015|BEHAVIORAL|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
41146391|NCT03277391|DEVICE|patient-controlled analgesia|Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.
41146392|NCT05145634|OTHER|Patient education related oral anticoagulants (OACs)|The interventions administered to the experimental group were one-on-one instruction and Health Belief Model (HBM)-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards. Patient education related oral anticoagulant: each subject in the experimental group was taught individually according to investigators' App in the outpatient department (OPD) by researchers. Every months, participants received a follow-up phone call to clarify any questions related to the knowledge of anticoagulants. The contents of the teaching material consisted of: the purpose of taking anticoagulant, side effects, adjustments to daily diet, and precautions (i.e.how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure and medical card after pretest and routine care in the OPD. All participants completed posttest at 3-month follow-up.
41146393|NCT01843049|RADIATION|Radiotherapy|Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
41146394|NCT01843049|DRUG|Chemotherapy (5-FU+DDP)|Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
40989476|NCT03441841|DRUG|Lidocaine + Prilocaine|Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.
40989477|NCT03441841|DRUG|Lidocaine|Single topical dose of 2g lidocaine 2.5 % formulation.
40989478|NCT03441841|DRUG|Prilocaine|Single topical dose of 2g prilocaine 2.5 % formulation.
41146395|NCT05541185|BIOLOGICAL|Nigella sativa oil|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
41146396|NCT05541185|BIOLOGICAL|Naproxen and lidocaine gel|1 ml of Naproxen and lidocaine gel was applied to both knee areas of the Naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
40989479|NCT02542631|DEVICE|Bolus Insulin Patch (Calibra Finesse)|
40989480|NCT02542631|DEVICE|Insulin Pen (Novo-Nordisk FlexPen®)|
40989481|NCT05435079|DEVICE|high-flow oxygen therapy device for tracheotomized patients|From the output end of the automatic pressure-adjustable oxygen flow meter, connect the oxygen suction tube, Venturi, Fisher \& Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, closed sputum suction tube and tracheostomy tube), Adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy tube at 37°C according to the feedback temperature, and adjusts the oxygen therapy device according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
40989482|NCT05973383|BEHAVIORAL|LongLife Active- Basic|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars."
40989483|NCT05973383|BEHAVIORAL|LongLife Active- Standard|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Standard are also offered a community with social support."
41146397|NCT05541185|BIOLOGICAL|Massage|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
41146398|NCT02642640|DIETARY_SUPPLEMENT|melatonin|5 mg of melatonin per os.
41146399|NCT02642640|DRUG|placebo|
41146400|NCT03153423|PROCEDURE|Strabismus surgery|Recession and resection of horizontal extra ocular muscles
41146401|NCT03945409|DEVICE|OPTIVENT|OPTIVENT (SIDAM SRL, Mirandola, Italy) is a new fully automated and self-calibrating system that allows a real-time monitoring and recording of airway pressure and esophageal pressure during mechanical ventilation. The system required the insertion of an esophageal balloon catheter and an airway pressure transducer.
41146402|NCT00543049|DRUG|Sunitinib|Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
41146403|NCT00543049|DRUG|SUNITINIB|Sunitinib, oral, 37,5 mg once daily continuously, up to one year
41146404|NCT03639649|DIAGNOSTIC_TEST|STHLM3|
41146405|NCT02994329|DEVICE|OraQuick® HIV Self-Test (Orasure Technologies, Thailand)|All individuals aged 16 and above who are approached by community health workers conducting door-to door HIV testing will be offered the choice to use an oral HIV self test kit or to have standard of care finger-prick rapid HIV testing
41146406|NCT02462278|DEVICE|TempuRing|
41307150|NCT03168256|DRUG|Apremilast 30mg|Apremilast tablets, 30mg BID for 16 weeks
41307151|NCT03168256|DRUG|Placebo Oral Tablet|Placebo tablets, BID for 16 weeks
41307152|NCT00228254|DRUG|Zinc (12.5 mg/day)|
41307153|NCT00228254|DRUG|vitamin A 10,000 IU per week|
41307154|NCT04091282|OTHER|No intervention|No intervention
41307155|NCT00266721|DRUG|Pancrelipase (Creon) 2 tablets with each meal|
40785177|NCT06282861|DRUG|Duaklir|As per product specifications
41465559|NCT05220969|GENETIC|Total Genotype Risk Score|A total genotype risk score has been generated based on the results of previously observed genetic association studies
41465560|NCT05305443|BEHAVIORAL|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
41465561|NCT05305443|BEHAVIORAL|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
41465562|NCT05305443|BEHAVIORAL|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
40785178|NCT06282861|DRUG|Ultibro|As per product specifications
40785179|NCT06282861|DRUG|Ulunar|As per product specifications
40785180|NCT06282861|DRUG|Xoterna|As per product specifications
40989484|NCT05973383|BEHAVIORAL|LongLife Active- Premium|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Premium are also offered a community with social support plus private on-line health consultations. The number of private health consultations is 3 for a 3 months subscription, 4 for a 6 months subscription, and 6 for a 12 months subscription."
40989485|NCT04571710|DRUG|SHR1258|Drug: SHR1258 400mg
40989486|NCT04563169|OTHER|Video consultation|The first video consultation with a nurse was planned one week after start with CPAP. Three focus points were discussed during the consultations: 1) adherence (\>6 hours per night); 2) rest AHI \< 5 (or \<10 if age \>70), and 3) (improvements in) complaints. If these objectives were achieved after one week, a new consultation was planned three weeks later (four weeks after start). As long as these objectives were not achieved, video consultations were planned weekly (until after four weeks).
40989487|NCT06415422|BIOLOGICAL|Biological samples|Biological samples are taken from the patient's catheter inserted upon admission (the usual access route for patients): A daily sample is collected into a dry tube for off-site analysis by VeriFyNow until platelet function normalizes (for example, if platelet function normalizes on Day 2, no further VeriFyNow analysis will be conducted on subsequent days).
40989488|NCT01075204|DRUG|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
40989489|NCT02563678|DRUG|Hyperbaric Oxygen|Hyperbaric oxygen therapy
41465563|NCT05305443|BEHAVIORAL|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing IL recommendations is e-mailed or texted to participants.
41465564|NCT01470417|DRUG|Chemotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
41465565|NCT01470417|DRUG|Chemotherapy + ChemoRadiotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
41465566|NCT05988424|OTHER|Left atrial mapping|Creation of a left atrial voltage map
41465567|NCT01618630|DIETARY_SUPPLEMENT|EAA Supplementation + Exercise Training|Amino acids in drinks between meals for exercise training period.
40785181|NCT06282861|DRUG|Anoro|As per product specifications
40785182|NCT06282861|DRUG|Laventair|As per product specifications
40785183|NCT06282861|DRUG|Spiolto Respimat|As per product specifications
40785184|NCT06282861|DRUG|Yanimo|As per product specifications
40785185|NCT06282861|DRUG|Foradil|As per product specifications
41307156|NCT00506077|DRUG|MK0249|MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
41465568|NCT01618630|DIETARY_SUPPLEMENT|Placebo + Exercise Training|Placebo supplementation as drinks in between meals for exercise training period.
40785186|NCT06282861|DRUG|Broncoral|As per product specifications
40785187|NCT06282861|DRUG|Formoterol stada|As per product specifications
40785188|NCT06282861|DRUG|Oxis|As per product specifications
40785189|NCT06282861|DRUG|Formatris|As per product specifications
40785190|NCT06282861|DRUG|Formoterol Aldo|As per product specifications
40785191|NCT06282861|DRUG|Onbrez|As per product specifications
40785192|NCT06282861|DRUG|Oslif|As per product specifications
40785193|NCT06282861|DRUG|Hirobriz|As per product specifications
40785194|NCT06282861|DRUG|Striverdi|As per product specifications
40785195|NCT06282861|DRUG|Beglan|As per product specifications
40785196|NCT06282861|DRUG|Betamican|As per product specifications
41307157|NCT00506077|DRUG|Comparator: Placebo (unspecified)|MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
40785197|NCT06282861|DRUG|Inaspir|As per product specifications
40785198|NCT06282861|DRUG|Serevent|As per product specifications
40785199|NCT06282861|DRUG|Soltel|As per product specifications
40785200|NCT06282861|DRUG|Eklira|As per product specifications
40785201|NCT06282861|DRUG|Bretaris|As per product specifications
40785202|NCT06282861|DRUG|Seebri|As per product specifications
41465569|NCT03838341|DEVICE|AtriClip™ LAA Exclusion System|The left atrial appendage is closed from the epicardial side of the heart. Operative access is totally thoracoscopic. The designed and dedicated clip - AtriClip® (AtriCure, Ohio, USA) is introduced to the left pleura through thoracoscopic port.
40785203|NCT06282861|DRUG|Tovanor|As per product specifications
40785204|NCT06282861|DRUG|Enurev|As per product specifications
41465570|NCT03838341|DRUG|Oral anticoagulation therapy|Anticoagulation therapy discontinuation - according to the standard of care at the discretion of the Investigator.
40785205|NCT06282861|DRUG|Spiriva|As per product specifications
40785206|NCT06282861|DRUG|Tavulus|As per product specifications
40785207|NCT06282861|DRUG|Sirkava|As per product specifications
40785208|NCT06282861|DRUG|Braltus|As per product specifications
40785209|NCT06282861|DRUG|Gregal|As per product specifications
40785210|NCT06282861|DRUG|Incruse|As per product specifications
40785211|NCT06282861|DRUG|Rolufta|As per product specifications
41146407|NCT03411408|DEVICE|HBO|"Hyperbaric oxygen is administrated in a multiplace hyperbaric chamber according to the following schedule:~Ten minutes of compression with a Fraction of inspired oxygen (FiO2) more than 90% from 152 to 253 kilopascal, 60 minutes of Fraction of inspired oxygen (FiO2) more than 90% at 253 kilopascal (three breathing cycles in oxygen for 22 minutes each, with two intervals breathing air for 2 minutes each) and 10 minutes of decompression with a Fraction of inspired oxygen (FiO2) more than 90% from 253 to 152 kilopascal."
41146408|NCT03411408|RADIATION|RT|tomotherapy (within 60 minutes from completion of decompression of hyperbaric chamber) with 3-5 consecutive sessions- one fraction per day, 5 Gy / die .
41146409|NCT01175980|OTHER|Laboratory Biomarker Analysis|Correlative studies
41146410|NCT01175980|DRUG|Vorinostat|Given PO
41146411|NCT01906073|DRUG|intranasal fentanyl spray|
41146412|NCT01906073|DRUG|slow release morphine|
41465571|NCT06126328|DEVICE|Materna Prep Device|Subjects are treated with Materna Prep Device prior to vaginal delivery
41465572|NCT04034654|OTHER|Questionaire|Child behavior checklist is a questionaire, designed to evaluate 1.5-5 years old child's behavior. The checklist is filled out by parents/caregivers.
40785212|NCT05399966|DIETARY_SUPPLEMENT|Monarda Didyma extract|Monarda Didyma extract; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
40785213|NCT05399966|DIETARY_SUPPLEMENT|Placebo|Maltodextrin; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
40785214|NCT03757507|DEVICE|MultiSpectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography is a new emerging imaging technique which uses laser light to heat up molecules with a high pulsed laser. The molecules undergo thermal expansion and produces sound waves, which can be detected by special transducers. The device can pick up different signals in different wavelength to produce images with anatomic and biological information.
40785215|NCT04317235|DRUG|Ropivacaine 0.5% Injectable Solution|Is to put 3 ml or 5 ml and show the difference
40785216|NCT00751478|DRUG|ALO-01|ALO-01 capsules
40785217|NCT00751478|DRUG|MSIR|immediate release morphine sulfate
40785218|NCT00751478|DRUG|Placebo|Placebo
40785219|NCT06224569|OTHER|Black tea flavoured, tea drink|Black tea powder containing 50.0 mg of caffeine and 11.5 mg of theanine, to be dissolved in 200 ml boiling water.
40785220|NCT06224569|OTHER|Black tea flavoured, caffeine-only drink|50.0 mg of caffeine in a black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
40785221|NCT06224569|OTHER|Black tea flavoured, placebo drink|A black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
40785222|NCT06224569|OTHER|Green tea flavoured, tea drink|Green tea powder containing 30.6 mg of caffeine and 11.1 mg of theanine, to be dissolved in 200 ml boiling water.
40785223|NCT06224569|OTHER|Green tea flavoured, caffeine-only drink|30.6 mg of caffeine in a green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
40785224|NCT06224569|OTHER|Green tea flavoured, placebo drink|A green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
41146413|NCT00915629|DIETARY_SUPPLEMENT|Lactibiane candisis 5M|2 gelules per day for 2 months then 1 gelule per day for 4 months
40785226|NCT01202240|DRUG|Tasocitinib (CP-690,55) plus Ketoconazole|Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
40785227|NCT04426747|OTHER|No intervention|No intervention
41146414|NCT00195988|DRUG|tacrolimus, steroids, mycophenolate mofetil|
41146415|NCT01207453|DRUG|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
41146416|NCT01207453|DRUG|Placebo|
41146417|NCT04113187|DRUG|Propranolol treatment|40 mg twice a day (morning and evening), per os, during three months
41146418|NCT04113187|DRUG|Placebo|per os, twice a day (morning and evening) during three months
41146419|NCT01648049|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein \& Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, \& Dick, 1995).
40785228|NCT00962871|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc/week for 2 weeks
40785229|NCT00962871|DRUG|tenofovir|300mg po daily for 2 weeks
40785230|NCT00059631|DRUG|Mitoxantrone (Novantrone)|Starting dose of 3 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
40785231|NCT00059631|DRUG|Bortezomib (PS-341)|Starting Dose of 1.4 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
40785232|NCT00263003|DRUG|Irbesartan/hydrochlorothiazide|
40785233|NCT00263003|DRUG|Irbesartan|
40785234|NCT01469039|DRUG|ALKS 9072|Intramuscular (IM) injection, 441 mg or 882 mg given monthly
40785235|NCT01469039|DRUG|Placebo|Placebo for IM injection, given monthly
40785236|NCT00569322|PROCEDURE|BG Test|
40785237|NCT06414083|DEVICE|Diathermy|Diathermy will be used to ablate the randomized sample.
40785238|NCT06414083|DEVICE|CO2 Laser|CO2 Laser will be used to ablate the randomized sample.
40785239|NCT06414083|DEVICE|Argon Beam Coagulator|Argon Beam Coagulator will be used to ablate the randomized sample.
40785240|NCT01010672|DRUG|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
40785241|NCT01977222|DEVICE|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
40785242|NCT04581785|BIOLOGICAL|hLB-001|hLB-001 via IV infusion
40785243|NCT03730610|BEHAVIORAL|Exercise training|Subjects are required to exercise four times a week during six months. Exercise training consists of endurance training, resistance training and high-intensity interval training adjusted to subject's fitness level.
40989490|NCT02563678|OTHER|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
40785244|NCT02590289|DRUG|BBI-5000|BBI-5000 low dose, middle dose, or high doses
40785245|NCT03619993|DEVICE|On-body injector|Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
41146420|NCT01648049|BEHAVIORAL|Treatment as usual|Standard Care - Treatment as usual
41146421|NCT04005248|DIAGNOSTIC_TEST|HCV IgG test|An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
40785246|NCT03619993|DEVICE|Pre-filled syringe|For subcutaneous injection of a supportive medicine (Pegfilgrastim).
40785247|NCT00441272|DRUG|Pioglitazone|
40785248|NCT05518006|DIETARY_SUPPLEMENT|PreMama Balance|Premama Balance is a blend of the following: Vitex (Chasteberry Extract), commonly used to help regulate hormones; Antioxidants, Selenium, and Magnesium, also help support the cleansing of hormonal birth control from the liver and help strengthen the uterine lining.
40785249|NCT05518006|DIETARY_SUPPLEMENT|Placebo Drink|Blended Placebo drink
40785250|NCT00820989|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
40785251|NCT01790373|BEHAVIORAL|Suubi+Adherence|"* Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~* Financial education and workshops on asset-building, future planning, and protection from risks~* Mentorship from a young adult/near-peer~* Family-based microenterprise development training~* Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
40785252|NCT01790373|BEHAVIORAL|Bolstered Standard of Care|"-Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
40785253|NCT01502514|PROCEDURE|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
41146422|NCT00051740|BEHAVIORAL|Cognitive Adaptation Therapy (CAT)|
41146423|NCT00051740|BEHAVIORAL|Minimal Environmental Supports (MES)|
40989491|NCT02563678|OTHER|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
40989492|NCT04784221|RADIATION|Radiation by protontherapy associated to nanoparticles injection|"Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles.~Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26.~The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy"
40989493|NCT03558243|PROCEDURE|Patent Hemostasis arm|Patent hemostasis with TR BAND
40989494|NCT03558243|PROCEDURE|ULTRA arm|Patent hemostasis protocol plus ipsilateral ulnar compression
40989495|NCT03558243|DEVICE|Hemostatic disc arm|StatSeal disc plus TR Band
40989496|NCT06005142|DIETARY_SUPPLEMENT|Eriomin|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day capsule of Eriomin for 12 weeks.
40989497|NCT06005142|DIETARY_SUPPLEMENT|Washout|After 12 weeks of treatment with the active component (Eriomin) or placebo, the participants will follow a washout for 2 weeks.
40989498|NCT06005142|DIETARY_SUPPLEMENT|Placebo|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day placebo capsule for 12 weeks.
41146424|NCT04692441|DIETARY_SUPPLEMENT|Heavy Cream|100 ml of dairy cream with 40.4g of total fat, to ingest orally
40989499|NCT00772707|DEVICE|Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)|OPTI-FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.
41465573|NCT01606228|DRUG|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
41465574|NCT03037424|DRUG|Octafibrin|Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation
41465575|NCT03037424|DRUG|Cryoprecipitate|Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
41465576|NCT02426541|DRUG|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
41465577|NCT02426541|DRUG|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
41465578|NCT02434263|DEVICE|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
41465579|NCT05049031|OTHER|Questionnaire|A questionnaire will be given to patients who will ask them about their possible fractures, their bone and oncological follow-ups and their possible cardiovascular events since the end of treatment with hormone therapy.
40785254|NCT02465931|OTHER|Paper and Pencil Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
40785255|NCT02465931|OTHER|Digital Informed Consent Tool|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
40785256|NCT05447689|BEHAVIORAL|Integrative-Mind-Body Skills Group|Integrative-Mind-Body Skills Group (I-MBS-G) is an 8-week group that teaches skills to build inner resources for effective mood management. This group incorporates a holistic approach to wellness through meditation and mindfulness practices, guided imagery, breath and body awareness, relaxation techniques, self-reflection, and mindfulness-based cognitive-behavioral skills. Mind-body approaches have demonstrated effectiveness in reducing stress mood symptoms and improving quality of life.
40989500|NCT00772707|DEVICE|Contact Lenses|Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
40989501|NCT02015780|DRUG|Fasiglifam|Fasiglifam tablets
40989502|NCT02015780|DRUG|Placebo|Fasiglifam placebo-matching tablets
41465580|NCT05231369|BIOLOGICAL|ChulaCov19 BNA159 mRNA vaccine|ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine
41465581|NCT03538925|BEHAVIORAL|AAC Generative Language Intervention|Parent/Caregiver AAC App Operational Training + Direct AAC Input-Output Language Intervention
41465582|NCT03538925|BEHAVIORAL|Standard of Care / Business as Usual|Parent/Caregiver AAC App Operational Training
41465583|NCT03767062|DRUG|Topamax|An antiepileptic agent used for migraine prophylaxis.
41465584|NCT03767062|PROCEDURE|Greater Occipital Nerve Block + Supratrochlear Nerve Block|An injection to paralyze the occipital and supratrochlear nerves.
41465585|NCT04244006|DRUG|Dupilumab Prefilled Syringe|administration of dupilumab corresponding to dupilumab arm
41465586|NCT04244006|OTHER|Placebo Prefilled Syringe|administration of placebo corresponding to placebo arm
41465587|NCT03297086|PROCEDURE|cataract surgery|cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
40989503|NCT02015780|DRUG|Antihyperglycemic therapy|Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
41465588|NCT03981978|BEHAVIORAL|Physical Activity|Self-report questionnaires assessing physical activity level.
41465589|NCT03132311|BIOLOGICAL|Yellow Fever vaccination (17 DD Biomanguinhos)|One intramuscular injection
41465590|NCT04167618|DRUG|177Lu-DTPA-omburtamab|Biological, radiolabeled DPTA-omburtamab
41465591|NCT05357287|DEVICE|PREVENA incision management system|We will apply Prevena on the surgical wound right after closure of the wound in the operating theater. Prevena will be used for 7 days, unless there is ongoing infection or much wound drainage that requires debridement.
41465592|NCT00005858|BIOLOGICAL|LMB-9 immunotoxin|
41465593|NCT01745068|OTHER|Integrated program|Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
41465594|NCT02771106|OTHER|neuro vision rehabilitation|Neuro vision rehabilitation used to treat vision dysfunction following TBI
41465595|NCT03237299|OTHER|Collection of data|Collection of data on clinical, bacteriological and computed tomography data concerning the case, which will be needed by the adjudication committee and for defining the index date.
41465596|NCT03237299|OTHER|No collection of data|The interviewer will note sociodemographic characteristics (age, weight, sex), symptoms and their evolution, and all drug intakes of the patient during the month before the index date.
41465597|NCT04288076|OTHER|PEEP Titrated Mechanical Ventilation|Subjects will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O and back down to 5 cmH20. Pleural pressure and intracranial pressure will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set \> 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. At the completion of the study patients will be returned to the PEEP level they were on prior to titration of the ventilator.
41146425|NCT02152111|DIETARY_SUPPLEMENT|Coconut flour|Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.
41146426|NCT02152111|BEHAVIORAL|Diet|Patients were instructed to follow the dietary treatment for 6 months.
41146427|NCT03536637|DRUG|DMT310|Topical Powder
41146428|NCT03536637|DRUG|Hydrogen Peroxide|Liquid Diluent
41465598|NCT01462578|DRUG|Azacitidine|Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
41465599|NCT04650750|DRUG|Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin|"Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect."
41465600|NCT04650750|DRUG|Placebo|Similar placebo 4g twice a day for two months
41465601|NCT02075034|DRUG|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
41465602|NCT03919292|DRUG|Neratinib|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
41465603|NCT03919292|DRUG|Divalproex Sodium|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
41465604|NCT03255434|DRUG|Oxaliplatin|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
41465605|NCT03255434|DRUG|Oxaliplatin LBM|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
41465606|NCT04205162|DEVICE|Verafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
41465607|NCT04205162|DEVICE|Etafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
41465608|NCT03545399|DIETARY_SUPPLEMENT|Ulva Lactuca|The dose was taken with a glass of water during the evening meal once daily
40785257|NCT06370039|DRUG|INV-102|INV-102 Ophthalmic Solution
40785258|NCT06370039|DRUG|Vehicle|Vehicle Ophthalmic Solution
40785259|NCT06069609|DEVICE|Kalifilcon a Contact Lens for Astigmatism|Kalifilcon A Daily Disposable Toric Contact Lens for Astigmatism
40989504|NCT05188209|DRUG|MRG003|Administered intravenously
41146429|NCT03536637|DRUG|Placebo|Placebo Topical Powder
41146430|NCT05148949|BIOLOGICAL|Standard dosage inactivated vaccine|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
41465609|NCT03545399|DIETARY_SUPPLEMENT|Placebo|The dose was taken with a glass of water during the evening meal once daily
41465610|NCT03644043|DEVICE|EEG scan|WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings
41465611|NCT05135624|DRUG|SP16 (6mg)|SP16 will be administered as 2 concurrent, separate 2 mL s.c injections of 3mg/mL SP16
40785260|NCT06069609|DEVICE|Acuvue Oasys 1-Day for Astigmatism|Commercially available contact lenses: Acuvue Oasys 1-Day for Astigmatism
40989505|NCT01758783|DRUG|Glutamine|amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
40989506|NCT03491995|DRUG|Quadruple therapy|Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
40989507|NCT03491995|DRUG|Classic treatment|Omeprazole, amoxycillin, clarithromycin
40989508|NCT03239587|BEHAVIORAL|Musical Intervention|Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
40989509|NCT03239587|PROCEDURE|Blood Draws|"No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music."
40989510|NCT03239587|BEHAVIORAL|Questionnaires|Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
40989511|NCT01369979|PROCEDURE|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
40785261|NCT04460183|DRUG|RESP301, a Nitric Oxide generating solution|Product application requires inhalation using a standard handheld nebulizer.
40785262|NCT04460183|OTHER|Standard of Care|Participants will receive institutional SOC for the treatment of COVID-19.
40785263|NCT01240863|DRUG|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
40785264|NCT01240863|DRUG|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
40989512|NCT01603459|DRUG|IncobotulinumtoxinA|"Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection."
41465612|NCT05135624|OTHER|Placebo|Placebo will be administered as 2 concurrent, separate 2 mL s.c. injections of sterile water
40989513|NCT01559896|DIETARY_SUPPLEMENT|protein hydrolysate capsules and placebo capsules|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
40989514|NCT00480597|DRUG|gemcitabine|
40989515|NCT00480597|DRUG|cisplatin|
40989516|NCT00480597|DRUG|vinorelbine|
40989517|NCT00480597|DRUG|capecitabine|
40989518|NCT03195088|DRUG|BI 473494|Solution for injection
40989519|NCT03195088|DRUG|Placebo|Solution for injection
40989520|NCT00399360|DRUG|Metformin|Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
41146431|NCT05148949|BIOLOGICAL|Double dosage inactivated vaccine|This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
40989521|NCT00399360|DRUG|Placebo|500 mg twice daily increasing to 850 mg twice daily after 3 Months
40989522|NCT00399360|BEHAVIORAL|Lifestyle Modification|Lifestyle Modification
41146432|NCT03671356|OTHER|risk score|risk score
41307158|NCT01151592|DRUG|Iron Sucrose|Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
41307159|NCT00773760|OTHER|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
41307160|NCT03703375|DRUG|Azacitidine|Azacitidine
41307161|NCT03703375|DRUG|Romidepsin|Romidepsin
41307162|NCT03703375|DRUG|Gemcitabine|Gemcitabine
41307163|NCT01387295|DRUG|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
41307164|NCT00313534|DRUG|masoprocol|
41307165|NCT05284578|OTHER|Self-compassionate writing intervention|Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.
41465613|NCT05135624|DRUG|SP16 (12 mg)|SP16 will be administered as a single 2 mL s.c. injection of 3 mg/mL SP16 and 1 concurrent separate 2 mL s.c. injection of sterile water
40989523|NCT01220882|RADIATION|Radiographic skeletal age assessment|bone age assessment from the elbow lateral radiograph
40989524|NCT02785107|BEHAVIORAL|M-PAC Group|Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
40989525|NCT04185246|DRUG|NH002 (Perflutren Lipid Microspheres) Injectable Suspension|NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
40989526|NCT04185246|DIAGNOSTIC_TEST|Echocardiogram|Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
40989527|NCT05057442|OTHER|Proprioception assessment, functionality assessment|Proprioception assessment, functionality assessment
41146433|NCT03327025|BEHAVIORAL|Health education counseling|Health education counseling
41146434|NCT00360035|DRUG|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
41307166|NCT05284578|OTHER|Expressive writing intervention|Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
41307167|NCT05284578|OTHER|Control writing task|Participants assigned to this condition were asked to engage in a neutral time management writing task.
41307168|NCT00584220|DEVICE|senofilcon A toric|contact lens
41307169|NCT00584220|DEVICE|alphafilcon A toric|contact lens
41307170|NCT01778387|PROCEDURE|Laparoscopic ventral hernia repair|Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
41307171|NCT04482491|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
41465614|NCT00175097|OTHER|Diet: soybeans and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
41465615|NCT00175097|OTHER|Diet: soybean flour and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
41465616|NCT00175097|OTHER|Diet: soybean milk|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
41465617|NCT00175097|OTHER|Diet: Animal protein based diet|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
41465618|NCT00827840|DRUG|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
41465619|NCT00827840|DRUG|Risperidone|1 to 6 mg of risperidone once or twice a day
41465620|NCT02911935|DRUG|Oral azithromycin|Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
41465621|NCT02911935|DRUG|Placebo|Placebo suspension
41465622|NCT04802551|OTHER|Sensory integration therapy|Sensory integration disorder is defined as the inability of a person to use the information he / she receives through his / her senses properly in order to continue his daily life properly. Intervention group have some therapy sessions which include sensory integration therapy exercises.
41465623|NCT05290493|DRUG|NB-001|NB-001 is a non-stimulant activator of multiple metabotropic glutamate receptors (mGluRs).
41465624|NCT05290493|OTHER|Placebo|Matching, inactive placebo
41465625|NCT04720287|DRUG|bupivacaine/ neostigmine.|will receive bilateral ultrasound guided QLB
41465626|NCT04720287|DRUG|bupivacaine/ neostigmine.|will receive ultrasound guided CB.
41465627|NCT00860743|DRUG|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
40785265|NCT01428219|DRUG|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
41146435|NCT03955341|DEVICE|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
41307172|NCT03446534|DRUG|Amoxicillin|Imacillin mixture
41307173|NCT03446534|DRUG|Placebos|Placebo manufactured to mimic amoxicillin mixture (Imacillin)
41307174|NCT02049255|DRUG|Chloroprocaine|"The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia"
40785266|NCT04021290|DRUG|DTG/3TC FDC|DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
41146436|NCT03955341|OTHER|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
41146437|NCT03127475|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
41146438|NCT06309745|PROCEDURE|retroperitoneal lymph node dissection|retroperitoneal lymph node dissection
41146439|NCT06309745|DRUG|Carboplatin AUC10|Carboplatin AUC10
41146442|NCT05404802|DEVICE|Experimental group intervention|"Training session~Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.~Free-play session~In these sessions, every participant can interact with one PARO without instructions but are under the safety supervision of a PARO facilitator."
41146443|NCT05404802|DEVICE|Control group intervention|Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.
41146444|NCT00963105|DRUG|lenalidomide|"Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:~* Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity"
41146445|NCT04727463|PROCEDURE|Sphincteroplasty|Overlapping sphincteroplasty
41146446|NCT02037568|BEHAVIORAL|fPER|"Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal."
41307175|NCT02049255|DRUG|Marcaine|"The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia"
41307176|NCT00429039|DRUG|L-leucyl-L-leucine methyl ester (LLME)|
40785267|NCT04021290|DRUG|CAR|Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
40785268|NCT01866748|DRUG|semaglutide|A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.
40785269|NCT01866748|DRUG|semaglutide|Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.
40785270|NCT01866748|DRUG|placebo|In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
40785271|NCT01866748|DRUG|placebo|In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
40785272|NCT02159625|DEVICE|Abdominal Compression Elastic Support|The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
40989528|NCT04152603|BEHAVIORAL|BRIEF Educational Module|The BRIEF Educational Module for research recruitment team members is intended to teach evidence-based approaches to improving participant experiences with research recruitment. It has three components: (1) asynchronous pre-work, including multimedia materials and an individual worksheet (approx. 30 min); (2) one synchronous in-person (or virtual if necessary) session, including didactics, discussions, and practice scenarios (approx. 90 min); and (3) an asynchronous, individual follow-up phone call to review individual questions (approx. 15 min).
41146447|NCT05452408|DRUG|Antitumor B KAC|ATB-KAC will be administered at a dose of 720 mg three times per day (roughly spaced every eight hours) as has been studied for ATB-KAC in human oral leukoplakia trials and in esophageal cancer prevention trials. ATB-KAC may be taken with or without food.
40989529|NCT01768481|DRUG|Atorvastatin|10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
40989530|NCT01768481|DRUG|sugar pill|placebo controlled arm receives similarly looking placebo.
40989531|NCT03523975|DRUG|Venetoclax|PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
41146448|NCT01123044|BIOLOGICAL|conservative|Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
41146449|NCT01123044|PROCEDURE|Medical Therapy|Under usual care treatment
41307177|NCT01952834|DIETARY_SUPPLEMENT|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
41307178|NCT01952834|DRUG|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
41465628|NCT02248506|OTHER|Clotrimazole|All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
40785273|NCT02267889|PROCEDURE|Image guided GP ablation|3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
41465629|NCT03105973|BEHAVIORAL|Technology-Enabled CBT Treatment|CBT-based modules delivered via tablet over 4 weeks.
41465630|NCT00519974|OTHER|counseling intervention|
41465631|NCT00519974|OTHER|study of socioeconomic and demographic variables|
41465632|NCT00519974|PROCEDURE|management of therapy complications|
41465633|NCT00519974|PROCEDURE|psychosocial assessment and care|
40785274|NCT02267889|DEVICE|D-SPECT dedicated cardiac nuclear camera|
40785275|NCT01152307|BEHAVIORAL|DVD/Booklet: Coping with Symptoms of Depression|DVD and booklet that provides information about treatment choices for depression symptoms
41465634|NCT05753982|OTHER|Kinesiotape placement|Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
41465635|NCT04118946|BIOLOGICAL|platelet enriched plasma|PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.
41465636|NCT04066413|OTHER|Standard infant formula|Standard infant formula
40785276|NCT04750486|DEVICE|Sequential compression devices|Two lower limb intermittent compression devices to be placed on the mid-calf of each leg.
40785277|NCT00806260|DRUG|VI-0521|Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
40785278|NCT00806260|DRUG|Placebo|Placebo daily for 4 weeks
40785279|NCT00806260|OTHER|Alcohol|
40989532|NCT03523975|DRUG|Lenalidomide|10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.
40989533|NCT03523975|DRUG|Rituximab|375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12
41146450|NCT00282061|DRUG|Melatonin|
41146451|NCT02411175|OTHER|Individualised Homeopathic Remedy|20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
41146452|NCT02411175|DRUG|20% ethanol|
41146453|NCT04876261|DIETARY_SUPPLEMENT|Oliphenolia® bitter|"* ingredients: concentrated watery extract of olives 94%, lemon juice 6%~* 35 mg hydroxytyrosol, 0,24 mg Oleuropein"
41146454|NCT04876261|DIETARY_SUPPLEMENT|Oliphenolia®|"* ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~* 38 mg hydroxytyrosol, 0,28 mg Oleuropein"
41465637|NCT04066413|OTHER|Infant formula supplemented with HMO|Infant formula supplemented with HMO
41465638|NCT00145613|PROCEDURE|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
40989534|NCT03128346|PROCEDURE|Transthoracic Transversus Plane Block|The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.
40989535|NCT03128346|DRUG|Hydromorphone Hydrochloride|IV, Hydromorphone
41465639|NCT00145613|DEVICE|Miltenyi Biotec CliniMACS|stem cell selection device
41465640|NCT00145613|DRUG|Systemic chemotherapy and antibodies|Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
41465641|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.
41465642|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - targeted-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting.
41465643|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - Standard-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.
41465644|NCT03699033|RADIATION|2.5 Gy/fraction|Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel
41465645|NCT03699033|DRUG|Carboplatin|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
41465646|NCT03699033|DRUG|Paclitaxel|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
41465647|NCT00944684|DRUG|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
41465648|NCT00944684|DRUG|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight \<65kg) or 1,200mg (body weight equal or \>65kg)
41465649|NCT04673825|OTHER|Patient initiated care + telemonitoring|See arm/group descriptions.
41465650|NCT02270034|DRUG|Crizotinib|Crizotinib is added to Stupp method
40785280|NCT00806260|OTHER|alcohol placebo|fruit juice
41465651|NCT02683291|DRUG|sirolimus|
41465652|NCT02683291|DRUG|tacrolimus|
41465653|NCT02683291|DRUG|mycophenolate|
41465654|NCT02683291|DRUG|Prednisone|Prednisone 30mg/day
40989536|NCT03128346|DRUG|Aspirin|Oral Aspirin
40989537|NCT03128346|DRUG|Acetaminophen|Oral acetaminophen
40785281|NCT02951637|DRUG|Pemetrexed plus carboplatin combined with gefitinib|Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
40785282|NCT02951637|DRUG|Gefitinib|Gefitinib (250mg daily)
40785283|NCT01720030|DRUG|Levosimendan|Verum therapy
40989538|NCT03128346|DRUG|Fentanyl|IV, fentanyl
41146455|NCT04876261|DIETARY_SUPPLEMENT|La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol|"* extra virgin olive oil~* 5 mg hydroxytyrosol"
41465655|NCT02683291|DRUG|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
40785284|NCT01720030|DRUG|Conventional therapy|Placebo therapy to safeguard blinding
40989539|NCT01032876|PROCEDURE|Deep Hypothermic Circulatory Arrest|DHCA will be employed for a maximum of 60 minutes. If more time (\>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
40989540|NCT01032876|PROCEDURE|Antegrade Cerebral Perfusion|One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
40989541|NCT04508842|BIOLOGICAL|CD19/CD22-Dual-STAR-T|Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
40989542|NCT03375411|DEVICE|Stent INC1|Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
40989543|NCT03831347|BEHAVIORAL|Hatha Yoga|12 weeks of Hatha Yoga
41146456|NCT06340191|OTHER|Pilates with cueing|"The Pilates with a cueing component of the intervention involved a specialized approach to Pilates training. Participants in this group underwent an initial phase of training before the main sessions began, which consisted of two smaller group sessions focused on learning explicit verbal and tactile cues. These cues were designed to assist participants in maintaining proper body alignment, engaging specific muscle groups more effectively, and refining their movement techniques to enhance the overall efficacy of the Pilates exercises.~During the actual Pilates sessions, the instructors, who were certified and brought extensive experience to the program, provided real-time feedback to the participants. This feedback was based on the cueing instructions, aiming to optimize the execution of the Pilates exercises."
41465656|NCT02683291|DRUG|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
41465657|NCT01710124|OTHER|Financial incentives|
41465658|NCT03398590|BEHAVIORAL|self-regulation theory-based mHealth behavior intervention|Participants will receive a self-regulation theory-based mHealth behavior intervention (5 biweekly group sessions, 60 minutes /session). An experienced Certified Diabetes Educator from the Joslin Diabetes Center and PI (Dr. Zheng) who has been trained using self-regulation for weight loss will co-facilitate group sessions. The intervention combines diet modification and increased physical activity with a weekly weight loss goal as well as focuses on improving participants' three typical self-regulation strategies - self-monitoring, self-evaluation and self-reinforcement. Intervention duration will last 2 months with subsequent 1-month follow.
40785285|NCT03809273|DRUG|Yangxinshi|Yangxinshi pill 3 pills /tid
40785286|NCT03809273|DRUG|Trimetazidine|Trimetazidine 20mg/tid
41465659|NCT02191566|DRUG|S-1 (452500ACH)|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
41465660|NCT02191566|DRUG|OXALIPLATIN (205803BIJ)|Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
40785287|NCT03809273|DRUG|Yangxinshi mimic|Yangxinshi mimic tablets 3 pills /tid
40785288|NCT03809273|DRUG|Trimetazidine mimic|Trimetazidine mimic tablets 20mg/tid
40785289|NCT00688857|DRUG|Diazoxide choline|Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
41465661|NCT06300606|DEVICE|NOL monitoring|Prospective observational study to assess pain during regional anesthesia for upper limb orthopedic surgery using NOL monitoring and the Algoplus pain scale
41465662|NCT01680016|BIOLOGICAL|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
41465663|NCT01680016|BIOLOGICAL|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
41465664|NCT04931160|OTHER|Blood, fluid, sells and urine samples|Blood, fluid, sells and urine samples will be collected.
41465665|NCT01114997|DRUG|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
41147084|NCT05835856|DEVICE|virtual coach with CelesTE robot|"The coaching device used is the CelesTE robot, a prayer companion designed for Christian Catholic users.The intended main function of CelesTE is to be a guardian angel, especially thought for elderly people. It can be a prayer companion, and contains a vast number of teachings, including the whole Bible. Its AI is capable of keeping a short conversation, in which the user may ask and receive an answer about a sensitive topic (such as happiness, death, faith, etc.). It can also printout a selection of contents.~The coaching device CelesTE will be substituted by DarumaTO for the Japanese centers."
41307179|NCT05024123|DIETARY_SUPPLEMENT|Placebo|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content."
40785290|NCT00688857|DRUG|Diazoxide choline|Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
40785291|NCT01180283|DRUG|lodenafil carbonate|Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
41147085|NCT05835856|OTHER|booklet|Participant in the control group will receive a booklet containing information and activities on well-being
41147086|NCT03307993|DRUG|Idalopirdine|Idalopirdine 60-120 mg daily dose
41147087|NCT03709472|BEHAVIORAL|Computer Assisted CIFFTA|This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
40785292|NCT05663463|DRUG|Fluzone High-Dose - 2 doses|2 doses of the High-Dose (HD) influenza vaccine separated by 4-6 weeks For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
40785293|NCT05663463|DRUG|Fluzone High-Dose - 1 dose of HD|1 dose of the High Dose (HD) influenza vaccine, followed by a placebo injection 4-6 weeks later For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
40785294|NCT05908838|DRUG|Modified Banxia Xiexin Decoction|The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.
40785295|NCT05908838|DRUG|combination chemotherapy with Placebo granules|combination chemotherapy with Placebo granules
40785296|NCT02448147|BEHAVIORAL|Interval training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.
40785297|NCT02448147|BEHAVIORAL|Continuous training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
41465666|NCT01114997|DRUG|Esmolol|Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min
41465667|NCT01114997|DRUG|Lidocaine + Esmolol (Combo)|"Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)~Maintenance Infusion rate after Induction:~Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
41465668|NCT04890964|DEVICE|Transcranial Direct Current Stimulation (tDCS)|A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
41465669|NCT00774241|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
40785298|NCT02031302|DEVICE|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] of \<1.0 cm2 or index of \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
40785299|NCT01976299|DEVICE|AVERT|
40785300|NCT01622296|DRUG|Sodium bicarbonate|8.4% neutralizing solution
40785301|NCT01622296|DRUG|Lidocaine|2% lidocaine with 1:100,000 ppm epinephrine
40785302|NCT06229691|BEHAVIORAL|30 minute treadmill walk|"Participants will walk on a treadmill at their preferred speed for 30 minutes. One minute challenge periods will occur at minutes 7, 17, and 27, when the treadmill speed will increase by 50%. This walk will induce a magnitude of muscle fatigue corresponding to an individual participant's fatigability."
41307180|NCT05024123|DIETARY_SUPPLEMENT|AstraGin|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content."
41465670|NCT00774241|DRUG|docetaxel|75mg/m2 every 3 weeks for 18 weeks
41465671|NCT06062550|DRUG|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative intravenous analgesia.
40785303|NCT00518050|BEHAVIORAL|Focus group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~* Screening, skin self-examination, sun protection, and other cancer preventive practices;~* Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~* Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
40785304|NCT00518050|BEHAVIORAL|Survey|History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
40785305|NCT03165786|BEHAVIORAL|FREE|Cognitive behavioral therapy with real-time continuous glucose monitoring.
40785306|NCT04301323|DRUG|BHVI1 eye drops|Including 35 children enrolled to receive BHVI1 eye-drops once nightly
41465672|NCT04979858|DEVICE|Focal Mask|The treatment group will receive and use the focal mask.
41465673|NCT05331391|BEHAVIORAL|Brief mobile SMART Exercise Support Program|Patients will receive 1) a brief SMART Exercise individual face-to-face session; 2) a theory-based instant messaging (WhatsApp/WeChat) and telephone-delivered health coaching on a 2-stage tapering schedule. Stage 1 (week 1 to 6): daily messages and two biweekly phone calls for exercise habit formation. Stage 2 (week 7 to 12): messages twice a week and monthly phone calls for exercise habit maintenance.
41465674|NCT02998541|DRUG|SHP640|Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
41465675|NCT02998541|DRUG|PVP-I 0.6%|Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
41465676|NCT02998541|OTHER|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
41465677|NCT00047047|DRUG|gemcitabine hydrochloride|Given IV
41465678|NCT00047047|DRUG|tanespimycin|Given IV
40785307|NCT04301323|DRUG|BHVI2 eye drops|Including 35 children enrolled to receive BHVI2 eye-drops once nightly
40785308|NCT04301323|DRUG|BHVI3 eye drops|Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
40785309|NCT04169464|DRUG|Sofosbuvir Oral Product|to investigate the drug effect on renal function and insulin resistance
40785310|NCT02171689|DRUG|[14C]- BIBW 2992 MA2|
40785311|NCT01267786|PROCEDURE|Liver surgery|hepatectomy
40989544|NCT02786147|OTHER|Breast Cancer Genetics Referral Screening Tool 3.0|"The B-RST is a simple yet effective validated screening tool to quickly identify individuals who may be at risk for hereditary breast and ovarian cancer and should be referred for cancer genetic counseling to formally evaluate their family history and discuss the benefits and limitations of genetic testing for hereditary breast and ovarian cancer.~Clinic staff will give each patient arriving for a screening mammogram appointment a packet and briefly inform them about the opportunity to participate in a research study and that these materials can help them decide whether or not to participate.~Patients who indicate that they are interested in completing the B-RST screening while in the clinic will be provided with an electronic tablet that has a secure internet browser tab open to the web-based study version of the screening tool (the B-RST 3.0)."
40989545|NCT02786147|OTHER|Standard Handout|A document explaining the patient's positive test result indicating that they are at increased risk for HBOC (Hereditary Breast or Ovarian Cancer) which includes information on how to obtain cancer genetics services through Winship.
40989546|NCT02786147|OTHER|Physician Notification|Primary care physician or ordering physician will be notified vie EeMR that the patient screened positive on the B-RST. The note provides specific instructions on how to refer the patient for cancer genetic counseling services.
40989547|NCT02786147|OTHER|Automatic Follow-Up by Genetic Counseling Staff|Within 1-2 weeks after the mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment.
40989548|NCT04038515|DRUG|Nicotine 0 mg/mL|E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
41307181|NCT05020652|DRUG|TQ05105 tablets|TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.
41307182|NCT05020652|DRUG|Hydroxycarbamide tablets|Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor.
41307183|NCT03152916|DEVICE|3d printing personalized plate|3d printing personalized plate will be used in the subtalar arthrodensis
41465679|NCT00047047|DRUG|cisplatin|Given IV
41307184|NCT00330720|DEVICE|Emergency Response System (Device)|
41307185|NCT02310802|DRUG|OBE001 dose 1|OBE001 dispersible tablets for single oral administration
41307186|NCT02310802|DRUG|OBE001 dose 2|OBE001 dispersible tablets for single oral administration
41307187|NCT02310802|DRUG|OBE001 dose 3|OBE001 dispersible tablets for single oral administration
40785312|NCT05376722|DRUG|pamiparib|pamiparib 40 mg orally, twice a day
40785313|NCT05376722|DRUG|abiraterone|biraterone acetate 1000 mg orally, once a day
40785314|NCT05376722|DRUG|prednisone|prednisone acetate tablets (prednisone) 5 mg, once a day
40785315|NCT02665533|DRUG|Dexamethasone|Dexamethasone 8 mg
40785316|NCT02665533|DRUG|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg
40785317|NCT01518790|DRUG|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
40785318|NCT04846387|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"A T1-weighted Anatomical Image, Diffusion Weighted Image, and functional MRI (fMRI) of empty bladder image will be obtained.~Additionally, fMRI image during full bladder state and voiding/holding tasks will be obtained."
40989549|NCT04038515|DRUG|Nicotine 6 mg/mL|E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
40989550|NCT04038515|DRUG|Nicotine 12 mg/mL|E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
40989551|NCT04038515|DRUG|Nicotine 24 mg/mL|E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
40785319|NCT04846387|DIAGNOSTIC_TEST|Post-Void Residual|The patient's post-void residual is determined using a portable ultrasound machine after emptying the bladder just prior to entering the MRI scanner and immediately after the MRI scan.
40989552|NCT04038515|OTHER|'Menthol' flavor|E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
40785320|NCT04846387|DIAGNOSTIC_TEST|Uroflowmetry|Patients will urinate into a funnel connected to an electric flow meter to record urine flow rates in mililters per second. This is used as part of the screening process.
40989553|NCT04038515|OTHER|'Menthol/Mint' flavor|E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
40989554|NCT04038515|OTHER|'Green Apple' flavor|E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
40989555|NCT04038515|OTHER|'Watermelon' flavor|E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
40989556|NCT04038515|OTHER|'Unflavored'|E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
41307188|NCT02310802|DRUG|Placebo|Placebo dispersible tablets for single oral administration
41307189|NCT02563288|DRUG|Esmolol|effect of esmolol on intraoperative sympathetic control and on extubation conditions.
41307190|NCT02563288|DRUG|Dexmedetomidine|effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
41307191|NCT01542359|OTHER|Yogic practice|breathing, meditation, physical postures
41307192|NCT01542359|OTHER|Conventional Exercise|Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
41307193|NCT05129722|DRUG|Low dose combination polydiuretic therapy|"Low dose combination polydiuretic therapy treatment consists of:~Loop diuretic bumetanide 0.5 mg Mineralocorticoid receptor antagonist eplerenone 25 mg Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg"
41307194|NCT05129722|DRUG|Comparator monotherapy empagliflozin|Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg
41307195|NCT05009459|BEHAVIORAL|eVIS|To facilitate individualized physical activity levels within the Swedish IPRP setting, an eVISualisation (eVIS) of physical activity and pain intervention has been systematically developed. eVIS is designed to target facilitating mechanisms for behavior change, such as outcome expectations, self-monitoring, self-evaluation, and self-efficacy, which are theoretically framed by the Social Cognitive Theory by Bandura. In eVIS, objectively measured physical activity tracking using a wrist-worn activity tracker (Fitbit Versa 2) is combined with a daily activity goal (steps/day) and daily patient reports of known important clinical outcome assessments: pain intensity and its affect on daily activities30-34 and pharmaceutical consumption. Data is collected and visualized in a purpose-developed web application, Pin And TRaining ON-line (PATRON), which can be used by the patient and the IPRP-team to follow and adjust individual physical activity levels.
41307196|NCT02469831|DRUG|Rocuronium|
41307197|NCT02597673|OTHER|Home Exercise Program (HEP)|All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. This program includes sessions with the study coordinator. A handout and given a demonstration of the daily exercises to be performed at home and weekly communication from the study coordinator regarding compliance with the exercises.
41307198|NCT02597673|DEVICE|NMES|To ensure consistent interventions across participants, a specified percentage of baseline maximal voluntary contraction (% MVC) will be used to determine the intensity of the training contraction. The electrical amplitude to obtain the desired intensity will be determined for each participant. Participants will train at 20-30% of MVC during weeks 1-3, 30-40% of MVC during weeks 3-6, and 40-50% of MVC during weeks 6-9. Incremental increases will be made at the 3 and 6 week clinic visits. Individualized instructions for adjusting the amplitude dial settings, with a return demonstration, will be used to maintain the appropriate percentage of MVC. During the home training sessions, participants will adjust the amplitude required to achieve the desired goal, as tolerated.
40989557|NCT00991666|PROCEDURE|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
41307199|NCT02597673|DEVICE|TENS|The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.
40785321|NCT04846387|BEHAVIORAL|Questionaire - AUA Symptom Score|Subjects will fill out questionnaire asking about urinary symptoms. The range is 0-35.
40785322|NCT00583219|DRUG|Botulinum-A toxin|A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
40989558|NCT06004115|DRUG|Lorazepam|1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form
40989559|NCT06004115|OTHER|Placebo|placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form
40989560|NCT03585439|PROCEDURE|Observational study evaluating the results of an intervention for isthmic spondylolisthesis: surgical procedure with double approach: Anterior lumbar Interbody Fusion then postero-lateral fusion|First in supine position, an ALIF is performed: with a Pfannenstiel incision, through a retroperitoneal approach, a discectomy is performed at the level of the spondylolisthesis then a cage is placed between the two vertebral bodies. Then, in prone position, a standard posterior approach is performed, pedicle screws are placed to achieve a postero-lateral fusion. A decompression may be associated.
41307200|NCT04258332|DIETARY_SUPPLEMENT|High Salt Diet|Patients will be randomized to be on a high salt diet for 7 days.
41307201|NCT04258332|DIETARY_SUPPLEMENT|Low Salt Diet|Patients will be randomized to be on a low salt for 7 days.
40989561|NCT04902716|BEHAVIORAL|Design course|Precision nursing is a new trend in nursing in recent years. It is based on individual differences in disease type, gender, lifestyle, family, race, social and cultural factors, etc., to provide the most suitable empirical-based nursing treatment.Diverse courses include music, breathing exercises, cognitive training, hand-made knitting, etc.
41307202|NCT05580172|DRUG|RH324|polymolecular
41465680|NCT00047047|OTHER|laboratory biomarker analysis|Correlative studies
41465681|NCT04413968|DIAGNOSTIC_TEST|Rapid detection test|Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff
40989562|NCT00484939|DRUG|Bevacizumab|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
40989563|NCT00484939|DRUG|Capecitabine|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
40989564|NCT00416559|OTHER|clinical observation|
40989565|NCT02532647|DRUG|Remimazolam|
40989566|NCT02532647|DRUG|Midazolam|
40989567|NCT02532647|DRUG|Placebo|
41147088|NCT03709472|BEHAVIORAL|Behavioral: Traditional face-to-face treatment-no technology|Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
41307203|NCT05465603|DEVICE|ETDNO (Elastic Tension digital neoprene orthosis)|A bespoke orthosis created from neoprene.
41307204|NCT03940924|OTHER|Training program|High Intensity Interval Training + Resistance Training (HIIT + RT)
41307205|NCT03029416|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy using different fractionation schedules
41307206|NCT02273050|DRUG|Saxagliptin 5 mg|Tablet, Oral, 5 mg, Once daily in the morning
41465682|NCT04413968|DIAGNOSTIC_TEST|Nasopharyngeal swab|Posterior nasopharyngeal swabbing in children
41465683|NCT04413968|DIAGNOSTIC_TEST|Stool collection|Stool collection in children
41465684|NCT05080608|OTHER|Surgery|Treatment according to clinical practise
41465685|NCT00361478|BEHAVIORAL|Exercise and education|Weekly exercise and education program for 8 weeks
41465686|NCT00361478|BEHAVIORAL|Education|Written educational material
40989568|NCT01370226|BEHAVIORAL|CBI|"The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
41465687|NCT00630903|DRUG|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
41465688|NCT00630903|DRUG|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
41465689|NCT00601406|GENETIC|gene expression analysis|
41465690|NCT00601406|GENETIC|gene rearrangement analysis|
41465691|NCT00601406|GENETIC|polymorphism analysis|
41465692|NCT00601406|OTHER|laboratory biomarker analysis|
40785323|NCT00583219|DRUG|Dimethyl sulfoxide (DMSO)|Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
41307207|NCT02273050|DRUG|Placebo 5 mg for Saxagliptin|Tablet, Oral, 5 mg, Once daily in the morning
41307208|NCT02273050|DRUG|Placebo 500 mg for metformin (with titration)|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
41307209|NCT02273050|DRUG|Metformin 500 mg with titration|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
41465693|NCT00601406|RADIATION|radiation therapy|
41465694|NCT02327325|BEHAVIORAL|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
41465695|NCT02327325|BEHAVIORAL|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
41465696|NCT05387070|DRUG|TransCon PTH|TransCon PTH is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for SC injection.
40989569|NCT01370226|BEHAVIORAL|TBI|"Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
40989570|NCT06443970|DEVICE|Exsalta Suction Device|Low flow endotracheal suction device
41465697|NCT05387070|DRUG|placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
40785324|NCT00786162|OTHER|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
40785325|NCT00786162|OTHER|BP cuff at workplace|Provided BP cuff for communal use at the worksite
40989571|NCT04675294|DRUG|evorpacept|IV Q3W
40989572|NCT04675294|DRUG|pembrolizumab|IV Q3W
40989573|NCT04626232|PROCEDURE|N-SLEEVE technique|The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).
40989574|NCT04626232|PROCEDURE|SLEEVE|SLEEVE Technique : Removal of 2/3 of the stomach
40989575|NCT00790881|DRUG|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
40989576|NCT00790881|DRUG|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
41307210|NCT00937560|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile solution for infusion.
41307211|NCT00937560|DRUG|Paclitaxel|Paclitaxel was supplied locally in commercial batches.
41465698|NCT03375749|BEHAVIORAL|Standing desk intervention|Standing desk converter
41465699|NCT03375749|BEHAVIORAL|Waitlist control|Control
41307212|NCT00937560|DRUG|Carboplatin|Carboplatin was supplied locally in commercial batches.
41307213|NCT06482554|DRUG|Lumateperone 42 mg|Standard treatment with lumateperone
41465700|NCT00076245|BEHAVIORAL|Light Therapy|Light therapy will involve exposure to bright light twice a day.
40989577|NCT02875860|DEVICE|GoldBal2 detachable balloon|Placement of the balloon using the plug/unplug method.
41307214|NCT06482554|DRUG|Risperidone 2 mg|Standard treatment with other antipsychotic drugs
41307215|NCT00882726|DRUG|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
41307216|NCT00882726|DRUG|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
41465701|NCT00076245|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
41465702|NCT03895229|DRUG|Empagliflozin 10 MG Oral Tablet [Jardiance]|Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
41465703|NCT00485004|DEVICE|Cutting balloon|Cutting balloon
41465704|NCT00485004|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent
41465705|NCT02618382|DRUG|Tranexamic Acid|1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
40785326|NCT04355650|OTHER|Clinical decision support tool|Adults (aged 18-64 years) who meet DSM-5 diagnostic criteria for non-psychotic unipolar major depressive disorder (MDD) and meet study eligibility criteria will receive 8 weeks of open-label treatment with an SSRI or SNRI antidepressant. Depressive symptoms will be assessed using the subject- and clinician-rated versions of the 16-items QIDS scale (QIDS-SR and QIDS-CR) and the 17-item HAMD at baseline, week 2 (via telephone), week 4, and week 8; with an additional phone contact at week 24. The QIDS scale scores at 2- and 4-weeks will be entered into the AHI-based clinical decision support tool, and the outcome predicted by the tool (e.g., the predicted eventual treatment outcome at 8 weeks) will be recorded. Clinicians and patients will be blinded to the clinical decision support tool prediction of outcome provided at the 2- and 4 weeks.
41465706|NCT02077335|RADIATION|HDR brachytherapy monotherapy|"Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~* V100 \> 95%~* V150 30-35%~* V200 \< 15%~* D90 \> 90% (12,15Gy)~Bladder~• V75 \< 1cc~Rectum~• V75 \< 1cc~Urethra~V125 = 0cc D10 \< 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure."
40785327|NCT03425916|OTHER|Physical therapy intervention|Primiparous women start a physical therapy intervention in week 6 after normal one-child delivery, based on abdominal and pelvic floor exercises, education and behavior advices. Abdominal muscle condition and activation are measured by transabdominal ultrasound and surface electromiography. This group is going to be examined after treatment and 6 and 12 months after treatment.
40785328|NCT02273921|OTHER|EEG recording|EEG is recorded once for each participant
40989578|NCT02875860|DEVICE|Baltaccidbpe100 Delivery Catheter|The catheter assists with implanting the balloon in the plug/unplug method.
40785330|NCT00012441|PROCEDURE|hemodialysis|
40785331|NCT03992469|DRUG|EBFAHF-2|EBFAHF-2 is a 0.55g capsule that is easy to swallow. The quality, safety and consistency of EBFAHF-2 are established per FDA guidance under a botanical drug title. Low dose (maximum of 2 capsules bid) and full dose (maximum of 5 capsules bid). Weight based dosing will ensure an equivalent amount is given to each individual.
40785332|NCT03992469|DRUG|Placebo|Placebo capsules made of cornstarch
40989579|NCT02875860|OTHER|Standardized postnatal care|After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
40989580|NCT01511523|DIETARY_SUPPLEMENT|RGMA001|3 capsules administered BID once a day.
40785333|NCT05252286|OTHER|video watching|"Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance."
40989581|NCT01511523|DIETARY_SUPPLEMENT|Sugar Pill|Placebo
40989582|NCT01042236|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
40989583|NCT04777162|DRUG|Tislelizumab|For included participants, tislelizumab would be administrated 200mg q3w iv.
40989584|NCT04777162|DRUG|Anlotinib|Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
40989585|NCT03679780|DRUG|BQ-788|This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
40989586|NCT03679780|DRUG|BQ-123|This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
40989587|NCT03679780|DRUG|L-Arginine|A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min
40989588|NCT03679780|DRUG|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
41465707|NCT00381823|BEHAVIORAL|Cognitive Behavioral Therapy|
41465708|NCT04445233|DEVICE|COVID-19 IgM-IgG Rapid Test|Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.
41307217|NCT00882726|DRUG|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
41307218|NCT00882726|DRUG|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
41307219|NCT00931671|OTHER|Exercise training|aerobic exercise training
41307220|NCT06553924|DRUG|Macitentan and Tadalafil film-coated tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
41307221|NCT06553924|DRUG|PrOpsynvi® macitentan and tadalafil film-coated tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
41307222|NCT00905021|DRUG|Exemestane|Exemestane 25 mg by mouth every day.
41307223|NCT00905021|DRUG|Sutent|Sunitinib 37.5 mg by mouth every day.
41307224|NCT00454155|DRUG|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
41307225|NCT00563836|DRUG|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
41307226|NCT01346371|DRUG|Refresh Tears 0.5% Lubricant Eye Drops|
41307227|NCT01346371|DRUG|Bepreve 1.5% Ophthalmic Solution|
41307228|NCT05159596|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
41307229|NCT05159596|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
41307230|NCT02590445|DEVICE|deep brain stimulation system|
41307231|NCT01830361|DRUG|midostaurin (PKC412)|Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
41307232|NCT03899129|PROCEDURE|simultaneous working length control using E-CONNECT S|E-CONNECT S (Eighteeth medical technology Co., Ltd, china) is an endomotor with integrated apex locator newly introduced in the market with continuous WL measuring function. It contains an optional module for rotary instrumentation, allowing the device to function as a low-speed handpiece, apex locator, or a combination of both. This motor has an attention-grabbing property that when an instrument reaches the predetermined working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).
41307233|NCT03899129|PROCEDURE|separate length determination and root canal preparation using Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
41307234|NCT04443127|DEVICE|Virtual Reality Training Session|VR based motor priming intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
41307235|NCT04443127|BEHAVIORAL|Motor-Relearning Program|Motor-Relearning Program intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
41465709|NCT04075656|BEHAVIORAL|Standard of Care|Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.
41465710|NCT04075656|BEHAVIORAL|UrApp|Caregivers/parents will download UrApp at the baseline visit. UrApp contains instructional videos to guide users. The telephone number of the patient's provider will be entered into UrApp and participants will be able to call their providers directly through UrApp. The email address of the Emory study staff will also be entered. UrApp will automatically e-mail test results to the research staff when elected by the users. Participants will be asked by study staff, and reminded by the app, to call their providers and send urine testing results to the study staff whenever there is a relapse or remission. When the study staff receives alerts of a relapse/remission via UrApp, the information will be communicated to the treating physician within 1 business day.
41465711|NCT01144403|DRUG|Cyclophosphamide|as prescribed, 6 cycles
41465712|NCT01144403|DRUG|Fludarabine|as prescribed, 6 cycles
41465713|NCT01144403|DRUG|Mitoxantrone|as prescribed, 6 cycles
41465714|NCT01144403|DRUG|Rituximab|375 mg/m\^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
41465715|NCT03442569|DRUG|Panitumumab|6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab
41307236|NCT03039127|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
41307237|NCT00605410|DRUG|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
41307238|NCT00605410|DRUG|placebo|Matched placebo
41465716|NCT03442569|DRUG|Nivolumab|240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab
41465717|NCT03442569|DRUG|Ipilimumab|1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab
41307239|NCT00633438|OTHER|Placebo|Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
41465718|NCT01595841|DRUG|Sirolimus|3 mg po od loading dose for two days, then 2 mg po od for thirty days
41465719|NCT03574337|DRUG|Sugammadex|No additional information
41465720|NCT03574337|DRUG|neostigmine/glycopyrolate|No additional information
40785334|NCT05252286|OTHER|paper group|In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.
40989589|NCT03679780|DRUG|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
41307240|NCT00633438|DRUG|Celecoxib|400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
41307241|NCT02165800|PROCEDURE|L-PANP-TME|
40785335|NCT05252286|OTHER|oral education group|the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
41307242|NCT02165800|PROCEDURE|O-PANP-TME|
41307243|NCT03920826|DEVICE|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
41465721|NCT00946491|DRUG|Haloperidol 10 mg Tablets (Cord Laboratories)|
41465722|NCT00946491|DRUG|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
41465723|NCT06051539|DEVICE|MR-001|MR-001 is an autonomous neurorehabilitation system based on the principles of Rhythmic Auditory Stimulation intended to improve walking and ambulation in adult chronic stroke patients. MR-001 is intended to be a prescription use only device for use at home/community. The user operates the MR-001 System autonomously and the therapy progresses automatically once a user engages in a session. The MR-001 system consists of two foot sensors that measure walking, a touchscreen device preloaded solely with a proprietary software application, a headset, and charging equipment. The electronic components are powered by lithium-ion rechargeable batteries. Participants are asked to walk with the device for 3 times per week for 12 weeks. Each walking session is 30 minutes in length.
41465724|NCT06473051|OTHER|Original set|The original set of implementation strategies will include the same strategies as applied in the INTERCARE study by the research group but will be updated to fit the current practice field.
41465725|NCT06473051|OTHER|Adapted set|The adapted set of implementation strategies will contain similar implementation strategies that are expected to achieve the same outcomes as the first set, but with less resources required (for instance, by providing group coaching sessions rather than single sessions).
41307244|NCT03920826|DEVICE|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
41465726|NCT04509050|DRUG|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|In Part B, approved CFTR modulator as prescribed at the discretion of the treating physician -not dictated by the BEGIN investigators
41465727|NCT04523480|DRUG|Testopel 75mg Drug Implant|75 mg Testosterone pellets administered subcutaneously.
40989590|NCT03679780|DRUG|Lactated Ringer's|Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
41147089|NCT01439399|DRUG|Lidocaine,|Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
40785336|NCT05046392|BEHAVIORAL|Face-to-Face ART Adherence Intervention|All participants will receive a one hour face-to-face session with an adherence coach, based on LifeSteps. The session will cover behavioral skills that are important for maintaining adherence to ART and will explore potential barriers for managing each skill. Cognitive-behavioral therapy, problem solving, and motivational interviewing techniques are used to explore barriers and create health goals.
41307245|NCT03732391|DRUG|Pembrolizumab 25 MG(milligram)/ML|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression
41307246|NCT06505057|OTHER|Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation|Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation
41307247|NCT04420416|OTHER|Survey|The investigators will use the Spanish language validated version of the Academic Self-Concept Scale (ASCS), the Patient Health Questionnaire-9 (PHQ-9) depression screening scale, and the General Anxiety Disorder-7 (GAD-7) screening scale. Additionally, the sample will be asked about their gender, age, preference of teaching modality, and finally, if the participants have perceived a change in their performance or any change in their grades.
41307248|NCT04699604|DRUG|Levocetirizine Dihydrochloride|At the end of the HILD assessment participants will be randomized to Levocetirizine Dihydrochloride or placebo. Children will be randomized by an investigational pharmacist to add-on either Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children \>11 years per recommended doses) or placebo to their current asthma regimen.
41307249|NCT04699604|DRUG|Placebo|Placebo
40989591|NCT01413555|OTHER|Blood Culture QI Program|The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
40989592|NCT00721786|BEHAVIORAL|UCSF/SFGH Internet Stop Smoking Study site|Internet stop smoking site in Spanish and English
41307250|NCT03367130|BEHAVIORAL|Mobile phone reminder|Intervention described already in arm/group descriptions.
41307251|NCT01005719|DRUG|Zegerid|Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.
41307252|NCT01005719|DRUG|Prevacid®|Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
41307253|NCT05460871|DRUG|Pregabalin 75mg|participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, then 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days, then stop.
41307254|NCT03765476|BEHAVIORAL|SALIENCE|"3 computer-based training sessions with program SALIENCE per week over 3 weeks (see study description)"
41307255|NCT03765476|BEHAVIORAL|TAU|treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.
41465728|NCT04523480|DRUG|Testopel 100mg Drug Implant|100 mg Testosterone pellets administered subcutaneously.
41465729|NCT04523480|DRUG|Testopel 200mg Drug Implant|200 mg Testosterone pellets administered subcutaneously.
41465730|NCT05778240|BEHAVIORAL|Phone call|"Participants were given the vaccination appointment card and participants received a telephone call every month two days before their appointment. Participants were reminded that they have a set appointment and were asked to plan the day of their appointment as detailed below. The standard script used in the telephone call in every hospital was as follows:Hello, we are calling you because you are enrolled in the palivizumab prophylaxis research program. As you know, you have a vaccination appointment on \[enter date\] at \[enter time\]. To help you plan your day of appointment, we have a few short questions.~1. At your appointment day, will you be coming to the hospital from home, or will you need to get permission from your workplace?~2. What kind of transportation do you plan to take to come to the hospital at your appointment day?~3. At what time do you plan to leave home or work to come to the hospital?"
40785337|NCT05046392|BEHAVIORAL|Carium Mobile Health Platform|Participants assigned to the experimental condition will receive access to a mobile health app, called Carium, for 12 months. The app will be used to facilitate continued coaching from the adherence coach. The app incorporates automated medications reminders with interactive adherence coaching via a secure messaging feature. Participants will receive custom medication reminders as push notifications that will ask them to indicate if they have taken their medication or not. This will allow adherence coaches to monitor self-reported adherence in the app. Adherence coaches will use the secure messaging feature to check-in with participants and reach out to participants who appear to be struggling with adherence and offer assistance.
40785338|NCT00742625|DRUG|daunorubicin hydrochloride|Given IV
40785339|NCT00742625|DRUG|cytarabine|Given IV
40785340|NCT00742625|DRUG|bortezomib|Given IV
40785341|NCT02869165|DRUG|Conjugated equine estrogen topical cream|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
40785342|NCT02869165|DRUG|Apricot kernel oil|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
40785343|NCT02423486|DEVICE|Electromagnetic stimulation therapy (BIOCON-2000)|
40785344|NCT02423486|DEVICE|Electromagnetic stimulation therapy with biofeedback|
40785345|NCT02609425|DEVICE|Stratafix PGA Suture|Subject leak Stricture rates post procedure
40989593|NCT01867827|OTHER|Neurofeedback and Physical Exercise|
40989594|NCT01867827|OTHER|Physical Exercise|
40989595|NCT02368795|DEVICE|Pancreatic Stent|A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
41307256|NCT02390115|OTHER|Elastic tape application in shoulder|
40785346|NCT05246202|BEHAVIORAL|Alcohol-Anxiety Personalized Feedback Intervention 2.0|AA-PFI 2.0 is a culturally adapted, brief, computer-delivered, personalized feedback intervention to address alcohol misuse in the context of clinical anxiety.
40785347|NCT05246202|BEHAVIORAL|Control Personalized Feedback Intervention|C-PFI is a brief, computer-delivered, personalized feedback intervention on exercise and nutrition.
40785348|NCT04124627|PROCEDURE|Ultrasound guidance in addition to radiographic guidance|Patients that will be operated will receive ultrasound guidance in addition to radiographic guidance, that is gold standard
40785349|NCT06451874|BEHAVIORAL|Functional Power Training (FPT)|Participants will receive twice weekly FPT, a progressive functional-based exercises that target optimizing leg force production and leg velocity.
40785350|NCT06451874|BEHAVIORAL|Music-Based Digital Therapy (MBDT)|Participants will receive twice weekly MBDT, a technology-driven gait training that is grounded in evidence-based rehabilitation treatment, rhythmic auditory stimulation.
40785351|NCT06451874|BEHAVIORAL|FPT + MBDT|For non-responders who were randomized to augment treatment, they will receive combined FPT and MBDT treatment.
40989596|NCT02368795|DRUG|Indomethacin|Indomethacin 100 mg suppository ten minutes before ERCP
40989597|NCT02368795|DRUG|Isosorbide Dinitrate|Sublingual Isosorbide dinitrate 5 mg before ERCP
40989598|NCT02368795|DRUG|Ringer's lactate|IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
40989599|NCT05678829|OTHER|Education|The trainings for the Virtual Reality group will continue in accordance with the training titles according to the weeks, using virtual reality glasses.
40989600|NCT04136925|OTHER|questionnaire|questionnaire before and after race
40989601|NCT00060931|DRUG|carvedilol|
40989602|NCT00060931|DRUG|metoprolol|
40989603|NCT04087707|DRUG|Step 1: TS-142|Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
40989604|NCT04087707|DRUG|Step 2: TS-142|Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
41465731|NCT05778240|BEHAVIORAL|Text message|Participants were given the vaccination appointment card and participants were included in a messaging group (on Whatsapp or SMS, depending on the participant's preference) where, twice a month they received a message informing them on RSV, on the additional risks caused by RSV infection in children with congenital heart diseases and on the benefits of adherence to the prophylaxis program. These messages also involved statements about the high number of patient families that kept their appointments in the previous month.
40989605|NCT04087707|DRUG|Step 2: Placebo|Elderly participants will receive placebo once daily for 7 consective days
40989606|NCT01569958|OTHER|transcranial direct current stimulation|transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
41465732|NCT05778240|BEHAVIORAL|Control|Participants were given the vaccination appointment card.
40989607|NCT01569958|OTHER|Sham stimulation|1 mA stimulation for 30 seconds every 900 seconds per session
40989608|NCT04341909|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
40989609|NCT03040466|DEVICE|reusable fiberoptic ureteroscope|We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
40989610|NCT03040466|DEVICE|disposable digital ureteroscope|We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
40989611|NCT03959020|PROCEDURE|Anti-reflux surgery|Anti-reflux surgery for verified GERD
40989612|NCT04859881|OTHER|No intervention|No intervention
40989613|NCT04067557|DIAGNOSTIC_TEST|molecuar test of BV|diagnosis of BV
40989614|NCT00022633|DRUG|gemcitabine hydrochloride|
40989615|NCT00022633|DRUG|paclitaxel|
41465733|NCT04729608|DRUG|Batiraxcept|Batiraxcept is an experimental drug
40785352|NCT03789981|GENETIC|Immunogenic profile|RNA sequencing (RNAseq), Whole exome sequencing (WES), NeoAntigens (NeoAg), Immune checkpoints analysis, Gene expression profiling
40785353|NCT03415503|DRUG|Medox® Anthocyanin capsules|Subjects were orally administered Medox® capsules daily for 12 weeks.
40989616|NCT04322747|DIAGNOSTIC_TEST|Distortion product otoacoustic emissions (DPOAE)|Audiometry for extended high frequencies, DPOAE, and, ECochG measurements will be collected before and after skull-based surgeries.
40785354|NCT02224534|DRUG|Ticagrelor|Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
40785355|NCT02224534|DRUG|Clopidogrel|Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
40785356|NCT03478670|GENETIC|Strimvelis|"Strimvelis is a CD34+ cell enriched dispersion of human autologous bone marrow derived hematopoietic stem/progenitor cells transduced with a retroviral vector containing the human ADA gene. It will be administered as an intravenous infusion once only.~This is an observational registry that includes all patients who have previously received Strimvelis™ or GSK2696273."
40785357|NCT00014729|DRUG|isotretinoin|
40785358|NCT04046393|DEVICE|"Taiwan Scientific noninvasive blood pressure meter TS-0411"|measure autonomic nerve
40785359|NCT04046393|DEVICE|Meridian Energy Analysis Device(MEAD)|measure meridian energy
40785360|NCT04046393|PROCEDURE|bacteria culture|use culture swab to culture nasal discharge
40785361|NCT04046393|PROCEDURE|nasopharyngoscopic examination|use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
40989617|NCT03889158|BIOLOGICAL|Typhoid Vaccine|All participants will receive the typhoid vaccine.
40989618|NCT03889158|DIETARY_SUPPLEMENT|Ascorbic Acid|All participants will receive ascorbic acid.
40989619|NCT05752760|OTHER|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
40989620|NCT05752760|OTHER|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
40989621|NCT04273217|DRUG|AV-1|Single dose, administered by IV infusion (volume: 250 mL)
40989622|NCT04273217|DRUG|Placebo|0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
40989623|NCT00768144|DRUG|Sunitinib|
40989624|NCT01237535|DRUG|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
40989625|NCT01237535|DRUG|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone \[(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg\].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
40989626|NCT01237535|PROCEDURE|Insemination without luteal support|Routine insemination procedure without luteal support
40989627|NCT01447810|OTHER|Focused rigidity bi-valve long arm cast|Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
41465734|NCT04729608|DRUG|Paclitaxel|Paclitaxel is the standard of care, background therapy
41465735|NCT04729608|OTHER|Placebo|Matching placebo
40785362|NCT04046393|COMBINATION_PRODUCT|TCM nasal irrigation|Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
40785363|NCT06024187|PROCEDURE|Cold dissection|The subcutaneous flap dissection was performed with a scissor in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally. Our tumescent technique utilizes a solution made by mixing 0.2ml of epinephrine with 250 ml of 0.9% Sodium Chloride solution to create a 1‰ ratio. 150ml to 150ml of the solution was injected into the subcutaneous tissue of the operated breast with a 20-gauge spinal needle to establish a bloodless plane. The septa between the skin flap and parenchyma then was dissected using a scissor.
40785364|NCT06024187|PROCEDURE|Electrocautery Dissection|The subcutaneous flap dissection was performed with electrocautery in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally.
40785365|NCT03905915|DEVICE|Virtual reality (VR) session with AQUA module|A device with virtual reality is given to the patients with a film of 15 minutes
40785366|NCT05125003|BEHAVIORAL|FITBI|parents learn to identify high probability cues in the environment that can elicit RRBI symptoms and teach their child to inhibit repetitive behaviors and instead replace them with alternative and flexible play behaviors; and (b) teach parents how to embed this FITBI approach into their child's everyday routines
40785367|NCT05125003|BEHAVIORAL|Parental Education|Sessions will cover relevant information on young children with ASD, including understanding the ASD diagnosis, developmental changes in ASD, educational planning, advocacy, and treatment options.
40989628|NCT03179995|DRUG|Octreotide|Octreotide will be administered 50 µg intravenously per hour for up to five days postoperatively, starting at the time of vascular inflow disruption.
40989629|NCT03179995|OTHER|Placebo|Normal saline will be administered in the same fashion as Octreotide
40989630|NCT05783687|DIAGNOSTIC_TEST|NCC-Sp Assay|Orphalan has developed a new NCC speciation assay (NCC-Sp) using liquid chromatography inductively coupled plasma mass spectroscopy (LC-ICP-MS) to measure serum copper and ceruloplasmin bound copper from which non ceruloplasmin bound copper (NCC) is estimated.
40989631|NCT01103687|BIOLOGICAL|Ad26.ENVA.01 (rAd26)|5 x 10\^10 virus particles (VP) vaccine delivered intramuscularly (IM)
40785368|NCT05880251|BEHAVIORAL|Operant Conditioning with Peripheral Stimulation|This is a training intervention to strengthen the weakened sensorimotor responses and reduce pain, after a limb amputation. Non-painful peripheral stimulation will be applied to elicit a response.
40785369|NCT05880251|BEHAVIORAL|Control Group with Peripheral Stimulation Only|This is a control intervention in which the non-painful peripheral stimulation will be applied, same as the operant conditioning group, but no training feedback will be provided.
40785370|NCT01842672|DRUG|Clofarabine|Dose Escalation of Clofarabine
40785371|NCT01842672|DRUG|Mitoxantrone|
40785372|NCT04302025|DRUG|Alectinib|Participants will receive oral alectinib twice per day (BID)
40785373|NCT04302025|DRUG|Entrectinib|Participants will receive oral entrectinib daily
40785374|NCT04302025|DRUG|Vemurafenib (Enrollment closed)|Participants will receive oral vemurafenib BID
40785375|NCT04302025|DRUG|Cobimetinib (Enrollment closed)|Participants will receive oral cobimetinib daily
40785376|NCT04302025|DRUG|Pralsetinib (Enrollment closed)|Participants will receive oral pralsetinib daily
40785377|NCT04302025|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion
40989632|NCT01103687|BIOLOGICAL|Placebo Vaccine|Placebo vaccine delivered IM
40989633|NCT00364884|DRUG|ketoaminoacid|
40785378|NCT04302025|DRUG|SBRT|Patients will receive SBRT given concurrently starting with the first dose of atezolizumab
40785379|NCT04302025|PROCEDURE|Resection|Participants will receive surgical resection of the primary tumor along with selected lymph nodes
40785380|NCT04302025|DRUG|Chemotherapy|Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician
40785381|NCT04302025|DRUG|Divarasib|Participants in the KRAS G12C cohort will receive divarasib for approximately 8 weeks until the day before surgery.
40785382|NCT05260749|PROCEDURE|real-time fMRI neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
40989634|NCT00520975|BIOLOGICAL|Bevacizumab|Given IV
40989635|NCT00520975|DRUG|Carboplatin|Given IV
40989636|NCT00520975|DRUG|Paclitaxel|Given IV
40989637|NCT00520975|OTHER|Placebo|Given IV
40989638|NCT00520975|BIOLOGICAL|Trastuzumab|Given IV
40989639|NCT03566368|DIAGNOSTIC_TEST|Electrocardiogram|a 12 lead surface electrocardiogram taken after connecting limb and chest electrodes
40989640|NCT03566368|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|Transthoracic echocardiogram performed to evaluate Cardiac function in parasternal - long and short axis, Apical - 4 chamber and 5 chamber views.
40989641|NCT03566368|DIAGNOSTIC_TEST|Cardiac enzyme - Troponin I Levels|Blood sample - venous collected to measure blood troponin - I levels.
40989642|NCT05348187|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|The primary objective is to utilize a clinical trial assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 2 of Amgen clinical trial, in order to identify patients (with NSCLC and CRC) with KRAS G12C mutation positive tumors
40989643|NCT00159250|DRUG|AVI-4658 (PMO)|morpholino antisense oligonucleotide
40989644|NCT03485820|BEHAVIORAL|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
40989645|NCT03485820|BEHAVIORAL|Stroke education|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
40989646|NCT01813539|DRUG|ARGX-110|ARGX-110 will be administered as an IV infusion.
40989647|NCT01799499|DEVICE|TC-3 hydrogel|
41465736|NCT04756596|DIAGNOSTIC_TEST|DDVIT testing|One randomly selected eye will be included for each study participant. Participants respond to the DDVIT test in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
41465737|NCT04756596|DIAGNOSTIC_TEST|ETDRS testing|The same eye is included for each study participant. Participants respond to the standard ETDRS chart of our Ophthalmology Department in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
41465738|NCT04272476|OTHER|acupuncture and moxibustion|
40785383|NCT05260749|PROCEDURE|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI sham neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
40785384|NCT03288844|PROCEDURE|Ophthalmologic examinations|epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.
40785385|NCT03288844|OTHER|Digital pictures|Digital pictures 2D to be taken at each visit
40785386|NCT03288844|OTHER|QoL Questionnaires|Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
40785387|NCT04564235|GENETIC|genome-wide analyses|genome-wide analyses will be done in patients and parents (father, mother)
40785388|NCT04564235|GENETIC|Search for de novo mutations in paternal sperm samples|Sperm analysis will be done in paternal samples
40785389|NCT05173376|BEHAVIORAL|Portion size manipulation|The intervention was administered via changing portion sizes of foods served to participants.
40785390|NCT06307847|DRUG|SP5M001 inj|pre-filled syringe
40785391|NCT06307847|DRUG|Synovian inj|pre-filled syringe
40785392|NCT03574961|BEHAVIORAL|e-Support group|Online (remote), web-based support group via private video link.
40989648|NCT01799499|DEVICE|TC-3 hydrogel|
40989649|NCT01799499|DEVICE|TC-3 hydrogel|
40989650|NCT04105933|OTHER|CS-CBT|Culturally sensitive Cognitive Behavioural Therapy was delivered individually, focused on potential cultural beliefs and attitudes that might collide with core values of CBT.
40989651|NCT04105933|OTHER|CBT|CBT was delivered at an individual level, dealing with thoughts, feelings and behaviours in the present. Thoughts are identified and then challenged, to make them more objective and rational.
40989652|NCT04508374|PROCEDURE|1470 nm intra-lesional diode laser treatment of right HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of right HS-tunnel randomized to active treatment.
40989653|NCT04508374|PROCEDURE|1470 nm intra-lesional diode laser treatment of left HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of left HS-tunnel randomized to active treatment.
40989654|NCT02378701|BEHAVIORAL|QUALMS-1 Questionnaire|Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.
40989655|NCT02378701|BEHAVIORAL|FACT-An Questionnaire|Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.
40989656|NCT00459836|DRUG|PR-104|
41307257|NCT06128590|DEVICE|Photobiomodulation|"Photobiomodulation was applied before the procedures at an infrared wavelength of 808nm, at a power of 100mW, 1 point with a total energy of 8J, time of 80s, irradiance of 3.33W/cm² and radiant exposure of 266.66 J/cm2. The application point was on the retromolar region where the needle was inserted to perform the anesthetic, in a single application before the procedure.~The patient and operator were properly protected with goggles in both the control and experimental groups."
41465739|NCT04272476|DRUG|Fluoxetine|
41465740|NCT02206841|PROCEDURE|Liver biopsy|Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
40785393|NCT03574961|BEHAVIORAL|e-Journaling placebo|Online journaling activity.
40785394|NCT03974269|PROCEDURE|TAVI : Transcatether Aortic Valve Implantation|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
40785395|NCT02271061|DEVICE|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
40785396|NCT02271061|DEVICE|Control tape|Apply tape in same technique without tension.
40785397|NCT00498043|DRUG|R-CHOP14 induction regimen|R-CHOP14 induction regimen
40785398|NCT00498043|DRUG|R-ACVBP14 induction regimen|R-ACVBP14 induction regimen
40785399|NCT02691026|DRUG|Pembrolizumab|
40785400|NCT02706925|DRUG|BI 443651|
40785401|NCT02706925|DRUG|Placebo|
40785402|NCT04608877|BEHAVIORAL|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
40989657|NCT00459836|DRUG|docetaxel|
40989658|NCT00459836|DRUG|gemcitabine hydrochloride|
40989659|NCT00459836|OTHER|laboratory biomarker analysis|
40989660|NCT00459836|OTHER|pharmacological study|
41465741|NCT02206841|DEVICE|ARFI|Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
41465742|NCT02206841|DEVICE|SWE|Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
41465743|NCT02206841|DEVICE|Transient elastography|Transient elastography will be performed for evaluate fibrosis of liver.
41307258|NCT06128590|DRUG|Mepivacaine hydrochloride in combination with epinephrine|"The anesthetic of choice will be Mepivacaine, which is widely used in dentistry with duration between 1.5 and 2 minutes. The maximum recommended dose is 6.6 mg/Kg, not exceeding 400 mg or 11 anesthetic tubes.~It is a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) in combination with epinephrine 1:100,000 (0.01 mg/mL). Each vial contains 1.8 mL, 36 mg of mepivacaine hydrochloride, and 0.018 mg of epinephrine. All patients will use anesthetics from the same brand (DLA Pharmaceutical LTDA), one of the most widely used on the market. All patients will be anesthetized with tubes from the same batch, one tube per procedure."
41307259|NCT06128590|DEVICE|Photobiomodulation simulation|The participants will be treated in the same manner as in group A. The person responsible for the application of FBM will simulate the irradiations by placing the device in the same location described for the experimental group, but the equipment will remain turned off. To prevent the participant from identifying their group, the activation sounds of the devices (beeps) will be recorded to simulate the device's operation.
41307260|NCT03798145|PROCEDURE|Surgical Retinotomy|Surgical removal of small areas of retinal to increase outflow through the posterior drainage pathway.
41307261|NCT00202631|DEVICE|Surface Functional Electrical Stimulation|
41307262|NCT00444223|PROCEDURE|fluorine F 18 FEQA + positron emission tomography|
41307263|NCT04212338|OTHER|Before intravitreal injection music intervention|The patients in the Before-IVTI group listened to music for a period of 15 minutes 30 minutes before the injection.
41307264|NCT04212338|OTHER|during intravitreal injection music intervention|The patients in the During-IVTI group listened to music during the injection (approximately 5 minutes).
41307265|NCT01037504|DRUG|AZD5423|Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
41307266|NCT01037504|DRUG|Placebo|Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
41307267|NCT00633581|DIETARY_SUPPLEMENT|Ascorbic acid (Vitamin C)|Single intravenous injection of vitamin C 10g(20ml) with 100ml of normal saline over 30 minutes
41307268|NCT00633581|DIETARY_SUPPLEMENT|Normal saline|Single intravenous injection of 120ml of normal saline over 30 minutes
41307269|NCT00107068|PROCEDURE|[A] Aerobic isokinetic cycling exercise|
41307270|NCT00107068|PROCEDURE|[B] Progressive Resistance Training|
41307271|NCT00107068|PROCEDURE|[A] + [B]|
41307272|NCT04212793|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery
41307273|NCT04212793|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal
41307274|NCT02772965|DRUG|Methotrexate|"1. Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to \<40 kg, and 10 mg for children 20 to \<30 kg.~2. A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
41307275|NCT02772965|OTHER|Sugar pill (placebo)|"1. Placebo for methotrexate: The weekly dose will mimic that of methotrexate.~2. Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided to maintain blinding.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
41307276|NCT02242994|DEVICE|Dynavox Maestro|Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.
40785403|NCT04608877|BEHAVIORAL|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
41465744|NCT04125615|BEHAVIORAL|Protected Time Intervention|Participants were assigned two hours of protected, non-clinical time by the chief resident of the service. Chief residents were instructed to assign this time when clinical learning opportunities were lowest. Each participant acted as their own control and was on the intervention phase of the study for the first or last 6 weeks of a quarterly rotation. Residents were concurrently assigned to the same phase of the study (intervention versus control). Participants were not specifically limited in what they could do during their non-clinical time, but they were encouraged to use this time in a way they felt would decrease their own personal burnout and increase their well-being, whether this be performing work-related administrative duties previously done on personal time or fulfilling obligations that are integral to personal health and well-being that can only be completed during normal business hours.
41465745|NCT03904901|DIETARY_SUPPLEMENT|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, ingest with water and drink before bed.
41146457|NCT06340191|OTHER|Pilates without cueing|"The Pilates without cueing portion of the study involved participants following the same comprehensive Pilates program as the Pilates with cueing group, with a significant distinction: they did not receive any additional training on cueing. This group engaged in 60-minute Pilates sessions twice a week for 8 weeks, under the supervision of certified and highly experienced Pilates instructors. The program included a variety of exercises, both mat-based and utilizing props, designed to improve participants\&#39; physical condition and wellness.~However, unlike their counterparts in the first group, these participants were not given explicit instructions on how to enhance their body alignment, muscle engagement, or movement techniques through verbal and tactile cues. They performed the Pilates exercises following the standard regimen, without the nuanced guidance and real-time feedback focused on optimizing exercise execution through cueing."
41146458|NCT03640078|OTHER|acquisition imaging|The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis
41465746|NCT03904901|DIETARY_SUPPLEMENT|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
41465747|NCT00003317|DRUG|carboplatin|
41465748|NCT00003317|DRUG|paclitaxel|
41465749|NCT00003317|RADIATION|radiation therapy|
41146459|NCT05512598|DRUG|HB0034|HB0034, a single dose
41146460|NCT02216448|OTHER|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
41307277|NCT02242994|DEVICE|Experimental App|Participant receives experimental app to test speed and error rate of communication.
41307278|NCT05610995|DEVICE|SENSIUM Patch|The SENSIUM device is a tool to monitor vital signs by applying a connected skin patch whose objective is to detect complications early. The health data is transmitted to the practitioner and in case of disturbance of the parameters, an alert is sent. The patient can be called for consultation or hospitalization if necessary. This device has been tested under real clinical conditions in surgical units. The continuous monitoring of vital signs resulted in earlier detection of sepsis, earlier administration of antibiotics, shorter average length of stay and lower 30-day readmission rates.
41307279|NCT06197945|OTHER|Mulligan bent leg raise|Mulligan bent leg raise
41307280|NCT06197945|OTHER|Mulligan bent leg raise with Bowen therapy|Mulligan bent leg raise with Bowen therapy
41307281|NCT03297099|PROCEDURE|Robot-assisted Laparoscopic operation|Thirty patients with hepatolithiasis were selected and divided into robot group as described in the detailed description. Under general anesthesia, the patient was placed in a supine 30-degree reverse Trendelengburg position with both legs separating. The surgeon work on the console, and assist surgeon stand between legs. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
41307282|NCT03297099|PROCEDURE|open surgery|surgery group as described in the detailed description.Open surgery was performed under general anesthesia with the patient in the supine position. Routinely, a reversed L-shape incision was performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
40989661|NCT03264287|PROCEDURE|3 times per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.
40989662|NCT03264287|PROCEDURE|1 time per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
41307283|NCT01117688|PROCEDURE|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
41307284|NCT01763281|DRUG|CRH|
41307285|NCT01763281|DRUG|Placebo|
41307286|NCT04719338|DIAGNOSTIC_TEST|presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .|samples of peripheral blood from each patient into EDTA tube will be collected and tested for HCV RNA in peripheral blood mononuclear cells (PBMCs) .
41465750|NCT00003317|PROCEDURE|surgery|
40989663|NCT00263146|PROCEDURE|recruitment maneuver|
40989664|NCT02074995|BIOLOGICAL|BVS857|Group 1A\&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
40989665|NCT02074995|OTHER|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
41465751|NCT05907148|OTHER|Sensory integration training|"Sitting position:~1. Sit in a chair without a backrest while the feet on firm surface. without backrest while the feet on soft surface.~2. Sit on a ball while the feet on firm surface. while feet on soft surface.~3. Sit in a chair without a backrest with the feet on firm surface and perform sit-to-stand motion.~   without a backrest with the feet on soft surface and perform sit-to-stand motion.~4. Sit on a ball with the feet on the firm surface and perform sit-to-stand motion. with the feet on the soft surface and perform sit-to-stand motion.~5. Perform bipedal standing on a firm surface. on a soft surface.~6. Perform a semi-tandem stance on firm surface. on soft surface.~7. Walk forward on firm surface. on soft surface.~8. Walk forward on firm surface, cross obstacle, and continue to walk.~9. Walk forward on the soft surface, cross obstacle, and continue to walk."
41465752|NCT05907148|OTHER|Routine physical therapy|It consist of active joint mobilization, muscle stretching, motor coordination exercises and general balance training
41465753|NCT05907148|OTHER|General coordination exercise|"In supine lying:~1. Patients are told to place heel of one leg on shin or knee of the other leg,~2. Patient bends one leg and extends the other leg like bicycling motion.~3. Flexing one leg while extending other leg~4. Flexing and extending of one leg while abduction and adduction of other leg.~In sitting:~1. Patient performs marching without backrest or back support,~2. Patient reaches forward and sideways with arms~3. Rotation of trunk with physioball in hand without back support.~4. Patient reaches with legs to marked point in sitting.~In standing:~Patient performs 10 repetitions of~1. Clock Reach~2. Side Leg Raises~3. Leg Swings and~4. Ball catch and throw"
41465754|NCT05484609|OTHER|OUD scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of a patient with opioid use disorder undergoing methadone treatment with an addiction physician.
41465755|NCT05484609|OTHER|Diabetes scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of patient with diabetes in treatment with an endocrinologist.
41307287|NCT05485532|DEVICE|Telemonitoring System using Cosinuss° Two and/or Garmin Vivoactive 4|Development and validation of a telemonitoring system using smart devices
41465756|NCT02510950|BIOLOGICAL|Personalized peptide vaccine|
41465757|NCT02510950|DRUG|Poly-ICLC|
41465758|NCT02510950|DRUG|Temozolomide|
41465759|NCT05398835|BEHAVIORAL|Online interventions promoting HIV self-testing|1) viewing an online video promoting HIVST, 2) visiting the project webpage containing demonstration video of how to use HIVST kits, information about local HIV epidemic and benefits of HIV testing and HIVST, and a discussion forum containing positive feedback of HIVST users, and 3) having access to a chargeable HIVST services implemented by the CBO
41465760|NCT01899196|BIOLOGICAL|blood sampling,|
40785404|NCT04860115|PROCEDURE|Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)|"PECS II: Ultrasound guided block involving injection of 20 ml of 0.25% L-bupivacaine with dexmetomidine into an interfascial plane between the serratus anterior muscle and the external intercostal muscles followed by the needle withdrawal into an interfascial plane between the pectoralis major and pectoralis minor muscle where further 10ml will be administered.~PIFB: Ultrasound guided block involving injection of 10 ml of 0.25% L-bupivacaine with dexmetomidine into an iterfascial plane between the pectoralis major and the intercostal muscles approximately 2 cm laterally from the sternum to cover T2 to T6 dermatomes."
40785405|NCT02804061|BEHAVIORAL|NELIP|
40989666|NCT00854074|DEVICE|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
40989667|NCT04504799|DEVICE|Body composition measurement with HAG-BIA scale|Bio-impendance analysis
41146461|NCT02216448|OTHER|OR Training|Training on diagnostic knee arthroscopy in the OR
41465761|NCT02330744|BEHAVIORAL|Approach-positive AAT|One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
41146462|NCT01189045|BEHAVIORAL|Aerobic Exercise Program|The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
41146463|NCT01189045|BEHAVIORAL|Non-aerobic Exercise Program|The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
41146464|NCT00062478|DRUG|Karenitecin (BNP1350)|Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
41146465|NCT01732757|DRUG|Alcaftadine 0.25%|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
40989668|NCT01132157|DRUG|Desflurane|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
40989669|NCT01132157|DRUG|Propofol|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
40989670|NCT02627430|DRUG|Hsp90 Inhibitor AT13387|Given IV
40989671|NCT02627430|OTHER|Laboratory Biomarker Analysis|Correlative studies
40989672|NCT02627430|OTHER|Pharmacological Study|Correlative studies
40989673|NCT02627430|DRUG|Talazoparib|Given PO
40989674|NCT03099447|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
41146466|NCT01732757|DRUG|Olopatadine 0.2%|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
41146467|NCT01732757|DRUG|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
41146468|NCT05185102|OTHER|Cognitive tasks|Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
41465762|NCT02330744|BEHAVIORAL|Control AAT|One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
41307288|NCT02245568|DRUG|LMTM|The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
41465763|NCT02300987|DRUG|LEE011|
41465764|NCT02300987|DRUG|LEE011 Placebo|
41465765|NCT02289937|DRUG|Ropivacaine|
41146469|NCT05044832|BEHAVIORAL|Personalized Music|Personalized music delivered during the perioperative and post-operative periods. Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit.
41146470|NCT01214109|DRUG|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
41146471|NCT01214109|DRUG|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
41146472|NCT01214109|DRUG|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
41146473|NCT01214109|DRUG|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
41465766|NCT02289937|DRUG|Placebo|
41465767|NCT02289937|DEVICE|An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively|
41465768|NCT00116480|DRUG|Misoprostol|600 mcg of sublingual misoprostol
41146474|NCT00896740|GENETIC|microarray analysis|
41307289|NCT00367640|DRUG|100 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
41307290|NCT00367640|DRUG|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
41465769|NCT05920330|OTHER|Nasal Plug|Please see the arm description for details.
41465770|NCT00983528|BIOLOGICAL|Alemtuzumab|3mg day 1,10mg day 2, 30mg day 3, 30mg day 5, 30mg day 8, then three times per calendar week thereafter for a total 12- 30mg doses
41465771|NCT00983528|DRUG|Clofarabine|"Dose Escalation~Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9~Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5"
40989675|NCT03099447|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
40989676|NCT03099447|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
40989677|NCT00668941|DRUG|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
40989678|NCT00668941|DRUG|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
40989679|NCT00668941|DIETARY_SUPPLEMENT|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
40989680|NCT00668941|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
40989681|NCT04249310|DRUG|Tiotropium/Olodaterol|Soft Mist Inhaler product
41146475|NCT00896740|PROCEDURE|biopsy|
40989682|NCT04249310|DRUG|Tiotropium|Soft Mist Inhaler product
41465772|NCT06535763|OTHER|professional caregiver|"Care professionals will be questioned using a self-administered Quality of Life at Work scale, as well as a second scale (before and after training, with one test per day for 3 consecutive working days) asking about the number of work situations involving behavioral disorders in the residents under their care, and how they use the HAPNeSS method to deal with these situations.~The effects of the HAPNeSS method on caregivers' professional practices (actions taken, performance of tasks, relations with residents, etc.) and their feelings on the subject, will be collected in two semi-structured interviews (with half the participants selected at random) conducted before and after the training course by the research team's occupational psychologist."
40989683|NCT05478447|PROCEDURE|Vibration|whole-body vibration, and tendon vibrations will be applied to the human body
40989684|NCT04609787|DEVICE|Immersive Virtual Reality|Participants are placed in three-dimensional, life-sized computer-generated environments via a computer headset shows potential as a treatment for chronic pain and central sensitization.
41465773|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene cocrystal (ccPT) - Gelatin capsule|Participants will intake one gelatin capsule with 75 mg of Pterostilbene cocrystal (ccPT).
41465774|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene free form (PT)|Participants will intake one capsule with 50 mg of Pterostilbene free form (PT)
41465775|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene cocrystal (ccPT) - Gastro-resistant capsule|Participants will intake one gastro-resistant capsule with 75 mg of Pterostilbene cocrystal (ccPT).
40989685|NCT04244513|DEVICE|Deep brain stimulation|the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
40989686|NCT03556579|DEVICE|senofilcon A with new UV blocker|Test Lens
40989687|NCT03556579|DEVICE|senofilcon A|Control Lens
40989688|NCT06171776|DRUG|RetroMTA|calcium silicate lining material work as dentin substitute
40989689|NCT06171776|DRUG|TheraCal|calcium silicat material light cured
40989690|NCT06171776|DRUG|Fuji IX|filling material bonded chemically to the tooth structure
40989691|NCT00951665|DRUG|paclitaxel|Intravenous repeating dose
40989692|NCT00951665|DRUG|pertuzumab [Perjeta]|Intravenous repeating dose
40989693|NCT00951665|DRUG|trastuzumab emtansine [Kadcyla]|Intravenous escalating dose
40989694|NCT00951665|DRUG|paclitaxel|Intravenous escalating dose
40989695|NCT00951665|DRUG|trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
40989696|NCT05023811|DRUG|[14C]RIST4271|\[14C\]RIST4271 oral solution
40989697|NCT06037720|DEVICE|Coaguchek testing|Patients scheduled electively to undergo cardiac surgery with cardiopulmonary bypass at Hospital de Base in the Federal District.
41307291|NCT00367640|DRUG|500 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
40989698|NCT02883634|OTHER|Specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.
40989699|NCT02883634|OTHER|Non-specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
40989700|NCT06358105|PROCEDURE|Simulator-based training|A two-day training program will be performed before starting their cath lab period as interventional cardiology fellows
40989701|NCT06358105|PROCEDURE|Standard training|Standard master-apprentice training interventional cardiology fellows' program during their cath lab period
40989702|NCT06114147|DEVICE|trans thoracic echocardiography measure|The trans thoracic echography would be carried out with cardiac classic sections to ensure the structural cardiac and valvular normality and then sections repeated 3 times over 10 minutes will be carried out to calculate the cardiac output.
40989703|NCT06114147|DEVICE|ICON measure|The ICON will be placed at the beginning of the consultation and the measurements will be taken at the same time as the trans thoracic ultrasound in the left lateral decubitus position.
40989704|NCT06114147|DEVICE|USCOM|Afterwards, measurements will be made with USCOM in left lateral position and 3 of the best spectra archived according to the Fremantle score.
40989705|NCT04010123|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions of blood vessels in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses.
40989706|NCT06291051|DEVICE|Electrical spinal cord stimulation|electrical spinal cord stimulation in Parkinson's patients presenting with painful camptocormia
40989707|NCT04674046|DEVICE|Nonoperative treatment|Patients where the ankle is evaluated as stable using arthroscopy will be treated with conservative treatment using a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
40989708|NCT04674046|PROCEDURE|Operative treatment|Patients where the ankle is evaluated as unstable using arthroscopy will be operated on. Standard operative treatment is open reduction and internal fixation (ORIF) of the fracture using plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
40989709|NCT04674046|BEHAVIORAL|Standardized education|All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.
40989710|NCT06180447|BIOLOGICAL|Hepatitis B vaccine, rabies vaccine, HPV vaccine, influenza vaccine|Exposure was defined as use of the vaccine 90 days before the last menstrual period and during pregnancy.
40989711|NCT02619292|BEHAVIORAL|Mindful Movement Program|Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
40989712|NCT02378363|OTHER|Write, draw and interview|Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
40989713|NCT05467150|DIETARY_SUPPLEMENT|Probiotic Supplement|The probiotic that will be used is Culturelle® Digestive Daily Probiotic Capsules. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG (LGG).
40989714|NCT00840294|DRUG|Ciprofloxacin|
40989715|NCT05323942|OTHER|Education and Exercise Therapy Group|"82 children were evaluated. Among those, 37 volunteered children were trained and demonstrated in practice about bruxism, parafunctional oral habits, sleep hygiene education, and 5x5 therapeutic exercises. Therapeutic exercises program 5x5 included breathing exercises, head-neck, and scapular posture exercises which included jaw muscle and neck muscle stretching and strengthening exercises. They were asked to repeat each exercise with 5 set and 5 times a day for 8 weeks.~Sleep hygiene education was given to parents and children with explanation of the parafunctional oral habits to raise awareness about being conscious about the oral habits. Sleep hygiene education includes routines about bedtime, sleeping room environment, and timing for exercise."
40989716|NCT04979741|OTHER|No interventions|Observational study, no intervention is required
40989717|NCT00763347|DRUG|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
41146476|NCT01288729|DEVICE|Sure-T Steel Infusion Set Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
41146477|NCT01288729|DEVICE|Quick-Set Teflon Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
41146478|NCT05496829|BEHAVIORAL|Multicomponent Adherence Intervention|The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
41146479|NCT05496829|OTHER|Usual Care|Receipt of usual care from providers
41147090|NCT01439399|DRUG|Ketamine|Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
41307292|NCT00367640|DRUG|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
41307293|NCT04358094|OTHER|Conversational hypnosis script|Conversational hypnosis during peripherical veinous catheter set up
41307294|NCT04358094|OTHER|Standard script|Standard script during peripherical veinous catheter set up
41307295|NCT00475462|DRUG|metoprolol|
41307296|NCT00475462|DRUG|conventional treatment|
41465776|NCT00320853|DRUG|Vitamin D|
41465777|NCT02106533|OTHER|Aerobic exercise training|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
40785406|NCT03694951|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (i.e., action planning and coping planning) to reduce sedentary behaviour.
41147091|NCT01439399|DRUG|association ketamine-lidocaine|Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
41307297|NCT00796601|DRUG|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
41307298|NCT00796601|DRUG|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
40989718|NCT00763347|DRUG|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
40989719|NCT00763347|DRUG|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
40989720|NCT00763347|DRUG|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
40989721|NCT00763347|DRUG|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
41307299|NCT01325831|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
41307300|NCT01325831|DEVICE|Sham repetitive transcranial magnetic stimulation(rTMS)|Sham repetitive transcranial magnetic stimulation(rTMS)
41307301|NCT00093080|DRUG|ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
41307302|NCT02261168|OTHER|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
41307303|NCT00487084|DRUG|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
41307304|NCT00487084|DRUG|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
40989722|NCT00763347|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
40989723|NCT03193931|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
40989724|NCT03193931|DRUG|Methotrexate Injectable Solution|Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
40989725|NCT01423487|DRUG|Metformin|0.5g bid 26 weeks
41465778|NCT03458364|DEVICE|High flow nasal cannula|High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.
41465779|NCT03458364|DEVICE|Noninvasive ventilation|Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
41465780|NCT05688358|DIAGNOSTIC_TEST|serum levels of interleukin-17A in JIA|IL17 A by Enzyme linked immunosorbent assay method
41465781|NCT00462839|PROCEDURE|blood loss estimation|Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
41465782|NCT04014582|BEHAVIORAL|Communal Coping Intervention|This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages-one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.
41307305|NCT00487084|DRUG|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
40785407|NCT03815149|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|Neurointerventional procedures to treat intracranial (cerebral) aneurysms are minimally-invasive procedures performed by Interventional Neuroradiologists. The physician accesses the arterial system through a blood vessel in the groin followed by the insertion of a catheter. Pipeline™ Flex Embolization Device(s) with Shield Technology™,a flow diversion device, is implanted under high-magnification subtraction fluoroscopy, requiring the use of ancillary devices, such as micro-catheters and guidewires to complete the procedure under general anaesthetic. Procedural heparinisation and preloading with dual antiplatelet therapy (DAPT) using acetyl-salicylic acid and P2Y12 inhibitors such as clopidogrel or prasugrel are required.
40785408|NCT00000134|DRUG|Ganciclovir|intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
40989726|NCT01423487|OTHER|Starch tablets|0.5g bid 26 weeks
40989727|NCT04505774|DRUG|theraputic heparin|increased dose of heparin above standard of care.
40989728|NCT04505774|DRUG|prophylactic heparin|standard of care dose of heparin
40989729|NCT04505774|DRUG|P2Y12|added P2Y12 inhibitor
41307306|NCT03873467|BEHAVIORAL|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting, and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems. The GLB curriculum used in this study has been adapted for people with stroke.
41307307|NCT03873467|OTHER|Usual Care|Participants randomized to the wait-list control group will receive usual care for 6 months before beginning the modified GLB program.
41307308|NCT05655156|DEVICE|OrthoPure XT|"Indication: reconstruction of knee ligaments to restore knee function and stability~The following device sizes are available for use in this indication:~* Size 5~  - Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 6~  - Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 8~  * Primary ACL reconstruction where autograft tissue is not suitable~ * Revision ACL reconstruction~ * Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 10~  * Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)"
41307309|NCT03172221|DIAGNOSTIC_TEST|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
41307310|NCT02615535|DEVICE|EEG neurofeedback-assisted meditation|meditation with auditory feedback regarding EEG status
41307311|NCT02615535|DEVICE|Non-EEG feedback-assisted meditation|meditation without auditory feedback regarding EEG status
41465783|NCT04014582|BEHAVIORAL|Diabetes Education|Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
40989730|NCT04505774|DRUG|Crizanlizumab Injection|crizanlizumab injection
40989731|NCT04505774|DRUG|SGLT2 inhibitor|sglt2 inhibitor
40989732|NCT00010465|PROCEDURE|Craniosacral Osteopathic Manipulative Treatment|
40989733|NCT00010465|DRUG|Botanicals|
40989734|NCT02235142|OTHER|Blood sample|
41147092|NCT01439399|DRUG|Placebo|The control group (C) received an equal volume of saline 0.9 % during 48 h.
40989735|NCT03629821|OTHER|Ballet|The classic ballet classes will respect biological limits of children. The sessions will be 75 minutes long, twice a week during 8 weeks. The class sequence will be: warm-up, follow by exercises about upper and lower limbs ballet positions and sequences of ballet jumps, and at the end a cool-down.
40989736|NCT01888796|DRUG|Linagliptin|
40989737|NCT01888796|DRUG|placebo|
40989738|NCT01824407|DEVICE|Electrohydraulic-generated shock wave|
40989739|NCT01824407|DEVICE|Sham device plus standard of care|
40989740|NCT04208490|OTHER|HN-STAR Intervention|The Head and Neck Survivorship Tool (HN-STAR) is a web-based tool used to assist clinicians in implementing the ACS/ASCO HNC survivorship guidelines.
41146480|NCT06105099|BEHAVIORAL|Motor-phonetic intervention|"Children will receive phonetic articulation therapy treating consonants in a phoneme-by-phoneme basis, emphasizing phonetic placement and shaping techniques.~Phonetic articulation therapy includes a progression of the target consonant from isolated level, syllable level, word level, sentence level, spontaneous speech level in five different steps:~identification of the target consonant using visual, tactile, and auditory feedback techniques, discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 90% of the time with minimal cues from the therapist."
41146481|NCT06105099|BEHAVIORAL|Phonological intervention|"The phonological approach consists of two phases. In the first phase, the child's attention is drawn to the contrastive features of the speech sound system which are relevant to the target consonants. Terms that describe the sound features will be introduced using words on the child's level, e.g. in the case of active nasal fricatives the words 'nose' and 'mouth' will be used. Child-friendly games will be played to illustrate the contrast between the concepts followed by activities that focus on the contrasts in non-speech sounds, in which child and therapist will alternate between being listener and speaker. At the end of this phase, minimal word pairs (e.g. tap/cap), only produced by the therapist, will be used to facilitate the child's awareness of sounds in words and meaningful differences based on distinctive features.~In the second phase, the child will produce minimal pairs providing the opportunity to monitor his/her speech and to make self-corrections."
41146482|NCT06105099|BEHAVIORAL|Combined phonetic-phonological intervention|Children will receive motor-phonetic articulation therapy supplemented with phonological principles. Therapy will be provided following the same five steps as the 'motor-phonetic group'. However, articulation errors will not be treated in a phoneme-by-phoneme basis. In contrast, multiple errors will be targeted simultaneously by focusing on a process. For example, if the child produces glottal stops for the /t/ and the /p/, these sounds will be treated simultaneously as sounds requiring oral front placements. Exercises will be embedded in meaningful language contexts such as minimal pairs
41146483|NCT05851170|OTHER|The use of warm compresses and almond oil on the perineum during second stage|"Hot water from the tap at a temperature of (45-590c) will be poured into a container, and will be changed every 15 minutes.~Timing of the start: when the baby's head descends in the pelvic canal and the woman feels the need to push The intervention: warm compresses will be attached to the perineum between the pressures During the pressing - almond oil will be applied. Meanwhile, the compresses will be returned to a bowl containing hot water. Every 15 minutes until birth the water will be replaced with hot water at an initial temperature of 45-590c.~It is necessary to use compresses for a minimum of 10 minutes, and a maximum of 30 minutes."
41146484|NCT05851170|OTHER|Use of almond oil use (routine care) during second stage|Routine care in the department is the use of almond oil during the second stage of pregnancy, during pushing.
41307312|NCT05956886|BEHAVIORAL|sleep chatbot|Personalized intervention algorithms will be developed based on CBT-I guidelines, focus group data, individual sleep baseline information and self-reported prioritized sleep goals. The CBT-I intervention will focus on principles of sleep restriction and stimulus control, with other CBT-I components used as on-demand content. The sleep chatbot system will facilitate sleep goal-setting with the participant and communicate weekly behavioral prescriptions and educational modules. After baseline data collection, the research coordinator will provide intervention orientation and set up the first-week sleep modification goal during the in-person/Zoom meeting. Sleep modification goals in the remaining weeks will be developed through the participant-chatbot interaction. The Chatbot system will send sleep-related information and behavioral reminders/feedback based on the interactive conversation with participants. Participants will also complete a sleep diary prompted by a chatbot.
41307313|NCT06288776|DIAGNOSTIC_TEST|Herbal based mouthwash|Herbal based mouthwash will be used to treat the tooth sensitivity in participants having VAS score values of tooth sensitivity ranging between 30-80
41465784|NCT03802617|DRUG|MR13A9|Intravenous administration
41465785|NCT03802617|DRUG|Placebo|Intravenous administration
41465786|NCT02488109|OTHER|Higher Calorie Refeeding|
41465787|NCT02488109|OTHER|Lower Calorie Refeeding|
41465788|NCT00055809|BIOLOGICAL|PEG-interferon alfa-2b|Given SC
41465789|NCT00055809|BIOLOGICAL|bevacizumab|Given IV
41465790|NCT00055809|OTHER|laboratory biomarker analysis|Optional correlative studies
41465791|NCT00278174|BIOLOGICAL|recombinant interferon alpha-1b|
40989741|NCT00367081|DRUG|TMX-SMX (Bactrim(R))|
40989742|NCT00367081|DRUG|Pyrimethamine plus Sulfadiazine plus leucoverin|
40989743|NCT04877470|OTHER|Consultation at spine-centre|All patients who visited the spine-centre for the first time in 2019 are included in this group.
40989744|NCT02847546|DEVICE|True™ Flow Valvuloplasty Perfusion Catheter|Balloon Aortic Valvuloplasty as preparation step in implantation of a Tanscatheter Aortic Valve Implantation (TAVI).
40989745|NCT04612556|DRUG|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
40989746|NCT04994379|DEVICE|1 mA tDCS|One session with stimulation intensity of 1 mA.
40989747|NCT04994379|DEVICE|1.5 mA tDCS|One session with stimulation intensity of 1.5 mA.
40989748|NCT04994379|DEVICE|Sham tDCS|One session of sham stimulation.
40989749|NCT04033601|BEHAVIORAL|Non-pharmacological intervention|The non-pharmacological intervention will comprise sleep hygiene education, exercise training and relevant modules of cognitive behavioral therapy.
40989750|NCT01909479|DRUG|MOD-4023|Individualized once weekly dose of MOD-4023
41465792|NCT00508040|DRUG|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
40989751|NCT01909479|OTHER|Placebo|Once weekly administration of placebo
41465793|NCT00508040|DRUG|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
41465794|NCT05829850|DEVICE|SYNOLIS VA 40/80|Three 2mL injections of SYNOLIS VA 40/80, one week apart
41465795|NCT03629106|BEHAVIORAL|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
41465796|NCT04325516|BEHAVIORAL|Daily activities|"Participants will perform four tasks in a randomized order:~* sit to stand~* dorsi flexion of the foot~* knee extension~* hip extension"
41465797|NCT03943134|OTHER|Minimally Processed Human Umbilical Cord Membrane|Implantation of minimally processed human umbilical cord membrane at the time of surgery
41465798|NCT03943134|OTHER|Standard Surgical Procedures|Standard surgical intervention for at least one targeted acute upper extremity trauma
41465799|NCT00476437|DRUG|biphasic insulin aspart|
41465800|NCT00476437|DRUG|biphasic human insulin|
41465801|NCT00160888|DRUG|sodium nitroprusside, bradykinin, acetylcholine|
41465802|NCT01863186|DRUG|Lofexidine HCl|Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
41465803|NCT01863186|DRUG|Placebo|Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
41465804|NCT01863186|DRUG|Open Label Lofexidine HCL|Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
41465805|NCT02339415|DRUG|Edoxaban 30mg daily|
41465806|NCT02339415|DRUG|Matching placebo|
41465807|NCT01592721|BIOLOGICAL|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
41465808|NCT01717937|PROCEDURE|Phase variance optical coherence tomography (PV-OCT)|Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
41465809|NCT02767947|DRUG|Luliconazole Cream 1%|Luliconazole cream will be applied per schedule specified in the arm.
41465810|NCT02767947|DRUG|Vehicle Cream|Vehicle cream will be applied per schedule specified in the arm.
41465811|NCT00429624|PROCEDURE|Chiropractic manipulation|
41465812|NCT00429624|DRUG|acetaminophen|
41465813|NCT05671952|OTHER|Application of integrated intervention system programs|Application of integrated intervention system programs
40785409|NCT00000134|DRUG|Foscarnet|intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
40785410|NCT04555174|DEVICE|Orsiro Mission DES|Percutaneous Coronary Intervention (PCI)
40785411|NCT01722929|DEVICE|Skin sensor|
41465814|NCT02850172|BEHAVIORAL|Walk, Eat, & Breathe|"1. Walking exercise: 3 times per week, 20\~30 mins per section~2. Eat: nutritional assessment and advice weekly~3. Inspiratory muscle training: twice every day, 7 days a week, 6\~8 weeks before surgery"
41465815|NCT01723150|DRUG|Ciprofloxacin|
41465816|NCT01723150|DRUG|Ceftriaxone|
41465817|NCT01723150|DRUG|Trimethoprim/sulfamethoxazole|
41465818|NCT01723150|DRUG|Ertapenem|
41465819|NCT02466334|DRUG|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins
41465820|NCT02466334|DRUG|Placebo|40 ml of normal saline over 20 mins
40785412|NCT01020461|DEVICE|Accuvein|Accuvein will be used to facilitate venous blood sampling
40785413|NCT01020461|DEVICE|Accuvein|Accuvein will be used to facilitate peripheral IV catheter placement
40785414|NCT04524260|BEHAVIORAL|perioperative painting art therapy (LOM® solution centered art therapy)|We plan to apply painting art therapy as a health-related intervention to patients coming to our department for elective major surgery of the pancreatic and lower gastrointestinal tract for malignant pathologies. Patients will have 3 patient art therapy sessions: one before surgery, one on day 3-5 after surgery during the hospital stay and one during the follow-up 6 weeks postoperative
40989752|NCT02280772|DIETARY_SUPPLEMENT|Glucomannan|
40989753|NCT02280772|DIETARY_SUPPLEMENT|Maltodextrin|
40989754|NCT04812054|PROCEDURE|Hypothermic oxygenated machine perfusion|Hypothermic oxygenated perfusion using a Liver Assist device (Organ Assist, Groningen, the Netherlands). Temperature of the perfusate will be set to 12 degrees Celsius. Dedicated cannulas will be placed in the aorta for arterial perfusion and in the portal vein for portal perfusion. Pressure will be set at 25 mmHg for arterial line (pulsatile flow, 30 mmHg systolic pressure and 20 mmHg diastolic pressure, 60 beats per minute) and 3 mmHg for portal line (continuous flow). 100% oxygen will be supplied to the oxygenators with a flow of 500 ml / min or higher, in order to achieve pO2 of at least 450 mmHg.
40989755|NCT04812054|PROCEDURE|Simple cold storage|Following back-table preparation, the allograft will either be transferred to the operating room for implantation or stored in preservation solution at 4 degrees Celsius in a refrigerator
40989756|NCT00199355|DRUG|Istradefylline (KW-6002)|
40989757|NCT04250571|OTHER|"information about No treatment group"|Participants will receive no pills and will be told that they are in the no treatment group
40785415|NCT04524260|BEHAVIORAL|perioperative painting art therapy (LOM® solution centered art therapy) - control|"usual care, no particular intervention during the perioperative setting. There will be 2-3 painting art therapy sessions after the follow-up 6 weeks postoperative. Therefore this group is called usual care- or delayed intervention group."
40785416|NCT02896257|OTHER|Guideline treatment recommendations|Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
40785417|NCT04093232|DRUG|Hymovis|All subjects will receive 2 ultrasound guided Hymovis injections and the goal of the study is to correlate responsiveness to subjects unique SF biomarker panel results before the first Hymovis injection and identify potential mechanism of action of those OA patients who receive the greatest benefit.
40785418|NCT02636387|DRUG|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
40785419|NCT05172700|DRUG|Pirtobrutinib|Administered orally.
40785420|NCT04734262|DRUG|Sitravatinib|Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
40785421|NCT04734262|DRUG|Tislelizumab|Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody
40785422|NCT04734262|DRUG|Nab-paclitaxel|Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin
40785423|NCT04097652|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
40785424|NCT05100134|DRUG|ceritinib|Patients receive ceritinib
40785425|NCT02472912|BIOLOGICAL|BMO-2|Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
40785426|NCT02472912|BIOLOGICAL|EU-Humira|Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
40785427|NCT02472912|BIOLOGICAL|US-Humira|Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
40785428|NCT04846231|DIETARY_SUPPLEMENT|Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
40785429|NCT04846231|DRUG|Rosuvastatin|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
40785430|NCT04846231|OTHER|Placebo|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
40785431|NCT04231071|DEVICE|Onlay Mesh group|Primary suture repair with a small only mesh on the closed defect
40785432|NCT05964179|BEHAVIORAL|time extended feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 14 hours per day.
40785433|NCT05964179|BEHAVIORAL|time restricted feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 8 hours per day.
40785434|NCT04154605|DEVICE|ClariFix cryotherapy|Bilateral freeze ablation of nasal tissue using the ClariFix device.
40785435|NCT04154605|DEVICE|Sham ClariFix cryotherapy|Bilateral sham ablation procedure using the ClariFix device.
40785436|NCT04419545|DIAGNOSTIC_TEST|Neural network diagnosis algorithm|we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
40785437|NCT02189798|DEVICE|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
40785438|NCT02189798|DEVICE|EAS sound processor|Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
40785439|NCT01861847|DRUG|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
40785440|NCT01861847|DRUG|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
40785441|NCT00682149|DIETARY_SUPPLEMENT|PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)|1 tablet/day for 3 months
40785442|NCT04204616|DRUG|Nemolizumab|Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
40989758|NCT04250571|OTHER|imaginary pill technique|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence). Participants in this group receive daily e-mail reminders.
40785443|NCT05295264|OTHER|Moderate exercise program|"Exercise program All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation, and final talk (comments and sharing) will be performed (12-15 minutes).~Healthy lifestyle advise This intervention consists of providing guidelines and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations, and fundamental exercises to perform during pregnancy."
40785444|NCT00888225|PROCEDURE|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
40785445|NCT00888225|PROCEDURE|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
40785446|NCT02961244|OTHER|Prewarming and perioperative warming with Forced Air Warming device and its blankets.|
40785447|NCT02961244|DEVICE|Forced Air Warming blanket|
40785448|NCT02212665|BEHAVIORAL|High intense interval training|
40785449|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer|
40785450|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer+HIIT|
40785451|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer+group intervention|
40989759|NCT04250571|OTHER|open label placebo|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo), combined with the following scientific rationale: (a) deceptive as well as open label placebos have been found to be effective in relieving symptoms in a variety of clinical conditions namely anxiety, depression, chronic pain (the placebo effect is powerful), (b) classical conditioning are one of the possible mechanism of this effect (the body automatically responds), (c) positive expectations may help but are not necessary, (suspend disbelief), (d) compliance with these instructions are important for outcome (taking the pills faithfully is important).~Participants in this group receive daily e-mail reminders."
40989760|NCT02016482|BIOLOGICAL|Adalimumab|
41465821|NCT01043926|DRUG|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
41465822|NCT01731886|PROCEDURE|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will undergo autologous peripheral blood stem cell transplantation on day 0.
40989761|NCT02016482|OTHER|Placebo|
40989762|NCT03927612|DEVICE|Virtual reality perspective taking training|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the alternate perspective condition, participants will then experience the scenario again from the counterpart's perspective, including internal thoughts of the virtual counterpart.
40989763|NCT03927612|DEVICE|Virtual reality control perspective|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the control perspective condition, participants will then experience the scenario again from identical perspective.
40989764|NCT04777695|OTHER|Decibel Monitor|Placement of a TeckPro data logging sound decibel meter at all patient bed-spaces to measure concurrent sound levels 24 hours per day, over a one (1) month period. Peak and mean sound levels per hour will be collected by the decibel monitor. Sound collected every 5 minutes will be logged by the decibel monitor and downloaded onto manufacturer software daily; data will then be imported into Microsoft Excel for further data analysis.
40989765|NCT04851678|OTHER|None - observational study|None - observational study
41146485|NCT05125549|DRUG|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
41465823|NCT01731886|DRUG|Lenalidomide|Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
41465824|NCT01731886|DRUG|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
41465825|NCT01731886|PROCEDURE|Stem cell collection|Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is \>2500 x 109 cells/liter; platelet count is \>20 x 103/mm3.
41465826|NCT01731886|DRUG|Melphalan|Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
40785452|NCT02808429|DRUG|Placebo|Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
41146486|NCT05125549|DRUG|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
41146487|NCT01185340|DRUG|LY2216684|
41146488|NCT01185340|DRUG|Placebo|
41465827|NCT01731886|DRUG|G-CSF|Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
41465828|NCT01731886|DRUG|Cyclophosphamide|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
41465829|NCT01731886|DRUG|Mesna|Mesna will be provided with the cyclophosphamide.
41465830|NCT06164730|DRUG|VERVE-102|Intravenous (IV) infusion
41465831|NCT04993131|PROCEDURE|Liver transplant|Liver transplant.
41465832|NCT06215196|DIETARY_SUPPLEMENT|Fiber Supplement Group|Semaglutide (2.4 mg weekly). Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
41465833|NCT06215196|OTHER|placebo|Semaglutide (2.4 mg weekly). Three daily packets of placebo powder, taken 30 minutes before each main meal.
41465834|NCT01110044|BIOLOGICAL|251154 vaccine|Intramuscular, single dose
41465835|NCT01110044|BIOLOGICAL|Infanrix hexa™|Intramuscular, four doses
41465836|NCT01110044|BIOLOGICAL|Synflorix™|Intramuscular, four doses
41465837|NCT01110044|BIOLOGICAL|Rotarix™|Oral, two doses
41465838|NCT06334276|OTHER|Drowning|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
41465839|NCT04916275|OTHER|Cognitive tests|Optional tests: Corsi block-tapping task, Stroop test and Iowa gambling task
41465840|NCT00117806|BEHAVIORAL|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
41465841|NCT00117806|BEHAVIORAL|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
40785453|NCT02808429|DRUG|Atacicept 25 mg|Participants received 25 milligrams (mg) of Atacicept once weekly as SC injection during this study up to a maximum of 73.6 weeks.
40785454|NCT02808429|DRUG|Atacicept 75 mg|Participants received 75 mg of Atacicept once weekly as SC injection during this study up to a maximum of 74.1 weeks.
40785455|NCT04240340|OTHER|semi-structured interview|Semi-structured, face-to-face interviews will be carried out with participants.
40785456|NCT00818090|DRUG|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
41465842|NCT05763849|BEHAVIORAL|Interoceptive Exposure Treatment (IE)|Interoceptive Exposure Therapy (IE) targets food avoidance in Anorexia Nervosa. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Early sessions include using exposure to foods and counterconditioning to pair a positive stimulus with a food that would typically produce food avoidance. Parents are trained to model this at home. Sessions mid-way through address the use of non-judgmental description of appearance during mirror exposure. Sessions at the end of the 20 weeks are focused on recognizing change, planning for future obstacles, and developing a relapse prevention plan to continue practicing distress tolerance, counter-conditioning, and food/body exposure.
41307314|NCT03790462|OTHER|Music intervention|"A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes \& data collected."
41465843|NCT05763849|BEHAVIORAL|Family-Based Treatment (FBT)|Family-Based Therapy (FBT) includes parent-enforced contingencies to increase value of eating and decrease the value of food avoidance. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Sessions consist of checking in with the patient, discussion of the week's implementation of refeeding, and helping parents separate the illness from their child. In session 2, a family meal provides the therapist with an opportunity for direct observation of the familial interaction patterns around eating. The therapist makes careful and persistent requests for united parental action toward re-feeding and/or regulating eating habits, the primary concern at this point of the treatment, and the therapist tries to create and reinforce a strong parental alliance around efforts at feeding the child.
41465844|NCT04381676|OTHER|Flipped Classroom Approach|In the Flipped Classroom, participants form groups of 2-3 and are instructed to work together through clinical cases of the in-class case based activity, committing to group answers to the clinical questions before advancing to the next case. At the end of class, the faculty instructor facilitated a short interactive group discussion.
41465845|NCT00037752|DRUG|Sibutramine|At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
41465846|NCT00037752|BEHAVIORAL|Behavioral Smoking Cessation Program|Both groups of participants will take part in a behavioral smoking cessation program.
41465847|NCT02251509|DRUG|Carvedilol|
41465848|NCT02251509|DRUG|Metoprolol tartrate|
41465849|NCT06109701|PROCEDURE|Debridement with ultrasonic device and scaling with plastic curettes|Supragingival and subgingival debridement
41465850|NCT06109701|PROCEDURE|Debridement with erythritol based air-polishing powde|Supragingival and subgingival debridement
41465851|NCT00030641|BIOLOGICAL|oblimersen sodium|
41465852|NCT00030641|DRUG|docetaxel|
41465853|NCT02743728|DEVICE|Magnetic Resonance Imaging|Anatomical and Diffusion Tensor Imaging Analysis.
41465854|NCT02743728|DEVICE|Transcranial Magnetic Stimulation|Assessment of brain (cortical) excitability
40785457|NCT00975520|OTHER|Observation|Patients will be observed after surgery until recurrence when they will be offered radiation therapy
40785458|NCT00975520|RADIATION|Radiation Therapy|Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
40785459|NCT00551889|DRUG|celecoxib|
41146489|NCT01185340|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
41146490|NCT05549713|PROCEDURE|Upper blepharoplasty|Upper eyelid surgery in local anesthesia performed by removing excess skin folds and closing with sutures placed on the skin crease.
41146491|NCT02153697|DEVICE|Q-switched SINON Ruby Laser|Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
41146492|NCT02153697|DRUG|Pigmanorm Cream|Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
41307315|NCT02769845|DRUG|Hydroxyurea|drug to be administered
41307316|NCT02769845|PROCEDURE|TCD examination|TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.
41465855|NCT02743728|BEHAVIORAL|General Movement Assessment|Spontaneous movement assessment of infant while lying in unperturbed state.
40785460|NCT00551889|DRUG|cyclophosphamide|
40785461|NCT00551889|OTHER|laboratory biomarker analysis|
41146493|NCT06201754|OTHER|Measure air quality|Measure air quality, including PM2.5、PM10
41307317|NCT02458079|DRUG|Pentoxiphylline|
41307318|NCT02458079|DRUG|Stool microbiota transplantation|
41146494|NCT00704548|DRUG|Simvastatin 40mg|Simvastatin once daily, orally in the morning period, during eigth weeks
41307319|NCT00210340|DRUG|intrathecal rituximab|
41307320|NCT06064786|DIAGNOSTIC_TEST|GCF levels of fetuin A and hsCRP evaluation|ELIZA kits are used for GCF levels of fetuin A and hsCRP evaluation
41307321|NCT05407090|DIETARY_SUPPLEMENT|probiotic supplementation|Participants enrolled in the probiotic group will receive probiotics for 12 weeks before surgery.
41307322|NCT05407090|DIETARY_SUPPLEMENT|placebo|Participants enrolled in the placebo group will receive a placebo instead of probiotics.
41307323|NCT04586868|BEHAVIORAL|An intervention development study|Assessing the acceptability for a virtual reality intervention among adolescents with psychosis
41146495|NCT00704548|DRUG|Placebo|Placebo once daily, orally in the morning period, during eigth weeks
40989766|NCT04923204|DIAGNOSTIC_TEST|Pharmacogenomic-testing with NEUROPHARMAGEN|"This observational retrospective study aims at evaluating the impact of the genetic variation in individual genes on the therapeutic response and side effects profile in a bipolar disorder cohort, using NEUROPHARMAGEN.~NEUROPHARMAGEN is a pharmacogenomic-based decision support tool that helps clinicians in the selection and dosing of psychoactive drugs based on the integration of pharmacogenetic information."
41307324|NCT04586868|BEHAVIORAL|A randomized feasibility study|Feasibility of virtual reality environment for adolescents with psychosis
41307325|NCT04586868|BEHAVIORAL|A single-case study|The clinical efficacy of a novel VR-assisted CBT interventions for adolescents with psychosis
40785462|NCT04016701|DEVICE|Floreo Joint Attention Module|Two sessions per week for eight weeks of the Floreo VR Joint Attention Module, delivered via a Google Cardboard compatible VR headset. Each session includes one or two 5-minute VR episodes and an intermission that is at least 3 minutes long
40989767|NCT04962061|OTHER|Cognitive Training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer- or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
41146496|NCT03543540|BIOLOGICAL|Nexvax2|Nexvax2 injections: 14 in total at twice weekly intervals
41307326|NCT03632681|DRUG|Intranasal Insulin|Intranasal insulin
41307327|NCT03632681|DRUG|Intranasal Placebo|Intranasal placebo manufactured to mimic smell of insulin
41307328|NCT00002789|DRUG|busulfan|
41307329|NCT00002789|DRUG|cyclophosphamide|
41307330|NCT00002789|DRUG|cyclosporine|
41307331|NCT00002789|DRUG|methotrexate|
41307332|NCT00002789|PROCEDURE|allogeneic bone marrow transplantation|
41307333|NCT00002789|PROCEDURE|peripheral blood stem cell transplantation|
41465856|NCT04950894|DEVICE|Hypoglossal Nerve Stimulation|Hypoglossal Nerve Stimulation started at Month 1 compared to no Stimulation (Control group will start stimulation at M7+1Day)
41465857|NCT04958252|DRUG|BI 1569912|BI 1569912
41465858|NCT04958252|DRUG|Placebo|Placebo
41465859|NCT02719704|BEHAVIORAL|"MEXA-SE"|"MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction (Espelho, espelho meu: School based Intervention) conducted by Physical Education researcher."
41146497|NCT03543540|BIOLOGICAL|Placebo|Placebo injections: 14 in total at twice weekly intervals
41146498|NCT02374294|DEVICE|Epiflo|"EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of \~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound."
41146499|NCT04004754|DRUG|Miltefosine (administration is not part of study procedures)|Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
41146500|NCT02035345|DRUG|Carboplatin|
41307334|NCT00689819|BEHAVIORAL|Exercise|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
41307335|NCT00689819|BEHAVIORAL|Exercise|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
41465860|NCT02719704|BEHAVIORAL|"Espelho, espelho meu"|"Behavioral: Espelho, espelho meu: School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters."
41465861|NCT00288925|DRUG|Z-360|
41465862|NCT06167473|BIOLOGICAL|umbilical cord-mesenchymal stem cells|Different dosage of umbilical cord-mesenchymal stem cells through peripheral vein
41465863|NCT05654194|DRUG|Azacitidine Combined With Venetoclax and ATRA group|AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles as the inductive therapy.ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles for consolidate therapy.ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month for Maintenance therapy
41307336|NCT00689819|BEHAVIORAL|Weight Loss|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
41465864|NCT06106152|DRUG|WTX212A injection|The WTX212A infusion is given every 21 days
41465865|NCT06106152|DRUG|PD -1/PD-L1 monoclonal antibody|The PD -1/PD-L1 monoclonal antibody is given every 21 days
40989768|NCT04962061|OTHER|Aerobic and resistance exercises|Participants will follow a periodized exercise training program with thrice-weekly 60 minutes trainings. The sessions will start with a 5-10mins warm-up, followed by aerobic and resistance trainings, and ends with a 5-10mins cool-down and stretching period. Intensity of aerobic sessions will be monitored with heart rate chest strap and should match with the moderate to vigorous intensity zone as defined by the ACSM (65% of Heart Rate maximum or more and a Perceived Exertion higher than 12 on the 6 to 20 Borg scale). Exercise intensity and duration will be gradually increased during the program. After aerobic training, a 15-20mins resistance training will be performed with a gradual progression of higher intensities and/or numbers of sets. The one maximal repetition (1RM) will be assessed for each RT movements at baseline, during (each 3 months) and at the end of the program. RT intensities will go from 40 to 70% of 1RM, with 8 to 10 forms of exercise involving majors muscle groups.
41146501|NCT02699619|DEVICE|Pinloc|3 hook pins interlocked in plate.
41146502|NCT02699619|DEVICE|2 Hansson pins|2 isolated hook pins.(Without plate)
41465866|NCT03300908|BEHAVIORAL|Project ADHERE|"This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals."
41465867|NCT03300908|BEHAVIORAL|MACE|This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
40785463|NCT04016701|BEHAVIORAL|Regularly Scheduled Therapy|therapy as regularly scheduled at therapy center
41146503|NCT00003731|DRUG|temozolomide|
41147093|NCT05134233|DEVICE|Low-intensity Focused Ultrasound|LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
40989769|NCT04962061|OTHER|Stretching and Toning|Participants in the active control condition will take part in three 60 minutes stretching and toning sessions per week. Each session will start with a five-minutes warm-up, followed by fifteen min of body stretching exercises mainly in a seated position and finish with a five-minutes cool down. Participants will engage in four muscle-toning exercises (light intensity) using dumbbells or resistance bands, two exercises designed to improve balance, one yoga sequence, and one exercise of their choice. Intensity of stretching and toning sessions will be monitored with heart rate chest strap and should not exceed the light intensity zone as defined by the ACSM (64% of Heart Rate maximum or less and a Perceived Exertion lower than 11 on the 6 to 20 Borg scale).
41465868|NCT01099306|OTHER|Pharmaceutical care services|Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
41465869|NCT03440424|DRUG|Lemborexant|oral tablet
41465870|NCT01058928|OTHER|Observation of fluid leakage around tracheal tube cuffs|One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
41465871|NCT04409587|DRUG|Aspart|"A population of well controlled patients with type 1 diabetes who are experienced in the use of both Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitor (CGM) was chosen in order to assess the effect of the change in glycemic profile using two different methods of basal insulin delivery. Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses.~Replacing basal insulin delivery by CSII with a single daily injection of degludec will add minimal, if any, treatment burden which will be offset by potential therapeutic benefits. These benefits include the potential for reduced glycemic variability and the elimination of the risk of hyperglycemia and DKA with basal insulin interruption which can occur with infusion set occlusion or disgorging inherent to Continuous Subcutaneous Insulin Infusion."
41465872|NCT04913519|DRUG|TDM-105795|TDM-105795 topical solution
41465873|NCT04913519|DRUG|Placebo|Placebo for TDM-105795 topical solution
41465874|NCT00217724|DIETARY_SUPPLEMENT|glutamine|Given orally
40989770|NCT03976063|DRUG|Nifedipine|Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
41465875|NCT00217724|OTHER|placebo|Given orally
41465876|NCT03490916|DRUG|Acetazolamide|Administration of Acetazolamide
41465877|NCT03490916|DRUG|Placebo|Administration of Placebo
41465878|NCT01165476|DRUG|Treprostinil diethanolamine|sustained release tablets. One 1mg tablet per period. Two total doses.
40785464|NCT01583673|OTHER|Amino Acid Formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
40785465|NCT01583673|OTHER|Amino Acid formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
40989771|NCT03976063|DRUG|Placebo of Nifedipine|Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
40989772|NCT04965545|DIETARY_SUPPLEMENT|low copper diet|All patients with wilson disease should receive low copper diet
40989773|NCT05283187|BEHAVIORAL|Mindfulness Based Cognitive Therapy Group|Mindfulness Based Cognitive Therapy
40989774|NCT03790839|DRUG|Sitagliptin|Sitagliptin (Januvia® 100 mg tablets for oral administration)
41465879|NCT03068949|BIOLOGICAL|FluBlok|FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly
41465880|NCT03068949|BIOLOGICAL|Fluzone|Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly
41465881|NCT03068949|BIOLOGICAL|FluCelVax|FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly
41465882|NCT03068949|BIOLOGICAL|Fluzone HD|Fluzone HD Trivalent High Dose Influenza Vaccine .5 mL given intramuscularly
41465883|NCT01940263|DIETARY_SUPPLEMENT|Anthocyanin|
41465884|NCT01940263|DIETARY_SUPPLEMENT|Placebo|
41465885|NCT06404541|DRUG|Dexamethasone, tobramycin, netilimicin|Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose
41465886|NCT04983524|DIETARY_SUPPLEMENT|propolis|resinous product of honeybees
41465887|NCT04983524|DRUG|Calcium Hydroxide|Gold standard control intracanal medicament
40989775|NCT03790839|DRUG|Dorzagliatin|Glucokinase activator currently under development
40989776|NCT05919303|RADIATION|CT Scan|CT scan study of abdomen
40989777|NCT05413707|PROCEDURE|Fixation of the posterior malleolus fractures|Fixation of the posterior malleolus fracture with screws and or plating.
41465888|NCT05440695|DEVICE|Continuous non-invasive arterial pressure (Infinity® CNAPTM, Dräger)|The basic working principle of CNAP is to keep the blood volume of the finger arteries constant by applying an exterior pressure to the vessel wall, that is done by an electronic system controlling the pressure inside a cuff around the finger. The pressure in the cuff, which is needed to keep the volume constant during arterial pulsation, corresponds to the AP.
41465889|NCT04514133|BEHAVIORAL|Participating in Action Civics program|Students in school classrooms participating in Action Civics program
41465890|NCT03355209|DRUG|ZX008 0.2 or 0.8 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.
41465891|NCT03355209|DRUG|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses.
41465892|NCT00194792|DRUG|exemestane|Given PO
41465893|NCT00194792|DRUG|triptorelin pamoate|Given IM
41465894|NCT00194792|DRUG|capecitabine|Given PO
40989778|NCT05413707|PROCEDURE|Fixation of lateral and/or medial malleolus fractures|Fixation with screws and/or plating
40989779|NCT05413707|PROCEDURE|Syndesmotic fixation|Fixation of unstable syndesmosis with one or two 3.5 mm tricortical screws, or with a suture button.
41146504|NCT02254200|OTHER|Fatmax group|For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
41146505|NCT02254200|OTHER|HIIT group|For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of \~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
41146506|NCT01019824|DRUG|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
41465895|NCT00194792|DRUG|methotrexate|Given IV
40785466|NCT05370274|PROCEDURE|Strength training intervention|The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb (the wrist extensors and the elbow and shoulder flexors). In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Training will start at 50% of 1RM and progress by 10% each week to reach 80% of 1RM by week 4. The same gradation of intensity will be applied to the grip muscles. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
40785467|NCT05370274|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each strength training session, the CN-NINM will be applied, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants for 20 minutes. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 μsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
40989780|NCT06063577|DEVICE|Stratafix suture|Stratafix symmetric suture
40989781|NCT06063577|DEVICE|Standard of care suture|Standard of care suture
40989782|NCT01679379|PROCEDURE|Absorbable suture group|Skin is closed with subcuticular stitches using \[Polyglactin 910 absorbable, synthetic, braided suture\]
40989783|NCT01679379|PROCEDURE|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
41146507|NCT01857245|OTHER|Intensive Models (mDOT and CGT) of HCV Care|Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
41465896|NCT00194792|DRUG|vinorelbine tartrate|Given IV
41465897|NCT00194792|DRUG|paclitaxel|Given IV
41465898|NCT00194792|PROCEDURE|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
40989784|NCT06095323|DEVICE|compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg)|The intervention group will wear compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg) during the day for 12 months.
40989785|NCT05372848|DIAGNOSTIC_TEST|Manual toothbrush|volunteers who used manual toothbrush for at least 2 years
40989786|NCT05372848|DIAGNOSTIC_TEST|Electric toothbrush|volunteers who used electric toothbrush for at least 2 years
41146508|NCT04462159|BEHAVIORAL|Risk Reduction Program|Education, exercise, teaching kitchen and nutrition, and psychological support
41146509|NCT00763087|BEHAVIORAL|weightbearing exercise|All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
41146510|NCT00763087|BEHAVIORAL|nonweightbearing exercise|All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
41146511|NCT00763087|BEHAVIORAL|nonexercising control|All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
41147094|NCT00884806|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
41465899|NCT00194792|RADIATION|radiation therapy|Undergo radiation therapy
41465900|NCT00194792|OTHER|laboratory biomarker analysis|Correlative studies
41307337|NCT00689819|BEHAVIORAL|Low Sodium Diet|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
41307338|NCT00689819|BEHAVIORAL|Smoking Cessation|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
41465901|NCT03086135|DEVICE|Osia System|An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
41465902|NCT05486832|DEVICE|Cardiovalve TR valve replacement System|The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
41465903|NCT03798340|OTHER|Vibratory perturbed task-specific movement training|The perturbation-based pinch task training was conducted with the affected hand placed on the pinch device. The horizontal vibratory perturbation was generated for a total of 20 minutes by two recoil-type actuators with a frequency of 30 Hz and an amplitude of 2 mm, and intermittent exposure (10 s per 30 s). Each training session was divided into eight cycles with a training interval of 2 min per 2.5 min.
41465904|NCT03798340|OTHER|Traditional task-oriented facilitation|Reach-to-grasp training and hand release training
41465905|NCT03798340|OTHER|Sensorimotor training|Targeted to goals that are relevant to the sensorimotor facilitation of the patient
41465906|NCT00271024|DRUG|Naltrexone (drug)|50 mg q.d. for 13 weeks
41465907|NCT00271024|DRUG|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
41465908|NCT06535490|PROCEDURE|EUS-FNA|Puncture of pancreatic cystic lesion with a fine needle under EUS guidance
41465909|NCT06535490|DRUG|ATBp|Antibiotic prophylaxis consists of a single intravenous administration before or at the beginning of the procedure according to the common practices of each practitioner or unit
41465910|NCT05149924|DRUG|QL1012|Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
41465911|NCT05149924|DRUG|Gonal-f ®|Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
41465912|NCT00587431|DRUG|GnRh (Leuprolide)|Leuprolide LUPRON
41465913|NCT00587431|DRUG|Testosterone Gel|Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
41465914|NCT00587431|DRUG|Docetaxel|70 mg/m2 given on day o1 of each 3 week cycle
41465915|NCT06390566|OTHER|calpaïnopathies|Identify and quantify the loss of strength of upper and lower limb muscle groups in patients with LGMD2A
40989787|NCT05883930|OTHER|'Let's Move' program|"Students will complete data collection forms as part of the program. According to International Physical Activity Questionnaire (IPAQ), those who are low in activity and inactive will be assigned to the appropriate intervention program based on their sedentary lifestyle stage.~Students will enter the module system prepared according to the five different stages of change \[not thinking (1), thinking (2), preparing (3), acting (4), continuing (5)\] of sedentary living.~There are 12 different initiatives for each phase/module of the program. Summary and reinforcing questions are asked at the end of each trial. If participants do not answer the questions, they cannot continue with the next week's initiative.~Participants' daily step counts with the smart wristband are recorded in the program.~Daily alerts/reinforcement messages related to that week's initiative will be sent during all phases."
40989788|NCT05883930|OTHER|no intervention|No intervention will be applied to the control group.
41147095|NCT00884806|DEVICE|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
41465916|NCT03170869|DEVICE|Surefire Precision Infusion System|All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
41147096|NCT00884806|DEVICE|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
41465917|NCT00876720|DEVICE|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
41307339|NCT00689819|DRUG|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
41307340|NCT00689819|BEHAVIORAL|Weight Loss|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
41307341|NCT00689819|BEHAVIORAL|Low Sodium Diet|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
41307342|NCT00689819|BEHAVIORAL|Smoking Cessation|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
41307343|NCT00689819|DRUG|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
41307344|NCT01093924|BEHAVIORAL|PILI 'Ohana 18-month weight loss maintenance|All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
41307345|NCT01263691|BIOLOGICAL|BioThrax|BioThrax
41307346|NCT01263691|BIOLOGICAL|AV7909 Formulation 1|AV7909 Formulation 1
41465918|NCT00876720|DEVICE|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
41465919|NCT05783856|COMBINATION_PRODUCT|LiveSpo X-secret|In Vietnam, LiveSpo X-secret is manufactured as a Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
41307347|NCT01263691|BIOLOGICAL|AV7909 Formulation 2|AV7909 Formulation 2
41307348|NCT01263691|BIOLOGICAL|AV7909 Formulation 3|AV7909 Formulation 3
41307349|NCT01263691|BIOLOGICAL|AV7909 Formulation 4|AV7909 Formulation 4
40989789|NCT05876741|DIAGNOSTIC_TEST|history taking , vital signs and labaratory investigations|"1. Complete history taking:~   With stress on age, sex, epigastric pain, comorbidities (ischemic heart disease, diabetes, liver cirrhosis, renal failure, malignancy), syncope, disturbed conscious level, blood transfusion, drug history .~2. Clinical examination:~   Pulse, blood pressure, calculating the shock index, pallor, jaundice, cachexia, purpura, ecchymosis, conscious level, abdominal examination.~3. Laboratory investigations:~   * Complete blood count (CBC).~  * Creatinine and blood urea nitrogen (BUN).~  * liver function tests (serum bilirubin, serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), prothrombin concentration (PC), and international normalized ratio (INR)).~  * Serum electrolytes and arterial blood gases.~  * Fasting blood sugar.~4. Assessment of risk and predicting outcomes by:~   * Pre-endoscopic Rockall score (pRS).~  * Glasgow-Blatchford score (GBS).~  * AIMS65 score.~  * ABC score.~  * Horibe score."
40989790|NCT05114616|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. The custom mold is created employing a 3D printer following capture of the geometry unique to each patients' ears with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality capture of signals reflecting brain activity, and head, and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consisten contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
41307350|NCT01263691|DRUG|Control|Saline control
41307351|NCT00688168|BEHAVIORAL|Questionnaire|Questionnaires measuring pain and other symptoms, mood, and quality of life.
41307352|NCT00688168|BEHAVIORAL|Neurocognitive Testing|A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
41307353|NCT00688168|BEHAVIORAL|Neurosensory Testing|Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
40989791|NCT05114616|DEVICE|Ellcie Healthy Glasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
40989792|NCT04796376|PROCEDURE|combined partial fistulectomy or fistulotomy and cutting seton procedure|Partial excision of fistulous tract or just fistulotomy plus cutting seton procedure which is a rubber band or threads put through fistulous tract
40989793|NCT03311503|BIOLOGICAL|autologous CD34+ cell transduced with G2SCID vector|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
40989794|NCT03038815|DEVICE|VACOped|restriction of ankle joint motion
40989795|NCT03038815|DEVICE|Ortho Tri|restriction of ankle joint motion
40989796|NCT01170494|DRUG|ergocalciferol 2000 IU orally, daily|ergocalciferol 2000 IU orally, daily
41307354|NCT01614236|DRUG|pregabalin|Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
41307355|NCT01614236|DRUG|epidural|patients will be randomized similarly but will undergo surgery under epidural analgesia
41307356|NCT00409201|DRUG|reboxetine adjuvant therapy|
40989797|NCT01170494|DRUG|ergocalciferol 25000 IU oraly every 2 weeks|ergocalciferol 25000 IU oraly every 2 weeks
40989798|NCT01170494|DRUG|ergocalciferol 50000 IU orally every 4 weeks|ergocalciferol 50000 IU orally every 4 weeks
40989799|NCT01170494|DRUG|ergocal1000 IU & cholecal 1000 IU orally daily|ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
40989800|NCT01170494|DRUG|cholecalciferol 2000 IU orally daily|cholecalciferol 2000 IU orally everyday
41307357|NCT06004141|BEHAVIORAL|Laguna Health|Laguna Health is a novel behavioral coaching intervention (Laguna Health) that provides supportive care to patients with cancer who are discharged from the hospital and their caregivers. The intervention includes four components: 1) behavioral coaching with a Laguna Health recovery coach; 2) digital psycho-educational content tailored to the needs of patients with cancer; 3) summary of post-discharge care tasks; and 4) behavioral strategies to promote self-efficacy.
41307358|NCT02687230|DRUG|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
41307359|NCT02687230|DRUG|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
41307360|NCT06206668|OTHER|Action observation videos|The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
41307361|NCT00975702|PROCEDURE|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
41307362|NCT00777491|DRUG|induction cisplatin|15 mg/m\^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.
41307363|NCT00777491|DRUG|induction 5-fluorouracil|400mg/m\^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
41307364|NCT00777491|DRUG|induction gemcitabine|27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
41307365|NCT00777491|RADIATION|Induction BID radiation therapy|Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
41465920|NCT05783856|DRUG|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 15 mL-bottle that is used for LiveSpo X-secret.
41465921|NCT03191838|OTHER|Audiovisual Distraction|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
41465922|NCT01616316|PROCEDURE|subfascial flap|subfacial dissection to thyroid
41465923|NCT01616316|PROCEDURE|subplatysmal flap|subplatysmal approach to thyroid
41465924|NCT00851409|DRUG|Recombinant Human C1 Inhibitor|"50 IU/kg rhC1INH, IV injection over 4 to 5 minutes, once weekly over an 8-week treatment period."
41465925|NCT02798419|DRUG|DFD05 Cream|
41465926|NCT02798419|DRUG|Active01 Cream|
41465927|NCT01955044|DIETARY_SUPPLEMENT|LCPUFA supplement|
40785468|NCT04065386|DEVICE|Active taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the cymba conchae, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
40785469|NCT04065386|DEVICE|sham taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the ear lobe, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
41465928|NCT01955044|DIETARY_SUPPLEMENT|placebo|
41465929|NCT05006131|OTHER|Screening for pancreatic cancer|Screening for pancreatic cancer using EUS or MRI
41465930|NCT02822196|DRUG|Lidocaine|Local Anesthesia using 1% Lidocaine
41465931|NCT02822196|DRUG|Bupivacaine|Local Anesthesia using 0.25% Bupivacaine
41465932|NCT06384729|DEVICE|EXOPULSE Mollii Ⓡ|The EXOPULSE Mollii method (EXONEURAL NETWORK AB, Danderyd, Sweden) is an innovative approach to non-invasive and self-administered electrical stimulation with multiple electrodes incorporated into a full-body suit. It consists of comfortable, breathable, and washable synthetic material pants and a jacket. It has been primarily designed to reduce disabling spasticity and improve motor function. The method refers to the concept of reciprocal inhibition induced by stimulating the antagonist of a spastic muscle, at low frequencies and intensities, which is considered to reduce spasticity.
41465933|NCT04086160|DEVICE|Transcranial direct current stimulation device (Soterix Medical, New York, NY)|Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.
41465934|NCT00496028|DRUG|AZD0530|oral tablet
41465935|NCT00496028|DRUG|Carboplatin|intravenous infusion
40989801|NCT01170494|DRUG|Cholecalciferol 25000 IU orally every 2 weeks|Cholecalciferol 25000 IU orally every 2 weeks
40989802|NCT01170494|DRUG|Cholecalciferol 50000 orally every 4 weeks|Cholecalciferol 50000 orally every 4 weeks
40989803|NCT01170494|DRUG|placebo orally everyday|placebo orally everyday
40989804|NCT02110342|DRUG|[14C] PF-04449913|Single oral dose of 100 mg PF-04449913 + 100µCi of \[14C\] PF-04449913
40989805|NCT02155647|DRUG|Avelumab|Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
41465936|NCT00496028|DRUG|Paclitaxel|intravenous infusion
41465937|NCT06110286|OTHER|Photorefractive keratectomy|Laser keratectomy by EX500 excimer laser after removal of corneal epithelium either mannually or by laser ablation
41465938|NCT02564016|DRUG|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
41465939|NCT02564016|OTHER|Capped Epidural|epidural will be capped with no saline infusion.
40785470|NCT04074564|COMBINATION_PRODUCT|MASCT-I, Camrelizumab,Apatinib|"Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) is a sequential immune cell therapy.~Camrelizumab is an immune checkpoint inhibitors against PD-1.~Apatinib is a highly selective tyrosine kinase inhibitor targeting VEGFR2."
40785471|NCT04298619|DIAGNOSTIC_TEST|Standard cohort: Clinical lab follow-up|
40785472|NCT04298619|DIAGNOSTIC_TEST|Imaging cohort: integrated imaging follow-up|
41465940|NCT02246088|PROCEDURE|MT + NE|"Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain)."
41465941|NCT02246088|PROCEDURE|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
40989806|NCT05161169|GENETIC|Genome Sequencing|20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.
40989807|NCT02266459|DEVICE|Microwave technology (Medfield Diagnostics)|A microwave measurement will be performed. The procedure will take approximately 15 minutes (the duration of the actual measurements is \< 1 minute) and will not interfere with the patient's standard of care at the Stroke Unit.
40989808|NCT01094496|BIOLOGICAL|CDX-1307 Vaccine Regimen|CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
40989809|NCT01094496|DRUG|Chemotherapy|
40989810|NCT02232425|DRUG|IX-01|
40989811|NCT02232425|DRUG|Placebo|
40989812|NCT00621894|DRUG|LGD-4665|LGD-4665 Thrombopoietin mimetic
41465942|NCT06476171|DIAGNOSTIC_TEST|Determination of the level of the studied biomarkers|Determination of the level of hematological indices based on a general blood test; Determination of the levels of the following biomarkers: isolation of neutrophils from the blood using the gradient centrifugation method; assessment using enzyme immunoassay (ELISA) of the content of neutrophil elastase in the supernatant; myeloperoxidase, ELISA; lactoferrin, ELISA; interleukin -1ß,17,10,6, ELISA; presepsin, ELISA; endothelin, ELISA; lipopolysaccharide, LAL test; lipopolysaccharide binding protein, ELISA; NETs release, immunofluorescence method; the number of neutrophils expressing PDL-1, flow cytofluorimetry method; procalcitonin in human plasma and serum, VIDAS B.R.A.H.M.S. PCT; ferritin, reagent for determination (FERRITIN); lactate dehydrogenase, reagent for determination of QSR6128;Endotoxin Activity Assay, chemiluminescent immunodiagnostics.
40785473|NCT03044444|DIETARY_SUPPLEMENT|citrus extract|Participants will receive either a low or high dose citrus extract
40785474|NCT03044444|OTHER|placebo|participants will receive 500mg of maltodextrin
40785475|NCT01184976|BIOLOGICAL|VGX-3400|Plasmid DNA delivered via IM injection with electroporation
40989813|NCT00621894|DRUG|Placebo|Placebo
40989814|NCT05084573|DRUG|Liposomal bupivacaine|Single bolus injection 10mL 1.33% LB
40989815|NCT05084573|DRUG|Standard bupivacaine|Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr
41307366|NCT00777491|RADIATION|Induction QD radiation therapy|Once daily (QD) on days (1-5,8-12,15-19,22-26). For the first 10 treatment days, 2 Gy is delivered to the pelvis. Then, 2 Gy is delivered to the bladder for the next 4 treatment days, followed by 2 Gy to the bladder tumor volume for the remaining 6 treatment days. The bladder tumor volume receives a total of 40 Gy.
41307367|NCT00777491|RADIATION|Consolidation BID radiation therapy|Twice daily (BID) for 8 days on days 1,2,3,4,5,8,9,10 of consolidation. 1.5 Gy per fraction for a total of 24 Gy delivered to the pelvis.
40989816|NCT06490263|DRUG|Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects|Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.
40785476|NCT05887037|DIAGNOSTIC_TEST|mNGS|mNGS is the direct extraction of nucleic acid from clinical samples. High-throughput sequencing technology and bioinformatics analysis were adopted to complete the detection of pathogens such as bacteria, fungi, viruses and parasites at one time
40785477|NCT05887037|DIAGNOSTIC_TEST|The traditional microbiological cultures|Traditional microbial culture is the gold standard for the diagnosis of central nervous system infection, but the traditional microbiological culture time is long and the detection rate is low.
40989817|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with single dose in healthy subjects|Parts Two: Administered by swallowing after meals with four distinct dosage groups.
40989818|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects|Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
41307368|NCT00777491|RADIATION|Consolidation QD radiation therapy|Once daily (QD) pelvic radiation therapy for 12 days on days 1-5,8-12,15-16 of consolidation. 2 Gy per fraction for a total of 24 Gy delivered to the pelvis.
41307369|NCT00777491|DRUG|consolidation gemcitabine|27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15 of consolidation.
41307370|NCT00777491|DRUG|consolidation 5-fluorouracil|400 mg/m\^2 administered as a 24-hour infusion on days 1, 2, 3 and 8, 9, 10 of consolidation.
40785478|NCT05067881|PROCEDURE|Pulmonary resection|Resection of pneumohematocele
40785479|NCT05816824|OTHER|Symptom monitoring software via visual feedback|With PhysioAnalyst software, individuals are evaluated using clinical tools (questionnaire, scale). These evaluations provide visual feedback to individuals in the form of tables and graphs. In this way, patients can observe the changes in their clinical status.
41307371|NCT00777491|DRUG|consolidation cisplatin|15 mg/m\^2 administered as a sixty-minute infusion on days 1, 2, 8, 9 of consolidation.
41465943|NCT01858350|OTHER|Active Music Therapy|
41465944|NCT01858350|OTHER|Passive Music Therapy|
41465945|NCT01858350|OTHER|Distraction Therapy|
41465946|NCT00708682|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|
40785480|NCT01382914|OTHER|chlorhexidine 0.12%|twice daily, 10 ml, topical
40989819|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects|Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
40989820|NCT04814576|BEHAVIORAL|Collaborative cares|The intervention consists of the co-design and implementation of therapeutic activities by the nurse and the mental health day hospital users following a collaborative care model. For this purpose, the participatory action research (PAR) method will be used and semi-structured interviews and focus groups will be used as data collection techniques.
40989821|NCT06418841|PROCEDURE|Computer-Assisted Paramedian Approach Technique|Computer-Assisted Paramedian Approach Technique
40989822|NCT06418841|PROCEDURE|Conventional Midline Approach Technique|Conventional Midline Approach Technique
41307372|NCT00777491|PROCEDURE|radical cystectomy|Operable patients who have a pT1 or worse tumor response on re-evaluation following initial transurethral resection and induction chemoradiotherapy will have a radical cystectomy 3-8 weeks following the post-induction response evaluation.
41307373|NCT00777491|PROCEDURE|Post-Induction Chemoradiotherapy Endoscopic Response Evaluation|Urine cytology, cystoscopy, tumor site transurethral biopsy, and bimanual examination after biopsy.
41465947|NCT02452528|DRUG|ARC-520|
41465948|NCT02452528|DRUG|Placebo|
40989823|NCT00525668|DRUG|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
41146512|NCT05063175|OTHER|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking. The conventional therapeutic protocol for every child was three sessions per week for 12 successive weeks. Every treatment session was applied for two hours with a few minutes rest in between them.
40785481|NCT06271824|BEHAVIORAL|Self-Compassion Based Resilient Caregiving Course|The Resilience Habits for Caregivers Course is a live, online, weekly 6 session program lasting 1.5 hours per session. The structure contains didactics, group discussions, guided exercises, and practices facilitated by a certified self-compassion instructor. Topics covered include: (1) noticing and accepting emotions (including conflicting emotions); (2) cultivating curiosity and self-compassion; (3) relating skillfully to difficult thoughts; (4) savoring and gratitude practices.
41465949|NCT02452528|DRUG|Entecavir|0.5 or 1.0 mg/day orally
41465950|NCT02452528|DRUG|Tenofovir|300 mg/day orally
41465951|NCT02452528|DRUG|diphenhydramine|50 mg orally as pretreatment antihistamine
40785482|NCT02207543|OTHER|Medical telephone contact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
41146513|NCT05063175|OTHER|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was conducted for 8 hours daily for 12 successive weeks. It is made to be fitted directly on the skin as undergarments.
41465952|NCT04012073|DEVICE|Invasive Mechanical ventilation|"Volume-control ventilation with tidal volume will be set at 6 mL/Kg of predicted body weight, respiratory rate to maintain pH\>7.30 and PaCO2\<50 mmHg and FiO2 will be set to achieve a SpO2\>88-95%.~In case of hypercapnia with Ph\<7.30 despite a respiratory rate=30-35, an increase in tidal volume up to 8 ml/kg will be allowed.~In both groups, the assigned ventilation protocol will be followed for a minimum of 72 hours from randomization and any time fully controlled ventilation is deemed necessary by the attending physician up to 14 days from randomization. After 14 days from randomization, PEEP will be set according to the clinical practice of each institution.~After 72 hours from the study protocol, the PEEP setting protocol according to the assigned treatment will be resumed at any time within 14 days from enrolment if fully controlled ventilation is established, according to the decision of the attending physician in charge."
40785483|NCT02459561|DEVICE|EndoBarrier TM Gastrointestinal Liner|If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
40785484|NCT02459561|OTHER|Best Medical Care|If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
40785485|NCT05922995|DRUG|Tasimelteon|20 mg capsules taken on a nightly basis
40785486|NCT04630821|OTHER|Dilute Sodium Hypochlorite solution|"Subjects will be treated with the dilute bleach compresses daily for the first 3 weeks of therapy.~While these subjects are undergoing radiation therapy, they will be assessed weekly before the day's compress treatment by a physician investigator on the study team. Subjects will be evaluated and photographs will also be taken at study visits 1-3. The subjects will also complete a subject questionnaire addressing patient-reported outcomes at baseline and each weekly check-in during these two weeks. They will be also interviewed about ease of use and treatment tolerability. Subjects will complete interview questions at the end of the study to determine if they would continue the treatment and any obstacles or barriers."
40989824|NCT00525668|DRUG|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
40989825|NCT00704535|DRUG|Ezetimibe|1 tablet of 10 mg once daily
41146514|NCT03933098|BIOLOGICAL|Test Vaccine Vi-DT Typhoid conjugate|"* Manufacturer: SK Bioscience Co., Ltd.~* Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~* Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial"
41465953|NCT04012073|DRUG|Neuromuscular Blocking Agents|All patients will receive NMBA for 48 hours after the enrolment. The decision to stop NMBA administration after 48 hours will be left to the attending physician, but muscle paralysis will be strongly encouraged if PaO2/FiO2 ratio remains lower than 80-100 mmHg. NMBA administration will be resumed anytime deemed necessary by the attending physician.
40989826|NCT03616899|DRUG|KPI-121 Ophthalmic Suspension|KPI-121 Ophthalmic Suspension
40989827|NCT03616899|DRUG|Vehicle|Vehicle for KPI-121 0.25% ophthalmic suspension
40989828|NCT04318509|DIETARY_SUPPLEMENT|GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
40989829|NCT00591942|DEVICE|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inclusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
40989830|NCT05899907|DRUG|Telitacicept|160mg once a week for 48 weeks
40989831|NCT05899907|DRUG|Standard of Care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
40989832|NCT04178187|DRUG|Caps Lactolevure|One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
40989833|NCT04178187|DRUG|Caps Placebo|Caps Placebo
41465954|NCT04012073|PROCEDURE|Prone positioning|Prone positioning will be used in all enrolled patients as a standard of care: the decision about the timing and the duration of prone position sessions will be left to the attending physician and the time spent by the patient in the prone and in the supine position will be recorded: PEEP will be re-set according to the protocol of the allocated treatment anytime patient's position is changed.
41465955|NCT04012073|PROCEDURE|Resume of spontaneous breathing|"Assist/control and assist ventilation will be allowed after 72 hours from the enrolment if deemed appropriate by the attending physician.~During spontaneous breathing, PEEP will be set according to the decision of the attending physician and the practice of each institution: however, in order to standardize the treatments, moderate PEEP (10-15 cmH2O) will be encouraged in case of moderate hypoxemia (PaO2/FiO2\<150 mmHg) in control group, while PEEP close to the value set during controlled ventilation according to the treatment protocol but \<15 cmH2O will be suggested in the intervention group.~During assist/control and assisted ventilation, PEEP will never be higher than the last PEEP set according to the assigned protocol during controlled ventilation.~Fully controlled mechanical ventilation will be resumed any time during the study period if the patient meets the criteria described above or any time deemed necessary by the physicians in charge"
41307374|NCT00777491|DRUG|adjuvant gemcitabine|1000 mg/m\^2 administered intravenously over 30-60 minutes (preferably 30 minutes) on days 1 and 8 of each 21-day cycle for four cycles.
41307375|NCT00777491|DRUG|adjuvant cisplatin|70 mg/m\^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
40989834|NCT01085799|BEHAVIORAL|Health Education Intervention|This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
41307376|NCT00300469|DRUG|ABT-335|135 mg, daily, 12 weeks
40989835|NCT06540209|DRUG|Bacillus clausii|Children will be give Bacillus clausii for 5 days
41307377|NCT00300469|DRUG|Atorvastatin|Daily, 12 weeks, see Arm Description for dosage information
41307378|NCT00300469|DRUG|Placebo|daily, 12 weeks, see Arm Description for placebo information
41307379|NCT00004284|DRUG|potassium citrate|
40989836|NCT06540209|DRUG|Saccharomyces boulardii|Children will be give Saccharomyces boulardii for 5 days
41307380|NCT00004284|DRUG|potassium phosphate|
41307381|NCT01641549|PROCEDURE|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
41307382|NCT01641549|DRUG|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
41465956|NCT04012073|PROCEDURE|Rescue treatments|Recruitment maneuvers, extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2-R) after randomization will be allowed in both groups as rescue therapies and according to the decision of attending physicians: any of these procedures will be accurately recorded on the case report form.
41307383|NCT04999826|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
41307384|NCT04999826|OTHER|Quality-of-Life Assessment|Ancillary studies
41307385|NCT04999826|OTHER|Questionnaire Administration|Complete questionnaires
40989837|NCT06540209|DRUG|Zinc|Zinc will be given to all children for 5 days
40989838|NCT06540209|DRUG|ORS|ORS will be given to all children for 5 days
40989839|NCT02984033|RADIATION|Head and Neck patients|Treatment consists of Intensity Modulated Radiation Therapy (until 2.2 Gy) with a total dose of 50-66 Gy in post-operative setting and 66-72 Gy in radical setting.
40989840|NCT06129721|PROCEDURE|Emergent Stenting|Emergent Stenting In Acute Vertebrobasilar Occlusions
40989841|NCT04265274|DRUG|Disulfiram|dosing 400mg daily
40989842|NCT04265274|DRUG|Vinorelbin|25mg/m2 day 1 and 8,
40989843|NCT04265274|DRUG|Cisplatin|75mg/m2 day 1
40989844|NCT04265274|DRUG|Copper|2 mg of elementary Copper daily
40989845|NCT05322642|BEHAVIORAL|UPA|UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).
41307386|NCT02730845|DRUG|Intra-articular dexmedetomidine|Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
41307387|NCT02730845|DRUG|Intravenous dexmedetomidine|Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
41465957|NCT04012073|PROCEDURE|Weaning from PEEP|"In order not to delay weaning from mechanical ventilation, when a patient is managed with assist/control or assist ventilation with PEEP higher than 8 cmH2O, a daily PEEP weaning trial will be performed whether PaO2/FIO2 ratio\>150 mm Hg and FIO2\<0.5: PEEP will be decreased to 8-5 cm H2O and arterial blood gas will be sampled after 20 -0 minutes. Previous ventilatory settings will be resumed if during the procedure transcutaneous oxyhemoglobin saturation decreases below 88%, PaO2/FIO2 falls below 150 mm Hg or if the patient experiences abnormal changes in respiratory rate or other clinical signs suggestive of respiratory distress.~When PaO2/FIO2 is no lower than 200 mm Hg at PEEP≤8 cmH2O, the patient will be considered to have acceptable gas exchange on 8-5 cmH2O of PEEP and will be deemed capable to tolerate this setting"
41465958|NCT04012073|PROCEDURE|Weaning from mechanical ventilation|"A 30-120-minute spontaneous breathing trial will be initiated as the following criteria are met and whether the patient tolerates fully assist ventilation with PEEP≤8 cmH2O for at least 4 hours without experiencing hypoxemia (SpO2\<88% or PaO2/FiO2\<150mmHg):~* improvement or resolution of the underlying cause of acute respiratory failure~* normal sensorium~* correction of arterial hypoxemia (PaO2 ≥ 60 mmHg at a FiO2 ≤ 0.4 with PEEP ≤ 8 cmH2O);~* absence of fever (≥ 38 °C) or sepsis;~* blood hemoglobin concentration of 7 g/dL or more;~* hemodynamic stability~For the purpose of the study, success of the spontaneous breathing trial will be defined as presence of the following criteria:~* respiratory rate \< 35/min,~* arterial oxygen saturation ≥ 90%,~* heart rate \< 120/min,~* systolic blood pressure \> 90 and \< 160 mmHg~* adequate cough. If the spontaneous breathing trial is successful, the patient will be extubated."
40989846|NCT05322642|BEHAVIORAL|Active control condition (Progressive Relaxation Training)|Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.
40989847|NCT00488163|DRUG|Atomoxetine|Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
40989848|NCT03533452|DRUG|Ropivacaine|Local anesthetic injection
40989849|NCT03533452|DRUG|Normal saline|Sham injection
41146515|NCT03933098|BIOLOGICAL|Control Vaccine Typbar TCV®|"* Manufacturer: Bharat Biotech~* Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein~* Dose: 0.5 ml"
41307388|NCT06099548|DEVICE|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
41465959|NCT04012073|PROCEDURE|Extubation|"Each extubated patient will undergo oxygen therapy via high flow nasal cannula (maximum flows tolerated and FiO2 titrated to obtain 96%\>SpO2\>92%). Pre-emptive noninvasive ventilation (NIV) after extubation will be allowed in prolonged to wean patients (i.e. more than 3 SBT failure or more than 7 days from the first spontaneous breathing trial to being extubated) if deemed necessary by the physician in charge.~In case of respiratory failure during oxygen therapy via high flow nasal cannula after extubation and, a rescue NIV trial will be allowed before intubation in both groups at the discretion of the attending physician."
41307389|NCT05701969|DIETARY_SUPPLEMENT|Melatonin|Melatonin
40785487|NCT01783210|BEHAVIORAL|Specific Therapeutic Lifestyle Changes program in pregnancy|"TLC Program includes diet and mild physical activity. The TLC comprises 1500 kcal/day (3 main meals and 3 snacks) composed of 55% carbohydrate, 20% protein, and 25% fat. The dietitian adds an 200 kcal/day for obese or 300 kcal/day for overweight. The exercise intervention is focused on increasing walking. All participants are advised to participate in 30 min of moderate intensity activity at least 3 days a week. Subjects wear a pedometer waist during walking session for the assessment of the adherence to the physical activity program. Women are told to consider using the talk test (being able to maintain a conversation during activity) to monitor exercise intensity, and to record the frequency and duration of the activity on a diary . Follow-up is performed at 16, 20, 28, 36 weeks."
40785488|NCT01783210|BEHAVIORAL|Dietary and behavioral counselling in pregnancy|"The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake.~30 minutes counseling session about the appropriate gestational weight gain (GWG) at term for each different BMI category is performed. Moreover, the importance of the limited GWG for preventing unfavorable maternal-neonatal outcomes related to excessive weight gain is explained. Women are scheduled to have a follow-up at 16, 20, 28, 36 weeks."
40785489|NCT02960425|DIETARY_SUPPLEMENT|Delivra TM Livsport preworkout cream|High versus low dose topical creatine
41307390|NCT05701969|OTHER|Placebo|Placebo control
40785490|NCT02960425|DIETARY_SUPPLEMENT|Placebo|Topical placebo
40785491|NCT04651205|DIETARY_SUPPLEMENT|vitamin B1 and magnesium supplements|vitamin B1 - 100 mg/day magnesium - 400 mg/day
40989850|NCT01271088|DRUG|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
41146516|NCT04448613|OTHER|MRI|"Patients with optic disc swelling diagnosed by a fundus and included in the study will have a brain MRI and visual pathways lasting 30 minutes.~Two additional 10-minute sequences will be added to the standard protocol."
41147097|NCT00884806|DEVICE|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
41307391|NCT00694512|DIETARY_SUPPLEMENT|Low fat diet|20% fat diet
41307392|NCT00694512|DIETARY_SUPPLEMENT|High fat diet|40% fat diet
41307393|NCT00694512|DIETARY_SUPPLEMENT|MCT diet|Medium chain triglyceride diet
41307394|NCT05663515|DRUG|Exenatide|All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs.
41307395|NCT05663515|DRUG|Non-GLP-1 RA based glucose lowering drugs|Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period.
41307396|NCT00782015|DIETARY_SUPPLEMENT|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
41307397|NCT00782015|DIETARY_SUPPLEMENT|Placebo Comparator:|NCEP Step 2 diet
41307398|NCT03188679|DEVICE|amniocentesis|mRNA sequencing on amniotic fluid samples of fetuses after maternal seroconversion for CMV
41465960|NCT04047563|DRUG|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
41465961|NCT04047563|DRUG|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
41465962|NCT05911919|DEVICE|brainQuant module of brainTale-care platform|brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
40989851|NCT04890327|OTHER|Web-based family health history tool|Web-based tool that collects subject's family health history through a series of questions and generates a pedigree which documents a risk assessment report for the physician to use. The risk assessment report uses standard, validated risk scores including GAIL , CLAUS, BRCAPRO which measure breast cancer risk, and MMRPRO which measures endometrial cancer risk, MELAPRO which measures melanoma cancer risk, and PANCPRO which measures pancreatic cancer risk
40989852|NCT03738891|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
41147098|NCT00884806|DEVICE|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
41147099|NCT06505252|PROCEDURE|enoscopic Myringoplasty|"general anesthesia. A single surgeon will perform all surgeries.~* A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon.~* Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle~* sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization~* the previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally in patients group A: 0.5 mL of HA vial will be injected directly over the fat graft and the TM remnant. After 5 minutes small gelfoam pieces soaked in 0.5 mL of HA vial will applied over the fat in patients group B PRPG was inserted into the external auditory canal on the outer face of the TM remnant and fat"
41147100|NCT05007600|OTHER|Online Interactive Courses|In the experimental group, after consensus was reached in the expert meeting (consisting of a doctor specializing in occupational therapy, a doctor specializing in nursing, and a doctor specializing in public health), a 5-days-per-week (Monday to Friday) 8-week intensive online interactive course was designed. The course was made accessible to the participants through a social network app (Line) from 12:00 to 20:30.
41307399|NCT02044159|DRUG|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
41465963|NCT02771028|BEHAVIORAL|Emotional Freedom Techniques|
41147101|NCT00368823|DEVICE|Electronic point-of-care delivery system|
41465964|NCT02044250|DRUG|Clopidogrel|Clopidogrel 75mg 1tab P.O. daily
41465965|NCT02044250|DRUG|Aspirin|Aspirin 100\~200mg 1\~2tab P.O. daily
41465966|NCT02510261|DRUG|Patisiran|Patisiran was administered IV.
41465967|NCT01413763|DRUG|Imiquimod cream 3.75%|3.75% cream, applied daily for 2 weeks
41465968|NCT01413763|DRUG|Placebo cream|placebo cream applied daily for 2 weeks
40989853|NCT00531024|DRUG|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
41307400|NCT02044159|OTHER|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
41307401|NCT00681967|DRUG|Gefitinib|250 mg; oral
41307402|NCT00681967|DRUG|Gefitinib|250mg; oral
41465969|NCT04113824|PROCEDURE|trapezuis motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
41465970|NCT04113824|PROCEDURE|other Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
41465971|NCT05825768|DEVICE|Breast MRI|Breast Magnetic Resonance Imaging prior to breast conserving surgery with and without intravenous contrast agent.
41465972|NCT05825768|DIAGNOSTIC_TEST|standard breast imaging|The control group that receives standard preoperative imaging only (breast ultrasound and mammography)
40989854|NCT00531024|DRUG|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
40989855|NCT06234501|DIETARY_SUPPLEMENT|Pyridoxal 5'-Phosphate (100 mg)|100 mg Pyridoxal 5'-Phosphate tablet once daily with food
40989856|NCT06234501|OTHER|Placebo|Placebo tablet once daily
40989857|NCT03420469|DRUG|Bupropion|Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)
40989858|NCT03410355|PROCEDURE|BMAC/PRP Injection|Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound.
40989859|NCT03410355|PROCEDURE|Cortisone Injection|An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound.
40989860|NCT00355862|DRUG|CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|center specific therapeutic regimen without mTOR inhibition
40989861|NCT00355862|DRUG|Sirolimus|Sirolimus based immunosuppression
41307403|NCT06536153|COMBINATION_PRODUCT|Amaranth grain flat bread|The recipe will be produced according to the recommended dietary allowance (RDA); based on RDA, 200 g of flat-bread (30% chickpea and 70% amaranth grain) comprised 30 mg of iron, which can satisfy 50% of RDA supposing 15-20% iron absorption (54). A prior study concluded that the acceptability was satisfactory in the community (55). Also, a study from the Hawassa University Department of Food Sciences reported that amaranth-grain flat-bread was safe for consumption for 48 hours after preparation and improved the nutritional values (56). To lower the phytate levels in the amaranth grain, home-level processing will be used. For 24 hours, amaranth grain will be soaked in water with 5 milliliters of lemon juice per 100 milliliters of water, and it will germinate for 72 hours. It will be sun-dried, roasted, and ground using a nearby electrical mill before fermented bread is made
41307404|NCT00347555|BIOLOGICAL|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
41307405|NCT00347555|DRUG|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
40785492|NCT05246969|OTHER|Sepsis detection|The aim of the study was to observe whether the treating physicians were able to detect sepsis by strictly applying the recommended SOFA score.
41465973|NCT06236412|BEHAVIORAL|Health education|Health education about the contents listed under each arm will be provided for the participants.
41465974|NCT03389087|DRUG|Apatinib and Etoposide Capsule|Apatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
41465975|NCT02146976|DRUG|propofol|introvenious infusion of propofol
41465976|NCT02146976|DRUG|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
40989862|NCT05153915|DRUG|Tacrolimus granules|Oral
40989863|NCT03384979|DRUG|Iopamidol|Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
40989864|NCT00013429|PROCEDURE|Visual|
40989865|NCT04022447|DRUG|Dupilumab|retrospective data collection
40989866|NCT05634551|BEHAVIORAL|Questionnaires|Participants will complete 5 questionnaires about any symptoms participants may be having, any anxiety and/or depression participants may be having, your preference in decision-making, and your expectations about your treatment. It should take about 30 minutes to complete all 5 questionnaires
40989867|NCT05634551|BEHAVIORAL|Interview|The interview will last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom or FaceTime (based on your preference)
41146517|NCT05997420|BEHAVIORAL|STAR Program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
41146518|NCT05997420|BEHAVIORAL|Usual Care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
41146519|NCT02294994|DRUG|tirofiban|
40785493|NCT05781152|DRUG|Anti-TNF therapy|Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool
40785494|NCT04474639|DEVICE|echocardiographic examination|conducting an echocardiographic study according to a standard protocol with the determination of diastolic dysfunction of the left ventricle
40785495|NCT06446583|OTHER|Chewing sugar-free gum|Upon arrival at the preoperative preparation room, patients begin chewing sugar-free gum provided by the preoperative nurse. They continue chewing until they enter the operating room (for at least 15 minutes). Before entering the operating room, it is confirmed that the gum has been discarded.
40785496|NCT00552071|DRUG|Octreotide LAR 30 MG Injection|Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.
40785497|NCT06012539|OTHER|Qualitative (interviews)|Interviews were held with participants at three different time points, approximately six months apart. Interviews were taped and analyzed for common themes.
40785498|NCT04803474|DIAGNOSTIC_TEST|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
40989868|NCT01825382|DEVICE|iBGStar meter|Subjects will receive iBGStar meter and iPhone to use as meter during the study.
40989869|NCT02109120|PROCEDURE|vein blood collection|5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
40989870|NCT00229632|DRUG|Idebenone|Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
40989871|NCT04102592|OTHER|Permethrin-treated Lesu (baby wrap)|0.5% permethrin application
40989872|NCT04102592|OTHER|Untreated Lesu (baby wrap)|Matching untreated lesu
40989873|NCT00000999|DRUG|Zidovudine|
40989874|NCT03316885|DEVICE|Clareon® IOL|Foldable, single-piece posterior chamber IOL intended for long-term use over the lifetime of the cataract patient. This device is CE-marked (European Conformity) in the countries with participating Investigators.
40989875|NCT03316885|PROCEDURE|Cataract Surgery|Routine small incision cataract surgery with unilateral IOL implantation
40989876|NCT04025996|DIAGNOSTIC_TEST|Cardiac Assessments and Eye Assessments|"Cardiac Assessments, include the following:~* transthoracic echocardiography~* computed tomography of coronary arteries~* position emission tomography computed tomography or single photon emission tomography computed tomography~Eye examinations, include the following:~* pupil dilation~* retinal photography~* dynamic vessel analyser~* IOL master"
41146520|NCT03037736|DRUG|5-Fluorouracil|5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
41146521|NCT03037736|DRUG|Bevacizumab|Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
41146522|NCT03037736|DRUG|Normal saline|Normal saline will be used as the placebo.
41146523|NCT03677271|BEHAVIORAL|Physical Activity|
41146524|NCT02297464|OTHER|Eggs - 2 per day for breakfast|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
41146525|NCT02297464|OTHER|1 packet of oatmeal per day|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
41146526|NCT02314000|DEVICE|Precision or Precision Spectra Spinal Cord Stimulator System|
41307406|NCT00347555|BIOLOGICAL|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
41307407|NCT01227538|OTHER|Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
41465977|NCT03430011|BIOLOGICAL|JCARH125|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).
40785499|NCT03521700|DRUG|Rosuvastatin|For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L.
40785500|NCT03240107|PROCEDURE|levator resection|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.~The skin incision closed by continuous suture with 6-0 prolene."
40785501|NCT03240107|PROCEDURE|levator tucking|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene."
40785502|NCT05110573|PROCEDURE|pancreatoduodenectomy|Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic
40785503|NCT01776853|DIETARY_SUPPLEMENT|Glucose|
40785504|NCT01776853|DIETARY_SUPPLEMENT|Fructose|
40785505|NCT01776853|DIETARY_SUPPLEMENT|Fructans|
40785506|NCT05039788|OTHER|Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements|"Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements At D30 and D90~Measurement of systolic and diastolic blood pressure, impedancemetry, weight, 3 times a week between D30 and D90 post-transplant,"
40785507|NCT05739825|OTHER|FMT from healthy donors|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through FMT
40785508|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
40785509|NCT02829996|DRUG|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
40785510|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
40785511|NCT02829996|DRUG|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
40785512|NCT02829996|DRUG|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
40785513|NCT03376464|DEVICE|Xeomin Cosmetic|Xeomin Cosmetic is the purest commercially available botulinum toxin type A available to date. It has been approved by Health Canada since 2012 for the temporary improvement in the appearance of moderate to severe glabellar lines.
40785514|NCT03965403|DEVICE|Arm motor function retraining with BURT|Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
40785515|NCT02965638|OTHER|Oxygen|The intervention arm (Oxygen Group) will receive oxygen via nasal cannula at a rate of 4L of FiO2 93-100% from an oxygen concentrator up to 24 hours daily
40989877|NCT01014429|DRUG|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
41465978|NCT03430011|BIOLOGICAL|JCARH125 + anakinra|Participants will undergo leukapheresis to isolate PBMCs for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by two doses of anakinra administered subcutaneously and one dose of JCARH125 administered IV. Subjects receive anakinra for 5 consecutive days following JCARH125 infusion.
41146527|NCT00461656|DRUG|Preoperative conjunctival irrigation with 5% or 1.25% PI|Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
41146528|NCT04459949|DEVICE|Sharkskin|Use of Sharkskin ILM forceps
41146529|NCT04459949|DEVICE|Grieshaber|Use of Grieshaber ILM forceps
41146530|NCT03042572|DRUG|Allogeneic Mesenchymal Stromal Cell|Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5\*10\^6 MSC per site; total 150\*10\^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
41146531|NCT03042572|OTHER|Placebo|Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
41146532|NCT05972161|DEVICE|Thermal Imaging camera|Thermal Imaging camera used to measure respiratory flow.
41146533|NCT01276080|DRUG|Donepezil|10 mg tablets
41146534|NCT04162977|BEHAVIORAL|Personality-targeted Interventions|The Personality-targeted Interventions (i.e., Preventure programme) are selective substance use prevention programme designed to target known personality risk factors for substance misuse based on the evidence from cross-sectional and longitudinal studies which connect these personality risk factors to early initiation and escalation of substance misuse in adolescents. This selected personality-targeted approach targets four personality-specific motivational pathways to substance misuse: Hopelessness, Anxiety Sensitivity, Impulsivity, and Sensation Seeking. Each intervention will involve two 90-minute sessions, with an average of 6 personality-matched adolescents per group, and will be conducted using manuals that incorporate psycho-educational, motivational enhancement therapy (MET), and cognitive behavioural therapy (CBT) components and include real life 'scenarios' shared by high-risk local youth with similar personality profiles.
41146535|NCT02188745|DRUG|17B-estradiol|Anti-estrogen
41146536|NCT02188745|DRUG|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
41146537|NCT02188745|DRUG|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
41465979|NCT02714296|DRUG|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
41465980|NCT02714296|DIETARY_SUPPLEMENT|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
40989878|NCT06482021|DEVICE|Low-intensity extracorporeal shock wave|Acetylcholine iontophoresis• The Iontophoresis comprises of electric impulses from a low voltage galvanic current stimulation unit to drive ions (Ach) (1%) into soft tissue structures.
40989879|NCT02400502|BEHAVIORAL|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
40989880|NCT03594279|BEHAVIORAL|Community Mobilization|Community Mobilization
40989881|NCT03594279|BEHAVIORAL|Community Mobilization and Community Incentive|Community Mobilization and Community Incentive
40989882|NCT03928847|DRUG|Epigallocatechin-3-gallate (EGCG)|Epigallocatechin-3-gallate (EGCG) capsules
40989883|NCT02922907|DIETARY_SUPPLEMENT|arabinoxylan rice bran|a proprietary product derived from rice bran treated with extracts from three mushrooms
40989884|NCT02922907|DIETARY_SUPPLEMENT|Placebo for arabinoxylan rice bran|inactive product
40989885|NCT01010308|DRUG|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
40989886|NCT01782664|DRUG|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
40989887|NCT01782664|DRUG|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
40989888|NCT01782664|DRUG|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
41465981|NCT02588820|DRUG|Antiretroviral Therapy (Experimental)|"1. Initial ART until HLA-B5701 results became available (48 hours):~   1. Tenofovir 245 mg once a day~  2. Emtricitabine 200 mg once a day~  3. Dolutegravir 50 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day~2. Three months continuation treatment (after HLA-B5701 confirmed as negative):~   1. Dolutegravir 50 mg once a day.~  2. Abacavir 600 mg once a day~  3. Lamivudine 300 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~3. Nine months continuation treatment (till complete 12 months treatment):~   1. Abacavir, 600mg once a day~  2. Lamivudine, 300 mg once a day~  3. Dolutegravir, 50 mg once a day"
41465982|NCT02662582|DRUG|Reldesemtiv|Oral tablet
41465983|NCT02662582|DRUG|Placebo|Oral tablet
41465984|NCT04171401|OTHER|In-patient stroke rehabilitation.|An in-patient multi-disciplinary stroke rehabilitation program was performed.
41465985|NCT05762887|OTHER|Probiotic Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The probiotic group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
41465986|NCT05762887|OTHER|Placebo Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The placebo group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
41465987|NCT01436643|DRUG|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
41465988|NCT01436643|DRUG|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
41465989|NCT01436643|DRUG|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
41465990|NCT01436643|DRUG|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
41465991|NCT05839145|OTHER|Strength force measurment|The grip and pinch strength of the patient will be evaluate using dedicated devices (MyoGrip and MyoPinch)
41465992|NCT05839145|OTHER|Time tests|Lower and upper limb capacities of the patients will be measured during timed tests
41465993|NCT05839145|OTHER|Motor scales|Patient's motor functional abilities will be evaluated using specific motor scales (MFM32, RULM)
41465994|NCT05839145|OTHER|Questionnaires|Patients and caregivers quality of life will be measured with different questionnaires (SMA-FRS, QOL-gNMD, SMAIS, PREM)
41465995|NCT05839145|DEVICE|Accelerometry|Patients physical activity will be measured at home using accelerometer sensors
41465996|NCT05839145|OTHER|MNR|Sub-group of patients will perform an NMR imaging to evaluate the intramuscular fatty infiltration in thighs and muscle volume in thighs
41465997|NCT05839145|OTHER|Bio-impedance analysis|The patients' muscular and fatty volume will be evaluated using BIA technic (compared to MNR)
41465998|NCT01626651|DRUG|Ibrutinib|A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.
41465999|NCT01626651|DRUG|Ketoconazole|Ketoconazole (400 mg \[2 x 200 mg\] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
41146538|NCT02188745|DRUG|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
41466000|NCT01363466|PROCEDURE|hysterectomy|
41466001|NCT02301858|GENETIC|Genome analysis of tissue samples.|Genome analysis of tissue samples.
41466002|NCT02762994|DRUG|BCD-085|
41466003|NCT02762994|OTHER|Placebo|
41466004|NCT02462434|BEHAVIORAL|Early palliative care team consultation|The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
41466005|NCT05583682|OTHER|Dental restoration|Restoration of carious mandibular first molar teeth are restored either with nano-filled resin modified glass ionomer or sub-micron resin composite restorative material
40989889|NCT01782664|DRUG|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
41146539|NCT00502359|DEVICE|capillary blood glucose measurement|
40989890|NCT04059679|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)
41466006|NCT06474481|DRUG|Zanubrutinib|Zanubrutinib, 160mg PO BID.on days 1-28 Induction treatment: 4-6cycles ; Maintenance: 1 year;
41466007|NCT06474481|DRUG|Obinutuzumab|Induction treatment: Obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-4/6); for 4-6 cycles, 1 cycle = 28 days Maintenance: Obinutuzumab (G), 1000mg, IV, every 2 months for 1 year;
41466008|NCT06474481|DRUG|Prednisone|Prednisone (P), 100 mg, PO, D2-6；for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
41466009|NCT06474481|DRUG|Cyclophosphamide|Cyclophosphamide (C), 750 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
41466010|NCT06474481|DRUG|Vincristine|Vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
41466011|NCT06474481|DRUG|Doxorubicin|Doxorubicin (H), 50 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment ，1 cycle = 28 days
41466012|NCT00055718|DIETARY_SUPPLEMENT|silymarin|
41466013|NCT00776568|PROCEDURE|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
41466014|NCT00776568|DRUG|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
41466015|NCT00480649|DRUG|Salmeterol/ fluticasone propionate|2 active arms (parellel group)
41466016|NCT05352477|OTHER|Balneotherapy with thermal water|Bath with Acquabios thermal water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
41466017|NCT05352477|OTHER|Balneotherapy with tap water|Bath with tap water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
41466018|NCT04292015|DIAGNOSTIC_TEST|Optos ultra-widefield retinal imaging (Optos California)|retinal imaging device
41466019|NCT00503230|BEHAVIORAL|Standard Care Intervention (SCI)|Standard Care Intervention (SCI)
41466020|NCT00503230|BEHAVIORAL|Culturally Tailored Intervention (CTI)|Culturally Tailored Intervention (CTI)
41466021|NCT00019734|BIOLOGICAL|aldesleukin|
41466022|NCT00019734|BIOLOGICAL|fowlpox virus vaccine vector|
41466023|NCT00019734|BIOLOGICAL|vaccinia-tyrosinase vaccine|
41466024|NCT00142987|DRUG|Tegaserod|
41466025|NCT05135819|BEHAVIORAL|Cyber School for Grandparents|Educational program for secondary school students to become cyber tutors for their grandparents or for senior citizens, who are interested to learn new digital use and skills.
41466026|NCT03934996|OTHER|Runners with educational training|"Intervention will consist of an educational talk to know the anatomy and function of the Pelvic Floor Muscles and 20 minutes of both strength and endurance exercises with biofeedback. An exercise protocol will be carried out. The participants will be instruct to contract and maintain maximum force for a mean period of 6 seconds (endurance training) and rest for twice the length of the endurance training time, followed by three fast contractions in a row as strength training. It will be done twice a week, during 12 weeks.~Pelvic floor assesment: Perineometry, manual palpation, electromyography Trunk and lower limbs electromyography and kinematics"
40989891|NCT04059679|DRUG|Aspirin 81 mg|EC aspirin 81 mg qd
40989892|NCT05058300|DEVICE|CT Thorax|CT Thorax (GE Revolution with chest pain algorithm)
40989893|NCT00502177|BEHAVIORAL|Questionnaire|QOL Questionnaires taking a total of 10 minutes to complete.
40989894|NCT02165436|OTHER|Chewing gum|Subjective assessment - subjective assessment of abdominal pain and nausea.
40989895|NCT02165436|OTHER|Control|No intervention will be assessed for this group.
40989896|NCT02576561|BIOLOGICAL|TVGV-1|Antigen + Adjuvant
40989897|NCT02576561|BIOLOGICAL|GPI-0100|Adjuvant Alone
40989898|NCT02576561|BIOLOGICAL|Placebo|Placebo
40989899|NCT02406651|DRUG|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
40989900|NCT02406651|DRUG|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
41466027|NCT02247050|BEHAVIORAL|Commitment invitation|Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
41466028|NCT03813225|OTHER|Bilateral serratus Intercostal plane Block|Will be performed by echo guided one puncture in the fifth costal arch with anterior axilary line, where the tip of the needle will be guided until it reaches a point above the external intercostal muscle, below the anterior serratus above the costal arch where they will be administered 21 ml of anesthesic mass, (20 ml of levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone.)
41466029|NCT03989011|DIAGNOSTIC_TEST|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celsius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
41466030|NCT03989011|DIAGNOSTIC_TEST|Arterial stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~* Peripheral pressure parameters~* Central and abdominal aneurysm pressure parameters (derived using a transfer function)~* Cardiac output parameters (SEVR, ED)~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
41466031|NCT04753853|PROCEDURE|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
41466032|NCT02981316|BIOLOGICAL|RBX7455|Microbiota capsule(s) given twice daily in the morning, and in the evening.
41466033|NCT01275157|DRUG|LY2452473|Administered orally as a liquid suspension
41466034|NCT00835939|DRUG|25% Dextrose and 1% Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
41146540|NCT06454578|DRUG|Adebrelimab + Apatinib|"the first 6 months or 8 cycles: Adebrelimab 1200 mg, every 3 weeks； Apatinib 250 mg/day~Maintenance phase： Adebrelimab 1200 mg, every 3 weeks, Maximum maintenance up to 2 years"
41146541|NCT03528356|BEHAVIORAL|Regular diet|Patients will not receive any information regarding their usual diet. They will simply perform home dental bleaching.
41146542|NCT04411771|BEHAVIORAL|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or MI. The common theme is that they are principle-based rather than manual-based and focus on behavioral change in relation to a problem that is perceived both possible to affect and relevant to the patient, rather than focusing on a specific diagnosis or condition. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. Usually a BI treatment consists of 1-4 appointments with several weeks apart and ends when the patient feels that they are moving in the right direction.
41466035|NCT00835939|DRUG|Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
41466036|NCT00835939|PROCEDURE|sclerotherapy|
41466037|NCT04219787|PROCEDURE|Long BPL LRYGB|LRYGB with an 180 cm BPL and an AL of 80 cm.
41466038|NCT04219787|PROCEDURE|Short BPL LRYGB|The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.
41146543|NCT04411771|BEHAVIORAL|Guided self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering shCBT will need four days of reading and two days of training to be able to make initial assessments and problem profiling and use the self-help books.
41466039|NCT06503887|OTHER|Stool sample collection|Following the approval of the legal guardians, a stool collection container was given to the parents in order to collect the stools. Stools were kept at 4ºC for 24h max, then transported to the laboratory, aliquoted and stored at -80ºC for further analysis
41146544|NCT04127110|DRUG|Lorlatinib|Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
41146545|NCT04366895|OTHER|conventional single implant overdenture|conventional manufactured implant overdenture
41146546|NCT04366895|OTHER|3d printed single implant overdenture|CAD-CAM manufactured implant overdenture.
41147102|NCT01072149|DRUG|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
41147103|NCT01072149|DEVICE|placebo|placebo
41466040|NCT02846233|DRUG|GLP1 receptor agonist|"Albiglutide or Dulaglutide will be added to a basal insulin."
41466041|NCT02846233|DRUG|basal insulin|The participant will continue with the basal insulin.
41466042|NCT02846233|DRUG|SGLT2 inhibitor|"Empagliflozin will be added to a basal insulin."
41466043|NCT02846233|DRUG|Metformin|The participant will continue with metformin.
41466044|NCT03756337|DEVICE|Neuro 1 & Neuro 2|participant common fitting map used for tests
41147104|NCT04050722|DRUG|Sensodyne Repair and Protect|Participants will brush their teeth with Sensodyne Repair and Protect (containing 0.454% stannous fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
41307408|NCT05789264|DEVICE|Nasal Compression Device|Participants assigned to the NasaClip arm will not receive routine care as the objective of this study is to compare the NasaClip device to routine digital compression in terms of feasibility, comfort, and efficacy. Limited data previously discussed in the background section indicates that application of nasal compression devices may be superior to digital compression.
41466045|NCT03756337|DEVICE|Neuro 2 & Neuro 1|participant common fitting map used for tests
40989901|NCT03456596|OTHER|ENABLE|This is an implementation science study in which an evidence-based early palliative care intervention, ENABLE (Educate, Nurture, Advise, Before Life Ends), is being implemented in rural community cancer centers that did not have a palliative care program.
41307409|NCT05789264|DIAGNOSTIC_TEST|Routine Care|Most first aid instructions for epistaxis management tell patients to apply firm digital pressure for 10 to 20 minutes, use a topical vasoconstrictor and apply an ice pack over the nose.
41466046|NCT03957694|DRUG|Romiplostim|Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
41466047|NCT03071913|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
41466048|NCT03071913|OTHER|Laboratory Biomarker Analysis|Correlative studies
41466049|NCT03442192|OTHER|PrEP Care Anywhere Services|"PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~* On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~* HIV and Sexually Transmitted Infection (STI) at Home Self-Testing"
41466050|NCT00768352|OTHER|Educational intervention|An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
41466051|NCT00233155|DRUG|Capsaicin Dermal Patch|
41307410|NCT03044015|BEHAVIORAL|community based integrated strategy for secondary prevention of OF|Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
41466052|NCT03209609|DEVICE|VEST|External support for vein grafts, cobalt chrome braid
41466053|NCT03209609|PROCEDURE|Coronary artery bypass vein grafts|Bypass coronary arteries with autologous saphenous vein grafts
40989902|NCT05303207|DIETARY_SUPPLEMENT|YOUR SUPER Detox Bundle|During days 1-5, participants will complete the 5-day Your Super Detox, consuming 2 smoothies daily (breakfast and dinner) containing Your Super Detox superfood powders.
41466054|NCT04813562|BIOLOGICAL|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
40989903|NCT01978587|DRUG|JTZ-951|
40989904|NCT03068273|DEVICE|Real-time CGM data|
40989905|NCT03341832|DRUG|NVP-1203|oral dose for 7 days
40989906|NCT03341832|DRUG|NVP-1203-R|oral dose for 7 days
41307411|NCT03044015|BEHAVIORAL|as usual|
41307412|NCT01156597|DRUG|pioglitazone|30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
40989907|NCT03341832|DRUG|NVP-1203 placebo|oral dose for 7 days
40989908|NCT03341832|DRUG|NVP-1203-R placebo|oral dose for 7 days
40989909|NCT03505944|DRUG|Venetoclax|venetoclax + lenalidomide + rituximab
40989910|NCT02770586|DIAGNOSTIC_TEST|Breast PET|imaging of the breast using the Breast PET system
40989911|NCT00117247|DRUG|darbepoetin alfa|
40989912|NCT06541184|DRUG|Ziconotide [Prialt]|Intrathecal injection of ziconotide, using an internal pump, surgically inserted by a trained neurosurgeon or anesthesiologist, under general anesthesia.
40989913|NCT02190812|DEVICE|Forearm supporter|The forearm supporter be use in tennis elbow.
40989914|NCT02190812|DEVICE|Grip ball|
41307413|NCT00300651|BEHAVIORAL|Cognitive Behavioral Therapy|
41307414|NCT04598581|RADIATION|Low Dose Radiation Therapy (LD-RT)|Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray
41307415|NCT04598581|OTHER|Sham irradiation|Sham irradiation
41307416|NCT02484196|BEHAVIORAL|Questionnaires|Questionnaires
41307417|NCT02488551|DEVICE|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
41307418|NCT02488551|OTHER|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
40989915|NCT02711046|PROCEDURE|single stage nasolabial flap|The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
40989916|NCT05268614|RADIATION|Radiation therapy|"Participants will receive either 70 gray (Gy), 60 Gy, or 50 Gy of radiation based on the following criteria:~70 Gy: Pretreatment level of plasma circulating free HPV DNA (cfHPV DNA) ≤ 12 copies/mL~60 Gy: Tumor tissue positive for HPV subtype other than 16 OR Pretreatment level of cfHPV DNA 13-99 copies/mL OR Pretreatment level of cfHPV DNA ≥ 100 copies/mL AND \<95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy~50 Gy: Tumor tissue positive for HPV subtype 16, pretreatment level of cfHPV DNA ≥ 100 copies/mL, AND ≥ 95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy"
40989917|NCT05268614|DRUG|Cisplatin|"All participants will receive 40 mg/m2 of cisplatin intravenously over 60 minutes weekly during radiation therapy.~If cisplatin is not recommended by the treating medical oncologist or is not tolerated, it is permissible to switch to an alternative chemotherapy regimen per institutional practice, but chemotherapy should not be discontinued unless mandated by the patient's condition."
40989918|NCT02009046|BEHAVIORAL|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
40989919|NCT02009046|BEHAVIORAL|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
40989920|NCT02009046|BEHAVIORAL|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
40989921|NCT02009046|BEHAVIORAL|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
41146548|NCT04843956|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided biopsy|"Capillary with suction (puncture with gradual withdrawal of the stylet, applying dry suction with a 10 ml air vacuum syringe after removing the stylet)~Capillary without suction (puncture with removal of the stylet gradually, without suction after removing the stylet)~wet suction (Prior to puncture, the stylet is removed from the needle and irrigated with 1-2 ml saline solution to replace the air column with liquid, then the solid lesion is punctured and suction is placed with a 10 ml vacuum syringe of air)"
41146549|NCT00150852|DRUG|Vancomycin|
41146550|NCT03258034|DRUG|SPA|S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
41146551|NCT02143713|DRUG|Elagolix|Elagolix tablets administered orally
41307419|NCT03393052|PROCEDURE|Coronary Angiography|Comparison of left radial versus femoral access during coronary angiography of patients who have undergone coronary artery bypass grafting surgery
41307420|NCT01815333|DRUG|Feraheme|6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.
41466055|NCT04813562|BIOLOGICAL|a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
41466056|NCT04813562|BIOLOGICAL|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
41466057|NCT04813562|BIOLOGICAL|a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
41466058|NCT04813562|BIOLOGICAL|a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
41466059|NCT04813562|BIOLOGICAL|a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
41466060|NCT04813562|BIOLOGICAL|a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
41466061|NCT04813562|BIOLOGICAL|a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
41466062|NCT01127776|DEVICE|APOS SYSTEM|The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
41466063|NCT01127776|OTHER|APOS SYSTEM without biomechanics units.|The control group will receive the same walking protocol as the trial group without biomechanics units
40989922|NCT04424017|BIOLOGICAL|Specific anti-SARS-CoV-2 antibodies|"A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA)."
40989923|NCT02861703|BEHAVIORAL|Online lifestyle intervention|Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
40989924|NCT00257842|PROCEDURE|Standard treatment, sham feedback and biofeedback therapy|
40785521|NCT06498115|DRUG|Norepinephrine|Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
40785522|NCT04955067|DIAGNOSTIC_TEST|Diagnositic test|The results of hip arthroscopy were taken as the gold standard, and MRI examination was taken as the research object
40785523|NCT04547465|DIAGNOSTIC_TEST|Echocardiography|2D Speckle-tracking echocardiography
41466064|NCT03559127|PROCEDURE|For the Group A. Applied Cryotherapy at 6 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System (Kerr Endo) for 5 minutes.
41466065|NCT03559127|PROCEDURE|For the Group B. Applied Cryotherapy at 2.5 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes.
40785524|NCT04044963|BEHAVIORAL|Exercise and Prehabilitation|"All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey."
40989925|NCT01472250|DRUG|Clinical chemo-drugs|"Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel"
40785525|NCT04305626|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms with flow diversion.
40785526|NCT00466180|BEHAVIORAL|Nevirapine from twice-a-day to once-a-day|
40785527|NCT05144789|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
40989926|NCT02467569|DRUG|Hemay020|
40989927|NCT02397421|DRUG|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
40989928|NCT02397421|DRUG|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
40785528|NCT05144789|DEVICE|Active TBS-DMPFC|"Participants in the active stimulation group will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
40785529|NCT05144789|DEVICE|Sham TBS-DLPFC or DMPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
40785530|NCT06447766|BEHAVIORAL|Feeding Families Your Way Program|Feeding Families Your Way is a video-based education program delivered by the University of Rhode Island Supplemental Nutrition Assistance Program - Education (SNAP-Ed).
40785531|NCT00608062|DRUG|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
40785532|NCT00608062|DRUG|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
40785533|NCT00608062|DRUG|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
41146552|NCT02727998|DRUG|Ketamine|Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
41307421|NCT01815333|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI scan performed before Feraheme injection. After Feraheme injection, MRI scan performed 2 days later, and then again the following day.
40785534|NCT04398576|BEHAVIORAL|Training and support|GP's receive the tools to make early identification of harmful and hazardous alcohol use possible. They are given guidelines to apply a brief intervention. At the start of the study, the T\&S-group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months.
40785535|NCT04398576|BEHAVIORAL|Community actions|There will be embedded community-based actions within a local strategy.
40989929|NCT06392542|BEHAVIORAL|Whole Selves|Whole Selves is a brief online self-guided intervention addressing transgender/nonbinary young adults' experiences with alcohol use and romantic relationships. The intervention is delivered in a single session of approximately 40 minutes. Whole Selves employs principles of technology-adapted motivational interviewing (e.g., eliciting and strengthening participants' internal reasons for behavior change through interactive activities) as well as personalized feedback on participants' self-reported alcohol use and romantic relationship experiences. The intervention incorporates text and video narratives from transgender/nonbinary people sharing their own experiences with alcohol use and romantic relationships. Content will be tailored based on participants' current alcohol use and romantic relationship experiences.
40989930|NCT00861146|BEHAVIORAL|behavioral counseling plus contingency management|Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
41307422|NCT01622920|OTHER|Ultrasound transducer|A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded
41307423|NCT02849990|DRUG|Abiraterone Acetate|Given PO
41466066|NCT03559127|PROCEDURE|Control Group (CG). Applied irrigant at room temperature|Patients assigned to this control group were treated identically to the experimental groups, except that receive a final flush with 5 mL (room temperature) 17% EDTA followed with twenty mL (room temperature) sterile saline solution delivered to the WL using a metallic micro-cannula included in the Endo Vac System for five minutes.
41466067|NCT02407067|DEVICE|ChatterVox|A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
41466068|NCT02407067|DEVICE|Easy Listener FM system (Phonic Ear Corp.)|"A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.~Personal Communication System"
40785536|NCT02115035|DRUG|Vermurafenib|960 mg of Vermurafenib twice daily orally on a 28 day schedule
40785537|NCT05993793|DEVICE|Fototherapy|The Antares brand Laser device was used for 3 sessions with an interval of 24 hours. The Visual Analogue Scale (VAS) was used before starting treatment, after the first and second sessions, and 1 week after the third session. In addition, at the end of the treatment, the closure, or not, of the lesion was verified, and the questionnaires performed prior to phototherapy were reapplied. The VAS assesses the patient's level of pain, which can be divided into mild pain (1-2), moderate pain (3-7), and severe pain (8-10). The Bristol Scale is based on the identification of the patient's consistency of stools, while types 1-2 correspond to constipation, 3-4 indicate normal intestinal rhythm, 5 indicate lack of fiber, and 6-7 correspond to diarrhea
40785538|NCT02479880|DRUG|Tenofovir DF|300 mg tablet administered orally once daily for up to 96 weeks
41146553|NCT02727998|DRUG|Midazolam|Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
41146554|NCT05773872|OTHER|Questionary|"In addition to the usual care, the patient will complete the following validated questionnaires :~SART (Sustained Attention to Response Task), IGT (Iowa Gambling Task), UPPS (Impulsive Behaviour Scale), TAS (Toronto Alexithymia Scale), BES (Basic Empathy Scale), FRET (Facial Emotions Recognition Task), ERF-CS, MASC (Movie for the Assessment of Social Cognition)"
41146555|NCT05107232|OTHER|MRI|MRI
41307424|NCT02849990|DRUG|Apalutamide|Given PO
41307425|NCT02849990|DRUG|Degarelix|Given SC
41307426|NCT02849990|DRUG|Indomethacin|Given PO
41307427|NCT02849990|OTHER|Laboratory Biomarker Analysis|Correlative study
41307428|NCT02849990|DRUG|Prednisone|Given PO
41307429|NCT03071705|DRUG|Metformin|500 mg PO BID
41466069|NCT01684527|OTHER|Respiratory secretions obtained|
41466070|NCT05985694|DRUG|AD17002|"The investigational intranasal pharmaceutical product named AD17002 contains a detoxified Escherichia coli heat-labile enterotoxin, LTh(αK).~Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32."
40785539|NCT02479880|RADIATION|DEXA Scan|Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
41307430|NCT03071705|DRUG|TKI|standard dose
41307431|NCT01152333|DRUG|Exendin-(9-39) Acetate|Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.
41307432|NCT01152333|DRUG|Saline 0.9%|Saline will be administered through IV infusion once for a maximum of 2.5 hours in length
41307433|NCT03851276|RADIATION|Multi-sliced computed tomography (MSCT)|Surgery planning done based solely on MSCT.
41307434|NCT04176432|OTHER|No intervention|Retrospective observational study with no intervention
41307435|NCT02195791|DRUG|Pioglitazone|Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
41307436|NCT02195791|DRUG|Placebo|Placebo (oral) 1 tab once daily for 7 days
41307437|NCT01035255|DRUG|LCZ696 200 mg BID|LCZ696 200 mg BID
41307438|NCT01035255|DRUG|Enalapril 10 mg BID|Enalapril 10 mg BID
41307439|NCT02279433|DRUG|DS6051b|DS-6051b 50 mg and 200 mg capsules for oral administration
41307440|NCT02660619|OTHER|Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)|
41307441|NCT00260637|PROCEDURE|Acupuncture|
41466071|NCT05985694|DRUG|Placebo|Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.
40785540|NCT02724241|OTHER|one time exposure to e-cig with nicotine|one time exposure to e-cigarette vapor with nicotine
41307442|NCT01351766|DRUG|Transdermal Nicotine Patch|Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
40989931|NCT04511793|DEVICE|Medtronic Synchromed II pump|The pump will be placed during surgery and the pump will be filled with a combination of floxuridine (FUDR), dexamethasone, heparin, and saline.
41307443|NCT02801630|DEVICE|PainShield SAW Patch Device|The PainShield is a self contained Surface Acoustic Wave device, where the waves are delivered locally through a trasnducer embedded into a patch that sits on the affected area.
41307444|NCT05079282|DRUG|ONO-4685|ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed
41307445|NCT03648840|BEHAVIORAL|Aversive cue|Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol
41307446|NCT03648840|BEHAVIORAL|Neutral cue|Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol
41307447|NCT02822339|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-030)
41307448|NCT00970528|DRUG|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
41466072|NCT03711916|DEVICE|PlasmaBlade 3.0S|PlasmaBlade (Medtronic) is approved by United States Food and Drug Administration (FDA) as a low thermal dissection device that has shown to be associated with effective cutting, and significantly lower temperature than traditional electrosurgical dissection devices.
41466073|NCT06235268|OTHER|Active systemic or non-systemic treatment (palliative or observation procedure)|The study includes medical visits and clinical-radiological re-evaluations according to clinical practice. The clinician will establish the number of visits necessary for each patient according to the needs encountered and depending on the treatment chosen.
41466074|NCT00464139|PROCEDURE|Laparoscopy|Laparoscopy
41466075|NCT02621463|DEVICE|Noninvasive Ventilator (V60, Philips)|The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
41466076|NCT04118868|COMBINATION_PRODUCT|Pembrolizumab administered using the Sofusa® DoseConnect™|pembrolizumab will be administered intralymphatically using the Sofusa® DoseConnect™ device
41466077|NCT01544439|PROCEDURE|stabilizing appliance|The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.
40989932|NCT00295347|DRUG|Spironolactone|
40989933|NCT00295347|DRUG|fludrocortisone|
40989934|NCT00295347|DRUG|escitalopram|
40989935|NCT00259077|DRUG|Omeprazole|
40989936|NCT04321148|PROCEDURE|standard of care PCI|optimal medical care PCI
40989937|NCT04321148|PROCEDURE|Impella-protected PCI|Impella-protected PCI
40989938|NCT00075582|PROCEDURE|conventional surgery|Some patients may undergo second-look surgery
40989939|NCT00075582|DRUG|dactinomycin|Given IV
40989940|NCT00075582|DRUG|cyclophosphamide|Given IV
40989941|NCT00075582|DRUG|vincristine sulfate|Given IV
40989942|NCT00075582|RADIATION|radiation therapy|Undergo radiotherapy
40989943|NCT04977076|OTHER|Uninterrupted NOAC use|Continuing NOAC use in advance of elective CAG or PCI.
40785541|NCT02724241|OTHER|One time exposure to e-cigarette without nicotine|One time exposure to e-cig without nicotine
40989944|NCT04977076|OTHER|Interrupted NOAC use|Usual care, interruption of NOAC prior to procedure.
40989945|NCT03209063|DIAGNOSTIC_TEST|polymerase chain reaction|diagnostic test as Polymerase chain reaction for detection of Prothrombin gene and methylenetetrahydrofolate reductase gene polymorphisms
40989946|NCT01395433|DRUG|Escitalopram|2 x 10 mg, single dose
40989947|NCT01395433|DRUG|Escitalopram|2 x 10 mg, single dose
40989948|NCT01395433|DRUG|Escitalopram|1 x 20 mg, single dose
40989949|NCT04294511|DRUG|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
41146556|NCT01285856|OTHER|hair and saliva samples|"Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.~Saliva sample, a method which gives similar results without the need for venous blood sampling."
41146557|NCT02541292|OTHER|No intervention, observational|
40785542|NCT02724241|OTHER|one time exposure to empty e-cigarette|one time exposure to empty e-cigarette (sham control)
40785543|NCT02712996|DRUG|Lisdexamfetamine|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
40785544|NCT02712996|DRUG|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
40785545|NCT05587660|PROCEDURE|Fully threaded cannulated screws|The most popular method in undisplaced neck of femur fracture include internal fixation by cannulated screws in which screws can be inserted relatively simply and atraumatically as compared to other methods. Screws can be used partially threaded or fully threaded; however studies on fully threaded screw fixation method are inconclusive.
40785546|NCT03793686|DRUG|PBCLN-003|Investigational drug
40989950|NCT03693079|PROCEDURE|Wet cupping therapy|"CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46). The cupping technique procedure was conducted in five phases:~1. Primary suction; cups are left attached to the skin for 5 minutes.~2. Area disinfection; areas are wiped with sterile gauze after disinfection with povidone iodine.~3. Scarification; Superficial incisions (20-30 gauge), 5 mm length and 1-2 mm depth, are made on the skin with a sterile, number 11 surgical blade.~4. Bloodletting and secondary suction; the cups which had been previously removed are placed again on the scarified areas Blood leaks from the capillary vessels of the skin and subcutaneous tissue and fills the cups, which are left in place for 15 minutes.~5. Removing and dressing; the cups full of blood are removed. The areas of application are wiped with sterile gauze and then a dressing is applied"
40989951|NCT04628676|DRUG|tranexamic acid|Tranexamic acid is added to the irrigation fluid used in arthroscopic shoulder surgery.
40989952|NCT04628676|DRUG|Epinephrine|Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
40989953|NCT05741515|OTHER|Vestibular Balance Therapy|see intervention arm description
40989954|NCT05741515|OTHER|Sham Intervention|see sham intervention arm description
41307449|NCT00970528|DRUG|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
40785547|NCT03793686|DRUG|Placebo|Placebo
40989955|NCT02488655|DEVICE|Echopulse|HIFU Under ultrasound guidance
40989956|NCT01990495|OTHER|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
40989957|NCT01990495|OTHER|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
40989958|NCT03319355|BEHAVIORAL|cognitive behavioral therapy|exercise therapy
40989959|NCT03571542|OTHER|pulmonary function|The aim of this study is to assess the respiratory function thanks to pulmonary function tests in renal transplanted children in France.
40989960|NCT01955161|DRUG|Placebo|Once daily, matching placebo capsules, orally
40989961|NCT01955161|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
41307450|NCT02076555|BEHAVIORAL|Education - Diabetes and Social Issues|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Social Issues was created. The module covers specific and detailed aspects of the topic social issues such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible."
41307451|NCT00782665|PROCEDURE|Biopsy|1 centimeter x 1/2 centimeter piece cut from uterus
40785548|NCT03767439|DRUG|Vismodegib|150 mg PO daily
40785549|NCT03767439|DRUG|Nivolumab|480 mg IV every 4 weeks
40785550|NCT03767439|DRUG|Ipilimumab|1 mg/kg IV every 6 weeks
40785551|NCT03255889|DRUG|Glyceryl Tridecanoate|Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%).
40785552|NCT03255889|OTHER|Placebo|Sunflower oil emulsion of equal calories.
40785553|NCT01057537|DRUG|polypill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg."
40989962|NCT00716911|DRUG|ganciclovir|
40989963|NCT00716911|GENETIC|polymerase chain reaction|
40989964|NCT00716911|OTHER|flow cytometry|
40989965|NCT00716911|OTHER|immunologic technique|
40989966|NCT00716911|PROCEDURE|allogeneic bone marrow transplantation|
40989967|NCT00716911|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40989968|NCT00716911|PROCEDURE|assessment of therapy complications|
40989969|NCT00716911|PROCEDURE|peripheral blood stem cell transplantation|
40989970|NCT05746442|BEHAVIORAL|Smartphone-delivered Automated Messaging|An interactive smartphone based intervention will provide weekly smoking-related assessments and personalized automated messages designed to increase motivation, self-efficacy, use of coping skills, social support and to reduce nicotine withdrawal symptoms and stress for a 26 week period.
40989971|NCT05746442|DRUG|Nicotine patch|Participants will be provided with a 8 week supply of nicotine patches
40989972|NCT05746442|BEHAVIORAL|Brief Advice to Quit and Smoking Cessation Self Help Materials|Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia
40989973|NCT05746442|BEHAVIORAL|Diet Assessment|Participants will be asked to complete brief weekly smartphone assessments about their diet for a 26-week period
40989974|NCT01142310|DRUG|Lamotrigine|Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
40989975|NCT01142310|DRUG|Placebo|
40989976|NCT01948973|DEVICE|Subsensory|The stimulation is here set to 90% of the sensory threshold
41146558|NCT03622372|PROCEDURE|Operative repair of Zone 2 FDP tendon lacerations|Zone 2 tendon laceration(s) will be surgically repaired either using the experimental device or the active comparator
41146559|NCT03622372|DEVICE|CoNextions TR Implant System|The CoNextions TR Implant System will be used to repair Zone 2 FDP tendon laceration(s).
41146560|NCT03622372|DEVICE|4-strand locked cruciate repair|A 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture will be used to repair Zone 2 FDP tendon laceration(s).
41146561|NCT05569018|BEHAVIORAL|Blended group transversal protocol (BLGr-TP)|It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,...) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.
41146562|NCT05569018|BEHAVIORAL|Face-to-face group transversal protocol (FFGr-TP)|It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).
40989977|NCT01948973|DEVICE|OFF|The stimulation is here turned OFF
40989978|NCT01948973|DRUG|Suprasensory|The stimulation is here set suprasensory
40989979|NCT03895996|DRUG|AVT001|autologous dendritic cell therapy
40989980|NCT03895996|OTHER|Placebo|matched placebo
40989981|NCT02344680|DRUG|Anti-HIV Agents|
40989982|NCT05771142|DEVICE|Smart t-shirt|24h ECG Monitoring with the smart t-shirt under study
40989983|NCT05771142|DEVICE|ECG Holter|24h ECG Monitoring with ECG Holter
40989984|NCT05771142|DEVICE|Smartwatch|24h ECG Monitoring with a smartwatch
40989985|NCT03327311|DEVICE|Bellafill|Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis \& deep dermis).
40989986|NCT04142021|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Surgery planning done based solely on coronary computed tomography angiography.
40989987|NCT06488963|OTHER|NatraCure Cold Therapy gloves and socks|These gloves and socks will be adjusted and tied to the child's wrists and ankles. There are sizes suitable for all ages and the dimensions of the gloves and socks can be adjusted with a snap fastener. The gloves and socks contain a soft Lycra lining and four inner gel cold packs to ensure full length cold therapy treatments. When the children wear these gloves and socks, they can still move their fingers and toes easily. In addition, it is a great advantage that the iced gel packs do not touch the child's skin directly.
40989988|NCT06031454|DRUG|Midazolam|oral
40989989|NCT06031454|DRUG|Omeprazole|oral
40989990|NCT06031454|DRUG|Rosuvastatin|oral
40989991|NCT06031454|DRUG|Verapamil|oral
40989992|NCT06031454|DRUG|Rifampin|oral
40989993|NCT06031454|DRUG|Leritrelvir|oral
40989994|NCT04467879|DEVICE|Zona Plus Device|Zona Plus 3.0 Individualized Isometric Handgrip Therapy Device
40989995|NCT04467879|DEVICE|Control Device|Zona Plus control sham device, with a nominal weaker grip
40989996|NCT01820455|DRUG|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
41466078|NCT01544439|PROCEDURE|Non-occluding splint, counseling|The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
41466079|NCT01139606|OTHER|Vibration resistance training|adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
40989997|NCT01820455|DRUG|Soap baths, Lubricating Jelly|Soap and water baths with lubricating jelly to the nares, once daily for 5 days
40989998|NCT02081482|RADIATION|18F-FDG PET|
40989999|NCT01435109|BEHAVIORAL|Patient Behavioral Intervention for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
40990000|NCT01435109|BEHAVIORAL|Provider Intervention for OA|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
40990001|NCT01435109|BEHAVIORAL|Combined Patient and Provider Interventions for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
40990002|NCT00451386|DRUG|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
40990003|NCT00451386|DRUG|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
41466080|NCT02241109|OTHER|no intervention|progression monitoring by echocardiography
41466081|NCT01321437|PROCEDURE|therapeutic conventional surgery|Undergo surgery
41466082|NCT01321437|OTHER|laboratory biomarker analysis|Correlative studies
41466083|NCT01321437|DRUG|Axitinib|Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
40990004|NCT04498728|OTHER|Mobile Health Application for Remote Monitoring|The use of the CATCH application (CATCH App), and any data and images obtained from the use of the CATCH App, will all be performed as standard of care for patients at Children's Mercy Kansas City, and will be for the clinical treatment of patients. Data will be collected for the repository for all patients submitting data through the use of the CATCH App. Clinical care team will follow the patients after discharge home from the hospital.
40990005|NCT06469372|DEVICE|Cardiac amyloidosis deep learning model|This is a deep learning algorithm which intakes a patient's age, sex, clinical factors known to be related to amyloidosis and their ECG and echocardiogram results and determines their estimated risk for having cardiac amyloidosis.
41146563|NCT00711022|DEVICE|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
41146564|NCT03189550|PROCEDURE|ERAS perioperative care|Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
41466084|NCT01321437|OTHER|pharmacological study|Correlative studies
41466085|NCT04593303|PROCEDURE|Internal iliac artery ligation with cervicoisthmic compression suture|Retroperitoneal approach will be performed to ligate both internal iliac arteries before bladder dissection followed by cervicoisthmic compression suture application at placental bed
40785554|NCT01057537|DRUG|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
41146565|NCT03189550|PROCEDURE|Standard perioperative care|Standard perioperative care prior to implementation of ERAS care pathway
41146566|NCT03189550|PROCEDURE|Noninvasive hemodynamic monitoring|Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
41146567|NCT02303509|DRUG|UCB5857 Part 1|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 1 mg, 5 mg, 10 mg or 15 mg~Route of administration: Oral"
41146568|NCT02303509|DRUG|UCB5857 Part 2|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 5 mg, 8 mg, 15 mg~Route of administration: Oral"
41146569|NCT02303509|OTHER|Placebo|"Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral"
41146570|NCT02825550|DEVICE|Taiwan ACE Beads|Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
41146571|NCT05843149|BEHAVIORAL|Manual Therapy/Exercises|Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.
41146572|NCT05843149|BEHAVIORAL|Physiotherapy/Back School|Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.
41146573|NCT00975078|PROCEDURE|adrenal insufficiency testing|"On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol."
41146574|NCT00975078|DRUG|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
41466086|NCT04593303|PROCEDURE|Cervicoisthmic compression suture without Internal iliac artery ligation|Bladder dissection followed by cervicoisthmic compression suture application at placental bed without Internal iliac artery ligation
41466087|NCT06535802|OTHER|Non-Interventional Study|Non-interventional study
41466088|NCT01124435|DRUG|Carboplatin plus Celecoxib|celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
41466089|NCT01754987|DRUG|Ascorbic Acid + Sorafenib|
41466090|NCT01754987|DRUG|Sorafenib|
41466091|NCT02863549|DEVICE|MitraClip in tricuspid valve|MitraClip in tricuspid valve
41466092|NCT05948033|BIOLOGICAL|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg)~Doseexpansion: RP2D~Drug: Fludarabine~Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3.~Drug: Cyclophosphamide~Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3."
40785555|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
40785556|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - medium|
40785557|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
40785558|NCT01706653|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
40785559|NCT04638751|DRUG|Immunotherapy|Checkpoint inhibitor
40785560|NCT04638751|DRUG|Chemotherapy|Any form of chemotherapy
40785561|NCT04638751|PROCEDURE|CRC surgical resection|Surgical resection to remove colorectal cancer
41146575|NCT02885610|BIOLOGICAL|Placebo plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
41146576|NCT02885610|BIOLOGICAL|RC18 80 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
41307452|NCT00582062|OTHER|washings for experimental marker testing|During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
41466093|NCT02096367|OTHER|Gait analysis|
41466094|NCT02096367|OTHER|Kinematic gait analysis in lower limb|
41466095|NCT02096367|OTHER|Analysis of static posture|
41466096|NCT02096367|OTHER|Gait on treadmill|Treadmill during 2 minutes
41466097|NCT02096367|DEVICE|Muscle vibration stimulation|Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
41466098|NCT00280969|DRUG|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
40785562|NCT04638751|PROCEDURE|Colonoscopy|Standard-of-care colonoscopy for CRC screening
40785563|NCT00364169|PROCEDURE|Degree of constipation|
40785564|NCT04344184|DRUG|L-ascorbic acid|50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
40785565|NCT04344184|OTHER|Placebo|Dextrose 5% Water
40785566|NCT05415488|OTHER|Online dietary group treatment|Dietary advice will be given during one 90 minute online group session
40785567|NCT00790049|DRUG|ARRY-371797, p38 inhibitor; oral|single dose and multiple dose, escalating
40785568|NCT00790049|DRUG|Placebo; oral|matching placebo
40990006|NCT03101137|DRUG|Caudal block with dexmedetomedine|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
40990007|NCT03101137|DRUG|Caudal dexamethasone|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
40990008|NCT03101137|DRUG|Control (bupivacaine)|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
40990009|NCT04853342|DRUG|Drug: Furmonertinib 80 mg|The initial dose of Furmonertinib 80 mg once daily
40990010|NCT04853342|DRUG|Furmonertinib 80 mg placebo|The initial dose of Furmonertinib 80 mg once daily
41466099|NCT00280969|DRUG|efavirenz|Patients are treated with efavirenz 300mg along with Epzicom.
41466100|NCT05775562|DIAGNOSTIC_TEST|Pre and post dive examinations|"Performing pre-dive examinations:~- EFR by plethysmography cabin~Realization of the examinations the day of the dive:~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Measurement of circulating bubbles~* ECG~* Venous blood sampling (biological collection)~* Water balance (Δweight/water intake)~* EFR by plethysmography cabin~* Weight measurement~Realization of the examinations the day after the dive:~* Venous blood sample (biological collection)~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Weight measurement"
40785569|NCT06487299|DRUG|Ferrous Lactate|The injection solution was 3 ferrous lactate (10ml:0.1g iron) mixed with 20ml saline.
40785570|NCT06487299|DRUG|Iron sucrose|The injection was 3 shots of ferrous lactate (5ml:100mg iron) mixed with 35ml saline.
40785571|NCT06487299|DRUG|0.9% NaCl solution|The same volume and color as Iron sucrose.
40785572|NCT02011269|BIOLOGICAL|Trichuris Suis Ova|
40785573|NCT03110029|DRUG|Efinaconazole 10% Topical Application Solution [JUBLIA]|Topical efinaconazole 10% solution (Jublia)
40785574|NCT03110029|OTHER|Application of Nail Polish|Application of Nail Polish
40785575|NCT03523689|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
40785576|NCT03523689|PROCEDURE|Radial Probe Endobronchial Ultrasound|Undergo RP-EBUS
40785577|NCT06181981|DIAGNOSTIC_TEST|MRI fingerprinting|This method allows to get quantitative magnetic resonance imaging for the simultaneous measurement of multiple tissue properties in a single, time-efficient acquisition
40785578|NCT02737501|DRUG|Brigatinib|Brigatinib tablets
40785579|NCT02737501|DRUG|Crizotinib|Crizotinib tablets
40785580|NCT00716001|DRUG|N-acetylcysteine|
40785581|NCT05390164|DIAGNOSTIC_TEST|skin biopsy|skin biopsy to be analyzed by ELISA
40785582|NCT05583344|DRUG|GSK4532990|GSK4532990 will be administered.
40785583|NCT05583344|DRUG|Placebo|Placebo will be administered.
40785584|NCT03776084|DEVICE|Continuous Positive Airway Pressure|CPAP indication
40785585|NCT05390684|OTHER|audit of complications, prospective data collection|Prospective colecction of data will be performed to create a predictive model of leak and major complication
40785586|NCT02927444|BIOLOGICAL|NBP606|A single intramuscular injection into the thigh
40785587|NCT02927444|BIOLOGICAL|Prevnar13|A single intramuscular injection into the thigh
40785588|NCT05346328|DRUG|Injection of A166|4.8 mg/kg for each 21 (±3) -day cycle
40785589|NCT01944020|DEVICE|CPAP|use of CPAP each night for 2 months
40990011|NCT02574247|PROCEDURE|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
40990012|NCT06482476|DIAGNOSTIC_TEST|Measurement of Lp(a) levels|Collection of a venous blood sample for the measurement of Lp(a) levels using standardized laboratory methods
40990013|NCT05849103|OTHER|Blood Pressure Control Targets|This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90
40990014|NCT05849103|OTHER|Hypertension Management|This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.
41146577|NCT02885610|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
41146578|NCT02885610|BIOLOGICAL|RC18 240 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
40990015|NCT01206647|DRUG|Metformin and Saxagliptin|Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
40990016|NCT03498742|OTHER|NO Intervention|Routine clinical data; asthma control test and spirometry
40990017|NCT03205410|PROCEDURE|remote ischemic preconditioning|The remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
40990018|NCT03205410|PROCEDURE|no - remote ischemic preconditioning|The sham - remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
41146579|NCT01351896|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41146580|NCT01351896|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41146581|NCT01351896|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41146582|NCT01351896|PROCEDURE|Computed Tomography|Undergo CT
41146583|NCT01351896|DRUG|Lenalidomide|Given PO
41146584|NCT01351896|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM (concurrently or sequentially)
41146585|NCT06393855|PROCEDURE|single-step Trans-PRK|Both eyes were treated consecutively in each patient by single-step Trans-PRK performed by SCHWIND Amaris 500 S excimer laser platform (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany). Topical Proparacaine Hydrochloride Eye Drops 0.5% (Alcaine, Alcon, Fort Worth, TX, USA) were used to anesthetize the eyes, and use povidone-iodine to disinfect the eyelid skin. After a lid speculum had been inserted, and the other eye was blocked. Epithelial and stromal ablations were performed using a single continuous laser shooting session on an excimer laser platform. After the appeals step, Mitomycin C 0.02 % was applied to the stromal surface for 20 s, then rinse with cold salt water.
40990019|NCT01820754|DRUG|Ipilimumab|"Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses"
40990020|NCT01820754|DRUG|Paclitaxel, Cisplatin, Carboplatin|"Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)"
40990021|NCT02740166|DRUG|propranolol|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
40990022|NCT03503786|DRUG|Carboplatin|Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles
40990023|NCT03503786|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles
40785590|NCT03579758|DRUG|Capecitabine|Given PO
40785591|NCT03579758|DRUG|Cisplatin|Given IV
40785592|NCT03579758|DRUG|Gemcitabine|Given IV
40785593|NCT00148863|DRUG|Peg-interferon alpha 2a (drug)|
40785594|NCT00148863|DRUG|Ribavirin (drug)|
40785595|NCT00148863|DRUG|Interferon gamma (drug)|
40785596|NCT06110403|DRUG|TRIXEO AEROSPHERE|BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days.
40785597|NCT06246747|OTHER|In clinic physical therapy|Patients visit the clinic to receive traditional physical therapy treatment
40785598|NCT06246747|OTHER|Telerehabilitation only|Patients receive remote treatment using the Wizecare platform
40785599|NCT00834821|BEHAVIORAL|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
41466101|NCT05563688|OTHER|Hypoxia exposure|"Each participant will be exposed to the hypoxic environment on 2 occasions (one after a normal sleep night and one after sleep deprivation).~Each exposure will be for 5 hours at a FiO2 of 13.2% (3500 m simulated altitude).~This exposure will be carried out in a normobaric hypoxic tent (Sporting Edge®)."
41466102|NCT05563688|OTHER|Sleep deprivation|"Each participant will be exposed to sleep deprivation on 2 occasions (one before normoxia exposure and one before hypoxia exposure).~Each sleep deprivation involves a time spent in bed of 3 hours (03h00 - 06h00). Sleep deprivation will be carried out in a sleep apartment. Sleep duration and quality will be assessed using a sleep headband (Dreem®), actigraphs Actiwatch® and E4 Empatica®) and a sleep diary."
40785600|NCT00834821|BEHAVIORAL|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
40990024|NCT03503786|DRUG|Avelumab|Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
40990025|NCT03949205|OTHER|Leg Extension Isometric Training|The leg extension isometric exercise will be performed tree times a week , in four 2 min bouts of isometric contraction, at a intensity of 30% of maximal voluntary contraction and an interval of two minutes between bouts.
40990026|NCT06516276|DEVICE|Mobile App M.I.O|This mobile app provides patients with access to various resources and therapies focused on nutrition, exercise, and emotional well-being. The main objective is to measure the quality of life of the app users through validated questionnaires in a randomized health education study to evaluate whether a substantial improvement in their well-being is achieved.
40990027|NCT01914185|OTHER|Comprehensive School Health (CSH)|APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
40990028|NCT00433823|DRUG|Atorvastatin, Ezetimibe|
40990029|NCT00713336|DRUG|ZD4054|ZD4054 10mg Tablet
40990030|NCT00713336|DRUG|Moxifloxacin|400 mg capsule
41466103|NCT05563688|BEHAVIORAL|Cognitive tasks|"Participants will perform several cognitive tasks in the following conditions:~* in normoxia (FiO2 = 21%) after a night of usual sleep (\> 6 hours) ;~* in normoxia (FiO2 = 21%) after a night of reduced sleep (3 hours);~* in normobaric hypoxia (FiO2 = 13.2%) after a night of normal sleep (\> 6 hours);~* in normobaric hypoxia (FiO2 = 13.2%) after a night of reduced sleep (3 hours)."
41466104|NCT06299709|DRUG|VNZ/TEZ/D-IVA|FDC tablet for oral administration.
40990031|NCT00713336|DRUG|ZD4054 Placebo|3 tablets
41466105|NCT06299709|DRUG|VNZ/TEZ/D-IVA|FDC granules for oral administration.
41466106|NCT04736758|DRUG|GP681 tablet|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
41466107|NCT04736758|DRUG|GP681 Simulant|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
41466108|NCT04478240|BEHAVIORAL|PeerLearning.net|"PeerLearning.net is a software package that supports teachers in designing and delivering peer learning lessons, either in-person or remotely while students are learning at home.~Peer learning is an instructional technique that puts students in groups under conditions of positive interdependence, where they are incentivized to work together and promote the success of one another. Peer Learning lessons also ensure individual accountability and explicitly observe for and reward specific group social skills (e.g., encouraging participation, checking for understanding). Peer Learning also includes group processing after the lesson is completed so that the students in the groups have an opportunity to discuss what they did well and what could use improvement; they also have the opportunity to provide positive reinforcement to one another for contributing to the success of the group."
40990032|NCT00713336|DRUG|Moxifloxacin placebo|1 capsule
40990033|NCT00713336|DRUG|ZD4054 Placebo|2 tablets
41146586|NCT06393855|BEHAVIORAL|Placing a bandage contact lens on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.|After surgery. A contact lens placed on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.
40785601|NCT02422329|BEHAVIORAL|Questionnaires|Participants complete questionnaires at baseline and after intervention.
40990034|NCT00713336|DRUG|ZD4054|30mg tablet
40990035|NCT00713336|DRUG|ZD4054|10mg tablet
40990036|NCT00977132|DRUG|Valproic aicd|"Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks."
40785602|NCT02422329|BEHAVIORAL|Video|Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
40785603|NCT02422329|BEHAVIORAL|Fact Sheet|Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
41466109|NCT02315261|PROCEDURE|Elective Thoracic and Abdominal Surgery Patients|This is an observational audit, reviewing the implementation of a standard care practice and requiring de-identified data collection in Elective Thoracic and Abdominal Surgery Patients only. All collected data will be that which is routinely part of normal clinical practice. The Research staff will systematically collect data on each patient. Some information can be obtained from the medical record, intraoperative anesthetic record, acute pain service record, etc whereas other information has to be obtained from direct observation at the bedside.
40785604|NCT04348071|DRUG|Ruxolitinib|Participants will receive 10 mg ruxolitinib twice daily.
40785605|NCT01887405|DRUG|Adrenaline auto-injector|"Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water"
40990037|NCT00977132|DRUG|Lenalidomide|"5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks"
41466110|NCT05507034|DIAGNOSTIC_TEST|Biomarkers|Each intervention is performed at 4 timepoints namely: before surgery, i.e. baseline (T0), 1-3 weeks post-surgery (T1), 3 months post-surgery (T2) and 1 year post-surgery (T4)
41466111|NCT00442650|DRUG|Efalizumab|
41466112|NCT02827396|BEHAVIORAL|Psychosocial intervention|"This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions."
41466113|NCT01878773|OTHER|High Quality Volume CT Scan; MRI Scan|"Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.~--------------------------------------------------------------------------------"
41466114|NCT00311220|DRUG|tuberculin for skin test|
41466115|NCT02321124|OTHER|connective tissue manipulation|We will apply connective tissue manipulation 5 days a week for four weeks.
41466116|NCT02321124|BEHAVIORAL|life style advice|We will apply life style advice for four weeks.
41466117|NCT00741754|OTHER|Mouthrinse with HcT20|Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
41466118|NCT00203320|DRUG|etanercept given by perispinal administration|
41466119|NCT05049811|BEHAVIORAL|mini program|To design, construct, and test the mini program in patients managing cancer pain
41466120|NCT05049811|BEHAVIORAL|conventional pharmaceutical care|Regular education includes medication guidance from doctors, nurses and pharmacists.
41466121|NCT02310516|DEVICE|preoperative adequate explanations about awake surgery|
41466122|NCT02310516|OTHER|no preoperative explanation|
40990038|NCT03411681|OTHER|Resistance Exercise|Participants will perform 4 sets of 12 repetitions of moderate intensity leg extension
41466123|NCT05377125|BEHAVIORAL|Computerized cognitive training|This intervention offers 45-minute computerized training sessions to each participant. This intervention aims to improve the individual's RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
41466124|NCT05377125|BEHAVIORAL|Computerized placebo training|This intervention offers 45-minute computerized placebo cognitive training sessions to each participant. This intervention aims to exert no focused training on RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
41466125|NCT04819373|DRUG|BDB001|BDB001 is an immunotherapy agent.
41466126|NCT04590768|OTHER|Fermotein based meals|various meal products: bread, soup and an occasional burgers
41466127|NCT04590768|OTHER|Matching control meals with whey protein and wheat bran|various meal products: bread, soup and an occasional burgers
41466128|NCT04187950|DIETARY_SUPPLEMENT|Yogurt with B. lactis and added honey|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with honey twice daily for 14 days.
41466129|NCT04187950|DIETARY_SUPPLEMENT|Yogurt with heat-inactivated B. lactis and added cane sugar|The control condition will utilize a commercially available yogurt (Activia) following heat inactivation of the probiotic Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of the heat-inactivated yogurt with added cane sugar twice daily for 14 days.The added cane sugar will be an isocaloric amount to the honey.
40785606|NCT02102243|DRUG|DEFINITY® infusion|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
40990039|NCT04415632|OTHER|low glycemic index diet|• Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
41307453|NCT02909673|BEHAVIORAL|Fourth R|Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
41466130|NCT01321697|PROCEDURE|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
41466131|NCT02409329|BEHAVIORAL|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, text messages assessing user's adherence with feedback on progress, plus text messaging targeting other self-care behaviors.
41307454|NCT06162260|PROCEDURE|ICU readmission|Children who underwent liver transplantation at Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 1, 2018 to December 31, 2021 and were transferred out of ICU for the first time during the same hospitalization cycle.
40990040|NCT04415632|OTHER|High glycemic index diet|Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
41307455|NCT02153450|DRUG|metformin hydrochloride|Given PO
41466132|NCT02409329|BEHAVIORAL|Helpline and A1c results|Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
41466133|NCT02409329|BEHAVIORAL|REACH + FAMS|The intervention consists of REACH individually-focused text messaging, plus family-focused phone coaching session, goal-focused text messaging, and the option to invite a family member/support person to receive text messaging.
41466134|NCT02654587|BIOLOGICAL|OSE2101|
41466135|NCT02654587|DRUG|Docetaxel|
41466136|NCT02654587|DRUG|Pemetrexed|
40785607|NCT02102243|DRUG|Human Recombinant Regular Insulin infusion|The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
40785608|NCT02102243|DRUG|Dextrose infusion|The plasma glucose concentration will be held constant at 90 mg/dl by a variable glucose infusion during euglycemic hyperinsulinemic clamp
40990041|NCT06044584|OTHER|No intervention|Observational study with no intervention - Monitoring
40990042|NCT01557296|DIETARY_SUPPLEMENT|dietary treatment: food of small particle size|Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
40990043|NCT01557296|RADIATION|Validate X-ray diagnostic method.|Follow 20 radiopaque markers throw the ventricle by X-ray.
41466137|NCT01953887|DRUG|EC905|Oral
41466138|NCT01953887|DRUG|solifenacin|oral
41146587|NCT06393855|BEHAVIORAL|Placing a bandage contact lens on the cornea,A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.|After surgery. A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.
41466139|NCT01953887|DRUG|tamsulosin|oral
41146588|NCT00690534|DRUG|Insulin Regular|insulin, 0.2 mU/kg/min for 3 hours
41146589|NCT00690534|DRUG|L-NMMA|variable rate for 3 hours
41307456|NCT02153450|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
41307457|NCT05531058|BEHAVIORAL|AI-driven Vaccine Communicator|The intervention will include five modules web-based psychoeducation programme (two module sessions weekly, each module lasts for 15-20 minutes) and interact with an MI communication skills-based AI, digital assistant.
41466140|NCT04417647|DEVICE|VZ powder (purified clinoptilolite)|VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).
41466141|NCT04417647|PROCEDURE|Standard of care (SoC)|wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.
41466142|NCT01758133|BEHAVIORAL|Exposure to medical clown activities|
41466143|NCT01782287|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
41466144|NCT01782287|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
40785609|NCT02102243|PROCEDURE|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
40785610|NCT02102243|PROCEDURE|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
40785611|NCT02102243|PROCEDURE|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
40785612|NCT02102243|PROCEDURE|Microneurography|Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
40785613|NCT05960487|OTHER|Cervical multifidus muscle area measurement at 3 levels (C4-C5, C5-C6, C6-C7)|Cervical multifidus muscle area measurement will be performed from both the side affected by radiculopathy and the unaffected side using the magnetic resonance (MR) imaging. Measurements will be made by two researchers, independent of each other.
40785614|NCT04099277|DRUG|LY3435151|Administered IV
40785615|NCT04099277|DRUG|Pembrolizumab|Administered IV
40785616|NCT03261921|DRUG|Dexamethasone|Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
40785617|NCT03261921|DRUG|Dexmedetomidine|Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics
40785618|NCT03261921|DRUG|Bupivacaine|local anesthetic agent
40785619|NCT04264039|BIOLOGICAL|anti-CD19 UCAR-T cells|Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg
40785620|NCT04264039|DRUG|Fludarabine|30mg/m\^2 per day for 6 days
40785621|NCT04264039|DRUG|Cytoxan|300mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
40785622|NCT04264039|DRUG|Melphalan|50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
40785623|NCT02471053|OTHER|Moderate Intensity Exercise|Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
40785624|NCT01547156|DEVICE|Intervention group|
40990044|NCT01557296|OTHER|Can the motility be improved|Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
40785625|NCT02227810|OTHER|electrical stimulation (high frequency)|Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days
40990045|NCT01557296|BIOLOGICAL|postprandial plasma glucose|Measure the blood glucose response and gastrointestinal symptoms after a test meal
40990046|NCT04477811|DRUG|Vitamin K1|vitamin k1 tablets
40990047|NCT04477811|DRUG|Vitamin k2|vitamin k2 45 ug tablets twice daily
40990048|NCT04477811|OTHER|placebo|placebo tablets
40990049|NCT04622839|OTHER|Tylenol and NSAIDS (Ibuprofen, diclofenac)|"This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~* Agents used in nerve block (lidocaine vs ropivacaine)~* Location of injection for analgesic~* Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~* Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~* Number of pills in the initial opioid prescription~* Instructions for sling wear (duration of use or type of sling)~* Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage."
40990050|NCT02988921|DEVICE|MRI and CT|
40990051|NCT02988921|RADIATION|Ratiotherapy|
40990052|NCT02988921|DRUG|Paclitaxel, platinum-based drug|
41146590|NCT00690534|DRUG|Sodium Nitroprusside|variable rate for 3 hours
41146591|NCT00690534|OTHER|mixed meal|mixed meal
41307458|NCT05531058|BEHAVIORAL|Self-learning of COVID-19 vaccine knowledge|Participants in the control group will be given HK government websites in COVID-19 vaccine and invite to join the online examination in relation to Covid-19 vaccine knowledge (using multiple choices questions similar to the intervention group), and this is to ensure that participants from the control group also use time to search relevant information of covid-19 vaccines, also this is to control the time effects.
41466145|NCT04157452|PROCEDURE|flexible ureteroscopy|flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.
41146592|NCT01668355|OTHER|Patient Aligned Care Team (PACT)|An integrated healthcare model to coordinate and address physical health needs of people with serious mental illness. This specialized PACT medical home model is designed for individuals with serious mental illness.
41466146|NCT03911596|DEVICE|Smart Autofocusing Eyeglasses|The smart eyeglasses system is meant to be a next generation alternative technology which replaces the generic eyeglasses used for correction of refractory defects in human vision. These smart eyeglasses do not fix any internal eye problems. They just externally compensate for the loss of eye focusing functions caused by presbyopia. This system is a medical assistive device which is meant to improve the quality of life of presbyopic patients.
41466147|NCT03776617|PROCEDURE|scalp block|Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.
41466148|NCT03239496|BIOLOGICAL|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
41466149|NCT03239496|BIOLOGICAL|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
41466150|NCT00866645|DRUG|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
41307459|NCT04496895|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
41307460|NCT04496895|DIETARY_SUPPLEMENT|orange peel fermentation|consume 1 sachet per day for 2 months
41307461|NCT00439673|DRUG|5-Azacytidine|
41307462|NCT00439673|DRUG|Valproic Acid|
41307463|NCT00439673|DRUG|ATRA|
41307464|NCT04520516|DEVICE|Active VAGUSTIM device|Settings: 25 Hz stimulation, 100 microsec pulse width, intensity escalation up to 8 mA or below if tingling sensation, 20 min/day of stimulation in one daily session
41307465|NCT04520516|DEVICE|Sham VAGUSTIM device|The sham device : no electrical signal for VNS will be delivered.
41307466|NCT03898336|OTHER|broad-spectrum micronutrient|daily intake of capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
41307467|NCT03898336|OTHER|placebo|daily intake of capsules
41307468|NCT03590262|DRUG|Metformin|take the metformin 500mg twice or three times a day
41307469|NCT01928108|BEHAVIORAL|iPhone Application|"The iPhone application waterlogged will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week."
41466151|NCT00866645|DRUG|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
41466152|NCT04982367|DEVICE|Sirolimus-eluting balloon catheter|Sirolimus-eluting balloon catheter designed and produced by Acotec
40785626|NCT02227810|OTHER|electrical stimulation (low frequency)|Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.
40785627|NCT02227810|OTHER|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
40785628|NCT02527395|OTHER|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
40785629|NCT02527395|OTHER|Pain during 1 min. thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
40785630|NCT02527395|OTHER|Heat pain detection threshold|The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered. 4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
41146593|NCT00251147|PROCEDURE|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
41146594|NCT00251147|PROCEDURE|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
41146595|NCT01903954|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
40785631|NCT04446312|DRUG|Bowel Prep|Orally ingested liquid bowel preparation
40785632|NCT04473781|PROCEDURE|Interstitial Radiation Therapy|Undergo interstitial brachytherapy
41146596|NCT01903954|DRUG|placebo|Orally b.i.d.
41146597|NCT01903954|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
41307470|NCT01928108|BEHAVIORAL|Android Application|"The Android application water my body will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week."
41307471|NCT05197595|BEHAVIORAL|Attachment-based compassion therapy|Compassion program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
41466153|NCT04982367|DEVICE|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter (trade name:DHALIA)
41466154|NCT02666417|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP+iron)|Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
41466155|NCT02666417|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP+iron+GOS)|Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
41466156|NCT06466161|DEVICE|Upper Arm Cylindrical Blood Pressure Cuff|In Group 1, the upper arm cylindrical cuff is inflated first, followed by inflation of the forearm conical cuff.
40785633|NCT02797756|PROCEDURE|Esophago-gastro-duodenoscopy (EGD) with biopsy|
40785634|NCT02797756|PROCEDURE|Esophageal Impedance Monitoring (EIM)|
40785635|NCT06105918|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40785636|NCT06105918|PROCEDURE|Computed Tomography|Undergo rhPSMA-7.3 PET/CT and SPECT-CT
41466157|NCT06466161|DEVICE|Forearm Conical Blood Pressure Cuff|In Group 2, the forearm conical cuff is inflated first, followed by inflation of the upper arm cylindrical cuff.
41466158|NCT00754468|DEVICE|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
41466159|NCT00754468|DEVICE|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
41466160|NCT02860819|DRUG|Veliparib|Veliparib 250mg BID, continuously
41466161|NCT02860819|DRUG|Gemcitabine|Gemcitabine 800mg/m2, day 1 and 8
41466162|NCT02860819|DRUG|Carboplatin|Carboplatin AUC = 4, day 1
41466163|NCT05307562|OTHER|Interval training + analytical strength|Patients will receive a training program
40785637|NCT06105918|RADIATION|External Beam Radiation Therapy|Undergo EBRT
41307472|NCT05197595|BEHAVIORAL|Relaxation program|Relaxation program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
40785638|NCT06105918|OTHER|Flotufolastat F-18|Given IV
40785639|NCT06105918|DRUG|Lutetium Lu 177 PSMA-10.1|Given IV
41307473|NCT02130427|DIAGNOSTIC_TEST|CT scan|Weekly 3D/4D CT scan
40785640|NCT06105918|PROCEDURE|Positron Emission Tomography|Undergo rhPSMA-7.3 PET/CT
41307474|NCT00055822|BIOLOGICAL|oblimersen sodium|
41307475|NCT00055822|DRUG|fluorouracil|
41307476|NCT00055822|DRUG|leucovorin calcium|
41307477|NCT00055822|DRUG|oxaliplatin|
41307478|NCT01488825|BEHAVIORAL|Yoga Therapy|Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
41307479|NCT03075462|DRUG|Fluzoparib|Fluzoparib either at 40,60,80mg twice daily,capsule oral.
41307480|NCT03075462|DRUG|Apatinib|Apatinib at 250mg once daily, tablet oral
41307481|NCT00149604|DRUG|conjugated estrogens|
40990053|NCT06363656|DEVICE|Wears the smartwatch during the sleep time to capture sleep characteristics and answer questionaires|"* Synchronization of smartwatch with smartphone (internet connection) to send sleep characteristics captured by the application~* Weight~* Height~* Body measurements (circumferences)~* Questionnaires about overall health status~* Pittsburgh Sleep Quality Index questionnaire~* Insomnia Severity Index~* Sleep Hygiene Index~* Epworth Sleepiness Scale~* NoSAS score (Neck, Obesity, Snoring, Age, Sex)"
40990054|NCT04025658|DRUG|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
40990055|NCT00281684|DRUG|SB705498 400 mg|SB705498 400 mg
40990056|NCT00281684|DRUG|SB705498 1000 mg|SB705498 1000 mg
40990057|NCT00281684|DRUG|Placebo|Placebo
41307482|NCT00149604|DRUG|Raloxifene|
41307483|NCT00149604|BEHAVIORAL|exercise plus mild caloric restriction for weight loss|
41307484|NCT03670641|DRUG|Glargine|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
41307485|NCT03670641|DRUG|Lispro|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
41307486|NCT03670641|DEVICE|Dexcom G6|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
41307487|NCT04360616|DIAGNOSTIC_TEST|imaging|perform US and mammography examination
41307488|NCT03633786|PROCEDURE|standard laparoscopic surgery|removal of endometriotic lesions with laparoscopic instruments (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) using 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm
41307489|NCT03633786|PROCEDURE|robot-assisted surgery|"removal of endometriotic lesions with da Vinci Xi robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), using 5 transperitoneal abdominal accesses and trocars from 8 and 12 mm.~The robotic mechanical arms are associated with the 8 mm abdominal trocars to allow intervention by the first operator, with the aid of a surgical console."
41307490|NCT03633786|DIAGNOSTIC_TEST|assessment of sexual function|assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery
41307491|NCT03633786|DIAGNOSTIC_TEST|assessment of bowel symptoms|assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery
41307492|NCT03633786|DIAGNOSTIC_TEST|assessment of urinary symptoms|assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery
40990058|NCT00281684|DRUG|Co-Codamol|Co-Codamol
40785641|NCT06105918|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT scan
40785642|NCT01804452|OTHER|Observational Study|
40785643|NCT02890277|DEVICE|the high intensity focused ultrasound (Mianyang Sonic electronic LLC)|
40785644|NCT02890277|DRUG|Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).|
40785645|NCT01978483|DRUG|Denosumab|
40785646|NCT01978483|RADIATION|UVB exposure|
40785647|NCT01978483|DRUG|Diphenylcyclopropenone|
40785648|NCT01978483|DRUG|Normal Saline|
40785649|NCT02709720|DRUG|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
40990059|NCT01906710|OTHER|integrated medicines management|"PITH includes the following interventions:~A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge"
40785650|NCT02709720|DRUG|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
40785651|NCT02709720|DRUG|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
40785652|NCT02709720|DRUG|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
40785653|NCT02709720|RADIATION|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
40785654|NCT04127526|OTHER|Connection to Environment with Cognitive Therapy (CONNECT)|8 sessions of strategies to reduce dissociation. Flexible, toolbox approach including but not limited to grounding strategies using objects, therapy oils and naming objects in the room.
40785655|NCT00836394|DEVICE|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
40785656|NCT05556889|PROCEDURE|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
40785657|NCT05556889|PROCEDURE|Traditional auriculotemporal nerve blockade|Traditional auriculotemporal nerve blockade
40785658|NCT00888914|DRUG|RT001|RT001
40785659|NCT00888914|DRUG|RT001|RT001
40990060|NCT00694759|DRUG|pioglitazone|30 mg for 2 weeks, then 45 mg daily
40990061|NCT00694759|DRUG|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
40990062|NCT00694759|DRUG|placebo|capsule twice daily
40990063|NCT05851859|OTHER|Cardiac coherence|Use of Cardiac coherence (complementary respiratory training) during 6 month
40990064|NCT04483908|DIAGNOSTIC_TEST|blood draw|2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)
40990065|NCT04483908|DIAGNOSTIC_TEST|fingertip tests for POC assays|performing POC test by taking two blood drops from the fingertip
41146598|NCT01903954|DRUG|setrobuvir|Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
40785660|NCT00888914|DRUG|RT001|RT001
40785661|NCT00888914|DRUG|RT001|RT001
40785662|NCT00888914|OTHER|Vehicle Comparator|Vehicle Comparator
40785663|NCT03173014|DEVICE|EEG|EEG monitoring
41146599|NCT01675063|DEVICE|Retia Non-Invasive Sensors|Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
41146600|NCT03426332|OTHER|No intervention|No intervention
41146601|NCT00636168|DRUG|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
41146602|NCT00636168|DRUG|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
40785664|NCT03589287|BIOLOGICAL|Chondrochymal®|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
40785665|NCT04824703|DRUG|Oxygen|"* Decreasing fraction of inspired oxygen and its effect on mortality and myocardial function~* administered by invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1"
40785666|NCT02432573|BEHAVIORAL|Delayed rounds|
40785667|NCT02071771|DEVICE|Nelfilcon A toric contact lenses|
40785668|NCT02071771|DEVICE|Etafilcon A toric contact lenses|
40785669|NCT01968122|DEVICE|intravascular stent therapy|Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (\<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
40785670|NCT00151450|DRUG|Pregabalin|
40785671|NCT00151450|DRUG|Venlafaxine XR|
40785672|NCT04818957|DIETARY_SUPPLEMENT|Oral Thin Film (OTF) Cholecalciferol (Vitamin D3)|Study participants will receive vitamin D OTF weekly for a maximum of 12 weeks. The dose may be increased or decreased based on the dosing schema.
40785673|NCT03323853|BEHAVIORAL|Computerized Assessment and Referral System (CARS) Self-Assessment Screener|Subjects will take the CARS-SA Screener.
40785674|NCT03323853|BEHAVIORAL|CARS-SA Summary Results|Subjects will be evaluated by emergency care providers using the CARS-SA Summary Results Report.
40785675|NCT06466525|DRUG|LBT-3627|Synthetic peptide
40785676|NCT06466525|DRUG|Placebo|Vehicle
40785677|NCT02193997|OTHER|Fiber|
40785678|NCT02193997|OTHER|Fiber|
40785679|NCT02193997|OTHER|Placebo|
40990066|NCT04483908|DIAGNOSTIC_TEST|saliva collection|saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.
40990067|NCT04483908|DIAGNOSTIC_TEST|collection of swabs|collection of nasopharyngeal and oropharyngeal swabs for PCR testing on the control group (eg negative subpopulation)
40990068|NCT03375918|OTHER|CONSULT-BP Educational Intervention|"The CONSULT-BP intervention includes two, 180-minute, in-persons sessions 5 weeks apart. Each session has 3 parts: 1. Pre-Clinical Practice Simulation Learning; 2. Trainee Self-Assessments of implicit bias; and 3. In-Person Clinical Practice Simulations to practice communication skills, trigger reflection, and frame group-based reflections on bias."
40990069|NCT04339296|DEVICE|Spencer|The MDS dispenses medications on time with visual and audio reminders. The audio alert get louder if the plastic medication packet is not dispensed from the system. The MDS allows participants to dispense their medications early if they are going to be away from home. The system also displays personalized and health-condition speciﬁc questions. The pre-packaged medications are delivered by pharmacy that inserted directly into the spencer device. Spencer system is non-inclusive and approved by Health Canada.
40990070|NCT02140099|BEHAVIORAL|Healthy Relationships Plus Program (HRPP)|The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.
40990071|NCT02140099|BEHAVIORAL|Control Condition (Classroom Activities)|
40990072|NCT00930579|DRUG|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
41146603|NCT06023745|GENETIC|genotyping|Genotyping. Measurement of SOD serum level. Measurement of IL-35 serum level.
41146604|NCT03657745|DEVICE|Combination of 40Hz light and cognitive therapy (ALZLIFE)|Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE
41146605|NCT00004250|BIOLOGICAL|dactinomycin|
40990073|NCT05321615|DEVICE|Palpator|Palpator for tumor localization
41146606|NCT00004250|DRUG|isolated limb perfusion|
41146607|NCT00004250|DRUG|melphalan|
41146608|NCT01330745|OTHER|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
41146609|NCT00880724|DEVICE|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
40990074|NCT05321615|DEVICE|Grasper|Atraumatic lung grasper
40990075|NCT05321615|DEVICE|Ultrasound|VATS ultrasound
41146610|NCT05500261|DRUG|Dexmedetomidine|intranasal administration of dexmedetomidine
41146611|NCT01274000|DRUG|YM060|oral
41146612|NCT01274000|DRUG|placebo|oral
41146613|NCT04432909|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.
41146614|NCT00123500|BEHAVIORAL|Diet|Diet
41146615|NCT00123500|BEHAVIORAL|Physical Activity|Physical Activity
41146616|NCT00123500|BEHAVIORAL|Environment|Environment
41146617|NCT00123500|OTHER|Control Group|Control Group
41307493|NCT03226223|DRUG|Intranasal Methamphetamine|Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
41307494|NCT03102944|DIAGNOSTIC_TEST|Minicare BNP|no real intervention since only leftover materials are used from volunteers and samples are not tested on Minicare BNP IVD device near any volunteer.
40990076|NCT05321615|OTHER|Finger palpation|Palpation of the lung/tumour using the surgeon's finger
40990077|NCT06283745|OTHER|Platelet-rich Plasma (PRP)|Platelet-rich plasma (PRP) intranasal injection in the treatment of qualitative olfactory dysfunction (parosmia). This is taken from a blog draw from the patient themselves, and thus no external drug/biologic product will be given - only the concentrated plasma portion from the patient's own blood.
40990078|NCT06283745|OTHER|Saline|Saline intranasal injection (sham injection)
40990079|NCT02393833|PROCEDURE|Blood samples collection|"Blood samples to be collected at the following time points:~1. Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.)~2. Months 12, 18 and 36 after start of induction chemotherapy~3. At time of confirmatory evidence of progression"
41146618|NCT01526850|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
41146619|NCT01526850|DRUG|Cyclosporine and Glucocorticoid|Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
41146620|NCT03796364|DRUG|Endostar|Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
41307495|NCT00977327|DEVICE|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
41307496|NCT00977327|DEVICE|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
41466164|NCT05307562|OTHER|Interval training + analytical strength and IMT|Patients will receive a training program + IMT
41307497|NCT01880268|DEVICE|BCI-controlled neurorehabilitation device|"Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)"
40990080|NCT03649698|BEHAVIORAL|Home-based training program|Exercise intervention: During the intervention period, the participant will perform the optimized and personally adapted Otago Exercise Program (OEP). The participant is encouraged to perform the resistance exercises three times a week with a rest day in between. The participant is advised to perform the exercises in close temporal proximity to one of the moments of the intake of the protein supplement. The participant will also follow a walking plan in which he or she needs to walk 30 minutes twice a week. These 30 minutes can be broken down to three 10-minute walks throughout the day. During the follow-up period, participants may continue the OEP, but no personal encouragement will be given during this period.
41307498|NCT01880268|BEHAVIORAL|Standard rehabilitation therapy|Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
41307499|NCT00339183|DRUG|Panitumumab|Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
41147105|NCT04050722|DRUG|Colgate Cavity Protection|Participants will brush their teeth with Colgate Cavity Protection repair and protect (containing sodium fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
41147106|NCT05797220|DRUG|Botulinum Toxin Type A Injection [Botox]|
41307500|NCT00339183|DRUG|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.
41307501|NCT05369416|OTHER|Low sodium diet|Subjects will be started on a low sodium (food will be provided) for two weeks.
41307502|NCT05369416|OTHER|high sodium diet|Subjects will be started on high sodium diet (regular diet supplemented with salt tablets to reach a daily intake of \> 4200 mg/Day) for two weeks.
41147107|NCT05797220|DRUG|Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel|
41307503|NCT03182400|BEHAVIORAL|Neurophysiological assessment|Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments
41307504|NCT03182400|BEHAVIORAL|Neuropsychological assessment|sub-tests, scales, surveys, reaction time measurement
41307505|NCT02641366|DEVICE|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
41147108|NCT03852485|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
41147109|NCT06319924|DRUG|Simethicone combined with Macrogol 4000 (PEG)|bowel preparation product for colonoscopy as part of CRC screening
41147110|NCT02835196|DEVICE|Optical Elastography|To image skin thickness, Optical Coherence Elastography (OCE)-scanning of 6 body surface areas will be preformed using the Phase-Stabilized Swept Source Optical Coherence Elastography (PhS-SSOCE) system.
41147111|NCT02835196|OTHER|Visual Assessment|Skin thickness will be visually assessed clinically in 6 body surface areas using the the modified Rodnan Skin Score (mRSS). The mRSS uses a 0-3 scale, where 0 = normal, 1= mild thickness, 2 = moderate thickness, and 3 = severe thickness
41147112|NCT00829517|OTHER|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
40990081|NCT03649698|DIETARY_SUPPLEMENT|High-quality protein supplement|The participant will receive an individually adapted protein supplement to achieve the recommend total (usual diet and supplements) daily intake of 1.5 g/protein/kg for frail elderly. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between meals, or before breakfast or after dinner, based on the subjects' food intake assessed by a food diary. The participant will take the protein supplement from 5 days before the start of the intervention. The protein powder is commercially available and consists of 4.5g protein/5g powder. During the follow-up, no protein supplement is added.
40990082|NCT03649698|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Four weeks before the start of the intervention, the participant will start the intake of 1 omega-3 capsule providing in total 500 mg EPA and 450 mg DHA until the end of the intervention. He or she has to take the supplement once daily at a chosen time. During the follow-up, no omega-3 supplement will be given.
40990083|NCT03649698|DRUG|Placebo protein powder|Isocaloric maltodextrin powder. Amount based on food diary.
40990084|NCT03649698|DRUG|Placebo omega-3|Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
40990085|NCT03647865|PROCEDURE|Osseous Genioplasty|Surgical Procedure that cuts the chin and reposition it in the correct place
40990086|NCT01983358|DRUG|JPI-289|PARP-1 inhibitor
40990087|NCT01983358|OTHER|Placebo|Placebo
40990088|NCT01288950|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
40990089|NCT04475679|DEVICE|Adhese Universal DC|Adhese Universal DC, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth surface
40990090|NCT04475679|DEVICE|Adhese Universal|Adhese Universal, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth
40990091|NCT05630014|BEHAVIORAL|Aliviado DSD Caregiving Mastery Program|Family caregiver intervention consisting of mHealth-app based educational videos and articles; caregiver-administered assessment tools and care plans; and motivational push notification reminders and encouragements.
40990092|NCT04592029|DRUG|TACE combined with sintilimab and bevacizumab|Sintilimab and bevacizumab are administered at 3-7 days after the first TACE. The study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then, Sintilimab 200mg/kg IV. q3w+ select specific dose of bevacizumab (7.5mg/kg or 15 mg/kg IV. q3w), expand to 36-39 patients for the further safety and efficacy study. The study treatment of sintilimab and bevacizumab lasts up to 24 months. TACE can be repeated when indicated clinically.
41146621|NCT03796364|DRUG|standard SRILI treatment|Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
41146622|NCT01435720|BIOLOGICAL|SNS01-T|0.05 mg/kg twice weekly x 6 weeks
41146623|NCT01435720|BIOLOGICAL|SNS01-T|0.2 mg/kg twice weekly x 6 weeks
41146624|NCT01435720|BIOLOGICAL|SNS01-T|0.375 mg/kg twice weekly x 6 weeks
40990093|NCT03839212|BEHAVIORAL|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
40990094|NCT03839212|BEHAVIORAL|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
40990095|NCT03839212|BEHAVIORAL|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
40990096|NCT03839212|BEHAVIORAL|HOLA Component 4|One booster walking session twice a month for three months post intervention for reinforcement.
40990097|NCT03717480|DEVICE|ClinicMACs|The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to participants
40990098|NCT00197730|DRUG|Multivitamins - vitamins B complex, C and E|Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
40990099|NCT00197730|DRUG|Placebo|Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
40990100|NCT02258321|DRUG|PPI-668 tablet|
40990101|NCT02258321|DRUG|PPI-668 capsule|
40990102|NCT02694237|BEHAVIORAL|Model|Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
41146625|NCT01435720|BIOLOGICAL|SNS01-T|0.0125 mg/kg twice weekly x 6 weeks
41146626|NCT02240810|DEVICE|Percutaneous coronary intervention (Promus PREMIER)|Interventional coronary artery stenting with Promus PREMIER study stent.
41146627|NCT06046209|DEVICE|Control Contact Lens|Daily disposable contact lens for 90 minutes
41146628|NCT06046209|DEVICE|Test Contact Lens|Monthly replacement contact lens for 90 minutes
41146629|NCT06335667|DIAGNOSTIC_TEST|mpMRI + Diagnostic TURBT|mpMRI in addition to the TURBT surgical procedure
41146630|NCT00512473|DRUG|Saline infusion|0.9 % NaCl
41146631|NCT00512473|DRUG|Human Growth Hormone|0.5 mg genotropin administered as a bolus at t = 0
41146632|NCT00512473|DRUG|Pegvisomant|30 mg Somavert administered at t = - 36 hours
40785680|NCT03395028|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
40785681|NCT05916300|OTHER|Diagnostic ultrasonography-guided physiotherapy group|"All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the initial diagnostic ultrasonography examination."
40990103|NCT02694237|BEHAVIORAL|Knee Anatomy Video|Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
40990104|NCT02694237|BEHAVIORAL|Verbal|Each participant will receive a verbal informed consent discussion without a visual aid.
40990105|NCT04919278|PROCEDURE|Chiropractic adjustments|Chiropractic adjustment is a procedure in which trained specialists (chiropractors) use their hands or a small instrument to apply a controlled, sudden force to a spinal joint. The goal of this procedure, also known as spinal manipulation, is to improve spinal motion and improve your body's physical function.
40990106|NCT04225299|DRUG|TOOKAD®|TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
40990107|NCT05185960|OTHER|ALLSWEET®|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be diluted in water.
40990108|NCT05185960|OTHER|ALLSWEET® and sucrose|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be added to sucrose (table sugar) and diluted in water.
40990109|NCT05185960|OTHER|Sucrose|Table sugar. It will be consumed by diluting it in water.
40990110|NCT03812887|DIAGNOSTIC_TEST|Photopatchtesting|Photopatchtesting to the sunscreen series and extended series, irradiated at both 24 and 48 hours
40990111|NCT01264978|DEVICE|Repetitive magnetic stimulation of the quadriceps muscle|"During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.~Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.~Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).~Coils are cooled down to 5ºC before sessions."
41146633|NCT02802176|DEVICE|INVOcell device|intra-vaginal culture of embryos using INVOcell device
41146634|NCT02802176|OTHER|Traditional IVF|traditional culture of embryos in-vitro
41146635|NCT02182245|DRUG|BIBF 1120|
41146636|NCT02182245|DRUG|Paclitaxel|
41146637|NCT02182245|DRUG|Carboplatin|
41146638|NCT05107921|DRUG|Bromfenac Sodium|The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
41147113|NCT00829517|OTHER|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
41147114|NCT04974021|DRUG|Ferric carboxymaltose|Intravenous ferric carboxymaltose for the treatment of iron deficiency in HFrEF as per 2016 European Society of Cardiology Heart Failure guidelines.
41147115|NCT06437327|PROCEDURE|Electrotherapy|Hot pack for 10 minutes Interferential Current (IFC) for 10 minutes
41307506|NCT02641366|PROCEDURE|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
40785682|NCT02308761|DRUG|RO6870810|Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
40785683|NCT02026011|DRUG|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
40785684|NCT02026011|DRUG|Placebo|Sugar pill, matched to the active study medication in capsule size and color
41147116|NCT06437327|PROCEDURE|Active release technique|Active release technique is applied (patient is prone lying with knee flexed, Pressure is applied on taut band and patient is asked to move the leg in internal rotation to achieve maximal lengthening) Repetitions 5 to 7 times hold for 5 to 20 seconds
40785685|NCT05065593|OTHER|resistance and aerobic exercise|Resistive exercises allow loading the muscle under suitable conditions with various weights or resistances. In order to increase the level of physical fitness with the increase of muscle strength and bone mass in individuals, resistance exercises were preferred. Aerobic exercises, on the other hand, are a special type of exercise that develops both the musculoskeletal system and the cardiovascular system, which includes large muscle groups and should be performed for at least 20 minutes when the heart rate accelerates at certain rates. Aerobic exercise was preferred in order to increase cardiovascular endurance, accelerate fat burning and reduce fatigue.
40785686|NCT05065593|OTHER|physical activity recommendation|Patients will be informed about the importance of lifestyle change in disease management, walking training will be given to increase their physical activity level, and participants will be asked to follow a 45-minute walking program every day within their own means.
40785687|NCT06282549|DRUG|Telmisartan/Amlodipine/Chlorthalidone(Truset)|Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/25 mg
40785688|NCT03637491|DRUG|Avelumab|IV treatment
40785689|NCT03637491|DRUG|Binimetinib|Oral treatment
40785690|NCT03637491|DRUG|Talazoparib|Oral treatment
40785691|NCT00314821|DRUG|ropinirole|
40785692|NCT01883024|OTHER|A decision support software|
40785693|NCT01883024|OTHER|Insulin Pump|
40785694|NCT01883024|OTHER|Continuous glucose monitoring|
40990112|NCT06451042|DIAGNOSTIC_TEST|FET-PET/MRI|Radiation planning target volume (PTV) when planned with FET-PET/MRI to PTV when planned with conventional (Standard of Care) MRI only. 0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) 180-200 megabecquerel (MBq) administered intravenously prior to PET/MRI imaging.
40990113|NCT02066467|DEVICE|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
40990114|NCT00529854|OTHER|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
40990115|NCT03120546|DEVICE|rigid video stylet intubation|intubation using rigid video stylet
40785695|NCT01342731|DRUG|Tigecycline|100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
40785696|NCT02525640|DEVICE|Hearing Aid|Hearing aid comparison
40785697|NCT05526053|OTHER|Lung volume preservation|Extubate the patient connected to the ventilator and PEEP of 5 cmH2O after a successful SBT also using PEEP.
40785698|NCT06117007|DIETARY_SUPPLEMENT|Betalains|"Betalains extracted from red beetroot (Beta vulgaris) encapsulated in edible capsules.~(25 mg betalains per capsule)"
40785699|NCT06117007|OTHER|Placebo|Placebo capsules containing rice hulls. (0 mg betalains per capsule)
40785700|NCT03596671|DEVICE|RENOVA iStim™ System|Tibial implantable neuromodulation device
40785701|NCT04819113|BIOLOGICAL|Nimenrix|MenACWY-TT vaccine
40785702|NCT04698070|DIETARY_SUPPLEMENT|Nutritional Strategy - OptiMA|"All children randomized to this arm will be treated with a RUTF, with weekly ration determined according to MUAC, weight and presence of nutritional edema. Ration will be adjusted weekly according to the change in MUAC and weight throughout the outpatient follow-up until the child achieves nutritional recovery.~RUTF dosage will 170 kcal/kg/d for the most severely wasted (MUAC \< 115 mm or edema) and reduced to 125 kcal/kg/d for children with MUAC 115-119mm and 75 kcal/kg/d for children with MUAC 120-124 mm.~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet nutritional recovery criteria, and then a monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition). Referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected)."
40785703|NCT04698070|DIETARY_SUPPLEMENT|Nutritional Strategy - ComPAS|All children randomized to this arm will be treated with RUTF, with weekly ration determined according to MUAC and presence of nutritional edema. Children enrolled with MUAC \< 115 mm or edema will receive 1000 kcal/d (2 sachets/day) RUTF until MUAC has surpassed 115 mm and/or edema is resolved for 2 weeks at which time ration will be reduced to 500 kcal/d (1 sachet/day) until MUAC \> or = to 125 mm is achieved for 2 consecutive weeks. Children enrolled with MUAC 115-124 mm will receive 1 sachet/day until MUAC \> or = 125 mm is achieved for 2 consecutive weeks and clinically well. Following nutritional recovery, a study nurse will conduct monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition) with referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected) for the remainder of the 6 month period following inclusion.
40990116|NCT03120546|DEVICE|video laryngoscope intubation|intubation using video laryngoscope
40990117|NCT00005888|BEHAVIORAL|Fortified Pasteurized Donor Human Milk supplement|
40990118|NCT00005888|BEHAVIORAL|Preterm Formula supplement|
40990119|NCT03741660|DIETARY_SUPPLEMENT|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ \[100kcal\] of glucommanan)
40990120|NCT03741660|DIETARY_SUPPLEMENT|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
40990121|NCT04324801|OTHER|Homeostatic plasticity induction using transcranial direct current stimulation|Homeostatic plasticity will be induced in the left primary motor cortex using tDCS applied for 7 minutes followed by an interval of 3 minutes and another block of 5 minutes of stimulation
40990122|NCT01626807|BEHAVIORAL|Walking School Bus|Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
40990123|NCT02083731|BIOLOGICAL|MSCs|
40990124|NCT05433961|DRUG|MagniXene Hyperpolarized Xenon MRI|Magnetic Resonance Imaging of lung function using Hyperpolarized Xenon as a contrast agent.
40990125|NCT06435533|DEVICE|low energy argonplasma coagulation|see above
40990126|NCT05133518|DRUG|MELT-300|Sublingual tablet
40990127|NCT05133518|DRUG|Midazolam alone|Sublingual tablet
40990128|NCT05133518|DRUG|Ketamine alone|Sublingual tablet
40990129|NCT05133518|DRUG|Placebo|Sublingual tablet
40990130|NCT02512432|DEVICE|INTACS|asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
40990131|NCT00631527|DRUG|Leuprolide|Injections given through a needle in the muscle every 3 months.
40990132|NCT00631527|DRUG|Goserelin|Subcutaneous injections given once every 3 months.
40990133|NCT00631527|DRUG|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
40990134|NCT00631527|DRUG|Casodex|Once a day by mouth for 2 weeks.
40990135|NCT00631527|RADIATION|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
40990136|NCT05669560|COMBINATION_PRODUCT|PerioProtect ™= plastic tray +1.7% hydrogen peroxide|Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.
40990137|NCT02941445|DRUG|sitagliptin and metformin|
40990138|NCT02941445|DRUG|Metformin|
40990139|NCT03388294|BEHAVIORAL|Parents and Infants Engaged|A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.
40990140|NCT05969873|OTHER|Pilates exercise|Patients in this group will be treated with pilates exercise and conventional physical therapy as baseline treatment.
40990141|NCT05969873|OTHER|Balance training|Patients in this group will be treated with balance training and conventional physical therapy as baseline treatment.
40990142|NCT00206869|BEHAVIORAL|exercise|
40990143|NCT00206869|BEHAVIORAL|heat|
40990144|NCT00206869|PROCEDURE|red light illumination|
40990145|NCT04540289|DRUG|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure"
40990146|NCT04540289|DEVICE|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
40785704|NCT04698070|OTHER|National nutritional Strategy (Niger)|"Different protocols for SAM and MAM comprise the Niger National Nutrition Protocol:~1. SAM: Children with MUAC\<115 or WHZ\<-3 or nutritional edema, will be treated with RUTF, according to a dosage table based on weight at each visit.~2. MAM: Children aged between 6-24 months with MUAC between 115 -124 mm and WHZ\>-3 will be treated with RUSF. Children with the same anthropometry but age 24-59 m will only receive supplementation if they develop criteria for SAM during the 6 month study period. They will be monitored via monthly home visits by a study nurse.~All children will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
40990147|NCT05508763|GENETIC|Genetic test for 14 pharmacogenes|Genotyping with the Global Diversity Array-8 v1.0 BeadChip with enhanced PGx
40990148|NCT06427954|BEHAVIORAL|Digital Health App|access to a digital health app
41307507|NCT02641366|PROCEDURE|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
41307508|NCT06117800|OTHER|TeamSTEPPS|Team Tools and Strategies to Enhance Performance and Patient Safety (TeamSTEPPS®) is an evidence-based framework that has been used in interprofessional education programs to develop and train newly graduate nurses to deal with difficult clinical situations.
41307509|NCT06128005|BEHAVIORAL|knowledge translation in nursing for pressure injury care|Pressure injury's knowledge and healing of wound.
40785705|NCT05021952|DEVICE|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
40990149|NCT04352855|DRUG|Ceftolozane/tazobactam|Administration
40990150|NCT05118451|PROCEDURE|3 d visualization technology|3D visualization technology refers to the conversion of 2d imaging data such as CT and MR into 3D stereoscopic images through computer calculation, analysis and reconstruction, visually separating the shapes and spatial distribution features of targets such as liver, blood vessels and tumors directly, accurately and quickly to present three-dimensional views. Combined with transparency, rotation, scaling and measurement techniques, real-time and interactive 3D dynamic analysis of 3d visual model is carried out. In addition, the computer was used to simulate the operation, and the feasible surgical plan was discussed. The best surgical plan was selected based on the patient's individual data.
40990151|NCT06096220|PROCEDURE|Enucleation|Enucleation is complete removal of the cyst from the bony defect of the jaw affected by the lesion. Osteotomy is performed to allow access to the cyst, cystic wall is detached from the bone and removed completely.
40990152|NCT06096220|DIAGNOSTIC_TEST|incisional biopsy|Lesions clinically abd radiographically consistent with OKC will be submitted for histological examination to confirm the diagnosis of OKC
40990153|NCT06096220|DRUG|Application of 5-fluorouracil|5% 5-fluorouracil cream will be applied immediately after the enucleation to the cystic cavity for 24 hours
41307510|NCT00849251|DRUG|cyclophosphamide|Given IV or PO
41307511|NCT00849251|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
41307512|NCT00849251|DRUG|bortezomib|Given IV
41307513|NCT00849251|DRUG|dexamethasone|Given IV or PO
41307514|NCT04644536|DEVICE|Bone graft substitute|Orthopaedic or Spine bony defects
41307515|NCT00120445|PROCEDURE|air|0.3 ml of filtered air
41307516|NCT00120445|PROCEDURE|expansile gas|0.3 ml of perfluoropropane gas
41466165|NCT01845116|DRUG|Omegaven®|10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
40785706|NCT04593550|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40785707|NCT04593550|BEHAVIORAL|BrainCheck Cognitive Assessment|Undergo cognitive function assessment BrainCheck
40785708|NCT04593550|PROCEDURE|Cognitive Assessment|Undergo 3D-Confusion assessment
40785709|NCT04593550|PROCEDURE|Electroencephalography|Undergo EEG
40785710|NCT01282866|DEVICE|LightSheer Duet|LightSheer Duet HS handpiece
40785711|NCT01482195|BIOLOGICAL|Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.
40785712|NCT02856022|DEVICE|Electrical ilioinguinal nerve stimulation|"Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1\~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks."
40785713|NCT02856022|PROCEDURE|Intravesical Irrigation|The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
40785714|NCT05924139|DIETARY_SUPPLEMENT|Omega-3 fatty acid|6 capsules per day of 3840 mg that included 1950 mg EPA and 1350 mg DHA
40785715|NCT05924139|DIETARY_SUPPLEMENT|Placebo|4 capsules per day of coconut oil
40785716|NCT01138475|DRUG|Paricalcitol|1 microgram by mouth daily for 6 weeks
40785717|NCT01138475|DRUG|Cholecalciferol|5000 IU (international units) by mouth daily for 6 weeks
40785718|NCT01138475|DRUG|Placebo|Inactive substance, one capsule daily for 6 weeks
40785719|NCT05996393|DRUG|Ciclosporin|3-5 mg/kg/d orally, trough concentrations: 100-200 ng/ml
40785720|NCT05996393|DRUG|Avatrombopag|60 mg/d orally, 24 weeks
40785721|NCT05996393|DRUG|Anti-Human Thymocyte Immunoglobulin, Rabbit|rabbit anti-human thymocyte immunoglobulin (r-ATG 3mg/kg/d), intravenously, 5 days;
40785722|NCT04023292|DRUG|Endocrine therapy|Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
40990154|NCT06096220|DRUG|Application of Carnoy solution|Carnoy solution will be applied during the enucleation as described previously
40990155|NCT01132547|DRUG|cyproheptadine hydrochloride|Given orally
40785723|NCT04023292|DRUG|Endocrine therapy|Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
40785724|NCT01612676|DRUG|FE 202158|
40785725|NCT06242847|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|Participants ingest 75 g of glucose in 10 fl oz aqueous solution (fruit flavored) after an overnight fast. Blood is drawn at baseline (t = 0 min) and at 120 min after ingestion. This test is non-experimental.
40990156|NCT01132547|OTHER|placebo|Given orally
40785726|NCT06242847|PROCEDURE|Skin punch biopsy|Punch biopsies are taken from lesional (psoriatic) and non-lesional skin after an overnight fast and at 120 min after ingestion of glucose during OGTT. This procedure is non-experimental.
40785727|NCT05600413|DIETARY_SUPPLEMENT|L-Citrulline|4 weeks of L-Citrulline supplementation (6 grams/day)
40785728|NCT05600413|DIETARY_SUPPLEMENT|Placebo|4 weeks of Placebo (crystalline cellulose)
40785729|NCT04051177|BEHAVIORAL|"Interactive Communication with Openness, Passion, and Empowerment ICOPE"|"The parent curriculum consists of five interactive training sessions (120 minutes each session for 10 hours total) with three specific focuses: understanding the stages of childhood cognitive development in the context of parental illness (Session #1 Child's readiness for disclosure); improving the parents' cognitive and behavioral skills related to parental HIV disclosure (Session #2 Benefits and risks of disclosure, Session #3 How to tell and what to tell, and Session #4 Disclosure is an ongoing process); and improving parental psychosocial well-being in adapting to living with HIV/AIDS (Session #5 Cope with my infection/illness). The curriculum addresses the issues of child and family strengths and community support across sessions."
41147117|NCT06437327|PROCEDURE|Hold relax technique|This technique is applied while the patient is in supine lying with one leg crossed over the other Patient is instructed to contract the piriformis against the manual resistance for 5 to 10 secs Then 15 secs of passive stretch is given repetitions x 5 times
40990157|NCT04273646|BIOLOGICAL|UC-MSCs|4 times of UC-MSCs(0.5\*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).
40990158|NCT04273646|DRUG|Placebo|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
40990159|NCT00613015|DRUG|Guanfacine|
41147118|NCT01863082|OTHER|exercise|practice of physical exercise
41147119|NCT04548778|DIAGNOSTIC_TEST|BÜHLMANN fPELA assay|BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
41147120|NCT04293718|OTHER|papillary gum biopsies|1 or 2 papillary gum biopsies were performed simultaneously, 1 for histological examination and 1 for immunohistochemistry
40785730|NCT04051177|BEHAVIORAL|Nutrition Curriculum|"The modified curriculum consists of five 2-hour interactive training sessions with aims to increase parents' knowledge of nutrition (Session #1: Food variety; Session #2: Food for growing child), healthy diets and cooking practice (Session 3: Fat, salt and sugar; Session 4: Fruits, vegetables and minerals), and food safety (Session #5 Food safety)"
40990160|NCT00613015|DRUG|Modafinil|
40990161|NCT00613015|DRUG|Placebo|
40990162|NCT04248608|PROCEDURE|serratus plane block|ultrasound guided block
40990163|NCT04248608|PROCEDURE|erector spinae block|ultrasound guided block
40990164|NCT04248608|DRUG|Morphine Sulfate|intravenous morphine sulfate 0.1 mg/kg
40990165|NCT03697668|DRUG|Imatinib|triple combination for the treatment of malaria
40990166|NCT03697668|DRUG|Dihydroartemisinin-piperaquine|standard malaria treatment
41307517|NCT04592432|OTHER|SIGN@L-A|Two prototypes of a serious game were developed as part of this study. The design of these prototypes is based on the conceptual model by Alexiou and Schippers (2018) linking the instructional design of a serious game to intrinsic motivation, engagement, and learning outcomes. The design of SIGN@L-A will include all elements of the serious game instructional design proposed by these authors which are game mechanics (i.e., objectives to meet, feedback, and rewards), a narrative (i.e., a protagonist, non-playable characters, and narrative events), and aesthetics (i.e., functional and hedonic aesthetics).
41307518|NCT04592432|OTHER|SIGN@L-B|The design of SIGN@L-B will include only some of these elements which are some of the game mechanics (i.e., objectives to meet, limited feedback), and a functional aesthetic.
40785731|NCT06301646|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
40785732|NCT06301646|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
40785733|NCT06301646|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
40785734|NCT00335166|DRUG|Pardaprunox|12-42 mg
40785735|NCT00335166|DRUG|pramipexole|1.5-4.5 mg
40785736|NCT00335166|DRUG|Placebo Comparator|Placebo
40785737|NCT05988736|DEVICE|MaCintosh Laryngoscope (DL)|A conventional Laryngoscope. It is battery powered, with a detachable MaCintosh blade that contains a light source.
40785738|NCT05988736|DEVICE|McGrath Laryngoscope (VL)|A video Laryngoscope that has a high-resolution video camera, and a light source at the cone end of the blade allowing for direct and indirect viewing of the glottis
40785739|NCT00152204|DRUG|Sulfadoxine-pyrimethamine used for IPTi|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
40785740|NCT00152204|DRUG|IPTi|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
40785741|NCT02950103|DRUG|Phosphoethanolamine|Phosphoethanolamine PO daily
40785742|NCT05719207|DEVICE|Balloon dilation of eustachian tube (Stryker XprESS LoProfile ENT dilation system)|Patients in the intervention group would undergo balloon dilation of the eustachian tube under local anesthetic in clinic. The Stryker XprESS LoProfile ENT dilation system will be used. Participants may undergo dilation under general anesthesia if a contraindication to in-clinic dilation exists.
40785743|NCT05719207|OTHER|Sham procedure|Patients in the sham group will undergo the motions of an in-office dilation of the eustachian tube, without actually dilating the eustachian tube.
40785744|NCT01937520|DEVICE|acupuncture|One half of subjects will receive a standardized acupuncture regiment
40785745|NCT01937520|DEVICE|no acupuncture|placebo
40785746|NCT05411107|PROCEDURE|Biospecimen Collection|Undergo collection of sputum sample
40785747|NCT05411107|PROCEDURE|Bronchial Brush Biopsy|Undergo bronchial brush biopsy
40785748|NCT05411107|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
40785749|NCT05411107|DRUG|Iloprost|Given PO
40785750|NCT05411107|DRUG|Placebo Administration|Given PO
41147121|NCT01062776|BIOLOGICAL|Dehydration|Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
41147122|NCT01062776|BIOLOGICAL|Placebo|No dehydration is induced
41307519|NCT05532098|PROCEDURE|Dry Needling|Dry Needling will be done for the patients with ADD of TMJ in the retrodiscal tissue and superior joint space .
41307520|NCT05532098|PROCEDURE|PRP|Patients with ADD are administered with 1ml of PRP into the retrodiscal tissue and the superior joint space. PRP will be prepared by method proposed by Okuda et al., 2003. Reinjection will be given after 2 weeks if required.
41307521|NCT00808782|DEVICE|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
41307522|NCT00808782|DEVICE|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
41307523|NCT04626843|OTHER|Intermittent fast|16/8 fasting method: fast for 16 hours of the day with an 8 hours feeding window for a duration of 3 months.
40785751|NCT05411107|OTHER|Questionnaire Administration|Ancillary studies
40785752|NCT04343573|RADIATION|Involved-field Photon Radiation Therapy|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions)
40785753|NCT04343573|RADIATION|Proton Craniospinal Irradiation (CSI)|Proton CSI (30Gy \[RBE\] in 10 fractions)
40990167|NCT00811577|DRUG|Placebo|Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
40990168|NCT00811577|DRUG|AZX100|AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
40785754|NCT04343573|OTHER|Neurocognitive Assessment|All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT. The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available. Patients will also complete self-report mood and fatigue scales at each of the same time points. This testing will only be done at MSKCC. Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments. Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
40785755|NCT04343573|OTHER|MDASI-BT and MDASI-SP|Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).
40785756|NCT02916069|DEVICE|Nearinfrared Spectroscopy (NIRS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
40785757|NCT02916069|DEVICE|Transcranial Doppler (TCD)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
40785758|NCT02916069|DEVICE|Bispectral index (BIS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
41307524|NCT02875821|DRUG|Ipragliflozin|Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)
40990169|NCT00885716|BEHAVIORAL|patient training in shared decision making|
40990170|NCT00885716|BEHAVIORAL|cognitive training|
40990171|NCT03878745|DEVICE|Terumo Nanopass® 34G pen needle|Insulin pen needle
40990172|NCT03878745|DEVICE|BD Nano™ PRO 32G pen needle|Insulin pen needle
40990173|NCT05215301|DIAGNOSTIC_TEST|Multidimensional Voice Program|"MDVP (Multidimensional Voice Program) is a computerized acoustic analysis used to analyze sound quality using various parameters. Multidimensional Voice Program (MDVP) 4500 produced by Kay Elemetric Corp was used for voice evaluation.~Research subjects were asked to make a vowel sound /a/ using the same tone and intensity as the subject's daily speech. The researcher will give an example before letting the research subject tries. Voice recording was done using a microphone connected to a computer with the MDVP program. Voice recording was done in a quiet room for at least 3 seconds with a microphone distance of 10 cm from the mouth of the research subject. The recorded sound will be directly analyzed with the MDVP program. Sound recording was done 3 - 5 times, and the best sound acoustic analysis results were used for the study."
40990174|NCT06393764|OTHER|Collection of biological samples|Collecte of blood and urine samples
40990175|NCT01232920|DRUG|Methotrexate|All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
40990176|NCT01232920|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
40990177|NCT02024620|BEHAVIORAL|Behavioral activation plus mobile app|
40990178|NCT02024620|BEHAVIORAL|Standard behavioral activation|
40990179|NCT00329407|DRUG|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM \& 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM \& 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM \& 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
40990180|NCT04615611|DRUG|salbutamol|inhalation of salbutamol
41307525|NCT02875821|DRUG|metformin with pioglitazone|Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
40785759|NCT05111145|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
40785760|NCT05111145|DRUG|IVA|Tablets for oral administration.
40785761|NCT00598650|DRUG|E2020|Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
40785762|NCT01288157|DRUG|Golimumab|Single dose of 100 mg subcutaneously
40785763|NCT01288157|DRUG|Golimumab|Single dose of 50 mg subcutaneously
40785764|NCT00558636|DRUG|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), \[400 mg, (2 tablets x 200 mg each) orally, twice daily\] on Study Days 2-19 and paclitaxel (175 mg/m\^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
40785765|NCT00558636|DRUG|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m\^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
40785766|NCT02559648|DRUG|Denosumab|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
41146639|NCT04610606|BEHAVIORAL|Multimodal intervention (MM)|"Exercise: Moderate intensity resistance and aerobic exercise, including one weekly supervised session and a home-based program. Participants were asked to 1) accumulate 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2) perform 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps.~Nutrition: Optimize diet with protein-rich foods to meet protein intake of \>1.2 g/kg/d and energy of 25-30 kcal/kg/d. The supplement consists of whey protein isolate (with the goal of reaching 1.5 g/kg/d, providing 25 g/meal), 6g of leucine, fruit-flavored fish oil added with vitamin D.~Relaxation strategies: private consultations with psychology-trained personnel whereby techniques aimed at reducing anxiety are practiced. Participants are also provided with a compact disc with relaxation exercises to be used at home 2-3 times per week."
41307526|NCT02094872|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
40990181|NCT04615611|DRUG|Placebo|administration of placebo
40990182|NCT00335972|DRUG|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
40990183|NCT00335972|DRUG|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
41146640|NCT03687554|DRUG|Venglustat GZ/SAR402671|Pharmaceutical form: Hard Capsule Route of administration: Oral
41146641|NCT04206618|DRUG|Teriparatide|1 subcutaneous injection daily for 12 months
40785767|NCT02559648|DRUG|Placebo|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
40785768|NCT04074083|BEHAVIORAL|electronic IMCI|Participants will be trained to use an electronic version of the Integrated Management of Childhood Illness (IMCI) guidelines
40785769|NCT04074083|BEHAVIORAL|paper IMCI|Participants will be trained to use routine paper version of Integrated Management of Childhood Illness (IMCI) guidelines
41146642|NCT04206618|DRUG|Denosumab|1 subcutaneous injection every 6 months for 12 months
41307527|NCT02094872|DRUG|MEK 162 therapy or molecularly targeted therapy|molecularly targeted therapy, MEK 162 therapy
41307528|NCT02094872|PROCEDURE|therapeutic procedure|
41307529|NCT02094872|OTHER|laboratory biomarker analysis|Correlative studies
41307530|NCT02094872|OTHER|quality-of-life assessment|Ancillary studies
41307531|NCT04729556|DEVICE|Sericin and chitosan cream|A novel film-forming cream containing sericin and chitosan
41466166|NCT03288402|OTHER|ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast|effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
40785770|NCT01667250|DEVICE|GammaCore Active Device|
40785771|NCT01667250|DEVICE|GammaCore Sham Device|
40785772|NCT00989508|DRUG|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
40785773|NCT00989508|DRUG|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
40785774|NCT03668964|DIETARY_SUPPLEMENT|Vitamin B2|One capsule of 75 mg Vitamin B2 once a day for 4 weeks
40785775|NCT03668964|DIETARY_SUPPLEMENT|Vitamin C|One capsule of 500 mg Vitamin C once a day for 4 weeks
40785776|NCT03668964|DIETARY_SUPPLEMENT|Vitamin B2 + C|One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks
40785777|NCT03668964|DIETARY_SUPPLEMENT|Vitamin A|One capsule of 250 µg Vitamin A once a day for 4 weeks
40785778|NCT03668964|DIETARY_SUPPLEMENT|Vitamin D3|One capsule of 60 µg Vitamin D3 once a day for 4 weeks
40785779|NCT03668964|DIETARY_SUPPLEMENT|Vitamin E|One capsule of 100 mg Vitamin E once a day for 4 weeks
40785780|NCT03668964|DIETARY_SUPPLEMENT|Placebo|One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
41146643|NCT04937049|OTHER|EMAeHealth digital tool|eHealth intervention to support Maternal Education
41146644|NCT05971199|DRUG|Fruquintinib|Fruquintinib:5 mg capsule orally once daily on day 1-21 in 28-day cycles；
41146645|NCT05971199|DRUG|Sintilimab|Sintilimab: 200 mg i.v. every 3 weeks
41146646|NCT05971199|DEVICE|Transcatheter arterial chemoembolization（TACE）|Transcatheter arterial chemoembolization（TACE）
40785781|NCT01541865|DEVICE|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
40785782|NCT05812326|DRUG|AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells|AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
40785783|NCT00203385|DRUG|Divalproex|Depakote up to 2000mg/d
40785784|NCT04576910|BIOLOGICAL|vaccinated with Sabin IPV|the 4th dose of polio vaccination
40785785|NCT04576910|BIOLOGICAL|vaccinated with bOPV|the 4th dose of polio vaccination
40785786|NCT04868344|DRUG|MRG003|Administered intravenously
40785787|NCT00003873|DRUG|fluorouracil|Given IV or orally
40785788|NCT00003873|DRUG|eniluracil|Given orally
40785789|NCT05217459|DEVICE|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
40785790|NCT06043336|DRUG|Dexamethasone, granisetron & palonosetron|. Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
40785791|NCT00648037|DRUG|Rituximab|Rituximab 375 mg/m\^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is \> 200 cells/ul or a maximum of 6 doses have been given.
40785792|NCT01406132|DRUG|ASP015K|oral
40785793|NCT01464749|BEHAVIORAL|Task-oriented circuit class training|5 sessions/week over 2 weeks (10 sessions) 120 minutes/each
40785794|NCT01464749|BEHAVIORAL|usual care|no specific rehabilitation
40785795|NCT00298636|DRUG|adenosine|
40785796|NCT03985280|DEVICE|Cooled radiofrequency|Under guidance of combined X-ray and ultrasound the nerves will be located . After local anesthetic aplication cooled RF needle will be apply in the objective position. Cooled RF will be performed for 2:30 minutes at 60 º C degrees.
40785797|NCT03985280|DRUG|Intraaticular steroids and local anesthetic injections|Intraaticular steroids and local anesthetic injections
40785798|NCT01730872|DRUG|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 4 days.
40785799|NCT01730872|DRUG|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 4 days
40785800|NCT06159504|DRUG|sofosbuvir/velpatasvir (SOF/VEL)|400mg of SOF and 100mg of VEL self administered daily as a tablet.
41146647|NCT02808676|DIETARY_SUPPLEMENT|Vitamin D3|Dose: 10000 IU, three times per week, orally.
41466167|NCT04912986|BEHAVIORAL|Early Lung Rehabilitation Training|It is implemented in accordance with the Early Lung Rehabilitation Training Program for Adult Double Lung Transplant Patients. Establish multidisciplinary collaboration teams, including competent doctors, nurses, rehabilitation physicians, and psychologists.
41466168|NCT04912986|BEHAVIORAL|Routine treatment|Provide rehabilitation training as usual, without standard program
40785801|NCT06159504|DIAGNOSTIC_TEST|Shortened read time of rapid diagnostic test for hepatitis C virus.|Administered once during hepatitis C testing. Test is read after 5 minutes rather than its usual time of 20 minutes.
40785802|NCT06498414|DRUG|rifampin standard arm|120 doses daily self-administered rifampin at 10mg/kg/day (max 600mg/day)
40785803|NCT06498414|DRUG|rifampin double dose|60 doses daily self-administered rifampin at 20 mg/kg (max. 1200 mg/day)
40785804|NCT06498414|DRUG|levofloxacin and rifapentine|30 doses daily self-administered levofloxacin (15 mg/kg, max 750mg/day and rifapentine (10mg/kg, max: 600mg)
40785805|NCT06121648|OTHER|hydrotherapy|30 degrees temperature pool balance and breathing therapy
40785806|NCT06121648|OTHER|neurological physiotherapy|Balance and neurological physiotherapy on land
40785807|NCT05795270|OTHER|Treatment|Nocturnal ventilotherapy, positional therapy and oro-mandibular devices
40785808|NCT05257928|BEHAVIORAL|CARE-CITE Gait|The CARE-CITE intervention content modified to address gait rehabilitation, and test 4-weeks of CARE-CITE-Gait in 15 CP/SS dyads.It will occur in the dyad's home.CP will complete 6 online CARE-CITE modules. Modules will include demonstration videos and instructive content covering the following areas:principles of functional task practice, the adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity. Examples are provided to address potential SS frustration and improve adherence.Underpinning the content is the concept of autonomy support,with examples of fostering empathy, problem-solving, instruction in the use of non-controlling language with role-playing situations and the importance of creating choice in activities. During the two home therapy sessions, the physical therapist will work with the CP and stroke survivor to collaboratively develop goals and an exercise program to improve mobility, gait and balance.
40785809|NCT05490758|OTHER|sensorimotor training|sensorimotor training include activities like play with dough, peg games, puzzles for 5 days a week for 4 week.
40785810|NCT05490758|OTHER|constraint induced movement therapy|constraint induced movement therapy in which arm was constraint for 6 hours a day for 5 days a week for 4 week.
40785811|NCT05011253|OTHER|Electronic Trigger Microhematuria Alert|To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).
40785812|NCT05112848|BIOLOGICAL|NVX-CoV2373|"Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70)."
40785813|NCT00185237|DRUG|Menostar (estradiol transdermal delivery system)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
40785814|NCT00185237|DRUG|Placebo|Placebo patch
40785815|NCT00672230|DIETARY_SUPPLEMENT|Lutein supplement|Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
40990184|NCT03343873|DRUG|Midazolam|Midazolam was administered intravenously at a dose of 0.1 mg / kg followed by continuous intravenous injection at 0.03 mg / kg / h and maintained until the course of the scan.
40990185|NCT03343873|DRUG|Propofol|Propofol group 1mg / kg intravenous injection, followed by 2mg / kg / h continuous intravenous injection, and maintained to the scanning process;
40990186|NCT03343873|DRUG|Dexmedetomidine|Dexmedetomidine group with total amount of 1μg / kg, infusion time 15min, followed by 0.6μg / kg / h, and maintained to the scanning process;
40990187|NCT01920919|DRUG|Dexamethasone|
40990188|NCT01920919|DRUG|Placebo|
40990189|NCT05537077|OTHER|Prolotherapy|DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.
40785816|NCT02735603|DRUG|Naltrexone HCl/bupropion HCl|Naltrexone HCl/bupropion HCl extended-release tablet.
40785817|NCT02735603|OTHER|Placebo|Naltrexone/bupropion placebo-matching tablets.
40785818|NCT02735603|DRUG|Moxifloxacin|Moxifloxacin tablet.
40785819|NCT06133881|DRUG|prilocaine|intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
40785820|NCT06133881|DRUG|bupivacaine|intrathecal 10 mg (2 ml) of bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml + 25 ug fentanyl (0.5 ml
40785821|NCT03644719|BEHAVIORAL|Cognitive behavioral skills training|A brief cognitive behavioral skills training was applied to teach ketamine abusers about stimulus control, refusal skills, communication skills, decisional balance, and infectious diseases prevention.
40785822|NCT01984047|DRUG|GSK3050002|GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
40785823|NCT01984047|DRUG|Placebo|Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
40990190|NCT05537077|OTHER|Home based exercise program|Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.
40990191|NCT05537077|OTHER|Hotpack therapy|Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.
40990192|NCT00962507|DRUG|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
40785824|NCT06432686|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is a safe, relatively cheap, and non-painful stimulation of the peripheral sensory and motor nerves. The stimulator is easy to operate and pwMS can apply the stimulation themselves at home. This makes TENS an interesting tool to augment sensory input. A high frequency and long pulse duration is used.
41307532|NCT06290947|DEVICE|BFR Cuffs for Intervention Group|"The intervention consists of supervised treadmill sessions incorporating specialized BFR cuffs, branded as H+ Curve, tailored for Blood-Flow Restriction Walk Training (BFRw). These cuffs are strategically positioned on the upper portion of the lower limbs to induce muscle adaptations and~improve metabolic health outcomes. The innovative protocol is designed to probe the potential benefits of BFRw in ameliorating insulin sensitivity and enhancing aerobic capacity, thus presenting a pioneering exercise approach for individuals with Type 2 Diabetes."
40785825|NCT06432686|BEHAVIORAL|Movement|Participants are instructed to perform plantar- and dorsi-flexion contraction in a relatively slow tempo. The movement of the ankle is measured by an MRI-compatible potentiometer and participants receive feedback of this movement on the screen inside the scanner.
40785826|NCT01339936|DEVICE|Carboxymethylcellulose sodium, glycerin and polysorbate 80|1 drop in each eye three times a day for a period of 30 (± 4) days
40785827|NCT00429754|DRUG|Aprepitant|
40785828|NCT02764996|DEVICE|Acupuncture|
40785829|NCT03483454|OTHER|Exercise class|Same as above.
40785830|NCT03483454|OTHER|Home exercise|Same as above.
40785831|NCT03576261|OTHER|Preoperative colloid fluid bolus (Gelofusine)|Preoperative colloid fluid bolus
40785832|NCT03576261|DIAGNOSTIC_TEST|Preoperative transthoracic echocardiography|Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
40785833|NCT01369043|DIETARY_SUPPLEMENT|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
40785834|NCT06178367|DRUG|Low molecular weight hyaluronic acid|Topical 0,1% low molecular weight (7 kDa) hyaluronic acid in vehicle
40785835|NCT06178367|DRUG|High molecular weight hyaluronic acid|Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid in vehicle
40785836|NCT06178367|DRUG|Vehicle|Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
40785837|NCT03657836|DIETARY_SUPPLEMENT|Sublimated mare milk supplement|The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
40785838|NCT03657836|DRUG|Standard antibiotic therapy|Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
40990193|NCT00962507|DRUG|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
41307533|NCT06290947|OTHER|Standard Walking Training Program|"The control group will engage in a standard walking training regimen, consisting of supervised treadmill sessions without the application of BFR cuffs. This protocol serves to uphold the scientific rigor of the study by offering a comparison group for the BFRw intervention.~Purpose:~To evaluate the impact of a typical exercise routine on insulin sensitivity and aerobic capacity, thereby establishing a control benchmark to contrast with the effects of the BFRw intervention."
40785839|NCT02136225|BEHAVIORAL|Means restriction counseling|Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
40785840|NCT00499200|DRUG|SRA-444|
40785841|NCT01328743|BEHAVIORAL|Brief alcohol intervention|3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
40785842|NCT04740580|DIETARY_SUPPLEMENT|Glycine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
40785843|NCT04740580|DIETARY_SUPPLEMENT|N-acetylcysteine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
40785844|NCT04740580|DIETARY_SUPPLEMENT|Alanine|The placebo arm will supplement Alanine
40785845|NCT03024424|BEHAVIORAL|Early disclosure|
40785846|NCT03024424|BEHAVIORAL|Late disclosure|
40785847|NCT01465035|BIOLOGICAL|TIV and MVA-NP+M1|1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
40785848|NCT01465035|BIOLOGICAL|Saline placebo and seasonal influenza vaccine TIV|Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
40990194|NCT00962507|OTHER|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
40990195|NCT00962507|OTHER|pharmacological study|Pre-study, day 1 and day 26
40785849|NCT01768949|DEVICE|Echocardiography|In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
40785850|NCT03500289|DRUG|Ketamine|One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes
40990196|NCT05188092|OTHER|Lung ultrasound guided deresuscitation|"With every new LUS examination, the following scenarios, with distinct recommendations, are possible:~1. LUS observations suggest massive pulmonary fluid overload, with the recommendation to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance of at least -1500 ml in the next 24 hours;~2. LUS suggests some pulmonary edema and/or significant pleural effusion. These LUS observations suggest little pulmonary fluid overload, with the suggestion to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance at least -500 ml in the next 24 hours;~3. LUS suggests absence of pulmonary edema and no pleural effusion. These LUS observations suggest no fluid overload, with the suggestion to target a neutral fluid balance in the next 24 hours."
40785851|NCT03500289|DRUG|Midazolam|One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes
41307534|NCT02694211|BEHAVIORAL|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
41307535|NCT03481127|BEHAVIORAL|Integrated psychological care|Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.
40785852|NCT05724082|OTHER|Clean Air Intervention|"Based on findings from preliminary focus groups/in-depth interviews, staff will introduce various components of established clean air interventions to each household. Each household will receive interventions, depending on their known risk factors, exposures, and willingness to trial the intervention.~Study staff will ask the primary cook to complete a time-activity diary during the intervention period that includes cooking episodes, duration of cooking, stove(s) used, type of food cooked, and number of people for whom the meal was cooked. Staff will continuously monitor use of the LPG/pellet stove and any other stoves owned by the household with the Berkeley Stove Use Monitoring System, a temperature logger attached to the stove to quantify the number of stove uses / time of use . Study staff will use similar loggers to monitor use of other devices installed including the air purifiers, lighting etc."
40785853|NCT01890096|RADIATION|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
41307536|NCT03481127|OTHER|Surveys|"* NCCN Distress Thermometer~* PROMIS Depression \& Anxiety~* Quality of Life (SF-12)~* Brief COPE~* Patient awareness and satisfaction survey"
41307537|NCT03481127|PROCEDURE|Blood draw|"* For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* Enrollment, 3 months after enrollment, and 6 months after enrollment"
41466169|NCT04812574|PROCEDURE|Periurethral injection|Patients were in the lithotomy position for the procedure. After preparation, topical Lidocaine gel was instilled around the meatus and a 16 F probe was attached. The catheter balloon was inflated to localize the bladder neck and to ensure that injections were performed in the correct anatomical plane. Hypertonic saline (10% NaCl) was injected to the alignment of the urethral meatus in the order of 3-6-9-12 hours of the clock (5 cc to each site, totaling 20 cc). Syringes with 27 Gauge (0.40 mm) outer diameter were used to ensure controlled injection. Since the female urethra is about 4 cm in length, the needle was advanced about 3 cm. Due to the possibility of significant pain with hypertonic saline, 2 cc of Lidocaine hydrochloride was added into the solution.
41466170|NCT04812574|DRUG|Hypertonic (10%) saline|Periurethral hypertonic saline (10%)
40785854|NCT01890096|RADIATION|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
40785855|NCT03999580|DRUG|vitamin D3|"3000 or 4000 UI/ day:~Weight at inclusion \< 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion \< 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance"
40785856|NCT03334838|DRUG|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
40785857|NCT05827289|DEVICE|Cancer Patients Better Life Experience (CAPABLE)|The CAPABLE system serves three main goals for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing. These are available to the patient as a smartphone application that is connected to a smartwatch to monitor activity, blood pressure, sleep and heart rate. Patients are able to report symptoms experienced from the treatment and are eligible to do interventions such as mindfulness or yoga. Patients will receive the CAPABLE application and smartwatch for a minimum 3 to a maximum of 6 months after start treatment.
40785858|NCT00987714|PROCEDURE|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
41307538|NCT03481127|PROCEDURE|Fresh tissue from ovary|"* For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* At time of standard of care surgery"
41307539|NCT02942849|DRUG|r-hFSH|As per standard clinical practice
41307540|NCT04552379|BIOLOGICAL|Peginterferon beta-1a|"Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at \~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use."
41466171|NCT01601691|DEVICE|DuraSeal|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
41466172|NCT05762484|PROCEDURE|Nd:YAG laser hair removal|Using the Nd:YAG laser (cynergy), hair of the axillae will be removed.
41466173|NCT05762484|DRUG|Clindamycin 1 % Topical Lotion|Clindamycin 1% lotion if needed
41466174|NCT03555994|DRUG|MEDI0382|MEDI0382 administered subcutaneously
41466175|NCT03555994|DRUG|Placebo|Placebo administered subcutaneously
41466176|NCT03555994|DRUG|Liraglutide|Liraglutide administered subcutaneously
41466177|NCT01910337|DEVICE|Use the Polar Cardiac rate meter|
41466178|NCT01235442|DRUG|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
40785859|NCT05723744|DEVICE|ECG Holter and investigational device recordings for the purpose of developing Continuous Measurement of Heart Arrythmias|"For Candidates for pacemaker implantation: ECG Holter and investigational device recordings (of PPG, ECG, and motion sensors tracings non-invasively) will be recorded before procedure, during patient's hospitalization at cardiology division. Blood pressure values that are collected by an automated cuff will be collected including any notes attached to the values.~All collected data will be analyzed offline"
40785860|NCT00613431|DRUG|CS8080|CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
40785861|NCT00613431|DRUG|Placebo|Some subjects will receive matching placebo instead of CS-8080.
40785862|NCT06028828|DRUG|Fludarabine|Given Day-5, Day-4, Day-3, Day-2
40785863|NCT06028828|DRUG|Melphalan|Given Day-5
40785864|NCT06028828|RADIATION|Total Body Irradiation|Given Day-1
40785865|NCT04298489|DIAGNOSTIC_TEST|Personalized drug sensitivity test|"The patients underwent surgery to remove tumor and took out tumor specimens for research. The tumor cells were expanded ex vivo drug sensitivity assay.~The drugs used in the study were 5-fluorouracil, Oxaliplatin, and irinotecan at C0 = 10 mM, 2.5 mM and 0.02 mM, respectively. They were applied either as single agents or in combinations of 5-fluorouracil and Oxaliplatin, 5-fluorouracil and irinotecan, or all three agents, or others. After 7 days of treatment, the tumor cells were stained with EdU, Hoechst and EpCAM with the Cell Quantitative Detection Kit. Images were acquired with an automated microscopic image-scanning system and analyzed with the built-in software."
40785866|NCT03323684|OTHER|Quadratus lumborum block Group (QL)|20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
40785867|NCT03323684|OTHER|Transversus abdominis plane Group (TAP)|20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
40785868|NCT03323684|OTHER|Control group (C)|No intervention will be done
40785869|NCT03323684|DRUG|Paracetamol infusion|Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.
40785870|NCT03323684|DRUG|Ketorolac analgesia|In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
40785871|NCT03323684|DRUG|fentanyl|With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
40785872|NCT03567889|DRUG|Daromun|Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.
40785873|NCT03567889|PROCEDURE|Surgery|Patients in Arm 2 will receive surgery within 4 weeks from randomisation.
40785874|NCT03567889|DRUG|Adjuvant therapy|Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
40785875|NCT01188941|BEHAVIORAL|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
40785876|NCT00939107|PROCEDURE|spinal manipulation|Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care
40785877|NCT00939107|PROCEDURE|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
41466179|NCT01235442|DRUG|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
40785878|NCT00981903|DRUG|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
40785879|NCT05278026|OTHER|guideline recommended routine treatment|
40785880|NCT05998486|DIAGNOSTIC_TEST|EMG in wrist flexor-pronators and extensor-supinators|The subject is asked to perform a series of tasks: resting posture, symmetrical posture arms forward, unilateral distal movement. Each task lasts 10 seconds.
40785881|NCT04919720|BEHAVIORAL|FRAM Model and Human Factors/Quality Improvement Intervention|The group will use semi-structured interviews and ethnographic observations to inform development of a Functional Resonance Analysis Method (FRAM) model of the process for rescue of deteriorating patients in EGS, using information from 3 hospitals. A focus group approach will be used in co-designing reform of the system for responding to post-operative deterioration, working with small groups of frontline clinical staff from relevant areas in the three Trusts involved.
40785882|NCT02621437|OTHER|Osteopathy sessions|- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
40785883|NCT02621437|OTHER|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~* pain questionnaire with digital scale,~* quality of life survey: SF-12~* HAD (Hospital and Anxiety Depression) questionnaire"
40785884|NCT00504439|DRUG|SB-656933-AAA|The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
40785885|NCT00504439|DRUG|Matching placebo|SB-656933-AAA matching placebo tablets will be administered orally.
40785886|NCT00504439|DRUG|Simvastatin|Simvastatin will be provided as a 40 mg tablet.
40785887|NCT05844228|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
40785888|NCT05935059|DRUG|Pregabalin|Pregabalin 50Mg Oral Capsule. Pre-operative administration of Pregabalin for prevention of Post mastectomy Pain Syndrome (PMPS)
40785889|NCT05935059|DRUG|Tianeptine|Tianeptine 12.5Mg Capsules. Prevention of Post Mastectomy Pain Syndrome
41466180|NCT02343965|OTHER|Touch-massage|
41466181|NCT00423709|PROCEDURE|Allogeneic Blood Stem Cell Transplantation|
41466182|NCT00423709|DRUG|Fludarabine|
40785890|NCT05511012|OTHER|motion control fault tests|Patients make 6 motion control fault tests, in the same order. Each test is performed three times
40990197|NCT04426591|DRUG|Biotin Labeled Red Blood Cells|On the day of transfusion, a 20 mL aliquot will be sterilely withdrawn from each RBC unit, washed and labeled with sulfo-NHS-biotin for 30 minutes, washed to stop the labeling reaction, then resuspended in plasma to a hematocrit of \~60%. The biotin-labeled RBC (BioRBC) will be transfused along with the remainder of the RBC unit (unlabeled volume). Standard blood bank and CTT protocols and minor antigen matching for SCD patients will be followed. Exact transfusion volume will be determined based on pre-transfusion hemoglobin (Hb), sickle cell hemoglobin (HbS), and body weight, per clinical protocol.
40990198|NCT04426591|DEVICE|INTERCEPT Blood System|In addition to the blood drawn for the main study, individuals participating in this optional intervention will have additional tubes of peripheral venous blood will be drawn for evaluating treatment-emergent antibodies specific to INTERCEPT RBCs and acridine surface label monitoring. Tests for treatment-emergent antibodies specific to INTERCEPT RBCs will be performed according to procedures developed by Cerus Corporation.
40785891|NCT05206331|DEVICE|contrast enhanced mammography|Dual-energy contrast images; low-energy CEM images will be obtained with a kilovoltage below 35 kVp while the high-energy images will be obtained with 45-49 kVp.The average glandular dose of the CEM procedure is approximately 2.44 mGy per view
40785892|NCT05206331|DRUG|Iodinated Contrast Media (ICM)|standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
40785893|NCT00201279|DRUG|13-cis Retino Acid|
40785894|NCT00775268|PROCEDURE|Biopsy|Biopsy taken
40785895|NCT00775268|DIAGNOSTIC_TEST|fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography|Imaging
40785896|NCT00775268|OTHER|[3'-deoxy-3'-[F-18] fluorothymidine|Undergo scans
40785897|NCT00775268|PROCEDURE|computed tomography|Undergo scans
40785898|NCT00775268|PROCEDURE|fine-needle aspiration|sample collected
40785899|NCT06243614|DRUG|Buagafuran capsules, 15mg/ capsule|Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
40785900|NCT06243614|DRUG|Buspirone tablets, 5mg/ tablet|Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
40785901|NCT06243614|DRUG|Buagafuran capsules mimic, 0mg/ capsule|Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
40785902|NCT06243614|DRUG|Buspirone tablets mimic, 0mg/ tablet|Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
40990199|NCT05852743|DEVICE|shear wave and strain elastography|shear wave elastography is a quantitative technique , while strain elastography is qualitative technique
40990200|NCT00105703|BEHAVIORAL|Case management using advanced nurse practitioners|
40990201|NCT03563417|PROCEDURE|Percuteneous Coronary Intervention|PCI of Chronic Total Occlusions
40990202|NCT03563417|OTHER|Optimal Medical Therapy|Initiation and titration of optimal medical therapy in the control arm.
40990203|NCT02255370|DRUG|Curcumin|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
40990204|NCT05257811|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device includes custom-fit earbuds with biometric sensors to detect EEG, motion (via tri-axial accelerometers), and heart rate. A ring laser scanner is used to capture the unique geometry of each participant's ear and external auditory canal. Digital models of the individual ear scans are generated and used to create custom fit, 3D-printed earbuds. This design process allows for consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, cardiac activity, and eye movements.
40990205|NCT05814367|DRUG|Blink® Tears eye drops in a multidose bottle|Control
40990206|NCT05814367|DRUG|Preservative-free investigational lubricating eye drops in a Novelia® eyedropper|Test
40785903|NCT02306811|DRUG|Vatelizumab|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
40785904|NCT03859076|BEHAVIORAL|MB-BP|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions \& a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, \& specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, \& stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
40785905|NCT03859076|OTHER|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
40785906|NCT01323985|DRUG|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
40785907|NCT01323985|DRUG|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
40785908|NCT01178840|DEVICE|WC then FC2|4 uses of WC followed by 4 uses of FC2
40785909|NCT01178840|DEVICE|FC2 then WC|4 uses of WC followed by 4 uses of FC2
40785910|NCT05896943|DRUG|Ustekinumab|Patients with ulcerative colitis treated with ustekinumab
40990207|NCT03935373|DIAGNOSTIC_TEST|DNA Exome sequencing|The DNA of Sjögren's syndrome patients and health subjects will take to do the DNA Exome sequencing.
40990208|NCT03935373|DIAGNOSTIC_TEST|Oral microbiome|The saliva of Sjögren's syndrome patients and health subjects will take to do the oral microbiome.
41466183|NCT00423709|DRUG|Melphalan|
40990209|NCT03935373|DIAGNOSTIC_TEST|Proteomics|The protein of Sjögren's syndrome patients and health subjects will take to do the proteomics.
40785911|NCT01864265|DRUG|Certolizumab Pegol|Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
40785912|NCT01864265|DRUG|Placebo|Placebo will be administered according to the label of the biological
40785913|NCT03643133|DRUG|Mifamurtide|48 doses overall over 36 weeks
40785914|NCT03643133|COMBINATION_PRODUCT|EI or M-API regimen depending on patient age|"M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days"
40785915|NCT05173974|DEVICE|Super Poligrip Free|A single application of 1 gram of Super Poligrip Free will be applied topically to oral tissues via the upper denture.
40785916|NCT05173974|DEVICE|Experimental Denture Adhesive 1|A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.
40785917|NCT05173974|DEVICE|Experimental Denture Adhesive 2|A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
40785918|NCT04067492|DRUG|RPH - 104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
40785919|NCT04067492|DRUG|Voltaren®|Enteric-coated tablets, 25 mg and 50 mg
40785920|NCT01273038|DEVICE|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
40785921|NCT01273038|DEVICE|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
40785922|NCT02651116|DRUG|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
40785923|NCT02651116|DRUG|Placebo|10 mL Placebo
40785924|NCT02651116|DEVICE|Cough recording device|FDA approved device validated for use in adults and children
40990210|NCT03935373|DIAGNOSTIC_TEST|RNA sequencing|The RNA of Sjögren's syndrome patients and health subjects will store to do the RNA sequencing.
40990211|NCT03935373|DIAGNOSTIC_TEST|Cytokine|The serum of Sjögren's syndrome patients and health subjects will store to do the cytokine detection in the future.
40785927|NCT01310530|RADIATION|Proton Beam Radiotherapy|Daily proton beam radiotherapy is delivered to the site of the breast tumor in ten treatment sessions over two week as an outpatient.
40990212|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pattern.
40990213|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine tongue diagnosis.
40990214|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine pulse diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pulse diagnosis.
40990215|NCT03935373|DIAGNOSTIC_TEST|Heart rate variability|Sjögren's syndrome patients and health subjects will take the heart rate variability.
40785928|NCT02603276|DIETARY_SUPPLEMENT|Plant sterols|Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
41466184|NCT00877617|BEHAVIORAL|QOL Questionnaire|Mailed survey.
41466185|NCT01961258|OTHER|Computerized data base analysis and sampling of patients for outpatient clinic evaluation|
40785929|NCT02603276|DIETARY_SUPPLEMENT|Red Yeast Rice|Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
40785930|NCT02603276|DIETARY_SUPPLEMENT|Red Yeast Rice plus Plant sterols|Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
40785931|NCT02552576|BIOLOGICAL|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
40785932|NCT02249403|DRUG|Talsaclidine 6 mg|
40785933|NCT02249403|DRUG|Talsaclidine 12 mg|
40785934|NCT02249403|DRUG|Talsaclidine 24 mg|
40785935|NCT02249403|DRUG|Talsaclidine 36 mg|
40785936|NCT02249403|DRUG|Placebo|
40785937|NCT03281629|DEVICE|Active TMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
40785938|NCT03281629|DEVICE|Sham TMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
40785939|NCT02619838|DEVICE|Aptus CCS 5.0 or/and 7.0 screws|Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
41466186|NCT02154802|BEHAVIORAL|video: community member|
40785940|NCT01595477|BEHAVIORAL|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
40785941|NCT03733938|OTHER|endodontic microsurgery|teeth with failed root canal treatment will be treated by endodontic microsurgery
40990216|NCT03935373|DIAGNOSTIC_TEST|Schirmer's test|Sjögren's syndrome patients will take the Schirmer's test.
40990217|NCT03935373|DIAGNOSTIC_TEST|Blood function test, liver function test, kidney function test, and immune function test|Sjögren's syndrome patients and health subjects will take the blood function test (WBC, RBC, Hb, HCT, Platelet, MCV, MCH, and MCHC), liver function test (AST and ALT), kidney function test (BUN and Cre), and immune function test (RF, Anti-SSA, Anti-SSB Ab, ESR, and CRP)
40990218|NCT04357015|DRUG|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
40785942|NCT04940130|BIOLOGICAL|Sanaria® PfSPZ Vaccine|non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).
40785943|NCT04940130|OTHER|Normal Saline|placebo control- saline
40785944|NCT03496168|DRUG|mavacamten|mavacamten capsules
40785945|NCT01639469|BEHAVIORAL|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
40785946|NCT01639469|BEHAVIORAL|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
40785947|NCT06391892|PROCEDURE|Neoadjuvant chemotherapy instead of upfront surgery|"All patients included into the study are recommended to go for upfront surgery (CT and CA19-9) by tumor board.~If preoperative ctDNA is positive, the investigators assume high risk for early recurrence (because of systemic tumor burden) and apply neoadjuvant chemotherapy at physicians choice instead.~* Apart from blood collection (within the scope of clinical routine), there is no additional diagnostic intervention performed on the patient.~* The respective neoadjuvant chemotherapeutical drug will be selected and applied by the treating medical oncologist at physicians choice (unaffected by study participation), usually mFOLFIRINOX or Gemcitabine/nabPaclitaxel at standardized dosage recommended by NCCN and local guidelines.~FOLFIRONOX: Folinic acid (also known as leucovorin), F - Fluorouracil (5-FU), IRIN - Irinotecan, OX - Oxaliplatin."
40785948|NCT06391892|PROCEDURE|Upfront surgery|Standard of care as recommended by tumor board (not affected by study conditions).
40785949|NCT00506038|PROCEDURE|fine needle technique|
40785950|NCT05365100|DRUG|BN102|oral tablets: BN102, BID
40785951|NCT01881815|OTHER|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
40785952|NCT03402100|DRUG|eye drops|children who received daily eye drops for myopia
40785953|NCT04596683|PROCEDURE|Same-day NSM or SSM|Discharge home same-day after nipple-sparing mastectomy (NSM), or skin-sparing mastectomy (SSM)
40785954|NCT04118543|OTHER|Intervention Group|Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
40785955|NCT04118543|OTHER|Sham-Exercise Group|Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.
40785956|NCT01251302|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
40785957|NCT02351011|BIOLOGICAL|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
40990219|NCT04357015|DRUG|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
40990220|NCT04357015|DRUG|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
40990221|NCT04479956|PROCEDURE|Varicose vein surgery|sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee
40990222|NCT05982275|GENETIC|CARTemis-1|A dose escalation design will be applied in successive patient cohorts until identification of Dose Limiting Toxicity (maximum dose: 6x10\^6 CAR-T/kg divided over 2 days).
40990223|NCT02750592|DRUG|Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.|Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
40990224|NCT03406858|BIOLOGICAL|HER2Bi-Armed Activated T Cells|Given IV
40990225|NCT03406858|OTHER|Laboratory Biomarker Analysis|Correlative studies
40990226|NCT03406858|BIOLOGICAL|Pembrolizumab|Given IV
40990227|NCT06265116|OTHER|One-step universal adhesive|Each patient will receive a class II restoration using the corresponding group adhesive
41466187|NCT02154802|BEHAVIORAL|video: physician|
40785958|NCT02351011|BIOLOGICAL|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
40785959|NCT02351011|BIOLOGICAL|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
40785960|NCT05983094|DRUG|Utidelone|Utidelone injection 30mg/m2, on days 1-5 of each cycle
40785961|NCT05983094|DRUG|Carboplatin|Carboplatin Area under curve(AUC)6, iv, was administered on day 1
40785962|NCT05983094|DRUG|Epirubicin|Epirubicin 75mg/m2 was administered on day 1
40785963|NCT05983094|DRUG|Trastuzumab|Trastuzumab 8mg/kg iv in first cycle on day 1, then 6mg/kg in the rest cycles
40785964|NCT05983094|DRUG|Pertuzumab|Pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles
40785965|NCT01082614|DEVICE|Vigileo|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV \> 12%.
40785966|NCT01646814|DRUG|PL2200|PL2200, containing 325 mg aspirin active ingredient
40785967|NCT01646814|DRUG|Aspirin tablets|325 mg aspirin tablets (USP)
40785968|NCT06216158|DRUG|Iberdomide|Iberdomide p.o. (1.0 mg, day 1-21 of each 29-days cycle)
40785969|NCT06216158|DRUG|Isatuximab|Isatuximab s.c. (1400 mg, cycle 1: day 1, 8, 15, 22; cycles 2-3: day 1 and 15; from C4: day 1)
40785970|NCT06216158|DRUG|Dexamethasone|Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)
40785971|NCT04904172|DEVICE|Masimo O3 Regional Oximetry|wo electrodes will be attached to the forehead area and connected to the Near Infrared Spectroscopy device after the consent of the patients who apply to Ege University Hospital Emergency Service with acute ischemic stroke and who are planned to have intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments, and / or their caregivers.
40785972|NCT00537537|DRUG|Telbivudine|
40785973|NCT04283656|DRUG|Doravirine/Lamivudine/Tenofovir|100mg/300mg/300mg orally for one dose, daily
40785974|NCT04283656|DRUG|Spironolactone 100mg|200mg orally for two doses, twice-daily
40785975|NCT04283656|DRUG|Estradiol 2mg|4mg orally for two doses, twice-daily
40785976|NCT04283656|OTHER|Placebo|Placebo for one dose, daily
40785977|NCT01514721|DRUG|Travoprost/Timolol Maleate BAK-Free Fixed Combination|Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
40785978|NCT04507906|DRUG|Nivolumab Combined with Anlotinib|In combination dose finding phase, Phase 1b will begin with Dose Level 1; anlotinib 12 mg/day orally (from days 1 to 14 in a 21-day cycle) and nivolumab (360mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (anlotinib 10 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously) and Dose Level 3 (anlotinib 8 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously).If RP2D was reached in Part A, eligible patients would be enrolled and receive nivolumab (360mg q3w, intravenously) plus anlotinib (RP2D, QD from day 1 to 14 of a 21-day cycle) .
40785979|NCT02020590|DRUG|ALLOB® implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
40785980|NCT06127433|DRUG|Insulin Glargine|Insulin Glargine
40785981|NCT06127433|DRUG|Metformin|Metformin
40990228|NCT00939276|DRUG|Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
41466188|NCT02154802|BEHAVIORAL|video: choice of video|
40785982|NCT06127433|DRUG|Dapagliflozin|Dapagliflozin
40785983|NCT06127433|DRUG|Insulin aspart|Insulin aspart
41466189|NCT02105909|OTHER|GWAS|
40785984|NCT01081158|DRUG|Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b(PegIntron)~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
40785985|NCT01081158|DRUG|Drug: SCH 900518 Biologic: Peginterferon alfa-2b|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
40785986|NCT01081158|DRUG|Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days."
40990229|NCT00939276|DRUG|Nepafenac ophthalmic suspension vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
40990230|NCT05009940|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
40990231|NCT02722850|BEHAVIORAL|ALIVE|ALIVE is an email-based platform designed to help participants increase their physical activity, increase fruit and vegetable consumption, and decrease their intake of saturated and trans fats and added sugars. This automated system contains content and tailoring that is delivered in the form of emails obtained directly from cancer patients. Additional information they will receive included: tips for achieving those goals, health information, and opportunities for interaction and engagement.
40990232|NCT04626947|BIOLOGICAL|Bezlotoxumab|Bezlotoxumab infusion
40990233|NCT03503903|PROCEDURE|Wet Cupping|CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46), which are the recommended sites for headache (12). The cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Secondary suction and bloodletting,Removing and dressing.
40990234|NCT05070065|DEVICE|Cognitive remedy intervention with virtual reality (CEREBRUM)|Cognitive Remedial method Virtual Reality (CEREBRUM)
40990235|NCT02723968|OTHER|glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT|At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
41307541|NCT02594475|PROCEDURE|Endoscopic retrograde cholangiopancreatography|"1. Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.~2. Selective bile duct cannulation is performed using wire-guided cannulation.~3. In case of difficult cannulation, precut is performed using a needle-knife.~4. After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed."
41307542|NCT00946777|OTHER|Systane® Ultra|Systane® Ultra 1-2 drops, 4 times per day for 30 days
40990236|NCT02723968|PROCEDURE|HGPIV diagnosis test|
40990237|NCT02723968|PROCEDURE|HOMAR-IR diagnosis test|
40990238|NCT02133287|DEVICE|AVI® Arsenic trioxide drug eluting stent delivery system|
40990239|NCT02133287|DEVICE|Firebird2® sirolimus eluting stent system|
40990240|NCT02489344|DRUG|GZ/SAR402671|"Pharmaceutical form:capsule~Route of administration: oral"
40990241|NCT00918658|OTHER|biologic sample preservation procedure|All specimens will be collected using the Pathology Residual Tissue Procurement.
40990242|NCT00918658|OTHER|immunologic technique|Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
40990243|NCT00918658|OTHER|laboratory biomarker analysis|Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
40990244|NCT00696514|DIETARY_SUPPLEMENT|Vitamin B12, folic acid, Vitamin D3|500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day
40990245|NCT00696514|DIETARY_SUPPLEMENT|Placebo (Vitamin D3) - 600 IU per day|600 IU vitamin D3 in one capsule, once per day
40990246|NCT03642392|OTHER|Identification and treatment of early tendinopathy|Participants receive initial guidance about load reduction when tendinopathy
41307543|NCT03231085|DRUG|Ferrous fumarate or ferrostrane|Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
41307544|NCT01794494|PROCEDURE|Bypass surgery|Patients are treated with femoro-popliteal bypass
41307545|NCT01794494|PROCEDURE|Endovascular recanalization|Patients are treated with PTA or subintimal angioplasty
41307546|NCT04738500|PROCEDURE|PENG Block combinated with PCA|After spinal anesthesia PENG block will be performed
41146648|NCT02808676|OTHER|Exercises (E)|All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
41307547|NCT04738500|PROCEDURE|PCA|PCA will be applied after surgery
41307548|NCT05795114|BEHAVIORAL|Reach Out, Stand Strong, Essentials for New Mothers (ROSE) Program|A 5-part interpersonal therapy based intervention
41307549|NCT00389740|DRUG|MK0217, /Duration of Treatment : 12 Months|
41307550|NCT00389740|DRUG|Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months|
41307551|NCT05250271|OTHER|15 g dextrose|15 g dextrose tablets
41307552|NCT05250271|OTHER|5 g dextrose|5 g dextrose tablets
41307553|NCT05250271|OTHER|Protein bar|5 g carbohydrates + 10 g protein
41307554|NCT02738996|BEHAVIORAL|Sedentary time breaks either every 60 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min
41307555|NCT02738996|BEHAVIORAL|Sedentary time breaks either every 30 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min
41307556|NCT02738996|BEHAVIORAL|Sedentary time breaks every 15 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min
41307557|NCT06491628|BEHAVIORAL|Avoiding the risk factors|Exercise, Salt and lipid reduction in diet, smoking cessation
41307558|NCT04897555|DEVICE|LLLT|This is a low-level light (LED) device configured in the shape of a headband, operating at 650 +/-10 nanometers and 940 +/- 10 nanometers, that contains 12 of each wavelength for a total of 24 LEDs.
41307559|NCT00695591|OTHER|Evaluation for Nocturnal non invasive ventilation|Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 \>6.0 Pa; and 2) nocturnal Sa,O2 \<88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
41307560|NCT01570712|OTHER|HOUSING FIRST PROGRAM|"Realization of a psychosocial organic evaluation and a citizen;~* Support in the development and the maintenance of the housing;~* Support in the diverse steps (administrative, judicial, financiers, etc.);~* Support around addictions / alcohol;~* Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)~* to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration."
40785987|NCT01081158|DRUG|Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days."
40785988|NCT04814953|OTHER|questionnaires|EQ-5D-5L questionnaire questioning their overall health on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). In addition patients will have to fill in the generic 15D questioning 15 specific dimensions on 5 levels as well as the BaSQoL, which is a disease specific questionnaire for patients with KC. The Time-trade off task is the final question.
41307561|NCT01570712|OTHER|traditional French services|"The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said  about common law  set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\\or the restoring, but this by means of the existing devices"
41307562|NCT02084784|DRUG|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
41307563|NCT02084784|DRUG|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
41307564|NCT01869062|DEVICE|SonR CRT Optimization 'On'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
41307565|NCT01869062|DEVICE|SonR CRT Optimization 'Off'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
41307566|NCT00279552|DRUG|Recombinant human intrinsic factor|
41307567|NCT02843295|OTHER|blood samples|
41307568|NCT02233400|DRUG|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
40785989|NCT01011114|DRUG|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
41307569|NCT06008249|DRUG|Lithium Carbonate 400 MG|Lithium carbonate vs placebo (2:1)
41307570|NCT06139679|PROCEDURE|ASD closure with fenestrated/non-fenestrated patch|A PTFE patch is used to surgically close the interatrial defect. If closure with fenestrated patch is deemed necessary, a small opening is created on the patch
41307571|NCT01755494|DRUG|Saxagliptin 5 mg|Saxagliptin oral tablet 5mg, single dose
41307572|NCT01755494|DRUG|Metformin XR 500 mg|Metformin XR oral tablet 500 mg, single dose
41307573|NCT01755494|DRUG|Mertformin XR 2 x 500 mg|Metformin XR oral tablet 2 x 500 mg, single dose
41307574|NCT01755494|DRUG|Komboglyze XR 5/500 mg|oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
41307575|NCT01755494|DRUG|Komboglyze XR 5/1000 mg|oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
41307576|NCT00780169|DRUG|sorafenib + FOLFIRI|"escalating doses of sorafenib and irinotecan~* sorafenib starting dose 400 mg/day~* irinotecan starting dose 80 mg/m2 on day 1"
41466190|NCT04448496|DRUG|Dexamethasone implant|Dexamethasone 0.7mg is injected into the vitreous cavity through the pars plana using applicator for diabetic macular edema.
41466191|NCT05654870|DRUG|Valbenazine|Oral treatment
41466192|NCT05654870|DRUG|Placebo|Placebo matching valbenazine
40785990|NCT01011114|DRUG|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
41307577|NCT04591470|DIAGNOSTIC_TEST|Mar test|Study of antisperm antibodies
41466193|NCT01737541|DRUG|Fluoxetine|
41466194|NCT01737541|DRUG|Placebo|
41466195|NCT03105817|DEVICE|Asymmetric cellulose triacetate (ATA™)|Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer
41466196|NCT04283370|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
40785991|NCT05745766|OTHER|Panoramic and lateral cephalometric radiography|The 2D-based assessments of the impacted maxillary canine will be achieved using panoramic and lateral cephalometric radiographs.
40785992|NCT05745766|OTHER|Cone beam computed tomography|The 3D-based assessments of the impacted maxillary canine will be achieved using a cone beam computed tomography (CBCT) image.
40785993|NCT05745766|OTHER|Surgery|The surgical exposure will be accomplished, and the impacted maxillary canine will be assessed by a direct vision.
40785994|NCT02866812|OTHER|questionnaires assessing the state of fatigue, depression and anxiety|
40785995|NCT00654537|DRUG|Rosuvastatin|
40785996|NCT00654537|DRUG|Atorvastatin|
40785997|NCT00654537|DRUG|Pravastatin|
40785998|NCT00654537|DRUG|Simvastatin|
40785999|NCT00467376|DRUG|Insulin Glulisine|3 times a day before each meal
41307578|NCT02509598|DRUG|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
41307579|NCT02509598|DRUG|Vital Blue Dye (optional)|A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
41307580|NCT02509598|PROCEDURE|Lymph Node Mapping|Intraoperative lymph node mapping will occur 15 minutes to 8 hours after Tc99m tilmanocept injection
41307581|NCT02893774|OTHER|quality of life assessment|"All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.~Those assessment will use standardized quality of life questionnaire :~* QLQ-C30~* SWLS (Satisfaction with Life Scale)~* PTGI (Post-Traumatic Growth Inventory)~* HADS (Hospital Anxiety and Depression Scale)~* Brief COPE~* MHLCS (Multidimensional Health Locus of Control Scale)"
41307582|NCT02491437|DRUG|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
41307583|NCT02491437|DRUG|intravaginal progesterone gel 90 mg|
40786000|NCT00467376|DRUG|Lispro|3 times a day before each meal
40786001|NCT00467376|DRUG|Insulin Glargine|once daily
41466197|NCT04283370|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
40786002|NCT03048773|DEVICE|shockwave therapy|Intervention with shockwave therapy
40786003|NCT03048773|OTHER|PT|Physical therapy 3 times per week for 3 weeks
40786004|NCT03048773|OTHER|placebo|sham shockwave therapy
40786005|NCT01659450|OTHER|low energy dense|This group received a diet appropriate with their weight in the form of low energy density diet
41466198|NCT05409521|OTHER|Kinesio taping|Kinesio taping with the mechanical correction technique will be applied on the thoracic region
41466199|NCT05409521|OTHER|Placebo taping|Placebo taping with no tension and technique will be applied on the arm
41466200|NCT02371837|OTHER|Pilates and fall prevention|A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
41466201|NCT03553563|DRUG|D961H capsule 10mg|All Groups can select either capsule or sachet during the study.
41466202|NCT03553563|DRUG|D961H sachet 10mg|All Groups can select either capsule or sachet during the study.
41466203|NCT05996406|DRUG|Venetoclax|Venetoclax 400mg po qd for 1 year
41466204|NCT05996406|DRUG|Dexamethasone Oral|Dexamethasone 40mg po qw for the first 6 months, then 10mg po qw for the next 6 months
41466205|NCT00004241|DRUG|tanespimycin|Given IV
41466206|NCT00004241|OTHER|pharmacological study|Correlative studies
41466207|NCT04252287|DRUG|Canagliflozin 100 mg|Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.
41466208|NCT04252287|DRUG|Placebo|Participants will receive matching placebo capsules orally once daily.
41466209|NCT03225014|DEVICE|Accelerated Recovery Performance Wave Therapy|ARP Wave therapy utilizes direct current compounded with a high frequency double exponential background waveform that creates an electromyostimulation with characteristics that contrast with more conventional therapeutic neuromuscular electrical stimulation, including: interferential, microcurrent, galvanic, Russian stimulation, and iontophoresis. ARPWave therapy is a class II FDA medical device that has been approved for muscle re-education, relaxation of muscle spasms, increased neovascularization, prevention of disuse atrophy, and maintaining/increasing joint range of motion. The ARPWave Rx100 uses a main electrostimulation pulse of 40 to 500 cycles per second that is coupled with a background high-frequency carrier signal at 10,000 cycles per second. The polarity direction of electron flow is reversible within the unit and this is utilized as part of the therapy.
40786006|NCT01659450|OTHER|control|This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.
40786007|NCT01659450|OTHER|diet|Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
40786008|NCT04087356|GENETIC|Blood draw|Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.
40786009|NCT04668599|OTHER|Cardiopulmonary rehabilitation|Patients will undergo standardized cardio-pulmonary rehabilitation program.
40786010|NCT02784392|DRUG|Ulimorelin|Active
40786011|NCT02784392|DRUG|Metoclopramide|Comparator
40786012|NCT02668341|OTHER|non-interventional|non-interventional survey study
41466210|NCT03225014|DIAGNOSTIC_TEST|Physical therapy|PT protocol for traumatic knee pain focuses on flexibility and development of hip core strength over a 6 week period, visiting the therapist twice per week and encouraged to maintain a home exercise program (HEP). They will all receive a handout with basic exercises to use at home to ensure that progress with their HEP is maximized (Appendix I). Basic stretches for the hamstring and quadriceps muscles will also be provided with line drawings. During this treatment period the patients will complete a daily diary of time spent on the HEP with attestation from their parents or guardians, in order to improve compliance.
41466211|NCT02958930|DEVICE|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
41466212|NCT06277050|DRUG|Maintenance Therapy with Toripalimab and Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.
41466213|NCT06277050|DRUG|Maintenance Therapy with Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.
41466214|NCT00004344|DRUG|leuprolide|
40786013|NCT04118829|DRUG|Perampanel|"For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day."
40786014|NCT00891150|DRUG|Oxytocin|"Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min)."
40786015|NCT01474304|DRUG|Acetaminophen|1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
40786016|NCT04187261|PROCEDURE|hip fracture surgeries|fixation or replacement
40786017|NCT01276106|DRUG|AC-201, 25mg|Capsule, 25mg BID
40786018|NCT01276106|DRUG|AC-201, 50mg|Capsule, 50mg BID
40786019|NCT01276106|DRUG|AC-201, 75mg|Capsule, 75mg BID
40786020|NCT01276106|DRUG|Placebo|Placebo BID
40786021|NCT03030898|DIAGNOSTIC_TEST|respiratory variation of the right internal jugular vein|respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
40786022|NCT06422143|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
40786023|NCT06422143|BIOLOGICAL|sac-TMT|IV infusion
40786024|NCT00638729|DRUG|midazolam|midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
40786025|NCT00638729|DRUG|clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
40786026|NCT00638729|DRUG|placebo|inert tablet p.o., 60-90 min prior to estimated induction time
40786027|NCT02343770|OTHER|blood sample for identifying biomarkers|
40786028|NCT00689806|DRUG|Lovastatin|Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not \> 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
40786029|NCT00689806|DRUG|Placebo|Placebo by mouth once daily for weeks 1-4.
40786030|NCT02838043|DIETARY_SUPPLEMENT|Probio'Stick|A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
41466215|NCT00004344|DRUG|testosterone|
41466216|NCT01563458|DRUG|activated recombinant human factor VII|120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
40786031|NCT05321329|DRUG|Capecitabine|Capecitabine is a deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.Capecitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of capecitabine is as a Nucleic Acid Synthesis Inhibitor.
41466217|NCT01563458|DRUG|activated recombinant human factor VII|60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
41466218|NCT01563458|DRUG|placebo|Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
40786032|NCT00272220|BEHAVIORAL|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
40786033|NCT03278548|DRUG|Volulyte 6%|Solution for infusion
40786034|NCT03278548|DRUG|Ionolyte|Solution for infusion
41466219|NCT03823287|DRUG|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
41466220|NCT03823287|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
40786035|NCT03605693|BEHAVIORAL|Written Exposure Therapy|Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
41466221|NCT03823287|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
41466222|NCT00754494|DRUG|erlotinib hydrochloride|Given PO
40786036|NCT04834726|BEHAVIORAL|Opt-In (Call-Back)|Messaging will include a prompt to agree to scheduling. If patient agrees, the access center will call these patients back to schedule, calling up to 3 times.
40786037|NCT04834726|BEHAVIORAL|Opt-in (In-Bound)|Messaging will include a prompt to agree to scheduling followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
40786038|NCT04834726|BEHAVIORAL|Standard Message|The message describes that the patient is eligible for the COVID vaccine.
40786039|NCT04834726|BEHAVIORAL|Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination.
40786040|NCT04834726|BEHAVIORAL|Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine.
40786041|NCT04834726|BEHAVIORAL|Opt-Out Framing|This will highlight that a vaccine is reserved for the patient, implying that they need to opt-out.
40786042|NCT04834726|BEHAVIORAL|Phone Call|The access center will call these patients to schedule their vaccine appointment. These patients will not receive text messaging.
41466223|NCT00754494|OTHER|placebo|Given PO
40786043|NCT01312519|DEVICE|OnControl Bone Marrow Biopsy and Aspiration System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
40786044|NCT01312519|DEVICE|Manual bone marrow sampling device|Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
40990247|NCT05972499|OTHER|task-oriented training with pretend play|"Pretend play: Children engage in pretend play by acting out themes, taking on roles, assigning attributes to inanimate objects, and using objects as if they were something else Props will be added to hold the child interest. Role play costumes, or occupation props (police officer's suit), stimulate pretending elements.~Task-oriented training: It is involving the active, repetitive practice of functional activities to learn or relearn a motor skill. Training implies that the behavioral experiences are not just repetition of the same sensorimotor skill but involves progressive challenges to a participant's capabilities and involves tasks that are meaningful to the participant. It is based on the following principles: functional goal-directed training focus on practicing specific activities of importance to the child during daily activities; planning activity-focused interventions by adapting knowledge of motor learning ; and allowing for the interest and participation of the children."
41466224|NCT00754494|OTHER|laboratory biomarker analysis|Correlative studies
41466225|NCT00785681|DRUG|Dermacyd PH_DETINBACK (Lactic Acid)|
41466226|NCT00792584|DRUG|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
41466227|NCT00792584|DRUG|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
41466228|NCT00025740|DRUG|clonazepam and paroxetine|
41466229|NCT01919541|OTHER|Prehabilitation|All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
41466230|NCT01919541|DEVICE|hyperinsulinemic euglycemic isoaminoacid clamp|A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
41466231|NCT01919541|DEVICE|hyperinsulinemic euglycemic hyperaminoacid clamp|
41466232|NCT01919541|DIETARY_SUPPLEMENT|whey protein supplementation|
41466233|NCT01919541|OTHER|Prehabilitation|All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
41466234|NCT00466843|DRUG|Antithymocyte globulin (ATG)|ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.
41466235|NCT00466843|DRUG|Prednisone|All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
41466236|NCT06123260|DIAGNOSTIC_TEST|renal function tests|BUN, eGFR , CBC , Electrolytes , Liver function tests
41466237|NCT02968719|DRUG|Donepezil TDS Version A|Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)
41466238|NCT02968719|DRUG|Donepezil TDS Version B|Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)
40786045|NCT01830348|DRUG|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
40786046|NCT01830348|DRUG|placebo vehicle gel|
41307584|NCT06129318|BEHAVIORAL|Clinical Pharmacist Led Pharmaceutical Care|Within the scope of pharmaceutical care, medication review services for past and current medication use were provided by the clinical pharmacist. The patients in the intervention group were given verbal information about the definition of stroke, symptoms, how to manage risk factors, and their medications by the clinical pharmacist on the day of discharge, in addition to the neurologist. Each patient in the intervention group had a scheduled meeting with the clinical pharmacist. During the 1-year follow-up the patient education given by the clinical pharmacist was repeated every 3 months.
40786047|NCT04344730|DRUG|Dexamethasone injection|Box of 10 DEXAMETHASONE 20 mg / 5 ml, solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
40786048|NCT04344730|DRUG|placebo|Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
40786049|NCT04344730|PROCEDURE|conventional oxygen|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
40786050|NCT04344730|PROCEDURE|CPAP|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment.The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
40786051|NCT04344730|PROCEDURE|HFNO|TIn the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier (Airvo-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 30 liters per minute and adjusted based on the clinical response. FiO2 will be adjusted for the target SpO2
40786052|NCT04344730|PROCEDURE|mechanical ventilation|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
40786053|NCT00412581|DRUG|Lenalidomide|25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
40786054|NCT00412581|DRUG|Dacarbazine|600 mg/m\^2 intravenously on Day 1 of every study cycle.
40786055|NCT06353386|DRUG|Opevesostat|Oral Tablet
40786056|NCT06353386|DRUG|Olaparib|Oral Tablet
40786057|NCT06353386|DRUG|Docetaxel|IV Infusion
40786058|NCT06353386|DRUG|Cabazitaxel|IV Infusion
40786059|NCT06353386|DRUG|Fludrocortisone acetate|Oral Tablet
40786060|NCT06353386|DRUG|Dexamethasone|Oral Tablet
40786061|NCT06353386|DRUG|Prednisone|Oral Tablet
41307585|NCT02860637|OTHER|Questionnaires|Sexual function was assessed by the International Index of Erectile Function (IIEF) and level and degree of injury were determined following the guidelines of the International Standards for Neurological and Functional Examination Classification of Spinal Cord Injury.
41466239|NCT02968719|DRUG|Aricept|Aricept (5 mg and 10 mg) Donepezil Hydrochloride
41466240|NCT02968719|DRUG|Donepezil TDS Version D|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
41466241|NCT02968719|DRUG|Donepezil TDS Version E|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)
41466242|NCT01785394|DRUG|5 grass allergen extract|30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
41466243|NCT03939949|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their current pain intensity and unpleasantness in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their pain throughout the day and asked to report on how their pain is changing over time as a part of each text message prompt."
40786062|NCT02328521|DRUG|Nicorandil|Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
40786063|NCT02328521|DRUG|nicorandil placebo|Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
40786064|NCT04377503|DRUG|Tocilizumab 180 MG/ML|Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.
40786065|NCT04377503|DRUG|Methylprednisolone Sodium Succinate|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use
40786066|NCT02941614|BEHAVIORAL|Distress screening|A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
40786067|NCT02046018|OTHER|ICCM delivered by VHT|VHT's deliver ICCM to children under five in their communities
40786068|NCT02046018|OTHER|ICCM delivered by VHT with Cell Phone|ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
40786069|NCT02046018|OTHER|No intervention|VHT's selected by no ICCM training given and no drugs or cell phones.
40786070|NCT03246607|DEVICE|MicroEye & ContinuMon|Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.
40786071|NCT06033287|DRUG|Different treatment regimens following progression on CDK4/6 inhibitors.|This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be evaluated.
40786072|NCT02870465|PROCEDURE|Closed Reduction Internal Fixation|K-wires placed percutaneously through the skin to achieve fixation of a hand after reduction of the fracture in a closed manner.
40786073|NCT00029250|DRUG|Garlic powder standardized to allicin|
40786074|NCT05613907|OTHER|CLTI Clinic|This is a specialist clinic designed to assess and manage patients with CLTI.
40786075|NCT05035043|OTHER|Determination of the economic burden NAFLD patients|Determination of the economic burden NAFLD patients (Healthcare costs, patient costs, burden of disease
40786076|NCT02558101|BEHAVIORAL|Control invitation materials|"In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:~1. a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes~2. an invitation letter with a pre-scheduled appointment plus the same information booklet~3. a reminder re-invitation letter for those who miss their appointment without cancelling"
40786077|NCT02558101|BEHAVIORAL|Intervention invitation materials|The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
40786078|NCT02022709|DRUG|Fluoxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
40786079|NCT02022709|DRUG|Sertraline|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
40786080|NCT02022709|DRUG|Paroxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
40786081|NCT02022709|DRUG|Citalopram|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
40786082|NCT02022709|DRUG|Fluvoxamine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
40786083|NCT02022709|BEHAVIORAL|Exposure and Response Prevention|8 exposure and response prevention (ERP) sessions,once a week
40786084|NCT04704024|DRUG|Tenofovir Disoproxil Fumarate|oral TDF medication 300 mg daily
40786085|NCT04704024|DRUG|Lamivudine Oral Solution|Oral lamivudine with weight-based dosing BID from birth until 6 months of age
40786086|NCT00526539|OTHER|Total hip replacement, Spectron and Taperloc|
40786087|NCT00143559|DRUG|Systematic chemotherapy and antibodies|"Systemic chemotherapy and antibodies as follows:~Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD"
40786088|NCT00143559|PROCEDURE|Allogeneic stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
40786089|NCT00143559|DEVICE|Miltenyi CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
40786090|NCT04473001|OTHER|Continuous vital signs and glucose monitoring|"The patients will have the following parameters and vital signs continuously monitored using wireless equipment:~* Glucose measurements (quasi-continuous, every 5 minutes)~* Heart rate~* Heart rhythm (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Signs of cardiac ischemia (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Respiration rate~* Oxygen saturation of arterial hemoglobin (%SpO2)~* Perfusion index (ratio of the pulsatile blood flow to the non-pulsatile or static blood in peripheral tissue)~* Blood pressure (quasi-continuous; every 30-60 minutes)~* Skin temperature~* Electrodermal activity~* Ambulatory activity (accelerometry)"
40990248|NCT05127889|DRUG|curodont|"* To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~* The varnish will be mixed with the brush to avoid separation of the material during storage~* However, to guarantee the best results suction will be used during application of the varnish.~* A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~* The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~* After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs."
41307586|NCT01035242|BEHAVIORAL|"association splitting"|"Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened."
41307587|NCT01035242|BEHAVIORAL|cognitive remediation|Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
41307588|NCT00088582|DRUG|Pasireotide (SOM230), Octreotide (Sandostatin)|
41307589|NCT00002887|DRUG|cisplatin|
41307590|NCT00002887|DRUG|etoposide|
41307591|NCT00002887|DRUG|hydroxyurea|
41307592|NCT00002887|DRUG|vinblastine sulfate|
41307593|NCT00002887|DRUG|vindesine|
41307594|NCT00002887|DRUG|vinorelbine tartrate|
41307595|NCT00002887|PROCEDURE|drug resistance inhibition treatment|
41307596|NCT01822691|DRUG|INCB024360|INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
41307597|NCT04601142|DRUG|Methylprednisolone|methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
41307598|NCT00734786|OTHER|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
41307599|NCT05445011|DRUG|Fludarabine + Cyclophosphamide + TAA05 Cell Injection|Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.
40786091|NCT02566811|PROCEDURE|Abdominal surgery|Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
40786092|NCT02566811|PROCEDURE|Lymphadenectomy|Bilateral pelvic and para-aortic lymph node dissection
40786093|NCT00852410|DRUG|1% lidocaine with 1:100,000 adrenaline|high dose
40786094|NCT00852410|DRUG|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
40786095|NCT01365793|DRUG|0.45% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
40786096|NCT01365793|DRUG|0.9% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
40786097|NCT01365793|DRUG|0.45% saline intravenous fluid|0.45% saline fluid
40786098|NCT01365793|DRUG|0.9% saline Intravenous fluid|0.9% saline fluid
40786099|NCT06292767|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
40786100|NCT03440073|OTHER|Mulligan Concept Intervention|The concept is a manual therapy paradigm that includes a clinician applying joint mobilizations and having the patient perform concurrent active, pain free, movement.
40786101|NCT03440073|OTHER|Sham Mulligan Concept Treatment|The treating clinician will ask the participant to perform the movements associated with the Mulligan Concept technique. The clinician will have her hands on the participant during the movement but will not apply any pressure or force.
40786102|NCT05783895|DIAGNOSTIC_TEST|Post screening diagnostic test|1) anti-PF4/heparin antibody test (ELISA) and 2) in vitro platelet aggregation tests. The diagnosis of HIT is made when both tests are positive or when a platelet aggregation test is positive.
40786103|NCT03675113|OTHER|Upper extremity aerobic exercise|"Range of maximal heart rate will be followed by a polar band during supervised session each week.~Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
40786104|NCT03675113|OTHER|Control Group|Deep breathing exercises combinated with arm movements
40786105|NCT03978039|DRUG|Chemotherapy|treatment as per standard of care
40786106|NCT03978039|DRUG|Immunotherapeutic Agent|treatment as per standard of care
41146649|NCT02808676|OTHER|Cognitive Training (CT)|CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
41307600|NCT01003080|DEVICE|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
41307601|NCT01003080|OTHER|Standard of care treatment for hemostasis during a total knee arthroplasty.|"The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device."
41307602|NCT02368340|OTHER|Pulmonary function test|Pulmonary function testing performed
41307603|NCT02368340|OTHER|Chest CT|Chest CT scan to evaluate for pulmonary fibrosis
41307604|NCT02368340|OTHER|Sample collection|Blood and urine sample collections
40786107|NCT03978039|DRUG|target treatment|treatment as per standard of care
40786108|NCT03978039|PROCEDURE|Surgery|treatment as per standard of care
41307605|NCT04043338|DRUG|XC130-A10H|XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets
40786109|NCT03978039|RADIATION|Radiotherapy|treatment as per standard of care
40786110|NCT01507701|DRUG|Clonidine|50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
40786111|NCT03387215|DRUG|ITI-214|Oral
40786112|NCT03387215|OTHER|Placebo|Oral
40786113|NCT02151656|DRUG|F17464|
40786114|NCT02151656|DRUG|Placebo|
40786115|NCT01205503|DRUG|Mesna|Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
40786116|NCT01205503|DRUG|Saline|Saline (used as a placebo) infused over the same time as mesna intervention
40786117|NCT01205503|DRUG|Doxorubicin|60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
40786118|NCT01205503|DRUG|Cyclophosphamide|600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
40786119|NCT06393803|DRUG|2mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
40786120|NCT06393803|DRUG|5mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
40786121|NCT06393803|DRUG|10mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
40786122|NCT06393803|DRUG|20mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
40786123|NCT06393803|DRUG|30mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
40786124|NCT06393803|DRUG|40mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
41146650|NCT02808676|OTHER|placebo D3|matching placebo for Vitamin D3
41307606|NCT04043338|DRUG|Placebo|Placebo supplied as matching capsules or tablets
41307607|NCT03523221|DRUG|Dexamethasone Oral|use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
41307608|NCT00065741|DRUG|silymarin|
41307609|NCT02813798|DRUG|Rivipansel|A single 840mg dose of Rivipansel over 20 minutes
41307610|NCT03506399|DRUG|Lanabecestat|Administered orally
41307611|NCT03506399|DRUG|Oral Contraceptive|Administered orally
41307612|NCT05877196|BEHAVIORAL|Moderate Intensity Continuous Training (MICT)|Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
40786125|NCT06393803|DRUG|50mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
40786126|NCT06393803|DRUG|60mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
40786127|NCT00710983|BIOLOGICAL|Oral polio vaccine|
40786128|NCT04764240|PROCEDURE|R0 resection with lymphadenectomy|Patients received a surgical R0 resection; patients who received an R1 or R2 resection were excluded.
40786129|NCT02194790|BEHAVIORAL|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
40786130|NCT01537315|DRUG|Hydroxychloroquine|200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
40786131|NCT01537315|OTHER|Matching Placebo|matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
40786132|NCT02848092|BEHAVIORAL|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
40786133|NCT02848092|OTHER|Rules of The road|Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
40786134|NCT02575144|DRUG|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle
40786135|NCT02575144|DRUG|Lenalidomide|25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of \>60 cc/min
40786136|NCT02575144|DRUG|Dexamethasone|40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
40786137|NCT03853967|OTHER|Low dose CT scan|low dose CT scan
40786138|NCT04046640|DEVICE|Infrared thermal imaging|"Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a NEC InfRec R450 infrared thermal imaging camera~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
40786139|NCT01252589|OTHER|HRQOL questionnaire|
41466244|NCT03939949|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 9pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9pm text to report on their pain intensity and unpleasantness at that time."
40786140|NCT02142088|DEVICE|GlySure Intravascular Continuous glucose monitoring sensor|Comparator device is an iSTAT device from Abbott Diagnostics
40786141|NCT01742884|OTHER|Thealoz|Instillation of 1 drop of Thealoz
41146651|NCT02808676|OTHER|control cognitive training|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
41466245|NCT03939949|BEHAVIORAL|Active Control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 9pm) asking them to report on the activity they are currently engaged in."
41466246|NCT00862537|DEVICE|Resonator Device|active pico-tesla magnetic fields treatment for Parkinson's disease individuals
41466247|NCT02001051|PROCEDURE|Adrenalectomy|Surgery to remove tumor when enrolled in the protocol.
40786142|NCT01742884|OTHER|Vehicle|1 drop of the vehicle will be instillated in the eye
40786143|NCT04405440|BEHAVIORAL|Behavioral avoidance task|Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times
40786144|NCT03826043|DIAGNOSTIC_TEST|Blood sample analysis|Thrombophilia, blood count and coagulation count
40786145|NCT02908581|DRUG|Placebo|Administered orally once daily
41146652|NCT02808676|OTHER|Placebo exercise|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
41307613|NCT05877196|BEHAVIORAL|Chair-based Stretch|Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
41466248|NCT02001051|OTHER|Observation|Observation for 6 months prior to surgery
41466249|NCT03437057|OTHER|acetylsalicylic acid (below or equal to) 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
40786146|NCT02908581|DRUG|Iron 150 mg and Folic acid 0.5 mg|Iron will be administered with folic acid orally
40786147|NCT01425476|DRUG|Celecoxib|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
41146653|NCT02201992|OTHER|Clinical Observation|Undergo observation
41146654|NCT02201992|DRUG|Crizotinib|Given PO
41146655|NCT02201992|OTHER|Laboratory Biomarker Analysis|Correlative studies
41146656|NCT05018065|BEHAVIORAL|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)|sexual dysfunction assesment
41146657|NCT00557518|DRUG|Alagebrium|200 mg bid
41146658|NCT00557518|DRUG|Placebo|bid
41146659|NCT00375323|DRUG|NovoSeven|
41466250|NCT06093204|OTHER|Dietary evaluation|Comparative evaluation of the dietary consumption of ultraprocessed foods and ultraprocessed foods-derived compounds
40786148|NCT01425476|DRUG|Placebo|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
40786149|NCT01425476|DRUG|Cholecalciferol|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
40786150|NCT05149820|OTHER|Electronic Point of Care Randomisation tool|Two designs of electronic point of care randomisation tool will be evaluated.
41466251|NCT01625507|BEHAVIORAL|PANDA intervention|Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
40786151|NCT05149820|DRUG|Magnesium|Liberal Strategy: magnesium supplementation at serum level \< 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level \< 1.0 mmol/L
40786152|NCT00363571|DRUG|GTN, Diamox|
40786153|NCT06093399|DEVICE|System ON|The DBS system will be turned on, and the individual's stutter will be assessed.
40786154|NCT06093399|DEVICE|System OFF|The DBS system will be turned off, and the individual's stutter will be assessed.
40786155|NCT03593174|DEVICE|Ossur Rigid Dressing|Removable Rigid Dressing
40786156|NCT03593174|DEVICE|Elastic Bandage|Usual modality: Elastic bandage
40786157|NCT05784818|BEHAVIORAL|Up To Me Intervention + No Booster|Participants will complete two-hour sessions once a week over three weeks in which they complete modules in the Up To Me Workbook. These sessions are facilitated by a peer facilitator and a member of the USF Counseling center. Other members in the group sessions are university students who are peers who are also experiencing some form of shame around their mental health challenges.
40786158|NCT05784818|BEHAVIORAL|Up To Me Intervention + Booster|In addition to the Up To Me Intervention, participants also complete a booster/additional session where additional topics of the Up To Me workbook are covered. This additional session occurs four weeks after the completion of the third session.
40786159|NCT06453031|PROCEDURE|Gastric Ischemic Preconditioning Before Esophagectomy|Does embolization of the left gastric artery prior oesophagectomy reduce postoperative complications, particularly anastomotic leaks and ischemia of the gastric conduit?
40786160|NCT00421512|DRUG|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
40786161|NCT02996422|BEHAVIORAL|School-based water campaign|Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
40786162|NCT02996422|BEHAVIORAL|Community cooking classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
40786163|NCT02717650|OTHER|A-STEP|"Study A) Study A) Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).~Feasibility/safety of a newly designed, incremental, maximal, standardised step test in adults with Cystic Fibrosis."
40786164|NCT02717650|OTHER|A-STEP (New Protocol)|Study B) Validation Study (random allocation of test order). Validity of an incremental, maximal, standardised incremental step test with breath-by-breath gas analysis using portable metabolic measurement equipment against CPET.
40786165|NCT02717650|OTHER|Comparator: CPET cycle ergometer (Gold Standard)|"Study B) Validation study (random allocation of test order) Gold standard CPET. An incremental, maximal standardised cycle ergometer exercise test (performed as per published protocol) using portable metabolic measurement equipment."
40786166|NCT03119168|DRUG|Simethicone Solution|Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
40786167|NCT03119168|OTHER|Polyethylenglycol|Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
40786168|NCT02381964|DIETARY_SUPPLEMENT|Supradyn® (1RDA+CoQ10)|
40786169|NCT02381964|DIETARY_SUPPLEMENT|Supradyn® (3RDA)|
40786170|NCT02381964|DIETARY_SUPPLEMENT|Placebo|
40786171|NCT00670566|DRUG|irbesartan/hydrochlorothiazide|50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
40786172|NCT03180229|DRUG|Granisetron 1 Mg/mL Intravenous Solution|1 milligram (mg) will use on group Granisetron before 5 min induction
40786173|NCT02157428|DRUG|Flumazenil|
40786174|NCT02157428|DRUG|saline|
40990249|NCT00590447|DRUG|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
41307614|NCT05877196|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
41466252|NCT01841073|DIETARY_SUPPLEMENT|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
41466253|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
41466254|NCT01841073|DIETARY_SUPPLEMENT|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
41466255|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
41466256|NCT01841073|DIETARY_SUPPLEMENT|Inulin|"Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
40786175|NCT04168931|DRUG|Trastuzumab|The first-line standard treatment for gastric cancer is based on fluoropyrimidine and platinum-containing chemotherapy (FOLFOX). When the tumor expresses HER2 3+ on IHC or 2+ and is confirmed by FISH, trastuzumab at the standard dose of 8 mg / kg in D1 of the first cycle is added, followed by 6 mg / kg every 2 weeks for the remaining cycles until disease progression, unacceptable toxicity. (3) We will use the same doses of trastuzumab, but HER2 positivity is determined by immunocytochemical expression and FISH in CTCs for patients with negative expression in tissue biopsy.
40786176|NCT03289143|DRUG|Semorinemab|Participants will receive Semorinemab intravenously (IV).
40786177|NCT03289143|DRUG|Placebo|Matching placebo doses of Semorinemab given intravenously (IV).
40990250|NCT00590447|DRUG|sequential R-CHOP|"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
40990251|NCT03627819|DIETARY_SUPPLEMENT|Plant sterol-enriched margarine|Margarine enriched with plant sterol esters
40990252|NCT03627819|DIETARY_SUPPLEMENT|Plant stanol-enriched margarine|Margarine enriched with plant stanol esters
40990253|NCT03627819|DIETARY_SUPPLEMENT|Control margarine|Margarine without any addition
40990254|NCT04176276|OTHER|no interventions required.|The study does not require any interventions.
40990255|NCT06029634|DIAGNOSTIC_TEST|T-bet B cell|The frequency, function, and phenotype of T-bet B cells was tested
41307615|NCT05877196|BEHAVIORAL|Combined Aerobic Resistance Exercise (CARE)|6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
40786178|NCT03289143|DRUG|[18F]GTP1|\[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
40990256|NCT04076774|DEVICE|Wondaleaf Female Condom|Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
40990257|NCT04076774|DEVICE|FC2 Female Condom|FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
40990258|NCT02045576|DEVICE|sleep position trainer|
40990259|NCT02045576|DEVICE|Oral Appliance Therapy|
40990260|NCT05762900|RADIATION|Ultra-fractionated radiation therapy|5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.
40990261|NCT03160742|DEVICE|Mespere VENUS 200CVP system|Non-invasive sensor placed on the neck
41466257|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|"Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
41466258|NCT00130234|DRUG|Xolair® (Omalizumab)|
40786192|NCT00705705|BEHAVIORAL|Network leader training|Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
40786193|NCT00705705|BEHAVIORAL|Standard HIV risk-reduction counseling|Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
40786194|NCT02795494|BEHAVIORAL|WOMAC questionnaire at baseline|Patient-reported pain, stiffness and physical function outcome score
40786195|NCT02795494|BEHAVIORAL|ASK-P questionnaire at baseline|Patient-reported activity level score
40786196|NCT02795494|BEHAVIORAL|WOMAC questionnaire at 2 weeks|Patient-reported pain, stiffness and physical function outcome score
40786197|NCT01266889|DEVICE|device:INVOS 5100|Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
40786198|NCT04892186|DRUG|Myo-inositol|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used myo-inositol 2g + folic acid 200mcg twice daily for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
41466259|NCT01134341|DRUG|Pralatrexate Injection|"Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~10 or 15 mg/m2, depending on cohort assignment.~Dose reductions allowed for protocol-specified criteria.~Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met."
41466260|NCT01134341|DRUG|Bexarotene Capsules|"150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.~Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.~Administered daily until criteria for study treatment discontinuation per the protocol are met."
41466261|NCT01134341|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
40990262|NCT01625455|DRUG|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
40990263|NCT01625455|DRUG|Placebo|Placebo will be given orally for a total of 7 days.
40990264|NCT05930210|DRUG|ENERGI-F703 GEL|Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
40990265|NCT05930210|DRUG|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
40990266|NCT00496093|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
40990267|NCT01985581|DRUG|Guanfacine extended release|
40990268|NCT01985581|DRUG|Placebo|
40990269|NCT01985581|DRUG|Stimulant therapy|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
40990270|NCT02392962|PROCEDURE|Static Stretching|To analyze the immediate effects of static stretching on performance of sprinters
40990271|NCT02392962|PROCEDURE|Dynamic Stretching|To analyze the immediate effects of dynamic stretching on performance of sprinters
40786199|NCT04892186|DRUG|Metformin|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used metformin 850 mg twice a day for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
40786200|NCT04933500|DEVICE|Whitacre spinal needle|25G Whitacre spinal needle
41307616|NCT05299814|BEHAVIORAL|Behavioral Parenting Intervention|8 session evidence based parenting intervention
41307617|NCT03219749|BEHAVIORAL|exercise training|Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
41307618|NCT00624572|DRUG|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
41307619|NCT03196271|DIETARY_SUPPLEMENT|Ketocal 2.5:1|A ketogenic feed for the dietary management of intractable epilepsy is given over a period of four weeks, after a control period of 4 weeks. The amount of the feed given is determined by the Dietitian and/or Doctor responsible for the patient's care (at least one carton per day).
41307620|NCT04398849|BIOLOGICAL|Licenced 4CMenB Vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds
41307621|NCT04078672|PROCEDURE|NOTAL-OCT V3.0|AMD and DR patients
41307622|NCT01344837|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
41307623|NCT01344837|OTHER|Immunohistochemistry Staining Method|Correlative studies
41307624|NCT01344837|OTHER|Medical Chart Review|Correlative studies
41307625|NCT01344837|GENETIC|Microarray Analysis|Correlative studies
41307626|NCT01344837|OTHER|Study of Socioeconomic and Demographic Variables|Correlative studies
41307627|NCT01344837|GENETIC|Western Blotting|Correlative studies
41307628|NCT02388022|DEVICE|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
41307629|NCT02893527|BEHAVIORAL|personalized coaching|personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
41307630|NCT03420131|DIAGNOSTIC_TEST|QFR and iFR|"iFR® (CE-Marked) is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option.~QFR® (CE-Marked) is an angio-based FFR estimation using the analytical Software QAngio XA 3D from Medis medical imaging B.V., The Netherland"
41307631|NCT02820376|OTHER|Differential renal function assessment by 4D CT|Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
41307632|NCT01288898|DRUG|ASP1941|Oral
40786201|NCT03534050|RADIATION|postoperative adjuvant RT|
40786202|NCT01724216|DEVICE|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
41307633|NCT01288898|DRUG|Placebo|Oral
41307634|NCT02103790|DEVICE|Home NIV installation|
41307635|NCT05622383|OTHER|aromatherapy|aromatherapy,
41307636|NCT05622383|OTHER|music concert|music concert
41307637|NCT05622383|OTHER|aromatherapy and music concert,|aromatherapy and music concert,
41307638|NCT00462020|DRUG|5 days of IV antibiotics (ceftriaxone and metronidazole)|5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
41307639|NCT00462020|DRUG|Home with oral antibiotics when eating (ampicillin/clavulanic acid)|Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
41307640|NCT02745223|DRUG|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
41307641|NCT02745223|DRUG|Placebo|Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
41307642|NCT05117229|DEVICE|MetaWear Sensor|Sensor placed on the pelvis to record spinopelvic movement. Lateral sitting and standing lumbar radiographs will be taken
41307643|NCT02528500|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
41307644|NCT03910998|DRUG|Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery|Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
41307645|NCT03910998|DRUG|Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2|Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
41307646|NCT04081935|DEVICE|Virtual Reality|virtual reality (VR) as a distracting intervention could reduce pain and fear during an IV placement for school-age children in the emergent department.
41307647|NCT02912806|PROCEDURE|Total Knee Replacement|Primary total knee arthroplasty for knee osteoarthritis
41307648|NCT02930798|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-116)"
41466262|NCT01134341|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
41466263|NCT05086198|BEHAVIORAL|Mindfulness-based intervention|An instructor trained in Mindfulness-based Stress Reduction (MBSR; Kabat-Zinn, 1990) will conduct meditations lasting 15 to 30 minutes. The participants will have a mobile application designed ad hoc with the practice of the week so they can do it individually at home.
40990272|NCT01086540|BIOLOGICAL|Rituximab|"Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions."
41307649|NCT00696111|DRUG|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
41307650|NCT00696111|DRUG|Depot Lupron followed by progesterone plus placebo.|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of progesterone (200mg) plus placebo for six weeks.
41307651|NCT00696111|DEVICE|CPAP|CPAP (continuous positive airway pressure) treatment at home for six weeks.
40990273|NCT01086540|OTHER|Placebo|"Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions."
40990274|NCT01086540|DIAGNOSTIC_TEST|CMRI|Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
40990275|NCT01086540|DRUG|prednisone|Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
40990276|NCT01086540|DRUG|methylprednisolone|Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
40990277|NCT01086540|DRUG|diphenhydramine|"Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
40990278|NCT01086540|DRUG|acetaminophen|"Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
40990279|NCT04139707|DEVICE|Caring4Dementia|A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.
40990280|NCT04139707|OTHER|White Paper|The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
40990281|NCT04475081|BIOLOGICAL|MMR vaccine|Merck MMR-II vaccine
40990282|NCT01528254|DRUG|Placebo of vildagliptin|
40990283|NCT01528254|DRUG|vildagliptin|One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
40990284|NCT01528254|DRUG|Metformin|Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
41307652|NCT01223872|OTHER|interview|"* Standard Interview (2-15 years from last treatment)~* Demographic data interview (pre-initial study interview)"
41307653|NCT01223872|OTHER|clinic visit and interview|"* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview (3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)"
41307654|NCT01223872|OTHER|interviews and clinic visit|"* Pre-REACH Clinic Interview(2-15 yrs from last treatment)~* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview(1mo from initial clinic visit)~* Post-REACH Clinic Interview(3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)"
41307655|NCT04930783|DRUG|CDX-301|Administered as an injection given underneath the skin
41307656|NCT04930783|BIOLOGICAL|NEOVAX|Personalized neoantigen vaccine administered as an injection given underneath the skin
41307657|NCT04930783|DRUG|Nivolumab|Administered intravenously (IV)
41307658|NCT04930783|DRUG|Pembrolizumab|Administered intravenously (IV)
41307659|NCT05841550|BIOLOGICAL|TG01|All participants will receive the same treatment as described under arm
41307660|NCT02686697|DRUG|L-Carnosine|
41307661|NCT02686697|DRUG|Placebo|
41307662|NCT02686697|BEHAVIORAL|Cognitive Training|Cognitive Training for 2 weeks
41307663|NCT05642013|PROCEDURE|Early prosthesis reimplantation|Early prosthesis reimplantation, within 16 to 30 days after implants removal
41307664|NCT05642013|OTHER|Retrospective analysis of medical records|Analysis of 50 records of operated patients managed with classical two-stage implant exchange
41307665|NCT03768531|DRUG|Nivolumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
41307666|NCT03768531|DRUG|Cabrilizumab|Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).
41307667|NCT03286088|DIAGNOSTIC_TEST|TransEsophageal Echocardiography and TransEsophageal Echocardiography|imaging as standard practice
41307668|NCT03286088|DIAGNOSTIC_TEST|Cardiac Magnetics Resonance|imaging as standard practice
41307669|NCT03286088|DIAGNOSTIC_TEST|MitraClip|imaging as standard practice
41466264|NCT05086198|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The participants will watch it in a video platform. They will not be able to do anaerobic exercise like weight lifting. The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
41466265|NCT00334763|BIOLOGICAL|bevacizumab|
41466266|NCT00334763|DRUG|carboplatin|
41466267|NCT00334763|DRUG|chemoprotection|
41466268|NCT00334763|DRUG|paclitaxel|
41466269|NCT00334763|RADIATION|radiation therapy|
41466270|NCT00908557|OTHER|readability improvement and good practice redaction|improvement using Flesch readability index and good practice in redaction of informed consent documents.
40786203|NCT04781348|PROCEDURE|Platelet Rich Plasma plus fat grafting|The study participants fulfilling the inclusion criteria giving consent will be randomly divided into two groups, one group will receive only fat grafting whereas another group will receive Platelet Rich Plasma plus fat grafting.
41466271|NCT00908557|OTHER|Control|information based on the classic informed consent document
41307670|NCT01914705|PROCEDURE|Landmark Procedure|Using Landmarks to guide SCVC placement
41307671|NCT01914705|PROCEDURE|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
41307672|NCT05481203|BEHAVIORAL|The Kaleidescope|During the nasopharyngeal swab collection process, the researcher held a kaleidoscope to each child's eye, leisurely turning it and asking about the colors and shapes seen within it.
41307673|NCT05481203|BEHAVIORAL|The visual illusion cards|Just before the nasopharyngeal swab participants were allowed to check the cards andwere askedwhat they saw in them.
41307674|NCT03623139|BEHAVIORAL|Standard nutritional education|Routine dietary care consists of three individual consultations with a trained dietitian. The individual guidance will be in accordance with the dietary guidelines in type 2 diabetes.
41307675|NCT03623139|BEHAVIORAL|Basic carbohydrate counting|The BCC concept is a group-based program consisting of three group sessions delivered by trained dietitians.
41307676|NCT00375817|PROCEDURE|Myoblasts injection with MyoCath catheter|
41307677|NCT04662242|DRUG|Selenium Supplement|Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days
41307678|NCT04662242|DRUG|normal saline|normal saline 100ml iv infusion for 7 days
41307679|NCT06083246|OTHER|Hybenix gel|Clinical application of Hybenix gel after professional dental hygiene of peri-implant mucositis sites.
41307680|NCT06083246|OTHER|Chlosite gel|Clinical application of Chlosite gel after professional dental hygiene of peri-implant mucositis sites.
41466272|NCT02625376|DIETARY_SUPPLEMENT|Resvega|Dietary supplementation with Resvega BD
40786204|NCT03089554|DRUG|Therapeutic Intervention|Therapeutic Intervention
40786205|NCT00054522|DIETARY_SUPPLEMENT|calcitriol|
40786206|NCT00054522|DRUG|dexamethasone|
40786207|NCT05367869|PROCEDURE|Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy|General anaesthesia ,supine position with hyperextension to the neck Low collar incision to the neck , incision to the skin and platysma muscle and fascia ,upper and lower flaps are developed ,separation of strap muscles and identification of the thyroid gland after freeing of investing fascia Ligation of the middle thyroid vein and ligation and separation of the superior pedicle away from the external laryngeal nerve At this point of operation and before ligation of inferior pedicle methylene blue 0.05% spraying is applied to the field the amount varies according to size of the thyroid lobe and variation in population and neck size Thyroid gland stained by bluish color , recurrent laryngeal nerve not stained or minimally stained so we can avoid injury to it parathyroid glands get red of the stain after about 3 minutes so we can avoid injury to it thyroid gland lose its stain in about 15 minutes so we can remove any residual and decrease residual tissue or recurrence
41307681|NCT00658372|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
41466273|NCT02625376|DIETARY_SUPPLEMENT|Trans-Resveratrol|Dietary supplementation with resveratrol 250 mg BD
41466274|NCT02625376|DIETARY_SUPPLEMENT|placebo|Dietary supplementation with a placebo BD
40786208|NCT05364710|DIETARY_SUPPLEMENT|Transfer factor from colostrum ultrafiltrate|Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.
40990285|NCT01822080|DRUG|Dienogest (Visanne, BAY86-5258)|2 mg dienogest (DNG) once daily by mouth
40990286|NCT01822080|DRUG|Placebo|Matching placebo once daily by mouth
41307682|NCT00658372|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
41307683|NCT00658372|DRUG|Paroxetine|Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
41307684|NCT00658372|DRUG|Placebo|Capsules, oral, placebo, BID, 8 weeks with 2 week taper
41307685|NCT04502550|DRUG|Propofol|Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
41307686|NCT03574935|DRUG|External Chinese medicine|"External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome."
41466275|NCT02297841|DEVICE|Experimental: Novel lubricant Miami Fragrance|
41466276|NCT02297841|DEVICE|Experimental: Novel lubricant Miami no Fragrance|
41466277|NCT02297841|DEVICE|KY Liquid lubricant|
41466278|NCT02297841|DEVICE|Astroglide Gel lubricant|
41466279|NCT04783545|DRUG|VLX-1005|VLX-1005 infusion
41466280|NCT04783545|DRUG|Placebo|Placebo infusion
41466281|NCT03904550|DRUG|Cisatracurium + Neostigmine|Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate
41466282|NCT03904550|DRUG|Rocuronium + Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
41466283|NCT02260635|DRUG|Evacetrapib|Administered orally
41466284|NCT02260635|DRUG|Placebo|Administered orally
41466285|NCT05310539|OTHER|assessment of the early recovery after wedge resection surgery|To assess the early recovery will be used 1 minute sit to stand, Numeric Rating scale to assess pain, incentive spirometer to assess vital capacity, Borg modified scale to assess dyspnea.
40786209|NCT03764969|BEHAVIORAL|standard smoking cessation program (SCP)|Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer 2004), and will be carried out by a qualified therapist.
41307687|NCT03574935|DRUG|External Western medicine|"For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear)."
41307688|NCT02876939|OTHER|kinesiology tape around the hip, knee and ankle joints|We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
41307689|NCT02876939|OTHER|No kinesiology tape around the hip, knee and ankle joints|Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
41307690|NCT05610852|PROCEDURE|Transvesical Single Port Robotic Partial Prostatectomy|A foley catheter is inserted on the sterile field. A suprapubic midline incision is made and the da Vinci SP surgical system is docked percutaneously directly to the bladder. Prior to the operation, a radiologist identifies and segments tumors and the urethra. A transrectal ultrasound probe is inserted and secured into a fixed position. The Koelis software is utilized to fuse MRI and ultrasound images to identify the target lesion in real-time, allowing for intraoperative guidance. The ultrasound probe rotates automatically, allowing for localization of the tumor intraoperatively. Then depending on the area of the tumor, a Hemi or quadrant resection is completed while preserving the nerves, vas deferens, and seminal vesicles. The urethrovesical anastomosis is then performed.
41307691|NCT05610852|PROCEDURE|High-intensity focused ultrasound (HIFU)|Three contoured measurements are required for the MR fusion system to reproduce the volume of the prostate. Following this, the area to be targeted will be selected in graded fashion from the anterior to posterior of the prostate. Once planning of ROI (region of interest) is complete, the HIFU treatment may begin. Quadrant or hemi ablation will be performed based on the size and complexity of the tumor. The distal margin of the ablation will be kept at least 4 mm away from the external sphincter. The rectal temperature and its distance from the probe will be carefully monitored throughout the procedure.
41307692|NCT03192527|DRUG|KN015|experimental drug
41307693|NCT03192527|DRUG|Placebo|Comparator.
41307694|NCT03192527|DRUG|Triptorelin|The drug is used for down-regulation of endogenous FSH.
41307695|NCT06253286|DEVICE|clear aligner treatment for orthodontics patients|patient are instructed to wear aligners
41307696|NCT00492947|BIOLOGICAL|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
41307697|NCT02315287|DRUG|Pioglitazone|Comparison of two different thiazolidinediones
41307698|NCT02315287|DRUG|Lobeglitazone|Comparison of two different thiazolidinediones
41307699|NCT01770873|BEHAVIORAL|Take Charge 2|Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
41466286|NCT04421976|PROCEDURE|PEEP|"Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
41466287|NCT01054352|DRUG|JNJ38224342|multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
41466288|NCT01054352|DRUG|JNJ38224342/placebo|up to four (4) additional cohorts consisting of healthy male volunteers may be added
41466289|NCT01054352|DRUG|JNJ38224342/placebo|.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
41466290|NCT01054352|DRUG|JNJ38224342/placebo|one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
41466291|NCT00646503|DRUG|Telbivudine|600 mg/day, oral telbivudine for 52 weeks
41466292|NCT02102932|DRUG|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
41466293|NCT02102932|DRUG|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
40786210|NCT03764969|BEHAVIORAL|Cognitive remediation treatment (CRT)|Cognitive remediation treatment (CRT) employing a chess-based battery of tasks two times per week over six weeks as a group treatment in our outpatient clinic (60 min duration per session).
41466294|NCT02102932|DRUG|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
41307700|NCT04575272|PROCEDURE|Ultrasound-guided continuous serratus anterior plane block|Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
41307701|NCT03531177|BEHAVIORAL|HEAL-D|HEAL-D is a 7 session programme of self-management education and behaviour change support for African and Caribbean patients with type 2 diabetes. The sessions will support participants with behaviour change to adopt evidence-based diet and physical activity targets for type 2 diabetes. The intervention has been systematically developed with defined theory and behavioural change techniques mapped to this theory.
41307702|NCT03531177|BEHAVIORAL|Control|Participants receive usual care from their healthcare team.
41307703|NCT00078962|BIOLOGICAL|GTI-2040|Given IV
41466295|NCT02102932|DRUG|850 mg metformin|850mg metformin tablet
41466296|NCT02102932|DRUG|5 mg empagliflozin|5 mg empagliflozin
41466297|NCT02102932|DRUG|5 mg empagliflozin|5 mg empagliflozin
41466298|NCT02102932|DRUG|850 mg metformin|850 mg metformin
41466299|NCT02102932|DRUG|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
41466300|NCT02102932|DRUG|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
40786211|NCT03764969|BEHAVIORAL|Implicit computer-based habit-modifying training (ICHT)|Implicit computer-based habit-modifying training (ICHT), applied twice a week for six weeks. In this training, the participants perform a two-part training. First, a subliminal presentation (20 ms) of negative valenced primes before smoking-cues in context and secondly, a subliminal presentation of positive valenced primes before potentially reinforcing events.
40990287|NCT05271955|DEVICE|"e-GOLIAH"|"Usual care plus electronic tablet with games application e-GOLIAH (Gaming Open Library for Intervention in Autism at Home)"
40990288|NCT05271955|BEHAVIORAL|Usual care|Usual care which combines speech therapy, psychomotor, educational or psychological care with a developmental and / or behavioral orientation and a school life support during schooling.
41146660|NCT06341998|DRUG|sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children|The oral dose of sirolimus is 1mg/m2 daily (maximum 2 mg). Sirolimus whole blood trough concentration is measured 5 days after administration, with blood collected within half an hour before morning administration. Dose adjustment occurs weekly until the target range of 10-15ng/ml is achieved, followed by review every 21 days. Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
41146661|NCT04099186|PROCEDURE|catheter directed hydro-mechanical fragmentation of pulmonary embolism|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery , then 200 ml saline will be injected via power injector to aid fragmentation of thrombus
41146662|NCT02765984|DEVICE|Transvaginal ultrasound|transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os
41146663|NCT02111499|DRUG|LAS41004-IMP1|daily topical application
41146664|NCT02111499|DRUG|LAS41004 IMP2|daily topical application
41146665|NCT02111499|DRUG|LAS41004 IMP3|daily topical application
41146666|NCT02111499|DRUG|LAS41004 IMP4|daily topical application
41146667|NCT02111499|DRUG|LAS41004 IMP6|daily topical application
41466301|NCT02102932|DRUG|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
41146668|NCT02111499|DRUG|LAS41004 IMP5|once daily, topical
41146669|NCT02991456|DRUG|Rolapitant|single 180 mg dose by mouth
41146670|NCT02991456|DRUG|Ondansetron|8 mg by mouth daily
41146671|NCT04223141|PROCEDURE|SIA|As indicated by arm description
41146672|NCT02736175|DRUG|Dexamethasone|
41146673|NCT02736175|OTHER|Placebo Vehicle|
41146674|NCT05873504|DEVICE|High Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
41146675|NCT05873504|DEVICE|Low Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
41146676|NCT01036932|DRUG|Granulocyte Colony Stimulating Factor|Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
41146677|NCT01036932|DRUG|Normal Saline|dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
41146678|NCT02784834|DRUG|dimethyl fumarate|
41146679|NCT00264654|DRUG|BRL29060A|
41146680|NCT00264654|DRUG|paroxetine hydrochloride hydrate|
41146681|NCT03094442|DRUG|Dexamethasone|An 8 mg dose of Dexamethasone is administered at the time of induction of general anesthesia. The medication is provided by the pharmacy in a blinded syringe.
41146682|NCT03094442|DRUG|Normal saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
41146683|NCT03139045|BIOLOGICAL|Venous puncture in elderly patients|Venous puncture in elderly patients
41307704|NCT00078962|DRUG|gemcitabine hydrochloride|Given IV
41307705|NCT00078962|OTHER|laboratory biomarker analysis|Correlative studies
41466302|NCT02102932|DRUG|500 mg metformin|500 mg metformin
41466303|NCT02102932|DRUG|500 mg metformin|500 mg metformin
41466304|NCT01561924|DRUG|eptacog alfa (activated)|Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
41466305|NCT04755621|OTHER|Core stability training|Core stability exercises
41466306|NCT04755621|OTHER|Rocabado Exercises|Exercises for Temporomandibular Disorders
41466307|NCT02498535|DRUG|Nitric Oxide 160 ppm|Nitric Oxide 160 ppm
40990289|NCT01669447|BIOLOGICAL|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
41307706|NCT00078962|OTHER|pharmacological study|Correlative studies
40990290|NCT05393141|BEHAVIORAL|diet and biopsychosocial exercise intervention|dietary intervention: biopsychosocial exercise intervention:
41307707|NCT06131554|BIOLOGICAL|batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
41307708|NCT06131554|BIOLOGICAL|batch 2 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
41307709|NCT06131554|BIOLOGICAL|batch 3 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
41307710|NCT06131554|BIOLOGICAL|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|1 dose of Menactra (0.5ml) on Day 0, Intramuscular injection
41307711|NCT05093413|BEHAVIORAL|Sleep deprivation|Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)
41307712|NCT02260908|DRUG|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
41307713|NCT02260908|OTHER|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
41466308|NCT00957216|DRUG|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
41466309|NCT00957216|DRUG|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
41466310|NCT03777345|DEVICE|cobalt-chromium framework partial dentures|It's a biocompatible metal alloy used in thin sections and are less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and is resistant to corrosion. Disadvantages include hypersensitivity, esthetic issues with metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production .
41466311|NCT03777345|DEVICE|PEEK framework partial dentures|It's a promising polymer-based framework material has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
41466312|NCT00063830|DRUG|Alicaforsen|
41307714|NCT05249088|OTHER|Protocolised reduction of non-resuscitation fluids|"* Maintenance fluids are discontinued in participants with positive cumulative fluid balance who are not dehydrated~* Intravenous fluid and enteral water are given as needed to correct electrolyte disturbances~* Enteral nutrition with energy density of at least 2 kcal/ml is administered according to local practice~* Starting 72 hours after inclusion, glucose at a concentration of at least 20% and a maximal dose of 1g/kg/day may be used as nutrition if enteral feeding is not tolerated. Glucose at this dose or lower may be started earlier in patients with insulin dependent diabetes if enteral feeding is not tolerated and local protocol mandates this~* Parenteral nutrition is administered according to local protocol~* Intravenous medications are concentrated according to a predefined protocol~* Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids such that total dose of fluids covers the daily need of water (about 1ml/kg/h)"
41307715|NCT05249088|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~* Maintenance fluids (crystalloids and/or glucose and/or enteral water) are given at a dose of 1 ml/kg/h unless local protocol states otherwise~* Glucose is used at maximal concentration of 10% unless local protocol states otherwise.~* Medications are concentrated according to local protocol"
41307716|NCT01188915|PROCEDURE|intensive screening|Each year, women will have breast cancer detection based on mammography, echography and RMI. Questionaries will also be completed.
41307717|NCT05281783|DEVICE|percutaneous radiofrequency ablation (RFA)|We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
41466313|NCT00498199|PROCEDURE|visual tests|
41466314|NCT01894230|GENETIC|SLCO1B1*5 allele testing, results reported at randomization|Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at randomization
41466315|NCT01894230|GENETIC|SLCO1B1*5 allele testing, results reported at end of study|Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at end of study
41466316|NCT01894230|GENETIC|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1\*5 allele
41466317|NCT02543151|PROCEDURE|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
41466318|NCT00898768|PROCEDURE|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
41466319|NCT03405857|OTHER|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
41466320|NCT04922294|OTHER|Clinical decision support system|To develop a clinical decision support system based on a published cardiometabolic disease staging system.
41466321|NCT05141630|PROCEDURE|sentinel lymph node biopsy or targeted axillary dissection alone|sentinel lymph node biopsy or targeted axillary dissection alone
40786212|NCT00122889|DRUG|Garlic powder with high allicin content|
41466322|NCT01942447|BIOLOGICAL|FMT|
41466323|NCT01942447|DRUG|Vancomycin|
41466324|NCT01074645|DRUG|Tenofovir disoproxil fumarate (TDF)|Tenofovir 300mg/day for 3 month
40786213|NCT00122889|DRUG|Garlic powder with low allicin content|
40786214|NCT00122889|DRUG|Garlic oil|
40786215|NCT00122889|DRUG|Aged garlic|
40786216|NCT05524831|OTHER|KINESIOTAPE|kinesiotape will be applied on orbicularis oris muscle
40786217|NCT05524831|OTHER|oromotor training|selected oromotor training: Perioral sensory stimulation ,Tapping,Tongue pressure,Jaw exercises andIntraoral stimulation
40786218|NCT03584906|PROCEDURE|DGG Harvesting approach|An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
40786219|NCT03584906|PROCEDURE|ET harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
40786220|NCT03584906|PROCEDURE|TDT harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
40786221|NCT03584906|PROCEDURE|MT harvesting approach|An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft
40786222|NCT03584906|PROCEDURE|Root coverage procedure|A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
40786223|NCT01245725|DRUG|Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive tirofiban (Aggrastat) on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
40786224|NCT01245725|DRUG|Placebo|"Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
40786225|NCT03101189|DRUG|ACT-541468|Capsule
40786226|NCT03101189|DRUG|placebo|Matching placebo capsule
40786227|NCT03245346|DRUG|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
40786228|NCT03245346|DRUG|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
40786229|NCT03245346|DRUG|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
40786230|NCT03245346|DRUG|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
41466325|NCT04850274|BEHAVIORAL|Remote Therapy Intervention (RTI)|A single ED session followed by 5 remote therapy sessions
40786231|NCT06305208|DEVICE|Endoscopic gastric suturing|Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.
40786232|NCT06305208|DEVICE|Endoscopic gastric plication|Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.
40786233|NCT06305208|DEVICE|Revisional gastroplasty|Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss
40786234|NCT06305208|DEVICE|Transoral outlet reduction endoscopy (TORe)|Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
40786235|NCT06305208|DEVICE|Duodenal mucosal resurfacing (DMR)|Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.
40786236|NCT06305208|DEVICE|Intragastric balloon(s)|The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.
40786237|NCT06168383|DRUG|HSK31679 80mg|once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
40786238|NCT06168383|DRUG|HSK31679 160mg|once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
41466326|NCT04850274|BEHAVIORAL|Artificial Intelligence Remote Therapy Intervention|Optimized by reinforcement learning to step up or down the intensity of treatment between three levels based on patient response to daily assessments.
40786239|NCT06168383|DRUG|Placebo|once daily, oral administration of placebo from Day 1 to Week 52.
40786240|NCT05159258|OTHER||
40786241|NCT01732991|DEVICE|prostatic photo-vaporization (PVP)|Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
40786242|NCT03259295|DEVICE|Digiclamp (Skin tag removal initial plus follow-up)|Skin tag will be assessed for size, location, and overall appearance. After assessment and confirmation that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site. Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
41307718|NCT00620971|DRUG|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
41466327|NCT05670145|OTHER|PRECISE|"The target group is working pregnant women. Further, a smaller group of non-pregnant women from the same workplaces and with the same work tasks (colleagues) will be included. Around 95% of pregnant women in Denmark have a 1st trimester ultrasound scan.(17) To ensure a representative population, the recruitment to the project takes place at four obstetric departments. After giving informed written consent for participation, the pregnant women receive a baseline questionnaire followed by short weekly questionnaires by SMS until maternity leave.~Exposure to occupational standing/walking and bending are measured by use of triaxial accelerometers (Axivity sensors) worn on the back and thigh for 24 hours/day. Exposure to lifting is quantified through continuous observations during a workday with registration of number of lifts, weight of burdens, and number of person-liftings."
41466328|NCT05008562|OTHER|COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT|there is no interventions to the patients.
40990291|NCT00878007|DRUG|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
40990292|NCT00878007|BEHAVIORAL|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness \& vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
40990293|NCT00878007|OTHER|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
40990294|NCT02121483|DRUG|empagliflozin medium dose|
40990295|NCT02121483|DRUG|empagliflozin high dose|
40990296|NCT02121483|DRUG|empagliflozin low dose|
40990297|NCT02492347|PROCEDURE|Electrocardiogram|The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
40990298|NCT00843921|DRUG|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
40990299|NCT01384396|DRUG|KW-3357|Intravenous infusion once a day
40990300|NCT04727229|DRUG|Bupivacaine Hydrochloride|Injection of Bupivacaine near the stellate ganglion
40990301|NCT04727229|DRUG|Normal Saline|Injection of Normal Saline near the stellate ganglion
41146684|NCT05612256|DIAGNOSTIC_TEST|Electrical impedance tomography (EIT)|EIT is the measurement of impedance changes of the lung against the flow of alternating electrical currents applied to the thorax. The signal of the electrodes is transmitted to a monitor, which enables real-time assessment of lung aeration and changes in lung volume. EIT is able to reconstruct impedance changes with a high temporal resolution and allows calculation of tidal volumes, relative stretch of lung tissue and areas of poor ventilation. Areas with impedance changes of \< 10 % of the maximum impedance changes are called 'Silent Spaces'.
41466329|NCT01228227|DRUG|ATORVASTATIN 80 mg|reload of Atorvastatin 80 mg before the procedure
40786243|NCT06307249|GENETIC|SNP|Diagnostics of patients' carriers or not of the risk allele(s)
40990302|NCT04432311|BEHAVIORAL|Binge Focused Therapy (BFT)|The BFT group will be provided Binge Focused Therapy, a group-based, guided-self help intervention. Participants in this group will attend three online group sessions spread over six weeks (Week 1, Week 2, and Week 6) and complete homework between sessions. Following Session 3, there is a four week period where participants complete self-guided check-ins once per week to monitor continued progress and/or signs of relapse.
40990303|NCT04432311|BEHAVIORAL|CBT Unguided Self Help (CBT USH)|The CBT USH group will be provided with the book, Overcoming Binge Eating by C. Fairburn, which is a well-established self-help book used to help individuals understand binge eating and control binge eating behaviours. After participants receive the book, they will have 10 weeks to read it and work through the exercises provided in the book.
40990304|NCT04542135|DRUG|Sulindac Pill|Randomized participants will receive either 150 mg oral sulindac twice daily.
40990305|NCT04542135|DRUG|Placebo|placebo pills twice daily
40990306|NCT02578654|OTHER|Strategies to improve HIV care engagement|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
40990307|NCT04022720|PROCEDURE|Platelet Rich Fibrin Application|Platelet Rich Fibrin application at first post-op visit.
41146685|NCT05612256|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|FOT enables non-invasive assessment of lung mechanics using sound waves to inform about the respiratory impedance of the respiratory system (Zrs). Reactance of the respiratory system (Xrs) as part of Zrs is a surrogate measure of compliance of the respiratory system. Xrs was previously used to identify optimal PEEP level, i.e., the PEEP at highest compliance equivalent, in newborn infants using a setup requiring research-specific hardware and software. The FOT module integrated in the commercially available neonatal ventilator is routinely used. FOT measurements are performed twice at each PEEP level to assess the reproducibility of the measurements.
41307719|NCT00620971|DRUG|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
41307720|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
41307721|NCT00620971|DRUG|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
41307722|NCT00620971|DRUG|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
41307723|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
41307724|NCT00620971|DRUG|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
41307725|NCT00620971|DRUG|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
41307726|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
40990308|NCT01165255|DRUG|3. Exposure to other antidepressants during the first trimester comparison cohort|"Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy."
40990309|NCT01165255|DRUG|2. Exposure to bupropion outside the first trimester comparison cohort|"Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester."
40990310|NCT01165255|DRUG|1. Exposure to bupropion during the first trimester|"Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy."
40990311|NCT04754737|OTHER|No antibiotic|No antibiotics will be given prior to intravesical injection of onabotulinumtoxinA
40990312|NCT04754737|OTHER|Prophylactic antibiotic|This is the current standard of care, this group of patients will be given a single dose of prophylactic antibiotic prior to the injection of onabotulinumtoxinA via cystoscopy
40990313|NCT04754737|PROCEDURE|cystoscopic injection of onabotulinumtoxinA|cystoscopic injection of onabotulinumtoxinA
40990314|NCT00927433|BEHAVIORAL|Psychoeducational intervention for cancer-related fatigue|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
40990315|NCT00629837|BIOLOGICAL|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Low dose of BAY 79-4980 \[13mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
40990316|NCT00629837|BIOLOGICAL|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|High dose of BAY 79-4980 \[22mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
40990317|NCT00629837|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 \[13mg of liposomes/kg\]
41307727|NCT02985905|DIETARY_SUPPLEMENT|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
41466330|NCT01228227|DRUG|ROSUVASTATIN 40 mg|reload of rosuvastatin 40 mg before the procedure
40786244|NCT06307249|DRUG|Palbociclib 125mg|Palbociclib 125mg/day/os over 21 days every 28 days
40786245|NCT06307249|DRUG|Bevacizumab|10mg/kg every 21 days
40786246|NCT02068144|DIETARY_SUPPLEMENT|Cranberry Extract|Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
40786247|NCT02068144|OTHER|Placebo|Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
40786248|NCT01343745|DRUG|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
40990318|NCT00629837|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 \[22mg of liposomes/kg\]
41307728|NCT02006667|DRUG|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
41307729|NCT02006667|DRUG|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
41307730|NCT02006667|DRUG|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
41307731|NCT06452628|OTHER|Mulligan mobilizations|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with Mulligan mobilizations.
41466331|NCT01039194|DRUG|galantamine|Capsule, Oral, 8 mg (ER), once daily, Days 1-7
41466332|NCT01039194|DRUG|galantamine|Capsule, Oral, 16 mg (ER), once daily, Days 8-24
40786249|NCT01343745|DRUG|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
40786250|NCT01343745|DRUG|Placebo|pressurised metered dose inhaler
40786251|NCT04741932|OTHER|Dementia Care Management (DCM)|"A computerized Information and Care Management System (IMS) will identify unmet nursing, medical, psychosocial and social needs of the PwD and its informal caregiver. Based on this data, the IMS generates suggestions for interventions: The DCM in cooperation with the general practitioner (GP) develops an individual treatment and care plan that is tailored to the needs of the PwD and its caregiver. The DCM will initiate the implementation of respective actions and monitor the status of implementation. Therefore, the DCMs are supposed to take on activities that were previously usually performed by doctors (redistribution of tasks between physicians and qualified nurses in primary care)."
40786252|NCT02592278|DRUG|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
40786253|NCT02592278|DRUG|Control Group|Twice a day brush with fluoride toothpaste.
40786254|NCT02117778|PROCEDURE|Continuous Nerve Block|
40990319|NCT05243225|PROCEDURE|Laparoscopic versus open surgical management of post cholecystectomy bile duct injury|Comparison between laparoscopic and open surgical management of post cholecystectomy bile duct injury.
40990320|NCT05773820|DRUG|WJB001|"Dose Escalation:~Accelerated titration (the first two dose groups) and BOIN combination (the subsequent dose group) were used for dose escalation.~Dose Expansion:~Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D.~Cohort Expansion:~The preliminary plan of cohort expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts."
40990321|NCT02007564|BEHAVIORAL|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
40990322|NCT04525950|PROCEDURE|Navio|New generation computer navigation with haptics and robotics
40990323|NCT04525950|PROCEDURE|Conventional|Total knee arthroplasty using conventional instruments
40990324|NCT03790527|PROCEDURE|CBM training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
40990325|NCT03790527|PROCEDURE|Sham training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
40990326|NCT04877379|DRUG|VNRX-7145|β-lactamase inhibitor
40990327|NCT04877379|DRUG|VNRX-5024 (ceftibuten)|β-lactam antibiotic
40990328|NCT04877379|DRUG|Placebo|Placebo
40990329|NCT02046408|OTHER|Computer Tablet|
40990330|NCT01854905|OTHER|No Treatment|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
40990331|NCT01187927|BIOLOGICAL|Cervarix®|Administered according to the prescribing information in the locally approved label by the authorities.
40990332|NCT01614990|DRUG|Macimorelin|Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
40990333|NCT01614990|DRUG|Placebo|placebo (Powerade®) daily for 7 days.
41146686|NCT05612256|DIAGNOSTIC_TEST|Saturation oxygenation pressure index (SOPI)|SOPI is assessed non-invasively and calculated from standard monitoring parameters such as PEEP, fraction of inspired oxygen pressure (FiO2) and peripheral oxyhaemoglobin saturation (SpO2) (PEEP x FiO2 x 100) / SpO2). SOPI is used to provide information on ventilation to perfusion ratio dependent on PEEP level.
41146687|NCT03107156|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their NSCLC patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
41146688|NCT02465632|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|
41146689|NCT02465632|DRUG|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|
40990334|NCT06069973|OTHER|No intervention, observational study|No intervention
40786257|NCT03100448|DEVICE|On1 Concept|NobelActive implant placement with simultaneous On1 Base placement
40990335|NCT03210610|DIAGNOSTIC_TEST|colchicine level measurement|levels of colchicine will be measured in FMF patients taking colchicine
40990336|NCT03993197|BEHAVIORAL|Psychological and corporal group management|"After inclusion, patient will be divided into groups of 6 or 8 patients either in pre-operative or post-operative phase. Patient care will take place entirely in pre-operative or post-operative phase.~Each group will benefit of six one hour and a half sessions.~The frequency is established as follows:~* First week a session of Body Strategy ©~* Second week a psychological session with group of speech (Photolanguage ©).~* Third week is a break Then the cycle currently described is repeated, for a total of 6 alternate sessions"
40990337|NCT00897988|GENETIC|gene expression analysis|
40990338|NCT00897988|GENETIC|mutation analysis|
40786258|NCT00664482|BIOLOGICAL|AGS-006|Autologous Therapy for Pancreatic Cancer
40786259|NCT05444738|DRUG|oral lollipop with oxytocin (24IU)|Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.
40990339|NCT00897988|GENETIC|polyacrylamide gel electrophoresis|
40990340|NCT00897988|GENETIC|polymerase chain reaction|
40990341|NCT00897988|GENETIC|protein expression analysis|
40990342|NCT00897988|GENETIC|reverse transcriptase-polymerase chain reaction|
40990343|NCT00897988|OTHER|flow cytometry|
40990344|NCT00897988|OTHER|immunoenzyme technique|
40990345|NCT00897988|OTHER|immunologic technique|
40990346|NCT00897988|OTHER|laboratory biomarker analysis|
40990347|NCT00897988|OTHER|pharmacological study|
41146690|NCT02465632|DRUG|Placebo|
41146691|NCT01428609|PROCEDURE|Amalgam|In all surgical intervention a zinc free amalgam (Tytin. Kerr Sybron Crop., Romulus, MI) was used in the root end prepared spaces as root end filling material. Blood samples were collected in three period of time immediately before and immediately after each surgery and also one week later.
40990348|NCT01352988|DRUG|Fumaric acid esters|Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
40990349|NCT05364931|DRUG|Cotadutide|Cotadutide administered subcutaneously once daily
40990350|NCT05364931|DRUG|Placebo|Placebo administered subcutaneously once daily
40990351|NCT02526888|DRUG|ACT-541468|Oral capsule (25 mg) as single dose
40990352|NCT02526888|DRUG|Diltiazem|Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7
40990353|NCT00204347|DRUG|risperidone|
40990354|NCT04967196|BIOLOGICAL|Ipilimumab|Given via DoseConnect device or IV
40990355|NCT04967196|BIOLOGICAL|Nivolumab|Given IV
41466333|NCT01039194|DRUG|BMS-708163|Capsule, Oral, 125 mg, once daily, Days 15-24
40990356|NCT04967196|PROCEDURE|Lymph Node Assessment|Undergo lymphatic imaging with ICG
40990357|NCT04967196|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40990358|NCT00971347|OTHER|Extra sugar-free chewing gum sticks|90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.
40990359|NCT00971347|BEHAVIORAL|nutrition brochure|one-time at baseline visit
40990360|NCT04306874|DIETARY_SUPPLEMENT|Ensure Max Protein|Liquid shake with 30 g protein per serving
40990361|NCT01214018|OTHER|Questionnaires and interview|Questionnaires and interview
40990362|NCT01811927|DEVICE|PRO-Kinetic Energy Stent|Bare-metal stent
40990363|NCT04136184|DRUG|Eplontersen|Eplontersen by subcutaneous injection
40990364|NCT04136184|DRUG|Inotersen|Inotersen by subcutaneous injection
40990365|NCT02233244|DRUG|CTX-4430|
40990366|NCT02233244|DRUG|Midazolam|
40990367|NCT01655017|PROCEDURE|biopsy|adipose tissue biopsy (to evaluate inflammation and fibrosis)
40990368|NCT04550260|DRUG|Durvalumab|Durvalumab intravenous infusion
40990369|NCT04550260|DRUG|Placebo|Durvalumab matching placebo for intravenous infusion
40990370|NCT04550260|DRUG|cisplatin + fluorouracil|cisplatin + fluorouracil, as per Standard of Care
40990371|NCT04550260|DRUG|cisplatin + capecitabine|cisplatin + capecitabine, as per Standard of Care
40990372|NCT04550260|RADIATION|Radiation|50-64Gy in total
40990373|NCT03774433|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
40990374|NCT01852942|DRUG|Losartan|Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
40990375|NCT01852942|DRUG|Placebo|one tablet by mouth daily
40990376|NCT01163487|DRUG|Dichloroacetate|25-50mg/kg per day; oral
40990377|NCT01163487|DEVICE|EF5|21 mg/kg; IV
40990378|NCT03630575|PROCEDURE|Umbilical cord blood and hair collection|At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
40990379|NCT04404738|PROCEDURE|MicroPort® robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System
40990380|NCT04404738|PROCEDURE|da Vinci robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System
40990381|NCT06404632|BEHAVIORAL|Lev-g|Lev-g includes three sessions + a booster session using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev-g is done in groups to enable support and tips from others.
40990382|NCT00539409|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
40990383|NCT00632255|DRUG|Imatinib|Conventional therapy with imatinib
40990384|NCT01195428|DRUG|Simvastatin|Simvastatin 40 mg daily
40990385|NCT01195428|DRUG|Placebo|Placebo
40990386|NCT01760512|PROCEDURE|Gastric bypass|Gastric bypass
40990387|NCT01511575|GENETIC|RNA analysis|
40990388|NCT01511575|GENETIC|reverse transcriptase-polymerase chain reaction|
40990389|NCT01511575|OTHER|laboratory biomarker analysis|
40990390|NCT05124951|RADIATION|Whole-ventricle irradiation|Whole-ventricle irradiation will be applied in patients with localized basal ganglia germ cell tumors after induction chemotherapy
40990391|NCT05124951|DRUG|Carboplatin/etoposide|Carboplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia germinoma
40990392|NCT05124951|DRUG|Ifosfamide/cisplatin/etoposide|Ifosfamide/cisplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia non-germinomatous germ cell tumors.
40786260|NCT05444738|DRUG|oral lollipop with placebo|Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
41466334|NCT00529217|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
40990393|NCT05124951|PROCEDURE|Second-look surgery|Second-look surgery would be applied to patients who presented residue disease after induction chemotherapy.
41466335|NCT01521078|BEHAVIORAL|Check Your Drinking University version|The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
40786261|NCT00994903|DRUG|Simvastatin|40mg orally, given 3-7 days pre-op and continued till 14 days post-op
40786262|NCT00994903|DRUG|Placebo|Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
40786263|NCT02135068|DEVICE|Medtronic MiniMed Closed Loop (CL) System|The Medtronic MiniMed Closed Loop (CL) System is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.
40786264|NCT02135068|OTHER|Snacking|Up to 45 g of oral glucose via Gatorade
40786265|NCT03714607|DEVICE|Erbium Yttrium Aluminum Garnet (Er:YAG) laser|5 Er:YAG laser therapies vaginally administered at monthly intervals
40786266|NCT06185790|OTHER|LCHF diet|Low-carb high-fat (LCHF) diet
40786267|NCT04092114|OTHER|Control|Standard of care (SOC) HIV prevention services in line with the South African DoH (Department of Health) PrEP (Pre-exposure Prophylaxis) rollout program that include daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine). In addition, risk reduction counseling, IPV (Intimate Partner Violence) screening using the VAWS (WHO Violence Against Women Survey) with referrals for counseling, medical care, or shelter assistance, among other care options, if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered
40990394|NCT04886986|DRUG|225Ac-J591|30 - 40 KBq/kg (dose-escalation) every 8 weeks, for up to 2 cycles. Administered together with 177Lu-PSMA-I\&T. Intravenous administration.
40990395|NCT04886986|DRUG|177Lu-PSMA-I&T|6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.
40990396|NCT04886986|DRUG|68Ga-PSMA-11|\[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening, 12 weeks, 24 weeks. Imaging agent for PSMA PET/CT.
41146692|NCT00019344|DRUG|alvocidib|
41146693|NCT04756986|DRUG|malic acid|1% malic acid spray
41466336|NCT06449755|DIAGNOSTIC_TEST|Radiologic examination|Posoperative first week, month and third month On the x-ray of Hand AP view: metacarpal shortening On the x-ray of Hand 30 degree pronation view: dorsal angulation
41466337|NCT06449755|PROCEDURE|Grip Strength|Postoperative first month and third month grip streng compare with Cambry hand dinamometer.
41466338|NCT06449755|OTHER|Quick DASH Questionnaire|Quick DASH is an 11-question questionnaire that assesses upper extremity functionality.
41146694|NCT06328296|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
41146695|NCT06328296|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
41307732|NCT06452628|OTHER|Active Release Technique|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with the Active release technique.
41307733|NCT06452628|OTHER|Mulligan mobilizations with active release technique|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with mulligan mobilizations with active release technique.
41466339|NCT00699244|PROCEDURE|Peripheral placement of local anesthesia|Peripheral placement of local anesthesia
41466340|NCT00699244|PROCEDURE|Central placement of local anesthesia|Central placement of local anesthesia
41466341|NCT00272272|BEHAVIORAL|Music Therapy|Listening to Music while standing
41466342|NCT03309917|OTHER|MAP set at 80-85 mmHg for 5 min|MAP is set at 80-85 mmHg for 5 min by infusion of noradrenaline.
41466343|NCT03309917|OTHER|MAP set at 70-75 mmHg for 5 min|MAP is set at 70-75 mmHg for 5 min by infusion of noradrenaline.
41466344|NCT03309917|OTHER|MAP set at 60-65 mmHg for 5 min|MAP is set at 60-65 mmHg for 5 min by infusion of noradrenaline.
40786268|NCT04092114|BEHAVIORAL|CHARISMA Intervention|"SOC (Standard of Care) per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable:~* Module A: General Partner Communication and Relationship Skills~* Module B: Partner Disclosure and Communication around PrEP Use~* Module C: Responding to Intimate Partner Violence and Safety Planning"
40786269|NCT04601129|PROCEDURE|enhanced recovery after surgery program|practice of an enhanced recovery after surgery program, according to the international reviews of literature and national recommendation
40990397|NCT03571581|BEHAVIORAL|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 20 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
40990398|NCT00116532|DRUG|Escitalopram|
40990399|NCT00199927|DRUG|Fluvastatin|Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
40990400|NCT00199927|DRUG|standard therapy|standard therapy
40990401|NCT01141881|DRUG|Tissue Plasminogen Activator,bevacizumab ,follow up|25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
40990402|NCT02909452|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
40990403|NCT02909452|DRUG|Pembrolizumab|A selective humanized monoclonal antibody (mAb)
40990404|NCT03371628|DEVICE|Non invasive ventilation|Non invasive ventilation is a mode of mechanical ventilation that does not require the use of artificial airway.
41307734|NCT00202111|PROCEDURE|Laparoscopic-assisted colectomy|
41307735|NCT00202111|PROCEDURE|Conventional open colectomy|
40990405|NCT05882240|OTHER|choice of initial position|current practice of correct application and interpretation of the PLR in critical care patients
40990406|NCT02955979|OTHER|CT scan with iodinated contrast agents|"Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.~After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.~Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary."
40990407|NCT05696912|GENETIC|Ex-vivo approach concerning 25 patients|Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis
40990408|NCT05696912|GENETIC|In-vitro approach concerning 25 patients|In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay
40990409|NCT03338426|DRUG|Fimasartan 120mg|Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
40990410|NCT03338426|DRUG|Atorvastatin 40mg|Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
41307736|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
40990411|NCT03338426|DRUG|Placebo for Fimasartan 120mg|Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
40990412|NCT03338426|DRUG|Placebo for Atorvastatin 40mg|Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
40990413|NCT02994160|OTHER|Fast electrode|Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
41146696|NCT05935072|BEHAVIORAL|Exercice and meal|The participants will carry out four experimental visits in a randomized order: CON_Calibré: control condition with a calibrated test meal; CON_AdLib: control condition with an ad libium test meal; EX_Calibré: exercise condition with a calibrated test meal; EX_AdLib: exercise condition with an ad libitm test meal. During each of the conditions, the participants will join the laboratory at 8:00 a.m. and will receive a calibrated breakfast. They will be asked at 11:00 a.m. either to rest in a semi-recumbent position for 30 minutes (CON conditions) or to perform a pedaling exercise on an ergocycle at 65% of their estimated aerobic capacity for 30 minutes. A test meal will be served to participants at 12:00 p.m., either ad libitum or calibrated. Appetite sensations will be assessed at regular intervals during each condition and their food reward preferences and ratio assessed 15 minutes before and 15 minutes after the test meals.
40990414|NCT03872089|OTHER|Infrared Thermography|Measurements of the temperature of the plantar arch by thermal imaging (Infrared Thermography)
40990415|NCT00614315|DEVICE|FLAIR™ Endovascular Stent Graft|The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
40990416|NCT06489782|OTHER|Model 1|Model 1 examines the impact of alcohol cues and alcohol availability on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
41146697|NCT00286013|DRUG|Association of gemcitabine, oxaliplatin and radiotherapy|
41307737|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
41307738|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
41307739|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
40786270|NCT01459666|DRUG|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
40786271|NCT01459666|DRUG|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
40786272|NCT04217018|DIAGNOSTIC_TEST|Prediction of molecular pathology|Prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
40786273|NCT04548206|OTHER|Pilates training|The program consisted of core-based Pilates exercises on the mat for 60 minutes.
40786274|NCT04548206|OTHER|control|The program consisted of progressive relaxation exercises at home.
40786275|NCT00994864|DRUG|FOLFOX|One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
40786276|NCT01385592|DRUG|AFQ056|
40786277|NCT01385592|DRUG|Placebo|
40786278|NCT04902989|OTHER|pollutants and pollen|Pollutants (ozone, SO3, NO3, PM2.5, diesel exhaust particles)
40786279|NCT00795028|OTHER|Standard Care for people after hip fracture|
40786280|NCT00795028|OTHER|Standard Care + exercise intervention|
40786281|NCT04786054|DIAGNOSTIC_TEST|BED Questionnaire|BED Questionnaire
40786282|NCT02146443|OTHER|Stretched arm test|Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
40786283|NCT02146443|OTHER|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
40786284|NCT02146443|DEVICE|Star shaped manual dexterity test|On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
40990417|NCT06489782|OTHER|Model 2|Model 2 examines the impact of alcohol cues and alcohol availability and a priming dose of alcohol (.04 g/dL) on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
40990418|NCT05870033|DEVICE|Electromyography (EMG) measurement|Electromyography (EMG) measurement of m. quadriceps femoris and semitendinosus muscle during static functional tasks
40786285|NCT01025557|OTHER|Dietary intervention|Dietary treatments with beverages
40786286|NCT00185302|DRUG|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
40786287|NCT00185302|DRUG|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
40786288|NCT05398016|BEHAVIORAL|low-intensity intervention for anxiety|Brief (4-6 weekly 30-min sessions) delivery of a structured behavioral treatment for mild-to-moderate anxiety. Treatment will be based on principles of cognitive behavioral therapy (CBT).
40990419|NCT05507255|OTHER|Relaxation training|Relaxation training in the form of deep breathing exercises
40990420|NCT05507255|OTHER|An aerobic exercise program|An aerobic exercise program of a moderate intensity, based on the target heart rate (THR) that will be calculated in accordance with Karvonen's equation, using resting heart rate (HRrest), maximal heart rate (HRmax) and training fraction. THR = HRrest (bpm) + (HRmax (bpm) - HRrest (bpm)) × training fraction.The exercise session will have three phases, warming up, active phase and cooling down.
41307740|NCT00586924|DRUG|CAT 8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
41307741|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
40786289|NCT04975308|DRUG|Imlunestrant|Administered orally.
40786290|NCT04975308|DRUG|Exemestane|Administered orally.
41466345|NCT03669016|BEHAVIORAL|Face-to-face group-based mindfulness|"An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. This training is based on Jon Kabat-Zinn's course Mindfulness Based Stress Reduction and book Williams \& Penman Mindfulness: a practical guide to finding peace in a frantic world and adapted for university students. In addition, a manual written in Cambridge University Mindfulness Skills for Students is utilized."
40786291|NCT04975308|DRUG|Fulvestrant|Administered IM.
40786292|NCT04975308|DRUG|Abemaciclib|Administered orally.
41466346|NCT03669016|BEHAVIORAL|Internet-based mindfulness|An eight-week course, including 60 minutes starting and ending meeting. Participants are practicing mindfulness, doing other tasks (writing, reading, reflecting) on their own. This course is created in University of Jyväskylä, Finland. It is based on mindfulness and Acceptance and Commmitment Therapy.
41466347|NCT01142141|OTHER|manual therapy, kinesiotherapy|
41466348|NCT01883791|BEHAVIORAL|SBIRT|See above Arm description.
41466349|NCT01883791|BEHAVIORAL|Health Education|See Arm Description.
41466350|NCT04760587|BEHAVIORAL|smart devices in adolescent weight control|The study will apply mobile phone applications and smart watches to understand the relationship between weight control behaviors and weight control health outcome in adolescent.
41466351|NCT04847999|DIETARY_SUPPLEMENT|Dark chocolate|Dark chocolate
41466352|NCT05853809|DIAGNOSTIC_TEST|FeNO measurement|FeNO measurement to guide anti-inflammatory asthma treatment
41466353|NCT00000555|DRUG|estrogen replacement therapy|
41466354|NCT00000555|DRUG|estrogens, conjugated|
40786293|NCT05534893|DIETARY_SUPPLEMENT|Blueberry powder group|Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder
40786294|NCT05534893|DIETARY_SUPPLEMENT|Placebo powder group|Participants in the placebo powder group will receive an isocaloric placebo powder
40786295|NCT04028687|DEVICE|Taperloc Complete Stem|Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.
40786296|NCT03745768|DEVICE|Intermittent Theta Burst Stimulation|Intermittent theta burst stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
40786297|NCT03745768|DEVICE|sham stimulation|Sham stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
40786298|NCT02948764|DEVICE|Vacuum-Assisted Biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, or by mammography (stereotaxy) during the second trial visit (V2) will be performed once. In analogy to the German S3 guideline on primary breast cancer management we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes.
41307742|NCT01966575|DRUG|Progestin|The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
41307743|NCT05858294|BEHAVIORAL|Cognitive Behavioral Therapy programme|This mobile application comprised CBT-based therapy for social anxiety based on the Clark and Wells model
41307744|NCT03118531|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)|The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
41307745|NCT02833116|DRUG|Betamethasone|
41466355|NCT00000555|DRUG|progesterone|
41466356|NCT00000555|DRUG|hormone replacement therapy|
41466357|NCT00000555|DRUG|supplementation, food|
41466358|NCT00000555|DRUG|ascorbic acid|
41466359|NCT00000555|DRUG|vitamin e|
41466360|NCT03877341|PROCEDURE|posterolateral fusion|Instrumented posterolateral fusion is a spinal surgery that combines bone graft fusion with the use of hardware like screws and rods to stabilize the spine, correct alignment, and promote successful fusion. It's used for various spinal conditions.
40786299|NCT04929964|PROCEDURE|MRM , Toilet Mastectomy , BCS|MRM , modified radical mastectomy : removing breast and axilla toilet mastectomy : palliative removal of tumor load BCS ,Breast conservative surgery
40786300|NCT02840279|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
40786301|NCT02840279|DRUG|Placebo|
40786302|NCT01621178|DRUG|Dulaglutide|Administered SC
40786303|NCT01621178|DRUG|Insulin glargine|Administered SC
40786304|NCT01621178|DRUG|Insulin lispro|Administered SC
40990421|NCT05643040|OTHER|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral block in patients who will have knee surgery.
40990422|NCT05643040|OTHER|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
40786305|NCT05840835|DRUG|IMX-110 combined with Tislelizumab|Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
41466361|NCT03877341|PROCEDURE|posterior lumbar interbody fusion|Posterior lumbar interbody fusion (PLIF) is a spinal surgery that involves removing problematic discs, inserting bone graft material, and sometimes a spacer, to promote fusion and stabilize the spine.
41466362|NCT05824949|PROCEDURE|osseodensification drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the osseodensification protocol.
41466363|NCT05824949|PROCEDURE|conventional drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the conventional drilling protocol.
40786306|NCT06139601|BEHAVIORAL|Virtual single session intervention|A single session, self-paced body empowerment program. The program consists of a single 45-minute self paced, interactive, virtual module.
40786307|NCT02701309|DEVICE|Non-invasive Iron detection device via Zinc-Protoporphyrin|In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
40786308|NCT05707338|PROCEDURE|Gastrectomy with lymph node dissection|"prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group)."
40786309|NCT01082627|DRUG|Somatostatin|250ug/h,Continuous I.V. infusion,maximal 14 days
40786310|NCT01082627|OTHER|common daily practice|common daily practice
40786311|NCT04674267|OTHER|Phase 2 Intervention - Geriatric Co-Management|"Participants will complete an electronic fitness assessment questionnaire - once completed, they will receive a score of Robust, Pre-Frail or Frail. Those who are Pre-frail or Frail will be randomized to meet with a study geriatrician for geriatric co-management in addition to usual oncology care. All participants will be followed for a duration of 1 year."
40990423|NCT05643040|OTHER|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
40786312|NCT00060671|DRUG|rituximab|
40786313|NCT00060671|DRUG|Pixantrone (BBR 2778)|
40786314|NCT02250872|DRUG|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
40786315|NCT02250872|DRUG|Placebo|100mg in 2 divided doses plus cisplatin
40786316|NCT02250872|DRUG|Cisplatin|All patients will receive intravenous cisplatin
40786317|NCT05922618|DEVICE|I-One|"I-ONE® is a medical device certified by the Ministry of Health as a Medical Device (risk class II A) for the treatment of inflammatory and degenerative tissue pathologies. The device consists of a signal generator and an applicator, called a solenoid. The solenoid will be placed on the joint, not necessarily in direct contact with the skin. The device works with a rechargeable battery and is equipped with an hour counter to assess patient compliance.~Treatment with I-ONE® therapy will start within 3-7 days of recruitment, will last 6 hours a day and will be maintained for 60 days. The treatment will be carried out at home and the device will be delivered directly to the patient's home by courier."
40786318|NCT03248388|DEVICE|Argus II Eyeglasses|The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
40990424|NCT04164615|DRUG|GB221|"GB221:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
40990425|NCT04164615|DRUG|Placebo control|"Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
40990426|NCT04641611|OTHER|Bicaval cannulation|Cannulation of SVC and IVC through right atrium in patients undergoing CABG. with snares applied
40990427|NCT04641611|OTHER|Cavoatrial cannulation|Cannulating the right atrium and Inferior vena cava with a 2-stage cannula
40990428|NCT03403959|DEVICE|light therapy|6 weeks morning treatment with bright light therapy in own home.
40990429|NCT04751825|BEHAVIORAL|I-EAET|See information in arm description.
40990430|NCT00546611|DRUG|PEP005|
40990431|NCT02167607|DIETARY_SUPPLEMENT|Active Comparator|Purple Potato
40990432|NCT02167607|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo Comparator
41307746|NCT02833116|DRUG|Dexamethasone|
41466364|NCT05630625|BEHAVIORAL|Drinking Dashboard|Day-level feedback on alcohol use and consequences
40990433|NCT06490029|DIAGNOSTIC_TEST|Auditory, vestibular and electrophysiological investigations|otoacoustic emissions, electrocochleography, vocal audiometry in noise and high-frequency tonal audiometry, impedancemetry
40990434|NCT06490029|DIAGNOSTIC_TEST|Biologic investigations; seric proteins|seric proteins
41307747|NCT05283889|PROCEDURE|Genicular Radiofrequency Ablation|After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
41307748|NCT05283889|PROCEDURE|Sham Genicular Radiofrequency Ablation|After the cannulae are placed and tines deployed, a single lesion (no electrical signal applied to patient) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
41307749|NCT02416362|OTHER|Vibration at 30 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.
41307750|NCT02416362|OTHER|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
41307751|NCT03378154|PROCEDURE|Orotracheal intubation in infants with Macintosh|Orotracheal intubation in infants using Macintosh laryngoscope
41307752|NCT03378154|PROCEDURE|Orotracheal intubation in infants with King vision|Orotracheal intubation in infants with King vision videolaryngoscope
41307753|NCT02047513|DRUG|perioperative nab-paclitaxel/gemcitabine|2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)
41307754|NCT02047513|DRUG|adjuvant nab-paclitaxel/gemcitabine|Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)
41307755|NCT04263142|DRUG|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
41307756|NCT04263142|DRUG|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
41307757|NCT06241755|DRUG|BCG for Therapeutic Use|"Specification: 60 mg (6.0×10\^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10\^6 CFU.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
40786319|NCT03248388|DEVICE|ORCAM|ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
40786320|NCT05038696|BIOLOGICAL|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.
40786321|NCT02184065|DRUG|Meloxicam|
40786322|NCT02170844|DRUG|BIBR 1048 MS|
40786323|NCT02170844|DRUG|Placebo of BIBR 1048 MS|
41307758|NCT06241755|DRUG|BCG for Therapeutic Use|"Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10\^6 CFU/mg.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
41307759|NCT03132480|OTHER|fluid resuscitation|when the patients showed the clinical signs of hypovolemia, the fluid resuscitation with 10ml/kg crystalloid solution was performed.
41307760|NCT00407914|DEVICE|Aquamid|Subcutaneous injection
41307761|NCT00407914|DEVICE|Restylane|Injection in dermis
40786324|NCT04476667|BEHAVIORAL|e-Psychotherapy|Module Content: The first 3 sessions will be designed to address the symptoms caused by fear of illness or concerns about personal safety in the context of pandemic. Electronic-CBT (e-CBT) modules will focus on problem solving techniques, with mindfulness practices included, to help build healthy coping skills to address the uncertainties surrounding the COVID-19 pandemic. e-CBT modules will involve guiding participants to develop constructive and balanced coping strategies through 5 focuses: stimulus control, cognitive therapy, sleep hygiene, relaxation therapy, and sleep restriction. Additional focus will be placed on the connection between thoughts, behaviours, emotions, physical reaction and one's environment.
40786325|NCT03807388|DEVICE|ReMindCare Intervention Group|Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.
40786326|NCT03807388|OTHER|Treatment as Usual|Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
40786327|NCT05561842|PROCEDURE|mHealth US-breast biopsy|During this study, women will undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
40786328|NCT00700648|DRUG|insulin aspart|Intravenous NovoRapid dose \& frequency as decided by treating physician
40786329|NCT00473109|PROCEDURE|Dialysis without systemic heparinization|Dialysis without systemic heparinization
40786330|NCT01103440|DRUG|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
40786331|NCT01103440|DRUG|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
40786332|NCT04133025|OTHER|Vestibular Rehabilitation|Vestibular Exercises and Software in vestibular rehabilitation
40786333|NCT00224081|DRUG|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
40786334|NCT00042237|BEHAVIORAL|Schema Therapy|
40990435|NCT03929861|DRUG|Fluconazole (BAYT006267) 150 mg capsules|Fluconazole 150 mg
41146698|NCT06049758|PROCEDURE|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
41146699|NCT06049758|DRUG|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation
41146700|NCT06049758|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg intravenous injection will be administered 1 hour before the operation.
41146701|NCT06049758|PROCEDURE|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
41146702|NCT05902572|OTHER|No intervention|Observational data collection only.
40786335|NCT00835289|DIETARY_SUPPLEMENT|n-3 polyunsaturated fatty acids|Omax3\[TM\] (Cenestra Health \[TM\]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
40990436|NCT03929861|DRUG|Fluconazole 150 mg capsules (DiflucanTM)|Fluconazole 150 mg
41146703|NCT04975386|DEVICE|Transthoracic echocardiogram|Transthoracic echocardiogram will be performed before the operation and at certain time intervals during the operation.
41466365|NCT04511572|PROCEDURE|embolization of the middle meningeal artery|The embolization procedure will be as follows: first femoral artery access will be obtained by using a 5 French micropuncture kit and common carotid and external carotid angiography is performed using a standard 5 French diagnostic catheter. A microcatheter is then advanced selectively under roadmap guidance into the middle meningeal artery (MMA), and MMA angiography is performed to evaluate for potential dangerous anastomoses such as the orbital branch to the ophthalmic artery. Embolization is performed using polyvinyl alcohol particles (100 microns in diameter) under blank fluoroscopic roadmap while carefully avoiding reflux. Particles are infused until lack of anterograde flow into the MMA branches is demonstrated on angiography, and the catheters are removed \[31\]. The procedure is performed under local anesthesia.
41466366|NCT02902055|DRUG|Neuromuscular Blocking Agents|Neuromuscular blockae
41466367|NCT02902055|DRUG|Isotonic saline|Placebo
40786336|NCT00835289|OTHER|Placebo|3 capsules of matching corn oil placebo
40786337|NCT02250976|DRUG|Livasupril Cap.160/2mg|Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
40786338|NCT02250976|DRUG|Lipilfen cap. 160mg|Micronized fenofibrate 160mg
40786339|NCT02250976|DRUG|Livaro tab. 2mg|Pitavastatin Ca 2mg
40786340|NCT05184335|DRUG|Brilaroxazine|RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.
40786341|NCT05184335|OTHER|Placebo|RP5063 matching Placebo
40786342|NCT03305952|BEHAVIORAL|CBCT|
40786343|NCT03305952|OTHER|TAU|
40786344|NCT05410418|DRUG|Mosunetuzumab|"Mosunetuzumab is administered subcutaneously using a step-up dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg."
40786345|NCT05410418|DRUG|Polatuzumab vedotin|Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.
40786346|NCT03406208|BEHAVIORAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
40786347|NCT03406208|BEHAVIORAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
40786348|NCT01160133|OTHER|Systane|Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)
40786349|NCT01160133|OTHER|Refresh Tears|Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)
40786350|NCT01535287|DRUG|Dexmedetomidine|"Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider."
40786351|NCT03115918|DEVICE|Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm to have a PD stent placed.
40786352|NCT03115918|OTHER|No Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm and not receive PD placement.
40786353|NCT05017870|DRUG|KSR-001|(0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
40786354|NCT05017870|DRUG|KSR-004|(0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
41307762|NCT00988741|DRUG|ARQ 197|The investigational drug ARQ 197 is supplied as capsules. A dose of 360 mg (3 capsules of 120 mg each) of ARQ 197 will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 720 mg. Under Amendment 2, a dose of 240 mg (2 capsules of 120 mg each) of ARQ 197/placebo will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 480 mg. A treatment cycle is defined as 4 weeks for both treatment arms. Cycles will be repeated every 4 weeks (28 days) based on toxicity and response.
40786355|NCT05017870|DRUG|KSR-001-02|KSR-001-02
40786356|NCT05017870|DRUG|KSR-001-03|KSR-001-03
41146704|NCT00211042|OTHER|No intervention|This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.
41146705|NCT02627586|OTHER|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-60% of peak heart rate). The total duration of the HIIT training is 38 min.
41146706|NCT02627586|OTHER|MICE|MICE is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform MICE training three times per week.
41307763|NCT00988741|DRUG|Placebo|The placebo is provided in a capsule form.
41307764|NCT03998475|BEHAVIORAL|Transition preparation intervention|Young adult participants and parents will complete transition preparation sessions that include meeting with a health behavior coach for in-person sessions and review of materials sent electronically between study visits.
41307765|NCT04434053|DEVICE|MIETHKE M.blue®|The programmable shunt will be adjusted through the MIETHKE M.blue® valve.
41307766|NCT04434053|DEVICE|MIETHKE proGAV 2.0® (with SA 2.0®)|The programmable shunt will be adjusted through the MIETHKE proGAV 2.0® valve that will be implanted together with a shunt-assistant SA 2.0®.
41307767|NCT02790671|DRUG|DS-8500a|DS-8500a 25mg tablet
41307768|NCT02790671|DRUG|Itraconazole|200mg itraconazole
41307769|NCT04229498|DRUG|Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)|In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
40786357|NCT05894057|OTHER|Data collection on acceptability of midazolam administration by 2- to 10-year-old pediatric patients at UKBB|On the day of entry to the Anesthesiology Unit for an elective surgery, or before an intervention at the Emergency Unit, all children, irrespective of their participation to the present study, will receive standard midazolam dose of 0.3-0.5 mg/kg as prescribed by the treating clinician at UKBB in line with clinical practice (as oral syrup, rectal suppository or ODMT). The children's spontaneous reactions after intake of midazolam (e.g., positive comments, spitting out of medication, crying) will be observed and recorded by the research staff. Children who are able to understand the Hedonic Scale (FHS) will be questioned on how they liked the medication by pointing to the appropriate face of a Facial Hedonic Scale (FHS) at the time of midazolam intake.
40786358|NCT01840033|DEVICE|group Piccnut|Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
41466368|NCT04015531|RADIATION|Conventional radiotherapy|50 Gy / 25 fractions / 5-6 weeks / Sequential boost of 10 Gy in 5 fractions, in case of conservative surgery.
40786359|NCT01840033|DEVICE|Tunnelled nutritional central catheter|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
40786360|NCT02554994|OTHER|Multifactorial intervention|"There are six components of intervention in this study.~* For all participants:~  1. Group exercise~ 2. Nutritional supplement(commercial liquid formula will be provided every day).~* For selected participants:~  1. Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~ 2. At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~ 3. Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it)."
41307770|NCT01266655|DRUG|Baclofen|Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.
41307771|NCT01266655|DRUG|Placebo|Placebo
41466369|NCT04015531|RADIATION|Hypofractionated radiotherapy|40 Gy / 15 fractions / 3 weeks / Concomitant boost with total dose of 48 Gy in 15 fractions, in case of conservative surgery.
41466370|NCT05039476|DIETARY_SUPPLEMENT|Retinol face cream|Retinol face cream
41466371|NCT05039476|DIETARY_SUPPLEMENT|Placebo face cream|Placebo face cream
41466372|NCT05424731|COMBINATION_PRODUCT|DBV712 250 mcg|Daily epicutaneous delivery.
40786361|NCT02554994|OTHER|Usual care|"Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS)."
40786362|NCT02923154|DRUG|MT-3995|
40786363|NCT02923154|DRUG|Placebo|
40786364|NCT01649713|DRUG|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
40786365|NCT01692288|BEHAVIORAL|First Born® Program home visiting services|Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
40990437|NCT00115856|PROCEDURE|Intravascular MRI|Arterial imaging of atherosclerosis
41307772|NCT05339724|OTHER|platelet count and mean platelet volume are obtained from whole blood count|The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
41307773|NCT00904540|DRUG|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (\<6 weeks) LBP, subacute (6 weeks to \<3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (\>12 months LBP)
41307774|NCT00462098|DEVICE|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
41307775|NCT00462098|DEVICE|non-treated control group|no change from routine care, no HBO
41466373|NCT03862534|PROCEDURE|CAF|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised, coronally advanced and sutured to cover the recession
41466374|NCT03862534|PROCEDURE|CAF + CTG|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised. Then a connective tissue graft was harvested from the palate and sutured over the exposed root. Finally the flap was coronally advanced and sutured to cover the recession
41466375|NCT00056381|DRUG|Anidulafungin|
41466376|NCT02203578|DRUG|romidepsin|Given IV
41466377|NCT02203578|OTHER|laboratory biomarker analysis|Correlative studies
41466378|NCT05443009|DRUG|Lidocaine|A buccal infiltration injection followed by palatal injections and interpapillary injections of 2% lidocaine with 1:100,000 epinephrine will be administered.
41466379|NCT05443009|DRUG|Articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
41466380|NCT00456482|DRUG|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
41466381|NCT00456482|DRUG|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
40786521|NCT02394626|PROCEDURE|Surgery followed by adjuvant second-line therapy|"Surgery:~Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.~Adjuvant second-line therapy:~Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol."
40990827|NCT06336460|PROCEDURE|Pericapsular Nerve Group (PENG) Block|"Under sterile technique, physician will identify relevant landmarks including the femoral artery, femoral vein, femoral nerve, ileopubic eminence (IPE), anterior inferior iliac spine (AIIS), psoas tendon (PT). Target area is bony space between AIIS and IPE adjacent to PT.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting fascial plane below the psoas tendon, above ilium bone. Landmark lies between the AIIS and IPE, just lateral to psoas tendon.~As needle tip reaches target, small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, lifting the psoas tendon from ilium, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush line of remaining anesthetic. Needle will then be withdrawn."
40786522|NCT02394626|PROCEDURE|Second-line therapy alone|Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
41341663|NCT06291545|DEVICE|Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）|One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the Coronary artery scoring balloon dilation catheter treatment group.
40786524|NCT05444543|DRUG|Fluticasone Propionate|Participants will cycle topical steroid in a three-months on three-months off fashion
40786525|NCT05444543|DRUG|Budesonide|Participants will cycle topical steroid in a three-months on three-months off fashion
40786526|NCT06379828|OTHER|Please note that this is an observational study; not applicable|Please note that this is an observational study; not applicable
40786527|NCT01731795|DRUG|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
41488588|NCT05757323|OTHER|infant formula based on intact protein|infant formula based on intact protein
40786528|NCT04842968|OTHER|Methylene blue injection|Methylene blue solution is injected ex vivo in the main supplying artery trunk of the freshly removed colorectal specimen. (50 mg in 30 ml saline)
40786529|NCT01349673|DRUG|Budesonide Foam|Topical
40786530|NCT06078475|OTHER|Postoperative analgesia management|Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
40786531|NCT01080417|DRUG|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
40786532|NCT03847831|BEHAVIORAL|Active School Flag Program|Schools enrolled in the program take part in the 17 actions described in the PPASF.
40786533|NCT01087593|DRUG|17β-estradiol|Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
40786534|NCT02061475|DRUG|Lidocaine Patches|
40786535|NCT00183014|BEHAVIORAL|The Lifetime Fitness Program|A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
40786536|NCT00183014|BEHAVIORAL|Exercise class|1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
40786537|NCT06299592|COMBINATION_PRODUCT|PET/MRI using [18F]FEPPA tracer|PET/MRI scans with \[18F\]FEPPA radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia
40786538|NCT01624935|BEHAVIORAL|interpersonal psychotherapy|interpersonal psychotherapy
40786539|NCT00418704|DRUG|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
40786540|NCT00418704|DRUG|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
40786541|NCT02149459|RADIATION|Partial brain re-irradiation.|Partial brain re-irradiation to a dose of 30-35Gy delivered over 2 weeks (10 fractions).
40786542|NCT02149459|DRUG|Metformin|Different cohorts will receive no, low dose or higher dose metformin.
40786543|NCT02149459|BEHAVIORAL|low carbohydrate diet|Under close supervision of a dietician, patients will receive a low carbohydrate diet, enriched as necessary with medium chain triglyceride (MCT) supplements.
40786544|NCT01787383|DRUG|Ingenol mebutate gel 0.05 %|Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
40786545|NCT01787383|DRUG|Ingenol mebutate gel 0.015 %|Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
40786546|NCT05672914|BEHAVIORAL|Tablet-based sustained care|A tablet-based motivational-interviewing intervention, tailored specifically to smokers with psychiatric disorders, to motivate the use of evidence-based tobacco treatment and cessation in cigarette smokers upon discharge from an inpatient psychiatric hospitalization. In addition, participants will receive standard hospital tobacco care (see Usual Care Arm).
40786547|NCT01123343|DEVICE|TrueVision 3D Visualization and Guidance System for MicroSurgery|Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
40786548|NCT05067205|PROCEDURE|Carpal tunnel release surgery|Preoperative, 3 days, 2 weeks, 4 weeks and 24 weeks postoperatively
40786549|NCT01387750|OTHER|Mentholated Cream|A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
40786550|NCT01387750|OTHER|Mentholated Cream with OGT|A Topical Cream that contained both menthol and oxygenated glycerol triesters.
40786551|NCT00484341|DRUG|low-dose NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
40786552|NCT00484341|DRUG|high-dose NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
40786553|NCT00484341|DRUG|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
40786554|NCT06160141|OTHER|Resistance training|"Resistance training program. The RT program was performed over 48 weeks, three times per week (Mondays, Wednesdays, and Fridays), during the morning, in the University fitness facility. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise) with substantial RT experience to ensure consistent and safe exercise performance.~Participants performed four exercises for the trunk and upper limbs and four exercises for the lower limbs in three sets of 8-12 repetitions. T Rest intervals were 1-2 and 2-3 min between sets and exercises. The training load was individually adjusted for each exercise weekly, according to the number of repetitions performed during the last training session, to ensure that the subjects kept performing at the ideal intensity for the repetition zone. In these situations, training loads were increased by 2-5% for upper-limb exercises and 5-10% for lower-limb exercises."
40786555|NCT04686344|DRUG|intermittent boluses of Hypertonic saline|intermittent boluses every 6 hours over 30 min for 48 hours
40786556|NCT04686344|DRUG|continuous infusion of Hypertonic saline|continuous infusion over a period of 48 hours
40786557|NCT05659849|OTHER|Manual therapy techniques|Passive joint mobilization techniques are applied to the affected knee joint. For the first week (three sessions), the joint mobilization exercises included grade I or II rhythmic oscillations. During the following weeks, grade III or IV oscillation techniques were applied, depending on the level of tolerance and pain of each patient. In knee distraction, the patients are in a prone position with 50° knee flexion, and the physical therapist applies the techniques. The dorsal and ventral glides was performed with the patient in a supine position.
40786558|NCT05659849|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) therapy treats pain using low-voltage electric currents. A small device administers the electrical current to or near nerves. TENS treatment inhibits or changes pain perception.
40786559|NCT01379807|DRUG|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
40786560|NCT04679038|BIOLOGICAL|SHR-1701|Intravenous (IV) on Day 1 of each cycle
40786561|NCT04679038|DRUG|Famitinib|Famitinib, po, qd
40786562|NCT01130337|DRUG|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
40786563|NCT01130337|DRUG|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
40786564|NCT01130337|DRUG|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
40786565|NCT00000226|DRUG|Buprenorphine|
40786566|NCT06127602|BEHAVIORAL|Reactive balance training with Neuromuscular Electrical Stimulation|REACT-NMES group: The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level. NMES will be delivered to the vastus lateralis synchronously with the perturbation, which will always occur 50 ms after slip-onset and last for 450 ms including the period between liftoff to touchdown of the first compensatory step.
40786567|NCT06127602|BEHAVIORAL|Reactive balance training without Neuromuscular Electrical Stimulation|REACT group: The REACT group will undergo the same reactive balance training (in terms of type, dosage: intensity, frequency) as the REACT-NMES group. The only difference will be that the REACT group will receive ShamNMES for same time after the compensatory step touchdown. The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level.
40786568|NCT00548834|DRUG|CDP870|
40786569|NCT02616731|DRUG|Tranexamic Acid|use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
40786570|NCT02616731|DRUG|Diosmin|use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
40786571|NCT02008994|OTHER|Genomic and Proteomic Profiling|Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
40786572|NCT04725019|DEVICE|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during 20 min of motor training.
40786573|NCT04725019|BEHAVIORAL|Motor training|Participants will engage in a high number of repetition of movements that use both hands while playing with toys and games. Training will be provided 20 min/day, for 5 consecutive days.
41341664|NCT06291545|DEVICE|ScoreFlex NC Coronary Dilatation Catheter|One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the ScoreFlex NC Coronary Dilatation Catheter treatment group.
41341665|NCT00183261|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
41341666|NCT00183261|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef placebo|1.0 mL administered intramuscularly
40786574|NCT03089047|BIOLOGICAL|Transfusion of rejuvenated and washed autolgous RBCs|Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
40786575|NCT03089047|BIOLOGICAL|Transfusion of washed autolgous RBCs|Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
40786576|NCT04422431|DRUG|Bis-Choline Tetrathiomolybdate|Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
40786577|NCT03814928|BEHAVIORAL|Caregivers eCourse|Investigators will request that family/caregivers/general public watch a self-paced (60-90 minutes) online e-learning training session for recovery after hip fracture.
40786578|NCT00002139|DRUG|Azithromycin|
40786579|NCT03046836|DRUG|Oxytocin|40 IU oxytocin nasal spray
40786580|NCT03046836|DRUG|Placebo|Saline
40786583|NCT03745638|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
40786584|NCT03745638|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
40786585|NCT04000061|OTHER|medical chart review|data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
40786586|NCT04000061|OTHER|data generated by direct IT export|data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
40786587|NCT04143230|OTHER|Screening for PC by means of two different screening tools|Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
40786588|NCT00746187|DEVICE|ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.|
40786589|NCT00746187|DEVICE|3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm|
40786590|NCT03117114|DEVICE|Endocuff Vision assisted polypectomy|EVD mounted to the tip of the endoscope, therefore EVD assisted polypectomy
40786591|NCT03117114|OTHER|Standard polypectomy|Absence of an EVD, standard polypectomy
40786592|NCT03565172|DIAGNOSTIC_TEST|isokinetic dynamometer with ultrasound|children are lying prone on a isokinetic dynamometer with ultrasound which stretches spastic and paretic plantarflexors muscles very slowly until maximal torque tolerated. The parameters can be measured.
40786593|NCT03565172|OTHER|Visual Analog Scale (VAS)|the discomfort level will be measured by Visual Analog Scale (VAS) completed by children. 0 = no discomfort and 10 = maximum discomfort
40786594|NCT03565172|DIAGNOSTIC_TEST|Stretching|the ankle of children will be mobilized for 5 minutes (first two weeks) to 10 minutes (last two weeks).
40786595|NCT00005579|DRUG|dolastatin 10|
41341667|NCT00198289|DRUG|Aurexis® (tefibazumab)|
41341668|NCT04095793|DRUG|ampreloxetine|Oral tablet, QD
40786596|NCT03186430|BEHAVIORAL|Comprehensive Vaccine Promotion Package|"Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room."
40786597|NCT03421886|DEVICE|Aerodentis system|The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.
40786598|NCT03421886|DEVICE|Invisalign clear aligner system|Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
40786599|NCT04608019|OTHER|Immediate Antibiotics|increase airway clearance/start oral antibiotics right away
41341669|NCT01305941|DRUG|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
41341670|NCT01305941|DRUG|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
41341671|NCT01305941|DRUG|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
41341672|NCT03874104|DIETARY_SUPPLEMENT|Extensively Hydrolysed Formula containing Pre- & Probiotics|Extensively Hydrolysed Formula containing Pre- and Probiotics
41341673|NCT02054936|DRUG|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
41341674|NCT02054936|DRUG|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
41341675|NCT05434936|PROCEDURE|Oophorectomy|Patients undergoing surgery for any indicated procedure for fertility-threatening treatment will have attempt at collecting ovarian tissue at time of surgery.
40786600|NCT04608019|OTHER|Tailored Treatment|increase airway clearance and start oral antibiotics later if symptoms get worse or do not get better
40786601|NCT02546882|BIOLOGICAL|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
40786602|NCT02546882|DRUG|saline|1 ml saline was injected for 1 cm2 area.
40786603|NCT02374541|BEHAVIORAL|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
40786604|NCT01101451|DRUG|Cisplatin|Given IV
40786605|NCT01101451|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
40786606|NCT01101451|RADIATION|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
40786607|NCT01101451|OTHER|Laboratory Biomarker Analysis|Correlative studies
40786608|NCT01101451|OTHER|Quality-of-Life Assessment|Ancillary studies
40786609|NCT01101451|OTHER|Questionnaire Administration|Ancillary studies
40786610|NCT02073162|PROCEDURE|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
40786611|NCT05705479|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
40786612|NCT05705479|PROCEDURE|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
40786613|NCT04037228|DEVICE|KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California)|The KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California) is an accelerometer-based, portable navigation device for TKA that attempts to combine the alignment accuracy of large-console CAS systems, with the ease of use and convenience of conventional alignment methods. It is used to perform the proximal tibial and distal femoral resections in TKA. It consists of a disposable display console (2 × 4 × 2 inches in size) and a reference sensor, both of which are used for the tibial and femoral resections The display console and reference sensor each contains triaxial accelerometers that communicate wirelessly with one another. Briefly, the tibial jig has 2 primary components (a fixed component and a mobile component) connected by a proximal articulation .The fixed component, with the attached reference sensor, is first pinned to the tibia. The purpose of the fixed component is to account for the movement of the tibia during cutting block alignment.
40786614|NCT06513065|DRUG|Mitomycin c|"Mitomycin is a tumour antibiotic isolated from the broth of Streptomyces species. It has alkylating properties, which results in DNA cross-linking. Once MMC enters the tumour cell, it needs microsomal modification by various enzymes to be transformed into active state; free radicals constituted of semiquinones of MMC are responsible for its cytotoxic effects.~Mitomycin is licenced in the UK and recommended by NICE for intraperitoneal chemotherapy."
40786615|NCT00844103|DRUG|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
40786616|NCT00844103|DRUG|Placebo|10ml oral solution administered once a day over 10 days.
40786617|NCT05341310|BEHAVIORAL|ADHDCoach|ADHDCoach is an individually-tailored intervention to reduce parents' of children diagnosed with ADHD distress.
40786618|NCT05341310|OTHER|Treatment as usual|Treatment as usual in the outpatient clinic
40786619|NCT01881282|DRUG|Carraghenates Cream|Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
40786620|NCT01881282|DRUG|Mayinglong Musk Hemorrhoid Ointment|Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
40786621|NCT06046248|DRUG|Belumosudil|200mg PO QD x 24 cycles (28-day cycle)
40786622|NCT06046248|DRUG|Rituximab|375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
40786623|NCT03333694|DRUG|Cutaneous Cream application|Cutaneous Cream application twice daily with experimental (CLL442)
40786624|NCT03333694|DRUG|Placebo Cutaneous Cream application|Cutaneous Cream application twice daily with placebo
40786625|NCT03635788|DRUG|Standard of Care (SOC) Oral ART|SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
40786626|NCT03635788|DRUG|Oral RPV|RPV 25 mg tablets
40786627|NCT03635788|DRUG|Oral CAB|CAB 30 mg tablets
40786628|NCT03635788|DRUG|RPV-LA Loading Dose|900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
40786629|NCT03635788|DRUG|CAB-LA Loading Dose|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
40786630|NCT03635788|DRUG|RPV-LA Maintenance Dose|600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
40786631|NCT03635788|DRUG|CAB-LA Maintenance Dose|400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
41488589|NCT00697684|DRUG|Antithymocyte Globulin|
40786633|NCT05200312|DRUG|Zanubrutinib|160 mg capsules administered by mouth twice daily (21-day cycles).
40786634|NCT05200312|DRUG|Lenalidomide|25 mg capsules administered by mouth once daily on Day 1 to Day 10 of each cycle (21-day cycles)
41341676|NCT03515616|DIAGNOSTIC_TEST|TP us in labour|TP US will be made to pregnant lady in first stage of labour with OS and PC angel measurements
40786635|NCT05200312|DRUG|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
40786636|NCT05200312|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
40786637|NCT05200312|DRUG|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
40786638|NCT05200312|DRUG|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
40786639|NCT05200312|DRUG|Prednisone (or equivalent)|40 mg/m2 capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
41341677|NCT04449991|PROCEDURE|Repeat kidney biopsy|Intensification of immunosuppression if NIH AI \> 3
41341678|NCT03621189|DEVICE|intermittent theta burst stimulation|stimulatory protocol
41341679|NCT00678249|DEVICE|FLAIR Endovascular Stent Graft|Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
41341680|NCT00678249|PROCEDURE|PTA|Percutaneous Transluminal Angioplasty
40786640|NCT02607410|DRUG|sitagliptin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
40786641|NCT02607410|DRUG|NPH insulin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
40786642|NCT06576427|DEVICE|Vertex Pulmonary Embolectomy System|Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
40786643|NCT03071861|DRUG|Darbepoetin Alfa|Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age
40786644|NCT03071861|DRUG|Normal Saline|Single dose of normal saline, IV, given at less than 24 hours of age
40786645|NCT05753462|DRUG|Phase 1, SQY51|SQY51 is administered by intravenous infusion.
40786646|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 1)|SQY51 is administered by intravenous infusion at dose 1
40786647|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 2)|SQY51 is administered by intravenous infusion at dose 2.
40786648|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 3)|SQY51 is administered by intravenous infusion at dose 3.
40786649|NCT02987257|DRUG|Harmonized supportive care|Harmonized supportive care with and etanercept placebo days 1 and 4
40786650|NCT02987257|DRUG|Etanercept 50 mg sc day 1 and day 4|Harmonized supportive care with placebo
40786651|NCT04514107|OTHER|Brazilian National Dengue Control Program|This program has 4 basic principles: 1) Adequate case finding, classification and treatment; 2) Epidemiological surveillance and reporting of all cases; 3) Mobilization and communication of risks to the public; 4) mosquito monitoring and control which consists fundamentally of detection of larva using a rapid larval index (LIRAa) followed by removal of breeding sites and local spraying.
40786652|NCT04514107|OTHER|Wolbachia-infected Aedes aegypti|Brazilian strain of Aedes aegypti infected with Wolbachia pipientis released into geographic clusters.
40786653|NCT01111227|DRUG|Propofol and isoflurane|Comparison of two anesthetic drugs
40786654|NCT00000857|DRUG|Interleukin-12|
40786655|NCT05533632|DRUG|Semaglutide|Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.
40786656|NCT02747758|DEVICE|cathodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using cathodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
40786657|NCT02747758|DEVICE|sham transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using a sham-stimulation including ramp up and ramp down of current.
40786658|NCT02747758|DEVICE|anodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using anodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
40786659|NCT02868424|DRUG|fRPE cells|fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
40786660|NCT02696603|BEHAVIORAL|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
40786661|NCT02696603|BEHAVIORAL|Phonation|"Participants are asked to record themselves saying Aaah for 10 seconds using the iPhone microphone. This activity is designed to assess vocal features, including vocal tremor. The investigators extract features from the digital audio signals of these sustained phonations. The investigators apply feature selection and classifier algorithms and analyze these phonations using methods similar to those employed in the Parkinson Voice Initiative."
40786662|NCT02696603|BEHAVIORAL|Gait and balance|Participants are asked to walk back and forth for 30 seconds and then stand still for 30 seconds. Gait and balance are measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
40786663|NCT02696603|BEHAVIORAL|Memory|Participants are asked to complete a visuospatial short-term memory game related to the Corsi block tapping test \[Corsi, P.M. (1972)\] as adapted by Kate Possin, PhD of the University of California San Francisco Memory and Aging Center (personal communication, 2015). In this activity, participants are presented with a grid of objects that change color in a set pattern. Participants are then asked to tap the objects in that same pattern. The investigators assess the sequence length completed.
40786664|NCT02696603|BEHAVIORAL|Dexterity|Participants are asked to tap on the phone screen with alternating fingers. This test can be done with either or both hands. The investigators record the rhythm, speed, and location of these taps using the touch sensors of the iPhone screen. The investigators assess participant dexterity through a combination of steadiness, speed, and tap precision.
40786665|NCT02696603|BEHAVIORAL|Participant open-response writing|Qualitative participant feedback is used to assess participant engagement with, understanding of, and acceptance of app-based research.
40786666|NCT02696603|OTHER|Parkinson mPower mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Parkinson mPower.
40786667|NCT03659110|BIOLOGICAL|HPV 4|1000 subjects will be received the HPV 4 vaccine
40786668|NCT05572840|OTHER|Training and activities|"The training program consists of two modules. The 1st module consists of a theoretical lecture (powerpoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (powerpoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks)."
40786669|NCT03314935|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
40786670|NCT03314935|DRUG|Oxaliplatin|Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
40786671|NCT03314935|DRUG|Leucovorin|Leucovorin at the protocol-defined dose and regimen.
40786672|NCT03314935|DRUG|5-Fluorouracil|5-Fluorouracil at the protocol-defined dose and regimen.
40786673|NCT03314935|DRUG|Gemcitabine|Gemcitabine at the protocol-defined dose and regimen.
40786674|NCT03314935|DRUG|Cisplatin|Cisplatin at the protocol-defined dose and regimen.
40786675|NCT03314935|DRUG|Paclitaxel|Paclitaxel at the protocol-defined dose and regimen.
41466567|NCT05647616|OTHER|Strengthening exercises|Participants in group A will be required to complete 12 sessions in 4 to 6 weeks. Resistance-Bands will be used to do ankle plantar flexion and eversion (3 sets of 10 repetitions). Participants will have to be seated on the floor with the knee extended and instructed to perform the movement at the ankle joint without allowing extraneous movement at hip and knee. The resistance band will be doubled and securely attached to the base of a table. The training resistance will be determined by calculating 70% of the resting length of the resistance band and adding this distance to the resting length of the resistance band. Using this calculated distance, the examiner will place a mark to which the resistance band will be stretched during exercise performance on the floor. Each week a study investigator will track each participant's completion. Participants will be instructed to move through their entire range of motion for the direction of each exercise.
40786676|NCT04720378|BIOLOGICAL|ST266|1X ST266
40786677|NCT04669093|BEHAVIORAL|"Placebo cream- promotion suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a promotion approach (promoting good feelings)."
40786678|NCT04669093|BEHAVIORAL|"Placebo cream- prevention suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a prevention approach (preventing pain)."
40786679|NCT04669093|BEHAVIORAL|Control cream|In a control condition, with the same cream as in the placebo interventions, participants will be instructed that the cream is a control cream with no effects.
40786680|NCT02579434|DRUG|Midazolam I.V.|Midazolam I.V. 1mg/ml
40786681|NCT06287372|OTHER|Cardioplegic solution|Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection
40786682|NCT02565992|BIOLOGICAL|CAVATAK|Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
40786683|NCT02565992|DRUG|Pembrolizumab|Intravenous pembrolizumab at 2 mg/kg solution.
40786684|NCT02746588|OTHER|Office hysteroscopy|Diagnostic hysteroscopy with biopsy
40786685|NCT02874443|OTHER|Knowledge Translation of labor management guidelines|
40786686|NCT03388541|DRUG|Dexmedetomidine|Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
40786687|NCT03388541|DRUG|Placebo|A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
40786688|NCT06266000|DRUG|Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
40786689|NCT06266000|DRUG|Commercial Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
40786690|NCT06266000|DRUG|Palm Oil capsule|Palm oil capsule
40786691|NCT06341881|BEHAVIORAL|Transitional Care Training Program|A nursing based transitional care training intervention would be carried out to prepare the family caregivers to take care of their elderly stroke survivors at home. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the family caregivers at their homes after hospitalization. The study participants would be evaluated after 8 weeks of the intervention. A structured, validated and literature based assessment checklist will be devised to assess the usefulness and feasibility of the intervention. Assistance of senior nurses and health professionals, specialized in stroke care will be taken during the training part of the program.
40786692|NCT01642446|PROCEDURE|Precise hepatectomy|Precise hepatectomy
40786693|NCT01642446|OTHER|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
40786694|NCT03117959|DEVICE|Stryker ShapeMatch Technology|Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.
40786695|NCT03117959|DEVICE|Stryker Triathlon Custom Fit Knee|
41307868|NCT05448560|BEHAVIORAL|Multi-level Intervention of shared model of survivorship care|1) Patient survivorship education via telehealth with the cancer center- The research registered nurse (RN) will discuss the contents of the survivorship care plan and coordination between the cancer center and PCP clinic. 2) Ongoing patient-tailored education program by MyChart within the EHR patient portal- Patients will be asked to select survivorship topics of interest from a panel (e.g. school issues, fertility, fatigue, physical activity, single kidney health, emotions/coping) that will then be sent over 1 year. 3) Structured interactive phone communication between the research RN at the cancer center and community PCP clinic- The discussion will explain the patient's cancer history, tumor recurrence monitoring schedule, individualized risk of late effects and surveillance schedule, psychosocial challenges, health behaviors, and coordination between the cancer center and PCP clinic. 4) In-person visit with the PCP clinic for survivorship care.
41307869|NCT05448560|OTHER|Comparison Group|Participants will be contacted by study staff at their cancer center to schedule an in-person visit at the survivorship clinic that will include a comprehensive history focused on cancer-related medical and psychosocial issues, physical examination, ordering of recommended surveillance for late effects, and delivery of hard copy of their survivorship care plan.
40786696|NCT03929666|DRUG|ZW25 (Zanidatamab)|"* Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~* Part 2: RD identified in Part 1"
40990828|NCT06336460|PROCEDURE|Fascia Iliaca Compartment (FIC) Block for Patients with Isolated Hip Fractures|"Under sterile technique, physician will identify relevant landmarks, including femoral artery, femoral vein, femoral nerve, iliacus muscle with overlying fascia iliaca.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting the fascial plane above iliacus muscle.~As needle tip reaches the target, a small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush the line of remaining anesthetic. The needle will then be withdrawn."
41307870|NCT05180110|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
41307871|NCT05180110|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
41307872|NCT02991937|DRUG|Piperacillin/Tazobactam|24 hours of IV antibiotic administration
41307873|NCT02991937|PROCEDURE|Surgical Treatment|Appendectomy
41307874|NCT02175173|DRUG|Rufinamide|Administration of Inovelon 100mg or 200mg Tablets
41466568|NCT02203617|BEHAVIORAL|Educational Content/Pediatric Anticipatory Guidance|educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
41466569|NCT02203617|BEHAVIORAL|Book provision|Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
40786697|NCT03929666|DRUG|Capecitabine|Administered orally twice daily (PO bid)
40786698|NCT03929666|DRUG|Cisplatin|Administered IV
40786699|NCT03929666|DRUG|Fluorouracil|Administered IV
41307875|NCT05127096|DIAGNOSTIC_TEST|FirstSight blood test|FirstSight blood test for colorectal cancer screening
41307876|NCT02554253|DRUG|Ketamine|Ketamine used for induction
40786700|NCT03929666|DRUG|Leucovorin|Administered IV
40786701|NCT03929666|DRUG|Oxaliplatin|Administered IV
40786702|NCT03929666|DRUG|Bevacizumab|Administered IV
40786703|NCT03929666|DRUG|Gemcitabine|Administered IV
40786704|NCT06026280|BEHAVIORAL|DRIVEN Application|Participants will complete the six-week DRIVEN program, which includes a smartphone application and job coaching.
40786705|NCT06026280|OTHER|Career Resources|Participants will receive weekly information about job-searching skills and resources from a study coordinator for six weeks.
41307877|NCT02554253|DRUG|Propofol|Propofol for induction
41307878|NCT00540553|DRUG|placebo|
41307879|NCT00540553|DRUG|GSK971086|
41307880|NCT01788306|DRUG|OOPEN+BBCC|Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
41341681|NCT00678249|DEVICE|FLAIR Endovascular Stent Graft|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
41341682|NCT04655690|DRUG|NNC0471-0119|Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
41307881|NCT03958682|DEVICE|AR smart wearing equipment combined with 4G + satellite information transmission system|"We are going to add a pair of wearable smart glasses with AR function to the original flight helmet .During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.~It can not only transmit the patient's information in the cabin to the ground medical institutions in real time, but also transmit the rescue plan of the ground medical experts to the rescue helicopter in real time to ensure the safety of patients in transit ,which will save the time for medical staff to hand over after landing and reduce errors."
40786706|NCT06319781|OTHER|Observational|The study is a prospective non-interventional, observational study.
40786707|NCT04924621|DEVICE|Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.|"The nasal cavity was disinfected with Iodophor cotton swab, and the appropriate nasal cavity was selected for endotracheal intubation assisted by fiberoptic bronchoscope according to the experience of anesthesiologists.~After the endotracheal intubation was fixed, the anesthesia machine was connected for mechanical ventilation. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg."
40786708|NCT04924621|DEVICE|Mask ventilation|The Control Group will receive sequential intravenous infusion of Sufentanil 5ug, midazolam 0.05mg/kg, and propofol 1-2ug/ml, to make the BIS between 70 and 80. 2ml tetracaine was injected with cyclothyroid membrane puncture, and the nasal cavity was disinfected with iodophor cotton swab. According to the experience of anesthesiologists, the appropriate nasal cavity was selected for intranasal endotracheal intubation assisted by fiberbronchoscope. After the endotracheal intubation was successful, the anesthesia machine was connected for mechanical ventilation, full narcotic inducer will be injected. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.
40786709|NCT04924621|DRUG|Midazolam(T group)|Midazolam 0.05mg/kg, intravenous injection
40990829|NCT05440279|DEVICE|digital patient support|"Intervention takes place through a regular electronic therapy support in addition to standard care that is defined as follows:~Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~1. electronic questionnaires (web-based) on possible problems during therapy and subjective therapy success,~2. possibility to set personal adherence goals every week,~3. links to explanations and videos on therapy and the handling of therapy equipment and accessories,~4. provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring."
41307882|NCT02125487|BEHAVIORAL|Teaching using Hybrid Simulation of breast examination|"Students in the intervention/experimental group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)"
40990830|NCT01393808|DRUG|Paricalcitol|1-month Paricalcitol 2mcg/day
41307883|NCT02125487|BEHAVIORAL|Teaching using traditional method|"Students in the control group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE."
41307884|NCT06250127|DEVICE|Modified 3D printed facemask|modified 3D printed customized maxillary protraction facemask will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
41307885|NCT06250127|DEVICE|Conventional facemask appliance|Conventional facemask appliance will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
41307886|NCT05238467|OTHER|COVID antibody titers in the blood|COVID antibody titers will be quantitatively assessed at baseline, 8 weeks and approximately 6, 9, and 12 months from date of study enrollment. Titers will be compared to levels in 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent,.and in 25 age matched cancer participants who are on non-immunosuppressive treatments as defined below.
40786710|NCT04924621|DRUG|Sufentani(T group)|Sufentanil 0.02-0.05ug/kg, intravenous injection
40786711|NCT04924621|DRUG|Propofol(T group)|Propofol 2-3ug/ml, intravenous injection
40990831|NCT01393808|OTHER|placebo|1-month Placebo Treatment
40990832|NCT01734330|BEHAVIORAL|Cognitive behavioral therapy in group|
40990833|NCT01734330|DRUG|Nicotine replacement|
40990834|NCT00862810|BIOLOGICAL|Received HPV vaccine first|
40990835|NCT00862810|BIOLOGICAL|Received concomitant vaccines first|
40990836|NCT00002304|DRUG|Ketoconazole|
40990837|NCT00002304|DRUG|Fluconazole|
40990838|NCT00245206|DRUG|Aripiprazole|Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
40990839|NCT00245206|DRUG|Olanzapine|Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
40990840|NCT00245206|DRUG|Risperidone|Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
41017737|NCT02403310|DRUG|Selinexor|"Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~* Dose Level 2: 80 mg twice weekly.~* Dose Level 1 (starting dose): 60 mg twice weekly.~* Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months."
41307887|NCT05381012|OTHER|Allodynia, quality of life, sleep, anxiety and depression, disability, and central sensitization|All patients will be evaluated for allodynia, quality of life, sleep, anxiety and depression, disability related to headache, and central sensitization.
41307888|NCT05381012|OTHER|Fibromyalgia syndrome|Patients who meet the diagnostic criteria for fibromyalgia syndrome will be evaluated with the Fibromyalgia Impact Questionnaire.
41307889|NCT03797040|BIOLOGICAL|Cell therapy|PLX-R18: Allogeneic ex vivo expanded placental stromal cells
40786712|NCT04924621|DRUG|Rocuronium(T group)|Rocuronium 0.06mg/kg, intravenous injection
41307890|NCT06552611|COMBINATION_PRODUCT|Transcutaneous electrical spinal cord stimulation + therapy|A two-channel transcutaneous spinal cord stimulator (SCONE, SpineX, Inc.) will deliver non-invasive electrical stimulation during hand therapy sessions. For each session, two self-adhesive hydrogel electrodes will be positioned along the midline of the C3-C4 and C6-C7 spinous processes over the skin as cathodes to stimulate the cervical spinal cord at two vertebral levels. An additional pair of electrodes will be symmetrically positioned over either the iliac crests or shoulders, functioning as anodes. The electrical current employed for the transcutaneous spinal cord stimulation is biphasic, featuring a 1-millisecond pulse width, a base frequency of 30 Hz, and an overlapping frequency of 10 kHz. Stimulation intensity will range from 0 to 120 milliamperes (mA), with incremental increases of 5 mA until reaching the level that facilitates voluntary movement. The stimulation amplitude will be fine-tuned for each specific activity based on the therapist's observation.
40786713|NCT04924621|DRUG|Drug use target(T group)|Make BIS \< 60 .
40786714|NCT04924621|DRUG|Sufentanil(C group)|Sufentanil 5ug, intravenous injection
41307891|NCT06552611|OTHER|Occupational Therapy|The hand therapy program is comprised of intensive, progressive, functional task practice following a standardized protocol. The protocol consists of repetitive activities of gross upper limb movement, isolated finger movements, bimanual task performance, simple and complex pinch, and grip performance. Several activities with various difficulty levels are designated for each category, and the participant will perform 1-2 activities within each category in each training session. Activities are chosen according to the participant's ability, interests, and needs and are modified as function progresses over time.
41307892|NCT05112016|PROCEDURE|Total mesorectal excision for rectal cancer|
41307893|NCT02278289|DEVICE|ultrasound|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
41307894|NCT02278289|PROCEDURE|paraffin therapy|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
41307895|NCT01592279|DRUG|liraglutide|
41307896|NCT01592279|DRUG|Insulin injections|
41307897|NCT06122428|DRUG|modified hyaluronic acid 0.1% covalently linked to Riboflavin|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
41307898|NCT06122428|DRUG|hyaluronic acid 0.1%|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
41307899|NCT00152815|DRUG|antioxidant vitamin E|Vitamin E 800IU per day for 12 months
41307900|NCT00152815|BEHAVIORAL|weight reduction and exercise|Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
41341683|NCT04655690|DRUG|Fast-acting insulin aspart|Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.
41341684|NCT02380482|OTHER|Transthoracic echocardiography on TBI patients|Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma
40786715|NCT04924621|DRUG|Midazolam(C group)|Midazolam 0.05mg/kg, intravenous injection
40786716|NCT04924621|DRUG|Propofol|Propofol 1-2ug/ml, intravenous injection
40786717|NCT04924621|DRUG|Tetracaine(C group)|2ml tetracaine was injected with cyclothyroid membrane puncture.
40786718|NCT04924621|DRUG|Drug use target|Make the BIS between 70 and 80.
40786719|NCT03196830|BIOLOGICAL|CAR-T|For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy
40822861|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living. This therapy has shown impressive improvements in children with PC."
41017738|NCT02403310|DRUG|Daunorubicin|"Induction: Daunorubicin 60 mg/m\^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m\^2/day (days 1-2)."
41017739|NCT02403310|DRUG|Cytarabine|"Induction: Cytarabine 100 mg/m\^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m\^2/day (continuous infusion on days 1-5)."
41017740|NCT06365853|DRUG|Mirvetuximab Soravtansine|Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα monoclonal antibody (mAb) M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
41017741|NCT06365853|DRUG|Lubricating Eye Drops|Lubricating artificial tears should be administered at least 15 minutes after corticosteroid or brimonidine eye drop administration.
41017742|NCT06365853|DRUG|Prednisolone acetate ophthalmic suspension 1% eye drops|Self-administration of prednisolone acetate ophthalmic suspension 1% eye drops as prescribed by the treating physician.
41017743|NCT06365853|DRUG|Brimonidine tartrate ophthalmic solution eye drops|Self-administration of brimonidine tartrate ophthalmic solution eye drops as prescribed by the treating physician.
41341685|NCT02380482|OTHER|Transthoracic echocardiography on control patients|Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
41341686|NCT02037204|OTHER|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
41341687|NCT03190967|DRUG|T-DM1|T-DM1 3.6 mg/kg intravenous (IV) every 21 days
41341688|NCT03190967|DRUG|TMZ|Phase I: TMZ 30, 40 or 50 mg/m\^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
40786720|NCT05647499|BEHAVIORAL|The Back 2 School program for problematic school absenteeism|We will use the Danish version of the revised manual developed within the B2S study in Aarhus, Denmark. The B2S program consists of a 3 to 3,5 -hour initial clinical assessment, a clinical conference, 11 sessions where the youth and/or parent are attending, and a booster session after three months including youth and parent. The B2S manual comprise four school meetings with the child, parents, school staff and therapists present. In the Norwegian pilot study, we will add an extended school module to the B2S-program. The school module includes a pre-meeting interview with the schools in week 1 and session 1 with the school in week 2 or 3. The B2S counselor and the school will decide whether there is a need for an additional meeting between school meetings 1 and 2. There is also a booster session with the child, parents, the school and the B2S team 3 months after the program.
41307901|NCT03349541|OTHER|Complex Care Curriculum|"A well-established approach to curriculum development was utilized to develop competency-based objectives aligned with the Canadian CanMEDS Physician Competency Framework, identify appropriate educational strategies and design relevant evaluations."
41307902|NCT00233259|BEHAVIORAL|Mediterranean Diet|Mediterranean dietary program
41307903|NCT00233259|BEHAVIORAL|Physical Activity|Physical activity program
41307904|NCT00233259|BEHAVIORAL|Stress Management|Stress management program
41307905|NCT00233259|BEHAVIORAL|Social Support|Social support
40786721|NCT01332214|DRUG|AZD2820|Subcutaneous Injection in abdomen or Thigh
41307906|NCT00233259|BEHAVIORAL|Smoking Cessation|Smoking cessation program
41307907|NCT00233259|OTHER|Control group|Usual Diabetes Care Control group
41307908|NCT06350344|DEVICE|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients with high-risk of VTE during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
41307909|NCT03354819|BEHAVIORAL|Modified MBCT|"Compared with the original protocol of Mindfulness-based Cognitive Therapy (Segal et al., 2002), the modified MBCT protocol in this pilot study has the following changes:~Outline:~Session 1 Awareness and automatic pilot:~Session 2 Living in our head~Session 3 Gathering the scattered mind~Session 4 Recognizing aversion \& allowing~Session 5 Thoughts are not facts~Session 6 Take care of myself~Session 7 Maintaining and extending new learning"
41307910|NCT03354819|BEHAVIORAL|SIRE on dementia|"The SIRE program includes routine education sessions on dementia care, caregiver skills training, and group sharing on caregiving tasks.~Outline:~1. Overview of dementia~2. Pharmacological and non-pharmacological treatment of dementia~3. BPSD in dementia care~4. Person center care~5. Advance planning in people with dementia~6. Principle of mindfulness~7. Non-pharmacological intervention on stress reduction"
40786722|NCT01332214|DRUG|Placebo|Subcutaneous Injection in abdomen or Thigh
40786723|NCT04512118|DIAGNOSTIC_TEST|PET-CT of 18F-FDG|Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)
40786724|NCT06486766|BEHAVIORAL|Norwegian SMS|Individuals receive a SMS in Norwegian language at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is applicable to all three populations (general population, immigrants born in Poland, immigrants born in Ukraine)
40786725|NCT06486766|BEHAVIORAL|Polish/Ukrainian SMS|Individuals receive an SMS in the official language of their native country (i.e., Polish or Ukrainian) at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is only applicable to the two immigrant populations (immigrants born in Poland, immigrants born in Ukraine)
41017744|NCT05428969|DRUG|Bexmarilimab|Intravenous
41307911|NCT01405846|DRUG|Gefitinib|250mg od for 6 months
41307912|NCT04767633|DRUG|split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing|The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
41307913|NCT05218850|DRUG|Butyrate|Butyrate enemas will be administered once a day for 12 weeks
41307914|NCT03191006|DEVICE|MEI BIN insoles|insoles
41307915|NCT01830543|DRUG|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
40786726|NCT05822154|OTHER|comprehensive geriatric assessment|The clinical, biological and functional characteristics will be collected in elderly subjects attending the hospitals of participating centers.
40786727|NCT05535114|OTHER|Yoga-resistance exercise|Breathing exercise (5 minutes), flexibility (5 minutes), resistance exercise (20 minutes), relaxation \& meditation (10 minutes).
40786728|NCT00414570|DRUG|[18]F-FLT PET scan|Injection of \[18\]F-FLT radiopharmaceutical followed by PET imaging.
40786729|NCT02235571|BEHAVIORAL|iChoose Kidney Decision Aid|Providers will use a shared decision making tool with patients via iPhone, iPad, or web which explains predicted individualized risk of mortality on dialysis vs. transplant during the evaluation appointment for kidney transplant.
40786730|NCT03420365|BEHAVIORAL|Aerobic exercise|30 minutes of either aerobic, or balance and coordination, or reading magazines
40786731|NCT03853044|DRUG|Chidamide|Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles
40786732|NCT03853044|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
40786733|NCT03853044|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
41017745|NCT05428969|DRUG|Azacitidine|As per label, subcutaneous
41017746|NCT05428969|DRUG|Venetoclax|Oral
41017747|NCT03122912|DIETARY_SUPPLEMENT|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
41307916|NCT01830543|DRUG|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
41466570|NCT02354911|BIOLOGICAL|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (\~10 million cells/injection).
40786734|NCT03853044|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
40786735|NCT03853044|DRUG|Prednisone|Prednisone 60mg/m2 , Maximum 100 mg , (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
40786736|NCT03584347|BEHAVIORAL|Injection of filler material|Subjects will be blind folded and asked to deposit 0.2cc's of each of the four investigational products, in a randomized order. First, over a weight and then into a porcine membrane.
40786737|NCT02574728|DRUG|Sirolimus|The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
40786738|NCT02574728|DRUG|Celecoxib|Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
40786739|NCT02574728|DRUG|Etoposide|Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
41017748|NCT03122912|DIETARY_SUPPLEMENT|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
41017749|NCT03878940|DIAGNOSTIC_TEST|Abdominal ´yes-no´ pathway|A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
41307917|NCT01830543|DRUG|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
41307918|NCT01830543|DRUG|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
41307919|NCT01830543|DRUG|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
41307920|NCT01830543|DRUG|clopidogrel|One 75 mg tablet once daily for up to twelve months
41307921|NCT01830543|DRUG|prasugrel|One 10 mg tablet once daily for up to twelve months
41307922|NCT01830543|DRUG|ticagrelor|One 90 mg tablet twice daily for up to twelve months
41307923|NCT05844345|OTHER|Hydrocolloid barrier group|In the hydrocolloid barrier group, Comfeel Plus brand hydrocolloid tape will be used. Hydrocolloid tape is a dressing cover made of soft, flexible and economic material in the form of a semi-permeable film or foam-supported gel. Air exchange continues due to the semipermeable film on the top, while entry of harmful microorganisms to the region is prevented, healing is accelerated by creating a humid environment for the wound and exudate from the wound is absorbed. These features reduce the risk of developing infection and ensure patient comfort. There is no specific change time, though generally the tape is changed every 3-5 days; however, it may remain in place for up to 7 days.
41341689|NCT04311437|PROCEDURE|Self-acupressure therapy|The self-acupressure therapy is as follows: Patients are in sitting position, applied firm pressure (3-5 kg of pressure) with the fingertips in a circular motion at a speed of two circles per second for a duration of one min per acupoint. A 1-2-s rest is applied after each ten circles. The complete process lasts for about 5 min.
41341690|NCT04311437|PROCEDURE|Combined Valsalva and Toynbee maneuvers|Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.
41466571|NCT02354911|OTHER|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
41466572|NCT05672745|DEVICE|WB-LIFE|WB-LIFE is a mobile application program grounded in validated psychotherapies (including cognitive behavioral therapy, interpersonal, and dialectical behavioral therapy), that enlists the relational agent Woebot to guide users in managing their mood. The user experience is driven by artificial intelligence and centers around mood tracking, evidence-based tools, and goal-oriented, tailored conversations.
40786740|NCT02574728|DRUG|Cyclophosphamide|Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
40786741|NCT01361217|DRUG|Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan|"1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water."
40786742|NCT06152198|DEVICE|Treatment|Allocation to hip arthroplasty or internal fixation. The choice between hemi- or total hip arthroplasty in the arthroplasty group and type of osteosynthesis are the surgeon preference.
40786743|NCT03882281|DRUG|HQP1351|Orally, single dose of 30mg on day 1 and day 8.
40786744|NCT05555342|PROCEDURE|Irreversible electroporation (IRE) ablation|IRE will be performed using the NanoKnife or Aliya System. CT or cone-beam CT will be used to direct electrode placement.
40786745|NCT05555342|RADIATION|Radiation Therapy|Moderate-dose radiation therapy to the target tumor(s) in 1 fraction.
40786746|NCT02581436|OTHER|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
41466573|NCT06327737|DIAGNOSTIC_TEST|Capnography|This is non-invasive follow-up method to the management of DKA and the reduction of the frequency of invasive procedures was investigated in patients diagnosed with diabetic ketoacidosis (DKA) in the pediatric emergency department and followed up with capnography.
41017750|NCT01711086|DEVICE|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
41307924|NCT05844345|OTHER|Facial Massage group|Premature infants in the facial massage group will have facial massage applied by the researcher. For facial massage, physiological serum used for routine moisturizing in the clinic will be used. When performing facial massage, the fingers will be placed in the middle of the infant's forehead and massage will be performed towards the temples. The eyelids will be lightly rubbed toward the temples. Both thumbs will be placed in the center of the eyebrows and the ridge of the nose will be rubbed toward the lips. The sides of the nose will be rubbed with light pressure. The nasal septum will be rubbed toward the tip of the nose along the philtrum. The fingers will be placed on the philtrum region above the gums and the mouth will be rubbed toward the ears to make a smiling expression. The chin will be lightly massaged toward the back of the ears. The thumbs of both hands will rub from under the infant's chin toward the temples to give make a smiling face (smiling motion).
40786747|NCT02581436|OTHER|Standard follow-up|Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine \>25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
40786748|NCT00411489|PROCEDURE|endolumenal surgery|
40786749|NCT04646577|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous) prime with anodal Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint induced movement therapy. Each session will last 20 minutes.
40990841|NCT00837655|DRUG|Sevelamer|sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of \<1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of \<1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
40990842|NCT00837655|DRUG|Calcium carbonate|Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration \<1.8 mmol/l.
40990843|NCT02395718|OTHER|QDU|Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
40990844|NCT02395718|OTHER|DIM|Treatment at a ward at the DIM. Traditional inward hospitalisation
40990845|NCT03747432|DRUG|Propofol|Procedural sedation during TAVR procedure using propofol
40990846|NCT03747432|DRUG|Dexmedetomidine|Procedural sedation during TAVR procedure using dexmedetomidine
41307925|NCT01008995|DRUG|placebo|Subcutaneous injection at Week 0 and 4
41466574|NCT02221440|DEVICE|Low flow nasal oxygen|Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
41466575|NCT02221440|DEVICE|Low flow room air|Sham: oxygen will be administered by nasal catheter at a flow rate of 0 L/min.
41466576|NCT00980408|DRUG|Sugar pill|250 mg, one dose, 60 min prior
41466577|NCT00980408|DRUG|Sugar pill|250 mg, one dose, 60 min prior
41466578|NCT00980408|DRUG|Sugar pill|20 mg, one dose, 8 hours prior
41466579|NCT00980408|DRUG|Sugar pill|20 mg, one dose, 8 hours prior
41466580|NCT00980408|DRUG|Glutamic Acid|250 mg, one dose, 60 minutes prior
41307926|NCT01008995|DRUG|ustekinumab|45 mg subcutaneous injection at Week 12 and 16
41307927|NCT01008995|DRUG|placebo|Subcutaneous injection at Week 12
41307928|NCT01008995|DRUG|ustekinumab|45 mg subcutaneous injection at Week 0, 4 and 16
41307929|NCT03878017|PROCEDURE|skin marking of clip axillary lymph node for localisation|to determine the feasibility of skin marking to localize clipped ln
40786750|NCT04646577|DEVICE|Transcranial Direct Current Stimulation (tDCS|Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
41307930|NCT06371651|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing creatine and guanidinoacetic acid
40786751|NCT00435630|OTHER|LapSim training|complete curriculum training on LapSim surgical simulator
41466581|NCT00980408|DRUG|Glutamic Acid|250 mg, one dose, 60 minutes prior
40786752|NCT05843331|PROCEDURE|implants|Four implants in the maxilla with locator attachments
40786753|NCT02107534|BEHAVIORAL|parent training (dyslexia)|The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
40786754|NCT00146861|DEVICE|sensor programming|
40786755|NCT00815386|DEVICE|Percutaneous transvenous mitral annuloplasty|Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
40990847|NCT03240679|DEVICE|Acell MatriStem® Surgical Matrix|Extracellular matrix (ECM) product that is composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling to facilitate constructive healing following endoscopic submucosal resection (EMR). Covers the defect site following mucosal resection using endoscopy clips or X-tac. The device will remain attached to the esophagus and integrate with native tissue over time.
40990848|NCT03220217|DRUG|Satoreotide trizoxetan 5-20μg|Positron emission tomography (PET) imaging agent
40990849|NCT03220217|DRUG|Satoreotide trizoxetan 30-45μg|Positron emission tomography (PET) imaging agent
40990850|NCT00379626|DRUG|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
40990851|NCT05213923|PROCEDURE|ED Sepsis Tracking Sheet|Implementation of an ED Sepsis Tracking Sheet. This sheet will track time of patient presentation, time of High-Acuity Medical Response (HAMR) page, time of bilateral 18g or larger IV access, time of initial lactate, time two sets of blood cultures were sent, time antibiotics were administered as well as which antibiotics and what dose, time initial IV fluid bolus was completed, time repeat lactate was sent, timing of post-IV-fluid bolus vital signs, as well as the presence of persistent hypotension following this IV fluid bolus and whether or not vasopressors were applied.
40990852|NCT05559255|OTHER|Counterstrain manual manipulative treatment|"The steps required to perform counterstrain in any region of the body are as follows:~1. Find the tender point.~2. Assess the tenderness using a pain scale.~3. Passively and gently place the patient in a position-of-comfort that results in the greatest reduction of tenderness at the tender point. Approximate the position first, then fine-tune through small arcs of movement. Aim to achieve at least 70% tenderness reduction, with the goal of 100%.~4. Maintain the position for 90 seconds while continuing to monitor the patient's tender point.~5. Passively return the patient to a neutral position.~6. Re-test for tenderness at the tender point."
40990853|NCT02443142|DRUG|Ibuprofen|Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
41307931|NCT06371651|DIETARY_SUPPLEMENT|Placebo|Inert substance
41307932|NCT02430662|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
41307933|NCT02430662|DEVICE|NanoKnife|
40786756|NCT05631093|DRUG|ART|Standard of care ART, per approved product list, taken orally
40786757|NCT05631093|DRUG|DOR/ISL|Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
40786758|NCT06391580|DEVICE|Poly-L-lactin Acid (PLLA) Based Facial Injectable|Poly-L-lactin Acid (PLLA) Based Facial Injectable
40786759|NCT06505746|OTHER|No intervention|No investigational drug will be administered to participants in this study.
40786760|NCT05017064|DEVICE|Cryotherapy group|The use of intraoral ice pack during root canal treatment
40990854|NCT02443142|DRUG|Acetaminophen|Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
40990855|NCT02225990|OTHER|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
41017751|NCT01711086|DEVICE|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
41017752|NCT03509948|DRUG|cytisine|cytisine 1.5 mg film-coated tablets
41307934|NCT01165723|BIOLOGICAL|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
41307935|NCT01165723|BIOLOGICAL|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
41341691|NCT00893763|PROCEDURE|Pre-intubation CHX|Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
41341692|NCT00893763|PROCEDURE|Control|No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
41466582|NCT00980408|DRUG|Memantine|20 mg, one dose, 8 hours prior
41466583|NCT00980408|DRUG|Memantine|20 mg, one dose, 8 hours prior
41466584|NCT01897987|BIOLOGICAL|Pneumostem®|
41466585|NCT01897987|BIOLOGICAL|normal saline|
41466586|NCT02486614|PROCEDURE|CRRT|citrate based continuous renal replacement therapy
41466587|NCT05637476|OTHER|Functional strength training of hip abductors|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Pelvic drop.~2. Single leg -bridge.~3. Side-lying hip abduction with hip internal rotation.~4. Lateral step-up.~5. Standing hip abduction on stance or swing leg with extra resistance ."
41307936|NCT03765255|OTHER|In the Know: sexual health education|The in-person sessions include modules on: sexual and reproductive health (2 hours - anatomy, gender and sexual orientation, pregnancy, contraception, sexually transmitted infections); healthy relationships and life skills (2 hours - communication and negotiation, consent, violence, online dating, goal setting, strengths); and educational and career success (2 hours - educational and career options, applying for scholarships and financial aid, job readiness, resume preparation, interview skills). The app includes: online referrals, personal life plans/goal setting, text message reminders, quizzes, and other resources.
41307937|NCT03959449|BEHAVIORAL|Action Observation plus motor imagery|Action observation (video) and motor imagery of running.
41307938|NCT03959449|BEHAVIORAL|Motor imagery|Motor imagery of running
41307939|NCT03959449|BEHAVIORAL|Exercise plus action Observation and motor imagery|Real exercise of running during 6 min plus action observation (video) and motor imagery of running.
41307940|NCT06433999|DRUG|Brepocitinib|Oral Brepocitinib PO QD
40786761|NCT05017064|OTHER|Control group|No cryotherapy will be used
40786762|NCT05609825|DRUG|LY3875383|Administered SC.
40786763|NCT05609825|DRUG|Placebo|Administered SC.
40786764|NCT04871477|OTHER|Communication Intervention|Audio record part of clinic visit
40786765|NCT04871477|OTHER|Questionnaire Administration|Ancillary studies
40786766|NCT02613520|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
41157000|NCT04472442|PROCEDURE|Sham hypoxia|"Sham acute intermittent treatment (sham AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. Sham AIH (using 20% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
41307941|NCT03696264|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intake will range between 0.2-3.0g/kg/d
41157001|NCT00187122|DRUG|Vincristine|See Detailed Description section for description of treatment plan.
41307942|NCT05520814|DRUG|PD-1 inhibitors|treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg \* q21d (until the disease progresses, intolerable toxicity or the investigator / subject decides to withdraw from the study, and the duration of PD-1 inhibitor is not more than 96 weeks)
41466588|NCT05637476|OTHER|A selected physical therapy exercise program|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Strength dorsiflexors of the ankle-using rubber band.~2. Eccentric calf exercise (calf raise) .~3. Balance and proprioceptive exercise using wobble boards.~4. Stretch planter flexors (three sets of thirty repetitions, thirty seconds rest in between, three times per week)"
41466589|NCT03544840|OTHER|Physical Therapy Home Program|On the first day of the intervention phase (B), the PI will deliver the dynamic standing home program device (Upsee) to the parent and child. The PI will provide training and education to the parent on the device and home program. At the weekly visit to score outcome measures, the PI will check the fit of the devices, ensure compliance, and answer any questions about the home program. Parents will be encouraged to use the device with their child 5 days per week, 30 minutes per day. Parents will keep a daily log sheet to record duration of device use, activities performed, and subjective observations of the child during the intervention (Appendix K). The PI will collect these log sheets each week. The baseline phases (A1 and A2) will last 4 weeks and the intervention phase (B) will last 6 weeks. Part 2 of the study is expected to last 14 weeks.
41466590|NCT00131755|DRUG|diazoxide|
41466591|NCT05265299|DRUG|Aspirin 81mg|Aspirin 81mg once daily
41466592|NCT05265299|DRUG|Aspirin 162 mg|Aspirin 162 mg once daily
41466593|NCT05265299|DRUG|Aspirin 325mg|Aspirin 325mg once daily
41466594|NCT01575262|BEHAVIORAL|Non-cash incentives|Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
41466595|NCT01575262|BEHAVIORAL|Self-monitoring physical activity levels|For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
41466596|NCT02150356|OTHER|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
41466597|NCT02150356|OTHER|Control|Diet based on refined cereal products for a period of 8 weeks.
40786767|NCT02613520|OTHER|Normal Saline|0.9% Sodium chloride
40786768|NCT02613520|BIOLOGICAL|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
40786769|NCT06042426|DRUG|Dexamethasone|Two 8 mg doses. One dose applied prior to incision and the other at POD1
40786770|NCT06042426|DRUG|Morphine|Morphine 0.1 mg per kg intravenous every 6 hours
40786771|NCT06042426|DRUG|Oxycodone and acetaminophen|2 tabs of oral oxycodone combined with acetaminophen every 6 hours (the same pill includes both drugs)
40786772|NCT01680926|DIETARY_SUPPLEMENT|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
41307943|NCT05520814|RADIATION|chemoradiotherapy|"Chemotherapy：~1. GP: gemcitabine 1g/m2 D1, 8 Cisplatin 80 mg/m2 d1~   \* Treatment courses every 3 weeks~2. Cisplatin 80mg/m2 d1 or carboplatin area under the curve 5mg/ml/min \* Treatment courses every 3 weeks~Radiotherapy： All the metastatic lesions received radiation dose from 30 to 60Gy according to different metastatic sites."
40786774|NCT03001661|DEVICE|Dilapan-S|DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
40786775|NCT03001661|DRUG|Dinoprostone|Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
40786776|NCT03417466|DEVICE|Enlite 1 connected to iPro2 recorder|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
40786777|NCT05305898|DRUG|Metformin|"Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation."
40786778|NCT00841061|DIETARY_SUPPLEMENT|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
40786779|NCT00841061|DIETARY_SUPPLEMENT|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
40786780|NCT03468777|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
40786781|NCT03468777|DRUG|Lansoprazole|Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
40786782|NCT03468777|DRUG|Ranitidine|Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
40786783|NCT04904367|PROCEDURE|Deep tissue massage|The amount of pressure during the massage was adjusted by the physiotherapist with reference to muscle tissue palpation in the patients. During the massage, olecranon, pisiform bone protrusion, metacarpophalangeal and proximal interphalangeal joint faces forearm, wrist and fingers were used during the massage to reach deep tissue. As a massage technique, compression and stretching techniques are used in combination.
40786784|NCT04904367|PROCEDURE|Conventional physiotherapy|For 4 weeks 20 session, this group were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
40786785|NCT04831437|RADIATION|Hypofractionated EBRT|EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2
40786786|NCT04831437|RADIATION|Standard EBRT|EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2
40786787|NCT03856359|DRUG|Rifaximin 550 milligrams (MG)|Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
40786788|NCT06356311|BIOLOGICAL|Sacituzumab tirumotecan|Participants will receive sacituzumab tirumotecan as 4mg/kg IV infusion on days 1, 15, and 29 of every 42-day cycle.
41147195|NCT00949234|DRUG|tenofovir + emtricitabine, lopinavir/ritonavir|"The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance \<30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily"
41157002|NCT00187122|PROCEDURE|Radiation Therapy|See Detailed Description section for description of treatment plan.
41157003|NCT00187122|DRUG|Daunomycin|See Detailed Description section for description of treatment plan.
41157004|NCT00187122|DRUG|L-Asparaginase|See Detailed Description section for description of treatment plan.
41157005|NCT00187122|DRUG|Cytarabine|See Detailed Description section for description of treatment plan.
41307944|NCT01705886|PROCEDURE|Total Knee Arthroplasty|Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee
40786789|NCT06356311|DRUG|Trifluridine-Tipiracil|Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.
40786790|NCT06356311|DRUG|Irinotecan|Irinotecan will be administered at a dose of 150 mg/m\^2 by IV infusion on days 1 and 15 of every 28-day cycle.
40786791|NCT06356311|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m\^2 by IV infusion on days 1, 8 and 15 of every 28-day cycle.
40786792|NCT06356311|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m\^2 by IV infusion on day 1 of a 21-day cycle.
40786793|NCT06356311|DRUG|Rescue medication|Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
41307945|NCT01705886|PROCEDURE|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
40786794|NCT06356311|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
40786795|NCT03738722|DRUG|Oxygen|HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher\&Paykel.
41307946|NCT01705886|DEVICE|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
41307947|NCT01705886|DEVICE|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
41307948|NCT01705886|DEVICE|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
41307949|NCT00137436|DRUG|Docetaxel|Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).
41307950|NCT00137436|DRUG|Prednisone|Prednisone Phase1/2 - 5 mg twice a day (BID), oral.
40786796|NCT06390956|DRUG|Pirtobrutinib|Administered once daily as an oral medication.
40786797|NCT06426446|DEVICE|Withings Body Comp Pro|Withings Body Comp Pro from which the following features will be used: body weight, body composition (fat, muscle and bone mass, cardiovascular health (pulse wave velocity, arterial stiffness, vascular age, standing heart rate), nervous health (electrochemical skin conductance)
40786798|NCT02534883|DRUG|Misoprostol|To be place vaginally
40786799|NCT02534883|DRUG|Placebo|To be placed vaginally
40786800|NCT03037125|PROCEDURE|Split Crest with PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap
41307951|NCT00137436|DRUG|SU011248|SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
41307952|NCT04864652|DEVICE|CHILLS Procedure|CHILLS Cryotherapy procedure
41307953|NCT04901065|DRUG|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle
41307954|NCT04901065|DRUG|Placebo|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
41307955|NCT01107275|BIOLOGICAL|rabies vaccine|intradermal vaccination
41307956|NCT03912025|OTHER|Relationship between positive mindset and exercise capacity|No intervention. Cross-sectional study looking at the relationships between questionnaire scores and outcomes
41307957|NCT02357849|DRUG|Aripiprazole|see arm description
41307958|NCT02357849|DRUG|Fluoxetine|see arm description
41307959|NCT02472925|BEHAVIORAL|MedSignals Pill Box|Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
41307960|NCT00841503|OTHER|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
41307961|NCT04807543|DRUG|17-hydroxyprogesterone caproate|intramuscular injection weekly
41307962|NCT04807543|DRUG|Castor Oil|intramuscular injection weekly
40786801|NCT03037125|PROCEDURE|Split Crest without PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting
41307963|NCT05067335|DRUG|Romosozumab|Subjects will receive romosozumab in a specified sequence during the treatment Period.
40786802|NCT06438198|OTHER|Pre-specified switch from controlled to assisted ventilation when PaO2/FiO2-ratio > 200 mmHg|A pre-specified switch from controlled to assisted ventilation will be initiated when PaO2/FiO2-ratio \> 200 mmHg. The moment of switch is pre-specified but patient management and ventilator settings are up to the clinical team. Switch is complete when the patient triggers all breaths spontaneously. Switch success is defined if patient reaches 72 hours on assisted ventilation. Switch failure is defined if patient switches back to controlled ventilation for more than 2 hours before 72 hours.
41307964|NCT05067335|DRUG|Placebo|Subjects will receive Placebo in a specified sequence during the treatment Period.
41307965|NCT01468909|OTHER|Laboratory Biomarker Analysis|Correlative studies
41307966|NCT01468909|DRUG|Paclitaxel|Given IV
40786803|NCT05623345|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
40786804|NCT05623345|DRUG|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
40786805|NCT06103344|BEHAVIORAL|4-7-8 Breathing Exercise Training|Participants in the intervention group will be taught 4-7-8 breathing exercises collectively, and the training will be repeated on specified days (twice a week for a total of 4 weeks). During the training, it will be checked whether each participant in the intervention group can perform the breathing exercise correctly and feedback will be given. Participants who fail to implement the exercise will be excluded from the study. 4-7-8 breathing exercise training, prepared in accordance with the literature, will be given by the assistant researcher who has training and certification in breathing exercises. Training will be planned in an empty classroom, for approximately 20 minutes and at the students' end time. Thus, educational activities in the institution will not be disrupted.
40786806|NCT01800786|DEVICE|CPAP|
40786807|NCT00132301|DRUG|Docetaxel|Chemotherapy agent
41307967|NCT01468909|DRUG|Pazopanib Hydrochloride|Given PO
41307968|NCT01468909|OTHER|Placebo|Given PO
41307969|NCT04564209|OTHER|Info Viz for Health|During the intervention, health care providers provide HIV-related health education using a mobile app that contains a bilingual database of relevant infographics.
41307970|NCT03011034|DRUG|Talacotuzumab|Talacotuzumab 9 mg/kg will be administered as an IV infusion.
40786808|NCT00132301|DRUG|Prednisone|steroid in combination with chemotherapy agent
40786809|NCT02453893|DRUG|Iloperidone|
40786810|NCT02453893|DRUG|Risperidone|
40786811|NCT00219596|DRUG|Xalacom|
40786812|NCT00219596|DRUG|unfixed Latanoprost and Timolol|
40786813|NCT05162638|PROCEDURE|thoracic duct cannulation|"Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel \& advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN \& OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter \& advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath \& pulled out. Catheter then threaded \& advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling."
40786814|NCT03320187|DRUG|Nitroderm TTS|Transdermal nitroglycerin 5mg skin patch
40786815|NCT03320187|DRUG|Dinoprostone|Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
40786816|NCT01402869|DRUG|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
40786817|NCT01402869|DRUG|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
40786818|NCT03141255|DEVICE|IVTM™ System|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
40786819|NCT03141255|DEVICE|Quattro® Catheter|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
40786820|NCT02329093|PROCEDURE|To MRI-detecting bone signal changes in radiographic hip OA|To examine whether or not non-weight bearing reduced OA progression
40786821|NCT00439335|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.
40786822|NCT00439335|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.
40786823|NCT00439335|DRUG|Placebo (IM)|The placebo will be 0.1 mL of saline administered by the IM route.
40786824|NCT00439335|DRUG|Placebo (ID)|The placebo will be 0.1 mL of saline administered by the ID route.
40786825|NCT01041430|OTHER|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
40786826|NCT01041430|OTHER|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
40786827|NCT00046904|BIOLOGICAL|etanercept|
40786828|NCT00553631|BIOLOGICAL|velaglucerase alfa|IV infusion, 60 U/kg every other week for 9 months
40786829|NCT00553631|BIOLOGICAL|imiglucerase|IV infusion, 60 U/kg every other week for 9 months
40786830|NCT00950651|DRUG|Tramadol HCl Contramid® Once A Day|The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
41157006|NCT00187122|DRUG|Methotrexate|See Detailed Description section for description of treatment plan.
41157007|NCT00187122|DRUG|Mercaptopurine|See Detailed Description section for description of treatment plan.
41466598|NCT03895619|OTHER|Safer conception strategies|Individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive.
40786831|NCT00950651|DRUG|Tramadol HCl Twice a day|The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
40822862|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities at home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
40822863|NCT05740605|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 4 hours per week in autonomy and 1 hour per week under supervision.
41157008|NCT00187122|DRUG|Etoposide|See Detailed Description section for description of treatment plan.
41157009|NCT00187122|DRUG|Cyclophosphamide|See Detailed Description section for description of treatment plan.
41157010|NCT00187122|DRUG|Prednisone|See Detailed Description section for description of treatment plan.
41307971|NCT03011034|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered as an IV infusion.
41307972|NCT04855123|OTHER|retinal imaging|OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer
41307973|NCT04855123|OTHER|paraclinical surveillance|blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)
41341693|NCT02031757|OTHER|perturbation training|training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
40990856|NCT02225990|OTHER|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
40990857|NCT02225990|OTHER|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
40990858|NCT02225990|OTHER|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
41307974|NCT01628016|BEHAVIORAL|a word dot-probe task for training procedure|In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
41307975|NCT00564954|DRUG|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
40786832|NCT06420193|BEHAVIORAL|AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)|Participants will receive access to a digital depression self-management tool (ASCENT), which aims to help AYAs manage symptoms of depression post-treatment. All users will have access to the core tool which includes daily mood tracking and a psychoeducational module about cancer and depression. Depending on assigned condition, participants will also receive access to up to 4 intervention modules which have been adapted from existing evidence-based treatments for digital delivery to AYAs through a rigorous user-centered design process. Within each module there are 6 micro-lessons that include an educational video, a real story from an AYA that demonstrates the topic, multiple choice questions that ask the participant to apply the educational information to the AYA story, open-ended questions that ask the participant to apply the educational information to their own experience, and a practice activity in which they are asked to try out a relevant skill.
40990859|NCT03295253|PROCEDURE|Autologous adipose tissue harvesting/grafting using Lipogems|Adipose tissue harvesting and grafting in the urethra using fat micro-fragmentation and processing device Lipogems
40990860|NCT02541747|BEHAVIORAL|massage|massage
41307976|NCT00564954|DRUG|Placebo|orally once a day for 7 days
41307977|NCT05347498|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
40990861|NCT00937443|OTHER|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
40990862|NCT00937443|BIOLOGICAL|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
40990863|NCT00715325|DEVICE|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
40990864|NCT05311332|PROCEDURE|Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin|Augmentation of horizontal deficient anterior maxilla using the conventional protocol of cortical shell technique
41466599|NCT04954690|BEHAVIORAL|Structured Program of exercise for Recipients of Kidney Transplantation (WC)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching)
41466600|NCT04954690|BEHAVIORAL|Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching + caregiver participation)
40990865|NCT05311332|PROCEDURE|Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin using patient specific surgical guide then positioned with another guide|using a patient-specific surgical guide to harvest bone cortical shell from the chin and another patient-specific surgical guide to fix it in the atrophied maxillary anterior area
40990866|NCT02190227|DEVICE|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
41157011|NCT00187122|DRUG|Dexamethasone|See Detailed Description section for description of treatment plan.
41157012|NCT03308383|OTHER|DOING TRANSTHORACIC ECHOCARDIOGRAM|TRANSTHORACIC ECHOCARDIOGRAM WILL BE DONE IN THE PARTICIPANTS WHICH IS NON-INVASIVE
41157013|NCT00598637|DEVICE|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
41157014|NCT00598637|DEVICE|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
41157015|NCT04091945|DRUG|LT3001 Drug Product|Active comparator
41157016|NCT04091945|DRUG|Placebo|Placebo comparator
41157017|NCT06646848|DEVICE|Vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the infants's extremity and routine heel blood collection procedure was performed.
41157018|NCT06646848|DEVICE|Heel Warming|The heel warning group will warm the heel of the infants using a hot thermal bag 3-5 minutes before the application. Then, the thermal bag will be removed and the nurse will take the heel blood.
41157019|NCT06646848|DEVICE|Shotblocker|The protruding surface of the Shotblocker was placed on the heel lance procedure site. While applying pressure on the skin through the Shotblocker, the nurse performed heel lancing with the needle through the opening in the center of the Shotblocker. During the 10-second waiting phase, the Shotblocker was kept at the procedure site with the same pressure. Then Shotblocker was removed from the skin and routine capillary heel collection procedure was performed.
41157020|NCT01766323|DRUG|Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
41157021|NCT01766323|DRUG|Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
41157022|NCT03237741|DRUG|Reference capsule GDC-0134|Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.
40786833|NCT00696033|DRUG|Diazepam|Diazépam drug (0,3 mg/kg) on a single oral intake
40786834|NCT00696033|DRUG|Lorazepam|Lorazépam drug (0,038 mg/kg) on a single oral intake
40786835|NCT00696033|DRUG|placebo|lorazépam placebo or Diazépam placebo
40786836|NCT05799118|GENETIC|GWAS|The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.
40786837|NCT01410929|PROCEDURE|Kyphoplasty/Vertebral Augmentation (Device-StabiliT)|Targeted Vertebral Augmentation for the treatment of pathological fractures of the spine caused by multiple myeloma
40786838|NCT06460038|DRUG|Tenapanor|Inhibitor of NH3
40786839|NCT06460038|DRUG|Placebo|Placebo drug
40990867|NCT05106192|DEVICE|Med-Jet Injector|The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue
40990868|NCT05106192|DRUG|Triamcinolone Acetonide|The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).
40990869|NCT05106192|DRUG|Bexarotene 1% Top Gel|Bexarotene can be applied up to four times daily according to patient tolerance directly to lesions. The gel is 1% bexarotene concentration.
40990870|NCT05106192|DRUG|Nitrogen Mustard|Nitrogen mustard is applied once daily as patient tolerates. It is sold in a concentration of 0.016% gel.
40990871|NCT05106192|DEVICE|Conventional syringe|A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
40990872|NCT05446402|COMBINATION_PRODUCT|Geologie Acne Regimen - one side of face|"Geologie is an over-the-counter cosmetic acne regimen with three products. The regimen also has three levels over the course of three months, in which the nighttime lotion is switched to a stronger formula each month. The Geologie Clear System regimen for acne prone skin includes:~1. Clarifying Gel Cleanser - SA Formula (2% Salicylic Acid)~2. Brightening Day Cream - SPF 15 (5% Azelaic Acid, 2% Hyaluronic Acid, 1%Niacinamide)~3. Repairing Night Cream -~   1. Level 1 (0.05% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  2. Level 2 (0.2% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  3. Level 3 (0.3% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)"
40990873|NCT05446402|COMBINATION_PRODUCT|Proactive Acne Regimen - other side of face|"ProActiv is an over-the-counter cosmetic regimen with three products. The~Proactiv Solution 3-Piece System regimen includes:~1. Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide)~2. Revitalizing Toner (Glycolic Acid)~3. Repairing Treatment (Active ingredient: 2.5% Benzoyl Peroxide)"
40990874|NCT02158338|OTHER|Asthma|mothers who have children that have been diagnosed with respiratory issues
40990875|NCT02158338|OTHER|Non-asthma|mothers who have children that do not have a diagnosis of respiratory problems
41466601|NCT04954690|BEHAVIORAL|Usual Care|Usual Care
41466602|NCT02928458|DRUG|Omnipaque|
40786840|NCT01883700|OTHER|Boiled Pasta|
40786841|NCT01883700|OTHER|Boiled Chickpeas with Oil|
40786842|NCT01883700|OTHER|Instant Mashed Potatoes|
40786843|NCT01883700|OTHER|Instant Mashed Potatoes with Egg Whites|
40786855|NCT04460781|BIOLOGICAL|Flublok Quadrivalent influenza vaccine RIV4|Route of administration: Intramuscular
40786856|NCT04460781|BIOLOGICAL|Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4|Route of administration: Intramuscular
40786857|NCT04098302|DRUG|Dutasteride Capsules|1 mg/day oral dutasteride (2 x 0.5 mg capsules)
40786858|NCT04098302|DRUG|Placebo Capsules|Placebo capsules with matching appearance as Dutasteride Capsules
40786859|NCT00913510|DEVICE|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
40786860|NCT00913510|DRUG|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
40786861|NCT04595643|OTHER|Combination of different dysphagia training modalities|Neuromuscular electrical stimulation, Masako exercises, Mendelsohn maneuver, chin down, mobilization, shaker exercises, eating different food consistencies.
40786862|NCT05000307|DIAGNOSTIC_TEST|Blood sample|Analysing blood samples for the presence of antibody against SARS-CoV2. When impossible to collect sufficient B-cells for further typing, leucapheresis will be performed if the patient agrees.
40786863|NCT02439905|DRUG|Dexmedetomidine|In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
40786864|NCT02439905|DRUG|Placebo control|In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
40786865|NCT04185350|DRUG|68Ga-NOTA-MAL-Cys39-exendin-4|After 68Ga-NOTA-MAL-Cys39-exendin-4 injection, the patient drank 300-500ml of water and urinated before the PET/CT scans.
40786866|NCT03790644|DEVICE|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
40822864|NCT05740605|BEHAVIORAL|Usual Care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
40822865|NCT05174221|DRUG|Mezagitamab|TAK-079 subcutaneous injection.
40822866|NCT04872933|OTHER|Kidney Beam Online Platform|Kidney Beam is a wellbeing digital health intervention platform that offers patients living with kidney disease a way to improve their physical activity and boost their mental health through live and on demand movement classes and expert educational videos, while remaining in their own home. Kidney Beam is led by specialist kidney professionals, including renal physiotherapists and renal counsellors, from a number of different NHS Trusts and backgrounds, as well as people living with kidney disease.
40786867|NCT05321459|OTHER|Neurological prognosis|"In usual practice, in intensive care unit, evaluating the neurological prognosis of comatose patients after cardiac arrest requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations (among them auditive evoked potentials or AEP).~An algorithm (PRECOM tool) which has been previously developed from the signal extracted from AEP allows to visually classify the patients after processing signal by the algorithm in a cluster of points with a high specificity into good neurological prognosis and bad neurological prognosis.~The AEP signals recorded in the 1st and 2nd week of patient inclusion are to be collected by the neurophysiologist. At the end of the patient's participation in the study, these data will be encrypted, anonymized and transmitted to the mathematician to be processed by the PRECOM tool."
40786868|NCT04179305|BEHAVIORAL|Oncolo-GIST|"Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months... with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
40786869|NCT04179305|BEHAVIORAL|Usual Care Arm|Oncologists will provide care in non-specific manner.
40786870|NCT03553537|DRUG|Decitabine|10mg/m² iv on day 1-5
40786871|NCT03553537|DRUG|Cyclophosphamide|750mg/m² iv on day 6
40786872|NCT03553537|DRUG|Doxorubicin|DOX
40786873|NCT03553537|DRUG|Vincristine|1.4mg/m² iv on day 6
40786874|NCT03553537|DRUG|Prednisone|100mg/m² po on day6-10
41307978|NCT05347498|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
40786875|NCT00833443|DRUG|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
40786876|NCT04753619|DRUG|Niclosamide Oral Tablet|"* NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days\]~* If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding."
40786877|NCT04143581|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg/die for 28 days
40786878|NCT02448199|DRUG|Meloxicam and Glucosamine|Experimental
40786879|NCT02448199|DRUG|Meloxicam|Active Comparator
40786880|NCT02448199|DRUG|Glucosamine|Active Comparator
40786881|NCT05030584|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
40786882|NCT05030584|DRUG|Placebo|Matching placebo orally once daily.
40786883|NCT05480176|OTHER|Comprehensive intervention and management Ⅰ|Mainly health advisory.
41307979|NCT02391844|DRUG|Oxycodone|Oxycodone with Acetaminophen Extended Release
41307980|NCT06310785|DRUG|Esketamine|The esketamine group used esketamine as an analgesic during induction and maintenance of anesthesia.
40786884|NCT05480176|OTHER|Comprehensive intervention and management Ⅱ|Health advisory and regular follow-ups.
40786885|NCT05480176|OTHER|Comprehensive intervention and management Ⅲ|Pharmaceutical and non-pharmaceutical (e.g. health advisory, rehabilitation, etc.) interventions according to standardized clinical guidelines, with regular follow-ups.
40786886|NCT05055076|DEVICE|PODEYE TORIC|Patients will be contacted consecutively and will be enrolled after the patient informed leaflet has been given to them and after obtaining their consent to the scientific use of their data collected retrospectively (preoperative, surgery, postoperative routine visits). Patients will only be enrolled after the routine 4-6 months visit has been performed.
40786887|NCT02748681|DEVICE|Auto CPAP AirSense™ 10(Resmed)|AutoSet CPAP without telemedicine monitoring
40786888|NCT02449941|DRUG|PPI (proton pump inhibitor)|"1. Pre ESD (endoscopic submucosal dissection)~   * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~  * Use of PPI for 2 months~2. Post ESD 1 (After 2 months)~   * Assess the distribution of helicobacter pylori after using PPI.~  * Stop of PPI~3. Post ESD 2 (After 4 months)~   * Assess the distribution of helicobacter pylori after stop of PPI."
40786889|NCT04100408|OTHER|Biospecimen Collection|Undergo saliva or buccal mucosa collection
40786890|NCT04100408|OTHER|Laboratory Biomarker Analysis|Correlative studies
40786891|NCT04100408|OTHER|Questionnaire Administration|Ancillary studies
41307981|NCT06310785|DRUG|Sufentanil|In the opioid group, sufentanil was used as an analgesic during anesthesia induction and remifentanil was used as an analgesic during anesthesia maintenance.
41307982|NCT06025487|BIOLOGICAL|Bexsero|two doses of Bexsero are applied intramuscularly with a one-month interval between doses
40822867|NCT02321189|DRUG|LONGEVINEX|let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
40822868|NCT02321189|DRUG|placebo|let everyone of the participants oral 1 capsule containing 100 mg placebo
40822869|NCT02673476|DRUG|ALS-008176|ALS-008176 tablets
40822870|NCT02673476|DRUG|Placebo|Identical placebo tablets
40822871|NCT02359357|DRUG|FDL169|
40822872|NCT02359357|DRUG|Placebo|
40822873|NCT00415064|DRUG|Perifosine|Perifosine given in either 50 mg or 100 mg / day
41307983|NCT05604469|DIAGNOSTIC_TEST|Isolation of skin microbiota|Isolation of skin microbiota including, Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes and Candida.
41307984|NCT03840083|BEHAVIORAL|Sleep|Participants will sleep (either a mid-day nap or normal overnight sleep)
41307985|NCT05781971|DIETARY_SUPPLEMENT|high protein|Patients in high-protein group will be given a target protein amount of 2.0 g/kg/d. Standard enteral nutrition is the first choice,the remaining target value will be met by intravenous amino acid infusion.
41307986|NCT05781971|BEHAVIORAL|rehabilitation|In this trial, the investigator will provide early rehabilitation treatment such as respiratory training, bicycle training, and medium frequency electrical stimulation to patients.
41307987|NCT05781971|DIETARY_SUPPLEMENT|standard protein|The investigator set a protein target of 1.2 g/Kg/d for the standard protein group, which will be supplied enterally or parenterally.
40786892|NCT03627949|BEHAVIORAL|E-intervention|The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
40786893|NCT00497900|DRUG|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
40786894|NCT06002009|RADIATION|MRI|MRI of shoulder
40990876|NCT05840146|OTHER|Kinesiotaping|"Two I-strips were used:~1. The first-third of one I-strip began at the posterior iliac crest, without tension as an anchor. Then the patient actively flexed and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.~2. The first-third of the second I-strip was applied starting at the anterior iliac crest, without tension as an anchor. The patient actively extended and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension."
40990877|NCT05840146|OTHER|Sham taping|A single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the hip.
40990878|NCT06547866|DRUG|zanubrutinib + BGB-11417|"The investigational medicinal products (IMP) are Zanubrutinib (BGB- 3111) and BGB-11417.Treatment will be administered for a total of twenty 28 day cycles:~Cycle 1 with zanubrutinib only~Cycle 2 with zanubrutinib plus BGB-11417 ramp-up cycle 2, day 1 : 10mg cycle 2, day 2 : 20 mg cycle 2, day 3 : 40mg cycle 2, day 4-7 : 80md daily cycle 2, day 8 and beyond : 160 mg daily~Cycles 3-20 with zanubrutinib plus BGB-11417 full dose"
40990879|NCT05262530|BIOLOGICAL|BNT142|Intravenous bolus/infusion
40990880|NCT06539676|DEVICE|Nighttime Aligners|Nighttime aligners worn 10-12 hours per day or night during 2-8 months
40990881|NCT06539676|DEVICE|Daytime Aligners|Daytime aligners worn 20-22 hours per day or night during 2-8 months
40990882|NCT05546931|BEHAVIORAL|Coaching application|A digital application for providing education and support for home-based blood pressure monitoring.
40990883|NCT05546931|OTHER|WebMD|Smartphone-based application for health education and/or monitoring.
40990884|NCT05546931|BEHAVIORAL|Home-based blood pressure monitoring|Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
40990885|NCT02068222|DRUG|ABT-450/ritonavir (r)|Tablet
40990886|NCT02068222|DRUG|ABT-530|Tablet
40990887|NCT02068222|DRUG|Ribavirin (RBV)|Tablet
41147196|NCT06428799|DEVICE|Carebot AI MMG|"Carebot AI MMG is a software solution that utilizes artificial intelligence methods, specifically deep learning and computer vision algorithms, to evaluate and localize suspicious regions of potential lesions during the interpretation of digital breast x-rays as part of standard mammography screening procedures. The Carebot AI MMG medical device is not intended for use in diagnostic mammography. The Carebot AI MMG is intended for use in women over the age of 18.~The predictive outputs of the Carebot AI MMG medical device are intended to aid decision-making in screening clinical practice, always in conjunction with other relevant patient information and based on the professional judgment of the examining clinician. The Carebot AI MMG is specifically designed to provide a supporting layer of analysis that helps in evaluating or prioritizing mammography images with additional patient information and the professional judgment of the examining physician."
41147197|NCT03074968|DRUG|Benzydamine Hydrochloride|Benzydamine Hydrochloride application
41147198|NCT03074968|DRUG|Normal saline|normal saline application
41157023|NCT03237741|DRUG|Prototype capsule GDC-0134|Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.
41307988|NCT01172587|OTHER|Behavioral Couples Therapy|Couples participate in 12 sessions of Behavioral Couples Therapy designed to reduce substance use and increase relationship functioning.
41466603|NCT02928458|DRUG|MD-Gastroview|
41466604|NCT03758573|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT)
41466605|NCT03758573|OTHER|Intensive Physiotherapy (IPT)|Intensive Physiotherapy (IPT)
41466606|NCT03270592|OTHER|Service dog|Use of a individualized certified service dog
41466607|NCT05631821|PROCEDURE|differential rod bending with rod contours (MESA Spinal System)|differential rod bending with rod contours and Mesa Spinal system evaluate the correction of adolescent idiopathic scoliosis deformity achieved utilizing a technique of differential rod bending with rod contours pre-operatively determined from a best-fit measure utilizing a computer-based software tool
40786895|NCT06002009|OTHER|Nerve conduction study|Nerve conduction study
40786896|NCT02129712|BEHAVIORAL|Cognitive training|
40786897|NCT01880151|DEVICE|EEG|EEG recorded during a resting condition and during an episodic memory task condition
40786898|NCT06568549|DRUG|Mycophenolate Mofetil (MMF) Maintenance Group|Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Maintenance in Immunosuppression medication.
40786899|NCT06568549|DRUG|Mycophenolate Mofetil (MMF) Withdrawal Group|Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Withdrawal of MMF immunosuppression medication.
40822874|NCT00415064|DRUG|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
40786900|NCT03358420|DIAGNOSTIC_TEST|Immunohistochemical staining|Pathological liver slides to be immunohistochemically stained for alpha-defensin
40786901|NCT02002988|PROCEDURE|endomyocardial BT injection|
40786902|NCT01176877|BEHAVIORAL|"Scripted lecture (educational information talk)"|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
40786903|NCT02065934|OTHER|cardio-pulmonary resuscitation|
41307989|NCT02653976|DRUG|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
40786904|NCT02583347|DEVICE|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
40786905|NCT02746406|DEVICE|Peritron+|Peritron+ device to measure intravesical pressure
40786906|NCT01642303|OTHER|vodcasting|listening to downloaded vodcasting files
40786907|NCT01642303|OTHER|no intervension|Listen to student book listening files
40990888|NCT04418986|PROCEDURE|opposite clear corneal incisions (OCCI)|"Coaxial small incision cataract surgery was performed for all cases using a 2.8 mm keratome placed at steep meridian and 1-mm paracentesis was made 90 degrees apart with a 20-gauge microvitrectomy blade. Surgery was performed with a 30-degree, 0.9-caliper phacoemulsification tip (microtip) with a divide and conquer technique.~In the OCCI group, a single penetrating incision was created with 2.8 mm keratome in the clear cornea, 1.5 mm anterior to limbal blood vessels, centered over the steep meridian and opposite the phacoemulsification incision."
41307990|NCT00437333|DRUG|Metformin cloridrate|
41307991|NCT01996202|DRUG|Ipilumimab|
41307992|NCT01996202|RADIATION|Radiation|
40786908|NCT06132945|DRUG|Cabozantinib|Cabozantinib (40 mg PO daily)
40786909|NCT06132945|DEVICE|Nivolumab|Nivolumab (480 mg IV Day 1)
41307993|NCT05960188|BEHAVIORAL|AI Opinion|For each case, we give the radiologist a numeric score reflecting the AI's rating of the abnormality of the case.
41307994|NCT05047640|BIOLOGICAL|BNT162b2 vaccine|Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle
41307995|NCT05047640|BIOLOGICAL|JNJ-78436735 Vaccine|Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle
40786910|NCT06132945|RADIATION|Stereotactic Radiosurgery (SRS)|Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.
41307996|NCT04146467|DEVICE|Renuvion APR Device|The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.
41307997|NCT01763268|BIOLOGICAL|Trivivac vaccine|Trivalent MMR vaccine
41307998|NCT01731301|DRUG|Ribavirin|Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
41307999|NCT01731301|DRUG|Peginterferon|After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
41308000|NCT01731301|DRUG|Boceprevir|Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
41308001|NCT03854643|OTHER|Pilates group|Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
41308002|NCT03854643|OTHER|Control group|These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
41308003|NCT02137590|DIETARY_SUPPLEMENT|Spanish Black Radish product|
40786911|NCT06353815|OTHER|4% articaine infiltration|Two injections using short needle and dental syringe will be given , the first injection is 1.5 ml out of 1.8 ml of 4% articaine with 1:100,000 epinephrine (ARTINIBSA 4% 1:100,000) in the mucobuccal fold adjacent to the mandibular first Molar, the second injection is 0.3 ml in the lingual side for lingual soft and hard tissues .
40786912|NCT03129464|DEVICE|Cold therapy via reusable cold gel pack|Patients in the experimental group will be asked to apply cold therapy to their abdominal incisions every 6 hours for the first 72 hours following their surgery (total laparoscopic hysterectomy). Cold therapy will be applied via a reusable cold gel pack.
40786913|NCT03389308|DRUG|diacerein 1% ointment|"Topically apply study medication to lesions identified by the Investigator that require.~treatment"
40990889|NCT03670550|DEVICE|Ossur Rebound ACL Brace|ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
41308004|NCT00003353|BIOLOGICAL|filgrastim|
41308005|NCT00003353|DRUG|melphalan|
41308006|NCT00003353|PROCEDURE|bone marrow ablation with stem cell support|
41308007|NCT00003353|PROCEDURE|peripheral blood stem cell transplantation|
40990890|NCT06099977|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
40786914|NCT00752492|OTHER|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
40786915|NCT00038948|DRUG|Sirolimus|Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled
40786916|NCT00038948|DRUG|tacrolimus|
40786917|NCT00038948|DRUG|Cyclosporine A|
40786918|NCT01355614|DRUG|QAX576|
41308008|NCT04056455|DRUG|Mobocertinib|Mobocertinib capsule.
41308009|NCT01301560|RADIATION|Radiosurgery|Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
40786919|NCT01355614|DRUG|Infliximab|
40786920|NCT04620889|DEVICE|AV Access|Arteriovenous shunting for blood access.
40786921|NCT04620889|DEVICE|PVP|Bypass or reconstruction of diseased or occluded blood vessels
40786922|NCT04877327|PROCEDURE|Ablation|Cryotherapy and radiofrequency
40786923|NCT06191042|DRUG|si-544|Subcutaneous injection in the abdomen
40786924|NCT06191042|DRUG|Placebo|Subcutaneous injection in the abdomen
40786925|NCT01823380|PROCEDURE|Blood test|Blood test
40786926|NCT01773928|BIOLOGICAL|Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)|
41308010|NCT01301560|RADIATION|Observation|No local treatment
40786927|NCT01773928|BIOLOGICAL|VCIV manufactured with the current manufacturing process (VCIV current)|
40990891|NCT06099977|PROCEDURE|Placebo|Only headphone without sound will be applied.
41308011|NCT03772938|BIOLOGICAL|Stem/progenitor cells transplantation|Human autologous bone marrow-derived stem/progenitor cell transplantation administered as an intravitreal injection in patients with degenerative disease of retina.
41308012|NCT04633473|BEHAVIORAL|SIB-Time Web-Application Tool|Parents used the dual-language SIBTime app to watch video stories about common sibling experiences, respond to question prompts, track connection routines, and listen to guided Acceptance and Commitment Therapy (ACT) exercises for parents. During the 4-week intervention period, parents used the app at their convenience.
41308013|NCT04773353|DRUG|Follitropin Delta (FE 999049)|FE 999049 will be administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 will have their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose will be 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose will be on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose will be fixed throughout the stimulation period and maximum allowed daily dose will be 12 μg. Participants could be treated for a maximum of 20 days.
41341694|NCT02031757|OTHER|balance exercises|specific exercises regularly used in rehabilitation aiming to improve balance
40786928|NCT01773928|BIOLOGICAL|Fluzone®, licensed trivalent influenza vaccine (TIV)|
40786929|NCT02593058|BEHAVIORAL|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
40822875|NCT00415064|DRUG|Dexamethasone|Dexamethasone given in 20 mg / day
40786930|NCT02593058|BEHAVIORAL|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
40786931|NCT05057013|DRUG|HMBD-001|Participants with advanced solid tumours will receive their assigned dose level of HMBD-001 diluted in 0.9% sodium chloride, administered once a week as a 120-minute intravenous (IV) infusion. Cycles are 28 days with no break in between; administration may continue for up to 6 cycles but may continue for longer if the participant is deemed to be benefitting.
40786932|NCT05057013|DRUG|HMBD-001 and enzalutamide|Participants with metastatic castration resistant prostate cancer (mCRPC) confirmed as HER3 positive with no PTEN loss or with a NRG1 fusion rearrangement will receive the HMBD-001 recommended Phase 2 dose (RP2D) as determined in Part A, diluted in 0.9% sodium chloride and administered once a week as a 120-minute IV infusion, in combination with enzalutamide administered at a fixed dose of 160 mg once daily, in 28-day cycles with no break between cycles. Immediately before commencing combination therapy, participants may receive one 28-day cycle of enzalutamide monotherapy to confirm that their disease does not respond to enzalutamide alone. HMBD-001 may be administered for up to 6 cycles; enzalutamide may be continued until disease progression or unacceptable toxicity.
40786933|NCT04774380|DRUG|Durvalumab|Participants will receive durvalumab via IV infusion on Day 1 of each cycle.
40786934|NCT04774380|DRUG|Cisplatin|Participants will receive cisplatin via IV administration on Day 1 of each cycle.
40786935|NCT04774380|DRUG|Carboplatin|Participants will receive carboplatin via IV administration Day 1 of each cycle.
40786936|NCT04774380|DRUG|Etoposide|Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.
40786937|NCT04709510|DIAGNOSTIC_TEST|Duplex Ultrasound|Duplex Ultrasound was performed for every participants for the diagnosis of symptomatic or asymptomatic deep vein thrombosis
40786938|NCT03128489|BIOLOGICAL|Infanrix-IPV/Hib|Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
40786939|NCT00881894|DRUG|Rotigotine transdermal patch|Rotigotine 4.5mg/10cm\^2 patch applied for 24 hours
40786940|NCT00142792|DEVICE|NMES device with EMG-triggered and Cyclic capabilities|All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
40786941|NCT02398526|DRUG|Radium-223 dichloride, (Xofigo, BAY88-8223)|Dosage and treatment duration according to the decision of the treating physician
40786942|NCT02878083|DRUG|VEDOLIZUMAB|Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
40786943|NCT02878083|DRUG|ADALIMUMAB|For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
41308014|NCT04773353|DRUG|Follitropin Alfa (GONAL-F)|GONAL-F will be administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F will be 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose will be 450 IU. Participants could be treated for a maximum of 20 days.
41466608|NCT01503333|BEHAVIORAL|Physical activity intervention|Receiving individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
40786944|NCT02173405|DRUG|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
40786945|NCT02173405|DRUG|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
40786946|NCT02701205|BIOLOGICAL|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
41308015|NCT05145075|OTHER|Survey|Patients are asked to fill in a survey concerning teleconsultations
40786947|NCT02701205|BIOLOGICAL|etanercept (half dose)|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
40786948|NCT02701205|DRUG|placebo|two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
40786949|NCT00827814|DRUG|Dutasteride|Dutasteride 0.5 mg od.
40786950|NCT05567705|OTHER|The attitudes of doctors working in the surgical clinic of a university hospital for patient blood management: a survey-based study|No intervention required
40786951|NCT00514930|DEVICE|Hexablate|
40786952|NCT04601116|DRUG|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg per day for 2 years
40786953|NCT04601116|DRUG|Placebo oral tablet|Placebo 1 tablet per day for 2 years
40786954|NCT03630146|BEHAVIORAL|iPeer2Peer program|In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.
40786955|NCT03630146|OTHER|Waitlist control|The control group will receive standard care but without the iPeer2Peer Program.
40786956|NCT02785692|RADIATION|Radiation|preoperative Radiotherapy/ IMRT
40786957|NCT06455722|DRUG|[68Ga]Ga-P15-041|Intravenous injection of one dose of 111-148 MBq (3-4 mCi) \[68Ga\]Ga-P15-041. Tracer doses of \[68Ga\]Ga-P15-041 will be used to image lesions by PET/CT.
41308016|NCT06287502|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB)|Ensure NutriVigor, a nutritional supplement, was provided to subjects according to the manufacturer's recommendation of two servings per day. Each serving consists of 54.1g of powder which provides \~231kcal, 8.61g protein, 1.21 g β-hydroxy β-methylbutyrate, 130 IU vitamin D and 0.29 g omega-3 fatty acid.
41308017|NCT06287502|BEHAVIORAL|Resistance, aerobic, flexibility and balance exercise training|The exercise intervention consists of 75-minutes sessions delivered by physiotherapists at the Integrated Rehabilitation Day Centre (IRDC) in Kowloon Hospital, twice per week for 12 weeks with a total of 24 supervised sessions. Each exercise session consists of 5 minutes of warm up, 30 minutes of resistance training, 20 minutes of aerobic training, 15 minutes of balance or neuromuscular exercises and 5 minutes of cool down.
41308018|NCT02898207|DRUG|Olaparib|Given PO
40786958|NCT00692887|DEVICE|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
40786959|NCT01458678|OTHER|Volume of colloid infusion|Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
40786960|NCT01458678|OTHER|Volume of colloid infusion|Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
40786961|NCT01738061|BEHAVIORAL|Multidimensional lifestyle intervention|Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
40786962|NCT02897115|BIOLOGICAL|Adalimumab|Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
41157024|NCT03237741|DRUG|rabeprazole|Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.
41308019|NCT02898207|DRUG|Onalespib|Given IV
40786963|NCT02897115|OTHER|Non-steroidal Anti-inflammatory Drugs (NSAIDs)|ASAS recommended NSAID doses to treat axial spondyloarthritis.
40786964|NCT02879513|DRUG|Paclitaxel|
40786965|NCT02879513|DRUG|Cisplatin|
40786966|NCT02879513|DRUG|Epirubicin|
40786967|NCT02879513|DRUG|Cyclophosphamide|
40786968|NCT02879513|DRUG|5-fluoruracil|
40786969|NCT02136043|DEVICE|PBASE system 1.1 (active treatment)|
40786970|NCT00839566|PROCEDURE|Ablation|AV-node ablation
40786971|NCT00839566|OTHER|Rate Control|Rate control by drug
40786972|NCT05853588|OTHER|training|On-the-job (toolbox) training given to the experimental group and containing brief information, lasting at most 10 minutes
40786973|NCT05480228|DRUG|NRD135SE.1|The double-blind treatment phase is up to 13 weeks.
40786974|NCT05480228|OTHER|Placebo|A matching placebo will be taken for up to 13 weeks.
40786975|NCT02358408|DEVICE|Blood glucose monitoring systems for self-testing|
41308020|NCT02683616|DEVICE|CPAP|Continuous Positive Airway Pressure in cases of moderate/severe OSA
41308021|NCT05331950|OTHER|Office Workers|Office Workers which will be observed/exposed with different task and different factors
41308022|NCT00403559|DRUG|Elidel|
41308023|NCT00403559|DRUG|Ketoconazole Cream|
41308024|NCT03111134|PROCEDURE|modified component separation technique|a new abdomen closure technique based on component separation technique
41308025|NCT02449954|DRUG|Intravenous morphine sulphate|Group I:received IV 0.1mg/kg morphine sulphate.
41308026|NCT02449954|DRUG|Intravenous tramadol HCL|Group II:received IV 2 mg/kg tramadol HCL.
41308027|NCT02449954|DRUG|Intravenous ketorolac tromethamine|Group III: received IV 30 mg ketorolac tromethamine
41308028|NCT03844048|DRUG|Venetoclax|oral; film-coated tablets or tablets for oral suspension
41308029|NCT01326169|BEHAVIORAL|Brief intervention|Telephone-delivered counseling
41308030|NCT01326169|BEHAVIORAL|Standard care|No intervention
41308031|NCT01218412|BEHAVIORAL|Web-based Motivational Interviewing|Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
41308032|NCT00262418|DRUG|Administration of ivermectin or permethrin|
41308033|NCT02665234|DRUG|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
41308034|NCT02665234|DRUG|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
41308035|NCT04477824|DIAGNOSTIC_TEST|Diagnostic imaging|Ultrasonography, computerized tomography, magnetic resonance imaging
41308036|NCT02223455|OTHER|Hand Hygiene Signs|Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
41308037|NCT06093763|PROCEDURE|Group without bone grafting|Open wedge corrective osteotomy and plate fixation without bone grafting.
41308038|NCT06093763|PROCEDURE|Group with bone grafting|Open wedge corrective osteotomy and plate fixation with harvesting and using bone from the iliac crest.
41308039|NCT01773135|OTHER|collection of blood sample and tocolysis adminstration|"investigators will abtain a blood sample from all patient to measure the serum level of ACTH.~all patients with threatened preterm labor will receive a fixed regimen of tocolysis in the form of nifedipine (Epilate) 10 mg orally every 15 minutes for the first hour or until cessation of uterine contractions. Then, 60 - 160 mg/day (1-2 tablets 3 times daily) of slowly releasing nifedipine (epilat retard 20 mg tablet) may be given depending on uterine activity. The patients will also receive 6 mg dexamethasone every 12 hours for 4 doses. All women will be followed up till delivery.~After delivery, investigators devide the pateints into 2 groups (full term delivery \& preterm delivery) and investigators compare between these 2 groups by level of hormone."
41308040|NCT00083070|DRUG|temozolomide|
41308041|NCT04860661|DRUG|Esketamine|After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump
41308042|NCT04860661|DRUG|Normal saline|10 ml normal saline
41308043|NCT02317406|DRUG|Biostime probiotics sachet children's formula|Biostime probiotics sachet children's formula,1.5g Oral Single dose
41308044|NCT02317406|DRUG|Biostime probiotics sachet children's formula（placebo）|Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
41308045|NCT02415439|DRUG|VBP15|
41308046|NCT02415439|DRUG|Placebo|
41308047|NCT02634099|DEVICE|blood measurement|Hemoglobin measurement
41308048|NCT02634099|DEVICE|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
41308049|NCT02634099|DEVICE|hemoCue|non invasive method of hemoglobin measurement
41308050|NCT02022696|GENETIC|Lentiviral Gene Transfer|
41308051|NCT02843334|BIOLOGICAL|Dried blood spot (DBS) sampling|DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
41308052|NCT05441137|BEHAVIORAL|Ride-On Cars Training with Different Postures|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual-effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
41308053|NCT05441137|BEHAVIORAL|Conventional Therapy|The other independent OT will be responsible for providing conventional therapy based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks.
41308054|NCT01055808|DRUG|Insulins|Individual dose and frequency and duration as determined by the treating physician
41308055|NCT01882998|BEHAVIORAL|Extended repeat HIV testing and enhanced counseling|Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
41308056|NCT00239317|DRUG|Tamusulosin|
41308057|NCT04585399|BEHAVIORAL|Contingency management|Financial incentives for attending bup appointments and demonstrating opioid abstinence. Rides will also be provided for up to two clinic visits per week.
41308058|NCT02364167|DRUG|Standard therapy|Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
40786976|NCT06106906|BIOLOGICAL|CD19 CAR-T cell infusion|CD19 CAR-T cell intravenous infusion
40786977|NCT04236271|DEVICE|connected objects|a combination of connected devices for measuring physiological parameters and for clinical self-assessment by the patient, for early postoperative coronary bypass surgeries.
40786978|NCT02393820|DRUG|pazopanib|treatment will be given until progression or unacceptable toxicity .
40786979|NCT06014307|BEHAVIORAL|Diet order: PBMA, Animal|Participants will follow the PBMA, and Animal diets (in this order) for 4-6 weeks each.
40990892|NCT05891678|RADIATION|doppler study of central retinal artery|pulsed wave Doppler after decreasing the sample volume to fit inside the center of CRA. We will measure the peak systolic velocity (PSV), end diastolic velocity (EDV), and the resistivity index which equal PSV-EDV/PSV, we will measure 3 times and the expected normal value is less than 0.7.
40990893|NCT03322033|DEVICE|Valiant PS-IDE Stent Graft|Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
41147199|NCT04505215|OTHER|Mulligan Technique|"First, the painless application angle was determined for each patient. The lateral condyle of the humerus was fixed by the web range of the physiotherapist. The elbow joint was glided until the elbow joint and the hand tightening position were not able to cause pain.~The patients were asked to repeat the motion of the elbow joint and the ball squeezing motion given to their hands 10 times without pain. For pain control, the same procedure was performed with three sets, each containing 10 repetitions of the exercise. The interval between sets was 15 to 20 seconds, and the interval between repetitions within each set was 30 seconds."
41147200|NCT04505215|OTHER|Muscle Energy Technique|Firstly, 5-7 sec opposite isometric muscle contraction was requested from the patient in the barrier by passively stretching by the physiotherapist until the barrier of the related muscle or dysfunctional joint. After a short rest period of 2-3 seconds, the physiotherapist continued to stretch passively until the second barrier. The application continued until the tension of the muscle or dysfunction of the joint disappeared.
41308059|NCT02364167|DEVICE|Verum acupuncture|"Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan"
40786980|NCT06014307|BEHAVIORAL|Diet order: Animal, PBMA|Participants will follow the Animal, and PBMA diets (in this order) for 4-6 weeks each.
40786981|NCT01544348|OTHER|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
41308060|NCT02364167|OTHER|Placebo acupuncture|"Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan"
41308061|NCT06121700|RADIATION|Radiotherapy targeted to the primary lesion|5 to 7 fractions of short course hypofractionated radiotherapy (HFRT) targeted to the primary lesion.
40786982|NCT01544348|BIOLOGICAL|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
40786983|NCT01544348|BIOLOGICAL|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
41341695|NCT05928104|OTHER|Medication review|Pharmacist-led medication review in primary care using a co-designed document
40786984|NCT01544348|BIOLOGICAL|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
40786985|NCT01544348|BIOLOGICAL|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
40786986|NCT01544348|BIOLOGICAL|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
40786987|NCT01544348|BIOLOGICAL|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
40990894|NCT01312090|BIOLOGICAL|Whole body cryotherapy|Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (-30°Cand-60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
40786988|NCT01544348|BIOLOGICAL|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
40786989|NCT01070979|DRUG|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
40786990|NCT01070979|DRUG|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
40786991|NCT01070979|DRUG|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
40786992|NCT00602524|DRUG|Pilocarpine|
40786993|NCT05510518|DIAGNOSTIC_TEST|oral glucose tolerance test (OGTT)|• The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.
40786994|NCT05160506|DRUG|Hydrocortisone|Hydrocortisone is a steroid (corticosteroid) medication.
40786995|NCT05160506|DRUG|Placebo|50ml of 0.9% NACL will serve as the placebo
40786996|NCT04161534|DEVICE|KT Tape|in addition to an arm sling, KT Tape will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
40786997|NCT04161534|DEVICE|Arm Sling|An arm sling will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
40786998|NCT00198328|COMBINATION_PRODUCT|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
40786999|NCT00198328|PROCEDURE|Surgical Excision|Patients have their tumor surgically removed.
40787000|NCT04945525|OTHER|Care Continuity Program|The Care Continuity Program is an online patient self-assessment tool used by prescribers of opioids to better identify patient risk factors and opioid therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber's electronic health records, mitigating the prescriber's civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. Prescribers may use the summary page to help them identify the appropriateness of initiating opioid therapy and/or continuing opioid therapy.
40787001|NCT02178319|PROCEDURE|open surgical procedure|open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
40787002|NCT02178319|PROCEDURE|laparoscopic surgical procedure|laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
40787003|NCT05230511|DRUG|Lactobacillus RhamnosusGG|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
40787004|NCT05230511|DRUG|Saline bladder wash|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
40787005|NCT05726331|OTHER|Chiropractic Care|Chiropractic care will be delivered by community-based chiropractors that meet pre-set qualifications. Chiropractic treatment protocol will be multimodal and will follow predefined standard operating procedures including the following 6 components: 1) Posture correction and spinal stabilization exercises; 2) Soft tissue release techniques; 3) Manual spinal manipulation; 4) Condition-specific education; 5) Myofascial strengthening and motor control training; 6) Ergonomic and lifestyle modifications/advice. Subjects randomized to chiropractic treatment groups will receive up to 10 chiropractic sessions over 16 weeks.
40787006|NCT05726331|OTHER|Tai Chi|Tai Chi (TC) will be delivered by community based Tai Chi schools that meet pre-set qualifications. TC programs will emphasize core principles including biomechanically efficient alignment, relaxed integrated movements, deep breathing, and heightened body awareness. Subjects randomized to TC treatment group will attend at least one TC class per week for 16 weeks.
40990895|NCT01312090|BEHAVIORAL|counseling and behavioral therapy for weight loss|Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
40787007|NCT05726331|OTHER|Enhanced Usual Care|Enhanced Usual Care will include educational materials about neck pain provided by the study, in addition to usual medical care for CNNP. Usual care for CNNP generally includes medications (non-narcotic analgesics, NSAIDs, muscle relaxants), interventional pain management (e.g., steroid injections), and self-care exercises (all of which will be monitored and recorded in all three study arms).
40787008|NCT04451759|OTHER|MRI exploration|ultra high field (7T) magnetic resonance imaging
40990896|NCT06291142|DEVICE|Observation - Nailfold capillaroscopy|Nailfold capillaroscopy examination
40990897|NCT00245674|DRUG|amisulpride|
40990898|NCT02232581|DRUG|Alovudine - low|
40990899|NCT02232581|DRUG|Alovudine - medium|
40990900|NCT02232581|DRUG|Alovudine - high|
40990901|NCT02232581|DRUG|Placebo|
40990902|NCT00426582|DRUG|Patupilone|
41341696|NCT02035241|DIETARY_SUPPLEMENT|Spices 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
40787009|NCT03460652|DRUG|KP415 oral capsule|Once-daily oral dose
41308062|NCT06121700|RADIATION|Radiotherapy targeted to the metastatic lesions|Hypofractionated radiotherapy (HFRT) or stereotactic body radiotherapy (SBRT) targeted to metastatic lesions. The target dose will be adjusted based on the lesion's site and diameter and organs at risk, with high-dose irradiation of 4-8 fractions. All metastatic lesions should be irradiated as much as possible, and partial lesion irradiation should be allowed when technically impractical.
41466609|NCT03304717|DRUG|Tenofovir (TDF) and Emtricitabine (FTC)|"Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate. This is used in children as young as age 2.~Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI), a synthetic analog of cytidine which binds at the active site of the reverse transcriptase."
41466610|NCT03304717|OTHER|Placebo|Placebo for Tenofovir and Placebo for Emtricitabine
41466611|NCT00819767|DRUG|Aliskiren|Aliskiren was supplied in 150 mg tablets.
41466612|NCT00819767|DRUG|Valsartan|Valsartan was supplied in 160 mg capsules.
41466613|NCT00819767|DRUG|Placebo to aliskiren|Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
40787010|NCT05288023|DRUG|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children (up to the maximum adult dose of 1g).~Dosage will be calculated by age for children aged 1-5 months. For children 6-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
40787011|NCT04240821|DRUG|Theophylline ER|Oral theophylline
40787012|NCT01389986|BEHAVIORAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
40787013|NCT06050122|DRUG|Patidegib Topical Gel|Patidegib Gel 2% is a smooth, clear, colorless-to-yellow, viscous, hydro-alcoholic gel for topical administration.
40787014|NCT06050122|DRUG|Patidegib Topical Gel with no active patidegib|Vehicle Gel consists of the excipients of Patidegib Gel with no active patidegib. It is a smooth viscous gel for topical administration.
40787015|NCT06041022|OTHER|Exposure factors|Including demographical data, laboratory features and liver histological indicators.
40787016|NCT02568722|OTHER|Standard RRT initiation|"In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI \> 72 hours following the time of randomization."
41466614|NCT00819767|DRUG|Placebo to valsartan|Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
41466615|NCT00730951|DIETARY_SUPPLEMENT|Korean Red Ginseng|500mg Capsulated Ground Dried Korean Red Ginseng Root
40787017|NCT02568722|OTHER|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
40787018|NCT03310944|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
40787019|NCT04305977|BEHAVIORAL|WAVE-TW|The WAVE-TW open pilot trial of the intervention consists of 5 sessions conducted individually with each part participant. Each session lasts approximately 30-50 minutes. The first session will be the LifeSteps Adherence session that focuses on cognitive-behavioral and problem-solving techniques to promote adherence. The next four sessions will be dedicated to trauma writing.
41341697|NCT02035241|DIETARY_SUPPLEMENT|Spices 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
41466616|NCT00730951|DIETARY_SUPPLEMENT|Corn Starch|500mg Capsulated Corn Starch
41466617|NCT01030887|BEHAVIORAL|Exercise programme|Moderate intensity exercise
41466618|NCT03485001|OTHER|Sham|This group will not receive argon laser medical treatment; instead, they will be only exposed to the slit lamp light.
41466619|NCT03485001|PROCEDURE|Argon Laser Treatment|This group will receive argon laser medical treatment to the body and head of pterygium
40822876|NCT06599983|OTHER|Educational program, Educational Storytelling, an Educational Program Against Child Abuse and Neglect.|One day educational program, aiming at increase dental personnels attitude, knowledge and behaviour in regard to detect and report child abuse and neglect, and to treat patients with known and unknown history of child abuse and neglect.
40822877|NCT04161963|DEVICE|SD-OCT|Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
41466620|NCT01419899|BEHAVIORAL|Brief motivational intervention|A 20-30 minute motivational based discussion
41466621|NCT05569330|OTHER|Air purification|Aerosol particles are removed from room air by several methods
41466622|NCT03510338|DRUG|Sublingual sildenafil|100 mg biphasic sildenafil tablet
40787020|NCT03567707|BIOLOGICAL|C-section -Vaginal seeding|Mother-infant pair randomized to vaginal microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the vaginal microbiota soaked gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding.
40787021|NCT03567707|DRUG|C-section - Placebo Seeding|Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds.
40787022|NCT03567707|OTHER|standard care|Mother-infant pair where mother undergoes spontaneous vaginal delivery, with both receiving standard of care.
40787023|NCT03584815|PROCEDURE|Surgery/Fasciotomy|Open fasciotomy of the anterior and lateral compartment + standard post-operative physiotherapy for 12 weeks
40787024|NCT03584815|OTHER|Physiotherapy|Intensive physiotherapy for 12 weeks including a change to forefoot/midfoot strike during running
40787025|NCT05223998|PROCEDURE|Full-thickness skin microcolumns implantation|Surgical harvest and implantation of FTSM on an open wound requiring coverage.
40787026|NCT05409469|PROCEDURE|surgery|surgery on patients with aortic dissection
40787027|NCT04145076|DRUG|Placebo|Two oral doses of placebo.
40787028|NCT04145076|DRUG|Citalopram|Single oral dose of citalopram (20mg) and single oral dose of placebo.
40787029|NCT04145076|DRUG|Tianeptine|Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.
40787030|NCT05116956|OTHER|non interventional|Multinational prospective, standard care data collection, non-interventional, study not involving human subjects
40787031|NCT02077231|DRUG|Vitamin A|use one drop in the eye
40787032|NCT02077231|DRUG|carbomer eye gel|use one drop in the eye
40787033|NCT04933292|DRUG|Methylprednisolone and Mycophenolate mofetil|Methylprednisolone combination of mycophenolate mofetil
40787034|NCT04933292|DRUG|Methylprednisolone and azathioprine|Methylprednisolone combination of azathioprine
40787035|NCT03142919|BIOLOGICAL|Lipopolysaccharide|Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
40787036|NCT03142919|BIOLOGICAL|Placebo|Saline solution
40787037|NCT05921617|OTHER|No intervention|Routine care
40787038|NCT05087498|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 32 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (2-10×107cells/kg) within 24 hours after birth
40787039|NCT05087498|BIOLOGICAL|normal saline|preterm neonates less than 32 weeks are assigned to receive normal saline within 24 hours after birth
40787040|NCT01652313|DRUG|Rasagiline|1 mg/day, tablets for 7 days, orally
40787041|NCT02582827|DRUG|ABI-011|ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
40787042|NCT05500651|OTHER|Dance and Movement Therapy (DMT)|Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
40787043|NCT04174859|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Treatment dose is following the description of physicians.
40787044|NCT03110705|BEHAVIORAL|sport|recreaational sport : diving or multisport
40787045|NCT04451005|OTHER|0|Elderly patients with sarcopenia
40787046|NCT05816746|DRUG|Low-Dose Decitabine plus anti-PD-1|Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
40787047|NCT05257486|DEVICE|Xoft eBx|The Xoft Axxent Electronic Brachytherapy (eBx) System allows for the administration of high dose rate brachytherapy treatments using an electronic source
40787048|NCT04602143|DRUG|Testosterone gel|Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
41341698|NCT02035241|DIETARY_SUPPLEMENT|Spices 3|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
41466623|NCT03510338|DRUG|Oral sildenafil|50 mg oral sildenafil (Viagra)
40787049|NCT05747274|DEVICE|SRDK0921|SRDK0921 is an IVD composed of IVD kit for qPCR (SRDK0921KIT) and a cloud-based software (SRDK0921SOFT). It is a class C, rule 3k, IVD according to Regulation (EU) 2017/746.
40787050|NCT04110106|OTHER|no intervention|All participants were evaluated with the PDQ-39, and the severity of PD was recorded according to the H\&Y scale by a neurologist.
40787051|NCT02491047|DEVICE|BonyPid-1000|BonyPid-1000 implantation concomitantly to standard of care (SOC) treatment
40990903|NCT01747109|DEVICE|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
40990904|NCT01747109|PROCEDURE|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)"
41308063|NCT06121700|BIOLOGICAL|Anti-PD-1 monoclonal antibody|"The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status.~The commonly used anti-PD-1 mAb usages are as follows: Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W."
41466624|NCT01560884|DRUG|Renazorb 1500 mg/day|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
40990905|NCT00196716|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
40990906|NCT00819468|DRUG|Teduglutide|Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
40990907|NCT04733365|OTHER|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
40990908|NCT02070835|DEVICE|autologous skin cell|autologous skin cell and skin graft
40990909|NCT02070835|PROCEDURE|skin graft|split-thickness skin graft
40990910|NCT01092533|DRUG|Myfortic|Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
41466625|NCT01560884|DRUG|Renazorb 3000 mg/day|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
40787052|NCT02491047|OTHER|Standard of Care (SOC) treatment|Standard of Care (SOC) treatment only
40787053|NCT01685814|DRUG|Lenalidomide, Bortezomib|Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
40990911|NCT01092533|DRUG|Decortin|Maintenance dose 5 mg/d
41466626|NCT01560884|DRUG|Renazorb 4500 mg/day|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
40787054|NCT01685814|BIOLOGICAL|autologous stem cell transplant|
40787055|NCT01685814|BIOLOGICAL|allogeneic stem cell transplant|
40787057|NCT05158920|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Suicidal individuals (MBCT-S)|MBCT-S is a group intervention of 8 weekly sessions of 2 hours combining techniques of mindfulness with important elements of cognitive therapy (e.g. safety plan and homework).
40787058|NCT03773003|DIETARY_SUPPLEMENT|Probiotics|"The administered probiotics are readily available on the market and contain~* Bifidobacterium breve, B. infantis, B. lactis, B. longum~* Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~* Streptococcus thermophilus"
40787059|NCT03773003|DIETARY_SUPPLEMENT|Placebo|Identically looking to verum, containing corn starch.
40787060|NCT02599480|DRUG|mirabegron|50 mg daily during 12 months
40787061|NCT02599480|PROCEDURE|Echocardiography|Echocardiography
40787062|NCT02599480|PROCEDURE|Cardiac MRI|Cardiac MRI
40787063|NCT02599480|PROCEDURE|Maximal exercise capacity|Maximal exercise capacity
40787064|NCT02599480|PROCEDURE|Blood sampling|Blood sampling for study assessments and future exploratory studies.
40787065|NCT02599480|PROCEDURE|Endothelial function measurement|EndoPAT assessment
40787066|NCT02599480|RADIATION|18FDG-PET|PET scanning for beige/brown fat activation
40787067|NCT02039830|BEHAVIORAL|Group physiotherapy|Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises
40787068|NCT02039830|BEHAVIORAL|Individual one-on-one physiotherapy|Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
40990912|NCT01912287|BEHAVIORAL|Cognitive Behavioral Therapy|CBT focused on Generalized Anxiety Disorder (12 sessions)
40990913|NCT01912287|BEHAVIORAL|Stress Education|Active control group (12 sessions)
40990914|NCT01912287|BEHAVIORAL|Yoga|12 sessions, mindfulness components
40990915|NCT05352009|OTHER|Sling exercise training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of sling exercise training and 10 min treadmill training.
40990916|NCT05352009|OTHER|Conventional balance training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of balance exercise training and 10 min treadmill training.
40990917|NCT01436812|PROCEDURE|zero end-expiratory pressure|positive end expiratory pressure 0 cm H2O during peumoperitoneum
40990918|NCT01436812|PROCEDURE|positive end expiratory pressure|PEEP 0 cmH2O
40990919|NCT01946373|DRUG|Cyclophosphamide|
40990920|NCT01946373|DRUG|Fludarabine|
40990921|NCT01946373|BIOLOGICAL|T cells|
40990922|NCT01946373|BIOLOGICAL|Interleukin-2|
40990923|NCT01946373|BIOLOGICAL|Dendritic cell vaccine|
41308064|NCT06121700|BIOLOGICAL|Trastuzumab|For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. The 3-weekly schedule of trastuzumab starts with a loading dose of trastuzumab of 8 mg/kg, followed by 6 mg/kg trastuzumab every 21 days.
41308065|NCT06121700|DRUG|Chemotherapy|"The investigator's choice of chemotherapy regimens included SOX, XELOX or FOLFOX. Their usages are as follows:~SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily; and oxaliplatin 130 mg/m2, day 1, every 3 weeks; XELOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks; FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks."
41341699|NCT02035241|DIETARY_SUPPLEMENT|Herbs 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
41341700|NCT02035241|DIETARY_SUPPLEMENT|Herbs 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
40990924|NCT02742987|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily
40990925|NCT02742987|DRUG|Clopidogrel|Clopidogrel 150 mg once daily
40787071|NCT06569121|BEHAVIORAL|Group Lifestyle Balance for People Post Stroke (GLB-CVA)|12-month healthy lifestyle and weight loss program modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB)
40787072|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
40787073|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
40990926|NCT02742987|DRUG|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
40990927|NCT05486221|OTHER|Extensive cardiologic work-up|Specific 3D and 2D echocardiography measuring left ventricule and left atrial dimensions as well as longitudinal strain. 30 day prolonged ECG monitoring.
40990928|NCT01578889|BIOLOGICAL|HIV-MAG vaccine|Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
40990929|NCT01578889|BIOLOGICAL|IL-12 pDNA adjuvant|Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
40990930|NCT01578889|BIOLOGICAL|VSV HIV gag vaccine|Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10\^8 plaque-forming units (PFUs) administered as 5x10\^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
40787074|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
40787075|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
40787076|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
40990931|NCT01578889|BIOLOGICAL|Placebo|Placebo will consist of sodium chloride for injection, USP 0.9%.
40990932|NCT01578889|DEVICE|Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device|The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
40990933|NCT00149487|BEHAVIORAL|Tailored Problem Solving Intervention|
40990934|NCT00149487|BEHAVIORAL|Family Education Intervention|
40787077|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
40787078|NCT01802099|OTHER|Enteral nutrition|
40787079|NCT01802099|OTHER|Parenteral nutrition|
40787080|NCT02625181|PROCEDURE|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
41308066|NCT06121700|PROCEDURE|R0 total/subtotal gastrectomy with D2 lymphadenectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For primary lesions, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper-third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle-third tumors, the gastric margin is recommended to be more than 5 cm, and total gastrectomy is performed. For lower-third tumors, a 2 cm duodenal margin is recommended, and subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
40787081|NCT02625181|PROCEDURE|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
40787082|NCT02625181|PROCEDURE|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
40787083|NCT02625181|PROCEDURE|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
40787084|NCT02625181|DEVICE|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
40787085|NCT02625181|DEVICE|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
40787086|NCT02625181|PROCEDURE|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
41308067|NCT06121700|PROCEDURE|Metastasectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For metastatic lesions, the surgical procedure and resection range are determined by the surgeon.
41308068|NCT06121700|PROCEDURE|Local ablative therapies|Local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) achieve high rates of complete tumor eradication of small metastases, and can be seen as alternatives if a widely invasive surgical approach is required or patient is inoperable.
40787087|NCT02625181|PROCEDURE|Elective surgery|Surgical procedures that are scheduled and not an emergency.
40787088|NCT02625181|DRUG|Propofol|Anesthetic drug used to maintain general anesthesia
40787089|NCT02625181|DRUG|Sevoflurane|Anesthetic drug used to maintain general anesthesia
40787090|NCT02625181|DRUG|Isoflurane|Anesthetic drug used to maintain general anesthesia
40787091|NCT02625181|DRUG|Desflurane|Anesthetic drug used to maintain general anesthesia
40787092|NCT02625181|DRUG|Scopolamine|Prophylactic antiemetic
40787093|NCT02625181|DRUG|Droperidol|Prophylactic antiemetic \& rescue antiemetic
40787094|NCT02625181|DRUG|Haloperidol|Prophylactic antiemetic \& rescue antiemetic
40787095|NCT02625181|DRUG|Dexamethasone|Prophylactic antiemetic \& rescue antiemetic
40787096|NCT02625181|DRUG|Promethazine|Prophylactic antiemetic \& rescue antiemetic
40787097|NCT02625181|DRUG|Meclizine|Prophylactic antiemetic \& rescue antiemetic
40787098|NCT02625181|DRUG|Aprepitant|Prophylactic antiemetic \& rescue antiemetic
40787099|NCT02625181|DRUG|Metoclopramide|Rescue antiemetic
40787100|NCT02625181|DRUG|Fentanyl|Analgesic drug / Opioid
40787101|NCT02625181|DRUG|Sufentanil|Analgesic drug / Opioid
40787102|NCT02625181|DRUG|Alfentanil|Analgesic drug / Opioid
40787103|NCT02625181|DRUG|Remifentanil|Analgesic drug / Opioid
40787104|NCT02625181|DRUG|Morphine|Analgesic drug / Opioid
40787105|NCT02625181|DRUG|Meperidine|Analgesic drug / Opioid
40787106|NCT02625181|DRUG|Hydromorphone|Analgesic drug / Opioid
41466627|NCT01560884|DRUG|Renazorb 6000 mg/day|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
41466628|NCT02320162|BEHAVIORAL|Experiential learning oral health education|
40787107|NCT02625181|DRUG|Methadone|Analgesic drug / Opioid
40787108|NCT02625181|DRUG|Oxycodone|Analgesic drug / Opioid
40787109|NCT02625181|DRUG|Oxymorphone|Analgesic drug / Opioid
40787110|NCT02625181|DRUG|Hydrocodone|Analgesic drug / Opioid
40787111|NCT02625181|DRUG|Ketamine|Analgetic / Analgesic drug
40787112|NCT02625181|DRUG|Ondansetron|Prophylactic antiemetic \& rescue antiemetic
40787113|NCT02625181|DRUG|Granisetron|Prophylactic antiemetic \& rescue antiemetic
40787114|NCT02625181|DRUG|Dolasetron mesylate|Prophylactic antiemetic \& rescue antiemetic
40787115|NCT02625181|DRUG|Palonosetron|Prophylactic antiemetic \& rescue antiemetic
41308069|NCT00312884|DEVICE|HomMed Telemonitoring System|The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
41308070|NCT02817815|DEVICE|Electrocardiogram (ECG)|
41308071|NCT02817815|BIOLOGICAL|Blood sampling from the cephalic vein|
41308072|NCT02817815|BIOLOGICAL|Blood sampling from the femoral vein|Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter
41308073|NCT02817815|BIOLOGICAL|First blood sampling from left atrium|Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction
41308074|NCT02817815|PROCEDURE|Atrial stimulation|Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF
41308075|NCT02817815|BIOLOGICAL|Second blood sampling from left atrium|After 20min of continuous AF, a blood sampling from left atrium will be done
41308076|NCT05403749|BIOLOGICAL|dose 1 IBI302|After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol.
41308077|NCT05403749|DRUG|Aflibercept|Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month
41308078|NCT05403749|BIOLOGICAL|dose 2 IBI302|After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol
41308079|NCT01005537|BIOLOGICAL|aldesleukin|Given IV and orally
41308080|NCT01005537|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
41308081|NCT01005537|DRUG|cyclophosphamide|Given IV
41466629|NCT05332886|BEHAVIORAL|MetaHealth Group|Three metaverse rooms will be created via metaverse technology that aims to develop healthy nutrition, physical activity, and psychological resilience skills to reduce the risk of of NCDs in youth.
40990935|NCT02334007|DRUG|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
41308082|NCT05366699|PROCEDURE|axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)|lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
41308083|NCT05366699|PROCEDURE|Axillary lymphadenetomy alone|oncologic axillary lymphadenectomy
41308084|NCT04141787|DRUG|Ceftriaxone|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
41466630|NCT05332886|BEHAVIORAL|MobileHealth Group|The intervention aims to develop healthy nutrition, physical activity, and psychological resilience skills using mobile application materials to reduce the risk of NCDs in youth.
41466631|NCT02050035|OTHER|Aerobic Exercise Training|Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
41466632|NCT00831233|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
41466633|NCT00831233|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
40787116|NCT02625181|DRUG|Tropisetron|Prophylactic antiemetic \& rescue antiemetic
40787117|NCT02625181|DRUG|Ramosetron|Prophylactic antiemetic \& rescue antiemetic
40787118|NCT01298843|DRUG|Ceftaroline fosamil|Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
40822878|NCT04161963|DEVICE|OCT-A|swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
40822879|NCT01955434|DRUG|Cyclophosphamide|Given PO
40822880|NCT01955434|OTHER|Laboratory Biomarker Analysis|Correlative studies
40822881|NCT01955434|OTHER|Pharmacological Study|Correlative studies
40822882|NCT01955434|OTHER|Quality-of-Life Assessment|Ancillary studies
40822883|NCT01955434|DRUG|Smac Mimetic LCL161|Given PO
41147201|NCT04505215|OTHER|Only Exercise (Control)|Eccentric training for the extensor Carpi Radialis Brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercise for the EKRB muscle were given as home exercise program. The best stretching position for the EKRB tendon is provided when the elbow joint is in extension, forearm pronation, when the wrist is flexed with ulnar deviation (Mills maneuver). Each exercise was taught to patients in 10 repetitions and 10 seconds, and one day of the week, participants in the control group performed their exercises under the supervision of a physiotherapist.
40787119|NCT01952743|PROCEDURE|AF ablation with Renal Denervation|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.
40787120|NCT01952743|PROCEDURE|AF ablation alone|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
40990936|NCT02334007|OTHER|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
41147202|NCT00244426|DRUG|indobufen|Indobufen capsules 100 and 200mg
41147203|NCT00244426|DRUG|aspirin|Acetylsalicylic acid capsules 300mg
41147204|NCT01282918|DEVICE|ICD implantation w/o DF test|ICD implantation without Defibrillation Test
41147205|NCT01282918|DEVICE|ICD implantation with DF test|ICD implantation with DF test according to standardized procedure
41147206|NCT02131792|PROCEDURE|Slanted recession of the lateral rectus muscle|All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
41341701|NCT02035241|DIETARY_SUPPLEMENT|Control drink|As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
41341702|NCT00260091|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
41466634|NCT00831233|DRUG|Bicalutamide|On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
41466635|NCT00006263|BIOLOGICAL|filgrastim|
41466636|NCT00006263|DRUG|carboplatin|
40990937|NCT00056563|DEVICE|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
40787123|NCT04105959|DRUG|RIST4721|RIST4721 oral solution
40787124|NCT04105959|DRUG|Placebo|Placebo oral solution
40787125|NCT03783598|BEHAVIORAL|Person centered, occupation based intervention support with problem solving therapy|This program that was developed from the occupational therapy perspective which is person centered and occupation based for T2D intervention was designed as 6 modules. The intervention group received person centered, occupation based intervention support with problem solving therapy as 6 modules. The control group had not any intervention, just had a education about effect of diabetes on life.
40990938|NCT00056563|OTHER|best medical therapy|"Participants will initially be randomized to DBS or to 6 months of best medical therapy. BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months."
40990939|NCT03876964|DEVICE|Transcatheter Aortic Valve Replacement|Minimally invasive replacement of the aortic valve through a catheter.
40990940|NCT00849160|DRUG|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
40990941|NCT02979145|OTHER|No intervention involved|
40990942|NCT06446765|BEHAVIORAL|mindfulness-based Neurofeedback|Participants will complete one session of mindfulness-based fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.
40787126|NCT00209937|DRUG|Gaboxadol|
40787127|NCT02861287|OTHER|Economic evaluation|
40787128|NCT01119287|DRUG|Dexamethasone 0.1% ophthalmic suspension|Maxidex
40990943|NCT06446765|OTHER|control Neurofeedback|Participants will complete one session of control fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.
40990944|NCT05346809|DRUG|Isatuximab|Isatuximab in IV form 10 mg/kg doses
41147207|NCT05928520|DRUG|Tramadol 5%|Topical tramadol 5%
41147208|NCT05928520|DRUG|Lidocaine 2%|Topical Lidocaine 2%
41147209|NCT03308500|BEHAVIORAL|High-intensity intermittent games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In HIIG children took part in 5 games per session; 2 velocity games and 3 small-sided games (such 3 vs 3 and 4 vs 4). This session included 4 minutes games and 2 minutes recovery. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
41147210|NCT03308500|BEHAVIORAL|Moderate intensity games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
41147211|NCT06545942|DRUG|MOMA-313|MOMA-313 administered orally
41147212|NCT06545942|DRUG|Olaparib|Olaparib administered orally
41147213|NCT00621842|DRUG|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
41341703|NCT00260091|PROCEDURE|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
41466637|NCT00006263|DRUG|temozolomide|
40787129|NCT01119287|DRUG|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
40787130|NCT01119287|OTHER|Inactive ingredients, used as placebo|Tears Naturale II
40990945|NCT05346809|OTHER|Standard Procedures|Standard procedures (standard of care) for transplant
40787131|NCT02574793|DEVICE|continuous glucose monitoring|Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.
40787132|NCT02429817|DRUG|Technetium-99m - Diethylenetriaminepentaacetic acid|99mTc-DTPA solution placed on the nebulizer reservoir
40787133|NCT02429817|DEVICE|Aeroneb Solo|
40787134|NCT02429817|DEVICE|Jet Nebulizer|
40787135|NCT02429817|OTHER|Single photon emission computed tomography|Imaging technique to investigate lung aerosol distribution
40787136|NCT02429817|OTHER|Spirometry|FEV1, FVC assessment
40787137|NCT05144672|DIAGNOSTIC_TEST|Laboratory tests|"Fasting blood glucose (FBG), postprandial blood glucose, total cholesterol (CHO), triglycerides (TG), high-density lipoprotein cholesterol and low-density lipoprotein cholesterol (LDL-C), urea, creatinine, and uric acid by point colorimetric assay.~Serum irisin."
40787138|NCT05144672|OTHER|Anthropometric measurements|Height, weight, waist circumference, and hip circumference were taken as a way of assessing the nutritional status and BMI
40787139|NCT05144672|PROCEDURE|Electrocardiogram and Fundus examination|Fundus examination by direct ophthalmoscope
40787140|NCT05144672|OTHER|Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR) was calculated by EPI equation.
40787141|NCT05144672|OTHER|Brachial index|The ankle-brachial index test compares the blood pressure measured at your ankle with the blood pressure measured at your arm
40787142|NCT05144672|DIAGNOSTIC_TEST|Laboratory tests|Glycosylated haemoglobin. ACR,urinary albumin (mg) and creatinine (g).
40787143|NCT05144672|RADIATION|Abdominal ultrasound.|It will be performed for patients only.
40787144|NCT03771339|PROCEDURE|Continuous Epidural analgesia|Continuous Epidural catheter is inserted at the Thoracic 11-T12 level, using Ropivacaine 0.375% 3 mL bolus followed by Ropivacaine 0.2% with rate 6 mL/hour for 24 hours after laparoscopic nephrectomy
40787145|NCT03771339|PROCEDURE|Bilateral Quadratus Lumborum block|Bilateral anterior Quadratus Lumborum block using Ropivacaine 0.375% 20 mL each injection as postoperative analgesia treatment for 24 hours
40787146|NCT00407719|DRUG|Bevacizumab|
40787147|NCT06312189|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
40787148|NCT05796388|DEVICE|Virtual Reality|Both groups will receive standard of care linaclotide 290 mcg.
40787149|NCT06269510|BEHAVIORAL|ENGAGE-ALD Application (APP)|"Participants randomized to this will complete the app at the time of enrollment.~If in-person, will complete the app on a research laptop or iPad. The ENGAGE-ALD app consists of two modules developed based on preliminary data: 1) a misconception correction module and 2) a treatment matching module designed to match patients to participant's preferred form of alcohol treatment based on preferences for 19 different dimensions of alcohol treatment. The intervention will consist of administering a single session of the ENGAGE-ALD app."
40787150|NCT06269510|BEHAVIORAL|Treatment Facilitation bundle|Participants will complete a survey. The module includes motivational interviewing-informed content tailored to address and assist in overcoming barriers. After taking the survey, participants will receive a virtual coaching session (either via phone or online virtual platform). Sessions will focus on identifying participant goals with respect to alcohol use and liver health, providing education on risks of alcohol use to liver health and risks of relapse, reviewing participants individually identified barriers to alcohol treatment, exploring benefits of and these barriers to alcohol treatment, and performing collaborative goal-setting, among other topics.
40787151|NCT06269510|BEHAVIORAL|Enhanced Usual Care|This group will receive standard hepatology care, and an educational pamphlet defining alcohol treatment resources available within Michigan Medicine and giving information on how participants can access these resources. This information will be given directly to participants that enroll in person or e-mailed to participants or sent via postal mail for those that enroll remotely.
40787152|NCT01361984|DRUG|Nebulized arformoterol|Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is \~9 minutes
40787153|NCT01361984|DRUG|Salmeterol|Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
40787154|NCT02078752|DRUG|PF-06647263|Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
40787155|NCT02078752|DRUG|PF-06647263|Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
40822884|NCT04213703|OTHER|No intervention|There is no intervention for this study
40990946|NCT00969787|DRUG|DWP05195|tablets, oral administration, single and multiple administrations
40990947|NCT01893554|BIOLOGICAL|RSV ΔNS2 Δ1313 I1314L Vaccine|"For participants in Groups 1, 3, and 4: 10\^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10\^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL)."
40990948|NCT01893554|BIOLOGICAL|Placebo|Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
40990949|NCT04693507|DRUG|teverelix TFA 120 mg|Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24
41466638|NCT01662024|DEVICE|Endoscopic gastric restrictive procedure|Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
40990950|NCT04693507|DRUG|teverelix TFA 180 mg|Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24
40787156|NCT02448134|BEHAVIORAL|Youth Access|Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
40990951|NCT04799899|BEHAVIORAL|Adapted MBCT|The adapted MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.
41308085|NCT04141787|DRUG|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
41466639|NCT00784979|DRUG|CMVIG|400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
41466640|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 100 mg
41466641|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 50 mg
41466642|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
41466643|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 25 mg
41466644|NCT00401245|DRUG|Placebo|Tapering placebo
41466645|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
41466646|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
41466647|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
41466648|NCT06384482|DRUG|SNC115 injection|SNC115 Injection is DLL3 CART.
41466649|NCT00793117|PROCEDURE|packing|packing in middle meatus for duration of 5 day
41466650|NCT00117117|DRUG|Aranesp|
41466651|NCT05455606|OTHER|Best Practice|Receive usual care
40990952|NCT04799899|BEHAVIORAL|Cardiac Health Enhancement|The cardiac health enhancement control group will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will learn about depression and cardiac health.
41466652|NCT05455606|OTHER|Chart Abstraction|Ancillary studies
41466653|NCT05455606|OTHER|Educational Intervention|Physicians access genomic testing education materials
41466654|NCT05455606|PROCEDURE|Genomic Profile|Patients undergo genomic testing
41466655|NCT05455606|OTHER|Interview|Ancillary studies
41466656|NCT05455606|OTHER|Questionnaire Administration|Ancillary studies
41466657|NCT05455606|OTHER|Tumor Board Review|Patients undergo genomic tumor board review
40990953|NCT03057665|DEVICE|Atomic Biomagnetometer|Measure magnetic field of fetal heartbeat
41466658|NCT05229822|DIAGNOSTIC_TEST|LBP|Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
41466659|NCT05229822|DIAGNOSTIC_TEST|sCD14-ST|Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
40787157|NCT00389753|DRUG|Application of Aruba Aloë formula F-BC-096 or control|
40787158|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
40787159|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
41466660|NCT05229822|DIAGNOSTIC_TEST|16s rRNA|Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.
41466661|NCT04253236|DRUG|RVT-1401 680 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
41466662|NCT04253236|DRUG|RVT-1401 340 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401
41466663|NCT02142231|DEVICE|Acupuncture|Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
41466664|NCT02142231|DEVICE|Laser Acupuncture|Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
41466665|NCT06337513|OTHER|Rehabilitation intervention|"The intervention consists of a physiotherapist-coordinated (PT) interdisciplinary outpatient rehabilitation offer for 6-months.~The intervention encompasses 3 individual sessions with the PT, if needed individual sessions with the interdisciplinary team (PT, occupational therapist, OT, nurse, and social worker) (a maximum of 6 hours), and patient education in two group seminars."
41466666|NCT06337513|OTHER|Usual care|Both the intervention and the control group will receive usual care.
41466667|NCT04195568|DEVICE|Surpass Evolve Flow Diverter System|The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.
41466668|NCT02666027|DEVICE|Fluid Intravenous Alert (FIVA) 'on'|Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
41466669|NCT02666027|DEVICE|Fluid Intravenous Alert (FIVA) 'off'|The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
41466670|NCT03129061|DRUG|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"* Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~* Anti PD-1 per standard of care~* Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~* \[18F\]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose."
41466671|NCT03129061|DRUG|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"* Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to treatment.~* Anti PD-1, single dose~* Blood sampling, tumor biopsy and \[18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection."
41466672|NCT00812318|DRUG|GSK1265744 10 mg oral solution|GSK1265744
40787160|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
40990954|NCT00510354|DRUG|Imatinib mesylate|
40990955|NCT02535845|BEHAVIORAL|Project Voice|Project Voice tablet-based intervention plus informational video
40990956|NCT02535845|BEHAVIORAL|HPV Informational Video|Informational video only
41308086|NCT05996731|PROCEDURE|Skin biopsy|A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.
41308087|NCT05362643|OTHER|Acupuncture|Manual acupuncture on acupoint Tai Xi(KI3), bilateral;Sanyinjiao (SP6), bilateral; Zusanli (ST36), bilateral; Shenmen (HT7) unilateral, in the arm without arteriovenous fistula;Guan Yuan (CV4), unilateral, attempt to achieve De qi sensation. After generating needling sensation, needles were manipulated for one minute, every ten minutes during needle retention (20 minutes), using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
41466673|NCT00812318|DRUG|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
41466674|NCT00812318|DRUG|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
41466675|NCT01954914|DRUG|Plerixafor|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
41466676|NCT03307811|OTHER|22 gauge needle liver biopsy|EUS will be performed. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
41466677|NCT05011006|DIAGNOSTIC_TEST|NT3 blood draw|blood draw
40787161|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
40787162|NCT00648648|DRUG|adavosertib|adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
40787163|NCT00648648|DRUG|gemcitabine|Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.
40787164|NCT00648648|DRUG|cisplatin|Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.
40990957|NCT05947201|DRUG|Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil|If the addition of Cadonilimab to neoadjuvant chemotherapy further improve the efficiency for locally advanced esophageal squamous cell carcinoma
40990958|NCT02208856|DRUG|BIBR 796 BS|
41157025|NCT02419040|PROCEDURE|Barbotage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
40787165|NCT00648648|DRUG|carboplatin|Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
40787166|NCT03678545|DRUG|Dupilumab (blinded)|Subcutaneous injection every two weeks as follows: 600 mg initial dose, and 300 mg subsequent doses for a total of 6 injections.
40787167|NCT03678545|DRUG|Placebo (blinded)|Placebo is matched to the active drug (dupilumab), and is given in the same manner: a subcutaneous injection every two weeks for a total of 6 injections.
40990959|NCT02208856|DRUG|Placebo|
40990960|NCT02208856|OTHER|high fat standardized breakfast|
40990961|NCT05552677|OTHER|Multicomponent Training|Participants will perform a multicomponent training that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 12 weeks
41308088|NCT05362643|OTHER|Sham Acupuncture|Manual acupuncture performed as superficial needling (5mm depth) on non-acupuncture points without an attempt to achieve De qi sensation and without stimulation, lasting 20 minutes, using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
40787168|NCT03678545|DRUG|Dupilumab (open-label)|After completing 6 doses of blinded study drug (dupilumab or placebo), participants can continue into the open-label portion of the study, in which all subjects will receive 12 doses (every 2 weeks for 24 weeks) of dupilumab.
40787169|NCT03017105|OTHER|Cross-education of strength-training|Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm
40787170|NCT03017105|OTHER|Usual rehabilitation|Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
40990962|NCT05152888|DRUG|Evolocumab|Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.
41308089|NCT00646971|DEVICE|CPAP device|for 4 weeks
41308090|NCT00646971|DEVICE|Placebo device|for 4 weeks
41308091|NCT01768598|OTHER|Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
41308092|NCT01768598|OTHER|Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
41308093|NCT01768598|OTHER|Non Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
41308094|NCT01768598|OTHER|Non Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
41308095|NCT04365985|DRUG|Naltrexone|Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to Ketamine arm. Naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..
41308096|NCT04365985|DRUG|Ketamine|Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage. Ketamine can be reduced back to 0.15 mg/kg at the clinical decision of the investigator and when patient has hypertensive emergency, the dose can be held until hypertensive emergency is controlled.
41308097|NCT04365985|OTHER|Placebo|Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.
41308098|NCT00130806|DRUG|MK0478 (muraglitazar)|
41308099|NCT00130806|DRUG|Comparator: placebo|
41308100|NCT04611685|DRUG|NSAID|Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.
41466678|NCT00029211|DRUG|Echinacea|
41466679|NCT02253069|DEVICE|Applying Prontosan antiseptic solution to tie-over dressings|Applying a PHMB-based antiseptic to tie-over dressings
41466680|NCT02253069|DEVICE|Applying Placebo to tie-over dressings|Placebo control
41466681|NCT03237117|BIOLOGICAL|Growth Hormone (GH)|to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
41488590|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
40787171|NCT02588469|OTHER|Interventional group|"Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.~To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA."
40787172|NCT02588469|OTHER|Control group|Standard obesity care with physical activity program
40787173|NCT04610983|DIETARY_SUPPLEMENT|Experimental: Control|2 x algal oil gel capsules delivering 400mg DHA in total
40787174|NCT04610983|DIETARY_SUPPLEMENT|Experimental: Treatment 1 - Semi-Solid food matrix|"Test Food 1: 200g serve soup + ingredient"
40990963|NCT04681170|DRUG|Lomitapide|2mg,5mg, 10mg and 20mg capsules
40990964|NCT03195114|DIAGNOSTIC_TEST|Multimodality Imaging and Biomarkers|Cardiac MRI, Cardiac MDCT, Echocardiography and Biomarkers Testing
40990965|NCT03637803|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
41308101|NCT04611685|DRUG|Tramadol|Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.
41308102|NCT05839431|BEHAVIORAL|Virtual Reality for Youth Phobias|The intervention will consist of up to 10, 50-minute-long weekly in-person individual sessions of virtual reality-assisted exposure therapy. This intervention also includes psychoeducation about anxiety/phobias and their maintenance, youth strategies for tolerating distress, and parent strategies for reducing accommodation of anxiety.
41466682|NCT02759549|BEHAVIORAL|eSMART-MH|eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programmed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. eSMART-MH will be used once a week throughout the duration of radiation treatment.
41466683|NCT02759549|OTHER|Mobile Mood Tracking (Mood 24/7)|Public social media data posted by participants will be accessed and downloaded to a computer program. Permission for the study team to access this data is optional.
41466684|NCT02759549|BEHAVIORAL|Theater Testing Workshop|The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement. Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
41466685|NCT02447887|DRUG|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
41466686|NCT02447887|DRUG|Pegylated IFN-alpha 2b|Weekly injection
41466687|NCT02036801|OTHER|Lung specific elastance|Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
41466688|NCT05155293|DRUG|AVT06 (proposed aflibercept biosimilar)|Patients will receive IVT injections of AVT06
41466689|NCT05155293|DRUG|Eylea® (Aflibercept)|Patients will receive IVT injections of Eylea®
41466690|NCT02904538|DRUG|Dexamethasone|
41466691|NCT02904538|DRUG|isotonic saline|
41466692|NCT04869371|DRUG|Docetaxel injection|75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
41466693|NCT04869371|DRUG|Triptorelin Pamoate for Injectable Suspension|15mg every 12 weeks
41466694|NCT04869371|DRUG|Prednisone Acetate Tablets|5 mg oral low dose prednisone, once daily
41466695|NCT03245437|DRUG|Oxytocin nasal spray|nasal spray
41466696|NCT03245437|BEHAVIORAL|Social Cognition Skills Training|Group based training in social cognition skills
41466697|NCT03245437|BEHAVIORAL|Health Management|Group-based training in mental health management
41466698|NCT03245437|DRUG|Placebo nasal spray|placebo condition
41466699|NCT02665884|OTHER|Intraocular Pressure Measurement|Diurnal fluctuations of intraocular pressure will be measured and compared
41466700|NCT00000425|DRUG|Nonsteroidal anti-inflammatory drugs (NSAIDs)|
41466701|NCT00000425|DRUG|Acetaminophen|
41466702|NCT01517867|BEHAVIORAL|Chicago Parent Program|The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems
41466703|NCT01517867|BEHAVIORAL|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
41466704|NCT03176433|DEVICE|Normothermic Machine Liver Perfusion|Liver Preservation Method
41466705|NCT00932724|DRUG|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
41466706|NCT00932724|DRUG|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
40990966|NCT03637803|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
41466707|NCT04117893|DRUG|Duloxetine|Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
41466708|NCT04117893|DRUG|intra-articular injection of corticosteroid and hyaluronic acid|Participants will receive a 3.5 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.
41466709|NCT06467851|DRUG|Suanzaoren Decoction and Huanglian Wenda Decoction|Twice daily. Chinese herbal medicine includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
41466710|NCT03212378|OTHER|percutaneous coronary interventions|Percutaneous coronary intervention.
41466711|NCT04130217|PROCEDURE|addition of positive end expiratory pressure in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
41466712|NCT04130217|PROCEDURE|addition of positive end expiratory pressure and recruitment maneuver in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
40787175|NCT04610983|DIETARY_SUPPLEMENT|Treatment 2 - Solid food matrix|"Test Food 2: 50g serve extruded snack (savoury snack) + ingredient"
41466713|NCT00798265|BIOLOGICAL|Gardasil|.5 mL dose injected IM at 0, 2 and 6 months
41466714|NCT00798265|BEHAVIORAL|Survey|Administration of online risk behavior and knowledge survey done at week 0.
41466715|NCT00108628|BEHAVIORAL|Imagery Rehearsal|IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.
41466716|NCT00108628|BEHAVIORAL|Sleep and Nightmare Management|This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
41466717|NCT04196348|PROCEDURE|Short BPL RYGB|Alimentary limb (AL) with 120 cm and BPL with 100 cm.
41466718|NCT04196348|PROCEDURE|Long BPL RYGB|AL with 120 cm and BPL with 200 cm.
40787176|NCT03645538|OTHER|Parkinson's disease patients|"The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
40990967|NCT05240404|DRUG|Toripalimab|toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months
41308103|NCT03648281|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
41308104|NCT03071536|DRUG|Furosemide Injection|Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
41308105|NCT01914419|DRUG|Oxytocin|
41308106|NCT05038033|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|The IPT group sessions follow three phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbating disinhibited eating and anxiety symptoms. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors and warning signs for excessive weight gain, such as eating in response to negative affect as opposed to hunger, or feeling a sense of loss-of-control while eating. IPT focuses on psychoeducation and general skill-building that can be applied to different relationships within the framework of four interpersonal problem areas: interpersonal role disputes, role transitions, interpersonal deficits, and grief.
41308107|NCT05038033|BEHAVIORAL|Cognitive Behavioral Theory (CBT)|The CBT program will be derived from Coping Cat, a manualized intervention for children and adolescents with elevated symptoms of anxiety. The group intervention builds skills for managing anxiety, in general, but with a focus on how anxiety prompts disinhibited eating, including attention to and restructuring of negative cognitions that perpetuate anxiety and behavioral exposure, rather than avoidance, of anxiety-provoking situations.
41308108|NCT04075201|BIOLOGICAL|One dose of investigational vaccine|One dose of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd.
41308109|NCT04075201|BIOLOGICAL|One dose of control vaccine|One dose of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
41466719|NCT01225055|DRUG|Teriparatide|20 ug daily over 12 months
41466720|NCT01225055|DEVICE|vibration|10 min/day for 12 months
41466721|NCT00071084|DRUG|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 16 weeks.
41466722|NCT00071084|DRUG|HuMax-CD4|HuMax-CD4 980 mg was administered as a SC infusion OD up to 16 weeks.
41466723|NCT00198224|PROCEDURE|phlebotomy|
41466724|NCT05416099|PROCEDURE|laser|grid vs micropulse laser
41466725|NCT06106334|DRUG|S309309|Administered as oral capsules
40787177|NCT03645538|OTHER|No drug|The neurophysiological evaluation in healthy subjects will be conducted by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG.
41147214|NCT00621842|DRUG|Lamotrigine novel formulation|"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
41147215|NCT00425971|DRUG|BMEC-1217B|
41147216|NCT05459974|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg once daily for 30 days after the atrial fibrillation ablation
41147217|NCT05459974|DRUG|Placebo|Placebo pill once daily for 30 days after the atrial fibrillation ablation
41147218|NCT01305551|DRUG|Saxagliptin|Tablet, Oral, 5 mg, once on Day 1 only
41147219|NCT01305551|DRUG|Metformin XR|Tablet, Oral, 500 mg, once on Day 1 only
41147220|NCT01305551|DRUG|Saxagliptin/Metformin XR FDC|Tablet, Oral, 5/500 mg, once on Day 1 only
41466726|NCT06106334|DRUG|Itraconazole|Administered as oral capsules
41466727|NCT05685524|DIAGNOSTIC_TEST|DNA methylation test|Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.
41466728|NCT02091310|DRUG|Placebo|
41466729|NCT02091310|DRUG|GFT505|
41466730|NCT02091310|DRUG|Moxifloxacin 400 mg|
41466731|NCT03819920|BEHAVIORAL|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
41466732|NCT03819920|BEHAVIORAL|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
41466733|NCT00028379|PROCEDURE|Transcranial magnetic stimulation (TMS)|
41466734|NCT00688298|DEVICE|Prefyx PPS™ System|A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
41466735|NCT00688298|DEVICE|Advantage ™ System|The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
41466736|NCT06210204|OTHER|Telehealth follow-up|Patients to follow-up via phone after surgery
41466737|NCT05230823|BEHAVIORAL|CR with added BWLT|12 week outpatient cardiac rehab (CR) program consisting of twice-weekly supervised exercise and risk factor modification (e.g. smoking cessation, support with medication). Concurrently, the patients will attend a weekly behavioural weight loss treatment (BWLT). Weekly goal-setting facilitated by the interventionist will focus on behavioural changes in nutrition and moderate calorie reduction while also emphasizing physical activity consistent with an individualized CR exercise prescription. Patients will track caloric intake, weekly exercise, weekly weight, and success/challenges with other health goals (e.g., challenging negative thoughts, body image, mindful eating, etc.) using a daily health diary. ASPIRE-AF will be delivered virtually to small groups (8-12 patients) by senior PhD students with advanced training in cognitive-behavioural therapy and motivational communication principles.
41488591|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
41488592|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
41308110|NCT04075201|BIOLOGICAL|Three doses of investigational vaccine|Three doses of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd. on the schedule of month 0,1,2
41308111|NCT04075201|BIOLOGICAL|Three doses of control vaccine|Three doses of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
40990968|NCT05240404|PROCEDURE|Thermal ablation|The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm.
41308112|NCT02648412|DRUG|ketamine|bolus 1 mg/kg
41308113|NCT02648412|PROCEDURE|Tetanic stimulations of incremental intensities|10-20-30-40-60 milliamps on the patient's left forearm
41308114|NCT01216592|OTHER|COPD treatment|Patients, will be asked to continue their previous medication (GOLD guidelines) during the study. No interventional change in COPD treatment will be performed during the study.
41308115|NCT02826733|DEVICE|Electroencephalogram (EEG)|
41308116|NCT02826733|DEVICE|Near Infra Red Spectroscopy (NIRS)|
41308117|NCT02826733|DEVICE|magnetic resonance imaging (MRI)|
40990969|NCT02816840|RADIATION|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
41308118|NCT00423410|DRUG|EPC2407 (crinobulin)|IV infusion 1 to 4 hours
41308119|NCT05524441|OTHER|Circadian Disruption - Quasi-Experimental|2 conditions: comparing trips with circadian disruption to trips without circadian disruption
41308120|NCT01911000|RADIATION|RT and hyperthermia after TACE|
41308121|NCT05800002|PROCEDURE|Intravascular ultrasound|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on intravascular ultrasound.
41308122|NCT05800002|PROCEDURE|Angiography|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on angiography.
41308123|NCT04569474|DEVICE|Transparent dressing|Use of sterile transparente dressing
41308124|NCT00001439|BIOLOGICAL|gp100 human melanoma peptide|
41308125|NCT01090089|DRUG|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
41308126|NCT01090089|DRUG|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
41308127|NCT05916677|OTHER|Virtual Reality-training in Theory of Mind|"Two social scenarios will be used in a virtual environement. Experimenter and subject participate in the scenario as friends of the main character, Nicolas. During the training session, experimenter asks structured questions about participant's awareness of a mental state. In the case of a wrong answer, a feedback-correction is provided via the avatar's thought bubbles. The participant has access to all avatars thought bubbles. In this way, he is able to compare the desires, beliefs or false beliefs of each story character.~Participants included in this condition will also have an eye-tracking assessment before and after the training procedure."
40787178|NCT04712123|OTHER|relapse due to S. aureus|to find out if it is the same S. aureus in both infections
40822885|NCT00716430|BEHAVIORAL|Quality Improvement Programme|Quality Improvement training programme
40990970|NCT02816840|RADIATION|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
40990971|NCT04652479|DRUG|Avexitide|Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
40990972|NCT04703439|BEHAVIORAL|Medication-taking reminders & educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
40990973|NCT04703439|BEHAVIORAL|Educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
40990974|NCT04710706|OTHER|Colonoscopy insertion technique used during procedure|Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.
40990975|NCT01375907|DRUG|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
40990976|NCT00014209|DRUG|cisplatin|
40990977|NCT00014209|DRUG|dexamethasone|
40990978|NCT00014209|DRUG|gemcitabine hydrochloride|
40990979|NCT01277523|DRUG|tiotropium high dose|2 actuations once daily
40990980|NCT01277523|DRUG|placebo|2 actuations once daily
40990981|NCT01277523|DRUG|tiotropium low dose|2 actuations once daily
41147221|NCT06197035|PROCEDURE|Coping With and Caring for Infants With Special Needs|The early intervention programme for infants and young children focuses on the active inclusion of the whole family. The coaching of parents is a central component. Parents learn how they can independently and optimally support their child's development as part of the child's everyday life. The programme was developed at the beginning of the 2000s in the Netherlands by child physiotherapist Tineke Dirks and professor of developmental neurology Mijna Hadders-Algra.
40787179|NCT05157061|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a prebiotic supplement is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
40787180|NCT05157061|DIETARY_SUPPLEMENT|Maltodextrine|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a placebo is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
40787181|NCT02885142|PROCEDURE|Local excision for early rectal cancer|
40787182|NCT05313763|OTHER|conventional physical therapy|A hotpack will be applied to the neck area for 15 minutes in the prone position of the patients. Conventional type Tens with a frequency of 50 Hz and a pulse duration of \<150 microseconds will be applied for 20 minutes, taking the painful area to the center. Ultrasound will be applied to the patients for 5 minutes with a dosage of 1-1.5 watts/cm2. Cervical joint range of motion exercises, stretching exercises for trapezius, scalenia, rhomboid, levator scapulae, pectoral and suboccipital muscles will be applied, then cervical isometric strengthening exercises and stabilization exercises will be carried out in a controlled manner. Conventional physical therapy will be applied by the same physiotherapist 5 days a week for 3 weeks.
40787183|NCT05313763|OTHER|Active Kinesiotaping|For kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, and the application will be started from the midline of the upper thoracic vertebrae. Initially, 4-5 cm stretching will be applied, and the arms of the Y strip will be adhered to the cervical paravertebral muscles without stretching. I strip will be applied to the painful area with the area correction technique, with maximum stretching in the middle and without stretching the ends. The applications will be made by the same physiatrist with 7 years of clinical experience.
40787184|NCT05313763|OTHER|Sham Kinesiotaping|For Sham kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, the application will be started from the midline of the upper thoracic vertebrae, and the Y and I bands will be applied without stretching. The applications will be made by the same physiatrist with 7 years of clinical experience.
40787185|NCT03330444|PROCEDURE|Endometrial biopsy and endometrial fluid collection|On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.
40990982|NCT04045678|DRUG|LY03003 ( Rotigotine, extended-release microspheres)|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
40990983|NCT04045678|DRUG|Placebo, extended-release microspheres|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
40990984|NCT04731168|DEVICE|Mandibular advancement device|Patients will have a mandibular advancement device during the first postoperative night
40990985|NCT03605797|OTHER|follow up of cases fixed by posterior tension band plate|Follow up of the reduction and functional outcome evaluation using the Majeed functional outcome score
41147222|NCT06197035|PROCEDURE|Standard Physiotherapy|Pediatric physiotherapy techniques aimed at improving the development of the baby and young child from manual therapy tools, or baby management.
41147223|NCT04179799|DEVICE|Diaphragm Pacing|"Intramuscular stimulation of the diaphragm, or diaphragm pacing' is achieved by laparoscopic placement of stimulation wires into each hemidiaphragm. Phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller."
40990986|NCT02003131|BIOLOGICAL|Trophic factors from umbilical cord mesenchymal stem cells|
40990987|NCT06387914|DEVICE|Stimulation ON|Neurostimulation of the periaqueductal gray matter and sensory thalamus at a level with potential to provide pain relief
41308128|NCT05916677|OTHER|Traditional training in Theory of Mind|The same two social scenarios are presented to the participant in a story-telling form. Participant has access to thought bubbles via an illustrated book. These trainings will take place in the same number of sessions and took place for a duration equivalent to those used in low immersion Virtual Reality mode. Each training session (EFB, BE, SOFB, ERA, FP, EFP) will be illustrated via visual aids taken from screenshots of the two virtual environments and the target protagonists.
41308129|NCT02145091|DRUG|Moderately-high dose of psilocybin|Oral dose of a moderately-high dose of psilocybin.
40990988|NCT06387914|DEVICE|Stimulation Pseudo-ON|Neurostimulation of the periaqueductal gray matter and sensory thalamus S at a low level, not designed to provide pain relief
40990989|NCT03098173|PROCEDURE|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
40990990|NCT03098173|PROCEDURE|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
41466738|NCT02966158|OTHER|AIT Group|"The AIT Group will begin with a one-month, run-in period where patients will perform current standard of care CR programming, which will involve traditional MICE. MICE at the Cardiac Rumsey Centre will consist of either track walking/jogging or treadmill walking/jogging for approximately 30-40 minutes, performed at an intensity of 60-80% of VO2peak, in addition to a warm-up and cool down period. In the second month of the study intervention, patients will begin to perform AIT three days per week, which involves performing 4-minute intervals at greater than 90% of peak heart rate, separated by 3-minutes of active recovery, with one of those AIT exercise sessions occurring at the Rumsey Centre under supervision, and 2 sessions per week of MICE, which will again consist of the 30-40 minutes of walking/jogging at an intensity of 60-80% of VO2peak, with an allotted warm up and cool down period."
41466739|NCT03815240|OTHER|No dressing|no dressing at sacrum
41466740|NCT03815240|OTHER|Mepilex® Border Sacrum|adhesive sacrum dressing
41466741|NCT03815240|OTHER|ALLEVYN Life Sacrum|adhesive sacrum dressing
41466742|NCT03815240|OTHER|Optifoam® Gentle Sacrum|adhesive sacrum dressing
40990991|NCT03760796|DEVICE|Corrie Health Digital Platform|The Corrie Health Digital Platform consists of the Corrie smartphone app for heart attack recovery which is paired with an Apple Watch and Bluetooth-enabled, iHealth blood pressure monitor.
40990992|NCT03245008|DRUG|MT-5547|Solution for injection in pre-filled syringe
40990993|NCT03245008|DRUG|MT-5547-matching placebo|Solution for injection in pre-filled syringe
40787190|NCT00537472|DRUG|Low dose bupivicaine in spinal anesthetic|Bupivacaine 9 mg intrathecal single shot injection at start of surgery
40787191|NCT00537472|DRUG|Standard dose bupivacaine in spinal anesthetic|Bupivacaine 13 mg intrathecal single shot injection at start of surgery
40787192|NCT05754333|DRUG|pudexacianinium chloride|Intravenous
40787193|NCT05521009|OTHER|Control grup, sticky tube holder|In patients using adhesive tube holders and non-adhesive tube holders, it will be investigated whether there is bacterial growth on the tube.
40990994|NCT01442870|DRUG|Metformin|Metformin
40990995|NCT05387317|BIOLOGICAL|Pfizer-BioNTech Standard dose|"Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
40990996|NCT05387317|BIOLOGICAL|AstraZeneca Standard dose|"Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
40990997|NCT05387317|BIOLOGICAL|Pfizer-BioNTech Fractional dose|"Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
40990998|NCT05387317|BIOLOGICAL|AstraZeneca Fractional dose|"Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
40990999|NCT05387317|BIOLOGICAL|Moderna Standard dose|Standard dose (50ug in 0.25ml)
40991000|NCT05387317|BIOLOGICAL|Moderna Fractional dose|Fractional dose (20ug in 0.1ml)
41466743|NCT02721706|OTHER|CIPA nutritional screening tool|The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h \<50%, serum albumin \<3 g/dl, body mass index \<18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
41466744|NCT04561336|DRUG|Avelumab|avelumab in combination with cetuximab
41466745|NCT04561336|DRUG|Cetuximab|avelumab in combination with cetuximab
41466746|NCT05693831|OTHER|Cellworks Report|Survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™ and Ventura™ reports in facilitating treatment decisions in pan-cancer patients.
40787194|NCT04980469|OTHER|Vitex negundo + Zingiber officinale|200 mg/ Capsule
40787195|NCT04980469|OTHER|Placebo (MCC)|200 mg/ Capsule
40787196|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
40787197|NCT05525910|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
40787198|NCT05525910|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
40787199|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
40787200|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
40991001|NCT04714996|DRUG|ES-481|"Treatment Period Week 1 - 25 mg qd, Week 2 - 25 mg bid, Week 3 - 50 mg bid, Week 4 - 75 mg bid.~Step-down and Washout Period Day 1 - 125 mg, Day 2 - 100 mg, Day 3 - 75 mg, Day 4 - 50 mg, Day 5 - 50 mg, Day 6 - 25 mg, Day 7 - 25 mg, Days 8 to 14 - 0 mg"
41147224|NCT03807947|PROCEDURE|Radial TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via left transradial access
41147225|NCT03807947|PROCEDURE|Transfemoral TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via right transfemoral access
40787201|NCT03101319|DRUG|Vitamin D3 cholecalciferol|As mentioned in the description of the study arm
40787202|NCT03101319|DRUG|B Complex Oral Tablet|As mentioned in the description of the study arm
41147226|NCT02271841|DEVICE|PVI|Pleth Variability Index
41466747|NCT00681473|RADIATION|Proton Radiation Therapy|Once daily, Monday through Friday, for 6 weeks.
41466748|NCT02853916|DIETARY_SUPPLEMENT|500 mg InSea2®|
41466749|NCT02853916|DIETARY_SUPPLEMENT|250 mg InSea2®|
41466750|NCT02853916|DIETARY_SUPPLEMENT|Placebo|
41466751|NCT06494826|OTHER|colonoscopy procedure|"Candidates for a medically-indicated colonoscopy due to suspected new-onset CD or non-specific GI complaints or routine screening for colorectal cancer as part of primary prevention.~colonoscopy will not be done for research purposes only ."
40991002|NCT04714996|DRUG|Placebo|Placebo on Week 1, Week 2, Week 3 and Week 4
41466752|NCT01362673|DRUG|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
40991003|NCT04714996|DRUG|Open-Label Extension Study|Dosing will be at the discretion of the Investigator with a minimum dose of 25 mg/day (25 mg qd) to a maximum dose of 150 mg/day (75 mg bid).
40991004|NCT01200654|DRUG|Linezolid|Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
40991005|NCT00912990|DRUG|Cisatracurium|One intravenous dose: 0.2mg/kg/dose
41308130|NCT02145091|DRUG|Moderately-low dose of psilocybin|Oral dose of a moderately-low dose of psilocybin.
41466753|NCT01362673|DRUG|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
41466754|NCT01362673|DRUG|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
41466755|NCT01362673|DRUG|Placebo|Oral single dose as matching placebo
41466756|NCT01362673|DRUG|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
41466757|NCT01362673|DRUG|Placebo|Oral multiple doses as matching placebo for 12 days
41466758|NCT06160388|DEVICE|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
41466759|NCT04193319|DRUG|Fluzoparib|PARP inhibitor
41466760|NCT04193319|DRUG|Fluconazole|inhibitor
41466761|NCT05247073|PROCEDURE|patients of controlled group with routine closure of episiotomy|"Perineal trauma is traditionally repaired in three stages: a continuous locking stitch is inserted to close the vaginal trauma, commencing at the apex of the wound and finishing at the level of the fourchette with a loop knot. The perineal muscles are then re-approximated with three or four interrupted sutures and finally, the perineal skin is closed by inserting continuous subcutaneous or interrupted transcutaneous stitches.~The skin is then closed with inverted interrupted stitches placed in the subcutaneous tissue a few millimeters under the perineal skin edges (not transcutaneously)."
41488593|NCT02288390|PROCEDURE|Oral care in mechanically ventilated patients|Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
41488594|NCT01172821|DRUG|placebo|Placebo that represents BI drug
40787203|NCT05986266|DRUG|Carbetocin|To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
40787204|NCT02448966|PROCEDURE|open esophagectomy|
40787205|NCT02448966|PROCEDURE|Minimally invasive esophagectomy|
40787206|NCT03431597|DIETARY_SUPPLEMENT|novel micronutrient|The supplements will be supplied to participants on a daily basis. The novel micronutrient supplement will be provided in powder form with instructions to dissolve one sachet in 250ml of clean water
40787207|NCT03431597|DIETARY_SUPPLEMENT|existing micronutrient supplement, UNIMMAP|UNIMMAP will be provided in tablet form and given one daily
40787208|NCT02034643|PROCEDURE|balloon pressure adjustment|Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
40787209|NCT06378437|DRUG|GLB-001|Administered orally according to the assigned treatment schedule
40787210|NCT02394158|DRUG|Metformin|
40787211|NCT02394158|DRUG|placebo|
40787212|NCT02859974|BEHAVIORAL|Respiratory retraining for PVFMD|"Patients serve as their own controls. During a three week baseline, participants will complete the Dyspnea Index (DI), and have their heart rate, Resp. minute volume and ETCO2 on days 1 and 21 (or on the day treatment commences). Participants will complete a daily log reporting their daily symptoms. This will serve as the baseline prephase.~Post 1 phase will include five individual therapy sessions teaching the respiratory retraining techniques over an estimated three week period.~Post2 phase will comprise of a six week home practice phase. There will be four measuring points per participant: pre1/pre2 measurements on day 1 and 21 (or on the day therapy begins), post1 upon completing five therapy sessions and post 2 upon completion of the home practice phase."
40787213|NCT00499668|DRUG|aprepitant|125 mg orally for 7 days
40787214|NCT00499668|DRUG|ondansetron hydrochloride|24 mg orally for 7 days
40991006|NCT00912990|DRUG|Normal saline|One Intravenous dose
40991007|NCT04989400|DRUG|Ulipristal Acetate|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
41017753|NCT03370328|OTHER|Peppermint oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
41308131|NCT02145091|DRUG|Very-low dose of psilocybin|Oral dose of a very-low dose of psilocybin.
41308132|NCT02145091|DRUG|Placebo|An oral placebo (lactose pill).
41488595|NCT01172821|DRUG|placebo|Placebo that represents comparator
41488596|NCT01172821|DRUG|placebo|Placebo that represents comparator
40787215|NCT03539757|DEVICE|Non-Contrast Magnetic Resonance Imaging|The investigators plan to prospectively assess the correlation of liver fibrosis and congestion measurements obtained from novel, non-contrast MR imaging methods to histopathologic data obtained from a clinically-indicated liver biopsy in Fontan patients.
40787216|NCT02164344|DIETARY_SUPPLEMENT|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
40787217|NCT03309982|DIETARY_SUPPLEMENT|Plant polyphenol blend|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
40787218|NCT03309982|OTHER|Placebo|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
40787219|NCT05590247|BEHAVIORAL|Intermittent Fasting Diet|Patients will follow the 16: 8 traditional intermittent fasting model, where they may only consume calories during 1 continuous 8-hour period of the day. Water may be consumed during fasting.
40991008|NCT04989400|DRUG|Misoprostol|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal. Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
40991009|NCT04123288|DRUG|ACT-709478|1 film-coated minitablet contains 2 mg of ACT-709478
40991010|NCT04123288|DRUG|ACT-709478|1 hard capsule contains 10 mg of ACT-709478.
40787220|NCT02132403|DRUG|BTH1704|BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
40787221|NCT02132403|DRUG|IMPRIME PGG|Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
41308133|NCT03302416|DRUG|Hydrocortisone|
40787222|NCT02132403|DRUG|Gemcitabine|Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
40787223|NCT02605408|DEVICE|LenSx® laser system|Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
41308134|NCT03302416|RADIATION|[C-11]NOP-1A|
41466762|NCT05247073|PROCEDURE|The Mostafa Maged four-stitch technique fore closure of the episiotomy|"Identification of the apex of the episiotomy, then a simple suture is taken (0.5 cm) behind the apex of the episiotomy. First, the needle is inserted at the vaginal mucosa of the right edge of the episiotomy then extract the needle.~The second stitch is inserted on the deep muscle layer of the same side (Right side) of the episiotomy cutting edge then extracting the needle.~Then, insert the needle again on the left side of the episiotomy incision in the deep muscle layer on the left side of the episiotomy incision directing the tip of the needle upwards parallel to the second stitch taken.~The fourth step is inserting the needle in the vaginal mucosa of the left side parallel to the first stitch. Continue suturing the episiotomy incision continuously in the same way till reaching the remnant of the hymen.~Then suture the superficial perineal muscle in a continuous manner and the skin in a subcuticular manner as well."
41466763|NCT06087718|DEVICE|Maastro applicator|The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size \< 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.
41466764|NCT02274662|BIOLOGICAL|Cultured Thymus Tissue|"Subjects receive cultured thymus tissue which is implanted into the quadriceps muscle. Subjects may receive pre and/or post-implantation immunosuppression.~Potential subjects are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted into the subject's quadriceps muscle under general anesthesia in the operating room. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one year post-implantation. At year 2 post-implantation, subjects are contacted for data collection."
41466765|NCT02274662|PROCEDURE|Blood Draw|
40787224|NCT02605408|PROCEDURE|Phacoemulsification|Removal of the cataractous lens
40787225|NCT01597726|DRUG|Misoprostol|Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D\&E, repeated once 3 hours after the first dose if needed
40991011|NCT06243887|OTHER|Enhanced Recovery After Surgery (ERAS) protocol in minimal invasive esophagectomy|Enhanced Recovery After Surgery (ERAS) refers to patient-centered, evidence-based, multidisciplinary team developed pathways for a surgical specialty and facility culture to reduce the patient's surgical stress response, optimize their physiologic function, and facilitate recovery.
40787226|NCT01597726|DEVICE|Laminaria|Laminaria tents inserted into the cervix 18 to 24 hours prior to D\&E
40991012|NCT06243887|OTHER|standard of care approaches in minimal invasive esophagectomy|standard of care approaches other than ERAS
41466766|NCT02274662|DRUG|Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus|RATGAM and Cyclosporine or Tacrolimus may be given, depending on the patient. The doses, timing, and trough levels will vary depending on the patient's clinical condition.
41466767|NCT02007668|OTHER|Kinesio Taping|Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
41466768|NCT01450241|OTHER|Early antibiotic discontinuation|Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever
41466769|NCT01450241|OTHER|Usual practice|Continued antibiotic treatment as accepted by guidelines for febrile neutropenia
41466770|NCT02010034|DRUG|Omegaven|Omegaven will be used in place of soy oil Intralipid
41466771|NCT01527838|BIOLOGICAL|Single FT1050 treated UCB unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
41466772|NCT04596397|OTHER|Inpatient setting|These women stay at the hospital.
41466773|NCT04596397|OTHER|Outpatient setting|These women can leave the hospital.
41466774|NCT02824887|OTHER|Electro-acupuncture|Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints
41466775|NCT02824887|OTHER|Conventional treatment of Western Medicine|Routine non operative treatment of Western Medicine
41466776|NCT04564404|OTHER|Survey|Questionnaire to ask about the willingness-to-buy applications in neuromuscular monitoring.
41466777|NCT06238128|BEHAVIORAL|Opioid Rapid Resonse System (ORRS) training|ORRS is on online system to train citizen responders to administer NARCAN to save the lives of opioid overdose victims. It capitalizes on the innovative PulsePoint technology to connect responders to overdose events. PulsePoint is an app that connects 911 requesting assistance for cardiac arrests to responders with Cardiopulmonary Resuscitation (CPR) training. ORRS allows us to partner with PulsePoint users to expand its reach to opioid overdoses, which share the need for a quick response that emergency responders are often unable to provide. ORRS has the advantage of expanding the population of responders with NARCAN, rescue breathing, and CPR training that can be connected to overdose events, increasing the likelihood of saving overdose victims' lives through a quick, efficient response. ORRS is delivered through an interactive, digital platform containing sequential, multi-media modules.
41466778|NCT06238128|BEHAVIORAL|Non-active opioid overdose response training|"Investigators will provide online training about opioid prevalence in US, opioid mechanism, side effect, and addiction. However, Investigators do not provide any knowledge about opioid overdose management and naloxone in this training.~Once the project is completed, participants will receive online Naloxone training."
41466779|NCT05659758|PROCEDURE|Head up positioning during preoxygenation|patients will be preoxygenated in head up position
40787227|NCT04116593|BEHAVIORAL|Nutrition education|Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
41308135|NCT02304536|DRUG|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
41308136|NCT02304536|PROCEDURE|Laparoscopic ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
41308137|NCT03736538|DRUG|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
41466780|NCT04874896|DIETARY_SUPPLEMENT|Microbiota autotransplantation|Patients received microbiota autotransplantation in capsules (1g per day) for 6 months
40787228|NCT04845672|OTHER|2% chlorhexidine gluconate|Children in 2% chlorhexidine gluconate group , which is the routine practice of the hospital, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
41466781|NCT04874896|DIETARY_SUPPLEMENT|Control|Patients will not received microbiota autotransplantation in capsules and will received usual medical care
41466782|NCT03635983|BIOLOGICAL|NKTR-214|Specified dose on specified days
40787229|NCT04845672|OTHER|soap-free body cleaning solution|Children in a wiping bath with soap-free body washing solution group, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
40787230|NCT02055950|PROCEDURE|Storage of kidney in refrigerated solution|
40787231|NCT02055950|PROCEDURE|Kidney perfused by pulsatile machine|
40787232|NCT03594110|DRUG|Empagliflozin|Taken daily with or without food
40787233|NCT03594110|DRUG|Matching placebo|Taken daily with or without food
40991013|NCT00854945|DRUG|ON 01910.Na|1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
40991014|NCT04094922|BEHAVIORAL|Swedish PTSD Coach smartphone app|Self-help smartphone app targeted towards posttraumatic stress that includes psychoeducation, rating/monitoring of distress, lists of support and treatment resources, and strategies for coping with distress.
40991015|NCT03463889|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
40991016|NCT03463889|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI in combination with PET
41308138|NCT03736538|DRUG|Placebo gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
41308139|NCT04708652|OTHER|No intervention|No intervention
41308140|NCT03730883|PROCEDURE|Central line removal at 100ml/kg/day.|In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake if well tolerated.
41466783|NCT03635983|BIOLOGICAL|Nivolumab|Specified dose on specified days
41466784|NCT04032847|BIOLOGICAL|ATL001|ATL001 infusion
41466785|NCT04032847|DRUG|Pembrolizumab|Checkpoint inhibitor
40787234|NCT06443892|PROCEDURE|Pericapsular Nerve Block (PENG)|Evaluation of postoperative analgesic efficacy of PENG block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
40991017|NCT03463889|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET in combination with MRI
40991018|NCT00495833|BEHAVIORAL|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
40991019|NCT00495833|BEHAVIORAL|Promotional gift|half of participants who go to a fire station will receive a gift card.
40991020|NCT02248610|OTHER|Non-interventional study|
41308141|NCT03730883|PROCEDURE|Central line removal at 140ml/kg/day.|In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake if well tolerated.
41466786|NCT04622930|DEVICE|Smartphone-delivered CBT for SAD|12-week Smartphone-delivered CBT for SAD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for SAD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
41466787|NCT01717040|DRUG|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
41466788|NCT01717040|DRUG|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
41466789|NCT04755673|OTHER|Atrantil (Medical Food)|All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
41488597|NCT01172821|DRUG|tiotropium Respimat® low dose|IMP
41466790|NCT02522780|DRUG|Mesalamine|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
40991021|NCT04425395|BEHAVIORAL|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance. Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min. The procedure is safe because the hand is removed before adverse effects can occur. The participant will be given a break of 5 min in between trials, and will interchange hands between trials. During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand.~Each participant will complete no more than three trials (conditions) in a randomised order."
40991022|NCT04425395|BEHAVIORAL|Acoustic Recordings|During the experiment, the vocalizations produced will be systematically recorded for each participant and an analysis of the acoustic structure of these vocalizations will be carried out.
40991023|NCT04425395|DIAGNOSTIC_TEST|Index measurement NOL™|Four sensors placed non-invasively on one finger. of the participants will be able to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
40991024|NCT04425395|DIAGNOSTIC_TEST|Video pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
41466791|NCT02522780|DRUG|Placebo|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
41466792|NCT06462131|BEHAVIORAL|Cultural Adapted Group cognitive Behaviroal therapy (CaGCBT)|In first session, introduction of the therapist/facilitator and group members will be made. Group rules will be discussed with members. Group members' introduction primarily focuses on participant/clients' expectations, addictive behaviors and its status, and goals. Moreover, it also emphasize on identification of any other significant issue that is contributing in burden of disease.
41466793|NCT02312479|DEVICE|Nyxoah SAT system|The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
40991025|NCT00230698|DRUG|topiramate|
41466794|NCT06285006|DRUG|Desmopressin|Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.
41466795|NCT03743610|OTHER|Simulated altitude|Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
41488598|NCT01172821|DRUG|placebo|Placebo that represents BI drug
40991026|NCT03891420|DRUG|Galidesivir|Galidesivir IV infusion
40991027|NCT03891420|DRUG|Placebo|Placebo IV infusion
40991028|NCT00587483|DRUG|Lidocaine|Lidocaine is a class I (sodium channel block) antiarrhythmic drug
40991029|NCT00587483|DRUG|Amiodarone|300 mg
40991030|NCT00587483|DRUG|Placebo|Saline
40991031|NCT01265849|BIOLOGICAL|LI|LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m\^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.
40991032|NCT01265849|DRUG|Cyclophosphamide|Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
40991033|NCT01265849|DRUG|Indomethacin|One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
41466796|NCT03743610|OTHER|Placebo simulated altitude|Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
41466797|NCT05824494|DRUG|Cadonilimab|Cadonilimab 10mg/kg,every 3 weeks,IV infusion
41466798|NCT05824494|DRUG|Nab paclitaxel|Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
41466799|NCT04826068|BEHAVIORAL|Emotional Processing|Processing Emotions of others based on photographs of faces
41466800|NCT04845841|DRUG|Elinzanetant (BAY3427080) treatment A|Single oral dose
41466801|NCT04845841|DRUG|Elinzanetant (BAY3427080) treatment B|Single oral dose
41466802|NCT00715091|DRUG|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
41466803|NCT00715091|DRUG|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
41488599|NCT01172821|DRUG|tiotropium Respimat® high dose|IMP
41488600|NCT01172821|DRUG|50 mcg salmeterol HFA MDI|Active comparator
41488601|NCT01172821|DRUG|placebo|Placebo that represents comparator
40991034|NCT01265849|DIETARY_SUPPLEMENT|Zinc|One capsule daily self administered beginning on day one of treatment with LI until one day before surgery
40991035|NCT01265849|PROCEDURE|Surgery|Excise tumor and nodes
40991036|NCT01265849|DRUG|Cisplatin|Cisplatin was administered 100mg/m\^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m\^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
40991037|NCT01265849|RADIATION|Radiotherapy|Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m\^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
40991038|NCT05856123|DEVICE|SimPull Lateral Transfer Device|Automated lateral transfer device
40991039|NCT05777681|PROCEDURE|Aortic Surgery|open surgical repair with resection of infected aortic segment, debridement of surrounding tissue and in situ graft replacement.
40991040|NCT04028752|BIOLOGICAL|Blood collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in the arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
41308142|NCT05607940|PROCEDURE|blood volume loss based blood transfusion|Blood transfusion is indicated based on the estimated intraoperative blood loss. When intraoperative blood loss exceeds 400ml, blood transfusion begin. At the end of the operation, we ensure that the volume of blood transfusion is no greater than the anticipated blood loss.
41308143|NCT05607940|PROCEDURE|hemoglobin concentration based blood transfusion|Blood transfusion is indicated based on the intraoperative hemoglobin concentration. Intraoperative blood transfusion begins when hemoglobin concentration is blow 70g/L. Intraoperative blood transfusion stops when hemoglobin concentration reaches 80g/L
41308144|NCT05337527|DIETARY_SUPPLEMENT|beetroot juice|Acute effects of beetroot juice or placebo juice ingestion
41308145|NCT01908621|DRUG|G-CSF (filgrastim)|
41308146|NCT01908621|DRUG|Cytosine arabinoside + G-CSF (filgrastim)|
41308147|NCT01450046|DRUG|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
41308148|NCT03108651|OTHER|Case|Motivational message will be administrated.
41308149|NCT04202861|DIAGNOSTIC_TEST|In vitro antibiotic combination testing (iACT)|CRGNB isolates from the index culture will be transported to the Pharmacy Research Lab,SGH for iACT testing. iACT results will be sent to the physicians and ID specialist managing the patient once completed. A subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and or the consulting infectious disease doctor may wish to continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement for the patient.
41466804|NCT05997940|DRUG|PENG block|The PENG block was performed with the patient in the supine position at preoperative waiting room. A curvilinear low-frequency ultrasound probe (2-5 MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22 gauge, 100 mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL
40991041|NCT02747420|DEVICE|NURO TM|The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.
41466805|NCT02675374|DRUG|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
41466806|NCT02675374|DRUG|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
41466807|NCT06437184|DIAGNOSTIC_TEST|ODP|se previously
41466808|NCT04655235|GENETIC|Genotyping|Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes
40787235|NCT06443892|PROCEDURE|Suprainguinal Fascia Iliaca Compartment Block (SFICB)|Evaluation of postoperative analgesic efficacy of SFICB block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
41147227|NCT02990845|DRUG|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
41308150|NCT05211011|DRUG|Fosfomycin|Infectofos 5 g
41308151|NCT05686473|BEHAVIORAL|Program of psychoeducation of parents and professionals|"The program consists of a standardized manual-based treatment package as an easily accessible treatment tool for use by professionals in the specialist health services, who have treatment responsibilities for children diagnosed with FASD in Norway.~The intervention program will last for about 2 months and includes eight sessions, including six digitally based, interactive psychoeducational sessions.~Topics will be:~1. General information about FASD~2. Intervention strategies in kindergartens/schools for children with FASD~3. Families living with FASD - activities of daily living~4. Self-regulatory deficits - how to cope~5. Executive functions in daily life~6. Social development in children with FASD~7. Guidance in social settings~8. Challenging behavior - what can be done"
40787236|NCT04240886|DRUG|fosmanogepix|IV and oral fosmanogepix
40787237|NCT04859101|OTHER|Gum|2 minutes of gum chewing prior to procedure
40787238|NCT04859101|OTHER|Control|2 swallows prior to procedure
40787239|NCT05648968|BIOLOGICAL|Ianalumab|i.v. infusion, prepared from concentrate solution
40787240|NCT05648968|DRUG|Placebo|i.v. infusion, prepared from matching placebo
40787241|NCT03982017|OTHER|Mobile Health Technology Platform|When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.
41308152|NCT00819533|DEVICE|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
41308153|NCT00862316|DEVICE|Oxford Unicompartmental Knee|Knee Arthroplasty
41308154|NCT03057457|DEVICE|NGAL Test|The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
41308155|NCT02221180|DRUG|Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]|Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
41308156|NCT02221180|DRUG|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
41308157|NCT02221180|DRUG|Metformin|Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
41308158|NCT01127126|DRUG|Bryophyllum pinnatum, Placebo in form of Lactose|"Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d."
41308159|NCT06405022|OTHER|Brain Endurance Training|Six week period with three weekly blocks with a 20 min brain endurance training program following a regular HIT session. Before the HIT session questionnaires are completed to measure the motivation for the HIT session and the current state of mood. In between the HIT session and the RCA session, questionnaires are completed to measure the experienced workload of the HIT session, the current state of mood, and the motivation for following the RCA session. Immediately after the RCA session, questionnaires are completed to measure the experienced workload of the RCA session and the current state of mood.
41308160|NCT06405022|OTHER|Control|No intervention
41308161|NCT03710941|DRUG|REGN2477+REGN1033|Single, sequential, repeat-dose Intravenous (IV) or matching placebo
41308162|NCT03710941|DRUG|Matching placebo|Single, sequential, repeat-dose Intravenous (IV)
41308163|NCT00006054|DRUG|anti-thymocyte globulin|
41308164|NCT00006054|DRUG|busulfan|
41308165|NCT00006054|DRUG|cyclophosphamide|
41308166|NCT00006054|DRUG|cyclosporine|
41308167|NCT00006054|DRUG|etoposide|
41308168|NCT00006054|DRUG|methotrexate|
41308169|NCT00006054|DRUG|methylprednisolone|
41308170|NCT00006054|DRUG|prednisone|
41466809|NCT04311944|OTHER|Early fast-track care|Participants will be eligible for fast-track care at 8 weeks if their HIV-1 RNA is \<200 copies/mL and they meet other eligibility criteria. If HIV-1 RNA is 200 copies/mL or higher at 8 weeks, then it will be repeated at 12 weeks, and those with HIV-1 RNA \<200 copies will then be eligible for fast-track care, if they meet other eligibility criteria.
41466810|NCT04311944|OTHER|Standard (deferred fast-track) care|Participants will be eligible for fast-track care at 24 weeks, if their HIV-1 RNA is \<200 copies.mL, and they meet other eligibility criteria.
41466811|NCT02523794|OTHER|Electro-kinetically Modified Water|Subjects assigned to this arm will receive the EMW
41466812|NCT02523794|OTHER|Placebo|Purified Drinking Water
41466813|NCT05860387|DIAGNOSTIC_TEST|Next generation improvement of early invasive aspergillosis|Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.
41466814|NCT05183711|BEHAVIORAL|Questionnaires|The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. (download the self-evaluating form via QR code)
41466815|NCT03419104|DIAGNOSTIC_TEST|preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
41466816|NCT02274558|DRUG|NBI-98854|NBI-98854 40 mg capsules
41466817|NCT02274558|DRUG|Placebo|NBI-98854 placebo capsules
40787242|NCT03982017|OTHER|Usual care|Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
41147228|NCT03796585|BEHAVIORAL|Immunization Registry Training|Education highlighting practical strategies to improve pharmacies' willingness to adopt the immunization registry and improve their ability to integrate the immunization registry into their pharmacy workflow.
41147229|NCT03796585|BEHAVIORAL|Informational flyer|Informational flyer with ImmPRINT contact information
41466818|NCT02725645|OTHER|loading conditions|Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
41466819|NCT03136406|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
41466820|NCT03136406|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
41466821|NCT03136406|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
41466822|NCT03136406|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
41466823|NCT03136406|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
41466824|NCT03136406|DRUG|nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
41466825|NCT03136406|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
41466826|NCT03136406|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
41147230|NCT01474265|DRUG|Varenicline|0.5-2 mg per day, oral use
41147231|NCT01474265|DRUG|Placebo|1-2 tablets per day, oral use
41147232|NCT01474265|DRUG|Nicorette TX|10-15 mg per day, transdermal use (patches)
40787243|NCT03302143|PROCEDURE|Guided bone regeneration with Bovine Bone Mineral|Guided bone regeneration with Bovine Bone Mineral
40787244|NCT03302143|PROCEDURE|Guided bone regeneration with freeze dried bone allograft|Guided bone regeneration with freeze dried bone allograft
40787245|NCT05874141|DIAGNOSTIC_TEST|HBA1C|blood sample on EDTA
40787246|NCT05874141|DIAGNOSTIC_TEST|Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides|serum sample
41147233|NCT01177644|DRUG|PDS 1.0|
41147234|NCT05071105|RADIATION|Stereotactic Body Radiation Therapy|In every group, the dose is prescribed at the edge of the PTV. To be approved, 95% of the PTV will be conformally covered by the prescription isodose surface and 99% of PTV will receive a minimum of 90% of the prescription dose.
41147235|NCT01266837|DRUG|Everolimus|10 mg p.o once daily
41147236|NCT02142218|DRUG|Nivolumab|
41147237|NCT01681394|DIETARY_SUPPLEMENT|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
41147238|NCT01681394|DIETARY_SUPPLEMENT|Chocolate cream|
41466827|NCT03136406|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
41466828|NCT03136406|BIOLOGICAL|aNK for Infusion|NK-92 cells
41466829|NCT03136406|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
41466830|NCT03136406|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
41466831|NCT00774943|DRUG|AMG 557|A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
41466832|NCT06348524|DRUG|Ferumoxytol injection|ferumoxytol will assess patency of coronary arteries
41466833|NCT04408534|OTHER|mode of noninvasive ventilation|administration of during 3 hours each 4 cycles
41466834|NCT05155579|BIOLOGICAL|R21/Matrix-M - single vial formulation|Adjuvanted malaria vaccine in a single vial formulation
41466835|NCT05155579|BIOLOGICAL|R21/Matrix-M - two vial formulation|Adjuvanted malaria vaccine in a double vial formulation
41466836|NCT05155579|BIOLOGICAL|Licensed vaccine - Measles-rubella|Licensed vaccine part of the EPI vaccination schedule
41466837|NCT05155579|BIOLOGICAL|Licensed vaccine - Yellow fever|Licensed vaccine part of the EPI vaccination schedule
41466838|NCT05155579|BIOLOGICAL|Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)|Licensed vaccine part of the EPI vaccination schedule
41466839|NCT05155579|BIOLOGICAL|Licensed vaccine - Oral Polio Vaccine (OPV)|Licensed vaccine part of the EPI vaccination schedule
41466840|NCT05155579|BIOLOGICAL|Licensed vaccine - Rotavirus|Licensed vaccine part of the EPI vaccination schedule
41466841|NCT05155579|BIOLOGICAL|Licensed vaccine - Pneumococcal vaccine|Licensed vaccine part of the EPI vaccination schedule
41466842|NCT05155579|BIOLOGICAL|Licensed vaccine - Inactivated Polio Vaccine (IPV)|Licensed vaccine part of the EPI vaccination schedule
40787247|NCT05874141|DIAGNOSTIC_TEST|Urine analysis and urinary albumin-to-creatinine ratio|Morning urine sample
40787248|NCT05874141|DIAGNOSTIC_TEST|Serum creatinine and estimated glomerular filtration rate|serum sample
40787249|NCT05874141|DIAGNOSTIC_TEST|Complete blood count|blood sample on EDTA
40991042|NCT02747420|DEVICE|Sham|"A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded."
40991043|NCT00999583|DRUG|EPOETINE ALPHA|5 injections of 40000 UI of EPO
40991044|NCT00999583|OTHER|Control arm|Usual take care of cardiac arrest
40991045|NCT04991181|DRUG|400 mg BIA 5-1058|Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).
40991046|NCT03078647|DEVICE|Profound|The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
40991047|NCT00642239|DRUG|placebo|placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
40991048|NCT00642239|DRUG|Sodium Glycididazole|Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
40991049|NCT05295927|DRUG|EPI-7386|EPI-7386 will be administered orally once daily.
40991050|NCT05295927|DRUG|Abiraterone Acetate|Abiraterone Acetate will be administered orally once daily.
40991051|NCT05295927|DRUG|Prednisone or Prednisolone|Prednisone or Prednisolone will be administered orally twice daily.
40991052|NCT05295927|DRUG|Apalutamide|Apalutamide will be administered orally once daily.
40991053|NCT02053181|DRUG|Cadazolid|Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
40991054|NCT05497492|DRUG|propofol|single administration of propofol
41147239|NCT05615506|PROCEDURE|Suction Diathermy Adenoidectomy|suction diathermy adenoidectomy
41466843|NCT04489017|DIETARY_SUPPLEMENT|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day
41466844|NCT04489017|DIETARY_SUPPLEMENT|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day
40787250|NCT05874141|DIAGNOSTIC_TEST|Thyroid-stimulating hormone|serum sample
40787251|NCT05874141|DIAGNOSTIC_TEST|Serum iron, TIBC, Transferrin saturation and serum ferritin if needed|serum sample
40787252|NCT05874141|PROCEDURE|Electrocardiography (ECG)|by electrocardiogram
40991055|NCT05497492|DRUG|propofol and sufentanil|administration of propofol and sufentanil in combination
40991056|NCT05497492|DRUG|propofol and esketamine|administration of propofol and esketamine in combination
40991057|NCT05497492|DRUG|propofol and lidocaine|administration of propofol and lidocaine in combination
40991058|NCT00006202|DRUG|Lutein|
40991059|NCT00035464|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
40991060|NCT00035464|DRUG|Placebo|placebo tablets, twice a day for 6 months
40991061|NCT00660582|DRUG|Cetuximab (Erbitux)|500 mg/m² every second week, intravenous infusion, 8 cycles
40991062|NCT00660582|DRUG|Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid|Given in combination day 1 and 2, every second week, 8 cycles
40991063|NCT02972554|DRUG|Propanolol hydrochloride|One-time dose of 40mg of propranolol
40991064|NCT02972554|OTHER|Placebo|Outside casing matching that of active drug
40991065|NCT05326477|BEHAVIORAL|Behavioral weight loss treatment|The weight loss intervention consists of the first 6 months of the Centers for Disease Control and Prevention's Prevent T2 program.
41147240|NCT03493282|DRUG|Active Treatment- CT1812 100 mg|CT1812
41147241|NCT03493282|DRUG|Active Treatment- CT1812 300 mg|CT1812
41147242|NCT03493282|DRUG|Placebo|Matching Placebo
41466845|NCT01537731|PROCEDURE|vaginal or laparoscopic hysterectomy|vaginal hysterectomy or laparoscopic hysterectomy
41466846|NCT05709769|OTHER|There are no interventions.|There are no interventions.
41466847|NCT00250133|PROCEDURE|Blood draws|
41466848|NCT03078478|DRUG|Insulin degludec|For subcutaneous (s.c., under the skin) injection once daily
41466849|NCT03078478|DRUG|Insulin glargine|For subcutaneous (s.c., under the skin) injection once daily
41466850|NCT01486108|PROCEDURE|dorsal column stimulator|test different settings of stimulation
41466851|NCT01383850|OTHER|NCPAP + standard air|NCAP (SiPAP, Vyasis) was used to administer standard air
40787253|NCT05874141|PROCEDURE|Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound|imaging
40787254|NCT05874141|PROCEDURE|Arterial duplex ultrasound of both lower limbs|imaging
40787255|NCT05874141|DIAGNOSTIC_TEST|Random blood glucose|serum sample
40787256|NCT05874141|DIAGNOSTIC_TEST|AST, ALT, albumin|serum sample
40991066|NCT01829555|BEHAVIORAL|contingency management|Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
40991067|NCT03009929|OTHER|Observational study|No intervention, observational only
40991068|NCT03696810|DIAGNOSTIC_TEST|Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
40991069|NCT06497114|OTHER|ABILHAND-Kids questioner|questioner
40991070|NCT03712319|BEHAVIORAL|REM Volver a casa|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).
40991071|NCT03712319|BEHAVIORAL|Mindfulness-Based Stress Reduction program|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
40991072|NCT04242004|DRUG|Docosahexaenoic acid (DHA) capsules|Treatment was provided as 7 omega-3 fatty acid (Lovaza) capsules daily. Each capsule contained 1 g of omega-3 fatty acids with approximately 450 mg of docosahexaenoic acid (DHA).
40991073|NCT04242004|DIETARY_SUPPLEMENT|Soy oil capsules|The placebo was identical looking capsules that contained soy oil
40991074|NCT02445495|DEVICE|GenesisPlus 1064 nm Nd:YAG laser|Genesis Plus 1064 nm Nd: YAG laser to treat onychomycosis
40991075|NCT05872581|BEHAVIORAL|Hand scanner instant feedback|Participants will be informed about their hand scanner results of the first hand washing attempt to get individualized feedback about their hand wash performance.
40991076|NCT05872581|BEHAVIORAL|Video training|Participants will watch a training video about the 7 steps of hand washing after the first hand washing attempt.
40991077|NCT04528979|OTHER|BioRoot RCS® root canal sealer|Root canal obturation with guttapercha and BioRoot RCS® root canal sealer
40991078|NCT04528979|OTHER|AH Plus® root canal sealer|Root canal obturation with guttapercha and AH Plus® root canal sealer
40991079|NCT00540345|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
40991080|NCT00540345|DRUG|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
40991081|NCT00540345|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
41147243|NCT01129375|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
41147244|NCT01129375|DRUG|placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
41147245|NCT01129375|DRUG|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
41466852|NCT01383850|OTHER|NCPAP + Heliox|Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
40787257|NCT03568747|DEVICE|noninvasive ventilation|dual-limb circuit NIV were given on maquet servo i apparatus
40787258|NCT03568747|DEVICE|oxygen therapy|oxygen therapy were introduced to the side port of the facemask
40787259|NCT00381654|DRUG|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
40787260|NCT03187509|DRUG|Torsemide|These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
40787261|NCT03187509|OTHER|Standard Outpatient Heart Failure Management|Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
40991082|NCT00540345|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
40991083|NCT00175721|PROCEDURE|The Combined Cardiac Kidney Diabetes Care Clinic|See Detailed Description.
40991084|NCT03233958|BEHAVIORAL|Systemic / family constellation|Systemic / family constellation integrates elements from psychodrama, family sculpture, and spontaneous dramatizations of intra- and interpersonal processes, while spatially visualizing family dynamics. Family constellations stimulate change through the following ways: 1) making visible the spatial arrangement of relationships within a conflictual system; 2) providing access to the insights of unrelated third parties regarding the sensations, feelings, and thoughts they experienced while representing family members within the constellation; and 3) making observable (from the outside) and experienceable (from within) the transformation of the problem constellation into the solution constellation \[Hunger, Weinhold, Bornhäuser, Link, \& Schweitzer, 2015\].
41308171|NCT00006054|PROCEDURE|Allogeneic Bone Marrow Transplantation|
41308172|NCT06360874|DRUG|ND-003 40mg|Participants receive 40mg ND-003 tablets once.
41466853|NCT03446599|DRUG|Hydroxocobalamin|One intravenous dose of 5mg hydroxocobalamin, which is the current FDA-approved adult dose for carbon monoxide poisoning, reconstituted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
41466854|NCT03446599|DRUG|Methylene Blue|One intravenous dose of methylene blue 2mg/kg, which has been the accepted dose for vasoplegia, diluted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
41466855|NCT03446599|DRUG|Normal saline|200ml normal saline will be administered intravenously over 10-15minutes at the time of initiation of cardiopulmonary bypass.
41466856|NCT00206596|DRUG|Sargramostim (Leukine)|Once daily via subcutaneous injection for up 22 weeks
41308173|NCT06360874|DRUG|ND-003 placebo 40mg|Participants receive placebo tablet matching to receive 40mg of ND-003.
41308174|NCT06360874|DRUG|ND-003 80mg|Participants receive 80mg ND-003 tablets once.
41308175|NCT06360874|DRUG|ND-003 placebo 80mg|Participants receive placebo tablet matching to receive 80mg of ND-003.
41466857|NCT00206596|DRUG|Placebo|Once daily via subcutaneous injection for up 22 weeks
41308176|NCT06360874|DRUG|ND-003 160mg|Participants receive 160mg ND-003 tablets once.
41466858|NCT00128817|RADIATION|Concurrent Chemoradiation|60-70 Gy at 2Gy/5days a week for 6 to 7 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
41466859|NCT00128817|PROCEDURE|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy|Surgery: Total Laryngectomy with or without partial pharyngectomy or Near-Total Laryngectomy with or wothout partial pharyngectomy Adjuvant Radiation 2- 3 weeks following surgery: 50-60Gy at 2Gy/5days a week for 5 to 6 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
41466860|NCT06142669|DEVICE|EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert|Primary knee arthroplasty or a revision knee that requires a revision procedure.
41466861|NCT05344716|DEVICE|Laser|Intraurethral and vaginal laser treatment
40991085|NCT00178035|DRUG|paroxetine|
41466862|NCT05659134|OTHER|Alfredson protocol|Alfredson eccentric therapeutical protocol.
41466863|NCT05659134|OTHER|Silbernagel protocol|Silbernagel concentric-eccentric protocol.
41466864|NCT06412211|DEVICE|Photoacoustic finder|Sentinel lymph node detector using photoacoustic signal
41466865|NCT03932331|DRUG|Acalabrutinib|Acalabrutinib 100 mg orally twice daily
41308177|NCT06360874|DRUG|ND-003 placebo 160mg|Participants receive placebo tablet matching to receive 160mg of ND-003.
41308178|NCT06360874|DRUG|ND-003 240mg|Participants receive 240mg ND-003 tablets once.
41466866|NCT02900274|DEVICE|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
41466867|NCT06083415|OTHER|Environmental health measures|MRI will be used to confirm the presence of breast buds, to measure the size of the ovaries and uterus, as well as the fraction of fat mass (abdominal, subcutaneous, liver and bone marrow). The bood and urine tests will allow to measure different biological and metabolic parameters. The presence of endocrine disruptors will be determined in the hair. The bone age x ray will be estimate the maturity of the child's skeletal system.
41466868|NCT03079388|DIETARY_SUPPLEMENT|Ready-to-use-supplementary food|Specially formulated supplementary food for pregnancy
41466869|NCT03079388|DIETARY_SUPPLEMENT|Corn-soy-blend|Standard of care for malnutrition in pregnancy in Sierra Leone
40787262|NCT05452252|DIAGNOSTIC_TEST|functional mandibular evaluation|Active mandibular movements including depression, protrusion, and left-right deviation, facial anthropometry was measured on facial shape on photograph, and phenotype and asymmetry
40787263|NCT04736472|DEVICE|Pharmacogenetic test|Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.
40787264|NCT01059357|DEVICE|Da Vinci Robotic Transoral Robotic Surgical System|(TORS) Da Vinci Robotic Transoral Robotic Surgical System
40991086|NCT00178035|BEHAVIORAL|One night of Total Sleep Deprivation|
40991087|NCT01828892|PROCEDURE|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
40991088|NCT01828892|PROCEDURE|Endoscopy exploration|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
41308179|NCT06360874|DRUG|ND-003 placebo 240mg|Participants receive placebo tablet matching to receive 240mg of ND-003.
41308180|NCT06360874|DRUG|ND-003 300mg|Participants receive 300mg ND-003 tablets once.
41308181|NCT06360874|DRUG|ND-003 placebo 300mg|Participants receive placebo tablet matching to receive 300mg of ND-003.
41466870|NCT03079388|DRUG|Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)|Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
41466871|NCT03079388|DRUG|Standard intermittent preventive treatment of malaria during pregnancy (IPTp)|Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
41466872|NCT03079388|OTHER|Insecticide-treated mosquito net|An insecticide-treated mosquito net at the time of enrollment into the study.
41466873|NCT03079388|DRUG|Azithromycin|Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
40991089|NCT01828892|DRUG|Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)|Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
40991090|NCT01828892|DIETARY_SUPPLEMENT|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition
40991091|NCT01103609|DRUG|Warfarin|Oral tablet od on Day 4
40991092|NCT01103609|DRUG|Placebo|Oral tablet bd, stepwise increased
40991093|NCT01103609|DRUG|AZD1656|Oral tablet bd, stepwise increased
41466874|NCT03079388|DRUG|Albendazole|Single dose albendazole 400mg given in the second trimester.
41466875|NCT03079388|COMBINATION_PRODUCT|Bacterial vaginosis testing and treatment|Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.
41466876|NCT00864799|DRUG|Misoprostol|Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
41466877|NCT03920306|DRUG|oral anti-acid treatment|This study investigates a bundle of three commonly used treatments
41466878|NCT01447225|DRUG|MM-121|MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
41466879|NCT01447225|DRUG|Carboplatin|administered at AUC 6
41466880|NCT01447225|DRUG|Pemetrexed|administered IV at 500 mg/m2
41466881|NCT01447225|DRUG|Cabazitaxel|administered IV at 20 mg/m2 or 25 mg/m2
41466882|NCT01447225|DRUG|Gemcitabine|administered IV at 1000 mg/m2 or 1250 mg/m2
41466883|NCT01148069|PROCEDURE|Surgery combined with IMRT-IGRT|Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
41466884|NCT04747184|OTHER|DNA extraction and 16S rRNA sequencing|DNA extraction using QIAamp® DNA mini kit (QIAGEN) was done under aseptic techniques in the sterile room for all samples according to the manufacturer instructions. The DNA extracts for the 54 samples collected (27 from asthmatic patients and 27 from healthy subjects) were stored at -80° C in a sterile Eppendorf tubes until they were sent to the Molecular Research (MR DNA) Lab (Molecular Research LP, Shallowater, TX, USA) for sequencing.
41466885|NCT05959486|DRUG|BR6002A|One tablet administered alone
41466886|NCT05959486|DRUG|BR6002B|One tablet administered alone
41466887|NCT05959486|DRUG|BR6002|One capsule administered alone
40787265|NCT05002348|DEVICE|Laser acupoint stimulation(Laser pen)|Select 5-7 acupuncture points according to physical fitness. Each acupoint is performed once a day. The acupuncture point stimulation process takes about 3-5 minutes. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat and blood oxygen) with a physiological monitor. , If the patient has any discomfort, the procedure will be stopped for a maximum of 10 days.
40787266|NCT02824523|DRUG|aspirin|
40787267|NCT00606489|DRUG|Caldolor|800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
40787268|NCT00606489|DRUG|Placebo|Placebo
41308182|NCT06360874|DRUG|MAD_ND003_Dose 1|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
41308183|NCT06360874|DRUG|MAD_placebo_Dose 1|Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 1
40787269|NCT00761345|DRUG|gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
40787270|NCT00761345|DRUG|Erlotinib|Erlotinib 100mg or 150mg daily of each 21 day cycle
40787271|NCT00761345|RADIATION|low dose fractionated radiotherapy|low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
41308184|NCT06360874|DRUG|MAD_ND003_Dose 2|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
41308185|NCT06360874|DRUG|MAD_placebo_Dose 2|Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 2
40787272|NCT01908140|DRUG|Aclidinium Bromide / Formoterol Fumarate|
40787273|NCT01908140|DRUG|Salmeterol / Fluticasone|
40991094|NCT05781295|DEVICE|TaurolockTM|The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.
41308186|NCT06360874|DRUG|MAD_ND003_Dose 3|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
41308187|NCT06360874|DRUG|MAD_ placebo_Dose 3|Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 3
41466888|NCT06330051|BEHAVIORAL|improvement acute reperfusion treatment quality for stroke through spatiotemporal computing|"1. Intelligent bracelet automatic positioning device and data feedback system based on spatiotemporal computing technology~2. Continuous in-hospital procedure improvement based on P-D-C-A cycle for AIS"
41466889|NCT04968106|DRUG|Doxorubicin|Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
41466890|NCT04968106|DRUG|Ifosfamide|Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles
41308188|NCT06360874|DRUG|Food effect_Cohort 1|Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
41308189|NCT06360874|DRUG|Food effect_Cohort 2|Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
40787274|NCT02047448|PROCEDURE|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
40787275|NCT01963988|PROCEDURE|Transurethral Coagulation (TUC)|
40787276|NCT01963988|PROCEDURE|Transurethral Resection(TUR)|
40787277|NCT00512278|DRUG|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
40787278|NCT00512278|DRUG|Placebo|Placebo
40787279|NCT04559061|DEVICE|Cardiac ablation procedure|Retrospective data will be collected from cases where successful ablation was completed.
40787280|NCT06021808|PROCEDURE|Thoracoscopic LAA clipping|The surgeons measured the length of the base of the LAA, an appropriately sized LAA clip is then inserted with the aid of a thoracoscope and placed parallel to the base of the LAA.
40991095|NCT05781295|DEVICE|Physiological serum|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
40991096|NCT04171973|DEVICE|Driving an electric wheelchair in real condition|For the control group, 3 test circuits of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
40991097|NCT04171973|DEVICE|Driving an electric wheelchair in virtual condition|For the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
40991098|NCT05847530|DEVICE|Potenza|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
40991099|NCT05847530|DEVICE|Icon|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
40991100|NCT04375488|OTHER|Resistance Exercise Training|60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week
40991101|NCT04375488|OTHER|Inspiratory Muscle Training|with % 30 of MIP, 20 minutes inspiratory muscle training for 8 weeks, 3 times per week
40991102|NCT04009655|OTHER|music|music selected by musician
40991103|NCT06460064|BIOLOGICAL|fH1 2 ug|2 administrations at 3-week intervals.
40991104|NCT06460064|BIOLOGICAL|fH1 8 ug|2 administrations at 3-week intervals.
40991105|NCT06460064|BIOLOGICAL|DSP-0546LP 2.5 ug|2 administrations at 3-week intervals.
41466891|NCT04968106|DRUG|INCMGA00012|Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles
41466892|NCT00808717|DRUG|Atorvastatin|Atorvastatin 10 mg vs. 80 mg before intervention
41466893|NCT04102345|OTHER|Lavender Aromatherapy|Commercially available lavender essential oil and diffuser.
41466894|NCT04102345|DRUG|Zolpidem|Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
40787281|NCT06021808|DRUG|Novel oral anticoagulant|For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.
40991106|NCT06460064|BIOLOGICAL|DSP-0546LP 5 ug|2 administrations at 3-week intervals.
40991107|NCT06460064|BIOLOGICAL|DSP-0546LP 10 ug|2 administrations at 3-week intervals.
40991108|NCT06460064|BIOLOGICAL|Placebo|2 administrations at 3-week intervals.
40991109|NCT04746703|RADIATION|Magnetic Resonance Imaging|Pancreatic MRI will be performed in severe-obese patients with a planned bariatric surgery, before and 6 months after bariatric surgery.
40991110|NCT02831166|PROCEDURE|Transradial primary percutaneous coronary intervention|Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.
41308190|NCT03136705|DRUG|Nicotinamide|Nicotinamide tablet
41308191|NCT03136705|DRUG|Lanthanum Carbonate|Lanthanum Carbonate tablet
41466895|NCT02317250|PROCEDURE|Amyloid imaging|Amyloid imaging brain scans are administered once to all arms.
40991111|NCT02831166|PROCEDURE|Transfemoral primary percutaneous coronary intervention|Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
41308192|NCT03136705|DRUG|Lanthanum Carbonate Placebo|Sugar pill manufactured to look like Lanthanum Carbonate tablet
40991112|NCT02127567|OTHER|online writing tool|The writing tool contained the main CONSORT item and extension items for non pharmacological treatments along with bullet points indicating key elements to report from the explanation and elaboration publications of the CONSORT. Participants were also instructed to detail information they felt important to report but that was not available in the study protocol they were provided.
41308193|NCT03136705|DRUG|Nicotinamide Placebo|Sugar pill manufactured to look like Nicotinamide tablet
41466896|NCT02317250|PROCEDURE|FDG-PET|\[F-18\] FDG-PET brain scans are administered once to all arms.
40991113|NCT02127567|OTHER|writing with no specific support|The control tool simply provided the domain or section heading with a space too write. Similar to for the experimental intervention, participants were to indicate information they felt important to report but unavailable in the provided study protocols.
40991114|NCT04287777|DRUG|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
40991115|NCT04287777|DRUG|Mupirocin ointment|Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days
40991116|NCT04287777|DRUG|Placebo|Topical administration of Placebo (ointment) TID during 7 days
40991117|NCT03388619|RADIATION|Prostate bed with integrated boost|Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed.
40991118|NCT03388619|RADIATION|Prostate bed irradiation only|Radiation will be delivered to the prostate bed only.
40991119|NCT03388619|DIAGNOSTIC_TEST|Whole Body Bone Scan|At screening, if required by clinician.
41308194|NCT04018469|OTHER|No Interventions|No Interventions
40991120|NCT03388619|DIAGNOSTIC_TEST|18F-NaF PET Imaging|At screening, if required by clinician.
40991121|NCT03388619|DIAGNOSTIC_TEST|CT|Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.
40991122|NCT03388619|DIAGNOSTIC_TEST|mpMRI|mpMRI of the prostate bed at screening and 6 month follow up.
40991123|NCT03388619|DRUG|ADT|After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).
40991124|NCT01791842|DRUG|Tocilizumab|8 mg/kg/month
40991125|NCT01791842|DRUG|Placebo|
40991126|NCT04474951|DIETARY_SUPPLEMENT|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of anemia.
40991127|NCT04474951|DIETARY_SUPPLEMENT|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of fatigue.
40991128|NCT04474951|DIETARY_SUPPLEMENT|Peppermint|Eligible patients will take 40 drops TID of Fluid Extract of Peppermint for control of nausea.
40991129|NCT01683981|DRUG|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
40991130|NCT00238121|DRUG|sorafenib tosylate|Given orally
40787282|NCT01508208|OTHER|Hypertensive disorder of pregnancy|Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
40991131|NCT04640090|BEHAVIORAL|Smartphone app (Wysa)|The commercially available smartphone application, Wysa, offers evidence-based wellness tools such as supportive listening, deep breathing techniques, guided meditation, yoga, and more. Users can communicate via text to a virtual artificial intelligence (AI) chatbot and/or a human well-being coach.
40991132|NCT03266991|DRUG|Rifapentine|Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
40991133|NCT03266991|DRUG|Isoniazid|Treatment with daily isoniazid in 6 months
40991134|NCT00463749|DRUG|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
40991135|NCT00463749|DRUG|Placebo|NaCl as placebo
40991136|NCT00651755|DRUG|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
40991137|NCT00651755|DRUG|Cyclophosphamide|750 mg/m\^2 By Vein On Day 1
41308195|NCT03204721|OTHER|Extracorporeal photophoresis (ECP)|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
41308196|NCT03606252|OTHER|Blood sampling|6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)
41308197|NCT03606252|OTHER|urine sampling|2 urine sample (1 at J0 and 1 at J7)
41308198|NCT06115161|DEVICE|Instrumented Orthosis|Gait analysis will be performed with the instrumented orthosis as well as the reference system.
41308199|NCT00745368|DRUG|Raltegravir|400 mg tablets twice daily during duration of trial
41308200|NCT01368393|PROCEDURE|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
41466897|NCT00292331|PROCEDURE|cyanoacrylate injection to treat gastric variceal hemorrhage|
41466898|NCT01546519|DRUG|Vismodegib|oral repeating dose of 150 mg once daily
41466899|NCT03319069|RADIATION|Hypofractionated radiotherapy|"Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.~."
41466900|NCT03319069|RADIATION|Conventional fractionated radiotherapy|50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region
41308201|NCT01368393|PROCEDURE|Sham acupuncture|"Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current."
41308202|NCT00978861|DRUG|Hydrogen Peroxide|Whitening product syringe type
40787283|NCT06632626|OTHER|Task oriented training exercises|Task oriented training is a type of exercises in form of tasks using papers, pens, scissors, clips, coins, screws and clay
40787284|NCT06632626|OTHER|Traditional physical therapy|Traditional physical therapy inform of mobilization, strengthening exercises of hand and streching exercises.
40991138|NCT00651755|DRUG|Doxorubicin|25 mg/m\^2 By Vein Over 48 Hours On Days 1-2
40991139|NCT00651755|DRUG|Vincristine|2 mg By Vein On Day 1
40991140|NCT00651755|DRUG|Prednisone|100 mg PO for 5 Days
40991141|NCT00651755|DRUG|Rituximab|375 mg/m\^2 By Vein On Day 1.
40991142|NCT00651755|DRUG|Ondansetron|8 mg daily for 2 days
40991143|NCT01132482|DRUG|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
40991144|NCT01132482|DRUG|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
40991145|NCT03403816|BEHAVIORAL|Before School Physical Activity Program|BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
40991146|NCT04150276|PROCEDURE|ZEEP during awakening|ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
40991147|NCT04150276|PROCEDURE|PEEP during awakening|PEEP will be maintained throughout emergence preoxygenation and awakening.
40787285|NCT02117011|OTHER|Physical Activity|Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
41308203|NCT03634358|PROCEDURE|Bipolar scissors|
41308204|NCT03634358|PROCEDURE|classic scalpel|
40822886|NCT04834154|BEHAVIORAL|Mindfulness|6 weekly 2.0 hour video-conferenced group sessions with the following components: 1) short grounding meditation, 2) check in/review of prior weeks practice and symptoms, 3) educational topic, 3) main meditation, 4) reflection on meditation, and 5) action plan formation
40991148|NCT02834104|DEVICE|RMI|
40991149|NCT02834104|OTHER|myocardial biopsy|
40991150|NCT02834104|BIOLOGICAL|blood sample|
41308205|NCT06266273|OTHER|No intervention|No intervention
41308206|NCT04556084|DRUG|Blinatumomab|"Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day"
41308207|NCT00905307|DRUG|OPC-34712|oral, once daily
41308208|NCT00905307|DRUG|Placebo|Placebo
41308209|NCT00905307|DRUG|Aripiprazole|oral, once daily
41308210|NCT03764202|OTHER|Detection of sufentanil concentration|"* Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point"
41308211|NCT02775760|BEHAVIORAL|Cardiovascular endurance|Physical exercise at the Boston University Fitness and Recreation Center
41308212|NCT02775760|BEHAVIORAL|Strength, balance, and flexibility|Physical exercise at the Boston University Fitness and Recreation Center
41466901|NCT03554317|DRUG|Testosterone cypionate|Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
41466902|NCT03554317|DRUG|Nivolumab|Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.
41466903|NCT06186219|DRUG|Rituximab|"Rituximab is a monoclonal antibody that targets cluster of differentiate 20 (CD20) present on B-cells and lowers humoral immunity. Rituximab has been used successfully as a desensitization agent to treat Highly Human Leukocyte Antigens (HLA)-sensitized patients planning renal transplant. All cases of antibody-mediated rejection were seen in the placebo group, none in the Rituximab group. Rituximab has been safely used with Methotrexate in the treatment of Rheumatoid Arthritis, where co-administration of Methotrexate and Rituximab results in better outcomes than either medication alone.~We propose this safety and feasibility open-label trial that will examine if Rituximab pre-treatment before Standard-of-Care Methotrexate-Pegloticase will result in recapture of Pegloticase efficacy as measured by serum urate (SU) \< 6 mg/dL throughout the trial and up to 6-months of Methotrexate-Pegloticase administration."
41466904|NCT04580849|OTHER|telerehabilitation with dance|Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.
41466905|NCT05305664|DRUG|Pelacarsen (TQJ230) 80 mg s.c.|Pelacarsen (TQJ230) 80 mg s.c. Q4W
41466906|NCT05305664|DRUG|Corresponding Placebo|Placebo to Pelacarsen
41466907|NCT02893280|DRUG|aspirin, clopidogrel, statin, enoxaparin, streptokinase|Acute coronary syndrome treatment
41308213|NCT01213433|DRUG|Artesunate-Amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
41466908|NCT00128141|BEHAVIORAL|Tactile stimulus|four times a day
41466909|NCT03026309|OTHER|no intervantion|no intervention is being performed, only observational evaluations.
40787286|NCT01450644|OTHER|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
40787287|NCT01730911|OTHER|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
40822887|NCT04834154|BEHAVIORAL|Control group|Wait list control
40991151|NCT03935009|BEHAVIORAL|Manual toothbrush Curaprox 5460 ultra soft|Soft manual toothbrush (Curaprox 5460 ultra soft) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chumswill will be used to brush teeth.
41308214|NCT01510808|PROCEDURE|orthodontic treatment|Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
41308215|NCT00851734|DRUG|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
41308216|NCT03268070|DEVICE|Repetitive TMS over contralateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
41308217|NCT03268070|DEVICE|Repetitive TMS over ipsilateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
41308218|NCT03268070|DEVICE|Repetitive TMS over contralateral primary motor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
41466910|NCT04238208|DRUG|Lidocaine 5% patch|5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm
41466911|NCT04238208|DRUG|Capsaicin 8% Patch, Per 10 Square Centimeters|8% Capsaicin patch \[8% w/w\] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)
41466912|NCT03668431|DRUG|Dabrafenib|"Dabrafenib will be taken twice a day for 28 consecutive days~."
41466913|NCT03668431|DRUG|Trametinib|Trametinib will be taken once a day for 28 consecutive days
41466914|NCT03668431|DRUG|PDR001|PDR001 will be administered IV every 28 days
40822888|NCT01602783|OTHER|11C Acetate Imaging|Single scan
40822889|NCT06606886|DRUG|Tablet Metformin (Group A)|Tablet Metformin 500 mg/dose orally twice a day with meal for 1 year
40822890|NCT06606886|DRUG|Tablet Hydroxyurea (Group B)|Tablet Hydroxyurea 10-20mg/kg once daily orally with breakfast for 1 year
41466915|NCT01294449|DEVICE|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
41466916|NCT01294449|DEVICE|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
41466917|NCT01405274|OTHER|Physiotherapy|Physiotherapy treatment bi-weekly, delivered at the child's home
41466918|NCT02582788|OTHER|Bathing Additive|
41466919|NCT06427187|DEVICE|an array of devices are used in thrombectomy. These include guide catheters, stent-retrievers, microcatheters, aspiration catheters, and aspiration pump systems|each patient with distal vessel occlusion subjected to mechanical thrombectomy using aspiration technique or stent retriever
41466920|NCT05965817|DRUG|SGM-101 op top of ICG|SGM-101 op top of ICG
41466921|NCT00987025|BEHAVIORAL|Telehealth|Use of telehealth blood pressure station every week
41466922|NCT00987025|BEHAVIORAL|Educational materials|Control
41466923|NCT02951936|DEVICE|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index \>3000+Mean arterial pressure \>70mmHG then add vasodilators.~If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index\>4.2 and Mean arterial pressure 70-100mmHG and HR \>100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
41308219|NCT03268070|DEVICE|Sham Repetitive TMS over contralateral premotor cortex.|Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
41308220|NCT03268070|DEVICE|Single TMS over extensor carpi ulnaris spot of motor cortex|Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
41466924|NCT02951936|DEVICE|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
41466925|NCT02853331|BIOLOGICAL|Pembrolizumab|Intravenous infusion
40787288|NCT06364917|DRUG|Pembrolizumab|The dosing regimens for Pembrolizumab (200 mg Q3W), are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
40991152|NCT03935009|BEHAVIORAL|Electric toothbrush Play Smart Brush N°1|Electric toothbrush (Play Smart Brush N°1) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App will be used to brush teeth.
41466926|NCT02853331|DRUG|Axitinib|Oral tablet
41466927|NCT02853331|DRUG|Sunitinib|Oral capsule
41466928|NCT06384794|DEVICE|Sperm capacitation through the ZyMōt®Sperm Separation Device®|This chip based on microfluidic properties will help us to separate and recover the semen sample with improved sperm quality. It is composed of two microwells, one initial and one final, and a porous membrane through which the sample will be filtered and the capacitated spermatozoa with better motility will be selected. Syringe 850µL of the initial seminal sample into the first well and 750µL of seminal wash medium into the second well. The device is incubated at 37°C for up to 30 minutes. During this incubation, the sample will travel by microfluidic properties from the first well through the porous membrane to the second well. This membrane will filter those spermatozoa with a higher motility. Thus, at the end of the established incubation time, the medium with the selected spermatozoa from the second well (final well) will be collected with a syringe. After this, the sample will be processed and ready for the following procedures.
41466929|NCT06384794|PROCEDURE|Swim-up|The swim-up is a sperm capacitation technique in which the motile spermatozoa of the seminal sample, after centrifugation and incubation, move to the upper part of the medium. In this way, spermatozoa with good progressive motility will remain in the supernatant.
41466930|NCT01114581|DRUG|Mucinex|Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study
41466931|NCT01114581|DRUG|Placebo|Placebo given as 2 tablets
41466932|NCT02010255|DRUG|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
40787289|NCT06364917|DRUG|Carboplatin|The combination therapy dosages for Carboplatin are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
40822891|NCT02088619|BEHAVIORAL|Quality of Life Therapy (QOLT)|
41466933|NCT02010255|DRUG|RBV|RBV tablets administered orally in a divided daily dose
41466934|NCT00242229|DRUG|DVS-233 SR|
41466935|NCT00062101|DRUG|erlotinib hydrochloride|Given orally (PO)
41466936|NCT00062101|DRUG|celecoxib|Given PO
41466937|NCT00062101|OTHER|laboratory biomarker analysis|Correlative studies
40822892|NCT02088619|BEHAVIORAL|Heart Healthy Education (HHE)|
40991153|NCT03935009|BEHAVIORAL|Electric toothbrush Play Smart Brush N°2|Electric toothbrush (Play Smart Brush N°2) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia will be used to brush teeth.
40991154|NCT00500292|DRUG|Vandetanib|once daily oral tablet two dose strengths
40991155|NCT00500292|DRUG|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
40991156|NCT03534154|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging
40991157|NCT03534154|DIAGNOSTIC_TEST|Blood Sampling|Sampling of serum
41466938|NCT00578968|DRUG|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
41466939|NCT00578968|DRUG|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
41466940|NCT06165692|BIOLOGICAL|PRF|Post-operative PRF placement in the post-extraction socket after third molar surgery
41466941|NCT00893451|DRUG|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
41466942|NCT00893451|DRUG|Placebo|Placebo orally twice daily
41466943|NCT00611325|DRUG|Avastin|Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.
41466944|NCT00611325|DRUG|Bortezomib|Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs \& 2.5 mg/m2 for patients taking EIAEDs.
41466945|NCT02283593|BEHAVIORAL|eChange.se|7 modules: 1. Making a decisional balance 2. Setting a goal for alcohol consumption 3. Learning self control skills 4. Identifying risk situations 5. Dealing with urges 6. Dealing with emotions and with social pressure 7. Developing a crisis plan
41466946|NCT04591652|DRUG|99mTc-MIRC208|99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.
41466947|NCT04066920|DRUG|IBER salvage chemotherapy followed by ibrutinib maintenance therapy|Induction therapy with IBER (up to 6 cycles) \[ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 \], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months
41466948|NCT03072654|PROCEDURE|Thyroidectomy|Remove the nodular goiter on the neck by thyroidectomy (standard procedure)
41466949|NCT01718730|DEVICE|Transcranial Magnetic Stimulation (TMS)|Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
41466950|NCT01718730|DEVICE|Magnetic Resonance Spectroscopy and Imaging|MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
41466951|NCT01873781|DRUG|Cyclopentolatehydrochloride|Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
41466952|NCT05600881|DRUG|Methylphenidate|Participants will take their regular medication or a placebo (vitamin C)
41466953|NCT06227117|DRUG|Disitamab Vedotin Injection （18 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
41466954|NCT06227117|DRUG|Toripalimab （18weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
41466955|NCT06227117|DRUG|Carboplatin|AUC 3 Q2W or AUC1.5 QW intravenous infusion
41466956|NCT06227117|DRUG|Disitamab Vedotin Injection （12 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
41466957|NCT06227117|DRUG|Sequential Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
41466958|NCT06227117|DRUG|Sequential CTX|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
41466959|NCT06227117|DRUG|Toripalimab （12weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed.
41466960|NCT01121107|DEVICE|Left Atrial Pressure Monitoring System|Left atrial lead is placed for ambulatory monitoring of left atrial pressure
41466961|NCT01121107|DEVICE|Patient Advisory Module|Handheld device that provides medication reminders
41466962|NCT05139758|DIAGNOSTIC_TEST|Biodex Balane System|The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.
40991158|NCT03534154|DIAGNOSTIC_TEST|Microdialysis|Monitoring of cerebral fluid protein levels
40991159|NCT03534154|DIAGNOSTIC_TEST|Neuropsychological tests|Battery of tests to assess cognitive function, patient outcomes
41466963|NCT00337987|DRUG|Ontak|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
41466964|NCT00337987|DRUG|CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
41466965|NCT06358963|DRUG|Receive 30 mg of Coq10|Group A received 30 mg of CoQ10, Group B was given 200 mg of Omega-3 daily supplements, and Group C did not receive any medication; after the two-month study period, teh clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
40822893|NCT03477851|DRUG|Tramadol Hydrochloride|Tramadol i.m. simultaneous with sciatic nerve block
40991160|NCT03534154|DIAGNOSTIC_TEST|MRI (advanced)|Advanced MRI
40991161|NCT05634252|BEHAVIORAL|Education|All conditions will receive education on skin cancer and strategies to prevention skin cancer, including sun protection strategies and avoidance of intentional and unintentional tanning.
41308221|NCT01815892|DRUG|Withdrawal of furosemide|The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
41308222|NCT01815892|DRUG|furosemide administration|The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
41308223|NCT01901731|PROCEDURE|transjugular coil embolisation of pelvic veins|
41466966|NCT06358963|DRUG|Non-Medicare Drugs|and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
41466967|NCT05934487|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP)"
41466968|NCT02179593|OTHER|2-Segment SARPE|Le Fort I osteotomy with oppening of the median palatal suture and SARPE.
41466969|NCT02179593|OTHER|3-Segment SARPE|Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
41466970|NCT04868864|DIAGNOSTIC_TEST|CT scan|Non-enhanced LDCT scans of the thorax will be taken using standard technology on helical CT system
41466971|NCT04868864|DIAGNOSTIC_TEST|Pulmonary Function Test|Standard pulmonary function testing will be conducted by trained pulmonary technologists following the American Thoracic Society standards
41466972|NCT05148533|DRUG|TJ1133 Injection|TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)
41466973|NCT02709629|BEHAVIORAL|Individualized and adaptive computerized cognitive training|
40787290|NCT06364917|DRUG|Paclitaxel|The combination therapy dosages for Paclitaxel are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
41147246|NCT01688388|PROCEDURE|Intraoperative Radiotherapy|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
41147247|NCT05705245|OTHER|recruitment|Automated alveolar recruitment menouever applied during mechanical ventilation in the intraoperative period
41308224|NCT01901731|PROCEDURE|endovenous treatment of leg varicose veins|
41308225|NCT04846751|BEHAVIORAL|TYPE OF EXERCISE (OR REST)|continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
41466974|NCT02709629|BEHAVIORAL|Active control|
41466975|NCT02838940|PROCEDURE|Blood samples.|"At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation."
41466976|NCT02838940|DRUG|Cefazolin|According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
41466977|NCT01270620|DRUG|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
41466978|NCT01270620|DRUG|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
41466979|NCT03004144|OTHER|FLOAT|
40822894|NCT03477851|DRUG|Placebo|0,9%NaCl i.m. simultaneous with sciatic nerve block
40822895|NCT01713283|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
40991162|NCT05634252|BEHAVIORAL|Action Plan|Participants will be guided through a worksheet for creating a personalized action plan for creating individualized sun protection and tanning plans for situations in which they receive UVR exposure. For the tanning worksheet, participants who report any tanning identify the locations at or activities during which they tan, select a tanning behavior to plan for, and then are guided through the steps of making a specific plan for an alternate activity that meets their goals while minimizing tanning and using sun protection.
41147248|NCT03425500|PROCEDURE|Bridging Rotator Cuff Reconstruction|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using a GRAFTJACKET™ allograft
41147249|NCT03425500|PROCEDURE|Superior Capsular Reconstruction|Superior Capsular Reconstruction of massive rotator cuff tear
41308226|NCT02231255|DRUG|Sifrol®|
41308227|NCT06049771|OTHER|Collect blood sample|Collect blood samples at different time points: after tigecycline administration 1 h, 2-4 h, 4-6 h, 6-11.5 h and 30 minutes before next dose
41308228|NCT05322863|DEVICE|High-definition Transcranial Direct Current Stimulation|The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.
41308229|NCT01308320|DRUG|fentanyl citrate|According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
41308230|NCT01308320|DRUG|saline|According to the enrolled group, certain dose of saline is intravenously administered by bolus just after sevoflurane discontinuation.
41147250|NCT03425500|DEVICE|GRAFTJACKET™ allograft|The acellular human dermal allograft in used in the bridging rotator cuff reconstruction
41147251|NCT03816878|BIOLOGICAL|H5N1 pISV|Administered as an intramuscular (IM) injection
41147252|NCT03536520|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
41147253|NCT03536520|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
41147254|NCT00507845|DRUG|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
41308231|NCT04289415|BEHAVIORAL|Individual Placement and Support|Employment specialist will work together with the participants in accordance to the method IPS in order to help the participant obtain competitive employment
41308232|NCT04169594|DIAGNOSTIC_TEST|3D Gait Analysis with Statistical Parametric Mapping|A 3D motion capture system will be used for gait analysis. Vector field statistics will be used to simplify the clinical interpretation of time varying movement patterns.
41466980|NCT06316063|DEVICE|Apnoeic oxygenation with high-flow nasal oxygen|The subjects in the intervention group will be oxygenated with HFNO during the surgical procedure.
41466981|NCT06316063|OTHER|Mechanical ventilation|Study subjects in the comparator group will be tracheally intubated and mechanically ventilated
41466982|NCT03705871|DEVICE|Differential Expansion|Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
41466983|NCT03705871|DEVICE|Fan-Fype Expander|Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
41466984|NCT05555927|DEVICE|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is an non-invasive brain stimulation that is proposed as a possible interventional tool for major depressive disorder. tDCS device that this study used is from Neuroelectrics, Starstim 8, USA.
41466985|NCT00817141|OTHER|Observational study, no intervention|Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
41466986|NCT02928978|DRUG|Ruxolitinib|tablet (taken by mouth)
41466987|NCT02928978|DRUG|Placebo (for Ruxolitinib)|tablet (taken by mouth)
41466988|NCT01774630|DRUG|Nilotinib|300 mg/twice a day
41466989|NCT02136238|DEVICE|Hosmer 5XA voluntary opening hook|"Voluntary opening prosthetic terminal device (hand)"
41147255|NCT02918045|DEVICE|HemCon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
41147256|NCT02918045|DEVICE|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions placed into the extraction socket.
41466990|NCT02136238|DEVICE|TRS Grip 3 voluntary closing hook|"Voluntary closing prosthetic terminal device (hand)"
41147257|NCT03861884|DIAGNOSTIC_TEST|Cognitive assessments|Cognitive assessment and MRI at 3T and/or 7T
41147258|NCT00749840|BEHAVIORAL|Questionnaire|Questionnaire taking 60-90 minutes.
41147259|NCT04546178|BEHAVIORAL|Prolonged exposure (PE)+ therapy|The intervention will be adapted prolonged exposure therapy, called PE+ therapy. Participants will receive 15 weekly 90-minute sessions of PE+; these appointments will be divided into five sets of three sessions each: 1) psychoeducation about AEs, SM, and the interplay of both with psychosis; 2) emotion regulation strategies; 3) imaginal exposures, 4) in vivo exposures, and 5) review of treatment and planning for termination and maintenance.
41147260|NCT04546178|OTHER|Treatment as usual (TAU)|The intervention will be antipsychotics prescribed by clinicians working within the Nova Scotia Early Psychosis Program (NSEPP) as well as case management supplied by their primary nurse. Program participants will have access to educational programs about psychosis, skills/vocational training, as well as familial education and support.
41147261|NCT06402201|BIOLOGICAL|CDR404|IV infusions
41147262|NCT04409132|DRUG|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
41147263|NCT04996186|OTHER|Clinical interviews|Semi-qualitative interviews and questionnaire STAR-Q
41308233|NCT01635751|DRUG|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)
41308234|NCT01635751|DRUG|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)
41308235|NCT01635751|DRUG|Pregabalin|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
41308236|NCT01196624|DEVICE|rapid TMS, EXPOSURE TO TRAUMATIC STIMULI|RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI
41308237|NCT01196624|DEVICE|rapid TMS, EXPOSURE|apid TMS, EXPOSURE
41466991|NCT06207669|OTHER|Music therapy|Music therapy will be applied to individuals in the clinic for 30 minutes after the 2nd hour of each hemodialysis session for 4 weeks.
41466992|NCT05386888|DRUG|GFH018|Administered as oral
41466993|NCT05386888|DRUG|Toripalimab|Administered as an IV infusion
41466994|NCT05386888|DRUG|Paclitaxel|Administered as an IV infusion
41466995|NCT05386888|DRUG|Carboplatin|Administered as an IV infusion
41466996|NCT05386888|DRUG|Cisplatin|Administered as an IV infusion
41466997|NCT05386888|DRUG|Pemetrexed|Administered as an IV infusion
41466998|NCT05386888|RADIATION|Thoracic Radiation Therapy (TRT)|Thoracic Radiation Therapy (TRT)
41466999|NCT05386888|DRUG|GFH018|Administered as an IV infusion
41308238|NCT06520319|DRUG|68Ga-MGS5|Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.
40991163|NCT05634252|BEHAVIORAL|UV Photo|Participants will receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system. Participants will receive a handout of their photos accompanied by an explanation of UV light, its harmful effects on skin, and that using sun safe behaviors early in life will have the greatest impact and help to decrease risk for skin cancer.
40991164|NCT05634252|BEHAVIORAL|MC1R Test|Participants will provide a saliva sample using an Oragene® clinical-grade saliva kit. Once sequenced, participants will receive their MC1R testing results via web as well as a standardized booklet that addresses personal risk level and population risk level, strategies to reduce skin cancer risk, and number to call or email for further information.
40991165|NCT04117347|DEVICE|Light therapy A via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
40991166|NCT04117347|DEVICE|Light therapy B via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
40991167|NCT04117347|DEVICE|Light therapy C via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
40991168|NCT04085198|PROCEDURE|Light physics enhanced 'no-touch' hysteroscopy|The light source used in hysteroscopy provides an illumined environment during the imagination with these techniques. During hysteroscopy, the light reflecting from the adjacent tissue appears bright, however, this reflection is weaker in farther tissue and these structures appear dark. This information will be used in determining the route from the vaginal introitus to the uterine cavity during the hysteroscopy.
40991169|NCT04085198|PROCEDURE|Standard hysteroscopy|Anatomical structures as illumined by the light source of the camera will be used to find the route from the vaginal introitus to the uterine cavity
40991170|NCT01871116|BEHAVIORAL|POWER-remote|Web-based weight loss program.
40991171|NCT01871116|BEHAVIORAL|Self-directed|"Pamphlet entitled Aim for a Healthy Weight will be given."
40991172|NCT01331954|DEVICE|Ultrasonic ablation device|One or two HIFU procedures
40991173|NCT01077947|PROCEDURE|Functional anesthetic discography|Functional anesthetic discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
40991174|NCT01077947|PROCEDURE|Provocative Discography|Provocative Discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
40991175|NCT02436421|OTHER|Best Practice Alert based in the Electronic Medical Record|
40991176|NCT02594839|DRUG|Bone marrow mesenchymal stem cells|Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
40991177|NCT02594839|DRUG|Placebo|intravenous infusion of 400 mL saline
40991178|NCT01203228|OTHER|Reduced Intensity Conditioning|"Busilvex®:~6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available)~Busulfan:~8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Fludarabine:~5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS"
41147264|NCT01892982|BEHAVIORAL|Problem Solving Education tailored to NICU|
41147265|NCT03152409|DRUG|Aspirin 325mg|Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
41147266|NCT03152409|DRUG|Placebo Oral Tablet|Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
41147267|NCT06416345|DEVICE|Cue2Walk|24 weeks of using of the Cue2Walk device in the own living environment + 8 weeks of naturalistic follow-up
41147268|NCT06416345|OTHER|Usual Care|24 weeks of receiving usual care + 8 weeks of using of the Cue2Walk device in the own living environment
41147269|NCT02975609|RADIATION|Conventional Fractionated Radiotherapy|5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
41147270|NCT02975609|RADIATION|Stereotactic Body Radiation Therapy|30Gy/3-5F for the primary and the metastases.
41308239|NCT03927508|DRUG|r-tPA|Pulse spray and infusion
41308240|NCT03927508|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
41308241|NCT02938585|DRUG|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
41308242|NCT02938585|DRUG|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
41147271|NCT06242184|PROCEDURE|Group A(Nano-fortified Adhesive)|Nano-fortified dentin adhesive
41147272|NCT06242184|PROCEDURE|Group B(Adhesive without nanoparticles)|Conventional adhesives without nanoparticles
41147273|NCT05701345|DEVICE|OMNIFIT DTx-MDD|This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session
41467000|NCT03676790|OTHER|Group I|"Group I In the first month, continuous ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the ultrasound treatment, the following parameters were used: frequency of 1 MHz, intensity of 1.5 W/cm2 (temporal and spatial mean SATA), duty cycle of 100%, with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
41467001|NCT03676790|OTHER|Group II|"Group II In the first month, pulsed ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
41467002|NCT03676790|OTHER|Group III|"Group III In the first month, the continuous ultrasound was applied 3 times a week. In the second month, 3 times a week, the continuous ultrasound was applied associated with exercises. The parameters were used: frequency of 1 MHz, intensity of 1.5 w / cm2 (temporal and spatial mean SATA), continuous mode (100%), with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
41308243|NCT01434888|DRUG|Preservative free tafluprost 0.0015% eye drops|Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
41308244|NCT01434888|DRUG|Preservative free timolol 0.5% eye drops|Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
41308245|NCT01434888|DRUG|Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops|Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
41308246|NCT01068041|DRUG|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
41308247|NCT03279783|DEVICE|LCI (Linked color imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
41308248|NCT05846997|DIAGNOSTIC_TEST|Liquid biopsy and imaging|Liquid biopsy and imaging
41308249|NCT05523713|BIOLOGICAL|Peripheral venous blood samples|10 ml in a sodium heparin tube and 5 ml in an EDTA tube
41308250|NCT06440161|OTHER|Primary exposures were venous congestion defined by central venous pressure (CVP) and mean arterial pressure (MAP).|"After the induction of anaesthesia, a central venous or pulmonary artery catheter was positioned. Based on prior studies, thresholds for central venous pressure were set at 10, 12, 16, and 20 mm Hg. Venous congestion was quantified by time exceeding each CVP threshold and the area under the curve (AUC) surpassing each CVP threshold in mmHg × min. Assessments were limited to pre- and post-CPB periods, as the venous drainage cannulate generated negative CVP during CPB.~An arterial catheter was installed upon room admission. Continuous arterial blood pressure monitoring commenced after exposure to atmospheric pressure and calibration to zero. The MAP was determined using the formula: 2/3 × diastolic blood pressure + 1/3 × systolic blood pressure. Data were logged by automated software every minute. Established thresholds for MAP were 55, 65, and 75 mm Hg. Hypotension was quantified as (1) time under each MAP threshold in minutes and (2) the AUC below each MAP threshold in mmHg × min."
41488602|NCT05970419|OTHER|high power laser acupuncture (HPLA)|High power laser therapy A Zimmer Opton pro, integrated High-power class IV laser device (serial N: 15200013306 \& REF: 4682, made in Germany, manufactured by Zimmer Medizin System). It emits radiation in the infrared range to deliver topical heating and raise tissue temperature. The simultaneous application of two wavelengths of laser light (810 and 980nm) provides the user with a huge variety of therapy options. The laser probe - with the small spacer (3.1cm2) , with parameters of 3 watts, 5Hz, 50% duty cycle, 20 joule/ point for 13 seconds with 6.4 j/cm2 . Although a maximum power of 8000 W was reported in two studies, the average power of the lasers used in t
41147274|NCT05701345|OTHER|standard treatment|"It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines."
41147275|NCT04231175|DIAGNOSTIC_TEST|DWI MRI of the pelvis, abdomen and thorax|Patients in Arm A will receive a MRI scan of their pelvis, abdomen, and thorax before possible surgery. During the MRI standard Gadolinium contrast agent and Buscopan is intravenously administered, which is standard clinical practice in abdominal MR imaging. Total scan time is 35 minutes and includes T2 weighted, T1 weighted, Diffusion weighted and dynamic contrast enhanced imaging of the abdomen and the thorax. The findings of this scan will be used to determine whether to proceed with CRS/HIPEC, DLS and then possibly CRS-HIPEC, or palliative care.
41147276|NCT04288440|PROCEDURE|Surgery|Removal of epiretinal membrane and ILM
41147277|NCT04288440|DEVICE|Vitrectomy machine|Pars plana vitrectomy
41147278|NCT04232202|DEVICE|Er:YAG and Nd:YAG lasers|Extraction followed by Er:YAG laser degranulation, Nd:YAG laser disinfection, Er:YAG deepithelialization, Nd:YAG blood clot stabilization and photobiomodulation. The photobiomodulation step repeated on day 3, 5, and 7.
41147279|NCT04232202|PROCEDURE|Standard extraction|Standard extraction procedure
41147280|NCT04232488|PROCEDURE|coronary angiography using distal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using distal radial artery ('snuff box'); color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
40787291|NCT06364917|DRUG|Pemetrexed|The combination therapy dosages for Pemetrexed are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
41308251|NCT01633996|PROCEDURE|Acupuncture|Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
40822896|NCT01713283|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
40822897|NCT04736953|DRUG|Sirolimus|Sirolimus
40822898|NCT04736953|OTHER|Placebo|Placebo
40991179|NCT01203228|OTHER|Myeloablative conditioning|"Busilvex®:~12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available):~Busulfan:~16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Cyclophosphamide:~120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW"
41308252|NCT03834571|DRUG|Carboplatin|Given IV
40822899|NCT00325676|DRUG|Pantoprazole|
41308253|NCT03834571|DRUG|Cisplatin|Given IV
41308254|NCT03834571|DRUG|Paclitaxel|Given IV
41308255|NCT03834571|PROCEDURE|Patient Monitoring|Undergo active monitoring
41308256|NCT03834571|RADIATION|Radiation Therapy|Undergo radiation
41308257|NCT00266019|BEHAVIORAL|Weight Management (diet, exercise, and behavior modification)|
41308258|NCT06422351|BIOLOGICAL|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKLR (Pyruvate Kinase L/R) gene
41308259|NCT05516108|BEHAVIORAL|Mindfulness|The mindfulness intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific meditation techniques through didactic explanation and guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention on the intended target, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts build on the skills trained in each lesson, encouraging participants to practice brief moments of mindful awareness, mindfulness while doing daily tasks, or formal meditation.
41308260|NCT05516108|BEHAVIORAL|Coping|The coping intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific coping techniques through didactic explanation and guided practice. Lessons train coping skills (reflection, reappraisal, and problem solving) without encouraging focus on or acceptance of present experience (i.e., mindfulness skills). Participants are instructed to: (1) reflect and let their minds drift, (2) reframe or reappraise past and anticipated events, and (3) analyze and solve personal problems. Practice prompts build on the skills trained in each lesson, encouraging participants to take brief reflection breaks or to practice reappraisal or problem-solving skills.
41308261|NCT01671969|OTHER|very low calorie diet|medically supervised diet
41308262|NCT05763342|DEVICE|The Phoenix Research System|Focused Multipolar Stimulation (FMS) strategy in adult cochlear implant recipients.
41308263|NCT01657448|DRUG|Methenamine and Methylthioninium chloride|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
41308264|NCT01657448|DRUG|Phenazopyridine|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
41308265|NCT04186000|BIOLOGICAL|Ad26.ZEBOV vaccine|The booster vaccination with Ad26.ZEBOV (5x10\^10 vp, same dosage as during the first dose) will be given at 1 year after the first dose or 2 years post-first dose.
41308266|NCT05557773|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
41308267|NCT05557773|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
41308268|NCT02288065|DRUG|sterile talc pleurodesis|medical thoracoscopy and talc pleurodesis. No specific device is studied.
40787292|NCT06364917|DRUG|Nivolumab|The dosing regimens for Nivolumab (360 mg Q3W) are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
41308269|NCT03761043|BEHAVIORAL|Professional Behavior Change Intervention|IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
40787293|NCT06364917|DRUG|Ipilimumab|The dosing regimens for Ipilimumab (1 mg/kg Q6W) are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
40787294|NCT02960087|RADIATION|Low dose rate brachytherapy|I-125 to a total dose of 144 Gy
40787295|NCT02960087|RADIATION|High dose rate brachytherapy|27 Gy in 2 fractions
41308270|NCT02361658|OTHER|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
40787296|NCT02257749|OTHER|Active Rehabilitation|The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
40787297|NCT02257749|OTHER|Comprehensive Education Intervention (Standard Care)|An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
40991180|NCT02981719|PROCEDURE|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment
40991181|NCT02981719|PROCEDURE|irreversible electroporation|percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.
41308271|NCT02361658|OTHER|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
41308272|NCT02361658|OTHER|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
41308273|NCT01442740|PROCEDURE|Reverse Trendelenburg Position|Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
41308274|NCT03407924|OTHER|Aerobic Exercise (AER)|Aerobic exercise will be performed with a treadmill or stationary tandem bike 3 times per week. Each exercise session will take about 30 minutes plus 5 to 10 min of warm-up and cool-down. Participants will wear a safety harness.
40822900|NCT06466941|PROCEDURE|regional anesthesia|Patients who underwent surgery and received an epidural or peripheral nerve block
40822901|NCT06466941|PROCEDURE|no regional anesthesia|Patients who underwent surgery and did not received an epidural or peripheral nerve block
41147281|NCT04232488|PROCEDURE|coronary angiography using proximal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using proximal radial artery; color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
41147282|NCT03031223|RADIATION|low-level laser therapy|low-level laser therapy
41147283|NCT06336642|BEHAVIORAL|SPOT-ON Early Start|Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
41308275|NCT03407924|OTHER|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
41308276|NCT03073655|OTHER|Negative Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
41308277|NCT03073655|OTHER|Neutral Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
41308278|NCT03073655|OTHER|Positive Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
41308279|NCT04255550|DIAGNOSTIC_TEST|Esophageal doppler|It is a prospective observational clinical study to correlate hemodynamic monitoring between non-invasive Electrical Cardiometry and minimally invasive Esophageal Doppler during major abdominal surgery.
41308280|NCT06450691|PROCEDURE|biopsy|skin biopsy and blood sampling
41308281|NCT02935634|BIOLOGICAL|Nivolumab|Specified dose on specified days
41308282|NCT02935634|BIOLOGICAL|Ipilimumab|Specified dose on specified days
40787298|NCT04910568|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment after Cycle 13. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.
40787299|NCT04910568|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
41467003|NCT03676790|OTHER|Group IV|"Group IV In the first month, the pulsed ultrasound was applied three times a week. In the second month, three times a week, the pulsed ultrasound associated with exercises was applied. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 Minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
40787300|NCT04910568|DRUG|Pomalidomide|Pomalidomide will be administered orally (PO) on a 28-day cycle.
40787301|NCT04910568|DRUG|Daratumumab|Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).
40787302|NCT04910568|DRUG|Dexamethasone|"Arm A: Dexamethasone will be administered as a premedication.~Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product."
41308283|NCT02935634|BIOLOGICAL|Relatlimab|Specified dose on specified days
41308284|NCT02935634|BIOLOGICAL|BMS-986205|Specified dose on specified days
41308285|NCT02935634|DRUG|Rucaparib|Specified dose on specified days
40787303|NCT02268110|OTHER|Exercise therapy|Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
41308286|NCT00143221|DRUG|Viagra|
41308287|NCT00143221|DRUG|Placebo|
41308288|NCT01291329|GENETIC|intracoronary human umbilical WJ-MSC transfer|intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.
41308289|NCT02768194|DEVICE|Stannous fluoride|Dentifrice containing 0.454% stannous fluoride
41308290|NCT02768194|OTHER|Sodium monofluorophosphate|Dentifrice containing 0.76% sodium monofluorophosphate
40787304|NCT02268110|OTHER|Abdominal binding|Wearing an abdominal binder for 12 weeks
40787305|NCT05741892|DEVICE|Fracture reposition with 3D printed patient specific repositions guides|Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
40787306|NCT01122979|DRUG|INSULIN GLARGINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
40822902|NCT06466941|OTHER|acute pain consultation|Patients who underwent surgery and had a perioperative (preop, intraop, or postop) acute pain consultation
41308291|NCT02768194|OTHER|Mineral water|Commercially available mineral water
41308292|NCT04619121|DEVICE|NIR-tPBM|The treatment will last for 8 weeks and be bilateral and applied to the frontal areas with one application site on the left side and one on the right side (left and right forehead centered on the frontal eminences and per EEG sites on F3 and F4). Energy is administered with a radiation wavelength of 830 nm. The duration of irradiation is from 20 minutes at each application site (the 2 sites are irradiated at the same time which is equivalent to 20 minutes of total time) to 40 minutes at each site, up to 2 times per day. The treatment will follow these specifications: PBM (IR) irradiance of 33.2 mW/cm2, each treatment window area is 28.7 cm2; PBM (IR) fluence of up to 60 Joules/cm2; energy delivered per session per device up to 1.72 kJ for a total of up to 3.44 kJ.
41308293|NCT04619121|DEVICE|Sham device|The sham device is completely identical in appearance, but only emits neglectable energy to the brain.
41308294|NCT02676076|DRUG|CHF 5993 100/6/12.5 µg|
40787307|NCT01122979|DRUG|NPH insulin (insulin isophane)|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
40787308|NCT01122979|DRUG|INSULIN GLULISINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
40787309|NCT01122979|DRUG|Regular insulin|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
40787310|NCT05004844|DIAGNOSTIC_TEST|Viscoelastic assays and aggregometry tests|Viscoelastic assays and aggregometry tests performed with ROTEM will allow us to characterize the clot forming abilities and platelet functions of our patients. ROTEM is used routinely for aiding clinicians in choosing the appropriate blood products for patients ROTEM requires samples of whole blood in an amount that does not entail additional burden or risk for patients. In our study, viscoelastic assays and aggregometry will be performed upon arrival, and 24-,48-,72-hours post-admission.
40787311|NCT04782349|OTHER|mulligan mobilization with low level laser therapy and traditional physical therapy exercises|"for mulligan mobilization: for improving the limited range of motion of shoulder joint, the therapist will apply posterolateral mobilization for the shoulder joint. Three sets of painless glides of 10 repetitions will be applied with a rest interval of 30 s between each set.~For low level laser application: Laser specifications is as follows: 850 nm wave length and pulsed application with 8 W applied for 20 minutes. laser will be applied over painful points of the shoulder.~For traditional physical therapy exercises: the patients will receive the following exercise program: self stretching exercises for shoulder joint, pully exercises, back climbing exercises, finger ladder exercises, circumduction exercises and pendulum exercises"
40787312|NCT04782349|OTHER|low level laser therapy and traditional physical therapy exercises|patients in this group will receive low level laser and traditional physical exercises as described before for group (A)
40787313|NCT04782349|OTHER|physical therapy exercises|The patients will receive traditional physical therapy exercises only as described before for group (A)
40787314|NCT05458518|PROCEDURE|Cesarean wound dressing removal|The cesarean wound dressing is to be removed and the surgical wound exposed
40787315|NCT05917093|BEHAVIORAL|Culturally tailored HLWD|"Participants receive the culturally tailored HLWD intervention for 6 weeks~* Week 0 - Baseline enrollment.~* Weeks 1-6 will consist of 6 separate group sessions. Diabetes self-management topics will be covered by 2 Black HLWD Facilitators. Participants will meet once a week, for a 2½-hour session, in community settings such as a community center, or church."
40822903|NCT06466941|OTHER|no acute pain consultation|Patients who underwent surgery and did not have a perioperative (preop, intraop, or postop) acute pain consultation
41308295|NCT02676076|DRUG|CHF 1535 100/6 µg|
41308296|NCT01364233|DEVICE|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
41308297|NCT04222439|DEVICE|AI for the Diagnosis of Gastrointestinal Diseases|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
41308298|NCT04359355|DEVICE|Artificial Intelligence System for Detection of colorectal polyps|In this group, an artificial Intelligence System will be used for computer-aided diagnosis of colorectal polyps. Diagnostic Performance of the artificial intelligence System for detection of polyps will be compared against Operator-based detection in the same group
41308299|NCT05311085|DRUG|Cytisine|"Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)"
41308300|NCT05311085|DRUG|Nicotine delivered via an e-cigarette|Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
41308301|NCT05311085|COMBINATION_PRODUCT|Cytisine plus nicotine delivered via an e-cigarette|"Cytisine: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)~Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco"
41308302|NCT04721236|OTHER|hyperimmune plasma|plasma collected from convalescent Covid-19 donors with titre 1:80 or more
41308303|NCT05248087|DEVICE|The bonded McNamara-type appliance|The patient will be asked to expand twice a day until obtaining an overcorrection of 2-3 mm. Then the expander will be kept in place for three months as a retention period.
41308304|NCT05248087|DEVICE|The removable palatal expansion appliance|The slow maxillary expansion will be applied using a removable palatal expansion appliance with a midline screw. The patient will be asked to expand twice a week until obtaining an overcorrection of 2-3 mm.
41467004|NCT03676790|OTHER|Group V|"Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
41147284|NCT06336642|BEHAVIORAL|SPOT-ON Delayed Start|Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
41147285|NCT03850847|OTHER|Step 1: Semi-structured Interviews|"1. Cover SDMs' experience around:~   * withdrawal of life sustaining therapies~  * organ donation among those who were approached (including with the medical team and the organ donation organisation)~  * understanding of the situation~  * views on any gaps in the quantity or quality of information and discussion they received concerning their loved one's end-of-life care or donation process~2. Explore factors they perceived to influence their decision to consent to organ donation or not (or that would have influenced their decision for those not approached), and how such factors may have changed over the course of making this decision and since the decision (or since the event for those not approached)."
41147286|NCT03850847|OTHER|Step 2: National Telephone Survey|Explore SDM's beliefs and experiences around end of life and assess which beliefs are associated with the decision taken at the end of life, including decision to donate organs or not (and the strength of this association)
41147287|NCT01867879|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
41308305|NCT02077387|BEHAVIORAL|CHild Inhibitory Control (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
41308306|NCT02077387|BEHAVIORAL|Attention control|Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
41308307|NCT05813171|DIETARY_SUPPLEMENT|Allicor|Participants will take Allicor capsules in addition to standard treatment for a year.
41308308|NCT05813171|DRUG|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
41147288|NCT01867879|DRUG|Placebo|Placebo tablets, orally, single dose.
41308309|NCT05329987|OTHER|Rehabilitation|Intervention focused on balance, gait and postural transfers rehabilitation. 20 session of 90 minutes (60 minutes of physiotherapy and 30 minutes of occupational therapy), 2 times a week, for 10 weeks.
41308310|NCT02306707|PROCEDURE|Endoscopic Mucosal Resection|
41308311|NCT00385268|DRUG|acamprosate|1998 mg/dau fpr 8 weeks
41308312|NCT00385268|DRUG|placebo|placebo pills
41308313|NCT05528003|PROCEDURE|Commercialized single-access port devices|Two kinds of commercialized single-access port devices were used.
41308314|NCT05271019|DEVICE|Threshold load device|"Inspiratory Muscle Training (IMT) for 3 months:~Though a threshold loading device (5 sets of 6 repetitions, 1session/day, 5 days/week). the inspiratory load will start at 30% of MIP, or up to the maximum patient-tolerable load (max 60% of MIP), no more than 3-5/10 on the modified Borg scale."
41308315|NCT02786732|BIOLOGICAL|210mg Brodalumab|Brodalumab 210mg administered subcutaneously
41308316|NCT02786732|BIOLOGICAL|140mg Brodalumab|Brodalumab 140mg administered subcutaneously
41308317|NCT02786732|BIOLOGICAL|Ustekinumab|Ustekinumab 45mg or 90mg adminstered subcutaneously
41308318|NCT02786732|BIOLOGICAL|Placebo|Placebo administered subcutaneously
41308319|NCT01333839|OTHER|exercise training|endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
41308320|NCT03483324|BIOLOGICAL|Unmanipulated Umbilical Cord Blood (UCB)|Human leukocyte antigen (HLA) matched umbilical cord blood
41308321|NCT03483324|BIOLOGICAL|AB-110|Expanded cord blood stem cells and engineered human endothelial cells
41308322|NCT04069013|PROCEDURE|PCNL|Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL
41308323|NCT03855137|DRUG|Atogepant 30 mg|Tablets containing 30 mg atogepant
41308324|NCT03855137|DRUG|Atogepant 60 mg|Tablets containing 60 mg atogepant
41308325|NCT03855137|DRUG|Placebo|30 mg/60 mg tablets containing atogepant-matching placebo
41308326|NCT01807715|OTHER|survey|Survey before procedure to obtain demographic information and contraceptive information
41308327|NCT00157937|DRUG|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
41308328|NCT00157937|DRUG|Comparator: theophylline ER/Duration of Treatment: 16 weeks|
41308329|NCT03571620|DRUG|Q301 Cream|1.0% or 1.4% Q301 Cream
41308330|NCT03571620|DRUG|Vehicle|Vehicle Control
41308331|NCT02871115|OTHER|Pharmacy Intervention|Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
41308332|NCT02871115|OTHER|Usual Care|Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
41308333|NCT02039180|DRUG|AZD3293 oral solution|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
41308334|NCT02039180|DRUG|AZD3293 tablet formulation A|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
41308335|NCT02039180|DRUG|AZD3293 tablet formulation B|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
41308336|NCT00665496|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg and 20 mg orally once a day as needed
41308337|NCT00665496|DRUG|Placebo|Matching Placebo
41308338|NCT00825955|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
41467005|NCT03208673|DEVICE|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
40787316|NCT05582681|DIAGNOSTIC_TEST|Cepheid POC HCV Viremia (RNA) test|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is for being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
40787317|NCT05582681|OTHER|HCV education from a health care provider|HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management
40787318|NCT05582681|DRUG|Glecaprevir and Pibrentasvir|G/P will be provided for 8 weeks.
40787319|NCT05531500|DRUG|Injection|Injection of local anesthetic + steroids
40787320|NCT05531500|DEVICE|Radiofrequency|Application of radiofrequency on the diseased nerve
40787321|NCT03521154|DRUG|Osimertinib 80mg/40mg|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
40787322|NCT03521154|DRUG|Placebo Osimertinib 80mg/40mg|"The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met"
40787323|NCT03795649|DRUG|Tranexamic Acid|Imunomodulatory effect
40787324|NCT04865289|DRUG|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
40787325|NCT04865289|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
40787326|NCT04865289|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
40787327|NCT04865289|DRUG|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
41308339|NCT00825955|OTHER|Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
40787328|NCT01111162|BIOLOGICAL|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
40787329|NCT05941442|DRUG|Darigabat|Oral tablets
40787330|NCT05941442|DRUG|Placebo|Oral tablets
40787331|NCT06209944|PROCEDURE|Cardiopulmonary resuscitation|cardiac compression, endotracheal intubation, defibrillation, and use of cardiovascular medications, to restore circulation in patients with cardiac arrest
40787332|NCT04773548|OTHER|VR-JIT|Job interview with virtual interviewer
40787333|NCT02827812|OTHER|Comprehensive evaluation|At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
40787334|NCT02827812|OTHER|Physical Intervention at home|A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
40787335|NCT02827812|OTHER|Home-Based telemedicine program|"1. A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.~2. A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences."
41308340|NCT00825955|PROCEDURE|Best Supportive Care|Trans-Arterial Chemo-Embolization (TACE) Therapy
40787336|NCT00366210|BEHAVIORAL|Constraint-Induced Movement (CI) Therapy|
40787337|NCT00366210|BEHAVIORAL|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
40787338|NCT01769053|OTHER|Variable Ventilation|
40787339|NCT03011749|OTHER|FLT PET/CT|FLT PET/CT before first series of Radium-223 and after 2 series
40787340|NCT02844985|OTHER|No Intervention|
40787341|NCT00368030|DRUG|Eszopiclone|Eszopiclone 3 mg QD
40787342|NCT00368030|OTHER|Placebo|Placebo tablet
40787343|NCT02126163|BEHAVIORAL|Treatment Group|Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
40787344|NCT06459180|BIOLOGICAL|Sacituzumab Tirumotecan|IV infusion
40787345|NCT06459180|DRUG|Pemetrexed|IV infusion
40787346|NCT06459180|BIOLOGICAL|Tisotumab Vedotin|IV infusion
40787347|NCT06459180|DRUG|Topotecan|IV infusion
40787348|NCT06459180|DRUG|Vinorelbine|IV infusion
40787349|NCT06459180|DRUG|Gemcitabine|IV infusion
40787350|NCT06459180|DRUG|Irinotecan|IV infusion
40822904|NCT00581269|BEHAVIORAL|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
41308341|NCT04997889|COMBINATION_PRODUCT|Artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
41467006|NCT06382506|DIETARY_SUPPLEMENT|Consumption of Cornbread with Hazelnut Bread|Cornbread was added to 15 grams and 30 grams of bread and consumed by the participants. Blood glucose levels were then measured. Obese and normal-weight individuals will be divided into two groups according to their anthropometric measurements.
41467007|NCT06616285|BEHAVIORAL|Self-Guided Multidomain Lifestyle Intervention|Participants will receive guidance on healthy dietary habits, physical activity, mental stimulation, and cardiovascular/metabolic monitoring based on national recommendations and individual consultations with the study physician. Based on this guidance, participants will create their own healthy lifestyle plan. Participants' cardiovascular/metabolic risk factors will be regularly monitored.
41467008|NCT06616285|BEHAVIORAL|Folk Dance Multidomain Lifestyle Intervention|"Participants will receive structured, intensive lifestyle intervention with the following components: diet, physical exercise, mental stimulation, cardiovascular/metabolic risk monitoring, social interaction.~One-hour long folk dancing sessions, delivered by professional teachers 3 times weekly, will provide opportunities for physical and mental exercise and social interaction. These sessions were specifically developed to foster physical and mental stimulation through the learning of coordinated movement and different choreographies (rhythmic and gradually more complex movements with folk songs) individually, in pairs, and circles. As such, social stimulation is naturally embedded in the sessions.~Participants will receive advice about diet and cardiovascular/metabolic risk factors based on national recommendations via group sessions and individual consultations. Participants' cardiovascular/metabolic risk factors will be regularly monitored."
40991182|NCT03403465|OTHER|FDG PET scan|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
41147289|NCT01590056|OTHER|Electrophysiological recording|"During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:~1. listening to nonverbal affect bursts corresponding to emotions~2. applying a simple go-no-go auditory test"
41147290|NCT03624023|DRUG|TWB-103|TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
41467009|NCT00132834|DEVICE|R-Tube or EcoScreen|Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)
41467010|NCT00676741|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
41467011|NCT00676741|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40787351|NCT05554458|BEHAVIORAL|ChildTaks+ intervention|The ChildTalks+ Intervention ChildTalks+ is a preventive intervention originally developed in the Netherlands, targeting children up to 18 years of age. It has been implemented in Norway, Italy, and Portugal. It has a clear and well-described theoretical basis focusing on psychoeducation. Its key strategy is to provide feasible and replicable interventions to improve the quality of life of families where parents are affected by a mental disorder.
40787352|NCT04815200|DEVICE|Copper Nickel titanium arch wire|Patient will receive 0.014 round Copper Nickel titanium CuNiTi archwire and will be ligated using a ligature wire.
41147291|NCT00796835|DRUG|ER OROS Paliperidone|
41308342|NCT04997889|OTHER|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
40787353|NCT04310696|OTHER|Buteyko Breathing exercises|Buteyko breathing technique was performed by asking the patient to take a small breath in and then out and hold his/her breath and count the time in seconds, as long as he or she can, until first signs of air hunger start to appear, followed by normal breathing once again. This procedure was repeated 15 times, three sets of 15 repetitions were given to the patient per day, 3 days per week and the treatment was continued for 4 weeks.
41467012|NCT00676741|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40787354|NCT04310696|OTHER|Pursed lip breathing|Pursed lip breathing was performed as nasal inspiration followed by expiratory blowing against partially closed lips. Participants received a total of 3 sets of 15 repetitions per day, 3 times a week and the treatment was continued for 4 weeks.
40787355|NCT02796833|DRUG|SMOFlipid20%|
40787356|NCT05350540|OTHER|ICG dye|Patients assigned to the intervention group will undergo surgery guided by tissue perfusion as directed by the ICG imaging
40787357|NCT00087698|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 4 cycles
40787358|NCT00087698|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 4 cycles
40787359|NCT01796288|RADIATION|simultaneous radiotherapy|
40787360|NCT01796288|DRUG|Erlotinib|
40787361|NCT01718158|BIOLOGICAL|Peginterferon Lambda-1a|
40787362|NCT01718158|BIOLOGICAL|Peginterferon Alfa-2a|
41147292|NCT03760809|DRUG|Dexmedetomidine 0.5μg／kg|Group A received dexmedetomidine 0.5μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
41467013|NCT06019117|DIETARY_SUPPLEMENT|Probiotic K10|clinical trial using 90 days of probiotic K10
41467014|NCT06019117|DRUG|Placebo|clinical trial using 90 days of placebo controlled
41467015|NCT00692952|DRUG|a novel Benzalkonium Chloride (BZK) contraceptive gel|insert 1 piece of the gel (containing 18mg BZK) into vagina before every coital act.
41467016|NCT00692952|DRUG|LELEMI® contraceptive gel containing 50mg nonoxynol-9|insert 1 piece ofLELEMI® contraceptive gel within half an hour before every coital act
41467017|NCT00865007|DRUG|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
41467018|NCT00865007|DRUG|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
41467019|NCT05757037|DEVICE|laser acupuncture|a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz\].
41467020|NCT02093871|DEVICE|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
40991183|NCT03862274|OTHER|CLN2 Treatment|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
40991184|NCT04781673|DRUG|Ketamine|Will receive titratable infusion.
40991185|NCT04781673|DRUG|Lidocaine|Will receive titratable infusion, will have daily lidocaine level labs drawn daily.
40991186|NCT01662518|DEVICE|Dexamethasone drug delivery system (DDS-25)|350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
40991187|NCT05086887|DIAGNOSTIC_TEST|Malaria diagnostic tests (RDT and PCR) and serology for malaria and other parasitic diseases|All individuals are tested. Individuals with demonstrated parasitic disease are referred to the Infectious diseases or Pediatric clinic for evaluation and treatment.
40991188|NCT03888872|DEVICE|High tone power therapy|"1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week."
40991189|NCT03888872|OTHER|Selected Physical Therapy Program|"Selected physical therapy program: (For both groups).~1. Wobble board training:~2. Active range of motion exercises (AROM):~3. Gentle manual stretching exercises for both UL \& LL:~4. Graduated gait training:"
40991190|NCT02971267|OTHER|Observational|None, observational only
41147293|NCT03760809|DRUG|Dexmedetomidine 1μg／kg|Group B received dexmedetomidine 1μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
41308343|NCT06519552|GENETIC|JWK008 Single intravenous infusion administration|"Six participants with MPS I will be enrolled in the study. The participantss will be divided into two different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^12vg/kg, and the high dose is 2.0×10\^13vg/kg. Only one intravenous infusion of JWK008 will be administered to each participant."
41308344|NCT03422406|OTHER|Dietary iodine intake restriction|All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.
40991191|NCT04016376|DRUG|PVB Protocol|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
40991192|NCT04016376|DRUG|PECS-1|For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
41308345|NCT03009058|BIOLOGICAL|IMM-101|A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365
41308346|NCT03009058|DRUG|Gemcitabine|Standard of Care chemotherapy
41308347|NCT03009058|DRUG|Nabpaclitaxel|Standard of Care chemotherapy
41308348|NCT03009058|DRUG|Capecitabine|Standard of Care chemotherapy
41308349|NCT03009058|DRUG|Folinic Acid|Standard of Care chemotherapy
41308350|NCT03009058|DRUG|Fluorouracil|Standard of Care chemotherapy
40991193|NCT04016376|DRUG|Serratus|For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
40991194|NCT01457885|DRUG|Clofarabine/Busulfan x 4|"* Clofarabine IV dose level: 40 mg/m2/day x 5 days~* Busulfan IV dose level: 3.2 mg/kg daily x 4 days"
40991195|NCT01457885|PROCEDURE|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
41147294|NCT05140109|OTHER|Arm 1: Cognitive-dissonance based program|The first four sessions focus on body image and the last four sessions on eating behavior.
41147295|NCT05140109|OTHER|Arm 2: Mindfulness-based program|The sessions focus on different contents as body image, eating behavior and emotion regulation.
41147296|NCT05140109|OTHER|Arm 3: Person-centered program|The sessions are not structured. Participants can bring any subject they need to talk.
41147297|NCT00124644|DRUG|cytarabine|
41147298|NCT00124644|DRUG|daunorubicin hydrochloride|
41147299|NCT00124644|DRUG|etoposide|
41308351|NCT03009058|DRUG|Irinotecan|Standard of Care chemotherapy
41308352|NCT03009058|DRUG|Oxaliplatin|Standard of Care chemotherapy
41308353|NCT03009058|BIOLOGICAL|cetuximab|Standard of Care immunotherapy
41308354|NCT03009058|BIOLOGICAL|Anti-PD1|Standard of Care immunotherapy
41308355|NCT03009058|BIOLOGICAL|Ipilimumab|Standard of Care immunotherapy
41308356|NCT03009058|DRUG|Cyclophosphamide|Standard of Care chemotherapy
41467021|NCT03816436|OTHER|Follow- up (FU) assessment|Follow- up (FU) assessment (clinical examination and patient questionnaires) at least 24 months after surgery (clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting)
41467022|NCT00313508|BIOLOGICAL|Autologous Dendritic Cells (DC)|Given intranodally
41467023|NCT00313508|DRUG|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
41467024|NCT00313508|BIOLOGICAL|Autologous Lymphocyte Infusion (ALI)|Infusion
41467025|NCT05144464|BIOLOGICAL|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
40991196|NCT02372851|DEVICE|Pureit As+ Filter|The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
40991197|NCT05711225|BEHAVIORAL|smoking cessation intervention given according to the web-based transtheoretic model during pregnancy on postpartum smoking relapse.|Smoking cessation videos prepared according to the Web-Based Transtheoretic model A module was created on the web, with 5 sections, prepared by the researcher according to the Web-Based Transtheoretic model, for quitting smoking or for pregnant women who quit smoking to maintain this behavior. The modules are prepared in the form of animated videos in which the researcher is educational. Each module is arranged for an average of 5-10 minutes. Theoretical information about the content has been added under each video.
40991198|NCT03365700|PROCEDURE|Radiofrequency Ablation|Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.
40991199|NCT03365700|PROCEDURE|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.
41467026|NCT02539784|DEVICE|"Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System"|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
41467027|NCT02082249|DRUG|ABT-SLV187|Dose levels will be individually optimized
41467028|NCT03261024|DEVICE|Friction mechanics|Nickel Titanium will be extended from the hook between the lateral incisors and canines to the first molar bands, to allow frictional en-masse retraction of anterior segment.
40991200|NCT04888546|DRUG|Anlotinib hydrochloride capsules＋ TQB2450 injection|"Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
40991201|NCT01184547|BEHAVIORAL|Combex|12 weeks of exercise with a trainer post discharge.
40991202|NCT01184547|BEHAVIORAL|Standard of Care|No exercise training received.
41147300|NCT00124644|DRUG|tipifarnib|
41308357|NCT01259752|DEVICE|compression stockings|compression stockings
41308358|NCT01259752|OTHER|standard non compressive stockings|standard non compressive stockings
40991203|NCT02963337|DRUG|remifentanil|Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
40991204|NCT02963337|DRUG|combined spinal-epidural analgesia|Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
41308359|NCT04136353|DRUG|Darolutamide|2 x 300mg oral tablets twice daily for 96 weeks
41147301|NCT00124644|PROCEDURE|chemotherapy|
41147302|NCT00124644|PROCEDURE|enzyme inhibitor therapy|
41147303|NCT00124644|PROCEDURE|high-dose chemotherapy|
41147304|NCT05650437|DEVICE|Ultraviolet Radiation|The therapist cut three holes, each measuring 2 by 2 cm, into a piece of cardboard that was about 4 by 20 cm in size.The first hole was exposed for 90 seconds, the second for 60 seconds, and the third for 30 seconds
41147305|NCT05650437|BEHAVIORAL|Aerobic exercise|The postmenopausal women in groups (A and B) exercised on the treadmill; women should always warm up before beginning exercise and stop if they experience pain or shortness of breath. Each session lasted 30 minutes and included 5 minutes of warming up and 20 minutes of walking at 60% of their maximum heart rate (MHR). The maximum heart rate that the circulatory system can support during physical exercise is MHR=220. Three sessions a week for three months, followed by a five-minute cool-down
41147306|NCT05650437|DIETARY_SUPPLEMENT|Vitamin D supplementation|Throughout three months, vitamin D supplements (800 IU) will be given to all postmenopausal women in both groups (A\&B)
41308360|NCT04136353|DRUG|Placebo oral tablet|2 oral tablets twice daily for 96 weeks
41308361|NCT04136353|DRUG|Luteinizing Hormone-Releasing Hormone Analog|All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.
41308362|NCT04136353|RADIATION|External Beam Radiotherapy|All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.
41467029|NCT03261024|DEVICE|Frictionless mechanics|T-loops retraction arch will be placed distal to the upper canines and cinched distal to the first molar bands, to allow frictionless en-masse retraction of anterior segment.
41467030|NCT01083238|DRUG|AZD5069|120mg single oral dose
41467031|NCT00487331|OTHER|Acupuncture|Acupuncture sessions 1-3 times per week.
41308363|NCT01239186|OTHER|methylation analyses on spermatozoa from infertile men|microarray analysis(www.EPIGENOMICS.com)
41308364|NCT05110716|BEHAVIORAL|Bundle-size 1|In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
41308365|NCT05110716|BEHAVIORAL|Bundle-size 3|In this condition, each choice in the adjusting-amount task produce a series of three consequences over time. o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
41467032|NCT00487331|BEHAVIORAL|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
41308366|NCT05110716|BEHAVIORAL|Bundle-size 9|In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time. To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
41308367|NCT00200252|DRUG|oxytocin|
41467033|NCT05279638|DIAGNOSTIC_TEST|serum ATG5|This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
40991205|NCT01912417|OTHER|Aerobic exercise with cycle ergometer during hemodialysis|Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
40991206|NCT02487212|DRUG|0.05% Clobetasol propionate|0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
40991207|NCT02487212|DRUG|Petrolatum gel|Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
40991208|NCT02487212|DEVICE|Fractional Erbium:Yag (2,940-nm) laser|The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
40991209|NCT00661076|DRUG|adefovir dipivoxil|10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)
40991210|NCT00661076|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 48 weeks
40991211|NCT01275274|DRUG|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of \< 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to \< 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
41147307|NCT04774198|DIAGNOSTIC_TEST|blood sample|Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory molecules assed by Olink inflammation panel, leucocytes, differential count, hemoglobin, thrombocytes and CRP)
41147308|NCT04122820|DIAGNOSTIC_TEST|Diagnostic of specific learning disabilities or of Developmental Coordination Disorder|Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
40991212|NCT01275274|DRUG|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
40991213|NCT05319795|BEHAVIORAL|Effortful Swallow Maneuver|Repeated practice of the Effortful Swallowing Maneuver generated by pushing the tongue with increased effort against the palate at the point of swallow initiation.
41147309|NCT00504101|DRUG|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
41147310|NCT00504101|DRUG|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
41147311|NCT00504101|DRUG|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
41467034|NCT05814133|DEVICE|Thulium Fiber Laser|Thulium Fiber Laser will be used to break renal stones \< 2 cm into fragments small enough to remove or pass spontaneously through the ureter.
40787363|NCT01718158|DRUG|Ribavirin|
40787364|NCT01718158|DRUG|Daclatasvir|
40787365|NCT01718158|DRUG|Telaprevir|
40787366|NCT05522738|DRUG|Combination: Fruquintinib + FOLFIRI|"Phase 1b Fruquintinib was administered in a 3 + 3 dose escalation regimen at the following doses: L1:3 mg/d, L2:4 mg/d, L3:5 mg/d.~Fruquintinib: QD po q2w~FOLFIRI regimen:~Irinotecan：180 mg/m2, i.v. , d1, q2w LV：200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w~Phase II Fruquintinib: RP2D, QD po q2w~FOLFIRI regimen:~Irinotecan： 180 mg/m2, i.v. , d1, q2w LV： 200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w"
40787367|NCT05517486|DRUG|GTX-101|Bupivacaine HCl metered spray
40787368|NCT05517486|DRUG|Bupivacaine HCl subcutaneous injection|Bupivacaine HCl, 50 mg/10 mL
40787369|NCT03069508|DRUG|Clemizole Hydrochloride|Clemizole Hydrochloride will be administered orally for up to 24 weeks
40787370|NCT05879952|BEHAVIORAL|TAU + BTsN session|BTsN treatment session included exercises aimed at identifying, finding, chasing or moving objects, with the aim of improving the perceptual-cognitive skills of each patient, through audio-visual stimuli and feedback implementing visuo-spatial skills and spatial cognition, allowing at the same time motor coordination and balance improvement.
40787371|NCT05879952|BEHAVIORAL|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
40787372|NCT06129019|BEHAVIORAL|Reiki|Reiki application will be done
40787373|NCT03126643|BIOLOGICAL|Nivolumab|"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an accelerated basis for some types of cancer. Please contact your physician for more details."
40787374|NCT05715060|PROCEDURE|Median sternotomy closure (sternal closure)|Comparison of Sternal closure after cardiac surgery between conventional way which is by stainless steel wire \& Polydioxanone (PDS)
40787375|NCT03172273|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
40787376|NCT03172273|PROCEDURE|paracentesis|paracentasis plus albumine invision
40787377|NCT04406103|BEHAVIORAL|Sleepwell|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
40787378|NCT04406103|BEHAVIORAL|Empower|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
40787379|NCT00410189|DRUG|ZD6474|300 mg by mouth daily for 28 Days.
40991214|NCT03720470|DRUG|PF-04965842 100 mg|"PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 subjects take PF-04965842 100 mg from Week 16 to Week 20."
40991215|NCT03720470|DRUG|PF-04965842 200 mg|"PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842 subjects take PF-04965842 200 mg from Week 16 to Week 20."
40991216|NCT03720470|DRUG|Dupilumab|Two subcutaneous injections of Dupilumab 300 mg as a loading dose administered on Day 1 (for a total of 600 mg) followed by one injection once every two weeks (q2w) until Week 16.
40991217|NCT03720470|DRUG|Oral Placebo|"Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows:~1. In the arm Dupilumab Injection + Oral Placebo followed by Oral Placebo, the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20;~2. In the arms Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 and Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842, subjects, take Oral Placebo from Day 1 until Week 16."
40787380|NCT02681081|OTHER|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
40787381|NCT02681081|OTHER|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
40787382|NCT02681081|OTHER|Control|Normal food intake
40991218|NCT03720470|DRUG|Injectable Placebo|Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
40991219|NCT00947973|BEHAVIORAL|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
40991220|NCT00947973|BEHAVIORAL|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
40991221|NCT03559179|OTHER|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers.
40991222|NCT01148745|DRUG|ferumoxytol|510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)
40991223|NCT00857220|DRUG|eszopiclone|One 2 mg tablet per day for 12 months
40787383|NCT06521814|PROCEDURE|REFLECT scoliosis correction system|(i.e. purpose of research) The Globus Reflect scoliosis correction system aims to provide curve correction for scoliosis patients who are still actively growing. Surgical correction is accomplished without spinal fusion, instead utilizing anterior vertebral body tethering. Reflect holds the convexity of the curve in place so that the concavity can grow, thereby harnessing the power of normal spine growth to correct the deformity.
40787384|NCT02099396|DRUG|Docetaxel+lobaplatin|
40787385|NCT02099396|DRUG|Gemcitabine+lobaplatin|
40787386|NCT04847440|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
40787387|NCT04847440|DRUG|Viread|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
40787388|NCT04847440|DRUG|AB-729|AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
40991224|NCT00857220|DRUG|eszopiclone|one 3mg tablet per day for 12 months
40991225|NCT02570061|BEHAVIORAL|telephone|information given at the primary contact by phone, or at a scheduled later time
40787390|NCT01726543|PROCEDURE|Canaloplasty and phacoemulsification|As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
40822905|NCT00581269|DIETARY_SUPPLEMENT|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
40823054|NCT03935724|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
40991226|NCT02570061|BEHAVIORAL|consultation face-to-face|information given at a scheduled consultation at the hospital
40991227|NCT03779711|BIOLOGICAL|Autologous (self) mononuclear cells derived from umbilical cord blood|The investigational product will be delivered into the right myocardium via sub-epicardial injections of 0.1 mL per kg body weight to achieve the target dose of 1-3 million TNC per kg body weight.at the time of Stage II surgical repair.
41147312|NCT00504101|BIOLOGICAL|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
41308368|NCT01214746|DRUG|Placebo|1 tablet Unikalk 1 time pr day for 5 days
41308369|NCT01214746|DRUG|Atorvastatin|Zarator, 80 mg pr day for 5 days
40991228|NCT03779711|PROCEDURE|Stage II Surgical repair|This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.
40991229|NCT06114355|PROCEDURE|EUS Portal pressure measurement|Direct portal pressure measurement under EUS-guidance (EUS-PPM) is a promising alternative to conventional indirect Hepatic Venous Pressure Gradient (HVPG). In patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (PV) pressure requires intra-operative portal vein inflow modulation (PIM)
40991230|NCT05418192|OTHER|Enriched Environment|Enriched Environment (EE) consisted of motor and sensory enriched play environment to promote participant's self-generated movements, exploration and task success. EE also included positioning in a graded manner. Visual stimulus and level appropriate vestibular stimulus was also given. Dosing of positioning and sensory inputs was done throughout the therapy. Primary Intervention will be given for 20 to 25 minutes intermittently for period of 4-5 hours a day, 5 days a week for 24 weeks.
40991231|NCT05418192|OTHER|Traditional Physcial Therapy|Participants of this group received traditional physical therapy based NDT. No additional dosing guidance was given to this group. No home program was specifically assigned to this group. No specific environmental modifications were made for this group.
40991232|NCT00631566|DRUG|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."
40991233|NCT00631566|DRUG|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
40991234|NCT03488654|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance|CMR including cine, late gadolinium enhancement (LGE) and stress perfusion sequences
40991235|NCT02514356|BEHAVIORAL|Own adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
40991236|NCT02514356|BEHAVIORAL|Own and group level adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
40991237|NCT01536379|DRUG|Belimumab|Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
40991238|NCT01536379|DRUG|Placebo|Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
40991239|NCT01053689|DRUG|Glimepiride tablets 1 mg|
40991240|NCT02939560|DEVICE|NeuroStar® TMS device (Neuronetics, Atlanta, GA)|Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).
40991241|NCT02168010|DRUG|Analgecine|Analgesic drug under test
40991242|NCT02168010|DRUG|Neurotropin|Analgesic drug as positive control
40991243|NCT02168010|DRUG|Placebo|Blank tablet as placebo.
40991244|NCT00142571|DRUG|Gemcitabine|
40991245|NCT00142571|DRUG|Docetaxel|
40991246|NCT00149747|BEHAVIORAL|Moderate-Intensity Aerobic Physical Activity|Moderate-Intensity Aerobic Physical Activity. 4+ days per week, 60+ minutes per day, moderate or greater intensity physical activity
40991247|NCT00149747|BEHAVIORAL|Health Education Class|2 classes a week, 90+minutes per class, general health education, excluding information on physical activity
40991248|NCT02071355|DRUG|TMC435 100 mg|Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
40991249|NCT02071355|DRUG|TMC435 150 mg|Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
40991250|NCT04130230|DRUG|Neostigmine|Neostigmine continuous infusion plus standard therapy for sepsis and septic shock.
40991251|NCT04130230|DRUG|Standard therapy|Standard therapy for sepsis and septic shock
40991252|NCT01988831|DRUG|Propranolol hydrochloride|This intervention apply to Propranolol group
40991253|NCT01988831|DRUG|Placebo pill|We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
40991254|NCT02118844|DRUG|rocuronium|
40991255|NCT02618174|BEHAVIORAL|Neutral Control Condition|Message about age of University of Birmingham
40991256|NCT02618174|BEHAVIORAL|Food-based Control Condition|Message about variety of vegetables in the world
40991257|NCT02618174|BEHAVIORAL|Health Condition|Message about the health benefits of eating vegetables
40991258|NCT02618174|BEHAVIORAL|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
40991259|NCT02618174|BEHAVIORAL|Liking Social Norm|Message suggesting most people like eating vegetables
40991260|NCT02604524|DEVICE|Closed-Loop Control|Subjects will use the CLC during 5 nights/6 days at a ski camp.
40991261|NCT02604524|OTHER|Sensor Augmented Pump Therapy|Subjects using their personal pumps with study CGM.
40991262|NCT00003679|DRUG|cyclophosphamide|
40991263|NCT00003679|DRUG|docetaxel|
40991264|NCT00003679|DRUG|doxorubicin hydrochloride|
40991265|NCT00003679|DRUG|tamoxifen citrate|
40991266|NCT00003679|PROCEDURE|conventional surgery|
40991267|NCT00003679|RADIATION|radiation therapy|
40991268|NCT05256667|COMBINATION_PRODUCT|RCT-SV|Group 1- Endodontic treatment in a single visit using chemomechanical preparation and passive ultrasonic irrigation, followed by obturation and final restoration.
41308370|NCT02389816|DRUG|Placebo|Placebo tablets
41308371|NCT02389816|DRUG|Vortioxetine|Vortioxetine tablets
41467035|NCT02655224|DRUG|Relugolix|Relugolix Tablets
41467036|NCT02655224|DRUG|Relugolix placebo|Relugolix placebo-matching tablets
41467037|NCT01188226|DEVICE|Denture teeth|Denture teeth made of nano hybrid composite material
40991269|NCT05256667|OTHER|RCT-TVWD|Group 2- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by intracanal dressing and temporary restoration for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
40991270|NCT05256667|OTHER|RCT-TVWOD|Group 3- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by temporary restoration for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
40991271|NCT00320099|DRUG|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
40787391|NCT01726543|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification|A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
40991272|NCT00320099|DRUG|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
40991273|NCT00320099|DRUG|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
40991274|NCT00320099|DRUG|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
40991275|NCT03205618|OTHER|Non-Interventional|Non-Interventional
40991276|NCT03103789|DIAGNOSTIC_TEST|single catheter mucosal impedance testing|
40991277|NCT03103789|DIAGNOSTIC_TEST|balloon assembly mucosal impedance testing|
40991278|NCT00003733|DRUG|carboplatin|
40991279|NCT00003733|DRUG|paclitaxel|
40991280|NCT00003733|DRUG|topotecan hydrochloride|
40991281|NCT02580357|PROCEDURE|Low Level Laser Therapy|Low Level Laser Therapy on the palatal donor site of connective tissue graft.
40991282|NCT02580357|DEVICE|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site.
40991283|NCT06520852|OTHER|Group using artificial intelligence tools in addition to traditional tools in preparing educational materials|Students in the intervention group used AI tools in addition to tools such as books, journals, and websites.
40991284|NCT01677975|PROCEDURE|FNA (fine needle aspiration)|
41467038|NCT01736748|BEHAVIORAL|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
41467039|NCT01736748|BEHAVIORAL|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
41467040|NCT03033524|DRUG|TTAC-0001|Calculated amount of drug will be diluted with normal saline and administered intravenously.
41467041|NCT00441233|DEVICE|Silicone hydrogel contact lens|
40823055|NCT00686322|DRUG|Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
40991285|NCT04896710|DEVICE|SD Biosensor|Nasal swab SD biosensor to be self administered
40991286|NCT00482235|DRUG|MK0359|
40991287|NCT00000586|DRUG|hydroxyurea|
40991288|NCT06000254|DEVICE|High energy density pulse electromagnetic field|The treatment coil is positioned over the area of the shoulder that experiences the most pain, and it remains in place for a duration of 9 minutes. The patient is subjected to a high-energy high-PEMF with a frequency of 3 pulses per second during the session.
40991289|NCT06000254|OTHER|physiotherapy|Physiotherapy includes a range of activities such as passive and active-assisted shoulder range of motion (ROM) exercises, Pendulum exercises, Codman's exercises, and Cross-body reach exercises. These exercises are conducted under the supervision of a physiotherapist and each training session lasts approximately 30 minutes.
40991290|NCT06000254|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is positioned over the area of the shoulder where maximum pain is experienced, and it remains in place for a duration of 9 minutes. The parameters are consistent with those used in the experimental group. The key distinction lies in the fact that the energy output is not delivered to the patient.
40991291|NCT06372015|OTHER|Nutritional Approach|Nutritional Approach
40991292|NCT06372015|OTHER|Surgery Approach|Bariatric surgery
40991293|NCT03784404|PROCEDURE|Transvaginal aspiration|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
40991294|NCT03784404|PROCEDURE|transvaginal aspiration and surgicel injection|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
41467042|NCT04072315|DRUG|PLN-74809|PLN-74809
41467043|NCT04072315|RADIATION|Knottin tracer|Radiotracer
41467044|NCT00949728|PROCEDURE|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
41467045|NCT03929809|DEVICE|Cochlear Implant|adults with unilateral hearing loss who wish to regain bilateral hearing will be implanted with a cochlear implant on their deafened ear.
41467046|NCT05927142|BIOLOGICAL|Durvalumab|Human anti-PD-L1 antibody
41467047|NCT05927142|DRUG|Rintatolimod|TLR-3 agonist, synthetic double-stranded ribonucleic acid (poly I:C12U)
41147313|NCT04110392|DIETARY_SUPPLEMENT|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
40991295|NCT03784404|DRUG|Intracytoplasmic sperm injection|"Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance."
40991296|NCT02695745|DRUG|V116517 aqueous suspension|300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
40991297|NCT02695745|DRUG|Celecoxib capsules|400 mg (2 capsules of 200 mg each) taken orally x 1 dose
40991298|NCT02695745|DRUG|Placebo|Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
40991299|NCT02695745|DRUG|Capsaicin|1% administered topically
41147314|NCT00440037|BIOLOGICAL|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
41147315|NCT03778788|OTHER|App group|Intervention group the participants will receive a Lifestyle Intervention Program (LIP) with the support of MetS mobile application (MetS app). The MetS app support include app installment and briefing by a research assistant after the educational talk. The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.
41147316|NCT03778788|OTHER|Booklet group|The participants will additionally receive a Hong Kong version LIP booklet to take home and use for 24 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
40991300|NCT03559153|OTHER|Shiatsu massage|The shiatsu massage will be during the rest break by 15 minutes.
40991301|NCT03559153|OTHER|Physical Exercise|The Physical Exercise will be during the rest break by 15 minutes.
41467048|NCT06002178|DIAGNOSTIC_TEST|Neck ultrasound|A neck ultrasound will be performed in order to map superficial arteries and veins of the neck
40787392|NCT06100146|DIETARY_SUPPLEMENT|Folic acid and vitamin B12 fortified flour|Standard bags of fortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. The dose of vitamins will be added to the flour of the intervention group and mixed with batch mixing technique. The concentration of folic acid and vitamin B12 per 1kg of flour will be 2mg and 0.02mg, respectively. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
40787393|NCT06100146|OTHER|Unfortified cereal flour|Standard bags of unfortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
40991302|NCT00257647|OTHER|SV40 vectors carrying siRNA|in vitro only use of gene therapy
40991303|NCT04471389|OTHER|Incidence and risk factors of hypertension|During the follow-up period, General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc). Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness, IMT, FMD) will be collected.
40787394|NCT02370472|OTHER|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
40991304|NCT05397665|DRUG|AT-007|AT-007, aldose reductase inhibitor
40991305|NCT05397665|DRUG|Placebo|Liquid oral suspension
40991306|NCT02032966|PROCEDURE|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
40991307|NCT02032966|PROCEDURE|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
41147317|NCT03778788|OTHER|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 24 weeks.
41147318|NCT04168437|OTHER|Health-Related Quality of Life Report|Two page report and interpretation guide based on SPADE cluster scores
41147319|NCT01250717|DRUG|Docetaxel|Given by an IV infusion over 1 hour on day 2 of a three-week cycle
41147320|NCT01250717|DRUG|Dexamethasone|Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
41467049|NCT01723917|DIETARY_SUPPLEMENT|PhytoSERM tablet|
41467050|NCT01723917|DIETARY_SUPPLEMENT|placebo|
40991308|NCT03350854|BEHAVIORAL|Patient Preference in Treatment Decision Making|The roles are divided into two active roles, a collaborative (or shared) role, and two passive roles in the Patient Preference scale questionnaire. Once the questionnaire is administered, the patient will then proceed to original surgical appointment. The provider is informed of the patient's preferred role and has a discussion with them patient about this in the intervention group, but not in the control group.
40991309|NCT05482009|OTHER|Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment|The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.
40991310|NCT01718652|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
40991311|NCT01718652|DRUG|Cyclosporine|Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
40991312|NCT00227305|DRUG|quetiapine fumarate|Oral dosing, flexible dosing
40991313|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.
40991314|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.
40991315|NCT04368988|OTHER|Normal saline solution (NSS), Placebo - Phase 1|Alternating intramuscular (deltoid) injections of placebo (0.6 mL) on Days 0 and 21.
40991316|NCT04368988|OTHER|Normal saline solution (NSS), Placebo - Phase 2|Intramuscular (deltoid) injections of placebo (0.5 mL).
40991317|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|Intramuscular (deltoid) injection of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Day 0.
40991318|NCT04368988|OTHER|Normal saline solution (NSS), Placebo, Day 21 - Phase 1|Intramuscular injection of placebo (0.6 mL) in alternate deltoid on Day 21.
40991319|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2|Intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL).
40991320|NCT03604042|COMBINATION_PRODUCT|Protein fortifier|Protein Fortifier to be added to Fortified human milk according to feeding regimen
40991321|NCT05024058|DRUG|Ligelizumab|Ligelizumab treated groups and arms
40991322|NCT05024058|OTHER|Placebo|Placebo treated groups and arms
40991323|NCT03454919|DRUG|Palbociclib|"Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance."
40991324|NCT02177279|OTHER|Visit A high wheat bran|
40991325|NCT02177279|OTHER|Visit B normal wheat bran|
40991326|NCT02177279|OTHER|Follow up normal (8days) and high (1day) bran consumption|
40991327|NCT05448651|DRUG|UPB-101|Subcutaneous injection
40991328|NCT05448651|DRUG|Placebo|Subcutaneous injection
40991329|NCT05752110|DRUG|Ketamine|0,5mg/kg single dose Ketamine (0.05ml/kg) intravenously administered
40991330|NCT05752110|OTHER|Saline|0.09% Saline (0.05ml/kg) intravenously administered
40991331|NCT05791045|PROCEDURE|single vs double|we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade
40991332|NCT02205333|BIOLOGICAL|MEDI6469 Monotherapy|single intravenous (IV) administration of MEDI6469
40991333|NCT02205333|BIOLOGICAL|MEDI6469 Plus Tremelimumab|MEDI6469 in combination with Tremelimumab
40991334|NCT02205333|BIOLOGICAL|MEDI6469 Plus Durvalumab|MEDI6469 in combination with Durvalumab
40991335|NCT02205333|BIOLOGICAL|MEDI6469 plus Rituximab|MEDI6469 in combination with Rituximab
40991336|NCT05338892|OTHER|Non-Interventional|No study treatment will be administered on this study.
40991337|NCT05068128|OTHER|Flow MRI|"4 flow acquisitions based on the 2D cine phase contrast sequence (present on all MRI systems) will be performed.~This sequence requires a cardiac synchronization by a plethysmograph put on the patient's finger.~32 cardiac phases are reconstructed per acquisition. The processing of the flow MRIs and the analysis of the flow curves of the LCS and blood during the cardiac cycle will be performed using the Amiens software.~Parameters measured via flow MRI are:~- Cerebral vascular flow, intracranial LCS dynamic volume, extracranial LCS dynamic volume"
40991338|NCT05068128|OTHER|PERFUSION TEST|"The test will be performed will include:~* Inserting a needle into the lumbar space, Ommaya reservoir or valve pre-chamber, as appropriate~* Connect the needle to the pressure transducer via saline filled manometer lines connected via a 3-way valve. The other end of the 3-way connection will be connected to a saline~* Recording of the opening pressure for 10 minutes~* The infusion test is terminated either when the pressure stabilizes again on a new plateau, or when the average pressure exceeds 40 mmHg, or in case of adverse effects or symptoms such as headache, nausea/vomiting or visual disturbances.~* At the end of the test, a depletion of 30 to 50 mL of CSF will be performed.~* The pressure recording during the test is then used to calculate the parameters of the mechanical properties of the CSF circulation and reported to the neurosurgeon ordering the test."
40991339|NCT00491010|PROCEDURE|radiofrequency catheter ablation|
41308372|NCT03578848|DEVICE|uAOBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
40991340|NCT02515045|DRUG|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
41147321|NCT01250717|DRUG|Estramustine|Taken orally three times a day for 5 days for the first part of every three week cycle
41147322|NCT01250717|DRUG|Zoladex|Given subcutaneously for 4 doses every three months
41147323|NCT01250717|DRUG|Casodex|Taken orally once a day for 6 months
41467051|NCT04101695|DEVICE|tDCS|Ybrain tDCS System (Ybrain, Korea) is used for anodal stimulation of cerebellar hemisphere. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on right buccinator muscle.
41467052|NCT05119049|OTHER|Exercise guideline|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
41467053|NCT06143527|BIOLOGICAL|AlloRx|Cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41467054|NCT02419625|BEHAVIORAL|questionnaires|questionnaires , serum samples will be used
41467055|NCT06146855|PROCEDURE|Tunneling procedure with Amnion Membrane|Root Coverage by tunneling procedure with the addition of Amnion Membrane as a soft tissue substitute
41467056|NCT06146855|PROCEDURE|Tunneling procedure with De-epithelialized Free Gingival Graft|Root Coverage by tunneling procedure with the addition of De-epithelialized Free Gingival Graft
41467057|NCT00546910|DRUG|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
41467058|NCT00546910|DRUG|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
41467059|NCT05335850|BEHAVIORAL|Isha Kriya|Isha Kriya is a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily.
41467060|NCT05335850|BEHAVIORAL|Nadi Shuddhi|Nadi Shuddhi is a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.
41467061|NCT05335850|BEHAVIORAL|Nada Yoga|Nada Yoga is a 6-minute meditation that uses sound to create balance and stability in the body and mind.
41467062|NCT05335850|OTHER|Routine Daily Activity|"Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.~Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm."
41467063|NCT04359537|DRUG|Hydroxychloroquine Sulfate 200 MG|Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described
41467064|NCT04359537|OTHER|Placebo|Control group will receive a Placebo tablet. Placebo 200mg will be given on Day 1 followed by Placebo 200mg every three weeks.
41467065|NCT00317434|DRUG|lapatinib|
41467066|NCT04826289|RADIATION|X rays|Radiological assessment of vertical distance between medial and lateral malleolus in normal opulation
41467067|NCT05247268|DRUG|Megestrol Acetate 160 MG Oral Tablet|At a dosage of 160 mg/day
41467068|NCT05247268|DRUG|Medroxyprogesterone Acetate 500 MG|At a dosage of 500 mg/day
41467069|NCT05247268|DRUG|Triprorelin Acetate|Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses
41467070|NCT05247268|DRUG|Letrozole 2.5mg|At a dosage of 2.5mg/day and no more than 24 weeks
41467071|NCT03676647|OTHER|Diagnostic DNA Methylation Signature|Undergo collection of tissue samples
41467072|NCT00332943|PROCEDURE|MR colonography with fecal tagging|
41467073|NCT00559741|BIOLOGICAL|cetuximab|
41467074|NCT00559741|DRUG|fluorouracil|
41467075|NCT00559741|DRUG|irinotecan hydrochloride|
40991341|NCT02515045|DRUG|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
41467076|NCT00559741|DRUG|leucovorin calcium|
40787395|NCT04763434|DRUG|dexamethasone; dexmedetomidine; ropivacaine|Ultrasound-guided multilevelTPVB is performed at the end of lobectomy
41467077|NCT00559741|OTHER|pharmacological study|
41467078|NCT05867524|OTHER|Oral Glucose Tolerance Test|75g oral glucose tolerance test, sampled over three hours
40787396|NCT05522283|DIAGNOSTIC_TEST|Stool and blood CMV PCR|Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.
40991342|NCT02515045|DRUG|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
40991343|NCT02515045|DRUG|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
40991344|NCT00230464|DRUG|LAF 237|
41467079|NCT05867524|OTHER|Cycling test|2 hours of moderate activity level cycling
41467080|NCT05317195|OTHER|NP-1|NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
41467081|NCT05317195|OTHER|NP-2|NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
41467082|NCT05317195|OTHER|NP-3|NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
41467083|NCT05317195|OTHER|NP-4|NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
41467084|NCT05317195|OTHER|Velo-NP|Velo-NP; 10 mg nicotine;
41467085|NCT05317195|OTHER|Zyn-NP|Zyn-NP; 3 mg nicotine;
41467086|NCT04212728|BIOLOGICAL|Auotologous AMSCs plus autologous PRP|150 mL subcutaneous abdominal adipose tissue will be harvested via liposuction . AMSCs will be isolated and cultured from adipose tissue. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.Cultured AMSCs will be collected and suspended by 3ml autologous PRP.
41467087|NCT04212728|BIOLOGICAL|Auotologous PRP|30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
41488603|NCT05970419|OTHER|conventional treatment|"Superficial heat (hot packs). Will be applied 10 - 15 minutes. Guideline-endorsed treatment is to stay active, return to normal activity, and to exercise. Different exercise types are used in the treatment of CLBP such as strength and aerobic training on land as well as specific exercises such as motor control exercises (MCE).~General exercises activating the extensor (paraspinals) and flexor (abdominals) muscle groups will be used."
41488604|NCT05970419|OTHER|Sham laser|sham laser (Not active)
41488605|NCT04665375|DRUG|DOR/3TC/TDF|switch antiretroviral regimen to doravirine/lamivudine/tenofovir disoproxil fumarate once daily for 1 year
40991345|NCT04364308|OTHER|Fetal Echography|Fetal ultrasound and its parameters
40991346|NCT00561756|BIOLOGICAL|plasmid DNA vaccine therapy|
40991347|NCT00561756|OTHER|flow cytometry|
40991348|NCT00561756|OTHER|immunoenzyme technique|
40991349|NCT01974375|DRUG|micafungin|Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing \<40 kg)
40991350|NCT01974375|DRUG|Fluconazole|Fluconazole 100\~200mg/day, IV care until oral medication becomes possible
40991351|NCT03056391|DRUG|Paracetamol|"\>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
40991352|NCT05155007|DRUG|Rilematovir|Rilematovir will be administered orally as per assigned treatment sequence.
40991353|NCT05155007|DRUG|Ciclosporin|Ciclosporin will be administered orally as per assigned treatment sequence.
40991354|NCT03853447|DIAGNOSTIC_TEST|Diagnostic imaging|MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS
40991355|NCT00001960|DEVICE|Pacemaker therapy|
41147324|NCT01250717|PROCEDURE|Radical Prostatectomy|after the chemo and hormonal therapy all patients have a radiacal prostatectomy
41147325|NCT04887597|DRUG|Secukinumab|The study is composed of a single arm receiving secukinumab for the duration of 6 months.
40991358|NCT06186765|DEVICE|Axonics SNM System (Model 4101)|Safety and performance/effectiveness assessment of the recharge free Axonics SNM System (Model 4101 in participants with overactive bladder (OAB) or fecal incontinence (FI).
40991359|NCT05422599|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
40991360|NCT05422599|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
40991361|NCT01695694|BEHAVIORAL|supporting positive and healthy relationships|
40991362|NCT01695694|BEHAVIORAL|community support group|
41147326|NCT00883272|DIETARY_SUPPLEMENT|DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]|a unique enzymatic isolate of the active complex in Tofu
40991363|NCT02011347|DRUG|Ketamine|
40991364|NCT02011347|DRUG|Placebo|
40991365|NCT02628795|BEHAVIORAL|PRT + FM|Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
40991366|NCT02628795|OTHER|Usual Care|Post-surgical usual care activities including any prescribed physical therapy
40991367|NCT04421911|DRUG|Ketoprofen topical|Ketoprofen topical for 21days
40991368|NCT04421911|DRUG|Diclofenac Topical|Diclofenac topical for 21days
40991369|NCT00720057|DRUG|Naproxen Sodium ER (BAYH6689)|Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
40991370|NCT00720057|DRUG|Placebo|Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
40787397|NCT03513315|BEHAVIORAL|Implementation of Community-based Home Heat Bundle|This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
41147327|NCT04614688|BEHAVIORAL|Patient Education Platform|The patient education platform for hysteroscopy surgery is a website platform which has patient education materials regarding hysteroscopy procedures in the format of pictures, videos, and text. Information on this platform includes anatomy of the surgery area, what to expect, reasons for the surgery, ways to prepare for the surgery, and recovering from the surgery.
41147328|NCT02326194|BIOLOGICAL|Low dose Ebola Zaire vaccine (Ad5-EBOV)|one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
40991371|NCT01785979|DRUG|prednisone induction - chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
40991372|NCT01785979|DRUG|Chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
40991373|NCT03626220|PROCEDURE|acupuncture|manually manipulate acupuncture at CV6 and three acupoints on each arms and legs
40991374|NCT01154621|DRUG|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
40991375|NCT01154621|DRUG|Placebo|Sterile 5% dextrose solution
40991376|NCT03051321|DEVICE|Wellness toilet system|Water-based toileting with capacity to apply zinc oxide barrier spray to treat incontinence associated dermatitis
40991377|NCT04564456|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test oproduct in one study period
40991378|NCT04564456|DRUG|ADVAIR DISKUS® 500/50|2 inhalations Reference product in one study period
41147329|NCT02326194|BIOLOGICAL|High dose Ebola Zaire vaccine (Ad5-EBOV)|two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
41147330|NCT02326194|BIOLOGICAL|placebo (one dose)|placebo, one doses
41147331|NCT02326194|BIOLOGICAL|placebo (two doses)|placebo, two doses, with one dose to each arm at a same time.
41147332|NCT04565873|DIAGNOSTIC_TEST|TSH|retrospective TSH level
41147333|NCT03616314|DEVICE|stepping verticalization plus functional electrical stimulation|patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles
41147334|NCT03616314|DEVICE|stepping verticalization|patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
40991379|NCT00949325|DRUG|temsirolimus plus liposomal doxorubicin|Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
40991380|NCT05464459|PROCEDURE|Novel elbow procedure|A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.
41467088|NCT05386095|PROCEDURE|0.25%Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with the linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle .The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.25% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
41488606|NCT05256134|DRUG|Gantenerumab|Gantenerumab will be administered as per the dosing schedule described in the Arm description.
40991381|NCT00159055|BIOLOGICAL|CMV vaccine|
40991382|NCT01650038|OTHER|treatment with faecal transplantation (donor faeces)|faecal transplantation
40991383|NCT01650038|OTHER|treatment with faecal transplantation (own faeces)|faecal transplantation
40991384|NCT01285245|DRUG|kineret|once daily 100 mg of kineret subcutaneously for 8 days
40991385|NCT06523504|DEVICE|DIMS|wear DIMS ,and use placebo,once nightly, both eye
41488607|NCT05256134|DRUG|Placebo|Placebo will be administered as per the dosing schedule described in the Arm description.
40991386|NCT06523504|DRUG|The 0.02% ATP Group|wear SP, and use 0.02%ATP eye drops, once nightly, both eye
40991387|NCT06523504|DRUG|The 0.04% ATP Group|wear SP, and use 0.04%ATP eye drops, once nightly, both eye
40991388|NCT06523504|COMBINATION_PRODUCT|0.02%ATP+DIMS|wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye
40991389|NCT06523504|COMBINATION_PRODUCT|0.04%ATP+DIMS|wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye
40991390|NCT04361981|OTHER|Deep Venous Disease Diagnostic|Clinical and/or echographic diagnosis of Deep Venous Disease in a patient with COVID-19 infection
40991391|NCT06063395|PROCEDURE|open surgery on the abdominal aorta by laparotomy|Laparotomy aortic surgery for the management of an abdominal aortic aneurysm has several distinct stages which will not be altered by the performance of this study. The patient arrives in the operating room and is taken care of by the anesthetic team. The patient is then placed in the correct position for optimal surgical management and a skin cleansing procedure is carried out. A sterile drape is applied and the preoperative checklist in force in the establishment is completed. Initial dissection of the aneurysm and its proximal and distal control is left to the discretion of the principal surgeon. Once the aortic aneurysm has been controlled, the main surgeon places self-static retractors and then prepares to clamp the aorta. The surgeon initiates aortic clamping to create the aorto-biliac or bifemoral bypass. Once the bypass has been created, the operation is completed by closing the surgical approach and the skin incision. The bandage is then applied.
40991392|NCT00982475|PROCEDURE|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
40991393|NCT02261714|BIOLOGICAL|TG01|"TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
40991394|NCT02261714|BIOLOGICAL|TG01|"For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
40991395|NCT05755009|RADIATION|High- and Low-dose radiotherapy|High- and Low-dose radiotherapy combined with immunotherapy and maintain immunotherapy. Immunotherapy (Envafolimab) once every week (maintain a total of two years). Continuous high-(8Gy×5F) and low-dose (1.33Gy×5F) Radiotherapy starts at the second week after immunotherapy.
40991396|NCT05275647|DRUG|BOTOX 100U in normal saline|LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
40991397|NCT05275647|DRUG|Normal saline|LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
41467089|NCT05386095|PROCEDURE|0.19% Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle.The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.19% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
41467090|NCT03882073|PROCEDURE|Modified amputation procedure|A fishmouth incision will be made. Radial and ulnar (BEA) or humoral (AEA) osteotomies will be performed. Segments of the flexor carpi radialis (FCR), extensor carpi radialis longus (ECRL), flexor digitorum profundi (FDP), extensor digitorum communis (EDC), flexor pollicis longus (FPL) and extensor pollicis longus (EPL) will be isolated, as well as the biceps (B) and triceps (T) groups in the AEA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. Sensory nerve endings of the distal median, ulnar and radial nerves will then be isolated and redirected to discrete skin patches in the proximal residual forearm or proximal brachium. Coaptation of the FCR/ECRL, FDP/EDC, FPL/EPL and B/T muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
40991398|NCT03788096|BEHAVIORAL|Peer Support with Motivational Interviewing|Mentors will trained in motivational interviewing and will conduct weekly telephone calls with participants randomized to the PS-PICS peer support intervention arm.
40991399|NCT03788096|BEHAVIORAL|Usual Care Group|Usual care.
41467091|NCT03882073|PROCEDURE|Standard amputation procedure|Amputation is performed via standard techniques at either the BEA or AEA level. No construction of agonist-antagonist muscle pairs will be performed.
41467092|NCT00828022|BIOLOGICAL|attenuated measles vaccine|4-week apart, two vaccines starting 4 weeks after last chemotherapy
41467093|NCT02292511|BEHAVIORAL|Square-stepping exercise|In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
41467094|NCT00074750|DRUG|DTGM|Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
41467095|NCT01806610|DRUG|BPS804|Single dose BPS804 administration.
41467096|NCT01806610|DRUG|Placebo|Single dose placebo administration.
41467097|NCT03310619|BIOLOGICAL|JCAR017|Gene modified autologous T cells
41467098|NCT03310619|DRUG|Durvalumab|Anti-PD-L1
41467099|NCT03310619|DRUG|CC-122|Pleiotropic Pathway Modifier
41467100|NCT03310619|DRUG|Ibrutinib|Ibrutinib
41467101|NCT03310619|DRUG|CC-220|CC-220
41467102|NCT03310619|DRUG|Relatlimab|Relatlimab
41467103|NCT03310619|DRUG|Nivolumab|Nivolumab
41467104|NCT03310619|DRUG|CC-99282|CC-99282
41467105|NCT05013619|OTHER|Circumstances of pain|It will be questioned in which situations the pain occurred in the previous week (at rest from spasms, at rest from splints, on feeding, on moving, on dressing, at night, on exercise, on other treatments, on botulinum toxin application) and record as yes/no.
41467106|NCT05013619|OTHER|Pain Questionnaire|"Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain."
41488608|NCT03435718|DRUG|Oxfendazole|oral suspension
41488609|NCT03435718|DRUG|Albendazole|tablet
41488610|NCT04341649|OTHER|Manual Head Massage|Duration 10 minutes.
40991400|NCT05634460|DRUG|potassium hydroxide|Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC.
40991401|NCT04611763|DRUG|Flurbiprofen axetil preoperatively|give Flurbiprofen axetil 15 min before surgery
40991402|NCT04611763|DRUG|Flurbiprofen axetil postoperatively|give Flurbiprofen axetil at the end of surgery
40787398|NCT03513315|BEHAVIORAL|Regular Community Healthcare provision|The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
40991403|NCT02295033|RADIATION|Boost irradiation|
40991404|NCT03200496|DRUG|DA-5206(Fasting)|Test drug l : DA-5206(Fasting)
40991405|NCT03200496|DRUG|DA-5206(Fed)|Test drug ll : DA-5206(Fed)
40991406|NCT03200496|DRUG|TALION®|Reference drug : Talion®
40991407|NCT00006028|DRUG|cisplatin|
40991408|NCT00006028|DRUG|gemcitabine hydrochloride|
40991409|NCT04665921|DRUG|SGN-STNV|Given into the vein (IV; intravenously)
40991410|NCT02289976|PROCEDURE|core decompression|Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
40991411|NCT05947682|OTHER|Adipose tissue harvesting|Adipose tissue harvesting (40-60g) during the abdominal liposuction or lipoaspiration under general anaesthesia which is performed according to usual care
40991412|NCT06082323|DRUG|LT-002-158/Placebo oral tablet(s)|Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
40991413|NCT04923503|BEHAVIORAL|diurnal fasting|subject conduct fasting in Ramadan for 30 days
41147335|NCT03616314|OTHER|conventional physiotherapy|patients are treated only with 60 minutes/day of conventional physiotherapy
40991414|NCT05780333|PROCEDURE|TAP block|Bilateral tap block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
40991415|NCT05780333|PROCEDURE|ESP block|Bilateral esp block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
40991416|NCT03451149|DEVICE|Radiofrequency wire (Powerwire)|Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.
40991417|NCT00366600|DRUG|neratinib|HKI-272
40991418|NCT00919776|DRUG|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
40991419|NCT00919776|DRUG|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
40991420|NCT05957796|DEVICE|"Novel Snaps Eye Shield"|"Using a novel eye shield, Snaps manufactured in Morgantown, WV by Intermed Labs after cataract surgery that has a different adhesive mechanism that utilizes adhesive and snap-on attachments to the shield."
40991421|NCT05957796|OTHER|Standard Alcon Eye Shield|Use normal Alcon eye shield with tape to adhere to shield to eye postop.
40991422|NCT04476979|DRUG|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3
40991423|NCT04476979|DRUG|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
40991424|NCT04390477|DIETARY_SUPPLEMENT|Probiotic|Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.
40991425|NCT02751515|OTHER|Bain De Soliel - Solid|0.05gm/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
40991426|NCT02751515|OTHER|Untreated skin|One site is patched without treatment as control
41147336|NCT00840788|PROCEDURE|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
41147337|NCT00840788|PROCEDURE|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
40991427|NCT04823637|DIAGNOSTIC_TEST|Ultrasonography vs Osteopathic manipulative medicine structural exam|Structural examination of the thoracic spine using ultrasound and osteopathic palpatory examination on skin.
40991428|NCT00374296|DRUG|MGCD0103|MGCD0103 administered orally three-times per week
40991429|NCT05693714|DIAGNOSTIC_TEST|Pcr|Polymerase chain reaction
40991430|NCT02018458|BIOLOGICAL|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
40991431|NCT02018458|BIOLOGICAL|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
40991432|NCT01455012|DRUG|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
40787399|NCT06073197|PROCEDURE|erector spinae plane block|Erector spinae plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block. Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
40991433|NCT01455012|DRUG|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
41147338|NCT05038319|PROCEDURE|EUS|The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.
41147339|NCT02412345|PROCEDURE|Extracorporeal shockwave therapy|
41147340|NCT02412345|PROCEDURE|Extracorporeal shockwave therapy - sham treatment|A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.
41147341|NCT02412345|OTHER|Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil|Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
41488611|NCT04341649|DEVICE|BREO Helmet Massager|Duration 10 minutes.
41488612|NCT04341649|DEVICE|Low Laser Therapy (LLT)|Duration 7 minutes.
40991434|NCT06406673|DRUG|Cadonilimab+EC/ET+RT|Cohort_1 patients with no history of previous systemic treatment for ES-SCLC received cadonilimab with EC/EP for two cycles (induction phase), then, those who did not progress received concurrent palliative RT and two cycles of cadonilimab with EC/EP (combination phase). Afterward they received cadonilimab every 3 weeks for a maximum of 2 years after study enrolment (maintenance phase).
40991435|NCT06406673|DRUG|Cadonilimab+vorolanib|Cohort_2 patients with recurrent SCLC and after at most one systemic treatment received cadonilimab plus vorolanib, until disease progression or unacceptable toxicity.
40991436|NCT03683758|OTHER|FIFA11+|"The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential."
40991437|NCT03683758|OTHER|'Usual' Soccer Warm-up|"This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement."
40991438|NCT01866514|PROCEDURE|proximal humerus intraosseous vascular access|The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.
40991439|NCT01866514|DRUG|2% preservative-free lidocaine|
40991440|NCT01866514|DEVICE|EZ-IO|
40991441|NCT04132960|DRUG|DS-8201a|Anti-HER2-antibody drug conjugate (ADC)
41467107|NCT05013619|OTHER|Gross Motor Functional Classification System|Severity of CP will be determined based on the Gross Motor Functional Classification System (GMFCS). GMFCS is a standardised measure that classifies gross motor functions in children with CP. Children in level I are very independent in motor functions while those in level V are the least independent
40787400|NCT06073197|PROCEDURE|combined deep and superficial serratus anterior plane block|Combined deep and superficial serratus anterior plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
41147342|NCT04240418|OTHER|Survey|The objective is to evaluate the eligibility of the responders, as defined by NELSON criteria and PLCOm2012 scoring, and their willingness to participate to a lung-cancer screening with low-dose computed tomography.
40787401|NCT00889707|DRUG|PRX302|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
40787402|NCT00889707|DRUG|Placebo|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
40787403|NCT06110559|DEVICE|Active transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received 1.5 mA stimulation for 30 minutes."
40823056|NCT00123578|DRUG|Lorazepam|Lorazepam
40991442|NCT04945629|DRUG|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
40991443|NCT04945629|DRUG|Blood clot and simple suture|Filling the alveolus with blood clot
41147343|NCT00353106|BEHAVIORAL|Interview|30-minute interviews of participating patients and their caregiver(s).
41147344|NCT00353106|BEHAVIORAL|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
41467108|NCT05013619|OTHER|The subtypes of Cerebral palsy|The subtypes of CP will be classified, using the Swedish classification, into spastic (tetraplegia, diplegia and hemiplegia), ataxic, dyskinetic and mixed
40823057|NCT00123578|DRUG|Pentobarbital|Pentobarbital
41147345|NCT01755130|PROCEDURE|Photoacoustic Imaging|Undergo LOUISA 3D
41147346|NCT05540951|DRUG|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
41147347|NCT05540951|DRUG|Bevacizumab Plus Chemotherapy|Bevacizumab Plus Doublet or Triplet Chemotherapy
41467109|NCT03223909|DRUG|PRO-087|0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
41467110|NCT03223909|DRUG|Systane Ultra|Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
41467111|NCT03223909|DRUG|Systane Ultra Preservative Free|Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
41467112|NCT02856087|DRUG|High dose Remifentanil|remifentanil infusion at 4ng/ml of Ce
40823058|NCT02609230|DRUG|ONC-201|
41467113|NCT02856087|DRUG|Naloxone|naloxone infusion
41467114|NCT02856087|DRUG|Low dose remifentanil|remifentanil infusion at 1ng/ml of Ce
40823059|NCT01384331|DRUG|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
40991444|NCT03608579|DRUG|Autologous Adipose Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
40991445|NCT04136392|DEVICE|ABIOMED, Inc. hemodynamic support devices|ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market. They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
40991446|NCT03613935|OTHER|Product 1|Comparison with products 2, 3, and 4
40991447|NCT03613935|OTHER|Product 2|Comparison with products 1, 3, and 4
40991448|NCT03613935|OTHER|Product 3|Comparison with products 1, 2, and 4
40991449|NCT03613935|OTHER|Product 4|Comparison with products 1, 2, and 3
40991450|NCT00045279|BIOLOGICAL|PEG-interferon alfa-2b|
41147348|NCT03463122|DEVICE|field of regard-focused visual exploration therapy|field of regard-focused visual exploration therapy in addition to conventional therapy
41147349|NCT03463122|OTHER|conventional therapy|conventional therapy for stroke rehabilitation
40787404|NCT06110559|DEVICE|Sham transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received effective stimulation of 1.5 mA for 30 seconds, after which the current was switched off. The entire session lasted 30 minutes, with 29 minutes and 30 seconds without stimulation."
40787405|NCT03226847|PROCEDURE|Pulmonary Vein Isolation|Standard antral pulmonary vein isolation using radiofrequency ablation catheters
40991451|NCT02158390|BEHAVIORAL|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
40991452|NCT02044133|OTHER|Dosage Vitamine D|
40787406|NCT03423433|BEHAVIORAL|Heel raise intervention|A daily heel-raise programme for ten weeks to determine any chronic effects of heel raises on the previously mentioned variables.
40991453|NCT02657707|DEVICE|Roadsaver™ Carotid Artery Stent Device|The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
40991454|NCT02657707|DEVICE|Nanoparasol® Embolic Protection System|The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
40991455|NCT04052984|PROCEDURE|Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section|Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
40991456|NCT03013439|DRUG|Iron Isomaltoside|The trial is a dose escalating trial.
41147350|NCT05053035|DRUG|AL001|Administered via intravenous (IV) infusion
41147351|NCT05053035|DRUG|Placebo|Administered via intravenous (IV) infusion
41147352|NCT02391389|PROCEDURE|CPAP or PPV during DCC|CPAP or PPV is provided during delayed cord clamping
41147353|NCT00242086|PROCEDURE|CT, PET and MRI|
40787407|NCT02213068|DRUG|belatacept|Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
40787408|NCT02213068|DRUG|Tacrolimus|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
40787409|NCT02213068|DRUG|MPA|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
41147354|NCT05881213|DRUG|CKD-378 (low-dose)|Quaque day (QD), PO
41147355|NCT04018521|BEHAVIORAL|PPN|Delivery of Coordinated Specialty Care (CSC) for Y/YA in New York's state program for FEP, called OnTrackNY (OTNY).
40991459|NCT05217251|OTHER|frontal alpha asymmetry in EEG|frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor. The power spectra will be log-transformed and averaged across the frontal left (FL) channels (FP1, F3, F7) and frontal right (FR) channels (FP2, F4, F8). A higher power spectrum value indicates lower neural activity. Frontal asymmetry (FA) power scores are calculated as follows, FA = (FR-FL)/(FR+FL). A positive FA value shows greater neural activity in the left frontal lobe than right frontal neural activity (relative left frontal asymmetry), while its negative value shows oppositely.
40991460|NCT00991055|DRUG|Pioglitazone|"A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)"
40991461|NCT01054781|DRUG|Rituximab|1st cycle R+R-CHOP 2-8th cycle R-CHOP
40991462|NCT02563795|DRUG|Bupivacaine|To compare low dose spinal anesthesia with bupivacaine alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
40991463|NCT02563795|DRUG|Fentanyl|To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
41147356|NCT04018521|BEHAVIORAL|CSC Usual Care|standard of care provided to youth following first episode of psychosis
41147357|NCT04531007|DIAGNOSTIC_TEST|iFR/ FFR/ IVUS/ OCT|intermediate lesion evaluation with intracoronary physiology and imaging
41147358|NCT05793489|OTHER|Silibinin|"WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.~Total dose and fractionation of WBRT: 30 Gy in 10 fractions."
41147359|NCT03060356|BIOLOGICAL|T cells modified with RNA anti -cMET CAR|Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains
41147360|NCT01764204|DRUG|Qingkailing Injection|Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
41147361|NCT02197494|DRUG|Valsartan|320mg tablets
41147362|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
41147363|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
40991464|NCT03137693|OTHER|Standard of Care Schedule Variation: SABR|SABR will be delivered over 3 days, prior to surgery.
40991465|NCT03137693|PROCEDURE|Breast-conserving Surgery|Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
41467115|NCT02856087|DRUG|Normal Saline|normal saline infusion
41467116|NCT06616363|BEHAVIORAL|Questionnaires to be competed|"* The Pain Coping Questionnaire short form~* Functional Disability Inventory (FDI), the primary clinical outcome measure.~* COMPASS-31 and orthostatic hypotension modified for POTS.~* The Pain Response Inventory (PRI)PROMIS Depression~* GAD-7 for anxiety~* Varni/Thompson Pediatric Pain Questionnaire~* Child and Parent Reports of Post-Traumatic Symptoms (CROPS/PROPS)~* Pain Catastrophizing Scale (PCS-C)~* Detailed account of natural history and evolution of POTS and COPCs through MEDYSA (facilitates the assessment of specific syndromic diagnoses based on published criteria, rather than organ-based classification of symptoms)"
41467117|NCT06616363|BEHAVIORAL|Provide list of medication and lifetime events|Participants will provide a list of all medications taken at each visit time, lifetime history of infections, traumas, and other significant life events.
41467118|NCT06616363|BEHAVIORAL|Use phone App to record new life events|Subjects will also record new life events, minor traumas, entrance into a flare and menses in Ilumivu's EMA (Ecological Momentary Assessment) phone App
41467119|NCT06616363|DEVICE|Will wear an activity monitor|Participants will have an activity monitor loaned for the duration of the study to track their physical activity.
41467120|NCT06616363|OTHER|Periodic 24-hour urine sodium check|POTS patients will have a periodic 24-hour urine sodium check to determine compliance to intake of salt.
40991466|NCT00368056|DRUG|Eszopiclone|eszopiclone 3 mg
40991467|NCT00368056|DRUG|Placebo|Placebo tablet
40991468|NCT03745937|DRUG|MEDI0382|Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.
40991469|NCT03745937|DRUG|Placebo|Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
40991470|NCT05571605|BEHAVIORAL|Exercise|Participants randomized to this arm will exercise on a stationary bicycle.
40991471|NCT05571605|BEHAVIORAL|Stretching|Participants randomized to this arm will perform stretching and balance exercise.
40991472|NCT01356654|DEVICE|Application of Transcranial direct current stimulation (TDCS)|Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
40991473|NCT01356654|DEVICE|Transcranial Direct current stimulation|Application of true TDCS for 20min, 4 times a week for 4 weeks.
40991474|NCT04804397|DIETARY_SUPPLEMENT|Sucrose|Sucrose sweetened soft drinks
40991475|NCT06167993|BEHAVIORAL|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy; It consists of manual therapy, skin care, compression therapy and therapeutic exercise.
40991476|NCT01996709|DEVICE|Hydrogen peroxide-based contact lens solution|
40991477|NCT01996709|DEVICE|Habitual contact lens solution|Biguanide-preserved
40991478|NCT01996709|DEVICE|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
41467121|NCT06616363|DIAGNOSTIC_TEST|A fMRI scan|• Participants will complete a fMRI scan without contrast and complete a looming animacy threat task; participants judge the valence of images via button press as they perceive the image.
41467122|NCT06616363|DIAGNOSTIC_TEST|A bedside tilt test will be performed|A bedside tilt test will be performed where blood pressure will be recorded supine and upright positions to confirm/exclude POTS.
40991479|NCT01540656|DEVICE|Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)|"A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
40991480|NCT02287064|DRUG|Intravenous Immune Globulin (IVIG)|"IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.~There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion"
40991481|NCT05422677|DRUG|Hanmi Tams® Capsule|Hanmi Tams®, Once daily administered per the locally approved product information
40991482|NCT00188513|PROCEDURE|conformal intensity modulated radiotherapy (IMRT)|
40991483|NCT01834287|BEHAVIORAL|Physical Activity Intervention|Participants in the Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
40991484|NCT01834287|BEHAVIORAL|Wellness Control|Participants will receive a Spanish language, Internet-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
41147364|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
41467123|NCT06616363|OTHER|IV placed to collect blood samples|• An IV will be place for collection of 4 blood samples, about 12 mL of blood. For each position (lying and standing) the study team will draw 2 tubes each times with 3 mL of blood, for a total of 4 lab tubes (12 mL). Physical exams to assess the 18-tender points described by the American College of Rheumatology for the diagnosis of fibromyalgia and hypermobility/Ehlers-Danlos Syndrome (EDS) exam will be performed in all subjects.
40787412|NCT06475768|DIAGNOSTIC_TEST|Stress Echocardiogram|Exercise testing via treadmill with simultaneous gas exchange analysis and pre- and post-exercise transthoracic echocardiography.
41147365|NCT02556606|DRUG|Midazolam|single 40 min infusion of MID 0.03mg/Kg
41147366|NCT06247267|DRUG|Fortesta|Primary/secondary untreated hypogonadism patients receive Fortesta injection, gel and transdermal treatment for 12 months with titration for a serum total T level between 300-600ng/dL.
41147367|NCT06247267|DRUG|Estradiol|Male-to-female (MTF) receive Estradiol orally and transdermal and/or spironolactone-orally) treatment for 12 months for hormonal transition period.
40787413|NCT06475768|DIAGNOSTIC_TEST|Cardiovascular Magnetic Imaging (cMRI)|Non-invasive imaging scan used to examine function and structure of the heart
40787414|NCT06475768|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Elastography (cMRE)|Non-invasive imaging scan used to measure myocardial stiffness
40787415|NCT06170788|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion
40787416|NCT06170788|BIOLOGICAL|Pembrolizumab|IV infusion
40787417|NCT00766116|DRUG|5-Azacitidine|Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.
40787418|NCT00766116|DRUG|Gemtuzumab ozogamicin|Mylotarg given 2 times over 2 weeks
40991485|NCT04754347|DEVICE|Computer Aided Detection device|The Computer Aided Detection device, Skout, is designed to help endoscopists detect potential colorectal polyps during colonoscopies. The system performs automated real-time analysis on endoscopic video data to identify potential polyps and produces an informational visual aid around the appropriate sections of the video frames on a display monitor.
40991486|NCT00188019|PROCEDURE|diagnosis methods|
41147368|NCT06247267|DRUG|Fortesta|Female-to-male (FTM) receive Fortesta injection, gel and transdermal treatment for 12 months for hormonal transition period.
41147369|NCT03225092|BIOLOGICAL|Ultrasound-guided platelet rich plasma injection|Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
40991487|NCT00004078|DRUG|irinotecan hydrochloride|Given IV
40991488|NCT00345137|DRUG|Ng-monomethyl-L-arginine (drug)|
40991489|NCT00017303|DRUG|carboplatin|
40991490|NCT00017303|DRUG|oglufanide disodium|
40991491|NCT00017303|DRUG|paclitaxel|
40991492|NCT00017303|PROCEDURE|conventional surgery|
40991493|NCT01799616|DRUG|Pamidronate|
40991494|NCT01799616|OTHER|Placebo|
40991495|NCT01648855|OTHER|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
40991496|NCT05405920|BEHAVIORAL|Team-based Care Strategy for Hypertension Control|The core component of the intervention is a stepped-care protocol, based on the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include task sharing and shifting, health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence.
40991497|NCT05405920|BEHAVIORAL|Enhanced Usual Care|We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics.
40991498|NCT02034461|DEVICE|Utah Slanted Electrode Array|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations or peripheral nerve trauma.
40991499|NCT05967455|BIOLOGICAL|Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
40991500|NCT05967455|BIOLOGICAL|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489
40991501|NCT00099554|DRUG|Etanercept|
40991502|NCT04120974|BEHAVIORAL|Optimal insulin injection|subjects receive training in optimal injection technique.
40991503|NCT03742609|OTHER|ii) the reminder|Participants assigned to the prompt group were received instruction to use their hearing aid box as a physical prompt to remind participants to use their hearing aid(s)
41147370|NCT00475969|DRUG|duloxetine|
41147371|NCT00475969|DRUG|placebo|
41467124|NCT06616363|OTHER|Stool Sample|• Participants will provide a stool biospecimen sample at each in-person visit. Stool will be collected in a hat and sample will be swabbed with the swab placed directly into PrimeStore collection tube and the remainder of the sample discarded
41467125|NCT00350987|BEHAVIORAL|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
41488613|NCT04341649|DEVICE|Sham LLT|Duration 7 minutes.
40991504|NCT03742609|OTHER|ii) written behavioural plan|Participants assigned to this group were received instruction to create at least one written plan for hearing aid use. Specifically, participants were asked to plan where and when to use their hearing aid(s).
40991505|NCT03742609|OTHER|iv) all materials|i) provision of written information regarding consequences of using a hearing aid and not using a hearing aid, ii) the provision of a physical prompt for the purpose of prompting or cueing the behavior (hearing aid use) development, and iii) creation of a written behavioural plan for hearing aid use.
40991506|NCT02382458|BEHAVIORAL|Newsletters on cancer prevention and control|E-mailed or mailed newsletters that provide information on how to prevent cancer
40991507|NCT02382458|BEHAVIORAL|Behavioral program to reduce inflammation|Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
41147372|NCT02205476|DRUG|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
41147373|NCT02205476|DRUG|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
41147374|NCT02100189|OTHER|Cytology Specimen Collection Procedure|Undergo esophageal cytology collection
41488614|NCT04341649|DEVICE|TENS ear stimulation|Duration 7 minutes.
40787419|NCT00784368|DRUG|ITCZ Oral Solution|ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
40787420|NCT00784368|DRUG|ITCZ-IV|200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
40787421|NCT06581250|BEHAVIORAL|Reminder Messages|Dental clinic staff will use scripts to contact patients 24 and 48 hours before appointments. These scripts will guide staff in confirming the patient will appear for their appointment.
40991508|NCT03144882|DRUG|Curcumin Pill|Turmeric rhizome at first was washed and dried out in a warm and dry place for a week , then powdered rhizomes were encapsulated by Clinical Pharmacy Research Center of Shahid Beheshti University of Medical Sciences, using hard gelatin capsules. Also placebo capsules were made by the same center using Sorbitol. Curcumin level of turmeric was measured by HPTLC analysis for quantification of variability in content of curcumin
41308373|NCT03578848|DEVICE|Home BP|As for the home BP measurements, a validated device (WatchBP Home; Microlife AG, Widnau, Switzerland) will be provided for all subjects allocated to the home BP arm to measure their BP at home. Subjects are requested to take BP in the morning (within 2 hours after awakening) and afternoon before meals for 7 consecutive days before the scheduled clinical visits. BP in the first day of the measurements will be discarded and an average of home BP (all BP reading and BP in the morning and in the afternoon) will be generated and provided for clinicians to guide their treatment.
41308374|NCT03578848|DEVICE|CBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
40787422|NCT06581250|BEHAVIORAL|Walk-in Visits|When contacting patients to schedule an appointment (by phone, email, text, or other methods), dental clinic staff will notify patients of times during which patients can walk-in for a dental visit, if convenient for them; otherwise, a regular appointment will be arranged. Scheduled appointments will continue to be available in addition to the walk-in hours.
40787423|NCT06581250|BEHAVIORAL|Motivation-enhanced Communication|Participating clinic site staff will be trained in motivation-enhanced communication techniques using the guide for dental clinic sites and coaching. Topics to be included in the motivation-enhanced communication training are a) to determine what patients hope to gain from their dental care, steps needed to succeed, how the agency and client will work together to attain the goals, and b) to identify patient barriers to attending their visit (e.g., transportation, payment, do not understand need for visit, etc.), and what the agency and patient will do to overcome those barriers. Staff will be instructed to use these techniques with patients at every contact about an upcoming appointment.
40787424|NCT02462031|DRUG|KD101|200mg, 400mg, 800mg, 1400mg
40787425|NCT02462031|DRUG|placebo|200mg, 400mg, 800mg
40991509|NCT03144882|DRUG|Placebo|placebo
40991510|NCT03082599|DEVICE|Presbyopia and astigmatism correcting intraocular lens|The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
40991511|NCT03214159|DRUG|Ritonavir Tablet 100mg|Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
40991512|NCT03214159|DRUG|NORVIR tablet 100mg|NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
41308375|NCT05127421|DRUG|Ruxolitinib cream|"Ruxolitinib cream 1.5% applied twice a day (BID)"
41488615|NCT04341649|BEHAVIORAL|Deep and Slow breathing|A full respiratory cycle of 10 seconds with 5 seconds for inspiration and 5 seconds for expiration.
40787426|NCT06036199|DEVICE|Focused Ultrasound Pallidotomy|Use of ExAblate Transcranial MR guided Focused Ultrasound as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
40991513|NCT00140647|DRUG|Ramipril|
40787428|NCT05545943|OTHER|2-days of zero calorie restriction and whole-body cold-water immersion|The 2-days (48 hours) of zero-calorie restricted diet (with water provided ad libitum) with two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min.
40787429|NCT05545943|OTHER|6-days of calorie restriction|The 6-days (144 hours) of prescribed zero-calorie prescribed diet with water provided ad libitum.
40787430|NCT05545943|OTHER|2-days of zero calorie restriction without whole-body cold-water immersion|2 days (48 hours) of prescribed zero-calorie diet with water provided ad libitum .
40787431|NCT05545943|OTHER|2-days of usual diet with whole-body cold-water immersion|Two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min. During intervention, participants were instructed to maintain their previous eating habits.
40787432|NCT00811720|DRUG|Placebo|as-needed use, tablets, orally, 6 months
40991514|NCT00140647|DRUG|Rosiglitazone|
40991515|NCT00882193|DRUG|Betaine|Betaine 20 gm/day in 2 divided doses for 48 weeks
40991516|NCT00882193|DRUG|Peginterferon alpha 2a|Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
40991517|NCT00882193|DRUG|Ribavirin|Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight \< or \> 75mg in 2 divided doses
40991518|NCT00625976|BEHAVIORAL|Graded exposure in vivo|Graded exposure in vivo according to the protocol of de Jong et al. (2005)
40991519|NCT00625976|BEHAVIORAL|Physiotherapy|Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
40991520|NCT03344042|DRUG|Fentanyl|100mcg Fentanyl
40991521|NCT03344042|DRUG|Sufentanil|10mcg sufentanil
41147375|NCT02100189|PROCEDURE|Esophagogastroduodenoscopy|Undergo standard EGD or endoscopy
41147376|NCT02100189|OTHER|Laboratory Biomarker Analysis|Correlative studies
41147377|NCT06468618|BEHAVIORAL|DREAMS Program Video and Care Kit|A pediatric, circadian health program comprised of an introductory video to sleep experiences for stem cell transplant recipients, strategies to improve sleep, and a Sleep and Circadian Care Kit which includes ear plugs, a white noise machine, an eye mask, a lightbox, and kit instructions. Actigraph, Fitbit, and tablet will be provided to participant and family.
40787433|NCT00811720|DRUG|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
40787434|NCT01605669|OTHER|Tranthoracic Echocardiogram|standard measurement
40787435|NCT01605669|DEVICE|Cardiac Ascultation Recordings with Electronic stethoscope|3M device
40787436|NCT03098563|DRUG|Blinded study medication|Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
40787437|NCT00107276|DRUG|capecitabine|
40787438|NCT00107276|DRUG|cyclophosphamide|
40787439|NCT04316559|OTHER|Placebo|Placebo capsule
40991522|NCT04734509|DEVICE|Silhouette breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
40991523|NCT00616460|DRUG|Bivalirudin|Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT \< 250
40991524|NCT05481177|DRUG|Ivabradine|Ivabradine is a drug approved to treat tachycardia in volunteers with heart failure. This study is to determine benefit of ivabradine treatment in postural orthostatic tachycardia syndrome (POTS) in participants with Long haul Covid.
41308376|NCT05127421|DRUG|Vehicle|Vehicle cream applied twice a day (BID) to affected areas
41308377|NCT03284294|DRUG|Cholecalciferol|cholecalciferol 2000 IU oral daily for 8 weeks
40787440|NCT04316559|DRUG|TRV734|biased agonist at mu opioid receptors
40787441|NCT01152801|DRUG|Everolimus (RAD001)|
40787442|NCT00447798|BEHAVIORAL|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building \& strengths based case management
40787443|NCT01302184|DEVICE|Lokomat®|"Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.~A physical therapist supervised the treatment, adjusting treadmill speed and BWS.~Treatment was performed for 3 days/week, for 4 weeks"
40787444|NCT01302184|DEVICE|Treadmill|"Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.~A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.~Treatment was performed for 3 days/week, for 4 weeks."
40787445|NCT04407338|DEVICE|B-DYN|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
40991525|NCT05577585|DRUG|Ketamine 50 MG/ML|See also Arm description
40991526|NCT05577585|DRUG|Midazolam|See also Arm description
40991527|NCT05577585|DRUG|Ketamine 50 MG/ML|Open Label Follow Up (up to 8 Infusions)
40991528|NCT05045144|COMBINATION_PRODUCT|RSVPreF3(120 μg)|A single dose of RSVPreF3(120 μg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 μg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.
40991529|NCT05045144|COMBINATION_PRODUCT|Flu Quadrivalent influenza vaccine (15 μg HA)|A single dose of Flu Quadrivalent influenza (15 μg HA) vaccine was administrated intramuscular (IM).
40991530|NCT05045144|COMBINATION_PRODUCT|Placebo|One dose of placebo, administered intramuscularly in the deltoid region of the right arm, at Day 1.
41308378|NCT03284294|DRUG|Placebo|Oral placebo daily for 8 weeks
41308379|NCT02651194|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
41308380|NCT01907594|DRUG|D-cycloserine|
41308381|NCT01907594|DRUG|Nicotine Replacement Therapy (patch)|
41308382|NCT01907594|BEHAVIORAL|Smoking Cue Exposure|
41308383|NCT01907594|BEHAVIORAL|Progressive Muscle Relaxation|
41308384|NCT01907594|DRUG|Placebo|The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
40787446|NCT04407338|DEVICE|Conventional Bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
40787447|NCT04379674|OTHER|FACILITATION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.
40787448|NCT04379674|OTHER|INHIBITION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
40787449|NCT04379674|OTHER|PLACEBO TAPING|Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
40787450|NCT00488514|DRUG|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
40787451|NCT00295607|DRUG|Tacrolimus|immunosuppression
40787452|NCT00295607|DRUG|steroids, monoclonal anti-IL2R antibody|immunosuppression
40787453|NCT00318669|DRUG|Paroxetine hydrochloride hydrate|
40991531|NCT01541137|DRUG|Diclofenac|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
40991532|NCT01541137|DRUG|parecoxib/ valdecoxib|oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
40991533|NCT01541137|DEVICE|patient controlled epidural analgesia|epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
40991534|NCT04639609|OTHER|Characterization of Neuromuscular Function and Fatigue|at inclusion
40991535|NCT06421389|DRUG|Tranexamic Acid Powder|2g of sucralfate powder, 1g of tranexamic acid powder, and 1g of barium will be sprayed through the endoscopy precisely on the bleeding site
40991536|NCT00101114|DRUG|sorafenib tosylate|Given PO
41147378|NCT04258306|DIETARY_SUPPLEMENT|Revifast|Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).
40991537|NCT00101114|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
41467126|NCT02721550|DRUG|Sodium Glycididazole|800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
40787454|NCT00286897|DRUG|E2007|
40787455|NCT03646760|BEHAVIORAL|HYCR|"This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site."
40787456|NCT03646760|BEHAVIORAL|CBCR|This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
40787457|NCT00000389|DRUG|Fluvoxamine|
40991538|NCT00101114|OTHER|laboratory biomarker analysis|Optional correlative studies
40991539|NCT02738333|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
41147379|NCT04258306|DIETARY_SUPPLEMENT|pure resveratrol|resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
41147380|NCT02124304|DEVICE|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
41147381|NCT02721849|BEHAVIORAL|Yoga for adolescents|12 week hatha yoga course for adolescents
41147382|NCT02721849|BEHAVIORAL|Yoga for parents|12 week hatha yoga course
41147383|NCT04317872|DRUG|High dose of peri-operative intravenous dexamethasone|25mg aacidexam is administered during induction followed by 10mg on the ward after 12 hours
41308385|NCT05158452|PROCEDURE|Discussion|Attend a focus group
40787458|NCT05926063|OTHER|Comparison short vs extended EBAT treatment group|This study compares two management strategies of patients undergoing treatment with chemotherapy or a stem cell transplantation. One strategy is to treat these patients at the time of febrile neutropenia with a fixed 72 hours course of EBAT. The other, more commonly followed strategy is a longer minimum EBAT duration of 5 days as well as other variables like neutrophil recovery and defervescence. In both arms, definitive treatment is given when an infectious cause of the fever is found according to local guidelines (e.g. pneumonia or mucosits with bacteremia).
40787459|NCT02949024|DRUG|IVT Aflibercept|IVT aflibercept \[2 mg (50 µL)\]
40787460|NCT02949024|DRUG|SC CLS-TA|\[4 mg (100 µL)\]
40991540|NCT02738333|DRUG|SOF|400 mg tablet administered orally once daily
41467127|NCT01523587|DRUG|afatinib|Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
41467128|NCT01523587|DRUG|erlotinib|erlotinib taken once daily
41467129|NCT02608424|DEVICE|Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)|The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
41467130|NCT00551616|DRUG|CDB-2914|Single dose
41467131|NCT00551616|DRUG|Levonorgestrel|Single dose
40787461|NCT06465784|PROCEDURE|Retrograde and Antegrade Ureteroscopic Laser Lithotripsy|Comparison Between Retrograde and Antegrade Ureteroscopic Laser Lithotripsy for Management of Medium Sized Proximal Ureteral Stones: A Randomized Prospective Study
40991541|NCT02738333|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
40991542|NCT04501367|DRUG|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with one DEXTENZA (lower eye lid canaliculus) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
40991543|NCT04501367|DRUG|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with two DEXTENZA (upper and lower canaliculi) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
40991544|NCT04501367|DRUG|Prednisone acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo vitrectomy with internal limiting membrane peel surgery
40991545|NCT05688241|DRUG|Donor-derived ex-vivo expanded EBV Tscm CTL|Cryopreserved cells will be thawed and infused at three time points. Dosing will be 2x10e6 EBV CTLs per kg of body weight. No prior lymphodepletion will be performed.
40991546|NCT00454987|BIOLOGICAL|Menitorix|Menitorix was only administered to subjects of the group Meningitic+Hiberix group at 40 to 43 months of age.
40991547|NCT00454987|BIOLOGICAL|Infanrix IPV|Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
40991548|NCT06023732|BEHAVIORAL|Behavioral activation and emotion-focused interventions|Behavioral activation with emotion-focused interventions comprises two consecutive phases. In the first phase, treatment focus is behavioral activation in line with Brief behavioral activation treatment for depression - revised (BATD-R; 11) During the second phase, treatment focus shifts to address participants' emotions. Difficulties in understanding, tolerating, and labeling emotions is addressed by observing and describing emotions (12). Under the guidance of the therapist, participants are instructed to explore emotions normally avoided or ruminated on. This is conceptualized as a form of exposure to aversive emotions, thoughts and memories, to initiate emotional processing (13).
40991549|NCT02280564|BEHAVIORAL|health coaching with technology support|Intensive behavior change support. Engaging participants to take an active role in their diabetes care using motivational interviewing, technology, family communication, problem solving skills.
40991550|NCT02139527|DEVICE|Total Disc Replacement|
40787462|NCT06263036|OTHER|Men|Laryngeal cartilages
40991551|NCT02225743|OTHER|Observation Of Temperature|Participants temperature will be recorded perioperatively.
40991552|NCT01474044|DRUG|Gastropylor Complex Capsules|3 pills, three times a day, after meal
40991553|NCT01474044|OTHER|Placebo Comparator|Placebo that is same as gastropyloric complex capsules
40991554|NCT05463510|DIAGNOSTIC_TEST|Videodermoscopy|Patients who had records for at least twice with videodermoscopy every 3 months were included.
40991555|NCT01763424|DRUG|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
40991556|NCT01763424|DRUG|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
40991557|NCT00002173|BIOLOGICAL|HIV-1 Immunogen|
40991558|NCT03636347|DRUG|Placebo Oral Tablet|twice daily administration
40991559|NCT03636347|DRUG|Alvelestat oral tablet - dose 1|twice daily administration
40991560|NCT03636347|DRUG|Alvelestat oral tablet - dose 2|twice daily administration
40991561|NCT03213821|OTHER|protein intake|For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (\>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
40991562|NCT02786628|OTHER|Physical performance testing and patient-generated health data|All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
40991563|NCT02064010|DRUG|SNC-102|Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
40991564|NCT02064010|DRUG|Placebo|Placebo tablet, administered orally for 4 weeks
40991565|NCT02132767|DRUG|Amiodarone|"Amiodarone Initial Dose~* Oral: 400 mg po TID for 3 days is recommended~* For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~* Oral: at least 200 mg/day to be continued until 60 days after randomization~* If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started"
40991566|NCT02132767|PROCEDURE|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
40991567|NCT02132767|DRUG|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
41488616|NCT04341649|BEHAVIORAL|Relaxed Reading time|Duration 10 minutes.
40787463|NCT06263036|OTHER|Women|Laryngeal cartilages
40787464|NCT05609357|DEVICE|Head-up Cardiopulmonary Resuscitation|Elevate patient's head to 30 degrees by EleGARD System during cardiopulmonary resuscitation
40787465|NCT02118948|BEHAVIORAL|Abuse-focused intervention|
40787466|NCT02118948|BEHAVIORAL|Sexual behavior-focused intervention|
40991568|NCT03496948|BEHAVIORAL|TeGeCoach|"12-month long telephone health coaching carried out by specially trained coaches. The health coaching is a patient-centered approach based on motivational interviewing, shared decision-making and active listening techniques. Primary care physicians will be constantly involved receiving regular health reports from the coach.~The walking exercise is based on the principle of interval training. Patients will continuously wear an activity monitor device to review their exercise performance and for remote exercise monitoring by the coach. This activity information will be regularly reviewed by the coach to ensure that the patient adheres to the individual walking exercise prescription."
40991569|NCT03613051|BEHAVIORAL|Movement Assessment Battery for children|this test measures manual dexterity , balance , aiming and catching
40991570|NCT03852303|DRUG|ivermectin|evaluate effect of ivermectin on frequency of seizures
40991571|NCT06258876|OTHER|PrEP in general practice|Prescription and follow-up of PrEP in general practice
40991572|NCT01630512|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
41467132|NCT00610324|DRUG|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
40991573|NCT01630512|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
40991574|NCT00437593|PROCEDURE|ppVE, MP, ICG|surgery with ILM staining
40991575|NCT00437593|PROCEDURE|ppVE, MP, MB|Surgery with ERM staining
40991576|NCT00071760|DRUG|GW433908|Fosamprenavir suspension bid
40991577|NCT00071760|DRUG|ritonavir|Ritonavir solution bid
41467133|NCT00610324|DRUG|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
41467134|NCT03427801|DRUG|Erythropoiesis-Stimulating Agent|erythropoiesis-stimulating agent: Mircera or Darbepoietin
40991578|NCT05568654|DIAGNOSTIC_TEST|Rapid Diagnostic Testing|Eligible patients in hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. A CDSS-based alert will be generated in real time. If the patient is not being admitted to the intensive care unit, the form will append orders for viral pathogen and UAT testing.
40991579|NCT05568654|OTHER|Pharmacist-led de-escalation|A CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for greater than 48 hours and generate a list for the antimicrobial stewardship pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities (temperature, heart rate, oxygen saturation, blood pressure and respiratory rate) b) normal mental status and c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page. The de-escalation recommendations made by the pharmacist will be based on a protocol developed by the research team.
40991580|NCT03283423|DEVICE|Image-guided Lymphadanectomy in AMIGO|Image guided laparoscopic lymph node biopsy
40991581|NCT05633693|BEHAVIORAL|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).
41467135|NCT04871516|OTHER|Quality-of-Life Assessment|Ancillary studies
40991582|NCT05633693|BEHAVIORAL|Baseline Stand|Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
40991583|NCT04116138|DIETARY_SUPPLEMENT|Salovum|Egg yolk powder enriched for anti secretory factor
40991584|NCT05278078|OTHER|psychological support|psychological support will be given to the patients in the experimental group.
40991585|NCT05278078|OTHER|nutritional education|nutritional education will be given to the patients in the experimental group.
40991586|NCT05278078|OTHER|psychological support and nutritional education|psychological support and nutritional education will be given to the patients in the experimental group.
40991587|NCT05278078|OTHER|no intervation|No intervention will be applied to the control group
40991588|NCT01718847|DRUG|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
41467136|NCT04871516|OTHER|Questionnaire Administration|Ancillary studies
41467137|NCT04871516|RADIATION|Radiation Boost|Undergo radiation therapy boost
41467138|NCT04871516|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard surgery
41467139|NCT04871516|RADIATION|Whole Breast Irradiation|Undergo standard WBI
41467140|NCT04871516|OTHER|Breast MRI|A baseline breast MRI
41467141|NCT03785691|DRUG|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
41467142|NCT03785691|DRUG|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
41488617|NCT00975286|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
41488618|NCT00975286|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
41467143|NCT03785691|DRUG|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
40787467|NCT06307392|PROCEDURE|First intubation attempt with endotracheal tube plus bougie|"Use of a straight, malleable, semirigid bougie on first-attempt intubation. The required bougie is at least 60cm length, a coudé tip is recommended but not required. Operator may choose whether to bend the bougie prior to intubation.~During laryngoscopy, the operator will insert the bougie into the trachea under direct or indirect visual control. If the bougie is successfully placed in the trachea, an assistant will load the endotracheal tube directly over the bougie while the operator will manually stabilize the bougie. Once the bougie has reached the mouth, the assistant will then stabilize the bougie, and the operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube. Then, the assistant will withdraw the bougie from the endotracheal tube.~The use of a stylet is not permitted."
40787468|NCT06307392|PROCEDURE|First intubation attempt with endotracheal tube alone|"During laryngoscopy, the operator will insert the endotracheal tube alone into the trachea under direct or indirect visual control. The operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube.~The use of a stylet is not permitted."
40787469|NCT06476288|OTHER|Low-intensity resistance exercise training|The intervention protocol will consist of 60 minutes of low-intensity resistance exercise training 3x/week for 6 weeks.
40787470|NCT06476288|OTHER|High-Dose Remote ischemic conditioning (RIC)|Treatment dose of RIC- the RIC cuff will be inflated to 20 mmHg over the participant's systolic blood pressure. The treatment dose of RIC will be applied in 4 sets of cycles with inflating the cuff and leaving it pumped for 5 minutes then deflating the cuff for an off period of 5 minutes. Total treatment time will be 35 minutes.
40991589|NCT06528392|BIOLOGICAL|Efgartigimod|Efgartigiomd-hyaluroidase (EFG) is a neonatal Fc receptor (FcRn) inhibitor, which blocks the recycling of Immunoglobulin G (IgG), including pathogenic IgG
40991590|NCT05700435|BEHAVIORAL|Stress Management and Resilience Training|The Stress Management and Resilience Training (SMART) program focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) or in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks. The modalities VTC and in-person are the two intervention conditions.
40991591|NCT06362187|DEVICE|Gut Directed VR|The VR experiences follow a protocolized gut-directed therapy
40991592|NCT06362187|DEVICE|Sham Control VR|The same Oculus Quest 2 device as the active treatment group but will use distractive therapy
40991593|NCT06370273|DRUG|Rivaroxaban|10mg once daily via oral ingestion
40991594|NCT06370273|DRUG|Apixaban|2.5mg twice daily via oral ingestion
41467144|NCT03631368|DRUG|Botox|Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
40991595|NCT06370273|DRUG|Enoxaparin Injectable Solution|40mg once daily via subcutaneous injection
40991596|NCT06370273|DRUG|Tinzaparin Injectable Solution|4500 IU once daily via subcutaneous injection
40991597|NCT06370273|DRUG|Dalteparin Injectable Solution|5000 IU once daily via subcutaneous injection
41467145|NCT03770338|DRUG|Teriparatide|20ug dosage daily injection, 1-month preoperative
41147384|NCT04317872|DRUG|Low dose of peri-operative intravenous dexamethasone|10mg aacidexam is administered during induction followed by placebo on the ward after 12 hours
40787471|NCT06476288|OTHER|Low-Dose Remote ischemic conditioning (RIC)|This dose will be the control for the study. Low-dose RIC- the RIC cuff will be inflated to 10 mmHg below the participant's diastolic blood pressure. The low-dose RIC will be applied in 4 sets of cycles with inflating the cuff and leaving it pumped for 5 minutes then deflating the cuff for an off period of 5 minutes. Total treatment time will be 35 minutes.
41147385|NCT01589211|BEHAVIORAL|Brief advice|Brief advice of about 10 min accompanied by self-help material
41467146|NCT06494800|DIAGNOSTIC_TEST|True cut needle biobsy|The biobsy procedure done at the radiology department and the cores are examined by the pathology department, the patient lie prone, supine or in lateral decubitus according to the location of the lesion. A thoracic CT scan was performed first to evaluate the needle pathway and distance from the puncture site to the lesion. The needle pathway was selected to avoid bone, visible vessels, bullae, and fissures. The puncture site was chosen by the CT gantry laser lights and landmarks using a homemade radiopaque grid on the patient's skin. Local anaesthesia was induced with 5 mL of 2% lidocaine. An 18-G coaxial needle was used to puncture the lung, and a repeat CT scan was performed to evaluate the site of the needle. When the needle tip reached the lesion, the specimen was obtained by pressing the trigger of the needle. The specimen was reviewed by the pathologist.The specimen was placed in 10% formaldehyde for pathological examination.
41467147|NCT02835963|OTHER|Data collection|Usual data collection
40787472|NCT02230189|BIOLOGICAL|Segmental airway allergen challenge|
40991598|NCT06370273|DRUG|Fondaparinux Injectable Product|2.5 mg once daily via subcutaneous injection
40991599|NCT05447364|DRUG|Pregabalin 75mg|1 tab of Pregabalin Brillior 75 mg and 1 tab of Placebo
41147386|NCT01589211|BEHAVIORAL|Compact cessation course|Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
41147387|NCT01589211|BEHAVIORAL|Standard cessation course|Cessation course over 6 dates. Group setting.
41308386|NCT04915677|PROCEDURE|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Subepithelial connective tissue graft will be harvested and inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
41308387|NCT04915677|PROCEDURE|Soft tissue augmentation with xenogenic volume stable collagen matrix|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Xenogenic volume stable collagen matrix will be inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
41308388|NCT03742401|PROCEDURE|Surgery|Traditional open excisional surgery
41308389|NCT03742401|DEVICE|HIFU (Echopulse)|High intensity focused ultrasound (HIFU) non invasive intervention
41488619|NCT00975286|DRUG|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
40991600|NCT05447364|DRUG|Pregabalin 150mg|2 tabs of Pregabalin Brillior 75 mg
41147388|NCT03966027|OTHER|Postoperative protocol (Immediate weight bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow an immediate weight bearing rehabilitation protocol using an offloading hindfoot brace
40787473|NCT02230189|PROCEDURE|Bronchoscopy|
40787474|NCT02230189|DIAGNOSTIC_TEST|Methacholine challenge test|
40787475|NCT02230189|DIAGNOSTIC_TEST|Spirometry|
40787476|NCT02230189|DIAGNOSTIC_TEST|Allergen skin prick test|
40787477|NCT01440764|DRUG|Furosemide|
40787478|NCT01440764|DRUG|Saline|
40787479|NCT04676893|DRUG|D418 Tab.|1T
40787480|NCT04676893|DRUG|CKD-388 Tab.|1T
40787481|NCT03918382|OTHER|Electronic Patient-Reported Outcome|Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
40787482|NCT01149330|DRUG|Adapalene-BPO Gel|Apply 1 gram of the investigational drug every night on whole face.
40787483|NCT05696847|DRUG|Tirzepatide|Administered SC
40787484|NCT05696847|DRUG|Placebo|Administered SC
40787485|NCT02699697|RADIATION|External Beam Radiation Therapy|Undergo EBRT
40787486|NCT02699697|RADIATION|Palliative Radiation Therapy|Undergo EBRT
40991601|NCT01886807|DEVICE|TrueView PCD Video Laryngoscope|
41147389|NCT03966027|OTHER|Postoperative Protocol (Delayed Weight Bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow a standard delayed weight-bearing rehabilitation protocol
41147390|NCT00470756|OTHER|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
40787487|NCT02699697|OTHER|Quality-of-Life Assessment|Ancillary studies
40787488|NCT02699697|OTHER|Questionnaire Administration|Ancillary studies
40787489|NCT02768285|PROCEDURE|APICAL PATENCY|After determining the working length, a small and flexible size 10 K-file was inserted 1 mm beyond the WL.
40787490|NCT05814237|OTHER|Data collection|Data collection from study participants to characterise diagnostic and therapeutic practices.
40787491|NCT01794910|OTHER|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
40787492|NCT06211699|PROCEDURE|Omentopexy with Laparoscopic Sleeve Gastrectomy|Patients with omentum sewed to the remnant gastric staple line during laparoscopic sleeve gastrectomy.
40787493|NCT06211699|PROCEDURE|Clips with Laparoscopic Sleeve Gastrectomy|Patients performed clips to the remnant gastric staple line during laparoscopic sleeve gastrectomy
40787494|NCT04152486|BIOLOGICAL|Ad26.ZEBOV, MVA-BN-Filo vaccine|"Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV."
40787495|NCT05807412|DRUG|PrabotulinumtoxinA-Xvfs|"All subjects will receive one injection of 4 units or 0.1 cc of prabotulinumtoxin A into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of prabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim."
40991602|NCT04969549|OTHER|Theta burst stimulation|It consists of 20 sessions of iTBS over the dlPFC.
40991603|NCT06529770|OTHER|NMP-e|"The US-PNM intervention uses a square-wave biphasic current (10 Hz, 250 ms pulse width) at maximum tolerable intensity for 1.5 minutes (10 seconds 10 times), per Fermín Valera and Fran Minaya's protocol. Participants will lie on their side, with the area cleaned and an ultrasound probe cover used.~Needles (Agu Punt, Spain) will be inserted perpendicularly to target the nerve perineurium. For the axillary nerve (C5-C6), a 0.40/0.50×25 mm needle will be used in a short axis at 80°. For the suprascapular nerve (C5-C6), a 0.30/0.40×25 mm needle will be used.~Each session involves two needle insertions, with the needle stationary and monitored by a physiotherapist with two years of experience."
40991604|NCT04466540|DRUG|Hydroxychloroquine|Hydroxychloroquine pharmaceutical form will be tablets of 400 mg.
40991605|NCT04466540|DRUG|Placebo|Hydroxychloroquine placebo
41147391|NCT04184609|OTHER|Control|In this condition, the participants will not receive any medications or drugs before exercise
41467148|NCT06367699|BEHAVIORAL|Usual Care|Parent/guardian and adolescent participants will not receive the ECA-HPV system intervention. A survey will be given via REDCap to the parent/guardian and adolescent participants at baseline, after the first well child clinic visit, and after the second well child clinic visit to assess self-reported vaccination attitudes and behaviors. Adolescent participants will receive usual care.
41488620|NCT00975286|DEVICE|Pen auto-injector|Lantus® SoloStar® OptiClik®
41488621|NCT00975286|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
40787496|NCT05807412|DRUG|OnabotulinumtoxinA|"All subjects will receive one injection of 4 units or 0.1 cc of onabotulinumtoxinA into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of onabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim."
40787497|NCT02886650|PROCEDURE|Thermocoagulation|Thermocoagulation During pre-surgical Invasive EEG Monitoring
40787498|NCT02954458|DRUG|TED|0.05 mg/kg SC injection once daily.
40787499|NCT02954458|OTHER|SOC|Standard safety assessments and adjustments in nutritional support.
40787500|NCT02954458|DEVICE|Syringe|Teduglutide will be administered using syringe.
40787501|NCT02954458|DEVICE|Needle|Teduglutide will be administered using needle.
40787502|NCT00997854|OTHER|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
40787503|NCT04446221|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
40787504|NCT01345929|DRUG|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
40787505|NCT01345929|DRUG|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
40787506|NCT06000969|DEVICE|Lung Recruitment Conventional|the recruitment maneuver will be performed by manual inflation with a pressure of 30 cmH2O for 30 seconds.
40787507|NCT06000969|DEVICE|Lung Recruitment Ultrasound|the recruitment maneuver will be performed under the direct real-time guidance of ultrasound if atelectasis (defined as LUS of ≥ 2 for any of the 12 regions) is present. This will be done by manual inflation with a pressure of 10 cmH2O for 10 seconds, increased 10 cmH2O every 10 seconds until no collapsed areas are visible on the ultrasound, the maximum airway pressure will be limited to 40 cmH2O. This could be repeated if needed.
40787508|NCT04726995|OTHER|CHOP and BFM regiments|used CHOP and BFM regiments
40787509|NCT03886948|DRUG|LY3074828|Administered subcutaneously (SC)
40787510|NCT03886948|DEVICE|Pre-filled syringe (PFS)|PFS used to administer LY3074828
40787511|NCT03886948|DEVICE|Autoinjector (AI)|AI used to administer LY3074828
40787512|NCT01187654|BIOLOGICAL|AC133|intra coronary injection of bone marrow derived AC133+ cells
40787513|NCT01187654|BIOLOGICAL|MNC|intra coronary injection of bone marrow derived MNC
40787514|NCT01187654|BIOLOGICAL|CONTROL|autologous serum injection
40787515|NCT00396617|DEVICE|prothesis voice|The device may be used for patient using another type of voice prosthesis, of for patient undergoing total laryngectomy. This device is definitively placed in two parts:The first one is introduced in the puncture (TEP) through the esophagus (retrograde way). The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
40787516|NCT00396617|PROCEDURE|total laryngectomy|The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
40787517|NCT01603043|DRUG|Al-78898A|0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
40787518|NCT01603043|DRUG|Sham injection|Mock injection administered as an empty hub without needle
40991606|NCT02749812|DEVICE|Constant Continuous Positive Airway Pressure|
41308390|NCT02802059|DRUG|EcN-Suspension|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
41308391|NCT02802059|DRUG|Placebo|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
41488622|NCT00975286|DRUG|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
41488623|NCT00257218|BEHAVIORAL|Life style modification|
41488624|NCT04928274|OTHER|ball attachment to retain mandibular over denture|each patient in group receive 3 locator attachment for over denture retention
41488625|NCT04928274|OTHER|locator attachment to retain mandibular over denture|each patient in group receive 3 locator attachment for over denture retention
40787519|NCT05894083|PROCEDURE|Surgery|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
40787520|NCT05894083|COMBINATION_PRODUCT|Chemoradiation|Patients will receive an initial plan with a single prescription of 30 Gy in 15 fractions to PTV_High and PTV_Low with RT given once daily, 5 days a week (Monday through Friday). After analysis of mid-treatment PET/CT, the remaining radiation treatment will be delivered as a conedown to the gross disease only. Patients will be planned to receive a total dose of 70 Gy, 54 Gy, or 44 Gy to PTV_High in 2 Gy per fraction.
40787521|NCT05894083|OTHER|Observation|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
40787522|NCT05894083|RADIATION|Post-operative radiation|Patients will receive adjuvant radiation based on pathologic features.Total radiation treatment doses and prescriptions will include 36 Gy in 18 fractions, 50 Gy in 25 fractions and 60 Gy in 30 fractions.
40991607|NCT02749812|DEVICE|Automatic continuous Positive Airway Pressure|
40991608|NCT00360828|DRUG|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride \[CPT-11; CAMPTOSAR\] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
41147392|NCT04184609|DRUG|Albuterol|180 mcg of Albuterol will be administered before exercise
40787523|NCT04800393|DRUG|Sevoflurane|induction of anesthesia with propofol, maintenance of anesthesia with sevoflurane during breast cancer surgery
40787524|NCT04800393|DRUG|Propofol|propofol-based total intravenous anesthesia during breast cancer surgery
40787525|NCT00156325|DRUG|Escitalopram (Lexapro)|
40787526|NCT04578756|DRUG|Cariprazine Flexible Dose|1 capsule to be taken orally at approximately the same time of day (morning or evening)
40787527|NCT04578756|DRUG|Cariprazine Flexible Dose|Dose solution (in milliliters) to be taken orally at approximately the same time of day (morning or evening)
40787528|NCT04941105|DRUG|Evolocumab|A single subcutaneous administration of 140 mg evolocumab
40787529|NCT04941105|DRUG|Saline solution|A single subcutaneous injection of 1ml of 0,9% saline solution
40787530|NCT01904929|OTHER|Walk-tests|"Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.~This series of test will be repeated 72 hours later for the study reproducibility.~It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2."
40787531|NCT00954161|OTHER|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
40787532|NCT00954161|OTHER|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
40787533|NCT02525926|PROCEDURE|denervation|The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
40787534|NCT02525926|PROCEDURE|sham procedure|"Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.~Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study."
40787535|NCT04454060|PROCEDURE|Extracapsular arthroscopy|Extracapsular arthroscopy method was used to treat refractory tennis elbow
40787536|NCT05955664|DIAGNOSTIC_TEST|MRI indlcuding DTI|A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.
40787537|NCT05955664|DIAGNOSTIC_TEST|Pelvic floor ultrasound.|"The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US."
40787538|NCT03381287|DRUG|HTD1801 Tablets, 500 mg|500 mg/day (250 mg BID)
40787539|NCT03381287|DRUG|HTD1801 Tablets, 1000 mg|1000 mg/day (500 mg BID)
40787540|NCT03381287|DRUG|HTD1801 Tablets, 2000 mg|2000 mg/day (1000 mg BID)
40787541|NCT03381287|DRUG|Placebo to match 500 mg HTD1801|2 tablets/day (1 tablet BID)
40787542|NCT03381287|DRUG|Placebo to match 1000 mg HTD1801|4 tablets/day (2 tablet BID)
40787543|NCT03381287|DRUG|Placebo to match 2000 mg HTD1801|8 tablets/day (4 tablet BID)
40787544|NCT02057965|DRUG|Mesenchymal Stromal Cells|Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10\^6 million MSCs per/kg body weight
40787545|NCT00100737|DRUG|interleukin-2|
40787546|NCT00100737|DRUG|rituximab|
40787547|NCT05922345|DRUG|TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules|"AL2846 capsules is a multi-targeted small molecule receptor tyrosine kinase inhibitor.~TQB2450 Injection is an anti-programmed death-1 (PD-L1)."
40787548|NCT05922345|DRUG|TQB2450 matching placebo, docetaxel injection, AL2846 matching placebo|Docetaxel injection is a type of chemotherapy for treatment of different types of cancer.
40991609|NCT00360828|DRUG|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
40991610|NCT02213393|DIETARY_SUPPLEMENT|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
40991611|NCT02213393|DIETARY_SUPPLEMENT|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
40991612|NCT05934682|PROCEDURE|Surgery|All children submitted to surgery will be followed until hospital discharge or 30 days postoperatively.
40991613|NCT01746979|DRUG|TH-302|TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
40991614|NCT01746979|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
40991615|NCT01746979|DRUG|Placebo (5 percent dextrose - D5W)|TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
40991616|NCT06429462|DIAGNOSTIC_TEST|smartphone camera sensor tool|The study will involve the development and validation of a computer vision-based approach (using cameras to assess movements) to monitor knee flexion and extension, and a walking pattern assessment.
40787550|NCT02619747|DRUG|Compound Sodium Alginate Oral Suspension sachet|
40787551|NCT02619747|DRUG|Matched placebo|
40787552|NCT04865666|DEVICE|movr mHealth App|The exercises prescribed through the movr app were accompanied with videos, images, and detailed instructions on how to complete them. These exercises consisted of basic movement and mobility patterns and are designed to promote functional movement. Participants were instructed to complete a total of four 'Minis' and two workout 'Builder' sessions per week. Workout Builders are designed to be longer exercise sessions tailored to the user's desired exercise time (15, 30, 45 or 60 min), equipment available (TRX Band, kettlebell, chin-up bar, dumbbells, foam roller, or none), target body region (lower, upper, or whole body), and specific exercise goal ('get sweaty,' 'build strength,' or 'develop mobility'). Version 3.6 of the movr app was used at the start of data collection and was updated to Version 4.1 over the course of the trial. No significant changes were made to the app or to the exercise prescription functionality throughout those updates.
40787553|NCT04918147|DRUG|elotuzumab|Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
40787554|NCT04918147|DRUG|placebo for elotuzumab|The placebo for elotuzumab is 0.9% sterile normal saline for injection.
40787555|NCT04918147|DRUG|methylprednisolone|Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
40787556|NCT04918147|DRUG|diphenhydramine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
40787557|NCT04918147|DRUG|acetaminophen|Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
40787558|NCT04918147|DRUG|famotidine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
40787559|NCT04918147|DRUG|prednisone|Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
40787560|NCT00002170|DRUG|Nelfinavir mesylate|
40787561|NCT00087984|BIOLOGICAL|MB-002|Dendritic Cell Immunotherapy
40787562|NCT04775550|DRUG|Daratumumab|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
40787563|NCT04775550|DRUG|Bortezomib|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
40787564|NCT04775550|DRUG|Lenalidomide|Oral, dosage per protocol, days 1-21 per cycle
40787565|NCT04775550|DRUG|Dexamethasone|Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
40991617|NCT02492620|DRUG|Ferric Citrate|Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
40787566|NCT01495325|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
40991618|NCT03777007|DEVICE|SPARTA force plate|The Sparta Platform includes force plate hardware coupled with Sparta Scan software that enables quick assessment of an individual's movement and balance within minutes
40991619|NCT00077103|BIOLOGICAL|filgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
40991620|NCT00077103|BIOLOGICAL|pegfilgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
41308392|NCT03545724|DEVICE|Neofitoroid®|NeoFitoroid® forms a protective barrier mucosa and on perianal region that can aid the physiological process of healing.
41467149|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification and Adolescent Functions Disabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app. The clinic notification and adolescent functions of the complete ECA-HPV app are disabled. Adolescent participants will receive usual care.
40787567|NCT01495325|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
40787568|NCT04412681|DIAGNOSTIC_TEST|Enhanced PE Screening|To better identify women at risk for pre-eclampsia during pregnancy.
40787569|NCT05362357|BEHAVIORAL|iSTART Web-app|30-day substance prevention web-app for students at a Hispanic Serving Institution.
40787570|NCT03362268|DRUG|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling. Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
40787571|NCT03362268|DRUG|omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min,Since 4th day, those patients were changed to take oral omeprazole tablets 20mg each day till 30th day
40787572|NCT04082130|PROCEDURE|(XCM)+(CAF)|The description of this intervention has been already given before.
40991621|NCT00077103|DRUG|cisplatin|cisplatin IV over 30-60 minutes on day 1
40991622|NCT00077103|DRUG|doxorubicin hydrochloride|doxorubicin IV over 5-10 minutes
40991623|NCT00077103|DRUG|fosbretabulin disodium|Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
40991624|NCT00077103|RADIATION|radiation therapy|Beginning on day 22, patients undergo radiotherapy twice daily, 5 days a week, for 3-4 weeks.
40991625|NCT03746769|BIOLOGICAL|Allogenic Human Islet Cells|islet cells transplanted into the portal vein in the liver
41488626|NCT04928274|OTHER|telescopic attachment to retain mandibular over denture|each patient in group receive 3 telescopic attachment for over denture retention
41488627|NCT02067429|PROCEDURE|Limbal Relaxing Incisions|
40787573|NCT04082130|PROCEDURE|(SCTG)+(CAF)|The description of this intervention has been already given before.
40787574|NCT03654274|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily
40787575|NCT03654274|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
40787576|NCT01892371|DRUG|Azacitidine|Given SC or IV
40991626|NCT03746769|DRUG|Gastrin 17|"Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.~Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets."
40991627|NCT05689307|DEVICE|SIVA-MVP|Participants receive a small, wearable data recorder, wear it during the day and charge it on the nightstand during sleep for 14x24 hours. The encrypted, recorded segments are uploaded to a server. The server provides a secure environment where the segments are decrypted after receiving the required keys from the patient's SIVA smartphone application. The decrypted segments are then classified as cough by a machine learning algorithm. Participants respond to questions on a smartphone once a day for additional context data. The audio data from the first 24 hours after the patient started wearing the device are used for the validation of the performance of the cough detection algorithm.
41308393|NCT03896880|DIAGNOSTIC_TEST|blood culture|"During the febrile episode, two blood samples per patient will draw from two separate sites including central venous catheter if present and directly injected to Bact/Alert® bottles and incubated in Bact/ALERT system instrument (bioMérieux Diagnostics, Lyon, France).~A-Identification of microorganisms including:~1. Isolation of microorganisms:~2. Blood culture samples with positive signals will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates.~B-Identification of the bacterial organism~Pure colonies of isolated microorganisms were identified by:~Morphology on agar,Gram stain film was made from the growth to identify morphology of the organism ,Biochemical tests~C-For fungi isolate the following will perform:~1. Microscopic examination of Lactophenol cotton blue (LCB) wet mounts.~2. Culture on Brilliance Candida differential agar"
41308394|NCT03896880|OTHER|Anti fungal susceptibility testing or antibiotic susceptibility testing|isolation of microbes from positive blood culture and anti fungal susceptibility testing or antibiotic susceptibility testing according to isolated microbes by disc diffusion method and Vitek2
40991628|NCT03342287|OTHER|questionnaires|Questionnaires rating IBS symptoms, constipation, anxiety and depression
40991629|NCT03342287|OTHER|cognitive evaluation|Administration of online cognitive battery
40991630|NCT03342287|OTHER|Blood|Measurement of cytokines/inflammatory biomarkers
41308395|NCT03896880|OTHER|phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France)|The VITEK 2 is an automated microbial identification system that utilizing growth-based technology. With its colorimetric reagent cards, the VITEK 2 offers a state of the art technology platform for phenotypic identification methods.
41308396|NCT03896880|OTHER|Identification of the isolated organism by multiplex PCR|FilmArray blood culture identification (BCID) is automated multiplex PCR assay, the FilmArray blood culture identification which directly identifies common pathogens, including 7 genera/ species of Gram-positive bacteria, 10 genera/species of Gram-negative bacteria, and 5 species of Candida (as well as 3 resistance determinants) in the positive blood culture bottles. The assay requires about 2 min of hands-on sample processing time and 1 h of instrument time (which includes DNA isolation, amplification, and detection).
41308397|NCT00760227|OTHER|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
41467150|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification Function Enabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app and the clinic notification feature. The clinic notification is enabled on the parent/guardian ECA-HPV app, however, the adolescent does not have access to the adolescent ECA-HPV app. Adolescent participants will receive usual care.
40787577|NCT01892371|DRUG|Cytarabine|Given SC
40787578|NCT01892371|DRUG|Quizartinib|Given PO
40787579|NCT04686500|DEVICE|Tidal volume measured by spirometer and DIBH surface from CT image|The SOC DIBH CT scan will be transferred to Eclipse treatment planning system for treatment planning. Tidal volume measured by spirometer and DIBH surface from CT image will be used as a reference surface for patient treatment initial setup. CBCT will be acquired before each fractional treatment for the patient alignment before beam delivery.
40787580|NCT04282850|PROCEDURE|Pulmonary Vein Isolation|The intervention will involve standard of care electrophysiology ablation for rhythm management of atrial fibrillation with a procedure called a pulmonary vein isolation.
40787581|NCT06362759|DRUG|TOUR006 - 50 MG|TOUR006 50 MG
40787582|NCT06362759|DRUG|TOUR006 - 25 MG|TOUR006 25 MG
40991631|NCT03342287|OTHER|Fecal sample|Measurement of the gut microbiome
40991632|NCT05591014|DEVICE|Novel ROTEM interpretation software|Clinicians will be asked to interpret ROTEM studies before and after exposure to a novel ROTEM interpretation software.
40991633|NCT05414279|DIAGNOSTIC_TEST|Sodium determination|Through a single finger prick 10 drops of capillary blood will be drawn. The venous blood sample will be taken through a standard venipuncture. Both samples will be send to the lab for indirect sodium determination
40787583|NCT06362759|DRUG|TOUR006 - 15 MG|TOUR006 15 MG
40787584|NCT06362759|OTHER|Placebo|Placebo
40787585|NCT05542459|DRUG|Biologics|Infliximab, adalimumab, vedolizumab, ustekinumab, and other biologics approved for IBD
40787586|NCT00972517|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Three intramuscular injections
40787587|NCT03487094|OTHER|Infant formula|Multi-centered, prospective, randomized clinical trial
40991634|NCT05171283|OTHER|Oats or Oat Fibre|Interventions that contain whole grain oats or oat beta-glucan.
40787588|NCT06075875|DIETARY_SUPPLEMENT|mixed animal and vegetable proteins|"mixed animal and vegetable proteins in the standard ratio (2/3:1/3; 60%:40% respectively) present in the nutritional menu over all hospitals in the general organization of teaching hospitals and institutes GOTHI; Egypt= as a control group) and continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm)."
40787589|NCT06075875|DIETARY_SUPPLEMENT|pure vegetable proteins|pure vegetable proteins continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm).
40787590|NCT02805543|DEVICE|Color doppler imaging|
40787591|NCT00718536|DRUG|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
40787592|NCT01518387|DRUG|Lanthanum Carbonate (BAY77-1931)|
40787593|NCT00636181|DEVICE|Auto AFlex|Positive pressure therapy treatment
40787594|NCT00636181|DEVICE|Auto CPAP|Positive pressure therapy treatment
40787595|NCT00636181|DEVICE|CPAP|Positive pressure therapy treatment
40787596|NCT06576466|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate. Guinama brand with CE marking. Code 89823.
40787597|NCT06576466|OTHER|Placebo|Dextrinomaltose. Guinama brand with CE marking. Code 91146.
40787598|NCT02579811|DRUG|Axitinib|The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
40787599|NCT00004227|BIOLOGICAL|cetuximab|
40787600|NCT00004227|PROCEDURE|conventional surgery|
40787601|NCT00004227|RADIATION|radiation therapy|
40787602|NCT02831660|DRUG|idarucizumab|
40787603|NCT02575443|DRUG|Rocuronium (MB group)|Count of train-of-four: 1-2 Titration of rocuronium dose
40787604|NCT02575443|DRUG|Rocuronium (DB group)|Post-tetanic count: 1-2 Titration of rocuronium dose
40787605|NCT05085483|DIETARY_SUPPLEMENT|Nutritional Ketogenic Supplement|This trial has 5 steps: (1) a 4-week run-in baseline; (2) a 4-week intervention phase to either active or placebo (3) a 4-week phase of washout; (4) the cross-over to the second 4-week active or placebo phase; (5) a 4-week follow-up.
40787606|NCT05085483|DIETARY_SUPPLEMENT|Isocaloric placebo supplement|Isocaloric placebo supplement
40787607|NCT03443635|BEHAVIORAL|Treatment|The intervention educates subjects through the hands-on cooking and nutrition education classes how to buy, cook, store, and consume healthy foods as an adjunct to healthy activity levels and avoidance of such health risks factors as smoking, excessive alcohol intake, and drug use.
40787608|NCT05915611|OTHER|Combined physical and psychological intervention|"Physical therapy components will include splinting, tendon and nerve gliding exercises.~Psychological components will include cognitive-behavioral therapy (CBT), delivered in individual sessions, targeting pain catastrophizing and fear of movement.~Participants will attend 2 physical therapy sessions and one CBT session per week. for a period of 12 weeks"
40787609|NCT05915611|OTHER|Standard care|Participants will be asked to wear a prefabricated wrist splint during the night and during strenuous activity. Also, they will receive tendon and nerve gliding exercises
40787610|NCT05935956|DEVICE|Magnetic Peripheral Nerve Stimulation|Magnetic Peripheral Nerve Stimulation
40991635|NCT05387733|DRUG|10 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (2 mL each); total of 10 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (2 mL each); total of 20 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (2 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (2 mL each); total of 50 mg CBL-514."
40991636|NCT05387733|DRUG|15 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (3 mL each); total of 15 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (3 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (3 mL each); total of 45 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (3 mL each); total of 75 mg CBL-514."
40991637|NCT00134160|DRUG|Olmesartan medoxomil|Olmesartan medoxomil 40mg/Day
40991638|NCT00134160|DRUG|Calcium channel blockers (amlodipine, azelnidipine)|Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
40991639|NCT02430675|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
40787611|NCT05596734|BIOLOGICAL|bivalent BNT162b2 (original/Omi BA.4/BA.5)|Intramuscular injection
40787612|NCT05596734|BIOLOGICAL|qIRV (22/23)|Intramuscular injection
40787613|NCT05596734|BIOLOGICAL|QIV|Intramuscular injection
40787614|NCT05596734|BIOLOGICAL|bIRV|Intramuscular injection
40787615|NCT05596734|BIOLOGICAL|tIRV|Intramuscular injection
40787616|NCT02315222|DIETARY_SUPPLEMENT|Regenium|
40787617|NCT02315222|DIETARY_SUPPLEMENT|Placebo|
40787618|NCT02315222|PROCEDURE|Full Mouth Disinfection|
40991640|NCT02430675|DEVICE|NanoKnife|
40787620|NCT03739151|BEHAVIORAL|Behavioral Obesity Treatment|"Self-monitoring. Participants will be taught to record their weight, the calories of each food item, and physical activity using a method of their choice (e.g., commercial smartphone app, paper diary). The clinician will review dietary intake and provide personalized feedback at the outset of session.~Diet. Per national guidelines for weight loss, a daily goal of 1200-1800 kcal/day will be prescribed depending on baseline weight. A Mediterranean diet will be prescribed to meet the recommended calorie goal and be consistent with dietary recommendations for CVD patients.~Exercise. Participants will be encouraged to achieve 250 minutes/week of moderate intensity activity in accordance with current national recommendations for physical activity among individuals attempting weight loss. Participants will be encouraged to gradually increase activity level to achieve approximately 50 minutes of activity over five days per week."
40991641|NCT00641862|DIETARY_SUPPLEMENT|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
40991642|NCT00641862|OTHER|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
40787621|NCT05155046|DRUG|18F-DCFPyL|18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.
40991643|NCT00300950|BIOLOGICAL|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
40991644|NCT00300950|DRUG|Gemcitabine|Chemotherapy
40991645|NCT01730755|DRUG|Ruxolitinib|Ruxolitinib 10 mg tablets twice daily
41467151|NCT06367699|BEHAVIORAL|ECA-HPV App with Adolescent Function Enabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction. The adolescent function is enabled, however, the clinic notification function is disabled. Thus, the ECA-HPV system app will have an adolescent-facing feature for adolescent participants to engage with the agent. Adolescent participants will receive usual care and will be able to engage with the adolescent version of the ECA-HPV app throughout the duration of the study.
40991646|NCT03149692|OTHER|Penile allograft transplantation|Proof of concept of surgical procedure
40991647|NCT03054870|DRUG|Xe-133|Xe-133 ventilation scintigraphy
41488628|NCT02067429|DEVICE|Toric Intraocular Lens|
40991648|NCT03054870|DRUG|Technegas|Technegas ventilation scintigraphy
40991649|NCT02532244|OTHER|sample collection|collection of blood
40991650|NCT03167879|BEHAVIORAL|safer conception counseling|Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.
40991651|NCT06146582|BEHAVIORAL|Laguna Coach and App Intervention Group|Behavioral, mental and contextual support was delivered through personal interactions with Laguna Coaches via mobile app, phone, video, or web chat. Care interventions were individualized to best match each participant's needs and strengths. Support will be provided to participants through interactions over approximately 90 days.
40991652|NCT05375695|OTHER|Time-restricted eating|"The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components.~Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care."
40991653|NCT04444414|OTHER|Manual therapy|bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
40991654|NCT04444414|OTHER|Control group|The control group received no treatment, they only attended the evaluations.
41147393|NCT05404178|OTHER|Type 2 diabetes group|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
41147394|NCT06462768|OTHER|Blood sample|Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.
41147395|NCT01878955|GENETIC|AMH level difference between patient with PCOS and multicystic ovaries.|
41147396|NCT00708799|OTHER|Azithromycin on admission - not enrolled in the RCT|One dose of azithromycin prior to inclusion to the RCT
41147397|NCT00230009|BEHAVIORAL|Brief motivational intervention|
40991655|NCT02192255|BEHAVIORAL|Intervention Phone Call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted \< than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
40991656|NCT04096625|DEVICE|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
40991657|NCT04096625|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.
40991658|NCT04096625|DEVICE|Sham tDCS|Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
40991659|NCT02530450|DEVICE|continuous glucose monitoring (CGM)|All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
40991660|NCT01611181|DRUG|Hemoboost|200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
40991661|NCT01611181|DRUG|Kräuterblut|40 mg iron, 20 ml twice daily.
40991662|NCT01611181|DRUG|Ferrofumerat|200 mg ferrous sulphate as 1 tablet twice daily.
40991663|NCT05431959|OTHER|balneotherapy|immersion in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l.
40991664|NCT00967993|DRUG|ferric citrate|KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
40991665|NCT01424254|DEVICE|Capsule GIVEN IMAGING|Injection of Capsule Endoscopy
40991666|NCT01424254|PROCEDURE|Push-Enteroscopy|currently recommended standard
40991667|NCT00600938|DRUG|Core Study: Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
40991668|NCT00600938|DRUG|Core Study: Deferoxamine|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
40991669|NCT00600938|DRUG|Extension: deferoxamine to deferasirox|40 mg/kg deferasirox once daily administered 30 minutes before taking food.
40991670|NCT00600938|DRUG|Extension: deferasirox to deferoxamine|DFO at a target range of 50 mg/kg/day to 60 mg/kg/day via subcutaneous (sc) infusion lasting a period of 8 to 12 hrs administered for 5 to 7 days per week,
40991671|NCT00600938|DRUG|Deferasirox|
40991672|NCT00600938|DRUG|Deferoxamine|
40991673|NCT03202147|DRUG|Cromolyn|Active capsules for inhalation.
40991674|NCT03202147|OTHER|Placebo|Non-active capsules for inhalation.
40991675|NCT05657678|DRUG|Vitamin D3 - 750 000 IU|a single administration of 750,000 IU of vitamin D3
40991676|NCT05657678|DRUG|Vitamin D3 - 500 000 IU|a single administration of 500,000 IU of vitamin D3
40991677|NCT05889598|OTHER|Ballistic Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40%1RM, the ballistic training group will complete eccentric phase hack squat exercise in approximately 3 seconds and the concentric phase as fast as possible with throwing type contractions. If participants can, participants will be allowed to take off in the concentric phase. To maintain high velocity in this group, lower loads will be used compared to the conventional group. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
40991678|NCT05889598|OTHER|Conventional Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at Loughborough University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40% of 1RM, the conventional training group will complete eccentric and concentric phases of hack squatting exercises for approximately 3 seconds each, with appropriate breathing techniques. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
40991679|NCT02486380|DEVICE|Toffee full face mask/toffee nasal mask|Toffee full face mask/toffee nasal mask
40991680|NCT00001053|BIOLOGICAL|HIV p17/p24:Ty-VLP|
40991681|NCT00001053|BIOLOGICAL|Aluminum hydroxide|
40991682|NCT00369551|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
40991683|NCT00369551|DRUG|paclitaxel|Given IV
40991684|NCT00369551|BIOLOGICAL|bevacizumab|Given IV
40991685|NCT00369551|DRUG|carboplatin|Given IV
40991686|NCT00369551|OTHER|laboratory biomarker analysis|Correlative studies
40787622|NCT00696124|BIOLOGICAL|VM202 2 mg|2 mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
40991687|NCT01366339|DRUG|Oral methylnaltrexone|
40991688|NCT01366339|DRUG|Oral placebo|
41147398|NCT03547648|PROCEDURE|peak airway pressure|Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.
41308398|NCT00760227|OTHER|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
40787623|NCT00696124|BIOLOGICAL|VM202 4 mg|4 mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
40787624|NCT00696124|BIOLOGICAL|VM202 8 mg|8 mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
40991689|NCT04187560|DRUG|LB-102|(N-Methyl amisulpride)
40991690|NCT03917420|DRUG|Tenofovir 300Mg Oral Tablet|Once daily dose of the combo tab x 5 days pre-sampling
40991691|NCT03917420|DRUG|Emtricitabine 200 MG|Once daily dose of the combo tab x 5 days pre-sampling
40991692|NCT04251598|BEHAVIORAL|I Am Protecting My Child from the Sun|"The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband."
40991693|NCT04251598|BEHAVIORAL|SMS for sun protection|While the education+SMS group, in addition to the program, also received a total of 25 short text messages twice a week.
40991694|NCT02250443|DRUG|BYM338 (Bimagrumab)|
40991695|NCT01978665|DRUG|prednisone|similar size tablets
40991696|NCT04422028|DRUG|Desogestrel 0.075 MG|Test Drug
40991697|NCT04422028|DRUG|Desogestrel 0.075 MG|Reference Product
40991698|NCT05174039|DRUG|Miglustat 100Mg Oral Capsule|Subjects will initiate miglustat at Week 1 and dosing will be escalated until 600mg/d. If a subject has not reached the maximum dose (600 mg/d) by Week 8, the Week 8 dose will be subject's MTD.
40991699|NCT01116297|DEVICE|Imaging with S-FLARE imaging system|Tissue oxygenation measurements during plastic surgery using the S-FLARE system.
40991700|NCT03375021|DRUG|CX717 200 mg|CX717 200 mg capsules BID
40991701|NCT03375021|DRUG|CX717 800 mg|CX717 4 X 200 mg capsules BID
40991702|NCT03375021|DRUG|Placebo|Placebo 200 mg or 800 mg capsules BID
40991703|NCT06341972|BEHAVIORAL|Cognitive behavioral therapy based self-management for anxiety|Evidenced based approach for educating patients about how to manage anxiety after respiratory failure.
40991704|NCT00464425|PROCEDURE|Electroacupuncture|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
40991705|NCT00464425|PROCEDURE|Sham Acupuncture|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
40991706|NCT00464425|OTHER|No Acupuncture|Control
40991707|NCT02653560|DRUG|Potassium chloride powder|
40991708|NCT02653560|DRUG|Potassium magnesium Citrate (KMgCit)|
40991709|NCT02653560|DRUG|Potassium citrate powder|
40991710|NCT02653560|DRUG|Placebo|
40991711|NCT06210490|DRUG|Disitamab Vedotin|Disitamab vedotin (RC48-ADC) is a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E via a cleavable linker. Two phase II studies, RC48-C005 (NCT03507166) and RC48-C009 (NCT03809013), have shown its significant antitumor potential in patients with la/mUC with HER2 overexpression (immunohistochemistry (IHC) 3+ or 2+). In 2022, RC48-ADC was approved for patients with HER2 overexpressing la/mUC who had received prior chemotherapy in China.
40991712|NCT06210490|RADIATION|Radiotherapy|Radiotherapy dose: 45-50 Gy/25f/5w to lymph node drainage area; 62.5 Gy/25f/5w to metastatic or suspected metastatic lymph nodes.
40991713|NCT06210490|OTHER|Standard of Care|Standard of Care
41308399|NCT00760227|OTHER|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
41308400|NCT05929144|OTHER|MRI sequences testing|Testing different MRI sequences in order to optimize them
41308401|NCT04654000|PROCEDURE|Rheopheresis procedure|rheopheresis is performed using an automated monitor (Plasauto, company HemaT) in a double-filtration cascade. Plasma purify from of high molecular weight proteins
40991714|NCT04696952|DRUG|TS-142|TS-142
40991715|NCT04696952|DRUG|Zopiclone|Zopiclone
40991716|NCT04696952|DRUG|Placebo|Placebo
41147399|NCT00930319|OTHER|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
41147400|NCT00801905|DRUG|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
41308402|NCT04654000|PROCEDURE|Sham-apheresis|Sham-apheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient.
41308403|NCT00077610|DRUG|Epoetin alfa or beta|intravenously 3 times weekly for 52 weeks, as prescribed
40991717|NCT03161431|DRUG|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
40991718|NCT03161431|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
40991719|NCT06279689|OTHER|Ultrasound scans|Ultrasound scans connected with an application enabling the measurement of the force applied.
40991720|NCT05624437|OTHER|data record|data record
40991721|NCT01482793|PROCEDURE|Vertebroplasty|AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
40991722|NCT01786954|DEVICE|Icare rebound tonometry|
40991723|NCT01786954|DEVICE|Tonopen applanation|
40991724|NCT01786954|DEVICE|Goldmann applanation|
40991725|NCT06073847|DRUG|Fedratinib|According to the approved label
40991726|NCT04917055|DRUG|ropivacaine 0.25% with epinephrine and 6mg dexamethasone|Regional Nerve block behind the knee for posterior knee pain following total knee arthroplasty using ultrasound guidance, to be done distally between femoral chondyles
40787625|NCT00696124|BIOLOGICAL|VM202 16 mg|16 mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
40787626|NCT03444324|BIOLOGICAL|BT524|BT524 was administered intravenously at a patient specific dosage depending on the type of surgery, the extent of bleeding and the subject's clinical condition.
40991727|NCT04917055|DRUG|Saline|Injection of Saline behind knee using ultrasound guidance
40991728|NCT00265343|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
40991729|NCT00265343|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
40991730|NCT03479476|DRUG|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
40991731|NCT03479476|DRUG|Metformin|Active medication.
40991732|NCT05772520|DRUG|TLL018 tablets|oral tablets administered BID for 12weeks
40991733|NCT06180590|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Evaluate the efficacy of Vosevi in DAAs-experienced patients
41308404|NCT00077610|DRUG|RO0503821 (1x/2 Weeks)|60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
41308405|NCT00077610|DRUG|RO0503821 (1x/4 Weeks)|120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
41308406|NCT01255046|DRUG|Donepezil,|10mg/tab, 1 tab/day for 72 weeks
41308407|NCT01255046|DRUG|STA-1|300mg/tab, 2 tab/tid for 72 weeks
41308408|NCT01255046|DRUG|placebo|2 tab/tid for 72 weeks
41308409|NCT01114958|DRUG|Cisplatin, Thiosulfate|Cisplatin (150 mg/m\^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m\^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m\^2).
41308410|NCT02198287|DRUG|BIIX 1 XX inhalation solution|single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
41308411|NCT02198287|DRUG|Placebo|
40787627|NCT03444324|BIOLOGICAL|FFP/Cryo|FFP/Cryo was administered intravenously; dosage according to local standards in mL per kg body weight.
40787628|NCT04038294|DIETARY_SUPPLEMENT|ISOlution protein supplement|EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.
40787629|NCT04038294|DIETARY_SUPPLEMENT|Placebo Supplement|PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
40787630|NCT02850978|DRUG|Spiolto|
40787631|NCT04828135|DRUG|Hyperpolarized 129Xenon gas|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
40787632|NCT00057057|BEHAVIORAL|Telephone Care|
40787633|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (full intervention)|The full ENRICH pilot intervention will consist of content related to diet, physical activity, stress/mental health, sleep, tobacco cessation, and child health. The investigators will use an adapted version of the Mothers and Babies stress management intervention to address mental health, an adapted version of the HEALTH curriculum to address diet/physical activity, and an adapted version of the INSIGHT curriculum to address child health.
40787634|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (partial intervention: only diet and physical activity)|The partial ENRICH intervention will focus only on diet and physical activity.
40787635|NCT05634330|OTHER|exercise treatment|core stabilization exercise
40787636|NCT05404971|OTHER|Joint integrity exercises|patients with three strokes followed by 3 sec rest period. Kinaesthetic stimulations will be given to the patients to increase proprioception proprioception in neglected limb in sitting position, the limb on the affected side of the body is supported and moved by the examiner in various directions but movement is only at one joint at a time. Stereognosis by placing the object in the patient's hand for a maximum 30 seconds with close eyes. Identification is by naming, description or by pair matching with an identical set.
40787637|NCT05404971|OTHER|Mirror therapy|A 5 cm × 35 cm mirror will be placed vertically between the upper limbs on the table, with the reflecting surface facing the uninjured limb. Patients will be asked to observe the motion of the upper limb on the uninjured side and imagine that the limb on the affected side was in motion, imagine the motion of the affected limb the same as that observed on the uninjured side, and complete 6 movements including shoulder joint forward flexion, elbow joint flexion and extension, forearm forward and backward rotation, wrist joint flexion and extension, finger extension and grasping, and thumb abduction. The participants will be asked to perform each movement for 5 min and try to reach the maximum range of motion of the joints. Training will be completed for 30 min per day) Session will be 3 days per week. Per day session will be for 30 minutes.
40787638|NCT02399787|OTHER|blastocyst biopsy|Performed on day 5
40787639|NCT05345548|DIAGNOSTIC_TEST|Cold Pressor test|Cold Pressor test will be done for 3 minute duration maximum
40787640|NCT05369364|DRUG|Zanubrutinib|Zanubrutinib 80mg qd po, 6 consecutive weeks
40787641|NCT05369364|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
40787642|NCT06139809|PROCEDURE|Intubation|Intubation will take place according to our local standard protocol for nasal intubation using NIPPV delivered through a nasopharyngeal tube. The intubation will be video-recorded to provide a clear view of the procedure and the pulse oximeter displaying the SpO2 and HR.
40787643|NCT03519997|DRUG|Pembrolizumab|Pembroluzumab 200mg IV once every 3 weeks
40787644|NCT03519997|DRUG|Bavituximab|Bavituximab 3mg/kg IV weekly
40787645|NCT04968392|DRUG|Dexmedetomidine Hydrochloride|20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
40787646|NCT04968392|DRUG|Levobupivacaine|20 mL of 0.25% levobupivacaine plus 1 mL normal saline
40787647|NCT03243773|OTHER|Lung ultrasound|Point-of-care ultrasound exam of both lungs in 4 predefined zones.
40787648|NCT03816722|DEVICE|Airvo2|Treatment with HighFlow through the Airvo2 device, 8 hours per day
40991734|NCT01030523|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
41308412|NCT02163304|OTHER|Sucrose|
41308413|NCT02163304|OTHER|Artificial Sweetner|
41308414|NCT02163304|OTHER|Tasteless Solution|
40991735|NCT01030523|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
40787649|NCT03816722|OTHER|Usual care|"High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients"
40991736|NCT03647228|DRUG|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
40991737|NCT03647228|DRUG|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
40991738|NCT04484454|DIETARY_SUPPLEMENT|ProdromeNeuro Omega 3 Oil Nutritional Supplement|ProdromeNeuro is an algae-derived Omega 3 oil nutritional supplement product comprised of naturally occurring alkylglycerol and natural fatty acids. ProdromeNeuro functions as a natural plasmalogen precursor which can be administered orally.
40991739|NCT00049439|BIOLOGICAL|filgrastim|filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
40991740|NCT00049439|DRUG|cyclophosphamide|Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
40991741|NCT00049439|DRUG|etoposide|Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
40991742|NCT00049439|DRUG|lomustine|Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
40991743|NCT00049439|DRUG|procarbazine hydrochloride|Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
40991744|NCT06449807|BEHAVIORAL|crossover point intensity exercise|crossover point intensity exercise
40991745|NCT06414967|OTHER|Music Intervention|Music therapy carried out with Music Care
40991746|NCT00089349|BIOLOGICAL|alemtuzumab|Given IV
40991747|NCT00089349|DRUG|methotrexate|Given IV
40991748|NCT00089349|DRUG|mercaptopurine|Given PO
40991749|NCT03710655|DRUG|Apitox - pure honeybee toxin|Intradermal injection of 0.01 microliters
40991750|NCT03710655|DRUG|Placebo|Intradermal injection of 0.01 microliters
40991751|NCT00739037|DRUG|Placebo|
40991752|NCT00739037|DRUG|PAZ-417|
41308415|NCT00242580|DRUG|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
41308416|NCT00242580|DRUG|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
40991753|NCT06397703|DRUG|Leuprolide, Degarelix or Relugolix|Patients assigned to the androgen deprivation therapy (ADT) arm will be treated with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.
40991754|NCT06397703|RADIATION|Stereotactic body radiation therapy/radiosurgery (SBRT)|SBRT will be directed to the prostate and delivered with a prescription dose of 40 Gy in 5 fractions prescribed to the 95% isodose line encompassing the planning target volume. Inter-fraction motion targeting and target position corrections will be utilized for each of the 5 treatment fractions.
40991755|NCT03779464|DRUG|S1 or Gemcitabine|Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area \< 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area \>1.5 m²; D1-14, q3w)
40991756|NCT02461225|DEVICE|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes that are applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
41488629|NCT04168190|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
41488630|NCT04168190|BIOLOGICAL|Pneumovax™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
41488631|NCT03485053|DRUG|IOP Injection / MPB-1514|Dilute with 5% Dextrose solution (D5W)
41147401|NCT00801905|OTHER|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
40787650|NCT05979961|RADIATION|IMRT and concurrent cisplatin|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated radiotherapy (IMRT)
40787651|NCT05979961|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy
41147402|NCT04712500|DRUG|AND017|AND017 oral capsule
40991757|NCT02461225|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light. It is applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
40991758|NCT00888095|PROCEDURE|deep brain stimulation|electrode implantation in either STN or cZI
40991759|NCT05027412|DEVICE|En bloc TURBT Collins Loop|En bloc TURBT Collins Loop
40991760|NCT05027412|DEVICE|Conventional TURBT|Conventional TURBT
40991761|NCT02601742|OTHER|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
40991762|NCT02601742|OTHER|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
40991763|NCT02420691|OTHER|Laboratory Biomarker Analysis|Correlative studies
40991764|NCT02420691|OTHER|Pharmacological Study|Correlative studies
40991765|NCT02420691|DRUG|Ribociclib|Given PO
40991766|NCT05506852|BEHAVIORAL|Web-based training strategy|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game using specific strategies, in order to optimize the performance."
40991767|NCT05506852|BEHAVIORAL|Web-based regular training (no strategy)|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game under regular game instructions."
40991768|NCT05110911|BIOLOGICAL|Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad|Influenza vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
40991769|NCT05110911|BIOLOGICAL|SARS-CoV-2 vaccination: Comirnaty or Vaxzevria|SARS-CoV-2 vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
40991770|NCT02825927|OTHER|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
40991771|NCT05169723|BEHAVIORAL|Exertional respiratory activities|participants will perform a series of exertional respiratory activities
40991772|NCT01591291|DRUG|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
40991773|NCT01591291|DRUG|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
41147403|NCT01709045|OTHER|Magnetic Resonance Imaging (MRI)|Multi-sequence MR protocol
41147404|NCT01709045|RADIATION|Dual-Energy Computed Tomography (DECT)|
41308417|NCT00242580|DRUG|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
41308418|NCT03820037|DRUG|Ongentys|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
41308419|NCT03820037|DRUG|BIA 9-1067 (test)|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
41308420|NCT03444818|DRUG|[14C]-E6007|Oral administration
41308421|NCT04094350|OTHER|ACF with a seed-and-recruit model|The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
40991774|NCT05968807|BEHAVIORAL|iParent2Parent Program|iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric solid organ transplant (SOT) recipients who are trained to offer vital peer support and mentorship.
40991775|NCT04668950|DRUG|Fluvoxamine|Up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days
40991776|NCT04668950|DRUG|Placebo|Will take 2 capsules per day as tolerated for approximately 15 days
40991777|NCT05020314|BEHAVIORAL|Healthy Weight Clinic|Patients meet with a multi-disciplinary team over a 12 month period. In addition to the clinical visits, group visits, and phone calls, patients will also receive education materials, community resources, and an optional text messaging/social media library of messages.
40991778|NCT03285971|OTHER|Electronic CPP pager alert|Anesthesia providers will receive a pager alert when CPP decreases beow 60 mmHG (median value over 5-minute epochs)
40991779|NCT01083212|DRUG|AZD1656|Single dose,oral tablet
40991780|NCT01083212|DRUG|Gemfibrozil|Oral tablet bid on day 1 - 5.
41147405|NCT01709045|OTHER|Ultrasound|
41467152|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification and Adolescent Functions Enabled|Parent/guardian participants will interact with the complete ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given to parent/guardian participants via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/ guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction and questions about the clinic notification feature. The complete ECA-HPV app includes the parent version and adolescent versions of the ECA-HPV app. Both versions have the clinic notification feature enabled. Adolescent participants will receive usual care and can engage with the adolescent version of the ECA-HPV app throughout the study.
40787652|NCT00443118|DEVICE|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
40787653|NCT00443118|DEVICE|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
40787654|NCT00443118|DEVICE|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
40787655|NCT06117345|BEHAVIORAL|PICU Journal|A hard-copy, customizable educational/therapeutic/expressive journal for parents/caregivers to seek information and document their child's PICU experiences and outcomes.
40787656|NCT02012218|DRUG|ADT|
40787657|NCT02012218|DRUG|Brexpiprazole|
40787658|NCT00004927|DRUG|ixabepilone|
40787659|NCT04509570|PROCEDURE|Biopsy|5\~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
40787660|NCT01490918|DRUG|Acarbose|Acarbose 50mg b.i.d at first, at the 2nd week 50mg t.i.d and the 4th week, 100mg tid.
40787661|NCT01490918|DRUG|Placebo acarbose|acarbose placebo
40787662|NCT01490918|DRUG|placebo metformin|metformin placebo
40787663|NCT00192543|BEHAVIORAL|diet of fish and fruit|fish and fruit in specified quantities
40787664|NCT00192543|BEHAVIORAL|fruit and fish|no drugs
40787665|NCT00192543|BEHAVIORAL|diet only|Fish and fruit
40787666|NCT00192543|BEHAVIORAL|regular diet|no change in regular diet
40787667|NCT00123825|DRUG|Gemcitabine|
40991781|NCT01083212|DRUG|Placebo|Oral tablet bid on day 1-5
40991782|NCT03441633|DRUG|apixaban|current or new medication
40991783|NCT03441633|DRUG|dabigatran|current or new medication
41467153|NCT02124902|DRUG|Docetaxel|
40991784|NCT03441633|DRUG|VKA|current or new medication
40991785|NCT03441633|DRUG|rivaroxaban|current or new medication
40787668|NCT00123825|DRUG|Cisplatin|
40787669|NCT01476540|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
40787670|NCT04093960|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
40991786|NCT03409926|DIETARY_SUPPLEMENT|Acacia Gum|dietary supplement will be added to the participant's usual diet
40991787|NCT06213168|OTHER|HFNC|Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization
40991788|NCT06213168|OTHER|CPAP and HFNC|Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions
40991789|NCT05211713|DEVICE|Opp|Opp is a universal mental health promoting mobile application for adolescents aged 13-25 years.
40991790|NCT03169673|DIAGNOSTIC_TEST|Hyperpolarized Helium 3 Magnetic Resonance Imaging|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 3He gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
41147406|NCT01709045|OTHER|Transcranial doppler|
41147407|NCT00845286|BEHAVIORAL|Munich Marathon|42,195 km marathon run
40787671|NCT03073525|BIOLOGICAL|Vigil|The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
40787672|NCT03073525|DRUG|Atezolizumab|"Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters."
40787673|NCT03053934|BEHAVIORAL|Online video-based counselling|Videoconferencing facilitates communication between individuals (i.e., the counsellor and the client) in different geographical locations enabling them to interact simultaneously with each other on a computer monitor in real time. In other words, both the client and the therapist communicate live using both visual and audio aids simulating in-person therapy albeit from two separate geographical locations.
40787674|NCT03053934|BEHAVIORAL|Traditional in-person counselling|"Traditional in-person counselling is often referred to as face-to-face and can be loosely defined as any mental health intervention, whereby the clinician is in the same room with a client. The terms in-person and same room are used less frequently, but it has been argued that these terms are more descriptive (since in videoconferencing, clients are also seen face-to-face on screen). Therefore, the current study uses the term in-person to describe traditional, face-to-face counselling."
40787675|NCT00432393|DRUG|levodopa-carbidopa|
40787676|NCT03211819|PROCEDURE|immediate implant placement|"A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement."
40787677|NCT05018689|OTHER|Aevidum curriculum|The Aevidum curriculum will be delivered to 9th grade students at participating high schools in both study arms. All school staff who plan to deliver the curriculum will participate in a web-based training workshop with the Aevidum Executive Director.
40787678|NCT05018689|OTHER|Club|Schools will identify ten students interested in participating in an Aevidum club. Following training of interested students, schools are asked to commit to running two Aevidum club activities during the school year.
40787679|NCT02538120|OTHER|Microvascular assessment|Microvascular assessment
40823060|NCT02062892|DRUG|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
40991791|NCT01059474|DRUG|transdermal DMPS|"12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.~Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS."
40991792|NCT02684643|OTHER|enhanced individualised therapy|additional dialysis dosage, modification of medication and prescribed dietary plan
40991793|NCT02684643|OTHER|non-enhanced individualised therapy|modified medication, prescribed dietary plan and regular three times/week dialysis dosage
40991794|NCT02684643|OTHER|regular intervention|Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
40991795|NCT00846755|DRUG|Levothyroxine, Propylthiouracile|Drugs were titrated to render euthyroid pregnant patients with thyroid disease
40991796|NCT00289809|DRUG|combination of TLC D-99 and Ifosfamide|"* TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~* Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks"
40991797|NCT03171987|DRUG|Lidocaine patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
41467154|NCT02124902|DRUG|Carboplatin|
41467155|NCT02124902|PROCEDURE|FDG-PET/MR|"* Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~* This is not optional for final 30 participants enrolled on the study"
41467156|NCT02443324|DRUG|Ramucirumab|Administered IV
41467157|NCT02443324|DRUG|Pembrolizumab|Administered IV
41147408|NCT04596917|BEHAVIORAL|Preferred music listening|The preferred music listening group will receive 15 minute patient-preferred music listening selection intervention in the Prep Room and unlimited music listening selection intervention in the PACU once cognitively ready until discharge criteria met.
41467158|NCT05365490|PROCEDURE|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
41467159|NCT00792207|OTHER|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
41467160|NCT00792207|OTHER|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
41488632|NCT06449326|DEVICE|Active Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is an efficient form of transcranial magnetic stimulation that allows up to 10x more pulses to be delivered in a given timeframe compared to conventional stimulation patterns.
41488633|NCT06449326|DEVICE|Sham Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is an efficient form of transcranial magnetic stimulation that allows up to 10x more pulses to be delivered in a given timeframe compared to conventional stimulation patterns.
40991798|NCT03171987|DRUG|Flurbiprofen patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
40787680|NCT01605357|DRUG|Induced, sustained hypernatremia using hypertonic saline|"Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines"
40787681|NCT01605357|DRUG|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium \< 135 mmol/L) is to be corrected at the discretion of the provider.
40787682|NCT02847169|DEVICE|filcon IV1 toric lens|toric contact lens
40787683|NCT02847169|DEVICE|ocufilcon D toric lens|toric contact lens
40787684|NCT05270148|OTHER|HIIT|12 weeks training High-Intensity Interval Training consists of 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes).Depending on the number of training session, the loadand the series will increase up to 40% more than the maximum load.
40787685|NCT05270148|OTHER|Fat Max|12 weeks training Fatmax consist in 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. MICTprogram will consist of sessions of approximately ˜45min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
40991799|NCT04353154|DIAGNOSTIC_TEST|Spartan Cube Point-of Care Covid-19 test|Throat and nasal swab for COVID-19 point-of-care test.
40787686|NCT03972618|BEHAVIORAL|Installation of water filtration system for filtering existing water source|Installation of water filtration system and education on hand washing.
40787687|NCT01465386|DRUG|bortezomib|Given SC
40787688|NCT03725956|PROCEDURE|Endoscopic sinus surgery|"Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice"
40787689|NCT03758261|DRUG|Paravertebral nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
40787690|NCT03758261|DRUG|Erector Spinae nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
40787691|NCT03224364|PROCEDURE|nonsolo LA|This patient is scheduled to undergo nonsolo laparoscpic appendectomy.
40787692|NCT03224364|PROCEDURE|solo LA|This patient is scheduled to undergo solo laparoscpic appendectomy.
40787693|NCT03051802|DEVICE|Navigated Endoscopy|Navigated endoscopy used to guide the placement of HDR applicators in the esophagus or lung as a replacement to current standard of practice using fluoroscopic imaging.
40991800|NCT03429179|DRUG|Butorphanol|intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
40991801|NCT03429179|OTHER|Physiological saline|intravenous infusion of the same volume of 0.9% saline
40991802|NCT02812316|DEVICE|HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens|Approximately At least one hundred and forty (140) subjects (280 eyes) will be enrolled in this study at approximately two (2) clinical sites in Taiwan. All subjects will be fitted for and dispensed study lenses by each Investigator.
40991803|NCT05945654|PROCEDURE|Anastomotic Leak after Ivor Lewis Oesophagectomy|Surgical resection of the esophagus with oesophagogastrostomy. Groups depend on postoperative complication
40991804|NCT00665353|DRUG|pioglitazone|Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
40991805|NCT00665353|DRUG|peginterferon|Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
40991806|NCT00665353|DRUG|ribavirin|Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
40991807|NCT04049851|DRUG|Moxidectin 2 MG Oral Tablet|One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.
40991808|NCT04049851|DRUG|Ivermectin 3Mg Tab|3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.
40991809|NCT04049851|DRUG|Placebo oral tablet|Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.
40991810|NCT04824131|DRUG|Oral cabotegravir (CAB)|30 mg tablets
40991811|NCT04824131|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
40991812|NCT04824131|DRUG|Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|300 mg/200 mg fixed-dose combination tablets
40991813|NCT03832582|DRUG|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
40787694|NCT04289558|DRUG|Sodium Nitrite|Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study
40787695|NCT03569124|OTHER|Teaching tool for identification of colorectal polyps|This is a teaching session on how to identify the colorectal polyps shot in blue light imaging.
40991814|NCT01299623|BEHAVIORAL|Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors|Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
40991815|NCT01818661|DRUG|AV-1451|This is used to assess Tau burden in the brain.
40991816|NCT01623323|DRUG|Fluticasone Propionate|Fluticasone Propionate 400 μg
40991817|NCT03668626|OTHER|Family-centered intervention program (FCIP)|This program included in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention emphasized modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education.
40991818|NCT04811170|OTHER|Counselling|Participants with mild to moderate mood symptoms will receive a maximum of 6 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W8), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention. Participants with severe mood symptoms will receive a maximum of 10 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W12), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention.
40991819|NCT02730325|OTHER|Serum-derived bovine immunoglobulin/protein isolate (SBI)|
40991820|NCT02730325|OTHER|Placebo|
40991821|NCT04459312|DIAGNOSTIC_TEST|Antibody test (SARS-CoV2)|Antibody test
41308422|NCT04094350|OTHER|ACF targeting household and neighborhood contacts|In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.
41308423|NCT04094350|OTHER|ACF targeting the older population using mobile screening units|The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.
41308424|NCT04094350|OTHER|Passive case finding|Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
41308425|NCT01763905|BIOLOGICAL|Evolocumab|Subcutaneous injection
41308426|NCT01763905|DRUG|Placebo to Evolocumab|Subcutaneous injection
41308427|NCT01763905|DRUG|Ezetimibe|Tablet for oral administration
40787696|NCT02234440|DRUG|Metformin|
40787697|NCT02234440|DRUG|Insulin|
40787698|NCT01781884|DRUG|Gamma Aminobutyric Acid (GABA)|two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
40787699|NCT01781884|DRUG|Placebo|
40787700|NCT04470297|DRUG|Ramelteon 8mg|Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
40991822|NCT02469454|DRUG|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
40991823|NCT02469454|DRUG|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
40787701|NCT00894595|BEHAVIORAL|Knäkontroll, SISU Idrottsböcker©, Sweden, 2005|The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
40787702|NCT00328796|PROCEDURE|acupuncture in 6 specific points|
40787703|NCT00328796|DRUG|lidocaine 10mg/ml|
40787704|NCT05494268|DRUG|Carbohydrate|Preoperative Carbohydrate Loading Drink
40787705|NCT01107639|BIOLOGICAL|cetuximab|Loading dose 400 mg/m2 2h infusion Weekly: 250 mg/m2 1h infusion
40787706|NCT01107639|DRUG|cisplatin|"* Cisplatin 75 mg/m2 1h infusion d1, 22~* Cisplatin 25 mg/m2 1h infusion weekly x5"
40787707|NCT01107639|DRUG|docetaxel|"* Docetaxel 75 mg/m2 1h infusion d1, 22~* Docetaxel 20 mg/m2 1/2h infusion weekly x5"
40991824|NCT05130931|OTHER|Multimodal conservative treatment|"15 min of Pain education + 20 min of Specific mobilization of the forearm musculature, pronator teres, tendons of the palmar flexors of the wrist and fingers, transverse carpal ligament and palmar fascia through manual mobilization assisted by Diacutaneous Fibrolysis technique + 10min of self-management and explanation of home-based exercise.~3 sessions of 45 minutes will be taken to perform this protocol and the patient will be shown a self-treatment to be performed 3-5 times a day. The protocol will be carried out over 3 weeks (1 session per week)."
40991825|NCT03774277|BEHAVIORAL|Packed Promise for a Healthy Heart|"Voucher for fresh vegetables and fruits (referred to as a fresh check); Home delivered food boxes that contain Dietary Approaches to Stop Hypertension (DASH)-approved ingredients for preparing low-salt, and traditional healthy Chickasaw meals; Heart-healthy recipes (available at getfreshcooking.com) that are tailored to traditional Chickasaw diet and culture; Educational materials; Personalized invitation to attend local cooking demonstrations; Assistance to link the Fitbit and AYA app"
40991826|NCT05819762|DIAGNOSTIC_TEST|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab LS screening panel on a specified Flow Cytometry
40991827|NCT04308837|DRUG|Paclitaxel|50 mg/m2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
40991828|NCT04308837|DRUG|Carboplatin|Carboplatin AUC = 2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
40991829|NCT04308837|DRUG|Dexamethasone|All patients receiving Paclitaxel will receive institutional standard premedications, which include Dexamethasone (10 mg IVPB)
40991830|NCT04308837|DRUG|Diphenhydramine|All patients receiving Paclitaxel will receive institutional standard premedications, which include diphenhydramine (50mg IVP)
41308428|NCT01763905|DRUG|Placebo to Ezetimibe|Tablet for oral administration
40787708|NCT01107639|PROCEDURE|adjuvant therapy|During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².
40787709|NCT01107639|PROCEDURE|neoadjuvant therapy|During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.
40787710|NCT01761513|DRUG|YH4808|"Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks"
40787711|NCT01761513|DRUG|YH4808|"Group2~1. adminitration of YH4808 dose2, qd for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose1, bid for 2weeks"
40787712|NCT01761513|DRUG|YH4808|"Group3~1. adminitration of YH4808 dose2, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of Nexium tab 40mg, bid for 2weeks"
40787713|NCT01761513|DRUG|YH4808|"Group 4~1. adminitration of Nexium tab 40mg, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, bid for 2weeks"
40787714|NCT06405490|DRUG|Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab|Use the above medications on a regular basis
40787715|NCT02101398|DEVICE|eldith DC-stimulator, configuration F7A|tDCS will be delivered during a 20 minutes speech-language therapy session
40787716|NCT02101398|DEVICE|eldith DC-stimulator, configuration F7C|tDCS will be delivered during a 20 minutes speech-language therapy session
40787717|NCT02101398|DEVICE|eldith DC-stimulator, configuration T5A|tDCS will be delivered during a 20 minutes speech-language therapy session
40787718|NCT02101398|DEVICE|eldith DC-stimulator, configuration T5C|tDCS will be delivered during a 20 minutes speech-language therapy session
40991831|NCT04308837|DRUG|Famotidine|All patients receiving Paclitaxel will receive institutional standard premedications, which include Famotidine (20mg IVPB)
40991832|NCT04308837|DRUG|Palonosetron|All patients receiving Paclitaxel will receive institutional standard premedications, which include Palonosetron (0.25mg IVP)
40991833|NCT04308837|RADIATION|3D conformal or intensity modulated radiotherapy|Treatment will be given 5 days per week. Photon beams \>6 MV are required. Treatment may be delivered either by a 3D conformal technique or IMRT. IMRT via dynamically moving MLCs, step-and-shoot with a multileaf collimator, Rapid Arc, binary multileaf collimator, and tomotherapy are allowed. Proton therapy is not allowed.
40991834|NCT04308837|PROCEDURE|Surgical resection|Surgical resection will constitute subtotal or total gastrectomy (depending on tumor size and location) and D2 lymphadenectomy.
40991835|NCT04308837|RADIATION|Adjuvant Chemotherapy|The patient will begin adjuvant chemotherapy 4-12 weeks after surgery. The adjuvant chemotherapy will consist of FOLFOX every 2 weeks for 6 cycles (i.e. 3 months)
40991836|NCT04946357|RADIATION|Protons|proton irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
40991837|NCT04946357|RADIATION|carbon ions|carbon ion irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
40991838|NCT04713475|BIOLOGICAL|PBGM01|AAVhu68 viral vector
40991839|NCT04653779|DRUG|Evogliptin 5mg/Metformin 1000mg|Size reduction of a tablet formulation
40991840|NCT02981342|DRUG|Abemaciclib|Administered orally
41308429|NCT02159326|DRUG|Microgynon|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
40787719|NCT02101398|DEVICE|eldith DC-stimulator, configuration Sham|Sham tDCS will be delivered during a 20 minutes speech-language therapy session
40787720|NCT04468373|DEVICE|WA-NG (NG-IMT) Telescope Prothesis|The WA-NG telescope prosthesis is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
40991841|NCT02981342|DRUG|LY3023414|Administered orally
40991842|NCT02981342|DRUG|Gemcitabine|Administered IV
41147409|NCT04596917|BEHAVIORAL|Relaxation breathing narrative over hypnotic music listening|The relaxation breathing group will receive the relaxation and breathing instructions over soft monotone hypnotic music in the PreOp unit before surgery and then in the PACU once cognitively ready to listen to the hypnotic music until discharge criteria met.
41147410|NCT05472883|PROCEDURE|blood samples|- Research blood sample: 2 additional tubes compared to the classic sample for the analysis of the 9 research molecules.
40991843|NCT02981342|DRUG|Capecitabine|Administered orally
40787721|NCT03445767|OTHER|MedSafer|An electronic deprescribing intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation. These recommendations are presented to the treating physicians for their consideration.
40787722|NCT03027674|DRUG|10% nifedipine cream|Topical treatment for Raynaud
40787723|NCT03027674|DRUG|5% sildenafil cream|Topical treatment for Raynaud
40787724|NCT05604443|OTHER|retrospective analyze|retrospective analyze of MS39 and Pentacam images
40991844|NCT01480076|DRUG|Fampridine|Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
40991845|NCT01163708|DEVICE|Prophecy Technique|Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively
40991846|NCT01163708|DEVICE|Navigation System|
40991847|NCT03106155|DRUG|vistusertib (AZD2014)|vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.
40991848|NCT02905682|DRUG|Desmopressin|
40991849|NCT02905682|DRUG|Placebo|
40991850|NCT00921180|DRUG|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
40991851|NCT00921180|DRUG|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
41308430|NCT02159326|DRUG|Riociguat (Adempas,BAY63-2521)|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
40823061|NCT02062892|DRUG|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
40991852|NCT01750008|PROCEDURE|Global Fibroid Ablation|
40991853|NCT01750008|PROCEDURE|Myomectomy|
40991854|NCT02940288|OTHER|Auricular Acupuncture|Participants will receive bilateral auricular acupuncture using the Battlefield Acupuncture (BFA) protocol while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. Acupuncture needles will be left in place for 30 minutes.
40991855|NCT02940288|OTHER|Sham Acupuncture|Participants will receive sham acupuncture while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. During the sham procedure, needles will be inserted bilaterally in five nonspecific ear acupoints. Acupuncture needles will be left in place for 30 minutes.
40991856|NCT02112669|DEVICE|VasQ|
40991857|NCT03583138|DRUG|buprenorphine|To provide buprenorphine for 12 months for those who are interested in receiving it.
40991858|NCT03449160|DEVICE|UPRIGHT|A small externally wearable device that is placed on the back, which gently vibrates when correct posture is not maintained. The device is removable, and used for only portions of the day
40991859|NCT03449160|OTHER|physical therapy|routine physical therapy
40991860|NCT03630809|BIOLOGICAL|HER2 DC1 Vaccine|Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.
40991861|NCT01413360|DRUG|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
40991862|NCT04754776|BIOLOGICAL|ChAdOx1 RVF|Single dose of ChAdOx1 RVF
40991863|NCT06143670|DRUG|Stannous fluoride toothpaste|0.454% w/w SnF2
40991864|NCT06143670|DRUG|Sodium fluoride toothpaste|0.243% w/w Sodium fluoride
40991865|NCT03561623|OTHER|magnetic resonance (MR) Imaging|MRI of spinal cord and brain
40991866|NCT03561623|OTHER|quantitative muscle force assessment|quantitative assessment of muscle force
41147411|NCT05472883|PROCEDURE|collection of body tissues|removal of intra-abdominal fat and muscle tissue
40787725|NCT06084351|DRUG|Convalescent Plasma|"Class: Blood product Physical Description: Opaque yellow fluid within a container labelled with the statement Caution: New Drug - Limited by Federal (or United States) law to investigational use). Container will also be labelled with the International Society of Blood Transfusion format for Blood Components. Label will contain the expiration date and the donor identification number. Label will also contain information pertaining to the ABO typing of the plasma. A copy of the IBST identifier will be placed with the patient chart.~Manufacture: Plasma will be collected via apheresis via collaboration with American Blood Bank Corporation, a FDA-registered blood establishment. The donors will be screened in accordance with the FDA guidance for donor eligibility for COVID-19:"
40787726|NCT06084351|OTHER|Standard of Care|Standard of care treatment for hospitalized COVID-19 patients
40787727|NCT04244266|OTHER|NO INTERVENTION, it is an observational study|No intervention
40787728|NCT02812745|DEVICE|recording of cardiac output|
40787729|NCT02812745|DEVICE|other parameters|BIS (bispectral index ), PI (perfusion index ), etCO2 (end-tidal carbon dioxide ), and brain NIRS (near-infrared spectroscopy)
40787730|NCT04523584|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will undergo MR imaging of the liver. Liver PDFF will be measured.
40991867|NCT02590939|DEVICE|CEFALY Active|Active external trigeminal nerve stimulation
40787731|NCT04523584|DEVICE|Ultrasound Imaging|Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.
40787732|NCT02717325|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-08)
40787733|NCT00572182|DRUG|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
40991868|NCT02590939|DEVICE|CEFALY Placebo|Placebo external trigeminal nerve stimulation
40991869|NCT03462550|DEVICE|Laryngeal mask|LMA insertion
40991870|NCT03193411|DEVICE|Visumax femtosecond laser|
40991871|NCT03193411|DEVICE|Moria M2 microkeratome (MK)|
40991872|NCT03828812|BEHAVIORAL|Breakfast promotion|Recommendation of having breakfast daily
41308431|NCT01021072|DRUG|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
41308432|NCT06445101|OTHER|Participatory Approach|The participatory approach is a stepwise, collaborative approach to the analysis and solvation of bottlenecks that cause stress in employees.
41308433|NCT04863014|DRUG|evinacumab|Intravenous infusion every 4 weeks (Q4W)
40787734|NCT04300387|BEHAVIORAL|multidisciplinary care|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
40991873|NCT03828812|BEHAVIORAL|Nighttime snack reduction|Recommendation of reducing frequency of nighttime snacking
40991874|NCT04850014|OTHER|Anthropomorphism|Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender
40991875|NCT04850014|OTHER|Relevant clinical datas|"Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation.~Imaging."
40991876|NCT05316831|BIOLOGICAL|PCV13|Pneumococcal polysaccharides conjugated to CRM197 carrier protein
40991877|NCT05316831|BIOLOGICAL|PPSV23|Pneumococcal polysaccharides
40991878|NCT00046696|DRUG|NM-3|
40991879|NCT05768152|DEVICE|RLRL|RLRL will be performed twice per day with an interval of at least 4 hours, each treatment last 3 minutes, in addition to single vision spectacles with power for correcting distance refraction.
41308434|NCT04863014|OTHER|Placebo|Intravenous infusion Q4W
41308435|NCT00756496|DEVICE|Mammography screening and diagnosis|Mammography screening and diagnosis
41308436|NCT00937768|DRUG|Goserelin Acetate|Given SC
40787735|NCT05450835|PROCEDURE|OGT group|In OGT group,the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Meanwhile, the OGT was sleeved on anvil fork extracorporeally and the linear stapler was put into abdomen through trocar on the right side and then cartridge fork was inserted through jejunum opening towards the oral side of the lumen. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube.
40787736|NCT05450835|PROCEDURE|Overlap group|In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al.
40787737|NCT02774434|DEVICE|JM-105|Measurement of TcB via the JM-105 device
40787738|NCT00544856|BEHAVIORAL|complex cognitive training|
40787739|NCT05363488|DRUG|Bosutinib|Patients receiving bosutinib treatment
40787740|NCT06184178|OTHER|Socio-health care|Socio-health care under TEC-MED model and an integral assessment
40787741|NCT00284180|DRUG|Vinflunine|Novel second generation vinca alkaloid
40787742|NCT00284180|DRUG|Trastuzumab|Anti-HER2 monoclonal antibody
40991880|NCT03322488|PROCEDURE|Fistulodesis|"Fistulodesis comprises the following treatment steps:~* Curettage and/or brushing of the fistula tract~* Mini-excision of the inner (endoanal) fistula opening~* Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~* Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~* Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~* Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~* Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline)."
40991881|NCT01476696|DRUG|Prasugrel|Administered orally
40991882|NCT05951530|OTHER|traditional physical therapy|this group received conventional upper extremity active ROMs and stretches for 30 minutes three to five times a week for 6 weeks without using the app-based cognitive training.
40991883|NCT05951530|OTHER|mobile app-based cognitive training|This group received mobile app-based cognitive training of 30minutes session three to five times a week for 6 weeks which includes a few activities such as the memory, coordination and alertness along with conventional UE exercises for 15 minutes three to five times a week for 6 weeks.
40991884|NCT05567055|DRUG|Capmatinib|Capmatinib is a medication for the treatment of metastatic non-small cell lung cancer tumors that have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR
40991885|NCT02266420|PROCEDURE|Blood samples of 10 mL|Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
40991886|NCT02002923|PROCEDURE|Pulmonary vein isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
40787743|NCT06345339|DRUG|Armour Thyroid|Oral Capsule or Tablet
40991887|NCT02002923|DRUG|Botulinum Toxin|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
41308437|NCT00937768|OTHER|Laboratory Biomarker Analysis|Correlative studies
41308438|NCT00937768|DRUG|Leuprolide Acetate|Given IM
41308439|NCT00937768|OTHER|Quality-of-Life Assessment|Ancillary studies
40787744|NCT06345339|DRUG|Levothyroxine|Oral Capsule
40787745|NCT06439121|PROCEDURE|4-7-8 Breathing Technique|Patients will be instructed to practice the 4-7-8 breathing technique once per hour (4 breaths) post-surgery. Pain and nausea-vomiting will be monitored at 0, 2, 6, 12, and 24 hours during their 24-hour hospital stay.
40787746|NCT00429182|DRUG|Carboplatin|Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
40787747|NCT00429182|DRUG|Cyclophosphamide|1.5 gm/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
40787748|NCT00429182|DRUG|Thiotepa|120 mg/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
40787749|NCT00429182|PROCEDURE|Stem Cell Transplant|Stem Cell Transplant on Day 0.
40787750|NCT02910141|DEVICE|Continuous subcutaneous insulin infusion|Infusion of short-acting insulin from a portable pump
40787751|NCT02405988|DRUG|Intravenous naloxone|Administer 2,5 mL, dose intravenous naloxone 1,0 mg
40787752|NCT02405988|DRUG|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
40787753|NCT05301543|BEHAVIORAL|Experimental: Behavioral approach 1|Includes changing sleep habits and cognitions around sleep from a mental level
40787754|NCT05301543|BEHAVIORAL|Comparator: Behavioral approach 2|Includes changing sleep habits and awarenes of sleep from a perception level
40787755|NCT03492047|DIETARY_SUPPLEMENT|low dose N-acetylcysteine|N-acetylcysteine 600mg twice daily
41147412|NCT05472883|PROCEDURE|routine care procedure|"* Routine care blood sample: Full vitamin panel, CBC, liver panel, urea, creatinine, blood ionogram, blood calcium, phosphorus, magnesium at all visits, except the morning of surgery when only ß HCG (for women of childbearing age), HbA1c.~* clinical examination : weight, height, waist measurement, cardiovascular examination, digestive system examination.~* dosage of ß HCG for womens."
40991888|NCT02418195|DRUG|ketamine|IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
40787756|NCT03492047|DIETARY_SUPPLEMENT|high dose N-acetylcysteine|N-acetylcysteine 1200mg twice daily
40787757|NCT03492047|DRUG|Paclitaxel|Paclitaxel 80mg /m2 IV
40787758|NCT03902795|DIAGNOSTIC_TEST|Microperimetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
40787759|NCT03902795|DIAGNOSTIC_TEST|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
40787760|NCT03004885|DEVICE|PrismaLung|Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
40787761|NCT02347085|DRUG|GFF MDI (PT003)|
40787762|NCT02347085|DRUG|Placebo MDI|
40787763|NCT00891696|DRUG|Rapamycin|Single 16-mg oral dose
40787764|NCT00891696|OTHER|Amino acid supplementation|Nutritional drink containing essential amino acids
40787765|NCT00891696|OTHER|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
40787766|NCT00891696|DRUG|Sodium nitroprusside|Variable rate for 3 hours
40787767|NCT00891696|DEVICE|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
41308440|NCT04898374|DRUG|Gemcitabin/cisplatin|chemotherapy combination
41308441|NCT03223857|PROCEDURE|Femtosecond-laser-assisted lens exchange|Bilateral implantation of multifocal intraocular lens (MIOL) following femtosecond-laser-assisted lens exchange
40991889|NCT01415063|PROCEDURE|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
40787768|NCT00891696|OTHER|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
40787769|NCT01600404|DRUG|antimuscarinic treatment|
40787770|NCT03070990|DRUG|Enfortumab vedotin|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
40787771|NCT01273571|DRUG|Canagliflozin/Metformin|Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
40787772|NCT02656836|OTHER|Home tonometry, diagnostic study|Evaluating intraocular pressure
41467161|NCT04467320|BEHAVIORAL|Teaching Recovery Techniques|Teaching Recovery Techniques is a 7-session group programme, with 5-sessions for the young person and 2-sessions for the carer. All sessions will be held online. The carer sessions are focused on psychoeducation around trauma and PTSD, as well as skills for supporting a young person through the intervention and with PTSD symptoms more broadly. The young person sessions are primarily focused on skill building and include: psychoeducation and understanding intrusive memories; intrusive images, worries and dreams; arousal, emotions, relaxation and coping; avoidance and triggers; and, memories.
41467162|NCT04467320|BEHAVIORAL|Care as usual|In the care as usual arm, social workers will follow their standard care protocol for young people experiencing psychological distress. A typical response may include a referral to either the specialist local CAMHS or general CAMHS.
41467163|NCT01956708|PROCEDURE|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
41467164|NCT03466827|DRUG|Selinexor|Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.
41467165|NCT04266652|PROCEDURE|tooth block|tooth root blocks were used to increase the bone width
41467166|NCT04266652|PROCEDURE|autogenous bone block|autogenous bone block were used to increase the bone width
41467167|NCT05303961|DRUG|SA001 240mg + Rebamipide 200mg or Placebo|Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo
40787773|NCT05556486|DEVICE|GlioStem|GlioStem is an oligothiophene derivative which can penetrate physiological cell membranes and selectively binds to structures inside the GSCs. GlioStem is conveniently administered ex-vivo onto the investigated tissue or cell culture by a pipette. After only a few minutes, the GSCs will emit green light from GlioStem molecules under blue illumination.
40787774|NCT02818465|OTHER|Vascular calcifications by Xray|
40787775|NCT02818465|OTHER|Vascular calcifications by tomodentimetry|
40787776|NCT02818465|BIOLOGICAL|Blood sample withdrawn|
40787777|NCT01131897|DRUG|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
40787778|NCT04902391|OTHER|Health Services|The Acute Mental Health Care Bundle consists of 3 core elements, including: (1) ED triage, (2) ED assessment and care, and (3) follow-up care.
40787779|NCT02098304|DEVICE|Calcivis Caries Activity Imaging System|Teeth imaged with the Calcivis Caries Activity Imaging System
40787780|NCT05254756|DEVICE|Bouquet speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
40787781|NCT05254756|DEVICE|Traditional plastic 2-blade disposable speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
40787782|NCT03557866|DIAGNOSTIC_TEST|running|individuals will be asked to run for 5 km in self selected speed
40787783|NCT03938051|OTHER|Experimental group|Multicomponent intervention for twice weekly 55-60 minutes 6 weeks
40787784|NCT03938051|OTHER|Control group|20 minutes treadmill walk thrice weekly, 5-7 /10 subjective rate of perceived exertion
40787785|NCT03533660|BEHAVIORAL|Feedback|Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources
40787786|NCT03533660|BEHAVIORAL|Enhanced Usual Care|Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources
40787787|NCT05046626|OTHER|Nutritional counseling|Intervention based on nutritional counseling under Cognitive Behavioral Theory and the used of strategies like self-monitoring, goals, cognitive restructuring and social support.
40787788|NCT01206517|DRUG|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
40787789|NCT01206517|DRUG|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
40787790|NCT01206517|DRUG|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
40787791|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
41467168|NCT05303961|DRUG|SA001 480mg or Placebo|Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)
40787792|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
40991890|NCT01415063|PROCEDURE|TACE-RFA|TACE first, then RFA within 2 weeks
41467169|NCT05303961|DRUG|SA001 710mg + Rebamipide 600mg or Placebo|Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)
41467170|NCT05303961|DRUG|SA001 1,080mg or Placebo|Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)
40787793|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
40991891|NCT01879774|OTHER|Neuropsychological and motoric tests|"1. Neuropsychological tests~   * Mini Mental Status Test~  * Dem-Tect~  * Rey-Osterrieth Complex Figure Test~  * Trailmaking Test~  * Beck Depression Inventory~  * d2-R (optional)~2. Motoric tests~   * modified UPDRS (Unified Parkinson Disease Rating Scale) Part III~  * Timed-up-and-go Test~  * Halstead Fingertapping Test~  * AIMS (Abnormal involuntary movement scale)~3. EEG (only in patients with hyponatremia)~4. MRI (only in patients with hyponatremia)"
40991892|NCT04819087|BEHAVIORAL|Questionnaires and Rehabilitation Programs|Questionnaires and Rehabilitation Programs
41017754|NCT03370328|OTHER|Ginger oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
40823062|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
40823063|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
40823064|NCT00803348|DRUG|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
40823065|NCT06542601|DEVICE|Motor cognitive intervention|Older adults were given cognitive training and motor training for 12 weeks using a tablet computer
40823066|NCT00273520|DRUG|Telithromycin|
41467171|NCT05303961|DRUG|SA001 360mg or Placebo|Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)
40823067|NCT02280902|BIOLOGICAL|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
40991893|NCT00984243|PROCEDURE|PHOTODYNAMIC THERAPY (PDT)|"Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm\^2 Excimer-dye laser: 100-200 Joules/cm\^2"
40991894|NCT02930421|OTHER|Exercise training|30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
40991895|NCT02937519|DEVICE|Chrono-chemotherapy pump:Melodie|
40991896|NCT02937519|DEVICE|Routine intravenous drip|
40991897|NCT02937519|DRUG|induction Chrono-chemotherapy|
40991898|NCT02937519|DRUG|induction Routine-chemotherapy|
40991899|NCT02937519|DRUG|cisplatin chrono-chemotherapy|
40991900|NCT02937519|DRUG|cisplatin routine-chemotherapy|
40991901|NCT02937519|RADIATION|intensity-modulated radiation therapy|
40991902|NCT06125288|OTHER|lab investigation and radiation|"1. . Full history taking including~   * Environmental factors such as long term exposure to environmental hazards as bacteria, fungi, chemicals, tobacco smoke and air pollution.~  * Host factors Family history (you have a higher risk of ILD if a close relative has ILD). History of recurrent chest infection. History of exposure to medication such as radiation and chemotherapy. History of Multisystem autoimmune diseases~2. Full examination general and systemic especially chest examination~3. investigation~   * pulse oximetry.~  * lab investigation include complete blood count parameters .~  * radiological investigation including ( echocardiography - MSCT chest - chest -x ray"
40991903|NCT00729027|DRUG|25 mg/day AVE5530|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
41308442|NCT00136773|DRUG|amlodipine/benazepril|
41467172|NCT05303961|DRUG|SA001 720mg or Placebo|Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)
41467173|NCT05303961|DRUG|SA001 1,080mg or Placebo|Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)
41467174|NCT05424380|DRUG|GSK3745417|GSK3745417 will be administered
41467175|NCT04651595|PROCEDURE|Caudal block|caudal block with low dose bupivicaine 0.25% to preserve tone
41467176|NCT04651595|DRUG|Morphine|morphine to control pain and avoid using muscle relaxant
40823068|NCT02881112|DEVICE|Provant Therapy System|Treatment with the Provant Therapy System
40991904|NCT00729027|DRUG|50 mg/day AVE5530|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
41017755|NCT04887805|DRUG|Lenvatinib Mesylate|Given PO
41017756|NCT04887805|BIOLOGICAL|Pembrolizumab|Given IV
41017757|NCT00912405|DEVICE|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
41017758|NCT02517580|DIETARY_SUPPLEMENT|Vitamin K2 (MK7)|
41017759|NCT04008134|BEHAVIORAL|CHoBI7 health facility program|The CHoBI7 health facility program focuses on promoting handwashing with soap and water treatment to diarrhea patients and their household members during the one-week period after the patient is admitted to the health facility, when their household is at highest risk for diarrheal diseases. The CHoBI7 program includes: (1) a WASH pictorial module delivered by a health worker bedside to diarrhea patient and their household members in a health facility on handwashing with soap, water treatment, and safe water storage; and (2) a diarrhea prevention package containing chlorine tablets for water treatment, a soapy water bottle (water and detergent powder), a handwashing station, and a water vessel with a lid and tap for safe drinking water storage. Households are instructed to boil their water once their supply of chlorine tablets is completed.
41017760|NCT04008134|BEHAVIORAL|CHoBI7 mHealth program|The CHoBI7 mHealth (mobile health) program targets five key behaviors: (1) preparing soapy water using water and detergent powder; (2) handwashing with soap at food and stool related events; (3) treating household drinking water using chlorine tablets during the one week high risk period after the diarrhea patient in the household was admitted to the health facility; (4) safe drinking water storage in a water vessel with a lid and tap; and (5) heating of household drinking water until it reaches a rolling boil after the one week high risk period. Participant households receive bi-weekly voice and text messages from the CHoBI7 mHealth program over a 12-month period. These mobile messages are sent using the VIAMO platform (www.viamo.io).
41017761|NCT04008134|BEHAVIORAL|CHoBI7 home visit program|The CHoBI7 home visit program involves two, 30-minute home visits conducted during the week after the index diarrhea patient was recruited at the health facility. A health worker reinforces the content of the CHoBI7 health facility program in the participant's home.
41017762|NCT06297824|BEHAVIORAL|ERGT-A|Emotion regulation group therapy for adolescents
41017763|NCT01787513|OTHER|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
41017764|NCT01787513|OTHER|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
41017765|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based assessments|Motor and cognitive testing in virtual reality
41017766|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based serious games|Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
41017767|NCT00175474|PROCEDURE|knee surgery|
41467177|NCT00636324|DEVICE|Nasal CPAP, level 7 to 9 cmH2O|Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation
41467178|NCT00636324|DEVICE|Nasal CPAP, level 4 to 6 cmH2O|Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
40787794|NCT00878592|BEHAVIORAL|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (\<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of \~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
40787795|NCT06106893|BIOLOGICAL|CD19 Universal CAR-γδ T Cells|Intravenous infusion of CD19 Universal CAR-γδ T Cells
40787796|NCT02035514|BIOLOGICAL|Bone marrow autologous mesenchymal stem cells transplantation|
40787797|NCT01951898|DRUG|Montelukast|10mg/day, once a daily after dinner, for 28dyas
40787798|NCT06347913|RADIATION|ultrasound|Umbilical Artery Systolic/Diastolic Ratio and Amniotic Fluid Index in Prediction of Fetal Outcome in Term Pregnancies
40787799|NCT00295646|DRUG|tamoxifen|20 mg/d
40787800|NCT00295646|DRUG|anastrozole|1 mg/d
40787801|NCT00295646|DRUG|zoledronic acid|4 mg q6m
40787802|NCT00295646|OTHER|goserelin|3.6 mg goserelin subcutaneously every 28 days
40787803|NCT04403308|BIOLOGICAL|ONO-7913|ONO-7913 will be administered by intravenous continuous infusion during the designated time.
40787804|NCT04967066|DIAGNOSTIC_TEST|Serum Levels of Adipocytokines|Serum leptin and adiponectin: venous blood samples (3 ml) will be obtained from children with FS (within 3 hours of seizures) as well as the two control groups. The serum will be obtained by centrifugation at 3,500 rpm for 5 min at 4 ℃. The serum will be immediately separated and stored at -70 ℃. Serum leptin and adiponectin will be assessed through enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.
40787805|NCT01828840|DRUG|epidural morphine via PCEA|
40787806|NCT01828840|DRUG|epidural fentanyl via PCEA|
40787807|NCT01828840|DRUG|epidural methadone via PCEA|
40787808|NCT01828840|DRUG|intravenous morphine via PCA|
40787809|NCT01789242|DRUG|Carfilzomib|IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
40787810|NCT01789242|DRUG|Dexamethasone|Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.
40787811|NCT00870480|DRUG|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
40787812|NCT00870480|DRUG|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
40991905|NCT00729027|DRUG|placebo|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
41308443|NCT06116877|PROCEDURE|implant supported overdenture|mandibular 2-implant retained overdenture of non-modified printable acrylate resins base material with Zirconium oxide nanoparticles
40787813|NCT03706365|DRUG|Abemaciclib|Administered orally.
40787814|NCT03706365|DRUG|Abiraterone Acetate|Administered orally.
40787815|NCT03706365|DRUG|Prednisone|Administered orally.
40787816|NCT03706365|DRUG|Placebo|Administered orally.
40787817|NCT04930315|DRUG|Apatinib Mesylate|250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery
40787818|NCT04930315|DRUG|Camrelizumab|200mg, iv, d1, q2w, both in two groups
40787819|NCT05544435|BEHAVIORAL|Motivational İnterviewing|Motivational Interviewing (MI), which is one of these methods, is an individual-based counselling approach that can easily be used by nurses who have been trained to help the management of disease in chronic diseases (Berhe et al., 2020; Kızılırmak \& Demir, 2018; Maslakpak et al., 2020). The core principles of MI includes expressing empathy by providing acceptance and understanding, realizing inconsistencies, avoiding discussions and supporting self-efficacy (Matinolli et al., 2012). The main purpose of MI is to identify the ambivalent emotions that occur in the patient in health-related activities, to strengthen and encourage insights of patients by supporting healthy lifestyle changes and self-confidence (R.Miller \& Rollnick, 2013). Because of its flexibility and ability to be applied in different behavioural aspects, MI can be administered individually and in groups by trained individuals (Maslakpak et al., 2020).
40787820|NCT04754269|BEHAVIORAL|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
40787821|NCT04754269|BEHAVIORAL|Reading Intervention|Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
40787822|NCT04402307|OTHER|Chin Tuck Against Resistance|Training in 6 weeks 3 times a day.
40823069|NCT02693054|DEVICE|HALO|Laser Treatment
40991906|NCT02794662|PROCEDURE|Oxygen Environment|FiO2 delivered by servo-controlled incubator
40991907|NCT02794662|PROCEDURE|Nasal Cannula Oxygen|FiO2 delivered by nasal cannula
40991908|NCT01997515|DRUG|Ketamine|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
40991909|NCT01997515|DRUG|placebo|Group P (placebo) will receive the same amount of saline.
40991910|NCT05221333|DEVICE|Sorrel Wearable Injector|Use of Sorrel Wearable Injector in pilot study
41308444|NCT02154126|DEVICE|Continuous Glucose Monitoring Device (Senseonics)|
41467179|NCT01075061|OTHER|healthy volunteers|morphological and functional brain MRI; transcranial magnetic stimulation
41467180|NCT01075061|OTHER|Kallmann|morphological and functional brain MRI; transcranial magnetic stimulation
41467181|NCT01075061|OTHER|Congenital Mirror Movement|morphological and functional brain MRI; transcranial magnetic stimulation
41467182|NCT01117987|DRUG|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
41467183|NCT01117987|DRUG|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
41467184|NCT05586724|DRUG|Micronized progesterone in continuous combination with oral estrogen|Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
41467185|NCT05586724|DRUG|Norethisterone acetate in continuous combination with oral estrogen|Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan
41467186|NCT00051831|DRUG|Emtricitabine|Will be administered as one 200-mg capsule orally daily
41467187|NCT00051831|DRUG|Enfuvirtide|Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
41467188|NCT00051831|DRUG|Ritonavir|Will be administered as one 100-mg capsule orally twice daily
41467189|NCT00051831|DRUG|Saquinavir|Will be administered as five hard gel capsules orally twice daily
41467190|NCT00051831|DRUG|Tenofovir disoproxil fumarate|Will be administered as one 300-mg tablet orally daily
41467191|NCT02642237|BIOLOGICAL|Fluenz|intranasal inoculation with Fluenz
41467192|NCT02642237|OTHER|placebo|
41467193|NCT02642237|OTHER|LPS|
41467194|NCT06401434|DIAGNOSTIC_TEST|On-site radiologist|All participants in this arm will be screened by CXR. All CXR images will be interpreted by only an on-site radiologist. Participants with an abnormal CXR result from the radiologist will be indicated for follow-on diagnostic testing with the Xpert MTB/RIF Ultra assay.
41467195|NCT06401434|DIAGNOSTIC_TEST|CAD-based triage (with INSIGHT CXR software)|All participants in this arm will be screened by CXR. All CXR images will first be processed with the INSIGHT CXR CAD software (Lunit, South Korea) to identify the totally normal/clear CXR images; only those with the possibility of containing an abnormality (abnormality score ≥ 20) will be sent to the on-site radiologist for reading/interpretation. Participants with an abnormal CXR result from the radiologist will be indicated for follow-on diagnostic testing with the Xpert MTB/RIF Ultra assay.
41467196|NCT04724980|DRUG|PRGN-2012|"In the Phase 1, 3+3 dose escalation clinical trial evaluating PRGN-2012 at two dose levels (1x10\^11 and 5x10\^11 particle units (PU)) administered as adjuvant therapy prior to standard-of-care debulking surgery.~In the Phase 2 segment, PRGN-2012 is evaluated at the RP2D."
41467197|NCT02502968|DRUG|Cytarabine|
41467198|NCT02502968|DRUG|BL-8040|
41467199|NCT02502968|DRUG|Placebo (for BL-8040)|Powder for solution for injection manufactured to mimic BL-8040
41467200|NCT01086345|RADIATION|radiosurgery|Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
41467201|NCT01086345|BIOLOGICAL|bevacizumab|Given IV
41467202|NCT01086345|DRUG|irinotecan hydrochloride|Given IV
41467203|NCT02644798|OTHER|Baseline-recorded data recorded|Baseline-recorded data recorded. Peripheral blood samples were drawn.
41467204|NCT00754871|DRUG|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
41467205|NCT00754871|DRUG|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
40787823|NCT02307448|PROCEDURE|Platelet Rich Plasma|Patients will receive weekly PRP treatments with standard of care.
40787824|NCT02307448|PROCEDURE|Standard of Care|Patients will receive weekly standard of care.
41467206|NCT00754871|DRUG|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
41467207|NCT00754871|DRUG|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
41467208|NCT05676983|OTHER|Spiky balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
41467209|NCT05676983|OTHER|Pediatric neurodevelopmental therapy|Bobath therapy
41467210|NCT05676983|OTHER|smooth balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
40787825|NCT05725122|PROCEDURE|Extracorporeal shock wave lithotripsy|Extracorporeal shock wave lithotripsy will given to the patients
40787826|NCT05725122|PROCEDURE|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy.|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy will be given to the patients
40787827|NCT03975153|BIOLOGICAL|guselkumab|Treatment at the FDA-approved psoriasis dosing for 20 weeks
41467211|NCT03624855|OTHER|Bone or joint infection due to Pseudomonas aeruginosa|Description of bone or joint infection on implant due to Pseudomonas aeruginosa
41467212|NCT05541640|DRUG|normal saline group|normal saline infusion at the start of surgery
41467213|NCT05541640|DRUG|lidocaine group|lidocaine infusion at the start of surgery
41467214|NCT03227133|OTHER|Neuropsychological evaluations|Neuropsychological evaluations including oral fluency, performed specifically for the study
41467215|NCT03227133|OTHER|Psychiatric interview|
41467216|NCT03227133|OTHER|Cardiovascular risk assessment|
41467217|NCT05354089|BIOLOGICAL|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
40787828|NCT02921295|DEVICE|Sidekick Stubbies|
41467218|NCT05354089|BIOLOGICAL|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
40787829|NCT04435314|DRUG|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days
40787830|NCT04435314|DRUG|Placebo|Subjects will receive placebo TID for 7 days.
41308445|NCT06065527|BEHAVIORAL|Map Our Life|The intervention takes participants through the process of planning using the Preparation for Future Care Model stages: care expectation, awareness, information gathering, decision making, and concrete planning. The intervention has 8 modules: (1) Letter of Intent for Your Loved One, (2) Caregiver Support and Well-Being, (3) Medical Decision Making for Your Loved One, (4) Daily Routines and Medical Management, (5) Medicaid Waiver for Your Loved One, (6) Financial Planning for Your Loved One, (7) Emergency Planning for Your Loved One, and (8) Managing Jobs, Day Programs, and Transportation. Map Our Life takes users - the caregiver alongside the individual with intellectual disability - through the stages of planning in each of the 8 modules until a concrete care plan is developed. The last component of the intervention is that this Care Plan is subsequently saved and shared with others such as care managers, clinicians, friends or family members.
41467219|NCT05354089|DRUG|Placebo|Placebo IM on day 0 and day 21.
40787831|NCT00746525|OTHER|Surface functional electrical stimulation (FES)|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
40787832|NCT00746525|OTHER|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
41308446|NCT06065527|BEHAVIORAL|Attention Control|The control group will have access to a CDC Website, CDC Healthy Living with a Disability.
41308447|NCT04169724|BEHAVIORAL|Calm Meditation|10 minutes per day of meditation via the Calm app.
40991911|NCT01586819|DRUG|Botulinum Toxin|"The botulinum toxin will be injected into the wrinkles crow's feet. The injections will take about 10 minutes to complete."
40991912|NCT01586819|PROCEDURE|Chemical Peel Only|After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution \[a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)\] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel \[35% Trichloroacetic acid\] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
40991913|NCT03816059|DIAGNOSTIC_TEST|Respiratory virus testing|All patients will be tested for respiratory viruses
41308448|NCT05834803|PROCEDURE|Renal artery stenting|Optimal medical therapy and percutaneous transluminal renal angioplasty with stent placement.
41308449|NCT05834803|PROCEDURE|Sham treatment|Optimal medical therapy and sham treatment.
41308450|NCT05062616|PROCEDURE|Toenail surgery|modified Winograd procedure
41308451|NCT01811849|DRUG|Insulin LISPRO|
41308452|NCT01811849|DRUG|Insulin LISPRO|
40787833|NCT00746525|OTHER|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
40787834|NCT02473471|DEVICE|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
41308453|NCT01811849|DRUG|Insulin LISPRO|
41308454|NCT02689232|BIOLOGICAL|Fresh Frozen Plasma|
41308455|NCT02689232|BIOLOGICAL|Platelets Concentrate|
41467220|NCT04316195|DIAGNOSTIC_TEST|Assessment of the bulbocavernosus reflex|"According to the International Standards for Neurological Classification of Spinal Cord : The standard examination consists of the contraction of the bulbocavernous muscle following stimulation of the glans of the penis in men and of the clitoris in women.~By electromyography: The electromyography consists to stimulate the bulbocavernosus reflex with a bipolar probe apply on the glans for men, and on the clitoris in women. A surface electrode will be positioned on the right or left bulbocavernous muscle at the base of the penis (or vagina) and the anus for recording. The bulbocavernous reflex will be obtained by stimulation at a frequency of 1.5Hz and an amplitude of 14 to 47 mA."
41467221|NCT00745719|PROCEDURE|parathyroidectomy|total parathyroidectomy with forearm autografting
41467222|NCT05931393|DRUG|Cabozantinib 80 MG|cabozantinib 80mg daily
41467223|NCT05931393|DRUG|Cabozantinib 40Mg Tab|cabozantinib 40mg daily
41467224|NCT05931393|DRUG|Nivolumab|nivolumab 480 mg IV every 4 weeks
41467225|NCT06350123|DRUG|Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
41467226|NCT06350123|DRUG|Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
41467227|NCT06350123|DRUG|Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin|1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
41467228|NCT01191606|PROCEDURE|the change of ventilatory mode|One lung ventilation initiated with volume controlled ventilation(OLV-VCV) with an inspired oxygen fraction (FIO2) of 1.0, a tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to pressure controlled ventilation and the inspiratory pressure was adjusted to obtain the tidal volume 6 mL/kg. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
41467229|NCT01191606|PROCEDURE|the change of ventilatory mode|One lung ventilation initiated with pressure controlled ventilation with an inspired oxygen fraction (FIO2) of 1.0, an inspiratory pressure provided the tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to VCV with a tidal volume 6 mL/kg based on PBW. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
41467230|NCT00388037|DRUG|sunitinib malate|Given PO
41467231|NCT00388037|OTHER|laboratory biomarker analysis|Correlative studies
41467232|NCT05233787|PROCEDURE|Tailored use of defunctioning stoma after TME|"Tailored use of defunctioning stoma after TME based on a 2-step process:~i) to perform or not a defunctioning stoma according to the personalized risk of anastomotic leakage (defunctioning stoma only if Anastomotic Failure Observed Risk Score=\[2-6\]), ii) to perform an early stoma closure at day 8-12, according to clinical (fever), biological (CRP level days 2 and 4 postoperatively) and radiological postoperative assessment (CT-scan with colonic contrast retrograde enema day 7-8 postoperatively)"
41467233|NCT05233787|PROCEDURE|Systematic use of defunctioning stoma|Systematic use of defunctioning stoma for 2-3 months after TME, according to French national and international guidelines
41467234|NCT00889252|DEVICE|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
41467235|NCT00889252|DEVICE|contact lens|Placebo contact lens
41467236|NCT05239182|DRUG|9-ING-41|9-ING-41 is a small molecule potent selective GSK-3β inhibitor
41467237|NCT05239182|DRUG|Retifanlimab|Humanized, hinge-stabilized, IgG4κ monoclonal antibody that recognizes human PD-1.
40787835|NCT00836771|DIETARY_SUPPLEMENT|Infant Formula|
40991914|NCT04537000|DIAGNOSTIC_TEST|clinical condition score|A score is firstly identified using a clinical condition scale including the concentration of inspired oxygen to maintain the percutaneous oxygen saturation (SPO2)≧95%, the fusion rate of catecholamine drugs to maintain normal blood pressure, the nasopharyngeal temperature and the oxygen saturation of central venous blood. The score was graded as 0, 1 and 2 points according to the patient's clinical condition. The score identified from the scale plus 7 finally makes the clinical condition score. If the score is higher than 10, it will be replaced with 10. That is to say, the highest clinical condition score is 10. If the clinical condition score≦Hb, blood red cell transfusion will not be started. If the clinical condition score\>Hb, blood red cell transfusion will be started, and the volume will be calculated using the following formulation, transfusion volume(ml)=(clinical condition score - Hb)\*body weight \*5.
40991915|NCT03768596|BEHAVIORAL|Nudge|Influenza Vaccine Prescription Form accompanied on the back of telephone numbers of occupational health centers of different hospitals where interns are likely to be on probation.
41308456|NCT02689232|BIOLOGICAL|Cryo Precitipitate|
41308457|NCT02280928|OTHER|Balance exercise|Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.
41308458|NCT02280928|OTHER|Cognitive training|Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.
40991916|NCT03768596|OTHER|vaccination form|a form about vaccination
40787836|NCT05497661|OTHER|448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.|448kilohertz Capacitive Resistive Radiofrequency Stimulation on Patellar tendon in a Sporty Population.
41467238|NCT05239182|DRUG|Gemcitabine|cytotoxic chemotherapy agent
41467239|NCT05239182|DRUG|Abraxane|cytotoxic chemotherapy agent
41467240|NCT02718287|BEHAVIORAL|Home visiting intervention PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.
41467241|NCT02718287|BEHAVIORAL|Home visiting without PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
41467242|NCT04868565|DRUG|Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]|"after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight."
41467243|NCT05515107|DEVICE|Videolaryngoscope size 1 Miller blade|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
41467244|NCT04643002|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
41467245|NCT04643002|DRUG|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
41467246|NCT04643002|DRUG|Pomalidomide|Pharmaceutical form: Capsule; Route of administration: Oral
41467247|NCT04643002|DRUG|Belantamab mafodotin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
41467248|NCT04643002|DRUG|Pegenzileukin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
41467249|NCT04643002|DRUG|SAR439459|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
41467250|NCT04643002|DRUG|Belumosudil|Pharmaceutical form: tablet; route of administration: oral
41467251|NCT04643002|DRUG|Evorpacept|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
41308459|NCT02280928|OTHER|Dual-task cognitive-cognitive training|The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
41467252|NCT02839993|DEVICE|tDCS|
41467253|NCT02839993|BEHAVIORAL|training|
41467254|NCT05470322|DEVICE|Er: YAG laser|Patients will be treated with laser for their HS scarring.
41467255|NCT02425384|BEHAVIORAL|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
41467256|NCT02425384|BEHAVIORAL|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
41467257|NCT02425384|OTHER|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
40787837|NCT05497661|OTHER|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
40787838|NCT02356536|DEVICE|Agilitas|WCD trial
40787839|NCT02722213|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR).|MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
40787840|NCT06462287|DRUG|Aprepitant 125 and 80Mg Oral Capsule|Aprepitant 1 oral capsule time a day for 4 days (First day: 125 mg and the 3 last days: 80 mg)
40787841|NCT06462287|DRUG|Placebo|Placebo:1 oral capsule time a day for 4 days
40991917|NCT03795311|DRUG|FOLFIRINOX Bevacizumab|"In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~* Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~* Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~* Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles."
40991918|NCT05705284|OTHER|Structured multidisciplinary medication review|Multidisciplinary process for medication review/deprescribing: The intervention will be a structured process for performing a shared-decision, person-centred medication review among those living with frailty involving GPs, PCN-pharmacist and ANPs.
40991919|NCT06327958|OTHER|Cormack-Lehane (C&L)|There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
41308460|NCT04396743|PROCEDURE|Periapical surgery with use of prf-high clot and membrane|Periapical surgery will be done followed by placement of prf-high clot into the defect and membrane over the defect before closure of the flap.
41308461|NCT04396743|PROCEDURE|Periapical surgery with use of prf-medium clot and membrane|Periapical surgery will be done followed by placement of prf-medium clot in the defect and membrane over the defect before closure of the flap.
41308462|NCT01805232|DRUG|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
41308463|NCT01805232|DRUG|Quinine|quinine infusion 80 mg/kg every 8 hours till the patient can take orally
41467258|NCT03600181|DEVICE|RAD - 97 pulse co-oximeter|"non-invasive sensor capable of measuring ORI (Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.~Values from the RAD 97 monitor will be blinded to clinicians who perform intubation (clinical research nurse will be in charge of watching RAD 97 monitor)"
40787842|NCT01421966|BIOLOGICAL|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
40787843|NCT01421966|BIOLOGICAL|Sham injection|The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
40991920|NCT06327958|OTHER|POGO score|There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
41308464|NCT01687413|RADIATION|Intensity-modulated radiation therapy (IMRT)|
41308465|NCT01687413|DRUG|Cisplatin|
41308466|NCT03623126|OTHER|Questionnaire|A questionnaire to evaluate clinical improvement and quality of life after ESSURE removal will be completed by patients at least one month after the procedure.
41308467|NCT03611322|DRUG|Semaglutide, 0.25 mg|Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
41308468|NCT03611322|DRUG|Semaglutide, 0.5 mg|Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
41308469|NCT03611322|DRUG|Semaglutide, 1.0 mg|Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
41308470|NCT03611322|DEVICE|DV3372|DV3372 device will be used for administration of semaglutide
41308471|NCT03611322|DEVICE|PDS290 pen-injector|PDS290 pen-injector will be used for administration of semaglutide
41308472|NCT02916030|DIETARY_SUPPLEMENT|Vit D|It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
41308473|NCT01202708|DEVICE|On line hemofiafiltration|hemodiafiltration with the Gambro AK 200 ULTRA
41308474|NCT01202708|DEVICE|On line hemodiafiltration|On line hemodiafiltration with the Gambro AK 200 ULTRA System
41308475|NCT04834882|OTHER|Data collection (|online survey
41308476|NCT02348411|DEVICE|ExAblate|
41308477|NCT06553378|OTHER|Geriatric Oncology Supportive Clinic|Subjects in the intervention arm will be seen within four weeks of recruitment. Clinical assessment involves a Comprehensive Geriatric Assessment (CGA) and Supportive Care Assessment conducted by a geriatric-oncologist. Both clinical assessments and targeted interventions are supported by a multi-disciplinary team comprising the geriatrician, geriatric trained nurse, physiotherapist, occupational therapist, speech therapist, pharmacist, dietician, and medical social worker. We will conduct an initial GOSC assessment, with a follow up review during oncology treatment. Subsequently, further GOSC clinic sessions duration of follow up will be determined by the subject's underlying disease, symptom burden and clinical course during treatment.
41308478|NCT03609528|DEVICE|CamPROBE|To be completed
41308479|NCT06354270|DRUG|Stannous fluoride toothpaste|Toothpaste containing 0.454 % weight/weight (w/w) SnF2.
41308480|NCT06354270|DRUG|Regular fluoride toothpaste (Crest Cavity Protection)|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
41308481|NCT02531373|BIOLOGICAL|V114 Medium Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
41308482|NCT02531373|BIOLOGICAL|V114 High Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
41308483|NCT02531373|BIOLOGICAL|V114 Medium Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
41308484|NCT02531373|BIOLOGICAL|V114 High Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
41308485|NCT02531373|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
40787844|NCT04103021|DEVICE|Port-A-Cath|Totally implanted central venous access device
40787845|NCT04635202|BEHAVIORAL|exercise training on elliptical device|This group (n=30) will receive aerobic training on an elliptical trainer for 16 weeks (3 sessions per week). The session will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
41308486|NCT02438995|DRUG|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
40991921|NCT00000751|DRUG|Anti-HIV Immune Serum Globulin (Human)|
40991922|NCT00000751|DRUG|Globulin, Immune|
40991923|NCT00000751|DRUG|Zidovudine|
41308487|NCT01131221|OTHER|laboratory biomarker analysis|
41308488|NCT05950477|DIAGNOSTIC_TEST|Depression Questionnaires|Center of Epidemiological Studies-Depression Scale (CES-D) Patient Health Questionnaire (PHQ-9) Diabetes Treatment Satisfaction Questionnaire (DTSQ) Well-Being Index (WHO-5)
40991924|NCT01068509|BIOLOGICAL|Cvac|Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.
40991925|NCT04926532|DRUG|Toripalimab|Toripalimab is a humanized anti-PD-1 monoclonal antibody
40991926|NCT04926532|DRUG|Sorafenib|Sorafenib is a multi-kinase inhibitor
40991927|NCT00304356|DRUG|Nitazoxanide|500 mg bid
40991928|NCT00004159|DRUG|gemcitabine hydrochloride|
40991929|NCT00004159|DRUG|paclitaxel|
41308489|NCT00005050|DRUG|ethynyluracil|
41308490|NCT00005050|DRUG|fluorouracil|
41308491|NCT00005050|DRUG|oxaliplatin|
41308492|NCT01290120|DRUG|Chemotherapy-Rituximab combination|Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.
40787846|NCT04635202|BEHAVIORAL|group B (control group)|this group will receive general advises on maintaining physical activities for 16 weeks without any additional supervised training
41308493|NCT02405052|OTHER|No intervention|Validation of the Panic Screening Score
41308494|NCT05357352|OTHER|NAFLD/NASH|the characteristics of patients with advanced fibrosis in a community-based referral center.
41308495|NCT03928431|OTHER|Maternal microbiota|See arm descriptions
41308496|NCT06254027|DEVICE|Forte|One application per day for a complete treatment period.
41308497|NCT06254027|DEVICE|Active Cover Light|One application per day for a complete treatment period.
41308498|NCT06254027|DRUG|Loceryl|One application per week for a complete treatment period.
41308499|NCT03134950|BEHAVIORAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions will be in person with a trained psychologist and the following 2-4 sessions will be web-based. Each web-based session will be followed by phone support.
41308500|NCT06512961|DEVICE|Tissue Flossing|Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
41147413|NCT03528447|OTHER|Pulmonary Rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band."
41147414|NCT05307653|PROCEDURE|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
41147415|NCT05307653|PROCEDURE|Erector spinea plain block|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
41147416|NCT05307653|PROCEDURE|Caudal block|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
41147417|NCT06168994|DRUG|Eplerenone|Amiodarone vs eplerenone in AF
41147418|NCT02846142|DRUG|PTI-428|
41147419|NCT02846142|OTHER|Placebo|
41147420|NCT02846142|DRUG|ethinyl estradiol and levonorgestrel|
41147421|NCT00308113|DRUG|Prednisone|Prednisone 0/75 mg/kg/day.
41147422|NCT00308113|DIETARY_SUPPLEMENT|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
41147423|NCT06470347|DRUG|A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy|During treatment, subjects were given 400 mg pyrrotinib once daily, within 30 minutes after breakfast.
41147424|NCT00732316|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor
41308501|NCT06512961|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
41308502|NCT06512961|OTHER|Training Protocol|The upper limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 15weeks, with 3 training sessions per week, with a day break between sessions.
41308503|NCT05594680|DRUG|Cilostazol|Cilostazol 50 MG
41467259|NCT04491396|BEHAVIORAL|Gentle Yoga and Yogic Breathing|"Gentle Yoga (GY) postures can be done while seated on a chair (sometimes called Chair Yoga) and have been shown to benefit people with symptoms associated with cancer.12 However, Yoga is under-studied in the area of scleroderma. While most traditional Yoga postures can be practiced by anyone, people with scleroderma often have limited physical movement and can be prone to injury. Gentle Yoga postures are physically much easier to do than traditional Yoga and, thus, may be more accessible for SSc patients with musculoskeletal and other impairments. Gentle Yoga postures that are done while seated on a chair also combine easily with YB, but little is known about the specific benefits of the GY+YB combination (GYYB). Further study is needed to determine whether GYYB may be an effective strategy for improving QoL in SSc patients. The Yoga intervention to be used in this study specifically involves GY done while seated in combination with YB."
40787847|NCT00000325|BEHAVIORAL|Gonadorelin|
40787848|NCT03662061|OTHER|Assessment of the follow-up of oncological and geriatric recommendations 4 months after the RCP|"After inclusion, patient's results are discussed at a weekly onco-geriatric multidisciplinary team meeting including surgeons, geriatrics, oncologists, radiotherapist, nurse, pharmacist. Oncological and geriatric recommendations are given.~A phone call is made to the patient to evaluate the follow-up of the oncological and geriatric recommendations defined during the RCP along with their survival, autonomy and quality of life."
40787849|NCT04868383|BEHAVIORAL|Use of smart phone technology to support medication adherence and uptake|Use of smart phone technology to support medication adherence and uptake
41308504|NCT05594680|DRUG|Methotrexate|Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.
41308505|NCT05594680|DRUG|Placebo|Placebo
40787850|NCT00710944|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
40787851|NCT03123770|DRUG|Pegylated liposomal doxorubicin|a new kind of doxorubicin
40787852|NCT03123770|DRUG|Cyclophosphamide|traditional chemotherapy drug
40787853|NCT03123770|DRUG|Epirubicin|traditional chemotherapy drug used in breast cancer
40787854|NCT03123770|DRUG|Docetaxel|traditional chemotherapy drug used in breast cancer
40787855|NCT03034707|DIETARY_SUPPLEMENT|biotin|
40787856|NCT00644826|BEHAVIORAL|preventive home visit|A multidimensional geriatric assessment within the dimensions: cognition, health related functioning, risk of falling, nutritional status, social situation, economic situation, mood. Two more home visits: (1) home counseling visit 2-3 weeks after assessment (2) booster session 1 month after home counseling visit
40787857|NCT00440817|OTHER|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
40787858|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water|
40787859|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water + carbohydrate|
40787860|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water + carbohydrate + protein|
40991930|NCT06045234|OTHER|Urine sampling|"Among the 300 people recruited:~* 300 will each provide 3 urine samples collected on 3 different days during a week (e.g. Monday, Wednesday and Friday)~* 50 will each provide 3 urine samples collected at sunrise, in the middle and then at the end of the day over a period of 24 hours, on 3 different days during a week (e.g. Monday, Wednesday and Friday)."
40991931|NCT04911283|OTHER|Brucella serology test|MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.
41147425|NCT00732316|PROCEDURE|peripheral blood stem cell transplantation|infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor
40787861|NCT02112539|OTHER|platelet aggregation measurement|
40787862|NCT00118274|BIOLOGICAL|incomplete Freund's adjuvant|Given intradermally and subcutaneously
40787863|NCT00118274|BIOLOGICAL|melanoma helper peptide vaccine|Given intradermally and subcutaneously
40787864|NCT00118274|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given intradermally and subcutaneously
40787865|NCT00118274|BIOLOGICAL|tetanus toxoid helper peptide|Given intradermally and subcutaneously
40787866|NCT00118274|DRUG|cyclophosphamide|Given IV
41308506|NCT04765826|PROCEDURE|Autologous mini punch grafting|"All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (\<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included.~. Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local inﬁltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site"
41308507|NCT04030104|DEVICE|Reader Study - Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of Reader study
40787867|NCT01494324|OTHER|CT guided percutaneous ablation|Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
40787868|NCT04122989|OTHER|MS-SUPPORT|MS-SUPPORT is a shared decision making tool designed to be used by patients and providers.
40787869|NCT05807373|PROCEDURE|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)
40787870|NCT05243628|BIOLOGICAL|Afrezza (insulin human) Inhalation Powder|"Pharmaceutical form: powder~Route of administration: inhalation"
40787871|NCT05243628|BIOLOGICAL|insulin degludec|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
40991932|NCT04911283|OTHER|Medical history for brucellosis|Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.
40991933|NCT04048642|BEHAVIORAL|DASH|7 days of a DASH diet
40991934|NCT04048642|BEHAVIORAL|Whole-Food, Plant-Based|7 days of a WFPB diet
40787872|NCT05243628|DEVICE|Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)|Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ
40991935|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (Abs 260)|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260
40991936|NCT04400838|BIOLOGICAL|MenACWY vaccine|Standard single dose of MenACWY vaccine
41147426|NCT05554991|DIETARY_SUPPLEMENT|HMO|Composition comprising of HMO
41147427|NCT05554991|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation having the same appearance and dosing regimen as the intervention
41147428|NCT05554991|BEHAVIORAL|Parental reassurance and support|Both groups will receive standardized written materials to provide parental reassurance and support, in alignment with local clinical practice
41308508|NCT04030104|DEVICE|Reader Study Imagio Ultrasound + Optoacoustic Imaging|Imagio Ultrasound + Optoacoustic images to be reviewed as part of Reader study
40991937|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later
40991938|NCT04400838|BIOLOGICAL|Two dose MenACWY vaccine|Two standard doses of MenACWY vaccine 4-6 weeks apart
41147429|NCT04540952|DEVICE|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
41308509|NCT04030104|DEVICE|Mammography|Mammography as available per standard of care
41308510|NCT02519049|OTHER|No intervention|This is an observational study
41467260|NCT04567758|OTHER|Telerehabilitation|"The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises~A web-based telerehabilitation platform (Fizyoweb) will be used to deliver the exercise program. Using the Fizyoweb web application, exercises will be presented to the patients in the form of audio-video and detailed instructions with explanations. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. The exercise protocol will be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each."
40991939|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (qPCR)|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR
40991940|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL prime plus boost|Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)
40991941|NCT04400838|BIOLOGICAL|Two dose MenACWY vaccine min. 4 weeks apart|Two standard doses of MenACWY vaccine minimum 4 weeks apart
40991942|NCT04400838|BIOLOGICAL|Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart
40991943|NCT04400838|BIOLOGICAL|Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL|Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart
40991944|NCT00428896|DRUG|ZD1839|ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
41147430|NCT04540952|DEVICE|Standard Hysteroscopy Drape|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
41147431|NCT05944666|PROCEDURE|Multimodal technology (MT)|"Only fo the patients of the Main group. It will be different programms depending on severety of UL or LL paresis. Patients will receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, in moderate paresis of the upper limb, the neurointerface Exokist-2 with EEG registration will be used. The program for IS patients includes 10 sessions in inpatient stage every day 15-30 min for the method, 15 sessions with the MT in outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
41308511|NCT00824187|DRUG|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
41308512|NCT00824187|DRUG|Placebo|Inert tablet
41308513|NCT01827059|DRUG|Bosentan|125-mg orange-white, round, biconvex, film-coated tablets
41308514|NCT01827059|DRUG|Placebo|
41308515|NCT02330549|DRUG|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
41308516|NCT02330549|DRUG|Placebo|Placebo-matching CVC administered orally once daily and taken every morning with food.
41308517|NCT05550948|DEVICE|Transcranial photobiomodulation (tPBM) - Mobile System|The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
41308518|NCT03262532|OTHER|Web-base simulator|Training manipulation of TEE using a Web-based simulator
41308519|NCT03262532|OTHER|No web-base simulator|Training manipulation of TEE with out a web-base simulator
41308520|NCT04489225|OTHER|Observational|Observational only without any intervention
41308521|NCT04084938|PROCEDURE|Prostate operation or prostate artery embolization|As described above.
41308522|NCT05157451|OTHER|Quality of Life|Ancillary studies
41308523|NCT05157451|OTHER|Questionnaire Administration|Ancillary studies
41308524|NCT05157451|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41308525|NCT05157451|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Given via injection
40991945|NCT01191580|BEHAVIORAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
41308526|NCT03334162|BEHAVIORAL|Sensorimotor training|"Supervised training sessions will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises, chosen from a standardized pool of exercises according to the child's age, with increasing difficulty (5 degrees of difficulty - e.g. by reducing the base of support, or dual task exercises - per exercise depending on the age group) in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue. Children will be given a training manual and diary to train at home after the study. Guardians will be instructed in order to be able to assist their children"
41308527|NCT05734326|DEVICE|Ultrasound elastography|ultrasound elastography (USE) is emerging as a promising additional tool to discern malignant thyroid nodules, allowing increased diagnostic accuracy, Due to its ability to assess stiffness as an indicator of malignancy, USE has recently become an additional tool for thyroid nodule differentiation, in combination with conventional US and FNA \[18\].
41308528|NCT01515995|DRUG|Nebulized magnesium sulfate|"15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour"
41308529|NCT02061722|RADIATION|PET Imaging with [18F]MNI-659|"The radioligands \[11C\]raclopride and \[18F\]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of \[11C\]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
41308530|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 25 mg b.i.d
41308531|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 50mg qhs
41308532|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 50mg b.i.d.
41308533|NCT00360243|DRUG|placebo|placebo
41308534|NCT03140930|DIETARY_SUPPLEMENT|Tastants duodenal|Duodenal infusion of combination of tastants (sweet, bitter and umami)
41308535|NCT03140930|DIETARY_SUPPLEMENT|Tastants ileal|Ileal infusion of combination of tastants (sweet, bitter and umami)
41308536|NCT03140930|DIETARY_SUPPLEMENT|Placebo duodenal|Duodenal infusion of placebo (tap water)
41308537|NCT03140930|DIETARY_SUPPLEMENT|Placebo ileal|Ileal infusion of placebo (tap water)
41308538|NCT04093518|DRUG|Estradiol|2 transdermal patches to be changed twice a week for the duration of 16 weeks
41308539|NCT04093518|DRUG|Placebo|2 transdermal patches to be changed twice a week for the duration of 16 weeks
41308540|NCT03868007|DEVICE|RIC|The RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
41308541|NCT03868007|DEVICE|sham-RIC|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
41308542|NCT00488579|DRUG|Two policies of iron prophylaxis|60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb\>9g/dl only folic acid, Hb\<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
41308543|NCT02733614|DRUG|SRX246|novel V1a receptor antagonist
41308544|NCT02733614|DRUG|Placebo|matching placebo
41308545|NCT03791645|BEHAVIORAL|Sky Intervention|SKY meditation has three sequential components of breathing interspersed with normal breathing. These include a) sound breath: breathing against airway resistance with slight tightening of the laryngeal muscles, (2-3 cycles/min) followed by b) bellows breath: rapid, forced expiration(20-30 cycles/min) and c) regulated, rhythmical breathing rotating through medium to fast cycles. Each session is focused upon proper breathing techniques, social interaction, and discussion of practical wisdom for everyday life to manage the mind and emotions. SKY will be administered over a 5 day period (\~3 hours/day), followed by 4 weekly follow-ups (\~90 min session/week) at Signature Health clinic situated in Ashtabula, Ohio.
41308546|NCT04339569|DIAGNOSTIC_TEST|Biomechanical analysis|3D analysis of landing manoeuvres.
41308547|NCT04339569|OTHER|Fatigue protocol|A circuit of different tasks (e.g. jumping, sprinting forward and backward, side-stepping exercise) was performed to induce fatigue.
41308548|NCT04232891|DIAGNOSTIC_TEST|liquid biopsy|detection of tumor DNA alteration in cf-DNA
41308549|NCT02322892|DRUG|Thiamine|200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
41308550|NCT02322892|DRUG|Normal saline solution|50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
41308551|NCT05909254|OTHER|Palatally impacted canine exposure using a surgical guide|Under local anaesthesia the tissues covering the palatally impacted canine are removed with the help of a surgical guide to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction.
41308552|NCT05909254|OTHER|Palatally impacted canine exposure using the conventional free.hand method|Under local anaesthesia the tissues covering the palatally impacted canine are removed to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction. The surgeon relies on the surgical plan and their experience to localize the impacted canine.
41308553|NCT02810262|OTHER|Bone metastases biopsy|The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
41308554|NCT06156358|OTHER|No intervention|No intervention
41308555|NCT01150955|DIETARY_SUPPLEMENT|Resveratrol|500 mg three times a day for five weeks.
41308556|NCT01150955|OTHER|Placebo|Placebo (starch capsules) 500 mg three times a day for five weeks.
41467261|NCT04567758|OTHER|Conventional Rehabilitation|"The home exercise program, which will be given with conventional rehabilitation, will be educated to the patient in the clinic on the first day. Exercise information form including explanation and picture of the exercises will be given to the patients. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.~The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises"
41467262|NCT00491907|DRUG|folic acid 5mg/day|
41467263|NCT05397795|DRUG|10000 IU hCG (Choriomon5000 IU; IBSA)|10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly
41467264|NCT05397795|DRUG|Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring)|GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.
41467265|NCT02228109|DEVICE|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
41467266|NCT02228109|DEVICE|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
41467267|NCT02228109|DEVICE|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
41467268|NCT05799196|PROCEDURE|Microfracture|Microfracture was made in the non-weight bearing chondral to provide the release of MSC and growth factor.
41467269|NCT01432028|DRUG|Estradiol and Progesterone|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
40991946|NCT01191580|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
40991947|NCT01191580|BEHAVIORAL|Brief Supportive Psychotherapy|"The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.~Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures."
40991948|NCT00302042|BEHAVIORAL|Brief counseling plus group diabetes prevention in community|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
40991949|NCT00302042|BEHAVIORAL|Brief Counseling for pre-diabetes alone|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
41147432|NCT05944666|PROCEDURE|Conventional rehabilitation|It will be different programms depending on severety of UL or LL paresis. Conventional rehabilitation (CR) includes physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients consists of 10 sessions of every day trainings for inpatients stage, 15 sessions with the CR for outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
41467270|NCT01432028|DRUG|Estradiol and Drospirenone|oral estradiol 1mg and drospirenone 2 mg/day
41147433|NCT04872166|DRUG|BTX-A51|One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of 5 days on/2 days off.
41467271|NCT02415387|BIOLOGICAL|typhoid vaccine|Given IM
41467272|NCT02415387|OTHER|Placebo|Given IM
41467273|NCT04661592|DEVICE|NeuroCatch Platform|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch™ Platform version 2.0, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. Version 2.0 of the NeuroCatch™ Platform consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
41467274|NCT01613794|DRUG|Rosuvastatin|20 mg od
41467275|NCT01740427|DRUG|PD-0332991|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
41467276|NCT01740427|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
41467277|NCT01740427|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
41467278|NCT01740427|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
41467279|NCT03401554|PROCEDURE|titanium mesh|closing the lateral window for maxillary sinus floor elevation with titanium mesh
41467280|NCT03401554|PROCEDURE|collagen membrane|closing the lateral window for maxillary sinus floor elevaion with collagen membrane
41467281|NCT02837133|BEHAVIORAL|integrated yoga program|the program as a one-time session for 3 hours as a component of a Stress Management Education program
41467282|NCT05667948|DRUG|Chemotherapy|different treatments based on the molecular analysis
41467283|NCT02668094|DRUG|Lidocaine|
41467284|NCT02668094|DRUG|Pregabalin|
41467285|NCT02668094|DRUG|propofol|
41467286|NCT01022684|OTHER|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
41467287|NCT02280187|PROCEDURE|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
41467288|NCT02020967|OTHER|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
41467289|NCT06498661|PROCEDURE|Biospecimen Collection|Undergo collection of cervical samples by clinician
41467290|NCT06498661|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy conducted by clinician
41467291|NCT06498661|PROCEDURE|Colposcopy|Undergo colposcopy conducted by clinician
41467292|NCT06498661|OTHER|Electronic Health Record Review|Ancillary studies
41467293|NCT06498661|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage conducted by clinician
41147434|NCT01812707|DRUG|Alirocumab|Two SC injections in the abdomen only
41308557|NCT03455309|BIOLOGICAL|NDV-3A|Single dose administered by intramuscular injection
41308558|NCT03455309|BIOLOGICAL|Placebo|Single dose administered by intramuscular injection
41308559|NCT06400836|OTHER|Carbohydrate timing - carbohydrate intake before or after exercise|The study aims to investigate how pre- or post evening exercise carbohydrate ingestion influences glucose metabolism and substrate oxidation (fat/CHO) during exercise and after exercise in athletes during the nocturnal period (21:00-06:00) and the morning after during an 120 minute oral glucose tolerance test (OGTT).
41308560|NCT03487640|PROCEDURE|TARMR|Transanal resection of rectal mucosa for at least 5cm in length.
41308561|NCT03487640|PROCEDURE|LARSC|We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
41308562|NCT03725995|DRUG|Midazolam|Patients received 0.5 mg/kg midazolam, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
41467294|NCT06498661|PROCEDURE|Excision|Undergo cervical excisional procedure conducted by clinician
41467295|NCT06498661|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal samples
41467296|NCT06498661|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal samples and cervical samples
41467297|NCT06498661|OTHER|Questionnaire Administration|Ancillary studies
41467298|NCT06498661|OTHER|Survey Administration|Ancillary studies
41467299|NCT01213836|DRUG|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
40787873|NCT04406207|OTHER|Demonstration of T cell responses|"Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest."
41147435|NCT01812707|DRUG|Placebo (for alirocumab)|"Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen"
41147436|NCT01812707|DRUG|Atorvastatin|"Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening"
41147437|NCT00002723|DRUG|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
41147438|NCT00002723|DRUG|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
41147439|NCT00002723|DRUG|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
41147440|NCT02910336|OTHER|Quantitative Sensory Testing|sensory testing profile
41147441|NCT00966888|PROCEDURE|standard follow-up care|No intervention
41147442|NCT00966888|RADIATION|radiation therapy|Chest wall radiotherapy
41147443|NCT05807542|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
41147444|NCT05807542|DRUG|Paclitaxel-albumin|Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.
41147445|NCT05807542|DRUG|Carboplatin|carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.
41147446|NCT05785975|OTHER|Certain ommunications(Nudge), community-outreach(landline call), and single FIT testing|The intervention is an integrated system made up of single FIT testing, community outreach (landline call), and specific messages (Nudge). In order to encourage people to attend the screening, a primary care physician will be used in addition to text messages that participants at the outreach get for information, education, and communication (IEC).
41147447|NCT06412029|OTHER|Non-Interventional|Non-interventional study
41147448|NCT00037934|DEVICE|Upper extremity robot|Robotic upper extremity neuro-rehabilitation
41467300|NCT01213836|DRUG|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
41467301|NCT01213836|DRUG|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
41467302|NCT01213836|DRUG|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
41147449|NCT00037934|OTHER|Traditional Supervised Upper Extremity Exercises|Arm ergometer, reaching, and stretching exercises
41147450|NCT03850678|DEVICE|Hearing Aid|Hearing Aid
41147451|NCT03199456|DEVICE|Zip surgical skin closure device|Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.
41147452|NCT03199456|DEVICE|Standard of Care sutures|Standard of Care sutures according to the hospitals current clinical praxis.
41467303|NCT03547817|DEVICE|Intermittent negative pressure device|Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels
41467304|NCT03123978|DRUG|Enzalutamide|Given PO
41467305|NCT03123978|DRUG|Niclosamide|Given PO
41467306|NCT06184867|DIAGNOSTIC_TEST|Relational Agent|Alex was developed as an interactive and personalized education and decision support intervention for smart devices, and guides participants through the key primary stages of assessing personal risk of hereditary cancer, providing genetic education, cancer family tree, patient testimonials, asks and answers questions and for those who choose, facilitates genetic testing, and streamlines disclosure of test results.
41467307|NCT06184867|OTHER|Clinical Letter|Letter will be signed by Dr. Toppmeyer and contain a recommendation to contact the Life Center for a cancer genetic risk assessment and to consider GT.
41147453|NCT01190488|BEHAVIORAL|End-of-Life / Advanced Care Decision Aid|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
41308563|NCT03725995|DRUG|Lidocaine-Midazolam|Patients received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg midazolam, with a maximum dose of 10 mg. , Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
41308564|NCT03725995|DRUG|Placebo|Patients received saline 9% (placebo), 0.5 mg/kg, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
41308565|NCT03862079|OTHER|Best Practice|Given standard of care
41467308|NCT00413218|DRUG|Isavuconazole|Administered by intravenous infusion.
41467309|NCT00413218|DRUG|Caspofungin|Administered by intravenous infusion.
41467310|NCT00413218|DRUG|Voriconazole|Administered by intravenous infusion.
41467311|NCT04664868|PROCEDURE|Sphinkeeper™|Sphinkeeper™ prostheses are self-expandable solid prostheses, made of inert Hyexpan (polyacrylonitrile) and are inserted into the intersphincteric anal groove.
40787874|NCT00783432|DRUG|Astepro Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
40787875|NCT00783432|DRUG|Astelin Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
40991950|NCT03229265|DRUG|Patiromer|Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
41147454|NCT01190488|BEHAVIORAL|Active Comparator|TAU
41147455|NCT00913562|DRUG|Rosuvastatin|one tablet rosuvastatin 10 mg per day for 12 weeks
41147456|NCT00913562|DRUG|Placebo|one tablet a day for 12 weeks
41147457|NCT00607789|DRUG|Duloxetine|30 mg/day - 120 mg/day
41147458|NCT00607789|DRUG|Placebo|identical to study drug
41147459|NCT05384808|BEHAVIORAL|Standard Psychotherapy|Participants receive a standard psychotherapy session with no dog being present.
41308566|NCT03862079|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
41308567|NCT03862079|DRUG|Nystatin|Given PO
41308568|NCT03862079|DRUG|Piperacillin-Tazobactam|Given PO
41308569|NCT02191709|DRUG|Dextromethorphan syrup|
41308570|NCT02191709|DRUG|Dextromethorphan soft pastilles|
41308571|NCT00129350|PROCEDURE|Pulmonary rehabilitation programme|
41308572|NCT06226506|DRUG|Test (T) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.
41308573|NCT06226506|DRUG|Reference (R) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.
41308574|NCT02629601|BEHAVIORAL|Active Rewards|Vitality standard active rewards wellness program for physical activity promotion
41308575|NCT02629601|BEHAVIORAL|Lottery 1|Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward
41467312|NCT03513536|OTHER|Citrus-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
41467313|NCT03513536|OTHER|Mint-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
40787876|NCT01541488|DRUG|BI 1021958|tablet
40787877|NCT01541488|DRUG|BI 1021958|drinking solution / tablet
40991951|NCT05190731|OTHER|Osteopathic cranial manipulative medicine|Osteopathic cranial manipulative medicine technique using compression of 4th ventricle technique
40991952|NCT05190731|OTHER|Sham|Touch only, no osteopathic cranial manipulation
40991953|NCT03210870|BEHAVIORAL|nutritional education classes|The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
40991954|NCT02664909|DRUG|Tranexamic Acid|
40991955|NCT02664909|DRUG|Placebo (saline)|
41147460|NCT05384808|BEHAVIORAL|Canine-assisted psychotherapy with dog actively integrated.|A dog is present and actively integrated into the therapeutic narrative.
41147461|NCT05384808|BEHAVIORAL|Canine-assisted psychotherapy with dog passively integrated.|A dog is present but not actively integrated into the therapeutic narrative.
41147462|NCT05594589|DRUG|Lemborexant|Lemborexant oral tablet.
41147463|NCT05594589|OTHER|PBO|Lemborexant-matched PBO tablet.
41147464|NCT01026116|DRUG|Epirubicin|75 mg/m2 every-3-week for four cycles
41147465|NCT01026116|DRUG|Cyclophosphamide|600 mg/m2 every-3-week for four cycles
41147466|NCT01026116|DRUG|Paclitaxel|175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
41147467|NCT02741297|DEVICE|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
41147468|NCT05825456|PROCEDURE|endoprosthetic reconstruction|This is a type of surgery in which the affected part of the bone and joint is removed, and replaced by a prosthesis.
40787878|NCT01541488|DRUG|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
40787879|NCT02082964|OTHER|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
40787880|NCT02082964|OTHER|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
40787881|NCT05228405|OTHER|All of the disabled children's caregivers will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness|All of the different type of disabled children's caregivers (cerebral palsy, muscular dystrophy, spina bifida and down syndrome) will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
40787882|NCT03051958|BEHAVIORAL|Internet mindfulness&exposure treatment|"See description under Arm."
40787883|NCT03051958|OTHER|Treatment as usual|Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
40787884|NCT01467336|PROCEDURE|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair for all groups
40787885|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\]
40787886|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 \[Treatment B\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\]
40787887|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\]
40787888|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment B\]
40787889|NCT04725006|DEVICE|Spinal cord stimulation system|These systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain. Stimulation will be applied to the system using an external stimulator to see if sensations can be evoked in the participant's limb/foot.
40787890|NCT05027139|DRUG|Zanidatamab|Administered intravenously (IV)
40787891|NCT05027139|DRUG|Evorpacept|Administered IV
40787892|NCT00972023|DRUG|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
40787893|NCT00972023|PROCEDURE|Surgical resection|Surgical procedure of the invasive breast cancer
40787894|NCT05461586|DEVICE|Refractive Technique (MR #1)|Fogging method that employs fogging lens to ensure there is sufficient visual defocus to induce blur.
40787895|NCT05461586|DEVICE|Refractive Technique (MR #2)|Duochrome method that employs the chromatic aberration of the eye, with the shorter wavelengths (green) focused in front of the longer (red) wavelengths
40991956|NCT05832333|BIOLOGICAL|VaxigripTetra®|Suspension for injection Injection intramuscular
41147469|NCT05825456|PROCEDURE|Intramedullary nailing|This is a type of surgery in which the affected bone is stabilized by a nail. The affected part could be removed or retained. If removed, the defect is filled with bone cement.
40787896|NCT00659841|DRUG|Ciclesonide|200µg Ciclesonide versus placebo
40787897|NCT00659841|DRUG|Placebo|placebo
40787898|NCT03765047|BEHAVIORAL|Intervention Arm|"The physical activity intervention consists of:~1. School Engagement and Assessment - Based on the customized assessment, training is provided for school staff to develop the capacity to increase PA. A school PA team is established.~2. Training - School teams are provided with ongoing in-person and virtual training to learn strategies for increasing PA before and during the school day. A training summit meeting will occur each summer, starting with the summer prior to the intervention. Teams will create a weekly calendar of activities to increase PA time to a minimum of 40 mts/day.~3. PA Equipment and Resources - After training, schools are provided with PA equipment, resources and teaching aids to facilitate the integration of PA into the school day.~4. Ongoing Assessment and Technical Assistance - Student accelerometer data will allow for monitoring of PA levels, so that additional technical assistance for classroom teachers can be provided if needed"
40787899|NCT03367169|PROCEDURE|minimally invasive method|type of surgical technique
40787900|NCT03367169|PROCEDURE|open reduction method|type of surgical technique
40787901|NCT05386342|DEVICE|TufTex Over-the-Wire Embolectomy Catheter|The OTW Catheter can be used for the removal of emboli and thrombi. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
40787902|NCT03729986|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% of maximal inspiratory pressure in sitting and supine positions. The orders of the two loaded test conditions will be conducted in random order with at least 20 minute separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
40787903|NCT04153695|OTHER|Music Therapy|to listen flamenco music during 30 minuts per day during 2 weeks
41467314|NCT03513536|OTHER|Spice-Scented Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
40787904|NCT05949918|BEHAVIORAL|Stage-matched interventions|"The study intervention will be designed based on each Stage of Change of the Transtheoretical Model of Change in that participants in each Stage of Change will receive the intervention that matches the Stage of Change they would be in.~A 12-week interval would be considered between administering the intervention and posttest 1 and the same interval would be used between posttest 1 and posttest 2."
40787905|NCT03693144|OTHER|Full LIITA3H App|This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.
40787906|NCT03693144|OTHER|Partial LIITA3H App|This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.
40787907|NCT03693144|OTHER|LIITA3H Location only|This is a version of the LIITA3H mobile app that will only track participants' location.
40787908|NCT05977218|OTHER|FoodSwitch|Access to the 'DiabetesSwitch' filter of the FoodSwitch app when food shopping. When a packaged food item bar code is scanned, the FoodSwitch app will show an interpretive nutritional information score for the scanned product and recommend alternate healthier food options in the same category.
40787909|NCT03110224|DEVICE|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the knee(Subchondroplasty (SCP) Procedure).
40991957|NCT00914615|RADIATION|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
40991958|NCT06145360|DRUG|Empagliflozin 10 MG|the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM
41308576|NCT02629601|BEHAVIORAL|Lottery 2|Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward
41308577|NCT02629601|BEHAVIORAL|Broadcasting winners|Participants are told how many individuals won the lottery during that week.
40787910|NCT05860348|DEVICE|Barostim™ System|Implantation of the Barostim™ System
40787911|NCT03061292|PROCEDURE|Pectoral Nerve Block|
41467315|NCT03513536|OTHER|Control|This control is a blend of plant derived oils which have been expressed from crude plant matter.
40787912|NCT03061292|PROCEDURE|Without Pectoral Nerve Block|
40991959|NCT06145360|DRUG|Insulin+Metformin+DPP4 inhibitor (DPP4I)|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
41308578|NCT02629601|BEHAVIORAL|Active Rewards Doubled|Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
41308579|NCT05600192|OTHER|Aerobic or anaerobic exercise|Aerobic or anaerobic exercise in the morning or in the afternoon
40991960|NCT00741884|DRUG|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
40991961|NCT00741884|DRUG|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
40991962|NCT00741884|DRUG|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
40991963|NCT00741884|DRUG|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
40991964|NCT00741884|DRUG|Placebo|Placebo BID for 7 weeks
40991965|NCT06042309|OTHER|Rubber accelerators and control chamber/solution for NON-SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Three different concentrations of rubber accelerators and one control chamber/solution will be applied on the arms.
40991966|NCT06042309|OTHER|SLS|Exposure to SLS on a randomized arm
41308580|NCT01894308|DRUG|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
41147470|NCT05825456|PROCEDURE|Open reduction internal fixation with plate and screws|This is a type of surgery in which the affected part of the bone is visualized completely, after the reduction is achieved, the fixation is provided with appropriate plates and screws. Again the affected part could be removed or retained. If removed, the defect is filled with bone cement.
41147471|NCT02558803|BEHAVIORAL|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
40991967|NCT06042309|OTHER|Rubber accelerators and control chamber/solution for SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Two different concentrations of rubber accelerators and one control chamber/solution will be applied on both arms.
40991968|NCT06042309|OTHER|Patch test on back|Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution
40991969|NCT05614375|PROCEDURE|endoscopic surgery|transnasal endoscopic surgery
40991970|NCT06093412|PROCEDURE|unilateral epidural anesthesia|The patients received unilateral epidural anesthesia
40991971|NCT06093412|PROCEDURE|combined lumbar and epidural anesthesia|The patients received combined lumbar and epidural anesthesia
40991972|NCT02256761|DRUG|BIRT 2584 XX - multiple escalating dose|
40991973|NCT02256761|DRUG|Placebo|
40991974|NCT02256761|DRUG|BIRT 2584 XX - single dose|
40991975|NCT02256761|OTHER|high caloric meal|30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
40991976|NCT00486694|DRUG|Sulfadoxine-pyrimethamine + artesunate|
40991977|NCT00486694|DRUG|Chloroquine|
40991978|NCT00566150|DRUG|Levetiracetam|Flexible dose up to 2500mg per day, for 6 weeks.
41147472|NCT04705779|BEHAVIORAL|HARMONY|The HARMONY intervention will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
41147473|NCT04705779|BEHAVIORAL|Nutrition and Exercise Education (NEEW)|The Nutrition and Exercise Workgroup (NEEW) group will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
41147474|NCT01280656|DRUG|Conventional Interferon|Conventional interferon according to the standard of care and aligned with the local prescription instructions
41147475|NCT01280656|DRUG|Peginterferon Alfa-2a|Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
41147476|NCT01280656|DRUG|Peginterferon Alfa-2b|Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
41147477|NCT01280656|DRUG|Ribavirin|Ribavirin according to the standard of care and aligned with the local prescription instructions
40991979|NCT00566150|DRUG|Placebo|Flexible dose up to 2500mg per day, for 6 weeks.
41157026|NCT02419040|PROCEDURE|Corticosteroid injection|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
40991980|NCT00199784|DRUG|Phenylephrine|
40991981|NCT01742741|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
40991982|NCT01741181|DRUG|Vitamin D supplementation|Vitamin D3 marketed by oneNine57
40991983|NCT01741181|DRUG|Placebo Pill|Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
40991984|NCT01571206|BIOLOGICAL|Infliximab|CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
40991985|NCT03395158|DIAGNOSTIC_TEST|Implementation of new alert criteria|The intervention is when the prior alert criteria are replaced by the present alert criteria
40991986|NCT02250755|OTHER|MRI T1 T2 sequences|MRI
40991987|NCT00930566|DRUG|methoxsalen|"UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
40991988|NCT00930566|PROCEDURE|Extracoporal Photopheresis (ECP)|"In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
40991989|NCT03646682|PROCEDURE|vitrectomy with membrane peeling|during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
40991990|NCT01865279|DRUG|insulin degludec|Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
40991991|NCT01865279|DRUG|placebo|Ascending single doses - 5 dose levels
40991992|NCT01865279|DRUG|insulin degludec|A single dose corresponding to that of isophane human insulin
40991993|NCT01865279|DRUG|isophane human insulin|A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
41308581|NCT01894308|DEVICE|Pump Sprayer|A dose of product solution is delivered by means of a metered pump spray.
41467316|NCT03573817|DRUG|Revefenacin|Revefenacin is administered via a nebulizer.
40787913|NCT03110718|DEVICE|ArmeoP+real MV|All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
40787914|NCT03632096|RADIATION|Photobiomodulation|The parameters are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
40787915|NCT03632096|RADIATION|Sham|The sham group will have a simulation of laser application, following the same procedures as the active group, but with the device switched off.
40787916|NCT03825757|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
40787917|NCT03825757|DRUG|Acetyl Salicylic Acid|Primaspan 250 mg tablet Acetyl Salicylic Acid
40787918|NCT06286332|OTHER|Music Therapy|30 minutes of self-selected music playback every day.
40787919|NCT01484457|DEVICE|Closed-loop session|"Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose \< 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.~Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched on on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.~After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia."
40787920|NCT05260320|OTHER|Standardized Anesthetic Course from Premedication to Induction|See information in intervention group description
40787921|NCT03710889|DRUG|Abaloparatide|Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH\[1-34\] and 76% homology to human PTHrP\[1-34\].
40787922|NCT00373607|DRUG|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
40787923|NCT00373607|DRUG|Mefloquine + Artesunate|Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
40787924|NCT06437847|OTHER|Questionnaire|Questionnaire assessing the use of cognitive tests.
40787925|NCT05554302|DRUG|18F-Fluciclovine|Patients will receive 5-mCi dose (+/- 20%) of 18F-Fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-Fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-Fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
40787926|NCT05322278|OTHER|Data collection|No interventions
40787927|NCT05595200|DIAGNOSTIC_TEST|Level III portable sleep study|Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge
40787928|NCT02125344|DRUG|non-pegylated liposomal doxorubicin|20 mg/m2, i.V. 18 times weekly
40991994|NCT05190198|OTHER|Proprioceptive neuromuscular facilitation|"* Weight shifting in each direction (anteriorly, posteriorly, and lateral side) combined with side-to-side head movements (5 times for each direction).~* One-legged stance with slight knee flexion of another leg for 15 seconds (5 times for each leg).~* One-legged stance with increasing knee flexion of the other leg for 15 seconds (5 times for each leg).~* Standing on a balance pad with shifting weight (anteriorly, posteriorly, and lateral side) 10 times in each direction.~* In standing position, moving the weight left and right maximally.~* In standing position, moving the weight forward and backward maximally.~* In standing position, moving both heels of feet up and down.~* In standing position, bending and stretching both knees by squatting as much as possible."
41308582|NCT00568958|BEHAVIORAL|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
41467317|NCT03573817|DRUG|Placebo|Placebo version of Revefenacin is administered via a nebulizer.
40787929|NCT02125344|DRUG|Carboplatin|Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
40787930|NCT02125344|DRUG|Paclitaxel|paclitaxel 80mg/m² 18 times weekly
40787931|NCT02125344|DRUG|Epirubicin|150mg/m² every 2 weeks for 3 cycles.
40787932|NCT02125344|DRUG|Cyclophosphamide|2000 mg/m² every 2 weeks for 3 cycles.
40787933|NCT02125344|DRUG|Pertuzumab|420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
40787934|NCT02125344|DRUG|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
40787935|NCT02125344|DRUG|Ferric carboxymaltose|after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is \<70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is \<50 kg, both dosages will be reduced to 500 mg each.
40787936|NCT06319209|OTHER|Preoperative resolved COVID-19|We observed postoperative outcomes only in patients who had or did not have COVID-19 before surgery, without any additional intervention.
41147478|NCT05075005|OTHER|Treatment Cohort|Subjects will walk on a specified University of Florida Natural Area Teaching Laboratory's (NATL) nature trail for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Time, distance, and GPS walking route will be recorded utilizing the MapMyRun smartphone application, which is free to download and easy to use. The study team will assist each subject with downloading the application onto their smartphone and provide a brief training on app use at their pre-trial visit. Subjects will be asked to save each training session within the app to report to the study team upon completion of the 8-week training protocol. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
41147479|NCT05075005|OTHER|Control Cohort|Subjects will walk on hardscapes (e.g. sidewalk, asphalt, track, etc) for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Similarly to the treatment group, subjects will be asked to utilize the MapMyRun smartphone application to record their training sessions. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
41147480|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the general population
41308583|NCT00568958|DRUG|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
41308584|NCT00568958|DRUG|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
40787937|NCT04821934|OTHER|TR|"TR is a specific remote tele rehabilitation program on exercise activity managed by the physiotherapist (PT) at home, this is the experimental group. PT will explain the rehabilitation program at hospital discharge by the use of a brochure and videos. TR will include an early exercise re-conditioning program \[aerobic exercise at the free body (with or without tools), cyclette and walking with a pedometer\] comprising 20 sessions of 60 minutes/day, 6 out of 7 days to be performed at home, for one month after discharge. The sessions will be self-managed by the patients 4 times a week and an expert PT will remotely supervise 2 times a week through a dedicated platform. The program will be progressively incremental and divided into 4 different levels of intensity (0- 3).~In addition to this specific rehabilitation program, the patients will be followed by a nurse tutor once a day for two weeks and once a week for a further two weeks in a program of Telesurveillance."
40787938|NCT04821934|OTHER|TSu|"The patients of this group will perform a usual Telesurveillance and will be considered as control group.~All patients, at discharge from the hospital, will be provided with a finger pulse oximeter and a dedicated application (app) on their personal smartphone and will be advised on free physical activity to be performed at home. The nurse will check through scheduled calls (once a day for two weeks and once a week for a further two weeks) the patient's health condition, vital parameters and drugs administration. Patients will be able to contact the nurse at each time, in case of specific need, out of the scheduled call, 7/7 days.~A follow up by phone will be planned by nurse tutor at 2 months from the end of the study."
40787939|NCT02611102|DIETARY_SUPPLEMENT|MCT oil + Butter in Coffee|2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
41147481|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)_cirrhosis|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population with liver cirrhosis
41308585|NCT02023164|DRUG|JDP-205 Injection|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
41308586|NCT02023164|DRUG|Diphenhydramine|Diphenhydramine Injection, 50 mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
40787941|NCT00442416|DRUG|Epoetin alfa|As prescribed, SC
40787942|NCT00442416|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
40787943|NCT00002593|DRUG|fluorouracil|Given IV as described in Arm Description
40787944|NCT00002593|DRUG|leucovorin calcium|Given IV as described in Arm description.
40787945|NCT00002593|DRUG|levamisole hydrochloride|Given as described in arm description
40787946|NCT03323138|PROCEDURE|Ex-PRESS and phacoemulsification|
40787947|NCT03566472|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
40787948|NCT03522961|DRUG|Nitrofurantoin Prophylaxis/Placebo|Drug: Nitrofurantoin Drug: Placebo
40787949|NCT03522961|DRUG|Cranberry capsules|Drug: TheraCran® One Cranberry capsules
40787950|NCT02965989|PROCEDURE|Online training of a nursing technique|The professionals with participant in the experimental arm receive an online training of a technique of extraction of blood culture and other arm the professionals no receive any training. They work as usual.
40787951|NCT03928041|DEVICE|Device: EVOS Lumbar Interbody System (EVOS-HA)|All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
40787952|NCT02668289|OTHER|consent|At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
40787953|NCT02668289|OTHER|Screening|At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
40787954|NCT02668289|OTHER|Xray|each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
40787955|NCT02668289|OTHER|PVS Impressions|PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
40787956|NCT02668289|OTHER|Photographs|Intraoral photographs will also be taken and subsequent study visits will be planned.
40787957|NCT02668289|OTHER|CBCT|The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
40787958|NCT02668289|OTHER|Anesthesia|After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
40787959|NCT02668289|PROCEDURE|Extraction|After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
40787960|NCT02668289|OTHER|Clinical measurements|Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
40787961|NCT04096105|DRUG|CC-93538|a single dose CC-93538 SC
40787962|NCT04086355|OTHER|oromotor exercises and neuromuscular electrical stimulations|treatment study group with occupational exercises and electrical stimulation
40787963|NCT02563145|BEHAVIORAL|Real-time fMRI feedback|feedback about activation patterns in brain regions related with instrumental aggression
40787964|NCT02563145|BEHAVIORAL|Treatment as usual|Psychoeducation, general counselling
40787965|NCT06213207|OTHER|Simulator based training to manage asphyxia and essential newborn care using neonatalie|The intervention, HBB training package will be used which was applied to train the hospitals staff in Nepal (Chaulagain et al., 2021) and Laerdal Global Health (Laerdal Global Health, 2021) to enhance the competencies on the resuscitation to newborn using NeoNatalie. Health workers will receive 5 days simulation training by expert pediatrician and pediatric nurse who have prior working experience in Neonatal Intensive Care Unit (NICU) or Special Neonatal Care Unit. After the training, mentoring and coaching will be provided experienced newborn coach/trainer on a monthly basis for six months.
40787966|NCT01070134|BEHAVIORAL|Mindfulness-based Behavioural Therapy (MIBT)|"The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).~The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness."
40787967|NCT01070134|BEHAVIORAL|PT (psychodynamic therapy)|"The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).~The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions."
40787968|NCT02351089|DIETARY_SUPPLEMENT|Capsules placebo|Capsules
40787969|NCT02351089|DIETARY_SUPPLEMENT|Capsules probiotic powder and corn starch|
40787970|NCT01470222|OTHER|Weight loss intervention|Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
40787971|NCT01265017|DRUG|Estradiol, medroxyprogesterone, hydrocortisone, GH|"* Estradiol 1mg every 8 hours administered orally~* Medroxyprogesterone 2.5 mg every 24 hours administered orally~* Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~* Growth hormone 2 mg once a day administered by subcutaneous injection,"
40787972|NCT01265017|DRUG|Matching placebo|matching placebo
40787973|NCT00368524|BEHAVIORAL|contingency management and behavioral day treatment|
40787974|NCT03082677|DRUG|Ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
40787975|NCT02432430|BEHAVIORAL|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage|Quality improvement technical support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
41147482|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)_no_cirrhosis|neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population without liver cirrhosis
41147483|NCT06095778|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
40787976|NCT02432430|BEHAVIORAL|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage|Financial incentives to support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
40787977|NCT05458297|BIOLOGICAL|Zilovertamab vedotin|IV infusion
40991995|NCT05190198|OTHER|conventional therapy|"(Dorsiflexion, planter flexion, eversion and inversion) 10 repetitions for each movement.~(A) Sit to stand (5 times). (B) Standing with shifting Weight anteriorly, posteriorly, and sideway (5 times for each direction). (C) Functional reach sideway and anterior for touching targets set by the therapist (5 times for each direction). (D) Standing on heels for 20 seconds (5 times). (E) Standing on toes for 20 seconds (5 times).~(A) Spot marching (2 min). (B) Walking over the heels, toes, lateral border of feet with the preferred speed (6 min). (C) Tandem walking in a straight line (2 min)."
40991996|NCT04996459|DRUG|Tislelizumab|Tislelizumab 200mg iv q3w
40991997|NCT05896553|DRUG|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
40991998|NCT05896553|DRUG|intranasal Placebo|Administration of intranasal Placebo
40991999|NCT04263701|OTHER|Therapeutic exercises|Conventional physiotherapy exercises for children with cerebral palsy
40787978|NCT05458297|DRUG|Nemtabrutinib|65 mg once daily (QD) orally
40787979|NCT02681653|DRUG|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
40992000|NCT04263701|OTHER|Dual Task Training|Dual task training in addition to conventional physiotherapy exercises for children with cerebral palsy
41147484|NCT04617197|DEVICE|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
41147485|NCT00674765|DRUG|Seroquel|400 mg/day
41147486|NCT00674765|DRUG|Placebo|400 mg/day
41147487|NCT00871494|DRUG|Azithromycin|The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
41147488|NCT02391714|PROCEDURE|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
41147489|NCT02391714|DRUG|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
41308587|NCT01712087|DEVICE|MedStream Programmable Infusion System|Intrathecal Infusion of Baclofen in the Treatment of Spasticity
41308588|NCT02024204|DRUG|Fluticasone propionate 230mcg for 3 Months|
41147490|NCT02391714|DRUG|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
40787980|NCT02681653|DRUG|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
41147491|NCT02391714|OTHER|Oxygen|100% oxygen via nasal mask.
41147492|NCT02391714|OTHER|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
41147493|NCT02854709|BEHAVIORAL|Sleep extension|Sleep extension by 1 hour for 2 weeks
41147494|NCT03833765|PROCEDURE|CAF+XCM|After flap elevation according to the Coronally Advanced Flap procedure for multiple recession defects, a Xenogeneic Collagen Matrix was applied and then covered by the flap.
41147495|NCT03833765|PROCEDURE|CAF alone|Coronally Advanced Flap procedure alone was performed to treat multiple recession defects
41147496|NCT00990132|DEVICE|Home mechanical ventilation|Nocturnal non-invasive ventilation
41147497|NCT00990132|DEVICE|Long term oxygen therapy|LTOT established as per national guidelines
41147498|NCT02526199|DRUG|Bupivacaine|Sciatic nerve block
41308589|NCT02024204|DRUG|Current Treatment or no treatment|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
41308590|NCT02024204|DRUG|Salmeterol 21mcg for 3 Months|
41308591|NCT06548035|BEHAVIORAL|Adapted Relaxation Response Resiliency Program (3RP)|The 3RP intervention is an integrated program of relaxation response (RR) eliciting meditation and mindfulness exercises, social support, cognitive skills training, and positive psychology focused on developing skills to reduce the stress response, elicit the relaxation response and enhance resiliency.
41308592|NCT03838172|OTHER|Family impact scale|The family Impact Scale (FIS) will be completed by the parents
41308593|NCT05685368|BEHAVIORAL|ACT for Race Related Stress|This intervention will be guided by: Payne, J. S. (2022). Out of the Fire: Healing Black Trauma Caused by Systemic Racism Using Acceptance and commitment Therapy New Harbinger Publications, Inc.
41308594|NCT05142514|BIOLOGICAL|COVID-19 Vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
41308595|NCT05142514|BIOLOGICAL|Cominarty (Pfizer-BioNtech)|Subjects will receive 2 injections of Cominarty administered 21 days apart
41308596|NCT04496596|DRUG|Suramin|Suramin is administered via IV infusion as a single dose of 3 mg/kg
41308597|NCT04496596|DRUG|Placebo|Placebo
40787981|NCT00305877|BIOLOGICAL|cetuximab|Given IV
40787982|NCT00305877|DRUG|gemcitabine hydrochloride|Given IV
40787983|NCT00305877|DRUG|capecitabine|Given orally
40787984|NCT00305877|RADIATION|radiation therapy|Undergo radiation therapy
40787985|NCT00305877|BIOLOGICAL|bevacizumab|Given IV
40787986|NCT00305877|OTHER|laboratory biomarker analysis|Correlative studies
41308598|NCT00521092|DRUG|sunitinib malate|Given orally
41308599|NCT00521092|PROCEDURE|laboratory biomarker analysis|Correlative study
41308600|NCT00521092|PROCEDURE|pharmacological study|Correlative study
41467318|NCT03573817|DRUG|Formoterol|Administered sequentially in both revefenacin and placebo arms using a nebulizer.
41467319|NCT01867606|BIOLOGICAL|serum-derived bovine immunoglobulin protein isolate|Given PO
41147499|NCT02526199|DRUG|Epinephrine|Adjuvant to perinerual block
41147500|NCT02526199|DRUG|Dexamethasone|Adjuvant to perinerual block
41147501|NCT03321175|OTHER|subcutaneous saline irrigation|200 cc saline irrigation
40787987|NCT01951664|OTHER|Baseline Study Measures|Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
40787988|NCT01951664|BEHAVIORAL|Yoga Evaluation|The evaluation includes an assessment of nine traditional Yoga components: energy, symptoms, emotions, posture, breathing patterns, gait, muscle/tissue quality, joint flexibility, and muscle strength. Emphasis will be placed on the assessment of jaw/neck/shoulder MSI requiring Yoga practice modification of those poses that are unsafe or not feasible for a patient to perform. Information from the evaluation will be used to establish the tailored Yoga program
40787989|NCT01951664|BEHAVIORAL|Yoga Program|The Yoga program has 5 components: 1) Awareness Practice to enhance self-awareness, 2)Poses - 16 core poses will be modified for each patient's specific needs, 3)Breath Work - breath awareness and proper breathing for maximum benefit, 4)Relaxation - alternating between methods of relaxation, 5)Mediation - awareness and practice of inner silence
40787990|NCT01951664|BEHAVIORAL|Yoga Practice Plan|To enhance fidelity, a standardized Yoga intervention was chosen that includes postures, meditation, relaxation, and breath work. To ensure safety, the practice plan for each patient will be reviewed prior to initiation. All MSI limitations will be discussed, and appropriate adaptive techniques will be formulated. Qualitative techniques will be used to describe and categorize the types of impairment and modifications. By developing a catalog of impairments and suitable modifications, a safe and uniform Yoga program can be further tested and widely disseminated.
40787991|NCT01951664|OTHER|Study Assessments|Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
40787992|NCT04402710|BEHAVIORAL|Self-compassion|Six week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes
40787993|NCT04402710|BEHAVIORAL|Control Group|Six week behavioural change program aimed to increase physical activity plus information on general health topics.
40787994|NCT02308293|BEHAVIORAL|High intensity exercise|3x30 seconds 'all out' sprints
40787995|NCT02308293|BEHAVIORAL|Lay down comfortably|rest
40787996|NCT00165789|DRUG|E2007|
40787997|NCT05573035|BIOLOGICAL|LYL845|LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology
40787998|NCT04614844|BEHAVIORAL|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
40787999|NCT04614844|BEHAVIORAL|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
40788000|NCT05489211|DRUG|Datopotamab deruxtecan (Dato-DXd)|Intravenous (IV) Antibody drug conjugate
40788001|NCT05489211|DRUG|Capecitabine|Administered orally
40788002|NCT05489211|DRUG|5-Fluorouracil|Administered as an IV
40788003|NCT05489211|DRUG|Volrustomig|Administered as an IV
41147502|NCT04893824|DEVICE|Grappler® Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
41147503|NCT05959057|DIETARY_SUPPLEMENT|ERr 731 - Micro-coated|natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
41147504|NCT05959057|DIETARY_SUPPLEMENT|ERr 731 - Enteric coated|natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
41308601|NCT05608317|DEVICE|ALLEVYN Non-Adhesive|"ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction.~ALLEVYN Non-Adhesive consists of the following layers:~* Breathable top film~* Highly absorbent foam core~* Non-adhesive wound contact layer"
41308602|NCT01424826|DRUG|Raltegravir|400 mg bd for minimum of 28 days and maximum 35 days
41308603|NCT01424826|DRUG|Rifampicin|\< 50 kg 600 mg 3 times/week for a minimum of 27 days and maximum of 34 days \> 50 kg 900 mg 3 times/week for a minimum of 27 days and maximum of 34 days
41308604|NCT01424826|DRUG|Raltegravir|800 mg bd for 4 days
41308605|NCT06137950|DRUG|gel Interferon arm|0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.
41147505|NCT03014024|OTHER|Low-Level Laser Therapy|The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser
41147506|NCT03014024|OTHER|Placebo Low Level Laser therapy|This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
41467320|NCT01867606|OTHER|placebo|Given PO
41467321|NCT01867606|OTHER|laboratory biomarker analysis|Correlative studies
40788004|NCT05489211|DRUG|Carboplatin|Administered as an IV
41467322|NCT01867606|OTHER|quality-of-life assessment|Ancillary studies
40788005|NCT05489211|DRUG|Leucovorin LV|Administered as an IV
40788006|NCT05489211|DRUG|Bevacizumab|Administered as an IV
40788007|NCT05489211|DRUG|Rilvegostomig|Administered as an IV
40788008|NCT05489211|DRUG|Prednisone/ prednisolone|Administered orally
40788009|NCT05489211|DRUG|Cisplatin|Administered as an IV
41147507|NCT01727193|DRUG|Azathioprine|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
41467323|NCT01867606|OTHER|questionnaire administration|Ancillary studies
41147508|NCT01727193|DRUG|Leflunomide|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
40992001|NCT02146573|BEHAVIORAL|Continuity Care Intensivist Communication Training|Physicians enrolled in the intervention arm will complete a two to three part communication training. Survey measures of communication competency and burnout will be administered at baseline, after training, and at the end of the study. After the communication training, physicians will undergo an OSCE assessment with a simulated patient to evaluate communication skills. At the end of the study, CCI providers will receive surveys that assess the experience and challenges of the role, repeat surveys assessing competency with communication and frequency of engaging families in goals of care conversations, in addition to a follow-up focus group that will assess their experience with the intervention, the time required and the potential tradeoffs in other duties required by them to participate as a CCI.
40992002|NCT02146573|BEHAVIORAL|Continuity Care Intensivist (CCI) Provider Program|"After undergoing CCI training, CCI providers will fulfill a standardized role with parent-patient dyads:~* CCI will meet with families on a regular basis and at change of physician of record throughout their entire PICU hospitalization.~* Help patients/families navigate decisions in concert with preferences and beliefs~* Help patients/families and other care providers look at bigger picture; trajectory of illness, goals, and hopes for the patient.~* Serve as point person for active intensivists on service and other specialists~* Help resolve conflict when multiple providers have different opinions on course of action"
40992003|NCT03762382|DRUG|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
40992004|NCT03762382|DRUG|TFV IVR|TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
40992005|NCT03762382|DRUG|Placebo IVR|Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
40992006|NCT04843748|DEVICE|cataract surgery and intraocular lens implantation - both eyes|cataract surgery and intraocular lens implantation for both eyes
40992007|NCT06328153|DEVICE|Fu's Subcutaneous Needling|Operation of the FSN will follow the KOA's Fu's Subcutaneous Needling Treatment Code of Practice24. After routine disinfection, a disposable Fu's subcutaneous needle ( Nanjing-Paifu Medical Technology Co., Ltd., Jiangsu, China ) is inserted parallel into the subcutaneous loose connective tissue of the pathological tight muscles ( gastrocnemius muscle, tibial anterior muscle and quadriceps femoris muscle ). The FSN needle is operated in a swaying movement. The fan angle is approximately 60°; perform a total of 45 round trips in 30 seconds. Swaying is accompanied by reperfusion approach: 20 sweeps with 10 seconds of reperfusion approach as a group, 3 groups for each pathological tight muscle. The reperfusion approach requires active, short and sharp contractions of the pathological tight muscle. The muscle alternates contraction and relaxation. The FSN group is treated 3 times a week for 2 weeks.
40992008|NCT06328153|DRUG|Celecoxib|Participants in the drug group will receive celecoxib (capsule) 200mg every day continuously for 2 weeks.
40992009|NCT02968303|DRUG|Vemurafenib and Cobimetinib|Combination of Vemurafenib with Cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with Nivolumab and Ipilimumab
40992010|NCT00458523|BIOLOGICAL|alemtuzumab|
40992011|NCT00458523|GENETIC|fluorescence in situ hybridization|
40992012|NCT00458523|GENETIC|mutation analysis|
40992013|NCT00458523|OTHER|flow cytometry|
40992014|NCT00944151|PROCEDURE|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
40992015|NCT02808130|OTHER|hyperlipidemia, periodontitis, gingivitis|GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
40992016|NCT06233487|DIAGNOSTIC_TEST|Repeat hip ultrasound measurements|See earlier
40992017|NCT02775344|DEVICE|Three dimension laparoscopy|Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
40992018|NCT01500707|DRUG|SCH 900800|SCH 900800, one 20 mg tablet, orally
40992019|NCT05333900|BEHAVIORAL|Plant-Based Diet then animal-based diet|Participants started with plant based diet: high in fiber, low in animal products for 7 days, with 14 day washout period between interventions. Following that, participants were switched to animal-based diet: high in animal products, low in fiber for 7 days.
40992020|NCT05333900|BEHAVIORAL|Animal-based diet then plant-based diet|Participants were started with animal-based diet: high in animal products, low in fiber for 7 days, with 14 days washout period between interventions. Following that, participants were switched to plant-based diet: high in fiber, low in animal products for 7 days
40992021|NCT03886220|DRUG|Elagolix|Oral; Tablet
40992022|NCT03886220|DRUG|Placebo|Oral; Tablet
40992023|NCT06110442|DEVICE|IbexBH Software|A software application applied to radiographs
40992024|NCT04475133|OTHER|Ultrasound guided percutaneous neuromodulation|It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
40992025|NCT04426682|DIAGNOSTIC_TEST|urodynamics parameters|"Urodynamics evaluation is performed in the preoperative period in patients whose operation is planned due to incontinence.~Urodynamics evaluation is performed again in patients who applied with postoperative relapse due to surgery failure or different reasons.~It will be shown whether there is a difference between the urodynamics parameters of preoperatively examined patients and those of urodynamics examined in case of postoperative failure."
41147509|NCT02084576|DRUG|Nepafenac|One drop in the study eye 3 times daily for 30 days
41147510|NCT02084576|DRUG|Ketorolac|One drop in the study eye 4 times daily for 30 days
41147511|NCT04136249|DIETARY_SUPPLEMENT|Over physical activity|105/5000 resistance training combined with nutritional monitoring on maximum strength of knee extensors
41467324|NCT03241745|DRUG|Nivolumab|Nivolumab 480 mg IV once every 4 weeks
40992026|NCT02711423|DRUG|Gantenerumab|Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
40992027|NCT02711423|DRUG|Placebo|Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
40992028|NCT02807350|DEVICE|Overminus treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
40992029|NCT02807350|DEVICE|Non-overminus treatment|spectacles with full cycloplegic refraction without overminus
40992030|NCT01593488|DRUG|liposomal cytarabine|given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
40992031|NCT02206555|DRUG|emtricitabine/tenofovir disoproxil fumarate|
40992032|NCT00470574|BIOLOGICAL|QS21|
40992033|NCT00470574|BIOLOGICAL|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
41147512|NCT03737188|DEVICE|Blood glucose monitoring systems for self-testing|Capillary blood samples will be used for the evaluation of system accuracy.
41147513|NCT01695993|DEVICE|Acupressure bands|Bilateral acupressure wrist bands
41147514|NCT01695993|OTHER|Expectancy-neutral handout|The expectancy neutral handout has neutral information regarding the acupressure bands
41308606|NCT06137950|DRUG|gel Interferon and interferon suppository arm|"0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.~3MIU suppository will be given to patients and will be trained how to use. Each patient in the arm will use the suppository twice a day for 10 days with vaginal therapy."
41467325|NCT06441903|OTHER|Ultrasound|Through systematic ultrasound visualization of the pectoralis major muscle, we seek to directly visualize and characterize the different intra- and extra-muscular connective structures of the muscle - Delto Pectoral Tendon (DPT) , Distal Pectoralis Major Tendon (PMT), Anterior Deltoid Tendon (ADT), Anterior Pretendinous Lamina of the Pectoralis Major (ALPM), Posterior Pretendinous Lamina of the Pectoralis Major (PLPM) and Deep Fascia of the Pectoral Major (DFPM) - constituting its connective skeleton, with particular attention to its distal portion near the humerus and on the search for this DPT tendon.
41467326|NCT05628181|BEHAVIORAL|Educational nudge intervention|This project will adapt the EMPOWER educational brochure for PLWD receiving CNS polyRx. The educational brochure will be mailed to intervention participants identified through EHR at Michigan Medicine and Henry Ford Health System. The brochure will describe what CNS polyRx is, present information about the associated risks, and suggest that participants speak with the prescribing clinician or pharmacist about ways to potentially simplify the medication regimen. The tool will be adapted through three successive rounds of focus groups (AIM one of this project) of PLWD.
41467327|NCT05284084|OTHER|Bed Head elevation, H2 blockers and mouth wash|Elevation of the bed head to 15, 30 and 45 degrees, daily H2 blockers administration and mouth wash BID.
41467328|NCT05284084|OTHER|Data collection for comparison|Data collection for comparison
41467329|NCT01376544|DEVICE|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
40992034|NCT00470574|OTHER|immunoenzyme technique|
40992035|NCT00470574|OTHER|immunologic technique|
40992036|NCT00470574|OTHER|laboratory biomarker analysis|
40992037|NCT05083793|DRUG|Pregabalin 150mg|The effect of pregabalin on post-operative pain
40992038|NCT05083793|OTHER|Placebo|patients will receive placebo one hour before operation
40992039|NCT06065579|OTHER|Well-Being Promotion Program|the well-being promotion program (Suldo,2016) , an intervention designed to improve subjective well-being. It was postulated that this intervention will eventually assist in managing emotional and behavioural problems among adolescents enrolled in the program.
40992040|NCT00913809|DRUG|Desipramine HCL 100 mg Tablets Cord Laboratories|
40992041|NCT00913809|DRUG|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc|
41147515|NCT01695993|BEHAVIORAL|Expectancy-neutral MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
41467330|NCT05486845|OTHER|survey|We are planning a questionnaire survey. We combine our own questions with validated, official questionnaires. Validated forms ask for an assessment of the extent of low back pain and the quality of experienced stress.
40992042|NCT02475577|DEVICE|Peripherals with HealthInterlink technology|home remote monitoring
40992043|NCT00195247|DRUG|TTI-237|
41147516|NCT01695993|OTHER|Expectancy-enhancing handout|The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
41467331|NCT03952988|DIETARY_SUPPLEMENT|Probiotic ice cream|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (\>10(exp7)/g) every day for 4 weeks
40992044|NCT01756495|DRUG|Losmapimod|Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
40992045|NCT01756495|DRUG|Moxifloxacin|17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
40992046|NCT01756495|DRUG|Losmapimod matched Placebo|Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
40992047|NCT01756495|DRUG|Moxifloxacin Placebo|16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
40992048|NCT01454570|DEVICE|powered exoskeleton|
40992049|NCT02336022|DEVICE|Respiratory Motion Inc|
41147517|NCT01695993|BEHAVIORAL|Expectancy-enhancing MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
41147518|NCT02350426|OTHER|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
41467332|NCT03952988|DIETARY_SUPPLEMENT|Placebo ice cream|One portion (50g) of an ice-cream without probiotic every day for 4 weeks
41467333|NCT06260501|OTHER|super-wet technique|Liposuction with super-wet technique using wetting-solution containing 0.5 gr lidocaine and 0.5 mg epinephrine in each liter
41467334|NCT03381196|DRUG|Pimodivir 600 mg|Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6).
41467335|NCT03381196|DRUG|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6).
41467336|NCT03381196|OTHER|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).
41467337|NCT03934749|DEVICE|Non Invasive Ventilation|NIV using standard mode or Lowenstein mode
41467338|NCT03454282|OTHER|FMD|The Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (about 600 Kcal on day 1, followed by about 300 KCal/day on days 2 to 5), low-carbohydrate low-protein diet
41467339|NCT02105311|DEVICE|Selective laser trabeculoplasty|Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
41467340|NCT02105311|DRUG|Travoprost|Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
41467341|NCT03808740|DRUG|Atomoxetine|atomoxetine 0.5 mg/kg/day.
41467342|NCT03808740|DRUG|Placebo|sugar pill
40788010|NCT01063790|BEHAVIORAL|Individualized Education|The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
40788011|NCT03744338|OTHER|questionnaire|"The questionnaire is composed of two parts:~The first part let know the characteristics of the patients as age, the BMI, the socio-professional category, the current treatments, the medical-surgical antecedents of interest."
40788012|NCT02271529|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
40992050|NCT03617081|DRUG|NNC0113-2023|Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
40992051|NCT03617081|DRUG|Placebo (NNC0113-2023)|Participants will receive NNC0174-0833 matched placebo orally.
40992052|NCT05316012|DEVICE|Smart diapers|"Residents receive standard continence care while using the smart diaper (without the alerting system) - fase 1~Diapers are changed as usual, e.g., after morning care, visual soiling, unpleasant odor, saturation, leakage.~Residents receive continence care while using the smart diaper with the alerting system - fase 2"
40788016|NCT00570713|DRUG|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
40788017|NCT00570713|DRUG|Placebo|As per package insert.
40788018|NCT00570713|DRUG|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
40788019|NCT02642211|PROCEDURE|cataract surgery|Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
40788020|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Original doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
41467343|NCT01734135|OTHER|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
41467344|NCT06326528|DRUG|SGLT2 inhibitor|Dapagliflozin 10 mg or Empagliflozin 25mg
41467345|NCT02298387|DRUG|OMP-305B83|intravenous (in the vein) infusions
41467346|NCT00272649|BIOLOGICAL|AGS-003|Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
41467347|NCT03680976|DRUG|CXA-10|Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
40992053|NCT03031093|RADIATION|inhalation protocol|technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
40992054|NCT03031093|DEVICE|High Flow Nasal Cannula|aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen.
40992055|NCT06069479|PROCEDURE|craniofacial surgery|Surgical treatment, either stripcraniectomy or fronto-orbital advancement
40992056|NCT06537349|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in OK lens related dry eye
40992057|NCT04950569|DRUG|levosimendan|On the basis of standard conventional anti-heart failure treatment, levosimendan was used for 24 hours. The first load was 12 μg/kg, intravenous injection for 10 minutes, followed by intravenous infusion of 0.1 μg/Kg/min for 24 hours.
40992058|NCT02157142|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
41308607|NCT04680078|PROCEDURE|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. The sutures are removed 1 week after the surgery.
41467348|NCT03680976|DRUG|Placebo|Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
41467349|NCT01829815|BEHAVIORAL|Parents Make the Difference|"The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children."
40992059|NCT03860428|DRUG|Ibuprofen|In the medical treatment arm the in-tention is to close the ductus arteriosus.
40992060|NCT03860428|DRUG|Paracetamol|In the medical treatment arm the in-tention is to close the ductus arteriosus.
40992061|NCT03860428|OTHER|Expectant Management|Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
40992062|NCT00884299|DIETARY_SUPPLEMENT|Diet rich in antioxidants|Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
40992063|NCT05311696|OTHER|psychoeducation|The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities
40992064|NCT03754894|DEVICE|ready made plastic stent application|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
40992065|NCT03754894|PROCEDURE|simple interrupted sutures|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement and securing the flap with simple interrupted sutures
40992066|NCT01536314|DRUG|Memantine EBIXA®|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
40992067|NCT01536314|DRUG|Placebo : lactose|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
40992068|NCT02503332|DRUG|Pegcetacoplan|
40992069|NCT02503332|OTHER|Sham Procedure|
41147519|NCT02350426|OTHER|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
41147520|NCT02350426|OTHER|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
40788021|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Monkey doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush monkey doll. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
40788022|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Dog without velcro doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush dog doll, without velcro in palms. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
40788023|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Bear doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush smiling bear doll. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
40788024|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Rabbit doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush rabbit doll, with a neutral expression. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
40788025|NCT02494154|DEVICE|Airvo 2; Ficher and Paykel HealthCare|High flow nasal cannulas
40788026|NCT02494154|DEVICE|Oxygen delivery via conventional nasal mask|Low flow of oxygen delivered through conventional nasal prongs
40788027|NCT01293136|PROCEDURE|Femoral nerve block|Ropivacaine
40788028|NCT01293136|DRUG|Intravenous opioids|Whatever opioids prescribed
41147521|NCT00874172|DRUG|Rapid optimized analgesic strategy|"Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus"
40788029|NCT05270018|DRUG|Bacterial Lysates|14mg once a day
40788030|NCT05270018|OTHER|normal saline|14.0ml once a day
40992070|NCT03231787|DIAGNOSTIC_TEST|Platelet function assay|"Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.~It will be used to measure platelet function after withdrawal of the antiplatelet agent.~If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours."
40992071|NCT03942354|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
40992072|NCT03942354|DRUG|Pretomanid|Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
40992073|NCT03942354|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
40992074|NCT03942354|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
40992075|NCT03942354|DRUG|Clofazimine|Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
40992076|NCT03942354|DRUG|Directly observed therapy (DOT)|Standard therapy
40992077|NCT04391790|PROCEDURE|Cystectomy and modified urinary conduit|The modified retrosigmoid conduit is extended aorund 5 cm, so the left ureter does not have to cross under the mesentery wheras the presumed more robust ileal segment does.
41147522|NCT00874172|DRUG|current analgesic strategy|"paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration"
41147523|NCT02720705|DRUG|Dexmedetomidine|oral dexmedetomidine
41147524|NCT02720705|DRUG|saline|2ml 0.9% saline administered orally half an hour before induction of anesthesia
41147525|NCT03670771|DIAGNOSTIC_TEST|Harrahill method for measuring of intraabdominal pressure|IAP obtained by using patient own urine as the transducing medium. One clamps the Foley catheter just above the urine collection bag. The tubing is then held at a position of 30-40 cm above the symphysis pubis and the clamp is released. The IAP is indicated by the height (in cm) of the urine column from the pubic bone. The meniscus should show respiratory variations.
41147526|NCT02018159|DRUG|menotropin|
40788031|NCT04902209|PROCEDURE|postural stability measurements|"Static balance assessment on bi-module stabilometric platform CQStab2P. It registers the movement of centre of foot pressure (COP).~Harris hip score- disability assesment"
40788032|NCT04421404|BIOLOGICAL|COVID-19 Convalescent Plasma (CCP)|COVID-19 Convalescent Plasma (CCP) is a form of passive antibody therapy that involves the administration of anti-SARS-CoV-2 antibodies to a susceptible individual for the purpose of preventing or treating the infectious disease it causes. Convalescent plasma for this trial will be obtained from Vitalant (or American Red Cross if necessary). Patients identified as having recovered from COVID-19 will serve as potential donors. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined.
40788033|NCT04421404|BIOLOGICAL|Placebo|Standard plasma will be obtained from Vitalant (or American Red Cross if necessary) and will be either collected prior to 12/1/2019 or tested and confirmed to be negative for anti-SARS-CoV-2.
40788034|NCT05086861|DEVICE|Oesophageal pacing after left atrial posterior wall isolation|Following AF ablation with the aim of isolating the left atrial posterior wall oesophageal pacing and sensing is performed to check for left atrial posterior wall. entrance and exit block.
40788035|NCT06288659|DEVICE|Intraventricular intracranial pressure monitoring|The postoperative management of ICP is guided by quantifiable Intraventricular ICP parameters. The remaining treatments are consistent with those in the control group.
40788036|NCT04739111|DRUG|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)|In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.
40788037|NCT01333410|DRUG|tacrolimus ointment|2 applications per days for 6 months
40788038|NCT01333410|DRUG|Mometasone furoate|2 applications per day for 6 months
40788039|NCT02321605|BEHAVIORAL|e-BPS|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero \& Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
40788040|NCT02321605|BEHAVIORAL|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
40788041|NCT04487197|PROCEDURE|blood sample for seroepidemiological investigation|blood sample for seroepidemiological investigation
40788042|NCT02911142|DRUG|Lenalidomide|Lenalidomide taken orally, daily at assigned dose level on days 1 to 10, up to 25mg.
40788043|NCT02911142|DRUG|Rituximab|During cycle 1, rituximab will be administered on day 4 prior to the start of EPOCH. During cycles 2 to 6, rituximab will be administered on day 1 of each cycle.
40788044|NCT02911142|DRUG|Prednisone|During cycle 1, Prednisone 60 mg/m2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m2 /day PO days 1-5.
40788045|NCT02911142|DRUG|Etopside|During cycle 1, Etoposide 50 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide 50 mg/m2/day continuous intravenous infusion days 1 to 4.
40788046|NCT02911142|DRUG|Doxorubicin|During cycle 1, Doxorubicin 10 mg /m2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
40788047|NCT02911142|DRUG|Vincristine|During cycle 1, Vincristine 0.4 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Vincristine continuous intravenous infusion days 1 to 4.
40788048|NCT02911142|DRUG|Cyclophosphamide|During cycle 1, Cyclophosphamide 750 mg/m2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m2 day 5.
40788049|NCT03265444|BIOLOGICAL|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.
40788050|NCT01212029|BEHAVIORAL|Behavioral measures|Behavioral tasks/ questionnaires
40788051|NCT01212029|DEVICE|fNIRS Devices &amp; Application|Device 1- fNIRSoft and Device 2 - NIRScout
40992078|NCT04391790|PROCEDURE|Cystectomy and standard urinary conduit ad modum Bricker|The conduit is constructed using approximately 15 cm of terminal ileum and placed in the right side of the abdomen. In order for the left ureter to reach the conduit, it is mobilized behind the sigmoideum to the conduit.
41467350|NCT00785876|OTHER|LRAR Implementation|"Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals."
41467351|NCT05287087|BEHAVIORAL|My Symptoms 1 (MySt-1)|"The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~These four provisions are identical to the first part of the MySt-2."
40992079|NCT03911895|DEVICE|Stent more than 26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
40992080|NCT03911895|DEVICE|Stent equal to or less than26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
40992081|NCT06316531|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
40788052|NCT01212029|OTHER|Physiological measures|A set of tasks.
40992082|NCT06316531|DRUG|T-DM1|Administration by intravenous infusion for a cycle of 3 weeks.
40992083|NCT01625247|PROCEDURE|Surgical drainage|Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
40992084|NCT00232258|DRUG|Nolpitantium besylate|
40992085|NCT01902342|DRUG|Oseltamivir 75 mg 1 cap|
40992086|NCT02147938|DRUG|Tacrolimus|oral
40992087|NCT05920421|PROCEDURE|diaghragm affection by ultrasound before and after the blocks|the participant will assess diaphragm sparing in each block and evaluate effectiveness of infraclavicular subomohyoid blocks and subomohyoid subscapularis blocks according to intraoperative and postoperative analgesia and diaphragm affection and comparing them with interscalen and with each others
41147527|NCT02332525|DEVICE|Oral Vibrational Stimulation|"Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place."
41147528|NCT00754533|OTHER|Continuous versus interval training|Influence of different exercise training programs
41308608|NCT04680078|PROCEDURE|Conventional Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is then removed .
41467352|NCT05287087|BEHAVIORAL|My Symptoms 2 (MySt-2)|"The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~5. Thorough symptom explanations~6. Physical energy (focus on sleep, diet and activity)~7. Values and choices (focus on meaning and existential issues)~8. Emotional health (focus on emotion regulation)~9. Mental energy (focus on stress regulation and thinking)~After 4-6 weeks, the patient will see the GP for a follow-up consultation."
41308609|NCT03435172|DEVICE|Device-ADRCs intravenously infusion|Medical Device: ADRCs Generated by Celution 800 IV Device and then Infused into Peripheral Vein.
41147529|NCT02122354|BEHAVIORAL|"Hide and Seek videogame"|
41147530|NCT03115619|DRUG|Pirfenidone|Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
40788062|NCT00853892|DRUG|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
40788063|NCT00853892|DRUG|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
40788064|NCT03313830|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate (WPH)|Subjects will ingest WPH on one occasion.
40788065|NCT03313830|DIETARY_SUPPLEMENT|Intact Whey Protein (WHEY)|Subject will ingest WHEY on another occasion.
40788066|NCT05847647|OTHER|Retrograde Filling Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect.
40788067|NCT05847647|OTHER|Retrograde Filling+L-PRF Group|2. Group: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect (
40788068|NCT05847647|OTHER|(Orthograde Filling Group / OG Group).|3. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect
41147531|NCT03338829|BEHAVIORAL|Positive incentive|Compensation is paid for each glucose test completed
41147532|NCT03338829|BEHAVIORAL|Loss aversion|Fixed compensation is offered to patients and they can earn a range of compensation at the completion of pregnancy depending on overall glucose testing adherence
41147533|NCT01442207|PROCEDURE|Placement of a Cervical Cerclage|Surgical placement of a cervical cerclage
40788069|NCT05847647|OTHER|(Orthograde Filling+L-PRF Group|4. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect
40788070|NCT05022173|DEVICE|Helmet Non-Invasive Ventilation|The helmet interface is a modality which is used to deliver NIV to patients with respiratory failure. A transparent hood is placed over the entire head of the patient with a seal at the neck using a soft collar.
40788071|NCT05022173|DEVICE|Facemask Non-Invasive Ventilation|The facemask interface is a modality which is also used to deliver NIV to patients with respiratory failure. A large mask covering the mouth and nose is strapped to the patient's face to create a seal.
40788072|NCT01628913|DRUG|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
40788073|NCT01628913|DRUG|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
40788074|NCT02521974|BIOLOGICAL|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
40788075|NCT00456573|PROCEDURE|tonsillectomy|medically indicated tonsillectomy in subjects with and without OAS
40788076|NCT02681367|OTHER|Freeze all policy|Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
41147534|NCT01442207|PROCEDURE|Standard Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~* Standard management for placenta previa.~* Hospital admission for vaginal bleeding/hemorrhage~* Antenatal corticosteroids \> 24w0d of gestation~* Tocolytic therapy per physician's discretion~* Magnesium sulfate for neuroprotection~* Fetal Heart Rate Monitoring~* Avoidance of digital examinations of the cervix~* Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM \> 34 wks, worsening maternal or fetal condition )~* Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
41147535|NCT05673772|RADIATION|short-course radiotherapy|25 Gy in 5 fractions for 5 days
41147536|NCT05673772|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours
41147537|NCT05673772|RADIATION|Chemoradiotherapy|45\~50.4 Gy/25fr with concurrent use of either capecitabine or 5-FU+leucovorin(or levoleucovorin or leucosodium)
41147538|NCT05673772|PROCEDURE|TME surgery|TME surgery
40788077|NCT06443333|OTHER|Data collection and follow-up observation|At the time of enrollment, the patient's biological samples are collected to obtain genetic information. Following enrollment, trained investigators carry out a 2-year follow-up observation through face-to-face, telephone call or online visits. During the follow-up, basic clinical information, laboratory tests, imaging examinations, neurophysiology, clinical classification, medication use, and scale assessments are collected.
40788078|NCT06443333|OTHER|Data collection|Collect demographic and genetic information from healthy volunteers upon enrollment.
40788079|NCT02849002|DEVICE|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
40788080|NCT00524121|DRUG|erlotinib hydrochloride|Oral
40788081|NCT00524121|OTHER|immunohistochemistry staining method|Correlative Study
40788082|NCT00524121|RADIATION|radiation therapy|Radiation Treatment
40788083|NCT02156193|PROCEDURE|Prophylactic clip|Prophylactic clipping
40788084|NCT02156193|PROCEDURE|No prophylactic management|No prophylaxis
40788085|NCT00572416|BEHAVIORAL|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
40788086|NCT00572416|BEHAVIORAL|Healthy Eating Control|Equal time and attention and information about healthy eating
40788087|NCT00190736|DRUG|Atomoxetine Hydrochloride|
40788088|NCT00190736|DRUG|placebo|
40788089|NCT00498992|DIETARY_SUPPLEMENT|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
40788090|NCT03366363|OTHER|acupuncture|acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.
40788091|NCT03776240|DRUG|HD201|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
40788092|NCT03776240|DRUG|EU-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
40788093|NCT03776240|DRUG|US-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
40788094|NCT04942431|BEHAVIORAL|Rebirth active SCHOOL 2.0 movement program|60 Minutes of physical activity per day integrated in every school-day.
40788095|NCT05912491|DIAGNOSTIC_TEST|Transperineal ultrasonography|Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
40788096|NCT04663594|OTHER|WofB|Online experience designed to reduce anxiety and depression and support mental health and wellbeing
40788097|NCT04663594|OTHER|Ashmolean Website|A generic museum website owned by the Ashmolean Museum of Art and Archaeology at the University of Oxford.
40788098|NCT05074823|DRUG|Ketamine 0.1 mg|Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
40788099|NCT05074823|DRUG|Ketamine 0.2 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
40788100|NCT05074823|DRUG|Ketamine 0.3 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
40788101|NCT05722366|OTHER|Active video game|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
40788102|NCT05722366|OTHER|aerobic exercise|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
40788103|NCT02251496|OTHER|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
40788104|NCT02251496|OTHER|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
41147539|NCT00221156|DRUG|Acarbose|
41147540|NCT00006104|BIOLOGICAL|trastuzumab|
41147541|NCT00006104|DRUG|docetaxel|
41147542|NCT05744505|PROCEDURE|1565nm Non-ablative Fractional Laser|Every 3 weeks
41147543|NCT05744505|PROCEDURE|placebo|Every 3 weeks
41017768|NCT03272594|OTHER|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
41147544|NCT00763919|BEHAVIORAL|Psychoeducation module|The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
41467353|NCT04233138|OTHER|SUPPORT online platform for people with type 1 diabetes|"All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).~The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform."
41467354|NCT00535028|DRUG|AER 001|AER 001 25 mgs s.c. once daily for 28 days
41467355|NCT00535028|DRUG|placebo|sterile saline
41467356|NCT02071368|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
41467357|NCT02071368|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
41467358|NCT02071368|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
41467359|NCT02071368|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
41467360|NCT06535464|DEVICE|Hypotension Prediction Index|Fluid management guided by Hypotension Prediction Index
41467361|NCT06535464|DEVICE|No Hypotension Prediction Index|Fluid management not guided by Hypotension Prediction Index
41467362|NCT01784237|PROCEDURE|anterior meatoscopy|The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.
40788105|NCT06184191|OTHER|Robotic hand rehabilitation|Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.
40788106|NCT03984773|BEHAVIORAL|Nudge|Oncology practices will be randomly assigned to receive an intervention, in which individual clinicians will receive a weekly audit email detailing how many serious illness conversations (SIC) they have had compared to the recommended level, and a link to a list of their patients scheduled in clinic next week at high risk of short-term mortality as identified by a mortality prediction algorithm. Clinicians will have the chance to review the opt-out list and pre-commit to a serious illness conversation with appropriate patients. Clinicians will receive nudge on the day of the patient visit via text message reminding them of their pre-commitment to conduct a serious illness conversation.
41147545|NCT00763919|BEHAVIORAL|Substance abuse module|The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
41147546|NCT00763919|BEHAVIORAL|Improved communication/rapport with provider module|The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
41147547|NCT00763919|BEHAVIORAL|Medication routines management module|The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
41147548|NCT04015050|OTHER|milk based infant formula|Cows milk ased infant formula
41467363|NCT01784237|PROCEDURE|Nasal sniff test|All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
41467364|NCT06013345|DRUG|Remimazolam|analgosedation without secured airway
41467365|NCT06013345|DRUG|Propofol|analgosedation with secured airway
41467366|NCT06013345|DRUG|Propofol|TIVA with secured airway
41467367|NCT03979833|GENETIC|Whole exome sequencing|DNA from CNS hemangioblastomas and normal tissue (blood) will be analysed using whole exome sequencing.
41467368|NCT00403949|DRUG|Azelaic acid 15% gel|gel, applied once daily, for 6 weeks
41467369|NCT00403949|DRUG|Non-active base from azelaic acid 15% gel|gel, apply once daily for six weeks
41467370|NCT01134627|DRUG|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
40788107|NCT03446898|OTHER|Chronic hypoxic environment|Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
40992088|NCT05293756|BEHAVIORAL|OPTIMA-BP Intervention|"Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention:~1. Six weekly web-based education sessions on hypertension management.~2. Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months.~3. Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months.~4. Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress.~5. Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: \< 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor."
40992089|NCT05595889|DRUG|Surufatinib|250 mg/day p.o. QD
40992090|NCT05595889|DRUG|Irinotecan|Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks
40992091|NCT01464346|DEVICE|Enlite Sensor|This is the Enlite sensor (all subjects)
40992092|NCT02385266|DRUG|D-Cycloserine|Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
40992093|NCT02385266|DRUG|Placebo (for D-cycloserine)|Lactose filled capsules to mimic DCS 200mg capsules
41308610|NCT03670316|DRUG|Algorithm Treatment|Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
41308611|NCT03670316|OTHER|Quitline only|eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.
41308612|NCT00143260|DRUG|Viagra (Sildenafil Citrate) 100 mg|
41308613|NCT00147732|RADIATION|Accelerated radiotherapy|68 Gy over 5.5 weeks
41308614|NCT00147732|RADIATION|ARCON|68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily
41308615|NCT01418664|DIETARY_SUPPLEMENT|D Max drops|Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
41308616|NCT02280941|OTHER|single photon emission computed tomography|Single photon emission computed tomography (SPECT) imaging will be done.
41308617|NCT00757939|OTHER|MRI|During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.
41308618|NCT00757939|OTHER|FDG-PET|2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable
41308619|NCT04766203|BEHAVIORAL|Treatment of REDS using a holistic treatment arm|This arm aims to treat athletes with REDS symptoms by implementing a holistic, individualized nutrition intervention to improve energy availability and thus restore impaired body function due to REDS.
41308620|NCT05631015|OTHER|AI recongnize disease and generate recommendations|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
41308621|NCT02645656|DRUG|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
41308622|NCT01554540|DRUG|Cutaneous iontophoresis of treprostinil|Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
41308623|NCT02940626|DRUG|ASN100|monoclonal antibody combination of ASN-1 and ASN-2
41308624|NCT02940626|DRUG|Placebo|Placebo
41308625|NCT02857855|PROCEDURE|80% fraction of inspired oxygen for 6 postoperative hours|80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
41308626|NCT02857855|PROCEDURE|28% fraction of inspired oxygen for 6 postoperative hours|28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
41308627|NCT01413048|DRUG|Carvedilol 25mg|Tablet, q.d.
41308628|NCT01413048|DRUG|AGSCT101 12.5mg|Tablet, q.d.
41308629|NCT05607589|DRUG|DWP213388|immunosuppressant
41308630|NCT05607589|OTHER|Placebo|Placebo
41308631|NCT03577093|OTHER|There is no intervention at all.|There is no intervention at all.
40992094|NCT04572607|DIETARY_SUPPLEMENT|The consumption of avocado honey was analyzed|The subjects of honey group consumed 25 g of honey each day for 4 weeks.
40788108|NCT04455828|DEVICE|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks heart rate, respiratory rate, sleep, and heart rate variability.
40788109|NCT05065801|COMBINATION_PRODUCT|GABRINOX|Patients in the experimental arm received sequential treatment: 3 cycles of GEMBRAX followed by 2 cycles of FOLFIRINOX
40992095|NCT05595512|BEHAVIORAL|Naser Al-Husban|depressive symptoms within 6 months of delivery
41147549|NCT03368300|OTHER|Clinical and biological exam|"The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.~All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors~All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma)."
41147550|NCT03984734|PROCEDURE|Pancreatoduodenectomy with antrectomy|
40992096|NCT04759872|OTHER|Hyperinsulinemic-euglycemic Clamp|Participants will be administered a constant-rate insulin infusion (to induce mild hyperinsulinemia), with an infusion of dextrose to maintain blood glucose concentration (to maintain euglycemia).
40992097|NCT04203628|DIAGNOSTIC_TEST|Xpert MTB/Rif Ultra on stool samples|"The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~* Standard sucrose flotation method~* Optimized sucrose flotation~* Stool processing kit (SPK)~* Simple One-step method (SOS)"
40788110|NCT05065801|COMBINATION_PRODUCT|FOLFIRINOX|Patients in this arm received reatment: 3 cycles of FOLFIRINOX
40788111|NCT01198821|DRUG|Sodium bicarbonate (g/kg/day)|Dose Escalation - Level 1: 0.3, Level 2: 0.5, Level 3: 0/7, Level 4: 1.0
40788112|NCT01198821|DRUG|Gemcitabine (mg/m²)|Dose Escalation - Level 1: 1000, Level 2: 1000, Level 3: 1000, Level 4: 1000
40788113|NCT02156024|DRUG|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
40788114|NCT03618381|BIOLOGICAL|second generation 4-1BBζ EGFR806-EGFRt|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt
40788115|NCT03618381|BIOLOGICAL|second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
40788116|NCT05871619|PROCEDURE|Remin Pro|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
40992098|NCT04203628|DIAGNOSTIC_TEST|Xpert MTB/Rif Ultra on respiratory sample|The Xpert MTB/Rif Ultra will be performed on gastric aspirate or expectorated sputum
40992099|NCT06181890|OTHER|Motivational Interview|The data of the research will be collected between October 2023 and June 2024. Each meeting will last approximately 15-30 minutes.
40788117|NCT05871619|PROCEDURE|X Pur Remin|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
40788118|NCT05871619|PROCEDURE|Fluoride varnish|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
40788119|NCT02062515|DRUG|icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
40788120|NCT06460870|OTHER|Mojzisova method|The home based regular exercises stretching and strengthning exercises twice daily along with hot pack. Manual therapy was applied in the first half of the menstrual cycle, once a month, for one hour. It includes mobilization of ribs, lumbar spine, and sacroiliac joints as well as coccygeal treatment, and internal rectal work. The patient was received 2 sessions per month for 3 months, for 45 minutes.
40788121|NCT06460870|OTHER|Stretching exercises|Stretching exercises was performed such as cobra pose, cat/cow pose and baby pose along with hotpack for 2 sessions per month for 45 min for 3 months.
40788122|NCT03194399|BEHAVIORAL|Personalized health care service|Physical activity coaching, other functional outcome observation
40788123|NCT05275673|DRUG|sapanisertib|capsules for oral administration
40788124|NCT05670327|OTHER|Diaphragmatic ultrasound assessment|TFdi, diaphragmatic dysplacement, NAVA assessment, respiratory paramenters
40788125|NCT05985707|DRUG|KN026|KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.
40788126|NCT05985707|DRUG|KN046|KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
40788127|NCT05985707|DRUG|XELOX|XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.
40788128|NCT00586794|DRUG|Sildenafil|3x per day 20 mg TID
40788129|NCT00586794|DRUG|Placebo|3x per day, 20 mg TID
40788130|NCT00361972|DRUG|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
40788131|NCT00361972|DRUG|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
40788132|NCT04609605|DEVICE|speckle tracking echocardiography|speckle tracking echocardiography of right ventricle
40992100|NCT05990400|DRUG|Finasteride|finasteride topical 0,1%
40992101|NCT05990400|DRUG|Minoxidil|minoxidil topical 5%
40992102|NCT04076735|PROCEDURE|Distal femoral replacement|The distal portion of the femur (up to two thirds) is excised and replaced by a endoprosthesis incorporating a hinged total knee replacement.
40992103|NCT04076735|PROCEDURE|Surgical Fixation (ORIF)|A trained orthopaedic surgeon uses open or minimally invasive reduction techniques and achieves stable fixation with internal fixation devices (plates/screws or intramedullary nail) to restore structural integrity and alignment of the distal femur
40992104|NCT02694406|DEVICE|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
41467371|NCT01134627|DRUG|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
40992105|NCT01855633|DEVICE|Traditional Theta burst stimulation (TBS)|
40992106|NCT01855633|DEVICE|Modified TBS rTMS|
40992107|NCT01855633|DEVICE|Sham rTMS|
40992108|NCT00387478|BIOLOGICAL|Tree MATA MPL or Tree MATA|"4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~1. 600 SU/0.5 ml~2. 1600 SU/0.5 ml~3. 4000 SU/0.5 ml~4. 4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo"
41467372|NCT01231373|DRUG|polidocanol injectable foam, 0.125%|active placebo for blinding
41467373|NCT01231373|DRUG|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
41467374|NCT01231373|DRUG|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
41467375|NCT01231373|DRUG|Vehicle|injection of vehicle comparator
41467376|NCT05167045|BEHAVIORAL|Brain Health PRO|The BHSP is an educational program designed to teach about dementia. It aims to provide best available evidence for lifestyle changes that can help lower dementia risk, and to provide specific recommendations for positive lifestyle changes (e.g., physical exercises to try at home, healthy recipes). The program was developed as a collaborative effort by Canadian investigators who have expertise in the different areas of dementia prevention, along with input from older-adult citizen advisors.
41467377|NCT06013111|BIOLOGICAL|Intravenous infusion anti-CEA-CAR-T cell|Anti-CEA-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 0.3×10\^7 CAR-T cells/kg, 1×10\^7 CAR-T cells/kg, and 3×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
41467378|NCT04649489|DRUG|Atezolizumab|atezolizumab 1200mg and bevacizumab 15mg/kg
41467379|NCT04649489|PROCEDURE|Surgery|hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg
40788133|NCT02049411|DRUG|Ketamine|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
40788134|NCT02049411|DRUG|physiological solution|physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
40992109|NCT01758380|DRUG|Vildagliptin|Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
40992110|NCT01758380|DRUG|Gliclazide|Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
41467380|NCT04107506|BEHAVIORAL|Filming Interactions to Nurture Development|FIND is a brief home-based video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly home visits lasting 30-45 minutes. The process begins with an initial visit in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
41467381|NCT04107506|BEHAVIORAL|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly home visits alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 home visits each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
40788135|NCT05168761|PROCEDURE|partial nephrectomy|
40788136|NCT05262244|DRUG|Bevacizumab-IRDye800CW|Bevacizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
40992111|NCT01758380|DRUG|Metformin|Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
40992112|NCT01758380|DRUG|Placebo to Gliclazide|Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
40992113|NCT01758380|DRUG|Placebo to Vildagliptin|Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
40992114|NCT03234660|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery
41147551|NCT03984734|PROCEDURE|Pylorus-preserving pancreatoduodenectomy|
40992115|NCT03234660|OTHER|control|0.9% normal saline continuous infusion
40992116|NCT00873509|DRUG|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
40992117|NCT00873509|DRUG|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
40992118|NCT00873509|DRUG|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
40788137|NCT05262244|DRUG|Vedolizumab-IRDye800CW|Vedolizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
40992119|NCT05264077|DRUG|Dexmedetomidine Hydrochloride|Inj dexmedetomidine and inj midazolam given to two groups of participants and effects of both drugs will be observed for 24 hrs
40992120|NCT04562285|DIAGNOSTIC_TEST|Serologic immunoassays to SARS-CoV-2 antibodies|Detect and characterize antibodies to SARS-CoV-2
40992121|NCT01708174|DRUG|LDE225|Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
40992122|NCT01708174|DRUG|TMZ|Temozolomide capsules were obtained locally by the Investigator
40992123|NCT06414174|DEVICE|Split septum needleless connector|Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
40992124|NCT06414174|DEVICE|Mechanical valve needleless connector|Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
40992125|NCT01528072|DEVICE|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
40992126|NCT04720729|BIOLOGICAL|Chemotherapy monitoring by circulating tumor DNA analysis|"During the screening step (2nd chemotherapy line, cycle 1) : at each time point (L2C1D1 \& L2C1D15), 30 ml of blood will be drawn on special tubes with conservative suited for ctDNA analyses (e.g. STRECK® tubes).Then cell-free circulating DNA (cfcDNA) will be extracted from plasma following the manufacturer recommendations. cfcDNA will be quantified, and minimum 500-1000 copies will be analyzed by droplet digital PCR (ddPCR). Analyses will define if ctDNA could be detected during L2.~For the interventional step, from L3 (3rd chemotherapy line) : 20 ml of blood will be drawn at L3C1D1 and L3C1D15. If ctDNA at D15 shows a major drop (\> 40%) from D1, treatment will be continued. If ctDNA at D15 shows no major drop from D1, chemotherapy will be changed."
40992127|NCT02360384|DRUG|Linaclotide|Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
40992128|NCT02360384|DIETARY_SUPPLEMENT|FODMAP diet|Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
40992129|NCT03318315|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
40992130|NCT03318315|BIOLOGICAL|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
40992131|NCT03318315|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).
40992132|NCT03318315|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)
40992133|NCT04819555|GENETIC|Blood|a blood sample will be taken during hospitalisation for diagnostic confirmation or during the quarterly multidisciplinary consultations scheduled as part of the standard follow-up set up for these patients in the ALS centres of the FILSLAN network. If the genetic status is not yet known, this sample will be taken (1 tube of 7mL EDTA) and then sent within 24-48 hours at room temperature to one of the 3 participating molecular biology laboratories according to the criteria defined in the manual of samples being taken in the 3 laboratories.
40992134|NCT04022096|DRUG|Tegoprazan 25mg QD|Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.
40992135|NCT04022096|DRUG|Lansoprazole 15mg QD|Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.
40992136|NCT04434365|DRUG|Berberine|Berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4 weeks (Stage 3).
40992137|NCT04434365|DRUG|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
40992138|NCT04434365|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
40992139|NCT04434365|DRUG|Statin|Statins once daily for 12±1 weeks.
40992140|NCT02273895|DRUG|Scopolamine|0.3 mg/mL, intravenously, once
40992141|NCT00405873|DRUG|AMT2003|
40992142|NCT03185728|OTHER|iLook Out for Child Abuse|"Online, interactive educational intervention that uses a video-based story-line and gamification to teach childcare providers about child abuse and mandated reporting."
40992143|NCT00735774|DRUG|11C-ORM-13070|Single dose of i.v. solution
40992144|NCT05695924|DEVICE|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
40992145|NCT05695924|PROCEDURE|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
40992146|NCT05850169|OTHER|Creative Dance Therapy|"After completion of the initial assessments, the intervention group received 3 sessions per week of creative dance training for 4 weeks (12 sessions), with each session lasting approximately 40 minutes. The creative dance training took place in a 40-square-metre mirrored hall with a tatami mat on the floor. The training was conducted individually for each child in the IG. Different children's songs were selected for each session in harmony with the rhythm of the dance movements. In each session, 10 minutes of warm-up movements and 20 minutes of creative dance training were conducted, accompanied by songs. Meanwhile, materials such as spiky and heavy balls, ribbons, rhythm sticks and holihop were included in the application.~The creative dance training was planned by diversifying the 8 movement models (breath, tactile, core-distal, head-tail, upper-lower, body side, cross lateral and vestibular) of Brain Dance, which is a part of creative dance (Gilbert, 2002,2015)."
40992147|NCT03830554|OTHER|Organic Atlas cedar wood essential oil (Cedrus Atantica)|At first day of admission, Intervention group received an intervention kit consist of 5 small glass essential oil bottles. Each essential oil bottle contains a small cotton ball saturated with two drops of Organic Atlas cedar wood essential oil (Cedrus Atantica). Participants were asked to open the bottle, inhale the smell directly and put it opened at 20 cm beside bed during night.
40992148|NCT03079323|RADIATION|PART-trial|Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
41308632|NCT03448718|DRUG|Olaparib|1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of \> 30 to \< 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
40992149|NCT00939913|DRUG|intravenous NAC|intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
40992150|NCT00939913|DRUG|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
40992151|NCT02874742|DRUG|Lenalidomide|Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
40992152|NCT02874742|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
40992153|NCT02874742|DRUG|Dexamethasone|Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
40992154|NCT02874742|DRUG|Daratumumab|Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
40992155|NCT06167109|RADIATION|CTV optimized IMRT|The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as a potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
40992156|NCT05420207|OTHER|No intervention|No intervention included
40992157|NCT04342039|DRUG|Budesonide Nasal|budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline
40992158|NCT04342039|OTHER|Placebo|2 sprays each nostril daily on days as indicated in the timeline
40992159|NCT05864911|DEVICE|the Gastric Bypass Stent System|The Gastric Bypass Stent System is a newly designed endoscopic duodenal-jejunal bypass liner for the treatment of obesity by Hangzhou Tangji Medical Technology Co., Ltd.. It consists of three main parts: a 60-cm polyethylene sleeve fixed into the duodenal bulb by anchors with barbs, a delivery system and a retrieval system. Compared to the Endobarrier, it has several technical adjustments. First, it improved sleeve materials to provide better barrier properties and reduce the breeding of bacteria resulting in hepatic abscess. Second, the barbs on the anchoring system have been modified to reduce duodenal injury. Third, the delivery and retrieval system have been optimized to eliminate the need of fluoroscopic guidance during implantation and explantation.
40992160|NCT05481567|OTHER|Questionnaire|A series of 14 questions about with the impact of periodontitis on quality of life.
40992161|NCT02599155|DRUG|Crystalloid|normal saline administration for volume expansion in hypovolemic status
41147552|NCT04873986|DIAGNOSTIC_TEST|Scoliosis Tele-Screening Test|Scoliosis Tele-Screening test will be applied to children by parents at home. Participants with moderate and high risks will be invited to the physical examination to the centers or virtual assessment via e-mail. The researchers will be evaluated the TRACE and Adams' test from the photo and sent their opinions to the parents via e-mail.
41147553|NCT00814554|BEHAVIORAL|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
41147554|NCT00814554|BEHAVIORAL|Screening strategy|2. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
41147555|NCT00814554|OTHER|Environmental strategy|3. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
41147556|NCT02985086|DRUG|Cefoxitin|
41467382|NCT05524428|BEHAVIORAL|Implementation Science Strategy|The investigators will be conducting focus groups and identifying barriers and facilitators, and the investigators will be matching identified barriers and facilitators to implementation strategies at the patient, provider, and system level which the investigators will be testing using rapid-cycle methods.
40992162|NCT02599155|DRUG|Colloid|HES 130/0.4 administration for volume expansion in hypovolemic status
40992163|NCT01592929|RADIATION|Magnetic Resonance imaging|11 MRI scans per subject will be taken, one for each mouthpiece design of an inhaler.
40992164|NCT01592929|OTHER|Pharyngometry|Pharyngometry will be carried out in supine and upright position. 11 different mouthpieces will be evaluated in both positions.
40992165|NCT01592929|RADIATION|Computed Tomography scan|One low dose CT scan of the upper airway will be taken. The scan will be taken at normal inhalation through a mouthpiece with moderate resistance.
40992166|NCT01592929|RADIATION|Cone Beam Computed Tomography scan|One CBCT scan of the upper airway will be taken. The scan will be taken at normal respiration through a mouthpiece with moderate resistance.
41147557|NCT02985086|DRUG|oxytocin/misoprostol|
41467383|NCT00081172|RADIATION|lutetium Lu 177 monoclonal antibody J591|
40992167|NCT01592929|OTHER|Dental impressions|Dental impressions will be taken. These will be optically scanned before registration in the 3D imaging modalities.
40992168|NCT03084588|DRUG|methadone|Patients will be given methadone at induction of anesthesia
40788138|NCT04764695|DIAGNOSTIC_TEST|D2O dilution technique|Body composition will be measured with the deuterium dilution technique and electrical bioimpedance, as well as anthropometric indicators at the beginning and 6 months later.
40788139|NCT00848458|OTHER|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
40788140|NCT00848458|OTHER|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
40992169|NCT03084588|PROCEDURE|Interscalene block|Patients will be given an interscalene block prior to induction of anesthesia
40992170|NCT04894396|DEVICE|Aetrex L2305 Premium Memory Foam Orthotics W/ Metatarsal Support|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. For medium to high arches with forefoot pain, featuring a cupped heel to cushion and stabilize the back of foot and a metatarsal pad to redistribute weight to relieve ball-of-foot discomfort. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
40992171|NCT04894396|DEVICE|Aetrex L2300 Premium Memory Foam Orthotics|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
40992172|NCT00006181|BEHAVIORAL|Team-based intervention|
40992173|NCT00006181|BEHAVIORAL|One-on-one intervention|
40992174|NCT01109225|BIOLOGICAL|blood sample|
40992175|NCT01109225|PROCEDURE|MRI|
40992176|NCT01109225|PROCEDURE|echocardiography|
40992177|NCT01109225|BIOLOGICAL|urine sample|
40992178|NCT01109225|PROCEDURE|pulmonary echography|
40992179|NCT01109225|PROCEDURE|vascular check|
40992180|NCT01109225|PROCEDURE|renal echography|
40992181|NCT00579956|DRUG|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
40992182|NCT00579956|DRUG|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
40992183|NCT05492565|DRUG|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection
40992184|NCT05228145|GENETIC|NGN-101|Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.
40992185|NCT03165110|DEVICE|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed the features of the App.
40992186|NCT00452491|DRUG|somatropin|0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years
40992187|NCT00452491|DRUG|somatropin|0.2 IU/kg/day 7 days per week given continuously for 3 years
40992188|NCT01334203|DRUG|Ranolazine|"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."
40992189|NCT02410954|DEVICE|NeuroConn Direct Current stimulator Multiple Channel -4|(tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
40992190|NCT05085275|DRUG|Ferric Citrate 1 GM Oral Tablet [AURYXIA]|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
40992191|NCT05085275|DRUG|Placebo|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
40992192|NCT06003556|DIAGNOSTIC_TEST|PSMA-1007 Positron Emission Tomography (PET) scan|Additional staging PET scan prior to focal therapy to focal therapy.
40992193|NCT02487238|BIOLOGICAL|Fecal Microbiota Enema|Active intervention.
40992194|NCT02487238|BIOLOGICAL|Normal Saline Enema|Placebo comparator.
40992195|NCT00005955|DRUG|temozolomide|
40992196|NCT02065232|DRUG|Tilmanocept|
40992197|NCT02065232|DRUG|Sulfur Colloid|
40992198|NCT01085097|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
40992199|NCT01085097|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.
41147558|NCT05723484|DEVICE|GIFT Device|The GIFT device - immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.
41467384|NCT00384306|DRUG|prednisolone|
40788141|NCT04130412|PROCEDURE|open release|Open release of lateral retinaculae
40992200|NCT01085097|DRUG|Prednisolone/Prednisone|Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.
40992201|NCT01085097|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
40992202|NCT01085097|DRUG|Methylprednisolone|Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
40992203|NCT05110456|BEHAVIORAL|Telephone support|"Participants will receive 10 telephone counseling calls by trained coaches: 9 during pregnancy (one call/week) and 1 at 6 weeks postpartum. We have included individual telephone calls by a trained coaches aimed to :~1. encourage the use of online material;~2. identify strategies for overcoming obstacles;~3. help apply content to real-life settings; and~4. underscore the participants' success in using effective coping strategies"
40788142|NCT03736148|OTHER|Manual Manipulation|Subject was in supine position, and the therapist applied a manual manipulation with right side bending and left rotation of the neck.
41308633|NCT03346369|DRUG|Lanthanum Carbonate|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period
40992204|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the medial orbitofrontal regions over long periods of time.
40788143|NCT03736148|OTHER|Instrument-assisted Manipulation|The instrument-assisted manipulation was applied using a handheld Activator IV Adjusting Instrument. Contacts were made firm enough to prevent slipping of the rubber tip but not so firm as to load the spring, in consistence with customary clinical use of the instrument. The spring was then loaded by means of the instrument's trigger mechanism, and the impulse was delivered in an anterosuperior direction, over the posterolateral aspect of the vertebra on the right lamina-pedicle junction of C3.
40992205|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the lateral orbitofrontal regions and networks over long periods of time.
40992206|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus)|CBOT device enhanced with BCP.
40992207|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device administering continuous olfactory stimuli (i.e., not programmed for short or long burst), and without BCP enhancement.
40992208|NCT03099044|OTHER|Placebo comparator|Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.
40992209|NCT03099044|OTHER|Single Active dose|Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.
40992210|NCT03099044|OTHER|Double Active dose|Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.
40992211|NCT05083988|DEVICE|virtual reality glasses|a system composed of a head-mounted wide view display placed in front of the eyes and headphones placed in ears, it has the ability to block the real-world stimuli. This could distract the patient from the dental environment, which helps reduce anxiety
40992212|NCT05083988|DEVICE|music|Music can be used to distract patients from the anxiety provoking stimulus. It helps the patient to escape from the stressful reality as it activates imaginary. Psychosocially music can offer peace and comfort to patients during dental treatment as it helps in making the environment less threatening.
40992213|NCT04035161|COMBINATION_PRODUCT|Investigational Product|2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation
40992214|NCT04035161|OTHER|Reference Standard|60% (v/v) 1-propanol skin preparation
40992215|NCT04035161|COMBINATION_PRODUCT|Active Comparator|ChloraPrep® SEPP® skin preparation
40992216|NCT04035161|OTHER|Negative Control|0.9% Normal Saline skin preparation
40992217|NCT01608659|DRUG|botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
40992218|NCT02526940|PROCEDURE|rectal biopsies|6 rectal biopsies
40992219|NCT02526940|OTHER|Blood samples|Blood samples
40992220|NCT01925404|BEHAVIORAL|Free physical activity classes|100 hours of free activity classes will be provided
41467385|NCT00063258|DRUG|Tarceva (OSI-774)|150 mg/day, starting day 1 and stopping night prior to surgery.
41467386|NCT00063258|DRUG|Paclitaxel|Planned dose of 200 mg/m\^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
41467387|NCT00063258|DRUG|Carboplatin|Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
40992221|NCT01925404|BEHAVIORAL|Frequent User|Participants can become eligible for prizes by visiting the park more frequently
40992222|NCT03878914|DRUG|Corticosteroids|Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
40992223|NCT04337983|DEVICE|Transpulmonary thermodilution|Obtained by averaging the results of three thermodilution measurements. Each thermodilution is performed by injecting a bolus (15 mL) of cold saline (less than 10°C)
41308634|NCT00850018|PROCEDURE|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
40992224|NCT04337983|DEVICE|Echocardiography|Daily echocardiography evaluation
40992225|NCT01556581|PROCEDURE|Usual Care (UC)|Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
40992226|NCT01556581|PROCEDURE|Early Physical Therapy (PT)|Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
41308635|NCT00850018|BEHAVIORAL|Usual care|Participants will receive usual care for the treatment of SCD.
41308636|NCT02273752|DRUG|Everolimus|Given PO
41308637|NCT00611897|DRUG|N-acetylcysteine and ketamine|Active drug (N-acetylcysteine)
41308638|NCT00611897|DRUG|placebo and ketamine|placebo N-acetylcysteine
41308639|NCT00005096|DRUG|docetaxel|
41467388|NCT06083636|OTHER|Single extra blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
40788144|NCT03736148|OTHER|Placebo|Subject was in supine position, and the therapist placed ths subject's cervical with right side bending and left rotation but no manual manipulation was applied.
40992227|NCT01002833|BIOLOGICAL|Exposure to Plasmodium falciparum infected mosquitoes|Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
40992228|NCT00680433|DRUG|Ketamine|Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.
40992229|NCT00680433|DRUG|Saline|Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
40992230|NCT03864315|DEVICE|HGM|To Study the Efficacy of Therapeutic Pulsed Ultrasound in the Treatment of Vitiligo: a Randomized, Intra-individual, Left-right Comparison Study
40992231|NCT02053753|DRUG|Denosumab CP4|Denosumab produced by a process referred to as CP4, administered subcutaneously.
40992232|NCT02053753|DRUG|Denosumab CP2|Denosumab produced by a process referred to as CP2, administered subcutaneously.
41467389|NCT06083636|OTHER|Single blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
41147559|NCT03473275|DIAGNOSTIC_TEST|Cold Pressor test|Both feet in icy waterbath alternated with body temperature water
41147560|NCT03473275|DIAGNOSTIC_TEST|PinPrick test|Pricking both feet with a needle using gravity (without penetrating) alternated with cotton swap
41147561|NCT01614899|DRUG|SM-13496 40mg|once daily orally
40788145|NCT04927481|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
40992233|NCT01120613|DRUG|Chronotherapy|"Patients identified with nocturnal hypertension while treated with blood pressure medications will have one medication switched from daytime to night time dosing in the following preference:~1. ACE or ARB~2. Calcium Channel Blockers~3. Alpha Blocker~4. Beta Blocker~If patient is on only one daytime BP medication, it will be switched to night time dosing. No dose adjustments will be made nor any new medications will be added. Only timing of BP medication will be changed."
40992234|NCT01774786|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m\^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
41147562|NCT01614899|DRUG|SM-13496 80mg|once daily orally
41308640|NCT05674838|OTHER|Leg Elevation|Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge and both of her legs elevated on an orange peanut ball. She will remain in this position for approximately 40 minutes.
41308641|NCT04983329|OTHER|Telemedicine intervention|Following education, the telemedicine center will subsequently monitor operating rooms included in this trial for protocol adherence for three-months. The telemedicine center is staffed by attending anesthesiologists, resident anesthesiologists, certified registered nurse anesthetists (CRNAs) and student registered nurse anesthetists (SRNAs) and is currently providing evidence-based support to clinicians in a subset of operating rooms and post-anesthesia care unit (PACU) beds at Barnes-Jewish Hospital.
41308642|NCT06102811|OTHER|Low Concentration Local Anesthetic Fascia Iliaca Compartment Block|Fascia iliaca block with Ropivacaine 0.075% (50 mL)
41308643|NCT06102811|OTHER|High Concentration Local Anesthetic Fascia Iliaca Compartment Block|Fascia iliaca block with Ropivacaine 0.25% (50 mL)
41308644|NCT03176797|DIAGNOSTIC_TEST|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
41308645|NCT01795287|PROCEDURE|General anesthesia|GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.
41467390|NCT00406016|DRUG|ATI355|
41467391|NCT04469400|DIETARY_SUPPLEMENT|Low fat diet intensive intervention|education and Compound protein solid beverage
41467392|NCT04469400|OTHER|Low-Carbon Water Diet Intensive Intervention|education and Nutrition bar
40992235|NCT01774786|DRUG|Capecitabine|Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
40992236|NCT01774786|DRUG|Cisplatin|Participants will receive cisplatin 80 mg/m\^2 IV q3w for 6 cycles.
40992237|NCT01774786|DRUG|Pertuzumab|Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
40992238|NCT01774786|DRUG|Placebo|Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
40788146|NCT06306157|DRUG|Low dose naltrexone|While naltrexone is FDA-approved for treatment of alcohol or opioid addition, this study will be looking at how naltrexone, when dosed very low, may reduce the painful symptoms associated with CRPS. Naltrexone is not FDA-approved for pain management treatment of CRPS at this time, and therefore the study intervention is using the drug in an off-label manner.
40992239|NCT01774786|DRUG|Trastuzumab|Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
40992240|NCT00097799|DRUG|Tipranavir|500 mg twice daily
41147563|NCT01614899|DRUG|Placebo|once daily orally
41147564|NCT00794573|DRUG|varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
40992241|NCT00097799|DRUG|Ritonavir|200 mg twice daily
40992242|NCT00060476|DRUG|rofecoxib|
40992243|NCT00060476|DRUG|Comparator: placebo (unspecified)|
40992244|NCT01859494|DEVICE|NINJA 3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
41147565|NCT00794573|OTHER|placebo|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
41157027|NCT02419040|PROCEDURE|Lidocain injection (sham)|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
40992245|NCT05643261|OTHER|Muscle and technique training|The strength training consists of three exercises (clam shell, side plank, calf raises) with an progressive overload after two to three weeks to ensure a continuous muscle stimulation. The technique training consists of different cutting variations with a focus on forefoot landings and conscious control of the knee to avoid high knee valgus movement and KAM respectively.
40992246|NCT02275481|DRUG|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
40992247|NCT02275481|DRUG|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
40992248|NCT02706509|DRUG|Tramadol|patient will receive oral Tramadol 50 mg an hour before IUD insertion
40992249|NCT02706509|BEHAVIORAL|Verbal anesthesia|patient will receive full explanation about the procedure for five minutes before IUD insertion
40992250|NCT02706509|DEVICE|Jaydess|Patient will go through an insertion of Jaydess intrauterine device.
40992251|NCT05825937|DEVICE|ClearSight System|Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.
40992252|NCT05328128|BEHAVIORAL|Toilet training|As the training model, Brazelton's child-oriented toilet training method was taken as the basis in study group. In addition, literature studies on toilet training in Turkey were scanned and the final form of training to be given to mothers was created. In the control group, families manage training process themselves.
40992253|NCT03149107|DRUG|N-Acetylcysteine|N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
40992254|NCT03149107|DRUG|Placebo|Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
40992255|NCT03149107|BEHAVIORAL|IPPI (Integrated Preventive Psychological Intervention)|IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician \& rater)
40992256|NCT03149107|BEHAVIORAL|PSM (Psychological stress management)|PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).
40992257|NCT06387992|OTHER|Three-dimensional dental acquisition|Consultation with a trained nurse who will perform a three-dimensional dental acquisition using a 3D intraoral camera
40992258|NCT02159664|OTHER|didgeridoo practice|instrument lessons, 1X/w and daily practice, 20 min /d
40992259|NCT03474887|OTHER|Physical Consultation|Regular physician consultation at the primary care clinic.
40992260|NCT03474887|OTHER|Online Consultation|An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.
40788147|NCT06306157|DRUG|Placebo sugar capsules|The external appearance of the capsules prepared by the pharmacy will be identical to the LDN capsules. The inactive capsule ingredients will be microcrystalline cellulose (MCC) and Magnesium stearate
40788148|NCT04802603|RADIATION|Spine stereotactic body radiotherapy|"Cohort 1 - De novo: Spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.~Cohort 2 - Prior radiotherapy: Risk-adapted spinal cord tolerance based on prior spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions."
40992261|NCT03680950|DEVICE|Upper Gastrointestinal Monitoring System|Participants will wear a monitoring system consisting of a tiny endoscopy and a mobile device. The endoscopy is inserted to upper gastrointestinal tract via nasal cavity and the mobile device is set to take and send images from the endoscopy to a server for analyzing if the abnormal condition occurs.
40992262|NCT03621852|DEVICE|Endoultrasound guided FNB|EUS FNB with Aquire TM device
40992263|NCT03096327|DRUG|Montelukast|Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
40992264|NCT03096327|DRUG|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
40992265|NCT01991158|DRUG|High dose of methotrexate|Methotrexate 3.0g/Kg, intravenous drip D1
40992266|NCT01991158|DRUG|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
40992267|NCT01991158|DRUG|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
40992268|NCT01991158|DRUG|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
40992269|NCT05106244|OTHER|Real-Time Guidance of Home Care for Patients with PICC or PORT|the experimental group adopted the family self-nursing mode, mainly by the patients' family members to observe the catheter and do regular nursing, and the specialist nurses provided remote real-time online guidance to monitor the family nursing of central venous catheter. The procedures are as follows: (1) make nursing videos recorded by central venous catheter specialist nurses; (2) evaluate the nursing operation ability of the patients' family members and carry out relevant training and health education, repeat until they are qualified; (3) distribute nursing guidance prescriptions and maintenance manuals for central venous catheters; (4) provide online simulated realistic nursing video materials; (5) provide real-time telephone audio and video connection to complete remote nursing guidance. (6) set up a home nursing volunteer service group, establish a doctor-patient exchange group by using Wechat and other media.
41017769|NCT03272594|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
41308646|NCT01795287|PROCEDURE|Spinal anesthesia|hyperbaric bupivacaine 10-15 mg i.t.
41017770|NCT00530023|DEVICE|MiniMed Paradigm REAL-Time System|MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
40992270|NCT05104515|BIOLOGICAL|OVM-200|"The first part (Phase 1a) comprises a first-in-human (FIH) multiple-dose, sequential-cohort 3+3 design to establish a dose of OVM-200 that is safe and tolerable, and that elicits an immune response in humans.~This dose will be taken forward into the second part (Phase 1b) of the study. Phase 1b will further assess the safety and tolerability of the selected dose and investigate the immune and tumour response in 3 expansion cohorts of additional patients with NSCLC, ovarian cancer, and prostate cancer."
40992271|NCT04891900|DRUG|TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine|"Initial treatment (6 cycles)：~1. TQB2450：1200 mg , Day 1 ivgtt ,once every 3 weeks~2. Anlotinib: 10 mg/day orally ，from days 1 to 14 in a 21-day cycle~3. Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~4. Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment：~1）TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2）Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle"
41308647|NCT02427594|DRUG|Sodium bicarbonate|Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
41308648|NCT02427594|OTHER|Controlled diet|Diet without sodium bicarbonate supplementation
40992272|NCT00698581|DRUG|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
40992273|NCT00698581|DRUG|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
40992274|NCT06348992|BEHAVIORAL|Acceptance commitment therapy and yoga|The intervention used a combination of online and offline methods, based on ACT, supplemented by hatha yoga exercise intervention, the intervention group used the combination of offline ACT psychological intervention and online hatha yoga training, and the control group used mental health education, so as to explore and validate the effect of ACT combined with yoga on the improvement of parental parental burnout in children with ASD. The offline ACT psychological intervention was implemented by the researchers and psychologists, and the ACT psychological intervention was carried out once a week in community health centers or hospitals for 8 weeks. Online, a WeChat group was set up for parents with ASD, and Hatha Yoga training content and videos were sent to the group chat, and the researchers and volunteers supervised the training and clocking in and out of the group, three times a week.
40992275|NCT06348992|BEHAVIORAL|Active Comparator: Mental Health Education Group|The control group was provided with 8 weeks of mental health education, including emotional management skills, positive coping styles, and scientific parenting methods.
40992276|NCT03603444|OTHER|No intervention are provided|
40992277|NCT03704961|BEHAVIORAL|music and audiobook listening|
40992278|NCT05132959|DIAGNOSTIC_TEST|magnetic resonance imaging|The MRI images of patients who had undergone to shoulder magnetic resonance imaging because of shoulder pain or another pathology were studied
40992279|NCT01787227|DEVICE|xTAG RPP|
40992280|NCT06050499|DEVICE|Microdialysis catheter + biosensor|"Microdialysis catheter from linton instrumetal 63 MD Catheter"
40992281|NCT01163279|BEHAVIORAL|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
40992282|NCT01163279|BEHAVIORAL|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
41157028|NCT02813447|DRUG|Sertraline|
41467393|NCT00549341|DRUG|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
41157029|NCT02813447|DRUG|Placebo|
41308649|NCT02460757|OTHER|Laryngoscopy|Observation of glottic width in different arms
41308650|NCT06468501|BEHAVIORAL|Price reduction on healthier foods|Price reduction (10%) on healthier foods based on the UK NPM
41308651|NCT06468501|BEHAVIORAL|Price increase to less healthy foods|Price increase (10%) on less healthy foods based on the UK NPM
41467394|NCT00549341|OTHER|Physiologic saline|Single injection.
41467395|NCT00703976|DRUG|Bevacizumab|Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
40788149|NCT05680493|PROCEDURE|Manual pressure release|lengthens the muscle up to the increasing resistance, then gradually applies gentle pressure on MTrp until fingers feels a definite increase in tissue resistance (first barrier). Pressure would maintain until clinician sense relief of tension
40788150|NCT05680493|PROCEDURE|Dry needling|A filiform needle is inserted at 45 degree in to trigger point and then twirl the needle up and down to release trigger point
41147566|NCT05383053|DEVICE|NeuroAI|"NeuroAI is an artificial brain diagnostic software that determines whether to perform amyloid PET tests for Alzheimer's by specialists through the detection of amyloid PET positive rates based on brain MR images (T1 weighted MRI, T2 FLAIR MRI) and clinical information (age, gender, and APOE) genotype.~When using this product, input gender, birth year, and apolipoproteinE (APOE) genotype and upload T1 MR image and T2 Flair image, input data and image analysis result data are integrated to infer the positive rate of amyloid PET by PET positive prediction model. The result report provides image analysis results and amyloid PET positive prediction results compared to normal groups."
41147567|NCT00135200|DRUG|Iodine I 131 Tositumomab|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose."
41308652|NCT06468501|BEHAVIORAL|Combination of price reduction on healthier foods and price increase on less healthy foods|Combination of price reduction (10%) on healthier foods based on the UK NPM and price increase (10%) on less healthy foods based on the UK NPM
41308653|NCT06468501|BEHAVIORAL|Control|Existing price structure
41467396|NCT00703976|DRUG|Cetuximab|Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
40992283|NCT04390945|DRUG|Camrelizumab|Camrelizumab combined with concurrent radiotherapy and chemotherapy
40788151|NCT05680493|PROCEDURE|Heat therapy|Hydro collator pack will be placed on affected area for relaxation and pain relief for 15 min
40788152|NCT04396821|DRUG|TST001|TST001 is a humanized IgG1 monoclonal antibody.
40788153|NCT04396821|DRUG|Nivolumab Injection [Opdivo]|Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
40992284|NCT03921931|OTHER|White light stimulation|Stimulation of the retina with white light
40992285|NCT06297174|DRUG|Racecadotril 100 mg Capsules|Racecadotril 100 mg Capsules (test drug)
40992286|NCT06297174|DRUG|HIDRASEC®|HIDRASEC® (reference drug)
40992287|NCT05952063|DIAGNOSTIC_TEST|Digital Psychological Test: Schema Scale|Thirty-five questionnaire, 5-point likert scale
40992288|NCT05142423|DRUG|AK109+AK104|It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.
40992289|NCT01813084|DRUG|RV1729 single dose|Safety and tolerability of single escalating doses
40992290|NCT01813084|DRUG|RV1729 matching placebo single dose|Safety and tolerability of single escalating doses
40992291|NCT01813084|DRUG|RV1729: 14 day repeat dose|Safety and tolerability of repeat escalating doses
40992292|NCT01813084|DRUG|RV1729 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
40992293|NCT04487054|OTHER|Pro-active palliative care|Patient with high risk of mortality in ICU will be identified using our previously validated prognostic model. Intervention phase will employ pro-active palliative care on eligible patients after they survive 48 hours in ICU.
40992294|NCT01153243|DRUG|Ergocalciferol|"Active Comparator: Ergocalciferol~The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)"
40992295|NCT01153243|DRUG|Placebo pill|The investigators will give control group 12 weeks of 1 placebo pill every week.
40992296|NCT05879107|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
40992297|NCT05879107|BIOLOGICAL|PCV20|One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
40992298|NCT00864877|DEVICE|biodegradable fixation system (Inion OTPS FreedomPlateTM)|
40992299|NCT00657007|BIOLOGICAL|belimumab|"1. 1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~2. 1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
40788154|NCT04396821|DRUG|mFOLFOX6|mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
40788155|NCT04396821|DRUG|Gemcitabine|Chemotherapy medication
40788156|NCT04396821|DRUG|Albumin-Bound Paclitaxel|Chemotherapy medication
40788157|NCT04240106|DRUG|Niraparib|Niraparib orally daily beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
40788158|NCT04240106|DRUG|Aromatase Inhibitors|Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
40788159|NCT03005730|OTHER|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
40788160|NCT03005730|OTHER|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
40788161|NCT04946695|OTHER|Telefisio India|Implement telephysiotherapy programmes in low-resource areas.
40788162|NCT05964335|DRUG|nalbuphine ER 27 mg|Oral tablets
40788163|NCT05964335|DRUG|Placebo|Oral tablets
40788164|NCT05964335|DRUG|nalbuphine ER 54 mg|Oral Tablets
40788165|NCT05964335|DRUG|nalbuphine ER 108 mg|Oral tablets
40992300|NCT00657007|BIOLOGICAL|belimumab|"1. 4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~2. 4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
40992301|NCT00657007|BIOLOGICAL|belimumab|"1. 10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~2. 10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
40992302|NCT00657007|BIOLOGICAL|belimumab|"1. 20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~2. 20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
41147568|NCT05001802|PROCEDURE|transverse scan, in-plane, posterior- anterior quadratus lumborum block|transverse scan, in-plane, posterior- anterior quadratus lumborum block The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
41147569|NCT05001802|PROCEDURE|paramedian sagittal longitudinal scan, in-plane, caudal-cranial quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
41147570|NCT05757063|OTHER|Sedation with propofol|After spinal anesthesia, patients will be sedated with propofol.
41147571|NCT05757063|OTHER|sedation with dexmedetomidine|After spinal anesthesia, patients will be sedated with dexmedetomidine.
41147572|NCT02006914|DIETARY_SUPPLEMENT|Chromium Picolinate|Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
40788166|NCT01261975|PROCEDURE|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
40788167|NCT01261975|PROCEDURE|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
41147573|NCT06289855|OTHER|MDS-UPDRS|"Movement disorder society- unified Parkinson disease rating scale (MDS-UPDRS) for Parkinson's disease.~Movement disorder society- non motor rating scale (MDS-NMS) Cognitive assessment using Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog)~Using Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale:~Timed up and go: originally aimed to clinically evaluate dynamic balance in elderly people during the performance of a task MR imaging of the brain will be performed with a 1.5T MR imaging scanner Assessment of Cortical excitability and unhibition by NIHON KOHDEN- neuropack2"
40788168|NCT01840943|DRUG|CAELYX|CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
40788169|NCT01840943|DRUG|Topotecan HCl|Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
40788170|NCT01734824|DRUG|Denosumab|sc RANKL-inhibitor
40788171|NCT01734824|DRUG|Teriparatide|daily subcutaneous injection of teriparatide
41147574|NCT05881161|BEHAVIORAL|Adherence self-efficacy-enhancing exercise|This exercise aims to increase self-efficacy to adhere to an internet intervention. It consists of a video and two text-based tasks. The contents are grounded in Social-Cognitive Theory.
41147575|NCT05881161|BEHAVIORAL|Med-Stress Student|Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
40992303|NCT00657007|BIOLOGICAL|Placebo|"1. IV (in the vein) on Day 0 (Cohorts 1-4).~2. IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
40992304|NCT02860715|DRUG|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
40992305|NCT02860715|DRUG|Placebo|This is the placebo of GX-I7 described above.
41147576|NCT06564077|OTHER|Eldoa technique with conventional therapy|"is myofascial stretching technique of the cervical spine. Patients were asked to adopt desired position to target intervertebral segments. Breathing is also important factor in ELDOA stretch. Patients were instructed to not to hold or strain breathing through promoting diaphragmatic breathing.~* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
40788172|NCT01734824|DRUG|Placebo Denosumab|one subcutaneous injection denosumab placebo
40788173|NCT01734824|DRUG|Placebo Teriparatide|daily subcutaneous placebo injection
40992306|NCT03895983|PROCEDURE|Percutaneous primary coronary intervention|Percutaneous primary coronary intervention
40992307|NCT04139954|OTHER|There is no intervention in the study|There is no intervention in the study
40992308|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0
40992309|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0
40788178|NCT06009822|OTHER|Postoperative outcome measurements|"Kinesiophobia; It will be assessed on the Tampa Kinesiophobia Scale. Function; Lysholm knee score, kujala knee score, single-leg hop test, Y balance test and single leg sway index will be evaluated.~Biodex Bio-balance system device will be used for single leg sway index."
40788179|NCT02869321|DRUG|Fentanyl|
40788180|NCT02869321|DRUG|Morphine Sulfate|
40788181|NCT02869321|DRUG|Fentanyl placebo|
40788182|NCT02869321|DRUG|Morphine Sulfate placebo|
40788183|NCT02869321|PROCEDURE|Gastrostomy|
40788184|NCT05196373|DRUG|STP705|STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
40788185|NCT02172729|DRUG|Adductor canal block with 20 ml lidocaine, single bolus|Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
40992310|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0
40992311|NCT00192504|OTHER|Placebo|Single dose of placebo administered intravenously (in the vein) on Day 0
40992312|NCT02625090|DRUG|UCB0942|"* Active Substance: UCB0942~* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg, 100 mg or 200 mg~* Route of Administration: oral"
40788186|NCT02679378|DEVICE|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
40788187|NCT06320600|OTHER|no intervention|It's an observational study, no intervention included
40788188|NCT04305041|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
40788189|NCT04305041|BIOLOGICAL|Quavonlimab|Administered via IV infusion at a specified dose on specified days
40992313|NCT04298996|DIAGNOSTIC_TEST|taking saliva samples to determine oxidative stress markers TAS and TOS|
40992314|NCT02817165|DIETARY_SUPPLEMENT|Probiotic (BioK+)|Probiotic (BioK+) with 3 stains of Lactobacillus
40992315|NCT02817165|OTHER|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
40992316|NCT04930354|DRUG|ECP-1014|Patients will be selected who (1) have failed all standard of care therapy (relapsed/refractory) or (2) have relapsed and are not a candidate for an available standard of care therapy as assessed by the investigator (such as, but not limited to, colorectal cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), head and neck, etc.) with COX-2 overexpression, ultimately resulting in elevated production of prostaglandin E2 (PGE2).
40992317|NCT02606188|DEVICE|Modified High-flow nasal cannula|Modified High-flow nasal cannula
40992318|NCT02606188|DEVICE|nasal cannula|Conventional oxygen therap
40992319|NCT00112502|DRUG|Celecoxib|400 mg orally twice a day continuous dosing
40992320|NCT00112502|DRUG|Isotretinoin|40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.
40992321|NCT00112502|DRUG|Temozolomide|150 mg/m2 orally daily, 7 days on treatment, 7 days off.
40992322|NCT00112502|DRUG|Thalidomide|400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
40992323|NCT04248933|BEHAVIORAL|Peer-Delivered Behavioral Activation (Peer Activate)|The Peer Activate intervention consisted of weekly one-hour BA sessions led by a peer recovery specialist (PRS) for up to 12 weekly sessions, with the first five being the core treatment sessions and content, and the subsequent seven designed to reinforce core content. In these sessions, participants received individualized support in learning skills to assist in their retention and persistence in methadone treatment and were guided through exercises aimed at incorporating substance-free, rewarding activities into their daily life.
40992324|NCT00150072|DRUG|imatinib|
40992325|NCT02716558|OTHER|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
40992326|NCT02716558|OTHER|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
40992327|NCT00002384|DRUG|Cidofovir|
40992328|NCT00817895|DRUG|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
40992329|NCT00817895|DRUG|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
40992330|NCT00817895|PROCEDURE|TACE|All patients will accept TACE one month after tumor was resected.
40992331|NCT04780763|OTHER|Milk product fermented by lactic bacteria or not fermented|2 bottles of 100g consumed daily during 28 days
41147577|NCT06564077|OTHER|conventional therapy|"* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
40788190|NCT04305041|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
40788191|NCT04305041|DRUG|Lenvatinib|Administered via oral capsules at a specified dose on specified days
40992332|NCT02157155|BIOLOGICAL|LPS|LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
40992333|NCT00076687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18
40992334|NCT00076687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18
40992335|NCT00076687|DRUG|saline|Saline injection at Day 1, Week 12, Week 18
40992336|NCT03170128|PROCEDURE|Outpatient physical therapy in addition to standard follow-up visits|Patients in Group 1 will be given a prescription for outpatient physical therapy.
40992337|NCT03170128|BEHAVIORAL|Home exercises in addition to standard follow-up visits|Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
40992338|NCT01194479|DRUG|Formoterol|Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
41147578|NCT05114811|PROCEDURE|Self-provided perineal massage|External massage should be applied with pump of the perineum central core. Internal massage should be applied intracavitary with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.
41147579|NCT05114811|PROCEDURE|Physiotherapist perineal massage: manual and instrumental (with EPI-NO)|"The treatment sequence included external massage with two manouvres: vulvar drainage and pump of the perineum central core. Intracavitary techniques were then applied through three maneuvers: massage with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.~After this, instrumental massage was applied with the EPI-NO® device."
40788192|NCT04305041|DRUG|ATRA|Administered via oral capsules at a specified dose on specified days
40788193|NCT03134859|BEHAVIORAL|Tummy Time|deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
40992339|NCT01194479|OTHER|Placebo|Participants in both arms received placebo on 1 of the 2 visits.
40992340|NCT01089088|DRUG|cisplatin|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
40992341|NCT01089088|DRUG|gemcitabine hydrochloride|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
40992342|NCT01089088|DRUG|sunitinib malate|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
40992343|NCT01236937|DEVICE|Bellows-based breath hold device|"Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed."
41467397|NCT00703976|DRUG|Pemetrexed|Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
41467398|NCT00703976|RADIATION|Radiation therapy|Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
41147580|NCT06359821|DRUG|ZA-001|Study drug ZA-001 administered via intravenous injection.
41308654|NCT02042729|DRUG|E2022- Current Formula Tape|"Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days."
41467399|NCT05201079|BIOLOGICAL|MBK-01|A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.
40992344|NCT00017147|DRUG|carmustine|"40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m\^2 IV over 1 hour on day 2 of each cycle for the active comparator arm."
40992345|NCT00017147|RADIATION|radiation therapy|5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
40992346|NCT00017147|DRUG|O6-Benzylguanine|120 mg/m\^2 IV over 1 hour on day 1 of each cycle
40992347|NCT05945277|BEHAVIORAL|Critical Time Intervention - Peer Support|CTI-PS is a time-limited, 9-month long intervention, provided at the critical time when a person is discharged from an inpatient psychiatric treatment facility.
41308655|NCT02042729|DRUG|E2022- New Formula Tape|"Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days."
41308656|NCT02042729|DRUG|E2022 Matching Placebo- Current Formula Tape|
41467400|NCT05201079|DRUG|Dificlir|Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
40992348|NCT05315518|DIAGNOSTIC_TEST|single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
40992349|NCT03772847|DRUG|ginkgolide|ginkgolide plus alteplase
40992350|NCT06189222|DEVICE|virtual reality glasses|The population of the study consisted of children who were aged between 7- 12 and were on treatment using an intravenous catheter in the pediatric emergency unit of a state hospital in Turkey.Participants were divided into two groups, namely experimental and control groups, by using simple randomization software. The design and implementation of the study were based on the principles in the CONSORT list (Consolidated Standards of Reporting Studies). Descriptive data form for children,this form was prepared to collect information about the children included in the sample. It consists of seven questions on children's sociodemographic characteristics and previous intravenous catheter insertion experience.The Children's Emotional Manifestation Scale (CEMS), this scale was developed by Li \& Lopez (2005) to measure children's emotional responses during stressful medical procedures. The VR glasses we used in our study were connected to a mobile phone.
41147581|NCT00422162|DRUG|Duloxetine hydrochloride|60 mg once or twice a day, by mouth
40788194|NCT02793687|DRUG|MEXIDOL® (ethylmethylhydroxypyridine succinate)|
41147582|NCT00422162|DRUG|Placebo|placebo capsule by mouth
41147583|NCT02465866|DRUG|CL-108|Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth
41147584|NCT02465866|DRUG|Vicoprofen|Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth
41147585|NCT02465866|DRUG|Ultracet|Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth
41308657|NCT02042729|DRUG|E2022 Matching Placebo- New Formula Tape|
41308658|NCT05842564|OTHER|Blood samples|Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)
41308659|NCT05842564|OTHER|Biopsies|5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy
41308660|NCT02547831|OTHER|Observational approach|Patients will be placed under wait and see approach without any specific treatment
41308661|NCT03374514|DRUG|Dexamethasone|instilation of the solution in the middle ear
41147586|NCT02465866|DRUG|Phenergan|Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth
41147587|NCT06138587|BIOLOGICAL|Cytokine Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
41147588|NCT06138587|BIOLOGICAL|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.
40992351|NCT04699682|OTHER|Control|During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).
40992352|NCT04699682|OTHER|BHR Case|"During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below:~- stool samples taken at different times:~* every 7 days during the first month (M1)~* every 14 days for the following months until the end of the patient's participation (M2 to M12)."
41147589|NCT01400945|DRUG|AGSPT201 Tab contains S-pantoprazole|comparison of Pantoloc Tab 40mg
41147590|NCT06266676|OTHER|micro-course|The experimental group adopts micro-course instruction, providing self-directed learning through online asynchronous courses, with instructional content delivered through short videos created by the researcher.
41147591|NCT06266676|OTHER|slide presentation|Provide online presentations.
41147592|NCT04043663|DEVICE|Virtual Reality glasses|Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
41147593|NCT04043663|PROCEDURE|standard perioperative care without virtual reality program|standard perioperative care without virtual reality program
41147594|NCT04168450|OTHER|WiSAT System, Passive Feedback|The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.
41147595|NCT04168450|OTHER|WiSAT System, Active Feedback|The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
40992353|NCT04259957|DEVICE|Immersive Virtual Reality|Immersive virtual reality games and mindfulness in Oculus Quest Virtual Reality headset
40992354|NCT01113632|DRUG|Ofatumumab|IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
40992355|NCT05657691|DRUG|Xanamem™|Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
41147596|NCT06325371|DEVICE|Visceral aneurysm stenting|Flow diverter stenting
41147597|NCT06389071|DEVICE|Fractional 2940 nm Laser|Fractional 2940 nm Laser
41147598|NCT03029689|DRUG|Raltegravir|Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
41147599|NCT03029689|DRUG|Placebo|Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
41147600|NCT03029689|DRUG|Current ART|3-drug antiretroviral treatment including PI/r/c or NNRTI
41308662|NCT03374514|DRUG|Sterile isotonic saline solution|Sterile isotonic saline solution
41308663|NCT06291181|DIAGNOSTIC_TEST|antibiotic sensitivity test|"Disc diffusion method using modified Kirby-Bauer technique on Muller Hinton agar (MHA) will be carried out for antimicrobial susceptibility of S. aureus isolates. The following antibiotics will be tested: cefoxitin (30 µg ), Tetracyclin 30 µg (TE), Chloramphenicol 30 µg (C), Gentamycin 10µg (CN), Erythromycin 15µg(E),Clindamycin 2 µg (DA), Ciprofloxacin 5 µg (CIP), Trimethoprim/sulphamethoxazole 1.25/23.75 µg (SXT), Rifampin 5µg (RA), Linezolide 30µg (LZD); cefoxitin disc (FOX 30 g)~zone diameters interpretation will be done according to Clinical and Laboratory Standard Institute (CLSI 2018),"
41308664|NCT01914887|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
41308665|NCT04713566|OTHER|oral rinces|natural and commercial oral rinses were compared for efficacy
41308666|NCT00587821|OTHER|Blood draw|Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
40788195|NCT02793687|OTHER|Placebo|
41147601|NCT06378320|OTHER|App access and Text message|Access to App and Text messages with app related breastfeeding related question
41147602|NCT06378320|OTHER|App access only|Access to App without Text messages with app related breastfeeding related question
41147603|NCT02970578|PROCEDURE|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
41147604|NCT00984334|DRUG|Naloxone SR 5 mg capsules|
41147605|NCT00984334|DRUG|Placebo|
41147606|NCT00984334|DRUG|Naloxone SR 10 mg capsules|
41147607|NCT00984334|DRUG|Naloxone SR 20mg capsules|
41147608|NCT00984334|DRUG|Naloxone SR 2.5 mg capsules|
41147609|NCT06388824|DRUG|normal saline|Patients undergoing surgical abortion received a single injection of 5ml 0.9% normal saline after the beginning of surgery
41147610|NCT06388824|DRUG|Esketamine|Patients undergoing surgical abortion received a single injection of 0.2mg/kg esketamine after the beginning of surgery
41147611|NCT03588195|OTHER|Educational Program|Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session
41147612|NCT03588195|DEVICE|Transcutaneous Nerve Electro-Stimulation|Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
41147613|NCT00041639|DRUG|hMN14 (labetuzumab)|
41308667|NCT01672021|PROCEDURE|PET/MRI|PET/MRI
41308668|NCT05220228|DRUG|Prucalopride|1mg prucalopride x 2d, 2mg prucalopride x 5-8d
41308669|NCT05220228|DRUG|Placebo|Lactose / sucrose placebo
41308670|NCT00219843|DRUG|PV-10 (rose bengal disodium, 10%)|
41147614|NCT03879252|DEVICE|Toothbrush|Brushing teeth three times a day (extra-soft toothbrush) with a 1.4% baking mouthwash solution.
40992356|NCT05657691|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
40992357|NCT03294395|DRUG|Ertapenem 1000 MG|single dose 1000mg intramuscular injection
40992358|NCT03294395|DRUG|Fosfomycin Oral Suspension|single dose 6g oral suspension
40992359|NCT03294395|DRUG|Gentamicin Sulfate, Injectable|single dose 5mg/kg (maximum 400mg) intramuscular injection
40992360|NCT03294395|DRUG|Ceftriaxone|single dose 500mg intramuscular injection
40992361|NCT04867265|PROCEDURE|Mout-to-mouth ventilation|we will record the visibility of chest rising
40992362|NCT04867265|PROCEDURE|Mout-to-mouth ventilation with quantitative analysis|we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter
40992363|NCT01425879|DRUG|Akt Inhibitor MK2206|Given PO
40992364|NCT01425879|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
40992365|NCT01425879|OTHER|Pharmacological Study|Correlative studies
40992366|NCT01465022|DRUG|Combined estrogen-progestin pill|1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
40992367|NCT01465022|DRUG|Progestin-only pill|.35 mg norethindrone once a day orally
40992368|NCT04553432|DEVICE|Amniotic membrane Omnigen[TM]|17mm circular disk of processed amniotic tissue donated by mother after birth with a 6mm laser cut aperture to allow unimpeded vision https://www.nu-vision.co.uk/omnigen
41308671|NCT00195689|BIOLOGICAL|Human anti-TNF monoclonal antibody/adalimumab|
41467401|NCT04649450|OTHER|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed just before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days at the neurosurgical ward they will receive music twice a day for 30 minutes.
41467402|NCT06031337|DIAGNOSTIC_TEST|ELISA|quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.
41467403|NCT04377048|DRUG|Nivolumab|"as described in NGS Arm"
40788196|NCT03665259|PROCEDURE|Pure oxygen group|pre-oxygenation with 100% oxygen during induction of anesthesia
40992369|NCT04553432|DEVICE|Bandage soft Contact Lens OmniLenz[R]|18mm soft silicone-hydrogel contact lens https://www.nu-vision.co.uk/omnilenz
40992370|NCT06449963|BEHAVIORAL|Health Belief Model Education|"Participants in this group will receive a structured training program with the aim of increasing daily water consumption and reducing symptoms of dehydration. The program is based on the principles of the Health Belief Model and includes the following components:~Initial and mid-Program training: Will be conducted by a trained health educator, each lasting 60 minutes. Two weeks after the first training, the same training will be given again for reinforcement purposes.~Session Content: Covers the importance of hydration, strategies to increase water intake (using reminders, setting goals, integrating water-rich foods), and the health benefits of adequate hydration (e.g., improved cognitive function, better physical health).~Training Materials: Booklet prepared for training. Behavioral Strategies: Practical tips for overcoming barriers to drinking more water, such as setting daily water intake goals and using diaries to track progress."
40992371|NCT03078621|BIOLOGICAL|Stem Cell Therapy|Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.
41308672|NCT04053452|DIAGNOSTIC_TEST|Peripheral nerve ultrasound|Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.
40992372|NCT05041296|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance including traditional and quantitative functional and structural parameters
40992373|NCT03809520|RADIATION|pedCAT|Weight-bearing CT scan (pedCAT) of ankles to measure 3D joint space width following ankle fracture.
40992374|NCT04735120|DEVICE|iLASE DIODE LASERS|940nm diode laser with 1.5 watts activated in a continuous mode and applied on to the canal orifices during root canal treatment to reduce intraoperative pain and further its effect on post operative pain is assessed
40992375|NCT04297137|DIETARY_SUPPLEMENT|Protein ingestion|Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.
40992376|NCT06523894|RADIATION|SBRT|Adapted to tumor volume BC SBRT
40992377|NCT00260858|DRUG|Test Meal: Reference food (glucose or white bread)|
40992378|NCT00260858|DRUG|Test Meal: Pirate's Booty|
40992379|NCT00260858|DRUG|Test Meal: Ceaprove wafer|
40992380|NCT00260858|DRUG|Test Meal: Stretch Island Strawberry Fruit Leather|
40992381|NCT00358566|BIOLOGICAL|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
40992382|NCT00358566|DRUG|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
41147615|NCT03879252|DRUG|Mouthwashes|Mouthwashes three times a day with a 1.4% baking mouthwash solution.
41147616|NCT00087516|DRUG|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
41147617|NCT00087516|DRUG|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
41147618|NCT00087516|DRUG|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
41147619|NCT00087516|DRUG|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
41308673|NCT04053452|DIAGNOSTIC_TEST|Measurement of strength|Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.
40992383|NCT01178593|OTHER|Gut-focused hypnotherapy in group sessions|weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
40992384|NCT05200754|OTHER|Convalescent/Vaccine-boosted Plasma (CP/PVP)|"Plasma from apheresis obtained from donors, who have recovered from SARS-CoV-2 infection or received a successful vaccination against SARS-CoV-2.~CP/PVP infusion is administered on two following days. Each CP/PVP bag contains approx. 238 - 337 ml anti-SARS-Cov-2 CP/PVP for infusion."
40992385|NCT03550703|BIOLOGICAL|V3-Myoma|Once daily oral pill of V3-Myoma
40992386|NCT04939935|DRUG|Metformin XR|Extended release metformin.
41308674|NCT04176055|DRUG|Haloperidol|haloperidol intervention
41308675|NCT00685620|BEHAVIORAL|Reinforcement Based Treatment|3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
41308676|NCT00094341|DRUG|Etanercept|
41308677|NCT04431661|PROCEDURE|Optical Coherence Tomography|OCT (DragonFly, Abbott Vascular) will be performed after angiography. OCT images will be acquired using the 6F guide catheter compatible DragonFly System (Abbott Vascular, Santa Clara, USA). The catheter will be introduced into the first coronary artery via a standard 0.014-inch angioplasty wire, after prior injection of an intracoronary bolus of nitro-glycerine (according to the hemodynamic conditions of the patient). To remove all blood adequately from the imaging site, nonocclusive flushing will be performed using continuously inject via an automated power injector, and the OCT catheter will be pulled back at a speed of 18 mm/second to guarantee sufficient time to acquire images of a 54 mm long segment (frame density: 10 frames/mm).
41308678|NCT04431661|PROCEDURE|Coronary Angiography|The coronary angiography will be performed according to the strategies described in the consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups.Transradial or transfemoral 6F/7F approaches are recommended. The choice of diagnostic catheters, guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation is let to the investigator's discretion.
41308679|NCT04431661|PROCEDURE|Per cutaneous coronary intervention|Based on coronary angiography and OCT analyses by the investigators, PCI will be performed, preferentially for the identified culprit lesion(s) only. The guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation are left to physician discretion. The use of semi- or non-compliant balloons number and diameter of drug eluting stent(s) will also be left to the physician discretion, but post dilation will be strongly recommended in case of PCI. OCT can eventually be performed after stent implantation to guide, post dilation strategy.
41467404|NCT04377048|DRUG|Gemcitabine|"as described in NGS Arm"
41467405|NCT04377048|DRUG|Tegafur-Gimeracil-Oteracil|"as described in NGS Arm"
40992387|NCT04939935|OTHER|Control|Placebo is inactive tablets that is identical to the intervention Metformin tablets.
40992388|NCT02917031|DRUG|Saxagliptin|5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
40788197|NCT03665259|PROCEDURE|Lower oxygen group|Pre-oxygenation with 60% oxygen during induction of anesthesia
40992389|NCT02917031|DRUG|Sitagliptin|50 mg or 100 mg, gray capsule
40992390|NCT02917031|DRUG|Placebo to match saxagliptin|2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
40992391|NCT02917031|DRUG|Placebo to match sitagliptin|50 mg or 100 mg, gray capsule
40992392|NCT00312091|DRUG|Lamivudine, nevirapine, and stavudine fixed-dose tablet|7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
40992393|NCT00312091|DRUG|Lamivudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
40992394|NCT00312091|DRUG|Nevirapine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
40992395|NCT00312091|DRUG|Stavudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
40992396|NCT01899534|OTHER|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
40992397|NCT06104358|DRUG|HU6|HU6 is being evaluated for its effect on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function
40992398|NCT02242851|DRUG|Telmisartan|
40992399|NCT02914652|DRUG|Salbutamol|Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
40992400|NCT02914652|DRUG|Norflouran (Placebo Evohaler(R) )|Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
40788198|NCT00253916|BEHAVIORAL|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
40788199|NCT00253916|BEHAVIORAL|Resistance Exercise Program|Resistance Exercise Program
40992401|NCT03390881|OTHER|Fasting condition|Subjects will fast over the whole experimental period (480 min)
40992402|NCT03390881|OTHER|Sugar condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% carbohydrate, 15% fat and 15% protein and providing 1.5 X hourly resting energy requirement.
40992403|NCT03390881|OTHER|Fat condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% fat, 15% carbohydrate and 15% protein and providing 1.5 X hourly resting energy requirement.
40992404|NCT04751149|PROCEDURE|Removal of Urinary Catheter|Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
40788200|NCT06257446|BEHAVIORAL|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
40788201|NCT00540696|DRUG|darbepoetin alfa|"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."
40992405|NCT01702701|DRUG|Montelukast|montelukast 10mg po pill q day for 12 weeks
40992406|NCT01702701|DRUG|Fluticasone|fluticasone 440mcg po q bid x 12 weeks
40992407|NCT01429272|DRUG|Minocycline|100 mg po bid for 6 weeks
40992408|NCT01429272|DRUG|Aspirin|81 mg po bid for 6 weeks
40788205|NCT04196725|OTHER|Physical therapy treatment|Two weeks rehabilitation programme focusing on physical therapy treatment, e.g. manual lymphatic drainage and compression bandaging
40788206|NCT04196725|BEHAVIORAL|Lifestyle treatment|Two weeks rehabilitation programme focusing on physical activity
40788207|NCT05091411|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
40788208|NCT01590368|DEVICE|Marketed electrode|12 electrodes will be placed on the subject for an ECG reading to be taken
40788209|NCT01590368|DEVICE|"Modified test electrode"|12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
40788210|NCT05357833|DRUG|Ferumoxytol infusion|Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.
40788211|NCT05357833|DRUG|Gadoteridol|Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).
40788212|NCT05357833|DIAGNOSTIC_TEST|MRI Brain and Cervical Spine|3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol
40788213|NCT04122846|BEHAVIORAL|Emotional Awareness and Expression Therapy|"Very much based on Unlearn your pain by Howard Schubiner."
40788214|NCT01973868|DRUG|Regorafenib (Stivarga, BAY73-4506)|
40788215|NCT01973868|DRUG|Cetuximab (ERBITUX)|
40788216|NCT05889325|PROCEDURE|DEB-TACE plus HAIC|the patients received HepaSphere DEB-TACE plus HAIC
40992409|NCT01429272|DRUG|placebo|placebo for minocycline and/or aspirin
40992410|NCT00101907|DRUG|AMG 706|AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
41467406|NCT02735694|DRUG|Cycloserine|Capsule containing 250 mg of Cycloserine
40788219|NCT02140021|PROCEDURE|Biospecimen Collection|Undergo anal, cervical, vaginal, and oral sample collection
40788220|NCT02140021|OTHER|Laboratory Biomarker Analysis|Correlative studies
40788221|NCT03345446|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
40788222|NCT00003365|DIETARY_SUPPLEMENT|curcumin|
40788223|NCT00003365|DIETARY_SUPPLEMENT|rutin|
40788224|NCT00003365|DRUG|quercetin|
40788225|NCT00003365|DRUG|sulindac|
40788226|NCT02248896|DRUG|Telmisartan|
40788227|NCT02248896|DRUG|Other angiotensin-receptor blockers (ARBs)|
40788228|NCT02248896|DRUG|Angiotensin-converting enzyme inhibitors (ACEIs)|
40992411|NCT00101907|BIOLOGICAL|Panitumumab|Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
40992412|NCT00101907|DRUG|Gemcitabine|Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
40992413|NCT00101907|DRUG|Cisplatin|Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.
40992414|NCT06169280|BIOLOGICAL|NSC-CRAd-S-pk7|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.
40992415|NCT06169280|DIETARY_SUPPLEMENT|N-acetylcysteine amide (NACA)|N-acetylcysteine amide (NACA) 600 mg oral, is taken daily from registration to just prior to dose 2 of NSC-CRAd-S-pk7.
40992416|NCT00078026|DRUG|Apomine|
40992417|NCT00177528|DRUG|venlafaxine-XR|
40992418|NCT04009421|DIAGNOSTIC_TEST|Coronary artery plaque assessment by CT coronary angiography QAngio CT RE|Assessment of segmental plaque volume and composition
40992419|NCT03156478|BEHAVIORAL|Digital lifestyle intervention group|Intervention with digital application for lifestyle changes
40992420|NCT03156478|BEHAVIORAL|Combined digital and face-to-face lifestyle intervention group|Intervention with digital application and group meetings for lifestyle changes
41467407|NCT02735694|DRUG|Placebo|Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
41467408|NCT01848210|DRUG|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
41467409|NCT01848210|DRUG|Placebo|Coumarin + troxerutin placebo-matching tablets
41467410|NCT00542360|BEHAVIORAL|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
41467411|NCT03651908|PROCEDURE|Conventional Flap Surgery|"After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back."
41467412|NCT04060134|OTHER|SimpliDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
41467413|NCT04060134|OTHER|AlloDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
41467414|NCT04060134|OTHER|AlloMax HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
40992421|NCT04851899|DIETARY_SUPPLEMENT|Phaeosol low dose|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 500mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
40992422|NCT04851899|DIETARY_SUPPLEMENT|Phaeosol high dose|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant. Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
40992423|NCT04851899|DIETARY_SUPPLEMENT|Placebo|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of natural stimulant). Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
40992424|NCT00002259|DRUG|Mitoxantrone hydrochloride|
40992425|NCT00319826|OTHER|No intervention|This is an observational study with no intervention
41467415|NCT04060134|OTHER|FlexHD HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
41467416|NCT04060134|OTHER|DermACELL HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
41467417|NCT03783988|COMBINATION_PRODUCT|DHEA and TRIAC|The new topical gel contains dehydroepiandrosterone (DHEA) and triiodothyroacetic acid (TRIAC)
41467418|NCT02056652|DEVICE|Bioteque cup pessary|
41467419|NCT00615849|PROCEDURE|thoracoscopic surgery|stapled wedge resection of the lung mechanical pleural abrasion
41467420|NCT05945667|DRUG|Monural|1 sachet, only 1st day of trial
41467421|NCT05945667|DIETARY_SUPPLEMENT|UroNext|1 sachet per day for the first 7 days, followed by 7 days break Same scheme to be repeated for 3 months
41467422|NCT00003350|DRUG|paclitaxel|Given IV
41467423|NCT00003350|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
41467424|NCT00003350|OTHER|laboratory biomarker analysis|Correlative studies
41467425|NCT00003350|PROCEDURE|quality-of-life assessment|Ancillary studies
41467426|NCT05700136|BEHAVIORAL|MOMENT|Prenatal and postnatal factors including maternal, environment, and infant circadian rhythm were studied to determine its effect on infant growth and temperament.
41467427|NCT03680079|OTHER|Group education sessions|Peer support and interaction both in-person during group education sessions and online via social media platforms
41467428|NCT04228627|DRUG|Parentral Iron|Correction of Iron stores without anaemia
40788229|NCT02248896|DRUG|Other major antihypertensive medication classes|e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
40992426|NCT02583776|DEVICE|Unblinded - CGM|Data from device will be readable and alarms on
40992427|NCT02583776|DEVICE|Blinded - CGM|Data from device will be blinded and alarms off
41147620|NCT00087516|DRUG|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
41147621|NCT01363206|BIOLOGICAL|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
41467429|NCT02898701|BEHAVIORAL|Motor Practice of a Standing Serial Reaction Time Task|Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
41467430|NCT01481857|OTHER|Segmental trunk exercise associated with proprioception|Proprioceptive exercise
41467431|NCT01481857|OTHER|Segmental trunk exercise|Segmental trunk exercise
41467432|NCT00316940|DRUG|bortezomib|
40788230|NCT02255539|DEVICE|Geelong Prototype Mask|A nasal pillows prototype mask to be trialled with a PAP therapy device for a period of 6 weeks. Participants will wear the mask in place of their current mask for the duration of the trial.
40788231|NCT00272792|DRUG|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
40788232|NCT00272792|DRUG|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
40992428|NCT00708942|DRUG|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
40992429|NCT00708942|DRUG|Placebo|Placebo suppository, for 3-7 hours application
40992430|NCT00708942|DRUG|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
40992431|NCT00708942|DRUG|Placebo|Placebo ointment for 5 hours application
40992432|NCT00799578|DRUG|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
40992433|NCT05326594|PROCEDURE|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
40992434|NCT05326594|PROCEDURE|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
40992435|NCT05326594|DEVICE|Inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
40992436|NCT05326594|PROCEDURE|Heat Therapy|superficial heating for 20 minutes
40992437|NCT00973024|DRUG|JNJ-42160443 3 mg|JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
41147622|NCT01363206|BIOLOGICAL|Ipilimumab|Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
40788233|NCT05095298|DRUG|Vaccine, COVID19|It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
40992438|NCT00973024|DRUG|JNJ-42160443 1 mg|JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
41147623|NCT01587703|DRUG|GSK525762|Begin at Dose Level 1 and increase up to 2 fold
41147624|NCT02316171|BIOLOGICAL|CVA21|CAVATAK is a purified preparation of CVA21
41147625|NCT02316171|DRUG|Mitomycin C|Chemotherapy
40992439|NCT00973024|DRUG|JNJ-42160443 6 mg/3mg|JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
40992440|NCT00973024|DRUG|JNJ-42160443 10 mg|JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
40992441|NCT00973024|DRUG|Matching Placebo|Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
40992442|NCT00897065|GENETIC|microarray analysis|
40992443|NCT00897065|GENETIC|polymerase chain reaction|
40992444|NCT00897065|GENETIC|protein expression analysis|
40992445|NCT00897065|OTHER|diagnostic laboratory biomarker analysis|
40992446|NCT00897065|OTHER|fluorescent antibody technique|
40992447|NCT00897065|OTHER|immunohistochemistry staining method|
40992448|NCT00897065|OTHER|immunologic technique|
40992449|NCT02325011|DRUG|Sativex® (Treatment A)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
40992450|NCT02325011|DRUG|Sativex® and fluconazole concomitantly (Treatment B)|"Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose."
40992451|NCT05933928|OTHER|Simulation-based electronic fetal monitoring training|"Practices will be carried out with the students in the intervention group with the NOELLA Birth Simulator, which is a high-reality simulator located in the Simulation laboratory of the Department of Midwifery of the Faculty of Health Sciences of Hamidiye. A simulator will be practiced with a separate scenario including early, late, variable deceleration, reactive, sinusoidal and non-reactive trace interpretation and intervention."
40992452|NCT03459378|OTHER|no intervention - retrospective analyses|retrospective data examination, there are no study related interventions
40992453|NCT03492255|DRUG|Cyclophosphamide|Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
40992454|NCT03492255|DRUG|Methylprednisolone|"Patients in EUROLUPUS group will receive Methylprednisolone \[750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)."
41467433|NCT00316940|RADIATION|samarium Sm 153 lexidronam pentasodium|
40992455|NCT03492255|DRUG|Prednisone|Patients in EUROLUPUS group will receive oral prednisone ≤ 30 mg/day with a reduction of 5mg/month until complete withdrawal.
40992456|NCT03492255|DRUG|Mycophenolate Mofetil|From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
40992457|NCT03410589|OTHER|Sinlge arm|application of scales for evaluation of sleep, fatigue and quality of life - Observational study
40992458|NCT02954510|DRUG|ferumoxytol|ferumoxytol will assess patency of coronary arteries
40992459|NCT02447133|DEVICE|3D OCT-1 Maestro|OCT Machine used for diagnostic purposes
40992460|NCT05289011|OTHER|Interviews and questionnaires|"* Evaluation of inflammatory rheumatism~* Dietary survey~* International Physical Activity Questionnaire IPAQ~* BASDAI self-questionnaire~* Assessment of quality of life by ASQol questionnaire~* Assessment of fatigue by FACIT questionnaire~* Assessment of digestive symptoms~* Collection of demographic and general data~* Collection of treatment"
40992461|NCT02220244|DRUG|MD1003 100mg capsule|
41147626|NCT04834167|DEVICE|OneDoc Picopulse|Eligible patients will proceed to receive skin cleansing prior to OneDoc Picopulse treatment. After the cleansing, the patients will receive OneDoc Picopulse treatment for 15 mins. Patients will receive ten picopulse treatments for bi-monthly.
41147627|NCT03633318|DEVICE|electrical impedance myography (EIM)|EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
41308680|NCT05787353|OTHER|Exercise programme|Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks.
41308681|NCT04855565|DRUG|ALY688-SR|single dose subcutaneous injection
41308682|NCT00103805|DRUG|levodopa|
41308683|NCT05256069|DRUG|Propranolol Pill|Participants will receive a β-blockade (propranolol pill, 1 mg/kg dosed based on participant weight).
41467434|NCT02833207|DRUG|Drug Trial 1 (EDD)|"Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description."
41467435|NCT02833207|DRUG|Drug Trial 2 (ROV)|"Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description."
40788234|NCT05730881|PROCEDURE|ECMO|VA-ECMO is a life support measures, we need to estimate the survival by different techniques to allocate therapeutic interventions properly
40788235|NCT06543615|DEVICE|Ultrasonography|Ultrasound assessment of residual gastric volume
40788236|NCT00251836|PROCEDURE|Laparoscopic hand-assisted donor nephrectomy|
40788237|NCT04467814|BEHAVIORAL|Better Together|"Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.~Caregiver participants in the intervention group will receive up to six telephone or video calls with the research assistant or Clinical Resource Therapist. Sessions will review the knowledge translation (KT) product with family members (\~15 minutes), art goals, brainstorm strategies, and discuss setbacks. The calls with the caregiver may occur 1 to 2 times in the hospital, within one week of going home, and then in Months 2 and 3."
40788238|NCT04467814|BEHAVIORAL|Usual Care|Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.
40992462|NCT04748315|OTHER|SEMT(1:1)|Soccer trainning protocolo will be performed on an work to rest ratio 1:1 and the trainning volume will consist of 1 set and 6 repetitions per set
40788239|NCT04111705|DRUG|Lorlatinib|100 mg once daily
40788240|NCT03663309|DIAGNOSTIC_TEST|detecting Gluten peptides in faecal and urine samples|"At each visit patient will:~* Bring 4-day food diary (attached)~* Fill symptoms and complaints questionnaire (attached)~* Provide 24 h diet recall in case a food diary absents~* Fill Biagi score questionnaire (attached)~* Perform blood test of TTG~* Provide stool and urine samples"
40788241|NCT02171026|DRUG|Dabigatran etexilate|
40788242|NCT02171026|DRUG|Amiodarone|
40788243|NCT04603001|DRUG|LY3410738|Oral LY3410738
40992463|NCT04748315|OTHER|SEMT (1:3)|Soccer trainning protocolo will be performed on an work to rest ratio 1:3 and the trainning volume will consist of 1 set and 6 repetitions per set
40992464|NCT00643422|DEVICE|Cirrus™ HD-OCT, Carl Zeiss Meditec AG|the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.
41308684|NCT05256069|DRUG|Placebo|Participants will receive a placebo in pill form.
41308685|NCT00133900|PROCEDURE|Phlebotomy|Peripheral blood draws for evaluation of circulating tumor cells
41467436|NCT05452434|DRUG|mirabegron|mirabegron 50mg QD for 12 weeks.
41467437|NCT05993767|DRUG|dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen|Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
40788244|NCT04603001|DRUG|Venetoclax|Oral venetoclax
40788245|NCT04603001|DRUG|Azacitidine|Subcutaneous or intravenous azacitidine
40788246|NCT05378412|BEHAVIORAL|3Cs|The 3Cs program is an educational strategy aimed at fostering resilience and compassion in people. It is based on improving the mental well-being of the participants by transforming their attitudes and behaviors through increased consciousness.
40788247|NCT01192126|DEVICE|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
40788248|NCT01192126|DEVICE|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
40788249|NCT05749471|DIAGNOSTIC_TEST|ASEX (Arizona Sexual Experience) administration|ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of \> 19, any one item with a score of \> 5, or any three items with a score of \> 4 would have sexual dysfunction.
40788250|NCT02868853|BEHAVIORAL|Photo App|Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.
40788251|NCT02868853|BEHAVIORAL|Diet App|Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.
40788252|NCT02868853|BEHAVIORAL|Podcasts|Listen to 2 podcasts per week about healthy eating and exercise.
40788253|NCT06151470|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
40788254|NCT06151470|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
40788255|NCT04003298|DEVICE|Electric toothbrush|Electric toothbrush and power interdental device
40788256|NCT04003298|DEVICE|Control|Oscillating-rotating
40992465|NCT01852812|DRUG|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
40992466|NCT01852812|DRUG|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
40992467|NCT00114465|DRUG|VSL#3|VSL#3 1 sachet twice a day
40992468|NCT00114465|OTHER|Placebo|Placebo 1 sachel twice a day
40992469|NCT03384550|BEHAVIORAL|Self-regulation coaching|Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.
41147628|NCT06060847|PROCEDURE|Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome|Patients in the experimental arm will undergo liver resection for HCC and sleeve gastrectomy for MS during the same surgical procedure.
41308686|NCT02069496|BIOLOGICAL|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
41308687|NCT02410902|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
40788257|NCT05317598|OTHER|Kindness and honesty psychoeducation based on positive psychotherapy: The Key Model Of Courtesy And Integrity (KMCI)|It is an application that investigates the effect of kindness and honesty psychoeducation based on positive psychotherapy on effective communication skills of nursing students.
40788258|NCT04661605|DIAGNOSTIC_TEST|Recurrent Neural Network|We will propose a similar Moiré feature analyzing approach based on Recurrent Neural Network to process the measured Slip Pulse wave-images with 'Chun', 'Guan' and 'Chy' in order to prepare this visualization engineering platform.
41308688|NCT02410902|DRUG|PLACEBO|Single unit dose powder of non-active substance administered 3 times per day for 90 days
40788259|NCT01001351|DRUG|PRT-201|Applied topically during surgery.
40788260|NCT01001351|DRUG|Placebo|Applied topically during surgery
40788261|NCT06028698|OTHER|Inducing positive emotion music|listening to music could induce emotion response, this study is going to investigate inducing positive emotion music countering mental fatigue.
40788262|NCT06220877|PROCEDURE|Buccal Pad of Fat|surgical procedure
41308689|NCT04704999|DRUG|Tafenoquine|Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
41467438|NCT05790707|PROCEDURE|Atrial fibrillation ablation + antiarrhythmic drugs|"Atrial fibrillation ablation will be performed with endovascular catheters and will be done either with radiofrequency, cryoballoon or pulsed field ablation.~Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed."
40788263|NCT06220877|PROCEDURE|A-PRF|blood sample
40788264|NCT06220877|PROCEDURE|fibrin glue|procedure
40788265|NCT06220877|PROCEDURE|oxidized cellulose|procedure
41467439|NCT05790707|DRUG|Antiarrhythmic drug|Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
41467440|NCT01856387|BIOLOGICAL|high neutrophil to lymphocyte ratio|
41467441|NCT01856387|OTHER|normal neutrophil-to Lymphocyte ratio|
41467442|NCT02741154|DRUG|induction with aromataze inhibitor|letrozole 2.5mg once daily start in the first day of menses for 5days
41467443|NCT02741154|DRUG|HMG|HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
41467444|NCT02741154|DRUG|GnRh a|antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
41467445|NCT02741154|DRUG|HCG|10.000 IU HCG injection when at least three follicles reach 17mm in diameter
41467446|NCT00769314|DRUG|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
41467447|NCT00769314|DRUG|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
41467448|NCT02800031|DEVICE|Transvaginal ultrasonography|
41467449|NCT03584217|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
41467450|NCT03584217|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
41467451|NCT03584217|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
41467452|NCT02103582|OTHER|Intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
41467453|NCT05931276|DRUG|Metoprolol Succinate|a dialyzable, beta-1 selective beta blocker
41467454|NCT05931276|DRUG|Carvedilol|a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties
41467455|NCT02969876|DRUG|Vortioxetine|Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
41467456|NCT06210945|DRUG|10 mg/kg CM-101|10 mg/kg CM-101
41467457|NCT06210945|DRUG|Placebo|Placebo
41147629|NCT06060847|PROCEDURE|Liver resection for HCC induced by metabolic syndrome|Patients in the active comparator arm will undergo liver resection for HCC
41308690|NCT04704999|DRUG|Chloroquine|Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
41467458|NCT02574338|DEVICE|Foley's Catheter|intracervical extraamniotic Foley's catheter
41467459|NCT02574338|DRUG|prostaglandin E1 analogue|intravaginal misoprostol
41467460|NCT03751709|DRUG|Blinatumomab|Blinatumomab per package insert - via continuous infusion days 1-28 of Cycle 1 and Cycle 2, every 42 days.
41467461|NCT03751709|OTHER|Haplo-Mismatched Cell Therapy (HMCT)|HMCT infusion Cycle 1, Day 15 and Cycle 2, Day 8 \& Day 15
41467462|NCT05509088|DEVICE|high flow nasal cannula|Patients in the intervention group receive oxygen through HFNC with a flow rate of set initially at 40 L / min, FiO2 adjusted to maintain SpO2 ≥ 92%, and will be humidified, heated to 34-37 °C, disconnection will be allowed only when ambulation is required, patients will be instructed to practice mouth closing throughout the HFNC therapy as much as possible
40788266|NCT05016258|DEVICE|KONTACT MB|Dental implant surgery
40788267|NCT04563767|PROCEDURE|Infinitome|Added sequence of rs-fMRI.
40788268|NCT05504759|OTHER|splint|Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
41308691|NCT04704999|DRUG|Artemether 20 mg-Lumefantrine 120 mg|Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
41308692|NCT01847664|DRUG|Rifamycin SV-MMX® 400 mg b.i.d.|
40788269|NCT05504759|OTHER|steroid|Betamethasone Dipropionate + Betamethasone Sodium Phosphate-1 ml will be administered once at the beginning of the study to patients who will receive steroid injection, one of the local injection treatments. Steroid injection will be applied to the most sensitive point on the lateral epicondyle. Afterwards, patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during daytime hours for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
40992470|NCT03384550|BEHAVIORAL|Planning|A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).
40992471|NCT03384550|BEHAVIORAL|Financial Incentives|Participants receive CHF 1 ($1) for each day they meet a personalized adaptive step goal.
40992472|NCT03384550|BEHAVIORAL|Charity Incentives|Participants donate CHF 1 ($1) to a charity of choice for each day they meet a personalized adaptive step goal.
40992473|NCT01946997|OTHER|OCT Imaging both Normal and diabetic groups|Images taken to determine thickness values in the retina
40992474|NCT04121260|DRUG|Daratumumab|Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.
40992475|NCT01242956|BEHAVIORAL|verum group|video-based training after stroke
40992476|NCT01242956|BEHAVIORAL|Placebo group|non-video group
40992477|NCT00994240|PROCEDURE|Electrodessication & Curettage|Electrodessication \& Curettage 1 or 3 cycles
40992478|NCT04225169|OTHER|Breathing exercises|The patient was taken to a quiet room and asked to lie on the bed. For the first 5 minutes, the researchers explained how the exercise is done with pictures and demonstrated it to the patient. The patient was asked to perform the exercise for 5 minutes under supervision by the researchers. If the patient performed DBE correctly, practice was discontinued. If not, the patient was asked to practice for another 5 minutes. If the patient still could not perform the exercise correctly at the end of this time, they were excluded from the sample. DBE was performed according to the Cleveland Clinic guideline as follows:
40992479|NCT04076995|OTHER|Water Intake|Increased water intake during the 11 h protocol
40992480|NCT00478985|BEHAVIORAL|Imatinib ending|Interruption of the treatment by Imatinib
40992481|NCT00455507|DRUG|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
40992482|NCT00455507|DRUG|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
40992483|NCT00455507|DRUG|Placebo|Two placebo tablets orally once daily for 12 weeks
40992484|NCT04283006|DRUG|CD20/CD22 dual Targeted CAR T-cells|Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
40992485|NCT03747965|BIOLOGICAL|Mesothelin-directed CAR-T cells|Cells will be infused one day after the completion of conditioning regimen of paclitaxel and cyclophosphamide
41308693|NCT01847664|DRUG|Rifamycin SV-MMX® 600 mg t.i.d.|
41467463|NCT06166264|OTHER|Progressive resistance training|It consists of patients who will receive both Resistance exercise training sessions and aerobic training 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercises used in the resistance exercise 1)Standing chess press;(2)Strengthening back muscles in sitting position;(3)Standing strengthening abduction of both shoulders;(4)Standing strengthening flexion of both shoulders;(5)Standing strengthening flexion of both forearms;(6)Standing strengthening extension of both forearms;(7)Strengthening extension of both knees in sitting position;(8)Strengthening flexion of both knees in sitting position;(9)Strengthening dorsiflexion of both ankles in sitting position.
41467464|NCT06166264|OTHER|Control group|The participants will receive information regarding health education.
41467465|NCT02676245|BEHAVIORAL|Viewing Newborn Screening movie|NBS Movie and printed brochure were viewed by the participants
41467466|NCT02676245|BEHAVIORAL|Viewing Residual Dried Blood Spot movie|DBS Movie and and printed brochure were viewed by the participants
40992486|NCT06009159|DEVICE|Transcutaneous Vagus Nerve Stimulation|30 minutes stimulation, twice per day for 4 weeks
40992487|NCT01361438|OTHER|Total therapy approach|Total therapy approach
40992488|NCT04067128|BEHAVIORAL|Health coaching|Brief telephonic intervention consisting of up to three phone calls
40992489|NCT04131634|RADIATION|Stereotactic Ablative Radiation|A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy
40992490|NCT04130399|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive 5 fractions of SBRT delivered over a five-day period. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week.
41467467|NCT00688402|DRUG|AZD3355|Single dose
41467468|NCT00351351|DEVICE|Cyberwand|FDA approved - dual probe intracorporeal lithotrite
41467469|NCT00351351|DEVICE|single probe ultrasonic|FDA-approved - single probe ultrasonic
41467470|NCT05827640|OTHER|data recording using conventional ventilation strategies (PCV and VCV)|no intervention
41467471|NCT03667859|DIAGNOSTIC_TEST|Vaginal Tactile Imaging|Vaginal elasticity measurements using the Vaginal Tactile Imaging system.
41467472|NCT01260337|BEHAVIORAL|Portion controlled diet|Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups
41467473|NCT01260337|OTHER|Diabetes Support and Education|The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
40992491|NCT04130399|DRUG|FOLFIRINOX|Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
40992492|NCT05540834|DRUG|Alteplase|The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.
40992493|NCT03388229|BEHAVIORAL|not an intervention|it was observation not intervention
41467474|NCT04147962|DEVICE|intense pulsed light (usual practice)|collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
41467475|NCT03437330|DRUG|Empagliflozin (Jardiance®)|Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)
40992494|NCT04630951|OTHER|Blood Flow Restriction Strength training with low load|Low Load (20-50% 1RM), 4 set of 30/15/15/15 repetitions, 30 seconds resting between sets.
41308694|NCT01847664|DRUG|Rifamycin SV-MMX® Placebo|
41467476|NCT03437330|DRUG|Insulin Glargine (Lantus®)|"insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L~If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)"
40992495|NCT04630951|OTHER|High Load Strength Training|High Load (60-80% 1RM) 4 sets of 8 repetitions, 2 minutes resting between sets
41467477|NCT04779034|OTHER|Measurement of heart rate variability|Heart rate variation will be evaluated with the Polar RS800CX model heart rate monitor
40788270|NCT05504759|OTHER|dry needling|The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x30 mm needles will be used for dry needling. Dry needle treatment will be applied to the painful trigger points in the forearm extensor group muscles with the stick-pull technique, 1 session per week, for a total of 2 sessions. Afterwards, the patients will be given a 2 weeks rest protocol (works that may strain the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The purpose of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. During the treatment of lateral epicondylitis, home exercises will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
40788271|NCT00441766|DRUG|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
40992496|NCT05616156|DEVICE|Cre8™ BTK|Implant of Cre8™ BTK stent the treatment of infrapopliteal peripheral artery disease
40992497|NCT02661360|BEHAVIORAL|Swaddling Intervention for Preterm Infants|Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.
40992498|NCT02661360|BEHAVIORAL|Unswaddled Control|Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
40788272|NCT00441766|DRUG|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
40788273|NCT00441766|DRUG|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
40788274|NCT00441766|DRUG|placebo|Part A: placebo capsule every 12 hours for 4 weeks
40788275|NCT04541082|DRUG|ONC206|ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.
40992499|NCT03170973|OTHER|Exercise|After a 12-hour fast, volunteers will collect blood in the antecubital vein to measure basal serum values. 12 after the first blood collection they will perform a physical exercise session on a treadmill. The same will be divided in 3 times: heating, conditioning and cooling. The heating will be of 7 minutes, the cooling of 5 minutes and the time of conditioning will correspond to the energy expenditure of 250Kcal with light intensity based on Borg's perception of effort, that is, in the original scale a value between 9 and 11. After 24 hours after the first blood collection the volunteers will return to the laboratory after a 12-hour fast and blood samples will be collected again.
40992500|NCT04606576|OTHER|Placebo|Fish Oil
40992501|NCT04606576|DRUG|ORMD-0801 QD|Oral Insulin once per day
40992502|NCT04606576|DRUG|ORMD-0801 BD|Oral Insulin, twice per day
40992503|NCT00005828|DIETARY_SUPPLEMENT|green tea extract|
40992504|NCT02790970|DEVICE|PReDicT Test|PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
40788276|NCT06219252|DEVICE|Intraoperative aberrometer|the patient intraocular lens will be optimized during the aphakic period after cataract extraction and before intraocular lens implantation, this will produce a possible change in the dioptric power of the intraocular lens
40788277|NCT06219252|OTHER|Preoperative intraocular lens calculation|the intraocular lens in this group will be calculated preoperatively with Barrett Universal II formula
40788278|NCT01085526|BIOLOGICAL|Alutard phleum pratense subcutaneous immunotherapy|standard regimen of SCIT
40788279|NCT01085526|DRUG|Alutard phl prat|
40788280|NCT03284060|BEHAVIORAL|Cognitive remediation program|"Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~1. pen and paper tasks focusing on specific emotion recognition component (20 min),~2. computerized tasks focusing on the same process (20 min),~3. a proposal of a home-based task (during 20 min)."
40788281|NCT00002798|DRUG|asparaginase|
40788282|NCT00002798|DRUG|daunorubicin hydrochloride|
40788283|NCT00002798|DRUG|fludarabine phosphate|
40788284|NCT00002798|DRUG|therapeutic hydrocortisone|
40788285|NCT00002798|PROCEDURE|allogeneic bone marrow transplantation|
40788286|NCT00002798|RADIATION|3-dimensional conformal radiation therapy|
40788287|NCT00002798|BIOLOGICAL|filgrastim|Given SC
40788288|NCT00002798|DRUG|cytarabine|Given IV or IT
40788289|NCT00002798|DRUG|idarubicin|Given IV
40788290|NCT00002798|DRUG|dexamethasone|Given PO
40788291|NCT00002798|DRUG|thioguanine|Given PO
40788292|NCT00002798|DRUG|etoposide|Given IV
40788293|NCT00002798|DRUG|methotrexate|Given IT
40992505|NCT02790970|OTHER|Treatment as Usual|Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
40992506|NCT00005831|BIOLOGICAL|trastuzumab|Given IV
41147630|NCT04513041|PROCEDURE|Pinhole surgical technique and tunnel technique in a split mouth design|Each subject will have the each surgical procedure which are both considered routine minimally invasive clinical care for gingival recession. Gum recession on one side will receive Pinhole surgical technique (test procedure). The other side will receive Tunnel technique (control procedure), Research component involved is the capture of digital impression using intra-oral scanner in the baseline (preoperative) and the final visit (6 months postoperative).
40788294|NCT00002798|DRUG|cyclophosphamide|Given IV
40788295|NCT00002798|BIOLOGICAL|aldesleukin|
40788296|NCT00002798|DRUG|busulfan|
40788297|NCT05820048|DRUG|Lansoprazole 15 mg|"1. Short-term treatment of active duodenal ulcer~2. Short-term treatment of active benign gastric ulcers~3. Thin heat of Helicobacter pylori to prevent recurrence of duodenal ulcer~4. Maintain duodenal ulcer after treatmentLaw~5. Treatment of nonsteroidal anti-inflammatory analgesics-induced gastric ulcers~6. Reducing the risk of developing nonsteroidal anti-inflammatory analgesic-induced gastric ulcers~7. Short-term treatment of gastroesophageal reflux disease~8. Short-term treatment of erosive reflux esophagitis~9. Post-treatment maintenance therapy for erosive reflux esophagitis~10. Pathological hyperdivision, including Zolinger Ellison syndrome"
40788298|NCT04934267|OTHER|Eccentric Exercise for subjects with JHS|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
40992507|NCT00005831|DRUG|paclitaxel|Given IV
40992508|NCT00005831|DRUG|carboplatin|Given IV
40992509|NCT00005831|DRUG|gemcitabine hydrochloride|Given IV
40992510|NCT00005831|OTHER|laboratory biomarker analysis|Correlative studies
40992511|NCT04898933|PROCEDURE|eyelid lesion excision|eyelid lesion excision was done under local anesthesia
40992512|NCT00163475|DRUG|Roflumilast|
40992513|NCT01113762|DEVICE|articular surface replacement ASR, DePuy|posterolateral incision
40992514|NCT01113762|DEVICE|ReCap/Magnum modular head, Biomet|posterolateral incision
40992515|NCT01113762|DEVICE|Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet|posterolateral incision
40992516|NCT01113762|DEVICE|28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)|posterolateral incision
40992517|NCT05734079|OTHER|Standard of care|A written hand out containing all information required for bowel preparation
40992518|NCT05734079|OTHER|Standard of care + Video call|Standard of care and in addition a video call with a professional nurse conducted via digital devices and a free software (Zoom video communication or What's app application)
40992519|NCT05734079|OTHER|Standard of care + Video call + Educational video film|Standard of care and in addition to a video call, an explanatory short video on bowel preparation (video film), streamed to the patient's mobile device or computer
40788299|NCT04934267|OTHER|Eccentric Exercise for Controls|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
40788300|NCT02638714|BIOLOGICAL|Stem Cells|Intervention: Transplantation of autologous purified stem cells
40788301|NCT02169011|PROCEDURE|Latissimus Dorsi Flap Reconstruction|Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.
40788302|NCT02169011|PROCEDURE|TAP Flap Reconstruction|Delayed, unilateral breast reconstruction with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
40788303|NCT00137059|DRUG|acetaminophen sustained-release|
40788304|NCT00936663|DRUG|Placebo|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
40788305|NCT00936663|DRUG|Sitagliptin|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
40788306|NCT02881775|DEVICE|rTMS and exercise|rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
40788307|NCT02881775|DEVICE|Sham rTMS and exercise|rTMS unit is on and running but mu metal is placed between the coil and the skull
40788308|NCT03475342|DRUG|Tranexamic Acid|Ampoules and packaging for both arms will be identical in appearance.
40788309|NCT03475342|OTHER|Placebo|Ampoules and packaging for both arms will be identical in appearance.
40788310|NCT00421148|DRUG|Sugammadex 0.5 mg/kg|IV infusion
40788311|NCT00421148|DRUG|Sugammadex 1 mg/kg|IV infusion
40788312|NCT00421148|DRUG|Sugammadex 2 mg/kg|IV infusion
40788313|NCT00421148|DRUG|Sugammadex 4 mg/kg|IV infusion
40788314|NCT00421148|DRUG|Placebo|IV infusion
40788315|NCT00421148|DRUG|Rocuronium bromide|IV infusion
40992520|NCT02115711|BEHAVIORAL|Community health worker|The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
40992521|NCT03042052|DRUG|detrusor infection of Botulinum toxin|detrusor injection
40992522|NCT00528723|DRUG|salbutamol 100 mcg|To be used as needed for symptom relief
40992523|NCT00528723|DRUG|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
40992524|NCT00528723|DRUG|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
40992525|NCT04585087|OTHER|Dietary Intakes|6 levels of threonine intake will be provided by the protein liquid drink
41308695|NCT05941949|DIETARY_SUPPLEMENT|Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E|2 softgels per day
41308696|NCT05941949|DIETARY_SUPPLEMENT|Placebo|2 softgels per day
41308697|NCT05726019|DRUG|Colchicine|Oral tablet colchicine 0.5mg, twice a day, will be started within 24 hours after randomization and maintained until 30 days after coronary artery bypass grafting.
41308698|NCT05429372|GENETIC|PF-06939926|All participants will receive a single dose of PF-06939926 on Day 1.
41308699|NCT03830008|BEHAVIORAL|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
40992526|NCT04680689|DIAGNOSTIC_TEST|128 Multislice CT coronary angiography|128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium
41467478|NCT04540718|OTHER|Exercise|50 minutes of exercise, consisting of 20 minutes of resistance followed by 30 minutes of aerobic, three times a week for eight weeks.
41467479|NCT04540718|OTHER|Sauna|15 minutes of sauna exposure immediately after exercise intervention, three times a week for eight weeks.
41467480|NCT00368316|BIOLOGICAL|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
41467481|NCT03539458|DEVICE|Tendyne Mitral Valve System|Mitral valve replacement
41467482|NCT01309217|BEHAVIORAL|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
41467483|NCT01309217|OTHER|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
41467484|NCT00627081|DRUG|remifentanil|dosage
41467485|NCT05951751|OTHER|TRI-MOM intervention|"The TRI-MOM strategy includes 4 main activities:~1. Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services)~2. Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests~3. Assessment and treatment of women positive for any of the 3 targeted infections~4. Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections"
41467486|NCT03105934|PROCEDURE|Patients with Pulmonary Arterial Hypertension|2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
41467487|NCT02119052|DRUG|octeotride|
41467488|NCT02119052|DRUG|placebo|
41467489|NCT04544137|BEHAVIORAL|BOKS|BOKS is an evidence-based physical activity program developed by Reebok to get kids active and establish a lifelong commitment to health and fitness. It was originally developed and tested as a 12-week program offered before or after school. In the present study, BOKS will be offered four days per week for eight weeks over the summer at a public park in one low-income community. The program will run one-hour prior to lunch service by the USDA's Summer Food Service Program. The BOKS curriculum includes lesson plans for 40-45 minute classes that follow the same daily format and focus on a functional fitness skill of the week (squat, plank, push up, etc) and engage participants in team-oriented games.
41467490|NCT01376037|DEVICE|Erchonia(r) ML Scanner (MLS)|The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.
41467491|NCT01376037|DEVICE|inactive placebo laser device|non-therapeutic light application
41467492|NCT01858987|PROCEDURE|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
41467493|NCT01858987|PROCEDURE|LigaSure hepatectomy|Liver resection using LigaSure for transection of the parenchyma
41467494|NCT01858987|DEVICE|Ligasure|
41467495|NCT01858987|OTHER|vascular staple|
41467496|NCT04414033|DEVICE|Bubble: A New VR-AI Way of Treatment for Hot Flashes|Bubble Bubble is a virtual reality (VR) mobile application. Bubble offers a psychological intervention based upon cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) protocols. The bubble mobile application offers the intervention in a virtual reality (VR) coaching environment and in a winter wonderland setting called Frosty. Frosty provides both a virtual reality winter wonderland experience as well as guided meditation. The cold, winter-like experience is designed to help patients calm down and feel cooler.
41467497|NCT00316394|DEVICE|Preventive Care Checklist Form|
40992527|NCT04680689|DIAGNOSTIC_TEST|2D Cardiac Transthoracic Echocardiography|2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions
40992528|NCT04680689|DIAGNOSTIC_TEST|Laboratory Blood tests|Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry
40992529|NCT06386835|PROCEDURE|Collagen Paste|Collagen paste injection
40992530|NCT06386835|PROCEDURE|Mucosal advancement|Mucosal advancement flap
40992531|NCT02453958|DEVICE|Multi-modal assessment system|Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
40992532|NCT00791518|DRUG|No intervention|No intervention
40992533|NCT04708938|OTHER|High voltage electrical stimulation+exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
40992534|NCT04708938|OTHER|Exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
40992535|NCT00123539|DRUG|Estrogen Replacement Therapy|
40992536|NCT00123539|PROCEDURE|Surgery|
40992537|NCT01061242|BEHAVIORAL|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
41467498|NCT03126422|DRUG|Dexmedetomidine|Pretreatment of different doses of dexmedetomidine
41467499|NCT04906330|DIAGNOSTIC_TEST|Oncoliq: test for early breast cancer detection.|Oncoliq is a novel early detection breast cancer test based on liquid biopsies and miRNAs. The main advantage of this test is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.
41467500|NCT06046326|BEHAVIORAL|virtual community of practice|The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
41467501|NCT05841524|DIAGNOSTIC_TEST|Vector flow imaging measurement|Ultrasound measurement, using high framerate measurement techniques.
41467502|NCT01709812|OTHER|individualized patient support program|individualized patient support with compliance supporting tools
41467503|NCT01709812|OTHER|Standard care|
40788316|NCT05763680|DIAGNOSTIC_TEST|Molecular Culture|PCR based technique that amplifies the interspace region in bacterial DNA, that is located between the genes coding for 16S and 23S ribosomal subunits. Primers are used for the majority of known pathogenic phyla, i.e. FAFV, Bacteroidetes, Firmicutes and Proteobacteria. The nucleotide length of the Interspace region is species specific for bacterial single species. Bacteria all have one or multiple alleles for this interspace region. The combination of the amount of alleles, as well as the nucleotide strand length, makes for a specific profile that is distinctive for the species. Available software is able to match this profile to a particular pathogen, enabling confirmation and identification of bacteria in samples within 5 hours in our experimental workflow.
40788317|NCT03917030|PROCEDURE|Open flap debridement with osteoplasty|Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the toot.
40788318|NCT03917030|PROCEDURE|Open flap debridement without osteoplasty|Treatment of furcation grade II defect with open flap debridement only.
40788319|NCT00066053|PROCEDURE|Periodontal Treatment: SRP|Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.
40788320|NCT00066053|PROCEDURE|Referral|
40788321|NCT01760070|DEVICE|Hybrid knife|Use Hybrid knife in ESD procedure
40788322|NCT01760070|DEVICE|IT knife|Use IT knife in ESD procedure.
40788323|NCT00181844|DRUG|lamotrigine|Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children \<12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
40788324|NCT04851574|DRUG|Sugammadex Injection|Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.
40788325|NCT01674790|BEHAVIORAL|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
40788326|NCT01674790|BEHAVIORAL|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
40788327|NCT01674790|BEHAVIORAL|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
40788328|NCT01674790|BEHAVIORAL|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
40788329|NCT02287194|DEVICE|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
40788330|NCT00666081|DRUG|GSK690693|Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
41467504|NCT02371096|DRUG|MabThera (rituximab)|
41467505|NCT02371096|DRUG|RGB-03|
40788331|NCT02102958|BEHAVIORAL|DSME with Nonvisual Foot Examination|Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
40788332|NCT02102958|BEHAVIORAL|DSME with Usual Foot Examination Instruction|DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
40788333|NCT02854995|PROCEDURE|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
40788334|NCT02854995|PROCEDURE|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.\[5\] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
40788335|NCT02837471|DEVICE|PiezoRx medical grade pedometer|"Participants will be asked to freely use the PiezoRx medical grade pedometer for 12 weeks.~Participants have access to a personal account created online and can record the daily steps count and physical activity.~Participants will receive the standard care by the FrancoForme Cardiovascular rehabilitation and prevention program"
41467506|NCT03588650|DRUG|HLX20|a Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (PD-L1) Protein
41467507|NCT02632175|BIOLOGICAL|Adalimumab|every other week or weekly subcutaneous injection
41467508|NCT02216799|DRUG|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
40788336|NCT03912610|DIAGNOSTIC_TEST|Functional magnetic resonance examination|Functional magnetic resonance examination by a Ultra high field magnetic resonance instrument named MAGNATOM 7T.
40788337|NCT02533310|OTHER|OST treatment with in-vivo spiders|Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
40788338|NCT02533310|OTHER|VR-OST treatment with virtual spiders|The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
40788339|NCT05579730|DRUG|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo
40788340|NCT05579730|DRUG|Ketotifen fumarate ophthalmic solution 0.035%|Ketotifen fumarate ophthalmic solution 0.035%
40788341|NCT05579730|DRUG|Brimonidine tartrate ophthalmic solution 0.025%|Brimonidine tartrate ophthalmic solution 0.025%
40788342|NCT05579730|DRUG|Vehicle ophthalmic solution|Vehicle ophthalmic solution
40788343|NCT02282228|DEVICE|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100.
40788344|NCT06406244|DEVICE|TEAS group|Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30 min before anesthesia until be discharged from the post-anaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
40788345|NCT06406244|DEVICE|sham group|Patients in the sham group will receive electrode attachment but without stimulation.
40788346|NCT05882006|OTHER|gallstones|fellow up if the patients have gallstones
40788347|NCT00835458|PROCEDURE|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
40788348|NCT03243565|BIOLOGICAL|OM-85|OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.
40788349|NCT03243565|BIOLOGICAL|Placebo|Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate
40788350|NCT02799550|BIOLOGICAL|allogeneic CART-19|allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
40788351|NCT00719992|PROCEDURE|coronary angiography|effect of level of HS-CRP
40788352|NCT04708886|DRUG|Romosozumab|Year 1 study drug
40788353|NCT04708886|DRUG|Alendronate|Year 2 study drug
40788354|NCT05837221|DIAGNOSTIC_TEST|Metagenomic sequencing|Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.
40788355|NCT05837221|DIAGNOSTIC_TEST|Metabolic analysis|Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host
40788356|NCT02971709|BEHAVIORAL|Shade Sail|Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.
40992538|NCT03854422|DEVICE|left position|colonoscopy will be performed in 3 different locations. Left position, the patient will be in the left-side position during the entire colonoscopy
40788357|NCT05374915|COMBINATION_PRODUCT|REM-001 photodynamic therapy|Infusion of REM-001 (iv) followed by light treatment to treatment field 24 hrs after infusion of REM-001
40788358|NCT01058239|DRUG|bortezomib|Given intravenously on days 1, 4, 8 and 11 of every cycle
40992539|NCT03854422|DEVICE|left supine position|Colonoscopy in the Left supine position
40992540|NCT03854422|DEVICE|dynamic position|Colonoscopy in the Dynamic position
41147631|NCT05287178|BEHAVIORAL|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
41467509|NCT02216799|DRUG|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
41467510|NCT05550792|DEVICE|optimizer smart|The CCM implantation procedure was performed in the right precordial region of the chest (the right subclavian area). Two active fixation Ingevity leads (Boston Scientific) were advanced via the right subclavian vein into the right ventricle (RV) and actively fixed to the right ventricular septum for ventricular sensing and delivery of CCM signals.
40992541|NCT03930446|DRUG|Ethanol|The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water
41147632|NCT03587272|DRUG|Alemtuzumab, low dose total body irradiation, Sirolimus|"The conditioning regimen (SUN regimen) will consist of alemtuzumab daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on Days -5 to -3) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."
40992542|NCT03930446|OTHER|Placebo|The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.
40788359|NCT01058239|DRUG|rituximab|given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
41147633|NCT00857909|DRUG|Amiloride|1 tablet twice a day
41147634|NCT00857909|DRUG|Spironolactone|1 tablet twice a day
41147635|NCT00857909|DRUG|Placebo|Placebo
41147636|NCT00857909|DRUG|Placebo and spironolactone|5mg twice daily
41147637|NCT00857909|DRUG|Spironolactone|25mg twice daily
40992543|NCT00574054|RADIATION|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
41147638|NCT03252899|OTHER|Survey therapists|A survey was conducted among therapists on upper limb treatment after stroke.
41147639|NCT03252899|OTHER|Survey patients|A survey was conducted among stroke survivors on upper limb treatment after stroke.
40992544|NCT05004155|DIAGNOSTIC_TEST|24 hour pH & impedance monitoring|24 hour pH impedance monitoring will be done on healthy subjects so that normative data specific to indian population can be generated.
40992545|NCT02258100|OTHER|Electronic Medical Record|Advent of EMR use for documentation of anesthetic care
41147640|NCT05982847|DIAGNOSTIC_TEST|Blood pressure screening|Blood pressure and anthropometric measurements will be performed in children and adolescents between ages 5-18 years to develop South African nomograms that will aid in the development of clinical practice guidelines to optimise hypertension care in South Africa youth.
40788360|NCT02580877|DRUG|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
40788361|NCT02580877|DRUG|500mg oral insulin crystals every other week|human insulin crystals in capsules
40788362|NCT02118519|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
40788363|NCT01436110|DRUG|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
40788364|NCT01436110|DRUG|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
40788365|NCT01436110|DRUG|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
40992546|NCT01277952|DEVICE|Deep Brain Stimulation|Brain pace maker, implanted in the brain
40992547|NCT00931749|DEVICE|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
40992548|NCT00931749|DEVICE|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
40992549|NCT06339073|DEVICE|mechanical ventilation|Abdominal trauma patients were treated with mechanical ventilation according to their conditions.
41147641|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo supervised CARE program
41147642|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo supervised TARE program
41147643|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo home-based stretching program
41147644|NCT03091842|OTHER|Informational Intervention|Receive instructional DVD and booklet of the flexibility exercises
41147645|NCT03091842|OTHER|Laboratory Biomarker Analysis|Correlative studies
41147646|NCT03091842|OTHER|Quality-of-Life Assessment|Ancillary studies
41147647|NCT03091842|OTHER|Questionnaire Administration|Ancillary studies
41147648|NCT05298709|OTHER|Hyperventilation and CO2 challenge|Subjects will also be asked to complete hyperventilation and CO2 breathing tasks based on instruction from the study investigators as described in study arm.
41147649|NCT01330472|DRUG|Xanax XR tablets 3 mg (sourced from Caugus)|Tablets, 3 mg, single dose
41147650|NCT01330472|DRUG|Xanax XR tablets 3 mg (sourced from Barceloneta)|Tablets, 3 mg, single dose
41147651|NCT02985476|OTHER|Health reports|Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.
41147652|NCT00993590|BEHAVIORAL|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
40788366|NCT03610854|DEVICE|Fitness Tracker|Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
40788367|NCT05016310|DIETARY_SUPPLEMENT|High Dose Vitamin D|High dose vitamin D: Subjects will receive 50,000 IU vitamin D2 weekly x 16 weeks followed by 4,000 IU of vitamin D3 daily with a goal 25(OH)D level of ≥45 but ≤80 ng/mL.
40788368|NCT05016310|DIETARY_SUPPLEMENT|Standard of Care Vitamin D|Standard of Care Vitamin D: Vitamin D will be supplemented to 25(OH)D levels, with a goal 25(OH)D level of \>30 ng/mL according to Endocrine Society Practice Guidelines.
40788369|NCT03533088|OTHER|Hospitalized rehabilitation|Patients will recive a rehabilitation prgram at the clinic twice in a week until the post-operative 12. weeks
40788370|NCT03533088|OTHER|Home-based rehabilitation|Patients will recive a home program once in a two weeks until the 6. weeks of post-operative period. Then will start to recieve a rehabilitation program ar the clinic once in a week auntil the 12. week of the post-operative period.
40788371|NCT02067507|BEHAVIORAL|Tailored education and referral|LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
40788372|NCT02067507|BEHAVIORAL|Staff training and patient reminders|AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities
40788373|NCT02067507|BEHAVIORAL|Clinic-level reminder systems|Northeast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder
40788374|NCT03149146|OTHER|Clinical Decision Making (CDM) Workshop|Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
40788375|NCT03149146|OTHER|Clinical Decision Making (CDM) Workbook|Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
40788376|NCT04294225|DRUG|Anastrozole|Given PO
40788377|NCT04294225|DRUG|Letrozole|Given PO
40788378|NCT06389058|OTHER|Recommendation for the diagnoses and treatment of Severe Asthma|No intervention planned in this phase for the patients. Recommendations to be developed for healthcare and condition.
40788379|NCT04764721|DEVICE|18F-FDG PET-CT|Enrolled patients in Neurocog-Covid will receive a 18F-FDG PET-CT
40788380|NCT03557125|OTHER|QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
40788381|NCT03557125|OTHER|Saline Skin Wheel|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
40788382|NCT01569815|DRUG|LCZ696|LCZ696 400 mg once daily
40788383|NCT06183489|DRUG|Elranatamab|Elranatamab will be administered via a subcutaneous injection (SC)
40788384|NCT03613155|OTHER|Administration of MEOPA as part of the care|Patients should be managed by a SMUR team from Toulouse and benefit from MEOPA administration as part of their management, with a view to analgesia for a painful complaint or prevention of induced pain (for example during mobilization or venous route).
40788385|NCT06549465|BIOLOGICAL|In-111 rosopatamab tetraxetan|A single dose of 148 ± 37 MBq In-111 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes.
40788386|NCT06549465|BIOLOGICAL|45 KBq/kg Ac-225 rosopatamab tetraxetan|45 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
41147653|NCT04217798|DRUG|Niraparib|Subjects will receive niraparib combined with oral etoposide (on day 1-20, every 30 days). After 6-8 cycles, oral etoposide will be terminated. Niraparib will be still given to subjects until disease progression, intolerable toxicity or withdrawal of informed consent.
41157030|NCT05456308|PROCEDURE|Hydrodistention during cystoscope|Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
41308700|NCT01182948|BEHAVIORAL|Aerobic Training|The aerobic training group will exercise on cardiovascular training equipment. The workload will be gradually increased up to 60% of the reserve heart rate. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
41308701|NCT01182948|BEHAVIORAL|Resistance Training|The resistance training group will perform different exercises on weight machines and free weights to exercise upper and lower extremity muscles. Participants will perform 8-10 different exercises each session, alternating abdominal, upper and lower extremity exercises. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
41308702|NCT02375633|DRUG|DW-330SR2|
41308703|NCT02375633|DRUG|Pelubiprofen|
41308704|NCT06503289|DEVICE|Cytosorb therapy|Extracorporeal treatment with cytosorb filter to patients diagnosed with rhabdomyolysis
40788387|NCT06549465|BIOLOGICAL|55 KBq/kg Ac-225 rosopatamab tetraxetan|55 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
41308705|NCT04991844|BEHAVIORAL|Intervention Group|Intervention group participants met once a week, for 2.5 hours, over a period of six weeks for the HES workshops. The HES workshops followed a scripted curriculum that incorporated information from the USDA's MyPlateTM, and the USDA 2015-2020 dietary guidelines. Participants were also taught goal-setting, problem-solving through brainstorming, group support, self-assessment and management of dietary and physical activity patterns.
40788388|NCT06549465|BIOLOGICAL|60 KBq/kg Ac-225 rosopatamab tetraxetan|60 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
40788389|NCT05601440|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
40992550|NCT01764568|BEHAVIORAL|Metacognitive Training (MCT)|The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz \& Woodward 2007a; Moritz \& Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8-module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
41147654|NCT06406361|BEHAVIORAL|stress management training|"-Nurses should have an idea about stress management training Awareness develops about the importance of attending sessions regularly. Nurses have information about the training program. Joint session dates are determined. The educator makes statements about himself and education. The benefits of education for nurses are explained. Nurses are informed about the general rules of education. The importance of regular attendance at sessions is emphasized. Privacy rules and limits are determined. The necessity of completing homework is explained. Nurses are enabled to share their feelings and thoughts. Ensuring that nurses are able to recognize stress and reactions to stress and identify sources of stress in individual and business life.~Being informed about the effects of stress and workload perception Being able to recognize the tension created by stress in the body Learning breathing and deep relaxation techniques to reduce or eliminate symptoms of stress"
41308706|NCT04281160|DEVICE|BeCare Mobile App|The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance
41467511|NCT06534931|PROCEDURE|High velocity low amplitude thoracic spine manipulation|Participants were supine on a treatment table. The chiropractor determined levels of apparent spinal dysfunction by means of static palpation. Participants were then asked to curl forward and bring their knees to their chest as the chiropractor placed a fist just inferior to the targeted level, anywhere between the T4 - T10 vertebrae. The participant was instructed to inhale and then exhale, at which point the chiropractor lowered the participant's torso back to the table and delivered a thrust using his body into his fist.
41467512|NCT06534931|PROCEDURE|Sham|A previously validated physiologically inert manual procedure to the thoracic spine
41467513|NCT00328679|DEVICE|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
41488634|NCT04467268|BEHAVIORAL|Sleep extension|The sleep extension programme was designed around four alternative assumptions: 1) that among this group of habitual short sleepers, extending time in bed (TIB) would represent a significant behavioral change to established night-time and daytime routines; 2) that for practical purposes (accommodating personal, family and work schedules) extended time in bed is best anchored against typical rise-times; 3) that sleep onset may represent a particular challenge for those advancing habitual bed-times by over 1 hour each night; and 4) that in consenting to the trial, participants were motivated to make and sustain behavioral change.
40788390|NCT05601440|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
40788391|NCT05601440|OTHER|Observation|Monitoring arm
40788392|NCT05601440|DRUG|Niraparib|Dose and schedule will be assigned at enrolment
40788393|NCT05601440|DRUG|Fulvestrant|Dose and schedule will be assigned at enrolment
40788394|NCT03725072|DRUG|Evobrutinib|Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib.
41488635|NCT05875220|OTHER|No intervention|No intervention
40992551|NCT01764568|BEHAVIORAL|Cognitive Remediation (CR)|The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
40992552|NCT04127786|BIOLOGICAL|Purified vero rabies vaccine - serum free - VRVg-2|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
40992553|NCT04127786|BIOLOGICAL|Purified inactivated rabies vaccine - Verorab®|Pharmaceutical form:Freeze-dried Route of administration: Intramuscular
41488636|NCT03929783|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CEM
40788395|NCT02433912|PROCEDURE|Test - Laterally positioned flap|Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
40788396|NCT02433912|PROCEDURE|Control-Coronally positioned flap|Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
40788397|NCT02433912|DRUG|750 mg paracetamol|Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
40788398|NCT02433912|DRUG|chlorhexidine gluconate|chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
40788399|NCT02491281|DRUG|LNA043|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
40992554|NCT04127786|BIOLOGICAL|Purified inactivated rabies vaccine - Imovax® Rabies|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
40992555|NCT00709774|DEVICE|Pacemaker Implantation|Implantation of right ventricular lead at septal or apex.
40992556|NCT04174911|DRUG|BOL-DP-o-08|BOL-DP-o-08 sublingual drops
40992557|NCT04174911|DRUG|Placebo|sublingual drops
40992558|NCT04495127|DRUG|Selumetinib|Selumetinib 25 mg/m2 BID
40992559|NCT03805022|DRUG|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
40992560|NCT03805022|DRUG|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
41147655|NCT02389894|DEVICE|Embol-X Embolic Protection Device|per the manufacturer's instructions for use (IFU).
41488637|NCT02930486|DEVICE|ZipTight suture endobutton|Zimmer Biomet ZipTight suture endobutton
40788400|NCT02491281|DRUG|Placebo|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
40788401|NCT00334568|DRUG|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
40788402|NCT00334568|DRUG|Placebo|Placebo
40788403|NCT02494635|OTHER|Laboratory Biomarker Analysis|Biomarker analysis
40788404|NCT04951102|BEHAVIORAL|Electronic Asthma Shared Decision-Making App|The electronic Asthma SDM App will ask questions related to medicine-related, non-medicine-related, and COVID-19-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment. They may also use the Asthma SDM app to find information about asthma, medication management, COVID-19 and COVID-19 vaccines.
40788405|NCT04951102|BEHAVIORAL|Shared Decision Making Physician Training Video|Training video to educate physicians on Shared Decision-Making and the use of Shared Decision-Making tools.
40788406|NCT04951102|BEHAVIORAL|Electronic Asthma Shared Decision-Making App- Patient Data|Data from the pre-visit electronic Asthma SDM app completed by the patients. Data includes medicine-related, non-medicine-related, and COVID-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment.
40788407|NCT04951102|BEHAVIORAL|Standard Care|Standard Care for asthma.
40788408|NCT01697085|DIETARY_SUPPLEMENT|Sea buckthorn oil|
40788409|NCT01697085|DIETARY_SUPPLEMENT|Placebo oil|
40788410|NCT00846846|DEVICE|Endeavor® Zotarolimus Eluting Coronary Stent System|Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
40788411|NCT04853914|DEVICE|HIFU treatment|HIFU treatment of Benign Prostatic Hyperplasia
41488638|NCT02930486|DEVICE|Tricortical 3.5 mm syndesmotic screw|Depuy Synthes 3.5 mm screw
41488639|NCT00409318|DRUG|Etanercept|50 mg SC q week
40788412|NCT01306643|DRUG|Idelalisib|Tablet(s) administered orally twice daily
40788413|NCT00563758|DRUG|tegaserod|
40788414|NCT03512574|DRUG|Pregabalin|One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery
41488640|NCT00409318|DRUG|Placebo|SC q week
41308707|NCT03994926|DEVICE|Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye|Device measures smooth eye pursuit and response to light flash after pt smokes cannabis
41308708|NCT03994926|DRUG|Cannabis cigarette - 4.0% THC|smoked cannabis 4.0% THC
40788415|NCT03512574|DRUG|Dexmedetomidine|One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery
40788416|NCT03512574|OTHER|Placebo|One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
40788417|NCT03512574|DRUG|Pregabalin and dexmedetomidine|One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
40788418|NCT00287950|DRUG|carboplatin|
40788419|NCT00287950|DRUG|cisplatin|
40788420|NCT00287950|DRUG|cyclophosphamide|
40788421|NCT00287950|DRUG|etoposide|
40788422|NCT00287950|DRUG|vincristine sulfate|
40788423|NCT00287950|PROCEDURE|adjuvant therapy|
40788424|NCT00287950|PROCEDURE|conventional surgery|
40788425|NCT00287950|PROCEDURE|neoadjuvant therapy|
40788426|NCT00287950|RADIATION|radiation therapy|
40788427|NCT03714438|DRUG|Medicago Sativa|Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.
40788428|NCT03714438|DIETARY_SUPPLEMENT|Placebo|Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.
40822906|NCT04983485|OTHER|Observational|Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
40822907|NCT02147223|DIETARY_SUPPLEMENT|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
40822908|NCT02147223|DIETARY_SUPPLEMENT|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
40822909|NCT00343369|DRUG|asparaginase|
40822910|NCT00343369|DRUG|cyclophosphamide|
41308709|NCT03614169|PROCEDURE|Implantation of a HIS-pacing lead|This intervention is attempted first
41308710|NCT03614169|PROCEDURE|Implantation of a LV-pacing lead|This intervention is attempted first
41308711|NCT00527215|DRUG|darbepoetin alfa|starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
41308712|NCT00244894|PROCEDURE|acupuncture therapy|Acupuncture treatments will be administered by a qualified practitioner twice a week for the first four weeks and once per week for an additional 6 weeks. Sterile, disposable Seirin needles will be placed bilaterally at the point Gallbladder 34, and along the spine at Bladder 15, Bladder 23, and Bladder 32. Low intensity electrostimulation at 2 Hz will be used for both Bladder 23 and Bladder 32. Points will also be placed unilaterally at Governing vessel 20, Heart 7, Pericardium 6, Liver 2, and Spleen 6
41308713|NCT00244894|PROCEDURE|fatigue assessment and management|Patients will utilize the Pittsburgh Sleep Quality Index (PSQI) to assess if the patient is an overall good sleeper or a poor sleeper.
41308714|NCT00244894|PROCEDURE|hot flashes attenuation|Patients will be asked to report hot flash frequency and severity daily using the hot flash diary (HFD) and hot flash severity guidelines (HFSG) throughout the treatment period.
40822911|NCT00343369|DRUG|cytarabine|
40822912|NCT00343369|DRUG|daunorubicin hydrochloride|
40822913|NCT00343369|DRUG|dexamethasone|
40822914|NCT00343369|DRUG|doxorubicin hydrochloride|
40822915|NCT00343369|DRUG|mercaptopurine|
40822916|NCT00343369|DRUG|methotrexate|
40822917|NCT00343369|DRUG|pegaspargase|
40822918|NCT00343369|DRUG|prednisolone|
40822919|NCT00343369|DRUG|teniposide|
40822920|NCT00343369|DRUG|thioguanine|
40822921|NCT00343369|DRUG|vincristine sulfate|
40822922|NCT00343369|RADIATION|radiation therapy|
40822923|NCT04422561|DRUG|Ivermectin Tablets|two doses 72 hours apart
40822924|NCT03794206|DEVICE|Vesair Balloon|Treatment with Vesair Balloon for one year
40822925|NCT00044681|DRUG|risperidone|
40822926|NCT06605508|PROCEDURE|Autologous Adipose Tissue-Derived Stem Cell Injection for Erectile Dysfunction|This intervention involves the use of autologous adipose tissue-derived stem cells (ADSC) to treat erectile dysfunction. The process begins with a minimally invasive liposuction procedure to harvest fat tissue from the participant\&#39;s own body. The harvested fat is then processed to isolate stem cells, which are subsequently injected directly into the erectile tissue of the penis. This approach aims to enhance erectile function by promoting tissue regeneration and improving blood flow. Unlike other treatments for erectile dysfunction, this intervention uses stem cells derived from the participant\&#39;s own fat, which may reduce the risk of immune rejection and offer a novel regenerative therapy option. The treatment is designed to address ED in patients who have not responded adequately to conventional therapies like PDE-5 inhibitors.
40822927|NCT02320812|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
41147656|NCT02389894|DEVICE|CardioGard Cannula|CardioGard Cannula, per the manufacturer's instructions for use (IFU).
40788429|NCT05219253|BIOLOGICAL|HZ/su|Two doses of the HZ/su vaccine administered intramuscularly, one each at Day 1 and Month 2.
40992561|NCT03805022|DRUG|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
40992562|NCT03805022|DRUG|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
40992563|NCT03805022|DRUG|At the discretion of the investigator|Drug at the discretion of the investigator.
40992564|NCT00415233|BIOLOGICAL|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
41308715|NCT00244894|PROCEDURE|management of therapy complications|Short Form Health Survey (SF-36) will be used to assess the patient's overall vitality.
41308716|NCT00244894|PROCEDURE|quality-of-life assessment|Hot Flash Related Daily Interference Scale (HFRDIS)will be used to self-report hot flash related quality of life.
41308717|NCT05649618|BIOLOGICAL|Tumor Infiltrating Lymphocytes|On day 0 patients will be intravenous infusion of TILs
41308718|NCT05649618|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen
41308719|NCT05649618|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
41308720|NCT05649618|DRUG|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.
41308721|NCT02367170|PROCEDURE|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation \>92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
41308722|NCT02367170|DRUG|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
40788430|NCT05219253|DRUG|Placebo|Two doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) administered intramuscularly, one each at Day 1 and Month 2.
40788431|NCT03774797|OTHER|Implementation Toolkit|Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
40788432|NCT02597530|DEVICE|TEAS|According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
40788433|NCT01308359|DRUG|IV glucose 5%|500 ml glucose 5% within 30 minutes
40788434|NCT01308359|DRUG|saline|saline
40992565|NCT00415233|RADIATION|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
40992566|NCT02540460|DRUG|LCB01-0371 800mg|LCB01-0371 800mg
40992567|NCT02540460|DRUG|LCB01-0371 800mg BID|LCB01-0371 800mg BID
41308723|NCT02367170|PROCEDURE|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
40992568|NCT02540460|DRUG|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
40992569|NCT02540460|DRUG|Placebo|Placebo
40992570|NCT06044376|COMBINATION_PRODUCT|Formula milk with triple Bifidobacterium probiotic strain|Formula milk with triple Bifidobacterium strain containing Bifidobacterium longum BB536 (6.9 x 10\^7 CFU/serving), Bifidobacterium breve M16-V (6.9 x 10\^7 CFU/serving), Bifidobacterium longum subsp. infantis M-63 (6.9 x 10\^7 CFU/serving).
40992571|NCT06044376|OTHER|Formula milk|Formula milk without any addition of probiotic strain
40992572|NCT03451877|GENETIC|TGFB1 AND LAMA1 GENE POLYMORPHISMS|we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
40992573|NCT01367158|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine|The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
40992574|NCT01367158|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine
40992575|NCT01367158|BIOLOGICAL|Tdap|Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection
40992576|NCT01324349|DEVICE|Veriset Hemostatic Patch|Topical hemostat
40992577|NCT01324349|DEVICE|Fibrin Sealant (TachoSil®)|Topical hemostat
41467514|NCT03547635|OTHER|AMNIOEXCEL Plus Amniotic Membrane|AMNIOEXCEL Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering. This product is an allograft tissue intended for homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AMNIOEXCEL Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271. All donor recoveries are performed by BioDlogics, LLC, and adhere to the regulations regarding HCT/P recovery and the screening and testing of the tissue donor as verified through supplier audits.
40788435|NCT00955474|DRUG|Quetiapine|Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
40788436|NCT00955474|DRUG|escitalopram|"Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
40788437|NCT00955474|DRUG|Sertraline|"Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
40788438|NCT00955474|DRUG|Citalopram|"Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m."
40788439|NCT02209935|OTHER|Early Rehabilitation Protocol|
40788440|NCT02209935|OTHER|Usual care|
40788441|NCT01705340|DRUG|Akt inhibitor MK2206|Given PO
41467515|NCT03547635|DEVICE|A Marketed Comparator|bi-layered skin substitute: the epidermal layer is formed by human keratinocytes and has a well-differentiated stratum corneum; the dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice. It is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1-month duration and which have not adequately responded to conventional ulcer therapy. This product is also indicated for use with standard DFU care for the treatment of full-thickness neuropathic DFUs of greater than three weeks' duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.
41467516|NCT03547635|OTHER|Standard of Care|"* Coban™~* Conforming gauze~* Optifoam® non-adhesive dressing~* Cotton Gauze~* Normal saline (liquid or gel)~* Non-adhering dressings~* Steristrips~* An offloading boot (Pneumatic Short Leg Walker), as appropriate"
40788442|NCT01705340|BIOLOGICAL|trastuzumab|Given IV
40788443|NCT01705340|DRUG|lapatinib ditosylate|Given PO
40788444|NCT01705340|OTHER|laboratory biomarker analysis|Optional correlative studies
41147657|NCT05540639|BEHAVIORAL|Modified Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by video, by a leaflet and at a website.
40788445|NCT03364231|DRUG|Umbralisib|Oral Daily Dose
40788446|NCT06167967|DIAGNOSTIC_TEST|ctDNA methylation|A blood-based circulating tumor DNA methylation assay that uses 6 different methylation markers, SEPT9 region1, SEPT9 region2, BCAT1, IKZF1, BCAN and VAV3.
40788447|NCT06167967|DIAGNOSTIC_TEST|standard treatment|This group was treated according to standard procedure
40788448|NCT01254448|DRUG|TC-5619|Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
40788449|NCT01254448|DRUG|Placebo|Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
40788450|NCT02540590|DEVICE|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
40788451|NCT02540590|DEVICE|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
40788452|NCT00051207|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|
40788453|NCT00051207|BEHAVIORAL|IPT for Depression with Co-occurring Panic and Anxiety Symptoms (IPT-PS)|
40788454|NCT06070818|OTHER|Healthy Body & Mind Program|12-week physical activity and lifestyle education program
40788455|NCT04160312|DIETARY_SUPPLEMENT|Mitopure™ (Proprietary Urolithin A)|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
40788456|NCT04160312|DIETARY_SUPPLEMENT|Pomegranate Juice|100% Pomegranate juice (approximately 1 glass equivalent)
40788457|NCT05752097|DEVICE|[18F]AlF-NOTA-FAPI-04 PET/CT examination|The intravenous radiotracer dose is 1.85-2.59 MBq/kg, and imaging will be performed 50-60 min after radiotracer injection. All patients are required to urinate as much as possible for imaging preparations, which reduces the influence of the residual radiotracer in the renal pelvis and calyces. Some patients with poor renal function (GFR\<60 mL/min, urine volume \< 1000 mL/24 h) will be given diuretics (Furosemide, 0.57 mg/kg). The scope of the whole-body inspection is from the base of the skull to the base of the thigh, using five to six beds (3 min/bed). The matrix was 128×128, the PET layer thickness was 3 mm, and all PET images are reconstructed iteratively.
40992578|NCT00196079|DEVICE|Coronary stent|
40992579|NCT00323492|DRUG|Truvada|Truvada + NNRTI or PI.
41147658|NCT00209053|PROCEDURE|Coronary Artery Bypass|
41147659|NCT04282863|PROCEDURE|RM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained. Trocar sites varied according to different procedures. Generally, umbilical site for the scope and 8-10 cm lateral to the scope at 15 degrees for the arms are the most commonly adopted sites for robotic myomectomy.
41467517|NCT01363011|DRUG|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
40788458|NCT05752097|PROCEDURE|Renal puncture biopsy|The patients undergo renal puncture biopsy one day after PET/CT examination. Pathological results of renal biopsy will be collected after surgery, including but not limited to: pathological diagnosis, proportion of glomerulosclerosis, extent of inflammatory cell infiltration, and degree of renal interstitial fibrosis.
40788459|NCT02164526|OTHER|Routine therapy|Routine therapy
41467518|NCT01363011|DRUG|COBI|COBI 150 mg tablet administered with food orally once daily
41467519|NCT01363011|DRUG|ATV|ATV 300 mg tablet administered orally once daily
41467520|NCT01363011|DRUG|DRV|DRV 800 mg tablet administered orally once daily
40788460|NCT03754322|DIAGNOSTIC_TEST|LAMP|LAMP testing involves taking a blood specimen using venous puncture, extracting DNA and performing a commercial CE-marked LAMP malaria assay to obtain a malaria result (presence/absence of parasite DNA) at the species level
40788461|NCT03754322|DIAGNOSTIC_TEST|Microscopy/RDT|Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
40788462|NCT02645565|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
40788463|NCT02645565|DRUG|Azathioprine|azathioprine will be given at 2 mg/kg.
40788464|NCT02645565|DRUG|Methylprednisolone|Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
40788465|NCT01658085|DEVICE|ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
40992580|NCT00323492|DRUG|Current HAART regimen|Maintain baseline regimen
40992581|NCT03304847|OTHER|ablation|radio-frequency applications on arrhythmogenic substrate
40992582|NCT04226066|BIOLOGICAL|T601|"Part1: T601 is injected once (Day1). Dose range: 1E+7, 3E+7, 1E+8, 3E+8, 1E+9pfu.Trial cycle: Day1-21.~For part1, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
41308724|NCT02367170|DEVICE|Inspiratory Muscle Strength Training (IMST)|"Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise."
41467521|NCT01363011|DRUG|NRTI|Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
41488641|NCT03591003|DIAGNOSTIC_TEST|Yellow fever neutralizing antibodies measure|Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
41488642|NCT00158600|BIOLOGICAL|alglucosidase alfa|IV infusion of 20mg/kg; qow for 78 weeks.
40992583|NCT04226066|COMBINATION_PRODUCT|T601+5-FC|"Part2: T601 is injected once (Day1). Dose range: MTD-2, MTD-1 and MTD of Part1. 5-FC is taken on Day5-18 for 14 consecutive days. Trial cycle: Day1-28.~Part3: T601 is injected 3 times (Day1, 8, 15). Dose range: MTD-1 and MTD, or MTD-2 and MTD-1 of Part2. 5-FC is taken on Day5-7, Day12-14 and Day19-32. Trial cycle: Day1-46.~Part4: Protocol revised based on results of Part1-Part3. Preliminary plan: 30 patients with gastric cancer, pancreatic cancer and hepatocellular cancer who have failed standard therapeutic options are enrolled (10 patients for each indication). Treatment plan is same as Part3.~For part2 and part3, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
41308725|NCT02367170|DEVICE|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
41308726|NCT02367170|PROCEDURE|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
40788466|NCT01658085|DEVICE|HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
40788467|NCT02905279|BEHAVIORAL|Biofeedback Relaxation Training|Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.
41308727|NCT02367170|OTHER|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
40788468|NCT02905279|BEHAVIORAL|Exposure Therapy|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.
40788469|NCT02905279|BEHAVIORAL|Exposure with Threat-Relevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
41308728|NCT05842070|PROCEDURE|Low-Intensity Egg Freezing Protocol|The low-intensity egg freezing protocol involves fewer ultrasounds, bloodwork and injections, contributing to a lower cost. Otherwise, this protocol does not differ significantly from the other routine high-intensity clinic protocols.
41308729|NCT05842070|PROCEDURE|High-Intensity Egg Freezing Protocol|The high-intensity egg freezing protocol is a routinely used clinic protocol where patients are coming for frequent ultrasounds and bloodwork, as well as more injections, contributing to a higher overall cost for egg-freezing.
41488643|NCT00158600|DRUG|Placebo|Placebo Comparator; qow for 78 weeks.
41488644|NCT02501434|DRUG|Continuous Low-Dose IV Unfractionated Heparin Infusion|Continuous intravenous infusion of a low-dose unfractionated heparin drip
41147660|NCT04282863|PROCEDURE|LM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained: a 10 mm port is inserted through the umbilicus to introduce the video-laparoscopic system. Other three accessory 5 mm trocar are inserted into the abdomen to the left lower quadrant, right lower quadrant, suprapubic area, for operative instruments and the suction irrigator cannula.
41308730|NCT03071224|DRUG|[18F] MNI-946|Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.
41308731|NCT03071224|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-946.
41488645|NCT05767606|BIOLOGICAL|NVX|Administration of NVX
41488646|NCT05767606|BIOLOGICAL|PCV20|Administration of PCV20
41488647|NCT05767606|BIOLOGICAL|Placebo|No intervention
41488648|NCT00435396|BIOLOGICAL|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
40788470|NCT02905279|BEHAVIORAL|Exposure with Threat-Irrelevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
40788471|NCT00003645|DRUG|Flutamide|10.8 mg intramuscularly once every 3 months for 12 months
40788472|NCT00003645|DRUG|Leuprolide Acetate|50 mg tablet orally daily for 12 months
40788473|NCT04718350|DRUG|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
41308732|NCT03988257|DIETARY_SUPPLEMENT|Imunoglukan PH4|Children allocated to experimental group will receive Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
40788474|NCT04718350|DRUG|milrinone at a dose of 50 mcg/kg|milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
40788475|NCT03306433|DEVICE|UDMA-K18 smooth surface sealant|The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
40788476|NCT00174850|DRUG|Gaitril|
40788477|NCT05197465|OTHER|Questionnaires|Participants will complete pain and quality of life questionnaires. Opioid consumption will also be assessed using validated questionnaires.
40788478|NCT02881736|OTHER|electroencephalographic,magnetic resonance imaging|
40788479|NCT01189344|DRUG|Levothyroxine|600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
40788480|NCT00769795|DRUG|IMC-A12|IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.
40788481|NCT00769795|DRUG|Bicalutamide|Bicalutamide 50 mg daily orally for 12 weeks
40788482|NCT00769795|DRUG|Goserelin|10.8 mg subcutaneous once
40788483|NCT06465290|DEVICE|Motor relearning training with wearable ankle robot|Ankle motor control relearning training under real-time feedback
40788484|NCT06465290|DEVICE|Passive stretching with wearable ankle robot|Passive stretching under intelligent robotic control
41147661|NCT02084589|OTHER|PCEA with basal infusion and demand dose using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
41308733|NCT03988257|DIETARY_SUPPLEMENT|Placebo (vitamin C syrup)|Children allocated to control group will receive a placebo: a vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
41147662|NCT02084589|OTHER|PCEA without basal infusion (demand only) using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
41147663|NCT01403922|DRUG|TC-5214|Tablet oral bid days 1 to 7
41147664|NCT01403922|DRUG|TC-5214|Tablet oral bid days 8 to 14
41308734|NCT01043185|DRUG|AZD3355|30 mg orally in the morning and 30 mg in the evening for 1 day
41308735|NCT01043185|DRUG|AZD3355|90 mg orally in the morning and 90 mg in the evening for 1 day
41147665|NCT05230056|BEHAVIORAL|PG|Shoulder Digital therapy
40788485|NCT06465290|DEVICE|Gamed-based active movement training with wearable ankle robot|Active movement training through movement games with robotic assistance
40788486|NCT06465290|DEVICE|Passive movement with limited wearable ankle robot|Passive movement in the joint middle range of motion
40788487|NCT06465290|DEVICE|Active movement training with limited wearable ankle robot|Active movement training without robotic assistance
40788488|NCT06465290|DEVICE|Ankle torque and motion measurement with limited wearable ankle robot|Ankle torque and motion measurement with no real-time feedback
40788489|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
40788490|NCT00938613|DRUG|Placebo|nasal spray, one spray per nostril at time 0
40788491|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
40788492|NCT04650230|DEVICE|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices|
40788493|NCT06363695|BEHAVIORAL|SafeCare Kenya|Adapted from SafeCare, this is a strengths-based program for parents with children ages 18 months through age 5, teaching parents skills and knowledge in three areas: 1) parent-child interactions, 2) child health, and 3) home safety.
40788494|NCT06363695|OTHER|Care as Usual by Community Health Volunteers|Community Health Volunteers support families with children up to age 5 around the physical health needs of family members, including delivering key health messages (e.g., importance of immunizations); treating minor injuries and illnesses; identifying/treating/referring common childhood illnesses (e.g., diarrhea, malaria); conducting home visits to evaluate the home environment and discuss improvements; and encouraging care at home and appropriate health seeking behaviors. These support services are not highly structured but rather tailored to the needs of each family.
41147666|NCT05230056|BEHAVIORAL|CTRL|Shoulder non-digital therapy
41308736|NCT01043185|DRUG|AZD3355|120 mg orally in the morning and 120 mg in the evening for 1 day
41308737|NCT01043185|DRUG|AZD3355|240 mg orally in the morning and 240 mg in the evening for 1 day
41308738|NCT01043185|DRUG|placebo|Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
40788495|NCT06515015|DEVICE|Endobronchial Silicon Spigots|The single-use endobronchial silicon spigot is injection-molded from implant-grade silicone and has a solid conical body. The endobronchial silicon spigot is used for the temporary occlusion of the target bronchus. It is delivered to the target bronchus through a bronchoscope using biopsy forceps, and the position of the blocker is adjusted to occlude the responsible bronchus leading to the pleural air leakage.
40788496|NCT01331681|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
40788497|NCT01331681|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
40788498|NCT01331681|PROCEDURE|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
40788499|NCT05632237|BEHAVIORAL|Family strengthening program|"Phase I: 2-day Family Strengthening Workshop. The specific topics included in the workshop include: emotions, Body Progressive Muscle Relaxation, body stretch, self care, apologizing, routines to promote attachment, teamwork, saving, delayed gratification, anticipating unexpected expenses, identifying family strengths and values.~Phase II: Case management with family strengthening curriculum. Curriculum is delivered over the course of four visits (about 3 months), some of which involve both caregiver and child while others are just for the caregiver. Topics included are using appropriate discipline, effective communication for family problem-solving, and home budgeting."
40788500|NCT00402844|DEVICE|Transvaginal mesh- PROLIFT®-system|
40788501|NCT00529269|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
40788502|NCT05856955|BEHAVIORAL|mHealth Coaching Intervention|The intervention uses a mHealth virtual tool that facilitates human-device interaction and is delivered by smartphone application. The program has coaching and education components that lead to chronic disease behavior change. It has been previously validated to improve self-management, medication adherence, and quality of life in individuals with CVD. The participant engages by selecting responses on the touch screen. In this manner, participants converse with the coach, develop a therapeutic alliance, and record responses. The investigators will institute behavior change methodology to enhance intervention efficacy.
40788503|NCT05856955|BEHAVIORAL|Enhanced Usual Care|Smart phone without health coach. A basic health application is installed on the smart phone provided to the participant.
41308739|NCT05099146|BEHAVIORAL|pictures|pictures with brushing technique demonstrated technique for proper brushing
40788504|NCT04649658|BEHAVIORAL|Prone position|Prone position maintained at least 3 hours/day
40788505|NCT04212078|DRUG|Levofloxacin Ophthalmic|0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
41308740|NCT05099146|BEHAVIORAL|video|video of brushing technique demonstrated technique for proper brushing
40788506|NCT04212078|DRUG|Cefuroxime|The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
40788507|NCT02626169|DRUG|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
41147667|NCT02784145|DIETARY_SUPPLEMENT|Resistant starch|
40788508|NCT02626169|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
40788509|NCT01471821|DRUG|antiretroviral treatment|antiretroviral treatment
40788510|NCT05238519|BEHAVIORAL|Motivational interview (MI)|"The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH."
40788511|NCT02184598|BEHAVIORAL|Cognitive training|12 weeks of cognitive training; 4 sessions/week; duration 30 min
41147668|NCT02784145|OTHER|Recommendation with regard to nutrition|Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
41147669|NCT05591937|BEHAVIORAL|Self-Guided Online Prevention|An online wellness program that contains self-guided online CBT prevention strategies with demonstrated efficacy for depression and anxiety in college samples. Participants can learn skills for coping with common stressful experiences and build resilience at their own pace.
41308741|NCT05099146|BEHAVIORAL|control|oral hygiene instructions provided
41308742|NCT04505696|OTHER|Speech-Language Pathology Presentation|45 minutes presentation on Speech-Language Pathology introduction and scope Introduction to speech and language Introduction to a range of disorders The scope of practice
41308743|NCT04655105|DEVICE|root canal rotary files|post operative pain evaluation using different rotary file system
41308744|NCT03017248|DRUG|Ketamine|ketamine
41308745|NCT03017248|DRUG|Placebos|0.9% normal saline
41308746|NCT03017248|DRUG|Morphine|Morphine
40992584|NCT03199027|OTHER|Adherence Club|Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
40992585|NCT05419076|RADIATION|Stereotactic Radiosurgery|All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.
40992586|NCT05419076|PROCEDURE|Cerebrospinal fluid collection|All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.
40992587|NCT03500133|RADIATION|No radiotherapy if CR at the end of chemotherapy.|Adapted chemotherapy without radiotherapy
40992588|NCT03500133|DRUG|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
40992589|NCT03500133|DRUG|Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
40992590|NCT03500133|RADIATION|IN 30Gy RT in case of PR at the end of chemotherapy|Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT
40992591|NCT03500133|DRUG|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
40992592|NCT03500133|DRUG|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
40992593|NCT03500133|DRUG|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
41147670|NCT05591937|BEHAVIORAL|Coach-Guided Online Cognitive Behavioral Therapy|An online digital therapy program that consists of online CBT modules supported by coaches through video chats. The modules are evidence-based and formatted into a unified approach for depression, anxiety and worry, panic, social anxiety, trauma and sleep dysregulation (developed as part of the University of California, Los Angeles (UCLA) Depression Grand Challenge). Lessons are designed to respond to participants' specific symptoms. Participants can access the system through any personal device (phone, tablet or computer) and speak to a certified student coach through remote video chat.
41147671|NCT05591937|BEHAVIORAL|Clinician-Delivered Psychological and Psychiatric Care|Evidence-based clinician-delivered CBT modules. Participants are connected to a team of clinicians who will evaluate participants' specific symptoms and create an individualized and tailored treatment plan. Treatment will include weekly sessions delivered through telehealth, and if deemed appropriate, participants may also have medication appointments.
41147672|NCT03618888|OTHER|Instructor-led training|The Instructor-led training contents a supervised practical training with a standard kit for training in BLS
41147673|NCT03618888|OTHER|Self-learning training|The self-learning training contents a standard kit for self-directed training in BLS
41157031|NCT06646705|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
41308747|NCT05915754|OTHER|Hip abductors stretching and strengthening exercises|Treatment consist of four stretches for the ITB including: ITB stretch with trunk side bend, ITB stretch with trunk side bend and upward lateral reach, trunk side bend with downward lateral reach and side lying leg adduction and Strengthening exercise plan involving the gluteal muscle groups. These exercises include clams, side-lying abduction, reverse clams and supine bridge
41488649|NCT03551496|COMBINATION_PRODUCT|Drug Eluting Stent - Below the Knee|Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm
40992594|NCT03500133|DRUG|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
40992595|NCT03500133|DRUG|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
40992596|NCT01897012|DRUG|Alisertib|Given PO
40992597|NCT01897012|OTHER|Laboratory Biomarker Analysis|Correlative studies
40992598|NCT01897012|DRUG|Romidepsin|Given IV
40788512|NCT02184598|BEHAVIORAL|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
40788513|NCT06405295|OTHER|no intervention|Observation of the prognosis of patients with different standard treatment protocols in the clinic without intervention
40992599|NCT04238351|DEVICE|Transnasal humidified rapid insufflation ventilator exchange|applying 40L of oxygen for 1min and afte that increase oxygen flow up to 70L for 1 min.
40992600|NCT04238351|DEVICE|Conventional face mask|applying oxygen using usual face mask
40992601|NCT03515772|DRUG|Co-administration of darunavir with a cardiovascular drug|Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).
40992602|NCT05150353|PROCEDURE|MRI|Wrist MRI
40992603|NCT02548520|OTHER|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
40992604|NCT00521768|BEHAVIORAL|Prolonged exposure|
41157032|NCT06178055|DRUG|KUS121 high dose|Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
41467522|NCT00097786|DRUG|Valsartan 160 mg + nateglinide 60 mg|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
40788514|NCT00394264|PROCEDURE|Soft Tissue|
40788515|NCT00394264|PROCEDURE|Myofascial release|
40992605|NCT04404855|OTHER|NGS + Antibiotic Recommendation|NGS results in addition to recommended antibiotic therapy made by infectious disease pharmacist
41488650|NCT03551496|DEVICE|Standard PTA Control Arm|The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
41488651|NCT01898325|DEVICE|Fibroscan|Fibroscan
40788516|NCT00394264|PROCEDURE|Counterstrain|
40788517|NCT00394264|PROCEDURE|Muscle energy|
40788518|NCT00394264|PROCEDURE|Sacro-iliac articulation|
40788519|NCT00394264|PROCEDURE|High-velocity, low amplitude|
40788520|NCT00833027|DRUG|sitagliptin phosphate|Sitagliptin 100 mg/day - tablet for 24 weeks
40788521|NCT02146131|DEVICE|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
40992606|NCT04404855|PROCEDURE|Standard of Care treatment|Subjects will have a standard of care urine culture and prophylactic antibiotic prescribed per routine care.
40992607|NCT01770561|DEVICE|Integrated sensor and infusion set.|Change patients from current devices to the Integrated sensor and infusion set.
40992608|NCT05819333|OTHER|Exercise Program + Respiratory Strength Training|Strength, Flexibility, Cardiovascular exercise + respiratory strength training
40992609|NCT05819333|OTHER|Exercise Program + Respiratory Relaxation Training|Strength, Flexibility, Cardiovascular exercise + respiratory relaxation training
40992610|NCT00409617|BIOLOGICAL|adalimumab|Adalimumab 40 mg Every Other Week dosing
40992611|NCT00409617|BIOLOGICAL|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
40992612|NCT03402685|DEVICE|ClearSight|Patients in the intervention group receive management of volume and vasopressor settings according to the non-invasive ClearSight system.
40788522|NCT02146131|DEVICE|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
40788523|NCT02869542|OTHER|Data collection|
40788524|NCT02311803|PROCEDURE|Preservation of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
40788525|NCT02311803|PROCEDURE|Excision of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
40788526|NCT00222144|DRUG|Gleevec and Taxotere|Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
40788527|NCT00934583|BEHAVIORAL|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
40788528|NCT05739292|BIOLOGICAL|EuNmCV-5|0.5mL single intramuscular dose on Day 0
40788529|NCT05739292|BIOLOGICAL|Menveo|0.5mL single intramuscular dose on Day 0
40992613|NCT02518867|OTHER|high intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.
40992614|NCT02518867|OTHER|low intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.
40992615|NCT02518867|OTHER|sham iTBS|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
41157033|NCT06178055|DRUG|KUS121 low dose|Participants will receive KUS121 low dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
40788530|NCT04384471|OTHER|Online survey|Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis
40788531|NCT05468281|OTHER|Checklist implementation|. Our strategies will include a) selection of local physician champions from the ED and cardiology; b) discussion of the goals of the study with the local physician groups; c) formal introduction of the CAEP Checklist to the physicians and nurses by means of presentations at staff meetings, emails, and an online video; d) development of an action plan to address local barriers to implementation; e) creation of a free smartphone application; f) regular reminders; and g) and distribution of charts of site compliance.
41308748|NCT05915754|OTHER|Posterior oblique sling strengthening exercises|Treatment consists of treatment A plus the intervention program of POSS consisted of four different exercises utilizing activation of the POSS. The intervention program focuses on one specific exercise each week that will progress in difficulty over the 4 weeks. The equipment used in the exercise progression included a blue, latex-free, medium-resistance theraband (TB), and the final exercise of the progression will include the use of a step stool. The TB will be used to increase the activation of the latissimus dorsi while simultaneously performing lower-extremity exercise to increase gluteal muscle involvement. The exercises are to be used in the 4-week progression.
41308749|NCT04424355|DIAGNOSTIC_TEST|Chest MRI|Patients referred by the primary care physician with suspected pneumonia
40788532|NCT01936883|RADIATION|HDR|High dose rate brachytherapy
40788533|NCT01936883|RADIATION|LDR|Low dose rate brachytherapy boost
40788534|NCT06512532|OTHER|fireworks eye injury|patients presented with eye injury during festivals due to fireworks
40788535|NCT05461599|DEVICE|SparkRx Mobile App|The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
40788536|NCT03154671|OTHER|Geriatric assessment and management|Each participant will receive a comprehensive geriatric assessment at baseline. Based on the issues identified, a tailored care plan will be developed with the participant to address the issues identified.
40788537|NCT01884363|OTHER|Once ounce per day of walnuts|
40788538|NCT03882593|PROCEDURE|Analysis of arterial filters after CPB|At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
41308750|NCT01975272|DRUG|Ferinject|
41308751|NCT01975272|DRUG|Ferrous fumarate|
40788539|NCT02901600|OTHER|Detection of the expression of DMTB1 by immunohistochemistry|
41147674|NCT04920045|OTHER|Red blood cell transfusion|All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
41147675|NCT02463292|OTHER|no intervention|no intervention
41308752|NCT01975272|DRUG|Placebo for ferrous fumarate|
41308753|NCT01975272|DRUG|Placebo for ferinject|
41488652|NCT03651258|BEHAVIORAL|Implementation of ALIJEU|"The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay."
40788540|NCT01964378|DRUG|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
40788541|NCT01964378|DRUG|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
40788542|NCT02132897|DRUG|Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose|Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
40788543|NCT02132897|DRUG|Tegretol CR 400 Single Dose-Auration CR 400 Single Dose|Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
40788544|NCT00102986|DRUG|Lopinavir/ritonavir|
40788545|NCT00572598|DRUG|4- [F-18] fluoropaclitaxel|4- \[F-18\] fluoropaclitaxel, \<84 micrograms, \<10 mCi, IV followed by PET/CT imaging
40788546|NCT02379195|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
40788547|NCT02379195|DRUG|Fludarabine|Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
40788548|NCT02379195|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 min on day 0
40788549|NCT02379195|DRUG|Interleukin-2|Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
40788550|NCT02379195|DRUG|Peginterferon alfa-2b|Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
41308754|NCT02796534|OTHER|Diagnosis of sleep apnea by oxymetry|
41308755|NCT03327753|BEHAVIORAL|Motor control exercises|The first stage of the treatment involves assessment of symptoms and implementation of a retraining program designed to improve activity of muscles assessed to have poor control and reducing activity of any muscle identified to be overactive. Participants are taught how to contract these muscles independently from the superficial trunk muscles and progress until the patient are able to maintain isolated contractions of the target muscles. During this stage exercises for breathing control, posture of spine and lower limb and movement are performed. The second stage of the treatment involved the progression of the exercises towards more functional activities. Throughout this process the recruitment of the trunk muscles, posture, movement pattern and breathing are assessed and corrected.
40788551|NCT02640027|PROCEDURE|Cast removal at home using a telemedicine tool|Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
40788552|NCT02648009|DRUG|Hyperpolarized (13) Pyruvate Injection|MRI with Hyperpolarized Pyruvate (13) Injection
40788553|NCT02648009|DRUG|Gadolinium|MRI with Gadolinium
40992616|NCT04868279|BEHAVIORAL|Web-Based Interactive Nurse Support Program Based on Health Promotion Model|Nursing education will be given on healthy behaviors such as nutrition, exercise, health responsibility and stress management according to the health promotion model. The researcher will make phone calls with the intervention group for 6 months (12 times in total), twice a month. During telephone interviews, individuals will be talking about the use of the website, the points that are not understood or need to be emphasized, their application of health promotion behaviors, the obstacles they experience during the application and the suggestions for this.
40992617|NCT01971450|DRUG|Iloprost (Ventavis, BAYQ6256)|
40992618|NCT03503721|PROCEDURE|BipolEP|the prostate will be transurethrally enucleated using a bipolar current
41467523|NCT00097786|DRUG|Valsartan 160 mg + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
41488653|NCT03275766|OTHER|DLPFC facilitatory|15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
41308756|NCT03327753|BEHAVIORAL|Graded activity|The program is based on activities that each patient identify as problematic and that they cannot perform or have difficulty performing because of their back pain. The activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Patients receive daily quotas and are instructed to only perform the agreed amount, even when they feel they are capable of doing more. Cognitive-behavioural principles are used to help patients overcome the natural anxiety associated with pain and activities. Physiotherapists use positive reinforcement, explain pain mechanisms and addressed negative behaviours and pain-related anxiety. A plan for managing relapses is developed between therapists and patients.
41147676|NCT02423707|DRUG|ALK Alutard Birch and/or 5-grasses|"3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use."
41147677|NCT02423707|DRUG|ALK Diluent|This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
41147678|NCT00110422|DRUG|Irbesartan|Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
41147679|NCT00110422|DRUG|Hydrochlorothiazide|Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
41147680|NCT04303858|DRUG|Eciskafusp Alfa|Participants will be administered eciskafusp alfa in different schedules.
40992619|NCT03503721|PROCEDURE|bipolarTURP|the prostate will transurethrally resected using a bipolar current
40992620|NCT02180412|BIOLOGICAL|Panhematin|Glucose loading
40992621|NCT02180412|OTHER|Glucose|Glucose is administered to both groups as routine care.
41147681|NCT04303858|DRUG|Atezolizumab|Participants will be administered 1200 mg of atezolizumab once every 3 weeks.
41308757|NCT05314218|DEVICE|Electrophysiology catheters and cables|"The Xtrem electrophysiology catheter was developed for diagnosis of cardiac arrhythmias. Their function is to collect by contact, electrical signals generated by the heart muscle.~Xtrem are inserted via femoral vena cava or via artery and can be used in two occasions:~* Exploration procedures for diagnosis alone~* Diagnosis before ablation procedure An extension cable is used to connect the catheter to a stimulation/ recording device."
41308758|NCT01869114|DRUG|Sirolimus|Given PO
41308759|NCT01869114|DRUG|Azacitidine|Given IV
41308760|NCT05138185|DEVICE|Exoskeleton assisted gait on a treadmill|Subjects were instructed to walk on a treadmill at a constant speed during trials of 5 minutes. All subjects carried out four trials: (1) NoExo: subjects only wore the sensors to acquire their basal motion; (2) Free: subjects wore the exoskeleton although the actuator was mechanically decoupled, so it enabled the free movement of the knee; (3) Echo: the device provided gait assistance following the Echo-control strategy; and (4) Pattern: the device provided gait assistance following the Pattern strategy. During trials, patients wore a safety harness that did not support any weight. Previously to the execution of the trials, the gait velocity was self-selected by the subjects to a comfortable level. Subjects rested between trials for five minutes. Healthy subjects also performed a previous trial under variable gait speed. They walked over the treadmill as in the NoExo condition, although the gait speed randomly varies from 1km/h to 3km/h in 0.2km/h steps for 15 seconds at least.
41308761|NCT00121992|DRUG|Docetaxel|
41308762|NCT00121992|DRUG|5-fluorouracil|
41308763|NCT00121992|DRUG|Doxorubicin|
40992622|NCT01057017|BIOLOGICAL|intervention|
40788554|NCT04044014|DEVICE|Gellan sheet|Gellan sheet.
40788555|NCT04044014|DEVICE|Gellan fluid gel|Gellan fluid gel.
40788556|NCT04044014|DEVICE|Mepitel One|Control dressing-- Mepitel One.
40788557|NCT05575700|DRUG|Ibuprofen|400 mg tablet three times daily
40788558|NCT05575700|DRUG|Placebo|tablet three times daily
40788559|NCT03579693|DIETARY_SUPPLEMENT|CoQ10|CoQ10 tablet
40788560|NCT03579693|DIETARY_SUPPLEMENT|Nicotinamide riboside|NR tablet
41147682|NCT05159726|OTHER|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
41147683|NCT00118937|DRUG|Metformin|Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
40788561|NCT03579693|DIETARY_SUPPLEMENT|Placebo|Sugar pill designed to mimic coQ10 and NR
40788562|NCT02478112|DEVICE|Biodegradable balloon implant|Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
41147684|NCT00118937|DRUG|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
40788563|NCT02560727|DEVICE|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
40788564|NCT02560727|DEVICE|colonoscope|FMT via colonoscope is the most common approach.
40992623|NCT00945581|OTHER|Experimental Nutritional Powder Formula|Powder twice a day
41147685|NCT00118937|DRUG|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
41147686|NCT03876678|OTHER|Lactobacillus salivarius AP-32|Taking 1 probiotic capsule two times everyday for 7 days.
41147687|NCT03876678|OTHER|Bifidobacterium animalis subspecies lactis CP-9|Taking 1 probiotic capsule two times everyday for 7 days.
41147688|NCT03876678|OTHER|Placebo|Taking 1 placebo capsule two times everyday for 7 days.
41147689|NCT02862288|DEVICE|Microwave ablation with Acculis Accu2i pMTA Applicator|
41147690|NCT00470990|DRUG|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
41147691|NCT01425697|OTHER|2% Chlorhexidine Gluconate cloths|2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
40992624|NCT00945581|OTHER|Placebo comparator|Powder twice a day
41147692|NCT01425697|OTHER|Standard of Care preoperative preparation.|Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
41147693|NCT03345199|OTHER|Inspiratory Muscle Trainer (IMT)|During the 10-week training period, participants will perform exercises using a Threshold Inspiratory Muscle Trainer (IMT) at 3 sets of 15 repetitions per day. The initial resistance of the IMT unit will be at 30% of participants' maximum inspiratory pressure (MIP). Resistance for the IMT unit will be increased progressively and adjusted weekly by a licensed physical therapist based on participant's MIP at baseline, Borg perceived rate of exertion, and symptoms.
41147694|NCT05793580|DEVICE|Vibrant Soundbridge active middle ear implant|active middle ear implant
41147695|NCT02774876|DEVICE|Patient's insulin pump|The patient's insulin pump will be used to regulate glucose levels.
41147696|NCT02774876|DRUG|Insulin|Patient's usual fast-acting insulin analog will be used.
41147697|NCT02774876|DEVICE|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
41147698|NCT02774876|OTHER|Single-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at IRCM at 6:30 am in a fasting state. At 7:00, single-hormone closed-loop will be initiated. At 8:00, if glucose levels are between 3.5 and 12.5 mmol/L, the meal will be served. Patients will have 20 minutes to consume the meal. If glucose levels are not in this target range, the meal will be delayed for a maximum of 45 minutes. If after 45 minutes, glucoses levels are still not between 3.5 and 12.5 mmol/L, the test will be cancelled and rescheduled. The test meals will be: 1) 75g of CHO; 2) 75g of CHO + 35g of protein; 3) 75g of CHO + 35g of fat; or 4) 75g of CHO + 35g of protein + 35g of fat. The intervention day will end at 13:00.
41147699|NCT03957759|DIAGNOSTIC_TEST|Structured self-monitoring during an altitude ascent and stay at high altitude|Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).
41308764|NCT00121992|DRUG|Cyclophosphamide|
41308765|NCT04827836|PROCEDURE|Cooled eye drops and povidone-iodine|Cooled oxybuprocaine HCl 0.4% and lidocaine HCl 2% eye drops and cooled povidone-iodine (cul-de-sac 5% povidone-iodine and 10% povidone-iodine).
41308766|NCT00853333|DRUG|dexmedetomidine|
41308767|NCT00853333|DRUG|midazolam|
41308768|NCT00853333|DRUG|propofol|
41308769|NCT03331666|DRUG|Evolocumab|140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
40788565|NCT00259844|BIOLOGICAL|TroVax|
40788566|NCT05459441|BIOLOGICAL|Autologous progenitor expansion -T|After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.
40992625|NCT00366158|DEVICE|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
40992626|NCT00366158|DEVICE|Ventricular Intrinsic Preference|Programming of pacemaker
40992627|NCT01759108|DRUG|Rebamipide|Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
41147700|NCT00416858|DRUG|cisplatin|
41147701|NCT00416858|DRUG|fluorouracil|
41147702|NCT00416858|PROCEDURE|adjuvant therapy|
41147703|NCT00416858|PROCEDURE|conventional surgery|
41147704|NCT00416858|PROCEDURE|neoadjuvant therapy|
41147705|NCT00416858|RADIATION|radiation therapy|
41308770|NCT00547378|DEVICE|InterStim|
41308771|NCT00547378|DRUG|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
41308772|NCT04136561|DEVICE|Midline catheter|Midline catheter placed in patients with existing standard of care CVC
41308773|NCT05623904|PROCEDURE|Carotid Revascularization|Carotid Artery Stenting/Carotid Endarterectomy
41147706|NCT03185143|DRUG|Naltrexone and Acetaminophen Combination|Treat a single Qualified Migraine attack.
41308774|NCT05623904|DRUG|Medical Treatment|"Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment."
41488654|NCT03275766|OTHER|SMA inhibitory|1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
41147707|NCT03185143|DRUG|Sumatriptan 100 mg|One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
41147708|NCT03185143|DRUG|Placebo|One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
40992628|NCT04902755|OTHER|Questionnaire|validation of the French linguistic version and the cross-cultural adaptation of the NBSS-SF.
41157034|NCT06178055|DRUG|Sham procedure|Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
41157035|NCT05361083|DRUG|F18CETO|Injection of F18CETO or O15water followed by PET/CT
41157036|NCT04542642|DEVICE|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
40788567|NCT05459441|DRUG|pemetrexed|For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
41157037|NCT04542642|DEVICE|PEAR-008|PEAR-008 is a new, game-based version of reSET-O, a mobile application treatment for opioid use disorder.
41308775|NCT06553274|PROCEDURE|Individualized nutrition intervention|"After the patients were enrolled, they were given nutritional assessment by full-time clinical nutritionist and designed individualized nutritional management program, which included: Nutritional Assessment once a week for 4 weeks after Transplantation + 30 days, and nutritional assessment once a week for 4 weeks after Transplantation + 60 days, nutritional assessment every 2 weeks for 8 weeks; nutritional assessment every 4 weeks for 1 year after Transplantation + 120 days after transplantation; nutritional assessment during hospitalization in the ward and after discharge from the hospital, they were followed up in the nutrition counseling clinic or by telephone. The total energy intake was 25-35 kcal/kg/d and the protein intake was 1.2-1.5 g/kg/d. According to theFive-step nutritional treatment principle, individual nutritional prescriptions were designed by clinical nutritionists."
41308776|NCT01594632|DRUG|Jadelle|LNG containing subdermal contraceptive implant
41308777|NCT01594632|DRUG|Sino-implant (II)|LNG containing subdermal contraceptive implant
41308778|NCT01100996|OTHER|control enteral nutrition|This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates
41308779|NCT01100996|OTHER|enriched enteral feeding|This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
41308780|NCT03245723|PROCEDURE|Pulmonary Function Testing|Subjects will undergo Spirometry and Plethysmography
41308781|NCT03245723|PROCEDURE|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
41308782|NCT03245723|PROCEDURE|Positron Emission Tomography|Subjects will undergo positron emission tomography to detect images of the heart
41308783|NCT03245723|PROCEDURE|Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
41308784|NCT00572806|DRUG|insulin aspart|
41308785|NCT00660504|DRUG|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
41157038|NCT05295992|DEVICE|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
41467524|NCT00097786|DRUG|Nateglinide 60 mg + valsartan placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
41488655|NCT03275766|OTHER|SMA facilitatory|Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
40788568|NCT01968538|RADIATION|Radiation Therapy|
41157039|NCT05610319|DRUG|Faricimab|Faricimab will be administered via intravitreal injection.
41308786|NCT00660504|DRUG|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
41308787|NCT05509231|BEHAVIORAL|High-intensity exercise|Gross motor physical fitness activities to improve proprioceptive awareness, motor control, and coordination.
41308788|NCT05509231|DEVICE|Wearable glove and arm sleeve device to measure movement|Sign language and other fine motor skills activities using wearable technology.
40788569|NCT05865301|OTHER|Questionnaire for patients receiving therapy|Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.
40788570|NCT04015011|COMBINATION_PRODUCT|LCD Intervention|composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
40788571|NCT04579666|DRUG|Pegcetacoplan (APL-2)|Complement (C3) Inhibitor
40788572|NCT04579666|OTHER|Placebo|Sterile solution of equal volume to active arm
40788573|NCT02903823|DRUG|Baclofen bolus injection|A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
40788574|NCT01023217|DRUG|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
40788575|NCT01023217|DRUG|Entecavir|Entecavir 1 mg/day orally
40788576|NCT01023217|DRUG|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
40788577|NCT01842373|DRUG|LMX4|
40788578|NCT01842373|DRUG|BLT|
40788579|NCT00808392|BIOLOGICAL|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
40788580|NCT00808392|BIOLOGICAL|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
41147709|NCT06479499|OTHER|Pilates Exercises|Group A will undergo Pilates exercise training, scheduled three times weekly over an 8-week period, for elderly individuals with COPD the duration and time interval time for Pilates exercise can vary depending on their overall health, fitness level, and tolerance. It begins with warm-up with 10-15 minutes which may include gentle stretches and deep breathing Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The exercise sessions lasting around 10-15 minutes and then gradually progressing to 20-30 minutes as the participants become more comfortable and their endurance improves. Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The rest interval will be 1-2 minutes between exercise and then gradually reducing it to 30 seconds or less. Pilates session ends with a cool-down which may involve stretching and relaxation with duration of about 5-10 minutes.
41147710|NCT06479499|OTHER|Aerobic Exercises|Group B will engage in Aerobic exercise plan, following the same frequency and duration as the Pilates exercise program-three sessions per week for 8 weeks, It begins with a warm-up of 5-10 minutes to prepare body for exercise it includes gentle movements, stretching, or a few minutes of low-intensity aerobic activity. It includes main exercise with moderate intensity like brisk walking or jogging with duration of 5-10 minutes and increase to 20-30 minutes as participants improves their endurance. The short interval begins with 1-2 minutes than gradually reducing it to 30 seconds or less as a person builds up stamina and fitness. The cool-down duration at end of exercise will be 5-10 minutes.
41147711|NCT04750772|DIAGNOSTIC_TEST|18F-FDG and 68Ga-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
41147712|NCT04750772|DIAGNOSTIC_TEST|18F-FDG and 18F-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
41147713|NCT04233411|OTHER|Mycoprotein ingestion|
40788581|NCT02292537|DRUG|Nusinersen|Administered by intrathecal (IT) lumbar puncture (LP) injection
40788582|NCT02292537|PROCEDURE|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
40788583|NCT00503425|DRUG|Rituximab [MabThera/Rituxan]|1000 mg IV on days 1 and 15
40788584|NCT01302925|DRUG|PEP005 Gel|PEP005 Gel 0.05% for 2 consecutive days
40788585|NCT01302925|DRUG|PEP005 Gel|PEP005 Gel 0.015% for 3 consecutive days
40788586|NCT03346083|DRUG|Betrixaban|Factor Xa inhibitor.
40788587|NCT06255405|BEHAVIORAL|Self-compassion|The dyadic parent-child self-compassion program is designed by the research team and validated by a panel of experts. It includes 5 weekly sessions. Each session lasts for 60 minutes. The dyads will be guided to do self-compassion practices (e.g. affectionate breathing, compassionate letters to oneself etc). Didactic topics, inquiry, and home practices are also involved.
40788588|NCT05214066|DRUG|Rabbit ATG|ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.
40788589|NCT01370304|OTHER|active rTMS and active Venlafaxine|"rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
40788590|NCT01370304|OTHER|active rTMS and sham Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
40788591|NCT01370304|OTHER|sham rTMS and active Venlafaxine|"rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
40788592|NCT00997789|DRUG|Rebamide|Rebamipide 100 mg Tablet, three times a day
40788593|NCT03811522|OTHER|carbon dioxide insufflation|Receives CO2 insufflation
40788594|NCT03811522|OTHER|Air insufflation|Receives air insufflation
40788595|NCT01730612|DRUG|TF2 - 68 Ga-IMP-288:|ImmunoTEP
40788596|NCT05637177|BEHAVIORAL|Anging Wisely|The program includes 11 meetings of two hours in a group of up to eight people. The sessions are held weekly. Each lesson is given a homework assignment. A total of 10 groups will take place.
40788597|NCT05637177|BEHAVIORAL|Music therapy|Music therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 12. A total of 10 groups will be implemented.
41147714|NCT01796834|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
41467525|NCT00097786|DRUG|Valsartan placebo + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
41467526|NCT03730779|DRUG|Hyperoxia|Patients will receive nocturnal normobaric hyperoxia therapy
41467527|NCT00540358|DRUG|gemcitabine/carboplatin|Gemcitabine and carboplatin administered according to instructions in the package inserts.
41467528|NCT00540358|DRUG|iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
40788598|NCT05637177|BEHAVIORAL|Reminiscence therapy|Reminiscence therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 10. A total of 5 groups will be implemented.
40788599|NCT05637177|BEHAVIORAL|Cognitive training|"Intervention cognitive training will take place once a week for 45 minutes for 20 weeks. Seniors can choose from two options: 1. group training full-time or home training (online) using the comprehensive training program MENTEM."
40788600|NCT05637177|BEHAVIORAL|Educational activities|Interventions in educational activities will run for one academic year. In total, seniors will attend 16 lectures in each educational module. The lectures will run 1 x 14 days for 90 minutes.
40788601|NCT04357561|BEHAVIORAL|Exercise group (Schroth best practice)|Exercise program will be structured with scoliosis specific exercises (schroth best practice). Schroth best pratice is a pattern spesific scoliosis rehabilitation concept which aimes active self correction during curve pattern specific curve activities of daily life. Exercises for rotational breathing, everyday activities, spinal mobilization and corrective exercises will be specified based on the curve type and applied under the supervision of a physiotherapist.
40788602|NCT04361500|DEVICE|Seraph 100|Seraph 100 therapy during a COVID-19 infection
40788603|NCT03855345|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
40788604|NCT03855345|RADIATION|aPDT|aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F \& A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
40788605|NCT01393795|DRUG|Qutenza|8% patch
40788606|NCT01393795|DRUG|Tegaderm|No active drug
40788607|NCT06136143|PROCEDURE|Group 1: Autogenous bone graft|The maxillary sinus will be grafted with the autogenous bone graft.
40788608|NCT06136143|PROCEDURE|Group 2: Plenum® Osshp|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device.
41147715|NCT04213235|BEHAVIORAL|Physical activity|The participants will receive the written exercise guidebook and a counselling by kinesiologist. Moreover, they will be instructed how to increase their physical activity level.
41147716|NCT02883985|RADIATION|6 Gy/ fraction|"All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.~In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment."
41147717|NCT03829371|DRUG|Velcade|Subcutaneous use
41147718|NCT03829371|DRUG|Melphalan|Oral use
41147719|NCT03829371|DRUG|Prednisone|Oral use
41147720|NCT03829371|DRUG|Lenalidomide|Oral use
41147721|NCT03829371|DRUG|Dexamethasone|Oral use
41147722|NCT03829371|DRUG|Daratumumab|Subcutaneous Injection
41147723|NCT00005771|DEVICE|Visual utrasound feedback|
41467529|NCT02137382|DRUG|Creon®|active comparator
41467530|NCT02137382|DRUG|Creon N|experimental drug
41147724|NCT00005771|PROCEDURE|Abdominal Hollowing Exercise|
41147725|NCT02762786|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation.
41308789|NCT00649467|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose applesauce
41467531|NCT05694130|DRUG|Prednisolone|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
41467532|NCT05694130|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
41467533|NCT03123757|OTHER|6 Minute Walk Test|The 6 minute walk test measures the distance walked in 6 minutes without sitting and without the use of a walker or the help of another person (a cane may be used). The walk was conducted in a wide hallway, specifically designed for this type of assessment, with a defined 20-meter course. The subject walked back and forth in the hallway for six minutes and the distance covered was recorded.
41467534|NCT03123757|OTHER|EQ-5D Survey|The EQ-5D is a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity.
40788609|NCT06136143|PROCEDURE|Group 3: Plenum® Osshp; + i-PRF|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with i-PRF.
40788610|NCT06136143|PROCEDURE|Group 4: Plenum® Osshp + autogenous bone graft|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with autogenous bone graft.
40788611|NCT01998061|DRUG|EGFR tyrosine kinase inhibitor|Arm A
40788612|NCT01998061|DRUG|EGFR tyrosine kinase inhibitor with chemotherapy|Arm B
40788613|NCT00127881|DRUG|HuMax-CD4 (zanolimumab)|Monoclonal Antibody, 12 weekly infusions.
41147726|NCT03686176|OTHER|Virtual Reality|A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
41308790|NCT00649467|DRUG|Topamax® Sprinkle Capsules 25 mg|25mg, single dose applesauce
41308791|NCT05681195|DRUG|Pemetrexed|Participants will receive 900 mg/m\^2 via IV infusion over 10 minutes every 3 weeks x 4-8 induction cycles (21 days per cycle) as part of the induction therapy.
41308792|NCT05681195|DRUG|Zanubrutinib|"Participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 3-19 of each induction cycle x 4-8 cycles (21 days per cycle) as part of the induction therapy.~For those on maintenance therapy, participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 1-28 of each maintenance cycle (28 days per cycle) until the transplant (if applicable) or disease progression."
41308793|NCT05681195|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|ASCT will occur in participants who are candidates for this procedure according to standard of care institutional protocols
41308794|NCT05681195|RADIATION|Whole Brain Radiation Therapy (WBRT)|WBRT will occur in participants who are candidates for this procedure but not candidates for ASCT according to standard of care institutional protocols
41308795|NCT02734589|OTHER|Fecal transplantation|Transplantation of fecal bacteria from a healthy individual into a recipient- ulcerative colitis patient via colonoscopy and enemas
41308796|NCT02734589|OTHER|Unique novel Diet for UC and Unique novel Diet for the donor + FMT|A developed unique diet that is geared to induces remission and decreases inflammation in patients with active UC. Also a conditioning diet for healthy subjects to be used by the donor prior to transplantation- a developed unique diet for two weeks.
41308797|NCT02734589|OTHER|Unique novel Diet for UC|A developed diet that is geared to induces remission and decreases inflammation in patients with active UC.
41308798|NCT02076321|DRUG|Acetaminophen|acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
41308799|NCT02076321|DRUG|Ibuprofen|ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
41308800|NCT04265586|BEHAVIORAL|Education|"Sleep hygiene education is either face-to-face appointment or video-meeting with trained nurse."
41308801|NCT04265586|BEHAVIORAL|Web-based Cognitive Behavioural Therapy (iCBT)|iCBT is a web-based programme (7-16 weeks) designed to treat the symptoms of insomnia.
41467535|NCT03123757|OTHER|Short Physical Performance Battery|The SPPB is a brief performance battery based on timed short distance walk, repeated chair stands and balance test administered by trained examiners. The measurement goal for this battery is to assess lower extremity functional limitations, which indicate functional abilities and are a strong measure of risk for future disability.
40788614|NCT02897687|BEHAVIORAL|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
40788615|NCT02897687|BEHAVIORAL|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
40788616|NCT01291108|DRUG|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
40788617|NCT01291108|DRUG|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
40788618|NCT01291108|DRUG|bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
40788619|NCT01634217|BIOLOGICAL|iTreg|The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
40788620|NCT04350801|DIAGNOSTIC_TEST|home-based cognitive monitoring|a newly developed home-based cognitive monitoring (about 3-5 minutes per test; total score ranges from 0\~30; higher score indicates better cognition)
40788621|NCT02931838|DRUG|BMS-986165|
40788622|NCT02931838|DRUG|Placebo for BMS-986165|
41308802|NCT06257498|PROCEDURE|MRI scan|MRI scan on open scanner and some questionnaires
41308803|NCT06200987|DEVICE|Penile vibrator|In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months
41467536|NCT06239714|DRUG|SGB-3403|SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
41467537|NCT06239714|OTHER|Atorvastatin|The dosage of atorvastatin was determined by the investigator
41147727|NCT01201278|DRUG|Insulin|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
41147728|NCT01201278|DRUG|Insulin|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
41467538|NCT06239714|OTHER|Placebo|Normal saline 0.9%
40788623|NCT05035459|DIAGNOSTIC_TEST|lung ultrasound|drug adjustment based on lung ultrasound results
40788624|NCT05035459|DIAGNOSTIC_TEST|Lung ultrasound|drug adjustment independent on lung ultrasound results
40992629|NCT01012622|DRUG|Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride|OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
40992630|NCT05441527|DEVICE|MI Paste, then, Biotene Dry Mouth Gel|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
40992631|NCT05441527|DEVICE|Biotene Dry Mouth Gel, then, MI Paste|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
41147729|NCT01201278|DRUG|Insulin LISPRO|Subcutaneous insulin lispro 8 U
41308804|NCT06317233|BEHAVIORAL|Chronic Pelvic Pain Treatment Guide|The treatment guide includes mobile and web-based resources and applications specifically chosen to empower patients with information and to promote self-efficacy. The treatment guide is designed to be easily understood, visually appealing, and largely translatable from institution to institution. Patients using the treatment guide will be followed with a clearly defined follow up schedule, which includes touch points between appointments to aid with resource navigation.
41308805|NCT01260766|DEVICE|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
41308806|NCT01260766|DEVICE|Placebo Patch|same as active patch
41308807|NCT02008838|DIETARY_SUPPLEMENT|Synbiotic|
40992632|NCT02912234|DRUG|Apixaban|Multiple-dose clarithromycin and single-dose Apixaban
40992633|NCT02912234|DRUG|Clarithromycin|Multiple-dose clarithromycin and single-dose Apixaban
40992634|NCT04103632|DIAGNOSTIC_TEST|EVH test|"* Spirometry~* Skin prick test~* Peripheral blood test~* FeNO measurement"
40992635|NCT01566955|PROCEDURE|transgastric adnexectomy|adnexectomy transgastrically with transvaginal support
41147730|NCT03347084|DEVICE|Excitation|Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
41308808|NCT02008838|DIETARY_SUPPLEMENT|Placebo|
41308809|NCT04041076|PROCEDURE|Major surgical operation|Surgical operation with magnitude defined as major or ultra-major
41147731|NCT03347084|DEVICE|Inhibition|Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
41147732|NCT02161588|DRUG|semaglutide|Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
41147733|NCT02161588|DRUG|placebo|Once-daily oral administration as tablets.
41147734|NCT02699398|BEHAVIORAL|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
41147735|NCT02699398|BEHAVIORAL|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
41147736|NCT03397147|BEHAVIORAL|Sleep Coach Jr.|A brief sleep education program for parents of school-aged children with type 1 diabetes, with a focus on resolving sleep disturbances with parent education and positive bedtime routines.
41147737|NCT03852771|DEVICE|Cirvo(TM) therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression to the lower leg.
41147738|NCT04618653|OTHER|assessment only|Three assessment will include computerized assessments, interviews, and subset will provide daily reports of prescribed AA behaviors and practices
41147739|NCT03366727|DEVICE|drug-coated balloon catheter （Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
41147740|NCT03366727|DEVICE|plain balloon catheter (Admiral, medtronic)|After predilation, using plain balloon catheter to cover the whole treated segment
41308810|NCT01947049|OTHER|Rapid Influenza Testing with Xpert Flu|Participants with recieve rapid influenza testing with Xpert Flu
41308811|NCT00604058|BIOLOGICAL|Inactivated Poliomyelitis vaccine (IMOVAX)|Fractional dose (1/5th) 0.1 mL, intradermally
41308812|NCT00604058|BIOLOGICAL|Inactivated Poliomyelitis vaccine (IMOVAX)|A full dose, 0.5 mL, intramuscular
41467539|NCT01016340|DRUG|MCS|MCS-5 Softgel 5 mg
40788625|NCT03534882|OTHER|Discontinuation of topical prostaglandin analogue therapy|Participants are asked to discontinue their prostaglandin analogue eye drops for the designated time period (42 days)
40788626|NCT05529251|RADIATION|Radiotherapy boost|"Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :~* 20 Gy if no more disease is visible (node \< 1 cm in large diameter)~* 24 Gy for nodes \<= 2 cm~* 30 Gy for nodes \> 2 cm"
41467540|NCT00386815|DRUG|pemetrexed|
41467541|NCT00386815|DRUG|cisplatin|
41467542|NCT02278718|DRUG|NexoBrid|NexoBrid is an enzymatic debriding agent for Eschar Removal.
41467543|NCT02278718|PROCEDURE|Standard of Care|Surgical or Non-Surgical methods for Eschar Removal
41467544|NCT00536588|GENETIC|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10\^9 to 3 x 10\^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
41467545|NCT02419833|PROCEDURE|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
41467546|NCT02419833|PROCEDURE|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission
41308813|NCT03430817|DRUG|Citicholine|Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.
41467547|NCT02419833|DEVICE|Coronary artery stenting|Implantation of coronary stents
40992636|NCT00493584|PROCEDURE|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
41467548|NCT01355302|DRUG|E7050|E7050 given orally at either 200, 300, or 400 mg once daily.
41467549|NCT01355302|DRUG|cisplatin|Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.
41467550|NCT01355302|DRUG|capecitabine|Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
40992637|NCT00493584|PROCEDURE|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
40992638|NCT00471848|DRUG|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
40992639|NCT05048121|OTHER|Cosmetic Active Ingredient CLS02021|Topical, face application of the cream base with the CLS02021, two times a day in a period of 30 days
41308814|NCT03430817|DRUG|Amantadine|Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.
41308815|NCT04202562|PROCEDURE|Ab interno trabeculectomy|Ab interno trabeculectomy performed after pupil contraction and 90 degrees ablation of the nasal trabecular meshwork
41308816|NCT04202562|PROCEDURE|Cataract|Cataract surgery with minimal clear cornea incision and phacoemulsification
41467551|NCT02784171|DRUG|Cisplatin|
41467552|NCT02784171|DRUG|Pemetrexed|
41467553|NCT02784171|DRUG|Pembrolizumab|
41467554|NCT04869709|DRUG|Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses
41467555|NCT06060184|GENETIC|Next-Generation Sequencing (NGS)|Sequencing of genomes (Long read NGS)
41467556|NCT01909739|DRUG|atrovastatin|Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
41467557|NCT01909739|DRUG|Placebo|Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
41467558|NCT01811368|BIOLOGICAL|rituximab|Given IV
41467559|NCT01811368|BIOLOGICAL|ibritumomab tiuxetan|Given IV
41467560|NCT01811368|BIOLOGICAL|anti-thymocyte globulin|Given IV
41467561|NCT01811368|RADIATION|total nodal irradiation|Undergo TLI
41467562|NCT01811368|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
41467563|NCT01811368|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
41467564|NCT01811368|DRUG|cyclosporine|Given PO or IV
41467565|NCT01811368|DRUG|mycophenolate mofetil|Given PO or IV
41467566|NCT05318976|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week
40788627|NCT05529251|DRUG|Carboplatin AUC7|Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
40788628|NCT05529251|DRUG|3 cycles of EP|3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
40788629|NCT03250143|DRUG|cyclosporine vs azathioprine|Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
40788630|NCT02546583|DRUG|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
40788631|NCT02546583|DRUG|IV Chlorothiazide|
40788632|NCT03182283|BEHAVIORAL|Person-centered psychosis care|Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
40788633|NCT05446935|PROCEDURE|HITOC|Doxorubicin(dose: 25mg/m2) + Cisplatin(dose: 50mg/m2).
40788634|NCT04500119|BEHAVIORAL|Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator|Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried), apply intermittent electrical stimulation (Blackrock Cerestim)
40788635|NCT06059677|DRUG|Active smoked cannabis|Assessment of active cannabis smoking and driving impairment
40788636|NCT06059677|DRUG|Placebo smoked cannabis|Assessment of placebo cannabis smoking and driving impairment
40788637|NCT05807399|DRUG|BTZ-043|BTZ-043 1,000mg once daily.
40788638|NCT05807399|DRUG|Rifampicin|Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.
41308817|NCT06339736|OTHER|Questionnaires administered to all study participants|Ten treatment sessions were performed, which initially involved muscular stretching and relaxation exercises and then strengthening and endurance exercises to achieve stabilization. An oral splint was applied to he upper dental arch.
41308818|NCT02307721|DRUG|Intranasal naloxone|Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
41308819|NCT02307721|DRUG|Intramuscular naloxone|Administer 2 mL, dose intramuscular naloxone 0,8 mg
41308820|NCT02307721|DRUG|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
41308821|NCT02307721|DEVICE|Aptar Unidose|This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
41308822|NCT04019275|BEHAVIORAL|ENGAGE|ENGAGE blends social learning, guided discovery and skill training focused on community participation
41308823|NCT05968976|PROCEDURE|Awake DBS|55 patients receive awake DBS (current standard procedure)
41308824|NCT05968976|PROCEDURE|Asleep DBS|55 patients receive asleep DBS
41308825|NCT00191074|DRUG|somatropin, rDNA origin, for injection|
41308826|NCT03446937|DRUG|Dexamethasone Sodium Phosphate Injection|Dexamethasone sodium phosphate injection 12 mg X doses to be given 12 hours apart
41308827|NCT03446937|DRUG|Betamethasone Sodium Phosphate Injection (Medication)|betamethasone sodium phosphate injection12mg X 2 doses given 12 hours apart
41308828|NCT03446937|DRUG|Water for injection|Two doses of intramuscular injection of water for injection given 12 hours apart
40788639|NCT05807399|DRUG|Isoniazid|Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.
40788640|NCT05807399|DRUG|Pyrazinamide|Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.
40788641|NCT05807399|DRUG|Moxifloxacin|Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2:.
40788642|NCT05074225|OTHER|Electrodesiccation and Curettage vs Excision|"Factorial Assignment.~At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS)."
41308829|NCT02370498|BIOLOGICAL|pembrolizumab|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
41308830|NCT02370498|DRUG|paclitaxel|80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
41308831|NCT04962737|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA.
41308832|NCT02104804|DRUG|Saxagliptin 5mg|Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
41308833|NCT02104804|DRUG|Placebo for Saxagliptin|Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
41467567|NCT05318976|DRUG|Placebo|Placebo will be delivered by subcutaneous injection once a week
41467568|NCT00935831|DRUG|GSK1278863A|50mg, 150mg
40788643|NCT04445792|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
40788644|NCT04445792|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
40788645|NCT01882335|BEHAVIORAL|Peer support for exclusive breastfeeding|Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
40788646|NCT02155101|DRUG|Darunavir|Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.
40788647|NCT02155101|DRUG|ART with 2 NRTIs plus LPV/r (or ATV/r)|Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
40788648|NCT02246491|OTHER|A-T iPS cell line|Reprogramming A-T patients iPS cell line
41467569|NCT00935831|DRUG|Placebo|matching placebo
41467570|NCT05454358|DRUG|Letrozole 2.5mg|Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
40992640|NCT05048121|OTHER|Placebo PLC01021|Topical, face application of the cream base, two times a day in a period of 30 days
40992641|NCT05805787|OTHER|Acupressure|Acupressure will be applied to the elderly in the experimental group once a day, 5 days a week (Monday-Friday) for a week. The application will last for 2 weeks. A total of 10 sessions of acupressure will be applied. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the elderly are in supine position, pressure will be applied to each acupressure point, respectively, Tianshu (ST25), Guanyuan (CV4) and Hegu (LI4) for 2 minutes for a total of 6 minutes.
40992642|NCT00559520|DIETARY_SUPPLEMENT|Impact|"Patient receiving 3 drinks Impact a day during 5 days before surgery"
40992643|NCT00559520|DIETARY_SUPPLEMENT|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
40992644|NCT05847283|PROCEDURE|Dydrogesterone priming ovarian stiumulation protocol|Patients will be co-administered with oral DYG (Duphaston) 30mg/d and Human Menopausal Gonadotrophin (hMG) 225 IU/day (IU/d) via intramuscular injection from menstrual cycle day 2 - 4 (CD2 - CD4) to the day of final oocyte maturation.
40992645|NCT05847283|PROCEDURE|GnRH antagonist protocol|In the fixed GnRH antagonist protocol, hMG 225 IU will be administered daily from menstrual cycle day 2 - 4 (CD2 - CD4) and s.c. administration of GnRH antagonist (Ganirelix 0.25 mg) will be initiated daily on the 5th day of stimulation. Treatment with hMG and GnRH antagonist will be continued until the day of final oocyte maturation triggering.
40992646|NCT06240156|OTHER|3D arch pad design Insole group|3D three-dimensional design that is already available on the market (patent number I315187). Its arch support principle is designed using 3DBS (Three-Dimensional Biomechanics System - 3DBS), which can conform to the user's feet.
40992647|NCT06240156|OTHER|flat Insole group|General Insole without any special features
40992648|NCT02030379|BEHAVIORAL|QPL-CT|Use the QPL-CT to prioritize questions
40992649|NCT05184114|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Blood Tests|Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)
40992650|NCT02773927|DRUG|Metformin|Metformin in tablet presentation of 500 mg
40992651|NCT02773927|DIETARY_SUPPLEMENT|Agave inulin|Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
40992652|NCT02773927|OTHER|Placebo of agave inulin|Calcinated magnesia powder
40992653|NCT02773927|OTHER|Metformin placebo|Calcinated magnesia tablet
40992654|NCT05398432|OTHER|motivational interview|"After the pre-test data were applied to all patients, before starting the motivational interview seans, the patients were informed about the interview intervals, duration, and how many times they would be held. In the second week, motivational interview seans were started with the patients. seans with patients took place during the hemodialysis seans. A total of 6 seans were held, one seans per week. After the first seans of the self-care supported motivational interview, the Self-Care and Adaptation to Disease Training Guide prepared by the researcher in line with the literature was given to the experimental group. Self-care training was given in the first, second and third seans. Motivational interviews were conducted in the fourth, fifth and sixth seans. Motivational interviewing techniques were used for patients to realize their self-care activities. seans were held individually with the patients and each seans lasted approximately 15-20 minutes."
40992655|NCT02865993|OTHER|betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
40992656|NCT02865993|OTHER|no betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
40992657|NCT01838993|DRUG|Lidocaine inhalation|Lidocaine inhalation before intubation
40992658|NCT01838993|DRUG|Placebo|
40992659|NCT04618133|BEHAVIORAL|Early time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine
41467571|NCT04000243|DIAGNOSTIC_TEST|Endoscopic diagnosis of Hp|Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature
40788649|NCT02246491|OTHER|Carrier patients iPS cell line|Reprogramming iPS cell line from carrier patients
40992660|NCT04618133|BEHAVIORAL|Late time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine
40992661|NCT04618133|BEHAVIORAL|Active control|Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
40992662|NCT01972737|BIOLOGICAL|Ad5-hGCC-PADRE vaccine|A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
40992663|NCT04571775|DEVICE|Qi-Shield user group|real device Qi-Shield (treatment)
40992664|NCT04571775|DEVICE|Sham Qi-Shield user group|sham device (placebo)
40788650|NCT02949011|DRUG|Baloxavir Marboxil|Tablets taken orally
40788651|NCT02949011|DRUG|Placebo to Baloxavir Marboxil|Matching tablets taken orally
40788652|NCT02949011|DRUG|Oseltamivir|Capsules taken orally
40788653|NCT02949011|DRUG|Placebo to Oseltamivir|Matching placebo capsules taken orally
40788654|NCT03618667|DRUG|GC1118|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
40788655|NCT01790607|DRUG|ONO-2745 /CNS 7056|
40992665|NCT01424423|DRUG|Placebo|Placebo
40992666|NCT01424423|DRUG|GSK1223249|I.V. Infusion
40788656|NCT04393623|BEHAVIORAL|Cognitive Reappraisal|This cognitive reappraisal microintervention lasts 45-60 minutes.
40788657|NCT04393623|BEHAVIORAL|Psychoeducation|This psychoeducational microintervention lasts 45-60 minutes.
40788658|NCT06550882|DRUG|OBIZUR|OBIZUR injection.
41147741|NCT00670449|DRUG|Fingolimod|Fingolimod was supplied in capsules.
41467572|NCT02063308|DIETARY_SUPPLEMENT|Oxaloacetate (OAA)|
41467573|NCT00035555|DRUG|Belatacept|Solution, intravenous
40788659|NCT03130998|BEHAVIORAL|Remote Knowledge Broker (rKB)|The intervention is the tailored support received by a knowledge broker via technology in Group B. The rKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the rKB, learn new evidence, and work with the rKB on how to best implement the evidence.
40788660|NCT03130998|BEHAVIORAL|Emails|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
40788661|NCT06246305|OTHER|conventional physical therapy training|conventional therapy rehabilitation program is divided into three phases: on-brace, off-brace, and active mobilization. The on-brace phase (post-op 0-6 weeks) mainly consists of low-intensity whole-body exercises with shoulder girdle, elbow, and hand mobilization exercises on the affected side. The off-brace phase (post-op 6-9 weeks) consists of passive shoulder ROM exercises using an exercise stick and an early scapular stabilization exercise. The active mobilization phase (post-op 9-12 weeks) consists of both active and passive shoulder ROM , strengthening exercise with progressive resistance, and scapular stabilization exercises. The intervention is done 3 times per week for 12 weeks.
40788662|NCT06246305|DEVICE|Virtual Reality (VR) training|During the on-brace phase (0-6 weeks), participants in this group will use the program as performed in the control group. During the off-brace (6-9 weeks post-op) and active mobilization phases (9-12 weeks post-op), participants will use the Virtual Reality machine. this program involves warming up and down stretching exercises and exercise training that includes bilateral shoulder elevation, boxing, bowling and tennis games accompanied by avatar. The intervention is done 3 times per week for 12 weeks.
40788663|NCT02587832|DEVICE|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
40788664|NCT02587832|DEVICE|NCPAP|Bubble CPAP System.
40788665|NCT02393339|DRUG|paracetamol|Pre-operative administration of Paracetamol syrup
40788666|NCT02393339|DRUG|placebo|Pre-operative administration of placebo syrup
40788667|NCT05340530|DRUG|The injectable TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibatam.
40788668|NCT05340530|DRUG|meropenem|Meropenem is a carbapenem antibiotic
40788669|NCT05340530|DRUG|Avibactam Sodium|Avibactam is beta-lactamase inhibitor.
40788670|NCT05340530|DRUG|Placebo|It is a placebo.
40788671|NCT00484796|PROCEDURE|MED-SEP|intraoperative neurophysiological monitoring
40788672|NCT00484796|PROCEDURE|TRI-SEP|intraoperative neurophysiologic monitoring
40788673|NCT00484796|PROCEDURE|neuropsychological tests|neurological short- and longterm outcome
40788674|NCT04232982|PROCEDURE|Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).|Treatment will be applied over the limbal area to treat the ciliary body. The treatment will be delivered with an energy of 2000mW, a cycle of 31,33% and an on/off time of 0,5ms and 1,1ms. It will be delivered around a 360° surface with avoidance of the 3 and 9 o'clock areas. The treatment will be delivered during 80 secondes in each hemisphere and will be repeated twice, for a total of 320 secondes.
40788675|NCT04232982|PROCEDURE|G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)|"Treatment will be applied over the limbal area to treat the ciliary body. Sixteen (16) shots in total, which is four (4) shorts per quadrants, will be transmitted with a power from 1750 to 2000mV (titrating according to an audible pop) for a length of 2,0 secondes per shots. Treatment will be delivered around a 360° surface and avoiding the 3 and 9 o'clock areas."
41147742|NCT00379210|BEHAVIORAL|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
41147743|NCT00379210|BEHAVIORAL|Nutrition Education course|8-week course in nutrition
41147744|NCT02542202|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
41467574|NCT00035555|DRUG|Cyclosporine|Oral, capsule
41467575|NCT00035555|DRUG|Mycophenolate mofetil (MMF)|Oral, capsule
41467576|NCT00035555|DRUG|Corticosteroids|Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
41467577|NCT02630290|DRUG|Ropivacaine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
41467578|NCT02630290|DRUG|Ropivacaine + Dexmedetomidine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
41467579|NCT00014391|BIOLOGICAL|palivizumab|
41467580|NCT00014391|DRUG|ribavirin|
41467581|NCT05372497|OTHER|Intervention group (IG)|"Participants randomized to this treatment will receive a central nervous system-focused intervention consisting of a 20-session treatment program delivered in 30-45-minute sessions scheduled 5 days a week over a 4-week period and standard physical therapy will be continued.~* Chronic pain training will be given according to the needs of the person and 5-10 minutes will be allocated every day for the first week and chronic pain education will be divided into modules.~* Right / Left Discrimination Training~* Localization Training Level 1- Level 2 Training~* Visual imagination Training~* Visual Imagery Training~* Mirror Therapy~* Isometric and functional exercises"
41308834|NCT04745793|OTHER|Hyperspectral and Fluobeam acquisition|"Once enough exposure of the operative site is achieved, an RGB (Red Green Blue) picture will be taken and the surgeon will depict the parathyroid glands on it, this picture will act as ground truth. At this point, without changing the surgical exposure, a second surgeon involved in the study will attempt once to detect the parathyroid glands intraoperatively using the HSI system and the Fluobeam® alternatively. The number and the position of the parathyroid glands visualized with each tool will be compared to the number and position of the glands previously visualized by the operating surgeon. The procedure will be repeated every time the surgeon attempts to visualize the parathyroid glands. The order of the detection tools randomized for each case will be preserved in case of repeated visualizations."
40788676|NCT05922605|DRUG|S-ketamine & Ropivacaine|The experiment group (Group E) will receive a mixture of ropivacaine 0.2% 0.7 ml／kg and preservative-free S-ketamine 0.5 mg/kg caudally for postoperative analgesia.
41308835|NCT06293625|DRUG|Folfox|Folfox chemotherapy (folinic acid, fluorouracil and oxaliplatin) for 6 weeks (3 courses) before surgery.
41308836|NCT06293625|PROCEDURE|Surgery|Experimental arm: Surgery should take place 21 days after the last dose of neoadjuvant chemotherapy Control arm: upfront surgery as soon as possible
41308837|NCT04115046|DEVICE|ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS)|ShearWave Measurement is a software option available on the ARIETTA 850 that uses transient pulses to generate shear waves in the body. The tissue's elasticity is directly deduced by measuring the speed of wave propagation.
41308838|NCT04115046|DEVICE|FibroScan|manufactured by Echosens
41308839|NCT04115046|DEVICE|ALOKA ARIETTA 850 -|manufactured by Hitachi Healthcare - included on the system is the ShearWave measurement software
41308840|NCT02051894|DRUG|Dobutamine|"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."
41308841|NCT05300243|DIAGNOSTIC_TEST|HPV integration test|The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.
41308842|NCT03251287|DRUG|Sodium Nitrate|Single dose of 14mmol oral inorganic sodium nitrate
41308843|NCT03251287|DRUG|Placebo|Single dose of oral matching placebo
41308844|NCT03251287|DIAGNOSTIC_TEST|Phosphorous Magnetic Resonance Spectroscopy|On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
41308845|NCT03251287|DIAGNOSTIC_TEST|Exercise Stress Transthoracic Echocardiogram|On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
41308846|NCT05700071|DIAGNOSTIC_TEST|MRI|MRI without contrast agent
41308847|NCT05796427|BEHAVIORAL|SupporT for ADHD and Related Treatment|Intervention will include 6 modules typically taught over 6-7 weeks. Participants will have up to 3 months to complete the intervention. Modules will provide more knowledge on ADHD, discuss stigma around ADHD, address barriers in receiving care, encourage communication with physician and child, and empower caregivers. Overall, the goal being to improve engagement in ADHD treatment for newly diagnosed or unengaged families. This intervention is mostly targeted towards primary caregivers. However, the last module explicitly includes the child.
41308848|NCT04100798|PROCEDURE|Entire Papilla Preservation technique|A minimally invasive technique that allow access to the intrabony defect without affecting the interdental papilla related to it
41308849|NCT04100798|PROCEDURE|Modified Minimally invasive Surgical Technique|a minimally invasive technique that allow access to the intrabony defect area from the buccal aspect through a horizontal incision below the papilla without elevating it.
41308850|NCT00953043|DRUG|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
41308851|NCT00953043|DRUG|Placebo|Placebo medication given for three days
41308852|NCT00953043|OTHER|Bowel preparation|Polyethylene glycol-based bowel preparation
41308853|NCT03242083|OTHER|quality of life questionnaire|quality of life questionnaire
41308854|NCT00696657|DRUG|semaglutide|0.1 mg, once weekly, s.c. injection
41308855|NCT00696657|DRUG|semaglutide|0.2 mg, once weekly, s.c. injection
41308856|NCT00696657|DRUG|semaglutide|0.4 mg, once weekly, s.c. injection
41308857|NCT00696657|DRUG|semaglutide|0.8 mg, once weekly, s.c. injection
41308858|NCT00696657|DRUG|semaglutide|0.8 mg with titration, once weekly, s.c. injection
40992667|NCT03632278|BEHAVIORAL|Mindfulness psychoeducation Programme|"A MBPP will be conducted for 2 hours for each session, one a week for eight weeks. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien \& Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).~The programme will be integration of mindfulness and psychoeducation to cultivate the client's mindfulness attitude. The clients will learn to apply the mindfulness in illness management and daily difficulties."
40992668|NCT01179477|DEVICE|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
40992669|NCT04657614|OTHER|Neutral Alignment|Alignment that is a neutral replicate of the participants prescribed prosthesis.
40992670|NCT04657614|OTHER|Anterior Alignment|Alignment that is anterior displaced pylon.
41308859|NCT00696657|DRUG|semaglutide|1.6 mg with titration, once weekly, s.c. injection
41308860|NCT00696657|DRUG|placebo|0.1 mg, once weekly, s.c. injection
41308861|NCT00696657|DRUG|placebo|0.2 mg, once weekly, s.c. injection
41467582|NCT05372497|OTHER|Control group (CG)|"The control group will receive only conventional physiotherapy. Conventional physiotherapy will be 5 days a week.~The conventional physiotherapy treatment session will take place as follows.~* Electrotherapy~* Scapular mobilization~* Passive stretches~* Stick Exercises~* Pendulum Exercises~* Shoulder flexion, extension, internal rotation, external rotation, horizontal abduction/ adduction strengthening exercises~Conventional physiotherapy intervention is planned for 45-60 minutes a day, five days a week for both groups."
41467583|NCT03304340|DEVICE|functional electrical stimulation (FES)|Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.
41467584|NCT03304340|DEVICE|transcutaneous nerve stimulation (TENS)|Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device \& Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.
41308862|NCT00696657|DRUG|placebo|0.4 mg, once weekly, s.c. injection
41308863|NCT00696657|DRUG|placebo|0.8 mg with titration, once weekly, s.c. injection
41467585|NCT03304340|OTHER|standard rehabilitation (SR)|The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
41467586|NCT06267794|DRUG|Pirfenidone 1200 mg|1200 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
41467587|NCT06267794|DRUG|Pirfenidone 1800 mg|1800 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
41467588|NCT06267794|DRUG|Placebo|0 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
41467589|NCT06143462|DRUG|Usual care|Include anti-dizziness medications, diuretics, or hormone therapy.
41467590|NCT06143462|OTHER|Health Education|Include comprehensive health education, fall prevention and lifestyle adjustments.
41308864|NCT00696657|DRUG|placebo|1.6 mg, once weekly, s.c. injection
41308865|NCT00696657|DRUG|liraglutide|1.2 mg with titration, once daily, s.c. injection
41308866|NCT00696657|DRUG|liraglutide|1.8 mg with titration, once daily, s.c. injection
41308867|NCT00791440|BEHAVIORAL|Cognitive-Behavior Therapy|Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
41308868|NCT00791440|OTHER|Standard Psychiatric Treatment|Standard psychiatric treatment.
41308869|NCT06061887|OTHER|Fall evaluation|Evaluation of the frequency of falls in patients with acute stroke and determining the risk factors associated with recurrent falls within the first six months after stroke
41308870|NCT01155648|DEVICE|Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.|
41308871|NCT01155648|DEVICE|Chest wall compression for ten minutes in chest|
41308872|NCT04818814|BEHAVIORAL|Mindfulness Meditation App|Listening to audio-guided meditation sessions using a mobile app.
41308873|NCT04818814|BEHAVIORAL|Engagement and Distraction App|Listening to engaging and distracting videos of interest to the participant using a mobile app.
41308874|NCT03671824|OTHER|Measurements|Physiologic measurements including but not limited to thyromental distance, sternomental distance, Mallampati score, mouth opening, interincisor distance, and mandibular protrusion will be measured and recorded. All measurements are non invasive.
41308875|NCT01917110|DEVICE|omafilcon A|
41308876|NCT01917110|DEVICE|Spectacle|
41308877|NCT03298412|DRUG|Blinatumomab|Blinatumomab is administered as a continuous IV infusion.
41467591|NCT06143462|BEHAVIORAL|vestibular rehabilitation|Encompass office-based sessions of vestibular rehabilitation treatment once weekly, supplemented by home-based exercises conducted two or three times daily for the remaining duration of the study.
41467592|NCT02396290|PROCEDURE|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
41467593|NCT02396290|PROCEDURE|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
41467594|NCT01588535|DRUG|benzocaine|benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
41467595|NCT01588535|DRUG|placebo|placebo solution, five drops in affected ear canal each hour as needed
41467596|NCT02152462|OTHER|Exergaming|The participants in the Wii Fit exergaming group will be encouraged to meet and then maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. Goals per individual will be based on their baseline data. Exercise duration will increase gradually from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, women will maintain \>150 min/wk of moderate-intensity physical activity. The training will consist of 3 days/wk of supervised physical activity using Nintendo Wii Fit active videogames.
41467597|NCT05530941|BEHAVIORAL|Online suicide prevention campaign|The online prevention campaign consists of two campaign videos, a website with information about suicide prevention and mental health tailored to men, and testimonials of men who struggled with their mental health.
41467598|NCT04142619|BIOLOGICAL|UCARTCS1A|Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
41467599|NCT02463838|OTHER|Care Support Intervention|Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
41467600|NCT04927325|OTHER|Set of Photos|A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.
41467601|NCT00697801|DRUG|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
41467602|NCT00697801|DRUG|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
41467603|NCT00697801|DRUG|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
41467604|NCT05767216|OTHER|Biological sampling|Blood, skin and stool samples for laboratory analysis
41467605|NCT00810862|DRUG|pimecrolimus active cream|Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
41467606|NCT00810862|OTHER|placebo base cream|apply to affected study area twice daily for 21 days
41467607|NCT03255863|OTHER|Questionnaire|Patient Self reported questionnaire filled in.
41467608|NCT03716739|DRUG|Testosterone Cypionate 100 MG/ML|100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
41467609|NCT03716739|DRUG|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks.
40788677|NCT05922605|DRUG|Ropivacaine|The experiment group (Group C) will receive ropivacaine 0.2% 0.7 ml／kg plain and equial volume saline caudally for postoperative analgesia.
41308878|NCT00920595|DRUG|CEP-9722|Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
41467610|NCT06418997|BEHAVIORAL|CBI|CBI sessions follow a detailed manual to teach a group of peers cognitive and behavioral strategies that they may utilize in their daily lives, often based around the cognitive-behavioral model as a teaching tool. CBI aims to develop cognitive-behaviorally-based skills and habits in participants, such as behavioral activation, mood tracking, the identification and reframing of automatic thoughts, and assertion training.
41467611|NCT00115024|DRUG|Micronized 17B-estradiol|
41467612|NCT03907241|DRUG|Octanorm 16.5%|Human normal immunoglobulin
41467613|NCT03357354|BEHAVIORAL|collective workshop|diet, sports games, food budget, feeling of satiety and hunger, self-image
41467614|NCT04379284|OTHER|Biospecimen collection|"Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab."
41467615|NCT00004424|DRUG|fentanyl|
41467616|NCT00004424|DRUG|Midazolam|
41467617|NCT00004424|DRUG|propofol|
41467618|NCT00951951|PROCEDURE|Anterior Approach|Anterior Minimal Invasive Surgery (AMIS)
41467619|NCT00951951|PROCEDURE|Posterior Approach|
40788678|NCT01719848|OTHER|Measurements of parameters related with physical examinations for difficult airway prediction|
40788679|NCT01405183|OTHER|Hepatitis C testing|Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
41467620|NCT05248204|DEVICE|Scotchbond™ Universal Plus Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU+ treatment group will undergo restoration with Scotchbond™ Universal Plus Adhesive using self-etch mode and Filtek Universal Restorative
40788680|NCT00771212|OTHER|Observational pain control study|Observational pain control study
40788681|NCT02126046|GENETIC|unrelated CB following haplo-identical hematopoietic stem cells transplantation|
40788682|NCT00134615|BEHAVIORAL|RQP patient health education module|
40788683|NCT01896687|DEVICE|Scrambler|Electrotherapy
41467621|NCT05248204|DEVICE|Scotchbond™ Universal Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU control group will undergo restoration with Scotchbond™ Universal Adhesive using self-etch mode and Filtek Universal Restorative
40992671|NCT04657614|OTHER|Posterior Alignment|Alignment that is posteriorly displaced pylon.
40992672|NCT02290509|BIOLOGICAL|Flublok Quadrivalent|Intramuscular injection of study vaccine
40992673|NCT02290509|BIOLOGICAL|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of study vaccine
40992674|NCT05988398|BEHAVIORAL|READY To Stand Curriculum|Students will receive the RTS programming over six consecutive school days, spread over two weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
40992675|NCT01123109|PROCEDURE|3-D Endoanal Ultrasound|The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
40992676|NCT03830944|DIAGNOSTIC_TEST|Blood sampling|Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules
40992677|NCT03830944|DIAGNOSTIC_TEST|transthoracic echocardiography|Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.
41467622|NCT00939627|BIOLOGICAL|cetuximab|Given IV
40992678|NCT03830944|DIAGNOSTIC_TEST|Late Gadolinium-Enhancement Cardiac Magnetic Resonance|Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.
40992679|NCT03830944|DIAGNOSTIC_TEST|Coronary Angio Computed Tomography|Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
40992680|NCT03326492|DRUG|Antivenom serum Inoserp Pan-Africa® injection|Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.
40992681|NCT04354207|DIAGNOSTIC_TEST|Peripheral vein punction|Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood
40992682|NCT04354207|DIAGNOSTIC_TEST|Stool collection|Gut microbiome will be investigated in stool samples.
40992683|NCT04829877|BEHAVIORAL|Web-based mind-body intervention with HRVB|The web-based mind-body intervention with HRVB contains the following components: 1) Breathing training with HRV biofeedback; 2) 5 different topics will be included ; 3) Home exercise of slow breathing and mindfulness exercise.
40992684|NCT04829877|BEHAVIORAL|Web-based mind-body intervention|The web-based mind-body intervention will receive 5 different topics courses.
40992685|NCT02287558|DRUG|Pomalidomide|
40992686|NCT03987061|DEVICE|MOTIV BVS|MOTIVS BVS in below-the-knee artery disease
40992687|NCT01510379|DEVICE|Reletex|Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
40992688|NCT01510379|DRUG|IV ondansetron 4 mg q 6 hours for a total of 4 doses|
40992689|NCT01510379|DRUG|IV promethazine 25 mg q 6 hours prn|
40992690|NCT01510379|DRUG|Elixir promethazine 25 mg q 6 hours prn after discharge|
40992691|NCT06460649|OTHER|Progressive relaxation techniques|Participants received Progressive muscle relaxation along with Benson relaxing 3 times a week for 12 weeks. 36 sessions overall
40992692|NCT06460649|OTHER|Benson relaxation techniques|Participants received Benson relaxation techniques 3 times a week for 12 weeks. 36 sessions overall.
40992693|NCT00652236|OTHER|Physiotherapy|The two groups passed an in-patient rehabilitation and a physiotherapy: FCT function-centred vs. PCT pain-centred
41467623|NCT00939627|OTHER|placebo|Given orally
40992694|NCT00263068|DRUG|Rotigotine|"Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day"
40992695|NCT04000204|DEVICE|HYAJOINT Plus|60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
40992696|NCT04000204|DEVICE|Durolane|60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
40992697|NCT03011255|BIOLOGICAL|peptide specific CTL|Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
40992698|NCT05303584|BIOLOGICAL|Ad5-nCoV-IH|The orally aerosolized Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. The Ad5-nCoV vaccine was supplied in 1.5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. 0.1 ml of Ad5-nCoV vaccine will be aerosolized by using Continuous Vapouring System. Then, the aerosolized droplets will be poured into a disposable suction cup and be inhaled by participants through mouth.
41147745|NCT01375777|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
41147746|NCT01375777|DRUG|Ezetimibe|Administered orally once a day
41467624|NCT00939627|DRUG|sorafenib tosylate|Given orally
41467625|NCT00939627|OTHER|laboratory biomarker analysis|Correlative studies
41467626|NCT00939627|PROCEDURE|quality-of-life assessment|Ancillary studies
41147747|NCT01375777|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
41467627|NCT00681018|OTHER|Liquid human milk fortifier|Liquid human milk fortifier added to human milk
41467628|NCT00681018|OTHER|Powder human milk fortifier|Powder human milk fortifier added to human milk
41467629|NCT02758548|PROCEDURE|Blood sample|Fingerprick and venous
41467630|NCT02758548|DEVICE|POCT device|Investigational device
41467631|NCT03429049|DRUG|CNTX-4975-05|Receiving CNTX-4975-05 injection
41467632|NCT03429049|DRUG|Placebo|Receiving Placebo injection
40992699|NCT05303584|BIOLOGICAL|Ad5-nCoV-IM|The Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. It was supplied in 1·5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. Participants will be administrated 0.5ml（5×1010VP）of Ad5-nCoV vaccine intramuscularly.
40992700|NCT05303584|BIOLOGICAL|CoronaVac|CoronaVac is an inactivated whole-virion vaccine with aluminium hydroxide as the adjuvant, prepared with a novel coronavirus (CZ02 strain) inoculated in African green monkey kidney cells (Vero cells). One dose of CoronaVac contains 3 μg of SARS-CoV-2 virion in a 0.5 mL aqueous suspension for injection with 0.45 mg/mL of aluminium.
40992701|NCT03169647|BEHAVIORAL|Listening-based intervention|Participants will listen to pre-specified material on a CD
40992702|NCT00181961|DRUG|Maca Root|
40992703|NCT01527279|DRUG|antazoline|Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
40992704|NCT01527279|DRUG|0.9% saline|Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
40992705|NCT05188651|BEHAVIORAL|face masks|wearing face masks
40992706|NCT03471195|DIAGNOSTIC_TEST|Total Salivary Cytokine profile|Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.
40992707|NCT04643262|PROCEDURE|Sleeve Gastrectomy|Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or _____proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.
40788684|NCT01198782|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|Patients will dose 4 times daily for 4 months.
40992708|NCT01042730|DRUG|Pitavastatin 1 mg daily or 4 mg daily|Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
40992709|NCT00208936|DRUG|Taxol, Cisplatin, 5-Fluorouracil, G-CSF|
40992710|NCT02434731|DEVICE|Buzzy® device|Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
40992711|NCT01327300|DRUG|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
40992712|NCT01327300|OTHER|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
40992713|NCT02075658|DEVICE|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
40788685|NCT03756116|PROCEDURE|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
40788686|NCT03756116|PROCEDURE|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope.
40788687|NCT04346511|OTHER|Acupuncture|Patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.
40788688|NCT01206829|BEHAVIORAL|8-session CBTcourse|Hearing impaired workers voluntarily sign up for an 8 session cognitive therapy course. The study has a waiting list control group design. Participants will be randomized assigned to either an experiment group that will be offered to start on an immediate course, or a control group that will be offered the same course 12 months later.
40992714|NCT02075658|DEVICE|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
41147748|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, 400 to 500 calorie|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
41147749|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
41467633|NCT03424655|PROCEDURE|Twisted File Adaptive|Twisted file adaptive SM1 (size 20, .04 taper) and SM2 (size 25, .06 taper) were used serially with a single controlled motion according to the manufacturer's instructions.
41467634|NCT03424655|PROCEDURE|Balance Force|Flex-R files sizes 15-45 taper .02 were used according to the technique
40992715|NCT05795439|BEHAVIORAL|Low-fat, vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
40992716|NCT04461782|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Oral food supplement
41147750|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, bedtime|A single oral dose of 330 mg controlled release tablet administered at bedtime
40992717|NCT02820896|DRUG|Placebo|Participants will receive single or multiple doses of RO7105705 matching placebo IV.
40992718|NCT02820896|DRUG|RO7105705|Participants will receive single or multiple doses of RO7105705 IV or SC.
41147751|NCT01291524|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
41147752|NCT03734614|DRUG|Low dose of aspirin|Low dose of aspirin, 100 mg daily for longer than one year
41147753|NCT04783389|DRUG|CBP-201|CBP-201 subcutaneous (SC) injection.
41147754|NCT04783389|DRUG|Placebo|Placebo subcutaneous (SC) injection.
41147755|NCT03577054|BEHAVIORAL|HBB Prompt|Mobile app developed through user-centred design in phase 1 of this study
41147756|NCT03577054|BEHAVIORAL|Low-Dose High Frequency training|Participants will be encouraged to practice their HBB skills daily
41147757|NCT00318591|DEVICE|SpeediCath|hydrophilic coated urinary intermittent catheter
41467635|NCT03424655|PROCEDURE|WaveOne|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
41467636|NCT03424655|PROCEDURE|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
41467637|NCT01722955|OTHER|Pre-warmed fluids|IV fluid will be stored at 41℃ set hot cabinet for 8hours
41467638|NCT01722955|OTHER|Room temperature fluids|Room temperature fluid will be stored at ambient temperature
41467639|NCT04336332|COMBINATION_PRODUCT|Hydroxychloroquine Sulfate + Azithromycin|Given PO
41467640|NCT04336332|DRUG|Hydroxychloroquine Sulfate|Given PO
40788689|NCT01206829|BEHAVIORAL|8 session cognitive behavioral therapy|8 sessions cognitive behavioral therapy in group
40788690|NCT04357184|OTHER|Blood flow restriction training|BFRT is done with 4 exercises with low load resistance of 30% 1 repetition maximum
41467641|NCT05845957|OTHER|Digital Education Group|Providing training on safe pediatric intravenous drug administration with digital storytelling method
40788691|NCT04577911|OTHER|Basic Science Experiment|participants complete cognitive tasks while undergoing functional magnetic resonance imaging (fMRI)
41147758|NCT00318591|DEVICE|Conveen Uncoated|Uncoated urinary intermittent catheter
41147759|NCT01293201|DRUG|STAHIST|STAHIST dosed one tablet, BID
41147760|NCT01293201|DRUG|Placebo|Placebo identical in appearance to IMP, dosed one tablet BID
41147761|NCT04103476|COMBINATION_PRODUCT|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
41147762|NCT04103476|OTHER|Placebo|Placebo
41147763|NCT03036722|OTHER|Flaxseed|Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).
41147764|NCT03036722|OTHER|Placebo control porridge|control porridge matched for energy and fat content.
41147765|NCT03701022|DRUG|SHR1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
41147766|NCT03161509|DRUG|Paracetamol|single dose of 1 gr paracetamol
41467642|NCT05252247|OTHER|Immobilisation|Eight hours prior to attending the immobilisation session, a splint will be fitted to the hand of the participant and remain until the session start.
41467643|NCT05252247|OTHER|Exercise|Eight hours prior to attending the exercise session, the participant will be instructed to perform 150 ballistic finger movements every hour until the session start.
41467644|NCT00105495|DRUG|Ferriprox (deferiprone)|
40992719|NCT01353417|OTHER|In this observational study no study specific intervention is planned|Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
40992720|NCT04780854|DRUG|Metformin|Participants in the intervention group will be administered metformin tablets 2 gm daily during the chemotherapy treatment duration
40992721|NCT04780854|DRUG|Placebo|Participants in the placebo group will be administered metformin free tablet as placebo twice daily
41147767|NCT03161509|DRUG|Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)|Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
41147768|NCT03943771|OTHER|Anxiety, renal anatomy and surgery questionnaires|"The day before surgery, all the patients will be visited by a member of the investigator team for preoperative consultation and will be given a questionnaire evaluating their anxiety based on STAI and VAS scores. The two experimental groups will be offered their renal modelization to be manipulated (virtually or physically) before the questionnaire.~A second survey assessing basic renal anatomy and surgery understanding will also be completed by the patients.~Anxiolytics prescription prior to surgery will be collected inside the medical file."
41467645|NCT00105495|DRUG|Desferal (deferoxamine)|
41467646|NCT02540837|DRUG|Bupivacaine|Obturator nerve block
41467647|NCT02540837|DRUG|Saline|Obturator nerve block with saline(placebo)
40992722|NCT06162156|OTHER|Back massage|For the intervention group, massage will be given to the participant's back area by the researcher for 20 minutes, 12 hours after the cesarean birth. Preliminary data forms will be filled out by the participant before the massage. One hour after the massage, 'Visual Analog Scala' and 'Physiological Parameter Form' data will be filled in again. The final data forms will be filled out by the participant 24 hours after the cesarean birth, that is, 12 hours after the back massage.
40992723|NCT04368286|BEHAVIORAL|pulmonary rehabilitation|Pulmonary rehabilitation (respiratory rehabilitation) is a comprehensive intervention based on a comprehensive patient assessment, targeted to the treatment of patients, including but not limited to exercise training, education and behavior change, aimed at improving the physical and mental health of patients with chronic respiratory diseases and promoting long-term adherence to health-enhancing behaviors.
40992724|NCT01108133|DRUG|10 mg HydrocortisoneHöchst|10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
40992725|NCT01108133|DRUG|Dexamethasone|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.
40992726|NCT01108133|DRUG|Placebo|Placebo
40992727|NCT04283162|DRUG|Calcium Dobesilate|use calcium dobesilate at the dosage of 500 mg, orally, 3 times per day, for 12 months
40992728|NCT04283162|OTHER|conventional treatment|maintain lifestyle habits and the usual treatment
40992729|NCT06053294|OTHER|CS- Beverage|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose. Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
40992730|NCT06053294|OTHER|CS+Fast|(CS+): Flavored beverage solution with 110 calories of sucrose. Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
40992731|NCT06053294|OTHER|CS+Slow|(CS+): Flavored beverage solution with 110 calories of maltodextrin. Participants will consume flavored beverage solutions containing 110 calories of maltodexrin in 6 exposure sessions within 1 week.One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
40992732|NCT03981081|DRUG|Prednisone|Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
40992733|NCT01176266|DRUG|asfotase alfa|
40992734|NCT04160364|OTHER|qualitative study|qualitative research via guided interview
40992735|NCT05487742|DRUG|Dexmedetomidine|dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient
40992736|NCT05487742|DRUG|placebo salin infusion|salin infused as aplacebo for 72 hours
40992737|NCT06427356|BEHAVIORAL|PREVAIL Interdisciplinary Team|Patient meets simultaneously with an interdisciplinary team (IDT) five pain specialists and develops an individualized treatment plan based on Whole Health. Participants receive five months of coaching calls then return six months later for a follow-up visit with the IDT.
40992738|NCT02684266|DRUG|SHR6390|SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
40992739|NCT02596269|DRUG|Nefopam|120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
40992740|NCT02596269|DRUG|Saline|i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
40992741|NCT01923415|PROCEDURE|No intervention, skin biopsy|All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).
41147769|NCT06130605|OTHER|Data collection|Data collection
40992742|NCT01923415|PROCEDURE|No intervention, blood collection|Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.
40992743|NCT01923415|PROCEDURE|No intervention, urine collection|Urine will be collected from all participants.
40992744|NCT02647086|DRUG|Dupilumab|
40992745|NCT02647086|DRUG|Midazolam|Cytochrome P450 substrate
40992746|NCT02647086|DRUG|Omeprazole|Cytochrome P450 substrate
40992747|NCT02647086|DRUG|Warfarin|Cytochrome P450 substrate
41147770|NCT01701089|DRUG|11C-L-deprenyl-D2|Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
41147771|NCT01701089|DRUG|RO4602522|Multiple doses of RO4602522 for 14 days
41467648|NCT03825367|DRUG|Nivolumab|"The dose of Nivolumab will be 3 mg/kg which is the adult recommended dose and is the recommended dose in children in the phase 2 portion of COG ADVL1412.~If 3 mg/kg is not tolerated in combination with 5-azacytidine, the dose will be stepped down to 1 mg/kg."
41467649|NCT03825367|DRUG|5-azacytidine|75mg/m2 subcutaneously will be given daily for 7 days on days 1 to 7.
41467650|NCT00230191|DRUG|RK-0202|
40788692|NCT01086696|DRUG|FPAC|Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
40788693|NCT03646058|DRUG|Buprenorphine|Buprenorphine, 0.4mg pills, sublingual
41147772|NCT01701089|DRUG|RO4602522|Multiple doses of RO4602522 for up to 17 days
41147773|NCT05735197|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin which is (SGLT2 inhibitor) will be used as add on medication.
41467651|NCT00067171|BEHAVIORAL|Behavior Therapy|
40788694|NCT03646058|DRUG|Placebo|Placebo pills, sublingual, specifically made to mimick buprenorphine pills
40992748|NCT02647086|DRUG|Caffeine|Cytochrome P450 substrate
40992749|NCT02647086|DRUG|Metoprolol|Cytochrome P450 substrate
40992750|NCT05860283|DEVICE|Core stabilization exercise using pressure biofeedback unit|"From crook lying:~* 1st and 2nd weeks LEVEL 1: ADIM and hold for 10 seconds LEVEL 2 : Hold for 5 sec. Repeat 10 times. Opposite lower extremity on plinth; bent leg fall out.~* 3rd and 4th week LEVEL 3 : Opposite lower extremity on plinth a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~* 5th and 6th weeks LEVEL 4 : Hold opposite lower extremity at 90˚ of hip flexion a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~From prone lying:~Extension of each lower extremity. The exercise progression each week will be evaluated.Each exercise session lasted 20 min. The patients had to hold each exercise for 10 seconds, three sets per session and each set 10 repetitions."
40992751|NCT05860283|PROCEDURE|Diaphragmatic release technique|This technique will be given 3 days per week for 6 weeks with total technique duration of 45 minutes. The maneuver will be repeated in 4 sets per session, each set will consist of 5 deep breaths with 2-min intervals in between sets.
40992752|NCT01886183|OTHER|Virtual Reality Training|The participants of the study will be trained 8 balance games during 14 sessions
40992753|NCT01886183|OTHER|Physical Therapy|Patients of the control group will be trained with balance exercises.
40992754|NCT00441311|BEHAVIORAL|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
40992755|NCT05551494|DIAGNOSTIC_TEST|Urinary sample|"At study entry, we will collect urinary samples from women. Participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).~In addition, women will be asked to report about their habits about consumption of plastic"
40992756|NCT04941456|OTHER|Open Tracheostomy|Participants will perform the six minute walk test with an open tracheostomy. Participants will complete 1 to 3 session over approximately three-weeks.
40992757|NCT04941456|DEVICE|PMV in place|Participants will perform the six minute walk test with a PMV in place. Participants will complete 1 to 3 sessions over approximately three-weeks.
41147774|NCT05735197|DRUG|Placebo|Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
41147775|NCT00153374|BEHAVIORAL|Women's health|
41147776|NCT01918852|DRUG|Capecitabine|
41308879|NCT06063408|BEHAVIORAL|Cognitive Functional Therapy|"Cognitive functional therapy (CFT) is a novel intergraded behavioral approach for individualizing the management of spinal pain, targeting the bio-psycho-social factors of rehabilitation, and enabling the patient to self-manage the condition.~CFT lies within the broad spectrum of the biopsychosocial approach for the management of spinal pain. CFT uses a multidimensional clinical reasoning framework with aim to enable the clinician to identify modifiable components of the condition, evaluate patients' behavioral responses to pain, and compose and drive a tailored rehabilitation program mainly based on self-management. The intervention is comprised by the interplay on making sense of pain, exposure with control, and lifestyle change."
41308880|NCT06063408|BEHAVIORAL|Conventional Therapy|Each individual session involve a combination of pain management with electrotherapy, massage and relaxation techniques. Also include some posture exercise these will be targeted on body alignment to the neutral position, and strengthening the whole neck area. strengthening program will be include isometrics on all cervical movements with a band which progressively increase the resistance of the band by change it and process to exercise against the band resistant. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
41308881|NCT05525767|DRUG|Bevacizumab|All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
41308882|NCT01274442|OTHER|anamnesis|To update the anamnesis.
40788695|NCT06632782|BEHAVIORAL|Breath Awareness using pyramid|Participants are provided 1-2 hr training for 6 weeks on bringing breath awareness to the present moment using a pyramid
41147777|NCT01918852|DRUG|Teysuno|
41147778|NCT01918852|DRUG|Bevacizumab|
41147779|NCT06139419|RADIATION|definitive radiotherapy|Participants were treated with definitive thoracic radiotherapy
41308883|NCT01274442|PROCEDURE|oral examination|A brief clinical oral examination will be performed.
41308884|NCT01274442|PROCEDURE|Blood sample|A blood sample will be taken to identify relevant genetic polymorphisms.
41308885|NCT01962714|BEHAVIORAL|Loving-Kindness Meditation|12-week loving-kindness meditation course
40788696|NCT06011954|DRUG|Enfortumab Vedotin|Intravenous
40788697|NCT05189210|DRUG|GV1001 Placebo|0.9% normal saline
40788698|NCT05189210|DRUG|GV1001 0.56mg|Lyophilized peptide from hTERT
40788699|NCT05189210|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
41147780|NCT06139419|DRUG|induction chemo-immunotherapy|All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.
41147781|NCT06139419|DRUG|concurrent chemotherapy|Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).
41147782|NCT06139419|DRUG|Immunotheapy consolidation|Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.
41308886|NCT01962714|BEHAVIORAL|Cognitive Processing Therapy|12-week CPT course
40788700|NCT06119516|OTHER|Esophageal pressure-guided strategy,|A catheter-balloon system will be positioned and calibrated in all included patients. The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used. It allows both enteral nutrition of the patients and monitoring of esophageal and gastric pressures during several days. A connection line will be inserted between the catheter (either esophageal or gastric balloon port) and the auxiliary pressure port of the mechanical ventilator (General Electric, R860, available in each center). Numeric recording of the respiratory signals will be achieved via the OhmedaCom Research Tool software, helping for centralization of the analyses, therefore ensuring reproducibility of the results.
40788701|NCT00709150|BEHAVIORAL|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
41308887|NCT01082718|DRUG|Mefloquine Artesunate|Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
41308888|NCT03096223|DRUG|KHK4083|IV administration
40788702|NCT00709150|BEHAVIORAL|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
40788703|NCT00417768|DRUG|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
40992758|NCT05726396|DRUG|RMT|A single loading dose of RMT capsules containing \~5 x 10 11 bacteria on day 1 followed by 2 x 10 11 bacteria daily for 6 days. The RMT capsule preparation (\~2-5 capsules, size 00) is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
40992759|NCT05726396|DRUG|Placebo|Participants will receive an identical looking placebo capsules daily for 7 days (i.e 5 placebo capsules on day 1), followed by 2 placebo capsules daily from Day 2-7. The placebo capsule preparation is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
40992760|NCT02034955|RADIATION|Post-operative Adaptive Radiation Therapy|
40992761|NCT00233051|DRUG|Salmeterol or Salmeterol/Fluticasone|
40992762|NCT04903327|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
40992763|NCT04903327|DRUG|Placebo|Excipient solution
40992764|NCT01150123|BIOLOGICAL|Group B streptococcus (GBS) vaccine- low dose|
40992765|NCT01150123|BIOLOGICAL|Group B streptococcus (GBS) vaccine- High dose|
40992766|NCT01150123|BIOLOGICAL|Placebo- Saline|
40788704|NCT00417768|OTHER|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
40788705|NCT00375466|DRUG|Tranexamic acid|Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
40992767|NCT01527682|DRUG|Latanoprost, Dorzolamide|"* Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~* Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost"
40788706|NCT00375466|DRUG|placebo|0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
40788707|NCT00002343|DRUG|Ethambutol hydrochloride|
40992768|NCT00783601|DRUG|Comparator: MK0524 + placebo|Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
41308889|NCT03594487|DRUG|FMP30 Donor Stool|FMP30 is manufactured by the non-profit stool bank Openbiome. Each FMP30 filtered donor stool engraftment has approximately 12.5g of stool per 30mL of normal saline. It is homogenized in sterile normal saline.
41467652|NCT01619579|DEVICE|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
41467653|NCT03439631|OTHER|Patient satisfaction questionnaire|Patient satisfaction questionnaire
41467654|NCT05418634|OTHER|point of care EEG|For pocEEG, scalp electrodes are applied in five locations.
40992769|NCT00783601|DRUG|Comparator: MK0524 + montelukast|Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
40992770|NCT00783601|DRUG|Comparator: placebo + montelukast|Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
40992771|NCT00783601|DRUG|Comparator: Placebo|During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
40992772|NCT06419972|OTHER|multimodal physiotherapy programme|The intervention to which the climacteric women will be subjected will consist of a combined program of education and general strength and pelvic floor muscles exercises of 8 weeks duration, at a rate of 2 sessions/week. Each of the sessions will last 60 min, except for the first one, which will be 90 min.
41467655|NCT00512538|DEVICE|Bi-layered cell therapy (Apligraf)|
41467656|NCT04483531|DRUG|Odevixibat|A4250 is a small molecule and selective inhibitor of IBAT
41467657|NCT01931345|BEHAVIORAL|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
41147783|NCT06139419|DRUG|Thymosin Alpha1|"Participants in the Tα1 treatment group will receive Tα1 from the beginning of induction chemo-immunotherapy until the completion of immunotherapy consolidation. In detail, Tα-1 would be administered according to the following three stages:~1. Induction chemo-immunotherapy: Tα-1 will be subcutaneously administered at 4.8 mg on d1 and d3 for each cycle.~2. Concurrent chemoradiotherapy: Tα-1 will be subcutaneously administered at 4.8mg biweekly.~3. Immunotherpay consolidation: Tα-1 will be administered concurrently with tislelizumab at 4.8mg (Q3W) for up to 12 months."
41147784|NCT04910399|DIETARY_SUPPLEMENT|Blue fish hydrolysate|"The experimental product is a dietary supplement composed of a hydrolysate of fatty blue fish containing low molecular weight peptides and n-3 polyunsaturated fatty acids.~One of the two study groups (28 volunteers) will take 4 capsules of the active product (blue fish hydrolysate), for 90 days.~Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
41308890|NCT03594487|PROCEDURE|Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|Three doses of filtered donor stool engraftments homogenized in sterile normal saline (FMP30), obtained from the non-profit stool bank OpenBiome, will be administered via colonoscopy in patients with Relapsing-Remitting Multiple Sclerosis. FMT dosage via colonoscopy may include a lower amount of transplanted stool at the discretion of the study gastroenterologist if there are any peri-procedural safety or technical considerations. Total FMT dose (in milliliters) will be documented.
41308891|NCT03594487|OTHER|Observational Control|Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
41308892|NCT04907006|DRUG|SY-004 capsule|After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule（80mg） orally with 240ml warm water. The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.
41467658|NCT01931345|BEHAVIORAL|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
41308893|NCT06473337|DIAGNOSTIC_TEST|Blood sample|Serum blood sample for Vitamin D testing
41467659|NCT00001554|DEVICE|intraoperative infrared (IR) neuroimaging|
41467660|NCT04157972|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
41467661|NCT04157972|DEVICE|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
41467662|NCT05678738|DIETARY_SUPPLEMENT|Antioxidant Berry Supplementation|Participants who opt-in will be instructed to consume 300mL of the bioactive (antioxidant berry) supplement every morning and afternoon during days of participation.
41467663|NCT05678738|OTHER|Acute and Chronic Exercise-Heat Stress|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.
41467664|NCT05678738|DIETARY_SUPPLEMENT|Placebo (non-juice) Supplementation|Participants who opt-in will be instructed to consume 300mL of the placebo (non-juice) supplement every morning and afternoon during days of participation.
41467665|NCT05861219|BEHAVIORAL|water immersion|mild physical activity then water immersion in tub
41467666|NCT04028856|DRUG|interferon|Chronic hepatitis B patients were treated with interferon for 48 weeks
41467667|NCT06148779|BEHAVIORAL|Digitally delivered first-line treatment for osteoarthritis|Digitally delivered first-line for osteoarthritis through the caregiver Joint Academy.
41467668|NCT06148779|BEHAVIORAL|Face-to-face first-line treatment for osteoarthritis|First-line for osteoarthritis delivered at a primary care clinic face-to-face with reported data to the BOA registry.
41467669|NCT05073250|DRUG|IBI376|IBI376 is administered orally once daily at a dose of 20 mg for 8 weeks, followed by an oral dose of 2.5 mg once daily. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of IBI376 at an oral dose of 2.5 mg once daily.
41467670|NCT05073250|BIOLOGICAL|Rituximab|Rituximab is administered at a dose of 375 mg/m\^2 intravenously in the first 4 weeks, once a week. Subsequently, rituximab will be dosed once every 4 weeks. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of rituximab at a dose of 375 mg/m\^2 intravenously once every 4 weeks.
41308894|NCT02942095|DRUG|Ixazomib|"Dose Escalation Phase Starting Dose: Ixazomib 3.0 mg on Days 1, 8, and 15 of a 28-day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase"
41467671|NCT03264664|DRUG|E7386|Oral immediate release tablets.
41467672|NCT05952089|DRUG|Danicamtiv|Specified dose on specified days
41467673|NCT05952089|DRUG|Midazolam|Specified dose on specified days
41467674|NCT05308680|BIOLOGICAL|BNT162b2|Administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19
41308895|NCT02942095|DRUG|Erlotinib|Dose Escalation and Dose Expansion Phase: Erlotinib 150 mg by mouth on Days 1 - 28 of a 29 day cycle.
41467675|NCT05554172|DEVICE|taVNS|Participants will receive vagal nerve stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
41467676|NCT05554172|DEVICE|Sham|Participants will receive sham stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
41467677|NCT05151393|DIAGNOSTIC_TEST|Measuring vitamin D3 level|Measuring vitamin D3 in both groups
41467678|NCT00631007|DRUG|INT131 besylate|Once-daily, oral
41467679|NCT00631007|DRUG|Pioglitazone HCl|Once-daily, oral
41467680|NCT00631007|DRUG|Placebo|Once-daily, oral
41467681|NCT03547414|OTHER|Nephrocheck test|A fresh urine sample was collected on inclusion (maximum 6 hours after starting catecholamines) through the urine collecting tube and frozen at -80°C. At the end of the study, urine samples were thawed and centrifuged as recommended by the manufacturer and the urinary TIMP2\*IGFBP7 concentration was determined using the Nephrocheck™ test. The Nephrocheck™ test simultaneously measures into the Astute 140™ meter (a bench top analyzer) the urinary concentrations of TIMP2 and IGFBP7 on 100 µl of urine mixed with 100 µl of buffer. The result is expressed as a single number corresponding to the product of TIMP2 and IGFBP7 concentrations.
40788708|NCT00002343|DRUG|Rifabutin|
40992773|NCT00070265|DRUG|oxaliplatin|Given IV
40992774|NCT00070265|DRUG|capecitabine|Given orally
40992775|NCT00070265|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
40992776|NCT00070265|OTHER|laboratory biomarker analysis|Correlative studies
40992777|NCT04809220|DRUG|Dulaglutide|Administered SC
40992778|NCT04809220|DRUG|Oral antihyperglycemics|Administered orally
40992779|NCT04747912|DRUG|Inotuzumab ozogamicin|Inotuzumab ozogamicin, sold under the brand name Besponsa, is an anti-cancer drug used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
40992780|NCT04747912|DRUG|Dasatinib|Dasatinib is a prescription treatment for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
41147785|NCT04910399|DIETARY_SUPPLEMENT|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~One of the two study groups (28 volunteers) will take 4 capsules of placebo per day, for 90 days.Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
41147786|NCT00783185|BEHAVIORAL|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
41308896|NCT05906056|DEVICE|Continuous Passive Motion (CPM)|CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)
41308897|NCT05906056|OTHER|Conventional physiotherapy (PT)|Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)
41308898|NCT05906056|DRUG|Zoledronic Acid Injection|one dose of intravenous zoledronic acid will be administered
40992781|NCT04747912|DRUG|Dexamethasone|Dexamethasone is a steroid that prevents the release of substances in the body that cause inflammation.
41308899|NCT00276978|DRUG|Aripiprazole|Addition of Aripiprazole 10 mg to concurrent medication
41308900|NCT01157416|DRUG|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
41308901|NCT01157416|DRUG|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
41308902|NCT01157416|BEHAVIORAL|CBT|12-session CBT protocol, called Youth PTSD Treatment.
41308903|NCT02728258|DRUG|Copanlisib|Given IV
41308904|NCT02728258|OTHER|Laboratory Biomarker Analysis|Correlative studies
41308905|NCT01249872|DRUG|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
40788709|NCT06078527|DEVICE|Cheung-Bearelly Aesthesiometer|The Cheung-Bearelly Aesthesiometer will be used to deliver a range of calibrated stimuli through the channeled flexible laryngoscope to assess sensation of the laryngopharynx.
40992782|NCT04747912|DRUG|Methotrexate|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia.
40992783|NCT04747912|DRUG|Vincristine|Vincristine, also known as leurocristine and marketed under the brand name Oncovin among others, is a chemotherapy medication used to treat various types of cancer such as acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer among others.
40788710|NCT06078527|PROCEDURE|Transnasal Laryngoscopy|A procedure to examine your larynx (voice box)
40788711|NCT06078527|OTHER|Questionnaires|Patient-reported health and behavioral outcomes measures will be administered
40992784|NCT04747912|DRUG|Ponatinib|A drug used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Ponatinib blocks BCR-ABL, which may help keep cancer cells from growing and may kill them.
41308906|NCT01249872|DRUG|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
40992785|NCT04747912|DRUG|Methotrexate for Injection|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia. When given intrathecally, it prevents leukemia cells entering the cerebrospinal fluid (CSF) around the spine and brain. Intrathecal chemotherapy is administered during a procedure called a lumbar puncture or through an ommaya reservoir (shunt).
40992786|NCT04747912|PROCEDURE|Allogenic Stem Cell Transplantation|A procedure in which a patient receives healthy blood-forming cells (stem cells) from a donor to replace their own stem cells that have been destroyed by treatment with radiation or high doses of chemotherapy. In an allogeneic stem cell transplant, the healthy stem cells may come from the blood or bone marrow of a related donor who is not an identical twin of the patient or from an unrelated donor who is genetically similar to the patient. An allogeneic stem cell transplant is most often used to treat blood cancers, such as leukemia and lymphoma, and certain types of blood or immune system disorders.
41308907|NCT01249872|DRUG|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
41308908|NCT01249872|DRUG|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
41467682|NCT04106817|BIOLOGICAL|Live, wild-type A/California/H1N1 2009 influenza virus|Live, wild type influenza A virus that was inoculated and manufactured in allantoic fluid of SPF embryonated hen eggs
41467683|NCT01816568|PROCEDURE|SILS appendectomy|Single incision laparoscopic appendectomy will be performed
40992787|NCT01050257|DRUG|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
40788714|NCT00912782|DRUG|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
41308909|NCT01249872|DRUG|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
40788715|NCT00912782|DRUG|Placebo|Placebo one time per week for 3 weeks
41147787|NCT00783185|BEHAVIORAL|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
40788717|NCT02843412|PROCEDURE|choose two tumor tissue paraffin blocks|
40788718|NCT06404268|DEVICE|Motor relearning training|Ankle motor control relearning training under real-time feedback
40788719|NCT06404268|DEVICE|Passive stretching|Passive stretching under intelligent robotic control
40788720|NCT06404268|DEVICE|Gamed-based active movement training|Active movement training through movement games with robotic assistance
41467684|NCT01816568|PROCEDURE|Three port laparoscopic appendectomy|Three port laparoscopic appendectomy will be performed
41467685|NCT06097663|DRUG|MAS825|Active MAS825 single dose
41467686|NCT06097663|DRUG|MAS825 Placebo|MAS825 placebo single dose
41467687|NCT06097663|DRUG|DFV890|Oral tablet of DFV890 active once daily
41467688|NCT06097663|DRUG|DFV890 placebo|Oral tablet of DFV890 placebo once daily
41488656|NCT03275766|OTHER|sham TMS|Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
40788721|NCT06404268|DEVICE|Passive movement|Passive movement in the joint middle range of motion
40788722|NCT06404268|DEVICE|Active movement training|Active movement training without robotic assistance
40788723|NCT06404268|DEVICE|Ankle torque and motion measurement|Ankle torque and motion measurement with no real-time feedback
40992788|NCT01050257|DRUG|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
41147788|NCT03968744|DRUG|Safinamide|Safinamide taken per Os for 12 weeks
40992789|NCT04100304|DIAGNOSTIC_TEST|resection|CT volumetry,liver function,biopsy before resection
40992790|NCT01916356|OTHER|educational video|Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
40992791|NCT00837707|DRUG|aripiprazole|Flexible dose: 5-30 mg/day
41147789|NCT00640354|DEVICE|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
41147790|NCT00640354|DEVICE|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
41147791|NCT04769219|OTHER|Secondary prevention training|Secondary prevention training will be given after acute myocardial infarction
41308910|NCT01249872|DRUG|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
41308911|NCT02982304|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation Electrode
41308912|NCT05115279|PROCEDURE|breast conservative surgery for post chemotherapy tumour size|"* Skin preparation by povidine iodine.~* Excision of the mass with safety margin.~* Sentinel axillary lymph node or complete axillary clearance depend on axillary lymph node status~* All specimens were oriented with sutures~* A frozen section examination of the specimen was performed intraoperative~* When the margin status was inadequate, a re-excision was performed~* Closure as drawn by different oncoplastic technique"
41467689|NCT02682186|DRUG|Ropivacaine after dilution with sodium chloride 0.9%|"After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.~Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.~In the other group, sterilization, sheating and US are performed but the needle is not inserted."
41467690|NCT05986136|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
41467691|NCT05986136|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin has emerged as a selective SGLT2 inhibitor for the management of type-2 diabetes mellitus with minimal risk of hypoglycemia and it exerts diuretic-like actions and lowering of blood pressure, thereby, reducing the risk of hospitalization in type-2 diabetic patients with co-existing heart failure
41467692|NCT05369091|DRUG|Simvastatin 10mg|Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
40788724|NCT01628068|DEVICE|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
40788725|NCT02765399|DRUG|Liraglutide|
40788726|NCT02765399|DRUG|Placebo|
40992792|NCT05473273|DRUG|Endometrin 100Mg Vaginal Insert|Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
40788727|NCT06169618|OTHER|cervical radiculopathy|this group will have patients with cervical radiculopathy
40788728|NCT06169618|OTHER|normal group|this group will have normal subjects
40992793|NCT05473273|DRUG|Estradiol Valerate|Estradiol valerate dose will be reduced to 4mg daily at 7 pm during the first two days of vaginal natural micronized progesterone supplementation and increased afterwards to 6 mg daily (2 mg at 10 am and 4 mg at 7 pm).
40992794|NCT03679910|DIAGNOSTIC_TEST|CEMIP , CA19-9 ,CEA|CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen
40992795|NCT03679910|DIAGNOSTIC_TEST|A) CBC . B) RBG. C)KFT. D) LFT.|A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
40992796|NCT02520011|DRUG|Alvocidib|
40992797|NCT02520011|DRUG|Cytarabine|
40992798|NCT02520011|DRUG|Mitoxantrone|
41147792|NCT05606809|DIAGNOSTIC_TEST|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
41147793|NCT05881005|DIAGNOSTIC_TEST|hepatic MRI|Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
41147794|NCT01518517|DRUG|GRASPA|one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
41147795|NCT01518517|DRUG|L-asparaginase|3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
40788729|NCT00106041|BEHAVIORAL|Veterans Integrated Palliative Care Nurse Case Manager|Palliative Care nurse case management
40788730|NCT04319250|OTHER|ischemic compression|ATNs detected in a total of 13 muscles around the shoulder were applied constant pressure at the level of pain tolerated with the thumb (discomfort severity level 7 to 8 out of 10) and for 90 seconds. This method was applied twice a week for 6 weeks.
40992799|NCT00930150|BEHAVIORAL|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
41147796|NCT03550014|PROCEDURE|Low Back Only|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will only be directed at the lower back. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
40992800|NCT00930150|BEHAVIORAL|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
40992801|NCT00930150|BEHAVIORAL|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
40992802|NCT00930150|BEHAVIORAL|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
40992803|NCT05128877|OTHER|relaxation techniques|Mitchell's physiological relaxation technique is based on reciprocal inhibition and involves diaphragmatic breathing and a series of ordered isotonic contractions.
40992804|NCT03559946|DEVICE|percutaneous tibial nerve stimulation (PTNS)|The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
40992805|NCT03559946|DEVICE|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
40992806|NCT00644969|DRUG|placebo|Randomization 2:1 treatment to placebo
40992807|NCT00644969|DRUG|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
40992808|NCT05409144|PROCEDURE|Thoracic epidural infusion|Upon locating the desired site spot, lidocaine 1% must be injected into the skin and underlying tissues to decrease the discomfort with the advancement of the epidural needle. Once achieving local anesthesia, the epidural needle advanced with its stylet in place and with its bevel point cephalad; this will ultimately contribute to the proper location of the epidural catheter. The epidural needle must be advanced through the skin, subcutaneous tissue, supraspinous, and interspinous ligaments. Once there, the stylet must be removed, and the Loss of Resistance syringe (filled up with saline, air, or both) must be attached to the needle. The needle must be advanced while applying pressure to the plunger. Once the ligamentum flavum is pierced, a loss in resistance will be noted; this is the epidural space, and 5 to 10 cc of saline is injected to expand the epidural space; this may decrease the risk of vascular injury.
40992809|NCT05409144|DEVICE|Erector Spinae Plane Block|The block-level will be at T5. The ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which the following layers will be visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle and T5 transverse process. 3ml lidocaine 1% will be used on skin and subcutaneous fat, Echogenic block needle will be inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process.
41147797|NCT03550014|PROCEDURE|Low Back+Hip|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will be directed at the lower back and the hips. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
40788731|NCT04319250|OTHER|IASTM|"In order to apply EDYDM in the treatment of ATN, titanium plated stainless steel was divided into two parts, front and back, with two tools. The sweep was applied to the anterior muscle fibers at an angle of 45 ° for 40 seconds.~For each TN, continuous pressure was applied with swivel movement at tolerable pain level (discomfort severity level 7 to 8 out of 10) for 1 minute. The back group muscles were applied in the same way."
41147798|NCT05486988|DRUG|Immunotherapy|PD-1/PD-L1 inhibitors
41147799|NCT05486988|DRUG|Chemotherapeutic Agent|2 cycles
41147800|NCT05486988|DRUG|Chemotherapy|4\~6 cycles
41147801|NCT02816645|PROCEDURE|Magnetic Resonance Imaging (MRI)|
41147802|NCT04610125|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
41147803|NCT04610125|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
41147804|NCT04610125|PROCEDURE|Leukapheresis|Leukapheresis
41147805|NCT00819078|DRUG|Bupropion|300 mg/d
41147806|NCT00819078|DRUG|Placebo|no dosage
41467693|NCT01556867|OTHER|Cord care by simple debridement (soaping, rinsing and drying)|For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
41147807|NCT01599221|DEVICE|EBA2|Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
41467694|NCT01556867|OTHER|Cord care with the use of antiseptics|"For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.~In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care."
41467695|NCT04397289|DRUG|Heparin and Rivaroxaban|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
41147808|NCT06020495|DRUG|DDAVP|Posology: 4µg in 2ml IV solution Route of administration: Intravenous Duration of treatment: 48h maximum (additional doses every 6h)
41147809|NCT06020495|DRUG|Standard hyponatremia treatment|"Standard hyponatremia treatment alone :~Presence of neurological symptoms :~sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
41147810|NCT00274287|DRUG|GM CSF|250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
41308913|NCT02175771|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening."
41308914|NCT02175771|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening."
40992810|NCT05409144|DEVICE|Serratus Anterior Plane Block|The block is performed with full aseptic precautions. Arm abduction is preferred. The ultrasound probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, then, 3ml lidocaine 1% will be used for skin and subcutaneous fat, using ultrasound guidance, a 38-mm 22-gauge regional block needle is going to be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep into the serratus anterior muscle.
40992811|NCT01998698|PROCEDURE|Phacoemulsification surgery|Phacoemulsification surgery with intraocular lens implantation and monovision correction
40992812|NCT01998698|PROCEDURE|Phacoemulsification surgery|Phacoemulsification surgery with multifocal intraocular lens implantation
40992813|NCT02171260|DRUG|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
40992814|NCT05339503|OTHER|enamel microabrasion|It is a non-restorative, conservative treatment that works both chemically and mechanically to remove up to 0.2 mm of affected enamel per application. Pumice either mixed with 18% hydrochloric acid or 5.25% sodium hypochlorite was used to remove fluorosis stains.
40992815|NCT05047081|BEHAVIORAL|Scoring Your College Goals Workshop|A two-hour virtual college readiness workshop.
40992816|NCT05047081|OTHER|Placebo|Placebo Treatment-As-Usual Group which does not receive the workshop intervention
40992817|NCT03642223|OTHER|Stable iron isotopes|Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
40992818|NCT00411164|DRUG|OROS hydromorphone HCI (slow release)|
40992819|NCT03684512|BEHAVIORAL|Group Exercise Sessions|Remote exercise sessions delivered over group video conference
40992820|NCT03684512|BEHAVIORAL|Individual Support Sessions|Individual education/support/feedback sessions delivered over video chat
40992821|NCT03684512|BEHAVIORAL|Facebook Group|Facebook group for parents to provide additional support and education
40992822|NCT06088550|DIETARY_SUPPLEMENT|BCAA|a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine \& 1.25 gm valine).
40992823|NCT06088550|OTHER|home-based graded exercise program|home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives
40992824|NCT06024044|BEHAVIORAL|Mobilization Training|"The participants in the training group were given hysterectomy postoperative mobilization training by the researcher (B.K) using presentation and verbal information technique. A Post-Operative Follow-up Chart was given to the participants to fill in the 1st and 2nd postoperative days. The training group participants were followed up by the researcher on the 0th and 1st days after the operation in line with the mobilization training they received. The Post-Operative Follow-up Chart questioning the patients' mobilization times, distances, bowel functions and pain scores was filled in by the researcher in detail by face-to-face interview method. Mobilization time (minutes) and distance (meters) were evaluated by the patients and their relatives, and recorded on the chart, using the stopwatch and pedometer on the personal mobile phones of the patients."
40992825|NCT02283710|DRUG|Pentoxifylline|Pentoxifylline 600 mg BD
41147811|NCT00135226|DRUG|Aspirin|
40992826|NCT02283710|BEHAVIORAL|Lifestyle modification|obtaining ideal body weight by calorie restriction diet and programmed physical activity.
41308915|NCT02175771|DRUG|FLOVENT HFA|"FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening."
40992827|NCT06081127|OTHER|MOve-ABC|"The intervention is called Moving On After Breast Cancer (MOve-ABC) and includes:~1. Three in-person visits for clinical measurements~2. Enhanced usual care (EUC)~3. Pre-hab ((Pre-Treatment) PT evaluation and individualized home therapeutic exercise prescription with safe progressions).~4. Teach Back (HEP, post-op movement precautions)~5. Self-management education with reinforcement check-ins via text messaging and phone calls at regular intervals."
41147812|NCT00135226|DRUG|Omega-3 Ethyl Esters|
41147813|NCT00135226|DRUG|Placebo Aspirin|
41147814|NCT00135226|DRUG|Placebo Omega-3 Ethyl Esters|
41147815|NCT03851809|DRUG|Wendan decoction combination in acute brain injury|In the intervention group, traditional Chinese medicine was given between 14 days of onset and TCM was used 1 month at least in intervention group.
41467696|NCT03966950|DIETARY_SUPPLEMENT|melatonin|melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.
40992828|NCT06081127|OTHER|Enhanced Usual Care|"All patients will receive EUC. However, half of our sample will have only EUC consisting of~1. Three in-person visits for clinical measurements~2. Planned oncology treatment (surgery, chemotherapy, radiation)~3. Nursing education on surgical site and drain care, post-operative movement precautions, pain management~4. If needed, laboratory and radiological testing to rule out disorders that interfere with treatment outcomes~5. Monthly monitoring with Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF) surveys beginning at baseline with alerts from scores = or \< 45 (indicating moderate or severe impairment) for physical therapy referral"
40788732|NCT04319250|OTHER|Rehabilitation Program|A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.
40788733|NCT05715658|DRUG|Dabigatran etexilate capsule|Adult healthy subjects and elderly healthy subjects only take one 110 mg dabigatran etexilate capsule (low-dose specification in the instruction manual) orally. Elderly patients with atrial fibrillation take dabigatran etexilate according to routine medical treatment.
40788734|NCT03007030|DRUG|Brentuximab Vedotin|Given IV
40788735|NCT03007030|OTHER|Laboratory Biomarker Analysis|Correlative studies
40788736|NCT06470516|DEVICE|high-frequency transcranial alternating current stimulation|The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA.
40788737|NCT06470516|DEVICE|sham high-frequency transcranial alternating current stimulation|The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
40992829|NCT01253759|PROCEDURE|TTT + ICG-based PDT|
41308916|NCT02175771|DRUG|ADVAIR DISKUS|"ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening."
41308917|NCT02175771|DRUG|albuterol/salbutamol HFA|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
41308918|NCT01980108|OTHER|water|water
41308919|NCT02215993|DRUG|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
40788738|NCT02255669|DEVICE|partially covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
40788739|NCT02255669|DEVICE|fully covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
40788740|NCT03257358|DRUG|Fingolimod|Commercially available 0.5mg hard capsules, taken orally once per day
41308920|NCT02215993|DRUG|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
41308921|NCT00006248|DRUG|cisplatin|
41308922|NCT00006248|DRUG|fluorouracil|
41308923|NCT00006248|DRUG|paclitaxel|
41308924|NCT00437606|DRUG|GK Activator (2)|100mg po
41308925|NCT00437606|DRUG|Ethanol|40g po
41308926|NCT03487900|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy for CD patients in clinical remission
41308927|NCT01201798|DRUG|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
41467697|NCT03966950|DRUG|Placebo oral tablet|placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
41467698|NCT05610449|DIAGNOSTIC_TEST|Testing Done Simple SARS CoV-2 Antigen Test|Collections of specimens from subjects presenting with Covid-19 like symptoms or known/suspected exposure to SARS CoV-2 via nasal swabs administered by trained medical personnel.
41467699|NCT05621954|PROCEDURE|Telehealth Monitoring|Connected devices and smartphone apps to measure symptoms and observations at home, with centralisation of results to a staffed hub
41467700|NCT03263078|DRUG|Propofol|For the maintenance of anesthesia, we used 2% propofol (Fresofol®, Fresenius Kabi, Germany) administered by the target controlled infusion (TCI) system (Orchestra® Base Primea; Fresenius Kabi, Germany) in Schnider mode with an effect concentration (Ce) of 2.5-3.5 µg ml-1
40788741|NCT05932173|BIOLOGICAL|Anti-CD19 Autologous CAR-T Cell Infusion|Autologous T cells modified with anti-CD19 ScFv expression and manufactured by OlyCAR platform
40788742|NCT01545596|BEHAVIORAL|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
40788743|NCT03929432|DEVICE|Active Transcranial Direct Current Stimulation with SLT|"Soterix Medical 1×1 transcranial Direct Current Stimulator for Clinical Trials (1x1 tDCS-CT).~Excitatory stimulation to the left hemisphere will be achieved through a 1x1 montage utilizing two carbon-rubber electrodes and 5x7 EASY pad sponges (A-tDCS \[excitatory\]left target; C-tDCS \[inhibitory\]right hemisphere). Each PWA will have a unique 5-digit tDCS program code for each treatment phase. One code will instruct the 1x1 tDCS-CT to administer active stimulation as describe above (i.e., 1.5 mA for 20 min). The other will administer 1.5 mA for only a few seconds to simulate active stimulation. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment"
40788744|NCT03929432|DEVICE|Sham Transcranial Direct Current Stimulation with SLT|Control condition in which only SLT is administered.Participant receives 1.5 mA for only a few seconds to simulate active stimulation, then the stimulation will cease. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment
40788745|NCT01862081|DRUG|Docetaxel|Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
40992830|NCT01380509|DRUG|Metronidazole|Capsules, single-dose, fasting
40992831|NCT01380509|DRUG|Flagyl|Capsules, single-dose, fasting
40992832|NCT00822458|DRUG|vismodegib|Given orally
40992833|NCT00822458|OTHER|laboratory biomarker analysis|
40992834|NCT00822458|OTHER|pharmacological study|
40992835|NCT06519760|DRUG|68Ga-C1|68Ga-C1 is injected intravenously with a dose of 0.05-0.10 mCi/kg
40992836|NCT03168152|RADIATION|Microwave Ablation (MWA)|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
40992837|NCT03168152|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
40992838|NCT05158868|DIAGNOSTIC_TEST|HiF-1 alpha measurement|HIF1- α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O2 sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology
40992839|NCT05184374|DRUG|Gonadorelin|GnRH pump pulse subcutaneous injection of gonadorelin in a month
40992840|NCT02478554|OTHER|Customized fetal growth curves|Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
40992841|NCT04327219|OTHER|CDED diet|examine the microbial, mucosal and immunological changes of the pouch during one year post IPAA, and examine the impact of the CDED on disease activity and dysbiosis in adults suffering from active pouchitis.
40992842|NCT02637778|DIETARY_SUPPLEMENT|Cardioprotective diet|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
41308928|NCT01201798|DRUG|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
41308929|NCT04913961|OTHER|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study
41467701|NCT03263078|DRUG|Sevoflurane|Anesthesia was maintained using 1-3% sevoflurane (ULTANE®, AbbVie Inc., USA) in the Sevoflurane group.
41467702|NCT00043576|DRUG|calcitriol|
41467703|NCT00043576|DRUG|docetaxel|
40992843|NCT02637778|DIETARY_SUPPLEMENT|Cardioprotective diet + 3 g EPA + DHA/d|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
40992844|NCT02804984|GENETIC|ICUS|
40992845|NCT02441933|DRUG|taxane plus carboplatin|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles"
40992846|NCT02441933|DRUG|Taxane|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses"
41147816|NCT02010086|BEHAVIORAL|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes, implementing the CBT manual for children with ASD (Wood et al., 2007).
41147817|NCT02010086|BEHAVIORAL|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to provide a standard community therapy treatment.
41147818|NCT01862679|OTHER|High-flux haemodialysis|High-flux haemodialysis is the standard dialysis modality currently in use in the UK
41308930|NCT04913961|OTHER|western medicine conventional therapy|The control group will get the western medicine conventional therapy with some additional tests for the study.
41308931|NCT02194101|PROCEDURE|Supernormal oxygen delivery goal therapy|A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
41467704|NCT01353248|DRUG|GS-5885|tablet, 30 mg QD
40788746|NCT01862081|DRUG|GDC-0032|Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
40788747|NCT01862081|DRUG|Paclitaxel|Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
40788748|NCT04188249|DRUG|Golimumab|This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.
40788749|NCT01506024|PROCEDURE|Total hip arthroplasty direct lateral approach|
40788750|NCT01506024|PROCEDURE|Total hip arthroplasty posterior approach|
40788751|NCT01506024|PROCEDURE|Total hip arthroplasty, anterior approach|
40788752|NCT00506779|DRUG|Imatinib Mesylate|Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily
40992847|NCT02970279|BEHAVIORAL|Behavioural Activation Group (BAG) Psychotherapy|Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
40992848|NCT05831761|DRUG|Comparison of analgesic efficacy protocol|Comparison of 4 possible analgesic protocols
40992849|NCT03329495|PROCEDURE|SMA-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMA. The left boundary of resection is the left side of SMA, and artery sheath is not necessarily being opened.
40788753|NCT00506779|DRUG|Paclitaxel|175 mg/m\^2 by vein over 3 Hours every 21 Days
40788754|NCT01521598|DRUG|SKL11197|SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
40788755|NCT01521598|DRUG|Placebo|This is the placebo. Patients will be randomized the placebo.
40788756|NCT03465722|DRUG|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
40788757|NCT03465722|DRUG|regorafenib|Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
41467705|NCT01353248|DRUG|Tegobuvir|capsule, 30 mg BID
40788758|NCT06285045|DRUG|Roujin Formula|48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.
40788759|NCT02091635|DRUG|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
40788760|NCT02091635|DRUG|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
40788761|NCT04231097|OTHER|MBCT intervention for ACS patients|The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health. Participants involved in the intervention will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
40788762|NCT03982277|DRUG|Rifampin 300 Mg Oral Capsule|High dose rifampicin at 35mg/kg
40788763|NCT00539240|DRUG|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
40788764|NCT00539240|DRUG|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast \& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
40992850|NCT03329495|PROCEDURE|SMV-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMV. The left boundary of resection is the left side of SMV, and SMA is not exposed.
40992851|NCT02762266|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
40992852|NCT02762266|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
40992853|NCT02762266|DRUG|embolic agent|". Acceptable embolic agents include:~* Gelatin sponge (gelfoam)~* Polyvinyl alcohol (PVA) particles~* Microspheres / Embolic beads"
40992854|NCT02762266|DRUG|lipiodol|
40788765|NCT00539240|DRUG|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
40788766|NCT03775317|PROCEDURE|Video Laryngoscopy|The direct, or conventional, laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Macintosh or Miller laryngoscope for direct visualization of the larynx.
40992855|NCT02417688|DEVICE|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
40992856|NCT01591876|OTHER|Intradialytic aerobic exercise|Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
41467706|NCT01353248|DRUG|GS-9451|tablet, 200 mg QD
41467707|NCT01353248|DRUG|ribavirin tablet|(weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
41467708|NCT01353248|DRUG|GS-5885|tablet, 90 mg QD
41467709|NCT03821792|DRUG|Abiraterone Acetate|Given PO
41467710|NCT03821792|DRUG|Apalutamide|Given PO
41467711|NCT03821792|DRUG|Prednisone|Given PO
41467712|NCT02076516|DEVICE|Drug-eluting stent: CORACTO®|
41467713|NCT04406194|DRUG|FAVICOVIR 200 mg Film Tablet|FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.
40788767|NCT03775317|PROCEDURE|Direct Laryngoscopy|The video-assisted laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Storz C-MAC S Video Laryngoscope to allow for indirect visualization of the larynx.
40788768|NCT03291132|OTHER|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
40788769|NCT01172444|DRUG|Mesalamine|Supporitory, Once Daily, Per Rectal for 6 Weeks
40788770|NCT01172444|DRUG|Canasa|Suppository, Once Daily, Per Rectal for 6 Weeks
40788771|NCT01172444|DRUG|Placebo|Suppository, Once Daily, Per Rectal for 6 Weeks
40788772|NCT05173012|DRUG|SAGE-324|SAGE-324 oral tablets.
40788773|NCT05173012|DRUG|SAGE-324 Matched Placebo|SAGE-324 matched placebo oral tablets.
40788774|NCT05802277|DIAGNOSTIC_TEST|Hamstring muscles function assessment|Ultrasound echographic evaluation of the hamstring muscles during stretching and voluntary contractions, before and after a strenuous physical activity.
40788775|NCT05850143|DRUG|Dexamethasone|Oral Dexamethasone a longer and potent corticosteroid with lesser sideffects and good compliance
40788776|NCT05850143|DRUG|Prednisolone|Oral Multidose Prednisolone
40788777|NCT03578250|OTHER|Robotic Training|Upper extremity training on a robotic device with or without error augmentation force field.
40788778|NCT01165125|DRUG|FF / GW642444|200mcg/25mcg Novel DPI
40788779|NCT01165125|DRUG|ketoconazole|400mcg overencapsulated tablets
40788780|NCT01165125|DRUG|ketoconazole (placebo to match)|placebo to match overencapsulated tablets
40788781|NCT02977338|OTHER|Retrospective review|
40788782|NCT04345484|BEHAVIORAL|Goal-management training|9-week goal-management program
40788783|NCT04345484|BEHAVIORAL|Control|Healthy Lifestyle Program
40788784|NCT00161889|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
40788785|NCT06288425|OTHER|Non interventional|Non interventional. Review of clinical, biopsy (histopathological and molecular) features associated with rejection and non-rejection pathology diagnosis
40788786|NCT06209489|OTHER|White cover|"* A white cover will be covered over the incubator during phototherapy.~* Baby massage will be applied during phototherapy."
40788787|NCT01008618|DRUG|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
41467714|NCT04406194|DRUG|AVIGAN 200 mg Film Tablets|AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
40788788|NCT01008618|DRUG|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
40788789|NCT05003908|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
40992857|NCT01591876|OTHER|Progressive Muscle relaxation|This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
41147819|NCT01862679|PROCEDURE|Haemodiafiltration|"During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood."
41467715|NCT05903339|DRUG|V3G CH848 Pr-NP1 60mcg|(60 mcg)
40788790|NCT03247634|BEHAVIORAL|Getting Ahead in a Just-Gettin'-By World|The Getting Ahead program is a unique welldeveloped program that allows carefully guided introspection toward the crafting of tailored solutions aimed at addressing complex social determinants of health among individuals living in vulnerable populations where the achievement of health equity often seems unattainable. The important lens of health equity is a key component of this proposal and is consistent with the American Cancer Society overarching emphasis on reduction of health disparities and achievement of health equity.
40788791|NCT05504512|OTHER|No intervention|No intervention
40788792|NCT00985647|DRUG|Lamivudine (3TC)|"3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days."
40788793|NCT04032925|DEVICE|PICSO|"PICSO therapy is delivered through the PICSO Impulse System, which consists of the PICSO Impulse console and PICSO impulse catheter. The PICSO therapy is delivered in each patient for a minimum of 20 minutes to a maximum of 45 minutes.~The PICSO Impulse catheter is automatically activated by the PICSO Impulse console. It is inserted in the coronary sinus via femoral vein access. The PICSO Impulse Console cyclically inflates and deflates the balloon at the tip of the PICSO Impulse catheter, generating transient increase in coronary sinus pressure."
40788794|NCT03201640|BEHAVIORAL|slideshow|Participants will be shown a slideshow showing a child being prepared for surgery
40992858|NCT04829773|DRUG|Palovarotene|oral capsules
40992859|NCT04829773|DRUG|midazolam|oral syrup
41467716|NCT05903339|DRUG|3M-052-AF 5mcg|(5 mcg)
41467717|NCT05903339|DRUG|Alum 500 mcg|(500 mcg)
41467718|NCT05903339|DRUG|V3G CH848 mRNA-Tr2 50mcg|(50 mcg)
41467719|NCT05903339|DRUG|ACU-026-001-1 2.0mg|(2.0 mg)
41467720|NCT05903339|DRUG|V3G CH848 Pr-NP1 100mcg|(100 mcg)
41467721|NCT02345291|DRUG|NRD135S.E1|A small chemical entity for treatment of neuropathic pain NRD135S.E1
41467722|NCT02345291|DRUG|Placebo to match NRD135S.E1|Placebo capsule to match NRD135S.E1 capsules
41147820|NCT06232005|DRUG|Mitomycin c|injection of antifibrotic drugs in urethral strictures after internal urethrotomy
41147821|NCT03720717|DRUG|Baclofen 10mg|Baclofen administration pre-operatively
41147822|NCT03720717|OTHER|Placebo|Placebo administration
41147823|NCT05280522|OTHER|Volitional Contractions (VOL)|Participants are provided visual feedback showing the 20% MVIC force and instructed to produce the target force for 10 s then relax for 50 s. The timing is provided by the research personnel until 10 contractions are completed. Participants rate their pain during each contraction on a visual analog scale. The pain ratings are averaged across all 10 contractions and the average is used in the analysis.
41147824|NCT05280522|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Participants are instructed to relax throughout the NMES contractions. The amplitude of the stimulation is increased until 20 percent MVIC force is achieved and the amplitude is recorded. The timing of the NMES is 12 s on: 50 s off for 10 contractions. The on-time included a 2s ramp up to the target amplitude. Participants rate their pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 contractions and the average was used in the analyses.
41147825|NCT05280522|DEVICE|Noxious Electrical Stimulation (NXES)|The intensity of the electrical stimulation is increased slowly over 30 s to the maximum tolerated level. Trains of NXES are delivered at the maximum tolerated intensity with a timing ratio of 12 s on: 50 s off for a total of 10 trains. The on-time included a 2s ramp up to the target amplitude. Participants rate the pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 trains of NXES and the average is used in the analyses.
41147826|NCT05457647|DEVICE|Riboflavin/UV-A corneal cross-linking|Corneal cross-linking procedure will be performed using the theranostic software module of the C4V CHROMO4VIS™ system in all participants. Participants will receive a single dose of the 0.22% riboflavin ophthalmic solution, RitSight™. Application of the riboflavin eye drop will be done for 15 minutes for the EpiOFF CXL treatment and 20 minutes for the EpiON CXL treatment. Estimates of riboflavin concentration into the cornea will be monitored by the C4V CHROMO4VIS™ system during the dosing phase of treatment. Once the dosing phase is completed, the C4V CHROMO4VIS™ system provides the Operator the access to the UV-A irradiation of the cornea with 5.4 J/cm2 total energy dose and 7.00 mm light beam diameter in all participants. Estimates of treatment efficacy by calculation of theranostic score will be performed by the C4V CHROMO4VIS™ system during UV-A irradiation.
41147827|NCT04175938|DEVICE|Wearing of contact lens|All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
41147828|NCT05386706|BEHAVIORAL|Digital Intervention|This study developed a mini-program that combined diet, exercise, sleep, and mood interventions for PCOS women.
41147829|NCT05386706|DRUG|Metformin|Traditional metformin monotherapy.
41147830|NCT00005971|DRUG|alvocidib|
41147831|NCT00224198|PROCEDURE|Lung Disease|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
41147832|NCT06390176|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG powder|Lactobacillus rhamnosus GG powder (PROBIOTICS Powder, USA) contained no less than 5×10\^8 CFU viable cells of Lactobacillus rhamnosus GG as the active ingredient.
41147833|NCT06390176|DIETARY_SUPPLEMENT|Placebo-containing tablets|Starch preparations that look and taste like Lactobacillus rhamnosus GG powder
41467723|NCT03160586|DIAGNOSTIC_TEST|Stuttering severity instrument-3|To measure of degree of stuttering in child
40788795|NCT03201640|BEHAVIORAL|virtual|Participants will be shown an immersive virtual reality preparation for surgery
40788796|NCT05490316|DRUG|IBI353 (Orismilast)|dose 1 or dose 2
40788797|NCT05490316|DRUG|placebo|placebo
41467724|NCT03160586|DIAGNOSTIC_TEST|Child Behavior Checklist for age 4-18|To measure of percent of anxiety in child by ask parents about his or her behaviour
41467725|NCT00098891|DRUG|entinostat|Given orally
40788798|NCT04912544|DEVICE|Noninvasive Ventilation Mask Microphone|Noninvasive Ventilation Mask Microphone is turned on to enhance speech intelligibility during the intervention portion of the crossover feasibility study
40788799|NCT01947335|DEVICE|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
40788800|NCT03672214|PROCEDURE|Without placement of indwelling catheter|No placement of indwelling catheter prior to Caesarean section
41467726|NCT00098891|DRUG|isotretinoin|Given orally
40788801|NCT03672214|PROCEDURE|With placement of indwelling catheter|Placement of indwelling catheter prior to Caesarean section
40788802|NCT04168567|DIAGNOSTIC_TEST|Microbiome analysis|Samples from the vagina, endometrium and anus and analyzing microbiome with NGS technique.
40788803|NCT04212130|OTHER|BCA method for assessing environmental cleanliness|"Evaluating the effectiveness and usability of BCA method which is a new approach in evaluating the effectiveness of environmental cleanliness in intensive care units.~In this study, fluorecan labeling, microbiological sampling and BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
40788804|NCT01154491|DRUG|Ferric carboxymaltose|"Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
41308932|NCT04461405|BEHAVIORAL|INTEGRATE-D|INTEGRATE-D provides primary care practices with evidence-based training and support which includes: (1) Electronic health record (EHR)-based support-to help align EHR use with ADA recommendations and enable screening for depression, anxiety, DM distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources including training on ADA-recommended care; and (4) Facilitation-to help implement the above strategies and the practice changes needed to align care with ADA recommendations.
40788805|NCT01154491|DRUG|Erythropoietin|Erythropoetin: 40,000 units subcutaneous (unique dose).
40788806|NCT01154491|DRUG|Placebo|"Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
40788807|NCT05573698|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
40788808|NCT05573698|DRUG|Placebo|Matching Placebo will be administered by intravenous (IV) injection
40788809|NCT03680885|DRUG|Lidocaine gel|Lidocaine gel 5%, PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
40992860|NCT00586183|PROCEDURE|PET scan|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
40788810|NCT03680885|DRUG|Placebo|PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
40788811|NCT03680885|DRUG|Injected lidocaine|Standard FDA-approved dental injectable lidocaine
40788812|NCT03530150|DRUG|Pirfenidone Oral Product|A pill containing 600 mg of pirfenidone
41308933|NCT06365671|OTHER|autologous stem-cell transplantation|high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT)
41308934|NCT06365671|DRUG|Relmacabtagene autoleucel (relma-cel)|relma-cel (CD19 CAR-T cell)infusion on day 3(±1d) after ASCT with a fixed dose of 100X10\^6.
41488657|NCT04727814|OTHER|Computer-aided detection system overlaid colonoscopy videos analysis|Analysis of computer-aided detection system overlaid videos from colonoscopies performed with water exchange or air insufflation method.
40788813|NCT01466491|DRUG|Paracervical block technique with lidocaine|The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
40788814|NCT00803361|DRUG|Duloxetine|60 to 120 mg, capsules, oral, once a day for 15 weeks
40788815|NCT00803361|DRUG|Placebo|placebo capsules, oral, once a day for 15 weeks
40992861|NCT00668044|DRUG|Ciprofloxacin (BAYO9867)|400 mg iv BID
40992862|NCT00668044|DRUG|Ciprofloxacin (BAYO9867)|400 mg iv TID
40992863|NCT00815438|PROCEDURE|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
40992864|NCT03465592|DRUG|Nivolumab|Administered IV
40992865|NCT00460031|DRUG|ketoconazole|400 tid
41147834|NCT06390176|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
41147835|NCT00409500|DRUG|AQW051|
41308935|NCT01506752|DRUG|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet without water.
41308936|NCT01506752|DRUG|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet without water.
41308937|NCT01506752|DRUG|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet with water.
41308938|NCT01506752|DRUG|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet with water
41308939|NCT03811678|DRUG|Kangdaprevir Sodium Tablet|Tablet，administered orally once daily
41308940|NCT03811678|DRUG|placebo|Tablet，administered orally once daily
41308941|NCT03848221|DRUG|Systane Complete|Systane Complete is an artificial tear.
41308942|NCT03848221|DRUG|Sensitive Eyes Rewetting Drops|Sensitive Eyes Rewetting Drops is a rewetting drop.
41308943|NCT00578864|DRUG|Protracted Oral Etoposide|"Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~* Hour 0: Etoposide 50 mg/m2 po daily~* Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~* Etoposide 50 mg/m2 po once daily"
41308944|NCT00578864|DRUG|Doxorubicin|"Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~* Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if \< 12 kg) with Mesna 400 mg/m2 (13 mg/kg if \< 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~* Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if \< 12 kg) IV over 15 minutes"
40788816|NCT03661177|OTHER|Sovereign nation diet|We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
40788817|NCT02830919|DRUG|Glucosamine and chondroitin sulfate combination (Eurofarma)|
40788818|NCT02830919|DRUG|Glucosamine and chondroitin sulfate combination (Zodic)|
40788819|NCT03269773|BIOLOGICAL|FURESTEM-AD Inj.|"0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL"
40992866|NCT00460031|DRUG|lenalidomide|Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
40992867|NCT00460031|DRUG|therapeutic hydrocortisone|20mg qam 10mg qhs
40992868|NCT00496756|DRUG|Sorafenib|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
40992869|NCT00256698|DRUG|Fulvestrant|intramuscular injection 250 mg loading dose (LD) regimen
40992870|NCT00256698|DRUG|Anastrozole|1 mg oral tablet
41467727|NCT05775848|DRUG|BBP-418 (ribitol)|The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
41467728|NCT05775848|OTHER|Placebo|A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
40788820|NCT03269773|OTHER|Placebo|0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)
40788821|NCT06512506|OTHER|non-intervention|non-intervention
40788822|NCT00994825|DRUG|Levosimendan|
40788823|NCT00994825|DRUG|placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
40788824|NCT01603225|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
40788825|NCT00968773|DEVICE|Rebound HRD|Laparoscopic TEP inguinal hernia repair using the Rebound HRD and no fixation
40788826|NCT00968773|DEVICE|Standard hernia mesh (VitaMesh)|Laparoscopic TEP inguinal hernia repair using standard hernia mesh with fixation
40788827|NCT05712980|DEVICE|Implanted pulse generator for SCS with different programming modalities|"Surgical technique~Patients recruited will be scheduled for the implantation of the SCS system in two phases. The implant procedure will be performed following our standardized clinical practice under local anesthesia and moderate sedation.~Clinical parameters~Clinical evaluation of study subjects shall include, in addition to demographic parameters, the assessment of parameters related to pain experience, disability, quality of life, as well as other psychological variables. All these parameters will be evaluated at different times of the study.~Sample processing~10 ml of peripheral blood will be obtained per venopuncture at different moments, always at the same time of day and in the same anatomical location.~Expression arrays~After a manual removal of RNA the expression arrays and the scanning of the crystals will be carried out after hybridization"
40788828|NCT01809886|DRUG|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC\<2).
40992871|NCT01466387|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|One dose of typhoid Vi polysaccharide vaccine.
40992872|NCT01466387|BIOLOGICAL|Yellow Fever Vaccine|One dose of yellow fever vaccine.
40992873|NCT01466387|BIOLOGICAL|Japanese Encephalitis Vaccine|Two doses of Japanese Encephalitis Vaccine.
40992874|NCT01466387|BIOLOGICAL|Rabies Vaccine|Three doses of Rabies vaccine.
40992875|NCT01466387|BIOLOGICAL|MenACWY-CRM Vaccine|One dose of MenACWY-CRM vaccine.
41147836|NCT06023771|PROCEDURE|Invasive intervention for acute pancreatitis|Invasive interventions include drainage (endoscopic transmural drainage, imaging-guided percutaneous catheter drainage) and debridement (endoscopic debridement, videoscopic assisted retroperitoneal debridement, laparoscopic surgical debridement, open surgical debridement).
41147837|NCT03694210|DEVICE|EndoRotor Therapy|To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
41467729|NCT01242618|BIOLOGICAL|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
41467730|NCT04584086|DEVICE|MRI 3 tesla|"1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months)~In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed:~* During treatment when half of the prescribed dose has been delivered.~* 1 month after the end of the irradiation."
40788829|NCT01809886|DRUG|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC\<2).
40788830|NCT01033084|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
40788831|NCT01033084|DRUG|Sertraline|Patient will receive sertraline 50mg/day.
40788832|NCT01033084|OTHER|double placebo|double placebo arm (sham stimulation/placebo pill)
40788833|NCT02811822|DRUG|GMI-1271|
40788834|NCT04157699|DRUG|TDF tablet|TDF tablet 300mg QD
40788835|NCT04157699|DRUG|QL-007|QL-007 tablet
40788836|NCT03369366|DEVICE|NobelActive|NobelActive's expanding tapered implant body condenses bone gradually while the apex with drilling blades enables a smaller osteotomy. These features help to achieve high primary stability in demanding situations, such as soft bone or extraction sockets. NobelActive enables immediate implant placement and Immediate Function where it might otherwise be challenging.
40992876|NCT06371742|OTHER|Liquid ingestion during labour|An assessment of the volume capacity of the water glasses was carried out using duly certified 50mL syringes in order to calibrate and control the correct measurement of the amount of water ingested. Water is measured using a graduated cup, which is pre-existing in the BP service, since its water intake policy is governed by the formula 1ml/kg/h of clear liquids (water or tea).
40992877|NCT01425554|OTHER|Doppler sonography of internal jugular veins|Doppler sonography of internal jugular veins
40992878|NCT01425554|OTHER|Magnetic resonance venography of internal jugular veins|Magnetic resonance venography of internal jugular veins
40992879|NCT01425554|OTHER|Air-plethysmography of the neck|Air-plethysmography of the neck
40992880|NCT01425554|OTHER|Catheter venography of internal jugular veins|Catheter venography of internal jugular veins
40992881|NCT02361255|OTHER|no intervention|
40992882|NCT05270954|BIOLOGICAL|Betuvax-CoV-2|Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)
40992883|NCT05270954|DRUG|Placebo|Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)
40788837|NCT03369366|DEVICE|KLS Martin Mandibular Reconstruction Implant|The prefabricated prosthesis will be secured onto the implants using non-engaging multiunit abutments with screws, followed by fixation of the patient-specific plate to the fibula with monocortical screws. The previously used cutting guides are fixated with the screw locations corresponding to the screw locations of the custom plate. This allows for accurate positioning and fixation of the custom construct of the plate and fibula without the need for intermaxillary fixation (IMF).
40992884|NCT05339620|PROCEDURE|implant driver facilitated micro-osteoperforations|"3 micro-osteoperforations(in a vertical pattern) are done on the randomly allocated experimental side , distal to canine under local anesthesia. the other side of the mouth is used as a control.~alginate impression is taken before the intervention ."
40992885|NCT04749953|PROCEDURE|Maxillary sinus floor augmentation|The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla
41147838|NCT01924468|DRUG|Oral methylphenidate and Oral haloperidol|
41147839|NCT03567356|OTHER|"MAT-PLUS Helping Hands"|"1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
41147840|NCT03557307|BIOLOGICAL|Benralizumab|Benralizumab subcutaneous injection
41147841|NCT04964206|PROCEDURE|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed according to the routine practice of each study center.
41147842|NCT04964206|PROCEDURE|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
40992886|NCT04695860|DRUG|Burosumab|Q4w, 1mg/kg Body weight, s.c.
41147843|NCT04389684|OTHER|Psycho-Social Questionnaire|Patients, after enrollmenet in the study, receive a paper questionnaire during the month following COVID19 related confinement and all the material to send it back to the institution. They receive the same questionnaire 3 months later with all the material to send it back to the institution. The intervention is the same for all patients wether their treatment was modified or not.
41147844|NCT04421456|DRUG|GWP42003-P|oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring
41147845|NCT04421456|DRUG|Placebo|oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
41147846|NCT05603442|PROCEDURE|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed by placing the needle tip over and behind the transverse process of vertebra, via the thoracic intervertebral foramen.
41147847|NCT02488733|PROCEDURE|LSG|In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
41147848|NCT02488733|DRUG|CMT|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
41147849|NCT01916447|DRUG|TAS-102|Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
41308945|NCT00578864|DRUG|IV Bolus Etoposide|"Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2"
41308946|NCT00578864|DRUG|Cisplatin|Cycle 1, 2, and 4
41488658|NCT03854786|DIETARY_SUPPLEMENT|Oxyjun|Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.
41308947|NCT00578864|DRUG|Cyclophosphamide|Cycle 3 and 5 with doxorubicin
41488659|NCT03854786|DIETARY_SUPPLEMENT|Pacebo|Methyl Crystalline Cellulose
40788838|NCT01997645|PROCEDURE|LIFT|
40788839|NCT01997645|PROCEDURE|RAF|
40788840|NCT00378638|DRUG|bevacizumab combined with dose dense chemotherapy|
40788841|NCT02311881|DRUG|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
41308948|NCT00578864|DRUG|Mesna|Standard weight-based dosing with cyclophosphamide
41308949|NCT00578864|DRUG|Hematopoietic Factor|Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
41308950|NCT00578864|PROCEDURE|Primary tumor resection|Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
41308951|NCT05136248|PROCEDURE|intraarticular injection|Ultrasound-guided intraarticular injection
41308952|NCT05136248|PROCEDURE|peng block|Ultrasound-guided PENG block
41308953|NCT02678741|DRUG|TLPLDC Vaccine|Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
41308954|NCT02896907|DRUG|Oxaliplatin|Given IV
41308955|NCT02896907|DRUG|Irinotecan Hydrochloride|Given IV
41308956|NCT02896907|DRUG|Leucovorin Calcium|Given IV
40788842|NCT02311881|DRUG|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
40992887|NCT04162028|DRUG|Nebutlized Ketamine|The PK-BAN package will be opened and weight -based dose of ketamine will be administered to the patient via BAN. The medication will be delivered with a minimum time of 5 min and maximum time of 15 min.
40992888|NCT03402009|BEHAVIORAL|Apps|Apps and weblinks to coach self-guided meditation.
40992889|NCT03402009|BEHAVIORAL|EEG neurofeedback|Device provides feedback based on EEG readings.
40992890|NCT04455269|DEVICE|AIRFLOW® with PLUS® powder and PIEZON® scaler|Air-polishing will be use as main instrument for biofilm and stains removal, followed by ultrasonic scaling
40992891|NCT04455269|DEVICE|PIEZON® scaler and rubber cup with abrasive paste|Application of ultrasonic scaler on the entire dentition, followed by residual biofilm and stains removal and polishing
40992892|NCT04001881|OTHER|Transthoracic echocardiography|A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).
40992893|NCT04001881|DRUG|Spinal anesthesia|Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
40992894|NCT02283515|DRUG|Rosuvastatin|Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
40788843|NCT02311881|DRUG|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
40788844|NCT01970228|DIAGNOSTIC_TEST|68Ga-citrate and 18F-FDG PET/CT imaging|Single-day study of the two PET tracers
40788845|NCT04469205|OTHER|Coaching sessions|There are 3 sessions : the first session will last 1h30 and will be in consultation within the Institut Curie. The second session will last 1h30 and will be done remotely (by phone or by videoconference). The duration of the 3rd and last session will be adapted according to the needs of each patient and will last a maximum of 1 hour. It will also be done remotely (by phone or by videoconference).
40788846|NCT01431898|DRUG|GS-9669 tablets|
40788847|NCT01431898|DRUG|Placebo to Match GS-9669 tablet|
40788848|NCT02516501|DIETARY_SUPPLEMENT|MyAmino|MyAmino is a supplement containing the eight essential amino acids. MyAmino has a theoretical net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.
40788849|NCT02516501|DIETARY_SUPPLEMENT|betaquik|betaquik is a medium chain triglyceride (MCT) emulsion. One bottle is 225ml corresponding to 45g MCT fats.
40788850|NCT02516501|RADIATION|Radio(chemo)therapy|Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.
40788851|NCT00361465|OTHER|EMG and Kinematics recording|"The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one)."
40788852|NCT02653092|DRUG|Insulin|
40788853|NCT02653092|DRUG|Intralipid|
40788854|NCT02653092|DRUG|Dextrose|
40788855|NCT02653092|DRUG|Heparin|
41308957|NCT02896907|DRUG|Fluorouracil|Given IV
40788856|NCT02653092|DRUG|GnRH|
41308958|NCT02896907|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
40788857|NCT02653092|PROCEDURE|Hyperinsulinemic Euglycemic Clamp|
40788858|NCT00339040|BIOLOGICAL|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
40992895|NCT04738344|DEVICE|Percutaneous Coronary Intervention and Stent Implantation|Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
40992896|NCT04227821|OTHER|Vasopressor and/inotrope therapy|In pediatric patients admitted to the pediatric intensive care, with the persistent hemodynamic instability after fluid resuscitation, the vasopressor and/or inotrope therapy will be initiated
40992897|NCT03539835|OTHER|Resistance training (RT)|Resistance training (RT) will include 15 repetitions for two sets and to exhaustion on the third set for seven major muscle groups: the leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl. Resistance is gradually increased to account for strength gains when subjects are able to complete 20 repetitions on the third set.
40992898|NCT03539835|BEHAVIORAL|Cognitively-based compassion training control (CBCT)|Cognitively-based compassion training control (CBCT) classes will be performed in a group setting for 1.5-2 hours per week, and consist of didactics, class discussion, and guided meditation practice. Each class will begin with a period of meditation to calm and focus the mind, followed by analytical practices designed to challenge unexamined assumptions regarding feelings, and actions toward others with a focus on generating spontaneous empathy and compassion for themselves and others.
40992899|NCT01623596|DRUG|Fingolimod|
41308959|NCT04115696|DEVICE|Percutaneous placement of biodegradable biliary stents|The bening biliary strictures stents used in this register are made of polydioxanone (PPDX) (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography using the standard micropuncture technique. Before stent implantation, balloon bilioplasty may be performed.
41308960|NCT04151537|BEHAVIORAL|Personal Activity Intelligence|The intervention group is provided with a PAI monitor (wristband) with a user interface (app) to track their own PAI level and are instructed to obtain at least 100 PAI on a weekly basis.
40788859|NCT00339040|OTHER|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
40788860|NCT02526303|DRUG|Nadroparin Calcium and Warfarin|Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
40788861|NCT00614419|DEVICE|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
40992900|NCT01623596|DRUG|Disease Modifying therapy|
40992901|NCT03810274|DEVICE|3DV+TPS；VARIAN TPS；FonicsPlan|
40788862|NCT00614419|DEVICE|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
40788863|NCT04831905|DEVICE|Micro-wave ablation|Micro-wave ablation
40788864|NCT02485587|BEHAVIORAL|Individualized Arousal-Biofeedback|biofeedback of biological measures of arousal (electrodermal activity)
40788865|NCT02485587|BEHAVIORAL|Treatment as usual|counseling, psychoeducation
40788866|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
40788867|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
40788868|NCT02620475|DEVICE|SutureSafe|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
40788869|NCT03867084|BIOLOGICAL|Pembrolizumab|IV infusion of Pembrolizumab 200 mg.
40788870|NCT03867084|DRUG|Placebo|IV infusion of 0.9% normal saline.
40788871|NCT02994966|DEVICE|Surrosense|
40788872|NCT02994966|OTHER|Standard care|
40788873|NCT03132558|DRUG|Radiopaque Media|
40788874|NCT00886769|DRUG|Canakinumab|Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
40788875|NCT00886769|DRUG|Placebo|Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
40788876|NCT04543916|DRUG|Venetoclax 50 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
40788877|NCT04543916|DRUG|Venetoclax 100 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
41467731|NCT03370107|DEVICE|rTMS|Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.
40788878|NCT04543916|DRUG|Venetoclax 200 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
40788879|NCT04543916|DRUG|Venetoclax 400|Escalating doses to determine recommended phase 2 dose (RP2D)
40788880|NCT04543916|DRUG|Venetoclax 600|Escalating doses to determine recommended phase 2 dose (RP2D)
40788881|NCT04543916|DRUG|Irinotecan 60 mg/m2|Intravenously (IV), days 1, 8, and 15
40788882|NCT04543916|DRUG|Venetoclax (RP2D)|orally, once per day
40788883|NCT03569358|DEVICE|Immersive Virtual Reality|The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
40788884|NCT03569358|DEVICE|EEG headband|The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
40788885|NCT03307538|RADIATION|Stereotactic body radiation therapy|15 fractions of 3-4,5 Gy (risk-adapted)
40788886|NCT03308682|DRUG|177Lu-DOTA-EB-TATE|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
40788887|NCT02394821|DRUG|Polihexanide 2%|
40788888|NCT02394821|DRUG|Metronidazole 0.8%|
40788889|NCT04589897|DEVICE|Manuka honey sinus rinse|Will follow a modified NHS nasal rinse protocol with the addition of manuka honey
40788890|NCT04589897|DEVICE|Standard sinus rinse|will follow the standard NHS nasal rinse protocol
40788891|NCT04084535|OTHER|High intensity interval training|Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.
40788892|NCT04084535|OTHER|Inspiratory muscle training|Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
40788893|NCT00107731|DRUG|quetiapine fumarate|
40788894|NCT00107731|DRUG|lithium|
40788895|NCT00107731|DRUG|divalproex|
40788896|NCT02527473|OTHER|Dispatcher-Assisted Basic Life Support CPR Education|"The training program focuses on working in a team with a dispatcher, re-enacting all steps during an emergency call from recognition of cardiac arrest to performing CPR.~The one hour training session is split into four parts:~1. Video self-instruction manikin practice (30 min), including a brief introduction to AED.~2. Practice in pairs (15 min): Role-playing a simulated emergency scenario as the dispatcher and the rescuer~3. Debriefing (15 min): Questions, answers and reflection~4. Homework: Information leaflet handed out including at-home tasks such as operating the speakerphone function on the layperson's own phone"
40788897|NCT05238415|DIAGNOSTIC_TEST|Psychological and Physiological Assessments|About N = 60 patients admitted to the study receive a 3-day assessment (a further examination) at the Kiliani-Klinik Bad Windsheim which considers physical and psychological parameters relevant for the diagnosis of a Post-/ Long-COVID Syndrom.
41467732|NCT00258505|PROCEDURE|Procedure: intracranial monitoring up to 9 days after injury|
41467733|NCT01987726|OTHER|cytology specimen collection procedure|Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H\&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.
40788898|NCT05302310|OTHER|integrated care|"i) Screening of older people for risk of frailty using a frailty screening tool, to identify the appropriate care they will require:~* Older adults with low risk of frailty will receive health promotion and preventive care from the Information and Advice Center nurse and/or social worker.~* Older adults at risk will receive the following:~ii) a Comprehensive Geriatric Assessment (CGA) delivered by the Information and Advice Center nurse and social worker over the course of multiple appointments, to identify the health and social care needs and goals of the older person; iii) Development of an individualized care plan by a multidisciplinary team, which will include evidence-based interventions and be coordinated by the Information and Advice Center nurse and/or the social worker; and iv) follow-up depending on the situation of each older person, and adaptation of the individualized care plan, as needed."
41467734|NCT01987726|OTHER|laboratory biomarker analysis|2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
41467735|NCT01780480|DRUG|Dynamic Chinese herbal granule formula|After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
40788899|NCT06287021|DEVICE|Jump System Traser® cup|Press-fit, cementless, 3D-printed, highly-porous trabecular titanium acetabular cup
41467736|NCT01780480|DRUG|Placebo|The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
40788900|NCT06287021|DEVICE|Jump System HAX-Pore® cup|Press-fit, cementless, hydroxyapatite/titanium plasma-sprayed acetabular cup
40788901|NCT04068454|DEVICE|Virtual reality device|Functional exercises will be done by virtual reality group
40788902|NCT04068454|OTHER|EBM rehabilitation exercises|scapular exercises will be done
41308961|NCT04151537|BEHAVIORAL|Physical Activity Guidelines|The control group is recommended to follow national PA guidelines, meaning 150 minutes of moderate-intensity PA or 75 minutes of vigorous-intensity PA, or a combination there of. The control group is provided with a PAI monitor (wristband) without any user interface and are thus blinded to track their own PAI level.
41308962|NCT00995345|DRUG|KRP-104|Tablet
41308963|NCT00995345|DRUG|Placebo|Tablet
41308964|NCT05955586|DRUG|SPR720|SPR720 1000 mg (250 mg\*4 capsules) will be administered orally.
41147850|NCT01916447|DRUG|CPT-11|Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
41308965|NCT06279130|DRUG|botensilimab|Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)
41308966|NCT06279130|DRUG|balstilimab|Anti programmed cell death protein-1 (anti-PD1)
41341704|NCT02782247|DEVICE|Transient elastography|"Transient elastography will be measured using a Fibroscan® machine which is manufactured by echosens®. It has a CE mark of 0459.~It is a non-invasive method to accurately measure stiffness of a patient's liver without the need for a liver biopsy. This is measured by an externally placed ultrasound probe which creates an elastic shear wave at 50Hz, and measures the velocity of the echo through the liver tissue. The liver stiffness is measured in kilopascals (kPa). It has been shown to be 99% effective in detecting cirrhosis in hepatitis C and has been shown to correlate with hepatoma production in both hepatitis C and hepatitis B. Values range from - normal \< 9.6 kPa, significant fibrosis 9.6-11.4kPa, cirrhosis \>11.5kPa. It cannot be used in patients with ascites."
41467737|NCT01780480|PROCEDURE|Standard medical care|Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
40788903|NCT03150381|BEHAVIORAL|Weight Loss Only|24- month weight loss program (year 1: weekly in person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
40788904|NCT03150381|BEHAVIORAL|Weight Loss Plus|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
40788905|NCT03150381|BEHAVIORAL|Control|Participants receive quarterly newsletters containing generic cancer prevention messages and participate in community-wide cancer awareness educational sessions.
40788906|NCT03368781|DEVICE|AcQMap Imaging and Mapping System|3D Cardiac Imaging and Mapping during ablation procedures
40992902|NCT00109395|DRUG|Lorazepam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
40788907|NCT02487966|DEVICE|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
40788908|NCT02487966|BEHAVIORAL|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
40788909|NCT02487966|DEVICE|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
40788910|NCT02487966|BEHAVIORAL|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
40788911|NCT03810846|BEHAVIORAL|Walking football exercise program|Participants will be organized in two teams of 20 players. Each team will have 60-min walking football exercise sessions three times per week (non-consecutive days), during three months (36 sessions). Different walking football exercise strategies will be developed according to participants' motor skills and tested with dose-escalated intensity for its safety and enjoyment. Exercise intensity will range between light to vigorous. No submaximal or maximal exercises will be tested. Exercise sessions will be conducted on a sports hall (indoor court) by a football coach and supervised by an exercise physiologist and a nurse.
40788912|NCT01082081|DRUG|Paracetamol 1000 mg|Paracetamol 1000 mg
40788913|NCT01082081|DRUG|Paracetamol 500 mg|Paracetamol 500 mg
40788914|NCT01082081|DRUG|Placebo|Placebo
40788915|NCT04375436|DRUG|NTRX-07-SDD|NTRX-07-SDD for oral administration
40788916|NCT05075889|DRUG|Indocyanine Green|Enrolled subjects will receive Indocyanine Green administered the day prior to surgery during their standard-of-care preoperative appointment
40788917|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
40788918|NCT04750343|BIOLOGICAL|GBP510 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 10μg/dose) on Days 0 and 28.
40788919|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
40788920|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
40788921|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
40788922|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
40788923|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
40788924|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
40788925|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
40788926|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
41467738|NCT01439724|DEVICE|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
40788927|NCT02743767|PROCEDURE|Introducing five different treating adaptations|Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
40788928|NCT02354261|DRUG|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
40788929|NCT03318445|DRUG|Rucaparib|All participants will take rucaparib by mouth
40788930|NCT03318445|DRUG|Irinotecan|Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
40788931|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
40788932|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
40788933|NCT05634473|DRUG|Methacholine Chloride|Cholinergic agonists
40992903|NCT00109395|DRUG|Midazolam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
40992904|NCT00109395|DRUG|Lorazepam CI|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
41467739|NCT01439724|DEVICE|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
41467740|NCT03561558|DRUG|Ibuprofen D|Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
40788934|NCT02644824|DEVICE|Biventricular Pacing (BiVp)|BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
40788935|NCT01041950|PROCEDURE|Lumbar drainage|Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
40788936|NCT02274961|DRUG|S-pantoprazole 10mg|
40788937|NCT02274961|DRUG|Placebo|
40788938|NCT05999331|OTHER|initial aspartate aminotransferase (AST) to platelet (PLT) ratio index|All eligible patients were given antibiotics therapy, actively control infection source, as well as other supportive therapy to maintain organ function.
40788939|NCT01808469|BIOLOGICAL|Monoclonal antibody|
40788940|NCT04643847|DRUG|Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
40788941|NCT02800733|DIETARY_SUPPLEMENT|Saffron|20 patients with mild to moderate GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IѴ (DSM-IѴ) who receive sertraline will randomly receive saffron (450 mg) as an add-on therapy on daily bases for 6 weeks. Hamilton Anxiety Rating Scale (HAM-A) will use to assess the effect of treatment.
40788942|NCT02800733|DIETARY_SUPPLEMENT|placebo|20 patients with mild to moderate GAD who receive sertraline will receive placebo too
40788943|NCT05578989|DEVICE|Virtual reality glasses|watching a video with music with virtual reality glasses.
41147851|NCT01916447|DRUG|Bevacizumab|Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
41147852|NCT04271254|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-surgery PET/MR within four weeks of scheduled surgery.
41147853|NCT06177067|DRUG|Revumenib|Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)
41467741|NCT03561558|DRUG|Nurofen® for Children|Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
41467742|NCT05359783|DRUG|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension.
41467743|NCT05352724|DIETARY_SUPPLEMENT|Hydration drink|Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice
41467744|NCT05628441|OTHER|Computer Aided Detection system for Barrett's neoplasia|CADe system running in the back, not directly interfering with patient care
40992905|NCT01012011|DRUG|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
40788944|NCT03039387|DEVICE|anodal transcranial direct current stimulation|
40788945|NCT03039387|DEVICE|transcranial direct current stimulation (sham)|for the placebo control condition, the transcranial direct current stimulation will only last for 30 seconds and will then be ramped down.
40788946|NCT00363142|DRUG|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
40788947|NCT00363142|DRUG|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
40788948|NCT06130566|DRUG|Amlitelimab|Injection solution SC injection
40788949|NCT06130566|DRUG|Placebo|Injection solution SC injection
40788950|NCT00572104|OTHER|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
40788951|NCT00572104|OTHER|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
40992906|NCT04528745|DIAGNOSTIC_TEST|Bio Impedance Spectroscopy (BIS)|Determination of fat free mass by BIS
40992907|NCT00279734|DRUG|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
40992908|NCT00279734|DRUG|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
41147854|NCT06177067|DRUG|Venetoclax|Given by mouth (tablet)
41147855|NCT06177067|DRUG|Azacitidine|Given intravenously (IV) infusion
41147856|NCT06177067|DRUG|intrathecal (IT) chemotherapy|Given intrathecal (IT)
41147857|NCT06177067|DRUG|Cytarabine|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
40788952|NCT04544735|BEHAVIORAL|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will provide pelvic health physical therapy interventions including: education about vaginal moisturizers and lubricants, low back and hip assessment and instruction in accommodations (e.g., strategies for accommodating sexual position of choice), instruction in vulvar massage, instruction and facilitation of vaginal dilator use, and pelvic floor muscle training (PFMT) and exercises. Women will be given a set of vaginal dilators. Cognitive behavioral techniques that have been successfully used by physical therapists in prior intervention studies will be integrated into the PT intervention including breathing and relaxation techniques, guided imagery, systematic desensitization, cognitive restructuring techniques and coping thoughts, and problem solving
40788953|NCT01558596|PROCEDURE|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
40788954|NCT01558596|PROCEDURE|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
40788955|NCT03273907|DEVICE|CyPass Micro-Stent implanted with CyPass 241-S applier|CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.
40788956|NCT03273907|PROCEDURE|Cataract surgery|Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit
40788957|NCT00577369|OTHER|Desflurane Levels|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
41308967|NCT03416738|BEHAVIORAL|Semantically focused treatment|"Tasks are as follows:~1. Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~2. Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~3. Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation."
41308968|NCT03416738|BEHAVIORAL|Phonologically focused treatment|"Tasks are as follows:~1. Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~2. Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~3. The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation."
41308969|NCT06285929|OTHER|ACS CARES Student Navigation|Student volunteers providing navigation support to patients, families and caregivers with a cancer diagnosis through an SDOH assessment.
41308970|NCT03535038|DIAGNOSTIC_TEST|Inferior vena cava (IVC) diameter using USG|IVC diameter is measured from the distal of right hepatic pain and inferior vena cava meeting point using Philips En Visor C USG.
41308971|NCT03535038|DIAGNOSTIC_TEST|Vascular pedicle width (VPW)|VPW is measured by drawing a line from the left subclavian artery exit point from aorta perpendicular to the point where superior vena cava crosses with right bronchi.
41467745|NCT02294448|DRUG|Qishe Pill|Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
41467746|NCT03559725|OTHER|VLN menthol cigarettes (A)|0.4mg nicotine / g tobacco king size filter menthol cigarette
41467747|NCT03559725|OTHER|Usual Brand Menthol Cigarettes (B)|Usual brand king size menthol cigarettes
41467748|NCT03559725|DRUG|Nicotine gum (C)|4 mg nicotine gum
41467749|NCT04323462|DRUG|Insulin Glargine|Three times bolus insulin with regular or Shorter acting insulin
41467750|NCT04323462|DRUG|Diabetic DM|Previously receiving OADs and/or basal insulin
41467751|NCT04845516|OTHER|Efficacy of apheresis|Efficacy of apheresis
41467752|NCT06614907|DRUG|QL2108 injection|300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
41467753|NCT06614907|DRUG|Dupixent®|300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
41467754|NCT06087406|DRUG|Imvotamab|Administered intravenously
41467755|NCT06087406|DRUG|Placebo|0.9% sodium chloride administered intravenously
41467756|NCT02182167|DRUG|IV N-acetylcysteine (NAC)|
41467757|NCT02182167|DRUG|Water|
40992909|NCT00279734|DRUG|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
40992910|NCT00279734|DRUG|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
40992911|NCT00012142|DRUG|temsirolimus|
40992912|NCT00669812|DRUG|carmustine|
40992913|NCT00669812|DRUG|cyclophosphamide|
40992914|NCT00669812|DRUG|cytarabine|
40788958|NCT03785184|DRUG|venetoclax|tablet; oral
40788959|NCT03785184|DRUG|lenalidomide|capsule; oral
40788960|NCT03785184|DRUG|dexamethasone|tablet; oral
40788961|NCT02573571|OTHER|Development of biomarkers|Blood sampling
40788962|NCT06141551|PROCEDURE|total laminectomy decompression|Surgical decompression
40788963|NCT00517699|DRUG|rituximab [MabThera/Rituxan]|750mg/m2 iv
40788964|NCT00517699|DRUG|Methotrexate|8g/m2 iv
40788965|NCT00517699|DRUG|Cytarabine|2g/m2 iv
40788966|NCT04069312|DRUG|Roflumilast|Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months
40788967|NCT04069312|DRUG|Azithromycin|Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
40992915|NCT00669812|DRUG|doxorubicin hydrochloride|
40992916|NCT00669812|DRUG|epirubicin hydrochloride|
41308972|NCT04899791|OTHER|Wheat bread enriched with hydroxytyrosol|Wheat bread enriched with hydroxytyrosol
41308973|NCT04899791|OTHER|Wheat bread|Wheat bread
41308974|NCT01933191|BEHAVIORAL|Aerobic treadmill exercise|Experimental training: Aerobic treadmill exercise (30 minutes, 70% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
41467758|NCT06090890|DRUG|Colchicine|Add 0.5mg QD orally and start using it within 48 hours after intervention.
41467759|NCT06090890|DRUG|Prednisone|0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.
41467760|NCT06090890|DRUG|Aspirin|Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.
41467761|NCT06090890|DRUG|P2Y12 Receptor Antagonist|Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.
41467762|NCT06090890|DRUG|Lipid-lowering drug|Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
41467763|NCT00432627|DRUG|Deferasirox|one dose of 20 mg/kg/day
41467764|NCT06038396|DRUG|RC118|RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
41467765|NCT06038396|DRUG|Toripalimab|Toripalimab is a recombinant humanized anti-PD1 monoclonal antibody
41467766|NCT00825864|DRUG|diclofenac drops|one drop 4 times a day for 3 months
41467767|NCT00825864|DRUG|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
41467768|NCT01226537|DRUG|Taurine|500 mg taurine capsules twice per day for 6 months
41467769|NCT01212549|PROCEDURE|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 more weeks imiquimod
41467770|NCT01212549|PROCEDURE|Cryoimmunotherapy|Cryosurgery(open spray liquid nitrogen, 2 cycles, 15 secs each), followed by 5 weeks imiquimod
41467771|NCT04683588|OTHER|Nursing Coaching|Different strategies, methods and training techniques are used in the implementation of preoperative and postoperative nursing care of surgical patients scheduled for total knee arthroplasty surgery. One of them is patient coaching. Coaching is a method that increases the quality of nursing care.While the coaching strategy contributes more to the recovery process of the patient with the role of the case manager of the nurse, it provides a reduction in the problems related to surgery (pain, nausea-vomiting, mobilization problems), reduction in repeated hospitalizations and positive contributions to the cost.
41467772|NCT05164835|OTHER|pharmaceutical follow-up|"Pharmaceutical follow-up over 1 year and pharmaceutical interviews during the various medical consultation appointments.~In addition to the usual care:~* Delivery of questionnaire at the time defined in the protocol. The questionnaires will be given during the waiting time of the patients at the University Hospital of Limoges.~* Extension of the duration of the usual interview by 10 minutes in order to collect the desired information."
41467773|NCT01589601|BEHAVIORAL|Usual heart failure care|Usual heart failure care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
40788968|NCT03571932|BEHAVIORAL|Family planning and immunization service integration|The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
41147858|NCT06177067|DRUG|Methotrexate|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
40788969|NCT01252082|PROCEDURE|Scaling and Rootplaning|All patients in the test group receive scaling and rootplaning under local anesthesia
40992917|NCT00669812|DRUG|etoposide|
41147859|NCT02548052|DRUG|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
41308975|NCT01933191|BEHAVIORAL|placebo exercise|placebo exercise: Aerobic treadmill exercise (30 minutes, 20% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
41308976|NCT01029886|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once weekly
41308977|NCT01029886|DRUG|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
41308978|NCT04905381|BEHAVIORAL|Usual care|This arm receives usual care (control group)
41147860|NCT02548052|DRUG|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
41308979|NCT04905381|BEHAVIORAL|LENA Star Program sessions|LENA Start is an evidence-based community program designed to engage families and help them learn how to increase conversation with their children during the first few years of life.
41308980|NCT00613418|DEVICE|IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System|Interwoven, self-expanding nitinol stent system, including delivery system and stent
41308981|NCT05676320|DEVICE|V-Flex|Bone cement including Inossia Cement Softener. Treatment for vertebral compression fracture
41308982|NCT05676320|DEVICE|V-Steady|Bone Cement alone
41308983|NCT04188340|BEHAVIORAL|Su-Man formula massage oil|bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
41308984|NCT05414617|DEVICE|Intra-articular single injection|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1."
41308985|NCT05414617|DEVICE|Intra-articular three injections|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injections will be performed at Days 1, 8 and 15."
40992918|NCT00669812|DRUG|ifosfamide|
41308986|NCT04851717|DRUG|Remimazolam|Remimazolam for intravenous sedation
41308987|NCT04246580|PROCEDURE|Indocyanine green-guided systematic pelvic lymphadenectomy|Injection of Indocyanine green within the uterine cervix before to perform laparoscopic/robotic systematic pelvic lymphadenectomy
41147861|NCT02548052|DRUG|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
41147862|NCT02548052|DRUG|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
41147863|NCT02548052|DRUG|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
41308988|NCT03375359|DIAGNOSTIC_TEST|cfDNA screening|cfDNA screening test for aneuploidy risk assessment
41467774|NCT01589601|BEHAVIORAL|Interdisciplinary palliative care|Interdisciplinary palliative care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
41467775|NCT00468793|PROCEDURE|Intravenous fluid|The same intravenous fluids will be used in both arms but the volume will be different
41308989|NCT00139854|DRUG|Alprazolam orally disintegrating tablets|
41308990|NCT01506778|DEVICE|Tenaculum|Single tooth tenaculum are use to the cervix for steady the cervix, straighten the cervicouterine angle and provide countertraction. Most of gynecological office procedure such as endometrial sampling procedure, hysterosalpingography, hysteroscopy, insertion of contraceptive intrauterine device, difficult intrauterine insemination or embryo transfer procedures often require the application of a tenaculum.
41308991|NCT01368341|DRUG|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
41467776|NCT04039490|DEVICE|SCENERGY|Use of the SCENERGY guidance device in conjunction with ultrasound to guide needles for pediatric vessel cannulations
40992919|NCT00669812|DRUG|melphalan|
40992920|NCT00669812|DRUG|methotrexate|
40992921|NCT00669812|DRUG|prednisolone|
40992922|NCT00669812|DRUG|vincristine sulfate|
40992923|NCT00669812|PROCEDURE|autologous hematopoietic stem cell transplantation|
40992924|NCT00669812|PROCEDURE|biopsy|
40992925|NCT00669812|PROCEDURE|peripheral blood stem cell transplantation|
40992926|NCT04429737|DIETARY_SUPPLEMENT|clam protein capsules|The prediabetes patients in this arm will receive Clam protein capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
40788970|NCT04347343|PROCEDURE|Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction|"Subjects will begin a standardized protocol on post-op day 2. Outpatient visits will be 2x/wk for weeks 0-4 and then 1x/wk for weeks 5-8.~Subjects will utilize NMES on the quadriceps in the home setting 2x/day for the first 3-4 weeks during isometric contractions at their highest tolerated intensity. Total treatment will begin at 10 minutes.~At the end of post-op week 2, subjects will be exposed in clinic to BFR on the surgical limb increasing to 80% limb occlusion pressure over weeks 3-4 as tolerated. Initially, BFR and NMES will be performed simultaneously. BFR will then be progressed using active exercises. After completing a safety checklist, subjects will be issued a home BFR unit for use 2x/week (3x total including clinic visit) at which time NMES will be discontinued. BFR exercise intensity will be progressed as tolerated to maintain 20-30% of 1RM."
41467777|NCT04819854|DRUG|EP395|capsule for oral treatment
41467778|NCT04819854|DRUG|Placebo|capsule for oral treatment
40788971|NCT06332976|OTHER|Completion of questionnaires|Completion of questionnaires at the time of study entry
40788972|NCT05084248|DRUG|Ergocalciferol Capsules|Capsules of ergocalciferol at 400 IU and 4000 IU
40788973|NCT05361174|BIOLOGICAL|IOV-4001|A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.
41467779|NCT04768634|DIAGNOSTIC_TEST|Provocative electrophysiology study|Provocative electrophysiology testing will be performed at the bedside using the temporary pacing wires placed at the time of surgery.
41467780|NCT00099957|DRUG|vildagliptin|
41488660|NCT06011616|OTHER|Sensory training|sensory training includes superficial sensory and deep sensory activities i.e. play with dough, painting with finger, recognizing objects with blocked vision, recognizing the drawn figure on palm, oint compression, bearing the weight on the paretic hand, leaning on the paretic side, walking with hand, rolling the heavy objects, dough squeezing etc.
41488661|NCT06011616|OTHER|Motor training|Motor training would involve activitoes such as throwing and catching a ball, targeted ball throwing, hand in hand ball transferring, ball rolling, hitting a ball to ground and wall, hand roller etc.
40788974|NCT02060929|DRUG|Esketamine|Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
40788975|NCT05608954|OTHER|Bobath Concept|Handling of the Bobath Concept
40788976|NCT05608954|OTHER|Pediasuit|Pediasuit
40788977|NCT05608954|OTHER|Locomotor training|Locomotor training
40788978|NCT05608954|OTHER|Stretching|Active, passive, active-assisted stretching
40788979|NCT05608954|OTHER|Psychomotricity|Psychomotor skills
40788980|NCT05608954|OTHER|Virtual reality|Virtual reality
41147864|NCT02548052|DRUG|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
40788981|NCT05232279|DRUG|Testofen 300mg|Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
40788982|NCT05232279|DRUG|Testofen 600mg|Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
41147865|NCT03596697|DRUG|CRV431|Single or multiple dose(s) of CRV431
41147866|NCT03596697|DRUG|Placebo|Single Placebo dose
41147867|NCT03596697|DRUG|TDF|Single or multiple dose(s) of TDF
41266365|NCT04459845|BEHAVIORAL|Child Parent Psychotherapy|Child-parent psychotherapy (CPP; Lieberman et al., 2005) is a relationship-based treatment that integrates attachment, cognitive-behavioral, social-learning, and psychodynamic theories. CPP focuses on the child-parent relationship as a way to improve the child's adaptive functioning. Various treatment strategies are employed including a focus on safety, affect regulation, the joint construction of a trauma narrative, and engagement in developmentally appropriate activities.
41266366|NCT06110052|OTHER|prospective follow up|compare preoperative and postoperative visual analog scale VAS of maximum perceived pain in ladies with OMAs
41266367|NCT06313437|DRUG|Revumenib|Menin inhibitor, 25 and 113 mg capsules, taken orally per protocol.
41266368|NCT06313437|DRUG|Midostaurin|Kinase inhibitor, capsule taken orally per protocol.
41266369|NCT06313437|DRUG|Cytarabine|Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
41266370|NCT06313437|DRUG|Daunorubicin|Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
41266371|NCT04589598|DEVICE|Femoral Neck System|femoral neck system using bolt and antirotation screw with one/two hole plate
41266372|NCT04589598|DEVICE|Multiple Cannulated Screw|multiple cannulated screw using 3 or 4 cannulated screw
41308992|NCT01368341|DRUG|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
40992927|NCT04429737|DIETARY_SUPPLEMENT|Clam peptide plus Chlorella capsules|The prediabetes patients in this arm will receive Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
40992928|NCT04429737|DIETARY_SUPPLEMENT|Placebo|The prediabetes patients in this arm will receive Placebo with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
40992929|NCT03226431|DRUG|Ascorbic Acid|ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
40992930|NCT03744533|OTHER|head-down position treatment|the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.
40992931|NCT03744533|OTHER|guideline-based treatment|guideline-based treatment
41467781|NCT01708655|OTHER|Sweat Evaporimeter measurement|"1. The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.~2. intracutaneous injection of 0.2 ml of atropine~3. Stimulation and inhibition of sweating in an adjoining test area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:~   1. Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.~  2. intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion~  3. intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .~The procedure would take about 45 minutes."
41467782|NCT06319079|DIETARY_SUPPLEMENT|Fortified powder milk|Super 1.000 Mamá It's made up of milk with added vegetable oils, fish oil, carbohydrates from corn, prebiotic fiber (inulin), vitamins, and minerals, with specifically defined proportions. It has medium energy content, is balanced in protein, fats, and carbohydrates, and provides a significant content of both polyunsaturated fatty acids, such as omega-6, and omega-3, and the added docosahexaenoic acid, as recommended by international organizations. The reconstituted 200 ml serving delivers between 20 and 40% of the Daily Reference Intake in critical nutrients for this particular group of people, which include minerals such as calcium, iron, zinc, iodine, and vitamins such as A, D, C, B12 and folic acid. The rest of the vitamins, and minerals are also at the same level, allowing those who consume it to incorporate a large amount of nutrients regularly. Addvance SA, an SME dairy company from the Province of Santa Fe, will carry out the production of this milk.
41308993|NCT01368341|DRUG|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
40788983|NCT05232279|DRUG|Placebo comparator|The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
40788984|NCT05869123|RADIATION|Online adaptive radiotherapy|PTV with 5 margins covers CTV
40788985|NCT03186625|DRUG|Compound Panax Notoginseng Granule|"Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months."
40788986|NCT03186625|DRUG|Placebo Granule|Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
41308994|NCT03879317|DEVICE|Continuous NIRS monitoring|Septic shock patients who have continuous NIRS and blood pressure monitoring at same time will be included. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
41308995|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
40788990|NCT03661840|BEHAVIORAL|Acceptance and Commitment Therapy|Intervention group participants will attend eight weekly, 90-minute, in person, group-based ACT sessions. Groups will be initiated with no more than 10 participants and no fewer than 6 participants. Sessions will include key theoretical ACT constructs and strategies as they relate to chronic pain. A licensed clinical psychologist or licensed clinical social worker trained in ACT will facilitate all sessions. Participants in the ACT intervention group will also continue to receive medication management and other behavioral management interventions that they would get as usual treatment.
40992932|NCT04430933|DRUG|NC318|NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
41308996|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
41308997|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
41308998|NCT00207766|DRUG|infliximab or placebo|
41467783|NCT06319079|OTHER|Powder milk|Commercial powder milk constitutes dehydrated commercially available cow's milk, which is fortified with Vitamins A and D by law.
41467784|NCT04556578|PROCEDURE|High-flow extracorporeal CO2 removal|Applying of a CO2 removal using an extracorporeal circulation with a flow of 2-3.5L/min in order to reduce the aggression induced by the mechanical ventilation.
41467785|NCT05070390|DRUG|Enlicitide Chloride|10 mg capsule administered orally
41467786|NCT04477200|DRUG|Mycophenolate Mofetil|500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)
41467787|NCT04477200|RADIATION|Radiation Therapy|40.5 Gy in 15 fractions
41467788|NCT04477200|PROCEDURE|Re-resection (as part of standard of care)|Re-resection or biopsy of tumor as part of standard of care
41467789|NCT04477200|DRUG|Temozolomide|Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
41467790|NCT04477200|DRUG|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT.
41467791|NCT04477200|DRUG|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.
41467792|NCT04477200|RADIATION|Radiation Therapy|60 Gy in 30 fractions
41467793|NCT01223235|BIOLOGICAL|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
41467794|NCT06286761|OTHER|endothelial cell collection|Participants may opt to have testing performed including blood sampling, intravenous catheter placement with endothelial cell collection, oral glucose tolerance test, consuming a test meal, having imaging performed such as MRI, DEXA, MRS to investigate use of different assays, different sample treatment approaches to determine optimal conditions that produce the most accurate and reproducible results, and/or repeat testing on different days or with different equipment that measures the same variable.
41467795|NCT02237547|BIOLOGICAL|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells|
40788991|NCT03661840|OTHER|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management. This includes continued medication management for cancer related chronic pain by prescribing providers, and access to supportive oncology services. It may also include other behavioral pain management such as physical therapy, acupuncture, or massage.
41308999|NCT02566941|DEVICE|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
41467796|NCT05436132|BEHAVIORAL|VR and AR oral healthcare curriculum training|HCWs in the VR/AR group received 2.5 hours VR and AR oral healthcare curriculum training. VR oral care training system was training the standard oral healthcare procedure for different physical and oral conditions in elderly people.AR oral care training system was training for the manual Bass brushing technique.
41467797|NCT05436132|BEHAVIORAL|traditional teaching methods oral healthcare curriculum|HCWs in the control group received 2.5 hours traditional teaching methods of oral healthcare curriculum training.
41467798|NCT01776567|DEVICE|Everolimus eluting stents|
41467799|NCT00508027|DRUG|Simvastatin|Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
41467800|NCT01009515|DRUG|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
41467801|NCT04353258|BEHAVIORAL|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
41467802|NCT04353258|BEHAVIORAL|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
41467803|NCT00697840|BIOLOGICAL|Engerix™-B|Intramuscular injection, 2 doses
41467804|NCT00697840|BIOLOGICAL|HBV-MPL 208129|Intramuscular injection, 2 doses
41467805|NCT00697840|BIOLOGICAL|Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation|Intramuscular injection, 2 doses; experimental formulation
41467806|NCT01937351|DEVICE|Pantheris System|Atherectomy using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries.
41467807|NCT00656968|DRUG|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
40788992|NCT04256473|DRUG|mutant pro-urokinase|Intravenous administration
41309000|NCT03041909|DRUG|GBT440|Oral drug
41309001|NCT01079962|DRUG|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
41309002|NCT01079962|DRUG|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
41309003|NCT00258427|BIOLOGICAL|anti-thymocyte globulin|Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.
41309004|NCT00258427|BIOLOGICAL|filgrastim|given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10\^9/L)
41309005|NCT00258427|DRUG|busulfan|Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if \<4 years old)
41309006|NCT00258427|DRUG|cyclophosphamide|10 mg/kg intravenously (IV) on Days -5 through -2.
41309007|NCT00258427|DRUG|fludarabine phosphate|35 mg/m\^2 intravenously (IV) on Days -5 through -2.
41309008|NCT00258427|DRUG|methylprednisolone|1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
41467808|NCT00656968|DRUG|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
41467809|NCT03702049|BEHAVIORAL|Nurse-led Community Health Worker TBI (RN/CHW TBI) program|Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.
41467810|NCT04572204|OTHER|Surgical|Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization
41467811|NCT05917691|PROCEDURE|Bariatric surgery|Current Procedural Terminology (CPT) codes: 43644, 43645, 43770, 43775, 43842, 43843, 43845, 43846, 43847.
41467812|NCT05917691|DRUG|General anesthetic|"Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database)."
41467813|NCT05917691|DEVICE|Indeterminate|Devices were indeterminate under the current study design (observational study of a deidentified database).
41467814|NCT01814358|DIETARY_SUPPLEMENT|Whey protein powder|Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
41467815|NCT01814358|DIETARY_SUPPLEMENT|Control protein|Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
41467816|NCT01758237|DEVICE|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser|This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
41309009|NCT00258427|BIOLOGICAL|Hematopoietic stem cell transplantation|Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
41309010|NCT02515617|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
41467817|NCT01758237|PROCEDURE|Nd:YAG Laser Peripheral Iridotomy|After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
41467818|NCT03088878|DRUG|Cirmtuzumab (2-16 kg/mg) plus Ibrutinib|Participants will receive escalating doses of cirmtuzumab (2-16 mg/kg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily, starting at week 4.
41467819|NCT03088878|DRUG|Cirmtuzumab (300mg) plus Ibrutinib|Participants will receive cirmtuzumab (300 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
41467820|NCT03088878|DRUG|Cirmtuzumab (600 mg) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
41467821|NCT03088878|DRUG|Cirmtuzumab (RDR) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily
41467822|NCT03088878|DRUG|Cirmtuzumab plus ibrutinib|Arm A: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
40788993|NCT04256473|DRUG|Alteplase|Intravenous administration
41309011|NCT02515617|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
41309012|NCT04129606|DIAGNOSTIC_TEST|Computed tomographic cystography|CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
40788994|NCT03180112|GENETIC|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
41309013|NCT03740607|DEVICE|Virtual reality|Healthcare virtual reality software implemented during peripheral intravenous catheter placement
41309014|NCT03740607|PROCEDURE|Peripheral intravenous catheter placement|Peripheral intravenous catheters are placed in the peri-operative suites in preparation for anesthesia during surgery.
41309015|NCT04770987|OTHER|lateral neck flexor endurance test|Individuals will maintain the head in a neutral position off the ground in sidelying for as long as possible.
41309016|NCT00396708|DEVICE|myomo e100 neurorobotic elbow brace|
41309017|NCT02626533|PROCEDURE|Total Knee Arthroplasty|Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
41467823|NCT03088878|DRUG|Ibrutinib alone|Arm B: Participants will receive ibrutinib (420 mg) orally once daily
41488662|NCT06011616|OTHER|Conventional exercises|stretching exercises, muscle strengthening exercises, static weight bearing exercises, positioning
41309018|NCT03051334|OTHER|diagnosed as bicuspid aortic valve|
41309019|NCT02524860|DEVICE|Focal-Fusion Bx|The Focal-Fusion Bx device uses hardware and software to overlay targets onto the live ultrasound image in real-time. This allows the urologist to take biopsy samples from tissue that looked suspicious on the patient's MRI.
41309020|NCT04671316|DRUG|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water"
41309021|NCT04671316|DRUG|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab without water"
41309022|NCT04671316|DRUG|Lixiana 60mg Tab|"single oral administration of 1 tablet of Lixiana 60mg Tab with 150mL water"
41309023|NCT01182623|OTHER|Observation of surface patterns of polyps|examination of the surface patterns of polyps using FICE and indigo carmine dye spray
41309024|NCT05909215|DRUG|Normal saline|Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes
41309025|NCT05909215|DRUG|Dexmedetomidine 0.5 microgram/kg|Dexmedetomidine 0.5 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
41467824|NCT02335957|RADIATION|Irradiation|Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
41467825|NCT02376660|OTHER|Oats|
41467826|NCT00377572|BIOLOGICAL|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
41467827|NCT00377572|BIOLOGICAL|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
41467828|NCT00606138|DRUG|ranibizumab|One 0.5 mg intravitreal injection
41467829|NCT00606138|PROCEDURE|Laser photocoagulation|panretinal photocoagulation (up to 500 300-500 um laser spots)
41467830|NCT05450991|PROCEDURE|Pull through|Children diagnosed with Hirschpsrung's Disease or an anorectal malformation, with or without operative intervention will be included
40788995|NCT01354522|DRUG|Docetaxel, Doxorubicin, Cyclophosphamide|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
41309026|NCT05909215|DRUG|Dexmedetomidine 0.75 microgram/kg|Dexmedetomidine 0.75 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
41309027|NCT02697513|BEHAVIORAL|simple infection management protocol|Implementation of a simple management protocol to improve care of patients with acute infection. Implementation will be assisted by a 1.5-day focused training program.
41309028|NCT01390116|DIETARY_SUPPLEMENT|Aged garlic extract|2 aged garlic extract capsules taken twice daily
41309029|NCT01390116|DIETARY_SUPPLEMENT|AGE|encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
41309030|NCT05282264|OTHER|device|closed-loop insulin
41467831|NCT00784134|DRUG|Alteplase|1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
41467832|NCT00784134|OTHER|Normal saline|1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
41467833|NCT02496208|PROCEDURE|Biopsy|Undergo biopsies
40788996|NCT01354522|DRUG|Docetaxel, Cyclophosphamide, Capecitabine|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
40788997|NCT03859037|OTHER|Umbilical cord milking|100 babies will have squeezing of blood from umbilical cord towards baby
40788998|NCT04895371|OTHER|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
40788999|NCT04895371|OTHER|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
40789000|NCT00702832|BEHAVIORAL|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
40789001|NCT00702832|OTHER|standard treatment|treatment as usual
40789002|NCT05079347|DIAGNOSTIC_TEST|HIV rapid test|Using a rapid test to assess a patient's HIV status
40789003|NCT01079325|DRUG|SB-509|SB-509 60 mg, 3 treatments, and 5 months treatment period
40789004|NCT01079325|OTHER|Saline|
40789005|NCT02337894|DIETARY_SUPPLEMENT|Essential amino acids plus arginine|Flavored drink containing essential amino acids plus arginine.
40789006|NCT02337894|DIETARY_SUPPLEMENT|Placebo|Flavored drink without essential amino acids plus arginine.
40992933|NCT04430933|DRUG|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
40992934|NCT04430933|DRUG|Nab paclitaxel/Carboplatin|Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
41309031|NCT03009539|BEHAVIORAL|eHealth Familias Unidas Primary Care|"The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family."
40992935|NCT04430933|DRUG|Docetaxel|Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
40992936|NCT01316276|DRUG|Liposomal amikacin for inhalation|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
40992937|NCT02049333|PROCEDURE|Phacoemulsification|
40992938|NCT02049333|PROCEDURE|Endoscopic Cycloplasty (ECPL)|
40992939|NCT05886296|BEHAVIORAL|Evaluation of the impact of a pre-surgical information session for people who must undergo shoulder rotator cuff surgery on empowerment for their functional rehabilitation process.|To evaluate the effect of the implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution of functionality, quality of life, empowerment and self-efficacy in the three months of the surgical intervention.
40789007|NCT05531565|DRUG|Litifilimab|Administered as specified in the treatment arm.
40789008|NCT05531565|DRUG|Placebo|Administered as specified in the treatment arm.
40789009|NCT05545410|OTHER|MRI calibration|Non-injected thoracic aorta MRI calibration
40992940|NCT04356690|DRUG|Etoposide|Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4.
40992941|NCT01548131|BEHAVIORAL|Psychoeducative group therapy|6 sessions during pregnancy and 1 after childbirth
40992942|NCT01139450|DRUG|0417|Topical 0417 test product applied twice daily for 4 weeks
40992943|NCT01139450|DRUG|Vehicle of 0417 test product|Vehicle of 0417 test product applied twice daily for 4 weeks
40992944|NCT01139450|DRUG|Tacrolimus Ointment 0.03%|Reference product for 0417 test product. Apply twice daily for 4 weeks
40992945|NCT03263208|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
40992946|NCT03263208|DRUG|Fludarabine|Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
40992947|NCT03263208|BIOLOGICAL|CD19 CAR-T|CD19 CAR-T cells will be administered after completion of the chemotherapy.
40992948|NCT04445428|BIOLOGICAL|oral polio vaccine + information|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
40992949|NCT04445428|BEHAVIORAL|Information|Advice regarding how to protect oneself from COVID-19
40992950|NCT02311738|OTHER|Training intensity intervention|High intensity training group describes the group performing high intensity exercise intervention. Moderate intensity training group describes the the group performing moderate exercise intervention
40992951|NCT01883687|PROCEDURE|Septoplasty|
40992952|NCT05696782|DRUG|Durvalumab|Participants will receive Durvalumab 1500 mg intravenously every two weeks for 60 minutes. Each treatment is called a cycle and lasts for four weeks (or 28 days).
40992953|NCT05696782|OTHER|the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)|Participants will be asked to answer all 30 items on the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30). This patient-reported outcome measure is designed to measure cancer patients' physical, psychological and social functions. The measure can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is approximately 11 minutes (
40992954|NCT05696782|DIAGNOSTIC_TEST|COPD Assessment Test (CAT)|Participants will be asked to answer all items on the COPD assessment test (8 items) and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
40992955|NCT05696782|DIAGNOSTIC_TEST|Modified Medical Research Council (mMRC) dyspnea scale|Participants will be asked to answer the modified medical research council dyspnea scale (1 item), and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
40992956|NCT02742012|OTHER|the study is observational|the study is observational
40992957|NCT00363779|DRUG|Cyclosporine|An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
40992958|NCT00363779|GENETIC|Gene expression analysis|A permutation test will be performed to examine whether the overall expression profile changes due to treatment. This will be done by comparing the number of significant genes to the distribution of this number if in fact there is no difference between pre-treatment and post-treatment gene expression.
40992959|NCT00363779|GENETIC|Microarray analysis|Gene expression profiling will be carried out on Affymetrix microarrays to compare pretreatment and posttreatment samples.
40992960|NCT00363779|OTHER|Laboratory biomarker analysis|Analysis of differential gene expression profiles in patients with LGL leukemia treated with cyclosporine.
40992961|NCT01290666|DEVICE|Fistula Plug|Bioabsorbable fistula plug
40992962|NCT01517672|BEHAVIORAL|Cognitive Trauma Therapy for Battered Women (CTT-BW)|10 individual sessions of this form of cognitive therapy, with a trained therapist.
40992963|NCT04518501|DRUG|Arsenic trioxide Tablet +Fuzuloparib Capsules|Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
40992964|NCT03879382|BIOLOGICAL|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
40992965|NCT03879382|DRUG|Fludarabine|30mg/m2/d
40992966|NCT03879382|DRUG|Cyclophosphamide|300mg/m2/d
40992967|NCT03281954|DRUG|Placebo|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose."
40992968|NCT03281954|DRUG|Atezolizumab|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose."
40992969|NCT02242708|BEHAVIORAL|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
40992970|NCT04286607|DRUG|Topical roflumilast|Active treatment
41147868|NCT00494416|OTHER|delivery approaches of malaria intermittent preventive treatment in pregnancy|"Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.~Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs)."
41147869|NCT01123356|DRUG|Ofatumumab|"* Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~* Treatment to be administered for up to 6 cycles"
41147870|NCT01123356|DRUG|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
41266373|NCT05176912|OTHER|Exercise|Reformer Pilates exercises will given for 8 weeks, 3 days in a week
41266374|NCT02934009|DEVICE|Dermal nuclear magnetic resonance (NMR)-profile measurement|Nuclear magnetic resonance (NMR)-profile measurement of the dermis
41266375|NCT02813122|DEVICE|x-ray|x-ray for the detection of leaks and bleeding
41266376|NCT02381379|DRUG|Peginterferon-α-2a|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
41147871|NCT04474691|BEHAVIORAL|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract can be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available. Knowledge of performance feedback could describe either the desired articulator placement or the auditory quality of the target sound.
41147872|NCT04474691|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum generated by the staRt app. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak or 'bump' on the visual display.
41147873|NCT04791917|BEHAVIORAL|Eccentric Biceps Flexion|Muscle lengthening biceps exercise
41147874|NCT04791917|BEHAVIORAL|Concentric Biceps Flexion|Muscle shortening biceps exercise
41147875|NCT04733989|OTHER|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of Alzheimer's disease. Some of the samples will be stored for future analysis.
41147876|NCT00386802|DRUG|Antifungal drug. VORICONAZOL. (VFEND®)|I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
41147877|NCT04542551|PROCEDURE|Dilation 60-Fr non stricture|Dilation of patients with subjective dysphagia and normal endoscopy
41147878|NCT04542551|PROCEDURE|Sham|Sham dilator for patients with subjective dysphagia and normal endoscopy
41147879|NCT04542551|PROCEDURE|Non severe stricture - dilation with 60-Fr|Dilation of non severe stricture with 60-Fr dilator
41147880|NCT04542551|PROCEDURE|Non severe stricture - dilation with 46-Fr|Dilation of non severe stricture with 46-Fr dilator
41147881|NCT04542551|PROCEDURE|Severe stricture - dilation with 51-Fr|Dilation of a severe stricture with 51-Fr dilator
41147882|NCT04542551|PROCEDURE|Severe stricture - dilation with 42-Fr|Dilation of a severe stricture with 42-Fr dilator
41147883|NCT02291861|DRUG|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
41147884|NCT02291861|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
41147885|NCT01028976|DIETARY_SUPPLEMENT|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
41147886|NCT01028976|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
41147887|NCT01732419|BEHAVIORAL|Home-based training|Home-based exercise training for cardiac patients.
41309032|NCT01226420|DRUG|Alefacept|Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
41467834|NCT02496208|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40992971|NCT02950077|BEHAVIORAL|mindfulness based stress reduction|The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
40992972|NCT00110058|BIOLOGICAL|recombinant interferon alfa|
40992973|NCT00110058|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40992974|NCT00110058|DRUG|cyclosporine|
41147888|NCT01732419|BEHAVIORAL|Centre-based training|Usual exercise training in an outpatient setting.
41147889|NCT05082493|DRUG|Berubicin Hydrochloride|Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions
41309033|NCT05595785|BEHAVIORAL|Physical-Based Yoga Practice|Physical-based yoga classes emphasized Bishnu Ghosh lineage hatha yoga. The 50 minute yoga classes were twice per week for four weeks. The yoga instructor had certifications in both Bikram and Amrit yoga practices and training in Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis
41309034|NCT05595785|BEHAVIORAL|Mindfulness-Based Yoga Practice|The mindfulness-based yoga classes included all elements of the physical-based yoga classes with the addition of mindfulness cues. The mindfulness cues included body scan, mindful movement, and yoga nidra. Certification of the instructor included the Integrative Amrit Method of Yoga Nidra that was inclusive of the use of mindfulness cues that coincided with the physical postures of yoga.
41309035|NCT05627934|DIAGNOSTIC_TEST|qICG|Evaluation of bowel fluorescence by pixel software, qICG
41467835|NCT02496208|DRUG|Cabozantinib S-malate|Given PO
41467836|NCT02496208|PROCEDURE|Computed Tomography|Undergo CT scan
41467837|NCT02496208|PROCEDURE|Echocardiography|Undergo echocardiography
41467838|NCT02496208|BIOLOGICAL|Ipilimumab|Given IV
41467839|NCT02496208|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41467840|NCT02496208|BIOLOGICAL|Nivolumab|Given IV
41467841|NCT06616571|DRUG|QL0605(PEG-rhG-CSF)|Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.
40992975|NCT00110058|DRUG|fludarabine phosphate|
40992976|NCT00110058|DRUG|imatinib mesylate|
40789010|NCT03751826|OTHER|Incentivised network delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the first intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV themselves and in their peers and friends. They will be counselled to receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
40789011|NCT03751826|OTHER|Peer navigator delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the second intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV and then receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
40789012|NCT03751826|OTHER|standard of care|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the standard of care arm encourage females aged 18-24 to test for HIV, receive sexual and reproductive health services, contraception and condoms, and link to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
40789013|NCT05356273|PROCEDURE|Baby massage|Starting from the baby's face first, then the abdomen and chest, back, upper extremities and finally the lower extremities were massaged with semi-circular movements, respectively.
40789014|NCT04408677|DEVICE|Zilia Ocular|Measurement of the oxygen saturation in the eye fundus
41309036|NCT05412394|DRUG|Prednisolone|Liquid, 5mg/kg per week, for one year
41309037|NCT05412719|BEHAVIORAL|THE EFFECT OF FINGER PUPPET MANIPULATION ON PAİN AND PHYSİOLOGıCAL PARAMETERS DURING URINARY CULTURE WITH URINARY CATHETERIZATION IN INFANTS|the effect of finger puppet manipulation on pain and physiological parameters during urinary culture with urinary catheterization
41309038|NCT01774344|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib, 40 mg tablets
41309039|NCT01774344|DRUG|Placebo|Placebo tablets matching in appearance
41309040|NCT01852097|BEHAVIORAL|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.|"The general approach to the intervention is the following:~1. Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.~2. Give feedback to individuals on their questionnaire responses.~3. Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.~4. Provide advice on overcoming practical barriers.~5. Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.~6. Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation."
41309041|NCT04417777|GENETIC|Blood Test|Blood analysis
41467842|NCT06616571|DRUG|QL0605(PEG-rhG-CSF)|Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.
41467843|NCT03882411|BEHAVIORAL|Electronic shared decision making (eSDM) tool|The web application includes depression screening, behavioral activation, and a patient preference driven treatment selection decision aid. Treatment options will include medications, cardiac rehab/exercise program, and therapy. In addition to education, providers will receive a patient preference report in real time with options for coordination of care
41309042|NCT02077634|DRUG|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
41309043|NCT02077634|DRUG|abiraterone acetate + prednisone|ormon therapy will be stopped
41467844|NCT00294892|DRUG|carbamazepine and nevirapine|Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.
41467845|NCT00294892|DRUG|Nevirapine|Nevirapine 200mg is taken prior to delivery during labor.
41467846|NCT00171340|DRUG|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
41467847|NCT00171340|DRUG|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
41467848|NCT01344616|BEHAVIORAL|lifestyle support|computer-based lifestyle improvement support and clinician support
40789015|NCT04041232|DRUG|PBA|Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutyrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
40992977|NCT00110058|DRUG|mycophenolate mofetil|
40992978|NCT00110058|PROCEDURE|peripheral blood stem cell transplantation|
40992979|NCT00110058|RADIATION|radiation therapy|
40992980|NCT06271252|DRUG|OriCAR-017|Anti-GPRC5D CAR-T cell product
41467849|NCT02974491|OTHER|Fuji apple juice|On two different days, each volunteer consumed 300 mL Fuji apple juice (AJ), immediately after a dialysis section. After a washout period of 3 weeks, the volunteers drank 150 mL Fuji AJ in a similar manner as described above. Before and after 30 and 60 min of AJ consumption, blood samples were withdrawn for biochemical analysis.
41467850|NCT04867811|OTHER|conventional therapy|conventional therapy
41467851|NCT04867811|OTHER|cupping therapy|cupping therapy
41467852|NCT04867811|DEVICE|TENS|transcutaneous electrical nerve stimulation
41467853|NCT04867811|OTHER|TENS and cupping therapy|TENS and cupping therapy
41467854|NCT01072799|BIOLOGICAL|Placebo|Two doses (Day 1 and Day 22); 0.5mL
41467855|NCT01072799|BIOLOGICAL|A/H1N1 2009 Influenza VLP Vaccine|Two doses (Day 1 \& Day 22); 0.5mL
40992981|NCT03369054|BEHAVIORAL|Minority Stress Treatment|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
40992982|NCT03369054|BEHAVIORAL|Treatment As usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
40992983|NCT03075917|OTHER|Self Questionnaire|self questionnaire for allergic rhinitis control
40992984|NCT01969903|DRUG|Precedex injection|
40992985|NCT01220258|DRUG|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
40992986|NCT00118976|DRUG|Lisinopril|
41467856|NCT02145624|DRUG|Repevax|vaccine
40992987|NCT03989440|DRUG|AXER-204|human NoGo Trap fusion protein
40992988|NCT03989440|DRUG|Placebo|Phosphate buffered saline formulation
41266377|NCT02157454|OTHER|Website access|Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
41266378|NCT05202145|DRUG|ALXN2050|Oral tablet.
41266379|NCT05202145|DRUG|Cyclosporine|Oral capsule.
41266380|NCT05202145|DRUG|Tacrolimus|Oral capsule.
41266381|NCT05202145|DRUG|MMF|Oral tablet.
41266382|NCT04940234|BEHAVIORAL|Exposure to a Photo|We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.
41266383|NCT04105777|DEVICE|Parenteral Nutrition Bag Eurotube|7-,8- or 9-chamber bags for individualized parenteral nutrition compounding.
41467857|NCT02145624|DRUG|Boostrix-IPV|vaccine
41467858|NCT06616922|DRUG|RD03/2016 eye drops|1 drop, 4 times a day (approximately every 4 hours while awake) for 5 days starting from Day 1.
40992989|NCT05064033|OTHER|Pragmatic Set of intervention and posterior capsular stretch|Group 1 will receive a pragmatic set of interventions, including Serratus Anterior Stretch,Rotator Cuff Facilitation,Acromilcalavicular joint Mobilization,Stretch of Pectoralis Major and Minor,Thoracic Manipulation and posterior capsular stretch.
40992990|NCT05064033|OTHER|Pragmatic Set of intervention and Sleeper Stretch|Group 2 will receive a pragmatic set of interventions, including Serratus Anterior Stretch, Rotator Cuff Facilitation, Acromilcalavicular joint Mobilization, Stretch of Pectoralis Major and Minor, Thoracic Manipulation and sleeper stretch.
40992991|NCT04589676|BEHAVIORAL|Naloxone training|The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
40992992|NCT05020496|DRUG|Diphenylcyclopropenone (DPCP)|Drug will be applied topically on the skin. It will cause contact hypersensitivity in patients
40992993|NCT00777647|OTHER|Sugar-sweetened soft drink|One litre a day for six months.
40992994|NCT00777647|OTHER|Aspartame-sweetened soft drink|One litre a day for six months.
40992995|NCT00777647|OTHER|Semi-skimmed milk|One litre a day for six months
40992996|NCT00777647|OTHER|Water|One litre a day for six months.
40992997|NCT02604212|DRUG|ARC-520|
40992998|NCT02604212|OTHER|Placebo|
40992999|NCT02604212|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
40993000|NCT02604212|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
40993001|NCT02604212|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
40993002|NCT02952339|BIOLOGICAL|RSV LID ΔM2-2 1030s vaccine|10\^5.0 PFU; administered as nose drops
40993003|NCT02952339|BIOLOGICAL|Placebo|Administered as nose drops
40993004|NCT05245708|DRUG|Intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
40993005|NCT05245708|DRUG|intranasal placebo|Each subject will be assigned to intranasal placebo.
40993006|NCT02999256|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|
40993007|NCT02999256|OTHER|Placebo|
40993008|NCT05812976|OTHER|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
40993009|NCT05812976|OTHER|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
40993010|NCT02687984|DRUG|RBP-7000|A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
41147890|NCT03161665|OTHER|BMT Roadmap|The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
41467859|NCT06616922|DRUG|Levofloxacin 0.5% eye drops solution (Oftaquix®)|1 drop, 8 times a day (approximately every 2 hours while awake) on Days 1 and 2, and 1 drop, 4 times a day (approximately every 4 hours while awake) on Days 3 through 5.
40993011|NCT01578395|RADIATION|Low-dose radiation exposure|what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
40993012|NCT01578395|RADIATION|High-dose radiation exposure|what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
40993013|NCT01578395|OTHER|No radiation exposure|Subjects not undergoing any radiation exposure
40993014|NCT04852458|DRUG|Intravenous (IV) hydrocortisone|"Participants (20) will be given IV hydrocortisone within 6-12 hours of the traumatic event.~90 - 150 mg. of intravenous hydrocortisone dosing regimen based on participant weight: 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg."
40993015|NCT06038201|PROCEDURE|LAMS placement for cholecystostomy|The EUS-guided cholecystostomy entails placing a 10 mm x 10 mm or 10mm x 15mm Electrocautery-Enhanced LAMS for direct cholecystoscopy with a transnasal gastroscope. Then, the cholecystostomy will be performed with an echoendoscope, assisted by fluoroscopy to allow the puncturing of the gallbladder form either the duodenal bulb (cholecysto-duodenoscopy) or the gastric antrum (cholecysto-gastrostomy). Subsequently, from the most optimal anatomic point it will be tutored with a 10mmx10mm or 10mm x 15mm LAMS to create anastomosis between the structures. Then, the stone clearance will be performed by endoscopy (basket catheters) or by cholangioscopy (mechanical lithotripsy with or without basket catheters).
40993016|NCT06038201|PROCEDURE|Laparoscopic cholecystectomy|A laparoscopic biliary exploration along with an elective laparoscopic cholecystectomy will be performed by experienced laparoscopic surgeons (over 100 laparoscopic procedures yearly) by three or four-trocar technique with transection of the cystic duct and artery.
41266384|NCT04105777|DEVICE|Parenteral Nutrition 2/3 chamber Bag|Premixed 2/3-chamber bags which are eventually completed with other supplements shortly before administration by infusion into the bag.
41266385|NCT03585140|OTHER|Normal diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins.
41467860|NCT01182662|OTHER|Human umbilical cord-derived MSCs and cyclosporin A|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months
40993017|NCT05875233|OTHER|Elix Daily Harmony|"Elix Daily Harmony is a clinical-strength, organic blend of hormone-balancing Traditional Chinese Medicine (TCM) herbs and adaptogens. Contains Angelica Sinensis, licorice, ginger, Bupleurum, Cyperus Rotundus, White Peony, Mint, Poria, Atractylodes, White Ginseng, Reishi, Rehmannia Root, and Astragalus.~Participants should add 3 droppers full (half a teaspoon or 2.5 ml) of Elix Daily Harmony to their tea or other warm or room temperature beverage each morning, 1-2 hours after their first meal. The product should not be taken with iced drinks or with food."
40993018|NCT05875233|OTHER|Elix Cycle Balance|A tailored blend of medicinal herbs to holistically support menstrual symptoms by treating underlying imbalances. Participants should take 3 droppers full (half a teaspoon or 2.5 ml) of Elix Cycle Balance daily before bed with tea or other warm or room temperature beverage. The product should not be taken with iced drinks or with food.
40993019|NCT03424265|DIETARY_SUPPLEMENT|EAA mixture|Dietary supplement intervention for 12-weeks
40993020|NCT03424265|DIETARY_SUPPLEMENT|Placebo (whey protein)|Dietary supplement intervention for 12-weeks
40993021|NCT01017237|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
40993022|NCT01017237|DRUG|Midazolam|Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
40993023|NCT01017237|DRUG|Ketamine|Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
40993024|NCT03900000|OTHER|Physiotherapy|Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.
40993025|NCT00002161|DRUG|Adefovir dipivoxil|
40993026|NCT00940212|DRUG|AZD2423|oral, single administration
40993027|NCT00940212|DRUG|Placebo|oral administration and single dose
40993028|NCT05748340|PROCEDURE|Unilateral cleft lip repair|Surgical repair unilateral cleft lip
40993029|NCT05883904|DRUG|Fedratinib|Fedratinib administered after AIFA reimbusement approval
40993030|NCT00369512|DRUG|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
40993031|NCT03795675|DEVICE|Cochlear Implant|Cochlear implant device to be implanted at time of surgical intervention.
40993032|NCT06390969|OTHER|Survey|Cross-sectional online survey
40993033|NCT04914845|DRUG|KPT-9274|KPT-9274 is a first-in-class orally bioavailable, non-competitive, small molecule, dual modulator of p21 protein (Cdc42/Rac)-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase /PBEF/visfatin (NAMPT). NAMPT is the rate-limiting enzyme in the metabolic scavenging pathway that utilizes nicotinamide to replenish nicotinamide adenine dinucleotide (NAD), an essential metabolic cofactor and second messenger. Recent investigations have shown that in in vitro and in vivo models, NAMPT is uniquely essential for relapsed or refractory AML stem cells. Targeting relapsed AML stem cells, through targeting of NAMPT, may allow for a promising therapeutic opportunity for patients with relapsed or refractory AML.
40993034|NCT02444572|DRUG|Enoxaparin 4000 IU|
40993035|NCT02206425|DRUG|Melphalan|Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
41147891|NCT05065099|DEVICE|Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)|Patients and families will be provided the smartphone app on their personal mobile phone (Android, iPhone) or provided with a phone if they do not own one. The patients will view educational videos on concussion management, input their daily exertional status and weekly symptom status upon receiving pre-programmed notification prompts on their phone. Healthcare Providers will monitor symptom recovery via an HCP dashboard and make management recommendations using evidence-based algorithms regarding symptom recovery status. School personnel will monitor progress via a dashboard and provide targeted supports, they may also view educational videos on concussion management. Opportunities for communication between the HCP, parent/patient and school will be provided by the app.
41147892|NCT02217098|PROCEDURE|GIC Restorations|Restorations using Glass Ionomer Cement
41147893|NCT02217098|PROCEDURE|Carbomer Restorations|Restorations using Glass Carbomer
41147894|NCT02217098|PROCEDURE|Compomer Restorations|Restorations using Compomer
41147895|NCT00158236|DRUG|Buprenorphine|
41467861|NCT01182662|OTHER|cyclosporin A|cyclosporin A 5mg/kg po for 12 months
41467862|NCT06377020|BEHAVIORAL|PACT2|Behavioral lifestyle intervention
41467863|NCT04969354|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at CAIX antigen.
40993036|NCT02206425|DRUG|Prednisone|Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
40993037|NCT02206425|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
40993038|NCT02206425|DRUG|Dexamethasone|Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
40993039|NCT02206425|DIETARY_SUPPLEMENT|Ascorbic acid|Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
40993040|NCT02206425|DRUG|PLD|Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
40993041|NCT02206425|DRUG|Lenalidomide|Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
40993042|NCT02206425|DRUG|Pomalidomide|Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
40993043|NCT01962129|BIOLOGICAL|Sampling of blood|
40993044|NCT02183831|DEVICE|Insertion of the capsular tension ring|
41309044|NCT05655637|OTHER|Exercise|There will be one group, and study will be Quasi Experimental Study. Treatment will be given to all 28 participants, 3 sessions in a week for 4 weeks. Pre and Post treat-meant evaluation will be checked by CFQR+14. All patients will be treated with exercise program of Active cycle breathing techniques(ACBT), Pursed lip breathing, Endurance Exercise 20 to 30 min ( walking, cycling) and strength training with Thera-Bands (Bilateral arm raising, Bilateral knee extension). Exercise capacity will be measured with 6MWT. Dyspnea and fatigue will be measured with Borg scale.
41309045|NCT05696171|PROCEDURE|Cochlear implant manual insertion|Manual insertion of the cochlear implant into the round window during the surgery
41467864|NCT04719611|DIETARY_SUPPLEMENT|Probiotic|Healthy women receive a probiotic supplement containing 6 x 10\^9 colony-forming units/capsule of Bifidobacterium and Lactobacillus strains.
41467865|NCT01023776|BIOLOGICAL|A/California/07/09 live monovalent H1N1 vaccine|0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
41467866|NCT05624528|DRUG|Tolcapone|catechol-O-methyl transferase inhibitor
41467867|NCT05624528|DRUG|Placebo|Pill that contains no medicine
41467868|NCT00605982|PROCEDURE|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
41467869|NCT06192641|DRUG|Melatonin 3 MG|patients received 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).
41467870|NCT02252445|DRUG|Propofol|Propofol will be administered.
41467871|NCT02252445|DRUG|Sevoflurane|Sevoflurane will be administered.
41467872|NCT02812771|DRUG|Efinaconazole|Solution
41467873|NCT05642169|BEHAVIORAL|HIIT|"The training sessions will have a frequency of 3 times per week (Monday, Wednesday and Friday) and the duration will be between 39 to 54 minutes, depending on the training week.~The training program will be developed with the own body weight of each participant. Therefore, a progression according to the needs of this population will be fulfilled. The session model could be multi-joint exercises with self-loads, where the difficulty of the exercises will be worked progressively. Throughout the main part of each workout, 30 seconds of work will be performed at the corresponding intensity and 30 seconds of rest. Halfway through the total repetitions, there will be 2 minutes of recovery."
41467874|NCT05642169|BEHAVIORAL|HIIT+PA|In relation to the 2 groups that will perform HIIT, the HIIT+AF will have to complete 10.000 steps per day. In this way, they will be focusing on increasing their daily physical activity. In addition, this group will perform the same HIIT training programme as the other experimental group.
40993045|NCT04120532|BEHAVIORAL|Perioperative Rehabilitation|Physical therapist will be consulted one day before and after the operation (OP) day. On the day before the OP day, they focus on education, including how to get up from bed and stand up from a chair. Five rehabilitation exercises are also demonstrated: 1) ankle flexion and extension, 2) knee flexion and extension, 3) hip joint abduction and adduction, 4) hip joint flexion and extension, and 5) drawing-in maneuver. The participants will be required to repeat each component to confirm that they can do it correctly. Each exercise is suggested to be done 10 times per day following MI-TLIF, and the number will be recorded 3 days (pre-OP day, post-OP day, and post-OP day 2).
40993046|NCT04093388|DIAGNOSTIC_TEST|Self-PAP|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
41147896|NCT00158236|DRUG|Buprenorphine and Naloxone|
41147897|NCT00158236|DRUG|Hydromorphone|
41147898|NCT02755909|BEHAVIORAL|Pre-anesthetic Education|Education was done before the anesthetic procedure, using a flip chart made by the researchers.
41147899|NCT02942771|DRUG|0.075mg/kg TT301/MW189|0.075 mg/kg IV twice daily on Days 1 through 5
41309046|NCT05696171|PROCEDURE|Cochlear implant robotized insertion|Robotic insertion of the cochlear implant into the round window during the surgery
41467875|NCT05642169|BEHAVIORAL|CON|This group will not suffer any changes in their lifestyle
41147900|NCT02942771|DRUG|0.15mg/kg TT301MW189|0.15 mg/kg IV twice daily on Days 1 through 5
41147901|NCT02942771|DRUG|0.25mg/kg TT301/MW189|0.25 mg/kg IV twice daily on Days 1 through 5
41147902|NCT02942771|DRUG|0.30mg/kg TT301/MW189|0.30 mg/kg IV twice daily on Days 1 through 5
41147903|NCT02942771|DRUG|Placebo|0.9% sodium chloride
41467876|NCT05294835|DRUG|Ketamine|ketamine infusion
41467877|NCT02979691|RADIATION|SIB-IMRT|
40789016|NCT02905578|DRUG|Gemcitabine|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
41147904|NCT01016275|DEVICE|Misago (stent placement)|Misago iliac stent
41147905|NCT03456778|DEVICE|Shear Wave Elastography|An ultrasound (US) technique, known as shear wave elastography (SWE), is used to examine structure and biomechanical function. The examination takes place in the ultrasound room at the study site and lasts for approximately 20 minutes.
41147906|NCT01746628|PROCEDURE|Hysterectomy with FloSeal|Evaluation of the effects of intrauterine FloSeal
41309047|NCT06530589|OTHER|Tupler's Technique|Patient will wear diastasis rehab splint and will follow Tupler's techniqe protocol for 6 weeks. In the first 2 weeks both elevator and contracting exercises will be performed and after 2 weeks in the 3rd week only contracting exercises will be perform and for these exercises we divide abdomen into 6 floors and will patient have to contract her tummy towards the 3rd to 5th floor in first week, towards the 4th to 5th floor in 2nd week and from 5th to 6th floor in the 3rd week. in the wek 4 to week 6 head lifts will also be started along with contracting exercises from 5th to 6th floor.
41467878|NCT02979691|DRUG|S-1|
41488663|NCT04434664|DRUG|Amlodipine Besylate|The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
41309048|NCT06530589|OTHER|Traditional Exercises|The traditional treatment includes traditional abdominal exercises that patient will be perform for 6 weeks and three times per week with 15 repetitions of each exercise. These exercises includes posterior pelvic tilt' static abdominal contractions', reverse sit up exercise, kegals, russian twist , trunk twist and reverse trunk twist.
40789017|NCT02905578|DRUG|nab-paclitaxel|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
40789018|NCT02905578|DRUG|Pharmacological ascorbate|"Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine~* given 3 times weekly~* given for 4 weeks out of the 4 week cycle~* no dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
40789019|NCT01586689|BEHAVIORAL|Oxford House|community-based recovery home for participants recovering from substance dependency
40789020|NCT01586689|BEHAVIORAL|Safe Haven|professionally-staffed treatment facility
41147907|NCT06087159|BEHAVIORAL|mHealth Toolkit for Wellness & Empowering Lives of School Community (mWEL)|mWEL-App is a preventive intervention tool for teachers and parents as a self-help support. It integrates three key mental health presentive service functions: i) comprehensive screen to assess mental health (anxiety, depression), stress, and related contextual risks; ii) a tailored strength and weakness profile/report with recommendations to promote self-awareness and mental health knowledge; and iii) tailored evidence-based strategies and additional support and clinical resources to improve skills in stress management, emotion regulation, and maintain mental wellness. mWEL will be designed as a self-administered tool. Participating parents and teachers can access to mWEL app after they sign up for an account. Intervention participants will have access to the App anytime within a 3-5 month study period.
41147908|NCT05762172|OTHER|early 18F-FDOPA uptake|"During the usual patient care protocol for the 18F-FDOPA TEP examination, a 10 min acquisition starts after a 15 minutes waiting period following the injection of the radiotracer. This allows the reconstruction of a single late image volume. In the framework of this project, the patient is placed in the machine at the time of injection so as to acquire early 18F-FDOPA uptake and then reconstruct intermediate image volumes in addition to the usual final volume.~The total duration of the patient's examination is therefore not changed."
41147909|NCT05333133|DIETARY_SUPPLEMENT|high calorie formula (oral nutritional supplement/ONS)|"every subject is given 400 ml (equal with 400 kcal) high calorie formula for 90 days. before (day 0) and after (day 91) the intervention was enrolled, blood samples was taken to investigate IGF-1 and total lymphocyte counts.~The body weight and body height will be measured at day-0, day-14, day-30, day 60 and 90."
41147910|NCT06227897|DRUG|Aumolertinib|Aumolertinib 110 mg per day orally for 3 years.
41147911|NCT04004806|DEVICE|Hill Rom tracking device|Location tracking devices from Hill Rom company.
41309049|NCT02356406|RADIATION|Celiac Plexus Radiosurgery|"5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.~It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis."
41309050|NCT02266186|BEHAVIORAL|Traditional Cognitive behavioural therapy|Therapist supported live therapy
41309051|NCT02266186|BEHAVIORAL|Internet based Cognitive behavioural therapy|Internetbased CBTwith limited therapist support
41309052|NCT04539249|DRUG|Magnesium sulphate|"1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
41309053|NCT04539249|DRUG|Pentazocine|"Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
41309054|NCT01943734|BEHAVIORAL|Information passed on anthropometric assessment|Information passed on worker's anthropometric assessment.
40789021|NCT01586689|BEHAVIORAL|Usual aftercare|control group - participants may or may not seek treatment on their own
40789022|NCT04204850|DRUG|Cabozantinib|Cabozantinib is a multi-tyrosine kinase inhibitor with activity against VEGFR 1,2,3, MET and AXL, as well as RET, KIT, ant FLT-3.
40789023|NCT06617286|BIOLOGICAL|CD30 CAR T-cell|After MAC and AutoHSCT patients will receive CD30+ CAR T-cells (Phase 1B dose level 1 - 1x108/m2 (max 2.5x108) or dose level 2 - 2x108/m2 (max 5.0 x108) 21-42 days after the AutoHSCT and the RP2D dose level obtained in the Phase IB part administered in the Phase II portion.
40789024|NCT05630781|DRUG|Belsomra|randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 7 days. After the first chronic scan, participants will switch to the other drug for an additional \~7 days and then scanned a final time.
41467879|NCT00232479|DRUG|trastuzumab, docetaxel and carboplatin in dose dense regimen|trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
40789025|NCT05630781|DRUG|Placebo|comparator taken for \~10 days
40789026|NCT05630781|DRUG|Methylphenidate|Control Arm: Baseline visit with 2 fMRI scans pre- and post-20mg methylphenidate, 4 acute drug administration (6-14 days in randomized order: 1. Placebo + placebo; 2. 20mg suvorexant + Placebo; 3. Placebo + 40mg methylphenidate; 4. 20 mg suvorexant + 40mg methylphenidate max)
41309055|NCT04998045|BEHAVIORAL|Screening and brief intervention for substance use|Screening will be done using the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST). The brief intervention will be delivered based on ASSIST risk scores: low risk - verbal positive reinforcement and brief advice on harmful consequences of substance use (ii) moderate risk - brief motivational interviewing (BMI) (iii) high risk - BMI and referral to child psychiatry out-patient clinic. The BMI will be delivered in a single session (approximately 15 minutes) using Feedback Listen Options model (15): (i) providing feedback on screening results (ii) exploring pros and cons of substance use, enquiring about importance of change (iii) exploring options for change.
40789027|NCT06199765|OTHER|Needlestick Injury Prevention|this intervention will be using needlestick injury prevention module which will involve lecture, demonstration, and role play
40789028|NCT00208065|DRUG|almotriptan or pseudoephedrine|
40789029|NCT04188990|DIETARY_SUPPLEMENT|Nutritional dietary intervention|The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.
40789030|NCT04188990|DIETARY_SUPPLEMENT|By demand|"In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now"
41309056|NCT00916370|DEVICE|Core size Xience Prime|Core size includes a range of stent sizes.
41309057|NCT00916370|DEVICE|Xience Prime Long Lesion (LL)|Long lesion stent sizes include a range of sizes.
41309058|NCT02454218|DEVICE|Transcranial Direct Current Stimulation|"The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions."
41309059|NCT02128763|DRUG|Omega-3 supplements|2000 mg EPA and 1000 mg DHA per day
41309060|NCT02128763|DRUG|Placebo|Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
41309061|NCT02786589|BIOLOGICAL|Blood-stage infection of P. vivax|Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10\^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.
41309062|NCT02005848|BIOLOGICAL|Alpha-1 Antitrypsin|
41309063|NCT02005848|OTHER|Placebo|Placebo
41309064|NCT06430112|DRUG|Liposomal Bupivacaine|After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).
41309065|NCT06430112|DRUG|Ropivacaine|Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).
41309066|NCT04005898|DEVICE|Near-infrared fluorescence cholangiography|Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
41309067|NCT04725370|OTHER|NA - survey instrument|Survey instrument was administered verbally to parents of the Guatemalan cohort.
41309068|NCT04153006|DEVICE|POC troponin analysis.|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Minicare® device.
41309069|NCT01262755|BEHAVIORAL|Structured Interview|Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
41309070|NCT01163253|DRUG|CP-690,550|5 mg oral BID
41309071|NCT01163253|DRUG|CP-690,550|10 mg oral BID
41309072|NCT03625362|DIETARY_SUPPLEMENT|Hydrogen|Hydrogen-rich water
41309073|NCT03625362|DIETARY_SUPPLEMENT|Placebo|Tap water
41309074|NCT05505968|OTHER|Virtual Reality Headset|Virtual Reality Headset of the society Healthy Mind and is a CE Class 1 medical device. This virtual reality headset is a Pico G2 4K and corresponds to the model A7510 and is connected to a Bose Sound Link 2 AE headset.
41309075|NCT02413125|DEVICE|ChitoRhino irrigation solution|ChitoRhino irrigation solution has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis.
41309076|NCT02413125|DRUG|Normal saline|Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
41309077|NCT01696734|DRUG|Domperidone|Given PO
41309078|NCT01696734|OTHER|Questionnaire Administration|Ancillary studies
41309079|NCT06472700|OTHER|No intervention|No intervention
41309080|NCT01716533|PROCEDURE|Blood sampling|Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
41147912|NCT02648737|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch \& Craske, 2009; Craske, 2010).
41309081|NCT01716533|OTHER|Stool sample collection|Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
41309082|NCT02477722|OTHER|EFP-NF|
41309083|NCT02477722|OTHER|Sham|
41309084|NCT04253977|BEHAVIORAL|HEALTH-P2|The HEALTH-P2 curriculum includes evidence based lifestyle change strategies to prevent excess gestational weight gain and postpartum weight retention embedded within and delivered as part of home visits.
41309085|NCT04253977|BEHAVIORAL|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
41309086|NCT00000741|DRUG|Methylprednisolone|
41309087|NCT02491073|OTHER|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
41309088|NCT02768649|DRUG|RBP-7000|Sequential dosing of each cohort
41309089|NCT02768649|DRUG|risperidone|All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
40993047|NCT04093388|DIAGNOSTIC_TEST|Traditional Pap smear|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
40993048|NCT05957783|OTHER|Cerebral palsy Gait analysis technique|Visual gait analysis in cerebral palsy new technique
40993049|NCT01620073|OTHER|HIV counseling and testing|Male partner HIV counseling and testing
41309090|NCT03943758|DIETARY_SUPPLEMENT|Prepackaged Low-residue diet|Subjects in the prepackaged Low-residue diet group were given 6 packs (60g/pack) pre-packaged formula LRD and asked to use the formula according to individual needs prior to colonoscopy.
41309091|NCT03943758|DIETARY_SUPPLEMENT|Self-prepared Low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
41309092|NCT00088868|DRUG|alvespimycin hydrochloride|
41309093|NCT06318663|OTHER|Survivor Mom Companion|Weekly intervention sessions will follow the survivor Moms' Companion manualized modules. One module each week. The module centers on reinforcement of information introduced in each previous module, then emotional support, and referrals to additional services or specialists as needed. Participants in each session will practice applying knowledge and skills using the module's vignettes. Process guides prompt inquiry about in vivo management of post-traumatic stress disorder reactions and emotional and interpersonal responses to events since the last session. Each module may require 45 minutes of self-study before each session and 45 minutes of in-session time spent with the interventionist.
40789031|NCT04188990|DIETARY_SUPPLEMENT|Usual current care|"In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide"
41467880|NCT03523845|OTHER|Observational intervention to diagnose an early apical peri-implantitis|diagnose an early apical peri-implantitis
40789032|NCT00800982|PROCEDURE|Narrow band (310-312 nm) ultraviolet light B phototherapy|Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
40789033|NCT00800982|DRUG|etanercept|Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
40993050|NCT06462651|DIETARY_SUPPLEMENT|L. reuteri|Supplementation with drops containing L. reuteri once daily for 21 consecutive days
40993051|NCT06462651|DIETARY_SUPPLEMENT|Placebo|Supplementation with identical drops without L. reuteri once daily for 21 consecutive days
40993052|NCT02942446|DEVICE|Investigative Headgear with CPAP mask|Investigative Headgear with CPAP mask
40993053|NCT06095284|OTHER|Pre-Extraction Phase|This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire
40993054|NCT06095284|OTHER|Extraction Phase|Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire
41147913|NCT02648737|OTHER|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
41147914|NCT04117659|OTHER|withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients|discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
41147915|NCT05185674|OTHER|Exposure: Coronavirus disease 2019 (COVID-19)|Having presented Coronavirus disease 2019 (COVID-19) and stay in the Intensive Care Unit
41147916|NCT05686343|DIAGNOSTIC_TEST|Echocardiography, Doppler ultrasonography, Near-infrared spectroscopy|Ecocardiography at 1st, 3rd and 7th day of life Doppler US (cranial and renal) at 1st, 3rd and 7th day of life Near-infrared spectroscopy monitoring after birth during first 3-days of life
41147917|NCT03773770|DRUG|Triheptanoin|Liquid for oral (PO) or enteral tube administration
41147918|NCT01898026|DIETARY_SUPPLEMENT|Bread|Samples of white bread, with or without the addition of PGX fibre blend
41147919|NCT01898026|DIETARY_SUPPLEMENT|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
41147920|NCT01898026|DIETARY_SUPPLEMENT|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
41147921|NCT01898026|DIETARY_SUPPLEMENT|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
41467881|NCT00314782|DRUG|ZD4054 (Zibotentan)|oral tablet
41467882|NCT00314782|DRUG|Docetaxel|intravenous infusion
40993055|NCT06095284|OTHER|Post-Extraction Phase|Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation
40993056|NCT02906774|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation after antibiotic pretreatment
41467883|NCT00314782|DRUG|Placebo|
41467884|NCT04055545|OTHER|HIIT|"* 5 min. warm up~* 10 × 60 seconds burst~* 60 seconds recovery after each burst~* Burst phase: HRR \>90%~* Recovery phase: HRR btw. 30-39%~* 5 min. cool down"
41467885|NCT04055545|OTHER|MICT|"* 5 min. warm up~* 20 min. continuous cycling: HRR btw. 40% - 59%~* 5 min. cool down"
41467886|NCT01731522|BEHAVIORAL|EF condition|
40789034|NCT02709512|DRUG|ADI-PEG 20 plus Pem Platinum|Investigational Drug in combination approved standard of care treatment for this indication
41467887|NCT00595335|DRUG|Rituximab|Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
41467888|NCT00595335|DRUG|Saline|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
40789035|NCT02709512|OTHER|Placebo plus Pem Platinum|Placebo in combination approved standard of care treatment for this indication
40993057|NCT05442944|PROCEDURE|Physiotherapeutic procedures|As part of the rehabilitation program, the patients performed two exercises in the Universal Therapeutic Rehabilitation Room (UTRR) system. The patient's task was to perform simultaneous abduction and adduction of the upper and lower limbs. The duration of the procedure was 10 minutes, the patient performed the exercises at a comfortable pace. In the second exercise - the patient's task was to alternately bend and straighten the opposite lower and upper limbs. The duration of the exercise was 10 minutes. The combined duration of both procedures used was 20 minutes. In addition, each patient underwent three physical therapy treatments. The procedures were carried out 5 days a week (Monday to Friday) for three weeks.
40993058|NCT02723149|BEHAVIORAL|Marijuana Approach Avoidance Training|Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
40993059|NCT06322329|OTHER|Dynamic MRI|Subjects receive a study-specific dynamic MRI scan. If the hypothesis of the study is confirmed, this examination can be used to inform future patients' treatment planning, replacing the use of 4D CT.
40993060|NCT05478499|DRUG|Deucravacitinib|Specified dose on specified days
40993061|NCT05478499|OTHER|Placebo|Specified dose on specified days
40993062|NCT01801150|DEVICE|CPAP nasal treatment|Treatment with titred CPAP nasal during the nighttime
40993063|NCT00000806|DRUG|Telinavir|
41266386|NCT03585140|OTHER|Low glycemic diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. A list of foods classified as having low index and glycemic load was used according to the mexican equivalent food system. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins. Milk and vitamin supplements will be eliminated from the diet.
41467889|NCT00595335|DRUG|Methylprednisolone|Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
41266387|NCT03585140|DRUG|Adapalene 0.1% Gel|Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
41467890|NCT03721627|DRUG|Ledipasvir/Sofosbuvir|Direct acting anti HCV drugs
40993064|NCT01376271|DRUG|Paroxetine|
40993065|NCT05632549|DRUG|Placebo|Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
40993066|NCT05632549|DRUG|L-Carnitine 500Mg Oral Tablet|Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
41266388|NCT03585140|DRUG|Doxycycline|Doxycycline 100 mg per day orally, before breakfast
41266389|NCT02078349|DRUG|KPT-330|Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
41266390|NCT00709202|DRUG|Betahistine|Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID (BID = 2 times a day)..
41266391|NCT00709202|DRUG|Placebo Oral Tablet|
41266392|NCT01731002|DRUG|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the evening (PM) for 28 days
41467891|NCT01529307|DRUG|TAS266|TAS266 IV infusions given weekly
41467892|NCT02514395|OTHER|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2\[32\] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
41467893|NCT00468338|DEVICE|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
41467894|NCT05660863|DRUG|MN-08 24 mg/day|Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
41467895|NCT05660863|DRUG|MN-08 60 mg/day|Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
41467896|NCT00869661|DRUG|Copegus|1000/1200mg po daily for 24 or 48 weeks
41467897|NCT00869661|DRUG|Copegus|1000/1200mg po daily for 48 weeks
41467898|NCT00869661|DRUG|Pegasys|180 micrograms sc weekly for 24 or 48 weeks
41467899|NCT00869661|DRUG|Pegasys|180 micrograms sc weekly for 48 weeks
41467900|NCT00869661|DRUG|RO5024048|1000mg bid for 24 weeks
41467901|NCT00869661|DRUG|RO5024048|500mg bid for 12 weeks
41467902|NCT00869661|DRUG|RO5024048|1000mg bid for 8 weeks
41467903|NCT00869661|DRUG|RO5024048|1000mg bid for 12 weeks
41309094|NCT00952237|DRUG|GM-CSF|"GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.~G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis."
40789036|NCT00848263|PROCEDURE|Volar plate|Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
40789037|NCT00848263|PROCEDURE|Dorsal nail plate|Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
40789038|NCT01179984|DEVICE|Bard® LifeStent® Vascular Stent System|Stent Implantation
40789039|NCT01399112|BEHAVIORAL|Web-based computer program|Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
40993067|NCT05632549|DRUG|Biotin Capsules|Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
41309095|NCT00952237|DRUG|IL-2|"IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.~Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).~Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above"
41488664|NCT04434664|DRUG|Metoprolol Succinate|The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
41488665|NCT03168594|DRUG|irinotecan cisplatin|Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
40789040|NCT01539447|DRUG|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
40993068|NCT05138653|DRUG|Drug: CVL-354|Oral solution/suspension
40993069|NCT05138653|DRUG|Drug: Placebo|Oral solution/suspension
40993070|NCT05180214|DRUG|Bupivacain|analgesic
40789041|NCT01539447|DRUG|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
40789042|NCT05171972|DRUG|Ofatumumab|This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
40789043|NCT03273686|PROCEDURE|Discharge the NG tube during the surgery|Discharge the NG tube during the surgery.
40993071|NCT05180214|DRUG|Ketorolac|analgesia
40993072|NCT04577287|DEVICE|Transcranial direct current stimulation|Cathodal/Anodal tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
40993073|NCT02601287|BIOLOGICAL|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
40993074|NCT05362747|BEHAVIORAL|Behavioral weight loss and produce vouchers|Participants will receive weekly 30-minute, individual, in-person lifestyle counseling delivered by trained interventionists (e.g., registered dietitians) that consists of behavioral, dietary, and physical activity counseling. ProduceRx vouchers will be in the form of Food Bucks and will be provided at each session.
40789044|NCT04554459|DRUG|Ponatinib 15 MG Oral Tablet|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
40789045|NCT00843336|BEHAVIORAL|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
40789046|NCT00843336|BEHAVIORAL|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
40789047|NCT01769976|OTHER|Periodic fasting|
40993075|NCT03533192|BEHAVIORAL|It's Your Game...Keep it Real|It's Your Game...Keep it Real consists of 12 50-minute lessons delivered in 7th grade (8 in class and 4 via computer) and 12 50-minute lessons delivered in 8th grade (7 in class and 5 via computer). In each grade, the curriculum integrates group-based classroom activities with personalized journaling and individually tailored computer-based activities. A life-skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal rules regarding risk behaviors, detect signs or situations that might challenge these rules, and use refusal skills and other tactics to protect these rules. The curriculum is grounded in social cognitive theory, the theory of triadic influence, and social influence models.
40993076|NCT00229255|OTHER|high frequency of meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
41266393|NCT01731002|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD in the PM for 28 days
40789048|NCT01769976|OTHER|Energy restriction|
40789049|NCT01769976|OTHER|Energy balance diet|
41266394|NCT01731002|DRUG|Latanoprost ophthalmic solution 0.005%|Administered to study eye, QD in the PM for 28 days
41266395|NCT04391725|PROCEDURE|Periapical surgery with guided tissue regeneration|periapical surgery will be done followed by placement of mixture of iPRF and type 1 collagen granules
41266396|NCT04391725|PROCEDURE|Periapical surgery without anyguided tissue regeneration|periapical surgery will be done followed by flap closure
41266397|NCT02357511|DEVICE|Study Monitor used|
41266398|NCT04608214|DRUG|Alisporivir|Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).
41266399|NCT04608214|OTHER|Standard of care (SOC)|Locally accepted regimen protocols for patient care and select agents based on the underlying diagnosis and the severity of COVID 19 (excepting e.g. azithromycin and other antibiotics listed as prohibited medications)
41266400|NCT04738357|DRUG|HSK21542|HSK21542：1 µg/kg
41488666|NCT03168594|DRUG|Etoposide cisplatin|Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
40993077|NCT00229255|OTHER|twice a day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
40789050|NCT05927116|OTHER|Mobile phone app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD)|TRIP is a mobile app-based intervention comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
40789051|NCT04199065|OTHER|Good Practice Guidelines implementation|Implementation of Good Practice Guidelines on the framework of the Best Practice Spotlight Organization in Spain (CCEC® / BPSO®), that allows a standardized methodology for providing care and registering indicators.
40789052|NCT01065025|DRUG|4SC-205|Repeated ascending oral doses of 4SC-205.
40789053|NCT05269459|DRUG|Cannabidiol (CBD) as Nantheia ATL5|Gel caps containing 100mg of Nantheia ATL5. Subjects will take 4 capsules twice daily.
40789054|NCT05269459|DRUG|Placebo|Matching gel caps containing no active drug. Subjects will take 4 capsules twice daily.
40789055|NCT04457986|DRUG|Erector spina plane block (ESP)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
40993078|NCT04064918|OTHER|Netarsudil 0.02% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
41488667|NCT03261765|OTHER|Assessment of adhesions|Modified Nair scoring system
40789056|NCT04457986|DRUG|Modified thoracolumbar interfacial plane block (MTI)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
40789057|NCT04457986|DRUG|Intravenous patient controlled analgesia (IV-PCA)|Patient will receive intravenous patient controlled analgesia with tramadol
40789058|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
40789059|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose A|Administration of Dose A of ACI-24.060
40993079|NCT04064918|OTHER|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
40993080|NCT00735787|BIOLOGICAL|Placebo|Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
41488668|NCT00968786|DEVICE|Home monitoring|automated measuring devices for patients using at home
41488669|NCT00390221|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|SC injection
41488670|NCT00390221|DRUG|Placebo|Placebo SC injection
40789060|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose B|Administration of Dose B of ACI-24.060
40789061|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose C|Administration of Dose C of ACI-24.060
40789062|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose D|Administration of Dose D of ACI-24.060
40789063|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
40789064|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose X|Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1
40789065|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose Y|Administration of Dose Y of ACI-24.060
40789066|NCT06406530|PROCEDURE|PRF|Patients blood is standardized centrifuged and split in to a red-phase (erythrocytes) and white-phase (PRF). The gained PRF is processed to a clot-fort and is inserted into the alveolus.
40993081|NCT00735787|BIOLOGICAL|Adalimumab|Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
40789067|NCT06406530|PROCEDURE|Natural Healing|After the tooth extraction, natural healing is aimed by allowing a blood clot formation without any further intervention.
41467904|NCT04048031|DIETARY_SUPPLEMENT|Nutrafol Supplement Capsules|NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
40789068|NCT02604459|DEVICE|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
40789069|NCT02604459|DEVICE|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
40789070|NCT02604459|PROCEDURE|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
40789071|NCT02604459|PROCEDURE|General anesthesia|General anesthesia will be used in both groups
40789072|NCT02604459|DRUG|propofol|propofol per protocol
40789073|NCT02604459|DRUG|fentanyl|fentanyl per protocol
40789074|NCT02604459|DRUG|sevoflurane|maintenance of anesthesia with inhaled sevoflurane
40789075|NCT00281437|BEHAVIORAL|choice of exercise program|
40789076|NCT03623438|BEHAVIORAL|Self-administered acupressure group|Subjects in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 hours each) to learn self-administered acupressure, which will then be performed every night for 4 weeks.
40789077|NCT03623438|BEHAVIORAL|Sleep hygiene education (SHE) group|Subjects in the comparison group will receive sleep hygiene education (2 sessions, 2 hours each, same as the treatment group) and be reminded to follow the sleep hygiene practice daily for 4 weeks.
40789078|NCT03358602|RADIATION|Radiotherapy|Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
40789079|NCT03358602|PROCEDURE|Selective neck dissection|Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
40789080|NCT00087087|DRUG|pemetrexed disodium|
40789081|NCT05496361|DEVICE|Tianyi Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
40789082|NCT05496361|DEVICE|Solitaire FR Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
40789083|NCT01024348|DRUG|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
40789084|NCT01024348|DRUG|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
40789085|NCT04419467|BIOLOGICAL|CSL346|VEGF-B antagonist monoclonal antibody
40789086|NCT04419467|DRUG|Placebo|Normal saline
40789087|NCT03166852|OTHER|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
40789088|NCT01352286|GENETIC|Autologous Genetically modified T cells|"Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above."
40789089|NCT00429143|RADIATION|Total Body Irradiation (TBI)|TBI twice daily days 6-9 prior to transplant (HSCT)
40789090|NCT00429143|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
40789091|NCT00429143|DRUG|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
40789092|NCT00429143|DRUG|Tacrolimus|Tacrolimus given one day prior to transplant (HSCT).
40789093|NCT00429143|DRUG|Mycophenolate Mofetil (MMF)|MMF given one day prior to transplant (HSCT).
40789094|NCT00429143|BIOLOGICAL|Hematopoietic Stem Cell Transplant (HSCT)|CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
40789095|NCT02499627|DRUG|Brentuximab Vedotin|Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
40789096|NCT02499627|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
40789097|NCT00876707|DEVICE|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
40789098|NCT00876707|DEVICE|ReSTOR implant|Implant of multifocal IOL ReSTOR
40789099|NCT00876707|DEVICE|ReZoom implant|Implant of multifocal IOL ReZoom
40993082|NCT00852709|DRUG|Clofarabine|On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
41266401|NCT04738357|DRUG|Placebo|Placebo
41467905|NCT04048031|OTHER|Placebo Capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
40789100|NCT01111643|DEVICE|Echocardiogram|An echocardiogram will be repeated at every step, from baseline to peak heart rate setting.
40789101|NCT06170151|DIAGNOSTIC_TEST|Diagnostic accuracy|evaluate the role of 18F-FDG PET-CT for assessing early response after 6 months of treatment in patients with relapsed/refractory multiple myeloma.
40789102|NCT03394989|DRUG|Fluticasone propionate/salmeterol 100/50 µg|Test Arm: Dry powder inhaler
40789103|NCT03394989|OTHER|Placebo|Placebo
40789104|NCT03394989|DRUG|Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT|Comparator Arm: Dry powder inhaler
40789105|NCT05515328|DRUG|[¹⁴C] BI 685509 formulation 1|\[¹⁴C\] BI 685509 formulation 1
40789106|NCT05515328|DRUG|[¹⁴C] BI 685509 formulation 2|\[¹⁴C\] BI 685509 formulation 2
40789107|NCT05515328|DRUG|BI 685509 formulation 3|BI 685509 formulation 3
40789108|NCT05962281|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS), a form of non-invasive brain stimulation which involves the use of low intensity currents propagated via the scalp, is widely implemented as both a fundamental and clinical neuroscientific tool. Over the last decades, tDCS showed significant therapeutic promise, as numerous studies revealed that it can result in improved attention and executive functions in patients with neurological disorders, through modification of neuronal excitability.
40993083|NCT00852709|DRUG|Cyclophosphamide|Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
40993084|NCT00001893|DRUG|TNFR:Fc|
41266402|NCT03604731|DEVICE|cytokine adsorbtion during extracorporeal circulation|preventive use of cytokine adsorption and modulation of the cytokine response in the course of artificial circulation
41266403|NCT00963950|PROCEDURE|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
41266404|NCT00963950|PROCEDURE|laparoscopic cholecystectomy|laparoscopic cholecystectomy
41467906|NCT06617026|DRUG|Sucralfate|a topical rectal ointment. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
41467907|NCT06617026|DRUG|Azadirachtin|a topical oil. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
41467908|NCT06617026|PROCEDURE|fissurectomy and lateral sphincterectomy|fissurectomy and lateral sphincterectomy
40789109|NCT00742170|DEVICE|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
40789110|NCT05160363|DRUG|Pyronaridine Tetraphosphate|A total of 24 participants will be dosed with pyronaridine tetraphosphate, sixteen participants will be additionally be dosed with piperaquine tetraphosphate, eight patients will additionally be dosed with placebo.
40789111|NCT05160363|DRUG|Piperaquine tetraphosphate|A total of 24 participants will be dosed with piperaquine tetraphosphate, sixteen participants will be additionally be dosed with pyronaridine tetraphosphate, eight patients will additionally be dosed with placebo.
40789112|NCT05160363|DRUG|Placebo|Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)
40789113|NCT03770858|DRUG|Crisaborole|Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
40789114|NCT03770858|DEVICE|Scratch sensor|advanced, flexible and wearable skin sensor
40789115|NCT00952705|BIOLOGICAL|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
40789116|NCT00952705|BIOLOGICAL|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
40789117|NCT00952705|BIOLOGICAL|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
40789118|NCT05498740|DEVICE|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
40993085|NCT02448238|OTHER|VSL#3® probiotic|"Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special canari, a commonly used earthenware water container also containing sand that works on the principal of trans-evaporation to keep contents at room temperature (\~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator"
40993086|NCT01075698|DRUG|Non-ARB (standard therapy)|Blood pressure lowering therapy except ARB
40993087|NCT01075698|DRUG|ARB (Telmisartan)|Telmisartan 20-80 mg/day
41309096|NCT04610034|BEHAVIORAL|"Resilient Caregivers"|"Resilient Caregivers is a 7-session group program developed for partner caregivers of patients with cancer (6 weekly sessions and 1 booster session). Each session takes place in groups of approximately 8 participants and lasts for two-and-a-half hours. Sessions 1 to 3 focuses on the caregiver and introduces the resilience components of coping strategies, meta-reflective skill and clarification of values. Sessions 4 and 5 focuses on these components in the relationship between the caregiver and the cancer patient and social support networks respectively, while Session 6 focuses on resilience in relation to self-care and care for the partner. A booster session will be scheduled one month after the end of Session 6 in order to follow-up on the intervention and allow participants to reflect on the benefits and challenges of the program."
41467909|NCT05212441|DEVICE|Light emitting diode therapy (LED therapy)|The patient's forearm is positioned on table with palm facuing upward during the therapy. For LEDT, the center of the light spot located at approximately 50% of landmark line from the medial epicondyle to the styloid process of the ulna, which is the center belly of ﬂexor digitorum superﬁcialis. The subject's forearm maintained in the rest state without moving during the therapy. LED is performed before exercise.
41309097|NCT04610034|OTHER|Care as usual|The control arm will receive usual care, which implies no systematic support.
40789119|NCT01722344|BEHAVIORAL|Individual Placement and support (IPS)|IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
40789120|NCT01722344|BEHAVIORAL|IPS plus|Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
40789121|NCT00186628|PROCEDURE|Total lymphoid irradiation|Total lymphoid irradiation (TLI) administered at 80cGy for 10 days
40789122|NCT00186628|DRUG|Rituximab|Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.
40789123|NCT00186628|DRUG|Anti-thymoglobulin, rabbit (ATG, rabbit ATG)|Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.
40789124|NCT00186628|DRUG|Cyclosporine|Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates \> 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).
40789125|NCT00186628|DRUG|Mycophenylate mofetil|Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
40789126|NCT00186628|DRUG|Filgrastim|Filgrastim provided as needed for neutrophil support
40789127|NCT00186628|DRUG|Granisetron|Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI
40789128|NCT00186628|DRUG|Solumedrol|Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
40789129|NCT00186628|DRUG|Acetaminophen|Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC
40789130|NCT00186628|DRUG|Diphenhydramine|Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC
40789131|NCT00186628|DRUG|Hydrocortisone|Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
40789132|NCT05197400|DIAGNOSTIC_TEST|preoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
40789133|NCT05197400|DIAGNOSTIC_TEST|postoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
40789134|NCT02175277|DRUG|Darbepoetin Alfa|The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
40789135|NCT06131905|DRUG|Magnesium Sulfate|40 mg/kg magnesium sulfate diluted with normal saline to a total volume of 100 ml was administered for 15 min.plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
40789136|NCT06131905|DRUG|Propofol|An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
40789137|NCT00971282|DRUG|adapalen 0.1%|"Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
40789138|NCT00971282|OTHER|Cetaphil®|"Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
40789139|NCT02377414|DRUG|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
40993088|NCT03331146|DRUG|Saline|A placebo (saline infusion) will be administered after induction of general anesthesia.
40789140|NCT02377414|DRUG|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
40789141|NCT04088968|BEHAVIORAL|Prehabilitation|Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
40789142|NCT01760616|DRUG|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
40789143|NCT03155763|PROCEDURE|Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy|
40993089|NCT03331146|DRUG|Sodium Nitrite|Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
40993090|NCT03025542|DRUG|Bimekizumab|Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
40993091|NCT03025542|OTHER|Placebo|Subjects will receive injections of Placebo.
40993092|NCT01224639|BIOLOGICAL|TDV - Low Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10\^3 PFU, TDV-2: 5 x 10\^3 PFU, TDV-3: 1 x 10\^4 PFU, and TDV-4: 2 x 10\^5 PFU, total virus per dose 2.2 x 10\^5 PFU
40993093|NCT01224639|BIOLOGICAL|TDV - High Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10\^4 PFU, TDV-2: 5 x 10\^4 PFU, TDV-3: 1 x 10\^5 PFU, and TDV-4: 3 x 10\^5 PFU, total virus per dose : 4.7 x 10\^5 PFU. TDV administered intradermally.
40993094|NCT01224639|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
40993095|NCT03013556|DRUG|Group A, TDF|TDF for 96 weeks
41309098|NCT01026701|DRUG|bortezomib|injection into a vein 1.3 mg/m2 twice a week for 21 days
41467910|NCT05212441|BEHAVIORAL|Patient/family education program (Home program)|Patients and their families will instructed to learn the anti contracture positioning/splinting, scar massage and exercises program, application of the custom garments and inserts, and functional training to perform them on their own at home. Written and illustrative instructions and reciprocal demonstration sessions will be provided to the children and their families to ensure successful acquisition and delivery of rehabilitation skills at home program. The therapist will be reported about compliance with the home program every couple of days
40993096|NCT03013556|DRUG|Group B:TDF then TDF and Peginterferon alfa-2a|Subjects will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
41467911|NCT05212441|PROCEDURE|Positioning & Splinting|"The wrist joint is splinted at 30 hyperextension, the MCP joint in 90 of flexion, the IP joints in extension, and the thumb in abduction. The webs of fingers kept in abduction. The hands are elevated above the level of the heart to minimize post-burn edema.~Splinting: Splints are tailored to help to maintain the functional or anti-contracture position of the injured body parts.The intervals for monitoring vary from once every hour to once every 4-6 hours, depending on types of splints and skin conditions. It is described as 10 hours on and two hours off. When the splint is taken off, active and/or passive ROM should be carried out."
40993097|NCT03013556|DRUG|Group C:TDF and Peginterferon alfa-2a then TDF|Subjects will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.
40993098|NCT00419198|PROCEDURE|Postconditioning|Postconditioning during angioplasty
40993099|NCT00419198|PROCEDURE|standard angioplasty|standard angioplasty without postconditioning
40993100|NCT02408393|DRUG|Saline|
40993101|NCT02408393|DRUG|Ropivacaine|
40993102|NCT03670303|BEHAVIORAL|Educational intervention|"Educational intervention will be given by trained optometrists to participants (requiring spectacles) their parents and teachers. Duration of Intervention will be about one hours and it includes:~1. Lectures on importance of spectacles use including visual materials such as pictures and videos.~2. An interactive classroom based demonstration carried out by trained optometrist. Children will be asked to read from blackboard, written to be visible with 6/6 vision, while seated at a distance of 6m. After this children will be given their glasses and asked to read again. The purpose of this demonstration is to make children aware of their poor vision and of the potential impact of corrected VA.~3. Posters~4. Brochures"
40993103|NCT01097018|DRUG|Capecitabine|1000 mg/m2 BID/ Days 1-14
40993104|NCT01097018|DRUG|Perifosine|50 mg daily x 21 days
40993105|NCT01097018|DRUG|Placebo|1 pill daily x 21 days
40993106|NCT01909908|DEVICE|ECM|ECM in saline applied to wound
40993107|NCT01909908|BIOLOGICAL|Blood Products|Autologous blood product applied to wound, with saline cleanse on alternating weeks
40993108|NCT01909908|DEVICE|ECM in Blood Products|Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
40993109|NCT04483713|BEHAVIORAL|Educational Workshop|"The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires."
40993110|NCT04483713|BEHAVIORAL|Educational Workshop plus J. H. N. EBP Guide Tools|"In addition to the workshop. It will follow the same molds as the case of group Educational Workshop plus the Johns Hopkins Nursing Evidence-based Practice guide tools since the beginning of this practical class, when the participant will receive a description of a problem as a basis for elaborating their clinical question, and thus, move on to the next stage.~The tools will be offered in the case of this group: question development, evidence level and quality guide, research evidence assessment tool, individual evidence tool, evidence synthesis and recommendation tool, action planning tool and tool dissemination."
40993111|NCT01950533|PROCEDURE|Oral food challenge|Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
40993112|NCT02701647|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric field in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim Rapid magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
41266405|NCT03603002|DIAGNOSTIC_TEST|Post-SABR Biopsy|Post-SABR Biopsy
40993113|NCT02701647|OTHER|Treadmill training|Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Participants will maintain the maximum speed achieved for the rest of the session or adjusted as needed. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
41467912|NCT05212441|OTHER|Therapeutic Exercises|"1. Passive ROM (PROM).~2. Active ROM (AROM) \& Active-assistive ROM (AAROM): The exercise will focus on extending the wrist to 45 degrees, flexing the MCP joints to 90 degrees and keeping the IP joints in full extension, while maintaining a thumb web space. The exercises will performed in the following sequences; (1) MCP joints flexion and extension with the wrist in neutral or slight extension and the IP joints in neutral position. (2) IP joints flexion to only 30-40 degrees with the wrist stabilized in the neutral or slight extension, while the MCP joints held in full extension, (3) thumb and fingers abduction and adduction, and (4) thumb opposition (tip of the thumb to tip of the small finger). Each exercise was performed for 8-10 repetition, daily, for 6 days/week.~3. Stretching exercises: A low-load (low-intensity), long-duration stretch~4. Strengthening exercises: done in static mode initially and progress to dynamic strengthening using elastic bands."
41309099|NCT05172193|BIOLOGICAL|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.
41467913|NCT00104247|DRUG|sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin|
41467914|NCT02882269|DRUG|Postoperative chemotherapy|Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
41467915|NCT02882269|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
41467916|NCT00706719|DRUG|25 mg Androxal|25 mg Androxal capsules, 1 capsule daily for 6 months
41467917|NCT00706719|DRUG|Testim 1%|Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
41467918|NCT02466386|DRUG|SPD489|Participants will receive 5 mg of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached.
41467919|NCT02122614|BEHAVIORAL|Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
41467920|NCT02122614|BEHAVIORAL|Pulmonary rehabilitation (PR)|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
41467921|NCT00385788|DRUG|Gemcitabine|800 mg/m\^2 IV over 30 minutes on Day -7 (1 day)
41467922|NCT00385788|DRUG|Fludarabine|33 mg/m\^2 IV over 30 minutes Day -5 to Day -2 (4 days)
41467923|NCT00385788|DRUG|Melphalan|70 mg/m\^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
40789144|NCT05101811|DRUG|Vitamin D Levels measurement using chemiluminescent assay|Measurement of serum vitamin D levels
41266406|NCT03908944|DRUG|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
41266407|NCT03908944|DRUG|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
41309100|NCT03817255|OTHER|Substance use questionnaire|Questions about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
41309101|NCT03817255|OTHER|Physical activity|Questions about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
41467924|NCT00385788|DRUG|Antithymocyte Globulin|"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."
41467925|NCT00385788|PROCEDURE|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
41467926|NCT00385788|DRUG|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
40789145|NCT05101811|DEVICE|Vitamin D level assessment|Using lIAISON DEVICE
40789146|NCT01778959|DEVICE|Malyugin Ring|insertion of a Malyugin Ring to stabilite the pupil during cataract surgery
40789147|NCT01778959|DEVICE|Iris hooks|insertion of iris retractors to stabilize the pupil during cataract surgery
40789148|NCT01778959|DEVICE|standard OVD|use of a standard cohesive OVD during cataract surgery
40789149|NCT01778959|DEVICE|OVD|use of a highly cohesive OVD during cataract surgery
40789150|NCT01288625|DRUG|Amifostine|500 mg sc, qod, 3 times per week
40789151|NCT01288625|RADIATION|Amifostine|500mg rinsing wash, qod, 3 times per week
40789152|NCT03980392|OTHER|Multidomain intervention program|Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
41147922|NCT05546021|PROCEDURE|NOL monitor|"NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuous monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics and avoiding overdose or underuse of these drugs.~The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation). The nociception level is a composite score derived from a set of physiologic variables (i.e., peripheral effectors of the autonomous nervous system): heart rate, heart rate variability, the amplitude of the photoplethysmogram, skin conductance, skin conductance variability, and the time derivatives of these variables."
41147923|NCT05755100|BEHAVIORAL|I MOVE!+UP|An individual psychotherapy that integrates behavioral weight management with evidence-based psychotherapy for PTSD (Cognitive Processing Therapy) for up to 6 months, augmented with evidence-based psychiatric and weight management medication management.
41147924|NCT02122484|DRUG|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
41147925|NCT05857163|DRUG|Rifasutenizol capsules|400 mg, BID
41147926|NCT05857163|DRUG|Rabeprazole sodium enteric-coated tablets|20 mg, BID
41147927|NCT05857163|DRUG|Amoxicillin Capsules|1 g, BID
41147928|NCT05857163|DRUG|Clarithromycin placebo tablets|BID
41147929|NCT05857163|DRUG|Bismuth potassium citrate placebo capsules|BID
41147930|NCT05857163|DRUG|Clarithromycin tablets|500 mg, BID
41147931|NCT05857163|DRUG|Bismuth potassium citrate capsules|240 mg, BID
41147932|NCT05857163|DRUG|Rifasutenizol placebo capsules|BID
41147933|NCT02724423|DRUG|NRL-1|
41147934|NCT05536895|DIAGNOSTIC_TEST|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
41147935|NCT05536895|DIAGNOSTIC_TEST|Multi-detector Computed Tomography|Conventional, standard of care perfusion imaging for AIS
41147936|NCT00317317|PROCEDURE|Acupuncture|4 acupuncture treatments will be conducted during the IVF cycle. The 1st one is at the beginning of egg stimulation, the 2nd one is before the egg retrieval, the 3rd and 4th one are before and after the embryo transfer
41147937|NCT00472082|DRUG|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
41147938|NCT05850858|DIAGNOSTIC_TEST|ascetic fluid study|ascetic fluid study parameter in diagnosis of spontaneous bacterial peritpnitis
41467927|NCT00385788|DRUG|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
41467928|NCT00385788|DRUG|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
40789153|NCT01955460|BIOLOGICAL|Aldesleukin|Given IV
40789154|NCT01955460|DRUG|Cyclophosphamide|Given IV
41147939|NCT06200818|PROCEDURE|Diode laser|
41147940|NCT06200818|PROCEDURE|Er:CrYSGG|
41147941|NCT06200818|PROCEDURE|Formocresol|
41147942|NCT01657552|DRUG|Eltrombopag|Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
41147943|NCT01657552|DRUG|Boceprevir|Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
41147944|NCT01657552|DRUG|Telaprevir|Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
41147945|NCT00003376|DRUG|carboplatin|
41147946|NCT00003376|DRUG|cisplatin|
41147947|NCT00003376|DRUG|doxorubicin hydrochloride|
41147948|NCT00003376|DRUG|methotrexate|
41147949|NCT00003376|DRUG|paclitaxel|
41147950|NCT00003376|DRUG|vinblastine|
41147951|NCT01940913|DIETARY_SUPPLEMENT|Probiotic capsules|
41147952|NCT01940913|DIETARY_SUPPLEMENT|Placebo capsules|
41147953|NCT05121376|GENETIC|Dose 1 of BMN 331|BMN 331 AAV Gene Therapy
41147954|NCT05121376|GENETIC|Dose 2 of BMN 331|BMN 331 AAV Gene Therapy
41147955|NCT05121376|GENETIC|Dose 3 of BMN 331|BMN 331 AAV Gene Therapy
41147956|NCT05121376|GENETIC|Dose 4 of BMN 331|BMN 331 AAV Gene Therapy
41147957|NCT05121376|GENETIC|Dose 5 of BMN 331|BMN 331 AAV Gene Therapy
41147958|NCT05121376|GENETIC|Dose 6 of BMN 331|BMN 331 AAV Gene Therapy
41147959|NCT05121376|GENETIC|Dose 7 of BMN 331|BMN 331 AAV Gene Therapy
41147960|NCT06549270|DRUG|MAbs|Monthly or quarterly mAbs administration
41147961|NCT03672188|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
41147962|NCT03672188|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection
41309102|NCT04579679|DRUG|Surufatinib|Surufatinib 300 mg oral once daily
41467929|NCT04991025|DRUG|Cisplatin|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
41467930|NCT04991025|DRUG|Pemetrexed|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle
41467931|NCT04991025|DRUG|Gemcitabine|Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
41467932|NCT04991025|DRUG|Carboplatin|Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.
41467933|NCT04991025|DRUG|Certolizumab|Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.
41467934|NCT04991025|DRUG|Nivolumab|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.
41467935|NCT00051818|BEHAVIORAL|Treatment interruption/reinitiation schedule|
41467936|NCT06054477|DRUG|ALE.C04|Q3W
40789155|NCT01955460|DRUG|Fludarabine Phosphate|Given IV
40993114|NCT01245270|DIETARY_SUPPLEMENT|Bilberry capsule first, then control cap|"Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
41147963|NCT01125345|PROCEDURE|Phacoemulsification|Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
41147964|NCT05960929|COMBINATION_PRODUCT|Infasurf Aero™|A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.
41147965|NCT05703477|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
41147966|NCT02181751|OTHER|Trauma Focused Cognitive Behavioural Therapy Group|Youth may participate in trauma focused cognitive behavioural group therapy (TF-CBT)
41147967|NCT00365599|DRUG|suberoylanilide hydroxamic acid (SAHA, Vorinostat)|Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
41147968|NCT00365599|DRUG|tamoxifen citrate (Tamoxifen)|Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
41147969|NCT05450822|DRUG|Levetiracetam|"Healthy subjects and patients in Cohort III will undergo a 120 min. \[11C\]-UCB-J PET-MR brain scan followed by intravenous administration of levetiracetam after approx. 60 min. in a displacement paradigm. Before, during and after the intervention arterial spin labeling and resting-state functional MRI will be acquired.~To measure the radiolabelled tracer's arterial input function, including its radiolabelled metabolites, blood samples will be drawn during the PET scan from an arterial catheter.~The selected regions for the primary analyses are the epileptogenic lesion(s) (patients) and the neocortex, hippocampus, entorhinal cortex, fusiform gyrus, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, orbitofrontal cortex, striatum, anterior cingulate cortex and amygdala. \[11C\]-UCB-J binding, volume of distribution and SV2A occupancy will be quantified by analyzing the PET images with well-validated kinetic models."
41266408|NCT01508741|DIETARY_SUPPLEMENT|5-Aminolevulinic Acid (5-ALA)|5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
41467937|NCT06054477|DRUG|Pembrolizumab|200mg Q3W
41467938|NCT04079582|OTHER|Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
41467939|NCT04079582|OTHER|Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
41467940|NCT01886937|DRUG|Phentermine|After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
41467941|NCT01886937|DRUG|placebo|Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
41467942|NCT03003364|DRUG|XCEL-UMC-BETA|Intrathecal allogeneic cell therapy in a blinded syringe
41467943|NCT03003364|DRUG|Placebo|Placebo in a blinded syringe
41467944|NCT04583696|DIETARY_SUPPLEMENT|The Investigation of effect on Blood Lipid parameters with walnut addition of Diet|Participants were asked to consume 30 g of walnuts daily for 21 days. Individuals have consumed walnuts on an empty stomach in the morning or with breakfast.
41467945|NCT04024319|PROCEDURE|Genicular Nerve Block|4 ml of local anesthetic were administered in 5 genicular nerves. A total volume of 20 ml were administered in GNB group.
41467946|NCT04920526|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|No intervention will be administered
40789156|NCT01955460|OTHER|Laboratory Biomarker Analysis|Correlative studies
40789157|NCT01955460|BIOLOGICAL|NGFR-transduced Autologous T Lymphocytes|Given IV
40789158|NCT01955460|BIOLOGICAL|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
40789159|NCT04679961|DEVICE|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.
41467947|NCT03135899|DRUG|BI 443651|Three doses, each 12 hours apart
41147970|NCT05450822|DRUG|Levetiracetam Tablets|Patients in Cohort II will be randomized to treatment with an ASM (levetiracetam) in accordance with standard treatment procedures. The patients will enter a 4 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to lamotrigine arm.
41147971|NCT05450822|DRUG|Lamotrigine tablet|Patients in Cohort II will be randomized to treatment with an ASM (lamotrigine) in accordance with standard treatment procedures. The patients will enter a 6 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to levetiracetam arm.
41147972|NCT05671055|OTHER|Custom study version of icompanion app|Patients complete patient-reported outcomes on cognition and covariates, as well as objective cognitive tests through a version of icompanion app customized specifically for this study. Patients complete all assessments remotely in an at-home situation.
41147973|NCT01662804|DRUG|3F8 Monoclonal Antibody Combined with Interleukin-2|One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
41147974|NCT02275806|DRUG|Irinotecan|
41147975|NCT02275806|DRUG|Cisplatin|
41147976|NCT01790659|DRUG|WR 279,396|WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
41147977|NCT01790659|DRUG|Paromomycin|Paromomycin alone
41147978|NCT01596894|DRUG|Azithromycin + Metronidazole|Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
41147979|NCT01596894|DRUG|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
41147980|NCT05450939|DIAGNOSTIC_TEST|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
41147981|NCT03262753|PROCEDURE|Surgery|Primary end-to-end surgical treatment of coarctation of the aorta
41147982|NCT03262753|PROCEDURE|Balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
41147983|NCT03262753|PROCEDURE|Stent|Primary stent dilation treatment of coarctation of the aorta
41147984|NCT05516511|DIAGNOSTIC_TEST|Angiotensin Converting Enzyme test|blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
41147985|NCT02283632|PROCEDURE|Jejunal Diversion|The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
41147986|NCT01093976|DRUG|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
41147987|NCT04232410|DIAGNOSTIC_TEST|Drug induced sleep endoscopy|DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.
41147988|NCT04232410|DIAGNOSTIC_TEST|Measurement of critical closing pressure of the uppper airway|After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
40789161|NCT05298943|OTHER|walking in 4 situations|Recording of cerebral hemodynamic with fNIRS during gait in exoskeleton with Four strength levels of aid : total aid (A100%), partial aid (A50%), no aid (A0%) and resistance of 25 % (R25%) to walking from the exoskeleton. Each subject are recorded during 8 trials for each level (32 trials). The order is counterbalanced among the subjects
41147989|NCT05624229|DRUG|Proton Pump Inhibitors|PPI infusion continued to use for 5 days in experimental group
40789162|NCT01479764|DRUG|Sugammadex|sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
40789163|NCT01479764|DRUG|Neostigmine|neostigmine, per usual practice
40789164|NCT01479764|DRUG|Glycopyrrolate|glycopyrrolate per usual practice
41147990|NCT05624229|DRUG|No Proton Pump Inhibitors|PPI infusion stopped in standard group after endoscopy.
41147991|NCT03245996|DEVICE|AAI 40 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm in the first and second part of the study
41147992|NCT03245996|DEVICE|AAI 60 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm in the first and second part of the study
41147993|NCT03245996|DEVICE|AAI 90 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm in the first and second part of the study
41147994|NCT03245996|DRUG|Atenolol Pill|50 or 100 mg of atenolol is administered to subjects in the second part of the study
40789165|NCT05618756|DIETARY_SUPPLEMENT|Acute oral CBD supplementation|1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.
41309103|NCT00016198|DRUG|FOLFOX regimen|
40789166|NCT05618756|DIETARY_SUPPLEMENT|Acute oral placebo supplementation|1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.
40789167|NCT05580354|DRUG|BCG combined with Tislelizumab|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
40789168|NCT00894699|DRUG|Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)|Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
40789169|NCT00894699|DRUG|Placebo NanoTab™|Single dose of sublingual placebo NanoTab™
40789170|NCT05177042|DRUG|ARV-110 in Combination with Abiraterone|ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles
40789171|NCT05809427|DEVICE|Periodontal probing|"Imaging/Scanning and recording : Ultrasonic periodontal probing per operator (10 teeth X 6 sites/teeth = 60 probing sites per operator). In addition, 2 teeth per patient will be probed with the ultrasonic probe a second time (2 teeth x 6 sites per tooth = 12 sites per patient) for intra-operator reproducibility purpose.~Manual probing per operator with the OMS probe (part of the routine of care)"
41147995|NCT03245996|DRUG|Nebivolol Pill|5 mg of nebivolol is administered to subjects in the second part of the study
41147996|NCT03245996|DRUG|Ivabradine Pill|5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
41147997|NCT02458794|PROCEDURE|function tests|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
41147998|NCT02458794|DEVICE|LMA SupremeTM|
41147999|NCT02458794|DEVICE|Ambu-Aura GainTM|
41148000|NCT00362258|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.
41148001|NCT01807234|DRUG|Ketorolac|Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
41148002|NCT01807234|DRUG|Sumatriptan|Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
41148003|NCT01807234|DRUG|Placebo|Placebo one spray in each nostril and placebo one nasal spray.
41148004|NCT05745259|DRUG|Alteplase|Alteplase 0.9mg/kg are being used.
41148005|NCT05745259|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
41467948|NCT03135899|DRUG|Placebo|Three doses, each 12 hours apart
41148006|NCT04186819|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
40789172|NCT01490255|DRUG|Ranolazine|os, 750 mg, twice per day, for 15 days
40789173|NCT01490255|DRUG|Amlodipine|os, 10 mg, once daily, 15 days
40789174|NCT01027650|DRUG|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
41148007|NCT04683900|OTHER|Standard of care + Mediterranean diet (intervention)|"Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.~Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consume ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fruits; d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish/seafood; f) ≥3 weekly serving of nuts/seeds; g) select white instead of red or processed meats; h) cook at least twice a week with sofrito. Limit consumption of cream, butter, processed meat, sugared beverages, industrial bakery products and desserts, and French fries or chips. For usual drinkers, the main source of alcohol should be wine."
41148008|NCT04683900|OTHER|Standard of care (control)|Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.
41148009|NCT03335722|BEHAVIORAL|Metronome-timed speech|Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
41148010|NCT03335722|DEVICE|Active tDCS|1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
41266409|NCT01508741|DIETARY_SUPPLEMENT|Placebo|Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
40789175|NCT01027650|DRUG|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
41309104|NCT00016198|DRUG|fluorouracil|
41467949|NCT06616441|DRUG|Bupivacaine|Group (A) only will receive intra-peritoneal 40 ml bupivacaine 0.2%, after laparoscopic procedure before removing trocars.
40789176|NCT06116981|OTHER|High Induction Magnetic Field Therapy|High Induction Magnetic Field Therapy is a method that has no side effects, is non-invasive and easy to apply, and is used to increase circulation in tissues.
40789177|NCT06116981|OTHER|Conservative Treatment|Shoulder exercises, transcutaneous electrical nerve stimulation, stretching.
40789178|NCT04949945|BEHAVIORAL|Self Help Culturally Cognitive Behavioral Therapy|Experimental group (CHF patients)will be screened on PHQ9 questionnaire for depression after receiving guided self help culturally adapted cognitive therapy they will be reassessed for their depression,improvement in functional disability ,improvement in classification of NYHA,reduction in hospital admission as compare to control group.
40789179|NCT06396403|OTHER|Collection of venous blood samples|collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL
40789180|NCT06369298|DRUG|JK07|JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.
40789181|NCT06369298|DRUG|Placebo|0.9% sodium chloride
40993115|NCT01245270|DIETARY_SUPPLEMENT|Control capsule first then bilberry cap|"Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
40993116|NCT00539578|DRUG|MK0777|Duration of Treatment: 4 weeks
40993117|NCT00539578|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 4 weeks
41148011|NCT03335722|DEVICE|Sham tDCS|Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
41309105|NCT00016198|DRUG|leucovorin calcium|
41467950|NCT05905796|OTHER|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
41467951|NCT06293443|OTHER|Lower extremity unilateral amputee|To evaluate the functionality of lower extremity unilateral amputees, to ensure that the results of the Medicare Functional K Classification System, which provides subjective data for the evaluator, become an objective evaluation method and to determine the functional levels of unilateral amputees; To create an objective data set by applying one-leg standing test, Ten meter walking test, L test, figure-8 walking test, joint range of motion, amputee mobility estimator scale, Houghton scale and joint position sense evaluation tests.
41467952|NCT04832334|OTHER|Kinesthetic and Visual Imagery Questionnaire, Box and Block Test, Hand Lateralization Test.|Imagery ability was determined.
41467953|NCT04832334|OTHER|Berg Balance Scale, Functional Reach Test|Balance level was determined.
40993118|NCT06454461|DRUG|Upadacitinib 15 MG|Upadacinib 15mg once daily for the 8 weeks after NECS
40993119|NCT06418503|OTHER|Balance Training|Participants will complete 16 sessions of balance training (30 min. each) over one month.
40993120|NCT06418503|OTHER|EMG-Biofeedback Training|Participants will complete 16 sessions of EMG-biofeedback balance training (30 min. each) over one month.
40993121|NCT00838058|DRUG|CE-224,535|one 250mg tablet, once in the morning in fasted state
40993122|NCT00838058|DRUG|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
40993123|NCT00838058|DRUG|CE-224,535|4x250mg tablets, once in the morning, in fasted state
40993124|NCT00838058|DRUG|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
40993125|NCT00838058|DRUG|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
41309106|NCT00016198|DRUG|oxaliplatin|
41309107|NCT00752609|DRUG|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
41309108|NCT01437670|DRUG|solifenacin 5mg, 10mg|solifenacin 5mg, 10mg
41467954|NCT04832334|OTHER|Timed Up and Go Test, Functional Independence Scale|Functionality was evaluated.
41467955|NCT00517192|DRUG|Tipranavir|
41467956|NCT00517192|DRUG|Darunavir|
41467957|NCT00517192|DRUG|Ritonavir|
41467958|NCT05085782|DRUG|Propranolol Hydrochloride|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
41467959|NCT05085782|DRUG|Placebo|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
41467960|NCT05085782|BEHAVIORAL|Reactivation procedure|Description/visualization of painful movements/activities
40993126|NCT00838058|DRUG|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
41309109|NCT03056495|DRUG|N-hydroxy-N'-phenyl-octanediamide (Vorinostat)|N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
41309110|NCT01201070|DRUG|antithrombin III|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
41309111|NCT02627131|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
41467961|NCT05085782|BEHAVIORAL|Pain neuroscience education|In the form of 10 videos that participants will watch on their own time
41309112|NCT05501574|DRUG|Tacrolimus Inhalation Powder|Tacrolimus powder for inhalation to prevent acute allograft rejection
41309113|NCT03677687|BEHAVIORAL|Mindfulness for Physical Activity|The Mindfulness for Physical Activity (MfPA) programme aims to change participants' relationship with physical activity by targeting psychological factors related to physical activity uptake and maintenance.
41467962|NCT03671187|OTHER|Exercise|8 week exercise program
40789182|NCT06196996|PROCEDURE|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
40789183|NCT00200967|DRUG|salmeterol|50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
40789184|NCT00200967|DRUG|beclomethasone HFA|240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
40789185|NCT01285024|DEVICE|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
40789186|NCT01762683|OTHER|Myometrium biopsy and blood samples|"The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study."
40789187|NCT01824290|DRUG|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
40789188|NCT01824290|DRUG|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
40789189|NCT01824290|DRUG|ERA as specific PAH treatment|All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
40789190|NCT04029207|PROCEDURE|Cesarean section|Abdominal, operative delivery of the fetus
40789191|NCT04180098|BEHAVIORAL|C-mill intervention|A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
40789192|NCT04180098|OTHER|No intervention|Participants in the control group are placed on a waiting list.
40789193|NCT00403143|PROCEDURE|cataract surgery|
40789194|NCT00002348|DRUG|Mitoguazone|
40789195|NCT00348946|DRUG|androgen oxandrolone|Oxandrolone ,06 \>mg/kg/day, orally, for 2 years
40789196|NCT00348946|OTHER|placebo|an inactive substance
40789197|NCT01344798|BIOLOGICAL|AAV1-gamma-sarcoglycan vector injection|single intramuscular injection into carpi radialis muscle under open procedure
40789198|NCT02782845|DRUG|Chemotherapy|The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
40789199|NCT02782845|DRUG|Immunochemotherapy|The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
41148012|NCT00459849|PROCEDURE|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
40789200|NCT02782845|DRUG|Pegfilgrastim|Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
40789201|NCT04691037|DIAGNOSTIC_TEST|CCTA|All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
41148013|NCT01803958|RADIATION|partial breast irradiation|
41467963|NCT01473147|DRUG|Exenatide|Exenatide 5 microgram bid sc.
41467964|NCT01473147|DRUG|Normal saline|Normal saline 2 u bid sc.
41467965|NCT02358733|PROCEDURE|Intra-cytoplasmic Sperm Injection|Selection of sperm at 400x for sperm injection
41467966|NCT02358733|PROCEDURE|Intra-cytoplasmic Morphologically-selected Sperm Injection|Selection of sperm at 6000x for sperm injection
40789202|NCT02733003|BEHAVIORAL|Women's Health CoOp (WHC)|Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues.
40789203|NCT01655186|DRUG|Bardoxolone Methyl|
40789204|NCT01655186|DRUG|Placebo|
40789205|NCT03410069|DEVICE|IKORUS UP system|Continuous assessment of the urethral microcirculation
40789206|NCT05501639|DRUG|tiotropium|tiotropium
41148014|NCT01803958|RADIATION|whole breast irradiation|
41148015|NCT05149976|DIAGNOSTIC_TEST|Voice recording before and after dietary intake|"* A person who is scheduled to undergo a VFSS test, and his/her voice is recorded before and after eating for the VFSS test~* For general subjects, only voice recordings were conducted before and after food/water intake without a VFSS test."
41148016|NCT02276937|DRUG|DVC1-0101|The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.
41148017|NCT04239976|DEVICE|FitBit|Wear FitBit for gait assessment test
41148018|NCT04239976|OTHER|Gait Assessment Test|Undergo gait assessment test
41148019|NCT04239976|OTHER|MC5-A Scrambler Therapy|Undergo scrambler therapy
41148020|NCT04239976|OTHER|Quality-of-Life Assessment|Ancillary studies
41148021|NCT04239976|PROCEDURE|Quantitative Sensory Testing|Undergo quantitative sensory test
41148022|NCT04239976|OTHER|Questionnaire Administration|Ancillary studies
41148023|NCT02450279|DRUG|technetium-99m - Diethylenetriaminepentaacetic acid|
41309114|NCT04114084|PROCEDURE|Bone Marrow Aspirate and Biopsy|The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
41309115|NCT06163456|OTHER|Acute submaximal exercise|30 min of treadmill running at 70% of the participants maximal oxygen consumption
41309116|NCT02750657|GENETIC|Molecular Profiling|Whole Genome Sequencing
41309117|NCT04069741|OTHER|Decision Aid|A website that contains information about de Quervain's tenosynovitis and the options for treatment
41309118|NCT04069741|BEHAVIORAL|Toolkit for de Quervain's|A website that offers 4 sessions of mind-body skills to help manage pain from de Quervain's tenosynovitis
40789207|NCT05501639|DRUG|long-acting β2-agonists (LABA)|long-acting β2-agonists (LABA)
40789208|NCT05501639|DRUG|inhaled corticosteroids (ICS)|inhaled corticosteroids (ICS)
40789209|NCT03801928|DRUG|Inflectra|The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.
41148024|NCT02450279|DEVICE|Vibrating-mesh nebulizer|
41309119|NCT03233412|PROCEDURE|Control|Exertion of the cervix transformation zone
40993127|NCT00838058|DRUG|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
41467967|NCT04228965|DRUG|Varenicline|Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
41467968|NCT04228965|BEHAVIORAL|Contingency Management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
41467969|NCT04228965|BEHAVIORAL|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.
41467970|NCT06228703|DEVICE|High-flow nasal cannula device with flow setting at 40 L/min or higher|Eligible participants will use the high-flow nasal cannula device (Airvo3 or HFT 750) with flow set at 40 L/min or higher
41467971|NCT04733209|OTHER|TENS, US, exercise|Physiotherapy
41467972|NCT01245842|OTHER|Hand exercise program|Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
41467973|NCT06614751|DRUG|DAT-2645 tablet|The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.
41467974|NCT06614751|DRUG|DAT-2645 tablet|The study set 6 dose level cohorts in dose escalation part.On C0D1, patient take DAT-2645 one time (Single use), The dosage is same as his enrolled cohort dose level. if no DLT, 7 days later(C1D1), patients will continue taking DAT-2645 tablet daily, dasage is same as before, 21days/cycle.
40789210|NCT03732209|BEHAVIORAL|Episodic future thinking|Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
40789211|NCT03732209|BEHAVIORAL|Control Thinking|Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
40789212|NCT00205764|DRUG|Melphalan|
40789213|NCT06154018|DRUG|Protamin|ACT and Clot- Pro test will be ran after initial and possible next protamine administrations
40789214|NCT05644717|DRUG|Ertugliflozin 5 mg, 15mg|Ertugliflozin 5/15mg once daily in addition to standard of care
40789215|NCT04210661|OTHER|prediction software with spell checker|test with prediction software with spell checker
40789216|NCT04704713|DRUG|Afamelanotide|
40993128|NCT00838058|DRUG|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
40993129|NCT03933787|DRUG|Saxagliptin 5mg|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
40993130|NCT03933787|DRUG|Placebo oral capsule|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
40993131|NCT03933787|OTHER|ergometric test in healthy volunteers|The volunteers will undergo an ergometric test in each session
41148025|NCT02450279|DEVICE|Jet Nebulizer|
41148026|NCT02450279|OTHER|Planar scintigraphy|
41148027|NCT02450279|OTHER|Preoperative spirometry|
41148028|NCT00160329|DRUG|Atazanavir|300 mg with ritonavir boosting or 400 mg without
41148029|NCT05428215|DRUG|17beta Estradiol|Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration
41309120|NCT03233412|DRUG|Imiquimod|Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks
41309121|NCT02969317|DRUG|Tiotropium|Fixed dose combination
41309122|NCT02969317|DRUG|Olodaterol|Fixed dose combination
40789217|NCT04704713|DRUG|Placebo|
40789218|NCT04584398|DEVICE|Respiratory muscle training with steam inhalation|
40789219|NCT00856635|DRUG|Glatiramer Acetate|20 mg injected daily subcutaneously
40789220|NCT00856635|DRUG|placebo|injected daily subcutaneously
40789221|NCT01757301|OTHER|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
40789222|NCT01757301|OTHER|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
40789223|NCT04631315|DRUG|Difluprednate Ophthalmic Emulsion 0.05%|1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
40789224|NCT04631315|DRUG|Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution|1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
40789225|NCT06199024|DIETARY_SUPPLEMENT|Oral cinnamon supplementation|In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
40789226|NCT02365181|PROCEDURE|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
40789227|NCT02365181|PROCEDURE|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
40789228|NCT02365181|DRUG|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
40789229|NCT03479450|DRUG|surfactant|surfactant is given when neonatal respiratory distress syndrome is diagnosed
40789230|NCT03228862|DRUG|Ergocalciferol|Ergocalciferol 40000, 60000 and 80000 once weekly
40993132|NCT03134755|DRUG|Inhaled corticosteroid (mometasone)|The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
40993133|NCT03249311|DRUG|Levomilnacipran|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
40993134|NCT03249311|DRUG|Duloxetine|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
40993135|NCT03249311|DRUG|Placebos|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
40993136|NCT02515955|DRUG|JNJ-54175446|Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
40993137|NCT02515955|DRUG|Minocycline|Participants will receive minocycline 100 mg as capsule twice daily.
40993138|NCT02515955|DRUG|JNJ 54175446 Matching Placebo|Participants will receive placebo matching with JNJ 54175446 once daily orally.
40993139|NCT02515955|DRUG|D Amphetamine|Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
40993140|NCT02515955|DRUG|D Amphetamine Matching Placebo|Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
40993141|NCT03610932|DIETARY_SUPPLEMENT|Vitamin C|Taken as 3 500mg capsules.
40993142|NCT03610932|OTHER|Placebo|Taken as 3 500mg capsules.
40993143|NCT00679263|DRUG|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
40993144|NCT00679263|DRUG|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
40993145|NCT00679263|DRUG|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
40993146|NCT05547074|PROCEDURE|pancreatic cancer surgery|Surgical resection of pancreatic cancer，including radical or palliative surgery
40993147|NCT05954624|DRUG|Digoxin|oral
40993148|NCT05954624|DRUG|Rosuvastatin|oral
40993149|NCT05954624|DRUG|ZSP1273|oral
40993150|NCT05954624|DRUG|Itraconazole|oral
40789231|NCT01337778|BEHAVIORAL|Primary care for Daughters-in-Law|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
40789232|NCT01337778|BEHAVIORAL|The Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
40993151|NCT05954624|DRUG|Probenecid|oral
41467975|NCT03670134|DEVICE|The Nvision VLE Imaging System|Volumetric laser Endomicroscopy (VLE) will be performed by using the Nvision VLE Imaging System (Nine Point Medical, MA) consists of an imaging console, monitor and optical probe. The optical probe is centered by a balloon (diameter: 14 mm, 17 mm, 20 mm; length: 6 cm) that is deployed through a diagnostic gastroscope's instrument channel. Imaging is performed by automatic helical pullback of the probe from the distal to the proximal end of the balloon over 90 seconds.
40789233|NCT04862559|DEVICE|NovaCross|A device that is intended to asisst interventional cardiologists during catheterization to cross and open coronary chronic total occlusions
40789234|NCT01816425|DEVICE|Thermoplastic partial denture|
40789235|NCT01816425|DEVICE|CoCr partial denture|
40789236|NCT02088125|OTHER|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
40789237|NCT02088125|OTHER|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
40789238|NCT03729635|PROCEDURE|Pectoral-intercostal fascial plane block (PIFB)|Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
40789239|NCT03509818|OTHER|plyometric exercise|acute plyometric exercise
40789240|NCT03509818|OTHER|Aerobic exercise|acute aerobic exercise
40789241|NCT03586375|OTHER|Intensive Support Team Care|Intensive Support Teams (ISTs) are specialist teams which have been advocated for many years as the right services to help people with intellectual disabilities (ID) and challenging behaviour stay in their local communities. They may be staffed by one or more professions, e.g. psychology, nursing, psychiatry, and usually deliver interventions such as positive behaviour support and accept people with ID who are in a crisis when challenging behaviour emerges or provide support when a person is admitted to a local inpatient facility.
40789242|NCT04141319|DRUG|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
40789243|NCT04141319|DRUG|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
40789244|NCT04141319|DRUG|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
40789245|NCT02777086|BEHAVIORAL|StaySafe|StaySafe is a self-administered tablet computer app designed to improve decision-making around health risk behaviors.
41467976|NCT00763555|DRUG|CD 2027|Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
40993152|NCT01763437|DRUG|Tetracycline|Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
40993153|NCT06250231|OTHER|No intervention|No intervention
40993154|NCT00527943|DRUG|Vorapaxar|oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
40993155|NCT00527943|DRUG|Placebo|oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
40993156|NCT03455660|OTHER|no intervention|no intervention
40789247|NCT02797912|OTHER|No intervention|
40789248|NCT02746328|DRUG|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
40789249|NCT05547386|PROCEDURE|Computed Tomography|Undergo PET/CT scan
40789250|NCT05547386|DRUG|Gallium Ga 68 Gozetotide|Given IV
40789251|NCT05547386|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
40789252|NCT03931226|DRUG|Drug consumption|number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
40789253|NCT00856609|DRUG|Byetta (exenatide)|Exenatide is an injectable medication
40789254|NCT00856609|BEHAVIORAL|Weight loss|Because response to weight loss
40789255|NCT00856609|OTHER|Metabolic Chamber|The subject stays in the small room
40789256|NCT00856609|DRUG|Placebo|
40789257|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
40993157|NCT00056030|BIOLOGICAL|cetuximab|
40993158|NCT00056030|DRUG|fluorouracil|
40993159|NCT00056030|DRUG|leucovorin calcium|
40993160|NCT00056030|DRUG|oxaliplatin|
41467977|NCT00763555|DRUG|Calcitriol Vehicle|Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
40993161|NCT05766930|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The relief genital itching evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
40789258|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
40789259|NCT01950728|DEVICE|Interferential current|Interferential current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kilohertz (kHz) and modulated frequency will be set at 100 Hz.
40789260|NCT01950728|DEVICE|Aussie Current|Aussie current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kHz and modulated frequency will be set at 100 Hz.
40789261|NCT01950728|DEVICE|TENS|TENS will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Pulse duration will be set at 125 microseconds and frequency will be set at 100 Hz.
40789262|NCT05694663|DEVICE|Vivistim|After one month of prehabiliatory training, the patient will then undergo surgical placement of the implantable VNS device (Vivistim System) consisting of an implantable neurostimulator and an implantable lead and electrode per standard of care. The device comes with a controller and software system which allows for control of the stimulation settings during the rehabilitation phase. The PMA number for this device is 210007 and the date of FDA notice of approval occurred on August 27, 2021.
40789263|NCT00532701|DRUG|Peg-IFN + WB RBV for 16 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 5-16"
40789264|NCT00532701|DRUG|Peg-IFN + LD RBV for 16 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-6~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16"
40789265|NCT00532701|DRUG|Peg-IFN + WB RBV for 24 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24"
40789266|NCT00532701|DRUG|Peg-IFN + WB RBV for 48 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48"
40789267|NCT00532701|DRUG|Peg-IFN + LD RBV for 24 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~2. Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved"
40789268|NCT06400745|DEVICE|CPO Pro IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.
40789269|NCT06400745|DEVICE|CPO IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.
40789270|NCT06400745|PROCEDURE|Cataract surgery|Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
40789271|NCT00856323|DRUG|Truvada|At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
40789272|NCT00856323|BEHAVIORAL|CM|Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
40993162|NCT03332576|BIOLOGICAL|DPX-Survivac|SubQ injection
41148030|NCT02440256|OTHER|Expanded HIV care in Opioid Substitution Treatment|The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
41467978|NCT06247501|GENETIC|SNUH-CD19-CAR-T|CD19 CAR-T is a gene therapy that uses genetically modified autologous peripheral blood T-cells to target CD19 on the surface of B-cells. In this approach using CARs, lymphocytes are genetically manipulated, introducing the chimeric antigen receptor gene into the lymphocytes to combine the function of effector T-cells with antibody-like abilities. The chimeric antigen receptor can recognize cell surface antigens without the need for antigen processing. By using a single-chain variable fragment (scFv) antibody, which combines the variable regions of the heavy chain (VH) and light chain (VL) through a peptide linker of approximately 15 amino acids in length, the CAR gains the ability to bind to tumor antigens.
40993163|NCT03332576|BIOLOGICAL|DPX-Survivac(Aqueous)|SubQ injection
40993164|NCT03332576|DRUG|Cyclophosphamide|PO BID
40993165|NCT00104455|DRUG|activated recombinant human factor VII|
40789273|NCT02560220|BIOLOGICAL|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
40789274|NCT03920241|BEHAVIORAL|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn, 1990) consisted of 2.5-hour of face-to-face weekly sessions, and 45 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. During the program, different mindfulness practices are performed, including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga.~Training is delivered by certificated instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
40789275|NCT03920241|BEHAVIORAL|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of 2.5-hour of face-to-face weekly sessions and 30 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering.~CCT program is delivered by certificated instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
40789276|NCT03920241|OTHER|Control Group|A group of participants, matched by age, gender, and meditation experience is selected to compare their performance on experimental lab tasks in relation to the MBSR and CCT participants.
40993166|NCT04863755|BEHAVIORAL|DASH|Patients receive DASH diet orientation and recommended to maintain their usual physical activity
40789277|NCT04361292|PROCEDURE|INTRAUTERINE INSEMINATION|Intrauterine insemination (IUI) combined with ovarian stimulation, has been an extensively used procedure for the treatment of patients with unexplained infertility. The fact that IUI is less expensive, less invasive, and easier to perform than other assisted reproductive techniques makes it the first-line treatment option in infertility treatments. Sperm that have been washed and concentrated are placed directly into the uterus around the time of ovulation. All patients had ovulation induction with gonadotropins and ovulation was triggered by recombinant hcg.
40789278|NCT00083980|DRUG|Venlafaxine ER|75 to 225 mg daily
40789279|NCT00083980|DRUG|Sugar pill|Upto 3 per day for venlafainxe and 4 per day for kava placebos.
40789280|NCT00083980|DRUG|Kava|140 to 280 mg per day
40789281|NCT03759600|DRUG|Niraparib|Niraparib capsule
40789282|NCT06169163|OTHER|Exhaled breath sampling|Participants will maintain a clear fluid diet for a minimum of 6 hours prior to breath collection. Participants will be asked to provide a breath sample by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto TD tubes at a controlled flow rate. This breath sampling procedure will be repeated once. When the participants' breath sampling is complete, room air (Blank) samples must be taken onto additional TD tubes using the same procedure. The TD tubes will be sealed with long-term storage caps using the CapLok Tool.
40789283|NCT06252844|BEHAVIORAL|Resistance exercise training|Supervised PRT will consist of leg extension, leg curl, leg press, and calf raises. Initially participants will start with a 4 weeks adaptation with low loads at 15 (repetition maximum, RM) conducting for 1-3 sets. Further on subjects will continue with a 5 month of PRT with intensity increasing every 2 weeks from 12 to 6 RM. Each exercise will be done for 3 sets with 2 min rest periods between sets. After the 2 weeks at 6 RM, 1 week of rest will be applied. After the rest week, the same cycle starting from 12 RM will be repeated until the end of intervention.
40789284|NCT06252844|BEHAVIORAL|Active control|Supervised static stretching exercises will be performed without causing an unpleasant feeling of stretching, up to pain, maintaining the stretching position for at least 30 s. Exercises will be performed slowly so that heart rate (HR) does not exceed 50% maximum. Subjects will calculate their HR before training, in the middle and after the training measuring the pulse for 10 s. Exercises will be repeated 3-5 times for each side of the body. The duration of the training will be match to PRT group and will take around 40 min. In order to keep the subjects interested and motivated, two of the stretching exercises will be changed every two weeks.
40789285|NCT00704067|BEHAVIORAL|Supported employment plus cognitive training|Supported employment for 12 months plus cognitive training for the first 12 weeks
40993167|NCT04863755|BEHAVIORAL|DASHPED|Patients receive DASH diet orientation and recommended to increase their usual activity with the use of a pedometer
40993168|NCT03336775|PROCEDURE|acupuncture|Acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks).
40993169|NCT03034421|BEHAVIORAL|Bed rest|Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
40993170|NCT05757921|DEVICE|Perisolv (A)|Intended for cleaning periodontal pockets for both periodontitis and peri-implantitis. Softens degenerative tissue and biofilm before depuration of periodontal pockets. Does not affect healthy tissue.
40993171|NCT05757921|OTHER|Standard (B)|Deepened periodontal pockets to be treated are performed by subgingivally debridement. This is performed with piezoelectric ultrasound (EMS) under rinsing water and subgingival debridement with hand instrument.
40993172|NCT04245384|OTHER|Internet-based dietetic treatment with video calls|The dietitian meets the patient through video calls, no physical meetings
40993173|NCT04245384|OTHER|Traditional dietetic treatment|The dietitian meets the patient through physical meetings
41467979|NCT00746291|OTHER|6 min walk test, Step climbing|walking for 6 minute and climbing steps
41148031|NCT01005563|OTHER|Beef/Pork|Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
41148032|NCT01005563|OTHER|Soy/Legumes|Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
41148033|NCT04352894|DIAGNOSTIC_TEST|Fluorescence guided peritoneal exploration|Intravenous injection of ICG
41148034|NCT03593798|OTHER|Lifestyle|Lifestyle intervention an effect on weight and physical capacity
41148035|NCT05491837|OTHER|Device induce acute intermittent hypoxia 9 % of Oxygen|Interventional group will be provided a brief sequence of mild hypoxia consisting of 9% oxygen for one minute followed by normoxia 21% of oxygen for a total of 15 episodes
40789286|NCT00704067|BEHAVIORAL|Enhanced supported employment|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
40789287|NCT03771040|DRUG|Masitinib|
40789288|NCT03771040|DRUG|Placebo|
40789289|NCT00540592|BIOLOGICAL|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
40789290|NCT00540592|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
40789291|NCT04848480|DRUG|insulin icodec|insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly
40789292|NCT04848480|DRUG|insulin degludec|insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily
40789293|NCT04848480|DRUG|insulin aspart|insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
40789294|NCT02789462|PROCEDURE|Laser-assisted percutaneous coronary interventions|Chart review and data collection of patients undergoing laser-assisted percutaneous coronary interventions
40789295|NCT05015478|DEVICE|Tailored Rhythmic Lighting Intervention|40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.
40993174|NCT04184531|OTHER|Medical Data Collect|It is a retrospective clinical study and we will collect only the medical data registered in our hospital software
40993175|NCT00000766|DRUG|Foscarnet sodium|
40993176|NCT00000766|DRUG|Ganciclovir|
40993177|NCT05863039|OTHER|Blood flow restriction|Strength training of the lower leg muscles using blood flow restriction
40993178|NCT05863039|OTHER|Regular training type 1|Strength training of the lower leg muscles using high loads
41467980|NCT05534048|BIOLOGICAL|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
40993179|NCT05863039|OTHER|Regular training type 2|Strength training of the lower leg muscles using low loads
40993183|NCT01048723|DRUG|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
40993184|NCT00245141|BIOLOGICAL|dactinomycin|
40993185|NCT00245141|DRUG|cyclophosphamide|
40993186|NCT00245141|DRUG|vincristine sulfate|
40993187|NCT00245141|RADIATION|radiation therapy|
40993188|NCT03662984|DRUG|Ciprofibrate 100Mg Tablet|Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
40993189|NCT03662984|DRUG|Placebo Oral Tablet|To compare ciprofibrate
41467981|NCT05534048|BIOLOGICAL|Comirnaty®|0.45 mL concentrate in a 2 mL clear multidose vial (type I glass) with a stopper (synthetic Bromo-butyl rubber) and a purple flip-off plastic cap with aluminum seal. Each vial contains 6 doses.
41467982|NCT04355299|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
40993190|NCT01782261|DRUG|Liraglutide|once daily subcutaneous injection
40993191|NCT01782261|DRUG|Saxagliptin|once daily tablet
40993192|NCT04355000|PROCEDURE|Hall technique|SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
40993193|NCT04355000|PROCEDURE|RMGIC restoration|Complete removal of caries and filling will be done with RMGIC material
40993194|NCT02879409|DRUG|Metformin|Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
41148036|NCT05491837|OTHER|Normoxia 21% of oxygen|SHAM group will be provided normoxia 21% of Oxygen
41467983|NCT04355299|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
40789296|NCT05015478|DEVICE|Placebo Rhythmic Lighting Intervention|Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered with a random interval determined by a Poisson process with an average interval of 40 hertz (Hz). The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.
40789297|NCT00754689|DRUG|Rimonabant|Tablet, oral administration
40789298|NCT00754689|DRUG|Metformin|Tablet, oral administration
40789299|NCT00754689|DRUG|placebo|Tablet, oral administration
40789300|NCT04680624|PROCEDURE|Fecal sample collection|During the study, patients will be ask to collect fecal samples using sample collection kits. A total of 4 stool samples per patient will be collected.
40789301|NCT04528238|OTHER|Relaxing Visual Immersion|During the intravenous treatment for cancer, a nature movie will be projected on the ceiling of the room, along with natural sounds or a relaxing music. The patient will choose the movie or movies he wants to watch and can decide to stop the Relaxing Visual Immersion (RVI) at any time. The RVI is a system that does not isolate the patient from his familiar or medical entourage and which integrates virtual scenarios in the environment of care.
40789302|NCT04458740|OTHER|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
40993195|NCT02879409|DRUG|Gliclazide|"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"
40993196|NCT02879409|DRUG|Sitagliptin|Oral: 100 mg once daily
40993197|NCT02879409|DRUG|Liraglutide|SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
40993198|NCT02879409|DRUG|Pioglitazone|"Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"
40993199|NCT02879409|DRUG|Dapagliflozin|5mg once daily increasing to 10mg once daily as required
40993200|NCT02879409|DRUG|human insulin|insulin dosage and administration according to physician
40993201|NCT01148511|DRUG|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
40993202|NCT06024421|DRUG|favipiravir|Light yellow, film-coated tablet, each containing 200 mg of favipiravir
40789303|NCT05677100|DEVICE|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and are resistant to diuretic therapy.
40993203|NCT06024421|DRUG|Placebo|Light yellow, film-coated tablet
41148037|NCT06527833|PROCEDURE|Non Packing of perianal abscess cavity after drainage|"* All patients will undergo incision and drainage under general anaesthesia.~* In Group (A \[Non-Packing group\]), The surgery will be performed by making a cruciate incision over the abscess and incision widened using forceps to allow complete drainage of the cavity containing, without any catheter drainage and packing avoided. The lesion will be left open to heal by secondary intention. The patient was advised to have a sitz bath and apply a dressing over the cavity."
41467984|NCT04355299|BEHAVIORAL|aerobic exercise|Aerobic exercise is any activity that gets your blood pumping and large muscle groups working. It's also known as cardiovascular activity.
40993206|NCT06362434|DEVICE|Audiovisual stimulation|The MOT IVR audiovisual stimulation task involves the 3D multiple-object-tracking paradigm composed of 6-8 high-contrast spheres which features are adapted to the visual ability of individuals with low-vision (luminosity = 80 nits, size = 1° to 3° visual angle). The spheres move for 20s. following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. The participant, comfortably seated, is asked to track the moving cued target among moving distractors for 20s. A spatial sound is correlated to the movement of the cued target. After 20s., the movement stops and the participant is asked to select, using a laser pointer, the cued sphere among the distractors (mark-all procedure). Speed of the spheres is regulated by a staircase 1:1 procedure. The stimulation can here be stopped by the participant if required. After 3 blocks of 15x20s., the system stops and goes on stand-by mode until the next session. Data are collected in real time.
40993207|NCT02337907|DRUG|Placebo|for blinding purposes
40993208|NCT02337907|DRUG|Placebo|
40993209|NCT02337907|DRUG|BI 409306|
40993210|NCT02337907|DRUG|Donepezil|
40993211|NCT00171223|DRUG|STI571|STI571 oral capsules or tablets.
40993212|NCT04172441|DRUG|dasiglucagon|Glucagon analogue
41467985|NCT04355299|BEHAVIORAL|usual care|received usual care
41467986|NCT05299567|DRUG|Azithromycin|Placebo with the same color and size than azithromycin tree days a wek for 6 months
40789304|NCT03110484|DRUG|Pemetrexed 500 MG|Pemetrexed 500 mg/m2
40789305|NCT03110484|DRUG|Erlotinib|Erlotinib 100mg once daily
40789306|NCT01981798|BEHAVIORAL|Physiotherapy and occupational therapy|Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
40993213|NCT04172441|DRUG|Placebo|Placebo for dasiglucagon
40993214|NCT00876954|PROCEDURE|Normothermia|Warming without increase in core temperature
40993215|NCT00876954|PROCEDURE|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
40993216|NCT01318447|RADIATION|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
40993217|NCT03645655|DIAGNOSTIC_TEST|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II, AFP, and biochemical tests.
40993218|NCT04130451|DRUG|PYODINE AND TALC SLURRY|"pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate"
40993219|NCT00208962|PROCEDURE|chemotherapy and blood stem cell transplantation|A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
40993220|NCT00430560|BEHAVIORAL|cognitive rehabilitation|computer training
40993221|NCT00430560|PROCEDURE|work therapy|opportunity to work in carefully supervised hospital job
40993222|NCT00430560|BEHAVIORAL|work therapy|work therapy
40993223|NCT00914810|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|2000 I.U. daily for 6 weeks
40993224|NCT00914810|DIETARY_SUPPLEMENT|Placebo|Placebo (sugar pill) daily for 6 weeks
40993225|NCT05361317|DEVICE|Nexis® PECA Bunion device|Hallux valgus correction with percutaneous chevron and Akin osteotomy.
40993226|NCT03200899|BEHAVIORAL|MAPSS-MS|MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.
40993227|NCT03200899|OTHER|Usual Care plus computer games|"Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website."
41309123|NCT02511951|PROCEDURE|pancreaticojejunostomy|"To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
41309124|NCT01842308|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
40789307|NCT04527055|DRUG|Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
40993228|NCT01815125|DRUG|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
41309125|NCT01842308|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
40993229|NCT01815125|DRUG|PLacebo|placebo
40993230|NCT04567875|OTHER|No Intervention on patients|No Intervention on patients
41309126|NCT01842308|DRUG|Carfilzomib|Given IV
40789308|NCT04527055|DIETARY_SUPPLEMENT|Lactobacillus acidophilus and Bifidobacterium lactis Bb12|"The probiotic powder per oral twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of \>= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
40789309|NCT04527055|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
40789310|NCT04527055|DRUG|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
40993231|NCT04816695|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
40993232|NCT02994732|DRUG|[14C]-BVD-523|\[14C\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
40993233|NCT02164305|OTHER|Strengthening group|Open-chain exercise for rotator cuff and scapular muscles
40789311|NCT04527055|DRUG|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
40993234|NCT02164305|OTHER|Neuromuscular group|Closed-chain exercise for shoulder muscles
40993235|NCT02164305|OTHER|Control|No exercise training
40993236|NCT04899414|DRUG|Dexamethasone, azacytidine, Pegaspargase, Tislelizumab|Dexamethasone 40mg intravenously daily on day 1-4; azacytidine 100mg intravenously daily on day 1-5; Pegaspargase 3750 IU intravenously daily on day 1； Tislelizumab 200 mg IV on Day 1 of each 21-day as a cycle.
40993237|NCT02517996|DRUG|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
41309127|NCT01842308|OTHER|Laboratory Biomarker Analysis|Correlative studies
41309128|NCT01842308|DRUG|Melphalan|Given IV
41309129|NCT03364608|DRUG|AS MDI 90 μg|AS MDI 90 μg (2 actuations of 45 μg/actuation)
41309130|NCT03364608|DRUG|AS MDI 180 µg|AS MDI 180 μg (2 actuations of 90 μg/actuation)
41309131|NCT03364608|OTHER|Placebo MDI|Placebo MDI (2 actuations)
41309132|NCT03364608|DRUG|Proventil 90 μg|Proventil 90 μg (1 actuation of 90 μg/actuation)
41309133|NCT03364608|DRUG|Proventil 180 μg|Proventil 180 μg (2 actuations of 90 μg/actuation)
41309134|NCT04415567|DRUG|Lenvatinib|The patients in lenvatinib group received oral lenvatinib (Eisai, Japan) 12 mg/day (for bodyweight (BW) ≥60 kg) or 8 mg/day (for BW \<60 kg) in 28-day cycles until HCC recurrence or serious adverse events (SAEs) or voluntary withdrawal. Dose interruptions followed by reductions for lenvatinib-related toxicities (to 8 mg and 4 mg/day, or 4 mg every other day) were permitted. All 14 patients took lenvatinib for more than 3 cycles.
40789312|NCT02590536|DRUG|Sildenafil citrate|"In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet."
40789313|NCT02590536|DRUG|placebo|
40789314|NCT02982655|PROCEDURE|Individualized BP lowering|
40789315|NCT02051478|OTHER|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
40789316|NCT02051478|OTHER|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
40789317|NCT02809885|BIOLOGICAL|Hepatitis E serology|
40789318|NCT05412264|BEHAVIORAL|Website intervention|12 week motivational emails, recording pedometer steps and waist circumference
40789319|NCT02946346|OTHER|vaginal sampling|
40789320|NCT01189786|DEVICE|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
40789321|NCT00125970|BIOLOGICAL|VRC-HIVDNA016-00-VP|4 mg administered in deltoid
40789322|NCT00125970|BIOLOGICAL|VRC-HIVADV014-00-VP|1 x 10\^10 PU administered in deltoid
40789323|NCT00125970|BIOLOGICAL|VRC-HIVDNA016-00-VP placebo|1 mL administered at study entry and Months 1 and 2
41467987|NCT00873106|DEVICE|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
40789324|NCT00125970|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|1 mL administered at Month 6
40789325|NCT05406726|DIETARY_SUPPLEMENT|palmitoylethanolamide|palmitoylethanolamide is an lipid based endocannabinoid naturally made by the body and is present in several common foods such as eggs
40789326|NCT05406726|DIETARY_SUPPLEMENT|Placebo|a capsule filled only with maltodextrin will be used as a placebo
40789327|NCT01896830|BIOLOGICAL|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
40789328|NCT01896830|BIOLOGICAL|0.9% normal saline|0.5 mL, intramuscular
40789329|NCT06487234|DEVICE|Functional band|Participants will wear the functional band for 1-hour electroacupuncture stimulation
40789330|NCT06487234|DEVICE|Placebo band|Participants will wear the nonfunctioning band for 1-hour with no electroacupuncture stimulation
40789331|NCT03511001|OTHER|E-Cigarette Vs. Smoking as Usual|6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual
40789332|NCT02981056|OTHER|Johnson's Baby Top-To-Toe Wash|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
41309135|NCT05795218|DEVICE|Deep Brain Stimulation|implant and DBS therapy with the directSTIM™ DBS system
40789333|NCT02981056|OTHER|Johnson's Baby Lotion|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
40789334|NCT02981056|OTHER|Water (in lieu of bathing products)|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
40789335|NCT00983034|DRUG|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
40789336|NCT02710877|DEVICE|Programmed Intermittent bolus|Programmed epidural bolus of 10 ml mixture every 75 minutes, plus patient controlled bolus of 5 ml same mixture; lock-out 15 minutes.
40789337|NCT02710877|OTHER|Manual epidural bolus|Epidural bolus of 15 ml levobupivacaine and sufentanyl 10 mcg or 5 mcg administered by anesthesist on maternal request.
41309136|NCT04850703|DEVICE|Transcranial Radom Noise Stimulation|tRNS against Dapoxetine in LPE patients
41309137|NCT04850703|DRUG|Take Dapoxetine|Dapoxetine against tRNS in LPE patients
40789338|NCT02710877|DRUG|Levobupivacaine|Levobupivacaine 0,0625% through peridural catheter
40789339|NCT02710877|DRUG|Sufentanil 4 mcg|Sufentanil 0,4 mcg/ml through peridural catheter
40789340|NCT02710877|DRUG|Sufentanil 5 mcg|Sufentanil 5 mcg through peridural catheter
40789341|NCT03134326|DEVICE|R1-25 and R2-25 Pulse Oximeter Sensor|
41467988|NCT01594359|OTHER|Biofortified beans|Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
41467989|NCT01594359|OTHER|BEAN|Placebo
41467990|NCT05042440|DRUG|Efanesoctocog alfa|Solution for injection Intravenous
41467991|NCT05042440|DRUG|Octocog alfa|Solution for injection Intravenous
40789342|NCT02113774|OTHER|antimicrobial treatment according to in-vitro susceptibility|
40789343|NCT01723969|GENETIC|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
40789344|NCT00196677|DRUG|Vitamins, minerals and medical herbs|
40789345|NCT00928187|DRUG|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening
40789346|NCT00928187|DRUG|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)|Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight \< 60 kg, 400 mg if weight \> 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening
40789347|NCT00928187|DRUG|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food
40789348|NCT00878267|BEHAVIORAL|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
40789349|NCT04176107|BEHAVIORAL|Informative video|Exposure to informative video before cesarean delivery
40789350|NCT00225914|DRUG|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
40789351|NCT00225914|DRUG|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
40789352|NCT04123301|DEVICE|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: first, continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
40789353|NCT04123301|DEVICE|Sham Theta Burst Stimulation (TBS)|The sham-TBS sessions will be performed using an identical coil that produces SHAM Stimulation: first, sham continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by sham intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
40789354|NCT06111638|GENETIC|Single dose intravenous injection of BBM-H803|Single dose intravenous infusion of BBM-H803, an adeno-associated viral (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII transgene in liver. The dose of BBM-H803 will be calculated according to participant's weight.
40789355|NCT03901638|DRUG|Tllsh2910|Tllsh2910 80mg twice per day orally for 12 weeks
40789356|NCT03901638|DRUG|Placebo|Placebo
40993238|NCT02517996|DRUG|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
40993239|NCT03905122|DEVICE|bioreactans tool|It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.
40789357|NCT00987285|BEHAVIORAL|CASM +|Computer Assisted Self Management plus Social Support
40789358|NCT00987285|BEHAVIORAL|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
40993240|NCT04990960|OTHER|Physiotherapy|During each session (45 minutes)the patient was assessed and trained in self-treatment exercises assigned to treat their cords. This later method was chosen to ensure regular participation in their exercises and early correction of any inaccuracies in the implementation of the exercises regarding AWS treatment . Or the Physiotherapist worked actively on cords with soft or vigorous stretching.
40789359|NCT06446115|DEVICE|Virtual Reality|Virtual Reality Headset applied to the participants during chemotherapy session. Participants select their preferred virtual reality experience (i.e., nature videos, meditations, interactive applications, etc). Virtual reality (VR) by definition, is a simulated experience consisting of an experiential environment created by hardware and software technology capable of provoking sensations of real experiences. It can be further divided into 1) immersive; 2) semi-immersive; and 3) non-immersive. Immersive VR employs head-mounted display (HMD) system technology to separate users from their surroundings and engage in real-time with a three-dimensional environment generated by a computer.
40993241|NCT04246606|DIAGNOSTIC_TEST|IHC4 score|"The IHC4 score is a prognostic tool that incorporates immunohistochemical parameters of ER (H-score), PR (% of positive cells), HER2 (positive or negative status), and Ki67 (% of positive cells).~IHC4 score, combined with nodal status and tumor grade, age, and the type of endocrine therapy (tamoxifen or aromatase inhibitors) provides a clinical score IHC4+C.~IHC4+C provides a prognostic risk of distant recurrence at 10 years for patients who underwent endocrine therapy for 5 years. IHC4+C defined three distinct risk categories:~* \<10%: low risk~* \[10-20%\]: intermediate risk~* \>20%: high risk"
40789360|NCT06446115|OTHER|Preferred activity|Participants will engage in a preferred activity such as reading, watching television, coloring, etc. during chemotherapy.
41467992|NCT05042440|DRUG|Rurioctocog alfa pegol|Solution for injection Intravenous
40789361|NCT06446115|OTHER|Questionnaires|Participants will be administered multiple pre and post intervention questionnaires including NCCN Distress thermometer, GAD-7 and CCVA.
40789362|NCT05937529|OTHER|Cream containing madecassoside and 5 % panthenol|Immediately after daylight PDT, Cicaplast is administrated as post treatment. The patients are instructed to apply the cream twice daily for 14 days.
40789363|NCT05937529|OTHER|Daylight PDT|Daylight PDT performed with 2 hours of artifical indoor light.
40789364|NCT04749745|DRUG|L-theanine|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.
40789365|NCT04749745|DRUG|Placebo|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.
40789366|NCT04830943|DRUG|Cerebrolysin|Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
40993242|NCT03674918|DIAGNOSTIC_TEST|24 h ambulatory blood pressure measurements|24 h ambulatory blood pressure measurements : an ambulatory 24 h blood pressure device that automatically measures blood pressure every 15 minutes is given to the patient for 24 h
40993243|NCT00030563|DRUG|irinotecan hydrochloride|
40993244|NCT00030563|PROCEDURE|adjuvant therapy|
40993245|NCT00030563|PROCEDURE|conventional surgery|
40993246|NCT00030563|PROCEDURE|radiofrequency ablation|
40993247|NCT01769833|DRUG|PEG-interferon-Alfa-2A|Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
40993248|NCT01769833|DRUG|Nucleosides|
40789367|NCT02025998|DRUG|Ibudilast|Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
40789368|NCT02025998|OTHER|Matched placebo|A matched placebo (suggar pill) will be administered as a control condition.
41148038|NCT06527833|PROCEDURE|Packing of perianal abscess cavity after drainage|an elliptical incision will be made, and the abscess will be fully drained then packing the cavity will be done with sterile gauze with a change of dressing every 24 hours until it is completely healed.
41309138|NCT04850703|COMBINATION_PRODUCT|Comparation EEG changes between Sham Group against tRNS and Dapoxetin participants|Compare EEG parameters like Theta Rhythm and Coherence between three groups of participants: sham, tRNS participants and Dapoxetine participants groups.
40789369|NCT06029062|DEVICE|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
40789370|NCT06029062|DEVICE|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
41309139|NCT04850703|DIAGNOSTIC_TEST|Compare LPE EEG endophenotype between participants and healthy controls|Define as precisely as possible the electrophysiological endophenotype of Longlife Premature Ejaculation, using healthy humans who do not express the LPE EEG endophenotype
41467993|NCT01684059|DIETARY_SUPPLEMENT|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
40789371|NCT06029062|DEVICE|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
40789372|NCT00751712|DEVICE|Cerebral oximeter sensor|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
40789373|NCT06017882|OTHER|Partial sleep deprivation|
40789374|NCT00507585|DRUG|Fluorouracil|300 mg/m\^2 IV over 10 Minutes, then 600 mg/m\^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
40789375|NCT00507585|DRUG|Avastin|10 mg/m\^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
40789376|NCT00507585|DRUG|Leucovorin|200 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
40789377|NCT00507585|DRUG|Oxaliplatin|60 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
40789378|NCT04825262|DRUG|Tacrolimus|Starting dose based on CYP3A5 genotype
40789379|NCT00292526|DRUG|Enalapril|enalapril orally administered
40789380|NCT00002186|DRUG|Crofelemer|
40993249|NCT03506750|DRUG|IVC|Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
40993250|NCT03506750|PROCEDURE|Blood and aqueous humor at the time of IVC|Initial blood and aqueous humor will be harvested at the time of IVC.
41148039|NCT03518450|PROCEDURE|Apex Femoral Triangle Block|Nerve block that aims the vastus medialis nerve, the saphenous nerve and the anterior femoral cutaneous nerve.
40789381|NCT00002186|DRUG|Acyclovir|
41148040|NCT03518450|PROCEDURE|Femoral Nerve Block|Regional anesthetic technique that blocks the sensory and motor information of the femoral nerve (and it's branches).
40789382|NCT04326218|OTHER|Blood sample|"Serum samples will be sent for centralised analyses in Nice.~On these samples, different analysis will be performed :~* anti-PLA2R1 and anti-THSD7A antibodies~* anti-PLA2R1 and anti-THSD7A epitopes~* HLA typing"
40789383|NCT02725905|BEHAVIORAL|Multi-Modal Education (MME)|"The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese."
40789384|NCT02725905|BEHAVIORAL|Traditional Education (TE)|Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
40789385|NCT04524221|DRUG|PTG-100|PTG-100, 600mg taken twice daily in capsule form for 42 days
40789386|NCT04524221|DRUG|Placebo|Placebo taken twice daily in capsule form for 42 days
40789387|NCT00973336|DRUG|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
40789388|NCT00375674|DRUG|Sunitinib malate|sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
40789389|NCT00375674|OTHER|Placebo|Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
40789390|NCT01864083|PROCEDURE|Positron Emission Tomography (PET)|
40789391|NCT01864083|DRUG|Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|
40789392|NCT01864083|PROCEDURE|Positron emission mammography (PEM) When available|
40789393|NCT01864083|PROCEDURE|MR|
40789394|NCT00412191|DRUG|Lamotrigine|In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
40789395|NCT02904369|DRUG|Emtricitabine|
41148041|NCT03518450|PROCEDURE|Adductor Canal Block|Interfascial block that targets mainly the saphenous nerve.
41148042|NCT01658176|DRUG|PF-04691502|PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
41467994|NCT06385288|OTHER|Blood and tissue collection for immunological studies, advanced imaging.|Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.
41467995|NCT06385288|OTHER|neoadjuvant Therapy|neoadjuvant Therapy
40789396|NCT02904369|DRUG|Tenofovir alafenamide|
40789397|NCT02904369|DRUG|Tenofovir disoproxil|
40789398|NCT00895362|DRUG|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
40789399|NCT00895362|DRUG|Cetuximab|Loading dose of 200 mg/m\^2 (maintenance 125 mg/m\^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
40789400|NCT05940311|DEVICE|Affinity Mediated Transport Amplification (AMT)|Rich format single-molecule detection powered by plasmotic nanostructures of the opto-fluidific chip and proteogenomics digital readout integrated into single biotech platform.
40789401|NCT01484496|BIOLOGICAL|Placebo|Placebo
40789402|NCT01484496|BIOLOGICAL|Belimumab 200 mg SC|Belimumab 200 mg SC
40789403|NCT01484496|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
41148043|NCT01658176|DRUG|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
41148044|NCT01658176|DRUG|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
41148045|NCT01452204|OTHER|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
40993251|NCT03506750|PROCEDURE|Collect blood, aqueous humor, and initial vitreous at the time of surgery.|Blood, aqueous humor, and vitreous will be collected at the time of surgery.
40993252|NCT03506750|PROCEDURE|IVC-sham|Patients with PDR will receive sham intravitreal injection of conbercept in the inferior-temporal sector 4 mm from the sclerocorneal limbus 4 days before PPV surgery.
40993253|NCT04339699|DEVICE|NobleStitch™EL Suture Mediated Closure System|Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System
40993254|NCT04339699|DEVICE|Amplatzer PFO Occluder|Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
40993255|NCT01637974|DRUG|INTERCOAT administration|Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
40993256|NCT06541249|DRUG|Methotrexate (MTX)|MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.
40993257|NCT04684381|DRUG|L-glutamine|Pharmacokinetic study
41467996|NCT01230645|DRUG|RV568|RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
41467997|NCT01230645|DRUG|Placebo|Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
41467998|NCT04139031|DEVICE|Ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 6-13 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
40993258|NCT03010111|OTHER|QFT-IT Test and other blood sampling|In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
40993259|NCT00858442|PROCEDURE|With PRP|Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width \& length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width \& length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
41467999|NCT03779568|OTHER|Dose adjustment of bupivacaine|Spinal bupivacaine dose will be adjusted according to previous patient experience.
41468000|NCT06419946|DRUG|Temozolomide|In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
41468001|NCT06419946|DRUG|Lomustine|In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
40993260|NCT05648370|GENETIC|ctDNA testing and whole exome sequencing|Blood samples will be obtained for ctDNA testing and tumor tissue for whole exome sequencing.
40993261|NCT01048021|PROCEDURE|Supraclavicular Block|"Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.~At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position."
40993262|NCT00164190|PROCEDURE|Routine Early Percutaneous Coronary Intervention after Thrombolysis|early or delayed PCI
40993263|NCT05874752|DIAGNOSTIC_TEST|Transthoracic echocardiography|noninvasive myocardial work
40789404|NCT00730756|DRUG|Fluticasone Furoate Nasal Spray|Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
40789405|NCT00730756|OTHER|Placebo Nasal Spray|Matching placebo nasal spray intranasally once daily for 4 weeks
40789406|NCT02126319|BEHAVIORAL|Cognitive Affective preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
40789407|NCT02126319|BEHAVIORAL|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
40789408|NCT02054975|DRUG|Vitamin D2 + vitamin D3|higher dose vitamin D
40789409|NCT02054975|DRUG|Vitamin D3|lower dose vitamin D
40789410|NCT04420858|BEHAVIORAL|Enhanced (experimental) education|See arm description.
40789411|NCT04420858|BEHAVIORAL|Standard (control) education.|See arm description.
40789412|NCT01435174|DRUG|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
40789413|NCT01435174|PROCEDURE|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
40789414|NCT01435174|PROCEDURE|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
40789415|NCT06401499|DRUG|etoricoxib 60mg|investigator will compare effects of etoricoxib alone and in combination with pregabalin on pain relief in chronic low back pain participants
40789416|NCT02890459|OTHER|Prize incentive - Low|Low expected prize value.
40789417|NCT02890459|OTHER|Prize incentive - High|High expected prize value.
40789418|NCT02890459|OTHER|Escalating payment incentive|"The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value."
40993264|NCT05324540|OTHER|Cool therapy|Application of cool therapy. A chilled (between 5C and 10C) instrument will be applied to the oblique sinus while the patient is in atrial fibrillation.
40993265|NCT01175733|DRUG|Panitumumab|During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
40993266|NCT05963087|DRUG|Cetuximab Dabrafenib Tislelizumab|Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks
41148046|NCT04916847|OTHER|blood collection|"Depending on the weight of the child, between 5ml and 15ml of blood will be collected during a blood test necessary for the conventional care of the patient. A second blood sample will be taken one year later. The volume of blood taken does not exceed the volume allowed by the guideline Ethical considerations for clinical trials of medicinal products conducted in the paediatric population.~We will analyse:~1. Specific antibody responses (IgM, IgG, and immunoglobulin A (IgA) anti SARS-Cov-2) by quantitative chemiluminescence analysis.~2. Protective neutralizing capacity of these antibodies (neutralizing antibodies against SARS-cOV-2) by neutralization test.~3. SARS-Cov-2 specific memory T cell responses by multiparametric flow cytometry in order to characterize their maturation, differentiation, senescence, activation, secretion of interleukin (cytokines 2) , IFN-g, TNF) or Interferon-gamma (IFN-g) ELISPOT assay."
41148047|NCT00825643|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
41148048|NCT04824456|PROCEDURE|bilateral sagittal split osteotomy using separators.|The final split is completed with a thin osteotomes, splitting the entire ascending ramus from the anterior to the posterior border of the ramus.
40993267|NCT00798538|OTHER|Services will be provided at one site|Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
40993268|NCT00798538|OTHER|Services remain dispersed; i.e., not centralized to one-location or provider.|Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
40993269|NCT00874523|DRUG|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
40993270|NCT00874523|DRUG|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
40789419|NCT02890459|OTHER|Travel Voucher|Travel voucher to assist with linkage to care.
40993271|NCT03815097|PROCEDURE|Mapleson circuit and nasal trumpet|The Mapleson Circuit is a breathing system used to deliver oxygen and remove carbon dioxide during anesthesia. It consists of fresh oxygen flow, a reservoir bag, an expiratory valve, tubing, and a connection to the patient. There are different types of Mapleson circuits depending on the different arrangements of its components. We plan to use a Mapleson D circuit attached to a nasal trumpet via a connector.
40993272|NCT01227941|DRUG|MK-4827 + pegylated liposomal doxorubicin|Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
41309140|NCT03533140|DEVICE|DUCEST Neurostimulator V Group A|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively to stimulate the R.auricularis of the vagus nerve located at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates the device. (The stimulation intensity can be adjusted from 0,05mA to 1,2mA, default value is 0,4mA). The starting stimulation intensity will be adjusted to 1mA and takes place at 1Hz continuously for 40 minutes, followed by a 20 minute break. The built-in 3V battery lasts for approx. 14 days. After 7 days the electrodes are replaced and applied to the other ear of the patient. A plaster with a plastic mounting clip is attached on the shoulder of the patient. The Neurostimulator is connected to the mounting clip. After 14 days or at hospital discharge of the patient, the device is unmounted and the needle-electrodes are removed.
41309141|NCT03533140|DEVICE|DUCEST Neurostimulator V Group B|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates only the signal lamp but not the device.
41309142|NCT00632190|OTHER|fluorophotometry|
41309143|NCT00632190|PROCEDURE|colposcopic biopsy|
41309144|NCT00632190|PROCEDURE|colposcopy|
40993273|NCT01227941|DRUG|MK-4827 + pegylated liposomal doxorubicin|MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of the cycle.
40993274|NCT04300855|DRUG|Sunphenon|The study agent will be administered in divided doses with food, three capsules twice a day (405 mg) for 24 months
40993275|NCT04300855|DRUG|Placebo|Matching placebo
40993276|NCT04536155|OTHER|questionnary SF36|"This is a validate questionnary:~Ware et al,1992, McHorney et al, 1993, McHorney et al, 1994 French version : Author : Alain Leplège; et coll. En 2001"
40993277|NCT04536155|OTHER|Hospital Anxiety and Depression Scale|this is a validate scale: author: Zigmond A.S., Snaith R.P. in 1983
41148049|NCT05690178|OTHER|Deep Tissue Massage|The Deep Tissue Massage lasted 45 minutes. The entire therapy included 4 treatments over a period of 2 weeks. The interval between treatments was 3 days. The conducted therapy included techniques for: quadratus lumborum muscle, erector spinae muscle, thoracolumbar fascia, iliopsoas muscle. All techniques were performed on both sides of the patient's body.
41148050|NCT03214471|BEHAVIORAL|Lifestyle intervention|Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
40993278|NCT04536155|OTHER|Chronic Pain Acceptance Questionnaire|"This is a validate questionnaire:~Fish, R., McGuire, B.E., Hogan, M., Stewart, I. \& Morrison, T. (2010)."
40789420|NCT02890459|OTHER|Standard care|Includes HIV viral load and treatment adherence counseling.
40993279|NCT04536155|OTHER|digital pain scale|this is a validate scale A.N.A.E.S. February 1999
40993280|NCT02653456|DEVICE|RA-308 Excimer Laser and DABRA Catheter|See information already included in arm description
40993281|NCT00862446|DRUG|Omegaven|1 gram/kg/day daily until on feeds
40993282|NCT04558931|DRUG|CellProtect|In vitro expanded and activated autologous NK cells
40993283|NCT04558931|DRUG|Isatuximab|Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
40993284|NCT03305328|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
40993285|NCT06020560|DRUG|Dalteparin Prefilled Syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
41148051|NCT02453971|OTHER|German Version of eCHECKUP TO GO|It is an online prevention program targeting alcohol consumption.
41148052|NCT01039506|DRUG|CPT-11 based regimens|
41148053|NCT05203822|DRUG|Tepotinib (HydroChloride hydrate)|Participants received Tepotinib (Hydrochloride hydrate) Film-coated tablet with food on Day 1 and 12 in the morning.
40993286|NCT06020560|DRUG|Tinzaparin profiled syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
40993287|NCT04684147|BIOLOGICAL|single dose of CNCT19|Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
40993288|NCT00862186|BEHAVIORAL|'Fatigue Facts & Fixes'|"'Fatigue Facts \& Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource."
40993289|NCT05384067|BEHAVIORAL|Mindfulness-based intervention|Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.
40993290|NCT03251820|DRUG|corticosteroid|Each patient will be subjected to a one month course of steroids and then re-evaluated
40993291|NCT01877629|DRUG|ACT-129968 500 mg tablet|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
40993292|NCT01877629|DRUG|ACT-129968 250 mg capsule|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
40993293|NCT05817019|DRUG|Sugammadex Sodium|Sugammadex Sodium 2mg/kg when TOF \>= 2, postoperative period
40993294|NCT05817019|DRUG|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg when TOF \>= 2, postoperative period
40993295|NCT01430481|DIETARY_SUPPLEMENT|Rosehip powder|The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
40993296|NCT04588649|DRUG|THK-5351|\[18F\]THK-5351 PET Imaging
40993297|NCT04588649|DRUG|AV-45|\[18F\]AV-45 PET Imaging
40993298|NCT01653496|PROCEDURE|Enhanced recovery after surgery|The main 18 elements of ERAS program included are described in detail in the brief summary of the study
40993299|NCT04865354|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
40993300|NCT04865354|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
40993301|NCT04905212|DRUG|Telitacicept 160mg|Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.
40993302|NCT04905212|DRUG|Telitacicept 240mg|Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.
40993303|NCT04905212|DRUG|Placebo|Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
40993304|NCT06008509|PROCEDURE|Gastric echography preoperative|Patients with acute abdomen that are going to surgery, are going to recieve a gastric echography in the surgery room before the start of anesthesia. This procedure include vision of the stomach during supine position and lateral position with curve transductor.
40993305|NCT00644293|DRUG|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
40993306|NCT00644293|DRUG|placebo|placebo
40993307|NCT00644293|DRUG|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
40993308|NCT00644293|DRUG|placebo|placebo
40993309|NCT05572112|DEVICE|Venous access port implantation|Venous access port implantation
40993310|NCT01375387|DRUG|Lacosamide|100 mg oral tablet, single dose
40993311|NCT01375387|DRUG|Lacosamide|Lacosamide 2 X 100 mg tablet
40993312|NCT01375387|DRUG|Lacosamide|Lacosamide 4 X 100mg tablet
40993313|NCT01375387|OTHER|Placebo 3|Placebo - 3 tablets
40993314|NCT01375387|OTHER|Placebo 4|Placebo - 4 tablets
40993315|NCT01375387|OTHER|Placebo 2|Placebo - 2 tablets
40993316|NCT05934877|BEHAVIORAL|PrEP navigation + text messaging|Using a client-centered approach, the PrEP navigator works to link participants into SUD treatment and other ancillary behavioral health and support services, according to their unique barriers, with the ultimate goal of PrEP initiation, adherence, and persistence; services may include mental healthcare, counseling for intimate partner violence, food insecurity, housing instability, hormone therapy. Text-messaging support includes once weekly text message.
40993317|NCT05934877|BEHAVIORAL|Standard of Care|The SOC arm provides PrEP education, information, and referrals. Those randomized to the SOC arm receive an approximate 20-30-minute educational session on PrEP, and will be given a PrEP pamphlet and list of clinics that provide PrEP in LAC.
41148054|NCT05203822|DRUG|Itraconazole|Participants received Itraconazole Hard-gelatin capsule with food once daily at the same time in the morning from Day 8 to Day 18; on Day 12 itraconazole is administered concomitantly with tepotinib.
41148055|NCT03937089|OTHER|Data collection|Data collection from medical file
41148056|NCT06310278|DIAGNOSTIC_TEST|Ossicular mobility measurement|Measurements of ossicular mobility i.e. the dynamic velocity of middle ear structures (umbo of malleus and incus at the incudostapedial joint) normalized to sound pressure incident on the tympanic membrane.
41148057|NCT05163678|OTHER|monitoring naturalistic of cohort|"Assessment at the start of care in the Relais (T0), at the end (T1) and 6 months later (T6)."
41148058|NCT03338491|BEHAVIORAL|Induction of Implemental Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
40789421|NCT02890459|BEHAVIORAL|Fixed Incentive - Prize|Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
40789422|NCT02890459|BEHAVIORAL|Loss Aversion - Prize|The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
40993318|NCT05934877|BEHAVIORAL|Contingency Management|Non-responders in the ASK-PrEP arm will be stepped and re-randomized (1:1) to Contingency Management (CM), either in concert with ASK-PrEP or alone. CM is a progressive contingency schedule. Participants submit a thrice weekly urine sample. Participants will receive a voucher-based escalating reinforcement schedule. Successive urine samples that are nonreactive for the metabolites of their identified SUD will escalate their voucher point value. Each three consecutive nonreactive urine samples will receive bonus voucher points. A reactive urine sample will place the participant at the initial voucher point value; however, a rapid reset procedure allows participants to return to their place in the escalating schedule following three consecutive nonreactive urine samples. Voucher points can be redeemed at any time during the study for goods or services that promote a pro-social and healthy lifestyle.
40993319|NCT03839511|PROCEDURE|Hyperinsulinemic-hypoglycemic clamp|Subjects will arrive at the inpatient unit in the morning after at least a 10 hour overnight fast. Upon arrival to PBRC, participants will be admitted to the inpatient unit. Following measurement of weight, vitals, and pregnancy test (women only), the 4-hour hypoglycemic clamp procedure (30 minute baseline, 120 minute insulin infusion, and 90 minute recovery) will be performed. Upon completion of the clamp procedure, participants will be provided lunch (Standard American Diet). Following lunch, the CGM sensor will be removed and pending a stable blood glucose level in the normal range, the participant will be discharged from the inpatient unit. This completes the study.
40993320|NCT00893087|DEVICE|Triggering mode of the ventilator|10 min of each triggering mode
40993321|NCT00893087|DEVICE|Triggering method of the ventilator|Flow triggering
40993322|NCT00893087|DEVICE|Triggering method of the ventilator|Pressure triggering
40993323|NCT00893087|DEVICE|Triggering method of the ventilator|NAVA triggering
40993324|NCT06203925|DIAGNOSTIC_TEST|Hepatitis C virus self-test (oral fluid HCVST)|"The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study.~At Ancyllary study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits."
40993325|NCT06203925|DIAGNOSTIC_TEST|Hepatitis C virus self-test (blood-based HCVST)|The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study. At Ancylary Study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.
40993326|NCT05162209|DIETARY_SUPPLEMENT|Synbiotic|Oral sachet, for 12 weeks
40993327|NCT02758392|DRUG|JNJ-61178104 Intravenous|Participants will receive JNJ-61178104 Intravenously on Day 1.
40993328|NCT02758392|DRUG|JNJ-61178104 Subcutaneous|Participants will receive JNJ-61178104 Subcutaneously on Day 1.
40993329|NCT02758392|DRUG|Placebo|Participants will receive placebo on Day 1.
40993330|NCT05861037|OTHER|Video-Assisted Thoracoscopy with blebectomy and pleural abrasion|Thoracoscopic management of pneumothorax
40993331|NCT05039710|DRUG|JNJ-75220795|JNJ-75220795 will be administered as SC injection.
40993332|NCT05039710|OTHER|Placebo|Matching placebo will be administered as SC injection.
40993333|NCT04595513|DRUG|TAVT-18 (sirolimus)|The investigational drug product to be used in this study is TAVT-18, a proprietary formulation of sirolimus in clinical development, by Tavanta Therapeutics, Inc. It is provided in a powder formulation in pre-measured vials.
40993334|NCT05749042|DRUG|Sintilimab|Concurrent Chemoradiotherapy Based of Cisplatin Plus Sintilimab.
40993335|NCT05749042|RADIATION|Radiotherapy|Concurrent Chemoradiotherapy Based of Cisplatin
40993336|NCT03463746|DEVICE|LYRA® gait trainer|The EG will get standard individual physical therapy (5x/week, 45min) whereby three sessions of electromechanical-assisted gait training on LYRA® gait trainer.
40993337|NCT03463746|DEVICE|Standard individual physical therapy|The CG will get standard individual physical therapy (5x/week, 45min) without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
41309145|NCT00632190|PROCEDURE|light-scattering spectroscopy|
41309146|NCT04105205|DRUG|Apramycin injection|30-min infusion
41309147|NCT04105205|DRUG|Placebo injection|30-min infusion
41148059|NCT03338491|BEHAVIORAL|Induction of Deliberative Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list a number of positive and negative, short- and long-term consequences of both deciding to act and deciding not to act; indicating the probability of the occurrence of each of these consequences is required."
41148060|NCT05478564|OTHER|Intraoperative fluids and vasoactive drugs management protocol|Limitation of hypotensive events during open surgery for abdominal aorta repair
41148061|NCT03385109|DEVICE|Surgery|Patients are approached surgically with the Senhance Surgical System
40993338|NCT06134479|DRUG|150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5|On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
40993339|NCT06134479|DRUG|150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger|On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
41148062|NCT04288661|PROCEDURE|No drain placement|The need of perianastomotic drain placement after Roux-en-Y reconstruction in total gastrectomy operations is investigated. As intervention, no drain placement is considered
40993340|NCT05148481|DRUG|BIIB104|Administered as specified in the treatment arm
40993341|NCT05148481|DRUG|Placebo|Administered as specified in the treatment arm
40789423|NCT02890459|BEHAVIORAL|Lottery - Prize|"Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability."
40789424|NCT02890459|BEHAVIORAL|Fixed Incentive - Voucher|A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
40789425|NCT02890459|BEHAVIORAL|Loss Aversion - Deposit|A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
40789426|NCT02990975|DRUG|ketamine|
40993342|NCT04821206|DRUG|DMARDs|New Initiation of a DMARDs
40993343|NCT04821206|DRUG|biologic DMARDs|New Initiation of a biologic DMARDs
40993344|NCT04821206|DRUG|JAK Inhibitor|New Initiation of a JAK Inhibitor
40993345|NCT02331147|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment
40789427|NCT00693927|PROCEDURE|Unmanipulated PBSC after nonmyeloablative conditioning|"Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).~Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor"
40789428|NCT00693927|PROCEDURE|CD8-depleted PBSC after nonmyeloablative conditioning|
40789429|NCT04828707|DEVICE|Nerivio active device|Nerivio neurostimulator of conditional pain modulation (CPM)
40789430|NCT04828707|DEVICE|Nerivio sham device|Nerivio neurostimulator with an electrical output not intended for neurostimulation
40993346|NCT02331147|OTHER|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
40993347|NCT00087451|DRUG|AP23573|ridaforolimus
40993348|NCT01524861|DRUG|Placebo|a placebo tablet bis in die for 12 months
40993349|NCT01524861|DRUG|alpha-lipoic acid|alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
41148063|NCT06367426|DRUG|DDN-A-0101 (SAD)|"Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture"
40993350|NCT01524861|DRUG|L-acetyl carnitine|L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
40993351|NCT01340092|OTHER|Family Navigator|"Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:~1. Help family identify key issues they need to address to get their child autism-specific services~2. Help family address barriers to obtaining these services and strategize approaches to overcome them."
41309148|NCT03920982|DIAGNOSTIC_TEST|Determination of the blood concentration of indoxyl sulfate (IS)|IS concentration will be determined in blood of patients with septic shock and acute kidney injury. IS blood concentration will be done every day during 7 first days after patient will be admitted in intensive care unit. Relation between IS peak serum concentration and mortality at day 28 will be determined.
41468002|NCT02806687|DRUG|Gene Therapy product CYL-02|"Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine.~Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression)."
41468003|NCT02806687|DRUG|Gemcitabine|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
41468004|NCT02421016|DEVICE|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
41468005|NCT02421016|DEVICE|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
41468006|NCT03055741|DRUG|Donepezil|5mg or 10mg, once a day, 24 weeks
41309149|NCT02140359|BEHAVIORAL|Motivational Network Interview|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
40993352|NCT03391596|BEHAVIORAL|Internet-based ACT intervention|The Internet-based ACT intervention is a 12-week program based on the processes of Acceptance and Commitment Therapy.
40993353|NCT03391596|BEHAVIORAL|Standardized rehabilitation|Standardized institutional rehabilitation in a rehabilitation center
40993354|NCT03391596|BEHAVIORAL|Support by voluntary caregiver associations|Support given by voluntary caregiver associations
40993355|NCT06352450|DIAGNOSTIC_TEST|Active isolated stretching (AIS)|Active isolated stretching (AIS) is a technique that involves stretching specific muscles or muscle groups while actively engaging the opposing muscles. It typically involves holding a stretch for 1-2 seconds and then releasing. This method aims to improve flexibility, increase range of motion, and enhance muscle function.
41468007|NCT03055741|DRUG|DHP1401|Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
41468008|NCT03055741|DRUG|Placebo|Placebo was administrated in two divided dosed a day for 24 weeks
41468009|NCT02609516|OTHER|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
40789431|NCT01043744|DRUG|Artemether-Lumefantrine|"Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~* 1 tablet (for patients weighing 5-14 kg)~* 2 tablets (for patients weighing 15-24 kg)"
40789432|NCT00337038|DRUG|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
40789433|NCT05859139|OTHER|DA Scaling Strategies|For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.
40993356|NCT06352450|DIAGNOSTIC_TEST|Myofascial release (MFR)|Myofascial release (MFR) is a technique used to release tension and tightness in the fascia, which is the connective tissue that surrounds and supports muscles and organs. It involves applying gentle, sustained pressure to specific areas of the body to help relax the fascia and alleviate restrictions. MFR aims to improve mobility, reduce pain, and enhance overall movement and function.
40993357|NCT04588987|BIOLOGICAL|PD-1|Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG
40993358|NCT05948202|BEHAVIORAL|Pivotal Response Treatment|Group-based parent training to teach parents behavioral strategies based on principles of learning to motivate their child.
40993359|NCT04139967|RADIATION|Short course radiation therapy|25 Gray in 5 fractions over 5-7 days
41468010|NCT01454440|DRUG|Eptifibatide|Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
40993360|NCT06326294|DEVICE|Thermal ablation|Thermal ablative uses heat (100°C to 120°C) to cause localized tissue damage at the cervical transformation zone and destroy the abnormal epithelium.
40993361|NCT06326294|PROCEDURE|LOOP ELECTROSURGICAL EXCISION PROCEDURE|Cervical tissue excision
40993362|NCT02444260|DRUG|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
40993363|NCT02444260|DRUG|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
40993364|NCT02444260|DRUG|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
40993365|NCT02444260|DRUG|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
40993366|NCT00982488|DRUG|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
40993367|NCT00982488|DRUG|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
40993368|NCT05046041|DRUG|Mifepristone + Misoprostol|A single 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally (buccal) every three hours until the abortion is achieved.
40993369|NCT06325956|DRUG|Metformin|Take metformin for six months.
40993370|NCT01522365|DEVICE|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
40993371|NCT01522365|DEVICE|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
40993372|NCT00445965|GENETIC|DNA analysis|
40993373|NCT00445965|OTHER|immunologic technique|
40993374|NCT00445965|OTHER|pharmacological study|
40993375|NCT00445965|RADIATION|iodine I 131 monoclonal antibody 3F8|
40789434|NCT05854836|BEHAVIORAL|CHOICES-PLEAS (Pregnancy Liberated from Exposure to Alcohol and Substances)|CHOICES-PLEAS includes four manual-guided motivational interviewing sessions delivered by a trained counselor and one family planning counseling session delivered by a family planning clinician. The intervention is based on the Transtheoretical Model (TTM) of behavior change and motivational interviewing that includes a decisional balance exercise, goal self-selection, self-monitoring, self-generated plans, and importance and confidence scales. By using a patient-centered approach based on the TTM that meets patients where they are, counselors can have a more effective impact on patient behaviors. This adaptation from the original CHOICES intervention contains unique features focused on the incarcerated setting, illicit polysubstance use, and risky sexual behaviors most common among women with illicit polysubstance use.
40789435|NCT03908203|PROCEDURE|Minimally invasive one-level lumbar deformity correction|The study treatment represents modified technique of MIS TLIF: one level screws fixation using Wiltse approach at one side, the other side - percutaneously, one level decompression, correction of segmental deformity by performing vertebrotomy and then intervertebral fusion.
40789436|NCT02343848|DEVICE|smart bracelet.|Physical activity will be evaluated using smart bracelet.
41309150|NCT02146079|DRUG|semaglutide|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
40993376|NCT00445965|RADIATION|131I-3F8|Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.
40993377|NCT04518254|BIOLOGICAL|Blood collection|A blood sample will be collected before and after treatment administration
40993378|NCT04518254|DRUG|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route
41148064|NCT06367426|DRUG|DDN-A-0101 (MAD)|"Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture"
40789437|NCT04642521|DEVICE|Jamar hydraulic hand dynamometer|"The strength of the dominant hand will be recorded before and after receiving intravenous iron.~Each participant will be positioned in a straight back chair with both hand and feet flat on the ground, elbow flexed to 90 degrees with forearm and wrist in the neutral position. Patient's muscle strength will then be tested three times with an interval of one minute between testing and the average of three times will be recorded to the nearest 0.1kg."
40789438|NCT02909088|DRUG|Ecopipam 50mg|
40789439|NCT02909088|DRUG|Ecopipam 100mg|
40789440|NCT02994745|DRUG|Fimasartan, Atorvastatin|
40789441|NCT06488690|OTHER|All patients who were pregnant and underwent cesarean section|Our study aims to evaluate the use of early warning scores as a screening tool to predict obstetric mortality and morbidity in pregnant women who will undergo cesarean section.
41148065|NCT06367426|DRUG|Placebo (SAD)|"Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture"
41309151|NCT02146079|DRUG|placebo|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
41309152|NCT03972358|DRUG|Mifepristone|All participants will receive 200 mg mifepristone, to be taken orally on day 1.
41309153|NCT03972358|DRUG|Misoprostol|All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)
41309154|NCT03262597|OTHER|enterade|Subjects will consume enterade, which is an amino acid-based oral rehydration solution.
41309155|NCT03262597|OTHER|Pedialyte|Subjects will consume Pedialyte
40789442|NCT01424358|OTHER|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
40789443|NCT05141838|DRUG|Vitamin D|Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state
40789444|NCT05141838|DIETARY_SUPPLEMENT|Oral nutritional supplement|Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition
40789445|NCT00825695|DIETARY_SUPPLEMENT|cocoa|two servings of cocoa daily for one month
40789446|NCT02336061|BEHAVIORAL|Evaluation of gender differences on the psychosocial and economic impact.|
40789447|NCT03619434|PROCEDURE|Femtosecond Laser|The laser will be used to make incisions in the cornea for the graft.
40789448|NCT03619434|PROCEDURE|Trephine blade|A trephine blade will be used to make incisions in the cornea for the graft
40789449|NCT06507579|DEVICE|Hydra transcatheter aortic valve (THV) series|The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
40789450|NCT00323531|PROCEDURE|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
40789451|NCT00323531|PROCEDURE|VATS decortication|thoracoscopic decortication
40993379|NCT04518254|DRUG|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route
40993380|NCT04518254|BEHAVIORAL|Cognitive tasks|The participants will perform cognitive decision-making tasks: Simon task and masking task after treatment administration
40993381|NCT04518254|OTHER|Stress exposure|Unpleasant but not painful skin stimulations will be administered to the participants at variable intervals on the left leg during the cognitive tasks
40993382|NCT04518254|BEHAVIORAL|Anxiety scale|Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks
40993383|NCT04518254|DEVICE|Electromyography (EMG)|Electromyography measurements will be performed during cognitive tasks.
40993384|NCT04518254|DEVICE|Electroencephalography (EEG)|Electroencephalography measurements will be performed during cognitive tasks.
40789458|NCT05799391|DRUG|SJC|Soothing cream jel
40789459|NCT05799391|OTHER|Placebo|Placebo cream jel
40789460|NCT03584126|DIAGNOSTIC_TEST|Electrocardiography, ecocardiography and MRI.|AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.
40789461|NCT00330369|DRUG|Darusentan|Darusentan administered orally once daily
40789462|NCT00330369|DRUG|Darusentan Placebo|Placebo to match darusentan administered orally once daily
41309156|NCT03262597|OTHER|Gatorade|Subjects will consume Gatorade
41309157|NCT03262597|OTHER|Water|Subjects will consume water as the control beverage
40993385|NCT06314074|OTHER|Oscillometric blood pressure monitoring at 2.5-minute intervals|Oscillometric blood pressure will be measured at 2.5-minute intervals during surgery.
40789463|NCT03128983|DEVICE|Participants wear a sensor bracelet for collecting physiological data and conducted urine tests to estimate the day of ovulation|
40789464|NCT00243139|DEVICE|Mandibular advancement device (activator)|
40789465|NCT01220102|DRUG|0.1% adapalene/ 2.5% benzoyl peroxide|topical application, once per day
40789466|NCT05238350|PROCEDURE|Acupressure|Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
40789467|NCT02409433|DRUG|lacosamide|"Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours."
40789468|NCT02409433|DRUG|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
40789469|NCT05573139|DIAGNOSTIC_TEST|Assessment of muscle strength by manual dynamometry|The reliability and validation of a new manual dynamometer was verified, compared to one already used, in the muscle groups: knee extensors and flexors; hip extensors, flexors, abductors, adductors, internal and external rotators.
41309158|NCT01899404|BIOLOGICAL|18-FDG PET/CT, DWI, DCE-MRI|All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
40789470|NCT00418093|DRUG|Gemcitabine|Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
40789471|NCT00418093|DRUG|Oxaliplatin|Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
40789472|NCT00418093|DRUG|Bevacizumab|Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
40789473|NCT03102983|OTHER|MRI functional|vowels records and MRI session
40789474|NCT03370211|OTHER|resistance training|Participants from TG performed program, executed in 3 sets of 10-15RM, 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was composed of 8 exercises comprising one exercise with free weights and seven with machines performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. All participants were personally supervised by physical education professionals with substantial RT experience to help ensure consistent and safe exercise performance. Participants were instructed to inhale during the eccentric phase and exhale during the concentric phase while maintaining a constant velocity of movement at a ratio of approximately 1:2 seconds (concentric and eccentric phases, respectively). Participants were afforded 1 to 2 min of rest between sets and 2 to 3 min between each exercise. The average duration of each session lasted approximately 50-60 minutes.
40789475|NCT02753478|OTHER|intracoronary infusion with saline on 22 and 4°C|"Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.~Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed."
40789476|NCT01615744|PROCEDURE|Open Reduction Internal Fixation|Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
41309159|NCT00058734|BIOLOGICAL|Dendritic Cells Pulsed with HIV antigens|
41309160|NCT03994263|DEVICE|ITind device implant|device implanted for 5-7 days
40789477|NCT01615744|PROCEDURE|Non-surgical management|Early active exercises and elevation to decrease swelling
40789478|NCT03961555|BIOLOGICAL|SYN023|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
40789479|NCT03961555|BIOLOGICAL|HRIG (HyperRab)|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
40789480|NCT03961555|BIOLOGICAL|Rabies vaccine|it should be administered in deltoid muscle
40789481|NCT05757167|DIAGNOSTIC_TEST|Malaria High-Sensitivity Rapid Diagnostic Test (HS-RDT)|"Detection of Plasmodium falciparum HRP-II antigen1~Method: Lateral Flow; Time to Result: 20 minutes; Sample Type: Fingerstick Whole Blood; Sample Volume: 5µl; Storage Conditions: 1-30°C; Shelf Life: 12 months; Sensitivity/Specificity: 99.0%/98.6%"
40789482|NCT05757167|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|oral tablets: 6 doses of 80/480 mg over 3 days
40789483|NCT02154516|DEVICE|ODH Hip System|
40789484|NCT01152125|OTHER|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
40789485|NCT00210847|DRUG|tramadol, acetaminophen|
40789486|NCT01474967|DRUG|Metformin|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
40789487|NCT01474967|DRUG|Metformin|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
40789488|NCT01938261|DRUG|paracetamol|
40789489|NCT01938261|DRUG|0.45 % saline solution|Placebo
40789490|NCT06046066|DRUG|NM6603|NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.
40789491|NCT04944615|PROCEDURE|The guidewire successfully passed the CTO lesion|"The successful passage of the guide wire through the CTO lesion was defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography.~Aspirin load dose (300 mg), clopidogrel load dose (300 mg), or ticagrelor load dose (180 mg) is recommended for all subjects prior to stent implantation and is recommended to be taken at least 6 hours prior to surgery."
40993386|NCT06314074|OTHER|Oscillometric blood pressure monitoring at 5-minute intervals|Oscillometric blood pressure will be measured at 5-minute intervals during surgery.
41309161|NCT01590680|RADIATION|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
40993387|NCT03525015|OTHER|A decision aid booklet about cataract surgery choice|Potential participants receive a decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
40993388|NCT03525015|OTHER|An usual booklet about cataract and cataract surgery|Potential participants receive an usual booklet with information about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
40993389|NCT01984775|DRUG|GSK2894512 cream|GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).
41468011|NCT04360408|OTHER|Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis|The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.
40993390|NCT01984775|DRUG|Vehicle cream|Vehicle cream does not contain any active pharmaceutical ingredient.
41309162|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 100 mg, Once daily, 14 days.
41309163|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 25 mg, Once daily, 14 days.
41309164|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 5 mg, Once daily, 14 days.
40789492|NCT02647476|DIETARY_SUPPLEMENT|Immunomodulating nutrition (Reconvan)|protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
41309165|NCT00162305|DRUG|Placebo|Capsules, Oral, 0 mg, Once daily, 14 days.
40789493|NCT02647476|DIETARY_SUPPLEMENT|Standard nutrition (Peptisorb)|oligopeptide, low-fat, isocaloric, non-residue diet
40789494|NCT01840488|DRUG|Irosustat (BN83495)|"Three parts (A, B \& C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression."
40789495|NCT01650948|DEVICE|RetnaGene AMD LDT|
40789496|NCT04666974|BEHAVIORAL|iCBT|Online CBT modules will be completed weekly with content mirroring in-person CBT for their diagnosis. Homework will be submitted weekly through the OPTT platform which will be reviewed by a trained professional who will provide personalized feedback.
40789497|NCT04666974|BEHAVIORAL|In-Person CBT|Participants will be assigned to in-person CBT that will mirror the content and homework covered in the iCBT group. It will be delivered by professionals and attended weekly.
40993391|NCT01984775|DRUG|Positive control|Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).
40993392|NCT01984775|DRUG|Negative control|Negative control contains petrolatum.
40993393|NCT03430596|DRUG|Pramipexole|The dose of pramipexole range from 0.375mg/d to 0.75mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
40993394|NCT03430596|DRUG|Trihexyphenidyl hydrochloride|he dose of Antan range from 2 mg/d to 4 mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
41309166|NCT06391073|BEHAVIORAL|Self-Measured Blood Pressure Monitoring|Prompted SMBP with tailored feedback
41468012|NCT06340230|DRUG|SHR-A1811 Injection + Adebrelimab Injection|Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
40789498|NCT01058252|COMBINATION_PRODUCT|INVOCell, Letrozole 2.5 mg, recFSH 75 IU|"OVARIAN STIMULATION:~In previous cycles, cycle length and ovulatory status must be assessed and documented.~STEP 1: ANOVULATION by ORAL CONTRACEPTION~* Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.~* Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst \> 10 mm).~* Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.~STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).~* On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.~* Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder."
40789499|NCT01058252|PROCEDURE|STEP-3: LH Suppression & Monitoring|"Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.~• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.~The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)~No need of LH testing, or E2 testsing during the stimulated cycle."
40789500|NCT01058252|PROCEDURE|STEP-4: HCG Timing|"IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:~* E2 level is over 150 pg/ml/per mature follicle (\> 15 mm)~* Domminent follicle is greater than 18 mm in mean diameter~* LH Remains as Baseline, OR~* The day when Urinary LH Surge is positive"
40789501|NCT01058252|PROCEDURE|STEP-5: OPU, ET, Cancellation|"Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.~Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.~Maximum of 2 embryos are transferred, using ultrasound guided transfer.~Cancellation Criteria:~* Poor patient compliance~* Premature Ovulation~* Premature LH Surge~* Endometrium \< 7 mm~* Poor Follicular Development~* E2 Level \> 2,500 pg/ml"
40789502|NCT01058252|PROCEDURE|INVOCell (Intravaginal Culturing)|Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 100000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
40789503|NCT00483054|DRUG|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
40789504|NCT00483054|DRUG|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
40789505|NCT01563900|DEVICE|Auto-titration CPAP|An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
40789506|NCT01563900|DEVICE|Sham-CPAP|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
40823070|NCT03200639|OTHER|Combined training|The CT and CTc protocol (total length time \~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.
40993395|NCT04244188|OTHER|Collection of datas|Collection of datas: pre- and postoperative scanner and endoprosthesis characteristics
41148066|NCT06367426|DRUG|Placebo (MAD)|"Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture"
41309167|NCT06391073|BEHAVIORAL|Physician appointment and transportation scheduling|Physician appointment and transportation scheduling or none dependent on current BP control
40993396|NCT05693285|OTHER|No intervention|No intervention
40993397|NCT04928677|DRUG|Codrituzumab|For Phase A (Dose Escalation), the starting dose (dose level 1) will be 10 mg/kg with 1 planned dose escalation to 20 mg/kg (dose level 2) if dose level 1 is determined to be safe and tolerable. Once a RP2D/MTD is identified in Phase A, then Phase B (hepatoblastoma expansion cohort) will open and allow for enrollment of up to 10 additional patients.For both phases, patients will receive codrituzumab IV once per week for a period of 21 days per cycle. Patients will be eligible for up to 25 cycles.
40993398|NCT02320500|BEHAVIORAL|Standard Physiotherapy|standard of care physiotherapy once every 2 weeks for 8 weeks
41148067|NCT02400372|DEVICE|medihoney dressing|to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
41148068|NCT05908136|OTHER|restorative materials|two types of composite with strip crown in primary molars
41148069|NCT01531699|DRUG|ALT005 Ophthalmic Prep Solution|single application for up to 6 hours
41309168|NCT02004587|DRUG|Gemigliptin|Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
41309169|NCT00480922|BEHAVIORAL|Low glycemic load diet|Outpatient behavioral counseling
41309170|NCT00480922|BEHAVIORAL|Low fat diet|Outpatient behavioral counseling
41309171|NCT03972124|DRUG|CBD 100 mg OD|CBD oil - purified to \<1% THC in soft-gel capsules
41309172|NCT03972124|DRUG|CBD 200 mg OD|CBD oil - purified to \<1% THC in soft-gel capsules
41309173|NCT03972124|DRUG|Placebo|Soft-gel capsules containing placebo
41309174|NCT05770050|OTHER|No intervention|No intervention
40789507|NCT01977365|BEHAVIORAL|Growth promotion based on child centered approach|"- Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.~Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.~Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.~- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers."
41468013|NCT06340230|DRUG|SHR-A1811 Injection + Adebrelimab Injection|Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
41468014|NCT06340230|DRUG|SHR-A1811 Injection|Drug: SHR-A1811 Injection
41468015|NCT02576717|DRUG|RPC1063|
41468016|NCT05345951|BEHAVIORAL|e-PBI+|The e-PBI+ is a preventive parent-based intervention emphasizing parent-teen communication on drinking/risks of alcohol abuse, with the addition of data-driven cannabis content to guide parent communications with their students (e.g., cannabis content focusing on the endocannabinoid system; acute and chronic cannabis use effects on the brain, cognition, and development; THC potency in present-day cannabis; cannabis use effects on mental and physical health, including psychosis, depression, and anxiety; respiratory/cardiovascular/sleep problems; cannabidiol (CBD) content, myths; and cannabis effects on psychosocial function). Together the goals are to reduce alcohol and cannabis use in college students.
41468017|NCT05345951|BEHAVIORAL|e-PBI|"The e-PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the e-PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
41468018|NCT05852925|OTHER|Traditional Venipuncture|Traditional blood collection is performed and the necessary amount of blood is collected into the collection tubes (either SST or Lithium Heparin tubes based on the biomarker being tested).
41468019|NCT05852925|DEVICE|Tasso+|The Tasso+ is the blood self-collection device used in the study and this device enables the collection of microliter capillary whole blood samples into compatible reservoirs. In this study, the reservoirs utilized include either SST or Lithium Heparin microtainers based on the biomarker being tested.
41468020|NCT05157035|BEHAVIORAL|Mindfulness/Acceptance-Based Smartphone App (MABSA)|This is a mindfulness- and acceptance-based smartphone app. The mindfulness and acceptance exercises embedded in the app are based on the principles of Acceptance and Commitment Therapy. Participants in the intervention group will be using the app for 6 weeks. They are expected to access the meditations and mindfulness exercises within the app on a daily basis.
41468021|NCT02033135|PROCEDURE|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
40993399|NCT02320500|OTHER|Myofascial-specific therapy|Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
41148070|NCT01531699|OTHER|saline control|single application for up to 6 hours
41468022|NCT02033135|OTHER|Best medical treatment|Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
41468023|NCT02033135|DEVICE|Zilver PTX|
41468024|NCT04983342|DEVICE|Apollo Armband|The Apollo armband is approximately the size of an Apple Watch and can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain. In addition to the wearable, Apollo is a software system that curates music for the body, rather than for the ears.
41468025|NCT06422481|OTHER|Fluid administration|Patients will receive fluid administration (500 mL of saline over 30 minutes). The indication of fluid administration will be left to the discretion of the attending physician.
41468026|NCT06422481|OTHER|Norepinephrine administration or increase in norepinephrine dosage|Patients will receive norepinephrine or norepinephrine dosage will be increased if necessary to achieve the appropriate mean arterial pressure level. The indication of norepinephrine administration or increase in norepinephrine dosage will be left to the discretion of the attending physician.
41468027|NCT06538038|DRUG|Osimertinib|Single agent Osimertinib by mouth once daily. Dosing and administration of osimertinib will be administered as per routine standard of care per the package insert or per institutional guidelines.
41468028|NCT06538038|DRUG|Osimertinib + Chemotherapy|Osimertinib by mouth once daily + Chemotherapy. Chemotherapy choice will be per treating physician. Dosing and administration of osimertinib +/- chemotherapy agents will be administered as per routine standard of care per the package insert or per institutional guidelines.
41468029|NCT06615830|DRUG|Standard chemotherapy|Each patient will receive the standard first-line chemotherapy (chosen among Gemcitabine-Abraxane, or Abraxane-Gemcitabine-FOLFOX or FOLFIRINOX, based on the clinical judgement of the treating oncologist) until disease progression.
40993400|NCT00206414|DRUG|Iressa Day 1 given with Arimidex and Faslodex|timing of administration of iressa is the study factor
40993401|NCT00206414|DRUG|Iressa Day 21 given with Arimidex and Faslodex|Timing of Iressa is the study factor
41148071|NCT01531699|DRUG|Betadine ophthalmic prep solution|single application for up to 6 hours
41148072|NCT04933188|DIAGNOSTIC_TEST|Myocardial work was estimated from left ventricular pressure-strain loop derived from speckle tracking echocardiography and non-invasive brachial artery cuff pressure|Baseline and follow-up examination of echocardiography is to be performed on study subjects.
40993402|NCT06155591|OTHER|Community Nurse Case Manager (CNCM)|"Their action protocol has been designed and sequenced according to the circumstances in which the Complex and Pluripathological Chronic Patient finds themself:~* Pre-hospital discharge. The hospital Nurse Case Manager (HNCM) will contact the CNCM to inform of the imminent hospital discharge.~* Hospital discharge: A comprehensive nursing assessment of the CPCP based on Marjory Gordon's functional patterns will be carried out.~* Planned visits: An infographic will be provided to identify signs and symptoms of decompensation/exacerbation and a direct dial telephone number.~* Proactive telephone follow-up: The CNCM will make comfort calls every week for the first month, every 15 days until the 3-months visit and every month until the 6- and 12-months visits.~* Exacerbations/decompensations: An appointment will be arranged with their Primary Care physician.~* Hospital readmission: The CNCM will be kept informed of the process through the HNCM and CPCP's digital clinical history."
41468030|NCT06615830|DRUG|Organoid-guided treatment|Upon disease progression confirmed radiologically, the patients will receive second-line chemotherapy. Second-line chemotherapy will be selected among the most promising effective drug (or drug regimens) as predicted in vitro by their benchmarking on patient-derived organoids.
41468031|NCT01205893|DEVICE|Neovasc Reducer|Implantation of the Reducer
41468032|NCT01205893|DEVICE|Control|Control - No device implanted
41468033|NCT03843515|DRUG|Nivolumab|Neoadjuvant nivolumab flat dose 400mg
41468034|NCT05423093|BEHAVIORAL|Single-Session Virtual Group Psychoeducational Session about Postpartum Depression|Session contents include (1) Introduction to clinic staff, contacts, and resources (2) A video-recorded testimonial of a patient with a history of perinatal depression followed by a group discussion about/reflection on the video; (3) Review of prevalence and signs of PPD; (4) Discussion of clinic PPD screening procedures and rationale for screening; (5) Discussion of self-care and mood monitoring; (6) Discussion of relevant local resources, including information about availability of primary care resources for parents (including uninsured parents) and information about resources addressing social needs.
41468035|NCT02414373|DRUG|Ropivacaine 2mg/ml|local anesthetics, which will epidurally administered
41468036|NCT02414373|DRUG|Bupivacaine|local anesthetics, which will epidurally administered
41468037|NCT02414373|DEVICE|6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)|
41468038|NCT02414373|DEVICE|14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)|
41468039|NCT04828434|OTHER|Virtual Individual Cognitive Simulation Therapy|Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.
41468040|NCT00760526|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor
40789508|NCT05607602|OTHER|Comparison of blood samples between the two groups|In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation\[18\]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.
40789509|NCT01201928|DRUG|Comparator administered in parent trial|Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
40993403|NCT04094467|DRUG|Cetrorelix|0.25 mg subcutaneous injection daily for 6 days
40993404|NCT04094467|DRUG|Leuprolide Acetate|0.1 mg subcutaneous injection daily for 12 days
40993405|NCT02608931|DRUG|Dronabinol|
40993406|NCT02608931|OTHER|Placebo|placebo
40993407|NCT04669587|DRUG|ZB716|Pharmaceutical form: capsule Route of administration: oral
41468041|NCT00760526|DEVICE|Home blood glucose monitor|Home monitoring 3 or more times a day
41468042|NCT05078827|DRUG|Test Product (A): Fluorouracil Cream, 5% topical cream|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
41468043|NCT05078827|DRUG|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
41468044|NCT05078827|DRUG|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
41468045|NCT05407818|DRUG|JNJ-63733657|JNJ-63733657 will be administered as an IV infusion.
41468046|NCT02805413|OTHER|Détermination and comparison of blood pressure|Rebreathings will be performed every parabola (2, 4, 6, 8, 10...). Ultrasound measurements will be performed during the remaining parabolas (1, 3, 5, 7, 9...). The procedure consists of a fixed breathing frequency of 20 breaths per minute and an exact triggered start point for the measurements. . Central blood pressure measurements, finger blood pressure measurements, impedance cardiography, carotid plethysmography and phonocardiography will be performed continuously during the flights. The breaks between parabolas 10 and 11 and 20 and 21 will be used to change subjects, which takes approximately 5 minutes.
41468047|NCT03337217|PROCEDURE|Position during colonoscopy|Position during colonoscopy
40993408|NCT04669587|DRUG|Palbociclib|Pharmaceutical form: capsule Route of administration: oral
40993409|NCT00915369|DRUG|Nanoxel (Paclitaxel Nanoparticle formulation )|Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
40993410|NCT01988103|DRUG|Apremilast|20 mg tablet BID for 68 weeks
40993411|NCT01988103|DRUG|Apremilast|20 mg tablet BID for 68 weeks
40993412|NCT01988103|DRUG|Placebo|Placebo tablet BID for 16 weeks
40993413|NCT05114135|DEVICE|Osteo3 ZP Putty|Transforminal Interbody Fusion at one spinal level (L2-S1) with instrumented posteriorlateral fusion on at least the contralateral side to the TLIF approach.
40993414|NCT03398031|DRUG|Magnesium Oxide|After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester
40993415|NCT03398031|DRUG|Placebo Oral Tablet|After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
40993416|NCT06032247|BEHAVIORAL|Resistance exercise program- UL|"Unilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include single-leg squats, split squats, single-leg deadlifts, single-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
40993417|NCT06032247|BEHAVIORAL|Resistance exercise program- BL|"Bilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include double-leg squats, double-leg deadlifts, double-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
40993418|NCT00725218|DRUG|Saline|Saline 5 ml injection 10 min prior to propofol administration.
40993419|NCT00725218|DRUG|Flurbiprofen Axetil|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
40993420|NCT00990496|DRUG|Fludarabine|30 mg/m2
40993421|NCT00990496|DRUG|Cyclophosphamide|600 mg/m2
41148073|NCT02403414|DEVICE|Fiberoptic|In the event of failed intubation under direct laryngoscopy, fiberoptic intubation will be performed.
40993422|NCT00990496|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
40993423|NCT01523886|DRUG|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
40993424|NCT01523886|DRUG|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
41148074|NCT05327270|DRUG|Nivolumab|Given by IT
40993425|NCT00253474|BIOLOGICAL|PEG-interferon alfa-2a|
41148075|NCT05843526|DEVICE|Experimental healing abutment|"Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment"
41148076|NCT03530644|DEVICE|WM3.4NR|The investigational medical device will collect spectral Raman data from tissue.
40993426|NCT03758196|DEVICE|Radiofrequency ablation instruments|Renal Sympathetic Denervation from the adventitia of renal artery
41148077|NCT03530644|DEVICE|P0.1|The investigational medical device will collect spectral Raman data from tissue.
41468048|NCT05120687|DRUG|noncorticosteroid systemic immunomodulatory therapy (NCSIT)|Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate 15mg/week or Adalimumab 40mg /2weeks or Mycophenolate Mofetil 1g/day or Cyclosporin 50mg-100mg/day or cyclophosphamide 10mg/kg on two consecutive days every 2 weeks.
41468049|NCT05999734|DRUG|Bupivacaine|Before skin incision, under complete aseptic precautions and sterilization, the patient will be placed in a lateral position. The spinous process of the fourth thoracic vertebra will be identified and marked. The ultrasound guided MTP block will be done by high frequency linear transducer will be placed in position just lateral to the spinous processes of thoracic vertebra target of the paravertebral space. A 50 mm 22-gauge echogenic needle will be inserted in an in plane technique from a caudal to a cephalad direction and will be advanced. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline will be injected. Once the needle tip has been confirmed and after careful aspiration to demonstrate the absence of air or blood, 0.5mL/kg 0.25% bupivacaine will be injected.
41468050|NCT05806931|DRUG|TAS-102, oxaliplatin, irinotecan with bevacizumab|Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
41468051|NCT03245892|DRUG|Carboplatin and Paclitaxel|Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.
41468052|NCT03245892|DRUG|Nivolumab|Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV over approximately 30 min on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks
41468053|NCT03245892|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery
41468054|NCT03245892|DRUG|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks x 3-6 cycles in the neoadjuvant setting (maximum 2 doses of ipilimumab)
41468055|NCT02593344|DEVICE|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
41468056|NCT05118477|DEVICE|Ambulatory monitoring system|Patients will use AMS.
41468057|NCT05118477|DEVICE|Active alerting system|Clinical staff alerted if AMS detects deterioration
41468058|NCT02991352|DEVICE|Image guided needle placement|Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
41468059|NCT03321474|PROCEDURE|modified gull wing preparation|"preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
41468060|NCT02553655|PROCEDURE|4x 5min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
41468061|NCT02553655|PROCEDURE|3x 10min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
41468062|NCT02553655|PROCEDURE|3x 10min Sham Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
41468063|NCT04475276|DRUG|Placebo|Lifestyle modification with placebo for 12 weeks
41468064|NCT04475276|DRUG|Alphalipoic acid|Lifestyle modification with Alphalipoic acid for 12 weeks
41468065|NCT03946917|DRUG|JS001|JS001 3 mg/kg, iv drip, d1, d15, q4w
41468066|NCT03946917|DRUG|regorafenib tablet|80/120/160 mg, po, d1-d21, Q4w.
41468067|NCT03766217|COMBINATION_PRODUCT|Mesenchymal stem cells associated with biomaterials|Deciduous dental pulp mesenchymal stem cells associated with hydroxyapatita/collagen.
41468068|NCT03766217|COMBINATION_PRODUCT|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest.
41468069|NCT04961567|DRUG|Litifilimab|Administered as specified in the treatment arm.
41468070|NCT04961567|DRUG|Placebo|Administered as specified in the treatment arm.
41148078|NCT02645578|DEVICE|Right median nerve stimulation|Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
41148079|NCT05799040|DEVICE|Self-developed pulmonary lobar ventilation detector|The participants would evaluated by the self-developed pulmonary lobar ventilation detector.
41148080|NCT05799040|DEVICE|Chartis detection system|The participants would evaluated by the Chartis detection system.
41148081|NCT03976102|BIOLOGICAL|DRL_RI (Proposed rituximab biosimilar)|Proposed rituximab biosimilar, 100mg and 500mg, concentrate for solution for infusion
41148082|NCT03976102|OTHER|MabThera®|Reference product rituximab, 100mg and 500mg, concentrate for solution for infusion
41148083|NCT01075815|DRUG|Recombinant human luteinizing hormone (rhLH)|
41468071|NCT02074267|DRUG|Carbatin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
41468072|NCT02074267|DRUG|Neurontin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
40993427|NCT00983151|DRUG|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
40993428|NCT00326443|BIOLOGICAL|CVD 909|5 X 10\^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.
40993429|NCT00326443|DRUG|Placebo|Buffer placebo administered on Day 0.
40993430|NCT00326443|BIOLOGICAL|Vi Polysaccharide|25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
40993431|NCT01707953|DRUG|Midodrine|Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
40993432|NCT01707953|DRUG|Placebo|Placebo capsule to mimic midodrine
40993433|NCT04070131|OTHER|Horse-Assisted Rehabilitation|One hour weelky session of hippotherapy.
40993434|NCT05514132|DRUG|Ceralasertib|Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
40993435|NCT05514132|DRUG|Durvalumab|Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.
40993436|NCT05103527|DEVICE|Dorsal Root Ganglion Stimulation|Stimulation at L2, L3, L4 and S1 spinal levels
40993437|NCT03016962|DEVICE|cap-assisted colonoscopy|cap-assisted colonoscopy
40993438|NCT03016962|DEVICE|Standard colonoscopy|Standard colonoscopy
40993439|NCT06301815|DIAGNOSTIC_TEST|Scale for Contraversive Pushing|Lateropulsion will be assessed using the Scale for Contraversive Pushing (SCP). It involves observation of the posture of the participant in sitting and standing. Scores are assessed in sitting and standing giving a maximum score of 6.
40993440|NCT06301815|DIAGNOSTIC_TEST|Catherine Bergego Scale|Neglect will be assessed using the Catherine Bergego Scale. The scale is a 10-point scale with each item scored between 0 (no neglect) and 3 (severe neglect). It involves observation of a participant completing daily activities such as eating, dressing and walking.
40993441|NCT06301815|DIAGNOSTIC_TEST|Bucket Test|"The bucket test involves the patient being sat upright and looking into a translucent bucket with the bucket covering their complete field of vision. On the inside of the bucket on the bottom is a dark straight line. On the outside of the bottom of the bucket is a matching dark line, the bottom of the bucket is divided into degrees with the zero-degree line being equivalent to the line inside the bucket. For measurement the bucket will be randomly rotated right or left by the examiner to 45 degrees and then slowly rotated back to the zero-degree position. Patients will signal when they estimate the inside bottom line to be truly vertical by saying stop or by raising their non-paretic hand."
40993442|NCT03510286|DIAGNOSTIC_TEST|Test-it™ PrCr Urinalysis Strips|The LifeAssay Diagnostics prototype PrCr dipstick has been designed to provide the measurement of both protein and creatinine while retaining a very low estimated cost that is comparable to the current protein-only dipsticks at $0.06-0.10 per test. In 2015, an initial laboratory-based validation study of the prototype LAD PrCr test was used on more than 500 characterized urine samples from pregnant women. This validation study demonstrated comparable accuracy for detection of severe proteinuria of the LAD PrCr test to the much more expensive commercial POC test available for PrCr determination, the Siemens Multistix® PRO 10LS. These results were compared to laboratory-based reference standard assays for proteinuria measurement.
40993443|NCT00446407|OTHER|Collaborative Stepped Care Intervention|Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
40993444|NCT00446407|OTHER|Enhanced Usual Care|Screening plus Antidepressants based on practice guidelines
40993445|NCT05778786|DEVICE|Acuvue Oasys 1 Day for Astigmatism|CONTROL
40993446|NCT05778786|DEVICE|TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore|TEST
40993447|NCT00946712|BIOLOGICAL|Bevacizumab|Given IV
41309175|NCT02405234|DEVICE|Carbon Modular Radial Head replacement|'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.
40993448|NCT00946712|DRUG|Carboplatin|Given IV
40993449|NCT00946712|BIOLOGICAL|Cetuximab|Given IV
40993450|NCT00946712|OTHER|Laboratory Biomarker Analysis|Correlative studies
40993451|NCT00946712|DRUG|Paclitaxel|Given IV
40993452|NCT06226779|BEHAVIORAL|Baduanjin exercsie|The Baduanjin exercise consists of 8 postures, with emphasis on different body parts. The exercise is commonly practiced as follows: (1) 2 hands holding up the heavens, (2) drawing the bow to shoot the eagle, (3) separating the heaven and earth, (4) wise owl gazing backwards, (5) swaying the head and shaking the tail, (6) 2 hands holding the feet to strengthen the waist, (7) clenching the fists and glaring fiercely, and (8) bouncing on the toes.
40993453|NCT06226779|BEHAVIORAL|Brisk walking|The brisk walking will be gradually increased physical exertion from light to moderate of intensity. During the training period, the heart rate of participants will be monitored.
40993454|NCT06226779|BEHAVIORAL|Health education|Health education will include lecture classes. Video watching will watch videos which were not aim at improving physical exertion, such as sports games or sports related variety shows
40993455|NCT00155337|PROCEDURE|photodynamic therapy|
40993456|NCT03739112|BIOLOGICAL|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
40993457|NCT03739112|BIOLOGICAL|Fluarix Quadrivalent® Comparator Vaccine|Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine
40993458|NCT01555268|BIOLOGICAL|trebananib|Given IV
41148084|NCT01075815|DRUG|Recombinant follicle-stimulating hormone (rFSH)|
40993459|NCT01555268|DRUG|cytarabine|Given SC
40993460|NCT01555268|OTHER|laboratory biomarker analysis|Correlative studies
40993461|NCT01555268|OTHER|pharmacological study|Correlative studies
40993462|NCT00119392|BIOLOGICAL|rituximab|Given IV
40993463|NCT00119392|DRUG|cyclosporine|Given orally
40993464|NCT00119392|DRUG|fludarabine phosphate|Given IV
40993465|NCT00119392|DRUG|mycophenolate mofetil|Given orally
40993466|NCT00119392|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
40993467|NCT00119392|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
40993468|NCT00119392|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
40993469|NCT00119392|RADIATION|total-body irradiation|Undergo TBI
40993470|NCT05296785|PROCEDURE|intramedullary nail with Limb Reconstruction System|bone transport by Limb Reconstruction System over intramedullary nail on fracture tibia
40993471|NCT01226381|DRUG|Von Frey electronic|This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
40993472|NCT02902510|OTHER|Therapeutic yoga for people with Parkinson's Disease|Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.
40993473|NCT02863133|DEVICE|Liquid Embolic|The Easyx liquid embolic, manufactured by Antia AG, is intended to occlude hypervascular lesions in the brain such as tumors, arteriovenous malformations (a tangle of abnormal and poorly formed blood vessels) and dural arteriovenous fistulas (abnormal connection of blood vessels).
40993474|NCT05413252|OTHER|Practice Facilitation|Practices will be assigned a practice facilitator who will support practices in implementing all practice redesign components associated with TBC for HTN management.
40993475|NCT00001442|DRUG|paclitaxel concurrent with radiation therapy|
40993476|NCT04488965|OTHER|Autologous transplant|Autologous transplant obtained from cortical biopsy
40993477|NCT03041246|PROCEDURE|Pelvic floor fascial mobilization|The manual manipulation of the pelvic floor involves intra vaginal superficial as well as pelvic skin area pressure points.
40993478|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
40993479|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
40993480|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
40993481|NCT03079609|PROCEDURE|subinguinal microscopic varicocelectomy|During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
40993482|NCT03079609|PROCEDURE|open hernia repair|During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
40993483|NCT04931433|DRUG|Lignocaine|Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.
40993484|NCT04931433|DRUG|Normal saline|Group B will receive saline of similar volume and rate as Group A
40993485|NCT03676322|DRUG|M5049|Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
40993486|NCT03676322|DRUG|Placebo|Participants will receive placebo matched to M5049.
40993487|NCT06113133|DIAGNOSTIC_TEST|measurement of oxygen uptake|oxygen uptake is obtained during a maximal exercise test
41148085|NCT03753256|DEVICE|Transbond XT|"Application of~• Transbond XT (activator comparator) to labial surfaces of teeth of randomized quadrants."
41148086|NCT03753256|DEVICE|Protecto®CaF2Nano|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
40993488|NCT01321125|BIOLOGICAL|Bacterial culture of the prepared skin's areas|Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.
40993489|NCT01321125|OTHER|Preparing skin's areas to be tested|Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.
40993490|NCT01321125|BIOLOGICAL|Antiseptic substantivity|Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
40993491|NCT01771432|DRUG|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
40993492|NCT01771432|OTHER|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
40993493|NCT05640570|DRUG|The individualized Jade Wind-Barrier Herbal Tea Bag|The individualized Jade Wind Barrier Herbal Tea Bag is composed of Astragali Radix (Zhi Huangqi) 4g, Saposhnikoviae Radix (Fangfeng) 2g, Atractylodes macrocephala Koidz (Baizhu) 2g, Nelumbinis Folium (Heye) 1g, Chrysanthemum morifolium Ramat (Juhua) 1g.
40993494|NCT03608514|DRUG|Experimental|Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
40993495|NCT00296933|DRUG|Escitalopram|
40993496|NCT00296933|DRUG|Bupropion XL|
40993497|NCT02166489|BIOLOGICAL|Intravenous injection autologous mesenchymal stem cells|Intravenous injection of mesenchymal stem cell in patients with PKD
40993498|NCT04739007|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation (VA-ECMO)|VA-ECMO used for resuscitation after cardiac arrest
41148087|NCT03753256|DEVICE|Pro Seal®|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
40993499|NCT04739007|DEVICE|Electrical Impedance Tomography (EIT)|EIT used to demonstrate ventilation and perfusion distribution in intubated patients on VA-ECMO
40993500|NCT04849806|DIAGNOSTIC_TEST|Assessments of the sympathetic nerve activity axis|"For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .~Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed."
40993501|NCT04849806|DIAGNOSTIC_TEST|OSA severity|OSA is defined as apnoea-hypopnoea index \[AHI\] \>15/h and obstructive apnoea index \[OAI\] \>5/h) and sleep architecture
40993502|NCT04849806|DIAGNOSTIC_TEST|Determination of PH and right HF severity|(defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography
40993503|NCT04849806|DIAGNOSTIC_TEST|Comprehensive lung function and inspiratory muscle function testing.|Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 \<55 mmHg) and hypercapnia (PaCO2 \>45 mmHg) using capillary blood gas analysis.
40993504|NCT04849806|DIAGNOSTIC_TEST|Assessment of systemic inflammation|Based on blood samples taken.
40993505|NCT05282719|DRUG|venetoclax combined with azacitidine|On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
41468073|NCT05342311|DIAGNOSTIC_TEST|preoperative ultrasonographic evaluation of right common femoral vein diameter|preoperative ultrasonographic evaluation of right common femoral vein diameter to predict spinal anesthesia-induced hypotension in elderly patients
41148088|NCT03753256|DEVICE|Opal®Seal|"Application of~• Opal®Seal (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
41148089|NCT05052151|OTHER|Low dialysate temperature|35°C
41148090|NCT05052151|OTHER|High dialysate temperature|37°C
41148091|NCT05052151|OTHER|Low dialysate bicarbonate concentration|30 mmol/L
41148092|NCT05052151|OTHER|High dialysate bicarbonate concentration|38 mmol/L
41148093|NCT04888208|BEHAVIORAL|Behavioral|The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
41468074|NCT03367936|BEHAVIORAL|One-on-one Session|Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.
41468075|NCT03367936|BEHAVIORAL|Self-monitoring|Participants will receive an orientation on how to self-monitor using the smartphone and other devises
41468076|NCT03367936|BEHAVIORAL|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings
41468077|NCT04276935|OTHER|Interview|Participate in cognitive interview
41468078|NCT04276935|OTHER|Quality-of-Life Assessment|Ancillary studies
41468079|NCT04276935|OTHER|Questionnaire Administration|Ancillary studies
41468080|NCT00550888|PROCEDURE|suture techniques|
41468081|NCT02241694|OTHER|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
41468082|NCT04540380|DRUG|Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab|Conditioning regimen .Patients will receive Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Thymoglobulin
41468083|NCT04540380|PROCEDURE|Combined bone marrow and kidney transplant|Recipients will receive a conditioning regimen that includes rituximab on study days -7 and -2, fludarabine 10mg/m2/day on days -6 to -3 (4 doses), cyclophosphamide (22.5mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumabon days -1, 0, and +1. Combined kidney and bone marrow transplant will be performed on study day 0. Methylprednisolone will be started at 250 mg/day on day 0 and tapered to prednisone 20mg by day 10 after which it will be continued until day 20. Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 52 weeks following transplantation. The proportion of patients successfully weaned off immunosuppression without chimerism transition syndrome (CTS) will be assessed.
41468084|NCT04397640|DIAGNOSTIC_TEST|Sonovue|Contrast myocardial echocardiography with sulphur hexafluoride microbubbles Sonovue (Bracco, Milan, Italy) injection and using the time-intensity curves profile to evaluate the myocardial microcirculation.
41468085|NCT00399893|DRUG|Octreotide|Octreotide to be administered by subcutaneous injection three times daily
41468086|NCT00399893|DRUG|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
41468087|NCT04396444|COMBINATION_PRODUCT|Aromastick|Vascular surgery patients will be randomized to either the intervention group and receive a lavender infused aromastick to use as an adjunct to their inpatient pain management plan, or to the control group, given a blank aromastick. Subjects will be blinded to their group.
41468088|NCT02875041|DEVICE|Transcranial Magnetic Stimulation (TMS)|
41468089|NCT02875041|DEVICE|MAGSTIM Rapid2|
41148094|NCT05796271|DRUG|R-Chop and Roflumilast|All subjects will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days (+/- 3 days) for a total of 6 cycles. All subjects will receive a fixed oral dose of one 500 microgram (μg) tablet of roflumilast per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses. Subjects will be asked to keep a drug diary to record the days and times when Roflumilast is taken. The first dose will be given on the day of the first R-CHOP treatment.
41468090|NCT03504761|DEVICE|ClariCore Optical Biopsy System|Demonstrate the efficacy and safety of the ClariCore System in obtaining prostate biopsies utilizing real-time tissue classification.
41468091|NCT05981287|OTHER|Task-oriented activities based on NDT (TOA-NDT) principle and Conventional Physical Therapy|This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
41468092|NCT05981287|OTHER|Gross motor task training and Conventional physical therapy (CPT)|This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
41468093|NCT06617572|GENETIC|Non-conforming afamitresgene autoleucel|Non-conforming afamitresgene autoleucel, suspension for intravenous infusion (NC afami-cel), single dose administration
41468094|NCT06136624|DRUG|Opevesostat|Administered orally
41468095|NCT06136624|DRUG|Abiraterone acetate|Administered orally
41468096|NCT06136624|DRUG|Enzalutamide|Administered orally
41468097|NCT06136624|DRUG|Hydrocortisone|Administered orally or IM as a rescue medication
41468098|NCT06136624|DRUG|Fludrocortisone acetate|Administered orally
41148095|NCT01714947|DRUG|[^14C]-alisertib|\[\^14C\]-alisertib oral solution
41148096|NCT01714947|DRUG|alisertib|Alisertib enteric coated tablets
41468099|NCT06136624|DRUG|Prednisone|Administered orally
41468100|NCT06136624|DRUG|Dexamethasone|Administered orally as rescue medication
41468101|NCT05132439|DRUG|Metformin ER|Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties
41468102|NCT05132439|DRUG|placebo|Matched to active study drug
41468103|NCT03701763|DRUG|Apremilast (CC-10004)|Apremilast (CC-10004)
41468104|NCT03701763|OTHER|Placebo|Placebo
41468105|NCT04692584|BEHAVIORAL|The Lullaby Group|"Approximately 15 seconds before the vaccination, each baby's mother began to sing a lullaby. Infant's mother continued to sing lullabies until all the vaccinations, which were given immediately after the BCG vaccination, were completed. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure. All the mothers sang the same lullaby, Sleep and Grow. Mothers were reminded of the words to the lullaby before vaccine administration."
41468106|NCT05298592|BIOLOGICAL|BMS-986406|Specified dose on specified days
41468107|NCT05298592|BIOLOGICAL|Nivolumab|Specified dose on specified days
41468108|NCT05298592|DRUG|Carboplatin|Specified dose on specified days
41468109|NCT05298592|DRUG|Pemetrexed|Specified dose on specified days
41468110|NCT05298592|DRUG|Paclitaxel|Specified dose on specified days
41468111|NCT03847363|PROCEDURE|epidural anesthesia|epidural anesthesia
41468112|NCT03847363|PROCEDURE|nerve block|paravertebral or serratus anterior plane block
41468113|NCT01321177|BEHAVIORAL|Integrated Treatment|"Integrated program of treatments and services delivered by a coordinated team of providers that includes:~* education about schizophrenia and its treatment for the participants and their family members~* medication for symptoms and preventing relapse that uses a computerized decision support system~* strategies for managing the illness and building personal resilience~* help getting back to school or work using a supported employment/education model"
41468114|NCT01321177|BEHAVIORAL|Community Care|"Standard mental health treatments and services offered at the local agency that may include :~* medication for symptoms and preventing relapse~* psychosocial therapy which may include a range of behavioral treatments and supportive services~* Case management"
41468115|NCT02972515|BEHAVIORAL|See Me Smoke-Free|See Me Smoke-Free is a multi-behavioral mobile application focusing on increasing smoking cessation, healthy eating, and moderate to intense physical activity. The app tracks the participant's quit date, and eating/physical activity goals. Participants have access to guided imagery audio files that they are instructed to listen to every day for at least 30 days. Participants can earn awards for meeting the study goals.
41468116|NCT02972515|DEVICE|Smart phone|See Me Smoke-Free mHealth app delivered via a smart phone
40993506|NCT04429893|DRUG|magnesium sulphate|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
40993507|NCT04429893|DRUG|bupivicaine|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
40993508|NCT00673179|DRUG|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m\^2.
40993509|NCT00673179|DRUG|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m\^2/day for 2 days continuous infusion.
40993510|NCT00673179|DRUG|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m\^2, max 20 gm over 4 hours.
40993511|NCT00673179|DRUG|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
40993512|NCT00673179|DRUG|Dexrazoxane|Dose 900 mg/m\^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
40993513|NCT00673179|DRUG|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2. Dose 2.8 grams m\^2/day.
40993514|NCT00673179|BEHAVIORAL|Questionnaire|Questionnaires to be completed on 5 different days during the study.
40993515|NCT00673179|DRUG|Gemcitabine|IV over 1 hour, every other week.
40993516|NCT00673179|DRUG|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
40993517|NCT00673179|PROCEDURE|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
40993518|NCT00673179|DRUG|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2/day.
40993519|NCT03445819|PROCEDURE|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon
41468117|NCT02456987|DEVICE|Samsung Gear|Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
41468118|NCT01162278|RADIATION|SBRT|Single fraction SBRT
41468119|NCT05783037|OTHER|New Organic Infant Formula|New organic infant formula fed daily ad libitum
41468120|NCT05783037|OTHER|Commercial Organic Infant Formula|Commercially available organic infant formula fed daily ad libitum
41468121|NCT06251960|PROCEDURE|socket preservation with completely demineralized dentin graft|socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
41468122|NCT06251960|PROCEDURE|socket preservation with partially demineralized dentin graft|socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
41468123|NCT03423667|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg) administered twice a day during 5 days
40993520|NCT03445819|OTHER|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery.
40993521|NCT03382119|DEVICE|Ultrasound with ARFI (acoustic radiation force impulse)|This technology uses sound waves to measure the stiffness of tissue.
40993522|NCT03382119|DEVICE|Ultrasound with backscatter imaging|This ultrasound tool gathers data from the waves returning from imaged tissue.
41468124|NCT03423667|DRUG|Lactose powder|Placebo comparator.
40993523|NCT04409743|BEHAVIORAL|Remote Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist through telehealth once a week for four weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
40993524|NCT01751386|DRUG|Baclofen|
40993525|NCT01751386|OTHER|Placebo|
41148097|NCT03444298|DRUG|Gamma Tocopherol|Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
41148098|NCT03444298|DRUG|Placebo|Each dose consists of two capsules by mouth once daily for a total of 7 days.
40993526|NCT03870828|DIAGNOSTIC_TEST|Bronchoalveolar lavage and taking bronchial mucosa samples|"Regional anesthesia and sedation with use of lidocaine and midazolam will be performed, according to anesthesia protocols applied in respective endoscopy units. Intravenous cannula will be inserted prior to BF. During endoscopy, the patient will be monitored according to safety protocols applied in respective endoscopy units.~Bronchoalveolar lavage will be performed in the bronchus from the middle robe of right lung or the lingula of left lung (B4, B5). Localization will be chosen based on HRCT results and will be recorded in patient's medical history. Sterile solution of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid is retrieved."
40993527|NCT03870828|DIAGNOSTIC_TEST|6minute walk test|a submaximal exercise test which entails measurement of distance walked over a span of 6 minutes. Blood pressure, pulse oximetry are measured directly before and after the test. The participant is also periodically asked about their dyspnea sensation
41468125|NCT04821739|DEVICE|AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.
41468126|NCT04002869|DIAGNOSTIC_TEST|Immunologic, molecular, metabolomic and radiolologic diagnostic|Evaluation and development of new technologies
41468127|NCT04057248|DEVICE|Dario Blood Glucose Monitoring System|Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform
41468128|NCT04057248|BEHAVIORAL|CDE|Certified Diabetes Educator Sessions
41468129|NCT05968963|BEHAVIORAL|Mindfulness-based Music Therapy (MBMT)|Participants will receive 8 music therapy sessions that will last approximately 60 minutes in length. A Music therapist will conduct the sessions. These sessions will be in person and/or virtual depending on patient status and the time between sessions will vary based on patient response to treatment.
41468130|NCT05968963|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive 8 mindfulness meditation sessions that will last approximately 60 minutes in length. These sessions will be participant led virtually.
41468131|NCT00267358|DRUG|RC-1291 HCl|
41468132|NCT00267358|DRUG|Placebo|
41468133|NCT06613269|DRUG|68Ga-NY104 PET/CT|"68Ga-NY104 PET/CT will be performed at baseline, 6 months, 12 months, and 24 months after radiation therapy if the tumor is under control. If CT or MRI shows any suspicious recurrence or metastasis, 68Ga-NY104 PET/CT can be performed at the decision of the urology oncologist or radiation oncologist.~The scan begins 1 hour after intravenous injection of 68Ga-NY104."
41468134|NCT06613269|DRUG|18F-FDG PET/CT|18F-FDG PET/CT will be performed at baseline and 6 months after radiation therapy. The scan begins 1 hour after intravenous injection of 18F-FDG.
41468135|NCT06613269|RADIATION|Radiation Therapy|Radiation therapy will be delivered to cover as much metastasis as possible if not all. For new lesions after radiation plus systemic therapy, if the new lesions are considered suitable for RT, RT can be delivered again without changing systemic therapy.
41468136|NCT06613269|DRUG|Systemic therapy|Systemic therapy will be delivered to patients to control the tumor. Possible regimen includes targeted therapy alone, immunotherapy alone, and targeted therapy combined with immunotherapy. The treatment regimen will be decided according to the urology oncologist.
41468137|NCT02413294|DEVICE|Re-Timer glasses|Participants will wear the Re-timer glasses for 30 minutes a day according to their sleep chronotype in weeks 3 and 4 of the study.
41468138|NCT05181800|OTHER|Degarelix Cohort|Non-interventional
41468139|NCT04158375|BEHAVIORAL|Resistance Exercise|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Participants will complete 2 progressing to 4 sets of 8 to 12 repetitions per exercise, with 1 minute rest between sets. Participants will warmup for 5 minutes on a treadmill, cycle ergometer or elliptical at \~50% VO2 peak then begin resistance training. Resistance will be performed 4 days per week with lower body exercise on Monday and Thursday, and upper body on Tuesday and Friday. Wednesdays are a rest day. Participants will begin at 2 sets per exercise on weeks 1 and 2, then 3 sets for week 3, and 4 sets for weeks 4 to 12.
41468140|NCT01915641|DEVICE|CPAP|Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
40993528|NCT03870828|DIAGNOSTIC_TEST|Arterial blood gas|If SpO2 is measured to be \< 92%, an artery (radial or femoral) is punctured in order to take a sample of arterial blood. Then, the artery is compressed in order to prevent bleeding/ hematoma.
41309176|NCT02405234|DEVICE|Metal Radial Head replacement|Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
41309177|NCT00395408|DRUG|MK0476, montelukast sodium / Duration of Treatment : 56 Weeks|
41309178|NCT00395408|DRUG|Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks|
41309179|NCT00962039|DRUG|Citalopram|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
41468141|NCT04474431|OTHER|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
41468142|NCT06322615|PROCEDURE|Acupressure Therapy|Undergo acupressure
41468143|NCT06322615|OTHER|Educational Intervention|Receive education session about using acupressure at home
41468144|NCT06322615|OTHER|Electronic Health Record Review|Ancillary studies
41468145|NCT06322615|OTHER|Questionnaire Administration|Ancillary studies
41309180|NCT00962039|DRUG|Placebo|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
41468146|NCT05264831|PROCEDURE|Pulmonary Vein Isolation (PVI) alone|PVI procedures correspond to point-by-point 50W AI-guided RF applications (400 posterior LA wall, and 550 elsewhere). The PVI will be validated by the absence of any activity recorded inside the PV encirclement by a multipolar catheter (either a Lasso catheter or a Pentaray catheter) (entrance block) and by the non-capture of the LA despite pacing maneuvers from inside the encirclement (exit block). The bidirectional block will be validated again after a 15-minutes waiting period.
40789510|NCT01201928|DRUG|Technosphere Insulin Inhalation Powder|Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
40789511|NCT00752921|DRUG|etoricoxib|120 mg
40993529|NCT03870828|PROCEDURE|Blood drawing|A vein will be punctured in order to take a blood sample for further tests
40993530|NCT04538703|BEHAVIORAL|acne vulgaris|Social media use of acne vulgaris patients, a questionnaire will be asked the patients and try to learn how they use social media for getting information about their disease.
41468147|NCT05264831|PROCEDURE|PVI procedure associated with substrate modulation|PVI procedure associated with substrate modulation
41468148|NCT00628979|BEHAVIORAL|CBT|cognitive- behavioral treatment for panic disorder.
41468149|NCT03969316|PROCEDURE|Transversus abdominis plane block, Quadratus lumborum block|The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.
41468150|NCT02344745|OTHER|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
40789512|NCT00752921|DRUG|placebo|placebo
40789513|NCT05659914|DRUG|olaparib+durvalumab|olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w
40789514|NCT05741723|DEVICE|OCS Heart|Transplanted with OCS preserved heart.
40789515|NCT04416113|PROCEDURE|photobiomodulation and photodynamic therapy|antiviral treatment
40789516|NCT00409955|PROCEDURE|Lamellar transplant with lyophilized corneas|
40789517|NCT05504681|OTHER|Observational study|It takes the patient on average 15 minutes to complete the Brainlab Cognition app.
40789518|NCT05066126|BEHAVIORAL|Mixed-Presentation of Content|Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.
40993531|NCT04231786|PROCEDURE|Breast ultrasonography findings|Breast ultrasonography findings in patients over 30 years of age diagnosed with polycystic ovary syndrome.
40993532|NCT03365817|DRUG|Opioids taper off|Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.
40993533|NCT03365817|DRUG|Opioid stable treatment|No changes on prescribed opioids and adjuvant medication for the next six months
40993534|NCT00204854|BEHAVIORAL|telephone counseling|
41148099|NCT01249794|PROCEDURE|non invasive ventilation|continuous positive airways pressure
41148100|NCT00171652|DRUG|Diclofenac sodium gel 1%|
41148101|NCT00219635|DRUG|UK-390,957|
40789519|NCT04452123|PROCEDURE|Laparoscopic argon plasma treatment of endometrioma|Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible
40789520|NCT04452123|PROCEDURE|Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary|Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.
40789521|NCT05190679|OTHER|None/Observational Studies|This is an observational study and there is no intervention.
40789522|NCT02404168|DRUG|lamotrigine (brand Lamictal)|an anti-epileptic drug (brand)
40789523|NCT02404168|DRUG|lamotrigine (generic Teva)|an anti-epileptic drug (brand)
40789524|NCT01775527|OTHER|blood test|
40789525|NCT02655718|OTHER|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
40789526|NCT02655718|DEVICE|MRI|
40789527|NCT04702386|BEHAVIORAL|Focus groups|Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF
40789528|NCT04702386|BEHAVIORAL|Individual interviews|Interview led by the psychologist about being the child of a parent with CF
40789529|NCT06057805|DEVICE|Blinded Dexcom G7 CGM|CGM that records blood glucose but not visible to patient or provider in real time
40789530|NCT00638300|DEVICE|large pore (FX80) compared to small pore dialyzer (F8HPS)|Effect of pore size
40789531|NCT00638300|OTHER|Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L|Effect of dialysate bicarbonate concentration
40789532|NCT00638300|OTHER|Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L|Effect of dialysate calcium concentration
40789533|NCT03732898|DEVICE|Novel Programming (nDBS)|The commercial CP installed with the investigational DBS programming software will be used to set up Novel Programming (nDBS) therapy on the IPG.
40789534|NCT03732898|DEVICE|Conventional Programming (cDBS)|The commercial CP installed with commercial software will be used to set up standard cDBS therapy on the IPG.
40789535|NCT01087983|DRUG|Lapatinib|Starting oral dose of 500 mg daily for 21 day cycle.
41148102|NCT01533896|BEHAVIORAL|Grow Nicely|Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
41148103|NCT03398889|DIAGNOSTIC_TEST|Plasma levels of metabolites|plasma levels of metabolites
41148104|NCT03398889|BEHAVIORAL|Dietary questionnaire|Harvard food frequency questionnaire
41148105|NCT03398889|DIAGNOSTIC_TEST|Intestinal microbiome|amplification and sequencing of 16S rRNA gene variable regions in stool samples
41148106|NCT03394508|DRUG|ALK Alutard birch or 5-grasses|Intralymphatic injection with 1000 units. 3 injections with 4-5 weeks interval (0,1 ml) and one additional booster injection with 1000 units before the second pollen season.
41468151|NCT02344745|OTHER|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
41468152|NCT06025552|DRUG|TU7710|In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1\~4 PK, PD, safety, and exploratory efficacy data.
40789536|NCT01087983|DRUG|Sirolimus|Starting oral dose 1 mg daily.
40789537|NCT01087983|DRUG|Metformin|Starting oral dose 1000 mg daily.
41309181|NCT05870644|OTHER|Cycling exercise in room temperature at 25 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 25 degree Celsius.
41309182|NCT05870644|OTHER|Cycling exercise in room temperature at 34 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 34 degree Celsius.
41309183|NCT03731364|DRUG|CA-008|5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)
41309184|NCT03731364|DRUG|Placebo|Placebo
41309185|NCT00900250|OTHER|Cytology Specimen Collection Procedure|Correlative studies
41468153|NCT06025552|DRUG|Normal saline|Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
41468154|NCT00686244|OTHER|Combined 3-monthly endurance and strength training|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
41309186|NCT06284018|OTHER|Progressive Muscle Relaxation Exercises|"* Focus on the targeted muscle group.~* Take a slow, deep breath while squeezing on muscle group as hard as she can (not to the point of strain). Keep the muscle tensed for 5 seconds.~Hands and arms, forehead ,Eyes and Cheek, Mouth and Jaw , Neck and Shoulder ,Stomach , Leg and Toes"
41309187|NCT06284018|OTHER|Pilates Exercises|Pilates exercise program consisted of floor exercises on a rubber mat, including the following exercises: a- Pelvic Curl. b- Single-Leg Lift. c- Chest Lift. d- Supine Spine Twist. e- Basic Back Extension.
41309188|NCT06166095|OTHER|high-dose|Participants will be asked to perform a high-dose (HD) (i.e., 300 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
41148107|NCT03394508|DRUG|ALK diluent 0,3% human albumin|Intralymphatic injection with 0.1 ml. 3 injections with 4-5 weeks interval
41148108|NCT01668498|DRUG|Erythromycin|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
41148109|NCT01668498|DRUG|Doxycycline|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
41309189|NCT06166095|OTHER|Walking attention control|The attention control group will be asked to wear the Fitbit activity tracker to monitor their sleep each night for 10 weeks.
41468155|NCT04005963|DIAGNOSTIC_TEST|13N-NH3 PET cardiac blood flow perfusion rest and load imaging|"Immediately after the bedside injection of 13N-NH3 370 MBq, dynamic 2D collection of heart images 10 min, scanning 1 bed; , a total of 6 min), 3min bedside injection 13N?NH3 370-540 MBq immediately after the dynamic 2D collection of heart image 10 min. Both rest and load imaging are corrected for CT attenuation.~Image reconstruction is carried out by the method of maximum expectation of an ordered subset, the dynamic image is divided into the early phase of the first 2 min and the late phase of the last 8 min, the captured image is replayed (VIP replay) of the volume image protocol and the gated data is reconstructed."
41468156|NCT02039063|DRUG|E6011 2 mg/kg|
41468157|NCT02039063|DRUG|E6011 5 mg/kg|
41468158|NCT02039063|DRUG|E6011 10 mg/kg|
40789538|NCT06041009|DIAGNOSTIC_TEST|Pancreatic elastase-1 in blood serum|Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.
41148110|NCT05911191|OTHER|Exercise based prehabilitation|A peripheral muscle strengthening program
41309190|NCT06166095|OTHER|moderate-dose|Participants will be asked to perform a moderate-dose (MD) (i.e., 150 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
41309191|NCT01485926|DRUG|Docetaxel, Carboplatin and Trastuzumab|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
41309192|NCT01485926|DRUG|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
41468159|NCT02039063|DRUG|E6011 15 mg/kg|
41468160|NCT04362332|DRUG|Chloroquine Sulfate|cluster randomized
41468161|NCT04362332|DRUG|Hydroxychloroquine|cluster randomized
41468162|NCT04362332|OTHER|Standard supportive care|cluster randomized
41468163|NCT06326034|DRUG|Dapagliflozin|Dapagliflozin 5 mg orally given once daily for four months.
41309193|NCT00536042|DRUG|Minocycline|addition of 150 mg to 250 mg po bid to standard asthma care regiment
41309194|NCT00132236|DRUG|nicotine sublingual tablets|
41309195|NCT00132236|BEHAVIORAL|low and high behavior support|
41309196|NCT03445858|DRUG|Pembrolizumab|Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
41309197|NCT03445858|DRUG|Decitabine|Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
41309198|NCT03445858|RADIATION|Hypofractionated Index Site Radiation|Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.
41309199|NCT05005741|DRUG|Beinaglutide|Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.
41309200|NCT05005741|DRUG|Dulaglutide|Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.
41309201|NCT01503073|DEVICE|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)|transcranial direct current stimulation
41309202|NCT06130852|BEHAVIORAL|Behavioral Parent Training|10 thematic sessions aimed at changing the parent's view of their child by encouraging them to focus on appropriate behaviors. The sessions focus on specific themes such as positive attention, the principle of reinforcement, or even homework management.
41309203|NCT02752529|DRUG|Tacrolimus（FK506）|
41309204|NCT03616665|OTHER|CBASPersonalized|"In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home.~Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented."
41309205|NCT05359016|BEHAVIORAL|HPV testing of women for cervical cancer screening|Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
41309206|NCT02508688|PROCEDURE|thoracoscopic diaphragmatic repair|patients with refractory hepatic hydrothorax (\> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
41309207|NCT04070352|DRUG|Fidaxomicin|patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI
41309208|NCT04378920|DRUG|LEAF-4L6715|LEAF-4L6715
41468164|NCT02452879|DEVICE|Electroacupuncture|For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.
40993535|NCT03966755|BEHAVIORAL|UFA dietary recommendations|The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA)), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
41309209|NCT01954303|OTHER|Progress of CHD|
41309210|NCT00005023|BIOLOGICAL|HER-2/neu peptide vaccine|
41309211|NCT00005023|BIOLOGICAL|sargramostim|
41309212|NCT02797704|DRUG|Aflibercept|Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
41309213|NCT02340988|DRUG|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
41309214|NCT02340988|DRUG|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
40993536|NCT03921697|DEVICE|Werable sensors|Parkinson Disease Patients monitored by werable sensors
41309215|NCT04596280|PROCEDURE|Colonic Resection|Resection of the colonic tract which has been interested by the acute diverticulitis
41309216|NCT02630082|PROCEDURE|Circumcision|
41309217|NCT02630082|PROCEDURE|Flexible sigmoidoscopy|
40993537|NCT06357533|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
40993538|NCT06357533|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
40993539|NCT06357533|DRUG|Pembrolizumab|Pembrolizumab IV (intravenous)
41309218|NCT03641209|DRUG|Paracetamol 10mg/mL infusion solution|Intravenous paracetamol solution for infusion
41309219|NCT03641209|OTHER|Placebo|Half physiological saline solution as the non-active placebo solution
41309220|NCT02500238|OTHER|Saliva sample|All participants will provide a saliva sample.
41309221|NCT02500238|OTHER|Urine Sample|All participants will provide a urine sample.
41309222|NCT02500238|OTHER|Toe nail clippings|All participants will provide toe nail clippings.
41309223|NCT02500238|OTHER|Breath carbon monoxide test|All participants will provide breath carbon monoxide tests
41309224|NCT03434964|DIAGNOSTIC_TEST|the intraoperative effectiveness of the AIFIB software in real time in the detection of atrial fibrillation drivers during an ablation procedure.|Real-time validation by an expert operator of the correct detection of atrial fibrillation driver
40993540|NCT06520709|OTHER|No intervention|No intervention
40993541|NCT03024307|OTHER|pharmacists involved OPCSP|This was an open labelled randomised study. Rheumatic diseases patients were recruited and arbitrarily divided into the intervention group (usual care plus OPCSP) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
40993542|NCT03849742|OTHER|Quality-of-Life Assessment|Ancillary studies
40993543|NCT03849742|OTHER|Questionnaire Administration|Ancillary studies
40993544|NCT03849742|PROCEDURE|Supportive Care|Receive Uber rides
40993545|NCT02093598|DRUG|Temsirolimus|
41148111|NCT04371445|DRUG|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
41148112|NCT04371445|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
41148113|NCT02683213|DRUG|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
41148114|NCT02683213|DRUG|Placebo|Matching placebo.
41148115|NCT03527329|DEVICE|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied following routine clinical practice. The pre-warming time will depend on the time the patient has to wait before entering in the operating room. Prewarming time will be recorded for each patient.
41148116|NCT04585048|BEHAVIORAL|Integrated Behavioral Therapy for Selective Mutism|Cognitive Behavioral treatment including 24 weekly sessions
41309225|NCT06295497|DEVICE|Lung-SIGHT|"* The LDCT images will be interpreted by an artificial intelligence-based programme (Lung-SIGHT) for lung nodules.~* LDCT with lung nodules ≥5mm detected by AI programme (AI+) will be sent for reporting by board-certified radiologists.~* Participants with abnormal LDCT reported by radiologists (Rad+) will be followed up at designated clinic. Management of lung nodules will follow the guidelines below for two years.~* Participants with negative LDCT determined by AI programme (AI-) will undergo LDCT thorax and blood taking two years later (T1). Patients with lung nodules detected by AI programme (AI+) will be sent for radiologist reporting and those with abnormal CT reported by radiologists (Rad+) will be followed up in lung nodule clinic as per standard of care. Patients with normal second-round LDCT as determined by AI (AI-) or radiologists (AI+ Rad-) do not require follow up."
41309226|NCT03744884|BEHAVIORAL|Force efforts with haptic feedback in virtual reality.|A virtual reality game-based intervention incorporating fully-automated robotic haptic feedback. The study consists of face-to-face assessments of movement before, after, and one-month following the completion of the six-session game-based intervention. Children with spastic/dystonic cerebral palsy between the ages of 7 and 17 will be recruited for this study along with a group of typically developing children in the same age range. Both groups of children will be randomly allocated into an intervention or control group using a blocked randomization method.
41309227|NCT01438749|DRUG|Placebo|Single dose
41488671|NCT06303973|DEVICE|IOE|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
40993546|NCT00001437|DRUG|pentoxifylline|
40993547|NCT02504567|DEVICE|Laser ablation|Pulmonary vein isolation using the laser ablation catheter
40993548|NCT02504567|DEVICE|RF ablation|Pulmonary vein isolation using the RF ablation catheter
41148117|NCT05377372|BEHAVIORAL|Breastfeeding support group|community-based breastfeeding support group aimed to increase exclusive breastfeeding success rates among Black women
41309228|NCT01438749|DRUG|RO4917838|Single doses (3 dose levels)
41309229|NCT01438749|DRUG|diazepam|Single dose
41309230|NCT00148733|DRUG|Zinc|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
41309231|NCT05781815|PROCEDURE|dynamic hip screw|using dynamic hip screw in treatment of trochanteric fracture and dynamic hip screw with trochanteric stabilizing plate
40993549|NCT05451979|DEVICE|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
40993550|NCT00699556|DRUG|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
40993551|NCT00699556|DRUG|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
40993552|NCT00699556|DRUG|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
40993553|NCT04222569|PROCEDURE|T-piece|Spontaneous breath trial with a T-piece
40993554|NCT04222569|PROCEDURE|PSV 7 and PEEP 0|Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure
40993555|NCT04222569|PROCEDURE|PSV 0 and PEEP 0|Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator
40993556|NCT04706143|BIOLOGICAL|COVID-19 Vaccines|different available vaccines: live inactivated, mRNA and viral vector vaccines
40993557|NCT01544751|DRUG|Low dose metformin|500 mg twice a day
40993558|NCT01544751|DRUG|Metformin|1000 mg twice a day
41309232|NCT03391687|DIAGNOSTIC_TEST|Amylase Test|body fluid amylase will be tested after radical gastrectomy in scheduled interval
41309233|NCT03516617|DRUG|Acalabrutinib|Given PO
41309234|NCT03516617|OTHER|Laboratory Biomarker Analysis|Correlative studies
41309235|NCT03516617|BIOLOGICAL|Obinutuzumab|Given IV
41309236|NCT03516617|OTHER|Patient Observation|Undergo observation
41309237|NCT03516617|OTHER|Quality-of-Life Assessment|Ancillary studies
41309238|NCT03374748|OTHER|N/A - observational study|N/A - observational study
41309239|NCT05167500|DRUG|Lorlatinib|"No treatment will be administered to the patient as an active treatment of this study. Only retrospective data about the patients treated in the compassion use program of Lorlatinib will be collected. The information below is related to Lorlatinib, target drug for the collection of data.~Lorviqua 25 mg film-coated tablets.The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. Dosing interruption or dose reduction may be required based on individual safety and tolerability.Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily."
41309240|NCT02667860|PROCEDURE|Intracorporeal anastomosis.|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
41309241|NCT02667860|PROCEDURE|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.
41309242|NCT02667860|DEVICE|Echelon Endopatch|Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.
41309243|NCT02667860|DEVICE|Proximate Linear Cutter|Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
41309244|NCT04762108|OTHER|Standard of care|Patients will be given standard of care as per their clinical needs
40993559|NCT01544751|DRUG|Atorvastatin|20 mg/day
40993560|NCT02704078|DEVICE|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
40993561|NCT02704078|DEVICE|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
40993562|NCT01516944|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
40993563|NCT01516944|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
40993564|NCT01516944|DRUG|Oxaliplatin; Capecitabine|Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
40993565|NCT03155074|BEHAVIORAL|High-intensity training|The exercise program will include a cardiovascular warm-up, high intensity interval training and progressive resistance training (PRT). The intervention will focus on high-intensity training, mainly by uphill walking on a treadmill at 80-95 % of the maximal heart rate and PRT in three series at 6-12 RM by leg press, chest press, back extension, seat row, and front raises. During the first four weeks, the patients will be introduced to the program while focusing on safety, techniques and familiarization. The endurance intensity and strength load will then continuously increase based on the patients' improvement, tolerance of dyspnea, and feelings of well-being or fatigue on each exercise day.
40993566|NCT03384121|DRUG|Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension|Starting Dose (V2): 5 mg/kg/day (max 600mg/day) orally for 2 months followed by a 2 month washout period V4: After washout period, only Non-responders will escalate dose to 10 mg/kg/day (max 600mg/day) orally for 2 months
40993567|NCT06302192|DIAGNOSTIC_TEST|ARDS+AKI|according to the clinical practice Reanl doppler and VeXUS score will be performed
40993568|NCT06304090|BEHAVIORAL|routine rehabilitation treatment|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
41148118|NCT05377372|OTHER|Observation|Observe prospectively for breastfeeding initiation, duration and longitudinal health of child with sickle cell disease
41309245|NCT00846261|DEVICE|Use it to treatment bone nonunion (Ilzarov)|Detect the variation of limb lengthening
41309246|NCT01972880|DRUG|ASP1941|Oral
41309247|NCT00139334|BIOLOGICAL|Rotavirus|
41309248|NCT03768830|BEHAVIORAL|Exercise training|Exercise program includes breathing and upper and lower limbs exercise.
41309249|NCT06555237|DRUG|Trametinib tablet|Trametynib orally once daily in 0,025mg/kg dose
41468165|NCT02452879|DEVICE|Sham Electroacupuncture|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
41468166|NCT02452879|DRUG|Solifenacin Succinate|made by the Anse Tailai Pharmaceutical (China) R \& D limited company) 5mg / tablet
41468167|NCT00894933|DEVICE|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
41468168|NCT01047891|DRUG|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
41468169|NCT04849364|DRUG|Capecitabine|Capecitabine 1000 mg/m2 BID Orally 14 days on and 7 days off Cycle = 21 days; Total of 8 cycles
41468170|NCT04849364|DRUG|Talazoparib|Talazoparib Cycle 1: 0.75 mg then Cycle 2-8: 1 mg Cycle = 21 days; Total of 8 cycles
41468171|NCT04849364|DRUG|Pembrolizumab|Per standard of care.
41468172|NCT04849364|DRUG|Inavolisib|Inavolisib Cycle 1: 6 mg then Cycle 2-8: 9mg Orally 21 days on Cycle = 21 days; Total of 8 cycles
41468173|NCT01416116|DRUG|QUTENZA|topical
41468174|NCT01416116|DRUG|Lidocaine|topical
41468175|NCT01416116|DRUG|Tramadol|oral
40993569|NCT06304090|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41468176|NCT04502498|DIAGNOSTIC_TEST|Lower limb duplex & doppler|Lower limb duplex and doppler one week before radical cystectomy
41468177|NCT04328870|OTHER|oxytocin and spinal anesthesia|start oxytocin 10 IU/200 ml saline at the insertion of the spinal anesthesia
41468178|NCT04328870|OTHER|General anesthsia|General anesthesia alone.
41468179|NCT03242616|DRUG|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 \& 8)~* Pemetrexed (500 mg/m2, day 1)"
40993570|NCT06304090|DRUG|Lidocaine Hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40993571|NCT00859235|DRUG|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
40993572|NCT00859235|OTHER|Plain water|Mouth wash prior to procedure
40993573|NCT04619524|DIAGNOSTIC_TEST|Cervical mucus will be collected from patients undergoing IVF|Patients undergoing hormonal stimulation for IVF will be sampled for cervical mucus.
40993574|NCT04619524|DIAGNOSTIC_TEST|Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos|Patients undergoing hormonal substitution for transfer of cryopreserved embryos will be sampled for cervical mucus.
41468180|NCT03242616|DRUG|Vinorelbine|Vinorelbine (25 mg/m2, day 1 \& 8)
41468181|NCT04972331|PROCEDURE|Arthroscopic Partial Meniscectomy|"Arthroscopic partial meniscectomy was performed by three senior surgeons using two standard portals, no outflow cannula, a 5.5-mm 30° arthroscope, and a pressure-controlled irrigation system.~A standard surgical protocol was used to document possible findings in the cartilage, ligaments, synovium, and medial and lateral meniscus. In each case, surgery was limited to resection with limited debridement of the articular surface lesion, preserving as much of the meniscus as possible. Patients who underwent additional procedures, such as removal of loose bodies or subchondral drilling for any articular lesions, were excluded from this study (Figure 1). No patients underwent total meniscectomy or meniscal repair."
41468182|NCT04972331|PROCEDURE|Platet- Rich-Plasma|Peripheral venous blood was collected from all patients, which was then centrifuged to isolate red blood cells from the upper plasma layer. We used the Arthrex® kit APC®. The upper plasma layer was carefully collected with a serological pipette and placed in a new centrifuge tube or set aside for injection. The 5 mL remaining upper plasma layer was centrifuged again to separate platelet-poor plasma from PRP for 7 min. We activated the PRP sample by adding calcium chloride through ultraviolet irradiation, and then a 4- to 8-mL sample was used for two injections. One injection was performed intra-articularly with a supero-lateral approach. One ultrasound-guided injection was performed at the meniscal wall. Our protocol allowed us to have \< 1% blood cells and \<1% white cells in the injection.
41468183|NCT04972331|OTHER|Post-intervention|All patients were discharged the day after surgery with no limitation of mobility but with restrictions on sports for four weeks. Interruption of work was given for 10-45 days. The same analgesics and NSAIDs were administered in both groups for two weeks. All patients then received a rehabilitation program conducted by a physiotherapist, using the same protocol as in the PRP group for four weeks.
41468184|NCT05795231|DEVICE|Macintosh Laryngoscope Vs Video Laryngoscope|Evaluate incidence of first trial success and complications
41468185|NCT00891098|BEHAVIORAL|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
40993575|NCT01145768|DRUG|TC-5214|4 mg tablet, oral, BID, group 1
40993576|NCT01145768|DRUG|TC-5214|TBD tablet, oral, BID, groups 2-6
40993577|NCT01145768|DRUG|Placebo|
40993578|NCT01860755|OTHER|Control postural education, general range of motion and strengthening in addition to the standard of care|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
41309250|NCT06555237|DRUG|Standard therapy|Disopiramide and Beta blockers orally
41468186|NCT00891098|BEHAVIORAL|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
40993579|NCT01860755|OTHER|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
40993580|NCT03486093|DEVICE|"Training and retraining to GAVECELT bundle recommendations plus port protector"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.~After the first training meeting, the use of Curos® Disinfecting Port Protector for needleless valves port-protector has been introduced."
40993581|NCT03486093|BEHAVIORAL|"Training and retraining to GAVECELT bundle recommendations"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed."
40993582|NCT05749198|DIAGNOSTIC_TEST|MRE|MRE was performed using a 3T system (Magnetom Skyra; Siemens, Erlangen, Germany) equipped with a combination of a 30-channel body and a 32-channel spine matrix coil.
40993583|NCT06504199|DRUG|Obinutuzumab|No dose adjustment of Obinutuzumab is allowed.
40993584|NCT06504199|DRUG|Zanubrutinib|Zanubrutinib was allowed to be titrated to 80 mg bid or 80 mg qd
40993585|NCT06504199|DRUG|Lenalidomide|Lenalidomide was allowed to be titrated to 15 mg/day (induction phase) or 5 mg/day (maintenance phase).
40993586|NCT06504199|DRUG|Cytarabine|The specific dose is determined by the investigator according to the actual situation of the patient.
40993587|NCT06504199|BIOLOGICAL|CAR-T|zanubrutinib in combination with lenalidomide was allowed for maintenance treatment in high-risk patients for 1 year and zanubrutinib for 2 years after recovery of hemogram 2 months after CAR-T. High-risk Patients with any of the following conditions: Mantle cell lymphoma International Prognostic Index (MIPI-c) high-risk, blastic/pleomorphic type, TP53 mutation/deletion, CDKN2A deletion, MYC amplification/translocation, or incomplete response at induction stage; Non-high-risk group: no high-risk features.
40993588|NCT05858346|BEHAVIORAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
40993589|NCT05858346|BEHAVIORAL|Cognitive Behavioral Therapy for Social Anxiety Disorder|To provide an evidence-based comparison for the TBT condition, the research-supported psychological treatment of CBT for SAD will be used. CBT for SAD demonstrates efficacy in improving SAD symptoms and quality of life for patients with SAD, with durable improvements evidenced at follow-up assessments. CBT for SAD was used as a comparison to TBT in previous preliminary research. CBT for SAD involves several primary components, including: 1) psychoeducation, 2) training in cognitive restructuring, 3) exposures, 4) advanced cognitive restructuring, and 5) termination.
40993590|NCT05718232|DRUG|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients ≥ 60kg)
41309251|NCT02037802|DEVICE|B-Braun, Perifix® ONE Paed, Germany|caudal epidural catheterization bupivacaine fentanyl
41309252|NCT02037802|DRUG|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
41468187|NCT03917355|BEHAVIORAL|Nonverbal synchrony, therapeutic alliance|Association between motor synchronisation in psychiatrist/patient dyad and patient therapeutic adherence in patients with a first psychotic episode will be measured, 6 months after the first post hospitalisation consultation, using video without sound. Nonverbal synchrony, therapeutic alliance and treatment will evaluated.In this purpose, videos of patients and psychiatrist will be made (for all patients included), and the images will be analyzed.
41468188|NCT00625326|DRUG|COL-121|75 µg/g COL-121 Ointment
41468189|NCT00625326|DRUG|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment
41468190|NCT00625326|DRUG|Placebo|Placebo
41309253|NCT02037802|DRUG|Propofol|fentanyl propofol atracurium besylate
41309254|NCT02037802|DRUG|Bupivacaine|
41309255|NCT02037802|DRUG|Fentanyl|
41309256|NCT02263482|OTHER|control|No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation
41468191|NCT00625326|DRUG|COL-121|150 µg/g COL-121 Ointment
40993591|NCT05718232|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
40993592|NCT05718232|RADIATION|SBRT|SBRT will be given within 3 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-5000 cGy in 5-8 fractions.
41309257|NCT02263482|OTHER|moderate-intensity group|Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).
41309258|NCT02263482|OTHER|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
40993593|NCT06496009|DRUG|PD-1 Inhibitors|advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice
40993594|NCT02486042|DRUG|Omegaven|Infants will receive nutritional supplementation with omega-3 fatty acids (omegaven).
40993595|NCT02486042|DIETARY_SUPPLEMENT|Standard lipids (primarily omega-6 fatty acids)|Infants will receive nutritional supplementation with standard intralipid, composed primarily of omega-6 fatty acids.
40993596|NCT05591326|PROCEDURE|i-PRF application procedure|Local anesthesia will be applied to the area with gingival recession. Before the procedure, the venous blood taken from the patient will be centrifuged at 700 RPM for 3 minutes in glass and non-addition tubes to obtain i-PRF. i-TZF will be taken into a 2 cc injector. In 2020, Özsağır et al. Decortication, that is, microneedling, will be performed with insulin needle tips according to the protocol defined by Dr. Then the prepared i-PRF will be infected to the apical mucogingival junction of the keratinized gingival area. This process will be repeated once a month for 3 months. After the 3rd month, the horizontal and vertical gingival recession values will be evaluated and recorded at the end of 6 months and 1 year.
40993597|NCT03022292|DRUG|Aflibercept Ophthalmic|IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC
40993598|NCT03022292|DEVICE|optovue angiovue|FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
40993599|NCT02877277|DIETARY_SUPPLEMENT|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
40993600|NCT02877277|DIETARY_SUPPLEMENT|Placebo|Oral intake of placebo tablet daily for 56 days
40993601|NCT01241903|DRUG|rosuvastatin|Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
40993602|NCT01241903|DRUG|placebo|frequency and duration
40993603|NCT06524310|DEVICE|Stimulation with low frequency rTMS at 1 Hz|Stimulation with low-frequency rTMS at 1 Hz with 90% MT will be applied with a total of 180 pulses each time, which contained 18 trains with ten pulses and an interval of 20 s between any two adjacent trains. The TMS treatment course will be administered twice per week for 9 weeks; the first six treatments will be over the left DLPFC, the second six sessions will be over the right DLPFC, and the remaining six times will be placed on the bilateral DLPFC stimulation (64).
40993604|NCT05289323|DRUG|Neostigmine Methylsulfate|0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
40993605|NCT05289323|DRUG|Dextrose 5%/Nacl 0.9% Inj|one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
40993606|NCT00704028|DRUG|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
40993607|NCT00704028|DRUG|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
41309259|NCT04004533|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
41309260|NCT02021526|DRUG|Triheptanoin|Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
41309261|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS A|High-whey protein, leucine-rich, low-caloric ONS in powder format
41468192|NCT00625326|DRUG|COL-121|300 µg/g COL-121 Ointment
41468193|NCT02043158|BEHAVIORAL|Questionnaire|Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
41468194|NCT02043158|BEHAVIORAL|Interview|Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
41309262|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS B|High casein-protein, low-caloric control product (isocaloric to product A)
41309263|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS C|High casein-protein, high-caloric control product.
41309264|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS D|high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
41309265|NCT02919488|OTHER|Exercise Condition|A bout of exercise in the evening followed by high-sugar meal consumption the following morning
41309266|NCT02919488|OTHER|Control Condition|Rest in the evening followed by high-sugar meal consumption the following morning
41309267|NCT03150095|BEHAVIORAL|Health coaching|Patients will work with a health coach by telephone
41309268|NCT04949841|DRUG|Delgocitinib|Delgocitinib cream 20 mg/g
41309269|NCT03605719|DRUG|Carfilzomib|Given IV
41309270|NCT03605719|DRUG|Dexamethasone|Given IV
41309271|NCT03605719|BIOLOGICAL|Nivolumab|Given IV
41309272|NCT03605719|BIOLOGICAL|Pelareorep|Given IV
41148119|NCT06057701|OTHER|corrective exercises|"corrective exercises:~1. Strengthening exercises :~   1. Thoracic extension exercises:~      * Mckanzie's thoracic extension exercise:~     * Thoracic spine stretching position~  2. Back extension exercise~  3. Abdominal curl up exercise~  4. Scapular retraction exercises~  5. Trunk rotation exercise~2. Stretching exercises:~   1. Pectoral muscles stretch from sitting~  2. self-stretch for pectoral muscle infront of door"
41309273|NCT03765619|DRUG|Aspirin|250 patients will be randomized to receive postoperative Aspirin.
41309274|NCT01680588|DRUG|[18F]NAV4694|
41309275|NCT02147704|DIETARY_SUPPLEMENT|High-sodium diet|"1. One of high- or low sodium intake for 7 days during each period~2. High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets"
41309276|NCT02147704|DIETARY_SUPPLEMENT|low-sodium diet|"1. One of high- or low sodium intake for 7 days during each period~2. Low sodium intake : 50 mmol/day by diet"
41309277|NCT05037097|BIOLOGICAL|ARCT-165|Dose 3
41309278|NCT05037097|BIOLOGICAL|ARCT-154|Dose 2
41309279|NCT05037097|BIOLOGICAL|ARCT-021|Dose 1
41309280|NCT04260334|OTHER|Preoperative Education|The first two hours after the hospitalization of the patient will be met and the aim of the study will be explained. On the same day, the patient will be given breathing and relaxation exercises and explained why it is important. On the second day after the hospitalization, the patient will be evaluated and the previous day's exercises will be repeated and leg exercises will be performed. The importance of mobilization will then be highlighted. the same day gradual relaxation exercise and surgical relaxation will be administered to the patient three times. The patient will be evaluated on the first postoperative day.
41309281|NCT05007249|PROCEDURE|Use of the Chalaxie pedagogical evaluation tool|Use of the Chalaxie pedagogical evaluation tool during two visits
41309282|NCT00459485|DIETARY_SUPPLEMENT|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
41309283|NCT00459485|DIETARY_SUPPLEMENT|Placebo|Daily placebo for 3 weeks
41309284|NCT02742922|BEHAVIORAL|Culturally adapted therapy (C-MAP)|C-MAP is a brief problem focused therapy, comprising of six sessions delivered within three months. C-MAP is a manual assisted intervention based on the principles of CBT .In this intervention there is an evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies.
41309285|NCT03779035|DRUG|Gemcitabine|1000mg/m2
41309286|NCT03779035|DRUG|Capecitabine|1250mg/m2
41309287|NCT00294502|DRUG|Gentamycin/citrate, Minocycline/EDTA|
41309288|NCT01522040|DRUG|Magnesium Sulfate|Continuous magnesium drip, titrated to effect until patient's symptoms improve
41309289|NCT01522040|DRUG|Placebo|Simple saline drip, without active drug
41309290|NCT06553443|DEVICE|Angioplasty of all peripheral AVF stenosis|All peripheral AVF stenosis are to be treated with the same type of balloon depending on allocation
41309291|NCT01504854|DRUG|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
41309292|NCT01504854|DRUG|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
41309293|NCT03036332|BEHAVIORAL|Aerobic interval training|Carried out 3 times per week for 16 weeks
41309294|NCT01790971|DRUG|Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
41309295|NCT01790971|DRUG|No Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
41309296|NCT02864537|OTHER|Training|Patients were trained to measure INR and dose warfarin
41309297|NCT04173442|DRUG|dupilumab|Dupilumab cohort
41309298|NCT05698277|DIAGNOSTIC_TEST|Automated fetal cardiac function evaluation|"Evaluation of ultrasound parameters by automated algorithms.~Ultrasound assessed parameters are:~1. Pulsed wave Doppler Modified Left and Right Myocardial performance indices~2. Spatio-temporal image correlation Tricuspid, Mitral and Septal Annular Plane Systolic Excursion"
41309299|NCT03785886|BEHAVIORAL|Walking group|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β-blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
41309300|NCT03785886|BEHAVIORAL|Chinese square dancing group|"Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study.~Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13."
41468195|NCT01583634|DEVICE|Mespere Oximeter|Mespere oximeter provides non-invasive venous blood oxygen saturation.
41468196|NCT01583634|DEVICE|Radiometer OSM-3 Co-Oximeter|OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
40993608|NCT01540708|DRUG|SERETIDE Rotacaps|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
41468197|NCT01694082|BEHAVIORAL|THRIVE|THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
41468198|NCT01694082|BEHAVIORAL|Brief brochure and assessment control|
41148120|NCT06057701|OTHER|resisted diaphragmatic breathing exercises|"1. Diaphragmatic breathing exercise: From the supine position, overlapping hands on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly.~2. Resisted diaphragmatic breathing exercise: From the supine position, with a weight of 1 kg on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly"
41148121|NCT03858556|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
41148122|NCT03858556|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
41148123|NCT03858556|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
41148124|NCT03858556|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
41148125|NCT03858556|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41148126|NCT03858556|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41309301|NCT03785886|BEHAVIORAL|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
41309302|NCT06552312|OTHER|Delphi Questionnaire|"Experts will be asked to rate the importance of each item for ECPR for OHCA using the Grading of Recommendations Assessment, Development and evaluation scale from 1 (strongly disagree) to 9 (strongly agree). The median score (IQR) will be calculated after eliminating one lowest and one highest value after each survey round. Statements will be classified as strong agreement (median score 7-9), neither agree or disagree (median score 4-6), or strongly disagree (median score 1-3). Panel members were also provided an Unable to Score response to use if they did not feel comfortable rating any specific domain. Recipients will be asked to recommend any wording/phrasing changes and to suggest any additional items for inclusion."
41309303|NCT05625386|DEVICE|transcranial magnetic stimulation|TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).
41468199|NCT05532007|DIETARY_SUPPLEMENT|Peanuts|2-3 ounces of peanuts to replace 20% of total daily energy intake
41468200|NCT05532007|OTHER|Habitual Diet|continue with habitual diet and abstain from eating peanuts
41468201|NCT04593147|OTHER|BBN|BBN to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
41468202|NCT04593147|OTHER|Brand|Brand to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks
41468203|NCT04789967|BEHAVIORAL|Guided Imagery|Individualized Guided Imagery (GI) technique, an alternative type of relaxation therapy. The content of GI usually includes scenery, places or any image projected to the mind. By using information generated, participants are guided to create a place in their mind using their senses of touch, sound, smell, sight and taste.
41148127|NCT03858556|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
41148128|NCT03858556|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
41468204|NCT04789967|BEHAVIORAL|Progressive Muscle Relaxation|Progressive muscle relaxation (PMR) therapy works by progressively relaxing and tensing the muscle groups throughout the entire body. Each muscle group will be tensed for about 5 seconds. If there's any pain or discomfort at any of the targeted areas, participants were told to omit that particular step. Constant purposeful deep breathing was instructed throughout the session especially in between changes of muscle.
41468205|NCT04789967|OTHER|Educational Audiobook|Participants in the control group will receive an audiobook that targets to educate patients regarding gut-brain disorders, functional gastrointestinal disorders, causes of functional abdominal bloating, and treatment modalities available. Relaxing musical background will be added to facilitate the delivery.
41468206|NCT00732160|DRUG|Aldosterone infusion (A)|Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
41468207|NCT00732160|DRUG|Vehicle Infusion (V)|Vehicle infusion for 12.5 hours
40993609|NCT01540708|DRUG|SERETIDE Diskus|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
41468208|NCT00732160|OTHER|High Sodium Diet (HS)|160 mmol/d sodium diet for 7 days
41468209|NCT00732160|OTHER|Low Sodium Diet (LS)|20 mmol/d sodium diet for 9 days
41468210|NCT01347320|OTHER|Preoperative MRI|Preoperative staging
41309304|NCT02078713|BEHAVIORAL|Contraceptive Decision Support Tool|"The decision support tool:~* Provides an educational session about different aspects of contraception~* Elicits patient preferences about different aspects of contraception~* Identifies potential contraindications to certain contraceptive methods~* Allows the patient to view details about and compare available contraceptive methods~* Suggests methods most appropriate based on the patient's preferences~* Collects questions the patient may have for her provider~* Generates a printout the patient can bring to her contraceptive counseling visit"
41309305|NCT00753935|DRUG|enteric-coated aspirin|enteric-coated aspirin 81mg daily for 2 weeks
41309306|NCT00753935|DRUG|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
41341705|NCT02782247|DEVICE|Indocyanine Green excretion|The machine to monitor the elimination of Indocyanine green is manufactured by PULSION medical systems (Munich, Germany) and consists of the PulsioFlex monitor and LiMON module. The LiMON module is a finger probe which measure near-infrared wavelengths between 805nm and 905nm. The absorption maximum for Indocyanine green is 800nm and emission at 830nm. This is then used to produce two calculations. The first is plasma disappearance rate of indocyanine green (PDRICG). This is based on working out the constant and backward extrapolation and expressed as a percentage per minute. The other is the retention ratio after 15 minutes (ICG15).
41341706|NCT05254925|DRUG|Sunscreen oil with 6% Bemotrizinol|Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
41468211|NCT01601938|DIETARY_SUPPLEMENT|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
41468212|NCT01601938|DIETARY_SUPPLEMENT|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
41468213|NCT00952224|OTHER|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
41468214|NCT04086524|OTHER|Binocular cartoon treatment at home|see arm description.
41468215|NCT04086524|OTHER|Patching|see arm description
41468216|NCT04086524|OTHER|Binocular cartoon treatment in office|see arm description.
41468217|NCT04458558|DRUG|Mifepristone|Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
41468218|NCT04438850|DRUG|Ivermectin|Patients will be administered a single oral daily dose of approximately 600 μg/Kg (486-679 μg/Kg as rounded to a whole number of tablets), or 1200 μg/Kg (1098-1286 μg/Kg).
41468219|NCT04438850|OTHER|Placebo|Patients should take placebo orally on an empty stomach with water
41468220|NCT02495532|OTHER|Lymph node clearing technique with Carnoy solution|"Procedure: lymph node clearing technique with Carnoy solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
41468221|NCT02495532|OTHER|Lymph node clearing technique with GEWF solution|"Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
40789539|NCT06522477|OTHER|Virtual reality gait training|Individuals will walk on a treadmill with overhead harness system in place while viewing 1st-person perspective walking videos on a television placed immediately in front of the treadmill.
41468222|NCT02274948|DRUG|Metformin|Metformin in the form of 500mg tablets were administer to the Metformin group
41468223|NCT02274948|DRUG|Placebo|A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
41468224|NCT05527158|BEHAVIORAL|Yi Jin Jing exercise|Yi Jin Jing of The General Administration of Sport of China, which consists of twelve operational processes as the standard intervention
41468225|NCT03840499|DRUG|Optimal medical therapy|Optimal medical therapy
41468226|NCT04454528|RADIATION|Hypofractionated radiotherapy|Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14
41468227|NCT04454528|DRUG|Pembrolizumab infusion|Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.
41468228|NCT04454528|PROCEDURE|Blood and tissue sampling|Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
41468229|NCT05016934|BIOLOGICAL|A vaccine composed of a recombinant S1 antigen|Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein
41468230|NCT02997722|DRUG|Ketamine|IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.
41468231|NCT02997722|DRUG|Normal Saline|IV infusion of 100 ml of normal saline over 45 minutes.
41468232|NCT01159106|OTHER|Pressure Support Ventilation|Spontaneous mode of ventilation whereby the patient initiates the breath and the ventilator delivers support with the preset pressure value
41468233|NCT01159106|OTHER|Neurally adjusted ventilatory assist (NAVA)|"Gas delivery from the mechanical ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi).~The ventilator is aware of the change in diaphragmatic EMG by the insertion of a specially designed nasogastric tube with EMG electrodes that cross the diaphragm."
41468234|NCT01629537|PROCEDURE|Stellate Ganglion Block injection with ropivicane|For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.
41341707|NCT05254925|OTHER|Sunscreen oil vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
41341708|NCT05254925|DRUG|Dispersion of 6% BEMT in petrolatum|Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
41341709|NCT05254925|OTHER|Petrolatum vehicle|Petrolatum vehicle
41468235|NCT01629537|PROCEDURE|Placebo Procedure|In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
41468236|NCT00814606|DRUG|Fluvastatin|Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
41468237|NCT00814606|DRUG|Peginterferon alfa2a|180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
41468238|NCT00814606|DRUG|ribavirin|1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
41468239|NCT00225563|DEVICE|Electronic Health Record|e-prescribing methods
41468240|NCT04158635|DRUG|Bosentan|Given PO
41468241|NCT04158635|DRUG|Gemcitabine|Given IV
41468242|NCT04158635|DRUG|Nab-paclitaxel|Given IV
41468243|NCT04158635|OTHER|Quality-of-Life Assessment|Ancillary studies
41468244|NCT04158635|OTHER|Questionnaire Administration|Ancillary studies
41468245|NCT00670241|DRUG|calcipotriol and betamethasone (LEO 80185 gel)|Once daily application
41468246|NCT00670241|DRUG|LEO 80185 vehicle|Once daily application
41468247|NCT00670241|DRUG|Tacalcitol ointment|Once daily application
41468248|NCT03527654|OTHER|Observational|Surveys, blood and urine collected prospectively over 24 months.
40789540|NCT03102294|OTHER|inspiratory muscle training|inspiratory muscle training with 50% of MIP
40789541|NCT03102294|OTHER|"Placebo training"|placebo training with PowerBreathe (without inspiratory load)
40789542|NCT04877678|DRUG|Bepotastine|10 mg Bepotastine, twice a day
40789543|NCT04877678|DRUG|Placebo|Identical looking placebo, twice a day
40789544|NCT04978493|DRUG|BI 706321|BI 706321
40789545|NCT04978493|DRUG|ustekinumab|ustekinumab
40789546|NCT04978493|DRUG|Placebo|Placebo
41341710|NCT03890497|BIOLOGICAL|IPV|The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally
40789547|NCT02745496|PROCEDURE|TRUS Biopsy|Standard of Care Treatment
40993610|NCT03842384|BEHAVIORAL|iENDURE|The proposed intervention will initially target motivational processes in combination with introductory strategies for managing physical and emotional distress through a single, brief, computer-delivered session followed by eight weeks of theoretically-informed text messages intended to enhance motivation and promote distress tolerance.
40993611|NCT00278954|BIOLOGICAL|Gammaplex (Intravenous immunoglobulin)|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
40993612|NCT02251951|DRUG|nab-Paclitaxel|Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
40993613|NCT00842660|DRUG|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
40993614|NCT00006101|DRUG|eflornithine|Take 500mg of DFMO per day for 12 months
40993615|NCT00006101|DRUG|Placebo|Take placebo per day for 12 months
40993616|NCT01755923|DRUG|Gefitinib|Gefitinib 250mg once per day until the progression disease or intolerant side effects
40789548|NCT02745496|PROCEDURE|TRUS/FUSION Biopsy|Interventional Treatment
40789549|NCT00881985|DEVICE|continuous positive airway pressure|Use CPAP whenever sleep
40993617|NCT01755923|DRUG|Docetaxel|Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
40993618|NCT05272904|PROCEDURE|Quilting|Following mastectomy and/or axillary lymph node dissection, the subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin.
40993619|NCT05272904|PROCEDURE|Conventional wound closure|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
40993620|NCT05409781|OTHER|No Intervention|No Intervention
40993621|NCT00283933|DRUG|migalastat HCl|
40993622|NCT01758653|OTHER|No study intervention|There is no study-related intervention.
40993623|NCT03189615|DRUG|Lu AF35700|Single oral dose of 10 mg Lu AF35700
40993624|NCT03145168|OTHER|High Target Mean Arterial Pressure|High target group (80-85 mm of Hg).
40993625|NCT03145168|OTHER|Low Target Mean Arterial Pressure|Low target MAP group (60-65mm Hg).
40993626|NCT04264910|BEHAVIORAL|Calm App|Calm is a subscription-based meditation app which provides guided meditations, sleep stories, soundscapes and calming music. Calm offers 7 Days of Calm for those new to meditation, the daily Calm, a meditation posted daily and a library of unique 10-12 minute meditations with topics related to acceptance, anxiety, self-compassion, and physical pain (to name a few).
40993627|NCT02062333|DRUG|Dexmedetomidine|1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion
41341711|NCT02748278|PROCEDURE|Transvaginal ultrasound-guided oocyte retrieval|Transvaginal ultrasound-guided oocyte retrieval will be performed 34-36 hours after hCG injection.
40789550|NCT05353686|DRUG|Placebo|Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
40789551|NCT05353686|DRUG|XEN-D0501|Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily
41341712|NCT02748278|PROCEDURE|Embryo transfer|One or two embryos will be replaced on day 2-5 after oocyte retrieval.
40789552|NCT03814356|DRUG|Methylphenidate|IV MPH
40993628|NCT02062333|DRUG|esmolol|500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
40993629|NCT01066988|OTHER|ORB Ocular Emulsion|lubricant eye drop
40993630|NCT01066988|OTHER|SootheXP Emollient (Lubricant) Eye Drops|lubricant eye drop
40993631|NCT03469479|DRUG|FOLFOX|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
40993632|NCT03469479|PROCEDURE|Hepatic resection|R0 resection
40993633|NCT03754712|DIETARY_SUPPLEMENT|Vitamin D3|Dietary supplement : Vitamin D3 one tablet of vitamin D3 (2000IU) per day for 8 weeks
40993634|NCT04477343|DRUG|SX-682|Allosteric inhibitor to human CXCR1 and CXCR2 receptor
40993635|NCT04477343|DRUG|Nivolumab Injectable Product|humanized monoclonal antibody to program cell death receptor 1 (PD1)
40993636|NCT03084887|BEHAVIORAL|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
40993637|NCT00789893|DEVICE|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis \& assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st \& 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, \& the 2nd will be one month ± 2 weeks from last day of radiation.
40789553|NCT05756023|PROCEDURE|the pregnancy rate at IVF / ICSI cycles|To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
40789554|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 1|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
40789555|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 2|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
40789556|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 3|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
40789557|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 4|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
40789558|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 5|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
40789559|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 1|Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
40789560|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 2|Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
40789561|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 3|Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
40789562|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 4|Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
40789563|NCT00143000|DRUG|Peginterferon alfa-2a 40KD and Ribavirin|
40789564|NCT00825994|DRUG|Omega-3 Fatty Acids|2 g omega-3 fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), PO \[by mouth\], qd \[every day\]
40789565|NCT02315703|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
40789566|NCT02315703|BIOLOGICAL|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
40789567|NCT02315703|BIOLOGICAL|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
40789568|NCT02315703|BIOLOGICAL|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
40789569|NCT02315703|DRUG|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
40789570|NCT00712387|BEHAVIORAL|LapSim simulator|Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
40789571|NCT01396590|DRUG|Perampanel|6 x 2 mg perampanel once per day
40789572|NCT01396590|DRUG|Perampanel|12 mg perampanel once per day
40789573|NCT03328832|DRUG|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule
40789574|NCT03328832|DRUG|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
40789575|NCT03328832|DRUG|rivaroxaban (10mg)|Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
40789576|NCT00980148|DRUG|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
40789577|NCT00980148|DRUG|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
40789578|NCT04765566|DEVICE|Endovascular revascularization of peripheral arteries|Endovascular revascularization of peripheral arteries involves placement of a self-expanding Nitinol Stent encapsulated with ePTFE in diseased vessel segments
40789579|NCT05895097|DEVICE|Left bundle branch pacemaker|Left bundle branch pacing (LBBP) will be the pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Final lead position will be confirmed according to ECG parameters. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory.
40789580|NCT05895097|DEVICE|Conventional pacing|Right ventricular pacing in patients with LVEF ≥ 40% and cardiac resynchronization therapy in patients with LVEF \< 40 %
40789581|NCT01918241|DRUG|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
40789582|NCT01918241|DRUG|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
40789583|NCT01918241|DRUG|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
40789584|NCT01918241|DRUG|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
40789585|NCT06007677|DRUG|STAR-0215|STAR-0215 will be administered as a subcutaneous injection.
40789586|NCT04570618|DEVICE|Unblinded AlgoDx Sepsis Prediction Algorithm|When applicable, a sepsis prediction alert is displayed in the AlgoDx Medical Device Software.
40789587|NCT04570618|OTHER|Blinded AlgoDx Sepsis Prediction Algorithm|Standard of Care, i.e. no sepsis prediction alert.
40993638|NCT03822247|PROCEDURE|Multidisciplinary Recovery Program|"Preoperative care:~* Patient's education~* Providing respiratory training~* Assessment of nutritional status~* Application of compression stockings~* Thromboembolism prophylaxis by low molecular weighted heparin~* Induction of hemodynamic support 12 hours before the surgery~* Oral carbohydrate solution loading until 2 hours before the surgery~Intraoperative care:~* Maintaining normothermia~* Multimodal prevention of postoperative nausea and vomiting~* Use of spinal anesthesia~* Prevention of excessive blood loss~* Local anesthetic infiltration~Postoperative care:~* Active pain control~* Early mobilization~* Early onset of oral nutrition~* Early delirium detection~* Application of compression stockings"
40993639|NCT05143970|DRUG|IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB|"Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.~Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD)."
40993640|NCT05628077|OTHER|No intervention|No intervention
40993641|NCT04287712|DIAGNOSTIC_TEST|Plasma lipids|Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.
40993642|NCT03726008|BEHAVIORAL|Perinatal health promotion program and regular prenatal care|Regular prenatal care and perinatal health promotion program including health promotion during pregnant period, health promotion during the ritual of Tso-Yueh-Tzu, health promotion during postpartum period, newborn care
40993643|NCT00116051|DEVICE|Acetabular implant, Monoblock cup|
40993644|NCT03175328|PROCEDURE|continuous renal replacement therapies|The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.
40993645|NCT00735878|DRUG|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
40993646|NCT03849885|DRUG|Benzoyl peroxide gel|Skin prep with Chlorohexidine wipes and BPO.
40993647|NCT03879655|DRUG|VTS-270|Administered IT via LP infusion of VTS-270
40993648|NCT02291055|DRUG|ADXS11-001|
40993649|NCT02291055|DRUG|MEDI4736|
40993650|NCT04369794|BIOLOGICAL|BCG|0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose
40993651|NCT04369794|BIOLOGICAL|Placebo|0.9% saline in the same volume as the BCG vaccine in a single dose
41468249|NCT05746130|BEHAVIORAL|Plastic-free diet program|"Applying the plastic-free diet as four meals (three main meals, one snack) in pension kitchen. Promoting of glass water bottle giving and daily use.~Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample."
41468250|NCT05746130|BEHAVIORAL|Plastic-free diet education program|"Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample"
40789588|NCT03800030|DEVICE|Theta-gamma tACS|NeuroConn technologies, direct current-stimulator plus
40993652|NCT03803280|PROCEDURE|ERAS program|ERAS pathway according to the Spanish Via RICA
40993653|NCT00827255|DRUG|Cyclosporine Ophthalmic Emulsion 0.05%|One drop two times a day approximately 12 hours apart
40789589|NCT03800030|DEVICE|Delta-beta tACS|NeuroConn technologies, direct current-stimulator plus
40789590|NCT03800030|DEVICE|Sham tACS|NeuroConn technologies, direct current-stimulator plus
40789591|NCT05731271|DRUG|TST003|IV humanized anti-GREM1 monoclonal antibody
40993654|NCT03404479|DRUG|Diacerein|For 12 weeks, administered twice a day by oral.
40993655|NCT03404479|DRUG|Celecoxib|For 12 weeks, administered twice a day by oral.
40993656|NCT02850458|DEVICE|implant-retained overdentures|patients treated with an implant-retained overdenture in the mandible
40993657|NCT02129985|DRUG|Exenatide|Exenatide (10 ug/bid for 3 months)
40993658|NCT02129985|DRUG|Metformin|Metformin 850 mg/bid for 3 months
40993659|NCT04617691|DRUG|Guselkumab|Guselkumab will be administered as IV solution derived from FVP or PFS-U.
40993660|NCT02719132|DRUG|Dapagliflozin|Dapagliflozin, 10 mg
40993661|NCT02719132|DRUG|Metformin|Metformin, up to 2500 mg
40993662|NCT03131440|BEHAVIORAL|Core|The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
40993663|NCT03131440|BEHAVIORAL|Support Calls|Participants will receive 6 bi-weekly phone calls from study staff.
40993664|NCT03131440|BEHAVIORAL|App+|"Participants will receive deluxe version of smartphone app with additional features."
41468251|NCT05746130|BEHAVIORAL|BPA exposure feedback|Feedback about BPA levels in theirs urinary sample
41309307|NCT06048237|DIAGNOSTIC_TEST|Diagnostic Ultrasound Imaging of the diaphragm|"In this reliability study, ultrasound imaging will be utilized by trained physiotherapists to assess diaphragm thickness and excursion. Participants will be positioned in a semi-recumbent position, while the scanning area will be marked with a surgical skin marker according to specific anatomical landmarks recommended, to ensure reproducibility of the procedure. Ultrasound probe will be placed at the zone of apposition to visualize the diaphragm through the liver window.~Diaphragm thickness will be assessed during both full inhalation and exhalation, capturing images in B-mode to measure distance between the diaphragmatic pleura and peritoneal fascia. Diaphragm excursion will be assessed during tidal volume diaphragmatic breathing, using M-mode to track the craniocaudal displacement of the diaphragm during respiratory cycle. Data obtained will contribute to the evaluation of the reliability of diaphragm thickness and excursion measurements for potential future clinical applications."
40993665|NCT03131440|BEHAVIORAL|Online gym|Participants will receive access to online exercise videos.
40993666|NCT03131440|BEHAVIORAL|App notifications|Participants will receive motivational app notifications
41309308|NCT00392262|DRUG|valsartan + amlodipine|
41309309|NCT03509207|DRUG|Vorinostat Oral Capsule|Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
41309310|NCT01334372|BEHAVIORAL|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
41309311|NCT00878657|DRUG|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
41309312|NCT00878657|RADIATION|intensity-modulated radiation therapy|"Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy"
41309313|NCT00406783|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
41309314|NCT00406783|DRUG|Placebo|Placebo tablet, once daily for 15 days
41309315|NCT04386564|DIAGNOSTIC_TEST|mRNA in urine test|Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed
41309316|NCT03001310|BIOLOGICAL|AAV - CNGB3|Comparison of different dosages of AAV-CNGB3
41309317|NCT04953650|BEHAVIORAL|Intermittent fasting|The intervention group is required to perform intermittent fasting for two days. The intermittent fasting method for this group will mimic the Sunnah Muslim fasting; they are allowed to consume food and calorie water without restriction in between dusk and dawn. During the five ad libitum days, they are allowed to have a variety of foods and drinks. Subjects will be informed about healthy food choices; choosing low-fat meat and dairy options, increasing fruit and vegetable intake.
41309318|NCT04953650|OTHER|No intervention|The control group will receive education training at the baseline as well, regarding blood pressure and nutrition. They will have usual exercise prior to the intervention. Furthermore, the group will have equal health education through health promotion leaflets which have been issued by the ministry of health.
41309319|NCT02874690|DRUG|Methylphenidate|single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg
41309320|NCT02874690|DRUG|Placebo|Placebo pill identical in appearance to methylphenidate
41309321|NCT04838106|OTHER|Not applicable as observational study|Not applicable as observational study.
41309322|NCT04723992|OTHER|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
41309323|NCT06555211|PROCEDURE|MRI|MRI will be performed
41309324|NCT06555211|PROCEDURE|PET/CT|PET/CT will be performed
41309325|NCT03157154|OTHER|Non interventional study|A query form to all concerned patients by each investigating centre will be send
41309326|NCT02058134|DEVICE|cardioPAT cell saver|
41309327|NCT04008901|DRUG|BST-104 (Lonicera Flos Extract)|175 mg of Lonicera Flos extract in 1 tablet (300 mg)
41309328|NCT04008901|DRUG|Placebo oral tablet|0 mg of Lonicera Flos extract in 1 tablet (300 mg)
41309329|NCT02515864|DRUG|FYU-981|
41309330|NCT02515864|DRUG|Placebo|
41309331|NCT02515864|DRUG|Moxifloxacin|
41309332|NCT02515864|DRUG|Moxifloxacin Placebo|
41309333|NCT01887028|DEVICE|Fisher and Paykel Humidifier (MR860AEU)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
41468252|NCT04154358|DIAGNOSTIC_TEST|HPV testing|will perform HPV testing with self-collected specimen
41468253|NCT03147924|OTHER|Improvisation Group|The aim of this pilot study is to investigate the effects of improvisational comedy in a group of help-seeking youth at risk of developing a range of mental health disorders, including social anxiety.
41468254|NCT02401841|DRUG|Two different types of drug for resolution of neuro-muscular blockade|
41468255|NCT00941720|DRUG|busulfan|IV busulfan 0.8 mg/kg every 6 hours x 16 doses
41468256|NCT00941720|DRUG|cyclophosphamide|IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
40993667|NCT03131440|BEHAVIORAL|Buddy|Participants will choose a buddy to receive a Fitbit and support them during the intervention.
40993668|NCT03837561|DRUG|Cunox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
40993669|NCT03837561|DRUG|Botox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
40993670|NCT01176227|DIETARY_SUPPLEMENT|Kyodophilus multi-strain probiotic capsules|"The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~* Lactobacillus gasseri KS-13 1.2~* Bifidobacterium bifidum G9-1 0.15~* Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
40993671|NCT01176227|DIETARY_SUPPLEMENT|Kyodophilus Matching Placebo Capsules|Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
40993672|NCT05715372|BEHAVIORAL|Mediterranean diet|12-week structured program for Mediterranean diet.
41468257|NCT00941720|PROCEDURE|autologous hematopoietic stem cell transplantation|infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
40789592|NCT04892719|DIAGNOSTIC_TEST|Fluoroscopic chest imaging with 4Dx technology software analysis|4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
40789593|NCT04013776|DIETARY_SUPPLEMENT|Phosphate supplemented diet|Participants will be asked to follow a 5 day menu of 750 mg of phosphorus daily along with a daily sodium phosphorus supplement of 500 mg
40789594|NCT02443701|OTHER|Exercise|Warmup program, maximum isometric strengthening, and jump training
40789595|NCT02443701|OTHER|LASER|a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member
40789596|NCT02443701|OTHER|NMES|electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
40789597|NCT06445608|DEVICE|Percutaneous Mechanical Circulatory Support|Patients are randomized to receive one of two types of percutaneous mechanical circulatory support devices during a high-risk PCI procedure.
40789598|NCT02135744|BEHAVIORAL|Bundle tool|Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
40789599|NCT04948112|DEVICE|real time continuous glucose monitor|CGM sensor will read blood glucose every 10 minutes
40789600|NCT04948112|DEVICE|blinded continuous glucose monitor|CGM that records blood glucose but not visible to patient
40789601|NCT03246087|DEVICE|Acupunture|"acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed."
40789602|NCT03246087|OTHER|Standard of care|standard of care home exercise program
40789603|NCT04858113|OTHER|Blephaclean|Blephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction.
40789604|NCT04858113|OTHER|Baby Shampoo|Conventional baby shampoo
40789605|NCT00374517|DRUG|Pimonidazole hydrochloride|
40993673|NCT05715372|BEHAVIORAL|AHA walking program|12-week structured AHA walking program.
41468258|NCT05249972|DRUG|AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)|Topical cutaneous spray
41468259|NCT05249972|DRUG|Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)|Topical foam
40789606|NCT00577694|DRUG|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
40789607|NCT00577694|DRUG|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
41468260|NCT05249972|OTHER|Placebo|Placebo cutaneous spray
41468261|NCT02992613|PROCEDURE|total knee arthroplasty with ultra-congruent (UC) insert|
41468262|NCT02992613|PROCEDURE|total knee arthroplasty with posterior-stabilized (PS) insert|
41468263|NCT03304431|DRUG|Orotracheal Lidocaine Oral Spray application|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
40993674|NCT05715372|BEHAVIORAL|Mindfulness-based stress reduction|8-week structured mindfulness-based stress reduction (Cabot).
41468264|NCT06010745|DIETARY_SUPPLEMENT|Biotin and silicon|The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.
41468265|NCT06010745|DIETARY_SUPPLEMENT|Placebo|Inert ingredients only
41468266|NCT02710214|DRUG|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
41468267|NCT02710214|DRUG|Placebo|Once-daily dosing of placebo for 8 weeks
41468268|NCT05160636|BIOLOGICAL|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
41468269|NCT01465932|OTHER|Control, no Proprioception|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.
41468270|NCT01465932|OTHER|Experimental, Proprioceptive exercises|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
41468271|NCT00031850|DRUG|goserelin acetate|
40789608|NCT01503814|OTHER|Simplified cardiovascular disease management|"This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)"
40789609|NCT03056235|DEVICE|ELAPR002f|30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
40789610|NCT03056235|DEVICE|Saline|Saline control
40789611|NCT04390399|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
40789612|NCT04390399|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
40789613|NCT04390399|BIOLOGICAL|PD-L1 t-haNK|PD-L1 t-haNK suspension for infusion
40789614|NCT04390399|DRUG|Nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
40789615|NCT04390399|DRUG|Gemcitabine|2', 2'-difluoro 2'deoxycytidine, dFdC
41309334|NCT04757909|DIAGNOSTIC_TEST|Monthly Haemoglobinometry|"Monthly measurement of capillary hemoglobin with non-invasive techniques in primary health care.~Inclusion in a transfusion circuit with referral to a hospital day hospital if necessary."
41468272|NCT00031850|DRUG|raloxifene|
41468273|NCT06286670|PROCEDURE|Single Implant Fixation|Single implant fixation with either a precontoured lateral locking plate or an intramedullary nail.
41468274|NCT06286670|PROCEDURE|Dual Implant Fixation|Dual implant fixation with either a lateral locking plate plus an intramedullary nail or a lateral locking plate plus a supplemental medial plate.
41468275|NCT01339377|DEVICE|AO-1000|Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
41488672|NCT06303973|DEVICE|PNG|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
41488673|NCT00712985|DRUG|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
40789616|NCT04390399|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
40789617|NCT04390399|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
40789618|NCT04390399|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
40789619|NCT04390399|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
40789620|NCT04390399|DRUG|Irinotecan liposome|Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano\[3',4':6,7\]-indolizino\[1,2-b\]quinolin-9-yl-\[1,4'bipiperidine\]-1'-carboxylate, monohydrochloride, trihydrate
40789621|NCT05878977|DRUG|Immune checkpoint inhibitor|Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
40789622|NCT06312137|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 40 weeks
40789623|NCT06312137|BIOLOGICAL|Pembrolizumab|Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
40789624|NCT06312137|DRUG|Cisplatin|Cisplatin is administered as 75 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase
40993675|NCT05715372|BEHAVIORAL|Unstructured Mediterranean diet|Unstructured 12-week program with basic outline for Mediterranean diet.
41309335|NCT00731393|BIOLOGICAL|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
41309336|NCT00731393|BIOLOGICAL|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
40993676|NCT05715372|BEHAVIORAL|Unstructured walking program|Unstructured 12-week walking program.
40993677|NCT05715372|BEHAVIORAL|Unstructured stress reduction|Unstructured program using mobile application for stress reduction.
40993678|NCT03519568|BIOLOGICAL|EV71 (inoculation vaccine)|EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China
40993679|NCT05004376|BEHAVIORAL|Text Messaging|Text messages based on behavioral theory to encourage scheduling colorectal cancer screening.
40993680|NCT04045496|DRUG|JAB-3312|JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
40993681|NCT02942355|DRUG|anastrozole|Anastrozole by mouth daily
40993682|NCT02942355|DRUG|Palbociclib|Palbociclib by mouth daily days 1-21 every 28 days
40993683|NCT02162342|OTHER|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
41309337|NCT04347317|PROCEDURE|Low Intensity IMT|"The control group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 30% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
41341713|NCT06283303|BIOLOGICAL|T3011 hepatic artery infusion|The study was divided into two dose groups, T3011 3×10\^8 PFU/time (HAI) and T3011 1×10\^9 PFU/time (HAI), with a 3+3 dose escalation design. After the completion of the lead-in period, the patient entered the combination therapy period（combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab）,and the dosage of T3011 was determined according to the safety observation results of the lead-in period, the dose of toripalimab was 80mg intravenously, and regorafenib was 80mg orally once a day.
41468276|NCT03978416|BEHAVIORAL|Healthy Weight for Living for Hispanics|"The Healthy Weight for Living (HWL) intervention, previously developed at the Energy Metabolism Laboratory (HNRCA), is broadly informed by the same behavior change theories as other interventions. For example, it also recognizes individual and environmental factors as potential areas to support behavior change for weight regulation, and provides practical tools for facilitating new habits. However, the HWL places greater emphasis on the role of biology in influencing eating behavior, giving a central role to hunger and food cravings as modulators of eating behavior. Therefore, HWL does not emphasize self-monitoring food intake and does not require increasing physical activity for effectiveness. The new intervention also targets autonomous motivation and prioritizes ease of implementation.~Information from focus groups and sequential pilots will be used to develop a culturally tailored prototype version of Healthy Weight for Living that is acceptable for Hispanic older adults."
41468277|NCT01758406|BIOLOGICAL|Intracoronary injection|stem cell transplantation
40993684|NCT00433563|RADIATION|Once daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
40993685|NCT00433563|RADIATION|Twice daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
40993686|NCT01218555|DRUG|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
40993687|NCT01218555|DRUG|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
40993688|NCT06348420|PROCEDURE|anti-reflux mucosal valvuloplasty (ARMV)|During the ARMV procedure, a segment of the mucosa at the esophagogastric junction (EGJ) is released and reconstructed to form a mucosal flap. Cautery markings are made on 3/4-4/5 of the mucosa along the lesser curvature, approximately 2 cm below the dentate line. After submucosal injection of saline with indigocarmine, the premarked mucosa is dissected from the caudal to cranial side using an endoscopic submucosal dissection technique. The cranial edge of the released mucosa is left in place, and the semi-free mucosa naturally curls to form a double-layer flap. Metal clips are then used to anchor the free edge of the mucosa to the exposed submucosa/smooth muscle to prevent flattening of the mucosal flap. Any visible bleeding on the exposed submucosa is coagulated using electric forceps.
40993689|NCT00006240|BIOLOGICAL|sargramostim|
40993690|NCT00006240|DRUG|dexamethasone|
40993691|NCT00006240|DRUG|oral sodium phenylbutyrate|
40993692|NCT03293732|BIOLOGICAL|DCB07010|A protein based adjuvant originated from prokaryotic organism.
40993693|NCT03293732|BIOLOGICAL|HA antigens|HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
40993694|NCT02761707|OTHER|Electrical Brainstem Responses|Eye blink responses will be induced using standard stimulating electrodes employed in surface electromyography (EMG). The subjects will recline with their eyes gently closed. Sticky electrodes will be placed to the left and below the left eye. 6 different facial regions will be stimulated. The electrical stimulation will be kept constant during the test sessions. To prevent habituation, the stimuli will be delivered randomly at intervals of 45-60 sec. Four 0.2 msec pulses will be presented. In some cases, paired pulse stimulation will be performed, and a conditioning stimulus will be applied to the target facial regions at the following intervals: 10, 200, 400, 600 and 800 msec. 4 pulses will be presented at each stimulus interval with randomized interval and pulse sequences.
41468278|NCT01758406|BIOLOGICAL|Intracoronary injection of Placebo|Injection of Placebo via coronary arteries in patients with heart failure.
41468279|NCT03655275|BIOLOGICAL|PRP prolotherapy|PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.
41309338|NCT04347317|PROCEDURE|High Intensity IMT|"The experimental group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 60% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
41309339|NCT01205555|DEVICE|urine LH testing|"The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :~13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.~If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (\<8 IU\\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\\L) the insemination will be the next day."
41309340|NCT03397927|DEVICE|orthosis|
41309341|NCT02645058|PROCEDURE|RIRS|Treatment by ureterorenoscopy (RIRS) and laser lithotripsy
41309342|NCT02645058|PROCEDURE|ESWL|Treatment by extracorporeal shock waves lithotripsy
41309343|NCT02645058|DEVICE|Rigid and flexible ureteroscope|
41309344|NCT02645058|DEVICE|Lithotripter|
41309345|NCT02645058|DEVICE|Holmium laser|
41309346|NCT02645058|DEVICE|Basket for fragment removal|
41309347|NCT02645058|PROCEDURE|General or spinal anesthesia|
40993695|NCT02761707|OTHER|Olfactory Tests|Olfactory testing will be performed using standard tests. The University of Pennsylvania Smell Identification Test (UPSIT) assesses a subjects ability to identify odors in a forced choice format. The Snap and Sniff Threshold Test provides a threshold measure of phenyl ethyl alcohol. Short-term odor memory will be assessed using a standardized 12-item four-alternative forced-choice Odor Memory Test. This non-lexical test employs 10-, 30-, and 60-second delay intervals between the presentation of the target odorant and the first of four successively presented odors from which the target is to be selected.
41309348|NCT02645058|DRUG|Intravenous pain medication|If required by the patient
41309349|NCT02645058|DEVICE|X-ray|To focus the stone
41309350|NCT02645058|DEVICE|Ultrasound|To focus the stone
41309351|NCT00319852|BIOLOGICAL|DTaP-IPV combined vaccine|0.5 mL, IM
41309352|NCT00319852|BIOLOGICAL|DTaP vaccine|0.5 mL, IM
41309353|NCT02112994|DRUG|Sebelipase Alfa|IV infusion of sebelipase alfa
41309354|NCT00472472|DEVICE|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
41468280|NCT03655275|BIOLOGICAL|Saline prolotherapy|Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.
41468281|NCT04244799|BEHAVIORAL|Behavioral nudges|"Behavioral nudges include the following:~1. Colorful pathway overlaid with footprints leading from the toilet to the handwashing station~2. Rotating posters in toilet areas with messages targeting behavioral motivators for handwashing (disgust, social affiliation)~3. Sticker of a pair of eyes placed above the handwashing station~4. Soap dish with an arrow beside it on the sink or counter to remind children to wash their hands with soap"
41468282|NCT04244799|BEHAVIORAL|National WASH policy|"The Philippines' Department of Education National WASH in Schools (WinS) policy promotes correct hygiene and sanitation practices among school children and a clean environment in and around schools and includes initiatives related to infrastructure, knowledge, and behavior change, but does not include other programs with an explicit focus on handwashing promotion."
41309355|NCT04200677|OTHER|Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following NMES parameters: (Monophasic Current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
41309356|NCT04200677|OTHER|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
41309357|NCT04200677|OTHER|Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
41309358|NCT04200677|OTHER|Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
41309359|NCT04200677|OTHER|Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Monophasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
41468283|NCT04964674|BEHAVIORAL|Behavioral Measurement|Take measurements of behavioral performance
41468284|NCT01129739|OTHER|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle
41468285|NCT01129739|OTHER|cyclosporine A (CsA)|CsA 5mg/kg po for 6 months
41468286|NCT02086344|PROCEDURE|PBS|TLH plus PBS
40993696|NCT02761707|OTHER|Visual Deprivation|During a 2-hour visual deprivation period, subjects will wear comfortable light-tight goggles with lenses that have been blackened by flat black paint. Subjects will be given the opportunity to recline comfortable in a padded reclining chair during this time.
40993697|NCT02761707|OTHER|Peripheral Nerve Stimulation|Electrical stimulation will be applied to a nerve of your arm. Sticky electrode pads will also be placed on a hand muscle. You will receive electrical stimulations that lasts less than a second. The stimulations will make your muscle twitch.
40993698|NCT06088433|DRUG|Ticagrelor|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
40993699|NCT06088433|DRUG|Clopidogrel|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
41309360|NCT04200677|OTHER|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
41309361|NCT04200677|OTHER|Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
41309362|NCT04200677|OTHER|Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
41309363|NCT04200677|OTHER|Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 25 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
41309364|NCT02723604|DEVICE|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
41309365|NCT01321294|PROCEDURE|laparoscopic anti-reflux surgery|
41309366|NCT04770610|DRUG|OT-101 Ophthalmic Solution|Atropine 0.01%
41309367|NCT04770610|DRUG|Vehicle|Investigational Product minus active ingredient
41309368|NCT05147558|DRUG|Pembrolizumab|Pembrolizumab (200mg every 3 weeks, intravenously)
41309369|NCT05147558|DRUG|Lenvatinib|Lenvatinib (20mg once daily orally)
41309370|NCT05123651|BIOLOGICAL|Lactobacillus rhamnosus X253|Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
41341714|NCT06283303|DRUG|toripalimab|The combination therapy period: toripalimab, 80mg intravenous ,D2 and D16, 4 weeks per cycle
41341715|NCT06283303|DRUG|regorafenib|The combination therapy period: regorafenib ,80mg orally once a day, D1-D21,4 weeks per cycle
40789625|NCT06312137|DRUG|Pemetrexed|Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.
40993700|NCT06088433|DRUG|Aspirin|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
40993701|NCT02280590|DRUG|Rosuvastatin(Cresnon®)|10mg
40993702|NCT02280590|DRUG|Rosuvastatin(Crestor®)|10mg
40993703|NCT00605475|DRUG|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
40993704|NCT00605475|DRUG|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
40993705|NCT00605475|DRUG|Metformin|Participants continued on their stable daily dose of metformin throughout the study
40993706|NCT06244355|OTHER|Extra blood tubes|Extra blood tubes
40993707|NCT00714519|DRUG|Xenaderm® Ointment|Topical, BID or as needed
40993708|NCT00714519|DRUG|Placebo Comparator|Topical, BID or as needed
40993709|NCT06310330|DIAGNOSTIC_TEST|Comprehensive echocardiographic follow-up|Comprehensive echocardiographic follow-up for identification of CRTCD in breast cancer patients
40993710|NCT06310330|DIAGNOSTIC_TEST|Simplified echocardiographic follow-up|Simplified echocardiographic follow-up for identification of CRTCD in breast cancer patients
40993711|NCT02522208|DRUG|BiDil XR|fixed combination capsule
40993712|NCT02522208|DRUG|BiDil Immediate Release (IR)|fixed combination tablet
41468287|NCT02086344|PROCEDURE|TLH _adnexal preservation|TLH without PBS
41468288|NCT03069417|BEHAVIORAL|Integrating Nuanced Support for Perinatal adherence and Depression|A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
40993713|NCT05449054|PROCEDURE|Anterior colporrhaphy|All patients will be operated by the vaginal route. They are prepared under strict aseptic conditions in the dorsal lithotomy position. The bladder is emptied preoperatively with a thin disposable catheter and antibiotic prophylaxis (cefazolin) is administered before incision. A vasoconstricting solution (combination of vasopression and NaCl) is administered and a vertical anterior vaginal incision is made from the apex to two centimeters short of the external urethral meatus using an electric cautery or a scalpel. The vaginal epithelium is grasped on both sides and the fibromuscular layer of the anterior vaginal wall is sharply dissected laterally to the inferior pubic ramus. The bladder is completely dissected from the apex and up to 4 to 6 cm from the pubic ramus. The anterior colporrhaphy is defined as a native tissue repair and rows of absorbable sutures (2/0 vicryl) are used.
40993714|NCT05750927|PROCEDURE|Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)|TAVI and PCI to be administered as per physician's indication and choice, in one or more stages
40993715|NCT01044082|PROCEDURE|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
40993716|NCT01044082|PROCEDURE|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
40993717|NCT00425867|BEHAVIORAL|PAR1 polymoprhisms and placental invasion|
40993718|NCT01603446|DRUG|L-Arginine|NOW® L-Arginine powder
40993719|NCT00973739|DRUG|Lapatinib|"Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (\<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (\>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response."
40993720|NCT04318236|BEHAVIORAL|HERMES (Online Self-Help Intervention based on problem-solving therapy)|"The Online Self-Help Intervention is an online program based on the problem-solving therapy (an evidence based approach of psychotherapy). All participants will receive the exact same intervention.~However, what will be experimentally varied are the four listed interventions."
40993721|NCT00371254|DRUG|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months)
40993722|NCT00371254|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months)
40993723|NCT03501758|DIAGNOSTIC_TEST|Ultrasound|Transabdominal ultrasound of the bowel for categorisation of disease activity
40993724|NCT03501758|DIAGNOSTIC_TEST|Analysis of prouroguanyline and uroguanyline in full blood|Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.
40993725|NCT05163028|DRUG|HBI-2376|SHP2 Inhibitor
40993726|NCT01894152|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
40993727|NCT01946399|DRUG|Ozurdex implant|Intravitreal injection of Dexamethasone implant
40993728|NCT05665790|RADIATION|radiotherapy|radiotherapy
40993729|NCT05665790|PROCEDURE|palliative surgery|palliative surgery
40993730|NCT01553006|DRUG|cefditoren pivoxil|comparison of different dosages of cefditoren pivoxil
40993731|NCT04272528|OTHER|uniform care|The leader develops training plan and trains nurses, who provide uniform care and education to patients according to the training.
40993732|NCT04272528|OTHER|conventional care|Nurses carry out the routine care procedures.
40993733|NCT03676881|DEVICE|Computerized cognitive battery: Cognigram (CG)|is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
40993734|NCT03676881|DEVICE|The NeuroCatch™ Platform (NCP)|the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
40993735|NCT02442778|DRUG|AVP-786-18|18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)
40993736|NCT02442778|DRUG|Placebo|Administered as capsules.
41309371|NCT04611295|PROCEDURE|Teleneurological evaluation and support|The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.
40993737|NCT02442778|DRUG|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
40993738|NCT02442778|DRUG|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
40993739|NCT04903405|OTHER|No intervention|No intervention is involved in this study
40993740|NCT01112852|DRUG|pantoloc 40 mg|pantoloc iv. infusion per day
40993741|NCT01112852|DRUG|somatostatin or terlipressin|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
40993742|NCT02685631|OTHER|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
41309372|NCT05565300|OTHER|Cycling exercise|30 minutes of cycling (90 rpm).
41309373|NCT05565300|OTHER|Cognitive tasks|30 minutes of cognitive tasks based on the different domains of the Mini Mental Scale.
40993743|NCT04434690|PROCEDURE|Simultaneous bilateral total knee arthroplasty|Two surgeons bilateral TKA group
40993744|NCT04434690|PROCEDURE|Sequenced bilateral TKA|Single surgeon bilateral TKA group
40993745|NCT00745992|OTHER|Blood drawn (lab data)|"1. Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~2. Check genetic polymorphism of liver enzyme 3-5 days after start of drug"
40993746|NCT03295708|DIETARY_SUPPLEMENT|fish oil capsule|N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.
40993747|NCT03295708|DIETARY_SUPPLEMENT|soybean oil capsule|placebo capsule
40993748|NCT01004588|DIETARY_SUPPLEMENT|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
40993749|NCT01004588|DIETARY_SUPPLEMENT|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
40993750|NCT05707117|OTHER|Tendon neuroplastic training (TNT)|Subjects will attend physical therapy for three non-consecutive days per week for a total 4 consecutive weeks. Exercise would involve isolated flexion, extension with a dumbbell. This exercise would be paced with external audio/visual cue on smart phone using proMetronome app. Patients will listen to the sound and track the movement of metronome with the eyes. Pace of metronome will be set at 20 beats per minute such that each beat will be 3 sec apart. This will allow a 3sec concentric and 3 sec eccentric phases.4 sets of 8 repetitions would be completed with a 2-minute rest between each set. Exercise will begin with 3 pounds weight, but it would be made sure that this wouldn't cause pain during exercise (more than 5/10), gradual progression in weight to 5 pounds after 2nd weeks.
40993751|NCT05707117|OTHER|group B Conventional treatment|Subjects assigned to this group will undergo static stretching of Extensor carpi radialis brevis and myofascial release for 4 weeks, 3 sessions a week. Myofascial release technique will be applied for 5 minutes and 2 reptations per session
40993752|NCT01526265|BEHAVIORAL|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
40993753|NCT01526265|BEHAVIORAL|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
40993754|NCT01526265|BEHAVIORAL|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
40993755|NCT01526265|BEHAVIORAL|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
41468289|NCT06615856|OTHER|Questionnaire|"Two questionnaires will be provided to participants to complete before their routine tests (which they would already be having regardless of the study and are not affected by their participation in the study).~The questionnaires include: A Gastro-Oesophageal Reflux Symptom Questionnaire; and the ROME-IV Diagnostic IBS Module Questionnaire"
40993756|NCT01526265|BEHAVIORAL|Collaborative Rewards|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
40993757|NCT05638685|OTHER|Questionnaire|The questionnaire comprises demographics, job or school related questions, screen work questions, the International Physical Activity Questionnaire (IPAQ) and questions about the participant's health.
40993758|NCT01169506|DEVICE|sublingual silicon capillary|Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
41309374|NCT00074841|DRUG|Azithromycin/Chloroquine|
41309375|NCT00074841|DRUG|Sulfadoxine-Pyrimethamine/Chloroquine|
41309376|NCT06191120|RADIATION|[18F]-ALF-FAPI-74 PET/CT scan|Participants will receive up to three \[18F\]-ALF-FAPI-74 PET/CT scans. \[18F\]-ALF-FAPI-74 is a PET tracer with high binding specificity and selectivity to FAP-expressing cells.
41309377|NCT00474162|DRUG|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
41309378|NCT00474162|DRUG|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
41309379|NCT00358917|DRUG|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once-daily (QD) tablet
41309380|NCT00358917|DRUG|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice-daily (BID) tablet
41468290|NCT05607563|DRUG|PM1009 injection|Participants receive PM1009 intravenously, every 2 weeks
41468291|NCT01876238|OTHER|T-PAT|
41468292|NCT01876238|OTHER|Surveys|Pre-test and posttest surveys and questionnaires
40993759|NCT05173649|OTHER|Calisthenic Training|"Calisthenic Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Abductor-Adductor leg raise~2. Alternate toe touch~3. Knee Bend~4. Prone leg extension~5. Forward Lunges~6. Toe Raise/ Calf raise Progressive training include following exercises.~1. Leg Lifts 2. Jack Twists 3. Side Lunges 4. Short bridge 5. Calf Raise with weight."
41468293|NCT03327350|DEVICE|WATCHMAN transplantation|WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic
41488674|NCT05885191|OTHER|2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture|Test meal with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture will be divided into 10 portions, which will be given hourly over the course of 7 hours. The first consumption will be the priming meal, comprised of 3 portions and will additionally contain 13C sodium bicarbonate.
40789626|NCT06312137|DRUG|Gemcitabine|Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m2 or 1250 mg/m2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.
40993760|NCT05173649|OTHER|Neuromuscular Training|"Neuromuscular Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Up and down step exercise in posterior and lateral directions.~2. Walking in anterior and posterior~3. Directions with eyes opened and eyes closed.~4. Walking in lateral direction with eyes opened and eyes closed.~5. Standing on one extremity~6. Inclination in anterior and lateral direction with eyes opened and closed. Progressive training includes following exercises.~1. Up and down on Bosu exercise. 2. Plantar flexion on minitrampoline. 3. Standing on one extremity on Bosu. 4. Standing on one extremity on minitrampoline"
40993761|NCT01923454|PROCEDURE|Paracentesis|At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
41148129|NCT04430400|DIAGNOSTIC_TEST|integrated diagnostic algorithm|"Diagnostic management was as follows. An acute aortic syndrome will be considered to be ruled out without advanced aortic imaging, in clinically stable patients at low clinical pre-test probability (defined by ADD score ≤1) and a D-dimer level \<500 ng/mL FEU. The other patients will be subjected to advanced aortic imaging for conclusive diagnosis.~Attending physicians will be allowed to derogate from protocol indications based on the clinical scenario and clinal gestalt, irrespective of patient's participation to the present study."
41148130|NCT02249429|DRUG|bimiralisib|60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
41148131|NCT02169089|DRUG|Spironolactone|Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
41148132|NCT02169089|DRUG|Placebo|Placebo
41148133|NCT01355692|DEVICE|Nd: YLF laser treatment|grid selective retinal treatment
41148134|NCT06172777|DIAGNOSTIC_TEST|suspected asthma|enrollment 200 asthma patients
40993762|NCT01923454|DRUG|Acetazolamide|All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
40993763|NCT01923454|PROCEDURE|Peripheral iridotomy|All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
41148135|NCT06172777|DIAGNOSTIC_TEST|suspected COPD|enrollment 200 COPD patients
41148136|NCT06172777|DIAGNOSTIC_TEST|confirmed asthma|enrollment 200 patients
40993764|NCT04311879|DEVICE|Soft tissue Diode laser application|post-operative soft tissue diode laser application
40993765|NCT04311879|OTHER|Placebo|mock diode laser application
40993766|NCT06142721|OTHER|3D Gait Analysis|3D gait analysis was applied to children. Static, kinematic and kinetic walking parameters were evaluated
40993767|NCT02120794|DEVICE|530G Insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
41148137|NCT06172777|DIAGNOSTIC_TEST|confirmed COPD|enrollment 200 patients
41148138|NCT04366648|DRUG|JK-1201I|malignant solid tumor that has been confirmed by histopathology and/or cytology
41148139|NCT05341713|BIOLOGICAL|inactive SARS-Cov-2 vaccine|We included epilepsy patients who were vaccinated with inactive SARS-CoV-2 vaccines
41309381|NCT05834764|DRUG|Pyrotinib|Pyrotinib after anti-HER2 therapy（Trastuzumab combined with Pertuzumab or T-DM1）
41309382|NCT05679973|DEVICE|Polybutester suture|After third molar surgery this suture used for primary closure.
40789627|NCT06312137|DRUG|Carboplatin|Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
41309383|NCT05679973|DEVICE|Polypropylene suture|After third molar surgery this suture used for primary closure.
41309384|NCT04393584|DRUG|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
41309385|NCT04393584|DRUG|5-FU|d1-2 5-FU 2450 mg/m² every two weeks
41309386|NCT04393584|DRUG|Leucovorin|d1 Leucovorin 200 mg/m² every two weeks
40789628|NCT06312137|DRUG|Paclitaxel|Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m2 or 200 mg/m2 IV infusion q3w for up to 12 weeks as background treatment.
40789629|NCT04763889|BEHAVIORAL|CBT|CBT for those with an allergy and anxiety
40789630|NCT04451408|DRUG|LY3372993|Administered IV or SC.
40789631|NCT04451408|DRUG|Placebo|Administered IV or SC.
40789632|NCT02228161|BEHAVIORAL|Yoga|Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
40789633|NCT05527600|DIAGNOSTIC_TEST|intensity of acute pain evaluation|the facial expression of each patient will be collected from a short video of 10 seconds, follow by with the evaluation of the pain intensity.
41468294|NCT03327350|DRUG|Oral anticoagulant drugs|This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
40789634|NCT06376864|BEHAVIORAL|Activity Breaks|The Activity Breaks intervention is a 5-minute Activity Breaks programme that allows classroom teachers of all ages and ability levels to lead simple movement activities within their classrooms, negating the need for additional personnel or space.
40993768|NCT00205426|DRUG|Natrecor|Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
40993769|NCT02451410|OTHER|Nutrition and physical activity|The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
40789635|NCT05125146|BEHAVIORAL|e-CBTi|See arm/group description
40789636|NCT05125146|DRUG|Trazodone|See arm/group edescription
40789637|NCT01476410|DRUG|brentuximab vedotin|Given IV
40789638|NCT01476410|DRUG|doxorubicin hydrochloride|Given IV
40789639|NCT01476410|DRUG|vinblastine|Given IV
40789640|NCT01476410|DRUG|dacarbazine|Given IV
40789641|NCT01476410|PROCEDURE|quality-of-life assessment|Ancillary studies
40789642|NCT01476410|GENETIC|DNA analysis|Optional correlative studies
40789643|NCT01476410|GENETIC|RNA analysis|Optional correlative studies
40789644|NCT01476410|RADIATION|fludeoxyglucose F 18|Correlative studies
40789645|NCT01476410|PROCEDURE|positron emission tomography|Correlative studies
40789646|NCT01476410|OTHER|laboratory biomarker analysis|Optional correlative studies
40789647|NCT01476410|OTHER|immunohistochemistry staining method|Optional correlative studies
40789648|NCT01476410|GENETIC|polymorphism analysis|Optional correlative studies
40789649|NCT06536543|OTHER|Acute Respiratory Distress Syndrom (ARDS) treated with Prone Position (PP) equipped with Electrical Impedance Tomography (EIT)|Positive End-Expiratory Pressure (PEEP) will be titrated with PEEP-EIT method as it is already done in usual care. A classical low flow Pression Volume (PV) curve will be done in order to detect airway closure and measure compliance, the acquisition of EIT data during PV curve will be analysed secondary with a dedicated software. Reconstruction of EIT derived PV curve will determine the regional airway opening pressures and compliances of the 2 lungs. Two decremental PEEP-EIT titrations will be compared, one in supine and the other just after turning in prone.
40789650|NCT06440252|DRUG|Grape Seed Extract|One daily dose of 1 capsule containing 600mg grape seed extract
40789651|NCT06440252|DRUG|Maltodextrin|One daily dose of 1 capsule
40789653|NCT03962959|DEVICE|TBS|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
40993770|NCT05744349|PROCEDURE|K-wires Fixation of Pediatric Shaft Both Bone Forearm Fractures|After administration of anesthesia, surgery will be performed with the patient supine on the operating table and fracture will be analyzed with an image intensifier. In radius, the wire will be inserted by surgical drilling through Lister's tubercle or the radial styloid while in ulna, the wire will be inserted through the tip of the olecranon.
40993771|NCT04153500|OTHER|Anatomy class with Pelvic+ methodology|Teaching of female pelvis anatomy using a interactive training model (Pelvic+ methodology)
40993772|NCT02620514|BEHAVIORAL|Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
40993773|NCT02620514|BEHAVIORAL|Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
40993774|NCT02620514|BEHAVIORAL|Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
40993775|NCT02620514|BEHAVIORAL|Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
40789654|NCT03591731|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
40789655|NCT03591731|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
40789656|NCT03650868|PROCEDURE|Thoracal paravertebral block|Thoracal paravertebral block will be performed before the surgery to the TPVB group.
40789657|NCT04277624|DRUG|fezolinetant - test formulation|Administered orally
40789658|NCT04277624|DRUG|fezolinetant - reference formulation|Administered orally
40789659|NCT06538662|DRUG|FID 123320 Ophthalmic Solution|Investigational sterile aqueous solution
40789660|NCT06538662|DRUG|Vehicle|FID 123320 Ophthalmic Solution inactive ingredients
40789661|NCT05908981|OTHER|sandalwood aromatherapy (Santalum album)|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
40789662|NCT06401551|DEVICE|CPO Pro IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.
40789663|NCT06401551|DEVICE|CPO IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.
40789664|NCT06401551|PROCEDURE|Cataract Surgery|Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
40789665|NCT04651465|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
40993776|NCT01733407|DRUG|L-serine|400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
40993777|NCT01733407|DRUG|placebo|400mg/kg/d divided TID for year 1 only.
40993778|NCT01701115|PROCEDURE|Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL"
40993779|NCT01701115|PROCEDURE|Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL"
40993780|NCT01701115|DRUG|Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
40993781|NCT01701115|DRUG|Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
40993782|NCT05017012|BIOLOGICAL|MK-3475A|MK-3475A is a fixed-dose formulation of pembrolizumab (either Conc1 or Conc2) and MK-5180 for SC administration.
40993783|NCT05017012|BIOLOGICAL|Pembrolizumab|Participants will receive pembrolizumab 400 mg IV.
40993784|NCT05017012|DRUG|Pemetrexed|Participants may receive 500 mg/m\^2 IV every 3 weeks (Q3W) Day 1 and Day 22 of Cycles 1 to 18 as background SOC treatment during the study, as applicable to their diagnosis.
40993785|NCT05017012|DRUG|Carboplatin|Participants may receive 5 mg/mL/min IV (nonsquamous) or 6 mg/mL/min IV (squamous) on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
40993786|NCT05017012|DRUG|Paclitaxel|Participants may receive 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
40993787|NCT05017012|DRUG|Nab-paclitaxel|Participants may receive 100 mg/m2 IV on Day 1, 8, and 15 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
40993788|NCT05017012|DRUG|Axitinib|Participants may receive 5 mg orally twice daily continuously as background SOC treatment during the study, as applicable to their diagnosis.
41309387|NCT04393584|DRUG|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
40993789|NCT05017012|DRUG|Cisplatin|Participants may receive 75 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
40993790|NCT00399009|DEVICE|AutoSuture Premium Plus CEEA/Ethicon Proximate ILS|
40993791|NCT01204476|BIOLOGICAL|Cixutumumab|Given IV
40993792|NCT01204476|DRUG|Everolimus|Given PO
40993793|NCT01204476|OTHER|Laboratory Biomarker Analysis|Correlative studies
40993794|NCT01204476|DRUG|Octreotide Acetate|Given IM
40993795|NCT01204476|OTHER|Pharmacological Study|Correlative studies
40993796|NCT00965991|DRUG|metformin|patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
40993797|NCT00965991|DRUG|Glyburide|Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
40789666|NCT06323928|DRUG|Lu AG09222|Lu AG09222 will be administered using subcutaneous (SC) injection.
40789667|NCT06323928|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered by SC injection.
40789668|NCT03440450|DRUG|FF-10832 Gemcitabine Liposome Injection|FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
40789669|NCT02390492|DRUG|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study
40789670|NCT02390492|DRUG|Period 2 treatment|200-mg/100-mcCi oral \[14C\]-ipatasertib on Day 15 of study
40789671|NCT00054743|PROCEDURE|Blood draw|
40789672|NCT05255302|DRUG|Pembrolizumab before randomization|Pembrolizumab 200 mg every 3 weeks before randomization
40789673|NCT05255302|DRUG|Chemotherapy|Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
40993798|NCT00006209|DRUG|Tucaresol|
40993799|NCT06086028|OTHER|Wrist worn sensor|Biostrap collects biometrics such as the following: (1) sleep pattern/ quality; (2) steps, activity, calories; (3) heart rate/ HRV; (4) respiratory rate. Participants will be randomly assigned to one of two groups.
40993800|NCT00262509|DEVICE|Egress Badge|Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
40993801|NCT02369341|BIOLOGICAL|Fluarix Tetra|One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
40993802|NCT04757636|BIOLOGICAL|2.0 mg OPT-302|intravitreal injection
40993803|NCT04757636|BIOLOGICAL|2.0 aflibercept|intravitreal injection
40993804|NCT04757636|PROCEDURE|Sham|intravitreal injection
40993805|NCT05720156|OTHER|99mTc-tilmanocept SPECT/CT scanning|99mTc-Tilmanocept SPECT/CT allows for visualization of macrophage-specific arterial infiltration
41309388|NCT04393584|DRUG|Docetaxel|d1 Docetaxel 50mg/m2 every two weeks
41309389|NCT02078882|BIOLOGICAL|abatacept|125 mg subcutaneously each week for 24 weeks
41341716|NCT00668772|DRUG|Tiotropium/Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
41468295|NCT06368141|DRUG|Serplulimab|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
41468296|NCT06368141|DRUG|Capecitabine|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
41468297|NCT06368141|DRUG|Oxaliplatin|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
41468298|NCT04372784|DEVICE|Cryotherapy|Cryotherapy entails introducing a 9 French catheter via the endoscope's accessory port. The catheter is advanced until it is visualized on the endoscopy monitor. Under 4 psi pressure, liquid nitrogen is sprayed from the catheter for twenty seconds over each four-centimeter segment of stricture
41468299|NCT04372784|PROCEDURE|Esophagogastroduodenoscopy with Balloon Dilatation|This procedure entails deploying a balloon via the accessory port of the esophagogastroduodenoscope under direct visualization and serially inflating the balloon. Balloon dilatation disrupts not only the muscular rings surrounding strictures but also the granulation tissue composing the strictures.
40789674|NCT05255302|DRUG|Pemetrexed|Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
40789675|NCT05255302|DRUG|Pembrolizumab after randomization|Pembrolizumab 200 mg every 3 weeks after randomization
40789676|NCT02694601|DIETARY_SUPPLEMENT|Control|4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
40789677|NCT02694601|DIETARY_SUPPLEMENT|Caffeine low dose|4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
40789678|NCT02694601|DIETARY_SUPPLEMENT|Caffeine high dose|4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
40789679|NCT06351839|BEHAVIORAL|Sleep-Well despite persistent pain|The Sleep-Well program covers four overarching topics stretched over 7 group sessions (each lasting \~1.5 hours): 1) providing information about sleep physiology, causes of sleep problems, sleep habits and hygiene and use of sleep assessment methods (i.e., sleep diaries) for deciding sleep restriction schedules; 2) behavioural strategies through the application of stimulus control and sleep restriction; , 3) mental strategies by addressing and changing unhelpful (meta)cognitions that commonly occur in sleep and persistent pain conditions; and 4) strategies related to maintenance of good sleep and prevention of relapse. The program has been developed by Diakonhjemmet hospital in Oslo and includes a guideline for therapist and a workbook for patients (that includes home tasks for the participant).
40789680|NCT06351839|BEHAVIORAL|TAU (treatment-as-usual)|The treatment-as-usual arm represents an active waiting-list arm as subjects receive standard care, which may involve some sleep assessment, rudimentary advice/education about sleep, and possibly also sleep medication. The type of sleep treatment this group receives during the waiting-list period will be recorded from the patients' journal.
40789681|NCT04632394|DIAGNOSTIC_TEST|Generation of computational model from cardiac MRI.|Routine cardiac MRI scan results will be sent to Johns Hopkins University where a computer-generated model of the heart will be made, which will demonstrate predicted areas critical to VT generation and maintenance. This data will be sent back to St George's, and integrated with the standard VT ablation mapping software to allow comparison of its accuracy with standard mapping techniques.
40789682|NCT04632394|PROCEDURE|VT ablation|Routine VT ablation as described elsewhere in the literature. However, a brief period of extra time (\~30 minutes) will be spent analysing the areas of the heart which the MRI scan predicted as being important for generation of VT. We will study the effect of ablation of these areas (if indicated) on distant parts of the heart.
40789683|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)|0.1 mL, Intradermal (ID)
40789684|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)|0.1 mL, Intradermal (ID)
40789685|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
41309390|NCT00764959|DEVICE|Encore Linear™ Hip System|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
41468300|NCT05116787|DRUG|BCX9930 monotherapy|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
41468301|NCT05116787|DRUG|Placebo|Administered orally twice daily
41468302|NCT03170102|OTHER|Building capacity through education|Participants engaged in 2 webinars and 3 online discussions following reading selected material.
41468303|NCT06493409|DRUG|Repotrectinib|Specified dose on specified days
41468304|NCT06493409|DRUG|Voriconazole|Specified dose on specified days
41468305|NCT06493409|DRUG|Quinidine|Specified dose on specified days
40789686|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (High-dose)|0.5 mL, Intramuscular (IM)
40789687|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
41468306|NCT04928664|DRUG|Liposomal bupivacaine|Single shot injection of 10ml 1.33% LB; Due to the milky colour of LB, syringe containing the LB will be covered; Followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml NS; The default fixed rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
41468307|NCT04928664|DRUG|Standard bupivacaine|Single shot injection of 10 ml 0.25% SB in ISB; In order to have blinding to the drug injected, syringe containing SB will be covered; followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml 0.2% SB; The default fixed-rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
41468308|NCT00561171|DRUG|SPP635|oral once daily
41468309|NCT02247518|DRUG|Cialis Tab. 5mg|
41309391|NCT01755468|DRUG|Intermittent insulin therapy|
41309392|NCT01755468|DRUG|Continuous metformin|
41468310|NCT02247518|DRUG|Harnal-D Cap. 0.2mg|
41488675|NCT06206382|PROCEDURE|Whipple operation|Whipple operation is the surgery used for pancreatic head cancer in the form of pancreaticoduodenectomy then reconstruction
41488676|NCT00276549|DRUG|docetaxel|docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
41468311|NCT04718649|DRUG|Celebrex with Joins or not|The enrolled patienst will be divided into the group taking celecoxib 200mg with Joins tab together and the group taking celecoxib 200mg with Joins placebo in the same probability of 2:1 according to the randomization table at the first outpatient visit. Among the co-researchers, one researcher who is in charge of patient assignment will create a randomization table through computer generated randomization. And this researcher who is charge of the patient assignment will not intervene in any other process of this study, and only participates in the task of selecting the assigned group using random checks. The evaluation will be evaluated by an researcher who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study
41468312|NCT06494397|DRUG|VHX-896 and iloperidone|oral tablet
41148140|NCT02531997|BEHAVIORAL|Hypnotic Relaxation Therapy|There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
41468313|NCT06494397|DRUG|Iloperidone and VHX-896|oral tablet
40789688|NCT01936233|DRUG|Aspirin|Aspirin 0.1 QD po
40993806|NCT04914910|DEVICE|Minimed 780G insulin pump|This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.
40993807|NCT06391736|GENETIC|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
40993808|NCT05133687|DRUG|Bupivacaine Hydrochloride|Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
40993809|NCT04254978|DRUG|Bomedemstat|Oral administration
40993810|NCT05931328|DRUG|thiotepa combined with pomalidomide|thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
40993811|NCT04797949|DRUG|Low-dose aspirin|Women will be prescribed 81 mg of aspirin to take daily during pregnancy.
40993812|NCT05046613|OTHER|Rimegepant|75mg
40993813|NCT05046613|OTHER|Not taking Rimegepant|No rimegepant
41148141|NCT02531997|BEHAVIORAL|Progressive Muscle Relaxation|Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
41148142|NCT05240729|PROCEDURE|Infraclavicular brachial plexus block|Using ultrasound in 3different techniques of infraclavicular brachial plexus block
41148143|NCT05196958|OTHER|GLP1 analogues|This cohort study has 2 phases: an observation phase to collect all initial clinical and biological parameters and an intervention phase (prescription of GLP1 analogues) of 6 months including a visit at 3 and 6 months.
41468314|NCT06616480|DEVICE|BenQ Materials DSFNC1 soft hydrophilic contact lenses|Test lenses were to be worn for approximately 90 days.
41468315|NCT06616480|DEVICE|Visco SiHy Color soft hydrophilic contact lenses|Control lenses were to be worn for approximately 90 days
40789689|NCT01936233|DRUG|Lamivudine|LAminvudine 0.1 QD po
40789690|NCT02192567|DRUG|DS-5573a|"Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1."
40789691|NCT05214352|OTHER|co-design in the intervention manual elaboration to increase the participation in the community|"It will co-design an intervention manual between all participants (families, young people with cerebral palsy and therapists) and researchers, using the involvement matrix to increase the participation of young people in the community.~Different focus grous will be created to work together and various online meetings, masterclass, workshops to increase the knowlodge in all groups."
40993814|NCT05197270|BIOLOGICAL|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept
40993815|NCT05197270|BIOLOGICAL|Aflibercept IVT|Commercially available Active Comparator Other Name: Eylea
40993816|NCT04982055|DRUG|Nadroparin (intravenous Infusion)|Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU
40993817|NCT04982055|DRUG|Nadroparin (subcutaneous group)|Subcutaneous route of administration of nadroparin 3800 IU
40993818|NCT06344754|OTHER|Gamified education|Training will be provided with gamification method. Data will be collected with \&#34;Introductory Information Form\&#34; and \&#34;Family Planning Attitude Scale\&#34;. The family planning attitude scale will be administered as both pre and post test.
40993819|NCT05264194|OTHER|Suturing technique|The technique (subcuticular or transcutaneous) that will be used to close skin post-surgery.
40993820|NCT02635516|DEVICE|Near-Infrared Phototherapy|"The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized."
40993821|NCT06250023|OTHER|Early shift til oral antibiotic treatment for osteomyelitis|To investigate whether early transition to oral AB treatment after one week of IV treatment is non-inferior to the current national guideline of continued IV AB treatment for two to four weeks followed by oral AB treatment for PVO.
40993822|NCT01577147|OTHER|Ovulation predictions products|Home diagnostics for ovulation prediction will be provided to study volunteers
40993823|NCT02981823|PROCEDURE|hip replacement|The patients undergo hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
40993824|NCT02496455|PROCEDURE|cesarean section|Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique
41468316|NCT06331130|DIAGNOSTIC_TEST|Computed Tomography|Computed Tomography done according to Clinical Practice to assess mesenteric involvment
41468317|NCT03856905|OTHER|Physical therapy program|It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.
40993825|NCT02496455|DRUG|Opioid Tramadol|Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
40993826|NCT03783871|DEVICE|Microwave ablation|Subjects will be treated with microwave ablation.
40993827|NCT00382954|DRUG|Velcade|velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
40993828|NCT00382954|DRUG|Idarubicin|I.V., 8, or 10 or 12 mg/m\^2 weekly (days 1, 8, 15, and 22) for 4 weeks
40993829|NCT04807192|RADIATION|stereotactic body radiotherapy|one administration of SBRT 8 Gy at D1
40993830|NCT04807192|DRUG|CMP-001|4 sequential administrations of CMP001 at Day 1 (SC), Day 5 (±1) (IT), Day 9 (±1) (IT) and Day 16 (±1) (IT)
40993831|NCT04672733|BIOLOGICAL|Hizentra|Solution for injection for subcutaneous use
40993832|NCT02556268|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg, Oral (fasted conditions), 1 single dose
40993833|NCT02556268|DRUG|ATRIPLA|600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
40993834|NCT02556268|DRUG|COMPLERA|200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
40993835|NCT02556268|DRUG|STRIBILD|150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
40993836|NCT02556268|DRUG|TRIUMEQ|600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
40993837|NCT02556268|DRUG|Antiretroviral protease inhibitor|Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
40993838|NCT06308809|OTHER|PNF training|The subjects underwent rehabilitation training for 8 weeks, three times a week (Monday, Wednesday and Friday, 6:00 PM to 10:00 PM in the Physical Education College of Guangxi Normal University), and the rehabilitation training time was about 40-45 minutes per person. Before each rehabilitation training, the subjects warmed up the ankle and lower leg muscles for 5 minutes, followed by the corresponding rehabilitation training for 30-35 minutes, and relaxed the ankle and lower leg muscles for 5 minutes after the training.
40993839|NCT02629341|DIETARY_SUPPLEMENT|Functional yogurt powder|"Once daily during 24 weeks, 150g of yogurt powder enriched with:~Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10"
40993840|NCT02629341|DIETARY_SUPPLEMENT|Control yogurt powder|Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
40993841|NCT03887364|OTHER|Group A-Diaphragmatic breathing|Patient was in casual and agreeable position in which gravity helped the stomach, for example, a semi fowler's position. Hand was put on the rectus abdominis just beneath the foremost costal edge and requested that the patient take in gradually and profoundly through the nose. Persistent was told to keep the shoulder casual and upper chest very, enabling the belly to rise marginally. At that point persistent was guided to remain loose and breathed out gradually through the mouth. The patient rehearsed this 3 to 4 times and the rest time frame was given so patient couldn't hyperventilate.This group was given 10 reps of 3 sets with 4 weeks of follow up
40993842|NCT03887364|OTHER|Group B-Icing and Airflow Stimulation|"Patient was lying comfortable in semi fowler position. Facial muscle icing was given using ice pack wrapped in cloth over cheeks and nose in butterfly pattern and over forehead for 5 minutes. Ice pack was applied on the patients face (around the cheek \& nose) and accessory muscles (sternocleidomastoid muscles, upper trapezius) for single session of 5 to 10 minutes.~After that airflow stimulation was given with the help of table fan. Table fan was placed on the central area of face. Duration of the fan for the patient was at least 5 minutes to relive dyspnea and distance kept approximate of 60 centimeter (2 rulers)."
40993843|NCT03095456|DRUG|Revefenacin|Revefenacin administered via nebulization.
40993844|NCT03095456|COMBINATION_PRODUCT|Spiriva Handihaler®|Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
40993845|NCT03095456|DRUG|Placebo for Revefenacin|Placebo administered as double blind, double dummy via nebulization.
41309393|NCT03733873|DRUG|Desmopressin|take desmopressin for 3 months
40993846|NCT03095456|DRUG|Placebo for Spiriva Handihaler®|Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
40993847|NCT02550847|DEVICE|The imaging biomarkers determined by MR-PET|The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.
40993848|NCT01094548|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
40993849|NCT01094548|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
41309394|NCT03733873|DRUG|Suoquan|take Suoquan mixture for 3 months
41341717|NCT00668772|DRUG|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
40993850|NCT01094548|DRUG|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
40993851|NCT01094548|DRUG|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m\^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m\^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
40993852|NCT03904758|DIAGNOSTIC_TEST|Pepsin in saliva test|The presence of pepsin in the saliva will be tested in both groups of patients.
40993853|NCT03169465|PROCEDURE|open approach|open excision of the bursa and deformity then debridement of Achilles tendon
40993854|NCT03169465|PROCEDURE|endoscopic approach|excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
40993855|NCT02669368|DRUG|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
40993856|NCT02669368|DRUG|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
40993857|NCT02669368|DRUG|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
40993858|NCT02669368|DRUG|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
40993859|NCT04988347|COMBINATION_PRODUCT|Spirulina platensis|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
40993860|NCT04988347|OTHER|Placebo comparator|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
40993861|NCT03560050|BEHAVIORAL|Nutrition assistance|Participating family child care home providers in and around the Oklahoma City (OKC) area will be randomized to either the Nutrition (n=26), or an environmental health comparison group (n=26). Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
40993862|NCT03560050|BEHAVIORAL|Children's environmental health|Participating family child care home providers in and around the OKC area will be randomized to either the Nutrition (n=26), or an environmental health intervention (n=26) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Intervention will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
41341718|NCT00668772|DRUG|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
40993863|NCT06434662|DRUG|mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (24 mg/m\^2) on day 1, every 4 weeks
40993864|NCT06434662|DRUG|Cytarabine|Cytarabine (1.0 g/m\^2, q12h ) on day 1,3,5, every 4 weeks
40993865|NCT06434662|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
40993866|NCT03274986|DEVICE|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL.
40993867|NCT03274986|DEVICE|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
40789692|NCT01692106|PROCEDURE|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
40789693|NCT03540420|DRUG|Atezolizumab|atezolizumab 1200 mg intravenous every 3 weeks in 12 months
40993868|NCT03274986|PROCEDURE|Cataract surgery|IOL bilateral implantation
40993869|NCT06133231|DIETARY_SUPPLEMENT|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|Participants will take 2-3 capsules of EMP+ two to three times per day for eight weeks.
40993870|NCT06092099|DEVICE|TENA SmartCare Change Indicator|The TENA SmartCare Change Indicator is an accessory to absorbent incontinence products, intended for use on individual(s) with urinary incontinence who are dependent on one or more caregivers to change the absorbent incontinence product. The TENA SmartCare Change Indicator estimates the degree of urine saturation in the absorbent incontinence product and notifies the caregivers. This facilitates the caregiver's decision regarding when to change the absorbent incontinence product. As the current study is needed to validate the updated device, the full system will not be used, only the sensor part.
41148144|NCT02416349|OTHER|Respiratory Muscles Stretching|"Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.~Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching"
41341719|NCT00668772|DRUG|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
40789694|NCT04137367|BEHAVIORAL|Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the active condition, the probe appears at the location of the most positive stimuli of each pair in 87 % of trials (encouraging a positive affective bias). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
40993871|NCT05446883|DRUG|QL1706|Intravenous Infusion
40993872|NCT05446883|DRUG|Placebo|Intravenous Infusion
40993873|NCT05446883|DRUG|Paclitaxel injection|Intravenous Infusion
40993874|NCT05446883|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
40993875|NCT06483854|DIAGNOSTIC_TEST|HIV counseling and testing from a traditional health practitioner|Healer provided HIV counseling and testing services offered to clients
40993876|NCT05815316|DRUG|18F-PSMA-1007|(3S, 10S, 14S)-1-\[4-\[\[(2S)-4-carboxy-3-\[(2S)-4-carboxy-2-(6-\[18F\]fluoropyridin-3- amido)butanamido\]butanamido\]methyl\]phenyl\]-3- \[(naphtalen-2-yl)methyl\]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane- 10,14,16-tricarboxilyc acid
40993877|NCT03644199|OTHER|Oral Glucose Tolerance Test (OGTT) assessment arm|Hormonal and motility responses to a standard OGTT evaluation arm
40993878|NCT03644199|OTHER|Mixed meal test evaluation test arm|Evaluate the hormonal and motility responses to a standard mixed meal test through the day
40789695|NCT04137367|BEHAVIORAL|Sham Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the sham condition, the probe appears at the location of the most positive stimuli of each pair in 50 % of trials (no contingency between facial expressions shown and the probe location). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
40993879|NCT06190431|OTHER|Learning the use of an in-exsufflation device with the guidance of a physiotherapist|Learning to use an in-exsufflation device with the guidance of a physiotherapist
40993880|NCT06190431|OTHER|Using the coaching mode|Learning the use of an in-exsufflation device using a coaching mode (playful visual stimulation) in addition to guidance of a physiotherapist
40993881|NCT03591016|OTHER|Recording number of IV attempts|Recording number of IV attempts in the operating room
40993882|NCT03461900|OTHER|Minifluid challenge|Pragmatic optimization fluid management protocol based on Mini-Fluid Challenge (MFC) in treating an acute circulatory failure. MFC consist of an infusion of 100 ml of colloid solution (4% human serum albumin) during 1 minute via a separate venous line. Before and after each MFC and depending on the hemodynamic device used, the attending physician will perform a first set of hemodynamic measurements, including cardiac index (CI) or cardiac output (CO); stroke volume (SV), indexed stroke volume (iSV) or velocity time index (VTI). If the variation in measurement is superior to 10%, the attending physician will infuse 400 ml of buffered crystalloid solution or saline solution. After an infusion of 500 ml, fluid responsiveness will be evaluated with CI or CO measurement. For non-responders, fluid challenge must be stopped and other therapeutics should be considered. For responder, another MFC should be consider if hemodynamic status is not stabilized.
40993883|NCT03461900|OTHER|Usual practice|Patients included in control group will be managed according to the last surviving sepsis recommendations edited in 2017.
41148145|NCT02416349|OTHER|Control Group|Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
41468318|NCT03856905|DEVICE|Extracorporeal shock wave therapy|It is an electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG). The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode.
40789696|NCT00776360|DRUG|oxytocin|80mIE/min as continuous infusion for 70 minutes
40993884|NCT04530006|DIAGNOSTIC_TEST|Amantadine Hydrochloride|"Patients who are eligible for the study will be administered a regular 200 mg dose of FDA approved drug amantadine. This will be done at the following timepoints:~1. Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~2. Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~3. Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
40993885|NCT05334901|DEVICE|High intensity light cure|Bulk fill resin composite restoration cured with high intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
40789697|NCT00776360|DRUG|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
40789698|NCT01297283|OTHER|LECG first|Measurement of the pacing threshold with the support of a leadless ECG
40993886|NCT04972084|DEVICE|Powerscope group|Treatment of Class II malocclusions using Powerscope appliance
40993887|NCT01412203|BEHAVIORAL|Action Schools! BC|AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
40993888|NCT05892003|OTHER|Phase 1 Control|Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
41148146|NCT00560209|DRUG|ONO-1101|placebo for 1 minute IV
41148147|NCT00560209|DRUG|ONO-1101|0.06 mg/kg for 1 minute IV
41148148|NCT00560209|DRUG|ONO-1101|0.125 mg/kg for 1 minute IV
41341720|NCT00668772|DRUG|Tiotropium|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
41468319|NCT03856905|DEVICE|Functional electrical stimulation|It is a highly advanced medical device that consists of a battery-operated, single-channel electrical stimulator, two electrodes, and electrode leads with a cuff holds the system in place. The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait.
41148149|NCT03578744|PROCEDURE|Conventional Flap surgery|After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
40789699|NCT01297283|OTHER|Programmer ECG first|Pacing threshold measurements are done with the support of the programmer ECG
41148150|NCT00203502|DRUG|Bevacizumab|IV 15mg/kg 21 days
41148151|NCT00203502|DRUG|Cyclophosphamide|500mg per meter squared, IV every 21 days
41148152|NCT00203502|DRUG|Docetaxel|60 mg per meter squared, IV every 21 days
41148153|NCT03449485|DRUG|Chlorprothixene|Patients are tested for their normal prescription chlorprothixene medication
40789700|NCT03924492|DRUG|ZULRESSO (brexanolone) injection|ZULRESSO
40789701|NCT03100318|DRUG|FYU-981|Oral daily dosing for 14 weeks
40789702|NCT03100318|DRUG|Benzbromarone|Oral daily dosing for 14 weeks
40993889|NCT05892003|OTHER|Phase 2 High Fibre Weight Loss|High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
40993890|NCT05892003|OTHER|Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss|High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
40993891|NCT03897452|DRUG|Fentanyl (5 microgram/ml) prediluted ampoules|"Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation)."
40993892|NCT00748267|OTHER|questionnaire administration|
40993893|NCT00748267|PROCEDURE|hypnotherapy|
40993894|NCT00748267|PROCEDURE|therapeutic conventional surgery|
40993895|NCT02607436|DRUG|Sarpogrelate|Sarpogrelate
40993896|NCT02607436|DRUG|Aspirin|Aspirin
41148154|NCT01541176|OTHER|Absence of corticotherapy post-transplantation|No study treatment
40993897|NCT00002504|BIOLOGICAL|aldesleukin|
40993898|NCT00002504|BIOLOGICAL|recombinant interferon alfa|
40993899|NCT02270827|DRUG|Aminophylline|intravenous medication
40993900|NCT02270827|DRUG|Hydrocortisone|Intravenous medication
40993901|NCT05930730|BIOLOGICAL|Comvigen (Bivalent, ChulaCov19 BNA159.2)|single dose of COMVIGEN at 50 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
40993902|NCT05930730|BIOLOGICAL|BIVALENT Pfizer/BNT vaccine|single dose of BIVALENT of Pfizer/BNT Bivalent vaccine at 30 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
40993903|NCT01530295|DRUG|DOCETAXEL|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
40993904|NCT03526458|DEVICE|Holmium:YAG laser|Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
41341721|NCT01766765|PROCEDURE|Jejunostomy|Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
41341722|NCT01766765|OTHER|Early oral nutrition|Free oral nutrition as tolerance allows on POD 1.
41468320|NCT04769752|OTHER|collection of the allocated treatment|collection of the allocated treatment
41468321|NCT04769752|OTHER|collection of medical complications|collection of medical complications
41468322|NCT03067740|DRUG|Bupivacaine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
40789703|NCT05855018|DRUG|Atropine sulfate eye drops|One drop once daily
40789704|NCT00761488|DEVICE|AcrySof® Toric IOL|Implanted into the study eye
40789705|NCT01526941|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
40789706|NCT01526941|DRUG|biphasic insulin aspart 70|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
41148155|NCT01541176|DRUG|Corticotherapy post-transplantation|"Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :~* D1 to D14 : 20 mg/day,~* D15 to M1 : 15 mg/day,~* M1 to M3 : 10 mg/day,~* M3 to M12 : 5 mg/day."
41148156|NCT00942188|DRUG|LY2189102|Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
41148157|NCT00942188|DRUG|Placebo|Participants received 2 SC injections weekly for 12 weeks.
41148158|NCT05281419|OTHER|Intralesional triamcinolone injection|Injecting 40mg triamcinolone into the abscess cavity through the aspiration needle or drainage tube every 1 week
41148159|NCT05281419|OTHER|No intralesional triamcinolone injection|No intralesional triamcinolone injection
41148160|NCT01946256|DRUG|Amoxicillin|
41148161|NCT01946256|DRUG|Erythromycin|
41148162|NCT06475690|OTHER|Psychological interventions|Psychological interventions is used for intervention group
41148163|NCT01558245|DRUG|tissue kallikrein|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
41148164|NCT03463291|DEVICE|MRI|"* T1 weighted image.~* Fast spin-echoT2 weighted image.~* Short inversion recovery (STIR).~* T1-fat suppressed images.~* Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values."
41468323|NCT03067740|DRUG|Dexmedetomidine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
41148165|NCT01973478|DEVICE|DBS|
41148166|NCT01973478|DEVICE|SHAM|
41148167|NCT00957918|DRUG|nicotine|Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.
41148168|NCT00957918|OTHER|placebo comparator|oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.
41148169|NCT01544309|DRUG|Atorvastatin|"Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.~(When not reach the LDL-C level of target in the Japan Atherosclerosis Society \[JAS\] Guidelines \[GL\] after 3 months, had the atorvastatin \[ATV\] dose of 20 mg.)"
41148170|NCT01544309|DRUG|Rosuvastatin|"Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin \[RSV\] dose of 10 mg.)"
41148171|NCT03599440|OTHER|Pressure line extensions|"Two types of extension lines are connected:~* Perfusor® line 150cm (polyethylene)~* conventional arterial extension line"
41148172|NCT04175392|DRUG|Align Probiotic Supplement Capsule|Align Probiotic 1 billion units, 1 capsule once daily
41148173|NCT04175392|DRUG|Placebos|Placebos capsule 1 capsule Once daily
41148174|NCT06234449|PROCEDURE|Vaginal pessary before surgery for pelvic organ prolapse|use of vaginal pessary for patients waiting for gynecological surgery for stage III and IV pelvic organ prolapse
41148175|NCT03640754|BIOLOGICAL|G-CSF|G-CSF injected subcutaneously 3 times (Days 0, 28, 56)
41148176|NCT03640754|OTHER|Placebo/Saline|Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)
41148177|NCT00002878|DRUG|dexamethasone|
41148178|NCT00002878|DRUG|doxorubicin hydrochloride|
40993905|NCT03967834|OTHER|Patient with Soft Tissue Sarcoma|"* Tumor specimens will be collected for the study at diagnosis.~* A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression.~* Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years."
40993906|NCT04087187|DRUG|Treatment A|Subject will be given AZD5718 Dose A tablet once daily
40993907|NCT04087187|DRUG|Treatment B|Subjects will be given AZD5718 Dose B tablet once daily
40993908|NCT04087187|DRUG|Treatment C|Subjects will be given AZD5718 Dose C tablet once daily
40993909|NCT04738916|DEVICE|Whole-body vibration training|Whole body vibration (WBV) is a form of treatment that has been shown to have an important role in increasing neuromuscular performance, improving muscular strength, balance. The technique involves standing and holding positions, or performing prescribed exercises, on a platform that is vibrating at a programmed frequency, amplitude, and magnitude of oscillationWhole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform.
40993910|NCT00115973|DEVICE|pump|
40993911|NCT00115973|DRUG|insulin aspart|
40993912|NCT05826899|OTHER|54Fe SO4|4 mg of iron as FeSO4 labelled with 4 mg of 54Fe
40993913|NCT05826899|OTHER|57Fe Oat-1|4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe
41148179|NCT00002878|DRUG|valspodar|
41468324|NCT05945810|DRUG|TLL-018 extended-release tablet|50mg TLL-018 extended-release tablet QD
41148180|NCT00002878|DRUG|vincristine sulfate|
41148181|NCT02741921|DEVICE|VivaSight DL|intubation using VivaSight DL tube
41148182|NCT02741921|DEVICE|conventional double-lumen tube|intubation using conventional double-lumen tube
41148183|NCT04932083|DRUG|Bupivacaine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added."
41148184|NCT04932083|DRUG|Fentanyl|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added."
41148185|NCT04932083|DRUG|Nalbuphine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added."
41148186|NCT04932083|DRUG|Midazolam|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added."
41148187|NCT02222649|DIETARY_SUPPLEMENT|Vitamin D3|High dose of 200,000 IU of cholecalciferol orally in a single dose
41148188|NCT02222649|DIETARY_SUPPLEMENT|Placebo|Capsules of starch, no therapeutic action
40993914|NCT05826899|OTHER|58Fe Oat-2|4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.
40993915|NCT05826899|OTHER|54 FeSO4 + Acai puree with honey|4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.
40993916|NCT05826899|OTHER|57Fe Oat-1 + Acai puree with honey|4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.
41148189|NCT04517604|DEVICE|Magventure MagProx100 with MagOption|iTBS will be delivered utilizing the MagVentrure MagPro X100 with MagOption stimulator that includes active and placebo coils (C-B60 Butterfly coils). Only the active setting will be used.A MagVenture C-B60 coil will be used to deliver single pulse TMS to the non-dominant MC to identify the ab-ductor pollicis brevis (APB) muscle coordinates. The integrated Localite neuronavigation system will be used.
41148190|NCT03740919|DRUG|LY900014|Administered SC
41148191|NCT03740919|DRUG|Insulin Lispro|Administered SC
41309395|NCT06330662|PROCEDURE|Testing the effectiveness of hyaluronic acid in experimental group using a coronally advanced flap compared to a control group using a coronally advanced flap only|The potential benefit of adding hyaluronic acid (HA) to the coronally advanced flap (CAF) operative technique to cover multiple adjacent recessions has not been sufficiently investigated. Improving aesthetics is one of the primary goals of root recession coverage periodontal surgery, and little is known about the same in multiple adjacent gingival recession coverage therapy. In patients with a sufficient amount (≥2 mm) of keratinized tissue, the coronally advanced flap (CAF) has been shown to be very effective in the treatment of multiple recessions, especially in terms of aesthetic results. The researchers concluded from a database search (Epistemonikos, Cochrane, Medline) that there is no evidence to support the use of HA + CAF to achieve greater root coverage in the treatment of multiple gingival recessions.
41468325|NCT05945810|DRUG|TLL-018 immediate-release tablet|20mg TLL-018 immediate-release tablet BID
41468326|NCT01069614|DEVICE|TopClosure 3S System|
41309396|NCT01062594|OTHER|Supervised exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
41309397|NCT01062594|OTHER|Role of exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
40993917|NCT05826899|OTHER|58Fe Oat-2 + Acai puree with honey|4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey
41309398|NCT01062594|OTHER|Supervised exercise program|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
41309399|NCT06429735|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface
40789707|NCT03707886|BEHAVIORAL|Pain SMART|Pain SMART is a brief, one-visit shared medical appointment where providers in primary care and a behavioral health specialist (e.g., a psychologist) meet with a group of patients with chronic pain to discuss pain management approaches.
40789708|NCT03707886|OTHER|minimally enhanced usual care|The minimally enhanced usual care group will receive educational information via mail about non-pharmacological approaches to pain management.
41468327|NCT05373641|OTHER|Repeated feedback|Repeated feedback monthly based on previous month pain documentation audit results.
40789709|NCT01215656|DIETARY_SUPPLEMENT|Lactobacillus fermentum|
40789710|NCT01215656|DIETARY_SUPPLEMENT|Follow on formula without probiotics|
41468328|NCT05373641|OTHER|Pain documentation audit|Monthly pain documentation audit
41468329|NCT05377606|PROCEDURE|Pars plana vitrectomy with silicone oil|Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.
41309400|NCT06429735|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
41468330|NCT05377606|PROCEDURE|Pars plana vitrectomy with SF6|Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.
40789711|NCT05762042|OTHER|dietary supplement|"Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally."
40993919|NCT03638310|PROCEDURE|intratympanic application of gentamicin|under local anesthesia is gentamicin instilled through tympanic membrane to tympanic cavity
40993920|NCT03638310|PROCEDURE|microsurgical removal of vestibular schwannoma|surgery under general anesthesia
40993921|NCT01824186|PROCEDURE|SILC|Underwent single-incision laparoscopic cholecystectomy
40993922|NCT01824186|PROCEDURE|LC|Underwent conventional 4-port laparoscopic cholecystectomy
41309401|NCT03235570|DRUG|Pemigatinib|Pemigatinib at the protocol-defined dose administered once daily.
41468331|NCT03710317|DRUG|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
41468332|NCT03710317|DRUG|Tranexamic Acid|1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
41468333|NCT03710317|DRUG|misoprostol|Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision
40993923|NCT03896243|DIAGNOSTIC_TEST|Uterine artery ligation (UAL)|"Uterine artery ligation (UAL) We will invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They will evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
40993924|NCT05383079|DRUG|Lutetium-177 PSMA-I&T|Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
40993925|NCT05383079|DRUG|Radium-223|During dose escalation, doses of Radium-223 that will be administered include 27.5 kBq/kg and 55 kBq/kg. The maximum tolerated dose of Radium-223 will be used during dose expansion. Radium-223 will be given once every 6 weeks for up to 6 doses between day 1-5 of each Cycle.
40993926|NCT05165615|DEVICE|Insulin Pump t:slim X2 with Control-IQ technology|Usage of Insulin pump t:slim X2 with Control-IQ technology in previous users of AndroidAPS
40993927|NCT04700358|OTHER|Blood sampling|"Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)"
40993928|NCT02820012|OTHER|Scoliosis|Questionnaires, radiography
41148192|NCT03740919|DRUG|Insulin Glargine|Administered SC
41148193|NCT03740919|DRUG|Insulin Degludec|Administered SC
41468334|NCT04871568|PROCEDURE|Temporary central dialysis catheterization|Placement of temporary central dialysis catheter
40993929|NCT02380664|DEVICE|Whole-body vibration (Powerplate®)|Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
40993930|NCT02380664|BEHAVIORAL|Jumping intervention|Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
40993931|NCT06078033|BIOLOGICAL|Mobilization with movement|Sustained neutral apophyseal glide (SNAG) mobilization with movement applied to targeted vertebra while patients performed their painful movement.
40993932|NCT06078033|BIOLOGICAL|Sham mobilization with movement|Manual contact (without any pressure) applied to targeted vertebra while patients performed their painful movement.
40993933|NCT06267079|OTHER|core stability exercise|Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).
40993934|NCT04382131|OTHER|NaCl Solution|NaCl Solution prepared by participants at home using water and salt
40993935|NCT05220579|DEVICE|"Exposure to TOR device"|"Specific wave spectrum is directed by the TOR device to human tissues affected by the SARS-CoV-2 virus in order to disrupt its activity."
40993936|NCT05220579|DEVICE|"Exposure to switched off TOR device"|"The TOR device has screened indicators on the front panel. The device was switched on / off by a medical monitor without the participation of medical personnel and investigators."
40993937|NCT06160063|BEHAVIORAL|Education intervention|Board game was created in line with current literature. In each interview, it is expected that the child's negative behaviors will be transformed into positive behaviors.
40993938|NCT03493984|OTHER|Ginger exosomes|Naturally occurring plant exosomes from ginger
40993939|NCT03493984|OTHER|Aloe exosomes|Naturally occurring plant exosomes from aloe
40993940|NCT03493984|OTHER|Placebo|Exosome placebo tablet
40993941|NCT01973985|OTHER|Pleural Manometry|Intrapleural pressure will be monitored with the use of an electronic pleural manometer (Mirador Biomedical CompassTM Thoracentesis Assist Device).
40993942|NCT01973985|OTHER|Thoracic ultrasonography|"Thoracic ultrasound scan will be done before drainage of pleural effusion - all participants.~Thoracic ultrasound scans will also be done during drainage of pleural effusion and the results will be recorded after every 100mL of pleural fluid drained - all participants.~Thoracic ultrasound scan will be done after drainage of pleural effusion - all participants.~Thoracic ultrasound scan will also be be done during clinic follow-up as part of routine clinical care - all participants."
41148194|NCT01071720|DRUG|CKD-501 1mg|This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
41468335|NCT00475917|DRUG|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
40993943|NCT01973985|PROCEDURE|Pleural aspiration catheter OR chest drain (standard care)|Insertion of pleural aspiration catheter OR intercostal chest drain under ultrasound guidance - all participants (standard care).
40993944|NCT01973985|PROCEDURE|Talc slurry pleurodesis via chest drain (standard care)|Talc slurry pleurodesis via intercostal chest drain where/when clinically indicated as part of routine clinical care participants with intercostal chest drain only (standard care).
40993945|NCT05091008|DRUG|Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet|proper history was taken. HCV genotyping was done revealed GT 4 in all included patients. Basic ECG and abdominal US were performed prior to treatment. Concomitant HBV infection was excluded by HBs Ag and anti-HBc antibody HIV screening was done prior to treatment. Basic investigations were done prior to therapy. All included patients received Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks. Regular visits were arranged at 4, 8, and 12 weeks with easy access to the pediatric hepatology unit and the treating physician if any urgent problem in between the visits. Every visit, laboratory investigations were checked. Adverse events (after excluding other possible causes) were reported for the safety profile of the drug. The efficacy of the drug, HCV-RNA was assessed by quantitative real-time PCR at 4 weeks and after the end of the treatment course (12 weeks)
40993946|NCT06264206|DIAGNOSTIC_TEST|Killer-cell immunoglobulin-like receptors (KIRs) testing|patients were tested for KIRs, and based on the divided in the 2 arms. Patient from ARM KIR AA received immunomuodulatorc treatment.
40993947|NCT03207932|PROCEDURE|Central vein catheterisation|ultrasound guided versus landmark central vein catheterisation
40993948|NCT04898673|DEVICE|CP1110|Sound Processor
40993949|NCT04898673|DEVICE|CP1000|Sound Processor
40993950|NCT00733746|DRUG|erlotinib hydrochloride|oral administration
40993951|NCT00733746|DRUG|gemcitabine hydrochloride|Intravenous administration
40993952|NCT00733746|PROCEDURE|therapeutic conventional surgery|
41148195|NCT06068803|DIETARY_SUPPLEMENT|Ketone drink|Participants will consume three daily ketone monoester (KME) drinks (0.282g KME/kg body weight/ serving) for 4 weeks.
41148196|NCT06068803|DIETARY_SUPPLEMENT|Placebo|Participants will consume three daily taste-matched calorie-free placebo drinks for 4 weeks.
41309402|NCT06295016|OTHER|High-intensity intensive training|"Participants will conduct a 3-weeks of 130% progressive high-intensity intensive training (increasing by 10% each week).~Week 1: Increase training to 110% of participants' regular training volume. Week 2: Increase training to 120% of participants' regular training volume. Week 3: Increase training to 130% of participants' regular training volume."
41341723|NCT05896410|DEVICE|splint (orthosis)|3D printed splint (orthosis) help prevent the joint from shifting during pinch activities. This reduces improper joint loading and helps reduce pain and the progression of degenerative change in patients with OA.
41468336|NCT00475917|DRUG|Gemcitabine|once-weekly 30-minute IV infusion
41468337|NCT04751045|PROCEDURE|EUS liver biopsy|Endoscopic ultrasound guided liver biopsy
41468338|NCT00190489|DRUG|AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|
41468339|NCT00190489|DRUG|Docetaxel 60mg/m2 every 21 days for 6 cycles|
41468340|NCT00190489|DRUG|AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles|
41468341|NCT00917735|DRUG|Green tea extract supplement|Two green tea extract capsules twice daily after breakfast and dinner for one year
40993953|NCT02983383|PROCEDURE|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
40993954|NCT02983383|PROCEDURE|spinal anesthesia|Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).
40993955|NCT05132764|PROCEDURE|Microosteoperforations|2 inter radicular bone microosteoperforations using temporary anchorage device tip.
40993956|NCT03035955|DRUG|Azelaic acid|15% gel twice daily for four weeks to one side of face
40993957|NCT05020340|PROCEDURE|External cephalic version|In the intervention group, ECV will be performed by two operators with one of them having experience of ≥ 5 successful ECV. The procedure will be performed by the first operator under real time continuous ultrasonographic guidance. The fetal head and buttock will be grasped by both hands and attempt to rotate the fetus to a longitudinal lie either in a clockwise or anti-clockwise fashion. The second operator will perform the ECV if the first operator fails the procedure.
40993958|NCT01508975|OTHER|White Rice, Brown Rice, Glucose|white rice, brown rice, glucose
40993959|NCT02233322|DIETARY_SUPPLEMENT|Iron|All subjects will receive iron supplementation based on iron levels in the blood
40993960|NCT01393340|DRUG|Omalizumab|"Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab."
40993961|NCT01393340|DRUG|Placebo|Placebo
40993962|NCT06362135|DEVICE|Virtual Home Visit|The virtual home visit will be made through the mobile application developed by the researchers. First, the patients who meet the sampling criteria will be included in the study after the caregivers of the patients apply to the Antalya Health Directorate Antalya Training and Research Hospital Home Health Unit. The virtual home visit is scheduled twice
40993963|NCT06362135|DEVICE|Control Group|"Face-to-face home visits will be carried out by the Antalya Education and Research Hospital home health team, as planned."
40993964|NCT00772499|DRUG|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
40993965|NCT00772499|DRUG|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
40993966|NCT03898596|DIAGNOSTIC_TEST|ECG|An ECG collects superficial readings of heart activity
40993967|NCT00749320|OTHER|Arterial Spin Labeling Magnetic Resonance Imaging|ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
40993968|NCT00937417|DRUG|docetaxel|
40993969|NCT00937417|DRUG|vandetanib|
40993970|NCT00937417|GENETIC|proteomic profiling|
40993971|NCT00937417|OTHER|laboratory biomarker analysis|
40993972|NCT00937417|OTHER|pharmacological study|
40993973|NCT00149916|DRUG|Mycophenolate sodium (enteric coated)|
40993974|NCT03197233|OTHER|Maternal vitamin A and D intake during pregnancy|Dietary exposures during pregnancy and infant supplement use were assessed from maternal questionnaire report
40993975|NCT02872779|PROCEDURE|Blood sampling for free mutant DNA analysis|Blood sampling for Patients Treated for Metastatic Colorectal cancer
40993976|NCT05298748|OTHER|Womb sound recordings|"Womb sounds will be chosen from commercially available (Amazon) womb recordings using a recording that most closely resembles the womb including maternal heart rate, fetal heartbeat, respiratory sounds, bowel popping sounds and frequency spectra as described by Parga, Daland 2018 et al."
40993977|NCT00963261|BEHAVIORAL|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
40993978|NCT01592344|DEVICE|StimRouter - active stimulation|"The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 100-250 µsec~* Pulse Rate: 50-100 Hz~* Intensity: 0-30mA Time Settings~* Constant Stim: On~* Total Time: 6 hour"
40993979|NCT01592344|DEVICE|StimRouter - Control|"The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 200 µsec~* Pulse Rate: 1 Hz~* Intensity: 0 mA Time Settings~* Constant Stim: On~* Total Time: 6 hour"
40993980|NCT02151526|DRUG|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.
41468342|NCT00917735|OTHER|Placebo|Two placebo capsules twice daily after breakfast and dinner for one year
41468343|NCT02902887|DEVICE|Controlled Intermittent Alternate Occlusion (CIAO ) glasses|Monitored CIAO therapy glasses
41468344|NCT00663715|OTHER|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
41468345|NCT05685277|DRUG|Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg|Ramipril/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
41468346|NCT05685277|DRUG|Tritace® Plus tablet 10 mg/25 mg|Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
41468347|NCT04314843|DRUG|Cyclophosphamide|Administered according to package insert
41468348|NCT04314843|DRUG|Fludarabine|Administered according to package insert
41468349|NCT04314843|BIOLOGICAL|Lenzilumab|Administered as an IV infusion
41468350|NCT04314843|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously.
41468351|NCT00680069|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.
40993981|NCT03552575|DRUG|sacubitril/valsartan|Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
40993982|NCT03552575|DRUG|Valsartan|is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
40993983|NCT05732623|BEHAVIORAL|Semi Quantitative Food Frequency Questionnaire (SQFFQ)|"The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:~* date of birth~* sex~* ethnicity~* weight (kg)~* height (m)~* BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old~* country where they live permanently~* tobacco smoking at the time of eoCRC diagnosis and at 18 years old~* sitting time~* TV-viewing time~* moderate-to-vigorous physical activity (MVPA)~* waist circumference (cm)~* home blood pressure levels (mmHg)~* fasting blood glucose (mg/dl)~* regular consumption of aspirin/NSAID and years of consumptions~* calcium and folate supplements and years of consumptions~* oral contraceptive agents and years of consumptions~* post-menopausal hormones and years of consumptions"
40993984|NCT02696642|DRUG|Anetumab ravtansine (BAY94-9343)|All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
40993985|NCT00301210|DRUG|Tramadol|oral doses four times per day
40993986|NCT02293226|DEVICE|CoopDech|Video-laryngoscopy 1
40993987|NCT02293226|DEVICE|CoPilot|video-laryngoscopy 2
40993988|NCT02293226|DEVICE|Intubrite|Video-laryngoscopy 3
40993989|NCT02293226|DEVICE|Vividtrack|video-laryngoscopy 4
40993990|NCT02510378|RADIATION|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
40993991|NCT03350360|BEHAVIORAL|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
40993992|NCT03350360|BEHAVIORAL|Comparison Task|Neutral- neutral stimuli prior to response task
40993993|NCT03276689|DRUG|Duloxetine|The patients will take duloxetine for 8 weeks.
40993994|NCT03276689|DRUG|Pregabaline|The patients will take pregabaline for 8 weeks.
40993995|NCT03276689|OTHER|Placebo|The patients will take placebo for 8 weeks.
40993996|NCT02086669|PROCEDURE|Pneumatic dilatation|
40993997|NCT02086669|PROCEDURE|Laparoscopic myotomy|
40993998|NCT05071183|DRUG|TPX-0005|Oral TPX-0005 capsules
40993999|NCT05071183|DRUG|Trametinib|Oral trametinib tablets
40994000|NCT02680028|DEVICE|targon pft nail|220 mm vs 175mm nail
40994001|NCT04380987|BIOLOGICAL|Biological sampling|For every symptomatic adult tested positive by RTqPCR, up to 45 mL of blood will be taken, nasopharyngeal and oropharyngeal swab will be performed, an induced sputum and a stool samples will be recovered at the inclusion. As follow-up, 3 weeks after inclusion, up to 45 mL of blood will be taken and a new induced sputum will be recovered.
40994002|NCT04914390|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
40994003|NCT04914390|DRUG|Tislelizumab|200mg on d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
40994004|NCT04914390|DRUG|Anlotinib|8mg on d1-14 of Cycles 1-5 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
40994005|NCT00746993|OTHER|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
40994006|NCT02440386|BEHAVIORAL|Conditional economic incentive|"Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:~1. Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and~2. send a text message to the study team to let us know they have started ART;~3. Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation."
40994007|NCT02455271|DRUG|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
40994008|NCT02670044|DRUG|Cobimetinib|Cobimetinib will be administered orally as per schedule in Arm description.
40994009|NCT02670044|DRUG|Idasanutlin|Idasanutlin will be administered orally as per schedule in Arm description.
41468352|NCT02124473|OTHER|Homeopathy|
41468353|NCT02124473|OTHER|Placebo|
40994010|NCT02670044|DRUG|Venetoclax|Venetoclax will be administered orally as per schedule in Arm description.
40994011|NCT02500784|DRUG|Formoterol A|20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
40994012|NCT02500784|OTHER|Formoterol B (placebo)|2mL, BID inhaler for 12 months
40994013|NCT03089203|BIOLOGICAL|CART-PSMA-TGFβRDN cells|autologous CAR T cells
40994014|NCT03089203|DRUG|Cyclophosphamide|300 mg/m2/day given over 3 days
40994015|NCT03089203|DRUG|Fludarabine|30 mg/m2/day given over 3 days
41488677|NCT00276549|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
40994016|NCT03341195|BEHAVIORAL|SMS messages and automated calls|The intervention consists of SMS and automated calls based messages
41488678|NCT01050608|DEVICE|Body worn alcohol gel dispenser|Records hand hygiene events of provider and tabulates on the group level.
40789712|NCT05592821|PROCEDURE|dental implant placement|In both groups, dental implants of the same brand will be placed into the bone with the same protocol.
40994017|NCT03805932|DRUG|Moxetumomab Pasudotox-tdfk|Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.
41309403|NCT06295016|OTHER|Taper|"Participants will conduct a 1-week taper phase by gradually reducing to 55% of their regular training volume.~Day 1: Decrease current training volume by 20%. Day 2: Decrease current training volume by 15%. Day 3: Decrease current training volume by 10%. Day 4: Decrease current training volume by 10%. Day 5: Decrease current training volume by 10%. Day 6: Decrease current training volume by 5%. Day 7: Decrease current training volume by 5%."
41309404|NCT05242549|BEHAVIORAL|Fitness and Nutrition Program for Seniors|"Fitness and Nutrition Program for Seniors uses the Trans-Theoretical Model (TTM) as the framework, which includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance).~Physical activity training comprised muscle training, joint strengthening, and upper and lower limb resistance exercises for older adults who were frail. After administering nutrition education- nursing Information, participants were encouraged to set their own goals to improve their diet. Home-based training and telecare group care depends on the stages of TTM behavior change of the elderly."
41309405|NCT03858062|DEVICE|Insulin pump therapy (with or without glucose sensor)|Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor
40994018|NCT03805932|BIOLOGICAL|Rituximab|Rituximab will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Rituximab is given on day -2, on subsequent cycles, Rituximab is given on day 1.
40994019|NCT03805932|BIOLOGICAL|Ruxience|Ruxience will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Ruxience is given on day -2, on subsequent cycles, Ruxience is given on day 1 (Delta)
40994020|NCT03805932|DRUG|Dexamethasone|12 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Administer 0.5-2 hours before rituximab/Ruxience. If participant has previous reaction to rituximab/Ruxience, give 12mg. If participants tolerate rituximab/Ruxience without problems, may hold at discretion of provider. Pre-medications are given prior to rituximab/Ruxience on day 1.
40994021|NCT03805932|DRUG|Acetaminophen|650 mg Cycle 1, Day -2, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
41309406|NCT03858062|DEVICE|Artificial pancreas (Inreda Diabetic)|Bi-hormonal reactive closed loop system without mealtime announcement
41309407|NCT06174181|DEVICE|Preservative-free ophtalmic lubricant emulsion|Use of a preservative-free ophtalmic lubricant emulsion continous during 6 months
40994022|NCT03805932|DRUG|Diphenhydramine|25-50 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Pre-medications are given prior to rituximab/Ruxience on day 1. May be given prior to moxetumomab pasudotox-tdfk at discretion of principal investigator.
40994023|NCT03805932|DRUG|Famotidine|20-40 mg Cycle 1, Day -2; Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
40994024|NCT03805932|DRUG|Aspirin|81 mg Cycle 1, Days 1-8; Cycles 2-8, Days 1-8. Only if platelet counts ≥ 100 x 109/L.
41148197|NCT04731428|BEHAVIORAL|Progressive Relaxation Exercise|Progressive Relaxation Exercise involves stretching sixteen muscle groups while breathing in sequentially, relaxing while exhaling. Exercise can be from head to toe or from foot to head. In order for the technique to be effective, it is important to have affective (music, etc.) and visual aids. During the exercise, the patient should complete the processes of perceiving the tension in his body, maintaining control and getting into a state of relaxation. After the patient is informed about the exercise, the person starts with breathing exercises. A deep but relaxing breath is taken from the nose, and lips are given by contracting simultaneously with relaxation. During this application, the patient keeps contracting the muscle group that he exercises for 10 seconds; the nurse provides the patient to notice the temperature / warming felt in the muscle group.
41309408|NCT06174181|OTHER|Routine treatment|Use of a preservative-free ophtalmic lubricant emulsion after each intravitreal injection during few days
40789713|NCT05010083|BEHAVIORAL|diet and lifestyle program|See description of main arm.
41148198|NCT00363389|DRUG|misoprostol and cervical ripening|
41148199|NCT02261519|DRUG|NaBen®|500 mg twice daily (1000 mg total)
41148200|NCT02261519|OTHER|Placebo|0 mg twice daily (0 mg total)
41148201|NCT00908193|DEVICE|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
41148202|NCT00908193|PROCEDURE|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
41148203|NCT00370747|DRUG|Ecabet|ophthalmic solution 2.83%
41148204|NCT00370747|DRUG|Ecabet|ophthalmic solution 3.70%
41148205|NCT00370747|DRUG|Placebo|
41309409|NCT03014440|DRUG|Cannabidiol|
41309410|NCT00163150|DRUG|Atorvastatin|
41488679|NCT01050608|DRUG|62% ethanol based hand cleanser|"CDC based guidelines with regard to utilization in the health care environment the nest"
41148206|NCT06128356|DRUG|Dexmedetomidine Sublingual|Dexmedetomidine 120 mcg on two thin dissolvable films for sublingual administration
41148207|NCT03387592|DRUG|CPT-11|180 mg/m2
41148208|NCT03387592|DRUG|Calcio levofolinate|200 mg/m2
41341724|NCT06455384|BEHAVIORAL|Genetics Navigator|The Genetics Navigator will be used to support patients during the delivery of genetic services, including intake, education, pre- and post-test counselling, and physician-generated management recommendations
41341725|NCT06455384|BEHAVIORAL|Standard Care with Genetics Professionals|Standard care for the delivery of genetic services, including receiving genetic counselling and test results
40994025|NCT00451867|DRUG|Mycophenolate Mofetil|
40994026|NCT00451867|DRUG|Mycofenolate Mofetil (MMF)|2000 mg per day divided into 2 equal doses.
41148209|NCT03387592|DRUG|5-Fluorouracil|400 mg/m2 + 2400 mg/m2
41148210|NCT03387592|DRUG|Capecitabine|1500 mg/m2
41148211|NCT03387592|DRUG|Temozolomide|200 mg/m2
41148212|NCT02617459|DRUG|Levobetaxolol eye drops|one drop per time; twice daily
41148213|NCT02617459|DRUG|Betaxolol eye drops|one drop per time; twice daily
40994027|NCT00451867|DRUG|Placebo|Placebo
41148214|NCT06584877|OTHER|sample collection|Surplus material from surgery. New or stored blood or saliva. Semen (from adult males).
40994028|NCT02474095|OTHER|Quality-of-Life Assessment|Ancillary studies
41148215|NCT06584877|OTHER|Seeking consent and assent|Consent or assent from all participants to be included in the study. Consent from parent / guardian for inclusion of children in study (as primary participant or relative/sibling, as applicable).
41309411|NCT02700100|DEVICE|Bioabsorbable Pulmonary Valved Conduit (PV-001)|"The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.~The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:~* Tetralogy of Fallot~* Truncus Arteriosus~* Pulmonary Atresia~* Transposition of Great Arteries with Ventricular Septal Defect (VSD)~* Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits."
41309412|NCT05881772|OTHER|Photobiomodulation|It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.
41309413|NCT05261672|DRUG|Midazolam/ bupivaciane|20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
40994029|NCT02474095|PROCEDURE|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
40994030|NCT05457569|OTHER|Focus group (FC) - WP1|"3 group meetings for each group of parents:~1. Parents only~2. Parents and representatives of patient support groups~3. Parents and health professionals specialized in the care of these children at risk"
40994031|NCT05457569|OTHER|Child Neurodevelopment Questionnaires - WP2|during the 4th month of corrected infant age
40994032|NCT05457569|OTHER|Evaluation of compliance for the acquired skills in terms of development support - WP2|during the 4th month of corrected infant age
40994033|NCT05457569|OTHER|Evaluation of physiotherapist satisfaction with the follow-up and the time spent at the consultation - WP2|at the end of the study
40994034|NCT05457569|OTHER|4 Focus Group (FC) - WP2|"* Parents who accepted the follow-up~* Parents who have partially completed the programme~* Maternal and Child Protection \& CAMSP professionals~* Physiotherapists in a private practice"
40994035|NCT01262482|DRUG|Oxaliplatin|130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
40994036|NCT01262482|DRUG|Sorafenib|400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
41148216|NCT03655704|DRUG|Apabetalone|A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given doses of apabetalone 100mg BID for 16 weeks. Patients will be regularly followed (Fig.1). At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function.
41148217|NCT03684772|DRUG|ICVT Topical Gel|Digoxin and Furosemide (0.125%)
41148218|NCT03684772|DRUG|Furosemide Topical Gel|Furosemide (0.125%)
41148219|NCT03684772|DRUG|Digoxin Topical Gel|Digoxin (0.125%)
41148220|NCT03684772|DRUG|Vehicle Topical Gel|Vehicle Gel
41148221|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide (NAM)|500 mg a day
41148222|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|1000 mg a day
41309414|NCT05261672|DRUG|Bupivacain|20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
40994037|NCT00006294|DRUG|Chlorthalidone|participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study
40994038|NCT00006294|DRUG|Lisinopril|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
40994039|NCT00006294|DRUG|Amlodipine|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
40994040|NCT00006294|DRUG|Doxazosin|participant's drug dose will be titrated from 2mg to 8mg over the course of the study
40994041|NCT01478321|DRUG|Temozolomide|Given PO
41148223|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide Mono Nucleotide (NMN)|1000 mg a day
40994042|NCT01478321|RADIATION|hypofractionated radiation therapy|Undergo hypofractionated radiation therapy
40994043|NCT01478321|BIOLOGICAL|bevacizumab|Given IV
40994044|NCT01478321|OTHER|questionnaire administration|Ancillary studies
40994045|NCT06514963|DRUG|HRS-9813|Specified dose on specified days
40994046|NCT06514963|DRUG|Placebo|Specified dose on specified days
40994047|NCT04930679|DRUG|Andiabet|Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
40994048|NCT04301765|DRUG|testosterone 1.62% gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
41148224|NCT05517122|DIETARY_SUPPLEMENT|Microcrystalline cellulose|500 mg a day
41148225|NCT02574910|DRUG|Abiraterone acetate|This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
41148226|NCT03057197|PROCEDURE|new caudal injection technique|new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
40994049|NCT04301765|OTHER|placebo gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
40994050|NCT05983770|DRUG|AT-1501|IV infusions of AT-1501 20 mg/kg over 1 hour.
40994051|NCT05983770|DRUG|Tacrolimus|Tacrolimus will be administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter.
40994052|NCT05757947|PROCEDURE|Сoronary bypass surgery according to the I-graft method|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and the formation of an anastomosis of the stump of the right internal mammary artery and end-to-end saphenous vein graft."
40994053|NCT05757947|PROCEDURE|Сoronary bypass surgery by the method of free conduit|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and anastomosis of the saphenous vein graft to aorta."
40994054|NCT01050985|DRUG|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
40994055|NCT03181854|BEHAVIORAL|Telephone coaching|Telephone coaching about overcoming the crisis is provided once a week for 3 months and once in 2 weeks for another 3 months.
40994056|NCT03181854|BEHAVIORAL|Consultation with PCT doctor|Consultation with PCT physician every 3 weeks.
40994057|NCT05749302|DRUG|Al18F-NOTA-FAPI|Al18F-NOTA-FAPI was injected into the patients before the PET/CT scans
40994058|NCT04877938|BEHAVIORAL|Echolgical physical activity Intervention|'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV).
40994059|NCT03330431|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|"All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation."
40994060|NCT06115265|BEHAVIORAL|Ketogenic diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
40994061|NCT06115265|BEHAVIORAL|Low Fat diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
40994062|NCT04922203|OTHER|in Situ Simulation|2 sessions of in situ simulation with 4 crisis scenarios and debriefing focused on non technical skills
40994063|NCT00001487|DRUG|Dehydroepiandrosterone|
40994064|NCT05301088|OTHER|Chocolate Scent|"Chocolate Scent:Children in this group will be given chocolate scent sniffing as a non-pharmacological distraction method.~Stress Ball:Stress ball squeezing will be used as a non-pharmacological distraction method for children in this group."
40994065|NCT01483105|BEHAVIORAL|DVD Self-Hypnosis Training Program|The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
40994066|NCT01343563|PROCEDURE|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
40994067|NCT04579042|PROCEDURE|cartilaginous batten graft septoplasty|septoplasty using cartilaginous batten graft in cases with caudal septal deviation
40994068|NCT00918021|DRUG|olanzapine|normal dosage of olanzapine (the same dosage as on hospital ward)
40994069|NCT00918021|DRUG|placebo|placebo
40994070|NCT03320772|DRUG|TMVP1-ICG|Detection of SLN
40994071|NCT03320772|DRUG|ICG|Detection of SLN
40994072|NCT04532099|DEVICE|Lehfilcon A contact lenses|Investigational soft contact lenses for daily wear worn in Part A of the study
40994073|NCT04532099|DEVICE|Senofilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part A of the study
40994074|NCT04532099|DEVICE|Comfilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part B of the study
40994075|NCT04532099|DEVICE|Hydrogen peroxide-based cleaning and disinfecting solution|For nightly cleaning and disinfecting of contact lenses in Part A and Part B of the study
40994076|NCT03337282|PROCEDURE|Protocolized general anesthesia|Induction and maintenance of general anesthesia, post-operative analgesia with protocolized drugs and doses. Maintenance of MAP +/- 20% of baseline with vasopressors as needed.
40994077|NCT06003530|BIOLOGICAL|hOMSC200|Human Oral Mucosal Stem Cells
40994078|NCT06003530|OTHER|Placebo|Animal component-free, defined cryopreservation medium with 5% DMSO
40994079|NCT00885755|DRUG|Standard taxane therapy|As prescribed
40994080|NCT00885755|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
40994081|NCT00885755|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
40994082|NCT02065960|RADIATION|Stereotactic body radiotherapy (SBRT)|
40994083|NCT01360658|DRUG|Intravenous immunoglobulins|Single administration of 2 g/kg intravenous immunoglobulins over 2 days
40994084|NCT05699083|OTHER|Body Image/Self-Esteem Questionnaires|Pre-operation and post-operation questionnaires to assess factors including but not limited to body image, quality of life, and self-esteem.
40994085|NCT04741828|DRUG|Vi-DT Typhoid Conjugate Vaccine|Typhoid Conjugate Vaccine
40994086|NCT00177970|DRUG|intravenous immunoglobulin G (IVIG)|IVIG to be given IV to patients with C-Diff .
40994087|NCT00177970|DRUG|Placebo|Placebo to be given IV to patients with C-Diff
40994088|NCT00801125|DRUG|natalizumab|
40994089|NCT00001086|DRUG|Indinavir sulfate|
41148227|NCT04880135|OTHER|Supervised stretching and strengthening exercise|The structure of the supervised exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
41148228|NCT04880135|OTHER|Home-based stretching and strengthening exercise|The structure of the home based exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
41148229|NCT05062226|DIETARY_SUPPLEMENT|PKU/TYR GMP Protein Substitute|After a 1-day baseline period during which patients will consume their usual protein substitute, each patient will receive one the case study product for 4 weeks (28 days).
41148230|NCT02954809|DEVICE|Morning bright light therapy|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
41148231|NCT02954809|DEVICE|Dim light|Exposure to dim light with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
40994090|NCT00001086|DRUG|Abacavir sulfate|
40994091|NCT00001086|DRUG|Efavirenz|
40994092|NCT01712256|BIOLOGICAL|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
41148232|NCT05092516|DEVICE|Active tDCS|2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.
41148233|NCT05092516|DEVICE|Sham tDCS|Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.
41148234|NCT04536779|OTHER|Training in the local departments of TT and cycling trips with CUA|in a minimum of 3 months, the individuals with low physical mobility will conduct a minimum of 8-10 training and cycling sessions.
41309415|NCT04786041|PROCEDURE|laparoscopic appendectomy|laparoscopic appendectomy
41309416|NCT04931316|OTHER|antiglaucoma|use antiglaucoma in ocular hypertension
41148235|NCT05570344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
41309417|NCT01511835|DIETARY_SUPPLEMENT|inositol + folic acid|2000 mg of inositol+200mcg of folic acid; 2 per diem
41309418|NCT01511835|DIETARY_SUPPLEMENT|inositol + folic acid|600 mg of inositol + 200mcg of folic acid; 2 cp per diem
41309419|NCT01511835|DRUG|Folic Acid|Folic Acid 400mcg; 1 cp/die
41309420|NCT00783341|DRUG|GAP-134|
41309421|NCT00783341|DRUG|placebo|
41309422|NCT04933721|DRUG|berotralstat|BCX7353 capsules administered orally once daily
41309423|NCT01409031|DRUG|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
40994093|NCT04148950|OTHER|Kinesio Tape|
41309424|NCT01409031|OTHER|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
41309425|NCT06420648|OTHER|Early passive mobilization|a rehabilitation protocol for post-surgical repair of flexor tendons of the hand
41309426|NCT06420648|OTHER|Controlled active motion|a rehabilitation protocol for post-surgical repair of flexor tendons of the hand
41309427|NCT03533725|OTHER|Breastfeeding counseling and education services|Breastfeeding counseling and education by educated and trained peer counselors using mHealth tools
41309428|NCT03498417|DIAGNOSTIC_TEST|Serum antibodies against the IGF-1R|Measurement of antibodies against the IGF-1R in serum samples by ELISA
41309429|NCT05056454|BEHAVIORAL|Online therapy with coaching within STAND|"Participants with moderate depressive symptoms on the CAT-MH (and no current suicidality) will meet with a trained coach, and receive access to online course materials from one of 2 lesson platforms - ThisWayUp's MUMentum course or UCLA DGC's ParentMood course. The efficacy of each online course will be compared for equivalency.~Participants are encouraged to practice their lesson homework for at least one week before meeting with their coach and starting the next lesson."
41488680|NCT01050608|BEHAVIORAL|Educational component with regard to teaching CDC guidelines|12 minute education prior to deploying device for all providers.
40994094|NCT04148950|OTHER|Compression Stockings|
40994095|NCT04148950|OTHER|Exercise Program|
40994096|NCT01038024|DIETARY_SUPPLEMENT|1 tablet composed of antioxidants and minerals|1 tablet daily
40994097|NCT04318496|OTHER|Press Tack Acupuncture|PYONEX Φ0.20×0.6 mm made by Seirin Corporation
40994098|NCT04318496|OTHER|Press Tack Placebo|PYONEX placebo sticker made by Seirin Corporation
40994099|NCT05584865|OTHER|Digital occluar prosthesis|Each patient will receive the full digital fabricated ocular prosthesis. DICOM data from the Computerized Tomography (CT) will be imported into Materializes Interactive Medical Image Control System (MIMICS) software++++ tool for visualizing and segmenting medical images (such as CT and MRI)
40994100|NCT05584865|OTHER|Conventional occluar prosthesis|An accurate impression of the patient's eye socket will be obtained to prepare a suitable wax mod. The wax model will be flasked and processed into heat cured acrylic resin of the same colour of the sclera of the other healthy eye of the patient
40994101|NCT00129363|DRUG|Carvedilol|
41309430|NCT05056454|BEHAVIORAL|Clinical care within STAND|Participants with severe depressive symptoms or significant suicidality on the CAT-MH will be allocated to access clinical care, which entails weekly psychotherapy sessions and psychiatric care, when needed or appropriate. While clinical care will be available for the entire 6-month duration of the treatment component of the study, participants will be informed that on average therapy is completed within 13 sessions. The schedule of psychiatric care will be determined by the provider.
40994102|NCT04588402|BIOLOGICAL|The study being observational in nature, there is no intervention. The investigators will only collect cervical samples from married women within a specified age range at different intervals.|"Women will be approached one time only, when they will attend the gynecology out-patients department for various reasons. After signing the informed consent, the participants will fill in a risk factor questionnaire to study the socio-demographic information, sexual history and HPV vaccination history and the determinent of HPV infection. The questionnaire will be administered by a trained social worker or nurse.~A gynecologist will collect cervical cells from the participant's cervix during a gynecological examination. The cervical specimen will be examined for presence of specific HPV genotypes and Chlamydia infection."
41148236|NCT05570344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) Plus Text4Support|"rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.~Text4Support:~Text4Support is one of the ResilienceNHope suites of supportive text messaging programs delivered by the Global Psychological eHealth Foundation \[80\]. The program allows users to receive daily supportive text messages which have been written by a team of cognitive-behavioral therapists and mental health professionals in collaboration with users of mental health services. The aim of this Text4Support depression program is to enhance positively the mood of patients with clinical depression. The program operates through the use of positive reinforcement to correct distorted or negative thought patterns."
41148237|NCT03503500|OTHER|Laid-back breastfeeding|"At randomization the Italian version of the video Biological nurturing, which provides detailed information on LB BF, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, adequately trained staff will support women to breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves. In the maternity ward a daily supervision by an external expert on LB BF will be provided"
41148238|NCT03503500|OTHER|Standard care|"2. the standard care in use at the Institute (WHO/UNICEF 20-hours course) (control group). At randomization, the Italian version of the video Breast is best (Allattare informati), which provides detailed information on standard support to breastfeeding, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, the staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast"
41148239|NCT03723902|OTHER|Heavy-load strength training|Three weekly sessions of heavy-load strength training for 10 weeks
41148240|NCT03723902|DIETARY_SUPPLEMENT|Protein supplementation|Daily supplementation of 2 x 17 grams of milk protein
41148241|NCT03799757|DRUG|40ml of 0.25% bupivacaine|
41148242|NCT03799757|DRUG|40ml of 0.9% normal saline|
41148243|NCT00804765|OTHER|Therapeutic education|Intensive training individual and collective teaching
41488681|NCT01050608|BEHAVIORAL|Provider and group feedback|Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
40994103|NCT00665977|DRUG|Thermosmart & placebo|a Fisher \& Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
41309431|NCT05056454|OTHER|Perinatal Psychiatric Care|Perinatal psychiatric care involves medication management and supportive therapy for up to six months, with referrals to relevant community resources by the final visit.
41309432|NCT00764400|BEHAVIORAL|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
41148244|NCT00804765|OTHER|Follow-up|classical follow-up with two individual consultations
41309433|NCT06032299|PROCEDURE|Single Distal Femur Implant|Single implant constructs will be either a retrograde intramedullary nail with interlocking screws or a single plate and screw construct.
41309434|NCT06032299|PROCEDURE|Dual Distal Femur Implant|Dual implant constructs will either be an intramedullary nail with an additional plate and screw construct or dual (two plates in any orientation) plate and screw construct.
41309435|NCT06496321|PROCEDURE|Conventional Saphenous vein harvest|The conventional one involves harvesting only the vein, without perivascular tissue or the nerve.
41309436|NCT06496321|PROCEDURE|No touch Saphenous vein harvest|"During the extraction of the saphenous vein using the no touch technique, it is sectioned with the perivascular adipose tissue and the saphenous nerve of the leg."
41148245|NCT03636295|DRUG|Warfarin|Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
41148246|NCT02694198|OTHER|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
41148247|NCT02822092|DRUG|Risperidone or Aripiprazole (patients only)|Inpatients deemed eligible for the study, we be put on open-label risperidone
41309437|NCT00590915|DRUG|Erwinia L-asparaginase|"Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.~NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics."
41341726|NCT01755325|DRUG|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
41341727|NCT01755325|DRUG|placebo|
40789714|NCT03919565|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
40789715|NCT03919565|DRUG|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
41148248|NCT01524120|DEVICE|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
41148249|NCT01524120|DEVICE|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
41148250|NCT01524120|DEVICE|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
41148251|NCT01524120|DEVICE|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
41148252|NCT05506319|OTHER|Norepinephrine|"The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).~Interruption means suspension for at least 24 hours."
41148253|NCT05506319|OTHER|Vasopressin|"The patients will be randomized for the initial suspension of vasopressin (vasopressin group).~Interruption means suspension for at least 24 hours."
41148254|NCT01125956|BEHAVIORAL|Assigned a peer counselor|Dyads will be given $20 per month if they have contact 4 or more times during a month.
41148255|NCT01125956|BEHAVIORAL|Financial incentives|Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
41148256|NCT03476954|OTHER|Respiratory Impedance (RI)|A non-invasive respiratory device is employed to generate resistance during the inspiratory phase of respiration.
41148257|NCT06388889|DRUG|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
41148258|NCT03770715|DEVICE|Respiratory polygraphy|The respiratory polygraphy consisted of continuous polygraphical recordings for a whole night from 22:00 h to 07:00 h with standardised equipment
41148259|NCT02699437|OTHER|Testing for antiphospholipid antibodies|Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
41148260|NCT03883217|DEVICE|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
41148261|NCT03522844|OTHER|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.
41148262|NCT03522844|DRUG|Escitalopram|Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.
41148263|NCT01493388|DRUG|insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
41148264|NCT02857686|PROCEDURE|intravenous regional anaesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
41148265|NCT02857686|PROCEDURE|forearm IVRA|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
41148266|NCT00444730|PROCEDURE|Radical Prostatectomy|Surgical procedure for prostate cancer.
41148267|NCT00444730|PROCEDURE|InterStim Implantation|surgical placement of the interstim
41341728|NCT03887052|DEVICE|ASSURE™ Wearable Cardioverter Defibrillator (WCD)|WCD with shock alarms and shock functionality disabled
41341729|NCT04450004|BIOLOGICAL|Intramuscular Vaccine|Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.
41148268|NCT00444730|PROCEDURE|Pelvic organ prolapse repair|Surgical pelvic organ prolapse repair
41148269|NCT06453759|PROCEDURE|Additional electrodes into bilateral anterior, centromedian and pulvinar thalamic nuclei|"The centromedian, anterior and pulvinar nuclei on each side will be chosen as target for new electrodes; up to 6 additional electrodes may be added but, where possible, existing electrode trajectories will be extended to facilitate recording.~At the beginning of the recording process, usually within the first 24-48 hours of implantation, we will conduct 2 study-specific stimulation experiments:~1. Single pulse electrical stimulation (SPES):~2. N-of-1 trials of simulated DBS: We will simulate high (130Hz) and low (6Hz) frequency DBS currents from each pair of thalamic nuclei (always bilateral) and record spontaneous interictal neuronal activity in all other cortical contacts for 15 minutes. We will also record SPES from each of the cortical contacts."
41148270|NCT02295293|DRUG|Rhus Coriaria L. (Rhus)|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
41148271|NCT02295293|DRUG|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
41148272|NCT01571440|DIETARY_SUPPLEMENT|No soluble corn fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day
41148273|NCT01571440|DIETARY_SUPPLEMENT|12 g soluble corn fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
41148274|NCT03800745|DRUG|Colace 100Mg Capsule|Prescribed to Arm B
41148275|NCT03800745|DRUG|Miralax|Prescribed to Arm C
40789716|NCT03919565|DRUG|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
41148276|NCT01241032|DRUG|Udenafil|200mg Single Oral Dose of
41148277|NCT01241032|DIETARY_SUPPLEMENT|Alcohol|Alcohol 39g / 240ml
41148278|NCT00609245|DRUG|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
41148279|NCT00609245|DRUG|Placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
41148280|NCT03680768|OTHER|Health Assessment|The protocol includes measurements of body composition, strength test, functional and fitness test as well as biochemical measurements from blood samples and AGEreader
41148281|NCT06173687|DEVICE|The impedance measurement task using the Mobile Research App (MRA)|Characterisation of impedance and real-world monitoring of hearing difficulty in range of listening environments.
41148282|NCT05494346|DEVICE|Measurement of peak nasal flow.|Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).
41148283|NCT03696342|DRUG|Pazufloxacin|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
41148284|NCT03696342|DRUG|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
41148285|NCT05563961|DRUG|Panadol®|Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)
41148286|NCT05563961|DRUG|SafeTynadol®|"Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)"
41148287|NCT05500313|BEHAVIORAL|Hypno-breastfeeding Education|The hypnobreastfeeding education program consists of 4 sessions and 12 hours. It includes information about breastfeeding, mental preparation for the breastfeeding experience, emotional studies, motivational practices, awareness and self-compassion practices.
41148288|NCT05500313|BEHAVIORAL|Experimental: Standart Breastfeeding Education|The standard breastfeeding education program consists of 1 session and 3 hours. It contains only information and applications about breastfeeding.
41148289|NCT04618211|DRUG|Deucrictibant|deucrictibant soft capsules for oral use
41148290|NCT04618211|DRUG|Placebo|Matching placebo capsules for oral use
40994104|NCT00665977|DRUG|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher \& Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
41148291|NCT01021683|DRUG|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
40994105|NCT00665977|DEVICE|Placebo Arm|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher \& Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
41148292|NCT04783272|DIAGNOSTIC_TEST|Photoacoustic Computed Tomography (PACT) Imaging|PACT will be completed prior surgery.
41148293|NCT06585189|DRUG|Pembrolizumab|
41148294|NCT06585189|DRUG|Pemetrexed|
41148295|NCT06585189|DRUG|Cisplatin|
41148296|NCT06585189|DRUG|Carboplatin|
41309438|NCT05364879|BEHAVIORAL|Prehabilitation Exercise Intervention|The exercise intervention will consist of light-to-moderate intensity aerobic, resistance, and mobility exercises. These exercises will be performed in a circuit type manner. Participants will perform similar exercises that are modified to meet their individual abilities. Exercise intensity, modifications and substitutions will be determined for each participant based on their medical history, 6 minute walk test results, and baseline frailty scores. Exercise sessions will be performed 3x/wk beginning at 30 min and progressing to 60-min as tolerated for a minimum of four weeks but will continue up until the time of the participants surgery. A hybrid approach will be used for the exercise sessions whereby the participant must attend the first exercise session in person and subsequent sessions will be delivered virtually. Sessions will be overseen by the study Clinical Exercise Physiologist.
41341730|NCT04767776|DRUG|Rivaroxaban|rivaroxaban 40 mg/day (1 day).
41341731|NCT04767776|DRUG|Activated charcoal|Activated charcoal 2 hours after rivaroxaban administration (1 day).
41309439|NCT05487716|BEHAVIORAL|High-intensity interval training (HIIT)|Included subjects who underwent an additional 36 sessions (2-3 sessions per week) of supervised bicycle ergometer (Ergoselect 150P, ergoline GmbH, Germany) training as in the previous protocol5 were classified as the HIIT participant. They exercised alternatively at 3-min interval of 80% VO2peak and 3-min interval of 40% VO2peak for 30 min each session.
40994106|NCT02229318|DIETARY_SUPPLEMENT|FruitiVits|Daily administration of FruitiVits dietary supplement
41148297|NCT01789593|OTHER|glucose clamp|Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
41309440|NCT00530530|DRUG|ASP8825|oral
41309441|NCT00530530|DRUG|Placebo|oral
41309442|NCT03453151|DRUG|splanchnic nerve anesthesia with a local anesthetic|regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
41309443|NCT02533518|PROCEDURE|Rigid bronchoscopy with ultraviolet transmission|
41309444|NCT02533518|OTHER|Biopsy|
41309445|NCT02683226|DRUG|Vipdomet|
41468354|NCT02148445|OTHER|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
41468355|NCT02148445|OTHER|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
41468356|NCT02148445|DRUG|Nicotine replacement therapy|
40994107|NCT05636930|OTHER|Test the accuracy of the wearable device|No intervention was done for the subjects
41148298|NCT03236818|DRUG|ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
41148299|NCT03946345|DRUG|Iohexol Inj 300 MG/ML|"* Administration of iohexol: each 24 hours one bolus IV (1-5ml) during 72 hours~* Blood samples are drawn for analysis of iohexol concentrations and other parameters of renal function at 2, 5 and 7 hours after administration~* Urine is collected from catheter between 4 and 6 hours after adminstration to determine urine creatinine and iohexol concentrations"
41468357|NCT00668447|DIETARY_SUPPLEMENT|Soy Isolate|20 grams of powder mixed in beverages or food daily for one year
41148300|NCT05734235|DIETARY_SUPPLEMENT|Vitamin C|Two Vitamin C tablets daily for 8 days.
41468358|NCT00668447|DIETARY_SUPPLEMENT|Control protein|20 grams of powder mixed in beverages or food daily for one year
41468359|NCT00668447|DIETARY_SUPPLEMENT|Novasoy isoflavones|3 tablets daily for one year
40994108|NCT00142870|DRUG|Bupropion|150 mg, twice a day
40994109|NCT05582668|PROCEDURE|Bariatric surgery|Bariatric surgery
40994110|NCT03090854|DIAGNOSTIC_TEST|ADASCog|Neuropsychological test
41148301|NCT05734235|DIETARY_SUPPLEMENT|Vitamin E|One Vitamin E tablet daily for 8 days.
41148302|NCT03643445|BEHAVIORAL|Motivational Orientated Treatment|The motivation-oriented treatment condition is intended to create a context for treatment that is patient-centered, non-judgmental, and will create a therapeutic environment wherein patients can make an informed decision around their goals for treatment and their willingness to commit to the behavioural changes required for recovery from an eating disorder. In general, MI is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices.
41309446|NCT02683226|DRUG|Incresync|
41309447|NCT00663455|DRUG|Reduction of cyclosporine A (CSA)-dosing|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
41309448|NCT01185145|RADIATION|Breast Brachytherapy with Mammosite RTS|Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
41309449|NCT01185145|RADIATION|Intensity Modulated Radiotherapy|Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
41309450|NCT01525927|DRUG|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
41309451|NCT01525927|RADIATION|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
41309452|NCT01525927|RADIATION|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
41309453|NCT02849912|OTHER|questionnaire|
41309454|NCT05324332|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
41309455|NCT05324332|DRUG|68Ga-PSMA-11|Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
41309456|NCT06317077|OTHER|PAP therapy setting|Subtherapeutic phases during titration to provoke breathing events after reaching the pressure level with which the breathing events are sufficiently treated
41309457|NCT06317077|OTHER|exclusive use of Löwenstein Medical full face masks|Use of a Löwenstein Medical full face mask as a requirement for participation in the clinical investigation
41309458|NCT03174821|DEVICE|Insulin pump|Blood glucose management device
41309459|NCT01710111|DEVICE|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
41341732|NCT01481506|PROCEDURE|Telemonitoring|Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
41468360|NCT00668447|DIETARY_SUPPLEMENT|Placebo tablets|3 tablets daily for one year
41468361|NCT05340582|DRUG|Acetaminophen Injection|Acetaminophen injection solution 1000 mg/100 mL (10 mg/mL) latex-free plastic bag - dosage for this protocol is 15mg/kg/dose IV four times a day for 3 days
41309460|NCT03880240|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
41309461|NCT03880240|OTHER|Sham Transcranial Alternating Current Stimulation|Placebo Control, simulation of transcranial alternating current stimulation without receiving any stimulation
40789717|NCT01914250|DRUG|Analgesic effect of topical tetracaine 2 %|The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
40789718|NCT02819531|DEVICE|Rotational atherectomy|Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
40789719|NCT02819531|DEVICE|Orbital atherectomy|Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
40789720|NCT02819531|DEVICE|Scoring balloon system|Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
40789721|NCT00720694|DEVICE|Duolith SD1|
40789722|NCT00720694|DEVICE|Sham Duolith SD1|
40789723|NCT00600067|DRUG|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
40789724|NCT00600067|DRUG|Placebo|Oral placebo capsules, once daily, 28 weeks
40789725|NCT00198471|DRUG|Vitrase|
40789726|NCT05073939|DRUG|Oral Oxytocin|Administration of oxytocin (24 international units) orally
40789727|NCT05073939|DRUG|Oral Placebo|Administration of placebo orally
40789728|NCT01581684|DRUG|BI 411034|Low dose solution for oral administration
40789729|NCT01581684|DRUG|Placebo|Solution for oral administration
40789730|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
40789731|NCT01581684|DRUG|BI 411034|Low dose solution for oral administration
40789732|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
40789733|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
40789734|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
40789735|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
40789736|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
40789737|NCT01946334|DEVICE|anorectal manometry and high-resolution three-dimensional|
40789738|NCT06457477|DRUG|Sintilimab|100mg/10ml/1bottle
40789739|NCT06457477|DRUG|NAs|tablets
40789740|NCT06457477|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
40789741|NCT00618007|DRUG|PF-00734200 30 mg QD|30 mg QD
40789742|NCT00618007|DRUG|PF-00734200 20 mg QD|20 mg QD
40789743|NCT00618007|DRUG|Placebo|Placebo
40789744|NCT03911856|OTHER|Echocardiography|We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
40789745|NCT03911856|OTHER|Pulmonary Gas Exchange|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
40789746|NCT05409703|BEHAVIORAL|reiki therapy|reiki therapy for nurses
40789747|NCT03670849|DEVICE|LapAR|LapAR system will map (transform) the live LUS image in the reference frame of the laparoscopic camera, and fuse it with the live laparoscopic video in real time. For thermal ablations that involve a needle, we also track the needle and overlay its path on the AR view.
40789748|NCT01451749|DRUG|Shenwu Capsule|"1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months."
40789749|NCT01451749|DRUG|Donepezil|"This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.~Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months."
40789750|NCT02922946|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
40789751|NCT01336348|DRUG|Prasugrel|60 mg loading dose given orally at presentation
40789752|NCT01336348|DRUG|Tirofiban|Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
40789753|NCT01651286|PROCEDURE|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
40789754|NCT01651286|PROCEDURE|full face mask|using a standard full face mask during the induction of general anesthesia.
40789755|NCT04011735|DRUG|Respimat|Soft Mist Inhaler product
40789756|NCT06513533|OTHER|Placebo|1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
40789757|NCT06513533|DRUG|Dimethyl fumarate|1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
40789758|NCT02490397|OTHER|Day Light|Patients are exposed to day light for 2 weeks after a heart attack. At the end of 2 weeks they will have blood drawn.
40789759|NCT02490397|OTHER|Room Light|Patients will be exposed to only room or natural light for 2 weeks after heart attack. At the end of 2 weeks they will have blood drawn.
40789760|NCT03510130|OTHER|Routine leg movement|Routine leg movement to the right and left in the supine position during the second stage of labor, for 3 minutes every 20-30 minutes by the attending physician or nurse.
40789761|NCT02629926|OTHER|GH Replacement (NutropinAq®)|GH Replacement continued.
40789762|NCT02629926|OTHER|No additional treatment|GH Replacement not continued.
41309462|NCT04377594|PROCEDURE|Radio frequency ablation|Two different radio frequency ablation procedures
40789763|NCT00976638|OTHER|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
40789764|NCT00976638|OTHER|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
40789765|NCT04896853|BIOLOGICAL|ProTrans®|Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells
40789766|NCT03293303|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
40789767|NCT01230320|PROCEDURE|Denture fabrication technique|"Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~1. the reproduction of denture-bearing tissues by means of impression techniques and casts;~2. the registration of maxillo-mandibular relations;~3. try-in of artificial teeth and carved denture bases."
40789768|NCT00473889|DRUG|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
40789769|NCT00473889|DRUG|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
40789770|NCT00473889|DRUG|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
40789771|NCT00473889|DRUG|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
40789772|NCT06393777|DIETARY_SUPPLEMENT|honey|analgesic effect of honey
40789773|NCT04263766|OTHER|Transcranial magnetic stimulation|TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
40789774|NCT00742521|PROCEDURE|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
41309463|NCT05542303|DRUG|ZB001 for injection|Dose Cohort1 (3mg/kg) ZB001 of single IV injection
41309464|NCT05542303|DRUG|ZB001 for injection|Dose Cohort2 (10mg/kg) ZB001 of single IV injection
41309465|NCT05542303|DRUG|ZB001 for injection|Dose Cohort3 (20mg/kg) ZB001 of single IV injection
41309466|NCT03342482|OTHER|Low-glutamate diet|The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
41309467|NCT02419183|OTHER|SAMSTAR|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
41309468|NCT02419183|OTHER|RAVLT|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
41309469|NCT05990881|DRUG|Botulinum toxin|Patients in this group will receive an injection of Botulinum toxin.
41309470|NCT05990881|DRUG|Standard-of-care corticosteroid injections|Patients in this group will receive an injection of corticosteroid injections, which are considered standard of care.
41309471|NCT00204425|DIETARY_SUPPLEMENT|exercise/soy isoflavone|Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
41309472|NCT02876055|DRUG|Single shot interscalene nerve block|Peripheral regional anesthesia nerve block - Single shot interscalene nerve block
41468362|NCT05340582|DRUG|Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)|Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)
41468363|NCT05340582|OTHER|Sodium chloride 0.9% injection|Placebo- IV q6h for 3 days
40789775|NCT00742521|PROCEDURE|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
40789776|NCT00742521|PROCEDURE|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
40789777|NCT00742521|PROCEDURE|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
40789778|NCT05026151|OTHER|Nutrition therapy according to ICU protocol|The study aims a verifying adherence to the ICU nutrition protocol
40789779|NCT04855630|DEVICE|DREEM 2 Headband|Participants will wear the DREEM 2 headband for 3 months for a minimum of 4 out of 7 nights per week and will participate in its digital therapeutic Cognitive Behavioral Therapy - Insomnia (CBT-I) intervention (entails brain stimulation to improve slow wave sleep and sleep hygiene counseling tips to improve sleep behaviors).
40789780|NCT04855630|OTHER|Exercise Routine|Participants will partake in a guided exercise routine. Each routine consists of 30-minute mild circuit training session twice per week for 3 months.
41309473|NCT02876055|DRUG|Continuous interscalene nerve block|Peripheral regional anesthesia nerve block - continuous catheter interscalene nerve block
41309474|NCT02876055|DRUG|Local Infiltration Analgesia (LIA)|Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
41148303|NCT03643445|BEHAVIORAL|Psychoeducation-Oriented Treatment|The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. In this condition, in order to maximize the differences between groups, no attention will be given to discussing the patient's stage of change, their level of motivation, or their own personal values around recovery. Rather, emphasis during individual meetings with their therapist will be on the importance of symptom abstinence and normal eating.
41148304|NCT05703256|BEHAVIORAL|Amygdala real-time fMRI neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
41148305|NCT05703256|BEHAVIORAL|Sham feedback|Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
41148306|NCT03420729|PROCEDURE|gastroscopy|a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)
41148307|NCT03420729|DEVICE|magnetic assisted capsule endoscopy|The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
41148308|NCT01686724|BEHAVIORAL|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
41148309|NCT01686724|OTHER|Business As Usual|
41148310|NCT03607578|BEHAVIORAL|Other: Control Group - Minimal Intervention|Basic Campaign Folder
41148311|NCT03607578|BEHAVIORAL|Experimental: Protection Routine 1|New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.
41148312|NCT03607578|BEHAVIORAL|Experimental: Protection Routine 2|The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
41148313|NCT03284840|DIAGNOSTIC_TEST|Assessement of nutritional status|Nutritional status for vitamin D, folic acid, vitamin B12 and iron.
41148314|NCT03284840|DIAGNOSTIC_TEST|Thyroid size|Thyroid size by ultrasound.
41309475|NCT05148585|OTHER|physiotherapy|Patients get physiotherapy intervention after the surgery. exercises are progressive. sessions start passive range of motion exercises for 5 weeks while they are using a static dorsal splint. then splints are removed and patients start active range of motion exercises. and exercises progress to blocking, tendon gliding and resistive exercises.
41309476|NCT05148585|OTHER|activity-based therapy|patients get from the seventh week to the twelfth week an activity-based therapy. Activities are diverse according to the patient's needs. activities have therapeutic efficacy for improving range of motion, tendon gliding and strength.
41309477|NCT01316991|DIETARY_SUPPLEMENT|Chewing Gum|chewing gum will be provided
40789781|NCT05039866|BIOLOGICAL|ST-920|No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
40789782|NCT05773495|OTHER|I-SITE Intervention|I-SITE is a coaching facilitated implementation program that guides clinical personnel through tailored integration of teleophthalmology into primary care workflows.
40789783|NCT05773495|OTHER|Usual Care Teleophthalmology|All sites will initially receive usual care teleophthalmology, consisting of having an active teleophthalmology program located in the primary care clinic and access to the I-SITE online toolkit. All sites will utilize non-mydriatic retinal cameras (e.g. Topcon NW400) located in their primary care clinic to obtain a single 45-degree photo of the disc and macula with an anterior photo in each eye to provide diabetic eye screening as part of patients' usual care. Images are captured by trained primary care personnel and securely transmitted to eye doctors for evaluation.
40789784|NCT04096586|OTHER|Red juice|To determine the effects of red juice on satiety and gut health
40789785|NCT04096586|OTHER|Watermelon juice|To determine the effects of watermelon juice on satiety and gut health
41309478|NCT01316991|DIETARY_SUPPLEMENT|No Gum|no chewing gum will be provided
41309479|NCT05452057|BEHAVIORAL|Prehabilitation|"A Registered Kinesiologist will provide your exercise prescription during your first visit for the study. Your exercise sessions will consist of moderate-intensity cardiovascular (or aerobic) exercise, like brisk walking, for 30 minutes. You will also perform resistance exercises (weight lifting) for 30 minutes that will help strengthen your muscles with a focus on muscles that may be affected by your surgery. To complete your exercises, you will receive resistance bands, exercise ball, and exercise manual.~You will also meet with a Registered Dietician within a week of consent to receive information on healthy eating and you will receive protein to improve your nutritional health.~A consult with an expert in psychology to discuss ways to reduce your stress within a week of consent. Some strategies to help reduce your stress may include breathing exercises, being mindful, or other relaxation methods."
41309480|NCT00003662|BIOLOGICAL|anti-thymocyte globulin|
41309481|NCT00003662|DRUG|busulfan|
41309482|NCT00003662|DRUG|cyclophosphamide|
41309483|NCT00003662|DRUG|cyclosporine|
41309484|NCT00003662|DRUG|melphalan|
40789786|NCT04340492|OTHER|Education to Adapted Physical Activity|4 group sessions (5 patients) aiming at promoting physical activity, the first three focusing respectively on endurance, posture and balance and power re-enforcement at one-week interval. A fourth session, 3 months latter is a consolidating session aiming at identify and overcome obstacles to practice physical activity in everyday life.
40994111|NCT03637465|BEHAVIORAL|Hydrate Philly|"Hydrate Philly is a multi-component intervention that includes water safety testing, provision of 1-2 hydration stations per recreation center, distribution of reusable water bottles for youth, a campaign to promote the acceptability of tap water, and the reduction of access to competing unhealthy beverages through vending machine standards and discouraging black bags (characteristic small, black, plastic bags provided to customers with their corner store purchases, typically including a sugar sweetened beverage and/or unhealthy snack foods)."
41309485|NCT00003662|DRUG|methylprednisolone|
41309486|NCT00003662|PROCEDURE|umbilical cord blood transplantation|
41309487|NCT00003662|RADIATION|radiation therapy|
41309488|NCT00116857|DRUG|Sertraline/omega-3|Sertraline (50 mgs) plus omega-3 (2 grams)
41309489|NCT00116857|DRUG|Sertraline/Corn Oil|Sertraline (50 mgs) plus corn oil (2 grams) (placebo)
41309490|NCT02345824|DRUG|Ribociclib|CDK4/6 INHIBITOR
41309491|NCT04188951|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
41309492|NCT06020274|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF. Upon logging on to the iCF-PWR, the viewer will see two paths (i.e., child with CF or sibling) and will be encouraged by program narrator to choose the appropriate path. Each pathway (i.e., child with CF or sibling) is comprised of five text/voice-delivered, animated, interactive modules: (1) CF education, (2) CF health, (3) emotions and CF, (4) cognitive behaviour model of emotions, and (5) coping strategies. Each module takes 15-20 minutes to complete.
41309493|NCT06072872|DEVICE|Use of portable CPAP|Patients use portable CPAP during exercise
41309494|NCT03396250|DRUG|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
41309495|NCT03396250|DRUG|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
41309496|NCT00246467|BIOLOGICAL|Alhydrogel|
41309497|NCT00246467|BIOLOGICAL|rF1 and rV protein antigens|
41309498|NCT00715611|PROCEDURE|Pleurectomy/Decortication|Pleurectomy/decortication will be performed as per standard technique
41309499|NCT00715611|DRUG|pemetrexed and cisplatin or carboplatin|The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.
41309500|NCT00715611|RADIATION|Intensity Modulated Radiation Therapy|IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
41309501|NCT03791437|DEVICE|Digital chest drainage system|patients who received Digital chest drainage system
41309502|NCT03791437|DEVICE|Not use Digital chest drainage system|patients who not received Digital chest drainage system( traditional drainage system)
40789787|NCT04340492|OTHER|Standard care|Standard care concerning Parkinson's disease and physical activity
40789788|NCT03968692|DIAGNOSTIC_TEST|Prostate-Specific Antigen test|Prostate-Specific Antigen (PSA) test as opportunistic screening or in the presence of symptoms
40789789|NCT03734822|OTHER|End tidal CO2 (EtCO2)|End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
40789790|NCT03734822|DEVICE|Transcutaneous CO2 (TCO2)|Continuous and noninvasive real-time monitoring of transcutaneous CO2.
40789791|NCT03734822|DIAGNOSTIC_TEST|Capillary CO2 (CapCO2)|Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.
40789792|NCT03734822|DIAGNOSTIC_TEST|Arterial blood gas (ABG)|Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
40789793|NCT05120583|OTHER|Pilates exercises|Side kick internal/ external rotation with Pilate's band
40789794|NCT05120583|OTHER|Traditional physical therapy program|strength, flexibility
40789795|NCT00937495|DRUG|vorinostat|400 mg given PO
40789796|NCT00937495|DRUG|bortezomib|1.3 mg/m\^2 given IV
40789797|NCT01239771|DRUG|TC-5214|Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
41309503|NCT00543569|DRUG|Alefacept|Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
40789798|NCT01239771|DRUG|Placebo|Two subjects in each cohort will be given placebo.
40789799|NCT05120700|BIOLOGICAL|Synovial Tissue and Fat Pad Stromal Vascular Fraction|Treatment of cartilage injury with a tissue engineering construct. It will be composed of stromal vascular fraction collected from the synovial membrane and infrapatellar fat of the injured knee, submitted to enzymatic processing in a single surgical time, associated with a collagen scaffold
40789800|NCT04477460|DIETARY_SUPPLEMENT|Thickened feeds|Thickened feeds directed by medical team
41309504|NCT00543569|DRUG|tacrolimus|The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
41309505|NCT00543569|DRUG|basiliximab|Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
41309506|NCT00543569|DRUG|mycophenolate mofetil|Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
41148315|NCT03157414|DRUG|Empagliflozin|Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
40789801|NCT04477460|DIETARY_SUPPLEMENT|Non-thickened feeds|Non-thickened feeds directed by medical team
40789802|NCT03637283|PROCEDURE|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
40789803|NCT03637283|PROCEDURE|fan-shaped photocoagulation|vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
40789804|NCT05495438|OTHER|Hypothetical AI|n/a - There is no intervention. Clinicians will review the suggestions of a hypothetical AI
40789805|NCT05842525|DRUG|intensive treatment|Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off Irinotecan 150 mg/m2 LV 400 mg/m2 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 on day 1, q2w （intensive treatment up to 8 cycels）
41468364|NCT06503354|DEVICE|Neural Sleeve and Zeno walkway|"A standard manual stopwatch will be used to record time. The Zeno pressure gait mat will be laid flat on the ground and used for all walking conditions. Overall, participants will perform four, 5-minute walking bouts while wearing the Neural Sleeve without electrical stimulation. Participants will not receive any intervention or treatment. Simultaneously, the Zeno walkway will be operated according to manufacturers instructions. Condition descriptions are as follows:~Condition 1 (normal walking speed): During this condition, participants will be asked to walk at their normal, comfortable pace for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course.~Condition 2 (fast walking speed): During this condition, participants will be asked to walk, covering as much distance as possible for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course."
40789806|NCT05842525|DRUG|Maintenance treatment|Fruquintinib 5mg, orally, once daily, 3 weeks on/ 1 week off
40789807|NCT02993627|DIETARY_SUPPLEMENT|Spirulina|2 g(4\* 500 mg tablets) daily intake of Spirulina Platensis
40789808|NCT02993627|OTHER|diet therapy|low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
40789809|NCT02852967|DRUG|Belumosudil|
40789810|NCT02852967|DRUG|Placebo|Placebo tablets matching belumosudil
40994112|NCT05794178|BEHAVIORAL|Education|Education about health benefits of physical activity, 2018 US Physical Activity Guidelines, assigned goals tailored to baseline step counts, and worksheet to develop action and coping plans (three of each)
40994113|NCT05794178|BEHAVIORAL|Activity tracker|Fitbit activity tracker and mobile app to provide ad libitum behavioral feedback and self-regulatory support
41148316|NCT03157414|OTHER|Placebo|Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
41148317|NCT05819177|OTHER|Rehabilitation program|This group of patients underwent standard rehabilitation programs set by national guidelines.
41148318|NCT03382535|BEHAVIORAL|Voice therapy|Voice therapy with direct and indirect therapy elements.
41148319|NCT03382535|BEHAVIORAL|Voice therapy with carryover strategies|Voice therapy with direct and indirect therapy elements and supplementary tasks and reminders.
41148320|NCT03382535|OTHER|Control group|No therapy during eight weeks. After the control period half of the group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
41148321|NCT01581476|DRUG|Statin|10mg daily for a minimum period of 2 years
40789811|NCT00977483|DRUG|Thioctic Acid|600mg tablet once daily 4 years double-blind treatment period
40789812|NCT00977483|DRUG|Placebo|1 tablet once daily 4 years double-blind treatment period
40789813|NCT02969642|DEVICE|Argus Migraine Treatment device|treatment of Migraines targeting Sphenopalatine ganglion
40789814|NCT04165863|PROCEDURE|total knee replacement surgery|total knee replacement surgery
40789815|NCT02852798|DRUG|Apatinib Combined With Docetaxel|Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration
40789816|NCT03138525|OTHER|Blood sampling (MS)|Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.
40789817|NCT03138525|OTHER|Blood sampling (controls)|Blood samples will be collected once at enrollment.
40789818|NCT02044679|OTHER|Water|
40789819|NCT02044679|OTHER|No intervention|
40789820|NCT00310375|DRUG|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
40789821|NCT03103854|BEHAVIORAL|BURST physical activity|BURST is a novel exercise regimen consisting of three daily periods of 10 minutes of high intensity physical activity spread throughout the day.
40789822|NCT03103854|BEHAVIORAL|Text Message Reminders|Patients were sent daily text message reminders to remind them to exercise.
40789823|NCT03103854|BEHAVIORAL|Moderate Intensity Continuous Training|This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.
40994114|NCT05794178|BEHAVIORAL|Text messaging (random timing and selection)|Four text messages/day at random times within a participant's availability window and drawn at random from one of three content libraries (move more \[40%\], sit less \[40%\], inspirational quotes \[20%\])
40789824|NCT02214069|DEVICE|Record and transmit heart rhythm|The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
41148322|NCT01581476|DRUG|ACE inhibitor|Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
41148323|NCT01581476|DRUG|Placebo|Participants receive statin placebo and ACEI placebo
41148324|NCT01581476|DRUG|Combination therapy|Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
41148325|NCT03704363|DRUG|Biosimilar Infliximab|Intravenous infusion(5 mg/kg). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
41148326|NCT03704363|OTHER|Placebo|Intravenous infusion. Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98,
40994115|NCT05794178|BEHAVIORAL|Text messaging (precision dosing)|Up to four text messages/day within a participant's availability window, timed and selected from one of three content libraries (move more, sit less, inspirational quotes) based on a person-specific dynamic model and contextual data
40994116|NCT05798390|DRUG|Bempedoic acid and/or its fixed dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided as part of this protocol to the patients. Medications will be as prescribed by the treating physician in line with clinical practice.
40994117|NCT04900688|DEVICE|LithoVue Elite|LithoVue Elite is a disposable flexible ureteroscope that offer novel pressure sensory capacity
40994118|NCT03004066|DRUG|Daptomycin|standard care
40994119|NCT00452829|DRUG|Folic Acid and inositol|Folic Acid and inositol
40994120|NCT00452829|DRUG|Folic acid and placebo|Folic acid and placebo
40994121|NCT06456333|DEVICE|High-density surface electromyography|Electromyographic signals were acquired from the paravertebral muscles in apical vertebral in patients with AIS using SAGA High Density Myoelectrics (TMSi International, New Zealand)
40994122|NCT05135520|PROCEDURE|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo Transvaginal NOSE
41309507|NCT00543569|DRUG|Corticosteroids|Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
41309508|NCT00074100|DRUG|amonafide dihydrochloride|
40994123|NCT05135520|PROCEDURE|Transabdominal specimen extraction|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo transabdominal specimen extraction with incision elongation
40994124|NCT03864874|DIAGNOSTIC_TEST|Intraoperative intracavitary lung ultrasonography|Ultrasonography on the deflated lung for detection of lung nodules
40994125|NCT02746211|BIOLOGICAL|High Titre Influenza virus|High Titre Influenza virus
40994126|NCT02746211|BIOLOGICAL|Medium - High Influenza virus|Medium - High Influenza virus
40994127|NCT02746211|BIOLOGICAL|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
40994128|NCT02746211|BIOLOGICAL|Low titre|Low titre
40994129|NCT02299557|DRUG|Oxymetazoline gel|Oxymetazoline gel applied intra-anally once daily
40994130|NCT02299557|DRUG|Placebo gel|Placebo gel applied intra-anally once daily
40994131|NCT00035854|DRUG|Zyvox® / Linezolid|
40994132|NCT03342742|BEHAVIORAL|Weight Loss|Weight loss behavioral intervention via one of two strategies.
41148327|NCT05067556|BEHAVIORAL|Acceptance and Commitment Therapy for chronic pain (ACT-CP)|Delivered virtually via Zoom or via telephone on an individual level; 30-minute sessions led by a trained psychologist and occur weekly for 6 weeks.
41148328|NCT01942551|DRUG|Tadalafil|
41148329|NCT01942551|DRUG|Dutasteride|
41148330|NCT04793555|OTHER|Monitoring by unobtrusive sensors|During the study the behavior of daily activities will be monitored by unobstructive sensors. Most of the sensors will be mounted on the wall or on furniture with direct sight to the participant and thus will not have any physical contact, except some wearables during the stay in the apartment and at home (e.g. watch, mobile polysomnography).
41309509|NCT03314519|DIAGNOSTIC_TEST|Lung ultrasonography by experienced anaesthesiologist|Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
41309510|NCT03314519|DIAGNOSTIC_TEST|Fiberoptic bronchoscopy for double lumen tube's position|Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
41309511|NCT02304315|BIOLOGICAL|GC1102 50,000 IU|a recombinant hepatitis B immunoglobulin
41309512|NCT02304315|BIOLOGICAL|GC1102 80,000 IU|a recombinant hepatitis B immunoglobulin
41309513|NCT00628953|DRUG|Esomeprazole|40mg twice a day
41309514|NCT00628953|DRUG|Placebo|40mg twice a day
41309515|NCT01921933|DEVICE|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
41309516|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
41309517|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
40994133|NCT02901535|OTHER|Spirometry|Spirometry in baseline
40994134|NCT02901535|OTHER|telemonitoring|telemonitoring (phone call nurse - 45 and 90 days)
40994135|NCT02901535|OTHER|teleconsultation|teleconsultation (general practioner received phone call to respiratory care)
40994136|NCT02901535|OTHER|Spirometry - 20 weeks|Spirometry (20 weeks)
40994137|NCT04458753|OTHER|Lumbar focused exercises|Transersus abdominis activation Multifidus activation Back extension exercise Curl up abdominal exercise
40994138|NCT04458753|OTHER|Knee focused exercises|Strengthening of quadriceps Stretching of calf and Hamstring muscles
40994139|NCT02621814|DIETARY_SUPPLEMENT|Low glycation formula feeding|Formula feeding on demand for 3 months
40994140|NCT02621814|DIETARY_SUPPLEMENT|Commercially common formula feeding|Formula feeding on demand for 3 months
41148331|NCT03145909|DRUG|ABBV-176|Intravenous infusion
41148332|NCT00322764|DRUG|Uridine|
41148333|NCT00101387|OTHER|Lumbar PENS + General Conditioning and Aerobic Exercise|As above
41148334|NCT00101387|OTHER|Lumbar PENS|As above
41148335|NCT00101387|OTHER|Control Lumbar PENS|Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.
41148336|NCT00101387|OTHER|Control PENS + exercise|as above
40789825|NCT05871580|RADIATION|Low frequency laser activated photobiomodulation|"Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients.~* apex tongue: 3 points~* lateral edge of the tongue: 4 points~* tongue dorsum: 10 points~* jugal mucosa: 8 points~* labial mucosa: 5 points~* hard palate: 8 stitches~* soft palate: 3 stitches~* gingiva or alveolar mucosa: 3 stitches per sextant.~Time of 30 seconds in each application point, with dosage: 3 J/point."
40789826|NCT05871580|OTHER|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
40789827|NCT01741493|DRUG|ABT-494|Oral administration of ABT-494 capsules
40789828|NCT01741493|DRUG|Placebo|Oral administration of placebo capsules
40789829|NCT01741493|DRUG|Tofacitinib|Oral administration
40789830|NCT01290146|DRUG|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
40789831|NCT01290146|DRUG|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min"
40789832|NCT04530201|DEVICE|Colli-Pee Small Volumes (10 mL) device|Women will self-collect two first-void urine samples at home the day prior to colposcopy using the new generation Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube will be prefilled with a non-toxic nucleic acid preservative including an internal process control.
40789833|NCT05818826|DRUG|normal saline solution|Prepare 100 ml of normal saline solution, packed out in the same format, dose, and administration of the drug were exactly the same as in the conventional cessation group.
40789834|NCT05818826|DRUG|Hydrocortisone and normal saline solution|Prepare hydrocortisone with normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min.
40994141|NCT06185959|BEHAVIORAL|Psychoeducation and Process Group for Asian and Asian American Psychiatric Outpatients|Participants will be individuals enrolling in a 1.5 hour weekly therapy group lasting 12 weeks and will be invited to participate in research on group processes and outcomes. The psychoeducation and process group will be a 12-session weekly closed group with 10-15 participants per group (2-3 groups total) conducted via Zoom to enhance accessibility and reduce barriers to care. Groups will be co-led by licensed clinical psychologists with experience providing both group psychotherapy and culturally responsive services. Group sessions will include brief check-ins, collaborative agenda-setting, a mini-didactic, individual reflection, and group discussion. The didactics curriculum will include topics such as intergenerational trauma, cultural differences in emotional expression, the model minority myth, family dynamics, racism, and positive connections to culture.
40994142|NCT04156568|DRUG|INH、RFT|6INH 10mg/kg 3INH+RFT 15mg/kg
40994143|NCT01870583|DRUG|Iodine povidone|Iodine skin preparation solution prior to cesarean delivery
40994144|NCT01870583|DRUG|Chlorhexidine|Chlorhexidine skin preparation solution prior to cesarean delivery
40994145|NCT01870583|DRUG|Combination iodine and chlorhexidine|Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
41148337|NCT02014402|BIOLOGICAL|Human thrombin|Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
41309518|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
41309519|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
41309520|NCT02555566|PROCEDURE|Blood sampling|Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
40994146|NCT03766854|DRUG|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks
40994147|NCT03766854|DRUG|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks
40994148|NCT03265197|DRUG|Intra-tympanic injection of drugs|Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
40789835|NCT00297739|DRUG|Risperidone|
40789836|NCT04889248|OTHER|Inspiratory Muscle Training with Powerbreath IMT device.|"Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax."
40789837|NCT01664754|DRUG|exemestane|Given PO
40789838|NCT01664754|DRUG|pemetrexed disodium|Given IV
40789839|NCT01664754|DRUG|carboplatin|Given IV
40789840|NCT01664754|OTHER|laboratory biomarker analysis|Correlative studies
40789841|NCT01664754|OTHER|pharmacological study|Correlative studies
40789842|NCT01664754|OTHER|questionnaire administration|Ancillary studies
40789843|NCT01664754|PROCEDURE|quality-of-life assessment|Ancillary studies
40789844|NCT05047133|DRUG|Tranexamic acid|TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
41468365|NCT06179693|DIAGNOSTIC_TEST|Diagnostic accuracy|As per standard procedure, patients will undergo FDG PET. Following the PET exam it will be acquired a standard CT with intravenous contrast medium, using the CT tomograph inserted inside the PET one.
41468366|NCT00754052|DRUG|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
41468367|NCT00754052|DRUG|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
41468368|NCT00754052|DRUG|Placebo|All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
40994149|NCT03265197|OTHER|Data management of intratympanic drugs|intervention by statistical analysis of Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
40994150|NCT01948739|DEVICE|MAHI EXO-II exoskeleton augmented with BMI system|In this longitudinal study, adult subjects with hemiparesis due to acute or chronic stroke will receive robotic-assisted training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG and fMRI). The training will be provided 3x/week for 12 sessions over one-month period.
40994151|NCT00752882|DRUG|ceftazidime|
41468369|NCT01774682|PROCEDURE|6-minute walk test|the test corresponds to that defined by Abdel Kafi et al in 2005
40994152|NCT03828799|COMBINATION_PRODUCT|Folfirinox + regorrafenib|folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days
40994153|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(Low dose)|0.2mL,Intramuscular other name:PBPV
40994154|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(Low dose)|0.2mL,Intramuscular other name:PBPV placebo
40994155|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(Middle dose)|0.5mL,Intramuscular other name:PBPV
40994156|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(Middle dose)|0.5mL,Intramuscular other name:PBPV placebo
40994157|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(High dose)|1.0mL,Intramuscular other name:PBPV
40994158|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(High dose)|1.0mL,Intramuscular other name:PBPV placebo
40994159|NCT03836963|BEHAVIORAL|cognitive training|Cognitive training consists of a set of computerize games played on an iPad at home. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
40994160|NCT03836963|BEHAVIORAL|active control cognitive training|The active control consists of a set of computerized games played on an iPad. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
40994161|NCT03836963|BEHAVIORAL|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
41468370|NCT00444236|DRUG|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
41468371|NCT00444236|DRUG|Placebo|matching placebo for active drug
40994162|NCT03836963|BEHAVIORAL|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
40994163|NCT06488482|DRUG|nivolumab or pembrolizumab|See above
40994164|NCT03546751|DEVICE|Continuous Positive Airway Pressure|This device delivers air pressure non invasively through a mask to stent open the upper airway to prevent obstruction during sleep. This is an FDA approved device that has been used for several decades to treat OSA.
41468372|NCT02550587|BEHAVIORAL|satisfaction|anesthesia satisfaction rates
41468373|NCT04108832|DRUG|TCM OA2|Usage: 3g twice daily
41468374|NCT04108832|DRUG|PLACEBO|Usage: 3g twice daily
41468375|NCT05680792|DRUG|Nitazoxanide|1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
41468376|NCT05680792|DRUG|Atazanavir/ritonavir|300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.
41468377|NCT03747185|OTHER|Lumbopelvic stiffening technique|"Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
40994165|NCT03546751|OTHER|Diet And Exercise|This will consist of weekly telephone and monthly face to face visits to monitor and suggest measures to improve diet and regular exercise as conducted by a registered dietician.
40994166|NCT03397082|DRUG|Lidocaine gel|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade.
40994167|NCT03397082|DRUG|Placebo|5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
40994168|NCT02615730|DRUG|GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
40994169|NCT02615730|DRUG|Paclitaxel|fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
40994170|NCT04404647|PROCEDURE|Irreversible electroporation|The IRE procedure will be carried out as ultrasound guided technique either percutaneously or during laparotomy. Needle spacing and electrical pulse delivery will be performed in a standardized way.
40994171|NCT01379742|DEVICE|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
40994172|NCT01379742|DEVICE|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
40994173|NCT02038582|OTHER|POC CD4 Testing|Point of Care CD4 testing
40994174|NCT02038582|OTHER|CD4 Referral|Referral to CD4 testing
41468378|NCT03747185|OTHER|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
41468379|NCT05016687|DRUG|CUR-N399|CUR-N399 will be administered as oral capsules.
40994175|NCT02038582|BEHAVIORAL|Lay Counselor Follow-up|Follow-up from a lay counselor
41468380|NCT05016687|DRUG|Placebo|Placebo capsules matching CUR-N399 will administered.
41468381|NCT01461291|DEVICE|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
41468382|NCT01461291|PROCEDURE|Cataract surgery|Cataract surgery alone
40994176|NCT02038582|BEHAVIORAL|Clinic Accompaniment|Accompaniment to the clinic by a counselor
40994177|NCT02038582|BEHAVIORAL|Clinic Referral|Referral to clinic
40994178|NCT02038582|BEHAVIORAL|SMS Reminder|SMS reminder for male circumcision
40994179|NCT02038582|BEHAVIORAL|Circumcision Promotion|Promotion of male circumcision at the time of HIV testing
40994180|NCT02038582|OTHER|POC VL|POC VL testing for HIV infected persons on ART
40994181|NCT02038582|OTHER|Laboratory based VL assay|Laboratory based viral load testing for HIV infected persons on ART
41148338|NCT02014402|BIOLOGICAL|Bovine thrombin|Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
41309521|NCT02555566|PROCEDURE|flow-mediated distal stimulation of the forearm radial artery by cutaneous heating|Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
41309522|NCT05170659|DRUG|Relatlimab|
41468383|NCT00164255|DRUG|sulfadoxine/pyrimethamine|
41468384|NCT00164255|DRUG|sulfadoxine/pyrimethamine plus artesunate|
41468385|NCT00146796|DEVICE|Rapid diagnostic test for malaria|
41468386|NCT02563769|DRUG|Clavulanic acid|Clavulanic acid will be administered orally in 250mg capsules
40994182|NCT01344187|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
40994183|NCT01344187|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
40994184|NCT01344187|DEVICE|KXL System|30 mW/cm2
40994185|NCT00209677|DRUG|Gemcitabine|
40994186|NCT00209677|DRUG|S-1|
40994187|NCT01960946|DIETARY_SUPPLEMENT|Modified Citrus Pectin (MCP) vs placebo|5 grams by mouth three times a day
41309523|NCT03114306|PROCEDURE|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
41309524|NCT03114306|PROCEDURE|regional-anaesthesiological catheter analgesia|Patients receive a single shot nerve block of the proximal Nervus ischiadicus and a catheter placed closed to the Nervus saphenus for perioperative pain control using ultrasound guided techniques.
41309525|NCT05744115|DRUG|Ga-68-PSMA-11|Ga-68-PSMA-11 is produced via a lyophilized Sterile Cold kit. Ga-68 is eluted from a Ge-68/Ga-68 generator into a vial containing the premixed peptide and buffer. PSMA-11 radiolabeled with Ga-68 is administered to patients following verification of standard quality controls including activity measurement, pH, radiochemical purity, and visual inspection
41309526|NCT03662620|DRUG|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White colored oval three-layer tablet
41309527|NCT03662620|DRUG|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White and pink colored oval two-layer tablet
41309528|NCT05749926|BIOLOGICAL|Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
41468387|NCT02563769|DRUG|Intravenous cocaine|20/40mg Cocaine will be administered by IV
41468388|NCT02563769|DRUG|Placebo|Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose
41468389|NCT05415124|DEVICE|HemoPill|The HemeoPill acute capsule is a small, single use, swallowable capsule with optical sensor. Blood detection by direct measurement of blood in the sensor gap, even in an unprepared digestive tract. Wireless transmission of measured values to the HemoPill Receiver. The maximum measuring time is 9 hours. The length of the capsule is 26.3 mm and the diameter is 7.0 mm.
41468390|NCT05405049|DRUG|Morphine hydrochloride|Group M will be given a 0.5% Bupivacain Dosage Regimen with weight and height adjustment+15 μg fentanyl +150 μg morphine intrathecally.
40994188|NCT04404075|OTHER|SkinTracker Mobile App|a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
40994189|NCT06363565|DIETARY_SUPPLEMENT|supplementation of compound nutrients|Folic acid, vitamin B6, vitamin B12, and betaine per day orally for 12 weeks.
41148339|NCT05959226|BEHAVIORAL|Exercise Intervention|"1. Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..~2. Exercise: under the guidance of the rehabilitation therapist, the patient gradually recovers Exercise from discharge (7-14 days after the operation) to 6 months after the operation, and should ensure at least 150 minutes of moderate intensity exercise or a combination of equivalent activities per week;"
40994190|NCT06363565|DIETARY_SUPPLEMENT|placebo control|The placebo is an excipient and the color, flavor, shape, taste, and weight are same with the tablet of supplement.
41309529|NCT05749926|BIOLOGICAL|VidPrevtyn® Beta vaccine (Sanofi/GSK)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
41309530|NCT05970744|BIOLOGICAL|RSV/Flu-01E low dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
41309531|NCT05970744|BIOLOGICAL|RSV/Flu-01E high dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (8.4 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
41468391|NCT05405049|DRUG|Bupivacain|Group LWI+IPLA will given 30 ml %0,5 bupivacaine+%2 lidocaine infiltration and instillation
41468392|NCT06295094|DRUG|Cisplatin|10.5 mg/m2 body surface in 150ml saline
41468393|NCT06295094|DRUG|Doxorubicin|2.1 mg/m2 body surface in 50ml saline
40994191|NCT04109664|PROCEDURE|laparoscopic sleeve gastrectomy|The greater omentum is carefully dissected from the stomach at a distance of 2cm for the patients with AR, and 6cm for patients with AP. The omental dissection was performed using 5mm-abdominal ligature (Ligasure®, Metronic-Covidien, Minneapolis, USA), from the antrum towards the angle of His. Transection from the omentum is continued until the left crus has been identified. All sleeves are transected using 36 French orogastric tubes. Green cartridges (4.8 mm staple height) are used for the first firing and blue cartridges (3.5 mm) for the rest. Neither oversewing sutures to the staple line nor staple line reinforcement products are used. Homeostatic metallic clips are used for bleeding at the staple line. If bleeding persists and cannot be controlled, an interrupted suture is performed at the point of bleeding. A leak test with methylene blue is performed to the gastric remnant to assess the integrity of the suture line.
40994192|NCT03394287|DRUG|SHR-1210|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
40994193|NCT03394287|DRUG|Apatinib|Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
40994194|NCT05031182|PROCEDURE|Laparoscopy|The hysterectomy is performed by laparoscopy as described in the EMC.
40994195|NCT05031182|PROCEDURE|vNOTES|The hysterectomy is performed by vNOTES as described Dr BAEKELANDT and this team.
40994196|NCT01848756|DRUG|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
40994197|NCT06034613|BEHAVIORAL|internet-based mindfulness intervention for emotional distress(iMIED）|The iMIED program integrates the rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from MBIs. In addition, the iMIED program selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks. In total, it took about 30 min per day to finish all the tasks. The program lasted for 49 days.
40994198|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
40994199|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
41148340|NCT05959226|DIETARY_SUPPLEMENT|Nutrition Intervention|(1) Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..
41148341|NCT03258983|OTHER|Alpha-linolenic acid|Exposure to dietary intake of alpha-linolenic acid (ALA) will be assessed using a detailed food frequency questionaire filled in by participants included in the Diet, Cancer and Health cohort at baseline. Exposure to adipose tissue content of ALA will be determined by gas chromatography in all incident cases and in subcohort of 3500 participants randomly drawn from the total cohort.
41148342|NCT03598023|DEVICE|Cytal® Burn Matrix|Cytal® Burn Matrix
41309532|NCT05970744|BIOLOGICAL|Placebo|Participants will receive single intranasal injection of Placebo
41309533|NCT06014554|OTHER|Low-risk subgroup|Self-managed exercise programme.
41309534|NCT06014554|OTHER|Medium-risk subgroup|Education, goal-orientated mobility programme, and enhanced discharge planning.
41309535|NCT06014554|OTHER|High-risk subgroup|Education, enhanced assessment, orientation, and goal-orientated activities of daily living training programme.
41309536|NCT06014554|OTHER|Control group|Usual care entails physiotherapy and occupational therapy from the day after surgery to the point of discharge, with a focus on discharge planning and sufficient recovery of activities of daily living and mobility for safe return to prefracture residence.
41309537|NCT00526149|DRUG|BI 2536|
41309538|NCT00526149|OTHER|high performance liquid chromatography|
41309539|NCT00526149|OTHER|mass spectrometry|
40994200|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
40994201|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
41148343|NCT03598023|DEVICE|EZ-Derm® Porcine Xenograft|EZ-Derm® Porcine Xenograft
41148344|NCT02097056|DRUG|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
41309540|NCT00526149|OTHER|pharmacological study|
41309541|NCT00103545|BIOLOGICAL|ACA 125|
41309542|NCT01337011|OTHER|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
41309543|NCT03758430|OTHER|Meal-Tagging App|Meal tagging app to capture frequently eaten meals and test meals for 16 weeks.
41309544|NCT03758430|DEVICE|Fitness Tracker|Fitness tracker will be worn around the clock for 16 weeks.
41309545|NCT00882999|DRUG|LY2127399|Administered via Injection
41309546|NCT00882999|DRUG|Placebo|Administered via Injection
41309547|NCT02121756|DRUG|Dipyridamole|Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
41468394|NCT00006473|DRUG|oxaliplatin|Given IV
41468395|NCT05882214|DIETARY_SUPPLEMENT|β-nicotinamide Mononucleotide|After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.
40789845|NCT05115435|BEHAVIORAL|neuro linguistic programming|Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
40789846|NCT05312840|DRUG|Cisplatin / Carboplatin，Gemcitabine，Cindilimab|1. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.
40789847|NCT05973708|OTHER|Clamshell Exercise|Clamshell Exercise: The clamshell exercise keeps the hips moving, it strengthens both the gluteus medius AND gluteus maximus. The gluteus medius is the main abductor (movement away from the midline of the body) and external rotator of the hip.
40789848|NCT05973708|OTHER|Frog pump exercise|Frog pump exercise: The frog hip thrust mainly targets the gluteal muscles responsible for thigh extension and abduction. The exercise also works the hamstrings on the back of the thighs which helps in hip extension.
40789849|NCT01684839|DEVICE|Pedicled nerve flap|This nerve flap is a vascularized nerve graft
40789850|NCT02431546|BEHAVIORAL|Mobile Health Application|"Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant."
40789851|NCT04076267|OTHER|Tool assessing symptoms validation|Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
40789852|NCT05233124|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15mg
40789853|NCT05233124|DRUG|Acetylsalicylic acid 100mg|Acetylsalicylic acid 100mg
40789854|NCT05233124|DRUG|Clopidogrel 75 Mg Oral Tablet|Clopidogrel 75mg
40789855|NCT01871025|OTHER|Hospital and home exercise training|Hospital exercise training (aerobic and strength) followed by exercise training
40789856|NCT01871025|OTHER|Usual care|Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
40789857|NCT03842046|PROCEDURE|phenylephrine infusion|In parturients allocated to the phenylephrine group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
40789858|NCT03842046|PROCEDURE|norepinephrine infusion|In parturients allocated to the norepinephrine group group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
40789859|NCT00129285|DRUG|Low Dose Modafinil|modafinil 200 mg/day
40789860|NCT00129285|DRUG|High Dose Modafinil|modafinil 400 mg/day
40789861|NCT00129285|DRUG|Placebo|placebo 400 mg/day
40789862|NCT00817934|DRUG|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
40789863|NCT06341361|DIAGNOSTIC_TEST|OCT-based machine learning FFR|OCT-based machine learning FFR and wire-based FFR
40789864|NCT01129492|DEVICE|Low-level Laser therapy|A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
40789865|NCT05361850|PROCEDURE|Extubation|Removal of the endotracheal tube
40789866|NCT05236322|DEVICE|soft tissue laser|Surgical laser used in excision purpose
40789867|NCT05834985|PROCEDURE|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches
40789868|NCT01163305|DRUG|Chemotherapy|The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
40789869|NCT02065323|DRUG|Standard ADT|Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
40789870|NCT02065323|DRUG|Dovitinib|Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
40789871|NCT03983330|BEHAVIORAL|Brief Motivational Interviewing (i-BMI)|"The trained RA will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period. They will be given a self-help smoking cessation booklet with Hotline number.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
40789872|NCT03983330|BEHAVIORAL|Control|Similar to the intervention group, the trained RA will first ask the subjects about the priority of engaging in any desirable health-related lifestyle practice and to state a targeted goal in which they perceive as the easiest to achieve after completing the baseline questionnaires. In addition, the subjects will be given a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months.
40789873|NCT02964806|DIETARY_SUPPLEMENT|Ordinary Diet|
40789874|NCT02964806|DIETARY_SUPPLEMENT|Modified Atkin's Diet|
40789875|NCT02964806|DIETARY_SUPPLEMENT|Ketogenic Diet|
40789876|NCT03506620|DRUG|Ropivacaine injection|Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc
41309548|NCT02121756|DRUG|Placebo, then Dipyridamole|Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
41468396|NCT05882214|DIETARY_SUPPLEMENT|Maltodextrin|After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.
40789877|NCT03506620|DRUG|Saline Solution for Injection|20 cc of saline will be injected in the form of a QL block as a placebo.
40789878|NCT01531998|DRUG|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
40789879|NCT01531998|DRUG|Bortezomib|"Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8."
41309549|NCT02979886|DRUG|GnRH-a|the hormone reaction to the down regulation of the patients
41309550|NCT02979886|DRUG|Human Menopausal Gonadotropins|the effects on the serum LH level of day of HCG
40789880|NCT01531998|DRUG|Siltuximab|"Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy."
40789881|NCT01531998|DRUG|Dexamethasone|"Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week."
40789882|NCT01531998|BEHAVIORAL|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
40789883|NCT02132572|DEVICE|BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
40789884|NCT03961243|BIOLOGICAL|YUVA-GT-F901|Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
40789885|NCT05312606|OTHER|Aftoral Oral gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
40789886|NCT05312606|OTHER|Unidea Chlorhexidine digluconate mouthwash 0.20%|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
40994202|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
40994203|NCT00798369|DRUG|Triamcinolone acetonide|Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
40994204|NCT01315756|DEVICE|Use of Few Touch Application (FTA)|"The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user."
40789887|NCT02003443|BEHAVIORAL|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
40789888|NCT02960633|DEVICE|Corail with collar.|
40789889|NCT02960633|DEVICE|Corail without collar.|
40789890|NCT00633763|DRUG|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
40789891|NCT00633763|DRUG|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
41148345|NCT01477177|DEVICE|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
41148346|NCT04973176|DEVICE|Standard Bougie|Standard Bougie for endotracheal intubation
41148347|NCT04973176|DEVICE|Flexi-tip Bougie (P3 Medical Bristol,UK)|Flexi-tip Bougie for endotracheal intubation
41148348|NCT01891006|DEVICE|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
41148349|NCT01891006|OTHER|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
41309551|NCT00133237|DEVICE|Sirolimus-eluting stent|cypher stent is implanted due to randomization.
40789898|NCT02491177|BEHAVIORAL|cMM|Home visits from community mentor mothers
40789899|NCT02491177|BEHAVIORAL|Text Messaging|Text messages received on mobile phone
41309552|NCT00133237|DEVICE|Paclitaxel-eluting stent|taxus stent is implanted due to randomization.
41309553|NCT03664973|PROCEDURE|Serratus plane block|Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
40789900|NCT05386147|DEVICE|Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)|see arm description
40789901|NCT00439101|DRUG|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
40789902|NCT00439101|OTHER|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
40789903|NCT00420381|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
41468397|NCT06564389|DRUG|PF-07832837|escalated doses of PF-07832837
41468398|NCT06564389|OTHER|Placebo|placebo
41468399|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular protein|Modular product supplementation is based on most recent breast analysis done for the participant.
40789904|NCT04904107|DIAGNOSTIC_TEST|modified HEART score (including POC hs cTnI analysis)|"The modified HEART score was developed in 2007 and has been validated to stratify the risk of short-term adverse cardiac events in patients with chest pain at the ED. Negative predictive value (NPV) of the modified HEART score for ACS as well as positive predictive value (PPV) for major adverse cardiac events (MACE) within 6 weeks after presentation is high.~The modified HEART score is an acronym for history, ECG, age, risk factors and troponin at arrival.The components can be rated 0,1 or 2 points each and result in a total score between 0 and 10."
40789905|NCT04904107|OTHER|Standard care and triage according to the local (EMT)protocol.|Standard care and triage of chest pain patients according to the local (EMT)protocol.
40789906|NCT06069830|DRUG|4 cycles of ESA regimen with sandwiched radiotherapy|Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
40789907|NCT06069830|DRUG|2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
40789908|NCT06069830|DRUG|2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|PD-1 monoclonal antibody, 200mg, i.v. d1
40789909|NCT04271358|BEHAVIORAL|Peer Health Coaching|The Peer Coaching group will receive 6 months of peer health coaching via a secure telephone and text messaging system.
40789910|NCT06084533|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.
40994205|NCT01315756|DEVICE|Use of FTA and health counseling based on TTM and CBT|The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
40789911|NCT02826408|DRUG|Rabeprazole sodium|WIll study effect of the medication on palpittions
40789912|NCT02826408|DRUG|Pacebo|Placebo comparison to active treatment
40994206|NCT00002670|DRUG|chemotherapy|
40994207|NCT00002670|DRUG|cisplatin|
40994208|NCT00002670|RADIATION|low-LET cobalt-60 gamma ray therapy|
40994209|NCT00002670|RADIATION|low-LET electron therapy|
41148350|NCT02794441|DRUG|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
41148351|NCT02794441|OTHER|Placebo|Matched oral solution
41148352|NCT05746585|BEHAVIORAL|The Talk Web-based resources|Educational videos and podcasts for parents and their sons
41148353|NCT05651334|DEVICE|Active repetitive Transcranial Magnetic Stimulation|Active stimulation
41148354|NCT05651334|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham stimulation
41148355|NCT00091520|DRUG|Nesiritide|
41148356|NCT01602900|DRUG|GSK356278|Investigational Medicinal Product
41148357|NCT01602900|DRUG|Rolipram|Challenge Agent
41148358|NCT00149565|DRUG|IFN-α2b|
41468400|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular carbohydrate|Modular product supplementation is based on most recent breast analysis done for the participant.
41148359|NCT05135845|DRUG|Capmatinib|Capmatinib 400mg BID for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
41148360|NCT05135845|DRUG|Spartalizumab|Spartalizumab 300mg Q3W for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
41148361|NCT03917342|DEVICE|EEG measure|Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women
41148362|NCT03628612|BIOLOGICAL|AUTO CAR T cell therapy|No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.
41148363|NCT03930173|DRUG|18F-fluciclovine|A single dose of 18F-fluciclovine will be administered intravenously for PET/CT imaging. The standard 10 mCi dose will be used for this study.
41148364|NCT03930173|DEVICE|PET/CT of the brain|Each subject will undergo 18F-fluciclovine PET/CT of the brain which will be performed ≤ 30 days from equivocal MRI brain
41148365|NCT05449756|OTHER|Self-administered questionnaires|Three-monthly self-administered digital questionnaires (accessed on smartphone, tablet or computer)
41148366|NCT01686256|DRUG|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
41148367|NCT06414213|BEHAVIORAL|Motor Imagery (MI)|Participants watched a standardized video sequence that consisted of an individual completing twenty walking trials (twenty video clips-each clip represents one trial). Participants were instructed to place their focus intently on the person performing the obstacle course and try to imagine themselves doing the skill. Periodically, a reminder would appear to help focus and redirect participant's attention to different aspects of the video or different versions of imagery (visual or kinesthetic). Participants will watch the video first at normal play speed and then in slow motion after a short break (30 secs to 1 min). Total training time will be approximately 20 mins which is consistent with the duration of the locomotor intervention and duration of stimulation.
41148368|NCT06414213|DEVICE|Active tDCS|"The participants received a 20-minute active session of tDCS at a 2-milliamp current."
40994210|NCT00002670|RADIATION|low-LET photon therapy|
40994211|NCT00149123|DRUG|hydrocortisone 200 mg/day|
41148369|NCT06414213|DEVICE|Sham tDCS|"The participants received a 20-minute session of sham tDCS."
41309554|NCT00881855|DRUG|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
41468401|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular fat|Modular product supplementation is based on most recent breast analysis done for the participant.
41468402|NCT03785145|DRUG|MT10109L|MT10109L will be injected into the LCL.
41468403|NCT03785145|DRUG|Placebo|Placebo will be injected into the LCL.
41468404|NCT06602492|DRUG|Lower nicotine e-liquid|A 3% nicotine concentration eliquid.
40994212|NCT04626037|BEHAVIORAL|WECS Relational Toolkit|The Cuddle and Calm Book, The Mommy Baby Book, mother and child mutual narrative, the Bottle of Emotions, and the WECS for emotional connection, make up the WECS Relational Health toolkit.
40994213|NCT01251380|BIOLOGICAL|Botulinum toxin type A|Intramuscular (IM) injection on day 1 of each treatment cycle.
40789913|NCT00680628|DRUG|Tenecteplase + Enoxaparin|"Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.~Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: \<60Kg=30mg; ≥60Kg to \<70Kg=35mg; ≥70Kg to \<80Kg=40mg; ≥80Kg to \<90Kg=45mg; ≥90Kg=50mg"
40789914|NCT00680628|DRUG|0.9% Saline + Enoxaparin|Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
40789915|NCT00645840|DRUG|Anakinra|Patients will receive daily anakinra therapy for 28 days
40789916|NCT02240121|DRUG|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
40994214|NCT01170806|DRUG|Orlistat|Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
40994215|NCT02063737|BEHAVIORAL|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
40994216|NCT02063737|BEHAVIORAL|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
40994217|NCT05877092|DEVICE|implants with overdentures|two implants with bar attachment placed in interforaminal of the mandible mandible of the participants, the patients were delivered conventional upper complete denture constructed from heat cured acrylic rein, but in implanted mandibular arch they were received complete overdenture constructed from heat cured acrylic resin for Group I, and complete thermoplastic denture was constructed for Group II.
40994218|NCT04834479|DEVICE|Ankle US and Ankle MRI|Ankle US and Ankle MRI
40994219|NCT06182644|DIAGNOSTIC_TEST|FAPI PET/CT|The same group of patients underwent FAPI PET/CT and FDG PET/CT examinations respectively
41148370|NCT05721898|DIAGNOSTIC_TEST|Cortical Bone Mechanics Technology|Cortical Bone Mechanics Technology (CBMT). CBMT testing will be performed bilaterally, and flexural rigidity (EI) will be calculated. If a participant has fractured a wrist or forearm bone in the prior 1-year, then only the arm that was not fractured will be tested. During testing, participants will lie supine in the CBMT instrument.
41148371|NCT02333747|DEVICE|the Hans electronic acupuncture apparatus|TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
41148372|NCT04479137|DIAGNOSTIC_TEST|PCR for COVID-19|Novel Coronavirus 2019 DNA will be analyzed by PCR in nasopharyngeal swab
41148373|NCT03906240|BEHAVIORAL|Moral Elevation intervention|The intervention will be administered twice per week for 8 sessions total. The intervention will include two types of moral elevation exercises related to witnessing virtuous behavior and subsequently setting session goals aimed to facilitate social engagement.
41148374|NCT04362059|DEVICE|COVSurf Drug Delivery System|Device introduces surfactant to the patients lungs
41148375|NCT04362059|OTHER|Standard of Care|Standard of care treatment for respiratory illness
41148376|NCT06000202|DEVICE|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 21 days. She receives 3 sessions, in total. Each session consists of application of PS03 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 6 passes followed by R11 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 3 passes.
41148377|NCT06000202|DEVICE|Sham|Er:YAG laser is applied with sham handpiece.
41148378|NCT03622242|DEVICE|Pain threshold index|In pain threshold index monitor, monitor patients' pain threshold index based on electroencephalography and adjust infusion rate of remifentanil and propofol according to pain threshold index
40789917|NCT02240121|DRUG|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
40994220|NCT02690610|PROCEDURE|EBUS TBNA of mediastinal lesions or lymph nodes|Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
40994221|NCT02437955|OTHER|Ferrous sulfate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
41148379|NCT03622242|DEVICE|Wavelet index|In wavelet index monitor, monitor patients' wavelet index based on electroencephalography as an indicator of depth of anesthesia and adjust infusion rate of propofol according to wavelet index
41148380|NCT01074996|DRUG|S-1|40-60mg bid , days 1-14, every 3 weeks
41148381|NCT01074996|DRUG|S-1 plus Leucovorin|S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
40994222|NCT02437955|OTHER|ferrous sulfate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
40994223|NCT02437955|OTHER|Ferrous fumarate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
40994224|NCT02437955|OTHER|Ferrous fumarate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
40994225|NCT00729729|DRUG|PCA|Placebo tablet, once
41148382|NCT03542721|DRUG|DA-5515|Crataegi ethanol extract, Garlic oil, Ginkgo leaf extract, Melissa folium extract (three times a day)
41148383|NCT03542721|DRUG|Placebo of DA-5515|Placebo (three times a day)
40789918|NCT01591265|PROCEDURE|Extraction of upper and lower FPM teeth|Extraction of upper and lower FPM teeth
40789919|NCT01591265|PROCEDURE|Extraction of lower FPM tooth|Extraction of lower FPM tooth only
40789920|NCT01327235|DRUG|Endostar|intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
40789921|NCT01327235|DRUG|Cisplatin|cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
40994226|NCT00729729|DRUG|PCA|PO, 700mg, once
40994227|NCT00729729|DRUG|PCA|PO, 1000mg, once
40994228|NCT02836899|DRUG|Nitric Oxide|Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
40994229|NCT02836899|OTHER|Placebo|This is the placebo group. Nitrogen will be added instead of nitric oxide.
40994230|NCT03317431|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
40994231|NCT00451321|DRUG|Otelixizumab|Infusion
40994232|NCT01813669|BEHAVIORAL|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
40994233|NCT06052007|BEHAVIORAL|LC-Based Debriefing|LC-based debriefing encourages reflection by allowing learners to identify and explore topics of particular interest. The model is defined as a structured post-event LC, which is useful for improving competence, professional development, and clinical judgment among intensive care unit and trauma nurses. The model is useful not only for one recipient by allowing reflection on positive and negative experiences but also for the whole group by allowing them to make connections to their own practice that day or to previous experiences, supporting teamwork. It also helps them understand what good practice is by doing their own self-assessment with peers' benchmarking.
40994234|NCT06052007|BEHAVIORAL|3D Model-Based Debriefing|The model has three parts: defusing, discovering, and deepening. The experiential learning theory on which this model is based facilitates learning goals. This model allows its participants to create new mental models for future practice, develop critical thinking skills, and identify knowledge gaps. In the model, a debriefing session starts with preliminary information and ends with a summary of what has been learned. Participants' gaps in understanding and learning are identified, and how they can apply their learnings to practice is discussed.
40994235|NCT04482504|DIAGNOSTIC_TEST|3 tests: Posturography, Questionnaire, vitamin D|Posturography platform Kistler 9281B Questionnaire focused on exercise activities and self-evaluation of postural stability The investigators also determine level of vitamin D in the blood.
40994236|NCT01283126|PROCEDURE|euglycemic and hypoglycemic clamp|Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
40994237|NCT05292560|OTHER|Training in positivity|The University of Twente developed an evidence-based positive psychology app that is aimed at increasing mental well-being and resilience (Training in positivity; TiP). TiP consists of a 3-week structured intervention, in which participants do two exercises every week for 6 days, aimed at increasing resilience and mental well-being. An exercise takes an average of 15 minutes per day.
40994238|NCT05629832|PROCEDURE|mechanical ventilation strategy guided by transpulmonary pressure|Mechanical ventilation parameters adjust guided by transpulmonary pressure monitoring. For pressure assist control or volumn assit control mode; inspiratory pressure or volumn setting needs to maintain Ppeak less than 25 cm H2O; PEEP was set at such a level that expiratory Ptp stayed between 0 and 5 cm H2O.
40994239|NCT01840774|DRUG|Low-dose pain medication (Ketalar) and saline placebo|
40994240|NCT05541549|BIOLOGICAL|CE-VST01-JC|CE-VST01-JC at a dose of 1 × 10\^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions
40994241|NCT00762398|DEVICE|Masimo hemoglobin-meter|Placing a probe on the finger
40789922|NCT03469167|DEVICE|CEGP003|Application of CEGP003 to peptic ulcer bleeding
40994242|NCT00762398|BIOLOGICAL|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
40994243|NCT01969812|DEVICE|Evie Slow-release Insemination Device|
40994244|NCT01969812|OTHER|Traditional Intrauterine Insemination|
40789923|NCT03469167|DEVICE|Injection Tx|Injection of epinephrine to peptic ulcer bleeding
40789924|NCT03595735|DEVICE|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
40789925|NCT03894891|DRUG|Nivolumab|Nivolumab is a type of immunotherapy.
40789926|NCT03894891|DRUG|Cisplatin|Cisplatin is a chemotherapy drug.
40789927|NCT03894891|DRUG|Docetaxel|Docetaxel is a chemotherapy drug.
40789928|NCT03894891|RADIATION|Intensity-modulated radiotherapy|IMRT is definitive treatment for head and neck cancer.
40994245|NCT06050551|PROCEDURE|uniportal VATS|"1. elective uniportal VATS lung resection, pleural tumor removal or mediastinal lymph node biopsy, etc.~   (exclude the bil. operation, extended wound length over 5 cm, conversion to thoracotomy or multiportal VATS procedure, surgeon's decision for exclusion during operation.)~2. thoracoscopic internal costal nerve block with 10 mL of 1% Ropivacaine at the end of the operation,~3. routinely prescribed with oral Tramadol 37.5mg and Acetaminophen 325mg four times a day postoperatively and intravenous morphine as extra dose if need."
40994246|NCT03412084|BEHAVIORAL|Stand up and move more|4 week behavioral intervention involving the development and implementation of action plans
40994247|NCT02482987|DEVICE|dense polytetrafluoroethylene (dPTFE) membrane Cytoplast|ridge preservation intervention using the dPTFE membrane device
40994248|NCT02482987|DEVICE|human amniotic-tissue derived membrane BioXclude|ridge preservation intervention using the dPTFE membrane device
40994249|NCT02482987|PROCEDURE|Ridge Preservation with overlay graft|ridge preservation intervention with additional freeze dried bone allograft (FDBA) placed buccal to the socket
40994250|NCT02482987|PROCEDURE|Ridge Preservation without overlay graft|ridge preservation without overlay graft / traditional FDBA placement into the socket only
40994251|NCT00778700|OTHER|Placebo Cream|Cream with no active drug
40994252|NCT00778700|DRUG|Ruxolitinib Phosphate|Ruxolitinib phosphate cream
41468405|NCT06602492|DRUG|Higher nicotine eliquid|A 5% nicotine concentration eliquid.
40789929|NCT03841942|OTHER|clinically-based spacing strategy|All patients (as there are free from symptoms) will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission is maintained (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC), patients will have a second step of a 2 weeks infliximab infusion spacing which will be maintained until the end of the study.
40789930|NCT03841942|OTHER|Trough level-based strategy|"patients will have at inclusion a determination of the infliximab trough level. According to this dosage, only patients with a trough level ≥ 7 µg/ml will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC) is maintained and if infliximab trough level is still ≥ 7 ug/ml, patients will have a second step of 2 weeks infliximab spacing until the end of the study.~Patients with a baseline infliximab trough level \< 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study."
40789931|NCT04892706|DRUG|IDP-126 Gel|Gel applied to face once daily in the evening.
40789932|NCT04892706|DRUG|IDP-126 Vehicle Gel|Gel applied to face once daily in the evening.
40789933|NCT04892706|DRUG|Epiduo® Forte Gel|Gel applied to face once daily in the evening.
40789934|NCT00888537|OTHER|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
40994253|NCT05612685|BEHAVIORAL|Healthcare provider referral to a tax filing app|Healthcare providers offer a referral to a tax filing app and briefly describe the potential benefits of tax credit receipt
40994254|NCT01452412|DRUG|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
40994255|NCT01452412|DRUG|Placebo|To be taken on the same schedule as the active arm
41468406|NCT04441645|OTHER|Acupressure|acupressure once per day, five times per week, a total of 12 weeks
40789935|NCT00888537|OTHER|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
40994256|NCT05215743|DRUG|Antioxidant therapy|Active therapy
40994257|NCT05215743|DRUG|NaCl 0.9%|Placebo
40994258|NCT05698147|DRUG|Selinexor|"Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death."
41148384|NCT00336375|DRUG|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
41148385|NCT04026555|OTHER|MEWS++ Monitoring|Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).
41148386|NCT04026555|OTHER|Predictor Score|A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
41148387|NCT03234049|OTHER|Checklist|The Alberta Children's Hospital Trauma Checklist was developed by the ACH Resuscitation Council Trauma Committee in response to a quality assurance review of high-acuity trauma activations. It is a cognitive aid and focuses in particular on pre-arrival preparation and a pre-departure review prior to patient transfer to diagnostic imaging or the operating room.
41148388|NCT04276649|DRUG|Caltrate|Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.
41148389|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC|Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type
41309555|NCT00881855|DRUG|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
41309556|NCT03264482|PROCEDURE|M-TURP|endoscopic resection of the prostatic adenoma
41468407|NCT03610828|OTHER|Vegetarian or Vegan Diets|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
41309557|NCT03264482|PROCEDURE|THUVAP|vaporization of prostatic adenoma via THULIUM laser
40994259|NCT05698147|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
40994260|NCT05698147|DRUG|Methotrexate|high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
40994261|NCT04944901|DRUG|SB-121|SB-121 is a formulation of L. reuteri
40994262|NCT04944901|DRUG|Placebo|Placebo oral formulation
40994263|NCT01218074|DEVICE|Aggregometry+Thromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
40994264|NCT01218074|DEVICE|Thromboelastography Alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
41309558|NCT01064024|DRUG|Phenazopyridine Hydrochloride|Tablets, 200 mg, every 8 hours for 48 hours.
41309559|NCT01064024|DRUG|Placebo|Tablets, every 8 hours for 48 hours
41309560|NCT00908206|DRUG|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
41309561|NCT02364947|DRUG|Nalmefene hydrochloride|As-needed; tablets, orally
41309562|NCT02364947|DRUG|Placebo|As-needed; tablets, orally
41309563|NCT06280157|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
41309564|NCT04068324|DIETARY_SUPPLEMENT|New Care No Nil Per Os|"The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant."
41309565|NCT00228306|BEHAVIORAL|Rehabilitation exercise|Rehab therapy is delivered for 8 weeks.
40994265|NCT02508493|OTHER|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~* Digit Symbol Substitution Test (DSST)~* Choice Reaction Time (CRT)~* One-back working memory tool~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
40994266|NCT02508493|OTHER|Pencil-and-paper Cognitive Tests|"Pencil-and-paper versions of the following cognitive tests:~* Digit Symbol Substitution Test (DSST)~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~* Variant of Choice Reaction Time (CRT)~* Variant of the One-back working memory tool"
40994267|NCT03355586|COMBINATION_PRODUCT|Electromagnetic navigation|Electromagnetic navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
40994268|NCT03622346|PROCEDURE|Semi-constrained total knee arthroplasty|Semi-constrained total knee arthroplasty
40994269|NCT04901494|DRUG|SSRI|Selective serotonin reuptake inhibitor
40994270|NCT02353247|DRUG|Norethindrone acetate|
41148390|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex PosteriorStabilized (PS) knee implant type
41148391|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex Revision knee implant type
41148392|NCT04348799|OTHER|BPD|It is a observation research.we didn't intervene anything.
41148393|NCT01922102|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
41148394|NCT01922102|DRUG|Ranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
41148395|NCT01922102|DRUG|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
41148396|NCT02397902|DIETARY_SUPPLEMENT|High fat dairy|Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
41468408|NCT05310045|BEHAVIORAL|Personalised primary prevention intervention|"Personalised primary prevention intervention~1. Consultation 1~   * Assess caregiver's situation regarding their cancer risk factors~  * Explain the causal links between risk factors and cancer~  * Inform about national recommendations to prevent and limit cancer risk~  * Clarify informal caregiver situation with respect to national screening programs~  * Define a personalised primary prevention program~2. Implementation: personalised primary prevention program~   * Carried out by the informal caregiver~  * Supervised by the coordinating nurse~3. Consultation 2~   * Assess prevention actions realised by informal caregiver in relation to actions defined in the personalised primary prevention program~  * Identify barriers and facilitators to their implementation whether actions or no actions have been done.~  * Adapt the personalised primary prevention program to informal caregiver needs."
40994271|NCT04634864|DEVICE|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation was delivered over both the right and left motor cortex simultaneously
40994272|NCT04634864|DEVICE|sham tDCS|The stimulator was switched off after 2 minutes of stimulation.
40994273|NCT04694677|DRUG|women receiving tranexamic acid|women receiving tranexamic acid during myomectomy
40994274|NCT04694677|DRUG|women receiving misoprostol|women receiving misoprostol in myomectomy
41468409|NCT00810173|BEHAVIORAL|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
40994275|NCT02466555|BEHAVIORAL|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
41309566|NCT05601024|BEHAVIORAL|Laughter Therapy|The first component of intervention is the laughter therapy that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy with whatsapp group call. Each group will consist of at least 5 people. Each session of laughter therapy will be offered one a weekly and 30-40 minutes each time.
41309567|NCT00617409|DRUG|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
41468410|NCT02999984|GENETIC|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
41468411|NCT02999984|DRUG|busulfan|Busulfan is used for non-myeloablative conditioning
41468412|NCT02999984|DRUG|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
40994276|NCT05697887|DIETARY_SUPPLEMENT|Ketogenic diet|The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy
40994277|NCT06083350|DIETARY_SUPPLEMENT|Yeast beta-glucan|Produced by Angel Yeast Co., LTD
40994278|NCT06083350|DIETARY_SUPPLEMENT|Starch|Produced by Angel Yeast Co., LTD
40994279|NCT04546165|PROCEDURE|manipulation plus exercise|HLVA manipulation was performed for 8 sessions (twice a week for four weeks) using a segment-specific technique for segmental dysfunctions of the upper cervical spine. . By bringing the cervical spine to light flexion and about 15-20º lateral flexion without any rotational motion, the middle finger of the manipulating hand provided deep contact, and an HVLA thrust was applied out of the rotational slack by applying a deep force from the dorsal to the ventral direction
40994280|NCT04546165|PROCEDURE|suboccipital inhibition plus exercise|Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region
41468413|NCT01563237|DEVICE|MIDI Arrow|Implantation of MIDI Arrow
41468414|NCT00251316|DRUG|Lithium Carbonate|30 mCi of 131I
41468415|NCT00251316|DRUG|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
41468416|NCT03700827|OTHER|Resistance Training|High-intensity Resistance Training Group
40994281|NCT04546165|PROCEDURE|exercise|Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).
40994282|NCT00000514|DRUG|chlorthalidone|
40994283|NCT00000514|DRUG|atenolol|
40994284|NCT00000514|DRUG|reserpine|
40994285|NCT03141281|BEHAVIORAL|BrainHQ|BrainHQ
40994286|NCT03141281|BEHAVIORAL|Rise of Nations|Rise of Nations
40994287|NCT03141281|BEHAVIORAL|IADL Training|IADL Training
40994288|NCT03141281|BEHAVIORAL|Active Control|Puzzle solving
40994289|NCT03797833|PROCEDURE|Spinal Anaesthesia|Spinal anaesthesia with Bupivacain 2.5 mg and Sufentanil 5 µg
40994290|NCT03137888|RADIATION|Dose-Escalated Radiation Therapy|Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
40994291|NCT03137888|PROCEDURE|Spectroscopic Magnetic Resonance Imaging|Patients will undergo sMRI scans within a 14 day window prior to starting treatment
41309568|NCT00617409|BIOLOGICAL|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
41309569|NCT00617409|DRUG|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
41309570|NCT03459131|DEVICE|Comfilcon A with Digital Zone Optics™ contact lenses|Silicone hydrogel spherical contact lenses with Digital Zone Optics™
41309571|NCT03459131|DEVICE|Comfilcon A contact lenses|Silicone hydrogel spherical contact lenses
40994292|NCT03137888|DRUG|Temozolomide|Given PO
40994293|NCT01284283|DEVICE|Scandinavian Total Ankle Replacement System (STAR Ankle)|For total ankle replacement
40994294|NCT02310464|DRUG|OBI-833/OBI-821|
40994295|NCT05180461|DRUG|emodepside|emodepside tablet
40994296|NCT05180461|DRUG|matching placebo of emodepside|emodepside matching placebo tablet
40994297|NCT05180461|DRUG|ivermectin|ivermectin tablet (overencapsulated for blinding)
40994298|NCT05180461|DRUG|matching placebo of ivermectin|matching placebo of overencapsulated ivermectin tablet
40994299|NCT01533454|OTHER|Financial Incentives|Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
40994300|NCT04681482|DRUG|Apixaban|Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation.
40994301|NCT03774589|PROCEDURE|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis will be used to complete the anastomosis during bilioenteric anastomosis.
40994302|NCT03774589|PROCEDURE|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
40994303|NCT04980677|DEVICE|Tangiball|"To enable baseline scores comparison, children will be matched according to age and score on the four-strand Hands-On assessment tool which takes 30 minutes to complete. Children will then play with the Smart Toy during a 20 minute session. Sessions will be recorded using an SD card within the Smart Toy which captures information on user speed and accuracy of placement of the detachable segments of the toy when placed into the main hub of the toy, allowing comparison between neuro-typical children and children with Autism. The intervention will run either in clinic (preferred option) or in children's homes-and in this case will be sent to them via post with the Standard Operating Procedure which can then be employed when children are taking part in the intervention via online video link (not recorded)."
41468417|NCT03700827|OTHER|Aerobic Training|Aerobic Interval Training Group
40789936|NCT04169516|DIAGNOSTIC_TEST|index of microcirculatory resistance|Physiological parameters of the culprit artery after PCI were determined with the restoration of Thrombolysis in Myocardial Infarction (TIMI) 3 flow. Aortic pressure (Pa), distal intracoronary pressure (Pd), fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) were measured using a 0.014 coronary temperature and pressure-sensing guidewire (PressureWireCertus, ST. Jude Medical, MN, USA).
40789937|NCT02775266|OTHER|Alpha lipoic acid|Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.
40994304|NCT01908257|DRUG|lesinurad 400 mg|
40994305|NCT01908257|DRUG|ranitidine 150 mg|
40994306|NCT01908257|DRUG|lesinurad 400 mg + ranitidine 150 mg|
41148397|NCT02397902|DIETARY_SUPPLEMENT|Plant-based|Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
41468418|NCT00860678|OTHER|Physical activity|
41468419|NCT00860678|OTHER|no Intervention|
40994307|NCT04252989|OTHER|data collection|"* Demographic data: age, sex~* Ophthalmological history: refraction of parents, previous refractions~* Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics~* Potential undesirable events (halos, photophobia...)"
40994308|NCT05913895|OTHER|hydrogen water|To investigate whether the intervention of hydrogen water adjuvant therapy can improve oral mucositis, oral frailty, pain and Quality of Life with head and neck cancer who have received radiation therapy or combined chemotherapy.
40994309|NCT02869594|OTHER|Data collection|
41148398|NCT06250374|PROCEDURE|Bilateral trans-cranial Doppler ultrasound|Velocity measurements in the middle cerebral artery are made using an ultrasound probe applied to the patient's temple during surgery.
41148399|NCT00409006|DRUG|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
41148400|NCT00409006|DRUG|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
41148401|NCT00409006|DRUG|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
41148402|NCT02697136|DRUG|CER-001|Recombinant human apoA-I/phospholipid complexes
41148403|NCT02697136|DRUG|Placebo|0.9% Sodium Chloride Injection, USP
41148404|NCT03500809|PROCEDURE|Aqueous release of the wound|"1. Anaesthetic drop (tetracaine 1%) followed by povidone iodine 5% drop is instilled. After 5 minutes, a sterile 30 gauge needle tip is pressed on the posterior lip of the one of the existing cuts (paracentesis or main wound) from cataract surgery to release the fluid and consequently the pressure.~2. This will be performed under careful monitoring to avoid any undesirable shallowing of the anterior chamber of the eye."
41148405|NCT02420509|DRUG|systemic chemotherapy|twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
41148406|NCT00817739|DRUG|Leuprorelin|Leuprorelin injection
41148407|NCT00817739|DRUG|Flutamide|Flutamide tablets
40789938|NCT02775266|PROCEDURE|Scaling and Root planing|Scaling and root planing will be done at baseline.
40789939|NCT06447155|DIETARY_SUPPLEMENT|Bolus feeding|The babies fed with bolus feeding during TH composed this group
40789940|NCT06447155|DIETARY_SUPPLEMENT|Continuous feeding|The babies fed with continuous feeding during TH composed this group
40789941|NCT06447155|DIETARY_SUPPLEMENT|Placebo|The babies who were not fed during TH composed this group
40789942|NCT04268069|DRUG|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.
40789943|NCT04268069|DRUG|Placebo Ophthalmic Solution|Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.
40789944|NCT06159283|DRUG|Immunoglobulins|Dosage is Immunoglobulin 1,000mg/kg IV. It administer over 2\~3 days.
40789945|NCT06487637|BEHAVIORAL|CardioCare Quest|CardioCare Quest will be the first telehealth game designed to enhance High Blood Pressure (HBP) treatment compliance and education about HBP, featuring a telemetry system that provides physicians and researchers data about sustainable healthy heart lifestyles beyond the clinic. The novelty of CardioCare Quest lies in its ability to compel HBP patients to playfully celebrate the mundane everyday practices that lead to sustainable habits and improved health outcomes using culturally sensitive and community-based design practices.
41468420|NCT05389670|DEVICE|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
41468421|NCT05389670|DEVICE|Sham Continuous Theta-burst stimulation (cTBS)|Sham cTBS, inhibitory-like patterned form of TMS.
40789946|NCT01055613|DEVICE|Vistakon Investigational Multi-Purpose Solution I|Multi-purpose contact lens care solution.
40789947|NCT01055613|DEVICE|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution
41468422|NCT05176379|DRUG|Fluconazole 150 mg|A single acute 150 mg dose
40789948|NCT02131311|DEVICE|disposable, single-use pessary|
40789949|NCT04942132|BEHAVIORAL|Cognitive-behavioral (CBT)|Treatment includes a smartphone-delivered CBT program designed to improve the quality of life of individuals with chronic pain. The treatment is condensed in nine weeks, and contains the following modules or units of treatment: sleep quality, anxiety management, pain coping, medication use, physical conditioning, mood regulation, problem solving, decision-making and relationships with others. All the content and settings are written in Spanish.
40789950|NCT05595343|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of performed laparoscopic distal pancreas surgery in two different surgeon groups
40789951|NCT03457610|BEHAVIORAL|Speech and language intervention|Speech therapy includes education about cough and vocal hygiene, teaching strategies to reduce cough, breathing and vocal exercises. The whole therapy consists of eight sessions once a week.
41468423|NCT03113578|DEVICE|DiLumen|The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons
41468424|NCT01604369|PROCEDURE|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
41468425|NCT05484141|OTHER|Rehabilitation with blood blow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
41148408|NCT00126620|DRUG|erlotinib hydrochloride|
41468426|NCT05484141|OTHER|Rehabilitation without blood flow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
41468427|NCT01013428|OTHER|Ultrasound|Ultrasound will be used to evaluate tendons.
41468428|NCT04440709|DEVICE|Brain/neural hand exoskeleton (B/NHE)|The brain/neural hand exoskeleton restores hand motor function by translating user's intention into grasping motions
40789952|NCT00622921|BEHAVIORAL|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
40789953|NCT04528589|OTHER|prenatal psychotherapy|Prenatal psychotherapy to break intergenerational risk of adverse childhood events
40789954|NCT04803513|DRUG|Galcanezumab|Galcanezumab according to clinical indication in real life
40789955|NCT02186483|DRUG|Metformin|Metformin,1000mg, once daily
40789956|NCT02186483|DRUG|Rosuvastatin|Rosuvastatin, 20 mg, once daily
40789957|NCT02186483|DRUG|Metformin and Rosuvastatin|Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
41148409|NCT00126620|DRUG|sorafenib tosylate|
40789958|NCT02959788|OTHER|Heart rate variability|All patients have a 10-minute recording analyzed for indices of heart rate variability.
40789959|NCT03069066|DEVICE|Bioresorbable vascular scaffold. Absorb GT1 (Abbott)|
40789960|NCT06074237|OTHER|Immersive resident education|Using the AIMS framework (Announce, Inquire, Mirror, Secure), residents will complete online modules designed to improve vaccine education, promote vaccine confidence and improve vaccine counseling in general. There will also be modules dispelling myths and controversies specific to HPV, MMR, Covid and influenza vaccines that often limit or prevent vaccination uptake.
41148410|NCT02077114|BIOLOGICAL|Vaccine consisting of a peptide derived from the protein IDO|All patients will receive seven vaccines containing IDOlong
41148411|NCT04547101|DRUG|AK104|AK104，6 mg/kg IV，every 2 weeks (Q2W)
40789961|NCT06074237|OTHER|Standardized patient (SP) encounter|"After completion of the Immersive Resident Education modules, residents will participate in a telemedicine standardized patient encounter. They will interview a vaccine-hesitant patient and this encounter will be video recorded. At the end of the encounter, the SP will provide the resident with patient-centered feedback on their communication skills. The SP will also complete a communication checklist regarding each resident encounter and the research team will review the recorded encounters for accuracy of medical content conveyed during each encounter."
40789962|NCT01109186|OTHER|biological parameters|blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
40789963|NCT01107964|DRUG|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
40789964|NCT01107964|DRUG|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
40789965|NCT01582334|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
40789966|NCT02945163|DRUG|Tenofovir|Tenofovir Disoproxil Fumarate
40789967|NCT02945163|DRUG|Lamivudine|Lamivudine
40789968|NCT02945163|DRUG|Efavirenz|Efavirenz
40789969|NCT06224907|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
41148412|NCT06076317|BEHAVIORAL|Telemedicine session|The content of telemedicine session is semi-standardized and includes: (1) evaluation of the tolerance and efficacy of drug treatment; (2) evaluation of depressive symptoms (PHQ9 scale); (3) identification of the daily difficulties; (4 ) personalized advice and orientation towards appropriate care pathways. Among the personalized advice, investigators will use the digital tools available to maintain remission, psychoeducation and monitoring tools (for example, application to learn mindfulness meditation, conversational chatbot coupled with artificial intelligence, etc.). Support on the use of these tools can be provided during telemedicine sessions.
41148413|NCT04161976|DRUG|LY900027|LY900027 administered to participants with T1DM using CSII.
41148414|NCT04161976|DRUG|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII.
41309572|NCT03357809|PROCEDURE|Endoscopic mucosal resection|"Mucosectomy performed at day 1. Endoscopic mucosal resection (EMR) and or endoscopic submucosal dissection (ESD), is at least 3 cm long. The mucosal resection is carried out along the side of the small curvature of the stomach, in order to preserve a valve of the cardia at the level of the large curvature of the stomach.~A coloured solution is injected into the submucosa following markers. The correct submucosal injection is confirmed by the lifting of the mucosal surface. A submucosal dissection is carried out using the dual knife. The mucosectomy is repeatedly performed until the mucosal zone is completely resected. The choice of the resection technique will depend on the anatomy of the patient."
41309573|NCT01451034|PROCEDURE|WHYX cancer group|WHYX cancer diagnosed by pathologic report
40789970|NCT01079364|DRUG|Insulin glulisine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
40789971|NCT01079364|DRUG|Insulin glargine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
40789972|NCT01079364|DRUG|Premixed insulin (Insulin Aspart 30/70 )|Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
40789973|NCT01746446|OTHER|Care team|Provides additional support to patients, family, and friends.
40789974|NCT04312477|DRUG|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
41309574|NCT06290895|OTHER|women having had a second IVF cycle with AOA|The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.
40789975|NCT04951011|DIAGNOSTIC_TEST|Serum beta HCG|Raising numbers of S BHCG or decreasing with different management of tubal Ectopic Pregnancy
40789976|NCT02991339|DRUG|Dexamethasone|Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day
40789977|NCT00729443|DRUG|AZD3241|single oral dose
40789978|NCT00729443|DRUG|Placebo|
41309575|NCT04196361|DIAGNOSTIC_TEST|Ultrasound|Point of care ultrasound as part of routine physical examination
40789979|NCT01888861|DIETARY_SUPPLEMENT|alpha-lipoic acid|the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
40789980|NCT01888861|DRUG|placebo|the patients in this arm were received 900mg placebo through NG tube.
40789981|NCT02274220|DIETARY_SUPPLEMENT|Rapid advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 1 mL/kg every three hours and up-titrated by 1 mL/kg every feed (Q 3 hours) to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will exceed 20 mL/kg/day by 6 hours following protocol initiation and reach target feeds by 27 hours of protocol initiation.
40789982|NCT02274220|DIETARY_SUPPLEMENT|Standard advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 3 mL every three hours for 24 hours. Bolus feeds then up-titrated by 1 mL/kg every-other feed (Q 6 hours) for 24 hours. Bolus feeds then up-titrated by 1mL/kg every feed for to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will reach target feeds by 60-63 hours after protocol initiation.
40789983|NCT05842486|OTHER|Anti-C5 antibody treatment|Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)
40789984|NCT01224236|DRUG|Iron Supplement|2 mg/kg/day elemental iron as multivitamin with iron solution
40789985|NCT01224236|DRUG|control|multivitamin solution without iron
40789986|NCT00871663|DRUG|SCH 727965|Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
40789987|NCT00593060|DRUG|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
40789988|NCT00593060|DRUG|Cetuximab|One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
40789989|NCT02664519|BEHAVIORAL|Forearm exercise training|Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
40994310|NCT03278990|BEHAVIORAL|Value Affirmation and Future Selves Combination|Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
40994311|NCT03278990|BEHAVIORAL|Control writing exercise|In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
40994312|NCT03022760|BEHAVIORAL|Work-related measures|After mapping the patient's psychosocial work situation using tools provided at the one-day training, the patient's employer will be contacted and involved in the rehabilitation planning.
40994313|NCT00217542|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
40994314|NCT00217542|DRUG|amifostine/azacitidine|Given SC
41148415|NCT04038723|BEHAVIORAL|High-intensity interval training|Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
41148416|NCT04552184|OTHER|GPOEM|gastric per oral endoscopic pyloromyotomy
41148417|NCT04552184|OTHER|SHAM Procedure|intrapyloric injection of saline solution
41148418|NCT06035601|DEVICE|EHR-integrated texting platform (Urotrust)|"* An evidence-based algorithm that provides symptom triage and clinical guidance during an episode of acute UTI~* Evidence-based prevention education material on recurrent UTIs~* 5 standing orders for urinalysis and urine culture in the EHR upon enrollment~* Standard-of-care management for recurrent UTI"
41148419|NCT06035601|OTHER|Usual care|• Standard-of-care management of recurrent UTI (phone calls and/or secure EHR messages for acute symptoms) and follow up visits as determined by patients and their providers.
41309576|NCT06155916|DRUG|Pregabalin|Pregabalin administration and titration to the highest dosage that the patient tolerates. The patient continues with the highest dose for one month and the pre-intervention studies are repeated.
41309577|NCT01525849|DEVICE|Balloon Sinus Dilation|Balloon sinus dilation using the XprESS Multi-Sinus Dilation Tool or the FinESS SInus Treatment
41309578|NCT01525849|PROCEDURE|Functional Endoscopic Sinus Surgery|Endoscopic sinus surgery, specifically, maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy
41309579|NCT05209932|BEHAVIORAL|Online New Beginnings Program (eNBP)|The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group-based NBP that can be used on a smart phone, tablet or computer. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations.
41309580|NCT00142519|DRUG|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
41309581|NCT00142519|DRUG|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
41309582|NCT00835887|DIETARY_SUPPLEMENT|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
41309583|NCT00562003|PROCEDURE|Tenckhoff Catheter placement|'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.
41309584|NCT00562003|DRUG|Ad5-delta24RGD|"Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed.~The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'."
41309585|NCT01603641|BIOLOGICAL|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
40994317|NCT02304263|DRUG|iohexol|5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
41309586|NCT03697928|OTHER|Exercise metabolism|Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
41468429|NCT02488031|BEHAVIORAL|Error-reduction|"During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.~The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed."
41468430|NCT02488031|BEHAVIORAL|International Cooperative Ataxia Rating Scale|The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
41309587|NCT01187108|DRUG|N-acetylcysteine|NAC 600 mg oral once daily
40789990|NCT01709552|BEHAVIORAL|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
40789991|NCT01709552|BEHAVIORAL|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
40789992|NCT06364397|PROCEDURE|ERCP|Participants will undergo ERCP and indomethacin will be administered rectally before procedure in participants with no known allergy to indomethacin. If the etiology of the participant is clearly defined during ERCP, the corresponding endoscopic treatment procedure will be performed. For others whose etiology are still unclear, pancreatic sphincterotomy and small caliber prophylactic pancreatic duct stent replacement will be performed. The participants will be observed closely after ERCP and record complications. Abdominal X-rays will be taken 2 weeks after ERCP to confirm spontaneous passage of the pancreatic duct stent, and the stent will be removed via gastroscopy if it still in place.
41468431|NCT02488031|BEHAVIORAL|Scale for the Assessment and Rating of Ataxia|The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
41468432|NCT02488031|BEHAVIORAL|Beck Depression Inventory, 2nd Ed|This is a 21 question self-report inventory for measuring severity of depression.
41468433|NCT02488031|BEHAVIORAL|Stroop|This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.
40994318|NCT01684371|OTHER|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
41309588|NCT01187108|DRUG|Acetazolamide|Acetazolamide 250 mg oral once daily
41309589|NCT01187108|DRUG|Placebo pills|1 (or 2 in the placebo group) empty gel capsules
41309590|NCT02530606|PROCEDURE|Photoacoustic Imaging|Undergo PAI
41309591|NCT05633134|PROCEDURE|Arteriography and precision preoperative embolization|Arteriography and transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
41309592|NCT05633134|PROCEDURE|Arteriography|Arteriography of pelvic tumors 0-24 hours prior to surgery.
40789993|NCT06364397|COMBINATION_PRODUCT|Health education and conservative management of clinical routines|Participants will be given health education and conservative management of clinical routines. Clinical management is based on the pancreatic endocrine and exocrine function.
40994319|NCT05787314|BEHAVIORAL|Low Glycemic Index Diet|"1. Participants who came to the hospital for control and were interested in the study contacted the study researchers and eligibility was determined through face-to-face interviews. Potential participants were invited to a screening visit to verify eligibility.~2. The LGID program was initiated as an outpatient treatment in patients who applied to a dietitian. 3) Medium and high GI carbohydrates (GI \> 55) were excluded from the diet and only low GI (GI \< 50) foodstuffs were allowed. 4) A list of low glycemic index foods were given to the patients. In addition, a list of foods to avoid (medium and high glycemic index) is provided."
40994320|NCT02846207|DRUG|Yiqi huoxue|Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
40994321|NCT02846207|DRUG|Yiqi group|Astragalus 60g.Oral administration, twice one day, for 12weeks.
40994322|NCT02846207|DRUG|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
40789998|NCT05923697|BEHAVIORAL|AF-EMDR|"Investigational treatment~All participants receive four 90 min. AF-EMDR sessions within a timeframe of two weeks following the baseline phase. The AF-EMDR treatment will be provided by the principal investigators, a level II EMDR therapist (RvdH) and an EMDR consultant in training who developed the AF-EMDR protocol. The EMDR therapist (RvdH) will be trained by the EMDR consultant (WM), who is available for consultation. Additionally, both participate monthly in peer-supervision whereby videotaped sessions are discussed. See appendix 1 for a detailed understanding of the AF-EMDR protocol."
40789999|NCT04336241|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation
40790000|NCT04336241|BIOLOGICAL|nivolumab|Programmed death receptor (PD-1) blocking antibody
40790001|NCT01525823|DRUG|BMS-754807 (IGR-IR/IR Inhibitor)|Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
40790002|NCT01525823|DRUG|Metformin|Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
40790003|NCT00363311|DRUG|Dutasteride|Dutasteride 0.5mg
40790004|NCT00363311|DRUG|Matching placebo|Matching placebo
40790005|NCT01123226|PROCEDURE|spinal manipulation|A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
40790006|NCT01123226|PROCEDURE|trigger point therapy|The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
40790007|NCT03976297|OTHER|Control Tower|A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
40790008|NCT02060786|DRUG|generic clopidogrel (Plavitor® )|
40994323|NCT02846207|DRUG|placebo|Dextrin,oral administration, twice one day, for 12weeks.
41309593|NCT04715308|PROCEDURE|Urinary diversion|The formation of a stoma to divert urine to the skin because of the need to resect the bladder as part of surgery for advanced pelvic malignancy
41309594|NCT03041194|OTHER|dietary affects|Dietary affects on urine pH in relation to Interstitial cystitis symptoms
40790009|NCT02060786|DRUG|original clopidogrel (Plavix® )|
40790010|NCT06151119|DIAGNOSTIC_TEST|68Ga FAPI PET/CT|68Ga FAPI PET/CT
40790011|NCT06094309|DRUG|Botulinum toxin type A injection|The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.
40790012|NCT01731847|PROCEDURE|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
40790013|NCT06348303|DRUG|Metaxalone m640 mg oral tablet|Metaxalone partially micronized 640 mg tablet
40790014|NCT06348303|DRUG|Metaxalone 800 mg oral tablet|Metaxalone non-micronized 800 mg oral tablet
40790015|NCT06316726|COMBINATION_PRODUCT|full bed silicone mattress plus other measures|full bed silicone mattress plus put silicone pads on the head and shoulders, cotton rolls wraps bony prominence (elbows and heels), petrissage every two hours on shoulders to fingers and lower legs to heels, change location of ankle pads, use round gel full of air sit pad, a pillow on the knees
40790016|NCT05951647|DRUG|Chamomile extract mouthwash|5% chamomile extract mouthwash in a dose of 15 ml twice daily.
40790017|NCT05951647|DRUG|Pomegranate peel extract mouth wash|5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily.
40790018|NCT05951647|DRUG|Combination of 5% chamomile extract and pomegranate peel extract mouthwash|Use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily.
40790019|NCT05951647|PROCEDURE|Scaling|Patients will be managed by scaling
40790020|NCT05951647|DRUG|Scaling and Chlorohexidine mouthwash|scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily.
40790021|NCT00784862|DRUG|Anastrozole|1mg, orally, once daily
40790022|NCT00784862|DRUG|Tamoxifen|20mg, orally, once daily
40790023|NCT01366573|DRUG|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
40790024|NCT01366573|OTHER|Placebo|Placebo
41309595|NCT02117167|DRUG|AZD2014|Target: m-TOR
41309596|NCT02117167|DRUG|AZD4547|Target: FGFR
41309597|NCT02117167|DRUG|AZD5363|Target: AKT
41309598|NCT02117167|DRUG|AZD8931|Target: HER2, EGFR
41309599|NCT02117167|DRUG|Selumetinib|Target: MEK
41468434|NCT02488031|BEHAVIORAL|Purdue Pegboard|This test consists of a series of timed hand coordination and dexterity tasks.
40994324|NCT06146946|PROCEDURE|Dissection of the No.253 lymph node|The range of the No.253 lymph node is as follows: medially, it extends from the root of the inferior mesenteric artery to the starting section of the left colonic artery; caudally, from the starting point of the left colonic artery to the intersection with the inferior mesenteric vein; laterally, it is bordered by the outer margin of the inferior mesenteric vein; and cranially, from the horizontal section of the duodenum to the beginning of the jejunum. In the controlled group, the surgery is performed with dissection of the No.253 lymph node.
40790026|NCT02507154|DRUG|Cetuximab + NK cells|
40790027|NCT03565341|DEVICE|PiQo4|PiQo4 Laser System for treatment of Melasma
40790028|NCT04495686|BEHAVIORAL|Telehealth-delivered Care Coordination Program|"Participants in the interventional arms of this program will be assigned a Dementia Care Manager (DCM) who will work with caregivers to develop goals and plans that are aimed at providing the best support possible, specific to your needs. These services include supportive counseling, education on dementia, information and referrals to community-based organizations, behavioral symptom management training and assistance with finding available community and government-sponsored programs.~DCM's will meet with you at least once monthly and will be available if you need assistance between meetings. At the first meeting, your DCM will explain the questionnaires you will take and how to use the technology in the program. They will then provide a link, via email, where you will download the free teleconferencing software that will be used throughout the program. Questionnaires will then be sent via email invitations through a secure survey platform."
40790029|NCT05465070|DEVICE|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
40790030|NCT05465070|DEVICE|Sham Control|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
40790031|NCT04570306|DRUG|Belimumab|The study will involve 80 adult patients diagnosed with SLE who will be started on belimumab (standard approved dose of i.v. 10 mg/kg or subcutaneous 200 mg/week) due to active disease. The intention to start belimumab will be made by the treating Rheumatologist(s), in accordance to the current standard of care, and on the basis of shared physician-patient decision making.
40790032|NCT02795299|DRUG|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
40790033|NCT02795299|DRUG|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
40790034|NCT02795299|DRUG|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
40790035|NCT02795299|DRUG|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
40790036|NCT00394576|BEHAVIORAL|Internet-based nutrition module along with usual care|usual care plus Internet-based nutrition module
40994325|NCT06146946|PROCEDURE|Omitting the dissection of the No.253 lymph node|In the experimental group, the surgery is performed without dissection of the No.253 lymph node.
40994326|NCT00943228|DRUG|mycophenolate mofetil|High dose 4gms daily
40994327|NCT00067678|DRUG|soy protein|
40994328|NCT01932827|BEHAVIORAL|Mock Package Questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
41148420|NCT02885714|PROCEDURE|Placebo surgery and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated. Nothing is to be removed or excised and the use of any vapour or shaver device is not allowed. The presence of a full-thickness rotator cuff tear is verified. Altogether 3 to 5 small stab wounds are made in typical locations resembling locations of typical rotator cuff repair. The time spent in the operating theatre with patients in placebo group should resemble the time spent with patients in the active treatment group and hence give an impression of a rotator cuff repair.
41309600|NCT02117167|DRUG|Vandetanib|Target : VEGF, EGFR
41468435|NCT02488031|BEHAVIORAL|Brief Test of Attention|A cognitive test assessing focus and attention.
41468436|NCT02488031|BEHAVIORAL|6-minute Walk|This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
41468437|NCT02488031|BEHAVIORAL|Hand Grip Dynamometer|This tests measures hand grip strength.
40790037|NCT00394576|BEHAVIORAL|usual care|usual care
40790038|NCT05461339|DRUG|TAB014 Monoclonal Antibody Injection|intravitreal injection at 1.25mg once every 4 weeks
40790039|NCT05461339|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection at 0.5mg once every 4 weeks
40994329|NCT05717010|DEVICE|Near infrared spectroscopy|The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.
40994330|NCT03340337|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
41309601|NCT02117167|DRUG|Standard maintenance for squamous NSCLC|
41468438|NCT02488031|BEHAVIORAL|Montreal Cognitive Assessment|This test is used to assess cognitive abilities.
41468439|NCT02488031|BEHAVIORAL|Physical Performance Function|This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
40790040|NCT03956173|OTHER|Hypoglycemic combined with either normo or hyperglycemic clamp.|Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
40994331|NCT03340337|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
40994332|NCT03340337|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
40994333|NCT06370156|DRUG|Adalimumab|To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.
40994334|NCT04851795|OTHER|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
40994335|NCT04851795|OTHER|unsupervised physical exercise|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
40994336|NCT00844272|BEHAVIORAL|Psychoeducation|"Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education."
40994337|NCT02722447|DRUG|rivaroxaban|Rivaroxaban 20 mg for 6 weeks
40994338|NCT02722447|DRUG|Placebo|Placebo for 6 weeks
40994339|NCT02413541|PROCEDURE|Polymyxin-B Hemoperfusion|Endotoxin removal
40994340|NCT02413541|PROCEDURE|Standard treatment|
40994341|NCT01662908|DRUG|edoxaban tosylate|edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
40994342|NCT01662908|DRUG|enoxaparin/unfractionated heparin|enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
40994343|NCT01662908|DRUG|warfarin|tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
40994344|NCT04848935|DEVICE|CURATE.AI|CURATE.AI will be utilised to provide personalised training intensity recommendations (low, medium or high) to the patients during the digital cognitive test battery DI session. The difficulty of each task will be modulated by CURATE.AI by adjusting the frequency of critical events that demand evaluation and/or response.
40994345|NCT00624676|DRUG|Lipo Hydroxy Acid|Twice a day
40994346|NCT00624676|DRUG|5% benzoyl peroxide gel|Once a day
40994347|NCT02310685|OTHER|Comprehensive e-health wellness program|"Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not of interest."
41309602|NCT02117167|DRUG|Pemetrexed|Standard maintenance for non squamous NSCLC
41309603|NCT02117167|DRUG|Durvalumab|Target: PD-L1
41309604|NCT02117167|DRUG|savolitinib|target : MET
41468440|NCT02488031|BEHAVIORAL|Biomechanical Assessments of Dysmetria|Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.
40790041|NCT01072721|OTHER|Elastometry|Fibrosis detection with FIBROSCANN
40790042|NCT00570323|DRUG|Arimidex|Aromatase inhibitors
40790043|NCT00570323|DRUG|Faslodex|Hormone Receptor
40994348|NCT06300333|DRUG|Methotrexate|use low dose of Methotrexate in treatment of un distectopic tubal pregnancy
41309605|NCT02117167|DRUG|Olaparib|target : PARP
41309606|NCT02365493|DRUG|Beta-Lactam|
41309607|NCT02364206|DRUG|LY2228820|
41468441|NCT02488031|BEHAVIORAL|Neurophysiological assessment of brain activity|Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.
40994349|NCT00063869|DRUG|Etanercept|
40994350|NCT05339451|DIAGNOSTIC_TEST|Blood biomarkers|Blood biomarkers in plasma and serum.
41468442|NCT02488031|BEHAVIORAL|Biomechanical gait analysis|Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
40994351|NCT06248229|DRUG|Dyanavel XR|"Dosing will begin the morning following Visit 2. Subjects in the active group will begin the study on 5 mg of Dyanavel XR. Subjects will be advised to take one capsule each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment."
40994352|NCT06248229|DRUG|Placebo|"Dosing will begin the morning following Visit 2. Subjects in the placebo group will begin the study on 5 mg of placebo. Subjects will be advised to take one tablet each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment."
40994353|NCT00548704|DRUG|Dexrazoxane|
40994354|NCT02149927|DRUG|Sevoflurane|
41148421|NCT02885714|PROCEDURE|Rotator cuff repair and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated and the presence of a full-thickness rotator cuff tear is verified. The cuff tear is repaired to its anatomic location using suture anchors according to surgeon preference. . A biceps tenotomy or tenodesis may be performed according to surgeon preference if the biceps tendon is noted to be frayed, unstable or inflamed. An additional acromioplasty may be performed according to surgeon preference.
40994355|NCT01023646|OTHER|Carbohydrate + Protein|Light Tuna Packed in water.
40790044|NCT02353858|OTHER|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
40790045|NCT02353858|RADIATION|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
40994356|NCT01023646|OTHER|Carbohydrate + Fat|Butter
40994357|NCT01023646|OTHER|Fiber|Unrefined Carbohydrate
40994358|NCT01023646|OTHER|Carbohydrate load|Carbohydrate
40994359|NCT01822132|DRUG|Extended release naltrexone|
40994360|NCT01822132|DRUG|Placebo|
40994361|NCT05466747|BIOLOGICAL|RYMPHYSIA|RYMPHYSIA administered through an IV injection.
40994362|NCT05466747|BIOLOGICAL|Another Available A1PI|Another available A1PI administered through an IV injection.
40994363|NCT02579265|DRUG|Smoflipid 20% (investigational lipid for parenteral nutrition)|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Smoflipid 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Smoflipid 20% will be infused into a central or a peripheral vein."
40994364|NCT02579265|DRUG|Intralipid® 20%|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Intralipid® 20% will be infused into a central or peripheral vein."
40994365|NCT00218296|DRUG|Usual Care Group|Nicotine replacement therapy
40994366|NCT00218296|OTHER|Reduction Group|Subject selects preferred method for reduction.
41148422|NCT04562714|DEVICE|FreeStyle Libre Flash Glucose Monitor|The FreeStyle Libre FGM device consists of a skin-worn disposable sensor that automatically measures and continuously stores glucose readings. The sensor is placed by a single-use applicator and is activated by a wireless scan with a handheld reader. It is designed to stay on the body for up to 14 days, and can be worn under clothing. After a 1-hour warm-up period, the sensor takes automatic measurements of glucose every 15 minutes for up to 14 days. The device collects the interstitial glucose values and stores them for subsequent upload at the end of the 14-day wear period. With each scan, users receive their glucose reading; the last eight hours of glucose data; and an arrow illustrating the direction their glucose is heading.
41148423|NCT04562714|OTHER|Diabetes self-management education|"The DSME curriculum is compromised of:~1. Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~2. Education modules for both in-person and remote delivery;~3. Handouts to support the curriculum objectives; and~4. Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning."
41148424|NCT02368288|DRUG|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
41148425|NCT01351597|DRUG|docetaxel/ oxaliplatin|"1. docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks~2. oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks"
41309608|NCT02364206|DRUG|Temozolomide|
41309609|NCT02364206|RADIATION|radiotherapy|
40790046|NCT02353858|DRUG|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
41148426|NCT01328483|PROCEDURE|Intrapartum Oropharyngeal Suctioning|After delivery of the head, the infant's mouth and nose were suctioned. Nose was suctioned after the mouth and throat. Oropharyngeal suctioning was performed using a 10 french suction catheter with suction pressure of 100mm Hg or De Lee's suction trap in event of electricity failure or non availability of suction machine
41148427|NCT03883984|DRUG|Cysteamine Bitartrate|Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
41148428|NCT03883984|DRUG|Placebo Oral Tablet|Placebo administered for 8 weeks. 125mg tablet QID.
41148429|NCT02831088|DRUG|Neu2000KWL High-does group|1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
41148430|NCT02831088|DRUG|Neu2000KWL Low-does group|1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
41148431|NCT02831088|DRUG|Placebo|1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
41309610|NCT02582580|OTHER|Perineal massage|"Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter U. All movements should be repeated four times."
41309611|NCT02582580|DEVICE|Vaginal Dilator|Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
41468443|NCT05504824|OTHER|Case-based education|"The education phase This stage included the explanation of the CR process, the analysis of CR cases, the drafting of new cases suitable for the CR process by students, and the analysis process.~The education program was carried out on a web platform (Zoom) consistent with the changes in the COVID-19 pandemic process. The CR cases to be used in case-based education were sent to the students via e-mail before the group interview to make sure students came prepared for the group discussion. In case-based education, after the students read the case, they were asked some questions to determine their decisions and reasoning."
41468444|NCT05585931|DRUG|TPN171H 10mg|Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.
41468445|NCT05585931|DRUG|TPN171H Placebo|Subjects were given Placebo with 240 mL warm water under fasting condition.
41468446|NCT02842684|DEVICE|TraumaCad software|restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
41468447|NCT01074008|DRUG|ABT-450|50 mg capsules co-administered with ritonavir
40994367|NCT02763852|DRUG|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
40994368|NCT02763852|DRUG|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
40994369|NCT02763852|DRUG|Madopar® 125|Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
40994370|NCT05304260|OTHER|clinical and radiographic examination|Prevalence of dental anomalies in deciduous dentition and risk factors associated with non-syndromic oral clefts patients: A cross-sectional study.
40994371|NCT03394768|OTHER|No additional intervention|Patients will be treated as per department protocols and no additional intervention will be performed
40994372|NCT02342340|OTHER|Navy Beans (cooked)|One time consumption of 3/4 cup of cooked navy beans.
40790047|NCT02288299|DEVICE|non invasive mechanical ventilation|instrumental increase of inspiratory capacity and cough
40994373|NCT02342340|OTHER|Red Kidney Beans (cooked)|One time consumption of 3/4 cup of cooked red kidney beans.
40994374|NCT02342340|OTHER|Pinto Beans (cooked|One time consumption of 3/4 cup of cooked pinto beans.
40994375|NCT02342340|OTHER|Black Beans (cooked)|One time consumption of 3/4 cup of cooked black beans.
40994376|NCT02342340|OTHER|Lentils (cooked)|One time consumption of 3/4 cup of cooked lentils.
40994377|NCT02342340|OTHER|White Rice|One time consumption of 3/4 cup of cooked white rice.
40994378|NCT05928585|DRUG|HIB210|Experimental monoclonal antibody
40994379|NCT05928585|DRUG|Placebo|Placebo
40994380|NCT01957748|BEHAVIORAL|SoC + ALERT Intervention|Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
40994381|NCT04566315|PROCEDURE|Arteriography knee arteriography|arteriography and an injection of inert microparticles of 75 μm in neovessels
40994382|NCT04059731|DIETARY_SUPPLEMENT|Nutrition supplement|Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
40994383|NCT04498806|OTHER|Fitbit|The Fitbit device monitors daily activity as a measure of physical function.
40994384|NCT02741908|BEHAVIORAL|Calorie counting diet|
40790048|NCT00953810|OTHER|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
40790049|NCT00047502|DRUG|Lonafarnib (SCH66336)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day."
41468448|NCT01074008|DRUG|ABT-072|50 mg tablet
40790050|NCT00047502|DRUG|Imatinib Mesylate (Gleevec)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day."
41468449|NCT01074008|DRUG|ABT-333|400 mg tablet
41468450|NCT01074008|DRUG|Ritonavir|100 mg capsules co-administered with ABT-450
40790051|NCT04088799|OTHER|No intervention|No intervention
40790052|NCT04635371|DEVICE|Non-invasive Monitoring|Wearable, wireless, non-invasive chest-patch devices will be attached to the patients following recruitment and aigning an informed consent form, and from that moment on, vitals will be collected automatically and analyzed retrospectively.
41148432|NCT00731913|OTHER|Absorable, monofilament sutures: Monosyn and Monocryl|Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
41341733|NCT04460300|OTHER|Aromatherapy-inhalation method|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil will be dropped directly on a sterile gauze and individuals will be allowed to breathe from a distance of 10 cm for 5 minutes."
41468451|NCT01074008|DRUG|Peginterferon alpha-2a|Syringe, 180 µg/0.5 mL for subcutaneous injections
41468452|NCT01074008|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
41468453|NCT01074008|OTHER|Placebo|Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
41468454|NCT04187924|OTHER|Autogenic drainage|Autogenic drainage is an airway clearance technique characterised by breathing control using expiratory airflow to mobilise secretions from smaller to larger airways. The secretions will be collected during the physiotherapy session and during the 24 hours following the session.
41468455|NCT04187924|DEVICE|SIMEOX + Autogenic drainage|SIMEOX is a device generating a succession of gentle depression at the mouth during the expiratory phase associated with autogenic drainage.
41468456|NCT04211766|DIETARY_SUPPLEMENT|Dietary Fiber|Given fiber supplement
41468457|NCT04211766|DIETARY_SUPPLEMENT|Fish Oil|Given fish oil supplement
40790053|NCT03810014|OTHER|Conditional ACT subsidy, Arm 1 levels|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
40790054|NCT03810014|OTHER|Conditional ACT subsidy, Arm 2 levels|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
40790055|NCT03810014|OTHER|Conditional ACT subsidy, Arm 3 levels|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
41148433|NCT03969251|DEVICE|Transcranial Magnetic Stimulation (rTMS)|active high frequency repetitive TMS of left Dorsolateral Prefrontal Cortex
40790056|NCT03810014|OTHER|Conditional ACT subsidy, Arm 4 levels|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
41148434|NCT03969251|DEVICE|Sham (SS)|repetitive sham rTMS
41148435|NCT01184755|BEHAVIORAL|Relaxation|Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
41468458|NCT04211766|OTHER|Comparator|Given fiber supplement placebo
41468459|NCT04211766|OTHER|Comparator|Given fish oil supplement placebo (corn oil)
41468460|NCT03532750|DEVICE|Particle|"1. 300-500 µm Embosphere Particles, Merit Medical (Rockland, MA) 501(k) number K991549.~2. 300-500 µm Embozene Particles, Boston Scientific (Marlborough, MA) 501(k) number K133447.~3. Ruby detachable coils, Penumbra (Alameda, CA) 501(K) number K103305.~4. Interlock detachable coils, Boston Scientific (Marlborough, MA) 501(k) number K132578."
41468461|NCT03532750|DEVICE|Coil|Ruby or Interlock detachable coils
41468462|NCT03476317|DRUG|Vancomycin|Oral suspension 4 times daily (Day 1-14)
41148436|NCT01184755|DEVICE|RESPeRate|
41468463|NCT03476317|DRUG|Neomycin|Oral three times daily (Days 1-3)
41468464|NCT03476317|DRUG|Ciprofloxacin|Oral twice daily (Days 4-14)
41468465|NCT03476317|DRUG|Polyethylene Glycol 3350|Dissolved in Gatorade on day 2
41468466|NCT03476317|DRUG|Fluconazole|Orally once daily (Day 1-14)
41468467|NCT04329715|BEHAVIORAL|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
41468468|NCT04329715|BEHAVIORAL|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
41468469|NCT03710902|DIAGNOSTIC_TEST|ECG monitoring for 3 weeks|A 3-week continuous ECG monitoring to detect occult AF.
41468470|NCT03710902|OTHER|Self-monitoring of BP and self-titration of antihypertensive medication|One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.
41468471|NCT04111588|OTHER|Diagnostic Amino acid PET/MRI examination|Diagnostic Amino acid PET/MRI examination
40994385|NCT02741908|BEHAVIORAL|Fixed diet plan|
40994386|NCT02159755|DRUG|Ibrutinib|Given PO
40994387|NCT02159755|OTHER|Laboratory Biomarker Analysis|Correlative studies
41148437|NCT04704986|DEVICE|PVI using the Arctic Front Cryoballoon (Medtronic)|"Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
41148438|NCT04704986|DRUG|PVI using the PolarX Cryoballoon (Boston Scientific)|"Patients randomized to PolarX cryoballoon group will undergo PVI using the PolarX Cryoballoon (Boston Scientific).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
41148439|NCT04908800|DRUG|KRP-A218|KRP-A218 tablet
41468472|NCT03002480|OTHER|Thromboelastography-Guided Treatment Regimen|"The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate."
40790057|NCT05911971|OTHER|Experimental|specific reeducation (not detailed to maintain blinding of participants)
40790058|NCT05911971|OTHER|Sham comparator|sham reeducation (not detailed to maintain blinding of participants)
40790059|NCT03683810|DIETARY_SUPPLEMENT|Lactoferrin|Lactoferrin in tablets 4g/daily
40790060|NCT03683810|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin (rHuEPO, epoetin alfa)
40790061|NCT01163396|DRUG|Bevacizumab|
41148440|NCT04908800|DRUG|Placebo|Placebo tablet
41148441|NCT04908800|DRUG|itraconazole|10 mg/mL oral solution
41148442|NCT03472118|DEVICE|Nasal High Flow Oxygen|Nasal High Flow Oxygen during apnoea using Optiflow device of Fisher and Paykel
41148443|NCT05186493|PROCEDURE|robot-assisted total pelvic exenteration|Patients with locally advanced pelvic cancer that require pelvic exenteration considered eligble, are operated minimmally invasive robot-assisted
41148444|NCT02319304|DRUG|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
41148445|NCT02319304|RADIATION|Low dose fractionated radiation therapy (LDFRT)|see arm description
41148446|NCT00674791|BIOLOGICAL|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
41148447|NCT06027216|DEVICE|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
41148448|NCT03717935|DIETARY_SUPPLEMENT|Essential Amino Acid (EAA) Supplement|Powder supplement
41148449|NCT03717935|OTHER|Placebo|Powder that will be similar to the essential amino acid supplement
40790062|NCT01163396|DRUG|Irinotecan|
40790063|NCT01163396|DRUG|Oxaliplatin|
40790064|NCT01163396|DRUG|5-fluorouracil/leucovorin|
40790065|NCT01803971|OTHER|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
40790066|NCT04684940|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
40790067|NCT02839278|BIOLOGICAL|Blood sample|
40790068|NCT02849834|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
40994388|NCT02159755|DRUG|Palbociclib|Given PO
40994389|NCT02159755|OTHER|Pharmacological Study|Correlative studies
40994390|NCT03392116|BIOLOGICAL|NGM120|Subcutaneous Injection
40994391|NCT03392116|OTHER|Placebo|Subcutaneous Injection
41148450|NCT03364803|OTHER|Cushing's QoL (Quality of Life Questionnaire)|Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
40790069|NCT00893841|DRUG|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
40790070|NCT00893841|DRUG|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
40790071|NCT00893841|DRUG|placebo|placebo
40790072|NCT00893841|DRUG|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
40790073|NCT04414540|DRUG|Metformin Extended Release Oral Tablet|Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily
40790074|NCT04414540|DRUG|Pembrolizumab|Pembrolizumab q 3 weeks
40790075|NCT00161044|DRUG|Galantamine|
40790076|NCT02266563|DRUG|Amyvid PET Scan|A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
40994392|NCT05228392|OTHER|listening to music|listening to lullaby or other music types
40994393|NCT03536403|RADIATION|EOS X-rays|EOS X-rays is done with et without a kyphosis induced corset
40994394|NCT03536403|OTHER|8-meters walk test|8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
41468473|NCT04707586|OTHER|Cold Application|Created by the researcher; A bandage with 3 pieces of 13x10 cm cold gel and a cold gel container in which they are placed will be used, which can be adjusted according to the head circumference of the patient between 60-80 cm in length. The ability of the cold gel cups of the bandage to be moved on the bandage will allow comfortable cold application to the patient's bilateral frontotemporal and occipital areas at the same time. After waiting for 20 minutes in the freezer part of the refrigerator, the temperature and temperature of the gels applied and the cold application area before and after each application will be measured and recorded. An Infrared Non-Contact Food Thermometer will be used for temperature measurement of cold gel packs, and an Infrared Non-Contact Thermometer device will be used for temperature measurement of the cold application area.
41468474|NCT00437190|DEVICE|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
40790077|NCT02266563|DRUG|T807 PET scan|Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
40790078|NCT04767672|DIETARY_SUPPLEMENT|Non digestible carbohydrates|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
40790079|NCT04767672|DIETARY_SUPPLEMENT|Placebo|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
40994395|NCT05492175|OTHER|robotic practice|According to the group assignment, participants will start from the BMT proximal mode (i.e., forearm pronation-supination movement), and then the distal mode (i.e., wrist flexion-extension movement), and vice versa. Each participant is expected to complete approximately 400 to 600 repetitions of the proximal mode session (i.e., forearm movements) and another 400 to 600 repetitions of the distal mode session (i.e., wrist movements), respectively.
40994396|NCT05492175|OTHER|kinetic exergaming|All of the participants in experimental and comparison groups will practice on the exergaming for 30 minutes per session. To avoid fatigue, the four domains of programs will be provided alternately. Each program will be executed for approximately 5 minutes with warm-up, followed by a 2-minute break between programs, and cool-down. The games will be selected and adapted according to the personal capacity, the occupational role, and the rehabilitation goal of each participant. The investigators will illustrate and guide the participants to play the games and stand next to them to prevent falls from occurring. To increase security, we will place a handrail in front of the participant for support as needed.
41341734|NCT04460300|OTHER|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
41468475|NCT00437190|DEVICE|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
41468476|NCT05210712|DEVICE|RS001.2 Respiree Cardio-Respiratory Monitor|The RS001.2 Respiree Cardio-Respiratory Monitor is intended as a noninvasive multiparameter monitor on the adult population
40994397|NCT05492175|OTHER|conventional therapy|Participants in control group will receive 30 minutes of therapist-mediated conventional therapy per session. The training protocols of the conventional therapy will use occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their personal needs. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The content of the functional tasks will be decided together by participants and therapists, such as picking up and putting down items in a box, lifting two soft drink bottles, and so on.
41468477|NCT00970255|PROCEDURE|Lingual Frenulum frenotomy|Clipping the lingual frenulum with scissors
41468478|NCT00970255|PROCEDURE|Sham frenotomy|Sham Clipping the lingual frenulum with scissors
41468479|NCT02235584|DRUG|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
41468480|NCT03393481|DRUG|MAA868|MAA868 dose 1 and dose 2, single administration, subcutaneous,
41468481|NCT03393481|DRUG|Enoxaparin|Enoxaparin 40 mg, o.d X 10 days
41468482|NCT06287268|OTHER|eltrombopag|This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.
41468483|NCT03371329|BIOLOGICAL|MSC|bone marrow derived cultured MSC (mesenchymal stem cell)
40790080|NCT03799003|DRUG|ASP1951|Intravenously (IV)
40790081|NCT03799003|DRUG|pembrolizumab|Intravenously (IV)
40790082|NCT04150289|DRUG|Farydak|non-interventional study
40790083|NCT01953211|DRUG|combined oral contraceptives|
40790084|NCT02778984|DEVICE|QuadraLite masks|The intervention is identical in the two group
40790085|NCT02778984|OTHER|standard mask|
40790086|NCT05827705|OTHER|need for Ephedrine hydrochloride|ephedrine dose in hypotension
40790087|NCT02606071|DEVICE|CRT-D|HF patients treated in clinical practice with a CRT-D device
40790088|NCT02955238|BEHAVIORAL|Special Intervention|"Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).~Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum."
40790089|NCT05006105|DEVICE|seven-day ECG Holter|Participants receive a seven-day ECG Holter after hospital discharge.
40790090|NCT05006105|DEVICE|24-hour blood pressure monitor|Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.
40790091|NCT05006105|OTHER|Questionnaire: vision of mHealth|Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.
40790092|NCT05006105|OTHER|Questionnaire: user experience & feeling of safety|Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.
40790093|NCT05006105|DEVICE|Insertable loop recorder|Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.
41309612|NCT02582580|OTHER|Pelvic floor muscles training|Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
41309613|NCT01625598|PROCEDURE|Photography of the retina|Every subject will undergo photography of the retina in both eyes
41309614|NCT01625598|PROCEDURE|Retinal photography|"Device~Subjects will have photography of both eyes"
40790094|NCT04453826|DRUG|Camrelizumab plus chemo-radiotherapy|"1. Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.~2. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~3. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~4. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
40790095|NCT04453826|DRUG|Chemo-radiotherapy alone|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
40790096|NCT05879731|OTHER|EEG-hd (high density electroencephalogram)|"Once in the operating room, the investigators will place a 128-channel Hd-EEG (high density electroencephalogram) saline net referenced to Cz on the patient's head. Impedances will be verified and maintained \<50 kΩ for the duration of the study. The patient will be positioned supine and all routine monitors will be installed. A 5 minutes baseline resting-state Hd-EEG with eyes closed will be performed before induction. Once under general anesthesia and intubated, a no pain period of 5 minutes will take place. During this 5-min period, resting-state Hd-EEG recording will be recorded. A standardized tetanic stimulation to the ulnar nerve of the non-dominant forearm delivered by a routine nerve stimulator (100 Hz, 70 mA) for a duration of 30 seconds will then be applied. Hd-EEG recording will take place during this 30 seconds and will continue during the 5 minutes after. Once this period will be over, the Hd-EEG net will be removed and the investigators will exit the operating room."
40790097|NCT01891981|DRUG|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
40790098|NCT00443703|DRUG|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
41309615|NCT00069420|BEHAVIORAL|Cognitive Motivational Behavior Therapy|
41309616|NCT05029115|DRUG|SGLT2 inhibitor|Dapagliflozin, Empagliflozin
41309617|NCT01453569|DRUG|Sodium oligo-mannurarate 600mg|sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
41309618|NCT01453569|DRUG|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
41309619|NCT01453569|DRUG|Placebo|simulant of sodium oligo-mannurarate capsule
40790099|NCT00443703|DRUG|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
41309620|NCT01570400|BEHAVIORAL|Internet-administered cognitive behavioral therapy (iCBT)|Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
40790100|NCT00443703|DRUG|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
40790101|NCT00443703|DRUG|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
40994398|NCT00729183|DRUG|Odanacatib|Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
41309621|NCT01570400|BEHAVIORAL|Cognitive bias modification training program variant 1|"Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
41309622|NCT01570400|BEHAVIORAL|Cognitive bias modification training program variant 2|"Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
41309623|NCT05650073|OTHER|Immersive soundscapes|Audio technology used to create a three-dimensional sound experience in which the user is immersed in a virtual soundscape
41309624|NCT00372034|DEVICE|Temporary Collagen Inserts|
41309625|NCT04459702|DRUG|hydroxychloroquine|Treatment with the drug hydroxychloroquine
41309626|NCT04459702|DRUG|Azithromycin|Treatment with the drug azithromycin
41309627|NCT04459702|DRUG|Ritonavir|Treatment with the drug ritonavir
41309628|NCT04459702|DRUG|Lopinavir|Treatment with the drug lopinavir
41309629|NCT00200499|DRUG|Nebivolol|
41309630|NCT03747224|DRUG|ARO-ANG3|single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections
41309631|NCT03747224|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
41309632|NCT04240288|OTHER|Procalcitonin-guided antibiotic treatment|Antibiotics will be administered based on the procalcitonin lab results.
41309633|NCT04240288|OTHER|Standard of Care Antibiotic Treatment|Antibiotics will be administered based on standard of care treatment. The treating physicians will determine the treatment course.
41309634|NCT04136288|DEVICE|MoreNova|Shockwave therapy delivered to the genital area with low dose shocks
41309635|NCT01154972|PROCEDURE|Preoperative sentinel lymph node identification and marking|SLN is identified using gamma probe and ultrasound. Percutaneous wire placement carried out to mark SLN for subsequent surgical verification.
41309636|NCT06552559|DRUG|Selinexor|Combination chemotherapy
41309637|NCT04677530|DRUG|JNJ-40411813|JNJ-40411813 will be administered orally.
41309638|NCT04677530|DRUG|Matching Placebo|Matching placebo will be administered orally.
41309639|NCT03020758|DIETARY_SUPPLEMENT|Dried Fruit|Mixture of equal parts 4 dried fruits (figs, raisins, dates, plums) totaling 3/4 cup daily.
41309640|NCT03020758|OTHER|High Carbohydrate Snack|Calorie-matched carbohydrate-rich snack.
41309641|NCT00696865|DRUG|AZD2624|oral suspension, 3 doses
41309642|NCT00696865|DRUG|Placebo|
41309643|NCT00050999|DRUG|ONTAK|
41309644|NCT03432910|OTHER|CPAP Titration using a Bilevel S/T mode with minimal pressure support and background rate|The study performs within clinical routine with this exception that instead of the usually applied CPAP mode a modified BiLevel S/T mode is used. The modified BiLevel S/T mode meets the same requirements as the CPAP mode while providing the Forced Breath Technique to classify apneas as central or obstructive.
41309645|NCT03776643|DRUG|ILT-101 ld-(IL2)|Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months
41341735|NCT00615459|DRUG|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
41341736|NCT00615459|DRUG|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
40994399|NCT00729183|DRUG|Placebo|Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
41309646|NCT03215394|BEHAVIORAL|Attention Training Program|The attention training involves 8 visits over 4 weeks with pre/post data collection before and after the training, and a follow-up 6 months later. Pre/post data collection involves the ESCS and a Laboratory Temperament Assessment Battery (LabTAB), and a series of on-screen assessment tasks that measure cognitive control, distraction tolerance, sustained attention, habituation, gap-overlap, disengagement, and attention to static images. Training runs from Wk 2-5 with 2 visits per week and is completed in home with the child sitting on the parents lap in front of a monitor. The parent and child are inside a tent to reduce environmental stimuli. The research trainer is outside the tent running the program from a laptop. The program consists of a battery of 9 gaze-contingent training tasks using custom MATLAB scripts. The animated tasks are designed to engage the child and present as developmentally appropriate games. At each visit 6 of the 9 tasks will run for a total of 4min each(24min).
40790102|NCT01728285|DEVICE|Electronic compliance device (Memozax®)|An electronic compliance device is distributed to patients allocated to the active arm
40790103|NCT00660972|DRUG|Raltegravir|400 mg tablet taken orally twice daily
40790104|NCT00660972|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
40790105|NCT03712774|OTHER|EORTC QLQ C30|standardized questionaire
40790106|NCT03712774|OTHER|EORTC QLQ OES-18|standardized questionaire
40790107|NCT03712774|OTHER|EORTC OG-25|standardized questionaire
40790108|NCT02432781|DIETARY_SUPPLEMENT|Carbohydrate-rich drink|
40790109|NCT02432781|DIETARY_SUPPLEMENT|10% dextrose solution mixed with insulin 16 unit 100 mL/h|
40790110|NCT04546919|OTHER|sepsis|Body temperature higher than 38°C or lower than 36°C; Heart rate higher than 90/min; Hyperventilation evidenced by respiratory rate higher than 20/min or PaCO2 lower than 32 mmHg; White blood cell count higher than 12,000 cells/ µl or lower than 4,000/ µl.
40790111|NCT05963243|OTHER|Ultrasound Scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
41309647|NCT03215394|BEHAVIORAL|Social ABCs|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
40790112|NCT05502237|DRUG|Zimberelimab|Administered intravenously
40790113|NCT05502237|DRUG|Domvanalimab|Administered intravenously
40790114|NCT05502237|DRUG|Pembrolizumab|Administered intravenously
40790115|NCT05502237|DRUG|Carboplatin|Administered intravenously
40994400|NCT00729183|DRUG|Vitamin D3|Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
40994401|NCT00729183|DRUG|Calcium supplement|Calcium supplement 500 mg tablet taken orally once daily (up to \~1200 mg total) for 24 months.
40994402|NCT03747874|DIAGNOSTIC_TEST|ventilatory polygraphy|we put a ventilatory polygraphy device on the patient in the evening, they come back home to sleep while the device is recording ventilatory parameters and they come back the morrow to give the device back
40790116|NCT05502237|DRUG|Cisplatin|Administered intravenously
40790117|NCT05502237|DRUG|Paclitaxel|Administered intravenously
40790118|NCT05502237|DRUG|Nab-paclitaxel|Administered intravenously
40790119|NCT05502237|DRUG|Pemetrexed|Administered intravenously
40790120|NCT00190333|DRUG|escitalopram|escitalopram
40790121|NCT04230616|PROCEDURE|total knee arthroplasty|total knee arthroplasty
40790122|NCT04230616|RADIATION|CT scan|The first 52 participants will recieve a pre- and postoperative CT scan of the hip, knee and ankle.
40790123|NCT03413904|PROCEDURE|transanal TME|transanal approach to TME in rectal cancer
40790124|NCT03413904|PROCEDURE|laparoscopic TME|laparoscopic approach to TME in rectal cancer
40790125|NCT01127932|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
40790126|NCT01127932|BEHAVIORAL|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
40790127|NCT00619918|DRUG|Nebulized 3% saline|4 ml inhaled q8h
40790128|NCT00619918|DRUG|Placebo|normal saline
40790129|NCT01980199|DRUG|Fexinidazole|"600 mg tablets given orally, after the main daily meal~* at the daily dose of 1800 mg (3 tablets) once a day for 4 days~* continued by 1200mg (2 tablets)once a day for 6 days"
40790130|NCT03284983|OTHER|Suture spacing for wound closure|The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.
40994403|NCT01827657|DRUG|GSK2336805|Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
40994404|NCT00132418|DRUG|Enbrel|Enbrel
40994405|NCT00132418|DRUG|Placebo|Placebo
40994406|NCT02646176|BEHAVIORAL|Inpatient rehabilitation|Inpatient rehabilitation includes activities and interventions provided by occupational, physical, therapeutic recreation and speech therapists, and psychologists.
40790131|NCT01326806|BEHAVIORAL|Families Talking Together|The intervention will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth fora non-acute care visit. A mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. The healthcare provider will endorse the intervention separately for mothers and adolescents. There will be one follow-up booster session administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
40790132|NCT01326806|BEHAVIORAL|Active Control on Hygiene & Nutrition|The active control group will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth for a non-acute care visit. The mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the active control on hygiene and nutrition will be delivered to the mother.
40790133|NCT05042648|DRUG|Buprenorphine patch|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest. The skin should be dry, clean, non irritated, non hairy (hair should be trimmed with scissors, not shaved), and without large scars.
40790134|NCT00364247|DRUG|CG5503 IR;tapentadol|
40790135|NCT01958255|BEHAVIORAL|planned intervention for tobacco cessation counseling|game session for rapport building followed by group discussion and tobacco cessation counseling
40790136|NCT00444925|DRUG|fesoterodine fumarate|4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
40790137|NCT00444925|DRUG|placebo|once daily (OD)for 12 weeks
40790138|NCT00444925|DRUG|tolterodine tartrate|4 mg once daily (OD) for 12 weeks
40790139|NCT03685981|OTHER|Incentives mailer|Participants will receive a letter that describes the incentives provided by their health plan for following appropriate preventative care guidelines.
40790140|NCT01475643|DRUG|Loteprednol etabonate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
40790141|NCT01475643|DRUG|Prednisolones acetate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
40790142|NCT03598049|DEVICE|densah burs osseo densification drills|osseo densification of the alveolar bone in maxillary posterior ridge during implant placement
40790143|NCT03598049|DEVICE|conventional surgical burs drilling|conventional implant osteotomy site drilling with implant surgical kit
40790144|NCT01084343|BIOLOGICAL|MYM-V101|"* Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~* Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks."
40790145|NCT03234647|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in AHF patients.
40790146|NCT02199093|OTHER|Functional Rehabilitation of apraxia|"The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence."
40790147|NCT02199093|OTHER|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
40790148|NCT04954534|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
40790149|NCT04074512|DRUG|Copper Histidinate|Restoring Copper Histidinate levels normally found in the blood to assist in the maintenance of copper homeostasis.
40790150|NCT00648258|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
40790151|NCT00648258|DRUG|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
40994407|NCT05818579|OTHER|Virtual reality experience|The VR experience is launched on the participants using all-in-one VR head-mount devices. Tablet computers are used to optimize the settings by the intervention facilitators. Each session lasts for approximately one hour with 10 minutes spent on the briefing, 20 minutes spent on the VR experience, and 30 minutes spent on the post-VR group discussion. There are two sessions per week. The whole course lasts for six weeks and there are a total of 12 sessions.
40994408|NCT00731770|DRUG|Advair 250|1 puff bid inhaled
40994409|NCT00731770|DRUG|Placebo- matched|1 puff bid inhaled
40994410|NCT00731770|DRUG|Placebo|Placebo 1 puff bid inhaled
40994411|NCT00731770|DRUG|Advair 250 - matched|i puff bid inhaled
41309648|NCT03215394|OTHER|Treatment As Usual|The Treatment as Usual group acts as a pre-existing convenience sample, consisting of families currently enrolled in a different approved research study run by the same group of investigators. Children in this group have comparable clinical concerns for ASD, and complete the same standardized measures (ADOS, MSEL, ESCS, AOSI) as the Baseline assessment in this RCT, but will not receive Social ABCs or the Attention Training Program. They are able to access any programs or interventions available to them in the general community. This is tracked on a Services Log form, included as part of that study's protocol. Families in this group will have consented to their child's data being shared across studies in this research group.
41309649|NCT03215394|BEHAVIORAL|Sham Attention Training|The sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training program (8 visits over 4 weeks including pre/post data collection). In this condition, infants will be exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (ie. clips of age appropriate television shows). Placebo stimuli will be presented until toddlers become fidgety or distressed.
41309650|NCT05605379|BIOLOGICAL|Next Generation Sequencing (DNA and RNA)|Targeted Next Generation Sequencing (DNA and RNA)
41468484|NCT02378051|BEHAVIORAL|Staying Strong with Schools Intervention|"1. On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.~2. Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her."
40790152|NCT01963767|DRUG|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries\* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract\*~* Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
40790153|NCT01963767|DIETARY_SUPPLEMENT|Placebo|
40790154|NCT01774812|DIETARY_SUPPLEMENT|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
40790155|NCT01774812|DIETARY_SUPPLEMENT|Ergocalciferol|50,000IU 1x per week for 6 weeks
41309651|NCT02946879|BIOLOGICAL|AAV OPTIRPE65|comparison of different doses of AAV RPE65
41468485|NCT02378051|OTHER|Waitlist Control|Receipt of an educational pamphlet outlining resources useful to support military-connected children distributed to all educators at the beginning of the school year.
41468486|NCT04992793|COMBINATION_PRODUCT|Congenital heart surgery|Paediatric congenital heart surgery
41468487|NCT05926635|DEVICE|ATLAS 2030|sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
40790156|NCT01312727|OTHER|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
40790157|NCT06000488|BEHAVIORAL|Reflective Writing Workshop Sessions|Three workshops of 75 minutes. Trained PA and/or MD student facilitators will then use prepared materials to guide each group through a series of prompts, each eliciting written reflections of varying lengths. While all participants are encouraged to reflect, write, and share their responses, participation at all levels remains optional.
40790158|NCT02920307|PROCEDURE|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
40790159|NCT02920307|PROCEDURE|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
40790160|NCT02920307|PROCEDURE|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
40994412|NCT03467113|DRUG|ZX008 0.2 to 0.8 mg/kg/day|ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
41148451|NCT03364803|OTHER|Nottingham Health Profile (NHP)|NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
41148452|NCT03364803|OTHER|Hospital Anxiety and Depression Scale (HADS)|HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
41148453|NCT03364803|OTHER|Perceived Stress Scale (PSS)|The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
41148454|NCT03364803|OTHER|Barratt's Impulsivity Scale (BIS)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
41148455|NCT03364803|OTHER|Beck Depression Inventory (BDI)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
41148456|NCT03364803|OTHER|State-Trait Anxiety Inventory (STAI)|The STAI provides data to help distinguish between anxiety and depression.
41309652|NCT05016947|DRUG|Venetoclax|Tablet, taken by mouth
41309653|NCT05016947|DRUG|Dexamethasone|Taken orally
41309654|NCT05016947|DRUG|Inotuzumab Ozogamicin|Intravenous infusion
41309655|NCT00987233|DRUG|triamcinolone acetonide aqueous nasal spray (Apotex Inc.)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
41468488|NCT00869440|DRUG|CNS 7056|Administered as a single intravenous injection by a syringe driver over 1 minute
40994413|NCT03467113|DRUG|Cannabidiol|Cannabidiol
41468489|NCT00869440|DRUG|Midazolam|Administered as a single intravenous injection by a syringe driver over 1 minute
41468490|NCT00602537|DRUG|Venlafaxine|75 to 375 mg
40790161|NCT02920307|PROCEDURE|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
40790162|NCT04791293|OTHER|MELD-Na score|MELD-Na scores will be compared between the groups
40790163|NCT05394506|PROCEDURE|Skin Biopsy|The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.
40790164|NCT05394506|PROCEDURE|Muscle biopsy|The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
40790165|NCT01294852|OTHER|surfactant prophylaxis|Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]).
40790166|NCT01778998|PROCEDURE|MICS-group|Micro incision cataract surgery is done
40790167|NCT01778998|PROCEDURE|SICS-group|small incision cataract surgery is done
40790168|NCT01778998|PROCEDURE|SICS pre-cut|Small incision cataract surgery with pre-cut is done
40790169|NCT01778998|PROCEDURE|SICS stab-incision|Small incision cataract surgery with stab-incision is done
40790170|NCT04001439|DRUG|Experimental drug|All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
40790171|NCT04242706|DEVICE|ETTEvac|Endotracheal tube with evacuation lumen without noble metal coating
40790172|NCT04242706|DEVICE|BIP ETTEvac|Endotracheal tube with evacuation lumen with noble metal coating
40790173|NCT05901571|OTHER|acupuncture|"The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation."
40790174|NCT05901571|OTHER|escitalopram|Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.
41309656|NCT00987233|DRUG|triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
40790175|NCT05901571|OTHER|sham-acupuncure|In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
40790176|NCT05901571|OTHER|escitalopram placebo|Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
40790177|NCT00360958|PROCEDURE|ultrafiltration|
40790178|NCT05115370|OTHER|Semi-structured qualitative interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
40790179|NCT01396187|DRUG|PF-05231023|5 mg IV twice a week for 4 weeks
40790180|NCT01396187|DRUG|PF-05231023|25 mg IV twice a week for 4 weeks
41148457|NCT03364803|OTHER|State Food Craving Questionnaire-State (FCQ-S)|The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
41309657|NCT00987233|DRUG|Placebo|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
41309658|NCT06502470|DEVICE|ellacor® Micro-Coring procedure|ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
41468491|NCT00602537|DRUG|Lithium Carbonate|300 to 2400 mg
41468492|NCT02302937|PROCEDURE|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )|laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
41468493|NCT02302937|PROCEDURE|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
40790181|NCT01396187|DRUG|PF-05231023|100 mg IV twice a week for 4 weeks
40790182|NCT01396187|DRUG|PF-05231023|200 mg IV twice a week for 4 weeks
40790183|NCT01396187|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
40790184|NCT04318054|OTHER|Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
40790185|NCT05761808|OTHER|exercises|Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. First of all, exercises to learn transversus abdominis activation will be performed in patients. They will then be included in the stretching and strengthening exercise program. Stretching and strengthening exercises were planned as dynamic abdominal bracing, finding and maintaining neutral position, and exercises on all fours. Exercise therapy will be applied by the same physiotherapist 3 days a week for 5 weeks. Patients will continue to exercise for 7 more weeks as a home program. During this period, they will be called once a week by phone.
40790186|NCT05761808|OTHER|neuromuscular electrical stimulation|NMES intensity will be planned individually according to the patients. Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. NMES application will be applied by a specialist physiotherapist 3 days a week for 5 weeks, for a total of 15 sessions. Exercises will be applied 3 days a week for 5 weeks, accompanied by a physiotherapist. Patients will continue to exercise for 7 more weeks as a home program. In this process, patients will be called once a week by phone.
40790187|NCT01088295|DRUG|Telmisartan|
40790188|NCT00130039|DRUG|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
40790189|NCT00130039|DRUG|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
40790190|NCT00625534|PROCEDURE|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
40790191|NCT00625534|PROCEDURE|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
40790192|NCT04550897|DRUG|BM7PE|BM7PE immunotoxin is supplied as a liquid solution and is diluted in 0.9% saline to a total volume of 250 ml.
40790193|NCT02769429|DEVICE|Ultrasound-guided CISB|This group will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
40790194|NCT02769429|DEVICE|nerve stimulator-guided CCPVB|This group will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
40790195|NCT04119765|BIOLOGICAL|Blood sampling|blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
40790196|NCT04119765|BIOLOGICAL|Urine sampling|urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
41309659|NCT02085876|OTHER|2 additional MRI sequences|
40790197|NCT04119765|PROCEDURE|Pulse Wave Velocity (PWV) measurement|PWV will be measured thank to the Complior® device
40790198|NCT04119765|PROCEDURE|central pressure measurement|central pressure will be measured thank to the Complior® device
40790199|NCT04714866|BEHAVIORAL|Cognitive behavioral therapy for ADHD|CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.
40790200|NCT00400517|BIOLOGICAL|sargramostim|administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
40790201|NCT00400517|DRUG|thalidomide|doses up to 400 mg/day
40790202|NCT00400517|PROCEDURE|conventional surgery|SOC care surgery
41468494|NCT01556282|DEVICE|TheraSphere|TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
41468495|NCT06347718|DRUG|anti-CD19 CAR T cell therapy|Single-dose
40790203|NCT00400517|PROCEDURE|neoadjuvant therapy|post radical prostatectomy
40790204|NCT04795375|BEHAVIORAL|Physical Activity counseling|"The Physical activity counseling techniques will be based on the Self Determination Theory and Five A's (Assess, Advise, Agree, Assist, Arrange). Guidelines for physical activity will include combined aerobic and resistance exercises.~Each participant in the intervention group will receive personal exercise prescriptions in accordance the post-surgical statues and exercise recommendations after bariatric surgery. Participants will receive long term follow-up and accompaniment during the first six months after the surgery, through Personal meetings with a certified nurse, Phone-calls, motivational massages, and Exercise Videos."
40790205|NCT01296750|OTHER|Early Physiotherapy start|Physiotherapy starting at one day post op
41309660|NCT02085876|OTHER|An additional blood sample|
40790206|NCT05557994|OTHER|Method|treatment of mature teeth with apical periodontitis
40790207|NCT01261364|BEHAVIORAL|GeneSightRx|Multi-genetic pharmacogenomic panel
40790208|NCT01261364|BEHAVIORAL|Treatment as usual|Treatment as usual
40790209|NCT06065475|BEHAVIORAL|Ultrasound-guided bilateral Thyroid Cartilage Plane Block|Use a SonoSite high-frequency linear array transducer (5-13 MHz, SonoSite, USA). Place the transducer parallel to the spine on one side of the neck, ensuring clear visualization of the thyroid cartilage plate under ultrasound. Employ ultrasound-guided in-plane or out-of-plane techniques to display the needle insertion path and tip. Once the needle tip contacts the upper half of the thyroid cartilage plate, inject 3ml of 2% lidocaine on the surface of the thyroid cartilage plate.
40790210|NCT01233024|DIETARY_SUPPLEMENT|Control|Dinner bar fortified with 0g fiber; breakfast bar fortified with 0g dietary fiber.
41341737|NCT00615459|DRUG|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
41468496|NCT05494502|PROCEDURE|Erector spinae plane block|Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
41468497|NCT05494502|PROCEDURE|Control group|General anesthesia alone.
41468498|NCT05103709|OTHER|MULTI-FORTIFIED|Treatment with multifortified bread for 120 days
41468499|NCT05103709|OTHER|FORTIFIED|Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
40790211|NCT01233024|DIETARY_SUPPLEMENT|Soluble corn fiber|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
40790212|NCT01233024|DIETARY_SUPPLEMENT|Resistant starch|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
40790213|NCT01233024|DIETARY_SUPPLEMENT|Fructooligosaccharide|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
40790214|NCT01233024|DIETARY_SUPPLEMENT|Inulin|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
40790215|NCT04590599|DRUG|IBI310|IBI310 3 mg/kg,Q3W, for a total of 4 cycles
40790216|NCT04590599|DRUG|Placebo|Placebo Q3W, for a total of 4 cycles
40790217|NCT04590599|DRUG|Sintilimab|Sintilimab 200mg,Q3W
40790218|NCT00837161|DEVICE|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
40790219|NCT03933683|DEVICE|Pudendal nerve terminal motor latency assessment|After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.
40790220|NCT01773954|DRUG|Intravitreal Aflibercept Injection|Increased or decreased time between visits
41468500|NCT03745417|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.
41468501|NCT06157463|RADIATION|Ga-68 FAPI|FAPI PET scans will be performed in addition to other staging/restaging work-up
41468502|NCT00031928|DRUG|mafosfamide|
41468503|NCT05930158|OTHER|Dual Task Exercises|Cognitive exercises to be added during walking and balance exercises will be given as a dual task. Cognitive exercises will consist of exercises for memory, executive functions, calculation, information processing speed (reaction time) and working memory areas. Cognitive exercises such as grouping the words given, giving appropriate answers to the simple situations described, simple addition, subtraction, multiplication, and asking the words that the patient is asked to remember before the exercise will be used. Cognitive exercises will be performed simultaneously with walking and balance exercises.
41468504|NCT05930158|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation content; relaxation exercises, stretching exercises, strengthening exercises, walking exercises, cycling exercises, balance exercises. Exercise intensity will be planned as moderate intensity. Walking and cycling exercises will have warm-up and cool-down periods.
41148458|NCT03364803|OTHER|Trait Food Craving Questionnaire-Trait (FCQ-T)|Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
41468505|NCT02263417|DEVICE|Deep Brain Stimulation (DBS) of Gpi|
41468506|NCT02263417|DEVICE|Deep Brain Stimulation (DBS) of STN|
41468507|NCT01841541|BEHAVIORAL|Referral of presumptive of TB cases by informal providers|Training of informal providers to effectively refer TB suspects in the community to the primary health care system
40790221|NCT03925571|OTHER|musicotherapy|If the patient is randomized in the experimental group, he listens the Music-care® playlists and chose two closed to his musical tastes. The playlists are unique compositions create by Music-care® (french company), not known from the general public, categorized by theme (jazz, rock, world music...).
40790222|NCT01946633|DEVICE|magnetic-controlled capsule endoscopy(Navicam)|
40790223|NCT01016067|DEVICE|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
40790224|NCT01016067|PROCEDURE|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
40790225|NCT00234130|PROCEDURE|nocturnal vs conventional dialysis|
40790226|NCT00002372|DRUG|Indinavir sulfate|
40790227|NCT00002372|DRUG|Amprenavir|
40790228|NCT00002372|DRUG|Nelfinavir mesylate|
40790229|NCT00002372|DRUG|Saquinavir|
40994414|NCT01921179|BEHAVIORAL|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
40994415|NCT01921179|BEHAVIORAL|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
40994416|NCT05525156|DRUG|aspirin enteric coated tablet 75 mg|blister packaged enteric coated tablet of 75 mg aspirin taken once daily for 24 weeks in addition to the conventional antiretroviral drugs
40994417|NCT05797493|DRUG|Atezolizumab|Upfront chemo-immunotherapy
40994418|NCT03048656|OTHER|static posturography|The measurement of the weight distribution and the static posturography was performed on the balance platform Good Balance by Metitur . The device is comprised of the triangular force platform with electronic system and computer software. The body weight distribution was evaluated in the upright standing with eyes open, feet placed 20 cm from each other.The individual stood motionlessly for 15 s, then the measurement was recorded. The static posturography was performed with 3 various positions of feet, both with eyes open and eyes closed. (1) Position : normal standing - an upright standing with feet placed parallel 20 cm apart for 30 s. (2) Position: tandem - a stance with one foot placed ahead of the other. for 20 s. (3) Position: one leg standing: stance on the one leg for 20 s.
40994419|NCT01880112|DRUG|Cefazolin|Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
40994420|NCT02642432|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
40994421|NCT02595086|PROCEDURE|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
40994422|NCT02595086|PROCEDURE|Laparoscopic DG|Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
40994423|NCT06198556|DRUG|HRS-1167 tablets; rifampicin|HRS-1167 tablets single oral dose of HRS-1167 or co-administered with rifampicin.
40994424|NCT00046033|DRUG|Lopinavir/ritonavir|
40790230|NCT03547908|DRUG|B/F/TAF|50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
40790231|NCT03547908|DRUG|Placebo to match DTG|Tablet administered orally once daily, without regard to food
40790232|NCT03547908|DRUG|Placebo to match F/TDF|Tablet administered orally once daily, without regard to food
40790233|NCT03547908|DRUG|DTG|50 mg tablet administered orally once daily, without regard to food
40994425|NCT00046033|DRUG|Ritonavir|
40994426|NCT00046033|DRUG|Saquinavir|
40994427|NCT00046033|DRUG|Tenofovir disoproxil fumarate|
41468508|NCT04666688|DRUG|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
40994428|NCT00046033|DRUG|Amprenavir|
40994429|NCT02347189|DEVICE|Melody Transcatheter Pulmonary Valve PB1016|
40994430|NCT05014022|DIAGNOSTIC_TEST|Multiparametric renal MRI|10 patients in the cohort will undergo MRI scanning at day 30 and 90
40994431|NCT01422863|BEHAVIORAL|Lifestyle Intervention|Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
40994432|NCT00000560|DRUG|adrenergic beta antagonists|
40994433|NCT01995084|DRUG|[F-18]HX4|400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
40994434|NCT01988142|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
41468509|NCT04666688|DRUG|Tislelizumab|anti-PD-1 monoclonal antibody
41468510|NCT04666688|DRUG|Gemcitabine/nab-paclitaxel|chemotherapy
41468511|NCT03186716|DIETARY_SUPPLEMENT|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
40790234|NCT03547908|DRUG|F/TDF|200/300 mg tablet administered orally once daily, without regard to food
40790235|NCT03547908|DRUG|Placebo to match B/F/TAF|Tablet administered orally once daily, without regard to food
40790236|NCT05617118|DRUG|Baclofen 10mg|Baclofen is a medication, a central myorelaxant, a GABAb stimulator.
40790237|NCT05617118|DRUG|Botulinum toxin type A|Botulinum toxin, often shortened to BoNT, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species.
40790238|NCT01121055|DRUG|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
40790239|NCT01121055|DRUG|Control|Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
40790240|NCT03541499|BIOLOGICAL|BPZE1|Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\^7 colony forming units (CFU) or 10\^9 CFU.
40994435|NCT02976974|OTHER|Manual therapy|Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
40994436|NCT02976974|OTHER|Therapeutic exercise|"* Shoulder extension: Elastic bands.~* Shoulder flexion: Elastic bands~* Shoulder external rotation: Elastic bands.~* Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~* Thoracic column movements: Flexion-extension"
40994437|NCT05836064|DEVICE|GastroBot|An artificial intelligence-developed and WhatsApp-based software bot. It will send the instructions to the patient through the WhatsApp application, guided by the software bot with multiple and personalized alternative instructions according to results.
40994438|NCT05836064|OTHER|Conventional explanation|Patients will receive in writing detailed explanation about bowel preparation with polyethylene glycol
40994439|NCT00733863|BIOLOGICAL|Placebo|
40994440|NCT00733863|BIOLOGICAL|CAD106|
40790241|NCT03541499|OTHER|Placebo|The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
40790242|NCT00921726|DRUG|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
40790243|NCT00921726|DRUG|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
40790244|NCT04163653|DIAGNOSTIC_TEST|Non-contrast MRI|Classification and characterization of the lymphatic vasculature using non-contrast MRI.
40790245|NCT04163653|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Cardiopulmonary exercise test, measurement of VO2 and heart rate.
40790246|NCT05819476|PROCEDURE|OLP-injection|Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.
40790247|NCT05819476|OTHER|Scripted Evidence-based treatment rationale|As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP. In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
40994441|NCT04991545|DEVICE|Application of Infrared (Active IRD/ IRRIS) device|"The first operator experienced with video-laryngoscopy intubation will do Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients After confirming lack of discomfort during application of the IRRIS/IRD device,~After complete relaxation, Laryngoscopy will be performed by the first operator using video laryngoscope (Glidescope Verathon Medical, BC, Canada or C-Mac Storz, Germany) to insert the tracheal tube. The endotracheal tube will be armed with a malleable stylet and to be molded to a curved 'hockey stick or the same curve of the laryngoscopic blade's shape. We will divide the patient according to device into two groups:~1. Group A: control group~2. Group B: Intervention group using Infrared"
40790248|NCT05819476|OTHER|Experimental model of acute pain|Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).
40790249|NCT03339310|DEVICE|Optimizer Smart System with 2-leads|The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
40790250|NCT03935178|DIAGNOSTIC_TEST|Measuring Right Ventricular Size and Function|This study focuses on evaluating different approaches to evaluation of right ventricular size and function using the Upper Valley Right Ventricle Algorithm and novel imaging modalities
40790251|NCT00173017|DEVICE|wearing N95 masks|
40790252|NCT02382991|DEVICE|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
40790253|NCT02382991|DEVICE|NMPK-3C60|1 month with NMPK - 3 months with 3C60
40994442|NCT03841734|DRUG|treatment|8 patients will be treat with bosentan at 145 mg per day during 14 days
40994443|NCT01165138|DRUG|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
41341738|NCT01522118|DEVICE|ExAblate 2100; InSightec|"Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.~MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens"
40790254|NCT06312163|DEVICE|The contact lens to be investigated in this study (Scheimpflug topography derived corneal RGP contact lens design). A CE (UKCA) marked class 2 medical devices.|The participants will be fitted with (i) the optimal lens design as specified by the virtual fitting module, in addition to (ii) lenses that are one clinically significant step (0.12 mm) flatter and (iii) steeper in axial edge lift (AEL).
40790255|NCT03491033|DRUG|chemotherapy|All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
40790256|NCT05015647|DIETARY_SUPPLEMENT|LP group|LP group patients replaced pasta, bread, biscuits etc. with low protein substitutes. We allowed them to consume more animal products than NP, preferring white meat to red meat and trying to limit cold cuts as much as possible. Furthermore, they were advised to prefer fresh or frozen fish, instead of dried or smoked one as well as to prefer fresh cheeses to seasoned ones. As for legumes, we advised to combine them with bread or normal cereals, for protein complementarity.
40994444|NCT01165138|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
40994445|NCT01165138|DRUG|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
40994446|NCT03830060|DIAGNOSTIC_TEST|Measurement of cortisol|Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP
40994447|NCT06039423|PROCEDURE|The M-TAPA block|A high frequency (6-12 MHz) US linear probe was placed in the sagittal plane on the 10 th costal margin in the midline. The probe was then angulated deeply to visualize the lower surface of the costal cartilage. Via in plane technique, a 21 gauge Tuohy needle was inserted cranially between the lower fascia of the costal cartilage and upper fascia of the transversus abdominis muscle by moving the needle tip towards the posterior aspect of the 10 th costal cartilage and 20 mL bupivacaine (0.25 %) was injected.
40994448|NCT06039423|DRUG|Ketorolac|conventional general anaesthesia receiving multimodal analgesia
40790257|NCT05015647|OTHER|NP group|NP group was given the indication to try to eat the second dish only once a day or to split the portion of the second plate between lunch and dinner, if they wanted to keep the habit of making the meal complete. It was also given the indication to prefer, among protein sources, those of plant origin. We also indicated to alternate or replace cow's milk with plant substitutes such as: rice, almonds' or oats' drinks. Furthermore, we suggested to prefer white meat and to avoid offal and processed meat. Moreover, we indicated to substitute dried or smoked fish with fresh or frozen one.
40790258|NCT04303429|DRUG|FOLFOX/XELOX/Capecitabine|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
40790259|NCT04161690|DRUG|Dexketoprofen Trometamol|intravenous dexketoprofen 50mg or intrathecal
40790260|NCT04161690|DRUG|Ropivacaine Hydrochloride 7.5 MG/ML|Local Infiltration Analgesia
40790261|NCT05063929|OTHER|Fruit (2 cup eq)|participants will receive 2 cup eq fruits
40790262|NCT05063929|OTHER|Fruit restriction (1/2 cup eq)|participants will receive 1/2 cups eq fruits
40790263|NCT05274412|OTHER|hypotension prediction index(HPI)|Implementing hypotension prediction index (HPI) in perioperative goal-directed hemodynamic therapy. Keep HPI \< 85; pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
41309661|NCT04423900|DIAGNOSTIC_TEST|smart phone application|Participants will be asked to provide information about their sociodemographic characteristics, chronic diseases, the history of the ankle injury, trauma, and surgery, the severity of the foot pain via using the mobile application.The app will be downloaded from the Google Play Store and available offline. Information from the patient will be stored in an SQLite database.The usability test will be carried out on the mobile application so that the latest releases contain clear, effective, loyal to the strategy, and easily understood messages by the intended audience and do not produce unwanted responses.Direct observation, individual interviews, and satisfaction surveys will be used to identify areas of improvement in a cross-sectional manner.Investigation of pes cavus, pes planus and ankle range of motion will be determined by image processing.All data can be analyzed and stored by Heel Analysis Systems established on an external server.The data will be transferred securely over HTTPS.
41309662|NCT01328249|DRUG|eribulin mesylate|Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks.
40790264|NCT05274412|OTHER|ordinary goal-directed hemodynamic therapy|Keep pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
40994449|NCT01787175|OTHER|Integrated Medication Manager|A theory based electronic health record. Half of the provider participants were assigned the IMM to use. The other half were assigned the VA's CPRS EHR to use for the simulation. Providers were randomly assigned to a EHR to use.
40994450|NCT00106782|PROCEDURE|Transcranial Electrical Polarization (TEP)|
40994451|NCT00912314|PROCEDURE|PTNS|Monthly PTNS after 12 weeks of weekly PTNS
41309663|NCT01553916|DRUG|Lithium Carbonate|
41309664|NCT01553916|RADIATION|Prophylactic cranial irradiation|
41309665|NCT02413619|PROCEDURE|Vitrectomy|Vitrectomy
41309666|NCT02413619|PROCEDURE|Cataract surgery|Cataract surgery
41309667|NCT02413619|PROCEDURE|Combined surgery|Combined vitrectomy and cataract surgery at the same time
41309668|NCT03924791|DRUG|Lidocaine|In combination with dexamethasone or methylprednisolone acetate
41309669|NCT03924791|DRUG|Methylprednisolone Acetate|In combination with lidocaine
41309670|NCT03924791|DRUG|Dexamethasone|In combination with lidocaine
41309671|NCT05550194|DRUG|ValACYclovir 1000 MG|Valacyclcovir is a targeted anti-viral for varicella zoster virus (VZV).
41309672|NCT05550194|BIOLOGICAL|Shingrix|Vaccine indicated for prevention of herpes zoster
41309673|NCT00283998|PROCEDURE|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
41309674|NCT06059300|DIAGNOSTIC_TEST|Digital Breast Tomosynthesis|Screening with Digital Breast Tomosynthesis instead of Digital Mammography, for two screening rounds
41309675|NCT00816907|DRUG|Metformin|500 mg to 1,000 mg taken twice daily for 16 weeks
41309676|NCT00816907|DRUG|Placebo|1 to 2 placebo capsules taken twice daily for 16 weeks
41309677|NCT06053216|OTHER|Indirect calorimetry|Weekly indirect calorimetry measurements using the Q-NRG+ device will be used to guide energy delivery up to day 28 of hospital admission.
41309678|NCT06053216|OTHER|Indirect calorimetry (Standard care nutrition arm)|Weekly indirect calorimetry measurements using the Q-NRG+ device will be conducted up to day 28 of hospital admission. In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry measurements.
40790265|NCT02904174|BEHAVIORAL|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 \& 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 \& 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 \& 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question \& answer session were included in the group education.
40994452|NCT03733821|DEVICE|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation tool
40994453|NCT05627882|DIAGNOSTIC_TEST|Forward viewing endoscope|Additional examination with standard forward viewing endoscope
41309679|NCT03203889|BEHAVIORAL|CRAFT-AI|Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
40790266|NCT00572429|DIETARY_SUPPLEMENT|l-carnitine|3 gram daily dose
41309680|NCT03203889|BEHAVIORAL|TSF-CSO|In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
40994454|NCT01914406|OTHER|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
40994455|NCT01914406|OTHER|continuous moderate training|Continued exercise 45 min.
40994456|NCT04822207|PROCEDURE|acupuncture|Patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. Every acupuncture lasts 20 minutes.
40994457|NCT01837992|DRUG|Primaquine|
41309681|NCT01262300|BIOLOGICAL|Varicella Zoster Virus Vaccine (Zostavax)|Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
41309682|NCT05998954|PROCEDURE|transmuscular quadratus lumborum and modified erector spinae plane (QLESP) block|Fifteen ml of 0.375% ropivacaine was administered between the erector spinae muscle and the transverse process. Fifteen ml of 0.375% ropivacaine was subsequently given between the quadratus lumborum and the psoas major muscles.
41309683|NCT05998954|PROCEDURE|suprainguinal fascia iliaca block|Thirty ml of 0.375% ropivacaine will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
41309684|NCT06555315|DIETARY_SUPPLEMENT|6 mg/kg of oral iron as ferrous sulfate administered every other day.|6mg/kg of oral iron as ferrous sulfate administered every other day instead of 6 mg/kg of oral iron daily supplementation.
41309685|NCT06555315|DIETARY_SUPPLEMENT|6 mg/kg of oral iron as ferrous sulfate administered every day.|6 mg/kg of oral iron as daily ferrous sulfate instead of 6mg/kg of oral iron supplementation administered every other day.
41309686|NCT00195260|DRUG|bosutinib|Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
41309687|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
40994458|NCT01837992|DRUG|delayed primaquine|
40994459|NCT00075426|DRUG|arsenic trioxide|
40994460|NCT06238076|DEVICE|Universal surgical device FIBUMAND|This device is made of biocompatible resin for type IIa medical devices with a 3D printer.
40994461|NCT00819338|DIETARY_SUPPLEMENT|Efamax|5g daily as capsules for 3 months
40790267|NCT00003869|DRUG|carboxyamidotriazole|Given PO
40790268|NCT00003869|OTHER|placebo|Given PO
40790269|NCT00003869|PROCEDURE|quality-of-life assessment|Ancillary studies
40994462|NCT02725047|OTHER|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
40994463|NCT02725047|OTHER|Placebo - Sand|Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
40790270|NCT00003869|OTHER|laboratory biomarker analysis|Correlative studies
40790271|NCT03856736|OTHER|MIAT|Moderated aerobic exercise
40790272|NCT03856736|OTHER|Control|Weekly body relaxation and sham group
40790273|NCT00535769|DEVICE|Electronic + no text message|Electronic monitor is attached but no text-messages are sent through cellular phones
41309688|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
41309689|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
41309690|NCT05254314|DRUG|Semaglutide Pen Injector 2.4mg weekly|Once weekly subcutaneous injection
41309691|NCT05254314|OTHER|Placebo|Once weekly subcutaneous injection
41309692|NCT01184716|OTHER|Vitamin D fortification|Bread and milk fortified with vitamin D3
41309693|NCT00717366|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Will be administered IV, every 4 weeks.
41309694|NCT05986097|BEHAVIORAL|Breakfast|We will provide participants recipes and information to support this dietary change.
41309695|NCT06186635|OTHER|Traditional yoga|This group will practice traditional yoga for an average of 2 hours, preferably once a week, for 12 weeks.
41309696|NCT06186635|OTHER|AI-Assisted Yoga|This group will practice AI-assisted yoga for an average of 2 hours, preferably once a week, for 12 weeks.
41309697|NCT00592852|DRUG|fluoxetine|capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
40790274|NCT00535769|DEVICE|Electronic monitor + text messages|Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
40790275|NCT04090957|DRUG|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily.
40790276|NCT04090957|DRUG|Placebo oral tablet|Placebo oral tablet will be administered orally once daily.
40790277|NCT01059006|PROCEDURE|PresbyLASIK|PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
40790278|NCT01119144|DEVICE|Polycaprolactone / Tri-Calcium Phosphate|Orbital implant for reconstruction of the orbital walls
40790279|NCT01119144|DEVICE|Titanium Mesh|Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
40790280|NCT01770743|BIOLOGICAL|AV7909|Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
40790281|NCT01770743|BIOLOGICAL|BioThrax|
40790282|NCT06379633|BEHAVIORAL|In vivo exposure|Exposure in vivo involves the confrontation with fear-evoking situations in real life.
40790283|NCT06379633|BEHAVIORAL|(Virtual reality) exposure|Exposure in virtual reality involves the confrontation with fear-evoking situations which are generated by a computer using VR technology.
40790284|NCT00158626|BEHAVIORAL|pelvic floor muscle training|
40790285|NCT01781377|DRUG|PROPOFOL|PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
40790286|NCT01781377|DRUG|METOCLOPRAMIDE|METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
40790287|NCT01781377|DRUG|PLACEBO|SALINE INFUSION
40790288|NCT00255905|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|
40790289|NCT00255905|BEHAVIORAL|Clinician monitoring|
40790290|NCT03542266|DRUG|CC-486 Administration|CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
40790291|NCT03542266|DRUG|CHOP Administration|"CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5"
40790292|NCT05249686|OTHER|Manual Therapy + Dry Needling|"Dry Needling: This is a minimally invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle in order to stimulate myofascial trigger points (MTrP) provoking one to six local twitch responses (LTR).~Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ)."
40790293|NCT05249686|OTHER|Manual Therapy|Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
40790294|NCT00235183|OTHER|plasma|transfusion of more than 15 mL/Kg of plasma
40790295|NCT02659813|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
40790296|NCT04389866|DEVICE|JUVÉDERM VOLUMA™ XC|Injectable gel
40790297|NCT06360653|RADIATION|Stereotactic Post-operative Radiotherapy for Endometrial Cancer|Patients candidate to receive adjuvant radiotherapy will be assigned to a shorter schedule of 30 Gy in 5 sessions.
40790298|NCT02402803|OTHER|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
40790299|NCT05793359|DRUG|Methylprednisolone|methylprednisolone applied as intravenous infusions or intramuscularly
40790300|NCT01545765|DRUG|Lidocaine 7% + Tetracaine 7% cream|Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
40790301|NCT05151744|DRUG|Vamikibart|Vamikibart will be administered by IVT injection in the study eye.
40790302|NCT05151744|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
40790303|NCT05151744|OTHER|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
40790304|NCT05531552|DRUG|clinical pharmacy application|assessment clinical pharmacist in management of CAD and ICU patients.
40790305|NCT04244071|DEVICE|Bair Paws Blanket 81003 and FOC device 87500|This study is a randomized, pretest - posttest controlled experimental design.
40790306|NCT04244071|OTHER|routine hospital care|routine hospital care
40790307|NCT05830318|OTHER|P-STEP Mobile Application|A mobile application that allows you track your walking habits while keeping you up to date with air quality information.
40790308|NCT00183144|BEHAVIORAL|Contingency management|
40790309|NCT06493045|DRUG|IRL757|IRL757 capsule
40790310|NCT06493045|DRUG|Placebo|Placebo capsule
40790311|NCT01810900|DEVICE|Protescal|
40790312|NCT04836442|OTHER|Alcohol-PTSD-PFI (AP-PFI)|Integrated computer-based personalized feedback intervention to specifically target anxiety sensitivity in the context of hazardous drinking and PTSD symptoms. The AP-PFI will focus on feedback about alcohol behavior in the context of PTSD symptoms, AS, and coping-oriented alcohol use.
40790313|NCT04836442|OTHER|Active Comparison Condition (C-PFI)|Participants in the time-matched comparison condition will receive personalized feedback on alcohol use but will not receive PTSD or AS-related personalized feedback. C-PFI will include alcohol-focused components identical to those provided in AP-PFI (e.g., alcohol profiles, normative feedback). Therefore, it will be possible to isolate the impact of personalized PTSD and AS feedback versus personalized alcohol feedback.
40790314|NCT06281977|DRUG|Dexmedetomidine|Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
40790315|NCT06281977|DRUG|Normal saline|Programed as dexmedetomidine on infusion pump.
40790316|NCT01538576|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
40790317|NCT05115565|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) Application|Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
40994464|NCT06361628|BEHAVIORAL|multicomponent intervention on vaccination awareness|Educational sessions to create awareness on HPV and MMR (were addressed) vaccination that is culturally sensitive health information and provided in an easily understandable manner by trained health promoters (and healthcare professionals) to underserved communities. Support for navigation and access to vaccines.
40790318|NCT05614661|BEHAVIORAL|Mom Power|Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
41309698|NCT06291116|DRUG|standard care + rotigotine at 4 mg/24h for 24 months.|standard care + rotigotine at 4 mg/24h for 24 months.
41468512|NCT03186716|DIETARY_SUPPLEMENT|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
41468513|NCT06261619|DEVICE|Adult Sotair Device|Adult Sotair® device employs a flow limiting valve mechanism.
41309699|NCT06291116|DRUG|standard care for 24 months.|standard care for 24 months.
41309700|NCT04353921|OTHER|No intervention will be administered as part of this study.|No intervention will be administered as part of this study.
41468514|NCT00761176|DEVICE|The Provant Therapy System|The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
41468515|NCT02159287|DRUG|Enoxaparin|1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
41468516|NCT02159287|DRUG|Heparin|1000 unit per hour continuous intravenous infusion of heparin sodium
41468517|NCT06616961|DRUG|Semaglutide Pen|"In this study, the intervention involves administering semaglutide (Fitaro) to participants for weight management. The treatment protocol includes the following steps:~Initial Dose: Participants will start with a subcutaneous injection of semaglutide at a dose of 0.25 mg once weekly for the first four weeks to allow for tolerance and adjustment.~Dose Escalation: After the initial period, the dose will be increased at four-week intervals as follows:~Week 5: Increase to 0.5 mg Week 9: Increase to 1 mg Week 13: Increase to 1.7 mg Week 17: Increase to a maximum dose of 2.4 mg, if necessary, based on individual weight loss response and tolerability."
41468518|NCT01668823|DRUG|HPPH|Given IV
41468519|NCT01668823|DRUG|photodynamic therapy|Undergo photodynamic therapy with HPPH
41468520|NCT01668823|PROCEDURE|therapeutic bronchoscopy|Undergo therapeutic bronchoscopy for endoscopic debridement
41468521|NCT03328429|OTHER|Excision|Bartholin gland will be excised
41468522|NCT03328429|OTHER|Marsupialization|Bartholin gland will be marsupialised
40790319|NCT06319404|OTHER||
40790320|NCT02615977|BEHAVIORAL|Zooming Joystick Task|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
40790321|NCT02615977|BEHAVIORAL|Zooming Joystick Task (Placebo)|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
40790322|NCT00772278|PROCEDURE|carotid artery stenting|carotid artery angiography, angioplasty and stenting
40790323|NCT00772278|PROCEDURE|carotid endarterectomy|open surgery including endarterectomy
41309701|NCT03860727|DIAGNOSTIC_TEST|Welch Allyn IExaminer|Fundus Examination
41309702|NCT03918603|OTHER|ventral décubitus|Patient will have one session at least more than 12 hours between inclusion and H48 of ventral décubitus
41309703|NCT04002154|DEVICE|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
41309704|NCT02034474|DRUG|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
41309705|NCT02034474|DRUG|Placebo|intravenously via iv drip over 60 min
41309706|NCT04767256|DRUG|Dexamethasone and dexmedetomidine|General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.
41309707|NCT04767256|DRUG|Dexmedetomidine|Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.
41468523|NCT01758341|PROCEDURE|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
41468524|NCT01758341|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
41468525|NCT01758341|DEVICE|HabibTM EndoHPB catheter|"Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)"
41468526|NCT01337882|OTHER|Forearm venous occlusion plethysmography study|Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin \[100, 300 \& 1000 pmol/min\]; acetylcholine \[5, 10 \& 20 µg/min\]) and -independent \[sodium nitroprusside \[2, 4 \& 8 µg/min\]; verapamil \[10, 30 \& 100 µg/min\]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
41468527|NCT02283190|DRUG|Erwinase|Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
41341739|NCT04437316|DEVICE|Use of Low level Laser after wisdom tooth removal|Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.
41468528|NCT00577148|DRUG|Rimonabant|Tablet, oral administration
41468529|NCT00577148|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
40790324|NCT05087680|BEHAVIORAL|ACTPrEP|ACTPrEP will include a 60-minute initial session and a series of 30-minute follow-up sessions. Sessions will focus on the Thoughts, Emotions, Associations, Memories, and Sensations (TEAMS) relevant to PrEP uptake and adherence.
40790325|NCT05087680|BEHAVIORAL|Enhanced Standard of Care|Enhanced Standard of Care (ESOC) will include one 30-minute PrEP education session.
40994465|NCT01689129|DRUG|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
40994466|NCT01689129|DRUG|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
40994467|NCT02293655|DRUG|OROS-Methylphenidate (MPH)|OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
40994468|NCT02437019|DRUG|PCI-32765 (Ibrutinib)|Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
40994469|NCT04079478|OTHER|AI|Artificial intellignece colonoscopy
41468530|NCT04424966|DRUG|Infigratinib|The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.
40790326|NCT02737319|DRUG|Rosuvastatin|40 mg of rosuvastatin before angioplasty
41309708|NCT04767256|OTHER|Ultrasound-guided lumbar erector spinae plane block|The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.
40790327|NCT01820650|DEVICE|iTotal G2 CR Knee Replacement System|Total Knee replacement
40994470|NCT04459117|DRUG|Acetaminophen|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
40994471|NCT04459117|DRUG|NACL 0.9%|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
40994472|NCT03507712|PROCEDURE|Symmetrical IO weakening|Bilateral IO Myectomy / Bilateral equal graded IO Recession
40994473|NCT03507712|PROCEDURE|Asymmetrical IO weakening|IO Myectomy in one eye - IO Recession in the fellow eye / Bilateral IO Recession (different amounts) in each eye
40994474|NCT04509843|BEHAVIORAL|socioeconomic status|it is a cross-sectional study for assessment the impact of socioeconomic status on periodontal health through using a definite scale mentioned in the protocol related to the middle east people.
40994475|NCT00649896|DRUG|Mylan Estradiol Transdermal System 0.025 mg/day|
40994476|NCT00649896|DRUG|Climara® Transdermal System 0.025 mg/day|
40994477|NCT02319005|DRUG|Revusiran (ALN-TTRSC)|
41309709|NCT04767256|OTHER|PCIA|Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
40790328|NCT06513039|DRUG|Erythropoietin carried on chitosan carrier|Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months to enhance bone healing
40994478|NCT02319005|DRUG|Sterile Normal Saline (0.9% NaCl)|
40994479|NCT00804518|OTHER|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at \~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
41309710|NCT02410850|DEVICE|Oral Appliance|Mandibular Advancement Splints
41309711|NCT04861480|BIOLOGICAL|C-4-29 Cells|Drug: C-4-29 Cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
41309712|NCT00335946|DEVICE|HANS non-needle acupuncture|
41309713|NCT00335946|PROCEDURE|Stimulation of two acupuncture points bi-lateral|
41468531|NCT01770002|PROCEDURE|Everted suture technique|
41468532|NCT01770002|PROCEDURE|Non-everted suture technique|
40790329|NCT06513039|OTHER|chitosan carrier|inert scaffold agent
40790330|NCT01030822|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
41468533|NCT00588731|DRUG|Cannabidiol|Active Cannabidiol daily over 6 weeks
40790331|NCT01030822|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
40790332|NCT05959317|OTHER|Pilates Exercises|Pilates exercises will be perform for 15-30 minutes for one session 3 days a week for 6-weeks than after 6 week reassess the QOL, pain and flexibility.
41468534|NCT00588731|DRUG|Placebo|Placebo
40994480|NCT02797847|DRUG|ALN-TTRSC02|Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection
40994481|NCT02797847|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
40994482|NCT03282292|PROCEDURE|Internal jugular vein CVC insertion|Double lumen CVC insertion in the internal jugular vein
40994483|NCT00110409|BEHAVIORAL|Asthma Education in Adults|The intervention involves enhancing asthma education, asthma self-efficacy and asthma-related social support and is administered during a single in-person session in the ED (or hospital for admitted patients) followed by telephone reinforcement.
40994484|NCT00110409|BEHAVIORAL|Standard Emergency Room Asthma Education|Participants will receive standard emergency room education about asthma.
40994485|NCT02560337|DRUG|Cabazitaxel|
40790333|NCT05959317|OTHER|Neural dynamic mobilization|Neural dynamic mobilization will be perform for 15-30 minutes for one session 3 days a week for 6-weeks after 6 weeks reassess the QOL, pain and flexibility.
40790334|NCT01102920|BEHAVIORAL|Behavioural strategies to promote physical activity and weight loss|"8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.~Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.~Treatments are provided by a physical therapist and a dietician."
40790335|NCT01102920|DEVICE|CPAP|CPAP-treatment as usual (during nights)
40790336|NCT05734664|DEVICE|Pulsify sensor|A positioning system will move the 1X1 cm Pulsify sensor step-by-step over a marked area of 10x10 cm on the subjects' chest to record a complete 3D data set of the heart. For accurate 3D reconstruction, the ECG and breathing cycle are also recorded during the acquisition using commercially available devices (Bitalino HeartBIT + Respiration Sensor). From the 3D dataset of the heart, the end-systolic and end-diastolic volumes will be extracted automatically to calculate the cardiac output.
40790337|NCT05734664|DEVICE|State-of-the-art ultrasound equipment|A complete 2D and 3D ultrasound data set using a GE Vivid E95 ultrasound machine, version 203 (General Electric Healthcare, Chicago, IL, United States) will be recorded. All data will be processed offline with a specialized software packet (EchoPAC, version 203, General Electric Healthcare, Chicago, IL, United States
40790338|NCT01247064|DRUG|Nebulized 3% saline|4 mL of nebulized 3% saline once
40790339|NCT01247064|DRUG|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
40790340|NCT04564443|OTHER|Medaxis Debritom+|Advanced micro fluid jet therapy to clean and stimulate wound
40994486|NCT02064881|DRUG|Metformin glycinate|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs) .
40994487|NCT02064881|DRUG|Metformin Hydrochloride|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs)
41309714|NCT04081883|OTHER|Biosensor algorithm|The biosensor DIABLO responses will be compared to the measurements of standard CGMS, using blood glucose measures every 10 minutes by taking interstitial fluid from Diabetes Type 1 (DT1) patients with an internal or external insulin pump.
40994488|NCT02052921|PROCEDURE|Rectal resection|Surgical rectal resection
40994489|NCT02052921|OTHER|Observation|
40994490|NCT03745144|DRUG|Cladribine|Participants received cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
40994491|NCT03745144|DRUG|Placebo|Participants received placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
40994492|NCT03745144|DRUG|Microgynon®|Participants received Microgynon® tablet once daily for 21 days in treatment period 1 and 2. Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle in Run-in period.
40994493|NCT00174655|DRUG|Doxorubicine + docetaxel sequential|doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
40994494|NCT00174655|DRUG|doxorubicine + cyclophosphamide sequential|doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
40994495|NCT00174655|DRUG|doxorubicine + cyclophosphamide combined|doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
40994496|NCT00174655|DRUG|doxorubicine + docetaxel combined|doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
40994497|NCT04662801|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will receive twelve weeks of BWL treatment.
40994498|NCT04662801|BEHAVIORAL|Early Responder: BWL continued|Participants categorized as experiencing early weight loss at the end of the first month of treatment will continue with BWL for the remainder of treatment.
41309715|NCT01043354|BEHAVIORAL|stage-matched intervention|6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling
41309716|NCT01043354|BEHAVIORAL|framing effects intervention|6 monthly telephone-delivered counseling sessions based on prospect theory
41309717|NCT01043354|BEHAVIORAL|attention placebo intervention|6 monthly counseling sessions about general health topics
41309718|NCT06102252|DRUG|Paclitaxel/epirubcin/carboplatin|adjuvant treatment in endometrial carcinoma
41309719|NCT06102252|DRUG|Paclitaxel/carboplatin|Dose dense paclitaxel/carboplatin
41309720|NCT04427787|DRUG|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day
41309721|NCT04427787|DRUG|Lanreotide|Lanreotide will be administrated 120 mg injection every 28 days
41309722|NCT02669004|DRUG|Intermittent bolus epidural morphine|morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
41309723|NCT02669004|DRUG|continuous epidural morphine|morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
41309724|NCT04146571|DRUG|Ensartinib|Oral, ALK inhibitor
41309725|NCT03448224|OTHER|Questionnaire Administration|Questionnaire
41309726|NCT03448224|OTHER|Internet-Based Intervention|Intervention
41309727|NCT02618980|OTHER|endoscopic hemostasis|At endoscopy, stigmata of hemorrhage (SRH) will be treated by dual endoscopic local therapy (combining at least two of the following treatments: epinephrine injection, coaptive thermocoagulation, hemoclip therapy, argon plasma coagulation, bipolar coagulation).
41468535|NCT02346851|PROCEDURE|Functional Electrical Stimulation (FES) treatment|This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
41468536|NCT00037687|DRUG|rPAF-AH|
41468537|NCT01529931|DEVICE|Hair2Go|Hair2Go treatment once a month for 6 months
40790341|NCT04564443|OTHER|Sharp Surgical Debridement|Scalpel or Curette to clean and debride wound
40790342|NCT04564443|OTHER|Additional Outer Dressing Application|Application of moisture retentive dressing, and a multi layer compression dressing
40790343|NCT04564443|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
40790344|NCT04564443|OTHER|Fibracol Wound Dressing|Application of a collagen alginate dressing
40790345|NCT00700908|BEHAVIORAL|automated telephone intervention vs. usual care|
40994499|NCT04662801|COMBINATION_PRODUCT|Early Non-responder: BWL continued with medication added|Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion) for the remainder of treatment.
40994500|NCT04846803|BIOLOGICAL|ABU bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)
40994501|NCT04846803|BIOLOGICAL|Saline bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline
40994502|NCT02474108|PROCEDURE|surgical prevention of atrial fibrillation|Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
40994503|NCT02474108|DEVICE|cardiomonitor|in both groups cardiac rhythm will be controlled by a cardiomonitor
41148459|NCT03364803|OTHER|Visual Analogue Scale (VAS)|"A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark."
41309728|NCT01193192|OTHER|Neevo®|"A prenatal medical food - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid"
41309729|NCT01193192|OTHER|Prenatal vitamins|for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
41309730|NCT00208741|DRUG|Gabitril|
41309731|NCT02709993|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
41309732|NCT02493816|DRUG|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
41309733|NCT03695991|PROCEDURE|percutaneous nephrostomy|The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
41309734|NCT05214898|BEHAVIORAL|24/7 Dad|"The 24/7 Dad curriculum is an evidence-based, skills driven curriculum (12 group sessions). The following topics are included: Family History, What it Means to Be a Man, Showing and Handling Feelings, Men's Health, Communication, The Father's Role, Discipline, Children's Growth, Getting Involved, Working with \& Co-Parenting, Dads and Work, and the My 24/7Dad Checklist. Healthy Relationship topics include: Communication Skills, including expression, discussion, and negotiation skills; Conflict Resolution and Anger Management; Problem-Solving; and Knowledge of the Benefits of Marriage. Responsible Parenting areas of focus include: children's growth/development; non-violent discipline; co-parenting; building conflict resolutions skills (for the child and the family); and, enhancing family relationships."
41309735|NCT02197429|OTHER|Acupuncture|
41309736|NCT05073835|DRUG|Semaglutide 3 mg|Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
41309737|NCT05073835|DRUG|Placebo|Placebo
41341740|NCT05049018|OTHER|Traditional Physical Therapy Program|"This intervention included:~* Strengthening and facilitation exercises for the affected upper extremity muscles.~* Stretching and mobilization exercises for the affected upper extremity muscles and joints.~* Postural reactions exercises.~* Facilitation of arm-reaching and arm-hand skills for the affected upper extremity.~* Facilitation of manipulative tasks (grasp and release activities) for the affected upper extremity.~* Training of daily living activities for the upper extremities."
41468538|NCT00328484|BEHAVIORAL|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
40790346|NCT04270344|DRUG|Pitavastatin 4mg|combination therapy with pitavastatin/valsartan (LivaloV)
40994504|NCT00418132|DRUG|Thalidomide|Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
40994505|NCT00418132|DRUG|Placebo thalidomide|Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
40994506|NCT03413813|DEVICE|Magmaris|Severe stenosis de novo, in native coronary arteries, treated with percutaneous coronary intervention with scaffold implantation.
40994507|NCT05277246|OTHER|Irrigant concentration|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on level of IL-8 different concentration will be evaluated.
40994508|NCT05277246|DRUG|NaOCI|NaOCI
40994509|NCT06475482|OTHER|Lip hydrant|lip hydrant containing peppermint oil, perilla frutescens, and Emblica fruit extract or petroleum gel.
40790347|NCT00983866|BEHAVIORAL|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
40994510|NCT06475482|OTHER|Petroleum gel|Vaseline
40994511|NCT02918851|BIOLOGICAL|Transfusion of 7-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.
40994512|NCT02918851|BIOLOGICAL|Transfusion of 28-day stored red blood cells|Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.
40994513|NCT02918851|BIOLOGICAL|Transfusion of 42-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.
40994514|NCT06038279|DRUG|INI-2004|INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.
40994515|NCT06038279|DRUG|Placebo|The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.
41148460|NCT03364803|OTHER|Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant|A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
41148461|NCT00585910|DRUG|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
41468539|NCT00328484|BEHAVIORAL|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
40823071|NCT03200639|OTHER|High intensity interval training with body weight|The HIITBW and HIITBWc protocol (total length time \~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (\<60% of HRmax or Borg Scale at \<5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
40994516|NCT03121326|DIAGNOSTIC_TEST|blood and urine sampling|Ten mL blood and 15mL urine are collected.
40994517|NCT01770483|DRUG|nitazoxanide|nitazoxanide 500mg twice daily
40994518|NCT01770483|DRUG|conventional interferon alfa|Inj interferon 3 Million International Units thrice weekly
40994519|NCT01770483|DRUG|Ribavirin|ribazole
40994520|NCT05398679|DRUG|Cefaclor|cefaclor intravenous 2 gr/day
40994521|NCT05398679|DRUG|Ciprofloxacin Tablets|500-750 mg/12 hrs (maximum 3g x day)
40994522|NCT05398679|DRUG|Ciprofloxacin Injection|1200 mg/day maximum dose IV
40994523|NCT05398679|DRUG|Clindamycin Oral Capsule|600 mg/8 hours (maximum 1.800 mg x day)
40994524|NCT05398679|DRUG|Clindamycin Injection|600 mg/8 hours (maximum 1.800 mg x day) IV
40994525|NCT05398679|DRUG|Dicloxacillin Oral Capsule|1g/8 hours (maximum 4 gr day)
40994526|NCT05398679|DRUG|Dicloxacillin|1g/8 hours (maximum 4 g x day) IV
40994527|NCT05398679|DRUG|Fusidic Acid Only Product in Oral Dose Form|0,750g/12 hours (maximum 1,5 g x day)
40994528|NCT05398679|DRUG|Fusidic Acid Only Product in Parenteral Dose Form|0,75 g/12 hours (maximum 1,5 g x day)
40994529|NCT05398679|DRUG|Levofloxacin Oral Tablet|0.5g/12-24hours (maximum 1 g x day)
40994530|NCT05398679|DRUG|Levofloxacin Injection|0.5g/12-24hours (maximum 1 g x day)
40994531|NCT05398679|DRUG|Linezolid Oral Tablet|0,6 g/12 hours (maximum 1200 mg x day)
40994532|NCT05398679|DRUG|Linezolid Injectable Product|0,6 g/12 hours (maximum 1200 mg x day)
40994533|NCT05398679|DRUG|Moxifloxacin tablet|0,4 g/day (maximum 400 mg x day)
40994534|NCT05398679|DRUG|Moxifloxacin Injectable Product|0,4 g/day (maximum 400 mg x day)
40994535|NCT05398679|DRUG|Rifampicin Only Product in Oral Dose Form|0,3-0,5 g/12 hours (maximum 1200 mg x day)
40994536|NCT05398679|DRUG|Rifampicin Only Product in Parenteral Dose Form|0,3-0,6 g/12 hours (maximum 1200 mg x day)
41468540|NCT04208256|DIETARY_SUPPLEMENT|Energy Stimulus|Energy stimulus (energy surplus v. energy neutral) will be randomly assigned at the first brain imaging visit. At the second brain imaging visit, the participant will receive the alternate stimulus from what they received at the first brain imaging visit.
41468541|NCT05376137|DEVICE|continuous positive airway pressure (CPAP)|CPAP comfort settings will be modified in the active group to be personalized to each participant
41468542|NCT00438659|DRUG|mometasone furoate|Applied to treatment area
41468543|NCT00438659|OTHER|placebo|Applied to treatment area
41468544|NCT00782561|DRUG|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
41468545|NCT00003242|DRUG|bryostatin 1|
41468546|NCT00003242|DRUG|cisplatin|
41468547|NCT00003242|DRUG|paclitaxel|
41468548|NCT02040311|DRUG|Topiramate 96 mg daily|
41468549|NCT02040311|DRUG|Topiramate 192 mg daily|
41468550|NCT02040311|DRUG|Placebo|
41468551|NCT05290233|BEHAVIORAL|TRE + Exercise|"We will compare the effects of TRE combined with resistance exercise versus TRE combined with aerobic training.~Other Names:~resistance training endurance exercise"
41468552|NCT06616454|BEHAVIORAL|Intervention group - Time restricted feeding|Participants will be applied with an ad libitum nutrition plan between 10:00-18:00.
41468553|NCT06466005|OTHER|UnityPhilly app|UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.
41468554|NCT00052520|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
41468555|NCT00052520|BIOLOGICAL|aldesleukin|Given SC
41468556|NCT00052520|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
41468557|NCT00052520|PROCEDURE|allogeneic bone marrow transplantation|Undergo transplantation
41468558|NCT00052520|OTHER|laboratory biomarker analysis|Correlative studies
40790348|NCT04692012|OTHER|FRESH CORNEAL MYOPIC LENTICULE IMPLANTATION|VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values. Current orientation was marked with a sterile skin marker. The lenticule was positioned around the marked center of the cone and flattened out from the surface using a blunt spatula.
40790349|NCT02099084|DRUG|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
41468559|NCT00052520|GENETIC|gene expression analysis|Correlative studies
41468560|NCT00052520|OTHER|immunologic technique|Correlative studies
41468561|NCT00052520|OTHER|flow cytometry|Correlative studies
41468562|NCT00052520|GENETIC|polymerase chain reaction|Correlative studies
40790350|NCT02099084|DRUG|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
40994537|NCT05398679|DRUG|Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
40994538|NCT05398679|DRUG|Sulfamethoxazole / Trimethoprim Injectable Product|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
41468563|NCT00052520|GENETIC|cytogenetic analysis|Correlative studies
41468564|NCT00052520|OTHER|staining method|Correlative studies
40994539|NCT05398679|DRUG|Tedizolid Oral Tablet|200 mg tedizolid (maximum x day)
41468565|NCT00435305|DRUG|Meropenem|
41468566|NCT00435305|DRUG|Vancomycin|
41468567|NCT00435305|DRUG|Linezolid|
41468568|NCT00435305|DRUG|Piperacillin/Tazobactam|
41468569|NCT00435305|DRUG|Cefepim|
40823072|NCT00149695|BEHAVIORAL|Weekly home delivery of milk products|
40994540|NCT05398679|DRUG|Tedizolid Injection|200 mg (maximum x day)
40994541|NCT05398679|DRUG|Amoxicillin Capsules|1 gr/6 hours (4 g x day)
40994542|NCT05398679|DRUG|Amoxicillin|1 gr/6 hours (4 g x day) Intravenous
40994543|NCT05398679|DRUG|Cefaclor Capsules|2 gr/day
40994544|NCT01625143|OTHER|laboratory biomarker analysis|Correlative studies
41468570|NCT00435305|DRUG|Ceftazidim|
41468571|NCT06172855|DEVICE|Electroacupuncture at ST36|Electroacupuncture at ST36, which located at the anterior aspect of the lower leg, 3 cun below ST 35, one finger-breadth (middle finger) from the anterior crest of the tibia. Twice or 3 times per week, for 6 weeks.
41468572|NCT03401073|DRUG|Intravenous immunoglobulin|Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
41468573|NCT03401073|DRUG|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
41468574|NCT05795348|DIAGNOSTIC_TEST|Personalised Musculoskeletal Modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop and inform personalised musculoskeletal models
41468575|NCT00117741|BEHAVIORAL|Dialectical Behavior Therapy|Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone
41468576|NCT00117741|BEHAVIORAL|Drug Counseling|Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
41468577|NCT06035276|OTHER|Exposure to clean air|"Subjects will be exposed to filtered indoor air (clean air) for 4 hours in the Fraunhofer Environmental Exposure Chamber. The chamber can accommodate up to 18 subjects, is ventilated by HEPA-filtered and conditioned air, ensuring a constant humidity (40 ± 10%), temperature (22 ± 2°C), and airflow (1500 ± 100 m3/hr). During exposure they will perform an intermittent bicycle ergometer activity at 50 W for 10 minutes alternating with 20 minutes rest."
41468578|NCT06035276|OTHER|Exposure to urban air|"Subjects will be brought to a traffic dense urban region (urban air) with high traffic density and increased levels of particulate matter and vehicle emissions. Subjects will stay in this area for 4 hours. During exposure, all subjects will walk together with study staff. Rest periods are only allowed outside. Intervals of activity and rest will be similar to the clean air regimen."
41468579|NCT01853371|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin. In this study, the wet cupping procedure was not done on certain days of the lunar month.
41468580|NCT01853371|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
41468581|NCT04493476|DRUG|Chinese herbal formula|Chinese herbal formula
41468582|NCT02225106|DRUG|Methylphenidate|Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
41468583|NCT03294616|DEVICE|transcutaneous electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
41468584|NCT04823130|DRUG|Dupilumab (SAR231893)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
41468585|NCT05487768|OTHER|EEG measurement|"EEG measurement to evaluate functional connectivity in the brain during 3 motor tasks:~* Knee extension while sitting (10x left - right)~* Bipodal squatting (10x)~* Unipodal stance (5x30 seconds left-right)"
41468586|NCT01158352|DIETARY_SUPPLEMENT|Nutritional supplementation formula|Nutritional supplementation formula
41468587|NCT01158352|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
41468588|NCT00560924|DRUG|estradiol, 25 mcg|
41468589|NCT06269211|DRUG|Toripalimab|240mg IV, Q3W
41468590|NCT05900531|DRUG|K-757|administered orally
40790351|NCT04164810|OTHER|Hydrotherapy|All sessions will be done by 3 physical therapists specialized in hydrotherapy under different modalities, and a pool equipped to perform this type of intervention. The most commonly used techniques in the institution are Bad Ragaz, for motor control, and the Watsu technique for relaxation and spasticity work.
40790352|NCT04164810|OTHER|Physical Therapy|All sessions will be done by 3 physical therapists expert in neurorehabilitation, following a physical therapy protocol, which includes stretching, aerobic excercise and muscle strengthening.
40790353|NCT01721486|DRUG|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
40790354|NCT01721486|DRUG|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
41468591|NCT05900531|DRUG|K-757 and open-label sitagliptin|both administered orally
40790355|NCT03107728|DEVICE|Advanced orthotic brace|Participants will use an advanced exoskeletal orthosis.
40790356|NCT03107728|DEVICE|Conventional orthotic brace|Participants will use the standard of care orthosis
40790357|NCT05318495|DEVICE|Standard Colonoscopy|The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).
40790358|NCT05318495|DEVICE|CAD-EYE|CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.
40790359|NCT05318495|DEVICE|G-EYE|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.
40790360|NCT05866692|DRUG|TY-2699a|"TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results"
40790361|NCT05182450|OTHER|Mango leaf extract capsule|Single dose
40790362|NCT05182450|OTHER|Placebo capsule|Single dose
40790363|NCT05415553|PROCEDURE|IOBT|Surgery of inferior oblique muscle belly transposition for treatment of primary position hypertropia with inferior oblique overaction
41468592|NCT05900531|DRUG|Matching placebo to K-757|administered orally
41468593|NCT05900531|DRUG|Matching placebo to K-757 and matching placebo to K-833|both administered orally
41468594|NCT05900531|DRUG|K-757 and K-833|both administered orally
41468595|NCT05900531|DRUG|Matching placebo to K-757, open-label sitagliptin|both administered orally
41468596|NCT03727698|DEVICE|MR Linac|MR guided radiotherapy treatment
41468597|NCT01301482|DEVICE|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
40790364|NCT05415553|PROCEDURE|IO-Rec|Surgery of inferior oblique muscle recession for treatment of primary position hypertropia with inferior oblique overaction
40790365|NCT00728156|DRUG|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
40790366|NCT00728156|DRUG|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
40790367|NCT01266330|DIETARY_SUPPLEMENT|Low Dairy|Less than 0.5 standard servings of dairy products per day
40790368|NCT01266330|DIETARY_SUPPLEMENT|Adequate Dairy|3.5 standard servings of dairy foods per day
40790369|NCT01062698|DRUG|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
40790370|NCT01062698|PROCEDURE|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
40790371|NCT02718235|OTHER|Overall survival|Observation of overall and disease free survival
40790372|NCT00039169|DRUG|ortataxel|
40790373|NCT01698931|DRUG|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
40790374|NCT01698931|DRUG|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
40790375|NCT01698931|DRUG|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
40790376|NCT00295282|DRUG|MDX-1100 (anti-CXCL10 human monoclonal antibody)|Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
40994545|NCT01365273|DEVICE|Mepitel One|Dressing
41468598|NCT05010824|BEHAVIORAL|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem. The second and third session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. Follow-up phone calls provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
40790377|NCT04042454|OTHER|milk based anti-regurgitation infant formula|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
40790378|NCT04042454|OTHER|Milk based infant formula|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
40790379|NCT04276194|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo intensity modulated proton therapy
40790380|NCT04276194|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40790381|NCT06074523|BEHAVIORAL|Behavioral Measurement and self-report|Measurements of behavioral performance and self-report
40790382|NCT00355030|DRUG|somatropin|0.05 mg/kg/day
40790383|NCT00355030|DRUG|leuprorelin|11.25 mg/3 months
40994546|NCT03632187|DRUG|Abatacept|Subcutaneous abatacept every weeks during 3 months
40994547|NCT03632187|DRUG|Placebos|Subcutaneous placebo every week during 3 months
40994548|NCT00684476|DRUG|venom immunotherapy|
40994549|NCT01482039|PROCEDURE|Sequential ultrasound|Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
40994550|NCT01482039|PROCEDURE|Transvaginal ultrasound|Obtain 3 transvaginal ultrasound cervical length measurements
41148462|NCT03015753|BEHAVIORAL|Tai Chi training|The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.
40790384|NCT01908543|DRUG|Ferrous sulphate 200mg oral tablet|Administration by mouth
40790385|NCT00049322|BIOLOGICAL|bevacizumab|"Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose."
40790386|NCT02375373|OTHER|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly."
40790387|NCT04342091|DEVICE|SOL Nova Device|A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
40790388|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
40790389|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
40790390|NCT02776683|DRUG|BI 695502|
40790391|NCT02776683|DRUG|Avastin|
40790392|NCT06284239|OTHER|Tell me about the game.|It is a game played with playing cards. On the game cards, there will be the word that the narrator student must explain to his group friends and five prohibited words right below this word. Prohibited words are synonyms, antonyms or close meanings of the word to be explained. According to the game rules, the student narrator will explain the word on the cards to his group friends without using prohibited words.
41148463|NCT03015753|OTHER|Waiting list control group|At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
41468599|NCT04643392|PROCEDURE|Complex decongestive physiotherapy|Each patient received a treatment protocol of Complex decongestive physiotherapy for 5 days a week until they were discharged from the clinic. All patients fully completed all components of the treatment routine daily. The treatment was performed by a physiotherapist who was certified with Manual Lymph Drainage Combined Decongestive Physiotherapy. After the daily treatment protocol was completed, patients wore standard or individually sized compression grade II or III medical compression stockings for the rest of the day.
41468600|NCT03543709|DIAGNOSTIC_TEST|fibromyalgia 2013 criteria|Frequency of fibromyalgia will be investigated in women diagnosed with Behcet disease
41148464|NCT00606723|BIOLOGICAL|Hematopoietic stem cells from bone marrow or peripheral blood|\> = 2 x 10\*8 nucleated cells (WBC)/kg body weight of the recipient or rather \> = 4 x 10\*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
41148465|NCT04590625|DRUG|Apatinib Mesylate|apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd
41148466|NCT04590625|DRUG|Abraxane|abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1
41148467|NCT04590625|DRUG|Cis Platinum|cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1
41148468|NCT04590625|DRUG|Carboplatin|carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
41148469|NCT04248881|BEHAVIORAL|Healthy Lifestyle Education|"Healthy lifestyle information (education) is distributed to participants during the World Cancer Day Walk via brochure, lectures, and professional counseling."
41148470|NCT02962622|OTHER|High intensity interval training (HIIT)|Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol
41148471|NCT05270096|OTHER|Advice|non-interventional study
41148472|NCT02907489|OTHER|triple antibiotic paste with an anti-inflammatory drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
41148473|NCT03792945|DRUG|local injection|In addition to the local injection, carpal tunnel brace will be given.
41148474|NCT03792945|DEVICE|extracorporeal shock wave therapy|In addition to all ESWT participants, carpal tunnel brace will be given.
41309738|NCT03086200|BEHAVIORAL|brief Motivational Interviewing|"All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."
41148475|NCT00722514|BEHAVIORAL|patient education|"* complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~* Patient education 6 x 90 Minutes"
41148476|NCT00722514|BEHAVIORAL|Standard Care|"* complex individual antiinflammatory rehabilitation program during inpatient~* complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~* further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)"
41148477|NCT05940805|PROCEDURE|Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|"1. Low-frequency transcranial electrical stimulation (2/100 Hz) applied through 0.3-mm-diameter and 40-mm-long needles placed subcutaneously on the scalp at the projection of Penfield's motor homunculus and sensory and frontal supplementary motor associative areas.~2. Paraspinous block at the levels of the C5, C6 and C7 vertebrae concordant with spasticity laterality.~3. Dry needling of spastic upper limb muscles, as identified through a thorough physical examination, using 0.3-mm-diameter and 40-mm-long needles.~4. Muscular functional electrical stimulation (FES) in the antagonists of the upper limb muscles with spasticity with the following parameters: 20-Hz frequency, 300-µs pulse width, zero-second ramp time, 5-second stimulation time, and 5-second resting time."
41309739|NCT03775772|PROCEDURE|Oral Health|"* test group will receive an dental hygiene program for one year~* control group will remain with dental hygiene regime like done before study participation (maximum of two dental hygiene Treatments per year)"
41468601|NCT03543709|OTHER|Behcet's disease current activity form|Disease activity will be investigated in women with Behçet's disease without fibromyalgia.
41468602|NCT01661634|DRUG|Ularitide|
41468603|NCT01661634|DRUG|Placebo|
41468604|NCT06081140|DIETARY_SUPPLEMENT|Standard Process Hemp Oil Complex|10 days of supplementation to determine the tolerance and palatability of Standard Process Hemp Oil Complex.
41468605|NCT05125562|DRUG|ExoFlo|Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1
41468606|NCT00703131|DEVICE|Anal Fistula Plug (SurgiSIS AFP)|Anal Fistula Plug
41309740|NCT03775772|PROCEDURE|Bite Force|"* test group will receive physiotherapy with the aim of increasing muscle strength in chewing muscles for 3 months~* control group will remain without such training"
41309741|NCT00366548|BIOLOGICAL|13 valent pneumococcal conjugate vaccine with Polysorbate 80|
41468607|NCT04405739|DRUG|EIDD-2801|Oral capsule of EIDD-2801
41468608|NCT04405739|DRUG|Placebo|Oral placebo capsule
41468609|NCT03209349|PROCEDURE|Water Exchange Sigmoidoscopy|See arm description.
41468610|NCT03209349|PROCEDURE|Air Insufflation Sigmoidoscopy|See arm description.
40790393|NCT03495726|BEHAVIORAL|Headspace app|Headspace is a Contemplative Application (App) for Well-being (CAW). Participants will be provided initial instructions for downloading and using the Headspace app. The Headspace app includes guided meditations, articles and videos. Participants will be asked to engage in meditation practice for an average of 10 minutes a day during the 6-week training period.
40994551|NCT01136096|BEHAVIORAL|Physical activity promoting intervention|"1. An interview with a physiotherapist~2. An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home~3. An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model~4. The daily record to check their body weight, exercise mode and duration~5. Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details~6. Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule"
40994552|NCT01136096|BEHAVIORAL|General instruction and education|"1. Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic~2. Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule~3. Without individualized exercise program and interview with a physiotherapist"
40994553|NCT05533918|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
40994554|NCT05533918|BEHAVIORAL|Patient Navigation (PN)|"Patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation, Request PN and No PN. Each person will be randomly assigned between the two types."
40790394|NCT03843151|DRUG|BI 1358894|tablet
40994555|NCT06388395|PROCEDURE|Accuracy of full-arch surgical guides|The accuracy of the surgical guides will be assessed by superimposing the pre and post-treatment CBCT scans.
40994556|NCT06388395|PROCEDURE|Survival and complications of the prostheses|Two different prostheses will be assessed (conventional and PEEK). All complications will be recorded for a period of 3 years
40994557|NCT06388395|PROCEDURE|Survival and complications of the implants|The effect of the two different prostheses on implants will be assessed in terms of survival and success rates.
40994558|NCT06388395|PROCEDURE|Conventional (metal-resin) implant-supported prosthesis|Full-mouth implant-supported conventional prosthesis will be constructed and evaluated for up to 3 years.
40994559|NCT06388395|PROCEDURE|PEEK implant-supported prosthesis|Full-mouth implant-supported PEEK prosthesis will be constructed and evaluated for up to 3 years.
40994560|NCT02449174|BIOLOGICAL|Frozen Microbiota|Frozen Microbiota will be delivered via enema route.
40994561|NCT02449174|BIOLOGICAL|Lyophilized Microbiota|Lyophilized Microbiota will be delivered orally.
40994562|NCT02344030|DEVICE|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
40994563|NCT02344030|DEVICE|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
40994564|NCT01496092|DRUG|Keto Acid|12 tablets per day
41148478|NCT05940805|PROCEDURE|SHAM Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|For simulation of transcranial electrical stimulation and FES, electrodes were placed on the scalp and in the upper extremity muscles and were connected to a device similar to the real electric current generator. This device did not transmit any electric current but had blinking lights and produced sound to provide the subjects visual and auditory feedback. To simulate dry needling and paraspinous block, retractile needles were used.
40790395|NCT03843151|DRUG|Itraconazole|oral solution
40790396|NCT04575545|DIAGNOSTIC_TEST|Serology test for COVID-19|ELISA test
40790397|NCT01007188|OTHER|1.5PD almonds|average American diet plus 1.5 oz per day almonds
40994565|NCT03672643|DRUG|Crizotinib|receive crizotinib orally
40994566|NCT03691064|DRUG|LUTATHERA|Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie \[mCi\]) every 8 weeks for a total of 4 doses.
40994567|NCT03131336|DRUG|PeproStat|solution for local application
40994568|NCT03131336|DRUG|Saline|solution for local application
40790398|NCT01007188|OTHER|3.0PD almonds|average American diet plus 3.0 oz per day almonds
40790399|NCT01007188|OTHER|Base (without almonds)|average American diet without almonds
40790400|NCT02863393|OTHER|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
40994569|NCT02009631|DRUG|Veliparib (ABT-888)|
40994570|NCT02009631|DRUG|Placebo|
40994571|NCT05455697|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40994572|NCT05455697|DRUG|Cyclophosphamide|Given IV
40994573|NCT05455697|DRUG|Doxorubicin|Given IV
40994574|NCT05455697|DRUG|Prednisone|Given PO
40994575|NCT05455697|BIOLOGICAL|Retifanlimab|Given IV
40994576|NCT05455697|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
40994577|NCT05455697|BIOLOGICAL|Tafasitamab|Given IV
40994578|NCT05455697|DRUG|Vincristine|Given vincristine
40994579|NCT05455697|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40994580|NCT05455697|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40790401|NCT01354223|DEVICE|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
40994581|NCT05455697|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT
40994582|NCT05455697|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
40994583|NCT05455697|PROCEDURE|Computed Tomography|Undergo FDG-CT
40994584|NCT05455697|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40994585|NCT05455697|DRUG|Polatuzumab Vedotin|Given IV
40994586|NCT05619276|DEVICE|Standard serving utensil toolkit|Serving a meal using standard kitchen utensils (100% of subjects experiment with these tools first)
40994587|NCT05619276|DEVICE|Optimsed portion-control toolkit|Serving a meal using optimised, portion-control utensils (100% of subjects experiment with these tools second)
40994588|NCT00719004|PROCEDURE|Ultrasound of the foot|These volunteers will have one ultrasound scan of each foot
40790402|NCT01354223|DEVICE|ocufilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
40994589|NCT02493738|DRUG|Lozanoc 50mg|Lozanoc 50mg single dose under fed and fasted condition
40994590|NCT02493738|DRUG|Sporanox 100mg|Sporanox 100mg single dose under fed condition
40994591|NCT04851886|DEVICE|BURT|Robot-assisted upper-limb individual (i.e. one-on-one) rehabilitation will be delivered using the BURT system by Barrett Technology
40994592|NCT04851886|DEVICE|BURT + PostureCheck|Robot-assisted upper-limb group (i.e. up to three subjects) rehabilitation will be delivered using the BURT system by Barrett Technology + PostureChek (a camera-based system to track the quality of the exercises)
40994593|NCT02730572|DRUG|Concerta|This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.
40994594|NCT02730572|DRUG|Concerta AG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
40994595|NCT02730572|DRUG|Concerta EG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
40994596|NCT00005926|DRUG|Gemcitabine|
40994597|NCT00005926|DRUG|Herceptin|
40994598|NCT00005926|PROCEDURE|Radiation therapy|
40994599|NCT00464568|DRUG|GSK256066|
40994600|NCT00980395|DRUG|rituximab|375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
40994601|NCT00980395|DRUG|bortezomib|1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
41148479|NCT02552706|DIETARY_SUPPLEMENT|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
41148480|NCT02552706|DIETARY_SUPPLEMENT|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
40790403|NCT01102491|DRUG|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
40790404|NCT00711152|OTHER|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
41148481|NCT06240806|OTHER|Manuka Honey|Manuka honey will be topically applied to the oral mucosa as oral rinse based on the Biswal et al., 2003 administration protocol.
41148482|NCT06240806|OTHER|Saline mouthwash|Saline mouthwash will be used 3 times per day for one month
41148483|NCT04194671|BIOLOGICAL|Mesenchymal stem cells|In experimental group, patients receive standard treatment and allogeneic human umbilical cord derived-mesenchymal stem cells (MSCs) is administered via intravenous infusion on day 0 and day 7
40994602|NCT00980395|DRUG|cladribine|4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
40994603|NCT01140321|DRUG|Neridronate|"Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication Osteogenesis Imperfecta."
40790405|NCT00711152|OTHER|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
40994604|NCT00590109|OTHER|Blood test|subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.
40994605|NCT00590109|OTHER|Questionnaire|A questionnaire encompassing medical, environmental exposure, and reproductive history.
40994606|NCT05287633|DRUG|Esomeprazole|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
40994607|NCT05287633|DRUG|Placebo|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
40994608|NCT03329690|DRUG|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
40994609|NCT03329690|DRUG|Physician's Choice|"Either:~Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)~Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)"
40994610|NCT06072651|BEHAVIORAL|Relative Reinforcing Value of Food|Researcher gives child opportunity to press a button to earn three types of rewards: a high-reward food, a low-reward food, and a non-food reward.
40994611|NCT04159233|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Participants will receive evidence-based 'Brief Behavioral Therapy for Insomnia' (BBTI), tailored to meet the needs of former football players. BBTi is a brief, efficacious treatment that focuses on modifying behaviors, rather than cognitive domains. The treatment emphasizes education, motivational tools, and specific behavioral recommendations (e.g., restricting time in bed) and will be administered through weekly phone calls with a trained sleep interventionist over 4-weeks.
40994612|NCT05109663|DRUG|SKLB1028|SKLB1028, capsule, oral
40994613|NCT03171454|PROCEDURE|Delayed Intrauterine Balloon therapy|D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
41309742|NCT00366548|BIOLOGICAL|13 valent pneumococcal conjugate vaccine without Polysorbate 80|
40790406|NCT00700622|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder 15U or 30U
40790407|NCT00700622|DRUG|Insulin glargine|Lantus-injectible supplied as 3mL (300 units) pens
40790408|NCT00700622|DRUG|Insulin lispro|Humalog autopen cartridges pre-filled with 3mL (300 units)
40790409|NCT02130674|DRUG|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
40790410|NCT01349205|DRUG|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
40994614|NCT03171454|PROCEDURE|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
40994615|NCT02859233|OTHER|Lack of hyperhydration|
40790411|NCT01349205|DRUG|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
40790412|NCT01349205|DRUG|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
40790413|NCT06374888|DRUG|Neratinib maleate in combination with capecitabine|Neratinib maleate tablets，Tablets, 40mg/ tablet, 180 tablets/bottle, orally, 240mg once daily, sealed, stored not above 25℃
40790414|NCT00976716|DRUG|Celecoxib|"Day 1~* The first dose: Celecoxib 400mg~* The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~- Celecoxib 200mg twice daily"
40790415|NCT00644943|DRUG|cefdinir (Omnicef)|oral suspension (7 mg/kg, ql2hr) for 5 days
40790416|NCT00644943|DRUG|amoxicillin|oral suspension (45 mg/kg/day, q l2 hours) for 10 days
40790417|NCT06425510|BEHAVIORAL|Viviendo las Ventajas de la Asistencia Tecnológica|It comprises 2-hours small group sessions of 8-10 participants, once a week, for six weeks of participatory discussions, experiential learning, multimodal instructions, and demonstration and practice with selected ATDs. The content of the VIVE-AT weekly sessions is as follows: Week 1 - Introduction to ATDs, funding and resources; Week 2 - ATDs for self-care and toilet use; Week 3 - ATDs for mobility; Week 4 - ATDs for dressing; Week 6 - ATDs for cooking and home tasks. Each session is designed with the following components: monitoring of participants\&#39; weekly goals, providing information on ATDs, resources, and services, reflection on the advantages and disadvantages of using these ATDs, hands-on practice with selected ATDs, goal setting, and addressing barriers to using ATDs. Group sessions will incorporate visual aids, including modeling and videos of older individuals using ATDs accessed through an AT web app in a tablet provided by this project.
40790418|NCT06425510|OTHER|Attention calls|Ten minutes attention calls, once a week for six weeks to the waitlist control participants will offer general health advice on topics like nutrition, exercise, sleep, stress, and social connections. These calls emphasize participant well-being without touching upon the specific VIVE-AT content, maintaining a clear distinction from the intervention group.
40790419|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula A|
40790420|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets|
40790421|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula B|
40994616|NCT02417012|BEHAVIORAL|U-TURN|Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
41148484|NCT04194671|OTHER|Saline|In placebo control group, patients receive standard treatment and saline is administered via intravenous infusion on day 0 and day 7
41148485|NCT00993278|DIETARY_SUPPLEMENT|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
41148486|NCT00993278|DIETARY_SUPPLEMENT|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
41148487|NCT04167150|DIETARY_SUPPLEMENT|tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)|Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.
40790422|NCT04677543|DRUG|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes.
40790423|NCT04677543|DRUG|Azithromycin|Oral tablet
40790424|NCT04677543|DRUG|Ethambutol|Oral tablet
40790425|NCT04677543|DRUG|ELC|Inhalation via nebulization over approximately 6 to 15 minutes.
40790426|NCT02822053|PROCEDURE|US-guided laser ablation for refractory neoplasms|
40790427|NCT03461939|OTHER|ePRIME symptom monitoring tool|ePRIME is an online system for patients to self-report symptoms and AE during cancer treatment. ePRIME allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating notifications for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
40790428|NCT00000763|DRUG|TNP-470|
40790429|NCT05135598|OTHER|Partners for Life health behavior change program|A health behavior change intervention based on partner learning, utilizing low-tech media and a workbook.
40790430|NCT03762161|DRUG|TAS 102|Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
40790431|NCT06085235|BEHAVIORAL|exercise|cycling exercise for 15min, with 5min warm up
40790432|NCT02789085|DEVICE|ULF TENS stimulation|
40790433|NCT03455894|DEVICE|DETECT'CHUTE CLINIBED|The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
40790434|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Completed at Week 1. Initial meditation exercises will be described and practiced to train attention skills (on breath) and create mental stability.
40994617|NCT02417012|BEHAVIORAL|Standard care|Standard individual diabetes support
40994618|NCT01434238|OTHER|Counseling and nutrition supplement|24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
40994619|NCT03133156|OTHER|Exercise Intervention|10-Week Aerobic Exercise Training
41148488|NCT00755794|DRUG|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
40994620|NCT00821470|PROCEDURE|core decompression|core decompression procedure only
40994621|NCT00821470|PROCEDURE|Bone marrow implantation into the necrotic lesion|
40994622|NCT04398069|PROCEDURE|hemodynamic optimisation aiming to achieve normal cerebral perfusion|hemodynamic optimisation aiming to achieve normal cerebral perfusion: titration of catecholamin infusion.
40994623|NCT02246673|DRUG|RDEA3170 15 mg|
40994624|NCT02246673|DRUG|RDEA3170 10 mg|
40994625|NCT02246673|DRUG|RDEA3170 2.5|
40994626|NCT02246673|DRUG|RDEA3170 5 mg|
40994627|NCT02246673|DRUG|Febuxostat 40 mg|
40994628|NCT02246673|DRUG|Febuxostat 80 mg|
40994629|NCT01769040|DRUG|Rifaximin|550 mg two times daily for 28 days
40994630|NCT01769040|DRUG|placebo|
40994631|NCT03997656|BEHAVIORAL|MyDiPP (Malaysia Diabetes Prevention Program)|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
40994632|NCT03997656|OTHER|usual care|standard health education from primary care providers in the clinic
41468611|NCT05311761|OTHER|CogMe Personal Assistant (PA)|Twice a day, in the morning and evening, the electronic tablet with the CogMe PA will be given to the patient by the research assistant. Patients will be asked to respond to a short question and answer (Q\&A) session of approximately 5-10 minutes duration. This intervention will continue throughout the hospitalization period, estimated at approximately 5 days.
41468612|NCT02868541|OTHER|Naso pharyngeal swab|Naso pharyngeal swab
40994633|NCT06036420|DEVICE|Flashed Light Therapy|Light flashes will be presented over 60 minutes as 3-millilisecond flashes of white light at 4,000 lux every 20 seconds
40994634|NCT06036420|BEHAVIORAL|Videoconference-delivered Cognitive Behavioral Therapy|Treatment will involve psychoeducation on sleep, circadian rhythms and light exposure, motivational interviewing, advancing of bedtime schedule, time management and coping with poor sleep, sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring for worry.
40994635|NCT06284226|DRUG|Allogeneic NK（CCT-ANK-11)|allogeneic natural killer cells
40994636|NCT01028157|BEHAVIORAL|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
41468613|NCT03060850|DRUG|AC0010MA|Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
40994637|NCT01028157|BEHAVIORAL|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
40994638|NCT05887882|BIOLOGICAL|Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells|The TGFβi NK cell product will be manufactured in the Cell Therapy Laboratory at Nationwide Children's Hospital and given via infusion.
40994639|NCT05887882|PROCEDURE|Implantation|Undergo placement of Ommaya reservoir
40994640|NCT05887882|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
41468614|NCT05787379|BEHAVIORAL|Concordant Care Training|Concordant Care training has four components. 1. Clinicians will complete \~3 hours of online, asynchronous training that will teach them practices including validate Veterans' experiences with Long-COVID, develop shared understanding with patients about Long-COVID, and develop patient-centered action plans. Clinicians will be provided with handouts, case examples, video demonstrations, and practice exercises to help them integrate these practices into care. 2. Tele-mentoring groups will be offered \~bi-weekly and be open to all clinician participant in the Concordant Training arm. Content will include review of specific cases, didactics on specific Concordant Care practices, role-play exercises, and review of session recordings. At least two sessions are required. 3. Clinician Pocket Card that serves as a reminder of the Concordant Care process. 4. An electronic prompt will be sent to enrolled Veterans encouraging them to speak with their clinician about their Long-COVID concerns.
40994641|NCT05887882|OTHER|Quality-of-Life Assessment|Ancillary studies
40994642|NCT03087968|DRUG|GS-4997|Experimental drug
40994643|NCT03087968|DRUG|Prednisolone|Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
40994644|NCT03087968|DEVICE|HepQuant SHUNT Test|"The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.~For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples."
40994645|NCT03087968|DRUG|Placebo|Placebo
40994646|NCT02838056|DRUG|epidural injection|drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
40994647|NCT04665050|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
40994648|NCT04665050|BIOLOGICAL|PNEUMOVAX™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
41148489|NCT03095378|PROCEDURE|Control|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with scaling and root planing
40994649|NCT02801942|PROCEDURE|Inguinal lymph node fine needle aspirate biopsy|Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
40994650|NCT02801942|PROCEDURE|Inguinal lymph node core biopsy|Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
40994651|NCT02801942|PROCEDURE|Peripheral blood collection|Blood sample (30 mL) will be collected, to derive immune cells.
40994652|NCT02801942|OTHER|Pre- and post-biopsy questionnaire|All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
40994653|NCT04500184|OTHER|cardiac rehabilitation|rehabilitation performed by professional trainers
40994654|NCT03903354|OTHER|Incidence of infections within 7 days postoperatively|Measure blood glucose concentration intraoperatively and evaluate incidence of infections 7 days after surgery
41468615|NCT05787379|BEHAVIORAL|Education Packet Training|Clinicians randomized to the control arm will receive a comprehensive information packet with the latest understanding of Long-COVID. Clinicians will also be provided a packet directing them to relevant VA trainings for Long-COVID. Whole Health trainings which focus on wholistic integrated approaches to care will be highlighted. Whole Health is important for all Veterans, and it is thought to be particularly relevant for poorly understood conditions that don't easily fit in traditional medical model.
40790435|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Completed at Week 2. Exercises to develop mindfulness will continue in order to promote mental stability and clarity.
40790436|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Self-compassion|Completed at Week 3: Techniques to analyze mental processes are introduced.
40790437|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Equanimity|Completed at Week 4. Further analysis of mental processes.
40790438|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Completed at Week 5. A reflection of all the things that bring us well-being are provided by or dependent upon other beings is encouraged.
40994655|NCT01329640|DEVICE|Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide|"1. Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;~2. Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks"
40994656|NCT03147365|BEHAVIORAL|Aerobic exercises|Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).
40994657|NCT03147365|BEHAVIORAL|Modified strength training|Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
41148490|NCT03095378|PROCEDURE|citric acid plus tetracycline|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with citric acid plus tetracycline
41468616|NCT00891423|DRUG|Meropenem short infusion|
40790439|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Affection and Empathy|Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.
40790440|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.
40790441|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Active Compassion|Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.
40790442|NCT02574559|BEHAVIORAL|Meditation Session|20 minute session completed weekly after the Cognitive Training Session
41148491|NCT03095378|PROCEDURE|antimicrobial photodynamic therapy|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with antimicrobial photodynamic therapy
41148492|NCT03180086|OTHER|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
41148493|NCT01180400|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
41148494|NCT01180400|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
41468617|NCT00891423|DRUG|Meropenem extended infusion|
41468618|NCT01497119|DRUG|JNJ-39758979, 300 mg|Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
41468619|NCT01497119|DRUG|JNJ-39758979, 100 mg|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
41468620|NCT01497119|DRUG|Placebo|Form=tablet, route=oral use, once daily for 6 weeks.
41468621|NCT02012452|BEHAVIORAL|Tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
41468622|NCT02012452|BEHAVIORAL|Health Education|Participants will be provided education on a variety of health topics and will set health goals around each topic
41468623|NCT05164913|OTHER|Achenbach Child Behavior Checklist （CBCL）scale|Use the Achenbach Child Behavior Checklist （CBCL）scale to assess children's behavior
40790443|NCT00331916|DRUG|quinolone|
40790444|NCT06450015|DEVICE|Vacuum Assisted Closure|VAC applied after debridement and saline packing
40994658|NCT06091280|DEVICE|Respiratory Muscle Strength Trainers|Devices provided to each participant. Resistance loading set at less than 50% of the peak inspiratory and peak expiratory flow rate.
40994659|NCT02162290|OTHER|Interval exercise training|Exercise bouts in low and high intensities
40994660|NCT02162290|OTHER|Continuous exercise training|
40994661|NCT01039896|DRUG|Period I : SLM0807, Period II : HKB0701 and SLM0807|
40994662|NCT01039896|DRUG|Period I : HKB0710 and SLM0807, Period II : SLM0807|
40994663|NCT04295421|PROCEDURE|adductor canal block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
40994664|NCT04295421|PROCEDURE|IPACK block|IPACK block was realized after spinal anesthesia with 40 ml 0.2% ropivacaine and at the end of surgery , patients were given ACB with 20 ml 0.2% ropivacaine and continued with 4 ml/H saline for 48H
40994665|NCT03624712|DIAGNOSTIC_TEST|uterine neoplasms|Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection
40994666|NCT03046199|OTHER|Questionnaire|Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
40994667|NCT03046199|OTHER|Coordination|Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
40994668|NCT00000533|BEHAVIORAL|social support|
41148495|NCT00965471|DRUG|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
41148496|NCT00965471|DRUG|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
41148497|NCT05621096|RADIATION|Bridging radiation therapy|Days -20 to -7: Patients will receive 2 fractions of 2 gray (Gy) for a total of 4 Gy received.
41148498|NCT05621096|BIOLOGICAL|Liso-cel|"Day 0: Patients will receive an infusion of liso-cel CAR T-cell product.~Prior to the liso-cell infusion (Days -5 to -3), patients will receive lymphodepleting chemotherapy using fludarabine 30mg/m2 and cyclophosphamide 300mg/m2 per institutional standard procedures."
41148499|NCT05621096|RADIATION|Post-infusion radiation|Days 30 to 80: Patients eligible for post-infusion radiation will receive a total dose of up to 32 Gy.
40994669|NCT04149600|PROCEDURE|Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.|Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.
41468624|NCT04735107|PROCEDURE|colorectal anastomosis reinforcement and trans-anal drainage|Circular mucosal flap created to cover stapled anastomosis + vacuum sponge drainage
41309743|NCT02878733|DRUG|Albumin|patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
41309744|NCT05912855|DEVICE|qNOX|Non
41309745|NCT05526794|PROCEDURE|Analgesic consumption|1 gr iv paracetamol for all patients with a VAS value of 2 or 3; for 4 and over, 1.5 mg/kg iv tramadol was administered additionally.
41309746|NCT06316882|DIAGNOSTIC_TEST|Screening endoscopy|We perform upper endoscopy, when the patient authorizes it, during their screening colonoscopy
41309747|NCT00218855|DRUG|thalidomide|tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
40994670|NCT03034954|DEVICE|Active HD-tDCS|Participants will receive active HD-tDCS at 3mA for 20 minutes
40994671|NCT03034954|DEVICE|Sham HD-tDCS|Participants will receive sham HD-tDCS
41309748|NCT00218855|DRUG|placebo|100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
41468625|NCT06615921|OTHER|No Intervention|This is a non-interventional study.
41468626|NCT01956487|DRUG|Propafenone|Comparison of drug from 2 manufacturing sites
40994672|NCT05793528|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|The patients are positioned prone. The injection site is cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) is applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle is inserted just below the pedicle. It is advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position is confirmed through a lateral view. Using lateral views, the needle is placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) is given and the distribution pattern is visualized. Once the epidural distribution of the contrast agent is confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 1 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride is injected.
41148500|NCT00045201|DRUG|Erlotinib Hydrochloride|Given orally
41148501|NCT00045201|DRUG|Irinotecan Hydrochloride|Given IV
41148502|NCT02869308|DRUG|stannous pyrophosphate|Injection of 1ml Angiocis
41148503|NCT02869308|DRUG|Technetium-99m|Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
41148504|NCT02869308|DEVICE|E-CAM Camera|Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
41148505|NCT02869308|DEVICE|CZT Semiconductor Camera (D-SPECT)|Acquisition of images of angioscintigraphy with D-SPECT camera
41309749|NCT06530602|OTHER|3 D SPA (shoulder complex pain alignment) Moblization|3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
41309750|NCT06530602|OTHER|Shoulder Moblization (KaltenBorn)|3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
41468627|NCT01007019|DRUG|YH4808 30mg|YH4808 30mg (single dose)
41468628|NCT01007019|DRUG|YH4808 50mg|YH4808 50mg (single dose)
41468629|NCT01007019|DRUG|YH4808 100mg|YH4808 100mg (single dose)
40994673|NCT05793528|PROCEDURE|Ultrasound Guided Transforaminal Epidural Steroid Injection|The patients are positioned prone placed. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a low-frequency convex ultrasound probe. The lateral edge of the relevant vertebral lamina is visualized by sonographic scanning in the horizontal plane. Local anesthesia is applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle is advanced to the lateral edge of the relevant vertebral lamina under ultrasound image guidance. Then, anteroposterior imaging is performed with fluoroscopy to confirm needle localization when the lamina margin is reached, and the needle is guided into the foramen under the guidance of fluoroscopy. The contrast agent is given and the distribution pattern is visualized. Once the epidural distribution of the contrast agent is confirmed without vascular flow, a mixture of 2 mL of dexamethasone, 1 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride is injected.
41148506|NCT05076578|DEVICE|Autologous Regeneration of Tissue (ARTTM) system|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
41148507|NCT03406299|DRUG|Tegafur|Tegafur(S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day)
41309751|NCT01465698|BEHAVIORAL|Exercise|"The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.~The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study"
41309752|NCT01465698|BEHAVIORAL|Counseling|Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.
41309753|NCT01465698|BEHAVIORAL|Exercise and counseling|Participants take part in both exercise and counseling as described in the separate interventions.
40994674|NCT00022828|DEVICE|3-D Laser Imaging Device|
40994675|NCT03663283|DRUG|Liposomal Bupivacaine|Interscalene Nerve Blocks
40994676|NCT03663283|DRUG|Bupivacaine Hydrochloride|Interscalene Nerve Blocks
41309754|NCT01465698|OTHER|Control group|Participants in the control group take part only in measurements of NURSE-RCT.
41309755|NCT01212172|DEVICE|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
40994677|NCT05102110|DIAGNOSTIC_TEST|Oricol Test|Assessment of rectal mucus for material from aero-digestive cancers.
41309756|NCT01212172|DEVICE|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
41309757|NCT02467387|DRUG|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
41309758|NCT02467387|DRUG|Lactated Ringer's Solution|One time infusion 1.5mL/kg
41309759|NCT02458157|DRUG|Furosemide (Furix)|"* Loading dose: 40 mg I.V.~* Infusion rate 40 mg/h~* Continued until neutral cumulative fluid balance is achieved (the overall treatment goal) or average negative fluid balance is below 1 ml/kg/h for 8 hours."
41148508|NCT03406299|DRUG|Leucovorin|Leucovorin 30 mg/b.i.d., day 1-7
41468630|NCT01007019|DRUG|YH4808 200mg|YH4808 200mg (single dose)
40994678|NCT03568357|PROCEDURE|Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in conservative group was increased at increments of 0.1 per minute to reach an FiO2 target of 40% that was adjusted to maintain an arterial PO2 in the range of 250 mm Hg or less during the bypass, while FiO2 in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 80% adjusted to maintain PO2 in the range of 300 mm Hg or more, on the basis of arterial PO2 level measured via a point of care blood gas analyzer.
41468631|NCT01007019|DRUG|YH4808|YH4808 400mg (single dose)
41148509|NCT03406299|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1
41468632|NCT01007019|DRUG|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
41468633|NCT01007019|DRUG|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
41468634|NCT01007019|DRUG|YH4808 600mg|YH4808 600mg
41468635|NCT01007019|DRUG|YH4808 800mg (single dose)|YH4808 800mg (single dose)
41468636|NCT01007019|DRUG|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
40790445|NCT06450015|OTHER|Saline Dressing|Wound was managed by saline dressing
41468637|NCT01007019|DRUG|Placebo|10 volunteers will be administered matched placebo.
41468638|NCT01007019|DRUG|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
40790446|NCT02032576|DEVICE|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
40823073|NCT06478797|OTHER|Fluid|Sepsis will be treated with standardized therapy protocol, where participants receive fluids (balanced or non-balanced crystalloids, or colloids) to be resuscitated. Specifically, they will receive 40-60 ml/kg of fluids before the initiation of inotropes.
40994679|NCT03759561|PROCEDURE|intubation with videolaryngoscope vs fiberoptic bronchoscope|Tracheal intubation was performed using either videolaryngoscope or fiberoptic bronchoscope under cervical collar application according to the group allocations
40994680|NCT03278964|PROCEDURE|Orbital decompression|
40994681|NCT01133184|BIOLOGICAL|Sci B vac|Sci B vac
40994682|NCT01024907|RADIATION|proton beam radiation therapy|Undergo radiation
40994683|NCT01024907|PROCEDURE|quality-of-life assessment|Ancillary study
40994684|NCT01024907|OTHER|questionnaire administration|Ancillary study
40994685|NCT03418909|PROCEDURE|Primary Trans Oral Robotic Surgery (TORS)|In the absence of severe mobidity patients with early stage disease (T1-2, N1, M0) were offered TORS, as an alternative to the standard of care (radiotherapy).
40994686|NCT03418909|RADIATION|Radio(chemo)therapy|As the standard of care radiotherapy was offered to all of the patients. Patients that qualified for both TORS and radiotherapy were free to choose between the two.
40994687|NCT03653936|DEVICE|HITT device|Rebion has developed a noninvasive, handheld device that uses retinal polarization scanning (RPS) to rapidly assess eye fixation and retinal integrity in adults and children. RPS can automatically detect the fixation of the human eye with proprietary technology that uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. RPS requires no calibration or imaging, and eye movement recordings are not required. The HITT device is a repurposed Pediatric Vision Scanner (PVS), Rebion's first commercial product which has passed all applicable safety and performance standards.
40994688|NCT05805761|PROCEDURE|Conventional Treatment|A bicarbonate jet will be used to remove the biofilm from the surface of the teeth.
40994689|NCT05805761|PROCEDURE|Antimicrobial Photodynamic Therapy|aPDT will be performed before each cleaning/prophylaxis session, only in one of the groups. Participants will swish with the photosensitizer erythrosine for 1 min of pre-irradiation time, so that the drug can stain all the bacterial biofilm. The D-2000 LED (DMC) will be applied, emitting at a wavelength of ʎ = 430-490 nm and 900-1100 mW/cm2. Irradiation will be performed until the biofilm of the cervical region is illuminated for 2 min per point. Each irradiation point will be approximately 0.4 cm2.
40994690|NCT05563064|DRUG|Karika Syrup|To evaluate the effects of Karika syrup on complete blood count specifically thrombocytes (platelets) collected from blood samples of patients after treatment of 15 days long period.
40994691|NCT04839094|DIAGNOSTIC_TEST|rapid antigen testing versus RT-PCR|Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19 hospitalized patients.
41148510|NCT03406299|DRUG|Gemcitabine|"Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin. in SLOG arm.~Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 ，in GC arm"
41148511|NCT03406299|DRUG|Cisplatin|Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
40994692|NCT01970839|DEVICE|tourniquet, sensory nerve conduction abnormality|
40994693|NCT00477672|DRUG|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
40994694|NCT00477672|DRUG|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
40994695|NCT00477672|DRUG|Placebo|tablet, once daily by mouth, 6 weeks
40994696|NCT00598663|DEVICE|insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|6 months of pump plus continuous glucose sensing in conjunction to SMBG
41148512|NCT05940649|PROCEDURE|Continuous norepinephrine administration|In patients randomized to continuous norepinephrine administration, hypotension (= mean arterial pressure \< 65mmHg) will be treated with continuous norepinephrine infusion. The norepinephrine perfusion line will be connected to the saline infusion line using a three-way valve. Treating anesthesiologists will be free to reduce or increase the norepinephrine infusion rate anytime.
41148513|NCT05507372|DRUG|Pimozide 1 MG|Dopamine Receptor Antagonist - Oral Pimozide
41148514|NCT01322347|DRUG|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
41148515|NCT01322347|DEVICE|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
40994697|NCT00598663|DEVICE|insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)|insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
40994698|NCT01475630|PROCEDURE|physical therapy|mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
40994699|NCT01475630|PROCEDURE|control|relaxation
40994700|NCT03425812|DRUG|To withdraw NSAIDs therapy|NSAIDs therapy will be withdrew after washout period.
40994701|NCT03425812|DRUG|To continue NSAIDs therapy|NSAIDs therapy will be continued.
41148516|NCT02233075|DRUG|REP 2139-Ca + Pegasys (TM)|15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
40994702|NCT04211701|PROCEDURE|Connective Tissue Massage|Connective tissue massage (CTM) will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions. Three to five pulling will be applied during massage. The treatment will be administered for four weeks, five days a week.
41309760|NCT02458157|OTHER|Continuous renal replacement therapy (CRRT)|"* Initiated in case of contraindications or inadequate effect of furosemide.~* Fluid removal is started at 2 ml/kg/h~* The efficacy is evaluated 3 times daily and removal rate increased by 0.5 ml/kg/h if the therapeutic goal is not achieved"
41309761|NCT02458157|OTHER|Resuscitation|"The physiologic response to fluid removal is monitored with three variables indicating inadequate circulation. These are:~* Mottling beyond the edge of kneecaps~* Hypotension (MAP \< 50) resistant to inotropes and vasopressors~* Plasma lactate ≥ 4 mmol/l~Mottling and MAP are monitored continuously and lactate is measured routinely 4-6 times each day and on clinical indication. If one or more variable is present:~1. Fluid removal is paused~2. A crystalloid fluid bolus of 250-500 ml is given~3. Circulatory status is reevaluated within 30 minutes~4. Step 1-3 is repeated until signs of inadequate circulation have been resolved for minimum 1 hour~5. Fluid removal is restarted in 25% reduced dose for minimum 4 hours before evaluation of effect."
41309762|NCT02458157|OTHER|Usual Care|"All interventions are performed at the discretion of the treating physician apart from initiation of renal replacement therapy which is discouraged unless one or more of the following criteria are met:~* Hyperkalaemia (p-K+ \> 6 mmol/l)~* Severe metabolic acidosis attributable to AKI (pH \< 7.25 and standard base excess \< -10 mmol/l) resistant to IV bicarbonate infusion~* Severe respiratory failure with PaO2/FiO2 \< 13 kPa and bilateral infiltrates/oedema on the chest x-ray.~* Progressive azotaemia and a blood urea nitrogen (BUN) \> 25 mmol/l."
41309763|NCT03996434|DRUG|Gonadotropin|withholding gonadotropin administration for at least 24 hours
41309764|NCT03996434|DRUG|Antagonist|Cetrorelix acetate 0.25 mg
41309765|NCT03935087|DIAGNOSTIC_TEST|two-dimensional echocardiogram|two-dimensional echocardiogram with evaluation of left ventricle volumes and of left ventricular ejection fraction
41309766|NCT00931580|DIETARY_SUPPLEMENT|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
41309767|NCT00673478|DRUG|Tiotropium+Salmeterol|
41468639|NCT04763278|DEVICE|Point Digit|The Point Digit partial hand prosthetic system consists of 1-4 ratcheting mechanical digits and a mounting bracket
40994703|NCT04211701|PROCEDURE|Classical Massage|Classic massage (CM) will be applied to the lower back and upper back while the patient is lying in the prone position. Three stroking will be applied during massage.The treatment will be administered for four weeks, five days a week.
40994704|NCT02270164|DIETARY_SUPPLEMENT|Artichoke Leaf Extract|Capsule
40994705|NCT02270164|OTHER|Placebo|Capsule
41468640|NCT05108506|BEHAVIORAL|No Strict need to void following surgery|Certain patient will be randomized without a strict need to void prior to discharge following surgery.
41468641|NCT05108506|BEHAVIORAL|Strict need to void following surgery|Certain patient will be randomized with a strict need to void prior to discharge following surgery.
41468642|NCT00176930|BIOLOGICAL|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
40823074|NCT06478797|DRUG|Adrenalin|Sepsis will be treated with early inotropes, where participants will receive adrenaline at a dose of 0.05 - 0.1 mcg/kg/min via peripheral intravenous, intraosseous, or central venous routes after the first fluid bolus of 20 ml/kg
40994706|NCT02073279|DRUG|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
40994707|NCT02073279|DRUG|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
40994708|NCT02338869|BEHAVIORAL|Dialogue-based psychosocial rehabilitation|
40994709|NCT04069156|DEVICE|LVAD Implant|Subjects will undergo Heartmate 3 LVAD implant prior to randomization
40994710|NCT04069156|DRUG|Aspirin 100mg|Subjects will be randomized to either Placebo or Aspirin post implant.
40994711|NCT04069156|DRUG|Placebo oral tablet|Subjects will be randomized to either Placebo or Aspirin post implant
40994712|NCT05686213|BEHAVIORAL|combined aerobic exercise + resistance exercise intervention (AE + RE)|The AE + RE intervention group will be offered a supervised exercise program which includes both aerobic and resistance exercise. Exercise sessions will take place twice a week with a duration of 60 minutes. The training load will be tailored to a patient's individual fitness level throughout the intervention. Patient will be asked to be physically active on an additional day in the week on their own (for at least 30 minutes at moderate intensity) according to the ACSM guidelines for patients with cancer.
41148517|NCT05248659|DRUG|Sibeprenlimab 400 mg s.c. Q4weeks|Sibeprenlimab 400 mg s.c. q 4 weeks
41148518|NCT03263117|DRUG|Sedation|"The protocol does not specify a particular combination of drugs that must be used for sedation.~The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist."
41309768|NCT00673478|DRUG|Salmeterol|
41309769|NCT00673478|DRUG|Tiotropium|
41309770|NCT01809418|DEVICE|keePAP|
41309771|NCT03771612|DRUG|Naproxen|Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)
41309772|NCT03771612|DRUG|Placebos|Half of the participants will be randomly assigned to receive a placebo pill twice daily
41309773|NCT02998424|DRUG|Propofol|Continuous infusion
41309774|NCT02998424|DEVICE|Pupillary diameter measurement|Instantaneous measure
41468643|NCT00176930|DRUG|Cyclophosphamide|60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
40994713|NCT05686213|BEHAVIORAL|Aerobic exercise prior to daily radiotherapy sessions (ExPR)|Patients in the ExPR in-hospital exercise intervention group will be offered an aerobic exercise program at moderate intensity. The exercise sessions will take place 5 days a week (only weekdays), and will have a duration of 30 minutes including a warming-up (5 min) and cooling-down (5 min). Total exercise volume will be aimed at 150 min per week. The sessions will take place within an hour before the daily radiotherapy session.
40994714|NCT02864849|DRUG|Oxaliplatin|
40994715|NCT02864849|DRUG|Capecitabine|
40994716|NCT02864849|RADIATION|Intensity modulated radiotherapy|
40994717|NCT02864849|PROCEDURE|Total mesorectal excision|
40994718|NCT01416727|OTHER|Emergency Psychiatry Immersion Course|A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
40994719|NCT01416727|OTHER|Observed SKills in the Emergency Room|For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
40994720|NCT01498458|DRUG|Pazopanib plus capecitabine|"Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~* dose level I: 400 mg~* dose level II: 600 mg~* dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level."
40994721|NCT03928951|OTHER|General practitioner reassessment of urinary infection antibiotherapy prescribed by emergency departments|Antibiotherapy will be prescribed by emergency physicians and general practitioners will be contacted 4 to 5 days later to know if antibiotherapy was modified
40994722|NCT03560531|DRUG|ZN-c5|ZN-c5 is a study drug
40994723|NCT03560531|DRUG|Palbociclib|Palbociclib (IBRANCE®) is an approved drug
40994724|NCT04990752|DRUG|ulinastatin|In the ulinastatin group, early application of ulinastatin was performed for inflammation management and organ protection before ECMO initiation.The recommended clinical routine dosage of ulinastatin is 300,000 IU, q8h (continuous administration for more than 5 days).
40994725|NCT00655967|DRUG|Acamprosate (Campral)|"During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.~Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above)."
40994726|NCT00655967|DRUG|Acamprosate|During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
41309775|NCT04742270|DEVICE|SIMEOX+ respiratory physiotherapy telecare|"Every 10 days, the patient's expert physiotherapist will contact the patient by video-transmission or telephone call for motivational reinforcement and technical support in the use of the device.~During these phone calls, a quick 3-question questionnaire will be administered to the patient to monitor events of hemoptysis, chest pain and clinical symptoms of gastroesophageal reflux disease: pyrosis.If patients report this type of event, the physiotherapist will inform the patient's physician for management at his/her discretion.~The expert physiotherapist will also conduct this sessions in order to increase the patient's motivation and compliance to the device. In order to do this, he will identify (in collaboration with the patient), the patient's difficulties and obstacles and he will try to find solutions with him."
41468644|NCT00176930|RADIATION|Total Body Irradiation|On Day -4, -3, -2, -1 total body irradiation is given twice daily.
41468645|NCT00176930|DRUG|Busulfan|When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
41468646|NCT00176930|DRUG|Equine ATG (ATGAM)|UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines
41468647|NCT00176930|BIOLOGICAL|CD4+/CD25+ cells|On days -2, patients will receive CD4+/CD25+ cells intravenously.
41309776|NCT05582811|DRUG|Dose Riociguat 2,5 or 5mg|A selective stimulator of soluble guanylate cyclase (sGC)
41309777|NCT05582811|DRUG|Riociguat|A selective stimulator of soluble guanylate cyclase (sGC)
41309778|NCT05582811|DRUG|Placebo|Placebo
41309779|NCT06270693|PROCEDURE|Endodontic treatment|Root canal treatment
41468648|NCT01325038|PROCEDURE|Isometric exercise|Isometric exercise several times/week for three months
41468649|NCT01314768|BEHAVIORAL|Brief intervention|Structured behavioural Brief intervention given by trained GPs
41468650|NCT01314768|OTHER|Business as usual|GPs to treat patient as they have until now based on best established practice
41468651|NCT01314768|OTHER|Screening and outcome evaluation only|No additional intervention
40823075|NCT05533203|BIOLOGICAL|Prodencel; an autologous dendritic cell therapeutic tumor vaccine|Subcutaneous injection, each injection point should not exceed 1ml.
40994727|NCT03581240|DRUG|eflornithine HCl|"In this study subjects without CNS disease will receive oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID~Subjects with CNS disease will receive a dose of 2500 mg/m2/dose BID in order to facilitate crossing into the CNS."
40994728|NCT03467087|DEVICE|Myopuls 2000D|Device: Myopuls 2000D (Curatec Services GmBH, 47443 Moers, Germany)
40994729|NCT01816893|OTHER|Hypoglycemic hyperinsulinemic clamp|
40994730|NCT01816893|OTHER|Euglycemic hyperinsulinemic clamp|
41468652|NCT01314768|OTHER|Screening and outcome evaluation only|No additional intervention
41468653|NCT04061577|DEVICE|Transcranial Direct Current Stimulation (tDCS)|20 minutes of Cathodal tDCS after +/- before endovascular thrombectomy (EVT)
41468654|NCT05050227|BEHAVIORAL|cCBT Enhanced Collaborative Care|"Computerized CBT (cCBT) will be delivered supported by a depression care manger who will facilitate access to cCBT, promote and monitor cCBT use, reinforce CBT concepts (during outside CBT session homework), and monitor mental health symptoms for each participant."
41468655|NCT05050227|BEHAVIORAL|Usual Care|Primary Care Provider supported usual care typically includes medication prescription and referrals to specialty mental health, including Primary Care - Mental Health Integration services.
41468656|NCT01363063|DRUG|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
41468657|NCT01363063|DRUG|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
41468658|NCT04487899|DEVICE|Analysis of heart rate variability|The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).
41468659|NCT01915940|DRUG|Bimatoprost|Bimatoprost ocular insert
41468660|NCT01915940|DRUG|Timolol 0.5%|Timolol 0.5% solution
40994731|NCT00453999|DRUG|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
40994732|NCT00453999|DRUG|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
41309780|NCT01503476|DEVICE|Bravo® pH Monitoring System|Bravo pH monitoring
41468661|NCT01915940|DRUG|Placebo Eye Drops|Placebo topical eye drops
41468662|NCT01915940|DEVICE|Placebo Ocular Insert|Ocular insert without any active drug
41468663|NCT03887416|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|"The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
41468664|NCT03887416|DRUG|Placebo Oral Tablet|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
41468665|NCT04431635|DRUG|Copanlisib|Copanlisib IV: day 1, 8, 15 every 28 days
41468666|NCT04431635|DRUG|Nivolumab|Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only
41468667|NCT04431635|DRUG|Rituximab|Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
41468668|NCT03438006|OTHER|Safety data collection (following routine vaccination)|"This study assessed the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine when administered routinely according to the Prescribing Information in female Chinese subjects aged between 9 and 45 years.~The intervention consisted in the active surveillance of adverse events following immunization and pregnancy outcomes if the vaccine was administered inadvertently during pregnancy. Information of potential adverse events and pregnancy outcomes were collected at immunisation visits, telephone contacts and through spontaneous reporting by the patient/LAR/physician."
41468669|NCT02636829|OTHER|QALCIMUM questionnaire|All patients will fill out the QALCIMUM questionnaire.
40790447|NCT02548910|PROCEDURE|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
40790448|NCT02548910|DEVICE|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
40790449|NCT05529407|DEVICE|Simple Vaginal Tampon|Use of single use vaginal tampons
40790450|NCT05529407|DEVICE|Glass Vaginal Trainer|Use of glass vaginal trainers
40994733|NCT00453999|DRUG|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
40994734|NCT00259506|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|
40994735|NCT02943733|DRUG|TAS-102|Anti-metabolite agent, taken orally.
41309781|NCT01503476|DEVICE|Bravo® pH Monitoring System|Bravo pH monitoring
41309782|NCT02444819|DRUG|HM61713|HM61713 will be administered to evaluate efficacy and safety of subjects.
40994736|NCT02943733|DRUG|Temozolomide|Oral chemotherapy drug.
41309783|NCT03629392|BEHAVIORAL|Low met/cys diet|Dietary intervention with low contents of methionine and cysteine
41309784|NCT03629392|BEHAVIORAL|Moderate met/cys diet|Dietary intervention with moderate contents of methionine and cysteine
41309785|NCT03629392|BEHAVIORAL|High met/cys diet|Dietary intervention with high contents of methionine and cysteine
41468670|NCT02636829|OTHER|Determination of calcium intake by a dietician interview|"All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL \*.~\* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital."
41468671|NCT06616077|DRUG|Micronized Progesterone 600 mg|Vaginal supplementary micronized progesterone will be given after postovulatory administration of the progesterone receptor antagonist mifepristone. Administration from LH+3 to LH+5 (LH peak=LH+0); 200 mg 3 times per day.
40994737|NCT02943733|DRUG|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
40994738|NCT02943733|DRUG|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
40994739|NCT00271349|DRUG|Budesonide|
40994740|NCT02182362|DRUG|BI 201335 NA|
40994741|NCT02182362|DRUG|Placebo|
40994742|NCT01139736|DIETARY_SUPPLEMENT|VSL#3|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
40994743|NCT02993003|DEVICE|Nasopharyngeal probe|nasopharyngeal probe insertion
40994744|NCT03501095|DIAGNOSTIC_TEST|Vocal analysis and Laryngostroboscopy|"Vocal analysis study the acoustic emission of the pneumo-phono-articulatory system, i.e. the vocal signal. Currently, digital technology instruments enable the processing and analysis of the verbal signal quickly and reliably, also offering graphical products and numerical data. Among the various existing software products for the study of the vocal signal, PRAAT is available. In practice, the vocal parameters are acquired in a non-invasive way with a microphone.~Laryngostroboscopy is one of the most widely used techniques for laryngeal clinical evaluation. This is a non-invasive endoscopic practice performed by means of a flexible fibroscope, which, through a pulsed light source, allows visualization of the chordal movement."
40994745|NCT03020823|DRUG|SCB01A|intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
40994746|NCT05580341|BIOLOGICAL|Zerun HPV-9|Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris), 0.5mL, three doses, 0,2,6 months
40994747|NCT05580341|BIOLOGICAL|GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
40994748|NCT00181207|DEVICE|pneumatic vest|
40994749|NCT00181207|OTHER|placebo pneumatic vest|
40994750|NCT05409872|DIETARY_SUPPLEMENT|Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol|The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.
40994751|NCT05409872|OTHER|Placebo|The subject takes the placebo twice a day for three months.
40994752|NCT02338765|BEHAVIORAL|mHealth Physical Activity|
40994753|NCT02338765|BEHAVIORAL|Buddy-partnered exercise|
40994754|NCT05210166|DEVICE|Active tSCS and Lokomat|"A symmetrical biphasic 30 Hz current of 1 ms pulse-width with an electro-stimulator will be applied.~For the stimulation intensity, the maximum intensity tolerated by the patient will be selected. The intensity will be increased in case of habituation to the current."
40994755|NCT05210166|DEVICE|Sham tSCS and Lokomat|The protocol and device of sham tSCS combined with Lokomat will be the same as active tSCS except for the stimulus intensity, which will be set at the sensory threshold, maintained for 30 seconds and then slowly will be decreased to zero, being this intensity maintained for the remaining 20 minutes of stimulation.
41309786|NCT00982241|DIETARY_SUPPLEMENT|water|drinking water / normal dietary fluids for oral intake
41309787|NCT00912015|DRUG|Tramadol OAD|
41309788|NCT00912015|DRUG|Tramadol OAD|
41468672|NCT06616077|DRUG|mifepristone 200 mg|Post ovulatory single oral administration (LH+2, LH peak=LH+0)
41309789|NCT00912015|DRUG|Tramadol OAD|
41309790|NCT00912015|DRUG|Tramadol OAD 100mg|
41468673|NCT06616077|DRUG|Oral Placebo Tablet|Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate
41468674|NCT06616077|DRUG|Placebo Vaginal|Cocoa butter
41468675|NCT06617078|PROCEDURE|long-term oxygen therapy (LTOT)|Usual care with LTOT for 2 weeks
40994756|NCT04779255|DRUG|Procedure (Tumesent anesthesia)|Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.
40994757|NCT04779255|DRUG|Control Arm (Paracetamol)|Photodynamic therapy of vertex with 1g of paracetamol intake 1 hour before cold water is applied during the session.
40994758|NCT00563953|DRUG|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
40994759|NCT01207518|BEHAVIORAL|Intervention Group|This group of healthcare organizations will be given the Guide, web-based tools and access to a Guide facilitator throughout the study.
40994760|NCT01207518|BEHAVIORAL|Control Group|This group will provide their immunization rates for the base and study years and will provide information on their campaign activities. No other intervention will be provided.
40994761|NCT06036576|DRUG|Levothyroxine Pill|all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.
40994762|NCT03535428|DIAGNOSTIC_TEST|VENOUS exploration|venous echo doppler ultrasound and abdo pelvic scanner in the 48h before surgery
41309791|NCT05674045|DRUG|EG017 3mg|EG017 3mg/day Oral administration for 12 weeks, once daily
41309792|NCT05674045|DRUG|EG017 6mg|EG017 6mg/day Oral administration for 12 weeks, once daily
41309793|NCT03072121|DRUG|Shexiang Baoxin pill|Conventional western medicine \& shexiang baoxin pill
41309794|NCT03072121|DRUG|SBP placebo|Conventional western medicine \& placebo (for shexiang baoxin pill)
41309795|NCT03072121|DRUG|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
41309796|NCT03072121|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
40790451|NCT01177124|BEHAVIORAL|MBSR 6 Weeks Program|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program (Kabat-Zinn et al. 1985; Teasdale et al. 1995).
40790452|NCT05407207|DEVICE|Tennant Biomodulator ®|Tennant Biomodulator ® (Avazzia, Inc., Texas, USA)(FDA Classification: 882.5890 Neurology, Biofeedback device) is FDA-cleared for symptomatic relief and management of chronic pain. The device is simply activated using device buttons and does not need to be adjusted or monitored once therapy begins, making it easy for the purpose of therapy under unsupervised conditions or for use in busy HD clinics. The device will be used with FDA-cleared TENS electrodes that will be connected to the device via wires, providing an electrically conductive interface between the device and the subject's skin.
40790453|NCT06251622|OTHER|Volumetric ultrasound of the quadriceps and fitting of an accelerometer|The research procedure will simply involve a volumetric ultrasound of the quadriceps and the fitting of an accelerometer (watch worn on the wrist) for one week (collection of usual physical activities).
40790454|NCT04898478|BEHAVIORAL|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|The investigators will design a culturally grounded treatment seeking intervention for Pacific Islanders with OUDs
40790455|NCT00383071|BIOLOGICAL|H5N1 vaccine|Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.
40790456|NCT00383071|PROCEDURE|Apheresis|Once subjects achieved a high antibody titer (\>1:160), they could begin apheresis to collect plasma.
40790457|NCT02695914|DRUG|Compound Qingre Granule|A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
40790458|NCT00551083|OTHER|Computerized Decision Support System for Depression (CDSS-D)|The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR\*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
40790459|NCT00551083|OTHER|Usual Care (UC)|"Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would."
40790460|NCT00776529|OTHER|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
40790461|NCT00776529|OTHER|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
40790462|NCT05495880|PROCEDURE|Laryngoscopy with forearm-support|forearm-supported head extension during direct laryngoscopy
40790463|NCT05495880|PROCEDURE|Laryngoscopy without forearm-support|without forearm-support for head extension during direct laryngoscopy
40790464|NCT01316458|DRUG|STI571 (Glivec®)|
40790465|NCT00579969|DRUG|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
40790466|NCT00579969|DRUG|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
40994763|NCT05345639|DRUG|LRA Loco-regional anesthesia|"Bilateral parasternal block or transverse thoracic block are performed ultrasound-guided, at the end of surgery in the operating room. Once in the desired plane depending on the randomisation (transverse or parasternal), a volume of 20 ml of ropivacaine at 2 mg/ml is injected on each side of the sternum.~The intervention (TTP or PSB) is performed by the anesthetist-resuscitator investigator."
40994764|NCT05345639|PROCEDURE|Standardized post-operative analgesia protocol|"The pain management protocol in intensive care is as follows:~* paracetamol 1g x 4 per day systematically (apart from the usual contraindications), IV then PO;~* PCA (Patient Controlled Analgesia) with oxycodone or morphine: 1mg bolus, 7min refractory period, maximum 4h dose 20mg.~The PCA is usually maintained until 24-48h after the intervention then relayed by oxycodone 5mg every 4h if EVA \> 3 sublingual and addition of oxycodone LP 10mg x 2 per day if daily intake on PCA \> 20mg.~Remedy molecules in case of ineffective analgesia:~ketoprofen 100mg q12h IV, or 50mg q8h PO; nefopam 20mg every 6h IV or PO; ketamine 1 to 1.5 mg/kg/24H IVSE."
40994765|NCT04278521|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
40994766|NCT04663555|DRUG|Dexamethasone|Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. If successful extubation occurs before day 10, treatment with dexamethasone is withdrawn.
40994767|NCT04339400|DRUG|TQ05105|TQ05105 is a JAK2 inhibitor.
40994768|NCT01196546|DRUG|vildagliptin/metformin|
40994769|NCT01293240|DEVICE|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
40994770|NCT02623803|DRUG|Lidocaine|
40994771|NCT02623803|DRUG|Placebo D5W|
40994772|NCT04855864|OTHER|Follow-up of BCR TKA|Pre- and postoperative follow-up of patients treated with the BCR design by measuring PROMs, and clinical- and radiographic evaluation
40994773|NCT04855864|OTHER|Follow-up of BCS TKA|Pre- and postoperative follow-up of patients treated with the BCS design by measuring PROMs, and clinical- and radiographic evaluation
41309797|NCT03072121|DRUG|Atorvastatin Calcium|10 mg tablet, two tablets each night.
41309798|NCT03072121|DRUG|Isosorbide Mononitrate Tab 20 MG|1 tablet two times daily.
41468676|NCT06617078|PROCEDURE|High Flow Nasal Therapy (HFNT)|High Flow Nasal delivered by myAirvo3 (4 hours minimum and during th 3-minute chair rise test, 30L/min, 34°C, identical O2 flow rate as LTOT) for 2 weeks
41148519|NCT03263117|DRUG|General Anesthesia (GA)|"The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.~The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)"
41148520|NCT03263117|PROCEDURE|Intra-arterial Thrombectomy|The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.
41148521|NCT06119802|DIAGNOSTIC_TEST|atrial fibrillation|ECG of atrial fibrillation last more than 30 seconds.
41148522|NCT05634161|OTHER|Cognitive improvement software|Cognitive improvement software
41309799|NCT03072121|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
41468677|NCT02114112|OTHER|NCPAP cycling|
41468678|NCT02114112|OTHER|NCPAP continuous|
41468679|NCT02948426|BIOLOGICAL|Autologous Monocytes + ACTIMMUNE + SYLATRON|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).
40994774|NCT04855864|OTHER|Follow-up of PS TKA|Pre- and postoperative follow-up of patients treated with the PS design by measuring PROMs, and clinical- and radiographic evaluation
40994775|NCT03257553|DIAGNOSTIC_TEST|fecal calprotectin , doppler and ultrasound|faecal sample for measurement of calprotectin level ultrasound and doppler
40994776|NCT04592965|BEHAVIORAL|Clinical and neuropsychological assessments|The assessment of disease state, clinical condition, and of cognitive and neuropsychological attributes.
40994777|NCT04592965|BEHAVIORAL|Induction of PH and associated bodily states|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls
40994778|NCT04592965|OTHER|Resting-state fMRI acquisition|Investigation of neural mechanisms at rest, that are potentially disrupted at different degrees, for the different clinical groups of PD patients, compared to the healthy aged-matched controls
41148523|NCT06046976|PROCEDURE|piesosurgical extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
41148524|NCT06046976|PROCEDURE|conventional extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
41148525|NCT06431360|OTHER|hyperthermia|hyperthermia (using a heater, 44℃for 15 min)
41148526|NCT05142553|BIOLOGICAL|COVID-19 Vaccine HIPRA|Subjects will receive one injection of COVID-19 Vaccine HIPRA
41148527|NCT05142553|BIOLOGICAL|Cominarty (Pfizer-BioNtech)|Subjects will receive one injection of Cominarty Vaccine
41148528|NCT03522909|OTHER|Seen in clinic|"We will be doing a retrospective chart review of patients seen in the Center for Peripartum Optimization to look for:~1. Primary outcome variable.~   - Hospital length of stay~2. Secondary outcome variables.~   * Number of admissions from outside hospitals~  * Adverse outcomes~  * Intensive Care Unit admissions~  * Opioid use~  * NICU admissions~  * Patient satisfaction~  * Cost of inpatient admission~  * Cost of outpatient care~  * Hospital readmissions rate"
41148529|NCT00476151|DRUG|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
41148530|NCT00476151|DRUG|placebo cream|inactive placebo cream applied two times daily
41148531|NCT03741634|OTHER|Multi-sectoral agricultural intervention|Adult participants in the intervention arm receive a loan (\~$175) from a well-established Kenyan bank used to get a human-powered water pump, seeds, fertilizers and, pesticides, and education in financial management and sustainable farming practices.
41148532|NCT01783379|DRUG|micafungin|100mg/day infusion in 1 hour
41148533|NCT01002586|OTHER|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
41309800|NCT03072121|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
41309801|NCT00028002|PROCEDURE|Conventional Surgery|Undergo surgical resection
41309802|NCT00028002|DRUG|Imatinib Mesylate|Given orally
41148534|NCT01002586|OTHER|Walking exercise program|walking exercise program
41309803|NCT03019770|BEHAVIORAL|PrEP Decision Aid|All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
41148535|NCT00389285|DRUG|rIL-21 only|Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course
41309804|NCT06154031|BEHAVIORAL|Dyad learning|All participants will perform a gamified exercise using a dyad learning protocol. This means that all participants will practice the gamified exercise in pairs (dyads), for 60 minutes on two consecutive days.
41309805|NCT04397406|DRUG|levobupivacaine|The patients will receive 15 ml of 0.125% levobupivacaine.
41309806|NCT04397406|DRUG|Dexmedetomidine|The patients will receive 13 ml of 0.125% levobupivacaine and 0.5μg/kg dexmedetomidine diluted in 2 ml saline.
41468680|NCT03509571|OTHER|Ketogenic Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with ketogenic diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that will include ≈75% total energy as fat, ≈20% as protein, and ≈5% as carbohydrate and fiber.
41468681|NCT03509571|OTHER|Standard Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with SD diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
41468682|NCT05906069|BEHAVIORAL|ICBT|The intervention will consist in a structured internet-based intervention with 10 modules that will combine cognitive-behavioral techniques to improve obsessive-compulsive symptoms as well as the emotion regulation ability.
41468683|NCT05532488|DIETARY_SUPPLEMENT|Inulin 20 mg|Inulin can increase gut Bifidobacterium count. Bifidobacterium has beneficial effects on the metabolic profile and insulin resistance biomarkers.
41468684|NCT05532488|OTHER|Placebo|Placebo
41468685|NCT04791488|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy protocol
41468686|NCT04791488|PROCEDURE|Diving simulation|Hyperbaric chamber diving simulation protocol
40790467|NCT03388892|DEVICE|paclitaxel-coated balloon, IN. PACT(Invatec-Medtronic, Brescia, Italy)|Arteriovenous graft (AVG) dysfunction or acute thrombosis is mainly caused by neointimal hyperplasia. Although endovascular intervention, such as percutaneous transluminal angioplasty (PTA), catheter-based directed thrombolysis with urokinase, mechanical thrombectomy with percutaneous thrombolytic device or even if graft stenting, can salvage the hemodialysis access, the long-term primary and secondary patent rate don't improve due to repeated restenosis from neointimal hyperplasia. Drug eluting balloon is used in reducing neointimal hypoplasia in patients with coronary in-stent restenosis and it's also effective in restenosis of peripheral arterial diseases. It's reasonable to hypothesize that PTA with PCB at venous anastomotic stenosis of AVG could prolong the patency and reduce the acute thrombosis rate.
40790468|NCT03388892|DEVICE|Plain Balloon|Traditional Plain Balloon was used to dilate the venous anastomotic stenosis of arteriovenous graft (AVG) as the usual intervention
40790469|NCT02622477|DRUG|Pirfenidone|This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
40790470|NCT00525434|DEVICE|Seraffix LTB|wounds closure by using laser and albumin
40790471|NCT00886418|DRUG|muscle relaxant|muscle relaxant administration throughout anesthesia
40790472|NCT00886418|DRUG|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
40790473|NCT06004297|PROCEDURE|ACL reconstruction|performed arthroscopically
40790474|NCT03952403|DRUG|HLX10, an engineered anti-PD-1 antibody|HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
40994779|NCT04592965|OTHER|Induction of PH and associated bodily states (MRI)|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls Assessment and comparison of the neural mechanisms responsible for the induction of the PH and associated bodily illusions, in different groups of PD patients and healthy aged-matched controls
40994780|NCT03273881|DRUG|glucose solution and Insulin|"Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour."
41148536|NCT00389285|DRUG|rIL-21 + sorafenib|Part 2: rIL-21 IV, Day 1-5 and 15-19 of each 6-week treatment course + sorafenib (up to 400 mg taken orally twice daily)
41468687|NCT05559463|DIETARY_SUPPLEMENT|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
41148537|NCT00748098|DRUG|GSK1838262 Extended Release Tablets|GSK1838262 extended release tablets
41148538|NCT00748098|DRUG|Placebo|Placebo
41148539|NCT01199302|BIOLOGICAL|Brodalumab|Administered intravenously once every 4 weeks
41148540|NCT03839355|DRUG|Apixaban|Dosage either 5mg or 2.5mg for 2 years
41148541|NCT03839355|DRUG|Warfarin|Dosage assessed by your treating physician for 2 years
41309807|NCT04397406|DRUG|Fentanyl|The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
41468688|NCT00389220|DEVICE|Coronary stent placement|Coronary stent placement
41468689|NCT06148714|DIETARY_SUPPLEMENT|Provitalize Natural Menopause Probiotic|Supplement containing a Probiotic blend of Bifidobacterium breve, Lactobacillus Gasseri, and Bifidobacterium animalis subsp. Lactis.
41468690|NCT06148714|OTHER|Placebo|Placebo comparator containing Pure hydroxypropyl methylcellulose (HPmC) with food dye.
40994781|NCT03273881|DRUG|glucose solution only|Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
40994782|NCT01583335|BEHAVIORAL|Lifestyle habits, including sleep and stress|The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
40994783|NCT04722796|DEVICE|TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)|Transcatheter aortic valve replacement (TAVR) with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
40994784|NCT04722796|DEVICE|TAVR with Venus A plus using annular sizing and THV implantation technique|Transcatheter aortic valve replacement (TAVR) with Venus A plus using annular sizing and THV implantation technique (Traditional sizing strategy)
40994785|NCT01443247|DRUG|anti-d|intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
40994786|NCT01020279|DRUG|Celecoxib, Ketoprofen|"Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d."
40994787|NCT01020279|DRUG|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
40994788|NCT02346084|DRUG|Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)|"Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling)."
40994789|NCT03226262|DEVICE|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
40994790|NCT05133999|BIOLOGICAL|Plasma determination of iron, transferrin and ferritin|Iron, transferrin and ferritin levels in plasma
40994791|NCT05133999|OTHER|Fundus Examination by wide field digital imaging camera (PanocamTM camera)|ROP screening using wide field digital retinal imaging according to current recommendations.
40994792|NCT04877275|DRUG|Selinexor (80mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I：80mg/d QW ;"
40994793|NCT04877275|DRUG|Selinexor (100mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II：100mg/d QW ;"
40994794|NCT04877275|DRUG|Pegylated liposomal doxorubicin|25 mg/m\^2 intravenously on day 1 , QW
40994795|NCT04877275|DRUG|Dexamethasone|Dexamethasone 40mg/d QW
40994796|NCT04877275|DRUG|Cyclophosphamide|Cyclophosphamide：300mg/m2, d1 QW，
40994797|NCT05891483|DRUG|SHR-1905 Injection|SHR-1905 Injection
40994798|NCT05891483|DRUG|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
40994799|NCT03198741|DRUG|Aspirin + clopidogrel|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
40994800|NCT03198741|DRUG|Clopidogrel monotherapy|After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
41148542|NCT06212596|DRUG|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumour suppressor proteins (TSPs). Selinexor is an oral, first-in-class, potent, slowly reversible, covalent-binding Selective Inhibitor of Nuclear Export (SINE) compound that specifically blocks the karyopherin protein Exportin 1 (XPO1), also called chromosome region maintenance 1.
41148543|NCT06212596|DRUG|Cyclophosphamide|Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).
41148544|NCT06212596|DRUG|Prednisone|Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.
41148545|NCT00702871|DRUG|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
41468691|NCT04880226|DEVICE|Magnetic Resonance Imaging (MRI)|Ongoing evaluations of magnetic resonance imaging (MRI) using the Philips Ingenua 1.5T scanner associated with MRI-guided procedures (e.g. ablations or biopsies) are essential to continued procedure improvement within the newly-built hybrid procedure suite.
41468692|NCT01879631|PROCEDURE|radial keratotomy|
40994801|NCT03198741|DRUG|Aspirin monotherapy|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
40790475|NCT03952403|DRUG|HLX04, a bevacizumab biosimilar|HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
40790476|NCT03952403|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
40994802|NCT04713826|DRUG|BAY2586116|160 µg, nasal spray administration.
40994803|NCT04713826|DRUG|Placebo|Placebo matching BAY2586116, nasal spray administration.
40994804|NCT00746941|DRUG|mefloquine|250 mg orally each day for 3 days and then weekly up to 6 months.
41148546|NCT00702871|DRUG|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
41148547|NCT05957822|DRUG|TXA|Tranexamic acid injection 8-10mg/kg
41148548|NCT05957822|DIAGNOSTIC_TEST|TEG6|performing thromboelastography (TEG6)
41148549|NCT06584734|OTHER|Not exercise|Patients were withdrawn from the exercise they had previously been doing during their hemodiafiltration sessions.
41148550|NCT06584734|OTHER|Exercise during hemodiafiltration session|Exercise with cycle ergometers during hemodiafiltration session, intensity was measure with power meters in Watts units.
41148551|NCT06286098|DRUG|Alpha lipoic acid|THIOTACID 600 MG ORIGINAL ® Tablets manufactured by EVA PHARMA
41148552|NCT06286098|OTHER|Placebo|Placebo identical Tablets are manufactured by EVA PHARMA containing the same excipients without Alpha Lipoic Acid.
41309808|NCT03586882|DEVICE|Spinal Cord Stimulation|Stimulation provided by the generator to electrodes on the leads inhibits ascending pain signals, thereby decreasing pain perception.
41309809|NCT00180596|DEVICE|Contak heart failure devices|
41309810|NCT02207699|DRUG|Benzonatate 200 mg|2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
41309811|NCT02207699|DRUG|Benzonatate 800 mg|8 benzonatate 100 mg perles given by mouth once
41309812|NCT02207699|DRUG|Moxifloxacin 400 mg|1 moxifloxacin 400 mg tablet given by mouth once
41309813|NCT02207699|DRUG|Placebo|8 placebo perles given by mouth once
41309814|NCT04419285|BEHAVIORAL|Locomotion task|The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.
40994805|NCT04782856|DRUG|Levothyroxine|levothyroxine sodium tablet for oral use
40994806|NCT04782856|DRUG|Liothyronine|Liothyronine sodium tablets for oral use treatment of hypothyroidism
40994807|NCT04782856|DRUG|Placebo|inert sugar tablets for oral use blinding for treatment of hypothyroidism
40994808|NCT05525533|BEHAVIORAL|Harnessing prosocial and social image motivations for behavior change|The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback
40994809|NCT01359254|DRUG|Melphalan|Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
40994810|NCT01359254|DRUG|Fludarabine|Fludarabine is given through the vein daily for 5 days.
40994811|NCT01359254|DRUG|Antithymocyte Globulin (ATG)|ATG is given every other day for 4 days.
40994812|NCT01359254|DRUG|Busulfan|Busulfan is given daily for 4 days.
40994813|NCT01359254|DRUG|Total Body Irradiation (TBI)|TBI is given twice on the last day.
40994814|NCT05577676|DRUG|Ultrasound-guided Hydrodissection of the Median Nerve|Hydrodissection for CTS includes injecting fluid around the median nerve (MN) with 5 ml volume, 3 ml of which is given in between the transverse carpal ligament \& MN, and 2 ml below the MN under Ultrasound guidance in-plane ulnar approach.
40994815|NCT03044132|OTHER|DermACELL AWM|Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology
40994816|NCT01257958|DRUG|19 nor vitamin d|
41148553|NCT05256836|OTHER|Tablet computer-based cognitive training program|"The subject of the study executes a program mounted on a tablet personal computer (PC) (Samsung Galaxy Tab S6 Lite) and performs a cognitive training task by touching the screen with the index finger.~It consists of 10 tasks related to the activity of daily living: 1) taking medicine, 2) making a phone call, 3) taking a shower, 4) doing laundry, 5) finding directions, 6) riding the bus, 7) buying goods, 8) Money management, 9) ingredient sorting, 10) meal preparation.~It is involved in cognitive functions in various domains such as attention, working memory, processing speed, problem solving, visuospatial ability, verbal and visuospatial memory.~There are three levels of difficulty for each task, high, medium, and low, and the difficulty becomes more difficult as session 1 to 36 progresses.~One cognitive training session lasts about 30 minutes."
41148554|NCT04150419|OTHER|Group 1|Attentional training to avoid threatening, negative or pain-related information.
41309815|NCT04419285|BEHAVIORAL|Posturology task SOT (Sensory Organization Test)|The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.
40790477|NCT03952403|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
40790478|NCT01132703|DRUG|Glyburide for Injection|Administered as specified in the Treatment Arm.
40994817|NCT05662579|OTHER|Exercises|"There will be 2 reevaluations of the participants, similar to the initial: at the end of the exercise protocol and in a follow-up of 12 weeks after the end of the protocol.~The contraction phase of each exercise will be 2 concentric seconds, 1 isometric second and 2 eccentric seconds, followed by 1 second of rest; there will be approximately 90 seconds of rest between each set of 10 repetitions, time the other member will be exercising.~At the beginning and at the end of each session, the participants will be asked to point out the pain they feel in the hip at that time. In each of the 8 sessions, the physiotherapist will take note of the presence, lateral pain in the hip at the beginning and end of the therapy (by VAS), number of repetitions performed in each exercise (for the group that will do core exercises, it will be noted the time in seconds of each exercise) and any adverse events. Each series of exercises will be repeated 3 times, all performed bilaterally."
41309816|NCT04419285|BEHAVIORAL|The quality of life questionnaire|Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.
41468693|NCT02839798|DEVICE|NEST (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Bipolar Depression.
40790479|NCT01132703|DRUG|Placebo|Administered as specified in the Treatment Arm.
40994818|NCT05959239|DRUG|TB006|TB006 will be provided as single-use injectable glass vials.
40994819|NCT04745403|DRUG|mRNA HBV/TCR T-cells|"Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW."
40994820|NCT04480255|OTHER|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
40994821|NCT04480255|OTHER|Group 2: NICU2HOME+ app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
40994822|NCT00983268|DRUG|capecitabine|1000 mg taken by mouth on the days of radiation only.
40994823|NCT00983268|DRUG|vorinostat|"Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~* Vorinostat,at 100 mg~* Vorinostat,at 200 mg~* Vorinostat, at 300 mg~* Vorinostat, at 400 mg"
40994824|NCT00983268|RADIATION|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
40994825|NCT00983268|PROCEDURE|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
41148555|NCT04150419|OTHER|Group 2|Attention training for vigilance for positive emotional information.
41309817|NCT02902913|OTHER|D2i2|Oleocanthal provided in a 2:1 ratio compared to oleacein
41309818|NCT02902913|OTHER|D2i0.5|Oleocanthal provided in a 1:2 ratio compared to oleacein
41468694|NCT06166758|BEHAVIORAL|Educational Video|Educational video regarding the benefits, risks, and limitations of genetic testing for hereditary cancer risk.
41148556|NCT04150419|OTHER|Group 3 (control group)|Neutral attentional training (control group).
41148557|NCT01769729|BEHAVIORAL|PEPP|
41148558|NCT01769729|BEHAVIORAL|Care management|
41468695|NCT06616428|OTHER|Bike group fitness class|Comprised a rhythmic indoor cycling session, characterized by fluctuations in intensity corresponding to changes in position, music rhythm, cadence, and revolutions per minute. Participants were instructed to strictly follow verbal cues from the instructor, adjusting cycling cadence and resistance as directed, for 45 minutes.
41309819|NCT02902913|OTHER|D2i0|No oleocanthal and no oleacein
40994826|NCT01852266|BIOLOGICAL|RSV cps2 Vaccine|10\^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
41468696|NCT06616428|OTHER|Pump Power|Entails a comprehensive total-body weight-training program with a focus on improving strength, muscular endurance, and overall fitness of large muscle groups. The class, choreographed to music, involved participants performing a combination of barbell, body-weight exercises, and free-weight plates, during 45 minutes. Participants selected weights based on the target muscle group for the specific song or track and their individual fitness goals.
40994827|NCT01852266|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
41468697|NCT06616428|OTHER|Global Training|Incorporated both aerobic and resistance components, combining athletic movements like running, lunging, and jumping with strength exercises such as barbells, body-weight exercises, and free-weight plates for the large muscle groups, during 45 minutes.
40994828|NCT02904057|DEVICE|Radiesse (+) Injectable Implant|Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.
40994829|NCT04177602|COMBINATION_PRODUCT|Trifluridine/tipiracil chemoradiation|Trifluridine/tipiracil based chemoradiation
41468698|NCT02025088|PROCEDURE|Laser|Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
40994830|NCT04177602|COMBINATION_PRODUCT|Capecitabine based chemoradiation|Capecitabine based chemoradiation
40994831|NCT05129878|PROCEDURE|scaling and OHI|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive scaling and oral hygiene instructions
40994832|NCT05129878|PROCEDURE|oral Hygiene instructions|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive oral hygiene instructions only
40994833|NCT05129878|PROCEDURE|Scaling and oral hygiene instruction|Systemically Healthy (age and BMI matched) females with gingivitis will receive with OHI and Scaling
40790480|NCT06156852|OTHER|Mindfulness-based stress reduction group|Mindfulness-based stress reduction (MBSR) group interventions were implemented for eight weeks.
40994834|NCT04773444|BEHAVIORAL|Eccentric cycling training|"1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
40994835|NCT04773444|BEHAVIORAL|Concentric cycling training|"1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
40994836|NCT01958775|DRUG|GLP-2|single subcutaneous dose of 1500mcg
40994837|NCT01958775|DRUG|Placebo|
40994838|NCT00210054|DRUG|denufosol tetrasodium (INS37217)|
40994839|NCT00277069|DRUG|Carboplatin|Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days
40994840|NCT00277069|DEVICE|Capecitabine|Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days
40994841|NCT00277069|DRUG|Vinorelbine|Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days
40994842|NCT05377528|DRUG|AGEN1571|A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.
40994843|NCT05377528|DRUG|Balstilimab|A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.
40994844|NCT05377528|DRUG|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
40994845|NCT02459028|BEHAVIORAL|Positive Psychology intervention|"Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
40994846|NCT02459028|BEHAVIORAL|Positive Psychology intervention (Control exercise)|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
40994847|NCT06544811|OTHER|Smoking Cessation Program|A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking.
40994848|NCT06544811|OTHER|Cultural Smoking Cessation Program|A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking and has been developed for American Indian and Alaska Native persons.
40994849|NCT05928052|DEVICE|Transcutaneous Biopac Electrical Stimulator|A transcutaneous electrical stimulator sends low levels of electrical current through surface hydrogel electrodes directly to the spinal cord to improve function.
41309820|NCT02902913|DRUG|Ibuprofen|400 mg of Ibuprofen
41309821|NCT01627067|DRUG|Everolimus|10 mg by mouth once daily.
41309822|NCT01627067|DRUG|Exemestane|25 mg by mouth once daily.
41309823|NCT01627067|DRUG|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
41309824|NCT03452553|DEVICE|LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin|Drug Eluting Beads loaded with chemotherapy
41148559|NCT00234299|DRUG|Aspirin|325mg, one tablet orally, six months
41148560|NCT00234299|DRUG|Placebo|325mg, one tablet orally every day, 6 months
41148561|NCT03627572|OTHER|No intervention|Not applicable (no intervention)
41148562|NCT03861078|OTHER|Own Brand Cigarette|Effects of own brand cigarette use.
41148563|NCT03861078|OTHER|ECIG 15 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, sweetened liquid
41148564|NCT03861078|OTHER|ECIG 15 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, unsweet liquid
41148565|NCT03861078|OTHER|ECIG 0 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, sweetened liquid
41148566|NCT03861078|OTHER|ECIG 0 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, unsweet liquid
41309825|NCT03703830|DEVICE|Cerebellar transcranial direct current stimulation|Cerebellar transcranial direct current stimulation (ctDCS) will be applied during 25 minutes at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle.
40994850|NCT00208195|DRUG|Divalproex ER|
40994851|NCT04173026|OTHER|Provider-level intervention|Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
40994852|NCT04173026|OTHER|Patient-level intervention|50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
40994853|NCT01718756|DRUG|Placebo|The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
40994854|NCT01718756|DRUG|Continuous infusion|"The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery"
40994855|NCT01718756|DRUG|Scheduled|"The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia."
40994856|NCT03760146|BIOLOGICAL|20vPnC|20vPnC
40994857|NCT03760146|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
40994858|NCT03760146|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
40994859|NCT03760146|OTHER|Saline|Placebo
40994860|NCT04199299|DEVICE|Heart rate and respiration rate sensors|The use of sensors to monitor physiological variables (e.g. heart rate, sleep). The design is a before-and-after comparison with respect to whether the use of sensors has changed the caregivers' practice and their (perceived) understanding of the participant. The frequency of participants' self harm or aggressive behavior after as compared to before the introduction of pulse- and respiration monitors will also be charted.
40994861|NCT04336891|DRUG|Testosterone gel|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
40994862|NCT04336891|DRUG|Estradiol ovules|Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
40994863|NCT04336891|DRUG|Moisturizer|Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed
41148567|NCT00312845|DRUG|Bortezomib + Rituximab|VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
41148568|NCT00312845|DRUG|Rituximab|rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
41148569|NCT01502241|DRUG|Temozolomide|100 mg/m2 per day on seven out of fourteen days.
41148570|NCT01502241|RADIATION|Radiotherapy of the partial brain.|60 Gy in 30 fractions à 2 Gy.
41309826|NCT03703830|OTHER|Treadmill locomotor training|The Treadmill Locomotor Training (TLT) will be performed through speed and step length progression protocol for 25 minutes and combined to ctDCS
41309827|NCT03703830|DEVICE|Sham Cerebellar transcranial direct current stimulation|Sham Cerebellar transcranial direct current stimulation (ctDCS sham) will be applied during 30 seconds at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle. However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
41309828|NCT03703830|DEVICE|Cerebello-spinal direct current stimulation|Cerebello-spinal transcranial direct current stimulation (csDCS) will be applied during 25 minutes at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11)
40994864|NCT04336891|DRUG|Testosterone gel + Estradiol ovules|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
40994865|NCT02916563|DEVICE|Blood Glucose Monitoring System Altitude Performance|Performance as assessed against a reference method at an altitude of approximately 10,000 feet.
41148571|NCT03465670|DEVICE|CHX|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
40994866|NCT02109146|DRUG|Prophylactic Transcatheter Arterial Chemoembolization|Participants enrolled in the adjuvant TACE group received one to two cycles of TACE with an interval of 4\~6 weeks, and the first TACE was given within 1 week after randomization.
40994867|NCT02109146|OTHER|Observation|Participants enrolled in the observation group were subjected to active surveillance without any adjuvant treatment.
40994868|NCT06523036|PROCEDURE|Combined chiropractic care and Tai Chi|Chiropractic will be personalized to the patients clinical needs within the scope of chiropractic practice in the Commonwealth of Massachusetts including: posture correction/spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation/mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports. Chiropractic will be administered by one of two chiropractors at the Osher Clinical Center. Tai Chi will take place at one of two schools used in prior NIH funded trials.
40994869|NCT06159140|DEVICE|MRI|In vivo MRI
40994870|NCT03869450|DEVICE|Restylane Volyme|Hyaluronic based filler
40994871|NCT03869450|DEVICE|Restylane Defyne|Hyaluronic based filler
40994872|NCT03869450|DEVICE|Restylane Lyft Lidocaine|Hyaluronic based filler
40994873|NCT02857777|DRUG|Esketamine|Subjects will self-administer intranasal esketamine as per the treatment regimen.
40994874|NCT03322215|DRUG|Palbociclib|75-125 mg capsule orally once daily for 21 consecutive Days followed by 7 Days of treatment.
40994875|NCT03322215|DRUG|Fulvestrant|500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
40994876|NCT03322215|DRUG|Capecitabine|Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
40994877|NCT03023865|PROCEDURE|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
40994878|NCT02290106|DRUG|pitavastatin|
40994879|NCT02290106|OTHER|PLACEBO|
40994880|NCT05673642|OTHER|Myofascial Release Techniques|Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection
40994881|NCT02508025|OTHER|Functional Capacity Evaluation|Assessment of work related physical capacity
40994882|NCT00929682|DRUG|Randomization between two referenced treatments|"Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1."
40994883|NCT03664752|DRUG|IDP-120 Gel|IDP-120 Gel, once-daily application
41309829|NCT03703830|DEVICE|Sham cerebello-spinal direct current stimulation|Sham cerebello-spinal direct current stimulation (csDCS sham) will be applied during 30 seconds at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11). However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
41309830|NCT06503861|BEHAVIORAL|Food Is Medicine intervention|The intervention provides regular meal kits as well as cooking and nutritional education.
41309831|NCT06219616|DIAGNOSTIC_TEST|BKV immune monitoring|Blood will be drawn and investigated for BKV-specific T cell response.
41309832|NCT01605591|PROCEDURE|the DLT bending to the right|bending the bronchial lumen of DLT 60\~90 degrees in the same side with the tracheal lumen
41309833|NCT01605591|PROCEDURE|the DLT bending to the left|bending the bronchial lumen of DLT 60\~90 degree opposed to the tracheal lumen
41309834|NCT02704221|BEHAVIORAL|Fitbit activity tracker|Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
41309835|NCT02704221|BEHAVIORAL|Monetary rewards|Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.
41309836|NCT02704221|BEHAVIORAL|BPT training sessions|Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
41309837|NCT00383422|DRUG|Arzoxifene|20 mg, oral, tablet, once a day for 52 weeks
41309838|NCT00383422|DRUG|Raloxifene|60 mg, oral, tablet, once a day for 52 weeks
41309839|NCT04546386|PROCEDURE|Endoscopic endonasal pituitary surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter
41309840|NCT00121030|DRUG|darbepoetin alfa|
41309841|NCT00121030|DRUG|recombinant human erythropoietin (rHuEPO)|
41468699|NCT02025088|PROCEDURE|Microneedling|"Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
41468700|NCT04346940|OTHER|Telerehabilitation|15 volunteers aged 65 and over will be included in this group. An online exercise program has been created for individuals who will participate in the study. It is planned that this program will continue for 3 days a week, 6 weeks, and the duration of exercise will reach 45 minutes in the last week due to the increase in the number of repetitions about 30 minutes at the beginning. The treatment sessions will start with warm-up exercises, complete with posture exercises, joint range of motion exercises, stretching exercises, and cool-down exercises in the main program.
41468701|NCT04346940|OTHER|Exercise brochure|The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
41468702|NCT04924699|DRUG|MRG002|Administrated intravenously
40994884|NCT03664752|DRUG|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
40994885|NCT02681120|PROCEDURE|Biopsy|
40994886|NCT02681120|PROCEDURE|Blood draw|
40994887|NCT02681120|PROCEDURE|Mammogram|
40994888|NCT02681120|PROCEDURE|MRI|
40994889|NCT03567837|OTHER|Fructose + Glucose Beverage|The intervention is an oral sugar challenge with blood sampling over three hours.
40790481|NCT06156852|OTHER|Cognitive behavioral-based stress reduction group|Cognitive behavioral-based stress reduction group interventions were implemented for eight weeks.
40790482|NCT02802293|DEVICE|repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver repetitive electromagnetic pulses in this research study's treatment of major depressive disorder.
40790483|NCT02802293|DEVICE|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
40994890|NCT05507983|DRUG|Tranexamic acid|Tranexamic acid 1500 mg
40994891|NCT05507983|DRUG|Placebo|Placebo, sodium chloride 0.9%
41468703|NCT04924699|DRUG|Trastuzumab Emtansine for Injection|Administrated intravenously
40994892|NCT01848587|OTHER|acupuncture|
40994893|NCT01848587|OTHER|usual care|
41468704|NCT01426737|DRUG|Vildagliptin|Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).
41468705|NCT01914016|OTHER|prolonged walk|Participants will be asked to walk for a duration of between 2 -6 minutes until they rate their perceived exertion as 'Hard' (RPE 16 on Borg Scale)
40790484|NCT05186935|DEVICE|Injectable Hydrogel treatment|The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
40790485|NCT05920811|OTHER|conventional obturator|restoration of midline maxillary defect with obturator made of cast metal , heat cure acrylic resin
40790486|NCT05920811|OTHER|3 d printed obturator|restoration of midline maxillary defect with obturator made of SLM metal , 3 d printed resin
40790487|NCT01901484|DRUG|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
40994894|NCT03357484|PROCEDURE|Leukocyte- and platelet rich fibrin|Prior to surgery, two 9 ml glass-coated tubes (Intra-Spin, Intra-Lock International, Boca Raton, USA) of patient venous blood were collected. Tubes were transferred to a centrifuge (Andreas Hettich GmbH \& Co.KG, Tuttlingen, Germany) and processed for 12 minutes at 2800 rpm to prepare L-PRF.
40994895|NCT03357484|PROCEDURE|Blood clot|Natural blood clot formed within extraction socket
41468706|NCT05768789|DIETARY_SUPPLEMENT|Buoy Electrolyte|Buoy intervention amount is 4% of total body weight given in 16 divided doses over 4 hours.
41468707|NCT05768789|DIETARY_SUPPLEMENT|Nuun|Nuun intervention given as 1L bolus and then free water in divided doses for a total of 4% total body weight.
41309842|NCT01428518|DRUG|Lamotrigine tablets|Administered according to the prescribing information in the locally approved label by the authorities.
41309843|NCT02660333|DIETARY_SUPPLEMENT|Placebo|Maltodextrin - 11g/day
41309844|NCT02660333|DIETARY_SUPPLEMENT|Prebiotic|Fructooligosaccharide - 11g/day
41309845|NCT02660333|DIETARY_SUPPLEMENT|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 11g/day
41309846|NCT05621824|DEVICE|Endoscopic ultrasound|Use endoscopic ultrasound to examine the pancreatic lesions.
41309847|NCT05621824|PROCEDURE|EUS-Fine needle aspiration|If solid mass of pancreas was found during EUS, EUS-FNA shall be conducted for diagnosis.
41468708|NCT05768789|OTHER|Water|Water serves as a control
41468709|NCT05203445|DRUG|Olaparib|Olaparib 300 mg orally BID
41468710|NCT05203445|DRUG|Pembrolizumab|Pembrolizumab 400 mg intravenously q6weeks
41468711|NCT02375217|DRUG|Sugammadex|half dose
41468712|NCT02375217|DRUG|Sugammadex|full dose
41468713|NCT02375217|DRUG|Neostigmine|IV = 50mcg/kg
41468714|NCT02375217|DRUG|glycopyrrolate|
41468715|NCT03756883|DRUG|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
41309848|NCT02649543|PROCEDURE|Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. Subcutaneous tissue was approximated with Polyglycolic Acid 3-0, and the skin is sutured using Polypropylene 2-0.
40994896|NCT02090127|DRUG|ficlatuzumab|humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
40790488|NCT03432494|DEVICE|Transcaval closure device (TCD)|Transcaval access and closure using the Transmural Transcaval Closure Device (TCD) at the time of medically-necessary transcatheter aortic valve replacement (TAVR).
40994897|NCT04552587|BEHAVIORAL|Heart APP|The HEART intervention includes a care planning visit for patients and caregivers and an App for caregivers focused on nutrition, self-care and support.
40790489|NCT00852579|DRUG|Azithromycin|Daily dose 250mg
41309849|NCT02649543|PROCEDURE|Vacuum Assisted Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.
41309850|NCT02649543|PROCEDURE|Delayed Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
41309851|NCT04361643|DRUG|Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
41309852|NCT04361643|DRUG|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
41309853|NCT01695057|DRUG|vorinostat|Given PO
41309854|NCT01695057|PROCEDURE|therapeutic conventional surgery|Undergo surgery
40790490|NCT00852579|DRUG|Placebo|Placebo
40790491|NCT06209294|DRUG|AK104|AK104(10 mg/kg) d1,22
40790492|NCT06209294|DRUG|Carboplatin|AUC=2 d1,8,15,22, 29, 36
40790493|NCT06209294|DRUG|Nab paclitaxel|125mg／m2 d1,8,15,22,29,36
40790494|NCT01986894|DRUG|Placebo|Single oral dose of Placebo
40790495|NCT01986894|DRUG|Pomalidomide|Single oral dose of 4 mg pomalidomide
40790496|NCT01986894|DRUG|Pomalidomide|Single oral dose of 20 mg pomalidomide
40790497|NCT01986894|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin tablet
40994898|NCT02602587|BIOLOGICAL|Blood sample|additional samples of blood in acts planned in the prognostic or follow-up protocols.
40994899|NCT02602587|BIOLOGICAL|Bone marrow sample|additional bone marrow sample in acts planned in the prognostic or follow-up protocols.
40994900|NCT02862431|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
40994901|NCT02862431|DRUG|Placebo|Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
40790498|NCT06512870|DIAGNOSTIC_TEST|Near infrared spectroscopy (NIRS)|A technique that relies on differential absorption of infrared light to provide relative estimation of tissue oxygenation, has been successfully used to monitor perfusion of various tissues, including muscle tissue of the lower extremity.
40994902|NCT00485238|PROCEDURE|Argon laser Iridoplasty|
40994903|NCT00485238|DRUG|Intravenous acetazolamide|
40790499|NCT05402215|BEHAVIORAL|The flipped classroom model was used to teach students' clinical practice skills.|Videos for clinical applications have been prepared by researchers. These prepared videos were shared with the students in the experimental group one week before the lesson day of each application for preliminary study and the students were asked to work on these videos. On the day of the lesson, group work, question-answer and discussion activities were held with the students in the classroom environment. At the end of the lesson, the students were asked to do the applications on the simulation models of the application and the checklists were filled.
40994904|NCT01484574|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of low dose of stem cells
40994905|NCT01484574|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of intermediate dose of stem cells
40994906|NCT04846790|BEHAVIORAL|Nature Only|See above for description.
41148572|NCT03465670|DEVICE|CHX+HA+ADS|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
41309855|NCT01695057|OTHER|laboratory biomarker analysis|Correlative studies
41309856|NCT03282357|DEVICE|Radiesse injectable implant (dermal filler)|Subdermal injection.
41309857|NCT03282357|DEVICE|Restylane injectable implant (dermal filler)|Subdermal injection
40994907|NCT04846790|BEHAVIORAL|Nature+Mindfulness|See above for description.
40994908|NCT03873870|DIAGNOSTIC_TEST|68Ga -DOTATATE PET scans|PET scan using 68Ga-DOTATATE contrast
40790500|NCT05402215|BEHAVIORAL|control group|To the students in the control group, the application was explained by the researcher (instructor conducting the course) using presentation and demonstration methods. Each application was made on different days. The prepared checklists were filled by the other researcher.
40994909|NCT01206179|BIOLOGICAL|cell injection|Injection of mesenchymal cells in fractured zone
40994910|NCT03492099|DRUG|buprenorphine|Patients in this study will receive dosages to be determined by a physician that are specific to each patient.
40994911|NCT04127331|DEVICE|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
41148573|NCT03873376|BEHAVIORAL|Opt-in; Receive offer to order self-sampling kit|Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program
41148574|NCT03873376|BEHAVIORAL|Opt-out; Receive self-sampling kit unsolicited|Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.
40994912|NCT01433510|DRUG|Grazax|1 tablet/day - pre and co-seasonal
40994913|NCT04475588|DRUG|Itolizumab IV infusion|"First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks.~BSC: similar to Arm B"
40994914|NCT04475588|DRUG|Best supportive care (BSC)|Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
40994915|NCT04260737|OTHER|Decision Aid for Men with Localized Prostate Cancer|The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.
40994916|NCT00004733|DRUG|levodopa|
41309858|NCT02913222|OTHER|Rehabilitation|Comparison of two rehabilitation approaches
41309859|NCT06170372|DRUG|200 ppm Nitric Oxide|NO will be supplemented at 200-ppm concentration 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
41309860|NCT06170372|DRUG|Sham treatment|Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
41309861|NCT03077126|OTHER|Fleet Enema|Since a probe will be introduced into the participant's rectal area, participants will be instructed to give themself one regular Fleet enema.
41309862|NCT03077126|DEVICE|Aixplorer® ShearWave Elastography (SWE™)|Pre-surgery ultrasound: Aixplorer® ShearWave Elastography (SWE™) Ultrasound System (made by SuperSonic Imagine, Inc.). The device is used transrectally. This device (ultrasound system) has been cleared by the United States Food and Drug Administration (FDA) for the indication for use as described in this consent form.
40994917|NCT03569332|OTHER|Alarm|"1. Alarm is provided from 9am to 9pm.~2. Alarm is active every 50 minutes if the exercise goal(10 times/hour) hasn't satisfied."
41309863|NCT03077126|DIAGNOSTIC_TEST|Pre-surgery Ultrasound|The ultrasound procedure referenced above will be performed at the participant's pre-op visit one to two weeks before their surgery.
41309864|NCT03077126|PROCEDURE|Prostatectomy|Participants will undergo radical prostatectomy as currently performed at our Moffitt Cancer Center. This procedure is performed under general anesthesia in the operating room. This is considered standard of care.
41468716|NCT03756883|DRUG|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
40790501|NCT02377843|BEHAVIORAL|Participatory|"The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
40994918|NCT03569332|OTHER|Nurse's dashboard|"1. Wireless data transmission system~2. The practicing rate of participants on study group is sent to Nurse's Dashboard.~3. It is only to display."
40994919|NCT03102931|OTHER|Reduced ROS/RNS content products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
41468717|NCT03756883|DRUG|Placebo Inhalation Powder|No active content
40994920|NCT03102931|OTHER|Typical to high (ROS/NOS) products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
40994921|NCT05138679|PROCEDURE|Revascularization|Endovascular or surgical restoration of arterial blood flow.
40994922|NCT05138679|PROCEDURE|Primary major amputation|Primary below- or above knee major amputation without prior revascularization.
41148575|NCT03873376|BEHAVIORAL|Control; Receive open reminder to be screened by physician|Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
41148576|NCT04301843|DRUG|Eflornithine|DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.
41148577|NCT03736265|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
41148578|NCT02835209|OTHER|Work of breathing during SBT|Pulmonary function tests and work of breathing indices will be collected during the spontaneous breathing test.
41309865|NCT00304265|BIOLOGICAL|COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)|0.5 mL, Intramuscular
40994923|NCT05138679|OTHER|Best medical treatment|Conservative treatment of acute lower limb ischemia - without prior revascularization.
40994924|NCT01198054|DRUG|Lenalidomide|"Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.~In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease"
41309866|NCT02114333|BIOLOGICAL|Zostavax|0.65ml, subcutaneous
41309867|NCT02114333|BIOLOGICAL|HZ/su vaccine|0.5ml, intramuscular
41309868|NCT02114333|BIOLOGICAL|Placebo|0.65ml, subcutaneous
41309869|NCT04379219|DRUG|Methotrexate|giving methotrexate at least 1 w week before surgery
41309870|NCT03480607|DRUG|Dexmedetomidine group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine
40994925|NCT03821493|DRUG|PF-06651600 10 mg tablets|"On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole."
41468718|NCT02060045|OTHER|Bundle implementation|
41468719|NCT03630419|DIETARY_SUPPLEMENT|Mito-Food Plan|Specialized anti-inflammatory diet plan based on subject's physiological results
41468720|NCT03630419|OTHER|Cellular Repair Therapy|the objective of this type of technology is to support the body's own processes to repair protein structures and maintain the health of the DNA, both of which have been damaged by internal and external factors.
40994926|NCT03821493|DRUG|Itraconazole Solution 200 mg|"Itraconazole 200 mg will be administered as 20 mL (10 mg/mL) oral solution once daily on Days 1-5 in Period 2.~On Day 4 of Period 2, co-administration of itraconazole 200 mg and PF-06651600 30 mg will occur. Itraconazole will be administered first followed by PF-06651600 tablets."
40994927|NCT01115595|BIOLOGICAL|Intervention|Dermatophagoides pteronyssinus from ALK company
40994928|NCT01115595|OTHER|Control|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid)
41309871|NCT03480607|DRUG|Dexamethasone group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone
41309872|NCT06554002|OTHER|Control|Participants will be asked to consume glucose on a daily basis (twice per day) for the entire 8 weeks. The supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
41309873|NCT06554002|OTHER|Treatment|Participants will be asked to consume a resistant dextrin on a daily basis (twice per day) for the entire 8 weeks. The test supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
41468721|NCT03449199|DRUG|TMX-049|A certain dose of TMX-049 to be taken orally, once daily
41468722|NCT03449199|DRUG|Placebo|Matching placebo to be taken orally, once daily
40994929|NCT03745092|DEVICE|normobaric oxygen|Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).
41468723|NCT05291351|OTHER|Crackers made with whole, coarse, or fine pea and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
40790502|NCT02377843|BEHAVIORAL|Efficient|"The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
40790503|NCT01898286|DRUG|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
40790504|NCT01242631|DRUG|Everolimus|Everolimus 10 mg orally per day.
40994930|NCT03745092|DEVICE|room air|The patient had a rest with lying, sitting or walking, did not performed with NBO intervention.
40994931|NCT05812521|PROCEDURE|Paravertebral block with methylene blue|The paravertebral space is identified under ultrasound guidance and after negative aspiration a 3 ml test dose of anesthetic is injected. After observing widening of the paravertebral space and anterior pleural displacement to confirm the correct needle positioning, a bolus dose of 20 mL 0.5% ropivacaine with a solution of 1 ml 1% methylene blue and 4 ml of saline will be injected in the paravertebral space. At the start of the surgery, the spread of the solution of anesthetic and methylene blue will be assessed through visualization in thoracoscopy and if necessary the block will be repeated. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
40790507|NCT01964183|DRUG|tolterodine|Oral
40790508|NCT01964183|DRUG|mirabegron|Oral
40790509|NCT01138085|DRUG|GSK1120212|MEK inhibitor
40790510|NCT01138085|DRUG|GSK2141795|AKT Inhibitor
40790511|NCT03679104|PROCEDURE|Closure of mucosotomy using endoscopic clips|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).
40790512|NCT03679104|PROCEDURE|Closure of mucosotomy using OverStitch™ suturing device|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
40790513|NCT03345511|PROCEDURE|Ultrasound Guided Caudal Block|Using an external ultrasound probe, the investigators guided a 18 gauge epidural needle into the caudal space and injected a local anesthetic solution consisting in bupivacaine 0.25%, lidocaine 1% and dexamethasone 8mg in the caudal space.
40790514|NCT03890523|PROCEDURE|Airway stent implantation|The segmented airway stent modified with 3D printing were implanted to treat gastro-respiratory fistula involving carina and distal bronchi. The stents were removed because of stent-related complications or tracheobronchial healing.
40790515|NCT01516632|BEHAVIORAL|SMS USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
40790516|NCT06393842|DEVICE|Cardiopulmonary Management Wearable Device|Fluid status and congestion can be determined by the CPM wearable device and correlates with non-invasive measures and biochemical markers of congestion and changes in congestion.
40790517|NCT05657652|DRUG|cladribine, cytarabine,venetoclax|Cladribine 5 mg/m2/day, cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
40790518|NCT05695170|BEHAVIORAL|PreventT2 (Individual intervention)|"PreventT2 will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the curriculum that will be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National Diabetes Prevention Program (DPP), which has full recognition from the CDC based on outcome data over the course of a number of years."
41148579|NCT03207620|DIAGNOSTIC_TEST|using serum periostin and eotaxin-2 level|"collect serum sample from each group and detection of serum periostin and eotaxin-2 are using Eliza kits.~each group is divided into two groups (patients who are already using ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity."
41148580|NCT03207620|DIAGNOSTIC_TEST|airway corticosteroid sensitivity|each group is divided into two groups (patients who are already using inhaled corticosteroid ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.
41148581|NCT06485947|BIOLOGICAL|Dinutuximab beta|Combination of immunotherapy with standard chemotherapy
41148582|NCT06485947|DRUG|chemotherapy treatment called GPOH|chemotherapy treatment called GPOH
40790519|NCT05695170|BEHAVIORAL|PreventT2 Together (Couple-based intervention)|PreventT2 Together will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes and their partners. The curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevention type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
40790520|NCT03067792|DRUG|5-fluorouracil, irinotecan and leucovorin|In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
40790521|NCT03067792|DRUG|docetaxel and cisplatin|In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
40994932|NCT05812521|PROCEDURE|Thoracic Epidural Anesthesia|The epidural catheter will be placed using the loss of resistance technique, and after ruling out intravenous or intrathecal catheter placement with a negative aspiration test dose, an initial dose of 10 mL 0.25% bupivacaine will be injected. Continuous infusion will be started with with 0.125 % bupivacaine + fentanyl 0.5 mcg/ ml at 6-10 ml/hour will be started based on the patient weight for 48 hours postoperatively. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
40994933|NCT04939415|DRUG|mQFPD|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
40994934|NCT04939415|DRUG|organic brown rice|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
40994935|NCT01380743|DRUG|duvoglustat|Single oral dose
40994936|NCT01380743|DRUG|rhGAA|Single intravenous infusion
40994937|NCT03451318|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray NASONEX
40994938|NCT03451318|PROCEDURE|tonsillar adenoidectomy|tonsillar adenoidectomy
41148583|NCT06485947|DRUG|chemotherapy treatment called rapid COJEC|chemotherapy treatment called rapid COJEC
41309874|NCT04003077|DEVICE|laser meridian massage|The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm\^2; power density, 300mW/cm\^2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm\^2.
41309875|NCT01232894|DRUG|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
41309876|NCT01232894|DRUG|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
41309877|NCT01996306|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
41309878|NCT01996306|DRUG|CPT-11 (Irinotecan)|150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
40994939|NCT03451318|PROCEDURE|Maxillary expander plus Twin-Block|Twin-block appliance combined with maxillary expander
40994940|NCT02646800|DRUG|Micafungin|Injection
41309879|NCT01996306|DRUG|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
41309880|NCT01996306|DRUG|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
40790522|NCT03417583|OTHER|Protocol Intervention Group|For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
40790523|NCT03018860|PROCEDURE|"Moderate management"|"After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration."
40790524|NCT03018860|PROCEDURE|"Intensive management"|This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
40790525|NCT02505373|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.~Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
40790526|NCT02505373|BEHAVIORAL|Control Group (CG)|Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
40790527|NCT02520492|DEVICE|noninvasive method of ICP measurements (Elios)|
40790528|NCT06049550|OTHER|no intervention|no intervention
40790529|NCT05276128|DIETARY_SUPPLEMENT|lipids|Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
40790530|NCT04062747|DEVICE|I-gel|After standard anesthesia i-Gel was placed into the patient
40790531|NCT04062747|DEVICE|Ambu aura i|After standard anesthesia ambu aura was placed into the patient
40790532|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The clinical symptoms will be evaluated before and after MT intervention.
40790533|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The acoustic features will be evaluated before and after MT intervention.
40790534|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The neuroimaging features will be evaluated before and after MT intervention.
40790535|NCT06128850|OTHER|disease|compare to diseases
40790536|NCT06395701|RADIATION|radioteraphy and chemotherapy after RTU --trimodality therapy--|TMT ( trimodality treatment) consists of complete and maximal TURBT of the bladder tumor, followed by definitive radiotherapy combined with a radiosensitizing agent.
40790537|NCT02342353|DRUG|Pacritinib|
40790538|NCT02342353|DRUG|Erlotinib|
40790539|NCT03093948|PROCEDURE|Remote ischemic post-conditioning|Remote ischemic post-conditioning will undergo in both thighs at the beginning of targeted temperature management. This will be done with noninvasive measurement of blood pressure, with cuffs inflated to 200 mmHg for four 5 min cycles and interrupted three times for 5 min with cuff deflation.
40790540|NCT04794699|DRUG|IDE397|IDE397 dosed orally
40994941|NCT00284479|BEHAVIORAL|Walking 45 mins 2x p.w.|
40790541|NCT04794699|DRUG|Docetaxel|Intravenous infusion
40790542|NCT04794699|DRUG|Paclitaxel|Intravenous infusion
40790543|NCT04794699|DRUG|Sacituzumab govitecan|Intravenous infusion
40790544|NCT04232943|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (IPV)|"IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~* Type 1 (Mahoney) 40 D-antigen units~* Type 2 (MEF1) 8 D-antigen units~* Type 3 (Saukett) 32 D-antigen units"
40994942|NCT02357147|DRUG|Placebo|"Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression."
40994943|NCT02357147|DRUG|Amatuximab|"Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression."
40994944|NCT02357147|DRUG|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
40994945|NCT02357147|DRUG|Cisplatin|Combination Phase - Cisplatin 75 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
40994946|NCT03548402|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of anxiety and self-injury.
40994947|NCT00004888|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
40994948|NCT00004888|DRUG|docetaxel|Given IV
41309881|NCT01996306|DRUG|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
40790545|NCT04232943|BIOLOGICAL|E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)|"LT (R192G/L211A), or dmLT, is a protein toxoid derived from wild-type enterotoxigenic Escherichia coli (ETEC) labile toxin (LT). The LT toxin has been shown to have inherent mucosal adjuvant properties for co-administered antigens and thus has potential as a mucosal adjuvant for different co-administered vaccines. LT has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites, which are critical for activation of the secreted toxin molecules."
40790546|NCT04232943|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|"Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3."
40790547|NCT03037866|BEHAVIORAL|LifeSkills Training for College|The intervention will consist of e-learning modules (self-guided) and small-group sessions (facilitator led). The intervention is designed for new college students and is aimed at providing tools and strategies to help them maximize opportunities and adeptly handle the challenges ahead. The intervention will teach them the knowledge and skills needed to stay safe from problems that are prevalent among new students on college campuses, such as alcohol and drug abuse and sexual violence.
40790548|NCT04826783|DEVICE|Lasers|The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
40790549|NCT02153437|DRUG|BMS-919373|
40994949|NCT00004888|BIOLOGICAL|trastuzumab|Given IV
40994950|NCT00004888|OTHER|laboratory biomarker analysis|Correlative studies
40994951|NCT01047956|DRUG|Methadone; NAC|Methadone NAC
41309882|NCT01996306|BIOLOGICAL|bevacizumab|7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
41309883|NCT01996306|DRUG|CPT-11 (Irinotecan)|150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
41309884|NCT01996306|DRUG|Capecitabine|1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
41309885|NCT05591599|DIAGNOSTIC_TEST|calponin 2|serum calponin 2 level
41309886|NCT01374776|DRUG|intravenous iron carboxymaltose|The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
40790550|NCT02153437|DRUG|Sotalol|
40790551|NCT02153437|DRUG|Placebo for BMS-919373|
40790552|NCT00456625|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 dose
40790553|NCT06023069|OTHER|Number of steps recorded by mobile phone as a proxy for physical activity|This cohort is likely to have patients with many steps/day (high activity) and few steps/day (low activity)
40790554|NCT05722834|BEHAVIORAL|SOAR intervention|"This program intervention will be over 6 weeks and participants will have two group sessions and individual sessions, all conducted by an asthma health coach over Zoom (or phone). The two Zoom group sessions will be recorded so that all the information from the conversations will be maintained and used for research purposes. Additionally, participants will keep track of asthma symptoms and complete surveys at specified time-points (the last one at 6 months after participation).~Primary care physicians will be sent emails regarding the self-management goals of their patients."
40790555|NCT02576548|BIOLOGICAL|MEDI4276|MEDI4276 is an investigational product
40790556|NCT00270127|DRUG|Epoetin alfa|
40790557|NCT03371199|DRUG|Sodium chloride|Sodium chloride tablets, 250 mg
40790558|NCT03371199|DRUG|Placebo Oral Tablet|Starch tablets
40790559|NCT00958477|BIOLOGICAL|EMD 525797|Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
40994952|NCT01047956|DRUG|Methadone|Methadone
40994953|NCT01073852|DRUG|Placebo|Placebo pill, 1 pill orally twice daily for 9 weeks.
40994954|NCT01073852|DRUG|Hydroxychloroquine|Patients will be taking hydroxychloroquine 200mg orally twice/daily.
40994955|NCT04983056|PROCEDURE|Necrotesectomy associated with cleanleness stoma|Excision of all necrotised tissues after stool diversion and wound dressing using
40994956|NCT03624660|RADIATION|HR-A|"The prostate and proximal seminal vesicles will be treated to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
40994957|NCT03624660|RADIATION|HR-B|"The prostate, proximal seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and proximal seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 16 fractions for a total of 32 cobalt gray equivalent.~Electively treat the entire uninvolved seminal vesicle to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent when part of the seminal vesicle is involved with tumor.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
40994958|NCT00032643|DRUG|DITPA|
40994959|NCT03134482|PROCEDURE|IVM|No gonadotropin is used, but hCG priming is utilized 36 hour before oocyte maturation.
40994960|NCT03134482|PROCEDURE|Minimal stimulation IVF|IVF with minimal use of gonadotropin, i.e. 150 or less IU of recombinant FSH, followed by hCG triggering in GnRH antagonist protocol.
41309887|NCT03838770|DEVICE|Active tDCS|Active target 2.0mA tDCS (n=60)
41309888|NCT03838770|DEVICE|sham tDCS|sham left-anodal dorsolateral prefrontal cortex (DLFPC) montage
40994961|NCT05344898|PROCEDURE|Subscap Tenotomy|Group will not have their subscapularis tendon repaired following a reverse shoulder replacement.
40790560|NCT05340998|PROCEDURE|Transradial access for percutaneous coronary procedures|Transradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion
40790561|NCT06525038|OTHER|All groups were observed for clinical end-points described in the study protocol|All groups were observed for clinical end-points (mortality, readmission to emergency service) described in the study protocol.
40790562|NCT05005221|BEHAVIORAL|Automated text messages|Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
40790563|NCT01907607|DRUG|PD 0332991|"PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.~PD-0332991 was dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day."
40790564|NCT01456130|DRUG|Alogliptin|Alogliptin tablets
40790565|NCT01456130|DRUG|Rapid-acting insulin secretagogue|Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
40790566|NCT00451399|DRUG|metformin|
40994962|NCT05344898|PROCEDURE|Subscap Repair|Group will have their subscapularis tendon repaired following a reverse shoulder replacement.
41309889|NCT01560897|DRUG|Oral C13|Ingestion of C13 and follow up of the ureogenesis
41309890|NCT05198752|DRUG|Neoantigen mRNA Personalised Cancer SW1115C3|Subcutaneous Injection
41468724|NCT05291351|OTHER|Crackers made with whole, coarse, or fine lentil and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
41468725|NCT05291351|OTHER|Porridge made with oat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
40790567|NCT00451399|BEHAVIORAL|lifestyle intervention|
41468726|NCT03755089|DRUG|Phenazopyridine|200mg PO Phenazopyridine taken 1-2 hours prior to the Botox® injection procedure
41468727|NCT03755089|DRUG|Lidocaine 2% Injectable Solution|30mL 2% lidocaine instilled into the bladder lumen 20 via a urinary catheter 20 minutes prior to the Botox® injection procedure
40994963|NCT05524181|OTHER|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in the study.
40790568|NCT05468645|DRUG|[14C]Hemay005|Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
40790569|NCT05373212|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
40790570|NCT05373212|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.
40790571|NCT03349255|BIOLOGICAL|autologous ET1402L1-CART cells|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct
40790572|NCT04315558|DRUG|Revefenacin Inhalation Solution [Yupelri]|nebulized drug comparison
40790573|NCT04315558|DRUG|Ipratropium Bromide|nebulized drug comparison
40790574|NCT00915889|BEHAVIORAL|telephone-based intervention|Either 6 or 8 telephone educational sessions
40790575|NCT00915889|OTHER|counseling intervention|counseling and communications studies
40790576|NCT00915889|OTHER|questionnaire administration|Ancillary studies
40790577|NCT00915889|OTHER|study of socioeconomic and demographic variables|Ancillary Studies
41468728|NCT02281331|DIETARY_SUPPLEMENT|Supplement|supplement/placebo plus exercise training
40994964|NCT02735551|DRUG|Long Acting Reversible Contraception (LARC)|Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
41309891|NCT00022035|BIOLOGICAL|trivalent influenza vaccine|
41309892|NCT01389622|OTHER|acupuncture|National Acupuncture Detoxification Association (NADA) points + digital pressure
40790578|NCT00915889|PROCEDURE|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
40790579|NCT00399074|DRUG|sulfadoxine pyrimethamine|Monthly SP
40790580|NCT02639247|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
40790581|NCT02639247|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
40790582|NCT03957863|BIOLOGICAL|Plasma collection for EPO assay|Plasma collection for EPO assay
40790583|NCT00476320|PROCEDURE|Magnetic Resonance Imaging|
40790584|NCT00476320|PROCEDURE|Revascularization|
40790585|NCT00476320|PROCEDURE|Echocardiography with myocardial deformation imaging|
40994965|NCT02735551|OTHER|Referral for Long Acting Reversible Contraception (LARC)|Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
41468729|NCT03460145|OTHER|Lavender Oil on Nasal Strip (Lx)|Usage of Aromatherapy for Preoperative Anxiety
40790586|NCT00002286|DRUG|Zidovudine|
41309893|NCT01389622|OTHER|acupuncture|random points + digital pressure
41309894|NCT05740293|PROCEDURE|VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism|Bilateral treatment with the approved VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism.
41309895|NCT01070524|DRUG|CHF 5188 pMDI|CHF 5188: fixed combination budesonide/carmoterol
41309896|NCT01070524|DRUG|Budesonide extrafine pMDI|Budesonide extrafine pMDI
41309897|NCT01070524|DRUG|Seretide(r) Evohaler(r)|Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
41309898|NCT00099359|DRUG|Zidovudine|Given for 6 weeks. 12mg PO BID if birthweight (BW) \> 2000 grams 8 mg PO BID if BW \< 2000 grams
41309899|NCT00099359|DRUG|Nevirapine (NVP)|"Standard of Care (Zidovudine) plus~NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :~12 mg PO per dose if BW \> 2000 grams, 8 mg PO per dose if BW \< 2000 grams"
41309900|NCT00099359|DRUG|Epivir (3TC)|"Stand of care (Zidovudine) plus~3TC, given for 2 weeks: 6 mg po bid if BW \> 2000 grams 4 mg po bid if BW \< 2000 grams AND~NFV, given for 2 weeks:~200 mg po bid if BW \> 3000 grams 150 mg po bid if BW \> 2,000 - 3000 grams 100 mg PO BID if BW \< 2000 grams"
41309901|NCT00099359|DRUG|Nelfinavir (NFV)|200 mg BID if birth weight (BW) \> 3000 grams for 2 weeks;150 mg BID if BW \> 2000-3000 grams for 2 weeks; 100 mg BID BW \</= 2000 grams for 2 weeks
41309902|NCT05201183|COMBINATION_PRODUCT|Fludarabine + Total Marrow Irradiation|"Patients will receive total marrow irradiation TMI on Day -11 to Day -7 in two fractions per day. The TMI dose will be escalated in successive cohorts compromised of 3-6 patients as follows:~Cohort 1 1.4 (Gy/fraction) Cohort 2: 1.6 (Gy/fraction) Cohort 3 1.8 (Gy/fraction) Cohort 4 2.0 (Gy/fraction) Cohort 5 2.2 (Gy/fraction)~Patients will receive Fludarabine (30 mg/m2/day) on Day -6 to Day -2 followed by allo-HSCT on Day 0."
41309903|NCT06242470|BIOLOGICAL|MGC026 Dose Escalation|Escalating doses of MGC026
41309904|NCT06242470|BIOLOGICAL|MGC026 Dose for Expansion|MGC026 recommended dose for expansion
41309905|NCT04802980|DRUG|HB002.1T|HB002.1T is a vascular endothelial growth factor receptor decoy
41309906|NCT04802980|DRUG|Oxaliplatin|Oxaliplatin is an anti-tumor drug
41309907|NCT04802980|DRUG|Capecitabine|Capecitabine is an anti-tumor drug
41309908|NCT04802980|DRUG|Paclitaxel|Paclitaxel is an anti-tumor drug
41309909|NCT04802980|DRUG|Gemcitabine|Gemcitabine is an anti-tumor drug
41309910|NCT04802980|DRUG|Cisplatin|Cisplatin is an anti-tumor drug
41309911|NCT04802980|DRUG|Carboplatin|Carboplatin is an anti-tumor drug
41309912|NCT06480305|DIETARY_SUPPLEMENT|Post dinner snack|one walnut, 2 cashews, 2 almonds, and 2 pistachios.
41468730|NCT03460145|OTHER|Strip without Lavender Oil (Px)|Strip without Lavender Oil (Px)
41468731|NCT03460145|DRUG|Propofol 1 % Injectable Suspension|Propofol 1% (10mg/mL)
41468732|NCT05237128|BEHAVIORAL|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their type 2 diabetes using a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
40790587|NCT00131521|DRUG|mucomyst|
41309913|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-1|Prepackaged dose of 25 peanuts.
41309914|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-2|Prepackaged dose of 25 raisins
41309915|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-3|Prepackaged dose of 25 peanuts on one day and 25 raisins as a pre-breakfast.
41309916|NCT00469755|DRUG|Adapalene Gel, 0.1%|Apply once daily in the evening for 12 weeks
41309917|NCT00469755|DRUG|Tazarotene Cream, 0.1%|Apply once daily in the evening for 12 weeks
41309918|NCT00469755|DRUG|Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%|Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
41309919|NCT00122356|DRUG|Alendronate sodium|70mg tablets, once weekly
41309920|NCT02876770|DIETARY_SUPPLEMENT|Experimental: Melatonin|Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
41309921|NCT02876770|DIETARY_SUPPLEMENT|Placebo|In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
41309922|NCT02236728|DRUG|Pramipexole|
41309923|NCT04869904|PROCEDURE|dental and plaque sampling|sampling of dental plaque and saliva during the treatment
41309924|NCT06324994|DRUG|Linperlisib in combination with Obinutuzumab and Venetoclax|Combined induction period: Linprixate: 80 mg, oral (pre - and post meal), once a day; Otuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Vineclavone: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle), one cycle every 28 days, for a total of 6 cycles。 Maintenance treatment period: Linprixate: 80 mg, oral (both before and after meals), once a day; Vinecala: 400 mg, oral, once daily; Cycle every 28 days.
41309925|NCT02976376|OTHER|The Box|The Box contains four smartphone compatible devices. Patients will measure their vital signs and automatically send them to the hospital.
41309926|NCT00458406|DEVICE|Bi-Flex|"Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months"
40994966|NCT02735551|OTHER|Prescription for Short-Acting Hormonal Contraception|Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
40994967|NCT01741922|DRUG|ASA evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
40994968|NCT01741922|DRUG|Acetylsalicylic morning|Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
40994969|NCT01741922|DRUG|Placebos morning|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
40994970|NCT01741922|DRUG|Placebo evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
40994971|NCT03608774|DRUG|Azithromycin|Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.
40994972|NCT03608774|DRUG|Doxycycline|Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.
40994973|NCT03608774|OTHER|Placebo|Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.
40994974|NCT02313025|OTHER|speech sound intervention|"An intervention that stimulates speech sound perception and production in four-year-olds.~Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks"
40994975|NCT02313025|OTHER|World-project|An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
40994976|NCT02990169|DEVICE|CATS tonometer prism|IOP tonometer prism for assessment of intraocular pressure
40994977|NCT02990169|DEVICE|Goldmann Tonometer prism|IOP tonometer prism for assessment of intraocular pressure
40994978|NCT04098276|BEHAVIORAL|WeWomen Plus technology based intervention|The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
40994979|NCT01938911|DRUG|Syntocinon-Spray|Intranasal oxytocin (24 IU)
41468733|NCT05237128|BEHAVIORAL|Moderate-carbohydrate plate-method diet|"Participants in this arm will be taught to manage their type 2 diabetes using a plate-method approach. This diet involves eating different categories of foods based on the proportions of a plate, balancing proteins, vegetables, fruits, starches, and fats.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
41468734|NCT06133309|BEHAVIORAL|Experiential Phenomenological Interview|"Consciousness fluidity of patients suffering from depressive disorder and treated with Esketamine will be evaluated thanks to Experiential Phenomenological Interview and EQFC Trait questionnaire"
41468735|NCT01657084|DEVICE|CDA Mask|The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
41468736|NCT01657084|DEVICE|Dummy mask|The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
41468737|NCT02177552|DRUG|Carboplatin|
41468738|NCT02177552|DRUG|Docetaxel|
41468739|NCT02177552|DRUG|Capecitabine|
41468740|NCT02177552|DRUG|Epirubicin|
41468741|NCT02177552|DRUG|Oxaliplatin|
41468742|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
41468743|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
40994980|NCT01938911|DRUG|Placebo of syntocinon|Intranasal administration
40994981|NCT01938911|BEHAVIORAL|Social support|Social support from the best friend
40994982|NCT00316199|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
40994983|NCT00316199|DRUG|paclitaxel|175 mg/m2, intravenous (IV), every 21 days until disease progression
41309927|NCT00458406|DEVICE|CPAP|"CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months."
40994984|NCT05792228|OTHER|nurse-led standardized intervention|Once the patient in the intervention group decided to undergo cisplatin-based chemotherapy, the nurses would assess the risk factors associated with chemotherapy-induced nausea and vomiting (CINV) and reported to the physicians. During the chemotherapy, nurses would provide education on prevention and control of CINV using web-based approaches. All patients received standard antiemetic regimen, which included Aprepitant, 5-Hydroxytryptamine3-receptor antagonists, and Dexamethasone. If the physician's prescription was not accordance with the standard antiemetic regimen, nurse would remind the physician to adjust the prescription. Patients were recommended to eat small and frequent meals slowly. Overly spicy, fatty, and sweet foods should be avoided. Music relaxation therapy was performed for 60 min each time, once a day, and 3 times in the whole chemotherapy cycle. Follow-up was delivered until the 5th day after chemotherapy.
40994985|NCT01631058|DRUG|Everolimus|"This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.~Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
41309928|NCT02857335|BEHAVIORAL|neurocognitive tests|Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
41309929|NCT04346134|PROCEDURE|mini-PNL|Percutaneous nephrolithotomy using miniature nephroscope. The procedure will be performed under general or spinal anesthesia under fluoroscopy guidance.
41309930|NCT04346134|PROCEDURE|SWL|Extracorporal shockwave lithotripsy using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
41309931|NCT04543474|OTHER|Low Lactose Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
41309932|NCT04543474|OTHER|Low FODMAP Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
41309933|NCT05742087|OTHER|Clinical examination|The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
41309934|NCT05742087|OTHER|electroneuromyography (ENMG)|Data from the ENMGs will be extracted from the cohort and analyzed.
41309935|NCT01981967|BIOLOGICAL|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
41309936|NCT01981967|BIOLOGICAL|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
41309937|NCT04550793|DRUG|Botulinum toxin injection|Botulinum toxin injection at affected brachialis and/or biceps brachials.
40994986|NCT05199454|OTHER|Exercise training|Aerobic exercise training using a treadmill or a bike for 12 weeks, 3 times per week, 60 minutes per session.
40994987|NCT03573986|BIOLOGICAL|[18F]fluoromisonidazole|positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)
40994988|NCT03573986|DRUG|Bevacizumab|Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
40994989|NCT03573986|RADIATION|positron emission tomography (PET/CT).|PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
40994990|NCT01678963|DRUG|Squalamine lactate|Ophthalmic solution 0.2%
40994991|NCT01678963|DRUG|Vehicle control|Ophthalmic solution vehicle control
40994992|NCT06333288|BEHAVIORAL|PST-APPLE Watch group|PST combined APPLE Watch is a tailored behavioral intervention that enables college students with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake and teach problem-solving skills.
41309938|NCT02559154|DRUG|Bortezomib|
41309939|NCT02559154|DRUG|Dexamethasone|
41309940|NCT02559154|DRUG|Doxorubicin|
41309941|NCT02559154|DRUG|Cyclophosphamide|
41309942|NCT02559154|DRUG|Mitoxsnteone|
41309943|NCT02559154|DRUG|Thalidomide|
41309944|NCT03026413|PROCEDURE|pulmonary vein antrum modification|
41309945|NCT01458509|BEHAVIORAL|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. The intervention will be an email alert to study personnel (EASP). Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
41468744|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
41468745|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
41148584|NCT00751088|PROCEDURE|MiniArc positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure."
41309946|NCT01458509|BEHAVIORAL|surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
40994993|NCT06333288|BEHAVIORAL|Education-only control group|Education-only control group receives Quit Drinking Motivation 20-min video created by the MotivationHub, followed by a 30-minute group discussion.
40994994|NCT02050282|OTHER|Supplementary NT-proBNP measurement|In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
40994995|NCT05543486|DEVICE|Levitation 2 Tri-Compartment Offloader (TCO) knee brace|Spring Loaded Technology Levitation 2 Tri-Compartment Offloader (TCO) brace containing proprietary spring technology providing a knee extension assist.
40994996|NCT05543486|DEVICE|Knee sleeve|Neenca soft knee sleeve comprised of elastic air knit fabric with a silicone padded patella inset and flexible stays on the medial and lateral sides.
40994997|NCT02600637|BEHAVIORAL|MBSR|Mindfulness-based Stress Reduction is an 8-week course designed to teach a number of mindfulness techniques to help improve stress- and depression-related symptoms.
41309947|NCT01458509|BEHAVIORAL|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not get a phone call.
41468746|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.
41468747|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
40994998|NCT02600637|BEHAVIORAL|Brain Health class|An 8-week course on brain health will be administered to participants as an active control group.
41148585|NCT00751088|PROCEDURE|TVT secur system positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure."
41148586|NCT00751088|PROCEDURE|Ajust positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure."
41148587|NCT00751088|PROCEDURE|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
40790588|NCT00131521|DRUG|sodium chloride (saline)|
40790589|NCT03211663|DEVICE|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
40994999|NCT03422393|DRUG|Venetoclax|On cycle 1, day 1, patients will initiate venetoclax. The dose of venetoclax will ramp-up from 20 mg PO daily to 400 mg PO daily over a 5 week period.
40995000|NCT03422393|DRUG|Ibrutinib|"During the screening period, patients will continue on ibrutinib at their previous tolerated dose, unless required to stop (e.g.: by a preceding clinical trial).~On cycle 1, day 1, the dose of ibrutinib will be assigned based on the dose cohort. Patients in cohort 1 will receive ibrutinib 420 mg PO daily. Patients in cohort 2 will receive ibrutinib 560 mg PO daily. Cohort 3 will be 840 mg PO daily."
40995001|NCT02357940|DRUG|Experimental Product|1% Colloidal Oatmeal Balm
40995002|NCT02890979|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
40995003|NCT02890979|OTHER|Laboratory Biomarker Analysis|Correlative studies
40995004|NCT02890979|OTHER|Quality-of-Life Assessment|Ancillary studies
40995005|NCT02890979|DEVICE|Swallowable Sponge Cell Sampling Device|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
40995006|NCT03025061|OTHER|Assessment of E-nose measurements|Breath sampling through E-nose pneumopipe
40995007|NCT02155023|DRUG|Insulin dosing|
40995008|NCT02155023|DEVICE|Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)|
40790590|NCT01147393|DRUG|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over \~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
40790591|NCT01147393|BIOLOGICAL|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
40790592|NCT01856322|DRUG|Sulindac|one tablet 150mg twice daily
40790593|NCT01856322|DRUG|Placebo|One tablet twice daily
40790594|NCT01856322|OTHER|Validate assays and shipping methods|
40790595|NCT00222976|DRUG|Naproxen|Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
40790596|NCT03489044|DRUG|Levetiracetam|To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks
40790597|NCT03489044|DRUG|Placebo Oral Tablet|To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
40790598|NCT04217707|BEHAVIORAL|Pre- and Post-Surgical Transgender Therapeutic Support Group|Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
40790599|NCT02116842|DRUG|0.1% bupivacaine|Epidural block in early labour.
40790600|NCT02116842|DRUG|0.075% bupivacaine|Epidural block in early labour.
40790601|NCT02116842|DRUG|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
40995009|NCT06141447|DRUG|Oxytocin + normal saline|40 units IV oxytocin once in a 1000 mL bag of normal saline
40995010|NCT06141447|DRUG|Normal saline|1000 mL bag of normal saline alone
40995011|NCT04816955|BEHAVIORAL|Dietary recommendations|Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
40995012|NCT00624494|DEVICE|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
40995013|NCT00624494|DEVICE|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
40995014|NCT03685084|DRUG|AAI101 i.v.|600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
40995015|NCT03685084|DRUG|Saline 0.9% infusion|Vehicle infusion
40995016|NCT03685084|DRUG|Piperacillin i.v.|piperacillin 3 g i.v.
40995017|NCT03685084|DRUG|Cefepime i.v.|cefepime 1 g i.v.
40995018|NCT03448185|BEHAVIORAL|High intensity exercise|Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.
40995019|NCT03448185|DIETARY_SUPPLEMENT|Omega-3 fish oil|Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.
40995020|NCT03448185|BEHAVIORAL|Yoga|Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.
40995021|NCT03448185|DIETARY_SUPPLEMENT|olive oil capsules|Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
41468748|NCT00830167|DRUG|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
40790602|NCT04621994|OTHER|Dermabond|Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips
40790603|NCT04621994|OTHER|Steri Strips|Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
40995022|NCT04535895|RADIATION|Simultaneous integrated boost|Adjuvant breast cancer irradiation including simultaneous integrated boost
40995023|NCT05863637|OTHER|Intensive Short-Term Dynamic Psychotherapy|A dynamic and intensive psychotherapy with eight therapeutic sessions
40995024|NCT03323346|DRUG|Disulfiram|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
41468749|NCT00830167|DRUG|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
41468750|NCT04079452|DRUG|Doravirine|Doravirine 100 mg tablet
41468751|NCT04079452|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
40790604|NCT02733744|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
40790605|NCT00028158|DRUG|G207, an oncolytic virus|
40790606|NCT00243191|DRUG|imatinib mesylate|400 mg orally twice a day for 10 - 14 days
40995025|NCT01814501|BIOLOGICAL|panitumumab|Given IV
40995026|NCT01814501|DRUG|irinotecan hydrochloride|Given IV
40995027|NCT01814501|DRUG|fluorouracil|Given IV
40995028|NCT01814501|DRUG|leucovorin calcium|Given IV
40995029|NCT01844609|BEHAVIORAL|Self Study Journal Club|This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
40995030|NCT01844609|BEHAVIORAL|Intensive Journal Club|This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
40995031|NCT03001258|OTHER|Presbyopia screening training|The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity
40995032|NCT05415696|PROCEDURE|Prostatic artery embolization|Patients will undergo PAE with 100-300 µm or 300-500 µm Embospheres following standard PAE technique performed by Interventional Radiology at Stanford University
41148588|NCT00412802|DRUG|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
41148589|NCT00412802|DRUG|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
41148590|NCT02473913|DRUG|Milk Thistle|
41148591|NCT02473913|DRUG|Placebo|
41148592|NCT02852499|OTHER|Urine sampling|
41468752|NCT01164215|DRUG|fluorouracil|200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
41468753|NCT01164215|DRUG|leucovorin|200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
41468754|NCT01164215|DRUG|oxaliplatin|85 mg/m2, intravenously for 2 hours, once every 2 weeks
41468755|NCT06535555|DEVICE|Investigational Safety and Feasibility|"Technical feasibility will be assessed based on a five-point rating scale assessing the ease-of-use, ureteral visibility, and time required to identify the ureter using ActivSight™. All images and video of the ureter will be recorded, but surgeon feedback will be used to assess technical success based on a five point scale, rather than these (subsequently de-identified) recordings.~Safety will be confirmed through clinical assessments and evaluation of adverse events intraoperatively and through a 28-day follow-up period using the criteria listed below. All adverse events will be adjudicated by the site's Principal Investigator (PI) to judge the relatedness of the adverse event to either the administration of riboflavin or the use of the prototype ActivSight™ device (or whether the adverse event was unrelated to either)"
41468756|NCT04724499|BEHAVIORAL|High-Intensity Intervals Training|16 week exercise program with stationary bike.
41468757|NCT04724499|OTHER|Attention Control|16 week stretching program.
41148593|NCT02852499|OTHER|Carry a GPS and BET|
41148594|NCT02852499|OTHER|Carry pollution sensor|
41148595|NCT02852499|OTHER|Sampling at the maternity|
41148596|NCT02852499|OTHER|Self-questionnaires|
41148597|NCT02852499|OTHER|Sampling in partum period|Meconium and a strand of hair.
41148598|NCT02720978|DRUG|Intravenous oxytocin|"Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
41148599|NCT02720978|DRUG|vaginal prostaglandin|"Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
41309948|NCT01458509|BEHAVIORAL|Surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not receive a phone call.
41468758|NCT03754530|DRUG|Icotinib|orally three times per day
41468759|NCT03754530|RADIATION|WBRT or SRS|\>3 with WBRT;\<=3 with SRS
41148600|NCT02732470|OTHER|Qi Gong|The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
41309949|NCT04761029|OTHER|RIIS|unilateral Rhomboid intercostal and subserratus block
41309950|NCT04761029|DRUG|Tramadol|intravenous patient-controlled analgesia (tramadol)
41468760|NCT03397953|DRUG|Vinorelbine|Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
41468761|NCT05044494|PROCEDURE|non-prompt surgery|
41468762|NCT01610609|BEHAVIORAL|Population Health Management Intervention|"This intervention includes:~* Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and~* Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention"
40995033|NCT03343483|BEHAVIORAL|Volunteering|"Volunteers provide non-medical caregiving for frail seniors-care receivers-to help them maintain their independence and improve their well-being. Friendly visiting is the primary service provided. Structured, intensive training is provided prior to placement. The target expectation is of interactions in person and/or by telephone for at least 16 hours per month. On-going training (booster sessions) as well as volunteer support groups, and educational activities are provided. Participants not interested in serving as peer companions are allowed other volunteer options as long as the activities are deemed 'social' by the volunteer coordinator and are options routinely provided as part of the AmeriCorps Senior RSVP Program. COVID update: due to physical distancing requirements, volunteer placements have transitioned to remote friendly calling/letter writing or activities that can be conducted with physical distancing, such as delivery for Meals on Wheels."
40995034|NCT03343483|BEHAVIORAL|Life Review|Subjects will complete a self-guided life review exercise over 12 months. Subjects will complete one section of the life review (with the self-help book) each month and send 'assignments' once per month to an email 'counselor' who will respond with supportive comments within three days.
40995035|NCT03147547|OTHER|Promotional Brochure|Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
40995036|NCT03147547|OTHER|Family Testimonial Flyer|Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
40995037|NCT03147547|OTHER|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
40995038|NCT03147547|OTHER|Provider Engagement Call|This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
40995039|NCT00325754|DEVICE|E-Cylinder|Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart
40995040|NCT00325754|DEVICE|Lightweight Cylinder|Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
40995041|NCT04366037|OTHER|Routine training|Training will be defined by each club coach
40995042|NCT04366037|OTHER|Routine training + proprioceptive exercise in warm-up|"Training will be defined by each club coach, adding four proprioceptive exercises in warm-up:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
40995043|NCT04366037|OTHER|Routine training + proprioceptive exercise in cool-down|"Training will be defined by each club coach, adding four proprioceptive exercises in cool-down:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
40995044|NCT02918149|OTHER|Palpation Landmark Technique|"Clinician will follow routine palpation landmark technique procedure for LP, such as identification of anatomic landmarks by palpation (i.e., superior borders of the posterior iliac crest lies in parallel with L4 spinous process). Palpation will be followed by blind stick of the appropriate inter-spinous process space. The study member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
40995045|NCT02918149|DEVICE|Ultrasound-Assisted Technique LP|"Clinician will use an ultrasound-assisted technique to perform the LP. The Phillips CX50 ultrasound machine is an FDA approved device and will be used in accordance with its approved labeling. Spinal ultrasound will be performed using a linear high-frequency transducer to locate and mark the termination of the conus medullaris, the narrowing of the spinal canal, and the midline to delineate a safe zone. The study team member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
41148601|NCT05714280|BEHAVIORAL|PA4Health Open Pilot|"The goal of this aim is to collect data that guide the refinement of intervention components and structure to increase appeal to AA women. Fifteen physically inactive AA women will participate in a 12-week study examining the feasibility, acceptability, and usage of the PA4Health app.~They will receive a Fitbit tracker to be worn during the trial. Following the trial, participants will complete self-report measures as well as a semi-structured interview to learn about their experience in using the app, any experienced difficulties, and recommendations for improving the acceptance and usage of the app."
41309951|NCT04773899|DIAGNOSTIC_TEST|Procedure : Multimodal microvascular assessment at study inclusion|"* Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.~* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.~* Morphological analysis of the microcirculation by sublingual videomicroscopy."
41309952|NCT02266758|OTHER|GDM Screening Methods|
41468763|NCT04950686|BEHAVIORAL|Media Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults that uses a media literacy education (MLE) approach.
41468764|NCT04950686|BEHAVIORAL|Health Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults.
41468765|NCT04231331|DRUG|Ertugliflozin|Ertugliflozin 5mg qd for 12 months
41468766|NCT04231331|DRUG|Placebo|Placebo qd for 12 months
40995046|NCT04748133|DEVICE|acupuncture needles|"Site of acupuncture points:~* Du 26: At junction of the upper and middle third of philtrum.~* Ren 17: On the midline level with the 4th intercostal space midway between the nipples.~* LI4 (Large Intestine 4): On the dorsum of the hand, between the 1st and 2nd metacarpal bones~* HT7 (Heart 7): On the ulnar end of the transverse crease of the wrist, in the small depression between the pisiform and ulna bones~* LV3 (Liver 3): On dorsum of the foot in a depression distal to the junction of the 1st and 2nd metatarsal bones.~* ST36 (Stomach 36): Antero-lateral leg, 1 middle-finger breadth next to the anterior crest of tibia, 3 cun under the depression lateral to the patellar ligament.~* PC6 (Pericardium 6): Palmar aspect of the forearm, between the tendons, 2 cun away from the transverse crease of the wrist"
40995047|NCT04748133|OTHER|placebo|no treatment
40790607|NCT04181229|PROCEDURE|Deep brain stimulation|Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.
40995048|NCT05442164|BEHAVIORAL|DANAKIR support network|"The DANAKIR intervention will consist of:~* Structured written discharge information~* Invitation to the DANAKIR monthly information meeting DANAKIR meetings The monthly meetings are a core component of the support network. One time each month, a meeting will be held at Herlev Hospital with the participation of an emergency surgeon, an emergency surgery dedicated nurse, a dietician, and a physiotherapist. Each professional (surgeon, nurse, dietician, physiotherapist) will host an informative 15 minute session regarding the postoperative course after major emergency surgery. Following the presentations time for questions in plenum and private with the different experts will be held. Furthermore, there will be an opportunity for networking at the DANAKIR meeting. Each meeting is planned to last 2 hours. At the end of each meeting the patients will be asked to evaluate the meeting and content."
40995049|NCT06244862|DRUG|Ruxolitinib|Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.
40995050|NCT02856633|DEVICE|Vitaliti|
40995051|NCT00994955|DEVICE|selective retina therapy (SRT)|laser treatment
40995052|NCT00925418|PROCEDURE|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
40995053|NCT00108056|DRUG|Enzastaurin (LY317615) monohydronchloride|
41148602|NCT03743597|DEVICE|SOCKNLEG|"Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other"
41148603|NCT03743597|DEVICE|Sigvaris COTTON|"Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other"
41148604|NCT02827851|PROCEDURE|Liposuction|
41148605|NCT02827851|OTHER|SVF isolation|SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
41148606|NCT02827851|OTHER|Intraarticular administration of autologous SVF|
41309953|NCT06395428|DRUG|Haloperidol|Intramuscular injection of drug
40995054|NCT01454921|BEHAVIORAL|Evolution: Young Women Taking Charge and Growing Stronger|The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).
40995055|NCT00860782|BEHAVIORAL|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
40995056|NCT00908726|DRUG|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
40995057|NCT01453283|DRUG|Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])|
40995058|NCT05263700|DRUG|68Ga-FAPi-46|FAPI-46 is a small molecular radiopharmaceutical that binds to the fibroblast activated protein on cancer associated fibroblasts. Gallium-68 (68Ga) is a positron-emitting isotope with a half-life of 68 minutes.
40995059|NCT05263700|PROCEDURE|PET/CT imaging|PET with the investigational tracer 68Ga-FAPI-46 with accompanying low-dose CT for anatomical localisation
40995060|NCT03432546|OTHER|Non-interventional|Non-interventional
40995061|NCT00575055|DRUG|Bapineuzumab 0.5 mg/kg|given by infusion every 13 weeks for a total of 6 infusions.
41309954|NCT06395428|DRUG|Ketorolac Tromethamine|Intramuscular injection of drug
41309955|NCT06483516|PROCEDURE|Open repair|Open repair via median laparotomy or lumbotomy
41309956|NCT06483516|PROCEDURE|Endovascular repair|EVAR if AAA simple F-BEVAR if Complex AAA
41468767|NCT00804024|DEVICE|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
41468768|NCT06453824|DRUG|MDI-2517|study drug
41468769|NCT06453824|OTHER|Placebo|matching placebo
40995062|NCT00575055|DRUG|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
40995063|NCT00575055|DRUG|Bapineuzumab 1.0 m/kg|given by infusion every 13 weeks for a total of 6 infusions.
40995064|NCT06259240|OTHER|Prone plank exercises|Patients in this group will recieve prone plank exercises, three times a week, for eight weeks, and with a moderate hard intensity. During the first four weeks, the exercises session began with light walking for five minutes followed by corrected exercises. Firstly, women will perform stable prone plank exercises. Secondly, women will be asked to apply the unilateral position of prone plank. Thirdly, using a 65 cm diameter Swiss ball, women will be asked to assume the prone bridge position. During the last four weeks, women will be asked to repeat the same program noting that the progressive prone plank exercises should be applied in a dosage of 20 repetitions, three sets, holding the contraction for one minute, and taking a break for two minutes.
40995065|NCT06259240|DEVICE|Electrical Stimulation|Electrical Stimulation
40995066|NCT02211131|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10\^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10\^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
40995067|NCT02211131|PROCEDURE|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
40995068|NCT06094647|DEVICE|Altitudes USA|Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self-care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
40995069|NCT05459103|OTHER|Bidirectional remote interaction intervention|Intervention group participants engaged in a 12-week bidirectional remote interaction. All interactions were conducted through the same group on Line. A one-hour interactive online group intervention was held every Monday to Friday from 14:30 to 15:30, for a total of 60 hours. The online interactive interventions were conducted in a structured course format, with a facilitator conducting live classes and alternating between static and dynamic classes.
40995070|NCT05459103|OTHER|Unidirectional remote interaction intervention|Control group participants engaged in a 12-week unidirectional remote interaction. All interactions were conducted through the same group on Line. Research assistants posted a YouTube video on the Line group at 14:30 every day, Monday through Friday, covering art, music, senior sports, long-term care resources, travel, and food preparation.
41309957|NCT00869765|DRUG|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
41309958|NCT00869765|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
41468770|NCT03799848|DRUG|Vadadustat|Oral tablet
41468771|NCT02419573|DEVICE|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
41468772|NCT02419573|DEVICE|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
40790608|NCT01056081|OTHER|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
40790609|NCT05248178|BEHAVIORAL|CO-OP Procedures|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
40790610|NCT05248178|DEVICE|tDCS|Each session will begin with 20 minutes of anodal tDCS applied to the ipsilesional dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. The cathode will be placed over the contralesional supraorbital area. Direct current will be applied through two saline soaked sponges placed on the scalp. The tDCS device contains software for double-blinded delivery.
40790611|NCT05248178|BEHAVIORAL|Computer Cognitive Training Procedures|Individuals receiving computerized cognitive training will receive an equal dosage of 12, 45-minute sessions directly following the assigned tDCS condition. The online training software of BrainHQ will be used. BrainHQ is a well-recognized cognitive training program that targets the areas of attention, memory, processing speed, people skills, intelligence, and navigation. BrainHQ tracks progress and automatically grades difficulty as appropriate.
40790612|NCT05248178|DEVICE|sham tDCS group|Sham tDCS will involve the same preparation as in tDCS, but the current will ramp up for only 30 seconds and then return to zero. This method allows for sensations on the scalp associated with tDCS without inducing any neural changes.
40790613|NCT00539123|BEHAVIORAL|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
40790614|NCT00539123|BEHAVIORAL|abstinence-contingent buprenorphine (ACB)|Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.
40790615|NCT04992468|DRUG|Ovulation triggering with GnRH-a+rhCG|recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)
41468773|NCT00981227|DRUG|Eslicarbazepine acetate|Scored tablets
41468774|NCT00981227|DRUG|Placebo|oral route
40790616|NCT04992468|DRUG|Ovulation triggering with GnRH-a|rFSH 225-300 IU (Gonal-F®/Puregon®/Ovaleap®/ Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®)
40790617|NCT03880045|DRUG|Topical TA|A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
40995071|NCT02784990|BIOLOGICAL|Lipase, amylase and CRP (C-reactive protein) dosages|
40995072|NCT02678676|OTHER|No Intervention|Participants who previously received Pioglitazone in the PROactive study (NCT00174993).
40995073|NCT02678676|OTHER|No Intervention|Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).
40995074|NCT00628602|DEVICE|BION|"30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group)."
40995075|NCT01273402|DRUG|TF2/IMP288|TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
40995076|NCT01064492|DRUG|PF-04620110|The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
40995077|NCT02618434|DRUG|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 9 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
41468775|NCT05734131|OTHER|Bio-psychosocial assessment|Kinematic parameters were analyzed by two functional tests, the 10-Meter Walking Test (10MWT) and the Time Up\&Go test (TUG).
40995078|NCT02618434|DRUG|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 18 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
40995079|NCT02618434|DRUG|Placebo|Subjects were randomized to receive Placebo twice each day with food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
41468776|NCT01494103|BIOLOGICAL|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
41148607|NCT05259592|BEHAVIORAL|Psychotherapy|Modular Patient Centred CBT (MPC) for CPTSD (Folke, Friis, Thomsen \& Roitmann, 2020) is a psychotherapy treatment manual consisting of up to 32 individual therapy sessions broken down by five treatment modules (each consisting of six sessions) that directly address the symptoms of CPTSD: 1) Affect dysregulation, 2) Disturbed relationships, 3) Negative self-concept, 4) PTSD symptoms, and 5) Insomnia and trauma-related nightmares.
41468777|NCT01494103|DRUG|AP1903|"AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."
41468778|NCT05510245|DRUG|PF-07081532|One PF-07081532 20 mg tablet, administered orally
41309959|NCT06064708|BEHAVIORAL|Mindfulness-based intervention|"The experimental group received 30 minutes of MBI according to Smith's (2005) MBI protocol, which is a standardized theory-based intervention.~Smith's (2005) MBI protocol comprises six components:~1. Being mindful of the breath (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of the thought (5 minutes)~4. Being mindful of the sound (5 minutes)~5. Being mindful during walking (5 minutes)~6. Full meditation (5 minutes)."
40995080|NCT05929183|DEVICE|Repetitive Transcranial magnetic stimulation|"Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of depressive symptom was dorsolateral prefrontal cortex (DLPFC). In this study, we use high frequency rTMS in the occipital lobe are precisely targeted by navigation, by stimulating the primary visual cortex（V1), can affect the orbitofrontal cortex (OFC), which is functionally connected to V1, and thus affect the entire nerve ring pathway excitability, thereby rapidly, effectively and safely improving mood symptoms in the acute phase of bipolar depressive episode.~After the target was determined by fMRI navigation and positioning, the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000."
40995081|NCT05929183|DEVICE|Sham Repetitive Transcranial magnetic stimulation|The stimulus intensity was 20% of MT in the Sham Comparator arm, and the remaining parameters were the same as the Active Comparator arm.
40995082|NCT01367574|DRUG|SC MNTX|Dose 1
40995083|NCT01367574|DRUG|SC MNTX|Dose 2
40995084|NCT01367574|DRUG|SC MNTX|Dose 3
41309964|NCT05591898|BEHAVIORAL|Progressive relaxation exercises|Training booklet and CD as a guide on the implementation of Progressive Relaxation Exercises prepared by the Turkish Psychological Association; muscle relaxation exercises, rhythmic breathing and music recital. In the first 10 minutes of this three-part CD, the definition and purpose of deep relaxation and the practices to be considered during exercise are explained. In the second part of 30 minutes; relaxation exercises are explained with the sound of the stream and verbal instructions. The third part, consisting of 30 minutes; it contains only relaxation music without instructions.
41309965|NCT05582785|DIAGNOSTIC_TEST|Hyperfine MRI|Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
41341741|NCT05049018|DEVICE|ArmeoSpring Virtual Reality Device (Upper Extremity Training Device with Virtual Reality Technology)|ArmeoSpring virtual Reality Equipment is a functional upper extremity rehabilitation device that provides specific therapy with augmented feedback. The ArmeoSpring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3 D workspace that allows functional therapy exercises in a virtual reality environment.
40995085|NCT03929848|PROCEDURE|Cuff pressure|observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery
40995086|NCT01188577|DRUG|Epinephrine Inhalation Aerosol, HFA|10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
40995087|NCT01188577|DRUG|Epinephrine Inhalation Aerosol|Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
40995088|NCT04922918|BIOLOGICAL|Ligilactobacillus salivarius MP101|Administration of the strain through a fermented milk
40995089|NCT00860912|PROCEDURE|Collagen Matrix|surgical/reinforcing material
40995090|NCT02142127|DRUG|14C-labelled GFT505 120 mg|
41468779|NCT06345963|DEVICE|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
41341742|NCT06032988|DIETARY_SUPPLEMENT|LactoLevure|Participants will receive LactoLevure\^R probiotic dietary supplement or matching placebo once a day.
40995091|NCT00834210|DRUG|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
40790618|NCT03880045|DRUG|vasopressin|intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy
40790619|NCT03880045|OTHER|placebo to TA|(120 ml of sodium chloride 0.9%) used to compress the myoma bed for 5 min.
40790620|NCT05287776|DEVICE|Narrow band UVB|Narrow band UVB emitting UVB at wavelength 311nm
41341743|NCT01871272|PROCEDURE|Arthroscopic Meniscus Surgery|Surgery to the meniscus - resection or repair.
40995092|NCT00834210|DRUG|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
40995093|NCT04930848|OTHER|Euphorbia hirta (Dudhiya)|Duration of the intervention was 2 consecutive weeks or 14 days. In each evening, one teaspoon full (3gm) powder should be mixed with two cups of water and boiled. When it becomes half(one cup), have to add one teaspoon of sugar and drink it as tea.
41468780|NCT01417351|DIETARY_SUPPLEMENT|400 IU vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
41468781|NCT01417351|DIETARY_SUPPLEMENT|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
41468782|NCT05051878|DEVICE|T-scan|occlusal analysis T-scan
41468783|NCT05051878|OTHER|articulating paper|articulating paper occlusal analysis
41468784|NCT04272489|DEVICE|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device in a home trial.
40790621|NCT05001971|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
41468785|NCT03900117|RADIATION|split-course radiotherapy|Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor.
41468786|NCT03900117|DRUG|concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
41468787|NCT03662256|OTHER|Current Primary Care Referral Process|Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
41468788|NCT03662256|OTHER|Telemedicine Referral Process|In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
40790622|NCT02041299|DRUG|Deferiprone|
41468789|NCT06533657|DRUG|Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)|Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.
40790623|NCT02041299|DRUG|Deferoxamine|
40790624|NCT06499103|DEVICE|Transcutaneous electrical nerve stimulation|The stimulation (TENS) will be performed by a physiotherapist using adhesive electrodes with an area of 5 cm2 in the region where the patient has the symptoms of neuropathy. Further, it will be will be on 10 days consequently, with the same physiotherapist for whole sessions. He will apply electrodes over the affected area, then he will increase the stimulation intensity gradually during the first session when he adjusts the settings till patient reach the maximum voltage that he/she will tolerate it. The evaluations for CIPN patients will be performed by a blinded evaluatorthe PI on the experimental groups at 3 time points; before the begging of the intervention, after 5 days, and after the last session. The intervention group will undergo TENS sessions daily for 10 days for 30 minutes each session ( Gibson et al., 2017). After session completed a structured interview will be conducted, by the primary investigator, to assess for CIPN using the CIPNAT.
40790625|NCT03611218|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX P600 (Fresenius Medical Care), comparator Sureflux-17UX and comparator Polyflux 170 H
40790626|NCT05956847|PROCEDURE|gastroscopy|When performing gastroscopy, the endoscopist will perform a biopsy based on the condition of gastric mucosal lesions, with one specimen retained and the remaining specimens subjected to pathological examination
40790627|NCT05312684|PROCEDURE|cardiac surgery|cardiovascular surgery including valve repair/replacement or CABG or combined procedures
40790628|NCT05088044|OTHER|training porogram|training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
41468790|NCT00500006|DRUG|MK0457|"Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour."
41468791|NCT00500006|DRUG|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
40790629|NCT04793282|BEHAVIORAL|Telephone Follow-up|Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.
40790630|NCT03374735|DEVICE|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
40790631|NCT02625350|OTHER|Instant noodle without soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
40790632|NCT02625350|OTHER|Instant noodle with soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
40790633|NCT02625350|OTHER|Glucose reference|First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
40790634|NCT04470882|BEHAVIORAL|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
40790635|NCT04470882|BEHAVIORAL|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
40790636|NCT04470882|BEHAVIORAL|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
40790637|NCT05882760|DRUG|Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Etch \& Rinse Tetric - N - Bond (Ivoclar)
40995094|NCT04930848|OTHER|PBO(Combined powder of Terminalia arjuna and Terminalia bellerica)|Duration of the intervention was 2 consecutive weeks or 14 days. In each evening, one teaspoon full (3gm) powder should be mixed with two cups of water and boiled. When it becomes half(one cup), have to add one teaspoon of sugar and drink it as tea.
41148608|NCT05161247|OTHER|Zona pellucida sperm selection|Sperm selection for ICSI based on the spermatozoa ability to adhere to immobilized zona pellucida proteins.
41148609|NCT05161247|OTHER|Conventional sperm selection|Sperm selection for ICSI based on the sperm morphology.
40995095|NCT03067805|BEHAVIORAL|Sexual Infidelity Condition|
40995096|NCT03067805|BEHAVIORAL|Emotional Infidelity Condition|
40995097|NCT03067805|BEHAVIORAL|Neutral Condition|
40995098|NCT03067805|BEHAVIORAL|Player in Jealousy Condition|
40995099|NCT03067805|BEHAVIORAL|Player in Non-Jealousy Condition|
40790638|NCT05882760|DRUG|Self Etch Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Tetric N Bond Universal®
40790639|NCT05882760|DRUG|GC Fuji IX, GC, Japan®|Cavities will be restored with GC Fuji IX, GC, Japan®
40790640|NCT05882760|DRUG|Activa TM Bioactive Restorative ®|Cavities will be restored with Activa TM Bioactive Restorative ®
40790641|NCT01672086|DEVICE|Stelkast Surpass Acetabular System implant|
40790642|NCT01419600|DRUG|AZD8683|Single Dose Inhaled IMP via Turbuhaler
40790643|NCT01419600|DRUG|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
40790644|NCT00945659|DEVICE|Continuous Glucose Sensor|Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
40995100|NCT03871127|PROCEDURE|Percutaneous coronary intervention|Using sirolimus eluting stent
40995101|NCT03871127|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
40995102|NCT04358887|PROCEDURE|piezoelectric surgery|after flap reflection bone and root end cutting are done with piezoelectric surgical insert
41148610|NCT05161247|OTHER|Intracytoplasmic Sperm Injection (ICSI)|Normal ICSI procedure.
41148611|NCT01391234|RADIATION|STAT RT planning and delivery workflow|"* Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~* Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~* Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques."
41148612|NCT06309641|DIAGNOSTIC_TEST|Blood sample after treatment|Blood samples for measurement of methemoglobin are obtained directly before and 30-120 minutes after drug administration.
41148613|NCT06309641|OTHER|Case reports|Description of clinical course and methemoglobin levels in patients with severe anemia who developed methemoglobinemia after intravenous administration of ferric derisomaltose.
41148614|NCT01596777|DRUG|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
41148615|NCT01596777|DRUG|Loperamide placebo|200 ml apple juice
41148616|NCT01596777|DRUG|Methylnaltrexone placebo|Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
41148617|NCT01596777|DRUG|Methylnaltrexone 12 mg sc.|RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
41148618|NCT01596777|DRUG|Methylnaltrexone IR capsule|Methylnaltrexone bromide 500 mg IR capsule
41148619|NCT01596777|DRUG|Methylnaltrexone ER capsule|Methylnaltrexone bromide 500 mg ER capsule
41148620|NCT01596777|DEVICE|Colon Transit|3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
41148621|NCT01596777|DRUG|Sulfasalazine|500 mg Azulfidine® (Pharmacia)
41148622|NCT05581108|DIETARY_SUPPLEMENT|Juice PLUS+® OMEGA|Daily dose of total Omega blend: 925 mg (2 capsules)
40790645|NCT00945659|OTHER|Standard Care|Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
40790646|NCT00945659|BEHAVIORAL|CGS + Behavior Therapy|Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
40790647|NCT02276430|OTHER|Vena punction|Once 90 ml
40790648|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
40995103|NCT04358887|PROCEDURE|conventional bur|after flap reflection bone and root end cutting are done with surgical bur
41148623|NCT05581108|DIETARY_SUPPLEMENT|Placebo|matched placebo (2 capsules)
40790649|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
40790650|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
40790651|NCT02088853|DIETARY_SUPPLEMENT|high fat diet (hfd)|Sixty % of the energy content is based on fat.
40790652|NCT02088853|DIETARY_SUPPLEMENT|high carb diet|Sixty % of the energy content is based on carbohydrates.
40995104|NCT04581642|DEVICE|PMD200|The NOL technology is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
40995105|NCT04353011|OTHER|questionnaire assesment|questionnaire assesment
40995106|NCT03509675|DRUG|Ibuprofen suspension 5mg/100ml|Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
40995107|NCT03509675|DRUG|Placebos|Placebo
40995108|NCT03492333|OTHER|Gluten free diet|Gluten-free diet- Instructions provided by a dietitian
40995109|NCT01083095|BIOLOGICAL|Sporozoite Challenge Model for Plasmodium vivax in Humans|Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
40995110|NCT03299192|BEHAVIORAL|Tai Chi|Yang Style Tai Chi
40995111|NCT03299192|BEHAVIORAL|Health Education|Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain
40995112|NCT03299192|OTHER|Usual Medical Care|Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
40995113|NCT04318782|DEVICE|Pharmacodynamic thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
41148624|NCT04205500|OTHER|Specific carbohydrate diet|Specific carbohydrate diet (see arm description)
40790653|NCT04463537|PROCEDURE|Body Temperature Measurements|"measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form."
40790654|NCT01295151|DRUG|Etanercept|"Etanercept will be administered at a dose of 50mg by subcutaneous injection per week for a total of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
40790655|NCT01295151|DRUG|Abatacept|"Abatacept will be administered at a dose determined by body weight:~Body Weight (kg) Dose (mg) \< 60kg = 500 mg~\> or equal to 60kg and \< or equal to 100kg = 750 mg \> 100 kg = 1000mg~The intravenous infusions will be administered in clinic on days 1, 15, 29 and every 28 days thereafter for a minimum of 24 weeks. Further treatment will be prescribed at the discretion of the treating clinician."
40790656|NCT01295151|BIOLOGICAL|Rituximab|"Rituximab will be given at a dose of 1000mg; 2 intravenous infusions will be administered at days 0 (week 0) and 15 (week 2).~In line with standard practice, a patient who loses an initial response with a DAS28 increase of at least 0.6 may receive a further cycle of rituximab at the discretion of the treating clinician.~Prior to receiving rituximab, intravenous methylprednisolone 100mg will also be given."
40790657|NCT01295151|DRUG|Adalimumab|"Adalimumab will be given at a dose of 40mg by subcutaneous injection every two weeks for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
40790658|NCT01295151|DRUG|Certolizumab Pegol|"Certolizumab Pegol will be given at a dose of 400mg by subcutaneous injection at weeks 0, 2, 4and then at a dose of 200mg every two weeks thereafter for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
40790659|NCT01295151|DRUG|Infliximab|"Infliximab will be given at a dose of 3mg/kg per intravenous infusion in clinic.~The intravenous infusions will be administered at week 0, 2, 6 and then 8-weekly thereafter for a minimum of 12 weeks.~Further treatment will be prescribed at the discretion of the treating clinician."
40790660|NCT01295151|DRUG|Golimumab|"Golimumab will be given at a dose of 50mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.~Further treatment will be prescribed in line with the study protocol and following week 48, at the discretion of the treating clinician.~The participant will be taught how to administer the subcutaneous injection and injections will be monitored according to local arrangements until the participant is proficient with the technique according to local practice."
40790661|NCT04722341|BEHAVIORAL|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
40790662|NCT04722341|BEHAVIORAL|Control|More than equal to a 12-hour daily eating period
40995114|NCT02235376|OTHER|weaning trial of mechanical ventilation|
40995115|NCT04205760|COMBINATION_PRODUCT|Nutrition + exercise|Patients will receive preoperative optimization consisting of oral nutrition support (Fresubin 3.2 kcal) and bed-cycling (50 minutes per day) for 5-14 days before surgery.
40995116|NCT01347541|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
40995117|NCT01347541|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
40995118|NCT01347541|DRUG|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
40995119|NCT01347541|BEHAVIORAL|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors
40995120|NCT01108536|DEVICE|adaptive prosthetic socket|trans tibial socket with actuator zones (inflatable fluid bladders)
41148625|NCT04595110|OTHER|Observational study|Coagulation factors, Hypercoagulation biomarkers, Endothelial, Fibrinolysis and neutrophil activation biomarkers
41148626|NCT06173063|DEVICE|Mobility+ Enteral Feeding System|Enteral feeding using a continuous feeding, self-powered, discreet, silent enteral feeding system.
40995121|NCT03873987|DRUG|Current Formulation of Oritavancin|Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
40995122|NCT03873987|DRUG|Kimyrsa|New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
40995123|NCT00073359|BEHAVIORAL|Cognitive Behavioral Therapy|
40995124|NCT03204513|DEVICE|Vanderbilt Powered Knee-Ankle Prosthesis|The Vanderbilt powered prosthesis is a transfemoral prosthesis with powered and coordinated knee and ankle joints. The Generation 3 prosthesis is actuated by two brushless direct current (DC) motors, providing up to 100 Nm of torque at the knee joint, and with the assistance of a parallel stiffness, up to 200 Nm in plantar flexion at the ankle. Sensors measure knee and ankle joint angles, axial load in the shank, and position and orientation of the prosthesis in space (via a 6-axis inertial measurement unit). An onboard lithium-ion battery provides sufficient energy for approximately 10,000 steps between battery charges. The prosthesis prototype weighs approximately 4.3 kg (9.5 lb), the mass of which is approximately equivalent to the intact limb of a 48 kg (105 lb) person.
40995125|NCT03204513|DEVICE|Microprocessor (MP) Knee Prosthesis|Participants enrolled will already have their own microprocessor controlled (MP) non-powered knee prostheses as per inclusion criteria. Examples: OttoBock's C-Leg, Ossur's Rheo, Freedom Plie, Endolite Orion,etc.
41148627|NCT00370188|DRUG|Topiramate|
41148628|NCT04304014|DIETARY_SUPPLEMENT|L. reuteri|(10\^8 CFU) once a day
41148629|NCT04304014|DIETARY_SUPPLEMENT|B. longum and P. Pentosaceus|(10\^9 CFU) once a day
41341744|NCT06071923|DEVICE|Fibroscan|Scan the liver for metabolic fatty changes
40995126|NCT06244264|PROCEDURE|Autoblood transfusion|Through a negative pressure suction device, the patient's blood that flows out during surgery is collected into a blood storage filter. During the suction process, it is mixed with an appropriate anticoagulant and passed through multiple layers of filters. When the volume of recovered blood reaches a certain level, it is continuously (or intermittently) centrifuged. Using a high-speed centrifugal blood recovery tank, the red blood cells are separated, and the plasma, waste, cell fragments, anticoagulants, and harmful components are diverted into a waste bag. A large amount of saline is used to repeatedly wash, purify, and concentrate the red blood cells. Finally, the concentrated red blood cells are prepared into a 70% red blood cell suspension with saline and stored in a collection bag for transfusion back to the patients. Open surgery is considered as the standard procedure for metastatic spinal cord compression
40995127|NCT03088254|DRUG|Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
40995128|NCT03088254|DRUG|Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)|Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
40995129|NCT03088254|DRUG|Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)|Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
40995130|NCT02996864|OTHER|Healthy Detours App|"The app features:~* Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.~* User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.~* Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring."
40995131|NCT02996864|OTHER|Fat Secret App|Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
40995132|NCT01052545|BEHAVIORAL|Audit-Feedback|Applied as a post-prescription antimicrobial review based on established guidelines.
41148630|NCT04749771|BEHAVIORAL|Filming Interactions to Nurture Development|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home.
40995133|NCT06029699|DEVICE|high flow nasal cannula|device are used for weaning patients after mechanical ventilation extubation
40995134|NCT06029699|DEVICE|non invasive positive pressure ventilation|device are used for weaning patients after mechanical ventilation extubation
40995135|NCT01938274|OTHER|Educational intervention|A 30-minute discussion and slide presentation with a trained member of the research team.
40995136|NCT01250587|DRUG|PDC31|This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
40995137|NCT04533672|DIAGNOSTIC_TEST|MRI Sequences|New multiparametric MRI techniques
40995138|NCT00542581|DEVICE|The Acrysof toric SN60T3 IOL|Intraocular Lens
40995139|NCT01516957|DRUG|AMG 827 140|140 mg AMG 827 SC (subcutaneous)
40995140|NCT01516957|DRUG|Placebo|Placebo SC (subcutaneous)
40995141|NCT01516957|DRUG|AMG 827 280|280 mg AMG 827 SC (subcutaneous)
40995142|NCT01516957|DRUG|AMG 827 210|210 mg AMG 827 SC (subcutaneous)
40995143|NCT04116164|DRUG|111In-DOTA-h11B6|4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
40995144|NCT03362281|DRUG|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
40995145|NCT03362281|DRUG|Omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
41468792|NCT03778723|DRUG|Total intravenous anesthesia (TIVA)|Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion
41468793|NCT03778723|DRUG|Inhalation Anesthesia|Sevoflurane at a concentration of 2-2.5%
40995146|NCT03362281|DRUG|Ilaprazole tablet|Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
40995147|NCT03362281|DRUG|amoxicillin and clarithromycin|The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
40995148|NCT03511612|DIAGNOSTIC_TEST|Measure ankle brachial index (ABI)|This is a head-to-head comparison of 2 methods of determination of the ABI, taking the Doppler method as the standard and the oscillometric device AVP as the challenger
40995149|NCT02191228|DRUG|Linagliptin - single dose|
40995150|NCT02191228|DRUG|Linagliptin - Multiple dose|
40995151|NCT04758377|PROCEDURE|Magnetic resonance imaging (MRI)|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
40995152|NCT03187457|OTHER|Metronidazole|Women with Bacterial Vaginosis treated with Metronidazole for 5 days
40995153|NCT03187457|OTHER|Control: no treatment|Healthy women without Bacterial Vaginosis
40995154|NCT05973851|DRUG|Esketamine Nasal Product|See arm description
40995155|NCT05973851|DRUG|Ketamine Hydrochloride|See arm description
40995156|NCT05973851|DRUG|Esketamine hydrochloride|See arm description
40995157|NCT05973851|DRUG|Second-line Antidepressants|See arm description
40995158|NCT00384800|DRUG|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
40995159|NCT03615807|PROCEDURE|Surgical debridement (if needed)|Surgical debridement
40995160|NCT03615807|DIAGNOSTIC_TEST|Microbiological sampling|Microbiological sampling
40995161|NCT03615807|PROCEDURE|Revascularisation (if needed).|Revascularisation (if needed).
40995162|NCT03615807|DEVICE|Off-loading|Off-loading by Special shoes
40995163|NCT03615807|BEHAVIORAL|Patient's education and instructions|Patient's education and instructions by specialized nurses
40995164|NCT03615807|PROCEDURE|Wound debridement|Regular wound debridement by specialized nurses
40995165|NCT03615807|DRUG|Antibiotic duration|Systemic antibiotic duration according to the study arms
41468794|NCT03778723|DRUG|Rescue fentanyl|Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
40995166|NCT01113879|BEHAVIORAL|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
40995167|NCT01113879|BEHAVIORAL|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
40790663|NCT05302427|BEHAVIORAL|Infant Massage|The training will start with a leg massage in the first session and the mother will be asked to do this once a day until the next lesson. The next week, the new massage movement will be shown to the mother and the training will continue, and the mother will be told to do the application throughout the week by integrating it with the previous movement this time, and the four-week training will be completed in this way. After the training, which massage movement was taught to the mothers every week, the application pictures of this part will be sent and at the end of the four-week training, the baby massage video and the baby massage guide will be sent to the mothers by e-mail.
41148631|NCT04749771|BEHAVIORAL|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction.
41468795|NCT06055673|GENETIC|DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD|Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.
41468796|NCT03180255|COMBINATION_PRODUCT|Dexamethasone phosphate|Ocular iontophoretic delivery of a steroid
40790664|NCT05663008|PROCEDURE|128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)|128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)
40995168|NCT06275282|DEVICE|Intramuscular electrodes|Participants will have regenerative peripheral nerve interfaces (RPNIs) created on nerves in their residual thighs. During either the same surgery or a separate surgery, small electrodes will be implanted into these RPNIs.
40995169|NCT02396836|OTHER|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
41148632|NCT04135183|PROCEDURE|changes of Pneumonia Severity Score|assessing effectiveness of CAP treatment by using continuous pneumonia severity score
41148633|NCT02637466|DRUG|Vortioxetine|
41148634|NCT06557733|PROCEDURE|Biopsy|Undergo biopsy
41148635|NCT06557733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41148636|NCT06557733|DRUG|EP2/EP4 Antagonist TPST-1495|Given PO
41148637|NCT06557733|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
40995170|NCT02396836|OTHER|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
40995171|NCT00805974|BIOLOGICAL|Biological examinations (blood and urinary).|
40995172|NCT02052232|OTHER|Experimental protein powder sachet|mixed with 8 oz. water
40995173|NCT02052232|OTHER|Control protein powder sachet|mixed with 8 oz. water
40995174|NCT01442415|BEHAVIORAL|Lifestyle modification|Weekly lifestyle modification sessions including dietary counseling and physical activity
40995175|NCT05687279|BIOLOGICAL|RSVt Vaccine|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
40995176|NCT05687279|OTHER|Control Group|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
40995177|NCT01771146|DRUG|FOLFIRINOX Regimen|6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
41148638|NCT06557733|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
40995178|NCT01215227|DRUG|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
40995179|NCT01215227|DRUG|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
40995180|NCT01215227|DRUG|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
40995181|NCT01215227|DRUG|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
40995182|NCT01314209|DRUG|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
40995183|NCT03163745|PROCEDURE|paracentesis|paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
41148639|NCT06557733|OTHER|Questionnaire Administration|Ancillary studies
41148640|NCT01628263|OTHER|Follow up Clinic for High risk participants|Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
41341745|NCT03989089|DRUG|Pembrolizumab|"The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol."
41468797|NCT03180255|OTHER|Placebo|Ocular iontophoretic delivery of a placebo
41468798|NCT01025219|GENETIC|Collect 10 ml of Saliva for DNA extraction|After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
40995184|NCT06274541|GENETIC|Somatic and Germline BRCA1/2 Testing|Germline BRCA1/2 mutation testing will be undertaken by NGS using blood samples. Somatic BRCA1/2 mutation testing will be undertaken by NGS using tumour tissue.
40995185|NCT02877784|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
40790665|NCT00726128|DEVICE|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
40790666|NCT01123148|DEVICE|Using a BCI to control wheelchair tilt|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
40790667|NCT00943631|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
40995186|NCT02877784|OTHER|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
40790668|NCT04982705|DRUG|[Part 1.1] IDG-16177|\[Part 1.1\] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
40790669|NCT04982705|DRUG|[Part 1.1] Placebo of IDG-16177|\[Part 1.1\] subjects will receive a single oral dose of IMP.
40790670|NCT04982705|DRUG|[Part 2] Sitagliptin|Administration of Sitagliptin 100mg once daily for 4 weeks.
40790671|NCT04982705|DRUG|[Part1.2] IDG-16177|\[Part 1.2\] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
40790672|NCT04982705|DRUG|[Part 2] IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
40790673|NCT04982705|DRUG|[Part 1.2] Placebo of IDG-16177|\[Part 1.2\] Administration once daily for 14 days.
40790674|NCT04982705|DRUG|[Part 2] Placebo of IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
40790675|NCT03111004|OTHER|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
40790676|NCT05671523|PROCEDURE|Dry needling|Firstly the skin is cleaned with a piece of cotton immersed in alcohol. Then sterilized disposable thin, stainless steel needles (25 × 0.30 mm) will be inserted into the skin over the nodule in A1 pulley anatomic location. The duration of needling will be 1 minute. The needle will be inserted deeply at 45° to the level of metacarpophalangeal level to the nodule. The needle may be inserted into the tendon. This is confirmed by needle movement when the patient ﬂexes and extends the distal phalanx. The needle is withdrawn slowly until this motion ceases, and the needle tip is in the A1 pulley. This will be repeated 2 times per week for 5 weeks.
40790677|NCT05671523|OTHER|conventional treatment|"Finger splint is designed to stabilize and immobilize a small finger joint. A wide, flat band offers comfortable pressure distribution and control. Contoured finger splint with a comfortable, close fit. The patient will use the splint at night. Can easily be adjusted to accommodate swollen digits. Suitable for a number of finger conditions.~Therapeutic ultrasound is often used by physiotherapists to reduce pain, increase circulation and increase mobility of soft tissues. Additionally, the application of ultrasound can be helpful in the reduction of inflammation, reducing pain and the healing."
41148641|NCT03630432|BEHAVIORAL|Pulmonary rehabilitation|"The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes."
41148642|NCT03630432|OTHER|Usual Care|Usual Care
40995187|NCT02877784|OTHER|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
40790678|NCT04114175|OTHER|Exercise BE|Basic exercises related to amputation will be applied
40790679|NCT04114175|OTHER|Exercise BE+SS|Basic exercises related to amputation + Spinal stabilization exercises will be applied
40995188|NCT00532285|DRUG|Paclitaxel/Gemcitabine|Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
40995189|NCT02488603|BEHAVIORAL|Decision aids (tamoxifen-related educational materials in brochure or mobile app)|Decision aids (tamoxifen-related educational materials in brochure or mobile app)
40995190|NCT02488603|DRUG|tamoxifen|
40995191|NCT01166477|DRUG|Lopinavir and ritonavir|The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
40995192|NCT01166477|DRUG|Triple therapy with ritonavir|The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
40995193|NCT04794790|DRUG|Buprenorphine/naloxone|Buprenorphine/Naloxone induction via a standard dose protocol
40995194|NCT05349149|DRUG|Tocilizumab/Actemra® (Roche)|The infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
40995195|NCT05349149|DRUG|Saline 9%|The infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
40995196|NCT03662542|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered as IV infusion.
40995197|NCT03662542|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered as SC injection.
40995198|NCT03662542|DRUG|Golimumab Dose 1|Golimumab Dose 1 will be administered as SC injection.
40995199|NCT03662542|DRUG|Golimumab Dose 2|Golimumab Dose 2 will be administered as SC injection.
40995200|NCT03662542|DRUG|Placebo|Placebo will be administered.
41148643|NCT05104684|OTHER|chest physical therapy|The program will consist of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment
41148644|NCT05104684|OTHER|routine medical treatment|medical treatment
41148645|NCT04463485|PROCEDURE|Delayed Clamping|Umbilical cord clamping was delayed 60 seconds at the end of second stage of labor.
40995201|NCT06372847|DEVICE|Hypoglossal nerve stimulation implant|The hypoglossal nerve stimulation (HNS) implantation and therapy will be performed according to the standard clinical practice without additional procedures. Information about the surgical procedure will be collected. HNS implant information and settings will be collected throughout the study until the last study measurement (one year follow-up PSG and DISE) for that patient. No additional measures or interventions as part of the research project will be performed during implantation or treatment with HNS.
41468799|NCT03474809|DEVICE|Blood sampling|Daily blood samples which will be taken for the PSP measurement using the AbioScope as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
41468800|NCT05752188|OTHER|Multimarker approach in acute coronary syndrome|The main objective of the study is to evaluate the prognostic role of the biochemical marker sST2 in patients attending the Emergency Department of our hospital with acute chest pain with suspected acute coronary syndrome.
40790680|NCT02536144|PROCEDURE|magnetic-controlled capsule endoscopy system|"1. A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.~2. The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.~3. While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.~4. The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
40790681|NCT02536144|PROCEDURE|Colonoscopy|"1. Bowel preparation should be well done before the examination.~2. A tube with illumination and camera system would insert into colon from anus.~3. From the pictures captured by the camera ,the doctor would see the mucous of the colon."
40790682|NCT00003935|DRUG|etoposide|
40790683|NCT00003935|DRUG|vincristine sulfate|
40790684|NCT00003935|RADIATION|radiation therapy|
40790685|NCT04194879|DIAGNOSTIC_TEST|multi-target FIT-DNA analysis|ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
40790686|NCT03688919|BEHAVIORAL|Self-Regulation Intervention|The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
40790687|NCT03254641|DRUG|human chorionic gonadotropin|5000 IE times one
40790688|NCT00590122|DRUG|Parcopa|at subjects current stable dose of comparator
40790689|NCT00590122|DRUG|carbidopa-levodopa (Sinemet)|at subjects current stable dose
40790690|NCT04365426|DEVICE|Mechanical stimulus|Electrical dynamometer to measure mechanical pressure
40790691|NCT04365426|PROCEDURE|Thermal (cold) stimulus|Water cold bath
40790692|NCT04365426|OTHER|Oral contraceptive (OC)|Oral contraceptive (OC)
40790693|NCT04365426|OTHER|No oral contraceptive (No OC)|No oral contraceptive (No OC)
40790694|NCT02398201|DRUG|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
40790695|NCT01798147|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
40790696|NCT01798147|PROCEDURE|SIRT|Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
41148646|NCT05627622|BEHAVIORAL|WhatsApp health education message|stone-prevention information on a monthly basis, using personal WhatsApp messages
41148647|NCT06079047|PROCEDURE|group Dexamethasone|Adductor canal block with dexamethasone
40790697|NCT03819387|DRUG|NBF-006|Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
41148648|NCT06079047|PROCEDURE|group Controle|Adductor canal block with saline solution
41148649|NCT00593528|DEVICE|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
40790698|NCT03402932|OTHER|Auditory amplified|The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.
40790699|NCT03402932|OTHER|Visual|The cognitive test will be administered visually by using timed computer slides.
40790700|NCT03402932|OTHER|Auditory unamplified|The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
40995202|NCT06372847|DIAGNOSTIC_TEST|Polysomnography|A PSG at one-year follow-up is part of the standard follow-up pathway in patients receiving HNS therapy. In this study, PSG data will be collected from both baseline and one-year follow-up PSGs to assess treatment effect. Additionally, PSG data will be used for non-invasive prediction of the site and pattern of collapse using a novel, validated tool developed at our research group.
41148650|NCT00593528|DEVICE|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
41148651|NCT00593528|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
41148652|NCT05670600|OTHER|foot and ankle exercise|"Foot and Ankle Exercise Phase~1. Pulling the foot upwards from the ankle~2. Bending the foot down from the ankle~3. Spreading the feet like a fan, moving the toes in and out to the right and left~4. Circle drawing exercise with ankle~5. Towel folding exercise~6. Bottle rolling exercise under the feet (The water in the bottle will be warm tap water)"
40790701|NCT01482130|BEHAVIORAL|Heavy, explosive strength training|All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
40790702|NCT01482130|BEHAVIORAL|recommendations|"The control group will be encouraged to follow a training program according to recommended exercise guidelines:~* Weight bearing activities (walking, jogging or strength training)~* 30 - 60 minutes, 3 - 5 times each week~* A total of 2 - 3 hours each week should be achieved"
40790703|NCT04966234|DRUG|Posaconazole 100 MG [Noxafil]|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
40790704|NCT04966234|DRUG|Posaconazole 40 MG/ML|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
40790705|NCT04379154|DEVICE|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air by electronic noses
40790706|NCT00017069|DRUG|arsenic trioxide|
40790707|NCT00017069|DRUG|dexamethasone|
40790708|NCT04904029|OTHER|Digital Assessment Routing Tool [DART]|"DART is a first contact web-based and mobile health system that uses clinical algorithms to triage patients and recommend management pathways. Participants complete an online web-based questionnaire that follows a clinical reasoning process commonly observed in face-to-face physiotherapy consultations. Based on the participant's answers, the clinical algorithm generates sets of questions, leading up to a triage disposition with recommended management pathway. The triage outcomes with management pathways are classified;~1. Medical care~   * A\&E referral~  * Urgent GP~  * Routine GP~  * Consultant review~2. Physiotherapy care~   * Post-fracture or surgery physiotherapy~  * Physiotherapy referral~  * Physiotherapy referral plus psychosocial support~3. Self-management~   * Self-management with SOS~  * Continue self-management advice"
40790709|NCT04904029|OTHER|Physiotherapy-led remote triage (usual care)|Participants will receive usual physiotherapy-led remote triage services by a registered health care professional. This service is either a telephone or video consult and includes any diagnostic procedure (e.g. patient history, remote assessments) and treatment, such as management advise or home-based exercise therapy. Participants may seek help elsewhere or opt-out the study at any point, which will not affect their usual physiotherapy-led remote care
40790710|NCT02092727|BEHAVIORAL|Behavioral Interventions for Dialysis Facilities|"1. Educational seminars and monthly educational webinars~2. Peer-to-peer mentoring program~3. Bulletin boards about transplantation~4. Facility-specific feedback reports detailing transplant referral data for their center compared to state average~5. Formulate a facility-specific improvement plan to increase transplant referrals.~6. Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.~7. Monthly monitoring and reporting of patient referrals to ESRD Network~8. Conduct a patient and family education session about transplantation~9. Host a movie day to show Living ACTS (About Choices in Transplantation \& Sharing) video"
40790711|NCT06191692|DRUG|Isoniazid|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
40790712|NCT06191692|DRUG|Rifapentine|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
40790713|NCT06191692|DRUG|Rifampicin|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
40790714|NCT06512688|OTHER||This is a cross-sectional study without intervention.
40790715|NCT01823081|DRUG|Intravitreal injection of bevacizumab (Avastin)|
40790716|NCT01823081|DRUG|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
40995203|NCT06372847|PROCEDURE|Drug-induced sleep endoscopy (DISE)|"Drug-induced sleep endoscopy (DISE) is the clinical standard diagnostic test to assess site, pattern and degree of upper-airway collapse in OSA. Baseline DISE is part of the standard clinical pathway for HNS eligibility.~In this study, DISE data will be collected from routine baseline DISE without any additional procedures for the patient. They will undergo an additional DISE at one-year follow-up to assess the effect of HNS-therapy on site, pattern and degree of collapse. Both DISEs will be performed according to routine clinical practice in the operating theatre. Sleep will be induced using 1.5 mg bolus injection midazolam and target-controlled propofol infusion (2.0 - 3.0 μg). A flexible fiberoptic nasopharyngoscope will be transnasally inserted. Site, pattern and degree of collapse will be assessed using a standardized scoring system. Other maneuvers, including chin-lift, the use of a simulation bite or lateral position of the head will be performed according to clinical practice."
40995204|NCT05087654|OTHER|Combination of 3D VR and Hands-on Horticultural Activities|The intervention program consisted of 8 two-hour sessions that were conducted once a week for 8 consecutive weeks.
40790717|NCT05772403|DIAGNOSTIC_TEST|CEUS|CEUS for atypical liver nodules
40790718|NCT01993134|PROCEDURE|Cefazolin|Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
40995205|NCT00433056|OTHER|STI|CD4 guided treatment interruption
40995206|NCT00433056|DRUG|stable HAART|continuous therapy
40995207|NCT01160068|DRUG|Metformin|Metformin Tablets 1000 mg
40995208|NCT01160068|DRUG|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
40995209|NCT03237728|DRUG|0.06mg/kg,KB|0.06mg/kg,Q8h,Day1-Day7
40995210|NCT03237728|DRUG|0.12mg/kg,KB|0.12mg/kg,Q8h,Day1-Day7
40995211|NCT03237728|DRUG|0.24mg/,KB|0.24mg/kg,Q8h,Day1-Day7
40995212|NCT03237728|DRUG|Placebos|Placebos,Q8h,Day1-Day7
40790719|NCT01993134|PROCEDURE|Cefazolin Single Dose|Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
40790720|NCT03382912|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus Nivolumab
40790721|NCT03382912|DRUG|Nivolumab|Nivolumab Alone
40995213|NCT00978068|DRUG|Lopinavir/Ritonavir (LPV/r)|
40995214|NCT00978068|DRUG|Nevirapine (NVP)|NVP will be used for children \< 3 years of age
40995215|NCT00978068|DRUG|Efavirenz (EFV)|EFV for children ≥3 years of age
40995216|NCT00978068|DRUG|2 nucleoside reverse transcriptase inhibitor (NRTI)|The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin \< 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
40995217|NCT02609334|DRUG|CRD007|One single dose given 3 hours prior to Mannitol challenge
40995218|NCT02609334|OTHER|Placebo|One single dose given 3 hours prior to Mannitol challenge
40995219|NCT06221033|DEVICE|manual hyperinflation|Each participant will assume a relaxed comfortable in supine position. Bag valve resuscitation circuit locked at pressure 35 cm H20 will be used. Six sets of six MHI breaths will be applied. MHI breaths had a slow inspiration for three seconds duration, a three second end inspiratory pause (hold) then an uninterrupted expiration as a quick release
40995220|NCT06221033|OTHER|Diaphragmatic proprioceptive neuromuscular facilitation technique|"Rhythmic initiation technique that is derived from the PNF concept will be initiated by four 20-second manual diaphragm stimulations. After every stimulation the patient rested for one minute. Therapist's hands will be placed below the rib cage, just below the costal arches and will support patient's exhalation phase by slight lengthening his diaphragm simultaneously in posterior-superior direction using a verbal cue exhale. At the same time, the patient will verbally be encouraged to take a deep breath"
40995221|NCT06221033|OTHER|traditional physiotherapy|This group will receive the traditional medical treatment and chest physiotherapy only.
41468801|NCT03981809|DIAGNOSTIC_TEST|"Diagnostic test (PainsCan) for the identification of the dominant pain mechanisms in cancer survivers with persistent pain"|Easy-to-use screening tool to identify the dominant pain mechanism by using quick clinical tests and compare their accuracy and validity with complicated reference tests.
41468802|NCT06614699|OTHER|abdominal fat and muscle area|Abdominal fat and muscle area were calculated based on abdominal CT.
41468803|NCT04725591|DEVICE|Dexcom G6 Continuous Glucose Monitoring|Collection of glucose data
40995222|NCT05682131|DRUG|Realgar Indigo naturalis formula|Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk
40995223|NCT05682131|COMBINATION_PRODUCT|Conventional chemotherapy|conventional chemotherapy
40995224|NCT04779684|OTHER|Advance care planning by proxy for health care proxies of people without medical decision making capacity|Two discussions between a trained health professional and a health care proxy of an RACF resident who no longer has decision making capacity. First discussion focuses on life story, values, previous experiences with medical treatments, illness and death. Second discussion also includes treating physician and focuses on establishing general goals of care and medical orders in case of emergency.
41468804|NCT04725591|DEVICE|MEDISAFE WITH External Insulin Pump|Insulin delivery
40790722|NCT04991493|DRUG|Tramadol hydrochloride|"pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured."
40995225|NCT01301495|DEVICE|HANAROSTENT TM covered Esophageal Stent|HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
40995226|NCT02514837|DEVICE|RTM|Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
40995227|NCT04230837|DEVICE|Inmediate abutment height|The placement of the implant was done following the manufacturing protocol and using a surgical guide according to the radiological guide previously used. At this time, the Permanent® abutment of 1 or 3 mm was chosen randomly and was placed at 35 Ncm.
40995228|NCT05735223|PROCEDURE|Maximal urethral length preservation technique of robot assisted radical prostatectomy (RALP).|Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery). The subjects were blinded to the measurements to prevent bias. Multiparametric MRI (MP-MRI) of the prostate were reviewed when available for surgical planning. All subjects underwent RALP with MULP using the technique previously published by Hamada et al. Continence defined as requiring no pads was assessed at 3 and 6 months postoperatively.
40995229|NCT03387163|DRUG|Sacubitril/Valsartan|commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103
40995230|NCT04829487|DRUG|Ergocalciferol Capsules|Given to subjects 50,000 IU per week for 8 weeks
41468805|NCT04725591|DEVICE|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
40995231|NCT04829487|DRUG|Placebo|Placebo capsules
40995232|NCT02407769|DIETARY_SUPPLEMENT|Late evening supplementation with branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
40995233|NCT02120976|DRUG|JTT-252 or Placebo|Subjects will receive JTT-252 or Placebo
41468806|NCT04725591|OTHER|Declaration of meals|Patient inputs related to meals
41468807|NCT04725591|OTHER|No declaration of meals|No patient inputs related to meals
41468808|NCT04725591|OTHER|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
41468809|NCT04570176|PROCEDURE|adrenalectomy for adrenal adenoma|adrenalectomy， cystectomy and nephrectomy
41148653|NCT05357599|DIAGNOSTIC_TEST|EUS|The decision to start a beta-blocker will be made at the conclusion of the EGD based on the endoscopic findings (presence of esophageal varices)
41148654|NCT02788305|DRUG|Misoprostol|Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
41148655|NCT01919489|DRUG|Liraglutide + OADs|Liraglutide subcutaneously daily
41148656|NCT01919489|DRUG|Glargine + OADs|Glargine once daily subcutaneously
41148657|NCT02776917|DRUG|Cirmtuzumab + Paclitaxel|Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
41148658|NCT03148353|PROCEDURE|Subacromial injection|"1. Modified ultrasound guided corticosteroid subacromial injection~2. Standardized ultrasound guided corticosteroid subacromial injection"
41148659|NCT06266494|DEVICE|Long-Acting silver dressings|Mepilex Transfer Ag
41148660|NCT06266494|OTHER|Aloe Vera|Dermaid Aloe Vera
41148661|NCT06266494|DRUG|Dalbavancin|1500mg IV dose
41148662|NCT01835847|DRUG|Tipepidine Hibenzate|
41148663|NCT03999294|OTHER|BMGIM Music Therapy Method|The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
41148664|NCT04564222|DIETARY_SUPPLEMENT|Micronutrient Enriched Crackers (MECs)|"MECs are manufactured according to the Standard Operational Procedures which have been developed taking into account the Hazard Analysis and Critical Control Point (HACCP) to maintain quality and safety and ensure the Ready-to-eat MEC products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detectable) in the MEC products have been obtained from analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of MEC products will be repeated at the middle and the end of the RCT to check on the quality and safety of the MEC product."
40995234|NCT02120976|DRUG|JTT-252|Subjects will receive JTT-252
40995235|NCT02857452|OTHER|SLA Questionnaire|
40995236|NCT02857452|OTHER|Lupus Qol Questionnaire|
40995237|NCT00001877|DRUG|Pentoxifylline|
41468810|NCT04618484|OTHER|Biomodulation (non-pharmacological)|cryo-, photo- and electro-biomodulation
40790723|NCT04991493|OTHER|Normal Saline|"pre-tramadol group: Normal Saline will be injected intravenously when the incision was washed and sutured.~post-tramadol group: Normal Saline will be injected intravenously 15 minutes before anesthesia."
40790724|NCT01569737|DRUG|ella|ella, single intake, tablet 30mg
40995238|NCT03645668|DRUG|Meropenem Injection|Different administration types between two groups
40790725|NCT02407743|BEHAVIORAL|Surgical patients' clinical progression|Study the dynamic nature of pain
40995239|NCT04578249|OTHER|Blue light-blocking goggles|Participants will be randomly assigned to one of the two intervention groups.
40995240|NCT04578249|OTHER|Clear goggles|Participants will be randomly assigned to one of the two intervention groups.
40995241|NCT05544838|DEVICE|LMA insertion with standard technique|"Standard LMA insertion technique; LMA held like a pen and index finger placed at the junction of LMA tube and cuff. Index finger used to press LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of hypopharynx. LMA then held with non- dominant hand and index finger removed.~Rotational LMA insertion; LMA inserted like guedel airway insertion: LMA proximally grasped close to anaesthesia circuit attachment. Insertion was conducted with LMA cuff facing towards nose, hard palate and then advanced into the base of hypopharynx until resistance was felt. At this point, LMA rotated at 180 degree anti-clockwise and LMA tube black line positioned and confirmed on the nasal side."
40995242|NCT06168487|DRUG|Telmisartan|Patients will be given telmisartan alone or with standard of care chemotherapy.
41148665|NCT04564222|DIETARY_SUPPLEMENT|Placebo|"Placebo crackers are manufactured according to SOPs which have been developed taking into account the HACCP to maintain quality and safety and ensure the Ready-to-eat placebo products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detected) in the placebo have been obtained based on the analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of placebo samples will be repeated at the middle and the end of the RCT to check on the quality and safety of the placebo product."
41148666|NCT05147545|OTHER|Moderate intensity physical effort|Pedaling 15 minutes at 75 Watt then 100 Watt of the ergometer
41468811|NCT06072157|DRUG|AK006-IV|Intravenous infusion
41468812|NCT06072157|DRUG|Placebo-IV|Intravenous infusion
40790726|NCT02407743|GENETIC|Genetic markers|Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
40790727|NCT05585073|OTHER|Whether lymph node dissection is qualified or not|Klass-02-QC LND scale and general error score tool were used to quantitatively evaluate the intraoperative performance of D2 LND
40995243|NCT06168487|OTHER|Standard of Care Regimen|Standard of Care Regimen
40995244|NCT05606042|DEVICE|IM Implant|Patients that have had surgical interventions with one or more IM Implant as part of standard of care for a pelvic and/or acetabular fracture
40995245|NCT02159521|DEVICE|EkoSonic® Endovascular System|
40995246|NCT02159521|BIOLOGICAL|Alteplase|Recombinant tissue plasminogen activator
40995247|NCT06340438|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
40995248|NCT06340438|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
40995249|NCT02876900|DRUG|Low Dose Asenapine maleate transdermal patch|The study will evaluate low dose Asenapine maleate transdermal patch
40995250|NCT02876900|DRUG|High Dose Asenapine maleate transdermal patch|The study will evaluate high dose Asenapine maleate transdermal patch
41148667|NCT05147545|OTHER|Low intensity physical effort|Pedaling 3 minutes at the 30 Watt level of the ergometer
41148668|NCT05147545|OTHER|Hyperlipidic meal|Eating an hyperlipidic meal 60 minutes after a physical effort
41148669|NCT05147545|DIAGNOSTIC_TEST|Measure of circulating DNA|"Multiple measure of circulating DNA: on an empty stomach, at the end of the physical effort, after 15, 30 and 60 minutes of rest, 120 minutes after an hyperlipidic meal.~An additional measure will occur for subjects free of malignancy during the effort."
41148670|NCT05910359|DIAGNOSTIC_TEST|Ultrasound|transabdominal and transperineal ultrasound by expert sonographers
41148671|NCT00003588|BIOLOGICAL|Ad5CMV-p53 gene|
41148672|NCT00003588|PROCEDURE|laparoscopic surgery|
41148673|NCT02722278|DRUG|Oral Testosterone Undecanoate|Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
41148674|NCT02722278|DRUG|Axiron Testosterone Topical Solution|"Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL."
41148675|NCT02125799|DEVICE|Accelerated HF-rTMS (Magstim Rapid 2 stimulator)|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
40790728|NCT01775553|DRUG|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
40790729|NCT00670930|DRUG|omalizumab at a dose of 0.016mg/kg/IU/mL|
41148676|NCT04451720|DRUG|Risankizumab|Subcutaneous (SC) injection
41148677|NCT04451720|DRUG|Placebo|Subcutaneous (SC) injection
40790730|NCT00670930|DRUG|Placebo|
41148678|NCT01497678|DEVICE|Extracellular Matrix|Extracellular Matrix
41148679|NCT05313945|PROCEDURE|Passive indwelling urinary catheter removal|"After washing the patient's perineal area with water and mild soap, the nurse deflates the indwelling urinary catheter balloon and instructs the patient to take a shower (standing).~During this time, the catheter will fall under gravity."
40790731|NCT02781961|OTHER|cellvizio|pCLE during gastroscopy
40790732|NCT05370365|PROCEDURE|Below elbow cast|Patients will be stay with a below elbow cast for 4 or 6 weeks
40790733|NCT02457247|DRUG|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
40790734|NCT02457247|DRUG|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
40790735|NCT02457247|DRUG|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
40790736|NCT04915638|DIETARY_SUPPLEMENT|Experimental intervention group with enriched cookies|Enriched cookies containing a micronutrients formula (vitamins, minerals, antioxidants, and omega-3 fatty acids) each day (Monday to Friday).
41148680|NCT05313945|PROCEDURE|Active indwelling catheter removal by a nurse|After washing the patient's perineal area with water and mild soap, the nurse deflates the balloon and removes the catheter from the urethra by manual traction.
41148681|NCT04349124|DRUG|Nifedipine Extended-Release Tablets|Antihypertensive
41148682|NCT06506578|RADIATION|Radiation|Radiation
41148683|NCT05852379|DEVICE|active taVNS|Transcutaneous auricular vague nerve stimulation
41148684|NCT05852379|DEVICE|sham taVNS|Scham transcutaneous auricular vague nerve stimulation
41148685|NCT00755716|DRUG|Placebo (sugar pill)|patients receive
41148686|NCT00755716|DRUG|Topiramate|25 mg per day for one week, 50 mg per day for one week, 100 mg per day for one week, 200 mg per day for 5 weeks, then one week taper
41148687|NCT00755716|DRUG|Nicotine patch|On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
40790737|NCT04298294|OTHER|injectable platelet rich fibrin|biologic activator
40790738|NCT04262479|DRUG|recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel|3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
40790739|NCT04262479|DRUG|Vitamin D|1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden
40790740|NCT00609752|DRUG|prednisolone|Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
40790741|NCT00609752|DIETARY_SUPPLEMENT|Alicalm (polymeric liquid formula)|"Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks."
40790742|NCT05687981|DRUG|Bupivacaine|the use of higher concentration of bupivacaine in ilioinguinal and iliohypogastric nerve block (IINB) might increase the efficacy of postoperative analgesia
41148688|NCT00451906|DRUG|Platinum-based chemotherapy|As prescribed
41148689|NCT00451906|DRUG|Bevacizumab [Avastin]|15 mg/kg IV on Day 1 of each 3 week cycle
41148690|NCT01061775|DRUG|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
41148691|NCT00988845|DIETARY_SUPPLEMENT|Indole-3-carbinol|200 mg bid po X 8 weeks
41148692|NCT00683371|PROCEDURE|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
41468813|NCT06072157|DRUG|AK006-SC|Subcutaneous
41468814|NCT06072157|DRUG|Placebo-SC|Subcutaneous
41468815|NCT06117813|DEVICE|Nu.T|Participants receive visual perceptual training using the Nu.T software.
40790743|NCT05687981|DRUG|Dexamethasone|2 mg dexamethasone
40790744|NCT00604552|DEVICE|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
40790745|NCT01571622|DIETARY_SUPPLEMENT|Whey before Breakfast|After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
40790746|NCT01571622|DIETARY_SUPPLEMENT|Water before breakfast|After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
40790747|NCT00658541|DRUG|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
40790748|NCT00658541|DRUG|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
40790749|NCT05068986|BEHAVIORAL|Asthma education|All the study participants were subjected to an educational asthma program for 3 months for providing parents and children with information and skills to manage their asthma ,which was presented from the the first session, through providing a written asthma action plan, information about avoiding triggers, training in the correct use of medicines, including inhaler technique, information and support to maximize adherence . All patients were followed up by a phone call every 2 weeks and follow up visit monthly to confirm compliance to the educational program
40790750|NCT04430361|DRUG|Megestrol|160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.
40790751|NCT04430361|DRUG|5-HT3 receptor antagonist|5-HT3 receptor antagonist 2.5mg/iv
40790752|NCT04430361|DRUG|dexamethasone|dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
40790753|NCT05530902|OTHER|Multidisciplinary Primary Rehabilitation Care|As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
40790754|NCT01326299|OTHER|Carbohydrate placebo|dissolve in water and consume with meal
40790755|NCT01326299|OTHER|Nutritional ingredient|Dissolve in water and consume with meals
40790756|NCT01326299|OTHER|#1 Nutritional ingredient +Fiber|Dissolve in water and consume with meal
40790757|NCT01326299|OTHER|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
40790758|NCT01326299|OTHER|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
40790759|NCT04716608|OTHER|physiotherapy program|"physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program."
40790760|NCT04716608|OTHER|usual care treatment|stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
40995251|NCT02876900|DRUG|Placebo|The study will evaluate placebo transdermal patch.
41468816|NCT06117813|OTHER|No-Treatment Control|No-treatment was administered during control period.
40790761|NCT03151122|BEHAVIORAL|Nurse-led Continuous Support|"The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.~After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age."
40790762|NCT03151122|PROCEDURE|routine follow-up care|after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
40790763|NCT06082167|DRUG|Zanzalintinib|Specified doses on specified days
40790764|NCT06082167|DRUG|Zanzalintinib-matched Placebo|Specified doses on specified days
40790765|NCT06082167|BIOLOGICAL|Pembrolizumab|Specified doses on specified days
40790766|NCT04939038|PROCEDURE|Revascularization|Depending on the condition of the patients, patients will have either endovascular or surgical revascularization
40995252|NCT03591237|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
41468817|NCT01676129|PROCEDURE|Nocipoint Therapy|
41468818|NCT01676129|PROCEDURE|Physical Therapy|
41468819|NCT00603863|BIOLOGICAL|IMMU-107 (hPAM4)|90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
41468820|NCT00265772|DRUG|MODULEN IBD (R) (specific Enteral Nutrition)|
41468821|NCT00265772|DRUG|prednisolon|
40790767|NCT04939038|PROCEDURE|Standard wound care|Standard wound care according to guidelines
40790768|NCT04149171|DRUG|with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.|The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
40790769|NCT04149171|DRUG|conventional treatment|standard treatment based on crystalloid fluid and tranexamic acid (TXA)
40790770|NCT01977898|DRUG|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
40790771|NCT01977898|DRUG|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
40790772|NCT05143333|OTHER|DANA app|The Defense Automated Neurobehavioral Assessment (DANA) is a battery of cognitive tests delivered via an electronic tablet or smartphone. The platform allows higher temporal precision and frequency of measurement than traditional neuropsychological methods while including previously standardized cognitive tests and allowing individuals to repeatedly self-administer the battery in their own homes without examiner supervision. Hence, the DANA battery bypasses several of the major limitations associated with in-person cognitive exams.
40790773|NCT05575544|PROCEDURE|Acupuncture plus morphine|The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure
40790774|NCT01361659|PROCEDURE|shockwave treatment|9 treatments in 3 months
40790775|NCT02861339|DEVICE|Opthalmologic measure with DM OPD scan III (Nidek)|Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
40790776|NCT02339805|OTHER|next generation sequencing|DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.
40790777|NCT02339805|DEVICE|Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|tumor Assessment tool during the study
40790778|NCT06285552|BEHAVIORAL|Positive parenting PAIF program|Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences
40790779|NCT03596788|DIETARY_SUPPLEMENT|Carbohydrate Beverage|The carbohydrate beverage will supply approximately 100 grams of carbohydrate per day (in the form of glucose and fructose)
40790780|NCT03596788|DIETARY_SUPPLEMENT|Placebo Beverage|The placebo beverage will contain aspartame.
40790781|NCT03886467|OTHER|Community-based nutrition education|Nutrition education will be included in community development training. The nutrition education will target child nutrition, particularly consumption of animal-source foods and especially milk. The importance of dietary diversity will also be emphasized. Demonstrations of food preparation techniques will also be included in the training.
40790782|NCT02989116|BEHAVIORAL|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
40790783|NCT02989116|BEHAVIORAL|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
40790784|NCT02989116|BEHAVIORAL|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
40790785|NCT02989116|BEHAVIORAL|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
40790786|NCT02989116|GENETIC|Saliva collection|Collection of a saliva sample for genotyping
40790787|NCT02989116|PROCEDURE|Brain Magnetic Resonance Imaging|Structural and functional MRI
40790788|NCT02989116|BEHAVIORAL|Cognitive testing|Battery of cognitive and academic tasks on executive functions
40790789|NCT00756275|DRUG|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
40995253|NCT06485063|OTHER|Myofascial Reorganization|It is a manual technique in which the therapist applies a manual sustained oblique load of 45° with subsequent shear load. In general, the technique is divided into two stages, the first when the oblique load is accompanied by a passive shear load (applied by the therapist) during 1minute, and the second stage, when the shear oblique manual load is maintained but the shear load provoked by the participants' active movement (active shear load) during 1minute.
40995254|NCT06485063|OTHER|PLACEBO Myofascial Reorganization|it is light touch to the skin applied by the therapist, without provoking compression, or any constant or shear load during the fist minute. In the second minute, the participant adds active movements to the light touch. This two stage (each one during 1minute) is constructed to mimic the passive and the active stages of the real myofascial reorganization technique.
40995255|NCT02477501|DRUG|Norepinephrine|continuous infusion
40790790|NCT00756275|DRUG|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
40995256|NCT02477501|DRUG|Ephedrine|continuous infusion
40995257|NCT03466476|DEVICE|Consensus TracPatch|Consensus TracPatch will be attached to the participant's shin approximately two inches below the knee through use of an adhesive strip similar to a standard bandage for 6 weeks after total knee arthroplasty.
40995258|NCT05129488|DEVICE|All participants received Biotrue ONEday lenses with and without an alternate packaging solution (EPG03)|Participants were given both Commercially available Biotrue ONEday lenses and Biotrue ONEday Contact Lenses with EPG03 Packaging Solution. Lens material is made from a hydrophilic copolymer of 2- hydroxyethyl methacrylate and N-vinylpyrrolidone and is 78% water by weight when immersed in saline solution.EPG03 Packaging Solution contains a phosphate buffered saline solution containing potassium chloride, poloxamine, poloxamer 181, glycerol (glycerin), erythritol, and polyquaternium-1.
40995259|NCT01613781|OTHER|TOF count-guided partial NMB|TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
40995260|NCT01613781|OTHER|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
41148693|NCT00683371|PROCEDURE|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
41148694|NCT03591263|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation as routine care includes, airway clearance techniques, breathing exercise, and physical training instruction
40995261|NCT03348085|OTHER|No intervention|No intervention.
40995262|NCT03435965|DIAGNOSTIC_TEST|AmnioQuickDuo+|AmnioQuickDuo+ kit for detection of PROM
40995263|NCT01485562|DRUG|Misoprostol|4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth
40995264|NCT01485562|OTHER|placebo|4 tablets, administered sublingually if the woman experiences a PPH
40995265|NCT02086864|DRUG|lactose/sucrose granule (Individualized homeopathic medicine treatment)|The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
41148695|NCT00508183|PROCEDURE|single row|This method involves using a single row of anchor(s) to reattach the cuff to the bone.
41148696|NCT00508183|PROCEDURE|double row fixation|"This technique, double row fixation, involves adding an extra anchor(s) over the number used for single row fixation. This extra anchor(s) is placed further inside the bone and may help to increase the fixation strength of the repair."
40995266|NCT02086864|DRUG|Placebo lactose/sucrose pill|
40995267|NCT02086864|BEHAVIORAL|Homeopathic consultation|
40995268|NCT02658136|OTHER|Cardiac Computed tomography|
40995269|NCT02816060|PROCEDURE|manual therapy|manual therapy with neural exercise will be applied on patients with neck pain
40995270|NCT00882258|DRUG|12.5 mg Proellex|12.5 mg Proellex administered orally daily
40995271|NCT00882258|DRUG|25 mg Proellex|25 mg Proellex administered orally daily
40995272|NCT00882258|DRUG|Placebo|Administered orally daily
40995273|NCT01419548|DRUG|ABT-888|
40995274|NCT01419548|DRUG|Carboplatin|
40995275|NCT01419548|DRUG|Paclitaxel|
40995276|NCT04079153|DEVICE|Mandibular advancement Appliance|Advances the mandible at desired range at a fixed vertical dimension
40995277|NCT06003010|BEHAVIORAL|Yoga|6 yoga videos to be done 2-3x a week for 6 weeks before and after surgery.
40995278|NCT03616353|PROCEDURE|Perineural Hydrodissection|The subcutaneous tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. While continuing to use ultrasound guidance and aseptic technique, the needle will then be angled superficial to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. The needle will be returned to its original angle deep to the median nerve, and the syringe will be changed to inject 40 mg Depo-Medrol in 1ml of saline.
40995279|NCT03616353|PROCEDURE|Corticosteroid Injection|The subcutaneous soft tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 40 mg Depo-Medrol in 1ml of saline will be injected into the area deep to the median nerve.
40995280|NCT01087086|BEHAVIORAL|Crononutrition|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
40995281|NCT01087086|BEHAVIORAL|American Heart Association|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
40995282|NCT02453763|DEVICE|Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
40995283|NCT02453763|PROCEDURE|MRI|All participants will receive an MRI. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
40995284|NCT02882555|BEHAVIORAL|Exercise|6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity \<10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
41148697|NCT00635752|OTHER|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
40790791|NCT00756275|BEHAVIORAL|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
40790792|NCT04173182|DIAGNOSTIC_TEST|Probe-based confocal laser endomicroscopy evaluation|Colonoscopy with confocal laser endomicroscopy evaluation of the peridiverticular and colonic mucosa on patients with diverticular disease
40790793|NCT05832892|DRUG|surufatinib|"In phase Ib, surufatinib will be orally administrated 200 mg once a day (QD) or 250 mg QD per cohort escalation assignment on a 21-day cycle.~In phase II, surufatinib will be orally administrated at RP2D as determined in phase Ib."
40790794|NCT05832892|DRUG|KN046|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
40790795|NCT05832892|DRUG|gemcitabine|Gemcitabine will be administrated at 1000 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
40790796|NCT05832892|DRUG|Nab paclitaxel|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
40995285|NCT02882555|DRUG|Capsaicin|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
40995286|NCT02882555|DRUG|Normal saline|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
40995287|NCT04122859|DEVICE|Zip Skin Closure Device|The device is a CE-marked, single use, sterile medical device that is designed to provide closure speed superior to sutures, while resulting in a suture-like cosmetic outcome. It adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives.
40995288|NCT01339351|BEHAVIORAL|Therapeutic Group by Teleconference|10 sessions
40995289|NCT00138944|DRUG|placebo|od
40995290|NCT00138944|DRUG|eplerenone|50mg od
40995291|NCT04305795|BIOLOGICAL|200 mg Pembrolizumab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
41148698|NCT00635752|OTHER|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
41148699|NCT03780634|PROCEDURE|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
41148700|NCT03780634|DRUG|PD-1 antibody|200mg intravenously every 3 weeks
40790797|NCT05262413|DRUG|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
40790798|NCT00811954|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
40790799|NCT00811954|DRUG|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
40790800|NCT00811954|DRUG|Darunavir|800 mg taken orally once daily. A protease inhibitor (PI).
40790801|NCT00811954|DRUG|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
40790802|NCT00811954|DRUG|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
40790803|NCT01761708|PROCEDURE|primary ventral hernia repair with mesh|
40790804|NCT04373343|BEHAVIORAL|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
40790805|NCT04211454|OTHER|No intervention|There is no intervention for this study.
40790806|NCT02537730|DEVICE|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
40790807|NCT02537730|DEVICE|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
40790808|NCT02537730|DEVICE|comfilcon A|contact lens
40995292|NCT04305795|BIOLOGICAL|350 mg Cemiplimab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
40995293|NCT04305795|COMBINATION_PRODUCT|ASP-1929|"ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months."
40995294|NCT00255593|DRUG|rituximab|
40995295|NCT03725189|DEVICE|PPG during exercise|PPG use for pulse waveform evaluation of healthy exercise group
40995296|NCT00336713|DRUG|Saredutant (SR48968C)|oral administration (capsules)
40995297|NCT00336713|DRUG|Placebo|oral administration (capsules)
40995298|NCT04029714|PROCEDURE|Active Surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
40995299|NCT05121883|DRUG|Edaravone Dexborneol|Edaravone dexborneol (Jiangsu Simcere Pharmaceutical, Co, Ltd) will be initiated within 48 hours of stoke onset at 37.5 mg/dose, once every 12 hours, and continuing for more than 7 days (maximum: 14 days)
40995300|NCT01559012|DRUG|Clonidine|transdermal clonidine patch 5 mg q. 5 days
40995301|NCT05112380|OTHER|Performing Xco endurance test|The subjects will perform the test two times, with 7-10 days between the two sessions
40995302|NCT03558399|OTHER|FET according to ERA|Single euploid FET will be performed at the time indicated by the ERA test results.
40995303|NCT03558399|OTHER|FET according to standard protocol|Single euploid FET will be performed according to our standard FET protocol.
41148701|NCT03780634|DRUG|Sorafenib|400 mg Bid Po
41148702|NCT05306483|PROCEDURE|Ventricular septal defect closure surgery|Ventricular septal defect closure surgery
41148703|NCT05306483|PROCEDURE|Ventricular septal defect closure catheter|Catheter closure of VSD
41148704|NCT01117532|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Four 90 minute group therapy classes of this behavioral intervention
41148705|NCT02632747|DRUG|Empagliflozin|Empagliflozin will be taken once daily
41148706|NCT02632747|DRUG|Placebo (matching empagliflozin)|Placebo will be taken once daily
41148707|NCT02632747|DRUG|ramipril|Ramipril will be taken once or twice daily
41148708|NCT05253066|DRUG|Chidamide combined with exemestane (+/- goserelin)|Chidamide combined with exemestane (+/- goserelin)
40790809|NCT03558646|OTHER|There is no intervention planned (observational)|There is no intervention planned (observational)
40790810|NCT02982811|DEVICE|i-ACT|3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)
40995304|NCT02891707|DEVICE|Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)|"The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation."
40995305|NCT06047353|BEHAVIORAL|Motivational Enhancement Therapy|Motivational Enhancement Therapy (MET) is based on the principles of motivational interviewing and is designed to promote self-efficacy and maximize behavioral change. MET will be given via phone and/or in person (approximately 30 minutes) at baseline, week 1, week 2, week 4, and week 8.
40790811|NCT02504372|BIOLOGICAL|Pembrolizumab|IV infusion
40790812|NCT02504372|OTHER|Placebo|IV infusion
40790813|NCT05895578|DIETARY_SUPPLEMENT|Probiotic|1 capsule of probiotic (Lactobacillus CECT 9422 + Bifidobacterium CECT 30257) every 12 hours for 6-months.
40790814|NCT05895578|DIETARY_SUPPLEMENT|Probiotic + placebo|1 capsule of probiotic + 1 capsule of placebo per day for 6-months.
40790815|NCT05895578|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo every 12 hours for 6-months.
40790816|NCT05640362|OTHER|Natural enzymes mouthwash|Natural enzymes mouthwash contains numerous natural protein-enzymes, including lactoferrin, lysozyme, lactoperoxidase, glucose oxidase. These active ingredients were proposed to render this mouthwash to act as salivary substitutes by reinforcing the functions of available saliva, hence reinforcing the immune system in the oral cavity. It was expected to relieve the symptoms in xerostomia patients, and even more if the patients have salivary flow reduction by improving the functions of the limited amount of saliva. The potential mechanisms of action of the mouthwash to treat xerostomia may be related to: (1) lubrication effects to wet the oral mucosal surfaces; (2) antimicrobial properties that will reduce risks of mucosal irritation by infections; (3) absence of alcohol in the mouthwash Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
40790817|NCT05640362|OTHER|Benzydamine mouthwash|Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
40790818|NCT00362895|DRUG|Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension|One drop in the study eye, single dose
40790819|NCT00362895|DRUG|Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)|One drop in the study eye, single dose
40790820|NCT05576324|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|Elexacaftor / Ivacaftor / Tezacaftor is a triple drug therapy that modulates CFTR availability at (apical) cell membranes and increases opening probability.
40790821|NCT02549989|DRUG|LY3023414|Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
40790822|NCT02444507|DRUG|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
40790823|NCT02444507|DRUG|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
40790824|NCT02065011|DRUG|Blood draw for the laboratory assessment|
40790825|NCT03542019|DEVICE|Dental prosthesis|Replacement of missing tooth structure using Lithium disilicate porcelain
40790826|NCT03542019|DEVICE|Dental crown|Replacement og missing tooth structure using monolithic zirconia
40790827|NCT03542019|DEVICE|Hybrid ceramic|Restroration of endodontically treated teeth using hybrid ceramic
40995306|NCT06047353|DEVICE|Positive Airway Pressure (PAP) therapy|Positive Airway Pressure (PAP) therapy will be administered as per standard of care.
40995307|NCT00763165|DRUG|Triclosan|Brush twice daily
40995308|NCT00763165|DRUG|Fluoride|Brush twice daily
40995309|NCT00763165|DRUG|Fluoride|Brush twice daily
40995310|NCT00446147|DRUG|Pyridoxine|100mg BID/daily, Per oral
40790828|NCT04144283|BEHAVIORAL|NAP|"For experiment 1, the NAP group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') without cues.~For experiment 2 the NAP+TMR group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') with auditory TMR. The learning related sounds will be presented to participants at 140% of their minimal auditory detection threshold during stage 2 and stage 3 of NREM sleep."
40790829|NCT04144283|BEHAVIORAL|WAKE|For experiment 1, the WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness without cues.
40790830|NCT03048201|DEVICE|Physica Kinematic Retaining Knee System|Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation
40790831|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
40790832|NCT03048201|DEVICE|Physica Posterior Stabilized Knee System|Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.
40790833|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System with LMC Liner|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
41148709|NCT05253066|DRUG|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
40790834|NCT05278845|DRUG|SLC-391|SLC-391 is an AXL inhibitor
40995311|NCT00446147|DRUG|Placebo|placebo 100mg BID/daily, Per oral
40995312|NCT02307006|DRUG|Ceftaroline|Surgical prophylaxis
40995313|NCT02307006|DRUG|Cefazolin / Vancomycin|Standard of care surgical prophylaxis
40995314|NCT04006665|DIAGNOSTIC_TEST|Lung Ultrasonography (Baseline)|Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.
40995315|NCT04006665|DIAGNOSTIC_TEST|Lung Ultrasonography ( At the end of surgery)|Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
40995316|NCT01120431|OTHER|Oral rehydration fluid|Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
40995317|NCT01120431|DRUG|Isotonic hydration fluid and recombinant human hyaluronidase|Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
40995318|NCT05010889|PROCEDURE|Peroral endoscopic myotomy (POEM)|POEM is performed as previously described by Inoue et al (Endoscopy 2010), including four main steps mucosal incision, submucosal tunneling, myotomy and mucosal entry closure.
40995319|NCT05810090|PROCEDURE|Total knee arthroplasty|patient who received a TKA in our hospital
40995320|NCT02689258|DRUG|HTX-011B|HTX- 011B (bupivacaine/meloxicam) via injection
40995321|NCT02689258|DRUG|Placebo|Saline placebo via injection
40995322|NCT02689258|DRUG|HTX-011A|HTX- 011A (bupivacaine/meloxicam) via injection
40995323|NCT02689258|DRUG|HTX-002|HTX-002 via combination
40995324|NCT02689258|DRUG|Bupivicaine HCl|Bupivacaine HCl via injection
40995325|NCT02627599|DEVICE|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
40995326|NCT02241499|RADIATION|Radiation therapy|Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.
40995327|NCT02241499|DRUG|Oxaliplatin and fluorouracil.|Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
40995328|NCT03818165|BIOLOGICAL|CAR2 Anti-CEA CAR-T cells|doses will be delivered by hepatic arterial infusions using pressure enhanced delivery device (PEDD)
40995329|NCT02400723|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
40995330|NCT02400723|BEHAVIORAL|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
40995331|NCT02400723|OTHER|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
40995332|NCT02403245|OTHER|Psychosocial stimulation|"Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the four season of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music."
40995333|NCT03934528|DEVICE|Virtual environment activity|Patients undertake an activity using simulated arm movement within a virtual reality environment every day for two months
40995334|NCT00414804|DEVICE|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
40995335|NCT00414804|PROCEDURE|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
40995336|NCT05252039|BEHAVIORAL|Goals in Focus|"Goals in Focus (GiF) is a symptom-specific treatment program that targets motivational negative symptoms in patients with schizophrenia-spectrum disorders.~The aim is to improve setting and pursuit of personal relevant goals.~GiF follows a 24-individual-sessions treatment manual. GiF includes five treatment phases: 1) Preparation, 2) Goal-setting, 3) Goal-pursuit, and 4) Reflection and preparation of autonomous goal-pursuit. The interventions include generating positive goals, behavioral activation, training of anticipatory pleasure, challenging demotivating beliefs, training of problem-solving skills and social skills training."
40995337|NCT05195281|PROCEDURE|Fine Needle Biopsy or Aspiration|A new sampling of the tumor will be performed after 4-6 months of neoadjuvant chemotherapy
40995338|NCT05796011|DEVICE|hearing aids|Hearing aid(s) fitted for one or two sides of ear.
40995339|NCT05796011|OTHER|without hearing intervention|neither earing aids nor other heaing treatment were applied.
40995340|NCT05796011|OTHER|healthy control|healthy control
40995341|NCT02641379|DRUG|Peginterferon alfa-2a|PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n
40995342|NCT02641379|DRUG|Ribavirin|Ribavirin is available as 200 mg tablets
40995343|NCT02436759|DRUG|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
40995344|NCT02436759|DRUG|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
40995345|NCT01527188|BIOLOGICAL|100IR|100IR sublingual tablet of
40995346|NCT01527188|BIOLOGICAL|300IR|300IR sublingual tablets of
40995347|NCT01527188|BIOLOGICAL|500IR|500IR sublingual tablet of
40995348|NCT01527188|OTHER|Placebo|Placebo sublingual tablet of
40995349|NCT00117559|BEHAVIORAL|Telehealth Treatment|Participants receive a 15-minute telephone call for 8 weeks
40995350|NCT05424536|OTHER|Bone measurement by DXA and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites plus femoral neck, one measurement will be performed by DXA to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
40995351|NCT03062956|DRUG|MYK-491 or placebo|Oral suspension
40995352|NCT05013983|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
40995353|NCT05013983|OTHER|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium
40995354|NCT01845792|DRUG|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
40995355|NCT01845792|DRUG|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
40995356|NCT00144365|DRUG|Antiretroviral therapy|
40995357|NCT01069133|DRUG|Rifaximin|550mg BID open-label
40995358|NCT01069133|DRUG|rifaximin|550mg PO BID
40790835|NCT04224922|DRUG|Paclitaxel|
40790836|NCT04224922|DRUG|Carboplatinum|
40790837|NCT04224922|DRUG|Epirubicin|
40790838|NCT04224922|DRUG|Cyclophosphamide|
40790839|NCT03991910|DRUG|Placebos|the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.
40790840|NCT03991910|DRUG|Ramipril 5Mg Oral Capsule|the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
40790841|NCT01151020|DEVICE|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
40790842|NCT05211349|OTHER|Dual-Task Timed Up and Go Test (cognitive)|It evaluates balance with a simultaneous cognitive and motor task. The cognitive task of the test is serial triple subtraction while the TUG test is a motor task. Balance performance will be recorded in seconds.
40790843|NCT05211349|OTHER|3-m Backward Walk Test|It is used to assess fall risk and balance. It is calculated in how many seconds an individual can walk backward a marked distance of 3 meters.
40790844|NCT05211349|OTHER|Modified Four Square Step Test|It is a performance test that evaluates dynamic balance in stroke individuals with the ability to avoid obstacles and take steps in all directions. Balance performance is recorded in seconds.
40790845|NCT05211349|OTHER|Timed Up and Go Test|It is used to assess balance and functional mobility. The participant is asked to get up from the chair she/he is sitting in, walk the marked distance of 3 meters and return to her/his seat again. The elapsed time is recorded in seconds.
40790846|NCT05211349|OTHER|Berg Balance Test|It consists of 14 items and evaluates dynamic balance and functional mobility in stroke. The maximum score is 56. Higher scores indicate better balance.
40790847|NCT00535418|DRUG|Letrozole|
40790848|NCT02512445|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|Trauma focused therapy
40790849|NCT02512445|BEHAVIORAL|Supportive Care Therapy|Supportive therapy
40790850|NCT04649216|DRUG|PCO371|PCO371 Capsule
40790851|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Oral solution
40790852|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Solution for infusion
40790853|NCT03396302|OTHER|Educational intervention|The self-applied on-line intervention will comprise a three months behavioural intervention composed by 8 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits.
40790854|NCT01369199|DRUG|Entecavir and peginterferon|Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
40790855|NCT03577262|OTHER|[11C]-UCB-J|IV radioligand given prior to and during positron emission tomography (PET) scan
40790856|NCT02122146|DRUG|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
40995359|NCT00733044|BEHAVIORAL|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
40790857|NCT02122146|DRUG|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
40790858|NCT02377557|DRUG|Topical Steroids|
40790859|NCT05743374|OTHER|Normal diet|These patients will be given advice about a normal healthy diet.
40790860|NCT05743374|DIETARY_SUPPLEMENT|E400 elimination|Patients in the intervention group will be given advice how to eliminate E440 additives with regard to carragenan, CMC and polysorbates.
40790861|NCT03116425|DEVICE|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
40790862|NCT03116425|DEVICE|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
40790863|NCT03116425|DEVICE|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
40790864|NCT03116425|PROCEDURE|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
40790865|NCT03116425|PROCEDURE|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
40790866|NCT03116425|PROCEDURE|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
40790867|NCT04762836|DRUG|D-cycloserine|Antibiotic medication that augments the function of NMDA-receptors
40790868|NCT04762836|BEHAVIORAL|Conditioning|During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.
40790869|NCT04762836|BEHAVIORAL|Extinction|During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.
40790870|NCT04762836|OTHER|fMRI|In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.
40790871|NCT04762836|DRUG|Placebo|Placebo control in oral form
41148710|NCT05546177|OTHER|instrumented assisted soft tissue mobilization|The subject will be treated with instrumented assisted soft tissue mobilization, applied to the upper and lower fibers of Pectoral, Trapezius (upper, middle and lower), Rhomboids major , Rhomboids minor, Teres minor, Teres major, and Latissimus dorsi muscles. The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers of each one of the selected muscle
41148711|NCT05546177|OTHER|traditional therapy|the patients will receive Transcutaneous electrical nerve stimulation (TENS) to manage the pain,Ultrasound , Exercise including (Range of motion exercises, stretching exercises, and strengthening exercises (Scapular stabilization exercises and rotator cuff strengthening exercises)
40790872|NCT05417672|DIAGNOSTIC_TEST|Nutritional Risk Screening-2002|Nutritional Risk Screening-2002
40790873|NCT05417672|DIAGNOSTIC_TEST|Nutritional Risk Index|Nutritional Risk Index
40790874|NCT05417672|DIAGNOSTIC_TEST|Mini Nutritional Assessment|Mini Nutritional Assessment
40790875|NCT05417672|DIAGNOSTIC_TEST|Glasgow Prognostic Score|Glasgow Prognostic Score
40790876|NCT05417672|DIAGNOSTIC_TEST|Prognostic Nutritional Index|Prognostic Nutritional Index
40790877|NCT05417672|DIAGNOSTIC_TEST|Anthropometric measurements|middle arm circumference
40790878|NCT05417672|DEVICE|Handgrip strength test|Handgrip strength test
40790879|NCT02523989|OTHER|study group|Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
40790880|NCT01543919|DRUG|PH-797804|0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
40790881|NCT01543919|DRUG|PH-797804|1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
40790882|NCT01543919|DRUG|PH-797804|3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
40790883|NCT01543919|DRUG|PH-797804|6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
40790884|NCT01543919|DRUG|PH-797804|10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
40790885|NCT01543919|DRUG|Placebo|Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
40790886|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
40790887|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
40790888|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
40790889|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
40790890|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
40790891|NCT02948582|DRUG|Placebo 0.5mL|Placebo 0.5mL via eFlow, once daily
40790892|NCT03943576|DRUG|GXCPC1|The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)
40790893|NCT03943576|DEVICE|HA|Hya Joint Plus synovial fluid supplement 3mL
41309966|NCT06217016|PROCEDURE|ICCAUT|In this study ,the ICCAUT strategy include intermittent catheter clamping and active urination training. For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
40995360|NCT00733044|OTHER|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
40995361|NCT03727412|DRUG|Drugs, Generic (Naprosyn)|naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
40995362|NCT03727412|DRUG|Placebo Oral Tablet|placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
40995363|NCT06447844|DEVICE|OsteoGen Plug|OsteoGen® Plug is contoured to fill the three roots of the socket. Plug is delivered dry into a thoroughly debrided and actively bleeding socket. The OsteoGen® Plug is condensed firmly into the socket.
40995364|NCT06447844|DEVICE|BioGide|BioGide is a resorbable collagen membrane
41309967|NCT06217016|PROCEDURE|Free drainage|For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
40790894|NCT05113654|DIAGNOSTIC_TEST|Sleep study|Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders
40790895|NCT04743713|OTHER|UWRI-Tr|Questionnaire
40790896|NCT00446329|DRUG|cinacalcet|Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
40995365|NCT01792947|PROCEDURE|Percutaneous electroneurostimulation of dermatome T6|The patients underwent a percutaneous electroneurostimulation of dermatome T6 during 30 minutes, every week during 12 weeks. This intervention was associated to a diet 1200 Kcal
40995366|NCT01792947|BEHAVIORAL|Diet 1200 Kcal|The patients assigned to this group must follow a 1200 Kcal diet during months
40995367|NCT05563753|DRUG|ABT|any antibiotic therapy in the first week of life
40995368|NCT00234988|DRUG|sibutramine hydochloride monohydrate|10 mg QD with the option to increase dose to 15 mg QD up until Week 4
40995369|NCT05861739|BEHAVIORAL|Endometriosis Self-care Support Program|ESSP will be applied to the women in the intervention group in four sessions, one week apart. In the first and second sessions, a self-care training program will be applied. In the third and fourth sessions, motivational interview will be made by contacting the women by phone.
40995370|NCT02281552|DRUG|Tofacitinib|tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
40995371|NCT02281552|DRUG|Tofacitinib|tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
40790897|NCT04149483|DRUG|Atorvastatin|One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
40790898|NCT04149483|DRUG|Placebos|One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
40790899|NCT02930707|DRUG|Magnesium Sulfate|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
40790900|NCT02930707|DRUG|Bupivacaine|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
40790901|NCT05043181|BIOLOGICAL|Low Density Lipoprotein Receptor mRNA Exosomes|"The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase."
40790902|NCT05837039|BEHAVIORAL|Healthcare Provider|Questionnaires
40790903|NCT05837039|BEHAVIORAL|Caregiver Perception|Questionnaires
40790904|NCT03954912|PROCEDURE|MAKO assisted unicondylar knee arthroplasty|MAKO assisted
40790905|NCT03954912|PROCEDURE|NAVIO assisted unicondylar knee arthroplasty|NAVIO assisted
40995372|NCT04706130|DRUG|Primaquine|After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites
40995373|NCT04706130|DRUG|Artesunate|All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites
41309968|NCT03105596|DRUG|Chidamide plus DICE Regimen|Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
41309969|NCT00029991|DRUG|Gingko Biloba (Herb)|
40790906|NCT04539834|OTHER|electrolytes|measuring level of electrolytes
40995374|NCT04626869|OTHER|Evaluation of Diaphragm Movement|Diaphragmatic movement will be evaluated with ultrasonography and a 5-2 MHz convex transducer will be used. The ultrasound probe is placed between the mid-clavicular line and the anterior axillary line by directing it vertically and slightly cranially. During quiet breathing and deep breathing, diaphragm movement will be measured. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block. Each test will be done 3 times and the values will be averaged. A decrease between 75% and 100% will be defined as complete paresis, a decrease between 25% and 75% as partial paresis, and less than 25% decrease in diaphragmatic movement will be defined as no paresis. In order to investigate the effect of continuous local anesthetic drug administration on diaphragm movement via nerve catheter, the same procedure will be repeated 24 hours after surgery.
40790907|NCT00209144|DRUG|Intensive insulin therapy|
40790908|NCT03549741|DRUG|Clomiphene Citrate 50mg|oral tablets
40790909|NCT03549741|DRUG|Cabergoline Oral Tablet|oral tablets
40790910|NCT03549741|DRUG|Placebo Oral Tablet|oral tablets
40790911|NCT00335738|DRUG|liposomal vincristine sulfate|Given IV
40790912|NCT00335738|DRUG|carboplatin|Given IV
40790913|NCT00335738|DRUG|etoposide|Given IV
40790914|NCT03138785|DRUG|topical voriconazole / levofloxacin systemic itraconazole|starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
40790915|NCT03138785|RADIATION|CXL|30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
40995375|NCT01542385|PROCEDURE|Stent|Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
40995376|NCT04430439|BEHAVIORAL|Psychosocial stress|The TSST is a 15 minute standardized lab-based challenge task that involves speech preparation, speech delivery while being evaluated by strangers and video taped, and complex mental arithmetic with critiques if errors are made.
40995377|NCT04430439|BEHAVIORAL|Control non-stress|Participants will have a relaxed 15 minute conversation with a familiar research team member.
40995378|NCT05235334|DEVICE|MySOLIUS|MySOLIUS is a portable light therapy device that is designed to deliver a small amount of targeted ultraviolet B (UVB) light to trigger the body's natural production of vitamin D.
40995379|NCT04338438|DRUG|Apatinib Mesylate tablets combined with S-1 capsules|Apatinib Mesylate tablets combined with S-1 capsules, p.o.
40995380|NCT05866861|DRUG|CUG252|CUG252 will be administered by subcutaneous injection.
40995381|NCT05866861|DRUG|Placebo|Placebo will be administered by subcutaneous injection.
40995382|NCT03904407|OTHER|Lactobacillus Probiotic Capsule|"One over-the-counter, probiotic capsule taken by mouth once daily for 4 weeks. Each capsule contains 10 billion cells comprised of:~* Lactobacillus crispatus LbV 88~* Lactobacillus jensenii LbV 116~* Lactobacillus gasseri LbV 150N~* Lactobacillus rhamnosus LbV 96"
40995383|NCT03904407|OTHER|Matching Lactobacillus Probiotic Placebo Capsule|Lactobacillus Probiotic placebo capsules identical in appearance taken by mouth once daily for 4 weeks
40995384|NCT03741556|OTHER|questionaire|a questionaire is sent to each participans
40790916|NCT04312503|DRUG|Lurasidone|Patients are treated with dosages according clinical practice
40790917|NCT04312503|DRUG|aripiprazole, olanzapine, quetiapine or risperidone|Patients are treated with dosages according clinical practice
40790918|NCT03573388|DEVICE|Optical coherence tomography (OCT)|Lesion OCT assessment
40995385|NCT00499096|BEHAVIORAL|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
40995386|NCT05161130|PROCEDURE|Lumbar Spinal Fusion|Lumbar Spinal Fusion with or without posterior stabilization
40995387|NCT03322228|OTHER|Music Therapy|Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
40995388|NCT06310850|DRUG|Ketamine|Patients will be administered 0.15 mg kg-1 intravenous ketamine (The sample provided contains equal proportions of two enantiomers, S and R ketamine hydrochloride.) 3 minutes before thoracic epidural catheter placement.
40995389|NCT06310850|OTHER|Placebo|Intravenous saline will be administered to patients 3 minutes before the thoracic epidural catheter is placed.
40995390|NCT00102700|DRUG|ARQ 501 in combination with gemcitabine|
40790919|NCT00005590|DRUG|levofloxacin|
40995391|NCT02539381|PROCEDURE|Formal Perimetry (Goldman or Octopus visual Field)|
40995392|NCT02539381|PROCEDURE|Albert's visual inattention test|
40995393|NCT02539381|PROCEDURE|Star cancellation visual inattention test|
40995394|NCT02539381|PROCEDURE|Visual field assessment to confrontation|
40995395|NCT02539381|PROCEDURE|Visual inattention assessment to bilateral stimuli|
40995396|NCT02539381|DEVICE|Digital tumbling E visual accuity assessment|
40995397|NCT02539381|DEVICE|Digital visual field assessment|
40995398|NCT02539381|DEVICE|Digital line crossing assessment|
40995399|NCT02539381|DEVICE|Digital shape cancellation assessment|
40995400|NCT05223855|OTHER|Physiotherapeutic hydrotherapy treatment|"Physiotherapeutic hydrotherapy treatment The intervention consists of physiotherapeutic one-on-one treatment in a 34-36 degrees centigrade hot water, where the participants are placed supine in the water supported by the physiotherapist as well as buoyant aqua noodles. The physiotherapist supports and moves the participants in the water and adapts to the participant's reaction.~The combination of heat, water, movement and touch affects the musculoskeletal and neuromuscular systems and thus has a depth-relaxing effect (Schoedinger, 2010)."
40995401|NCT02428881|DRUG|onabotulinumtoxinA|Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
40995402|NCT05420558|DIAGNOSTIC_TEST|Fibroblast activation protein inhibitor PET/CT imaging|All participants will receive a 68Ga-labelled fibroblast activation protein inhibitor PET/CT imaging
40995403|NCT03962153|DIAGNOSTIC_TEST|Obstetric Ultrasonography|Obstetric Ultrasonography
40995404|NCT00559546|DRUG|montelukast|10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
40995405|NCT01830439|DRUG|PA-824 200mg|Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
40995406|NCT01830439|DRUG|PA-824 50mg|Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
40995407|NCT05113186|DRUG|Lenvatinib Pill|"The design of study is summarized as follows:~* Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~* PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~* Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)"
40995408|NCT05528237|DEVICE|Flocked swab paired with Roche Cobas 4800|Consenting individuals will insert the sterile flocked swab into the vagina, rotate at least once, and store in the provided dry tube. The sample will be stored at ambient temperature and routed to the lab for HPV testing with Roche Cobas 4800.
41468822|NCT05924334|OTHER|reiki|"Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average."
41468823|NCT05924334|OTHER|placebo|placebo
41468824|NCT04051216|BEHAVIORAL|Education information system|Participants will receive a mobile tablet as an educational intervention
41468825|NCT04051216|OTHER|Activity monitor|Participants will receive at least 1 of 4 activity monitoring devices
41468826|NCT04051216|OTHER|Interview|Participants will be interviewed about their experience using the device(s)
40995409|NCT06372444|RADIATION|Positron emission tomography (PET)|Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT
40995410|NCT01470742|DRUG|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
40995411|NCT01470742|DRUG|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
40995412|NCT01279408|OTHER|None: Questionnaire Study|Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
40995413|NCT05747144|DIAGNOSTIC_TEST|Biometry|Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed
40995414|NCT05747144|DIAGNOSTIC_TEST|Retinography (Color) + Autofluorescence (AF)|Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)
40995415|NCT05747144|DIAGNOSTIC_TEST|OCT B-scan and OCT angiography (OCTA)|"OCT B-scan:~2 scans (6 mm)~1 cross line~OCTA:~3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve"
41468827|NCT04051216|OTHER|Survey Administration|Participants will receive surveys
41468828|NCT04051216|OTHER|Laboratory Biomarker Analysis|Correlative studies
41468829|NCT06207123|DRUG|LP-118|LP-118 is an experimental anti-cancer drug that is currently being studied in clinical trials for multiple types of hematological cancers and solid tumors.
41468830|NCT06207123|DRUG|Ponatinib|Ponatinib is used to treat certain types of chronic myeloid leukemia (CML; a type of cancer of the white blood cells).
41468831|NCT06207123|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, neuroblastoma, and Wilms tumor. Vincristine belongs to the category of vinca alkaloids, a class of drugs that function by impeding the proper division of cancer cells.
41468832|NCT06207123|DRUG|Dexamethasone|Dexamethasone is used to treat cancer, to decrease inflammation and sometimes used before and after chemotherapy to prevent or treat nausea and/or vomiting. It is given in the vein (IV) or orally (by mouth)
41468833|NCT06207123|DRUG|Methotrexate|Methotrexate is a drug used to treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.
41468834|NCT05229055|DRUG|Ketamine|giving ketamine intranasal
41468835|NCT04273555|DRUG|[18F]-FDG|\[18F\]-FDG will be injected prior to PET/MRI imaging up to three times over the course of six months.
40995416|NCT05747144|DIAGNOSTIC_TEST|Microperimetry|1) fixation pattern 2) retinal sensitivity map
40995417|NCT05747144|DIAGNOSTIC_TEST|Electrophysiological exams|Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus \< 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.
40995418|NCT02795728|OTHER|Application of the GIC based sealant|Application of the GIC based sealant was carried out according to the manufacturer's instructions.
40995419|NCT02795728|OTHER|Resin based sealant|Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
40995420|NCT03632655|PROCEDURE|prostate biopsy|Men will be randomized to receiving either TPM or TRUS targeted biopsy
41309970|NCT06411808|BEHAVIORAL|Sensory-Adapted Dental Environment|The Sensory-Adapted Dental Environment (SADE) involves altering the dental setting to reduce sensory stimuli that can cause discomfort or anxiety in children with sensory processing disorders. This includes the use of controlled lighting, ambient sounds, and non-threatening tools to create a calming atmosphere conducive to positive dental experiences.
41309971|NCT02410772|DRUG|rifapentine|Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
41468836|NCT05987072|DRUG|Sisunatovir|Will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state
41468837|NCT06215131|BEHAVIORAL|In-person dietary weight loss counseling|The counseling content will be 30 minutes of RDN delivered educational session on energy density and portion sizes then the second 30 minutes being the RDN answering participant questions and providing feedback.
40995421|NCT00736008|OTHER|Observational|Data summary only
40995422|NCT04664933|DRUG|Intra-arterial administration of neuroprotective agents|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
40995423|NCT05000983|DRUG|PluroGel|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
40995424|NCT05000983|DRUG|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
40995425|NCT02477995|BIOLOGICAL|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
40995426|NCT02477995|BIOLOGICAL|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
41468838|NCT06215131|BEHAVIORAL|Virtual reality dietary weight loss counseling|The counseling content will be 30 minutes of virtual reality delivered educational session on energy density and portion sizes with an RDN remotely monitoring then the second 30 minutes being the RDN answering participant questions and providing feedback through synchronous audio/video.
41468839|NCT01662934|DEVICE|I RUNE|
41468840|NCT01662934|DEVICE|sham|
41468841|NCT04487288|DIAGNOSTIC_TEST|SONAZOID|CEUS using SONAZOID with fusion technique
40995427|NCT06197789|BIOLOGICAL|TPX-105|Subjects will be administered with autologous fibroblasts through injection
40995428|NCT06197789|BIOLOGICAL|Placebo|Subjects will be administered with Placebo through injection
40995429|NCT00573755|DRUG|anastrozole|given orally
40995430|NCT00573755|DRUG|exemestane|given orally
40995431|NCT00573755|DRUG|letrozole|given orally
40995432|NCT00573755|DRUG|sorafenib tosylate|given orally
40995433|NCT00573755|OTHER|placebo|given orally
40995434|NCT06110988|DEVICE|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
40995435|NCT00002137|DRUG|Tecogalan sodium|
40995436|NCT01093911|BIOLOGICAL|CDP7657|Ascending single doses of CDP7657
41148712|NCT03254524|OTHER|Statewide Planning and Research Cooperative System Database|The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
40995437|NCT01093911|OTHER|Placebo|Placebo: 0.9% sodium chloride aqueous solution
40995438|NCT01315704|DRUG|Drug intervention|before-after interventional (anti-dementia drugs and/or vitamin D) study
40995439|NCT04972019|DEVICE|Telerehabilitation Experimental Group|"Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals and subjective pain level being measured and logged.~They will wear a computer system modified with biosensors, then do motor and cognitive baselines. Subsequently, participants will play an increasing number of games, targeted at cognitive domains of executive function (primary), memory and attention. At the end of every session vitals and subjective pain will be measured and logged.~Clinical Coordinator will call homes weekly to ascertain general health and issues with participation.~At the end of week 4 and 8 participants and their caregivers in the experimental group will fill a subjective evaluation questionnaire to gauge perceived benefits and technical difficulties when using the experimental system. Questions will be scored on a 5-point Likert scale."
41148713|NCT02192645|DRUG|Sanfujiu|
41309972|NCT02410772|DRUG|rifapentine and moxifloxacin|Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
41309973|NCT02410772|DRUG|control|standard six-month treatment
40995440|NCT04972019|OTHER|Telerehabilitation Sham Control Group|"Sham control group will train playing web games while wearing a biosensor connected to a laptop provided, showing the web games. However biosensor data will not be used to control game difficulty.~Sham group controls will start every session with vitals and subjective pain levels being measured and logged. Then participants will play the same frequency and duration of sessions, however those will consist of web games training the same domains (memory, focusing, executive function). Interaction will be through a mouse, and data will be downloaded to a server maintained by the company doing the web games. Data will then be transferred to the research team.~At the end of every session vitals and subjective pain levels will again be measured and logged.~Once a week the Clinical Coordinator will call the home to ascertain general health and determine is there were issues with that week participation."
41148714|NCT02192645|DRUG|Placebo|The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
41148715|NCT05990088|DEVICE|Heat Cured Conventional Polymethylmethacrylate Complete Removable Dentures based on neutral zone concept|The patients will receive complete removable dentures designed based on neutral zone concept and manufactured by heat cured conventional technique of polymethylmethacrylate
41148716|NCT05990088|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machineز
41148717|NCT01243086|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
41148718|NCT01243086|DRUG|OZURDEX|OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
41309974|NCT01848054|DRUG|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
40995441|NCT05936866|OTHER|Pelvic floor stretching|Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises , seated pelvic tilts, cat stretches, seated hip openers (2 sets, 8 reps, sustained for 6 seconds) Week 5 to 8: Pelvic floor muscles awareness, Breathing exercises ,seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog (2 sets, 8 reps, sustained for 6 seconds) Week 9 to 13: Pelvic floor muscles awareness, Breathing exercises, seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog side lying clamshells, mini squats with support (2 sets, 9 reps, sustained for 7 seconds)
41468842|NCT04523246|BIOLOGICAL|SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|The Shingrix vaccine is a subunit vaccine that contains the recombinant varicella zoster virus (VZV) glycoprotein E (gE), adjuvanted with the proprietary Adjuvant System (AS01B). The AS01B Adjuvant system consists of two immune-stimulants, the saponin, Quillaja saponaria Molina, fraction 21 (QS21), and the toll-like receptor 4 (TLR4) agonist, MPL (3-O-desacyl-40-MPL) that enhance the release of interferon gamma (IFNϒ), which in turn stimulates activation and recruitment of blood monocyte-derived and resident lymph node dendritic cells to take up and present gE to cluster of differentiation 4 (CD4+) T cells.
41148719|NCT04937920|BIOLOGICAL|DBI-002 probiotic gel|Topical application on skin affected with tinea versicolor
41148720|NCT04937920|BIOLOGICAL|Aqueous gel|Topical application on skin affected with tinea versicolor
41148721|NCT03539497|DIAGNOSTIC_TEST|Biomarker|Plasma mitochondrial DNA, plasma Cytochrome C
41148722|NCT00067808|DRUG|Decitabine|10 mg/m\^2 by vein over 1 hour daily for 10 days
41148723|NCT00067808|DRUG|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days
41148724|NCT00067808|DRUG|Decitabine|20 mg/m2 subcutaneous (SQ) daily x 5 days
41148725|NCT06291935|DRUG|VG901|"Administered as specified in the treatment arm. Study Cohort 1 - Low dose; Study Cohort 2 - High dose~Other Names:~Gene Therapy (AAV2.NN-CNGA1)"
41148726|NCT02114502|DRUG|Carfilzomib|27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
41309975|NCT01848054|DRUG|Buprenorphine|Buprenorphine sublingual tablets
41468843|NCT04523246|DRUG|Normal Saline|Sterile normal saline, inactive control.
41148727|NCT02114502|DRUG|SAHA|1,000 mg by mouth on Days -8 to -3.
41148728|NCT02114502|DRUG|Gemcitabine|Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
41148729|NCT02114502|DRUG|Busulfan|Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.
41468844|NCT00116493|DIETARY_SUPPLEMENT|Iron-folic acid and mebendazole|"100 mg iron for pregnant women, 25 mg iron for children~1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children"
41468845|NCT00116493|DRUG|Mebendazole|100 mg twice a day for 3 days; Iron-folic acid also given
40790920|NCT03280693|DIAGNOSTIC_TEST|Diagnostic test|Body balance was assessed using Berg Balance Scale (BBS), while BMD of the lumbar spine was measured by dual energy X-ray absorptiometry (DEXA) scan.
40995442|NCT05936866|OTHER|Pelvic floor strengthening|"Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises, 2 Sets of 10 Reps for pelvic floor squeeze and release Seated marching with elastic band with pelvic floor squeeze.~Week 5 to 8: 2 sets x 9 Reps for Pelvic floor squeeze and release, Seated marching with elastic band with pelvic. 2 Sets x 8 Reps for bridging with pelvic floor squeeze, side lying hip circles Week 9 to 13: 2 sets 10 reps for Pelvic floor squeeze-and-release, Seated marching with elastic band with pelvic floor squeeze, pelvic bridging with pelvic floor squeeze, side lying hip circles with pelvic floor squeeze. 2 sets, 8 reps for . side lying Clamshells with resistance band and pelvic floor squeeze and plie squats with pelvic floor squeeze"
40790921|NCT04916392|DRUG|Liposomal bupivacaine|5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
40790922|NCT06413147|DEVICE|PFO closure|Surgery of PFO closure
40790923|NCT00178074|BEHAVIORAL|total sleep deprivation|
40995443|NCT02771990|DEVICE|Sham transcranial direct current stimulation|sham stimulation
40995444|NCT02771990|DEVICE|transcranial direct current stimulation|2 milliamp (mA) 20 minutes
40790924|NCT00178074|PROCEDURE|PET imaging|
40995445|NCT04582110|DIAGNOSTIC_TEST|Optical coherence tomography angiography|Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)
40995446|NCT05078853|DEVICE|Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node|"FNA Clinic: When a bloody material is seen in the needle, 100 µL of 0.9% saline is drawn via the needle into the syringe. The aspirate is then transferred into an Eppendorf tube. 40 µL is aspirated from the Eppendorf tube and dripped into the middle of the sample well of the POC-Tg kit. Two drops of the buffer are then dispensed into the middle of the sample well. The result of the POC-Tg is obtained and documented after 10 minutes. To compare the accuracy of the POC-Tg kit to the formal immunoassay for Tg, 0.9% saline is added to the aspirate that was left in the Eppendorf tube to a final volume of 0.6 mL. This volume is transferred into a gel containing tube and sent to the clinical laboratory that performs Tg measurement.~Operating room: When an indeterminate or suspicious LN is found, the LN is dissected and evaluated by both the formal evaluation and the POC-Tg. Following dissection of the LN, the ex-vivo POC-Tg is conducted as described above."
40995447|NCT03379649|COMBINATION_PRODUCT|Platelet rich plasma|Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
40995448|NCT03379649|COMBINATION_PRODUCT|Placebo|Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
40995449|NCT02596646|PROCEDURE|Early Precut|Early precut was performed during ERCP with difficult biliary cannulation
40995450|NCT02596646|PROCEDURE|Prolonged cannulation attempts|Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
40995451|NCT02935790|DRUG|ACY-241|tablet
40995452|NCT02935790|DRUG|nivolumab|infusion
40995453|NCT02935790|DRUG|ipilimumab|infusion
40995454|NCT00855036|OTHER|Attenuated bedrest|Patients are allowed to ambulate the morning after admission and then can be discharged when eating well and pain is controlled on oral pain medication regardless of hematuria
40995455|NCT00210821|DRUG|topiramate|
40995456|NCT04347382|DRUG|Honey|1gm/Kg/Day
40995457|NCT04347382|DRUG|Nigella Sativa / Black Cumin|80mg/Kg/day
40995458|NCT04347382|DRUG|Placebos|Empty capsule with 250ml of distilled water
40995459|NCT00002188|DRUG|Alitretinoin|
41148730|NCT02114502|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
41148731|NCT02114502|PROCEDURE|Stem Cell Transplant (SCT)|Stem cell transplant on Day 0.
41148732|NCT02114502|DRUG|Palifermin|60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
41148733|NCT02114502|DRUG|Dexamethasone|8 mg by vein twice a day from Day -9 PM to Day -2 PM.
41148734|NCT02114502|DRUG|Caphosol|30 mL oral rinse four times a day from Day -9 until discharge.
41148735|NCT02114502|DRUG|Glutamine|15 g four times a day, swished, gargled and spit on Day -9 until discharge.
41148736|NCT02114502|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
40790925|NCT06003777|DRUG|PF-06954522|PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.
40790926|NCT06003777|DRUG|Placebo|Placebo will be administered as oral suspensions as escalating single doses to be determined.
40790927|NCT02782585|OTHER|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
40790928|NCT02782585|OTHER|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
40790929|NCT02782585|OTHER|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
40790930|NCT00599352|DIETARY_SUPPLEMENT|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
40790931|NCT03806530|DRUG|Gabapentin|100 mg capsule
40790932|NCT03806530|DRUG|Ropinirole|0.50 mg capsule
40790933|NCT03806530|DRUG|Placebo Gabapentin|Placebo capsule
41148737|NCT05166317|OTHER|This is an observational study|This is an observational study
41309976|NCT01336179|PROCEDURE|Salvadora persica|twice daily use, two minutes interval
41309977|NCT01336179|PROCEDURE|Toothbrush|Twice daily use two minutes interval
40995460|NCT06146530|DEVICE|Treatment|The intervention consists of 7 sessions of CBT for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will be applicable to them. The intervention is based on an evidence-based treatment protocol; hence the sessions will flow from one to the other and the user will complete the sessions in a progressive direction. However, they can repeat a session before going on to the next session. Once all sessions have been completed, the user can go back over any of the sessions. There are anxiety management exercises, which the user can go to whenever they wish. There are also a therapy reflection journal and self-care resources including further anxiety management techniques, resources, and podcasts that the user will have access to whenever they want.
40995461|NCT05715203|DEVICE|Pulsotonometry|Evaluation of arterial stiffness
40995462|NCT06083506|DEVICE|NOVALOC TiN retained maxillary overdenture|4 implants immediately loaded by means of a NOVALOC TiN retained maxillary overdenture
40995463|NCT04458168|BEHAVIORAL|Use of Purposeful app|"Patients will be asked to use the Purposeful app every day, which should take no longer than 5 minutes. The app includes three key components: Explore, Act and Reflect. The Explore section provides thematically organized resources that suggest discrete actions users can try out and potentially incorporate into their lives. The app uses machine learning to customize resources presented to the user. The Act section is where users place actions they'd like to keep track of or build into a habit. Finally, the Reflect section includes daily reflections where the patient answers open ended questions regarding their alignment with their best self qualities, their sense of purpose, and more. Depending on whether users choose to allow push notifications, they will be notified daily to complete morning, afternoon, and/or evening reflections.~Participants will complete questionnaires at enrollment and at 1, 3, and 6 months after enrollment."
41468846|NCT00116493|DIETARY_SUPPLEMENT|Multivitamins|Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2
41468847|NCT00116493|DRUG|Mebendazole + Multivitamin|Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
41468848|NCT03417830|DRUG|GSK2315698 (CPHPC)|GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.
41468849|NCT03417830|DRUG|GSK2398852 (unlabeled anti-SAP mAb)|Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
40995464|NCT02283112|OTHER|antivirals, antimicrobials, oral contraceptive, erectile dysfunction agents|
40995465|NCT00422331|DRUG|Lithium Carbonate Capsule|
40995466|NCT06463951|OTHER|Psychotherapy - Gestalt psychotherapy|Gestalt psychotherapy is an aesthetic-phenomenological approach that aims to improve self-awareness and integration by promoting emotional and relational well-being through what is happening in the present moment in the relationship with the therapist. The patient's current experiences are explored to better understand problems and behaviors and by promoting relational self-regulation
40995467|NCT06032312|OTHER|description|no intervention, just description of the groups
40995468|NCT05372796|OTHER|IASTM|instrument-assisted soft tissue mobilization
40995469|NCT05372796|OTHER|home exercise|home exercise
40995470|NCT05372796|DEVICE|Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom)|OTES (Occipital Transcutenous Electric Stimulation)
40995471|NCT05609955|DRUG|MgSO4|The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
41148738|NCT01393964|DRUG|Lenalidomide|Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug
41309978|NCT02875847|DIETARY_SUPPLEMENT|HMO1|
41309979|NCT02875847|DIETARY_SUPPLEMENT|HMO2|
41309980|NCT02875847|DIETARY_SUPPLEMENT|Dextropur|
41309981|NCT04363489|DEVICE|Wearable Medical Device (Empatica E4)|A wearable medical device (Empatica E4) which is a smart wristband that detects skin temperature, heart rate and sleep. It is CE and FDA approved.
41309982|NCT04363489|DIAGNOSTIC_TEST|COVID-19 PCR Swab|COVID-19 PCR Swab will be self-taken by doctors every day. Fischer nasopharyngeal PCR Swabs
41309983|NCT04363489|DIAGNOSTIC_TEST|Pulse Oximeter|Participants will measure their oxygen saturations every day, and report them on the survey. Pulmolink A310 pulse oximeters
41309984|NCT02742350|DEVICE|IMT - POWERbreathe Plus Light Resistance®, SP, BR|POWERbreathe Plus Light Resistance®, SP, BR
41468850|NCT03417830|DRUG|89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)|89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
41468851|NCT02959476|DRUG|Ropivacaine|Anesthetic
41468852|NCT02959476|DRUG|Placebos|Inactive comparator
40995472|NCT04818190|PROCEDURE|Sensory neurotization|The donor nerve is a cutaneous nerve that is identified with the most inferior lateral perforator vessels. The nerve is then dissected for neurotization and divided at the level of the fascia where it is a pure sensory nerve. The recipient intercostal nerve is usually easily identified in the third intercostal space during the dissection of the internal mammary artery and vein. The anterior branch of the third intercostal nerve can usually be found at the junction of the inferior portion of the third rib and the sternum, approximately 80% of the time. The nerve is dissected and transected medially. It is then mobilized to give it the longest length possible in preparation for neurotization. Neurotization is performed by coapting the donor nerve to the third anterior intercostal nerve directly with a 9-0 nylon suture in standard fashion.
41309985|NCT04103255|OTHER|High frequency and intensive prevention program|This study is a 4 week non-randomized controlled trial (RCT)
41309986|NCT03509337|DIAGNOSTIC_TEST|shear-wave elastography|Measurement by shear-wave elastography of the nerve, muscle and ulnar tendon before and after the tension of the ulnar nerve
41468853|NCT00658957|DRUG|gentamicin-collagen sponge|5 × 5 cm sponge
41468854|NCT00658957|DRUG|placebo collagen sponge|5 × 5 cm sponge
41468855|NCT00274885|DRUG|oxaliplatin|
41468856|NCT00274885|PROCEDURE|management of therapy complications|
41468857|NCT01847924|DRUG|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
41468858|NCT01847924|DRUG|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
41468859|NCT03259789|DRUG|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
41468860|NCT03259789|DRUG|Bexagliflozin tablets, placebo|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
41468861|NCT03259789|DRUG|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
41468862|NCT06175247|OTHER|Low Glycemic Index Diet|A low glycemic diet will be initiated with dietician support and guidance.
41468863|NCT01119586|GENETIC|DNA analysis|
41468864|NCT01119586|GENETIC|genetic linkage analysis|
41468865|NCT01119586|GENETIC|microarray analysis|
41309987|NCT01234857|DRUG|ridaforolimus + dalotuzumab|Ridaforolimus 20 mg once daily (QD) five days a week, with the possibility of escalation to 30 mg once daily (QD) after the first cycle and dalotuzumab intravenous infusion 10 mg/kg once weekly (QW). Treatment will continue until disease progression.
41309988|NCT01234857|DRUG|exemestane|Exemestane 25 mg daily (QD). Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
41309989|NCT01234857|DRUG|ridaforolimus|Ridaforolimus 40 mg QD five days a week. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval. Note: the Sponsor-recommended dose of ridaforolimus when administered as a single agent is 40 mg/day, but when given in combination with dalotuzumab, it is given at 30 mg/day.
41309990|NCT01234857|DRUG|dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg QW. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
41309991|NCT03777371|OTHER|Anti HIV Seropositive Pregnant Women|
41468866|NCT01119586|GENETIC|nucleic acid sequencing|
41468867|NCT01119586|GENETIC|polymerase chain reaction|
41468868|NCT01119586|GENETIC|polymorphism analysis|
41468869|NCT01119586|OTHER|laboratory biomarker analysis|
41468870|NCT05930431|BEHAVIORAL|Physical activity variety intervention|The counseling in the variety condition will serve many purposes. The first session will concentrate on informing participants on the importance of having variety in their physical activity routine and how to access the variety of physical activities available to them. The variety condition will be instructed to complete at least three different HIIT workouts per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting variety in physical activity but also to support participants' basic psychological needs.
41468871|NCT05930431|BEHAVIORAL|Physical activity consistency comparison condition|The counseling in the consistency condition will serve many purposes. The first session will concentrate on informing participants the importance of having consistency in their physical activity routine and how to access the HIIT workout available to them. The consistency condition will be instructed to complete the provided HIIT workout three times per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting consistency in physical activity but also to support participants' basic psychological needs.
41468872|NCT03738787|PROCEDURE|Pancreatic duct occlusion with Neoprene|Pancreatic duct occlusion of the pancreatic stump with Neoprene-based glue after Pancreatoduodenectomy.
41468873|NCT03738787|PROCEDURE|Pancreato-Jejunal anastomosis|Standardized pancreato-jejunal anastomosis after Pancreatoduodenectomy
41468874|NCT03460899|OTHER|Euglycaemic Clamp|All 14 subjects will undergo an euglycaemic clamp at Visit 2 with a plasma Glucose target of 5.5 mmol/L +/- 10% (4 timepoints for platelet activity parameter blood sampling)
40790934|NCT03806530|DRUG|Placebo Ropinirole|Placebo capsule
40790935|NCT05442580|DRUG|3x10(6) CART-38 cellls|3x10(6) CART-38 cells via intravenous infusion
40790936|NCT05442580|DRUG|7x10(5) CART-38 cells|7x10(5) CART-38 cells via intravenous infusion
40790937|NCT05442580|DRUG|7x10(6) CART-38 cells|7x10(6) CART-38 cells via intravenous infusion
40790938|NCT05442580|DRUG|3x10(7) CART-38 cells|3x10(7) CART-38 cells via intravenous infusion
40790939|NCT05442580|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered at physician discretion
40790940|NCT05442580|DRUG|Fludarabine|Lymphodepleting chemotherapy administered at physician discretion
40790941|NCT04217109|DIAGNOSTIC_TEST|Odour sampling|"Upon receipt of the samples at the Institute Curie-Paris, the compresses will be packed in jars and then transmitted to the dog center and analyzed by the study dogs.~Positive marking is characterized by a sitting position of the dog in front of the sample."
40790942|NCT00872274|DRUG|sumatriptan 100mg|
40790943|NCT05542446|DRUG|Colistin|"Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection."
40790944|NCT00967681|DIETARY_SUPPLEMENT|Oncoxin|(caplets 300 mg), three oral caplets per day for 24 weeks
40790945|NCT00967681|DIETARY_SUPPLEMENT|Placebo|(caplets 300 mg), three oral caplets per day for 24 weeks
40790946|NCT02776046|DRUG|High FiO2|High FiO2 with a perioperative open lung strategy
40790947|NCT02776046|DRUG|Conventional FiO2|Conventional FiO2 with a perioperative open lung strategy
40995473|NCT05468437|BEHAVIORAL|Telenutrition|Nutrition education and individualized nutrition counseling will be done with a Registered Dietitian via video-conferencing with iPad FaceTime, which is aimed to decrease the risk of complications like obesity, high cholesterol, or diabetes, and explore associations between bowel and bladder function and nutrition. The telenutrition counseling consists of 6 sessions that are scheduled approximately 2 weeks apart. The first session will last approximately 1 hour, while sessions 2-6 will last approximately 30mins. During these sessions, the Registered Dietitian will share nutrition education tailored towards people with SCI. You will be involved in developing personal nutrition goals and the dietitian will help you address barriers to meeting your goals and provide individualized feedback to improve and maintain your nutrition. Telenutrition appointments will maintain privacy and will not be recorded.
40995474|NCT03365310|DRUG|C. longa, curcuminoids , Z. officianale, O. sanctum along with 200 ml of Milk|Polyherbal formulation along with standard of care
40995475|NCT03365310|OTHER|Standard of Care|Usual standard of care for consist of exercise, caloric and protein support, vitamin D, reduction of polypharmacy along with medical management of health condition, assessment of care needs and provision of care. These will be determined on case by case basis by research clinician.
41148739|NCT01393964|DRUG|Dexamethasone|Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
41468875|NCT03460899|OTHER|Hyperinsulinaemic/Hypoglycaemic Clamp|All 14 subjects will undergo a hypoglycaemic/hyperinsulinaemic clamp at Visit 3 with 4 timepoints for platelet activity Parameter blood sampling 30 minutes after reaching certain plasma glucose plateaus (5.5 mmol/L; 3.5 mmol/L; 2.5 mmol/L; after recovery again at 5.5 mmol/L)
40790948|NCT01807325|PROCEDURE|pancreas biopsy|patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
40790949|NCT00098033|DRUG|clofarabine|
40790950|NCT03019887|DRUG|reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine|
40790951|NCT04335448|OTHER|No intervention is planed|No intervention is planed
40790952|NCT00932074|DRUG|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
40790953|NCT02441101|DEVICE|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
40790954|NCT02441101|DEVICE|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
40790955|NCT06126419|DRUG|High-Dose Insulin Therapy|A baseline blood glucose value will be obtained. Two units of insulin will be administered IV if the blood glucose is \> mmol/L. An insulin infusion of 0.12 units/kg/hr will be started. Ten minutes after starting the insulin, and when the blood glucose is \< 6 mmol/L, dextrose 20% supplemented with phosphate (30 mmol/L) will be infused. Blood glucose levels will be measured every 15 minutes, and the dextrose infusion rate adjusted to maintain glycemic levels between 4 and 6 mmol/L for a duration of 6 hours. At the end of the 6 hour period, the insulin will be stopped and the dextrose will be weaned off.
41309992|NCT04048525|PROCEDURE|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
41309993|NCT04048525|PROCEDURE|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
40790956|NCT02480088|DRUG|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
40790957|NCT02480088|DRUG|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
40790958|NCT06029114|DIAGNOSTIC_TEST|Magnetic Resonance Elastography (MRE)|Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.
40790959|NCT04244240|BEHAVIORAL|BEARNI Tool|"BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory.~The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available."
40790960|NCT00392977|DIETARY_SUPPLEMENT|remove Mn from PN if evidence of increased brain Mn on MRI|trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.
40790961|NCT05782985|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)|Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.
40790962|NCT01015755|BEHAVIORAL|combined therapy treatment|mouth care
40790963|NCT02214901|DRUG|BIBW 2948 BS for oral inhalation|
40790964|NCT02214901|DRUG|Placebo|
40995476|NCT04898751|DRUG|Immune checkpoint inhibitor (ICI)|Immune checkpoint inhibitors included were targeting either PD-1, PD-L1 or CTLA-4, and had received FDA approval at the time of study (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), and Cemiplimab (L01XC33).
41309994|NCT01364350|OTHER|standard of care in general clinical practice|Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
40995477|NCT03981133|BEHAVIORAL|offer a pacifier|offer a pacifier to normal newborn infants the first days of life
40995478|NCT03981133|BEHAVIORAL|no pacifier|not to offer a pacifier at 15 days of life
40995479|NCT02210936|OTHER|Educational Intervention|"The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers)."
40995480|NCT04222712|DRUG|TRS01 eye drops|Dosed four times a day (QID)
40790965|NCT05205616|DEVICE|Sonopet ultrasonic saw|Ultrasonic saw to be used on a randomized side of the mandible, reciprocating saw will be used on other side
40790966|NCT05205616|DEVICE|Reciprocating saw|See above description
40790967|NCT00003312|RADIATION|iodine I 125|
40790968|NCT02666313|BEHAVIORAL|Exercise|"The physiotherapist will select exercises which are appropriate to that participant. Participants will complete online exercise diaries which are reviewed remotely by the physiotherapist. Depending on progress, exercises can be progressed, added or removed from the patient's individualised programme.~Participants will be encouraged to undertake their exercise programme, according to evidence base guidelines, five days/week for 30 minutes/day. Participants will receive weekly phone calls for the first two weeks of the programme. Thereafter, every two weeks the physiotherapist will review the exercise diary of each participant and remotely alter the participant's exercise programme as appropriate, by changing any combination of exercises, level of difficulty or number of repetitions."
40790969|NCT05329753|DEVICE|Mobile health application|Health intervention through a smartphone application that favors the process of learning
40790970|NCT00288548|DRUG|Metoprolol|
40790971|NCT04603469|OTHER|Non invasive blood pressure|measurement of blood pressure during induction of general anesthesia
40995481|NCT04222712|DRUG|TRS01 eye drops|Dosed four times a day (QID)
40995482|NCT04783805|DIAGNOSTIC_TEST|Conservative management with regular follow-up|Women will be followed-up every 4 months, with colposcopy and cytology at each visit.
40995483|NCT04783805|PROCEDURE|Conization|Women with progression of HSIL, HSIL persistence after 24 months of follow-up, or that no longer meet the criteria for surveillance will have conization
40995484|NCT00118807|DRUG|Amodiaquine plus artesunate (AQ/AS)|
40995485|NCT00118807|DRUG|Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ)|
40995486|NCT00118807|DRUG|Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)|
40995487|NCT02259309|DRUG|Misoprostol - buccal|buccal administration
41468876|NCT00535080|DRUG|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
40790972|NCT05434494|DRUG|Remimazolam|"Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19."
40995488|NCT02259309|DRUG|Misoprostol - vaginal|vaginal administration
40995489|NCT05019924|DIETARY_SUPPLEMENT|Semaine|The dietary supplement is designed, and marketed commercially to be taken in servings of two capsules per day, up to four times per day (a total of 8 capsules daily). Most consumers, however, will only take a serving three times per day, or one with each major meal (breakfast, lunch and dinner).
40995490|NCT03720912|BEHAVIORAL|Online Learning Modules|The modules will include information about common family management skills: social support, problem solving, communication, and supportive behavior change strategies.
40995491|NCT01697865|PROCEDURE|Transfer group|
41309995|NCT04949880|DEVICE|Neurovascular Drug-Eluting Balloon Dilatation Catheter|The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
41468877|NCT05365035|DRUG|Cladribine|Given by Vein (IV)
40790973|NCT05434494|DRUG|remifantanil|25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
40790974|NCT01771874|DRUG|MDMA|125 mg per os, single dose
41468878|NCT05365035|DRUG|Cytarabine|Given under the skin; subcutaneous injection (SQ)
41468879|NCT05365035|DRUG|Venetoclax|Given by PO
41468880|NCT05365035|DRUG|Azacitidine|Given by IV or subcutaneous injection (SQ)
41468881|NCT03569488|DIAGNOSTIC_TEST|FT-LARS questionnaire|FT-LARS questionnaire
41468882|NCT01938235|DRUG|Exenatide|Intravenous bolus and 24-hour infusion of exenatide
41309996|NCT02860533|DEVICE|cuff device|Measurement of blood pressure during stress testing with cuff device
41468883|NCT01938235|DRUG|Placebo|Intravenous bolus and 24-hour infusion of placebo
41468884|NCT00641199|OTHER|Jarro-Dophilus EPS probiotics|Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
40995492|NCT01697865|PROCEDURE|Control group|
40995493|NCT00593671|PROCEDURE|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
40995494|NCT03877627|PROCEDURE|Pelvic and Peritoneal Lymphadenectomy|Patients in arm 2 will be randomized to undergo pelvic and peritoneal lymphadenectomy to treat their endometrial carcinoma.
40995495|NCT06484998|BEHAVIORAL|Dental anxiety level and child's compomer colors selection|Patients without any syndromes or systemic disorders, without mental retardation, who needed restorative treatment for primary molars were included in the study. The examination forms of 275 patients requiring restorative treatment of primary teeth were analysed at the session they came for restorative treatment. To determine the child's anxiety, the Modified Child Dental Anxiety Scale-faces version was administered to the children before restorative treatment. The children were asked to choose from a scale consisting of 9 colours (pink, blue, gold, silver, orange, yellow, green, purple, white) for the compomer restoration color selections. The patients were asked what their favourite color was after the compomer restoration color selection so that the previous question would not have any effect on the child's restoration color selection.
41468885|NCT02138981|PROCEDURE|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
40790975|NCT01771874|DRUG|Bupropion|Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
40790976|NCT01771874|DRUG|Placebo|per os
40790977|NCT01417221|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
40995496|NCT01002755|DRUG|Lenalidomide|Given PO
40995497|NCT01002755|BIOLOGICAL|Ofatumumab|Given IV
40995498|NCT02067377|DIETARY_SUPPLEMENT|Serum bovine immunoglobulin (SBI) medical food|Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.
40995499|NCT02067377|DIETARY_SUPPLEMENT|Placebo (for serum bovine immunoglobulin)|
40995500|NCT04843709|DRUG|MRG004A|Administrated intravenously
40995501|NCT00480779|BEHAVIORAL|GLB Group|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
40995502|NCT00480779|BEHAVIORAL|GLB DVD|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
40995503|NCT03801564|DEVICE|Platelet Rich Plasma Treatment Group (PRP)|EASY PRP is in category IIa and manufactured by Neotec Biotechnology Industry and Foreign Trade Company. (Item No. 8680976403603; UNSPSC 42295470; GMDN 46923; certificate no: M.2016.106.7294).
40995504|NCT03801564|DEVICE|Hyaluronic Acid Treatment Group (HA)|REGENFLEX STARTER is a class III intraarticular viscosupplementation device (Art. No. 8681065100076; UNSPSC 42295509). Sodium hyaluronate is obtained by bacterial fermentation (STREPTOCOCCUS EQUI) method. The product is in disposable packages, sterile and contained in a 2 ml pyrogen-free syringe.
40995505|NCT01816828|BEHAVIORAL|Gay Poz Sex|Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
40995506|NCT01816828|OTHER|Wait List/Standard of Care|Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
40995507|NCT03893552|DEVICE|Negative expiratory pressure|Using a cough assist, a negative expiratory pressure will be applied while recording the respiratory flow in patients suffering from sleeping disorders or snoring.
40995508|NCT01859507|DRUG|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
40995509|NCT04954963|DIAGNOSTIC_TEST|Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
40995510|NCT06253065|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model (developed)|Collect pathological slides of resected lymph nodes of the enrolled patients. Digitise these slides into whole-slide images (WSIs). Analyze the WSIs using the AI model to generate diagnostic results (with or without lymphatic metastasis). No intervention to patients would be performed in this diagnostic test study.
40995511|NCT00322192|BEHAVIORAL|Conventional UK Physical therapy|
40995512|NCT00322192|BEHAVIORAL|Increased intensity of UK conventional physical therapy|
41309997|NCT02860533|DEVICE|iphone|Measurement of blood pressure during stress testing with iPhone
41309998|NCT05297422|PROCEDURE|Forearm surgey|Microsurgery Clinic , KAT Hospital Athens
41309999|NCT05297422|DRUG|Ropivacaine|Ropivacaine
40790978|NCT04285697|OTHER|infection prevention bundle|"The infection prevention bundle (IPB) implemented items:~Preoperative counseling and questionnaire: patient counseling and preparation instructions, screening questions for signs of infection, and presence of open or nonhealing wounds.~Nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization: preoperative 24 hours ago twice-daily application of 2% mupirocin ointment to bilateral nares with final application on the morning of surgery.~Body decolonization: Cleansing with 4% chlorhexidine gluconate shower the evening before surgery and the morning of surgery.~Preoperative weight-based antibiotics within 60 minutes of incision~Strict draping and surgical techniques the standardization Irrigation of the surgical site with warm Isotonic NaCl solution before skin closure Postoperative wound care education to patient and family"
40790979|NCT00898170|PROCEDURE|myoma removal|surgical removal of myoma by hysterectomy
40790980|NCT05875844|DIAGNOSTIC_TEST|Wrist Splint|Wrist Splint to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
40790981|NCT05875844|DIAGNOSTIC_TEST|Occupational Therapy|Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
40790982|NCT03672851|DRUG|anti-CD123 CAR-T treatment|Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
40790983|NCT02735421|DRUG|ABPO Forte Gel|Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
40790984|NCT02735421|DRUG|Vehicle gel|Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
40790985|NCT01484652|DRUG|COV795|2 tablets taken every 12 hours
40995513|NCT00322192|BEHAVIORAL|UK conventional physical therapy plus functional strength training|
40995514|NCT01296295|BEHAVIORAL|Lifestyle counseling and spirometry|The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
40790986|NCT01484652|DRUG|Placebo|2 tablets taken every 12 hours
40790987|NCT00427011|DRUG|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
40790988|NCT03680534|PROCEDURE|Root canal preparation|Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
40790989|NCT01923766|DRUG|Cytotoxic T lymphocytes (CTLs).|"This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated."
40790990|NCT03372161|DRUG|SP-102|injection
40995515|NCT01296295|BEHAVIORAL|Smoking cessation advice|Brief smoking cessation advice
40995516|NCT01018199|OTHER|CRP|C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
40995517|NCT01018199|OTHER|PCT|Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
40995518|NCT02614911|OTHER|Biological sampling|Biological sampling including blood, feces, biopsies...
40995519|NCT05509699|DRUG|Surufatinib|The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.
40995520|NCT05509699|DRUG|Anti-PD-1/L1|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
40995521|NCT06080386|DIAGNOSTIC_TEST|UDFF|quantification of liver fat: UDFF (lipid fraction derived from ultrasound) from one of the probes of an ultrasound system
40995522|NCT01889316|DEVICE|Novii|The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
40790991|NCT03372161|DRUG|Placebo|injection
40790992|NCT02607124|DRUG|Ribociclib|
40995523|NCT01889316|DEVICE|AN24|
40995524|NCT04092166|OTHER|Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
40995525|NCT01168635|BEHAVIORAL|Spirometry 360 program - Virtually-delivered spirometry quality improvement program|"The Spirometry 360 program includes:~1. Spirometry Fundamentals™: A basic guide to lung function testing, a computer-based training program that teaches primary care providers how to coach patients to produce high-quality spirometry tests and accurately interpret spirometric data;~2. Spirometry Learning Lab: Case-based teaching of spirometry in practice guides test administrators and interpreters through clinical examples in an interactive virtual classroom setting. These sessions are led by expert clinical faculty and are archived for future reference and review;~3. Spirometry Feedback: Tailored analysis of providers' spirometry testing sessions offers monthly individualized feedback reports by clinical experts on spirometry tests performed in the clinic."
40995526|NCT03468907|DRUG|Telbivudine 600mg|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.
40995527|NCT03468907|DRUG|Tenofovir disoproxil fumarate 300mg|Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.
40995528|NCT04073758|DRUG|Dexmedetomidine|Comparing effects of remifentanil versus dexmedetomidine
41148740|NCT01393964|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on days 8, 15 \& 22 (cycle 1); days 8 \&22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
41310000|NCT05297422|DRUG|Ketamine|Ketamine
40790993|NCT03526094|OTHER|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
40790994|NCT03526094|OTHER|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
40790995|NCT03526094|OTHER|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
40790996|NCT03526094|OTHER|Flavanol-berry blend|Flavanol-berry blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
40790997|NCT03526094|OTHER|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
40790998|NCT03526094|OTHER|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
40790999|NCT03526094|OTHER|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
40791000|NCT03526094|OTHER|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
40995529|NCT03634553|OTHER|Training with e-health product|The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
40995530|NCT03634553|OTHER|Usual care|usual care, i.e. participates in regular training regime at the physiotherapy department
40995531|NCT01781442|DRUG|Temsirolimus|"The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.~Treatment will continue until disease progression or unacceptable toxicity.~The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity."
40995532|NCT02519712|DRUG|Induction Chemotherapy|Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
40995533|NCT02519712|PROCEDURE|G-PBSC Infusion|G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
41148741|NCT01393964|DRUG|Dexamethasone|Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
40791001|NCT03526094|OTHER|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
40995534|NCT05048810|RADIATION|68Ga-DOTA-NT-20.3|In this study, all patients will receive one injection of 68Ga-DOTA-NT-20.3, a PET radiopharmaceutical selective for neurotensin receptor 1 (NTR-1). For the injection, subjects will receive a target dose of 2-4 MBq per kg of body weight as a bolus injection. 68Ga-DOTA-NT-20.3 injection will be followed by a 10 ml saline flush.
40791002|NCT03526094|OTHER|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
41148742|NCT01393964|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
40995535|NCT05820347|DEVICE|Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation|Estimation of inspiratory muscle pressure by an artificial intelligence algorithm integrated in the mechanical ventilator (FlexiMag, Magnamed, Brazil).
40791003|NCT06259318|BEHAVIORAL|Kanasina Gulabi|Kanasina Gulabi is a theory-driven, educational-behavioral intervention designed to improve the quality of life and diabetes management among young adults living with type 2 diabetes in Mysore district, South India. In this intervention, young adults with type 2 diabetes were matched to non-specialist peer navigators -- trained young adult peers who were also managing type 2 diabetes -- and developed action plans to improve their physical and mental health outcomes. Intervention components included group education, mindfulness activities, self care activity tracking, and phone follow-ups to address knowledge gaps and misinformation about type 2 diabetes, build self-efficacy for type 2 diabetes-related self care activities, and provide emotional support for diabetes management.
40791004|NCT01558284|DRUG|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
40791005|NCT01558284|DRUG|Placebo|Placebo
40791006|NCT01280786|DRUG|Elesclomol Sodium|Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
40791007|NCT00211289|BEHAVIORAL|Education by community pharmacist|
40791008|NCT03392428|OTHER|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
40791009|NCT03392428|DRUG|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
40791010|NCT00249587|DRUG|Methadone|dosed to effect, every six hours
40995536|NCT01599507|DRUG|FG-4592|TIW dosing, capsule
40995537|NCT01599507|DRUG|Placebo|TIW dosing, capsule
40995538|NCT02813603|PROCEDURE|EBUS|19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.
40995539|NCT01080898|OTHER|tests|color photographs, FLUORESCEIN angiography and OCT
41310001|NCT03470649|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 would be intravenously administrated to treatment group after main procedure of total knee arthroplasty.
41310002|NCT03650686|OTHER|Food weighing (gold standard)|Method which consists in weighing precisely the main dish at the beginning and then end of meal using a SOEHNLE scale (+/- 1g).
41148743|NCT04734236|DIAGNOSTIC_TEST|New technique vs Xpert|New technique vs Xpert
41148744|NCT00004311|DRUG|leuprolide acetate|
41148745|NCT00004311|DRUG|spironolactone|
41468886|NCT02138981|PROCEDURE|Immediate Resection|patients received immediate surgical resection.
41468887|NCT04702763|OTHER|Eye-Tracker®T2 + e-VOG|"* 1st step: eyes movements assessed with standard video-oculography device~* 2° step: eyes movements assessed with e-VOG digital application~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
41310003|NCT03650686|OTHER|Automated photographic method (method to be evaluated)|The nursing staff will position the tray for automatic picture taking before and after the meal. Taking a photograph of the entire tray will allow the patient's identity to be identified by his meal card which will then be coded for analysis and the plate will be targeted at the time of the nutritional analysis by the software. This method will automatically provide the percentage of each main dish food consumed using an advanced image processing algorithm and an optimized artificial intelligence system that will recognize the food before and after consumption. Automatic processing and transfer will enable food intake to be collected.
40995540|NCT00535548|BIOLOGICAL|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
41310004|NCT03650686|OTHER|Semi-quantitative method (routine method)|Staff will indicate whether 1, ¾, ½, ¼ or 0 (corresponding to 100%, 75%, 50% 25% or 0) of the food in the main course has been consumed.
41468888|NCT04702763|OTHER|e-VOG + Eye-Tracker®T2|"* 1st step: eyes movements assessed with e-VOG digital application~* 2° step: eyes movements assessed with standard video-oculography device~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
40791011|NCT04040062|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
40791012|NCT00803595|DRUG|CS-8958|CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
40791013|NCT00803595|DRUG|CS-8958|CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
40791014|NCT00803595|DRUG|oseltamivir phosphate|CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
40995541|NCT00896337|DEVICE|Epic™ Nitinol Stent System|The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
40995542|NCT00896337|DRUG|Anti-platelet therapy|Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
41468889|NCT00088049|DRUG|Olanzapine|
41468890|NCT00088049|DRUG|Aripiprazole|
41468891|NCT01272089|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
41468892|NCT01949116|DRUG|LDMTX|"LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly"
41468893|NCT01949116|DRUG|Placebo|"Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly"
41468894|NCT01949116|DIETARY_SUPPLEMENT|Folic acid|1-mg tablet of folic acid by mouth once a day
41468895|NCT05735886|DIETARY_SUPPLEMENT|Softgel containing placebo|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
41468896|NCT05735886|DIETARY_SUPPLEMENT|Softgel containing 250mg of Urolithin A (Mitopure)|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
41468897|NCT02674633|DEVICE|AKL-T01|Videogame-like digital therapy
41468898|NCT02674633|DEVICE|AKL-T09|Videogame-like digital therapy
41468899|NCT05996692|OTHER|Evaluation of adherence to walking prescriptions|Adherence to walking prescriptions was evaluated according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.
41468900|NCT03088852|DRUG|Magnesium Citrate 100 MG|initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.
41468901|NCT05765617|DRUG|Calcitriol|The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma
41468902|NCT05765617|OTHER|Placebo|Placebo give 2x1 per day for five day
41468903|NCT06467552|PROCEDURE|control group|The entire process is carried out according to Severance Hospital surgical protocols.
41468904|NCT06467552|DIETARY_SUPPLEMENT|Nucare Curact group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery. In addition, the patients of control group will be instructed to take up to 4 doses of the nutritional supplement (Nucare Curact provided by DAESANG Wellife Inc.) per day for approximately 2 weeks before surgery and for about 4 weeks after surgery.
41468905|NCT00203541|DEVICE|TELFA™ A.M.D. Island dressing|
41468906|NCT01530308|DRUG|Haloperidol|An oral dosage of 1mg twice daily at 12am and 8pm.
41468907|NCT01530308|DRUG|Placebo|An oral dosage of 1mg twice-daily at 12am and 8 pm.
40995543|NCT00896337|DRUG|Anti-coagulation therapy|Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
41310005|NCT02312817|OTHER|Mailed Outreach Invitation|"Individuals randomized to Group 2 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
41468908|NCT05309720|PROCEDURE|Glyaderm|All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. Next, the dermal substitute Glyaderm followed by a split thickness skin graft will be transplanted on the wound.
41468909|NCT06276530|OTHER|EOS imaging for musculoskeletal disorder|The patients will have a low radiation 2D/3D biplane imaging of the rib cage, and spine before and after surgery.
41468910|NCT06276530|OTHER|Movement analysis by an optoelectronic camera.|Movement analysis by an optoelectronic camera before and after surgery.
41468911|NCT06276530|OTHER|Stabilometric measurement by strength platform|Stabilometric measurement by strength platform before and after surgery.
41468912|NCT00823199|DRUG|Allopurinal|300mg once daily by mouth for four weeks
41468913|NCT01647711|DRUG|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
41468914|NCT04251858|PROCEDURE|Dental Scaling|The individuals will be treated by a single periodontist and the scaling and root planing procedures will be performed on all teeth as follows: local anesthetic infiltrative type of the areas to be treated, dental and root scaling using Grace 5/6 carbon steel curettes, 11/12, 13/14 and MacCall 13/14, 17/18 curettes, according to their therapeutic indications. Polishing the quadrants treated with abrasive paste; oral hygiene instructions including Bass toothbrushing, dental floss and sometimes inter-dental brush.
41468915|NCT04251858|OTHER|Oral hygiene instruction|Oral hygiene instructions should be given to all study participants. Guidance on the most appropriate toothbrush, toothpaste and interproximal cleaning method.
41468916|NCT02246686|DRUG|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
41468917|NCT02246686|DRUG|Placebo|Application over 12 weeks 20 drops three time daily
41468918|NCT06350617|DEVICE|High-Frequency, ipsilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
40995544|NCT01667978|DRUG|Norethindrone acetate|
41148746|NCT06012877|BEHAVIORAL|Health Friendly Program|"The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021)."
41468919|NCT06350617|DEVICE|High-Frequency, bilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
41468920|NCT06350617|DEVICE|High-Frequency, Lt. DLPFC|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: Lt. DLPFC~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
41148747|NCT00274976|BIOLOGICAL|alemtuzumab|
40791015|NCT04728646|DRUG|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
40791016|NCT04728646|DEVICE|Regular dissolvable intracanalicular plug|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
40791017|NCT01276548|DRUG|Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC|
40995545|NCT05735301|PROCEDURE|Endovascular|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA"
40791018|NCT01276548|DRUG|Genexol® 175mg/m2 plus Carboplatin 5 AUC|
40791019|NCT02067143|DRUG|Prephase PDN + CY|
40791020|NCT02067143|DRUG|Cycle 1 Induction|
40995546|NCT05735301|DRUG|Drug|best drug conservative therapy could be uesd in patients who with no indication of surgery
40995547|NCT05769959|DRUG|RO7515629|RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
40995548|NCT05769959|DRUG|tocilizumab|Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).
40995549|NCT02276612|DRUG|E/C/F/TAF|150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
40995550|NCT03063476|DRUG|C-13 labeled Lysine|Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
40995551|NCT03063476|DRUG|Normal saline|Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
40995552|NCT02927379|DRUG|Dexmedetomidine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
40995553|NCT02927379|DRUG|Ketamine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
40791021|NCT02067143|DRUG|Cycle 2 Induction / Early consolidation|
41148748|NCT01092689|DRUG|PhiP|1 capsule of 84 micrograms; 15.6 micro-curies \[14C\]PhIP
41148749|NCT05024396|DIAGNOSTIC_TEST|maximum jump height|Three single leg countermovement jumps were performed. The maximum jump height is measured with a sensor that is adapted at the subjects'leg and with a force plate.
41148750|NCT06458296|OTHER|Control Group|Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
41148751|NCT06458296|OTHER|AI-Guided Group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
41148752|NCT04639752|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
40791022|NCT02067143|DRUG|Cycle 3 Early consolidation|
40791023|NCT02067143|DRUG|Cycle 4 Consolidation|
40791024|NCT02067143|DRUG|Cycle 5 Consolidation|
40791025|NCT02067143|DRUG|Cycle 6 Consolidation|
40791026|NCT02067143|DRUG|Cycle 7 Consolidation|
40791027|NCT02067143|DRUG|Cycle 8 Reinduction|
40791028|NCT02067143|DRUG|Maintenance|If MRD negative MRD u/k SR
40791029|NCT02067143|PROCEDURE|Allogeneic SCT or Autologous SCT|If MRD positive MRD u/k HR
40791030|NCT05975346|DRUG|Ketamine|description
40791031|NCT05975346|OTHER|saline nebulization|description
40791032|NCT01534481|BIOLOGICAL|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
40791033|NCT01534481|DIETARY_SUPPLEMENT|Preterm Formula|Preterm Formula determined by center practice.
41468921|NCT06350617|DEVICE|High-Frequency, bilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
41148753|NCT04639752|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
41468922|NCT02288494|OTHER|stewart approach|Prospective study, for ICU patient with severe hypoalbuminemia \< 20g/L, determining biological parameters from Stewart approach for acid base disorders (pH, SIDe, SIDa, SIG, Atot, PaCO2) before, and at 1hour, 2hours and 24 hours after a 200mL 20% human al Clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.
40995554|NCT02927379|DRUG|Bupivacaine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
41468923|NCT06287437|DRUG|HRS9531|HRS9531 escalated to the protocol-specified dose once weekly injection for 24 weeks ，then low frequency injection for 12 weeks.
41468924|NCT06287437|DRUG|HRS9531 placebo|HRS9531 placebo low frequency injection for 12 weeks.
41468925|NCT01573533|BIOLOGICAL|Rituximab|Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
41468926|NCT04489186|DEVICE|Wearable device|Multimodal electrocardiography (ECG), bioimpedance (bioZ) and tri-axial accelerometry (ACC) monitoring with a single wearable device (Byteflies Sensor Dot) to derive heart rate, respiratory rate and actigraphy.
41468927|NCT05270486|PROCEDURE|Electromagnetic navigation system|The aim of this study is to assess the safety and efficacy of TELD assisted by electromagnetic navigation for treating lumbar disc herniation (LDH).
40791034|NCT04983771|DEVICE|Annotate ultrasound scans|Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
40791035|NCT02898922|BIOLOGICAL|hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae|20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
40791036|NCT03924544|DRUG|Decorin|Antifibrotic agent
40995555|NCT04356963|BEHAVIORAL|Virtual Reality Session (VR Blu)|20-30 minute session of virtual reality immersive content.
40791037|NCT03924544|DRUG|Mitomycin c|Antifibrotic agent
41468928|NCT01698593|DRUG|Bupivacaine 0.5%|
41468929|NCT01698593|DRUG|Bupivacaine 0.5% + Epinephrine (1:200,000)|
41468930|NCT03695055|DRUG|Maintenance therapy post-HSCT|Rituximab vs DPP/DCEP-G vs observation
41468931|NCT02994251|DRUG|gemcitabine|1000 mg/m\^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
41468932|NCT02994251|DRUG|Cisplatin|25 mg/m\^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
41468933|NCT02994251|DRUG|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C|If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
41468934|NCT03084809|DRUG|Cytokine-induced killer cells+ FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks. Collected CIK cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days.
40791038|NCT03390517|DEVICE|Fluorescence angiography with indocianyne green|The fluorescence angiography was performed after mobilization of the bowel, transection of the rectum, division of the rectal and colon mesentery and central vessels, before specimen extraction or resection and creation of the anastomosis. This site was selected by the surgeon using his or her best judgment and typical standard of care assessment. After this selection, the anesthesiologist administered a bolus of 1 to 2 ml indocianyne green intravenously. Perfusion of the colon was visualized and assessed via fluorescence angiography and the line of demarcation between perfused and nonperfused tissue was noted and compared with the initial planned transection point.
40791039|NCT04023760|DRUG|Apixaban|Study subjects given a single-dose of apixaban 10 mg.
40791040|NCT00167375|DRUG|eszopiclone 3 mg qHS|
40791041|NCT00167375|BEHAVIORAL|General cognitive/behavioral interventions for insomnia|
41148754|NCT02652455|DRUG|Nivolumab|Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
41148755|NCT02652455|PROCEDURE|Surgery to Remove Tumor for Growth of TIL|All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
41468935|NCT03084809|DRUG|FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
41468936|NCT04126343|DRUG|Padsevonil|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period"
41310006|NCT02312817|OTHER|Mailed Outreach Invitation and Patient Navigation|"Individuals randomized to Group 3 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
40791042|NCT03310359|DIETARY_SUPPLEMENT|Astaxanthin|The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
40791043|NCT03310359|OTHER|Placebo|Matching placebo pill
40791044|NCT01623505|DRUG|Champix|"Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
40791045|NCT01623505|DRUG|Transdermal Nicoderm patch combined with gum or inhaler|"Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~\*Off-label dosage approved by Health Canada via No Objection letter."
40791046|NCT01623505|DRUG|Transdermal Nicoderm patch|"Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
40791047|NCT00626535|DRUG|Esomeprazole|20mg Oral Once Daily
40791048|NCT00626535|DRUG|Matching placebo|Oral Once Daily
40791049|NCT01193452|DRUG|S-1, Leucovorin|"S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week."
40791050|NCT01193452|DRUG|leucovorin, 5-fluorouracil|"leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks"
40791051|NCT00737724|DRUG|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
40995556|NCT04356963|BEHAVIORAL|Tablet-based Session (Tablet Blu)|20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.
40995557|NCT04356963|BEHAVIORAL|Use of Virtual Reality Head Mounted Display without Content (VR Blank)|20-30 minutes session using head mounted display to reduce light and sound.
40995558|NCT02482025|OTHER|SMMRT|Includes My HealtheVet registration and enrollment
40995559|NCT02088983|DIETARY_SUPPLEMENT|CDP-Choline|Capsule
40995560|NCT02088983|DIETARY_SUPPLEMENT|Cellulose|Capsule
40995561|NCT05403242|DRUG|RC48-ADC|2.0 mg/kg, IV, d1, every 2 weeks; or 2.5 mg/kg, IV, d1, every 2 weeks
40995562|NCT05403242|DRUG|S-1|40-60 mg, bid po, d1-10, every 2 weeks
40995563|NCT01064557|DRUG|all-trans retinoic acid (ATRA)|
40995564|NCT03724812|DEVICE|Portico Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach
40995565|NCT03733171|DRUG|PLATELET RICH PLASMA|PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
40995566|NCT03733171|DRUG|diluted epinephrine|diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
40995567|NCT03733171|DEVICE|hemoclips|diluted epinephrine was injected followed by application of hemoclips
40995568|NCT05764187|OTHER|Orthodontic fixed appliance therapy|Follow up of white spot lesion development using quantitative light induced fluorescence in patients bonded with ceramic brackets versus patients bonded with conventional metal brackets
40995569|NCT04277754|OTHER|Observational|To Observe and describe motor and visual development
40995570|NCT01216475|PROCEDURE|Femtosecond LASIK|LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.
40995571|NCT01216475|PROCEDURE|Small incision lenticule extraction (SMILE)|Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.
40791052|NCT00737724|DRUG|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
40791053|NCT05765058|OTHER|Group A|Application of SDF (silver diamine fluoride) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
40791054|NCT05765058|OTHER|Group B|Application of Sodium Fluoride varnish on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
40791055|NCT05765058|OTHER|Group C|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Biosmalto tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
40995572|NCT03554356|DEVICE|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation System
40995573|NCT01152463|PROCEDURE|thoracic ultrasound|daily thoracic ultrasound evaluation of the chest
40791056|NCT05765058|OTHER|Group D|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
40995574|NCT02310139|PROCEDURE|Colonoscopy|
40995575|NCT04099160|OTHER|Evaluation|The Turkish version of the Revised Neurophysiology of Pain Questionnaire will be applied to patients with chronic spinal pain at the beginning of the study and a week later. The Visual Analogue Scale and the Short Form-36 (SF-36) questionnaire will be applied to patients only at the beginning of the stuy.
40995576|NCT02450032|BIOLOGICAL|G17DT|
40995577|NCT00885066|DRUG|capecitabine|
40791057|NCT00790582|DRUG|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
40995578|NCT00885066|DRUG|erlotinib hydrochloride|
41468937|NCT04126343|DRUG|Moxifloxacin|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive moxifloxacin once during the Treatment Period"
40791058|NCT04514731|DRUG|Magnesium sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of isotonic saline over 15 minutes after spinal anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/hour) until the end of surgery.
40791059|NCT04514731|DRUG|Isotonic Saline|Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.
40791060|NCT06432400|OTHER|Patient questionnaires|Patients questionnaires, on paper and data collection on patients medical file
40791061|NCT04114916|DIETARY_SUPPLEMENT|Apigenin, luteonin, grapefruit extract and citrolive|Two capsules daily at breakfast and dinner.
40791062|NCT04114916|DIETARY_SUPPLEMENT|maltodextrina|Two capsules daily at breakfast and dinner.
40791063|NCT05123989|BEHAVIORAL|Personalized move goals|Personalized move goals delivered by the Welltory mobile app
40995579|NCT00885066|DRUG|gemcitabine hydrochloride|
40995580|NCT03184181|OTHER|EPTE® group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
40995581|NCT03184181|OTHER|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
40995582|NCT03890770|DRUG|BMS-986165|Oral administration
40995583|NCT01574612|DRUG|acyclovir/hydrocortisone cream|cream applied topically to lesion five times daily for five days
40995584|NCT05375552|DEVICE|Transcranial direct current stimulation|Participants will experience two repeated 20 minute sessions of tDCS (1.2 mA), with a 10-minute break.
41468938|NCT04126343|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding"
41468939|NCT00531362|DRUG|Plain aspirin|Plain aspirin 75 mg or 150 mg
41468940|NCT06074263|DRUG|Dexamethasone 8mg|Dexamethasone 8mg will be taken orally just prior to surgery.
41468941|NCT06074263|OTHER|Placebo|Placebo capsule which looks identical to dexamethasone capsule
41468942|NCT04382430|PROCEDURE|Ultrasound guided venous access|Each physician/ provider will perform 2 assisted ultrasound (US) guided venous access and pocket creation for cardiac device implant and 10 solo ultrasound guided cardiac device implant.
40791064|NCT05123989|BEHAVIORAL|Constant move goals|Static move goal delivered by the Welltory mobile app
40791065|NCT05175274|DRUG|Colchicine|Colchicine 0.5mg/tablet
40995585|NCT02881645|BEHAVIORAL|Best practices|Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
40995586|NCT01734564|BIOLOGICAL|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
40791066|NCT05175274|DRUG|Placebo|matching placebo
40791067|NCT02558062|OTHER|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
40791068|NCT02589197|DEVICE|Group 1 (Medial-Pivot)|EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
40995587|NCT01734564|RADIATION|Hiltonol, dendritic cells and radiation|Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
40995588|NCT04538144|OTHER|Simulated heat wave|Individuals will be exposed to thermoneutral climate conditions and two simulated heat wave conditions.
41148756|NCT02652455|DRUG|CD137|All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
41148757|NCT02652455|DRUG|Cyclophosphamide|All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
41148758|NCT02652455|DRUG|Fludarabine|All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
41148759|NCT02652455|BIOLOGICAL|TIL Infusion|After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
41148760|NCT02652455|DRUG|Interleukin-2|After TIL infusion, in-patient high dose IL-2 treatment.
40995589|NCT04173117|DIETARY_SUPPLEMENT|Low energy meal replacement plan (12 weeks)|Low energy meal replacement plan (12 weeks)
40995590|NCT01802658|DRUG|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
40995591|NCT01802658|DRUG|NA Cl|NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
40995592|NCT05838131|DRUG|Experimental: CAR-T cells Infusion|"Biological:~chimeric antigen receptor T cells"
40995593|NCT01420289|DEVICE|High pressure intermittent pneumatic compression (HPIPC)|Apply therapy for 45 minutes twice daily
40995594|NCT01420289|BEHAVIORAL|Excercise|Treadmill walking 45 minutes once daily
40995595|NCT02295995|BEHAVIORAL|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
40995596|NCT05773547|DEVICE|MSOT measurements|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
40995597|NCT04792632|DEVICE|Veye Lung nodules|Veye Lung Nodules
40995598|NCT00506155|DRUG|Avastin|10 mg/kg by vein over 90 minutes
40995599|NCT00506155|DRUG|Cisplatin|70 mg/m\^2 by vein over 4 hours
40995600|NCT00506155|DRUG|Doxorubicin|30 mg/m\^2 by vein over 15 minutes
40995601|NCT00506155|DRUG|Methotrexate|30 mg/m\^2 by vein over 30 minutes
40995602|NCT00506155|DRUG|Vinblastine Sulfate|3 mg/m\^2 by vein over 30 minutes
41148761|NCT02240836|OTHER|Intervention. Exercise|Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
41310007|NCT02489565|OTHER|Telemedicine|Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
41310008|NCT03458832|DIAGNOSTIC_TEST|FSHD-specific functional rating scale|The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.
40791069|NCT02589197|DEVICE|Group 2 (Posterior-Stabilized)|Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
40791070|NCT06122103|DEVICE|Clareon Monofocal|Clareon Monofocal Intraocular Lens (toric and non-toric)
40791071|NCT06122103|DEVICE|Light-Adjustable Lens|Light-Adjustable Lens (Intraocular Lens)
40791072|NCT04624308|DRUG|Toripalimab|Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.
40995603|NCT05812014|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
40995604|NCT05812014|DRUG|0.9% sodium chloride solution|One dose was administered by intramuscular injection, 1.0ml/dose
40995605|NCT03483675|BIOLOGICAL|Immunosuppressive Therapy|Discontinued IST
40995606|NCT03483675|BIOLOGICAL|Immunosuppressive Therapy|Continued IST
40995607|NCT03483675|OTHER|Survey Administration|Ancillary studies
41148762|NCT04818918|DEVICE|Absolute coronary flow measurement|Absolute coronary flow will be measured.
41148763|NCT04818918|DEVICE|Microvascular resistance measurement|Microvascular resistance will be measured.
41148764|NCT04818918|OTHER|Cardiac MRI|Cardiac MRI will be performed to evaluate myocardial viability.
41148765|NCT00538629|OTHER|no intervention|no intervention
41148766|NCT00538629|OTHER|no intervention|no intervention
41148767|NCT00104364|DRUG|MK0731|
40995608|NCT03999892|BEHAVIORAL|ACHIEVE|The investigators will test two modules of the adapted video-assisted curriculum format of 45 to 60-minute multipurpose classes, which will include a segment on group weight management (\~20-30 minutes) and group exercise (\~20-30 minutes). Within each module, the group weight management topic varies by week, and within each week the content of the three weight management groups builds gradually and is purposely repeated. Within each module, the group exercise classes will focus on mild to moderate intensity aerobic exercise using an exercise video. In this pilot study, a trained study interventionist will deliver the ACHIEVE-D curriculum.
40791073|NCT04176393|DRUG|ivosidenib|subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
40791074|NCT05858177|DRUG|Temozolomide capsule|Temozolomide was given orally per day for 5 days, every 28 days until disease progression or intolerable toxicities.
40791075|NCT02264743|DRUG|Femoston Conti|Ultra-low-dose oral E2/D \[Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg\] oral Femoston Conti 0.5mg Estradiol\&Dydrogesterone vs Oestradiol\&Norethisterone acetate
40791076|NCT02264743|DRUG|EVOREL® CONTI|Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
40791077|NCT01021176|OTHER|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
40791078|NCT01021176|DRUG|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
40791079|NCT05624983|DIAGNOSTIC_TEST|acoustic otoemisions|TOAE and DPOAE
40791080|NCT05624983|DIAGNOSTIC_TEST|Otoscopy|presence of earwax checked by video otoscop
40995609|NCT03642717|DRUG|JARDIANCE DUO®|empagliflozin and metformin
40995610|NCT00841529|DEVICE|Medtronic LAA Occlusion Device|Placement of the occlusion band on the LAA
40995611|NCT04146064|OTHER|Breathprint analysis and patient-reported outcomes|"Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints."
40995612|NCT00046332|DRUG|GW810781|
40995613|NCT05543512|DEVICE|Algorithm to diagnose food allergens|An algorithm to diagnose food allergens that will drive diet intervention assignment for those in the active arm. Subjects randomized to this group will receive a diet assignment based on results of the algorithm.
40995614|NCT05543512|OTHER|Sham diet|Sham diet developed via selecting a random number of foods from a random list of the potential eliminated foods.
41468943|NCT04382430|PROCEDURE|Conventional technique|Physician will perform 5 cardiac device implant using conventional technique of venous access and pocket creation
40791081|NCT05624983|DIAGNOSTIC_TEST|Audiometry|Hearing Threshold will be measured with the AD528 interacoustics
40791082|NCT05624983|DIAGNOSTIC_TEST|Tympanometry|Tympanic mobility will be measyred with the Titan interacoustics
40791083|NCT00020150|DRUG|O6-benzylguanine|
40791084|NCT00020150|DRUG|temozolomide|
40995615|NCT02071524|DRUG|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
40995616|NCT02071524|DRUG|Cristalloid administration|Only Ringer Lactate administration
40995617|NCT05836207|BEHAVIORAL|Abstinence-focused Contingency Management (CM) - stand alone|Outpatient abstinence-focused contingency management (CM) as stand-alone treatment (12 weeks). Monetary incentives (vouchers) are provided for cannabis abstinence, based on twice-weekly rapid test urinalysis and an escalating reward scheme with bonuses. Urine samples are collected at the treatment centre during 15-minute sessions by a trained CM-practitioner. For each cannabis-negative urine, patients receive a monetary voucher starting at €5 and escalating to max. €35 after eight consecutive weeks of cannabis abstinence, with an additional €10 bonus after two consecutive cannabis-negative urines. The voucher-value is reset to €5 after a cannabis-positive urine test. Total earnings can be max. €675 for 12 weeks of consecutive cannabis abstinence (average: €8 p/day). Youths sign an agreement stating that vouchers must be spent on recovery-oriented goals.
40995618|NCT05836207|BEHAVIORAL|Standard Outpatient Cognitive Behavioural Therapy (CBT)|"CBT is the usual care first line treatment for CUD in youth, in the Netherlands. CBT for CUD is focused on learning cognitive, emotional, motivational and behavioral skills to reduce or cease cannabis use, and generally consists of 12 once-weekly 60-minute sessions and 'homework' exercise assignments, provided by a psychologist.~Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist. CBT-youths receive the same cannabis urine-testing procedures as CM-youths, but test results will not be disclosed to treatment staff or patient, and no rewards will be given for cannabis abstinence."
40791085|NCT04797377|BIOLOGICAL|Autologous ovarian PRP injection|The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
40791086|NCT01969539|DRUG|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
40791087|NCT01969539|DRUG|Combivent Respimat via ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
40995619|NCT05644704|OTHER|Lower extremity and core muscle training|Lower extremity training: single leg balance training Core muscle training: pelvic control training
40791088|NCT03842267|DRUG|Gemigliptin 50mg|"* The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day"
40791089|NCT03842267|DRUG|Gemigliptin Placebo|"* The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* - The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day"
40791090|NCT01459094|DRUG|A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
40791091|NCT01459094|DRUG|B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)|Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
40791092|NCT00395109|DEVICE|PET/CT|All study participates will be scanned with PET/CT scan before surgery.
40995620|NCT05098145|BIOLOGICAL|FCR001|Enriched hematopoietic stem cell infusion
40995621|NCT01673035|BEHAVIORAL|CBT, exposure and response prevention|This intervention entails different exercises aimed exposure to health anxiety stimuli.
40995622|NCT01673035|BEHAVIORAL|BSM, stress management and applied relaxation|BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
40995623|NCT01126996|PROCEDURE|Venepuncture|"1. Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.~2. A booster dose of a MenC conjugate vaccine (optional)."
40995624|NCT04420156|OTHER|No intervention administered.|Eye exams are standard of care and would be performed regardless of participation in this study.
40995625|NCT02402985|OTHER|High animal protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
40995626|NCT02402985|OTHER|High plant protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
40995627|NCT04976842|DEVICE|OFA|Anesthesiology technique based on Mulier protocol. Before induction, loading dose of dexmedetomidine 0,25mcg/kg (max 20mcg). Induction with dexmedetomidine 0,1mcg/kg, lidocaine 1mg/kg, ketamine 0,1mg/kg plus propofol 2mg/kg plus rocuronium1mg/kg IBW (if required). Maintenance with dexmedetomidine 0,1mcg/kg/h, lidocaine 1mg/kg/h, ketamine 0,1mg/kg/h and propofol infusion adjusted according to bispectral index indication ( BIS maintained 40-60). 15 minutes prior to end of surgery, the dose of drugs is reduced to dexmedetomidine 0,05mcg/kg/h, lidocaine 0,5mg/kg/h, ketamine 0,05mg/kg/h.
41468944|NCT02377180|PROCEDURE|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
40791093|NCT02938247|DIETARY_SUPPLEMENT|High caloric, high protein ONS|
40791094|NCT02110485|OTHER|Patient Activation Tool|An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
41148768|NCT05470465|DRUG|Placebo and Oxycodone|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
40995628|NCT04976842|DRUG|OBA|Total intravenous anesthesia with propofol for maintenance of anesthesia. Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).
40791095|NCT02314676|BIOLOGICAL|PEG-somatropin|
40791096|NCT05822037|BIOLOGICAL|CT0594CP|Cell injection
40791097|NCT05040646|OTHER|Delphi exercise|"During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W\&W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item.~After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached."
40791098|NCT01158443|BEHAVIORAL|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
40995629|NCT02164227|OTHER|Respiratory pattern|
40995630|NCT05517499|DRUG|Dexamethasone|Randomized clinical trial
40995631|NCT00001731|DRUG|Cyclosporin A|
40995632|NCT03251573|OTHER|cognitive impairment|one are of patients were exposed to cognitive impairment
41310009|NCT03458832|DEVICE|Electrical Impedance Myography|EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
41468945|NCT02377180|PROCEDURE|Suprascapular nerve block|"Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.~Evaluates the diagnostic validity of suprascapular nerve block for muscle pain."
41468946|NCT02377180|PROCEDURE|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
40791099|NCT01158443|BEHAVIORAL|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
40791100|NCT03056833|DRUG|ribociclib|Ribociclib (LEE-011) will be given on days 1-4, 8-11, and 15-18 of a 28 day cycle at 200, 400, or 600mg/day during the dose escalation phase. During the maintenance phase, ribociclib (LEE-011) will be given at 600mg/day, 3 weeks on, 1 week off until progression.
40791101|NCT03056833|DRUG|Paclitaxel|During the escalation phase Paclitaxel will be given on days 1, 8, and 15 of a 28 day cycle.
40791102|NCT03056833|DRUG|Carboplatin|During the escalation phase Carboplatin will be given on days 1, 8, and 15 of a 28 day cycle.
40791103|NCT02791347|OTHER|Nutrition Intervention|
40791104|NCT00003846|BIOLOGICAL|filgrastim|
40791105|NCT00003846|DRUG|carboplatin|
40791106|NCT00003846|DRUG|cyclophosphamide|
40791107|NCT00003846|DRUG|thiotepa|
40791108|NCT00003846|DRUG|vincristine sulfate|
40791109|NCT00003846|PROCEDURE|bone marrow ablation with stem cell support|
40791110|NCT00003846|PROCEDURE|peripheral blood stem cell transplantation|
40791111|NCT00003846|RADIATION|radiation therapy|
40791112|NCT05173844|OTHER|SleepFix mobile application|Digital behavioural therapy (dBTi) mobile application SleepFix® is specifically designed to treat insomnia and has been shown to be engaging and clinically efficacious.
40995633|NCT04193475|OTHER|Analysis|No intervention planned. Novel analysis of echocardiographic data.
40995634|NCT01441674|BEHAVIORAL|Animal Assisted Therapy|There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
40995635|NCT00211458|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
40995636|NCT00176553|DRUG|Dextromethorphan|Patients will receive an inert carrier with or without dextromethorphan. The study drug will be administered at 1.5 mg/kg/dose on a BID schedule. The first dose to be given prior to each scheduled intravenous and/or intrathecal administration of methotrexate and continued for a total of seven days.
41148769|NCT05470465|DRUG|Paroxetine and Oxycodone|Participants will receive 40 mg paroxetine (2 x 20 mg tablets) on days 1-6 and 60 mg paroxetine (3 x 20 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
41148770|NCT05470465|DRUG|Escitalopram and Oxycodone|Participants will receive 20 mg escitalopram (2 x 10 mg tablets) on days 1-6 and 30 mg escitalopram (3 x 10 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
40995637|NCT03899948|BEHAVIORAL|Teacher Anxiety Program for Elementary Students|TAPES consists of three core components: 1) training in evidenced-based anxiety reduction strategies that teachers will implement to identify and assist specific anxious students and classroom-wide strategies helpful to all students, 2) evidenced-based material for teachers to review with parents regarding how to reduce student anxiety at home, thus improving school-home communication and shared goals and 3) training in how to conduct 5 brief (30 minute) teacher-parent-student meetings to teach and practice the TAPES anxiety-reduction strategies.
40995638|NCT03899948|BEHAVIORAL|Teacher Anxiety Training|The TAT is a 3-hour professional development training for teachers. Training focuses on recognizing the signs and symptoms related to child anxiety and utilizing classroom-wide strategies to help reduce anxiety in the classroom.
40791113|NCT06193564|OTHER|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) A constant current of 2 mA was applied to the experimental group for 20 minutes.
40791114|NCT06193564|OTHER|Cervical Stabilization Exercises|"Before initiating the stabilization exercises, individuals included in the study were instructed on correct postural alignment. Cervical chin tuck movement was taught during the exercise along with postural alignment and craniocervical flexion movement was requested. After teaching craniocervical flexion exercises in all positions (supine, lying on the side, prone, crawling, sitting, and standing), participants were instructed to perform the movement slowly.~The purpose of this phase was to establish the relationship between vision and motor learning using the Pressure Biofeedback Stabilizer device. The device was positioned on the neck area and inflated to 20 mmHg. The pressure level gradually increased in 2-mmHg increments from 20 to 30 mmHg. For each pressure value (22, 24, 26, 28, 30 mmHg), participants were asked to maintain craniocervical flexion for 10 seconds, and this exercise was repeated ten times."
40791115|NCT06193564|OTHER|Sham-Transcranial Direct Current Stimulation (tDCS)|tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) (Figure 2). As shown in the figure, a constant current of 2 mA was applied to the experimental group for 20 minutes. For the sham group, electrodes were placed in the same areas and a current of 0 mA was applied.
40995639|NCT01515683|BEHAVIORAL|Only support from an anaesthetic nurse on the surgery ward|Additional staff are only present if required by law.
40995640|NCT01515683|BEHAVIORAL|Support: a theatre nurse + an anaesthetic nurse|Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized
40995641|NCT01515683|BEHAVIORAL|Support: a nurse from the ward + an anaesthetic nurse|A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.
40995642|NCT01515683|BEHAVIORAL|Optional relative supports|Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
40995643|NCT01276093|PROCEDURE|PVI ablation|Pulmonary Vein Ablation using RF.
40995644|NCT01276093|DRUG|Amiodarone|Amiodarone tablets
40995645|NCT03030690|OTHER|Glass Carbomer Cement|Restoration of proximal lesions in primary molars using glass carbomer cement
40995646|NCT03030690|OTHER|Composite Resin|Restoration of proximal lesions in primary molars using composite resin.
40995647|NCT03030690|OTHER|Resin Modified Glass Ionomer Cement|Restoration of proximal lesions in primary molars using resin modified glass ionomer cement
40995648|NCT04728269|OTHER|Lactibiane Topic AD|Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area
41468947|NCT03290313|DRUG|shu gan yi yang capsule|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
40995649|NCT04728269|OTHER|Placebo|Application of placebo twice a day (morning and evening) on the symmetrical lesional area
40995650|NCT04988217|DRUG|Interferon-Alpha2B|Nebulized interferon alpha 2B
40995651|NCT04988217|DRUG|Placebo|Nebulized placebo
40995652|NCT03427359|DRUG|cisplatin, capecitabine|Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
40995653|NCT04381845|DIAGNOSTIC_TEST|COVID19 immunization testing|serological COVID19 test with confirmation at J15 during hospitalization
41310010|NCT04755465|DEVICE|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) is based on the principle of creating a contraction by stimulating the nerve fibers innervating the related muscle in the healthy muscle and the muscle fibers in the denervated muscle with electrical current. The electric currents used in stimulation of muscles and nerves perform this function by changing the electrical potential of cell membranes.~It is contraindicated in pregnancy, presence of pacemaker, severe heart disease, epilepsy, fracture, dementia and impaired consciousness. We prevent contraindicated situations by excluding volunteer participants with these characteristics."
41148771|NCT04407442|DRUG|Azacitidine|Given IV
41148772|NCT04407442|BIOLOGICAL|Daratumumab|Given SC
40995654|NCT00951028|BEHAVIORAL|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
40995655|NCT00951028|BEHAVIORAL|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
40995656|NCT00951028|BEHAVIORAL|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
40995657|NCT01747083|DRUG|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))|
40995658|NCT06007599|PROCEDURE|Skin closure using skin adhesive|Wound closure using subcuticular running 3-0 monocryl sutures with skin adhesive
40995659|NCT06007599|PROCEDURE|Skin closure without skin adhesive|Wound closure using subcuticular running 3-0 monocryl sutures without skin adhesive
40995660|NCT02234375|DRUG|Gadolinium|agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
40995661|NCT03045965|PROCEDURE|Salpingectomy|The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
40995662|NCT01478126|DRUG|N(2)-L-Alanine L-Glutamine dipeptide|Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
40995663|NCT01478126|DRUG|Placebo|Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.
41468948|NCT03290313|DRUG|shu gan yi yang capsule simulation agent|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
41468949|NCT03290313|OTHER|Supportive psychotherapy|Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
41468950|NCT02107079|DRUG|Melatonin|swallowing 1 piece, collecting saliva afterwards
41468951|NCT02104869|BIOLOGICAL|Trivalent influenza vaccine (inactivated and fragmented).|
40995664|NCT05473312|BEHAVIORAL|Community Sensitization|One event will be developed and delivered for households in each cluster area. Approach and content will be informed by the formative research and CAC input (may include drama and nutrition fairs).
40995665|NCT05473312|BEHAVIORAL|28-day PD/Hearth Sessions|Mothers will come together in a home-like setting to rehabilitate their malnourished child (8 dyads/Hearth), learn and practice new feeding and childcare behaviours (during Covid-19: 4 dyads/Hearth). Curriculum and activities will be informed by CAC, CORE Guide and formative research. Two female facilitators will demonstrate, encourage, convey key messages and guide practices.
40995666|NCT05473312|BEHAVIORAL|Supplemental Print Information|The content will be informed by the formative research and CAC, will reinforce Hearth messages, and be adapted for each gender group. Material will be locally produced, engaging, user friendly, and target an illiterate audience (i.e. culturally relevant images with minimal text).
40995667|NCT01609920|DRUG|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
40995668|NCT05086796|BEHAVIORAL|Substance Use Treatment and Recovery Team (START)|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare.~The components of the START intervention are as follows:~1. Triage~2. Engage, Assess, and Plan~3. Treat~4. Communicate and Coordinate~5. Follow up~6. Monitor"
40995669|NCT01407913|PROCEDURE|caudal epidural steroid injection|injecting steroids in the epidural space via caudal route
40995670|NCT04836299|DRUG|Ivermectin|Participants will be randomly assigned to receive a single 600 µg / kg dose of ivermectin or placebo.
40995671|NCT04836299|DRUG|Placebo|Participants will be randomly assigned to receive a single of placebo.
41468952|NCT05811221|DRUG|Esketamine of single injection|Single group: give esketamine 0.75 mg/kg at the time of induction
41468953|NCT05811221|DRUG|Esketamine of Intermittent injection|Intermittent group: give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
41148773|NCT04407442|DRUG|Dexamethasone|Given IV or PO
41148774|NCT00327314|PROCEDURE|Transplantation|
41148775|NCT00327314|PROCEDURE|Hematopoietic cell transplantation|
41148776|NCT05236868|DRUG|Seltorexant|Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
41148777|NCT00507702|PROCEDURE|phlebotomy|Standard of care
41148778|NCT06209411|BEHAVIORAL|Home Based Testing|Community Health Workers (CHWs) will offer at home OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
41148779|NCT06209411|BEHAVIORAL|Clinic Based Screening|Community Health Workers (CHWs) will offer referral to clinic based OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
41148780|NCT05976828|DRUG|IBRX-042|"* Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose"
41148781|NCT03364556|OTHER|No intervention|
41148782|NCT03249961|DEVICE|Sham TDCS|Placebo stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
41148783|NCT03249961|DEVICE|Anodal TDCS|Excitatory stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
40791116|NCT06205446|BEHAVIORAL|Healthy subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
40791117|NCT06205446|BEHAVIORAL|Laryngopharyngeal reflux disease subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
40995672|NCT04233970|BEHAVIORAL|web-based intervention programme|"The intervention will be designed as an individualized, dialogue-based system that will provide PwMS coordinated, individually tailored information based on the software platform broca®. The intervention programme will consist of three sections:~1. EBPI/decision aid (five modules plus decision aid in case of an acute relapse) provided by the broca® programme. The key element of the EBPI/decision aid is the information on glucocorticosteroids for the treatment of acute relapses.~2. A webinar led via WebEx by a trained MS nurse with questioning/chat session (approx. 60-75min).~3. A supervised chat room provided via the DMSG (https://www.dmsg.de/ms-connect). In addition, email reminders will be used to enhance involvement of participants."
40995673|NCT04233970|BEHAVIORAL|web-based information material offered via the same platform (broca®) in addition to usual care|Participants in the control group will have access to web-based information material offered via the same platform (broca®) in addition to usual care. The control group intervention will be based on material of the German Multiple Sclerosis Society (DMSG) on relapse management. The programme will accompany the participants over a period of 4 weeks and a reminder system with neutral e-mail reminders will be used to promote the use of the programme.
40995674|NCT02051036|PROCEDURE|Moxibustion|"In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session."
40995675|NCT02308462|BEHAVIORAL|CHIMPS intervention|"CHIMPs intervention (Family-Intervention composed of 8 Topic-related sessions over a period of 6 month, based on the evaluated manual: a preliminary talk with the family, two sessions with the parents, one session with each child, three sessions with the family).~The sessions are semi-structured and cover the topics illness and coping, education, family relationships and trusting attachement figures, social network and support of the Family. A detailed description of the procedure is found in the Manual (Wiegand-Grefe, Halverscheid \& Plass, 2011)."
40995676|NCT03407742|BEHAVIORAL|CAPAS Youth|9-week parenting intervention
41468954|NCT00351286|DRUG|L-citrulline tablets, 1000 mg|
41468955|NCT00351286|DRUG|Placebo tablets matching L-citrulline tablets|
40995677|NCT02245542|DRUG|ALNA®OCAS®|
40995678|NCT05305872|DRUG|Gandouling|The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
40995679|NCT00022321|DRUG|gemtuzumab ozogamicin|
40995680|NCT02953379|DRUG|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
40995681|NCT02953379|DRUG|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
40995682|NCT05346263|DEVICE|Intermittent Abdominal Pressure Ventilation|Patients of experimental group will use IAPV in daytime ventilation. Intermittent abdominal pressure ventilation (IAPV) is a portable ventilator with an internal battery and PneumoBelt corset as an interface.
40995683|NCT05346263|DEVICE|Usual ventilation|NIV
41310011|NCT04755465|OTHER|Structured Exercise|Warm-up exercise, main training program and cool down exercise. Main training consists of resistance exercises to be applied with resistance bands of different resistance or with the patient's own body weight. Our prescribed training protocol includes 4-6 different exercises for each limb (bench press with resistance band, upper extremity proprioceptive neuromuscular facilitation exercises, biceps/triceps curl, leg press, knee extension, 4-way hip motion, mini squat). Intensity, sets, and number of repetitions will be adapted to a target score between 12 and 14 using the Borg scale. It will be applied as low intensity, long-term passive stretching exercises to the pectoral, hamstring, and gastrosoleus muscle groups. Patients will perform 1 set of 10 repetitions of each resistance exercise determined by their level of fatigue. Resistance will be increased every three visits. If the patient complains of excessive fatigue, the resistance will be reduced to the previous level.
41310012|NCT04873284|DRUG|fosaprepitant|"Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.~Fosaprepitant: 4 mg/kg IV"
41310013|NCT04873284|DRUG|aprepitant|"Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with aprepitant, dexamethasone dose was halved.~Oral aprepitant: D1：Powder for suspension 3.0 mg/kg (up to 125 mg),D2，D3：Powder for suspension 2.0 mg/kg (up to 80 mg)."
41468956|NCT00351286|DRUG|Background simvastatin at a stable dose of 40 mg qHS|
41468957|NCT00513617|DRUG|Arginine|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
41468958|NCT00513617|DRUG|Placebo|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
40791118|NCT06205446|BEHAVIORAL|Dyspepsia subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
40791119|NCT06205446|BEHAVIORAL|Irritable bowel disorder : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
40791120|NCT02264613|DRUG|ALRN-6924|ALRN-6924 will be administered as an IV infusion
40791121|NCT04967872|OTHER|Implementing risk management and control plan for the elderly during perioperative period|Visualization technology is used for preoperative evaluation, anesthesia management, bedside real-time monitoring and intervention, etc., to achieve accurate perioperative management of elderly patients and whole-process whole-person management
40791122|NCT05282875|DRUG|management of immunosuppressive therapy|"3 groups :~* Discontinuation of immunosuppressive agents~* Reduction of immunosuppressive agents~* Maintenance of immunosuppressive agents"
40791123|NCT05060692|DIAGNOSTIC_TEST|Bloot testing|NFL measruments in serum
40791124|NCT05249205|BEHAVIORAL|REHIT1|This intervention involves a single REHIT exercise session per week. REHIT involves 10 minutes of unloaded cycling on a stationary bike interspersed with two 20-second 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
40791125|NCT05249205|BEHAVIORAL|REHIT2|This intervention is the same as that for the REHIT1 intervention, but with 2 sessions per week instead of 1.
40791126|NCT00376636|DRUG|SPP635 (drug)|
40791127|NCT05402007|OTHER|Pulmonary rehabilitation exercises at the Rehabilitation Center|Face-to-face intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will prescribe pulmonary rehabilitation exercises that will be performed at the pulmonary rehabilitation center.
40791128|NCT05402007|OTHER|Home Intervention|Home Intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will provide a portfolio of self-explanatory exercises, and guide participants on safety precautions.
40791129|NCT00178971|DRUG|adjunctive treatment with buspirone|buspirone 15-30 mg qd
40995684|NCT02598180|DEVICE|VergenixTM Flowable Gel|The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
40995685|NCT01112527|DRUG|PF-00299804|Taken orally once a day
40995686|NCT06308068|DRUG|Diacerein 50 mg Capsule|Diacerein 50 mg Capsule
40791130|NCT00178971|DRUG|placebo|placebo
40791131|NCT02631291|BEHAVIORAL|Behavioral self-monitoring|Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
40791132|NCT02631291|BEHAVIORAL|Behavioral self-monitoring + Motivational interviewing|Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
40791133|NCT05124353|DRUG|Cerebrolysin|Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
40995687|NCT01059370|PROCEDURE|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
40995688|NCT05159895|DRUG|[14C]-DZD9008|Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration
40995689|NCT05280704|PROCEDURE|Volar digital block with lidocaine|Volar digital block with lidocaine
40995690|NCT05280704|PROCEDURE|Volar digital block with saline|Volar digital block with saline
40995691|NCT05280704|PROCEDURE|Dorsal digital block with lidocaine|Dorsal digital block with lidocaine
40791134|NCT02669589|DRUG|Heparin|
40791135|NCT02669589|DRUG|Citrate|
40791136|NCT02135627|DRUG|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.|
40791137|NCT02135627|OTHER|Current standard therapy|
40791138|NCT04280016|BEHAVIORAL|Exercise|Participants will participate in an exercise session with non-weight-bearing exercise that the participant is able to perform with off-loading (e.g. total contact cast) intact. They will also be instructed in a home exercise program so that exercise can be performed three days per week with no more than two days between sessions. These participants will also receive standard wound care with off-loading.
40995692|NCT05280704|PROCEDURE|Dorsal digital block with saline|Dorsal digital block with saline
40791139|NCT06176846|BEHAVIORAL|Immersive Virtual Reality Exergaming Program|"Oculus Quest 3 glasses will be used as hardware for the IVR exergame program, and Boxing, HIIT, Combat, Sculpt and Dance, among the Fit-XR games that offer virtual reality experience for fitness, will be selected according to the physical fitness level of the subjects and personalized multicomponent ( balance, strength, agility, endurance) IVR exergame program will be created. The exercise program is limited to 25-30 minutes a day and will be applied 2 days a week for 8 weeks in the clinic under the supervision of a physiotherapist. The exergaming program will be progressed according to the difficulty level, duration and technical characteristics of the games."
40791140|NCT06176846|BEHAVIORAL|Home-Based Exercise Program|In the home-based exercise program, a personalized multicomponent (balance, strength, agility, endurance) exercise program will be applied according to the physical fitness level of the subjects. The exercises will progress by increasing the difficulty level and number of repetitions of the exercises. An e-brochure will be given to the subjects for the exercises, the exercises will be shown to the subjects on the 1st day, and exercise control will be carried out in the 1st week and the 4th week.
40791141|NCT00976157|PROCEDURE|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
40791142|NCT01979718|DEVICE|Mirrored Virtual reality|Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
40791143|NCT04365686|DRUG|Ketofol as induction agent|Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
40791144|NCT04365686|DRUG|Propofol as induction agent|Patients who received propofol (2mg/kg) only at the induction of general anesthesia.
40791145|NCT00153413|BEHAVIORAL|Cookin' Up Health|A brief nutrition intervention designed to improve dietary habits
40791146|NCT02492243|DEVICE|PCI|
40791147|NCT02492243|DEVICE|ILR implantation|
40791148|NCT04144114|DIETARY_SUPPLEMENT|ProHydrolase®|Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
40791149|NCT04144114|DIETARY_SUPPLEMENT|Whey protein|Subjects received 25g of whey protein powder mixed to together in a drink
40791150|NCT04144114|DIETARY_SUPPLEMENT|Placebo|Placebo
40995693|NCT02340299|DEVICE|nHFOV|Extubation to ventilator-derived nHFOV using binasal prongs
40995694|NCT02340299|DEVICE|nCPAP|Extubation to ventilator-derived nCPAP using binasal prongs
40995695|NCT01289847|BIOLOGICAL|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
40995696|NCT04059146|OTHER|Pain Education and Exercise|Participants will be randomly assigned to a pain education group, following biopsychosocial model, or standard of care education, following biomedical model. The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain. Participants will be given weekly online exercises to promote engagement with the material, give individual feedback to participants, and assess understanding. In person sessions with the physical therapist will reinforce self-learning and application to a home exercise program.
41148784|NCT03249961|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.
41310014|NCT04873284|DRUG|Granisetron plus dexamethasone|Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
41310015|NCT02969447|DRUG|Administration of 10 units of intra venous oxytocin after fetal expulsion|
41310016|NCT02856269|DIETARY_SUPPLEMENT|Zinc gluconate|Participants will take a daily dose of zinc gluconate.
40791151|NCT01168843|OTHER|computerized analysis of sonographic images|Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
40791152|NCT03794440|DRUG|Sintilimab|200mg IV d1， Q3W
40791153|NCT03794440|DRUG|IBI305|15mg/kg IV d1， Q3W
40791154|NCT03794440|DRUG|Sorafenib|400mg PO BID
40791155|NCT01603173|DRUG|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
40791156|NCT01603173|DRUG|Quetiapine Fumarate|25 mg tablet once a day
40791157|NCT05412043|BEHAVIORAL|Dance therapy|The dance group will attend choreo-based dance therapy which includes both cognitive training to remember the choreo's and motor training to execute them (with and without music). Each session will consist of a ten-minute warm up, dance training and a ten-minute cool down. The participants will be taught three choreographies, which will increase in difficulty level. 1) floor work on a slow rhythm with focus on proprioception, abdominal muscle strength, coordination and working memory. 2) slow paced with a group part and a canon part with focus on working memory, static and dynamic balance and strength. Furthermore, it will require dynamic balance, walking and cognition. 3) higher rhythm and will be danced with a cane which will require more speed, coordination and dual tasking.
40791158|NCT05412043|OTHER|Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability|The study consists of 2 test sessions, separated by 5-7 days of interval. The sessions 1 and 2 will be composed of cognitive test battery, questionnaires to be filled, information about the use of actigraph, clinical outcomes and interlimb coordination tests
40791159|NCT01198574|DIETARY_SUPPLEMENT|Iron group|Ferrous fumarate, 60 mg, weekly dose
40791160|NCT01198574|DIETARY_SUPPLEMENT|Vitamin A group|Retinol, weekly dose, 15,000 IU
40791161|NCT01198574|DIETARY_SUPPLEMENT|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
40791162|NCT01198574|DIETARY_SUPPLEMENT|Placebo group|folic acid only as placebo group
40791163|NCT02596139|OTHER|No Interventions|
40791164|NCT04660175|OTHER|non-resistance therapy|The non-resistance technique, created in Jaseng Hospital, is a combination of ischemic compression and mobilization It is a treatment that improves the limited range of motion of the cervical spine and relieves pain by applying ischemic pressure to the induration of the neck and at the same time firmly supporting the patient's head to give passive joint movements and completely relax.
40791165|NCT04660175|OTHER|acupuncture|According to the judgment of the oriental medicine doctor, select acupuncture point and tender spots such as BL10, TE14, GB20, GV16, etc. to a depth of 10 mm 6 -Self needle in 12 blood spots.
40791166|NCT04660175|OTHER|chuna|Chuna treatment is administered once a day during the hospitalization period. Chuna is Korean manual therapy using methods such as joint mobilization, joint distraction, fascia relaxation and manipulation.
40791167|NCT04660175|OTHER|pharmacoacupuncture|This is an oriental medical practice in which a certain amount of a drug extracted from a specific herbal medicine is injected with an injector to treat the patient's constitution, disease state, etc., and then injected into the treatment acupuncture points and body surface reaction points. Depending on the condition of the inpatient, acupuncture is used in parallel.
40791168|NCT04660175|DRUG|Korean herbal medicine|Formulated with herbal medicinal and pack the extract in a pouch, and have the hospitalized patient take it once in the morning and afternoon for 30 minutes after meals.
40791169|NCT03289533|DRUG|Avelumab (MSB0010718C)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
40791170|NCT03289533|DRUG|Axitinib (AG-013736)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
40791171|NCT02462187|DRUG|NVN1000 8% Gel|once and twice daily
40791172|NCT02462187|DRUG|NVN1000 16%|once daily
40791173|NCT02462187|DRUG|Vehicle|placebo comparator
40791174|NCT02462187|DRUG|NVN1000 24%|once daily
40791175|NCT02678754|OTHER|No intervention required, purely observational|
40791176|NCT02054065|OTHER|CAUTI Decision Support|Decision support used to prevent Catheter Associated Urinary Tract Infections
40791177|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1g phosphorus/d\]
40791178|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[0,5 g calcium\]
40791179|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[1 g calcium\]
40791180|NCT02095392|DIETARY_SUPPLEMENT|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
40791181|NCT01941927|DRUG|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
40791182|NCT01941927|DRUG|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
40791183|NCT02414516|DRUG|OBP-801|OBP-801 will be administered IV
40791184|NCT04532125|BIOLOGICAL|ARGX-117|Subjects treated with ARGX-117
40791185|NCT04532125|OTHER|Placebo|Subjects treated with placebo
40791186|NCT04532125|BIOLOGICAL|ARGX-117 + rHuPH20|Subjects treated with ARGX-117 + rHuPH20
41148785|NCT02781233|OTHER|Progressive resistance training|Progressive resistance training program
40791187|NCT04532125|OTHER|placebo + rHuPH20|Subjects treated with placebo + rHuPH20
40791188|NCT04532125|BIOLOGICAL|ARGX-117 PH20 SC|Subjects treated with ARGX-117 PH20 SC
40791189|NCT04532125|OTHER|Placebo PH20 SC|Subjects treated with placebo PH20 SC
40791190|NCT03723980|DRUG|Propolis|it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.
40791191|NCT03723980|DRUG|Calcium Hydroxide|it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
40791192|NCT04222192|OTHER|Epidural block|Epidural catheter insertions
40791193|NCT00661830|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
40791194|NCT00661830|DRUG|Placebo|Placebo
40791195|NCT00661830|DRUG|Sorafenib|Sorafenib 400 mg bid orally continuously
40791196|NCT05176951|DRUG|Treprostinil Palmitil|Oral inhalation using a capsule-based dry powder inhaler device.
40791197|NCT05176951|DRUG|Placebo|Oral inhalation using a capsule-based dry powder inhaler device.
40791198|NCT05394610|DEVICE|Sana Device|Audio Visual Stimulation patterns intended to produce a therapeutic benefit.
40791199|NCT05394610|DRUG|Sana Device (Control)|A control device that mimics the physcial appearance of the Sana device.
40791200|NCT00006261|BIOLOGICAL|therapeutic allogeneic lymphocytes|Beginning on day 120 after PBSC transplantation, eligible patients receive unmobilized donor lymphocyte infusion (DLI) over 15-30 minutes. Treatment continues monthly for a total of 3 DLIs in the absence of grade III or IV graft versus host disease or marrow aplasia.
40791201|NCT00006261|DRUG|cyclophosphamide|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
41148786|NCT02781233|OTHER|Normal daily activities|Usual daily activities
40995697|NCT04059146|OTHER|Standard Education and Exercise|The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage. The videos, handouts, and exercises will be equivalent to the pain education group in terms of time and learning requirements.
40995698|NCT00102674|DRUG|cangrelor|
40995699|NCT00116441|BIOLOGICAL|Therapeutic Cellular Vaccine, GM-CSF Producing|
40791202|NCT00006261|DRUG|docetaxel|Docetaxel IV over 1 hour. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
40995700|NCT04909775|DRUG|Tislelizumab|200 mg per cycle, IV on day 1 of 3-week
40791203|NCT00006261|DRUG|doxorubicin hydrochloride|Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
41468959|NCT02546024|DRUG|Standard care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
40791204|NCT00006261|DRUG|fludarabine phosphate|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of fludarabine IV over 30 minutes on days -8 to -4.
40791205|NCT00006261|PROCEDURE|peripheral blood stem cell transplantation|Filgrastim (G-CSF) and sargramostim (GM-CSF) mobilized allogeneic peripheral blood stem cells (PBSC) IV on day 0.
40791206|NCT05938348|BEHAVIORAL|angiopuncture|we conducted acupuncture on perforators by using acupuncture needles.
40791207|NCT04403919|DEVICE|Conventional Closure: Knee|Traditional closure will consist of arthrotomy (deep layer) closed with figure of eight number 1 vicryl plus followed by closure of the intermediate layer with 0 Vicryl plus. The intermediate layer will be performed at surgeon's discretion especially in thin patients. Subdermal layer with 2-0 vicryl suture followed by subcuticular 3-0 monofilament suture (monocryl PLUS, Ethicon; Johnson \& Johnson) and Dermabond advanced.
40995701|NCT04909775|DRUG|Cisplatin|70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.
40995702|NCT04909775|DRUG|Gemcitabine|1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
40995703|NCT00000644|DRUG|Clarithromycin|
40995704|NCT05839457|BEHAVIORAL|Empowerment Pilot|The Empowerment Pilot is a school-based program aimed to raise awareness and change attitudes around SRGBV among students and teachers and promote gender equality. This intervention includes training provided by Teacher Mentors to other teachers in school, learning sessions delivered via safe spaces for student learners, and guidance for engaging parent-teacher committees.
40995705|NCT03202264|OTHER|TAPER|"The intervention is medication reduction. This arm is comprised of:~* Medication reconciliation~* Identification of patient priorities for care~* Identification of medications that are potentially appropriate for discontinuation/dose reduction~* Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~* Identification of medications for trial of discontinuation/dose reduction (shared decision making)~* Pause of medication and clinical monitoring"
41310017|NCT01156610|BEHAVIORAL|Tobacco Treatment|"Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol)."
41310018|NCT00074412|DRUG|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
41310019|NCT00074412|DRUG|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
41310020|NCT01336556|PROCEDURE|Oral appliance|Anterior mandibular repositioner: used for two months
41310021|NCT00682916|DIETARY_SUPPLEMENT|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
41310022|NCT00682916|DIETARY_SUPPLEMENT|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
40995706|NCT04602637|OTHER|Training load|Monitoring training load during covid
40995707|NCT02629692|DRUG|Vodobatinib (K0706) capsules|"Part A: Vodobatinib (K0706) capsules in single ascending doses.~Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.~Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily."
41310023|NCT03230474|DRUG|Morphine|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
41310024|NCT03230474|DRUG|Morphine-Naloxone|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\\ kg naloxone in 0.5 ml volume (total volume 2mL).
41310025|NCT01636752|BEHAVIORAL|Deprexis|Online self-help with and without e-mail-support
41310026|NCT02019394|DRUG|Lu AE58054|"Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.~Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10."
41310027|NCT01891760|DEVICE|Dermagraft|Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
41310028|NCT01891760|DEVICE|Profore|Four-layer compression bandaging therapy.
41468960|NCT00857818|DRUG|Aripiprazole|Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
41468961|NCT00857818|DRUG|Oanzapine, risperidone, or quetiapine|Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
41310029|NCT01435239|DEVICE|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
40995708|NCT01248299|DRUG|FU-CDDP|"every 21 days:~* Fluoro-uracil \[800 mg/m2, day 1 to day 5\]~* CisPlatin \[75 mg/m2, day 1 or day 2\]"
41310030|NCT01435239|DEVICE|The cuff inflation by the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
40791208|NCT04403919|DEVICE|Barbed suture closure: Knee|The barbed suture closure will consist of number 2 Stratafix symmetric PDS PLUS for the arthrotomy, intermediate layer will be performed at surgeon's discretion in thin patients, if performed will entail stratafix spiral, subdermal 2-0 stratafix spiral monocryl plus. Followed by subcuticular 3-0 stratafix spiral monocryl plus suture and Dermabond advance.
41148787|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
41148788|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
41148789|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
41468962|NCT04152369|PROCEDURE|Anti-microbial prophylaxis for an endourological procedure or ESWL|anti-microbial prophylaxis according to urine culture results
41468963|NCT04640012|DRUG|DC371739|Participants received one of 6 dose levels of DC371739 administered as single oral doses.
41468964|NCT04640012|DRUG|Placebo|Placebo orally administered
40995709|NCT01248299|DRUG|LV5FU2-CDDP|"every 14 days:~* Elvorin \[200 mg/m2, 2h IV, day 1 and day 2\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, 22h continous infusion, day 1 and day 2\]~* CisPlatin \[50 mg/m2, day 2\]"
40995710|NCT01248299|DRUG|FOLFOX|"every 14 days:~* Oxaliplatin \[85 mg/m2 by 2h infusion, day 1\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, by 22h continous infusion, day 1 and day 2\]~* Elvorin \[500 mg/m2, day 1 and day 2\]"
40995711|NCT01248299|DRUG|TPF|"every 21 days:~* Docetaxel \[30 mg/m2, day 1 and day 8\]~* CisPlatin \[60 mg/m2, day 1\]~* Fluoro-uracil \[200 mg/m2/day by continous infusion\]~Or every 21 days:~* Docetaxel \[50 mg/m2, day 1\]~* CisPlatine \[70 mg/m2, day 1\]~* Fluoro-uracile \[700 mg/m2 /day, day 1 to day 5\]"
41468965|NCT04801719|DEVICE|Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK|Randomised patients in selected arm received endoluminal RFA by 8F catheter (Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK) before stenting procedure. Repeated ablations were processed through stenotic areas of bile ducts (10W, 90-120s, Rita 1500, Angiodynamics Ltd), all drained biliary tracts were used for introducing catheter and performance of ablation. Ablation procedure was followed with uncovered self-expandable metal stent insertion.
41468966|NCT03936933|DRUG|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
41468967|NCT03936933|DRUG|ZOLADEX® 3.6mg Injection|3.6 mg, Subcutaneously at every 28 days
41468968|NCT04139863|DIAGNOSTIC_TEST|aMMP-8 chairside test|No test
41468969|NCT01813435|DRUG|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
41468970|NCT01813435|DRUG|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
41468971|NCT01813435|DRUG|Clopidogrel|"Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy"
40995712|NCT01248299|OTHER|Best Supportive Care|See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
40995713|NCT01571895|DRUG|DF2156A|DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 \[CXCL8; formerly interleukin (IL)-8\] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
41148790|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
41148791|NCT03868202|DRUG|Estradiol Transdermal Product|Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
41148792|NCT04642495|DIAGNOSTIC_TEST|"Visual acuity testing with SW , Landolt-C and Tumbling-E symbols"|Establish prediction intervals for acuity tests
41148793|NCT05736237|GENETIC|Whole exome sequencing|With Next Generation Sequenzing
41148794|NCT01167816|DRUG|Vidaza|Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
41148795|NCT00816816|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly."
41148796|NCT05658445|OTHER|evacuation|after complete evacuation of uterus follow abortion
41148797|NCT02885376|DEVICE|Dentoxol|Mouthrinse
41148798|NCT02885376|DEVICE|Placebo|Mouthrinse
41148799|NCT03292744|DRUG|Alfacalcidol|alfacalcidol 0,5 mcg
41468972|NCT04091802|PROCEDURE|interdental papilla reconstruction with L-PRF|interdental papilla reconstruction with single layer of L-PRF versus multiple layers of L-PRF
41468973|NCT04461340|DRUG|Sirolimus|oral dose of 6 mg on day1 followed by 2 mg daily for 9 days
41468974|NCT01735786|DEVICE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
41468975|NCT05029934|PROCEDURE|use of EndoClot|deployment of EndoClot adhesive spray
40791209|NCT04403919|DEVICE|Conventional Closure: Hip|"1. The capsule will be closed with Vicryl Plus number 1~2. Deep fascia with figure of eight interrupted number 1 braided absorbable suture (Vicryl plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal fat layer simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl plus)~4. Subcuticular 3-0 monofilament suture (monocryl plus , Ethicon; Johnson \& Johnson)~5. followed by the use of skin adhesive (Dermabond Advanced, Ethicon; Johnson \&Johnson)."
40791210|NCT04403919|DEVICE|Barbed suture closure: Hip|"1. The capsule will be closed with stratafix symmetric PDS Plus~2. Deep fascia will be closed with Stratafix Symmetric PDS Plus (Stratafix symmetric PDS plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal layer with running number 2-0 barbed suture (stratafix spiral monocryl plus, Ethicon; Johnson \& Johnson, Somerville, NJ)~4. Subcuticular suture with stratafix spiral monocryl plus, Ethicon~5. followed by the use of skin adhesive (Dermabond advanced, Ethicon; Johnson \&Johnson)."
40791211|NCT02714491|OTHER|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
40791212|NCT02714491|OTHER|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
40791213|NCT02714491|OTHER|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
40791214|NCT02862977|DRUG|ketoprofen and cyclobenzaprine association with caffeine|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
40791215|NCT02862977|DRUG|Cyclobenzaprine with caffeine|The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
40791216|NCT04288856|DRUG|BIIB078|Administered as specified in the treatment arm.
41148800|NCT02522299|DRUG|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
41468976|NCT03662763|DRUG|Extended-release Guanfacine Hydrochloride (SPD503)|dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
41468977|NCT03662763|DRUG|Placebo oral capsule|
41468978|NCT04398979|PROCEDURE|Thoracoscopic Atrial fibrillation Ablation|After blunt dissection of the oblique and transverse sinus, an AtriCure Lumitip Dissector was introduced around the pulmonary veins. Pulmonary vein isolation was achieved with an AtriCure Isolator Synergy ablation clamp around the pulmonary vein antrum at least six times for each side. Ganglionated plexus identification and ablation were performed using an AtriCure Synergy ablation pen. The additional superior and inferior ablation lines connecting the bilateral pulmonary vein isolations were created by applying the AtriCure Synergy ablation pen. Following completion of the ablation on the right side, ablation on the left side was accomplished in a similar manner. The ligament of Marshall was dissected by electrical cautery. Conduction block was confirmed upon completion of the ablation procedure on the left side.
41468979|NCT05987085|OTHER|Diet and exercise|Routine intervention included diet control and exercise
40791217|NCT04504630|DEVICE|High Definition Transcranial Direct Current Stimulation|This wireless device delivers a very low electrical current to focused regions on the scalp in order to modulate underlying brain circuits to promote neuroplasticity. The device will be fitted onto a neoprene EEG cap, with 1 anode electrode placed and surrounded by 4 cathode electrodes in a ring pattern. Electrical stimulation will be applied using a constant voltage cortical stimulator (Model D185, Digitimer Ltd, UK, maximal output 1000 V/1.5 A) with single square-wave 50-μs pulses (0.1 A/μs rise time).
40791218|NCT04504630|DEVICE|Sham HD-tDCS|Sham HD-tDCS
40995714|NCT02732834|BEHAVIORAL|Questionnaire|patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
40995715|NCT02732834|BEHAVIORAL|Patient Interview|Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
40995716|NCT02732834|BEHAVIORAL|Audio recordings of clinical consultations|
40995717|NCT02732834|BEHAVIORAL|Questionnaire|Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
40995718|NCT02732834|BEHAVIORAL|2-hour empathic communication skills training|2-hour empathic communication skills training
40995719|NCT02732834|BEHAVIORAL|Standardized Patient Assessments|pre-training SPA, post-training SPA
41148801|NCT02522299|DRUG|Placebo|Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
41148802|NCT02522299|DEVICE|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
41148803|NCT02522299|DEVICE|ELLIPTA|It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
41148804|NCT02069379|DRUG|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
41310031|NCT04102878|DRUG|Topical Anesthetic|Topical anaesthetic drops (proxymetacaine 0.5% and tetracaine 1%) applied
41310032|NCT04102878|PROCEDURE|Transconjunctival anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transconjunctival route
41310033|NCT04102878|PROCEDURE|Transcutaneous anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transcutaneous route
41148805|NCT02069379|DRUG|Placebo|Placebo capsules prepared identically to Metformin capsules
40791219|NCT01774773|DRUG|Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
40995720|NCT02732834|BEHAVIORAL|Training evaluation|Clinicians will complete an evaluation assessing the empathic communication training module.
40995721|NCT02732834|BEHAVIORAL|Patient recruitment|6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
41310034|NCT04102878|OTHER|Patient comfort questionnaire|The patient will be asked to rate the level of pain during each local anaesthetic injection on a 0-10 scale
41468980|NCT04194606|PROCEDURE|Use of radial artery for access for a coronary angiography or intervention|After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
41468981|NCT00810628|BEHAVIORAL|Cognitive Behavioral Therapy|Individual interviews and group discussion/training.
41468982|NCT06472271|DRUG|Polymyxin e|Increased starting colistin dose
41468983|NCT02304068|OTHER|Home monitoring|
41468984|NCT02304068|OTHER|Hospital assessment|
40995722|NCT06296667|OTHER|core muscles training exercises|The sessions will be conducted three times per week for four weeks and each exercise will be performed two sets of 10 repetitions. For the static exercises, the final position will be held for 6 second. There will be a pause of 3 second between repetitions, and a 60 sec rest between each exercise. The exercise will be performed in three forms: abdominal bracing, dynamic stabilization, and advanced core strengthening.
41468985|NCT00983476|BEHAVIORAL|in-person MOVE! SMI|Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
41468986|NCT00983476|BEHAVIORAL|web-based MOVE! SMI|online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
41468987|NCT03046082|DRUG|Antibiotics|Observation of antibiotic types given to patients with pneumonia.
40995723|NCT01526889|DRUG|LFG316|LFG316 administered intravitreally (IVT)
41148806|NCT04432129|BEHAVIORAL|IBBIS II|"The IBBIS-II service consists of:~1. Mental health assessment.~2. Planned integrated service. The participant has the same employment specialists and care manager throughout the intervention. A joint plan is made with shared decisions between the participant, the employment specialist and the care manager. There is a focus on disclosure (openness about illness) and involvement of relatives and significant others.~3. Vocational rehabilitation. Focus on return to work with ongoing assessment of job goals, competencies and need of support. Participants receive help in contacting existing employers (employed) and potential employers (unemployed). Unemployed participants are offered an individualized job search effort. The focus is on competitive jobs within the community.~4. Treatment consists of stepped care with structured treatment guidelines.~5. When the participant has obtained work the team continues to offer support."
41148807|NCT04432129|BEHAVIORAL|Service as Usual|Service as usual consists of standard mental health care and vocational rehabilitation
41468988|NCT01139294|DRUG|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
40791220|NCT01774773|DRUG|Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
40995724|NCT01526889|DRUG|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
41148808|NCT00003541|BIOLOGICAL|filgrastim|
40995725|NCT01460433|PROCEDURE|Genital and rectal swabbing|Subjects swabs their genitals and rectum daily. The amount of HSV shed over the previous 24 hours is measured and the daily HSV shed rate is calculated.
40995726|NCT03640585|OTHER|Music therapy|Only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
40995727|NCT03574740|OTHER|Tobacco Smoking|Influence of Tobacco Smoking on the development of OSA
40995728|NCT01549964|DRUG|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
41148809|NCT00003541|DRUG|CHOP regimen|
40995729|NCT01549964|DRUG|Sitagliptin|Sitagliptin tablets
40995730|NCT01549964|DRUG|Placebo|Placebo-matching tablets
40995731|NCT00828191|DRUG|Progesterone|25 mg, once a day, SC
41148810|NCT00003541|DRUG|carboplatin|
40995732|NCT00828191|DRUG|Progesterone|100 mg, twice a day, vaginally
40995733|NCT05773430|BEHAVIORAL|Targeted Neurocognitive Training|Only two cognitive domains will be targeted for training (10 hrs of training in each, for a total of 20 hours). Two or more cognitive exercises may be employed within a cognitive domain. These exercises provide both immediate and intermittent feedback and are customized to the participants' individual ability; the difficulty and/or complexity of each game are systematically decreased/increased based on participants' performance to always be challenging, but not overly frustrating. Typically, in an hour session, one exercise (e.g., Mental Map) will be engaged at a time (20-30 minutes) before switching to another exercise (e.g., Hawkeye) in another domain for 20-30 minutes. This helps the participant remain engaged but avoid fatigue.
41148811|NCT00003541|DRUG|cyclophosphamide|
41148812|NCT00003541|DRUG|doxorubicin hydrochloride|
41468989|NCT01706718|DIETARY_SUPPLEMENT|Bread|
40995734|NCT01926080|OTHER|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
41148813|NCT00003541|DRUG|etoposide|
41148814|NCT00003541|DRUG|ifosfamide|
41148815|NCT00003541|DRUG|prednisone|
41148816|NCT00003541|DRUG|vincristine sulfate|
41148817|NCT00003541|PROCEDURE|peripheral blood stem cell transplantation|
41148818|NCT00003541|RADIATION|radiation therapy|
41148819|NCT02570971|DRUG|Mannitol|
41148820|NCT03409276|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid.
41148821|NCT03409276|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid.
41148822|NCT03409276|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
41468990|NCT05746377|DRUG|Metoclopramide 10mg|IV Metoclopramide
41468991|NCT05746377|DRUG|Saline|Placebo
41468992|NCT01118117|DEVICE|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
41468993|NCT06617325|DRUG|DZP|Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.
41468994|NCT06617325|OTHER|Placebo|Study participants will receive placebo at prespecified time-points.
41468995|NCT05791747|OTHER|semi-structured interviews|This is an observational study Patients included in the study will conduct semi-structured interviews to discuss their knowledge and/or experience with supportive care, particularly hypnosis
40791221|NCT01774773|DRUG|Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
40791222|NCT06199128|DIETARY_SUPPLEMENT|carboxymethyl β-glucan|It is a vaginal spray gel designed for the prevention and treatment of cervical lesions caused by HPV. This is achieved by controlling the physiological conditions of the transformation zone of the cervico-vaginal mucosa. The composition of the gel, which includes polycarbophil and carboxymethyl-beta-glucan, effectively shields the cervico-vaginal mucosa from the damaging effects of external agents due to its bioadhesive capacity. Additionally, it contributes to the re-epithelialization and regression of cervical lesions
40791223|NCT00894777|OTHER|Clinical record review|
40791224|NCT03599518|DRUG|DS-1205c|DS-1205c 200 mg capsule for oral administration
40791225|NCT03599518|DRUG|Gefitinib|Gefitinib 250 mg tablet for oral administration
40791226|NCT04665804|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
40995735|NCT03027128|BIOLOGICAL|haNK™ for Infusion|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
40995736|NCT03823248|DRUG|MoLuoDan|oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
41310035|NCT04102878|OTHER|Facial photograph|The patient will have a photograph taken following the anaesthetic injections to document the presence or absence of bruising
41310036|NCT04102878|PROCEDURE|Eyelid surgery|Eyelid surgery will be performed as per the plan from their preoperative appointment
41310037|NCT06336551|BEHAVIORAL|Acceptance and Commitment Therapy for insomnia (ACT-I)|During ACT-I patients are encouraged to let go of the struggle to control sleep and to focus on meaningful daytime activities. Treatment goals are addressed through ACT processes of creative hopelessness and self-as-context (session 1), acceptance (session 2), defusion (session 3), followed by values, committed action, and present moment awareness (sessions 4 and 5).
40995737|NCT03823248|DRUG|Sanchi powder|oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
40995738|NCT03823248|DRUG|Folic Acid Tablet|oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
40791227|NCT04665804|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin sulfate supplementation|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
40791228|NCT04665804|OTHER|Supervised Exercise training|"Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
40791229|NCT04665804|OTHER|Home Exercise Program|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
40995739|NCT03823248|DRUG|MoLuoDan simulation|oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
40995740|NCT03823248|DRUG|Sanchi powder simulation|oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
40995741|NCT03823248|DRUG|Folic Acid Tablet simulation|oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
40995742|NCT01602250|DRUG|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
40995743|NCT01602250|DRUG|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
40995744|NCT02786485|BIOLOGICAL|rivogenlecleucel|T cells transduced with iCasp safety switch
41310038|NCT05848830|DIETARY_SUPPLEMENT|Mult-ingredient supplement|A mult-ingredient supplement containing Protein, both whey and casein, Creatine, Vitamin D, and Calcium. As well as antioxidants and other dietary supplements including Vitamin E, CoQ10, Alpha Lipoic Acid, L-Arginine, Beet Root Extract, Green Coffee Bean Extract, Green Tea Extract, Black Tea Extract, Curcumin, and Forskolin
40995745|NCT02786485|DRUG|Rimiducid|administered to treat GVHD
40995746|NCT06127459|BEHAVIORAL|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma).
41148823|NCT03409276|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
41148824|NCT02834624|DRUG|Poractant alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
41310039|NCT05848830|DIETARY_SUPPLEMENT|Placebo|The placebo sachet will contain micro-crystalline cellulose (inactive compound) and will be identical in look and taste to the active supplement.
41310040|NCT05848830|BEHAVIORAL|Concurrent exercise training|All participants will undergo 16-weeks of exercise training, containing 3 days/week of resistance training and 2days/ week of aerobic training.
41468996|NCT03840382|BEHAVIORAL|Tele-PrEP Intervention|Telemedicine conferences with PrEP-specialists
41468997|NCT05777382|OTHER|inquiry to postnatal mothers|structured questionnaires was asked to postnatal mothers
41468998|NCT05708482|OTHER|Sling-Swing Position|The device is hammock which look likes a rope
40995747|NCT06127459|BEHAVIORAL|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
40995748|NCT03051048|PROCEDURE|Reperfusion|
40791230|NCT04665804|PROCEDURE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
40995749|NCT03559712|OTHER|Collaborative care, Telemental health|Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
40995750|NCT01520363|DRUG|dextromethorphan|The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.
40995751|NCT01520363|DRUG|placebo|The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
40995752|NCT01147861|DRUG|GSK256073|5mg in the AM and 5mg in the PM
40995753|NCT01147861|DRUG|GSK256073|10mg in the AM
40995754|NCT01147861|DRUG|GSK256073|50mg in the AM
40995755|NCT01147861|DRUG|GSK256073|25mg in the AM and 25mg in the PM
41148825|NCT02834624|DRUG|calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
41148826|NCT04546360|PROCEDURE|Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.|Time frame between elastography measurement and esophagogastroduodendoscopy is within 2 weeks.
41148827|NCT03348800|PROCEDURE|Dental anesthesia|A tooth extraction will be performed
41148828|NCT05363839|DRUG|ACH-000029|ACH-000029 will be administered orally via a capsule.
40791231|NCT04665804|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
40791232|NCT02270281|DRUG|Dexmedetomidine 0.7 Mcg/kg/h|CIF 0.7mcg/kg/h
40791233|NCT02059564|DRUG|HM11260C|doses of 6 mg, 16 mg
40791234|NCT02059564|DRUG|Placebo|Normal saline solution
40791235|NCT02059564|DRUG|Victoza|doses of 1.8 mg
40791236|NCT03160456|DEVICE|Transcutaneous electrical stimulation|The device needs to be started by pressing the 'on' button. Once the device is turned on the current intensity can be increased by pushing the '+' button and lowered by pushing the '-' button. When a comfortable skin sensation is felt the patients should press the '-' button once more. At that time the device stimulates with a low current which is not felt but provides a neuromuscular tone to the muscles whilst asleep. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Once disconnected it should be turned off by pressing the 'off' button.
40791237|NCT03160456|DEVICE|Continuous positive airway pressure|CPAP will be applied according to usual clinical care, the follow up will be organised in the same way as the active intervention group.
40995756|NCT01147861|OTHER|Placebo|2 placebo tablets in the AM and 2 placebo tablets in the PM
40995757|NCT01271868|BIOLOGICAL|IB1001|
40995758|NCT05568784|OTHER|Straight Leg Raise exercise|Patient lying supine will lift leg to the height of the contralateral knee flexed to 90 degrees with the ankle positioned and tested in all three positions (dorsiflexion, neutral, and plantarflexion)
40995759|NCT01888146|BEHAVIORAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
40995760|NCT02020005|OTHER|Non-flavored 2mg nicotine gum|
40995761|NCT02020005|OTHER|Non-flavored 4mg nicotine gum|
41148829|NCT05363839|DRUG|Placebo|Placebo will be administered orally via a capsule.
41148830|NCT03594045|DRUG|Apixaban|Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
41148831|NCT02917434|DIETARY_SUPPLEMENT|Very Low Energy Diet (VLED)|Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.
40791238|NCT01130181|DRUG|Cholecalciferol|loading dose of 540,000 IU of cholecalciferol via feeding tube or orally, then 5 monthly doses of 90,000 IU
40791239|NCT01130181|DRUG|Placebo|Matching placebo
40791240|NCT02477527|DRUG|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
40791241|NCT00124930|DRUG|Olanzapine|
40791242|NCT00124930|DRUG|Haldol|
40791243|NCT01179269|DRUG|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
40791244|NCT00997984|DRUG|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
40791245|NCT00997984|DRUG|placebo|dosed in the AM or PM
40995762|NCT02020005|OTHER|Mint-flavored 2mg nicotine gum|
40995763|NCT02020005|OTHER|Mint-flavored 4mg nicotine gum|
40995764|NCT02020005|OTHER|Non-flavored nicotine inhaler|
40995765|NCT02020005|OTHER|Mint-flavored nicotine ihaler|
40995766|NCT01213979|DRUG|500 mg iron isomaltoside 1000|500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
40995767|NCT01213979|DRUG|1000 mg iron isomaltoside 1000|1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
40995768|NCT06114758|DRUG|Cytotec 200Mcg Tablet|the admistiration of 400 Mcg rectal cytotec while starting the surgery, just before the patient is covered
40995769|NCT06114758|DRUG|Transamine|1 gram intravenous slow infusion intraoperatively as we start the laparatomy
41148832|NCT02782273|DRUG|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
41148833|NCT02782273|DRUG|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
41310041|NCT05602441|BEHAVIORAL|VALID - diabetes supportive clubs|"The VALID - diabetes supportive clubs comprised diabetes classes and diabetes clubs, to highlight two prominent aspects of diabetes self-management: education and peer support.~The diabetes club meeting was held twice a month during a 9-month intervention, consisting of a focused delivery of the knowledge and discussion following the topic in the monthly class. Club meetings also included dedicated time for blood glucose testing and sharing experiences to deal with the difficulties of the periodic insurance examinations process. Finally, the club meetings provided the participants with emotional support to deal with the stigma and sadness in their daily lives.~Core messages aimed to strengthen daily self-management and boost the spiritual bond between individuals with T2D toward a healthy, happy life with T2DM. In addition, the intervention aimed to strengthen the capacities of grassroots health care workers in diabetes consultations and communication in rural communities."
40791246|NCT00997984|DRUG|extended-release guanfacine hydrochloride|Dosed in the PM
40791247|NCT03841851|PROCEDURE|sub epithelial connective tissue graft|"* Local anesthesia will be injected intra-orally at the implant site.~* Atraumatic extraction of badley decayed teeth in the aesthetic area traditional drilling for immediate implant placement .~* immediate temporization .~* subepithelial connective tissue graft from the palate"
40791248|NCT03218280|DRUG|Vitamin C|
40791249|NCT04878393|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
40791250|NCT04463940|OTHER|No intervention|No intervention
40791251|NCT00001964|DRUG|Cyclosporine A|Cyclosporine A
41310042|NCT05312424|DIETARY_SUPPLEMENT|Placebo|300 mg olive oil
41310043|NCT05312424|DIETARY_SUPPLEMENT|Low GG|150 mg GG
40791252|NCT00001964|DRUG|ATG|ATG
41310044|NCT05312424|DIETARY_SUPPLEMENT|High GG|300 mg GG
40995770|NCT01632202|DEVICE|Seprafilm|Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
40995771|NCT01632202|DEVICE|Sterile Saline Solution|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
41148834|NCT04728347|BIOLOGICAL|ARCT-021|ARCT-021 single dose
41148835|NCT05018455|OTHER|Fall prevention program training based on Otago principles|balance and strength exercises
41148836|NCT02244775|DEVICE|SR™MCP|
41310045|NCT04830800|BIOLOGICAL|COVIVAC|COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19
40791253|NCT00001964|DRUG|MMF|MMF
40791254|NCT00326599|DRUG|carboplatin|Given IV
40791255|NCT00326599|DRUG|cediranib maleate|Given orally
40791256|NCT00326599|DRUG|gemcitabine hydrochloride|Given IV
40791257|NCT02599311|DEVICE|transvaginal synthetic mesh|transvaginal synthetic mesh
41148837|NCT03042156|RADIATION|Palliative Radiation Therapy|
41148838|NCT00407485|BIOLOGICAL|ziv-aflibercept|Given IV
41148839|NCT00407485|OTHER|pharmacological study|Correlative studies
41148840|NCT05065008|OTHER|Cranberry juice|The responders and non-responders will drink 20-30 oz of (590-885 mL) 27% cranberry juice daily for 3 weeks.
41148841|NCT05065008|OTHER|Apple juice|The participants will drink apple juice with matching sugar content and calories for 3 weeks
40791258|NCT02599311|DRUG|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
40791259|NCT02820844|DRUG|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
40995772|NCT06281236|DRUG|Prednisolone|Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.
40995773|NCT06281236|DRUG|SPI-62|SPI-62 administered once daily.
40995774|NCT05893420|DEVICE|eCARTv5 clinical deterioration monitoring|eCART is a predictive analytic used for the identification of acute clinical deterioration built upon more than a decade of ongoing scientific research and chronicled in numerous peer-reviewed publications. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts the likelihood of critical illness onset.
40995775|NCT05893420|OTHER|Standard of care control|Standard of care is the health system's clinical best practices and workflows for identifying high-risk patients for clinical deterioration, including other tools already built into the electronic health record (EHR). Hospitals that do not implement eCARTv5 will be compared as a control against hospitals that do implement eCARTv5.
41310046|NCT04830800|BIOLOGICAL|Phosphate-buffered saline|Phosphate buffer solution (pH 7.2), manufactured by IVAC
41310047|NCT06419868|BEHAVIORAL|"Universal preventive intervention for depression and anxiety for university students"|"This is a self-applied online intervention with six modules. It should be implemented over a period of 4 to 8 weeks. It includes emotion regulation, mindfulness exercises, coping strategies, problem-solving strategies, psychoeducation of anxiety and depression, and the development of healthy behaviors, explained through the following theoretical components: mindfulness and cognitive behavioral therapy.~Participants will be guided through the program in a structured manner. They will start by accessing the CANVAS online platform, where they will find the content of the sessions in video, audio, and text formats. They will then be directed to practice exercises at home, with audiovisual material to guide them. It's crucial that participants complete the six sessions sequentially, as each session is designed to build upon the previous one, ensuring a comprehensive learning experience and effective learning."
41468999|NCT01503463|PROCEDURE|Home telemonitoring of patients with CHF|"Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.~If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified."
40995776|NCT03961542|OTHER|Chewing|Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
40995777|NCT01121692|BEHAVIORAL|Couples Intervention|The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
40995778|NCT01121692|BEHAVIORAL|Women's CoOp|The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
40791260|NCT02820844|DRUG|Placebo|Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
40791261|NCT02820844|DRUG|Antibiotic therapy|Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
40791262|NCT02820844|OTHER|Bladder diary|The bladder diary is a self-reporting tool to record subject's data on micturition. Subjects will enter data in the diary over 3 consecutive days. During Screening, data will be collected within 28 days prior to first treatment. During treatment periods, data will be collected within a week prior to each scheduled visit. The bladder diary will capture the following information: 1) Date and time of urinary episode, 2) episodes of micturition, 3) episodes of urinary incontinence, 4) episodes of urgency, 5) intensity of urgency, 6) episodes of nocturia, 7) use of CIC, and 8) urine volume. Diary data will not be collected when a subject experiences symptoms of a UTI.
40791263|NCT02820844|OTHER|King's Health Questionnaire (KHQ)|The KHQ will assess the impact of urinary incontinence on QOL. It is a questionnaire with 21 items and the following 9 domains: 1) General health, 2) Incontinence impact, 3) Role limitations, 4) Physical limitations, 5) Social limitations, 6) Personal relationships, 7) Emotion, 8) Sleep/energy, 9) Severity measure. The items are answered by subjects themselves, and scores are summated using a defined algorithm.
40791264|NCT02820844|OTHER|Overactive Bladder Symptom Score (OABSS)|The OABSS will comprehensively assess symptoms of OAB, such as frequency of micturition, nocturia, urinary urgency, and urge incontinence. It consists of 4 questions which will be responded by subjects themselves, by selecting the most appropriate answer for each question.
40995779|NCT01121692|BEHAVIORAL|Women's CoOp and Men's Intervention|The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
40995780|NCT05048446|OTHER|observational|Non intervention
40995781|NCT01452308|BIOLOGICAL|Simtuzumab|
40995782|NCT03659305|BIOLOGICAL|RPH-001|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
40995783|NCT03659305|BIOLOGICAL|Avastin|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
40995784|NCT05616858|BEHAVIORAL|Complex exercise program|Stretching exercise, aerobic exercise, strengthening and balancing exercise
40995785|NCT03413553|DEVICE|immediate implant|Patient will receive immediate implant alone.
41310048|NCT01258972|DEVICE|Tryton Side Branch Stent with main branch DES|Tryton Side Branch Stent
40995786|NCT03413553|BIOLOGICAL|connective tissue graft|patient will receive immediate implant with connective tissue graft and platelet rich fibrin
41469000|NCT03634059|DRUG|Apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
41469001|NCT06495580|PROCEDURE|Optic Nerve Stimulation|Anterograde Stimulation of the Optic Neve.
40995787|NCT03413553|BIOLOGICAL|platelet rich fibrin|patient will recieve immediate implant combined with connective tissue graft and platelet rich fibrin
40995788|NCT02028988|DRUG|Enzalutamide|
40995789|NCT02028988|RADIATION|External Beam Radiation|
40995790|NCT01452464|BIOLOGICAL|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
40995791|NCT00657241|DRUG|Carvedilol CR|
40995792|NCT00657241|DRUG|Valsartan|
40995793|NCT00123864|PROCEDURE|Intensity-modulated radiation therapy|
41469002|NCT00909571|DRUG|FK506E (modified release tacrolimus)|oral
41469003|NCT00909571|DRUG|Prograf (tacrolimus)|injection
41469004|NCT04915911|OTHER|cross-sectional study|cross-sectional study
41469005|NCT06617143|OTHER|mindfulness-based cognitive therapy|In this study, it is planned to apply MBCT to asthmatic inpatients in the patient room in groups of 2 or 3. This application is planned to continue for one hour.
41469006|NCT06617143|OTHER|routine treatment and care|routine treatment and care
41310049|NCT01258972|DEVICE|POBA|Balloon angioplasty
40995794|NCT03465332|OTHER|Doctor's questionnaire|The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.
40995795|NCT03465332|OTHER|Subject file|All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.
40995796|NCT05281614|DRUG|Etanercept|Etanercept is a fully humanized monoclonal antibody that targets TNFα.
40995797|NCT05281614|DRUG|Vedolizumab|Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.
40995798|NCT03393156|BEHAVIORAL|Internet-based metacognitive therapy|Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
41469007|NCT03558035|DRUG|Induction CT+ CRT group|Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
40995799|NCT02800356|PROCEDURE|Subthreshold 577 nm yellow wavelength laser photo-coagulator|"Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management."
40995800|NCT03777293|DEVICE|ultrasound viscoelasticity|use these devices to do ultrasound examination in chronic liver disease patients
40995801|NCT04574804|OTHER|Online training program in weight management for osteoarthritis|"An evidence based online education training program for physiotherapists in weight management for osteoarthritis. Training modules cover the following topic areas:~1. Overweight and obesity and osteoarthritis~2. Overview of weight regulation, overweight and obesity~3. Examining weight stigma in physiotherapy and personal beliefs about weight~4. Communication approach for addressing weight management~5. Interventions for weight management~6. Health behaviour change support~These 6 e-learning modules comprise the online training program, access to which comprises the study intervention."
40995802|NCT05251376|DRUG|Levomethadone HCl|One dose given orally on Day 8 of the study.
40995803|NCT05251376|DRUG|Methadone|Daily usual oral dose given on Day 1 and Day 2 of the study.
40995804|NCT05251376|DRUG|Morphine Sulfate|Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.
40995805|NCT05251376|DIAGNOSTIC_TEST|x-ray|Abdominal x-rays done at specific study timepoints to assess the location of the LYN-014.
40995806|NCT05251376|DIAGNOSTIC_TEST|blood tests|Done at specific timepoints throughout the study for PK (pharmacokinetics), genotyping and safety labs.
40995807|NCT02660320|DEVICE|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
40791265|NCT02820844|OTHER|Treatment Benefit Scale (TBS)|"The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820."
40995808|NCT02660320|DEVICE|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
41469008|NCT03558035|RADIATION|Concurrent CRT group|cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
40995809|NCT00965822|OTHER|North American ginseng|3 day, once daily, dosing
40995810|NCT00965822|OTHER|Placebo|3 day, once daily dosing
40995811|NCT02261636|DRUG|mesalazine|
40995812|NCT00492310|BEHAVIORAL|yoga|vinyasa yoga
40995813|NCT00492310|BEHAVIORAL|cognitive therapy|cognitive behavioral therapy once weekly
41310050|NCT01173341|DIAGNOSTIC_TEST|Echocardiography|Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
41469009|NCT01899326|DRUG|Desipramine Hydrochloride|Given PO
41469010|NCT01899326|BIOLOGICAL|Filgrastim|Given PO
41469011|NCT01899326|OTHER|Laboratory Biomarker Analysis|Correlative studies
41469012|NCT00527917|DEVICE|placebo|bladder instillation
41469013|NCT00527917|DEVICE|Uracyst|20 ml sterile solution for weekly intravesical instillation
41469014|NCT03936218|DRUG|Inj. Goserelin (Test) Subcutaneously|10.8 mg, subcutaneously at every 3 month
41469015|NCT03936218|DRUG|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
40995814|NCT00492310|BEHAVIORAL|yoga|vinyasa yoga twice weekly with smoking cessation once weekly
40995815|NCT00492310|BEHAVIORAL|wellness|wellness program with smoking cessation
40995816|NCT01936116|DEVICE|sonohysterography with inflated catheter in uterine cavity|during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
40995817|NCT01936116|DEVICE|sonohysterography with inflated catheter in cervical cavity|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
40995818|NCT05868070|DEVICE|Conventional rehabilitation plus multimodal exercise|Depending on the patient's condition, the intervention gradually progressed to passive, active assistive, active, and resistive exercise modes and the frequency of exercise interventions is gradually increased, and the application time of cycling/stepping is 20 minutes per session, and up to 3 times if there is no serious problem corresponding to the safety standards.
40995819|NCT04916795|DRUG|Vupanorsen|80 mg subcutaneous injection
40995820|NCT04916795|DRUG|Vupanorsen|80 mg subcutaneous injection
40995821|NCT05325528|DRUG|Tislelizumab in Combination with Oxaliplatin and Tegafur|6 cycles of Tislelizumab plus SOX regimen every 21 days
40995822|NCT01912144|OTHER|Coffee|
40995823|NCT03532620|DRUG|Pitavastatin Calcium|"In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
40995824|NCT03532620|DRUG|Atorvastatin Calcium|"In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
41469016|NCT02184741|DRUG|GB-0998|Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.
41469017|NCT02184741|DRUG|Placebo|Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
40791266|NCT06348641|OTHER|baby massage|The infant massage to be applied before the examination will be applied by a single nurse=researcher. Video recordings will be taken before and during the ROP examination and evaluations will be made by two neonatal nurses other than the researcher.
41469018|NCT03153787|OTHER|Probiotic|Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
41469019|NCT02382367|OTHER|Blood sampling|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
41469020|NCT00442351|DRUG|Asmanex twisthaler|Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
41469021|NCT00442351|OTHER|Placebo for Asmanex twisthaler|Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
41469022|NCT00671073|DRUG|Oglemilast|Oglemilast low dose, oral administration, once daily for 12 weeks
40791267|NCT04336657|OTHER|Questionnaire|Survey to identify number of people who got unusual severe flu- like illness in last October- November
40791268|NCT04336657|DIAGNOSTIC_TEST|IgG|Measure the past immunity of the disease (if possible)
40995825|NCT05845879|OTHER|delivery|delivery
41469023|NCT00671073|DRUG|Placebo|Placebo, oral administration, once daily for 12 weeks
41469024|NCT00671073|DRUG|Oglemilast|Oglemilast middle dose, oral administration, once daily for 12 weeks
40995826|NCT00358085|PROCEDURE|Endovascular Repair of Abdominal Aortic Aneurysm|
41469025|NCT00671073|DRUG|Oglemilast|Oglemilast high dose, oral administration, once daily for 12 weeks
41469026|NCT02208752|OTHER|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
40995827|NCT00358085|PROCEDURE|Conventional open repair of Abdominal Aortic Aneurysm|
41469027|NCT01367717|DIETARY_SUPPLEMENT|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
41469028|NCT01367717|DIETARY_SUPPLEMENT|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
40791269|NCT00705770|DRUG|Anecortave Acetate|"Low dose~Sustained release depot suspension"
40791270|NCT00705770|DRUG|Anecortave Acetate|"Middle dose~Sustained release depot suspension"
40791271|NCT00705770|DRUG|Anecortave Acetate|"High dose~Sustained release depot suspension"
40791272|NCT00705770|DRUG|Placebo|Placebo treatment with vehicle
40995828|NCT02631863|DRUG|Aminolaevulinic acid|Aminolaevulinic acid with illumination
40995829|NCT02631863|DRUG|Placebo|Placebo with illumination
40995830|NCT05566210|DEVICE|acupuncture|acupuncture
40995831|NCT05566210|DEVICE|Sham acupuncture|Sham acupuncture
40995832|NCT04128163|DRUG|QL1206|"subcutaneous injection of 60 mg（60mg:1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
40995833|NCT04128163|DRUG|Placebos|"subcutaneous injection of（1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
40995834|NCT02712944|DRUG|Testosterone|Testosterone
40995835|NCT02712944|DRUG|Saline|Placebo
41310051|NCT01173341|OTHER|Blood Collection|Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.
40791273|NCT04778748|DIAGNOSTIC_TEST|Under-mattress sleep monitor|Under-mattress sleep monitor for patients with a confirmed diagnosis of Obstructive Sleep Apnea.
40995836|NCT01583972|DIETARY_SUPPLEMENT|retinyl palmitate|50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
40995837|NCT01583972|DIETARY_SUPPLEMENT|Placebo|edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
40995838|NCT00324467|DRUG|Cyclophosphamide|"Dose: 750 mg/m\^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
40995839|NCT00324467|DRUG|Doxorubicin|"Dose: 50 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
41469029|NCT04228978|BEHAVIORAL|Weight loss|Walking exercise combined with weight loss
41469030|NCT04228978|BEHAVIORAL|Exercise|Walking exercise
41469031|NCT04116151|COMBINATION_PRODUCT|Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)|Application on the affected skin of the cream to be tested
41469032|NCT04116151|COMBINATION_PRODUCT|Usual treatment|Application on the affected skin of the emollient and moisturizing substance
41469033|NCT03766139|BIOLOGICAL|SUPERCELL GLUE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method)
41310052|NCT01173341|OTHER|Symptoms Questionnaire|Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
41310053|NCT00000513|BEHAVIORAL|diet, reducing|
40791274|NCT06486181|OTHER|Thrombolysis/Thrombectomy|"Endovascular interventions will be either catheter directed thrombolysis or mechanical thrombectomy procedures both of which have been cleared by FDA for the treatment of acute DVT.~Catheter-directed thrombolysis involves the use of a catheter to deliver thrombolytic agents directly to the site of the clot, effectively dissolving the thrombus. Mechanical thrombectomy, on the other hand, employs specialized devices to physically remove the clot from the vessel. These procedures have been cleared by FDA as they are targeted approaches to safely and effectively restore blood flow and reduce the risk of complications associated with acute DVT."
41310054|NCT00000513|BEHAVIORAL|diet, sodium-restricted|
41310055|NCT00000513|DRUG|chlorthalidone|
41310056|NCT00000513|DRUG|atenolol|
41310057|NCT04330755|DRUG|Saline Solution|Placebo
41310058|NCT04330755|DRUG|Levosimendan|Levosimendan
41310059|NCT04330755|DRUG|Magnesium Sulfate|Magnesium Sulfate
41310060|NCT01141634|OTHER|Homeopathic Remedies|Homeopathic remedies prepared according to the standards as set out by Health Canada
41310061|NCT05341505|BEHAVIORAL|Emotion Regulation Intervention|We will administer a cognitive-behavioral treatment targeting emotion dysregulation, including mindfulness skills and other cognitive and behavioral emotion regulation skills.
41310062|NCT02572128|OTHER|Fortified rice|"Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2."
41310063|NCT03330899|BIOLOGICAL|H7N9 antigen + adjuvant IB160|H7N9 monovalent (fragmented and inactivated)
41310064|NCT03330899|BIOLOGICAL|H7N9 antigen + adjuvant SE|H7N9 monovalent (fragmented and inactivated)
41310065|NCT03330899|BIOLOGICAL|H7N9 antigen without adjuvant|H7N9 monovalent (fragmented and inactivated)
41310066|NCT03330899|BIOLOGICAL|Placebo (PBS)|Placebo (Phosphate Buffered Saline -PBS)
41310067|NCT01676402|BIOLOGICAL|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
41469034|NCT03766139|BIOLOGICAL|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)
40791275|NCT04937634|DRUG|Melphalan|The subject receives conditioning regimen including melphalan as a part of hematopoietic stem cell transplantation. Dosage of melphalan is 50mg/m\^2/day. Infuse Melphalan over 30 minutes.
40791276|NCT00616642|DRUG|rosiglitazone maleate|Given orally
40791277|NCT00921388|OTHER|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
40791278|NCT00921388|BEHAVIORAL|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
41310068|NCT01676402|BIOLOGICAL|TIV|2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
41310069|NCT03870711|DRUG|lidocaine spray|10% lidocaine spray 4 puffs
41310070|NCT03870711|DRUG|Placebo|Sterile water 4 puffs
41310071|NCT04764409|PROCEDURE|Chemoembolization|Transarterial Chemoembolization (TACE)
41310072|NCT04764409|PROCEDURE|Chemoinfusion|Transarterial Infusion (TAI)
41310073|NCT03838068|BIOLOGICAL|Biodentine|Biodentine is considered a calcium silicate cement
41310074|NCT03838068|BIOLOGICAL|mineral trioxide aggregate|calcium based silicate cement
41310075|NCT03838068|PROCEDURE|cervical pulpotomy|coronal pulp tissue was removed till the orifice
41310076|NCT03838068|DRUG|Local Anesthetics Procaine|40 mg/0.01 mg/ml contains sodium metabisulfite and sodium and articaine as an active substance
41310077|NCT05094999|DEVICE|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
41310078|NCT05094999|DEVICE|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
41310079|NCT06250894|DRUG|PD-1inhibitor|Patients receive 3 cycles of preoperative chemotherapy with Sintilimab（PD-1 inbibitor） and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22 fractions) during cycle 1 of the combination. Radical surgery for gastric cancer will be performed within 4-6 weeks after completion of neoadjuvant treatment, followed by 3-5 cycles of postoperative adjuvant chemotherapy with the SOX regimen.
41310080|NCT06429878|DIAGNOSTIC_TEST|Biparametric prostatic MRI|
41310081|NCT02607254|DRUG|Pregabalin|Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.
41310082|NCT02607254|DRUG|Placebo|Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
41310083|NCT01015482|DRUG|Remifentanil|Remifentanil Infusion
41310084|NCT01015482|DRUG|Midazolam|Midazolam Infusion
41310085|NCT01260363|PROCEDURE|Femoral nerve block|Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml
41310086|NCT01260363|PROCEDURE|Local infiltration analgesia|Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.
41310087|NCT04868006|PROCEDURE|End-range Maitland mobilization + proprioception training|End-range Maitland mobilization performed in end position of internal rotation of the shoulder accompanied with 8--week long proprioception training
40995840|NCT00324467|DRUG|Vincristine|"Dose: 1.4 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
40995841|NCT00324467|DRUG|Prednisone|"Dose: 45 mg/m\^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
40995842|NCT00324467|DRUG|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
40995843|NCT00324467|DRUG|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
40995844|NCT00324467|DRUG|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
40995845|NCT00324467|DRUG|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
40995846|NCT00324467|DRUG|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
41310088|NCT04868006|PROCEDURE|Non end-range Maitland mobilization + proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
41310089|NCT04868006|PROCEDURE|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
41469035|NCT04569786|BIOLOGICAL|V590|Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).
40791279|NCT01187095|BEHAVIORAL|Expressive writing|3 consecutive days of writing
40791280|NCT01187095|BEHAVIORAL|Active ctrl|Control
40791281|NCT02973997|OTHER|Laboratory Biomarker Analysis|Correlative studies
40791282|NCT02973997|DRUG|Lenvatinib|Given PO
40791283|NCT02973997|DRUG|Lenvatinib Mesylate|Given PO
40791284|NCT02973997|BIOLOGICAL|Pembrolizumab|Given IV
40791285|NCT05528406|DRUG|HLX208|900mg bid po
40791286|NCT03606486|OTHER|Biospecimen Collection|Undergo collection of tumor sample and blood draw
40791287|NCT03606486|OTHER|Laboratory Biomarker Analysis|Correlative studies
40791288|NCT03606486|DEVICE|Lavage|Undergo uterine lavage
40791289|NCT03606486|OTHER|Pap Smear|Undergo pap smear
40791290|NCT03079531|DRUG|Secukinumab|Secukinumab 300 mg administered subcutaneously.
40995847|NCT00324467|DRUG|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
40995848|NCT00324467|DRUG|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
40995849|NCT00324467|DRUG|Carboplatin|"R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl\*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)~\*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.~Estimate Creatinine Clearance (CrCl)"
41148842|NCT04160871|BEHAVIORAL|Family Connections|Intervention includes 12 sessions that follow a group format of 2 hours with a weekly frequency. FC program (Hoffman and Fruzzetti, 2005) is divided into six modules: 1: Updated information and research on BPD; 2: Psychoeducation on the development of BPD, available treatments and comorbidity; 3: Individual skills: self-control of emotions, mindfulness, reality acceptance skills, validation skills, etc. and skills of relationship to promote emotional well-being problem management (family skills); 4: Family skills to improve the quality of relationships in family interactions; 5: Communication skills and effective self-expression; and 6: Problem management. All modules include Practice exercises and homework. In addition, throughout the program, in order to increase social support, the FC program provides a forum where participants can stay in touch, share common problems and solutions.
41310090|NCT02840890|PROCEDURE|osteopathic technique|Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
41310091|NCT02840890|PROCEDURE|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
41310092|NCT00502307|DRUG|Tivozanib (AV-951)|solid oral dosage form taken daily for three weeks per one month cycle
41310093|NCT00502307|DRUG|Placebo comparator|solid oral capsule containing excipients dosed daily for three weeks per month
41310094|NCT00625365|DRUG|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
41310095|NCT01433458|DRUG|RLX030A|RLX030 is administered as a continuous 24 hour infusion
41469036|NCT04569786|OTHER|Placebo|Placebo administered via IM injection.
41469037|NCT01215903|DIETARY_SUPPLEMENT|Fish gelatin and omega-3 polyunsaturated fatty acid|
41469038|NCT01215903|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid|
41469039|NCT06437314|BEHAVIORAL|Aquatic program based on the back school|Participants will undertake a back school-based program. This program will follow the recommendations of the biopsychosocial model of chronic pain and will be conducted in an aquatic environment. The intervention will be carried out by physiotherapists in a sports center. The duration of the intervention will be six weeks, with a frequency of two sessions per week, totaling 12 sessions of 45 minutes each. Of all the sessions, 10 will have a practical focus (centered on trunk exercises) and the other two will have a theoretical focus (providing education on pain and risk factors for low back pain).
40995850|NCT00324467|DRUG|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m\^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
40995851|NCT00324467|DRUG|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m\^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
40995852|NCT00324467|DRUG|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
40995853|NCT00324467|DRUG|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
40995854|NCT00324467|DRUG|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
40995855|NCT00324467|DRUG|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
40995856|NCT00324467|OTHER|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
40995857|NCT01540058|OTHER|Cancer Type ID test|"CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).~CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York."
40995858|NCT01540058|OTHER|No test Empiric strategy|Empiric strategy
40995859|NCT04434131|DRUG|Convalescent Plasma|Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.
40995860|NCT03072134|BIOLOGICAL|Neural stem cells loaded with an oncolytic adenovirus|The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.
40995861|NCT04083807|BIOLOGICAL|TISSEEL Lyo|The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.
41148843|NCT04160871|BEHAVIORAL|Treatment As Usual|"The intervention lasts for 3 months and includes 12 sessions that follow a group format of 2 hours and with a weekly frequency. It includes the following components: Psychoeducation about personality disorders and, specifically, BPD and how these disorders evolve. Problems associated with BPD (eg, alcohol and / or drug use, eating disorders, etc.). The importance of modeling in family members: change of attitude towards difficult situations to reduce the escalation of tension and re-establish a healthy relationship between the patient and family. The handling of problems. Crisis management: Development of safe plans for when the patient is in emotional escalation."
41148844|NCT03966599|DIAGNOSTIC_TEST|Pain|Patient's pain in order to VAS
41310096|NCT01763476|PROCEDURE|paclitaxel-coated balloon angioplasty|plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
41310097|NCT01763476|PROCEDURE|atherectomy|atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
41310098|NCT00703833|DRUG|MK0777|Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
41148845|NCT03966599|DIAGNOSTIC_TEST|Hemodynamic changes|changes in hemodynamic states
41148846|NCT04374175|BIOLOGICAL|Blood sample|Blood sample will be performed
41310099|NCT00703833|DRUG|Placebo (unspecified)|matching placebo
41310100|NCT05364905|DRUG|Chemotherapy|Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
41310101|NCT01345877|PROCEDURE|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
41310102|NCT03796091|BEHAVIORAL|Educational Brochure|Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.
41310103|NCT03796091|BEHAVIORAL|Body Project Traditional|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice \& Shaw, 2001).
41310104|NCT03796091|BEHAVIORAL|Body Project Expanded|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).
41310105|NCT00364845|DRUG|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
41310106|NCT00364845|DRUG|Placebo|Prefilled syringe placebo, to match active arm
41310107|NCT00194272|DRUG|Methotrexate|Two dose methotrexate
41310108|NCT06373445|DEVICE|repetitive transcranial magnetic stimulation active stimulation|This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of active rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
40995862|NCT04083807|PROCEDURE|Manual compression with surgical gauze pads|Surgical 4x4 inches gauze pads
40995863|NCT00954642|DRUG|bevacizumab|Intravenous repeating dose
41148847|NCT04694859|DEVICE|Transcatheter Aortic Valve Implantation|Transfemoral or transapical Transcatheter Aortic Valve Implantation
41148848|NCT03231579|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS, enabling providers to deliver evidence-based and personalized treatment care plans to their CLL patients on/starting treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
41310109|NCT06373445|DEVICE|repetitive transcranial magnetic stimulation sham stimulation|This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of sham rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
41310110|NCT02067091|DEVICE|stent implant in a coronary artery|"Implantation of device called a stent in a coronary artery~Percutaneous coronary intervention"
41310111|NCT01743014|DRUG|Ramipril|Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
41469040|NCT04674683|DRUG|HBI-8000 in combination with nivolumab|Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight \< 40 kg, nivolumab will be dosed at specific doses on specific days.
41469041|NCT04674683|DRUG|Placebo in combination with nivolumab|Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
41469042|NCT00576303|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
41469043|NCT00487929|DEVICE|nasal CPAP|Nocturnal
41469044|NCT00487929|DEVICE|Sham CPAP|Nocturnal
41469045|NCT01317784|DEVICE|Rapid tests for HIV, HCV, HBV, and syphilis|Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
41469046|NCT01317784|DEVICE|HIV/HCV|Choice of 10 different tests for HIV and hepatitis C.
40995864|NCT00954642|DRUG|MNRP1685A|Escalating intravenous dose
40995865|NCT00954642|DRUG|paclitaxel|Intravenous repeating dose
40995866|NCT04222582|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
41469047|NCT01317784|DEVICE|HIV/syphilis|Choice of 7 different tests for HIV and syphilis
41469048|NCT01317784|DEVICE|HIV only|Choice of 4 different tests for HIV only.
40995867|NCT05434806|DIETARY_SUPPLEMENT|Jarlsberg cheese|Daly oral intake
41469049|NCT06609538|OTHER|Control Group|Receives standard preoperative instructions and propofol or ketamine infusion.
41469050|NCT06609538|OTHER|Suggestion Group|Receives positive preoperative suggestions and propofol or ketamine infusion.
41469051|NCT01712815|OTHER|laboratory biomarker analysis|Correlative studies
41469052|NCT01712815|OTHER|pharmacological study|Correlative studies
40995868|NCT01611987|OTHER|MStep|Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
41469053|NCT01712815|OTHER|questionnaire administration|Ancillary studies
41469054|NCT01712815|RADIATION|fluorine F 18-clevudine|Undergo fluorine F 18-clevudine PET/CT scan
41469055|NCT01712815|PROCEDURE|positron emission tomography/computed tomography|Undergo fluorine F18-clevudine PET/CT scan
41469056|NCT05529368|BEHAVIORAL|Conventional Exercise and Tai Chi Exercise interventions|Subjects diagnosed with IAD were randomly assigned to the exercise group, the tai chi group, or the control group. The exercise group and tai chi group received conventional exercise and tai chi for 8 weeks.
41469057|NCT02031237|RADIATION|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
41469058|NCT02031237|RADIATION|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
41469059|NCT02031237|RADIATION|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
41469060|NCT02031237|DEVICE|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
40995869|NCT01611987|OTHER|General guideline approach|Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
40995870|NCT02264002|DRUG|Cilobradine low dose 1|
40995871|NCT02264002|DRUG|Cilobradine low dose 2|
40995872|NCT02264002|DRUG|Cilobradine medium dose|
40995873|NCT02264002|DRUG|Cilobradine high dose 1|
40995874|NCT02264002|DRUG|Cilobradine high dose 2|
40995875|NCT02264002|DRUG|Metoprolol succinate tablets|
40995876|NCT02264002|DRUG|Placebo|
40995877|NCT05622279|PROCEDURE|Percutaneous tenotomy + PRP|The patients will receive a percutaneous ultrasound-guided treatment including a needle tenotomy followed by a PRP injection in the plantar fasciitis.
40995878|NCT00729339|DRUG|mosapride for the first month and placebo for the 2nd month|lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
40995879|NCT00729339|DRUG|placebo for the first and mosapride for the second month|lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
40995880|NCT05093296|DRUG|Oxytocin nasal spray|24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.
40995881|NCT05093296|DRUG|Naltrexone Pill|All participants will receive 50mg Naltrexone daily as oral tablet throughout the study
40995882|NCT05093296|DRUG|Placebo|Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)
40995883|NCT00002130|DRUG|Vesnarinone|
40995884|NCT00521196|DEVICE|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
40995885|NCT01921335|DRUG|ARRY-380 Twice Daily Dosage|ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
40995886|NCT01921335|DRUG|ARRY-380 Once Daily|ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
40995887|NCT01921335|DRUG|Trastuzumab|6 mg/kg IV every 3 weeks
40995888|NCT05735561|DIAGNOSTIC_TEST|X-Ray|Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.
40995889|NCT04504383|DRUG|PN-943|Administered by the oral route BID for the duration of the study.
40995890|NCT04504383|DRUG|Placebo|Administered by the oral route BID for 12 weeks.
40995891|NCT05978154|OTHER|Thigh muscle mass and muscle wasting (exposure)|Thigh muscle mass and muscle wasting (exposure variable)
40995892|NCT01807897|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
40995893|NCT01807897|DEVICE|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
40995894|NCT01807897|BEHAVIORAL|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
40995895|NCT00870363|DRUG|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
41469061|NCT05058872|DRUG|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg
41469062|NCT05058872|DRUG|Placebo|Placebo comparator
41469063|NCT04619550|OTHER|High tibial osteotomy|Realignment surgery
40995896|NCT00870363|DRUG|maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
40995897|NCT00870363|DRUG|efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]|efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
40995898|NCT02356692|DEVICE|enfilcon A|Test lens
40995899|NCT02356692|DEVICE|senofilcon A|Control lens
40995900|NCT04338295|DEVICE|Tattoo machine (SOL Nova Device)|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
40995901|NCT03437109|DIAGNOSTIC_TEST|Laboratory tests|Testosterone HSBG Hb1Ac LH
40995902|NCT00151320|DRUG|Bortezomib, CHOP, Rituximab|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4"
40995903|NCT00549562|DRUG|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
40995904|NCT06225726|PROCEDURE|urethral bladder resection|urethral bladder resection. Per-operative bladder ultrasound elastography and simultaneous cystometry
41469064|NCT05598879|OTHER|anonymized data collection during programmed surveillance clinical follow up|anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
40791291|NCT02194946|DRUG|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
40995905|NCT04992221|PROCEDURE|arterial line|arterial line inserted for invasice mointroing and sampling
40791292|NCT02194946|DRUG|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
40791293|NCT01941771|DRUG|Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
40791294|NCT01941771|DRUG|Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
40995906|NCT01356797|DRUG|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
40995907|NCT01356797|DRUG|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
40995908|NCT00592566|DRUG|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
40995909|NCT00235872|BIOLOGICAL|adalimumab|40 mg eow, sc
40995910|NCT02479256|DRUG|Clomiphene citrate|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
40995911|NCT02479256|DRUG|Tamoxifen Placebo|Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
40995912|NCT02479256|DRUG|Tamoxifen|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
40995913|NCT02479256|DRUG|Clomiphene citrate placebo|Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
40995914|NCT02726074|DRUG|Perampanel|
40995915|NCT01120756|BEHAVIORAL|Goal-oriented attentional self-regulation|This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
40995916|NCT01120756|BEHAVIORAL|Brain Health Education|Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
40995917|NCT04959968|DEVICE|eye patch and earplug|The use of eye patch and ear plugs in post-operative intensive care in craniotomy cases.
40995918|NCT03936361|DRUG|Statins|Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
40995919|NCT06271733|DEVICE|TMS|2 sessions of iTBS per day for 5 days
40995920|NCT06271733|DEVICE|Sham|2 sessions per day for 5 days of sham condition
40995921|NCT00328913|DRUG|5-hydroxytryptophan (food supplement)|
40995922|NCT04649164|BEHAVIORAL|Peer mentor support and caregiver intervention|Sixteen-week modular curriculum with printed/online workbook, additional resources, and weekly phone discussion with Lewy Body Dementia peer mentor.
40995923|NCT04649164|OTHER|Focus group to provide feedback on educational materials and mentoring program|Participation in a 2-3 hour focus group to review pilot and revised materials and provide feedback
40995924|NCT05727228|OTHER|cytology, p16/ki67 dual stain cytology (DS), extended genotyping, DNA methylation, viral load,|p16/Ki67 dual stain cytology, extended genotyping and DNA methylation will be performed from the residual cell-pellet from the HPV-positive screening samples. If no cytology-triage testing is performed as a part of the screening algorithm, a cytology will be performed at inclusion. If any residual material is left after DS, extended genotyping and DNA methylation, it will be stores at -80 degrees for future purposes.
41469065|NCT04235257|BIOLOGICAL|HPV vaccine|Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose
41469066|NCT00151216|BIOLOGICAL|AAV2CUhCLN2 (3x10^12 particle units)|gene transfer; one-time administration via neuro surgery procedure
40791295|NCT01626781|DEVICE|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
40995925|NCT03464006|OTHER|Online Support Module|The online support module is a computer software program which helps patients monitor factors related to their peripheral artery disease
40995926|NCT03464006|OTHER|Standard of Care|The normal care that patients receive at the institution.
40995927|NCT05778396|PROCEDURE|Active spinal manual therapy protocol|The chiropractor will start by (1) placing one hand over L4-L5 or L5-S1 and then will apply a high-velocity, low-amplitude (HVLA) thrust with a therapeutic line of drive. Side-lying lumbar manipulation will be performed bilaterally, with the treating clinician choosing any suitable technique and with or without occurrence of the characteristic audible joint cavitation associated with spine manipulation. The chiropractor will then perform (2) prone lumbar mobilisation by placing the contact hand and applying downward pressure over L4-L5 or L5-S1 with the other hand guiding a manual flexion-distraction piece to apply therapeutic mobilization of the lumbar spine. The chiropractor will deliver (3) a prone thoracic manipulation by placing two hands over the transverse processes of T5-T6 or T6-T7 and applying a HVLA thrust in a posterior-to-anterior direction.
40995928|NCT05778396|PROCEDURE|Control spinal manual therapy protocol|(1) Control side-lying lumbar manipulation will be operationalised as the application of a low-velocity broad push manoeuvre to the gluteal region following a non-therapeutic line of drive. The chiropractor will then perform (2) control prone lumbar mobilisation, consisting of a non-therapeutic manual manoeuvre involving minimal oscillations (0 to ±2°) of the flexion-distraction piece with light touch over the lumbar spine region, and (3) control prone thoracic mobilisation consisting of two-handed left and right scapula pushes with a nontherapeutic line of drive.
40995929|NCT02838212|DRUG|adverse drug reaction|drug-related death
40995930|NCT00437684|DRUG|LPV/r|200/50 mg 2 cpr bid monotherapy
40995931|NCT00437684|DRUG|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
40995932|NCT00437684|DRUG|Ribavirin|Ribavirin 1-1.2 g/day
40995933|NCT00437684|DRUG|NUCS|Nucleoside Reverse Transcriptase Inhibitors
40995934|NCT03858946|PROCEDURE|Simple trapeziectomy|A curvilinear incision is made over the base of the 1. metacarpal towards the tendon of the extensor pollicis brevis in the distal part of the anatomical snuffbox. The joint is opened as widely as possible and the trapezium is dissected free in a proximal direction until the articulation with the scaphoid is reached. Then trapezium is removed taking care not to damage tendon of the flexor carpi radialis. The joint capsule is closed and skin sutured in the usual manner. At the completion of the procedure two small shame incision are made (1 cm each) involving only epidermis on the volar aspect of the palm and forearm. Each of them will be closed with one stitch
40995935|NCT03858946|PROCEDURE|Weilby|The first part of the surgical procedure is identical to simple trapeziectomy. In addition, the tendon sheath of the first extensor compartment is divided. After this, a strip consisting of approximately one-third of flexor carpi radialis tendon is dissected using two small incisions on the volar aspect of the wrist and distal forearm. The distally based tendon strip is tunneled to its insertion on the second metacarpal bone. Then the strip of tendon is winded around the abductor pollicis longus tendon and the rest of the tendon at least twice, pulling those tendons together into the space created after excision of the trapezium. The tendons are sutured together with non-absorbable sutures while the skin is sutured in the usual manner
40995936|NCT06539117|OTHER|Early feeding post caesarean section|In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.
40995937|NCT02140658|BEHAVIORAL|multiple health education interventions|
40995938|NCT02140658|BEHAVIORAL|conventional health education|
40995939|NCT05141721|DRUG|GRT-C901|A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.
40995940|NCT05141721|DRUG|GRT-R902|A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
40995941|NCT05141721|DRUG|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
40995942|NCT05141721|DRUG|Ipilimumab|Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
40995943|NCT05141721|DRUG|Fluoropyrimidine plus leucovorin|Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
40995944|NCT05141721|DRUG|Bevacizumab|Bevacizumab administered as maintenance therapy per standard of care.
40995945|NCT04078685|PROCEDURE|Standard catheter ablation|Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing
40995946|NCT04078685|PROCEDURE|Contact Force-sensing-based catheter ablation|Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
40995947|NCT01869283|OTHER|Kinesiotherapy|
40995948|NCT01869283|OTHER|Ultrasound|
40995949|NCT01869283|OTHER|Diadynamic currents|
41469067|NCT00955552|DRUG|Glucosamine sulphate and chondroitin sulphate association|glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
40995950|NCT06316752|OTHER|Observational study|It is an observational study involving non-invasive routine examinations without treatment, thus posing no additional risk to patients. This project does not involve the use of medications, medical techniques, or the market status of medical equipment.
40995951|NCT00353405|BEHAVIORAL|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
40995952|NCT00353405|BEHAVIORAL|Mass media|Mass media provides messages that support sexual health skills.
40995953|NCT00353405|BEHAVIORAL|Control|Control group received no social skills training and no media mass media messages.
41469068|NCT00955552|DRUG|Cosamin DS® (Nutramax)|oral capsule of glucosamine hydrochloride 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
40995954|NCT03634787|DIAGNOSTIC_TEST|CT Scan Day 5-7|Computed Tomography on Day 5-7 according to a clinical protocol.
40995955|NCT01591473|DRUG|Poly I:Poly C12U 50 ug|Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
40995956|NCT01591473|DRUG|Poly I:Poly C12U 200 ug|Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
40995957|NCT01591473|DRUG|Poly I:Poly C12U 500 ug|Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
40995958|NCT01591473|DRUG|Poly I:Poly C12U 1250 ug|Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
40995959|NCT01591473|DRUG|Placebo|Placebo; 3 doses; nasal administration every 28 days
40995960|NCT01591473|DRUG|FluMist|FluMist 0.2 ml; 3 doses; nasal administration every 28 days
40995961|NCT03601754|DIAGNOSTIC_TEST|Treadmill/Bicycle exercise testing|"Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W"
40995962|NCT01976832|BEHAVIORAL|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
40995963|NCT01976832|BEHAVIORAL|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
40995964|NCT03883932|BEHAVIORAL|Fatherhood Focused FVEP (F3)|F3 is designed to focus specifically on the importance of fathering within a cognitive-behavioral intervention.
40995965|NCT03883932|BEHAVIORAL|Family Violence Education Program (FVEP)|FVEP is a court-mandated program intended to treat those arrested for intimate partner violence (IPV).
40995966|NCT00624533|BEHAVIORAL|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
40995967|NCT00624533|BEHAVIORAL|Conventional Physical Therapy in Primary Health Care|"Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks."
40995968|NCT00386412|DRUG|Valganciclovir|900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks
40995969|NCT03635710|DEVICE|The patient will undergo no intervention|Night coughs will be monitored using smartphone a app and interpreted using machine learning algorithm.
40995970|NCT03773731|BEHAVIORAL|High intensity interval training (HIIT)|Exercise training on bicycle ergometer with high intensity bouts of 1 min interspersed by low intensity recovery intervals
40995971|NCT03773731|BEHAVIORAL|Moderate intensity continuous training (MICT)|Exercise training on bicycle ergometer with moderate intensity (60 - 65 % of individual maximal power output)
40995972|NCT04445558|DIETARY_SUPPLEMENT|oral nutritional supplementation|Adjunction of oral nutritional supplementation
40995973|NCT04445558|DIETARY_SUPPLEMENT|intradialytic parenteral nutrition|Adjunction of intradialytic parenteral nutrition
40995974|NCT02090517|DEVICE|Pulsed Dye Laser|Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.
40995975|NCT02090517|DEVICE|Long Pulsed Alexandrite Laser|Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.
40995976|NCT02090517|DEVICE|Pulsed Dye Laser Plus Nd:YAG Laser|The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.
40995977|NCT02090517|PROCEDURE|Electrodesiccation|A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
41148849|NCT05517577|BEHAVIORAL|Behaviour Change Communication and Male involvement intervention|For the integration of the intervention, it is planned to deliver both service at the same time a by the same means to the women and the men. Pregnant women who fail to take one of the intevetion will not be considered as the participant who received integrated intervention. The intervention will be provided through Women Developmental army (WDA) leaders imparted through gatherings and home visits whereas the Broadcast will be used to strengthen and as a frequent remidinng of the conveyed messages.
41148850|NCT00801749|BEHAVIORAL|sleep|
41310112|NCT01743014|DRUG|Clopidogrel|12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
41148851|NCT04572425|OTHER|Guided imagery|10 minutes of guided imagery experience delivered on tablet
41148852|NCT04572425|OTHER|Virtual reality|10 minutes of virtual reality experience delivered by Facebook Oculus Go VR device
41310113|NCT00264602|DRUG|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
41310114|NCT04448808|DRUG|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
41310115|NCT04448808|DRUG|Placebo|Placebo of BX-1, oral solution
41310116|NCT00490763|BEHAVIORAL|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
41469069|NCT00612677|DRUG|Oxaliplatin|Dose Regimen: 120 mg/m\^2 on Days 1 every 21 days
41469070|NCT00612677|DRUG|Pemetrexed|Dose Regimen: 500 mg/m\^2 on Days 1 every 21 days
40995978|NCT05465265|BEHAVIORAL|Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)|Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
40995979|NCT04308317|DRUG|Tetrandrine|Tetrandrine 60mg QD for 1week
40995980|NCT05094219|OTHER|No intervention will be offered|No intervention will be offered
40995981|NCT04391387|PROCEDURE|prone position|a position with the patient lying face down with arms bent comfortably at the elbow and padded with the armboards positioned forward
40995982|NCT04797260|GENETIC|Gene therapy|Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).
40995983|NCT06111365|DEVICE|CHLOE|"the system will provide to the user a CHLOE™ score, which is a blastocyst development prediction value, a discrete grading for blastocyst associated with the likelihood of the embryo reaching the blastocyst stage at Day 5"
40995984|NCT05772936|BEHAVIORAL|Balance training|perturbation induce step training to improve reactive stepping with paretic leg.
40995985|NCT05403879|PROCEDURE|fixation of greater tuberosity fractures|deltopectoral approach for shoulder, then open reduction and fixation of displaced greater tuberosity fractures using hooked Kirshner wires
40791296|NCT01626781|OTHER|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
40995986|NCT04720196|DEVICE|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
40995987|NCT04720196|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
40995988|NCT00352521|DRUG|bevacizumab|
40995989|NCT00352521|DRUG|irinotecan|
40995990|NCT00352521|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
40995991|NCT01318031|DRUG|Period 1|Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
40995992|NCT01318031|DRUG|Period 2|Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
40995993|NCT06294418|DEVICE|Field Cycling Imaging (FCI)|FCI scan
40995994|NCT01301872|OTHER|check biomarker :RAGE|We will check RAGE for all patients who have ARDS included in our study
41310117|NCT01368159|DEVICE|Compression Stockings|"The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied."
41310118|NCT02321137|PROCEDURE|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
41310119|NCT02321137|PROCEDURE|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
41469071|NCT02608476|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
40995995|NCT03471533|DIETARY_SUPPLEMENT|nutraceutical: experimental product|84 days of consumption
40995996|NCT03471533|DIETARY_SUPPLEMENT|placebo|84 days of consumption
40995997|NCT06030882|OTHER|Biologic Care Pathway|Receiving care administered through a biologic care pathway.The central biologic intake nurse will touch base with the IBD program nurse navigator at preselected time points as per the pathway in order to coordinate the baseline pre- biologic work-up, clinical and biomarker assessments, and clinical assessments. Clinical management decisions will be informed by a combination of data points including clinical risk factors, TDM, fecal calprotectin concentrations, endoscopic and clinical disease activity indices as well as drug tolerance and adverse events. Within the care pathway, time- bound clinical and biomarker data will be provided to the treating clinician to help inform their clinical decisions.
40995998|NCT05453942|DRUG|SAR441566|Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
41469072|NCT02608476|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
41469073|NCT03296813|DRUG|Torsemide|Loop diuretic
41469074|NCT03296813|DRUG|Furosemide|Loop diuretic
41469075|NCT02666924|DIETARY_SUPPLEMENT|Chinese-canadian specific cooking classes|Series of four, four-hour cooking classes, occurring monthly for four months. Each of the cooking classes in the series will have diabetes self-management learning objectives: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.
40791297|NCT04698239|DEVICE|LASER MILESMAN 445 NM|Laser application
40791298|NCT01072136|OTHER|Placebo|Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
40791299|NCT01072136|DRUG|Azithromycin|Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
40791300|NCT01072136|DRUG|Cefixime|Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
40995999|NCT05453942|DRUG|Placebo|Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
41148853|NCT03939871|DRUG|fluvestrant + oral vinorelbine|Eligible patients will be treated with the fluvestrant + oral vinorelbine regimen until the disease progresses or intolerable toxicity
41148854|NCT00620230|DRUG|NVP-VAK694|
41148855|NCT00620230|DRUG|NVP-VAK694|
41148856|NCT06450275|DRUG|Dolutegravir 50 MG Film Coated Tablet|1 tablet of Dolutegravir 50mg film-coated tablets
41148857|NCT06450275|DRUG|Tivicay 50mg, film-coated tablets|1 tablet of Dolutegravir 50mg film-coated tablets
41148858|NCT04751019|DEVICE|Amber Glasses|It is hoped that the use of amber glasses to complement the natural sleep-wake by inducing a perceived 'physiological darkness' to aid the secretion of melatonin should help sleep and reduce the use of hypnotic medication
41148859|NCT01277302|DRUG|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
40791301|NCT03175731|DRUG|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
40791302|NCT03175731|DRUG|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
40791303|NCT00720577|DRUG|Simvastatin|40 Mg. tablet, 1 tablet daily
40996000|NCT01188603|DRUG|flibanserin 100 mg dose every evening|all subjects receive flibanserin
40996001|NCT02180282|DEVICE|M22-IPL|"The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm."
41148860|NCT00014235|DRUG|fludarabine phosphate|Given IV
41148861|NCT00014235|RADIATION|total-body irradiation|Undergo TBI
41148862|NCT00014235|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
41148863|NCT00014235|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo PBSCT
41148864|NCT00014235|DRUG|cyclosporine|Given PO or IV
41148865|NCT00014235|DRUG|mycophenolate mofetil|Given IV or PO
41148866|NCT00014235|OTHER|laboratory biomarker analysis|Correlative studies
40791304|NCT00720577|DRUG|Losartan|50 mg., tablets, 1 tablet once daily
40791305|NCT00720577|DRUG|Pioglitazone|30 mg, tablet, 1 tablet once daily
40791306|NCT01023152|PROCEDURE|Automated cuff-inflator|RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
40996002|NCT02006277|DRUG|Crizotinib prototype microsphere 0.529 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
41148867|NCT03650972|OTHER|Samarin|Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL \> 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
40791307|NCT04368377|DRUG|Tirofiban Injection|Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.
40791308|NCT04368377|DRUG|Clopidogrel|Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
40791309|NCT04368377|DRUG|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
40791310|NCT04368377|DRUG|Fondaparinux|Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
40791311|NCT05566938|OTHER|Tailored nutritional recommendations for each metabotype|Tailored nutritional recommendations for each metabotype detected (at the group level), that will be delivered through a mobile application. Moreover, each volunteer will recieve individualized nutritional recommendations.
41148868|NCT06547775|DRUG|KN069|Solution for SC injection
41148869|NCT05967793|OTHER|kinesio tape|Kinesio Tape will be applied on paraspinal trunk extensors muscles for 8 weeks, changed every 3 days.
41148870|NCT04428619|DEVICE|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial PENFS device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial PENFS device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
41310120|NCT03342391|OTHER|Transnasal esophagoscopy|single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE
41310121|NCT00986427|DRUG|Restasis (cyclosporine ophthalmic emulsion) 0.05%|cyclosporine ophthalmic emulsion 0.05%
41310122|NCT00986427|DRUG|Refresh® Dry Eye therapy|Emulsion contains glycerin 1% and polysorbate 80
41310123|NCT02808533|DRUG|Topiramate|Topiramate capsules starting with 25 mg b.i.d with an incremental increase of 25 mg b.i.d weekly upto a maximum of 100 mg b.i.d.
41310124|NCT02808533|OTHER|Placebo|Placebo capsules visually identical to those containing topiramate will be administered.
41310125|NCT02817152|PROCEDURE|Periodontal ultrasonic debridement|Periodontal pockets received periodontal ultrasonic debridement intervention.
41310126|NCT02817152|DEVICE|Debridement plus low-level laser therapy|Ultrasonic debridement plus low-level laser therapy.
40791312|NCT02663336|OTHER|Comparison ABPM with OBPM|No interventions
40791313|NCT04451200|DRUG|Busulfan Injection|injections doses will be personalized by PK at days -7 and -4
40996003|NCT02006277|DRUG|crizotinib prototype microsphere 0.470 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
40996004|NCT02006277|DRUG|crizotinib prototype microsphere 0.420 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
40996005|NCT02006277|DRUG|crizotinib oral solution|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
41310127|NCT06065267|DRUG|sequential|amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week
40996006|NCT02006277|DRUG|crizotinib prototype microsphere 0.529 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
40791314|NCT01122446|OTHER|Placebo comparator|"Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo."
40791315|NCT01122446|DRUG|Diamyd|"20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of Diamyd followed to children originally receiving Diamyd"
40996007|NCT02006277|DRUG|crizotinib prototype microsphere 0.470 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
40791316|NCT03938818|BEHAVIORAL|Tu'Washindi intervention|"The intervention includes the following components:~1. PrEP sensitization for men (community level). These activities will aim to provide men with basic information about PrEP and will be used to prepare men for more effective engagement in Buddy Days, described below.~2. Buddy Days (partner level). Buddy days will target male partner engagement by inviting couples to attend a community-wide event with health screenings, and PrEP sensitization, which aim to facilitate further communications about PrEP and increase men's support for AGYW's PrEP use.~3. Adherence support clubs (individual and peer levels). Support clubs will provide a forum for AGYW to discuss challenges and successes around PrEP use in relationships, including in the context of partner violence. Participation in these groups is hypothesized to increase self-efficacy for PrEP use by reducing social isolation and providing additional positive role-modeling from peer leaders."
40996008|NCT02006277|DRUG|crizotinib prototype microsphere 0.420 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
40996009|NCT02006277|DRUG|crizotinib capsule|Subjects will receive a single 250-mg oral dose of crizotinib.
40996010|NCT02006277|DRUG|crizotinib oral solution|Subjects will receive a single 250-mg oral dose of crizotinib.
40996011|NCT05834517|DRUG|Hyaluronic acid|Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts
41310128|NCT06065267|DRUG|Levofloxacin 500Mg Oral Tablet|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
41310129|NCT02854137|DRUG|BAY987521|10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
41310130|NCT02854137|DRUG|Control|10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
40996012|NCT05834517|PROCEDURE|non surgical periodontal therapy|NSPT, with or without adjunctive therapies, is an effective treatment for periodontitis. It reduces PD and results in formation of some new attachment; however, it also has several limitations, and surgical therapy might be required to control inflammation and optimize outcomes. When used for non-surgical scaling and root planing, periodontal curettes can reach a mean PD of up to approximately 5.5 mm. The mean PD in which a plaque-free and calculus-free surface can be established is \<4 mm
41148871|NCT04428619|DEVICE|Sham Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial sham device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial sham device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
41148872|NCT05791305|BEHAVIORAL|double duty intervention packages|The intervention employed in this study will serve as double-duty interventions. The WHO policy short report from 2017 and Hawkes et al2020 .'s were amended and used as the basis for the DDIs packages. The main components of the intervention packages are the promotion of a minimum level of dietary diversity, avoiding unwarranted harm from high-energy foods, and controlling market foods from the perspective of the consumer. The following central criteria will be used to evaluate the study's intervention packages.
41148873|NCT01975701|DRUG|BGJ398|Capsule for oral use.
41148874|NCT03209492|DRUG|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
41148875|NCT00022399|DRUG|celecoxib|400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
41148876|NCT00022399|DRUG|Placebos|Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
41148877|NCT01153997|DRUG|catridecacog|Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
41148878|NCT01153997|DRUG|placebo|Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
41148879|NCT01153997|DRUG|catridecacog|Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
41148880|NCT01153997|DRUG|placebo|Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
40996013|NCT05725512|DRUG|Prednisolone|Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks
40996014|NCT05725512|DRUG|Placebo|Placebo identical to prednisolone tablets
40996015|NCT05463185|OTHER|Stretching exercises|Stretching exercises along with manual lymphatic drainage
41148881|NCT00992030|DRUG|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
41310131|NCT05618496|DEVICE|Sodium Hyaluronate Lyophilizate|Device is placed directly onto the treated wound. The wound should be cleaned with antiseptic solution prior to the device administration. The device is fixed on the wound by secondary dressing: e.g. plaster, compression.
40996016|NCT05463185|OTHER|Soft tissue mobilization|Soft tissue mobilization along with manual lymphatic drainage
40996017|NCT00605046|DRUG|SPECT scan|AV151-01: Evaluation of \[123I\] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
40996018|NCT01722253|PROCEDURE|Electroacupuncture|Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
41310132|NCT02204241|DRUG|Carfilzomib|
40996019|NCT02307851|BIOLOGICAL|Quadrivalent VLP Vaccine|
40996020|NCT02307851|BIOLOGICAL|Comparator TIV|
41469076|NCT02666924|OTHER|Diabetes educational classes|Series of two, four-hour diabetes education classes, occurring weekly for two weeks. Each class is run by a registered dietitian and nurse, trained as clinical diabetes educators, as per standards of the canadian diabetes association. Classes include focused teaching of the background of diabetes, dietary recommendations for diabetes, lifestyle recommendations for diabetes, medications for diabetes, and general standard of living recommended for diabetes mellitus type 2.
40791317|NCT03938818|OTHER|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures, including attendance at routine Safe Space meetings and routine PrEP provision at the Safe Space, if applicable.
40996021|NCT02138903|OTHER|trans thoracic echocardiography|
40996022|NCT01154309|BEHAVIORAL|Group CBT for Depression and AOD Disorders|18 sessions of 2-hour group CBT
40996023|NCT00564655|PROCEDURE|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
41310133|NCT02204241|DRUG|Cyclophosphamide|
41310134|NCT02204241|DRUG|Dexamethasone|
41310135|NCT02238496|PROCEDURE|Cytoreductive surgery|Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
41310136|NCT02238496|DRUG|Perifosine|Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
41310137|NCT02238496|DRUG|Temsirolimus|Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
41310138|NCT05825651|OTHER|no interventions|This is an observational study without any intervention.
41310139|NCT04467177|OTHER|30% glucose|Male neonates will receive 2 ml of 30% glucose two minutes prior to circumcision
41469077|NCT05704673|DRUG|nalbuphine on N and V and pain with intrathecal morphine onInguinal hernia repair surgery. randomized, prospective, double blinded and placebo-controlled trial study.|investigate the effect of Iv nalbuphine on postoperative nausea and vomiting and pain with intrathecal morphine on inguinal hernia repair surgery.
40996024|NCT00564655|PROCEDURE|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
40996025|NCT03048396|PROCEDURE|Uterus transplantation|
40996026|NCT01249612|OTHER|Thermotherapy|Knee joint icing
40996027|NCT01249612|OTHER|Thermotherapy|Elbow joint icing
40996028|NCT04100707|PROCEDURE|Genicular block was applied|This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
40996029|NCT05775978|BEHAVIORAL|Más Presente, the UGRComp program|Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life.
40996030|NCT05775978|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
40996031|NCT05775978|BEHAVIORAL|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
40996032|NCT00275951|DRUG|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
40996033|NCT00002644|DRUG|Tamoxifen Citrate 20Mg Tab|Tamoxifen Citrate 20Mg Tab
40996034|NCT00002644|OTHER|Placebo|Placebo 20Mg Tab
40996035|NCT04936646|DEVICE|RepetitiveTranscranial Magnetic Stimulation (rTMS)|The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.
40996036|NCT02236429|BIOLOGICAL|vaginal flora transplant|
40996037|NCT04526483|DEVICE|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System
40996038|NCT01885546|DEVICE|AgaMatrix Blood Glucose Monitor|
40996039|NCT03145896|DIETARY_SUPPLEMENT|vitamin D|After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
40996040|NCT06338345|DIAGNOSTIC_TEST|Therapeutic drug monitoring of beta-lactam|During the 24 first hours after inclusion, 5 blood samples will be collected to mesure plasmatic concentrations of the studied beta-lactam, of creatinin and of albumin
40996041|NCT03979638|DRUG|BLU-5937|Four escalating doses of BLU-5937 administered BID over the course of the study
40996042|NCT03979638|DRUG|Placebo|Matching placebo for BLU-5937
40996043|NCT00665600|DRUG|Levalbuterol HCl|Levalbuterol 0.63 TID
40996044|NCT00665600|DRUG|Levalbuterol HCl|Levabuterol 1.25 mg TID
40996045|NCT00665600|DRUG|Albuterol Sulfate|Racemic albuterol 2.5 mg TID
40996046|NCT00665600|DRUG|Placebo|Placebo TID
40996047|NCT02063516|DEVICE|Guardian Laryngeal Mask|Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
40996048|NCT02063516|DEVICE|Proseal Laryngeal Mask Airway|Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
40996049|NCT04721912|DRUG|Probiotic dietary supplement|GBS positive patients, at ≥ 36 weeks gestation, will begin taking oral Florajen Digestion probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth.
40996050|NCT03373383|DRUG|Padsevonil|Padsevonil in different dosages.
40996051|NCT03373383|OTHER|Placebo|Placebo will be provided matching Padsevonil.
40996052|NCT04400279|BEHAVIORAL|Yoga group|At-home yoga exercise instruction provided by a mobile/tablet app or through a computer web browser
40996053|NCT04400279|BEHAVIORAL|High Intensity Interval Training group|At-home HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
40996054|NCT04400279|BEHAVIORAL|Combination|At-home yoga \& HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
41310140|NCT04467177|OTHER|Placebo|Male neonates will receive 2 ml of sterile water two minutes prior to circumcision
41310141|NCT02062528|DIETARY_SUPPLEMENT|omega-3 fatty acids|highly dosed in EPA
41148882|NCT00992030|RADIATION|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
41148883|NCT01894750|BEHAVIORAL|group-based skill building self-care program|
41148884|NCT03131271|OTHER|cold application|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
41148885|NCT00198666|DRUG|Zinc|Elemental Zinc
41148886|NCT06438549|BEHAVIORAL|HCP-CHW Integration into Prenatal Care for Smoking Cessation|CHWs will be integrated into primary care, and subjects will receive CHW home visits (up to 8) that will provide brief behavioral smoking cessation interventions before, during, and after a quit date. This brief behavioral intervention will include watching a video and reviewing self-help materials.
41148887|NCT06438549|OTHER|Control Arm|Standard of Care which provides referrals to community-based smoking cessation resources.
41148888|NCT02440698|BEHAVIORAL|Genetic test for personalized nutrition|
41148889|NCT04854096|DRUG|NS-018|Experimental
41148890|NCT04854096|DRUG|Best Available Therapy|Active Comparator
41148891|NCT04277273|OTHER|Questionnaire|Questionnaires WHOQOL-BREF and GOHAI
41148892|NCT00208832|PROCEDURE|Graphic medication schedule (Pill card)|
41148893|NCT00208832|PROCEDURE|Refill reminder postcard|
41148894|NCT06037057|OTHER|no intervention name|no intervention description
41148895|NCT05801068|DRUG|Factor Xa Inhibitor|Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
41148896|NCT05279417|DRUG|ATI-450 50 mg oral tablet BID|Oral, small molecule MK2 inhibitor
41148897|NCT05279417|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
40996055|NCT01832025|PROCEDURE|internal maxillary sinus floor elevation technique|The internal lift procedure uses a drilling instrument (a drill that cuts through bone) to break through the bone for where the implant will later go. This creates an opening in the necessary area to allow more bone material to be added, which will move the sinus up and allow for the implant to be securely placed.
41148898|NCT05279417|DRUG|Methotrexate|15 mg to 25 mg weekly
41148899|NCT05279417|DRUG|ATI-450 20 mg oral tablet BID|Oral, small molecule MK2 inhibitor
41148900|NCT00003245|DRUG|irinotecan hydrochloride|
41148901|NCT04156256|BIOLOGICAL|CD123-CD33 cCAR T cells|CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.
41148902|NCT04869046|DRUG|Instillation of levobupivacaine in surgical wound|Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
40996056|NCT01832025|PROCEDURE|external maxillary sinus floor elevation technique|The external lift procedure involves cutting through the upper-most part of the gums to then cut through the bone to create an opening in the necessary area. The sinus will be manually lifted and the bone material will be added, which will allow for the implant to be securely placed.
40996057|NCT05505513|DEVICE|percutaneous Utah Slanted Electrode Arrays (pUSEAs)|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations.
40996058|NCT03342976|OTHER|My-AHA platform|ICT strategy for early detection of frailties
40996059|NCT05552872|DIAGNOSTIC_TEST|mNGS, IDSeq UltraTM|pathogen detection
41148903|NCT03555708|OTHER|Physical Therapy|Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
41148904|NCT06509477|DEVICE|Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.)|Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
41148905|NCT06509477|DEVICE|Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)|Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
41148906|NCT02332096|DEVICE|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
41148907|NCT00158886|DRUG|Topotecan|Topotecan will be provided as capsules for oral administration and will be administered at least 3 hours before radiation therapy.
41148908|NCT00158886|RADIATION|Radiation therapy|For radiation therapy, subjects will receive 180 centigray (cGy) per fraction to a total dose of 4500 cGy to the pelvis using a 3 or 4 field technique and high energy photons (\>=6 megavolt \[mv\]).
41148909|NCT01090076|DIETARY_SUPPLEMENT|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)|Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
41148910|NCT05534269|BIOLOGICAL|autologous muscle precursor cells|Patients own Muscle Precursor Cells are isolated and injected into the rhabdomyosphincter
41310142|NCT02062528|DIETARY_SUPPLEMENT|placebo|
41310143|NCT04456517|DRUG|Ranolazine|500 mg tablet
41310144|NCT04456517|DRUG|Placebo|Ranolazine-matched placebo tablet
40791318|NCT05745649|OTHER|Resistance exercises|Resistance exercises
40791319|NCT05745649|OTHER|Ankle weights|Ankle weights
40791320|NCT04064476|DRUG|Paliperidone Palmitate|This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.
40791321|NCT04787731|DRUG|Bupivacaine Local Anesthetic|Long lasting local anesthetic administered to be compared to Lidocaine for quality of life outcomes in dental patients undergoing endodontic treatment
40791322|NCT05358743|OTHER|Probiotic group|Participants will use the probiotic product once daily (1 tablet/day) for 8 weeks
40791323|NCT05358743|OTHER|Placebo group|Patients will chew placebo products (blueberry tablets) once daily (1 tablet/day) for 8 weeks.
40791324|NCT00080574|PROCEDURE|Skin Biopsy|
40791325|NCT02887157|DEVICE|Swept Source OCT|The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
40996060|NCT02124863|DEVICE|Intrapulmonary Percussive Ventilation|20 min IPV freq 300/min, p 10cmH2O
40996061|NCT03034720|BEHAVIORAL|Collaborative Care|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
40996062|NCT05620576|DRUG|LY3857210|Administered orally
40996063|NCT05620576|DRUG|Placebo|Administered orally
40996064|NCT05756686|BEHAVIORAL|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
40996065|NCT05756686|BEHAVIORAL|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
40996066|NCT03811756|DIETARY_SUPPLEMENT|Test syrup containing CoQ10 and collagen|Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.
40996067|NCT03811756|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
40996068|NCT00868933|OTHER|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
40996069|NCT00868933|OTHER|simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
40996070|NCT04444609|OTHER|Blood tests sputum, nasal lavage and brushing|Venesection, sputum nasal lavage and brushing if appropriate
41148911|NCT04127747|DRUG|Standard dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day and on the 6th, 12th,18th and 24th month after that.
41310145|NCT01680419|BEHAVIORAL|Mission Reconnect|Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
40791326|NCT02887157|OTHER|Magnetic Resonance Imaging|Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
40791327|NCT02887157|OTHER|Scavenged blood collection|Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
40791328|NCT06295380|BEHAVIORAL|Virtual environment practiced on the Caren|The virtual environment practised on the Caren will make the scenario totally immersive and allow the subject to perform the motor task by recruiting muscles according to a motor coordination scheme different from the traditional one.
40791329|NCT06295380|BEHAVIORAL|Conventional physiotherapy|Conventional physiotherapy
40791330|NCT00291031|BEHAVIORAL|Imagery Rehearsal Therapy (IRT)|"Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.~IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments."
40791331|NCT02374125|DEVICE|Diacutaneous Fibrolysis|Applied only around teres major muscle.
40791332|NCT02374125|OTHER|Trigger Point Pressure Release|Applied only in teres major muscle trigger points.
40996071|NCT04620083|OTHER|Integrative Learning Program for Old People with Dementia|The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.
40996072|NCT01434524|DRUG|LIVACT|LIVACT contains 13.0 g of free amino acids
40996073|NCT05851105|BIOLOGICAL|α-globin restored autologous hematopoietic stem cells|α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C
40996074|NCT01381133|BEHAVIORAL|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
40996075|NCT01381133|BEHAVIORAL|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
40996076|NCT01381133|BEHAVIORAL|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
40996077|NCT00020696|DRUG|cisplatin|
40996078|NCT00020696|DRUG|tirapazamine|
40996079|NCT04709328|DRUG|SCTA01|Diluted by 0.9% normal saline，IV
40996080|NCT04709328|OTHER|Placebo|IV
40996081|NCT00002007|DRUG|Zidovudine|
40996082|NCT00002007|DRUG|Sargramostim|
40996083|NCT02418858|PROCEDURE|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery awake vs. asleep
40996084|NCT06497049|DRUG|GP40221|Solution for Subcutaneous Administration 1.34 mg/ml
40996085|NCT06497049|DRUG|ozempic|Solution for Subcutaneous Administration 1.34 mg/ml
40996086|NCT00272571|PROCEDURE|External counter pulsation therapy|
40996087|NCT02897674|DIETARY_SUPPLEMENT|Palm olein|two thirds of the 30% fat calories will come from palm olein
40996088|NCT02897674|DIETARY_SUPPLEMENT|Interesterified palm olein|two thirds of the 30% fat calories will come from interesterified palm olein
40996089|NCT02897674|DIETARY_SUPPLEMENT|soybean oil|two thirds of the 30% fat calories will come from soybean oil
40996090|NCT03581656|DEVICE|ChordArt System|The ChordArt System is intended for chordal replacement in mitral valve insufficiency due to leaflet prolapse or flail. One or more ChordArt System may be utilized within the same intervention for optimal mitral valve treatment.
40996091|NCT04860102|PROCEDURE|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
40996092|NCT05096416|DEVICE|The three-dimensional (3D) printed hemodialysis vascular model|The three-dimensional (3D) printed hemodialysis vascular model will be used as a guide map to cannulate the patients for hemodialysis and to minimize the risk of vascular access complications
40996093|NCT04052542|BEHAVIORAL|Traditional online continuing education|30-minute, online, interactive, educational video describing the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV
40791333|NCT02374125|OTHER|Protocolized physiotherapy|Exercises, TENS and cryotherapy
40996094|NCT04052542|BEHAVIORAL|Interprofessional education|One-time, 90-120-minute, in-person, interprofessional educational workshop consisting of a 30-minute didactic session and a 60-90-minute small group session
40791334|NCT05558488|OTHER|Meatless, restrictive ketogenic diet|"Each participant received a nutritional plan that was the same qualitatively but differed quantitatively - a 500 kcal reduction based on Estimated Energy Requirement (EER) was assumed. Before the start of the study, each participant obtained information about the basic principles of the ketogenic diet. Diet was designed to be isoproteic (1.8gxKg-1xbody weight-1xday-1) with three meals a day. The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 gxKg-1xbody weight-1xday-1(\~25-30%), fats (\~65-70%,with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (\<30gxday-1;\<10%).~The food lists encouraged the consumption of fish,raw and cooked vegetables, eggs,fruits with the lowest glycemic index (blueberry, raspberry), plant oils and fats from avocado,olives.Drinks permitted were tea, coffee without sugar and the foods and drinks to be avoided were alcohol,meat (any kind of meat),bread,pasta,rice,milk,dairy and potatoes."
40996095|NCT04052542|BEHAVIORAL|Just-in-time education|"Just-in-time, point-of-care education provided by trained advanced practice providers who will be on-hand in the study ICU, where they will deliver the education at the bedside during rounds when a patient meets criteria for preventive post-extubation NIV"
40996096|NCT03302988|OTHER|Everted closure|Suturing technique to obtain wound eversion. Type of suturing technique at surgeon's discretion
40996097|NCT03302988|OTHER|Planar closure|The planar side will be closed with traditional buried simple closure and running cuticular sutures
40996098|NCT03221595|DEVICE|Operative|This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
40996099|NCT04390581|DEVICE|Juvéderm® VOLIFT with Lidocaine|Consists of one injection of Juvéderm® VOLIFT with Lidocaine to both hands no more than 6ml for both hands total on Day 1. Optional on Day 30.
40996100|NCT02666183|BEHAVIORAL|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
40996101|NCT02666183|BEHAVIORAL|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
40996102|NCT02666183|BEHAVIORAL|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
40996103|NCT06378099|OTHER|Patient guided and followed by the pharmacist|"The Study Coordinating Group will train the pharmacy Staff regarding these protocols.~The training will include both pharmacological and non-pharmacological aspects of managing MA. In the pharmacological component, emphasis will be placed on the appropriate selection of OTC medications to address different MA, with special attention to identifying potential drug interactions, contraindications, and potential ADRs. Tools will also be provided to advise patients on the correct and safe use of these medications, and the criteria for referral to a physician.~The staff will be divided into three groups, and every group will have a minimum of two sessions, each one of 4 hours. Additionally, there will be a practical component where simulations of real situations will be conducted.~Throughout the 12-month follow-up and intervention period, one of the researchers will be available to receive phone calls to address doubts and concerns about the Pharmaceutical Indication Protocol."
40996104|NCT00625677|BIOLOGICAL|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
40996105|NCT00625677|BIOLOGICAL|Menjugate (Meningococcal C conjugate vaccine)|Dosage
40996106|NCT04287738|BEHAVIORAL|Navigated Care|Telephone-based collaborative dementia care was delivered by a trained care team navigator, who provided education, support and care coordination with a team of dementia specialists (advanced practice nurse, social worker, and pharmacist). For more details, please see references below.
40996107|NCT04426565|BEHAVIORAL|motivational enhancement interview|Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.
40996108|NCT04426565|BEHAVIORAL|the individual psychotherapy|It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.
40996109|NCT04426565|BEHAVIORAL|the group psychotherapy|Group psychotherapy is a key component of milieu therapy in a therapeutic community. The total environment or milieu is regarded as the medium of therapy, all interactions and activities regarded as potentially therapeutic and are subject to exploration and interpretation, and are explored in daily or weekly community meetings. A form of group therapy has been reported to be effective in psychotic adolescents and recovering addicts.
40996110|NCT04426565|BEHAVIORAL|the family therapy|"According to a 2004 French government study conducted by French Institute of Health and Medical Research, family and couples therapy was the second most effective therapy after Cognitive behavioral therapy. The study used meta-analysis of over a hundred secondary studies to find some level of effectiveness that was either proven or presumed to exist. Of the treatments studied, family therapy was presumed or proven effective at treating schizophrenia, bipolar disorder, anorexia and substance dependence."
40996111|NCT00952107|DEVICE|FLARE imaging system|Testing of operation of imaging system
40996112|NCT03725007|DRUG|Upadacitinib|Upadacitinib is administered as an oral solution or tablet as described in protocol.
40996113|NCT04707261|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10 mg once daily
40996114|NCT04707261|DRUG|Placebo|Participants will receive placebo 10 mg once daily
40996115|NCT00176592|DRUG|Betaseron|Betaseron 250 micrograms injected SQ every other day
40996116|NCT00176592|DRUG|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
40996117|NCT00222547|DRUG|Vitamin A|
40996118|NCT00222547|DRUG|Albendazole|
40996119|NCT04828889|DEVICE|Anal dilators|Anal sphincter training for relaxation
40996120|NCT04828889|PROCEDURE|lateral internal sphincterotomy|lateral internal sphincterotomy is a firmly established method for treating anal fissures.
40996121|NCT03057938|DRUG|18F-Florbetaben (FBB)|All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
40996122|NCT04624321|BEHAVIORAL|Health and lifestyle tool|Health and lifestyle tool used online
40996123|NCT04624321|OTHER|Usual care|Usual care at ordinary healthcare provider
41148912|NCT04127747|DRUG|Individualized dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day of admission. Patients will be followed-up every 3 months, and will receive one RTX 500mg treatment, if CD19 B cell count ≥ 1%, or dsDNA titer increased (dsDNA antibody positive, and increased more than 100% compared with the previous time), or complement C3 level decreased (lower than normal value, and decreased more than 50% compared with the previous time).
41148913|NCT01562288|GENETIC|DNA analysis|
41148914|NCT01562288|GENETIC|gene expression analysis|
41148915|NCT01562288|GENETIC|polymerase chain reaction|
41148916|NCT01562288|OTHER|enzyme-linked immunosorbent assay|
41148917|NCT01562288|OTHER|laboratory biomarker analysis|
41148918|NCT01094665|PROCEDURE|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
41148919|NCT05265247|DRUG|Esomeprazole 20 mg Delayed-Release Capsules|Esomeprazole 20 mg delayed-release capsules will be given as one capsule once daily as oral administration.
41148920|NCT05265247|DRUG|Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)|Esomeprazole 20 mg delayed-release capsules (Nexium 24HR) will be given as one capsule once daily as oral administration.
41148921|NCT00799188|DRUG|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
40996124|NCT02910167|DRUG|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
41148922|NCT03771573|OTHER|Physical exercise|Participants will perform physical exercises with constant, or intermittent professional supervision or will interrupt the exercise after ambulatorial physical therapy
41148923|NCT03771573|OTHER|monitoring|the patients will be under monitoring to investigate the evolution of the disease
40996125|NCT02910167|DRUG|Paracetamol|Paracetamol 500 mg
40996126|NCT02910167|DRUG|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
40996127|NCT02910167|DRUG|Paracetamol|Paracetamol 500 mg
40996128|NCT03495882|DRUG|AGEN1884 + AGEN2034|AGEN1884 + AGEN2034 according to protocol design
40996129|NCT02265055|PROCEDURE|transfer early cleavage embryos|transfer early cleavage embryos
40996130|NCT02265055|PROCEDURE|transfer non early cleavage embryo|
40996131|NCT01215370|OTHER|High-fat shake with Pea protein|Shake containing 95 gram of fat, additive 30 gram pea protein
40996132|NCT01215370|OTHER|High-fat shake with Pea protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
40996133|NCT01215370|OTHER|High-fat shake - Control|Shake containing 95 gram of fat, no protein additive
40996134|NCT01215370|OTHER|High-fat shake with Gluten protein|Shake containing 95 gram of fat, additive 30 gram gluten protein.
41148924|NCT01655199|DRUG|Combination ipratropium/salbutamol or placebo (nebulization)|For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
41148925|NCT01654289|OTHER|Mindfulness Meditation|"Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills."
41148926|NCT01654289|OTHER|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
41469078|NCT04986098|DEVICE|TurboHawk|Directly remove the diseased plaque in the blood vessel to increase the effective lumen in the blood vessel
40791335|NCT04306562|DIETARY_SUPPLEMENT|enteral nutrition supplement|enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day for at least 14 days from a preanesthetic clinic visit to a day of surgery.
40996135|NCT01215370|OTHER|High-fat shake with Gluten protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
40996136|NCT00484237|DRUG|etanercept|
40996137|NCT03027895|DEVICE|Lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage of WON with LAMS
40996138|NCT03027895|DEVICE|Double pigtail plastic stent (DPPS)|Endoscopic Ultrasound-guided Drainage of WON with DPPS
40996139|NCT00694967|PROCEDURE|McDonald cerclage placement|Transcervical McDonald cerclage placement
40996140|NCT00694967|DRUG|17 hydroxyprogesterone caproate|Weekly 250mg intramuscular injections
40996141|NCT06495918|DRUG|OTX-TKI|Intravitreal Injection of OTX-TKI
40996142|NCT06495918|DRUG|Aflibercept|Intravitreal Injection of 2mg of aflibercept
40996143|NCT06495918|DRUG|Aflibercept|Intravitreal Injection of 8mg of aflibercept
40996144|NCT05659628|COMBINATION_PRODUCT|CD19-7×19 CAR-T combined with Tislelizumab|Participants will receive 2×106/Kg CD19-7×19 CAR-T cells infusion and Tislelizumab 200mg every 21 days for 6 cycle on the 31st day after CAR-T infusion.
40996145|NCT00639834|BIOLOGICAL|MDX-1342|One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
40996146|NCT02265822|DRUG|melatonin in children premedication|
40996147|NCT02265822|DRUG|midazolam in children premedication|
41148927|NCT02379078|OTHER|Shared decision-making aid|The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.
41469079|NCT04986098|DRUG|Paclitaxel|Paclitaxel
41469080|NCT06402682|PROCEDURE|Right approach|Right approach of the management of esophageal atresia with a right aortic arch
40996148|NCT05839210|BEHAVIORAL|LIFE-L Mediterranean Diet|Mediterranean Diet will include goals of: 4+ vegetable servings (2-4 cups) daily, 2+ fruit servings (1.5-2 cups) daily, 2+ whole grain servings daily, 1+ legume serving daily, 1+ serving nuts and seeds daily, and seafood 2 times per week. Limit or avoid highly processed foods, sugar-sweetened beverages and foods, processed meats, red meat, and alcohol.
41148928|NCT02379078|OTHER|Generic hard copy diabetes resources|A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
41148929|NCT02379078|OTHER|Generic online diabetes resources|Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
41310146|NCT01680419|BEHAVIORAL|PREP|"The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others."
41310147|NCT03926559|DRUG|Morphine.|Pregnant patients with a perineal tear postpartum receive 2mg of morphine through their epidural. This will be a one time dose immediately postpartum.
41310148|NCT00064129|BIOLOGICAL|Ipilimumab|Given IV
41310149|NCT00064129|OTHER|Laboratory Biomarker Analysis|Correlative studies
41310150|NCT00064129|OTHER|Pharmacological Study|Correlative studies
41310151|NCT00064129|BIOLOGICAL|Sargramostim|Given SC
41310152|NCT00509496|DRUG|fludarabine phosphate|25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days.
40996149|NCT05839210|BEHAVIORAL|LIFE-L Home-Based Exercise Program|The Home-Based Exercise Program will include goals of: 150+ minutes moderate or 75+ minutes vigorous exercise per week, completed in sessions of at least 10-minute duration, including daily aerobic exercise plus two resistance-based exercise sessions per week.
40996150|NCT05839210|BEHAVIORAL|Supportive Materials|"Participants will receive an informational study notebook, an exercise reference poster and videos, a Fitbit, and three stretch bands of different intensities. Participants will also receive supportive and informational text messages or emails three (3) times per week during the study; participants can opt-out of these messages.~Participants will be requested to utilize the Fitbit app to track exercise sessions, as well as the MyFitnessPal app to track their diet. Support to set up apps will be provided by research staff. For participants who choose not to use the app, a laminated diet and exercise tracking sheet with dry erase marker will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to research staff each week."
40996151|NCT00784511|DIETARY_SUPPLEMENT|cholecalciferol|4000 IU/d
40791336|NCT06145971|BEHAVIORAL|brief Cognitive Behavioural Therapy for Insomnia (bCBTi)|Two sessions of Cognitive Behavioural Therapy for Insomnia, encompassing a cognitive therapy technique and a behavioural technique as a minimum.
40791337|NCT05334472|OTHER|Kesimpta|There was no treatment allocation. Patients administered Kesimpta by prescription that started before inclusion of the patient into the study were enrolled.
40791338|NCT00763256|DRUG|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
40791339|NCT00763256|DRUG|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
41148930|NCT01290471|DRUG|U3-1565|U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
41148931|NCT05442593|OTHER|Plyometric training|Participants will perform: 8 sets of 10 maximal countermovement jumps
40791340|NCT03467256|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|anti-CD19 chimeric antigen receptor - transduced T-cell given IV
40791341|NCT03467256|DRUG|Fludarabine|given IV
40791342|NCT03467256|DRUG|Cyclophosphamide|given IV
40791343|NCT03467256|DRUG|Tocilizumab|given IV
40791344|NCT03467256|DRUG|Cytarabine|given IV
40791345|NCT03467256|DRUG|Etoposide|given IV
40791346|NCT03467256|DRUG|Dexamethasone|given IV
40791347|NCT00237237|DRUG|vildagliptin|
40791348|NCT02539186|BIOLOGICAL|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
40791349|NCT02539186|DEVICE|splint|
40791350|NCT04280991|OTHER|Moderate intensity exercise under mild normobaric hypoxia and normoxia|The participant will perform the exercise interventions consisting of cycling at the heart rate corresponding with 50%WMAX (normoxia) or heart rate corresponding with 50% WMAX (hypoxia) for 30 minutes, twice a day, for 4 consecutive days. 24h glucose concentration will be monitored continuously.
40791351|NCT03291106|DIAGNOSTIC_TEST|immunohistochemical staining|immunohistochemical staining for MLH1, MSH2, MSH6 and PMS2
40791352|NCT03291106|DIAGNOSTIC_TEST|tests of microsatellite instability|microsatellite instability in tissues of endometrial cancer
40791353|NCT03291106|DIAGNOSTIC_TEST|clinical criteria of Lynch syndromes|Amsterdam I or II criteria and Bethesda criteria
40791354|NCT03291106|DIAGNOSTIC_TEST|sequencing for mismatch repair genes|next-generation sequencing, Sanger method or qPCR for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)
40791355|NCT03634111|PROCEDURE|TAP block|TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
40791356|NCT03634111|DRUG|Morphine|Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
40791357|NCT03634111|DRUG|Ropivacaine|Ropivacaine 0.25% 20 ml each side
40791358|NCT02988726|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
41148932|NCT02227888|DRUG|N91115|S nitrosoglutathione reductase inhibitor
41148933|NCT03276806|BEHAVIORAL|tobacco dependence/smoking cessation counseling|Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
41148934|NCT03276806|BEHAVIORAL|SDM|SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
41148935|NCT03276806|OTHER|Decision Aid|The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
40791359|NCT03717623|DRUG|Posaconazole pharmacokinetics|Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
40791360|NCT04677491|DRUG|Ospemifene 60 mg|Ospemifene vs placebo
40791361|NCT04677491|BEHAVIORAL|fMRI experiments|Participants will see sexually explicit video clips that alternate with non-sexual clips and neutral color projection and b) smell alternate pheromones with clear air and pine aroma.
40791362|NCT04715841|OTHER|gait assessment|gait assessment were done using 3DMA system
40996152|NCT00784511|OTHER|microcrystalline cellulose|1/d
40996153|NCT02436278|OTHER|4MGS|Usual walking speed measured over 4 metres
40996154|NCT01901003|DRUG|Lorazepam|
40996155|NCT01901003|OTHER|no premedication|
40996156|NCT01901003|DRUG|Placebo (microcrystalline celluloses)|
40996157|NCT04166838|BIOLOGICAL|CD19 UCARTcells|This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 \^ 6 cells/kg,3 × 10 \^ 6 cells/kg,5 × 10 \^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
40996158|NCT05211128|PROCEDURE|Robotic Surgery|Surgical procedure using robotic technologies.
41148936|NCT03276806|OTHER|LDCT brochure|A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
41148937|NCT01786915|DRUG|Bendavia 10mg|
41148938|NCT01786915|DRUG|Bendavia 50mg|
40791363|NCT05188638|DRUG|SoftOx Inhaled Solution (SIS)|SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).
40996159|NCT05211128|PROCEDURE|Open Surgery|Surgical procedure using a large, open cut in the skin.
40996160|NCT05211128|PROCEDURE|Laparoscopic Surgery|Surgical procedure using small incisions and trochars.
41148939|NCT01786915|DRUG|Placebo|
41148940|NCT02619045|OTHER|Telephone follow-up nursing device|"Telephone follow-up nursing device involving:~* telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),~* specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),~* actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);"
41148941|NCT05153161|DEVICE|Memesto|Edgewater plans to develop the next generation Memesto, a wearable device able to sense increasing agitation in ADRD sufferers and automatically deliver agitation-reducing personalized voice messages and music most effective at calming the individual based on past interventions. This innovative product will be the first wearable ADRD device to track agitation via body-worn sensors and automatically deploy agitation-reducing voice and music therapy without any caregiver interaction. The new system will use analytics to track the effectiveness of the various media and update the calming 'play list' over time.
41148942|NCT02854657|BEHAVIORAL|Skin Self- examination structured training|A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
40791364|NCT05188638|DRUG|Placebo|Sterile isotonic saline
40791365|NCT05771714|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
40791366|NCT01715389|OTHER|MyAsthma Patient Portal|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
40791367|NCT03317743|DRUG|NOV140101 (IDX-1197)|The dose levels will be escalated following a 3+3 dose escalation scheme.
40791368|NCT02903693|OTHER|cross sectional|
40791369|NCT02705612|DRUG|Cisplatin|
40791370|NCT02705612|RADIATION|External Beam Radiation Therapy|
40791371|NCT02705612|RADIATION|Internal Radiation Therapy|
40791372|NCT02705612|DRUG|nimotuzumab|
40996161|NCT06167395|DIETARY_SUPPLEMENT|Beta Alanine high dose|Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.
40996162|NCT06167395|DIETARY_SUPPLEMENT|Beta Alanine low dose|Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.
40996163|NCT06167395|DIETARY_SUPPLEMENT|Control product|Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.
40996164|NCT03646110|PROCEDURE|Minimally invasive esophagectomy|Minimally invasive esophagectomy is a surgical procedure for esophageal resection
40996165|NCT01297907|OTHER|Methacholine Challenge Test|Methacholine challenge test to evaluate airway hyperreactivity
40996166|NCT01297907|OTHER|Fractional Exhaled NO (FENO)|Fractional Exhaled NO to evaluate eosinophilic inflammation
40996167|NCT01297907|OTHER|Blood Test|Blood Tests (Eosinophil Count)
40996168|NCT01297907|OTHER|PCDAI|Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
40996169|NCT02894177|PROCEDURE|tcPCO2 measurement|tcPCO2 continuous monitoring during spontaneous breathing trials
40996170|NCT05777031|DRUG|Collagenase Clostridium Histolyticum (CCH)|Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
40996171|NCT04327999|DRUG|Artificial Tears|Self-Administered - utilizing eye drop preservative free vials
40996172|NCT05011864|BEHAVIORAL|Behavioral Activation|In BA, depressive symptoms are viewed as depressive behaviors. Compared to those without depression, people with depression engage in fewer overt behaviors that provide positive reinforcement and pleasure/enjoyment and in more behaviors that function to escape or avoid aversive stimuli (e.g., staying in bed all day).55-59 Thus, BA is aimed at increasing and reinforcing meaningful, healthy, and enjoyable behaviors while decreasing depressive behaviors and is well-suited to help depressed, disabled older adults increase mood-enhancing activities, self-care management skills, and social connectedness.
40996173|NCT05011864|BEHAVIORAL|Fall Prevention|Following FP psychoeducation based on the Centers for Disease Control and Prevention (CDC)'s STEADI tool kits, lay coaches will assist clients in implementing evidence-based FP strategies that have been adapted for low-income homebound seniors. These include referrals to healthcare providers as needed, home safety checks, practice of safe ambulation/transfer and mobility aid use, medication review, and in-home exercise routines with an innovative, gamified tablet-based exercise app for balance and strength building.
40996174|NCT05011864|OTHER|Telephone support|Subjects in this arm will receive 9 weekly support calls last 30 minutes each. These calls are intended to provide an opportunity for social support and check safety.
40996175|NCT04657133|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
40996176|NCT04657133|DEVICE|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric autocontrol device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (30 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
40996177|NCT04657133|DRUG|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
40996178|NCT00648596|DRUG|sildenafil|sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
40996179|NCT00648596|DRUG|placebo|placebo tablet by mouth 1 hour before sexual activity for 12 weeks
40996180|NCT01340157|DRUG|Fexinidazole|Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
40996181|NCT02013167|DRUG|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV).
40996182|NCT02013167|DRUG|Standard of Care Chemotherapy|"* FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients \> 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~* HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~* High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~* Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
40996183|NCT01599273|DRUG|subconjunctival triamcinolone injection|Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
40996184|NCT01643993|OTHER|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
40996185|NCT01643993|OTHER|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
40996186|NCT03526419|DRUG|Bupivacaine liposome|blood and milk samples will be obtained from those subjects after TAP block
40996187|NCT02921048|DIETARY_SUPPLEMENT|omega-3 fatty acids|
40996188|NCT00816725|BEHAVIORAL|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
40996189|NCT04640519|OTHER|Usual care|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
40996190|NCT04640519|OTHER|TASC intervention|TASC patients will receive a BP monitoring kit and electronic tablet with patient tailored BP infographics. They will be scheduled with 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
40996191|NCT00731887|PROCEDURE|Blood and urine testing|complete blood count, routine chemistries, liver function test, retinol binding protein, transferrin, prothrombin time, partial thromboplastin time, fibrinogen, Vitamin A and Zinc, Insulin Growth Factor levels and binding proteins, cytokines (interleukins 1, 6, 12), insulin, thyroid hormones, cortisol, 25-hydroxyvitamin D, and osteocalcin.
40996192|NCT02433236|DRUG|Fostamatinib Disodium tablet 100 mg|
40996193|NCT02433236|DRUG|Fostamatinib Disodium tablet 150 mg|
40996194|NCT02196792|DEVICE|E-Poly liner|E-Poly liner with a titanium cup
40996195|NCT02196792|DEVICE|ArComXL liner|ArComXL liner with a titanium cup
40996196|NCT02196792|DEVICE|32 mm femoral head|Stem with a 32 mm CoCr femoral head
40996197|NCT02196792|DEVICE|36 mm femoral head|Stem with a 36 mm CoCr femoral head
41148943|NCT00465699|DRUG|Topical B12 0.07%|
41148944|NCT02542293|BIOLOGICAL|Durvalumab +Tremelimumab|
41148945|NCT02542293|DRUG|Paclitaxel + carboplatin|Chemotherapy Agents
40791373|NCT04410965|DRUG|TERIFLUNOMIDE|Pharmaceutical form:tablet Route of administration: oral
40996198|NCT05044806|OTHER|Ultrasound-guided remote ischemic conditioning|Before conducting RIC, Doppler ultrasound was used to measure the total occlusion pressure (TOP) of brachial artery, which was then determined as the cuff inflation pressure during RIC. The RIC program encompasses four main components of (1) three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2) one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3) three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of RIC with 3 min intervals of reperfusion in between, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning.
41148946|NCT02542293|DRUG|Gemcitabine + cisplatin|Chemotherapy Agents
40791374|NCT00207220|PROCEDURE|arterial tonometry|used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.
40791375|NCT00207220|PROCEDURE|echocardiography|ultrasound test using sound waves to create a moving picture of the heart
40791376|NCT00537043|DRUG|SK&F-105517 (COREG CR FDC)|
41148947|NCT02542293|DRUG|Gemcitabine + carboplatin|Chemotherapy Agents
41148948|NCT02542293|DRUG|Pemetrexed + cisplatin|Chemotherapy Agent
41148949|NCT02542293|DRUG|Pemetrexed + carboplatin|Chemotherapy Agent
41310153|NCT00509496|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenous
41310154|NCT00509496|BIOLOGICAL|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
40791377|NCT02276742|BEHAVIORAL|Social Cognitive Theory|focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states
40791378|NCT02276742|OTHER|Monitoring|Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
40791379|NCT01405404|BEHAVIORAL|Parent Training and childcare discount|12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
40791380|NCT01405404|OTHER|Parent Training|12-session group on parenting skills and child behavior management
40996199|NCT05044806|OTHER|Traditional remote ischemic conditioning|The RIC program encompasses four main components of (1)three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2)one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3)three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of upper limb ischemia on the arm that is opposite to the PCI side with 3 min intervals of reperfusion in between delivered by an automated cuff inflation/deflation device, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
40996200|NCT05044806|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.
40996201|NCT00649675|DRUG|Meloxicam Tablets 15 mg|15mg, single dose fed
41469081|NCT06402682|PROCEDURE|Left approach|Left approach of the management of esophageal atresia with a right aortic arch
40791381|NCT04587037|PROCEDURE|fascia lata allograft|underwent superior capsule reconstruction using fascia lata allograft
40791382|NCT04587037|PROCEDURE|human dermal allograft|underwent superior capsule reconstruction using human dermal allograft
40791383|NCT01607125|DRUG|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
40791384|NCT01607125|DRUG|Placebo|capsules, orally, once daily for 13 to 14 days
40791385|NCT00848419|DRUG|Epidural administration of bolus|
40996202|NCT00649675|DRUG|Mobic® Tablets 15 mg|15mg, single dose fed
40791386|NCT04195490|PROCEDURE|feminizing genitoplasty|feminizing genitoplasty including vaginoplasty,clitroplasty, labioplasty and urethroplasty
40791387|NCT06438185|DEVICE|IRE System|Irreversible Electroporation (IRE) System for Inferior Turbinate Hypertrophy with Nasal Obstruction.
40791388|NCT04749147|OTHER|Black and White Printed Survey|This survey will feature black and white text and graphics.
40791389|NCT04749147|OTHER|Red Printed Survey|This survey will feature red text and graphics.
40791390|NCT03355248|OTHER|Oxycodone Acetaminophen|Decrease in opioid prescribing for post-operative cesarean pain management
40996203|NCT03594097|OTHER|Treatment cookies|Plain flour, Coconut Nourish, Queen Garnet Plum, Unsalted Butter, Artificial Sweetener
41469082|NCT06079255|DEVICE|IscAlert sensor(s) in patient with risk of acute compartment syndrome|of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)
40791391|NCT03157895|BEHAVIORAL|Connecting|Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
40791392|NCT03018158|DEVICE|denture wear.|MR Imaging was collected with or without denture wear.
40791393|NCT00761982|PROCEDURE|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
40791394|NCT02261207|DRUG|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
40791395|NCT01154335|DRUG|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
40996204|NCT03594097|OTHER|Control cookies|Plain flour, Coconut Powder, Unsalted Butter, Artificial Sweetener, Food Colour
40996205|NCT06284785|PROCEDURE|Bariatric surgery|Patients included in our obese patient group are all scheduled to undergo bariatric surgery
41469083|NCT04459130|BEHAVIORAL|Child Obesity Program|"The program consists of 10 sessions, each lasting 40 minutes. An EOP booklet containing session programs will be distributed to children.~The topics of the sessions are as follows:~Session 1: Healthy lifestyles~* Session 2: Self-esteem and positive thinking, Setting goals Session 3: Stress and Coping, Coping with Emotions in Healthy Ways Session 4: Personality and effective communication~* Session 5: Activity: Time for action Session 6: Nutrition basics Session 7: Reading tags Session 8: Portion size, nutrition and healthy food choices in schools Session 9: Snacks can also be healthy: Healthy choices~* Session 10: Together for a healthy life (Melnyk et al., 2006; 2007; 2009). Detailed information about the sessions is given in annex -3."
40791396|NCT01154335|DRUG|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
40791397|NCT04073901|OTHER|Endocrowns|Adhesive monoblock restoration for pulpotomized primary molars
40791398|NCT05384834|BEHAVIORAL|#HerHeart tool|An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
40791399|NCT06292377|DIAGNOSTIC_TEST|ECG|An electrocardiogram (ECG) is a simple, non-invasive test that records the electrical activity of the heart.
40791400|NCT06292377|DIAGNOSTIC_TEST|Transthoracic echography (TTE)|A transthoracic echocardiogram (TTE) is a test that uses ultrasound (sound waves) to create images of the heart.
40791401|NCT06292377|DIAGNOSTIC_TEST|Blood sampling|Blood sampling will include: complete blood count, serum creatinine and electrolytes, liver enzymes, fast lipid profile, glucose, HbA1C, thyroid-stimulating hormone (TSH), CRP, iron status, cardiac troponin (cTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP).
40791402|NCT03218774|BEHAVIORAL|Home Exercise Group|The Home group will meet with an exercise professional once and be given a home exercise program to complete 3 to 5 times per weeks at home.
40996206|NCT00165425|PROCEDURE|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
40791403|NCT03218774|BEHAVIORAL|Fitness Center Group|The Center group will be given an exercise program, a membership to a community fitness gym where they will be asked to exercise 3-5 times per week, and will be provided with 6 individual personal training sessions.
40791404|NCT01718899|BIOLOGICAL|PVX-410|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
40791405|NCT05086965|OTHER|Playing the virtual game simulation|The virtual game simulation developed by the researchers and designed by the researchers will be played on the computer for the students of the intervention group. Virtual game simulations are virtual games developed by researchers, specific to a clinical scenario, and prepared by transferring the videos taken with an action camera to the computer environment and displaying them in two dimensions.
40791406|NCT05359939|DIAGNOSTIC_TEST|18F-FDGal PET/CT versus 18F-choline PET/CT|Fifty patients with known HCC are investigated with two PET/CT-scans with 18F-FDGal and 18F-choline. In some of the cases one of the CT-scans will be altered to a contrast-enhanced MRI scan. A contrast-enhanced CT scan will be performed as part of the standard diagnostic work-up. We include patients with known HCC as the aim is to compare the diagnostic performance of the two tracers. Images will be analyzed for focal lesions and compared to other modalities by an experienced specialist in PET and an experienced radiologist.
40791407|NCT06468787|DEVICE|Kosmos Anatomical Object Labeling and View Identification Algorithms|Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers. Algorithm's performance on the view identification task and the object labeling task is compared to majority opinion of 5 radiologists.
40996207|NCT02208609|OTHER|Day 1: Maize Tortillas with 20% Amaranth|Subjects received Maize tortillas with 20% Amaranth added.
40996208|NCT02208609|OTHER|Day 2 Maize Tortillas without 20% Amaranth|Maize tortillas without Amaranth.
40996209|NCT04253288|OTHER|Morbidity Mortality Review (MMR)|"* Standardization of Morbidity Mortality Review (MMR) in radiotherapy centers~* National database from MMR board meetings which include clinical , radiation technique and biological parameters of intrinsic radiosensitivity of patients"
40791408|NCT02628444|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
41310155|NCT00509496|BIOLOGICAL|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|"Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes."
40791409|NCT02628444|BIOLOGICAL|Placebo (Sodium chloride 0.9%)|0.5 mL, Subcutaneous
40791410|NCT00003631|BIOLOGICAL|filgrastim|
40791411|NCT00003631|DRUG|carboplatin|
40791412|NCT00003631|DRUG|carmustine|
40791413|NCT00003631|DRUG|cyclophosphamide|
40791414|NCT00003631|DRUG|cytarabine|
40791415|NCT00003631|DRUG|etoposide|
40791416|NCT00003631|DRUG|ifosfamide|
40791417|NCT00003631|DRUG|melphalan|
40791418|NCT00003631|PROCEDURE|bone marrow ablation with stem cell support|
40791419|NCT00003631|PROCEDURE|peripheral blood stem cell transplantation|
40791420|NCT00003631|RADIATION|radiation therapy|
40791421|NCT03429738|DRUG|Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets|Experimental drug
40791422|NCT03429738|DRUG|RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets|Active Comparator
40791423|NCT01337193|OTHER|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
40791424|NCT01337193|OTHER|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
40791425|NCT00283946|DRUG|Zolpidem MR|Oral
40791426|NCT00283946|DRUG|Zolpidem|Oral
40791427|NCT01798888|PROCEDURE|Implantation of Deep Brain Stimulation|
40791428|NCT06004154|DIAGNOSTIC_TEST|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries added to the usual follow-up at 1, 3, 6 and 12 months
40996210|NCT01089439|DRUG|Nitric oxide by inhalation INOMAX|"Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours"
40996211|NCT01089439|DRUG|Placebo|placebo
40996212|NCT02803307|DRUG|TLC599|Single dose via intra-articular injection
40996213|NCT05410470|DRUG|Ruxolitinib|
40996214|NCT02311465|OTHER|Palliative Care|"Components of the palliative care service intervention are expected to include:~* Establishment of a palliative care plan~* Care coordination by palliative care team~* Informational, patient friendly materials supporting Palliative Care~* Communication by palliative care team to all providers and teams involved in patient's care~* Systematic collection of information, including identification of surrogate or health care proxy and advance care planning~* Questionnaires capturing health related quality of life at regular intervals throughout the intervention period"
40996215|NCT00003814|DRUG|eflornithine|
40996216|NCT04927936|BIOLOGICAL|Vaccination once with Janssen vaccine (only priming)|Vaccination (priming) with janssen vaccine. There is no boosting.
40996217|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Janssen vaccine.
40996218|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Moderna vaccine.
40996219|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Pfizer vaccine.
41310156|NCT00509496|BIOLOGICAL|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|"Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes."
41310157|NCT02523664|DRUG|Hydrocortisone|effects of hydrocortisone on memory while fMRI
41310158|NCT02523664|DRUG|Placebo|
41310159|NCT01656681|DIETARY_SUPPLEMENT|THIAA|A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day
40996220|NCT01740596|DEVICE|C-Pulse® System Counterpulsation|The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
40996221|NCT01028508|DRUG|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
40996222|NCT01028508|PROCEDURE|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
40996223|NCT05921019|DEVICE|laser acupuncture|This study will use the Handylaser Trion laser manufactured by RJ Laser, Germany.
40996224|NCT05921019|DEVICE|sham laser acupuncture|This study will use the sham Handylaser Trion laser manufactured by RJ Laser, Germany,and without any laser beam delivering
40996225|NCT00400647|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
40996226|NCT00400647|DRUG|Mycophenolate mofetil|
40996227|NCT02564614|DRUG|RO7070179|RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
40996228|NCT04344314|DEVICE|Peripheral Intravenous Catheter|Randomised controlled
40996229|NCT01565109|DRUG|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
40996230|NCT01565109|RADIATION|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
40996231|NCT01498952|DRUG|MEDI-573 (1 of 3 doses)|MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
40996232|NCT01498952|DRUG|Sorafenib|Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
40996233|NCT05203263|DEVICE|(810A-v1) device prototype|Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).
40996234|NCT05203263|DEVICE|(810B-v1) device prototype|Sequence with Serial Number (810-v1 141) to (810-v1 160). Application on brown spots located on the face (6 treatments during the study).
40996235|NCT05203263|DEVICE|(810C-v1) device prototype|Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
40996236|NCT03468881|OTHER|Communication Skills Training Package (KEW)|A training package (called KEW: Know, Encourage and Warm-up) for therapeutic radiographers to manage emotional talk with breast cancer patients in treatment.
40996237|NCT00880347|DEVICE|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
40996238|NCT05128851|PROCEDURE|HTO|Hight Tibial Osteotomy
40996239|NCT05128851|PROCEDURE|Arthroscopy treatment|Arthroscopy treatment
40996240|NCT05128851|PROCEDURE|Micro fractures|Micro fractures
41148950|NCT05319444|DEVICE|Off-brand Waterpik®|"Study staff will use the Waterpik® device and brush for approximately two to five minutes on the participant's scalp until all scale and other debris appears to be resolved. Their scalp will then be rinsed and gently dried with a towel.~The off-label design utilizes the Waterpik® device, but with adjustments optimized for scalp health. The device settings are adjustable during the treatment, ranging from settings of 2-10. Study staff plan to utilize the setting of 10 unless the participant indicates discomfort. Investigators attached a small Losophy brush in replacement of the Waterpik® toothbrush. The small Losophy brush was connected to the device via PVC heat shrink and a hole was drilled on the brush in order to deliver water while simultaneously utilizing the brush on the scalp."
41148951|NCT02305667|DEVICE|Macintosh|double lumen tube intubation using the Macintosh laryngoscope
41310160|NCT01656681|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
41310161|NCT03639883|DRUG|AIV001|Intradermal injection
40791429|NCT01738633|BEHAVIORAL|nutritional counseling|
40791430|NCT01738633|BEHAVIORAL|respirology counseling|
40996241|NCT00975533|DEVICE|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
40996242|NCT00975533|DRUG|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
40996243|NCT03606954|COMBINATION_PRODUCT|Combination topical corticosteroid|Comparison of a vasoconstriction index between the 2 study arms
40996244|NCT01306370|DRUG|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
40996245|NCT01306370|DRUG|Fibrin glue|Topical administration, before to close the surgical wound. Dosage: 2 mL.
40996246|NCT01306370|BIOLOGICAL|Fibrin glue|Topical administration, before to close the surgical wound.
40996247|NCT01306370|OTHER|Habitual haemostasis|The surgical habitual haemostasis.
40996248|NCT06404827|OTHER|Horseback riding simulator|Horseback riding simulator (HRS) will be applied in addition to routine Physiotherapy and Rehabilitation.
40996249|NCT06404827|OTHER|Routine Physiotherapy and Rehabilitation|Routine Physiotherapy and Rehabilitation within a spesific programme
40996250|NCT04667039|BIOLOGICAL|GNR-067|GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
40996251|NCT04667039|BIOLOGICAL|Lucentis®|Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
40996252|NCT02935465|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
40996253|NCT02935465|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
40996254|NCT03125434|OTHER|EOS full-spine, MRI, gait analysis|full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
40791431|NCT02487160|DEVICE|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
40791432|NCT02487160|DEVICE|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
40791433|NCT03977545|DIAGNOSTIC_TEST|Actigraphy|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
40791434|NCT00133341|DRUG|Goldnatriomthiosulphate, MDBGN, parthenolide|
40791435|NCT04530305|DRUG|Upadacitinib <15 MG [Rinvoq]|Patients with RA for who the introduction of upadacitinib has been decided will be proposed the study. If they accept, they will be followed for 6 months with 3 visits (baseline, 3 and 6 months) which is the usual standard care. In addition to routine markers, stool and blood will be collected at baseline and 3 months specifically for the study.
40791436|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
40791437|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
40791438|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
40791439|NCT02065349|DRUG|ASP8477|oral
40791440|NCT02065349|DRUG|Placebo|oral
40791441|NCT06059612|PROCEDURE|injection|steroid injection into superior cluneal nerve
40791442|NCT05679349|OTHER|Survey Administration|Complete survey
40791443|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
40791444|NCT05679349|OTHER|Survey Administration|Complete survey
40791445|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
40791446|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
41148952|NCT02305667|DEVICE|Glidescope®|double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction
41148953|NCT02305667|DEVICE|Airtraq®|double lumen tube intubation using the Airtraq® videolaryngoscope.
40996255|NCT04702477|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a well-documented approach to reduce participants' stress level \[19\], with the existing group-based peer support, self-empowerment, and lifestyle counseling intervention. MBSR is a type of meditation therapy with the goal of actively cultivating conscious attention and awareness to enhance health benefits. This included 10 hours of intervention with groups of 3-5 people.
41310162|NCT05105438|DIETARY_SUPPLEMENT|Consecutive Day Dosing|100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.
41469084|NCT02270216|PROCEDURE|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
40791447|NCT05679349|OTHER|Counseling|Undergo shared decision making counseling
40996256|NCT03221803|OTHER|OT Vertical attachment|new extra coronal castable attachment
40791448|NCT05679349|OTHER|Survey Administration|Complete survey
40791449|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
40791450|NCT00384215|DRUG|insulin glargine [rDNA origin] injection|
40791451|NCT05124717|DRUG|Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
40791452|NCT05124717|DRUG|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orallyn with 240 mL of water.
40791453|NCT05357768|OTHER|data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue|"Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution.~Treatment, outcome, and prognostic factors will be related with the molecular re-classification."
40996257|NCT03221803|OTHER|OT cap attachment|standard extra coronal attachment
40996258|NCT02533336|DRUG|abamectin and fenpyroximate|
41310163|NCT05105438|DIETARY_SUPPLEMENT|Alternate Day Dosing|100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.
41310164|NCT00666133|DEVICE|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
41310165|NCT04905537|OTHER|No intervention|It's only observational study. No interventions.
40791454|NCT00258908|BIOLOGICAL|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
40791455|NCT05812352|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application
40791456|NCT05812352|BEHAVIORAL|Instructional flashcard|Single page (instructional flashcard) with pictures corresponding to each of the 6 steps of tourniquet application
41469085|NCT02270216|PROCEDURE|cycling exercise|"The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7\*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes."
40791457|NCT05812352|BEHAVIORAL|In-person training|Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt
40791458|NCT01973010|OTHER|Massage|Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
40791459|NCT01973010|DRUG|Ibuprofen|Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
40996259|NCT05537571|DRUG|SLN360|SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
40996260|NCT05537571|DRUG|Placebo|Sodium chloride, solution for injection
40996261|NCT04884685|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
40996262|NCT04884685|BIOLOGICAL|Placebo|aluminium hydroxide solution only
40996263|NCT05767632|DRUG|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
40996264|NCT05767632|DRUG|Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test)|1 tablet Mirfenacin MR contains Solifenacine succinate 5 mg \& Mirabegron 50 mg orally administrated followed by 240 ml of water
40996265|NCT05767632|DRUG|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
40996266|NCT04220372|DRUG|Tongxinluo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
40996267|NCT04220372|DRUG|Placebo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
40996268|NCT03975907|BIOLOGICAL|CAR-BCMA T Cells|The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
40996269|NCT03025828|DRUG|ACTHar|for 6 months
40996270|NCT04013620|DRUG|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
40996271|NCT02117375|DEVICE|spinal cord MRI follow-up|Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio
40996272|NCT02117375|OTHER|clinical follow-up|Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty
40996273|NCT02117375|OTHER|brain MRI follow-up|
40996274|NCT01498640|BIOLOGICAL|Collagenase clostridium histolyticum|up to three 0.58 mg injections
41148954|NCT02305667|DEVICE|King Vision™|double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
40996275|NCT05602415|DRUG|Anlotinib|Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles). The dose could be reduced to 8-10 mg once daily for patients who had grade 3 or 4 treatment-related toxicities, or for patients with intolerable grade 2 toxicity, despite maximum supportive care measures. If dose reduction was necessary, then the dose of anlotinib was reduced to 10 mg once daily. If further dose reduction was necessary, the dosage was reduced to 8 mg once daily. If the dosage of 8 mg once daily was not tolerable, then the patient stopped receiving anlotinib.
41148955|NCT00003996|DRUG|carmustine|
40791460|NCT00465608|DRUG|propranolol|propranolol by mouth (per os)
40996276|NCT05602415|RADIATION|Radiotherapy|Postoperative radiotherapy would be performed. Postoperative intensity-modu¬lated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction). No boost dose would be added if the margin was negative, a boost dose of 10-16 Gy would be added if the margin was microscopically positive, and a boost dose of 16-18 would be added if the margin was gross positive.
40996277|NCT05602415|PROCEDURE|Surgery|Surgery
40996278|NCT00864747|DRUG|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
41148956|NCT00003996|DRUG|chemotherapy|
41148957|NCT00003996|DRUG|cisplatin|
41148958|NCT00003996|DRUG|etoposide|
41148959|NCT00003996|RADIATION|radiation therapy|
41148960|NCT06138522|BEHAVIORAL|Semi-structured interviews|Semi-structured interviews
41148961|NCT06138522|BEHAVIORAL|Child Post-Traumatic Stress Response Index (CPTS-RI) scale|Child Post-Traumatic Stress Response Index (CPTS-RI) scale
41148962|NCT06138522|BEHAVIORAL|- Therapeutic Alliance Questionnaire (HAQ-CP)|- Therapeutic Alliance Questionnaire (HAQ-CP)
41148963|NCT05980247|DEVICE|Thimble Application|Use of of thimble application to practice mindfulness before needle procedure.
41148964|NCT02286245|OTHER|focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board
41310166|NCT06014710|OTHER|Swallowing evaluation|"For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.~For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)"
41310167|NCT00407264|DRUG|Fluticasone propionate|
40996279|NCT00864747|DRUG|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
40996280|NCT00002052|DRUG|Ceftriaxone sodium|
40996281|NCT00002052|DRUG|Ampicillin sodium|
40996282|NCT00002052|DRUG|Amoxicillin trihydrate|
40996283|NCT03979794|BEHAVIORAL|Behavioral Intervention for Wellness and Engaged Living (Be-WEL)|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
40996284|NCT05017194|DRUG|Emodepside|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.
40996285|NCT02858219|DRUG|Botulinum Toxin Type A|
40996286|NCT02858219|OTHER|Saline solution|
40996287|NCT02858219|OTHER|Indexes|Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)
40996288|NCT05902039|OTHER|MRI|All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2\*-weighted gradient echo (T2\*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.
40996289|NCT04656132|BEHAVIORAL|Physical activity assessment, promotion and monitoring in a preventive cardiology clinic|physical activity assessment promotion and remote home step-count monitoring in a clinical cardiology center
41148965|NCT02286245|OTHER|Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
41148966|NCT00006428|DRUG|Amitriptyline|
41148967|NCT06149533|DRUG|Edoxaban|Edoxaban, an oral selective factor Xa inhibitor, had been approved by the National Medical Products Administration in 2018. It is used for the treatment and recurrence prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults.
41148968|NCT00959634|DRUG|ABT-126|Dose administered twice daily on Study Days 1-10
41148969|NCT00959634|DRUG|Placebo|Dose administered twice daily on Study Days 1-10
41310168|NCT01009788|DRUG|ABT-888|Capsules taken orally twice a day on days 1-7 of each 28 day cycle
41310169|NCT01009788|DRUG|temozolomide|capsules taken orally once a day on days 1 through 5 of a 28 day cycle
41148970|NCT03022747|DRUG|Allopurinol|Allopurinol is added to standard oral 6-mercaptopurine and methotrexate
41148971|NCT03022747|DRUG|Standard treatment|Oral 6-mercaptopurine and methotrexate
41148972|NCT03754686|DRUG|Oseltamivir|Best medical care and oral oseltamivir 75 mg twice daily for five days. Dose adjustments of oseltamivir will be made according to manufacturer's instructions.
40996290|NCT05777915|OTHER|Usability testing|Usability testing
40996291|NCT00850031|DEVICE|AcuFocus Corneal Inlay|Inlay implanted in cornea for improvement of near vision
40996292|NCT00244712|DRUG|emtricitabine/tenofovir|The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
40996293|NCT00244712|DRUG|abacavir/lamivudine|The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
41148973|NCT03754686|DRUG|Paracetamol|Best medical care and oral paracetamol twice daily for five days
41148974|NCT04081818|OTHER|Nutritious Mushrooms|The Intervention group will consume antioxidant rich and Vitamin D2-enhanced mushrooms as a snack daily for 3 months.
40996294|NCT03886558|OTHER|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months.|The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
40996295|NCT03961100|DRUG|Entrectinib 600 mg (T1)|Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets
40996296|NCT03961100|DRUG|Entrectinib 600 mg (T2)|Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets
40996297|NCT03961100|DRUG|Entrectinib 200 mg (R)|Reference formulation (R): entrectinib hard capsules
40996298|NCT03961100|DRUG|Entrectinib 200 mg (T)|Test formulation (T): entrectinib HPMC capsules
40996299|NCT03689166|DIETARY_SUPPLEMENT|Probiotic|Reduce preterm birth with this dietary supplement
40996300|NCT03689166|OTHER|Placebo|Placebo
40996301|NCT00278109|DRUG|cyclophosphamide|chemotherapy
40996302|NCT00278109|DRUG|Doxorubicin|doxorubicin
40996303|NCT00278109|RADIATION|radiation|radiation
40996304|NCT06315699|DRUG|Clemastine Fumarate Tablets|The dose was administered 2mg once daily in a double-blind random crossover method
40996305|NCT06315699|DIETARY_SUPPLEMENT|fructose|The dose was administered 2mg once daily in a double-blind random crossover method
40996306|NCT01720433|PROCEDURE|intervention|The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
40996307|NCT02478242|DRUG|Nafamostat mesilate|nafamostat mesilate use for anticoagulation
40996308|NCT02478242|DRUG|Normal saline|
40996309|NCT05952622|DEVICE|Continuous passive motion therapy|Patients will be supplied with a continuous passive motion device which will allow additional individual treatment of the affected shoulder for 6 weeks.
40996310|NCT04724954|DEVICE|Rehabilitation Therapy on Experimental Robotic Table and standard of care|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). They will also receive Standard of Care rehabilitation
40996311|NCT04724954|GENETIC|Rehabilitation Therapy as part of Standard of Care (Control)|Control group will receive Standard of Care training only
40996312|NCT02867709|DRUG|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
40996313|NCT02867709|DRUG|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
40996314|NCT00273572|OTHER|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
40996315|NCT00273572|OTHER|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
40791461|NCT02341651|OTHER|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
40996316|NCT01839552|DRUG|Fentanyl Citrate Nasal Spray (FCNS)|
41148975|NCT01064180|DRUG|Carvedilol|Carvedilol Tablets 25 mg
41148976|NCT03180788|PROCEDURE|Traction assisted ESD|A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD
40996317|NCT05071885|OTHER|games based exercise|Range of motion and strengthening exercises
40996318|NCT04695938|DIAGNOSTIC_TEST|MRI|MRI examination with Black Bone, and ultrashort/zero echo time MRI techniques
40996319|NCT00853554|DRUG|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
40996320|NCT00853554|DRUG|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
40996321|NCT03326011|DEVICE|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
40996322|NCT01157507|DRUG|Intravesical injection of Botulinum A Toxin|One treatment, 100 U vials diluted in 10 ml normal saline
40996323|NCT01157507|PROCEDURE|Bladder overdistension|Bladder overdistension
40996324|NCT01157507|DRUG|Placebo|One single injection of placebo
40996325|NCT02166983|OTHER|computer-assisted cognitive training|Complete Lumosity cognitive exercises
40996326|NCT02166983|OTHER|cognitive intervention|Complete Active Journaling cognitive exercises
40791462|NCT00257569|DRUG|Cetirizine Dry Syrup|
40996327|NCT02166983|PROCEDURE|mind-body intervention procedure|Complete relaxation exercises
40996328|NCT02166983|OTHER|memory intervention|Complete compensatory strategies
40996329|NCT02166983|OTHER|questionnaire administration|Ancillary studies
40996330|NCT02075944|BEHAVIORAL|High intensity aerobic exercise|
40996331|NCT02075944|BEHAVIORAL|Low intensity aerobic exercise|
41148977|NCT03180788|PROCEDURE|Traditional ESD|Endoscopic submucosa dissection
41310170|NCT00382980|BIOLOGICAL|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
41148979|NCT03529942|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
41148980|NCT00926978|RADIATION|Radioactive Iodine 124|"After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is \< 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
41148981|NCT00986661|DRUG|PV-10 (10% rose bengal disodium)|Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
41148982|NCT04826393|DRUG|ASP8374|every 3 weeks by intravenous infusion
41148983|NCT04826393|DRUG|cemiplimab|intravenous infusion
41148984|NCT04737889|DRUG|Rituximab|Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
41148985|NCT04737889|DRUG|Lenalidomide|"Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles."
41148986|NCT04737889|DRUG|Methotrexate|Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
41148987|NCT04737889|DRUG|Temozolomide|Induction Chemotherapy: 150mg/m2/d oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
41148988|NCT06029803|PROCEDURE|Adrenal Venous Sampling via Antecubital Approach|Patients assigned to the antecubital approach group (experimental group) will undergo AVS via antecubital approach.A 5F introducer sheath will be introduced into the antecubital vein. After heparinization,a diagnostic catheter with side holes will be introduced. Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
41148989|NCT06029803|PROCEDURE|Adrenal Venous Sampling via Femoral Approach|Patients assigned to the femoral approach group (active comparator group) will undergo AVS via femoral vein approach.The introducer sheath will be introduced into the femoral vein.Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
41148990|NCT02469493|DEVICE|acupuncture (Huatuo)|The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25\*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
41148991|NCT05250362|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|"MYELOABLATIVE CONDITIONING REGIMEN: Patients with myeloid malignancies receive busulfan on days -7 to -4, fludarabine IV over 1 hour on days -7 to -3, cytarabine IV over 4 hours on days -7 to -3. Patients with lymphoproliferative disorders receive busulfan on day -7 to -4, cladribine IV over 1 hour on days -7 to -3, gemcitabine IV over 4 hours on days -7 and -3.~TRANSPLANT: Patients undergo PBSC transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, cyclosporin IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO BID beginning on day 5 for 30 days.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28."
41148992|NCT01823926|OTHER|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
41469086|NCT02746419|DEVICE|Vessix|Renal denervation using radio-ablation
40791463|NCT04875494|BEHAVIORAL|Counseling/support group therapy|6 weeks of counseling group therapy; 2 sessions of 30 min each week, with a psychologist and two former victims
41148993|NCT01823926|DEVICE|Jet nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min."
41148994|NCT01823926|DEVICE|The vibrating mesh nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
41469087|NCT06616974|DRUG|TX000045- Dose A|The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks.
41469088|NCT06616974|DRUG|TX000045- Dose B|The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.
41469089|NCT06616974|DRUG|Placebo|The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.
40791464|NCT04875494|BEHAVIORAL|Physical Exercise|6 weeks of physical exercise training; 2 sessions of 30 min each week, with an instructor
40791465|NCT06059807|DEVICE|maxillary expansion|Maxillary Expansion Using Hyrax and Hybrid Hyrax Appliances
40791466|NCT04005495|BEHAVIORAL|Teaching kitchen program|The teaching kitchen program will include five 4-hour Saturday classes every other weekend over the course of 10 weeks (5 sessions totaling 20 hours of instruction). It will be taught by subject matter experts from the Emory University faculty and staff as well as potentially from the community. The classes will include the scientific rationale, practical applications, and recommendations for implementing self-care components into participants' daily lives. Experiential learning will include hands-on cooking demonstrations, mindfulness-based lunches, a yoga session, and a group exercise session. Rather than being prescriptive, the lectures and demonstrations are geared to inspire self-designed and personalized alterations in dietary patterns and behaviors that will match participants' culture, preferences, and health conditions. Biometrics and survey instruments will be assessed at 4 times: at baseline, after the 10-week program, and at 6 and 12 months after the program.
40791467|NCT04891913|DRUG|SY-007/ Placebo 15mg|15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
40791468|NCT04891913|DRUG|SY-007/ Placebo 30mg|30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
40791469|NCT04891913|DRUG|SY-007/ Placebo 60mg|60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
40791470|NCT06424821|DRUG|Cadonilimab|Cadonilimab + chemotherapy
40791471|NCT05117151|DIAGNOSTIC_TEST|hypotension prediction index|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
40791472|NCT00781638|DEVICE|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
40791473|NCT05007327|OTHER|Exposure to pollen and air pollution|For all subjects of the cohort, we will follow exposure to pollen and air pollution.
40791474|NCT06112470|OTHER|Interview|Semi-structured interview on experiences, perceptions, beliefs and knowledge of drug allergy and barriers to allergological testing, with a view to content analysis.
40791475|NCT04328896|OTHER|CGM-Tele-monitoring|"Baseline Visit-Visit 0~1. Obtain informed consent~2. Administer questionnaires~3. Measure A1C~4. Start study Dexcom CGM device (those already on CGM will change to the study device).~5. The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~1. 14 days worth of data will be downloaded from the patient's CGM device.~2. Systems will be checked to be sure they are functioning~3. Remote monitoring program will be activated.~4. Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~1. Administer questionnaires~2. Measure A1C.~3. Collect CGM data and compare to baseline~Testing and Assessments:~* Continuous glucose monitoring~* Tidepool cloud upload~* HbA1c~* T1D REDEEM diabetes distress questionnaire~* Hypoglycemia Fear Survey~* Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis"
40791476|NCT03369015|DRUG|10 mg d-amphetamine|10 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
40791477|NCT03369015|DRUG|20mg d-amphetamine|20 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
40791478|NCT03369015|DRUG|Placebo|Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
40791479|NCT05886153|DEVICE|Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Measurements recorded by the Vitaliti CVSM device will be compared to the recordings from various standardized comparator devices.
40791480|NCT05685420|DRUG|Herombopag|Thrombopoietin receptor agonist
40996332|NCT02945176|DEVICE|ARGOS-IO system|This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
40996333|NCT00851799|DRUG|Emtricitabine/tenofovir disoproxil fumarate|"200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC"
41310171|NCT00382980|BIOLOGICAL|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
40791481|NCT02081313|OTHER|Biopsy|
40996334|NCT00851799|DRUG|Ritonavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
40996335|NCT00851799|DRUG|Atazanavir|"300 mg taken orally once daily. A protease inhibitor (PI).~Other Name: ATV"
40996336|NCT00851799|DRUG|Raltegravir|"400 mg taken orally twice daily. An integrase inhibitor (INI).~Other Name: RAL"
40996337|NCT00851799|DRUG|Darunavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
40996338|NCT06256042|PROCEDURE|Occlusal splint|a stabilizing maxillary acrylic occlusal splint was made, flat, total and adjusted in central relation (RC).
40996339|NCT06256042|PROCEDURE|Arthrocentesis|The patient then underwent arthrocentesis of the temporomandibular joint itself, following the Nitzan technique.
41148995|NCT02020200|DRUG|MPH|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight\<40 kg; 30 mg in case weight\>90 kg; otherwise 20 mg.
41148996|NCT02020200|DRUG|Placebo|
41148997|NCT04371029|OTHER|PSG|Polysomnography at 3 times, actimetry measure and Pittsburgh questionnaire
41148998|NCT05020886|BEHAVIORAL|turning task|Several trials included bilateral turning in 30, 60, 90, 120, 150, 180 degree.
41148999|NCT00278395|DRUG|Vorinostat|Given orally
41149000|NCT04533334|PROCEDURE|FOB measurement|A FOB will be inserted after anesthesia induction and the distances will be measured by direct observation via the bronchoscope.
41149001|NCT03395197|DRUG|Talazoparib with enzalutamide|Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
41149002|NCT03395197|DRUG|Placebo with enzalutamide|Placebo plus enzalutamide 160 mg/day
41469090|NCT05539716|DEVICE|PAP Therapy|Auto-PAP device (ResMed AirsenseTM Autoset) with a heated humidifier will be provided along with an appropriate mask and connecting hose for nightly use
41469091|NCT05539716|BEHAVIORAL|Lifestyle Counseling Intervention|Lifestyle intervention will include counseling on (a) education on nutrition and exercise; and (b) behavioral support for identifying lifestyle change strategies and problem-solving barriers to improve the regularity and duration of sleep. This will be conducted using brochures on weight loss and sleep hygiene
41469092|NCT01510860|DRUG|UDCA (Ursodeoxycholic acid)|250 mg
40996340|NCT05678556|BEHAVIORAL|all2GETHER|all2GETHER is an HIV prevention and relationship education program designed for young MSM and other individuals who have sex, date, and are in relationships with MSM. all2GEHTER consists of 3 online didactic skills modules that include videos, activities, and other self-paced education components and 2 videoconference-based skills coaching sessions The 3 online modules focus on developmental skills related to sexual health and relationship functioning, including HIV and STI prevention in couples, effective communication skills, coping skills for LGBTQ and relationship stress, problem-solving and acceptance. Individualized couple sessions led by facilitators focus on implementation of skills specific to the needs of each couple.
41469093|NCT01510860|DRUG|UDCA (Ursodeoxycholic acid)|500 mg
41469094|NCT01961687|DEVICE|Resorbable Mesh|Phasix Mesh
41310172|NCT00382980|DRUG|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
41469095|NCT00779220|DRUG|placebo|Intravenous repeating dose
41469096|NCT00779220|DRUG|methotrexate|Oral repeating dose
41469097|NCT00779220|DRUG|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
41469098|NCT00779220|DRUG|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
41469099|NCT00779220|DRUG|ocrelizumab 500mg|Intravenous repeating dose (500mg)
41469100|NCT05193773|OTHER|multifactorial interventions|The experimental group underwent multifactorial interventions to reduce physical restraint, including developing routines for physical restraint, promoting institutional policies to reduce the use of physical restraint, developing alternative methods, education, and consultations.
41469101|NCT02696941|DRUG|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
41469102|NCT02696941|DRUG|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
41149003|NCT01670942|OTHER|hypobaric chamber|We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
41149004|NCT04839289|DEVICE|Receiver-in-canal hearing instrument; Manufacturer A|Commercially available receiver-in-canal hearing instrument from manufacturer A
41149005|NCT04839289|DEVICE|Receiver-in-canal hearing instrument; Manufacturer B|Commercially available receiver-in-canal hearing instrument from manufacturer B
40996341|NCT00044954|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41310173|NCT06206278|DRUG|Infigratinib|Infigratinib is a selective ATP-competitive inhibitor of fibroblast growth factor receptor (FGFR) 1-3 that inhibits FGFR downstream signaling and proliferation in human cancer cell lines with FGFR genetic alterations, significantly inhibiting the growth of several types of cancers driven by FGFR amplification, fusion and mutation.
41469103|NCT02589886|OTHER|Education and self-help internet intervention|The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
41469104|NCT04541901|OTHER|Massage|12 minutes of effleurage and petrissage on the upper limbs
41469105|NCT04541901|OTHER|Cold water immersion|12 minutes of cold water immersion at the shoulder level with water temperature between 11 to 15°C
40791482|NCT02081313|OTHER|Blood sample|
40791483|NCT00104390|BIOLOGICAL|Grass MATA MPL|
40996342|NCT00044954|DRUG|cyclosporine|
40996343|NCT00044954|DRUG|fludarabine phosphate|
40996344|NCT00044954|DRUG|mycophenolate mofetil|
41469106|NCT04689893|DRUG|68Ga-Dotatate|68Ga-Dotatate was injected into the patients before the PET/CT scans
40996345|NCT00044954|PROCEDURE|allogeneic bone marrow transplantation|
40996346|NCT00044954|PROCEDURE|peripheral blood stem cell transplantation|
41149006|NCT01884376|DEVICE|Neuromaix|
41469107|NCT04689893|DRUG|68Ga-DOTA-JR11|68Ga-DOTA-JR11 was injected into the patients before the PET/CT scans
41469108|NCT01254461|DRUG|AZD1981|100 mg per oral, twice daily for 8 days
41469109|NCT01254461|DRUG|AZD1981|4x100 mg per oral, twice daily for 8 days
41469110|NCT01254461|DRUG|pravastatin|40 mg, once daily at Day 1, period A and Day 8, period B
41469111|NCT00996437|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
41469112|NCT00996437|DRUG|Saline|Saline injection of 0.5mg at baseline, 4 and 8 weeks
41469113|NCT00982501|DRUG|WS® 1442 900 mg/d|
41469114|NCT00982501|DRUG|WS® 1442 1800 mg/d|
41469115|NCT00982501|BEHAVIORAL|Nordic walking training 2 x 30 min/week|
41469116|NCT00982501|BEHAVIORAL|Nordic walking training 4x45 min/week|
41469117|NCT05909969|OTHER|Pelvi-Fit app Training|This group will receive Pelvic Floor Muscle Strengthening exercises through software application.
41469118|NCT05909969|OTHER|Control|This group will receive Pelvic Floor Muscle Strengthening exercises through instructions and pamphlets describing exercises.
41149007|NCT03985228|DIETARY_SUPPLEMENT|Fortified milk|Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.
40996347|NCT00044954|RADIATION|radiation therapy|
41149008|NCT03985228|DIETARY_SUPPLEMENT|Placebo milk|"Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a."
40996348|NCT05719012|BIOLOGICAL|UC-MSCs|Intravenous injection three times with one-month interval
40996349|NCT03732885|DEVICE|densah burs osseo densification drills|maxillary sinus floor elevation during implant placement using Densah burs
40996350|NCT03732885|DEVICE|Summer's Osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
40996351|NCT03462238|PROCEDURE|Blood collection for Ppi assay|A 4.5 ml blood sample will be taken with a citrate vacuum tube.
40996352|NCT03462238|RADIATION|CT Scan|A scanner will be performed
40996353|NCT00908960|DRUG|Enoxaparin|
40996354|NCT00267722|DRUG|Visilizumab|
40996355|NCT02319031|DRUG|Daclatasvir|
40996356|NCT02319031|DRUG|Sofosbuvir|
40996357|NCT02319031|DRUG|Ribavirin|
40996358|NCT04110483|PROCEDURE|Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a circumferential incision around the tumor is made in the visually intact bladder mucosa (approximately 10 mm from the edges of the tumor). It allows for accurate morphological evaluation of the surgical margin. After that, the incision is continued deeper into the muscular layer. Having identified the layer, the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers. Making incisions in the muscular layer requires precision, a full bladder and adequate guidance with visualization techniques. Traction may be employed with the help of the tip of the resectoscope or working element. After complete tumor resection, local hemostasis was performed.
40996359|NCT04110483|PROCEDURE|Transurethral resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a step-by-step resection of a tumor is done. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
40996360|NCT04566419|DEVICE|HFNC - Airvo 2|high flow nasal cannulae delivering 60 l/min
41149009|NCT05182671|OTHER|Scales and measurements for bladder and bowel dysfunction, pelvic angle, proximal hip strength, femoral hip anteversion|"Assessments Children whose physical examination has been completed and diagnosed with BBD will be evaluated with following assessments.~Demographic Data Form Questionnaire Forms Dysfunctional Voiding and Incontinence Scoring System Bladder Diary Bowel Diary EMG-uroflowmetry Ultrasonography~Post Voiding Residual Measurement:~Bladder wall thickness~Pelvic Floor Muscle Activation Measurement:~Pelvic Floor Muscle Strength Assessment:~Hip agonist-antagonist muscle ratios Pelvic angle measurement Femoral anteversiyon angle measurement~Femoral internal and external rotation angle:"
41310174|NCT03213613|BEHAVIORAL|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
41310175|NCT03213613|BEHAVIORAL|Active Control|Participants in the expectancy-matched active control group will play a visuo-spatial iPad game, in which players use their finger to move an object to different successive square platforms. Expectancy matching to the adaptive attention training was pre-confirmed in 121 participants (18-20 years of age), using targeted surveys on MTurk about their expectations of either training exposure on our specific outcome measures. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
41149010|NCT01040299|DEVICE|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
40996361|NCT04566419|OTHER|Oxygen|oxygen delivered by Venturi mask
40996362|NCT04546347|RADIATION|[14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|Dose of \[14C\]AZD9833 Solution for Infusion
40996363|NCT04546347|DRUG|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet A Dose 1
40996364|NCT04546347|DRUG|AZD9833 Oral Solution|AZD9833 Oral Solution
40996365|NCT04546347|DRUG|AZD9833 film-coated tablet B Dose 1|AZD9833 film-coated tablet B Dose 1
40996366|NCT04546347|DRUG|AZD9833 film-coated tablet A Dose 2|Dose 1 of AZD9833 film-coated tablet A Dose 2
40996367|NCT04546347|DRUG|AZD9833 film-coated tablet B Dose 2|Dose 1 of film-coated tablet B Dose 2
40996368|NCT00174915|DRUG|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
40996369|NCT00174915|DRUG|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
40996370|NCT00174915|DRUG|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
41149011|NCT01040299|DEVICE|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
41149012|NCT01040299|OTHER|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
41149013|NCT00579475|DRUG|Mifegyne|tablets, 50 mg every other day
41149014|NCT00579475|DRUG|placebo|
41149015|NCT04163835|DRUG|Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 5g + Wenxin Granules placebo 5g."
41149016|NCT04163835|DRUG|1/2 Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g."
41149017|NCT04163835|DRUG|Twice Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g."
41149018|NCT04163835|DRUG|Placebo|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g."
41149019|NCT03713229|DIAGNOSTIC_TEST|Screening for anal squamous intraepithelial lesions|digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy
41149020|NCT06000371|DEVICE|Vacuum assisted Closure application|Vacuum assisted Closure Application in Diabetic Foot Ulcers
41149021|NCT06177938|DIETARY_SUPPLEMENT|Lactose solution/Glucose solution|Single ingestion of a lactose/glucose solution.
41149022|NCT03994185|DEVICE|Placement of WRAPSODY stent graft|Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
41149023|NCT00035919|GENETIC|Mx-dnG1 Retroviral Vector|
41149024|NCT04183803|PROCEDURE|anatomic anterior cruciate ligament (ACL) reconstruction|The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
41149025|NCT01774929|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
41149026|NCT00420498|DRUG|Atomoxetine (Strattera™)|
40996371|NCT00174915|DRUG|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine \>1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
40996372|NCT00174915|DRUG|Placebo|Placebo, orally, once daily for up to 28 weeks.
41149027|NCT06367244|BEHAVIORAL|Transplant Wellness Program - Kidney and Liver|The exercise prescription for the intervention will be multimodal, , will follow current chronic disease exercise guidelines, and will be tailored to meet the unique needs of each participant. . All participants will receive two 30-45-minute individual session with a CEP during their first week and two additional sessions during the second week if needed. The individual sessions will be followed by group sessions. Each participant will get a total of 24 individual and group sessions combined. These sessions can be conducted either in-person or online, based on participant preference and TWP logistics. For aerobic-based activities, a moderate rate of perceived exertion of 4-6 on a scale of 0-10 will be used. Resistance exercise will begin with functional movements and bodyweight exercises targeting major muscle groups with modifications for beginners and exercise progressions when deemed. Balance and flexibility training activities will also be included.
41149028|NCT04969900|OTHER|Placebo oil|The placebo group will receive placebo oil.
41149029|NCT04969900|OTHER|Lavender oil.|Investigational Product. This group will receive Lavender oil.
40996373|NCT05216874|DEVICE|Oclusal Splint|"Cl III Laterognati volunteer group using occlusal stabilization splint before orthognathic surgery~-Splint will be used for at least two months"
41149030|NCT03590067|OTHER|Questionnaire|The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian
41149031|NCT02967822|GENETIC|Biological samples for patients|Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
41310176|NCT03213613|BEHAVIORAL|Low-dose Adaptive Attention Training|Participants in the low-dose training group will play a reduced number of sessions as the Adaptive Attention Training group. Specifically, they will train for two 30-minute sessions at the start and middle of a six-week period. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
41310177|NCT00621855|DRUG|placebo|matched placebo
40996374|NCT00145873|DRUG|nesiritide, continuous infusion|
40996375|NCT00353743|DRUG|placebo|placebo
40996376|NCT00353743|DRUG|doxycycline plus metronidazole|doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
40996377|NCT05092009|OTHER|Tissue and blood|Tissue and blood will be derived from patient during a standard of care procedure
40996378|NCT04608500|DRUG|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
41149032|NCT02967822|GENETIC|Biological samples for healthy relatives|Blood samples.
41149033|NCT05395078|OTHER|Conventional physical therapy treatment along with thoracic extension exercises|"Thoracic Extension Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic spine extension and trunk muscle flexibility. A specialized program of thoracic extension in sitting, in prone lying, in quadruped position, on foam roller, wall angle stretch, corner stretch + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks.~Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week."
41310178|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
41310179|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
41310180|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
40996379|NCT04608500|DRUG|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
40996380|NCT01023581|DRUG|Alogliptin|Alogliptin tablets.
40996381|NCT01023581|DRUG|Metformin|Metformin capsules
40996382|NCT01023581|DRUG|Alogliptin Placebo|Alogliptin placebo-matching tablets.
40996383|NCT01023581|DRUG|Metformin Placebo|Metformin placebo-matching capsules.
40996384|NCT00877695|BEHAVIORAL|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
40996385|NCT05462028|DEVICE|Vibration training|The vibration sessions were performed and supervised by a stroke care experienced registered nurses/researchers who had both nurse and physiotherapist license. The wearable leg vibration training with vibration frequency = 30 Hz, vibration amplitude = 1 mm in the WG was applied by the wearable leg vibration device (Myovolt, New Zealand) which fits comfortably around the knee and hamstring or calf and delivers focal vibration treatment. While the lower-extremity weight bearing vibration training with vibration frequency = 20 Hz, vibration amplitude = 3 mm in the LG was applied the Cozy Fit (HY-806, China) vibration device with vertical direction, which participants stand with both feet upright on the vibrator in a seated position.
40996386|NCT05462028|BEHAVIORAL|ergometer exercise|ergometer exercise training
41149034|NCT05395078|OTHER|Conventional physical therapy treatment along with thoracic stabilization exercises|Thoracic Stabilization Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic musculature, static and dynamic thoracic posture. A specialized program of Draw- in and chin tucks in crook lying, prone, sitting and standing, prone chin- tuck elevation exercises with arm at sides, arms behind head or overhead (4) + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week.
41149035|NCT02371278|DIETARY_SUPPLEMENT|Leucine|5 g leucine with sucrose and maltodextrin
41149036|NCT02371278|DIETARY_SUPPLEMENT|Placebo|5 g glycine with sucrose and maltodextrin
41149037|NCT05557253|DRUG|Remimazolam|Anesthesia induction: remimazolam 6-12 mg/kg/h Anesthesia maintenance: remimazolam 1-2 mg/kg/h
40996387|NCT00291668|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
41149038|NCT05557253|DRUG|Balanced Anesthesia|Anesthesia induction: propofol 1.5-2 mg/kg Anesthesia maintenance: Desflurane 6-8 vol%
40996388|NCT00291668|OTHER|Placebo|"* Active Substance: isotonic sodium chloride solution~* Pharmaceutical Form: Solution for injection~* Concentration: 1 mL~* Route of Administration: Subcutaneous use"
40996389|NCT05518968|BEHAVIORAL|Acceptance and commitment therapy|8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
41149039|NCT04608357|DIAGNOSTIC_TEST|Needle Core Biopsies|Not an interventional study
41149040|NCT00084409|DRUG|iloprost|Given orally
41149041|NCT00084409|OTHER|placebo|Given orally
40996390|NCT04910009|OTHER|Four sessions of practical privacy education|Two sessions of theoretical, four sessions of practical privacy education
40996391|NCT00392431|DRUG|amiodarone|
40996392|NCT05174910|DEVICE|Obsidian ASG|Application of an autologous platelet-rich fibrin matrix
40996393|NCT02038595|RADIATION|PET imaging|
40996394|NCT03738943|DRUG|Adenosine Triphosphate|See arm/group descriptions
40996395|NCT03738943|DRUG|Acetylcholine|See arm/group descriptions
41149042|NCT02261922|DRUG|ticagrelor|
41310181|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
41310182|NCT03760848|DRUG|Aramchol|Aramchol 600 mg
40996396|NCT03738943|DRUG|Sodium Nitroprusside|See arm/group descriptions
40996397|NCT03738943|DRUG|Adenosine Diphosphate|See arm/group descriptions
40996398|NCT03738943|DRUG|Adenosine Monophosphate|See arm/group descriptions
40996399|NCT03738943|DRUG|Uridine Triphosphate|See arm/group descriptions
40996400|NCT03738943|DRUG|Adenosine|See arm/group descriptions
40996401|NCT03738943|DRUG|Vitamin B 6|See arm/group descriptions
40996402|NCT03738943|DRUG|Pyridoxal 5'-Phosphate|See arm/group descriptions
41149043|NCT02261922|DRUG|prasugrel|
41149044|NCT01072071|DRUG|furosemide|"Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.~Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h."
41149045|NCT05197504|DRUG|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
41310183|NCT03760848|DRUG|Midazolam|Midazolam 2 mg
41310184|NCT03760848|DRUG|Atorvastatin|atorvastatin 40 mg
40791484|NCT06513000|DIAGNOSTIC_TEST|Dry eye diagnostic system|"following tests:~1. Non-invasive tear film break up time (TBUT), a parameter of tear film stability.~2. Non-invasive tear meniscus height.~3. Evaluation of Meibomian glands function.~4. Lipid layer thickness.~5. Eyelid margin.~6. Analysis of conjunctival hyperemia.~7. Cornea sodium fluorescein staining.~8. Schirmer I test"
40791485|NCT05525039|DEVICE|Low-magnitude High-frequency Vibration|0.3g, 35Hz, 20mins/day, at least 3 times/week
40996403|NCT01650662|DRUG|Cyclosporine A|In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
40791486|NCT05525039|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB) supplement|Oral nutritional HMB supplement at 3g/day
40791487|NCT05525039|DIETARY_SUPPLEMENT|Protein supplement|Daily protein supplement intake
40791488|NCT03335150|BEHAVIORAL|CogSMART-PD|Cognitive Rehabilitation for persons with PD-MCI
40791489|NCT03335150|BEHAVIORAL|Supportive Care|Support Group for persons with PD-MCI
40791490|NCT02445014|DEVICE|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
40791491|NCT04227327|DRUG|Abemaciclib|Abemaciclib will be administered orally at 150 mg twice daily
40791492|NCT04227327|DRUG|Aromatase Inhibitors|Letrozole 2,5 mg daily or Anastrozole 1 mg daily
40791493|NCT01534286|DRUG|Theramine|Theramine 2 capsules 3 times per day
40791494|NCT01534286|DRUG|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
40996404|NCT02599181|OTHER|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke \& Mayr, Zurich, Switzerland.
40996405|NCT04874974|BEHAVIORAL|Metacognitive and Defusion Training|Module I will give a brief introduction into the rational of the therapy and explain the terms cognitive biases and relational responding and their role in the development of psychological problems (psychosis) in a simple language and with the help of examples and small exercises. The principle of metacognition and cognitive defusion in psychotherapy will be made clear. An outlook on the procedures and the goals of the group therapy will be given. Module II will include interventions adapted from the MCT manual (Moritz et al., 2017) and Module III with consist of defusion strategies taken from the ACT group manual (Dambacher et al., 2020) and existing studies on ACT and psychosis (Bach et al., 2013; Gaudiano \& Herbert, 2006).
40996406|NCT03168464|DRUG|Ipilimumab|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
40996407|NCT03168464|DRUG|Nivolumab|On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
40996408|NCT03168464|RADIATION|Radiation therapy|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study.
40996409|NCT01267396|DRUG|Sertraline|Sertraline Hydrochloride Tablets 100 mg
40996410|NCT01743287|DRUG|Imotun capsule|Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
40996411|NCT01743287|DRUG|Imotun capsule placebo|Imotun capsule placebo: per oral, a capsule a day during 24 weeks
40996412|NCT01318096|DRUG|raltegravir and tenofovir and lamivudine|raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks
40996413|NCT01318096|DRUG|efavirenz+tenofovir+lamivudine|efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
41310185|NCT04829019|RADIATION|Osimertinib and whole-brain irradiation|Osimertinib at a dose of 80 mg once per day, and WBI
41310186|NCT04829019|DRUG|Osimertinib|Osimertinib at a dose of 80 mg once per day, until unacceptable adverse events or disease progression occurred. WBI could be given to patients in experimental arm at any time base on investigator's decision after treatment initiated.
41310187|NCT04705324|PROCEDURE|Operative Hysteroscopy|Separation of the non-viable gestational sac from the uterine wall will through operative hysteroscopy
41310188|NCT04705324|PROCEDURE|D&C|Separation of the non-viable gestational sac from the uterine wall through dilation and curettage
41310189|NCT04705324|PROCEDURE|Operative Hysteroscopy - safety and feasibility|Operative hysteroscopy - safety and feasibility phase
40791495|NCT00429871|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
40791496|NCT00429871|DRUG|Capecitabine|Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
40791497|NCT00429871|DRUG|Epirubicin|Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
40791498|NCT00429871|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
40791499|NCT04734158|OTHER|corneal imaging|corneal imaging using AS-OCT
40791500|NCT05742412|DEVICE|Video streaming (smartphone camera)|Adding video streaming as a technical adjunct to the otherwise audio-based-only communication during emergency medical dispatch
40791501|NCT05742412|DEVICE|Telephone (telephone microphone)|Usual care: Audio-based-only communication using telephone during emergency medical dispatch
40791502|NCT01133665|DRUG|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
40791503|NCT01775072|GENETIC|molecular profiling of tumors|"Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational next-generation profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, \& others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection \& research biopsies."
41149046|NCT04400214|BEHAVIORAL|Food Allergy Superheroes Training (FAST) Program|The primary aim of the FAST intervention is to 1) increase the young child's understanding of food allergies (FA) and 2) promote-adherence to FA safety guidelines through active skills training. We will achieve this aim through the use of educational materials (session 1) and a developmentally-tailored skills training intervention (session 2-5). Core components embedded within each skill straining session include instructions, modeling, rehearsal, and reinforcement/corrective feedback. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials (i.e., educational content, skills training components) are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session.
41149047|NCT04400214|OTHER|Food Allergy Knowledge Intervention|"The primary aim of the FAK intervention is to increase the young child's understanding of FAs including prevalence, symptoms, and management strategies among other topics. We will achieve this aim through the use of educational materials targeting knowledge acquisition through a variety of didactic materials made freely available through the Food Allergy Research Education (FARE) website (www.foodallergy.org). More specifically, we will employ information embedded within the Food Allergy 101 segment of the FARE website. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session. All FAK sessions will occur within the child's home and will include informational handouts relevant to the day's session."
40996414|NCT03669120|OTHER|Informational Intervention|Receive advice to quit smoking and materials to promote smoking cessation
40791504|NCT01775072|GENETIC|Clinical Germline Analysis|"Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the ACMG list).~Part D: Germline Profiling for Individuals at Elevated Cancer Risk"
40791505|NCT00495235|BEHAVIORAL|Questionnaire|Questionnaire taking about 20 minutes to complete.
40791506|NCT02065492|DRUG|Standard Chelation|This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
40791507|NCT02065492|DRUG|Amlodipine|doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
40791508|NCT04062084|DEVICE|Multifunctional Cataract-assisted Retractor|Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens
40791509|NCT06513390|DEVICE|Exoskeleton of default mode|Default mode: A standard control system offering a conventional assistive function of Exo-H3.
40996415|NCT03669120|BEHAVIORAL|Telephone-Based Intervention|Receive individualized text based messages
40996416|NCT03893136|BIOLOGICAL|Tocilizumab|The scramble TA group is given bioagents such as IL-6R antibody, CD20-antibody, TNF-alpha antibody, and other bioagents which are safe to use in human to treat other refractory diseases. The sham group is given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
40996417|NCT03893136|DRUG|Leflunomide|The scramble TA group is given new molecules such as Leflunomide, Iguratimod, and other molecules which are safe to use in human to treat other refractory diseases. The sham group is also given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
40996418|NCT06031974|BEHAVIORAL|DISCO Intervention|optimal medical management in accordance with European Society of Cardiology recommendations + dietary intervention based on Dietary Approaches to Stop Hypertension (DASH diet) + strict monitoring of eating and lifestyle behaviors
40996419|NCT04105998|DRUG|Oxytocin|Oxytocin 10 IU
41149048|NCT00119314|DRUG|capecitabine|
41149049|NCT00119314|DRUG|docetaxel|
40996420|NCT04105998|DRUG|Placebo|Placebo
40996421|NCT06482008|DRUG|Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib|HAIC every 3 weeks until 6 treatments have been completed, or HAIC therapy is terminated if patients have not reached 6 treatments and experience intolerable adverse effects; adebrelimab, fixed dose 1200 mg, IV, D1, every 21 days (Q3W), in combination with apatinib, 250 mg (0.25 g), orally, once daily (QD), consecutively dosing in 3-week (21-day) treatment cycles. Study treatment will continue until the subject develops an intolerable toxic reaction, withdraws informed consent, and progresses according to RECIST v1.1 as confirmed by the investigator (after the subject develops disease progression as defined by RECIST v1.1, if the investigator assesses that the subject is still clinically beneficial and can tolerate the study treatment, the subject may continue to receive the study drug; if it is considered that the subject no longer has clinical benefit, then treatment may be terminated), or other termination criteria specified in the protocol, whichever occurs first.
40996422|NCT04400903|DEVICE|Activity Monitor|Undergo HRV monitoring via WHOOP device
40996423|NCT04400903|OTHER|Quality-of-Life Assessment|Ancillary studies
40996424|NCT04400903|OTHER|Questionnaire Administration|Complete questionnaires
40996425|NCT02128191|DRUG|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
40996426|NCT02128191|DRUG|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
40791510|NCT06513390|DEVICE|Exoskeleton of Intelligent mode|Intelligent mode: The adaptive CPG-based control system developed by our researchers from Exo-H3.
40996427|NCT03843879|PROCEDURE|Transversus Abdominis Plane Block|Single-injection transversus abdominis plane block with 30 mL of 0.25% Bupivacaine with 1:400,000 epinephrine
40996428|NCT03843879|DRUG|Intravenous Lidocaine|Continuous intravenous lidocaine infusion
41469119|NCT01518335|PROCEDURE|Platelet rich plasma injection|50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
41469120|NCT01518335|PROCEDURE|Placebo Comparator: Placebo/Standard of Care|50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
41469121|NCT05435976|DEVICE|CELLIS Dental (Porcine Acellular Dermal Matrix, PADM)|Biological membranes used in dental surgery
41469122|NCT06269354|DEVICE|3D printed prostheses|3D printed prostheses
41469123|NCT05348837|PROCEDURE|Deep brain stimulation|Candidacy for DBS implantation will be determined by the treating team, which includes a neurologist, neurosurgeon, neuropsychologist, neuro-radiologist, and palliative care physician.
40996429|NCT03448315|DEVICE|tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
40996430|NCT00113659|DIETARY_SUPPLEMENT|Probiotic|Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
40996431|NCT00113659|DIETARY_SUPPLEMENT|Placebo|Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
40996432|NCT05402995|DRUG|Irrisept (Irrigation Solution)|Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms from wounds.
40996433|NCT05402995|DRUG|Saline|Saline irrigation
40996434|NCT04985812|DRUG|JNJ-67484703|Participants will receive JNJ-67484703.
40996435|NCT04985812|DRUG|Placebo|Participants will receive placebo to JNJ-67484703.
40996436|NCT06219460|OTHER|Ventilation using two types of face masks|ventilation using two types of face mask
41469124|NCT03102151|OTHER|Community Campaign La CLAVE|A community campaign to teach community residents and professional networks the signs and symptoms of psychosis using social media, community talks, and advertising.
40996437|NCT03044405|DIAGNOSTIC_TEST|Fluid challenge|Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
40996438|NCT03044405|DIAGNOSTIC_TEST|Focused transthoracic echocardiography|Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
40996439|NCT03143699|OTHER|Immediate Feedback|Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
40996440|NCT05450471|DRUG|Corticosteroid Topical|The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.
40996441|NCT05450471|OTHER|Placebo|Placebo
40996442|NCT01025427|DRUG|Raltegravir, tenofovir/emtricitabine|16 controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
40996443|NCT01485211|DRUG|cross-linking with hypo-osmolar riboflavin|Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
40996444|NCT01124643|BIOLOGICAL|Replagal|0.2 mg/kg administered intravenously \[IV\] every other week
41469125|NCT02607137|BEHAVIORAL|Health Education|Information on healthy living style in relation to physical activity
41469126|NCT03257215|DRUG|Stoss vitamin D|A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
41469127|NCT03257215|DRUG|Daily vitamin D|Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
41469128|NCT03257215|DRUG|Stoss placebo|A single 1.5 mL dose administered on Day 1
41469129|NCT03257215|DRUG|Daily placebo|A once daily 0.2 mL dose administered from Day 1 to 90
40996445|NCT02220270|DEVICE|ASD and PDA closure|
40996446|NCT01060033|DEVICE|MR Spectroscopy|
40996447|NCT01060033|DEVICE|Fat-Saturation and Diffusion-Weighted Imaging|
40996448|NCT01060033|DEVICE|Dynamic Contrast Enhancement MRI (MR-DCE)|
40996449|NCT01060033|DEVICE|Diffusion Tensor Imaging (DTI)|
40996450|NCT03741036|PROCEDURE|Autogenous bone graft as space filling in immidiate implant placment|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with autogenous bone graft)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
41149050|NCT00119314|DRUG|gemcitabine hydrochloride|
41469130|NCT06421142|PROCEDURE|imaging examinations:FAPI PET/MRI, FDG PET/MRI, MRI|"FAPI PET/MRI and FDG PET/MRI examination Data acquisition was performed using a GE Healthcare SIGNA PET/MR instrument. Enrolled patients were injected intravenously with 68Ga-FAPI or 18F-FDG tracer and underwent simultaneous PET and MRI scanning approximately 30-60 minutes after intravenous administration of the tracer at a dose of 1.85-3.7 MBq/kg.~MRI examination MRI examination was performed using a Skyra 3.0T MRI scanner from Siemens, Germany, with a 16-channel phased-array surface coil, and the scanning range was from the superior margin of the iliac wing to the inferior margin of the pubic symphysis."
40996451|NCT03741036|PROCEDURE|Deprotinized bovien as space filling in immidate implant placement|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with deprotinized bovien material)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
40996452|NCT03741036|PROCEDURE|Nano-hydroxiapatite alloplast in immidiate implant placement|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with nano-hydroxiapatite alloplast material )~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
40996453|NCT06131008|DIAGNOSTIC_TEST|Diastology|We will follow American Society of Echocardiography criteria to determine the degree of diastolic dysfunction after performing each focused echocardiogram.
40996454|NCT06131008|BEHAVIORAL|Diastology-Guided Diuresis|If the daily urine output or weight loss are less than study-specified targets, then the research team will recommend changes to the diuretic regimen based on the degree of diastolic dysfunction.
40996455|NCT06131008|BEHAVIORAL|Usual Care|Clinicians will rely on usual care metrics and parameters to guide diuresis.
40996456|NCT01726738|DRUG|BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
40996457|NCT04164979|DRUG|Cabozantinib|Given PO
40996458|NCT04164979|DRUG|Pembrolizumab|Given IV
40996459|NCT01678417|DRUG|131I-rituximab|
40996460|NCT01531387|DRUG|Hydroxyurea|Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
40996461|NCT04227106|BIOLOGICAL|EB-101|autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7
40996462|NCT02578784|DEVICE|Angioplasty with drug-coated balloon|"Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)"
40996463|NCT02578784|DEVICE|Angioplasty with plain old balloon|"Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)"
40996464|NCT00982813|OTHER|Periodontal screening|"Periodontal screening in all patients giving birth between 24 and 37 gestational weeks.~Bacteriological sampling in the periodontal pocketing. Search for specific cytokines in the periodontal pocketing. Professional prophylaxis and oral hygiene instruction."
40996465|NCT04196946|DRUG|25 mcg fentanyl|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
40996466|NCT04196946|DRUG|250 mcg alfentanil|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group II received 10 mg hyperbaric bupivacaine (2 cc) and 250 mcg alfentanil (0.5 cc) intrathecally.
40996467|NCT02250196|DRUG|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
41149051|NCT00119314|PROCEDURE|positron emission tomography|
41469131|NCT01443689|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus hUCMSCs transplantation.
41469132|NCT01443689|BIOLOGICAL|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
41469133|NCT01443689|DRUG|Conventional therapy|Participants will be given conventional therapy only.
40996468|NCT02250196|DRUG|SPMC 2|received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
41149052|NCT06585332|OTHER|Assessment of respiratory paramenters (Maximal inspiratory pressure, maximal expiratory pressure, and voluntary peak cough flow))|"The voluntary peak cough flow is measured using a pneumotachograph (BTL cardiopoint Spiro, BTL industries), which meets the recommendations of the American Thoracic Society and the European Respiratory Society for range and accuracy in forced expiratory maneuvers.~Maximal expiratory and inspiratory pressures assessments were performed using a flanged rubber mouthpiece connected to a pressure manometer (Micro RPM, Vyaire Medical). Assessments are conducted according to the statements on respiratory muscle testing of the American Thoracic Society and the European Respiratory Society.~Hand grip strength Grip strength is measured using DHD-1 digital hand dynamometer (SAEHAN®,Seahan Corporation), assessment follows recommendation of The American Society of Hand Therapists."
41469134|NCT05907655|DRUG|Nitroglycerin 0.3 MG|Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls.
41469135|NCT05907655|DIAGNOSTIC_TEST|MRI|The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images.
41469136|NCT05907655|DIAGNOSTIC_TEST|Blood sampling|Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis.
40791511|NCT03653806|OTHER|computerized algorithm for automated analysis|"First: to develop a computerized algorithm for automated analysis of the electrical impedance tomography (EIT) data. The algorithm calculates the optimal positive end-expiratory pressure (PEEP) and inspiratory pressure defined as the optimal balance between stretch, ventilation distribution and collapse.~Second: to compare the results of the algorithm with the current standard of care clinical judgement of experienced EIT users"
40791512|NCT05211180|BEHAVIORAL|Vida Sana|Weekly group or individual education sessions with a health coach and fitness tracking with a fitbit.
40791513|NCT05211180|BEHAVIORAL|Vida Sana y Completa|Weekly group or individual education sessions with a health coach, fitness tracking with a fitbit, and weekly food box delivery.
40791514|NCT05814718|DRUG|modified BEAM|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
40791515|NCT05814718|DRUG|BEAM|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
40791516|NCT00556803|PROCEDURE|radiofrequency ablation|radiofrequency ablation
40791517|NCT00556803|PROCEDURE|TACE after RFA|TACE after RFA within one month
40791518|NCT03855566|BEHAVIORAL|Intensive behavioral therapy for obesity|Approximately 24, 20 minute sessions over 12 months focused on diet and physical activity behavior change goals to promote weight loss. Framework includes health belief model, transtheoretical model and motivational interviewing.
40791519|NCT05064046|BEHAVIORAL|LuCa + Health Disparity module|"The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making."
40791520|NCT06235918|DRUG|Tislelizumab|Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
40791521|NCT06235918|DRUG|Nab-paclitaxel|260mg/m\^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
40791522|NCT06235918|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles
40791523|NCT03341637|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
40791524|NCT03341637|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
40791525|NCT02076854|BEHAVIORAL|Text-Message Intervention|
40791526|NCT02225652|DRUG|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
40791527|NCT06308601|OTHER|Laughter yoga|Laughter is an innate, most natural, sincere and universal response to humorous stimuli. Philosophically, it is explained by relief theory, conflict theory and superiority theory (Öztürk \& Tezel, 2021). The emergence of laughter yoga was made by Dr., an Indian medical doctor, in 1995. It was created by combining breathing exercises and unconditional laughter with the work of Madan Kataria and his wife Madhuri Kataria. In laughter yoga, the individual can laugh in a simulated way with the interaction of group members, without a funny situation, joke or joke. The body cannot distinguish between real and unreal laughter, and fake laughter begins to turn into real laughter (Kataria, 2011).
40791528|NCT04595786|DRUG|Tranexamic acid|20mg/kg TXA was prepared in a 50ml syringe for intravenous pump
40791529|NCT04595786|DRUG|0.9% saline|0.9% saline was prepared in a 50ml syringe for intravenous pump
40791530|NCT04987827|OTHER|No intervention|No intervention
40791531|NCT04921852|PROCEDURE|costoclavicular brachial plexus block|A transverse scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed immediately below the midpoint of the clavicle and over the medial infraclavicular fossa. 20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected in to the middle of the three brachial plexus cords with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance .Readiness for surgery time will be evaluated after costoclavicular block.
40791532|NCT04921852|PROCEDURE|lateral sagittal infraclavicular block|A sagittal scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed medial to the coracoid process to obtain a transverse view of the axillary artery.20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected posterior to the axillary artery near to the three cords of brachial plexus with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance.Readiness for surgery time will be evaluated after lateral sagittal infraclavicular block.
40791533|NCT05915585|DEVICE|High-Intensity Laser Therapy|"The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters:~Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session"
41149053|NCT04507503|DRUG|TAS-120|Futibatinib 20mg QD orally on a 28 days cycle
41149054|NCT03856814|DEVICE|ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
41310190|NCT03204435|PROCEDURE|Microsurgical aneurysmal operating techniques|The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.
40996469|NCT03030079|DEVICE|Experimental Electrical Stimulation Regimen|The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
40996470|NCT05840354|DEVICE|repetitive transcranial magnetic stimulation|"1-4 weeks after administration of the SJI, participants will attend their first rTMS session. rTMS will be delivered using a biphasic stimulator (DuoMag) and a figure-of-eight coil to the corticomotor representation of the first dorsal interosseous muscle contralateral to the side of worst pain. Recording electrodes will be positioned in a belly-tendon montage over the FDI for electromyography recording. The hotspot and resting motor threshold (rMT) of the FDI will be determined and saved using a Brainsight Neuronavigation system to ensure accurate coil repositioning within and between sessions.~The hotspot and rMT will be confirmed and adjusted if needed at each intervention session. Each rTMS session will consist of 40 trains of 5s delivered at 10Hz, at an intensity of 85% of the resting motor threshold for the FDI muscle and an intertrain interval of 25s (total of 2000 stimulations in a 20-minute session)."
40996471|NCT05840354|DEVICE|sham repetitive transcranial magnetic stimulation|Sham intervention will follow same protocol as active rTMS using a sham coil that does not deliver actual magnetic stimulation.
40996472|NCT05840354|DRUG|Steroid Joint Injection|The steroid joint injection will be given 1-4 weeks ahead of active rTMS and sham rTMS commencement. A dose of 0.5mL of 40mg/mL triamcinolone and 0.5mL of 2% lidocaine will be given per joint via spinal needle. The treatment team will determine how many joints will be injected based on their standard clinical assessment. Usually, about 2-4 joints are injected depending on a person's pain presentation. Standard practice is to place the needle in the region of the facet joint opening, resulting in a peri- +/- intra-articular infusion of the injectate. This project will utilize standard clinical practice without modification.
40996473|NCT03829748|PROCEDURE|Intermittent aspiration|Endoscopic ultrasound is done for the localization of the lesion and to localize the site of puncture.Prior to the puncture of the lesion the stylet is removed and a vacuum syringe is prepared with 10 cc of vacuum allowing the generation of continous pressure inside and connected to the end of the needle. Once the lesion is punctured 15 movements in and out of the lesions will be made while the syringe is opened and closed on and off for a total of 3 times each pass. A total of 4 passes will be done in each lesion.
40996474|NCT06145009|BEHAVIORAL|Time restricted eating|Limit food intake to 10 hours per day as described in the experimental arm section.
40996475|NCT03718442|DEVICE|PhotonBlade vs Bovie for lumpectomy shaved surgical margins|For each enrolled patient, six shaved margins will be obtained (superior, inferior, medial, lateral, anterior, and posterior). For each patient, electrocautery will be used to obtain 3 of the shaved margins, and PhotonBlade to obtain the other 3 shaved margins. Once the lumpectomy site shaved margins have been obtained, the shaved surgical margins will be evaluated by a pathologist whom is blinded in regards to the dissection device that was used for each margin. The pathologist will be evaluating each shaved margin and reporting the outcomes (qualitative severity and depth of thermal artifact)
40996476|NCT01999595|DEVICE|Control TENS|Control TENS was the application of electrical stimulation via skin with no current
40996477|NCT01999595|DEVICE|Sham TENS|"Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told TENS is at a turn-on level whether or not you feel it"
40996478|NCT01999595|DEVICE|High frequency TENS with large pads|High frequency TENS was delivered on large electrodes
40996479|NCT01999595|DEVICE|Low frequency TENS with large pads|Low frequency TENS was delivered on large electrodes
40996480|NCT01999595|DEVICE|High frequency TENS with small pads|High frequency TENS was delivered on small electrodes
40996481|NCT01999595|DEVICE|Low frequency TENS with small pads|Low frequency TENS was delivered on small electrodes
41149055|NCT04434222|DEVICE|Compressive stockings|Compressive stockings with built in Orthotimer Sensor
41149056|NCT04563026|DRUG|DUR-928 30 mg|IV infusion
41149057|NCT04563026|DRUG|DUR-928 90 mg|IV infusion
41149058|NCT04563026|DRUG|Placebo+ Standard of Care (SOC)|IV infusion
41149059|NCT01964118|OTHER|Intermittent Fasting group|Intermittent fasting for 12 months
41149060|NCT01964118|OTHER|control group|usual diet for 6 months and intermittent fasting for other 6 months
41149061|NCT00582855|DRUG|AQW051|
41149062|NCT00582855|DRUG|Placebo|
41149063|NCT03981120|PROCEDURE|Laser and Traditional Acupuncture|Acupuncture (traditional and laser) and photobiomodulation will be performed by a certified acupuncturist on-site with experience in reproductive health and the initial visit will include an assessment and traditional Chinese medicine (TCM) diagnosis.
41149064|NCT00559871|DRUG|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
41310191|NCT03204435|PROCEDURE|endovascular techniques for cerebrovascular stenosis|The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
41310192|NCT03204435|PROCEDURE|endovascular techniques for intracranial aneurysms|The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.
41310193|NCT03204435|PROCEDURE|carotid endarterectomy|A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
41310194|NCT03150108|DRUG|rhPTH(1-84)|25 mcg rhPTH(1-84) SC injection
41310195|NCT03150108|DRUG|rhPTH(1-84)|50 mcg rhPTH(1-84) SC injection
41310196|NCT03150108|DRUG|rhPTH(1-84)|100 mcg rhPTH(1-84) SC injection
41310197|NCT01666678|DRUG|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
41310198|NCT01666678|DRUG|Naproxen Sodium (Aleve, BAYH6689)|2 x Naproxen Sodium 220 mg under fasting conditions
41310199|NCT01666678|DRUG|Diphenhydramine HCl|2 x Diphenhydramine HCl 25 mg under fasting conditions
41310200|NCT01666678|DRUG|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
40791534|NCT00883948|BEHAVIORAL|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
40791535|NCT00883948|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
40791536|NCT01990976|DEVICE|MRI|In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
40791537|NCT01990976|PROCEDURE|Biopsy|biopsy of the vastus lateralis muscle
41469137|NCT05907655|DEVICE|Sleep profiler|Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging.
40791538|NCT00480740|DRUG|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
40791539|NCT01237431|DIETARY_SUPPLEMENT|500ml water intake|subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
40791540|NCT04486547|BEHAVIORAL|Information-Motivation-Behavioral Skills model-based intervention|Home visits were made to the study group and nursing interventions were administered in accordance with the components of the Information-Motivation-Behavioral Skills model
40791541|NCT05976659|DEVICE|Transcranial direct current stimulation (tDCS); Transcranial alternating current stimulation (tACS)|Transcranial electrical stimulation (tES), via direct and alternating current, will be administered to the participants in their home by trained caregivers/study companions administrators. All training and intervention sessions will take place in the participant's home.
40791542|NCT00903422|DRUG|eltrombopag olamine|thrombopoietin receptor agonist
40791543|NCT00903422|OTHER|Placebo|Placebo tablets with no active pharmaceutical ingredient
40791544|NCT01736267|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
40791545|NCT00000906|DRUG|Ritonavir|
40791546|NCT00000906|DRUG|Saquinavir|
40791547|NCT00000906|DRUG|Methadone hydrochloride|
40791548|NCT06288204|DIETARY_SUPPLEMENT|Propolis + Royal Jelly|The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis, for 2 months.
40791549|NCT06288204|DIETARY_SUPPLEMENT|Royal Jelly|The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
40791550|NCT06288204|DIETARY_SUPPLEMENT|Placebo|The participant will consume 4 capsules a day of placebo, for 2 months.
40791551|NCT05247450|DEVICE|Functional electrical stimulation therapy (FES-t)|Functional electrical stimulation therapy (FES-t) that will use a multichannel device (MyndSearch device).
40791552|NCT05247450|OTHER|Conventional physiotherapy|Conventional physiotherapy is the current standard of care for rehabilitation of C5 palsy
41310201|NCT04452227|OTHER|questionnaire|Filling the menstrual distress questionnaire, short-form McGill pain questionnaire, present pain index, visual analog scale
40791553|NCT04745988|DRUG|Lenvatinib 20mg|Lenvatinib will be administered at a dose of 20mg as oral dose, once a day.
40791554|NCT04745988|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
40791555|NCT04745988|DRUG|Lenvatinib 8mg|Lenvatinib will be administered at a dose of 8mg as oral dose, once a day.
40791556|NCT04745988|DRUG|Docetaxel|Docetaxel will be administered at a dose of 50mg/m\^2 as a IV infusion, Q2W.
40791557|NCT04745988|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 85mg/m\^2 as a IV infusion, Q2W.
40791558|NCT04745988|DRUG|Levofolinate|Levofolinate will be administered at a dose of 200mg/m\^2 as a IV infusion, Q2W.
40791559|NCT04745988|DRUG|Fluorouracil|Levofolinate will be administered at a dose of 2600mg/m\^2 as a IV infusion, Q2W.
40791560|NCT02269696|DRUG|Metoprolol|Intraoperative metoprolol infusion.
40791561|NCT02269696|DRUG|Normal saline|Equal of volume compared to metoprolol.
41310202|NCT00200694|DRUG|ramipril 5 mg + valsartan 80 mg/day,|
41310203|NCT00200694|DRUG|ramipril 10 mg + valsartan 160 mg/day,|
40791562|NCT02014805|RADIATION|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
40791563|NCT05155124|DRUG|Cetuximab + trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
40791564|NCT05713071|PROCEDURE|Bariatric Endoscopic Antral Myotomy|BEAM will be performed using a standard gastric peroral endoscopic myotomy (G-POEM) technique, however with the myotomy targeting only the antrum and leaving the pyloric ring intact. G-POEM is commonly and widely employed for gastric emptying and nutritional issues and is covered by most insurance plans. This involves injecting fluid into the submucosal space, making a mucosal incision to enter the submucosal space, and tunneling along the antrum to the pylorus. A myotomy is then performed, however, in BEAM the pyloric ring is spared and the myotomy is only performed in the antrum. The incision is then closed with clips. No endoscopic suturing will be performed.
40791565|NCT04619667|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
41310204|NCT00200694|DRUG|ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|
40996482|NCT01613521|OTHER|DCE-MRI and 18F-FMISO PET|DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
40996483|NCT05179421|DRUG|Low dose oxytocin|10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms
40791566|NCT04619667|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
40791567|NCT04858542|BEHAVIORAL|Educational Vocal Health Modules|We have developed four educational health modules (total duration of approximately 30 minutes). First, these modules explain how masks impact communication and voice, then they describe health strategies to improve communication and voice, and finally, they give real-life examples of how the strategies can be implemented into the work setting.
40996484|NCT05179421|DRUG|High dose oxytocin|10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
40996485|NCT05534763|BEHAVIORAL|IERGD|A 10 week behavioral treatment focusing on gender minority stress, maladaptive and adaptive emotion regulation, emotional awareness, the functionality of emotions, interpersonal skills and values and valued actions.
40996486|NCT05534763|OTHER|IER SUPPORT|A 5-week behavioral course for a designated support person (family, friend, other) to the person with GD. The course focuses on teachings on living with minority stress, maladaptive and adaptive emotion regulation, emotional awareness, validation, interpersonal skills and values.
40996487|NCT02865915|DRUG|MLE4901|For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.
40996488|NCT02865915|DRUG|Placebo|Placebo to match active drug
41149065|NCT06274632|BEHAVIORAL|ADELANTE|A manualized problem-solving intervention that addresses barriers to viral suppression in Latinos with HIV. At the patient-level, CHWs use motivational interviewing to facilitate problem-solving skill development around attending HIV care and adherence and establish an individually tailored goal-setting plan. We target emotional well-being and self-management through a rapport with CHW and the integration of an HIV-centered telenovela to facilitate participant reflection on difficult topics for skill-building. The CHW will also link the participant to needed services.
40996489|NCT05033639|DRUG|Melatonin 6 MG|Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.
40996490|NCT05033639|OTHER|Breast Milk|Naturally occurring milk from the mother of the infant.
40996491|NCT02086929|DRUG|Trazodone|
40996492|NCT02086929|DRUG|Venlafaxine|
40996493|NCT04127916|DRUG|Bendamustine|To investigate the efficacy and safety of bendamustine plus rituximab in patients with mantle cell lymphoma.
40996494|NCT03488212|BEHAVIORAL|Training to Identify Eligible Patients and Direct them to Online Obesity Treatment Program|Primary care clinic staff are trained to identify patients who meet study inclusion and exclusion criteria. They are then trained to provide patients with the information necessary to enroll in the study and access the online behavioral obesity treatment.
40996495|NCT03488212|BEHAVIORAL|Training to Motivate and Support Patients' Weight Loss|Primary care clinic staff are trained in psychological and behavioral strategies for: talking to patients about weight and weight loss in a way that patients find acceptable and helpful, increasing motivation for weight loss, overcoming common barriers to weight loss, and persevering with a weight loss attempt. They are trained in strategies to provide this support by telephone in addition to during clinic visits.
40996496|NCT03488212|BEHAVIORAL|Online Behavioral Weight Loss Intervention|For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.
40996497|NCT03488212|BEHAVIORAL|Control Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online newsletters with educational information pertaining to healthy weight, diet, and physical activity habits.
40996498|NCT03488212|BEHAVIORAL|Monthly Lessons and Feedback Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; monthly feedback on the self-monitoring record.
41149066|NCT02823886|OTHER|MRI at D7|The infarct size measured on MRI at 7 days.
41149067|NCT02823886|BIOLOGICAL|Blood samples|Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
41149068|NCT04009902|BEHAVIORAL|Beck Depression Scale and Pittsburgh Sleep Quality Index|postoperative depression and sleep disorders in patients with endometriosis will be evaluated
40996499|NCT03488212|BEHAVIORAL|Refresher Courses for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive two month-long refresher courses with weekly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record; weekly challenges focuses on specific behavior change and weight loss goals.
40996500|NCT00180895|DRUG|Rituximab|
40996501|NCT05721274|BEHAVIORAL|Community mobilization and Conditional community incentives|Non-cash, incentives would be given to clusters which improve the polio vaccine coverage and reduce the refusals and these incentives would be decided with consensus by community and costs would be shared
40996502|NCT04307446|DEVICE|Immersive Virtual Reality|Immersive Virtual Reality
40996503|NCT06112938|DRUG|Antibiotic|We aim to examine differences in clinical outcomes and failure rates between standard and alternative treatment strategies such as minocycline (or moxifloxacin, ciprofloxacin, ceftazidime) alone or in combination with TMP-SMX, alternative TMP-SMX dosing regimens, or variations in durations of therapy for the treatment of S. maltophilia infections within Methodist Health System (MHS).
40996504|NCT00112658|DRUG|fluorouracil|
40996505|NCT00112658|DRUG|gemcitabine hydrochloride|
40996506|NCT00112658|DRUG|irinotecan hydrochloride|
40996507|NCT00112658|DRUG|leucovorin calcium|
40996508|NCT00112658|DRUG|oxaliplatin|
40996509|NCT03200678|OTHER|isokinetic assessment|muscle torque assessement
40996510|NCT02226003|DRUG|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
40996511|NCT02226003|DRUG|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
40996512|NCT02226003|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
40996513|NCT02226003|DRUG|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
40996514|NCT02226003|DRUG|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
40996515|NCT00451035|DRUG|LBH589|
40996516|NCT03437785|DRUG|CKD-495 75mg|CKD-495 75mg Tab.
40996517|NCT03437785|DRUG|CKD-495 150mg|CKD-495 150mg Tab.
40996518|NCT03437785|DRUG|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
40996519|NCT03437785|DRUG|Rebamipide 100mg|Rebamipide 100mg Tab.
40996520|NCT03437785|DRUG|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
40996521|NCT03437785|DRUG|Placebo of the CKD-495 150mg|Placebo of the CKD-495 150mg Tab.
40996522|NCT03437785|DRUG|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
40996523|NCT03437785|DRUG|Placebo of the Rebamipide 100mg|Placebo of the Rebamipide 100mg Tab
40996524|NCT00089570|DRUG|terlipressin|
40996525|NCT00089570|DRUG|Placebo|
40996526|NCT01524627|DRUG|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
40996527|NCT01524627|DRUG|Placebo|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
40996528|NCT05533853|OTHER|Posture corrective exercises|The exercises are of two types strengthening exercises and starching exercise ,). The strengthening exercises are to be done for 15 repetitions in 2 sets, Progression will be by increasing to 3 sets and adding 1 Kilogram of resistance in dumbbells exercises, the targeted muscles are teres minor, infraspinatus, medial and lower trapezius, rhomboids, and cervical flexor muscles. On the other hand, stretching exercises are to be hold for 30 seconds for 2 sets then progressed to 3 sets, the targeted muscles are pectoralis minor, sternocleidomastoid and levator scapulae.
40996529|NCT05533853|OTHER|Denneroll extension traction|The participants will be instructed to lie supine and keep their legs extended. Based on the apex of each participant's cervical curvature on the initial radiograph, the therapist will position the apex of the denneroll in one of two regions (mid cervical placement or lower cervical placement). The duration of the traction session will start at 2-3 min and increased 1 min per session until reaching the goal of 20 min, the traction will repeated three times per week for 6 weeks
41310205|NCT00694694|DRUG|azithromycin + artesunate|Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
41310206|NCT00694694|DRUG|artemether-lumefantrine|"Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days"
41310207|NCT06259279|BEHAVIORAL|High intensity high impact exercise intervention|"Patients in the intervention group will receive a 32-week exercise-based intervention that includes:~- Supervised and group-based exercise training in the hospital, twice a week. Each session lasts approximately 30 minutes."
40996530|NCT04031833|DRUG|MAT2203|Encochleated amphotericin B
40996531|NCT04031833|DRUG|Amphotericin B|Intravenous amphotericin B
40996532|NCT05312229|BEHAVIORAL|Critical Time Intervention|An evidence-based, structured, and time-limited case management practice
40996533|NCT05312229|OTHER|External Facilitation|Site-specific support to help sites develop tailored plans to implement CTI.
40996534|NCT05312229|OTHER|Replicating Effective Programs|A stakeholder-informed training and technical assistance implementation strategy
41149069|NCT04968249|OTHER|Observational|Observational Cohort to understand risk factors for early COPD.
41469138|NCT02614833|BIOLOGICAL|IMP321 (eftilagimod alpha)|In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
41469139|NCT02614833|DRUG|Placebo|In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
40791568|NCT01170234|DEVICE|NIOX MINO® Airway Inflammation Monitor|We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
40791569|NCT02544347|OTHER|gingival crevicular fluid|gingival crevicular fluid was collected
40791570|NCT02544347|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
40791571|NCT05342298|OTHER|prediction model|Data will be pre-processed prior to final analysis, including data cleaning, imputation of missing values, dimensionality reduction, and removal of outliers. Data will be utilized as Xi and Yi where Xi presents input (features) and Yi presents dependent variables (outcomes). Different classification algorithms will be tested for accuracy to build the final model including logistic regression, SVM, XGboost and random forest algorithms. Data will be split at 0.8:0.2 for model training and testing, respectively.
40791572|NCT00753948|DRUG|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
40791573|NCT06511895|DRUG|AZD4205|AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.
40791574|NCT01158755|DRUG|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
40791575|NCT06337981|DRUG|(AJU-S56 5% and placebo)|(AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
40791576|NCT06337981|DRUG|AJU-S56 5%|(AJU-S56 5%), 1drop/1times, 6times in a day
40791577|NCT06337981|DRUG|Placebo(Vehicle)|Placebo(Vehicle), 1drop/1times, 6times in a day
40791578|NCT00360178|DRUG|Valsartan plus Hydrochlorothiazide|
40791579|NCT00360178|DRUG|Candesartan plus Hydrochlorothiazide|
40791580|NCT00360178|DRUG|Amlodipine|
40791581|NCT04321512|OTHER|There is no intervention given to the subjects|Not appicable
40791582|NCT00893854|DRUG|Diclophenac|
40791583|NCT00893854|DRUG|Triamcinolone|
40791584|NCT04286152|DRUG|Mirabegron 50 MG|The experimental drug is administered to patients PO once a day for 7 days from stent insertion until removal
40791585|NCT04286152|DRUG|Placebo oral tablet|A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
40791586|NCT03531814|BEHAVIORAL|Medication Event Monitoring System (MEMS^TM)|A computerized method of tracking the dates and times of a pill bottle being opened.
40791587|NCT03531814|OTHER|Questionnaires|Adult and pediatric participants completed a series of questionnaires to assess medication adherence, demographics, life events, and barriers to adherence.
40791588|NCT00066339|DRUG|gefitinib|
40791589|NCT02415244|PROCEDURE|TEE|Spinal cord segments will be imaged using the TEE
40791590|NCT00413439|DRUG|Isavuconazole|Intravenous solution or oral capsules
40791591|NCT02503085|DRUG|Nurofen for Children®|
40791592|NCT02503085|DRUG|Algifor Dolo Junior®|
40791593|NCT01822769|OTHER|Cardiopulmonary rehabilitation|See Arm Description
41149070|NCT04879823|DRUG|Dexamethasone|IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup
41469140|NCT02614833|DRUG|Paclitaxel|Paclitaxel will be given in both treatment arms (classified as Non IMP)
40791594|NCT01822769|OTHER|Standard of care|See Arm Description
40791595|NCT04074226|PROCEDURE|Erector Spinae Plane block|The Erector Spinae Plane (ESP) block is a new block first described in 2016 which blocks terminal branches of the lower thoracic and lumbar nerve roots. It is performed by injection of local anesthetic in the fascial plane below the erector spinae muscle group.
40791596|NCT04074226|PROCEDURE|Quadratus Lumborum Block|Ultrasound-guided QL block has been reported to provide effective analgesia in patients undergoing lower abdominal surgical procedures, including in patients undergoing abdominal hysterectomy. Ultrasound guidance offers a number of advantages, including the ability to visualize the anatomy, perform real-time navigation, and direct observation of local anesthetic spread. The QL block is performed via ultrasound-guided injection of local anesthetic in the fascial planes above or below the QL muscle
40791597|NCT01444430|DRUG|Symbicort pMDI|Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.
40791598|NCT01444430|DRUG|budesonide pMDI|Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.
40791599|NCT05207748|DIAGNOSTIC_TEST|Bone mineral density|Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method.
41469141|NCT04611594|BEHAVIORAL|Fluid restriction|Ingestion of approximately 20 ml / kg of ideal weight,
40791600|NCT06183281|BEHAVIORAL|CBT, Mindfulness, and Movement|Blended CBT, mindfulness, and movement delivered through a mobile app and supported by a weekly telehealth pain management coach.
40791601|NCT05135572|DIAGNOSTIC_TEST|Fibromiyalgia and foot pain|Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.
40791602|NCT00614133|OTHER|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
40791603|NCT00614133|OTHER|Intravenous nutrition with glucose and amino acids.|Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
40791604|NCT05680467|OTHER|Manual Therapy|"The protocol will last 30 minutes and will include the application of the following manual techniques:~* Lumbar soft tissue and joint cranial and lateral mobilization with the patient in the supine position~* Bilateral medial lumbar soft tissue mobilization~* Functional massage on the quadratus lumborum muscle with the patient in a lateral position on both sides~* Extension with coupled sidebending mobilization of the thoracic area with the patient in a lateral position on both sides~* Soft tissue lateral mobilization of the thoracic area with the patient in a lateral position on both sides"
40791605|NCT05680467|OTHER|Manual Therapy plus TECAR|The participants of this group will be given the same manual protocol as the first group in combination with the application of high frequency current. Soft tissue mobilization manipulations will be applied in combination with a capacitive conventional electrode and with a special electrode bracelet that makes the therapist's own hand as an antistatic electrode. The frequencies of the high frequency current will be 300khz, 500khz, and 1MHz, while as a reference electrode a flexible self-adhesive ground will be used placed on the abdomen
40996535|NCT03812692|DEVICE|MATRx plus|The MATRx plus device is a feedback-controlled mandibular positioner that uses data collected during sleep to control movement of the mandible in real-time using a mandibular positioner. The test provides a prediction of the individual's response to oral appliance therapy; i.e., if the individual can treat his or her obstructive sleep apnea using a mandibular advancing oral appliance. For individuals predicted to respond to the therapy, the test also provides a mandibular position at which the appliance will be effective.
41149071|NCT04879823|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
40996536|NCT04918212|DEVICE|Fabulous Stent Graft System|All patients received endovascular surgery using fabulous stent graft system
41149072|NCT04879823|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
40996537|NCT02140437|DRUG|Fulvestrant|Adding fulvestrant to the standard endocrine therapy, anastrozole
40996538|NCT02140437|DRUG|Anastrozole|standard endocrine therapy
40996539|NCT05322174|BEHAVIORAL|Baby Sleep|See arm description
40996540|NCT05322174|BEHAVIORAL|Baby Care|See arm description
41149073|NCT04879823|DRUG|Placebo|An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.
41149074|NCT00730392|DRUG|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
41149075|NCT00730392|DRUG|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
41149076|NCT04551469|BEHAVIORAL|music|Music intervention for 30 minutes
41149077|NCT02879448|DEVICE|Amulet Left Atrial Appendage Occluder|Transcatheter left atrial appendage closure
41149078|NCT02879448|DEVICE|WATCHMAN Left Atrial Appendage Closure|Transcatheter left atrial appendage closure
41149079|NCT02894216|PROCEDURE|radionuclide shuntography|the investigators retrospectively enrolled patient who received radionuclide shuntography
41149080|NCT00120952|DEVICE|Bi-Metric femoral implant (titanium versus cobalt-chromium)|
41149081|NCT06360445|DRUG|Olaparib Tablet test formulation 100mg|A generic product manufactured by CSPC Ouyi Pharmaceutical Co., Ltd.
41149082|NCT06360445|DRUG|Olaparib Tablet reference formulation 100mg|Olaparib Tablet reference formulation 100mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
41149083|NCT06360445|DRUG|Olaparib Tablet test formulation 150mg|Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
41149084|NCT06360445|DRUG|Olaparib Tablet reference formulation 150mg|Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
41149085|NCT03481725|DEVICE|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
41469142|NCT00199901|BIOLOGICAL|NY-ESO-1 ISCOMATRIX®|"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of NY-ESO-1 ISCOMATRIX® vaccine. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
41149086|NCT03481725|DEVICE|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
41149087|NCT02109718|DRUG|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.
41149088|NCT02109718|DRUG|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
41149089|NCT04620733|DRUG|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
41149090|NCT04620733|DRUG|Placebo|One capsule daily for double-blind period, for a duration of up to 12 months
41149091|NCT04620733|DRUG|Seladelpar 5 mg|If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
40996541|NCT05871359|DEVICE|Transcranial Direct Current Stimulation|The stimulator will be connected to two electrodes .The active electrode will be placed on the areas of the dorsal lateral pre-frontal cortex (DLPFC) contralateral to the more affected side.The other one on the supra orbital area.
40996542|NCT05871359|PROCEDURE|Dual task|The Dual Task consists of walking for 20 minutes along a hallway, simultaneously patient has to answer to a different ecological cognitive (attention, fluences, calculation) and motor tasks (hold a tray, turn head, ecc..)
41149092|NCT04107688|OTHER|Control|Subjects will use plain water as an oral rinse twice a day for 3 days.
41149093|NCT04107688|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
41149094|NCT04993976|OTHER|Resistant training (Prehabilitation)|Resistance training (10-15 repetitions: major muscle groups of upper and lower limbs \[eg, shoulder overhead press, biceps curl, knee lift, and quadriceps extension in sitting and hamstrings curl exercises\], one to three sets each) for 20-60 minutes five days a week.
41149095|NCT04993976|OTHER|Active Comparator: Control group|Conventional physiotherapy group followed basic pre-operative respiratory physiotherapy including deep breathing exercises, instructions in coughing techniques, mobilization, and active exercises of the upper limbs and thorax. Walk 30 m in the hospital ward.
41149096|NCT01840124|PROCEDURE|Radiofrequency ablation of fibroids|The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
41149097|NCT06232655|DRUG|Cladribine|A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.
41149098|NCT06232655|DRUG|Venetoclax|A medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
41149099|NCT06232655|DRUG|Azacitidine|Medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA.. Azacitidine and its deoxy derivative, decitabine were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.
41149100|NCT02032134|BIOLOGICAL|Transfusion of Pooled Platelets Cryopreserved In DMSO|"Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic P. Giaccone- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing"
41149101|NCT02501616|DRUG|Metformin|
41149102|NCT02501616|DRUG|Dapagliflozin|
41149103|NCT03935152|DRUG|Dydrogesterone|dydrogesterone capsule
41149104|NCT03935152|DRUG|placebo|placebo capsule
41149105|NCT00489697|DEVICE|real-time contrast-enhanced ultrasound imaging (CEUS)|Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)
41149106|NCT06450041|DRUG|Universal Donor (UD) TGFβi NK Cells|Patients will receive a dose of 1x108 UD TGFβi NK cells/kg per treatment cycle on day 8 of each cycle
41149107|NCT06450041|DRUG|Temozolomide|Enteral or IV daily on days 1-5 of each cycle For patients ≥ 0.5 m2: 100 mg/m2/dose For patients \< 0.5 m2: 3.3 mg/kg/dose MAXIMUM dose = 200 mg
41149108|NCT06450041|DRUG|Irinotecan|50mg/m2/dose IV daily on days 1-5 of each cycle
40996543|NCT02799758|DRUG|NK-104-CR|NK-104-CR 8 mg for 52 weeks
40996544|NCT02799758|DRUG|Livalo® IR|Livalo® IR 4 mg daily for 52 weeks
40996545|NCT02799758|DRUG|Placebo (for NK-104-CR)|NK-104-CR 8 mg placebo for 52 weeks
40996546|NCT02799758|DRUG|Placebo (for Livalo® IR)|Livalo® IR 4 mg placebo for 52 weeks
40996547|NCT06074913|OTHER|infrared thermography (IRT)|Temperatures and infrared thermograms were recorded in the region of the extremities of three groups of subjects by using an infrared thermographic camera.
40996548|NCT06074913|PROCEDURE|Basal therapy+EA|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen. 2. Acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject.
40996549|NCT06074913|OTHER|Basal therapy|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen.
40996550|NCT04026607|DIETARY_SUPPLEMENT|Protein Supplementation|Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
41149109|NCT06450041|DRUG|Dinutuximab|17.5mg/m2/dose IV daily on days 2-5 of each cycle
41149110|NCT06450041|DRUG|GM-CSF|250mcg/m2/dose subcutaneous (preferred) or IV daily on days 6-12 of each cycle
41149111|NCT02634528|DRUG|Julphar Insulin N (human isophane insulin)|investigational insulin: Julphar N (human isophane insulin), biosimilar
41149112|NCT02634528|DRUG|Huminsulin® Basal (NPH, human isophane insulin)|marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
41149113|NCT06585761|DRUG|SGLT2 inhibitor|patients with HF are subjected to regular dose of SGLT2I member according to patient status.
40791606|NCT05680467|OTHER|Control|Participants in this group will only receive general instructions about managing their back pain and counseling about avoiding activities that may worsen their symptoms.
40791607|NCT04363242|BIOLOGICAL|SYN125|Administered by IV infusion
40791608|NCT04363242|BIOLOGICAL|SYN004|Administered by IV infusion
40791609|NCT01559415|OTHER|Meal replacement diet using Modifast|modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
40996551|NCT04328324|PROCEDURE|Endoscopy|Diagnostic upper Git endoscopy
40791610|NCT01559415|OTHER|Normal diet combined with Modifast diet|Combination of modifast and regular diet (1250 kcal/d) for 3 months
40791611|NCT05252208|OTHER|Stretching exercise|Stretching (30-45 minutes, 5 days per week, 6 months)
40996552|NCT04716127|BEHAVIORAL|Proximity-incentive strategy based on vaginal self-sampling for women 50 to 65 years who do not participate to cervical cancer screening|"* Direct offer of a vaginal self-sampling kit with information to perform at home and send back to the laboratory for HR-HPV testing~* The psychosocial determinants involved in decision-making process and compliance to cervical cancer screening will be collected from open questionnaires and by semi-directive phone interviews~* Control ; Receive reminder to send the self-sample to the laboratory : After 3 and 6 months without return, women receive a remind letter to send the vaginal self-sample to the laboratory. We call return the receipt of the vaginal self-sample at the laboratory.~* Control ; Receive reminder to perform cervical smear in case of positive HR-HPV test : In case of a positive HR-HPV test, women are asked to perform a control cervical smear. After 3, 6 months and 12 months without return, women and their health-care professional will receive a remind letter or a call to perform a cervical smear for control. We call return the performance of a pap smear."
40996553|NCT06385587|DEVICE|Oleena|Oleena™ is a software medical device for patients and their healthcare team which digitalizes some aspects of their supportive care, allows remote monitoring by healthcare professionals (HCP) and supports the management of targeted symptoms in adult cancer patients while they are being actively treated for their cancer.
40996554|NCT01660854|BIOLOGICAL|Heterologous challenge|challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
40996555|NCT01660854|DRUG|Malarone treatment|Three days: 4 tablets 250/100mg per day
40996556|NCT01885091|OTHER|Kinerase|
40996557|NCT00165893|DEVICE|Accu-Spina Device/IDD therapy|
40996558|NCT00165893|PROCEDURE|Physical Therapy|
40996559|NCT03823053|OTHER|Home Based Traditional Scoliosis Exercise|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. Exercises will be applied 1 sets of 10 repetitions and once a day.
40996560|NCT03823053|OTHER|Home Based Core Stabilization Training|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. In addition, the training group received core stabilization exercises for multifidus, transversus abdominis, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and pelvic floor muscles.Exercises will be applied 1 sets of 10 repetitions and once a day.
40996561|NCT01011842|PROCEDURE|Radiotherapy|Standard of care
40996562|NCT01011842|PROCEDURE|Align RT|Standard of care
40996563|NCT03163888|PROCEDURE|Navigation TKR|Traditional over Conventional TKR
40996564|NCT01464658|PROCEDURE|panniculectomy|surgery
40996565|NCT00210704|DRUG|Dapoxetine|
40996566|NCT00331175|DRUG|Peptide YY3-36|
40996567|NCT00003120|DRUG|paclitaxel|135 mg/m2 IV every 28 days
40996568|NCT04211337|DRUG|Selpercatinib|Administered orally
40996569|NCT04211337|DRUG|Cabozantinib|Administered orally
40996570|NCT04211337|DRUG|Vandetanib|Administered orally
40996571|NCT05771259|OTHER|Assessment of knowledge and behaviour|Assessment of knowledge and behaviour
40996572|NCT03791216|OTHER|Fasting blood draw for lipid assessments|Fasting blood draw for lipid assessments
40996573|NCT01350128|DRUG|PT001 MDI|PT001 MDI administered as two puffs BID for 7 days
40996574|NCT01350128|DRUG|Ipratropium Bromide HFA Inhalation Aerosol|Taken as 2 inhalations of the 17 µg per actuation strength MDI QID
40996575|NCT01350128|OTHER|Placebo MDI|Matching placebo to PT001 MDI administered as two puffs BID for 7 days
40996576|NCT02253810|DRUG|Tranexamic Acid|Medication administered intra-operatively to promote blood clotting.
40996577|NCT02253810|DRUG|Placebo|Saline solution
41149114|NCT06585761|DEVICE|echo cardiogram|the patients are subjected to ECHO to determine their EF prior to and post the study
41149115|NCT01239056|PROCEDURE|Endoscopy|Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
41149116|NCT00645320|DRUG|Ziprasidone|Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
40791612|NCT05252208|OTHER|Walking exercise|Walking (30-45 minutes, 5 days per week, 6 months)
40791613|NCT02202967|DRUG|Misoprostol|Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
40791614|NCT02202967|DRUG|Placebo|Placebo contains lactose granules
40791615|NCT05563662|PROCEDURE|Cardiac surgery|Patients with infective endocarditis undergoing open heart surgery
40791616|NCT04718740|DRUG|fluzoparib|Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib
40791617|NCT03573245|DRUG|Tranexamic Acid|Tranexamic acid effect on perioperative bleeding in orthopedic surgery
40791618|NCT03983447|BEHAVIORAL|School-based intervention to promote PA and reduce ST|"This intervention was realized with all the children (1st grade-5th grade) and involved :~1. Physical (Environmental) adaptation of playgrounds~2. Time adaptation of lunch breaks~3. Curriculum-based program for children~4. Workshops and newsletters for parents~5. Meetings for teachers"
40791619|NCT02559635|PROCEDURE|Bowel stimulation|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
41469143|NCT00199901|BIOLOGICAL|ISCOMATRIX® adjuvant|"120 μg of ISCOMATRIX® adjuvant~Each patient will receive four intramuscular injections of ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
41469144|NCT06189911|PROCEDURE|Open liver resection|The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
41469145|NCT02536469|DRUG|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
41469146|NCT02297750|PROCEDURE|double-wire technique in patients undergoing ERCP with biliary cannulation|
41469147|NCT02297750|PROCEDURE|single-wire technique in patients undergoing ERCP with biliary cannulation|
41469148|NCT00164034|DEVICE|Real time computer prompted trauma algorithms|
41469149|NCT05468008|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is an outpatient procedure to remove deep tumors from the gastrointestinal (GI) tract
41469150|NCT02464241|OTHER|only examination|
40791620|NCT02559635|DRUG|Nestle Resource|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
40791621|NCT05746182|DIAGNOSTIC_TEST|Hereditary Cancer Panel|UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
40791622|NCT04339413|DRUG|Gantenerumab|Gantenerumab was administered as SC injection Q4W.
40791623|NCT05225519|DEVICE|long-sleeved white shirt impregnated with a long-infrared irradiation|Usage of an experimental shirt for a period of 12 weeks.
40791624|NCT05225519|DEVICE|long-sleeved white shirt|Usage of an experimental shirt for a period of 12 weeks.
40996578|NCT05337410|BEHAVIORAL|YES-ERACE|YES-ERACE is an adapted version of the evidence based YES (Youth Empowerment Solutions) program. Through the YES program, youth design and implement their own projects to help improve their own communities. The adapted YES-ERACE curriculum empowers youth from diverse backgrounds to address racism and racial discrimination as a way to reduce violent behavior. Over the course of the program, youth carry out a community change project aimed at promoting inclusion, diversity, equity, appreciation, and solidarity in their community.
40996579|NCT05995158|PROCEDURE|Metagenomic testing of the subgingival plaque samples|sampling, extraction and sequencing of the oral microbiome in the samples
40996580|NCT00703885|DRUG|0.25 mg alprazolam|"0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
40791625|NCT00792311|PROCEDURE|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
40791626|NCT04538131|DEVICE|sensor-driven position-adaptive SCS|Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.
40996581|NCT00703885|DRUG|1.0 mg alprazolam|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
40996582|NCT00703885|DRUG|placebo|"Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
41469151|NCT02238132|DRUG|ATROVENT® inhalets|
40791627|NCT04538131|DEVICE|conventional SCS|Conventional SCS can not change the parameter when the body position changes.
40791628|NCT02253095|DRUG|Albendazole|
40791629|NCT02253095|DIETARY_SUPPLEMENT|Zinc|
40791630|NCT02253095|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|
40791631|NCT02253095|DRUG|Placebo|
40791632|NCT03951610|DEVICE|Test lens|contact lens
40791633|NCT03951610|DEVICE|Control lens|contact lens
40791634|NCT00932035|PROCEDURE|axillary lymph node dissection|Undergo reverse mapping-guided axillary lymph node dissection
40791635|NCT00932035|DRUG|isosulfan blue based lymphatic mapping|
40996583|NCT04486846|OTHER|eVisit|electronic surveillance program in lieu of in-person clinic visit
40996584|NCT04497077|DIETARY_SUPPLEMENT|tart cherry|Either tart cherry juice or freeze dried powdered tart cherry in capsule was given
40996585|NCT04497077|DIETARY_SUPPLEMENT|placebo|either cornstarch capsule or kool-aid
40996586|NCT02886377|BIOLOGICAL|blood test of anti-AQP4 antibody|Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
40996587|NCT04171037|PROCEDURE|Oxygen Therapy|Receive oxygen via Optiflow THRIVE
40996588|NCT04171037|PROCEDURE|Oxygen Therapy|Receive oxygen via non-rebreather
41469152|NCT01388452|DEVICE|Point of care HIV RNA PCR|The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
41469153|NCT01779388|PROCEDURE|Bronchoscopy|During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
41469154|NCT05227586|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.
41469155|NCT05227586|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.
41469156|NCT06358573|DRUG|INT230-6|"INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate.~The IMP is without marketing authorization in Switzerland and anywhere in the world."
41469157|NCT06358573|OTHER|neoadjuvant immuno-chemotherapy|Standard of care
41469158|NCT05780996|DEVICE|QMODE +|Atrial fibrillation radiofrequency ablation of the anterior and posterior wall with 90W (vHPSD)
41469159|NCT05780996|DEVICE|QMODE|Atrial fibrillation radiofrequency ablation of the anterior wall with 50W (HPSD). Ablation of the posterior wall with 90 W (vHPSD)
40791636|NCT00932035|PROCEDURE|axillary lymph node dissection|Undergo standard axillary lymph node dissection
40791637|NCT00932035|PROCEDURE|quality-of-life assessment|Ancillary studies
40996589|NCT04171037|OTHER|Questionnaire Administration|Ancillary studies
40996590|NCT04171037|DEVICE|Optiflow THRIVE|Oxygen Administration
40996591|NCT03227887|OTHER|Two samples of saliva|"1. Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~2. With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation"
40996592|NCT03227887|OTHER|Chewing behaviour|Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.
40996593|NCT03227887|OTHER|Study of the food bolus|"2 tests:~1. Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~2. The bolus will be analysed visually"
40996594|NCT03227887|OTHER|Mouthfeel|Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
40996595|NCT01400516|DRUG|Teriparatide|20 μg, subcutaneous injection, 1 injection per day
40996596|NCT01400516|DRUG|calcium citrate|1000 mg of calcium citrate
40996597|NCT01400516|DRUG|Vitamin D|800 IU of Vitamin D
40996598|NCT01400516|DRUG|TNF antagonist|TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
41469160|NCT00981799|DRUG|Nelarabine|Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.
41469161|NCT00981799|DRUG|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5
41469162|NCT00981799|DRUG|Cyclophosphamide|Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
41469163|NCT00981799|DRUG|Methotrexate|"Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age"
41469164|NCT00981799|DRUG|Filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000/mm3 for two consecutive days.
41469165|NCT05848258|DRUG|LY3871801|Administered orally
41469166|NCT05848258|DRUG|Placebo|Administered orally
41469167|NCT04239495|OTHER|Observational study: range of clinical and lifestyle factors|Medical conditions and medications. Educational and occupational history. Lifestyle exposures, assessed using reduced Food Frequency Questionnaire, Rapid Assessment of Physical Activity questionnaire and objectively-measured physical activity levels over 7 days using a GeneActiv wrist-worn accelerometer (Activinsights, Cambridge, UK).
40791638|NCT00932035|OTHER|Questionnaire administration|Ancillary studies
40791639|NCT01179308|OTHER|General-epidural anesthesia|General anesthesia combined with epidural anesthesia
40791640|NCT01179308|OTHER|Balanced general anesthesia and postoperative opioids|General anesthesia alone
40791641|NCT00560092|DRUG|intrathecal magnesium sulfate|intrathecal magnesium sulfate
40791642|NCT02682459|DRUG|Lisinopril|
40791643|NCT03710356|DRUG|Danazol 200 MG|DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months
40791644|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using bupivacaine: xylocaine|Patients will have the cotton swab soaked in the LA medication introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
40791645|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using normal saline|Patients will have the cotton swab soaked in normal saline introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml normal saline injected via a syringe connected to a 20G catheter into their nostrils bilaterally.
40996599|NCT02492529|OTHER|Neuropsychological tests|"Scales and tests to evaluate:~* Global cognitive performance~* Handedness~* Memory functions performance~* Gestural praxis functions performance~* Lexical and semantic functions performance~* Executive functions performance~* Memory disorders~* Way of life~* Mood"
40996600|NCT02492529|DEVICE|A cranial MRI|
40996601|NCT02492529|OTHER|Experimental procedure|
40996602|NCT06095791|DRUG|Immunomodulators with FDA approval on the 1st January 2023.|Disproportionnality analysis studying the association between immunomodulators with FDA approval on the 1st January 2023 and atrial fibrillation in the World Health Organization pharmacovigilance database.
40996603|NCT04252755|BEHAVIORAL|EEG Neurofeedback|Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
40996604|NCT00895466|BIOLOGICAL|PEP-223/CoVaccine HT|
40996605|NCT04732975|DEVICE|CardioFlux|Non-invasive screening for ACS
40996606|NCT01808430|PROCEDURE|VATS for confirmed non-small cell lung cancer (NSCLC)|Video-Assisted Thoracoscopic Surgery for NSCLC patients
40996607|NCT01388075|DRUG|Rifampicin|oral, 450 mg/day , 7 days
40996608|NCT00429507|DRUG|153 Sm-EDTMP|Tracer dose = 30 mCi by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose.
40996609|NCT00429507|BEHAVIORAL|Questionnaire|Questionnaires taking about 15 minutes to complete.
41149117|NCT00741689|DRUG|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
41469168|NCT00757679|DRUG|Milnacipran|capsules
41469169|NCT00757679|DRUG|Placebo|capsules
41469170|NCT01472926|DRUG|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
41469171|NCT01472926|DRUG|alteplase|Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
41469172|NCT04688047|BEHAVIORAL|Nursing care based on the transtheoretical model|Nursing care consists of urinary incontinence training, motivational interview and telephone/mail counseling processes.
41469173|NCT00661921|BIOLOGICAL|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
41149118|NCT03479671|DRUG|Intralipid, 20% Intravenous Emulsion|Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)
40791646|NCT03974074|DRUG|Albumin infusion|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.
41149119|NCT02183961|OTHER|Restech|
41149120|NCT02183961|OTHER|Peptest|
41149121|NCT02183961|OTHER|Detection of pepsin in adenoid specimen|
40996610|NCT00429507|PROCEDURE|Stem Cell Transplant|Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP.
40996611|NCT05400928|DEVICE|Pulsed Field Ablation|pulmonary vein isolation will be performed with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
40996612|NCT05904457|DRUG|bevacizumab|Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.
40996613|NCT05904457|DRUG|erlotinib|Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.
41149122|NCT02105688|DRUG|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
41149123|NCT02105688|DRUG|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet|Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
40996614|NCT06546904|DEVICE|Artificial intelligence empowers anesthesia with ultrasound assistance|Artificial intelligence empowers anesthesia with ultrasound assistance
40996615|NCT02363725|DRUG|Colchimax®|
40996616|NCT02363725|DRUG|Conventional treatment|
40996617|NCT00752583|PROCEDURE|Peritoneal dialysis|Blood, urine and dialysate sampling
40996618|NCT00752583|PROCEDURE|Haemodialysis|Blood, urine and dialysate sampling
40996619|NCT05021367|DRUG|TQB3823 tablets|TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.
40996620|NCT03314727|OTHER|High salt (NaCl) intake|Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels
40996621|NCT06224842|DRUG|mitoxantrone liposome 16 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
40996622|NCT06224842|DRUG|mitoxantrone liposome 18 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
40996623|NCT06224842|DRUG|mitoxantrone liposome 20 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
40996624|NCT02017314|DRUG|Morphine|
40996625|NCT01995799|DEVICE|Ferumoxytol enhanced MRI|Ferumoxytol enhanced MRI scan
40996626|NCT03335982|PROCEDURE|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia.
40996627|NCT03921060|DRUG|Denosumab|treatment with denosumab every 6 months for up to 5 years
41149124|NCT06584786|COMBINATION_PRODUCT|Jing Si herbal tea (JSHT)|JSHT has been approved by the Ministry of Health and Welfare of Taiwan (registration number MOHW-PM-060635).
41149125|NCT06584786|OTHER|Placebo|Placebo of JSHT
41149126|NCT06184321|BIOLOGICAL|Alteplase|Instilled into IPC
41149127|NCT06184321|DRUG|Placebo Administration|Instilled into IPC
41149128|NCT06384859|DEVICE|ESWT|Receive ESWT once a week for 4 weeks
41469174|NCT00661921|BIOLOGICAL|Placebo|AMG 108 volume matching placebo
41469175|NCT05661461|DRUG|nab-sirolimus|This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
41469176|NCT01071031|BIOLOGICAL|HIV-v (Low Dose)|"Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection"
41149129|NCT06384859|BIOLOGICAL|PRP|Receive PRP injection at week 5
41149130|NCT04958434|DRUG|TST005|TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
41149131|NCT00525642|DRUG|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
41469177|NCT01071031|BIOLOGICAL|HIV-v (High Dose)|"High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection"
41469178|NCT01071031|BIOLOGICAL|HIV-v (Control)|"Adjuvant only or Water for injection only~Administration: A single subcutaneous injection"
41469179|NCT04359407|OTHER|Prone positioning|Change the positioning of the COVID patients who are intubated and mechanically ventilated from supine to prone
41469180|NCT06085339|BEHAVIORAL|Social Media|The social media arm participants will receive a diabetes curriculum designed to address diabetes self-efficacy and independence with diabetes management over the course of 6 months. Participants will have the option to engage with the study team and other participants through Instagram posts and direct messaging.
40996628|NCT06115811|BEHAVIORAL|Radiation Treatment Plan Evaluation Learning Tool|Web-based program comprised of a systematic, oncology treatment plan review system and learning modules. The case bank of radiation treatments plans is accessible via econtour.org.
41469181|NCT01764750|DRUG|Intrasite Vancomycin|Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.
40791647|NCT02378285|DEVICE|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
40996629|NCT02174848|DRUG|Deferiprone oral solution|Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
40996630|NCT01339728|PROCEDURE|far-infrared ray|The duration of far-infrared ray is 20 minutes.
40996631|NCT03678155|OTHER|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
40996632|NCT01765153|BEHAVIORAL|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
40996633|NCT01765153|BEHAVIORAL|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
40996634|NCT04924829|DRUG|Tocilizumab|Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.
40996635|NCT00589316|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given via central line
40996636|NCT00589316|DRUG|Cyclophosphamide|Given IV
40996637|NCT00589316|DRUG|Fludarabine Phosphate|Given IV
40996638|NCT00589316|RADIATION|Iodine I 131 Monoclonal Antibody BC8|Given IV (dosimetry dose) or via central line (therapeutic dose)
40996639|NCT00589316|OTHER|Laboratory Biomarker Analysis|Correlative studies
40996640|NCT00589316|DRUG|Mycophenolate Mofetil|Given IV or PO
40996641|NCT00589316|DRUG|Tacrolimus|Given IV or PO
40996642|NCT00589316|RADIATION|Total-Body Irradiation|Undergo TBI
40996643|NCT03144674|DRUG|Parsaclisib|Parsaclisib at the protocol-defined dose.
40996644|NCT01803633|OTHER|Cheddar cheese|Tillamook medium cheddar cheese brand
40996645|NCT01803633|OTHER|Vegan cheese|Daiya brand vegan cheese
40996646|NCT03666923|DRUG|THR-687 dose level 1|single intravitreal injection of THR-687 dose level 1
40996647|NCT03666923|DRUG|THR-687 dose level 2|single intravitreal injection of THR-687 dose level 2
40996648|NCT03666923|DRUG|THR-687 dose level 3|single intravitreal injection of THR-687 dose level 3
41469182|NCT01764750|DRUG|IV Vancomycin|IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.
41469183|NCT04890080|OTHER|Pulmonary Rehabilitation|Exercise training consisted of supervised breathing, aerobic, strengthening and stretching exercises for 8 weeks, 2 days a week. Breathing exercises included pursed lip, diaphragmatic, thoracic expansion and basal expansion exercises. Strength training included the lower and upper extremities, and it was performed 8-10 repetitions, either against gravity or using free weight, according to patient tolerance.
41469184|NCT03529565|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40996649|NCT05603416|DIETARY_SUPPLEMENT|Perilla frutescens extract|oral dissolvable powder - dosage 300mg
40996650|NCT05603416|DIETARY_SUPPLEMENT|Placebo|oral dissolvable powder - dosage 300mg no active ingredient
40996651|NCT06055855|PROCEDURE|Traditional Two-Needle Arthrocentesis|Participants in this group will undergo arthrocentesis using the traditional two-needle technique. The procedure involves the placement of one or two needles into the temporomandibular joint (TMJ) to irrigate the joint space. Needle placement is guided by anatomical landmarks.
40996652|NCT06055855|PROCEDURE|Surgery-Guided Arthrocentesis|Participants in this group will receive arthrocentesis facilitated by a surgical guide. The guide is generated through pre-operative planning and is designed to aid in the accurate placement of the needle into the TMJ.
41469185|NCT03529565|OTHER|Laboratory Biomarker Analysis|Correlative studies
40996653|NCT00386867|DRUG|800 mcg misoprostol via oral or buccal administration|
40996654|NCT05141474|BIOLOGICAL|NEXTGEN-TIL|"NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor.~Each dose contains at least 5 x 10\^8 total viable lymphocytes, and a maximum of 1.11x10\^11. It will be administered IV on Day 0 (24h after the last dose of Fludarabine)."
40996655|NCT05141474|DRUG|Non-myeloablative Lymphodepletion (NMA-LD) Regimen|Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).
40996656|NCT05141474|DRUG|Interleukin-2|"Patients will receive sequential doses of 720,000 IU/kg IV IL-2 every 8-24 hours depending on patient tolerance. It will be administered on Days 0 to 2, starting between 3 and 24 hours after the completion of NEXTGEN-TIL infusion.~IL-2 doses may be skipped in case of toxicity. If 2 sequential doses or more than 2 non-sequential doses of IL-2 are skipped due to patient intolerance or the discretion of the investigator, IL-2 administration must be stopped."
40996657|NCT02374879|DEVICE|Blood Glucose Monitoring Systems.|In vitro diagnostic medical device.
40996658|NCT02562651|DRUG|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
40996659|NCT02562651|OTHER|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
40996660|NCT00902564|DRUG|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
40996661|NCT00697515|DRUG|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
40996662|NCT00697515|DRUG|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
41149132|NCT00525642|DRUG|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
41469186|NCT03529565|OTHER|Quality-of-Life Assessment|Ancillary studies
40996663|NCT02113956|BEHAVIORAL|Guy2Guy (G2G)|"G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active."
40996664|NCT02691299|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
40996665|NCT02691299|DRUG|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
40996666|NCT01860456|DRUG|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
40996667|NCT04721249|DIETARY_SUPPLEMENT|D-serine|Patients will receive four 500mg capsules of D-serine each day over a course of six weeks (two after breakfast and two after dinner).
40996668|NCT04721249|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive four placebo capsules each day (two after breakfast and two after dinner). The placebo capsules will contain Mannotol / Mannitol-Silica (99.5/0.5, respectively) and will be indistinguishable from D-serine by matching colour, shape, size and packaging.
40996669|NCT04782531|OTHER|peripheral ECG|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
40996670|NCT04782531|OTHER|Standard MRI|Standard MRI examination using a torso coil consists of morphological and phase-contrast flow sequences(standard and EPI acquisitions).
40996671|NCT00901758|DRUG|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
40996672|NCT00901758|DRUG|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
40996673|NCT04924036|DRUG|glycopyrronium cloths|Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
40996674|NCT04924036|DRUG|Placebo|Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.
40996675|NCT04073381|COMBINATION_PRODUCT|Prehabilitation Program|This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
40996676|NCT05075226|DEVICE|Vivity Extended Depth of Focus|Cataract surgery
40996677|NCT02196272|BEHAVIORAL|Nurse-led reminder program through email|"Both groups will receive an educational program and usual care. The educational program will consist of:~- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form."
40996678|NCT05505032|DRUG|Oxygen|Determination of FiO2 threshold value as an indicator of hyperoxemia in anesthesia stages.
40996679|NCT05505032|DEVICE|Masimo Root Radical 7|We use it to measure the oxygen reserve index (ORi).
40996680|NCT00264355|DRUG|cyclosporine A|
40996681|NCT01991002|BEHAVIORAL|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
40996682|NCT01892631|OTHER|Text message influenza vaccination reminder|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
40996683|NCT01892631|OTHER|Standard care|Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
40996684|NCT05830474|PROCEDURE|Continuous intra-airway monitoring and intervention during surgey|Continuous monitoring was performed by visual double lumen bronchial catheter. Once sputum or blood gushing into the tracheal carina was found in the distal bronchus on the surgical side, the above secretions were sucked out with a sputum suction tube under video monitoring until the removal was complete
40996685|NCT06546254|DRUG|Lidocaine 1% Injectable Solution|10 cc 1% lidocaine paracervical injection
40996686|NCT06546254|DRUG|Saline|10 cc normal saline paracervical injection
40996687|NCT06546254|OTHER|Capped needle|Tapping the cervicovaginal junction with a capped needle
41149133|NCT02665624|DRUG|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
41149134|NCT02665624|DRUG|Senna alone|comparison of bowel cleansing and patient comfort.
41469187|NCT03529565|OTHER|Questionnaire Administration|Ancillary studies
41469188|NCT06193369|BEHAVIORAL|Digital Peer Navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for cancer. Participants will be matched through a digital app with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Patients will communicate with their peer navigator through digital direct messaging, videoconference or by telephone. Participants will also have access to a health resource library on the digital app that contains local and national resources about cancer.
41469189|NCT05561140|DRUG|Voxelotor Oral Tablet|Synthetic small molecule supplied as 500 mg tablets, administered Orally
41469190|NCT05561140|OTHER|Placebo|Placebo
40996688|NCT05348382|PROCEDURE|Intradermal acupuncture|In addition to basis standard pharmacological treatments, intradermal needles will be inserted in each selected acupoint and retained in place for 48 hours. Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster. The operator will tear off the adhesive tape of intradermal needles and stick them on the selected acupoints, and then apply pressure on intradermal needles over the selected acupoints perpendicularly according to the patient's tolerance. In addition, patients will be instructed to press the intradermal needles 4 times per 24 hours throughout the needle retention period, with the aim to increase stimulation for treatment enhancement, each time lasting around 30 seconds.
40996689|NCT05348382|PROCEDURE|Sham intradermal acupuncture|In addition to basis standard pharmacological treatments, sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling. Additionally, participants in the sham intradermal acupuncture group will be treated in another room to avoid direct communications with subjects in the IDA group.
40996690|NCT03380585|PROCEDURE|Reciprocating single-file system|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.The device in the experimental group moves in CW and CCW direction with different angles. It is a single-file endodontic file system. The intervention is reciprocating single-file system. A Reciproc single-file will be used for enlarging apical foramen. In the active comparator group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
41149135|NCT03722602|OTHER|Standard rehabilitation after stroke|The program of the rehabilitation was designed specifically for each patient. It was prepared to match the patient's functional status and the defined goals. The subjects participated in exercise five days per week, for five weeks. During their stay at the Clinic, the patients took part in morning exercise and received individual practice, based on neuro-developmental treatment (Bobath concept), and proprioceptive neuromuscular facilitation (PNF) method, addressing the impaired motor abilities; if it was needed they also performed exercise based on equipment using biological feedback: Balance Trainer (static and dynamic parapodium) and Pablo system designed for upper limb training.
41149136|NCT06062147|BEHAVIORAL|Teacher training|Training for teachers in the intervention arm in the learning process, SLLD and early warning signs, with an identification grid. Observation of identified pupils and implementation of educational and environmental adjustments.
41149137|NCT05728619|DRUG|HTMC0435|Oral administration.
41149138|NCT05728619|DRUG|Temozolomide|Oral administration.
41149139|NCT04867499|OTHER|No intervention|Descriptive study. No intervention.
41149140|NCT01234675|DRUG|Milnacipran|50 mg twice daily
41149141|NCT01234675|DRUG|Placebo|50 mg twice daily
40996691|NCT03380585|PROCEDURE|Rotational multi-file system.|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged. In this group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
40996692|NCT04076800|PROCEDURE|Acupuncture|Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).
41149142|NCT04182542|DEVICE|Radiofrequency|The volunteers will receive radiofrequency (TECAR-BTL® device, with epidermal temperature above 40ºC) in the right infraumbilical abdominal region, with an application time of 10 minutes (2 minutes per applicator area) and the left region will be used as control. A single session will be held. After approximately 30 days of this application the material for histological analysis will be collected during the surgical act, at which point the skin and the subcutaneous tissue of the infraumbilical region are discarded by the surgeon.
41149143|NCT01979822|OTHER|PH patients with LenusPro pump|Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump
41149144|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Astus©|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will use coagulation with bipolar tweezers Astus Medical© in this group.
41469191|NCT01035476|BEHAVIORAL|Data Card Report|Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
41469192|NCT00273416|DRUG|PF-00592379|
41469193|NCT00273416|DRUG|Sildenafil 100mg|
41469194|NCT03026517|DRUG|Dabrafenib|
41469195|NCT03026517|DRUG|Trametinib|
40791648|NCT02378285|OTHER|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
40791649|NCT01537471|DRUG|Placebo|Placebo
40791650|NCT01537471|DRUG|Meclizine|Meclizine 12.5 mg
40791651|NCT01537471|DRUG|Meclizine|Meclizine 25 mg
40791652|NCT03710265|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
40791653|NCT04432922|OTHER|Hospitalized Patients for COVID-19 Infection|Face to face semi-directed interviews about perceptions, representations and experiences of septic isolation, including nine opened-questions.
40791654|NCT00736112|OTHER|Food Allergy Testing|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
40791655|NCT00736112|PROCEDURE|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
40791656|NCT00736112|PROCEDURE|BMT|The standard protocol for children presenting with initial Chronic OME is to perform a BMT
40996693|NCT03628911|DEVICE|Tetanizing Burst Therapy|Tetanizing Burst Therapy tetanizes skeletal muscle with a brief burst of stimulation prior to ICD shock, thereby reducing muscular contraction due to the shock
40996694|NCT01495585|DRUG|Lonafarnib|Commercially approved products used to test the research hypothesis
40791657|NCT00006695|DRUG|carmustine|300 mg/m2 IV on Day -6
40791658|NCT00006695|DRUG|cytarabine|100 mg/m2 BID on Days -5 through -2
40791659|NCT00006695|DRUG|etoposide|100 mg/m2 BID on Days -5 through -2
40791660|NCT00006695|DRUG|melphalan|140 mg/m2 IV on Day -1
40996695|NCT01495585|OTHER|Placebo|Placebo control
40996696|NCT05942261|OTHER|Survey to collect data|The study is a survey aimed to collect data about rehabilitation methods
40996697|NCT00225381|DEVICE|connection of measuring device to anesthesia circuit|same as name
40996698|NCT00225381|PROCEDURE|drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team|same
40996699|NCT00225381|PROCEDURE|changing operating room bed position (head down and up position)|same
40996700|NCT00225381|PROCEDURE|adding PEEP during anesthesia|same
40996701|NCT00225381|PROCEDURE|placement of esophageal Doppler for cardiac output measurements|same
40996702|NCT00225381|DEVICE|Humidity sensor|Small conventional anesthesia T piece including tiny 2 thermometer inside
40996703|NCT00225381|DEVICE|A mixing chamber (bymixer)|2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
40996704|NCT00225381|DEVICE|Pneumotachometer cuvette|The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
40791661|NCT00006695|PROCEDURE|peripheral blood stem cell transplantation|Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
40791662|NCT00006695|RADIATION|tositumomab and iodine I 131 tositumomab|"Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject"
40791663|NCT05074017|DEVICE|3 nasopharyngeal swab|3 nasopharyngeal swabs to conduct 2 rapid antigen tests for SARS-CoV-2 and a RT-PCR
40996705|NCT00225381|DEVICE|Mass spectrometer sampling port|Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
40996706|NCT06224933|DEVICE|Augmented Reality System|Subjects will undergo image guided needle aspiration, injection, or biopsy facilitated by the Augmented Reality system. The Augmented Reality guidance system will be operated by the interventional radiologist in the MRI suite.
40996707|NCT02037542|BEHAVIORAL|Diet and exercise|Upon enrollment, the patient will be asked to meet with a dietitian to assess the individual patient's current diet and exercise routines. In the first session, the dietitian will provide individual counseling and together with the patient devise weight loss / exercise strategies that fit the patients' lifestyle. Following the initial assessment, patients will embark on a weekly program, with weekly meetings lasting 30min - 1h. Patients will be asked to record meal portions weekly in a Food Log (Appendix B), according to the established goal. At each meeting, the dietitian will review the Food Log with the patient and evaluate progress.
40996708|NCT00719836|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
40996709|NCT02472938|DRUG|dimethyl fumarate|dimethyl fumarate 120 mg capsules
40996710|NCT02472938|OTHER|Placebo|Placebo for BG00012
40996711|NCT02493699|OTHER|physical exercise- based intervention (Karate techniques training)|
40996712|NCT01272830|DRUG|Placebo|Two capsules taken twice daily with meals
40996713|NCT01272830|DRUG|Apatone®B|Two capsules taken twice daily with meals
40996714|NCT06375733|DRUG|GFH009|administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.
40996715|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
41469196|NCT03026517|DRUG|Phenformin|
41469197|NCT02173652|DRUG|BI 1356, high dose|
40791664|NCT04313738|OTHER|Assigned Interventions|Home visit, health education
40791665|NCT04299386|DEVICE|NeoPhylaxis|NeoPhylaxis® gel is designed for the non-surgical decontamination of the implant surface and can be used for professional regular implant maintenance, with or without peri-implant mucositis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in non-sterile form.
40791666|NCT04299386|DEVICE|ImplanTreat|ImplanTreat® gel can be used for the surgical decontamination of the implant surface and can be used to decontaminate implants with peri-implantitis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in sterile form.
40791667|NCT04858438|PROCEDURE|Insufflation during surgery|This is the amount of insufflation using during the surgical procedure.
40791668|NCT03719963|DEVICE|Cochlear implant|Cochlear implant for hearing process by surgical intervention
40791669|NCT06257225|PROCEDURE|Guided Bone regeneration|After local anesthesia, a crestal incision will be performed followed by full-thickness mucoperiosteal flap elevation Flap advancement will be attained through periosteal scoring of the buccal; The resorbable collagen membrane (Bio Gide, Geistlich AG) will be trimmed to the defect size. Xenograft (Bio-Oss) together with scrapped autogenous bone will be mixed and placed at the surgical site. The membrane will positioned over the graft and tucked into the lingual flap. Patient allocation concealment will be broken and the patients will be randomly assigned into two groups Patients receiving horizontal bone augmentation with resorbable collagen membrane stabilized with no tacks. The first layer will be closed with horizontal mattress sutures placed 4 mm from the incision line, and single interrupted sutures are used to close the edges of the flap. Vertical incisions are closed using single interrupted sutures and mattress suture should remain in place for at least 2 to 3 weeks
40791670|NCT03301337|DIETARY_SUPPLEMENT|Meat protein absorption|Meat protein absorption when digested together with a full meal.
40791671|NCT04210492|RADIATION|45 Gray (Gy) regimen|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
40791672|NCT05346276|DIAGNOSTIC_TEST|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
40791673|NCT04078269|BIOLOGICAL|Dendritic cell immunotherapy|Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
40791674|NCT04078269|BIOLOGICAL|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIXNEO-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
40791675|NCT04078269|BIOLOGICAL|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
40791676|NCT03407092|OTHER|ADAPT cohort|Thrombectomy with distal aspiration technique
40791677|NCT03407092|OTHER|Stentriever Cohort|Thrombectomy with stent retriever
40791678|NCT00777595|DRUG|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
40791679|NCT00777595|DRUG|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
40791680|NCT00777595|DRUG|Placebo|Inhaled solution, single dose of placebo
40791681|NCT00777595|DRUG|Moxifloxacin|Tablet, oral, 400mg, single dose
40791682|NCT00989976|BEHAVIORAL|normal sleep times|8.5 h bedtimes
40791683|NCT00989976|BEHAVIORAL|bedtime restriction|4.5 h restricted bedtimes
40791684|NCT01110057|DRUG|Placebo|Placebo to match GW856553
40791685|NCT01110057|DRUG|GS856553|GW586553 7.5mg bid
40791686|NCT02621476|BEHAVIORAL|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
40791687|NCT02621476|BEHAVIORAL|Usual care|Usual care
40791688|NCT03727971|DRUG|Omalizumab Injection|The treatment is initiated with one injection with weight and serum-immunoglobulin E balanced omalizumab. After omalizumab treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
40791689|NCT03727971|DRUG|NaCl|The treatment is initiated with one injection with placebo. After placebo injection treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
40996716|NCT06375733|DRUG|GFH009|the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.
40996717|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
40996718|NCT03095066|DRUG|Placebo|Administered as capsules
40996719|NCT03095066|DRUG|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
40996720|NCT03095066|DRUG|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
40996721|NCT03700697|BEHAVIORAL|Family Stress Module Intervention|as above
40996722|NCT04296552|OTHER|Dietary lowFODMAP intervention|Twelve week strict lowFODMAP dietary intervention, involving restricted intake of fermentable carbohydrates (FODMAPs).
40996723|NCT05231590|BIOLOGICAL|Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (12.5 µg) with Advax-SM adjuvant (7.5 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
40996724|NCT05231590|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
40996725|NCT05261984|PROCEDURE|Resistance exercise|Knee extensions in flywheel inertia machine in four sets of 10 repetitions.
40996726|NCT05261984|DIETARY_SUPPLEMENT|Oral protein supplementation|24 grams of hydrolyzed whey protein.
40996728|NCT04774978|DEVICE|TTE|Transthoracic echocardiography
40996729|NCT03202862|DRUG|Fulvestrant|Fulvestrant 500 mg given as two 5 ml intramuscular inections, one in each buttoc, on days 1, 15, 2 and every 2 ( ) days thereafter.
40996730|NCT02154555|PROCEDURE|debridement|post-operative debridement at 1 week follow-up visit
41149145|NCT03430609|DIAGNOSTIC_TEST|AMH Level|"The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery."
40791690|NCT04430608|DEVICE|Dexcom G6|"The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC."
41469198|NCT02173652|DRUG|BI 1356, low dose|
41469199|NCT06563245|DRUG|Brentuximab Vedotin for Injection|1.8mg/kg/dose (MAX 180 mg)
41469200|NCT06563245|RADIATION|response-adapted radiation|For patients who did not achieve complete metabolic response at early response assessment based on PET/CT result.
40791691|NCT00703742|DRUG|Escitalopram|A,1: Escitalopram, oral, 20 mg/day, 8 weeks
40791692|NCT02308267|OTHER|Lung explants|Lung explants from end-stage CF, which were obtained for a reason independent from the study in the Paris (Prof Burgel) and Leuven (Prof Dupont) centres will be analysed for pIgR and IgA expression as well as for Pseudomonas aeruginosa colonization. Some lung explants from control patients will also be obtained from the Leuven centre.
40996731|NCT02078583|DRUG|Fentanyl|
40996732|NCT02078583|DRUG|Remifentanil|
40996733|NCT02078583|DRUG|Normal saline|
40996734|NCT01617057|DRUG|tiludronic acid|400 mg / day for 3 months
41469201|NCT06563245|DRUG|Doxorubicin|25mg/m2/dose,
41469202|NCT06563245|DRUG|Etoposide|125 mg/m2/dose
41469203|NCT06563245|DRUG|Prednisone|20 mg/m2, BID, orally
41469204|NCT06563245|DRUG|Cyclophosphamide|600 mg/m2/dose
41469205|NCT06563245|DRUG|Dacarbazine|250 mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at early assessment based on PET/CT results.
41469206|NCT06563245|DRUG|Tislelizumab Injection|3mg/kg/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
41469207|NCT06563245|DRUG|Bedamustine|180mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
40791693|NCT02308267|OTHER|Sputum, nasal fluid and serum|Sputum, nasal (fluid) and serum samples from CF patients and controls patients will be collected (Leuven, Paris, Torino, Verona and Saint-Luc Brussels) for S-IgA and microbiological assays. Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal lavage. Control subjects will consist of COPD patients and healthy subjects (smokers or not).
40791694|NCT02308267|PROCEDURE|Bronchoscopy|Endobronchial biopsies (EBB) and broncho-alveolar lavage (BAL) will be sampled at the KULeuven centre (Prof Dupont) in some CF patients (homozygous for the DF508 mutation) and colonized or not with Pseudomonas aeruginosa and who must have a general anaesthesia for a reason independent from the study. In these patients, a bronchial endoscopy will be performed during narcosis to take EBB (n=8) and BAL (2x50mL). If possible, nasal and rectal biopsies will also be performed in some patients. Samples will be assessed for pIgR and IgA expression and for primary broncho-epithelial cultures (carried out at the UCL centre, Pr Pilette). Control subjects will be patients without CF and without evidence of lung disease and who are undergoing narcosis for an independent reason at the KULeuven centre.
40996735|NCT01617057|DRUG|Placebo|400 mg / day for 3 month
40996736|NCT00360464|DRUG|Azithromycin SR|
40996737|NCT01045109|DIETARY_SUPPLEMENT|cholecalciferol|4,000 I.U. softgel daily orally for 48 weeks
40996738|NCT01045109|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
40996739|NCT05016232|BEHAVIORAL|PrEP N' Shine: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
40996740|NCT05016232|BEHAVIORAL|PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2)|"1. Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~2. Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
41469208|NCT00585260|DRUG|mannitol|indirect mannitol challenge
41469209|NCT02026544|DEVICE|Low Frequency Therapeutic Ultrasound|29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
41469210|NCT06135376|BEHAVIORAL|comprehensive multi-component interventions|It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.
41469211|NCT01787110|DRUG|Oxygen|see arm description
41469212|NCT06180694|OTHER|Reminiscence therapy|In the research, reminiscence therapies will be carried out once a week for 8 weeks, in sessions of approximately 45 minutes.
41469213|NCT01981317|BEHAVIORAL|Stepped Care Cognitive Behavioral Therapy|
41469214|NCT01981317|BEHAVIORAL|Cognitive Behavioral Therapy|
41469215|NCT04087863|OTHER|Not applicable(observational study)|Not applicable(observational study)
41469216|NCT03245216|BEHAVIORAL|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning
41469217|NCT03245216|BEHAVIORAL|rest|Seated rest before motor learning
41469218|NCT03245216|BEHAVIORAL|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
40996741|NCT06276959|DIAGNOSTIC_TEST|intraoral scanning|The patients underwent intraoral scanning using an iTero Element 5D imaging system (Align Technology, San Jose, CA, USA). This imaging system uses near-infrared light with a wavelength of 850 nm and provides multiple layers of data in a single scan, including a three-dimensional (3D) model, two-dimensional (2D) color images, and NIRI mapped to the 3D model
40996742|NCT06276959|DIAGNOSTIC_TEST|clinical oral examination|Under illumination in the dental unit, a UVE of the proximal surfaces of the patient's entire dentition was conducted by clinicians using a mouth mirror, dental probe, and an air-water syringe. Visual and tactile methods were performed according to the guidelines of the American Dental Association. Clinicians assessed the soundness of the proximal surfaces based on the presence of discoloration, surface alterations, or cavitation.
40996743|NCT06276959|DIAGNOSTIC_TEST|cone-beam computed tomography|All enrolled patients underwent CBCT scans because clear aligner treatment required real root/bone visualization features. We would like to clarify that due to the retrospective cross-sectional nature of this study, the patients involved were not subjected to radiation beyond what was initially necessary for their orthodontic treatment.
40996744|NCT03678467|COMBINATION_PRODUCT|EB-CMF|Autologous, anatomically shaped bone graft
40996745|NCT03127657|DRUG|Cock's comb extract 0.01%|Applied topically twice daily for 12 weeks
40996746|NCT03553732|OTHER|Registry|Patients who are diagnosed with prostate cancer and elect to be monitored by an Active Surveillance protocol by the Urology Clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing but suboptimal systems for tracking patients. All Active Surveillance patients monitored by the clinic will be included.
41149146|NCT03430609|DIAGNOSTIC_TEST|Transvaginal ultrasound for antral follicle count|The participants will be subjected to transvaginal ultrasound for antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery. This test will be performed during the early proliferative stage (days 3 to 6 of the menstrual cycle); the size of the endometrioma and the ovary volume will be recorded, and functional cysts or suspected malignant cysts will be ruled out. For measurement of cysts, the average diameter of the three perpendicular ovary dimensions will be considered. For antral follicle count, the total number of follicles with diameters under 9 mm will be considered.
41149147|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Vicryl®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will perform suture with 2-0 Vicryl® in this group.
41149148|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Surgicel®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In this group, for hemostasis , the investigators will use matrix Surgicel®
41149149|NCT01332318|DRUG|XP13512|XP13512 once daily for 16 days
41149150|NCT01332318|DRUG|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
41149151|NCT01332318|DRUG|Placebo|XP13512 placebo once daily for 16 days
41149152|NCT03449979|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
41149153|NCT03449979|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
41149154|NCT06375018|OTHER|Placebo Technique|In the control group, manual contact will be carried out without any therapeutic intention. This contact will be maintained for the same period of time as the experimental group.
41149155|NCT06375018|OTHER|Diaphragm Stretching|The participant will be in supine position and the researcher will be at the headrest of the examination table, placing his hands on the lower costal margin. Superior direction traction is performed during inspiration, remaining during expiration. The procedure is repeated for a maximum period of 4 minutes.
41149156|NCT05299099|DRUG|IN-C006 inj.|IN-C006 will be injected continuously for 3 days.
41149157|NCT05299099|DRUG|RCN301|RCN301 will be injected continuously for 3 days.
41149158|NCT01604499|BEHAVIORAL|Feedback letters|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
41149159|NCT01604499|BEHAVIORAL|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
41149160|NCT03183856|DEVICE|Morning walk|a end-effector typed gait robot with a saddle
41149161|NCT03183856|OTHER|no Morning walk|ambulation voluntary or with a help of walker
41149162|NCT03371849|DRUG|montelukast and levocetirizine FDC|HCP1102
40791695|NCT05323890|DRUG|Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy|Patients received tislelizumab at a fixed dose of 200 mg every three weeks (q3w, 21 days) for 2 cycles.
41149163|NCT03371849|DRUG|Singulair + xyzal|HGP0813 + HGP1408
41149164|NCT02241980|OTHER|Patient survey|
41149165|NCT02241980|OTHER|Physician survey|
41149166|NCT05556967|DIETARY_SUPPLEMENT|Immulina|Immulina is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
41149167|NCT03834909|DRUG|Standard dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
41149168|NCT03834909|DRUG|Pregnancy-adjusted dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
41149169|NCT04722471|DRUG|Vaginally administered progesterone|The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)
40996747|NCT02181062|BEHAVIORAL|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
40996748|NCT03371901|OTHER|Physical therapy with BFR-LLST|"The criteria-based rehabilitation protocol for the patients with cartilage or meniscus repair may vary according to the surgical procedures.~Patients will attend 5 individual treatments, and a 6-week supervised group-based rehabilitation program with BFR-LLST (Blood Flow Restriction - Low Load Strength Training) twice a week at the rehabilitation centre. Patient will be instructed to perform BFR-LLST 5 times a week in total (twice supervised, 3 times at home).~During each BFR-LLST session, patients are encouraged to perform 4 sets of 30 repetitions, 15 repetitions, 15 repetitions, and 15 repetitions (or to fatigue in the final set), respectively.~The exercise intervention will adhere to TIDieR (template for intervention description and replication)."
40996749|NCT01630330|PROCEDURE|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
41469219|NCT04212377|BIOLOGICAL|Dendritic Cells for endometrial cancer|Our study population consists of 8 mEC patients who receive carboplatin / paclitaxel chemotherapy in a weekly schedule on weeks 1, 2, 3 and weeks 5,6 and 7. In week 8, myeloid and plasmacytoid DC (nDC) are loaded with tumor lysate and MUC1 and survivin PepTivators, injected intranodally. An extensive immuno-motoring will be performed on all patients. Patients who show stable disease, partial response, or full response continue with extended three-week chemotherapy regimens with intranodal injections of nDC at weeks 17, 20, and 23.
41469220|NCT00798681|DIETARY_SUPPLEMENT|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
41469221|NCT00798681|OTHER|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
41469222|NCT00798681|OTHER|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
41469223|NCT01279655|DEVICE|tDCS|20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
40791696|NCT04968626|RADIATION|PI-LL|The pelvic parameters were collected including PI, pelvic tilt (PT), sacral slope (SS) and LL ,and compared between IS patients and the AS group. Besides, spinopelvic malalignment was defined as an absolute value of PI-LL greater than 10.In the IS group,the clinical symptoms were assessed with the Japanese Orthopaedic Association (JOA) score and the visual analogue scale (VAS). We compared spinopelvic parameters between the asymptomatic adults and the IS patients. Additionally, we investigated correlations between spinopelvic parameters and clinical symptoms.
40791697|NCT01195818|DRUG|RAS Inhibitors|Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
40996750|NCT01630330|PROCEDURE|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
40996751|NCT01334866|PROCEDURE|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
40996752|NCT03173716|PROCEDURE|Definity|Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
40996753|NCT06266455|DIETARY_SUPPLEMENT|Standardized Fortification|Fortification with liquid, bovine-based HMF to assumed human milk content of 24kcal/oz
40996754|NCT06266455|DIETARY_SUPPLEMENT|Adjustable Fortification|Additional liquid protein supplementation to maintain serum BUN levels within goal range (9-14mmol/dL)
40996755|NCT06266455|DIETARY_SUPPLEMENT|Adjustable Fortification|Additional liquid protein and/or MCT oil supplementation to maintain protein, fat, and energy intake within goal range based upon mid-infrared human milk analysis
40996756|NCT06543446|PROCEDURE|ICD implantation|Surgical implant of ICD device
40996757|NCT06383663|PROCEDURE|Supraclavicular lymph node dissection combined with radiotherapy|Breast cancer patients in the expreimental cohort with only ipsilateral supraclavicular lymph node metastasis were first treated with supraclavicular lymph node dissection and received standard radiotherapy after surgery.
40996758|NCT06383663|RADIATION|radiotherapy|Patients in the control group received only standard radiation therapy.
40996759|NCT03189628|BIOLOGICAL|stromal vascular fraction|The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
41149170|NCT05288504|DRUG|AVTX-002|Dose of 600 mg administered subcutaneously three times during the study.
41149171|NCT05288504|DRUG|Placebo|Placebo sourced as normal saline administered subcutaneously three times during the study.
41469224|NCT01279655|BEHAVIORAL|Bimanual Training|The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
41469225|NCT04105114|DRUG|Buspirone|Oral Buspirone 7.5mg - 10mg daily during the treatment phase.
41469226|NCT04105114|DEVICE|Non-invasive Spinal Cord Stimulation|A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.
41469227|NCT04105114|DEVICE|Ekso Bionics Exoskeleton|This robotic exoskeleton is designed to assist people with neurological injuries for balance, standing, and stepping overground.
41149172|NCT03687918|OTHER|Assessment of the performances of QCAD/Lyon in characterizing Gleason ≥7 cancers among contoured lesions|"Principal Objective:~To assess the performances of QCAD/Lyon (AUC and its 95% confidence interval) in characterizing Gleason ≥7 cancers among the lesions delineated on mpMRI from the Dijon University Hospital.~Secondary Objectives:~* To compare the diagnostic performance (AUC) of QCAD/Lyon and of the Likert score~* To compare the diagnostic performance (AUC) of QCAD/Lyon and of the PIRADS v2 score~* To define the best combination of quantitative parameters in the Dijon cohort (if different from that defined in Lyon)"
41149173|NCT02630147|OTHER|Vanilla scent|A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).
41149174|NCT06243666|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
41149175|NCT06243666|OTHER|No intervention|No intervention was implemented.
41149176|NCT06243666|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
40996760|NCT03189628|DRUG|Saline|1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
40996761|NCT02146482|OTHER|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
40996762|NCT03203902|OTHER|Psychoeducation and Therapeutic Touch|6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
40996763|NCT01411306|OTHER|Toronto Bedside Swallowing Screening Test (TOR-BSST©)|All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.
40996764|NCT01411306|PROCEDURE|Videofluoroscopic Swallow Study|All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
40996765|NCT01736696|DRUG|tofacitinib|5 mg BID For 13 days and once on Day 14
40996766|NCT01736696|DRUG|tofacitinib|10 mg BID for 13 days and once on Day 14\*
40996767|NCT01736696|DRUG|tofacitinib|20 mg BID for 13 days and once on Day 14
40996768|NCT01736696|DRUG|tofacitinib|30 mg BID for 13 days and once on Day 14
40996769|NCT01736696|DRUG|tofacitinib|60 mg tablet once a day (QD) for 14 days
40996770|NCT01736696|DRUG|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
40996771|NCT05768854|DRUG|Bisphosphonate|Administered per investigator discretion via intravenous (IV) infusion
40996772|NCT05768854|BIOLOGICAL|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
40996773|NCT03938194|PROCEDURE|Aquablation|a novel minimally invasive water ablation therapy combining image guidance and robotics for the targeted and heat-free removal of prostate tissue
40996774|NCT02596854|DEVICE|Neurological MRI|Neurological MRI image collection
40996775|NCT06158191|BEHAVIORAL|Lifestyle modification program|Participants will take part in a lifestyle modification program focused on physical activity and diet.
41149177|NCT03044951|PROCEDURE|cryoballoon ablation|cryoballoon ablation：pulmonary vein isolation by cryoballoon
41149178|NCT03044951|PROCEDURE|radiofrequency ablation|radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
41149179|NCT05955222|DEVICE|PEEK|Participants receiving splints produced with CAD/CAM from PEEK blocks,
41149180|NCT05955222|DEVICE|PMMA|Participants receiving splints produced with CAD/CAM from PMMA blocks,
40996776|NCT00685243|PROCEDURE|Laser treatment|Fraxel and pulsed dye laser
41149181|NCT05955222|DEVICE|Traditional|Participants receiving splints from vacuum forming system
40996777|NCT05828251|PROCEDURE|Vitrectomy (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
40996778|NCT05828251|PROCEDURE|Combined phako-vitrectomy|Phakoemulsication and pars plana vitrectomy are performed in the same setting. This procedure is normally only offeres to selected cases at our department.
40996779|NCT05828251|PROCEDURE|Phako (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
40996780|NCT00253383|OTHER|counseling intervention|
40996781|NCT00253383|OTHER|educational intervention|
40996782|NCT00253383|PROCEDURE|psychosocial assessment and care|
40996783|NCT00253383|PROCEDURE|quality-of-life assessment|
40996784|NCT05053529|OTHER|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
40996785|NCT05053529|OTHER|CIMT group|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
40996786|NCT04766242|OTHER|Spiritual healing|"The spiritual healing will be based on an assessment of the total health situation of the individual patient. Spiritual healing will mainly consist of a treatment where the healers hold their hands for some time at different parts of the patient's body, known as power points, outside the patients clothing. The consultation might also include possible life-style advice. The treatments will last for 45-60 minutes each time."
40996787|NCT04766242|OTHER|Usual care|The care the general practitioner (GP) prescribe when the patients are diagnosed with moderate depression.
41149182|NCT02854436|DRUG|Niraparib|Participants will receive 300 mg niraparib (3 capsules\*100 mg) orally once daily.
41149183|NCT03255785|DEVICE|Cataract surgery plus one iStent and one iStent Supra implanted|Cataract surgery via phacoemulsfication plus one iStent and one iStent supra
41149184|NCT00319878|DRUG|Sirolimus|"Oral loading dose followed by a once daily dose:~* Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~* Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~* Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~* Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg"
40996788|NCT01794052|OTHER|Evidence based, DSS enabled, health care delivery model|"The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~1. A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~2. Treating patients as per a standard clinical guidelines~3. Giving health education to patients on lifestyle changes for better self-care~4. Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~5. Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm"
41149185|NCT00319878|DRUG|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
41149186|NCT03330197|BIOLOGICAL|Ad-RTS-hIL-12|2.0 x 10\^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12
41149187|NCT03330197|DRUG|Oral Veledimex - Arm 1 (Pediatric Brain Tumor)|1 dose level (10mg/day) 15 oral daily doses of veledimex
41149188|NCT03330197|DRUG|Oral Veledimex - Arm 2 (DIPG)|2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex
41149189|NCT04404699|DIAGNOSTIC_TEST|Stimulation TcPO2 test|"During measurement of TcPO2 in various angiosomes the stimulation test will be performed. We modify the Ratschow test (elevation of the lower limbs, rhythmic flexion and extension in talocrural joints for 2 minutes, then return to horizontal position). TcPO2 is measured continuously. Depending on the type of detected flows by DUS in the evaluated arteries supplying the relevant angiosome, in which TcPO2 values are measured, the patients and their angiosomes will be divided into 2 baseline groups - group M with monophasic flows or arterial obliterations and group T with triphasic flows.~We will compare macrocirculation parameters-systolic pressure on dorsalis pedis artery (DPA), posterior tibial artery (PTA) and their doppler indexes. The resting TcPO2, the minimal TcPO2 found during the stimulation test, their delta (resting TcPO2 - minimal TcPO2) and the percentage decrease in TcPO2 will be compared between the study groups, as well as the duration of TcPO2 recovery."
41149190|NCT01535625|DEVICE|Momo stent|Patients with PCI
41149191|NCT05362253|PROCEDURE|Micro-Conjunctival Autograft Combined with Amniotic Membrane Transplantation|"1. Disinfection, anaesthesia and excision of recurrent pterygium are the same as conventional autologous conjunctival transplantation.~2. The biological freeze-dried amniotic membrane (Jiangxi Ruiji Biological engineering technology Co., Ltd., Nanchang, China), equivalent in size to the exposed scleral surface, was flat mounted on the exposed scleral area , and the amniotic membrane was fixed on the superficial sclera with 10-0 suture.~3. After amniotic membrane graft was fixed, 2% lidocaine was applied to the superior temporal conjunctiva.~4. Take the conjunctival epithelial graft with the length equivalent to the neck of recurrent pterygium and the width of 1.5mm \~ 2.0mm, and translate it on amniotic membrane surface near corneal limbus. The conjunctival flap was secured with 10-0 suture.~5. Last, tobramycin and dexamethasone eye ointment was applied and bandaged with dressing."
41149192|NCT05362253|PROCEDURE|Conventional Autologous Conjunctival Transplantation|"1. Routine disinfection and anaesthesia.~2. To bluntly separate and excise pterygium.~3. Remove pterygium tissue on the corneal surface with a round blade.~4. Place a cotton ball slightly infiltrated with diluent Bleomycin A5 Hydrochloride for Injection on the exposed sclera for 1 minute and flushed away later.~5. After anesthesia, take the superior temporal conjunctival epithelium equal to the size of the exposed scleral and translate it to the exposed scleral surface (the limbus side of the graft corresponds to the limbus of the graft bed), and fixed with 10-0 suture.~6. The free conjunctival margin of the conjunctival flap sampling area was sutured intermittently with 10-0 suture.~7. Apply tobramycin dexamethasone eye ointment and wrap the eyes with dressing after operation."
41149193|NCT00080119|DRUG|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
41149194|NCT00080119|DRUG|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
41149195|NCT00080119|DRUG|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
41149196|NCT06119386|DEVICE|Rexon-Eye|In this prospective, interventional study, 81 patients were randomly allocated to received 4 treatment sessions of QMR at one-week intervals (Rexon-Eye ® , Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute 4 times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo ® , Thea Pharma, France) (SH-TH group). Outcomes measures included ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM) and meibomian gland dysfunction (MGD) grade, which were assessed at baseline, 1-month and 3-months follow-up.
41149197|NCT01537263|DEVICE|Ultrasound Perfusion Imaging|Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
41149198|NCT02855892|OTHER|Placebo|
41149199|NCT02855892|DRUG|GV1001|
40996789|NCT03439969|DEVICE|Mobile Text Messages|Dental inter-proximal control with floss holder and receiving 16 SMS during 4 months.
41149200|NCT02659488|DRUG|Lisdexamfetamine|20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
41149201|NCT03090893|DRUG|ATryn continuous infusion|replenish serum thrombin levels
41149202|NCT01586494|DRUG|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
41149203|NCT01586494|DRUG|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
41149204|NCT00004276|DRUG|thalidomide|
41149205|NCT06228209|BEHAVIORAL|Tier - Palliative Care|TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. It represents an adaption of the Mount Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines.
41149206|NCT03990376|OTHER|Radioisotope I-131-labeled albumin|1 mL of radioisotope I-131-labeled albumin x 2
40791698|NCT00589173|BEHAVIORAL|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
40791699|NCT00589173|BEHAVIORAL|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
40791700|NCT04089527|DRUG|CC-95775|CC-95775
40791701|NCT03941418|DIETARY_SUPPLEMENT|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
40791702|NCT03941418|DIETARY_SUPPLEMENT|Placebo|Patients will be administered with placebo of same appearance, colour and taste once daily.
41149207|NCT02092285|DRUG|Golimumab|50mg or 100mg solution for injection; subcutaneous injection
40791703|NCT01905189|PROCEDURE|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
40791704|NCT04190680|BEHAVIORAL|Kokkerelli Learning Street|"The Kokkerelli Learning Street focusses on one specific food product (kale, tomato, asparagus, pepper, strawberry, blue berry, mushroom, carrot, or leek) and consists of multiple components:~1. An introduction lesson at school. Children are introduced to the product and familiarised with growing and harvesting processes and the importance of the product regarding health.~2. A visit to a grower's farm during which children are introduced to the precise planting, growing and harvesting procedures of the product. Children are allowed to enter the facilities (e.g., the greenhouse) and observe and experience the farming of the product.~3. A cooking workshop at the facilities of Kids University for Cooking BV. Children prepare a meal with help of volunteers. After preparing the meal, children help to set the table and consume their self-prepared meal.~4. An evaluation lesson at school. Children evaluate the Learning Street together with their peers and teacher."
40996790|NCT03439969|DEVICE|Intra Oral Camera|"SPT - Appointment with Intra-Oral Camera~* Examination and diagnosis (15 min) using Intra-oral camera.~* Motivation, discussion about desired outcomes and treatment needs (using Intra-oral camera) followed by instrumentation (scaling, polishing) (30 min)."
40996791|NCT02079688|DRUG|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
40996792|NCT02079688|DRUG|Multiple W/O/W formulation, active ingredient-free vehicle|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
40996793|NCT01642017|DRUG|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
41149208|NCT01361789|DRUG|parecoxib, valdecoxib, etoricoxib|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
41149209|NCT01361789|DRUG|Dexamethasone|8 mg IV
41149210|NCT01361789|DRUG|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
41149211|NCT03723057|DRUG|AG-221|Oral AG-221 administered as directed by treating physician.
40996794|NCT04947332|PROCEDURE|Auto-inoculation|A wart will be excised from the body, minced and will be inoculated in a subcutaneous pocket on forearm.
40996795|NCT04733651|DRUG|Hospital standard of care for COVID-19|Standard care for COVID-19 as per the hospital guidelines
40996796|NCT04733651|DRUG|Isoquercetin|Daily 1000 mg Isoquercetin as 4 capsules
40996797|NCT01065519|DEVICE|Xience V everolimus eluting stent|Xience V everolimus eluting stent
40996798|NCT01065519|DEVICE|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
41149212|NCT01159756|DRUG|Travacom|Travacom ophthalmic solution (1 drop per day)
40996799|NCT02367703|PROCEDURE|laparoscopic hysterectomy|
40996800|NCT05134207|DIETARY_SUPPLEMENT|oral carbohydrate solution|Patients in the intervention group; Preop oral carbohydrate solution was ingested orally twice within 10 minutes, as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the surgery.
40996801|NCT05261711|DRUG|AB1|This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
41149213|NCT02250911|OTHER|webcasts|
41149214|NCT02250911|BEHAVIORAL|Assessments|
41149215|NCT02250911|OTHER|Usual care|
41149216|NCT05384522|OTHER|blood samples collection|Blood samples will be drawn at baseline and at 6 and 12 months from baseline
41149217|NCT00614354|DRUG|99mTc-glucarate solution|Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
40791705|NCT01303952|DRUG|Eculizumab|Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
40791706|NCT04888988|BEHAVIORAL|Exercise Intervention|Participate in the Exercise for Cancer Patients (EXCAP) intervention
40791707|NCT04888988|OTHER|Tactile Sensitivity Test|Participants undergo tactile sensitivity test
40791708|NCT04888988|OTHER|Questionnaire Administration|Participants complete questionnaires
40791709|NCT04888988|PROCEDURE|Brain Magnetic Resonance Imaging|Participants may have options to complete brain MRI scans
40791710|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
40791711|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
40791712|NCT02140970|DRUG|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
40791713|NCT02140970|DRUG|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
40791714|NCT04021316|OTHER|dCELL® Human Dermis (decellularised dermal skin allograft - DCD)|DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
40791715|NCT04021316|OTHER|Compression bandaging therapy|Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
40996802|NCT02523846|DRUG|morphine|"Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).~So, half of the total 24-hour morphine requirement will be infused over 24 hours.~e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)"
40996803|NCT02523846|BEHAVIORAL|Patient re-education|A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
40996804|NCT05928910|DEVICE|SmileyScope VR|The SmileyScope Virtual Reality Headset is a VR headset to reduce pain and anxiety undergoing medical procedures. The device comes pre-loaded with a static virtual reality scenario. Participants will use the device in person when coming to clinic during an in-person, one time PNE procedure.
40996805|NCT05928910|OTHER|Standard of Care Treatment|Participants in this group will receive standard of care treatment during an in-person, one time PNE procedure.
40996806|NCT01908361|BEHAVIORAL|Unilateral Hybrid (InMotion3 plus CIT) Intervention|"During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.~During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions."
40996807|NCT01908361|BEHAVIORAL|Bilateral Hybrid (BMT plus BAT) Intervention|"During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.~During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands."
41149218|NCT03974308|OTHER|Comprehensive physiotherapy including balneotherapy and filling questionaire|Three-week stay in a sanatorium with comprehensive physiotherapy including balneotherapy and three time filling questionaire.
41149219|NCT03974308|OTHER|Comprehensive physiotherapy without balneotherapy and filling questionaire|Two-week outpatient treatment with comprehensive physiotherapy without balneotherapy and three time filling questionaire
41149220|NCT03974308|OTHER|No intervention, only filling questionaire|No physiotherapy nor balneotherapy applied but three time filling questionaire
40791716|NCT00335309|PROCEDURE|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
40791717|NCT00335309|DRUG|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
40791718|NCT06114940|DRUG|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
40791719|NCT06114940|DRUG|Lenvatinib|18 mg by mouth once each day for 12 weeks prior to nephrectomy
40791720|NCT05945498|BIOLOGICAL|TB/Flu-05E vaccine|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the TB10.4 and HspX antigens of M. tuberculosis
40791721|NCT05945498|BIOLOGICAL|Placebo|Participants will receive single intranasal injection of placebo buffer solution
40791722|NCT03931499|DIAGNOSTIC_TEST|Metabolomic analysis|Blood will be collected in all patients blood before surgery and after surgery (postoperative day 1). Our study is based on a polar metabolomics profiling of plasma and/or serum using hybrid triple quadrupole mass spectrometer coupled with chromatographic system.
40791723|NCT03554018|DRUG|Acetaminophen|Acetaminophen 500-1000mg every 6 hours
40791724|NCT03554018|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg every 6 hours
40791725|NCT03554018|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp)
40791726|NCT03554018|DRUG|Placebo oral capsule|To match acetaminophen, patients will take one or two capsules every 6 hours
40791727|NCT00984594|OTHER|Primary injury site|Autograft will be placed in the primary defect site.
40996808|NCT01908361|BEHAVIORAL|Conventional Rehabilitation|Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.
40996809|NCT02285907|OTHER|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
40996810|NCT02285907|OTHER|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
40996811|NCT02285907|OTHER|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
40996812|NCT02285907|OTHER|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
40996813|NCT01104636|DRUG|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
40996814|NCT03455465|OTHER|Community Health Worker Assessment|Participants will be approached by a community health worker who will ask them to complete an assessment of needs and offer to enroll them in post-discharge services to help address the needs identified.
40996815|NCT03533387|DRUG|MN-166|an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
40996816|NCT01049321|DIETARY_SUPPLEMENT|DASH diet|
40996817|NCT01049321|DIETARY_SUPPLEMENT|a usual diabetic diet|
41149221|NCT02070289|DRUG|PF-06372865|Tablets, 2.5 mg BID, 14 days
40996818|NCT03585452|DRUG|Dexmedetomidine Infusion|Patients with additional dexmedetomidine infusion
40996819|NCT03585452|DRUG|Propofol based general anesthesia|Patients with typical anaesthetic regimens
40996820|NCT04419038|PROCEDURE|conjunctival autografting augmented with topical application of Mitomycin C|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
40996821|NCT04419038|PROCEDURE|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
40996822|NCT02822469|OTHER|Manual Therapy Treatment|"Treatment starts with 10 deep breathing movements for global relaxation. The anterior and posterior neck muscles, shoulder girdle and subdiaphragmatic will be addressed with myofascial techniques repeated 10 times in each stroke. The cervical spine will be pulled in the longitudinal direction. The draw will be held 1 time, lasting 1 minute. The thoracic region will receive mobilization technique in the anteroposterior direction,10 repeated movements involving all thoracic segment.~The treatment will be applied previously trained therapists, 4 weeks, 2 times a week, totaling eight sessions. The treatment time per session is about 25 minutes."
40996823|NCT02822469|DEVICE|Placebo Ultrasound|A detuned pulsed ultrasound will be applied to regions of the muscles around the shoulder girdle and anterior posterior cervical, for 25 minutes (2.5 minutes in each zone ). The device will be used with the internal cables disconnected for the placebo effect . However, you can handle it and adjust the doses and alarms as it is connected in order to simulate clinical practice and increase the credibility of the use of this device in the voluntary . The placebo treatment will be applied by previously trained therapists. Treatment will have 4 weeks, 2 times a week, totaling eight sessions.
41149222|NCT02070289|DRUG|Placebo|Tablets, BID, 14 days
41149223|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
41149224|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
41149225|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
41149226|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
41149227|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
41149228|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
41149229|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
41149230|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
41149231|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
40996824|NCT03263416|OTHER|Dedicated and coordinated follow-up|"* Coordinated follow-up performed by a dedicated nurse with consultations (before treatment initiation and during treatment) and a telephone follow-up during treatment period~* Pharmaceutical conciliation before treatment initiation made by the Center Pharmacist~* Completion of QLQ-C30 and GIRERD questionnaires"
40996825|NCT03263416|OTHER|Standard follow-up|- Completion of QLQ-C30 and GIRERD questionnaires
40996826|NCT01250470|OTHER|Laboratory Biomarker Analysis|Correlative studies
40996827|NCT01250470|DRUG|Montanide ISA-51/Survivin Peptide Vaccine|Given SC
40996828|NCT01250470|BIOLOGICAL|Sargramostim|Given SC
40996829|NCT04468932|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"Aim 1: To determine the clinical effects of rTMS targeting the cerebellum on postural instability in PSP. The hypothesis to be tested is that TMS augmentation of cerebellar inhibition will improve cerebellum-dependent balance symptoms of PSP for a period of time sufficient to improve rehabilitation outcomes. The investigators will measure a battery of objective posturography metrics and other measures of motor control, including sway and center of pressure changes to backward tilt and forward translation.~Aim 2: We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS. The hypothesis to be tested is that premotor and motor cortical activity will decrease after cerebellar rTMS compared to sham TMS, reflecting improved cerebellar inhibition of the motor cortex after the intervention."
41149232|NCT03317288|DEVICE|Dabir Air overlay|The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
40996830|NCT00798109|BEHAVIORAL|Motivational therapy|One hour of motivational therapy each weak during 4 weeks
40996831|NCT00798109|BEHAVIORAL|Usual care|Patients received at least six hour of usual therapy, as in the experimental group
41149233|NCT00561678|DRUG|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
41149234|NCT00561678|DRUG|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
41149235|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as tablet in fed state
41149236|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as tablet in fasted state
41149237|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as oral solution
40791728|NCT00984594|OTHER|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
40791729|NCT00899418|GENETIC|gene expression analysis|
41149238|NCT03676400|OTHER|conditioned media of umbilical cord blood-derived stem cells|Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
41149239|NCT03676400|OTHER|Placebo|Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
41149240|NCT00587171|DEVICE|Patching|2 hours daily patching
41149241|NCT00587171|PROCEDURE|Near activities|30 minutes daily near activities at home
40996832|NCT06302816|OTHER|TUPLER exercises|"will be conducting tupler exercises, exercises that are designed to target core muscles in order to improve posture, regain core strength and reducing discomfort.~Each exercise will be repeated 10reps for 3 times on 3 days a week for 8 weeks."
40996833|NCT06302816|OTHER|SCOOP EXERCISES|will be required to complete scoop exercises basically deals with Pilates which is deep core and hip strengthening and stability through breathing patterns with the utilization of transversus abdominis muscle majorly. In each exercise participant will be asked to hold pelvic floor muscles for 8sec, then relax the muscles and count to 10, repeat I for 10 times each day for 3 days a week for 8weeks. Basic commands about the positing, activation and engagement of core along with breathing control were given to the subjects.
40996834|NCT04428892|BEHAVIORAL|Pedagogyc Strategy|Simulation can be used as a pedagogic tool that provides students with significant learning regarding decision-making in interacting with people, in this case patients with LBP. It is a potential strategy for developing diverse skills focused on the safety of the patient and the therapist.
40996835|NCT02731872|DEVICE|Airvo humidifier|"The Airvo humidifier has adjustable flow settings for delivery of fully saturated breathing gases at 37 °C, 100% humidity.~Flow rates are adjustable between 15 and 45 l/min. Ambient air is drawn in by a low-capacity motor. When coupled to a medical oxygen supply, the regulation of delivered oxygen concentration is ensured."
40791730|NCT00899418|GENETIC|polymerase chain reaction|
40791731|NCT00899418|GENETIC|polymorphism analysis|
40791732|NCT00899418|OTHER|immunohistochemistry staining method|
40791733|NCT05593705|OTHER|observation|photograph for maxillary labial frenum and measurements with a periodontal probe
40996836|NCT02381912|OTHER|EORTC QLQ-C30 and EORTC BLS-24 questionnaire|Questionnaires answered at baseline and 4 months follow up.
40791734|NCT03965182|DRUG|PEG|2 sachets of PEG will be used as the bowel prep regimen.
41149242|NCT00587171|PROCEDURE|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
41149243|NCT00587171|PROCEDURE|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
41149244|NCT03795792|DIETARY_SUPPLEMENT|Curcumin|Will be provided in capsules
40791735|NCT03965182|DRUG|PEG plus SPMC|one sachet of PEG and one sachet will be administered as the bowel prep regimen
40791736|NCT03965182|DRUG|SPMC|2 sachets will be administered as the bowel prep regimen.
41149245|NCT03795792|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Will be provided in capsules.
41149246|NCT05010499|DRUG|Levobupivacaine|femoral nerve block receives 20 ml of levobupivacaine 0.25%
41149247|NCT05010499|DRUG|Levobupivacaine|Fascia iliaca block receives 40 ml of levobupivacaine 0.25%
41149248|NCT04397185|DEVICE|Breast Cancer Locator (BCL) guided partial mastectomy|The BCL is a patient-specific, plastic, bra-like form which is placed on the breast to localize the tumor during surgery.
41149249|NCT04397185|DEVICE|Wire Localized (WL) partial mastectomy|Standard of care procedure
40791737|NCT02625220|DEVICE|Prototype toric lens senofilcon A|Investigational prototype
40791738|NCT00002395|DRUG|Topotecan|
40791739|NCT06554249|PROCEDURE|Vulsellum group|"The patients are asked to empty the bladder before IUD insertion. The vulsellum is applied on the cervix, sounding of the uterus is done and the IUD is inserted according to the standard technique of IUD insertion.~Pain intensity is assessed after the procedure using a visual analogue scale."
41149250|NCT00527371|DEVICE|GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.
40996837|NCT04675216|PROCEDURE|Posterior fossa intracranial pressure measurement|Measurement of posterior fossa pressure in an invasive way
40996838|NCT02694146|DRUG|Platelet rich plasma|Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
40996839|NCT02694146|DRUG|Hylan G-F 20|Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
40996840|NCT04000048|GENETIC|sequencing of the complete exome|Once the pathological diagnosis is confirmed (WHO 2016), a tumor fragment will be selected and frozen for each lobe. DNA extraction will be performed for each fragment. The samples (4 different DNAs per GDBG corresponding to the DNA extracted from each of the 3 lobes and the blood DNA) will be sent to the Montpellier Genomix platform for sequencing of the complete exome.
40791740|NCT06554249|PROCEDURE|Ultrasound group|"During the two hour period before IUD insertion, the patients are asked to drink about one liter of water and to avoid micturition.~Abdominal ultrasound is used to obtain a sagittal view of the uterus and the IUD is introduced into the uterine cavity under ultrasound guidance.~The vulsellum and uterine sound are not used during IUD insertion. Pain intensity is assessed after the procedure using a visual analogue scale.."
40791741|NCT01030120|DRUG|etanercept|etanercept 50mg BIW S.Q.
40791742|NCT01030120|DRUG|placebo|placebo
40996841|NCT00576277|DRUG|AV411|
40791743|NCT06090812|OTHER|Ultrasound evaluation|Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
40791744|NCT04284501|BEHAVIORAL|Non|questionnaire
40996842|NCT04428996|BEHAVIORAL|Social Cognition and Interaction Training (SCIT)|The social cognition and interaction training (SCIT) is a manual-guide group intervention that can apply to people with serious mental illness. There have been evidences showing that the SCIT could improve emotional perception, theory of mind, attribution bias, and social relationship.
40996843|NCT01437007|DRUG|TKM-080301|
40791745|NCT03413033|OTHER|Resonance tube|Participants will phonate into a tube (10cm length 4mm inner diameter) during 5 minutes. They will produce series of the vowel /u/ into the tube. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
40996844|NCT00002115|DRUG|Adefovir|
40996845|NCT00302458|DRUG|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
40791746|NCT03413033|OTHER|Tongue trill|Participants will produce series of a similar /r/ Spanish sound during 5 minutes. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
40996846|NCT00302458|DRUG|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
40996847|NCT00302458|DRUG|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
40996848|NCT04800003|DIAGNOSTIC_TEST|Gonial angle and submandibular fossa depth measurements from CBCT images|CBCT images were obtained from dry human mandibles
40996849|NCT02509065|DEVICE|Bionic Pancreas|Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.
40791747|NCT01096108|BEHAVIORAL|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
40791748|NCT01096108|BEHAVIORAL|Motivational and Problem-Solving|Counseling phone calls
40791749|NCT01096108|BEHAVIORAL|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
40791750|NCT05509062|PROCEDURE|Pressure|Subjects are randomized to one of three treatment groups
40791751|NCT05433701|RADIATION|Stereotactic Body Radiotherapy|"* Verify the setup position and respiration of patients as in the simulation CT image.~* To precisely align the tumor prior to each treatment, cone-beam CT and gated fluoroscopy using the On-board Imager mounted on the linear accelerator are performed.~* The Real-time Position Management system is used to monitor the accuracy of breathing phase during treatment."
40996850|NCT02509065|OTHER|Usual Care|Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
40996851|NCT00544258|DRUG|PEP005|
40996852|NCT01248858|DRUG|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
40996853|NCT03377777|OTHER|No intervention|
40996854|NCT01727141|DRUG|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
40996855|NCT01727141|DRUG|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
40996856|NCT01727141|DRUG|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
40996857|NCT01727141|DRUG|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
40996858|NCT02490722|OTHER|Patient education|Four times two hours group based patient education
41149251|NCT00527371|PROCEDURE|Transurethral resection of the prostate|Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
41149252|NCT01525875|DRUG|Magnesium Oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
40996859|NCT05276245|BEHAVIORAL|Structured Protocol of Nature Contact|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
40996860|NCT05915767|DIETARY_SUPPLEMENT|Olive leaf tea|Fresh olive leaves will be procured from Chakwal, Pakistan. The leaves will be rinsed to remove dust and debris and dried at 40℃ in the oven. The leaves will be ground into powder form and then incorporated in tea bags containing 1.8 g leave powder/tea bag. Participants in treatment group will be instructed to dip the tea bag in 200-250 ml boiling water for 3-5 minutes.
41469228|NCT04105114|DEVICE|Gravity Neutral Device|This device is used to train and assess non-weight bearing stepping movements. When using the device, participants will be lying on their side with their legs suspended off the end of a table supported by small slings that are anchored securely to the apparatus.
41469229|NCT04105114|DEVICE|Body Weight Supported Treadmill Training|Participants will be supported by a special harness while they are stepping on a treadmill. Trained technicians or therapists will be assist the trunk and legs during stepping as needed.
41469230|NCT04105114|DEVICE|Rolling Walker|A standard rolling walker will be used for balance support and stability during stepping overground.
41469231|NCT02983032|BEHAVIORAL|BBTI|3 group sessions over 4 weeks
41469232|NCT05751876|DRUG|Dienogest|Dienogest 2mg was prescribed once per day orally
41469233|NCT05557370|BIOLOGICAL|Human Papilloma Virus vaccine (GARDASIL 9)|Patients will be scheduled to receive 3-dose 9vHPV vaccination (vaccination at enrollment \[time 0\], 2 months \[+ 6 weeks\], and 6 months \[+ 6 weeks\] per standard guidelines).
41469234|NCT00535041|DRUG|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
41469235|NCT05577806|DRUG|Dydrogesterone|progestin primed ovarian stimulation
40791752|NCT05433701|PROCEDURE|Radiofrequency Ablation|- RFA are performed under local anesthesia or monitored anesthesia care with either a 15-gause or 17-gause internally cooled electrode, depending on the size of the tumor.
40996861|NCT00424138|RADIATION|FDG|
40996862|NCT00702117|DRUG|flecainide|2 mg/kg iv in 10 minutes
41469236|NCT02644161|PROCEDURE|Dense cranial electroacupuncture stimulation|"DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs)."
41469237|NCT02644161|PROCEDURE|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered."
41469238|NCT02644161|DRUG|Antidepressant|Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
41469239|NCT02644161|OTHER|Rehabilitation|Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
41469240|NCT02644161|PROCEDURE|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
40791753|NCT04525144|DRUG|Tebonin Forte|Dietary supplement: Gingko biloba EGb 761
40791754|NCT04764097|DRUG|Dapagliflozin|SGTL2 Inhibitor
40791755|NCT04764097|DRUG|Placebo|Placebo
40996863|NCT00702117|DRUG|ajmaline|1 mg/kg iv in 10 minutes
40996864|NCT00702117|DRUG|procainamide|10 mg/kg iv in 10 minutes
40996865|NCT05392361|DRUG|gabapentin (neurontin® capsule 300mg) treatment|Taking gabapentin (neurontin® capsule 300mg, Pfizer) medication at night as a conservative treatment
40996866|NCT05392361|DRUG|baclofen (baclofen Tab. 10mg) treatment|Taking baclofen (baclofen Tab. 10mg, Handok co, Seoul, Korea) medication at night.
40996867|NCT03656419|PROCEDURE|photodynamic therapy|aPDT with methylene blue and red led irradiation.
40996868|NCT03656419|PROCEDURE|Tongue scraper|Tongue scraper 10 times from de back to the top.
41149253|NCT01525875|DRUG|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
41469241|NCT05254158|DRUG|NNC0174 0833|Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)
40791756|NCT05329337|DIAGNOSTIC_TEST|Blood test|Sixteen mL of blood will be collected on EDTA for the purpose of this study
40791757|NCT06198062|OTHER|Paraffin wax bath therapy|this group receive paraffin wax. Each session will last between 40 and 50 min, 2 sessions per week, for total 6 weeks
40791758|NCT06198062|OTHER|Paraffin Wax Bath Therapy and Muscle Energy Techniques|This group receive paraffin wax bath therapy along with muscle energy techniques. Each session will be conducted for 40 to 50 mins, 3 sessions in a week for total 6 weeks
40791759|NCT05811754|OTHER|Data collection|"This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum."
40996869|NCT03684915|DEVICE|Rotary files|using rotary files in cleaning root canals of infected primary molars
40996870|NCT02599753|DRUG|18-FDTBZ|"During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
40996871|NCT05235191|DRUG|methadone tablets|The intervention with the active drug (methadone) will start with the dose of 1 tablet (5 mg) twice a day (every 12 hours) and titrated on subsequent visits up to the maximum dose of 6 tablets a day (totaling 30 mg divided into 2 daily doses to facilitate therapeutic adherence).
40996872|NCT05235191|DRUG|Placebo|In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
40996873|NCT02848677|BEHAVIORAL|Nutritional counseling|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
40996874|NCT02848677|BEHAVIORAL|usual care|usual care of hypertensive patients.
40791760|NCT01170273|DIETARY_SUPPLEMENT|vitamin D|cholecalciferol
40791761|NCT01170273|DIETARY_SUPPLEMENT|placebo|placebo tablet
40791762|NCT00508105|PROCEDURE|subscapularis peel|"Detachment of the subscapularis tendon from its insertion on the lesser tuberosity the peel."
40791763|NCT00508105|PROCEDURE|osteotomy|This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
40791764|NCT03240861|OTHER|18F-FHBG|Given IV
40791765|NCT03240861|BIOLOGICAL|Aldesleukin|Given SC
40791766|NCT03240861|DRUG|Busulfan|Given IV
40791767|NCT03240861|BIOLOGICAL|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
40996875|NCT02107599|DRUG|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
40996876|NCT01616485|DRUG|TA-1790|2 TA-1790 100 mg capsules
40996877|NCT01616485|DRUG|Sildenafil citrate|2 sildenafil citrate 50 mg capsules
40996878|NCT01616485|DRUG|Placebo|2 placebo capsules for TA-1790 100 mg capsules
40996879|NCT01616485|DRUG|Nitrostat|glyceryl trinitrate tablet, USP 0.4 mg
40996880|NCT01408121|OTHER|Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay|All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
41149254|NCT04759599|PROCEDURE|Shock Wave Lithotripsy (SWL)|Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks or Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
40791768|NCT03240861|PROCEDURE|Computed Tomography|Undergo PET/CT
40791769|NCT03240861|BIOLOGICAL|Filgrastim|Given SC
40791770|NCT03240861|DRUG|Fludarabine|Given IV
40791771|NCT03240861|PROCEDURE|Leukapheresis|Undergo leukapheresis
40791772|NCT03240861|DRUG|Plerixafor|Given SC
40791773|NCT03240861|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40791774|NCT02317497|OTHER|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
40996881|NCT04523233|DIAGNOSTIC_TEST|Amniocentesis|Amniocentesis is a procedure in which amniotic fluid is removed from the uterus for testing or treatment.
40996882|NCT02014363|DRUG|ETS6103 (low dose)|
40996883|NCT02014363|DRUG|ETS6103 (high dose)|
40996884|NCT02014363|DRUG|Amitriptyline|
40996885|NCT01992731|OTHER|Drug: Follitropine Bèta|
40996886|NCT03562039|PROCEDURE|M-MIST|minimal invasive surgical technique without thorough removal of granulation tissue
40996887|NCT02522390|OTHER|Research activities|"Measurements are primarily based on do-it-yourself non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.~The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts."
41149255|NCT05189288|DRUG|D418 Tab.|1T
41149256|NCT05189288|DRUG|CKD-388 Tab.|1T
40791775|NCT02317497|DRUG|Vasopressors to maintain normal blood pressure values, if needed|
41469242|NCT03793920|OTHER|Facial Emotion Test|All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
40791776|NCT02317497|DRUG|Osmotherapeutics to lowr intracranial pressure, if needed|
40791777|NCT02317497|PROCEDURE|Endovascular stroke care to treat brain vessel occlusions, if needed|
40996888|NCT03696433|DIETARY_SUPPLEMENT|Low-salt diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
40996889|NCT03696433|DIETARY_SUPPLEMENT|High-salt diet|The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
41469243|NCT02507440|DRUG|Lidocaine|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
41469244|NCT02507440|DRUG|Placebo|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
41469245|NCT02507440|DRUG|Propofol|All patients will receive intravenous propofol as anesthesia for EGD
40791778|NCT02317497|PROCEDURE|Decompressive neurosurgery, if needed|
41469246|NCT03844828|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
40791779|NCT04732923|OTHER|Assigned intervention - procedure|"This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks 6 minute walk test, questionnaires~STEP 2 : monitoring at 6 months after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires~STEP 3 : monitoring at one year after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires"
40791780|NCT01350674|PROCEDURE|EBUS-TBNA|endobronchial ultrasound transbronchial needle aspiration
40791781|NCT01836536|DRUG|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
40791782|NCT04475159|PROCEDURE|Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)|Pressurized Intraperitoneal Aerosol Chemotherapy will be delivered to the abdominal cavity by means of laparoscopy.
40791783|NCT06172595|DIAGNOSTIC_TEST|FET PET|There is only one study visit during which study subjects will undergo a 18F-FET PET/CT in SGH. Following that, they will be followed up as per their routine clinical care. Data collection timepoints will be at 30 days, 4 months, 8 months and 1 year.
40791784|NCT01552512|DIETARY_SUPPLEMENT|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
41469247|NCT01358396|OTHER|Respond to therapy for diabetic macular edema|Correlate HBA1c with visual acuity outcome to therapy.
40791785|NCT01552512|OTHER|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
40791786|NCT00787839|OTHER|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
40791787|NCT00787839|OTHER|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
40791788|NCT00540930|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
40791789|NCT01177085|BEHAVIORAL|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
40996890|NCT05225558|DRUG|Delpazolid|BID, PO
40996891|NCT05225558|DRUG|Vancomycin|IV infusion per 2020 IDSA guideline
40996892|NCT05225558|DRUG|Placebo of Delpazolid|BID, PO
40996893|NCT01538862|DRUG|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
40996894|NCT03010878|OTHER|Yoga|"The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.~Yoga was delivered in sitting, standing, and floor postures"
40996895|NCT03010878|OTHER|Self-management|The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
40996896|NCT01462357|BIOLOGICAL|Cervarix|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6.
40996897|NCT01462357|BIOLOGICAL|Gardasil|2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gardasil 2 dose Group) or at Day 0, Month 2 and Month 6 (Gardasil 3 dose Group), respectively.
41149257|NCT05144854|DRUG|ONO-4538|Specified dose on specified days
41149258|NCT05144854|DRUG|Ipilimumab|Specified dose on specified days
41469248|NCT00000302|DRUG|Buprenorphine|
41469249|NCT06001801|BEHAVIORAL|Diabetes Prevention Program|"The DPP group is led by the Community Health and Social Services Center (CHASS) community health workers (CHWs). For this study, the workers will deliver 16 weekly sessions (core phase) followed by two monthly sessions (maintenance phase). Each session lasts one hour plus the time required to weigh each participant and review food and activity logs.~This program will help participants make healthy lifestyle changes. Examples are improvements in eating and physical activity. The goal is that participants lose some weight and eat healthier food.~Sessions will be offered in-person in a room with video capacity to allow attendance of participants that cannot attend in person. For those participating virtually, the CHWs will briefly review with them what participants logged.~Participation in this project should last approximately 6-months."
40791790|NCT04533646|DRUG|Insulin|Participants will be asked to dose insulin during the first week using fixed doses. During the second week of the study, participants will dose insulin based on carbohydrate counting. Blood sugar control will be compared between the 2 weeks to determine the outcomes of the study.
40791791|NCT04533646|DEVICE|Continuous glucose monitor (CGM)|Participants will be required to wear a CGM to measure glucose trends
40791792|NCT01520467|DRUG|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
40791793|NCT01520467|DRUG|Placebo|1 placebo tablet /day administered orally for 18 months.
40791794|NCT00869635|DRUG|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
40791795|NCT00869635|PROCEDURE|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
40791796|NCT00869635|PROCEDURE|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
40791797|NCT06556082|OTHER|Training|"Proprioceptive Neuromuscular Facilitation(PNF) based upper extremity strengthening exercises to increase upper extremity muscle strength will be applied to the participants in the training group 3 days a week for 8 weeks. PNF-based upper extremity strengthening exercises will be performed with an elastic resistive band using bilateral symmetrical PNF patterns of Flexion-Adduction-External Rotation-Extension-Abduction-Internal Rotation, Flexion-Abduction-External Rotation-Extension-Adduction-Internal Rotation on two different diagonals while individuals are in a sitting position in a supported chair. Core Stabilization Training will be continued for 8 weeks by increasing the difficulty and intensity of the exercises with limb movements and floor modifications after the amputee football players are taught how to find their neutral spine and how to maintain the position."
40791798|NCT06556082|OTHER|Control Group|The control group will be trained with isotonic strengthening exercises of upper extremity muscles with free weights and core stabilization training 3 days a week for 8 weeks. Isotonic exercises involve muscle contraction with movement, where the muscle length changes while maintaining constant tension. Free weights such as dumbells will be used in the implementation of the exercises. 1 Repetition Maximum (1RM) method will be used to determine the progression of the exercises.
40791799|NCT02228044|BEHAVIORAL|Prevention program|
40996898|NCT01462357|DRUG|Placebo|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
40996899|NCT03244865|DEVICE|LaborView Electronic Fetal Monitor|"Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and FHR data acquired for comparison with CTG data obtained through the traditional monitoring system. The comparison will be performed off-line.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus."
40996900|NCT00620438|DRUG|Lumefantrine-artemether and nevirapine|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
40996901|NCT00620438|DRUG|lumefantrine-artemether and efavirenz|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
40996902|NCT00620438|DRUG|Lumefantrine-artemether and rifampicin|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
41149259|NCT05144854|DRUG|Oxaliplatin|Specified dose on specified days
41149260|NCT05144854|DRUG|Capecitabine|Specified dose on specified days
41149261|NCT05144854|DRUG|S-1|Specified dose on specified days
41149262|NCT06584591|DEVICE|Combined (Robotic balance training and high-definition transcranial direct current stimulation)|The robotic platform will train the participants to maintain dynamic balance in the sagittal and the transverse planes (mediolateral and anterior-posterior directions) and engage in core stability and trunk control with seated balance exercises. In addition, high-definition transcranial direct current stimulation (HD-tDCS) will be used as an adjuvant to robotic balance training by priming the corticospinal circuits.
41149263|NCT06584591|OTHER|Standard of Care Balance Training|Participants in this group will receive a standard-of-care balance training administered by the Physical therapist.
41149264|NCT03023878|DRUG|Blinatumomab|Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.
40791800|NCT06231706|OTHER|Prebiotic-like nut and seed mix|A mixture of nuts, seeds and other plant based ingredients.
40791801|NCT06231706|OTHER|Bread Crouton|A commercially available bread crouton product.
40791802|NCT06231706|DIETARY_SUPPLEMENT|Probiotic capsule|Contains the single strain Lactobacillus rhamnosus GG at 15 billion CFUs per capsule.
40791803|NCT06231706|OTHER|White bread and low fat spread|Consists of 3 slices of bread (providing approx. 55-60g CHO; 3g fibre) + low fat spread (10-15g)
40791804|NCT02688270|DRUG|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
40791805|NCT02688270|DRUG|Vehicle Cream (placebo)|Vehicle administered topically
40791806|NCT02808923|OTHER|Foam Rolling|"Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller."
41149265|NCT03023878|DRUG|Investigator's Choice Chemotherapy|"During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows:~* R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)~* R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or~* R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide)."
40791807|NCT02808923|OTHER|Static Stretching|Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
40996903|NCT06216431|OTHER|Physical Evaluations of individuals|Participants will be evaluated on posture, chest mobility, cough strength, flexibility, hand grip strength and pinch strength. They will be asked to answer the Modified Medical Research Council Scale, Cornell Musculoskeletal Disorders Questionnaire, International Physical Activity Questionnaire Short Form and Short Form -36. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
41149266|NCT03023878|DRUG|Dexamethasone|Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).
41149267|NCT03639792|PROCEDURE|gastric cancer surgery|Gastric cancer surgery
40791808|NCT02076529|DRUG|Ramosetron 0.3mg|
40791809|NCT02076529|DRUG|Ramosetron 0.45mg|
40996904|NCT04820790|OTHER|Mobile applications|Monitoring of patients with home oxygen through a mobile application
40996905|NCT05762146|DRUG|Riociguat|Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.
41149268|NCT03214198|DRUG|Vonoprazan|Vonoprazan tablets
41149269|NCT06233045|DRUG|Dapagliflozin-Test product|Dapagliflozin tablet 10 mg Test product Manufactured by: ZYDUS LIFESCIENCES LIMITED, India
40791810|NCT02076529|DRUG|Ramosetron 0.6mg|
40791811|NCT05113316|BEHAVIORAL|Messy Memories App|"The Messy Memories mobile app is an intervention targeting stress-related problems based on practices with proven effectiveness, to overcome barriers and provide access to evidence-informed intervention strategies aimed to improve mental health in frontline healthcare workers.~The app allows the user to self-administer exposure therapy techniques outside of the traditional psychotherapy context. The Messy Memories app was initially released in a written form for self-help, but with widespread use of smartphones, a mobile application has the potential to further reduce barriers and increase access to care among frontline healthcare workers. The current study proposes to examine this newly developed application for usability and feasibility in a small sample of frontline healthcare workers (Phase I) and then test efficacy of the application in a larger-scale RCT (Phase II) where the application will be compared to a TAU condition."
40791812|NCT02177630|OTHER|Endomyocardial Biopsy|
41149270|NCT06233045|DRUG|Dapagliflozin-Reference product|Dapagliflozin tablet 10 mg Reference product Manufactured by: ASTRAZENECA PHARMACEUTICALS LP, USA
41149271|NCT00095251|DRUG|Dexmedetomidine|a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
41149272|NCT00095251|DRUG|Lorazepam|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
40791813|NCT03749928|DEVICE|OstiSense biosensor - active|The activated biofeedback back night guard will be used to reduce sleep bruxism
40791814|NCT03749928|DEVICE|OstiSensor biosensor - not activated|A not-activated night guard will be used as control device
40791815|NCT01042067|OTHER|Blood specimens (whole blood, serum, plasma)|The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
40996906|NCT05762146|DRUG|Propylthiouracil|Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors
40996907|NCT05762146|DRUG|Perphenazine|Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.
40996908|NCT00232310|DRUG|CELIVARONE (SSR149744C)|
41149273|NCT06106256|DEVICE|Galvanic Vestibular Stimulation (GVS)|Four electrodes, forehead, behind both ears, and back of your neck, provide bidirectional electrical stimulation and receive information about the amplitude delivered accounting for skin impedance
41149274|NCT06106256|OTHER|Flight simulations in virtual reality (VR)|Highly immersive, 3D virtual flight simulation environment
41149275|NCT06106256|OTHER|3-DOF Bertec Portable Essential's dual-balance force plate system|Firm surface/plate to stand on while being presented disorienting visual patters of moving vertical and/or horizontal bars of alternating black and white.
41149276|NCT03435809|PROCEDURE|Intrauterine insemination|Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination
41149277|NCT01985945|OTHER|Yoga|
41149278|NCT00700999|DRUG|Paroxetine|Paroxetine 20-40mg po QD for 12 weeks
41149279|NCT00784277|DRUG|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
41149280|NCT00784277|DRUG|oxycodone IR|10mg for 14 days
41149281|NCT00784277|DRUG|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
40791816|NCT05778994|DEVICE|INTORUS|Exercise protocol with intorus
40791817|NCT00370266|DRUG|Triamcinolone|
40791818|NCT02270658|DEVICE|CPAP|
40791819|NCT00293228|DRUG|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
40791820|NCT00293228|DRUG|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
40791821|NCT06160596|GENETIC|Long term survival multimodal analysis|"* To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)"
40791822|NCT03399942|PROCEDURE|Deep brain Stimulation of cingulum anterior|The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
40791823|NCT03247582|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
40996909|NCT06377397|DRUG|Antibiotics|"In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment"
40996910|NCT01341600|DRUG|Clopidogrel|Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.
40791826|NCT00322413|DRUG|Epoetin|
40791827|NCT04951219|DRUG|Resmetirom|Tablet
40791828|NCT02359032|DRUG|ASP6858|Oral tablets
40791829|NCT02359032|DRUG|Placebo|Oral tablets
40791830|NCT00573391|DRUG|Velcade, Thalidomide, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
40996911|NCT01341600|DRUG|Omeprazole/Clopidogrel|After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
40996912|NCT04329312|RADIATION|Thoracic computed tomography|Patients undergo contrast-enhanced thoracic computed tomography as part of their routine clinical work up.
40996913|NCT05339139|COMBINATION_PRODUCT|Dialysis|In this study critically ill adult patients requiring Continuous Renal Replacement Therapy (CRRT) will receive Regional Citrate Anticoagulation (CRA) which will be delivered by multiFiltratePRO system.
40791831|NCT00573391|DRUG|Velcade, Melphalan, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
40791832|NCT00331032|DRUG|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
40791833|NCT00331032|DRUG|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
40791834|NCT04456764|BEHAVIORAL|SaFTiE|A multi-modal fatigue risk management program.
40791835|NCT04456764|BEHAVIORAL|Attention Placebo Control|A multi-modal teamwork assessment program.
40791836|NCT00255216|DRUG|Policosanol supplement (oral capsule) vs. placebo|
40791837|NCT00868829|DEVICE|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
40791838|NCT01747915|DRUG|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
40791839|NCT01747915|DRUG|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
40791840|NCT01747915|DRUG|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
41149282|NCT00784277|DRUG|Tapentadol IR (CG5503)|50mg for 14 days
40791841|NCT00652171|DRUG|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
40996914|NCT02231346|DRUG|Berodual® Respimat® - inhaler|
40996915|NCT00265512|BEHAVIORAL|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
40996916|NCT00265512|BEHAVIORAL|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
41149283|NCT00784277|DRUG|Tapentadol IR (CG5503)|75mg for 14 days
41149284|NCT00784277|DRUG|placebo|1 capsule for 14 days
41149285|NCT00784277|DRUG|placebo|Tablets and capsules 2 x a day for 28 days
41149286|NCT00888394|PROCEDURE|chiropody|basic procedure of chiropody in podiatry
40791842|NCT00652171|DIETARY_SUPPLEMENT|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
40791843|NCT04126018|DIAGNOSTIC_TEST|MRI with strain measurement|CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
40791844|NCT04126018|DIAGNOSTIC_TEST|Echocardiography|Doppler, PISA, VCA, volumetric method as performed during echocardiography
40791845|NCT05982912|DIAGNOSTIC_TEST|breath sampling|We collect a breath sample of exhaled air and analyse the VOC profile in this sample
40791846|NCT01244035|DRUG|Treatment A|MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
40791847|NCT01244035|DRUG|Treatment B|MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
40791848|NCT01244035|DRUG|Treatment C|Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
40791849|NCT01244035|DRUG|Treatment D|MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
41149287|NCT00888394|PROCEDURE|basic orthesis|individual basic orthesis of foot
40791850|NCT01244035|DRUG|Treatment E|MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
40791851|NCT01244035|DRUG|Treatment F|Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
40791852|NCT05842746|DRUG|Elemene|Elemene of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
40996917|NCT01566448|DRUG|Ketamine|20mg/5ml swish and spit four times daily
41469250|NCT06001801|BEHAVIORAL|INSPIRA|"This intervention will include the DPP plus additional interventions. The additional interventions include: participants to stay for an extra 30 minutes following the regular DPP sessions. In these INSPIRA sessions, participants will be trained in providing mutual peer support, be matched with a peer partner and asked to talk at least once a week, receive vouchers or gift cards, discuss participants action plans with the peer partner, and share challenges, successes, and tips from the CHW and others in the session.~CHWs will provide brief trainings on autonomy-supportive peer support approaches over the first three weeks of sessions.~Participation in this project should last approximately 6-months."
40791853|NCT05842746|DRUG|Placebo|Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
40791854|NCT01048398|DRUG|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
40791855|NCT01048398|DRUG|paracetamol|Control group: intravenous paracetamol 1g
40791856|NCT00838812|DRUG|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
40791857|NCT05032547|BEHAVIORAL|Therapist-supported digitally delivered transdiagnostic emotion regulation treatment|Please see description of experimental arm (arm one)
40791858|NCT05032547|BEHAVIORAL|Therapist-supported digitally delivered supportive treatment|Please see description of active comparator arm (arm two)
40791859|NCT05145699|DEVICE|VR-based post-stroke hemineglect evaluation system|Evaluation system applied with virtual environment using Pico Neo 2 eye
40791860|NCT05557643|DRUG|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the issues that arise in this participant population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
40791861|NCT05557643|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) is a well-established evidence-based mindfulness training program initially developed by Jon Kabat-Zinn that has been shown to reduce symptoms of depression, anxiety, and burnout. The 8-week MBSR curriculum provides training in formal meditation practices including body scan techniques, mindfulness meditation, and yoga. Mindfulness can be understood as the non-judgmental acceptance and investigation of present experience, including body sensations, internal mental states, thoughts, emotions, impulses and memories, in order to reduce suffering or distress and to increase well-being.
40791862|NCT01145963|OTHER|Control pasta|control pasta
40791863|NCT01145963|OTHER|Experimental pasta B|experimental pasta
40791864|NCT01145963|OTHER|Experimental pasta C|experimental pasta
41469251|NCT00060294|BIOLOGICAL|rituximab|
41149288|NCT00888394|PROCEDURE|advantage orthesis|advantage orthesis of foot with special material and design
40996918|NCT03408015|DRUG|Lifitegrast|Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed.
40996919|NCT02325336|DEVICE|BCMA (bar-code-assisted medication administration)|"Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.~In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification."
40996920|NCT04694313|DEVICE|OPM|Simultaneous MEG SQUID + SEEG acquisition followed by a simultaneous MEG OPM + SEEG acquisition.
41149289|NCT00888394|PROCEDURE|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
41469252|NCT00060294|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
41469253|NCT02650141|DRUG|ziyinxiehuo Granules|"Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper"
41469254|NCT02650141|DRUG|zishenqinggan Granules|"Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper"
40791865|NCT05730946|DIAGNOSTIC_TEST|Interview- based questionnaire|Interview-based questionnaire by the use of an interview guide to explore and understand the Challenges faced in the past and the concerns for the future experienced by parents of CLP patients.
40791866|NCT00131352|DEVICE|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
41469255|NCT06318871|BIOLOGICAL|Cytokine Induced Memory-like Natural Killer (CIML NK) Cells|Autologous, cytokine induced memory-like natural killer cells, via intravenous (into the vein) infusion per protocol.
41469256|NCT06318871|DRUG|Interleukin-2 (IL-2)|Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity
40791867|NCT00131352|OTHER|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
40791868|NCT00858325|DRUG|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
40791869|NCT06090123|DRUG|TPN171H|"Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10."
40791870|NCT06090123|DRUG|Itraconazole|Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
40791871|NCT06090123|DRUG|Rifampicin|Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
40791872|NCT01139541|BEHAVIORAL|Social walking intervention|In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
40791873|NCT03896477|BIOLOGICAL|Pneumosil|One single dose contains 2 μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4 μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer
40791874|NCT03896477|BIOLOGICAL|Prevenar 13|One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate
40791875|NCT03896477|BIOLOGICAL|Synflorix|One single dose contains 1 μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
41469257|NCT00559364|DRUG|Viokase® 16|Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
41469258|NCT00559364|DRUG|Placebo|Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
40996921|NCT00014365|DRUG|MKC-1|
41469259|NCT00559364|DRUG|Proton pump inhibitor (PPI)|Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
41469260|NCT00559364|DRUG|Omeprazole|Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
41469261|NCT03974893|OTHER|Vegetarian Diet|Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
41469262|NCT02215772|DRUG|BI 44370 BS|
40791876|NCT03204877|DRUG|Melatonin|Oral capsules
40791877|NCT03204877|OTHER|Placebo|Oral capsules
40791878|NCT01466205|DRUG|DAR-0100A|DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
40791879|NCT01466205|DRUG|Placebo|150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
40996922|NCT03395769|BIOLOGICAL|AB-SA01|AB-SA01 is an investigational bacteriophage therapeutic for treatment of Staphylococcus aureus infections
41469263|NCT03988452|DRUG|Darunavir|Antiretroviral therapy
41469264|NCT03988452|DRUG|Ritonavir|Antiretroviral therapy
41469265|NCT03988452|DRUG|Dolutegravir|Antiretroviral therapy
41469266|NCT03988452|DRUG|Zidovudine|Antiretroviral therapy
40791880|NCT01042158|DRUG|tadalafil and ambrisentan upfront combination therapy|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
40996923|NCT02380651|PROCEDURE|Limb salvage|Local or free flaps
40996924|NCT05578287|DRUG|Anti-HER2 ADC|Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid
40996925|NCT04400396|DIETARY_SUPPLEMENT|standard HM fortification|Based on the assumed energy and macronutrient composition of HM, the commercial multi-component HM fortifier was added, in order to compensate identified nutritional deficits.
40996926|NCT04400396|DIETARY_SUPPLEMENT|target HM fortification|Based on the measured energy and macronutrient composition of HM, modular protein and fat supplements are added, in addition to the commercial multi-component HM fortifier, in order to correct identified specific nutritional deficits. For this purpose, an Excel program to calculate modular protein and fat supplements to be added to fortified HM was developed and registered (Nona R, Cardoso M, Portuguese Directorate of Intellectual Property Services, IGAC-DSPI, nº 480/2020, 26 February 2020)
40996927|NCT06460896|OTHER|pharmacokinetic study|Multicenter pharmacokinetic study of the bioavailability of four compounds in GBP patients: candesartan, amlodipine, metformin and rosuvastatin.
41469267|NCT03988452|DRUG|Tenofovir|Antiretroviral therapy
41469268|NCT03988452|DRUG|Lamivudine|Antiretroviral therapy
41469269|NCT00921284|DRUG|NaCl 9/00|Same volume as in the dexmedetomidine group
40791881|NCT04590053|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
40791882|NCT05431361|OTHER|Prehabilitation|A Registered Kinesiologist (RKin) will provide the exercise prescription, consisting of 4-5 days of aerobic exercise training and 2-3 days of resistance exercise training of major muscle groups, during a remotely delivered familiarization session using Microsoft Teams. The 60-minute remote program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. Patients will be prescribed an individualized exercise program considering: (1) their exercise preferences, (2) their current physical capacity, (3) previous medical history, and (4) presence of underlying comorbidities, mobility, and skeletal fragility concerns \[NOTE: the location/impact of a tumour is not applicable for PROPELLER as it was in REB#5901, and is thus not included here\]. The participant will have an opportunity to execute the exercises in the remote presence of the RKin who will provide corrective feedback where applicable.
40791883|NCT03807050|DIETARY_SUPPLEMENT|Astaxanthin|Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
40791884|NCT04264923|OTHER|HyGIeaCare Prep|Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
40791885|NCT00938912|DRUG|Lacosamide|Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
40791886|NCT00938912|DRUG|Lacosamide|"Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).~The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day."
40791887|NCT00358033|BEHAVIORAL|Counseling|
40791888|NCT00358033|BEHAVIORAL|Interactive Education|
40791889|NCT00358033|BEHAVIORAL|Group Support|
40791890|NCT00358033|PROCEDURE|Pharmacologic case management|Provided by clinical pharmacists
40791891|NCT01162252|BEHAVIORAL|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
40791892|NCT01162252|BEHAVIORAL|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
40791893|NCT01763333|DRUG|BI 1026706 Placebo|Placebo to BI 1026706
40791894|NCT01763333|DRUG|BI 1026706|different dose formulations
40791895|NCT06511544|DEVICE|Transcranial magnetic stimulation|rTMS delivered at 1 Hz for 1800 pulses over 30 minutes for 20 daily sessions, 5 days/week. Treatment will be directed to the ventromedial prefrontal cortex using each participant's structural MRI.
40791896|NCT04853771|BEHAVIORAL|progressive muscle relaxation exercise training|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
40791897|NCT05207111|DRUG|Revefenacin Inhalation Solution|Revefenacin Inhalation Solution, 175 mcg/3 mL following a single nebulized inhaled 175 mcg (1 x 175 mcg/3 mL) dose administered under fasting conditions.
40791898|NCT04587882|BEHAVIORAL|Telehealth|Participants will receive weekly activity summaries and tailored notifications about their activity and goal setting behaviors.
40791899|NCT04587882|BEHAVIORAL|Control|Participants will get usual care and wear a smartwatch.
40791900|NCT05863403|DIAGNOSTIC_TEST|Neuromuscular Training|Neuromuscular Training on Balance and Fall in Geriatric Population With Fall Risk
40791901|NCT05863403|DIAGNOSTIC_TEST|Traditional Exercise|Traditional Exercise on Balance and Fall in Geriatric Population With Fall Risk
40791902|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire for gastrointestinal tract|To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied
40996928|NCT02098577|OTHER|Crossover|Crossover cycle
40996929|NCT02098577|OTHER|Stabilometric Platform|This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition
40996930|NCT01482260|PROCEDURE|Biopsy|Biopsy
40996931|NCT04951934|DEVICE|EmoLED|This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the wound has a greater extension than the irradiated area, multiple repeated applications will be performed on adjacent areas, until the entire wound is covered.
41149290|NCT02199171|DRUG|carboplatin|Given via HIPEC
40996932|NCT04951934|PROCEDURE|Standard treatment|"The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging."
41149291|NCT00718744|OTHER|Standardization of allergenic extract (Ch. arcuatus)|Allergenic extract for cutaneous prick-test
41469270|NCT00921284|DRUG|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
40791903|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire|To assess quality of life, the SF-36 questionnaire will be applied
41469271|NCT05332054|BIOLOGICAL|Allogeneic CAR-T therapy|N/A this is an observational study
41469272|NCT05814432|DRUG|Single high dose of liposomal amphotericin B|Single high dose (10 mg/kg) of liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
41469273|NCT05814432|DRUG|L-AmB standard dose|Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
40791904|NCT03487484|BEHAVIORAL|Faecal Incontinence Score|To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
40996933|NCT01589081|DRUG|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
40996934|NCT01589081|DRUG|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
40996935|NCT05935007|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention will be conducted in this study.
40996936|NCT03509038|OTHER|Exploratory pathophysiology Study|Urodynamic tests before and after bariatric surgery in obese incontinent women before and after bariatric surgery
40996937|NCT04895592|DRUG|Dexamethasone|Given PO or IV
40996938|NCT04895592|PROCEDURE|Resection|Undergo surgical resection
40996939|NCT04895592|RADIATION|Stereotactic Radiosurgery|Undergo SRS
41469274|NCT02577068|DRUG|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
41469275|NCT02577068|DRUG|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
41469276|NCT02305173|DRUG|Intravenous Dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
40996940|NCT02653651|DRUG|Ketamine|Ketamine infused at 0.1 mg/kg/hour
41469277|NCT02305173|DRUG|intravenous salin water|Patients of the control group received homologated placebo 60 minutes before surgery.
41469278|NCT03207958|DRUG|Belimumab|-Given over 1 hour
41469279|NCT01789957|DRUG|AC2993|4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
41469280|NCT03462836|DRUG|IV ketamine/lidocaine/IV PCA apply|In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.
41469281|NCT03462836|DRUG|IV PCA only apply|IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
41469282|NCT04080609|DRUG|Dorzagliatin|GKA currently under clinical development
41469283|NCT05878431|OTHER|Foot Reflexology|"The patients in the experimental group underwent 12 sessions of foot reflexology in a quiet room, twice a week, for 6 weeks. No application was made to the patients in the control group.~FOOT REFLEXOLOGY APPLICATION STAGES~* Application of heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts about 3 minutes,~* Pressure on the brain, cervical region, solar plexus (the projection of the central nervous system on the sole of the foot), lymph system, adrenal glands, urinary system, digestive system, sciatic nerve, hips, knees and reflex points on the soles of the legs for about 10-15 minutes. implementation (Figure 3.4),~* Ending the application by applying heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts approximately 3 minutes after the application."
40791905|NCT06513416|PROCEDURE|Elective upper abdominal surgery|The included elderly patients are those who are preparing for elective upper abdominal surgery and the surgery time exceeds 2 hours.
40791906|NCT05071612|DRUG|AD109|Oral administration at bedtime
40996941|NCT02653651|DRUG|Lidocaine|Lidocaine infused at 1 mg/kg/hour
40996942|NCT02653651|DRUG|Placebo|An equal volume of saline
40996943|NCT01398956|DRUG|Levetiracetam|"formulation: tablet or dry syrup~strength: 250 mg tablet, 500 mg tablet, dry syrup 50%~dosage: Sb ≥16 years and ≥4 and \<16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and \<16 years (\<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day~frequency: twice daily"
40996944|NCT02281136|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
40996945|NCT02281136|DEVICE|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
40996946|NCT03447665|BEHAVIORAL|Bedtime routine|Tailored bedtime routine
40996947|NCT03447665|BEHAVIORAL|Sleep schedule|Tailored sleep schedule, including morning rise time, cut-off for last nap of the day, and bedtime.
40996948|NCT03447665|BEHAVIORAL|Intervention (bedtime)|Parents implement behavioral sleep intervention at bedtime.
40996949|NCT03447665|BEHAVIORAL|Intervention (after night wakings)|Parents implement behavioral sleep intervention following each night waking.
40996950|NCT05457374|PROCEDURE|PVE|Portal vein embolization (PVE) mainly embolizes the portal vein of the resected liver lobe, causing the non-tumor lobe to proliferate, and after tumor lobectomy, the volume of the non-tumor lobe proliferates so that patients with hepatocellular carcinoma that could not be directly surgically resected are given the opportunity to be surgically resected
40996951|NCT05457374|PROCEDURE|LVD|Combining PVE and Hepatic Vein Embolization (HVE) in the same procedure
40996952|NCT05751837|BIOLOGICAL|Lipopolysaccharide|One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
40996953|NCT03870152|PROCEDURE|Electrocautery Ablation (EC)|For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC bronchoscopy in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment bronchoscopy confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
40791907|NCT05071612|DRUG|AD504|Oral administration at bedtime
40791908|NCT05071612|DRUG|Atomoxetine Hydrochloride|Oral administration at bedtime
40791909|NCT05071612|DRUG|Placebo|Oral administration at bedtime
40791910|NCT04145297|DRUG|Ulixertinib|"Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles"
41469284|NCT05361486|OTHER|Training on revised algorithm|relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for RC and choosing the appropriate treatment as per their role accordingly
41469285|NCT05361486|OTHER|Enhancing Pharmacovigilance|Refresher training on PV reporting in the selected facilities. National PV forms will be reviewed and if required, modified in consultation with the national PV system.
40791911|NCT04145297|DRUG|Hydroxychloroquine|Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
40791912|NCT03137953|PROCEDURE|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
40791913|NCT03137953|DIAGNOSTIC_TEST|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
40791914|NCT00382265|DRUG|tamsulosin|tamsulosin 0.4mg po qd for 28 days
40791915|NCT00382265|OTHER|Placebo|placebo po qd for 28 days
40791916|NCT05367193|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy for vitreoretinal disease in highly myopic eyes
40791917|NCT05367193|DEVICE|NGENUITY® 3D Visualization System (Alcon, TX, USA)|Injection of ICG to stain internal limiting membrane
40996954|NCT01814306|DEVICE|Supreme LMA|Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion
40996955|NCT01814306|DEVICE|Proseal LMA|Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
40996956|NCT05263154|OTHER|Goal directed low oxygen|Oxygen is titrated until oxygen saturation is 100% in one-minute steps before the induction of anesthesia, with increasing fraction of inspired oxygen (FiO2) from 0.25 to 0.30 to 0.35 and so on. After intubation, the FiO2 is set to 0.25 to achieve a target saturation of 94-96%. Supplementary oxygen after surgery will be given with the same targets and with as little oxygen as necessary.
40996957|NCT05263154|OTHER|High oxygen|FiO2 1.0 before induction until end-tidal oxygen concentrations of 0.80 occur. The FiO2 will be reduced to 0.35 during anesthesia, followed by an increase in FiO2 to 0.80 during 5 minutes before extubating the patient, followed by FiO2 0.40 for at least thirty minutes after anesthesia. Oxgen will then be given at 3 liters a minute with a oxygen saturation goal of 98%
40996958|NCT06162286|DRUG|Omadacycline|Omadacycline IV/PO
40996959|NCT06162286|DRUG|Moxifloxacin|Moxifloxacin IV/PO
40996960|NCT04270916|DIAGNOSTIC_TEST|High frequency pure tone audiometry|Hearing test carried out routinely, non invasive
40791918|NCT05335252|DRUG|Dronabinol|5mg 2x daily for 7 days
40791919|NCT05335252|DRUG|Placebo|1 caplet 2x daily for 7 days
40791920|NCT00052910|DRUG|cisplatin|Given IV
40791921|NCT00052910|DRUG|epirubicin hydrochloride|Given IV
40996961|NCT02061969|DRUG|linagliptin|5mg linagliptin tablets
40996962|NCT02061969|DRUG|insulin glargine|
40996963|NCT04022135|DIETARY_SUPPLEMENT|Folic acid|Participants will supplement with 0.6mg/day for 16 weeks.
40791922|NCT00052910|DRUG|fluorouracil|Given IV
40791923|NCT00052910|DRUG|leucovorin calcium|Given IV
40791924|NCT00052910|RADIATION|radiation therapy|Given 5 days a week for 5 weeks
40791925|NCT03191162|DRUG|Benznidazole|To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
40996964|NCT04022135|DIETARY_SUPPLEMENT|(6S)-5-methyltetrahydrofolic acid|Participants will supplement with 0.625mg/day for 16 weeks.
40996965|NCT04010721|DEVICE|Experiment 1|Stimulation of one electrode at a time
40791926|NCT04406402|BEHAVIORAL|Acute dietary protocols and lifestyle modification|The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).
40791927|NCT02284256|DRUG|Fibrocaps|
40791928|NCT02284256|DRUG|TachoSil|
40791929|NCT05701553|DRUG|Anti-PD-1/PD-L1|Intravenous injection at indicated dose for at least 6 months
40791930|NCT05701553|DRUG|S-Adenosyl-Methionine|Taken orally at indicated dose for at least 6 months
40791931|NCT03843528|DRUG|Vorinostat|Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.
40791932|NCT03843528|DRUG|Azacitidine Injection|Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
40791933|NCT03150147|OTHER|Non-ischemic preservation|The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.
40996966|NCT04010721|DEVICE|Experiment 2:|Stimulation in groups of 4, 8 and 12 electrodes
40996967|NCT04010721|DEVICE|Experiment 3|Stimulation total duration from 10 to 600 ms
40996968|NCT03905785|BEHAVIORAL|Samarthan|Samarthan intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
40996969|NCT04916730|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician but will not be required to adopt a 10-hr eating window.
41469286|NCT05361486|OTHER|Supervision of malaria services in selected facilities.|Supervisors in target regions will be trained as for the HCPs.
41469287|NCT05361486|DIAGNOSTIC_TEST|G6PD testing|G6PD test after Malaria Vivax diagnosis
41469288|NCT05361486|DRUG|Tafenoquine|300 mg (2x150mg tablets) tafenoquine
40791934|NCT03150147|OTHER|Ischemic cold static storage|Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
40791935|NCT03884153|DEVICE|CRP apheresis|"selective CRP apheresis by use of the PentraSorb-CRP"
40791936|NCT04556526|BIOLOGICAL|Ad26.ZEBOV|Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
41469289|NCT05361486|DRUG|Primaquine|0.5mg/kg/7 days
41469290|NCT05361486|OTHER|Follow Up Visit at Day 3 [+2 days] after treatment start|It will be checked if all patients have a Follow Up Visit at Day 3 \[+2 days\] after treatment start
41469291|NCT03605524|OTHER|Sensory training|12 weeks sensory training
41469292|NCT01935648|DRUG|Ropivacaine|
40996970|NCT04916730|BEHAVIORAL|Time Restricted Eating|Participants in this arm will adhere to a daily, consistent self-selected 10-hr eating window for the course of the study intervention period as well as receive nutritional counseling from the study dietitian.
41341746|NCT06039657|OTHER|SEAS training|Patients who opted to participate in the SEAS group underwent SEAS therapy. The SEAS therapy program initially comrised patient education and active self-correction. Subsequently, stabilization of active self correction was tried to be performed through various functional activities. These activities were selected from everyday life examples, with increasing levels of difficulty over time. With SEAS exercises, the activation of self-correction was aimed to be increased through various activities in sitting, standing and walking conditions, with the goal of correcting scoliosis in this way
40791937|NCT04556526|BIOLOGICAL|MVA-BN-Filo|Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
40996971|NCT00706641|DRUG|Dasatinib|Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)
40996972|NCT00706641|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
41469293|NCT05111886|BEHAVIORAL|Communication Skills Training|The training will focus on communication skills based on key constructs in the Health Belief Model and motivation/resistance research (described in section A3), the training will focus on: (1) conveying the benefits of parenting programs, (2) knowledge of and responses to common perceived barriers to attending parenting programs, and (3) skills and strategies to effectively motivate and refer parents in ways that are least likely to elicit resistance. The in-person training will last 60-90 minutes. It will include a theoretical background and experiential learning; each step of the referral process will be demonstrated and role-played. The investigators will work to ensure that personnel receive continuing education credits for the training.
41469294|NCT05111886|BEHAVIORAL|eHealth GenPMTO|The GenPMTO is delivered over the phone (not online). This version is up to 6 sessions in length. This brief eHealth version of GenPMTO will be delivered through community therapists. The program will be delivered one-on-one (i.e., between a therapist and a parent or couple).
41469295|NCT05111886|BEHAVIORAL|Written Referral Process|"A written summary and process map of the referral process, modeled on the Institute for Healthcare Improvement (IHI) 9-step process for closing the loop on referrals."
41469296|NCT05111886|BEHAVIORAL|One Session Education about Resources|"One online or phone conversation with the therapist in which the therapist guides the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) a website, behaviorchecker.org, which includes behavioral prescriptions for common behavior issues; and (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools."
41469297|NCT05111886|DIAGNOSTIC_TEST|Survey of Experience|Satisfaction with referral process
40996973|NCT06146660|DRUG|Mavacamten|According to approved product label
40996974|NCT02084771|DRUG|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
40791938|NCT03063606|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|CBT specialist treatment
40791939|NCT03063606|DRUG|NB Medication (on-going from acute treatment)|Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
40791940|NCT05242601|OTHER||no intervention
40791941|NCT03950258|PROCEDURE|endovascular embolization|Transarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.
40791942|NCT04450030|DRUG|Methyl Prednisolonate|2000mg intravenous methyl prednisolone per day for five consecutive days
40791943|NCT04450030|PROCEDURE|Immunoadsorption|6 courses of tryptophane-based immunoadsorption within up to 12 days
40791944|NCT04744948|DEVICE|Treadmill exercise|high intensity interval training
40996975|NCT02084771|BIOLOGICAL|Oral Salt and Water|Oral salt capsules and water, based on patient weight
40791945|NCT04744948|OTHER|low caloric diet|low caloric diet (1200ca/lday)
40791946|NCT02661204|DEVICE|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
40791947|NCT04393662|DIAGNOSTIC_TEST|Measurement of Muscle strength using a dynamometer|"Muscle strength will be measured in the elbow bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). Supination tests will be performed with the forearm in neutral position, 60° pronation and 60° supination. The elbow will be in 90° flexion, and the shoulder in 45° flexion. Constant pressure is applied to lever of device for 3 to 5 seconds. Maximum torque will be recorded automatically. For each position, three repetitions of 3s (to 5s) contractions will be performed with a break of 15 (or 30s) between the repetitions. There will be an additional break of 2 minutes between measurements of the supination strength in the different positions. This parameter will be analysed regarding asymmetry between both limbs.~Isometric endurance of forearm supination will be measured in neutral forearm. Flexion tests will be carried in the same setting as for supination. Flexion tests will be performed with the elbow in 90, 45 and 0° of flexion."
40791948|NCT04393662|DIAGNOSTIC_TEST|Range of motion clinical measurement (shoulder and elbow)|The range of motion parameters (degree) of both shoulders and elbows will be documented. The circumference of the arm will be measured on the line between the medial acromion and the cubital fossa at 1/3 from the cubital fossa
40996976|NCT06376240|DIETARY_SUPPLEMENT|Pyridoxamine 300mg per day|oral supplement
40996977|NCT06376240|OTHER|Placebo 300mg placebo per day|oral supplement
40996978|NCT01203592|DRUG|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
40996979|NCT01851720|DRUG|Low dose fentanyl PCA|
40996980|NCT01851720|DRUG|Standard IV fentanyl bolus|
40996981|NCT02229942|DRUG|Rituximab|"Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months."
40996982|NCT02229942|DRUG|Placebo|Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
41341747|NCT06039657|OTHER|Standard Care|Patients who declined or were unable to participate in outpatient exercise programs received standard care. Standard care included exercises for postural re-education, traditional strengthening and stretching exercises for one session, followed by observation for one year.
41469298|NCT03868579|PROCEDURE|Biopsy|Undergo biopsy
41469299|NCT03868579|OTHER|Medical Chart Review|Review medical chart
41469300|NCT03868579|PROCEDURE|Thoracoscopy|Undergo pleuroscopy
41469301|NCT05230602|DIETARY_SUPPLEMENT|opuntia (tzabar fruit)|consuming of the tzabar fruit twice a day
41469302|NCT00159835|DRUG|atorvastatin|
41341748|NCT05226143|OTHER|Gel Cream|Gel Cream
41341749|NCT06120192|BEHAVIORAL|Piano|Receives the piano training
41469303|NCT00159835|DRUG|simvastatin|
40996983|NCT06231303|GENETIC|DNA extraction and PCR amplification|"Microbial community genomic DNA extraction from fecal samples will be done using extraction kit in accordance with the manufacturer's instructions. The DNA extract will be checked on a 1% agarose gel, and the DNA concentration and purity will be determined using the NanoDrop 2000 UV-vis spectrophotometer.~The hyper-variable region V3-V4 of the bacterial 16S rRNA gene will be amplified with the primer pair 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTATCTAAT) on a PCR thermocycler. PCR amplification of the 16S rRNA gene will performed as follows:~Initial denaturation at 95 ℃ for 3 min. 27 cycles of denaturing at 95 ℃ for 30 s, annealing at 55 ℃ for 30 s, and extension at 72 ℃ for 45 s.~Final extension step at 72 ℃ for 10 min and incubation at 10 ℃. The PCR product will then be used to quantify different bacterial species in stool samples of patients and controls using real time PCR."
40791949|NCT04393662|DIAGNOSTIC_TEST|Electromyography (EMG)|Electromyographic (EMG) data will be collected using a wireless EMG system (myon AG, Schwarzenberg, Switzerland). Surface electrodes will be placed bilaterally on biceps and triceps following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles)
40791950|NCT02967679|DRUG|MD1003|
40791951|NCT00606645|BIOLOGICAL|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
40791952|NCT03704038|PROCEDURE|PEEP level|Patients will have variable PEEP levels and will be monitored
40791953|NCT02848456|PROCEDURE|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
40996984|NCT02581696|DRUG|Lafutidine|Lafutidine 10mg, 1 tablet, bid
40996985|NCT02581696|DRUG|Irsogladine maleate|Irsogladine maleate 2mg, 2 tablet, qd
40996986|NCT02212587|DRUG|TOBI|New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
40996987|NCT04248816|BEHAVIORAL|Usual care|Subjects will receive outreach through their providers as is standard of care.
40791954|NCT02848456|PROCEDURE|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
40791955|NCT02848456|PROCEDURE|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
40996988|NCT04248816|BEHAVIORAL|Opt-out|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.
40791956|NCT01074073|DRUG|Lurasidone HCl|"lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast."
40791957|NCT00373048|DRUG|mefloquine|tablet, once weekly
40791958|NCT00373048|DRUG|placebo|tablet, once weekly
40791959|NCT04758481|RADIATION|primary tumour radiotherapy|The study subjects will undergo primary tumour radiotherapy.
40791960|NCT04758481|RADIATION|stereotactic body radiotherapy|The study subjects will undergo stereotactic body radiotherapy.
40791961|NCT04758481|RADIATION|maintenance radiotherapy|The study subjects will undergo maintenance radiotherapy.
40791962|NCT00283101|DRUG|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
40996989|NCT04248816|BEHAVIORAL|Opt-out + Incentive|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.
40996990|NCT04750031|PROCEDURE|Liver Biopsy|Liver biopsy is a procedure to obtain small amount of liver by a needle.
41341750|NCT06071780|OTHER|organic product - Virgin Coconut Oil|A commercially available sterilized contact lens was soaked in VCO for 4 hours in a sterile condition to allow absorption of VCO into the contact lens polymer. The contact lens here is a vehicle to transport the VCO into the eye.
41469304|NCT05545111|DRUG|NBI-1117568|Active treatment with orally administered NBI-1117568
41469305|NCT05545111|DRUG|Placebo|Placebo matching NBI-1117568
40791963|NCT06419439|DRUG|Ketamine hydrochloride|Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.
40791964|NCT06419439|BEHAVIORAL|Minimally Enhanced Usual Care|Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).
40791965|NCT06419439|BEHAVIORAL|Brief narrative intervention|"Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions.~Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention."
40791966|NCT01492426|DRUG|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
40791967|NCT01492426|DRUG|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
40791968|NCT01492426|DRUG|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
40791969|NCT01492426|DRUG|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
40996991|NCT00128921|DRUG|VELCADE™|"Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated."
40996992|NCT04965194|PROCEDURE|erector spinae plane block|Superficial probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic (LA), and 20 ml of 0.25% bupivacaine will be administered to perform ESP block. LA spread to both cranial and caudal directions will be seen.
40996993|NCT04965194|PROCEDURE|Quadratus lumborum plane block|"A curved array transducer for the transmuscular QL (TQL) nerve block is placed in the axial plane on the patient's flank just cranial to the iliac crest. The shamrock sign is visualized: The transverse process of vertebra L4 is the stem, whereas the erector spinae posteriorly, QL laterally, and psoas major anteriorly represents the three leaves of the trefoil. The target for injection is the fascial plane between the QL and psoas major muscles. The needle is inserted using an in-plane technique from the posterior end of the transducer through the QL muscle. The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1."
40996994|NCT04965194|OTHER|placebo|patients received no regional block
40996995|NCT04842539|OTHER|Fecal Microbiota Transplantation|In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.
40996996|NCT04842539|OTHER|Standard of care|Nutritional supplementation and other supportive measures as per standard guidelines
40996997|NCT03258827|PROCEDURE|Exercise with a towel|Exercise program composes with warm-up, strengthening exercise, cold-down, 60 minutes/time, 3 times/week. A towel is an important tool for exercise. Total duration of the program is 3 months.
40996998|NCT03258827|PROCEDURE|Home-based exercise|Home-based program focuses on walking activity at fast speed, 3 times/week, 60 minutes/times. The total duration is 3 months.
40996999|NCT04931056|DEVICE|Titanium Facial Plates|The Facial Plating System provides a comprehensive titanium fixation solution for maxillofacial surgery procedures. More than twenty-five different plating options in two systems, the 1.5 mm and 2.0 mm with a variety of instruments, and high torque screws, including meshes, are part of this system. Plates and screws are made of commercially pure titanium per ASTM F-67, Titanium 6Al 4V Alloy per ASTM F-136.
40997000|NCT04931056|DEVICE|Titanium Mandibular Plates|"The Mandibular Plating System provides a comprehensive titanium fixation solution for mandibular surgical procedures. Several plating options, a variety of instruments, and high torque screws with various plate shapes are part of this system.~Plates in the Mandibular Plating System have profiles of various thicknesses. Screws are available in self-tapping, locking and non-locking varieties, and in various sizes between 2.0 mm and 2.3 mm in diameter, and 5 mm to 18 mm in length."
40997001|NCT04931056|DEVICE|Add-on Condyle|The Add-On Condyle is intended to be implanted in the human jaw to replace the mandibular condyle to functionally reconstruct the temporomandibular joint on a temporary basis for patients undergoing ablative tumor surgery requiring the removal of the native mandibular condyle. This device is not for permanent implantation, traumatic injuries, or for treatment of temporomandibular joint disease.
41341751|NCT06198504|PROCEDURE|Protocol using end-tidal oxygen monitoring during preoxygenation before intubation|"According to previous studies a target of EtO2 ≥ 90% is proposed to trigger RSI and intubation. If this target is judged impossible to achieve and/or there is an imperative need to interrupt the pre-oxygenation phase, the operator is free to continue the procedure according to current recommendations.~Before the start of the inclusions, a training session on the use of the module will be organized with a reminder of the recommendations.~During the procedure, preoxygenation modalities and duration, achieved EtO2 level, conduction of the induction and intubation, minimum SpO2 and occurrence of complications will be recorded.~The procedure will stop ten minutes after completion of the orotracheal intubation procedure (defined as inflation of the balloon,clinical and capnography control)."
41469306|NCT00472953|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
41469307|NCT00472953|DRUG|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
41469308|NCT05432206|DRUG|Cannabis Sativa Oil|Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
41469309|NCT05432206|DRUG|Placebo|Hemp virgin seed oil
41469310|NCT05934513|DRUG|GFH009|patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
41469311|NCT02286973|DRUG|Tranexamic Acid|
40791970|NCT03877003|OTHER|Eggs|Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
40791971|NCT01916486|BEHAVIORAL|Exercise training|The EX Program will provide objective progression in the guided exercises of each participant.
40791972|NCT01916486|BEHAVIORAL|Complex mental and social activities|The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
40791973|NCT01916486|BEHAVIORAL|Control: stretching and relaxation program|The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
40791974|NCT06084000|DEVICE|Drug-coated balloon (Bingo© [Paclitaxel-coated Balloon], Yinyi Ltd., China)|"* Patients treated with DCB will receive dual antiplatelet therapy (DAPT, aspirin plus P2Y12 inhibitor) for 1-3 months, followed by long-term single antiplatelet therapy (SAPT, aspirin or P2Y12 inhibitor).~* Patients with bailout stenting will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration in Drug-eluting stent Arm), and then followed by long-term SAPT."
40997002|NCT04931056|DEVICE|HTR-PEKK|The HTR-PEKK implants are fabricated from polyether-ketone-ketone (PEKK) via selective laser sintering (SLS), a 3D manufacturing technique. The laser sintering machine builds the implant in layers as dictated from a stereolithographic (STL) file of the approved implant. The HTR-PEKK implants are designed individually for each patient to replace bony voids in the facial anatomy using a patient's own CT imaging data. The implant is made to fill an existing or planned void (where appropriate) using computer-aided design technology for anatomy enhancement, correction of trauma injuries, and/or to correct congenital defects in the craniofacial bone.
40997003|NCT03228004|BEHAVIORAL|Glooko MeterSync|The participant and caregiver will receive a reminder via text or email to upload glucose data via Glooko on a biweekly basis.
40791975|NCT06084000|DEVICE|Drug-eluting stent|"* Patients treated with DES will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration below), and then followed by long-term SAPT.~* Special consideration:~  1. Patients will take additional assessment (both DAPT score and PRECISE-DAPT score) to determine their personalized duration of DAPT.~ 2. The duration of DAPT is extended to 12 months for patients diagnosed as acute coronary syndrome within 12 months.~ 3. If anticoagulation is indicated, patient will receive a short-term triple antithrombotic therapy (generally 1 to 4 weeks), followed by a variable length of dual antithrombotic therapy (oral anticoagulation (OAC) plus a single antiplatelet agent, preferably clopidogrel) and subsequent long-term OAC mono-therapy. The duration of dual antithrombotic therapy is determined by bleeding risks (HAS-BLED score) according to current guidelines."
40791976|NCT03216720|PROCEDURE|CABG|"* Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula~* Grafting: pedicled left internal mammary artery, and no-touch~* saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System~* Target activated coagulation time of \>400 seconds"
40791977|NCT03216720|PROCEDURE|Miniaturized extracorporeal circulation|"* Centrifugal pump to reduce mechanical stress~* Circuit coated with biosurface to increase haemocompatibilty.~* Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution~* Collapsible soft-shell reservoir for blood volume management~* Cell-saving device~* Venous air removing device and electric clamp system to air embolism"
40791978|NCT03216720|PROCEDURE|Conventional extracorporeal circulation|"* Roller pump~* Circuit uncoated~* Hard-shell venous reservoir~* Intermittend cold blood Harefield cardioplegia"
40791979|NCT04624516|OTHER|self-structured foot exercise|The exercise was done 3 times a week (15x/until they tired x 2set). The exercise used a flexible band with difference thickness (0,5 mm in the first 12 weeks and 0,65 mm in the second 12 weeks)
40791980|NCT03678051|BEHAVIORAL|Treatment as Usual (TAU)|Standard of care residential treatment
40997004|NCT05881473|DIAGNOSTIC_TEST|pain assessment after clavicular fracture repair|This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.
40997005|NCT03266055|DIETARY_SUPPLEMENT|50 g of blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
40997006|NCT03266055|DIETARY_SUPPLEMENT|50g of placebo blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
40997007|NCT02284646|OTHER|Personalized physical training program|9-week personalized physical training program (ergometric bicycle)
40997008|NCT00323154|DRUG|Nalbuphine|
40997009|NCT05514158|DRUG|RC48-ADC|RC48 for injection is a novel antibody-drug conjugate, with a her-2-targeting antibody and a microtube inhibitor
40997010|NCT05514158|DRUG|RC98|RC98 is a recombinant humanized IgG1 monoclonal antibody targeting programmed cell death-Ligand 1 (PD-L1)
40997011|NCT04126395|DIAGNOSTIC_TEST|Movement Assessment Battery for Children 2(M-ABC-2)|The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.
40997012|NCT04126395|DIAGNOSTIC_TEST|Developmental Coordination Disorder - Questionnaire (DCD-Q)|The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.
40997013|NCT04126395|DIAGNOSTIC_TEST|Social Responsiveness Scale 2 (SRS-2)|The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.
40997014|NCT04126395|OTHER|Retrospective Video Analysis|Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.
40997015|NCT03669445|DRUG|Ixazomib|21-day cycles induction and 28-day cycles consolidation
40997016|NCT03669445|DRUG|Lenalidomide|21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy
40997017|NCT03669445|DRUG|Dexamethasone|21-day cycles induction and 28-day cycles consolidation
40997018|NCT03669445|DRUG|Daratumumab|21-day cycles induction and 28-day cycles consolidation
40997019|NCT00623064|DRUG|cisplatin|
40791981|NCT03678051|BEHAVIORAL|TAU+CBT4CBT|45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
40791982|NCT02871817|OTHER|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
40791983|NCT03888378|DRUG|0.3% Topical Minocycline Ointment|0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
40791984|NCT03888378|DRUG|1% Topical Minocycline Ointment|1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
40791985|NCT03888378|OTHER|Topical Vehicle Ointment|Topical vehicle ointment to treat inflamed Meibomian Gland Dysfunction
40791986|NCT00537160|BEHAVIORAL|Behavior modification, Nutrition Education, Exercise|
40791987|NCT00550186|OTHER|placebo|
40791988|NCT00550186|DRUG|Ringers Lactate|
40791989|NCT00550186|DRUG|HaemoHES 6%|
40791990|NCT02458872|BEHAVIORAL|safety huddle alarm intervention|The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
40791991|NCT03971175|PROCEDURE|Forceps biopsy|Endobronchial biopsy with the forceps
40791992|NCT03971175|PROCEDURE|Cryobiopsy|Endobronchial biopsy with the cryobiopsy probe
40791993|NCT06301308|DRUG|Intraurethral lidocaine gel alone|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
40791994|NCT06301308|DRUG|Intraurethral lidocaine gel + lidocaine 2% injection|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2% and using the injection of lidocaine 2% to irrigate the urethra using a 20 ml syringe.
40791995|NCT06301308|DRUG|intraurethral lidocaine gel + liquid paraffinl|Liquid paraffin were used to lubricate hte cystoscopy tube AND participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
40791996|NCT05674227|PROCEDURE|Robotic surgery|Surgical treatment of operable lung cancers using robotic systems
40791997|NCT05674227|PROCEDURE|Video-assisted thoracoscopy|Surgical treatment of operable lung cancers using a video-assisted thoracoscopy approach (VAT)
40791998|NCT05674227|PROCEDURE|Open surgery|Surgical treatment of operable lung cancers using open surgery
40791999|NCT01416740|PROCEDURE|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
40997020|NCT00623064|DRUG|gemcitabine hydrochloride|
40997021|NCT00623064|DRUG|lapatinib ditosylate|
40997022|NCT00623064|OTHER|pharmacological study|
40997023|NCT02843035|DRUG|venglustat (GZ402671)|"Pharmaceutical form: capsule~Route of administration: oral"
40997024|NCT02843035|DRUG|imiglucerase|"Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous"
40997025|NCT04629287|DRUG|KPCXM18|KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
40997026|NCT04629287|DRUG|Placebo|Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
40997027|NCT00357188|DRUG|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
40997028|NCT00357188|DRUG|Atazanavir Sulphate + Ritonavir + Efavirenz|Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
40997029|NCT02416427|DRUG|Atorvastatin|Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
40997030|NCT05360953|DRUG|Clonidine|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 0.375 clonidine. Using capsules of 0,075 mg clonidine.
40997031|NCT05360953|DRUG|Doxazosin|"All patients enrolled establish their individually tolerable dose by dose. Dosage up to a maximum of 10 mg doxazosin. Using capsules of 2 mg doxazosin.~Titration."
40997032|NCT05360953|DRUG|Placebo|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 5 capsules. Using capsules of placebo.
40792000|NCT01416740|DRUG|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
40997033|NCT01865162|OTHER|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
40997034|NCT03920631|DRUG|Nivolumab|Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule
40997035|NCT03920631|BIOLOGICAL|Microtransplantation|HLA-mismatched peripheral blood stem cells
40997036|NCT00102232|PROCEDURE|supplementation with phosphatidylcholine|
40997037|NCT02360163|PROCEDURE|Traditional Landmark Technique (TLT)|
40997038|NCT02360163|DEVICE|ultrasound guided peripheral intravenous access (USGPIVA)|
40997039|NCT05983497|OTHER|Self-Care Skill Educational Intervention|An evidence-based interactive self-care skill educational intervention that supports the clinical nurses to reduce compassion fatigue and increase the compassion satisfaction. The intervention will be delivered as 1-day activity-based educational training. The educational activity consists of the following content: the concept of compassionate fatigue, burnout awareness and recognition, eight dimensions of well-being, and followed by a demonstration of 7 guided self-care skill activities \*on practicing sleep hygiene, self-talk, gratitude practice, Journaling, breathing exercise, heartfulness relaxation, and heartfulness meditation. After the activity participants will develop their own self-care plan for practicing the self-care skills. At the end of the session, they will receive the instructional leaflet to practice the 7 self care skills that they gained from the educational activity.
40997040|NCT04762134|DRUG|Doxycycline Hyclate|STI PrEP arm: doxycycline capsules 100mg orally daily for 12 months STI PEP arm: doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
40997041|NCT01530321|OTHER|Spinal Manipulation|5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
40997042|NCT01530321|OTHER|Light Massage|5 minutes of light pressure massage to the neck and upper back
40997043|NCT02492139|DEVICE|Pumping CE-marked Symphony Pumpset|Pumping with the CE-marked Symphony Pumpset
40997044|NCT02492139|DEVICE|Pumping BrownieForSymphony Pumpset|Pumping with the the BrownieForSymphony Pumpset
40997045|NCT02679859|OTHER|BNP guided medical therapy optimisation|
40997046|NCT06321133|OTHER|High flow nasal cannula immediate ending|High flow is immediately ended
40997047|NCT06321133|OTHER|High flow nasal cannula weaning|High flow is gradually weaned by reducing the flow rate
40997048|NCT06045091|DRUG|Human BCMA targeted CAR-NK cells injection|Allogenic genetically modified anti-BCMA CAR transduced NK cells
40997049|NCT00802399|PROCEDURE|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
40997050|NCT05244629|DEVICE|BMS vs. CS|Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)
41341752|NCT00879047|DRUG|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
40792001|NCT06046092|BIOLOGICAL|H7HLAII|DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules
40792002|NCT00180557|DEVICE|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
40997051|NCT00682188|BEHAVIORAL|Counseling Intervention|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
40792003|NCT01633840|OTHER|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
40997052|NCT00682188|BEHAVIORAL|Information Intervention|Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
40997053|NCT02141997|BIOLOGICAL|adalimumab|adalimumab administered as subcutaneous injection every other week (EOW)
40997054|NCT02141997|BIOLOGICAL|ABT-122|ABT-122 administered as subcutaneous injection every other week (EOW)
40997055|NCT02130063|DRUG|iron isomaltoside 1000 (Monofer®)|
40997056|NCT02130063|DRUG|iron sucrose (Venofer®)|
40997057|NCT04384302|OTHER|Visual training|Pre-defined visual training protocol including the optometrical unit exercises
40997058|NCT02787473|DRUG|pemetrexed|Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles
40997059|NCT02787473|DRUG|cisplatin|Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles
40792004|NCT01633840|OTHER|Elemental E028|Elemental E028 with no added food allergens
40792005|NCT01580410|DRUG|mitomycin C|Given by HIPEC
40792006|NCT01580410|DRUG|oxaliplatin|Given by HIPEC
40792007|NCT01580410|PROCEDURE|therapeutic conventional surgery|Undergo surgery
40792008|NCT01580410|OTHER|quality-of-life assessment|Ancillary studies
40997060|NCT02787473|RADIATION|thoracic radiation therapy|Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin
40997061|NCT02787473|DRUG|docetaxel|Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles
40997062|NCT03302585|DRUG|Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 10,000 IU/d of oral vitamin D3 x 85 days
40997063|NCT03302585|DRUG|Placebo/Standard of Care Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 40,000 IU/d of oral vitamin D3 x 85 days
40997064|NCT01430013|DRUG|Endostar and CHOPT|Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
40997065|NCT02311439|DRUG|FOLFIRINOX + CRT|"Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.~In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.~Radiotherapy :~A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator."
40792009|NCT01580410|DRUG|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
40792010|NCT05395039|OTHER|VCHIPS|Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
40792011|NCT02074943|BIOLOGICAL|PRP|PRP will be inject to half head. The other half will be injected with normal saline.
40997066|NCT01814735|OTHER|Brown rice|
40997067|NCT01814735|OTHER|White rice|
40997068|NCT05041933|DRUG|outsourcing of chemotherapy to Hospital at Home|outsourcing of chemotherapy to Hospital at Home
40997069|NCT04154228|DIAGNOSTIC_TEST|PET/MR scan|"Patients will undergo 18F-FDG PET/CT scans before therapy initiation, interim after 2/3 treatment cycles and end of treatment after therapy completion, as part of their routine evaluation, as well as additional follow-up scans, as clinically indicated and requested by referring physicians. Given signed written informed-consent forms, patients will undergo at each time point, immediately after completion of PET/CT, a PET/MR scan, following the same single injection of 18F-FDG. Standard preparation and acquisition protocols for FDG PET imaging will be employed.~PET/MR imaging will include conventional sequences as T1, T2, diffusion weighted imaging, and advanced vascular imaging (DCE-MRI)."
40997070|NCT02485106|DRUG|Rifaximin|400mg three times per day for 28 days
40792012|NCT00500461|DRUG|GSK233705|GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
40792013|NCT04630925|OTHER|isCGM|As previously described
40792014|NCT03484429|DEVICE|Peripheral nerve stimulation|Up to 60 days of peripheral nerve stimulation
40792015|NCT03484429|OTHER|Standard Medical Therapy|Medications, physical therapy, or other pain treatments
40792016|NCT04965298|DRUG|Lansoprazole|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
41469312|NCT05050981|DRUG|Hormone replacement therapy|Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.
40792017|NCT04965298|OTHER|Matched placebo|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
40792018|NCT02824393|BIOLOGICAL|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
40792019|NCT05949580|DEVICE|MS Care Platform (icobrain ms and icompanion ms)|"The MS care management platform consists of the following components:~1. icobrain ms which is a a cloud-based solution to quantify brain volume and brain abnormalities and changes thereof on MRI scans;~2. icompanion ms which consists of free participant mobile application (app) and a web portal for HCPs.~The information collected in the icompanion ms patient app and icobrain ms is then brought together in the icompanion ms HCP web portal which allows a comprehensive overview of disease data for every single participant."
40792020|NCT03353662|OTHER|Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
40792021|NCT03353662|OTHER|Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
40792022|NCT03353662|OTHER|Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
40792023|NCT03353662|OTHER|Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between the age of 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
40792024|NCT03353662|OTHER|Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
40792025|NCT03353662|OTHER|Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
40792026|NCT01658605|DRUG|GSK1605786|500 mg twice daily administered orally
40792027|NCT01658605|OTHER|Placebo|500 mg twice daily administered orally
40997071|NCT02485106|DRUG|Corticosteroid or pentoxifylline|Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
40997072|NCT02622828|BEHAVIORAL|Participant-identified community based activity|The Canadian Occupational Performance Measure (COPM) is a client-centered outcome measure designed to detect changes in performance and satisfaction in occupations that the individual has self-identified as being important and difficult to perform. The COPM will be used to set self-identified, community-based activities as treatment goals.
40997073|NCT05788458|DRUG|Bupivacain|"The blocks will be performed in supine position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) will be initially placed in a transverse plane over the anterior superior iliac spine (ASIS) and then alignes to identify the following landmarks: Anterior inferior iliac spine, ilio-pubic eminence, iliopsoas muscle and tendon, the femoral artery, and Pectineus muscle. Point of injection will be musculo-fascial plane between the psoas tendon and ilio-pubic eminence."
40997074|NCT06202781|DRUG|SOX plus PD-1 inhibitor|S-1, Oxaliplatin and nivolumab/sintilimab
40997075|NCT06202781|PROCEDURE|Gastroscopic biopsy|Gastroscopy and biopsy
40997076|NCT03349216|PROCEDURE|Intravenous Regional Anesthesia|in this research patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes (A.T.S. 2000, Zimmer, Inc., Bloomfield, CN) will be deflated (hence named Rapid MiniBier's block). the pain score will be assessed by NRS system before during and after the procedure.
40997077|NCT03349216|DRUG|Systemic Analgesia|in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
40997078|NCT05540964|OTHER|Antiretroviral Therapy Interruption(ATI)|Study participant that were previously infused with autologous genetically modified cell product will be taken off ART and followed closely by monitoring HIV rebound.
41469313|NCT05050981|DRUG|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
41469314|NCT04703517|DIAGNOSTIC_TEST|Point of care ultrasound|Patients will receive a point of care ultrasound at the bedside in the Emergency Department and compare the impression to the x ray result
41469315|NCT05274633|DRUG|Ravulizumab|Participants will be observed for 52 weeks after the start of ravulizumab.
41469316|NCT03885219|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel: 120 mg/m2 d1, 8, S-1:Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 , \< 1.5 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14; repeat every 21 days.
41469317|NCT03658473|DRUG|550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
41469318|NCT03658473|DRUG|550 mg naproxen + placebo + 20 mg rabeprazole|Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
40997079|NCT01336075|PROCEDURE|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
40792028|NCT03225248|DRUG|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
40792029|NCT03225248|DRUG|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
40792030|NCT03177538|DRUG|Corifollitropin alfa and menotropin|"Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle"
40997080|NCT01336075|PROCEDURE|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
40997081|NCT01110746|DRUG|Viaject 7|100IU/mL administered subcutaneously
40792031|NCT03177538|DRUG|Follitropin alfa and lutropin alfa|"Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle."
40792032|NCT04812535|DRUG|IFX-1|IFX-1 Monotherapy
40792033|NCT04812535|DRUG|IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
40792034|NCT05641012|OTHER|data collection|helioderma evaluation
40792035|NCT06513884|DRUG|HB-202/HB-201 alternating 2-vector therapy|Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
40792036|NCT06513884|DRUG|Placebo|Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
40792037|NCT06513884|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.
40792038|NCT02962245|DRUG|berberine|
40792039|NCT02962245|DRUG|regular treatment|such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
40792040|NCT03042429|DRUG|Cycles N8, N5 and N6|two chemotherapy cycles N8 followed by standard arm therapy
40792041|NCT03042429|DRUG|Cycles N5 and N6|Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin
40792042|NCT06513949|BIOLOGICAL|Atibuclimab|monoclonal antibody against human CD14
40997082|NCT01110746|DRUG|LISPRO|100IU/mL administered subcutaneously
40997083|NCT04605328|OTHER|Two dimension and three dimension ultrasound|Patient will undergo 2D and 3D ultrasound evaluation after CS for detection of CSD
40997084|NCT06167018|BEHAVIORAL|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8-12 sessions), were given either in an individual manner or in a group setting.The hypnosis treatment is administered by two nurses specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment was based on the North Carolina protocol. Patients assessed gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
40997085|NCT02526069|BEHAVIORAL|Acceptance and Commitment Therapy|An application based on Acceptance and Commitment Therapy
40997086|NCT02865031|DRUG|Decorin|Intravitreal Injection following ocular trauma to prevent scar tissue formation.
40997087|NCT06250062|DRUG|Recombinant humanized IL-17A Monoclonal Antibody（JS005）|Injection
40997088|NCT06250062|DRUG|Placebo（JS005）|Injection
40997089|NCT01399242|DRUG|Certican|Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
40997090|NCT04055597|OTHER|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
40997091|NCT04055597|OTHER|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
40792043|NCT06513949|OTHER|Placebo|Sterile normal saline for injection
40792044|NCT00843440|DRUG|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
40792045|NCT04495946|BEHAVIORAL|Sepsis Transition and Recovery (STAR) program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
40792046|NCT04495946|BEHAVIORAL|Usual care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
40997092|NCT00149981|DRUG|everolimus (RAD)|Everolimus
40792047|NCT04575051|OTHER|Consult Model|The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
40792048|NCT04575051|OTHER|Engage Model|The Engage Model is a chronic care approach to supportive hearing loss self-management of ARHL. Engage includes (a) hearing screening for all residents, (b) an individualized communication plan for those with an identified hearing loss (e.g., one-to-one, group, telephone, television plans, hearing aid trouble shooting, communication strategies, etc.), (c) provision of simple, non-custom amplifiers, (d) referral to audiology if needed, and (e) ongoing support provided by trained personnel (Communication Facilitator) under the supervision of the audiologist.
40792049|NCT02569567|PROCEDURE|Smart-Shear Wave(SSW) imaging|"1. All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.~2. The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.~3. Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement."
40997093|NCT05492669|DRUG|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
40792050|NCT02569567|PROCEDURE|Transient elastography(TE)|"1. Using the M probe in patients with BMI \<30 kg/m2.~2. Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.~3. Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results."
40792051|NCT03976505|OTHER|reading a table format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
40792052|NCT03976505|OTHER|reading a textual format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
40792053|NCT03976505|OTHER|filling a virtual pillbox displayed on the screen as prescribed in the prescription|filling a virtual pillbox displayed on the screen as prescribed in the prescription
40792054|NCT03976505|OTHER|eye-tracker|In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
40792055|NCT03976505|OTHER|cognitive tests and questionary|Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
40792056|NCT01885650|OTHER|Airway Clearance Techniques|
40792057|NCT05340673|DRUG|Agent Affecting Integumentary System|Apply Miaderm
40792058|NCT05340673|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Apply to skin
40792059|NCT05340673|OTHER|Quality-of-Life Assessment|Ancillary studies
40792060|NCT05340673|OTHER|Questionnaire Administration|Ancillary studies
40792061|NCT06367660|DRUG|Intrathecal Bupivacaine-Fentanyl and Bupivacaine-Dexmedetomidine|In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml and group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale.
40997094|NCT05492669|DRUG|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
40997095|NCT05320991|DRUG|Ketamine|Ketamine is applied with a Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA). Target plasma levels are 100 ng/ml with an initial bolus administered as a 2 mg/ml solution.
41469319|NCT03658473|DRUG|550 mg naproxen + 300 mg rebamipide + placebo|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
41469320|NCT03658473|DRUG|550 mg naproxen + placebo + placebo|Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.
40792062|NCT00355368|DRUG|Succinylcholine|1mg/kg iv
40792063|NCT00355368|DRUG|Rocuronium|0.6mg/kg iv
40792064|NCT01563705|PROCEDURE|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
40792065|NCT01563705|PROCEDURE|Manual dexterity assessment|Purdue pegboard test
40792066|NCT05174338|OTHER|Registry|Observational, data collection
40792067|NCT05247684|DRUG|AK112|IV infusion
40792068|NCT05247684|DRUG|Carboplatin|IV infusion
40792069|NCT05247684|DRUG|Cisplatin|IV infusion
40997096|NCT05320991|DRUG|Nacl 0.9%|Saline solution will also be applied with the Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA).
40997097|NCT00814086|DRUG|Paclitaxel|Given IV or intraperitoneally
40997098|NCT00814086|DRUG|Cisplatin|Given intraperitoneally
41469321|NCT05021484|DRUG|Felzartamab|Intravenous infusion in regular intervals over 6 months
40792070|NCT05247684|DRUG|Paclitaxel|IV infusion
40792071|NCT01435694|BEHAVIORAL|Lokomat (Hocoma, Switzerland)|
40792072|NCT01435694|BEHAVIORAL|Conventional Therapy|
40792073|NCT00690430|DRUG|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
40792074|NCT00690430|DRUG|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
40997099|NCT02852096|OTHER|Dual or Multiple Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
41469322|NCT05021484|DRUG|Placebo|Intravenous infusion in regular intervals over 6 months
40792075|NCT02215057|DRUG|topical anesthesia|topical anesthetic drops and Group 2
40792076|NCT02215057|DRUG|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
40792077|NCT06493175|DIAGNOSTIC_TEST|Application of large language model in emergency chest pain triage.|The large language model MedGuide-V5 is able to quickly extract key information from a patients description, and by analyzing these descriptions, it provides physicians with a possible initial diagnosis to help them quickly prioritize the treatment of patients.
40792078|NCT06493175|DIAGNOSTIC_TEST|According to the normal procedures to receive medical treatment|After the artificial intelligence system evaluation, the patients will receive the diagnosis and treatment according to the normal procedure. The overall time of artificial triage, the triage of patients, and other data will be recorded. Patient visits should not be delayed by the use of artificial intelligence systems for evaluation.
40792079|NCT06013722|DIAGNOSTIC_TEST|18F-Na PET Scan|For the intermediate risk population who would demonstrate within 6 to 18 months after first calcium score either an increase of percentile of more than 20% or an increase above 20 points of the calcium score and for high risk population, 18F-Na PET scan will be recommended and repeated 6 months later. Secondary prevention treatment will then be administered in the event of an abnormal examination.
40792080|NCT05795673|OTHER|Peer support program (intervention phase)|"Implementation and Evaluation:~Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation.~The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone.~The mentor will know the themes that the teenager would like to address in the context of peer support.~The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints."
40792081|NCT06107985|OTHER|Structured exercise program|This intervention will be based on shoulder kinetic control, load modification exercises and lumbopelvic stabilization with core stability exercises which is not a part of conventional exercise program for shoulder impingement syndrome patients.
40792082|NCT06107985|OTHER|Conventional Exercise Program|Conventional exercise program for shoulder impingement syndrome patients
40792083|NCT04887194|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
40792084|NCT04887194|DRUG|Warfarin|CYP2C9 probe substrate
40792085|NCT04887194|DRUG|Dextromethorphan|CYP2D6 probe substrate
40792086|NCT04887194|DRUG|Midazolam|CYP3A4 probe substrate
40997100|NCT02852096|OTHER|One Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With One Tumor Tissue Paraffin Blocks
40997101|NCT04374890|DEVICE|CP308|3 weeks of baseline followed by 2x3 weeks use of the test device
41341753|NCT00879047|DRUG|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
40792087|NCT04887194|DRUG|Digoxin|P-gp probe substrate
40792088|NCT04887194|DRUG|Rosuvastatin|BCRP probe substrate
40792089|NCT04887194|DRUG|Nivolumab|Nivolumab is a programmed death receptor (PD-1) blocking antibody
40792090|NCT02980107|OTHER|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
40792091|NCT02980107|OTHER|PLS|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
40792092|NCT01945996|BEHAVIORAL|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
40792093|NCT01945996|BEHAVIORAL|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
40792094|NCT06543459|DRUG|MY008211A tablets|Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
40792095|NCT06543459|DRUG|Placebo|Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
40792096|NCT05325229|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion，75 mg/m\^2 or 100 mg/m\^2 once every 3 weeks.
40997102|NCT02676505|BEHAVIORAL|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
41149292|NCT06361914|BEHAVIORAL|Digital CBT-I|"Sleep restriction includes behavioral instructions to limit the time spent in bed to increase sleep drive and further reduce time awake in bed.~Stimulus control therapy entails behavioral instructions to strengthen the association between bed and sleep and to eliminate conditioning of non-sleep behavior and bed.~Deactivation/relaxation training involves methods to reduce somatic tension and limit intrusive thought processes that interfere with sleep.~Cognitive therapy helps to identify, challenge, and modify dysfunctional beliefs about sleep.~Sleep hygiene education entails specific information relating to lifestyle and environmental factors that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake."
41341754|NCT03782844|DEVICE|Simple CPAP+Conventional fixed CPAP|Patients used simple CPAP and conventional fixed CPAP during overnight polysomnography.
41469323|NCT06617299|BEHAVIORAL|Intervention Identifies and Responds|"The treatment of Experimental Group is described, which is made up of eight individual sessions taught over three months. Session one will be in face-to-face format, the content, resources and activities are described in tables 2 and 3. The remaining seven sessions will be follow-up sessions (four sessions by message (WhatsApp®) where motivational messages and reinforcement information will be sent; and 3 sessions by phone call for feedback, see details of time, content, activities and resources in tables 2 and 3.~The design of the intervention is aimed at increasing the practice of Responsive Feeding in mothers with children under 6 months of age, is based on the methodology of Sidani and Braden (2021); on CHW (Bandura, 1986); and behavior change techniques to help people have healthy eating habits (Michie et al., 2011)."
41469324|NCT03259191|PROCEDURE|anti-reflux mucosectomy|Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
41469325|NCT06610760|DRUG|Ursodeoxycholic Acid|Subjects will be instructed to take one capsule (250mg) of ursodeoxycholic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
41469326|NCT06610760|DRUG|Placebo|Subjects will be instructed to take one capsule (250mg) of placebo three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
40792097|NCT05325229|DRUG|Bevacizumab|Bevacizumab, by intravenous infusion, 15 mg/kg once every 3 weeks.
40792098|NCT04171505|DRUG|HPV vaccine|". Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account."
40792099|NCT04144738|DIAGNOSTIC_TEST|mt-sDNA 2.0 screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
40792100|NCT04144738|DIAGNOSTIC_TEST|FIT test|Stool samples will be collected by the subject for the FIT test.
40792101|NCT04144738|PROCEDURE|Colonoscopy|Subjects will undergo a screening colonoscopy.
40792102|NCT06371157|DRUG|AK104|intravenous
41341755|NCT03782844|DEVICE|Simple CPAP + Auto CPAP|Patients used simple CPAP and Auto CPAP during overnight polysomnography.
41469327|NCT03643926|PROCEDURE|Arthroscopic Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by arthroscopic view
40792103|NCT06371157|DRUG|Lenvatinib|oral
40792104|NCT06371157|PROCEDURE|TACE|TACE (chemo and embolic agent injection into the hepatic artery)
40792105|NCT06371157|OTHER|Placebo for AK104|intravenous
40997103|NCT02676505|BEHAVIORAL|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
40997104|NCT00816699|OTHER|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
40997105|NCT02912026|DRUG|IV F901318|Metabolic profile AUC 0 to infinity
40997106|NCT02912026|DRUG|Oral F901318|Metabolic profile AUC 0 to infinity
40997107|NCT06011018|OTHER|Mirror Therapy|"Sitting, mirror place at the midline between the legs. Unaffected leg is placed in front of the mirror and perform ankle dorsiflexion exercises.~Duration: 5 seconds, Rest: 5 seconds"
40997108|NCT06011018|OTHER|Mirror Therapy + Electrical Stimulation|Same as the mirror therapy protocol. Affected leg: electrical stimulation on tibialis anterior muscle. Frequency: 35 Hz, Pulse width: 250µs, Duration: 5 seconds, Rest: 5 seconds.
40997109|NCT06011018|OTHER|Mirror Therapy + Binaural Beat|Same as the mirror therapy protocol. Listen to music (mozart's clarinex concerto in A major K622), with Alpha (8Hz) binaural beat stimulation
40997110|NCT01674231|OTHER|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
40997111|NCT01674231|OTHER|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
40997112|NCT05834296|BIOLOGICAL|ALZN002 (autologous DCs pulsed with E22W mutant peptide).|The cellular immunotherapy product consists of autologous dendritic cells (DCs) pulsed with a novel amyloid-beta peptide (Aβ1 42) containing a mutation at position 22 from glutamic acid to tryptophan (E22W). This mutation produces novel CD4+ T cell epitopes specific for the mutant E22W peptide that can facilitate an anti-Aβ1-42 antibody response. The activated E22W peptide specific CD4+ T cells license Aβ1-42-specific B cells to secrete anti Aβ1-42 antibodies, resulting in systemic reduction of amyloid and reduction or slowed accumulation of amyloid plaques in the brain.
40997113|NCT05834296|DRUG|Placebo|Saline
40997114|NCT04346472|OTHER|Repeated Measurements of the relative regional cerebral blood volume|Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.
40997115|NCT02853240|PROCEDURE|Muscle biopsy|A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
41469328|NCT03643926|PROCEDURE|Open Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by an open approach.
40997116|NCT03752307|DRUG|Isoxsuprine Hydrochloride|Compounded Isoxsuprine hydrochloride capsules
40997117|NCT03752307|DRUG|Placebo|Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
41469329|NCT01258101|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
41469330|NCT01258101|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
41469331|NCT01258101|DRUG|ribavirin|800 mg orally daily
41469332|NCT01258101|DRUG|ribavirin|400 mg orally daily
40792106|NCT06371157|OTHER|Placebo for Lenvatinib|oral
40792107|NCT03232827|BEHAVIORAL|Flavored-Sweetened Waterpipe Tobacco|Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.
40792108|NCT03232827|BEHAVIORAL|Unflavored-sweetened waterpipe tobacco|Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
40792109|NCT03232827|BEHAVIORAL|Unflavored-very low sweetened waterpipe tobacco|Pre-weighed unflavored-very low sweetened waterpipe tobacco will be prepared.
40997118|NCT03752307|DRUG|Corticosteroid|This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
41469333|NCT05393128|PROCEDURE|Control group (Supine Position)|"In this group the patients will be given supine position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be given supine position.~3. The arms and the hands will be elevated and supported, the legs will be elevated and supported.~4. The patient will be covered.~5. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
40792110|NCT03232827|BEHAVIORAL|Flavored-very low sweetened waterpipe|Pre-weighed flavored-very low sweetened waterpipe tobacco will be prepared.
40792111|NCT05072054|DRUG|Atorvastatin Oral Tablet|Atorvastatin 40 mg
40792112|NCT05072054|DRUG|Rosuvastatin Oral Tablet|Rosuvastatin 20 mg
40997119|NCT01829776|BEHAVIORAL|Educational intervention|This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
40997120|NCT03127891|BEHAVIORAL|pranayama yoga|providing short term pranayama yoga for 5 sessions before surgery patients under going cardiac surgery.
41469334|NCT05393128|PROCEDURE|Experimental Group (Right Lateral position)|"In this group the patients will be given right lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the right side of the patient and the patient will be turned with 60-90 degrees right lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
40792113|NCT05054491|BEHAVIORAL|Group Antenatal Care|Group ANC is an integrated approach that incorporates physical assessment, education and skill development, and peer support and takes a broader, more holistic, woman-centered approach to traditional antenatal care
40792114|NCT03926910|DIAGNOSTIC_TEST|Detection of hypovolemia using a ventricular stimulation without atrial pacing|"Upon the return in intensive care:~* Baseline measurements: 1) Three measurements of blood pressure during inspiration and 3 during expiration will be collected for averaging systolic blood pressure, diastolic blood pressure, mean arterial pressure and ΔPP. Data from a pulmonary artery catheter will be also collected.~* Realization of VESAP pacing with adjustment of the pacemaker (PM) at a heart rate 5 bpm higher than the heart rate of the patient. After 20 seconds of stimulation, recording of the blood pressure curve as done at baseline during at least 3 respiratory cycles,~* Then vascular filling with 500 ml of physiologic saline solution over 10 minutes and new set of measurement (same than at baseline)~* Second realization of VESAP pacing, and new set of measurement (same than at Baseline)~* Then, if the ΔPP is \>10%, new vascular filling with 500 ml of physiologic saline solution over 10 min and new set of measurements as previously performed."
40792115|NCT01786681|PROCEDURE|Positive pressure|
40792116|NCT04476381|PROCEDURE|Dry needling|Insertion of a Optimed 40mm x 0.30 single use, sterile acupuncture needle into a active trigger point in the infraspinatus muscle
40792117|NCT05959746|OTHER|AI-STROKE application|Complete neurological exam of stroke patients will be filmed by healthcare workers and themselves using the AI-STROKE application
40792118|NCT03564730|PROCEDURE|Simultaneous Knee Arthroplasty (UKA)|Patient will have both knees completed under one anesthetic.
40792119|NCT03564730|PROCEDURE|Staged Knee Arthroplasty (UKA)|Patient will have knees completed under 2 anesthetics.
40792120|NCT04483258|PROCEDURE|Sedation with sevoflurane insufflation|Induction with %8sevoflurane after adequate sedation reducing %3
40792121|NCT04483258|PROCEDURE|intravenous sedation|midazolam +ketamine + atropine
40792122|NCT03849664|DRUG|Cytoflavin® solution|Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
40792123|NCT03849664|DRUG|Cytoflavin® enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
40792124|NCT03849664|DRUG|Placebo solution|Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
40792125|NCT03849664|DRUG|Placebo enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
40997121|NCT03127891|OTHER|control group|no intervention should be given to patients allocated to this group
40792126|NCT05595265|DIAGNOSTIC_TEST|immunohistochemical|Immunohistochemical Evaluation: Corresponding sections of 4µm thickness from each Formalin-fixed paraffin blocks will be immunohistochemically stained by anti- PD-L1 antibody according to the recommended protocol.
40792127|NCT00933439|DRUG|Duloxetine|Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
40792128|NCT02248766|DEVICE|somofilcon A|somofilcon A lens
40792129|NCT03391830|DRUG|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
40792130|NCT03391830|DRUG|Placebo|Placebo
40792131|NCT04361448|OTHER|samling of oropharynx and nasopharynx|Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
40792132|NCT03762460|OTHER|Online eHealth tool|Mobile-optimized online eHealth tool to support MBC.
40792133|NCT03762460|OTHER|Informational website|Participants randomized to this group will receive information about online resources for mental health
40792134|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
40792135|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
40792136|NCT05036161|OTHER|Nasal high flow|Newborns with respiratory distress treated with NHF.
40792137|NCT05036161|OTHER|Continuous Positive Airway Pressure|Newborns with respiratory distress treated with CPAP.
40792138|NCT00610259|BEHAVIORAL|brief behavioral therapy for insomnia (bBT-I)|4 50-minute individual sessions every week for 4 weeks
40792139|NCT00610259|OTHER|Treatment as usual (TAU)|The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
40792140|NCT04092777|BEHAVIORAL|Strong Minds|The proposed intervention integrates cognitive behavioral therapy techniques combined with mindfulness exercises and promotion of behavioral activation through pleasant activities and developing supportive relationships. The intervention is led by CHWs and organized into 10 sessions, tailored to the participant using a collaborative approach, to improve mood symptoms, augment self-reported functioning, and increase self-reported quality of care among participants with moderate to severe symptoms of depression and/or anxiety. It is complemented by a care manager that links participant to services for needs related to social determinants of health (i.e. education, housing). The intervention has been tailored for delivery by CHWs in Spanish, Mandarin, Cantonese, and English.
40792141|NCT04092777|OTHER|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. The Care Manager will call the participant 4 times over the course of 6 months to administer the PROMIS depression (8 item) and anxiety (7 item) short forms, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. With patient's permission, the care manager will inform the PCP about screening and other assessments and determine if participants should be referred to mental health or substance services and removed from control group given symptom severity.
40792142|NCT00961740|BEHAVIORAL|Cognitive Behavioural Therapy|See summary
40792143|NCT00961740|OTHER|Waitlist condition|See Summary
40792144|NCT03486782|DEVICE|IFG stimulation|stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes
40792145|NCT03486782|DEVICE|DLPFC stimulation|stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
40792146|NCT03486782|BEHAVIORAL|aphasia therapy|aphasia therapy for 30 minutes during transcranial direct current stimulation
40792147|NCT00161915|DRUG|Fibrin Sealant|
40792148|NCT04742777|DRUG|rapamycin|Taken orally 1mg daily for 8 weeks
40792149|NCT05497739|DRUG|Intraperitoneal chemotherapy|5-Fu 1 g/m\^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m\^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
40792150|NCT05497739|DRUG|Adjuvant systemic chemotherapy|Oxaliplatin 85 mg/m\^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA \< 1.25 m\^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m\^2), 60 mg Bid, Days 1-10 (BSA \> 1.50 m\^2).
41469335|NCT05393128|PROCEDURE|Experimental Group (Left Lateral position)|"In this group the patients will be given left lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the left side of the patient and the patient will be turned with 60-90 degrees left lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital findings, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
41469336|NCT02310789|DRUG|Ivacaftor|150mg administered orally twice daily.
40792151|NCT02877576|PROCEDURE|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
40792152|NCT02877576|BEHAVIORAL|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter...). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
40792153|NCT02877576|BEHAVIORAL|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
40792154|NCT06302465|DRUG|narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide|Narlumosbartmab is combined with neoadjuvant chemotherapy at 120mg i.h. in day 1, 8, 15, 28 and every 28 days after that.
40792155|NCT06302465|DRUG|doxorubicin、cisplatin、methotrexate、ifosfamide|doxorubicin(37.5mg/m\^2/d)、cisplatin(120mg/m\^2/d)、methotrexate(8-12g/m\^2/d)、ifosfamide(2.4g/m\^2/d)
40792156|NCT06270446|OTHER|Community based physiotherapy|Physiotherapy at community rehabilitation center
40792157|NCT06270446|OTHER|Outpatient physiotherapy|Physiotherapy at hospital
40792158|NCT04832529|PROCEDURE|No packing of perianal abscess cavity|introducing new method to no packing of abscess cavity.
40997122|NCT01763775|DEVICE|Transtek 125X|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).
40997123|NCT01763775|DEVICE|Transtek 950D|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
40997124|NCT00615277|DIETARY_SUPPLEMENT|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
40997125|NCT04692961|DEVICE|Elastography|Use elastography to evaluate the stiffness of lower leg muscle after peroneal artery-based free flap harvested
40997126|NCT01257373|DEVICE|Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent|Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.
40997127|NCT02382081|PROCEDURE|Patient-initiated shared care|
40997128|NCT02653742|DRUG|Ketorolac|Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
40997129|NCT02653742|DRUG|Fentanyl|Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
40997130|NCT00037921|PROCEDURE|Bacterial colonization|
40997131|NCT02122536|DRUG|Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects|Subjects were randomized to which side of the face would be treated with Xeomin.
41149293|NCT06361914|BEHAVIORAL|Digital Sleep hygiene education|Sleep hygiene education entails specific information relating to lifestyle (diet, exercise, substance use) and environmental factors (light, noise, temperature) that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake.
40997132|NCT02122536|DRUG|Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects|Subjects were randomized to which side of the upper face would be treated with Botox
40997133|NCT04149951|DEVICE|Vestal Device|Vestibular nerve stimulator
40997134|NCT04149951|DEVICE|Placebo device|Sham nerve stimulator
40997135|NCT01552239|RADIATION|IMRT/IGRT, Tumor resection, Brachytherapy|"All:~Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)~Tumor resection after 4-6 weeks~Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection"
40997136|NCT01817725|BIOLOGICAL|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those \<= 20 years old and 40μg in those \> 20 years old.
40997137|NCT00001445|BIOLOGICAL|HIV-1 Immunogen|
40997138|NCT04357210|PROCEDURE|fistula tract excision and anal sphincter reconstruction|The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed
40997139|NCT00142675|BEHAVIORAL|Physical Activity|
40997140|NCT01749722|DEVICE|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
40997141|NCT01324388|BIOLOGICAL|LY2189265|Administered subcutaneously
40997142|NCT01324388|DRUG|Metoprolol|Administered orally
40997143|NCT01324388|DRUG|Lisinopril|Administered orally
40792159|NCT04464811|DIAGNOSTIC_TEST|Furosemide stress test|Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.
40792160|NCT00922246|DEVICE|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
40792161|NCT01408277|BIOLOGICAL|Santyl|2 mm Santyl applied once daily
40792162|NCT01408277|PROCEDURE|Control|Standard Care
40792163|NCT06512610|OTHER|Middle Eastern or North Coast of Africa patients with newly AML|Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia in MENAFC patients
40792164|NCT03199677|DRUG|Apatinib|Apatinib is an oral tyrosine kinase inhibitor.
40792165|NCT00124969|DRUG|Amlodipine|10mg
40792166|NCT00124969|DRUG|Placebo|10mg
40792167|NCT01825330|DEVICE|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
40792168|NCT01825330|DEVICE|sham|
40792169|NCT04297150|DRUG|Apixaban|Drug indicated for the treatment of NVAF
41149294|NCT05360134|DRUG|Carica Papaya Leaf Extract|Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7
41149295|NCT05360134|OTHER|Placebo|Placebo will be given in a similar manner
40997144|NCT01324388|DRUG|Placebo|Administered subcutaneously
40997145|NCT01869296|PROCEDURE|higher flow rates|higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec
40997146|NCT01869296|PROCEDURE|lower flow rates|lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
40997147|NCT00243178|DRUG|clopidogrel (SR25990C)|75 mg once daily in combination with aspirin
41469337|NCT02310789|DRUG|β-Adrenergic cocktail|Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).
41469338|NCT02310789|DRUG|Pilocarpine Nitrate 5%|Administered subcutaneously using Macroduct sweat stimulator device.
40792170|NCT04297150|DRUG|Edoxaban|Drug indicated for the treatment of NVAF
40792171|NCT04297150|DRUG|Rivaroxaban|Drug indicated for the treatment of NVAF
40792172|NCT04297150|DRUG|Dabigatran|Drug indicated for the treatment of NVAF
40792173|NCT04003844|DRUG|Immunoglobulin G|single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
40792174|NCT04003844|DRUG|Acetylsalicylic acid|Coadministration
40792175|NCT05041998|DEVICE|Trans-femoral prosthetic socket|"Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis~1. Soft socket (Socket made from softer material than unmodified original)~2. Stiff socket (Socket made from stiffer material than unmodified original)~3. moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)~4. slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)~5. Oversized socket (The socket volume is 6% larger than the unmodified original)~6. Undersized socket (The socket volume is 6% smaller than the unmodified original)~7. CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))~8. MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)"
40792176|NCT03272555|OTHER|WILD 5 Wellness Interventions|Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
40792177|NCT02805959|DEVICE|MTS2|
41149296|NCT00814359|DRUG|Combination of Magic Mouthwash Plus Sucralfate|"Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.~The concentration of the sucralfate suspension will be 1g/5ml.~Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy."
41149297|NCT00814359|DRUG|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
41469339|NCT02310789|DEVICE|Macroduct sweat stimulator|
40792178|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
40792179|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
40792180|NCT04263844|DRUG|Intranasal dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
40792181|NCT04263844|DRUG|Intranasal Midazolam|subject will receive premedication with intranasal midazolam thirty minutes before induction
40792182|NCT02281656|PROCEDURE|Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer|
40792183|NCT02281656|PROCEDURE|Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.|
40792184|NCT03685058|DEVICE|Light curable resin modified glass ionomer varnish|Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
40997148|NCT06097208|BEHAVIORAL|community-based health promotion and obesity prevention intervention|The intervention involving measurements of children aged three- to four-years old in kindergartens, parents of the children had the opportunity of individual contact with a community health nurse, and education to kindergartens manager and employees e.g. pedagogues and kitchen staff. as well to parents of children in kindergartens.
41469340|NCT02770144|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
41469341|NCT02770144|BEHAVIORAL|Access to Referral to Social Services|
40997149|NCT00048542|BIOLOGICAL|Double-Blind Adalimumab/Placebo + MTX|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
40792185|NCT03685058|OTHER|standard-of-care preventive measures|Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
40792186|NCT04335630|DIAGNOSTIC_TEST|Electrocardiogram, telemetry, echocardiogram, laboratory values|Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
40792187|NCT04475107|DRUG|Pyronaridine-Artesunate|Pyramax
40792188|NCT04475107|DRUG|Placebo|Placebo
40792189|NCT01527422|DRUG|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
40792190|NCT05137691|OTHER|Adapted NHS weight management 1:1 programme|Adapted NHS 1:1 weight management programme with a low carbohydrate dietary focus, incorporating enhanced behaviour change via telehealth, step count and pedometer
40997150|NCT00048542|BIOLOGICAL|Double-Blind Adalimumab/Placebo|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
40997151|NCT00048542|DRUG|OLE BSA Adalimumab +/- MTX|Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
40997152|NCT00048542|DRUG|OLE FD Adalimumab +/- MTX|Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
40792191|NCT05137691|OTHER|NHS 1:1 weight management programme|NHS 1:1 weight management programme
40997153|NCT01011517|DIETARY_SUPPLEMENT|Muscadine grape seed supplement|Nature's Pearl 650 mg, two capsules daily
40997154|NCT03904238|BEHAVIORAL|Cognitive-Behavior Therapy for Hypersomnia (CBT-H)|"The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups. Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person. The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., I cannot live a full life because of my illness), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia."
40997155|NCT04508270|BEHAVIORAL|Early mobilization|Mobilization as soon as patients can, which is not limited on walking
40997156|NCT02098109|DRUG|XM02 Filgrastim|
40997157|NCT02098109|DRUG|Filgrastim|
40997158|NCT02098109|PROCEDURE|Apheresis|
40997159|NCT02098109|DRUG|Plerixafor|
40997160|NCT02098109|PROCEDURE|Stem Cell Transplant|
40997161|NCT01505608|DRUG|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
40997162|NCT01505608|DRUG|Temozolomide|Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
40997163|NCT01505608|DRUG|Irinotecan|Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
40997164|NCT00314366|BIOLOGICAL|Stem Cell Therapy|Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
40997165|NCT00314366|OTHER|Control (plasma)|Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
40997166|NCT06193746|DEVICE|non-invasive laser therapy|(diode laser, continuous output, in skin contact mode, 0.005W,0.2cm,beam spot area 0.03cm2, 288j/cm ,1800s) in the morning session, we measured lipid profile and kidney function before and after treatment to measure improvement
40997167|NCT05674552|DRUG|Exogenous ketone ester|500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
40997168|NCT04941508|BEHAVIORAL|the mother's recorded voice|Children will be assigned to listen to the mother's recorded voice at 2 times (in the holding area 3 minutes before induction of anesthesia till induction of anesthesia is ended) and (during emergence from anesthesia till complete recovery).
40997169|NCT04941508|DRUG|Dexmedetomidine|Children will be given a single bolus of dexmedetomidine 0.2 µ/kg IV at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
40997170|NCT04941508|OTHER|saline 0.9% placebo|Children will be given the same volume of saline at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
40997171|NCT00925483|PROCEDURE|dialysis|different dialysis schedules for each arm
40997172|NCT00619879|DRUG|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|"Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2."
41149298|NCT03130699|BEHAVIORAL|Dulce Digital|One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
41469342|NCT02671682|PROCEDURE|Immunoadsorption|
41469343|NCT02671682|PROCEDURE|Plasmapheresis|
40792192|NCT03922464|DEVICE|Poly-L-lactic acid (Sculptra® Aesthetic)|"Sculptra® Aesthetic is a commercially available product that is licensed for sale in Canada. It is an injectable implant that contains microparticles of poly-L-lactic acid (PLLA), a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Sculptra® Aesthetic is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging. Sculptra® Aesthetic is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).~The safety and efficacy of Sculptra® Aesthetic has been investigated in the literature and is generally considered safe and effective. PLLA has been used successfully to reverse HIV-associated lipoatrophy as well as to rejuvenate the face, neck, décolletage, hands, abdomen and gluteal regions."
40792193|NCT01474785|DRUG|human ghrelin|0.5-1 pmol/kg.min of human ghrelin administered by IV two times
40792194|NCT01474785|OTHER|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
40792195|NCT01474785|PROCEDURE|Hyperinsulinemic/Euglycemic Clamp|Insulin and glucose infusions to measure glucose kinetics.
40792196|NCT05670639|BEHAVIORAL|CAPABLE Care Partner|The CAPABLE Care Partner intervention consists of three components: 1) up to 3 sessions with a Care Partner Support person focused on developing action plans for self-care goals of the care partner 2) educational materials provided in a folder at the beginning of the program 3) inclusion in the CAPABLE clinician visits as deemed appropriate by the client, CAPABLE clinicians, and care partner
40997173|NCT00619879|DRUG|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|"Busulfan administration:~* For children \>/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.~* For children \< 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.~* Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols\*min for the 16 doses.~Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2."
40997174|NCT00619879|OTHER|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
41149299|NCT03130699|BEHAVIORAL|Dulce Digital-Me (Automated Delivery)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
40997175|NCT00619879|RADIATION|CNS radiation treatment for ALL with prior CNS disease patients|"Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.~Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) \< 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:~* Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count~* Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count"
40997176|NCT00218673|BEHAVIORAL|Peer mentor intervention|groups sessions, 8
40792197|NCT00712478|DRUG|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40792198|NCT06163196|OTHER|acupressure|Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
40997177|NCT05217407|OTHER|Genomic sequence|Genomic sequence
40997178|NCT04262037|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China
40997179|NCT00542919|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
40997180|NCT02398552|DRUG|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
40997181|NCT02431754|DRUG|Tadalafil|Administered orally
41149300|NCT03130699|BEHAVIORAL|Dulce Digital-Me (Medical Assistant)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
41149301|NCT05639166|BIOLOGICAL|IBIO123|IBIO123 10 mg
40997182|NCT02431754|DRUG|Placebo|Administered orally
40997183|NCT02431754|DRUG|Alpha1 Blocker|Administered orally
40997184|NCT01742338|DRUG|Low Dose Corticosteroids|
40997185|NCT01742338|DRUG|High Dose Corticosteroids|
41149302|NCT05639166|OTHER|Placebo|Matching Placebo
41149303|NCT01287624|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
40792199|NCT05508646|BEHAVIORAL|Music therapy intervention|The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.
40792200|NCT05508646|BEHAVIORAL|Personalized music CD|Participants will receive a personalized music CD that they keep and can listen to as they wish.
40792201|NCT00110045|DRUG|caspofungin acetate|
40792202|NCT03350451|DRUG|Lumasiran|Multiple doses of lumasiran by SC injection
40792203|NCT01962428|DRUG|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
40792204|NCT00199615|PROCEDURE|PET|Intravenous injection of glucose labeled Fluor 18.Le patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during which the patient should not move.
40792205|NCT00343564|DRUG|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
40792206|NCT00343564|DRUG|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
40792207|NCT06197152|OTHER|Nasopharyngeal swabs and biological collection|"* Nasopharyngeal PCR~* Blood and virological samples taken as part of the research will be included in a biological collection"
40792208|NCT05034809|DRUG|Melatonin 20 MG|Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.
40792209|NCT03037762|PROCEDURE|Flexible Endoscopic Evaluation of Swallowing|
40792210|NCT03168893|DEVICE|Deep brain stimulation ON|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
40792211|NCT03168893|DEVICE|Deep brain stimulation OFF|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
40997186|NCT05357911|DRUG|AB-106, digoxin|Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin
40997187|NCT01150929|DEVICE|P.F.C. Sigma knee arthroplasty|Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
40997188|NCT00000833|DRUG|Ribavirin|
40997189|NCT00000833|DRUG|Didanosine|
40997190|NCT06059911|DIETARY_SUPPLEMENT|Multi-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA)|Administration of a multi-ingredient dietary supplement consisting of 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g branched chain amino acids
40997191|NCT06059911|DIETARY_SUPPLEMENT|Placebo dietary supplement (97% maltodextrin)|Administration of an isoenergetic placebo comparator dietary supplement consisting of 97% maltodextrin
40997192|NCT02822989|DEVICE|Vagus nerve stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
40997193|NCT02822989|DEVICE|Sham vagus nerve stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
40997194|NCT04663581|OTHER|Left Sided Colonoscopy|Starting colonoscopy with the patient in left decubitus
41149304|NCT01287624|DRUG|Gemcitabine, Paclitaxel|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1
40792212|NCT01533441|DIETARY_SUPPLEMENT|Vitamin K2|4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
40792213|NCT05493878|DIAGNOSTIC_TEST|mRNA expression|Tumor educated platelets ITGA2b and SELP mRNA by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
40792214|NCT02616939|OTHER|Cardiac CT scanning (with the SpotLight CT)|Cardiac CT scanning
40792215|NCT04868942|OTHER|Assisting to the event|"Participant will attend a concert respecting the Following measures :~* Individual protection kit: disposable FFP2 masks (3), Hydroalcoholic solution, disposable tissues, garbage bag, water bottle~* Health mediation, information on barrier measures~* Physical distancing (sitting participation)~* Person flow management"
40792216|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum precipitated autoclaved L. major
40997195|NCT04663581|OTHER|Right Sided Colonoscopy|Starting colonoscopy with the patient in right decubitus
40997196|NCT02046148|BIOLOGICAL|GBS trivalent vaccine|Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein
40997197|NCT02046148|BIOLOGICAL|Placebo|Intramuscular injection - Normal saline
40997198|NCT01980043|PROCEDURE|endoluminal rectal prolapse repair under sedation|endoluminal rectal prolapse repair under sedation
40997199|NCT00100243|DRUG|Plenaxis|
40997200|NCT03522766|OTHER|urine sample|The subjects are asked to give a maximum of 15 urine samples during the study
41341756|NCT05478538|PROCEDURE|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
40997201|NCT02497027|OTHER|pharmacogenetic testing|pharmacogenetic testing report released to physician at 4 weeks post enrollment
40997202|NCT02497027|OTHER|pharmacogenetic testing|pharmacogenetic testing report released to physician at 12 weeks post enrollment
41341757|NCT01666990|DRUG|TwHF|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
40997203|NCT06366880|OTHER|Parenteral nutrition cycling|"This study is a single-centre, non-blinded RCT in the NICU of Pediatric Hospital of Sinaloa, Northwest, Mexico.~A total of 66 infants born ≥34 weeks of gestation who have a high likelihood of intolerance to enteral nutrition (EN) for at least 10 days will be randomised to PNC o PNT after informed parental consent. In both groups, EN will be commenced as early as clinically feasible."
40997204|NCT02808286|BEHAVIORAL|Hybrid|The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
41469344|NCT03886649|DRUG|Copanlisib|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The only dose level 1 (DL1) is 60 mg copanlisib.
41469345|NCT03886649|DRUG|Venetoclax|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The starting dose is dose level 1 (DL1): 600 mg venetoclax.
41469346|NCT06613867|OTHER|Wakobotikodro|Wakobotikodro : an intervention combining (i) training matrons to identify and monitor high-risk pregnancies, (ii) integrating them into the healthcare system and (iii) using a digital decision-support application installed on a smartphone and adapted to their profile, could improve the identification and monitoring of high-risk pregnancies.
41469347|NCT04010734|PROCEDURE|Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography|"The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH)."
41469348|NCT01764867|DRUG|Escitalopram|Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
41469349|NCT01764867|DRUG|Mirtazapine|Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
40792217|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
40792218|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum-ALM + BCG
40792219|NCT04068948|DRUG|Meperidine|This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
40792220|NCT04068948|DRUG|Hydroxyzine|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
40792221|NCT04068948|DRUG|Midazolam|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
40792222|NCT04888806|DRUG|Camrelizumab|d1，200mg, iv, q3w
40792223|NCT04888806|PROCEDURE|ablation|the 37 enrolled patients received ablation of liver/lung metastases ，If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times.
40792224|NCT04888806|DRUG|chemotherapy|standard treatment plan for mCRC, determined by the investigator
40792225|NCT02824692|DEVICE|heart lungs and abdomen ultrasound|
40997205|NCT02808286|BEHAVIORAL|internet Cognitive Behavior Therapy (iCBT)|A state-of-the-art CBT pain treatment, delivered via the internet.
40997206|NCT02990208|BEHAVIORAL|Diaphragmatic breathing|Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens \& Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
41341758|NCT01666990|DRUG|placebo treatment|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
41341759|NCT06086782|OTHER|autogenic inhibition|Group 1 will receive AI-MET with conventional treatment. AI include stretching of the affected muscle and performing isometric contraction with 50% of the total patient's effort in the same muscle that will being stretched and position hold for 10 seconds, with 5 seconds of rest after every repetition. This procedure will repeat 5 times.
40997207|NCT02990208|BEHAVIORAL|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger \& Pauli, 2011)
40997208|NCT01900028|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with olaparib+/- itraconazole
40997209|NCT01900028|DRUG|Olaparib tablet dosing|Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).
40997210|NCT01900028|DRUG|Itraconazole|Itraconazole 200mg od Part A days 5 to 11 only
40997211|NCT00370474|DEVICE|Bi-ventricular lead placement|
40997212|NCT06061627|PROCEDURE|LOT-CRT group|"In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads~LBBAP includes LBBP and LVSP.~LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met, while the pacing threshold ≤ 1.5V/0.5ms:~   1. Selective LBBP capture pattern appears, with an iso-electrical window between the pacing spike and QRS onset;~  2. When reducing the output voltage, the LVAT undergoes a sudden change of\>10ms;~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
40997213|NCT06061627|PROCEDURE|BiVP group|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
40997214|NCT01076712|OTHER|Physiotherapy Interventions|Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill
40997215|NCT01076712|OTHER|Education Classes|Education Classes
40792226|NCT01027858|BEHAVIORAL|Aerobic-based exercise training|Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
40792227|NCT01027858|BEHAVIORAL|CON (control; usual care)|Nutrition education and usual care as prescribed by neurologist
40792228|NCT04893512|DRUG|Orally Suspension of CoV2-OGEN1|CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
40792229|NCT04321876|BEHAVIORAL|Collaborative Behavioral Health Program|Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.
40997216|NCT00002524|BIOLOGICAL|Bleomycin Sulfate|
40997217|NCT00002524|BIOLOGICAL|Filgrastim|
40997218|NCT00002524|DRUG|Cisplatin|
40997219|NCT00002524|DRUG|Cyclophosphamide|
40997220|NCT00002524|DRUG|Cytarabine|
40997221|NCT00002524|DRUG|Doxorubicin Hydrochloride (DOX)|
40997222|NCT00002524|DRUG|Etoposide|
40997223|NCT00002524|DRUG|Fluorouracil|
40997224|NCT00002524|DRUG|Ifosfamide|
40997225|NCT00002524|DRUG|Leucovorin calcium|
40997226|NCT00002524|DRUG|Methotrexate|
40997227|NCT00002524|DRUG|Methylprednisolone|
40997228|NCT00002524|DRUG|Pentamidine|
40997229|NCT00002524|DRUG|Prednisone|
40997230|NCT00002524|DRUG|Trimethoprim-Sulfamethoxazole|
40997231|NCT00002524|DRUG|Vincristine Sulfate|
40997232|NCT00002524|DRUG|Zidovudine (AZT)|
40997233|NCT00002524|RADIATION|Radiation Therapy|
40997234|NCT02345967|DEVICE|Model 100 Sensor|One Model 100 Sensor to be implanted per subject.
40997235|NCT05584553|DEVICE|ToggleLoc 2.9 mm soft tissue device|The ToggleLoc 2.9 mm Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
40997236|NCT05584553|DEVICE|JuggerLoc soft tissue device|The JuggerLoc Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
40997237|NCT05081856|OTHER|mobilization with moduler medical equipment carring vehicle|Mobilization of the patients was carried out with the vehicle in their modular vehicle.
40997238|NCT03051542|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/￼￼￼￼dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
41341760|NCT06086782|OTHER|reciprocal inhibition|Group 2 receive RI-MET with conventional treatment. The RI also include stretching of the affected muscle but contrary to AI, isometric contraction of the antagonist muscles with the 50% of total patient's effort will follow. This position holds for 10 seconds, while agonist's muscle will still in the stretched position, with 5 seconds of rest after every repetition. This procedure will repeat 5 times too.
40997239|NCT05092893|OTHER|Online parental questionnaires|"The SRS-2 is a parental 65-item questionnaire to detect difficulties in social responsiveness in children with autism spectrum disorder. Four different forms are available: preschoolers (2.5-4.5 years), school-aged children (4-18 years), adults (≥ 19 years) and adults self-report. In this study, only the form for school-aged children will be used.~The DCDQ'07 is a parental 15-item questionnaire to detect the risk of DCD in children between 5 and 15 years of age. Parents are asked to compare their child's motor performance to his/her peers using a 5-point Likert scale. The total sum score is compared to age-specific cut-off scores to determine the risk of DCD. Belgian norms are available since 2007."
40997240|NCT06372288|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS using Intermittent theta burst stimulation (iTBS)
41469350|NCT01764867|OTHER|modified electroconvulsive therapy|Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
41469351|NCT01764867|OTHER|repetitive transcranial magnetic stimulation|Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
41469352|NCT01764867|DRUG|Fluoxetine|Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
40792230|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep is crucial for processing emotional memories and consolidating implicit memories. By using targeted memory reactivation (TMR), a known method where sound S1 and sound S2 are associated with a waking experience(i.e.negative emotional words is associated with alcohol-related cues and positive emotional words is associated with healthy lifestyle cues) and strengthened during REM sleep, the investigators aim to augment the control of craving levels in patients with Alcohol Use Disorder.
40792231|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification|These patients will receive the treatment of emotional attention bias modification (EABM) without association with the sound S1 and sound S2.
40792232|NCT02707965|DRUG|Oxcarbazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
40997241|NCT06372288|DEVICE|Sham Transcranial Magnetic Stimulation|Participants will not receive intermittent theta burst stimulation during the sham-TMS sessions
41469353|NCT01764867|DRUG|Citalopram|Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
40792233|NCT02707965|DRUG|Divalproex Sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
40792234|NCT02707965|DRUG|Carbamazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
40997242|NCT01928862|DRUG|Prepopik® ½ Sachet x 2 (9-12 years)|
40997243|NCT01928862|DRUG|Prepopik® 1 Sachet x 2 (9-12 years)|
40997244|NCT01928862|DRUG|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
40997245|NCT01928862|DRUG|Prepopik® 1 Sachet x 2 (13-16 years)|
40997246|NCT01928862|DRUG|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
40997247|NCT04291339|PROCEDURE|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
41341761|NCT01010776|DRUG|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
41341762|NCT01611922|OTHER|Ophthalmic dye|Topically instilled for the purpose of assessing lid margin staining
41469354|NCT01764867|DRUG|Escitalopram|Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
41469355|NCT01764867|DRUG|Paroxetine|Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
41469356|NCT01764867|DRUG|Sertraline|Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
41469357|NCT01764867|DRUG|Fluvoxamine|Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
41469358|NCT01764867|DRUG|Venlafaxine|Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
40997248|NCT04291339|PROCEDURE|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
40792235|NCT02707965|DRUG|Lamotrigine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
40997249|NCT02733536|DEVICE|Standard endotracheal tube|1) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube
40997250|NCT02733536|DEVICE|C-MAC|C-MAC introduced with a h size 3 blade.
40792236|NCT02707965|DRUG|levetiracetam (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
40792237|NCT02707965|DRUG|Topiramate (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
40997251|NCT03379207|OTHER|Blood samples|Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose
40792238|NCT02707965|DRUG|Zonisamide (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
40792239|NCT02707965|DRUG|Phenytoin sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
40997252|NCT03379207|OTHER|Tracheal Aspirates|Only for mechanically ventilated participants.
40997253|NCT03379207|OTHER|Surplus of Broncho-alveolar lavage fluid|Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion
41469359|NCT01764867|DRUG|Duloxetine|Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
40997254|NCT03179176|OTHER|High Frequence Ultrasound Doppler (HFUD) utilisation|Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
40997255|NCT05398978|OTHER|e-Registration and mHealth|Registration to the electronic database Counseling through voice calls for facility delivery Text messages to promote facility delivery
40997256|NCT04753164|DRUG|ACT-539313|ACT-539313 as capsules at a strength of 100 mg, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
40997257|NCT04753164|DRUG|Placebo|Matching placebo as identical capsules indistinguishable from ACT-539313, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
41469360|NCT01764867|DRUG|Mirtazapine|Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
40997258|NCT00417092|PROCEDURE|Postoperative Pacing|
40997259|NCT02815228|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-034)
40997260|NCT06163248|OTHER|Chrono nutrition|An integral nutritional strategy involving timing, order and distribution of macronutrients
40997261|NCT06163248|OTHER|Standard|Conventional nutritional strategy involving isocaloric distribution with no specific timing
40997262|NCT02430337|BEHAVIORAL|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
40997263|NCT02430337|BEHAVIORAL|SafeCare|SafeCare, an evidence-based home visiting program
40997264|NCT06160466|DEVICE|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a follow-up pateints in the screening population.
40997265|NCT06160466|DEVICE|White light|White light endoscopy
40997266|NCT01147185|DEVICE|Locomotor training using a robotic device|50min walking time, 3-5 trainings/week.
40997267|NCT01147185|DEVICE|Locomotor training using a robotic device|25min walking time, 3-5 trainings/week.
40997268|NCT02823275|OTHER|Functional mobilisation|functional mobilisation
40997269|NCT02823275|OTHER|Short term plaster cast fixation|2 weeks cast immobilisation
40997270|NCT05970315|BEHAVIORAL|PPC|Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities.
41469361|NCT01764867|DRUG|Bupropion|Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
41469362|NCT01764867|DRUG|Trazodone|Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
41469363|NCT06422494|DRUG|hyperinsulinaemic hypoglycaemic clamp|Insulin will be infused at a continuous rate of 60 mU∙m-2 ∙min-1 and glucose 20% will be infused at a variable rate, aiming for stable plasma glucose levels of 5.0 mmol/L. The infusion rate of glucose will be adjusted by plasma glucose levels, measured at 5-minute intervals. After 30 minutes of stable euglycaemia, plasma glucose levels will be allowed to drop gradually to 2.8 mmol/L and will be maintained at this level for 60 minutes. Then, insulin infusion and adrenergic blockade infusions will be stopped. Glucose infusion will be increased and then tapered until stable euglycaemia plasma levels are reached.
41469364|NCT06422494|DRUG|Propranolol Hydrochloride 1 MG/ML|When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
41469365|NCT06422494|DRUG|Phentolamine|When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
41310208|NCT06216015|OTHER|Exercise training|"Participants will engage in combined training five times a week, with activities including 2 minutes of stationary marching and a set of 15 repetitions for squats, bilateral hip abduction, plantar flexion, floor abdominal exercises, and arm flexion with the knee close to the ground. Additionally, twice a week on non-consecutive days, volunteers partake in 20 minutes of aerobic walking.~The second program starts with a 2-minute stationary march, followed by 2 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion with knee support, floor abdominal exercises, and concludes with 30 minutes of aerobic exercise.~The third program starts with a 2-minute stationary march, followed by 3 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion, floor abdominal exercises, and includes thrice-weekly aerobic sessions lasting 30 minutes each."
40997271|NCT05970315|BEHAVIORAL|Usual care|Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden.
40997272|NCT02098590|BIOLOGICAL|CPS-immunization|Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
40997273|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
40997274|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
41310209|NCT06216015|OTHER|Continue exercising|Following the 12-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will include individuals who choose to persist with their exercise routine.
40997275|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
40997276|NCT02098590|DRUG|atovaquone/proguanil|All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
40997277|NCT04014075|DRUG|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion
40997278|NCT02793518|BEHAVIORAL|psychological tests|
40792240|NCT04944576|DEVICE|Total Ankle Prosthesis, EasyMove®|Patients who will be implanted with a total ankle prosthesis, EasyMove.
40997279|NCT03784573|BEHAVIORAL|Dog + handler|Dog + handler
40997280|NCT03784573|BEHAVIORAL|No dog|No dog
40997281|NCT01660412|DRUG|Standard of Care First|For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40.
40997282|NCT01660412|DRUG|ph Altered first|For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
40997283|NCT04908670|BEHAVIORAL|Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI|Watching pain neuroscience education video
40997284|NCT04908670|PROCEDURE|PA manipulation|Low grade PA manipulation on the cervical, thoracic and lumbar spine
40997285|NCT04601545|BEHAVIORAL|Pulmonary rehabilitation|"Three weeks of pulmonary rehabilitation conducted in an outpatient care facility:~* 5- time a week for 30 minutes a specific respiratory exercises- relaxation exercises for breathing muscles, exercises to increase breathing, prolonged exhalation exercise, chest percussion~* 5- time a week for 20-30 min training on a cycle ergometer - until the Heart Rate reaches 60% of the HRmax~* 5- time a week for 30 minutes a fitness and respiratory exercises - coordination and balance exercises, stretching exercises~* relaxation by Schultz Autogenic Training. The technique involves the daily practice of sessions that last around 15 minutes. During each session, the practitioner repeats a set of visualisations that induce a state of relaxation."
40997286|NCT04601545|DEVICE|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.~By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
40997287|NCT06025630|DRUG|TUDCA|Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
40997288|NCT06025630|DRUG|Placebo|Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
40997289|NCT04854811|DRUG|Roflumilast Oral Tablet|Once daily for 12 weeks
40997290|NCT01076504|DRUG|Amrubicin|30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
40997291|NCT01076504|DRUG|Carboplatin|AUC=5 IV, Day 1 of each 3-week treatment cycle
40997292|NCT01076504|DRUG|Pegfilgrastim|6 mg SQ on Day 4 of each 3 week treatment cycle
41310210|NCT06216015|OTHER|Discontinue exercising|Following the 12-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will comprise individuals who opted not to continue their exercise routine.
41310211|NCT04958863|OTHER|Surgical mask|Use of a surgical mask during test
40792241|NCT01637896|DEVICE|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
40792242|NCT01637896|DEVICE|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
40997293|NCT00588822|BIOLOGICAL|Rituximab|Rituximab will be given as a 375 mg/m\^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
40997294|NCT00204620|DRUG|Bendamustin|
41149305|NCT05635994|DIAGNOSTIC_TEST|AID strategy|AID strategy encompasses a hierarchical algorithm intended to investigate both obstructive and non-obstructive causes of myocardial ischaemia. AID strategy starts with an ICA. Angiographically severe-grade stenosis (≥70%) can be safely considered flow-limiting without further physiological assessment. Conversely, by means of a pressure guidewire, intermediate-grade stenosis should be evaluated with FFR and/or NHPR in order to determine if they are physiologically significant. Those patients with non-obstructive CAD or normal epicardial coronary arteries should undergo functional coronary tests to investigate the presence of microcirculatory and vasomotor coronary disorders, which would account for non-obstructive causes of ischaemia.
40997295|NCT05531435|DRUG|local anaesthetic injection|Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
40997296|NCT04152889|DRUG|Camrelizumab|Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
40997297|NCT04152889|DRUG|S-1|Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
40997298|NCT04152889|DRUG|Docetaxel|Docetaxel: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
40997299|NCT01261182|OTHER|In School Feeding|The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
40997300|NCT01261182|OTHER|Take Home Rations|The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
40997301|NCT05096936|OTHER|Pilates|"The solo Pilates method will be applied twice a week for 12 weeks using the following exercises:~20 Breaths, Double leg stretch, Single leg stretch, Leg circles, Hip lift on ball, Abdominal tightening on ball, Alternating two supports, Side bend, Side kick - side kick, Side kicks, Shell and Swan and Neck pull stretches; in the tenth session, we evolved some exercises: The saw, Swan dive, Book close series, Hip lift on the ball and Front pulls; in the eighteenth session we changed again some exercises for: Leg pull back, Rolling like a Ball, Swimming, Roll over and Leg pull front."
40997302|NCT05096936|OTHER|Photobiomodulation|Applications of FBM or placebo (MR4 ACTIVet PRO Laser Shower Portable, MRM, USA) will last for 115s and will deliver 60 J at each point. The mode of application, with the patient supine on a stretcher, with the grouping probe held stationary in contact with the skin, at a 90-degree angle, in the pubic mound and in the perineum region.
40792243|NCT05673824|DRUG|Huaier Granule|"Treatment period: oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, failure of treatment, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.~If the treatment of hepatobiliary malignancies needs to be changed due to disease progression, whether to continue the medication or not should be determined by the researcher."
40792244|NCT05673824|DRUG|VEGFR-TKIs|Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib. Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
40792245|NCT06008262|OTHER|Cold Application|An ice pack will be applied to the posterior upper neck regions of patients with nausea in Group-I, with an interval of 5 minutes. The vital signs of the patients will be recorded. The severity of nausea and pain of the patients will be evaluated with a numerical rating scale. The effectiveness of its application as perceived by the patient will be evaluated.
40997303|NCT01328860|BIOLOGICAL|bone marrow progenitor cells (BMPC) autologous transplantation|Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
40997304|NCT04612647|OTHER|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)
41149306|NCT02638558|OTHER|written + oral explanation|
40997305|NCT04612647|BEHAVIORAL|Physical Activities & Activity Booklets|expected to engage in physical activity at least 3 hours per week
40997306|NCT05160688|BEHAVIORAL|Contingency management|Participants will be paid to abstain from cannabis use.
40997307|NCT03194451|OTHER|non-interventional study|teeth collection
40997308|NCT03465878|DRUG|LY900014|Administered via SC injection
40997309|NCT03465878|DRUG|Insulin Lispro|Administered via SC injection
41149307|NCT02638558|OTHER|written explanation|
41149308|NCT03873714|DEVICE|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
41310212|NCT04958863|OTHER|Polyester reusable mask|Use of a polyester reusable mask during test
40997310|NCT04200807|DEVICE|Ultrasound Cardiac Output Monitor (USCOM 1A)|doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)
40997311|NCT00511693|BEHAVIORAL|centralized osteoporosis coordinator|The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
40997312|NCT00511693|BEHAVIORAL|fall prevention|Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
40997313|NCT06186037|DRUG|Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg|Oral administration once a day, taking it for 3 years
40997314|NCT06186037|DRUG|Mono drug group of Rosuvastatin 20 mg|Oral administration once a day, taking it for 3 years
40997315|NCT03832374|OTHER|Descriptive|
40792246|NCT06342765|DEVICE|Pedicle fixation surgery|Pedicle fixation surgery indicates a surgical approach in the thoracic spine down to sacral spine to either support interbody fusion (fusion of the discal space between two vertebrae) , or to correct spinal deformity.
40792247|NCT04420052|OTHER|Osteopathic manipulative treatment|"Osteopaths will executed several high velocity low amplitude (HVLA) techniques on the upper thoracic spine and cervical spine. These techniques are assumed to modulate the sympathetic cervical ganglia and reduce inflammation in chronic rhinosinusitis.~This procedure takes around 15 minutes."
40792248|NCT04420052|OTHER|Placebo manipulation|"The osteopath will lay hands without movement on the nose, the throat and the thorax of patients.~This procedure takes around 15 minutes."
40792249|NCT02840253|DEVICE|NIRS|
40792250|NCT04304079|DEVICE|ARssist system|As stated in ARssist system arm description
40792251|NCT01433042|DEVICE|capsule endoscopy|capsule endoscopy procedure
40792252|NCT01927263|BIOLOGICAL|NI-071|100mg/vial
40792253|NCT01927263|BIOLOGICAL|Infliximab|100mg/vial
40792254|NCT01744067|DRUG|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
40997316|NCT03946397|OTHER|Mulstisensory massage|7 minutes of hand massage followed by multisensory immersion (lights and music) for 23 minutes
40792255|NCT01744067|DRUG|Placebo|Placebo capsules 3 times a day (oral administration)
40792256|NCT04434547|BIOLOGICAL|PRP|During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
40792257|NCT05614752|DRUG|Fexuprazan|Fexuclue Tablet 40mg
40997317|NCT06327399|DRUG|Dexmedetomidine infusion|patients will receive Dexmedetomidine infusion dose of 1 mcg/kg over 10 min before induction.
40997318|NCT06327399|DRUG|Dexmedetomidine bolus|patients will receive Dexmedetomidine bolus dose of 0.3 mcg/kg over 60 seconds.
41149309|NCT00360971|BIOLOGICAL|palifermin|Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
41149310|NCT00360971|DRUG|cisplatin|Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
41310213|NCT05580861|DRUG|Sulfasalazine|Sulfazalazine 500mg-tablets ; 7 dose levels explored in the phase I part of the trial.
40792258|NCT01602263|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
40997319|NCT06327399|DRUG|Atropine Sulfate|If heart rate falls below 45 bpm, rescue dose (500 mcg) of atropine will be given.
40997320|NCT06327399|DRUG|Ephedrine|If mean blood pressure decreases below 50 mmHg, boluses of 10 mg ephedrine will be given
40997321|NCT06327399|DRUG|Propofol|Propofol 20 mg boluses till loss of contact
40792259|NCT03938831|DRUG|Dexmedetomidine|dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
40792260|NCT03938831|DRUG|Fentanyl-based PCA infusion|Fentanyl-based PCA infusion
40792261|NCT00337831|PROCEDURE|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration is followed.
40792262|NCT00589797|DEVICE|Activ-L Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
40792263|NCT00589797|DEVICE|ProDisc-L Total Disc Replacement or Charité Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
40792264|NCT04970173|OTHER|use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy|Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
40792265|NCT01128725|OTHER|Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~* psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~* Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
40792266|NCT03183765|DRUG|Measles-Mumps-Rubella Vaccine|"MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
40792267|NCT03183765|PROCEDURE|cryotherapy|"patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison.~The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
40792268|NCT06107543|DRUG|Nebulized Lidocaine|Before induction of anesthesia, 2% lidocaine + physiological saline was added to a nebulizer and inhaled for 3-5 minutes in the presence of 4-6 liters/minute of oxygen.
40997322|NCT05172661|BEHAVIORAL|Integrated physical-cognitive training|Perform a postural task and a cognitive task at the same time (dual-task model) 70 minutes/session\*2 sessions/week\*6 weeks
40792269|NCT06107543|DRUG|Iv Lidocaine|Intravenous %2 lidocaine was administered before induction of anesthesia.
40792270|NCT05540626|DEVICE|Cala Trio|transcutaneous afferent patterned stimulation (TAPS)
40792271|NCT01669746|BIOLOGICAL|Autologous cultured mixed population of dermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
40997323|NCT05172661|BEHAVIORAL|Consecutive physical-cognitive training|Perform a postural task and a cognitive task separately for identical durations 70 minutes/session\*2 sessions/week\*6 weeks
40997324|NCT00764621|PROCEDURE|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
40997325|NCT00764621|PROCEDURE|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
40997326|NCT00764621|PROCEDURE|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
40997327|NCT02051465|DEVICE|LumenR Retractor|Polyp removal using LumenR Retractor Modified overtube
40997328|NCT02051465|DEVICE|Removal without overtube|Endoscopic removal of polyp without overtube
40997329|NCT06208436|OTHER|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (5-FU-based or gemcitabine-based regimens) or underwent surgery alone
40997330|NCT05263492|DRUG|Lenvatinib|Lenvatinib once a day by mouth every day
40997331|NCT05263492|DRUG|Pembrolizumab|Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.
40997332|NCT03666078|PROCEDURE|cesarean delivery|women delivered by cesarean section
40997333|NCT02008448|PROCEDURE|Pulmonary vein isolation|
40997334|NCT02008448|PROCEDURE|Linear Lesion Ablation|
40997335|NCT02008448|DRUG|BT injection|
40997336|NCT03602469|DRUG|Bupivacaine|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline
40997337|NCT03602469|DRUG|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)
41149311|NCT00360971|OTHER|placebo|Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
40997338|NCT03602469|DRUG|Propofol|Using propofol 1.5-2.5 mg/kg
40997339|NCT03602469|DEVICE|Ultrasound|Ultrasound-guided suprascapular nerve block
40997340|NCT03602469|DRUG|Sevoflurane|Sevoflurane 0.7-1.5 MAC in 40% oxygen
40997341|NCT03602469|DRUG|Rocuronium|Rocuronium 0.6 mg/kg
40997342|NCT03729336|DEVICE|Midstream urine collection device|Non-invasive midstream urine collection device
40997343|NCT03729336|DEVICE|Catheter for urine collection|In-and-out catheter obtains urine through the urethra.
40997344|NCT00281203|PROCEDURE|blood drawing|blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy
40997345|NCT00281203|PROCEDURE|fiberoptic bronchoscopy|A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
40997346|NCT01034449|OTHER|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
40997347|NCT06404151|DEVICE|monitoring|rc02, ORI , spO2
41149312|NCT00360971|PROCEDURE|neck dissection|A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
41310214|NCT04520763|OTHER|5min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-80% MVV 15-30min after ingestion of 75g of glucose
41469366|NCT02626208|DEVICE|Nestorone®/Estradiol Contraceptive Vaginal Ring|Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
41469367|NCT04747795|DRUG|Vitamin C|IV
40792272|NCT05389748|OTHER|Placebo|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to placebo in association with standard of care
40792273|NCT05389748|BIOLOGICAL|dodecafluoropentane emulsion (DDFPe)|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to DDFPe in association with standard of care
40792274|NCT02775630|PROCEDURE|hypnosis|It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
40792275|NCT03116997|DRUG|Neostigmine+glycopyrrolate|At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
40792276|NCT03116997|DRUG|Sugammadex|At the conclusion of surgery neuromuscular blockade reversed with sugammadex
40792277|NCT04729348|DRUG|Pembrolizumab|Oral, daily, dosage per protocol
40792278|NCT04729348|DRUG|Lenvatinib|Oral, daily, dosage per protocol
40792279|NCT02253082|DRUG|OctaplasLG®|OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
40792280|NCT02253082|BIOLOGICAL|Fresh frozen plasma|Standard FFP from the Blood Bank
40792281|NCT00000277|DRUG|Mazindol|
40792282|NCT00881530|DRUG|BI 10773|BI 10773 high dose once daily
40792283|NCT00881530|DRUG|Metformin|open label comparator
40792284|NCT00881530|DRUG|BI 10773|BI 10773 low dose once daily
40792285|NCT00881530|DRUG|Sitagliptin|open label comparator
40997348|NCT06416696|DRUG|Toripalimab|"1. Radiotherapy: Both external beam and brachytherapy, with radiation therapy techniques, target delineation, prescribed doses, and organ-at-risk constraints following established guidelines.~2. Chemotherapy: The preferred regimen is cisplatin at a dose of 40mg/m\^2 administered intravenously once weekly for 5-6 cycles; for patients intolerant to cisplatin or with renal impairment, carboplatin (AUC=2) may be considered, also administered once weekly.~3. Toripalimab concurrent immunotherapy: Following the regimens of phase III RCTs such as JUPITER-02, JUPITER-06, CHOICE-01, NEOTORCH, and RENOTORCH, Toripalimab is administered at a fixed dose of 240mg per infusion, given intravenously once every 3 weeks for three doses.~4. The concurrent chemoradiotherapy and immunotherapy phase does not exceed 8 weeks in duration."
41310215|NCT04520763|OTHER|15min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-70% MVV 15-30min after ingestion of 75g of glucose
41310216|NCT03050359|DRUG|TAK-438|TAK-438 tablets
41469368|NCT04747795|DRUG|Normal saline|IV
41469369|NCT06207630|DEVICE|Dressing Device|Use of a dress at the end of surgery in the operating room, making sure not to stick it on the openings of the chest drains.
40792286|NCT05697653|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
40792287|NCT04961138|PROCEDURE|Transhepatic Arterial Chemotherapy And Embolization (TACE)|Receiving TACE and lenvatinib before surgery.
40792288|NCT04961138|PROCEDURE|Surgery|Removing tumor by surgery.
40792289|NCT04805476|DEVICE|Non invasive mechanical ventilation|Prophylactic non invasive mechanical ventilation
40792290|NCT04805476|DEVICE|GP|GP subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to team routine and patient need.
40792291|NCT06226597|DEVICE|Fitbit device|Daily use of a fitbit wearable activity tracker device.
40792292|NCT00466947|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
40792293|NCT00466947|BIOLOGICAL|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
40792294|NCT00466947|BIOLOGICAL|Engerix-B|Intramuscular injection, 3 doses
40792295|NCT00466947|BIOLOGICAL|Infanrix hexa|Intramuscular injection,3 doses
40792296|NCT00466947|BIOLOGICAL|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
40792297|NCT01853462|OTHER|PNF training|Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
40792298|NCT01853462|OTHER|Balance training|Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
40792299|NCT03399864|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
41310217|NCT03050359|DRUG|Lansoprazole|Lansoprazole capsules
41469370|NCT06444321|BEHAVIORAL|INTERCARE-HF|Develpent of an individualized treatment and follow-up plan tailored to co-morbidities, risk areas, cognitive function and functional level as well as the patients' symptoms and needs.
41469371|NCT02457611|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
41469372|NCT01350934|DRUG|alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)|one combination tablet once weekly
41469373|NCT01350934|DRUG|Calcitriol|0.25 μg once daily orally
41469374|NCT01350934|DIETARY_SUPPLEMENT|Calcium 500 mg|one 500 mg tablet once daily
41469375|NCT02653729|BEHAVIORAL|cognitive behaviour therapy|
41469376|NCT02653729|DRUG|Espidone|
41469377|NCT02653729|DRUG|Olepra|
41469378|NCT02653729|DRUG|Donu|
41469379|NCT00779402|OTHER|Control|Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.
40997349|NCT04130243|OTHER|Blood test|Withdrawal of (extra) blood to measure serum biomarkers with a blood test
40997350|NCT05542927|DIAGNOSTIC_TEST|urine chloride|Serum chloride, urinary chloride \& serum creatinine will be requested on the first day of admission in Intensive Care Unit (ICU). 2. Serum chloride \& urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI \& mortality. 3. Serum creatinine will be requested every 24 hours in ICU. 4. Monitoring of Urinary Output (U.O.P.) every 24 hours
40997351|NCT01966965|DRUG|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
40997352|NCT01966965|DRUG|NEDAX|AS SPECIFIED AT THE LEAFLET
40997353|NCT04693390|PROCEDURE|Acupuncture|Application of acupuncture
40997354|NCT03388138|COMBINATION_PRODUCT|etafilcon A with ketotifen|Etafilcon A with ketotifen
40997355|NCT03388138|DEVICE|1-Day ACUVUE|1-Day ACUVUE
40997356|NCT04147312|DRUG|Fufang E'Jiao Jiang|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
40997357|NCT04147312|DRUG|placebo containing low-dose fufang E'Jiao Jiang|placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
40997358|NCT06115538|OTHER|Levodopa|Levodopa benserazide (100+25 mg) will be given to one group of study patients, and levodopa carbidopa entacapone (100+25+200 mg) will be given to the other group of study patients. Just before the drugs are given (0th minute), at 90 and 180 minutes after the drugs are given, a total of 3 doses will be given.
40997359|NCT03500146|DRUG|Anticholinergic|Patients prescribed medication for OAB
40997360|NCT03500146|PROCEDURE|PTNS|Patients prescribed PTNS for OAB
40997361|NCT01492322|RADIATION|TRODAT|Smoker will receive a TRODAT injection
40997362|NCT04991571|DRUG|Zibotentan (Treatment A)|Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.
41149313|NCT00360971|RADIATION|radiation therapy|A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
41149314|NCT03185858|BEHAVIORAL|SINEMA intervention|"Provider-facing intervention includes the following components:~(1) Systematic cascade training for village doctors; (2) monthly follow-up visits with the support of the SINEMA APP; (3) village doctor group activities; (4) performance feedback and incentives.~Stroke survivor-facing intervention program includes the following components:~(1) Briefing session; (2) monthly follow-up visits and follow-up handout; (3) daily voice message for health education."
41149315|NCT05991947|OTHER|No intervention|No intervention measures are needed.
41149316|NCT06455527|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using the 1x1 Mini CT tDCS device. For active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (29 minutes), and then ramp down (for 30 seconds) at the end. Participants will receive 10 sessions of tDCS over the course of this study on weekdays (M-F).
40997363|NCT04991571|DRUG|Dapagliflozin (Treatment A)|Dapagliflozin tablet will be administered orally as single dose in Part 2.
41149317|NCT06455527|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS will be delivered using the 1x1 Mini CT tDCS device. For sham tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end. Participants will receive 10 sessions of sham tDCS over the course of this study on weekdays (M-F).
41149318|NCT04363645|OTHER|Multicontext (MC) approach|The Multicontext approach is a metacognitive intervention designed to improve awareness, strategy use, and executive functioning.
40792300|NCT03399864|OTHER|usual care|The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
40792301|NCT01797757|DIETARY_SUPPLEMENT|Fish oil enriched with EPA|
40997364|NCT04991571|DRUG|Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
40997365|NCT04991571|DRUG|Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
40997366|NCT05813158|DRUG|Group 1(low concentration-high volume bupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive low concentration-high volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline} for each patient
41310218|NCT03050359|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets.
40997367|NCT05813158|DRUG|Group 2(high concentration-low volumecbupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive high concentration-low volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% } for each patien).
40792302|NCT01797757|DIETARY_SUPPLEMENT|MAG-EPA oil|
40792303|NCT01797757|DRUG|Orlistat|
40997368|NCT05605340|BEHAVIORAL|Meal Delivery|10 healthy, home-delivered meals per week + brief weekly remote behavioral support
40997369|NCT03047109|DRUG|Phenylephrine|30 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
40997370|NCT03047109|DRUG|Ephedrine|30 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
40997371|NCT03356496|DEVICE|AirLife 4000 cc incentive spirometry device|Incentive spirometry device provides improved lung expansion and respiratory muscle strength
40997372|NCT04328831|BIOLOGICAL|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
40997373|NCT03226340|DRUG|S-amlodipine 2.5mg + Chlorthalidone 25mg|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
40997374|NCT03226340|DRUG|S-amlodipine 2.5mg + Telmisartan 40mg|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
40997375|NCT01894165|DRUG|ALXN1101|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
40997376|NCT01894165|DRUG|Placebo|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
40997377|NCT02638142|DRUG|Continuous Furosemide Infusion|Intravenous continuous Furosemide infusion
40997378|NCT02638142|DRUG|Intermittent Furosemide Infusion|Intravenous bolus intermittent Furosemide Infusion
40997379|NCT01209442|DRUG|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
40997380|NCT01209442|DRUG|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
40997381|NCT01209442|RADIATION|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
40997382|NCT06220708|OTHER|dance movement therapy|Our DMT program was adapted from an integrated somatic dance and visual arts program previously applied to the older population (Hsu, 2023). The intervention was scheduled in the afternoon and lasted for approximately 2 h. As previously recommended, rhythmic and contralateral movements on both sides of the body were emphasized in this study to enhance coordination and stimulation between the left and right cerebral hemispheres (Phillips-Silver and Trainor, 2007). The experimental groups were then subdivided into six groups. Balloons half-filled with water were used as the game in this study to guide individual and grouping rhythms and movements. Additionally, painting was incorporated to help participants understand their bodies and psychological states (Tjasink et al., 2023). Finally, group discussions and mutual support, along with verbal sharing after the DMT exercise, were encouraged.
40997383|NCT06220708|OTHER|yoga training|The yoga program included breathing exercises, Asanas, eye focus, body lock, and meditation. Participants were instructed to adjust their positioning based on their skill level to mitigate the risk of injury. The yoga intervention was scheduled at 2 pm and lasted for approximately 2 h.
40997384|NCT05923203|OTHER|Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)|This is a clinical fitting of an FDA approved EAS system for study participants that have received or who are scheduled to receive a CI based on clinical recommendations (i.e. not study related). The investigators will activate the CI sound processor's integrated HA circuit to allow for low-frequency acoustic amplification and mid-to-high frequency electric stimulation in the implanted ear(s) using recommended and accepted clinical practices and audiologic verification. EAS fitting will be completed using FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
40997385|NCT03532997|OTHER|ELOS|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel web-based application called ELOS (stands for extra layer of support) in a prospective cohort study."
40997386|NCT01463371|DRUG|Azithromycin|250 mg three times a week during three months
40997387|NCT00533533|DRUG|docetaxel, oxaliplatin|"Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.~Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1"
40997388|NCT04566510|OTHER|long lasting insecticidal nets with alpha-cypermethrin + pyriproxyfen (PPF LLIN, Royal Guard))|Next-generation bed net combining insecticides with different modes of action
40997389|NCT04566510|OTHER|long lasting insecticidal nets with deltamethrin + piperonyl butoxide (PBO LLIN, PermaNet 3.0))|Next-generation bed net combining an insecticide with a synergist
40997390|NCT04566510|BEHAVIORAL|Social behaviour change communication|SBCC activities will use digital and other platforms, similar to those used for the COVID-19 response, including the following: (1) LLIN launch on television and radio; (2) regional advocacy meetings on Zoom; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about COVID-19, malaria, and use, care, repair and repurposing of LLINs.
40997391|NCT02423863|BIOLOGICAL|Hiltonol|"Wk 1 Days 1, 3 and 5: Poly-ICLC (Hiltonol®) 1 mg (0. 5 ml) IntraTumoral (priming treatment course). Weeks 2-25 Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND either:~No additional immunotherapy OR~ONLY ONE of the Anti-PD1 or anti-PDL-1 regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows: (Not to be Administered on the same day as Poly-ICLC \[Hiltonol®\]) Either Nivolumab, OR Pembrolizumab, OR Atezolizumab, OR Cemiplimab, OR Durvalumab"
40997392|NCT01166685|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
40997393|NCT01166685|DEVICE|Bare-metal stent|Bare metal stent
40997394|NCT01166685|DEVICE|Biodegradable Polymer-DES|drug-eluting stent with bioabsorbable polymer
40997395|NCT01187043|DRUG|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
41149319|NCT05159037|BEHAVIORAL|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
41149320|NCT05159037|BEHAVIORAL|Music Booster|Participants listen to a musical track they ranked as highly liked before a stressful situation
41149321|NCT01099878|DEVICE|Cycling Exercise with Functional Electrical Stimulation|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
40792304|NCT05498532|DIAGNOSTIC_TEST|Functional MRI|Anatomical MRI : T2 fiesta, SSFE, HASTE ; 3D T2 ; T1 FAT SAT ; LAVA Functional MRI : T1 FAT SAT with gadolinium
41149322|NCT01099878|DEVICE|cycling exercise|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
41149323|NCT02674295|DRUG|Esketamine 50 mg|50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)
40792305|NCT03074201|PROCEDURE|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
40997396|NCT04389125|DIETARY_SUPPLEMENT|Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures|One packet once a day, after breakfast, for 12 week
41469380|NCT00779402|BIOLOGICAL|Sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
40792306|NCT03074201|DEVICE|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
40792307|NCT06554119|PROCEDURE|Huanlei Huang|tricuspid valve replacement or plasty
40997397|NCT04389125|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 week
40997398|NCT03891654|DIAGNOSTIC_TEST|Dynamic Contrast Enhanced Computed Tomography|Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.
40997399|NCT00632333|BIOLOGICAL|URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil|Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
40997400|NCT06307275|OTHER|Fasting|Fasting for 16 hours from participant last meal of the previous evening's meal to the first meal of the next day. Then for 8 hours, participant is able to eat. During the fasting, participants are allowed to consume water and black coffee/tea. Participants will also keep their normal weekly exercise routine.
40997401|NCT06307275|OTHER|non fasting|Participants will not be fasting during these four weeks. They will eat their normal food intake and keep their normal physical activity levels.
40997402|NCT04416633|DRUG|Durvalumab|500-mg/120-mg IV
41149324|NCT02674295|DRUG|Esketamine 20 mg|20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
41149325|NCT02097420|DEVICE|Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
41149326|NCT05440578|DRUG|olaparib plus bevacizumab maintenance therapy|First-line olaparib plus bevacizumab maintenance therapy initiated from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required).
40792308|NCT00582712|DRUG|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
40792309|NCT01791517|OTHER|Solution 1 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
40792310|NCT01791517|OTHER|Solution 2 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
41149327|NCT02607293|DRUG|Gonal-f®|Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
41149328|NCT02607293|DRUG|Long GnRH agonist|As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
41149329|NCT02607293|DRUG|GnRH antagonist|As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
41149330|NCT03780699|PROCEDURE|Diagnostic hysteroscopic examination|The hysteroscopic criteria of the cesarean scar defect will be observed with comment on different niche features
41149331|NCT05340426|DEVICE|UKidney|The intended clinical product is a kidney derived from a domestic pig that contains an intentional genomic alteration (IGA) to protect it after transplantation from the human immune response via inactivation of endogenous porcine genes responsible for expression of pig epitopes and inclusion of human transgenes to inhibit host immunogenic response.
41469381|NCT01140737|DRUG|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
40792311|NCT01791517|OTHER|Solution 3 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
40997403|NCT00942396|DEVICE|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
40997404|NCT02893072|BEHAVIORAL|Individualized medical nutrition therapy|The intervention group involves dietary and exercise advice and monitoring.
40997405|NCT00634088|DRUG|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
40997406|NCT00634088|DRUG|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
40997407|NCT00634088|DRUG|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
40997408|NCT00634088|DRUG|Ixabepilone + Lapatinib + Capecitabine|Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
40997409|NCT00165412|PROCEDURE|breast MRI|Repeated once a year for three years
40792312|NCT01791517|OTHER|Solution 4 (Control)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
40792313|NCT00000696|DRUG|Interferon alfa-2a|
40792314|NCT00000696|DRUG|Zidovudine|
40792315|NCT04157881|DRUG|RABEprazole 20 Mg Oral Delayed Release Tablet|Absorption of APO-Dabigatran measured with and without influence of rabeprazole
40792316|NCT04157881|DRUG|APO-Dabigatran 150mg|Absorption of APO-Dabigatran post single dose
40792317|NCT05851885|DIAGNOSTIC_TEST|AI-based reporting system|AI-based reporting system is a software platform for real-time analysis and records of abnormalities and landmarks during endoscopy.
40792318|NCT04422691|DIAGNOSTIC_TEST|Lung ultrasound|After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
40997410|NCT00165412|PROCEDURE|Mammogram|Repeated once a year for three years
40997411|NCT00527930|DRUG|TS-1 and Eloxatin|"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week~Number of Cycles: until progression or unacceptable toxicity"
40997412|NCT04650477|PROCEDURE|Fixation while forearm in extension-pronation position|Fixation was performed after tenodesis in the extension-pronation position, which is the anatomically most suitable position of the biceps tendon.
40792319|NCT04789720|BEHAVIORAL|Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS)|Participants will complete a 9-item SyMon-SAYS symptom assessment checklist every week during the intervention phase (Intervention Group: weeks 1-16; Waitlist Control: weeks 9-16) through Epic MyChart via mobile app, computer or tablet. Patients' symptom scores will be monitored and reported to their oncology care providers. When a patient symptom score trigger threshold is met, the system will generate an email alert through Epic (electronic medical record system) messaging to the provider. The provider will take appropriate actions using his/her clinical judgement, including contacting patients and families when needed. Symptom scores overtime will be available in MyChart (patient-facing component of the Epic electronic medical record system) for patients and parents to review and to discuss with the child's provider during clinical visits.
40792320|NCT01480726|PROCEDURE|Surgery|
40792321|NCT01694433|DRUG|Calcipotriene|1g daily BID
40792322|NCT01694433|DRUG|Placebo|1g daily BID
40792323|NCT00283543|DRUG|Gliadel Wafer|
40792324|NCT00283543|DRUG|Temozolomide|
40792325|NCT00283543|PROCEDURE|Limited field radiation|
40792326|NCT00328718|DRUG|montelukast (5mg QD)|
40792327|NCT00328718|DRUG|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
40792328|NCT00773643|OTHER|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
40997413|NCT05673096|BEHAVIORAL|PACT|Paediatric Autism Communication Therapy
40997414|NCT05673096|BEHAVIORAL|MAU|Management as usual
40997415|NCT04457609|DRUG|Oseltamivir|Current standardized treatment for Covid-19
40997416|NCT04457609|DRUG|Azithromycin|Current standardized treatment for Covid-19
40997417|NCT04457609|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Adjuvant therapy on top of current standardized treatment (Oseltamivir + Azithromycin)
41149332|NCT02303613|OTHER|Mapping|Mapping of current triage situation regarding 30 days mortality
41149333|NCT00513292|DRUG|Cyclophosphamide|Given IV
40792329|NCT03456700|DRUG|Auranofin|Given PO
40792330|NCT03456700|OTHER|Laboratory Biomarker Analysis|Correlative studies
40792331|NCT03456700|DRUG|Sirolimus|Given PO
40792332|NCT03187405|DRUG|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
40792333|NCT00566046|DRUG|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
40792334|NCT00566046|DRUG|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
40792335|NCT04535089|DRUG|Dexmedetomidine injection|receive IV bolus dose of 0.5 ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5 ug/kg/h
40792336|NCT04535089|DRUG|Lidocaine Iv|IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h
40792337|NCT00269607|DRUG|Implantation of naltrexone implants|
40792338|NCT02556281|BIOLOGICAL|Blood sampling|Blood sampling is done for patient with colorectal cancer
40792339|NCT06459596|BEHAVIORAL|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
40792340|NCT04588636|BEHAVIORAL|behavioral and self-care therapy|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
40792341|NCT04588636|DEVICE|rigid occlusal splint (ROS)|Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).
40792342|NCT04588636|DEVICE|soft occlusal splint (SOS)|Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).
40792343|NCT04588636|DEVICE|non-occlusive splint (NOS)|non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
40792344|NCT03174626|BEHAVIORAL|WLSCC|"Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy."
40792345|NCT03174626|OTHER|Usual Care|No training provided. After data collection period is over, participants have the option to receive the WLSCC training
40792346|NCT06513611|DIAGNOSTIC_TEST|Serum cortisol.|Serum cortisol levels obtained on admission.
40792347|NCT00004891|DRUG|chemotherapy|
40792348|NCT00004891|PROCEDURE|computed tomography|
40792349|NCT00004891|PROCEDURE|conventional surgery|
40792350|NCT00004891|PROCEDURE|neoadjuvant therapy|
40792351|NCT00004891|PROCEDURE|positron emission tomography|
40792352|NCT00004891|PROCEDURE|radionuclide imaging|
40997418|NCT03225911|DEVICE|Lateral wedge insole (insole)|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation.
41149334|NCT00513292|DRUG|Epirubicin Hydrochloride|Given IV
40792353|NCT00004891|RADIATION|fludeoxyglucose F 18|
40792354|NCT00004891|RADIATION|radiation therapy|
40792355|NCT05321017|BEHAVIORAL|MEP Operant Up-conditioning of the Wrist Extensor|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the wrist extensor (extensor carpi radialis), the muscle the bends the wrist back.
40792356|NCT03286192|BEHAVIORAL|compassion cultivation training|Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
40792357|NCT05674812|DIAGNOSTIC_TEST|Comprehensive evaluation|Non-ultrasound parameters:oxygenation index;arterial blood gas analysis;Type of surgery;ultrasound parameters:Diaphragmatic displacement, Mitral Annular Plane Systolic Excursion,Triscuspidal annular Plane Systolic Excursion, Lung score
40792358|NCT04762082|DRUG|Tadalafil 10 MG|comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
40792359|NCT01658553|DRUG|GSK1120212|GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
40792360|NCT02370992|RADIATION|I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
40792361|NCT00777959|DRUG|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
40792362|NCT00777959|DRUG|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
40997419|NCT03225911|DEVICE|simple knee sleeve (sleeve)|The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
41149335|NCT00513292|OTHER|Laboratory Biomarker Analysis|Correlative studies
41469382|NCT00908882|BEHAVIORAL|Motivation Interviewing Counseling|Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
41149336|NCT00513292|DRUG|Paclitaxel|Given IV
41149337|NCT00513292|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41149338|NCT00513292|BIOLOGICAL|Trastuzumab|Given IV
40997420|NCT03225911|DEVICE|simple knee sleeve + lateral wedge insole|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation. The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
40997421|NCT00506090|PROCEDURE|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
40997422|NCT01659112|OTHER|Core Stabilization|A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
40997423|NCT01659112|OTHER|Traditional upper extremity rehabilitation|A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
40997424|NCT02023450|DRUG|saquinavir and ritonavir|micro and low dose
40997425|NCT02023450|DRUG|saquinavir and ritonavir|standard dose
40997426|NCT05751330|PROCEDURE|Transcatheter ablation of cardiac ganglionated plexi|"The ablative procedure involves applying radiofrequency deliveries in the two~Right atrium anatomical sites close to the two main ganglionic plexuses of the right atrium:~* Inferior-posterior area (site of first ablation) corresponding to the right inferior atrial ganglion located between the inferior vena cava, coronary sinus ostium and near the atrioventricular node~* Upper-posterior area (site of second ablation) corresponding to the right superior atrial ganglion located between the superior vena cava and the posterior surface of the right atrium"
40997427|NCT06429501|DRUG|Bupivacaine/Epinephrine|injection
40997428|NCT06429501|DRUG|Saline|injection
41149339|NCT05943509|BEHAVIORAL|Alternative rehabilitation strategies|Counseling intervention.
41469383|NCT01109758|DRUG|Fenofibrate|145 mg
40997429|NCT03293251|PROCEDURE|Trabeculectomy with MMC|glaucoma surgeries
40997430|NCT00445328|DRUG|Dalteparin (Fragmin)|Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
40997431|NCT00445328|DRUG|Unfractionated heparin|Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
40997432|NCT05776654|DEVICE|Biometric wearable devices|Passive data collection using biometric wearable devices.
41149340|NCT05943509|BEHAVIORAL|Usual Care|Usual care audiology pathway.
41149341|NCT00768716|DRUG|Acetaminophen|2 x 500 mg by mouth once
41149342|NCT06055400|DEVICE|AR-US|The ultrasound imagery is projected onto the glasses, and participants use the AR-US throughout the entire CVC placement procedure
41149343|NCT06381388|DEVICE|cTBS|A single cTBS session delivered to the contralesional primary motor cortex.
41149344|NCT04528368|BIOLOGICAL|Convalescent plasma|The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.
41149345|NCT00282009|BEHAVIORAL|Basic Internet|Basic Internet control intervention
41149346|NCT00282009|BEHAVIORAL|Enhanced Internet|enhanced Internet cessation intervention
41149347|NCT00282009|BEHAVIORAL|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
41149348|NCT00179478|DRUG|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
41469384|NCT05371639|DRUG|Tian Ma Bian Chun Zhi Gan Tablets|Tian Ma Bian Chun Zhi Gan Tablets, 0.1g per pill which contains 14mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
41149349|NCT02650661|BEHAVIORAL|Online health management program|"Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior."
41149350|NCT02650661|BEHAVIORAL|Health coaching|Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
41310219|NCT03050359|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
41469385|NCT05371639|DRUG|Placebo|Placebo identified to Tian Ma Bian Chun Zhi Gan, 0.1g per pill which contains 0mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
40997433|NCT00951093|PROCEDURE|Gastric bypass|Open Silastic® ring Roux-en Y gastric bypass was performed through an upper midline incision. A gastric pouch was created by dividing the stomach with a 10-cm stapler from the lesser curvature (7 cm vertically from the cardia) to 1 cm to the left of the Hiss angle. The estimated volume of the gastric pouch was 20 to 30 ml that was banded with a 6.5 cm long Silastic® ring. A gastrojejunal anastomosis was performed with two-layers hand sewn absorbable suture over a 1.2 cm bougie distal to the ring, keeping an alimentary limb with 100 cm in length, and a biliopancreatic limb ranging 60 and 80 cm.
40997434|NCT00963573|DRUG|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
40997435|NCT00963573|DRUG|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
41469386|NCT04999696|PROCEDURE|radical hysterectomy|To compare disease-free survival and overall survival of patients with early stage cervical cancer undergoing total laparoscopic radical hysterectomy versus total abdominal radical hysterectomy
41469387|NCT01376206|DRUG|Fluticasone|Collection of safety data
40997436|NCT01254435|PROCEDURE|Colonoscopy|Recording of colonoscopic extubation
40997437|NCT01116258|DRUG|AZD5847|oral suspension, 15 days
40997438|NCT01116258|DRUG|Placebo|oral suspension, 15 days
40997439|NCT05151263|DRUG|Acetyl Salicylate|Aspirin is an effective antiplatelet agent, exhibiting its action by irreversibly inhibiting platelet cyclooxygenase-1 enzyme, thus preventing the production of thromboxane A2 (TXA2). It has been used in the primary and secondary prevention of thromboembolic vascular events
40997440|NCT05151263|DIAGNOSTIC_TEST|Optical Platelet Aggregation test|The evaluation of platelet aggregation was performed using an optical aggregometer (AggRAM, using fresh citrated blood. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 190 g for 5 min. The platelet count was adjusted to 200,000 to 300,000 platelets/mm3. Platelet-rich plasma (250 μl) was deposited in each equipment channel, and the activators adenosine diphosphate, epinephrine, collagen, and arachidonic acid were used according to the manufacturer's instructions. aspirin resistance was defined as platelet aggregation ≥ 20% with arachidonic acid and ≥70% with adenosine diphosphate.
40997441|NCT06100666|BEHAVIORAL|Observational Tests|The Sustainable and Healthy Eating Behaviors Scale will be used to assess sustainable eating behaviors, one-day food consumption records will be collected with the 24-hour Dietary Recall method, the International Diet Quality Index and EAT-Lancet Diet Score will be used to assess diet quality, and body weight, height, waist circumference and neck circumference will be measured to determine nutritional status.
40997442|NCT04912934|PROCEDURE|A survey form was applied to individuals included in the study face-to-face.|This study was completed with a descriptive, cross-sectional and relational screening model
40997443|NCT06386614|OTHER|Routine treatment|Both groups were given routine treatment
40997444|NCT06386614|OTHER|Transcranial Direct Current Stimulation|The common group routine training used sham TDCS stimulation, and the experimental group used real TDCS stimulation
40997445|NCT03488316|PROCEDURE|Carie removal|Carie removal with a low speed handpiece
40997446|NCT03488316|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
40997447|NCT03488316|DRUG|Manipulation of the temporary filling material based on Calcium Hydroxide|Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
40997448|NCT03488316|DRUG|Manipulation of the temporary filling material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations.
41149351|NCT02650661|BEHAVIORAL|Workshop|Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
41149352|NCT02650661|BEHAVIORAL|Standard health educational booklet|"Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).~Booklets are provided at 0-, 2-, and 4-month after the enrollment."
40997449|NCT03488316|PROCEDURE|Material insertion on the root canal|Material insertion on the root canal according to the manufacturer's recommendations
40997450|NCT03488316|PROCEDURE|Material re-insertion on the root canal accordging to the infection needs.|Material re-insertion on the root canal according to the manufacturer's recommendations
41149353|NCT02804347|DEVICE|Cognitive Function Imaging and Battery|Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
41149354|NCT02804347|DEVICE|Sniffin Sticks|Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
40997451|NCT03488316|PROCEDURE|Definiteve canal root obturation|Definiteve canal root obturation with gutta-percha and definitive cement.
40997452|NCT03488316|PROCEDURE|Definitve restoration|Definitve restoration confecction.
40997453|NCT02888847|DEVICE|Philips Zoom! White Speed whitening lamp|bleaching protocol with descending built in light intensities
40997454|NCT02888847|DEVICE|Philips Zoom! Advanced power whitening lamp|bleaching protocol with high light intensity
40997455|NCT05102786|OTHER|40007388|A non-combusted cigarette used with heated tobacco device 20020064
40997456|NCT05102786|OTHER|40007385|A non-combusted cigarette used with heated tobacco device 20020064
40997457|NCT05102786|OTHER|40007387|A non-combusted cigarette used with heated tobacco device 20020064
40997458|NCT05102786|OTHER|40007386|A non-combusted cigarette used with heated tobacco device 20020064
40997459|NCT05252611|OTHER|Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8)|The aim of this study is to test the validity of the Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8).
40997460|NCT02177448|DRUG|BIBR277 low dose|
40997461|NCT02177448|DRUG|BIBR277 medium dose|
40997462|NCT02177448|DRUG|BIBR277 high dose|
40997463|NCT02177448|DRUG|Enalapril low dose|
40997464|NCT02177448|DRUG|Enalapril medium dose|
40997465|NCT02177448|DRUG|Enalapril high dose|
40997466|NCT02177448|DRUG|Placebo matching BIBR277|
40997467|NCT02177448|DRUG|Placebo matching enalapril|
40997468|NCT05464654|DRUG|3 g Polynucleotide vaginal suppositories|3 g polynucleotide vaginal suppositories were administered nightly for 6 days.
40997469|NCT05464654|DRUG|Conjugated estrogens cream 1g Tube|Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.
40997470|NCT00919399|DRUG|Exemestane|25mg a day during 4 months
40997471|NCT00919399|DRUG|tamoxifen|One 20 mg tablet a day started 1 week after the first Aromasine intake
40997472|NCT00004258|DRUG|cilengitide|dose escalation of cilengitide
40997473|NCT00177892|PROCEDURE|sleep disruption|experimentally-induced Sleep Fragmentation
40997474|NCT00177892|PROCEDURE|sleep with and without positive pressure|OSAH patients with and without chronic positive airway pressure therapy
40997475|NCT02306135|OTHER|n/a- this is an observational study|
41149355|NCT02804347|OTHER|Cognitive Batteries|Participants will conduct the following cognitive batteries: DSST, TMT A \& B, RAVLT
41149356|NCT04779047|DRUG|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.
41149357|NCT04779047|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.
40997476|NCT03459664|BEHAVIORAL|RECOVER|"For each patient baseline assessment and individual support by a diagnostic and crisis resolution home treatment team is available. In addition, patients will be treated with specific interventions based on their severity grade:~Grade 1 (mild): social support, information about mental disorder, e-therapy, consultation, self help, peer-support, supported employment.~Grade 2 (medium): psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 3 (medium to severe): case management, psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 4 (severe): assertive community treatment, psychotherapy, medical treatment, e-therapy, peer-support, supported employment."
40997477|NCT03459664|BEHAVIORAL|Treatment as usual|"For each patient all common care options within the German health care system are available, depending on the severity grade 1 to 4.~This includes the following options: hospital based in-patient, out-patient treatment and day care, community based health care services, general practitioners, private psychiatrists and psychotherapists, self help."
40997478|NCT01459965|PROCEDURE|ERCP with 10 French biliary plastic stent placement|Stent placement of a 10 French biliary plastic stent
40997479|NCT01459965|PROCEDURE|ERCP with 11.5 French biliary plastic stent|biliary plastic stent placement
40997480|NCT00896558|DRUG|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
40997481|NCT00896558|DRUG|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
40997482|NCT05825898|PROCEDURE|Surgery or Transcatheter tricuspid valve intervention|Isolated tricuspid valve surgery or Transcatheter tricuspid valve intervention
40997483|NCT06368232|OTHER|püPatients undergoing bariatric surgery|Patients will not be intervened. Only nutritional status after bariatric surgery will be evaluated.The data of 76 patients aged 19-64 years who had undergone bariatric surgery and were followed by a dietitian dietitian for at least 6 months were included.
40997484|NCT01862887|DRUG|PH-797804|Tablet, 24 mg, single dose
40997485|NCT01862887|DRUG|Moxifloxacin|Tablet, 400 mg, single dose
40997486|NCT01862887|DRUG|Placebo|Tablet, PH-797804 matched placebo, single dose
40997487|NCT00481546|GENETIC|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
40997488|NCT02586493|DRUG|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
40997489|NCT02586493|OTHER|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
40997490|NCT03500328|OTHER|Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy|Early Aggressive Therapy
40997491|NCT03500328|OTHER|Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod|Traditional Therapy
41149358|NCT04779047|DRUG|Tocilizumab|Tocilizumab 800 mg once.
41149359|NCT04779047|DRUG|Lopinavir/ Ritonavir|Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
41149360|NCT04779047|DRUG|Ivermectin|Ivermectin 36 mg at day 1,3 and 6.
40792363|NCT00777959|DRUG|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
40997492|NCT02586896|BEHAVIORAL|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
40997493|NCT02586896|BEHAVIORAL|Screening, Assessment, and Referral (SAR)|"The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment."
40997494|NCT05401955|OTHER|Physical exercise|An adapted physical exercise protocol
40997495|NCT01874262|DEVICE|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
40997496|NCT01874262|DEVICE|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
40997497|NCT04646499|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied at 40 Hz (gamma band) during eight sessions over the course of a month.
40997498|NCT00312494|DRUG|Placebo|Placebo with mood stabilizer (either lithium or divalproex)
40997499|NCT00312494|DRUG|Ziprasidone|Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
40997500|NCT00312494|DRUG|Ziprasidone|Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
40997501|NCT00004065|DRUG|tanespimycin|
40997502|NCT02051530|DIETARY_SUPPLEMENT|tryptophan depletion|tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
40997503|NCT01119989|DIETARY_SUPPLEMENT|Fructose+maltodextrin placebo|
40997504|NCT01119989|DIETARY_SUPPLEMENT|amino-acid + fructose|
40997505|NCT00254007|DRUG|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
40997506|NCT05873465|DRUG|Sedation with Midazolam, Fentanyl, and Propofol|Patients will have teeth extracted under sedation with Midazolam, Fentanyl, and Propofol
40997507|NCT05873465|PROCEDURE|Extraction of teeth|The necessary teeth will be extracted
40997508|NCT04049539|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
40997509|NCT03266120|OTHER|Art|Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.
40997510|NCT03266120|OTHER|Gardening|Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
40997511|NCT00006478|BIOLOGICAL|autologous tumor cell vaccine|
40792364|NCT05439551|DIAGNOSTIC_TEST|MeMed BV®|Patients Serum and Whole blood samples will be examined using the MeMed BV® test. Test results will have no impact on patient management.
40997512|NCT00006478|BIOLOGICAL|keyhole limpet hemocyanin|
40997513|NCT00006478|BIOLOGICAL|sargramostim|
40997514|NCT00006478|PROCEDURE|adjuvant therapy|
40997515|NCT02292290|DRUG|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
40997516|NCT02292290|DRUG|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
40997517|NCT02292290|DRUG|Sulfonylurea or Pioglitazone|Addition to Metformin
40997518|NCT02292290|DRUG|Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide|As per clinical guidelines for prescription
40997519|NCT00256919|DRUG|GW856553|
40997520|NCT02636465|OTHER|flight simulationin obese healthy adults or obese patients with or without COPD, OHS|
40997521|NCT02467465|OTHER|Physical therapy modalities|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
40997522|NCT02467465|DEVICE|Invasive Physical therapy modalities|Dry needling added to massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
40997523|NCT02094001|RADIATION|Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
41469388|NCT05335382|BEHAVIORAL|Brief Interventions (BI)|'Brief Interventions' (BI) is a multitude of interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI), however interventions from other schools of therapy can also be used. The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
41469389|NCT05335382|BEHAVIORAL|Care As Usual (CAU)|Care As Usual includes the PCC's current routine care for patients with mental and behavioral problems. This can include a multitude of procedures and treatment, such as pharmacological treatment, supportive care, cognitive behavioural therapy (CBT) and psychodynamic therapy of varying lengths. Interviews with patients as well as medical journals will be used to categorise what type of care each individual patient has received.
41469390|NCT04912375|BEHAVIORAL|Priming intervention|The pilot RCT will ask participants to complete a simple word-searching exercise as a goal-priming of healthy eating and can be completed in 5 min.
41469391|NCT01491633|DRUG|Dasatinib|140 mg orally, daily in 28 day cycles
41469392|NCT01331577|BEHAVIORAL|Cognitive Behavioural Training|Two day seminar
41469393|NCT01331577|BEHAVIORAL|Integrative Kinesiology Intervention|Two day seminar
41469394|NCT05085769|PROCEDURE|Bariatric surgery|A procedure for morbidly obese patients whose body mass index (BMI) is higher than 40 kg/m2 or 35 kg/m2 and having comorbidities of obesity.
41469395|NCT00781092|OTHER|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
41469396|NCT00781092|OTHER|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
41469397|NCT03579134|DEVICE|partial overlay denture|removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth
41469398|NCT03579134|OTHER|fixed temporary crowns|fixed crowns made from temporary material placed to the newly altered vertical dimension
40792365|NCT02336815|DRUG|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
40997524|NCT02202733|OTHER|Cooking|The aim is to test the feasibility of a skill-based cooking intervention to reduce the consumption of foods prepared away from home for the evening meal (e.g., pre-prepared frozen foods, restaurant foods, fast food, take-out), energy intake from evening meals, and parent/child weight status.
40997525|NCT01883427|DRUG|Placebo|placebo containing saline+glucose
40997526|NCT01883427|DRUG|Glucose oxidase|a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
40997527|NCT01976234|OTHER|Fresh RBC|Patients will receive fresh blood only
41469399|NCT04270006|BIOLOGICAL|adipose derived stem cells exosomes|they are small extracellular vesicles
41469400|NCT04444349|DRUG|Coenzyme Q10|Coenzyme Q10 is a cardiovascular health supplement. It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. The ingredients in Coenzyme Q10 help regulate the body's production of free radicals, strengthen the arteries and heart, and reverse oxidation.
41469401|NCT04444349|DIETARY_SUPPLEMENT|Placebo|placebo that looks and tastes identical to Coenzyme Q10
41469402|NCT03358160|BEHAVIORAL|Action discrimination tasks.|The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.
41469403|NCT01706861|DEVICE|Celotres|Celotres following surgical removal of earlobe keloid.
40792366|NCT02336815|DRUG|Dexamethasone|20 mg was given with each dose of Selinexor.
40792367|NCT01673776|DEVICE|PulsioFlex® Monitoring|"* goal directed therapy according to PulsioFlex® Monitoring- measurements~* femoral catheter~* extended perioperative monitoring~* nutritional supplementation, (if necessary)"
40792368|NCT05465005|BEHAVIORAL|Torque Generation|Relaxed, or flexing about the elbow to 25% or 50% of the maximum elbow torque that one can generate.
40792369|NCT04380623|BEHAVIORAL|Mobile Phone-Based Web-Page: HPV vaccine|Website to be accessed via mobile phone to deliver tailored educational material
40792370|NCT02088099|OTHER|Complex clinical intervention|The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
40997528|NCT01976234|OTHER|Old RBC|
40997529|NCT03626714|DRUG|Sustained Release Injectable Tacrolimus|Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
40997530|NCT02149173|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
40997531|NCT02149173|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
40997532|NCT02149173|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
40997533|NCT02149173|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
40997534|NCT02149173|OTHER|Laboratory Biomarker Analysis|Correlative studies
40997535|NCT02149173|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
40997536|NCT02149173|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
40997537|NCT03806920|DIETARY_SUPPLEMENT|Intervention A|
41469404|NCT00407745|DRUG|placebo|Placebo
41469405|NCT00407745|DRUG|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
41469406|NCT04615845|BIOLOGICAL|Cellgram-DC-PC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes
41469407|NCT05445609|DRUG|VLP-encapsulated TLR9 Agonist CMP-001,|Given SC or IT
40997538|NCT03806920|DIETARY_SUPPLEMENT|Intervention B|
40997539|NCT03806920|DIETARY_SUPPLEMENT|Intervention C|
40997540|NCT03806920|DIETARY_SUPPLEMENT|Intervention D|
40997541|NCT02260284|OTHER|Yaotong points acupuncture|Patients receive the treatments of Yaotong points penetration
40997542|NCT02260284|OTHER|the usual care|participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))
40997543|NCT02260284|OTHER|standardized acupuncture|Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
40997544|NCT05224505|OTHER|GNT0006|Single intravenous infusion
40997545|NCT05224505|OTHER|Day 0: Placebo|Single intravenous infusion
40997546|NCT05224505|OTHER|Day 0: GNT0006|Single intravenous infusion
40997547|NCT05224505|OTHER|Day 365 (year 1): Placebo|Single intravenous infusion
40997548|NCT05224505|OTHER|Day 365 (year 1): GNT0006|Single intravenous infusion
40997549|NCT02452151|DRUG|Infliximab-Biosimilar|
40997550|NCT02452151|DRUG|Infliximab-Innovator|
40997551|NCT01194947|DEVICE|RCM imaging|RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
40997552|NCT06300164|DIETARY_SUPPLEMENT|Unripre Carob|The standard cookies and test cookies (with carob addition) to be used in the study will be produced by Dr. Lecturer Özlem ÖZPAK AKKUŞ at Toros University Nutrition Principles Laboratory. Prof. Dr. Özlem ÖZPAK AKKUŞ will produce the cookies. For standard cookies, 1 egg, 325 g gluten-free flour (Söke flour), 75 grams butter, 50 grams sugar, 10 grams baking powder, 10 grams vanilla will be added and the prepared bread mixture will be divided into 50 equal parts. To make cookies with the addition of unripe carob, the same recipe as the standard cookie will be used to make the test cookie with the addition of unripe carob fruit flour, divided into 50 equal parts, and the amount of unripe carob fruit flour will be added by calculating the daily fiber consumption amount of the patients participating in the study to be 25 g.
40997553|NCT01071928|DRUG|Docetaxel|Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
40997554|NCT01071928|DRUG|ASA404|ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
40997555|NCT04448210|BEHAVIORAL|DigiKnowIt News: Teen|Teens will interact with a multimedia educational website that will teach them about pediatric clinical trials including topics such as participant rights and safety, benefits and costs to participating in a study, and different types of procedures used in trials.
40997556|NCT03365596|OTHER|Conventional therapy|According to the status of a patient, optimized therapy will be applied.
40997557|NCT04666064|DIAGNOSTIC_TEST|Covid19 RT-PCR|patients admitted to ER for suspicion of COVID-19 infection will have a SARS-CoV-2 RT-PCR test
40997558|NCT04666064|OTHER|lung ultrasound|patients admitted to ER for suspicion of COVID-19 infection who has a SARS-CoV-2 RT-PCR test and for whom the emergency doctor decide to perform a lung ultrasound
40997559|NCT05164237|OTHER|nerve flossing technique|subjects will receive NFT with conventional physical therapy modalities in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
40997560|NCT05164237|OTHER|multimodal electrotherapy|subjects will receive multimodal approach of electrotherapy (LLLT , US and IFC) with conventional physical therapy modalities in the form of ( splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
40997561|NCT05164237|OTHER|exercises|subjects will receive with conventional physical therapy modalities only in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
40997562|NCT00006481|DRUG|Biafine cream|
40997563|NCT00006481|PROCEDURE|quality-of-life assessment|
40997564|NCT00006481|RADIATION|radiation therapy|
40997565|NCT00260754|BEHAVIORAL|Community-Popular Opinion Leader Model|
40997566|NCT00260754|BEHAVIORAL|Diffusion of Innovations|
40997567|NCT05965856|DRUG|BL-B01D1|Administration by intravenous infusion
40997568|NCT05965856|DRUG|SI-B003|Administration by intravenous infusion
40997569|NCT02692677|DRUG|JNJ-42756493|Participants will receive a single oral solution at a dose of 12 milligram (mg) of unlabeled JNJ--42756493 admixed with 14C- labeled JNJ--42756493.
40997570|NCT00006489|BEHAVIORAL|Cognitive-Behavioral Therapy|Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
40997571|NCT00006489|DRUG|Naltrexone|Daily dosing 100 mg for 24 weeks
40997572|NCT00006489|DRUG|Placebo|Pill Placebo daily dosing 24 weeks
40997573|NCT03561415|OTHER|Universal Posaconazole Prophylaxis|All patients assigned to this arm will start posaconazole between Day 4 and Day 14 post lung or heart-lung transplant for a minimum of 3 months.
40997574|NCT03561415|OTHER|Pre-emptive Posaconazole Therapy|Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease for 3 months.
40997575|NCT04595864|OTHER|Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|TAI
40997576|NCT01015586|DRUG|Lamotrigine|Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks
40997577|NCT01015586|DRUG|Placebo|Placebo once daily for 12 weeks
40997578|NCT01885312|BEHAVIORAL|Adaptive Tailored Intervention|Adaptive
40997579|NCT01885312|BEHAVIORAL|Consequence-based Intervention|Loss Framed
40997580|NCT01885312|BEHAVIORAL|Tailored, not adaptive, based Intervention|Baseline tailored not adaptive
40997581|NCT01885312|OTHER|Assessment only|EMA only
40997582|NCT01871610|DRUG|[18F]AV-45 PET amyloid binding imaging|
40997583|NCT05471050|DRUG|TAC|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
40997584|NCT05471050|DRUG|Danazol|Danazol is given at 200mg bid for 12 weeks.
40997585|NCT04274647|DEVICE|NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
40997586|NCT05694728|BIOLOGICAL|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|"For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6.~For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6."
40997587|NCT05694728|BIOLOGICAL|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)|A 3-dose regimen administered at months 0, 2 and 6.
41149361|NCT01693393|DRUG|Cyclosporine A|Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
41149362|NCT00079235|DRUG|temsirolimus|Given IV
41149363|NCT00079235|OTHER|laboratory biomarker analysis|Correlative studies
41149364|NCT05712850|PROCEDURE|SiJoin® Transfixing Sacroiliac Fusion Device|Sacroiliac Fusion
41149365|NCT05248425|OTHER|Nurse Monitoring|Questionnaire responses that indicate new or worsening symptoms will be monitored by a study nurse who will contact the participant for clinical assessment and develop a management plan following irAEs management guidelines.
41149366|NCT01864200|BIOLOGICAL|Crotalidae polyvalent immune fab (ovine)|crotalidae antivenom
41149367|NCT01864200|BIOLOGICAL|Placebo|Saline placebo
41149368|NCT04999800|DRUG|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer
41149369|NCT04999800|DRUG|Anlotinib|Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor
41149370|NCT02112799|DRUG|NVR 3-778|
41149371|NCT02112799|DRUG|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
41149372|NCT02112799|DRUG|Pegasys|
41149373|NCT06381219|OTHER|Implementation of cow's milk in decreasingly heated forms|Implementation of cow's milk in decreasingly heated forms to assess maintained remission of EoE
40997588|NCT06229873|DEVICE|App-Based Inspiratory Muscle Strength Training|Participants will perform inspiratory muscle strength training guided by a smartphone application. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. All training sessions will be guided by the smartphone application.
40997589|NCT06229873|DEVICE|Clinic-Based Inspiratory Muscle Strength Training|Participants will perform inspiratory muscle strength training guided by researchers. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. One training session each week will be performed in the research clinic.
40997590|NCT04330560|DEVICE|Exercise telemonitoring connects to healthcare platform|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) link to the healthcare practitioner
41149374|NCT06381219|OTHER|Implementation of hen's egg in decreasingly heated forms|Implementation of hen's egg in decreasingly heated forms to assess maintained remission of EoE
41149375|NCT04650763|BIOLOGICAL|PRP injection|PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.
41149376|NCT04650763|DEVICE|Automated blood cell separator to extract PRP|Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.
41149377|NCT05634083|DIETARY_SUPPLEMENT|Uremic pateints with itching|Activated charcoal
41149378|NCT05807555|OTHER|Ambulatory ECG|24h ECG monitoring
41149379|NCT05807555|BIOLOGICAL|Blood sample|The usual biological tests necessary for the management of the child and the addition of 1 tube of 2 ml
41149380|NCT04088305|DRUG|Individualized therapy|Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician
41149381|NCT04408495|PROCEDURE|Intervention group_MRA|"Tidal Volume (Vt) =6-8 mL/kg of predicted body weight (PBW), Peep=8 cmH2O, recruitment maneuvers=30cm H2O every 30 min after intubation (except during CPB), after any disconnection and at the admission in ICU.~Recruitment maneuvers are performed in accordance with the surgical team an if SAP≥90 mmHg or MAP≥65 mmHg.~Ventilation is maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O"
41149382|NCT04408495|PROCEDURE|Control group|Vt=6-8 mL/kg of PBW, Peep=5 cmH2O , No recruitment maneuvers. Ventilation maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O.
41149383|NCT06057038|BIOLOGICAL|GEN1042|Intravenous
41149384|NCT06057038|DRUG|Pembrolizumab|Intravenous
41149385|NCT06057038|DRUG|Cisplatin|Intravenous
41149386|NCT06057038|DRUG|Carboplatin|Intravenous
41149387|NCT06057038|DRUG|5-Fluorouracil|Intravenous
41149388|NCT03663049|DRUG|discontinue statin|Discontinue statin as prescribed for 12 weeks
41149389|NCT04174170|DRUG|Brexpiprazole|Up to 3 mg pill
41149390|NCT04174170|DRUG|Sertraline|Up to 150 mg pill
41149391|NCT04174170|OTHER|Placebo|Pill
41149392|NCT06315621|DEVICE|Scanning using intraoral scanner with markers|Scanning different types of nasal defects using intraoral scanner with skin markers.
41149393|NCT06315621|DEVICE|Scanning using intraoral scanner without markers|Scanning different types of nasal defects using intraoral scanner without skin markers.
41149394|NCT06315621|DEVICE|Physical Impression|Recording different types of nasal defects using physical impressions
41310220|NCT03050359|DRUG|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
41310221|NCT02702427|BIOLOGICAL|virus-specific T-Cells|infusion
41469408|NCT05445609|BIOLOGICAL|Nivolumab|Given IV
40997591|NCT04330560|DEVICE|Exercise self-monitoring|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) for exercise self-monitoring.
41469409|NCT05472116|DEVICE|Mobile Health application (CapApp)|Mobile Health application (CapApp) will be used to measure capillary refill time in a healthy pediatric population and compared to two additional manual methods to include both human and computer annotation and mobile health application (Cap App).
41469410|NCT05646979|BEHAVIORAL|EFT group|EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
41469411|NCT05423587|PROCEDURE|Genicular Artery Embolisation|Transarterial catheter directed embolisation of hypervascularity in patients with mild to moderate knee osteoarthritis
41469412|NCT05423587|PROCEDURE|Genicular Artery Injection|Transarterial catheter directed injection of normal (0.9%) saline in patients with mild to moderate knee osteoarthritis
41469413|NCT06616935|OTHER|Intervention group one, community activities.|"Intervention group one: participants will have a list of free activities in the community provided by third sector organisations to choose from. Participants will be referred to their chosen activities and expected to attend for six months.~Intervention group two: Participants will attend weekly online exercises and activities led by the researcher."
41469414|NCT06616935|OTHER|Intervention group two|Online exercises and activities
41469415|NCT01483014|DRUG|imatinib mesylate|
41469416|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
41469417|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
41469418|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
41469419|NCT01021631|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
41469420|NCT01021631|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
41469421|NCT02752386|BEHAVIORAL|Biofeedback Training|Participants will received biofeedback training to reduce arousal and pain
40997592|NCT04330560|DEVICE|Exercise teleconsultation|Conducted through smartphone video call app.
40997593|NCT04330560|PROCEDURE|Other CR components|Including dietary, psychology, education conducted at the center.
40997594|NCT04330560|PROCEDURE|Standard care|Undergoing standard care by cardiac rehabilitation at the center
40997595|NCT00854581|BIOLOGICAL|PEG-interferon alfa-2b|Administered subcutaneously.
40997596|NCT00854581|BIOLOGICAL|Interferon alfa-2b|Administered intravenously.
40997597|NCT00854581|DRUG|Valproic Acid|Administered orally.
41310222|NCT00782418|DRUG|Comparator: exenatide|exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
41469422|NCT02266849|DRUG|Loperamide|12 mg Loperamide each day for three days
41469423|NCT02266849|DRUG|Placebo|6 tablets daily for three days
41469424|NCT03143387|OTHER|Caries removal using only manual instruments|Caries removal using only manual instruments according to Atraumatic Restorative Treatment
41469425|NCT03143387|OTHER|Caries removal using Papacarie gel|Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
40997598|NCT00854581|DRUG|Zidovudine|Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
40997599|NCT01913366|BEHAVIORAL|CM-PST|
40997600|NCT01913366|BEHAVIORAL|SG-PST|
40997601|NCT00149942|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
40997602|NCT02245256|DRUG|Precedex|infusion of 0.1mcg/kg/hr of precedex
40997603|NCT02245256|DRUG|placebo control|placebo
40997604|NCT03919461|DRUG|Propranolol and etodolac|A perioperative combined drug regimen
40997605|NCT03919461|OTHER|Placebo|Placebo
40997606|NCT05347316|DRUG|Colchicine|0.5 mg per day colchicine for 12 months
40997607|NCT01311193|OTHER|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
41310223|NCT00782418|DRUG|Comparator: exenatide|exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
41310224|NCT00782418|DRUG|Comparator: Placebo|5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
41469426|NCT03235609|DRUG|Fentanyl|fentanyl used with propofol for sedation
41469427|NCT03235609|DRUG|Ketamine|ketamine used with propofol for sedation
41469428|NCT05633082|DEVICE|Lens 1 (omafilcon B)|Toric daily wear contact lens for 15 minutes
41469429|NCT05633082|DEVICE|Lens 2 (fanfilcon A)|Toric daily wear contact lens for 15 minutes
41469430|NCT03907917|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
41469431|NCT03806335|OTHER|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 2.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 10 ml xylocaine 2% an d10 ml bupivacaine 0.5%
41469432|NCT03806335|OTHER|Placebo|Patients will receive 2.5 ml normal saline in each tonsil
41469433|NCT03806335|OTHER|General anesthesia|All patients will receive general anesthesia prior to infiltration
41469434|NCT05269992|OTHER|Real food products|As per arm/group descriptions.
41469435|NCT06616805|DEVICE|treadmill|Treadmill JAGUAR treadmill:( T900, China) motorized treadmill model (T900) motor power (6.OHP) input voltage (AC220-240 V, 50Hz) speed range (1-20KM/H), inclination range (1-15%) was used for exercise treatment
41469436|NCT04751474|OTHER|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
41469437|NCT00468208|DRUG|Abatacept|"A participant's abatacept dose depended on body weight and will remain the same throughout the study:~* 500 mg of abatacept for body weight less than 60 kg~* 750 mg of abatacept for body weight between 60 and 100 kg~* 1000 mg of abatacept for body weight greater than 100 kg~Abatacept is administered in a 30-minute intravenous infusion."
41469438|NCT03716635|PROCEDURE|cryotherapy|2.5c cold saline is used as a final flush after chemomechanical preparation
41469439|NCT03716635|PROCEDURE|normal saline|a room temperature saline is used as a final flush after mechanical preparation
41469440|NCT04552912|BEHAVIORAL|Build Stamina Program|Build StaMINA intervention is a self-management intervention that provides information, motivation, behavioral skills to engage in PA, and ultimately a tailored PA program for adults with AL who are receiving consolidation/maintenance chemotherapy.
41469441|NCT05999994|DRUG|Ramucirumab|Administered IV
41469442|NCT05999994|DRUG|Cyclophosphamide|Administered orally
41469443|NCT05999994|DRUG|Vinorelbine|Administered IV
41469444|NCT05999994|DRUG|Gemcitabine|Administered IV
41469445|NCT05999994|DRUG|Docetaxel|Administered IV
41149395|NCT04212442|BEHAVIORAL|Independent Living Program for Affordable Housing.|"Two-month program intended to increase physical activity and function, including the following 4 steps:~1. Environmental and Policy Assessments: Nurse facilitator works with the affordable housing staff to identify and recommend feasible interventions to alter the environment, policy, and procedures to optimize resident function and physical activity.~2. Education: Nurse educates residents and study partners in the principles of the Independent Living Program, using established materials and adult learning techniques.~3. Establishing Resident Goals: The nurse completes Capability Assessment Forms and helps resident set goals to increase function and physical activity.~4. The nurse helps to motivate and mentor residents and study partners to achieve and maintain their goals, using evidence-based approaches."
41469446|NCT05999994|DRUG|Abemaciclib|Administered orally
41469447|NCT05999994|DRUG|Irinotecan|Administered IV
41469448|NCT05999994|DRUG|Temozolomide|Administered orally
41469449|NCT03551873|DRUG|Plecanatide|Subjects will have been breastfeeding or pumping for at least 4 weeks and must have been prescribed and taking TRULANCE® for at least 14 continuous days prior to Baseline. Breast milk for measurement of TRULANCE® (plecanatide) concentrations will be collected at Day 1.
41469450|NCT03367689|DRUG|Olaparib|Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
41469451|NCT02682550|PROCEDURE|blood drawing|blood drawing
41469452|NCT06416917|DEVICE|bubble inclinometer|to measure range of motion
41469453|NCT00459823|DRUG|E7107|E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
41469454|NCT03400917|BIOLOGICAL|AV-GBM-1|Investigational treatment with AV-GBM-1
41310225|NCT03673072|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
41310226|NCT03673072|DRUG|Cisplatin|Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
41310227|NCT03673072|PROCEDURE|Oncologically radical margin-free (R0) resection|Oncologically radical margin-free (R0) resection
41469455|NCT02157363|PROCEDURE|Repositioning|
41469456|NCT02157363|PROCEDURE|Single positioning|
41469457|NCT02966184|DRUG|preservative free albuterol|Preservative free albuterol for nebulization
41469458|NCT06030856|DEVICE|STI test kits (NG, CT and TV) for home use|The adolescent randomized to the at-home STI testing arm will be provided with in-person instruction at enrollment and flyers (in English and isiZulu) with printed step-by-step instructions for kit use. Information will include details on how to store the kits, criteria for adequate specimen collection and preparation, how to run the test, and how to interpret the test results. Video-based instructions with accompanying text subtitles and audio options may also be provided for home use.
41469459|NCT06030856|BEHAVIORAL|Self Administered Behavioural Risk Assessment|Self Administered assessment to determine risk of HIV, STIs and pregnancy
41310228|NCT03673072|DRUG|Adjuvant chemotherapy|Can be selected by Investigator's Choice
41469460|NCT01507090|DEVICE|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
41469461|NCT02928536|OTHER|no intervention|This is an observational study. No intervention is considered
41469462|NCT01825837|DRUG|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
41469463|NCT01825837|DRUG|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
41469464|NCT01825837|DRUG|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
41469465|NCT01825837|DRUG|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
41469466|NCT01938352|BIOLOGICAL|CR8020|CR8020 15 mg/kg, administered by intravenous infusion
41469467|NCT01938352|BIOLOGICAL|Placebo|Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
41469468|NCT06469697|BEHAVIORAL|School music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at both school and community levels.
40997608|NCT04134247|DRUG|PD-1 combined with chemotherapy|"PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
41149396|NCT03613571|DRUG|ILB|The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.
41149397|NCT05481996|OTHER|App-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a smartphone application created especially for the study that will contain a program of progressive physical exercises with images and descriptions, educational messages and an online booklet for the study subjects, totaling 8 weeks of training and pain education.
41149398|NCT05481996|OTHER|Online booklet|An online booklet containing information about chronic low back pain and weekly messages about low back pain causes, suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
41149399|NCT04335656|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum|Probiotic capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
41149400|NCT04335656|OTHER|Placebo|Placebo capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
41149401|NCT01478256|DRUG|Erythromycin|Topical erythromycin ointment twice a day
41149402|NCT01478256|DRUG|Besifloxocin|Topical Besifloxocin twice a day
41149403|NCT04367506|BEHAVIORAL|BecomeAnEX|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
41149404|NCT04367506|BEHAVIORAL|Usual Care|Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
41149405|NCT04555694|DRUG|Cyclosporine|Used to increase tear production in patients who have dry eye caused by inflammation
41149406|NCT04555694|DRUG|Loteprednol Etabonate|Used to treat inflammation of the eye
41149407|NCT04555694|DRUG|Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert|Used to treat inflammation of the eye
41149408|NCT05182242|OTHER|Collection of clinical data|family history, clinical data, ultrasound and all other data necessary for the study on a e-CRF (CleanWEB), allowing the collection of the family tree, and if necessary photographic elements.
41149409|NCT05182242|BIOLOGICAL|Collection of samples|"Collected during fetal and blood sampling performed as part of care for ACPA:~* 4 Streck tubes maximum for the pregnant woman for NIPD-Exome, collected prior to invasive fetal sampling~* 1 additional vial of fetal sample (amniotic fluid or fetal blood) and 1 EDTA tube for each of the two parents"
41310229|NCT05437757|DEVICE|Surgical implantation of the PCL Breast scaffold with autologous fat grafting|Single shot of prophylactic perioperative antibiotics is given to the patient. A suitable incision is made to provide access followed by mobilisation of the breast gland.If present, the silicone implant is removed and capsulectomy performed. The implant pocket shall be rinsed with saline or antiseptic and a surgical drain shall be placed in the pocket at the discretion of the PI. The PCL Breast scaffold shall be inserted into the pocket and fixed using 2 to 4 sutures. The incision is closed. Liposuction is performed from another area of the body and lipofilling is performed within the breast scaffold. Sterile bandaging is applied and a daily wound revision is performed whilst an inpatient. A prophylactic antibiotic shall be administered to the patient.The patients shall be hospitalized overnight for clinical observation.
41310230|NCT03702530|BIOLOGICAL|3x 50 L3 larvae immunisation with albendazole treatment|Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
41310231|NCT03702530|OTHER|3x placebo immunisation with albendazole treatment|Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
41310232|NCT03702530|BIOLOGICAL|2x 50 L3 larvae infection|After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
41310233|NCT05753280|DRUG|Vitamin D|Patients take 800 mg vitamin D capsules daily during the whole treatment period
41310234|NCT05233449|DEVICE|NoL monitor|NoL monitor : non invasive, adhesive digital device
40997609|NCT04134247|DRUG|chemotherapy|"Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
40997610|NCT01878201|DRUG|Fimasartan|Fimasartan 30 mg
40997611|NCT01878201|DRUG|Valsartan|Valsartan 80 mg
40997612|NCT02735161|OTHER|Muscle strength training|Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
40997613|NCT02735161|OTHER|Endurance exercise training|Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
41310235|NCT05233449|PROCEDURE|Stimulation|Stimulation : 100 Hertz, 5 seconds, 10-30-60 milliamps, inner forearm
40997614|NCT00258453|OTHER|metabolic assessment|
40997615|NCT00258453|OTHER|physiologic testing|
41310236|NCT04185480|DEVICE|Hemopatch|Before closure of the wound this hemostatic sealant (Hemopatch), a pad of collagen derived from bovine dermis will be applied in the axilla
40997616|NCT00258453|PROCEDURE|biopsy|
40997617|NCT00258453|PROCEDURE|computed tomography|
41310237|NCT05556733|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4, week 8
40997618|NCT00258453|PROCEDURE|conventional surgery|
40997619|NCT00258453|PROCEDURE|magnetic resonance imaging|
40997620|NCT00258453|PROCEDURE|management of therapy complications|
40997621|NCT00258453|PROCEDURE|psychosocial assessment and care|
40997622|NCT00258453|PROCEDURE|quality-of-life assessment|
40997623|NCT00258453|RADIATION|radiation therapy|
40997624|NCT00847444|DRUG|Drug-based intervention|Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22
40997625|NCT00847444|BEHAVIORAL|Lifestyle-based Intervention|"All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:~Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention."
40997626|NCT01652664|DRUG|Travoprost 0.004% PQ ophthalmic solution|
40997627|NCT01652664|DRUG|Timolol, 0.5% or 0.25% ophthalmic solution|Patients 2 months to \< 3 years of age received 0.25%
41149410|NCT05182242|OTHER|Questionnaires|within the framework of the pilot study (optional): questionnaires (about 20 minutes) for the evaluation of the experience, perceptions, impact of the analyses on the decision, satisfaction and concerns regarding exome sequencing (ES) and its results, opinion on certain types of results currently not reported, anxiety, possible psychological difficulties
41149411|NCT05182242|OTHER|Parent interviews|as part of the pilot study (optional): interview (about 1 hour) with a sociologist to explore perceptions of ES and the impact of the results, expectations about certain types of results that are not currently available, emotional situation, position regarding the continuation of the pregnancy
41310238|NCT05087641|DEVICE|IAB System|Bronchoscopic implantation of one or multiple IABs
41310239|NCT03179592|DRUG|Ultravist 370Mg I/Ml Solution for Injection|Reduced contrast-volume injection protocols based on patient specific tube voltage.
41310240|NCT04987541|DEVICE|intermittent theta burst stimulation|stimulatory protocol
41310241|NCT03412474|DRUG|Bupivacaine|"The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection. Patients will be randomly allocated into two groups of 40 patients each:~Group A: will receive 0.2 ml/kg/side of bupivacaine (0.125%)."
41310242|NCT03412474|DRUG|Dexmedetomidine|Group B: will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
40997628|NCT01652664|DRUG|Travoprost Vehicle|Inactive ingredients used to maintain masking
40997629|NCT05062265|DEVICE|Tight rope fixation|a traditional tight rope fixation is performed on one randomized set of subjects
40997630|NCT05062265|DEVICE|Tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace|A tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace set of subjects to compare syndesmotic volume
40997631|NCT01063595|BIOLOGICAL|Octaplas LG|Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.
40997632|NCT01063595|BIOLOGICAL|Octaplas SD|Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
40997633|NCT01525147|BIOLOGICAL|YHB1411-2: Level 2|IV infusion
40997634|NCT01525147|BIOLOGICAL|YHB1411-2: Level 3|IV infusion
40997635|NCT01525147|BIOLOGICAL|YHB1411-2: Level 4|IV infusion
40997636|NCT01525147|BIOLOGICAL|YHB1411-2: Level 5|IV infusion
40997637|NCT01525147|BIOLOGICAL|Placebo|IV infusion
40997638|NCT01525147|BIOLOGICAL|YHB1411-2: level 1|IV infusion
40997639|NCT02327923|DRUG|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
41149412|NCT05182242|OTHER|Professional interview and focus groups|Interview (approximately 45 minutes) to understand how the decision is formed Focus groups to help clarify whether the Variants of Unknown Significance (VUSs) should potentially be returned to the clinicians, or even the patient via the clinician
40792371|NCT02088099|OTHER|Treatment as usual|Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
40792372|NCT01699126|DEVICE|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
40792373|NCT01699126|DRUG|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
40792374|NCT02131662|DRUG|BAY1002670|Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
40792375|NCT02131662|DRUG|BAY1002670|Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
41310243|NCT03412474|DRUG|paracetamol|paracetamol
40997640|NCT02327923|DRUG|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
40997641|NCT02327923|DRUG|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
40997642|NCT02327923|DRUG|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
40997643|NCT02327923|DRUG|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
40997644|NCT02327923|DRUG|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
40997645|NCT02327923|DRUG|Vecuronium|Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.
40997646|NCT02327923|DRUG|Atropine|Inj Atropine 0.4 mg IV will be given for bradycardia (HR \< 50/min)
40997647|NCT02327923|DRUG|Ephedrine|
40997648|NCT02327923|DRUG|Morphine|
40997649|NCT02327923|DRUG|Ketorolac|
40792376|NCT02131662|DRUG|BAY1002670|Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
40792377|NCT02131662|DRUG|BAY1002670|Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
40997650|NCT02327923|DRUG|Ondansetron|
40792378|NCT02131662|DRUG|Placebo|Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
40792379|NCT02263872|DRUG|Minocycline|Minocycline 200mg perday
40997651|NCT02327923|DRUG|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
40997652|NCT02327923|DRUG|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
40997653|NCT02327923|DRUG|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
40997654|NCT02327923|DRUG|Glycopyrrolate|10 mcg/kg with neostigmine
40997655|NCT05888129|PROCEDURE|surgery after neoadjuvant chemotherapy|surgery after neoadjuvant chemotherapy
40997656|NCT00256152|DEVICE|AF Suppression Pacing Algorithm|
40792380|NCT03773900|DIETARY_SUPPLEMENT|Kiotransine (chitin-glucan from aspergillus niger)|The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water.
40792381|NCT03773900|DIETARY_SUPPLEMENT|Placebo|The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water.
40997657|NCT04401696|DEVICE|Bubble CPAP|"The bCPAP will be delivered using an oxygen flow meter as the oxygen source. This inspiratory limb containing oxygen from the flow meter will be connected to humidifier and tubing from humidifier will be connected to short binasal prongs, which would be applied to neonate with the help of adhesive bandage on both cheeks. It will be ensured that binasal prongs make appropriate seal. An orogastric tube will be placed for gastric decompression. A 1000 ml/500ml bottle filled with sterile water be used and marks will be made on it at 1cm distance, with '10' marked at base and '0' mark at the water interface.~The expiratory limb from the nasal prongs was connected to tubing that will be dipped in water up to the desired level to provide positive end expiratory pressure. Pressure is varied by varying the depth of the dipped end of tubing."
40997658|NCT04401696|OTHER|Nasal Oxygen|The oxygen will be delivered from a wall oxygen source, delivered between 1 to 6 L/min and the rate varied via a flow regulator.
40997659|NCT04043312|DEVICE|Magstim SuperRapid|Transcutaneous magnetic stimulation targeting the left stellate ganglion.
40997660|NCT04043312|DEVICE|Magstim SuperRapid|Sham transcutaneous magnetic stimulation.
40997661|NCT02103283|DRUG|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
40997662|NCT00004238|DRUG|pralatrexate|
40997663|NCT02082210|DRUG|Emibetuzumab|Administered Intravenously (IV)
40997664|NCT02082210|DRUG|Ramucirumab|Administered Intravenously (IV)
40997665|NCT00788827|BIOLOGICAL|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
40997666|NCT00253578|DRUG|sorafenib tosylate|Given PO
40997667|NCT00253578|OTHER|laboratory biomarker analysis|Correlative studies
41149413|NCT00841165|DEVICE|Continuous Positive Airway Pressure|Full face CPAP at 5cm H2O and 100% oxygen
41341763|NCT01611922|DEVICE|Contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
41469469|NCT06469697|BEHAVIORAL|Community music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at community levels.
40997668|NCT05859295|DEVICE|Red Low-Level Light Therapy|Visible red light (633nm) projected onto the face using an light emitting diode (LED) mask
40997669|NCT02844296|BEHAVIORAL|Video about exercise|Video about short-bout exercise will be played for the participants.
40997670|NCT02844296|BEHAVIORAL|App about exercise|A smartphone App about exercise will be installed in participants' mobile phone.
40997671|NCT02844296|BEHAVIORAL|Leaflet about exercise|A leaflet about exercise will be provided for the participants.
40997672|NCT02844296|BEHAVIORAL|Video about diet|Video about healthy diet will be played for the participants.
40997673|NCT02844296|BEHAVIORAL|App about diet|A smartphone App about healthy diet will be installed in participants' mobile phone.
40997674|NCT02844296|BEHAVIORAL|Leaflet about diet|A leaflet about healthy diet will be provided for the participants.
40997675|NCT02394938|OTHER|MUSIC|In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
40997676|NCT02978287|DRUG|BAVU Solution|Tissue preservation solution for transplantation
41149414|NCT00841165|DEVICE|Non-rebreather oxygen mask|Oxygen administered through a non-rebreather mask
40997677|NCT04407130|DRUG|Ivermectin + Doxycycline + Placebo|"Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5"
40997678|NCT04407130|DRUG|Ivermectin + Placebo|Arm II: Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5 + Placebo two tablets D1 followed by Placebo one tablet D2-5
40997679|NCT04407130|DRUG|Placebo|Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
40997680|NCT01087047|DEVICE|Acoustic reflection method|An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
40997681|NCT00846937|DIETARY_SUPPLEMENT|Plant stanolester and fatty acid|Plant stanol ester 2gr/day and fatty acid in a beverage compared to plant stanol ester 2gr /day and placebo
40997682|NCT03114228|DRUG|Midostaurin|Midostaurin 50 mg (two 25 mg capsules) twice a day on days 8-21
40997683|NCT02245789|PROCEDURE|Tracheal intubation|Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
40792382|NCT04948268|BEHAVIORAL|Adaptive messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Content and messages will be tailored using machine learning.
40792383|NCT04948268|BEHAVIORAL|Non-personalized messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Psychological content will center on a single psychological strategy each week. There will not be any tailoring of messaging and content based on group or individual level data.
40997684|NCT02245789|DRUG|Propofol and remifentanil anesthesia|The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
40997685|NCT00000537|BEHAVIORAL|meditation|
40997686|NCT00000537|BEHAVIORAL|relaxation|
40997687|NCT02171481|DRUG|Dabigatran etexilate polymorph II|
40997688|NCT02171481|DRUG|Dabigatran etexilate polymorph I|
40997689|NCT01347138|OTHER|case management|confirmation of hospital visit date, checking the adverse effect and treatment compliance
40997690|NCT05300295|BEHAVIORAL|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
41149415|NCT03915717|DEVICE|EchoMark|EchoMark is implanted during surgery to mark the at-risk blood vessels to enable EchoSure ultrasound-based monitoring
41149416|NCT03915717|DEVICE|EchoSure|EchoSure ultrasound scans are performed to monitor the free flap
41149417|NCT06290453|DIAGNOSTIC_TEST|micro RNA 27- FLP1 gene expression|"From each participant, 2 mL of blood will be drawn and store at 25-degree C. The expression of miRNA-27 and FLP1 gene will be measured using real time PCR.~Relative expression values will be normalised to the housekeeping gene GAPDH. The comparative cycle threshold (Ct) approach will be used to measure the relative expression of miRNA 27 and FLP1 gene. Then, using the equation -ΔΔCT, the fold change of each gene will be determined"
41149418|NCT06290453|DIAGNOSTIC_TEST|The Expanded Disability Status Scale (EDSS)|"The Expanded Disability Status Scale (EDSS) is a way of measuring how much someone is affected by their MS. Neurologists use it to monitor changes in the level of someone's disability over time. The EDSS has a range from 0 to 10.~Zero points is normal neurological examination. 10 points shows the MS-related death cases. Patients with EDSS score up to 5 are fully ambulatory patients."
41149419|NCT06290453|DIAGNOSTIC_TEST|Electrophysiological assessment:|Electromyography and nerve conduction velocity will be performed for all MS patients.
40792384|NCT04948268|BEHAVIORAL|Coaching|Human coaching to support intervention use and engagement via telephone calls, text or email
40792385|NCT04948268|BEHAVIORAL|Psychoeducational links|SMS messages with URLs containing brief psychoeducational information.
41149420|NCT06290453|DIAGNOSTIC_TEST|MRI examination MRI brain:|will be done on all MS patients to detect the number, the site, and the enhancement of lesions
41149421|NCT04441073|DRUG|Lignocaine|preoperative nebulization of lignocaine
41149422|NCT04441073|DRUG|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
41149423|NCT04269811|DRUG|Flu-Bu-Mel|5-day fludarabine + 2-day busulfan (3.2mg/kg) + 2-day melphalan (50-70mg/m2)
41149424|NCT03052478|DRUG|Vismodegib 150 mg|Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
40792386|NCT04067791|DIETARY_SUPPLEMENT|Prolonged-Release Melatonin|4.47 mg melatonin in a bi-layer prolonged-release capsule
40792387|NCT04067791|DIETARY_SUPPLEMENT|Immediate-Release Melatonin|4.47 mg melatonin in a standard release bi-layer capsule
40792388|NCT05055609|DRUG|TRE-515|TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
40792389|NCT02345616|DRUG|Nitric oxide|
41149425|NCT00001280|DRUG|itraconazole|
40792390|NCT03696550|DRUG|Eravacycline (TP-434)|"Subjects will be stratified by age into 2 cohorts, as follows:~* Cohort 1: from 12 to \<18 years of age (N=8)~* Cohort 2: from 8 to \<12 years of age (N=12 or at least 60% of subjects)"
40792391|NCT03943290|DRUG|ACE-083|Recombinant fusion protein
40792392|NCT06372639|DEVICE|Trans-Cranial Magnetic Stimulation|Brain stimulation by the TMS device will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, the target area will be determined based on an fMRI scan in the resting state of the subject.
40792393|NCT00153673|DRUG|celecoxib|Celecoxib 200mg bd
40792394|NCT00153673|DRUG|Dologesics|Dologesics 2 tablets bd
40792395|NCT00008801|DRUG|hOKT3gamma1 (Ala-ala)|
40792396|NCT03844087|DEVICE|Multiplanar neuromuscular training|See arm description
40792397|NCT03069833|DIAGNOSTIC_TEST|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
41149426|NCT00597779|DEVICE|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
41149427|NCT05833737|DRUG|Belantamab mafodotin|Injection for refractory/relapsed multiple myeloma
41149428|NCT00161434|DRUG|valacyclovir|1 gram daily for 8 weeks
41341764|NCT00925067|PROCEDURE|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
41341765|NCT00925067|DEVICE|lightweight TiMesh|
41341766|NCT00925067|DEVICE|lightweight VyproII|
40792398|NCT00249652|BEHAVIORAL|TAP|12-session motivational interviewing-based telephone intervention.
40792399|NCT00249652|OTHER|TAU|The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
40792400|NCT04356300|BIOLOGICAL|Exosome of MSC|Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
40792401|NCT02056028|PROCEDURE|Hepatic resection|
41149429|NCT00161434|DRUG|placebo|matching placebo for 8 weeks
41149430|NCT03130127|DRUG|Terlipressin|According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.
41149431|NCT04355832|DRUG|Glucagon-like peptide-1|Infusion of Glucagon-like peptide-1
41149432|NCT04355832|DRUG|Placebos|Infusion of normal saline solution that will mimic Glucagon-like peptide-1
41341767|NCT00925067|DEVICE|Heavyweight Marlex|
41469470|NCT01076556|DRUG|Alvocidib Hydrochloride|Given IV
40792402|NCT03154476|DRUG|Sildenafil|Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
40792403|NCT03154476|DRUG|Placebo|Placebo capsules matching study drug
40997691|NCT06215963|DEVICE|App for Independence-O (A4i-O)|A4i-O is a digital health platform designed to support individuals with opioid use disorders. A4i-O will focus on providing education on treatment options, recovery navigation, social activation and connections to a range of resources. It aims to assist with fostering self-management and recovery through identifying risks for relapse, navigating urges/cravings, coping with shame/guilt, avoiding relapse, moving forward after relapse, and lived experiences. Daily wellness and goal attainment check-ins to highlight mental health trajectories will be prompted. With appropriate consent from both the client and provider, a provider dashboard is accessible to the client's provider prior to their appointment, generating a summary of day-to-day wellness ratings, responses to reminders, goal progressions, and other self-reported measures from the platform.
40997692|NCT03858491|DRUG|Cobicistat|Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat will gradually be escalated to 600 mg per day (150 mg cobicistat, four times per day).
40997693|NCT05009810|DIETARY_SUPPLEMENT|astaxanthin 4 mg|They will take astaxanthin 4 mg 1 capsule once daily for 2 months.
40997694|NCT05009810|DIETARY_SUPPLEMENT|astaxanthin 6 mg|They will take astaxanthin 6 mg 1 capsule once daily for 2 months.
40997695|NCT05009810|DIETARY_SUPPLEMENT|Placebo|They will take placebo 1 capsule once daily for 2 months.
40997696|NCT04761068|DEVICE|VEST|Venous External Support for vein grafts in CABG
40997697|NCT05289609|PROCEDURE|Liver Transplantation|Individuals with end-stage liver disease will be subjected to liver transplantation from deceased or living donors
40997698|NCT03387449|DEVICE|Bimanual Arm Training|Device-based bimanual-to-unimanual training will be provided with the Bimanual Arm Trainer (BAT, Mirrored Motion Works, NC). The device provides bimanual-to-unimanual training of simultaneous shoulder external rotation and elbow extension, and independent training of pronation-supination and grasp and release of each hand. Range of motion and speed are recorded during training and feedback and motivation are provided through age-appropriate gaming modules.
40997699|NCT05044455|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|A 9 week CBT group, 2 hours weekly, is delivered by trained Peer facilitators to mothers randomized to this arm.
40997700|NCT02612532|DEVICE|ReCIVA breath sampler|Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva
40997701|NCT03427736|DRUG|Ketorolac Tromethamine|IV ketorolac will be given per standard of care, not prescribed for this study
41149433|NCT03722732|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy either laparoscopically or open will be done
41149434|NCT00049751|DRUG|Adalimumab|
41149435|NCT03785041|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
41149436|NCT05815693|BEHAVIORAL|mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)|Patients with long-term consequences of COVID-19 (Chronic pain, anxiety, depression or insomnia) enrolled and randomly assigned to receive MBSR (n = 63), or usual care (n = 62). MBSR (training in mindfulness meditation and yoga) were delivered in 12 months with 2-hour groups each 2 months. Usual care included anything care participants received such as drug therapy.
41149437|NCT01815294|DRUG|DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|Cycle 1 = Treatment A, Cycle 2 = Treatment B
41149438|NCT01815294|DRUG|DOXIL/CAELYX (doxorubicin) Treatment Sequence BA|Cycle 1 = Treatment B, Cycle 2 = Treatment A
40792404|NCT03484728|BEHAVIORAL|placebo manipulation|application of nonactive body cream on forearm
40792405|NCT05836831|DRUG|Tranexamic acid injection|The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes.
40792406|NCT06138938|OTHER|Intraoperative abdominal irrigation|All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
40792407|NCT01527045|DRUG|Atorvastatin Calcium|Given PO
40792408|NCT01527045|DRUG|Cyclosporine|Given PO
40997702|NCT03427736|DRUG|Hydromorphone|IV Hydromorphone will be given per standard of care, not prescribed for this study
41149439|NCT03869411|BEHAVIORAL|supervised aerobic exercise or home-based aerobic exercise|"The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation."
41149440|NCT05667740|BIOLOGICAL|Gamma-PN3|Inactivated whole-cell pneumococcal vaccine
41149441|NCT05667740|BIOLOGICAL|Prevenar-13|Licensed polysaccharide conjugate pneumococcal vaccine
41341768|NCT03519841|DEVICE|P0.1|Investigational Medical Device collecting spectral Raman data from tissue.
41469471|NCT01076556|DRUG|Cyclophosphamide|Given IV
41469472|NCT01076556|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
41469473|NCT01076556|OTHER|Pharmacological Study|Correlative studies
41469474|NCT01076556|BIOLOGICAL|Rituximab|Given IV
41469475|NCT02506218|DIETARY_SUPPLEMENT|10 + 20 g protein consumption|whey isolate
41469476|NCT02506218|OTHER|30 g protein breakfast|30 g mixed meal breakfast
41469477|NCT02506218|OTHER|10 g protein breakfast|10 g mixed meal breakfast
41469478|NCT05386056|DRUG|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
41469479|NCT05386056|DRUG|Sinoporphyrin Sodium|0.2mg/kg, intravenously on day -2 of cycle 1.
40997703|NCT03427736|DRUG|Ketamine|IV Ketamine will be given per standard of care, not prescribed for this study
40792409|NCT01527045|DRUG|Fludarabine Phosphate|Given IV
41149442|NCT05667740|BIOLOGICAL|Pneumovax-23|Licensed polysaccharide pneumococcal vaccine
41469480|NCT05386056|PROCEDURE|Photodynamic therapy|PDT to primary site of ESCC will be given on day -1 of the treatment (24 hours after injection of DVDMS).
41469481|NCT02900053|DEVICE|tDCS|tDCS for transcranial Direct-Current Stimulation
41469482|NCT02900053|DEVICE|Placebo tDCS|Placebo tDCS for transcranial Direct-Current Stimulation
41469483|NCT00374049|DRUG|MUC_1|Pretreatment with Poly-ICLC alone week 1 \&2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
41469484|NCT02992626|OTHER|Human-dog interaction|The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
41469485|NCT02992626|OTHER|Stuffed toy dog|The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
41469486|NCT02445287|RADIATION|Radiation|Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT). Human subjects will be imaged with CARESTREAM Cone Beam Computed Tomography (CBCT) 3D only.
41469487|NCT01607177|BEHAVIORAL|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
41469488|NCT06023862|DRUG|Dostarlimab|Intravenous (IV) infusion
41469489|NCT06023862|DRUG|Bevacizumab|Intravenous (IV) infusion
41469490|NCT06023862|DRUG|Doxorubicin|Intravenous (IV) infusion
41469491|NCT06023862|DRUG|Gemcitabine|Intravenous (IV) infusion
41469492|NCT06023862|DRUG|Paclitaxel|Intravenous (IV) infusion
41469493|NCT06023862|DRUG|Pegylated liposomal doxorubicin|Intravenous (IV) infusion
41469494|NCT02453633|OTHER|Emotional SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.~tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.~No-show fee: Kr. 640.~Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS."
40997704|NCT03427736|DRUG|Oxycodone|PO Oxycodone(solution or tablet) will be given per standard of care, not prescribed for this study
41469495|NCT02453633|OTHER|Standard SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS."
41469496|NCT01283646|DRUG|Apevitin BC|3.5 to 5 ml 3 times a daily
41469497|NCT01283646|DRUG|Vitamin B Complex + Vitamin C|3.5 to 5 ml 3 times a daily
41469498|NCT00616044|PROCEDURE|continuous spinal anesthesia|bupivacaina isobaric 0.5%, 5 mg
41469499|NCT00616044|PROCEDURE|Spinocath a catheter for continuous spinal anesthesia|Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric
41469500|NCT00616044|PROCEDURE|combined spinal epidural anesthesia|CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
41469501|NCT04413032|DEVICE|DreaMS|The dreaMS App is a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). We analyze app-based tests, surveys and sensor data.
41469502|NCT02013531|DRUG|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
41469503|NCT02612181|DRUG|Dexmedetomidine for dexmedetomidine group|The effect of dex and placebo for sedation on microcirculation
40792410|NCT01527045|OTHER|Laboratory Biomarker Analysis|Correlative studies
40792411|NCT01527045|DRUG|Mycophenolate Mofetil|Given PO or IV
40792412|NCT01527045|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
40997705|NCT03427736|DRUG|Morphine|IV Morphine will be given per standard of care, not prescribed for this study
40997706|NCT03462212|DRUG|Carboplatin|chemotherapy medication
40997707|NCT03462212|DRUG|Paclitaxel|chemotherapy medication
40997708|NCT03462212|DRUG|Bevacizumab|Angiogenesis inhibitor
40997709|NCT03462212|DRUG|Rucaparib|PARP inhibitor
41469504|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
41469505|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
41469506|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
41469507|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
41469508|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
40792413|NCT01527045|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
40792414|NCT01527045|RADIATION|Total-Body Irradiation|Undergo TBI
40792415|NCT04073862|OTHER|Stepped-Care TF-CBT|SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
41149443|NCT05667740|DRUG|Placebo|Saline
41149444|NCT00570804|BEHAVIORAL|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
40997710|NCT01539187|DEVICE|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
40997711|NCT05947136|BEHAVIORAL|Interpretation of the results from the detection visit|"- An interpretation of the results of the detection tests concerning~* the 7 complications of interest assessed at T1, T2, T3 and T4 ;~* the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;"
40997712|NCT05947136|BEHAVIORAL|Explaining detection results and referrals to the patient|"Explanation of results and directions to the patient using plain language;The aims of this call are as follows:~* Clearly explain the results of the detection visit and the action to be taken for each referral;~* Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network;~* Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications."
40997713|NCT05947136|BEHAVIORAL|Early medical care through the network|Early, proactive medical care through a network of dedicated healthcare professionals.
40997714|NCT05947136|BEHAVIORAL|Transmission of results from each detection visit to the referring onco-haematologists - Control Group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.
40997715|NCT04152720|DEVICE|Foley catheter|"If the subject is enrolled in this clinical trial, the test and control devices will be applied at baseline. All subjects will receive a urinary catheter at the site of the artificial bladder and the urethra after surgery, and temporary urinary replacement should be selected by the investigator at each institution in preparation for the possibility of postoperative blockage of the urinary catheter.~After surgery, urine analysis and culture are performed on the 4th and 7th day, and urine analysis and culture are performed before the urethral catheter removal on the 14th (2 weeks) and the urethral catheter is removed. At this time, the urethral catheter tip is cut about 5-8 cm and cultured."
40997716|NCT03902951|DRUG|Abiraterone Acetate|Given PO
40997717|NCT03902951|DRUG|Apalutamide|Given PO
40997718|NCT03902951|DRUG|Leuprolide Acetate|Given SC
40997719|NCT03902951|OTHER|Quality-of-Life Assessment|Ancillary studies
40997720|NCT03902951|OTHER|Questionnaire Administration|Ancillary studies
40997721|NCT03902951|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
40997722|NCT05912699|OTHER|Slimbiotics Postbiotic|"SlimBiotics postbiotic formula contains the following ingredients:~* Heat-inactivated L. fermentum K8 Postbiotic.~* Microcrystalline cellulose."
40997723|NCT05912699|OTHER|Placebo|The placebo capsules contain microcrystalline cellulose only.
40997724|NCT00694369|DRUG|Comparator: etoricoxib|etoricoxib 90 mg; 120 mg (once daily) over three days.
40997725|NCT00694369|DRUG|Comparator: ibuprofen|ibuprofen 2400 mg (600 mg Q6h) over three Days
40997726|NCT00694369|DRUG|Comparator: acetaminophen + codeine|acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
40997727|NCT00694369|DRUG|Comparator: placebo|matching placebo over three Days
40997728|NCT04975555|DRUG|Siltuximab|Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.
40997729|NCT01177540|DRUG|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
40997730|NCT01177540|DRUG|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
40997731|NCT01266213|DRUG|Fulvestrant plus Goserelin|Fulvestrant s.c. plus Goserelin s.c.
40997732|NCT01266213|DRUG|Anastrozole plus Goserelin|Anastrozole 1 mg p.o. plus Goserelin s.c.
40997733|NCT01266213|DRUG|Goserelin|Goserelin s.c.
40997734|NCT03000699|BEHAVIORAL|Cognitive Bias Modification|Training paragraphs describe scenarios designed to be ambiguous at the outset and to resolve in a positive direction, with the intention of establishing a learning contingency between the ambiguity at the beginning of the scenario and the positive resolution that becomes clear towards the end of the statement.
40997735|NCT02656108|PROCEDURE|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
40997736|NCT02656108|PROCEDURE|controlled cord traction|active management of third stage of labor in the form of uterine massage with controlled cord traction
40997737|NCT03071575|BIOLOGICAL|Measles-rubella (MR) vaccine at 6 and 9 months|Arm A will receive MR vaccine dose at 6 and 9 months of age
40997738|NCT03071575|BIOLOGICAL|Measles-rubella (MR) vaccine at 9 months|Arm A will receive MR vaccine dose at 9 months of age
40997739|NCT06287983|DEVICE|Inspiratory Muscle Trainer (IMT) (POWERbreathe Medic Classic)|Inspiratory muscle training will be started at an intensity of 50% of the patient's measured PIMAX value and will be increased by 2 cm/H20 per day according to patient tolerance, and will be applied for a total of 6 weeks / 5 days per week / 3 sessions per day / 10 breaths per session.
40997740|NCT06287983|OTHER|The Sample Spondylitis Exercise Program|The Sample Spondylitis Exercise Program recommended by the Spondylitis Association of America will be translated into Turkish and each exercise will be applied in 3\*10 sets. The exercise program will be applied to both groups, 3 sessions a week for 60 minutes for 6 weeks.
41149445|NCT00570804|BEHAVIORAL|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
41310244|NCT01155297|BEHAVIORAL|Physical training|"The exercise program will be held three times a week and will have three stages: local and global stretching, aerobic exercise for 30 minutes ( with 50 and 60% of maximal heart rate) and strength training. The strength training will be done after assessment of one repetition maximum (1RM) and the prescription will be made with 50% load of 1RM, where the patient will hold three sets of 10-12 repetitions. Reassessments will be conducted monthly for readjustment of the charges. The duration of the training protocol will be six months.~After completing this exercise program, patients will undergo a reassessment repeating the ET and reapplication of the SF-36, redone the collection of ADMA serum concentration."
41310245|NCT01155297|BEHAVIORAL|Stretching and metabolic exercises|At the control group will be performed stretching and metabolic exercises and will make the assessments and the reassessments after the end of the program.
41310246|NCT03612180|DRUG|Metoprolol Succinate|Pharmacokinetics
41310247|NCT03357146|DEVICE|Optical coherence tomography angiography|OCTA scans per built-in device protocol
41310248|NCT04894006|BEHAVIORAL|Community Health Worker (CHW) Home Visit Intervention|The on-site intervention will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions. The education of dementia caregiving skills will include (1) understanding about Alzheimer's and dementias, (2) appropriate communication skills with PWD, (3) daily activities for or with PWD together (e.g., puzzles, writing, reading, singing, taking a walk, etc), and (4) care resources including support groups, adult day centers, or other dementia related social services (legal and financial matters). For stress reduction techniques to be effective, the investigators have installed an app on the smartwatch to remind them to practice mindful breathing exercises two times a day and when needed.
41310249|NCT04894006|BEHAVIORAL|Attention Control Group with WIoT Technology|The caregivers randomly assigned to the AC group will be asked to wear the smartwatch during the day time and the smartring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, and sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months answering general questions from participants. CHW will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
41469509|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
41469510|NCT00984516|DRUG|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
41469511|NCT00984516|DRUG|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
41469512|NCT04602793|DIAGNOSTIC_TEST|ultrasonography|All ultrasonographic examinations were performed by a single physiatrist experienced in musculoskeletal sonography. The full course of the sciatic nerve (SN), tibial nerve (TN), and common peroneal nerve (CPN) was assessed in a craniocaudal direction starting from the subgluteal fold to the popliteal fossa. The probe was placed axially on the nerves (perpendicular to the nerve) and the cross-sectional area (CSA) was measured at the same level proximal to the bifurcation for the SN , and at a point distal to the bifurcation of the SN for the TN and CPN (Figure 2). The values from the normal sides were accepted as controls.
41469513|NCT06378788|OTHER|Demographic information form|aims to collect basic demographic data( Age reported by years , weight and height will be combined to report Body Mass index (BMİ) in kg/m2, Smoking habit reported as smoker or non-smoker , Level of Education reported as illiterate, literate, Primary school, Middle school, High school, University or Post-graduate, Profession type, Significant medical records and Medications.
41469514|NCT06378788|DIAGNOSTIC_TEST|widespread pain index (WPI)|"The Widespread Pain Index is a 19-point checklist that assesses the presence of pain or tenderness (within the prior seven days) in 19 specific areas of the body; each affected area receives one point. The 19 regions on the WPI include the following:~Right and left jaw, Right and left shoulder girdle, Right and left upper arm, Right and left lower arm, Right and left hip/buttock Right and left upper leg Right and left lower leg Upper and lower back Neck Chest Abdomen A fibromyalgia diagnosis is confirmed if a WPI is ≥7 with an SS scale ≥5 OR a WPI range between 4-6 with an SS scale ≥ 9."
40997741|NCT03356249|DIAGNOSTIC_TEST|Next-Generation Sequencing|In 500 patients with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions), patients´ characteristics and routine blood parameters will be determined at sepsis onset as well as 72 hours afterwards. At the same time points, 2 sets of blood cultures and one blood tube for Next-Generation Sequencing (NGS)-diagnostics will be collected. An evaluation of outcome will be performed at 28 days after sepsis onset.
40997742|NCT02612428|BIOLOGICAL|ELAD System|An extracorporeal human hepatic cell-based liver treatment
41149446|NCT04641156|OTHER|Exercise Therapy program added to laser therapy|a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release
40997743|NCT02612428|OTHER|Standard of Care (Control)|Standard medical treatment as defined by the protocol
40997744|NCT04210752|DRUG|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
41149447|NCT05398042|DIETARY_SUPPLEMENT|Ketone ester|A daily dose of 3x20g of ketone ester supplementation during a six week intervention period
41149448|NCT05398042|DIETARY_SUPPLEMENT|Medium Chain Triglyceride (MCT) oil|A daily dose of 3x12.8g of MCT oil supplementation during a six week intervention period
40997745|NCT04210752|DRUG|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
41149449|NCT01489163|BEHAVIORAL|Lifestyle Counseling|The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
41149450|NCT01763645|DRUG|Bevacizumab|Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
40792416|NCT04202185|OTHER|Data collection|Retrospective collection data from diagnostic Data collected following to medical exam as part of care
40792417|NCT04202185|GENETIC|Genetic analysis|Research of mutation and identification of genetic panel as part of care
40792418|NCT05794737|BIOLOGICAL|Immunohistochemical staining|Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.
40792419|NCT03632707|RADIATION|Magnetic Resonance Imaging of the knee|After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
41149451|NCT01763645|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
41149452|NCT01763645|DRUG|Carboplatin|Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
41149453|NCT00452322|DRUG|Testosterone Substitution by Testosterone Undecanoate i.m.|
40997746|NCT04210752|DRUG|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
40997747|NCT04210752|DRUG|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
40792420|NCT03632707|PROCEDURE|Knee Arthroscopy|Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
40792421|NCT05406128|OTHER|preoperative erector spina plane block|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
40792422|NCT05406128|OTHER|intraoperative erector spina plane block|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
40997748|NCT04210752|DRUG|Treatment 5|"Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: IM injection"
40997749|NCT04846725|OTHER|Data collection|"Collect in medical records :~* Filter's retrieval rate~* Complications of vena cava filters~* Predictive factors of attempted inferior vena cava filters retrieval: age, the distance between the patient's home and the hospital, the indication or not given by the therapeutic medicine department, patients referred by external structures, patients whose filter was installed during the medical on-call period, the absence of a written request for filter placement, the presence of active neoplasia at the time of filter placement, a peri-surgical context."
40997750|NCT00046735|DRUG|Lenalidomide|The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
40997751|NCT04750837|PROCEDURE|debridement of the wound|The edges and the floor of the wound were firstly debrided, and any callosities around the wound were removed. This was repeated if needed when callosities around the wound reappeared. By this technique, the chronic wound was transformed into an acute one
40997752|NCT04750837|BIOLOGICAL|platelet rich plasma|Part of activated PRP was injected around the wound and under the base of the wound, while another portion of PRP was left over the floor of the wound and let to coagulate and form a gel.
41149454|NCT05224596|DIAGNOSTIC_TEST|Blood draw and blood-based biomarkers analyses|blood-based biomarkers analyses
41149455|NCT04031534|DRUG|F-Miso PET scan coupled with MRI|Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
41149456|NCT01064856|BIOLOGICAL|Adalimumab|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.
41149457|NCT01064856|BIOLOGICAL|Placebo|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
41149458|NCT02853188|OTHER|venous thromboembolism|
41149459|NCT03554200|DRUG|Empagliflozin|Standard of Care + Empagliflozin: 10 mg (tablets) once daily
41149460|NCT03554200|DRUG|Placebo|Standard of Care + Placebo: Matching Placebo (tablets) once daily
41149461|NCT03658018|DEVICE|Intracept System Ablation|Radiofrequency ablation using Intracept System
40997753|NCT04750837|PROCEDURE|conventional dressing|The wound was irrigated by normal saline, covered by vaseline gauze then sterile dressing. Repeated dressing every two days till 20 weeks, if the wound failed to heal at that time
40997754|NCT04248595|DRUG|Homoharringtonine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
40997755|NCT04248595|DRUG|Azacitidine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
40997756|NCT02856542|DRUG|calcipotriol/betamethasone dipropionate gel in Applicator|Topical treatment of scalp using applicator device. The study as such is non-interventional as the intervention has been decided prior to and independently from the inclusion of the patient in the cohort to be observed.
40997757|NCT02550496|DEVICE|Dermoscopy|
40997758|NCT01909037|DIETARY_SUPPLEMENT|Flexofytol (bio-optimized curcumin)|2x3 caps/day (before breakfast and in the evening) for 3 months
40997759|NCT02051777|DIETARY_SUPPLEMENT|Oral Nutritional Supplement 1|Containing macro and micronutrients
40997760|NCT02051777|DIETARY_SUPPLEMENT|Oral Nutritional Supplement 2|Containing macro and micronutrients
40997761|NCT02051777|DIETARY_SUPPLEMENT|Dietary Advice|
40997762|NCT06151587|DRUG|QLM3004 Concentration 1|"Low dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
40792423|NCT00120627|BEHAVIORAL|Mantram Repetition Program (MRP) plus Usual Care|"The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting."
40997763|NCT06151587|DRUG|QLM3004 Concentration 2|"Medium dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
40997764|NCT06151587|DRUG|QLM3004 Concentration 3|"High dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
40997765|NCT06151587|OTHER|Placebo|Vehicle
40997766|NCT03002051|DEVICE|EUS-guided drainage|"* Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage.~* EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen.~* After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm).~* After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen.~* After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance."
40997767|NCT04832464|OTHER|RACE Protocol: Balance training along with resistance, aerobic and cognitive exercises.|therapy for the preservation, enhancement, or restoration of movement and physical function impaired or threatened by disease, injury, or disability that utilizes therapeutic exercise, physical modalities (such as massage and electrotherapy), assistive devices, and patient education and training.
40997768|NCT00751348|BIOLOGICAL|PriorixTM|Subcutaneous administration in left upper arm
40997769|NCT00751348|BIOLOGICAL|VarilrixTM|Subcutaneous administration in right upper arm
40997770|NCT00751348|BIOLOGICAL|Priorix-Tetra®|Subcutaneous injection in left upper arm
40997771|NCT00314574|DRUG|omalizumab (Xolair)|Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.
40997772|NCT00314574|DRUG|placebo|Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
40997773|NCT00314574|DRUG|corticosteroids|Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
40792424|NCT00120627|OTHER|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
40997774|NCT00314574|DRUG|long-acting beta-agonists|50 µg salmeterol twice daily or 12 µg formoterol twice daily.
40997775|NCT01373749|DRUG|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
40997776|NCT01373749|DRUG|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
40997777|NCT05511142|OTHER|Classic Peyton's Four-Step Approach|Instructor demonstrated endotracheal intubation and mask ventilation procedural skills directly to the preclinical students, followed by direct hands-on practice using manequin, ended with giving feedback to the students
40997778|NCT05511142|OTHER|Modified Peyton's Four-Step Approach|Video tutorial of endotracheal intubation and mask ventilation were given to the students without explanation, followed by video tutorial making using manequin (without instructor) by the students which will be uploaded to Youtube
40997779|NCT05650476|DRUG|Talazoparib|capsules
41149462|NCT03452735|OTHER|Questionnaire about fertility|Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
41310250|NCT04894006|BEHAVIORAL|Usual Care|The caregivers randomly assigned to UC group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. CHWs will contact them monthly for 6 months by phone asking general questions from participants. CHWs will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
40997780|NCT02759666|DRUG|SHR3162|SHR3162 capsule(s) is administered orally QD.
40997781|NCT01988116|DRUG|Oral Calcitriol 0.5 mcg once daily for 6 weeks|
41310251|NCT00861367|DRUG|transurethral surgery with or without aspirin|aspirin 100mg once a day, transurethral surgery with or without aspirin
40997782|NCT01988116|DRUG|Placebo|
40997783|NCT02993159|DRUG|Afimoxifene|Applied to the breast
40997784|NCT02993159|OTHER|Laboratory Biomarker Analysis|Correlative studies
40997785|NCT02993159|OTHER|Placebo|Given PO
40997786|NCT02993159|OTHER|Placebo|Applied to the breast
40997787|NCT02993159|DRUG|Tamoxifen Citrate|Given PO
40792425|NCT01637584|DRUG|Prazosin|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
40792426|NCT01637584|DRUG|Placebo|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
40792427|NCT00731861|DRUG|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
40792428|NCT01495533|DEVICE|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
40792429|NCT01495533|COMBINATION_PRODUCT|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
40792430|NCT03115372|OTHER|Educational Intervention|Attend CRC education session
40792431|NCT03115372|OTHER|Educational Intervention|Attend healthy nutrition session
40792432|NCT03115372|OTHER|Informational Intervention|Receive CRC screening brochure
40792433|NCT03115372|OTHER|Survey Administration|Ancillary studies
40792434|NCT03115372|BEHAVIORAL|Telephone-Based Intervention|Receive telephone reminder about CRC screening
40792435|NCT03115372|BEHAVIORAL|Telephone-Based Intervention|Receive telephone reminder about healthy nutrition
40792436|NCT05265858|PROCEDURE|Total Hip Arthroplasty|Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
40997788|NCT02881996|DRUG|IV tylenol|IV tylenol given scheduled in addition to standard PCA
40792437|NCT01448538|DRUG|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
40792438|NCT05317026|PROCEDURE|Vertebroplasty|"SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~* Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~* Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~* Decubitus position for 2 hours following procedure, then hospital discharge on the same day."
40792439|NCT05317026|PROCEDURE|Stereotactic Body Radiation Therapy only|SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
40792440|NCT03929354|BEHAVIORAL|Risk Factors Modification Programme|12-week supervised risk factor modification programme derived from the EuroAction Study standards.
40792441|NCT03929354|BEHAVIORAL|Standard Care|Patients advised to adjust lifestyle without the support of the structured supervised programme.
40792442|NCT04342676|DEVICE|k ras|K ras
40792443|NCT04342676|DRUG|Panitumumab|vectibex in stage iv
40792444|NCT03400046|DRUG|Nutritional Product Supplementation|Patients with chronic intestinal failure were administered nutritional support including enteral and parenteral nutrition.
40792445|NCT02770027|DRUG|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
40792446|NCT02770027|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
40792447|NCT03687242|DRUG|SPR001|Open label SPR001
40997789|NCT02881996|DRUG|No IV tylenol|No additional IV Tylenol given
40997790|NCT02881996|DRUG|Ketorolac|both groups receive as part of our standard postop pain protocol after all operations
40997791|NCT05939492|BEHAVIORAL|Mindfulness-Based Intervention|"Participants in the mindfulness-based intervention (MBI) group will be asked to use the Headspace app to sequentially complete the Basics, Basics 2, and Basics 3 courses. Each of these courses lasts 10 days, and participants have the ability to choose how long daily sessions last. Participants can choose between 3, 5, or 10-minute sessions for the Basics course; 10 or 15-minute sessions for the Basics 2 course; and 10, 15, or 20-minute sessions for the Basics 3 course. These daily sessions are audio recordings that prompt users to engage in a variety of mindfulness techniques, including focusing on their body and breathing, as well as acknowledging thoughts and emotions in a non-judgmental manner."
41149463|NCT05457296|DRUG|Hydrocortisone (capsule)|salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
41310252|NCT04980976|DEVICE|Blind insertion technique|Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.
41310253|NCT04980976|DEVICE|C-MAC videolaryngoscope insertion technique|Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique
41310254|NCT02608437|DRUG|SGI-110|SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
41310255|NCT02608437|DRUG|Ipilimumab|ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
41310256|NCT04915664|DEVICE|Pessary|Use of Pessary as treatment of POP
41310257|NCT03907982|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
41310258|NCT03907982|PROCEDURE|Pulmonary vein isolation|The cryoballoon (CE marked) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential freeze around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
40792448|NCT04855240|DRUG|ACP-044 Dose A|Oral dose of ACP-044 Dose A
40792449|NCT04855240|DRUG|ACP-044 Dose B|Oral dose of ACP-044 Dose B
40792450|NCT04855240|DRUG|Placebo|Oral dose of placebo
40997792|NCT06343064|DRUG|Vebreltinib|Phase Ib is a dose escalation study, the initial dose of Vebreltinib is 100mg/150mg/200mg,according to the result of Phase Ib, will confirm the RP2D.
40792451|NCT04379453|PROCEDURE|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention
40792452|NCT03926377|PROCEDURE|bone densitometry|Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment).
40792453|NCT03926377|BIOLOGICAL|blood test|Blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 hours to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 hours cortisolemia.
40792454|NCT03926377|PROCEDURE|radiographs of the thoracic and lumbar spine|standard radiographs of the thoracic and lumbar spine will be done at the initiation of treatment and at 6 months.
40792455|NCT03926377|PROCEDURE|Clobetasol propionate|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
40792456|NCT00925002|DRUG|Tafamidis|20 mg oral Fx-1006A daily
40792457|NCT02043145|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
40792458|NCT05551156|BEHAVIORAL|Animal-assisted interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the participant will be able to pet the dog if they wish. The handler will talk with the participants about the dog, the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
40792459|NCT05551156|BEHAVIORAL|Conversational interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants without a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the handler will talk with the participants about the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
40792460|NCT01724229|DRUG|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
40792461|NCT05939752|OTHER|ophthalmological examination|OCT-retinal angiography At inclusion, 3 months and 6 months
40792462|NCT05939752|BIOLOGICAL|blood test|"a 2-mL tube of blood will be taken to test for blood markers predisposing to cardiovascular complications.~At inclusion"
40792463|NCT02213497|RADIATION|18F-FDG (Fluorodeoxyglucose) PET|
40792464|NCT02213497|DRUG|Carboplatin|
40792465|NCT02213497|DRUG|Paclitaxel|
40792466|NCT05681338|OTHER|the medium intensity coughing technique|The medium intensity coughing technique: Immediately before the subcutaneous LMWH injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
40997793|NCT06343064|DRUG|PLB1004|Phase Ib is a dose escalation study, the initial dose of PLB1004 is 80mg/160mg,according to the result of Phase Ib, will confirm the RP2D.
40997794|NCT05169788|DEVICE|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
40997795|NCT01318642|DRUG|Gemcitabine|Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
40997796|NCT01318642|DRUG|AMG 479|Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.
40997797|NCT01318642|DRUG|Placebo|Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
40997798|NCT00560690|DRUG|Metformin|500 mg oral three times a day for 6 months
40997799|NCT00560690|DRUG|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
40997800|NCT00560690|DRUG|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
40997801|NCT05542875|PROCEDURE|Thrust Manipulation|Prone thoracic extension manipulation technique will be applied from T2 - T6 to participants of Group A (Experimental group). Intervention will be applied on alternate days with a total of 4 treatment sessions
41149464|NCT03034772|DRUG|Dorzolamide-timolol|Topical eye drop (active comparator) used twice daily for study duration
41149465|NCT03034772|OTHER|Artificial tears|Topical eye drop (placebo comparator) used twice daily for study duration
40997802|NCT05542875|PROCEDURE|Non-Thrust manipulation|Maitland grade III or IV thoracic 0manipulation will be given to participants of Control group from T1 to T6. Posterior to anterior glide over spinous process will be maintained for 30 seconds. Intervention will be applied on alternate days with a total of 4 treatment sessions
40997803|NCT05542875|PROCEDURE|Standard Treatment|"Standard treatment protocol includes moist heat, TENS and Post isometric relaxation technique. Standard treatment will be given to both groups on every session. Standard treatment consists of:~Superficial Moist Heat (Device): Superficial moist heat will me applied for 10 minutes on Upper Trapezius TENS (Device): TENS will be applied for 10 minutes at 80-100Hz, the electrodes will be placed at upper trapezius.~Post-isometric Relaxation (procedure/surgery): 5-10 repetions of Post Isometric relaxation technique will be applied on various muscle groups which include Upper trapezius, levator scapulae, sternocleidomastoid and scalenes."
40997804|NCT05695716|DEVICE|CSI pVAD System|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
40997805|NCT06407466|OTHER|taping|"Kinesiology taping; In order to facilitate the muscle, while the subject is standing and his body is flexed to ensure hip flexion, both I bands will be applied from the origin to the insertion, with 30% stretching from the medial and lateral, starting from the Ischial Tuberositas to the border of the Popliteal Fossa."
40997806|NCT06407466|OTHER|Control|The routine training program will continue without intervention.
40997807|NCT06407466|OTHER|mobilization|Instrument-assisted soft tissue mobilization; The subject is in a prone position on a bed, with the lower extremity in a neutral position, and a hazelnut-sized amount of lubricant will be applied to the working surface, and will be applied to the skin on the back of the upper leg for 5 minutes, targeting the tissue structures. (Hamstring and deep fascia covering this muscle) Pressure and speed will be adjusted according to the subject's tolerance so as not to cause pain.
40997808|NCT05422781|DRUG|ITI-3000|ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
40997809|NCT03303833|OTHER|No intervention, observational study.|
40997810|NCT06407089|OTHER|Spinertial Group|"Endurance training program of deep cervical flexors and deep cervical extensors with Spinertial device for treatment.~Endurance training program of deep cervical flexors and deep cervical flexors with Spinertial device for treatment."
40997811|NCT04584710|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
40997812|NCT04584710|DRUG|Placebo|Oral matching placebo once daily for 2 weeks
40792467|NCT02970591|OTHER|Traditional dietary advice and low FODMAP content|Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
40997813|NCT04384965|DEVICE|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single iTBS treatment, delivering 600 pulses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / \~3 minutes) at a target of 110% of the subject's resting MT.
41149466|NCT01320683|DRUG|oxaliplatin|Given IV
40792468|NCT02970591|OTHER|Low carbohydrate diet|Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.
41149467|NCT01320683|DRUG|leucovorin calcium|Given IV
40792469|NCT02970591|OTHER|Optimized Medical treatment|Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
40792470|NCT00561522|DRUG|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
40792471|NCT00561522|OTHER|No other preventive treatment|No other preventive treatment
41149468|NCT01320683|DRUG|fluorouracil|Given IV
41149469|NCT01320683|BIOLOGICAL|bevacizumab|Given IV
41149470|NCT01320683|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
40792472|NCT01478464|OTHER|Massage|"The hamstring muscle will be massaged with a massage roller for ten minutes."
40792473|NCT04880239|PROCEDURE|Posterior colpoperineorrhaphy|Patients having a sacralcolpopexy will be randomized to ultra lightweight mesh (Coloplast Restorelle) with posterior colpoperineorrhaphy or the same procedure without the posterior colpoperineorrhaphy
41149471|NCT01320683|OTHER|laboratory biomarker analysis|Correlative studies
41149472|NCT01320683|OTHER|pharmacological study|Correlative studies
41149473|NCT01320683|DRUG|irinotecan hydrochloride|Given IV
41149474|NCT03850964|DRUG|Pazopanib|gel capsule, with 25mg-similar fills
41149475|NCT03850964|DRUG|Placebo oral capsule|identical gel capsule without active pharmaceutical ingredient
41149476|NCT03436433|DRUG|Lacosamide|LCM 100mg twice a day.
41149477|NCT03436433|DRUG|Levetiracetam|LEV 1000mg twice a day.
40997814|NCT04607993|BEHAVIORAL|Prone position ventilation technique|"1. Inform the children's family members of the purpose and method of prone position ventilation~2. Assess the fixation of various catheters~3. Suspend feeding before placing prone position~4. Confirm the time to start prone position ventilation under the joint assessment of medical staff~5. Place the child in a prone position with the participation of researchers, doctors and nursing staff, with the child's head tilted to one side to avoid damage to the eyes and nose due to compression, and the arms are bent upward to form a W . Bend both lower limbs downward to form an M shape, and use a soft pillow cushion to measure the knee joints to avoid compression~6. The whole process ensures the smooth fixation of tracheal intubation and various catheters~7. Proper sedation during prone position ventilation to achieve good human-machine synchronization~8. At least 6-8 hours in prone position every day"
40997815|NCT05918679|BEHAVIORAL|Effects of speech variability on speech motor learning|This intervention will examine whether reducing normal variability of speech could improve error detection and speech motor learning. We will design training tasks to change subjects' speech variability. We will train subjects to decrease/decrease their speech variability. Upon completing the training tasks, subjects will complete a motor learning task.
40997816|NCT05918679|BEHAVIORAL|Effects of error-detection training on speech motor learning|This intervention will examine whether improving subjects' ability to detect and estimate auditory perturbation could improve speech motor learning. For this purpose, we will design training tasks to change subjects' estimation of the perturbation magnitude. After completing the training tasks, subjects will complete the motor learning task.
40997817|NCT05918679|BEHAVIORAL|Contributions of error awareness to speech motor learning|This intervention will examine the contributions of error awareness to speech motor learning. Subjects will produce a target word while receiving perturbed auditory feedback with different magnitudes. Subjects will be trained to indicate the magnitude of the error they perceived with or without visual feedback.
41149478|NCT04892004|BEHAVIORAL|Symptom recognition|The patient receives a leaflet, which includes information about HF, primary symptoms, awareness of its detection and the fluid management plan. It also receives a weight diary, which helps him/her recall weight fluctuation and contact the nurse or doctor to call for help in a previous stage and avoid hospitalisation. Patients have to explain what they understand by HF, on follow-ups contacts, which are the main symptoms, if they are experiencing any of them and which difficulties managing fluid restriction and weight control. The leading investigator validates the information and teaches back contents if required.
41149479|NCT05893693|OTHER|Biological|CT0594CP
41149480|NCT03985020|OTHER|Stevia Intervention|We will use commercially available stevia sweetened soft drink Zevia.
41469515|NCT06378788|DIAGNOSTIC_TEST|symptom severity scale (SSS)|SS scale score: Fatigue, waking unrefreshed, and cognitive symptoms. For each of the three symptoms above, indicate the severity level over the past week utilizing the following scale: 0 no problem; 1 slight or mild problems, generally mild or intermittent; 2 moderate, considerable problems, often present and/or at a moderate level; 3 severe: pervasive, continuous, life-disturbing problems. Considering somatic symptoms in general, indicate whether the patient has: 0 for no symptoms, 1 for a few symptoms, 2 for a moderate number of symptoms, and 3 for many symptoms. The SS scale score sums the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the severity) of general somatic symptoms. The final score is between 0 and 12.
41469516|NCT06378788|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire (FIQ)|The FIQ is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes. The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
41469517|NCT06378788|DIAGNOSTIC_TEST|Tender Point examination|Tender points are specific sites on the body that cause pain when pressed.. There are 9 pairs of tender points. Each pair has one point on each side of the body, for a total of 18 points.Prior to 2010, the diagnosis of fibromyalgia required at least 11 painful point of 18 but now tender points are no longer used as a diagnostic tool. The score will be reported as the number of tender points found with palpation.
41469518|NCT06378788|OTHER|Muscle Architecture visualized with ultrasound|The three head of Quadratus femoris ( Vastus lateralis, Vastus Medialis and Rectus Femoris), Tibialis Anterior, the two heads of Gastrocnemius ( vastus Lateralis and vastus Medialis) ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.
41469519|NCT06378788|OTHER|Sarcopenia assessed by measuring isometric strengths of different parts of the body|Cervical Flexion (CF), Cervical Extension (CE), Right and Left Cervical Lateral Flexion (CLF R/L), Truncal flexion (TF), Truncal extension (TE), Shoulder flexion (SF), Shoulder extension (SE), Shoulder abduction (SAB), Shoulder internal rotation (SIR) and Shoulder external rotation (SER), Hip flexion (HF), Hip extension (HE), hip abduction (HAB), hip internal rotation (HIR), hip external rotation (HER), knee extension (KE), Knee Flexion (KF), Ankle Dorsiflexion (ADF) and Ankle Plantar flexion (APF) muscle strengths will be evaluated with hand held dynamometer
41469520|NCT06378788|OTHER|Timed Up & Go (TUG)|The test will be used by investigators as a simple evaluative test used to measure participants functional mobility.
41469521|NCT02551679|BIOLOGICAL|ACP-01|Injection into lower extremity
41469522|NCT02551679|BIOLOGICAL|Placebo|Injection into lower extremity
41469523|NCT01736787|DIETARY_SUPPLEMENT|Cauliflower Mushroom extract|Cauliflower Mushroom extract (1g/day)
41469524|NCT01736787|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
41469525|NCT03567525|PROCEDURE|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels|After pelvic lymph node dissection, lymphatic vessels will be sealed by formation of a peritoneal iliac flap in which the bladder in folded over the area of lymph node dissection
41149481|NCT03985020|OTHER|Water Intervention|Bottled Water
41149482|NCT04072809|OTHER|No intervention|This study does not involve any interventions.
41149483|NCT05603299|OTHER|Educational Materials on the Dawn test|Receive educational materials and sample test results replicating what physicians would receive in the real-world market as they learn about the probability of IO therapy response from the Dawn™ test.
40792474|NCT05163327|PROCEDURE|Oxygen-enhanced Cardiac MRI|The MRI scan will include assessment of cardiac function. Myocardial magnetic properties (T1, T2, T2\*) will be measured while patients are breathing room air, oxygen and during an infusion of adenosine. The scan will last for approximately 60 minutes. Prior to the scan patients will have an intravenous cannula (venflon) placed in an arm vein.
40792475|NCT01277822|DRUG|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
40792476|NCT01277822|DRUG|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
40792477|NCT01277822|DRUG|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
40997818|NCT05918679|BEHAVIORAL|Enhancing auditory-to-motor mapping with augmented visual feedback|This intervention will determine the contributions of enhanced auditory-to-motor mappings to speech motor learning. We will design training tasks in which we will use visual feedback to provide feedback regarding subjects' accuracy of auditory-to-motor mapping.
40997819|NCT05918679|BEHAVIORAL|Effects of enhanced auditory-motor awareness on speech motor learning|In this intervention, subjects will be trained to control their articulators more accurately and be more aware of their articulators' position and their auditory consequences. After the training tasks, subjects will complete a motor learning task.
40997820|NCT05584696|OTHER|Green light exposure|The experimental group wears green color glasses ten minutes before surgery until it ends.
40997821|NCT05584696|OTHER|Normal light exposure|The control group wears green color glasses ten minutes before surgery until it ends.
40997822|NCT03323658|DRUG|Bexarotene|Given topically
40997823|NCT03323658|OTHER|Questionnaire Administration|Ancillary studies
40997824|NCT03792672|DRUG|TAK-653|TAK-653 tablets.
40997825|NCT03792672|DRUG|Placebo|TAK-653 placebo-matching tablets.
40997826|NCT03792672|DRUG|Ketamine|Ketamine intravenous infusion.
40997827|NCT05262634|OTHER|Data collection (laboratory and obstetric results)|"Maternal data: age, pregnancy, parity, singleton or multiple pregnancy, BMI, obstetric history data, and ethnicity.~Laboratory chemical results: hemoglobin (Hb), number of erythrocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), number of hypochromic erythrocytes (HRC), erythrocyte distribution width (EBW), ferritin, C reactive protein (CRP).~Maternal pregnancy outcomes and complications: Hb before and after delivery, mode of delivery, placenta abruption, preeclampsia/eclampsia, gestational diabetes, gestational cholestasis, pregnancy-induced hypertension, bacteriuria or urinary tract infections, peripartum and postpartum hemorrhage, puerperal infections, uterine subinvolution.~Perinatal outcomes: gestational age, birth weight, intrauterine growth retardation, preterm birth, macrosomia, premature rupture of membranes, Apgar score, intrauterine fetal death, pH values, admission to neonatology"
41149484|NCT01863368|OTHER|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
41149485|NCT01863368|OTHER|Systane® ULTRA lubricant eyedrops|
41149486|NCT01863368|OTHER|OPTIVE® lubricating eyedrops|
40792478|NCT01277822|DRUG|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
40792479|NCT02272946|DRUG|Canakinumab|150mg Canakinumab received subcutaneously
41149487|NCT04675086|DRUG|alpha1-proteinase inhibitor|Alpha1-Proteinase Inhibitor (Human), AralastÔ, is a sterile, stable, lyophilized preparation of purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin.
40792480|NCT02272946|DRUG|Placebo|150mg Placebo received subcutaneously
40792481|NCT04662931|DRUG|crizanlizumab|Crizanlizumab will be taken by IV infusion, at Week 1 Day 1, Week 3 Day 1, and Day 1 of every 4-weeks cycle until Week 51 Day 1
40792482|NCT03998800|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
40792483|NCT03998800|BEHAVIORAL|Endurance exercise on a cycle ergometer|On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
41149488|NCT04675086|DRUG|Antiviral Agents|a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
41469526|NCT03567525|PROCEDURE|Standard surgical approach|After pelvic lymph node dissection, lymphatic vessels will be sealed using the standard approach
40792484|NCT00730353|DRUG|Sunitinib malate|Sunitinib malate 37.5 mg orally, daily
40792485|NCT00730353|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
40792486|NCT04750863|OTHER|diagnosis criteria performance|
40792487|NCT01144325|PROCEDURE|thoracoscopic esophagectomy|"In prone position group, patients are intubated with single lumen endotracheal tube. Surgeon and assistant stand on the right of the patient. A 10 mm camera port is placed 7th intercostals space in posterior axillary line, CO2 pneumothorax is created with pressure of 8mmHg. A 5 mm port is placed just posterior to the scapular tip. The last 10mm port is placed at 9th intercostals space in the scapular line for. The tumor and esophagus are dissected with cleaning of the lymph nodes along bilateral recurrent nerve.~In controlling group, The four chest ports were similar to that described by the University of Pittsburgh group. The left two ports are used for surgical exposure, the right two ports is to divide and dissect the esophagus. The dissection is similar to that of the prone position."
40792488|NCT05598905|DRUG|Pregabalin 150mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
40792489|NCT05598905|DRUG|Oxycodone 10mg|one 10mg tablet
40792490|NCT05598905|DRUG|Lacosamide 150 mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
40792491|NCT04552119|DEVICE|HEALICOIL Knotless PEEK|HEALICOIL Knotless PEEK Self-Tapping HEALICOIL Knotless Non-Self Tapping
40792492|NCT04552119|DEVICE|HEALICOIL Knotless REGENESORB|HEALICOIL Knotless REGENESORB Self -Tapping HEALICOIL Knotless REGENSORB Non-Self Tapping
40792493|NCT04769817|OTHER|177Lu-PSMA|Lu-PSMA will be administered as a standard-of-care procedure following assessment of suitability by a nuclear medicine physician and managed in close collaboration with the patient's medical oncologist.
40792494|NCT01266226|DEVICE|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
40792495|NCT01266226|DEVICE|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
40792496|NCT01737762|BIOLOGICAL|HP802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
40792497|NCT01737762|BIOLOGICAL|Vehicle|
40792498|NCT04345692|DRUG|Hydroxychloroquine|oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
40792499|NCT06275828|DEVICE|slow beat mesic listening by headphone|classic slow beat type from researcher
40792500|NCT05152251|OTHER|Evaluation|Individuals' activity participation levels and the restrictive or supportive factors affecting their participation levels and their effects on quality of life will be evaluated.
41310259|NCT03907982|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at the end of the procedure clinic by the electrophysiologist performing the procedure. The device will provide a continuous recording of the heart rhythm and rate, and will be able to down load duration of AF episodes via a home monitoring system to establish the primary endpoint of the study.
41469527|NCT05543252|DRUG|Minzasolmin (UCB0599)|Minzasolmin (UCB0599) Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive minzasolmin (UCB0599) in a pre-specified sequence during the Treatment Period.
41469528|NCT06153160|DEVICE|HemaShock device|The HemaShock is a tight silicone ring attached to a pressure stocking. It comes wrapped into a doughnut and has a set of handles. The operator simply puts the doughnut over the foot or hand, and pulls on the handles to unravel the HemaShock while applying pressure throughout the appendage. The device displace blood from limbs to central blood system, thus improving preload and cardiac output.
40792501|NCT05255692|DIAGNOSTIC_TEST|invasive urodynamic evaluation|Invasive urodynamic evaluation to define maximum cystometric capacity. By means of catheterisation the bladder gets filled and volumes en pressures are measured.
40792502|NCT05255692|DIAGNOSTIC_TEST|functional magnetic resonance imaging during bladder filling|Functional MRI is used to capture brain activity during tasks. The task in the current study is bladder infusion and withdrawal by means of the INFSYS-2 infusion/withdrawal pump (Leitner et al. 2017)
40792503|NCT05325762|DRUG|Propofol|At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
40792504|NCT05325762|DRUG|Dexmedetomidine|Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
40792505|NCT05325762|DRUG|Saline|At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
40792506|NCT01687881|OTHER|Chiropractic|Chiropractic Spinal Manipulative Therapy
40792507|NCT01687881|OTHER|Sham Chiropractic|Sham manipulation
41149489|NCT00303017|DIETARY_SUPPLEMENT|flavocoxid|flavonoid mixture
41149490|NCT00303017|DRUG|Naproxen|non-steroidal anti-inflammatory drug
41149491|NCT04061772|DRUG|Bortezomib|Bortezomib injection
41469529|NCT03012659|BEHAVIORAL|Contraceptive Counseling Training|"Intervention sites will receive:~1. In person training: All staff at an intervention health center will participate in a one-day counseling training.~2. On-site shadowing: Trainers will shadow staff in-clinic the day following the training to observe the counseling implementation and provide additional coaching and support.~3. Technical assistance: A Planned Parenthood clinic operations expert will provide follow-up technical assistance."
41149492|NCT04061772|DRUG|Etoposide|Etoposide injection
41149493|NCT04061772|DRUG|Cyclophosphamide|Cyclophosphamide injection
41149494|NCT04061772|DRUG|Pharmorubicin|Pharmorubicin injection
40997828|NCT05796674|DEVICE|Clareon UVA IOL|Clareon UVA IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery to replace the natural crystalline lens. Models CC60WF and CCA0T0 are indicated for the visual correction of aphakia. Models CCW0T3, CCW0T4, CCW0T5, and CCW0T6 are indicated for the visual correction of aphakia and preexisting corneal astigmatism.
40997829|NCT05796674|DEVICE|WaveTec Optiwave Refractive Analysis (ORA) System|Intra-operative system used during refractive cataract surgery to capture wavefront images of the patient's eye for the purpose of optimizing IOL implantation
41469530|NCT05633238|BEHAVIORAL|Visual Search Information Type (target or distractor information)|Participants will have information about targets, distractors, or neither in different blocks of the intervention.
40997830|NCT05796674|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon UVA IOL
40997831|NCT04395937|OTHER|exercises|One hour twice a week to practice respiratory exercises, postural exercises, muscular exercises
40997832|NCT02519920|DRUG|fluorescein sodium 0.01ml/kg|fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
40997833|NCT02519920|DRUG|fluorescein sodium 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
40997834|NCT02519920|DRUG|fluorescein sodium 0.05ml/kg|fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
40997835|NCT02519920|DRUG|fluorescein sodium 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
40997836|NCT03616288|DIETARY_SUPPLEMENT|thiamine (as thiamine hydrochloride)|Opaque capsules containing varying amounts of thiamine hydrochloride and cellulose filler. All thiamine is delivered as thiamine hydrochloride, calculated using a 1.271 correction factor (ratio of molecular weights of thiamine hydrochloride and thiamine).
40997837|NCT04760158|OTHER|Exercise|Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
40997838|NCT01137942|DRUG|clarithromycin, metronidazole, proton pump inhibitor|appropriate dose of antibiotics and proton pump inhibitor
40997839|NCT04785274|DEVICE|non-invasive hemoglobin (SpHb)|hemoglobin measuring device
40997840|NCT00490516|DRUG|ACP-104|200 mg, tablet, BID, 6 weeks
40997841|NCT00490516|DRUG|ACP-104|100 mg, tablet, BID, 6 weeks
40997842|NCT00490516|DRUG|Placebo|placebo, tablet BID, 6 weeks
40997843|NCT01026051|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, Melanoma
40997844|NCT04263974|OTHER|Smartphone Application|Exercises and recommendations, based on current scientific evidence, and delivered through the app for Smartphone called CareHand. The intervention protocol is based on strengthening and stretching recommendations for rheumatoid arthritis and osteoarthritis in hands, transferred to an application format through explanatory videos together with tools to improve the autonomy, motivation and adherence of the patient
40997845|NCT04263974|OTHER|Conventional treatment|Conventional approach provided by the Andalusian Public Health System in Primary Care settings. This approach consists of routine visits to the general practitioner specialist, and the delivery of an exercise sheet and recommendations. This general mobility and stretching worksheet contains detailed images, as well as a description of how to perform the exercises and the dose to be taken. While most exercises are intended for the wrist and hands, this sheet also includes basic exercises for the elbow joint.
40792508|NCT03535311|PROCEDURE|Measurement of sternal-notch to umbilicus distance|"* The sternal notch to upper border of umbilicus length measurement in centimetres.~* The length of the umbilical stump in centimetres.~* The length of the UVC and/or UAC inserted in centimetres which will be identified using the printed markers on the catheter. The marker which is closest to the end of the umbilical stump will be the recorded value.~* The length of the UVC and/or UAC in centimetres when the umbilical stump length is subtracted."
40792509|NCT05393999|BIOLOGICAL|BMS-986414|Broadly neutralising antibodies BMS-986414
40997846|NCT03444974|OTHER|adapted treatment according to the MATRIX-A therapy|cognitive and behavioral treatment of drug abuse/dependency issues, as well as connected parameters
40997847|NCT02018289|PROCEDURE|Triclosan coated suture|Suture of the abdominal wall with triclosan coated suture
40997848|NCT02018289|PROCEDURE|No triclosan|Suture of the abdominal wall with suture without triclosan coat
40997849|NCT03998553|PROCEDURE|IN VITRO MATURATION AND OOCYTE ACTIVATION|This study aims to fine-tune the in vitro maturation (IVM) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase II stage. In addition, an artificial oocyte activation (AOA) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos.
40997850|NCT05495581|DRUG|pudexacianinium chloride|Intravenous
40997851|NCT05255770|DEVICE|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
40997852|NCT05255770|DEVICE|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
41149495|NCT04061772|DRUG|Prednisone|Prednisone tablet
41149496|NCT05824078|PROCEDURE|Arthroscopic surgery|Arthroscopic approach involves smaller incision, offering less traumatic procedures and faster healing, but due to the limited space in this closed field with significant vasculature and nerve distribution, scoping has increased risk for iatrogenic injuries.
41469531|NCT04881734|OTHER|Overtime pancreaticoduodenectomy|Compared with daytime surgery, the intervention in this study is to work overtime after 17:00 to perform pancreaticoduodenectomy.
41469532|NCT00095862|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|
41469533|NCT00095862|BIOLOGICAL|recombinant interferon alfa|
41469534|NCT00095862|DRUG|cyclophosphamide|
40997853|NCT05255770|DEVICE|Control NRL condom|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
40997854|NCT05067296|OTHER|By TVS|Uses of TVS to diagnosis of Cesarean section niche in patients with abnormal uterine bleeding
40997855|NCT01820416|RADIATION|Low-level Laser Therapy|Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
40997856|NCT01820416|OTHER|Placebo Comparator: Disabled Laser|Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
40997857|NCT05421689|BIOLOGICAL|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|The study will treat 62 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.
40997858|NCT05421689|OTHER|Placebo|two doses of placebo will be administered and spaced 4-6 weeks apart.
40997859|NCT05638373|OTHER|One shade universal composite|A resin composite with new smart chromatic technology and chameleon effect. It has the ability to match the new lighter shade of the bleached teeth unlike the conventional composite
40997860|NCT05638373|OTHER|Nanohybrid resin composite|A conventional resin composite with multiple shades
40997861|NCT00066066|PROCEDURE|Scaling and root planing|Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.
40997862|NCT00066066|DRUG|Metronidazole|Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
40997863|NCT00066066|DRUG|Amoxicillin|Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
40997864|NCT00066066|DRUG|Doxycycline|The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
40997865|NCT04437966|BEHAVIORAL|Enhanced Chronic Disease Self-management program|CDSMP workshops will last for approximately 2.5 hours and occur weekly for six weeks. Sessions will focus on appropriate diet for persons with hypertension and to facilitate weight loss; managing medications, adherence to medical clinic appointments; physical activity and stress management. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management program. Participants will also be given pill boxes and will be prompted by social media messages to make and keep clinic appointments as well as maintain a healthy lifestyle.
40997866|NCT06112665|DRUG|Tofacitinib 5 MG|Patients receive Tofacitinib and Naproxene
40997867|NCT03257631|DRUG|Pomalidomide|: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
40997868|NCT03257631|DRUG|Pomalidomide|Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
40997869|NCT00107211|BIOLOGICAL|therapeutic autologous dendritic cells|
41310260|NCT06146296|BIOLOGICAL|Local Vitamin C injection|An injection of 1-1.5 ml of L-ascorbic acid, locally introduced in relation to the keratinized gingival tissues, with extension to the whole target region successively. The injected area will be massaged for equal distribution of the injected vitamin. Injections will be performed on the first day of retainer delivery (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3). Hence, a total of 4 local Vit-C injections will be performed over the study period.
40997870|NCT00107211|PROCEDURE|conventional surgery|
40997871|NCT00107211|PROCEDURE|neoadjuvant therapy|
40997872|NCT02363465|OTHER|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
40997873|NCT03247166|DEVICE|TOPS™ System|The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
41149497|NCT05824078|PROCEDURE|Open Surgery|The open approach requires dissection of capsuloligamentous structures, which can lead to stiffness of the joint due to capsular scarring as it heals. However, it offers good visual field when treating the injury, allowing maneuverability to avoid iatrogenic soft tissue injuries.
40792510|NCT05393999|BIOLOGICAL|BMS-986413|Broadly neutralising antibodies BMS-986413
41149498|NCT00399945|DRUG|Tobramycin|
41149499|NCT01721759|DRUG|Nivolumab|
41310261|NCT06146296|BIOLOGICAL|Oral Vitamin C supplement|Patients will be prescribed a daily oral (systemic) Vit-C supplement to be taken over the follow up period.
41310262|NCT05728671|DRUG|IP2015|Test drug
40997874|NCT06332716|OTHER|Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time.|Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time. The sending doctor can choose from the following relevant treatment drugs and confirm with the responsible researcher for drug sensitivity testing.
40997875|NCT00718328|DRUG|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
40997876|NCT00718328|DRUG|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
40997877|NCT03072966|DEVICE|Wearable device (Fitbit Charge HR® or Fitbit Alta ®)|Physical activities will be monitored by wearable device.
40997878|NCT02531321|DRUG|Levonorgestrel and Ethinyl Estradiol|All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
40997879|NCT03987893|DRUG|PEG-3350 with Electolytes|experimental arm will receive 2 doses of PEG3350 spaced over 12 hours after randomization to arm1. PEG as dose of 2litres (1 sachet dissolved in 2L of water) will be administered via a nasogastric tube.
40997880|NCT03987893|DRUG|Lactulose|Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day
40997881|NCT02174458|PROCEDURE|Body Contouring Surgery|Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
40997882|NCT01919658|PROCEDURE|nerve block|A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
40997883|NCT04685304|GENETIC|Pharmacogenetic Testing|Genetic results will be reported for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4, CYP3A5, SLCO1B1, TPMT, and VKORC1.
40997884|NCT04685304|OTHER|Pharmacist Consultation Note|Recommendations will be based on phenotypes translated from genetic data in accordance with CPIC guidelines. Drug interactions will be incorporated into phenotype assignments when appropriate.
40997885|NCT04685304|OTHER|Delayed pharmacogenetic testing|Pharmacogenetic testing and a pharmacist consultation note will be provided to participants provided to the standard care arm once 3 months have passed since their baseline visit.
40997886|NCT06252220|DRUG|DA-1726|Active
40997887|NCT06252220|DRUG|Placebo to DA-1726|Placebo
40997888|NCT04702490|DRUG|MET409 Active|MET409 Active (50mg)
40997889|NCT04702490|DRUG|MET409 Placebo|MET409 Placebo (50mg)
40997890|NCT04702490|DRUG|Empagliflozin|Empagliflozin (10mg)
40997891|NCT01869192|DRUG|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
40997892|NCT01869192|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
40997893|NCT01869192|DRUG|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
41310263|NCT04597034|PROCEDURE|AN69-Oxiris|To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy.
41310264|NCT04597034|PROCEDURE|AN69-Standard|Standard treatment.
40997894|NCT01869192|DRUG|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
40997895|NCT01869192|RADIATION|Radiation Therapy|Standard dosing, fields depending on clinical findings
40997896|NCT00607282|DRUG|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
40997897|NCT03583424|DRUG|Carmustine|Given IV
40997898|NCT03583424|DRUG|Cytarabine|Given IV
40997899|NCT03583424|DRUG|Etoposide|Given IV
40997900|NCT03583424|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
40997901|NCT03583424|DRUG|Melphalan|Given IV
40997902|NCT03583424|DRUG|Venetoclax|Given PO
40997903|NCT00891137|BIOLOGICAL|human myeloid progenitor cells|Single intravenous injection/infusion
41310265|NCT00003539|BIOLOGICAL|trastuzumab|
41310266|NCT00003539|DRUG|paclitaxel|
40997904|NCT05844852|DEVICE|P200TE|The P200TE provides OCT imaging including retinatopography and ONH (optic nerve head) scans.
40997905|NCT00005669|DRUG|Metformin HCL|Medication studied for ability to alter body weight and body composition.
40997906|NCT00005669|DRUG|Placebo|Control capsules for metformin
40997907|NCT05001165|OTHER|Proactive Panel Management Clinics for HFrEF|Novel clinic based on review of panel HFrEF data and impromptu telephone or video patient contacts/visits.
41310267|NCT04258059|DEVICE|Active household UV water treatment device|This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.
41310268|NCT04258059|DEVICE|Inactive household UV water treatment device|This sham device will use a lamp not emitting germicidal UV.
41310269|NCT03689504|DIETARY_SUPPLEMENT|Standard of care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
41310270|NCT03689504|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
40997908|NCT02290821|DRUG|placebo|
40997909|NCT02290821|DRUG|Placebos|
40997910|NCT03489395|DRUG|Edoxaban|Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.
40997911|NCT04489706|DRUG|Arsenic trioxide for injection|Arsenic trioxide for injection, 0.16 mg/kg (maximum single dose is 10 mg), daily IV drip, d1 to d14, once every 28 days, for six cycles of treatment or until one of the following events occurs: Initiation of new anti-tumor therapy, disease progression, withdrawal of Informed consent form (ICF) and/or death.
41310271|NCT03689504|BEHAVIORAL|Home-based family gardening|Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
41149500|NCT03799965|OTHER|ERAS (Enhanced Recovery After Surgery ) are evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
41310272|NCT06335368|OTHER|Nutrition and Growth Status|Nutrition and Growth Status
40792511|NCT05715138|PROCEDURE|GPi-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into the posteroventral part of bilateral GPi nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
40792512|NCT05715138|PROCEDURE|STN-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
40792513|NCT05715138|DEVICE|GPi-DBS devices|"1. DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
40792514|NCT05715138|DEVICE|STN-DBS devices|"1. DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
40792515|NCT00227084|DRUG|Arista AH hemostasis powder|
40792516|NCT02655757|DRUG|Sitagliptin|5 mg, 1 tablet per day for 12 months
40792517|NCT02655757|DRUG|Placebo|Placebo,1 tablet per day for 12 months
40792518|NCT00038090|DRUG|Thalidomide|100 mg capsules by mouth daily each evening
41310273|NCT04777643|DRUG|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
41310274|NCT04777643|OTHER|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
40792519|NCT00038090|DRUG|Dexamethasone|20 mg/m\^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
41149501|NCT03799965|OTHER|ERAS are not evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will not be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
41149502|NCT06179719|DRUG|Propofol|Anesthesia will be induced intravenously using the hypnotic drug propofol. The drug is used regularly in everyday clinical practice to carry out general anesthesia, and the intended concentrations are within the usual clinical dosage range. Propofol will be applied via target-controlled infusion (TCI) with a perfusor using TCI set to effect mode as described by Schnider (Schnider et al., 2016). Starting at low concentrations, the effect site concentration will be increased stepwise to achieve the target level of sedation as measured by the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale. We aim for three different levels of sedation: low (MOAA/S=5-4), mid (MOAA/S=3-2) and high (MOAA/S=1).
41149503|NCT06179719|BEHAVIORAL|visual flickering stimulation at the alpha frequency|Participants will receive visual stimulation as a flickering light during the different sedation levels, including wakefulness pre- and post-anesthesia. Stimulation will be done with eyes closed in all conditions.
41149504|NCT04928196|OTHER|Microperimtery and optical coherence tomography angiography OCTA|observational: Investigations are done to assess the retinal microvasculature and function before and after silicone oil removal
41310275|NCT04710524|DRUG|Placebo|Placebo BID for 13 weeks
41310276|NCT04710524|DRUG|FM101 150 mg BID|FM101 (150 mg) BID for 13 weeks
41149505|NCT03514745|DEVICE|GlideScope|Endobronchial intubation is performed using the GlideScope.
40792520|NCT00819156|DRUG|degarelix|Degarelix was given as subcutaneous injections.
40792521|NCT03069040|PROCEDURE|nerve sparing radical hysterectomy|Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
41149506|NCT03514745|DEVICE|Lighted stylet|Endobronchial intubation is performed using a lighted stylet.
41310277|NCT04710524|DRUG|FM101 300 mg BID|FM101 (300 mg) BID for 13 weeks
41310278|NCT06115434|PROCEDURE|cystectomy|cystectomy either radical or salvage involves removal of urinary bladder together with prostate, seminal vesicles and urethra with lymph node dissection.
41310279|NCT04065087|BIOLOGICAL|GX-I7|Investigational drug
41310280|NCT04065087|OTHER|Placebo|Placebo drug
41310281|NCT00906074|PROCEDURE|Elective or emergency abdominal surgery|Clinical record review.
41310282|NCT00906074|PROCEDURE|Elective or emergency abdominal surgery|Clinical record review
41310283|NCT04128579|DRUG|Itolizumab [Bmab 600]|EQ001
41310284|NCT03371160|DEVICE|Nutriplace™ System|The Nutriseal™ Nutriplace™ System is an electromagnetic tracking system for feeding tube placement designed to aid qualified operators in the placement of the Nutriseal™ Enteral Feeding Tube™ into the stomach or small intestine.
41310285|NCT04027569|OTHER|Patient Specific Functional Scale|A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.
41310286|NCT04027569|OTHER|PROMIS PF|A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
41310287|NCT03021434|OTHER|Community and household water safety education sessions|Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.
40792522|NCT03069040|PROCEDURE|radical hysterectomy|In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
41149507|NCT02007421|PROCEDURE|Participants asked questions about recent experiences of anal intercourse in the last six months.|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
41310288|NCT03021434|OTHER|Household-specific water quality information|Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.
41310289|NCT03021434|OTHER|Low-cost microbiological water test kits|Intervention component consists of low-cost, biodegradable that tests for the presence of E. coli in water samples. The test uses Aquatest broth medium with resorufin methyl ester chromogen. Presence of E. coli (positive test) imparts bright red color, making it easy to use/interpret at the household level with minimal training
41310290|NCT01012193|DRUG|cilostazol 100mg bid or clopidogrel 150-mg daily|Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
41310291|NCT02696915|DRUG|Placebo|Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
41310292|NCT02696915|DRUG|Bupivacaine|Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml
40792523|NCT06305585|OTHER|Primal Reflex Release Technique (PRRT)|Primal Reflex Release Technique (PRRT) is a non-invasive complementary hands-on treatment method intended to help relax the central nervous system by gently stimulating innate protective reflexes. A certified practitioner applies light tactile stimulation to targeted areas in a structured sequence postulated to help release hypertonic muscles, restore regulation of automatic responses, and enable a calm, parasympathetic state.
40997912|NCT05742451|OTHER|kids yoga|"The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.~Kids yoga training included: 5-minute warm-up consisting of jogging, jumping, stretching, relaxation exercises; 20 minutes of asanas (positions) consisting of standing, sitting, prone, supine postures and pranayamas (breathing exercises) consisting of vigorous inspiration and expiration, slow and rhythmic alternating nostril breathing; 10-minute yogic games about balance, reaction time and agility; meditation with focus for 5 minutes with resuscitation techniques."
40997913|NCT03054662|OTHER|Education|Education of patients and caregivers about haemophilia and carriers of haemophilia.
40997914|NCT03054662|DIAGNOSTIC_TEST|Improve biological diagnosis and follow-up of haemophilia|train the laboratory to the diagnosis ans follow-up un haemophilia
40997915|NCT03054662|DRUG|Implement haemostatic non substitutive care of haemophilia|Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers
40997916|NCT03054662|OTHER|Implement non haemostatic care of haemophilia|Implement regular physiotherapy, develop dental care, promote the regular use of pain killers
40997917|NCT00189228|DRUG|Xolair|Patients are administered Xolair
40997918|NCT03061110|BIOLOGICAL|Stromal Vascular Fraction|Stromal Vascular Fraction will be produced from the subject's own adipose tissue by the Tissue Genesis Icellator device.
40997919|NCT03061110|OTHER|Usual Care|Usual care will include over-the-counter and prescription methods to treat xerostomia.
40997920|NCT04106310|DEVICE|High-flux dialyzer|a dialyzer meeting the definition of high-flux
40997921|NCT04106310|DEVICE|Theranova dialyzer|a middle cut-off dialyzer
40997922|NCT05107258|DIAGNOSTIC_TEST|The Pine Trees Health Test System|Consists of the Pine Trees Health Reader and the Pine Trees Health COVID-19 Test Kit, which contains the Pine Trees Health Cartridge, Pine Trees Health Sample Vial containing Sample Lysis Buffer and the Pine Trees Health Nasal Swab (anterior nares) for collection. The Test System is a point-of-care test used for the qualitative detection of nucleic acid from SARS-CoV-2 viral RNA in nasal swabs taken from individuals who are suspected by a healthcare professional of having COVID-19. The COVID-19 test is a rapid molecular, in vitro diagnostic test using isothermal nucleic acid amplification technology and detection of the resulting amplicon using CRISPR-mediated collateral reporter unlocking.
40997923|NCT02871388|BEHAVIORAL|CONECT|1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
40997924|NCT03782428|DIETARY_SUPPLEMENT|Probiotic|30 billions colony-forming unit (CFU) of a mixture of six viable strains including 107 mg of Lactobacillus acidophilus BCMC® 12130, Lactobacillus lactis BCMC® 12451, Lactobacillus casei subsp BCMC® 12313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis BCMC® 02129
40997925|NCT03782428|OTHER|Placebo|Placebo samples produced were identical to the probiotics in term of taste and texture without live microorganisms.
40997926|NCT01752855|BIOLOGICAL|New formulation adalimumab|New formulation adalimumab 40 mg every other week
40997927|NCT00816075|DRUG|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
41310293|NCT02696915|DEVICE|Ultrasound guided fascia iliaca compartment block|Ultrasound guided fascia iliaca compartment block
41310294|NCT02696915|DRUG|Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)|Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
41310295|NCT05566652|DEVICE|Neural Pressure Support|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
40792524|NCT03749824|DIETARY_SUPPLEMENT|Omega-3|Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
40997928|NCT04384510|PROCEDURE|Planned Cesarean hysterectomy|This procedure refers to planned delivery of the fetus through Cesarean incision, leaving the placenta in situ and proceeding with hysterectomy
40997929|NCT04384510|PROCEDURE|Conservative management|This term describes a single or combined intervention of uterine artery ligation, internal iliac artery ligation, prophylactic balloon placement in the aorta or internal iliac artery, uterine artery embolization, compression sutures, or excision and reconstruction of uterine wall
40997930|NCT06452940|OTHER|Exercise|A 16-week clinical pilates exercise program will be applied 3 days a week for 60 minutes each session. It will consist of a warm-up, main exercise and a cool-down period.Exercises will start with 10 repetitions and will be gradually increased in 3-week periods.
40997931|NCT04026477|BEHAVIORAL|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop
40997932|NCT04026477|BEHAVIORAL|Waitlisted Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop following waitlist period
40997933|NCT02780804|DRUG|Entinostat|Given PO
40997934|NCT02780804|OTHER|Laboratory Biomarker Analysis|Correlative studies
40997935|NCT02780804|OTHER|Pharmacological Study|Correlative studies
40997936|NCT04366167|OTHER|Cardiac surgery|Cardiac surgery during the COVID-19 pandemic
40997937|NCT03006913|BEHAVIORAL|In-person|At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.
41149508|NCT02007421|PROCEDURE|High Resolution Anoscopy|The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
41149509|NCT05180526|DRUG|QLETLI|80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
41149510|NCT03778957|DRUG|Durvalumab|Durvalumab IV (intravenous)
41149511|NCT03778957|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
41310296|NCT05566652|DRUG|Pressure Support Ventilation|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
40997938|NCT03006913|BEHAVIORAL|By phone|Patients in the phone arm will receive a scheduled call at their home.
40997939|NCT03006913|BEHAVIORAL|By video|Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
41149512|NCT03778957|OTHER|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)
41149513|NCT03778957|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
41310297|NCT02972034|DRUG|MK-8353|PO capsule
41310298|NCT02972034|BIOLOGICAL|Pembrolizumab|IV infusion
41310299|NCT06260644|PROCEDURE|VertiseTM flowable composite (Kerr,USA)|self adhesive flowable resin composite restoration.
41310300|NCT02953392|DEVICE|Anorganic Bovine Bone Graft Material|Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
41310301|NCT02953392|DEVICE|Collagen Membrane|Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
41310302|NCT02953392|DEVICE|Shelta Platform Switching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
41310303|NCT02953392|DEVICE|Shelta Platform Matching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
41310304|NCT03180359|BIOLOGICAL|Recommended vaccine scheme according to French Vaccine Schedule 2015|"* BCG~* Measles mumps rubella (MMR)~* Varicella (chicken pox)~* Rotavirus~* Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~* Yellow Fever~* Diphteria tetanus poliomyelitis whopping cough (DTwP)~* Haemophilus influenzae type b~* Hepatitis B~* Meningococcus conjugate~* Pneumococcus~* Human papillomavirus~* Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children"
41310305|NCT00216099|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
41310306|NCT00216099|DIETARY_SUPPLEMENT|Folic Acid|All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.
41310307|NCT00216099|DIETARY_SUPPLEMENT|Vitamin B12|All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
41310308|NCT04580394|DRUG|AD109|Oral administration before bed
41310309|NCT04580394|DRUG|Atomoxetine|Oral administration before bed
41310310|NCT04580394|DRUG|R-oxybutynin|Oral administration before bed
41310311|NCT04580394|DRUG|Placebo|Oral administration before bed
41149514|NCT03341312|BIOLOGICAL|LY900014|Administered SC
41149515|NCT03341312|BIOLOGICAL|Insulin Lispro|Administered SC
40997940|NCT03569228|DEVICE|Study 1 - ITE hearing aids|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
40997941|NCT03569228|DEVICE|Study 1 - BTE hearing aids|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
40792525|NCT03749824|DIETARY_SUPPLEMENT|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
40997942|NCT03569228|DEVICE|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
40997943|NCT03569228|DEVICE|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
40997944|NCT03569228|DEVICE|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
40997945|NCT03569228|DEVICE|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
40997946|NCT06338592|BEHAVIORAL|MyLungHealth|MyLungHealth is a patient-centered, EHR-integrated smoking data-quality improvement and education intervention. A key component of the MyLungHealth intervention is a pre-visit LCS eligibility questionnaire asked through the Epic EHR patient portal for individuals with unclear LCS eligibility due to missing or potentially inaccurate data in the EHR. Another key component of the MyLungHealth intervention is an interoperable, patient-centered educational app delivered through the EHR patient portal.
40997947|NCT06338592|BEHAVIORAL|DecisionPrecision+|DecisionPrecision+ is a multi-faceted intervention which includes provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders.
40997948|NCT01810029|BEHAVIORAL|Cardiac Rehabilitation plus Transcendental Meditation|The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
40997949|NCT04414709|OTHER|Double short implant|Patients receives 2 short implants to restore missing posterior teeth, loaded with splinted screw retained crowns.
40997950|NCT04414709|OTHER|Single short implant|Patients receives single short implants, loaded with single screw retained crowns.
40997951|NCT03146988|DRUG|RGB-02 or Neulasta® (pegfilgrastim)|Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
40997952|NCT03214627|DEVICE|Anemia Control Model (ACM)|The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.
41149516|NCT04306445|DEVICE|GF-IGB: Obalon Balloon|The balloon, which is attached to a thin catheter, is swallowed by the patient in a standing position. Once the two-step verification of balloon passage into the stomach by both fluoroscopy and pressure reading, the balloon is inflated to a volume of 250 ml with a nitrogen-mix gas, additional imaging of the inflated balloon is obtained, the catheter is ejected from the balloon, and the catheter is pulled out through the patient's mouth. The process is repeated at week 2 for the second balloon and between weeks 4-8 for the third balloon. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. The balloons are removed endoscopically 6 months after placement of the first balloon. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
40792526|NCT00828958|DRUG|Risperidone long-acting injectable|
40997953|NCT03214627|DRUG|IV iron|IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
41149517|NCT04306445|DIETARY_SUPPLEMENT|Medically Supervised Meal Replacement Program: My New Weigh|Patients are given an individualized calorie prescription by a registered dietitian for a goal of 2 pounds weight loss per week. Patients are seen in a group-based program once a week focused on long-term behavior change and use meal replacements for a nutritionally balanced very low-calorie diet for 20 weeks. 4-5 meal replacements are consumed per day. If only 4 meal replacements are consumed, individuals eat 3 servings of vegetables and 2 servings of fruit per day as well.
41310312|NCT04580394|DIAGNOSTIC_TEST|Digit System Substitution Test|a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.
40792527|NCT04792034|DRUG|Cocaine Hydrochloride Topical Solution|Topical Anesthetic
40997954|NCT03214627|DRUG|Erythropoiesis-Stimulating Agent (ESA)|ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
40997955|NCT01153412|OTHER|Osteopathic Manipulative Treatment|Osteopathic manipulation to determine balance and stability in elderly
40997956|NCT01422499|DRUG|zolinza/vorinostat|orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
40997957|NCT00164346|BEHAVIORAL|neurocognitive habilitation|
40997958|NCT04813770|BEHAVIORAL|Theory-based messages|COVID-19 vaccination information structured to address vaccination necessity and concerns.
40997959|NCT04813770|BEHAVIORAL|General messages|General messages about the COVID-19 virus and the vaccination programme.
41149518|NCT04306445|PROCEDURE|Endoscopic sleeve gastroplasty: (ESG)|Endoscopic sleeve gastroplasty is a weight loss procedure that uses an FDA 510K cleared endoscopic suturing device known as Overstitch to reduce the size of the gastric body. The procedure is completed with an endoscope. It is inserted through the mouth, down the esophagus, and into the stomach. Sutures with 8-10 bites 1.5-2 cm apart in a U-shape pattern are placed starting distally 6 cm proximal to the pylorus. Additional sutures are placed moving proximally up to 2 cm distal to the gastroesophageal junction. An additional row of sutures is then placed again in the distal to proximal stomach to complete the gastroplasty. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
40997960|NCT04849156|OTHER|Sperm selection by thermotaxis|Selection of healthy sperm by thermotaxis procedure
41310313|NCT03338751|DIAGNOSTIC_TEST|cognitive testing with HAD (PockeTalker) First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
41310314|NCT03338751|DIAGNOSTIC_TEST|Cognitive testing without HAD First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
41310315|NCT04032171|DRUG|Evobrutinib|Participants received evobrutinib twice daily (BID).
41310316|NCT04032171|DRUG|Avonex®|Participants received avonex® IM injection once a week.
41310317|NCT04032171|DRUG|Avonex® matched Placebo|Participants received IM injection of placebo matched to avonex® once a week.
41310318|NCT04032171|DRUG|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
41310319|NCT00914836|DRUG|Betamethasone Sodium Phosphate|1cc:2cc
41310320|NCT00914836|DRUG|1 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
41310321|NCT00914836|DRUG|2 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
41310322|NCT02952326|PROCEDURE|XP Endo Finsher as final step of the irrigation protocol|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
40997961|NCT02750891|DRUG|DSP-7888|Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
40997962|NCT00603746|DRUG|GW685698X|GW685698X
40997963|NCT00584558|PROCEDURE|Catheter Ablation|Catheter Ablation of arrhythmias
40997964|NCT00181012|DRUG|Lidocaine|
40997965|NCT03756298|DRUG|Atezolizumab|Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
41310323|NCT02952326|PROCEDURE|Conventional needle irrigation only|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
41310324|NCT05204511|OTHER|endurance training|endurance training of low to moderate intensity on a bicycle ergometer, crosstrainer or treadmill performed for 30-60 minutes per session
41310325|NCT05204511|OTHER|concurrent training|combination of endurance training of low to moderate intensity on a bicycle ergometer, crosstrainer or treadmill performed for 20-40 minutes per session and resistance training of moderate intensity performing 2-3 sets of leg press, leg curls, chest press and seated horizontal rows
41310326|NCT02822443|BEHAVIORAL|Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
40997966|NCT03756298|DRUG|Capecitabine|capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
40997967|NCT04998591|BEHAVIORAL|Fasting|fasting for 7 days (caloric intake \<500 kcal in liquid form)
40997968|NCT02410499|DRUG|MLN1202 Placebo|MLN1202 placebo-matching solution for SC injection
41310327|NCT02822443|BEHAVIORAL|Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
40997969|NCT02410499|DRUG|MLN1202|MLN1202 solution for SC injection
40997970|NCT01184274|DRUG|SB939|"Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~1. (starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~2. - 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~3. - 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing"
40997971|NCT01214707|OTHER|Exercise|Exercise during EMU stay
40997972|NCT04519931|OTHER|Stress ball|The stress ball is a toy, usually no larger than 7 cm. It is used to relieve stress and muscle tension. Stress ball is one of the cognitive and behavioral therapy methods used in pain control. Stress ball is used as a method of diverting attention during painful procedures. It appears to reduce pain and anxiety.
40997973|NCT01523548|DRUG|Carbon Monoxide|150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
41149519|NCT04376255|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
41149520|NCT05318716|DEVICE|Fat grafting - Revolve device|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
41310328|NCT05958095|DEVICE|MamaLift Plus|MamaLift Plus is a digital therapeutic designed to augment usual care and support the treatment of mild-to-moderate postpartum depression (PPD). This mobile-based intervention is grounded on principles of Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) and includes key content areas for the treatment management of PPD. It also includes recent developments in acceptance and commitment-based therapies, specifically for the perinatal context.
40997974|NCT04157595|OTHER|Reproductive Genetic Carrier Screening|Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition
40997975|NCT02420028|DEVICE|Insertion of OptiVein IV catheter|Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
41310329|NCT05958095|DEVICE|Digital Sham App|The digital sham app delivers content, tips, and suggestion for general wellbeing support.
40997976|NCT02420028|DEVICE|Insertion of Vasofix Certo IV catheter|Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
40997977|NCT02869490|OTHER|Data collection|
41310330|NCT05066828|OTHER|two pieces obturator|patient received two pieces obturator connecting by magnet attachment
40997978|NCT04817826|DRUG|Durvalumab|durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
40997979|NCT04817826|DRUG|Tremelimumab|tremelimumab 300 mg single administration (day 1)
40997980|NCT00504686|OTHER|manual therapy|manual therapy - thoracic spine thrust manipulation
40997981|NCT00504686|OTHER|exercise|therapeutic exercise
40997982|NCT02134132|BIOLOGICAL|Platelet Gel|Application of platelet gel in patients suffering from diabetic foot ulcers.
40997983|NCT02134132|OTHER|Placebo|The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
40997984|NCT04413084|OTHER|Gaze stability exercises|Business card will be placed at eye level. Begin with simpler exercises and progress toward harder one.
40997985|NCT04413084|OTHER|Brandt-Daroff Exercises|"Brandt-Daroff Exercises~1. Start sitting upright on the edge of the bed.~2. Turn your head 45 degrees to the left, or as far as is comfortable.~3. Lie down on your right side.~4. Remain in this position for 30 seconds or until any dizziness has subsided.~5. Sit up and turn head back to center.~6. Turn your head 45 degrees to the right, or as far as is comfortable.~7. Lie down on your left side.~8. Remain in this position for 30 seconds or until any dizziness has subsided.~9. Sit up and turn head back to center."
40997986|NCT02857478|DRUG|BAY 987519, SPF 50, Y51-002|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
40997987|NCT02857478|DRUG|BAY 987519, SPF 50, P04-147|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
40997988|NCT01981447|DRUG|IV Lacosamide|Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
40997989|NCT02196285|BIOLOGICAL|Double viral (MR) vaccine|Measles and Rubella vaccine, as single arm
40997990|NCT02818777|DRUG|cannabidiol|"Purified CBD, is a strawberry flavored liquid, in sesame oil, provided as 100 mg/ml, extracted from high CBD plant material.~A component of cannabis that has evidence suggesting it is relatively safe and perhaps neuroprotective, reduces tremor, anxiety and psychosis and is well tolerated in PD. Besides limiting the psychoactive effect of THC, studies support that CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties."
40997991|NCT05008991|DEVICE|Spirometry|Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity \[TLC\]) to maximal expiration (residual volume \[RV\]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.
40997992|NCT05742880|DIAGNOSTIC_TEST|6 Minute Walking Test|6 Minute walking test
40997993|NCT05742880|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analyisis
41149521|NCT05318716|DEVICE|Fat grafting - Decantation|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
41469535|NCT05659992|DRUG|azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte|"1. azacytidine (75 mg/m2/day, days 1 to 7).~2. cytarabine (75 mg/m2 bid, days 1 to 5).~3. aclamycin (10 mg/m2/day, day1,3,5).~4. Chidamide (30 mg/day , days 0,3).~5. venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~6. granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)"
41469536|NCT03516487|DRUG|SYNB1618|SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
41149522|NCT00324571|DRUG|Sevelamer hydrochloride|
41149523|NCT00324571|DRUG|Calcium-based phosphate binder|
41310331|NCT00538824|DRUG|dexamethasone|"Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)"
40997994|NCT05742880|PROCEDURE|Wearing a Surgical Facemask|Wearing a Surgical Facemask
40997995|NCT05742880|PROCEDURE|Wearing a FFP2- Facemask|Wearing a FFP2- Facemask
40997996|NCT05742880|PROCEDURE|Wearing no Mask|Wearing no Mask
40997997|NCT06011239|BEHAVIORAL|Team-building processes|"All staff in one of the four role groups (medical assistants (MAs); clerical/administrative staff; nursing staff; and physicians/nurse practitioners/physician assistants) will be sent an anonymous survey. The survey will ask staff to consider what help participants wish to ask for and what help participants can offer to staff in the other three roles at times when people are busy or overwhelmed. These ideas will be combined into a typed idea list for each role and then staff in clinics will discuss. Once these are finalized the clinics will implement these.~At several points during the year, the study team will send out brief surveys. These surveys will collect the clinic and job role and ask participant to rate how much effort has been made in different ways, and if there are open-ended comments about what is or is not working. This information will be used to improve the intervention at each clinic."
40997998|NCT00045747|DRUG|7-hydroxystaurosporine|
40997999|NCT00045747|DRUG|fluorouracil|
41310332|NCT00538824|DRUG|thalidomide|"Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy."
41310333|NCT00538824|DRUG|lenalidomide|"Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of \< 40cc/min\*"
41310334|NCT03195062|OTHER|Test meal|Liquid test meal (fructose+glucose)
41310335|NCT03909191|DIAGNOSTIC_TEST|serum HBV RNA|serum HBV RNA level was determined by using HBV-SAT kit at different time point
41469537|NCT03516487|DRUG|Placebo|Subjects receive placebo orally in a chilled buffered solution (100 mL).
41469538|NCT04944472|BEHAVIORAL|HDKQ questionnaire|Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram
41469539|NCT04900909|DEVICE|Aortic Valve Replacement|Surgical replacement of aortic valves
40998000|NCT05096507|PROCEDURE|Hip fracture Surgery (Primary)|Surgery for primary hip fracture requiring general or neuro-axial anaesthesia
40998001|NCT00311896|DRUG|Bemiparin|
40998002|NCT00311896|DRUG|Placebo|
40998003|NCT00880529|DEVICE|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
40998004|NCT00880529|DRUG|IV opioid administration|Patient controlled analgesia with IV narcotics
40998005|NCT01672476|DRUG|Placebo|Placebo
40998006|NCT01672476|DRUG|Valsartan|Valsartan 80mg
40998007|NCT01672476|DRUG|Fimasartan|Fimasartan 30mg
40998008|NCT02469116|DRUG|Docetaxel|
40998009|NCT02469116|DRUG|Carboplatin|
40998010|NCT02469116|DRUG|Pegylated G-CSF|
40998011|NCT00679185|BEHAVIORAL|expressive writing|four non-emotional writing assignments
40998012|NCT03057028|DRUG|Anakinra|
40998013|NCT00748475|BEHAVIORAL|Neurofeedback|
40998014|NCT03422120|OTHER|Natural Killer Cell Activity Assay|Subjects had a blood test to measure NK cell activity (NKA) at different time points
41149524|NCT06018233|OTHER|New proposal for regime creation|Interviews and building of proposals in the light of the information obtained and desk based research
41149525|NCT05414435|BEHAVIORAL|Reading of informed consent form|Patients that adequately read informed consent forms
41149526|NCT02516202|DRUG|Vagifem|One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
41149527|NCT02516202|DEVICE|Replens|2.5 gm to be applied vaginally every 3 days over 12 weeks.
41149528|NCT02516202|OTHER|Placebo tablet|Dispensed in visually identical bottle and tablet form to Vagifem.
41149529|NCT02516202|OTHER|Placebo gel|Dispensed in visually identical tube and gel form to Replens.
41149530|NCT01118429|DRUG|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
41149531|NCT01118429|DRUG|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
41310336|NCT05286073|PROCEDURE|Endodontic Root Canal Treatment|Root canal shaping procedures were performed. Irrigation was done after each three pecks of endodontic file. After instrumentation (Groups 1-3), the canals were dried with sterile paper points. The dentinal walls were then coated with Sealapex. For vertical root fracture resistance testing, sample preparation was done in acrylic blocks. Then roots were coated with polyvinylsiloxane impression material. After that roots were inserted again into acrylic resin blocks. The acrylic blocks with the vertically aligned roots were mounted in the Instron testing machine. 0.5 mm diameter round tip stainless-steel rod was fixed to the universal testing machine. The universal testing machine was adjusted and vertical compressive force was applied at a crosshead speed of 1mm/min. The Instron tester applied a slowly increasing force, until the root fractured. The maximum amount of force necessary to fracture every sample was recorded in Newton (N).
41310337|NCT00004986|DRUG|Nitazoxanide|
41310338|NCT05019040|DRUG|PA1010|TDF as control
41310339|NCT01592669|PROCEDURE|passive leg raising|bilateral PLR was achieved by raising the legs of patient
41310340|NCT06187987|DEVICE|Mechanical thrombectomy|Aspirational mechanical thrombectomy
41310341|NCT06187987|DRUG|Intravenous thrombolysis|Intravenous thrombolysis with tissue-type plasminogen activator (tPA)
41310342|NCT02074306|DEVICE|UROSHIELD®|An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
41310343|NCT02074306|DEVICE|SHAM UROSHIELD®|SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
41310344|NCT06552507|PROCEDURE|Duroplasty|The investigators open the dura from midline and repaired with fish mouth for dura augmentation
41310345|NCT05155475|PROCEDURE|Ultrasound endoscopy|After identification of the lesion, the common bile duct will be identified and followed by the point of dilation due to the compression of the known lesion up to the hilum of the liver
41310346|NCT03802838|DEVICE|acupuncture|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks. These patients were combined with acupuncture. Acupuncture points include:'Yintang', 'Shenting', 'Taiyang', 'Jingming', 'Zanzhu', 'Yuyao', 'Jiaosun', 'Baihui', 'Fengchi', 'Anmian'.
41310347|NCT03802838|DRUG|Amisulpride|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
41310348|NCT05477342|BEHAVIORAL|Board Game|The BG group that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player) GP1- GP 2- GP 3- GP 4.
40998015|NCT05026684|OTHER|Personalized cost handout|Patients will be given a personalized cost handout to make transparent the full costs to Veterans of different types of ambulatory visits in order to optimize the value of their health care investments.
40998016|NCT04427969|BEHAVIORAL|prone position|to lay in prone position at least 12 hour in a day at ICU
40998017|NCT03974815|DEVICE|ACTIVE|"We will use 28.26cm\^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
41149532|NCT05707585|DIAGNOSTIC_TEST|Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)|Visualize and quantify the allelic expression status of imprinted genes by in situ hybridization using probes targeting the nascent RNAs
41149533|NCT04254965|OTHER|Music therapy|Treatment including instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process.
40998018|NCT03974815|DEVICE|SHAM|"We will use 28.26cm\^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
41149534|NCT04254965|DEVICE|Biosignal analysis|Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.
41149535|NCT00599599|BEHAVIORAL|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
41149536|NCT03748680|DRUG|Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy|"Six months of adjuvant combination chemotherapy with Capox (or FOLFOX) Patients will receive adjuvant chemotherapy with eight cycles of CAPOX (oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.~(Patients with an ileostomy are only eligible for FOLFOX and will be treated with 12 cycles of FOLFOX (oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every second weeks)"
41149537|NCT03748680|OTHER|Intensified Follow-up Schedule|Close monitoring with Imaging during follow-up Patients included in this trial will undergo intensified follow-up with CT-chest and abdomen every four months after surgery for the first 2 years, then every 6 months for 1 years and finally once yearly for the last 2 years up to 5 years follow-up is completed.
41149538|NCT01189994|PROCEDURE|Acupuncture|Needling of acupoints, some of them receiving electrostimulation
41149539|NCT01189994|BEHAVIORAL|Orientation|Orientation sessions focusing in fibromyalgia
41149540|NCT02160548|DRUG|Standard care|Standard management for OP poisoning
41149541|NCT02160548|DRUG|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
40998019|NCT00496847|DRUG|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
40998020|NCT00496847|DRUG|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
40998021|NCT00367952|DRUG|apricitabine|800mg apricitabine twice daily orally for 96 weeks
40998022|NCT02131402|DEVICE|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
40998023|NCT02131402|DEVICE|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
40998024|NCT02131402|DEVICE|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
40998025|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
40998026|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
40998027|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
40998028|NCT00081614|DRUG|Avastin (bevacizumab)|
40998029|NCT00081614|DRUG|Tarceva (erlotinib HCl)|
40998030|NCT03728894|DRUG|Midazolam-hydroxyzine with 100% O2|Patients received Oral Sedatives with 100% O2 ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
41149542|NCT02160548|DRUG|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
41149543|NCT01345253|DRUG|Belimumab|10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
41149544|NCT01345253|DRUG|Placebo|Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
41149545|NCT02988232|DRUG|Sogyeonghwalhyeol-tang|herbal extract
41149546|NCT02988232|DRUG|Placebo|extract powder with same appearance, odor and color as SGHH
41149547|NCT02332434|OTHER|stable isotope enrichment methodology (5,5,5-D3-L-Leucine)|
41149548|NCT05174988|PROCEDURE|Angle stitch|Surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) vaginal cuff apexes.
41149549|NCT04503629|DRUG|Anaprazole Sodium|Anaprazole Sodium 20mg
41149550|NCT04503629|DRUG|Anaprazole Sodium|Anaprazole Sodium 40mg
41149551|NCT04503629|DRUG|Rabeprazole sodium|Rabeprazole sodium 10mg
41149552|NCT06027424|OTHER||observational study, no intervention
41149553|NCT02164578|DRUG|Rivaroxaban|
41149554|NCT02164578|DRUG|Aspirin|
41149555|NCT01110551|DRUG|Placebo (SC)|Phosphate buffered saline administered subcutaneously.
40998031|NCT03728894|DRUG|Midazolam-hydroxyzine with 50% N2O/O2|Patients received Oral Sedatives with 50% nitrous ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
40998032|NCT03224702|DRUG|M6495|Subjects will receive M6495 on Day 1
40998033|NCT03224702|DRUG|Placebo|Subjects will receive placebo matched to M6495 on Day 1
41149556|NCT01110551|DRUG|Placebo (ID)|Phosphate buffered saline administered intradermally.
40998034|NCT03592147|OTHER|Guided Imagery Relaxation Tape|The meditation is approximately 7 minutes in duration.
40998035|NCT03592147|OTHER|Music Listening|Participants have the option of selecting one of the following music categories: New age, classical, and oriental. The songs were selected based on criteria established in a previous study to induce relaxation. All songs were also modified in length to be approximately 7 minutes in duration.
40998036|NCT03592147|OTHER|Relaxation Lighting|The participants were asked to select either orange or blue lighting settings using the Philips Hue lighting. The intensity of the light will be fixed to control for that measure. They were asked to sit for approximately 7 minutes in duration.
40998037|NCT03592147|OTHER|Meditation and Relaxation Light|The guided imagery meditation and relaxation lighting were combined.
40998038|NCT03592147|OTHER|Music and Relaxation Light|The music and relaxation lighting were combined.
40998039|NCT03592147|OTHER|Control/Silence|The participants were asked to relax for a duration of 7 minutes, with no explicit advice given. Lighting was adjusted to a specific intensity and colour (basic yellow light) as was used in the music and guided imagery interventions.
40998040|NCT04016545|DEVICE|Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)|Aortic aneurysm exclusion through endovascular procedure
40998041|NCT00641095|BIOLOGICAL|rituximab|concentrate for solution for infusion
40998042|NCT00641095|DRUG|Cyclophosphamide|Tablets
40998043|NCT00641095|DRUG|Fludarabine|Film coated tablet
40998044|NCT01467999|DRUG|Guanfacine|Guanfacine, 4mg given once daily
41149557|NCT01110551|BIOLOGICAL|Modified Live Tetravalent Chimeric Dengue Vaccine (SC)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered subcutaneously.
41310349|NCT05477342|BEHAVIORAL|Tobacco Cesseation Education|The TCE group were divided three group that E1 (Precontemplation) -E2 (Contemplation)-E3 (Preparation) according to the thinking stages scale.
40792528|NCT05807152|DEVICE|RenalGuard device|Patients will be given an intravenous loading dose of 40 mg of furosemide and continuous infusion of furosemide based on baseline eGFR. An additional bolus of 40 mg of furosemide will be administered and the infusion rate increased according to the same protocol of the control group (Figure 1). The venous peripheral cannula will be connected with the extracorporeal circuit of the RenalGuard System (PLC Medical Systems Inc., MA) for fluid infusion. The RenalGuard System is capable of delivering sterile replacement solution to a patient in an amount matched, or higher or lower, to the volume of urine produced by the patient. Thus, in the RenalGuard group, estimated daily targeted negative fluid balance will be utilized to define, for each patient, hourly negative fluid balance to be set in the RenalGuard system display.
40792529|NCT02645032|BIOLOGICAL|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
40792530|NCT02645032|BIOLOGICAL|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
40792531|NCT02645032|BIOLOGICAL|VAXIGRIP®|"Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~\*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort."
40792532|NCT04067089|PROCEDURE|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
40792533|NCT04067089|PROCEDURE|Surgical aortic valve replacement|Surgical aortic valve replacement
40792534|NCT01427218|OTHER|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
40792535|NCT01427218|BEHAVIORAL|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
40792536|NCT01427218|BEHAVIORAL|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
40792537|NCT01427218|OTHER|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
40998045|NCT03587935|OTHER|3D-Colonoscopy Progression Score|The score is based on a movement analysis of the colonoscope from anus until max insertion(cecum). It is scaled from 0-1000. A score of zero equals an incomplete procedure and a score of 1 is a very poor score but the cecum was reached. Increasing score represents better technical performance with a maximum score of 1000.
40998046|NCT03587935|OTHER|3D-Colonoscopy Retraction Score|The score is based on a movement analysis of the colonoscope from cecum to the anus. It is scaled from 0-1000. A score of zero equals a very poor score, Increasing score represents better technical performance with a maximum score of 1000.
40998047|NCT06297707|OTHER|aquatic high intensity resistive training|The experimental group participants will involve in aquatic high intensity resistive training sessions. The participants in the intervention group will receive 1 h of supervised lower limb aquatic resistance training three times a week for 12 weeks, for a total of 36 training sessions.
40998048|NCT06297707|OTHER|usual care|The control group will maintain usual care and will be asked to continue their usual leisure time activities. They will be offered the possibility of participating in two sessions consisting of 1 h of light stretching and relaxation during the 3-month intervention period.
40998049|NCT00386087|DRUG|Enzastaurin Hydrochloride|
40998050|NCT03576248|DEVICE|In-phase 6 Hz prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
40792538|NCT02529111|DEVICE|"Echonavigator software"|
40792539|NCT03886493|DRUG|Dupilumab|dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.
40792540|NCT04177537|DEVICE|Low Intensity Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
40792541|NCT00841412|BEHAVIORAL|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
40792542|NCT00841412|BEHAVIORAL|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
40792543|NCT00815048|DRUG|Atropine/Remifentanil|"Atropine 20mcg/kg~Remifentanil 3mcg/kg"
40998051|NCT03576248|DEVICE|Sham prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
40998052|NCT03576248|DEVICE|2 mA left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
40998053|NCT03576248|DEVICE|Sham left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
40998054|NCT00178841|DRUG|Rosiglitazone and Bexarotene|rosiglitazone added to bexarotene capsules
40998055|NCT02393885|DEVICE|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation|
40998056|NCT04535791|DRUG|Cholecalciferol|4,000 IU orally daily for 30 days
40998057|NCT02086110|DIETARY_SUPPLEMENT|Synbiotic|
40998058|NCT02086110|DIETARY_SUPPLEMENT|Prebiotic|
40998059|NCT00702403|DRUG|nilotinib|Given PO
40998060|NCT00702403|DRUG|imatinib mesylate|Given PO
40998061|NCT00702403|OTHER|pharmacological study|Correlative studies
40792544|NCT00815048|DRUG|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg"
40998062|NCT01561352|DRUG|activated recombinant human factor VII|If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
40792545|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
40998063|NCT05129072|DEVICE|kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D|kalifilcon A Daily Disposable Toric LD213001 lens
40792546|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
40792547|NCT00394329|DRUG|Albuterol sulfate|Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
40998064|NCT01188408|DRUG|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
40998065|NCT02457403|DEVICE|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
40792548|NCT01284959|DRUG|risperidone|risperidone 3mg, PO, 3 times
40998066|NCT02457403|OTHER|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
40998067|NCT00668486|DRUG|Lactic acid (Dermacid)|
41149558|NCT01110551|BIOLOGICAL|Modified Live Tetravalent Chimeric Dengue Vaccine (ID)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered intradermally.
41149559|NCT01181193|OTHER|Surgery|Craniotomy with total or partial removal of the brain tumor
40998068|NCT00422266|DRUG|Omega 3 fatty acids and plant sterol enriched drink|
40998069|NCT00422266|DIETARY_SUPPLEMENT|Omega 3 fatty acids and plant sterols|Capsules and Yoghurt based minidrink
40998070|NCT01978028|DRUG|ferric carboxymaltose|
41149560|NCT01181193|RADIATION|Radiotherapy to tumour bed and/or residual tumour|60 Gy in 30 fractions over 6 weeks
40998071|NCT01978028|DRUG|placebo|
40998072|NCT00212953|PROCEDURE|Advanced Life Support|
40998073|NCT04056195|DRUG|SKI-O-703|The SKI-O-703 capsules will contain 100 mg of drug substance.
40792549|NCT01284959|DRUG|paliperidone ER|paliperidone ER 6mg, PO,3 times
40792550|NCT01284959|DRUG|placebo|lactose PO, 3times
40792551|NCT03072472|DEVICE|Endocuff Vision|The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
40792552|NCT04963075|DEVICE|multisensory rehabilitation paradigm|"In initial (training) sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between training/testing and testing only sessions in which performance on the visual battery will be re-assessed."
40998074|NCT04056195|DRUG|Placebo oral tablet|Placebo capsules are filled with microcrystalline cellulose.
40998075|NCT04470999|OTHER|Leukapheresis|Blood collection and PBMC collection via apheresis machine will be conducted
40998076|NCT00790439|DRUG|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
40998077|NCT00790439|DRUG|Heparin|Anticoagulant
40998078|NCT00790439|DRUG|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
40998079|NCT00790439|DRUG|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
40998080|NCT00790439|DRUG|Tacrolimus|Calcineurin inhibitor
41149561|NCT01181193|DRUG|Temozolomide|"1. 75 mg/m2/day for entire period of radiotherapy~2. 150-200 mg/m2/day for 5 days every 28 days, 6 cycles total"
41149562|NCT01181193|DRUG|Vitamin D3|4000 IU started 1 week before commencing radiotherapy and discontinued immediately after completing last chemotherapy cycle
41149563|NCT01018992|DRUG|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
41149564|NCT01018992|DRUG|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
41149565|NCT05861089|DIAGNOSTIC_TEST|end-tidal CO2 measurement|Measurements will take place day before surgery, under resting conditions (while sitting in a quiet room with no disruptions) using the Capnography monitor from Nonin Medical (breath by breath data will be recorded and analyzed). Patients will be allowed to get used to the nasal cannula for the first two minutes. Mean end-tidal CO2 value will then be calculated from the following two minutes of spontaneous breathing.
41149566|NCT02305797|DRUG|Extended-release lorazepam|Extended-release lorazepam capsules
41149567|NCT02305797|DRUG|Placebo|Placebo capsules
41149568|NCT03003715|PROCEDURE|PET Scans|Two 90 minute scans whose maximum radiological dose is 15 mCi \[11 C\] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
41149569|NCT03003715|PROCEDURE|transcranial direct current stimulation (tDCS)|In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
41149570|NCT03003715|PROCEDURE|MRI|No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.
41310350|NCT05477342|BEHAVIORAL|Combined İntervention|"The CI group was divided into five groups for play that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player)GP 5- GP 6- GP 7- GP 8- GP 9).~The CI group was divided into three groups for education that E4 (Precontemplation) -E5 (Contemplation)-E6 (Preparation) according to the thinking stages scale."
41310351|NCT06249256|BIOLOGICAL|Fast CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of Fast CAR T cells. During Fast CAR T cells production, subjects will receive cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with Fast CAR T cells by intravenous (IV) injection.
40998081|NCT00790439|DRUG|Cyclosporine|Calcineurin inhibitor, immunosuppressant
40998082|NCT00790439|DRUG|Daclizumab|Monoclonal IL-2 receptor blocker
40998083|NCT00790439|DRUG|Basiliximab|Monoclonal IL-2 receptor blocker
40998084|NCT00790439|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|
40998085|NCT01302912|PROCEDURE|Lymphoma-Biopsy|Patients after biopsy of orbital lymphoma
40998086|NCT05980533|DIAGNOSTIC_TEST|Ultrasound|Ultrasound at hospital discharge and at follow up at 7-10 days
40998087|NCT06212219|BEHAVIORAL|Neurofeedback procedure|Personalized NF will consist of adding to these motor imagery tasks, personalized aspects depending on the patient's profile, for example in terms of level of support and emotional support (addition of a relaxation exercise using an audio recording at the start of training - and in the middle of training if necessary, adding the presence of a companion is to provide social presence and emotional support, depending on the user's performance and progress.), of the virtual environment.
40998088|NCT06212219|OTHER|Fugl-Meyer test|419 / 5 000 Résultats de traduction Résultat de traduction This questionnaire assesses the motor selectivity of the upper limb. Several questions are asked about the movements that the patient can perform and to each question, the patient can answer either 0 (minimum) and 2 (maximum)
40998089|NCT06212219|OTHER|Intrinsic Motivation Inventory questionnaire|This psychometric motivation questionnaire offers the patient words representative of their motivation to carry out the neurofeedback session and for each proposition they can respond between rather positive (maximum) or rather negative (minimum)
40998090|NCT06212219|OTHER|Hospital Anxiety and Depression Scale|This questionnaire assesses the patient's state of anxiety and depression. Concerning anxiety, to each proposition, the patient can answer a number between 0 at minimum (never/not at all) and 3 at maximum (very often) and about depression, the patient can answer a number between 0 at minimum (often, always) and 3 at maximum (never/not at all) The patient can calculate his score at the end
40792553|NCT04566939|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
40998091|NCT06212219|OTHER|State Anxiety Inventory scores|"This questionnaire measures the patient's anxiety at a given time. It features a number of statements that people have previously used to describe themselves. For each statement, choose a grade from 1 (not at all) to 4 (Very much)"
40998092|NCT06212219|OTHER|Acceptability questionnaire (BCI-ACCEPT)|This questionnaire asks the patient about their level of acceptability of NF training using words representative of their motivation to carry out the neurofeedback session and for each proposal they can respond on their feelings regarding the proposals.
40998093|NCT06212219|OTHER|System Usability Scale questionnaire|This questionnaire evaluates the usability of personalized NF procedures compared to standard procedures. To each statement, the patient can respond between a minimum of 1 (strongly disagree) and a maximum of 5 (totally agree).
40998094|NCT06212219|OTHER|NASA Task Load Index questionnaire|"This scale assesses psychological validity from the perspective of mental workload. 6 words are offered to the patient about his mental load and he can respond at least little and at maximum A lot"
40998095|NCT06212219|OTHER|Agency test|Questionnaire in which statements referring to the patient's general feeling and/or beliefs are presented. the patient has the choice between completely disagree (minimum) and totally agree (maximum)
40998096|NCT06212219|OTHER|Visual and Kinesthetic Imagery Questionnaire|"The aim of this questionnaire is to obtain an index of individuals' ability to mentally represent different movements. Different movements to imagine are indicated and the patient responds based on their ability to imagine the movement.~He has the choice between as clear as a film (maximum) and no image (minimum)"
40998097|NCT06212219|OTHER|Technology Locus of Control Assessment Questionnaire|"The questionnaire focuses on patients' opinions on problems related to the use of technical devices. It presents twelve statements that the patient can affirm or deny, depending on their personal point of view. The patient can respond at least disagree at all and at maximum agree completely"
40998098|NCT06212219|OTHER|POSITIVE AFFECTIVITY AND NEGATIVE AFFECTIVITY SCALE|"This scale is made up of a list of words that indicate certain emotions or feelings. The patient must carefully read each of these words and spontaneously indicate at what level he feels this way at the time he responds to this scale. To do this, he can answer at least Very little or not at all and at maximum A lot"
40998099|NCT06212219|OTHER|Self-questionnaire: OCEAN of the five major factors of per- sound (or Big Five model)|"The model for measuring personality factors is the Anglo-Saxon model known as the Big Five or OCEAN in French. It measures 5 major personality traits: openness to experiences, conscientiousness, extroversion, agreeableness and neuroticism. The OCEAN questionnaire is a self-administered questionnaire to be given to a person who wishes to evaluate themselves. It includes 45 items presented in the table below. For each item, patients have 5 response possibilities numbered from 1 to 5: 1 for strongly disapproves and 5 for strongly approves. The patient can calculate his score at the end"
40998100|NCT06212219|OTHER|Feeling VAS scores|"The EVA scale relates to the patient's personal feelings: perceived difficulty, perceived fatigue, perceived ease of learning, level of embodiment, Relevance, Demonstrability of results, Fun aspect, Benefit/risk ratio, Self-efficacy.~For each statement, the patient can respond on a scale ranging from strongly disagree (minimum) to totally agree (maximum)."
40998101|NCT06212219|OTHER|Reaching Performance Scale|This scale analyzes the evolution of speed, precision and range of movement using motion capture tools. For each statement, the patient has a rating between 0 (corresponds to not possible) and 3 (corresponds to entirely possible)
40998102|NCT05165212|DRUG|Amoxicillin|Patients will be given 10% of a standard weight-based dose of amoxicillin and observed for signs/symptoms of allergic reaction for 30 minutes. If no reaction occurs, they will given the remaining 90% of the standard dose and observed for an additional 30 minutes.
40998103|NCT01217060|DRUG|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
40998104|NCT01217060|DRUG|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
40998105|NCT01217060|RADIATION|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
40998106|NCT01217060|PROCEDURE|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
40998107|NCT01217060|DRUG|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
40998108|NCT05461131|BIOLOGICAL|BPZE1|Live attenuated vaccine
40998109|NCT05461131|BIOLOGICAL|Placebo|Placebo
40998110|NCT05461131|DRUG|Azithromycin|Antibiotic
40998111|NCT05461131|OTHER|Bordetella Pertussis Challenge Strain|Challenge Strain
40998112|NCT00666757|DRUG|duloxetine|30-120 milligrams (mgs) orally daily for 12 weeks
40998113|NCT00666757|DRUG|fluoxetine|20-80 mgs orally daily for 12 weeks
40998114|NCT00666757|DRUG|citalopram|20-40 mgs orally daily for 12 weeks
40998115|NCT00666757|DRUG|paroxetine|20-50 mgs orally daily for 12 weeks
40998116|NCT00666757|DRUG|sertraline|50-200 mgs orally daily for 12 weeks
40998117|NCT04562896|DEVICE|Custom Carbon Fiber Dynamic Orthosis (CDO)|The custom carbon fiber dynamic orthoses will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
40998118|NCT04501614|DRUG|Ponatinib|Ponatinib tablets.
41149571|NCT03003715|OTHER|sham tDCS (prior to real tDCS)|For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.
40998119|NCT04501614|DRUG|Ponatinib AAF|Ponatinib age appropriate formulation i.e., capsules with ponatinib minitablets.
40998120|NCT04501614|DRUG|Chemotherapy Agents|Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), daunorubicin. Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine. Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), cyclophosphamide, etoposide, CNS-1/2: IT methotrexate chemotherapy, CNS-3: ITT chemotherapy methotrexate, hydrocortisone, cytarabine. The doses for chemotherapy agents for reinduction will be given as per standard of care.
41469540|NCT06227351|PROCEDURE|completely limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to the zygoma anatomy-guided approach classification and previously planned surgery using Cone beam C.T lateral window and sinus foor lifting will be decided to be done or not.~After securing the surgical templates in its proper position, sequential osteotomy drilling will be performed in a steady in and out movement under copious sterile saline irrigation.The drills will be entering the maxilla palatally and puncturing the alveolar crest to reach the buccal side.The drills will be visualized through the bony window created until it reaches the zygomatic bone.Sequential drills with the uses of guided tubes,sleeves and keys will be used to guarantee that the implant have been placed in a fully completely guided manner.Afterwards the zygomatic implants will be placed."
40998121|NCT03733288|BEHAVIORAL|Education and training sessions|Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.
40998122|NCT03733288|BEHAVIORAL|Support emails|Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.
41149572|NCT03573375|BEHAVIORAL|Questionnaires|Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.
41149573|NCT00233207|DRUG|IC14|
40998123|NCT03733288|BEHAVIORAL|Team leader training|Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.
41469541|NCT06227351|PROCEDURE|Partially limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full -thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to zygoma anatomy-guided approach classification and previously planned surgery using cone beam C.T.lateral window and sinus floor lifting will be decided to be done or not.After securing the surgical templates,The first drill only will be used using the guide then it will be removed and the other drills will be completed in a free hand without the use of guide to guarantee that the implant will be placed in partially guided manner.Afterwards the zygomatic implants will be placed."
41469542|NCT02399631|OTHER|Enhanced recovery program|Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
41469543|NCT03388502|OTHER|Automated Text Messaging (SMS) Bot (intervention group)|Patients will be enrolled in an 'Automated Text Messaging (SMS) Bot (intervention group)' which is a computer program that sends patients timely reminders, instructions, and videos to help them prepare and recover from surgery.
41149574|NCT01157442|BEHAVIORAL|cell phone sms text messaging|At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
41149575|NCT00331799|DRUG|Duloxetine|Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
41469544|NCT03388502|OTHER|Routine perioperative education & teaching (control group)|Patients will receive the 'Routine perioperative education \& teaching (control group)' and will not be enrolled in the physician-specific SMS bot.
40998124|NCT03733288|DEVICE|Height-adjustable workstation|After baseline, agents in the SLAMM+ arm will have a height-adjustable workstation installed on their existing workplace desk. This will enable work in a seated or standing position, with flexibility to alternate between postures. Desk installation will occur with support from the onsite organisation health and safety team. The research team will brief participants on safe and effective workstation use. A laminated sheet will be fixed to each workstation to remind participants of safe and effective use.
40998125|NCT03448965|DIAGNOSTIC_TEST|random blood sugar|do random blood sugar at 0 hour - 2 hours- 4 hours and after 6 hours
40792554|NCT04566939|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the shoulder at the physician's discretion.
40998126|NCT00663052|DRUG|Etanercept|ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
40998127|NCT00663052|DRUG|Etanercept|ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
40998128|NCT02245841|DRUG|H.P. Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
40998129|NCT02506504|DEVICE|Inspiratory help then sham ventilation|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
40998130|NCT02506504|DEVICE|Sham ventilation then Inspiratory help|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
40998131|NCT02342483|DIETARY_SUPPLEMENT|MSM|
40998132|NCT03804112|DIAGNOSTIC_TEST|Ultrasound exam with Doppler|Ultrasound exam of the neck to search a perivascular inflammation at the level of the carotid bifurcation.
40998133|NCT03804112|BIOLOGICAL|Blood samples|blood count , CRP and viral serologies (herpes virus, chlamydia, mycoplasma),
40998134|NCT03031808|DRUG|Lidocaine spray (2%)|Spraying trachea from 2 cm above the vocal cords and 5 cm down with a straw with multiple side holes
40998135|NCT03031808|DRUG|Muscle Relaxant (Rocuronium)|After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
40998136|NCT03031808|OTHER|No Muscle relaxant, no Lidocaine|This group get general anesthesia without Rocuronium or Lidocaine
40998137|NCT06028945|DEVICE|HMD: Virtual Reality Exposure Therapy|The virtual reality exposure therapy uses 360-degree videos delivered through a head mounted display (HMD). Participants will be matched with one of three available exposure hierarchies: Social Party Scenario, Subway Scenario, or Shopping Mall Scenario. Each hierarchy comprises seven 5-min scenes ordered in increasing intensity (from low to high anxiety). Participants are gradually exposed to scenes, viewed twice per day for up to 10 days, while rating their anxiety immediately before and after the exposures. Anxiety ratings will inform when participants may advance to the next level intensity in the exposure hierarchy.
40792555|NCT04566939|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Gyunwoo (LI15), Gyunryo(TE14), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
40998138|NCT06028945|DEVICE|HMD: Neutral Game|The neutral game is a virtual-reality based game that is not designed to provoke anxiety. Participants assigned to the neutral game will play for 5 minutes twice per day for up to 10 days.
40998139|NCT06402188|DEVICE|ColoSeal ICD Device|The subject will undergo scheduled resection per the surgeon's preferred technique. Following completion of the anastomosis, the Intraluminal Colonic Diversion (ICD) Device will be inserted, advanced and positioned with the ICD Delivery System transanally. The ICD Device will remain in place for 10± 2 days. Anastomotic leak testing will be performed prior to scheduled removal.
40998140|NCT02576028|OTHER|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
40998141|NCT02576028|OTHER|standard active exercises|two sessions of 45 minutes of active exercises
41149576|NCT03581344|DIAGNOSTIC_TEST|Repetition of Re-staging|Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
41149577|NCT03015415|PROCEDURE|Elbow Open Arthrolyses|Elbow arthrolysis by posterior access
40998142|NCT00001749|DRUG|Antithymocyte globulin|
40998143|NCT00001749|DRUG|Cyclosporine|
40792556|NCT04566939|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
40998144|NCT05696834|PROCEDURE|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
40998145|NCT01302574|DIETARY_SUPPLEMENT|lactisole|Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
41149578|NCT03015415|PROCEDURE|Non-surgical intervention|Rehabilitation with splinting protocols
41469545|NCT05053724|OTHER|Star to move Protocol|"Progressive physical therapy according to the Gosslink protocol called Start to move."
41469546|NCT05332834|BIOLOGICAL|SM17|Peripheral intravenous injection
41469547|NCT05332834|OTHER|Placebo|Peripheral intravenous injection
41469548|NCT02865148|BEHAVIORAL|Cognitive behavioral therapy|CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
41469549|NCT00471991|DRUG|SH T04769G|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
41469550|NCT00471991|DRUG|Ethinyl estradiol / dienogest (SH D00659 AF)|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
41469551|NCT05186779|DRUG|Progestagen|Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer
41469552|NCT01115855|DRUG|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
41469553|NCT01115855|DRUG|Placebo|Placebo once daily or every once daily
41469554|NCT04489303|BEHAVIORAL|Caring Response App|Participants will receive the Caring Response mobile app containing the Virtual Patient Behavioral Response Training.
41469555|NCT04489303|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
41469556|NCT05220891|OTHER|Paracentesis|Paracentesis from ascitic patient
41469557|NCT05672199|DRUG|Efavaleukin alfa|Subcutaneous (SC) injection
41469558|NCT05672199|DRUG|Placebo|SC injection
41469559|NCT02063087|OTHER|Head CT Decision Aid|The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
41469560|NCT04172025|DIAGNOSTIC_TEST|Analysis of Bacterial Genome|genome assembly; prediction of sequence type (MLST); core genome MLST tree to rapidly compare strains within a project; core genome single nucleotide polymorphism (SNP) tree to compare all Swiss Pathogen Surveillance Platform (SPSP) strains belonging to a same species; whole genome SNP tree to compare all SPSP strains within the same species and ST;; prediction of resistance and virulence factors within pathogen submitted genomes; time trees and calculation of transmission rates, including basic reproduction number; analysis of classical epidemiological data with advanced statistical methods including machine learning.
41469561|NCT03499366|DIAGNOSTIC_TEST|HFMS, MRC, ACTIVLIM, PedsQl-4.0|Clinical performance tests, quality of life, activity of daily life form.
41469562|NCT00583518|DRUG|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
40792557|NCT04566939|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41310352|NCT02987764|OTHER|cord milking|For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
41310353|NCT05322018|DIAGNOSTIC_TEST|Faces Thermometer Scale (FTS)|The Faces Thermometer Scale (FTS) is a one-item measure with 11 numeric rating scale steps (0, no pain to 10, much pain). Each step is associated with different faces and colors. The app presents all information in text, sound, and picture. FTS is part of PicPecc, an application for mobile devices. The child/adolescent assesses their pain on a tablet by moving the finger on the scale and points to the color and face that represent their appraised level of pain.
41310354|NCT02509494|BIOLOGICAL|Ad26.ZEBOV|Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.
41310355|NCT02509494|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).
41310356|NCT02509494|BIOLOGICAL|MenACWY|MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
41310357|NCT02509494|BIOLOGICAL|Placebo|0.9% saline for injection.
41310358|NCT01410266|OTHER|Alternative follow-up|Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
40998146|NCT01652391|DEVICE|Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)|
41149579|NCT00946010|BIOLOGICAL|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
40998147|NCT04930887|DRUG|Exparel (Bupivacaine Liposome)|Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally
41149580|NCT00967915|PROCEDURE|Frentomy|Frenotomy will be performed. This procedure involves crushing frenulum tissue with straight hemostat for hemostasis and anesthesia while tongue is elevated with elevator. Frenulum then cut to desired length with iris scissors. Patient then returned to parents and immediately breastfeeds without parent observing infant's mouth.
41149581|NCT00967915|OTHER|Sham procedure|Infant taken into room away from parents and no frenotomy performed. Infant's mouth is examined but no interventions made.
41149582|NCT00910871|DRUG|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
41149583|NCT00910871|DRUG|Background Regimen (BR) for MDR-TB|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
41149584|NCT01498354|PROCEDURE|2-D high definition vision systems, transanal endoscopic operation (TEO)|Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
41149585|NCT01498354|PROCEDURE|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
41149586|NCT03651271|BIOLOGICAL|Nivolumab Monotherapy|Single-agent nivolumab will be administered at 360 mg IV Q3W. Participants who continue to show clinical benefit after the first disease assessment will receive nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
41149587|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab and Combination for Metastatic Cancer|For nivolumab and ipilimumab combination therapy, nivolumab will be administered at 360 mg IV Q3W, and ipilimumab will be administered at 1 mg/kg IV Q3W for the first 2 doses and then Q6W for the 3rd and 4th doses, followed by single-agent nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
41149588|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort A will receive nivolumab 1 mg/kg Q3W and ipilimumab 3 mg/kg every 6 weeks (Q6W) for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If the safety profile of Prostate Cohort B is deemed unacceptable, an additional 10 participants will be enrolled in Prostate Cohort A.
41149589|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort B will receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If Prostate Cohort B is determined to have a tolerable safety profile, an additional 10 participants will be enrolled to receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity.
41149590|NCT04475497|OTHER|Blood management|The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels \<11.0 g/dL. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
41149591|NCT04475497|OTHER|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
41149592|NCT06584994|OTHER|sample collection|Collection of blood, skin, semen, urine and/or saliva samples. Access to previously collected tissue samples (if applicable).
41149593|NCT03240471|PROCEDURE|One week of plaster cast|One week of plaster cast as treatment for a non-reduced distal radius fracture.
41149594|NCT03240471|PROCEDURE|Four-Five weeks of plaster cast|Four-Five weeks of plaster cast as treatment for a non-reduced distal radius fracture.
41149595|NCT00524693|DRUG|Montelukast|4mg sachets
40792558|NCT04566939|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
41149596|NCT00524693|DRUG|Placebo granules|
41149597|NCT04195334|DEVICE|internal fixation by IMN|using retrograde or antegrade IMN for femooral fractures fixation using a fit nail to the femoral intramedullary canaland follow up for union
41149598|NCT03385447|BEHAVIORAL|Physical Activity|Participants underwent 12-weeks of exercise prescription aimed at the federal guidelines (3 days/week).
41149599|NCT04703244|PROCEDURE|chemotherapy or endocrine therapy for breast cancer|Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.
41310359|NCT02843373|DEVICE|TMS|
41310360|NCT01151579|DRUG|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
41310361|NCT01151579|DRUG|Albuterol|Nebulized albuterol 2.5mg
40998148|NCT04930887|DRUG|Saline|Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
40998149|NCT05023928|BIOLOGICAL|Tumor antigen-sensitized DC vaccine|subcutaneous administration
40998150|NCT03513484|DRUG|Azacitidine|Given IV or SC
40998151|NCT03513484|OTHER|Laboratory Biomarker Analysis|Correlative studies
40998152|NCT03513484|DRUG|Nintedanib|Given PO
40998153|NCT00624962|DIETARY_SUPPLEMENT|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
40998154|NCT00624962|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
41149600|NCT03514667|DIETARY_SUPPLEMENT|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
41149601|NCT03514667|DIETARY_SUPPLEMENT|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
41149602|NCT02297945|DRUG|metyrapone|Single arm study
40998155|NCT06093464|OTHER|Natural Compound A (masked essential oil A)|"Participants will use Natural Compound A in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
41149603|NCT01912521|BEHAVIORAL|Mfangano Health Net Microclinic Program|Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
41469563|NCT05481879|DRUG|DYNE-101|Administered by IV infusion
41469564|NCT05481879|DRUG|Placebo|Administered by IV infusion
41469565|NCT00132054|DRUG|amrubicin hydrochloride|
40792559|NCT04566939|PROCEDURE|Herbal hot pack|Herbal hot pack treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
40792560|NCT04566939|PROCEDURE|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
40998156|NCT06093464|OTHER|Natural Compound B (masked essential oil B)|"Participants will use Natural Compound B in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
40998157|NCT00145665|PROCEDURE|FLT-PET scan|PET scan using FLT
41149604|NCT05607147|DEVICE|Testing for SARS CoV2 Antigen and Antibody|Antigen testing: Rapid Antigen testing (Point-of-care) Antibody testing: ELISA testing of microsampling 'finger-prick' specimen DHCW Survey for adoption of risk mitigation practices and for perceptions of safety
41149605|NCT05848102|DRUG|dapagliflozin|FORXIGA（Dapagliflozin Tablets), manufacturer/marketer: AstraZeneca, salt composition: Dapagliflozin (10mg), one tablet once and once a day.
41149606|NCT04971889|BEHAVIORAL|Diabetes MNT|Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake
41149607|NCT04971889|BEHAVIORAL|Motivational Interviewing|Group-based support for dietary self-care motivation using culturally-adapted motivational interviewing exercise
41469566|NCT00132054|DRUG|irinotecan hydrochloride|
41469567|NCT01622608|BEHAVIORAL|Vaccine Information Kiosk|The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
41469568|NCT03749954|DIAGNOSTIC_TEST|Detachable string magnetically controlled capsule endoscopy|Esophagogastroduodenoscopy is performed 2 hours after the magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
41469569|NCT04857151|BEHAVIORAL|App based mindfulness program (ABMP)|App based mindfulness program (ABMP)
41469570|NCT06027229|BIOLOGICAL|NVX-CoV2372|Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5
41469571|NCT02555319|DEVICE|Transcatheter Pulmonary Valve (TPV)|Transcatheter Pulmonary Valve Replacement
41469572|NCT03703453|DEVICE|ER-REBOA catheter|The ER-REBOA™ catheter is a device that has been gaining increased use in the setting of severe trauma for the purposes of stopping intra-abdominal hemorrhage. The catheter is advanced through a femoral artery sheath into the aorta, where a balloon at its tip is inflated, occluding all distal blood flow (and stopping any hemorrhage while the patient can be prepared for definitive operative intervention).
41469573|NCT02218307|DRUG|Mupirocin|
41469574|NCT02218307|DRUG|Placebo|
40792561|NCT04566939|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
40792562|NCT01589146|DRUG|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
40792563|NCT05593354|DEVICE|Micropulse Transscleral laser therapy|Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine
40792564|NCT01922882|BEHAVIORAL|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
40792565|NCT02550444|DRUG|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
40792566|NCT02550444|DRUG|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
40792567|NCT02550444|DRUG|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
41469575|NCT01191476|DRUG|Sevoflurane Inhalational Induction and Maintenance|Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.
40792568|NCT04011592|DRUG|Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg)
40998158|NCT04802265|PROCEDURE|Epiretinal membrane surgery|"The surgery consists of a 23 or 25-gauge pars plana vitrectomy (PPV). The surgery was performed peri-bulbar anesthesia and could be combined with phacoemulsification.~An intraocular dye is used to well visualized and facilitate ERM peeling. The ILM is not actively peeled. A search for iatrogenic breaks is performed towards the end of the procedure. Areas suspicious for breaks are treated with cryotherapy or peripheral endolaser."
40998159|NCT03050619|DRUG|Empagliflozin|
40998160|NCT03050619|DRUG|Other SGLT2 inhibitors|
40998161|NCT03050619|DRUG|Other non-insulin GLDs|metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists
40998162|NCT02972216|DRUG|Nolbaxol|
40998163|NCT02972216|DRUG|Taxotere|
40998164|NCT02972216|DRUG|cisplatin|
40998165|NCT03588221|PROCEDURE|four sets of hand hygiene measurements per participant|"1. Six-step hand hygiene technique with an application time of 30 seconds~2. Six-step hand hygiene technique with an application time of 15 seconds~3. Three-step hand hygiene technique with an application time of 30 seconds~4. Three-step hand hygiene technique with an application time of 15 seconds"
41310362|NCT04538885|BIOLOGICAL|The pleiotropic factor derived from mesenchymal stem cells|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
40998166|NCT04104009|OTHER|Education|"Following the randomization process, group education of pregnant women will be conducted through four one-hour meetings.~Education program: teaching about the basics of childbirth physiology, visit to the maternity ward with the aim of reducing the fear of childbirth, applying the deep inhale and exhale exercise in the first birth stage, applying the classical music listening technique that will continue until the end of pregnancy daily (in the evenings before bedtime) (for 15 minutes), teaching and applying techniques for successful breastfeeding, maternal and infant health care after delivery. The training program will be implemented so that after 4 workshops a 5-week break will be taken. At the end of the program, the educator arranges with the respondents a weekly telephone check (for the sake of communication quality) to inform them of adherence to the agreed classical music listening.Pregnant women who do not meet expectations will be excluded from the study."
41469576|NCT01191476|DRUG|Propofol Target Controlled Infusion for Induction and Maintenance|Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.
40998167|NCT04104009|OTHER|No education|In the control group there will be no education, no breathing exercises and no listening to classical music.
40792569|NCT04011592|DRUG|Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg)
40792570|NCT00792740|DRUG|ITF2357|ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
40998168|NCT04599296|DEVICE|Hip brace|Hip brace
41469577|NCT01191476|DRUG|Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance|Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
40998169|NCT03491618|OTHER|PAIN REDUCTION ON VAS/NRS|Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.
40998170|NCT05066971|COMBINATION_PRODUCT|Self-adjustment of medication|Each week, based on the information provided by HM (heart rate and hours of activity each day), the rate control medication is adjusted to increase the total of activity time.
40998171|NCT06034509|OTHER|No intervention. This is an observational study.|There are no interventions being tested in the Cognitive and Vascular Functioning Following TBI study.
41469578|NCT03011879|OTHER|clinical pathway|
40998172|NCT04991961|DIAGNOSTIC_TEST|withdraw antihypertensive drugs|patients need to withdraw of all antihypertensive drugs or change therapy to Doxazosin/Diltiazem for 2-4 weeks prior
41149608|NCT02769390|DRUG|Clonidine 1 mcg/Kg|Clonidine 1 mcg/Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
41149609|NCT02769390|DRUG|Clonidine 2 mcg/ Kg|Clonidine 2 mcg//Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
41149610|NCT02769390|DRUG|Clonidine 3 mcg/ Kg|Clonidine 3 mcg //Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
41469579|NCT05516888|PROCEDURE|radiofrequency of gasserian ganglion|radiofrequency ablation of the gasserian ganglion
41469580|NCT05516888|PROCEDURE|radiofrequency of the peripheral trigeminal branches|radiofrequency of the peripheral trigeminal branches ( maxillary, mandibular, supraorbital)
41469581|NCT02176668|DRUG|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
41469582|NCT02176668|DRUG|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
40792571|NCT00792740|OTHER|Placebo|Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)
41310363|NCT04471064|DRUG|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.
40792572|NCT03127696|PROCEDURE|Fecal Microbiota Transplantation|FMT
40998173|NCT02467101|OTHER|Corticosteroid/Saline|"Corticosteroid/Saline~Two groups were defined: group A and group B.~* Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head~* Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.~Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.~Each patient will be injected on half-head."
40998174|NCT04497779|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or nasopharyngeal swabs
41310364|NCT02281903|DEVICE|The TrueCPR feedback device|feedback devices
41310365|NCT02281903|DEVICE|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
40998175|NCT04497779|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
40998176|NCT04497779|OTHER|Electronic Health Record Review|Donors and recipients have their medical records reviewed.
41149611|NCT04861571|DIETARY_SUPPLEMENT|Dietary intervention with very low calorie diet (VLCD)|The VLCD program will last 8 weeks. The only sources of nutrition during this phase are the Optifast® products providing up to 800 kcal per day. Two liters (67.63 fl oz) of water should also be consumed each day. Participants will be instructed to use 5 replacement meals per day (800 kcal total) with 40% of calories as protein, 40% as carbohydrate, and 20% as fat.
41149612|NCT04861571|OTHER|Control Arm|The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
41310366|NCT02230878|DRUG|JNJ-42847922 5 mg|Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
40792573|NCT03127696|BEHAVIORAL|Lifestyle Modification Program|Lifestyle
40998177|NCT04497779|OTHER|Questionnaire Administration|Ancillary studies
41310367|NCT02230878|DRUG|JNJ-42847922 10 mg|Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
41310368|NCT02230878|DRUG|JNJ-42847922 20 mg|Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
41469583|NCT02176668|DRUG|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
41469584|NCT02176668|DRUG|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
40792574|NCT03127696|PROCEDURE|Sham|Sham
40998178|NCT01280552|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with immunogenic antigens
40998179|NCT01280552|BIOLOGICAL|Placebo DC|Autologous dendritic cells (DC) that have not been pulsed with antigens
41149613|NCT03363009|DEVICE|Optimized group|The data provided by the connected devices is analyzed daily; the patient receives a phone call in case of no realization of the objectives.
41310369|NCT02230878|DRUG|JNJ-42847922 40 mg|Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
41469585|NCT01593969|DIETARY_SUPPLEMENT|RUTF/Flax Oil|Ready to Use Therapeutic Food
41469586|NCT01593969|DIETARY_SUPPLEMENT|RUTF/Flax Oil plus additional Fish Oil|Ready to Use Therapeutic Food
41469587|NCT01593969|DIETARY_SUPPLEMENT|Standard RUTF|Standard formulation RUTF given according to National Guidelines
41469588|NCT02389699|RADIATION|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
40792575|NCT05948904|DIAGNOSTIC_TEST|Cryo Ex Vivo|"Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon.~Tissue samples will be taken from the models and images will be performed."
40792576|NCT05113199|BEHAVIORAL|Virtual Dignity Therapy|Virtual Dignity Therapy will be facilitated by a registered nurse or medical doctor trained in Dignity Therapy.
40792577|NCT00533130|PROCEDURE|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
40792578|NCT00533130|PROCEDURE|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
41310370|NCT02230878|DRUG|Placebo|Participants will receive matching placebo from Day 1 up to Day 10.
41310371|NCT04270994|DRUG|Misoprostol|
41310372|NCT00923819|PROCEDURE|Laparoscopic gastric bypass|Patients are referred to Morbid Obesity Center from Vestfold Hospital Trust and other hospitals in Norway. The procedure will take place at Morbid Obesity Center, Vestfold Hospital Trust.
41310373|NCT00923819|BEHAVIORAL|Standard conservative treatment|Participants from Child Obesity Registry who undergoes conservative treatment at Morbid Obesity Center, Vestfold Hospital Trust.
41310374|NCT00297362|DRUG|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
41310375|NCT04788108|DRUG|Dydrogesterone|Dydrogesterone tablet
41310376|NCT04788108|DRUG|Placebo|Placebo tablet
40998180|NCT00363974|DRUG|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
40792579|NCT01751672|BEHAVIORAL|SBIRT|Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
40792580|NCT01751672|BEHAVIORAL|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
40792581|NCT06090058|DIAGNOSTIC_TEST|Measurement of neurofilament light chain|Serum samples will be collected into a serum gel with clotting activator tube (Sarstedt). After delivery to the laboratory, the serum samples were centrifuged at 2500 × g for 6 min at 4 Celsius degree, then aliquoted into at least three vials (0.3 mL per vial) and stored at -70 Celsius degree until the analysis.
40792582|NCT00005739|BEHAVIORAL|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
40792583|NCT00005739|BEHAVIORAL|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
40792584|NCT05211089|OTHER|Optical Coherence Tomography imaging of choroid|A single expert retinal specialists used a Topcon DRI-1 SS-OCT to do the Choroidal Thickness measurements. A 12, 9-mm radial line scan procedure was performed. Each radial line was automatically scanned 32 times in the same spot, followed by the creation of 12 high-resolution average B-scan images. Each scan was double-checked to confirm that it was centred on the fovea. Only scans of good quality were included. The perpendicular distance between the outer border of the RPE and the junction of the choroid and sclera was used to calculate CT. It was calculated automatically using the mapping software incorporated into the device and displayed as a colourful topographic map with nine subfields defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) style grid.
40792585|NCT05646225|OTHER|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
40998181|NCT03093428|DRUG|Radium-223|Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.
41469589|NCT02389699|RADIATION|Whole breast radiation|whole breast radiation after BCS with 46-50 Gy
40998182|NCT03093428|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor. Pembrolizumab binds to human PD-1 and blocks the interaction between PD1 and its ligands.
40792586|NCT05646225|OTHER|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes
40998183|NCT04049942|OTHER|Multimodal prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
40998184|NCT04049942|BEHAVIORAL|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
40998185|NCT04151290|DIAGNOSTIC_TEST|Cognoa ASD diagnostic device|Cognoa device is intended to aid healthcare providers in diagnosing Autism Spectrum Disorder (ASD)
41149614|NCT03363009|DEVICE|Control group|Data will be recorded but not analyzed daily during the period of participation. The patient receives a phone call one time a week to answer possible questions and modify the prescription of physical activity if need.
41149615|NCT00841321|DRUG|Ginkgo biloba|120 mg orally twice a day for 12 weeks
41149616|NCT00841321|DRUG|Placebo|One capsule orally twice a day for 12 weeks
41149617|NCT02422355|DEVICE|FNS|Surgical intervention using the FNS
41149618|NCT04904731|OTHER|Prone position|Patients were assisted in NIV in supine position that was switched in prone position for clinical purpouse
41149619|NCT01317771|PROCEDURE|Open proximal biceps tendon tenodesis with an EndoButton|Surgical fixation for bicipital pathology
41149620|NCT02031445|DRUG|MRX-6|
41149621|NCT02031445|OTHER|Placebo|
41149622|NCT02338310|DRUG|Aromatase Inhibitors|Choice of AI is according to centre policy; any brand can be used
41149623|NCT01836497|DEVICE|SD01 ICD lead|
41149624|NCT04669119|DIETARY_SUPPLEMENT|Bromelain/Boswellia Serrata Casperome|Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton
41149625|NCT04669119|DIETARY_SUPPLEMENT|Centella Asiatica/Vitamins|Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton
41149626|NCT04669119|DIETARY_SUPPLEMENT|Placebo|Placebo
41149627|NCT00104845|BIOLOGICAL|human gp100 plasmid DNA vaccine|
41149628|NCT00104845|BIOLOGICAL|mouse gp100 plasmid DNA vaccine|
41149629|NCT01799993|DRUG|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
41149630|NCT01799993|DRUG|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
41149631|NCT00872404|DRUG|CP-751,871|20mg/kg/3 weeks
41149632|NCT00490243|DRUG|budesonide and montelukast|
41149633|NCT00490243|DRUG|budesonide and formoterol|
41149634|NCT00490243|DRUG|montelukast|
41149635|NCT00490243|DRUG|budesonide|
41149636|NCT00490243|DRUG|placebo|
41149637|NCT01943370|OTHER|Early saline irrigation|Initiation of post-operative saline irrigation earlier during the post-operative course
40998186|NCT05124665|BEHAVIORAL|Social Support|"The intervention to be evaluated in this study is a multidimensional, socio-behavioral Norming intervention. The various components of this intervention are designed to harness household dynamics and prosocial inclinations to encourage individuals to accept the HIV testing invitation. Each component is briefly described in the arm description."
40998187|NCT03517527|BEHAVIORAL|Exercise|
40998188|NCT02984566|DEVICE|Kilovoltage Intrafraction Monitoring|KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
40998189|NCT04745897|OTHER|eTB Catalogue of Recommendations (eTB)|eTB Catalogue of Recommendations (eTB)
40998190|NCT04745897|OTHER|World Health Organization Tuberculosis Website (WHO TB)|World Health Organization Tuberculosis Website (WHO TB)
41149638|NCT01943370|OTHER|Routine Irrigation|Routine initiation of saline irrigation
41149639|NCT03809858|OTHER|Klue App|The Klue App utilizes an Apple Watch to detect eating or drinking behavior. The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
41149640|NCT01776749|DEVICE|SubQ|Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
40998191|NCT02180334|DRUG|Mosapride citrate|On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
40998192|NCT02180334|DRUG|Linagliptin|During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
40998193|NCT02180334|DRUG|Acetaminophen (paracetamol)|On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
40998194|NCT01945489|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
40998195|NCT01945489|DRUG|Normal saline|Normal saline (placebo) injected into the detrusor.
40998196|NCT00978328|DRUG|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
40792587|NCT01135992|DRUG|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
40998197|NCT06545370|OTHER|Intervention 1 / Nurse-led patients' education|nurse-led education through oral sessions, educational materials, and regular phone calls
40998198|NCT06545370|OTHER|Intervention 2 / Nurse-led patients' & caregivers' education|nurse-led education while caregivers also undergo training through oral sessions, phone calls, and appropriately designed educational materials
40998199|NCT06186778|PROCEDURE|secondary colonoscopy|After the routine colonoscopy, a repeat colonoscopy of the sigmoid colon is performed
41149641|NCT00928265|DEVICE|Endovascular treatment of intracranial aneurysm.|"Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.~Accomplishes this by providing coil support at the neck of the aneurysm"
41149642|NCT03811743|BEHAVIORAL|Brenner FIT|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
41310377|NCT03993964|DRUG|Pyrotinib combine with SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
40998200|NCT06186778|PROCEDURE|conventional colonoscopy|It starts from the rectum and progresses forward to the cecum, with observations made during withdrawal: from the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon to the rectum.
40998201|NCT01010048|DRUG|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
40998202|NCT01785576|BEHAVIORAL|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
40998203|NCT05798572|DRUG|Sildosin group|Patients in this group had flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.
40998204|NCT05798572|PROCEDURE|Placebo/control group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with daily preoperative intake of placebo tablets.
40998205|NCT05111691|PROCEDURE|Dry needling|Dry needling
40998206|NCT04516083|DIAGNOSTIC_TEST|Mismatch repair instability somatic and germline testing|Each Endometrial Endometrioid adenocarcinoma is routinely stained for MMR mutation to seek for tumor genetic instability. If stains positive, the patient is called in for genetic blood testing to look for the same mutation in the germline.
40998207|NCT06423911|DRUG|olverembatinib|olverembatinib QOD
40998208|NCT06423911|DRUG|Bosutinib|Bosutnib QD
40998209|NCT04439032|OTHER|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
40998210|NCT02561975|OTHER|Double pulmonary diffusing|"Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~* Alveolar volume (VA)~* Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~* Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc"
40998211|NCT00736801|DRUG|Salmeterol and Salmeterol / Fluticasone|Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
40998212|NCT06040021|OTHER|standardized treatment|Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
40998213|NCT03561857|DEVICE|Confocal Laser Endomicroscopy|"The study is divided in 2 parts.~1. Ex vivo study~   * Prostate specimens will be stained using Fluorescein~  * Images/sequences of normal and abnormal prostatic tissues, and peri-prostatic tissues will be acquired.~2. In vivo study~   * Intravenous injection of contrast agent~  * pCLE imaging every 5mm of the NVB dissection zone."
40998214|NCT00885599|DRUG|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
40998215|NCT00885599|DRUG|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
40998216|NCT00885599|DRUG|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
40998217|NCT00885599|DRUG|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
40998218|NCT04471636|DEVICE|Withings ScanWatch|The smart watch is capable of recording SpO2, ECG, and heart rate.
41310378|NCT02727270|OTHER|No Intervention - Observational Study|No Intervention - Observational Study
40998219|NCT01440738|BEHAVIORAL|health workshops|health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
40998220|NCT03075670|DRUG|N9-GP|A single dose of 50 IU/kg for intravenous (i.v.) injection
40998221|NCT03075670|DRUG|ALPROLIX®|A single dose of 50 IU/kg for intravenous (i.v.) injection
40998222|NCT00754754|PROCEDURE|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
40998223|NCT02926859|DRUG|Cannabidiol as add-on|Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
40998224|NCT02926859|DRUG|Placebo as add-on|Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
40998225|NCT03034785|DEVICE|FlexiMitt|The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
40998226|NCT00747968|DRUG|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
40998227|NCT04779866|BEHAVIORAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
40998228|NCT04779866|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
41149643|NCT03811743|BEHAVIORAL|By Design|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
41310379|NCT01085058|DRUG|lenograstim|
41310380|NCT06011746|DRUG|Ketamine + Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with 1ml ketamine (50mg)
40792588|NCT01135992|DRUG|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
40792589|NCT03763734|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
40998229|NCT00696137|DRUG|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
40792590|NCT04226625|DRUG|Propofol|Intravenous administration
40792591|NCT04226625|DRUG|Desflurane|Volatile administration
40998230|NCT02984358|OTHER|Animal protein based diet|
40998231|NCT02984358|OTHER|Low-nucleotide mycoprotein based diet|
40998232|NCT02984358|OTHER|High-nucleotide mycoprotein based diet|
41310381|NCT06011746|DRUG|Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with (50mg) or normal saline
41149644|NCT03811743|BEHAVIORAL|Coordination|"This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.~Essentials (adults), with four additional components: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment"
41149645|NCT01219400|DRUG|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
40998233|NCT06156592|PROCEDURE|Cardiac valve replacement surgery under high spinal anesthesia combined with light general anesthesia|Before induction of general anesthesia, a high spinal anesthesia will be given using 37.5 mg of 0.75% heavy bupivacaine with 20 mcg fentanyl and 250 mcg epimorphine in sitting position at the lumbar intervertebral spaces between the L2-3 or L3-4 vertebrae. Patients will lie supine immediately afterwards, and sensory loss to ice will be performed every 15 seconds. Subsequently, the patient will be placed in 15-degree Trendelenburg (ensured by clinometer). Following general anesthesia will be induced and trachea will be intubated after 5 ml of 4% lignocaine spray on vocal cords and trachea. Hemodynamics will be aimed at MAP between 65-100 mmHg and heart rate between 50-100 beats /min by use of various inotropic, inodilators and vasoactive cardiac drugs based on anesthesiologists' clinical judgement.
40998234|NCT05894642|BEHAVIORAL|0|It is a case-control study, cross-sectional, so there is no intervention possible.
40998235|NCT00642668|DRUG|methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
40998236|NCT00802412|DRUG|Topiramate|Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
40998237|NCT00802412|DRUG|Placebo|Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
41149646|NCT00026078|DRUG|docetaxel|
41149647|NCT00026078|DRUG|ifosfamide|
41149648|NCT05415722|DRUG|TERN-501|Investigational drug
41149649|NCT05415722|DRUG|TERN-101|Investigational drug
41149650|NCT05415722|OTHER|Placebo|Matching placebo
41149651|NCT02272608|OTHER|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
41149652|NCT02320045|DRUG|ITCA 650 (Exenatide in osmotic mini pump)|
41149653|NCT02122042|BIOLOGICAL|HBOT|
41149654|NCT00246389|DRUG|cyclobenzaprine hydrochloride|
41469590|NCT04761471|DEVICE|TI transcranial electrical stimulation|"Participants will undergo transcranial electrical stimulation, which will be delivered with low current amplitudes (\<= 2 mA) established with international safety guidelines for electrical stimulation. Threshold for the current amplitude will be established by participants themselves, such that they cannot distinguish when stimulation is applied and not applied.~Duration of stimulation will not last longer than 30 minutes."
41469591|NCT03313778|BIOLOGICAL|mRNA-4157|IM injection
41469592|NCT03313778|BIOLOGICAL|Pembrolizumab|Intravenous infusion
41469593|NCT03313778|BIOLOGICAL|SoC Treatment|Intravenous infusion
41469594|NCT06616168|DIAGNOSTIC_TEST|Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest)|Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) produced by Erba Lachema leads to bacteria detection via biochemical features
41469595|NCT06616168|DRUG|Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)|Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.
40998238|NCT01280292|DRUG|Eltroxin|Eltroxin dosage titration according to free T4 measurement every 3 months
40998239|NCT02851537|OTHER|an advanced technique as magnetic resonance spectroscopy (MRS)|subjects who had an advanced technique as magnetic resonance spectroscopy (MRS) It is based on the detection of cerebral metabolites, and the variations of their concentration to characterize different pathologies.
40998240|NCT03863613|DEVICE|Pessary|A soft, flexible, silicone pessary (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix.
40998241|NCT03863613|PROCEDURE|Cervical cerclage|Cervical cerclage using Mc Donald technique, under anaesthesia
41149655|NCT03899844|OTHER|Blood collection, PiB PET/MRI, and cognitive testing|Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.
41149656|NCT00004578|DRUG|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
41149657|NCT00004578|DRUG|Lamivudine|150 mg, every 12 hours
41149658|NCT00004578|DRUG|Stavudine|40 mg every 12 hours
41149659|NCT01330875|OTHER|survey|no intervention. Only questionnaire after lumbar infiltration with steroids - effects on pain reduction
41149660|NCT04376788|BIOLOGICAL|exchange blood transfusion from normal donor|IV method
41149661|NCT04376788|BIOLOGICAL|plasma from convalescent patients with COVID-19|IV method
41149662|NCT04376788|DRUG|Methylene Blue 5 MG/ML|IV method
41149663|NCT06147440|OTHER|Dietary intervention|Participants receive diets following different dietary patterns for 1 week.
41149664|NCT05054361|DIAGNOSTIC_TEST|MAIT cells analysis|For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression.
41469596|NCT06616168|COMBINATION_PRODUCT|Suppositoria for vaginal microflora recovery (Giynoflor)|Prescription of suppositoria for vaginal microflora recovery after antibiotic therapy. Probiotic grug includes Lactobacilli acidophillis as the main compound.
40998242|NCT03863613|DRUG|Vaginal progesterone|Cyclogest® 400mg, Actavis, United Kingdom, applied once daily at bedtime
40998243|NCT02184221|DEVICE|High frequency stimulation|The parameter of DMS: alpha frequency
40998244|NCT02184221|DEVICE|Low frequency stimulation|The parameter of DMS: 0.5Hz
40998245|NCT05985538|BEHAVIORAL|Vaping prevention text messages|Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28. Each vaping prevention text message will focus on one of six topics: nicotine addiction, monetary costs of vaping, chemical exposures from e-cigarette vapor, cosmetic effects of vaping, mental and physical use symptoms of vaping, and health impact on organs from vaping. Some text messages will ask participants for a reply (i.e., two-way messages).
40998246|NCT05985538|BEHAVIORAL|Wellness behaviors text messages|Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28. Each wellness text message will focus on one of six topics: sleep hygiene, safe driving, sun safety, study habits, nutrition, and exercise. This attention control condition is matched with the intervention condition in that participants will receive the same number of text messages over the same number of days, the same intervention structure (e.g., 6 topics), and the same number and types of two-way messages.
40998247|NCT02895958|DRUG|Zepatier|Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
40998248|NCT03232385|DEVICE|MR-US Fusion Arm|Use of Clear Guide SCENERGY for MR-US fusion guidance
40998249|NCT03232385|PROCEDURE|Renal Biopsy or Ablation|Standard of Care
40998250|NCT03957512|PROCEDURE|Heart surgery|All invasive procedures
40998251|NCT04175093|DIAGNOSTIC_TEST|asymmetric dimethylarginine|measurement by ELISA of asymmetric dimethylarginine
40998252|NCT04697693|DRUG|Escitalopram|The participant will be begun on either escitalopram 10mg or duloxetine 30mg. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the HRSD \>7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study.
40998253|NCT04697693|DRUG|Duloxetine|Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study.
40998254|NCT00355186|PROCEDURE|intracoronary bone marrow cells infusion|"intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described"
40998255|NCT01514968|DRUG|cyclosporine|Single oral dose
40792592|NCT00556439|DRUG|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept."
40792593|NCT00556439|DRUG|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
40792594|NCT04554732|DRUG|Keratinocyte growth factor|At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.
40792595|NCT00355355|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
40792596|NCT00355355|DEVICE|Interstitial Light Emitting Diodes|200 J/cm per Light Source at 20 mW/cm light energy
40792597|NCT00355355|PROCEDURE|Percutaneous placement of device in the liver|Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
40792598|NCT00355355|PROCEDURE|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
40792599|NCT04522934|BEHAVIORAL|Pain Neuroscience Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of pain neuroscience education. The latter was focused on the influence of psychosocial factors in the experience of pain, differences between acute and chronic pain and central-peripheral awareness.
40792600|NCT04522934|BEHAVIORAL|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of biomedical education. The latter was focused on the anatomy and pathomechanics of the shoulder.
40792601|NCT06397859|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
40792602|NCT01340664|DRUG|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
41310382|NCT04343521|BIOLOGICAL|Targeted Indoor Residual Spraying (TIRS)|Spraying of insecticide Actellic 300CS will start May-June and extend for 1-2 months. Residents will be asked to temporarily leave the house during treatment and wait 0.5-1 h for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed in CDC-Emory-UADY collaboration.
40792603|NCT01340664|DRUG|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
40792604|NCT01340664|DRUG|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
40998256|NCT01514968|DRUG|danoprevir|Single oral dose
40998257|NCT01514968|DRUG|ritonavir|Single oral dose
40998258|NCT00228592|DRUG|HepeX-B|
40998259|NCT00228592|DRUG|Hepatitis B Immune Globulin (HBIg)|
40998260|NCT05594394|BEHAVIORAL|Orai: Master Public Speaking|"Participants will access the Orai: Master Public Speaking (Sani, Dhamani, \& Gupta, 2020) platform with mobile and web-based applications. Communication skill-building moduleswill be assigned using exercises, case scenarios, and AI-assisted feedback debriefing through the Orai application.~Participants will also complete case scenarios created with specific nursing conflict issues a charge nurse may encounter in an acute care facility. Upon completion of the competency development program, participants will complete the CMCSS to determine the effect on confidence levels and a brief survey (Appendix C) to assess the amicability of the program."
41469597|NCT06616168|DRUG|Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)|Prescription of antifungal drugs. Triazoles (Fluconazole, Itraconazole, Voriconazole), Imidazoles (Ketoconazole), Nystatin and Amphotericin B are used the most
41469598|NCT05772572|OTHER|Questionnaires|"Questionnaires are completed only once and assess:~* recorded questions about the disease and the operation for the parents and the patient, human figure drawing test and drawing of the operation for the patient~* psychiatric questionnaires for parents and patients on anxiety and depression~* behavior questionnaires for the parents and the patient: assessment of attachment~* questionnaires for the parents and the patient concerning the family context, the quality of life"
41469599|NCT05118516|DRUG|ASC43F|One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
41469600|NCT02277431|DIETARY_SUPPLEMENT|Probiotic dietary supplement (Trenev Trio®)|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am \& pm) offering a total daily serving of:~* Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units \[CFU\])~* Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~* Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
40792605|NCT01340664|DRUG|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
40792606|NCT05134610|DEVICE|AEROBIKA POSITIVE EXPIRATORY PRESSURE DEVICE|Intervention arm patients use the OPEP device twice daily for 2 weeks before and after surgery
40792607|NCT02052869|PROCEDURE|esophagus intubation|In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
40792608|NCT04190823|DRUG|RC98|Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.
40792609|NCT04233528|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
40792610|NCT02988544|PROCEDURE|Artificial shrinkage|Artificial shrinkage of blastocyst
40792611|NCT01211392|OTHER|magnetic resonance imaging|magnetic resonance imaging is compared to dual-energy computed tomography for the detection of bone marrow changes
40792612|NCT03981744|DRUG|Ustekinumab 6 mg/kg|Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
40792613|NCT03981744|DRUG|Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
40998261|NCT01757119|DRUG|Tardyferon 80 mg|Oral administration (2 tablets)
40792614|NCT03981744|DRUG|Placebo IV|Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
40792615|NCT03981744|DRUG|Placebo SC|Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
40792616|NCT00581048|DRUG|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
40792617|NCT03215381|DRUG|[11C]AZD1390|\[11C\]AZD1390
40792618|NCT02250469|DEVICE|Treatment with the Axium SCS system|
40792619|NCT02250469|DEVICE|Treatment with the Medtronic SCS System|
40792620|NCT06121726|OTHER|Ilioinguinal-Iliohypogastric nerve block|local anesthetic will be administered near ilioinguinal-iliohypogastric nerves under ultrasound guidance. Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
40792621|NCT06121726|DRUG|Local anesthetic|Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
40998262|NCT04446065|DRUG|Previfenon®|Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.
40792622|NCT00682175|OTHER|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
40998263|NCT04446065|DRUG|Placebo|Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.
41310383|NCT04161586|DRUG|Prilocaine Hydrochloride|Spinal Prilocaine for Ambulatory Surgery
41469601|NCT02277431|DIETARY_SUPPLEMENT|placebo|
41469602|NCT01374724|BEHAVIORAL|Tobacco Use Ban|Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.
41149665|NCT05054361|DIAGNOSTIC_TEST|MAIT cytokines production analysis|Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.
41149666|NCT05054361|DIAGNOSTIC_TEST|Lactulose/Mannitol Test|After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
41149667|NCT05054361|PROCEDURE|UGI Endoscopy|Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
41149668|NCT05054361|DIAGNOSTIC_TEST|Coxsackie virus B infection status|Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.
41149669|NCT05054361|DIAGNOSTIC_TEST|Coxsackie virus B infection status|Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
40998264|NCT04020133|PROCEDURE|saphenous nerve block|"The skin is disinfected and the saphenous nerve is located via Ultrasound . the transducer is placed anteromedially, approximately at mid-thigh level a high-frequency linear probe 5Y12 MHz prepared in a sterile fashion (Phillips HD11) .~The block needle (Stimuplex; Braun Medical, Bethlehem, Pa), is inserted in plane in a lateral-to-medial orientation and advanced toward the femoral artery .Once the needle tip is visualized anterior to the artery and after careful aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site . When injection of local anesthetic does not appear to result in its spread around the femoral artery, additional needle repositions and injections may be necessary."
40998265|NCT04020133|PROCEDURE|popliteal plexus block|After doing saphenous nerve block , we will move distally with the artery in the adductor canal until it moves away from the sartorius muscle to enter adductor hiatus . here , we will inject L.A above artery and so , popliteal plexus block will be accomplished
40998266|NCT04020133|DRUG|Plain bupivacaine|15ml of plain bupivacaine 0.5% will be given in both blocks
41149670|NCT01883297|BIOLOGICAL|Re-stimulated tumor-infiltrating lymphocytes (TILs)|Intravenous infusions: Dose level 1 (3 patients): 3x10\^7 TILs (with maximum 3x10\^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10\^8 TILs (with maximum 1x10\^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10\^8 TILs (with maximum 3x10\^8 autologous dendritic cells)
41149671|NCT01883297|BIOLOGICAL|Interleukin-2|Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing
41149672|NCT01883297|DRUG|Cyclophosphamide|Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
41149673|NCT05583331|PROCEDURE|Cataract surgery|Cataract surgery will be performed as per local practice and standard guidelines.
41149674|NCT05583331|PROCEDURE|Vitrectomy|Vitrectomy will be performed as per local practice and standard guidelines.
41149675|NCT06480500|DRUG|Ketamine hydrochloride|55 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.
41149676|NCT06480500|BEHAVIORAL|i-CBT (Internet-based Cognitive Behavioural Therapy)|Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.
41149677|NCT06480500|DRUG|Midazolam Hydrochloride|55 patients will receive midazolam hydrochloride, over six infusions, flexibly dosed between 0.02 mg/kg to 0.035 mg/kg.
41149678|NCT04296409|OTHER|Turkish Deglutition Handicap Index|Swallowing function will be evaluated by the Turkish Deglutition Handicap Index.
41149679|NCT06585644|DRUG|Furmonertinib in combination with Anrotinib and chemotherapy|The enrolled patients are planned to receive preoperative treatment with a combination of furmonertinib and anrotinib, along with platinum-based doublet chemotherapy. Three weeks after the completion of this treatment, they will undergo curative lung lobe resection and systemic lymph node dissection. Postoperatively, they will continue taking furmonertinib for one year. In case of disease progression, they will be switched to comprehensive therapy.
41310384|NCT05209412|DEVICE|Lepu Paclitaxel coated balloon|Paclitaxel is the pharmacologically active substance for anti-neointima. The active drug coating is located on the surface of the balloon, which contains 1.5 μg Paclitaxel per 1 mm2.
40998267|NCT04020133|DRUG|0.05 mg epinephrine|0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
40998268|NCT01200797|DRUG|SJG-136|Given IV
40998269|NCT01200797|OTHER|laboratory biomarker analysis|Correlative studies
40998270|NCT01438320|DIETARY_SUPPLEMENT|Quercetin|Bioflavonoid
40998271|NCT04471753|BEHAVIORAL|Coma Recovery Scale-Revised|Data were collected according to the Coma Recovery Scale-Revised operation guideline, the sum of the highest score on the evaluated subscales was taken as the final score, and the final diagnosis of patients was obtained (the highest score of each subscale was recorded). All participants were diagnosed by using CRS-R five times at least within 7 days. According to the results of the Coma Recovery Scale-Revised assessment, minimally conscious state and unresponsive wakefulness syndrome were distinguished.
41149680|NCT01072058|DRUG|TNF blockers (infliximab, adalimumab, etanercept)|Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
41149681|NCT06270199|BIOLOGICAL|Control|Standard treatment
41469603|NCT01374724|BEHAVIORAL|Tailored Pamphlet|A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.
40998272|NCT06254053|OTHER|zirconia reinforced glass ionomer|Restorative material
40998273|NCT06254053|OTHER|Glass ionomer cement|Restorative material
40998274|NCT05206474|DEVICE|IRADYN|"One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2 ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
40998275|NCT05635851|DRUG|Glyceryl Trinitrate Only Product in Oromucosal Dose Form|Glyceryl trinitrate will be administered via sublingual spray.
40998276|NCT05635851|OTHER|Placebo sublingual spray|A placebo sublingual spray will be administered.
40998277|NCT02413827|DRUG|Combination of varlilumab and ipilimumab|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg."
40998278|NCT02413827|DRUG|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC."
40998279|NCT06049056|OTHER|Invitation|During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,
40998280|NCT03398720|DRUG|HTI-1066 dose level 1|Starting dose level
40998281|NCT03398720|DRUG|HTI-1066 dose level 2|2nd dose level
40998282|NCT03398720|DRUG|HTI-1066 dose level 3|3rd dose level
40998283|NCT03398720|DRUG|HTI-1066 dose level 4|4th dose level
40998284|NCT05379439|OTHER|Structured Family Deliberation|Intervention families will be guided through the six modules included in the web-based decisional aid using a Structured Family Deliberation Tool. Parents will view narrated videos corresponding to each module and will be asked a series of questions related to their own lives and values. The process will continue until all modules are reviewed and all questions are completed.
40998285|NCT01878539|DEVICE|coagulometer|
40998286|NCT01878539|BEHAVIORAL|training programme|
40998287|NCT05506202|OTHER|Individual basic body awareness therapy|"Basic Body Awareness Therapy (BBAT) is a physiotherapeutic intervention directed toward patients' functional movement quality. The development of BBAT was based on the hypothesis of persons' lacking contact with and lacking awareness on their own body, with their inner life, external environment and in the relation to other persons. Thus, it leads to dysfunctional movement, pain and other body functions. BBAT focus on multi-perspective within a person including physical, physiological, psycho-social-cultural and existential perspectives. It directs patients to be aware, guides patients to have mental contact with their body, monitors internal sensations and external environment, and thus, to enhance the self-regulated behavior and positive emotional state."
40998288|NCT05506202|OTHER|Respiratory physiotherapy interventions|Comprehensive physical and psycho-social assessment and treatments are included. Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings.
40998289|NCT02515409|DEVICE|HHHFNC|After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.
40998290|NCT02515409|DEVICE|CPAP|CPAP, as a first line treatment in OSAS.
41469604|NCT01374724|BEHAVIORAL|Informational Pamphlet|"The National Cancer Institute Pamphlet Clearing the Air was provided to subjects."
40998291|NCT04616807|DRUG|Mexiletine|Observational Study
41149682|NCT06270199|BIOLOGICAL|Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions|3 doses of 5 million MSC will be administered
41149683|NCT06270199|BIOLOGICAL|Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions|6 doses of 5 million MSC will be administered
41149684|NCT04243954|DRUG|PCA IV Hydromorphone (continuous dose = 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
41469605|NCT01374724|BEHAVIORAL|Relapse Prevention Intervention|A 15 - 30 minute relapse prevention intervention designed to increase motivation to remain tobacco free.
40998292|NCT05655611|OTHER|first rib mobilization|To perform the first rib mobilization, the patient remained lying supine with the head in the examiner's right hand. Examiner then palpated the left first rib and passively side-bended the patient's head to the left to relieve any muscular tension on the first rib. Patient was then asked to take a deep breath in and out. During exhalation, the examiner applied pressure to depress the first rib, holding it in place at the end of the exhalation. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation. This process was repeated three times in two sets, for a total of six first rib depression mobilizations.
41149685|NCT04243954|DRUG|PCA IV Hydromorphone (continuous dose ≠ 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
41149686|NCT04243954|DRUG|Oral morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
41149687|NCT05119231|PROCEDURE|Pulmonary Vein Isolation|Catheter ablation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standard
41149688|NCT05119231|OTHER|Sham-Pulmonary Vein Isolation|Sham-Pulmonary Vein Isolation in deep sedation for at least one hour including femoral vein/artery puncture with introduction of sheaths and electrical cardioversion in presence of current atrial fibrillation
41149689|NCT01396122|PROCEDURE|Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System|Perform surgery with GYNECARE PROSIMA\* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
41149690|NCT05683639|OTHER|warming of the follicular aspiration needle|the follicular aspiration needle will be heated overnight before the ovarian aspiration procedure.
40998293|NCT05655611|OTHER|muscle energy technique|Muscle energy technique for glenohumeral joint restricted abduction-The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the glenohumeral joint to palpate for motion and the subjects are directed to press the elbow towards their body. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for three weeks with each repetition maintained for the duration of 7-1 seconds.
41149691|NCT06342635|DEVICE|Hydra Transcatheter Aortic Valve (THV) Series|The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
41149692|NCT06172699|DEVICE|Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device|All enrolled subjects who meet eligibility criteria will undergo an attempted implant within 30 days of consent. After successful device implant, subjects will be followed at 1 and 12 months. Subjects will be fitted with a Holter monitor during the 1m follow-up visit and will complete a minimum of 72 hours and maximum of up to 7 days of Holter monitoring.
41149693|NCT01970072|DRUG|Remimazolam Tosylate|
41149694|NCT01970072|DRUG|Midazolam|
40998294|NCT02963649|DEVICE|DCB|Drug Coated Balloon
40998295|NCT02963649|DEVICE|PTA|Percutaneous Transluminal Angioplasty
40998296|NCT02271191|DRUG|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
40998297|NCT01675882|BIOLOGICAL|Viaskin Peanut 50 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
40998298|NCT01675882|BIOLOGICAL|Viaskin Peanut 100 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
40998299|NCT01675882|BIOLOGICAL|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
40998300|NCT01675882|BIOLOGICAL|Viaskin Placebo|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
40998301|NCT01903304|OTHER|Olive Oil|3 months intervention
41149695|NCT05401669|PROCEDURE|Trans-radial access|Cerebral angiography performed by trans-radial access
41149696|NCT05401669|PROCEDURE|Trans-femoral access|Cerebral angiography performed by trans-femoral access
41149697|NCT01074229|DRUG|Placebo|placebo injection
41149698|NCT01074229|DRUG|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
41149699|NCT01074229|DRUG|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
41149700|NCT02025023|DRUG|5-fluorouracil Injection|If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
41149701|NCT02025023|DRUG|Triamcinolone Acetonide|If chalazion present at follow-up, another Triamcinolone injection will be done.
41149702|NCT02025023|PROCEDURE|Incision and Curettage|If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
41149703|NCT02025023|DRUG|Triamcinolone Acetonide/5-fluorouracil mixture|If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.
41149704|NCT05736458|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
41149705|NCT05736458|PROCEDURE|High controllability TMS target|Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
41149706|NCT01358175|DRUG|Secukinumab (75 mg)|Secukinumab (75 mg)
41149707|NCT01358175|DRUG|Secukinumab (150 mg)|Secukinumab (150 mg)
40998302|NCT05115383|OTHER|VO2 Max test|The participant will be equipped with a vo2 mask or mouthpiece. They will get on the bike and begin with a 5 minute warmup ranging from 30-100 watts. After the warm up there will be a 15-30 watt increase every minute in the cadence that the participant is required to maintain. Once the participant has decided to stop pedalling, the participants mask will be removed to ensure they are feeling well. They will allowed to continue pedaling at their own pace for a cool down for up to two minutes.
41149708|NCT01358175|DRUG|Placebo|Placebo
40998303|NCT02203487|DRUG|BIIF 1149 BS - single rising dose|
41149709|NCT05698888|DRUG|VP301|VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.
41469606|NCT05451940|DRUG|Hydroxyurea|Hydroxyurea is an orally available antimetabolite medication that has been shown to reduce the frequency of painful crises and acute chest syndrome in adults and children with sickle cell disease. Hydroxyurea treats sickle cell disease by a number of different mechanisms, including increasing the expression of fetal hemoglobin (HbF), which reduces sickling of red blood cells.
40792623|NCT05045859|BEHAVIORAL|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning. It assumes that PTSD exists within the couple's relationship and that partners can join together to reduce the presence of PTSD in their relationship. Sessions are organized into three phases of treatment: (1) psychoeducation about PTSD and relationships; (2) behavioral interventions to enhance relationship functioning; and (3) dyadic cognitive intervention designed to contextualize trauma memories and address trauma-relevant cognitions held by either partner that keep the PTSD and/or relationship distress alive. Out-of-session assignments are designed to assist the couple in reinforcing skills learned in the sessions.
40792624|NCT04760483|DEVICE|SoracteLite(TM) TPLA for BPH|see prior section
40998304|NCT02203487|DRUG|Placebo|
41149710|NCT02274116|OTHER|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 5 times per week for 2 weeks.
40792625|NCT02804490|DIETARY_SUPPLEMENT|Conventional white maize|Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
40998305|NCT00146874|DEVICE|cardiac resynchronization therapy|
40998306|NCT04327986|DRUG|M7824|Intravenous (IV) on Days 1 and 15 of every cycle
40998307|NCT04327986|DRUG|M9241|Subcutaneous injection on Day 1 of every cycle
41149711|NCT02274116|OTHER|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 5 times per week for 2 weeks.
41149712|NCT00111163|DRUG|sulfadoxine-pyrimethamine with artesunate|
40792626|NCT02804490|DIETARY_SUPPLEMENT|Provitamin A carotenoid biofortified maize|Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
40998308|NCT04327986|RADIATION|SBRT|Radiation therapy will be starting on Day 17 (+5 days) of Cycle 1 and continue for 5 consecutive business days.
40998309|NCT04216927|DRUG|Nitric Oxide|gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit
40998310|NCT04216927|DRUG|Oxygen|Oxygen alone will be entrained for placebo arm
41149713|NCT00111163|DRUG|amodiaquine with artesunate|
40998311|NCT05819164|DEVICE|Masimo oximeter|During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
40998312|NCT05819164|DEVICE|Nellcor oximeter|During this period, the Nellcor oximeter N-600 was used for SpO2 reading
41149714|NCT00111163|DRUG|chlorproguanil-dapsone|
41149715|NCT06432959|BEHAVIORAL|Psychotherapy, Positive Affect Promoting Activities|"The specific activities that constitute the positive affect interventions will be determined by the therapist and participant collaboratively. Some examples of positive affect promoting activities are:~* Watch videos of animals and babies~* Eat a piece of candy~* Recall and describe a past positive experience~* Describe the positive attributes of the participant~* Engage in gratitude practice~* Do something nice for someone~The in-session positive affect activities will last approximately five minutes. For the first four weeks, the positive affect activities will be completed at the beginning of the session. After that, therapists will look for opportunities to incorporate positive affect activities at stuck points or before learning a new skill in-session. Additionally, therapists will work with participants to identify ways in which the participants can incorporate positive affect activities into their lives between sessions."
41149716|NCT06432959|BEHAVIORAL|Psychotherapy|Meet with treatment providers individually or in group to learn skills to address symptoms associated with depression and emotion dysregulation
40998313|NCT05819164|DEVICE|Nonin oximeter|During this period, the Nonin oximeter was used for SpO2 reading
40998314|NCT00959842|DRUG|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
40998315|NCT01388842|DRUG|inhaled nitric oxide|Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
40792627|NCT02804490|DIETARY_SUPPLEMENT|Preformed vitamin A fortified maize|Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
40792628|NCT06511960|OTHER|Astaxanthin (12 mg/day) intervention|12 mg/day astaxanthin was administrated to all participants in the astaxanthin 12 mg/day groupfor 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
40792629|NCT06511960|OTHER|36 mg/day astaxanthin intervention|36 mg/day astaxanthin was administrated to all participants in the astaxanthin 36 mg/day group for 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
40792630|NCT06511960|OTHER|Placebo|12 mg/day placebo was administrated to all participants in the placebo group for 4 weeks. Following the placebo supplementation, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
40792631|NCT00286299|OTHER|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
40792632|NCT00286299|OTHER|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
40792633|NCT00286299|OTHER|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
40998316|NCT01388842|DRUG|Placebo|The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
40998317|NCT05685290|OTHER|Pushing with saline technique|Peripheral venous catheter placement by pushing with saline technique
40998318|NCT05685290|OTHER|Traditional method|Peripheral venous catheter placement with the traditional method by nurses in the clinic routinely.
40998319|NCT05657665|OTHER|Observational measurements of skin tone|Objective and subjective skin tone measurements will be performed.
40998320|NCT05677542|DRUG|secukinumab|all patients who received secukinumab
40998321|NCT02293070|OTHER|Delayed Enhanced Cardiac Magnetic Resonance Imaging|Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
40998322|NCT02293070|PROCEDURE|Cryoablation|All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
40998323|NCT05751239|OTHER|Questionaire|All participants answered an online questionaire. Out of the 837 participants 641 were included
40998324|NCT05078164|BEHAVIORAL|Bridging the Gap (BTG)|"Bridging the Gap: Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program: The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
40998325|NCT04396093|BEHAVIORAL|psychological support|specific questionnaires administration: EORTC QLQ 30, EORTC- PAN 26, HADS, Millon Clinical Multiaxial Inventory
40998326|NCT01212718|DRUG|FUFA|2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
40998327|NCT01212718|DRUG|systemic chemotherapy|CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
40998328|NCT00365196|BEHAVIORAL|CBT Hostility Reduction Program|
40998329|NCT02925546|DRUG|GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
40998330|NCT02925546|DRUG|GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
40998331|NCT02925546|DRUG|GSK2798745 milled API without SLS and hypermellose (Tablet C)|This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
40998332|NCT01102413|DRUG|Monofer|Infusion or injections
40998333|NCT01102413|DRUG|Iron Sulphate|Oral intake
40998334|NCT01380184|DRUG|ridaforolimus|4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
40998335|NCT00080743|DRUG|gefitinib|250 mg po once daily
41469607|NCT05451940|DRUG|Epoetin Alfa|Epoetin alfa is a first-generation erythropoiesis-stimulating agent (ESA), which are recombinant versions of erythropoietin (EPO) produced using recombinant DNA technology. Erythropoietin (EPO) is a glycoprotein hormone, naturally produced mainly in the kidneys in response to hypoxia and stimulates red blood cell production (erythropoiesis) in the bone marrow.
40998336|NCT00080743|DRUG|tamoxifen citrate|20 mg po once daily
41469608|NCT04223284|OTHER|D-Limonene|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes
41469609|NCT04223284|OTHER|SLVO|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes
40998337|NCT00080743|DRUG|Placebo|One pill po once daily
40998338|NCT00316979|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
41469610|NCT06233461|DRUG|TAK-279|TAK-279 capsules.
41469611|NCT06233461|DRUG|Placebo|TAK-279 placebo-matching capsules.
40998339|NCT03594383|DEVICE|ULTRASOUND|Lung ultrasound done through POCUS to diagnose pneumonia
40998340|NCT04190134|BEHAVIORAL|Socially Assistive Robot for Low Vision Rehabilitation|A socially assistive robot will be customized to engage in dialog and conversations to motivate and encourage optimal use of new magnification devices for reading at home by individuals with vision loss.
40998341|NCT04783506|OTHER|Observational Study|There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.
40998342|NCT04090554|DEVICE|Cytosponge™|The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.
40998343|NCT02165319|DEVICE|Barrel|Barrel-shaped endotracheal tube will be used during general anesthesia.
40998344|NCT02165319|DEVICE|Tapered|Tapered-shaped tube will be used during general anesthesia.
40998345|NCT00741481|PROCEDURE|FDG-PET imaging|FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
40998346|NCT02532296|BEHAVIORAL|Transition Coach (TC)|"TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.~Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.~Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care."
40998347|NCT02532296|BEHAVIORAL|Control|Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
41149717|NCT01622023|PROCEDURE|intra-uterine insemination|Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
41149718|NCT05531149|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
41149719|NCT05531149|DRUG|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
41469612|NCT06490406|BEHAVIORAL|Multimodal intervention (communication and education simulations) for EG1|"In summary, students in EG1 received the following multimodal intervention flow: 1) Health communication training, 2) Structured educational simulation using standardized patients (SPs), and 3) simulation feedback and self-assessment using a systematic guide that included the health literacy practices."
41469613|NCT00375791|DRUG|perifosine|100 - 150 mg daily
41469614|NCT00375791|DRUG|dexamethasone|20 mg twice weekly
41469615|NCT06113913|DRUG|Infliximab|Weekly administration of subcutaneous infliximab.
41469616|NCT06113913|DRUG|Infliximab|Bi-weekly administration of subcutaneous infliximab.
41469617|NCT06113913|DRUG|Infliximab|Optimized dosing schedule of intravenous infliximab.
41469618|NCT06132152|PROCEDURE|Open hemorrhoidectomy with 'cold' scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. 'Cold' scalpel will be used for cutting the perianal skin and anal mucose. To stop and prevent bleeding the monopolar coagulation may be used but on low energy level and with no touching the skin and mucose.
41469619|NCT06132152|PROCEDURE|Open hemorrhoidectomy with electrosurgical scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Electrosurgical scalpel will be used during all steps including cutting the perianal skin and anal mucose and to stop and prevent bleeding.
41469620|NCT05481736|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
41469621|NCT00759434|PROCEDURE|Surgery - Saphenofemoral ligation, saphenous strip and avulsions|Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
41469622|NCT00759434|PROCEDURE|EVLT|Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
41469623|NCT03074864|DRUG|Erlotinib Hydrochloride|Subjects receive erlotinib tablet 150mg orally once daily, after 12 weeks of induction phase, local radiotherapy is intercalated, and followed by 24-week erlotinib maintenance phase. At the end of maintenance, the subjects enter into the follow-up period.
41469624|NCT02710591|DRUG|Rimeporide|"Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight \> 30kg at Baseline"
41469625|NCT02629588|BEHAVIORAL|Multimodal or Unimodal Sensory stimulation|multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
41469626|NCT04046549|DRUG|Belatacept|Protocol versions 1 through 4: Belatacept 10 mg/kg by intravenous (IV) infusion on post-op Day 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), and at the end of Weeks 2, 4, 8 and 12; then 5 mg/kg IV every 4 weeks from Week 16 to Week 48.
41469627|NCT04046549|DRUG|VIB4920|"Protocol versions 1 and 2: VIB4920 1500 mg by IV infusion on post-op Days 1 and 14, and at the end of Weeks 4, 6, 8 and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.~Protocol versions 3 and 4: VIB4920 1500 mg by IV infusion on post-op Days 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), Week 2, and at the end of Weeks 4, 6, 8, and 10; then 1500 mg every 4 weeks from Week 12 to Week 48."
40792634|NCT01623167|DRUG|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 6
40792635|NCT01623167|DRUG|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 3
40792636|NCT01623167|DRUG|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months at higher dose, then reduced dose for 18 months, eltrombopag (experimental) administered Day 1 to month 6
40792637|NCT01623167|DRUG|Extension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
40792638|NCT05198076|DEVICE|High Frequency Repetitive Transcranial Magnetic Stimulation|The High Frequency repetitive TMS will be delivered to the scalp over the primary motor cortex contralateral to the more affected side using a MAGSTIM rapid2 machine (Model P/N 3576-23-09, MAGSTIM Company LTD, UK) connected with a figure - of- eight shaped coil. Each patient will receive 12 sessions over four weeks. Position of the coil will be adjusted to find the optimal scalp position and the location of stimulation that will be marked to maintain consistency among sessions. The session will consist of 24 trains of 50 stimuli each delivered at five Hz. The procedure will be conducted with the patients in the ''On'' state (75 min. after medications)
40792639|NCT03218839|DEVICE|PrePex male circumcision device|PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
40792640|NCT05918965|DEVICE|transcutaneous electrical vagal neurostimulation|daily for 12 weeks
40792641|NCT05792163|DRUG|SNP318 (A)|Capsule for oral administration
40792642|NCT05792163|DRUG|Placebo (B)|Placebo capsules matching the SNP318 capsules
40792643|NCT01626573|DRUG|Itacitinib|
40792644|NCT01626573|DRUG|Itacitinib Placebo|
40792645|NCT00415870|BEHAVIORAL|Printed Material|Printed Material
40792646|NCT00415870|BEHAVIORAL|Weekly Weighing|Weekly Weighing
40792647|NCT00415870|BEHAVIORAL|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
40792648|NCT00415870|DEVICE|Text Message|Text Message
40792649|NCT00415870|BEHAVIORAL|Diet Goals via Cell Phone|Diet Goals via Cell Phone
40792650|NCT00415870|BEHAVIORAL|Food Monitoring|Food Monitoring
40792651|NCT01673659|DRUG|Mometasone furoate|
40792652|NCT01673659|DRUG|Nasonex Nasal Spray|
40792653|NCT01673659|DRUG|Placebo nasal spray|
40792654|NCT04103112|DEVICE|Graduated compression stocking|"Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling."
40792655|NCT01662739|BEHAVIORAL|Questionnaire|
40792656|NCT04388215|DRUG|CKD-828|orally, 1 tablet once a day for 8 weeks
40792657|NCT04388215|DRUG|CKD-828(placebo)|orally, 1 tablet once a day for 8 weeks
40792658|NCT04388215|DRUG|D326|orally, 1 tablet once a day for 8 weeks
40792659|NCT04388215|DRUG|D326(placebo)|orally, 1 tablet once a day for 8 weeks
40792660|NCT04388215|DRUG|D337|orally, 1 tablet once a day for 8 weeks
40792661|NCT04388215|DRUG|D337(placebo)|orally, 1 tablet once a day for 8 weeks
40792662|NCT04388215|DRUG|D013|orally, 1 tablet once a day for 8 weeks
40792663|NCT04388215|DRUG|D013(placebo)|orally, 1 tablet once a day for 8 weeks
40792664|NCT02615119|DRUG|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
40792665|NCT02615119|DRUG|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
40792666|NCT04382027|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (monoacylglycerol form)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
40792667|NCT04382027|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (ethyl ester)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
40792668|NCT00921115|DRUG|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
40998348|NCT03530579|BEHAVIORAL|Educational group trainings|"Participants will receive 6 two and a half hour educational group training's over the course of 6 months. These sessions will be led by a trained CHW in your language and will be held on a monthly basis in a community based location.~Session 1: What is Diabetes~* Why is Prevention Important~Session 2: Nutrition Session 3: Physical Activity Session 4: Cardiovascular Disease \& Diabetes Complication Session 5: Stress Management Session 6: Access to Service"
40792669|NCT00921115|DRUG|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
40792670|NCT05309681|OTHER|Epworth's sleepiness scale; unstimulated saliva sample|Unstimulated saliva sample; Epworth's sleepiness scale
40998349|NCT03530579|BEHAVIORAL|Community Health Care Worker|A community health care worker answer your questions about diabetes and refer participant to a physician. Survey will be completed at the start of the study and during the 3rd, 6th and 12th months
40998350|NCT03237767|OTHER|MIE|"The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold."
40998351|NCT03237767|OTHER|HIIE|"The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery."
40998352|NCT06126757|DEVICE|PelviSense-assisted pelvic floor muscle training|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays the electrical activity of the PFMs on the user's mobile device. The re-usable sensor can be attached to the user's perineal region, and when positioned correctly, the width of the sensor is oriented along the medial-lateral axis, and the length is oriented along the anterior-posterior axis of the perineal region. The sensor detects PFM activity as the voltage between the two surface electrodes and transmits this activity to the data acquisition unit, which processes the signal and conveys it to a smartphone via a Wi-Fi connection. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts.
40998353|NCT06126757|OTHER|Active Comparator|Pelvic Floor Muscle Training Exercise will be performed without the assistance of the PelviSense Device.
40998354|NCT03301194|OTHER|RAMP-HT|RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
40998355|NCT01358604|GENETIC|polymerase chain reaction|
40998356|NCT01358604|GENETIC|protein expression analysis|
40998357|NCT01358604|GENETIC|western blotting|
40998358|NCT01358604|OTHER|flow cytometry|
40998359|NCT01358604|OTHER|immunohistochemistry staining method|
40998360|NCT01358604|OTHER|laboratory biomarker analysis|
40998361|NCT05512507|BEHAVIORAL|Physical Therapy Program|Physical Therapy Program
40998362|NCT04377360|RADIATION|Diffusing Alpha-emitter Radiation Therapy|Diffusing Alpha-emitter Radiation Therapy (DaRT) is a method of delivering interstitial brachytherapy, based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life). These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. As the radioisotope has a short half-life, the majority of radiation absorption happens in the tumor.
40998363|NCT03096652|PROCEDURE|Approach for cancer resection|
40998366|NCT01581632|DEVICE|LipiScan/LipiScan IVUS|Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
40998367|NCT05993611|PROCEDURE|Biopsy|Undergo biopsy
40998368|NCT05993611|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40998369|NCT05993611|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD6-CAR Tregs IV
40792671|NCT04037098|DIETARY_SUPPLEMENT|Magnesium lactate.|2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months
40792672|NCT04037098|DIETARY_SUPPLEMENT|Placebo|2 tablets orally every 12 hours of on inert placebo for three months
40792673|NCT01433406|DRUG|TAK-875|
40792674|NCT01433406|DRUG|TAK-875|
40792675|NCT01899638|DRUG|UMEC/VI 125/25 mcg|Combination in high dose
40792676|NCT01899638|DRUG|UMEC/VI 62.5/25 mcg|Combination in low dose
41149720|NCT04158323|DEVICE|Airway Management in patients with a anticipated difficult airway|survey of anesthesists and intensive care physician of the perfomans with the flexible endoscope in patients with a anticipated difficult airway
41149721|NCT00248794|BEHAVIORAL|Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
41149722|NCT00248794|BEHAVIORAL|Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
41149723|NCT00248794|BEHAVIORAL|Skills Group (SDG)|Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
41469628|NCT04046549|DRUG|Thymoglobulin|"Protocol versions 1 and 2: Thymoglobulin 3.0 mg/kg by intravenous (IV) infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0) (1 dose).~Protocol versions 3 and 4: Thymoglobulin 1.5 mg/kg by intravenous infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0), prior to VIB4920+belatacept infusion on post-op Day 1, on post-op Day 2, and prior to VIB4920+belatacept infusion on post-op Day 3 or 4."
41149724|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.|Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.
41149725|NCT05029089|DEVICE|Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)|Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.
41149726|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.
41149727|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft for regenerative periodontal therapy.
41149728|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft and sCTG For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft and sCTG for regenerative periodontal therapy.
41149729|NCT01000415|OTHER|Neoadjuvant chemotherapy followed by surgery|Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
41469629|NCT04046549|DRUG|Methylprednisolone|"Protocol versions 1 and 2: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, and 6.~Protocol versions 3 and 4: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, 6 and 7. Participants may be tapered to at least 20 mg per day on Day 8, to at least 10 mg per day on Day 15, and to at least 5 mg per day on Day 22. Discontinuation of prednisone following the post-op Day 28 visit."
41469630|NCT02866591|OTHER|mammography according to an auto-compression procedure|
41469631|NCT02866591|OTHER|mammography according to a standard procedure|
41469632|NCT02866591|OTHER|questionary|
41469633|NCT05929066|DRUG|Retatrutide|Administered SC
41149730|NCT02823171|DRUG|Treatment A: 400 mg Pacritinib P3CT|400-mg oral dose of pacritinib P3CT (reference) formulation capsules
41149731|NCT02823171|DRUG|Treatment B: 400 mg of pacritinib FMI|400-mg oral dose of pacritinib FMI (test) formulation capsules
41149732|NCT05293691|BEHAVIORAL|Body, Breath & Mind|"The program Body, Breath \& Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich \& Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks."
41469634|NCT05929066|DRUG|Placebo|Administered SC
41149733|NCT05293691|BEHAVIORAL|Moodgym|Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored. The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
41149734|NCT03151109|DIAGNOSTIC_TEST|CT Scan|CT scan at minimum 1 year post op
41149735|NCT04004663|DRUG|PF-06651600|PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods
41149736|NCT00475436|DRUG|GSK573719|
41149737|NCT01341418|PROCEDURE|Suprapatellar approach|Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
41469635|NCT00973934|DEVICE|Magstim Theta|
41469636|NCT00973934|DEVICE|Thymatron System IV|
41469637|NCT04974619|BEHAVIORAL|Online survey|Aim 1 Participants will be asked to complete a Qualtrics survey to identify knowledge gaps, health beliefs, attitudes, and educational learning preferences.
41469638|NCT04974619|BEHAVIORAL|Focus groups or Individual Interviews|Focus groups and/or individual interviews will be conducted in-person and/or remotely to receive feedback on the HPV vaccine education materials. Focus groups and/or individual interviews will be conducted with 24 young adult Latino men who have sex with men (YLMSM) in either English or Spanish (approximately 12 in Puerto Rico and approximately 12 in Florida). The purpose will be to gain feedback on the acceptability, accessibility, content, delivery preference, and aesthetics of the theoretically informed HPV education materials culturally targeted for Spanish- and/or English-speaking YLMSM.
41469639|NCT04974619|BEHAVIORAL|Interviews|In-depth interviews (n=20) will be conducted with key stakeholders (10 in PR and 10 in FL) eliciting feedback to inform intervention content and delivery methods and identify potential facilitators and barriers to intervention implementation.
41149738|NCT01341418|PROCEDURE|Infrapatellar approach|The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
41149739|NCT03770156|BEHAVIORAL|Questionnaires|Overall Impression of the current state and evolution since the attacks
41149740|NCT05542589|OTHER|Phenytoin phonophoresis|Phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
40792677|NCT01899638|DRUG|UMEC 125 mcg|LAMA mono in high dose
41149741|NCT05542589|OTHER|Sham phenytoin phonophoresis|Sham phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
41149742|NCT01613456|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae CNCM I-3856|2 capsules/day during 12 weeks
40792678|NCT01899638|DRUG|UMEC 62.5 mcg|LAMA mono in low dose
40792679|NCT01899638|DRUG|VI 25 mcg|LABA mono
41149743|NCT01613456|DIETARY_SUPPLEMENT|Placebo|"Capsule with comparable organoleptic properties and weight than the experimental product.~2 capsules/day during 12 weeks"
41149744|NCT05863871|DRUG|Linperlisib|80 mg, qd
41149745|NCT05057078|BEHAVIORAL|mindfulness-based stress reduction program|groups of 10 people will be formed among the patients included in the mindfulness program group. A mindfulness-based stress reduction program will be done once a week for eight weeks and will take approximately 60-120 minutes. A plan will be made with the patients for the day and time of the session. During this process, no application will be made to the control group. Meetings will be held as an online session via Zoom Video Communications.
41149746|NCT05256758|DRUG|Fenofibrate Capsules|49 patients randomised to receive fenofibrate for 6 months.
40998370|NCT05993611|PROCEDURE|Computed Tomography|Undergo CT
40998371|NCT05993611|PROCEDURE|Echocardiography|Undergo ECHO
41149747|NCT05256758|DRUG|Placental Lactogen|13 patients randomised to receive placebo for 6 months.
41149748|NCT03044756|DRUG|Omit Citrotide 0.25 dose on the day of triggering of ovulation|Omit Citrotide 0.25 dose on the day of triggering of ovulation
41469640|NCT00919178|BIOLOGICAL|DEN4 Vaccine Candidate|"DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
40792680|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered orally
40792681|NCT06102512|DRUG|LOXO-783|Administered orally
40792682|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered IV
40792683|NCT04871828|DRUG|Leukotriene Receptor Antagonist|Zafirlukast
40792684|NCT04871828|OTHER|Placebo|Placebo
40792685|NCT01384851|DRUG|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
40792686|NCT01384851|DRUG|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
40792687|NCT01384851|DRUG|Refresh Contacts|One drop both eyes four times daily for two weeks
41149749|NCT00483171|DRUG|CP-945,598|CP-945,598
41149750|NCT00483171|BEHAVIORAL|Non-pharmacological weight loss program (NPP)|Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
41149751|NCT00483171|BEHAVIORAL|Low Calorie Diet|Low calorie diet
41149752|NCT05483478|COMBINATION_PRODUCT|mobile health combined Multi-course Program|mobile health combined Multi-course Program
41310385|NCT05209412|DEVICE|Resolute Integrity Zotarolimus eluting stents|The device consists of a balloon-expandable intracoronary drug-eluting stent pre-mounted on the MicroTrac Rapid Exchange stent delivery system. Drug eluting stent is composed of metal stent, primer and drug coating. The Stent is manufactured from a cobalt alloy (MP35N). The strut thickness is 88.9 μm and the length elements is 0.9 mm. The drug coating consists of the zotarolimus and BioLinx polymer (C10/C19/PVP) system. A coating of polymers loaded with zotarolimus in a formulation applied to the entire surface of the stent at a dose of approximately 1.6 µg/mm2 which results in a maximum nominal drug content of 380 µg on the largest stent (4.0 x 38 mm).
40792688|NCT03506139|RADIATION|External beam radiation therapy|Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
40998372|NCT05993611|OTHER|Electronic Health Record Review|Ancillary studies
40998373|NCT05993611|PROCEDURE|Leukapheresis|Undergo leukapheresis
40998374|NCT05993611|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
40998375|NCT05993611|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/CT
40998376|NCT05993611|OTHER|Quality-of-Life Assessment|Ancillary studies
40998377|NCT05993611|BIOLOGICAL|Tafasitamab|Given IV
41310386|NCT05209412|DRUG|Aspirin|Aspirin is required for 3 months be a part of the dual antiplatelet therapy (DAPT) after PCI.
40792689|NCT01080924|DEVICE|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
40792690|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
40792691|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
40792692|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
40792693|NCT04256278|OTHER|Spermotrend|oral administration of antioxidants for three months
40998378|NCT05993611|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
40998379|NCT05296603|DRUG|IBI-322 Plus Lenvatinib|"IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg"
40998380|NCT05739851|DRUG|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
40998381|NCT05739851|DRUG|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
40998382|NCT03674060|DRUG|SYO-1644|"100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet"
40998383|NCT03674060|DRUG|Nexavar tab|Nexavar 200mg/tablet, PO, 1 tablet
40998384|NCT02242357|DRUG|Micardis®|
40998385|NCT02242357|DRUG|Micardis® Plus|
40998386|NCT06400433|PROCEDURE|Ultrasound-guided median nerve hydrodissection|Injected wrist will be supinated and slightly dorsiflexed. The transducer of the ultrasound will be placed transversely at the proximal carpal inlet. After sterile preparation, a 22 gauge needle will be inserted using the short-axis technique, in-plane ulnar approach. During hydrodissection, separation of either between the median nerve and flexor retinaculum or between the median nerve and the underlying flexor tendons will be visually confirmed.
40998387|NCT02639104|RADIATION|Radiography|"Obtaining patients lateral spot cervical spine radiography and will measure;~1. The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~2. If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~3. The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates"
41149753|NCT05602571|OTHER|ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught a home exercise program including stretching and eccentric strengthening exercises by an experienced physiotherapist. The eccentric exercises consisted of the following: three sets of 10 repetitions for wrist and elbow ﬂexion; two sets of 10 repetitions for wrist extension strengthening, starting with 50% of maximum strength and density and increasing the resistance each week; and ﬁnally, two sets of 10 repetitions for the wrist ﬂexor and extensor muscle groups comprising 20s of stretching and 10s of relaxing using the unaﬀected hand. Exercise program will be done twice a day for 3 months."
41149754|NCT05602571|PROCEDURE|PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged. Approximately 3 cc of the PRP obtained will be applied to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
41310387|NCT05209412|DRUG|Ticagrelor|Ticagrelor is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI.
41310388|NCT05209412|DRUG|Clopidogrel|Clopidogrel is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI when Ticagrelor is unfeasible or contradicted.
40998388|NCT02639104|OTHER|Electromyography|"Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms."
40998389|NCT05659173|DIAGNOSTIC_TEST|Blood taking|Blood test for vitamin D level and DNA extraction for VDR gene polymorphism
41469641|NCT00919178|BIOLOGICAL|DEN4 Vaccine Placebo|"DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
41469642|NCT04766229|COMBINATION_PRODUCT|Citalopram +/- Gabapentin + Sleepio + support person|All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person
41469643|NCT05062148|OTHER|Float-REST|Subjects receiving Float-REST will float for 60 minutes three times a week.
41469644|NCT05062148|OTHER|Photobiomodulation|Subjects receiving photobiomodulation will undergo a 20-minute therapy session three times a week.
41469645|NCT06616519|DEVICE|BenQ Materials MSENCI soft hydrophilic contact lenses|Test lenses were to be worn for approximately 90 days.
40998390|NCT02331225|OTHER|No intervention given|There is no intervention for this study
40998391|NCT03283020|DRUG|RemifentanilMNTX|Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
40998392|NCT03283020|DRUG|PlaceboMNTX|Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
41310389|NCT01057719|OTHER|Physiotherapy|Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
40998393|NCT03818516|OTHER|Oral Glucose Tolerance Test (OGTT)|Participants will undergo a fasting blood draw for inflammatory and metabolic markers before a 75gm oral glucose tolerance test (OGTT) and at 1, 2 and 3 hours post-OGTT. Behavioral assessments will also be administered pre- and post-OGTT administration.
41310390|NCT03571256|DRUG|TEV-50717|6-, 9-, 12-, 15-, and 18 mg oral tablets
41310391|NCT03571256|DRUG|Placebo|Placebo matched to TEV-50717 tablets will be taken BID.
41469646|NCT06616519|DEVICE|Visco Oxypure Color soft hydrophilic contact lenses|Control lenses were to be worn for approximately 90 days
41469647|NCT01998386|OTHER|Placebo gel without hydrogen peroxide|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.
41469648|NCT01998386|OTHER|6.0% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
40998394|NCT04098458|BEHAVIORAL|NDURE|NDURE consists of 6 key functions including (1) Improve patient knowledge about guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care. Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each at the pre-surgical consult, hospital discharge, and first postoperative visit.
40998395|NCT01139333|GENETIC|gene expression analysis|
40998396|NCT01139333|GENETIC|western blotting|
40998397|NCT01139333|OTHER|flow cytometry|
41469649|NCT01998386|OTHER|7.5% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
41469650|NCT01998386|OTHER|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
41469651|NCT00992563|DRUG|AL-39324 ophthalmic suspension|
41469652|NCT00992563|DRUG|Ranibizumab 10 mg/mL|
41469653|NCT03702634|BEHAVIORAL|Spiritual Care Assessment and Intervention (SCAI) framework|The study chaplain will work with the surrogate, using questions in four domains of spiritual care, to assess them and tailor the visit to their specific needs. The study chaplain will then utilize a pre-determined list of spiritual care interventions, and also document observable outcomes that occur at each visit (which are also listed within the SCAI framework).
41469654|NCT05025631|DRUG|Fruquintinib|Fruquintinib was administered for 21 consecutive days of a 28-day treatment cycle. The starting dose of fruquintinib was 3 mg/day, weekly incremental dose escalation occurred up to the maximum of 5 mg/day if no significant drug-related toxicities were observed. The highest tolerated dose from cycle 1 would be administered in cycle 2 and all subsequent cycles.
41469655|NCT04991012|DEVICE|PDT Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
41469656|NCT04991012|DRUG|Triamcinolone (Substance) therapy side|th The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
41469657|NCT06248645|DRUG|Oxygen|High-flow oxygen (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
41469658|NCT06248645|DRUG|Placebo|High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
41469659|NCT01772355|DEVICE|semi automated core needle biopsy of orbital tumors|
41469660|NCT00968019|DEVICE|Presillion stent|Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
40998398|NCT01139333|OTHER|laboratory biomarker analysis|
40998399|NCT03389464|BEHAVIORAL|computer-based confrontation with dysfunctional beliefs|"Patients will be presented with a virtual agent confronting them with their dysfunctional core beliefs (e.g. You are worthless). Participants will be instructed to contradict these virtual agents (e.g. That's not true, I'm a wonderful person)."
40998400|NCT02480556|PROCEDURE|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction \& cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
40998401|NCT02480556|PROCEDURE|Conservative separation of placenta|"Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu \& uterus is massaged awaiting spontaneous placental separation"
40998402|NCT00558103|DRUG|lapatinib|Oral administration
40998403|NCT00558103|DRUG|Pazopanib|Oral administration
40998404|NCT00367172|BEHAVIORAL|Directly Administered Antiretroviral Therapy|
40998405|NCT02495311|PROCEDURE|myomectomy or adenomyomectomy|
40998406|NCT04196478|DEVICE|doppler ultrasound|a 7.5 MHz ultrasound (US) linear probe is needed, grey-scale ultrasound and Color Doppler and a minimum display facility of the Doppler velocity spectrum for blood flow calculation are mandatory tools.
41310392|NCT04715230|BIOLOGICAL|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
40998407|NCT05929092|PROCEDURE|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, the TFBC regimen (TBI/Flu/Bu/Cy) combined with UCBT is safe and feasible for the treatment of patients with high-risk malignant hematological diseases, which has enormous potential to improve patient outcomes.
40998408|NCT02150655|BIOLOGICAL|Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|
40998409|NCT02150655|BIOLOGICAL|Placebo|
40998410|NCT00772356|DEVICE|Accu-Chek Spirit Insulin Pump|
40998411|NCT00772356|DEVICE|Comparator insulin pump|
40998412|NCT05209022|DIETARY_SUPPLEMENT|Beetroot juice|140 mL of beetroot juice or beetroot juice placebo
40998413|NCT02734810|DRUG|Liprotamase Powder for Oral Solution|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
40998414|NCT03601221|OTHER|Sample collection|Collection of one sampling pouch from each blood donor
40998415|NCT01734551|DRUG|Morphine|"Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.~Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is \<0.1mg/kg/day, may discontinue."
40998416|NCT01734551|DRUG|Clonidine|Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
40998417|NCT00443586|BEHAVIORAL|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
40998418|NCT00443586|BEHAVIORAL|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
40998419|NCT00443586|BEHAVIORAL|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
40998420|NCT00443586|BEHAVIORAL|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
40998421|NCT02346136|BEHAVIORAL|Tai Chi training|
41310393|NCT04715230|DRUG|Lorazepam|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting.
41310394|NCT04715230|DRUG|Haloperidol|Haloperidol is commonly used to treat agitation due to psychosis.
40998422|NCT02346136|BEHAVIORAL|Educational Control|
40998423|NCT00486265|DRUG|AZD4877|intravenous infusion administered on days 1, 2 and 3
40998424|NCT02449239|BIOLOGICAL|Vicinium|Intravesical administration
40998425|NCT02889094|OTHER|Routine care|Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
40998426|NCT05233566|DRUG|Ketamine|NMDA antagonist
40998427|NCT05233566|DRUG|Normal saline|IV fluid acting as a placebo
40998428|NCT00178191|OTHER|Bladder diary|3-day bladder diary
40998429|NCT00178191|OTHER|Questionnaires|Incontinence Quality of Life questionnaires
40998430|NCT00178191|PROCEDURE|Urodynamics|Urodynamics
40998431|NCT00178191|OTHER|Pad weight|Pad weight
40998432|NCT00654277|DRUG|Ondansetron|ODT, 8 mg, single-dose
40998433|NCT00654277|DRUG|Zofran|ODT, 8 mg, fasting conditions
41310395|NCT01842607|BIOLOGICAL|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
40998434|NCT03375541|OTHER|Risk Aversion Calculator|The calculator asks the participant to rate their level of aversion to having a set list of potential medication side effects (0 = no concern; 1 = mild concern; 2 = moderate concern; 3 = moderate to severe concern; 4 = severe concern)
40998435|NCT01890772|DRUG|Telaprevir|
40998436|NCT01890772|DRUG|Peginterferon alfa-2a|
40998437|NCT01890772|DRUG|Ribavirin|
40998438|NCT01890772|DIETARY_SUPPLEMENT|Vitamin D|
40998439|NCT02699203|BEHAVIORAL|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
40998440|NCT02699203|BEHAVIORAL|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
41310396|NCT01264094|DRUG|Clevudine|clevudine 30 mg qd
41310397|NCT00123851|DRUG|Tarceva (OSI-774)|
41310398|NCT00123851|DRUG|Capecitabine|
41310399|NCT00123851|DRUG|Oxaliplatin|
41310400|NCT06148896|BEHAVIORAL|GrExPACT|Combining physiotherapy group exercise with acceptance and commitment therapy delivered by physiotherapy
41310401|NCT06148896|BEHAVIORAL|GrEx|Group physiotherapy exercise
41310402|NCT03629041|DEVICE|Microneedle Patch|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
40998441|NCT04968132|OTHER|Multicomponent opioid reduction and pain management pathway|Pre-operative pain education and expectation setting, identification and modification of risk factors in high risk patients, postoperative individualized analgesic prescriptions, and continued support for pan control and recovery facilitated by an interventions coordinator.
40998442|NCT04968132|OTHER|Standard care|Standard perioperative care, surgical treatment, and pain medications.
41310403|NCT03629041|DEVICE|Patch with no microneedles|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
40792694|NCT04652804|BEHAVIORAL|Low intensity HCV treatment adherence support|A 28-day supply of medication will be dispensed to participants at entry, 4 weeks, and 8 weeks. Participants will receive standard adherence counseling at entry and every refill pickup/home or field delivery. Participants will have access to all of the services available at the ICC including facilitated linkage to referrals as needed. Site staff will routinely track clients who miss refill appointments in real-time using standard tracking measurements
40998443|NCT03323489|RADIATION|Celiac Plexus Radiosurgery|patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
40998444|NCT00012558|DRUG|lithium|
41310404|NCT04774042|DIETARY_SUPPLEMENT|Infloran probiotic|Infloran
41310405|NCT04774042|DIETARY_SUPPLEMENT|HAC probiotic|HAc probiotic
41469661|NCT04768296|DRUG|Berzosertib|Participants received Berzosertib at a dose of 105 milligrams per square meter (mg/m\^2 ) intravenously on Day 2 and Day 5 of each 21-day cycle until disease progression or other criteria for study intervention discontinuation are met.
41469662|NCT04768296|DRUG|Berzosertib|Participants received Berzosertib at a dose of 210 mg/m\^2 intravenously on Day 2 and Day 5 of each 21-day cycle in DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
40998445|NCT00012558|DRUG|valproate|
40998446|NCT00012558|DRUG|bupropion|
40998447|NCT00012558|DRUG|paroxetine|
40998448|NCT00012558|DRUG|lamotrigine|
40998449|NCT00012558|DRUG|risperidone|
40998450|NCT00012558|DRUG|inositol|
40998451|NCT00012558|DRUG|tranylcypromine|
40998452|NCT00012558|BEHAVIORAL|Cognitive Behavioral Therapy|
40998453|NCT00012558|BEHAVIORAL|Family-focused Therapy|
40998454|NCT00012558|BEHAVIORAL|Interpersonal and Social Rhythms Therapy|
41310406|NCT04774042|DIETARY_SUPPLEMENT|Infloran placebo|Infloran placebo
41310407|NCT04774042|DIETARY_SUPPLEMENT|HAC placebo|HAC placebo
40998455|NCT05326165|DEVICE|Juzo Compression Sleeve and Glove|Elasticized garment sized for arm and hand to create pressure to reduce swelling
41469663|NCT04768296|DRUG|Topotecan|Participants received Topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
41469664|NCT03399578|BIOLOGICAL|ChAdOx1 MERS|The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
41469665|NCT05882045|DRUG|Retatrutide|Administered SC
40998456|NCT05326165|DEVICE|Compression Sleeve Sensor|Small device embedded within compression sleeve garment collecting usage information
41469666|NCT05882045|DRUG|Placebo|Administered SC
40792695|NCT04652804|BEHAVIORAL|Medium intensity HCV treatment adherence support|The medium intensity intervention will include standard of care dispensation of a 28-day supply of medication at entry, 4 weeks and 8 weeks. Participants will be assigned to a patient navigator (PN) and receive tailored patient navigation support for medication reminders, picking up medication refills (or home or field delivery of study medications), overcoming barriers as well as service linkage. Participant will be contacted by the PN at least once every two weeks.
40998457|NCT04155008|DRUG|Dexamethasone|If the patient's prognosis is extremely poor (less than 12 weeks expected survival, based on discussion with the patient's treating physicians) and there is no additional disease modifying therapy planned, the patient will be prescribed 4mg dexamethasone (which is FDA approved), once daily, to be taken orally in the morning.
40998458|NCT04155008|DRUG|Dronabinol|If the patient has a history of marijuana use or has tried it in the past and had a positive experience with it, then the patient will be prescribed dronabinol (which is FDA approved) 2.5mg, twice daily before meals.
40998459|NCT04155008|DRUG|Mirtazapine|If the patient does not have any history of marijuana use, mirtazapine will be prescribed. If the patient is under the age of 70, then the patient would be prescribed 15mg of mirtazapine (which is FDA approved), once daily, to be taken orally at bedtime. For geriatric population (if the patient is over the age of 70), then the patient would be prescribed 7.5mg of mirtazapine, once daily to be taken orally at bedtime.
40998460|NCT04155008|BEHAVIORAL|Nutrition Intervention|"Nutrition intervention will be in accordance with the Academy of Nutrition and Dietetics guidelines. The intervention will involve purposefully planned action(s) designed with the intent of changing a nutrition-related behavior, risk factor, environmental condition, or aspect of health status"
40998461|NCT01168024|DEVICE|CINCOR™ System and contrast conservation unit (CCS-1)|Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
41310408|NCT00335504|DRUG|oligofructose-enriched inulin|Given orally
41310409|NCT00335504|DRUG|sulindac|Given orally
41310410|NCT00335504|DRUG|placebo|Given orally
41310411|NCT00335504|DRUG|atorvastatin calcium|Given orally
41310412|NCT00335504|OTHER|laboratory biomarker analysis|Correlative studies
41310413|NCT02305901|DRUG|repaglinide|single dose on day 1 of visits 2 and 3
41310414|NCT02305901|DRUG|BI 187004 tablet|multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3
41310415|NCT02305901|DRUG|bupropion extended release tablet|single dose on day 3 of visits 2 and 3
41469667|NCT05990231|DRUG|Cadonilimab combined Anlotinib|Cadonilimab: intravenous administration at a dose of 10mg/kg on day 1 of each cycle, every 3 weeks (Q3W) Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle
40998462|NCT01168024|OTHER|Standard of Care plus peri-procedural hydration|The control group will receive a peri and post-procedural hydration rate.
40998463|NCT03925727|DRUG|Tavilermide ophthalmic solution|BID topical dosing
41149755|NCT05602571|PROCEDURE|Sham PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~In Sham-PRP group,10 ml of venous blood will be taken and after the same waiting time 3 cc of 0.9% saline will be injected to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
41149756|NCT06047795|OTHER|Experimental|"Cycling 2 days per week with Borg dyspnea 4-6 level for 15-20 minutes/ day with 5 minutes warm-up and cool-down.~Strengthening exercises for upper limb muscles (pull-ups and biceps curls) and for lower limb muscles (sit-to-stand and step-up exercises) with 3 sets of 8-12 repetitions \* 2 days per week.~Pursed Lip breathing exercise 3 sets of 5-10 repetitions for 6 weeks"
40998464|NCT03925727|OTHER|Placebo|BID topical dosing
41149757|NCT06047795|OTHER|Control|"Usual care: frontal chest radiographs, verbal advice to quit smoking, and reduce exposure to biomass smoke.~Spirometry to screen for airway diseases. Antibiotic and systemic glucocorticoid therapy."
41149758|NCT02714244|OTHER|Volume expansion|Volume expansion with rapid administration of 500 ml of crystalloid
41149759|NCT01709071|DRUG|IPV|
41149760|NCT01709071|DRUG|Low dose Sabin-IPV|
41149761|NCT01709071|DRUG|Low dose adjuvanted Sabin-IPV|
41149762|NCT01709071|DRUG|Middle dose Sabin-IPV|
41149763|NCT01709071|DRUG|Middle dose adjuvanted Sabin-IPV|
40998465|NCT04813055|PROCEDURE|Therapeutic EUS|"1. EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy~2. EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents).~3. EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy~4. EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents~5. EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents)~6. EUS-guided pancreatic duct drainage"
40998466|NCT04813055|PROCEDURE|Percutaneous Procedures|Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)
40998467|NCT04813055|PROCEDURE|Surgical Interventions|Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)
40998468|NCT04813055|PROCEDURE|non-EUS-based endoscopic procedures|Other endoscopic procedures not involving EUS (enteral stenting, Enteroscopy-assisted ERCP)
41149764|NCT01709071|DRUG|High dose Sabin-IPV|
41149765|NCT01709071|DRUG|High dose adjuvanted Sabin-IPV|
41149766|NCT01767376|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
41149767|NCT01767376|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
41149768|NCT01599078|DRUG|Paclitaxel|Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
41149769|NCT01599078|DRUG|Placebo|Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
41149770|NCT02815709|DRUG|Oliceridine|
41149771|NCT02815709|DRUG|Placebo|
41149772|NCT02815709|DRUG|Morphine|
41469668|NCT05062915|DIAGNOSTIC_TEST|HINTS|HINTS (Head Impulse, Nystagmus, test of skew) V-HIT (Head impulse test google assisted) MRI: 3-4 MRI of the brain including the posterior fossa Vestibular rehabilitation for all patients with a vestibular deficit.
41469669|NCT02506231|DRUG|Folinic acid|
41149773|NCT00474409|DRUG|Merislon|
41149774|NCT00291928|DRUG|Part A|Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14
41149775|NCT00291928|DRUG|Part B|Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
41149776|NCT00575081|DEVICE|Stereotactic brain procedures|Stereotactic brain procedures
41310416|NCT04321317|OTHER|Measure of body composition by Air Displacement Plethysmography (ADP)|Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.
41469670|NCT02506231|DRUG|Placebo|
40998469|NCT03352921|OTHER|clinical pilates exercises|servikal, deep flexor muscles, posture exercsises
40998470|NCT03352921|OTHER|home exercises program|stretching, strengthening, and posture exercises to reduce functional disability, to relieve the pain and to provide postural straightening.
40998471|NCT03566628|OTHER|Warmed Isotonic Saline|Isotonic saline warmed to 39ºC.
40998472|NCT03566628|OTHER|Room-Temperature Isotonic Saline|Isotonic saline at room temperature
40998473|NCT02306512|PROCEDURE|H&E|Sample will be stained with H\&E according to standard procedures
41149777|NCT05172843|PROCEDURE|Surgical knee arthroplasty|"Surgery will be performed 3 months from inclusion in the trial (at week 13). The procedure and type of prosthesis and postoperative program will be at the discretion of the involved surgeon and the participating department.~Post-surgical care and rehabilitation will follow current clinical standards."
41469671|NCT05866718|BEHAVIORAL|Self-Compassionate Touch Intervention|Participants will be taught the micropractice (\<20-second/day personal practice) via video recording.
41469672|NCT05866718|BEHAVIORAL|Habit Formation Tools|Participants will receive evidence-based tools for promoting habit-formation.
40998474|NCT02306512|PROCEDURE|IHC MART-1|Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.
40792696|NCT04652804|BEHAVIORAL|High intensity HCV treatment adherence support|The high intensity intervention will involve patient-centered DOT with flexibility in terms of the frequency of pickup and the site of DOT (ICC, field-based) with a minimum of at least 1 observed dose per week. Participants in this arm will also receive PN support for overcoming barriers and service linkage similar to participants in Arm 2. The main differences between Arms 2 and 3 are: (i) medications will not be dispensed for more than one week at a time (to coincide with opioid agonist therapy (OAT) dosing, where applicable); and (ii) ≥1 dose/week will be observed.
41469673|NCT04526093|OTHER|Medical Cannabis|Verified medical cannabis products available within the current real-world study conform to Health Canada testing requirements
41469674|NCT00113724|DRUG|TPI 287 Injection|
40792697|NCT01991483|DRUG|LY2928057|Administered intravenously
40792698|NCT01991483|DRUG|Placebo|Administered intravenously
41469675|NCT04184206|BEHAVIORAL|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness component
41469676|NCT04184206|BEHAVIORAL|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness component
40792699|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
40792700|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
40792701|NCT05165732|BIOLOGICAL|Experimental vaccine 1|Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
41469677|NCT04184206|BEHAVIORAL|attention training intervention 3|14-day smartphone-based audio-guided attention training program without mindfulness component
40792702|NCT05165732|BIOLOGICAL|Experimental vaccine 2|Inactivated COVID-19 vaccine manufactured by Beijing Institute of Biological Products Co.,Ltd.4ug inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
40792703|NCT05165732|BIOLOGICAL|Experimental vaccine 3|Inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.200WU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
41469678|NCT03282149|BIOLOGICAL|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
41469679|NCT01236417|BEHAVIORAL|Exercising block|Exercising for 8 weeks using an elastic band
41469680|NCT01610063|OTHER|Pharmacogenomic algorithm|Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
41469681|NCT04087317|DRUG|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
40792704|NCT04845594|BEHAVIORAL|MySmileBuddy (MSB)|The technology-based MSB program equips community health workers (CHWs) with an iPad-based app that facilitates assessment of a child's early childhood caries (ECC).
40792705|NCT04650438|DEVICE|Transcranial Magnetic Stimulation (TMS) over the left inferior frontal gyrus (IFG)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
40792706|NCT04650438|DEVICE|Transcranial Magnetic Stimulation (TMS) over the left inferior parietal lobule (IPL)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
40792707|NCT00532129|DRUG|Rituximab|375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.
40792708|NCT00532129|DRUG|Chlorambucil|10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
40792709|NCT02359006|DRUG|Minocycline|Minocycline will be compared with placebo
40792710|NCT02359006|DRUG|Placebo|Placebo will be compared with minocycline
40792711|NCT03768089|DRUG|Placebo (matched to VX-121 suspension)|Placebo matched to VX-121 suspension for oral administration.
40998475|NCT02306512|PROCEDURE|IF MART-1|Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.
40998476|NCT02306512|PROCEDURE|IF cocktail|The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
40792712|NCT03768089|DRUG|VX-121 (Suspension)|Suspension for oral administration.
40792713|NCT03768089|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
40792714|NCT03768089|DRUG|IVA|Tablet for oral administration.
40998477|NCT03463564|DEVICE|Insulin pump|Continuous subcutaneous insulin infusion consisting of the delivery of insulin lispro as basal rate and boluses administered before meals.
40998478|NCT03463564|DRUG|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or degludec at bed-time of basal insulin
40998479|NCT02338752|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
41469682|NCT04087317|DRUG|Ibuprofen 400Mg Tab|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
40792715|NCT03768089|DRUG|Placebo (matched to TEZ/IVA)|Placebo matched to TEZ/IVA for oral administration.
40792716|NCT03768089|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
40792717|NCT03768089|DRUG|VX-121 (Tablet)|Tablet for oral administration.
41310417|NCT05942937|OTHER|Education Intervention (The HepPEd Program)|"All healthcare providers, correctional officers, and people in prison (HepPEd Program target audience groups) at each participating site are anticipated to be exposed to the HepPEd Program over the course of the three-month education intervention phase.~The HepPEd Program involves a suite of multi-modal resources targeting each target audience group and a peer education program (for correctional officer and people in prison groups only). The HepPEd Program resources will be delivered in an informal, mass education-style, as well as in peer to peer format."
40998480|NCT02338752|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
40998481|NCT01070316|DRUG|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
40792718|NCT03768089|DRUG|Placebo (matched to VX-121 tablet)|Placebo matched to VX-121 tablet for oral administration.
40792719|NCT02954224|OTHER|CPAP treatment|Patients who are randomized to auto-titrating CPAP will use an auto CPAP device on postoperative days 1, 2, and 3
40792720|NCT05940506|DRUG|KX-826-2.5 mg (0.25%)/60 mL BID|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
40792721|NCT05940506|DRUG|KX-826-5 mg (5%)/60 mL QD|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily.
41149778|NCT05172843|BEHAVIORAL|Supervised weight loss|"The supervised intensive dietary weight loss program will be initiated 3 months from inclusion in the trial (at week 13) and lasts for 12 weeks.~The program includes full meal replacement by a standard liquid energy intake in a supervised dietary program. Participants will attend the nutrition department weekly. They will be weighed on a decimal scale, given nutritional and dietetic instructions by an experienced dietitian and formula diet products are handed in sessions of 1-2 h. The participants will be taught to make diet plans.~Following the 12 weeks intensive dietary weight loss program participants will be scheduled for two booster follow-up sessions with a dietician at weeks 39 and 51."
40792722|NCT05940506|DRUG|KX-826-5 mg (5%)/60 mL BID|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
40792723|NCT05940506|OTHER|Placebo|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm),starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily for QD dose groups, and once in the morning and once in the evening for the BID dose groups.
40792724|NCT04972188|DRUG|ZYIL1 Capsule|NLRP3 inflammasome inhibitor
41149779|NCT06430151|DEVICE|CUE1|Sternal worn focused vibrotactile stimulation and cueing device
41149780|NCT02976363|RADIATION|Radiotherapy breast cancer|
41149781|NCT02976363|OTHER|Evaluation Maximal Respiratory Pressures|
41310418|NCT00793676|OTHER|spirometry|
41310419|NCT00793676|OTHER|blood test|
40792725|NCT06032858|DRUG|Apremilast 30mg|Apremilast 30mg twice daily
40792726|NCT01411423|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
40792727|NCT01798381|DIETARY_SUPPLEMENT|Essential fatty acids|
40998482|NCT04306809|BEHAVIORAL|Internet-delivered ACT for PTSD and chronic pain|The participants will go through an active internet-based ACT treatment focused on education about PTSD, value-based exposure for the traumatic memory and avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
40998483|NCT06322056|DRUG|Intensive control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 70 mg/dL.
41310420|NCT00002358|DRUG|Sorivudine|
41469683|NCT04087317|DRUG|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
41469684|NCT04087317|DRUG|Ibuprofen 400 mg|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
41469685|NCT04087317|DRUG|MIR|At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
41469686|NCT05768178|DRUG|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg orally on a twice daily schedule throughout a 28-day cycle.
41469687|NCT05768178|DRUG|Cobimetinib|Participants will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.
41469688|NCT04225065|OTHER|Chlorhexidine|Chlorhexidine prep prior to surgery
40998484|NCT06322056|DRUG|Intensive control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 100 mg/dL.
41310421|NCT04474899|DRUG|Moxonidine 0.4 MG|Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
41469689|NCT04225065|OTHER|Betadine|Betadine prep prior to surgery
41469690|NCT05709782|PROCEDURE|Spine Radiosurgery|scan
41310422|NCT04474899|DRUG|Amlodipine 5mg|Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
40998485|NCT06322056|DRUG|Standard control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.
40998486|NCT06322056|DRUG|Standard control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.
41469691|NCT05709782|DEVICE|Magnetic Resonance imaging|scan
41469692|NCT05709782|RADIATION|MR-LINAC|scan
41469693|NCT03689894|DRUG|Ibrutinib|"Subjects will receive oral (PO) Ibrutinib 140 mg once daily with Rituximab 375 mg per meter squared IV weekly x4 (with pre-medications and infusion procedure as per standard protocol) Rituximab Pre-medications:Acetaminophen 650 mg PO; Diphenhydramine 25 mg PO/IV; Dexamethasone 20 mg IV.~If no adverse events \>Grade 3+ are noted after 1 week, the Ibrutinib dose schedule will be increased to 280 mg daily. If no adverse events \>Gr3+ are noted after an additional 1 week, the Ibrutinib dose will be increased to 420 mg daily."
40792728|NCT00618735|DRUG|BIIB021|Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
40792729|NCT00618735|DRUG|BIIB021|Twice daily dosing
40998487|NCT04424238|BEHAVIORAL|m-health management|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care.
40998488|NCT03741764|DEVICE|Vivosorb|Resorbable implant device
40998489|NCT04010942|DRUG|Vit D|Injection
40998490|NCT04010942|DRUG|Metformin|tablets
40998491|NCT04010942|DRUG|Clomiphene|Tablet
40998492|NCT03437200|DRUG|Nivolumab|Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
41469694|NCT03689894|DRUG|Rituximab|Subject will receive an intravenous infusion of 375mg per meter squared weekly for 4 weeks, which may be repeated 8 weeks after initial therapy if only a suboptimal response is achieved.
40998493|NCT03437200|DRUG|Ipilimumab|Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
41310423|NCT03867669|OTHER|Open Bay Unit|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
41310424|NCT03867669|OTHER|Single patient room|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
41310425|NCT04079894|OTHER|Standard Movement Protocol|Participant walking, cycling and sitting according to a pre-specified protocol.
40792730|NCT02345655|PROCEDURE|urine drug testing|Performed a OS-UDT test in general practice on patients starting buprenorphine
40792731|NCT02345655|OTHER|no test|normal procedure decided by the general practitioner
40792732|NCT06551675|DIETARY_SUPPLEMENT|Silkworm pupa tablets|Participants will begin taking the silkworm pupa tablets immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
40998494|NCT03437200|OTHER|Chemoradiation|All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.
40998495|NCT04066426|DRUG|naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol|NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
40998496|NCT03701490|DRUG|Progesterone subcutaneous|25 mg/twice a day.
40998497|NCT03701490|DRUG|Progesterone Vaginal Product|200 mg three times a day.
40998498|NCT06281041|DRUG|Antiplatelet Agents|Aspirin or clopidogrel
41149782|NCT05006859|OTHER|Cohorte|Assessment of postural wheelchair disorders, as well as PW pain, and pressure ulcers associated with sitting
41149783|NCT05757622|DRUG|Propofol|Procedural sedation provided with propofol and remifentanil using target controlled infusions
41469695|NCT06565208|DRUG|SAT-3247|SAT-3247 is an oral tablet that is a potent, muscle penetrant, small molecule inhibitor of AAK1; inhibition of AAK1 rescues perturbed asymmetric division of satellite stem cells, resulting in increased muscle regeneration in animal models of DMD. In vitro and in vivo animal pharmacology studies have demonstrated the efficacy of SAT-3247 in improving muscle strength and the necessary target coverage to maximize functional muscle improvement.
40792733|NCT06551675|DIETARY_SUPPLEMENT|Control product|The sham comparator contains 0.5% of the active ingredient of the study product, indistinguishable in appearance. Participants will begin taking the control immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
40792734|NCT03008070|DRUG|IVA337|1200mg
40792735|NCT03008070|DRUG|IVA337|800mg
40792736|NCT03008070|DRUG|Placebo|Placebo to match
40792737|NCT05140356|DEVICE|Applied high amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(100%RMT) for 20 minutes each time, 5 times a week
40792738|NCT05140356|DEVICE|Applied low amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(15%RMT) for 20 minutes each time, 5 times a week
40792739|NCT06227533|PROCEDURE|Endodontic regeneration using concentrated growth factor compared with Platelet rich fibrin|regeneration of mature necrotic teeth with periapical abscess using concentrated growth factor compared with Platelet rich fibrin to allow healing of periapical lesion and regaining sensibility
40792740|NCT02325570|DEVICE|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
40792741|NCT02325570|PROCEDURE|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
40998499|NCT02287311|BIOLOGICAL|MABEL CTLs|"Dose escalation:~DL1:2x10\^7 cells/m2+2x10\^7 cells/m2~DL2:2x10\^7cells/m2+5x10\^7 cells/m2~DL3:5x10\^7 cells/m2+1x10\^8 cells/m2~\*Doses are based on total CD3+cells/m2~Patients with active disease that have apparent clinical benefit at the 8 wk post 1st infusion (6 wks after 2nd infusion) or subsequent evaluations may receive up to 6 additional doses of CTLs at intervals at least 6 wks apart, each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) before additional infusions. Patients cannot receive additional doses until the initial safety profile is completed at 6 wks following the second infusion."
40998500|NCT02287311|DRUG|Cyclophosphamide|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
40998501|NCT02287311|DRUG|Fludarabine|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
40998502|NCT05388942|PROCEDURE|Virtual reality hypnosis|VRH offers predefined hypnosis sessions with no need of trained physician or nurse or caregiver mobilization. Consisting of a headset including headphones and a virtual reality screen, VRH allow patients to select a visual and sound environment (e.g.: tropical beach, space, underwater...) into which the hypnotic speech is delivered. That way, the patient's attention is distracted and muscular relaxation is obtained, a major relaxation factor. HRV is simple, quick, and presumably safe.
41310426|NCT04079894|DEVICE|Accerelerometer Monitoring|7 days of accelerometer monitoring in participants home-environment.
41310427|NCT03888391|DEVICE|Active TNS|
41310428|NCT03071549|DRUG|Trichloroacetic acid peel|Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
40792742|NCT01446887|OTHER|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
40792743|NCT05267535|DRUG|Piromelatine 20 mg|Tablets
40792744|NCT05267535|DRUG|Placebo|Tablets
41310429|NCT03071549|DRUG|combined azaleic and salicylic acids|Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
40792745|NCT04747626|DEVICE|B-SAFER|Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.
40792746|NCT02655276|OTHER|microencapsulated Glycine|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
40792747|NCT02655276|OTHER|Placebo tablets|Placebo t.i.d. from Biotiki® in a crossover-design.
40792748|NCT04735653|BEHAVIORAL|Personalized Glaucoma Coaching|This is a six-month personalized glaucoma coaching program where a coach trained in motivational interviewing (MI)-based counseling uses a web based tool that generates tailored education to help glaucoma patients identify their barriers to optimal medication adherence and explore potential solutions during three in-person coaching sessions. The coach provides between-session support through four phone calls, with two phone calls between the first and second session and one phone call after each subsequent session. Participants can elect to receive any of the following type of alarm when a dose of medication is due: visual or audible alert or automated text or phone call reminder. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
40792749|NCT04735653|BEHAVIORAL|Enhanced Standard care|Participants will receive non-tailored educational materials about glaucoma from leading sources by mail every 2 months for a total of 3 mailings during the 6-month study period. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
40792750|NCT04106128|DIAGNOSTIC_TEST|ultrasound examination|Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
40998503|NCT05388942|DRUG|Nitrous oxide|inhalation of NO usually used to help with ASD reduction but inhaled NO has safety and maintenance issues.
40998504|NCT01581463|DRUG|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
40998505|NCT00579111|DRUG|Campath|10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
40998506|NCT00579111|DRUG|Busulfan|3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
40998507|NCT00579111|DRUG|Fludarabine|30mg/m2/day IV daily for 4 days on Day -5 to D -2
41469696|NCT06565208|DRUG|matched placebo|matched placebo
41469697|NCT02389842|DRUG|Palbociclib + Taselisib / Pictilisib|
40998508|NCT00579111|PROCEDURE|Hematopoietic stem cell infusion|Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.
40998509|NCT00579111|DRUG|FK-506|FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
40998510|NCT00375843|DRUG|Escitalopram|Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
40792751|NCT03497039|DRUG|Diclofenac Diethylamine (DDEA) gel|Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
40792752|NCT03497039|OTHER|Placebo gel|Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
40792753|NCT05225883|GENETIC|GWAS|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
40792754|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^8 vp/mL administered on Day 0
40792755|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^9 vp/mL administered on Days 0, 28, and 56
40792756|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^10 vp/mL administered on Days 0, 28, and 56
40792757|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^11 vp/mL administered on Days 0, 28, and 56
40792758|NCT01509846|BIOLOGICAL|Placebo: 1-3 doses|Placebo administered on Day 0 (if 1 dose) or Day 0, 28, and 56 (3 doses)
40792759|NCT00658489|BEHAVIORAL|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
40792760|NCT02955888|DRUG|PBI4050|Investigational Medicinal Product
41149784|NCT05757622|DRUG|Remifentanil|Procedural sedation provided with propofol and remifentanil using target controlled infusions
40998511|NCT00375843|DRUG|Sertraline|Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
40998512|NCT04950777|BEHAVIORAL|patient education document|The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
40998513|NCT02861950|DRUG|Caudal block with ropivacaine|Patients in this arm will receive a caudal block with ropivacaine
40998514|NCT02861950|DRUG|penile nerve block with bupivacaine|Patients in this arm will receive a penile block with bupivacaine
40998515|NCT02481895|BEHAVIORAL|E-neurocognitive module|The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
40998516|NCT04342104|OTHER|Monitoring for aggravation|"Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~* lymphopenia~* thrombocytopenia~* CRP~* ferritin~* LDH~* troponin I~* NT-ProBNP~* Liver enzymes~* D-dimers~* radiologic aggravation  1 day and 1 week after starting NIV or CPAP"
40998517|NCT04342104|OTHER|Evaluate HACOR score effectivity in this patients|Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
40998518|NCT06392243|DEVICE|Intracardiac ultrasound imaging system|The control group was treated with SOUNDSTAR 3D Diagnostic Ultrasound catheter (SNDSTR10G) and Vivid IQ, intracardiac and macrovascular imaging of the heart, assessment of intracardiac Doppler flow, and guidance for intracardiac intervention
40998519|NCT00217360|BEHAVIORAL|a customised multifactorial falls prevention program|
40998520|NCT04548674|OTHER|Whiteness HP 35%|Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm
41149785|NCT06075433|DEVICE|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
41310430|NCT04783532|BEHAVIORAL|Telehealth Mindfulness Program|Enrolled participants will participate in an individual (one-on-one) Telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight sessions lasting 75 minutes each (except the first session which lasts 90 minutes) over a 3-month period.
41310431|NCT01744509|DEVICE|Capsule colonoscopy;|All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
40792761|NCT02955888|DRUG|Placebo|Comparator
40792762|NCT06300177|DRUG|D-1553 Tablet|D-1553 is a KRAS inhibitor.
40792763|NCT06300177|DRUG|Docetaxel injection|Docetaxel, is an anti-tumor drug, significantly reduces the number of free tubules by promoting tubule polymerization into stable microtubules and inhibiting their depolymerization.
40792764|NCT05369598|DEVICE|Post-operative ABF followed by fitting according to clinical standard|Cochlear implant will be fitted first with anatomy-based fitting for 6 months and followed by default fitting for 2 months.
40792765|NCT05369598|DEVICE|Fitting according to clinical standard followed by post-operative ABF|Cochlear implant will be fitted first with default fitting for 6 months and followed by anatomy-based fitting for 2 months.
40792766|NCT04054336|BEHAVIORAL|Inhibit AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
40792767|NCT04054336|BEHAVIORAL|classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
40792768|NCT04054336|BEHAVIORAL|Control Group|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
40792769|NCT01900522|DRUG|ITI-214 Dose A|ITI-214 Dose A Oral Solution
40998521|NCT04548674|DEVICE|Whiteness HP 35% + LASER|A dose of LASER (60 J / cm2, for 16 seconds) was applied at two points, one point in the cervical region and another in the center of the buccal surface of the third molars, using visible infrared LASER therapy (Photon III / DMC, São Carlos, SP, Brazil), with a wavelength of 808 nm, and AsGaAl, as an active medium.
40998522|NCT04548674|OTHER|Whiteness HP 35% + CPP|Topical application of casein phosphopeptide amorphous calcium phosphate fluoride CPP-ACPF (My Paste Plus, Recaldent, GC, USA) with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes.
40998523|NCT04548674|OTHER|Whiteness HP 35% + NANO|A topical application of nanohydroxyapatite (Nano P FGM, SC, Brazil) was performed with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes after teeth whitening.
40792770|NCT01900522|DRUG|ITI-214 Dose B|ITI-214 Oral Solution Dose B
40792771|NCT01900522|DRUG|ITI-214 Dose C|ITI-214 Dose C Oral Solution
40792772|NCT01900522|DRUG|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
40792773|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
40792774|NCT01900522|DRUG|ITI-214 Dose E|ITI-214 Dose E Oral Solution
40792775|NCT01900522|DRUG|ITI-214 Dose F|ITI-214 Dose F Oral Solution
40792776|NCT01900522|DRUG|ITI-214 Dose G|ITI-214 Dose G Oral Solution
40792777|NCT01900522|DRUG|ITI-214 Dose H|ITI-214 Dose H Oral Solution
40792778|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
40792779|NCT05123339|OTHER|Questionnaire|Questionnaire
40792780|NCT03440554|DIAGNOSTIC_TEST|Whole Body Non-Contrast MRI|Whole Body Non-Contrast MRI in Prostate Cancer Patients
40792781|NCT04462029|DRUG|BR4002|"* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours"
40792782|NCT04462029|DRUG|BR4002-1|Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
40998524|NCT00483964|DRUG|Bacopa monnieri|
40998525|NCT00483964|DRUG|Nardostachys jatamansi|
40998526|NCT00483964|DRUG|Olanzapine|
40998527|NCT00476021|DEVICE|Levonorgestrel-releasing IUD (Mirena)|levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
40998528|NCT02909556|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via transfemoral access
41149786|NCT00183209|BEHAVIORAL|Family First|Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
40998529|NCT04905056|OTHER|Ablation therapy|Ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
40998530|NCT00017706|BEHAVIORAL|physician-delivered weight control|
41149787|NCT04057300|DRUG|Ticagrelor 90mg|Ticagrelor tablet
41149788|NCT04057300|DRUG|Clopidogrel 75mg|Clopidogrel tablet
40792783|NCT01978145|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
40792784|NCT01978145|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
40792785|NCT01889108|BEHAVIORAL|SPEEDI|Behavior intervention combining parent education and physical therapy intervention for preterm infants
40998531|NCT00385528|BEHAVIORAL|Multi-faceted psychiatric intervention|
40998532|NCT02459977|DRUG|Basiliximab|Basiliximab induction therapy
41149789|NCT04057300|DRUG|acetylsalicylic acid (ASA) 81mg|acetylsalicylic acid tablet
41149790|NCT02501876|OTHER|There is a retrospectiv observational study. No intervention|There is a retrospectiv observational study. No intervention will be performed
41149791|NCT01504178|DRUG|duloxetine|administration during 28 days
41149792|NCT01504178|DRUG|placebo of duloxetine|administration during 28 days
41149793|NCT01504178|DRUG|injection of apomorphine|injection performed at D28
41149794|NCT01504178|DRUG|injection of placebo of apomorphine|performed at D28
40998533|NCT02459977|DRUG|No basiliximab|No basiliximab induction therapy
40998534|NCT02459977|PROCEDURE|Kidney transplantation|kidney transplantation
40998535|NCT06220838|DRUG|SC-101|All subjects will receive a single intravenous (IV) infusion of SC-101 once weekly.
40998536|NCT04180696|DEVICE|aCRT ON|CRT device with AdaptivCRT enabled
40998537|NCT04180696|DEVICE|aCRT OFF|CRT device with AdaptivCRT disabled
41149795|NCT01504178|DRUG|L-Dopa|performed at D28
41469698|NCT03762746|DEVICE|Transcranial Magnetic Stimulation|A custom TMS stimulator (MagStim) is used to generate repetitive biphasic magnetic pulses. Magnetic pulses are delivered with a figure-8-coil (Magnetic Coil Transducer). During the experiment, rTMS pulse intensity is adjusted to 90% of the motor threshold. Patients will be randomly assigned to receive a 1 Hz. The target area is stimulated for 10 consecutive days. Stimulation at 1 Hz was applied once a day for 10-days
40998538|NCT04982614|BIOLOGICAL|Gardasil ® 9|"GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months"
41469699|NCT03762746|DRUG|Control|The control group is receiving treatment as usual. EEG recording and psychopathological ratings are performed one day before the start and on the last day of the study
40998539|NCT01063764|DRUG|Levetiracetam|"First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted."
40998540|NCT02605668|BEHAVIORAL|Intensified psychological intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)
40998541|NCT02605668|BEHAVIORAL|Standard intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
40998542|NCT03341988|DRUG|Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram|To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD
40998543|NCT03454984|DRUG|Guadecitabine|30/m2/day SubCutaneous for 5 days (Cycle = 28 days). total of 10 cycles
41469700|NCT03375307|PROCEDURE|Biopsy|Undergo tumor biopsy
41469701|NCT03375307|PROCEDURE|Biospecimen Collection|Undergo blood collection
40998544|NCT06329869|DRUG|Sacituzumab govitecan|Sacituzumab govitecan, 10 mg/kg intravenous infusion (the first infusion is to be administered over 3 hours; subsequent infusions may be administered over 1 to 2 hours if previous infusions were well tolerated) on day 1 and 8 of 21-day cycle.
41469702|NCT03375307|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41469703|NCT03375307|PROCEDURE|Bone Scan|Undergo bone scan
41469704|NCT03375307|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40998545|NCT01391975|PROCEDURE|Active ultrasound surveillance of fistula and proactive treatment of stenosis|Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
40998546|NCT01492634|OTHER|Prescription of post-dialytic weight based on BCM device|"Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).~The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.~Prescription steps will be calculated weekly for all study patients. TAFO \< -0.2 L: Increase post-dialytic weight by Cw x 0.5 kg/week, TAFO between -0.2 to 1.3 L: No action, TAFO between 1.3 to 2.8 L Decrease post-dialytic weight by Cw x 0.5 kg/week, TAFO \> 2.8 L: Decrease post-dialytic weight by Cw x 1.0 kg/week."
41149796|NCT01504178|DRUG|injection of placebo of L-Dopa|performed at D28
41469705|NCT03375307|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41469706|NCT03375307|DRUG|Olaparib|Given PO
41149797|NCT04891536|PROCEDURE|Salvage cryoablation of the prostate (SCAP)|Cryotherapy of the prostate through transperineal freeezing needles
41149798|NCT00319670|DRUG|MiraLax|
41149799|NCT04988958|PROCEDURE|hydatid cyst resection|radical resection of hydatic cyst
41149800|NCT05781984|PROCEDURE|Microsugical Excsosion|Microsurgical excision of pineal region tumor or endoscopic biopsy
41149801|NCT00292409|DRUG|Aripiprazole|
41149802|NCT01161953|GENETIC|Genetic Analysis|Perform Genome Wide Association Studies.
41149803|NCT00371696|DRUG|diclofenac|
41149804|NCT00371696|DRUG|paracetamol|
41149805|NCT00371696|DEVICE|heat retaining knee support|
41149806|NCT00371696|DEVICE|standard knee support|
41149807|NCT01621087|OTHER|Safflower oil|Liquid safflower oil and safflower oil polyunsaturated margarine
41469707|NCT03375307|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41469708|NCT00655278|DRUG|T2000|T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
41469709|NCT05259904|DRUG|L-citrulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
41469710|NCT05259904|DRUG|Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
41469711|NCT01752530|OTHER|Computer program C8|Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
41469712|NCT01752530|OTHER|Treatment as usual|Treatment as usual at the clinic
41469713|NCT01246713|DRUG|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
41469714|NCT01246713|DRUG|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
41469715|NCT04889391|DRUG|[14C]-Danicopan|Liquid-filled capsules.
40792786|NCT00848237|DEVICE|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
41469716|NCT02351167|DRUG|Combination NRT (Nicotine patch, Nicotine lozenge)|
41469717|NCT02351167|DRUG|Varenicline|
40792787|NCT05096637|OTHER|PreventiPlaque App|PreventiPlaque is an app that supports patients with atherosclerotic plaque by strengthening their adherence.
40792788|NCT06172816|OTHER|SARS-CoV-2|a virus infection
40792789|NCT05789459|DEVICE|Stapler|Stapler
40792790|NCT05789459|OTHER|Suture|Suture
40792791|NCT01654874|DRUG|99mTc-MIP-1404|
40792792|NCT03087604|PROCEDURE|Thoracic epidural block|Thoracic epidural block with epidural placed with a loss of resistance technique alone.
40792793|NCT03087604|PROCEDURE|Electrical Nerve stimulation|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
40792794|NCT03087604|DRUG|Solution For Thoracic epidural block|Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
40792795|NCT03666338|OTHER|Early, goal-directed mobilization|Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
40792796|NCT01558115|DRUG|Denosumab|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
40792797|NCT01558115|OTHER|Placebo|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
40792798|NCT04902430|PROCEDURE|Power chain and Crimpable hook for En-Masse Retraction|"Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew"
40792799|NCT04902430|PROCEDURE|T- Loop|Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
40998547|NCT00918515|DRUG|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
41469718|NCT02351167|DRUG|Placebo|
40998548|NCT02528162|BEHAVIORAL|education|Evaluation of education for GDM
40998549|NCT05783635|BEHAVIORAL|Enhanced Usual Care (pre-operative)|The enhanced usual care will receive standard surgical care, and a resource brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources. The resource brochure will be e-mailed to patients or sent via postal mail.
40792800|NCT02528942|RADIATION|Radiation therapy|Radiation therapy will be given to study patients.
40792801|NCT05964491|OTHER|No intervention|No intervention studied
40792802|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
40792803|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
40792804|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
40792805|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
40792806|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
40998550|NCT05783635|BEHAVIORAL|Preoperative Virtual Health Coaching|"Preoperative Virtual Coaching is based on principles of health coaching, collaborative care, and motivational interviewing. Health and educational content is framed using the Health Belief Model. During two sessions, that take place approximately 3 and 5 weeks prior to surgery, the health coach presents alcohol use reduction/abstinence as important for surgical health (rather than addiction or chronic health reasons) and engages participants in discussion and patient-centered goal-setting.~Participants will also receive a brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources."
40998551|NCT05783635|BEHAVIORAL|Usual surgical care (post-operative)|This group will receive standard post-operative care.
41149808|NCT02122822|BIOLOGICAL|gp96|vaccination of autologous gp96 derived from tumor tissue + basal treatment
41149809|NCT00605384|DRUG|Entecavir + Tenofovir|Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
41149810|NCT00605384|DRUG|Adefovir + continuing Lamivudine|Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
41149811|NCT06506630|DIETARY_SUPPLEMENT|coenzyme Q10|300 mg capsule twice a day
41149812|NCT06506630|DIETARY_SUPPLEMENT|placebo|300 mg capsule twice a day
41469719|NCT02351167|BEHAVIORAL|Intensive smoking counseling|
41469720|NCT02480231|DEVICE|Retropubic Midurethral Sling|
41469721|NCT03558139|DRUG|Magrolimab|Administered intravenously
41469722|NCT03558139|DRUG|Avelumab|Administered intravenously
40792807|NCT00413660|DRUG|CP-690,550|Oral tablets
40792808|NCT00413660|OTHER|placebo|Placebo
41469723|NCT03589196|PROCEDURE|Ejaculation Preserving Photoselective Vaporization|Ejaculation Preserving Photoselective Vaporization
41469724|NCT03589196|PROCEDURE|Ejaculation Preserving Plasma Kinetic Vaporization|Ejaculation Preserving Plasma Kinetic Vaporization
41469725|NCT03589196|PROCEDURE|Ejaculation Preserving Transurethral Resection Of The Prostate|Ejaculation Preserving Transurethral Resection Of The Prostate
40792809|NCT03953677|DRUG|Dexmedetomidine 100 Mcg/mL Intravenous Solution|Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
40792810|NCT03953677|DRUG|5% glucose Infusion solution|Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
40792811|NCT02907658|BEHAVIORAL|PROTECT intervention group|The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
40792812|NCT04096950|BIOLOGICAL|MT-3921 Low dose|MT-3921 Low dose, intravenous, single dosing
40792813|NCT03040089|DEVICE|PICO+4|picosecond, neodymium-doped yttrium aluminum garnet laser
40792814|NCT03040089|DRUG|Neoquine Cream 2%|2% hydroquinone cream
40792815|NCT06295900|OTHER|Intervention 1 Group|20 patients were included in this group and aromatherapy was applied once a day, for a total of 30 minutes, for three days, with a mixture of lavender, medicinal chamomile, and neroli oil (2 drops of lavender oil, 4 drops of medicinal chamomile, 6 drops of neroli oil in 20 ml of sweet almond oil). Massage is planned.
41310432|NCT03064295|DEVICE|Myocardial Perfusion Cardiac MRI.|MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
40792816|NCT06295900|OTHER|Intervention 2 Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with a mixture of only lavender oil (12 drops of lavender oil in 20 ml of sweet almond oil), once a day for three days, for a total of 30 minutes.
40792817|NCT06295900|OTHER|Placebo Control Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with only almond oil (20 ml sweet almond oil) mixture, once a day for three days, for a total of 30 minutes.
40792818|NCT02385903|OTHER|Flammacerium|
40792819|NCT02385903|OTHER|Standard dressing procedure|
40792820|NCT04035343|BEHAVIORAL|Face down positioning|See description of the face down positioning group
40792821|NCT04035343|BEHAVIORAL|Supine positioning|See description of the supine positioning group
40998552|NCT05783635|BEHAVIORAL|Postoperative Virtual Health Coaching|Postoperative Virtual Coaching uses the same framework and structure as Preoperative Virtual Coaching. These sessions will be delivered by a health coach using a collaborative, and motivational interviewing-based approach. The goal of these sessions is to promote well-being and help participants maintain alcohol abstinence or reduction long-term (or initiate change in alcohol use if they have not already). These sessions promote low-risk alcohol use, provide education on chronic health effects of heavy alcohol use, and teach skills for coping with or avoiding triggers for alcohol use including coping with stress and mood challenges. These sessions introduce skills to help participants manage alcohol, stress, and mood as they recover from surgery.
41310433|NCT03064295|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
40998553|NCT05783635|BEHAVIORAL|On-Track (Post-operative)|"On-Track is a mobile and web-accessible health tool that uses self-monitoring and provision of feedback on progress towards goals to engage participants in self-management of alcohol use and motivate behavior change through increased self-awareness and accountability for health.~The On-Track application includes a) daily tracking of alcohol and other substance use; b) daily tracking of stress, mood, and pain; c) personalized health goals; and d) visual displays of alcohol use, stress, mood, pain, and goal achievement including graphs of trends over time.~On-Track also uses novel monetary and non-monetary incentives to encourage utilization including an escalating monetary incentive schedule for self-monitoring."
40792824|NCT05257590|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
40998554|NCT00097721|DRUG|E7389|The first cohort of subjects were to receive E7389 1.4 mg/m\^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m\^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
40792825|NCT05257590|DRUG|CVM-1118|CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
40792826|NCT03011112|PROCEDURE|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
40998555|NCT02280135|BIOLOGICAL|Intravitreal injection of Autologous bone marrow Stem Cell|"We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.~After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
41310434|NCT03064295|DRUG|Pharmacologic Stress Agent|The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
41310435|NCT05977699|DRUG|salbutamol aqueous solution|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer
41310436|NCT05977699|DRUG|salbutamol pressurized metered dose inhaler|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer
40792827|NCT02742233|DRUG|saxagliptin|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment"
40792828|NCT02742233|DRUG|placebo|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment"
40792829|NCT01732705|BEHAVIORAL|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
40792830|NCT05572736|DEVICE|Conduction system pacing|Pacing from the His-Purkinje system (His-bundle pacing, left bundle branch area pacing, or deep septal pacing).
40792831|NCT05572736|DEVICE|Biventricular pacing|Pacing from the coronary sinus and right ventricular leads.
40792832|NCT02316353|BIOLOGICAL|C1-esterase inhibitor|
40792833|NCT05292690|DEVICE|Powered Wheelchair Obstacle Alerting System|Evaluation of an Obstacle Alerting System
40792834|NCT06024551|OTHER|Telerehabilitation|Patients in this arm will be given telerehabilitation three times a week, for four weeks.
40792835|NCT06024551|OTHER|home exercise program|Patients in this arm will receive home exercise program for four weeks
40792836|NCT03864146|BEHAVIORAL|Brief Behavioral Compliance Enhancement Treatment|This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
40792837|NCT01783197|DRUG|Paclitaxel|
40792838|NCT01783197|DRUG|Carboplatin|
40792839|NCT01783197|DRUG|Selumetinib|
40792840|NCT01783197|DRUG|Pemetrexed|
40792841|NCT01783197|DRUG|Cisplatin|
40792842|NCT01715363|DRUG|Oxaliplatin|
40792843|NCT01715363|DRUG|Folinic Acid|
40998556|NCT02280135|OTHER|Subconjunctival injection of saline|"In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
40998557|NCT04255355|OTHER|Pelvic alignment and forceful expiration|"The participant will be in supine with feet flat on a wall and the knees and hips flexed to 90 degrees. A standard 5 ball will be placed between the knees. The participant will hold a standard 9-inch balloon in the mouth with one hand. The subject will be instructed to isometrically contract the hamstrings to lift the ischium off the table while maintaining a posterior pelvic tilt. In this position, subject will be instructed to perform isometric hip adduction by squeezing the ball placed between the knees. The subject will then be instructed to breathe in through the nose and blow the air out into the balloon with full exhalation to activate the transverse and oblique abdominals. The participant will hold the breath for 3 seconds while maintaining hamstring contraction, adductor contraction, and transverse and oblique abdominal contraction. This process will be repeated four times. This exercise will be performed once daily under the supervision of the therapist for 5 days."
41149813|NCT06096142|DEVICE|Solaris DE|Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.
41149814|NCT06096142|DEVICE|PTA|Percutaneous Transluminal Angioplasty (PTA) in the treated vessel alone.
41149815|NCT05612009|COMBINATION_PRODUCT|Toothpastes|"Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride)."
41310437|NCT05977699|OTHER|placebo|matching placebo delivered via pressurized metered dose inhaler plus spacer or normal saline via vibrating mesh nebulizer
40792844|NCT01715363|DRUG|Fluorouracile|
40792845|NCT00451061|DRUG|Alfuzosin|
40792846|NCT00451061|DRUG|Tamsulosin|
40792847|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
40792848|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
40792849|NCT02245321|OTHER|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
40792850|NCT02245321|OTHER|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
40792851|NCT02245321|DIETARY_SUPPLEMENT|Placebo|Receive pills to take daily that contain 0 mg iron.
40792852|NCT02974829|OTHER|follow-up|
40792853|NCT06239038|PROCEDURE|total knee arthroplasty|total knee arthroplasty surgery with Police Arthroplasty joint academy center(PAJAC) Subvastus Approach
40792854|NCT01466283|GENETIC|DNA methylation analysis|
40792855|NCT01466283|GENETIC|fluorescence in situ hybridization|
40792856|NCT01466283|GENETIC|gene expression analysis|
40792857|NCT01466283|GENETIC|reverse transcriptase-polymerase chain reaction|
40792858|NCT01466283|OTHER|laboratory biomarker analysis|
40792859|NCT06363474|PROCEDURE|Decompressive Craniectomy|Patients allocated to this arm will undergo decompressive craniectomy, which involves the surgical removal of a section of the skull (bone flap). This procedure is performed to alleviate intracranial pressure (ICP) by providing additional space for the swollen brain to expand. The surgery will be performed by a single surgical team under general anesthesia. After the procedure, patients will be closely monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
40792860|NCT06363474|PROCEDURE|Cisternostomy|Patients allocated to this arm will undergo cisternostomy, a microsurgical technique used in neurosurgery. Cisternostomy involves the creation of an additional space for cerebrospinal fluid (CSF) circulation to alleviate brain edema and lower intracranial pressure (ICP). The surgery will be performed by the same surgical team under general anesthesia. Following the procedure, patients will be monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
40792861|NCT04975659|BEHAVIORAL|Placebo and Nocebo effect|Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group
40792862|NCT00737932|DRUG|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
40792863|NCT00737932|OTHER|placebo|Matching placebo for 8 weeks of treatment
40792864|NCT00459641|DRUG|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
40998558|NCT04255355|OTHER|Pelvic repositioning exercise|The participant will be positioned supine with their feet flat on a wall and the knees and hips flexed to 90 degrees. The subject will be instructed to isometrically contract the hamstrings to allow the ischial tuberosities to lift off the table while also maintaining a posterior pelvic tilt. The tailbone should be slightly lifted off the table, the abdominal muscles should be relaxed, and the low back should be flat on the table. While maintaining the posterior pelvic tilt, the subject will be instructed to perform isometric hip adduction by squeezing the ball that is placed between the knees. The subject will hold for 3 seconds and then relax. This process will be repeated four times. This exercise will be performed daily under the supervision of the therapist for 5 days.
40998559|NCT04255355|OTHER|Diaphragmatic breathing exercise|For diaphragmatic breathing exercise, the subject will be in supine position. The investigator places both hands around the participant's lower ribs and abdominal area. The investigator applies slight manual resistance to the chest and abdominal wall during inhalation phase of breathing.The participant is instructed to apply outward pressure against the investigator resistance and to raise the chest and abdominal wall simultaneously with inhalation. Then participants performs a full exhalation and hold his/her breath for 3 seconds before breathing in again. This process is repeated for 4 breathing cycles. Participants will perform this exercise once a day under investigator supervision.
40998560|NCT03119415|BEHAVIORAL|Cooperative Learning|CL is an umbrella term that includes peer tutoring, reciprocal teaching, collaborative reading, and other methods in which peers help each other learn in small groups. CL is not prescriptive but rather is a conceptual framework within which teachers design their own small-group activities. Johnson, Johnson, and Holubec's approach to CL combines positive interdependence with individual accountability, a high degree of face-to-face social interaction among youth, and support for the development of cooperative social skills. The Johnsons' approach offers teachers the combination of specific cooperative activities and the conceptual tools to create their own lesson plans using positive interdependence.
40998561|NCT04813796|BIOLOGICAL|mRNA-1283|Sterile liquid for injection
40998562|NCT04813796|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
41310438|NCT04526756|PROCEDURE|Mechanical Thrombectomy|Solitaire stent and manual aspiration thrombectomy were performed as the first-line endovascular treatment
41310439|NCT05656404|DEVICE|TorEx Lung Perfusion System|When donor lungs with clinical indication for EVLP are allocated to consented recipients, the lungs will be assessed using the second generation TorEx Lung Perfusion System rather than the first generation Toronto EVLP technique (standard of care).
41469726|NCT01905059|DRUG|monoPI - boosted lopinavir or boosted darunavir|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
41469727|NCT01905059|DRUG|bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
41469728|NCT01951287|OTHER|Acute beverage (water) consumption|Acute beverage consumption includes water.
40792865|NCT00459641|OTHER|Standard of Care|Bone marrow aspirate or steroids
40792866|NCT00592631|DEVICE|CPAP-Continuous Positive Airway Pressure|Cpap will be worn at night by subjects 6 to 7 days duration.
40792867|NCT00592631|DEVICE|SHAM|SHAM will be worn at night by subjects 6 to 7 days duration.
40792868|NCT06250608|DEVICE|Pulse oximeter, NIRSITX|It is a device that non-invasively continuously monitors blood oxygen saturation (rSO2) in localized areas of the brain. This device is attached to patients with symptoms suspected of stroke or diagnosed with stroke to continuously monitor the level of oxygen supply to the brain.
40792869|NCT05481983|OTHER|Walk exercise|The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).
40792870|NCT05481983|OTHER|One-on-one clinical exercise training|One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
41469729|NCT01951287|OTHER|Acute beverage (Black Coffee) consumption|Acute beverage consumption includes black coffee.
40792871|NCT02278315|DRUG|I-131-CLR1404|Single IV dose of I-131-CLR1404, increased/decreased by cohort
40792872|NCT02278315|DRUG|dexamethasone|40 mg dexamethasone orally once weekly for up to 12 weeks
40792873|NCT02278315|DRUG|I-131-CLR1404|Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
40792874|NCT05604573|DIAGNOSTIC_TEST|cell free DNA in blood, genetic mutation in tissue|Diagnostic test for cell free DNA in blood, genetic mutation in tissue
40792875|NCT06260605|OTHER|Education|Nursing students learning about diabetes complications
40792876|NCT06092112|DRUG|CD-801|The subjects with advanced HCC will be treated by 100 μg CD-801 through the hepatic artery injection at two-week intervals. The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For example, it may be adjusted to administer the medication once every three weeks or four weeks.
40792877|NCT00892008|DRUG|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
40792878|NCT04796129|OTHER|the patients with hip osteoarthritis and their inflammatory status|The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.
40792879|NCT01745653|DEVICE|Low level laser therapy|
40792880|NCT01745653|PROCEDURE|sham procedure|
40792881|NCT01184677|DEVICE|insertion of the ProSeal LMA (PLMA)|ProSeal LMA size 3 is inserted to the patients of Group size 3.
40792882|NCT01184677|DEVICE|insertion of the PLMA|ProSeal LMA size 4 is inserted to the patients of Group size 4.
41469730|NCT01951287|OTHER|Acute beverage (Orange Juice) consumption|Acute beverage consumption includes Orange Juice..
41469731|NCT01951287|OTHER|Acute beverage (Whole Milk) consumption|Acute beverage consumption includes whole milk
40792883|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under conscious sedation|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
40792884|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under local anesthesia|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
40792885|NCT03271164|DEVICE|FBPM10 System|Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
40792886|NCT03271164|OTHER|Massages with vitamin E cream|The other breast will be treated with wound massages with vitamin E cream.
40998563|NCT04813796|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
40998564|NCT01968642|BEHAVIORAL|Educational Intervention|
40998565|NCT02427321|DEVICE|Video recording of flexible cystoscopic examination|The video feed from the flexible cystoscopic examination will be recorded for all participants in the study. Proof-of-concept device will record high-definition video in a lossless format to a computer hard-drive from any existing cystoscopy equipment
40998566|NCT04889742|DEVICE|loco-regional hyperthermia|loco-regional hyperthermia by the use of microwave, capacitive, or superficial hyperthermia devices.
40792887|NCT01918865|DRUG|ISIS-PTP1BRx|
40998567|NCT00218517|DRUG|Selegiline hydrochloride|Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
40998568|NCT00218517|DRUG|Placebo|Matching placebo capsules using blue 00 capsules
40998569|NCT06290765|DRUG|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), 250 µg at Day 1, 350 µg at Week 2, and target optimal dose of 500 µg at Week 4.
40998570|NCT06290765|PROCEDURE|Phlebotomy|Control group patients will receive phlebotomy only
40998571|NCT03216447|DRUG|Advagraf|Tacrolimus prolonged-release hard capsules (QD)
40998572|NCT03216447|DRUG|Prograf|Tacolimus capsules (q12h)
40998573|NCT02670655|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
40998574|NCT02670655|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
40998575|NCT02670655|DRUG|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
40998576|NCT02670655|DEVICE|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
40998577|NCT02670655|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
40998578|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
41310440|NCT01206010|DRUG|Varenicline|Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.
41310441|NCT01206010|DRUG|Placebo|Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
41469732|NCT01951287|OTHER|Acute beverage (2% Milk) consumption|Acute beverage consumption includes 2% milk
41469733|NCT01951287|OTHER|Acute beverage (Skim Milk) consumption|Acute beverage consumption includes skim milk
41469734|NCT01853241|PROCEDURE|Single Balloon|All patients in this group will undergo single balloon enteroscopy
41469735|NCT01853241|PROCEDURE|Spirus|All patients in this group will undergo Spirus Enteroscopy
41469736|NCT04313010|OTHER|PRF|A sample of whole venous blood was drawn from the patient's forearm. The blood sample was transferred into a tube without anticoagulant and centrifuged immediately using a centrifuge.
41469737|NCT04313010|OTHER|BC|According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
41469738|NCT03227575|BEHAVIORAL|Exercise Intervention|The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.
40792888|NCT01918865|DRUG|Placebo|
40792889|NCT01918865|DRUG|daily OAD (metformin and/or sulfonylurea)|
40792890|NCT01899547|PROCEDURE|laparoscopic-assisted rectal resection|Arm I: Patients undergo laparoscopic-assisted rectal resection.
41469739|NCT03786419|DRUG|Atezolizumab|Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
41469740|NCT04143282|DRUG|Metformin plus chemotherapy|determine the effect of metformin along with standard chemotherapy
40998579|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
40998580|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
40998581|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
40998582|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
40998583|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
40998584|NCT00984854|DRUG|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
40998585|NCT05601310|DEVICE|liquid chromatography-mass spectrometry (LC/MS) analysis|To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
40998586|NCT00422032|DRUG|Clofarabine|"Group A: 15 mg/m\^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days"
40998587|NCT05820971|OTHER|C-short plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~* Outcomes (6a)~* Sample size (7a)~* Sequence generation (8a)~* Allocation concealment (9)~* Blinding (11a)~* Outcomes and estimation (17a/b)~* Harms (19)~* Registration (23)~* Protocol (24)~* Funding (25)"
40998588|NCT00277212|DRUG|Lamotrigine + Aripiprazole|"Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~Aripiprazole 10-30 mg/day"
40998589|NCT00277212|DRUG|Lamotrigine + Placebo|"Tablets, Oral, once daily, Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~placebo 0 mg/day"
40998590|NCT05510869|PROCEDURE|"Bimanual 1.4 mm microincision cataract surgery (B-MICS) with IOL implantation in a wound-assisted technique. In bimanual MICS group a self-sealing 1.4 mm wide incision was created supratemporally"|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
40998591|NCT05510869|PROCEDURE|Coaxial 1.8 mm microincision cataract surgery (C-MICS) with IOL implantation with an injector through the 1.8 mm wide incision created temporally.|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
40998592|NCT05510869|PROCEDURE|Coaxial 2.4 mm small incision cataract surgery (C-SICS) with IOL implantation with an injector through the 2.4 mm wide incision located temporally.|small incision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
40998593|NCT01485315|BIOLOGICAL|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing
40998594|NCT01485315|BIOLOGICAL|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
40998595|NCT01277354|BEHAVIORAL|Cognitive Processing Therapy|"CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify stuck-points, i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others."
40998596|NCT01277354|BEHAVIORAL|Waitlist Placebo|Behavioral ratings are conducted by a blind rater.
40998597|NCT00922883|DRUG|Eltrombopag|
40998598|NCT06042036|OTHER|Spontaneous mode of mechanical ventilation|any mode of mechanical ventilation classified as spontaneous or proportional, mainly pressure support ventilation, but also CPAP, APRV, NAVA, PAV+
40998599|NCT04827043|COMBINATION_PRODUCT|Ultrasound guided quadratus lumborum block|prospective randomized comparative study between Group (1) : quadratus lumborum block
40998600|NCT04827043|COMBINATION_PRODUCT|Ultrasound guided thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
41469741|NCT04143282|DRUG|Chemotherapy|standard chemotherapy
41469742|NCT05429489|PROCEDURE|Bilevel erector spinae plane block|Bilevel erector spinae plane block at 3rd and 5th thoracic vertebral levels
41469743|NCT05429489|PROCEDURE|Single level erector spinae plane block|Single level erector spinae plane block at 5th thoracic vertebrae
41469744|NCT05429489|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
40998601|NCT03549247|BEHAVIORAL|quality of life in healthy,gingivitis,periodontitis groups|a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied
40792891|NCT01899547|PROCEDURE|conventional open rectal resection|Arm II: Patients undergo conventional open rectal resection.
40792892|NCT03112291|PROCEDURE|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
40792893|NCT05524519|DRUG|Basic treatment|"1. Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~2. The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist."
40792894|NCT05524519|PROCEDURE|PSA|Four PSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
40792895|NCT05524519|PROCEDURE|TSA|Four TSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
40792896|NCT05524519|PROCEDURE|CCA|Acupoints: LR3 (Taichong), PC6 (Neiguan), SP6 (Sanyinjiao), and HT7 (Shengmen). PC6 and HT7 will use φ0.20\*1.2mm acupuncture needle. LR3 and SP6 will use φ0.20\*1.5m acupuncture needles. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
40792897|NCT03167138|BIOLOGICAL|Autologous micro-fragmented adipose tissue|Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
40792898|NCT03167138|DEVICE|Lipogems system|The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
40792899|NCT01847092|DRUG|AZD1722|
40792900|NCT01847092|DRUG|Placebo|Placebo for AZD1722
40792901|NCT05605730|OTHER|Maitland mobilization for thoracic spine|The thoracic spine mobilization will be consisting of oscillations to the thoracic vertebrae from the prone positions for repeated 30 times with 1 min interval between each 4 sets for 15 minutes. For central posterio-anterior mobilization, a grade III large amplitude rhythmic oscillation in the postero-anterior direction will be applied to the joint sign segment which is defined as the patient's most painful or hardest to move segment. It will be detected through a passive accessory intervertebral motion (PAIVM) test. T6,7 will be used as a site for application if the joint sign can't be detected. The frequency of treatment sessions will be 3 sessions per week for 4 weeks.
40998602|NCT05433454|OTHER|Outreach From Navigators|Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.
40998603|NCT00099125|DRUG|irinotecan hydrochloride|
40998604|NCT00099125|DRUG|temozolomide|
40998605|NCT00099125|PROCEDURE|adjuvant therapy|
40998606|NCT00099125|RADIATION|radiation therapy|
40998607|NCT02385175|OTHER|Different objective clinical tests of Eustachian tube function|
40998608|NCT02385175|OTHER|Different patient-completed questionnaires relating to Eustachian tube dysfunction|
40998609|NCT05093699|DEVICE|Butterfly iQ+ ultrasound probe|Diagnostic ultrasound probe on-market (FDA approved) capable of dual-plane viewing
41469745|NCT01451320|DRUG|Streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
40998610|NCT05093699|DEVICE|Ultrasound probe|Standard single-view ultrasound probe
40998611|NCT02745964|DEVICE|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
41469746|NCT01451320|DRUG|Streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
40998612|NCT02745964|DEVICE|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
40998613|NCT05037838|PROCEDURE|Longitudinal strain obtained thanks to transesophageal ultrasound data recorded during liver transplantation|Longitudinal strain of Left Ventricule and longitudinal strain of Right Ventricule free wall obtained thanks to TransEosophagal Ultrasound performed during the Liver Transplant
41469747|NCT01451320|DRUG|Tissue plasminogen activator|5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
40998614|NCT02029534|DRUG|Atorvastatin 20 mg|
40998615|NCT02029534|DRUG|Atorvastatin 80 mg|
40998616|NCT04874506|DRUG|MBM-02|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
40998617|NCT01856816|OTHER|Meal Pattern Treatment A|"In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
41469748|NCT01451320|DRUG|Tissue Plasminogen Activator|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
41469749|NCT01451320|DRUG|Tissue Plasminogen Activator|6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
41469750|NCT02288208|DRUG|Antiviral Therapy (tenofovir or entecavir)|
41469751|NCT02288208|DRUG|Birinapant|
40998618|NCT01856816|OTHER|Meal Pattern Treatment B|"In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
41149816|NCT05487209|DIAGNOSTIC_TEST|MRI,SCC-Ag|Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen
40792902|NCT05605730|OTHER|Mulligan thoracic sustained natural apophyseal glide (SNAGS)|Verbal instructions will be provided for the patient to move into thoracic extension and do over-pressure at the end of ROM while a transverse glide is maintained by the therapist for a set of 10 repetitions. The significance of performing a pain-free movement will be emphasized to the patient all the time. There will be 3 sets of 10 repetitions with one minute rest between each set.
40792903|NCT05605730|OTHER|Traditional exercise management|"Prone back extension. Shoulder external rotation starting in 45° of internal rotation, with the arm by the side and the elbow flexed to 90 °.~Shoulder internal rotation starting in 45 ° of external rotation, with the arm by the side and the elbow flexed to 90 °..~Shoulder abduction (scapular plane) through a 0- to 60-° with the elbow flexed 90 ° and the shoulder in neutral rotation.~Shoulder flexion (sagittal plane) through a 0- to 60-°starting with the elbow flexed 90 ° and the shoulder in neutral rotation and punching forward, simultaneously extending the elbow and flexing the shoulder.~Internal rotation towel stretch: Subjects will be instructed to sit or stand while holding a towel with the affected arm behind the back and to use the other arm to pull the affected arm up the back."
40792904|NCT00583674|DRUG|AMG 386 placebo|AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
40792905|NCT00583674|DRUG|AMG 386 10mg/kg|AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
40998619|NCT01856816|OTHER|Meal Pattern Treatment C|"In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
40998620|NCT01039181|DRUG|Calcitriol|12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).
40792906|NCT00583674|DRUG|AMG 386 3mg/kg|AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
40792907|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
40792908|NCT00583674|DRUG|Capecitabine|Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
40792909|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
40792910|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
40792911|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
40792912|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
40792913|NCT00965289|DRUG|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
40792914|NCT06524271|DIETARY_SUPPLEMENT|Fermented Soybean|Same as described earlier
40792915|NCT06524271|DIETARY_SUPPLEMENT|Supplement without fermented soybean|Same as described earlier
40792916|NCT03462758|DEVICE|IUD|Postpartum IUD placement
40792917|NCT03358810|DEVICE|PES|The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
40792918|NCT01818843|OTHER|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide in newborn
40792919|NCT03150537|BIOLOGICAL|Fluviral influenza vaccine|Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection
40792920|NCT02389465|DRUG|Escitalopram + Celecoxib|Participants will receive celecoxib in addition to escitalopram
40792921|NCT02389465|DRUG|Escitalopram + Placebo|Participants will receive a placebo in addition to escitalopram.
40792922|NCT03536325|DRUG|Guselkumab Dose 1|Participants will receive Dose 1 of guselkumab on Day 1.
40792923|NCT03536325|DRUG|Guselkumab Dose 2|Participants will receive Dose 2 of guselkumab on Day 1.
40792924|NCT03536325|DRUG|Guselkumab Dose 3|Participants will receive Dose 3 of guselkumab on Day 1.
40998621|NCT01172652|DRUG|Ziprasidone|The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
40998622|NCT01172652|DRUG|Placebo|Inactive control
41149817|NCT02995278|OTHER|Does not include a drug needing FDA approval and therefore it is not by definition, a Clinical Drug Trial as defined by FDA.|
40998623|NCT03984422|OTHER|Smartphone application|use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.
40998624|NCT01185795|DIETARY_SUPPLEMENT|Cardioviva™ yogurt|L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
41149818|NCT03574649|DRUG|Nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
41149819|NCT03574649|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
41149820|NCT03574649|DRUG|5Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
41149821|NCT03574649|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
41149822|NCT03574649|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
41149823|NCT03574649|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
41149824|NCT03574649|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
41149825|NCT03574649|BIOLOGICAL|GI-4000|RAS yeast vaccine
41149826|NCT03574649|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
40792925|NCT03536325|DRUG|Placebo|Participants will receive matching placebo on Day 1.
40792926|NCT04014426|OTHER|Blood sample|"Exposed group:~* 15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~* 2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)"
40792927|NCT04014426|OTHER|Urinary sample|"Exposed group:~* 15 to 30 min before the PIPAC procedure (T0)~* 2hours after the end of the procedure (T1)~* The next morning after the procedure (T2)~Non-exposed group:~- During the morning (8 to 10 a.m) (T0)"
40792928|NCT00347932|DRUG|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
40792929|NCT00347932|DRUG|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
40792930|NCT00362882|DRUG|docetaxel|Given IV
40792931|NCT00362882|DRUG|bortezomib|Given IV
40792932|NCT00362882|OTHER|laboratory biomarker analysis|correlative study
40792933|NCT00362882|OTHER|immunoenzyme technique|correlative study
40792934|NCT00362882|OTHER|immunohistochemistry staining method|correlative study
40998625|NCT01185795|DIETARY_SUPPLEMENT|Placebo yogurt|yogurt, twice per day (BID), 6 weeks
41310442|NCT01206010|DRUG|Varenicline|All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
40998626|NCT05768477|OTHER|Consultation|Consultation with the pain specialist, which might entail prescription of medication of vitamins.
40998627|NCT05768477|PROCEDURE|Interventions|Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation
40998628|NCT05768477|DRUG|Baxter therapy|Ketamine or Linisol baxter therapy
40792935|NCT00362882|OTHER|pharmacological study|correlative study
40792936|NCT00414323|DRUG|Duloxetine|
40792937|NCT00414323|DRUG|Escitalopram|
40792938|NCT00414323|DRUG|Placebo|
40792939|NCT02578160|PROCEDURE|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
40792940|NCT05442567|DRUG|Vedolizumab IV|Vedolizumab IV infusion
40792941|NCT05442567|OTHER|No Intervention|Participants will not receive any intervention in the Observational Cohort.
40998629|NCT05768477|BEHAVIORAL|Interdisciplinary therapy|Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.
40998630|NCT02567071|OTHER|perineal impregnated swab|After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
40998631|NCT02567071|OTHER|clean swab|After planned C-section birth, newborns will suck on clean swab.
41310443|NCT02681380|OTHER|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
41310444|NCT02681380|OTHER|Control group|No session will be planned for the participants.
41310445|NCT01376713|BIOLOGICAL|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
40792942|NCT04593368|OTHER|FMT|oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
40792943|NCT03862612|PROCEDURE|regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block|Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
40792944|NCT05703217|PROCEDURE|classical physical therapy with physiotherapy.|C-Mill device: It is possible to stand and walk on the treadmill. The patient is fixed to the moving band by attaching a garment made of corset-like straps, and thanks to this system, the risk of falling of the patient is prevented. There are virtual reality applications on the treadmill floor and on the giant screen opposite: ball collection It provides adaptation of walking to normal life with animal figures, forest or street images, sounds. In classical physical therapy, muscle strengthening, sitting, standing and walking exercises will be performed with physiotherapy.
40792945|NCT03689569|DIETARY_SUPPLEMENT|Resistant starch|Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion
40792946|NCT03689569|BEHAVIORAL|Exercise|Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity
40792947|NCT03689569|BEHAVIORAL|Starch|Patients will be given 30 grams of corn starch
40792948|NCT02151786|DRUG|Lansoprazole|Lansoprazole intravenous 30 mg
40792949|NCT03939637|DRUG|Eltrombopag|"Starting dose for eltrombopag will be based on manufacturer recommendations, and drug will be titrated to effect per guidelines.~* Children 1 to 5 years: Initial: 25 mg once daily~* Children ≥6 years and Adolescents: Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity \[e.g., Chinese, Japanese, Korean, Taiwanese\])~Dose should be titrated based on platelet response. Maximum dose: 75 mg once daily."
40792950|NCT03939637|DRUG|Steroids|Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day
40792951|NCT03939637|DRUG|IVIG|IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
40792952|NCT03939637|DRUG|Rho(D) Immune Globulin|Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)
40998632|NCT01833403|OTHER|Hyperinsulinemic-euglycemic clamp|"Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery~--------------------------------------------------------------------------------"
41149827|NCT03574649|DRUG|Aldoxorubicin|INNO-206
41149828|NCT03574649|DRUG|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
41149829|NCT03574649|DRUG|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
41149830|NCT03574649|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
41149831|NCT03574649|DRUG|Docetaxel|Docetaxel
41149832|NCT03574649|DRUG|carboplatin|carboplatin
41149833|NCT01651650|DEVICE|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
40792953|NCT05711927|DEVICE|SNOO Smart Sleeper|"Infants will be secured in the SNOO Sleep Sack. They will be placed in the center of the SNOO Smart Sleeper. The SNOO will be powered on and will start playing white noise and rocking from side-to-side. The SNOO's movement and sound settings will automatically ramp up and down as needed in response to the infant's sensed level of fussiness or crying per the manufacturer's programming. The preemie mode will be enabled, which caps motion at level 2 out of 5."
40792954|NCT05711927|DEVICE|Traditional bassinet|Infants will be swaddled using a standard hospital blanket. They will be placed in the center of the SNOO Smart Sleeper, but the SNOO will be left powered-off. No white noise will be played. No side-to-side rocking motions will occur.
40998633|NCT04093778|OTHER|Low dose high frequency training and Safe Delivery Phone Application|The intervention period is a 9-month period where we will facilitate a quality improvement cycle using Low Dose High Frequency training with the Safe Delivery App as an anchor point and facilitate the integration into clinical practice through our Safe Delivery Focal Points at each hospital. All staff in maternity, paediatric wards and outpatient clinics will receive training and be encouraged to use the Safe Delivery App on a weekly basis.
40998634|NCT06447090|DRUG|Mitoxantrone hydrochloride liposome|Veneclatra (VEN) 400 mg/d (reduced to 100 mg when combined with an azole), d1-7; Mitoxantrone Liposomal 30 mg/m2, d1; Cytosine arabinoside(Ara-C) 100 mg/m2/d, d1-7; Cyclophosphamide (CTX) 400 mg/m2/d, d2, 5); After 1 day of rest, cryopreserved donor stem cells MNC1-2X10\^8 /kg infusion, add low-dose (25 mg Bid) and short-course treatment (stop 2-3 weeks after DLI) oral cyclosporine (CSA) to prevent graft-versus-host disease (GVHD) 3 days before cryopreserved stem cell infusion.
40998635|NCT01779193|DIETARY_SUPPLEMENT|lactic acid bacteria|oral lactobacillus capsule (dose of 2 \* 10\^9 cfu per capsule), one pill daily
40998636|NCT01779193|DIETARY_SUPPLEMENT|cranberry|oral cranberry capsule, one pill daily
40998637|NCT01779193|DIETARY_SUPPLEMENT|placebo|placebo capsule without lactic acid bacteria and cranberry, one pill daily
40998638|NCT03365674|DEVICE|Vibration|Vibration applied with vibrator switch-on state (100Hz)
40998639|NCT03365674|DEVICE|Placebo vibration|Vibrator applied with switch-off state
40998640|NCT02956733|PROCEDURE|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
40998641|NCT02956733|PROCEDURE|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 \& 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
40998642|NCT01794091|DRUG|Eplerenone|Eplerenone 25 mg daily for 6 months
40998643|NCT01794091|DRUG|Placebo|
40998644|NCT02479152|DEVICE|LUCAS2 AD|LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
40998645|NCT06321874|PROCEDURE|Oxygen|
40998646|NCT02265978|DEVICE|CopeSmart|Participants will use the CopeSmart app at least once per day for four weeks
40998647|NCT02674620|OTHER|Aerobic Exercise|Patients are treated with progressive exercise
40998648|NCT03909009|DEVICE|rTMS + Neuronavigation|Repetitive Transcranial Magnetic Stimulation (Neuro-MS/D) + Neural Navigator
40998649|NCT00265473|BIOLOGICAL|Allogeneic Islets of Langerhans|Intraportal infusion of islets of Langerhans
40998650|NCT00127712|DRUG|Amiodarone|
40998651|NCT04147442|DEVICE|Hearing aid with fine-tuned and standard programs|A digital, wireless hearing aid is programmed specifically to each subject's hearing loss and fitted with both a program that is fine-tuned for their specific music playing as well as the standard music program that uses pre-determined settings.
40998652|NCT01354496|DRUG|LY2409021 Reference Form|Administered orally
40998653|NCT01354496|DRUG|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
40998654|NCT01354496|DRUG|LY2409021 Test-High Formulation (high particle size)|Administered orally
40998655|NCT01354496|DRUG|LY2409021 Test-Low Formulation (low particle size)|Administered orally
40998656|NCT00382538|DRUG|Addition of mifepristone 200 mg 24 hours before induction|
40998657|NCT04709666|PROCEDURE|Endsocopic Retrograde ColangioPancreatography (ERCP)|
41149834|NCT02672345|DRUG|Sevoflurane|The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
40792955|NCT03706768|OTHER|Glycocalyx|Measure Degradation of the Glycocalyx
40792956|NCT01616277|BIOLOGICAL|PF-06252616|1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
40998658|NCT02572466|OTHER|Hemodialysis|ESRD group received long-term hemodialysis
40998659|NCT03488979|OTHER|educational interventional group|• Patient Education Tool (Appendix 3) and the patient's own IVC images will be shared with each patient in the intervention group in real time. If feasible, each intervention patient will also receive a printed copy of his or her IVC image.
40998660|NCT04844554|OTHER|Active HD-tDCS 3mA|This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min.
41149835|NCT04035733|DRUG|rVA576|BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
41149836|NCT04566276|BIOLOGICAL|ChulaCov19 vaccine|SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine
41149837|NCT04566276|OTHER|Placebo|Saline
40998661|NCT04844554|OTHER|Sham HD-tDCS|This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off.
40998662|NCT01760083|DEVICE|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
40998663|NCT05010928|COMBINATION_PRODUCT|mouthwash with tea|Using tea as a base, supplemented with licorice to make mouthwash to relieve stomatitis.
41149838|NCT04745338|DEVICE|3max cool shaping device|cryolipolysis sessions are applied on abdomen area each session for 40 min. each
41149839|NCT04745338|DIETARY_SUPPLEMENT|low calolric diet|low caloric diet (1200cal/day)
41149840|NCT03018288|DRUG|Pembrolizumab|Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy (RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with heat shock protein peptide complex -96 (HSPPC 96) or placebo vaccine if any is available.
41149841|NCT03018288|BIOLOGICAL|HSPPC-96|One week post RT, patients will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
41310446|NCT01376713|BIOLOGICAL|Ofatumumab plus Dacarbazine|"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."
40998664|NCT01395329|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
40998665|NCT01395329|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
40998666|NCT01395329|DRUG|Placebo|gelatin capsule to be taken by mouth once per day for 12 weeks
40998667|NCT01395329|OTHER|Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)|The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.
40998668|NCT01395329|OTHER|FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
41310447|NCT05625217|DIAGNOSTIC_TEST|Total Body PET/CT Imagin|Total-body PET imaging at different timepoints
41310448|NCT00128700|DRUG|temozolomide|
40998669|NCT01395329|OTHER|FBF response to Acetylcholine|The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.
40998670|NCT01395329|OTHER|FBF response to Sodium Nitroprusside|The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.
40998671|NCT01395329|OTHER|FBF response to BQ-123+BQ-788+ACh|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
40998672|NCT01116232|BIOLOGICAL|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
41310449|NCT00128700|DRUG|vatalanib|
41310450|NCT00128700|PROCEDURE|adjuvant therapy|
41310451|NCT00128700|RADIATION|radiation therapy|
41310452|NCT02555761|DRUG|Alcaftadine Ophthalmic Solution 0.25%|Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
41310453|NCT01260376|DRUG|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
41310454|NCT01473810|BIOLOGICAL|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
41310455|NCT01473810|BIOLOGICAL|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
41310456|NCT01473810|BIOLOGICAL|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
41310457|NCT01473810|BIOLOGICAL|Zero dose|300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
41310458|NCT06046495|DRUG|PLB1004|PLB1004 will be orally self-administered by the patient as a mono-therapy.
41310459|NCT05682820|DIAGNOSTIC_TEST|Measurements on knee MRI performed during routine clinical practice|Patients after knee injury are often advised to undergo knee MRI for diagnosis. Measurements on knee MRI performed during routine clinical practice will be made.
41310460|NCT02684019|DRUG|Dexmedetomidine|added to propofol sedation
40792957|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
40792958|NCT01616277|BIOLOGICAL|PF-06252616|3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
40792959|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
40792960|NCT01616277|BIOLOGICAL|PF-06252161|10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
40792961|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
40792962|NCT01616277|BIOLOGICAL|PF-06252616|3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
40792963|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, Subcutaneous injection, single dose
40998673|NCT01116232|BIOLOGICAL|rituximab|"The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes."
40998674|NCT01116232|DRUG|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
40998675|NCT01116232|DRUG|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
40998676|NCT01116232|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
40998677|NCT01116232|PROCEDURE|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
40998678|NCT01116232|PROCEDURE|management of therapy complications|management of therapy complications
40998679|NCT01116232|PROCEDURE|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
40998680|NCT05754606|DIAGNOSTIC_TEST|Audio recordings|Automatica analysis of audio recordings
41149842|NCT03018288|DRUG|Temozolomide|Temozolomide (TMZ) will be administered on day 1 of radiation therapy (before radiation therapy (RT) treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
40998681|NCT03087656|DRUG|Ceftriaxone|Intravenous Ceftriaxone will be given during the procedure.
41149843|NCT03018288|OTHER|Placebo|One week post radiation therapy (RT), participants will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of Temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
41149844|NCT03018288|PROCEDURE|Surgery|Tissue for vaccine production and neo-epitope monitoring.
41149845|NCT03956147|OTHER|Munich Shoulder Questionnaire|Validation and Reability study
41149846|NCT05322447|DRUG|L Carnitine ( low dose)|will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
41310461|NCT02684019|DRUG|Magnesium Sulphate|added to propofol sedation
41310462|NCT00510328|DEVICE|Whole Body Vibration|
41310463|NCT02891798|DRUG|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
41310464|NCT02891798|DRUG|Bupivacaine Only (control arm)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
40998682|NCT03087656|DRUG|Levofloxacin|Oral Levofloxacin will be given for 3 days after the procedure.
40998683|NCT02592746|DRUG|Palbociclib|Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
40998684|NCT02592746|DRUG|Exemestane|Exemestane 25mg, orally once daily
40998685|NCT02592746|DRUG|Leuprolide Acetate|Leuprolide Acetate 3.75mg SC q 4weeks
41310465|NCT01593501|DIETARY_SUPPLEMENT|vitamin D3|pharmaceutical grade D3
41310466|NCT02757066|DRUG|NPC-15 Granules Lower Dose|NPC-15 granule which contains 1mg melatonin
40998686|NCT02592746|DRUG|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
40998687|NCT04566237|PROCEDURE|Objective Scatter Index (OSI)|On Optical Quality Analysis System (OQAS) device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
40998688|NCT04566237|PROCEDURE|Average Lens Density (ALD)|on IOLMaster® 700 device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
40998689|NCT06213402|OTHER|Data collection from EHR.|Collection of clinical and laboratory data. Reviwe of the electronic health record
40998690|NCT02889640|OTHER|SAGA Innovations|An intensive math tutoring program
40998691|NCT02889640|OTHER|Scale-up tutors|Tutors who have been selected for hire via the one in three-and-a-half randomization process
40998692|NCT02889640|OTHER|Standard Tutors|Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
40998693|NCT02221310|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 7.5 mg/m\^2/dose given IV over 2 hours once during conditioning
41149847|NCT05322447|DRUG|L-Carnitine ( high dose)|will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
41149848|NCT03423537|DRUG|hCG|the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.
41310467|NCT02757066|DRUG|NPC-15 Granules Higher Dose|Melatonin granule which contains 4 mg melatonin
41310468|NCT02757066|DRUG|NPC-15 Placebo Granule|Melatonin placebo granule which does not contains melatonin.
40998694|NCT01183169|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
40998695|NCT01183169|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
40998696|NCT01183169|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
40792964|NCT01616277|BIOLOGICAL|PF-06252616|10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
40792965|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, repeat dose
40792966|NCT01616277|BIOLOGICAL|PF-06252616|20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
40792967|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
40998697|NCT01183169|DRUG|Placebo|ALV placebo soft gel capsules administered orally
40998698|NCT05667922|DRUG|Tacrolimus|0.05-0.10mg/kg/d, twice orally, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it is effective.
41149849|NCT03423537|DRUG|Placebo|100IU per day containing N/S 0.9% will be injected
41149850|NCT00593983|BEHAVIORAL|Peer-driven intervention|Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
41149851|NCT00593983|BEHAVIORAL|Time-matched health education|Health education and standard of care treatment
41149852|NCT02077556|DRUG|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
41149853|NCT02077556|DRUG|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell \< 4000/mcL)
41149854|NCT02077556|DRUG|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
41310469|NCT05539586|OTHER|Tecartherapy|Patients will receive therapeutic exercise sessions for 7 weeks and 7 tecartherapy sessions.
41310470|NCT05539586|OTHER|Sham|Patients will receive therapeutic exercise sessions for 7 weeks and 7 sessions of simulated tecartherapy.
40792968|NCT01616277|BIOLOGICAL|PF-06252616|40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
40792969|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
40998699|NCT05892848|DIAGNOSTIC_TEST|serum ostecalcin,serum sclerostin and parathroid profile|evaluation of bone turnover markers in blood
40998700|NCT06344741|BEHAVIORAL|Accepted in latent phase|Participants admitted to the delivery room in the latent phase will be included. Routine procedures will be performed.
40998701|NCT06344741|BEHAVIORAL|Accepted in active phase|Participants admitted to the delivery room in the active phase will be included. Routine procedures will be performed.
40998702|NCT06481306|DRUG|BMS-986470|Specified dose on specified days
40998703|NCT06481306|DRUG|Placebo|Specified dose on specified days
40998704|NCT04512248|BEHAVIORAL|Quit and Stay Quit Monday Model|Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT.
40998705|NCT03794037|DRUG|dydrgesterone 10 mg( tab)/12hs/14 days|Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
40998706|NCT03794037|COMBINATION_PRODUCT|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days|montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&
40998707|NCT01889784|DEVICE|Phototherapy through light emitting diode (LED) - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
40998708|NCT01889784|DEVICE|Placebo phototherapy - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
40998709|NCT01889784|DEVICE|Phototherapy through light emitting diode (LED) - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
40998710|NCT01889784|DEVICE|Placebo phototherapy - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
40998711|NCT00378703|BIOLOGICAL|Bevacizumab|Given IV
40998712|NCT00378703|OTHER|Laboratory Biomarker Analysis|Correlative studies
40998713|NCT00378703|OTHER|Pharmacological Study|Correlative studies
40998714|NCT00378703|DRUG|Sorafenib Tosylate|Given PO
40998715|NCT00378703|DRUG|Temsirolimus|Given IV
40998716|NCT02067910|DRUG|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept
40998717|NCT04865432|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 4 weeks of UVB exposure intervention
40998718|NCT00793338|DRUG|Sildenafil|Sildenafil 20mg three times a day for 3 months.
40998719|NCT02016625|DRUG|Faldaprevir|
40998720|NCT02016625|DRUG|Faldaprevir|
40998721|NCT02016625|DRUG|Cyclosporine|
40998722|NCT02016625|DRUG|Tacrolimus|
41310471|NCT01204619|BEHAVIORAL|Intensive training group|an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
40998723|NCT03183414|OTHER|echocardiographic measurements|echocardiographic parameters of the RV, measured with TEE and the right ventricular ejection fraction (thermodilution)
40998724|NCT01222975|DRUG|Risperidone|orally disintegrating tablets
40998725|NCT04484324|OTHER|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
40998726|NCT01386736|DRUG|Vitamin D drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
40998727|NCT01386736|DRUG|Placebo drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
41310472|NCT04917744|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41310473|NCT04917744|OTHER|Laboratory Biomarker Analysis|Ancillary studies
41310474|NCT04917744|OTHER|Medical Chart Review|Review of medical charts
41310475|NCT06494878|DRUG|Aspirin|75-100 mg taken once daily by mouth.
41310476|NCT06494878|DRUG|Low-molecular-weight heparin|Low-molecular-weight heparin injections daily as prescribed by the treating physician.
41310477|NCT06164444|OTHER|Intervention: Reusable drapes and gowns|Reusable drapes and gowns used during surgery.
41310478|NCT06164444|OTHER|Comparator: Disposable (single-use) drapes and gowns|Disposable drapes and gowns used during surgery.
41469752|NCT02288208|DRUG|Placebo (for birinapant)|
41469753|NCT06080659|DIAGNOSTIC_TEST|fMRI|functional MRI
40792970|NCT03565822|OTHER|Interview|individual interview and/or focus group Grounded theory qualitative analysis of data related to socio-demographic and child characteristics data First, data will be prepared for qualitative analysis. Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel/word data file. Second, focus group data will be qualitatively analyzed using the constant comparative process. A qualitative data analysis program, NVivo11 (Victoria, Australia/ QSR International)) will be used to assist with this coding process.
40792971|NCT04543877|DIETARY_SUPPLEMENT|Inulin|Consume 12 grams/day of inulin for 5 weeks (Day 9 - 43).
40792972|NCT04543877|DIETARY_SUPPLEMENT|Maltodextrin|Consume 12 grams/day of maltodextrin for 5 weeks (Day 9 - 43).
40792973|NCT04543877|BIOLOGICAL|Ty21a Typhoid Fever Vaccine|All participants will receive the vaccine. One capsule is swallowed on alternate days, e.g. days 30, 32, 34, and 36 for a total of 4 capsules.
40792974|NCT02727322|DRUG|Nitrofurantoin|Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.
40792975|NCT02727322|DRUG|Placebo|Placebo
40792976|NCT03202212|PROCEDURE|mixed on-line hemodiafiltration|This is a mixed hemodepurative technique exploiting diffusion and convection through a semi-permeable membrane. Dialysis solution is not only interfacing with blood through the membrane (as in bicarbonate hemodialysis) but it is also mixed with it with a pre- and a post- filter dilution. The same amount of fluid added to the bloodstream is then removed within the filter through an appropriate negative pressure in the dialysis solution compartment and thanks a high permeability membrane. Patients will be treated three sessions per week, four hours per session
40792977|NCT03202212|PROCEDURE|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
40792978|NCT02811120|OTHER|venepuncture only|single venepuncture
40792979|NCT03133585|DEVICE|2 piece appliance for stomy|Use of the Flexima®/Softima® 3S during 6 months following the patient's usually frequency of appliance change
40998728|NCT04075487|OTHER|Web-module for patient education and planning|Our goal is a mobile web-based application (App) that provides immediate feedback to Veterans seeking to develop their own pain self-management plan
40792980|NCT03251027|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IM-SRT
40792981|NCT03251027|OTHER|Quality-of-Life|Ancillary studies
40792982|NCT02663427|DEVICE|serological examination and gastroscope|
40998729|NCT03189030|BIOLOGICAL|pLADD|via IV infusion
41310479|NCT01986218|DRUG|BMS-986115|
40792983|NCT00329576|BIOLOGICAL|Hepatitis B vaccine|
41469754|NCT06080659|DIAGNOSTIC_TEST|CONFMEM|The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
40792984|NCT05629455|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
40792985|NCT03045588|OTHER|Combined exercise and diet intervention|Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
40792986|NCT00938262|DRUG|Fimasartan, Ketoconazole, Rifampicin|"Fimasartan (1 day)~Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)~Rifampicin (9 days) Rifampicin + Fimasartan (1 day)"
40792987|NCT06062264|BEHAVIORAL|Portal-based Video Message|Video recorded by physician encouraging patients to receive influenza vaccine. Sent via the patient portal.
40792988|NCT06062264|BEHAVIORAL|Portal-based Infographic Message|Infographic with information about the influenza vaccine and an image of the physician. Sent via the patient portal.
40792989|NCT03645278|DRUG|SHR0532|Ascending dose oral adminstration
40792990|NCT03645278|DRUG|Placebo|Ascending dose oral administration
40792991|NCT06012630|DIAGNOSTIC_TEST|Ultarsound|Median nerve evaluation of participants with ultrasound
40792992|NCT00876863|DRUG|CERE-110: Adeno-Associated Virus injection Surgery|Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure.
40792993|NCT00876863|PROCEDURE|Placebo Surgery|Placebo Surgery
40792994|NCT05040698|DRUG|Fostamatinib|Open label Fostamatinib
40792995|NCT01575236|DEVICE|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
40792996|NCT01575236|DEVICE|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
40792997|NCT02990715|DEVICE|C-Scan System|"1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
40792998|NCT01279876|DRUG|Melatonin|3mg oral, daily, one hour before sleep
40998730|NCT01909349|BEHAVIORAL|self-regulation|Web-based support for behavior change regarding physical activity and fruit \& vegetable consumption
40998731|NCT01001442|DRUG|BT062|intravenous administration
40998732|NCT00469482|OTHER|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
40998733|NCT00469482|OTHER|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
40998734|NCT01835743|DEVICE|Erchonia HPS Laser|The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
40998735|NCT01835743|DEVICE|Placebo Laser|The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
40998736|NCT00703547|DRUG|GSK586529 capsules|GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
40998737|NCT00703547|DRUG|GSK586529 tablets|GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
40998738|NCT00703547|DRUG|Placebo|Placebo tablets and capsules will be provided to subjects.
41310480|NCT05560815|PROCEDURE|Any surgical procedure|Might differ for substudies.
40792999|NCT01166217|DRUG|PF-04620110|"The five treatments are:~A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state."
40793000|NCT04971967|COMBINATION_PRODUCT|Crowdsourced partner services intervention|The intervention includes the provision of provider referral and dual referral services, crowdsourced materials such as postcards and an HTML aiming to promote PS, as well as free take-home HIV self-testing kits.
40998739|NCT05268159|OTHER|Cognitive assessment|Assessment of unilateral spatial neglect, attention, executive functions and memory
40998740|NCT00454168|BIOLOGICAL|PR1 leukemia peptide vaccine|Given subcutaneously
40998741|NCT00454168|BIOLOGICAL|sargramostim|Given subcutaneously
40998742|NCT00454168|OTHER|placebo|Given subcutaneously
40998743|NCT05117411|DIAGNOSTIC_TEST|OCTA and pseudophakin cystoid edema|Patients underwent OCT angiografia after cataract surgery
40998744|NCT06367465|DRUG|Glecaprevir-pibrentasvir|Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.
40998745|NCT01251588|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|Implantation received in the previous MACI00206 study
40998746|NCT01251588|PROCEDURE|Microfracture|Arthroscopic Microfracture treatment received in the previous MACI00206 study
40998747|NCT02721316|OTHER|Supported with intensive nursing follow post hospitalization|Intensive nursing follow post - hospitalization
40998748|NCT01990274|PROCEDURE|GeneXpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
40998749|NCT01990274|PROCEDURE|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
41310481|NCT01879670|DEVICE|CircuLite Synergy left ventricular assist device|
40998750|NCT00655564|DRUG|Alefacept|"Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose)."
41310482|NCT02822404|DIETARY_SUPPLEMENT|Urinary and blood sample for Cystatine dosage|Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
40793001|NCT01791660|DEVICE|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
40793002|NCT01590745|DEVICE|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
40998751|NCT00005833|DRUG|R115777|300mg P.O. BID.
40998752|NCT01995695|BIOLOGICAL|Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10\^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).
40998753|NCT01995695|BIOLOGICAL|Inactivated subvirion H7N9 influenza vaccine|Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
40998754|NCT06176950|OTHER|Oral History Interviews|I will ask interview subjects about their educational and career path, their research interests and clinical work in the field of neonatology. I will also ask them about their personal and professional motivations and thoughts about their work. And we will discuss how their interactions with colleagues and patients/caregivers shaped their work experience and decision making.
40998755|NCT00129129|BIOLOGICAL|GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine|Primary phase: 3 IM doses Booster phase: 1 IM dose
40998756|NCT00129129|BIOLOGICAL|ActHIB|Primary phase: 3 IM doses Booster phase: 1 IM dose
40998757|NCT00129129|BIOLOGICAL|Pediarix|Primary phase: 3 IM doses
40998758|NCT00129129|BIOLOGICAL|Prevnar|Primary phase: 3 IM doses Booster phase: 1 IM dose
40998759|NCT00129129|BIOLOGICAL|Menomune|Primary phase: 1 SC dose
40998760|NCT01515800|BEHAVIORAL|Text message reminder|Receive text message
40998761|NCT02812758|DEVICE|transthoracic echocardiography|recording of data on cardiac output measured non-invasively by transthoracic echocardiography, including the SVV
41310483|NCT04400409|OTHER|Intervention A - Vascular Care + site 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
41469755|NCT00129116|BIOLOGICAL|Hib-MenCY-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
40998762|NCT01246947|PROCEDURE|Tricuspid valve repair|Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
40998763|NCT01246947|OTHER|Mitral surgery alone|Randomized to Mitral surgery alone
40998764|NCT05525845|OTHER|Functional Magnetic Resonance Imaging (pCASL-MRI)|MRI's will be performed at multiple points on each visit day.
40998765|NCT05525845|OTHER|Intragastric Balloon|Intragastric Balloon will be placed during Visit 2 study day and inflated to maximum tolerated volume. Patient will then be scanned in the MRI.
40998766|NCT05525845|OTHER|Elemental Meal|Patient will ingest the tasteless elemental meal until their maximum level of fullness. Once full, the patient will be scanned in the MRI.
40793003|NCT03882437|BIOLOGICAL|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
40793004|NCT05502003|OTHER|High Intensity Interval Training|Telerehabilitation-based high-intensity exercise training will be applied to the participants for 6 weeks, 3 times a week for 35 minutes, under the control of a physiotherapist.
40793005|NCT05502003|OTHER|Moderate Exercise Training|The participants will be given telerehabilitation-based moderate exercise training under the control of a physiotherapist for 55 minutes, 3 times a week for 6 weeks.
40793006|NCT01837680|DRUG|Insulin|
40793007|NCT05020301|DEVICE|external meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
40793008|NCT05020301|DEVICE|internal meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
40998767|NCT05525845|OTHER|Hedonic Meal|Patient will ingest meal of their choice from a local food delivery service and eat until they reach their maximum level of fullness. Once full, the patient will be scanned in the MRI
40998768|NCT03152539|RADIATION|MRI|
40998769|NCT03152539|DEVICE|EEG|
40998770|NCT03152539|DEVICE|NIRS|
40998771|NCT04145258|DRUG|Aspirin|Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
40998772|NCT04145258|DRUG|Placebo of aspirin|Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
40998773|NCT04145258|DRUG|WHO TBM treatment|2 months of (R-H-Z-E) + 7 months of (R-H)
40998774|NCT04145258|DRUG|Intensified TBM treatment|2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
40793009|NCT02243683|DRUG|AX-024.HCl|
40793010|NCT02243683|OTHER|Placebo|
40998775|NCT01622855|BEHAVIORAL|PPRS|Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
40998776|NCT06241027|OTHER|Nerve flossing technique|The nerve flossing technique will be perform actively with the participant sitting on the chair. The participant flexed the knee of the target lower extremity backward beside the chair as far back as possible and flexed the neck at the same time, holding both the flexed knee and neck in thisposition for 5 seconds. The participant in turn extended the neck and knee of the target lower extremity, abducted and flexed the hip until pain will feel and did not push beyond that point. This extended position will be hold for 5 seconds.
40998777|NCT06241027|OTHER|Myofascial release|Myofascial release therapy involved the application of a low load, long duration stretch along the line of maximal fascial restriction. Pressure will be applied directly on the skin toward the direction of restriction until resistance of the tissue barrier will felt, Once found , the collagenous barrier will engaged for 90-120 seconds without sliding over the skin or forcing the tissues until the fascia complex started to yield and a sensation of softening will achieved.This stage will be repeated up to 5 times for new barrier until the sensation of tissue restriction during stretching became weaker.
40998778|NCT00779103|DRUG|Histrelin Subcutaneous Implant|histrelin subcutaneous 50 mg implant
40998779|NCT05112692|DRUG|Dydrogesterone Tablets|first arm will be coadministered gonadotrophins with 20mg dydrogesterone till day of trigger second arm will be subjected to fixed GnRH antagonist protocol then will do Freeze All in both arms then frozen embryo transfer next cycle
40998780|NCT05112692|DRUG|cetrorelix 0.25mg|In the fixed GnRH antagonist protocol, daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation. HMG (150-225IU) will be administered daily from menstrual cycle day 3.
40998781|NCT05112692|DRUG|human menopausal gonadotropin|(150-225IU) will be administered daily from menstrual cycle day 3 till day ot trigger
40998782|NCT05112692|DRUG|triptorelin 0.1 mg|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
40793011|NCT05350215|DRUG|Placebo oral capsule|Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
40998783|NCT05112692|DRUG|human chorionic gonadotropin|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
40998784|NCT05112692|PROCEDURE|cryopreservation|All of the follicles greater than 10mm in diameter will be aspirated. The oocytes are inseminated approximately 4-6hours after follicular aspiration by a conventional IVF method or intracytoplasmic sperm injection, based on the sperm quality On day 3, high quality embryos are cryopreserved by means of vitrification
40793012|NCT05350215|DRUG|Atomoxetine Oral Capsule [Strattera]|Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
40793013|NCT02690766|BEHAVIORAL|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
40793014|NCT06497751|BEHAVIORAL|Couple-based Dyadic Coping Group|"Session one: We-disease appraisal (30 minutes). Couples will work toward a congruent perception of HIV as a shared disease, enhancing illness control.~Session two: Couple communication (30 minutes). Couples will learn basic knowledge of effective communication and undertake skill-building exercises focusing on effective communication techniques.~Session three: Dyadic coping (60 minutes). Couples will learn basic knowledge of dyadic coping and work on skill-building exercises (e.g., three-phase dyadic coping exercise) to enhance support mobilization."
40793015|NCT06004206|DEVICE|nPSV and PSV|Ventilation with neurally adjusted modes or pressure support modes
40793016|NCT02018029|OTHER|cardiac resynchronisation therapy|
40793017|NCT04062188|OTHER|Telephone Interview Form|Telephone Interview Form is an original simple questionnaire developed based on the combination of Barthel Index questionnaire and simplified modified Rankin Scale questionnaire with internal rules.
40793018|NCT03121300|OTHER|CT Scan|Quantitative lung SPECT-CT
40793019|NCT03121300|OTHER|Lung CT|CT lung ventilation
40998785|NCT05112692|DRUG|Estradiol Valerate and progesterone|Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET
40998786|NCT02048553|DEVICE|Tablet-guided ventriculostomy|"In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand )."
40998787|NCT02048553|PROCEDURE|Freehand|Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
40998788|NCT03072485|DRUG|Sirolimus|Topical sirolimus applied to the skin
40998789|NCT03072485|DRUG|Metformin|Topical metformin applied to the skin
40793020|NCT03121300|OTHER|MRI|DCE MRI
40793021|NCT03121300|OTHER|Walk Test|6 minute hall walk test
40793022|NCT03121300|OTHER|SGRQ|St. George Respiratory Questionnaire
40998790|NCT03072485|DRUG|Diclofenac|Topical diclofenac applied to the skin
40998791|NCT03382483|DEVICE|Low intensity pulsed ultrasound|bone growth stimulator
40793023|NCT03121300|OTHER|Biological Sample Collection|Blood Draw
40793024|NCT03121300|OTHER|Toxicity|Toxicity Evaluation
40793025|NCT03121300|OTHER|Cardiac Assessment|Cardiac MRI Scan
40793026|NCT00260728|DEVICE|vascular access graft implantation|vascular access graft implantation
40793027|NCT03948802|DIAGNOSTIC_TEST|Interleukine 33 test in blood plasma|ELISA test for Interleukin 33
40998792|NCT02148172|PROCEDURE|Standard Plyometric Training|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises.
40998793|NCT02148172|PROCEDURE|Plyometric Training with BWS|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises while their body weight is supported via adjustable harness.
40998794|NCT02072967|OTHER|Ribomustin|Routine practice
40998795|NCT02072967|OTHER|rituximab|Routine practice
40793028|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
40793029|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
40793030|NCT00251693|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
40793031|NCT01333722|DRUG|Hydrocodone/Acetaminophen Extended Release|
40998796|NCT03094754|PROCEDURE|nevi excision|After general anesthesia, nevi excision in children is performed.
40998797|NCT03152370|DRUG|E7046|oral administration
40998798|NCT03152370|RADIATION|Long Course Chemoradiotherapy (LCRT)|pelvic radiotherapy
40998799|NCT03152370|RADIATION|Short Course Radiotherapy (SCRT)|pelvic radiotherapy
40998800|NCT03152370|DRUG|capecitabine|chemotherapy
40793032|NCT01333722|DRUG|Placebo|Placebo tablet
40793033|NCT05195086|DRUG|endoxan|Immunosuppressant
40793034|NCT05195086|DRUG|cellcept|Immunosuppressant
40793035|NCT00405249|DRUG|elvucitabine|
40793036|NCT04900844|DEVICE|CGuard Carotid Stent implantation|Implantation of CGuard carotid stent in the eligible patients
40793037|NCT04021446|OTHER|Exercise|personalized exercise prescription
40793038|NCT04580043|BEHAVIORAL|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
40793039|NCT04580043|DEVICE|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
40793040|NCT04580043|BEHAVIORAL|Sham Training|Computer-based task practice in a non-active/inert task.
40793041|NCT04580043|DEVICE|Sham Transcranial Magnetic Stimulation|Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
40793042|NCT03525002|DRUG|Bromocriptine|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
40793043|NCT03525002|OTHER|Placebo|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
40793044|NCT04130893|BEHAVIORAL|stimulation of G13 then G15|Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
40793045|NCT04130893|BEHAVIORAL|stimulation of G15 then G13|Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
40998801|NCT03152370|DRUG|folinic acid/5-FU/oxaliplatin (mFOLFOX-6)|chemotherapy
40998802|NCT02858245|OTHER|No intervention - registry|
40998803|NCT03946735|BEHAVIORAL|Cognitive Behavioural Therapy as an Effective Treatment for Social Anxiety, Perfectionism, and Rumination|Week one involved introducing CBT and assessing the negative effects of perfectionism, rumination, and social anxiety. Week two allowed participants to specify stressful social activities, stressful social situations, and enjoyable activities. Week three to week six allowed participants to identify automatic thoughts and thinking errors (for example, all or nothing thinking, self-criticism, dysfunctional schemas for self-evaluation, and unrealistic standards). Assignments were provided to participants with the content of exposure to anxiety evoking situations in the treatment sessions and at home. Achievable behavioural goals were set for participants in the treatment sessions and at home.
40998804|NCT04249258|DRUG|Dobutamine|Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.
40998805|NCT04398758|DRUG|SanaCutan Basiscreme|In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).
41469756|NCT00129116|BIOLOGICAL|Hib-MenC-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
40793046|NCT02790840|DRUG|Omeprazole|20 mg oral capsules administered once daily for 10 days
40793047|NCT02790840|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 10 days
40793048|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
40793049|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
40793050|NCT05474456|OTHER|SNAGs|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
40793051|NCT05474456|OTHER|Manipulation|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
40793052|NCT00981162|DRUG|sorafenib tosylate|Given PO
40793053|NCT00981162|DRUG|everolimus|Given PO
40793054|NCT00981162|OTHER|laboratory biomarker analysis|Correlative study
40793055|NCT00981162|OTHER|pharmacogenomic studies|Correlative study
40793056|NCT00981162|OTHER|pharmacological study|Correlative study
40793057|NCT01104480|DRUG|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks given by IV infusion
40793058|NCT03833557|PROCEDURE|Nanohydroxyapatite Pulpotomy|Biphasic calcium phosphate 500-1000 Um Straumann BoneCeramic
40998806|NCT01100242|DRUG|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
40998807|NCT01433107|DRUG|Terbinafine|1% single application
40998808|NCT01433107|DRUG|Terbinafine Placebo|single application
41149855|NCT02077556|DRUG|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
40793059|NCT03833557|PROCEDURE|MTA pulpotomy|Angleus grey MTA
40793060|NCT03833557|PROCEDURE|Formocresol Pulpotomy|Buckley's Fromocresol. diluted full strength foromocresol
40793061|NCT00043745|DIETARY_SUPPLEMENT|Soy isoflavones|Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
40793062|NCT00043745|DIETARY_SUPPLEMENT|Extract tablets|Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
40793063|NCT00853710|OTHER|PSA assay|rapid prostate specific antigen assay.
40793064|NCT03949868|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their memory performance over the past 30 minutes in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their memory performance throughout the day and asked to report on how their memory performance is changing over time as a part of each text message prompt."
40793065|NCT03949868|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 8pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9am text to report on their memory performance over the past 30 minutes."
40793066|NCT03949868|BEHAVIORAL|Active control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 8pm) asking them to report on the activity they are currently engaged in."
40793067|NCT03579069|OTHER|Ductus venosus Doppler|Ductus venosus Doppler
41149856|NCT02077556|DRUG|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
41149857|NCT04132999|BEHAVIORAL|Family-informed intervention|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team
40793068|NCT02185261|DRUG|Interferon Alfa-2b|Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
40793069|NCT01871727|DRUG|E7777 9 mcg/kg|administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
40793070|NCT04684212|DEVICE|LAmbre PlusTM Left Atrial Appendage Closure System|The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
40793071|NCT04684212|DRUG|Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)|Continuation of market approved OAC drug.
40793072|NCT00542126|DRUG|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
40793073|NCT03751371|DEVICE|Training with HWA device|Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.
40793074|NCT03751371|OTHER|Usual Care|The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
40793075|NCT00465972|DRUG|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
40793076|NCT00465972|DRUG|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
40793077|NCT00465972|DRUG|Placebo|Placebo capsule nightly for duration of study
40793078|NCT02692963|BIOLOGICAL|BCG vaccination|BCG vaccine InterVax
40793079|NCT04796558|OTHER|AVAS Classification|Validation of AVAS classification
40998809|NCT01567969|BEHAVIORAL|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
40998810|NCT01567969|BEHAVIORAL|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
40998811|NCT02012595|OTHER|[11C]donepezil PET|Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand \[11C\]donepezil
40998812|NCT01520129|OTHER|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
40998813|NCT00805935|DRUG|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
41149858|NCT04132999|BEHAVIORAL|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
41469757|NCT00129116|BIOLOGICAL|Menjugate ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
41149859|NCT02195180|DRUG|ERY001|
41149860|NCT02195180|DRUG|Gemcitabine|
41149861|NCT02195180|DRUG|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
41149862|NCT05859529|DRUG|JS002|The drug was administered by a single subcutaneous injection
40793080|NCT02722005|BEHAVIORAL|Financial Coaching|One-to-one financial coaching focused on credit, debt, savings, and income supports.
40793081|NCT02722005|BEHAVIORAL|Access to referral to social services|Access to referral to a host of social services.
40793082|NCT01582009|DRUG|panobinostat|Given orally
40793083|NCT01582009|DRUG|everolimus|Given orally
40793084|NCT01582009|OTHER|laboratory biomarker analysis|Correlative studies
40793085|NCT01582009|OTHER|pharmacological study|Correlative studies
40793086|NCT01582009|OTHER|liquid chromatography|Correlative studies
40793087|NCT01582009|OTHER|mass spectrometry|Correlative studies
40793088|NCT01582009|OTHER|enzyme-linked immunosorbent assay|Correlative studies
40793089|NCT01582009|OTHER|immunohistochemistry staining method|Correlative studies
40793090|NCT06493643|OTHER|Measurement of perfusion index after supraclavicular brachial plexus block at blocked & unblocked limb|The PI (Perfusion Index) was measured using Masimo SET pulse oximetry applied on the index finger. The PI was recorded at baseline and at 10 , 20 , and 30 min after local anaesthetic injection in both the blocked limb and the contralateral unblocked limb using two separate oximeters. The PI ratio was calculated as the ratio between the PI at 10min after injection and the baseline PI. In every patient, a comparison between the blocked and unblocked limb was performed .
40998814|NCT00805935|DRUG|Progesterone vaginal insert|100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
40998815|NCT00805935|DRUG|Follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
40998816|NCT00805935|DRUG|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
40998817|NCT00805935|DRUG|leuprolide acetate|Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
40998818|NCT00136084|DRUG|Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
40998819|NCT00136084|DRUG|Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
40998820|NCT00973479|DRUG|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
40998821|NCT00973479|OTHER|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
40998822|NCT00973479|DRUG|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
40998823|NCT04200248|DRUG|RBM-007 Injectable Solution|RBM-007 Injectable Solution
40998824|NCT04200248|DRUG|Aflibercept|EYLEA® (aflibercept) Injection, for Intravitreal Use
40998825|NCT04200248|DRUG|Sham|Sham intravitreal injection
40998826|NCT05077943|BEHAVIORAL|Breathing and chest mobilization exercises|Patients walk regularly 5 times per week and increase the distance day by day according to their improved ability. Patients also do breathing and chest mobilization exercise 3 times per week. It is a recorded moderated exercise for 30 minutes duration. Patients can access the video as a home-based activity through an online videos platform and will be supervised.
40998827|NCT05077943|BEHAVIORAL|Second phase cardiac rehabilitation|Independently, patients walk regularly 5 times per week and increase the distance day by day according to their improved ability without breathing and chest mobilization exercise.
40998828|NCT04984655|DEVICE|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|All participants will go through the same intervention described above
40998829|NCT03080961|DEVICE|VIBLOK barrier cream|VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
40998830|NCT00656630|DRUG|Acamprosate|Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
40998831|NCT00656630|DRUG|Naltrexone|50mg capsule, Once daily, 1 week duration
40793091|NCT03480893|PROCEDURE|small size interarcuair decompression|A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.
40998832|NCT00656630|DRUG|Placebo|Matched placebo capsule, 1 week duration
41149863|NCT06430606|PROCEDURE|Tint Time|Arterial blood gas was obtained immediately after intubation(Tint) in supine position. Ventilator parameters and hemodynamic parameters were recorded.
40793092|NCT03480893|PROCEDURE|Laminectomy|A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.
40793093|NCT02977910|PROCEDURE|repair of deltoid ligament|intraoperative repair of deltoid ligament combined with ORIF
40793094|NCT02013349|DEVICE|coronary intervention|
41149864|NCT06430606|PROCEDURE|T0 Time|Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
40998833|NCT04892238|DIAGNOSTIC_TEST|13-C urea breath test|"Standard urea breath test (UBT) (HELICARB, LLC ISOCARB, reg. cert. #РЗН 2016/3773 issued by Roszdravnadzor on 29.02.2016) with 13C-carbamide of 99% purity used for the study.~Samples of exhaled air obtained before and after 20 minutes after 50 mg 13C-urea intake are analysed for 13C/12C isotope ratio with the use of infrared spectrometer IRIS.Doc (Kibion, Sweden). Delta over baseline (δ) of 13C / 12C is calculated based on the results of the initial and second samples, the results were shown in ppm (‰). The results of the test is negative if δ was \<4.0‰; test results with δ ≥4.0‰ are considered positive."
40998834|NCT02444091|DRUG|Cyclophosphamide|Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
41469758|NCT00129116|BIOLOGICAL|Infanrix penta ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
40998835|NCT03219697|BEHAVIORAL|Parenting education program|8-week parent/caregiver education program, followed by two booster sessions. You and/or your partner will attend weekly parenting sessions which will take place either at the office of your child's primary care provider or virtually. Our Toronto Public Health Nurse, will arrange 2 home visits/virtual visits with you and your family along with 4 coaching calls during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions for your family, and making connections in your community that you find helpful such as recreational or nutrition programs or other supports for your family.
40998836|NCT02998801|OTHER|IPAD|Patients undergoing surgery will watch the video using an PAD
40998837|NCT02998801|OTHER|VR Goggles|Patients undergoing surgery will watch the video using goggles
40998838|NCT02057471|DRUG|Intravenous ferric carboxymaltose|1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
40998839|NCT04882527|DEVICE|Non-invasive brain stimulation|Stimulation will be applied once per subject with one mA for 20 minutes over either the left inferior frontal lobe, the right inferior frontal lobe or the right superior parietal lobe.
41149865|NCT06430606|PROCEDURE|T1|Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
41469759|NCT00129116|BIOLOGICAL|Infanrix hexa ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
41469760|NCT02601768|DEVICE|Transcatheter closure of ASD II|Transcatheter closure of ASD II performed in our center.
41149866|NCT05346484|BIOLOGICAL|CF33-hNIS|CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)
41469761|NCT04676880|DEVICE|Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)|Currently, there are two devices available on the Dutch market, Watchman and Amulet. After randomization to the intervention arm, additional randomization for type of device will follow. If the amount of procedures is too small to implant two devices, the centre will implant a device of choice.
41469762|NCT00625755|BIOLOGICAL|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
41469763|NCT01960868|OTHER|standard physiotherapy|
41469764|NCT01960868|OTHER|experimental physical therapy|
41149867|NCT05346484|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).
41149868|NCT00004045|DRUG|exatecan mesylate|
41149869|NCT00501111|DRUG|AZD3480|3 oral doses
41149870|NCT00501111|DRUG|Donepezil|
41149871|NCT06431126|OTHER|Nature and animal-assisted activities|Supervised activities on a farm, 2 half day/week for 12 weeks
41469765|NCT00339872|DRUG|IMA-638|
41469766|NCT06357780|OTHER|close-loop synchronization controller with spontaneous mode|30 minutes period where the pressure support of spontaneous effort will be automatically titrated based on pressure and flow waveform analysis obtained from the patient during NIV mode.
41469767|NCT06357780|OTHER|Conventional|30 minutes period where the synchronization of pressure support of patient effort during NIV mode will be manually set.
41469768|NCT00002787|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|Given SC
41469769|NCT00002787|BIOLOGICAL|sargramostim|Given SC
41469770|NCT00002787|BIOLOGICAL|aldesleukin|Given SC
41469771|NCT00002787|OTHER|laboratory biomarker analysis|Correlative studies
41469772|NCT05171894|DRUG|Hemopfin+Green Light|All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.
41469773|NCT05171894|DEVICE|Vehicle+Green Light|All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.
41469774|NCT00500318|DRUG|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
41469775|NCT00500318|DRUG|Placebo|Dose matched placebo, once daily oral inhalation.
41469776|NCT00333476|DRUG|MSI-1256F (Squalamine Lactate)|
41469777|NCT05966207|BEHAVIORAL|Individual Cognitive Stimulation|"The Individual Cognitive Stimulation will be conducted by caregivers, with support by the research team. The intervention will span 12 weeks, consisting of three weekly sessions (30 minutes each session), totaling 36 sessions. Caregivers in this study will utilize a previously translated and validated version of Making a Difference 3 - Individual Intervention of Cognitive Stimulation - A manual for caregivers, specifically adapted for the European Portuguese population."
40793095|NCT06266026|DIAGNOSTIC_TEST|ThermoBreast - AI-based evaluation of dynamic breast thermography imaging|"Index test: AI-based evaluation of dynamic breast thermography imaging (ThermoBreast). The ThermoBreast evaluation will be performed independently of the routine breast cancer diagnostic evaluation. Some baseline risk variables (e.g. patient age, hormonal status) may be included in the ThermoBreast evaluation.~Reference test: Routine breast diagnostics will serve as a reference test against which the ThermoBreast outcome will be compared. Depending on national guidelines and clinical scenarios, routine breast cancer diagnostics can consist of several routine procedures, including clinical examination, ultrasound, mammography, tomosynthesis, MRI, follow-up imaging, biopsy, surgical excision, and histopathologic evaluation. All procedures will be performed as indicated and specified by the respective, current national guidelines."
40793096|NCT05069727|PROCEDURE|Regular Protocol with advanced carbohydrate counting|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD~* Finetune ICR~* Target 100 or 110 mg/dl~* AIT: 2-3 hour~* Insulin Bolus for meal (advanced carb counting)~* The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.~* Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use)."
40793097|NCT05069727|PROCEDURE|Simplified Protocol with fixed carbohydrate content|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD \>60)~* Target 100 mg/dl~* AIT: 2 hours~* Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.~* The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits."
40998840|NCT04882527|DEVICE|Sham stimulation|The electrode positions and the attachment procedures correspond to those of real tDCS but the electrical current will only be ramped up to 1 mA and switched off completely after 30 s of stimulation.
40998841|NCT01955057|BEHAVIORAL|Research interviews|
40998842|NCT01955057|BEHAVIORAL|Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)|
40998843|NCT01955057|BEHAVIORAL|Projective methods (Thematic apperception Test, Rorschach)|
40998844|NCT01955057|BEHAVIORAL|Carbon monoxide test|
40998845|NCT01352494|DRUG|docetaxel|docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles
40998846|NCT01352494|DRUG|gemcitabine|gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
40998847|NCT02717481|DEVICE|US-CT Fusion examination|Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
40998848|NCT02189564|BEHAVIORAL|Feedback about good performance|
40998849|NCT02189564|BEHAVIORAL|Feedback about good performance + money|
41469778|NCT02932917|DEVICE|MapMySmoke|Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
40998850|NCT02189564|BEHAVIORAL|Feedback about average performance|
40998851|NCT05624346|OTHER|Deep-Breathing Exercises|In addition to routine care in the hospital, the patient will be taught pre-operative breathing exercises. After surgery the patients do deep-breathing exercises every hour.
41469779|NCT03083977|OTHER|Safe and Sound Protocol|The intervention features music processed based on the resonating frequencies of the middle ear
40998852|NCT00651027|DRUG|PF-868554|200 mg, Child-Pugh Class A
40998853|NCT00651027|DRUG|PF-868554|200 mg, Child-Pugh Class B
41469780|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
41469781|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
41469782|NCT06617013|OTHER|Discontinuation of GERD therapy|GERD therapy will be discontinued at time of enrollment.
40998854|NCT00651027|DRUG|PF-868554|200 mg, healthy volunteers
40998855|NCT01957462|DEVICE|Coloplast Test V|Coloplast Test product V is a newly developed 1-piece ostomy appliance
40998856|NCT01957462|DEVICE|Coloplast Test X|Coloplast Test X is a newly developed 1-piece ostomy appliance
40998857|NCT01904604|BIOLOGICAL|Placebo Viaskin® Patch|Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
40998858|NCT01904604|BIOLOGICAL|Low-dose DBV712 Viaskin® Patch|100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
40998859|NCT01904604|BIOLOGICAL|High-dose DBV712 Viaskin® Patch|250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
40998860|NCT00233727|PROCEDURE|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
40998861|NCT00233727|PROCEDURE|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
40998862|NCT02680639|DEVICE|BiPAP Synchrony ventilator|The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
40793098|NCT04824664|OTHER|survey|survey among surgeon
40793099|NCT06105515|PROCEDURE|Laparoscopic and Endoscopic Collaborative Surgery (LECS)|Minimal invasive surgery in collaboration between endoscopy and laparoscopic surgery, to locally remove the tumor
40998863|NCT04002414|BEHAVIORAL|Sufficient physical activity|Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
40998864|NCT04002414|BEHAVIORAL|Insufficient physical activity|Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
40998865|NCT05976035|OTHER|Exercise|Structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks
40998866|NCT05976035|OTHER|Supplement|Receiving supplement that are prescribed by a orthopedist every day for 8 weeks
40998867|NCT06151236|DRUG|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
40998868|NCT01418209|DRUG|Low-dose 17-ß-estradiol with progesterone taper|Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
40998869|NCT01418209|DRUG|Venlafaxine XR|Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
40998870|NCT01418209|DRUG|Placebo|The placebo is an inactive pill that looks like the active medication.
40998871|NCT01500642|BIOLOGICAL|Slit One|slit one sublingual immunotherapy 200 stu
40998872|NCT01500642|BIOLOGICAL|Slit One|slit one vestibular immunotherapy 200 stu
40998873|NCT01500642|BIOLOGICAL|Slit One ragweed|slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
40998874|NCT06162754|OTHER|A questionnaire and TREALD scales were applied to parents.|The survey, which included questions about sociodemographic characteristics and space maintainer awareness, was administered to parents face to face. Then, parents' oral health literacy levels were measured with TREALD-30 and TREALD-30A scales.
40998875|NCT01615471|BEHAVIORAL|Group weight loss with companion internet|Monthly in-person group sessions with an companion internet weight loss intervention
40998876|NCT01661712|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
40793100|NCT04535973|DIAGNOSTIC_TEST|unstimulated saliva sample for hormone analysis|hormone levels will be determined in frozen samples of unstimulated saliva
40793101|NCT04535973|OTHER|quality of life questionnaire|all participants will fill out self-perceived quality of life questionnaire
40793102|NCT06184230|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine
40793103|NCT00315510|DRUG|Rosuvastatin|
40998877|NCT01661712|DEVICE|Sham stimulation|Sham stimulation for one night (no electrical stimulation)
40998878|NCT02701972|DEVICE|BACE Device|Implanted BACE device
40998879|NCT00747435|DEVICE|Electric Acoustic System|Combination of a cochlear implant and a hearing aid
40998880|NCT03521986|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
40998881|NCT03521986|PROCEDURE|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
40793104|NCT00758693|DRUG|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
40793105|NCT00758693|DRUG|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
40793106|NCT03032159|BEHAVIORAL|Text2Breathe Study Group|
40793107|NCT01069393|OTHER|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
40998882|NCT02484703|DRUG|Placebo|Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
40998883|NCT02484703|DRUG|RO5186582|Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
40793108|NCT02235792|DEVICE|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
40793109|NCT03449849|OTHER|Base Diet|Base Diet
40793110|NCT03449849|OTHER|Kale Treatment|Base Diet plus Kale
40998884|NCT01776788|DRUG|insulin lispro injection, exenatide injection|First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
40998885|NCT01776788|DRUG|insulin lispro injection|Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
40793111|NCT02049346|DRUG|Epoetin alpha or beta (Epoetin group)|"Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.~Doses of erythropoetin were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
40793112|NCT02049346|DRUG|Darbepoetin alfa|"Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used."
40793113|NCT02049346|DRUG|Methoxy polyethylene glycol-epoetin beta|"Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
40998886|NCT03062475|BEHAVIORAL|lifestyle intervention with dietary and exercise recommendation|"With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat.~With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy."
40998887|NCT02768675|DEVICE|LOADPRO|The Intellirod LOADPRO sensor is a single-use, disposable instrument for the intra-operative measurement of posterior instrumented, spine rod strain.
40998888|NCT00963339|DEVICE|Foresee Home|Home Monitoring
40998889|NCT02611622|BEHAVIORAL|LUMA ENT™|
40998890|NCT02611622|OTHER|Survey|Demographic and Patient Satisfaction Survey
40998891|NCT02245243|DRUG|Delafloxacin|Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
40998892|NCT05080452|DIAGNOSTIC_TEST|Dynamic infrared thermography (DIRT)|Visualizing hot spots
40998893|NCT03249779|DEVICE|Scrambler|Scrambler Therapy is a specific form of electrical stimulation which has also been utilized in chronic neurogenic pain11. This modality of therapy differs from TENS in that the goal is to mediate the patient's perception of pain, rather than masking the peripheral pain signal. The results of this modality of treatment may be longer-lasting than TENS, presumably via reduction in central signal generation. Scrambler therapy works through C fibers to retrain the peripheral sensation in the area being treated. Further description of this technology is available at: International Patent PCT/IT2007/000647 and U.S. Patent No. 8,380,317. Literature search does not yield prior studies regarding efficacy of Scrambler therapy in treating RLS
41310484|NCT04400409|OTHER|Intervention B - Standard Care + site 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
41310485|NCT04400409|OTHER|Intervention A - Vascular Care + CPC EQuIP 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
40793114|NCT04389905|BEHAVIORAL|Dental education - Motivational Interviewing|Motivational Interviewing - Focusing on oral/dental health
40793115|NCT03159546|DEVICE|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
40998894|NCT05693610|DEVICE|Portable OSP|The portable open-source speech processing platform (OSP) is accessed on a browser via a wireless fidelity (WiFi)-enabled portable communication device that carries out all the signal processing. The processed sounds are transmitted to the ears via earpieces known as behind-the-ear receivers in the canal (same as those available with commercial hearing aids). The amount of amplification with the portable OSP will be customized for each listener based on a validated prescription.
40998895|NCT05693610|DEVICE|Cloud-based OSP|The cloud-based open-source speech processing platform (OSP) is hosted on a web-server which includes the software for all the signal processing. The processed sounds are transmitted to the ears via calibrated headphones. The amount of amplification with the cloud-based OSP will be customized for each listener based on a validated prescription.
40793116|NCT04657185|OTHER|OR PathTrac Feedback Optimization|OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
40998896|NCT04935021|DRUG|ATTR-CM|Current treatment
40998897|NCT02246803|PROCEDURE|CABG+Pulmonary vein isolation procedure|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG
40998898|NCT02246803|PROCEDURE|Isolated CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
40998899|NCT06312878|OTHER|Describe the anatomy of the IVC in the case of an anatomical variant|Evaluated technique by collecting data from the medical record.
40998900|NCT05548192|DEVICE|SmartPICC-1 System|The SmartPICC system is indicated for use as an alternative method to chest x-ray or fluoroscopy confirmation of PICC tip placement in adult patients when proper ECG detection is available. The SmartPICC system provides a supplemental intravascular ionic dilution feature that provides qualitative blood flow information to the user to aid catheter navigation during PICC placement.
40998901|NCT06112028|DRUG|Tongxinluo capsule|On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.
40998902|NCT06112028|OTHER|Primary therapy|Routine oral aspirin enteric-coated tablets, clopidogrel bisulfate tablets and rosuvastatin calcium tablets (or atorvastatin calcium tablets)
41310486|NCT04400409|OTHER|Intervention B - Standard Care + CPC EQuIP 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
41310487|NCT05651139|DEVICE|Electrical Vibration Device|An electrical Vibration Massage device will be used to induce deep tissue vibration stimulation
41310488|NCT01940016|BEHAVIORAL|communication intervention|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.
41310489|NCT01940016|BEHAVIORAL|exercise intervention|Participants participate in a 12-week physical activity intervention administered using an IVR system.
41310490|NCT02671695|DRUG|Spirulina|Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
41310491|NCT02671695|DRUG|Amlodipine|Amlodipine in a dose of 5 mg/day orally for 3 months
41310492|NCT04310150|DRUG|Collastat|hemostatic agent that combine porcine-derived collagen thrombin
40793117|NCT03138551|BEHAVIORAL|Mealtime PREP (Promoting Routines of Exploration and Play)|
40793118|NCT03621072|DRUG|Fluconazole 150mg Capsule Originator|150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France
40793119|NCT03621072|DRUG|Fluconazole 150mg Capsule Localized Originator|150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
40998903|NCT05953662|PROCEDURE|Reduced-port laparoscopic surgery|compare different operational styles of colon and upper rectal cancer
40998904|NCT05953662|PROCEDURE|conventional laparoscopic surgery|conventional laparoscopic surgery
40998905|NCT00449956|DRUG|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
40998906|NCT00449956|DRUG|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
40998907|NCT00449956|DRUG|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
40998908|NCT02952014|DIETARY_SUPPLEMENT|C4 Extreme|Pre-Workout Dietary Supplement
40998909|NCT02952014|DIETARY_SUPPLEMENT|C4 Extreme (without Advantra Z|Pre-Workout Dietary Supplement
40998910|NCT02952014|DIETARY_SUPPLEMENT|Placebo|Pre-Workout Dietary Supplement
40998911|NCT05471362|DEVICE|Postpartum IUD|Postpartum IUD prevents pregnancy and short inter-pregnancy interval and allow spacing and family regulation
40998912|NCT02397330|DRUG|bupivacaine|
40998913|NCT02397330|DEVICE|ultrasound|ultrasound guided nerve blocks
40998914|NCT02397330|DRUG|morphine|
40998915|NCT03239470|BIOLOGICAL|Cohort 1: 1.0 x 10^8 PolyTregs|Each participant will receive a target cell dose of 1.0 x 10\^8 polyclonal Tregs.
40998916|NCT03239470|BIOLOGICAL|Cohort 2: 2.5x10^8 PolyTregs|Each participant will receive a target cell dose of 2.5x10\^8 polyclonal Tregs.
41310493|NCT04310150|DEVICE|Floseal|hemostatic agent that combine bovine-derived gelatin
40793120|NCT04125329|DRUG|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
40793121|NCT03338400|DRUG|Dexamethasone|Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.
40793122|NCT03338400|DRUG|Normal saline|Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
40793123|NCT02901691|OTHER|musical rhythmic stimulation|
40793124|NCT00496431|DRUG|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
40793125|NCT02575729|DRUG|betamethasone|Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
40793126|NCT03527511|OTHER|Measure of etecalcetide on osteoclastic biology|In vitro evaluation of osteoclastic biology after blood sampling of patients.
40793127|NCT06283277|DEVICE|Obstetric Ultrasound|Measuring fetal clavicular length and estimated fetal weight using Hadlock IV formula and Youssef's formula.
40793128|NCT02918669|RADIATION|CT Scan|"Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.~There are no other interventions. It is just a onetime CT post 60 month time point."
40793129|NCT02099825|DRUG|d-cycloserine and mifepristone|All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
40793130|NCT04944771|DRUG|Capivasertib|Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.
40793131|NCT04944771|DRUG|Rabeprazole|Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.
40793132|NCT01302327|DRUG|Exenatide|Exenatide
40793133|NCT04375956|DRUG|Pembrolizumab|Experimental
40793134|NCT01992224|OTHER|early mechanical Ventilation|"Fulfillment of three or more criteria below:~respiratory rate \> 28 per minute serum lactate \> 3 mmol/L PaO2/FiO2 Index \<300 mmHg SvO2 \< 65% lung infiltration or atelectasis, pleural exudation"
40793135|NCT01992224|OTHER|Conventional Mechanical Ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate \> 28 bpm dyspnea PaO2/FiO2 Index \<200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
40793136|NCT00276406|DRUG|Pyridostigmine|Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
40793137|NCT00276406|DRUG|Placebo|If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
40793138|NCT03571360|OTHER|PD-L1 positive vs PD-L1 negative NSCLC patients|Genomic analyses of PD-L1 positive vs PD-L1 negative NSCLC patients
40793139|NCT06511687|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered in a single dose at birth for newborn cohort and at the beginning of the campaign for the other cohorts under study
40793140|NCT02154165|OTHER|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
40998917|NCT04221685|OTHER|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg
40998918|NCT04221685|OTHER|Artinibsa|"Powerful local anaesthetic with a short latency time.~Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains:~Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg"
41310494|NCT03617133|RADIATION|Increased use of IC/IS technique in BT|In EMBRACE II, the improved therapeutic window (through increased application of IC/IS) will be exploited for tumour dose-(de-)escalation and/or OAR dose de-escalation. In tumours with large residual CTVHR volumes at time of brachytherapy, dose-escalation has the potential to improve local control significantly. In limited size CTVHR volumes dose-de-escalation will be performed since dose de-escalation has minor impact on local control while it has potential to reduce morbidity. The strategy of EMBRACEII is to aim for an application of the IC/IS technique in at least 20% of the patients in each institution. The threshold of 20% is relevant for a classical stage distribution of \~20% IB, \~50% IIB, \~20% IIIB and \~10% others. If a given patient population includes significantly higher proportions of limited or extensive disease, the threshold of 20% IC/IS applications must be adapted.
40998919|NCT01716013|DEVICE|BondEase|topical skin adhesive
40998920|NCT01716013|PROCEDURE|CWCD|traditional closure methods of sutures, staples or adhesive strips
41149872|NCT04173000|OTHER|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
41469783|NCT05188183|DEVICE|M1 anodal home-based tDCS|During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10 mA.
40793141|NCT03033680|DRUG|[F-18]PBR06|PET radiopharmaceutical
40793142|NCT01845246|DEVICE|Prospective TDM Arm of colistin|
40793143|NCT02752490|DRUG|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
40998921|NCT06255951|DRUG|Itraconazole|The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.
40998922|NCT06255951|DRUG|Rifampicin|The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.
41469784|NCT05188183|BEHAVIORAL|Somatosensory Training|The somatosensory training will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks. Sessions will start with relaxation exercises using a body scan technique, whereby subjects in a relaxed state will be instructed to sequentially interchange their mind to different regions of the body while perceiving it and establishing contact with the body part. Subjects will be asked to concentrate on any feeling (kinetic, kinesthetic or exteroceptive) related to each body part. Phantom exercises will involve the use of imagined movements of the phantom limb. Therefore, patients will be asked to perform general exercises with their phantom limb. Exercises will include hip, knee, ankle, and toe movements.
40998923|NCT05408416|PROCEDURE|preoperative group and intraoperative group|ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
41310495|NCT03617133|RADIATION|Reduction of vaginal source loading|A multicenter investigation in 50 EMBRACE patients from 3 institutions (Mohamed SM. et al, in submission 2015) shows that reduced loading in ring/ovoids and increased loading in tandem (and needles when available) can be applied without compromising CTVHR and GTVres dose. Decrease of relative vaginal loading from a mean of 50% to 33% had potential to reduce ICRU recto-vaginal dose by a mean of 4±4Gy, and furthermore, bladder and rectum doses could be reduced by 2-3Gy with the same re-arrangement of loading. Similar evidence is available from a study on simulation of different intracavitary standard loading patterns in EMBRACE patients, where it was shown that limited size tumours could often be covered by tandem loading alone (Nkiwane KS. et al. 2013).
41310496|NCT03617133|RADIATION|Systematic utilisation of IMRT|Many institutions deliver 3D conformal radiotherapy (3D CRT) based on a four-field box technique although IMRT has been available for a number of years. The practice in EMBRACEI has been utilisation of IMRT and 3D CRT in 27% and 73% of the patients, respectively. However, EMBRACE morbidity data as well as data published by Mundt et al (Mundt AJ. et al. 2003) indicate that IMRT significantly reduces the incidence of bowel morbidity, and therefore IMRT is considered as instrumental for reducing the incidence of bowel morbidity and with a potential also to be beneficial for urinary morbidity.
41310497|NCT03617133|RADIATION|Utilisation of daily IGRT (set-up according to bony structures)|PTV margins of 10 mm to the elective lymph node target are currently applied in many institutions. This margin is related to set-up uncertainties with patient positioning performed based on skin marks. However, currently, most institutions have in-room imaging available which makes it possible to perform daily imaging and couch correction according to fusion on bony anatomy. With daily imaging, bony image fusion, and couch correction, a margin reduction from 10mm to 5mm can be performed without compromising target coverage (Laursen LV. et al. 2012). The 5mm margin reduction has potential to decrease the volume irradiated to 43Gy by approximately 500cm, which is expected to decrease bowel morbidity by \~50%.
41310498|NCT03617133|RADIATION|EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring|New target concepts are introduced for EBRT related to primary tumor: initial CTV-T, initial CTV-HR, initial CTV-LR and ITV-LR. Use of this novel contouring approach in conjunction with available MRI allows to target safely the visible tumor (CTV-T) and the high risk region (CTV-HRintitial) while consenting for dose to a low risk region (CTV-LRinitial). Anatomical changes due to organ filling variation and cervix/uterus position are considered. ITV-LR is outlined using planning scan and MR images in patients with MRI in treating position while a fixed margin is added to the CTV-LR initial in patients with only diagnostic MRI. New concepts are introduced for OAR contouring. Bowel loops are outlined in one volume restricted to the outer contour, including the mesenterium, for better approximation of the bowel volume and dose constraints. Rectum/sigmoid structures are contoured distinctly. Vaginal lower border is 2,5cm from the caudal extend of the tumor (2cm ITV-LR initial + 0,5cm PTV).
41310499|NCT03617133|RADIATION|EBRT dose prescription and reporting|There is currently a significant variation with regard to EBRT dose and fractionation in the EMBRACE study with doses ranging from 45Gy to 50Gy and being delivered in 25-30 fractions. Furthermore, there is a wide variety of lymph node boosting strategies. In EMBRACEII, the EBRT dose and fractionation to the elective lymph node CTV and initial CTV-T is fixed at 45Gy in 25 fractions, and lymph node boosting must be performed as a simultaneous integrated boost. The dose de-escalation from 50Gy to 45Gy has potential to reduce morbidity. A system of reporting dose to targets and OARs is introduced in terms of dose volume parameters and a system of point dose reporting for the vagina.
41469785|NCT05188183|OTHER|Usual Care|Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
41469786|NCT06254950|DRUG|TAK-279|TAK-279 capsules.
41469787|NCT06254950|DRUG|Placebo|TAK-279 placebo-matching capsules.
41469788|NCT06227377|DRUG|QTX3034|QTX3034 will be administered at protocol defined dose
41469789|NCT06227377|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
41469790|NCT05155605|DEVICE|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
41469791|NCT05472155|DEVICE|Bulb syringe|Suctioning with a bulb syringe
41469792|NCT05472155|DEVICE|Suction catheter|Suctioned with a suction catheter
40998924|NCT01165866|DRUG|Treatment 1. Metoclopramide|metoclopramide 0.3mg/kg maximum dose 10mg will be added in the burette and mixed with normal saline to make up 50cc of medication for intravenous administration.
40998925|NCT01165866|DRUG|Treatment 2 Ondansetron|Single dose of Ondansetron 0.15 mg/kg
40998926|NCT02308735|OTHER|N/A - No intervention|
40998927|NCT01378793|BEHAVIORAL|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
40998928|NCT01378793|BEHAVIORAL|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
40998929|NCT01393405|DRUG|Methotrexate|"Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine"
40793144|NCT02752490|DRUG|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
40998930|NCT00017134|DRUG|fenretinide|
40998931|NCT00017134|PROCEDURE|conventional surgery|
40998932|NCT04409288|DRUG|Apalutamide|Androgen receptor inhibitor.
40998933|NCT04409288|DRUG|Enzalutamide|Androgern receptor inhibitor
40998934|NCT02395796|PROCEDURE|Epidural Pressure Waveform|When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
40998935|NCT01723163|BEHAVIORAL|Abstinence Reinforcement Therapy (ART)|Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
40998936|NCT01723163|BEHAVIORAL|Telephone Counseling and NRT|Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
40998937|NCT04014257|DRUG|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
40998938|NCT04693585|BEHAVIORAL|MESSSSAGE - live|mHealth education and social support intervention, synchronous via call
40998939|NCT04693585|BEHAVIORAL|MESSSSAGE - asynchronous|mHealth education and social support intervention, asynchronous via text
41469793|NCT06615778|BEHAVIORAL|Motivated Social Emotional Learning|"MSEL arm consists of three intervention components: 1) CSEL, 2) the meaningful role tasks, and 3) the Secret Angel activity. First, participants in the MSEL arm will receive the same 6-session SEL as participants in the Curriculum-based Social-Emotional Learning arm.~Second, other than the CSEL, the second component is the Class Diploma tasks adopted from the pupil responsibilities intervention developed by Ellies et al. (2016). Participants will be provided with a list of meaningful roles and select the role they are willing to take based on their talents and interests. Each participant will take the role for two weeks, fulfilling the related duties and responsibilities. The third component is the Secret Angel, in which participants will anonymously recognize each other via the appraisal notes on Shout Out for Your Board."
40793145|NCT00232323|BEHAVIORAL|simulation training|
40793146|NCT01141998|DRUG|Calcium, Dietary|400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
40793147|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. Week 0-10.
40793148|NCT01141998|RADIATION|UVB|Ultraviolet radiation type B administered in a tanning bed. One time weekly.
40793149|NCT01141998|RADIATION|UV-filtered light.|Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.
40793150|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. From week 14 to 52.
40998940|NCT06197594|OTHER|Proprioceptive neuromuscular facilitation techniques|Proprioceptive neuromuscular facilitation techniques
40998941|NCT06197594|OTHER|Rebound Therapy|Rebound Therapy
40998942|NCT03327610|OTHER|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
40998943|NCT03327610|OTHER|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
40998944|NCT03327610|OTHER|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
40998945|NCT03327610|OTHER|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
41310500|NCT03617133|RADIATION|Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrence|"EMBRACEII applies a risk adapted target concept for nodal CTV. This target concept is based on pattern of nodal recurrence analysis which shows 50% of recurrences beyond the classical L5/S1 cranial pelvic field border. A target volume Large Pelvis is defined for intermediate risk patients and includes internal, external, common iliac, obturator and presacral nodes. For high risk patients, defined as common iliac or \>2 nodes involved, the para-aortic region is included. For low risk patients, defined as stage IA/IB1/IIA1, N0, small cell carcinoma (SCC), no uterine invasion, Small Pelvis is defined which is Large Pelvis without common iliac nodes. Intermediate risk is defined as not high and not low risk."
40793151|NCT05439343|OTHER|Pain scores (numerical rating scale at rest and motion)|As the primary outcome of the present clinical study, pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
40793152|NCT05439343|OTHER|Secondary outcomes|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale will be used as the questionnaires for functional assessment. Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of knee joints.
40793153|NCT04592471|DEVICE|kneeMID500-STRONG700|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (2 device types: Knee MID 500 and Knee STRONG 700) totalling 60 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
40793154|NCT04364815|DRUG|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine and standard preventive measures
40793155|NCT04364815|DRUG|Placebo plus standard preventive measures|Placebo tablet plus standard preventive measures as defined by PGH-HICU
40793156|NCT02309658|DRUG|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
40793157|NCT02309658|DRUG|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
40793158|NCT02309658|RADIATION|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
40793159|NCT03269539|OTHER|MRI Imaging|
40793160|NCT03388762|DIETARY_SUPPLEMENT|GlucoSupreme™ Herbal|This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.
40793161|NCT03388762|OTHER|Placebo|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
40793162|NCT01053533|DRUG|Chinese herbal medicines plus western therapy|injections of Chinese herbal medicines and Chinese herbal medicines decoction\& supportive therapy and antivirus therapy when necessary
40793163|NCT01053533|DRUG|western therapy|supportive therapy and antivirus therapy when necessary
40793164|NCT02332785|OTHER|Data Collection|Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
40793165|NCT01597648|DRUG|Maraviroc|300 mg
40793166|NCT01597648|DRUG|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
40793167|NCT01597648|DRUG|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
40793168|NCT05370976|DRUG|Cytotect®CP|"Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose \< 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained"
40793169|NCT06266559|OTHER|Chang Geng Healthy Drink|Chang Geng Healthy Drink consists of Zingiberis Rhizoma, Codonopsis pilosula, Atractylodis Macrocephalae Rhizoma, Poria cocos, Citri reticulatae Pericarpium
40793170|NCT02588417|DRUG|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
40793171|NCT02588417|DRUG|Levobupivacaine|levobupivacaine 2.5 mg
40793172|NCT00252512|BEHAVIORAL|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.
40998946|NCT03327610|OTHER|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
40998947|NCT03327610|OTHER|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
40998948|NCT06357611|OTHER|Simulated technique|"The participant was in a supine position, with her upper limbs at her sides and her neck in a neutral position.~The researcher sat in a cephalic position, making contact with the participant's shoulders, without any movement, until 5 minutes had elapsed."
40793173|NCT00252512|OTHER|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
40793174|NCT03446963|BEHAVIORAL|Groups for Health|Group sessions, 5 modules x 1.5 hours (once per week). Modules focus on psychoeducation, mapping existing social networks, examining barriers to engagement in existing networks, goal setting and identifying new groups to join.
40793175|NCT01542463|DRUG|insulin detemir|Prescribed at the discretion of the physician
40793176|NCT03667989|DIAGNOSTIC_TEST|Assessment of cardiac sympathetic innervation by 123I-MIBG|Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
40793177|NCT01412125|OTHER|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
40793178|NCT01412125|OTHER|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
40793179|NCT05480982|BEHAVIORAL|Cognitive functional therapy via tele rehabilitation|Participants in the CFT group will be treated by a physiotherapist with seventeen years of clinical experience and that has attended six CFT workshops with three of the international tutors of the method. She has completed 212 hours of training including workshops, patient examinations and a pilot study under the supervision of a physiotherapist with more than seven years of clinical experience in CFT. Another two physiotherapists, one with more than fifteen years and the other with more than ten years of clinical experience, and both with more than 106 hours of CFT training including CFT via tele physiotherapy, will complete the staff.
40793180|NCT05480982|OTHER|Pilates via tele rehabilitation|Physiotherapist will have the freedom to judge about the exercises´ progression and the need of adaptation considering both the level of difficulty to perform each exercise according to the original proposal and the individual´s demands. The treating physiotherapists will have at least 2 years of clinical practice in Pilates and clinical experience in Pilates via teleconference.
40793181|NCT06292663|DEVICE|Virtual Reality|The subjects get a supplement of information via. a Vitual Reality (VR) headset. The information they get through the VR headset is about their course on the day of their surgery.
40793182|NCT00170326|PROCEDURE|dual-chamber pacemaker implantation|Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.
40793183|NCT00170326|PROCEDURE|biventricular dual-chamber pacemaker implant|Biventricular pacemaker system or in case in ICD indication a BIV ICD
40998949|NCT06357611|OTHER|Muscle energy technique|"The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~The researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. He then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively until the motor barrier was reached, and instructed her to perform an isometric contraction of the hamstrings. She was asked to perform three 7-second contractions with a 2 to 3-second interval, using approximately 20% of her maximum strength, gaining a new motor barrier between each set, for a total of three sets."
40793184|NCT00014274|DRUG|carboplatin|
40793185|NCT00014274|DRUG|gemcitabine hydrochloride|
40793186|NCT00014274|DRUG|methotrexate|
40793187|NCT00014274|DRUG|vinblastine sulfate|
40793188|NCT03858517|DEVICE|ReUnion TSA System|The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
41469794|NCT06615778|BEHAVIORAL|Curriculum-based Social Emotional Learning|"In the CSEL arm, 6-session SEL training will be delivered as the experimental component. The primary goal of the SEL training is to reduce traditional bullying and cyberbullying perpetration and victimization by enhancing students' social-emotional competence, which has been examined to be the protective factor for bullying-related behaviors.~Each session lasts 40 minutes and is delivered by the headteacher in each class weekly as an after-school workshop. The SEL curriculum is tailored to the social-emotional needs of primary school students, as suggested by CASEL (2013). Also, building on past literature highlighting the lack of SEC as a risk factor linked to bullying behaviors both in the physical and cyber world, specific topics such as self-appreciation (self-awareness), stress management (self-management), respect and acceptance (social awareness), and conflict resolution (relationship skills) incorporated into the curriculum design."
41469795|NCT06600100|BEHAVIORAL|Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation, Rossi et al., 2009). Images of food and non-food appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, or lose 1 point. Participants must respond as quickly and accurately as possible. Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal
41469796|NCT06600100|BEHAVIORAL|Placebo Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation, Rossi et al., 2009). Images appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, or lose 1 point. Participants must respond as quickly and accurately as possible. Here, three separate categories of non-food items (stationery, flowers and clothing) would be Go signal (associated with green 100%), No-Go signal (associated with red 100%) and control (50% red 50% green) respectively.
41469797|NCT01082224|DRUG|iodinated contrast dye|iodinated Radiocontrast dye for imaging enhancement
41469798|NCT01082224|DRUG|motexafin gadolinium|motexafin gadolinium
41469799|NCT01082224|OTHER|Eovist-enhanced MRI|A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
41469800|NCT03497819|BIOLOGICAL|CARTmeso CART19|Autologous chimeric antigen receptor T cells with murine scFv, 41BB co-stimulatory domain and CD3ζ signaling domain targeting mesothelin or CD19
41469801|NCT02900482|OTHER|Sampling saliva|
41469802|NCT00003862|DRUG|cisplatin|
41469803|NCT00003862|DRUG|fluorouracil|
41469804|NCT00003862|DRUG|leucovorin calcium|
41469805|NCT00003862|DRUG|paclitaxel|
41469806|NCT00003862|PROCEDURE|conventional surgery|
41469807|NCT00003862|PROCEDURE|neoadjuvant therapy|
41469808|NCT00003862|RADIATION|radiation therapy|
41469809|NCT03206567|DIETARY_SUPPLEMENT|Nutrafol Supplement capsules|NUTRAFOL's Synergen Complex® is a patent-pending formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some patented ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin), all of which are standardized and clinically tested. the Nutrafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
41469810|NCT03206567|OTHER|Placebo capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
41469811|NCT06087328|DRUG|Regular Nicotine patch and lozenge dose|1mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]
41469812|NCT06087328|DRUG|Augmented Nicotine patch and lozenge dose|21mg patch + 14mg patch qd + 4mg lozenge prn \[minimum of 5 \& up to 30 per day\] OR 2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]
41469813|NCT03346954|OTHER|[11C]-Methionine PET/MRI|Implementation \[11C\]-Methionine PET/MRI performed for each patient in one place (department of nuclear medicine of the Hospices Civils de Lyon). The \[11C\]-Methionine PET/MRI will be performed after a pituitary MRI and before a transsphenoidal surgery.
41310501|NCT03617133|DRUG|Systemic application of simultaneous chemotherapy|According to international standard and evidence, simultaneous chemotherapy (CHT) (min. 5x40 mg/m2 cis Platinum) was prescribed in the EMBRACE protocol for all patients, who qualify for its administration. Certain rules were given for adaption according to international guidelines. 90-95% of EMBRACE patients received simultaneous CHT. Most of the EMBRACE cohort is consecutive patients representing the cervix cancer patient population in the respective centers. About 70% of patients received ≥5 cycles, while 30% received 0-4 cycles. CHT has impact on systemic control, which is pronounced in high risk patients (node positive and/or stage III/IV) with a 20% difference in systemic recurrence. A center effect has been found in the ability to administer chemotherapy with 15-85% of the patients receiving ≥5 cycles of CHT. To reach optimal outcome, particularly in the high risk group, the EMBRACEII protocol also focusses on appropriate administration of CHT following international guidelines.
40998950|NCT06357611|OTHER|4th ventricle technique and muscular energy technique|"The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~For CV-4, the researcher contacted the squamous portion of the occiput laterally, bringing it close to the posterior convexity of the occiput, bringing the skull into extension, changing the compression movement with decompression, until 3 minutes had elapsed.~For the MET, the researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. She then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively to the motor barrier, having been instructed to perform an isometric contraction of the hamstring. A total of 3 7-second contractions with a 2-3 second interval were requested, using approximately 20% of her maximum strength, and with a new motor barrier being gained between each series, for a total of 3 series."
40998951|NCT01161329|OTHER|High-Intensity Functional Exercise Programmes (HIFE)|Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
40998952|NCT03146234|GENETIC|CAR-GPC3 T cells|"Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study."
41310502|NCT03617133|OTHER|Reduction of overall treatment time|Several studies indicate that maintaining an overall treatment time (OTT) of \<=50 days is important for local control. RetroEMBRACE data confirms that OTT remains of importance in the realm of IGABT. As there is significant variation of OTT across patients and institutions in retroEMBRACE, the EMBRACEII study aims to reduce the OTT so that the majority of patients (\>80%) will adhere to the \<=50 day threshold. The measures to reduce OTT in EMBRACE is to systematically apply 25 fractions of EBRT including lymph node boost, and furthermore to carefully plan the BT schedule, so that brachytherapy is delivered towards the end of EBRT and/or directly after EBRT.
40998953|NCT01554618|DRUG|Exenatide Once Weekly|2 mg exenatide once weekly
41149873|NCT04173000|OTHER|Mehealth for ADHD software without medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
41149874|NCT01070199|BEHAVIORAL|liquid to liquid|"• One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid."
41310503|NCT00019500|DRUG|raloxifene|
41310504|NCT00019500|PROCEDURE|evaluation of cancer risk factors|
40998954|NCT01554618|DRUG|Placebo|Placebo
40998955|NCT01238614|OTHER|CHICA PSF plus JIT|
40998956|NCT01238614|OTHER|CHICA maternal depression PSF|
40998957|NCT01238614|OTHER|Control|
40998958|NCT03770650|PROCEDURE|Stenting|DK crush technique with SYNERGY (Boston Scientific) drug-eluting stent implantation.
40998959|NCT02251795|DRUG|Tipranavir|
40998960|NCT02251795|DRUG|Ritonavir|
40998961|NCT02251795|DRUG|Darunavir|
40998962|NCT02251795|DRUG|Aspirin|single dose on day 2
40793189|NCT05940064|DRUG|Zanubrutinib, Polatuzumab Vedotin, Rituximab|Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m\^2 ivgtt D1
40793190|NCT02015481|DRUG|Cabaletta|
40793191|NCT02895178|BEHAVIORAL|Combined aerobic and strength exercise training|Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
40998963|NCT01044602|OTHER|Laboratory evaluations, sleep study|Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
40998964|NCT01044602|OTHER|Best Medical Management|Standard of care.
40998965|NCT01044602|PROCEDURE|Roux-en-Y gastric bypass surgery|Surgical treatment.
40998966|NCT03040635|DRUG|Risdiplam|Single oral doses of Risdiplam will be administered on Day 1.
40998967|NCT03040635|DRUG|Placebo|Single oral doses of Risdiplam matching placebo will be administered on Day 1.
40998968|NCT02200848|DRUG|Lenalidomide, Ibrutinib, Rituximab|Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
40998969|NCT05837936|OTHER|Total intravenous anesthesia (TIVA)|TIVA anesthetic -no inhalational gases for surgery
40998970|NCT05837936|OTHER|Sevoflurane initiated intravenous anesthesia (SIIVA)|SIIVA - sevoflurane anesthetic gases for surgery
40998971|NCT01550419|DRUG|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
40998972|NCT01550419|DRUG|Placebo|The smell and shape of placebo are the same as atorvastatin
40998973|NCT05687435|DRUG|Changyanning tablet|"Changyanning Tablet is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd，composed of Euphorbia humifusa, golden ear grass, camphor tree root, Elsholtzia splendens and maple leaves. It is mainly used for the treatment of acute and chronic intestinal diseases caused by various reasons.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation."
40998974|NCT05687435|OTHER|Changyanning tablet placebo|"Changyanning Tablet placebo is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd. Changyanning Tablet placebo has the same appearance, smell, taste, specifications and packaging with Changyanning Tablet, but does not contain active pharmaceutical ingredients.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation."
40998975|NCT01802957|OTHER|Training of health workers in Basic Obstetric Emergency Care|Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
40998976|NCT01802957|OTHER|Hospital-health center networking system|A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
40998977|NCT01802957|OTHER|Post Basic Emergency Obstetric Training Mentorship|At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
40998978|NCT01802957|OTHER|Team-Based Supportive supervision|Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
40793192|NCT04794868|DIAGNOSTIC_TEST|CCTA-derived high risk plaque characteristics|Presence of CCTA-derived high risk plaque characteristics
40998979|NCT01802957|OTHER|Midwives exchange program|Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
40998980|NCT01802957|OTHER|Strengthening the referral network|Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
41310505|NCT00443378|BEHAVIORAL|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
41310506|NCT04573452|DIAGNOSTIC_TEST|Galectin-3|Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).
41310507|NCT04573452|DIAGNOSTIC_TEST|Placental Galactin-3|Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
41310508|NCT03810690|BIOLOGICAL|mRNA-3704|mRNA-3704 dispersion for intravenous (IV) infusion
41310509|NCT00149851|DRUG|Tegaserod|
41310510|NCT04058119|BEHAVIORAL|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates), oriented by certified instructors. Every sessions will be 60-minutes long, biweekly, with a total duration of 6 months.
41310511|NCT01800006|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
40998981|NCT01802957|OTHER|Facility Checklists|Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
40998982|NCT01802957|OTHER|Emergency Drills|Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
40998983|NCT04466865|OTHER|Best Case/Worst Case communication tool training|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of kidney disease. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning the intervention is designed to lead to a discussion of participants preferences and consideration of outcomes.~The nephrologist verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The nephrologist also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
40998984|NCT02286193|BEHAVIORAL|Patient clinical encounters with Community Resource Specialist (CRS)|CRS will work with patients to create goals, develop action plans and link to community resources to support goals
41149875|NCT01070199|BEHAVIORAL|liquid to solid|This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
41149876|NCT01070199|BEHAVIORAL|solid to liquid|"• This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form."
40998985|NCT05811546|DIAGNOSTIC_TEST|Immunohistochemical staining for DNMT1 and EZH2|Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.
41149877|NCT01070199|BEHAVIORAL|solid to solid|"Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage."
41149878|NCT03310372|RADIATION|Ultrafractionated brain irradiation|0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)
41149879|NCT03310372|DRUG|Temozolomide|75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
41149880|NCT01549171|DRUG|Iloprost|supplement in culture medium during culture in the lab. The concentration is 1 uM.
41149881|NCT01549171|OTHER|normal saline|Supplement with vehicle only no Iloprost.
41149882|NCT05788536|GENETIC|DB-OTO|"DB-OTO will be administered as a single intracochlear injection into one ear (Part A).~* LD Cohort (starting dose)~* HD Cohort (high dose)"
41149883|NCT05788536|GENETIC|DB-OTO|DB-OTO will be administered as a single intracochlear injection into both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.
41149884|NCT01991678|DRUG|145 mg/m2 NKTR 102|
40998986|NCT00589953|DRUG|Erythropoietin|"5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour."
40998987|NCT00589953|DRUG|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
40998988|NCT01335958|DRUG|DMUC5754A|Escalating intravenous dose
40998989|NCT03088176|DRUG|Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Up to 4mL administered on C1D1 intratumorally
40998990|NCT03088176|DRUG|Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
40998991|NCT03088176|DRUG|Dabrafenib|150mg PO qday
40998992|NCT03088176|DRUG|Trametinib|2mg PO qday
40998993|NCT02439320|DRUG|Lasmiditan 100 mg|
40998994|NCT02439320|DRUG|Lasmiditan 200 mg|
40998995|NCT02439320|DRUG|Placebo (matches lasmiditan doses)|
40998996|NCT02975921|DRUG|Povidone-Iodine|Intrapleural administration of Povidone-Iodine
40998997|NCT01091792|DRUG|Bevacizumab|Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
40793193|NCT04794868|DIAGNOSTIC_TEST|CFD-derived hemodynamic parameters|CFD-derived hemodynamic parameters
41149885|NCT01991678|DRUG|120 mg/m2 NKTR 102|
41149886|NCT01991678|DRUG|50 mg/m2 NKTR 102|
40793194|NCT00649285|DRUG|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
40793195|NCT00649285|DRUG|Macrobid® Capsules 100 mg|100mg, single dose fed
41469814|NCT04684680|DIETARY_SUPPLEMENT|zamzam water|will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
40998998|NCT06269081|BEHAVIORAL|Supportive-Expressive Peer Social Support Group Intervention|The social support group intervention involves weekly virtual support group meetings for 8 consecutive weeks. The groups, facilitated by trained research staff, will last approximately 90 minutes each week and include 5-12 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Facilitators will encourage mutual support among group members, promote greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy.
40998999|NCT06269081|BEHAVIORAL|Individual Strengths-Based Case Management Intervention|The strengths-based case management (SBCM) intervention helps participants address the multiple structural barriers faced by rural older people living with HIV. This intervention, delivered by trained research staff, includes two 60-minute telephone- or video-based SBCM counseling sessions, with shorter follow-up sessions to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
40999000|NCT04056559|DEVICE|Adaptable mouthguards|Validate a prototype of Adaptable Intra-Oral Protections patented by Bordeaux University and Bordeaux University Hospital according to 3 levels (ventilation, comfort, cervical muscle activity).
40999001|NCT01536431|DRUG|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
40999002|NCT01536431|DRUG|Pro insulin peptide|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
40999003|NCT01536431|DRUG|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
41149887|NCT03602547|DRUG|CM082 plus JS001|CM082：200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
41149888|NCT00122707|DEVICE|catheters|
41149889|NCT03656822|DIAGNOSTIC_TEST|Routine CT|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions.
41149890|NCT03656822|DIAGNOSTIC_TEST|Routine imaging CT with a 3D printed model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + 3D Printed Model
40999004|NCT01649375|DRUG|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
40999005|NCT01649375|DRUG|Placebo|Placebo
40999006|NCT01649375|DRUG|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
40999007|NCT03424031|PROCEDURE|Verticalization|To allow the verticalization of hemiplegic patients, we will use a device commonly used in rehabilitation: the standing (or standing) brand Thera Trainer . This device makes it possible to keep the patient standing despite the motor and postural deficits thanks to knee, buttocks and an anterior support for the upper limbs. Verticalization with this device requires the presence of one or two caregivers (including at least one re-educator), depending on the possibilities of participation of the patient.
40999008|NCT03175094|BEHAVIORAL|Holistic Health Recovery Program for HIV+|Holistic Health Recovery Program for HIV+ (HHRP+) is a CDC-recommended, evidence based behavioral (psychoeducational) group intervention focused on harm reduction principles. The investigators systematically adapted HHRP+ using findings from qualitative interviews with the target population of adult women living with and at-risk for HIV who are justice-involved (on probation, parole, or recently released from prison or jail).
41469815|NCT04684680|DIETARY_SUPPLEMENT|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
40999009|NCT05970432|DRUG|TQH2722 injection 300mg-150mg|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
41149891|NCT03656822|DIAGNOSTIC_TEST|Routine imaging MRI with a 3D printed model|will measure post-operative lesion volume as visualized on the post-operative MRI + 3D Printed Model
41310512|NCT01735617|DRUG|Hydrocortisone Modified Release Capsules|Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
41469816|NCT05076513|DRUG|Niraparib|"In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~* For patients weighing \<77 kg (\<170 lbs) OR with a platelet count \<150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~* For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily."
41469817|NCT05076513|RADIATION|Radiation therapy|Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.
41469818|NCT00700245|BEHAVIORAL|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction)|The exercise intervention for subjects in the EXO consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session. The subjects could choose between different modes of exercise; stationary bicycling, jogging on a treadmill or stair stepping.
40999010|NCT05970432|DRUG|TQH2722 injection 600mg-300mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
40999011|NCT05970432|DRUG|TQH2722 injection 900mg-450mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
40999012|NCT05970432|DRUG|TQH2722 injection matching Placebo|Placebo without active substance.
40999013|NCT02280174|DRUG|linagliptin|linagliptin 5 mg/d for12 weeks
40999014|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 1|QD and/or BID dosing for 28 days
40999015|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 2|QD and/or BID dosing for 28 days
40793196|NCT04169646|OTHER|Multi-component intervention|Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.
40793197|NCT04169646|OTHER|Control|No intervention takes place during the control phase.
41469819|NCT00700245|BEHAVIORAL|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet|Subjects in the DIO group were prescribed a liquid VLED(Nupo, Copenhagen) of respectively 600 and 800 kcal pr. day (proteins 41 g, carbohydrates 29 g, fat 5.6 g. pr 100 gram) for eight weeks followed by a weight maintenance diet for four weeks.
40793198|NCT04095702|OTHER|Weighted Pacifier|The weighted pacifier is a standard of care pacifier with a weighted, breathable star attachment to help keep the pacifier from popping out of the neonates mouth during non-nutritive suck.
40793199|NCT04095702|OTHER|Non-Weighted Pacifier|The non-weighted pacifier is a standard of care pacifier that a neonate would receive if they were not part of this study.
40793200|NCT05460897|BEHAVIORAL|Health behaviour change|weekly sessions addressing strategies to tackle behavioural risk factors for chronic disease
40999016|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 3|QD and/or BID dosing for 28 days
40999017|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 4|QD and/or BID dosing for 28 days
40999018|NCT01520116|DRUG|Stage 1 - Vehicle|QD and/or BID dosing for 28 days
41149892|NCT03656822|DIAGNOSTIC_TEST|Routine MRI|will measure post-operative lesion volume as visualized on the post-operative MRI
41149893|NCT03656822|DIAGNOSTIC_TEST|Routine imaging CT with a VR model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + VR Model
41149894|NCT03656822|DIAGNOSTIC_TEST|Routine imaging MRI with a VR model|will measure post-operative lesion volume as visualized on the post-operative MRI + VR Model
41149895|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic A - inulin|Pre-weighed packages will be given twice daily for 5 days.
40999019|NCT01520116|DRUG|Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|QD and/or BID dosing for 4 days
40999020|NCT01520116|DRUG|Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|QD and/or BID dosing for 4 days
40999021|NCT01520116|DRUG|Timoptic|0.5%
40999022|NCT05940974|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the surgery and after the surgery (on 4 dates over a 1-year period); the DASH and ASES questionnaires to measure their functional outcomes before the surgery and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the surgery and after the surgery (on 4 dates over a 1-year period).
40999023|NCT04413578|DEVICE|Dexcom G6|Continuous Glucose Monitor that, after applied, sends continuous glucose readings to to the patient's smartphone every 5 minutes. This allows the patients to receive more readings over a 24 hour period versus standard of care glucometer finger sticks.
40999024|NCT04413578|DEVICE|Contour NextOne|A Standard of Care Glucometer with Bluetooth capability. The patient inserts a test strip into the device, takes a finger stick and collects a small blood sample on the tip of the strip to initiate the device to detect a glucose reading.
40999025|NCT05222061|DEVICE|Drug coated balloon for the side brunch|Intervention is explained in group description
40999026|NCT05222061|DEVICE|Conventional balloon for the side brunch|Intervention is explained in group description
40999027|NCT05027581|DRUG|Bone marrow mesenchymal stem cells|The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.
40999028|NCT05027581|DRUG|hyaluronic acid|(60 mg/3 mL hyaluronic acid \[HA\])
40999029|NCT02883296|OTHER|Pelvis Magnetic resonance imaging|
41149896|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic B - galactooligosaccharides(GOS)|Pre-weighed packages will be given twice daily for 5 days.
41149897|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic C - wheat dextrin|Pre-weighed packages will be given twice daily for 5 days.
41469820|NCT00700245|BEHAVIORAL|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).|The exercise intervention for subjects in the DEX group consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session
40999030|NCT04079985|OTHER|Animal-assisted therapy|The sessions were held in the primary care centre, and had specific objectives agreed in advance by the research team. The sessions had the following schedule: Session 1, lower extremities in sitting position; Session 2, upper extremities in sitting position; Session 3, cervical spine in sitting position; Session 4, dorsal spine in sitting position; Session 5, lumbar spine in sitting position; Session 6, Static Standing and Upper Extremities; Session 7, Static Standing; Sessions 8, 9, 10 and 11, Dynamic Standing; and Session 12, Safety Reinforcement.
40999031|NCT06481540|DEVICE|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period).
40999032|NCT06481540|DEVICE|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period).
40999033|NCT00922766|DRUG|Dalteparin|Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).
40999034|NCT00076011|DRUG|Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor|
40999035|NCT05064956|BIOLOGICAL|Ad26.ZEBOV|"Ad26.ZEBOV is a non-replicating, monovalent vaccine expressing the full-length Mayinga glycoprotein (GP) of the Ebola virus (formerly known as Zaire ebolavirus), and is produced in human cell line.~Participants will receive a 0.5mL intramuscular injection of Ad26.ZEBOV, at a concentration of 1x10\^11 vp/mL, into the anterolateral deltoid muscle."
40999036|NCT03317171|DIETARY_SUPPLEMENT|Flavonoids, DHA, EPA|oral administration
40999037|NCT03317171|DIETARY_SUPPLEMENT|placebo compound|oral administration
40999038|NCT00390975|DRUG|Tegaserod|
40999039|NCT01433432|DRUG|80 mg DR-6MP|All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.
40999040|NCT00886210|PROCEDURE|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
40999041|NCT00886210|PROCEDURE|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
40793201|NCT02634242|OTHER|Si-Wu-Tang (SWT)|The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.
40999042|NCT00981032|BEHAVIORAL|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
40999043|NCT00981032|BEHAVIORAL|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
40999044|NCT04037319|DIAGNOSTIC_TEST|24 Hour Holter Monitor|24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
40999045|NCT05192746|OTHER|control group|Exercise Therapy and hot pack This tendon exercise program is very effective if done consistently. There are five steps to the program: warm up, stretching exercise, strengthening exercise, stretching exercise, and heat.
40999046|NCT05192746|DEVICE|extracorporeal shock wave therapy|Shock Master 500 device will be applied once a week for four weeks in total. Each treatment consists of 2000 shocks 3 bar pressure, 20 Hz. Each rESWT session will take about 10 minutes. rESWT application will be performed on the supraspinatus trigger point. In successive treatments, there will be using of an energy density equal to 0.28 mJ/mm2
41149898|NCT03133455|OTHER|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
41469821|NCT03889691|PROCEDURE|Third molar surgery|Surgical extraction of impacted lower third molar tooth under local anesthesia
40793202|NCT02634242|OTHER|placebo|The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
40793203|NCT03073863|DRUG|Atorvastatin|Analysis
40999047|NCT05192746|DEVICE|high power pain threshold ultrasound|"High-power, pain-threshold, ultrasound therapy application (in W/cm2) in continuousmodes, to elicit threshold pain, the ultrasound probe must be kept static on the tendon.~Intensity will be gradually increased to the level of maximum pain the patient could bear. It will be kept at that level for 4 to 5 seconds and then will be reduced to the half-intensitylevel for another 15 seconds. This procedure will be repeated 3 times.High-power,"
40999048|NCT04270838|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 1x10\^10 and 5x10\^10
40999049|NCT04270838|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units
40793204|NCT03644810|DIAGNOSTIC_TEST|PPT measurement|The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg
40793205|NCT03644810|DIAGNOSTIC_TEST|Pain catastrophizing scale|A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification
40999050|NCT02371707|DRUG|Idalopirdine 60 mg formulation A (test)|Tablet for oral use, single dose
40999051|NCT02371707|DRUG|Idalopirdine 60 mg formulation B (reference)|Tablet for oral use, single dose
41310513|NCT03480282|OTHER|Prognosis information and Provider Scripts|An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.
41310514|NCT05912413|OTHER|there is no intervention|there is no intervention
41310515|NCT02481726|RADIATION|68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG|
41310516|NCT03047148|OTHER|Data mining from records|The relevant data for this investigation is extracted from the patient records database as well as from the assessment results of the ongoing quality control process that were collected by the nursing staff of the postoperative recovery units.
41469822|NCT05498493|BEHAVIORAL|Cognitive Rehabilitation|The virtual small group format will include two to five participants and one facilitator per group. The three individual sessions are distributed at the beginning, middle, and towards the end of the training program. Individual Session 1 occurs after Group Session 1. It covers orientation to the training program, including orientation to and clarification of the Participant Handbook. Individual Session 2 occurs after Group Session 5 and involves review and implementation of training strategies. Individual Session 3 occurs after Group Session 9 and covers review of learned strategies, implementation of training strategies in daily life, and review of execution, obstacles, and adjustments required for individual projects.
40793206|NCT03644810|PROCEDURE|Cold Pressor Test|The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
40793207|NCT03200483|OTHER|Control Protocol|In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.
40793208|NCT03200483|OTHER|Classical Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.
40793209|NCT03200483|OTHER|Rock Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
40793210|NCT02097628|PROCEDURE|tidal volume|In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
40793211|NCT02097628|PROCEDURE|peak airway pressure|In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
40793212|NCT03225391|BEHAVIORAL|nap from 0:00 to 3:00 hours|A nap from 0:00 to 3:00 hours during a night shift.
40999052|NCT05676957|DEVICE|Thermogard XP3|Patients received endovascular hypothermia for 12 hours following endovascular treatment and recanalization.
40999053|NCT02279186|DRUG|Tranexamic Acid|Intravenous Injection
40999054|NCT00806546|DRUG|NP101|NP101 study patch four hour application
40999055|NCT06432530|OTHER|C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.|Patients' hematological parameters were recorded, and hematological inflammatory indexes (NLR: neutrophil/lymphocyte; MLR: monocyte/lymphocyte; PLR: platelet/lymphocyte; NLPR: neutrophil/(lymphocyte\*platelet); SII (neutrophil\*platelet/lymphocyte): systemic inflammatory index; SIRI (neutrophil\*monocyte/lymphocyte): systemic inflammatory response index; AISI (neutrophil\*platelet\*monocyte/lymphocyte): aggregate index of systemic inflammation. ) were derived from baseline CBC tests.
40999056|NCT02549508|DEVICE|AutoCPAP with SensAwake On|The comfort feature 'SensAwake' will be turned on
40999057|NCT02549508|DEVICE|AutoCPAP with SensAwake Off|The comfort feature 'SensAwake' will be turned off
40999058|NCT04939727|OTHER|OUD-CDS + Suicide Risk Model associated CDS|Access to OUD-CDS + Suicide Risk CDS
40999059|NCT05808712|OTHER|validation|Translation and validation design
41310517|NCT06444243|DRUG|Psilocybin|Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi.
40999060|NCT00753116|DEVICE|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
41149899|NCT04785261|DRUG|Methylhydroxypropylcellulose|1-2 drips each time, every 4 hours, for 12 weeks.
40793213|NCT03225391|BEHAVIORAL|nap from 3:00 to 6:00 hours|A nap from 3:00 to 6:00 hours during a night shift.
40999061|NCT01136304|DRUG|Imiglucerase|Imiglucerase intravenous infusions regardless of dose or schedule of administration.
40999062|NCT03454074|BEHAVIORAL|Problem-solving|Individualized goal-setting and group problem-solving to help older adults effectively integrate realistic, healthy behavioral changes into their everyday lives
41149900|NCT04785261|DRUG|Carbomer|1 drip each time, at bedtime, for 12 weeks.
41149901|NCT04785261|DRUG|TCM Formula|6.0g Chi-Ju-Di-Huang-Wan plus 6.0g Jia-Wei-Xiao-Yao-San, 6.0g twice daily for 12 weeks.
41149902|NCT05472532|PROCEDURE|Patient sampling.|"One or several bio-specimens will be sampled depending on the cohort :~* Blood (40 ml)~* Pleural Fluid (40 ml)~* Peritoneal liquid (40 ml)~* Solid tumors"
41149903|NCT02938286|DEVICE|Fractional CO2 laser, 2.5 mJ, 5% density|Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density
41149904|NCT02938286|DEVICE|Fractional CO2 laser, 2.5 mJ, 15% density|Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density
41310518|NCT06444243|DRUG|Niacin|"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Niacin helps some enzymes work properly and helps skin, nerves, and the digestive tract stay healthy. Niacin is found in many plant and animal products.~Niacin will be used at a concentration of 250mg as an active control."
41310519|NCT01727713|DRUG|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
41310520|NCT03700008|DIAGNOSTIC_TEST|Speech analysis tool|Using the speech analysis tool with recording 120 seconds of free speech and analysis of 200 content-free parameters of the speech including factor analytic process to compress the data to 5-10 core parameters.
41310521|NCT03700008|DIAGNOSTIC_TEST|Conventional psychological measurements|Using well known and validated psychological measurements to identify the mental state of the participants.
41310522|NCT05279612|RADIATION|Short-term neoadjuvant chemoradiotherapy|Short-term radiotherapy ( 25 Gy, 5f ) + XELOX regimen was performed before operation for two cycles. After the condition was evaluated by enhanced CT, whether the patients belonged to PD, SD, PR and CR was analyzed (reference RECIST 1.1). Surgery was performed four weeks after chemotherapy.
41310523|NCT03660813|DIAGNOSTIC_TEST|Follicle measurment|Follicle will be measured before aspiration
41310524|NCT03660813|DRUG|Ovitrelle ( Hcg 250 mcg)|Drug used for triggering
41310525|NCT03660813|DRUG|Decapeptyl ( GnRH Agonist 0.1 mg*2 )|Drug used for triggering
41310526|NCT00375115|DRUG|Sambucol|
41310527|NCT00115804|DRUG|Fluoxetine|Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
41310528|NCT06516666|BEHAVIORAL|Music|"Participants went through four stages. In the rest stage, they were instructed to relax. In the neutral control stage, they watched an informative video about plastic injection molding. In the sadness induction stage, they viewed sad clips from either Hachi: A Dog's Tale or My Brother and Sister, with the order randomized across participants. In the music intervention stage, they listened to the cheerful Cuckoo Waltz. Each stage lasted for about 6 minutes.~The interventions for the two groups were exactly same.~PS: On the basis of the PHQ-9, this HAMD interview was conducted to further group the participants. So, following the experimental protocol, participants who scored ≥ 5 on the PHQ-9 measure underwent the HAMD interview, while the remaining individuals were simply interviewed about their feelings during the experiment."
40999063|NCT03454074|BEHAVIORAL|Education|Education about healthy brain aging behaviors provided.
40793214|NCT00302354|DRUG|OROS methylphenidate HCl|
40999064|NCT02032147|DRUG|NGF group|This group will be treated with NGF 18u per day im for 60 days
40999065|NCT01289769|DRUG|Dexmedetomidine|dexmedetomidine 0.7 microgram per kilogram in saline 20 ml given within 10 minutes before intubation
40999066|NCT01289769|DRUG|Placebo|normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
40999067|NCT02972632|DRUG|Vortioxetine|Vortioxetine tablet
40999068|NCT04425746|DRUG|Afamelanotide|
40999069|NCT04425746|DRUG|Placebo|
41149905|NCT02938286|DEVICE|Fractional Er:YAG laser, 9 mJ, 5% density|Pretreatment at 9 mJ and 5% density.
41149906|NCT02938286|DEVICE|Fractional Er:YAG laser, 9 mJ, 15% density|Pretreatment at 9 mJ and 15% density.
41149907|NCT02938286|DEVICE|Fractional CO2 laser, 50 mJ, 5% density|Pain stimulus at 50 mJ/microbeam and 5% density
41149908|NCT02938286|DRUG|AHES|Topical application at test region I-IV under occlusion for 15 minutes
41310529|NCT02156869|OTHER|Decision aid|Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
41310530|NCT02586753|OTHER|Paclitaxel plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
40999070|NCT05464004|OTHER|Nintendo Wii balance board|"Experimental group was given Nintendo Wii balance board therapy in combination with conventional physical therapy for 16 sessions/8 weeks~Control group was conventional physical therapy which include stretching of the hamstrings, quadriceps and calf muscles. strengthening of the lower limb. Balance exercises include walk in parallel bar"
40999071|NCT04959838|BEHAVIORAL|Impact of prolonged work|Evaluate the impact of prolonged work (up to 60 consecutive hours) on the surgical capacities evaluated on a simulator, as well as on stress markers (questionnaires, saliva assays, skin conductance, quality of sleep) compared to a standard day.
41469823|NCT05498493|BEHAVIORAL|Brain Health Education Program|The active control group will control for non-specific effects inherent to supervised CR. Participants will receive a manualized brain health education (BHE) training program, matched with the adapted CR intervention for therapist time and homework. Once these participants complete the 12 weeks of the control intervention and undergo the post-intervention assessments, participants will be offered the 12 weeks active intervention to ensure that all study participants have the potential of benefitting from CR.
41469824|NCT02555982|DRUG|BOTOX ® 200 Unités|"Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
41469825|NCT02555982|DRUG|Placebo|Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
41469826|NCT01477099|DEVICE|Toothbrushing with a manual brush|Toothbrushing with a manual brush
40999072|NCT02724904|PROCEDURE|Allogeneic stem cell transplantation|Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
40999073|NCT02724904|DRUG|Fludarabine|Standard Treatment
40999074|NCT02724904|DRUG|Thiotepa|Standard Treatment
40999075|NCT02724904|DRUG|Methotrexate|IV Bolus
40999076|NCT03385239|DRUG|ISIS 678354|ISIS 678354 solution for SC injection.
41149909|NCT05269004|DRUG|Ocrelizumab|Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
41149910|NCT04530721|OTHER|no intervention|we don't do any intervention
41149911|NCT02891018|DEVICE|paclitaxel controlled release balloon catheter Vasoguard TM|
41149912|NCT02891018|DEVICE|paclitaxel release coronary balloon catheter SeQuent Please|
41149913|NCT04882956|DRUG|intravitreal injection|Brolucizumab-Dbll intravitreal injection
41149914|NCT04882956|DRUG|intravitreal injection|Aflipercept intravitreal injection
41149915|NCT06565416|BEHAVIORAL|Implementation Strategies|Culturally centering screening and brief intervention for chronic pain and opioid misuse/opioid use disorder among American Indian/Alaska Native clients
41149916|NCT02223299|DIETARY_SUPPLEMENT|L-tyrosine|6g/d daily for 30 days
41149917|NCT02223299|DIETARY_SUPPLEMENT|L-Tryptophan|2g/d daily for 30 days
41149918|NCT02223299|DRUG|deplin|15mg daily for 30 days
41149919|NCT02223299|OTHER|Placebo A|a sugar-pill that looks like a real medication
41149920|NCT02223299|OTHER|Placebo B|a sugar-pill that looks like a real medication
41149921|NCT01672255|DRUG|Fluoxetine|20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
41149922|NCT01672255|DRUG|Placebo control|20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
41149923|NCT05033158|OTHER|Blood sampling|Blood sampling before and after COVID-19 vaccination
41149924|NCT03819647|DRUG|stiripentol (Diacomit)|Administration of stiripentol per os
41149925|NCT01242345|DEVICE|Capnography|Monitoring of the capnography curve for early detection of apnea
41469827|NCT00559026|BIOLOGICAL|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
41469828|NCT00559026|OTHER|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
41469829|NCT01629576|OTHER|economic incentive|economic incentive for weight loss
41469830|NCT01629576|OTHER|economic incentive|economic incentive for weight loss
41149926|NCT05890781|PROCEDURE|Skin biopsy|Skin biopsy
41149927|NCT05890781|PROCEDURE|Fresh tumor sample|Fresh tumor sample
41149928|NCT05890781|BIOLOGICAL|Blood sample|Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
41149929|NCT05890781|PROCEDURE|Healthy tissue from the tumor|Healthy tissue from the tumor site whenever possible
41149930|NCT05890781|PROCEDURE|Spinal cerebrospinal fluid (SCF)|Spinal cerebrospinal fluid (SCF) whenever possible
41149931|NCT01469442|PROCEDURE|External Biliary duct stent in the bile duct by cystic way|The size of the external biliary duct stent depending of cystic duct size
41149932|NCT05150704|DRUG|Methylprednisolone|Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care
41149933|NCT05150704|DRUG|saline solution|Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.
41149934|NCT05115721|OTHER|no intervention|It's only observational study. No interventions.
41149935|NCT05942833|PROCEDURE|Sigmoid resection|Timing of sigmoid resection
41149936|NCT00083148|DRUG|capecitabine|
41149937|NCT00083148|DRUG|irinotecan hydrochloride|
41469831|NCT03187587|DEVICE|imILT|The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.
41469832|NCT03187587|DRUG|Standard chemotherapy treatment|The standard chemotherapy treamtment arm recieves only chemotherapy.
41469833|NCT05735652|DEVICE|SpaceOAR Hydrogel|The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum
41469834|NCT04351347|DRUG|Ivermectin|ivermectin
41310531|NCT02586753|OTHER|S1 plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).~Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
41310532|NCT02352610|PROCEDURE|LRTI|
41310533|NCT02352610|DEVICE|Biotenodesis Screw|
41310534|NCT01947608|DRUG|LDK378|750 mg. orally
41310535|NCT05312710|DRUG|APG-157|Treatment
41310536|NCT03745196|DRUG|PC945|Study drug under investigation
41310537|NCT03745196|DRUG|Placebo|Placebo control
41310538|NCT04182607|PROCEDURE|kidney transplant|Clinical data will be collected from electronic medical records (EMRs) on donors and recipients who underwent a minimally invasive kidney transplantation procedure
41310539|NCT03329651|DRUG|Metformin treatment|"Daily treatment with metformin tablets for 24 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2"
41310540|NCT03329651|DRUG|Placebo treatment|"Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2"
41310541|NCT03163199|DEVICE|Translesional Hemodynamic Measurement|Measurement of hemodynamics using the NAVVUS catheter during endovascular therapy
41310542|NCT03379610|DIAGNOSTIC_TEST|Nasopharngeal brush|"1. Baseline nasopharngeal brush before treatment~2. Post-treatment reassessment of residual NPC"
41310543|NCT03744546|DRUG|ABBV-8E12|Solution for infusion
41310544|NCT02524652|DRUG|Ropivacaine 0.5% 20 mLs|Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
41310545|NCT01915004|OTHER|Educational Intervention|Bladder Training Video
41469835|NCT03822273|PROCEDURE|Traditional acupuncture (TA)|"Procedure: real acupuncture.~Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min."
41469836|NCT03822273|PROCEDURE|Laser acupuncture (LA)|"Procedure: laser acupuncture.~Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz\]; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2)."
41469837|NCT03822273|PROCEDURE|Sham laser acupuncture (SLA)|"Procedure: sham laser acupuncture.~Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group."
41469838|NCT06616220|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
40793215|NCT00302354|DRUG|SODAS methylphenidate HCl|
40999077|NCT03385239|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl).
41310546|NCT04131517|DRUG|Padsevonil|Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)
41149938|NCT04113226|DRUG|Rituximab|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.
41149939|NCT04113226|DRUG|Lenalidomide 20 MG|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with Rituximab plus Lenalidomide. Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression
41310547|NCT04131517|DRUG|Microgynon 30®|Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
41310548|NCT03622593|DRUG|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
41310549|NCT03622593|DRUG|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
41310550|NCT03622593|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
41310551|NCT01640925|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
41310552|NCT01640925|OTHER|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
41310553|NCT05380674|BEHAVIORAL|The short questionnaire of healthy habits|collects sociodemographic data, weight, height, and physical activity, self-reported.
41310554|NCT06157398|OTHER|Increased EPA, DHA, fruit, and vegetable intake|Participants will receive food deliveries for approximately 4-weeks via online ordering, meal delivery, and dietician counseling.
41310555|NCT02969850|DIETARY_SUPPLEMENT|Vitamin D Supplementation|Subjects in this group will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level.
41469839|NCT06616220|DRUG|0.9%NaCl|0.9% NaCl
41469840|NCT02121041|DRUG|Amlodipine|Amlodipine 5 mg or 10 mg
41469841|NCT02121041|DRUG|Chlorthalidone|Chlorthalidone 12.5 mg or 25 mg
41310556|NCT02969850|OTHER|Placebo|Subjects in this group will receive a placebo.
41310557|NCT02969850|DIETARY_SUPPLEMENT|Calcium|If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
41310558|NCT02456545|OTHER|≥ 1 potential risk factor for BD|exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)
41310559|NCT02456545|OTHER|depressive syndrome|in- and outpatients with depressive syndrome
41310560|NCT02456545|OTHER|ADHD|in- and outpatients with ADHD
41310561|NCT06207422|OTHER|Moderate intensity training program|A 10-week intervention program performed at 60-70% of the heart rate reserve. Heart rate reserve will be calculated using the Karvonen formula (target heart rate = \[(predicted maximum heart rate (= 220 - age) - resting heart rate) x %intensity\] + resting heart rate). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
41310562|NCT06207422|OTHER|High intensity training program|A 10-week intervention program performed at ≥80% of the predicted maximum heart rate (target heart rate = predicted maximum heart rate (= 220 - age) x %intensity). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
41310563|NCT04898426|OTHER|Enhanced bowel preparation instruction|Automated delivery of SMS, pre-recorded phone call, and link to an information website.
41310564|NCT00668655|DRUG|Metronidazole Gel|Topical, Once daily for 2 weeks
41310565|NCT02947516|PROCEDURE|Endoscopic ultrasound-guided liver biopsy|Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
41469842|NCT02121041|DRUG|Losartan|Losartan 50 mg or 100 mg
40793216|NCT02522169|DRUG|Infliximab|"This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year."
40793217|NCT00126152|BEHAVIORAL|Exercise, education and medical management|
40793218|NCT02750046|PROCEDURE|total hip arthroplasty or proximal femoral nails|Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.
40793219|NCT02372695|DRUG|Paricalcitol|
41310566|NCT02947516|PROCEDURE|Percutaneous liver biopsy|Participants will undergo percutaneous liver biopsy per standard protocol.
41310567|NCT02964286|DEVICE|The Electric vibrating massager,SAMPO®|The technique used is The electric vibrating massager ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follow the points are used to stimulate the hematopoietic function. According to their anatomical location: upper extremity are Hegu (LI4), Quchi (LI11); lower extremity are Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3); and the top of head is Baihui (GV20). The used of all the points, except for Baihui (GV20), is bilateral.
40793220|NCT05672368|DEVICE|Robot-Assisted Surgery|Undergo surgery using the da Vinci SP device
41310568|NCT02040818|DRUG|tigecycline, N-acetylcysteine, heparin combination|
41469843|NCT04869839|OTHER|oral examination|examination done by dentist
41469844|NCT06502587|OTHER|blood flow restriction training|"we will apply blood flow restriction training with low intensity exercises like knee flexion ,knee extension and straight leg raise 10 repetitions 2 sets a day and 3 times/week a rest interval of 2 minutes between exercises, for 30 minutes of this whole procedure.~total 12 sessions given in 4 weeks each session of maximum 30 minutes"
41469845|NCT06502587|OTHER|ultrasound therapy|All subjects will be given Ultrasound therapy as per patient requirement with 1.5 Watts/cm\^2 in continuous mode around knee joint. Conservative exercises(quads isometric exercise, pillow squeeze, heel raise, straight leg raise and side leg raise) will be applied for 3 times per week (daily one set of 10 repetitions) They will be given this treatment for 3 times per week
41469846|NCT03858023|OTHER|Hippotherapy|The hippotherapy program consists of 2 sessions per week for 15 weeks. One session is 30-minute session. The program involves 2 therapists and 3 personnel for safety issues.
40793221|NCT01553292|DEVICE|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
40793222|NCT01553292|DEVICE|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
41310569|NCT02040818|DEVICE|guide-wire exchange|
41310570|NCT03573128|BEHAVIORAL|Students with Autism Accessing General Education|With study team coach support, teacher implemented modules addressing student behavioral/academic goals.
41310571|NCT03573128|OTHER|Enhanced Services As Usual|Teaching staff access in-service presentations and print materials with no active study team coaching.
41310572|NCT00724724|DRUG|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
41310573|NCT00724724|DRUG|Aspirin|Aspirin 100mg Qd for 1 year
41469847|NCT03509662|DRUG|Vitamin C|Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).
41310574|NCT02719470|BEHAVIORAL|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
41310575|NCT02471664|DEVICE|Mitral Loop Cerclage Annuloplasty|
41469848|NCT03509662|DRUG|Thiamine|All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.
41469849|NCT03509662|DRUG|Placebos|One group receives a placebo.
41469850|NCT00660088|OTHER|Ketasyn|10g for 7 days, 20g for 7 or 14 days
41469851|NCT05505305|BEHAVIORAL|Time-restricted eating and high-intensity interval training|Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
41469852|NCT02096588|DRUG|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
41469853|NCT02096588|DRUG|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
40793223|NCT04690218|DIAGNOSTIC_TEST|Hospital anxiety and depression scale|Self assessment scale suitable for hospital community as well as public community. Applying the scale does not require any psychopathologic training.
40793224|NCT04690218|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index|Self assessment scale for public community. Applying the scale does not require any specially trained personnel.
40793225|NCT04690218|BEHAVIORAL|Nutritional Status Questionnaire|It consists of 26 items, questioning the frequency and amount of certain nutritional elements (ones known to worsen and benefit mastalgia) consumed by the individual.
40793226|NCT04771689|DRUG|Buprenorphine/Naloxone|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for the length of their hospital stay, at least 6 days.
40793227|NCT02449811|DRUG|Perindopril|
40793228|NCT02449811|DRUG|Olmesartan|
40793229|NCT02449811|DRUG|Amlodipine|
41310576|NCT05939596|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
41310577|NCT05939596|OTHER|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
41310578|NCT02909842|DIETARY_SUPPLEMENT|Drinking fermented milk|Drinking fermented milk containing Lactobacillus paracasei (IMULUS)
41310579|NCT02909842|DIETARY_SUPPLEMENT|placebo|Acidified placebo milk with similar physical characteristics to the yoghurt drink
41469854|NCT05934838|DRUG|Tazemetostat Pill|Participants will take 800 mg of tazemetostat twice a day starting 7 days before apheresis and continue to take tazemetostat until lymphodepletion, which is chemotherapy given prior to receiving the CAR T cells. Participants will stop taking tazemetostat after lymphodepletion until after CAR T cell infusion. Once lymphocyte counts increase, tazemetostat will be resumed and tazemetostat will be taken for 6 - 12 months, depending on participant response.
41469855|NCT05183087|DIAGNOSTIC_TEST|3T Connectome MRI|MRI scan of structural connectivity
41469856|NCT05183087|DIAGNOSTIC_TEST|7 Tesla MRI|MRI scan of functional connectivity
41469857|NCT05183087|DIAGNOSTIC_TEST|TSPO PET|PET scan of neuroinflammation
41469858|NCT05183087|DIAGNOSTIC_TEST|Tau PET|PET scan of tau deposition
40793230|NCT02449811|DRUG|Hydrochlorothiazide|
40793231|NCT02941328|DRUG|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
40793232|NCT02941328|DRUG|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
40793233|NCT04498286|DIAGNOSTIC_TEST|Testing of SARS-CoV-2 antibodies|Sars-CoV-2 RBD total antibody test developed by Sanquin
40793234|NCT02027727|OTHER|No Intervention|no intervention- tihs is an observational study
40793235|NCT06095869|OTHER|progressive relaxation exercise|Breastfeeding mothers in the progressive relaxation exercise group were applied gradual relaxation exercise before going to bed 3 days a week and for 4 weeks, under the supervision of the researcher, accompanied by a training CD prepared by the Turkish Psychologists Association.
40793236|NCT06095869|OTHER|relaxation background music|In the relaxation background music group, breastfeeding mothers were listened to relaxation background music on the Progressive Relaxation Exercise CD before going to bed 3 days a week and for 4 weeks.
40793237|NCT06095869|OTHER|control group|Mothers in this group received routine care practices in the clinic. No intervention was made to the mothers in the control group, only data collection tools were applied.
40793238|NCT01668160|PROCEDURE|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
40793239|NCT04149665|DEVICE|simple blind observation|Device that measures continuously the angle of bed by mechanical Ventilation to assess the time the bed is above 35°.
40793240|NCT00851331|GENETIC|genome analyzes (genetic defects and pathophysiological mechanisms )|
40793241|NCT04209374|DEVICE|THA with SYMBOL CUP DM HA|
40793242|NCT06349824|DRUG|injection Dextrose water|dextrose will be injected around median nerve in wrist
40793243|NCT06349824|DEVICE|USG machine|usg guided nerve hydrdissection
40793244|NCT02075086|DRUG|Xelox or Xeliri Bevacizumab|Chemotherapy treatment
41310580|NCT02909842|BIOLOGICAL|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)|Intramuscular injection of a single shot of influenza vaccine
41310581|NCT03871517|DRUG|Indobufen|Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.
41310582|NCT03871517|DRUG|Aspirin|Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.
41310583|NCT03456713|BIOLOGICAL|LY3074828|Administered SC
41310584|NCT01419483|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
41149940|NCT04113226|OTHER|Comprehensive Geriatric Assessment (CGA)|A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,...) on which treatment may impact.
41310585|NCT04969133|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|To compare TAP block versus local infiltration of the trocar wounds with levobupivacaine 2.5 mg/ml for post operative pain relief after laparoscopic appendicectomy in children
41310586|NCT00895518|BEHAVIORAL|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
41310587|NCT02176291|DRUG|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
41310588|NCT02176291|DRUG|Placebo|matched placebo
41310589|NCT04124536|BEHAVIORAL|HIV self-testing with partner notification.|HIV self-test kits are oral swabs. Partner notification will be offered to all women in the intervention arm, regardless of HIV status.
41310590|NCT01463865|DRUG|ropivacaine|Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
41310591|NCT01463865|DRUG|Sodium chloride|Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
41310592|NCT03326154|OTHER|No intervention, observational|Observation
41310593|NCT06553534|OTHER|SAMURAI PICU Bundle|"The proposed multifaceted SAMURAI PICU Bundle is an intervention with the following core elements: 1) PICU Warning Tool: an automated clinical decision support (CDS) tool to provide a non-interruptive interprofessional predictive alert, 2) twice daily safety huddles with unit leadership, and 3) bedside assessment including the care team and patient's family to complete and display a bedside mitigation plan to prevent deterioration. This intervention combines the automated accurate prediction of the PICU Warning Tool with the use of provider intuition or a gut feeling from huddles to improve decision making at the bedside. Peripheral elements and possible adaptations will be suggested during Aim 1 and additional peripheral elements may be added by local sites after discussion with the PI through a user-centered design approach."
41310594|NCT00062634|BEHAVIORAL|Female condom skills training|
41310595|NCT00541138|DRUG|carboplatin|CBDCA AUC=3
41310596|NCT00541138|DRUG|tamoxifen citrate|Tamoxifen 100mg bid
41310597|NCT00541138|DRUG|topotecan hydrochloride|Topotecan 0.75 g/m2/d
41310598|NCT00541138|OTHER|pharmacological study|Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.
41310599|NCT04381429|DRUG|A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
41310600|NCT04381429|DRUG|F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
41310601|NCT04116814|DIAGNOSTIC_TEST|wall-to-lumen ratio measurement|wall-to-lumen ratio measurement in patients with renal insufficiency
41310602|NCT01848899|DRUG|Iodixanol|contrast media used during coronary angiography
41310603|NCT01848899|DRUG|Ioxaglate|contrast media used during coronary angiography
41310604|NCT01848899|DRUG|Bivalirudin|A direct thrombin inhibitor
41310605|NCT00913718|DRUG|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)|
41310606|NCT00913718|DRUG|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)|
41310607|NCT04500041|PROCEDURE|Casting|Use of casts applied using corrective maneuvers
41310608|NCT04500041|DEVICE|Bracing|Use of full-time spinal orthosis
41310609|NCT05931016|DIAGNOSTIC_TEST|6-MWT|Measurement of saturation and blood gas parameters under 6-MWT with different masks.
41310610|NCT05931016|DIAGNOSTIC_TEST|Spiroergometry|Measurement of saturation and blood gas parameters under spiroergometry with different masks.
41310611|NCT01928043|DRUG|Curcumin|
41310612|NCT00783211|DRUG|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
41310613|NCT00783211|DRUG|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
41310614|NCT00783211|DRUG|placebo|placebo, once daily for 15 days
41310615|NCT02771249|DRUG|rifapentene (RPT)|RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.
41310616|NCT02771249|DRUG|darunavir/cobicistat (DRV/c)|DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).
41310617|NCT02771249|DRUG|Isoniazid (INH)|INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)
41310618|NCT02771249|DIETARY_SUPPLEMENT|Pyridoxine|
41310619|NCT04395534|PROCEDURE|Complete mesocolic excision|
41310620|NCT02683525|DRUG|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
41310621|NCT00848549|DRUG|Zonisamide|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
41469859|NCT05183087|DIAGNOSTIC_TEST|Cognitive and Behavioral Assessments|Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains
41469860|NCT05183087|DIAGNOSTIC_TEST|Blood Biomarkers|Blood-based assessments of proteomic and metabolic biomarkers of brain injury
41310622|NCT00848549|DRUG|Carbamazepine|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
41469861|NCT00139906|DRUG|Bifeprunox|
40793245|NCT02975804|DEVICE|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
40793246|NCT03396627|DIAGNOSTIC_TEST|pathological examination|fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
40793247|NCT01976871|DRUG|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
40793248|NCT06440603|DIAGNOSTIC_TEST|PCR|"Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of EKLF:~* The method of total RNA extraction: TRIZOL and TRIZOL LS.~* The purity and concentration of the RNA will be measured using Nano Drop 2000 instument.~* cDNA will be done with primers using thr Goscript Reverse Transcription System"
40793249|NCT04352543|BEHAVIORAL|Active Video Game Exercise|Play during 30 minutes in the easy level
40793250|NCT04352543|BEHAVIORAL|Treadmill walking exercise|30 minutes (65 - 75% heart rate maximal)
40793251|NCT04352543|BEHAVIORAL|Sedentary Behavior|Quiet Rest: 30 minutes
40999078|NCT04590495|DRUG|300 mg Cannabidiol (CBD) oil|Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
40999079|NCT04590495|DRUG|Placebo|Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
40999080|NCT03867136|DRUG|PZA sensitivity guided ultra-short all Oral Regimen|Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, \>50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, \>50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;
40999081|NCT03867136|DRUG|Standardized Shorter Regimen|Pyrazinamide 1500 mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, \>50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, \>50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. All treatment is taken daily.
40999082|NCT00819988|DRUG|Pregabalin|Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
40999083|NCT00819988|OTHER|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
41149941|NCT04113226|OTHER|Activities of daily living (ADL) scale|Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
40999084|NCT02535741|DEVICE|Triathlon CR Total Knee System|Primary total knee replacement
40999085|NCT00531232|DRUG|Clofarabine|"Pharmaceutical form: Tablet,~Route of administration: Oral"
41149942|NCT05888272|BEHAVIORAL|Stress managment|The Doing What Matters in Times of Stress self-help manual materials and lay helper scripts utilized in the study are rooted in the principles of Acceptance and Commitment Therapy (ACT). They are designed to improve psychological flexibility which refers to an individual's ability to adapt to changing situations, reallocate mental resources, shift perspectives, and balance competing priorities. The ACT approach teaches individuals how to manage challenging thoughts and emotions through mindfulness techniques, while also guiding them to live in alignment with their personal values.
41149943|NCT02232009|DEVICE|3.0 T Neonatal MRI Scanner|Eligible subjects will undergo neonatal MRI scanning procedures.
41469862|NCT02147587|DRUG|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
41469863|NCT02147587|DRUG|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
40793252|NCT05480735|BEHAVIORAL|Prehabilitation|Multimodal prehabilitation program
40793253|NCT05265923|DRUG|CM310|IL-4Rα monoclonal antibody
40793254|NCT05265923|OTHER|Placebo|Placebo
41469864|NCT05741931|DEVICE|mobile application REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting)|The mobile application will be installed on the mobile phone. The application is used to monitor pregnant women. Users of the application are midwives and pregnant women. The application contains documentation of the health condition of pregnant women.
41310623|NCT03463941|BEHAVIORAL|Peer Support Dyad Intervention|"Phase I: At baseline and at post-intervention, participant height, weight, BMI, fruit and vegetable intake and exercise habits will be measured. Participants will complete surveys and meet each week to learn about nutrition and exercise.~Phase II: Dyads will attend a communication training session to discuss 1) benefits of working with a partner; 2) supportive communication tips; and 3) expected activities for the next 8 weeks, including filling out daily logs. After the training session, the dyads will work together to achieve their health goals. The dyads will return to the church for two check in sessions. At these sessions, participants will turn in their logs, and be weighed. At the end of the intervention, BMI will be reassessed, and surveys and interviews will be completed."
41310624|NCT01259856|DRUG|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
41310625|NCT01259856|DRUG|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
41310626|NCT01259856|DRUG|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
41310627|NCT02300415|BIOLOGICAL|blood sample|Dosage of presepsine
41310628|NCT02474667|DRUG|ANG-3777|
41310629|NCT02474667|OTHER|Placebo|
41310630|NCT04442958|OTHER|Convalescent Immune Plasma|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
40793255|NCT06436313|OTHER|Educational Sessions|"Two online educational sessions will be organized before DBS surgery. These will be scheduled between consultation with the neurologist and the consultation with the neurosurgeon. Each virtual session will last about 1 hour. Patients can login from home, together with their caregivers. The virtual sessions will be held on MS Teams virtual platform.~One of the sessions will include a DBS patient where patients will have the opportunity to ask peer-to-peer questions. The session includes testimonials from patient before and after their surgery.~The second session (about two weeks later) is a summary presentation, a quiz and time for Q\&A. During one of the sessions (first or second), a DBS patient (who has been implanted) can be invited to participate togive the attendees the opportunity to ask peer-to-peer questions. The quiz contains questions to assess the patients' knowledge of DBS."
40793256|NCT03595150|DRUG|Diclofenac|Diclofenac rectally given before the ERCP to prevent pancreatitis
40793257|NCT01458301|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
40793258|NCT01458301|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
40793259|NCT01458301|DRUG|TAK-385|TAK-385 20 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
40999086|NCT04458428|OTHER|SMS|"Patients who are randomized to the intervention arm will be signed up for the automated SMS program. This cohort will receive text messages after surgery, timed from the day of discharge through 14 days post-op. Patients in this cohort will receive text messages each day. The number of text messages varies on patient interest and yes responses to see additional information."
40999087|NCT05550051|PROCEDURE|Awake nasal fiberoptic intubation|Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation
41310631|NCT02096861|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
41310632|NCT02096861|BIOLOGICAL|Remicade|Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
41310633|NCT06081036|OTHER|Questionnaire|Questionnaire about children development
41310634|NCT05844124|OTHER|Exercise for Knee Osteoarthritis -(Land Based Treadmill or Community Walking)|Standard-of-care Land-based walking exercise
40793260|NCT01458301|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
40793261|NCT01458301|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate injection, subcutaneously, once every 4 weeks for up to 12 weeks
41310635|NCT05844124|OTHER|Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking)|Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise
41310636|NCT05844124|OTHER|Exercise for Knee Osteoarthritis - (Aquatic Walking)|Aquatic Walking exercise
41310637|NCT01591226|DIETARY_SUPPLEMENT|Caffeine|gelatine capsule 6mg/kg bodyweight 60min prior test
41469865|NCT01834209|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily for 28-day cycles
41310638|NCT01591226|DIETARY_SUPPLEMENT|Sodium Citrate|0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
41310639|NCT01591226|DIETARY_SUPPLEMENT|Mannitol|gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
41469866|NCT01834209|DRUG|Prednisone or prednisolone|5 mg tablet taken orally once daily
40793262|NCT02445729|OTHER|Dressing removal at 24 hours|Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
40793263|NCT02445729|OTHER|Dressing removal at 48 hours|Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
40999088|NCT02933242|RADIATION|Stereotactic Ablative Body Radiotherapy|The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks
40999089|NCT02462967|DRUG|GR-MD-02|GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
40999090|NCT02462967|DRUG|Placebo|Placebo for GR-MD-02
41310640|NCT01591226|DIETARY_SUPPLEMENT|Sodium Chloride|sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
41310641|NCT04664855|OTHER|Trauma-Informed Yoga|8 weeks of twice weekly trauma-informed yoga for 45 minutes per session
41310642|NCT02991157|DRUG|Nimodipine|
41310643|NCT02819115|BIOLOGICAL|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Butantan Fragmented Inactivated Trivalent Influenza Vaccine
41310644|NCT04221906|DRUG|BOS-475|topical cream
41310645|NCT04221906|DRUG|Active ingredient-free vehicle cream|topical cream
41310646|NCT04221906|DRUG|Daivonex cream (calcipotriol 0.005%)|topical cream
41310647|NCT04221906|DRUG|Betnesol-V cream (betamethasone 0.1%)|topical cream
41310648|NCT01753076|DRUG|Ozanezumab|Ozanezumab injection solution
40793264|NCT03439644|OTHER|Measurement of the upper eyelid laxity|Measurement using a soft slider of the distance between our 2 marks The difference obtained between the measurement and the initial 10 millimeters corresponds to the tarsal laxity.
40793265|NCT03386435|PROCEDURE|remote ischemic preconditioning|Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
40793266|NCT00343005|BIOLOGICAL|AMA1-C1|
40793267|NCT00343005|DRUG|AMA1-C1/alhydrogel Malaria Vaccine|
40793268|NCT06513741|BEHAVIORAL|Mentoring Workshop|"Faculty mentoring workshop with the title Faculty Mentoring; building stronger by digging deeper was designed as a two-day workshop of three hours each for the faculty members of the two institutions at separate times"
40793269|NCT00002548|BIOLOGICAL|recombinant interferon alfa|"3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)"
40793270|NCT00002548|DRUG|carmustine|20 mg/m2 I.V. day 1 q 35 days
40793271|NCT00002548|DRUG|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
40793272|NCT00002548|DRUG|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
40793273|NCT00002548|DRUG|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
40793274|NCT00002548|DRUG|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
40793275|NCT00002548|DRUG|prednisone|40 mg/m2 PO days 1-7 q 35 days
40793276|NCT00002548|DRUG|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
40793277|NCT00002548|PROCEDURE|allogeneic bone marrow transplantation|day 0
41310649|NCT01753076|DRUG|Placebo|Normal saline (0.9% sodium chloride) infusion
41310650|NCT01432262|BIOLOGICAL|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
40793278|NCT00002548|PROCEDURE|autologous bone marrow transplantation|day 0
40793279|NCT00002548|PROCEDURE|peripheral blood stem cell transplantation|day 0
40793280|NCT00002548|RADIATION|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
40793281|NCT05754476|OTHER|Low-dose GBCA levels|MRI examinations for patients at two dose levels: low-dose (10% or 25%）can be chosen.
41310651|NCT01432262|BIOLOGICAL|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
41310652|NCT05219422|BEHAVIORAL|Project ALERT|14 session drug prevention program for 7th and 8th grade youth.
41310653|NCT05219422|BEHAVIORAL|Getting to Outcomes|The Getting To Outcomes (GTO) implementation support intervention provides technical assistance, training, guides, and tools to improve community-based practitioners capacity to complete tasks associated with implementing an EBP, which in turn leads to improved implementation fidelity.
40793282|NCT04636567|DRUG|Nerindocianine for injection|Procedure: routine minimally invasive abdominopelvic surgery.
40793283|NCT00725686|DRUG|PF-04523655|This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
40793284|NCT03417310|DEVICE|"H joystick"|A joystick that corrects lateral displacement and angulation for multi-direction reduction
40793285|NCT03417310|PROCEDURE|Common reduction methods|Manual reduction methods without the assistance of any devices
40793286|NCT03235193|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
40793287|NCT03235193|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
40793288|NCT05365789|DEVICE|Blocked Nose Baby nasal spray|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for a maximum of 10 days.
40793289|NCT05365789|OTHER|Standard of care|Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.
40793290|NCT01146613|DRUG|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
40793291|NCT01146613|DRUG|Placebo|identical matched placebo x 2, 2xday, 13 weeks
40793292|NCT00329823|DRUG|Etanercept sc 50mg per week for 12 weeks|
40793293|NCT04804696|DRUG|Toripalimab|Patients received toripalimab 240 mg I.V. drip on days 1 and 22.
40793294|NCT04804696|DRUG|Paclitaxel|Patients received paclitaxel of 175mg/m2 I.V. drip on days 1 and 22.
40793295|NCT04804696|DRUG|Cisplatin|Patients received cisplatin of 70mg/m2 I.V. drip on days 1 and 22.
40999091|NCT02574871|OTHER|Psychological and biological data collection|Psychological and biological data collection for identification of the chronic stress presence
41310654|NCT05637723|OTHER|schroth exercise|The schroth exercise program will be given 3 days a week for 6 weeks.
41310655|NCT05637723|OTHER|traditional scoliosis exercises|The traditional scoliosis exercises program will be given 3 days a week for 6 weeks.
41310656|NCT01397305|DRUG|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
41310657|NCT01397305|DRUG|Pemetrexed|500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.
41310658|NCT05052775|OTHER|Chlorhexidine Mouthwash|Patients were given chlorhexidine mouthwash 2 times per day for 15 days
41310659|NCT05052775|OTHER|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
41310660|NCT05052775|OTHER|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
41310661|NCT02855411|DRUG|PF-04958242|Administered as specified in the treatment arm
40999092|NCT00198016|DEVICE|Coil|
41469867|NCT04035382|PROCEDURE|Labor induction|The study intervention is labor induction from 39 0/7 to 39 6/7 weeks. The individual labor induction process will be at the discretion of the physician or midwife managing the subject's care. Methods of induction that may be used include misoprostol, intracervical Foley catheter, oxytocin, and/or amniotomy. Participating clinicians will be encouraged to use only one course of cervical ripening followed by oxytocin infusion and amniotomy.
40793296|NCT06351982|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"1. Disclosure of biofilm with erythrosine,~2. Removal of supragingival and subgingival (up to 4 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS- Dental, Nyon Switzerland).~3. Supra- and sub- gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
40793297|NCT06351982|OTHER|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥4 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
40793298|NCT04155528|OTHER|Music therapy|The intervention is listening to selected prerecorded music, specific Raga, on the individual CD player.
40793299|NCT01212471|DRUG|Bromfenac Ophthalmic Solution A|sterile ophthalmic solution
40793300|NCT01212471|DRUG|Bromfenac Ophthalmic Solution B|sterile ophthalmic solution
40793301|NCT01212471|DRUG|Placebo Comparator|sterile ophthalmic solution
40793302|NCT04731896|PROCEDURE|Amniotomy|artificial rupture of the amniotic sac
40793303|NCT04091191|DIETARY_SUPPLEMENT|Meta19.01|A specialized nutraceutical containing plant extracts, vitamins and fish oil
40793304|NCT06385457|BEHAVIORAL|Mindhelper- A national youth mental health promotion website|Mindhelper is an open-access, digital self-directed mental health service that provides information, self-help tools and guidance to young people in Denmark.
40793305|NCT05264415|BEHAVIORAL|Families OverComing Under Stress (FOCUS) for Early Childhood (FOCUS-EC)|Trauma-informed, family-centered, skill-building preventive intervention for families with preschool-aged children.
40793306|NCT05264415|OTHER|Parenting Education Website|A website providing parenting education resources in four primary domains relevant for families with preschool-aged children (parenting, child development, transitions, and self-care).
40793307|NCT00608049|BEHAVIORAL|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
40793308|NCT00608049|BEHAVIORAL|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
40793309|NCT00608049|BEHAVIORAL|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
40999093|NCT01299922|DRUG|cyclosporine +mycophenolic acid+prednison|Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
40999094|NCT01299922|DRUG|Mycophenolic Acid + prednison|Mycophenolic Acid + prednison for 106 weeks
40999095|NCT01485523|OTHER|Nasal provocation test|"TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites."
40999096|NCT04384757|PROCEDURE|Distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
41310662|NCT02855411|DRUG|placebo|placebo, twice daily (BID) for 12 weeks, capsule
41310663|NCT06121336|DIAGNOSTIC_TEST|Plasma levels of BD-tau|Plasma levels of BD-tau will be assessed using a single-molecule array assay.
41310664|NCT05973669|DEVICE|MED-EL Remote Care|Remote cochlear implant support
41310665|NCT04884815|GENETIC|UX701|Nonreplicating, recombinant gene transfer vector
41310666|NCT04884815|OTHER|Placebo|Normal saline
41310667|NCT00186056|DRUG|Mifepristone|Glucocorticoid antagonist
41310668|NCT00186056|DRUG|Placebo Oral Tablet|Inactive placebo tab
41310669|NCT04402268|DEVICE|Cardioverter-defibrillator|We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.
41310670|NCT05277649|OTHER|Exercise programme|Performing a programme of warm-up and stretching exercises for the cervico-mandibular region aimed at improving mobility and muscle condition.
41310671|NCT03670914|DIAGNOSTIC_TEST|WatchPAT 200|The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
41310672|NCT04838925|DEVICE|Mobile Neurofeedback App|Neurofeedback intervention delivered via mobile app. Participants wear an EEG headset which is connected to a mobile app that delivers feedback about brainwave data indicating whether they are in a calm, relaxed state. Participants hear a lower/simple sound when they are below a target level and higher/richer sound when they approach or achieve their target.
41310673|NCT02986893|BEHAVIORAL|Dietary Intervention|Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.
41310674|NCT02986893|BEHAVIORAL|Non-dietary Intervention Arm|Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
41310675|NCT02731391|PROCEDURE|Pelvic floor reconstruction（with or without mesh）|
41469868|NCT02255188|PROCEDURE|blood sampling procedure|30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
41469869|NCT05118360|DRUG|ASC41 2 mg|2mg of ASC41 orally once daily for 52 weeks
41469870|NCT05118360|DRUG|ASC41 4 mg|4mg of ASC41 orally once daily for 52 weeks
41469871|NCT05118360|DRUG|Placebo|Matching placebo orally once daily for 52 weeks.
41469872|NCT06614504|OTHER|Varying the nicotine content of cigarettes|Altering the nicotine content of the tobacco research cigarettes
41469873|NCT06614504|OTHER|Varying the nicotine content of e-cigarettes|Altering the nicotine content of the research e-cigarettes
40793310|NCT00608049|BEHAVIORAL|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
40793311|NCT05771805|OTHER|Vagus nerve stimulation with task oriented training|VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.
40793312|NCT05771805|OTHER|Task oriented training|Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
40999097|NCT05938361|OTHER|Psoriasis clinical assessments|Global evaluation of psoriasis and specific evaluation by areas
40999098|NCT05938361|OTHER|Quality of life evaluation|DLQI questionnaire at each visit
40999099|NCT05938361|OTHER|Satisfaction assessment|Visual analogic scale at W16, W28, W52
40999100|NCT05938361|OTHER|Pruritus evaluation|Visual analogic scale at each visit
40999101|NCT00605774|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
40999102|NCT00605774|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
40999103|NCT05452395|OTHER|Post-acute care|"A personalized care program, focusing on managing geriatric syndromes and improving functional performances.~Strength training, activities of daily living (ADL) and instrumental activities of daily living (IADL) practice, basic mobility training, reconditioning exercise, and home environment assessment and modification."
40999104|NCT01527292|RADIATION|Stereotactic Radiation Therapy|SRT only
40999105|NCT01527292|RADIATION|SRT with Vertebral Augmentation Procedure|SRT with VAP
41310676|NCT02307669|BEHAVIORAL|INCA feedback|The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
41469874|NCT06596499|DEVICE|CH-VAD|The CH-VAD pump is a fully magnetically levitated (maglev), centrifugal continuous-flow blood pump.
41469875|NCT05480306|DRUG|DKN-01|30 minute IV infusion (400mg) every two weeks with an additional loading dose in the first cycle of treatment
41469876|NCT05480306|DRUG|FOLFIRI|90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
41469877|NCT05480306|DRUG|Bevacizumab|90-min IV infusion (5mg)
41469878|NCT05480306|DRUG|FOLFOX|2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
41469879|NCT03321526|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 capsule orally.
41469880|NCT03321526|DRUG|Placebo Matching to JNJ-42847922|Participants will receive placebo capsule matching to JNJ-42847922 orally.
41469881|NCT03321526|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
41469882|NCT03321526|DRUG|Placebo Matching to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
40793313|NCT05833412|DIAGNOSTIC_TEST|Septicyte Rapid ®|SeptiCyte RAPID is based on the measurement of two gene expression biomarkers in peripheral blood (PLAC8 and PLA2G7) using quantitative reverse transcription-polymerase chain reaction (RT-qPCR). Based on the results obtained in 1 hour from whole blood (100 mcl), the device issues a report with a sepsis probability scale according to 4 bands (1 low probability, 2-3 intermediate probability and 4 high probability).
40999106|NCT06209736|DRUG|OMS906 study drug|OMS906 study drug dose 5mg/kg IV administration at 4-week internals
40999107|NCT03254134|DRUG|Warfarin|patients treated with warfarin
40999108|NCT03254134|DRUG|Dabigatran|patients treated with Dabigatran
40999109|NCT01654965|OTHER|Laboratory Biomarker Analysis|Correlative studies
40999110|NCT01654965|BIOLOGICAL|Pegfilgrastim|Given SC
40999111|NCT01654965|OTHER|Pharmacological Study|Correlative studies
40999112|NCT01654965|DRUG|Tivantinib|Given PO
40999113|NCT01654965|DRUG|Topotecan Hydrochloride|Given IV
40999114|NCT00606892|DRUG|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
40999115|NCT00606892|DRUG|Placebo|Sugar Pill
40999116|NCT00606892|DRUG|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
40793314|NCT05833412|DIAGNOSTIC_TEST|FilmArray® blood culture identification (BCID2®)|After 6 to 8 hours of blood culture incubation, BCID2 will be performed on each of the 4 bottles. The BCID2 assay is an approved molecular test for the direct identification of pathogens causing bloodstream infections from blood cultures. The BCID2 Panel analyzes 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeasts and 10 antimicrobial resistance genes, all with a single test and with results available in approximately one hour from the blood culture. In addition, the BCID2® Panel menu includes seven additional resistance genes, including carbapenemases, colistin resistance genes and a MREJ assay that enables more speciﬁc MRSA identiﬁcation.
40793315|NCT04304053|DRUG|Treatment and prophylaxis|"Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7."
40793316|NCT04304053|OTHER|Standard Public Health measures|Isolation of patient and contact tracing as per national guidelines.
40793317|NCT00457678|DRUG|Visudyne|
40793318|NCT00457678|DRUG|Lucentis|
40793319|NCT00457678|DRUG|Dexamethasone|
40999117|NCT04129788|DRUG|Bisacodyl 5 milligram|three doses taken, one per day on three consecutive days
40999118|NCT04129788|DRUG|Placebo oral tablet|three doses taken, one per day on three consecutive days
40999119|NCT03254238|OTHER|Monitoring prEscriptiondruG Abuse using DOctor Shopping bEhavior|development and identification of systems and tools able to detect earlier misuse phenomenon
40999120|NCT02143908|DIETARY_SUPPLEMENT|lysine supplementation|
40999121|NCT02143908|DIETARY_SUPPLEMENT|Placebo|
40999122|NCT03884621|OTHER|EHP Group|The Enhanced post-discharge home-based care program (EHP) plus usual care
40999123|NCT04287504|DIAGNOSTIC_TEST|SavvyCheck Vaginal Yeast Test|Point-of-care test for the detection of vaginal candidosis
40999124|NCT04287504|DIAGNOSTIC_TEST|OSOM BVBLUE Test|Point-of-care test for the detection of bacterial vaginosis
40999125|NCT05284838|OTHER|Error Management Training (Difficult)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter difficult questions.
40999126|NCT05284838|OTHER|Error Management Training (Easy)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter easy questions.
40999127|NCT05284838|OTHER|Error Avoidance Training|Error Avoidance Training used to teach head computed tomography interpretation.
41149944|NCT05181839|DRUG|Burosumab|To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.
41149945|NCT03439800|OTHER|Mental and Physical Practice|"1. Subjects will see a video of the typical gait and will attempt to analyze the sequence of the gait cycle.~2. They will imagine themselves walking in the first-person perspective (kinesthetic) using the gait of the non-pathological pattern during 2 minutes.~3. From the 1st to 4th session, the subjects will perform gait with corrections identified in previously in the video for 2 minutes.~4. From 5th to 8th session: the subjects will do the protocol already described, however, the imagined gait will be in an environment with obstacles, also for 2 minutes. They will continue with the physical practice of the gait with obstacles.~5. From 9th to final training session: both mental and physical practice of the dual task gait."
40999128|NCT01944995|DEVICE|glasses broadband|
40999129|NCT01944995|DEVICE|nasal CPAP|
41310677|NCT02307669|BEHAVIORAL|Usual Care|"The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines."
41310678|NCT04087421|DEVICE|Qufora Irrisedo Cone System|The system works by connecting a tube from a water bag to a cone. The cone is placed into the rectum and the prescribed water volume is pumped into the rectum. When the water has been installed the valve is closed and the cone removed. Residual water and stool will then flow into the toilet.
40999130|NCT01167231|DRUG|Acarbose (Glucobay, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
40999131|NCT00017264|DRUG|atrasentan hydrochloride|
40999132|NCT01253252|RADIATION|[18F] Fluorodeoxyglucose PET Scan Imaging|"Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.~The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.~The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations."
40999133|NCT01253252|RADIATION|CT scan|Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.
40999134|NCT01253252|BIOLOGICAL|Blood sampling for biological investigations|A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
40999135|NCT03947151|DRUG|Degarelix injection(s)|1 or 2 degarelix injection(s)
40999136|NCT05276492|DRUG|Abiraterone Oral Tablet|Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
40999137|NCT05276492|DRUG|Prednisone tablet|Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.
40999138|NCT05276492|OTHER|Drug Dairy/Log|A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.
40999139|NCT05276492|DRUG|Low-fat meal|"A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff."
40999140|NCT01274403|DRUG|Melphalan, Prednisone and Thalidomide|
40999141|NCT06178172|OTHER|Remote home monitoring|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. At home, patients receive guidance for the management of pain, nutrition and pancreatitis-related complaints by a daily phone call from a nurse from the Virtual Monitoring Centre (VMC). The pancreatitis-related complaints, intake of fluids and food, pain and the use of analgesics are assessed using short questionnaires in a smartphone app. Core temperature is monitored using an ear thermometer and a wearable sensor measures heart rate, respiratory rate, posture and movement every 5 minutes. Remote home monitoring will continue for at least 4 days.
40999142|NCT00464828|PROCEDURE|Internal jugular vein cannulation|
40999143|NCT00464828|DEVICE|ultrasound|
40999144|NCT00161707|DRUG|Aerosolized, Recombinant Alpha 1-Antitrypsin|
40999145|NCT02135575|BEHAVIORAL|Spinning|After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
41310679|NCT04087421|DRUG|"Glycerol OBA"|Rectal suppository. Stimulates the rectum and softens and loosens stool.
41310680|NCT04979832|DRUG|GM-CSF, fosfomycin and metronidazole|GM-CSF 50 micrograms Fosfomycin 400 milligrams Metronidazole 100 milligrams applied as a gel in the pouch
40793320|NCT05836558|PROCEDURE|mitral valve repair in right minithoracotomy|reparative surgery of the mitral valve accessing heart via an incision in the right 3rd or 4th intercostal space.
40999146|NCT01331616|DRUG|Bevacizumab (Avastin)|Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
40999147|NCT00945022|DEVICE|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
40999148|NCT01977586|OTHER|Magnetic Resonance Imaging (MRI)|
40999149|NCT03721419|DEVICE|High Flow High Humidity device|High Flow High Humidity device has a flow generator built into the body of unit and can deliver flows between 10 to 60 Liters per minute (LPM) with oxygen bled in as needed in order to deliver specified Fraction of inspired Oxygen (FiO2)
40999150|NCT03721419|DEVICE|Low Flow High Humidity device|Standard high humidity trach collar utilizing venturi device bleed in
40999151|NCT02009410|DRUG|Creon|Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
40999152|NCT02009410|DRUG|Creon 25000 matching Placebo|Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
40999153|NCT03898661|DRUG|Collagenase histiolyticum|local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
40999154|NCT06350175|COMBINATION_PRODUCT|Nicotine Replacement Therapy Agent|The NRT Agents-- 21mg nicotine patches (x14) and 2 mg nicotine lozenges (\~210).
40999155|NCT06350175|OTHER|West Virginia Quit Line|Instructional Pamphlets and contact information for the WV QL. A telehealth line set up to assist people of WV to quit smoking.
41310681|NCT03498781|OTHER|Exercise-only|Participants will write goals related to exercise, the most desired outcome of reaching their goals, anticipated obstacles/barriers which may prevent them from achieving their goals, and if-then statements proactively describing how to overcome or avoid obstacles.
41310682|NCT03498781|OTHER|Control|Participants will be asked to identify stress-reduction techniques which they can use in their daily lives and will be encouraged to practice them as necessary.
41310683|NCT00230100|BEHAVIORAL|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
41310684|NCT00230100|BEHAVIORAL|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
40999156|NCT01200628|BEHAVIORAL|DEPITAC|heteroevaluation scale by a nurse during hospitalization
41310685|NCT05044260|PROCEDURE|Direct sinus lift with titanium reinforced PTFE membrane|Implants will be placed immediately after sinus lifting procedure and maintaining the sinus membrane in position using PTFE titanium reinforced membrane.
41310686|NCT03259997|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement
41310687|NCT03259997|DIETARY_SUPPLEMENT|Placebo|Placebo
40793321|NCT05582512|OTHER|sequelae tracking|"An integrated outpatient clinic for Long COVID-19 Syndrome in Children will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial flora, immune function and incidence of allergic diseases after long-term COVID-19 infection"
41469883|NCT03321526|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)|Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
40999157|NCT01810666|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
40999158|NCT04280367|DIAGNOSTIC_TEST|Standardised semi-structured talk|Comprehensive assessment of at-risk mental states (CAARMS) will be used.
40999159|NCT04280367|DIAGNOSTIC_TEST|Autistic spectre disorder screening|Autism-spectrum quotient (AQ) auto-questionnaire will be used.
40999160|NCT04280367|DIAGNOSTIC_TEST|Anxiety measuring|An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
40999161|NCT01892930|RADIATION|stereotactic body radiation therapy|Undergo SBRT
40999162|NCT01892930|PROCEDURE|therapeutic conventional surgery|Undergo partial or radical nephrectomy
41310688|NCT06368687|OTHER|Anorexia nervosa plus autism|In the inpatient care the treatment model takes into account the patient's perception disorders, meaning e.g. an adapted mealtime situation where the patient can eat separately or wear hearing protection if necessary. The patients have an adapted meal plan regarding difficulties with specific textures or foods. To meet their need for continuity, they have the same contact persons throughout the entire period of care. The healthcare staff receive training in working with the specific subgroup and have regular exchanges of experience regarding the patient group, 15 minutes every or every two weeks.
41310689|NCT02073435|BEHAVIORAL|Donor pain management|"The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~* Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~* Bowel preparation (e.g. Colace or Golytely)~* Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~* Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~* I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is \> 500cc)~* I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~* NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~* Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression"
41310690|NCT04502810|RADIATION|High-level laser therapy|Nd:Yag 1064 nm pulsed high-level Laser will be applied to the vulvar area.
41310691|NCT05091294|OTHER|Local anesthetic injection rate in spinal anesthesia|Administering intrathecal local anesthetics for all patients according to height and weight.
40999163|NCT01892930|OTHER|laboratory biomarker analysis|Correlative studies
40999164|NCT00902642|BEHAVIORAL|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
40999165|NCT06468709|DRUG|Glucocorticoids|The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group A was the GC monotherapy maintenance group
40999166|NCT06468709|DRUG|Glucocorticoids+MMF|The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group B was the GC+MMF maintenance group
40999167|NCT04257812|DRUG|Ceftolozane/tazobactam|"The dose will be 1g ceftolozane + 0,5 g tazobactam every 8 hours or 2 g ceftolozane + 1 g tazobactam, it´s recommended to use this last dose regimen in patients with pneumonia or septic shock of any focus.~The patients will be followed as it´s done habitually. There will be done infection focus cultures and others according to usual clinical practice. It´ll be determined the clinical response and mortality in the days 14 and 30 after the beginning of the medicine, respectively.~The Ceftolozane-Tazobactam levels determination will always be made in state of equilibrium (after the third dose). Four samples will be collected:~1. Just before the antibiotic infusion.~2. One hour after the antibiotic infusion.~3. Three hours after the antibiotic infusion.~4. Six hours after the antibiotic infusion."
41310692|NCT02036593|BEHAVIORAL|Walk Your Heart to Health|Walking group sessions conducted 3 times per week for 32 weeks.
41310693|NCT02010216|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
41310694|NCT00444626|DEVICE|Dermal Gel Extra (DGE)|Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
41310695|NCT00444626|DEVICE|Restylane|Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
41310696|NCT00444626|DRUG|EMLA Cream|EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
41310697|NCT02393573|DRUG|Metformin|Patients will take metformin for two weeks before Surgery and 2 days after the surgery
41310698|NCT02393573|DRUG|Placebo|Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
41310699|NCT02902172|DRUG|Acetaminophen|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
41310700|NCT02902172|DRUG|NSAID|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
41310701|NCT02466321|PROCEDURE|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
41310702|NCT02868216|BEHAVIORAL|anger management training|
41310703|NCT03106493|OTHER|None (observational)|None (observational)
41469884|NCT03321526|DRUG|Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
40793322|NCT05289089|BEHAVIORAL|Positive Psychology Intervention|Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
40793323|NCT01234181|PROCEDURE|Hypoxia-stressed BMSCs transplantation to cure MI|Experimental group: intracoronary injection of 10\^7 BMSCs Sham Comparator: inject the same volume saline
41310704|NCT03078036|GENETIC|Germline BRCA Test (blood)|If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice. (Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)
41310705|NCT03078036|GENETIC|FoundationOne Dx Genomic Profile (archival Tumour Specimen)|"Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:~* Tumour Specimen: Acceptable samples include formalin-fixed, paraffin embedded (FFPE) tissue (preferred) or FFPE specimens, including core needle biopsies, fine-needle aspirates and effusion cytologies.~* Tumour Testing (optional): archival tumour specimens, where available, will be tested for mutations in HRR genes including BRCA1 and BRCA2 and other genomic alterations using the FoundationOne Dx genomic profile."
41310706|NCT03078036|OTHER|Follow-up|"Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months.~- Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study."
41310707|NCT02034604|DRUG|Naftofidil|
41310708|NCT02034604|DRUG|Tamsulosin|
41310709|NCT03146052|DRUG|PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl|PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
41469885|NCT05872334|DEVICE|Monofix|a new absorbable barbed suture device
40793324|NCT00876252|BIOLOGICAL|IC43|
40793325|NCT00876252|DRUG|Placebo|NaCl
40793326|NCT00132990|DEVICE|Deep brain stimulation|
40793327|NCT04545879|DIETARY_SUPPLEMENT|Raw garlic juice containing allicin|Fresh garlic juice containing around 48mg allicin for 7 days
40793328|NCT02967419|OTHER|No Intervention|
40793329|NCT04873440|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg/d twice a week
40793330|NCT04873440|RADIATION|Radiotherapy|Measurable lesions were targeted for radiotherapy at the discretion of the treating physician.Standard-of-care radiotherapy or SBRT were both allowed.
41310710|NCT03025217|BEHAVIORAL|Total Lifestyle Coaching (TLC)|
41310711|NCT00575952|DRUG|Cisplatin|Given IV or IP
41310712|NCT00575952|DRUG|Doxorubicin Hydrochloride|Given IV
41310713|NCT00575952|BIOLOGICAL|Filgrastim|Given SC
41310714|NCT00575952|DRUG|Paclitaxel|Given IV or IP
41469886|NCT02249117|DRUG|BIWH 3|
41310715|NCT00575952|BIOLOGICAL|Pegfilgrastim|Given SC
41310716|NCT02586233|DRUG|DS-1040b|DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
41469887|NCT02249117|DRUG|Placebo|
41469888|NCT05922488|PROCEDURE|Umbilical cord milking|Umbilical cord milking : uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.
41469889|NCT05922488|PROCEDURE|delayed cord clamping|delayed cord clamping: delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord
41469890|NCT02695940|DRUG|LEO 124249 ointment 30 mg/g|
41469891|NCT02695940|OTHER|LEO 124249 ointment vehicle|
41469892|NCT00552149|DRUG|Gemox, Cetuximab|"GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"
41469893|NCT06148545|DRUG|Elemental iron|Group A who received standard therapy (Fe preparations) 3 mg/kg BW/day
41469894|NCT06148545|DRUG|Elemental iron and Vit D|Group B received standard therapy (Fe preparations) 3 mg/kgBW/day combination with vitamin D, 400IU).
41469895|NCT03195452|DRUG|Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)|All virologically suppressed
41469896|NCT02423317|DEVICE|Intubation with Miller's blade|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
40793331|NCT04873440|DRUG|Chemo-immunotherapy|The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed. Whether and which should be given depends on the treatment regimen before enrollment.
41149946|NCT03439800|OTHER|Physical Practice|"1. Subjects will see a video about PD which does not mention physiotherapy treatments related to gait and they will explain their understanding about the theme.~2. Then, the patients will make the physical gait protocol. Patients will be invited to perform the gait, in flat and firm ground with a length of 60 meters. The execution will be carried out for 10 minutes.~3. From the 5th to 8th session, the subjects will do the physical practice of the gait with obstacles (which will be: going through 2 cones zigzag, going up and down 1 step, going through a narrow door, going up and down 1 ramp, going over 1 box of shoes, climbing a ramp, going down 1 step) for 2 minutes.~4. From the 9th to the final training session, the subjects will do physical practice of the dual task gait."
41149947|NCT03353649|BEHAVIORAL|Now vs. Later Cue|"As we collect data from all participants, we will include manipulations (or motivating operations) meant to modulate putative targets within the self-regulation domain in each clinical group - to assess the extent to which we can shift self-regulatory function both in desired and undesired directions. More specifically, subjects will see a now cue instructing them to think of immediately using/consuming that stimulus or a later cue instruction them to think about the long-term consequences of using/consuming that stimulus. The latter cue is intended to down-regulate desire to use/consume the stimulus, and this down-regulation is measured by a subsequent probe asking subjects the degree to which they want to use/consume that stimulus."
41149948|NCT03353649|DEVICE|fMRI|Subjects will complete the tasks inside a functional magnetic resonance imaging device, allowing us to measure brain activity that while completing each task.
41310717|NCT02586233|DRUG|Placebo|0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
41310718|NCT01107756|DRUG|LENOGRASTIM (GRANOGYTE 34)|Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
41310719|NCT01097473|PROCEDURE|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
41310720|NCT05886634|DRUG|Etrumadenant|Will be administered PO daily for 24 weeks
41310721|NCT05886634|DRUG|Zimberelimab|Will be administered IV every 2 weeks for 24 weeks
41310722|NCT05902546|OTHER|High intensity interval training|Patients will receive interval training exercise of high intensity. This includes several rounds that alternate between several minutes of high intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of rest
41149949|NCT01385683|DRUG|Dabigatran then dabigatran and clarithromycin|D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
41310723|NCT05902546|OTHER|moderate intensity aerobic exercise|Patients will receive moderate intensity continuous aerobic exercise (walking) for 40 minutes (preceded by 10 minutes warming up and followed by 5 minutes cooling down)
41310724|NCT03404596|DRUG|Nicotine Patch|Nicotine patches and thorough education of the indications for the patch will be provided to all participants.
41310725|NCT03404596|BEHAVIORAL|Counseling|Brief counseling sessions, 10-15 minutes each.
41310726|NCT03404596|BEHAVIORAL|Smartphone|Ecological momentary assessment (EMA) assesses participants' moment-to-moment subjective experiences via self-report assessments on a smart phone. Participants will receive mindfulness strategies for 10 days pre- and post-quit via smart phone to aid in their cessation attempt. Text messages will be sent to provided study phones throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts.
41469897|NCT02423317|DEVICE|Intubation with Airtraq|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
41469898|NCT02168140|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
41469899|NCT02168140|DRUG|bendamustine hydrochloride|Given IV
41469900|NCT02868723|OTHER|Aggressive Management|With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
41469901|NCT02775539|DRUG|Mirabegron|Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
41469902|NCT02775539|DRUG|Placebo|
41469903|NCT05962268|OTHER|Video based education|The video was prepared by the researchers in line with the literature. Expert opinion was obtained from 10 individuals with at least a doctorate and studies on the subject of video content. In line with expert opinions, the video content was updated and finalized. Patient education with the prepared video was provided by one of the researchers involved in the study. The video education took 20 minutes in total.
41310727|NCT03404596|OTHER|AutoSense|Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. AutoSense unobtrusively and objectively collects physiological and behavioral data (i.e., negative affect (NA), self-regulatory capacity (SRC), and smoking) via wearable chest and wrist sensors.
40999168|NCT00458653|BIOLOGICAL|Dendritic Cell Tumor Fusion|"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"
40999169|NCT03476083|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.|All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
41469904|NCT05962268|OTHER|Face to face education|The patients were trained on fistula care by the researcher. Fistula care training was given to the patients in the control group using face-to-face education technique. In this training, researcher verbally explained fistula care to patients. The training was conducted one-on-one with the patient in the patient's room and lasted 10 minutes. The training was presented to the patient through the lecture method. The training was also supported by the question-and-answer method. The training was given twice, one week apart, when patients came for hemodialysis treatment after the condition of the patients on dialysis stabilized.
41469905|NCT01215799|DRUG|Bafetinib|Bafetinib 240 mg bid
40793332|NCT05658250|DEVICE|CRE8 polymer-free Amphilimus-eluting stent, Cre8 evo stent|Percutaneous coronary intervention using a Cre8 stent, Cre8 evo stent for long lesions
40793333|NCT00463086|DRUG|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
40793334|NCT00463086|DRUG|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
41469906|NCT05500768|PROCEDURE|hypothermic compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants, a frozen prosthesis is added
41469907|NCT05500768|PROCEDURE|Conventional compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants
41469908|NCT01992016|DRUG|Ranolazine|1000mg given orally twice daily for 1 day (2 doses).
41469909|NCT04640779|DRUG|Choline Salicylate|Given PO
40793335|NCT01696773|OTHER|Tangerine tomato juice|Post-prandial feeding study
40999170|NCT00748215|DRUG|calcium aluminosilicate anti-diarrheal|Given orally
40999171|NCT00748215|OTHER|placebo|Given orally
40999172|NCT05375734|DRUG|Tislelizumab in combination with anlotinib|Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
41310728|NCT00554892|PROCEDURE|bowel preparation|oral laxatives, retrograde enemas
40793336|NCT01696773|OTHER|Red tomato juice|Post-prandial feeding study
40793337|NCT01127633|DRUG|Solanezumab|400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
40999173|NCT05332769|GENETIC|FLIM parameters|Cumulus samples (CCs) will be collected following the protocol on the day of oocyte pick up (OPU). CCs are frozen by the cryo-tech method, then stored in liquid nitrogen at -196oC. Information of CC samples and processed date/time is recorded. After all, samples are collected, they will be transferred to The Needleman Lab, Northwest Lab Building 359,52 Oxford Street Cambridge MA 02138 to measure mitochondria metabolism using FLIM.
40999174|NCT04551846|DIETARY_SUPPLEMENT|Oligomeric enteral feeding|Oligomeric enteral feeding will be administered to the PICU patients
40999175|NCT04551846|DIETARY_SUPPLEMENT|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
40999176|NCT03679871|OTHER|Questionnaire validation|"Participants will fill in the questionnaire Spiritual Resources and Distressplus additional questionnaires required for validation purposes. Three weeks later, a sub-sample will fill in the questionnaire one more time for consistency testing (test-retest)"
40999177|NCT00213837|DEVICE|Mandibular prosthesis made of a new highly biointegratable material|Replacement of mandibular bone after partial or total mandible resection,avoiding then bone grafting. The porous titanium prosthesis is implanted under general anaesthesia in laryngeal surgeries. Bone resection and prosthesis placement is performed during the same surgical intervention. The prosthesis is attached onto the healthy bone with surgical screws. Simultaneous grafting of vascularised tissues may be done if the prosthesis surrounding area has been strongly irradiated.
40999178|NCT00545857|DRUG|pioglitazone|Pioglitazone daily; dose varies with size
40999179|NCT00545857|DRUG|Placebo control|Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
41310729|NCT00554892|PROCEDURE|no preparation bowel|no preparation bowel
40999180|NCT00966238|BIOLOGICAL|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
41310730|NCT02955134|DRUG|Talcid®|Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.
40999181|NCT05336058|OTHER|No intervention|In this non-intervention study, 10ml of whole blood of enrolled subjects was collected for multi-target PCR detection of cfDNA methylation.
41469910|NCT04640779|DRUG|Selinexor|Given PO
41469911|NCT00353652|DRUG|Study#1: chlorthalidone (CTD), titrated dose|Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg
40793338|NCT01127633|DRUG|Placebo|Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
40793339|NCT04186533|BEHAVIORAL|Default Option|The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.
41469912|NCT00353652|DRUG|Study #1: spironolactone (SP), titrated dose|Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.
41149950|NCT01385683|DRUG|Clarithromycin and dabigatran then dabigatran|D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
41469913|NCT00353652|DRUG|Study# 2 chlorthalidone (CTD), fixed dose|Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
41469914|NCT00353652|DRUG|Study# 2 spironolactone (SP), fixed dose|Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
41149951|NCT03370861|BIOLOGICAL|Immunotherapy|Medications that increase the activity of the immune system.
41149952|NCT01852851|BEHAVIORAL|Employment and Arthritis: Making it Work|A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
41149953|NCT02462447|DRUG|11C-sarcosine|Radiotracer injection for PET/CT scan
41149954|NCT02462447|DRUG|11C-choline|Radiotracer injection for PET/CT scan
41149955|NCT02211859|DRUG|BI 2536|
41149956|NCT05866289|OTHER|Prone position|Each prone position session had a minimum duration of one hour and a maximum duration of 12 hours for a minimum of 3 hours per day.
41149957|NCT05396755|PROCEDURE|Endoscopic retrograde cholangiography (ERC)|invasive evaluation of the biliary tract with ERC and endoscopic interventions every 8 weeks until 6 months (24 weeks)
41149958|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
41469915|NCT00353652|DRUG|Study# 2 irbsesartan (IR), fixed dose|Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
41149959|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered at lower dose \[2x10\^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose\] by intradermal (ID) route on Days 0 and 28.
41149960|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
41149961|NCT06426511|DRUG|Toripalimab+Chemotherapy|After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment. Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.
41469916|NCT02244931|DEVICE|Servomatic™ assisting device|Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
41469917|NCT02244931|DEVICE|E.Motion© assisting device|E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
41469918|NCT02244931|DEVICE|Standard manual Wheelchair|Standard manual Wheelchair
41469919|NCT00496262|BIOLOGICAL|Human Fibrinogen Concentrate|Single intravenous infusion of 70 mg/kg body weight
41469920|NCT00641784|DRUG|Magnesium|Intravenous Magnesium 6 gram load, 3 grams/hr
41469921|NCT00641784|DRUG|Nifedlipine|Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
41469922|NCT02497131|DRUG|Brentuximab Vedotin|Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
41469923|NCT06223373|DEVICE|Blood Flow Restriction|In the BFR group, the tourniquet will be pressurized to 50% limb occlusion pressure (LOP), which is the pressure necessary for occluding 50% of arterial limb flow in the upper extremity.
41469924|NCT06223373|DEVICE|"sham Blood Flow Restriction"|In the sham BFR group, the tourniquet will be pressurized to 0% occlusion pressure, while maintaining enough pressure to keep the tourniquet in place.
40793340|NCT04186533|BEHAVIORAL|Nutrition Education|The nutrition education materials were adapted from materials currently utilized by the Supplemental Nutrition Assistance Education Program
40793341|NCT00912626|BEHAVIORAL|One week follow up assessment results|FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
41469925|NCT06132048|DEVICE|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
41469926|NCT01293266|DRUG|Propofol|Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
40793342|NCT03194308|BEHAVIORAL|PrEP for Safer Conception|Evaluation of uptake of and adherence to PrEP and safer conception strategies including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive by enrolled women, during periconception and pregnancy follow up.
41469927|NCT02076776|BEHAVIORAL|Repetitive Task Practice (RTP)|This group will preform arm and hand therapy.
41469928|NCT02076776|BEHAVIORAL|Voluntary cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
41469929|NCT02076776|BEHAVIORAL|Assisted cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
40793343|NCT04633369|DIETARY_SUPPLEMENT|dietary fibers|during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.
40793344|NCT04075305|RADIATION|Radiation therapy|Radiation therapy on the CE marked and FDA approved MR-Linac
41469930|NCT00469053|DRUG|Buprenorphine|
41469931|NCT04883424|BEHAVIORAL|Diabetes Education Program Based on Health Belief Model|After the application, increase in family support and decrease in blood sugar levels are expected in diabetic patients. Family members' diabetic attitudes are expected to increase.
41469932|NCT04080596|DRUG|Dorzagliatin|GKA for T2DM currently under clinical development
41469933|NCT01438476|PROCEDURE|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
40999182|NCT04606979|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
41149962|NCT06426511|DRUG|Toripalimab+Chemotherapy followed by consolidation toripalimab|"After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment, and then maintenance treatment with single-agent toripalimab (240 mg) once every 3 weeks for up to 13 cycles.~Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians."
41149963|NCT00004806|GENETIC|Cystic fibrosis transmembrane conductance regulator|
41149964|NCT00443820|DRUG|terbinafine|Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
41469934|NCT01438476|PROCEDURE|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
41469935|NCT01438476|BEHAVIORAL|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
41469936|NCT01438476|BEHAVIORAL|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
41469937|NCT04067193|OTHER|usability survey|usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.
41469938|NCT05017779|BEHAVIORAL|Unstuck & On Target: High School|Unstuck \& On Target: High School (UOT:HS) is a group-based curriculum for high school students that targets executive function skills using Cognitive Behavior Therapy (CBT) techniques. UOT:HS focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Lessons are delivered by school personnel within the school setting. Home extension activities are provided to parents.
41469939|NCT05017779|OTHER|Treatment as Usual|Participants in schools assigned to the Treatment as Usual (TAU) condition will continue to receive the standard school-based IEP accommodations and school supports that would typically be provided. Data will be collected on the types of supports TAU schools offer, and what supports TAU students receive.
41149965|NCT00443820|DRUG|Placebo|Vehicle (placebo) once daily for 48 weeks
41149966|NCT00443820|DRUG|terbinafine|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
41149967|NCT00443820|DRUG|Placebo|Vehicle (placebo) once daily for 24 weeks
41310731|NCT02955134|DRUG|Chinese medicine prescription|"The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.~Patients take 200ml each time, twice a day. Treatment duration are 24 weeks."
41310732|NCT02955134|DRUG|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
41149968|NCT03677856|PROCEDURE|Paravertebral blockade|Type of anaesthesia
41149969|NCT03677856|PROCEDURE|Thoracic epidural block|Type of anaesthesia
41310733|NCT02955134|DRUG|Compound Azimtamide Entieric-coated Tablets|Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.
41310734|NCT05869487|RADIATION|Dual-energy X-ray absorptiometry|Whole body x-ray absorptiometry
41310735|NCT02918266|DRUG|Scopolamine|Scopolamine subcutaneous injection
41310736|NCT02918266|DRUG|TAK-071|TAK-071 DIC
41310737|NCT02918266|DRUG|Donepezil|Donepezil over-encapsulated tablet
40999183|NCT05378620|BEHAVIORAL|Project Dulce + Dulce Digital|Project Dulce will consist of a group diabetes self-management program consisting of a 5-week curriculum delivered by a peer educator in Tagalog. The curriculum provides new knowledge as well as skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants will learn and practice self-management skills, and help one another address family, cultural, or health system barriers to managing your diabetes. Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Tagalog.
40999184|NCT02676531|OTHER|Exercise|Walking meditation exercise program
41310738|NCT02918266|DRUG|Scopolamine Placebo|Scopolamine placebo-matching subcutaneous injection
41310739|NCT02918266|DRUG|TAK-071 Placebo|TAK-071 placebo-matching DIC
41310740|NCT02918266|DRUG|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
41310741|NCT04302610|DEVICE|Heat and Moisture Exchange mask (ColdAvenger® expedition balaclava, USA,|A heat and moisture exchange mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough amongst athletes engaging in sports in cold dry environments
41469940|NCT05623852|DIETARY_SUPPLEMENT|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
41310742|NCT04302610|DEVICE|Sham treatment|Same as the HME mask but active HME parts withdrawn from devices and multiple holes made in mouth piece to improve ventilation of mask and reduce HME ability of mask
41310743|NCT02417233|BEHAVIORAL|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
41310744|NCT02417233|BEHAVIORAL|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
41310745|NCT01604304|PROCEDURE|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
41310746|NCT01604304|PROCEDURE|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
41469941|NCT03547726|OTHER|Physical Therapy|These patients will receive a formal physical therapy protocol by seeing a physical therapist in clinic.
41469942|NCT03547726|OTHER|Self-Rehab|These patients will be provided with a list of actions NOT to perform and allowed to self rehabilitate. They will not see a physical therapist.
41469943|NCT04743817|DEVICE|OtoSet - Ear Cleaning System|Up to five (5) cleaning cycles using the OtoSet - Ear Cleaning System
41469944|NCT01391845|DRUG|ulipristal acetate|30mg of ulipristal acetate orally the day of hCG injection in a unique dose
40999185|NCT01971853|DRUG|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
40999186|NCT01971853|DRUG|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
40999187|NCT05028504|DRUG|Penpulimab|Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
40999188|NCT05028504|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
41149970|NCT05534854|GENETIC|Gene test|Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
41149971|NCT03627299|DRUG|300mg glecaprevir/pibrentasivir 120mg|300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant
41149972|NCT05813145|DRUG|Placebo|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
41149973|NCT05813145|DRUG|Fenofibrate 160mg|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week in addition to 160mg fenofibrate once daily for 3 month.
41149974|NCT03063983|DRUG|Cyclophosphamide|Continuous oral cyclophosphamide
41149975|NCT03063983|DRUG|Methotrexate|Continuous oral methotrexate
41469945|NCT01391845|DRUG|placebo|placebo orally in a unique dose the day of hCG injection
41469946|NCT01391845|DRUG|ulipristal acetate|ulipristal acetate 30mg orally in a unique dose the day of hCG administration
41469947|NCT01391845|DRUG|placebo|placebo orally in a unique dose the day of hCG injection
41149976|NCT05353062|PROCEDURE|Hemostatic therapy|Bipolar hemostatic forceps
41149977|NCT05353062|PROCEDURE|Endoscopic therapy with hemoclip +/- injection of epinephrine solution|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
41310747|NCT04820543|DRUG|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
41310748|NCT03370991|DIETARY_SUPPLEMENT|Blueberry Powder|22 g/day freeze-dried blueberry powder for 12 weeks
41310749|NCT03370991|DIETARY_SUPPLEMENT|Placebo Powder|22 g/day placebo powder for 12 weeks
41310750|NCT04949178|OTHER|No intervention|This is an observational study.
41469948|NCT01590251|OTHER|Yoga|Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
41469949|NCT01590251|BEHAVIORAL|Educational Counseling|One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
41469950|NCT03844724|DEVICE|ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
41469951|NCT03844724|DEVICE|Peripheral Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
41310751|NCT02233205|DEVICE|ultrasonic microbubbles|inject 1ml once and five times in 20min, locate the probe on the lesion at the same time
41310752|NCT02233205|DRUG|platinum and gemcitabine|Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.
41310753|NCT04068064|PROCEDURE|EABM training|"The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, in response to each gaming picture, selecting one word will have a 70% chance to get a monetary reward and the other word will have a 30% chance to get a monetary reward. A similar rationale applies to the pictures of healthy activities. The reward setting will help consolidate target associations.~Each training session includes 300 times/trials of each type of association, presented in pseudorandom way. The whole training includes 6 training sessions. Participants will receive one training session every days."
41310754|NCT04068064|PROCEDURE|sham training|In the control group, neutral words instead of emotional words are used. All other settings are the same with those in the intervention group
41469952|NCT04429841|PROCEDURE|Radical gastrectomy with D1 lymphadenectomy|
41469953|NCT04429841|PROCEDURE|Radical gastrectomy with D2 lymphadenectomy|
41469954|NCT00867048|DRUG|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
41469955|NCT02091349|OTHER|polydextrose|polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
41469956|NCT02091349|OTHER|soluble corn fiber|nutirose- 7, 14, or 21 grams/day
41469957|NCT00890331|BEHAVIORAL|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
41469958|NCT00890331|BEHAVIORAL|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
41149978|NCT04211194|PROCEDURE|Upper GI Endoscopy|Patients with upper gastrointestinal bleeding undergoing endoscopic therapy. Information regarding the need for interventional radiology procedures or surgical interventions will also be collected in patients in whom endoscopic therapy is not successful.
41149979|NCT00310050|DRUG|pemetrexed disodium|500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
41149980|NCT00310050|DEVICE|Radiotherapy|During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).
41149981|NCT04802954|OTHER|Video acquisition|One to three video acquisitions of 10 seconds will be carried out via the intercostal route. Data acquisition will be standardized according to a mandatory protocol and previously recorded in each ultrasound machine (cross shots, harmonic, filter, depth, focal length, mechanical index, etc.).
41149982|NCT04246905|DRUG|sulforaphane|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
41149983|NCT04246905|OTHER|placedo|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
41149984|NCT04246905|DRUG|selective 5 - HT reuptake inhibitors (SSRI)|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
41149985|NCT05942183|DIAGNOSTIC_TEST|ONSD|ultrasound measurement of the optic nerve sheath diameter
41149986|NCT02674971|BEHAVIORAL|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
41149987|NCT03152474|DRUG|Solumedrol 20mg|Dosed Intravenous every 8 hrs.
41469959|NCT05890092|OTHER|Observation|Observing for disease prevalence - actual and self-reported
41469960|NCT00744172|PROCEDURE|laparoscopy|laparoscopic hysterectomy
41469961|NCT00744172|PROCEDURE|vaginal|vaginal hysterectomy
41469962|NCT00744172|PROCEDURE|abdominal|abdominal hysterectomy
41469963|NCT00775528|DRUG|Pancrelipase Delayed Release|3,000, 6,000 and 12,000 unit Lipase Capsules
41469964|NCT06176755|OTHER|Treadmill training with weighted ankle cuffs|"Group A: Treadmill training and Ankle cuff.~Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently."
41469965|NCT06176755|OTHER|Treadmill training|Treadmill training only
40793345|NCT02425787|BEHAVIORAL|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be conducted by the study PI or designee. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.~In order to ensure that the interviewer does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
41149988|NCT03152474|DRUG|Vitamin A 100,000 IU|Dosed Intramuscular once daily
41149989|NCT03152474|OTHER|Placebo|Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
41310755|NCT03922360|BEHAVIORAL|Smartphone-based Financial Incentives|"Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.~Best Practices + Financial Incentive- Women assigned to this condition will receive the best practices treatment described above plus the remote incentives intervention.~Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced and incentives will be contingent on submitting a negative saliva cotinine test."
41310756|NCT03922360|BEHAVIORAL|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.
41310757|NCT02167841|BEHAVIORAL|Knee-Chest Position|
41310758|NCT04343079|DIAGNOSTIC_TEST|PET CT|measurement of surgical margins during lumpectomy
40793346|NCT02425787|BEHAVIORAL|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:~1. With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews \&/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.~2. With Hematology/Oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
40793347|NCT02425787|BEHAVIORAL|Interview|The interview will be conducted by study team members and will center around legacy item-related questions.
40793348|NCT02872870|BEHAVIORAL|auditory lexical decision task|
40793349|NCT02872870|DEVICE|electroencephalogram|
41149990|NCT05514899|DRUG|THC|THC capsule
41149991|NCT05514899|DRUG|CBD|oral solution
41149992|NCT03337204|BEHAVIORAL|Technology-assisted self-monitoring|Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
41149993|NCT03337204|BEHAVIORAL|Workshop and Peer Mentoring|Participants receive a 3-hour Engaged4Life Workshop (psychoeducation + goal setting) and one-on-one peer mentoring via phone 2X/week for 3 weeks.
41149994|NCT02747459|BEHAVIORAL|Sensory Supported Swimming|A swimming and water safety program for children with autism spectrum disorders. Individualized instruction utilizing evidence-based teaching methods and sensory modifications.
41149995|NCT04107844|DIAGNOSTIC_TEST|Novel facilitating agility dual-task test combined with already known tests|We will investigate if a combination of a novel Dual-task test combined with already known tests can identify more athletes, not ready to return to play, although symptoms of concussion have stopped.
41149996|NCT03317509|PROCEDURE|repetitive transcranial magnetic (rTMS)|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
41149997|NCT02243488|DEVICE|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
41149998|NCT03981328|DEVICE|Dexcom G6 Continuous Glucose Monitoring System|Users insert a tiny sensor wire just under their skin using an automatic applicator. The sensor can measure glucose readings in interstitial fluid throughout the day and night.
41149999|NCT03981328|DEVICE|self-monitored blood glucose|Each participant in the control group will be assigned a study blood glucose meter to measure and store their blood glucose values during the study. Therefore, the Contour® Next One system (or a comparable device) will be used. The meter has CE Mark clearance and is commercially available in Europe. Participants will receive an ample supply of meter test materials based on quantities routinely used.
41150000|NCT02361983|DEVICE|DLT versus bronchial blockers|Safety and efficacy of the double-lumen tubes (DLT) and bronchial blockers (BB) for lung isolation in patients undergoing thoracic surgery have been extensively studied and most of the results show similar rates of successful placement and lung collapse. DLT and BB are more frequently inserted by anesthetists who are expert in thoracic anesthesia, with dedicated but different training.
41310759|NCT05431517|PROCEDURE|Analysis of ERCP records|Data will be extracted from ERCP records of stenting, mainly including: 1) Age at the time of ERCP; 2) Gender; 3) Indication; 4) Papilla selection (major or minor); 5) Whether endoscopic sphincterotomy (EST) was performed; 6) Presence of nipple diverticulum; 7) Morphology of the pancreatic duct; 8) Status of pancreatic duct stones; 9) Number, shape, material, diameter and length of the stent; and 10) Operation of the bile duct. Additional data were extracted from the pertinent ERCP records of stent migration: 1) Shape, material, diameter and length of the displaced stent; 2) Type of migration; and 3) Removal tools.
41310760|NCT01818050|OTHER|Liver Function Tests|LFTs will be checked periodically after Wing stent placement to evaluate stent patency
41310761|NCT01850745|OTHER|Multidisciplinary support program|Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.
41310762|NCT01511419|BIOLOGICAL|LAIV H7N3|2 doses of vaccine
41469966|NCT06351696|DIETARY_SUPPLEMENT|Bromlein|1500 mg/day
41150001|NCT05105425|DIETARY_SUPPLEMENT|NUTRIOSE®|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
41310763|NCT01511419|BIOLOGICAL|placebo|2 doses of placebo
41310764|NCT04018196|OTHER|motor imagery as training manual task|They will have a motor imagery as training manual task for 30 minutes. They will have 3 tests for performing manual task before training (pretest) and after training (post-test).
41469967|NCT06351696|OTHER|Placebo|Placebo (1500 mg/day)
40793350|NCT05593315|OTHER|Mindfulness and Buteyko techniques|Joint implementation of a general relaxation program and a respiratory rehabilitation program in patients with poorly controlled asthma.
41150002|NCT05105425|DIETARY_SUPPLEMENT|GLUCIDEX® IT21 (Placebo)|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
41150003|NCT03933735|DRUG|TNB-383B|Intravenous (IV) Injection
41150004|NCT06090760|BEHAVIORAL|Mindfulness|"Mindfulness is paying attention in a particular way: on purpose, in the present moment, and non-judgmentally (Kabat-Zinn 1994, 4) and has five facets: awareness, nonjudgement, nonreactive, observe, and describe (Baer et al., 2006)."
41150005|NCT02362100|OTHER|Non operative|non operative treatment
41150006|NCT02362100|PROCEDURE|locking plate surgical fixation|
41310765|NCT04018196|OTHER|motor imagery as training motor task|"They will have a motor imagery as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
41310766|NCT04018196|OTHER|emotionally neutral film as training of manual task|"They will have to watch an emotionally neutral as training manual task for 30 minutes before performing this task.~They will have 3 tests for performing manual task before training (pretest) and after training (post-test)."
41310767|NCT04018196|OTHER|emotionally neutral film as training of motor task|"They will have to watch an emotionally neutral as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
41310768|NCT01732185|GENETIC|Patient|Blood and histological samples will be done at day of the inclusion.
41310769|NCT03780556|DRUG|Lornoxicam and mepridine|compare the effect of each to control pain
41310770|NCT06337292|DEVICE|Incisional Negative Pressure Wound Therapy (NPWT)|Participants in the treatment group will be standardized and will receive incisional NPWT using the any incisional VAC system that can apply 75-125mmHg continuous suction to the incision. The VAC sponge will be placed over the surgical wound at least 2cm in width and \>3cm in length.
41310771|NCT05102708|OTHER|Prognostic factors of severe COVID-19|prognostic factors: patients´ epidemiological characteristics (such as age, sex), comorbidities, length of hospitalization, critical care admission, treatments received, laboratory results, vital signs.
41310772|NCT00129805|DRUG|MCI-9042|
41310773|NCT00129805|DRUG|Aspirin|
41469968|NCT05787067|BEHAVIORAL|Health Belief Model-Based Mobile Online Training|Health Belief Model-Based Mobile Online Training
41469969|NCT04871009|BEHAVIORAL|Neurofeedback Intervention|"InteraXon, Inc. produces the MUSE 2 wearable neurofeedback device and mobile application (heretofore referred to as the MUSE app), respectively comprising the electroencephalogram (EEG) hardware and interactive software components that will be used in this intervention. The MUSE 2 is an adjustable headband that is placed across the forehead and over and behind the ears. It contains EEG sensors for active sites across the forehead and behind the ears, and an additional reference site behind the ear. These sensors use EEG technology to passively record children's brainwaves. During a session, caregivers will help children place the MUSE 2 on their heads and connect it to the app on their personal device. Children's brain activity is recorded by the MUSE 2 and is represented on the app through audio-based feedback that children will listen to with earbuds, and use their volition to influence in real time, with the goal of gaining increased control over their own brain activity."
41469970|NCT04871009|BEHAVIORAL|standard of care|trauma focused cognitive behavioral therapy or other behavioral therapy at the discretion of therapist
41469971|NCT00869687|DEVICE|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
41469972|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
41469973|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
41469974|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
41469975|NCT01139684|BEHAVIORAL|Repeated sprint test|
41469976|NCT03571659|PROCEDURE|Laser|
41469977|NCT00672776|DRUG|paroxetine|
41469978|NCT00672776|DRUG|placebo|
41469979|NCT05305950|OTHER|Patient population|Questionnaire, standard of care
41469980|NCT04782752|RADIATION|Radiation: Varying Doses of RT|3+3 radiation dose escalation model to see the maximum tolerated dose
41310774|NCT02029508|PROCEDURE|Modified Epley maneuver|For Modified Epley maneuver, the patient was placed in the upright position with the head turned 45 degrees toward the affected ear. And then the patient was rapidly laid back to the supine head-hanging position for 1 minute. Next, the head was turned 90 degrees toward the other (unaffected) side for 1 minute. Next, the head is turned a further 90 degrees (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient' head is nearly in the facedown position for 1 minute. The patient is then brought into the upright sitting position for 1 minute, completing the maneuver.
41310775|NCT02029508|PROCEDURE|Semont maneuver|Patient's head was turned 45 degrees toward the healthy side. And then patient was rapidly moved to affected side-lying position and sustained for 2 minutes. Next, Patient is rapidly taken to the opposite side-lying position without pausing in the sitting position or changing the head position relative to the shoulder for 2 minutes. Next, Patient returns slowly with the head still tilted and fixed until the seated position for 1 minute.
41310776|NCT02029508|PROCEDURE|Reverse Epley maneuver|Like the modified Epley maneuver, but the direction was reverse.
41310777|NCT00158548|DRUG|SP, chloroquine, amodiaquine, primaquine, artesunate|
41310778|NCT02512068|DRUG|Trelagliptin 25 mg|Trelagliptin 25 mg Tablets
41310779|NCT02512068|DRUG|Placebo|Placebo Tablets
41310780|NCT01718509|DRUG|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
41310781|NCT01718509|DRUG|Placebo|Administered once-daily, orally, for up to 12 weeks
41310782|NCT04026152|BEHAVIORAL|Resistance training|Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.
41310783|NCT04026152|BEHAVIORAL|Unified Protocol|This intervention consists four weekly sessions adapted from the Unified Protocol. The first module is Psychoeducation and Motivational Interviewing. During this module, participants will develop an understanding of their own pattern of emotional responding to exercise as well as increasing participants' readiness and motivation for behaviour change.The second module is Cognitive Flexibility, during which participants will learn about how automatic negative interpretations can influence their emotional reactions and prevent them from considering alternative explanations. The third module is Countering Emotion-Driven Behaviours during which participants will identify and counter behaviours used to dampen strong emotions, particularly those associated with exercise. Lastly, module four will use Exposure to external and internal emotional triggers to increase participants' tolerance to the emotions that arise in exercise environments.
41310784|NCT01993862|OTHER|Same Day Discharge|Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
41310785|NCT01013909|DRUG|Bifonazole spray once daily|Application of one dose daily by means of an metered dose
41310786|NCT01013909|DRUG|Bifonazole spray twice daily|Application of two dose daily by means of an metered dose
41310787|NCT01013909|DRUG|Placebo|Application of one dose daily by means of an metered dose
41469981|NCT02394691|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
41469982|NCT06293352|DEVICE|All-cement articulating spacer|Two-stage intervention
41469983|NCT06293352|DEVICE|Durable, real-component articulating spacer|Single stage intervention
41469984|NCT06293352|DEVICE|Rigid Spacer|Observation intervention
41310788|NCT01013909|DRUG|Placebo|Application of one dose daily by means of an metered dose
41310789|NCT01013909|DRUG|Lamisil Once|One application of Lamisil Once
41469985|NCT01469260|OTHER|Pedometer|Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
40793351|NCT04175340|DEVICE|BL-300-PFM04|Preservative Free Lubricating and Rewetting Drops for use during contact lens wear
40793352|NCT04175340|DEVICE|OPTI-FREE|Replenish Rewetting Drops
41310790|NCT03754608|DIAGNOSTIC_TEST|MRI including cf-MRI, DTI, ASL and CVR.|A paradigm developed at Yale University called Cognitive Predictive Modelling which takes connectivity data and reduces it to two smaller network which predict higher and lower performance in a particular task for which these networks have been optimized. This will be supplemented by MRI vascular measures.
41310791|NCT05096871|GENETIC|Genotyping by Real Time PCR|"3 mL of blood will be withdrawn by venipuncture in EDTA tube. DNA extraction will be done after centrifugation and used for genotyping assay of ( BDNF ) gene with the Real- time polymerase chain reaction.~BDNF level in serum will also be analyzed by Sandwich enzyme linked immunosorbant assay kit ( ELISA)."
41469986|NCT02370459|OTHER|AFIX in-person consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
41150007|NCT05817864|DIAGNOSTIC_TEST|Capnography|"Index test: Capnography, which monitors ETCO2, the percentage concentration, or partial pressure of CO2 at the end of exhalation, will serve as the index test. It will be performed by connecting the end of the nasogastric tube with the sensor of the bedside sidestream capnography device. Placement within the airway is defined as detecting a capnogram waveform or an ETCO2 level \> 10 mmHg.~Reference standard: This study will use radiography (chest/abdominal X-ray) as the reference standard for determining the correct placement of nasogastric tubes. Radiology will be performed as soon as possible and interpreted by a physician. A repeat radiography will be performed if necessary. We will also use pH-Fix-4.5-10 to determine the pH value, and its accuracy is +/- 0.2 pH with minimum increments of 0.5. A pH of 5.5 or below indicates gastric placement."
41150008|NCT00892970|DRUG|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
41150009|NCT00892970|DRUG|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
41310792|NCT00903032|BEHAVIORAL|Intervention|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
41310793|NCT00903032|BEHAVIORAL|Usual care|Usual care following ACS hospital discharge.
41310794|NCT03414762|DEVICE|PICO Negative Pressure Wound Therapy|The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.The dressing is applied to the wound and extra strips are placed over the outside edge to help hold the dressing in place. When the pump is turned on, air is pulled out of the dressing and excess fluid from the wound will start to enter the dressing.
41310795|NCT03414762|DEVICE|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing
41469987|NCT02370459|OTHER|AFIX webinar consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
41469988|NCT01962649|BIOLOGICAL|ICG|
41469989|NCT01962649|DEVICE|Optical molecular imaging|
41469990|NCT06308133|OTHER|apheresis procedure|collection of hematopoietic stem cells carried out using the single-chamber and continuous mononuclear cell (cMNC) collection system with Spectra Optia (Terumo BCT)
41469991|NCT06617429|DRUG|GTX-102|antisense oligonucleotide
41469992|NCT06617429|PROCEDURE|Sham-LP|Small needle prick on the lower back at the location where the LP injection is normally made
41469993|NCT04938973|PROCEDURE|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
41469994|NCT04938973|PROCEDURE|Open Transthoracic Esophagectomy (OTE)|Open Transthoracic Esophagectomy (OTE) is the current standard of care.
40793353|NCT03287323|OTHER|Proactive Palliative Care|In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
40793354|NCT03024112|DEVICE|Heated humified high-flow nasal cannula Oxygen|
40793355|NCT03024112|OTHER|Standard oxygen therapy|
41469995|NCT04938973|DEVICE|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
40793356|NCT03047967|DIAGNOSTIC_TEST|lung function tests|baby-body plethysmography
41469996|NCT03359837|DRUG|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
40793357|NCT03047967|DIAGNOSTIC_TEST|Nasal brushing|Epithelial sample collecting for in vitro study
40793358|NCT05779228|BEHAVIORAL|Mode Switching Training|Wear of colored lenses for 1 hr, 5 times per day, for 5 days
40793359|NCT05156944|OTHER|physiotherapeutic intervention|"The intervention consists of a brief physiotherapeutic assessment, the short physical performance battery, a brief information on the expected course of the condition, a check of fall hazards at home using the Bundesamt für Unfallverhütung (bfu) checklist, and instructions on self-management (eg. staying active, adaptation of behavior and surrounding at home). Additionally, two exercises for daily self-guided therapy will be instructed, namely, sit-to-stand and balance performance exercises."
40793360|NCT04505644|DRUG|lidocaine patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
40793361|NCT04505644|DRUG|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
40793362|NCT04505644|DRUG|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
41310796|NCT03855748|OTHER|Healthy group|"Subjects undergo the following activities:~1. Walking~2. Jogging (8-11 km/h)~3. Maximal 5 meters sprint acceleration~4. Single leg drop jump from 35 cm height~5. Horizontal jump with single leg landing with a distance of 100% and 150% of leg length~6. Maximal change of direction at 45, 135, 180 degrees~7. Single-leg cross-country skiing exercise"
41310797|NCT01902953|DRUG|Lymphoseek and VBD Sln dissection|See detailed description of study design
41310798|NCT05132816|DIAGNOSTIC_TEST|high-resolution manometry|"High-resolution manometry is an outpatient examination and part of our routine diagnostic or pre-operative evaluation in GERD.~A thin catheter is placed through the nose into the esophagus, local anaesthesia can be used if the patient experiences a discomfort. Once the tip of the manometry catheter is placed below the esophagogastric junction, the patient is asked to take in water and bread. In rest and during deglutition, pressure measurements are registered with the manometry catheter, allowing the investigator to detect IEM. The examination takes about 1.5 hours. The manometry is a standard and routine intervention being performed for over 30 years with minimal risks.~The GSRS questionnaire pre- and postoperatively is part of our standard workup, no additional assessment for this study is needed."
41310799|NCT03673241|DEVICE|Guardian System|The Study arm will have the Guardian system applied to their bed and recovery chair with the intent for the patient to have the inflatable surface utilized underneath them .
41310800|NCT01413984|BEHAVIORAL|Helping Women Recover/Beyond Trauma|Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
41469997|NCT03359837|DRUG|Insulin Glulisine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
41469998|NCT03359837|DRUG|Biphasic insulin aspart 30|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
41469999|NCT03359837|DRUG|Repaglinide|"Pharmaceutical form: tablet~Route of administration: oral administration"
41470000|NCT03359837|DRUG|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
40999189|NCT04893447|BEHAVIORAL|SPI+|Suicide prevention hotline follow-up specialists will call participants to (1) conduct a brief suicide risk assessment; (2) review and discuss the participant's connection and support plan or safety plan; and (3) provide referrals to social services or other support with treatment engagement, if indicated. Participants will receive at least one and optional additional phone calls, generally delivered according to the following schedule: days 3, 7, 14, 30, 60, 90. Modifications may be made to the schedule due to weekends, holidays, or participant availability, and additional calls may be scheduled as desired by the participant. The follow-up will stop once the participant is successfully engaged in outpatient treatment or does not desire further follow-up support.
40999190|NCT04893447|BEHAVIORAL|SP+CC (Caring Contacts)|SP+CC follow-up includes one phone conversation with a suicide prevention hotline follow-up specialist and a series of personalized caring messages sent over the course of 12 months via text or email (based on participant preference). Caring contacts will generally be sent according to the following schedule: 3 in the first week, 6 weekly, 6 bi-weekly, 4 monthly; 2 bi-monthly, and one each for the participant's birthday, Thanksgiving, Christmas, and New Year's (total of 25 over 12 months). Slight variation in the schedule is allowed. There is no expectation that participants respond to the text messages; if they do, follow-up specialists reply to any incoming texts. Replies are individually-tailored and caring.
40999191|NCT02112825|BEHAVIORAL|Exercise|Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
40999192|NCT03657355|DRUG|ACT-541468|ACT-541468 will be administered as 50 mg tablets for oral use.
40999193|NCT03657355|DRUG|Suvorexant|Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.
40999194|NCT03657355|DRUG|Zolpidem|Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.
40999195|NCT03657355|DRUG|Placebo|Matching-placebo will be used.
40999196|NCT01998451|DRUG|Tauroursodeoxycholic acid|patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
40999197|NCT01446965|DEVICE|wearable defibrillator|LifeVest wearable defibrillator
40999198|NCT06366633|BEHAVIORAL|Web-TIRELESS|This is a self-administered web-based intervention that consists of 4 30-45-minute video sessions that teach mind-body skills, cognitive-behavioral strategies (e.g., reframing, pain and substance use urge surfing), activity pacing, acceptance and commitment skills, and psychoeducation on the association between substance use and pain. The program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive substance use behaviors.
40999199|NCT00621881|DRUG|naproxcinod|750 mg bid
40999200|NCT06255535|DEVICE|active iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.
41150010|NCT03847220|DIAGNOSTIC_TEST|BOMET-QoL questionnaire|study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM
41470001|NCT03359837|DRUG|Metformin|"Pharmaceutical form: tablet or capsule~Route of administration: oral administration"
41470002|NCT04614584|DRUG|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
41150011|NCT03219216|DRUG|Glecaprevir/Pibrentasvir|Film-coated tablet
41470003|NCT04614584|DRUG|Methamphetamine|Methamphetamine 30 mg IV once
41470004|NCT00255151|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
41150012|NCT00739388|DRUG|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
41310801|NCT03306134|DIAGNOSTIC_TEST|Dysphagia|"An overall assessment is going to be carry out by a multidisciplinary team during the visit.~Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire \[4\]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present.~All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)"
41310802|NCT04400539|DEVICE|intrapleural photodynamic therapy with videothoracoscopy|MPM patients will be first administrated 20 mg/kg of oral photosensitizer, 5-Aminolevulinic Acid (5-ALA) {Gliolan®}, 4 to 6 hours prior undergoing thoracoscopy (VATS). During VATS procedure, after a qualitative control of the fluorescence of tumor lesions and some guided pleural tumor biopsies, the pleural cavity will be illuminated using a flexible probe and laser source at a specific wavelength for 5-ALA (400-500 nm; 25 J/cm2) during 15 minutes (6 fractions of 2.5 minutes separated by 5 pauses of 2 minutes each to improve tissue oxygenation for the PDT reaction). An IPC device (but no talc) will be inserted and used for pleurodesis and may permit to collect further pleural effusion samples. As 5-ALA has a short half-life and thus does not need extensive precautions to avoid patient photosensitivity, the patient would not stay longer than a standard procedure (about 2-3 days in the hospital)
41310803|NCT04400539|DRUG|Nivolumab Injection|Seven to 10 days after VATS, patients will start to be treated by Nivolumab 240mg IV every 2 weeks till progression (CT-scan reassessment every 8 cycles), unacceptable toxicity, or maximum 2 years.
40999201|NCT06255535|DEVICE|sham iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.
41150013|NCT00647452|BEHAVIORAL|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
41310804|NCT03893773|DEVICE|doppler ultrasonagraphy|"The following parameters will be measured:~Hepatic artery Resistance index (HARI), Diameter, peak systolic velocity (HAPSV, cm/s).~Portal vein peak velocity (PVPV) and diameter at the anastomotic and non-anastomotic sites.~Hepatic vein peak velocity and wave form"
41310805|NCT00066625|DRUG|oxaliplatin|Given IV
41310806|NCT00066625|DRUG|bortezomib|Given IV
41310807|NCT00066625|OTHER|laboratory biomarker analysis|Correlative studies
41310808|NCT00066625|OTHER|pharmacological study|Correlative studies
41310809|NCT05097053|BIOLOGICAL|MVC-COV1901(3 Months)|MVC-COV1901 vaccine after a 3-month Interval
41470005|NCT00255151|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
41470006|NCT00255151|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
41470007|NCT05462353|DRUG|2mg of ASC41|ASC41 tablet administered orally once daily.
41470008|NCT05462353|DRUG|4mg of ASC41 (2 tablets of 2 mg ASC41)|ASC41 tablets administered orally once daily.
41470009|NCT05462353|DRUG|Placebo|Placebo tablets administered orally once daily.
41470010|NCT05057793|DEVICE|geko|The geko device will be self-administered and deliver 12 hours of therapy daily.
41470011|NCT00387517|DRUG|Aliskiren/HCTZ|
41470012|NCT01740791|DRUG|Velpatasvir|Tablets administered orally
41310810|NCT05097053|BIOLOGICAL|MVC-COV1901(6 Months)|MVC-COV1901 vaccine after a 6-month Interval
41310811|NCT05120960|DRUG|tepotinib|Given by PO
41310812|NCT05120960|DRUG|tepotinib plus osimertinib|Given by PO
41310813|NCT01734486|DRUG|somatropin|0.9 UI/kg/week. Subcutaneous injection for 3 years
41310814|NCT01734486|DRUG|somatropin|1.8 UI/kg/week. Subcutaneous injection for 3 years
41310815|NCT03329040|OTHER|No Intervention.|No intervention.
41310816|NCT04507438|DRUG|Donepezil 5-10 Mg Oral Tablet|Donepezil 5mg or 10mg oral tablet administered daily for an 8 week period
41310817|NCT04507438|DRUG|Placebo Oral Tablet|Placebo oral tablet administered daily for an 8 week period
41310818|NCT05199350|OTHER|Device Name: ANSiscope|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
41310819|NCT04264455|DEVICE|Biomonitor|Patients receive a Biomonitor only
41310820|NCT04264455|DEVICE|Life Vest|Patients receive a Wearable Cardioverter-Defibrillator; a Biomonitor is implanted additionally
41470013|NCT01740791|DRUG|Placebo|Tablets administered orally
41310821|NCT04264455|DEVICE|Implantable Cardioverter-Defibrillator (ICD)|Patients receive an Implantable Cardioverter-Defibrillator (ICD)
41470014|NCT02390310|DEVICE|Shang Ring|Comparison of healing times at 7 day and more than 7 days after circumcision.
41470015|NCT02390310|DRUG|injectable anesthesia (lidocaine 1%)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
41470016|NCT02390310|DRUG|topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
41470017|NCT05382156|DRUG|Osilodrostat|oral administration of Osilodrostat tablets at different doses according to patient's need
41470018|NCT03655119|BEHAVIORAL|Parent toolkit|The parent tookit is a resource that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth.
41470019|NCT03655119|BEHAVIORAL|Enhanced Care|PES clinical staff will receive training on the best practices in brief crisis-focused interventions in emergency settings with parents and youth.
41470020|NCT03655119|BEHAVIORAL|Caring Follow-Up Messages|Parents will receive caring contacts via phone, text, or email to provide support, additional education, and problem solving assistance in the days and weeks post-discharge.
41470021|NCT02973581|DRUG|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
41470022|NCT02973581|DRUG|Acetaminophen|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
41310822|NCT02020096|PROCEDURE|Ultrasound and nerve stimulator guided lumbar plexus block|An insulated nerve block needle connected to a nerve stimulator that was delivering a current of 1.5 mA at a frequency of 2 Hz was then inserted in the long axis (in- plane) of the ultrasound transducer towards the the hypoechoic psoas compartment. If the quadriceps contraction which produces patella twitching was elicited with an initial current of 1.5mA,then the current should be reduced until contraction is still present between 0.3 to 0.5 mA .Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
41310823|NCT02020096|PROCEDURE|Nerve stimulator guided lumbar plexus block|The block was conducted following traditional Winnie approach. The accepted end point for the lumbar plexus is stimulation of the femoral nerve component, observed by contraction of the quadriceps muscle. Quadriceps contraction which produces patella twitching should be sought with an initial current of 1.5mA, and once elicited the current should be reduced until contraction is still present between 0.3 to 0.5 mA. Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
40999202|NCT04027738|OTHER|PRP|The patients received a single 3-ml injection of PRP. Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes. The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
41310824|NCT02144454|DIETARY_SUPPLEMENT|Saturated fat|
40999203|NCT04019743|DRUG|CKD-330 16/10mg Tab. 1T and D086 Tab. 1T|single oral administration under fasting condition
40999204|NCT04019743|DRUG|CKD-333 16/10/40mg formulation 1 Tab. 1T|single oral administration under fasting condition
40999205|NCT04019743|DRUG|CKD-333 16/10/40mg formulation 2 Tab. 1T|single oral administration under fasting condition
40999206|NCT03690388|DRUG|Cabozantinib|Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
40999207|NCT03690388|DRUG|Placebo|Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
40999208|NCT00311337|DRUG|bortezomib|
40999209|NCT02746562|PROCEDURE|Freeze all|Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle
40999210|NCT01417481|DIETARY_SUPPLEMENT|Glycine|Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
40999211|NCT01417481|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
40999212|NCT02871739|BEHAVIORAL|Webinar|1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.
41150014|NCT04650919|PROCEDURE|Total laryngectomy and reconstruction by stented aortic allograft (using human tissue and device).|"The procedure consists of 2 operating times:~* Surgery S1 (1st surgical procedure): total laryngectomy and placement of the stented aortic graft (human tissue + device: NOVATECH GSS TM (trademark) TD), under tracheotomy cover.~* Surgery S2 (2nd surgical procedure) (between S1 +24 weeks and S1 +36 weeks) : opening of the proximal part of the graft by endoscopic way with maintenance of the tracheotomy orifice to ensure patient safety."
41470023|NCT02973581|DRUG|0,5 % bupivacaine with of 2% lidocaine|in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
40999213|NCT02871739|BEHAVIORAL|DA viewing|Participants will receive 3 decisions aids to review.
40999214|NCT02871739|BEHAVIORAL|SPI feedback|Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction
41150015|NCT04321096|DRUG|Camostat Mesilate|Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2
41150016|NCT04321096|DRUG|Placebo oral tablet|Placebo
41150017|NCT03258905|BEHAVIORAL|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
41150018|NCT03258905|BEHAVIORAL|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
41150019|NCT06417229|DRUG|BMS-986365|Specified dose on specified days
41310825|NCT02144454|DIETARY_SUPPLEMENT|Monounsaturated fat|
41310826|NCT02144454|DIETARY_SUPPLEMENT|n-6 polyunsaturated fat|
41310827|NCT00189241|DRUG|imiquimod|
41470024|NCT02973581|DRUG|Proxymetacaine|in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
40999215|NCT05411822|DEVICE|Lighting Intervention Blue light|Custom made lighting fixture that will deliver the blue lighting intervention
40999216|NCT05411822|DEVICE|Lighting Intervention Green light|Custom made lighting fixture that will deliver the green lighting intervention
40999217|NCT02888548|PROCEDURE|botulinum toxins (Dysport°) alone|botulinum toxins (Dysport°) alone
40999218|NCT02888548|PROCEDURE|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
40999219|NCT04963582|PROCEDURE|Acupuncture|LI4 is located on the dorsum of the hand, midway between the 1st and 2nd metacarpal bones, approximately in the middle of the 2nd metacarpal bone on the radial side. Acupuncture is practiced by using 0,25x25mm sized needles. LI4 point is punctured perpendicularly 2cm in the direction of the palm center.
40999220|NCT01132495|OTHER|Stenting plus OMT|FFR guided PCI, plus OMT
40999221|NCT01132495|OTHER|OMT|OMT alone
40999222|NCT01132495|OTHER|Standard of care|FFR \> 0.80; treatment according to local practice
40999223|NCT02389504|OTHER|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
40999224|NCT02389504|OTHER|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
40999225|NCT02149342|DRUG|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
41150020|NCT06417229|DRUG|Rabeprazole|Specified dose on specified days
41470025|NCT01311427|BEHAVIORAL|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
41470026|NCT01311427|BEHAVIORAL|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
41470027|NCT05488886|DIETARY_SUPPLEMENT|Whole Aronia Berry Powder Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce A will additionally contain whole aronia berry powder (Milne MicroDried, Nampa, ID).
41470028|NCT05488886|DIETARY_SUPPLEMENT|Aronia Berry Extract Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce B will additionally contain aronia berry extract (Artemis International, Fort Wayne, IN).
41470029|NCT05488886|DIETARY_SUPPLEMENT|Phospholipid-Polyphenol Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce C will additionally contain PLP which will be prepared with commercially-available aronia juice concentrate (Greenwood Associates, Niles, IL) and soy lecithin (Whole Foods, Austin, TX).
41470030|NCT05488886|OTHER|Low-Polyphenol Control Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce D will not contain additional polyphenol-rich ingredients and is thus considered a low-polyphenol control.
40793363|NCT00188617|DRUG|GEFITINIB|250 mg once a day for 28 days before surgery
40999226|NCT02149342|DRUG|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
40999227|NCT01556529|PROCEDURE|risk profile information|(1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
41150021|NCT02173561|BEHAVIORAL|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only version (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT-C is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted in groups of 8-12 participants. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
41150022|NCT02173561|BEHAVIORAL|Individual Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for six weeks; each session is 60 minutes.
41310828|NCT03021291|DEVICE|Gelesis100 (2.25 g)|Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
41310829|NCT01912716|DRUG|high dose indomethacin|patients randomized to this intervention receive 200mg indomethacin
41310830|NCT01912716|DRUG|standard dose indomethacin|patients randomized to this intervention receive 100mg indomethacin
41310831|NCT04435145|BEHAVIORAL|Sugar-sweetened beverage warning label|A sugar-sweetened beverage warning label appropriate for the college-aged population was developed and applied to beverage stations at one large campus dining hall
41310832|NCT01734980|PROCEDURE|Endobronchial Ultrasound|The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
41310833|NCT05176431|DEVICE|ESWT (wave type: focused)|Extracorporeal Shock Wave Therapy, device: Electronica, Pagani, Italy
41310834|NCT05176431|DEVICE|ESWT (wave type: radial)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
40999228|NCT01556529|PROCEDURE|standard DMP care|standard disease management of T2DM care
40999229|NCT01556529|PROCEDURE|standard DMP care|standard disease management of T2DM care
40999230|NCT04529889|OTHER||
40999231|NCT02134873|OTHER|sucrose|Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
40999232|NCT01274624|BIOLOGICAL|REOLYSIN®|1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.
40999233|NCT01274624|DRUG|Irinotecan|90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.
40999234|NCT01274624|DRUG|Leucovorin|2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
40999235|NCT01274624|DRUG|Fluorouracil (5-FU)|400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
40999236|NCT01274624|DRUG|Bevacizumab|30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.
40999237|NCT06330922|OTHER|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be performed two times a week for one hour in small groups (4-5 people). The training will be conducted outdoors at track and field facilities with at least two coaches.
40999238|NCT05680922|BIOLOGICAL|LB2102|DLL3 directed autologous Chimeric Antigen Receptor T-cells
41310835|NCT05176431|DEVICE|ESWT (wave type: sham)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
41310836|NCT05801809|DEVICE|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
41310837|NCT06226246|BEHAVIORAL|HEROS VR CPR training program|HEROS VR training program which combined video training and VR session
40999239|NCT05145829|DIAGNOSTIC_TEST|Diagnostic Test: Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
40999240|NCT00665184|BEHAVIORAL|Resistance Exercise via Negative Eccentric Work|High intensity resistance training delivered 2-3 times per week for 12 weeks
40999241|NCT00665184|BEHAVIORAL|Standard care exercise training|Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
40999242|NCT03595878|RADIATION|Parotid sparing WBRT|Whole Brain Radiation Therapy with avoidance of the parotid glands
41310838|NCT06226246|BEHAVIORAL|Conventional HEROS CPR training program|Conventional HEROS training program using video learning
41310839|NCT04910763|BEHAVIORAL|Resistance Exercise|Increasing strength and fitness and thereby influencing hormones and perceptions involved in appetite regulation.
40999243|NCT03595878|RADIATION|Standard WBRT|Standard Whole Brain Radiation Therapy
41310840|NCT04524286|OTHER|Interviews only.|Interviews will be conducted with childbearing women and midwives.
41310841|NCT06383351|OTHER|Questionnaire|"Two sets of questionnaires will be administered to patients:~* Questionnaire about their perception of peri-implant disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire."
41310842|NCT06552442|DRUG|Methylprednisolone|High-dose intracoronary glucocorticoid methylprednisolone to abrogate no-reflow: a unique study for restoration of infarct-related artery patency and reduction of ischemia-reperfusion injury
41310843|NCT01600183|DEVICE|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
41310844|NCT01600183|PROCEDURE|cast|casting of the infant legs
41310845|NCT05519046|DEVICE|Cardiac Contractility Modulation (CCM)|Cardiac Contractility Modulation (CCM) implantation
41470031|NCT05719337|DEVICE|Echocardiography|Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
41470032|NCT06071195|DIAGNOSTIC_TEST|Prostate Cancer Patients|see arm/group description
41470033|NCT05021237|RADIATION|Ultra-fractionated radiation therapy|Patients enrolled in this study are planned to receive systemic therapy. Imaging based Ultra-fractionated radiation therapy using a PULSAR technique, which is 5 pulses to gross tumor in pelvis.
41470034|NCT02512055|DRUG|Ketamine|Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions
40999244|NCT06195397|OTHER|Evidence-Based Education intervention|A total of 12 hours of Evidence-Based Education intervention was applied to students in the intervention group, spread over 7 sessions.
41310846|NCT05519046|DEVICE|CRT|Cardiac Resynchronization Therapy
41310847|NCT01398033|DEVICE|paclitaxel-coated balloon|Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
41310848|NCT01398033|DEVICE|non-coated balloon|percutaneous transluminal angioplasty with a non-coated balloon
40999245|NCT02829593|OTHER|hypoglycemia (low blood sugar) and MRI|hypoglycemia (low blood sugar) and MRI
40999246|NCT00891358|BEHAVIORAL|Prevention Empowerment Intervention for Young Women|"Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs."
40999247|NCT00813358|DEVICE|Zenith TX2® TAA Endovascular Graft|Endovascular treatment with the study device
40999248|NCT03756610|DEVICE|Active tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.
40999249|NCT03756610|DEVICE|Sham tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 sham tACS sessions.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
41150023|NCT02577315|DRUG|Empagliflozin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
41150024|NCT02577315|DRUG|Metformin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
41310849|NCT04889534|PROCEDURE|Analgesia|Patients will be observed during postoperative period,
41470035|NCT04395599|OTHER|Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.|Air sampling, operating room surfaces sampling and patients' biological fluid sampling for Sars-Cov2 quantification
41470036|NCT01713088|OTHER|Multisystemic therapy|
41470037|NCT01713088|OTHER|YOT (usual services)|
41470038|NCT06615999|PROCEDURE|Simple fracture Tension band wiring|OPS 5-793.27
41470039|NCT06615999|PROCEDURE|Simple fracture locked plate fixation|OPS 5-793.k7
41470040|NCT06615999|PROCEDURE|Multi-fragmented tension band wiring|OPS 5-794.17
41470041|NCT06615999|PROCEDURE|Multi-fragmented locked plate fixation|OPS 5-794.k7
40999250|NCT03756610|DEVICE|Active boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of active tACS.The active boosting group will be stimulated with a 2 mA current for 20 minutes.
40999251|NCT03756610|DEVICE|Sham boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
41310850|NCT02309164|PROCEDURE|Acupuncture|10 acupuncture sessions of 30 minutes each, twice a week
41310851|NCT02309164|BEHAVIORAL|Orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
41310852|NCT03496467|COMBINATION_PRODUCT|Nepafenac PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that contains nepafenac, a nonsteroidal anti-inflammatory drug.
41310853|NCT03496467|COMBINATION_PRODUCT|Placebo PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that does not contain nepafenac.
41310854|NCT01824264|DRUG|LIK066|Experimental treatment doses
41310855|NCT01824264|DRUG|Sitagliptin|Active comparator treatment dose
41310856|NCT01824264|DRUG|Placebo|Placebo comparator dose
41310857|NCT01290133|DRUG|GW597599|Single dose IV infusion
41310858|NCT01290133|DRUG|Placebo|Single dose IV infusion
41470042|NCT04726189|OTHER|Standard exercises|Consists of a a standard exercise program with range of motion exercises from the third week and elastic band exercise from the sixth week.
40793364|NCT02021786|BEHAVIORAL|Mobile phone based intervention|Parents in the intervention group receive a six month mHealth program (the MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet and physical activity behaviors. The program includes information, advice, and strategies to change unhealty behaviours and the possibility to register the child's intake of fruits, vegetables, candy, sweetened beverages, moderate-to-vigorous physical activity, and sedentary time. Feedback is then provided on reported variables. In addition, the parents are able to ask questions through the app to a dietician and a psychologist.
40793365|NCT05432830|OTHER|E-liquid Flavor 1|E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.
40999252|NCT01666756|DIETARY_SUPPLEMENT|Chinese herbal formulation PHY906|Given PO
40793366|NCT05432830|OTHER|E-liquid Flavor 2|E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.
41310859|NCT04889573|GENETIC|Blood sample|The blood samples will be collected from healthy volunteers : 7 tubes of 7 ml with anti-coagulant Héparine Lithium and 1 tube of 7ml with anti-coagulant EDTA
41310860|NCT00001019|BIOLOGICAL|rgp120/HIV-1 SF-2|
41310861|NCT00001019|BIOLOGICAL|MTP-PE/MF59|
40793367|NCT05432830|OTHER|E-liquid Flavor 3|E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.
40999253|NCT01666756|DRUG|sorafenib tosylate|Given PO
40999254|NCT01666756|OTHER|laboratory biomarker analysis|Correlative studies
40999255|NCT01666756|OTHER|pharmacological study|Correlative studies
41310862|NCT05804409|DIAGNOSTIC_TEST|FECAL ELASTASE|screening for pancreatic exocrine insufficiency in MAFLD patients
41310863|NCT03577912|PROCEDURE|TAP block administered by Surgery|TAP block administered by Surgery
41470043|NCT04726189|OTHER|Standard exercises plus Early progressive exercises|This exercise program consists of standard exercises plus the early progressive program that initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration. Exercises are isometric exercises from the second week and then gradually progression of load in seated heel-rise and resistance band exercises.
40793368|NCT03635632|GENETIC|C7R-GD2.CART cells|"Active dose levels:~C7R-GD2.CART cell without lymphodepletion (Arm A or Arm B)~Dose Level 2b = 3 x 10\^7 on day 0 and day 7~Dose Level 3b = 1 x 10\^8 on day 0 and day 7.~Day 7 dose (+- 2 days) will be omitted if patients have persistent CRS (Grade 2 or higher) experienced a DLT or for other clinical concerns at the discretion of the PI."
40793369|NCT06525688|OTHER|Bone, Serum and Plasma sample|Intervention: Bone samples will be collected during surgery from the femoral neck (which is typically removed and discarded in these operations) and fasting morning blood samples.
40793370|NCT01063348|DRUG|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
40999256|NCT01453842|DIETARY_SUPPLEMENT|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
40999257|NCT01453842|DIETARY_SUPPLEMENT|Olive oil|Carrot and olive oil and 1½ g of paracetamol
40999258|NCT01453842|DIETARY_SUPPLEMENT|Carrot|Carrot and 1½ g of paracetamol
41150025|NCT02577315|DRUG|Empagliflozin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
41310864|NCT03577912|PROCEDURE|TAP block administered by Anesthesia|TAP block administered by Anesthesia
41470044|NCT05735626|COMBINATION_PRODUCT|Piperine 150μM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 150μM + tDCS 2mA (cross-over randomized study).
40793371|NCT01063348|DRUG|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
41310865|NCT03257930|DRUG|ethanol injection|inject ethanol in cystic thyroid nodule and follow up until complete recovery
41310866|NCT03684291|PROCEDURE|Mode of Mechanical Ventilation|Adjustment of mechanical ventilation mode
41310867|NCT03085706|BIOLOGICAL|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
41310868|NCT04405505|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
41310869|NCT04405505|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
41470045|NCT05735626|COMBINATION_PRODUCT|Piperine 1mM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 1mM + tDCS 2mA (cross-over randomized study).
41470046|NCT05735626|COMBINATION_PRODUCT|Capsaicin 10μM + tDCS 2mA|2 days treatment with either sham + placebo or capsaicin 10μM + tDCS 2mA (cross-over randomized study).
41470047|NCT03224078|OTHER|data extraction|No Special interventions except from data extraction form the respective routine data sources are planned .
41310870|NCT04405505|DRUG|Paclitaxel for Injection (albumin bound)|a anti-microtubule drug.
41310871|NCT01562704|DRUG|Paracetamol (drug)|The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
41310872|NCT02470052|DEVICE|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
41310873|NCT00745186|DRUG|Glucagen|0.2 mg or 1 mg Glucagen single injection
41470048|NCT06470334|DRUG|Ropivacaine|Ultrasound-guided PENG block - 20ml 0,2% ropivacaine
41470049|NCT06470334|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone
41470050|NCT00001842|DRUG|Granulocyte colony-stimulating factor|
41470051|NCT00001842|DRUG|Dexamethasone|
41310874|NCT00745186|DRUG|Mayne Glucagon|0.2 mg or 1 mg Mayne Glucagon
41470052|NCT01901172|DRUG|RO5503781|Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
41470053|NCT01901172|DRUG|RO5503781|Daily for 5 days followed by 23 days rest per cycle
41470054|NCT01901172|DRUG|RO5503781|Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
41470055|NCT01901172|DRUG|RO5503781|Single doses Days 1 and 11
41470056|NCT01901172|DRUG|posaconazole|Multiple doses Days 8-14
41470057|NCT03645382|DIETARY_SUPPLEMENT|baked barley powder|The baked barley was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The baked barley powder capsule had approximately 900 mg/day, 336 mg of baked barley and 564 mg of nondigestible maltodextrin.
41470058|NCT03645382|DIETARY_SUPPLEMENT|jeju steam onion|The jeju steam onion was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The jeju steam onion capsule had approximately 900 mg/day, 336 mg of jeju steam onion powder and 564 mg of nondigestible maltodextrin.
41470059|NCT03363698|OTHER|Cough variant asthma treatment|Evaluation of the treatment response to inhaled corticosteroids, long-acting beta-agonists, montelukast, prednisone.
41470060|NCT02374203|DIETARY_SUPPLEMENT|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
41470061|NCT03868826|PROCEDURE|Orthopaedic surgery and/or rehabilitation|The avulsion is repaired and hereafter the patient follows rehabilitation. Some are treated conservatively and only follow rehabilitation.
40793372|NCT00002493|DRUG|cisplatin|
40793373|NCT00002493|DRUG|doxorubicin hydrochloride|
40793374|NCT00002493|RADIATION|low-LET photon therapy|
40793375|NCT03276728|DRUG|AMG 986 IV|AMG 986 solution for infusion
41310875|NCT00042250|DRUG|Chemotherapy for hematologic malignancy|
41310876|NCT00004816|DRUG|monoclonal antibody M-T412|
40793376|NCT03276728|DRUG|AMG 986 PO|AMG 986 tablets for oral (PO) administration
40793377|NCT03276728|DRUG|Placebo PO|Matching placebo tablets for oral administration
41310877|NCT05580471|DEVICE|Use 4DryField|Patients randomly use 4DryField in Colorectal resection combined with temporary stomy before fascia closure. We observed the adhesion severity and adhesion extent when stomy closure.
41310878|NCT02998060|PROCEDURE|Pedicle Screw Placement|As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
41310879|NCT02998060|DEVICE|SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)|This robot will be used to guide pedicle screws into their trajectories.
41470062|NCT04766216|OTHER|Patient self-management|Patient makes independent decisions regarding warfarin therapy changes using warfarin dosing tools
41470063|NCT04766216|OTHER|Usual care provided by anticoagulation providers|Normal care provided by anticoagulation providers
41470064|NCT03144479|PROCEDURE|right-sided double lumen tube|Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
41470065|NCT05188924|DRUG|DKF-306|Active ingredients
41470066|NCT05188924|DRUG|Placebo|Placebo
41470067|NCT01368302|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
41470068|NCT03211039|GENETIC|Genomic sequencing and molecular diagnostic results, if any.|Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
41470069|NCT03098186|BEHAVIORAL|Intervention SMS|The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
41470070|NCT03098186|BEHAVIORAL|Control SMS|Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
41470071|NCT00687882|OTHER|Shortened duration (6 weeks) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.
41310880|NCT02998060|DEVICE|3D C-Arm (Ziehm Imaging, Nuremberg, Germany)|This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
41310881|NCT03247205|BEHAVIORAL|HipERS|This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
41310882|NCT01363557|OTHER|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
41310883|NCT01363557|DRUG|Gefitinib (IRESSA)|250 mg/day
41310884|NCT04876599|BEHAVIORAL|IN FOCUS|Adapted Resiliency Group Intervention
41310885|NCT04876599|BEHAVIORAL|Usual Care|Referral to Virtual Group Support
41310886|NCT05027529|DEVICE|CytoSorb|An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit
41310887|NCT05027529|OTHER|VA-ECMO only|only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added
41310888|NCT01665755|DEVICE|Upstroke Compression Defibrillation|
41310889|NCT01665755|DEVICE|Precompression Defibrillation|
40999259|NCT06443762|DRUG|[68Ga] MDM2/MDMX Peptide|"Utilizing a peptide with high affinity to MDM2/MDMX as the targeting moiety for radiopharmaceuticals, this study explores the diagnostic efficacy of \[68Ga\] MDM2/MDMX Peptide in patients with malignant tumors exhibiting high MDM2/MDMX expression. This approach not only provides a basis for the early diagnosis of malignant tumors but also facilitates the formulation of effective precision therapy strategies tailored to the tumor's MDM2/MDMX expression profile, particularly for patients with recurrent and metastatic disease.~\[68Ga\] MDM2/MDMX Peptide, a novel MDM2/MDMX-targeted molecular probe labeled with 68Ga, utilizes DOTA as a bifunctional chelator for complexing with 68Ga3+. The labeling process is straightforward, allowing for direct use without purification, and demonstrates high in vivo stability."
40999260|NCT04262895|DRUG|TTI-0102|TTI-0102 is a cysteamine precursor.
41310890|NCT06216938|BIOLOGICAL|Vusolimogene oderparepvec (RP1)|Vusolimogene Oderparepvec is a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities.
41310891|NCT03056976|DEVICE|Single-implant mandibular overdenture|Complete mandibular denture retained by a single midline implant
41310892|NCT03056976|DEVICE|Two-implant mandibular overdenture|Complete mandibular denture retained by two implants in the canine region
41310893|NCT03056976|DEVICE|Fixed mandibular denture|A fixed mandibular denture retained by four implants
41310894|NCT01052987|DRUG|Tranilast|Tranilast tablets, 300 mg, QD
41310895|NCT01052987|DRUG|Allopurinol|Allopurinol tablets 300 mg, QD
41310896|NCT01052987|DRUG|Combination - Tranilast and Allopurinol|Tranilast, 300 mg QD; Allopurinol 300 mg QD
41310897|NCT01052987|DRUG|400 mg Allopurinol|400 mg Allopurinol administered once daily for 7 days
40793378|NCT03276728|DRUG|Placebo IV|Matching placebo solution for infusion
40793379|NCT02103127|DEVICE|755nm Alexandrite laser with lens array|
40999261|NCT04262895|DRUG|Placebo|Placebo
40999262|NCT04076969|BEHAVIORAL|Integrated educational session|The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.
41150026|NCT02577315|DRUG|Metformin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
41310898|NCT01052987|DRUG|High dose combination|Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
40793380|NCT02720523|DRUG|Placebo|Tablet; Oral
40793381|NCT02720523|DRUG|Upadacitinib|Tablet; Oral
40793382|NCT00524888|PROCEDURE|suturing laceration|suturing simple lacerations of the hand
40793383|NCT00524888|PROCEDURE|bioadhesive|using bioadhesive on simple lacerations of the hand
40793384|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
40793385|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
41310899|NCT05619562|DIAGNOSTIC_TEST|Device for CTC/DTC detection|The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.
41310900|NCT00239837|BEHAVIORAL|Middle School Success Intervention (MSS)|This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
41310901|NCT00207259|BEHAVIORAL|Reiki & Relaxation Response Therapy with Cognitive Restructuring|"Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.~Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant."
41310902|NCT00804739|OTHER|Mother-Infant Treatment Team|This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
41310903|NCT01449682|DRUG|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
41310904|NCT01449682|DRUG|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
41310905|NCT04538911|DRUG|BCG-PPD|BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)
41310906|NCT04703322|DRUG|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
41310907|NCT00206895|PROCEDURE|Photodynamic therapy|
41310908|NCT04905199|PROCEDURE|Temporary transvenous cardiac pacing|Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.
41310909|NCT02239770|DRUG|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
40999263|NCT06304142|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
40999264|NCT06304142|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41310910|NCT02239770|DRUG|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
41310911|NCT04937816|DRUG|Placebo|Placebo
41310912|NCT04937816|DRUG|Empagliflozin|Empagliflozin once daily
41310913|NCT00209521|DRUG|fospropofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
41310914|NCT00209521|DRUG|propofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
41310915|NCT01533935|DRUG|Placebo|placebo matching tiotropium + olodaterol
41310916|NCT01533935|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
41310917|NCT01533935|DRUG|tiotropium + Olodaterol|tiotropium 5 mcg + olodaterol 5 mcg once daily
40793386|NCT01530529|DRUG|PF-05180999|Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
40999265|NCT06304142|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
40999266|NCT02179996|BIOLOGICAL|Three vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections at two, three, four months after birth
40999267|NCT02179996|BIOLOGICAL|Two vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections are administered at two and four months after birth
40999268|NCT05771181|DRUG|Vitamin E|Vitamin E: 400mg (QD), oral, once daily, continued until disease progression or intolerable toxicity.
40999269|NCT05771181|DRUG|Fruquintinib|Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
40999270|NCT05771181|DRUG|Tislelizumab|Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
41310918|NCT01533935|DRUG|Tiotropium|tiotropium
41310919|NCT01533935|DRUG|Olodaterol|Olodaterol 5 mcg once daily
41310920|NCT01533935|DEVICE|Respimat|Respimat inhaler
41310921|NCT01977079|OTHER|procalcitonin|
41310922|NCT04631120|OTHER|Integrated Dementia Practice Unit Design|"* Dementia Central: monthly review of participant progress~* Dementia Mobile: monthly nurse/lay health educator visits for assessments, education and coaching~* Dementia Link: communication between Dementia Central and Dementia Mobile using the eTransX mHealth platform and HealthStream educational interface for care providers and the patient/caregiver dyad."
41310923|NCT04631120|OTHER|Standard of Care|Standard clinical practices of the physician and institution including an initial assessment, Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard patient- and caregiver-centered educational material. Two phone sessions with a study nurse post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment.
41310924|NCT02713191|DRUG|Dexmedetomidine|Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
41310925|NCT02713191|DRUG|Midazolam bolus|Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
41310926|NCT02713191|OTHER|Saline placebo|100 mL saline infusion over 10-15 minutes immediately prior to procedure
41310927|NCT02713191|DRUG|Rescue midazolam|Rescue boluses of 0.5 mg midazolam, if needed during procedure
41310928|NCT02713191|DRUG|Fentanyl|1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
41310929|NCT01672437|OTHER|Birth and parent preparation|4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
40793387|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
40793388|NCT05703425|DRUG|Sulfasalazine|Sulfasalazine will be administered between 24 and 36 weeks of pregnancy
41310930|NCT02822911|BEHAVIORAL|Alcohol Used Disorders Identification Test (AUDIT C)|"The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women."
41310931|NCT02822911|PROCEDURE|Carbohydrate deficient transferrin|Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
41310932|NCT02822911|PROCEDURE|Gamma glutamyl transpeptidase|Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
41310933|NCT02822911|PROCEDURE|Mean Corpuscular Volume|Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
41310934|NCT01879176|DEVICE|CytoSorb|
41310935|NCT01829802|DRUG|Ritonavir boosted Atazanavir|Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
41310936|NCT01829802|DRUG|Raltegravir|Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
41310937|NCT01829802|DRUG|TDF/FTC (or 3TC)|Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
41310938|NCT04136080|OTHER|vasopressors|control the mean arterial pressure with vasopressors
41310939|NCT01337063|OTHER|Mentored medication reconciliation quality improvement|"Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls."
41310940|NCT02370355|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood samples
41310941|NCT02370355|OTHER|Laboratory Biomarker Analysis|Correlative studies
41310942|NCT03532984|DIAGNOSTIC_TEST|Beam test to predict falls|Dynamic balance will be determined in all participants during beam walking. The beams are 4m long, 2cm high, and 4, 8, and 12cm wide. After a practice trial, participants will perform three trials on each width with and without a calculation task. Trials will be block-randomized based on beam width then on task. Instructions: 'Traverse the entire length of the beam safely at your preferred speed without stepping off, facing forward, with your arms folded in front of your chest. Trials end when you step off, walk sideways, or unfold the arms.' Outcomes are the sum of length traversed, average velocity, number of steps, and average step length determined from video recordings made at 90° relative to the walking direction with full beam length in view using off-the-shelf video cameras.
40999271|NCT01986868|OTHER|Coronary MR Angiography (CMRA)|Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.
40999272|NCT03606525|PROCEDURE|subarachnoid block|Vertebral column length and abdominal girth will be measured before routine subarachnoid block is given to recruited patients
41310943|NCT00805545|DRUG|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
41310944|NCT00805545|DRUG|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
41310945|NCT02709473|DRUG|Propofol|Propofol will be used in either two arms. The injection sequence will be changed. In propofol arm of the study, general anesthesia will be started with 2 mg/kg propofol administered within 15 seconds. And, then remifentanil will be given. In remifentanil arm of the study, 2 mg/kg propofol will be applied within 15 seconds following remifentanil injection.
41310946|NCT02709473|DRUG|Remifentanil|Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
41310947|NCT02709473|DRUG|Rocuronium|Rocuronium will be used for either two study arms. Rocuronium will be given in a 0.8 mg/kg dosage in the first study subject. And then, if the intubation condition is acceptable, the dose of the rocuronium will be decreased by 0.1 mg/kg for the next patient. Otherwise, if the intubation condition is not acceptable, the rocuronium dosage will be increased by 0.1 mg/kg for the next patient. This will be continue for ten crossover points (the point that turn from unsuccessful intubation to successful intubation).
41310948|NCT02056535|BEHAVIORAL|Brief Motivational Intervention|A short discussion is held with patients identifying pros and cons of their drinking, readiness for change is assessed, and a brief prescription drawn for behavior change signed by the patient.
41310949|NCT05384158|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy
41310950|NCT05384158|BEHAVIORAL|valuation with instruction|repeat laboratory sessions of computerized learning game
41310951|NCT05384158|BEHAVIORAL|valuation without instruction|repeat laboratory sessions of computerized learning game
41310952|NCT01211964|DRUG|LEO 22811|Oral administration of solution and tablet.
40793389|NCT03436498|DRUG|Insulin aspart SAR341402|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
40793390|NCT03436498|DRUG|Insulin aspart|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
40793391|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
40999273|NCT00175890|DRUG|Levetiracetam|Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
40999274|NCT00175890|OTHER|Placebo|Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
40999275|NCT05445765|BIOLOGICAL|anti-CD33 CAR T cells|Anti-CD33 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
41310953|NCT01157052|OTHER|(supplement) Calcium and Magnesium|"FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.~XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.~Ca2+/Mg2: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 1 (Arm A) or cycle 2 (Arm B)"
41310954|NCT01498081|DRUG|AZD2115|AZD2115 administered via inhalation
41310955|NCT01498081|DRUG|Placebo|Placebo administered via inhalation
41310956|NCT01498081|DRUG|Indacaterol|Indacaterol administered via inhalation
41310957|NCT01498081|DRUG|Indacaterol + Tiotropium|Indacaterol + Tiotropium administered inhalation
41310958|NCT02850991|RADIATION|High-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
41310959|NCT02850991|RADIATION|Standard-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
41310960|NCT05120934|DRUG|Amitriptyline 25 MG|25 mg orally for 4 weeks
41310961|NCT05120934|DRUG|Amitriptyline 50 MG|50 mg orally for 4 weeks
41310962|NCT05120934|DRUG|Duloxetine 30 MG|30mg orally for 4 weeks
41310963|NCT05120934|DRUG|Duloxetine 60 MG|60mg orally for 4 weeks
41310964|NCT05120934|DRUG|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
41310965|NCT05120934|DRUG|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
41310966|NCT06183164|OTHER|Mindfulness: Awareness-Based Stress Reduction Program|The mindfulness-based stress reduction program was applied to the patients in the experimental group once a week, for 150 minutes, for 8 weeks and 8 times in total. Then, an intermediate test is applied to the patients. After the interim test, patients are asked to repeat the mindfulness-based stress reduction program individually for 8 weeks (between weeks 8-16). In addition, after the conscious awareness-based stress reduction program is applied to the patients in the experimental group by the researcher, the 'Conscious Awareness-Based Stress Reduction Program' booklet prepared by the researcher is given to the patients as a guide. experimental group.
41310967|NCT05236881|DEVICE|ANíMATE mobile application|mHealth tool ANíMATE (Adherence, Nutrition, PhysIcal Activity, Motivation, medicAtion, Technology and Empowerment) allows the recording of data related to diet and exercise and feedback on behavior through an intelligent data analysis system.
41310968|NCT00683475|BIOLOGICAL|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
41310969|NCT00683475|DRUG|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m\^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m\^2) or until there is evidence of disease progression, death, or intolerable toxicity.
41470072|NCT00687882|OTHER|Conventional duration (3 months) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.
41310970|NCT00683475|DRUG|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
41310971|NCT00683475|BIOLOGICAL|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
41310972|NCT06152250|OTHER|Liver Fine-Needle Aspiration|"At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy."
41310973|NCT04099732|DRUG|Rosuvastatin|Tablet
41310974|NCT04099732|DRUG|BI 1358894|Tablet
41310975|NCT04099732|DEVICE|Dabigatran etexilate|Capsule
41310976|NCT00568880|DRUG|bortezomib|bortezomib 1.0-1.3mg/m2 IV
41310977|NCT00568880|DRUG|hydroxychloroquine|hydroxychloroquine 200 mg pill
41470073|NCT00687882|OTHER|No Intervention|Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.
41470074|NCT00687882|OTHER|No Intervention|Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
41470075|NCT00079521|PROCEDURE|Therapeutic Touch|
41470076|NCT05944250|DEVICE|Spincare matrix|The Spincare device, developed by Nanomedic, is the first portable tool that delivers a non-invasive, non-therapeutic electrospun, nanofibrous matrix dressing to wounds to promote healing.
40999276|NCT05049993|DEVICE|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty using the Aequalis Pyrocarbon Humeral Head
40999277|NCT02511470|OTHER|Metronome on|Metronome on during participants performance of CPR on a pediatric manikin
40999278|NCT02511470|OTHER|Metronome off|Metronome off during participants performance of CPR on a pediatric manikin
40999279|NCT05067582|DRUG|L1-79|tyrosine hydroxylase inhibitor
40999280|NCT06342843|PROCEDURE|Total Hip Arthroplasty|a surgical procedure in which an orthopaedic surgeon removes the damaged bone and cartilage and replaces this with prosthetic components.
40999281|NCT06287346|DEVICE|dental implant|ceramic dental implant
41150027|NCT05057767|DRUG|Midazolam injection|No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
41150028|NCT06286592|BEHAVIORAL|Ultra-brief mindfulness intervention video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
41150029|NCT06286592|BEHAVIORAL|Forgiveness video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
41150030|NCT06286592|BEHAVIORAL|ACT values video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
41150031|NCT06185699|DIAGNOSTIC_TEST|standard superficial skin biopsy (SSSB)|standard superficial skin biopsy (SSSB) was applied to the face that was wiped with dry sterile gauze after dropping cyanoacrylate by marking 1 cm2 area on the slide that was wiped with dry sterile gauze from 3 areas of the face, right cheek, nose and the mid-forehead. After the slide was left for 60 seconds and slowly removed from the face, immersion oil was dripped onto the slide and covered with a coverslip, and Demodex mites were counted first under the light microscope at x10 and then x20 magnification (Demodex foliculorum and brevis were not differentiated). The process was repeated for each region.
41150032|NCT05283200|BEHAVIORAL|Yoga|Yoga instructor will teach gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction
41150033|NCT05283200|BEHAVIORAL|Cognitive Behavioral Therapy|Psychologist will provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills
41150034|NCT05283200|BEHAVIORAL|Music|Music therapist will teach a variety of ways that participants might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.
41150035|NCT04741984|BIOLOGICAL|MT-201-GBM monocyte vaccine|monocytes isolated from patient's leukapheresis loaded with CMV pp65-LAMP (Lysosomal-associated Membrane Protein) mRNA (Messenger Ribonucleic Acid)
41150036|NCT05791552|DIAGNOSTIC_TEST|Collection of nasal secretion|Standardized collection of nasal secretion in the vicinity of the olfactory cleft
41470077|NCT04699630|DRUG|U3-1402|All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.
41470078|NCT00685035|DEVICE|HFCWC with higher pressure/variable-frequency settings|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
41470079|NCT00685035|DEVICE|HFCWC with lower pressure/mid-frequency settings|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
41470080|NCT05753813|DRUG|Phexxi|intravaginal gel twice weekly for 4 weeks.
41470081|NCT05305768|DRUG|IncobotulinumtoxinA|Injection of glabellar rhytids
40999282|NCT01876069|DEVICE|22 gauge ProCore needle aspiration|Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
40999283|NCT01876069|DEVICE|22 gauge Fine needle aspiration|Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
40999284|NCT01268111|DRUG|Ergocalciferols|ERgocaclciferol 50,000 units weekly for 8 weeks
40999285|NCT01268111|DRUG|Placebo|matching placebo
40999286|NCT05393557|OTHER|Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury|Tirofiban (intra-coronary bolus of 25µg/Kg) + Nitroglycerin (intracoronary 100-200 µg) + Verapamil (intracoronary 100-200 µg, yet excluding patients with 2nd or 3rd degree AV block, HR \< 60, or SBP \<100 mmHg) + 2 cycles of intermittent balloon inflation
40999287|NCT00407563|DRUG|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
40999288|NCT00407563|DRUG|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
40999289|NCT05935579|DRUG|Durvalumab|Durvalumab 1500 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle.
40999290|NCT05935579|DRUG|Lenvatinib Oral Product|The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily.
41310978|NCT04675359|PROCEDURE|Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint|Injections of the two adipose tissue derived products containing MSCs into the knee joints with osteoarthritis
41310979|NCT05940727|OTHER|Habitual macroalgae consumption|The participant have a habitual macroalgae consumption at baseline.
41310980|NCT05940727|OTHER|No macroalgae consumption|The participants exclude any macroalgae products from their diet
41310981|NCT02617342|BEHAVIORAL|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
41310982|NCT01547910|DIETARY_SUPPLEMENT|Fish Oil|Fish oil given in supplementary dose
41310983|NCT04534569|OTHER|Experts consensus|Consensus opinion using Delphi Methodology
40999291|NCT05935579|DRUG|Chemotherapy|GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
41310984|NCT04536337|DRUG|ALG-000184|Single or multiple doses of ALG-000184
41470082|NCT06617780|RADIATION|X-ray (wrist)after 3 months and CT (wrist) the day after closed reduction|One addition x-ray and on addition CT scan of the wrist
41470083|NCT03630094|DRUG|FEP-ZID|A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
41470084|NCT01138345|GENETIC|gene expression analysis|blood samples will be analyzed for the expression of the p16 gene.
41470085|NCT01138345|GENETIC|reverse transcriptase-polymerase chain reaction|perform reverse transcriptase-polymerase chain reaction on all blood samples.
41470086|NCT01138345|OTHER|laboratory biomarker analysis|perform laboratory biomarker analysis on all blood samples
41470087|NCT01138345|OTHER|medical chart review|perform medical chart review for all subjects
41470088|NCT01138345|OTHER|questionnaire administration|each cohort will be given the same questionnaire
40793392|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
41470089|NCT06471491|OTHER|Driving pressure-guided positive end-expiratory pressure|Driving pressure-guided positive end-expiratory pressure during the surgical procedure
41470090|NCT02244073|DRUG|Human insulin - Insulin administration to control blood glucose level.|On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
41470091|NCT06616103|DIAGNOSTIC_TEST|computerized tomography|noncontrast abdominal CT
41470092|NCT04998422|DRUG|HG381|HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
40793393|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 0.76 g|
40999292|NCT05372692|DRUG|mesothelin-specific chimeric antigen receptor T cell injection|Autologous T cell injection
40999293|NCT03639766|DRUG|AbobotulinumtoxinA|AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution
40999294|NCT03639766|OTHER|Saline solution|Non-bacteriostatic saline solution
40999295|NCT02643654|DRUG|MABp1|This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
41150037|NCT00988429|DRUG|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
41150038|NCT00988429|DRUG|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
41150039|NCT00988429|DRUG|Placebo|Placebo tablet given QD
41470093|NCT01467479|DRUG|Telaprevir|Tablet
40793394|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 1.15 g|
40793395|NCT02244372|DIETARY_SUPPLEMENT|Placebo|
40999296|NCT02643654|DRUG|Placebo|The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
41310985|NCT04536337|DRUG|Placebo|Single or multiple doses of Placebo
41310986|NCT04536337|DRUG|Entecavir|multiple doses of Entecavir
41310987|NCT04208334|DIETARY_SUPPLEMENT|Curcumin|We give an Intervention arm to consume Curcumin 4000mg/day for 60 consecutive days.
41310988|NCT04208334|OTHER|Placebo|We give a control arm to consume placebo for 60 consecutive days.
41310989|NCT02308345|OTHER|Pre-chemotherapy visit summary Video|
41310990|NCT02125331|PROCEDURE|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
41310991|NCT03097224|BEHAVIORAL|Prehabilitation|Four weeks of tele-supervised prehabilitation
41310992|NCT02014935|OTHER|Low intensity laser|"The study wants to evaluate the use of low intensity laser on the spastic muscle.~Want to assess whether the Low level laser prove change in muscle performace of the individual but also alters muscle activity and blood lactate."
41310993|NCT03440437|DRUG|FS118|Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.
41310994|NCT03440437|DRUG|Paclitaxel|Dosing on Days 1, 8 and 15 of each 28 day cycle in combination with FS118 given on days 1, 8, 15 and 22 of each 28 day cycle.
41310995|NCT01987167|DRUG|ACTHAR|Injectable Gel
41310996|NCT01911234|BIOLOGICAL|TNF-Kinoid|IM administration
41310997|NCT01911234|OTHER|Placebo|IM administration
41310998|NCT01858610|DRUG|Irbeasartan/hydrochlorothiazide|
41310999|NCT01858610|DRUG|Irbesartan|
41311000|NCT01858610|DRUG|Hydrochlorothiazide|
41311001|NCT04382898|BIOLOGICAL|BNT112|Intravenous bolus injection
41311002|NCT04382898|DRUG|Cemiplimab|Intravenous infusion
41470094|NCT01467479|DRUG|Ribavirin|Tablet
41311003|NCT04284904|DIAGNOSTIC_TEST|aGVHD biomarker|To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks
41311004|NCT00637364|PROCEDURE|High intensity focused ultrasound, HIFU|"The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).~The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue."
41311005|NCT02710266|DRUG|Preoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the preoperative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
41470095|NCT01467479|BIOLOGICAL|Pegylated Interferon Alfa-2a|Subcutaneous Injection
41470096|NCT01467479|DRUG|Highly Active Antiretroviral Therapy (HAART)|Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
40793396|NCT05280665|OTHER|Specialization|"* Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~* Who identified themselves as primarily gastric surgeons during the study period~* Whose annual gastric cancer surgery volume is more than 21"
40793397|NCT03780751|BEHAVIORAL|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
40793398|NCT03780751|BEHAVIORAL|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
40793399|NCT01838460|DRUG|sublingual nicotine tablets|6 mg = 3 tablets
40793400|NCT01838460|OTHER|Smokeless tobacco|Swedish type moist snuff
41150040|NCT05480280|DRUG|Dalpiciclib|Dalpiciclib is orally administered at 125mg qd for 21 days and discontinue for 7 days.
41150041|NCT05480280|DRUG|Oxaliplatin injection|85mg/m², ivdrip, D1
41311006|NCT02710266|DRUG|Intraoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the operative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
41470097|NCT05510115|DRUG|Empagliflozin|Empagliflozin: The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-\[4-chloro-3-\[\[4-\[\[(3S)-tetrahydro-3furanyl\]oxy\]phenyl\]methyl\]phenyl\]-, (1S). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Empagliflozin power will be added in white and bovine origin gelatin capsules. Each capsule of empagliflozin will contain 10 mg or 25 mg of empagliflozin (free base) and the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
41470098|NCT05510115|DRUG|Placebo|Placebo capsules will be matched in size and color to empagliflozin capsules. Each placebo capsule will contain the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
40793401|NCT05448729|DIAGNOSTIC_TEST|Elastography EUS|Comparison between the values of strain ratio and shear wave in concordance with the final diagnosis
40793402|NCT02664480|OTHER|Salivary alpha-Amylases|Investigators will collect Salivary alpha-Amylases before and after ovulation
40793403|NCT04132414|DIAGNOSTIC_TEST|NIRS open|Treatment according to protocol in phases of cerebral hypoxia.
40999297|NCT05712408|BEHAVIORAL|800g Challenge|The intervention will involve 8 weeks of an online diet program. Outcomes testing will occur at baseline and post-intervention (following 8 week diet program). During the first 4 weeks, participants will receive educaitonal material and log their daily points in an online application and attend a weekly check-in call with members of the research team. During weeks 5-8, participants will log their daily points in the online application.
40999298|NCT00733109|PROCEDURE|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
40999299|NCT00733109|OTHER|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
41150042|NCT05480280|DRUG|Calcium folinate|400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
41150043|NCT05480280|DRUG|5-fluorouracil|400mg/m², iv, D1; and 2400mg/m², civ, 46-48h
41150044|NCT05646602|DRUG|Collagenase Clostridium Histolyticum|Intralesional injection
41150045|NCT05646602|DEVICE|Duolith SD1 T-TOP|Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz
40999300|NCT05698966|OTHER|we will use reduced dose of acceptable corticosteroids treatment for preterm birth|the two different group will differ in the doses of corticosteroids
41150046|NCT03467594|BEHAVIORAL|High-intensity interval training|• Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be conducted 3 times per week for 8 weeks and will last between 15-25 minutes.
41311007|NCT02710266|DRUG|hepatectomy with dextrose water|Gabexate Mesilate is not administered. As placebo, 500cc of 5% dextrose water is administered at 40cc/hr for 12 hours
41311008|NCT02529293|DRUG|BioChaperone Lispro U-100|Injection of BioChaperone Lispro U-100
41150047|NCT05300217|OTHER|Strategies for promoting mental health|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding strategies for promoting mental health"
41150048|NCT05300217|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
41150049|NCT01524887|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion every 2 weeks over 18 months
41150050|NCT01524887|BIOLOGICAL|Human albumin 0.25%|Intravenous infusion every 2 weeks over 18 months
41150051|NCT03623776|DRUG|JS001|JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
41311009|NCT02529293|DRUG|BioChaperone Lispro U-200|Injection of BioChaperone Lispro U-200
41311010|NCT02222454|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
41311011|NCT02257164|PROCEDURE|Femoral nerve block|2 mg/ml
41311012|NCT02257164|PROCEDURE|obturator nerve block|
41311013|NCT02257164|PROCEDURE|intraarticular injection|
41311014|NCT04004078|DEVICE|other antifungal agents,breathing machine|If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
41311015|NCT02815241|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-046)
41311016|NCT02191241|DRUG|Red Vine Leaf Extract|
41311017|NCT03338517|OTHER|Helium Neon Laser|
41311018|NCT02316756|DRUG|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension
41311019|NCT02316756|DRUG|Placebo|Placebo which will be given as oral suspension
41311020|NCT03608904|OTHER|Music listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
40793404|NCT04189302|PROCEDURE|connective tissue graft harvest using KPM blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using KPM blade.
40793405|NCT04189302|PROCEDURE|connective tissue graft harvest using 15 C blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using 15C blade.
40793406|NCT00004049|DRUG|apomine|
41311021|NCT03608904|OTHER|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
41311022|NCT04852406|DRUG|Protocol-based management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.
40793407|NCT05029310|DRUG|Patiromer Oral Product|interaction study
40793408|NCT05934383|DEVICE|Paradise® ultrasound renal denervation system.|Bilateral renal sympathetic denervation of the native kidneys using the Paradise® ultrasound renal denervation system.
40793409|NCT02543853|OTHER|direct trocar entry|direct trocar entry to provide pneumoperitoneum
40793410|NCT02543853|OTHER|veres needle entry|veres needle entry to provide pneumoperitoneum
40793411|NCT03235882|DIAGNOSTIC_TEST|LS-ratio|Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
40793412|NCT03466398|BEHAVIORAL|Vivify Health RPM Protocol|The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
40793413|NCT00992056|DRUG|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
41150052|NCT03623776|DRUG|Pemetrexed|Subjects receive pemetrexed of 500 mg/m\^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
41150053|NCT03623776|DRUG|Carboplatin|Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
41150054|NCT03623776|PROCEDURE|Thoracic Surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
41150055|NCT06337799|BEHAVIORAL|Research Pharmacist|The goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers.
41150056|NCT01518127|OTHER|intravitreal injection of autologous bone marrow stem cells|intravitreal injection of autologous bone marrow stem cells
41150057|NCT01072734|DRUG|Vaccine|Influenza vaccine
41150058|NCT01876823|DRUG|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
41150059|NCT01876823|DRUG|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
40793414|NCT00992056|DRUG|Metoprolol|Metoprolol 50 mg titrated to 100 mg
40793415|NCT05507125|BEHAVIORAL|Mental health|Early life exposure to abuse and development of hidradenitis suppurativa
40793416|NCT01014806|BIOLOGICAL|Influenza VLP Vaccine|Single dose; 0.5mL
41311023|NCT04852406|DRUG|Routine management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to current routine practice.
41311024|NCT01985633|BIOLOGICAL|Mesenchymal stem cell suspension|About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.
40793417|NCT01014806|BIOLOGICAL|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
40793418|NCT05361382|DRUG|18F-Flortaucipir radiopharmaceutical|Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
40793419|NCT05361382|DRUG|18F-MK-6240 radiopharmaceutical|MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.
40999301|NCT04246385|BEHAVIORAL|CO-OP Group|"Participants in the intervention group will attend one 1:1 session where one goal will be selected from their COPM results to focus on during the group, group expectations will be reviewed, caregivers will be invited, and questions answered. The group will run six sessions as supported by the literature (Chan, 2007; Lee, Fischer, Zera, Robertson, \& Hammel 2017).~Day Rehab CO-OP Group Curriculum Session Content~Introduction One on one session. COPM, introduction to group, education for caregiver. Session 1 Introduction to group and CO-OP approach, homework. Session 2 Review CO-OP approach, practice, homework. Session 3 Review CO-OP approach, plan outing, homework. Session 4 Review CO-OP approach, experiential learning according to participants' alternate COPM goals, homework. Session 5 Review CO-OP approach, outing, homework. Session 6 Review CO-OP approach, focus group, lessons learned, final COPM, homework"
40999302|NCT00590954|DRUG|Perifosine|"Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4."
40999303|NCT01243359|DRUG|sunitinib malate|Given PO
40999304|NCT01243359|BIOLOGICAL|bevacizumab|Given IV
41311025|NCT01985633|BIOLOGICAL|PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
41311026|NCT01115738|DRUG|Prasugrel|Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
41311027|NCT01115738|DRUG|Clopidogrel|Loading dose administered once orally.
41311028|NCT01115738|DRUG|Placebo|Loading dose administered once orally
40793420|NCT05361382|DRUG|Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)|"The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.~Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical."
40793421|NCT02685826|DRUG|Durvalumab|single use vials administered via intravenous infusion
40999305|NCT01243359|OTHER|pharmacological study|Correlative studies
40999306|NCT01243359|OTHER|laboratory biomarker analysis|Correlative studies
40999307|NCT01243359|OTHER|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
41311029|NCT02518152|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
40793422|NCT02685826|DRUG|Lenalidomide|capsules for oral administration
40793423|NCT02685826|DRUG|Dexamethasone|tablets for oral administration
40793424|NCT04504344|DEVICE|Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)|We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.
40793425|NCT05952297|DEVICE|Sleep Wellness Device (BeCurie)|This device emits micro electromagnetic stimulation
40793426|NCT01078792|OTHER|CT pulmonary angio, blood tests|
40793427|NCT03271320|OTHER|appearance scales|appearance scales : AVS; ASWAP; DAS 59
40793428|NCT06511947|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
40999308|NCT01243359|PROCEDURE|positron emission tomography|Undergo FLT PET/CT
41150060|NCT01125436|DIETARY_SUPPLEMENT|Cholecalciferol|50,000 units of oral vitamin D3(cholecalciferol) weekly plus 800 calcium daily
41311030|NCT02518152|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
41311031|NCT02518152|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Alendronate|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
41311032|NCT05279989|OTHER|Seated Tai Chi Qigong|Participants will receive seated Tai Chi Qigong videos.
41311033|NCT05279989|OTHER|Health Information Videos|Participants will receive videos of health information.
41311034|NCT05725382|DEVICE|The NOL monitor (Pain Monitoring Device monitor-PMD200™)|NOL-guided perioperative remifentanil administration
41311035|NCT02520518|DRUG|Dapagliflozin|
41311036|NCT02520518|DRUG|Placebo|
41311037|NCT02520518|BEHAVIORAL|Weight maintenance|
40793429|NCT05354492|OTHER|Program to Support Well-Being after Adversity|You will be asked to meet on Zoom weekly for 6 weeks with our trained program facilitators along with the other 6-10 members of the intervention group. Meetings will last approximately 75-90 minutes each, and will involve a variety of discussions and activities related to navigating the changes you may face after experiencing a difficult life event. These sessions will be audio-recorded for research purposes and to ensure that facilitators are doing a good job delivering the program.
40793430|NCT01770405|DEVICE|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
40793431|NCT06322030|DIETARY_SUPPLEMENT|FOCUS-15 Lifestyle Management Program|15 week weight management program
40793432|NCT06322030|BEHAVIORAL|Exercise Training|15 weeks of progressive exercise training
41311038|NCT02520518|BEHAVIORAL|Ad libitum dietary intake|
40999309|NCT01243359|PROCEDURE|computed tomography|Undergo FLT PET/CT
40999310|NCT04656210|RADIATION|MRI|Non conventional MRI (35 minutes)
40999311|NCT04656210|OTHER|neuropsychological tests|Standardized and quantified neuropsychological assessment
40999312|NCT03169946|PROCEDURE|RCT with CHX-MTZ,OFD|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
41311039|NCT02520518|BEHAVIORAL|Dietary restriction|
41311040|NCT03917719|DRUG|Edasalonexent|100 mg/kg/day
41311041|NCT03076190|BEHAVIORAL|Psychoeducational My Surgical Success Video|The 90-minute video includes instruction by Dr. Beth Darnall, PhD, a pain psychologist at the Stanford Pain Management Center. She teaches the viewer about the relationship between stress, pain, and catastrophizing and provides instruction and skills to reduce catastrophizing, decrease stress, and increase relaxation.
41311042|NCT05380934|DRUG|TQH3821 tablets|TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.
40793433|NCT02175485|DRUG|Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg|Pharmaceutical form:tablet Route of administration: oral
40793434|NCT03652389|BEHAVIORAL|MJS Diabetes|patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
40793435|NCT04436445|COMBINATION_PRODUCT|dry cupping|represents the location and clinical importance of each acupoint. First, the position of the patient will be supine lying for SP6, SP9, KI6, GB34 and CV6 acupoints and it will be prone lying for B23 acupoint. Second, the skin will be cleaned by alcohol then cups will be placed on the acupoints. Dry cupping for SP6, SP9, KI6 and GB34 acupoints will be applied using small cups while dry cupping for CV6 and B23 will be applied using large cups. Third, a negative pressure will be applied with a manual handle. Finally, the cups will be removed after 5 to 15 minutes by pressing one side of the skin with a finger to release the vacuum slowly.
40793436|NCT04436445|OTHER|Life style modification|Life style modification
40793437|NCT05455125|DIAGNOSTIC_TEST|CMR CGI|High resolution ECGI plus advanced CMR
40793438|NCT00529776|PROCEDURE|Continuous lateral rotation therapy|
40793439|NCT00401843|BIOLOGICAL|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
40793440|NCT00401843|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
40999313|NCT03169946|PROCEDURE|RCT with CHX,OFD|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
40999314|NCT00380393|BIOLOGICAL|GSK malaria vaccine 257049 Vaccine|3 dose intramuscular injection
40999315|NCT00380393|BIOLOGICAL|Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine|3 dose intramuscular injection
40999316|NCT02290288|PROCEDURE|vaginal surgery|
40999317|NCT02290288|PROCEDURE|laparoscopic surgery|
41311043|NCT05380934|DRUG|TQH3821 tablets (Placebo)|TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.
41311044|NCT05380934|DRUG|Methotrexate tablets|Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition
41311045|NCT00615251|DRUG|DR-2011|Progesterone vaginal ring for approximately 10 weeks
41311046|NCT00615251|DRUG|Crinone 8%|progesterone vaginal gel for approximately 10 weeks
41311047|NCT04554849|OTHER|Gender dysphoria psychosocial health|Retrospective analysis of medical records
41311048|NCT06106321|PROCEDURE|Transalveolar crest maxillary sinus floor lift|Transalveolar crest maxillary sinus floor lift + bone grafting + implant implant is used
41311049|NCT06106321|PROCEDURE|transalveolar crest parietal maxillary sinus floor secondary lift|Transalveolar crest parietal maxillary sinus floor secondary lift + bone grafting + implant implantation were used body
41311050|NCT00798694|DRUG|Xalatan|one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
41311051|NCT00798694|DRUG|Travatan Z|one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
41311052|NCT04508673|OTHER|GH provocation tst|All patients underwent insulin-induced hypoglycaemia stimulation test also called insulin tolerance test (ITT), considered the 'gold standard' test for GHD diagnosis. Following insulin administration by venipuncture (1UI/mL), levels of hGH and glucose were monitored on serum and fluoride tube plasma, respectively, at intervals of 0, 30, 45, 60 and 90 minutes (T0, T30, T45, T60 and T90).
40999318|NCT03419728|BEHAVIORAL|Healthy Families, Healthy Futures|Home visiting program for pregnant and parenting teens
41311053|NCT06187623|OTHER|Clinic based exercise|"15 patients and their parents in the clinic-based group will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 3 days a week (24 sessions) with a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 4 days of the week."
41311054|NCT06187623|OTHER|Home based exercise|"15 patients in the home-based group and their parents will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 1 day a week (8 sessions) accompanied by a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 6 days of the week."
41311055|NCT03777722|DEVICE|Tailored Lighting Intervention|Lighting Intervention - active or placebo
41311056|NCT00418834|DRUG|ezetimibe and atorvastatin|ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
41311057|NCT00418834|DRUG|atorvastatin|Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
40793441|NCT00401843|DRUG|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
40999319|NCT00803881|OTHER|nasal lavage and sputum collection|non-invasive longitudinal assessment of pathogen colonization in both airway levels
40999320|NCT04025528|PROCEDURE|Bariatric Surgery|Weight loss surgery with either gastric sleeve or gastric bypass surgery
41150061|NCT01125436|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly placebo plus 800 calcium alone
41150062|NCT05567224|OTHER|Access to primary care services|Those in the pilot group will be referred to primary care services and allowed to utilize them for at least two years. Primary care services include access to a primary care physician, medical management, and other tasks typically performed by a general practitioner. Those referred to primary care services will not have access to other VUMC outpatient services.
41150063|NCT04120623|DRUG|Dapagliflozin 10 MG|Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).
41311058|NCT00418834|DRUG|Placebo (unspecified)|Placebo (unspecified) daily for 12 weeks
41311059|NCT05556642|OTHER|Biospecimen collection|Clinical information and biospecimens will be collected
41150064|NCT04120623|DRUG|Insulin Aspart|Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)
41150065|NCT00447499|DRUG|Somatuline Autogel (lanreotide acetate)|Injections
41150066|NCT00447499|BEHAVIORAL|Home administration|Questionnaire
41150067|NCT01379989|DRUG|Carboplatin|Carboplatin AUC 5
41311060|NCT01699620|PROCEDURE|BAHA implant insertion|The intervention is insertion of the Cochlear Bi300 to be used for bone anchored hearing aid.
41311061|NCT03014167|DRUG|Albendazole|All eligible individuals will receive a single dose of 400 mg albendazole.
40793442|NCT00401843|DRUG|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
40999321|NCT02234921|DRUG|Cyclophosphamide|A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
40999322|NCT02234921|BIOLOGICAL|DRibble Vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
40999323|NCT02234921|BIOLOGICAL|HPV Vaccinations|Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
41150068|NCT01379989|DRUG|Pegylated Lipoxomal Doxorubicin (PLD)|PLD 30 mg/m² i.v.
41150069|NCT01379989|DRUG|Trabectedin|trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
41150070|NCT04394585|BEHAVIORAL|smart phone app based human coaching program|"1. experimental arm~   * 1:1 coaching using smart phone app~  * Patients are provided several articles about postoperative care (symptom management, diet, and exercise) in the app.~  * Patients are encouraged to report their diet diaries and exercise everyday by the coach.~  * Patients can ask to the coach using the app and the coach answer when they check them.~2. Comparator arm - Patient have consulting with clinical nutritionist at 1 month and 3 months postoperatively."
41311062|NCT03472235|DEVICE|Microneedle|"TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedle will be done for 4session with 4 weeks interval between each session."
41311063|NCT02131948|DRUG|Intranasal insulin|Intranasal spray
40793443|NCT01485796|BIOLOGICAL|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
41150071|NCT04051645|DEVICE|Breathing through a system with adjustable flow resistance|"The proband will breathe through the adjustable flow resistance within the experiment, to which a standard D-lite Flow sensor will be connected, and the airway pressure, flow, minute consumption, oxygen and carbon dioxide, tidal volume, oxygen saturation of peripheral blood and oxygen and carbon dioxide concentrations in both inspired and expired air will be recorded using the Datex-Ohmeda S/5 Patient Monitor vital signs monitor.~The proband will breathe through the flow resistors in a randomized order, and pre-defined three-minute pauses will be maintained between measurements with different flow resistance values. Each measurement will take approximately two minutes and will be measured on ten different flow resistances."
41311064|NCT02131948|DRUG|Intranasal placebo|Intranasal spray
41311065|NCT00492856|DRUG|mercaptopurine|Given orally
41311066|NCT00492856|DRUG|methotrexate|Given orally
41311067|NCT00492856|DRUG|tretinoin|Given orally
41311068|NCT05433194|BIOLOGICAL|ABO1009-DP|Vaccine
41470099|NCT06276621|BEHAVIORAL|Family Bridge Program|The Family Bridge Program consists of 7 components, delivered by a trained lay navigator, the Guide. The program includes: (1) orientation to the hospital, unit, room, and hospital resources (e.g., toiletries, loaner phone chargers); (2)unmet social needs assessment, followed by connection to appropriate resources (e.g., food vouchers, community-based transportation); (3)communication and cultural preference assessment (eg, preferred language, comfort asking questions, and health-related cultural beliefs), which is communicated to the medical team and documented in the electronic health record;(4)communication coaching for parents/caregivers to help them clarify and practice asking questions of the medical team; (5)emotional support via daily check-ins during the hospital stay; (6)assistance with logistics ; and (7)one follow-up phone call, 2 days post-discharge, to address remaining questions and connect families to ongoing services if needed.
40793444|NCT01485796|BIOLOGICAL|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
40793445|NCT01143961|DEVICE|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
40793446|NCT03691298|DEVICE|Suturefix Ultra and Suturefix Curved Suture Anchor|Fixation device intended to provide secure fixation of soft tissue to bone to stabilize hip
40999324|NCT02234921|DRUG|Imiquimod|Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
40999325|NCT00003196|DRUG|chemotherapy|Undergo cytoreductive chemotherapy
41150072|NCT00755248|PROCEDURE|Coronary Artery Bypass Grafting|Coronary Artery Bypass Grafting on- or off-pump
41150073|NCT05500963|DEVICE|Transcutaneous electrical nerve stimulation|Electrical stimulation applied over selected leg muscle will activate sensory receptors that will transmit signals back into the central nervous system.
41150074|NCT05349630|DRUG|Ferrous sulfate 325mg|Participants will take one tab of ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) daily for 30 days.
40999326|NCT00003196|RADIATION|total-body irradiation|Undergo TBI
40999327|NCT00003196|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
40999328|NCT00003196|DRUG|cyclosporine|Given IV or PO
40999329|NCT00003196|DRUG|mycophenolate mofetil|Given PO
40999330|NCT00003196|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
40999331|NCT00003196|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
41311069|NCT02136199|OTHER|Active Implementation of ShareEBM Toolkit|
41311070|NCT02136199|OTHER|Passive Dissemination of Share EBM|
41311071|NCT03824925|DRUG|Placebo oral Zinc capsule|Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
41311072|NCT03824925|DRUG|Zinc Sulfate 220 MG|Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
41311073|NCT05722795|DRUG|Imatinib 400 MG Oral Tablet|One tablet daily 10 days before surgery.
41311074|NCT05154149|OTHER|Neck Disability Pain Index|Single time collection of the data
41311075|NCT05124795|DRUG|IMU-935|IMU-935 capsules
41311076|NCT01947244|BEHAVIORAL|Doula Home Visiting|The intervention is a doula enhancement to evidence-based home visiting services. Doulas provide home visits during pregnancy and for the first six weeks postpartum, which focus on prenatal health, preparation for childbirth, bonding with the baby, and breastfeeding education. Family support workers provide longer term home visiting services. These home visits focus on sensitive and responsive parenting, early infant care, bonding with the baby, child health and development, and maternal mental health.
41311077|NCT01947244|BEHAVIORAL|Case management|Mothers are offered two prenatal and two postpartum case management meetings to assess whether mothers' basic needs (housing, nutrition, health care, mental health) are being met and make appropriate referrals.
41150075|NCT04109651|OTHER|Nursing intervention|"Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants."
40793447|NCT02433496|OTHER|Physician coaching|"The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.~The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice."
40793448|NCT04790747|DRUG|CAR-T cells|Each subject receives sequential radiotherapy and CAR-T cells by intravenous infusion
40999332|NCT05851183|DRUG|Vitis Vinifera seed extract medication plus therapeutic lifestyle change|Administer 150mg of Vitis Vinifera seed extract (Entelon®) orally twice a day
41150076|NCT04181775|DIAGNOSTIC_TEST|ADE-RED scoring tool|The ADE-RED scoring tool will reduce the incidence of future visits to the ED or future admissions by identifying patients who are at high risk for ADE-related readmissions.
40999333|NCT05851183|BEHAVIORAL|Therapeutic lifestyle change only|Implementing TLCs is a critical component of a comprehensive treatment plan for varicose veins. A key aspect of TLCs is the optimization of postural habits. Patients are advised to avoid extended sitting or standing periods, which exert additional pressure on the venous system in the lower extremities and exacerbate venous insufficiency. During rest periods, elevating the legs closer to the heart is recommended because this simple yet effective adjustment promotes venous return and reduces the gravitational burden on the venous valves of the legs. The use of graduated compression stockings during waking hours is another therapeutic lifestyle intervention that is often prescribed for patients with varicose veins. Additional TLCs include maintaining optimal body weight and engaging in regular physical exercise Walking or cycling are often recommended because of their effectiveness in promoting lower limb venous return.
41150077|NCT02489799|BEHAVIORAL|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
41150078|NCT02489799|BEHAVIORAL|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
40999334|NCT01499888|PROCEDURE|Allogeneic Non-Myeloablative Stem Cell Transplantation|"Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.~Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion"
40999335|NCT01499888|DRUG|Alemtuzumab|In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
40999336|NCT01499888|DRUG|Sirolimus|On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
40999337|NCT02832310|PROCEDURE|valsalva maneuver|the effects of valsalva maneuver on arterial pressure
40999338|NCT04685876|DRUG|Liposomal bupivacaine|4-quadrant TAP block with liposomal bupivacaine
40999339|NCT04685876|DRUG|Plain bupivacaine|4-quadrant TAP block with plain bupivacaine
40999340|NCT04685876|DRUG|Normal saline|placebo (normal saline).
40999341|NCT02665208|OTHER|Treatment As Usual (TAU)|informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
40999342|NCT02665208|DRUG|Nicotine Replacement Therapies|a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
40999343|NCT02665208|BEHAVIORAL|Text Message Intervention (TMI)|
40999344|NCT05667623|DRUG|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks/24 weeks.
40999345|NCT05667623|OTHER|0% OPA-15406 Vehicle|Twice-daily administration for 4 weeks/24 weeks.
40999346|NCT01488097|DRUG|sebelipase alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase.
41150079|NCT01699802|OTHER|Inhaled anaesthetic agent|
41150080|NCT03414515|DEVICE|Endovascular intervention|Endovascular treatment with stent or balloon according to current practice
41150081|NCT04745819|BEHAVIORAL|1. The Child Behavior Checklist (CBCL), parent form|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
41150082|NCT02045745|BIOLOGICAL|"Implantation of autologous mesenchymal stem cells (CSM) expanded in vitro and administered directly into the lung suture line"|Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro
41150083|NCT01134497|DRUG|Placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle
40999347|NCT05404061|OTHER|Gut hormones|"Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.~For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:~1. 0.9% saline,~2. GLP-1"
40999348|NCT06165796|DEVICE|routine cataract surgery and intraocular lens implantation|routine cataract surgery and intraocular lens implantation
40999349|NCT00017433|DRUG|arsenic trioxide|
40999350|NCT02294877|DRUG|Vimizim® (elosulfase alfa)|Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
41311078|NCT02279524|DRUG|Aramchol|"Subjects will be administered Aramchol as follows:~* One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~* One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~* Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study."
41311079|NCT04398199|DRUG|Hypofractionated Radiation Therapy|The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).
40999351|NCT03050879|DRUG|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
41311080|NCT04398199|RADIATION|Radiation Boost|Undergo simultaneous integrated boost (SIB) to treat both planned target volumes with daily image guidance. This approach allows daily confirmation of target localization and simultaneous delivery of lower dose per fraction to low risk areas while maintaining a high dose per fraction to the highest risk areas.
41311081|NCT01726920|DRUG|naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
41311082|NCT01726920|DRUG|naratriptan|Tablets containing naratriptan 2,5 mg
40999352|NCT03442738|PROCEDURE|Endocuff group|Endocuff Vision cap on Standard colonoscope
40999353|NCT01027481|DRUG|Lucentis|intravitreally administration of 0.05 ml Lucentis
40999354|NCT00550095|DRUG|valsartan|
41311083|NCT01726920|DRUG|naproxen|Tablets containing naproxen 500 mg
41311084|NCT00240188|PROCEDURE|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
40999355|NCT05943912|OTHER|Single Vision Spectacle Lens|36 months of therapy
40999356|NCT05943912|OTHER|Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens|36 months of therapy
40999357|NCT01874496|DIETARY_SUPPLEMENT|GDS, no meal|GDS, no meal
40999358|NCT01874496|DIETARY_SUPPLEMENT|GDS, meal|GDS, meal
41150084|NCT01134497|DRUG|ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
41150085|NCT01384916|BEHAVIORAL|Yoga|2x weekly
41150086|NCT01384916|BEHAVIORAL|Healthy Living Workshop|2x weekly
41150087|NCT02181192|DEVICE|PET/CT|PET/CT
41150088|NCT02181192|RADIATION|Instant Radiotherapy according to guidelines|Instant Radiotherapy according to guidelines
41150089|NCT02181192|RADIATION|Radiotherapy after achievement of PSA marginal value|Radiotherapy after achievement of PSA marginal value
41150090|NCT03621683|PROCEDURE|blood rich plasma platelets|Injection of blood rich platelet into the ovaries.
41150091|NCT03621683|DIETARY_SUPPLEMENT|Antioxidant therapy|"Antioxidants:~Q10, DHEA, Vitamina E, Vitamin C, Omega 3"
41311085|NCT00240188|PROCEDURE|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
41311086|NCT01951235|DRUG|Imeglimin|
40999359|NCT01874496|DIETARY_SUPPLEMENT|control, no meal|control, no meal
40999360|NCT01874496|DIETARY_SUPPLEMENT|control, meal|control, meal
40999361|NCT04869072|DRUG|Convalescent plasma|"Convalescent plasma will be delivered as FFP. Three units of 200ml CP/FFP harvested from one donor will be transfused to one recipient, i.e. there will be a match between donor and recipient and each recipient will receive CP/FFP only from one donor.~CP/FFP will be administered intravenously at the infusion rate of 100ml/hour, starting from day 0, with a new transfusion every 24 hours, for a total of 3 transfusions (see scheme)."
41150092|NCT06014788|DEVICE|NPWTi|The wound was filled with black foam (Granufoam®, KCI). The instillation was performed via gravity from i.v. bag through a drain put within the foam. Chlorhexidine 0.1% 300 ml in 700 ml saline was used for continuous instillation three times daily (3 L per day) on the background of continuous pressure of 125 mmHg.
41150093|NCT06014788|DEVICE|Conventional NPWT|Conventional NPWT
41150094|NCT04456296|DRUG|Aveed Injectable Product|Testosterone undecanoate administered by intramuscular injections.
41150095|NCT04456296|DRUG|Fortesta|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
41150096|NCT04456296|DRUG|Testim|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
41150097|NCT01913444|DRUG|Recombinant Antithrombin|
41150098|NCT02959866|OTHER|online income tool|An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
41150099|NCT05088122|OTHER|no intervention|no intervention, not applicable
41150100|NCT05618509|DEVICE|STENDO session|"It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. The capacity for physical exercise is potentially improved.~STENDO : 45 minutes, 2 legs and the pelvis, pression of 65mm Hg"
41150101|NCT05618509|OTHER|A six-minute walking distance test|Before and after STENDO session, the patient has to walk 6 minutes in a flat corridor (30m long)
41311087|NCT01951235|DRUG|Placebo|
41311088|NCT00093860|DRUG|Propranolol|
41311089|NCT04494633|OTHER|Clinical Encounters Medical School 3D Simulation|A 3D simulation related to coping with the stresses of medical school and burnout.
40793449|NCT05006976|OTHER|NSAC health only|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health only, clinicians are provided survey information on potential health problems only."
40793450|NCT05006976|OTHER|NSAC health + MBW|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health + MBW clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors."
40793451|NCT03243227|OTHER|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
40793452|NCT03243227|OTHER|Exercise therapy|AROM exercise stretching exercise strengthening exercise 4 sessions
40793453|NCT00945373|DRUG|calcium dobesilate|2.5% gel
40793454|NCT00945373|PROCEDURE|pulsed dye laser|All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
40793455|NCT02267291|OTHER|Non-invasive positive pressure ventilation|Ventilatory support to alter intrathoracic pressure
40793456|NCT02810795|OTHER|Diagnostic detection of coronary artery disease|Myocardial perfusion defect on dynamic CT perfusion imaging, and diagnostic accuracy as compared invasive FFR.
40793457|NCT01340222|BIOLOGICAL|biological samples|4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
40793458|NCT00603941|DRUG|CS-7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
40793459|NCT00603941|DRUG|Paclitaxel|Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
40793460|NCT02877069|DEVICE|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
40793461|NCT00654225|DRUG|Rosuvastatin|
41150102|NCT05618509|OTHER|Near Infrared Spectroscopy|The goal is to measure the evolution of the oxygen consumption of the right leg during an effort on a bicycle at constant power for 5 minutes.
41150103|NCT05618509|DEVICE|STENDO placebo|STENDO placebo : 45 minutes, on 2 legs and the pelvis, pression of 10 mmHg
41150104|NCT02033668|DRUG|GSK933776 for SQ administration|Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks
41150105|NCT02033668|DRUG|GSK933776 for IM administration|Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose
41311090|NCT05542329|DEVICE|Monitoring by Tele-Medecine|Monitoring by Tele-Medecine
41311091|NCT02632695|DEVICE|FOOTFIT|Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
41311092|NCT02711215|DIAGNOSTIC_TEST|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
41311093|NCT02711215|DRUG|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
41311094|NCT02711215|DRUG|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
41470100|NCT06276621|BEHAVIORAL|Care as usual - resources only|Families randomized to the control arm will receive FBP written resources, which the Guide (and interpreter, as needed) will review with them over \~5-15 minutes one time. This includes information on hospital services (e.g., cafeteria coupons), community resources (e.g., food and housing support), the structure and roles of the medical team, and the daily hospital schedule. Parents will be informed that their child's nurse is available to help them.
40793462|NCT00654225|DRUG|Atorvastatin|
41311095|NCT02711215|DRUG|Placebo|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
40793463|NCT05218941|PROCEDURE|Implant surgery assisted by passive robotics|Implant surgery without flap assisted by passive robotics (X-Guide®)
40793464|NCT05218941|PROCEDURE|Conventional implant surgery|Flap implant surgery
40999362|NCT02315235|BIOLOGICAL|Normal saline|Normal saline is injected in one leg of patient.
40999363|NCT02315235|BIOLOGICAL|stem-cell|"Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.~The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient."
40999364|NCT05188859|DRUG|Sintilimab+Anlotinib+Pemetrexed+Cisplatin|Sintilimab 200mg+Anlotinib 12mg+Pemetrexed 500mg/m²+Cisplatin 75mg/m2
40999365|NCT04656067|DRUG|Oxytocin ,Tranexamic acid and Ethamsylate|Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate
40999366|NCT01358227|DRUG|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
40999367|NCT02479737|DEVICE|Blood drainage post cardiac surgery using PleuraFlow System|
41150106|NCT02033668|DRUG|GSK933776 for IV administration|Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour
41311096|NCT03007485|OTHER|Telehealth Pulmonary Rehabilitation|Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
41311097|NCT01518426|DEVICE|EEG Recording (Emotiv)|"Record EEG during auditory oddball paradigms:~* with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)~* with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)"
41311098|NCT00803010|DRUG|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
41311099|NCT00803010|DRUG|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m\^2, and a dose of 10 mg/m\^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
41470101|NCT02425501|DRUG|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
41470102|NCT06400485|DRUG|AMT-676|Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
41470103|NCT02095886|DRUG|BMS-955176|BMS-955176
40793465|NCT04694118|OTHER|rebound therapy|3 days a week in 12 weeks
40999368|NCT03417388|DRUG|High dose potent statin|The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.
40999369|NCT03417388|DRUG|ACE-I (lisinopril) or ARB (losartan)|Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.
40999370|NCT03417388|DRUG|Aspirin|Will be recommended to IMT women without contraindications or bleeding risk.
40999371|NCT03417388|BEHAVIORAL|Lifestyle Counseling|The PACE Lifestyle Assessment Intervention which is a program to assist with smoking cessation, weight loss, and exercise.
41150107|NCT02862158|DEVICE|FDT visual field|
41150108|NCT02862158|DEVICE|Standard HVF|
41470104|NCT05044663|OTHER|No intervention|This is an observational study
41470105|NCT02429375|DRUG|Mocetinostat Plus Brentuximab Vedotin|All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
41150109|NCT01655498|DEVICE|vaginal bowel control system (LivSure)|
41150110|NCT01107795|PROCEDURE|Transoral Robotic Surgery|Base of tongue resection with transoral robotic-assisted surgery (TORS).
41150111|NCT03918187|DRUG|Bupivacaine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
41311100|NCT00803010|DRUG|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
41311101|NCT03314441|BEHAVIORAL|Yoga|4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
41311102|NCT01087411|BEHAVIORAL|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
40793466|NCT00364650|DRUG|Probiotic Supplement|2 capsules twice daily
40793467|NCT00364650|OTHER|Placebo|placebo
40793468|NCT05961683|DEVICE|NIV plus software|interventions received by infants studied after placing them on ventilator using NIV plus software
40793469|NCT02278341|DRUG|Roxadustat|Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
41311103|NCT01087411|BEHAVIORAL|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
41311104|NCT01087411|DIETARY_SUPPLEMENT|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
41311105|NCT01087411|DIETARY_SUPPLEMENT|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
41311106|NCT05957497|BIOLOGICAL|Biological samples transport and analysis|Biological samples transport and analysis
41311107|NCT04724382|BEHAVIORAL|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
41311108|NCT04724382|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations
41311109|NCT00244699|BEHAVIORAL|MI Alone or Plus Mindfulness-Based Skills Training|
41311110|NCT04026854|BEHAVIORAL|Quality of live at work|The judging criteria will be collected using two questionnaires: a questionnaire sent to the local referent of each center and a questionnaire for each nurse. Because the study is longitudinal (two collections of data), the questionnaires will be completed twice to twelve months apart by the same nurses.
41311111|NCT01621152|OTHER|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
41311112|NCT01621152|OTHER|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
40793470|NCT02278341|DRUG|Epoetin alfa|Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.
40793471|NCT02278341|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.
40793472|NCT02278341|DRUG|Iron|Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was \< 100 ng/mL (\< 220 pmol/L) or TSAT \< 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
40793473|NCT04616170|OTHER|Hip extension|Hips extended at the time of vaginal delivery
40793474|NCT04616170|OTHER|Usual Care|"Hips positioned in the usual care position per provider preference at the time of vaginal delivery"
40793475|NCT03139032|DRUG|APD334|APD334 active treatment for 12 weeks.
40793476|NCT00804050|DRUG|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
40999372|NCT03417388|BEHAVIORAL|Quality of Life Questionnaires|Quality of Life Questionnaires will be obtained.
40999373|NCT05898295|OTHER|no intervention|No intervention: only observation of the child behavior
40999374|NCT02064907|DRUG|Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
40999375|NCT02064907|DRUG|Dexlansoprazole Delayed Release Capsules|Dexlansoprazole delayed-release capsules
40793477|NCT00804050|DRUG|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
41311113|NCT04037436|OTHER|Strength and Balance Training & Nutrition Education|Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.
41311114|NCT04037436|OTHER|Usual Care|During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
41311115|NCT03388996|DIAGNOSTIC_TEST|microbiomes|16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube
41311116|NCT05138783|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
41470106|NCT02371928|OTHER|Neuromuscular exercise program|"Exercises can be individually progressed from basic to elite level.~Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.~Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.~Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.~Supervision will be given two times a week for the first two weeks and then once a week for the remaining period."
41470107|NCT02371928|OTHER|Standard home exercise program|"Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.~All exercises are performed three times a week with 2 sets of 10 repetitions."
41470108|NCT04241185|DRUG|Pembrolizumab|400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
41470109|NCT04241185|RADIATION|Conventional Radiotherapy (Bladder only)|64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
40793478|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
40999376|NCT01933867|PROCEDURE|Water immersion|Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.
40793479|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Placebo group will have sham treatment by standing on the LMHFV platform for 20 minutes/day
40793480|NCT02030769|DRUG|Pronase|use pronase to improve visibility during endoscopical iodine staining
40793481|NCT02030769|DRUG|Control|No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
40793482|NCT03464513|DEVICE|Multislice CT Angiography|Multislice CT angiography (MSCTA) provides a relatively non-invasive and effective way of localising the source of bleeding, especially in patients with continuous bleeding.
40793483|NCT03181971|BEHAVIORAL|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
40793484|NCT06071598|OTHER|Surgical specimens of CRC-affected patients|Specimens of CRC-affected patients will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
40999377|NCT01933867|PROCEDURE|Air insufflation insertion|
40793485|NCT04767061|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
40793486|NCT04165551|BIOLOGICAL|Probiotic|Volunteers will take 1 capsule a day of the Probiotic during lunch without any restrictions on diet or lifestyle.
41150112|NCT03918187|DRUG|Nalbuphine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
41150113|NCT03918187|DRUG|Midazolam|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
40999378|NCT04839159|OTHER|Blood sampling|Blood sampling at the age of 6 and 12 months, 2-3-4 years
40793487|NCT04165551|BIOLOGICAL|Placebo|Volunteers will take 1 capsule a day of the Placebo during lunch without any restrictions on diet or lifestyle.
40999379|NCT04839159|OTHER|Blood sampling|Blood sampling before any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
41311117|NCT05138783|DEVICE|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
41311118|NCT02074774|DEVICE|IntellO2|Automated FiO2 regulator that responds to pulse oximetry measures
41311119|NCT02074774|OTHER|Manual control|Standard practice of manually titrating FiO2 as needed.
41311120|NCT02040883|DRUG|Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole|Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
41311121|NCT02040883|DRUG|Tandospirone|Tandospirone，30mg per day
40793488|NCT05211193|DEVICE|eTNM delivered by URIS I nerve stimulation device|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
40793489|NCT04735315|OTHER|Preterm birth|The study compares young adult subjects born premature (\< 29 weeks) versus term \> 37-41 weeks)
40793490|NCT02454530|BIOLOGICAL|Nivestim®|
40793491|NCT06090955|DRUG|Dexmedetomidine Injection [Precedex]|The study drugs(dexmedetomidine 80 μg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
40793492|NCT06090955|DRUG|Lidocaine IV|The study drugs(lidocaine 400 mg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
40793493|NCT06090955|DRUG|normal saline|The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
40793494|NCT00088270|DRUG|OSI-7904L|
41311122|NCT06347991|BEHAVIORAL|SelfBack|The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
40793495|NCT00088270|DRUG|5-Fluorouracil/Leucovorin|
40793496|NCT00974155|DRUG|Escitalopram, venlafaxine, lithium|oral application, highest tolerable dose, once daily
40793497|NCT00974155|DRUG|Escitalopram, venlafaxine|oral application, highest tolerable dose, once daily
40793498|NCT03359369|DIAGNOSTIC_TEST|level of serum cholesterol and triglyceride|other
40999380|NCT01652716|DRUG|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
40793500|NCT00225862|DRUG|ropinirole|
41311123|NCT05923476|DRUG|Lithium|Placebo + ECT
41311124|NCT05443672|DEVICE|Yizhun BUSMS|During the breast scanning, Yizhun BUSMS uses different color box to identify the breast lesion, and the box color indicates the risk grade of the lesion.
41311125|NCT02486952|DRUG|Cyclophosphamide|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
41311126|NCT02486952|DRUG|Hydroxydaunorubicin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
41311127|NCT02486952|DRUG|Oncovin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
41470110|NCT04241185|RADIATION|Conventional Radiotherapy (Bladder and pelvic nodes)|64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
41470111|NCT04241185|RADIATION|Hypofractionated Radiotherapy (Bladder only)|55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
41470112|NCT04241185|DRUG|Cisplatin|35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
40793501|NCT04194944|DRUG|Selpercatinib|Administered orally
40793502|NCT04194944|DRUG|Carboplatin|Administered IV
40793503|NCT04194944|DRUG|Cisplatin|Administered IV
40793504|NCT04194944|DRUG|Pemetrexed|Administered IV
40793505|NCT04194944|DRUG|Pembrolizumab|Administered IV
40793506|NCT05600829|BEHAVIORAL|BWLT+CR|Patients will attend twelve 2-hour group-based weekly sessions (over Zoom) in addition to their twice-weekly CR exercise sessions, followed by biweekly follow-up sessions alternating between individual phone-based sessions with a facilitator, and group-based sessions for an additional 12 weeks. The empirically validated ASPIRE BWLT was recently adapted for an AF population with obesity. Briefly, the BWLT was modified to incorporate education and practical strategies requested by patients, including AF risk factor management, pathophysiology, medications, and disease course; exercising with AF; and coping with difficult emotions regarding AF. Weekly treatment goals focus on nutrition and moderate calorie reduction while emphasizing adherence to an individualized CR exercise prescription. The BWLT program will be delivered by senior clinical psychology PhD students and supervised by a registered Clinical Health Psychologist.
40793507|NCT05600829|BEHAVIORAL|CR-Only|The CR program consists of education, medication management, risk factor modification and 12 weeks of twice-weekly supervised cardiovascular exercise sessions. Patients with AF undergo a symptom-limited graded exercise stress test at intake, 12-weeks, 24-weeks, and 1-year post-randomization, where cardiorespiratory fitness (i.e., peak metabolic equivalents \[METS\]) and cardiometabolic risk factors (blood pressure, blood lipid profile, BMI, waist circumference, depression and anxiety symptoms, tobacco use, and exercise volume) are assessed.
40793508|NCT02661152|DRUG|Nimorazole|Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
40999381|NCT01652716|DRUG|Exenatide twice daily|5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
40999382|NCT04881357|OTHER|test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
41311128|NCT02486952|DRUG|Prednisone|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
41470113|NCT04241185|DRUG|Fluorouracil (5-FU)|5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
41470114|NCT04241185|DRUG|Mitomycin C (MMC)|MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
41470115|NCT04241185|DRUG|Gemcitabine|Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
40793509|NCT03369665|DRUG|Mavenclad®|Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
40793510|NCT04738994|DIETARY_SUPPLEMENT|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
40999383|NCT04881357|OTHER|control group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
40793511|NCT04738994|OTHER|Control group|Standard hospital diet
40999384|NCT03960151|DRUG|Rolapitant|Rolapitant 180mg PO, Days 1 and 5
40999385|NCT03960151|DRUG|Palonosetron|Palonosetron 0.25 mg IV, Days 1,3, and 5.
40999386|NCT03960151|DRUG|Olanzapine|Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8
40999387|NCT03960151|DRUG|Dexamethasone|Dexamethasone 20 mg AM, Days 1,2 and 3
41311129|NCT02486952|DRUG|Rituximab|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
40793512|NCT00807183|OTHER|woodstove|installation of new EPA-certified woodstove
40793513|NCT00807183|OTHER|inactive air filter|air filter units without filter in place
40793514|NCT00807183|OTHER|Active air filter|air filter units correctly operating
40793515|NCT00331877|PROCEDURE|family conference with bereavement information leaflet|
40793516|NCT02804633|DRUG|IV Acetaminophen|1 gram every 6 hours
40793517|NCT02804633|DRUG|Placebo|100 ml of normal saline every 6 hours
40999388|NCT02945410|OTHER|Caloric Restriction|Participants will consume 30 kcal/kg FFM/day.
40999389|NCT02945410|OTHER|Protein|Participants will consume 1.7 g protein/kg BW/day.
40999390|NCT02945410|OTHER|Exercise|Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
40999391|NCT02945410|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
40999392|NCT02945410|OTHER|Maltodextrin|Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
40999393|NCT01846975|DRUG|IV Abatacept|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
40999394|NCT01837628|DRUG|Lidocaine Gel|
40999395|NCT01837628|DRUG|Paraffin Oil|
40793518|NCT03394781|DRUG|DUR-928|oral suspension daily for 28 days
40793519|NCT05892991|OTHER|interferential current|this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.
40793520|NCT02468440|OTHER|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
40793521|NCT03723798|DRUG|SA001 Low dose|3 tablets b.i.d for 12 weeks
40793522|NCT03723798|DRUG|SA001 Mid dose|3 tablets b.i.d for 12 weeks
40793523|NCT03723798|DRUG|SA001 High dose|3 tablets b.i.d for 12 weeks
40793524|NCT03723798|DRUG|Placebo|3 tablets b.i.d for 12 weeks
40999396|NCT03547388|DEVICE|Moderate whole body hyperthermia using water-filtered IR-A-radiation|four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging
41311130|NCT00912899|DRUG|Noscapine HCl|Escalating doses given twice per day
41311131|NCT03420378|DIETARY_SUPPLEMENT|vitamin D|Vitamin D replacement
41311132|NCT01976819|DEVICE|TW speaking valve/HME|The TW speaking valve with HME will be used during the day, whereas during sleep patients will use an HME without an automatic speaking valve. Data from TW15 and TW22 will be combined.
41470116|NCT04241185|DRUG|Placebo to Pembrolizumab|Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
41470117|NCT00521989|DRUG|CRx-102 (2.7/90)|CRx-102 dose 1
41311133|NCT00924352|DRUG|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD.
41311134|NCT00924352|DRUG|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
41311135|NCT06552858|DRUG|Fluzoparib|150mg oral bid. A PARP inhibitor that mainly exerts its inhibitory effect on tumor cells by inhibiting DNA repair.
41311136|NCT06552858|DRUG|Dalpiciclib|150mg oral qd d1-21, q4w. Inhibitor of Cyclin D-CDK4/6 that can inhibit the cell cycle, thereby inducing cell apoptosis.
41311137|NCT05917366|OTHER|Exercises|Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
41470118|NCT00521989|DRUG|Prednisolone|Prednisolone
41470119|NCT00521989|DRUG|Placebo|Placebo
41470120|NCT00521989|DRUG|CRx-102 (2.7/180)|CRx-102 dose 2
41470121|NCT00521989|DRUG|CRx-102 (2.7/360)|CRx-102 dose 3
41470122|NCT00890279|DRUG|Cilnidipine|Cilnidipine up to 20 mg
41470123|NCT00890279|DRUG|Imidapril|Imidapril up to 10 mg per day
41470124|NCT03993587|OTHER|Ultrasound assessment of vessels|Subclavian vein and related structures are examined using ultrasonography
41470125|NCT00147914|DRUG|Cefdinir (drug)|cefdinir 300mg per orally twice daily for 10 days
40793525|NCT05567445|DIAGNOSTIC_TEST|Echocardiography, CBC, Liver function, kideny function|Echocardiography, AST, ALT, UREA,CREAT. , CBC,may blood cultures.
40793526|NCT03269357|OTHER|LARC forward structured contraceptive counselling|Training of health care providers (HCPs), use of information material and counselling tools
40793527|NCT01970241|DRUG|NPH|NPH given per study table based on steroid dose and patient weight in kg.
40999397|NCT02327858|OTHER|Supportive text messages|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
41150114|NCT00296686|DRUG|Tranylcypromine|standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.
41150115|NCT00296686|DRUG|Dextroamphetamine|up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.
41311138|NCT05917366|OTHER|Coccyx Manipulation|Application of manipulation to relax the levetor ani muscle
41311139|NCT00239772|BEHAVIORAL|Cognitive Processing Therapy|
41311140|NCT00239772|BEHAVIORAL|Prolonged Exposure Therapy|
41311141|NCT04279379|DRUG|Sintilimab|200mg d1,ivdrip, repeated every 3 weeks
41311142|NCT04279379|DRUG|Decitabine|10mg d1-5, ivdrip,repeated every 3 weeks
41311143|NCT00006604|DRUG|ATV|Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
41311144|NCT00006604|DRUG|Ritonavir|Administered as 100 mg capsules or oral solution.
41311145|NCT05657782|BIOLOGICAL|PanChol|PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.
41470126|NCT00147914|DRUG|amoxicillin/clavulanate|1000mg /62.5mg extended release per orally twice daily for 10 days
41470127|NCT06457620|BEHAVIORAL|Conventional Physiotherapy|Each participant received conventional physiotherapy at the clinic as a part of their management plan. Group A exercise was five times a week for thirty minutes, beginning on the third day after total knee arthroplasty (TKA). The program aimed to improve leg strength, core stability, balance, and overall performance through exercise instructions. The baseline evaluation was completed one day before the TKA, and the posttest was completed four weeks after the TKA.
41470128|NCT06457620|OTHER|Traditional Physical Preatment|Each participant got traditional physical treatment during a video conference as part of telerehabilitation. The physiotherapy assistant contacted Group B to arrange a virtual follow-up clinic appointment via Zoom or WhatsApp, along with a 4-week program. We inquired about the patient's level of satisfaction with their TKR procedure. The patient was informed that clinical photos were taken, and the video call was to be recorded. Before the virtual clinic, each patient's verbal agreement was acquired. With workout instructions, the program pursued to enhance leg strength, core stability, balance, and overall performance. The posttest was conducted four weeks after the TKA, and the baseline assessment was finished one day before the procedure.
41470129|NCT05421104|OTHER|Ruxolitinib|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
41470130|NCT05811819|DEVICE|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
41470131|NCT03359915|BEHAVIORAL|COPD Self-Management Plan|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
41470132|NCT00348816|DRUG|docetaxel|Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
41311146|NCT03218982|BEHAVIORAL|Enhanced psycho-education about dementia and caregiving|Enhanced psycho-education re dementia and caregiving helping family members come to shared understanding of the nature and cause of dementia. Discussion of cultural values in Vietnamese and American cultures and how this can influence perceptions of dementia and caregiving strategies will help family members who disagree on the etiology of dementia and strategies for care to empathize with each other's perspective. Other sessions will teach skills to develop self-efficacy in dealing with patient symptoms, to access resources (e.g., in-home support), and to gain family support in culturally-congruent ways. Mindful Tai Chi is rooted in East Asian traditions and philosophies that promote balance and healing of the mind and body, thus addressing holistic beliefs Vietnamese have about wellness.
41311147|NCT03328585|BEHAVIORAL|CBT-I in person|6 weeks of CBT-I in person, one 1-hour long session per week
41470133|NCT00348816|DRUG|prednisone|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
41470134|NCT00348816|PROCEDURE|Radical prostatectomy|Radical prostatectomy as part of standard care
41470135|NCT00348816|RADIATION|Radiation therapy|Doses for standard care radiation therapy: The initial target volume will be the lower pelvis followed by a boost to the prostate fossa and immediate periprostatic tissue. The initial dose will be 4500 cGy. With the final boost, the total dose will be 6840-6900 cGy. (4500/25 plus 2340/13 or 2400/12) with a total of 37 or 38 fractions.
41470136|NCT03034434|DEVICE|Trans-vaginal ultrasound|Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
41470137|NCT02803931|DEVICE|Cardiogoniometry|Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany
41470138|NCT02803931|DEVICE|12-lead ECG|
41470139|NCT00618033|PROCEDURE|Hemodialysis|varying concentration of glucose in dialysate
41470140|NCT06600750|PROCEDURE|Arteriovenous fistula|Patients who underwent Radiocephalic arteriovenous fistula surgery
41470141|NCT04676815|PROCEDURE|NBI and interventional bronchoscopy|NBI used to enhance the contrast between the mucosal surface and underlying blood vessels
40999398|NCT03995212|DRUG|CR845 1.0 mg|Oral CR845 1.0 mg administered twice daily
40999399|NCT03995212|DRUG|Placebo|Oral Placebo administered twice daily
41311148|NCT03328585|BEHAVIORAL|CBT-I via Telemedicine|6 weeks of CBT-I via telemedicine, one 1-hour long session per week
41311149|NCT03328585|OTHER|No intervention|Patients in this arm will receive no intervention but will receive CBT-I treatment after conclusion of the study
41470142|NCT04447287|DRUG|ASP8062|Oral
41470143|NCT04447287|DRUG|Placebo ASP8062|Oral
41470144|NCT04447287|DRUG|buprenorphine/naloxone|Sublingual
41470145|NCT01502124|DRUG|somatropin|Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
41470146|NCT01502124|DRUG|somatropin|Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
41470147|NCT06292546|DRUG|Vonoprazan|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
41470148|NCT06292546|DRUG|Amoxicillin|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
41470149|NCT06292546|DRUG|Bacillus subtilis enteric-coated capsules|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
41470150|NCT06495190|DIETARY_SUPPLEMENT|Blueberry|52 g/d blueberry powder supplement
41470151|NCT06495190|BEHAVIORAL|Walking|Five 45-min walking sessions per week
41470152|NCT06495190|DIETARY_SUPPLEMENT|Placebo|52 g/d placebo powder supplement
41470153|NCT06495190|BEHAVIORAL|Stretching|Five 45-min stretching sessions per week
41470154|NCT00757549|BIOLOGICAL|cetuximab|
41470155|NCT00757549|DRUG|cisplatin|
41470156|NCT00757549|GENETIC|TdT-mediated dUTP nick end labeling assay|
41470157|NCT00757549|OTHER|3'-deoxy-3'-[18F]fluorothymidine|
41470158|NCT00757549|OTHER|immunohistochemistry staining method|
41470159|NCT00757549|OTHER|laboratory biomarker analysis|
41470160|NCT00757549|RADIATION|fludeoxyglucose F 18|
41470161|NCT00757549|RADIATION|radiation therapy|
41470162|NCT00964106|DRUG|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
41470163|NCT00964106|DRUG|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
41470164|NCT00964106|DRUG|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
41470165|NCT00964106|DRUG|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
40999400|NCT04738110|OTHER|MRI|Structural MR (T2, FLAIR, T1 and T1+C), DCE, DSC
40999401|NCT03190070|DIETARY_SUPPLEMENT|Ingestion of protein|Oral protein load as a physiological stimulus to temporarily increase glomerular filtration rate
40793528|NCT01970241|DRUG|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
40999402|NCT02584504|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
40999403|NCT02584504|DRUG|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
40999404|NCT02584504|DRUG|Atorvastatin|Atorvastatin 5 mg tablet orally.
41311150|NCT00809458|DRUG|Vitamin E|Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
41311151|NCT05631327|DRUG|JZP341|JZP341 will be administered as a single, intravenous infusion over 2 hours.
41311152|NCT01670214|PROCEDURE|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
41311153|NCT00788775|DRUG|Nilotinib|
41311154|NCT00740883|DRUG|warfarin|18 months of warfarin therapy, once daily
41311155|NCT00740883|DRUG|placebo of warfarin|18 months of placebo of warfarin therapy, once daily
41311156|NCT03535324|BEHAVIORAL|PROA for optimization|The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.
41311157|NCT03535324|OTHER|Control|There will be no intervention
41311158|NCT03815487|DEVICE|Medtronic MiniMed 670G Insulin Pump in Auto Mode|This kind of intervention will be part of the intensified insulin therapy for type 1 diabetic patients. The system will help to keep blood glucose in a defined range by automatic assisted adaption of insulin dosing.the HCL provides a lot more automatic functions to keep glucose in target compared to SAP.
41311159|NCT03815487|DEVICE|Medtronic MiniMed 670G Insulin Pump without Auto Mode|Sensor augmented pump therapy means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. There is no automatic adaption of insulin dosing. The patients must respond manually after alarm or according to the trend arrows.
41311160|NCT02922634|OTHER|Mini Cog|short cognitive screen, short Frailty screen
40793529|NCT04133350|BEHAVIORAL|Active Patient Engagement|The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
40793530|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day
40793531|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
40793532|NCT00114127|DRUG|Placebo|60mg placebo 1x per day
40793533|NCT00004215|BIOLOGICAL|filgrastim|
40793534|NCT00004215|BIOLOGICAL|leridistim|
40793535|NCT00004215|DRUG|cytarabine|
40793536|NCT00004215|DRUG|daunorubicin hydrochloride|
40793537|NCT00568594|DRUG|APL180|
40793538|NCT00568594|DRUG|Placebo|
40999405|NCT02584504|DRUG|Non-statin Lipid-Modifying Therapy|Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
40999406|NCT02584504|OTHER|Diet Alone|Stable cholesterol-lowering diet as background therapy.
41150116|NCT00296686|DRUG|Triiodothyronine|For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
41150117|NCT06281639|DEVICE|RAPID|test the clinical screening potential for congenital heart disorders using a single ECHO image taken by the RAPID device
41150118|NCT01550822|OTHER|HEALS|
41150119|NCT02127892|BIOLOGICAL|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
41150120|NCT02127892|BIOLOGICAL|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
41150121|NCT02127892|BIOLOGICAL|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
41150122|NCT02127892|DEVICE|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
41150123|NCT02607176|DRUG|Heweizhixie capsule|3 #, Tid, Oral for 3 days
41311161|NCT01870024|DRUG|Clonazepam|clonazepam 0,015 mg/kg
41311162|NCT01870024|DRUG|Fosphenytoin|fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
41311163|NCT01870024|DRUG|Placebo|placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
41311164|NCT01870024|DRUG|Lorazepam|lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
41150124|NCT03443739|OTHER|Intermittent Fasting|Intermittent Fasting with abstinence from food and drink daily from sunrise to sunset for nineteen consecutive days in March 2018
40793539|NCT06149923|GENETIC|quantitative Real-time PCR|: quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems
40793540|NCT04292197|DRUG|18-MC Compound|18-MC
40793541|NCT06192290|BEHAVIORAL|Home-based transitional Cardiac Telerehabilitation|This comprehensive series is divided into 16 parts, each addressing crucial aspects of open-heart surgery recovery. Part 1 introduces open-heart surgery, heart disease symptoms, and preoperative preparations for elderly patients. Part 2 delves into cardiac rehabilitation, defining objectives and detailing recovery stages. Part 3 covers care for surgical incisions and infection signs. Part 4 explores sleep and rest, while Part 5 guides patients on a healthy post-surgery diet. Part 6 focuses on nursing interventions for dyspnea, and Part 7 addresses post-surgery cough. Part 8 discusses nursing interventions for thrombosis prevention
41470166|NCT00964106|DRUG|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
41470167|NCT00964106|DRUG|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
40793542|NCT03336190|BEHAVIORAL|avatar-based training|Interaction with an avatar-based module to practice skills learned during the toolkit training
40793543|NCT01849315|BEHAVIORAL|AKIDS II|Physically active intervention
40793544|NCT04952428|BEHAVIORAL|"Re-examination visit (today visit)"|"Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom \& Richmond test will be conducted."
40793545|NCT04209023|DEVICE|Transcranial Magnetic Stimulation|Individual pulses (100% motor threshold intensity, continuous temperature of 24 degrees C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes.
40793546|NCT04780529|BIOLOGICAL|gucy2c cart cells|Patients with advanced malignant gastrointestinal tumors were injected with CART cells
40793547|NCT01135459|DRUG|CEP-33457|CEP-33457 will be administered per dose and schedule specified in the arm description.
40793548|NCT01135459|DRUG|Placebo|Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
40793549|NCT02652910|DRUG|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
40793550|NCT01994746|DRUG|Nasal Glucagon|
40793551|NCT01994746|DRUG|Intramuscular Glucagon|
40793552|NCT03153501|DIAGNOSTIC_TEST|CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy|
40793553|NCT00675831|DEVICE|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
40793554|NCT06123273|BEHAVIORAL|Exercise-oriented training|IG received an exercise-oriented training with a 20-minute presentation including graphics, in line with clinical guidelines, in addition to routine recommendations. The training included information about the benefits of exercise and the harms of a sedentary life, the relationship between exercise and chronic diseases, suggestions to have a more active lifestyle and on how to exercise, the duration and form of exercise necessary for a healthy life, and the things to be considered while exercising. During the three-month follow-up, the subjects in the IG were called every two weeks to ask about their weight measurements, their level of exercise, and how much they walked. The subjects' questions, if any, were answered, and the interview was completed by making exercise suggestions.
40793555|NCT06025318|DRUG|PanCytoVir™|PanCytoVir™ 100 mg/mL oral suspension
40793556|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
41150125|NCT03442309|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
41150126|NCT03442309|DEVICE|Fluoride Varnishes|Fluoride varnish (FV)
41150127|NCT03442309|DEVICE|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
41150128|NCT05503550|DRUG|Talquetamab|Talquetamab will be administered subcutaneously (SC).
41311165|NCT05276050|DEVICE|active F8-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
41311166|NCT05276050|DEVICE|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
41470168|NCT00964106|DRUG|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
41470169|NCT00964106|DRUG|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
40999407|NCT05385419|DIAGNOSTIC_TEST|Bronchoscopic and thoracoscopic frozen section biopsies|Flexible bronchoscopy for patients with lung endobronchial lesion, the bronchoscopic biopsy will be sent for frozen section and permenant paraffin section Medical thoracoscopy for patients with undiagnosed pleural effusion, the thoracoscopic biopsy will be sent for both frozen section and permenant paraffin section
40999408|NCT04699331|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
40999409|NCT02766244|DEVICE|ICG/SPY|indocyanine green fluorescence imaging
40999410|NCT02766244|DRUG|Antibiotic Ointment|Antibiotic ointment
40793557|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|"Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks"
40999411|NCT02603835|DEVICE|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
40999412|NCT03897400|OTHER|AMH levels in young women with crohn's disease will be considered.|Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.
40999413|NCT05798416|DRUG|Exercise under inhalation CO2|Participants perform shuttle walk test at high altitude while using the novel portable device for inhalation of CO2
41311167|NCT04980352|OTHER|real world treatment by doctors|real world treatment by doctors
40999414|NCT05798416|OTHER|Exercise under inhalation ambient air|Participants perform shuttle walk test at high altitude while inhaling ambient air
40999415|NCT03073590|COMBINATION_PRODUCT|Intervention factory with hot lunch|A nutritionally enhanced lunch meal program (increased dietary diversity plus inclusion of multi-nutrient fortified rice), provision of once weekly iron/folate supplement to female workers, and a BCC program conducted in the factory setting focused on improving health and nutrition for women and children, with a focus on anemia prevention.The BCC program will be enhanced to include modules on nutrition (balanced diets/dietary diversity, iron/folate rich foods), infant and young child nutrition (IYCN), and an overview module on anemia prevention, hand-washing with soap and dietary diversity at the very beginning of the intervention.
40999416|NCT03073590|COMBINATION_PRODUCT|Intervention factory without lunch program|In a selected garment factory that does not have a lunch program, the intervention will consist of the twice weekly provision of iron/folate supplements to female workers, and the enhanced BCC program, as described above.
41311168|NCT05971004|DEVICE|Arthrys (Collagen Peptide solution)|one injection of collagen peptide solution (Tiss'You, Republic of San Marino) at the site of the inflamed ligament attachment point
41311169|NCT05971004|DRUG|Depo medrol|one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar 50mg) for 3 consecutive months.
41470170|NCT00964106|DRUG|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
41470171|NCT00964106|DRUG|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
40793558|NCT00220155|DRUG|Gemcitabine|
40793559|NCT02109289|DRUG|etanercept|Etanercept is a tumor necrosis factor antagonist
40793560|NCT05065073|DRUG|Iodixanol|Iso-osmolar Contrast Media
40793561|NCT05065073|DRUG|Iohexol|Low-Osmolar Contrast Media
40793562|NCT01296971|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
40793563|NCT01296971|DRUG|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
41311170|NCT00348582|DRUG|Ketorolac, Nepafenac|
41311171|NCT00282789|DEVICE|bilevel positive airway pressure|
41311172|NCT00282789|DEVICE|bilevel positive airway pressure (Device)|
41311173|NCT01874652|DEVICE|Light Weight Breast Implants|Light Weight Breast Implants
40793564|NCT01296971|DRUG|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
40793565|NCT05547412|DEVICE|NovaGuide 2 Intelligent Ultrasound System|The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.
40793566|NCT04163523|DRUG|Zanubrutinib|
40793567|NCT00941525|DRUG|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
40793568|NCT01352208|DRUG|ASP9521|oral
40793569|NCT03700164|OTHER|Temperature|Water-perfused suit.
40793570|NCT02257242|DRUG|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
41311174|NCT04547894|DRUG|ASC09F|ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
41311175|NCT03591146|DRUG|TLC590|TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
41311176|NCT03591146|DRUG|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
41311177|NCT02900404|OTHER|XAPPORT|A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
41470172|NCT00964106|DRUG|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
41311178|NCT02900404|OTHER|"Expert Panel (gold standard)"|A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
41311179|NCT05578235|PROCEDURE|stapled side-to-side anastomosis|Standard procedure for CD
40793571|NCT02257242|DRUG|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
40999417|NCT03073590|COMBINATION_PRODUCT|Control factory with lunch program|One control factory who provides regular lunch meal and a nutrition and health behavior change communications (BCC) program.
40999418|NCT03073590|BEHAVIORAL|Control factory without lunch program|One control factory was selected where only the standard Behavior change communication (BCC) was implemented.
41311180|NCT05578235|PROCEDURE|Handsewn anastomosis|handsewn end-to-end or Kono-s anastomosis
41311181|NCT00946946|DRUG|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
41311182|NCT00946946|DRUG|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
41311183|NCT00946946|DRUG|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
41311184|NCT00946946|DRUG|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
41311185|NCT00001165|DRUG|combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin|
41311186|NCT04989010|DRUG|89Zr-NY005|89Zr-NY005 injection followed by 89Zr-NY005 PET scan
40999419|NCT02871128|DIETARY_SUPPLEMENT|Natureheme-iron|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
40793572|NCT02257242|DRUG|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
40999420|NCT02871128|DIETARY_SUPPLEMENT|Placebo|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
41311187|NCT03169010|OTHER|laboratory biomarker analysis|Laboratory results will be analysed to identify disease related biomarkers.
41311188|NCT03169010|GENETIC|Genetic analysis|Gene sequencing results will be analysed to identify disease related mutations.
41311189|NCT04825145|OTHER|Pregnancy|Pregnancies complicated by preeclampsia
41311190|NCT02268006|RADIATION|IMRT-SIB|
41311191|NCT02268006|DRUG|Capecitabine|
41311192|NCT02268006|PROCEDURE|Surgery|
41311193|NCT02681952|DRUG|Renamezin capsule|
41311194|NCT02681952|DRUG|Kremezin granule|
40793573|NCT02626936|OTHER|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
40793574|NCT02626936|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
40793575|NCT02626936|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
40999421|NCT02871128|DRUG|supplement|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
41311195|NCT01804322|OTHER|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~* The cause and nature of the adverse event and/or drug interaction~* The tolerability profile of each drug present in the schedule~* The clinical manifestations associated with the current drug interactions~* Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~* The reasons for and the potential benefits of the suggested treatment change~* An encouragement to withdraw any potentially interfering or contraindicated drug"
40793576|NCT02626936|DEVICE|Dexcom G4 Platinum glucose sensor|
40999422|NCT02224911|DEVICE|Laser Interstitial Thermal Therapy|
40999423|NCT01024712|DRUG|carboplatin|
41311196|NCT01804322|OTHER|usual care|usual care according to the participating Epilepsy Centers
41311197|NCT05468944|PROCEDURE|Transanal specimen extraction robotic surgery|Participants in this group underwent robotic rectal cancer resection ,the specimens were extracted through anus.
41311198|NCT05468944|PROCEDURE|Transabdominal specimen extraction robotic surgery|Participants in this group underwent robotic assisted rectal cancer resection ,the specimens were extracted through the incision on the abdominal wall.
41311199|NCT01767194|BIOLOGICAL|Dinutuximab|Given IV
41311200|NCT01767194|DRUG|Irinotecan Hydrochloride|Given IV
41311201|NCT01767194|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41311202|NCT01767194|BIOLOGICAL|Sargramostim|Given SC or IV
41311203|NCT01767194|DRUG|Temozolomide|Given PO
41470173|NCT05815368|DEVICE|REMO|REMO training will consist of sEMG-biofeedback exercises provided by REMO device. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
40793577|NCT02626936|DEVICE|Accu Chek Combo insulin pump|
40793578|NCT05833035|DRUG|BI 1291583 mixed with [C-14] BI 1291583|BI 1291583 mixed with \[C-14\] BI 1291583
40793579|NCT04023383|DRUG|40 cc HyaRegen NCH gel|After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
40793580|NCT04023383|DRUG|40 cc sterile saline solution|After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
40793581|NCT03323216|DIAGNOSTIC_TEST|6-minute walk test|"The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the intervention and 6 months after the intervention."
40793582|NCT03323216|DIAGNOSTIC_TEST|Study specific questionnaire|"Study specific questionnaire~The questionnaire is performed prior and 6 months after the intervention."
40999424|NCT01024712|DRUG|gefitinib|
40999425|NCT01024712|DRUG|paclitaxel|
40999426|NCT01024712|PROCEDURE|quality-of-life assessment|
41311204|NCT01767194|DRUG|Temsirolimus|Given IV
40793583|NCT03323216|PROCEDURE|Blood collection|"Blood collection during surgery:~* coronary sinus~* arterial~* peripheral venous~Blood collection 6 months after surgery:~- peripheral venous"
40793584|NCT04501939|DRUG|Cirmtuzumab|Cycle 1, Day 1 \& 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg
40999427|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 1 for 84 days
40999428|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 2 for 84 days
41311205|NCT04121312|BEHAVIORAL|Facilitation Intervention|"See arm description"
41311206|NCT04513834|OTHER|GP will receive the educational outreach visit by a DAM (healthcare representative).|GP will receive the educational outreach visit by a DAM (healthcare representative).
41311207|NCT04513834|OTHER|Patient education material on PPI deprescribing will be sent to the patients|Patient education material on PPI deprescribing will be sent to the patients
41470174|NCT05815368|OTHER|Task-Oriented Training|Task-Oriented training will consist of task-specific functional exercises. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
41470175|NCT05808166|BIOLOGICAL|Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).|Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).
40999429|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 3 for 84 days
40999430|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 4 for 84 days Other interventions may be added
40999431|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 5 for 84 days
40999432|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 6 for 84 days
41311208|NCT01883934|OTHER|Enhanced clinic-based support/counseling|Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
41311209|NCT01883934|OTHER|Control|
41311210|NCT00004879|BIOLOGICAL|panitumumab|
40793585|NCT04501939|DRUG|Venetoclax|Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.
41311211|NCT06081998|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
41311212|NCT06081998|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
40793586|NCT02288000|DRUG|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
40999433|NCT01403038|DRUG|elagolix|Elagolix plus Activella Dose Regimen 7 for 84 days
40999434|NCT02752932|OTHER|Drug testing on PDX per Investigator's choice (upto 4)|Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
40999435|NCT00133874|DRUG|SB-275833 ointment, 1%|
41311213|NCT03861546|BEHAVIORAL|Healthy lifestyle Shared Medical Appointment (SMA) program|Social network-based, culturally-tailored healthy lifestyle SMA program for high risk SAs will be piloted to collect pre-post data on diet and exercise habits, and to determine feasibility and acceptability. Patients will participate in physician-led group visits every other week focused on improving dietary and exercise practices to reduce weight. Biometric measurements (weight, height, blood pressure) will be collected, point of care glucose and lipid testing will be done.
41311214|NCT01902082|DRUG|Mesenchymal stem cells|
41311215|NCT01902082|DRUG|Placebo|
41311216|NCT00239187|DRUG|E1 and G1|
41311217|NCT05214781|PROCEDURE|modified radical mastectomy|excision of the whole breast tissue including nipple and skin with axillary clearance
41311218|NCT00712322|DRUG|Darifenacin|Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.
41311219|NCT02783794|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
41311220|NCT02783794|DRUG|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
41311221|NCT05960019|DIETARY_SUPPLEMENT|Fermented milk product|This is a type of cultured bovine milk, that is prepared through mesophilic fermentation of milk, that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
41311222|NCT05960019|DIETARY_SUPPLEMENT|Fermented cereal based product|This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
41311223|NCT05960019|BEHAVIORAL|Behavioural modification counselling|Standard of care shall comprise behavioural (lifestyle) modification counselling delivered monthly. This shall consist of provision of counselling on lifestyle modification in an effort to help the patients prevent progression of the pre-diabetes and provide help with any emerging complications of the disease. Counselling on lifestyle modification shall comprise provision of standard dietary and exercise advice for pre-diabetics by a study doctor.
41311224|NCT05139368|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
40793587|NCT02288000|DRUG|Placebo|the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
40793588|NCT03544593|DEVICE|Revolve System|Fat grafting system
40793589|NCT03534505|OTHER|Ketorolac group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
40793590|NCT03534505|OTHER|Bupivacaine group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
41150129|NCT03256305|DEVICE|"personalized rTMS+drug treatment"|High frequency（10HZ）stimulation of brain regions corresponding to lesion, low-frequency （1HZ）stimulation of the contralateral brain, intensity=90%MT（motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
41150130|NCT03256305|DEVICE|Traditional rTMS +drug treatment|Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
41311225|NCT01015664|DRUG|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
41311226|NCT01015664|DRUG|cisplatin|75 mg/m2 IV over 60 minutes on day 1
41311227|NCT01015664|DRUG|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
41311228|NCT00601796|BIOLOGICAL|Vaccine Treatment|We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
40793592|NCT01559545|DRUG|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
40793593|NCT01559545|DRUG|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
41311229|NCT00601796|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m\^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
40793594|NCT01559545|DRUG|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
40793595|NCT06525610|OTHER|Periprosthetic Fracture Knee Repaired CT Scans|We will be assessing the use of weight-bearing CT, specifically its imaging, with RSA-like software, for analyzing fracture healing over time for a periprosthetic distal knee fracture.
40793596|NCT01627626|DRUG|Pilocarpine|"0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute."
40793597|NCT01627626|DRUG|saline|0.9% saline solution
40793598|NCT00271908|BEHAVIORAL|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
40793599|NCT03123900|BEHAVIORAL|Physical exercise|The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
40793600|NCT03123900|BEHAVIORAL|Cognitive training|We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
41311230|NCT00601796|DRUG|All-trans retinoic acid (ATRA)|All-trans retinoic acid was given (150/mg/m\^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
41311231|NCT05397899|OTHER|Abdominal hypopressive Exercises (AHE)|Active and specific Therapeutic exercises will be used to treat postpartum low back pain in this study. AHE consisted of exhaling to their expiratory reserve volume, then holding their breath (apnea), and expanding their rib cage, to draw their abdominal wall inward and cranially without inhalation. Each exercise will have a specific frequency, intensity, and duration.
40793601|NCT03123900|BEHAVIORAL|Combined training|Subjects included in this group receive both types of intervention.
40793602|NCT00628498|DRUG|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
40793603|NCT00628498|DRUG|Defibrotide|
41311232|NCT05397899|OTHER|General exercises|General exercises are therapeutic exercises for core muscles for the treatment of postpartum low back pain.
41311233|NCT03877120|DRUG|Dexmedetomidine 0.004 MG/ML|Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.
41311234|NCT03877120|DRUG|Diazepam Injectable Solution|diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.
41311235|NCT04512469|DEVICE|Low molecular weight mesh|Following liver implantation, the subcostal incision will be closed using a running fascial closure with absorbable 1-0 Polydioxanone (PDS) suture and staples, with the treatment group also receiving a mesh.
41311236|NCT03285074|OTHER|No intervention|No intervention
41311237|NCT06289166|DRUG|STSP-0601 for Injection|A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.
41311238|NCT04641312|DRUG|LY3457263|Administered SC
41311239|NCT04641312|DRUG|Dulaglutide|Administered SC
40793604|NCT00169702|BEHAVIORAL|weight management program|12 sessions, psychoeducation
40793605|NCT00169702|BEHAVIORAL|weight management program|2 weekly, 12 sessions, psychoeducational weight management
41311240|NCT04641312|DRUG|Placebo|Administered SC
41311241|NCT03238586|BEHAVIORAL|WELL Program|
41311242|NCT04866303|DIAGNOSTIC_TEST|Home-based SARS-CoV-2 test kit|A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.
41470176|NCT05808166|OTHER|Isotonic Sodium Chloride injection|Placebo will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 2)
40793606|NCT04963283|DRUG|Cabozantinib|Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.
40793607|NCT04963283|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
40793608|NCT04099498|BEHAVIORAL|Online Program: Healthy Eating Promotion with Self-regulation|Online-Intervention group
40793609|NCT04099498|BEHAVIORAL|Enhanced Online Program: Healthy Eating Promotion with Self-regulation|Enhanced-online-Intervention Group
40793610|NCT01714323|BEHAVIORAL|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free \& Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
40793611|NCT01714323|BEHAVIORAL|Standard Care|Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
40793612|NCT02452385|DRUG|CM082 tablet|CM082 tablets taken orally
40793613|NCT03942198|DRUG|Taodan Granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
40793614|NCT03942198|DRUG|Taodan Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
40793615|NCT03837990|DRUG|Helicobacter Pylori eradication therapy|Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.
41311243|NCT03936816|OTHER|GBS vaginal double swab|The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
40793617|NCT01000506|BIOLOGICAL|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
40793618|NCT01000506|BIOLOGICAL|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
40793619|NCT01000506|BIOLOGICAL|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
40793620|NCT01000506|DRUG|Placebo saline|Placebo saline every four weeks by i.v.
41311244|NCT03416686|DEVICE|Radiofrequency (RF star electrode electrode_Fixed)|"The radiofrequency will be performed under ultrasound control after local anesthesia by a trained operator, after finding the lesion to be treated by the operator.~Medical device used: RF star electrode electrode_Fixed (Starmed Co,Gyeonggi-do, Korea, French representative Cosysmed)."
41311245|NCT02346500|DEVICE|Transrectal Ultrasound|The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
41311246|NCT00138424|DRUG|Cidofovir|Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
41311247|NCT00138424|DRUG|Placebo|The control for this study is sterile, 0.9% normal saline for intravenous use.
40793621|NCT01206634|PROCEDURE|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
40793622|NCT01206634|BEHAVIORAL|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
40793623|NCT05767788|OTHER|Movement with Mobilization (MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
40793624|NCT05767788|OTHER|Sham Movement with Mobilization (Sham MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior light-touch glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
40793625|NCT01393899|DRUG|Placebo|oral tablets twice daily
40793626|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
40793627|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
40793628|NCT00377897|PROCEDURE|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
41311248|NCT01123122|OTHER|Strict glucose control|Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
41311249|NCT04472364|DEVICE|HemoPill Acute ®|Capsule positive: Endoscopy endoscopy will be performed within 12 hours. Capsule negative: Endoscopy will be performed after 48 to 96 hours.
41311250|NCT04431154|BEHAVIORAL|Provision of HIV self-screen kit with incentives and linkage promotion|This arm will receive a HIV self-screen kit and additional incentives to promote adherence and linkage to care
41311251|NCT06023173|DIAGNOSTIC_TEST|Deep radiomics-based fusion model|This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
41311252|NCT00608530|BEHAVIORAL|Cognitive Behavioral Therapy-Psychologist-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist
41311253|NCT00608530|BEHAVIORAL|Supportive Psychotherapy-Psychologist-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
41311254|NCT00608530|BEHAVIORAL|Cognitive Behavioral Therapy Nurse-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse
40793629|NCT03345355|DIAGNOSTIC_TEST|Imaging|Coronal oblique T1, Coronal oblique and axial STIR, Coronal oblique T1 Dixon, Coronal oblique and Axial T2 Dixon and T1 Dixon post Gadolinium
40793630|NCT01440673|DRUG|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
41311255|NCT00608530|BEHAVIORAL|Supportive Psychotherapy-Nurse-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
41311256|NCT04593693|DEVICE|Invia Motion Endure NPWT system|lightweight portable single patient use pump, that provides continous or intermittent operation and multiple negative pressure selection options
41311257|NCT02975440|DRUG|Rifampicin|11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.
41311258|NCT02975440|DRUG|Midazolam|2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam
41311259|NCT02975440|DRUG|BAY1002670_Vilaprisan|2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
41311260|NCT00501215|PROCEDURE|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
40793631|NCT06289946|DRUG|NitroBid|We will apply nirobid to the wrist prior to left heart catheterization.
40793632|NCT06289946|DRUG|Placebo|We will apply placebo moisturizing cream to the wrist
40793633|NCT03118505|DEVICE|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
41311261|NCT00501215|BEHAVIORAL|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
41311262|NCT00501215|PROCEDURE|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
41311263|NCT00501215|BEHAVIORAL|Polysomnography (PSG)|"2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview"
40793634|NCT03118505|DEVICE|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
41150131|NCT06452888|BEHAVIORAL|Clinical decision support system.|The clinical decision support system includes evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures. Patients in the intervention group will receive the organizational management based on the guidelines and conduct intervention management for patients with actue ischemic stroke. The clinical decision system will classify the patients into risk factors, automatically generate treatment measures according to the guidelines, in order to standardize the treatment of physicians. Such as the management of complications after stroke, the treatment of antiplatelet, anticoagulation, antihypertensive and hypoglycemic.
41311264|NCT03320291|DEVICE|Regjoint|Implant of poly-L / D-lactide (Regjoints®) in the treatment of trapezo-metacarpal osteoarthritis
41311265|NCT04901741|DRUG|Olaptesed pegol|400 mg per week as continous infusion until progression or intolerable toxicity
41311266|NCT04901741|DRUG|Pembrolizumab|200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations
41311267|NCT06245044|BEHAVIORAL|No MI Help|Participants will complete the medication verification task without any MI help
41470177|NCT03190772|OTHER|Placebo nasal spray|The placebo nasal spray consists of sesame oil and does not contain any active drug.
41470178|NCT03190772|OTHER|Film sequence|All groups watch the film sequence that is supposed to induce sadness.
41470179|NCT06393660|DEVICE|CliniMACS® CD34 TCR Alpha/Beta|CliniMACS System uses an automated antibody/magnetic beads column system that allows efficient depletion of TCRαβ and CD19+ cells without relevant loss of cell viability. Hematopoietic stem cells are retained in sufficient numbers to permit engraftment and hematopoietic reconstitution. Humanitarian Exemption IDE approval has been obtained for CD34+ cell selection as a method of T-cell depletion.
41150132|NCT06452888|BEHAVIORAL|no intervention|No intervention indicated that the physicians among control hospital provide routine
41150133|NCT01601925|OTHER|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
41311268|NCT06245044|BEHAVIORAL|Scenario #1|Participants will receive MI in the form of a pop-up message if their decision differs from the MI's determination.
41311269|NCT06245044|BEHAVIORAL|Scenario #2|MI help will be displayed concurrently with the filled and reference images.
41311270|NCT03555084|DEVICE|Extension of Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
41311271|NCT03555084|DEVICE|Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
41311272|NCT01766817|DRUG|BMS-986020|
41470180|NCT05840471|DRUG|Tranexamic acid injection|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
41470181|NCT05840471|OTHER|Glucose water 5%|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
41470182|NCT04258280|BEHAVIORAL|Education and counseling|Education includes a workbook, counseling includes peer support.
41470183|NCT04258280|BEHAVIORAL|Education|Education includes a workbook.
41470184|NCT02824731|RADIATION|Radiation with protons|
41470185|NCT02824731|RADIATION|Radiation with photons|
41150134|NCT05031065|RADIATION|Breast Cancer Radiotherapy|4000-4250 cGy in 15-16 daily fractions
41150135|NCT06459869|DRUG|NG-350A IV administration|a tumour-selective anti-CD40-expressing adenoviral vector
41150136|NCT06459869|DRUG|Capecitabine oral administration|chemotherapy
41470186|NCT04810169|DEVICE|Smart inhaler|"* Automatic record (number of actuations and their timing) of the use of the emergency treatment through the smart inhaler~* Questionnaire sent to the parents at each use of the smart inhaler to get information regarding the reason of use and the efficacy of the treatment given"
40793635|NCT03159468|BEHAVIORAL|Cognitive Restructuring|Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.
40793636|NCT03159468|BEHAVIORAL|Mindfulness|Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.
41150137|NCT06459869|RADIATION|Radiotherapy|long-course intensity-modulated radiotherapy
41150138|NCT05387785|DRUG|ANG-3070|Orally administered tyrosine kinase inhibitor capsule.
41150139|NCT05387785|DRUG|Placebo|Orally administered placebo capsule
41150140|NCT02468882|DIETARY_SUPPLEMENT|Watercress|100g of watercress daily during radiation therapy
41150141|NCT05523388|OTHER|Collection of health-related data|A multimodal set of data including experimental, clinical, functional, radiological and biomechanical data is compiled before and after routine surgical intervention at baseline and at one-year follow-up.
41150142|NCT05149716|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day
41150143|NCT05149716|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day
41311273|NCT01766817|DRUG|Placebo matching with BMS-986020|
41311274|NCT03147274|BEHAVIORAL|Intervention|Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
41470187|NCT06616493|OTHER|kinesio taping|measure the subjects' lower extremity biomechanical characteristics with 3 different conditions respectively (kinesio taping, placebo kinesio taping, no taping)
41470188|NCT06077461|BEHAVIORAL|mandala painting|Patients in this group will be subjected to mandala painting.
40793637|NCT03159468|OTHER|Alcohol consumption|Participants consume an alcoholic beverage in the lab.
40793638|NCT05702489|DRUG|ZX-7101A|a drug to treatment influenza in Chinese adults
41311275|NCT04961814|OTHER|liberal fasting|preoperative fasting according to 6-4-0 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
41470189|NCT02116894|BIOLOGICAL|PF-03446962|PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
41470190|NCT02116894|DRUG|Regorafenib|We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
41470191|NCT00883935|DRUG|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
41470192|NCT00883935|DRUG|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
41470193|NCT00883935|DRUG|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
41470194|NCT00883935|DRUG|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
41470195|NCT05108376|DEVICE|Visensia Safety Index (VSI)|Enrolled patients will undergo continuous vital sign monitoring, to be used by the Visensia Safety Index (VSI) to identify early deterioration. If early deterioration is identified, the VSI will produce an alert to notify the RACE team.
41311276|NCT04961814|OTHER|standard fasting|preoperative fasting according to 6-4-2 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
41311277|NCT03542045|DEVICE|Cemented ATTUNE® Knee System|This product is for total knee arthroplasty. Four implant configurations are permitted: Cruciate Retaining Fixed Bearing (CR FB), Cruciate Retaining Rotating Platform (CR RP), Posterior Stabilizing Fixed Bearing (PS FB) and Posterior Stabilizing Rotating Platform (PS RP)
41311278|NCT01066195|DRUG|iressa|iressa 250mg per day every day
41311279|NCT01066195|DRUG|alimta|alimta 500mg/m2 every 3 weeks
41311280|NCT02173496|OTHER|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
41311281|NCT00987012|DIETARY_SUPPLEMENT|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
41311282|NCT00987012|DIETARY_SUPPLEMENT|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
41311283|NCT05088616|BEHAVIORAL|Virtual Diabetes Wellness Classes and Medically Tailored Meals|Four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals.
41311284|NCT04445493|DEVICE|MindRhythm Harmony|Passive recording of the head pulse
41311285|NCT00797797|DRUG|No Treatment Added|No added treatment
41311286|NCT00797797|DRUG|Milnacipran Added|Milnacipran 100 mg/d added
41311287|NCT04741334|DRUG|direct anticoagulant|exposure to direct anticoagulant
41311288|NCT04741334|DRUG|antiplatelet drugs|exposure to antiplatelet drugs
41311289|NCT04741334|DRUG|Dicumarols|exposure to dicumarols
41311290|NCT04752098|DIAGNOSTIC_TEST|Vibro-acoustic analysis (VAA), based on ultrasound radiation force|The study will develop and validate a new ultrasonic method for assessment of infant bone by evaluating structural and mechanical characteristics of the infant tibia. This project will utilize a novel, non-invasive method, vibro-acoustic analysis (VAA), to evaluate infant bone properties in a wide frequency range while reducing the artifacts from soft tissue.
41311291|NCT02527551|OTHER|Massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
41470196|NCT02598245|DEVICE|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
40793639|NCT02409641|DRUG|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
41150144|NCT05740904|OTHER|New defocus spectacle lenses|The children in the new defocus spectacle lens group will wear new defocus spectacle and receive follow-up examinations every half year.
41470197|NCT02598245|DEVICE|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
41470198|NCT04296201|DEVICE|DMA treatment|Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
41470199|NCT06105021|DRUG|AFNT-211|Engineered TCR T-Cell
40793640|NCT03441529|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
41311292|NCT00736580|OTHER|Blunt tipped needle|The Cesarean delivery is performed using blunt tipped needles.
40793641|NCT03441529|DRUG|Piperacillin/Tazobactam|Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.
40793642|NCT05691192|BEHAVIORAL|Cognitive Leisure Activities|Participants in the active phase of the study will be asked to increase engagement in certain cognitive leisure activities. The activities are chosen on the basis of previous research and measures of cognitive reserve-building activities.
40793643|NCT01679678|DEVICE|PolyHeal 2|PolyHeal is a sterile medical device
41311293|NCT00736580|OTHER|Sharp needles|The cesarean is performed using standard sharp surgical suture needles.
41311294|NCT05700747|BEHAVIORAL|Health Through Activity|Six, weekly, customized sessions with licensed physical and occupational therapists.
41311295|NCT03236428|DRUG|Daratumumab|Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule
41311296|NCT02477228|PROCEDURE|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
41311297|NCT02477228|PROCEDURE|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
41311298|NCT00588250|OTHER|EmbryoGlue|G2 culture media from Vitrolife which contains hyaluronic acid
41311299|NCT04848454|DRUG|Camrelizumab with vinorelbine and cisplatin|Camrelizumab: 200mg iv., every 3 weeks(one cycle), for 1 year(17cycles in total); Vinorelbine: 25mg/m2 day 1, 8 iv. or 60-80 mg/m2 or. day1, 8, every 3 weeks(one cycle), for 6 cycles; Cisplatin: 75mg/m2 (divided into 2 days), every 3 weeks(onr cycle), for 6 cycles.
41311300|NCT03450369|BIOLOGICAL|NB01|Use an existing therapy designed to kill existing facial bacterial followed by populating facial skin with a single application of NB01
41470200|NCT06214559|DEVICE|Sérum VERRUPRO|To be applied twice a day
40793644|NCT01679678|DEVICE|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
40793645|NCT00003776|BIOLOGICAL|filgrastim|
40793646|NCT00003776|DRUG|cisplatin|
40793647|NCT00003776|DRUG|doxorubicin hydrochloride|
40793648|NCT00003776|DRUG|ifosfamide|
40793649|NCT00003776|DRUG|leucovorin calcium|
41311301|NCT05272527|BEHAVIORAL|Transition to Motherhood Program|Transition to Motherhood program includes 5 sessions. The first session covers the pregnancy process, the second session deals with the birth process, the third session deals with the postpartum period, the fourth session deals with infant care, and the fifth session deals with breast milk and breastfeeding and immunity. Trainings are online. In addition to the lecture technique, the training includes auxiliary techniques such as models, videos, case studies, training cards, and applied demonstrations. The program was completed by telephone follow-up in the first and fourth weeks postpartum.
41311302|NCT00319228|DRUG|Plasma-derived AT-III concentrate|"Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan."
40793650|NCT00003776|DRUG|methotrexate|
40793651|NCT00003776|DRUG|trimetrexate glucuronate|
40793652|NCT00003776|PROCEDURE|surgical procedure|
40793653|NCT03103646|DRUG|Lu AF35700|Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg
40793654|NCT03103646|DRUG|Itraconazole (200 mg)|100 mg Capsules for oral use, 200 mg/day. In a fed state
40793655|NCT03103646|DRUG|Itraconazole (300 mg)|100mg Capsules for oral use, 300 mg/day. In a fasted state.
40793656|NCT04014699|PROCEDURE|modified 2.2mm microincision|enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
40793657|NCT04014699|PROCEDURE|conventional 2.2mm microincision|conventional 2.2mm coaxial microincision phacoemulsification
40793658|NCT00088491|DRUG|Intramuscular Olanzapine Depot|
40793659|NCT00088491|DRUG|Oral Olanzapine|
40793660|NCT01389674|PROCEDURE|2D-strain echo|"2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis."
40793661|NCT04133662|BEHAVIORAL|Sleep Manipulation Protocol|A structured sleep duration intervention will be taught to patients
40793662|NCT04426773|DEVICE|High-Definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA for 20 minutes. Cathode electrode will be localized in front of the OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8).
40793663|NCT02819297|DRUG|BLI400 Laxative|21 gm BLI400 powder
40793664|NCT02819297|DRUG|BLI400 Placebo|Equivalent amount of placebo powder
40793665|NCT05072860|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
40793666|NCT05072860|OTHER|: normal saline|temporary uterine packing with gauze of the dimensions soaked with placebo to 2 gm tranexamic diluted in 60ml saline acid
40793667|NCT06063681|DRUG|SR-8541A|orally administered ENPP1 inhibitor
40793668|NCT01619761|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic umbilical cord blood transplant
40793669|NCT01619761|DRUG|Cyclophosphamide|Given IV
40793670|NCT01619761|DRUG|Fludarabine Phosphate|Given IV
40793671|NCT01619761|OTHER|Laboratory Biomarker Analysis|Correlative studies
40793672|NCT01619761|DRUG|Lenalidomide|Given PO
40793673|NCT01619761|DRUG|Melphalan|Given IV
40793674|NCT01619761|DRUG|Mycophenolate Mofetil|Given IV or PO
40793675|NCT01619761|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
40793676|NCT01619761|BIOLOGICAL|Rituximab|Given IV
40999436|NCT05754151|BEHAVIORAL|MAYA Mobile Application|The mobile cognitive behavioral therapy (CBT) application, MAYA, teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, exposure and psychoeducation (i.e. information about anxiety and depression). The application includes an interactive dashboard to provide the user with statistics for tracking progress toward their goals. Although the MAYA application is new, its content and structure are similar to how CBT- a well-established and widely used psychosocial intervention - is commonly delivered in the more traditional setting of a psychotherapist's office.
40999437|NCT00962104|DRUG|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
41150145|NCT05740904|OTHER|Convenional aspheric single-vision spectacle lenses|The children in the convenional aspheric spectacle lenses group will wear conventional aspheric single-vision spectacle and receive follow-up examinations every half year.
41150146|NCT03279172|PROCEDURE|direct laryngoscope|procedure entubatıon
41311303|NCT03086317|DEVICE|Standard Catheter-Directed Thrombolysis|Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
41311304|NCT03086317|DEVICE|Ultrasound-Accelerated Thrombolysis|USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
41311305|NCT00910429|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
41470201|NCT06616896|DEVICE|vibration|Each participant will randomly receive four different vibration conditions (2 frequencies × 2 vibration modes = 4 conditions) in a different order. Considering that the current research range of local vibration frequency is 10 to 150 Hz the frequencies with low and high frequencies (30/60Hz) will be selected. The location chosen for this study is the quadriceps muscle belly. Two-minute vibrations will improve muscle strength without any fatigue side effects. Two vibration modes include providing a two-minute continuous vibration intervention and only providing vibration during the rest position before executing the functional test.
41150147|NCT03279172|PROCEDURE|videolaryngoscope|
41470202|NCT05800145|BEHAVIORAL|Resource information Supplemental Nutrition Assistance Program (SNAP)|Participants randomized to the resource referral arm will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address FI (e.g. SNAP).
40793677|NCT01619761|DRUG|Tacrolimus|Given IV or PO
40793678|NCT01619761|RADIATION|Total-Body Irradiation|Undergo TBI
40793679|NCT01619761|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo allogeneic umbilical cord blood transplant
40793680|NCT03423030|DRUG|PBTZ169 Formulation|PBTZ169 Formulation supplied as powder for oral solution
40793681|NCT03423030|DRUG|Placebo|matching placebo supplied as powder for oral solution
40793682|NCT03423030|DRUG|PBTZ169 NCP|PBTZ169 NCP supplied as powder for oral solution
40793683|NCT00181818|DRUG|bupropion SR (sustained-release)|
40793684|NCT03549286|OTHER|Questionnaire passation|Questionnaires assessing general knowledge about Down's syndrome screening, specific knowledge of NIPT for Down's syndrome and patient's satisfaction about provided information.
40999438|NCT00962104|DRUG|Placebo|Taken by mouth, once daily for 10 weeks.
40999439|NCT04112017|DEVICE|YVOIRE Y-Solution 360|Hyaluronic acid
41470203|NCT05800145|BEHAVIORAL|community health worker (CHW)|Participants randomized to the CHW intervention will have an initial baseline visit scheduled at a mutually convenient location.
40999440|NCT06310512|BEHAVIORAL|Structured drug therapy management|Interventions mainly included (1) information collection, clinical assessment, and evaluation of medication regimens; (2) identification of and intervention for medication-related problems; (3) pharmacy instruction and education, and development of personal medication lists; and (4) follow-up and reassessment
40999441|NCT00987116|DRUG|Prednisone - Azathioprine|"Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days."
40999442|NCT03054857|DRUG|Dexmedetomidine|After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
40999443|NCT03054857|DRUG|Placebo|The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
40999444|NCT02165046|DRUG|Budesonide|
40999445|NCT02165046|DRUG|Procaterol|
41470204|NCT05800145|BEHAVIORAL|medically tailored meals|Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
41470205|NCT03443817|BEHAVIORAL|Tele rehab|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month~Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist.~Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA.~Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
41470206|NCT05698927|PROCEDURE|Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)|Comparison of the postoperative opioid consumptions between Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)
41470207|NCT04440280|DRUG|N-acetyl cysteine (NAC) 10% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.
40999446|NCT02201303|DRUG|Danirixin|Powdered form for in-vitro administration to blood sample
40999447|NCT02201303|OTHER|CXCL1|Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
40999448|NCT05811611|BEHAVIORAL|WeChat Mini Program plus tailored online health promotion videos|Participants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.
41470208|NCT04440280|DRUG|N-acetyl cysteine (NAC) 20% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.
40999449|NCT05811611|BEHAVIORAL|WeChat Mini Program Only|Participants only have access to a WeChat Mini Program.
41470209|NCT04440280|DRUG|Visine Dry Eye Relief eye drops|Visine Tears Dry Eye Relief artificial tears ophthalmic solution
41470210|NCT03788356|DEVICE|Inspiratory muscle training|Inspiratory muscle training with a device
41470211|NCT03788356|OTHER|Diaphragmatic breathing|Diaphragmatic breathing exercise
40793685|NCT00411385|DRUG|albumin interferon alfa-2b|900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
40793686|NCT00411385|DRUG|peginterferon alfa-2a|180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
40793687|NCT00411385|DRUG|Ribavirin|800mg/day for 24 weeks
40793688|NCT05895123|DRUG|Rosuvastatin 20 mg|patients will receive one tablet rosuvastatin 20 mg every night
40793689|NCT05895123|DRUG|Atorvastatin 40mg|patients will receive one tablet Atorvastatin 40 mg every night
40793690|NCT04930146|OTHER|acupuncture and bloodletting|bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
40793691|NCT00595296|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
40793692|NCT02478814|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
40793693|NCT02649452|OTHER|vibration|vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
40999450|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
40999451|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
40999452|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
40999453|NCT04102865|DEVICE|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
40793694|NCT02419378|DRUG|Alemtuzumab|
40793695|NCT06511193|DRUG|Budenoside/Glycopyrronium/Formoterol|Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria
40793696|NCT02242058|OTHER|Quantitative sensory testing|
40793697|NCT02094118|BIOLOGICAL|Point-of-care washed red blood cell transfusion.|
40793698|NCT02094118|BIOLOGICAL|Standard of care red blood cell transfusion.|
40793699|NCT00432068|DRUG|Octreotide pamoate|
40793700|NCT04020471|OTHER|Pain Scale/Medication Log|Daily recording of pain level after surgery and recording of medication taken for pain relief.
40793701|NCT01344486|PROCEDURE|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
41311306|NCT05606224|BEHAVIORAL|internet-based mindfulness intervention for emotional distress|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
40793702|NCT01344486|PROCEDURE|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
40793703|NCT01506635|DRUG|Timolol|
40793704|NCT01506635|DRUG|Placebo|artificial tear twice a day
40793705|NCT00472654|BEHAVIORAL|Weight Loss|Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
40793706|NCT00472654|DIETARY_SUPPLEMENT|Vitamin D 2500 IU|Daily Vitamin D 2500 IU supplement for 6 weeks
40793707|NCT00472654|BEHAVIORAL|Weight Maintenance|Diet for weight maintenance for 6 weeks
40793708|NCT00945568|DRUG|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
41311307|NCT05656716|BEHAVIORAL|Nutritional intervention|The nutritional intervention will be based on a nutritional education program adapted for patients with breast cancer in active treatment. The nutritional intervention program will be based on the practical guidelines for nutrition in the oncology patient. The main objectives of the nutritional intervention will focus on preventing malnutrition, maintaining an adequate nutritional status and dietary adaptation to secondary symptomatology. To this end, an adequate energy and protein intake will be ensured and the consumption of plant-based foods will be promoted to ensure an adequate intake of vitamins, minerals and antioxidants
40793709|NCT03075852|DEVICE|Heads- Up Display Surgery|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.
40793710|NCT00974506|OTHER|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
40793711|NCT00974506|OTHER|Routine care therapy|Routine care therapy by general practitioner
40793712|NCT04106544|PROCEDURE|Investigational Procedures|The investigational assessments will be performed
40793713|NCT00619944|DRUG|Lumefantrine - lopinavir/ritonavir drug interaction|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
40793714|NCT00619944|DRUG|Lumefantrine only arm|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
40793715|NCT02456753|DEVICE|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
40793716|NCT06368843|DRUG|Gargle with ketamine|The patients asked to gargling with ketamine solution in the preoperative waiting area after explain the whole procedure and the goals of the study.
40793717|NCT02012036|DRUG|Hexvix|"As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.~The detection with Hexvix should be in accordance with local Summary of Product Characteristics \[SmPC\].~Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required."
40793718|NCT01550406|DEVICE|Tachocomb|"A kind of Mesh:~ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin"
40793719|NCT01550406|DEVICE|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
40793720|NCT02986633|OTHER|Echocardiography|
41150148|NCT06095817|BEHAVIORAL|Internet Delivered Brief Intervention (IDBI)|The intervention is an online module that can be accessed through smartphone, tablet, computer or other device. Participants will receive information about alcohol expectancies, alcohol use and norms, identity (service member, veteran, civilian), sleep, stress, and strategies for coping on the job.
40793721|NCT02477488|DRUG|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
40793722|NCT00109252|DRUG|Raptiva (efalizumab)|
40793723|NCT02589028|DIETARY_SUPPLEMENT|premeal protein-enriched bar intake|Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
40793724|NCT02589028|OTHER|breakfast follows by protein bar|Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
40793725|NCT03084705|DEVICE|Manumeter|A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
40793726|NCT04830839|BEHAVIORAL|Recovery after Stress Toolkit (ReSeT)|ReSeT involves online modules with parallel videoconferencing sessions. ReSeT integrates two evidence-based treatment methods: cognitive behavioral therapy coping skills (coping CBT) and direct exposure to trauma reminders through a trauma narrative.
40793727|NCT06069180|DRUG|Busulfan|Conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
40793728|NCT06069180|DRUG|Flu/Cy/ATG or Cy/ATG|Conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
40793729|NCT02905838|DEVICE|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
40793730|NCT02905838|DEVICE|CAD/CAM CARES Abutment|"Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).~All implant-supported crowns were fabricated in the same dental laboratory by the same dental technician (Dominique Vinci, Geneva, Switzerland). The implants were placed by experienced oral surgeons in a prosthetic ideal position."
40793731|NCT01462929|DRUG|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
40793732|NCT01462929|DRUG|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
41150149|NCT03505801|DEVICE|Confirm Rx ICM insertion procedure|Insertion of Confirm Rx ICM device
41470212|NCT05916716|PROCEDURE|Restorative procedure|Under local anesthesia, a rubber dam isolation will be placed at the site and a coronal bevel will be performed at the incisal margin of the NCCL allowing a correct tooth emergence profile. In sequence, acid etching with 35% phosphoric acid will be applied to the area and washed for 30 seconds with a water-air jet. The lesion will be dried with sterile cotton pellets to prevent dehydration. Active application of the adhesive will be performed for 20 seconds, followed by light curing for 30 seconds. The apical margin of the restoration will be placed 1 mm beyond the estimated position of the cementoenamel junction(CEJ) in order to rebuild only the anatomical part of the crown destroyed by the NCCL and 1 mm of the root surface to give the appropriate emergence profile. After rubber dam removal, the restoration will be finished with ultrafine-grained burs, and 48 hours after the restoration procedure, polishing will be completed with diamond paste and felt discs.
41470213|NCT05916716|PROCEDURE|Coronally Advanced Flap (CAF).|Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
40793733|NCT01462929|DRUG|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
40999454|NCT06014073|BIOLOGICAL|TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)|"Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (1 × 10\^7 cells/kg); Phase 2 : dose of RP2D.~No more than 2 × 10\^5 per kilogram of allogenic residual CD3+T cells harbouring in grafts can only be released for recipient infusion."
41470214|NCT05916716|DEVICE|Volume-stable collagen matrix (VCMX)|VCMX will be cut according to the recession defect and moistened with saline solution. The biomaterial will be placed at the cementoenamel junction (CEJ) level and stabilized in the adjacent surgical papillae by interrupted sutures.
41470215|NCT05916716|DRUG|Amoxicillin 500mg|Participants enrolled in the PR +CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
40999455|NCT06014073|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
40999456|NCT06014073|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
40999457|NCT02558790|DRUG|L-Threonic Acid Magnesium Salt (L-TAMS)|
41150150|NCT05680415|BIOLOGICAL|Mycobacterium Vaccae for Injection|The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, and a total of 6 doses were injected.
41150151|NCT03856294|DRUG|Rikkunshito|Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
41470216|NCT05916716|DRUG|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
40999458|NCT03434041|DRUG|Esketamine 56 mg|Participants will self-administer 56 mg of esketamine as intranasal spray.
40999459|NCT03434041|DRUG|Esketamine 84 mg|Participants will self-administer 84 mg of esketamine as intranasal spray.
40999460|NCT03434041|DRUG|Placebo|Participants will self-administer matching placebo as intranasal spray.
40999461|NCT03434041|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).
40999462|NCT03434041|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.
40999463|NCT03434041|DRUG|Sertraline (Oral Antidepressant)|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.
40999464|NCT03434041|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
41150152|NCT03856294|DRUG|Placebos|Placebo, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
41150153|NCT04475874|OTHER|supervised stretching exercises|30 to 45-minute supervised active stretching program by a trained physical therapist, three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
41150154|NCT04475874|OTHER|non-supervised active stretching home program|non supervised 30 to 45-minute supervised active stretching program three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
41150155|NCT06451705|DRUG|PECS II block|Treatment group that received the PECS II block using isobaric bupivacaine 0.5% 50 mg
41150156|NCT06451705|DRUG|LIA|Treatment group that received the local infiltration anesthesia using isobaric bupivacaine 0.5% 50 mg
41470217|NCT06537232|DIETARY_SUPPLEMENT|Greens-based Supplement|Participant will consume one serving of greens-based supplement per day in the morning, for 30 days.
41470218|NCT00422045|DEVICE|Low Level Laser Therapy|Low Level Laser Therapy done after surgery.
40999465|NCT00313612|DRUG|oxaliplatin|Given IV
40999466|NCT00313612|DRUG|topotecan|Given IV
40999467|NCT04952194|DRUG|Stalevo|The dose of Stalevo initially ranges from (Levodopa/Carbidopa/Entacapone) 50/12.5/200 mg 3 times a day to a target dose of 100/25/200 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
40999468|NCT04952194|DRUG|Carbidopa and Levodopa Controlled Release Tablets|The dose of Carbidopa and Levodopa Controlled Release Tablets initially ranges from (Levodopa/Carbidopa) 50/12.5mg 3 times a day to a target dose of 100/25 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
40999469|NCT00254995|BIOLOGICAL|None administered in this study|N/A in this study
40999470|NCT02347566|BEHAVIORAL|Physical activity enhancing programme|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.
40999471|NCT02347566|OTHER|Usual care|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.
40999472|NCT03942978|OTHER|Longitudinal Equity Action Plan|Patients admitted to general medicine pod randomized to intervention will receive a Longitudinal Equity Action Plan (LEAP), which will include a program manager to ensure they are on appropriate medical therapy, that cardiology is consulted when appropriate, that patient is set up with appropriate follow-up appointment with cardiology, that transportation is set up for follow-up visits, and a post-discharge follow up call to remind patients of the appointment and identify any post-discharge issues. This is in addition to standard of care, and there will not be any drug or device interventions.
41150157|NCT01309802|DRUG|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
41311308|NCT05656716|BEHAVIORAL|Physical exercise intervention|Weekly physical exercise guidelines will be given following the published Canadian clinical guideline recommendations combining moderate and vigorous aerobic activity. Walking will be performed 3 days a week for 30 minutes at a modified Borg scale intensity of 4-5/10, and 2 days a week for 15 minutes at a modified Borg scale intensity of 7-8/10. There will also be 5 minutes of warm-up and 5 minutes of recovery, in moderate activity at 3/10, and in vigorous activity at 4/10. In addition, 3 days per week (not coinciding with vigorous aerobic activity) of strength training at a modified Borg scale intensity of 7/10 will be included. Two sets of 8-10 repetitions will be performed, adaptable to that intensity according to the progression of the subjec
40793734|NCT02869672|BIOLOGICAL|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
40793735|NCT02869672|BIOLOGICAL|Hualan Biology ACYW135 meningococcal polysaccharide vaccine|Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
41150158|NCT05456061|DRUG|3% diquafosol eyedrops|Diquas® (Santen, Osaka, Japan), six times per day.
41150159|NCT05456061|PROCEDURE|Silicone punctal plug insertion|a silicone punctal occluder (Parasol® Punctal Occluder, BVI, Waltham, Massachusetts, USA), inserted into the lower eyelid
41311309|NCT06128798|DIETARY_SUPPLEMENT|Oral Impact|A serving of 74 gm (containing 309 kcal ) of oral impact mixed with 250 ml of water. Each participant will receive total of 3 servings daily for 7 days pre operatively .
41311310|NCT06128798|DIETARY_SUPPLEMENT|Nutren Optimum|A serving of 66.8 gm ( containing 304 kcal ) of nutren optimum mixed with 300 ml of water.Each participant will receive total of 3 servings daily for 7 days pre operatively .
40999473|NCT05413135|DRUG|ARO-APOC3|ARO-APOC3 Injection
40793736|NCT00047905|BEHAVIORAL|examine the process of prenatal genetic counseling|
40793737|NCT05991583|DRUG|IBB0979|IBB0979 should be subcutaneous injected，qw
40793738|NCT04335838|OTHER|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
40793739|NCT02574039|DIETARY_SUPPLEMENT|Oat bran|66g oat bran made up in 350ml skimmed milk
41311311|NCT04453696|BEHAVIORAL|Assessment scales-the Spielberger's State-Trait Anxiety Inventory, Modified Dental Anxiety Scale and a visual analog scale.|"STAI-S, like kinetic energy, refers to a palpable reaction or process taking place at a given time and level of intensity. STAI-T, like potential energy, refers to individual differences in reactions. Both of STAI-S and STAI-T scales includes 20 questions. For each question, the scores range from 1 (almost never) to 4 (almost always) points. For both scales, the sum of the scores ranges from 20 to 80. A score between 36 and 41 refers to a mean anxiety level, with values greater than 41 classified as a high level of anxiety.~The MDAS consists of 5 questions that measure anxiety at different stages of dental treatment. The options range from 1 (not anxious) to 5 (very anxious) for each question. The sum of the scores varies from 5 to 25; values between 19 and 25 indicate a high level of dental anxiety.~The VAS scale was included in the present study to determine how anxious the patients felt according to their own thoughts. Scores range from 0 (no anxiety) to 10 (extreme anxiety)."
41311312|NCT05078255|DRUG|Semaglutide 1.34 MG/ML [Ozempic]|Semaglutide 1.34 mg/ml
41311313|NCT05078255|DRUG|Glucose-dependent insulinotropic polypeptide (GIP)|GIP
41311314|NCT05078255|OTHER|Semaglutide 1.34 mg/ml placebo|Saline
41311315|NCT05078255|OTHER|GIP placebo|Saline
41311316|NCT02625324|DEVICE|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
40793740|NCT02574039|DIETARY_SUPPLEMENT|refined grain|refined grain product and 350ml skimmed milk
40793741|NCT05216718|PROCEDURE|Mini-flap|Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage
40793742|NCT05216718|PROCEDURE|Conventional flap|Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
41150160|NCT00839306|DRUG|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
41150161|NCT00839306|DRUG|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
41150162|NCT01819428|DRUG|NOV120101 (Poziotinib)|NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
41150163|NCT04493125|DRUG|Mosapride citrate|Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.
41150164|NCT04493125|DRUG|Placebo|Placebo
41150165|NCT01539902|BIOLOGICAL|Human Umbilical Cord derived MSCs|Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion
41150166|NCT01539902|DRUG|Cyclophosphamide|Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
41150167|NCT03219788|DRUG|Normal Saline|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
41150168|NCT03219788|DRUG|Remifentanil 0.1 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
41150169|NCT03219788|DRUG|Remifentanil 0.2 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
41150170|NCT02674867|OTHER|Blood draw|
41150171|NCT04301947|OTHER|Standard warm-up protocol|Stationary cycling and lower limb stretching exercises
41150172|NCT04301947|OTHER|Gluteal activation warm-up protocol|Standard warm-up protocol + Clam exercise (3 sets of 12 repetitions each)
41150173|NCT05033054|DRUG|SGLT2 inhibitor|Participants will ingest a standard dose of SGLT2i prescribed by the standard of care physician.
41150174|NCT02440919|OTHER|Hyperoxygenation 100% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 100% oxygen.
41311317|NCT04110418|DRUG|Methylene Blue|"Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h"
41311318|NCT03628430|PROCEDURE|lidocaine with epinephrine|Local anesthesia with lidocaine with epinephrine
41311319|NCT03628430|PROCEDURE|sodium bicarbonate|sodium bicarbonate as adjuvant to lidocaine with epinephrine in Local anesthesia
41311320|NCT03628430|PROCEDURE|Normal saline|normal saline as adjuvant to lidocaine with epinephrine in Local anesthesia
40793743|NCT03577834|DIETARY_SUPPLEMENT|liquid vinegar|6% red wine vinegar (2 tablespoons providing 1.7 g acetic acid)
40793744|NCT03577834|DIETARY_SUPPLEMENT|vinegar pill|Apple Cider Vinegar Tablets (1 tablet providing 0.0225 g acetic acid)
40793745|NCT06397378|OTHER|short videos related to HPV vaccines|We will develop 4 new videos and revise 2 existing videos and hope to increase college students\&#39; intention to receive HPV vaccines.
40793746|NCT06397378|OTHER|CDC HPV Fact Sheet|This intervention is an educational information that CDC provided to explain why you should receive HPV vaccines. https://www.cdc.gov/std/hpv/stdfact-hpv.htm
41150175|NCT02440919|OTHER|Hyperoxygenation 20% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
41150176|NCT02440919|OTHER|Hyperinflation (PEEP- ZEEP) Basal FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and involved no hyperoxygenation, keeping the oxygen already offered to the patient.
41150177|NCT02440919|OTHER|Hyperinflation (PEEP- ZEEP) 20% FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and hyperoxygenation involved supplying 20% oxygen.
41150178|NCT04597047|DIAGNOSTIC_TEST|Capillary Collection & Testing|Two (2) fingersticks will be performed on each subject and capillary blood tested in the LumiraDx SARS-CoV-2 Ab test
41150179|NCT04597047|DIAGNOSTIC_TEST|Venous Draw & Testing|One (1) Venous Draw (to include one (1) 6.0 mL EDTA tube and one (1) 3.5 mL serum separator tube) will be collected from each subject. Blood will be tested in the LumiraDx SARS-CoV-2 Ab test
41150180|NCT00547716|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
41150181|NCT00547716|DRUG|Placebo comparator|
41150182|NCT01217723|BIOLOGICAL|Anti-Thymocyte Globulin (Rabbit)|Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.
41150183|NCT01217723|OTHER|Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)|The standard preparative regimen can be myeloablative or reduced intensity.
41150184|NCT00795392|OTHER|ASA scale|ASA scale evaluation before operation
41150185|NCT00795392|OTHER|Full-scale psychological assessment|Full-scale psychological evaluation before operation
41150186|NCT00000940|DRUG|Ritonavir|
40793747|NCT02578446|DEVICE|Uncemented Triathlon Tritanium CR Total Knee System|Primary Total Knee Replacement
40793748|NCT02578446|DEVICE|Cemented Triathlon CR Total Knee System|Primary Total Knee Replacement
40793749|NCT03240562|PROCEDURE|serratus anterior plane block|before surgery :ultrasound-guided serratus anterior plane block
41150187|NCT00000940|DRUG|Abacavir sulfate|
41150188|NCT00000940|DRUG|Amprenavir|
41150189|NCT00000940|DRUG|Lamivudine|
41150190|NCT00000940|DRUG|Stavudine|
41150191|NCT06266390|DEVICE|Transcranial Magnetic Stimulation (TMS)|The TMS intervention will involve two sets of Intermittent Theta-Burst Stimulation (iTBS) delivered every weekday for 4-6 weeks. Each iTBS set consists of 40 trains and a total of 1200 pulses, delivered approximately 15 minutes apart, resulting in 2400 pulses per session.
41150192|NCT05850286|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, double infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
41150193|NCT05850286|DRUG|VRD-based Regimen|Bortezomib, Lenalidomide and Dexamethasone
41150194|NCT03669965|DRUG|KRT-232|KRT-232, administered by mouth
41150195|NCT03669965|DRUG|Ruxolitinib|Ruxolitinib per approved prescribing label
41150196|NCT06320171|DEVICE|Non-Invasive neuromodulation|This program involves changes in stimulus times and frequencies, varying from 192 Hz to 1429 Hz, generating symmetrical positive and negative polarity impulses. The intensity for all sessions is set to low, following the Arndt-Schulz law. A maximum total time of 10 minutes is considered for connecting the patient to the device at the beginning and for removing the device at the end of the session.
41311321|NCT04792437|PROCEDURE|surgery|surgery
41311322|NCT00471536|DRUG|pazopanib hydrochloride|800 mg Given orally
41311323|NCT06468982|OTHER|Intra-aortic Balloon Pump|in patients with acute myocardial infarction involving elevated troponin levels and recurrent or persistent chest pain at rest, hemodynamic instability, multivessel disease, left main coronary artery disease, and narrow and/or tortuous coronary artery anatomy in which PCI has failed or is not feasible.
41311324|NCT03850327|DEVICE|BIOMONITOR III|Patients with ICM indication receive a third-generation implantable cardiac monitor
41150197|NCT01596517|DRUG|Peginterferon alfa-2a plus ribavirin for HCV genotype 1|Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight \<75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
41150198|NCT01596517|DRUG|Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3|Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
41150199|NCT01636258|BEHAVIORAL|Stress Management|Every other week
41150200|NCT01636258|BEHAVIORAL|Diet|Every other week
41150201|NCT01636258|BEHAVIORAL|Exercise|Every week
41150202|NCT01636258|BEHAVIORAL|Culinary education|Every other week
40793750|NCT03240562|DRUG|patient controlled analgesia|two groups have same intravenous patient controlled analgesia
41150203|NCT05576233|PROCEDURE|disinfection of the surface that the blood culture is taken|lood cultures can be routinely performed with alcohol/povidine-iodine or alcohol/chlorhexidine. The topical disinfectants used in the two applications are the topical disinfectants included in the guidelines and currently applied in our hospital.
41150204|NCT01786551|DRUG|Eplerenone|50 mg daily for 14 days
41150205|NCT00090558|DRUG|nitroglycerin|
41150206|NCT00463957|DRUG|sildenafil|
41150207|NCT00463957|DRUG|tadalafil|
41311325|NCT02365584|DRUG|lanreotide (Autogel formulation)|Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
40793751|NCT05792007|PROCEDURE|Biological sampling in patients|blood and bone marrow samples from patients with Acute Leulemia.
40793752|NCT05792007|PROCEDURE|Biological sampling in control patients|blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).
41150208|NCT00463957|DRUG|placebo|
41150209|NCT02179086|RADIATION|3-dimensional conformal radiation therapy|Undergo standard-dose 3D-CRT
41150210|NCT02179086|RADIATION|intensity-modulated radiation therapy|Undergo standard-dose IMRT
41311326|NCT03704441|DRUG|Bupivacaine|bupivacaine dose
40793753|NCT04635709|DEVICE|biofeedback training and interferential therapy|compare the effect of applying both types of devices on the pelvic floor muscles
40793754|NCT04572646|OTHER|NRT proposition and exhaled CO measurement|"Nicotine replacement therapy is proposed to every patient included in the study.~Whether the patient accepts the therapy or not, exhaled carbon monoxide is measured at the preoperative consultation (about 15 days before surgery) and the day of surgery by a nurse. These two measures are compared to assess efficacy of nicotine replacement therapy."
41150211|NCT02179086|RADIATION|photon beam radiation therapy|Undergo dose-escalated and -intensified photon IMRT
41150212|NCT02179086|RADIATION|intensity-modulated radiation therapy|Undergo dose-escalated and -intensified photon IMRT
41150213|NCT02179086|RADIATION|proton beam radiation therapy|Undergo dose-escalated and -intensified proton beam radiation therapy
41150214|NCT02179086|DRUG|temozolomide|Given PO
41150215|NCT02179086|OTHER|laboratory biomarker analysis|Correlative studies
41150216|NCT06470945|PROCEDURE|Glass ceramic sectional veneer|partial laminate veneer
41150217|NCT06470945|PROCEDURE|Glass ceramic laminate veneer|Glass ceramic laminate veneer
41150218|NCT06187155|OTHER|INR self-management|will receive full education class of minimum one-hour time and training about how to interpret INR levels independently and adjust their medication dose according to a pre-determined dose-INR schedule.
41150219|NCT05717725|PROCEDURE|Pulsed-field ablation|Patients will receive catheter ablation, i.e. pulmonary vein isolation by means of pulsed-field energy
41150220|NCT05717725|PROCEDURE|Sham procedure|Patients will receive sham procedure, no ablation.
41311327|NCT00414960|DRUG|Enzastaurin|500 mg po QD for 6 months
41311328|NCT00414960|DRUG|Placebo|po QD for 6 months
41311329|NCT04155710|BIOLOGICAL|IOV-2001|Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.
41311330|NCT04155710|DRUG|Low dose IL-2|6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
41311331|NCT04155710|DRUG|High dose IL-2|6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
41311332|NCT04155710|DRUG|IL-2|6 doses of IL-2 will follow the infusion of IOV-2001
41311333|NCT01626911|PROCEDURE|Continuous regional arterial infusion of low molecular weight heparin in celiac trunk|Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
40793755|NCT05128032|DEVICE|Standard microcatheter|Small device used for mapping as part of radioembolization procedure
41311334|NCT01626911|OTHER|General treatment|Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
41311335|NCT04915924|DEVICE|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
41311336|NCT03579953|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key).
40793756|NCT05128032|DEVICE|PEDD device|Pressure enabled small device used for mapping as part of radioembolization procedure
41150221|NCT01411683|DEVICE|Implant-retained mandibular overdenture|Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
40793757|NCT01430143|BEHAVIORAL|Exercise|Daily exercise for 12 weeks.
40793758|NCT04755764|DRUG|Labetalol|Beta blocker
40793759|NCT04755764|DRUG|Atenolol|Beta blocker
40793760|NCT04755764|DRUG|Nifedipine|Calcium channel blocker
40999474|NCT01902446|DRUG|Chlorhexidine gluconate|Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
41150222|NCT05986851|DRUG|Azeliragon|Oral capsule
40793761|NCT03136653|BIOLOGICAL|MP0250 plus BOR+DEX|"6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.~Number of Cycles: until progression or unacceptable toxicity develops."
41150223|NCT04573946|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
41311337|NCT03579953|DEVICE|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
41311338|NCT00003444|BIOLOGICAL|recombinant interferon alfa|
40999475|NCT05368740|DEVICE|integrated pulmonary index monitor|Integrated Pulmonary Index (IPI) is a new monitoring method calculated using respiratory rate (RR), end-tidal carbon dioxide (EtCO2), peripheral oxygen saturation (SpO2), and heart rate (HR). It is designed to obtain information about the patients' oxygenation and ventilation in the form of a single value or waveform from 1 to 10 with a mathematical algorithm using fuzzy logic. According to this scoring system; 10= normal, 8-9= within normal range, 7= close to normal range, requires attention, 5-6= requires attention and may require intervention, 3-4= requires intervention, 1-2= requires immediate intervention \[2\].
41311339|NCT00003444|RADIATION|radiation therapy|
40793762|NCT04531280|OTHER|Home hospital care|Patients receive hospital-level care in their home.
40793763|NCT00854789|BIOLOGICAL|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
40793764|NCT02916511|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
40793765|NCT02916511|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
40793766|NCT02916511|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
40793767|NCT04152954|DEVICE|Radiofrequency ablation of cervical medial branches|Radiofrequency ablation of cervical medial branches
40999476|NCT01575184|OTHER|caudo-ipsilateral traction of shoulder|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
40999477|NCT01575184|OTHER|The ultrasonographic measurements without shoulder traction|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
41150224|NCT04573946|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
41150225|NCT04573946|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
41150226|NCT04573946|DIETARY_SUPPLEMENT|Vitamin D3|"Vitamin D3 (cholecalciferol), 2000 IU per day.~Other Names: cholecalciferol"
41150227|NCT05072795|BEHAVIORAL|Trier Social Stress Task (TSST)|The TSST is a standardized psychological stress challenge which provokes a stress response in a laboratory setting. During the task, saliva samples will be collected for hormone testing along with physiological and subjective measures.
41311340|NCT04694547|OTHER|There is no intervention, as this is a survey study|Survey
41311341|NCT03319615|BEHAVIORAL|Dietary energy restriction|
41311342|NCT06215222|OTHER|Microbiota Sampling|We will sample the Saliva, Feces, and intestinal microbiome for genetic microbiome analysis and bacterial isolation
41311343|NCT03292679|PROCEDURE|3D template|"A 3D-printed model of relevant portions of the patient's facial skeleton, based on patient's CT scan will be created. This model will be used to bend titanium reconstruction plates that are used to stabilize the facial fracture for subjects in the treatment group.~Bending of the plates will be performed in the operating room during the patient's surgery. Titanium reconstruction plates are used to stabilize the fracture whether or not the individual is in the study. However, for patients that are in the treatment arm of the study, the plates are bent with the aid of the 3D-printed model as template, rather than by free-hand."
41470219|NCT01997684|PROCEDURE|Colonic Stenting with Elective Surgery|"After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.~If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.~Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.~Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis."
41470220|NCT01997684|PROCEDURE|Emergency Surgery|Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
40793768|NCT01251562|DRUG|Sterile Compound C31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
40793769|NCT02653339|DRUG|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
40793770|NCT02653339|DRUG|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD"
41470221|NCT03230734|DRUG|Radium-223|Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
41470222|NCT03230734|DRUG|Docetaxel|Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
41470223|NCT05209906|DRUG|Fentanyl Buccal Soluble Film|Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.
41470224|NCT01755117|OTHER|Sciatic, femoral, obturator nerve blocks|
40793771|NCT03909412|DRUG|Carfilzomib|Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
41150228|NCT06090487|DIAGNOSTIC_TEST|myocardial function after surgery|This group includes (15) patients who will have 200 mg twice daily oral (5) sacubitril-valsartan 1 month before the operation. transthoracic echo will be done before and after surgery, also total dose if inoptropic drugs will be noted
41470225|NCT01755117|OTHER|Sciatic nerve block, posterior lumbar plexus block|
41150229|NCT01350102|DRUG|Bacitracin|Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.
41470226|NCT05974449|DRUG|Vaginal Lactobacillus capsules|This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
41150230|NCT01350102|DRUG|AmeriGel®|Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
41150231|NCT01350102|DIETARY_SUPPLEMENT|Vitamin C|Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve
41150232|NCT05640245|DRUG|Sonelokimab|randomized treatment; parallel group
41150233|NCT05640245|DRUG|Placebo|randomized treatment; parallel-group
41470227|NCT04452149|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.
41150234|NCT05640245|DRUG|Adalimumab|randomized treatment; parallel-group
41150235|NCT05658484|DRUG|Dimethyl fumarate|Administered as specified in the treatment arm.
41150236|NCT03462771|DRUG|Fish oil|4g of fish oil daily for 14 weeks
41150237|NCT03462771|DRUG|sunflower oil|4g of sunflower oil daily for 14 weeks
41150238|NCT03386344|DRUG|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
41150239|NCT03386344|DRUG|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
41150240|NCT00183599|BEHAVIORAL|5 Minutes of Simple Advice|
41150241|NCT00183599|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
41150242|NCT00183599|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
41150243|NCT04364035|BIOLOGICAL|ChAdOx1.HTI|ChAdOx1.HTI at week 0 and week 12; Vaccine delivered as one 0. 5 mL IM injection
41150244|NCT04364035|BIOLOGICAL|MVA.HTI|MVA.HTI at week 24 and week 36; Vaccine delivered as one 0. 5 mL IM injection
41150245|NCT04364035|DRUG|GS-9620|GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets
41150246|NCT04364035|BIOLOGICAL|Placebo|Saline placebo delivered as one 0. 5 mL IM injection
41470228|NCT04452149|OTHER|Medication intervention|Risk status guided medication intervention.
41150247|NCT04364035|DRUG|Placebo Oral Tablet|Unit-dose placebo tablet delivered as two 3-mg placebo tablets
40793772|NCT03909412|DRUG|Cyclophosphamide|Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.
40793773|NCT03909412|DRUG|Dexamethasone|Dexamethasone 40mg IV/PO to be administered as a premedication.
40793774|NCT03909412|DRUG|Granulocyte Colony-Stimulating Factor|On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
40793775|NCT02461199|BIOLOGICAL|Fecal microbiota transplantation|Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
40793776|NCT04708808|BEHAVIORAL|music therapy|cases will randomly assigned to receive music therapy group with routine care, plus music given via headphone, or assign to control group with no music given.
40793777|NCT02981862|OTHER|CaptHPV method|"20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly."
40793778|NCT02656394|DRUG|GL101|Topical Gel
40793779|NCT02656394|DRUG|Placebo|Placebo topical gel
40793780|NCT05271747|DIETARY_SUPPLEMENT|AB-Kolicare|Probiotic multi-strain formulation containing Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 for 21 days, 5 drops/day preferably during the first intake of milk
40793781|NCT05271747|DIETARY_SUPPLEMENT|Reuteri gotas|Probiotic single-strain formulation containing Lactobacillus reuteri DSM17938 for 21 days, 5 drops/day before or after any daily meal.
40793782|NCT01899781|DRUG|Antibiotic-Cefamezin|
40999478|NCT03970863|DIAGNOSTIC_TEST|Prostate Health Index|Use Prostate Health Index for the follow-up after focal therapy.
40999479|NCT05063110|DRUG|Itacitinib|Administration of 300 mg of ITACITINIB per os every day for 30 days.
41311344|NCT01149642|DIETARY_SUPPLEMENT|Oral Impact|"The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.~This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes."
41311345|NCT01149642|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
41311346|NCT03596359|BEHAVIORAL|Education with Teach-Back method|
41311347|NCT03596359|OTHER|Received routine treatment|
41311348|NCT02981277|DRUG|Transcricoid injection|Lignocaine delivery using Transcricoid Injection
41311349|NCT02981277|DRUG|Spray as you go|Lignocaine delivery using Spray as you go method
41311350|NCT04039191|BEHAVIORAL|SMS education|Patients will receive additional educational SMS messages post-operatively
41311351|NCT04039191|BEHAVIORAL|SMS survey|Patients will receive survey questions about post-operative pain and opioid use but no education
41311352|NCT04224285|OTHER|Dayzz app|Personalized sleep training app that evaluates sleep issues and offers a complete, holistic sleep improvement solution
41311353|NCT05605509|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
41311354|NCT05605509|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
41311355|NCT05605509|DRUG|FOLFIRI Protocol|Irinotecan Leucovorin FU
40999480|NCT01782651|DRUG|Lapatinib plus capecitabine|Lapatinib plus capecitabine
40793783|NCT04923334|BEHAVIORAL|Brief Pain Teleconsult|The Brief Pain Teleconsult intervention includes 2 sessions provided by a licensed physical therapist over about 1 week. The sessions focus on pain education from a biopsychosocial perspective that is designed to address negative pain appraisals and catastrophizing thoughts, providing advice to be active and engage in exercise and physical activity, and reassurance that activity is beneficial and safe.
40793784|NCT04923334|BEHAVIORAL|Telehealth Physical Therapy|The Telehealth Physical Therapy intervention involves weekly telehealth sessions provided over 10 weeks. Telehealth Physical Therapy is provided by a licensed physical therapist. Key components of the intervention include reinforcing biopsychosocial education messages and developing an exercise and physical activity program using cognitive behavioral principles such as goal setting and positive reinforcement. Pain coping strategies including mindful breathing and progressive relaxation techniques will be included.
40793785|NCT03263065|DIETARY_SUPPLEMENT|Bran|220g rice pudding meal with raspberry jam with added bran flakes
40793786|NCT03263065|DIETARY_SUPPLEMENT|Nopal|220g rice pudding meal with raspberry jam with added nopal flakes
40793787|NCT03263065|DIETARY_SUPPLEMENT|Psyllium|220g rice pudding meal with raspberry jam with added psyllium flakes
40793788|NCT03502915|DRUG|Nitrous Oxide|50% nitrous oxide/50% oxygen via Nitronox delivery device
40793789|NCT03502915|OTHER|Placebo|100% oxygen via Nitronox delivery device
40793790|NCT03961191|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
40793791|NCT03961191|DIAGNOSTIC_TEST|high-risk HPV|High-risk HPV testing for the cervical cytology
40793792|NCT03961191|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
40793793|NCT06309602|OTHER|Free Water Protocol|Intake of plain, un-thickened water is allowed even when a patient has orders for thickened liquids. Risks of pulmonary complications are decreased with use of a strict oral care regimen and timed intake of water related to meals. Patient satisfaction and comfort is increased with ingestion of plain water.
40793794|NCT06309602|OTHER|Control / Standard Care|Standard care will be given to patients with orders for thickened liquids. This will include oral care twice a day and implementation of swallowing strategies and precautions as prescribed by the treating speech-language pathologist. Only fluids thickened to the recommended viscosity will be available to the patient.
41470229|NCT06268860|DRUG|Rocatinlimab vial injection|Vial solution for SC injection administered on Day 1
40793795|NCT01313910|DIETARY_SUPPLEMENT|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
40793796|NCT04187248|DRUG|Asparaginase|
41311356|NCT05605509|DRUG|Trastuzumab|standard doses q3weekly
40793797|NCT02477917|BIOLOGICAL|Allergovac depot with Parietaria judaica pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
41311357|NCT00000524|DRUG|cyclosporine|
41311358|NCT00000524|DRUG|prednisone|
40793798|NCT03564574|COMBINATION_PRODUCT|Lipid Emulsion|All patients in the 'Study group' received a single dose of 100 ml of 20 percent Lipid emulsion as an infusion over 1 hour along with routine treatment as per institution protocols. Atropine was administered to patients by doubling dose method, which comprised of administering atropine starting from 2mg and to double the dose and administer till complete atropinization. Following this an infusion of 10 percent of the atropinizing dose was given every hour. Patients were evaluated using a standardized clinical interview, physical examination, laboratory tests.
40793799|NCT02391324|PROCEDURE|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
40793800|NCT02391324|PROCEDURE|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
40793801|NCT02391324|PROCEDURE|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
40793802|NCT01693198|PROCEDURE|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
40793803|NCT05204095|DEVICE|Portable slit-lamp photography|The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.
40793804|NCT03215498|DRUG|Faster-acting insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
40999481|NCT01203072|DRUG|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
40999482|NCT01203072|DRUG|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
41311359|NCT05398276|BEHAVIORAL|Behavioral Exposure For Introceptive Tolerance|BE-FIT will consist of a 6-session one-on one program with a clinician that are approximately 45 minutes delivered, over the course of 3 weeks (twice/week). Sessions will coincide with scheduled cardiac rehabilitation sessions at RWJ Cardiac Rehabilitation Program. The elements of BE-FIT are (1) psychoeducation about avoidance/anxiety and values clarification and committed action for exercise and lifestyle PA; (2) graded, repeated exposure to bodily sensations and exercise to build tolerance of discomfort; (3) fading safety behaviors and elimination of exercise avoidance behaviors to promote tolerance of uncertainty and reduce catastrophizing; and (4) use of Fitbit activity tracker to facilitate physical activity monitoring and provide physical activity feedback and goal-setting.
41470230|NCT06268860|COMBINATION_PRODUCT|Rocatinlimab prefilled syringe|Prefilled syringe solution for SC injection administered on Day 1
41470231|NCT00660868|DRUG|Pentoxifylline retard 400mg|Agapurin retard 400mg 3/day per os for 3 weeks
41470232|NCT00613860|DEVICE|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
41470233|NCT01017094|DRUG|silversulfadiazine|apply once a day
40793805|NCT03215498|DRUG|Insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
40793806|NCT05794880|DEVICE|Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)|Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.
40793807|NCT06011265|DRUG|Myrbetriq 25Mg Extended-Release Tablet|Participants take 4x 25mg Myrbetriq 25Mg Extended-Release Tablet orally.
40793808|NCT06011265|DRUG|Placebo|Participants take empty capsule orally
40793809|NCT06361966|DEVICE|3d printed prosthetic socket|3d printed prosthetic socket produced through multi-jet fusion (MJF)
40793810|NCT00344175|DRUG|pitavastatin|
40793811|NCT00344175|DRUG|simvastatin|
40793812|NCT00290719|DRUG|cisplatin|
40793813|NCT00290719|DRUG|gefitinib|
41311360|NCT05398276|BEHAVIORAL|Health Education Control|HEC is a time-matched control intervention that will be administered on the same delivery schedule as BE-FIT. The intervention content includes: (1) educational information about health topics relevant to healthy aging, and (2) Use of the Fitbit activity watch for PA monitoring. The 6 topics introduced in the HEC include: nutrition, sleep, brain health, emotional health, living with chronic conditions, how to be a smart patient. The health information will be conveyed through lectures and handouts. The goal of sessions will be to provide education, particularly as it relates to healthy aging. Patients will be given the same Fitbit as in the BE-FIT but will not be given PA goals.
41311361|NCT06349733|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
41311362|NCT06502444|BEHAVIORAL|Moving Forward Together Activity Intervention|The activity intervention program consists of videos and handouts to encourage participants to access these materials if they wish to increase their physical activity. The program lasts 8 weeks. Participants may access program materials for an additional four weeks after the program ends
40793814|NCT00290719|DRUG|irinotecan hydrochloride|
40999483|NCT01203072|DRUG|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
40999484|NCT01203072|DRUG|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
41470234|NCT01033578|OTHER|PVIC, TACE|"PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.~TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles."
40793815|NCT00290719|PROCEDURE|conventional surgery|
40999485|NCT01203072|DRUG|Placebo|Matching placebo oral tablets, once daily for 2 weeks
40999486|NCT02311491|DEVICE|Ceramic coated orthodontic archwire|Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
40999487|NCT05527431|DEVICE|high flow nasal cannula|high flow nasal cannula
40999488|NCT05527431|DEVICE|noninvasive ventilation|noninvasive ventilation
40999489|NCT06224530|DRUG|Levetiracetam|Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.
40999490|NCT06224530|DRUG|Placebo|Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.
40793816|NCT00290719|PROCEDURE|neoadjuvant therapy|
40793817|NCT00290719|RADIATION|radiation therapy|
40793818|NCT05978674|BEHAVIORAL|rocking bed group|Babies assigned to the intervention group first will be placed on a rocking bed after routine care such as feeding and diaper changes and when the newborn is stable. A rocking attempt will be applied to the baby placed in the rocking bed for 30 minutes. After 30 minutes, the baby will not be lifted from the bed and will lie in bed for 90 minutes. After a period of two hours in total, the babies will be cared for and fed. Then, babies will be quota and control group measurements will be made.
40793819|NCT02442505|DEVICE|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
40793820|NCT00135616|DEVICE|surgical placement of a suburethral sling tvt or tvt-o|
40793821|NCT05869253|BEHAVIORAL|The efficacy of Equine Assisted Occupational Therapy, for children with Attention Deficit Hyperactivity Disorder (ADHD) on cognitive-emotional aspects, daily function and participation|: A prospective cohort study with Interrupted Time-Series design will be conducted. Forty participants and their parents who were referred to EAOT will be recruited from the waiting list of Harey Yehuda stables. Assessments will take place at four time points. Time 1: baseline-when referred for EAOT. Time 2: pre-test, before first treatment session, end of 12 week waiting period. Time 3: post-test after 12 weeks of intervention and time 4: post intervention assessment, three months follow up. The intervention will be administered by a licensed EAOT, and assessments will be done by a blinded licensed occupational therapist (OT). Standardized assessment measures will be used to measure EFs, cognitive-emotional and sensory-motor aspects as well as participation at each time point.
40999491|NCT01072201|DRUG|Triclosan and Fluoride|Brush twice daily
40999492|NCT01072201|DRUG|Fluoride|Brush twice daily
40999493|NCT01959152|DEVICE|HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode|
40999494|NCT01125111|PROCEDURE|surgery(robot versus laparoscopy)|
40999495|NCT02843945|DEVICE|Directional Brachytherapy Source Implant|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
40999496|NCT05702593|PROCEDURE|Static stretching|The participant was positioned supine for static stretching to be applied to the hamstring muscles. The physiotherapist flexed the participant's hip to the point where resistance to the movement was first observed, with the knee extended.At this point, after waiting for 40 seconds, it was returned to the previous position. This application was made on both sides \[Bretischwerdt\]. The technique was repeated three times, with a 15-second rest interval between each repetition.
40999497|NCT05702593|PROCEDURE|Myofascial Release|For hamstring muscles, the participants were asked to assume a long sitting position on a firm, flat surface with their arms behind their backs and their body weight on their palms. A foam roller was placed under the hamstring muscles and slowly moved the tuberositas ischii popliteus back and forth with pressure for 4 minutes.
40793822|NCT02626156|DEVICE|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
40793823|NCT02626156|DEVICE|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
40793824|NCT04162470|DRUG|REGN3918|Subcutaneous (SC) every week (QW) over the treatment period
40999498|NCT03215329|PROCEDURE|abdominal or vascular surgery|Intermediate or high risk abdominal or vascular surgery
40999499|NCT01275495|BEHAVIORAL|Telephone Assessment and Skill-Building Kit (TASK II)|
40999500|NCT01275495|BEHAVIORAL|Information, Support, and Referral (ISR)|
41150248|NCT04361617|BEHAVIORAL|Daily consumption of tree nuts and extra virgin olive oil|All participants will receive a 4-week supply of extra virgin olive oil and tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day supply of each type). Participants will be asked to include in their normal diets these products and will be provided recipes and other information that will allow them to replace other foods with the nuts and oil. We will ask participants to consume one ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods into their diet.
41150249|NCT04119778|BEHAVIORAL|Aerobic Exercise, Tai chi|They are aerobic and mind-body exercise respectively.
40793825|NCT03584048|OTHER|Alert to provider|Providers receive alerts of sub-optimal patient attendance using 4 rules.
40793826|NCT03513913|PROCEDURE|ICSI|Oocytes are fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
40999501|NCT05420246|DRUG|Ainuovirine|The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.
40999502|NCT04557228|DIETARY_SUPPLEMENT|Placebo|4 weeks of placebo supplements
40999503|NCT04557228|DIETARY_SUPPLEMENT|Phosphatidylserine|4 weeks of phosphatidylserine supplements
41150250|NCT02574234|OTHER|Determination of apelin and inflammatory cytokines|A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
41150251|NCT02574234|OTHER|Assessment of cognitive functions|Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
40999504|NCT00892567|BIOLOGICAL|9 Peptides from Her-2/neu, CEA, & CTA|Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
41150252|NCT02574234|OTHER|Liquid sampling cerebrospinal|Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
41150253|NCT02574234|OTHER|Postoperative delirium research|Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
41470235|NCT02269956|BEHAVIORAL|12 week feasibility study|: At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for three meals over two days, and a medical record review will be conducted to ascertain technical and adaptive interventions also in place for the PWD (e. g., high density protein supplements, appetite stimulant medications, weighing, diet texture modifications). After baseline data is collected, the training program will delivered in five weekly modules with group coaching sessions completed the same week
40793829|NCT03278795|PROCEDURE|pressure support ventilation mode|PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.
40793830|NCT03278795|PROCEDURE|volume support ventilation mode|"VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated."
40793831|NCT06027658|BEHAVIORAL|RECREATION therapy|Dance as therapy program with speech and movement co-therapy via body activity.
40793832|NCT02524145|OTHER|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
40793833|NCT02524145|DRUG|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
40793834|NCT02524145|DRUG|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
40793835|NCT02524145|DRUG|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
40793836|NCT00403013|PROCEDURE|Positioning and anesthesia|Positioning during axillary plexus block
41311363|NCT03741920|DEVICE|Personal KinetiGraph™ (PKG™)|"The Personal KinetiGraph™ (PKG™) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by Global Kinetics (GKC).~The Personal KinetiGraph™ (PKG™) Movement Recording System consists of the following:~* A wrist-worn data logger designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording.~* A series of algorithms that analyze the uploaded data, producing a report that is delivered to the clinician. The report contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
40793837|NCT05634824|DRUG|intravenous immunoglobulin plus low dose recombinant human thrombopoietin (rhTPO)|rhTPO at an initial does of 150U/kg qd subcutaneously for 28 days and IVIg 400mg/kg qd for 5 days. The maintenance treatment consisted rhTPO 150U/kg qd.
40793838|NCT05634824|DRUG|intravenous immunoglobulin|intravenous immunoglobulin
40793839|NCT04089852|DRUG|Nitrous oxide gas for inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. Environmental safety will be maintained with an N2O scavenger system and Porter Miniature Vacuum System. The treatment group will receive inhaled N2O/O2. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2 and will be administered as outlined in the treatment arm description.
41311364|NCT00878917|DRUG|Dorzolamide 2 % eye drops solution|1 drop into eye(s) three times a day for the duration of each treatment phase
41311365|NCT05685667|DEVICE|needless laser injector (Mirajet)|Mirajet injection was performed 2-3 passes until a total of 2cc of diluted PLA/HA solution was completely injected to the one half of the face.
41311366|NCT05685667|DEVICE|needle injection|For traditional method of needle injection, intradermal injection using multi-puncture/micro-papule technique was used. A series of injections at 0.5-1 cm apart was performed on one half of the face so that a total of 2cc of diluted PLA/HA solution was injected.
41150254|NCT02574234|OTHER|Residual cognitive dysfunction research|Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
41150255|NCT06359483|OTHER|Meal Frequency Manipulation|The intervention involves altering meal frequency among participants. One group consumes three standardized meals per day, while the other consumes eight smaller, more frequent meals. Meals are designed to meet nutritional needs and adhere to dietary guidelines. The aim is to assess the impact of meal frequency on bone remodeling by measuring the blood biomarker P1NP at various points during the study.
41150256|NCT02246556|DEVICE|Dichoptic therapy|Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
41311367|NCT05092399|PROCEDURE|Bariatric Surgery|No study interventions
41311368|NCT06080776|DRUG|SH-1028 tablets|The initial dose of SH-1028 tablets is 200 mg once daily.
41311369|NCT06080776|DRUG|Placebo SH-1028 tablets|Placebo SH-1028 tablets.
41311370|NCT01872741|PROCEDURE|Minipterional craniotomy|Minipterional craniotomy approach for ruptured and unruptured aneurysms
41311371|NCT01872741|PROCEDURE|Pterional craniotomy|Pterional craniotomy approach for ruptured and unruptured aneurysm
40793840|NCT04089852|DRUG|Oxygen Gas for Inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. The control group will receive inhaled O2 alone. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered continuously throughout the procedure as outlined in the control arm description.
40793841|NCT03177018|DIAGNOSTIC_TEST|Cardiomyocytes collection|collect intact cardiomyocytes from which high quality DNA extraction will be achieved
40793842|NCT04863053|OTHER|Blood samples will be taken to assess platelet function. There is no change in treatment.|
40793843|NCT02569463|DRUG|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
40999505|NCT03780842|DEVICE|NAVA level|"A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV."
40999506|NCT00193882|DRUG|Cisplatin|80mg/m2 IV day 1
40999507|NCT00193882|RADIATION|Radiotherapy|35 Gy in 15 fractions
40999508|NCT00193882|DRUG|5-Fluorouracil|800mg/m2/day IV days 1 - 4
40793844|NCT00786305|DRUG|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
40793845|NCT00786305|DRUG|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
40793846|NCT02855879|OTHER|Collection of biological data|
40793847|NCT02855879|OTHER|Collection of clinical data|
40793848|NCT06004388|DEVICE|Click Digital Therapeutic|Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
40999509|NCT02753699|DRUG|Alisporivir|Intervention of interest; follow-up after ALV-active study
40999510|NCT02187588|DRUG|Eschscholtzia Californica - low dose|
40999511|NCT02187588|DRUG|Eschscholtzia Californica - high dose|
41150257|NCT02246556|OTHER|Patching therapy|Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
41150258|NCT02246556|DEVICE|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
41150259|NCT05653609|DEVICE|Cureety TechCare|Weekly adverse event questionnaires completed by the patients using a digital tool called Cureety
41150260|NCT05888142|BEHAVIORAL|in clinic pain VR reduction exercises|"During the first two weeks of treatment, participants will use commercially available VR during in clinic VR physical therapy exercises, to help reduce their pain and improve functionality."
41150261|NCT05888142|BEHAVIORAL|In clinic VRpain reduction exercises + VR homeworks|"During the first two weeks of treatment, participants will use commercially available VR during in clinic physical therapy exercises, and during homeworks to help reduce their pain and improve functionality."
41150262|NCT06584929|DRUG|Nicoderm CQ nicotine patch|Two week supply provided to participants on study.
41150263|NCT06584929|DRUG|Nicorette Nicotine Lozenges|Two week supply provided to participants on study.
41150264|NCT04585815|DRUG|Sasanlimab Prefilled syringe|prefilled syringe
40793849|NCT04512677|DEVICE|Timed Inspiratory Effort (TIE index)|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
40793850|NCT04295811|DEVICE|EsoGuard (lab assay)|EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
40999512|NCT02187588|DRUG|Ibuprofen|
40999513|NCT02187588|DRUG|Eschscholtzia Californica - low dose Placebo|
40999514|NCT02187588|DRUG|Eschscholtzia Californica - high dose Placebo|
41150265|NCT04585815|DRUG|Encorafenib|capsules
41150266|NCT04585815|DRUG|Binimetinib|tablets
41150267|NCT04585815|DRUG|Sasanlimab|solution supplied in vials
41150268|NCT04585815|DRUG|Axitinib|tablets
40793851|NCT04295811|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
40793852|NCT05165069|DRUG|Mecobalamin 5 MG Disintegrating Oral Tablet|Mecobalamin 0.5mg / time, 3 times / day,was taken continuously for 6 months
40793853|NCT05165069|DRUG|placebo|placebo 0.5mg / time, 3 times / day,was taken continuously for 6 months
41311372|NCT04903184|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in a total volum of 0,3mL.
41311373|NCT04903184|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo.
41470236|NCT06368024|OTHER|This is a retrospective analysis study of data collected with a diagnostic medical device|Transcranial Magnetic stimulation and Electroencephalogram
41470237|NCT02485158|DRUG|THC|This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
41470238|NCT02485158|DRUG|AMP|This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
41470239|NCT02485158|DRUG|ALC|This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
41470240|NCT02485158|DRUG|Placebo capsules|This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
40793854|NCT03549338|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
40999515|NCT02187588|DRUG|Ibuprofen Placebo|
41150269|NCT04585815|DRUG|SEA-TGT|solution in vials
41150270|NCT02536729|DRUG|Oral Sodium Phosphate - Normal preparation|
41470241|NCT02485158|DRUG|Placebo beverage|This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
41470242|NCT04478708|BIOLOGICAL|maridebart cafraglutide|Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.
41470243|NCT04478708|DRUG|Placebo|Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
41150271|NCT02536729|DRUG|Oral sodium phosphate - Modified Preparation|
41150272|NCT02536729|DRUG|polyethylene glycol + Electrolytes|
41150273|NCT05266209|OTHER|Coconut oil skin care group|No special technique was used for sample selection, random sample selection will be made. In the evaluation made according to the large effect size, the number of samples determined for Power: 0.80, :0.20 and :0.05 was determined as 66, with a minimum of 22 for each group. Calculations were made in computer environment using Power analysis (G\*Power 3.1.9.2) program. Random selection method will be used while creating research groups. Coconut oil, sunflower oil and control groups will be formed according to the order of admission to the unit. E.g; Coconut oil is planned for the first hospitalized newborn, sunflower oil for the second newborn, and third hospitalized newborn control group. This order will be repeated until a sufficient number of cases is reached when the newborns are included in the groups.
41470244|NCT06276686|OTHER|Supervised Vigorous intensity aerobic interval exercise|11-weeks course of aerobic and resistance exercise, delivered 2 weeks before long course NACRT, 5-weeks during NACRT and 4 weeks post NACRT. Alongside twice weekly unsupervised resistance exercise training.
40793855|NCT03549338|DRUG|Futuximab|Futuximab is one of two mAb components that constitute Sym004.
40793856|NCT03549338|DRUG|Modotuximab|Modotuximab is one of two mAb components that constitute Sym004.
40793857|NCT01136525|DRUG|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
40793858|NCT00162214|DRUG|Dasatinib + Ketoconazole|Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
40793859|NCT01540786|PROCEDURE|High resolution urodynamic assessment|
40999516|NCT02473315|OTHER|cryotherapy|"The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).~The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks)."
40999517|NCT04407910|COMBINATION_PRODUCT|AIRFLOW® Master device +Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
40999518|NCT04407910|COMBINATION_PRODUCT|rubber-cup+Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
41311374|NCT00032019|BIOLOGICAL|filgrastim|Cycle 1: 300 ug (BW \< = 70 kg) or 480ug (BW \>70 kg) sub Q injection Day 6 until ANC \> 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity
41311375|NCT00032019|BIOLOGICAL|rituximab|375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities
41311376|NCT00032019|DRUG|cyclophosphamide|750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
40793860|NCT01540786|PROCEDURE|Conventional urodynamic assessment|
40793861|NCT04556357|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
40793862|NCT04556357|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
40793863|NCT03667313|COMBINATION_PRODUCT|sirolimus-eluting balloon (SEB) MagicTouch|Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon
40793864|NCT03667313|COMBINATION_PRODUCT|paclitaxel-eluting balloon (PEB) Sequent Please|Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon
40793865|NCT03000556|DRUG|0.3% Sodium Hyaluronate Eye Drop|The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
40793866|NCT01214473|DIETARY_SUPPLEMENT|Synbiotics|Lactobacillus plantarum with fructo-oligosaccharide
40793867|NCT01214473|DIETARY_SUPPLEMENT|Maltodextrin|Only maltodextrin as placebo
40793868|NCT06059456|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
40793869|NCT06059456|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
41311377|NCT00032019|DRUG|doxorubicin hydrochloride|10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
40793870|NCT04138511|DEVICE|ECOFISIO|The ECOFISIO application is focused on sports pathologies and contains relevant written and digital information about ultrasound imaging and managing as well as diagnosis of sport injuries.
40793871|NCT05971992|DIETARY_SUPPLEMENT|Chicory-derived inulin-type β-fructans|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of prebiotic. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-weeks intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of prebiotic per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
40793872|NCT05971992|DIETARY_SUPPLEMENT|Maltodextrin|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of maltodextrin. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-week intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of placebo per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
40793873|NCT06147076|BEHAVIORAL|Social Support Network Counseling Intervention|Social support counseling intervention for kidney transplant candidates along with their social support networks.
40793874|NCT06339450|OTHER|walk tours|"* During 5 days the patient will walk 4 hours in urban green space (open-space areas reserved for parks and other green spaces, including plant life, water features -also referred to as blue spaces and other kinds of natural environment). The 3 hours walk tour includes a lunch break of one hour in the green space.~* During 5 days the patient will walk 4 hours in urban space (including 3 hours walk around the city and one-hour lunch break."
40793875|NCT06099223|DEVICE|Acupuncture needles|"The acupuncture intervention includes a combination of auricular and body acupuncture. The auricular points used are Shen men, Zero point, Tranquilizer point, and Master cerebral.~The body points used are the wrist PC6."
40793876|NCT03226327|DIETARY_SUPPLEMENT|formula salt with very low sodium (Brand name: Manlikang)|hypertension patients will use the formula salt with very low (\<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
41311378|NCT00032019|DRUG|etoposide|50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
41311379|NCT00032019|DRUG|prednisone|60 mg/sq m PO bid days 1-5 of ea cycle
41311380|NCT00032019|DRUG|vincristine sulfate|0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
41470245|NCT06590350|OTHER|Clinical nutrition counseling|"In the first phase, all patients admitted to the Departmental Simple Operating Unit Admission Room of Policlinico Universitario A. Gemelli will be screened for NRS-2002 upon admission.~Only patients with NRS-2002 ≥ 3 will subsequently be tracked via the Foundation's computer system (TrackCare®).~The patients will be managed by caregivers who may spontaneously request nutritional counseling, as is currently the case.~Patient data (laboratory tests, medical history, reason for admission, any instrumental test reports) and clinical outcomes (average length of hospitalization, complications, antibiotic therapy use, intensive care admission, mortality, re-hospitalization within 30 days) will be obtained from the Foundation's computer system (TrackCare®) and recorded in a dedicated Excel® spreadsheet.~Costs related to hospitalization and management of any complications will also be assessed."
41470246|NCT05464719|DRUG|Loncastuximab Tesirine|Given by IV
40999519|NCT01876485|BEHAVIORAL|Empowering Patients in Chronic Care (EPIC)|EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
41311381|NCT02730936|DEVICE|Antimicrobial Hernia Repair Device|hernia repair
41311382|NCT04790552|OTHER|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
41311383|NCT04790552|OTHER|Fasting|Subjects will be asked to fast overnight for approximately 15 hours.
41311384|NCT04790552|OTHER|Fast Bar|Subjects will be asked to consume a Fast Bar.
40793877|NCT06249334|OTHER|Whole-body electrical stimulation|The protocol with whole-body electrical stimulation will begin in the intensive care unit and will be completed in the inpatient unit. To stimulate all proposed muscle groups, self-adhesive electrodes will be positioned bilaterally on the quadriceps femoris, tibialis anterior, biceps brachii and lower rectus abdominis muscles. The frequency of 75 Hz will be adopted and the intensity will be adjusted to cause visible muscle contraction. The progression of the therapy protocol will occur throughout the sessions aiming to reach 20 minutes of therapy and 80 contractions.
40793878|NCT06249334|OTHER|Routine physical therapy|The protocol will be based on knee and hip flexion and extension movements; hip adduction and abduction; flexion and extension of shoulders, elbows and wrists; shoulder abduction and adduction; respecting the range of each joint. Volunteers will also perform transfers from lying to sitting and standing positions. Respiratory conduct will be based on ventilation patterns, bronchial hygiene maneuvers and cough.
40793879|NCT03023306|OTHER|Antiemetics perioperatively|Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
40793880|NCT04861779|DRUG|HSK29116|Oral HSK29116
40793881|NCT06453343|PROCEDURE|Surgical approach: cochleostomy or extended round window|Surgical placement of a cochlear implant electrode array
41150274|NCT00887471|PROCEDURE|PITA or T&A|PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T\&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
41470247|NCT01533649|BEHAVIORAL|Andrews/Reiter approach to epilepsy|"The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook (Taking Control of Your Epilepsy) as an on-going step-by-step guideline."
41311385|NCT04790552|OTHER|Bar with Coffee|Subjects will be asked to consume a Fast Bar with coffee.
41311386|NCT04790552|OTHER|Bar with Tea|Subjects will be asked to consume a Fast Bar with tea.
41311387|NCT05636371|OTHER|Written Communication|Written patient care updates provided to families of ICU patients each day
41311388|NCT00004880|BIOLOGICAL|dendritic cell vaccine therapy|
41470248|NCT01533649|BEHAVIORAL|Relaxation/Meditation|Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
41470249|NCT04873817|DEVICE|IonicRF Generator andcompatible accessories|Participants will recieve IonicRFRF lesion generator, along with any country-specific market-released accessory (i.e. electrode,cannula, grounding pad, and adaptor cable) compatible with theIonicRF Generator
41470250|NCT00833508|OTHER|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
41470251|NCT06613893|DRUG|TIVA|Anesthesia will be maintained by total intravenous anesthesia with propofol infusion (4 to 12 mg/kg/min) and fentanyl infusion (3-4.8 mic /kg/hour)(Ting 2019) that will be stopped 30 min before the end of the operation ,The heart rate and blood pressure will be maintained within the range of ±20% of the baseline
41470252|NCT06613893|DRUG|Inhalational anesthesia|Anesthesia will be maintained with inhaled isoflurane from (0.7 to 1.4%)(Hawkley, Preston, and Maani 2018) and fentanyl 0.35 to 0.5 mcg/kg supplementary dose will be given if needed to maintain the heart rate and blood pressure within the range of ±20% of the baseline
41470253|NCT05282108|DRUG|Carcemia|Generic Imatinib
40793882|NCT04010097|OTHER|chewing gum|The test involves chewing a chewing gum for 4 minutes
40793883|NCT02137642|DRUG|RM-131|Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
40793884|NCT02137642|DRUG|Placebo|Double blind placebo will be delivered once by injection during study procedure.
40793885|NCT04495530|OTHER|Non-interventional study|semi-structured interviews will take place on one occasion with participants in this study. This is qualitative research, and does not involve any interventions
40793886|NCT05025410|DRUG|Remimazolam|Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring
41150275|NCT02627534|PROCEDURE|Ultrasonic debridement|All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
41150276|NCT02627534|PROCEDURE|Antimicrobial photodynamic therapy|After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
41150277|NCT01598454|DRUG|racotumomab|Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
41150278|NCT02409888|BEHAVIORAL|Motivational Enhancement Therapy|The motivational enhancement therapy will be delivered according to the Project MATCH manual.
41150279|NCT02409888|BEHAVIORAL|Cognitive Behavioral Therapy|The cognitive behavioral therapy will be delivered according to the Project MATCH manual.
41150280|NCT02409888|OTHER|FC Assessment|FC Assessment study participants are exposed to quarterly assessments across broad domains of functioning.
41311389|NCT00004880|PROCEDURE|conventional surgery|
41470254|NCT05282108|DRUG|Glivec|Imatinib
41470255|NCT05418985|BEHAVIORAL|Monthly reminder message about breast self-exam.|Monthly reminder message about breast self-exam.
40793887|NCT03938987|BIOLOGICAL|autologous CD19-directed chimeric antigen receptor (CAR) T-cells|Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
40793888|NCT05821452|DRUG|Camrelizumab|200mgQ3w
40793889|NCT05821452|DRUG|Paclitaxel|175mg/m2，D1，Q3w
40793890|NCT05821452|DRUG|Cisplatin|75mg/m2，D1，Q3w
40793891|NCT05821452|RADIATION|Radiotherapy|41.4Gy, 1.8Gy each time, 5 times a week
40793892|NCT02748499|OTHER|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
40793893|NCT02748499|OTHER|Control|Participants maintain their daily acitvities.
40793894|NCT05094063|OTHER|patient education by mobile application|Training will be given to the patients in the experimental group.
40793895|NCT00924014|DRUG|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
41150281|NCT02409888|OTHER|IB Assessment|IB Assessment study participants are exposed to semi-annual alcohol specific assessments
41311390|NCT04986449|BEHAVIORAL|nutritional and culinary intervention|"Each family will attend a total of 4 culinary-nutritional workshops between April and June 2021. Workshops 1 and 2 will be held in the kitchen located at the Science Building of the University of Navarra and will be given individually to each family.~Workshops 3 and 4 will be online (Zoom) and will be held in groups of 5 families. These workshops will be held from 5.30 pm to 7.30 pm on Fridays or from 11.30 am to 1.30 pm on Saturdays.~Finally, a meeting will be organized with all the families (parents and children) where the recipes prepared by the children for the n-CHEF challenge will be shared and prizes will be awarded."
41311391|NCT04068311|OTHER|Geriatric Screening tools|Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.
41311392|NCT03369106|OTHER|Composite severity score calculation|Neurological examination, cognitive testing, and MRI exam
41311393|NCT00205296|BEHAVIORAL|exercise|this will test the effect of exercise on insulin sensitivity, fitness and body composition
41311394|NCT03982771|DRUG|Bortezomib|-Bortezomib: 1.3mg/m2 subcutaneous injection on Day 1,8,15,22 every month for 9 months; And maintained with 1.3mg/m2 subcutaneous injection every two weeks from Month 9 to 21;
41311395|NCT03982771|DRUG|Cyclophosphamide|-Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
41311396|NCT03982771|DRUG|Dexamethason|Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.
41311397|NCT05397223|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
41311398|NCT05397223|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
41311399|NCT05397223|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
40793896|NCT00924014|DRUG|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
40793897|NCT00924014|DRUG|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
40793898|NCT03954548|DEVICE|CB-17-08 CADe|CB-17-08 Augmented Endoscopy System with Computer Aided Detection (CADe) function
40793899|NCT03815448|DRUG|Methotrexate|Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
40793900|NCT03815448|OTHER|Placebo|Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
40793901|NCT03654118|OTHER|Phone follow-up|"Through a short phone interview :~* Determination of a complication (Infection, capsulitis, recurrence)~* Determination of the Rowe score~* Determination of the Walch-Duplay score"
40793902|NCT06105411|DIAGNOSTIC_TEST|68Ga-labelled TAFC PET/CT scan|68Ga-labelled TAFC PET/CT scan (whole body)
40793903|NCT02002507|OTHER|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
40793904|NCT00844142|DRUG|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
40793905|NCT00844142|DRUG|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
40793906|NCT04060004|OTHER|Dry needling|Dry needling is a technique used by physiotherapists.
40793907|NCT04060004|OTHER|Sham dry needling|Sham dry needling is a technique used by physiotherapists to compare the effects of dry needling.
40793908|NCT04060004|OTHER|Electrotherapy + therapeutic exercise|Standard care of neck pain.
40793909|NCT02325024|DRUG|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
40793910|NCT03384459|DEVICE|the 308-nm excimer laser|For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
40999520|NCT01876485|BEHAVIORAL|Enhanced Usual Care (EUC)|Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
41150282|NCT03897270|PROCEDURE|Photoacoustic Imaging|Undergo photoacoustic imaging of the breast
41150283|NCT03916159|PROCEDURE|Extrauterine placental transfusion (Intervention group)|At delivery by caesarean section, the infant is born with the placenta still attached via the umbilical cord and placental transfusion is performed at least 1 minute but not more than 10 minutes by holding the placenta \~40-50cm above the babies' heart level while respiratory support by mask continuous-positive-airway-pressure (CPAP) is initiated simultaneously.
40793911|NCT03549494|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|Ocoxin-Viusid group (Experimental). Oral solution of Ocoxin-Viusid (vials of 30 ml), at a rate of 60 ml daily (1 vial every 12 hours), administrado preferably administered after breakfast and dinner. The product will dilute in water, milk or juice. The treatment will have a period of 19 weeks, starting 2 weeks before the onco-specific treatment with FOLFOX chemotherapy and will end 3 weeks after the end of the sixth cycle of chemotherapy. QT FOLFOX will be prescribed intravenously every 14 days for 6 cycles as follows: Oxaliplatin (85 mg x m2) on day 1 Folinic acid (200 mg x m2) on day 1 and 2 5 Fluoracil (400 mg x m2, bolus) on day 1 and 2 5 Fluoracil (600 mg x m2, continuous infusion) on day 1 and 2
40793912|NCT06421714|DRUG|Venglustat|Pharmaceutical form:Capsule-Route of administration:Oral
41470256|NCT05140668|DEVICE|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
41470257|NCT05261789|OTHER|Turkish Get Up exercise|"Before the exercise, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes. 7 different steps (1. Starting position, 2. Supine kettlebell lift, 3. Elbow-supported kettlebell lift, 4. Hand-supported kettlebell lift, 5. High bridge, 6. Half-kneeling and lunge position, 7. Standing up) and the return of these different steps, a total of 2 stages exercise program was applied.~The exercise was started with 3 repetitions for each side and 3 sets with a 30-second rest period between repetitions, and 2 minutes of rest between sets. At the beginning of the 3rd week, the exercise was applied as 3 sets of 4 repetitions, and at the beginning of the 5th week, 3 sets of 5 repetitions were applied. At the end of the exercise, cool-down exercises (low intensity jogging and static stretching) were applied for 5 minutes."
41470258|NCT05261789|OTHER|Core Stability exercise|"After the individuals were taught how to activate their core muscles before the exercise, they were asked to do bridge, prone and lateral bridge exercises by contracting their core muscles. Before the exercises, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes.~Bridge exercise, prone bridge exercise, lateral bridge exercise were applied"
40793913|NCT06421714|DRUG|Itraconazole|Pharmaceutical form:Capsule-Route of administration:Oral
40793914|NCT02289365|DRUG|2000 mg of JBM-TC4 per day|2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
40793915|NCT02289365|DRUG|3000 mg of JBM-TC4 per day|3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
40793916|NCT02289365|DRUG|3000 mg of PEG-400 per day|3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
40793917|NCT03902392|DIETARY_SUPPLEMENT|NaturOx Group (A)|Comparison between dietary supplement and placebo
40793918|NCT03902392|OTHER|Placebo Group (B)|Comparison between dietary supplement and placebo
40793919|NCT02805465|DEVICE|CRT Device and Bi-ventricular pacing|Bi-ventricular pacing by a CRT device
41311400|NCT05397223|BIOLOGICAL|FLUAD®|adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine
40793920|NCT02805465|DEVICE|CRT Device and His-bundle Pacing|His-bundle pacing by a CRT device through the pacing lead at His-bundle region
40793921|NCT05849090|DRUG|Cephalosporin or clindamycin/vancomycin antibiotics..|Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).
40793922|NCT05849090|DRUG|Vancomycin and Tobramycin antibiotics.|Vancomycin (1 gram) and tobramycin (1.2 grams).
40793923|NCT03343340|OTHER|Early CRRT|Continous Renal Replacement Therapy
41150284|NCT03916159|PROCEDURE|Delayed cord clamping (Control group)|At delivery by caesarean section, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 30 seconds with initiation of respiratory support by mask CPAP after cord clamping.
41150285|NCT00755924|DIETARY_SUPPLEMENT|Vinegar|Apple cider vinegar 2 TBlsp/day
41150286|NCT00755924|OTHER|Placebo|Water placebo colored with balsamic vinegar
41311401|NCT05397223|BIOLOGICAL|mRNA-1647|Sterile lyophilized product
41311402|NCT00093678|DRUG|celecoxib|
41311403|NCT00093678|PROCEDURE|anticachectic therapy|
41311404|NCT00093678|PROCEDURE|nutritional support|
41311405|NCT00093678|PROCEDURE|pain therapy|
41311406|NCT00093678|PROCEDURE|supportive care/therapy|
41470259|NCT05261789|OTHER|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
40793924|NCT03343340|OTHER|Late CRRT|Continous Renal Replacement Therapy
40793925|NCT03343340|OTHER|Standard Medical Therapy|Standard Medical Therapy
40793926|NCT03355950|PROCEDURE|Lichtenstein Repair|Well defined Lichtenstein Repair for inguinal hernias
40793927|NCT03355950|PROCEDURE|TEP Repair|Laparoscopic totally extraperitoneal repair for inguianal hernias
40793928|NCT01330095|DIETARY_SUPPLEMENT|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
40793929|NCT03782623|DIAGNOSTIC_TEST|Analysis of eicosanoid profile prior to and after PRBC transfusion|Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
40793930|NCT01621984|OTHER|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
40793931|NCT02417610|DEVICE|Polynucleotide - PNHA - Newart|gel polynucleotides and hyaluronic acid
40793932|NCT02417610|DEVICE|Hyaluronic acid - HA - Ialart|Hyaluronic acid
41150287|NCT01124656|DRUG|Pioglitazone-Azilsartan|Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
41311407|NCT05519371|DRUG|Remimazolam|"During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h~During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped."
41470260|NCT00213057|DRUG|Carraguard (PC-515)|
41311408|NCT05519371|DRUG|Propofol|During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
41470261|NCT00603564|PROCEDURE|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
41470262|NCT05632692|OTHER|Menthol solution|Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
41470263|NCT05925244|OTHER|Control Condition|Control (no alteration to body mass).
41470264|NCT05925244|OTHER|+12% Body Mass|Loaded walking exercise (12% increase in body mass using a weighted vest).
40793933|NCT00353301|DRUG|Erlotinib hydrochloride|Patients will receive single-agent Tarceva, 150 mg/day
40793934|NCT00353301|DRUG|Sirolimus|Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
41150288|NCT04733950|OTHER|Forced choice psychoacoustic task for the evaluation of modulation detection performance and selective auditory attention. (for both arm)|"Description:~3-interval, 3-alternative forced choice amplitude modulation detection task using a target sinusoidal carrier and a spectrally distant, interfering (distracting), sinusoidal carrier that may or not be modulated at the same rate as the target."
40793935|NCT03522415|DRUG|HLX01|HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
40793936|NCT03522415|DRUG|Methotrexate（MTX）|Methotrexate is a slow-acting antirheumatic drug.
41150289|NCT04733950|OTHER|Measurement of the pupil diameter for the evaluation of listening effort during speech perception|Pupil diameter is recorded using an eye-tracker device (Tobii Pro TX300) while the subject performs a 16-alternative consonant identification task both in silence and in the presence of interfering speech.
41150290|NCT03953209|DRUG|Spironolactone 50Mg Tablet|Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
41150291|NCT03953209|DRUG|Spironolactone 100Mg Tablet|Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
41470265|NCT05925244|OTHER|-12% Body Mass|Unloaded walking exercise (12% decrease in body mass using lower body positive pressure).
41311409|NCT03972644|PROCEDURE|Aortic valve replacement|Open heart surgery or transcatheter surgery
41470266|NCT05039437|DIETARY_SUPPLEMENT|MGF-4|Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
41470267|NCT05039437|DIETARY_SUPPLEMENT|MGF-7|Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
41470268|NCT02025231|RADIATION|External beam radiotherapy|Study group 1: 3.5 Gray x 10, 5 fractions per week. Study group 2: 3.5 Gray x 10 + 7 Gray boost to biological target volume, 5 fractions per week. Study group 3: 5.9 Gray x 10, 5 fractions per week. Study group 4 (planning target volumes: 100 millilitres - 300 millilitres): 3.5 Gray x 10, 5 fractions per week. Phase II dosis: to be chosen based on results of phase I study.
40793937|NCT02933879|DRUG|NVXT topical|topical treatment
40793938|NCT02933879|DRUG|Placebo (Vehicle) Topical|Placebo (Vehicle) Topical
40793939|NCT06513754|OTHER|Ozone|Ozone is a pollutant that forms as a result of nitrogen oxides or volatile organic compounds interacting with UV radiation. Ozone will be created via a generator in the lab
40793940|NCT06513754|BEHAVIORAL|Heavy Intensity|Heavy intensity exercise between the first and second ventilatory threshold for 45 minutes
41150292|NCT03953209|DRUG|Spironolactone 200Mg|Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
41150293|NCT00730925|DRUG|BIBW2992|tablet BIBW high dose
41150294|NCT00730925|DRUG|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
41311410|NCT01747278|DRUG|Trimethoprim/Sulfamethoxazole|Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
41311411|NCT03892330|DRUG|Vincristine|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
41311412|NCT03892330|DRUG|Oxytetracycline/ Cyclophosphamide|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
40793941|NCT06513754|BEHAVIORAL|Moderate Intensity|Moderate intensity exercise below the first ventilatory threshold for approximately 75 minutes
40793942|NCT06513754|OTHER|Filtered Air|Exposure to filtered air (\<10 ppb ozone)
40793943|NCT02063685|DRUG|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
40793944|NCT02063685|DRUG|Observation|not maintenance therapy and followed-up with MRD monitoring.
40793945|NCT02063685|DRUG|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
40793946|NCT02063685|DRUG|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
40999521|NCT00951431|DRUG|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
40999522|NCT00951431|DRUG|Placebo|Placebo in the form of study drug
41150295|NCT00402298|DRUG|MDMA|Participants will receive an initial dose of 125 mg MDMA orally followed 2.5 hours later by 62.5 mg MDMA orally during the course of a day-long therapy session.
41150296|NCT00402298|DRUG|MDMA|Participants will receive an initial dose of 25 mg MDMA orally followed 2.5 hours alter by a supplemental dose of 12.5 mg MDMA orally during the course of each of two day-long therapy sessions.
41150297|NCT02339506|DRUG|Cosyntropin|Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
41150298|NCT02339506|DRUG|Placebo|Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
41150299|NCT00113009|DRUG|VLTS-934|
41150300|NCT00170950|DRUG|Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
41311413|NCT03892330|DRUG|Liposomal doxorubicin|The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
41311414|NCT03892330|DRUG|Doxorubicin|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
41311415|NCT03892330|DRUG|Pharmorubicin|The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
40793947|NCT02063685|DRUG|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
40999523|NCT06062966|DRUG|Anakinra|Anakinra 100 mg SC daily will be administered to sujects on chronic inotrope treatment who are not candidates for transplantation or left ventricular assist device (LVAD).
41150301|NCT00170950|DRUG|Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
41311416|NCT03892330|DRUG|Pirarubicin|The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
40793948|NCT05224427|BEHAVIORAL|Near-Peer Coaching|Targeted coaching by near-peer medical students
40999524|NCT00457938|OTHER|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
40999525|NCT00457938|OTHER|Diet|10 % versus 35 % fat in diet
40999526|NCT05145166|BIOLOGICAL|Safety group|All of the participants(N=10000) received one dose of live attenuated mumps vaccine.Vaccine will given by single intramuscular injection(0.5 ml) on day 0.
40999527|NCT02143570|DRUG|Darifenacin|Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.
41311417|NCT04191967|DEVICE|Thermocoagulation|Treatment of positive screening results will be performed using the Liger Thermocoagulator device
41311418|NCT05041452|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance, including functional and structural parameters
41311419|NCT06527612|OTHER|Pulmonary rehabilitation exercise programme|In addition to standard medical treatment, the EGr will undergo an exercise program. The initial exercise training will be conducted in the hospital, followed by online exercise sessions via video conferencing three times a week during the first week. From the second week onwards, they will be asked to perform their exercises at home three times a week using provided exercise videos and will be monitored for one year. Compliance with the exercise regimen will be assessed through a weekly survey shared in a WhatsApp group established for the exercise group patients.
40999528|NCT02143570|PROCEDURE|Physiotherapy|All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
40999529|NCT00454090|DRUG|AZD8330|oral tablet
40999530|NCT04218058|PROCEDURE|reduction of zygomatic arch in zygomaticomaxillary complex fracture|ultrasound guided reduction of zygomatic arch
41470269|NCT04395248|PROCEDURE|Exploring potential risk factors of difficult intubation using ultrasound|Before surgery, ultrasound will be used to assess pretracheal soft tissue depth and height and width of tongue base. The distance from the skin to the anterior aspect of the trachea will be measured at three levels: vocal cords, thyroid isthmus, and suprasternal notch. With the patient in a seated position, the convex transducer of a portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be introduced to the skin of the neck in the submental region coronally, immediately cephalad to the body of the hyoid bone, and then in the area between the hyoid bone and the symphysis of the mandible. Maximal width of tongue base, tongue base height, and maximal height of mid-tongue will be measured. The laryngoscopy intubation will be performed using a size-3 or -4 Macintosh (Rüsch Inc., Duluth, GA, USA) blade and a styletted endotracheal tube. The laryngoscopic view will be graded according to Cormack and Lehane's classification with external laryngeal pressure applied.
40999531|NCT05478070|DEVICE|Dexcom G6|Continuous glucose monitor
40999532|NCT03878472|DRUG|SHR1210|The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
41311420|NCT00084916|DRUG|temsirolimus|Given IV
41311421|NCT00084916|OTHER|laboratory biomarker analysis|Correlative studies
40999533|NCT03878472|DRUG|Apatinib|The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
40999534|NCT03878472|DRUG|S1|The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
40999535|NCT03878472|DRUG|Oxaliplatin|The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
40999536|NCT05250024|DEVICE|UHMWP Cranioplasty|patient specific cranial implant
40999537|NCT05250024|DEVICE|PEEK Cranioplasty|patient specific cranial implant
40999538|NCT01716728|OTHER|enzyme analysis|
40999539|NCT04796831|DRUG|Quizartinib dihydrochloride|Single oral dose of 60 mg quizartinib (2 x 30 mg tablets)
40999540|NCT04796831|DRUG|14C-Quizartinib solution for infusion|50 μg solution for infusion containing NMT 22.84 kBq 14C in 5 mL; administered once as a 15-minute infusion
41150302|NCT00170950|DRUG|Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
41150303|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
41150304|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
41311422|NCT06550128|DRUG|AHB-137 injection|AHB-137 injection will be administered subcutaneously.
41311423|NCT06550128|DRUG|Placebo|Placebo will be administered subcutaneously.
41311424|NCT02612441|DEVICE|real Acupuncture Needles|Acupuncture needles
41311425|NCT02612441|DEVICE|sham Acupuncture Needles|sham Acupuncture Needles
40999541|NCT03768115|DRUG|Autologous Plasma Eye Drop|Autologous plasma crimped segments
40999542|NCT04081948|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
41150305|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
41150306|NCT05813132|DRUG|BEAM Protocol|BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
41150307|NCT05813132|DRUG|CEM protocol|CEM (Carboplatin, Etoposide, Melphalan)
41311426|NCT02199106|DEVICE|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Arms: Left temporal verum cTBS"
41311427|NCT02199106|DEVICE|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Arms: Left temporal placebo cTBS"
41311428|NCT06131320|DIAGNOSTIC_TEST|PVSE Test|Completion of the PVSE test
41311429|NCT06131320|OTHER|Cerebral MRI|Cerebral MRI scan
41311430|NCT04428684|DRUG|Pepti 3.6 mg|Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation
40793949|NCT00625586|BIOLOGICAL|RAV12|RAV12 at 0.375 mg/kg weekly escalated to 0.75 mg/kg weekly, intravenously.
40793950|NCT00625586|DRUG|Gemcitabine|1000 mg/m2 weekly, intravenously
40793951|NCT00514722|OTHER|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
40793952|NCT04311112|DRUG|Placebos|Placebo
40793953|NCT04311112|DRUG|ZA Low dose|ZA low dose
40793954|NCT04311112|DRUG|ZA high dose|ZA high dose
40793955|NCT04868305|PROCEDURE|Intramedullary nail|"Intertan nail (Smith \& Nephew)\* or Gamma 3 nail (Stryker)\*~\* All of the above-mentioned products are subjects to change into an equivalent product"
40793956|NCT04868305|PROCEDURE|Hip arthroplasty|"Total hip arthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~* Cup: Cemented Avantage dual mobility cup (Zimmer Biomet)\*~Hemiarthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~  * All of the above-mentioned products are subjects to change into an equivalent product"
40793957|NCT03096392|DRUG|HDV insulin lispro 100 UNT/ML|HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
40793958|NCT03096392|DRUG|Insulin Lispro 100 UNT/ML|Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
40793959|NCT02985177|DRUG|INF2.0 + IBU|Analgesics
40793960|NCT02985177|DRUG|INF1.0 + IBU|Analgesics
40793961|NCT02948699|DIETARY_SUPPLEMENT|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
40793962|NCT05658718|PROCEDURE|refractive surgery|refractive surgery
40793963|NCT02668705|OTHER|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
40793964|NCT03699566|OTHER|Assessment of Respiratory Muscle Strength|The maximal voluntary inspiratory (PImax) and expiratory (PEmax) pressure measurements of the subjects were performed using Cosmed Pony FX model (Italy 2001) while the subjects were in the sitting position with a nose clip.
40793965|NCT03699566|OTHER|Spirometer|Spirometric measurements were conducted with Cosmed, Pony FX (descopt spirometer- Italy 2001) spirometer using a nose clips while the subjects were in 90 degree relaxed sitting position.
40793966|NCT03699566|OTHER|Trunk Muscles Endurance Tests|Trunk muscle endurance of the subjects was measured using four different tests (Side Bridge Test- SBT, Prone Bridge Test- PBT, Flexor Endurance Test- FET, Sorenson Test- ST).
40793967|NCT03633955|DRUG|FLT|F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
40793968|NCT04009239|BEHAVIORAL|Time Restricted Feeding|Consuming energy during a short interval during the day
40793969|NCT05473455|PROCEDURE|Experimental: Follicular aspiration with addition of follicular flushing.|Follicular flushing if necessary up to 5 times using a double lumen needle for oocyte recovery
40793970|NCT01503346|DRUG|DaHuang GanTsao Tang|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
40793971|NCT00553566|PROCEDURE|medical chart review|
40793972|NCT00553566|PROCEDURE|questionnaire administration|
40793973|NCT00553566|PROCEDURE|study of socioeconomic and demographic variables|
40793974|NCT05870462|DRUG|Semaglutide Pen Injector|"* 0.25 mg/week (non-therapeutic dose) during Weeks 1-4~* 0.50 mg/week during Weeks 5-8~* 1.0 mg/week during Weeks 9-24~Participants experiencing side effects (e.g. nausea, stomach pain, constipation, diarrhea, vomiting) at the maximum dose (1.0 mg/week) may be down-titrated to 0.50 mg/week.~Participants who had been receiving a dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, saxagliptin, linagliptin, alogliptin) will stop taking their DPP-4 inhibitor upon randomization to this arm."
40793975|NCT02581891|DRUG|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
40793976|NCT02581891|DRUG|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
40793977|NCT04799457|OTHER|Suture technique|We wil apply additional sutures to classical caesarean procedure.
40793978|NCT02909660|OTHER|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
40793979|NCT02708316|GENETIC|sequencing faecal metagenome|sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
40793980|NCT05130970|DRUG|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
40793981|NCT05130970|DRUG|Placebo|Same as the CSL312 formulation buffer
40793982|NCT03399279|PROCEDURE|Open flap debridment|Full mucoperiosteal flap reflected+ Debridement of infrabony defect
40793983|NCT03399279|OTHER|Perforated collagen membrane|Membrane perforations using dental needle
40793984|NCT03399279|OTHER|Occlusive membrane|Biotech collagen membrane
40793985|NCT03399279|OTHER|Nanohydroxyapetite|Nanbone Particles
41311431|NCT05232422|BEHAVIORAL|Hatha yoga course|Participants will join a free hatha yoga course, conducted by a professional yoga teacher, over a time period of eight weeks with a frequency of at least three up to five times a week. The quality of the implementation of the intervention will be checked through post-monitoring by short questionnaires to be filled out by participants.
41311432|NCT01566643|DRUG|RA5-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
41311433|NCT01566643|DRUG|RA3-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
41311434|NCT01566643|DRUG|RA7-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
40793986|NCT01235663|BEHAVIORAL|advisory support|regular advisory support to the prolong breast-feeding period
40793987|NCT03475069|OTHER|Custom Designed Exercises|
41470270|NCT04395248|PROCEDURE|Radial artery catheterization using ultrasound guidance or blind palpation|For all patients, the wrist will be extended and taped to a board to maintain wrist extension. All patients will receive local skin anesthesia at the anticipated puncture site. All radial artery catheterizations will be performed by anesthesiology residents with similar levels of experience in both blind-palpation and ultrasound-guided radial arterial catheterization. In the ultrasound group, a linear vascular probe of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image. In the palpation group, the radial artery will be identified by palpation, and the cannula will be directed by continuous or intermittent palpation of arterial pulsation. An attempt is defined as a new penetration of the skin with the needle, followed by an unlimited number of subcutaneous needle redirections.
41470271|NCT04395248|DEVICE|Comparing the effectiveness of preoxygenation between high-flow nasal cannula and facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher \& Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs. After tracheal intubation, correct placement of the endotracheal tube will be confirmed by capnography and the nasal prongs of the HFNC group will be removed.
41470272|NCT04395248|DRUG|Type of volatile anesthetics and M-Entropy guidance of anesthesia depth|"At the operating room, a M-Entropy™ sensor and S/5™ module (GE Healthcare, Helsinki, Finland) will be applied to all patients' forehead before induction of anesthesia according to the manufacturer's recommendations. Patients will be randomized to Sevoflurane or Desflurane as the single volatile anesthetics for general anesthesia.~Besides, patients will be randomized to M-Entropy group or controls. In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the Response and State Entropy value between 40 and 60 from the start of anesthesia to the end of surgery. In the usual care group, dosage of volatile anesthetics will be titrated according to clinical judgment. M-Entropy monitoring will be continued in the usual care group, but the Entropy number and EEG waveform will be concealed from the anesthetist in charge."
41470273|NCT00386646|DRUG|0.5% carboxymethylcellulose (CMC) with purite and CMC alone|
41470274|NCT04347525|OTHER|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
40793988|NCT03475069|OTHER|Plates Exercises|
40793989|NCT03475069|OTHER|Calisthenics Exercises|
40793990|NCT02636504|DEVICE|Laser Doppler Flowmetry|Pulp vitality of teeth is tested with three pulp vitality testing including laser Doppler flowmetry, cold testing, and electric pulp testing.
40999543|NCT04081948|OTHER|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
41150308|NCT05620888|BEHAVIORAL|Walk behavior change: Tailored messages (TM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood! The intervention is provided for 30 days."
41311435|NCT03273205|DEVICE|Anodal tDCS|This group gets a real stimulation
40793991|NCT01594840|DEVICE|Changing chat|Diapers with tips
41311436|NCT03273205|DEVICE|Sham tDCS|This group gets a sham stimulation
40793992|NCT02748252|OTHER|stroke center referral|
40793993|NCT04301661|OTHER|Blood collection|Blood will be collected from participants at defined time points during the study to measure drug levels and assess platelet activity.
40793994|NCT04301661|DRUG|Abacavir/lamivudine|Participants who are already taking abacavir/lamivudine as part of standard HIV care will continue taking their therapy.
40793995|NCT04301661|DRUG|Tenofovir alafenamide/emtricitabine|Participants who are already taking tenofovir alafenamide/emtricitabine as part of standard HIV care will continue taking their therapy.
40793996|NCT04301661|DRUG|Switch|Participants who are planning to switch from abacavir/lamivudine as part of standard HIV care will change therapy to per the discretion of their HIV provider.
40793997|NCT00221546|DRUG|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
40793998|NCT03020004|DRUG|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
41150309|NCT05620888|BEHAVIORAL|Walk behavior change: Non tailored messages (NTM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: walking regularly in the fresh air improves your mood. The intervention is provided for 30 days."
41150310|NCT05770193|OTHER|Pursed lip breathing|The position for every patient will be long sitting, and then he will be instructed to breathe in through the nose for 2 seconds. Purse the lips as if about to blow out the candles on a cake. Breathe out very slowly through pursed lips for 4 to 6 seconds, and then repeat for 5 to 10 minutes. The intervention will be done two days a week, through six weeks for all participants by a physiotherapist.
41150311|NCT05770193|OTHER|Cognitive Behavior Therapy|A structured, 6-session psycho-therapeutic intervention, occurring once weekly, will be performed According to the CBT session structure provided by Cully and Teten, with some modifications, Each session will be approximately 1 hour.
41150312|NCT05770193|OTHER|Diaphragmatic breathing exercise|"The patient will lie in supine position, and then he will be asked to rest for 5 min and lay on their back on a flat surface with pillows under their head and knees for support. One hand will be placed on the abdomen and the other on the upper part of the chest wall. When inhaling, the hand on the abdomen will move upward, while the other hand will remain as still as possible. When exhaling, the hand on the abdomen will move downwards, while the other hand will remain as still as possible again. Breathing will be performed quickly, deeply and without causing tiredness. The breaths should be inhaled through the nose and exhaled through the mouth.~The diaphragmatic breathing exercise will consist of three sets of 10 repetitions, with 30 seconds of rest between each set"
41150313|NCT05770193|OTHER|Kinesio tape|"The position for every patient will be sitting during application of the tape. The diaphragm muscle will be covered with kinesio tape both anteriorly and posteriorly along the subcostal region. Anteriorly, the base point of an I shaped kinesio tape will be applied on xiphoid process with 50_75% tension on the linea Alba and the tails of the tape were applied toward subcostal curvature. Posteriorly, a second I shaped Kinesio Tape will be applied from the back The base point of the tape will be applied on the projection of 12th Thoracic vertebra with 50 _75% tension and the tails will be applied toward the ribs."
41150314|NCT05610254|DRUG|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
41150315|NCT03437902|DIETARY_SUPPLEMENT|Rutin in combination with Vitamin C|Rutin and Vitamin C will be supplied as tablets containing 60 mg Rutin and 160 mg Vitamin C. The use of Rutin and Vitamin C will be under the trade name of RUTA C 60 ® manufactured by KAHIRA PHARM.\& CHEM. IND. Company
41150316|NCT03437902|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C will be supplied as capsules containing500 mg of Vitamin C. The use of Vitamin C will be under the trade name of C-Retard ® manufactured by HIKMA Quality Company.
41311437|NCT03903744|PROCEDURE|Cardioneuroablation|The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
41311438|NCT03365427|OTHER|APP|An APP designed for patients experienced TKA, including on-line lessons on the action, frequency, intensity of rehabilitation exercises, and reporting system monitored by stuff from surgery team.
41311439|NCT00424333|DRUG|Inhaled human insulin|
41470275|NCT06308263|DRUG|M1774 [14C]M1774 microtracer|Participants will receive single oral dose of M1774 containing a \[14C\]M1774 microtracer solution on day 1 of period 1 under fasted conditions.
41470276|NCT06308263|DRUG|M1774|Participants will receive a single oral dose of M1774 on Day 1 of Period 1, and daily single oral dose of M1774 for 2 weeks in 21 days cycle of Period 2.
40793999|NCT03020004|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
40794000|NCT03020004|DRUG|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
40794001|NCT03020004|DRUG|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)
40794002|NCT01202201|OTHER|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
40794003|NCT03783962|BEHAVIORAL|Active Intervention - Cooking|"Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted and reinforced throughout the program. In-person sessions facilitated by an interventionist provide the group meetings. The program provides 24 weekly facilitated group sessions over 6 months. In addition to attending weekly classes, participants will track food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on individual progress.~Twelve cooking classes will be run every other week after the in-person weight loss meetings."
40794004|NCT03783962|BEHAVIORAL|Demonstrations - Cooking|The Demonstrations group will receive the exact same behavioral weight loss intervention as the cooking group. The only difference is that this group will attend cooking demonstrations as opposed to actively cooking.
40794005|NCT00740753|DEVICE|Yttrium 90 (TheraSphere)|Y-90 embedded glass microspheres
40794006|NCT03948893|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.
40794007|NCT03948893|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
40794008|NCT01525862|DEVICE|Balloon sinus dilation|
40794009|NCT00548197|DRUG|Bevacizumab|one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy
40794010|NCT04140786|DRUG|Gentamicin Sulfate, Injectable|10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
40999544|NCT06021561|DIAGNOSTIC_TEST|Diagnosis of pain|Pain will be investigated - type, origin, level
40999545|NCT02076828|DRUG|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
40999546|NCT02076828|DRUG|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
41150317|NCT02446912|BIOLOGICAL|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
41470277|NCT06531642|DRUG|Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days|Within 2 hours of ED admission after inclusion criteria is met, administer 1st dose of Protonix (pantoprazole) 40mg, then followed by 40mg q12hrs for 2 additional days.
41470278|NCT06531642|DRUG|Protonix (pantoprazole) 40 mg q 24 hrs for 2 days|Administer 1st dose of 40mg Protonix (pantoprazole) at the usual timing (current practice: in the intensive care unit), then followed by 40mg daily for 2 additional days.
41470279|NCT01131962|PROCEDURE|Endoscopic control of hematemesis|Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
40999547|NCT02076828|DRUG|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
41470280|NCT05828667|OTHER|Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).|CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This is done with the intent to limit the repeated number of inductions and prolonged point-by-point voltage mapping that often result in hemodynamic instability.
41470281|NCT06069544|BIOLOGICAL|BNT165e|Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection
41470282|NCT06069544|OTHER|Placebo|Isotonic NaCl solution (0.9%)
40999548|NCT03367377|DRUG|LY3209590|Administered SC
41470283|NCT03645499|DRUG|Topical TA-102 A|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
41470284|NCT03645499|DRUG|Topical TA-102 B|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
40794011|NCT03302403|GENETIC|CAR-CD19 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
40794012|NCT03302403|GENETIC|CAR-BCMA T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
40999549|NCT03367377|DRUG|Insulin Glargine|Administered SC
40999550|NCT00889954|BIOLOGICAL|TGFBeta resistant HER2/EBV-CTLs|"Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals."
40999551|NCT03146442|BEHAVIORAL|Breakfast|For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
40999552|NCT02419118|DRUG|Daratumumab|Treatment of myeloma patients with Daratumumab
40794013|NCT03302403|GENETIC|CAR-GPC3 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
41150318|NCT02446912|DRUG|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48
40999553|NCT02419118|DRUG|Lenalidomide|Treatment of myeloma patients
41150319|NCT01233089|DEVICE|Lotrafilcon B contact lens, investigational|Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly
41470285|NCT03645499|DRUG|Topical TA-102 C|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
41470286|NCT03645499|DRUG|Topical TA-102 D|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
41470287|NCT03645499|DRUG|Topical TA-102 E|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
41470288|NCT01620723|OTHER|New Breastfeeding Counselling|An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
40794014|NCT03302403|GENETIC|CAR-CLD18 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
40794015|NCT03302403|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
40794016|NCT03302403|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
40999554|NCT02419118|DRUG|Dexamethasone|Treatment of myeloma patients
40999555|NCT06146036|BEHAVIORAL|HIIT snacks|Cycling Exercise. 3 times per day 6 x 1 min at approximately 85-95% of HRmax
40999556|NCT06146036|BEHAVIORAL|Sprint snacks|Cycling Exercise. 3 times per day one ''all out'' sprint
40999557|NCT06146036|OTHER|Control|No exercise, sedentary.
40999558|NCT03121092|DRUG|ACEI or ARB|Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
41150320|NCT01233089|DEVICE|Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)|Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.
41150321|NCT01233089|DEVICE|Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)|Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.
41150322|NCT01233089|DEVICE|Contact lens care system (ClearCare)|Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
40794017|NCT05399927|OTHER|Music Intervention|The objective of this study is to observe the effects that music produces on physiological parameters, in patients with Acute Cardiovascular Disease (ACVD), and to determine its influence on the types or doses of drugs administered during initial care. The intervention study is carried out in the ambulance cabin during the time of transfer to the destination Hospital.
40794018|NCT01913847|DRUG|Sildenafil|Oral sildenafil 20 mg TID for 12 weeks
40794019|NCT01913847|DRUG|Placebo|Oral placebo TID for 12 weeks
40794020|NCT04766320|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-3x10\^11 autologous TILs to patients i.v. in 30-120 minutes.
40794021|NCT01718522|DEVICE|sensor augmented pump (SAP)|
40794022|NCT05877560|DEVICE|Anodal-Transcranial Direct Current Stimulation|Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
40794023|NCT05877560|BEHAVIORAL|Office-Based Vergence/Accommodative Therapy|Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.
40794024|NCT05877560|DEVICE|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be applied over the left frontal eye field with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 20 minutes.
40794025|NCT06386978|PROCEDURE|Transverse Facia Plane Block (TAP Block)|Spinal Anesthesia + TAP block
40794026|NCT06386978|PROCEDURE|Transversalis Facia Plane Block (TFP Block)|Spinal Anesthesia + TFP block
40794027|NCT06386978|PROCEDURE|Control|Spinal anesthesia + No block
40794028|NCT05892419|OTHER|No intervention|There is no intervention
40794029|NCT02342769|DRUG|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
40794030|NCT04404101|PROCEDURE|1). EUS-FNA plus MFB|The cyst will be punctured using a 19-G EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed and the wall of the cyst biopsied using the micro forceps passed through the 19 G needle under direct EUS visualization. A minimum of 4 cyst wall biopsies will be obtained to procure at least 4 visible tissue fragments. Cyst fluid will be aspirated and sent for CEA and cytology.
41311440|NCT06411119|DEVICE|Meta Oculus Quest 2™ Virtual Reality Exergaming|Participants utilised the Meta Oculus Quest 2™ Virtual Reality headset to play the Beat Saber game, which involves striking blocks in time to music using hand controllers. Gameplay was configured at a moderate difficulty level in 'no-fail' mode to encourage continuous activity across pre-selected songs, requiring participants to perform movements such as lateral steps, squats, and arm motions. Each session lasted for 20 minutes, including 30-second rest intervals between songs, to maximise physical activity and monitor heart rate, perceived exertion, and technology acceptance.
41311441|NCT00093093|DRUG|Viramidine|
41311442|NCT00093093|DRUG|Ribavirin|
41311443|NCT00093093|DRUG|pegylated interferon alfa-2a|
41311444|NCT05339243|OTHER|ES 1|Two capsules orally once daily after breakfast for 84 days
41311445|NCT05339243|OTHER|HT ES1|Two capsules orally once daily after breakfast for 84 days
41311446|NCT05339243|OTHER|Placebo|Two capsules orally once daily after breakfast for 84 days
41311447|NCT05059418|DRUG|Clonazepam 0.5 MG|Topical treatment of oral mucosa with lozenge pill
41311448|NCT05059418|DRUG|Capsaicin Topical|Topical treatment of oral mucosa with capsaicin rinse
41311449|NCT05059418|OTHER|Placebo|Mouth rinse with no capsaicin
41311450|NCT05669352|DRUG|CA-4948|Subjects on both the phase I and phase II portions will take 200 mg CA-4948 orally two times daily.
41311451|NCT05669352|DRUG|Pembrolizumab|Subjects on both the phase I and phase II portions will receive 400 mg pembrolizumab intravenously once every six weeks.
41470289|NCT01620723|OTHER|Treatment as usual|Health professionals offer the usual care for the breastfeeding mother
40999559|NCT03302611|BEHAVIORAL|Physical Activity-based Interventions|Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
40999560|NCT04448899|DRUG|Ivabradine Oral Tablet|Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.
40999561|NCT04448899|DRUG|Blacebo plus standard treatment|Blacebo plus standard treatment
41311452|NCT06273306|DEVICE|IMIDOC|Patient´s Mobile App for recording clinical data
41311453|NCT05966532|BEHAVIORAL|Hot Cognitive Task|"1. Emotion processing:~   * Participants will be shown a series of faces that appear quickly and be asked to identify what emotion is shown.~  * Participants will be shown a face of an emotion and indicate if participant can see the emotion changing.~  * Participant will be shown a series of emotions and asked to respond to only a specific emotion.~2. Motivation reward and processing:~   * Participant will play with a simulated roulette and make a bet to evaluate their decision-making behavior.~  * Participant will be shown colored circles and choose the one more likely to win money.~3. Impulsivity:~   • Participant will be shown a series of stimuli where they will be asked to respond to the correct stimulus.~4. Social cognition:~   * Participant will be shown a series of moral situations in which a character is accidentally or intentionally harmed and be asked to rate the degree of guilt from the perspective of the victim or perpetrator."
40794031|NCT04404101|PROCEDURE|2). EUS-FNA Alone|The cyst will be punctured using an EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed, and cyst fluid will be aspirated and sent for CEA, and cytology.
40794032|NCT00469833|DRUG|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
40794033|NCT03810547|DRUG|Propofol 10 Mg/mL Intravenous Emulsion|when spinal anesthesia is not satisfactory intervention drugs are used
40794034|NCT04012827|DRUG|Apatinib Mesylate, doxorubicin, ifosfamide|Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
41311454|NCT05966532|BEHAVIORAL|Cold cognitive tasks|"* Montreal Cognitive Assessment (MoCA) - This will ask participants questions related to their cognition such as visuospatial skills, naming, memory, attention, language, and recall.~* Measurement of Everyday Cognition (ECog) - This scale will ask participants about their everyday memory, language, visuospatial ability, organization, and divided attention.~* Test of Premorbid Function (TOPF) - This test will evaluate memory performance and abilities of stud participants before onset pre-morbid status.~* California Verbal Learning Test -3rd Edition (CVLT-3) -This test will measure verbal learning and memory of study participants.~* Three tests from the Delis-Kaplan Executive Function System (D-KEFS; Verbal Fluency, Color-Word Interference, and Tower Tests). -These measures assess word finding and problem-solving ability."
41311455|NCT05966532|OTHER|Structural magnetic resonance imaging (sMRI)|This is a non-invasive procedure to assess the structure and function of participant's brain. Structural neuroanatomical data will be acquired using structural magnetic resonance. Imaging (sMRI) with the University of Texas Southwestern (UTSW) 3T (three Tesla field) MRI scanner. Prior to participation, the investigator's team will screen participant's to ensure eligibility to participate in the sMRI scan.
41470290|NCT06152705|DEVICE|repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
40794035|NCT01194245|DRUG|Insulin lispro|
40794036|NCT01194245|DRUG|recombinant human hyaluronidase PH20|
40794037|NCT01194245|DRUG|Insulin aspart|
40794038|NCT01194245|DRUG|Insulin glulisine|
40794039|NCT01194245|DRUG|Insulin glargine|
40794040|NCT05139927|BEHAVIORAL|Motivational interviewing (MI) counseling|Those assigned to receive Component A will engage in a MI single session lasting approximately 30-45 minutes. The overall goal of the session is to increase participants' motivation and readiness to test for COVID-19 in various circumstances.
40794041|NCT05139927|BEHAVIORAL|Text messages (TMs) and quiz questions (QQs)|"This intervention lasts 6 weeks. This component is grounded in principles of behavioral economics. Its main goal is to add interest and excitement to the goal of COVID-19 testing, serve as a reminder that COVID-19 testing is recommended in a number of scenarios, and nudge participants toward testing and creating a habit of serial screening and COVID-19 testing as needed. Participants first receive a brief orientation to the component (15 min.), and the participant will put the study phone number into his/her phone and a test TM and QQ will be sent. TMs and QQs are programmed into the Telerivet program and sent automatically. Twice a week participants will receive a TM with information about COVID and COVID-19 testing followed by a true/false question about that TM two days later, for which they earn 10 points for a correct answer, and 5 points for an incorrect answer. Participants earn modest prizes based on their points."
40794042|NCT05139927|BEHAVIORAL|Peer education|This component has two aspects: Participants are trained to educate their peers on core messages about the importance of COVID-19 testing that address social norms about COVID-19 testing and highlight COVID-19 testing as an altruistic act (15-20 min. training). Then, participants are given the opportunity to educate three peers who are Black and Latino/Hispanic frontline essential workers on the core messages. These peers contact the study directly and receive a brief assessment and referrals to testing, but are not enrolled in the study.
40794043|NCT05139927|BEHAVIORAL|Access to COVID testing|Component D is an adaptive intervention component that avoids unnecessary costs; it is only provided if needed. Level 1: Over a 2-3 week period, navigation includes a brief needs assessment and guidance to assist participants in prioritizing, accessing, and completing COVID-19 testing sequences in a timely fashion and resolving barriers such as transportation or the possible need to take off work if diagnosed with COVID-19. Level 2: 1 month after enrollment, participants will be contacted by phone. If they have not been tested, we will provide them with a BinaxNOW test kit which can be picked up or mailed to them.
40794044|NCT02777411|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
40794045|NCT02777411|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
40794046|NCT02777411|BIOLOGICAL|EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
40999562|NCT03689556|DIAGNOSTIC_TEST|FLT PET/CT|Patients will receive 3'-deoxy-3'-\[18F\]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.
40999563|NCT03012113|DRUG|Mirabegron|
40999564|NCT03012113|OTHER|Short term mild cooling|
40999565|NCT03012113|DRUG|Placebo Oral Capsule|
40999566|NCT02815748|DRUG|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
40999567|NCT00016952|DRUG|fluorouracil|
40999568|NCT00016952|DRUG|irinotecan hydrochloride|
40999569|NCT00016952|DRUG|leucovorin calcium|
40999570|NCT04082988|DIAGNOSTIC_TEST|18F-FDG PET-CT|18F-FDG PET-CT scan
40999571|NCT01542216|BEHAVIORAL|Nutrition and Exercise Group|Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
40999572|NCT01542216|BEHAVIORAL|Yoga and Stretching Group|Patients randomized to this arm will receive consultations on yoga and stretching exercises.
40794047|NCT02777411|BIOLOGICAL|EV71 vaccine (2 μg total protein per dose)|Two vaccinations at 28 days apart
40999573|NCT05886959|OTHER|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
40999574|NCT05886959|OTHER|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
41470291|NCT06222593|DRUG|Bicalutamide in combination with Sunitinib|Antineoplastics, Antiandrogen; CYP3A4 Inhibitor
40999575|NCT05886959|OTHER|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
41311456|NCT05966532|OTHER|Magnetoencephalography imaging (MEG)|This is a non-invasive procedure to measure participant's brain activity. Participants will be sitting inside the machine in a chamber, with more space than a traditional MRI machine. A hat will be placed on top of participant's head which records their brain activity. Resting-state and task-based MEG recordings will occur in a three-layer magnetically shielded room (MSR) following our UTSW Advanced Neuroscience Imaging Research (ANSIR) established procedures. Before the scan, five coils will be secured to participant's head and a three-dimensional (3D) digitizer will be used to map the location of the coils, fiducials, and scalp surface. During recording, an electric current with a unique frequency label (i.e., 320 Hz) will be fed to each coil, which will permit real time head location tracking and subsequent offline head motion correction.
41311457|NCT04705727|DRUG|Budesonide Formoterol Drug Combination|This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).
41311458|NCT04705727|DRUG|nebulisation of terbutaline|Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.
41311459|NCT05607017|DRUG|Losartan|Taken Orally
41470292|NCT01382745|DRUG|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
41311460|NCT05607017|RADIATION|Radiation Therapy|Photon Radiation Therapy
41311461|NCT04245527|DEVICE|Joovv Infrared Light Device|Joovv is the leading manufacturer of personal, in-home red light therapy devices
41470293|NCT01382745|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
41470294|NCT01662362|DEVICE|Testing Donor Specimens with ESA Chagas|Donors will be asked to return for a follow-up blood draw.
40794048|NCT02777411|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
40794049|NCT02777411|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
40794050|NCT02777411|BIOLOGICAL|EV71 vaccine (1 μg total protein per dose)|Two vaccinations at 28 days apart
40794051|NCT01453972|BEHAVIORAL|Long distanse moderate training|Moderate exercise
40794052|NCT01453972|BEHAVIORAL|Long interval training|High-intensity exercise, long duration
40794053|NCT01453972|BEHAVIORAL|Short interval training|High intensity exercise, short duration
40794054|NCT02924259|DEVICE|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
40794055|NCT05757180|BEHAVIORAL|Positive Events Training (PET)|PET is a group-based training program combining Memory Specificity Training (MEST; Raes, 2007) and Future Event Specificity Training (FEST; Dutch version of Hallford et al. (2020): Changing the Future: An initial test of Future Specificity Training). It comprises four sessions of 50 minutes each. The training is delivered in a standardized manner, using the Positive Event Training Manual developed for this study (content adapted from our MEST and FEST manuals). Following brief psychoeducation on the rationale, participants practice generating detailed specific memories and future events using neutral and positive cue-words. Participants are maximally supported and challenged by the trainer and by the other group-members to generate very specific and highly detailed memories and future events using mental imagery and drawing upon visual, olfactory, auditory and emotional elements of the events, including both contextual and sensory-perceptual details.
40794056|NCT05757180|BEHAVIORAL|CREAtive writing Training (CREAT)|CREAT follows the exact same format and length as the PET training (i.e., delivered by a trainer in group over 4 x 50-minute sessions, including homework exercises). Following brief psychoeducation on the (bogus\*) rationale behind PET, participants complete a series of creative writing exercises using funny and thought-provoking writing prompts. Just as in PET, participants are maximally supported and challenged by the trainer and by the other group-members, in this case to generate completions that are as creative and funny as possible. The investigators used CREAT successfully before in an online format as a bogus control training for a memory specificity training. (\*) The investigators tell participants that these creative writing exercises have been found to be beneficial for mental wellbeing, as creative writing exercises cultivate creativity and stimulate participants' imagination skills.
41470295|NCT06267209|OTHER|Observational group|"After confirming that the patients not meet any of the exclusion criteria, dependent and confounding study variables will be assessed.~Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia.~The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol.~The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors."
40794057|NCT02484443|BIOLOGICAL|Dinutuximab|Given IV
40794058|NCT02484443|OTHER|Laboratory Biomarker Analysis|Correlative studies
40794059|NCT02484443|OTHER|Pharmacological Study|Correlative studies
40794060|NCT02484443|BIOLOGICAL|Sargramostim|Given SC
40794061|NCT00678171|DEVICE|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
40794062|NCT03606148|DIAGNOSTIC_TEST|SurePathTM|In the liquid-phase cytology, a fine-aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
40794063|NCT00750035|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
40794064|NCT00750035|PROCEDURE|Subtotal abdominal hysterectomy|
40794065|NCT03069742|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
41470296|NCT04088747|DIAGNOSTIC_TEST|Ultrasound Imaging|B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.
41470297|NCT04374188|DRUG|Ciprofloxacin|drug adminstration to ameliorate sepsis incidence
40794066|NCT03069742|OTHER|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
40794067|NCT02075424|OTHER|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
40794068|NCT06164691|DEVICE|Blue light|Participants undergoing this intervention will be exposed to blue (442nm) light.
40794069|NCT06164691|DEVICE|Amber light|Participants undergoing this intervention will be exposed to amber (617nm) light.
40794070|NCT06164691|OTHER|Ambient White Light|This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments
40794071|NCT00820144|BIOLOGICAL|CTB by nasal way|
40794072|NCT00820144|BIOLOGICAL|absorption of CTB by oral way|absorption of CTB by oral way
40999576|NCT05886959|OTHER|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
41470298|NCT04374188|DRUG|Levofloxacin|levofloxacin pill
40794073|NCT00820144|BIOLOGICAL|absorption of dukoral by oral way|absorption of dukoral by oral way
40794074|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
40999577|NCT05886959|OTHER|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
40794075|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
40794076|NCT04081662|BEHAVIORAL|compACT Intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of distress, depressive symptoms, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
40794077|NCT00777348|DRUG|Combination DSCG and Reproterol|1:
40794078|NCT04312139|DIAGNOSTIC_TEST|Echocardiography|Baseline and prospective follow-up echocardiography
40794079|NCT04312139|DIAGNOSTIC_TEST|Computerized Tomography Aortic Valve Calcium Score|Baseline and prospective follow-up CT calcium score of aortic valve
40794080|NCT04312139|OTHER|Untargeted LC/MS and LC-MS/MS|Serum samples untargeted proteomics and metabolomics
40794081|NCT04312139|OTHER|Targeted LC/MS and LC-MS/MS|Serum samples targeted proteomics and metabolomics
40794082|NCT04312139|DIAGNOSTIC_TEST|multiplex ELISA|Implementation of novel multiplex ELISA assay on serum samples of aortic valve stenosis prospective cohort.
40794083|NCT03230318|DRUG|derazantinib|Derazantinib was administered orally at 300 mg once daily
40794084|NCT00212836|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
40794085|NCT00212836|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
40794086|NCT03800277|DIETARY_SUPPLEMENT|Cranberry|Supplementation of polyphenols from cranberry extract
40794087|NCT03800277|DIETARY_SUPPLEMENT|Agaves|Supplementation of inulin from Agaves powder
40794088|NCT03800277|DIETARY_SUPPLEMENT|Placebo|Supplementation with placebo
40794089|NCT05989139|PROCEDURE|NPPV/HFNC|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each. NPPV will be delivered through a full-face mask with a FiO2 starting at 100% and then titrated to achieve an SpO2 of 92-98%. Expiratory positive airway pressure (PEEP) will be firstly set to 5 cmH2O and then increased to a maximum of 15 cmH2O based on SpO2. Pressure support (PS) will be set to an initial value of 10 cmH2O and then increased if signs of respiratory distress persisted or worsened to a maximum value of 20 cmH2O. After 40 minutes, patient is shifted to HFNC ventilation support for 40 minutes.~At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
40794090|NCT05989139|PROCEDURE|HFNC/NPPV|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each.~HFNC oxygen therapy will start at a flow rate of 60 L/min and will be gradually decreased by 5 cmH2O at time if the patient experienced discomfort. FiO2 will be started at 100% and then titrated to maintain a peripheral oxygen saturation of 92%-98%. Active heating and humidification were provided using MR850, Fisher and Paykel, with a temperature chamber of 37°C. After 40 minutes, patient is shifted to NPPV ventilation support for 40 minutes At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
40794091|NCT04236050|DRUG|Rocuronium|Rocuronium administered in continuous infusion or multiple bolus doses
40794092|NCT04914156|OTHER|Genetic based dietary advice|Genetic test results for 70 genes relating to nutrition and physical activity will be used in conjunction with participants current dietary intake to create nutrition advice tailored to each individual.
40794093|NCT04914156|OTHER|Personalised population based dietary advice|Current dietary intake will be compared with current best practice population-based sports nutrition dietary advice to create tailored nutrition advice for each of the participants
40794094|NCT00003322|DRUG|cisplatin|
40794095|NCT00003322|DRUG|paclitaxel|
40794096|NCT00003322|PROCEDURE|quality-of-life assessment|
40794097|NCT01324960|DRUG|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
40794098|NCT01324960|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
40794099|NCT03632460|DRUG|Dexmedetomidine Injection [Precedex]|epidural administration of dexmedetomidine added to ropivacaine
40794100|NCT03463863|PROCEDURE|rectus sheath midurethral sling|
40999578|NCT05886959|OTHER|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
40794101|NCT02560090|BEHAVIORAL|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
40794102|NCT02560090|BEHAVIORAL|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
40794103|NCT02560090|BEHAVIORAL|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
40999579|NCT05886959|OTHER|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
40999580|NCT05886959|OTHER|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
40999581|NCT03098342|PROCEDURE|Methylene blue-mediated photodynamic therapy|Using the 2% MB aqueous solution as a photosensitiser. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
41311462|NCT02921919|DRUG|Talazoparib|Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
41311463|NCT00301782|BIOLOGICAL|bleomycin sulfate|
41311464|NCT00301782|DRUG|carboplatin|
41311465|NCT00301782|DRUG|cisplatin|
40794104|NCT04819529|BEHAVIORAL|Early and Intensive Occupational Therapy|"Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 1 one session each 48 h and SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: daily visits by trained family members and health staff about the intervention process"
40794105|NCT05626140|DRUG|Lacosamide 50 MG Oral Tablet [Vimpat]|Oral tablet lacosamide is a 3rd generation anti convulsant drug. it is given in a dose of 50 mg 12 hourly for 15 days. It has a longer half life than the other two drugs in comparison and fewer drug interactions as it doesnot interact with the hepatic cytochrome enzymes.hence it is seen to have better pharmacokinetics and pharmacodynamics than the other drugs in study
40794106|NCT05626140|DRUG|Codeine Phosphate|Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite
40999582|NCT03098342|DRUG|Amorolfine 5% Nail Lacquer|Patients will be detailed instruction regarding the use of 5% Amorofine Nail Lacquer (Loceryl®) as its recommended protocol.
40999583|NCT05372120|DRUG|ICP-192|ICP-192 is a round, uncoated tablet, 4mg, 5mg. It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression
40999584|NCT05588102|DRUG|Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）|Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)
40999585|NCT03647540|PROCEDURE|fluorescent laparoscopic radical gastrectomy|The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
40999586|NCT03647540|PROCEDURE|traditional laparoscopic radical gastrectomy|The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
40999587|NCT04585516|PROCEDURE|endoscopy|Colonoscopy or gastroscopy
40999588|NCT05150535|RADIATION|Hypofractionation Radiotherapy.|Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.
40999589|NCT05150535|RADIATION|Ultra-hypofractionation radiotherapy|Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.
40999590|NCT01035944|DEVICE|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
40999591|NCT01035944|DEVICE|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
40999592|NCT00903812|OTHER|No intervention|No intervention as observational study
40999593|NCT02045511|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner
41150323|NCT04945356|OTHER|upper limb training|The 6-week exercise program will consist of evidence-based exercises covering the breadth and depth of rehabilitation interventions. The therapist will choose the appropriate exercises for each participant's level of function from more than 15,000 exercises implemented within the Physiotec app and developed by rehabilitation experts. Personalized upper limb exercises will be based on the therapist initial assessment of participants, using the TERA+ telerehabilitation platform, and their goals. After each training session, participants will have to rate their perceived level of effort on a Borg scale (/10). The Borg scores will be monitored by the therapist as a precautionary measure to ensure safety and appropriateness of intensity of exercises. Participants will be instructed to train at a target score of around 7/10 (somewhat hard) on the Borg scale.
41311466|NCT00301782|DRUG|etoposide phosphate|
41311467|NCT00301782|DRUG|vincristine sulfate|
41470299|NCT03648879|DEVICE|Endoscope+Cellvizio(R) 100 microscope|Patients will undergo white-light, upper endoscopy. In addition, during this endoscopy patients will undergo Confocal Endoscopic Microscopy (CEM) using the Cellvizio probe (Mauna Kea Technologies) to scan the same anatomic zones.
41470300|NCT01961882|DRUG|OCV-501|
40999594|NCT02045511|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
40999595|NCT00640705|DRUG|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
40999596|NCT00640705|DRUG|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
41150324|NCT00001079|DRUG|Testosterone enanthate|
41150325|NCT00001079|DRUG|Megestrol acetate|
41150326|NCT04125342|DEVICE|Preventive Conditioned NIV Therapy after planned extubation|Conditioned NIV during 48 hours following extubation.
41470301|NCT01961882|DRUG|Placebo|
41470302|NCT06479278|BEHAVIORAL|Talk with Me Baby|Primary care providers will embed Talk With Me Baby (TWMB) within standard-of-care Well-Child Care visits for children ≤36 months of age. Children will receive usual care plus a brief language-promotion intervention (TWMB) in up to 4 consecutive Well-Child Care visits during their 12-month period.
41311468|NCT03933423|DEVICE|Home based phototherapy and referral|CHWs will visit the household twice in a month and will counsel mother and families on use of preventive care such as routine antenatal check care and newborn care. The investigators will conduct blood grouping and rhesus (Rh) typing. If the mother is Rh negative, investigators will also measure the Rh status of the father prior to delivery to determine the risk of Rh disease in the newborn. The investigators will establish an emergency contact system both in intervention and comparison arm where mothers and family members contact and inform the research team about delivery. The trained phlebotomist will collect cord blood for measuring glucose 6-phosphate dehydrogenase and infant blood type, Rh status, direct antigen testing. The investigators will develop a protocol for treating infants at home based on the ETAT (Emergency Triage Assessment AND Treatment) AAP (American Academy of Paediatrics) guidelines and treat with LED based phototherapy
40794107|NCT05626140|DRUG|Diclofenac Sodium|Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
40794108|NCT01055717|OTHER|Avenanthramide-enriched oats|Single dose, 24 hour pharmacokinetic trial
40794109|NCT01144624|DRUG|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
40794110|NCT01144624|DRUG|Placebo|Intravenous infusion of a saline solution
40794111|NCT02383186|PROCEDURE|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
40794112|NCT02383186|PROCEDURE|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
40794113|NCT03930771|DRUG|Capecitabine|1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
40794114|NCT03930771|DRUG|Temozolomide|150 to 200 mg/m2 orally on days 10 through 14.
40794115|NCT01664247|DRUG|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
40794116|NCT01664247|DRUG|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
40794117|NCT01664247|DRUG|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
40794118|NCT06388239|DRUG|Apixaban 5MG|Apixaban 5 mg Film-coated tablets
40794119|NCT03890900|OTHER|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
40794120|NCT04612829|DEVICE|Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic
40999597|NCT01199211|OTHER|Exercise training, women, marathon|Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
41311469|NCT02042495|DRUG|Metformin|
40794121|NCT00074139|DRUG|cyclophosphamide|
40794122|NCT00074139|DRUG|docetaxel|
40794123|NCT00074139|DRUG|doxorubicin hydrochloride|
40794124|NCT01460069|DRUG|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
40794125|NCT01460069|DRUG|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
40794126|NCT02538536|DRUG|PBI4050|
40794127|NCT00285285|DEVICE|Point of Care Device; i-Stat Analyzer|
40794128|NCT00924001|DRUG|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10\^9 and 1 x 10\^11 lymphocytes) after expansion in interleukin-2 and OKT-3
40999598|NCT03669835|DIETARY_SUPPLEMENT|Mare milk supplement|Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.
40999599|NCT03669835|DRUG|Standard therapy|For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
40794129|NCT00924001|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
40794130|NCT00924001|DRUG|Fludarabine|25 mg/m\^2/day intravenously x 5 days
40794131|NCT00924001|DRUG|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
40794132|NCT05313607|OTHER|Designed physical therapy|Attention is given to improve motor function, conducted for 30 minutes
40794133|NCT05313607|OTHER|Occupational therapy|included exercises facilitating hand skills, conducted for 30 minutes
40794134|NCT05313607|OTHER|Conventional Therapy|aimed to improve the affected upper extremity function, conducted for 30 minutes
40794135|NCT05313607|OTHER|Plyometric training|basically focuses on upper extremity strength training conducted for 30 minutes
40794136|NCT03973112|DRUG|HLX10 3mg/kg|anti-PD-1
40794137|NCT03973112|DRUG|HLX04 5mg/kg|anti-VEGF, a biosimilar to Avastin
40794138|NCT03973112|DRUG|HLX04 10mg/kg|anti-VEGF, a biosimilar to Avastin
40794139|NCT04910529|OTHER|Yoga|Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students.
40794140|NCT04807166|DRUG|Drug: Anlotinib|Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle
41311470|NCT01591772|OTHER|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
40794141|NCT04807166|DRUG|Drug: Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1
41470303|NCT03804788|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. A sixth week of treatment will be included - and scheduled for the same date as the post-treatment assessment - if the participant and research team agree that it would be beneficial (e.g., if a participant has difficulty grasping cognitive therapy concepts). Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
41470304|NCT03804788|BEHAVIORAL|Sleep Hygeine|All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
41470305|NCT04701424|DEVICE|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
41470306|NCT04701424|OTHER|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
41470307|NCT03746106|DRUG|Trimethoprim|300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.
41470308|NCT03746106|DRUG|Metformin|1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.
41470309|NCT03746106|DIETARY_SUPPLEMENT|Vitamin B1|5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.
41470310|NCT03795389|DRUG|DM199|Single SC dose
41470311|NCT03062358|BIOLOGICAL|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
41470312|NCT03062358|DRUG|placebo|Normal saline solution administered as an IV infusion Q3W
41470313|NCT03062358|OTHER|best supportive care (BSC)|BSC will include pain management and management of other potential complications including ascites per local standards of care.
40794142|NCT05110781|BIOLOGICAL|Atezolizumab|Given IV
40794143|NCT05110781|RADIATION|Radiation Therapy|Undergo radiation therapy
41150327|NCT04125342|DEVICE|Preventive HFOT after planned extubation|HFOT set according to patients tolerance during 48 hours following extubation
40794144|NCT05110781|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40794145|NCT00745290|DRUG|Bupivacaine HCl|200 mg bupivacaine HCl
40794146|NCT00745290|DRUG|SKY0402|600 mg SKY0402 (study drug).
40794147|NCT02012855|BEHAVIORAL|Exercise|
40794148|NCT02012855|OTHER|Diet (meal type)|
40794149|NCT03440567|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplantation
40794150|NCT03440567|DRUG|Avelumab|Given IV
41150328|NCT03614923|BIOLOGICAL|Etokimab|Administered by subcutaneous injection
41150329|NCT03614923|BIOLOGICAL|Placebo|Administered by subcutaneous injection
41150330|NCT03614923|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
41150331|NCT01181206|PROCEDURE|Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs|
41150332|NCT05057819|DRUG|Empagliflozin 25 MG|Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days
41150333|NCT05057819|DRUG|Placebo|Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days
41150334|NCT04463888|OTHER|occupational therapy|occupational therapy targeted to goals that are relevant to the functional needs of the patient
40794151|NCT03440567|DRUG|Carboplatin|Given IV
40794152|NCT03440567|DRUG|Etoposide Phosphate|Given IV
41150335|NCT02211508|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
41150336|NCT05588193|BEHAVIORAL|PVO|post-visit outreach
41150337|NCT05588193|BEHAVIORAL|TSH|tele-sexual health visit during the ED visit
40794153|NCT03440567|DRUG|Ibrutinib|Given PO
41311471|NCT01591772|OTHER|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
41470314|NCT01453153|DRUG|Gemcitabine|1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
41470315|NCT01453153|DRUG|PEGPH20|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
40794154|NCT03440567|DRUG|Ifosfamide|Given IV
40794155|NCT03440567|OTHER|Laboratory Biomarker Analysis|Correlative studies
40794156|NCT03440567|BIOLOGICAL|Rituximab|Given IV
40794157|NCT03440567|BIOLOGICAL|Utomilumab|Given IV
40794158|NCT00273091|DEVICE|ICD with CRT therapy|permanently CRT pacing
40794159|NCT02168062|BEHAVIORAL|Behavioral Dietary Intervention|Receive individualized nutrition counseling
40794160|NCT02168062|OTHER|Counseling|Receive individualized symptom management service counseling
40794161|NCT02168062|OTHER|Educational Intervention|Review educational modules
40794162|NCT02168062|BEHAVIORAL|Exercise Intervention|Receive individualized exercise counseling
40794163|NCT02168062|DRUG|Goserelin Acetate|Given SC
40794164|NCT02168062|OTHER|Laboratory Biomarker Analysis|Correlative studies
40794165|NCT02168062|DRUG|Leuprolide Acetate|Given SC or IM
40794166|NCT02168062|OTHER|Quality-of-Life Assessment|Ancillary studies
40794167|NCT02168062|DRUG|Triptorelin Pamoate|Given IM
40794168|NCT00399607|PROCEDURE|Rectal biopsy during colonoscopy|Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
40794169|NCT00399607|PROCEDURE|Rectal biopsy at randomization|Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
40794170|NCT00399607|PROCEDURE|Rectal biopsy at 1 year|Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
40794171|NCT00399607|PROCEDURE|Rectal biopsy prior to colonoscopy|Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
40794172|NCT00399607|PROCEDURE|Biopsies during colonoscopy|Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
40794173|NCT06455878|BEHAVIORAL|Full usage of diet management app group and with the full usage of an intelligent weight scale|Subjects will use the fully functional diet management application and an intelligent weight scale with full function designed for obese heart failure patients to help them losed weight and invitigate some important composite cardiovascular endpoint.
40794174|NCT06455878|BEHAVIORAL|Limited usage of diet management app group and with the limited usage of an intelligent weight scale|Subjects will use the limited function diet management application and an intelligent weight scale with limited function designed for obese heart failure patients as a comparator.
40794175|NCT06215365|BEHAVIORAL|Adult cancer survivors who have completed their heavy treatments|"The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.~Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected."
40794176|NCT05439278|RADIATION|Hypofractionated radiotherapy|40.05 Gy in 15 fractions (daily treatment, 5 per week)
41311472|NCT04300062|PROCEDURE|Rebiopsy|Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.
40794177|NCT05439278|RADIATION|Conventional radiotherapy|60 Gy in 30 fractions (daily treatment, 5 per week)
40794178|NCT05439278|DRUG|Temozolomide|concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
40794179|NCT01222819|DRUG|filgrastim|5 mcg/kg (rounded to 300 mcg or 480 mcg)
40794180|NCT03412110|OTHER|active surveillance: electronic platform|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
40794181|NCT05144776|DIAGNOSTIC_TEST|GeneXpert HBV DNA Viral Load Assay|The Xpert venous blood HBV DNA viral load assay will be adapted to operate using fingerstick capillary blood samples.
40794182|NCT05144776|DIAGNOSTIC_TEST|Dried Blood Spot HBV DNA test|HBV DNA viral load will be measured from a fingerstick capillary dried blood spot sample using a gold standard HBV DNA viral load assay
40794183|NCT03706027|DEVICE|radiation therapy-3 fractions|Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
40794184|NCT03706027|DEVICE|Radiation therapy-5 fractions|Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
40794185|NCT01768910|OTHER|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
40794186|NCT01768910|OTHER|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
40794187|NCT01768910|OTHER|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
40794188|NCT01768910|OTHER|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
40794189|NCT01508910|BIOLOGICAL|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
40794190|NCT01508910|BIOLOGICAL|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
40794191|NCT01508910|OTHER|Standard of care|Standard of care for refractory angina
40794192|NCT05401539|DEVICE|Cardboard VR|Google Cardboard is a discontinued virtual reality (VR) platform developed by Google. Named for its fold-out cardboard viewer into which a smartphone is inserted, the platform was intended as a low-cost system to encourage interest and development in VR applications. To use the platform, users run Cardboard-compatible mobile apps on their phone, place it into the back of the viewer, and view content through the lenses. The parts that make up a Cardboard viewer are a piece of cardboard cut into a precise shape, magnets or capacitive tape, a hook and loop fastener, a rubber band, and an optional near field communication tag. Smartphone is inserted in the back of the device and held in place by the selected fastening device. A Google Cardboard-compatible app splits the smartphone display image into two, one for each eye, while also applying barrel distortion to each image to counter pincushion distortion from the lenses.The result is a stereoscopic image with a wide field of view.
40794193|NCT04083703|PROCEDURE|Interbody cage insertion in lumbar disc prolapse|Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse
40794194|NCT03337802|BEHAVIORAL|mediterranean diet|The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.
40794195|NCT03765580|DIETARY_SUPPLEMENT|Fish|Lunch containing fish
40794196|NCT03765580|OTHER|Control|Lunch containing no fish
40794197|NCT00996658|DRUG|Placebo|Placebo matching linagliptin tablets once daily
40794198|NCT00996658|DRUG|Linagliptin|Linagliptin tablets once daily
41470316|NCT01453153|DRUG|Placebo|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
40794199|NCT00912574|DRUG|GM-CSF-in-adjuvant|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
40794200|NCT00912574|DRUG|Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
40794201|NCT00912574|BIOLOGICAL|GM-CSF and Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
40999600|NCT02645266|DRUG|Aflibercept Injection [Eylea]|Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.
40999601|NCT05451771|DRUG|Venetoclax Oral Tablet, 200 mg|200 mg oral tablet daily
41311473|NCT04501679|DRUG|Nemolizumab|Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
41311474|NCT04501679|DRUG|Placebo|Participants received matching placebo as SC injection.
41311475|NCT00125190|DRUG|rhIGF-1 (mecasermin) for a period of 86 weeks|Once a day rhIGF-1 injections
41311476|NCT04729491|DRUG|Dutasteride 0.5 mg|Use of dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
41311477|NCT04729491|DRUG|Azithromycin|Azithromycin 500mg/day for 05 days
40794202|NCT00912574|DRUG|Saline|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
40794203|NCT03578107|BEHAVIORAL|improvement of quality of stroke care|"1. hospital tool kits for quality improvement of reperfusion therapy ;~2. organizational stakeholder and opinion leader meetings;~3. data monitoring and feedback reports；~4. webinar for hospital teams"
40794204|NCT04513769|BEHAVIORAL|Vegan diet|Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
41311478|NCT04729491|DRUG|Nitazoxanide|500mg twice daily for 06 days
40794205|NCT01861561|DRUG|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
40794206|NCT01861561|DRUG|High-dose intravenous cyclophosphamide|"Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose"
40794207|NCT02882438|DRUG|infected group|Ginkgo Biloba in different dosage forms
40794208|NCT02882438|DRUG|control group|placebo without Ginkgo Biloba
40794209|NCT04798222|DRUG|Treatment A|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.
40794210|NCT04798222|DRUG|Treatment B|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
40794211|NCT04798222|DRUG|Treatment C|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition
40794212|NCT04798222|DRUG|Treatment D|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.
40794213|NCT04798222|DRUG|Treatment E|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.
40794214|NCT04798222|DRUG|Treatment F|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.
40794215|NCT04798222|DRUG|Treatment G|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.
40794216|NCT04798222|DRUG|Treatment H|Participants will receive oral dose of dapagliflozin capsule in fasted condition.
40794217|NCT00096642|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behaviour versus standard care
40999602|NCT05451771|DEVICE|FISH assay|Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.
40999603|NCT05451771|DRUG|Venetoclax Oral Tablet, 400 mg|400 mg oral tablet daily
40794218|NCT04665427|OTHER|bilioenteric anastomosis i|The creation of communication between a bile duct and a segment of the digestive tract, often to restore a flow of bile in the digestive tract,
40794219|NCT00710398|BEHAVIORAL|Exercise - Aerobic and Resistance|Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
40999604|NCT05451771|DRUG|Dexamethasone Oral, 10 mg|10 mg oral tablet weekly
40999605|NCT05451771|DRUG|Dexamethasone Oral, 20 mg|20 mg oral tablet weekly
41150338|NCT04343989|DRUG|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
41150339|NCT04343989|DRUG|Clazakizumab 12.5 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
41311479|NCT04729491|DRUG|Placebo|Use of placebo q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
41311480|NCT05060666|DRUG|Ivermectin|"2 doses of Ivermectin will be administered with 48 hours time interval.~The dosage is based on body weight calculated as follows:~* 15 mg for 40-60 kg = 5 tablets à 3 mg~* 18 mg for 60-80 kg = 6 tablets à 3 mg~* 24 mg for \> 80 kg = 8 tablets à 3 mg each~This corresponds to an ivermectin dose of about 300 µg / kg."
41311481|NCT05060666|DRUG|Placebo|"An analogous number of tablets is administered for placebo:~* 5 tablets for 40-60 kg~* 6 tablets for 60-80 kg~* 8 tablets for \> 80 kg~The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin."
40794220|NCT00710398|BEHAVIORAL|Dietary - Caloric Restriction|"Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.~Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake."
40794221|NCT02466477|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
40999606|NCT05451771|DRUG|Daratumumab Injection|Daratumumab will be administered at a dose of 16 mg/kg by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter for a maximum of 6 months of therapy. If subcutaneous formulation is available, participants can also receive subcutaneous daratumumab (1800 mg in 15 ml) in the same schedule.
40794222|NCT02466477|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
40999607|NCT05451771|DRUG|Bendamustine|Bendamustine will be given at an initial dose of 100 mg/m\^2 intravenously on days 1 and 2 in each 28-day cycle.
40794223|NCT02466477|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
40794224|NCT06164522|OTHER|Abdominal ultrasound|Abdominal ultrasound to detect sliding sign
40794225|NCT00962728|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
40794226|NCT00962728|DEVICE|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
40794227|NCT04077489|PROCEDURE|cataract surgery|To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
40794228|NCT05242835|PROCEDURE|Standard duodenal switch|Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
40794229|NCT05242835|PROCEDURE|Single-anastomosis duodenal switch|Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
40794230|NCT01648023|DEVICE|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
40794231|NCT01648023|DRUG|Gem-Cis or Gem-Carbo|
40794232|NCT01877681|PROCEDURE|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
40794233|NCT01877681|PROCEDURE|Active comparator|Usual care as specified in the PU practice guideline
40794234|NCT03686878|DRUG|Lifitegrast|Lifitegrast used twice a day
40794235|NCT03270059|DRUG|Ferumoxytol|Given IV
40794236|NCT03270059|DRUG|Gadolinium|Given IV
40999608|NCT05451771|DRUG|Pomalidomide|Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.
40999609|NCT05451771|DRUG|Ixazomib|Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.
40999610|NCT05451771|DRUG|Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
41150340|NCT04343989|OTHER|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
40999611|NCT04122378|OTHER|acupuncture|The acupuncture will be provided by the licensed acupuncturist using standard methods.
40794237|NCT03270059|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40794238|NCT04650997|BEHAVIORAL|Eccentric exercise|Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
40794239|NCT01789359|OTHER|Blueberry Juice|Dietary intervention
40794240|NCT00390897|DRUG|Glivec|
40794241|NCT00390897|DRUG|Interferon|
40794242|NCT05672940|BEHAVIORAL|Aerobic plus resistance training|Aerobic plus resistance training
40794243|NCT05672940|BEHAVIORAL|Stretching plus breathing training|Stretching plus breathing training
40999612|NCT00091299|DRUG|warfarin|
40999613|NCT03255343|DEVICE|IMDENDRIM|In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
40999614|NCT03413059|DRUG|Morphine Sulfate|Thoracic Epidural morphine
40999615|NCT03413059|DRUG|Triamcinolone Acetonide|thoracic epidural triamcinolone acetonide
40999616|NCT01074164|OTHER|Standard-of-care treatment for AD|Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.
40999617|NCT01074164|DEVICE|Accu-patch pellet|The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
40999618|NCT00439556|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
40999619|NCT00439556|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
40999620|NCT00439556|DRUG|Bortezomib|Given IV
40999621|NCT00439556|DRUG|Carmustine|Given IV
40999622|NCT00439556|DRUG|Cytarabine|Given IV
40999623|NCT00439556|DRUG|Etoposide|Given IV
40794244|NCT01037998|DRUG|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
40999624|NCT00439556|BIOLOGICAL|Filgrastim|Given SC
40794245|NCT05483023|DRUG|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
40794246|NCT05219708|DIETARY_SUPPLEMENT|Calorie protein supplement|Participants assigned to the intervention group will receive the calorie and protein supplement (i.e. Ensure Original) to be consumed twice daily between meals for 30 days in addition to standard of care for heart failure
40794247|NCT05219708|OTHER|Control|Standard of care for heart failure
40794248|NCT01106157|DRUG|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
40794249|NCT01106157|DRUG|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
40794250|NCT01106157|DRUG|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
40794251|NCT06553105|DIAGNOSTIC_TEST|ct scan|use ct scan for diagnosis fistula
40794252|NCT03856463|BEHAVIORAL|Lay Navigator Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning and documenting goals of care.
40794253|NCT03856463|OTHER|Usual Care|Usual care as provided by local oncologists
40794254|NCT00642707|DRUG|PRO 140 (humanized monoclonal antibody to CCR5)|
40794255|NCT00642707|DRUG|Placebo Comparator|
40794256|NCT03167788|DEVICE|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
40794257|NCT03167788|OTHER|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood \& Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
40794258|NCT04078204|DRUG|Butylphthalide Soft Capsules|The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
40794259|NCT04078204|DRUG|placebo Soft Capsules|The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
40794260|NCT00327925|PROCEDURE|Find Cancer Associated Antibodies|
40794261|NCT03740399|PROCEDURE|spinal anesthesia|Investigators will perform spinal anesthesia for section
40999625|NCT00439556|DRUG|Melphalan|Given IV
40999626|NCT00439556|DRUG|Methotrexate|Given IV
40999627|NCT00439556|BIOLOGICAL|Rituximab|Given IV
40999628|NCT00439556|DRUG|Tacrolimus|Given IV and PO
40999629|NCT04925011|DRUG|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
40999630|NCT04537858|DEVICE|Virtual reality therapy first|First day of the protocol with Virtual Reality intervention in the morning and conventional intervention in the afternoon
40999631|NCT04537858|DEVICE|Conventional therapy first|First day of the protocol with conventional intervention in the morning and Virtual Reality intervention in the afternoon
40999632|NCT01845285|DEVICE|Aortic Valve Replacement|Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
40999633|NCT01742793|DRUG|lenalidomide (Revlimid) and romidepsin (Istodax)|
40999634|NCT02204748|DEVICE|DePuy Attune posterior stabilizing fixed bearing knee system|
40999635|NCT05369858|DRUG|[14C] SKLB1028|A single 150 mg oral dose of \[14C\] SKLB1028 containing approximately 120 microcurie of \[14C\] SKLB1028
40999636|NCT03212625|DRUG|Urea Cream 20%|Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
40999637|NCT03212625|DRUG|Placebos|Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
40999638|NCT05669456|DEVICE|Halo Alert System|The Halo Alert System consists of an EEG sensor headband and is paired with a data transfer device.
40999639|NCT02178384|PROCEDURE|Altered cast technique|This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.
40794262|NCT04995484|DRUG|Belzutifan|Two 40 mg tablets given as a single oral 80 mg dose.
40999640|NCT02178384|DEVICE|Precision Attachments|These are minor attachments used to split the loading forces during appliance wear
40999641|NCT02178384|PROCEDURE|Resilient layer|This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
40794263|NCT03925103|PROCEDURE|3D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system
40794264|NCT03925103|PROCEDURE|2D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system
41311482|NCT04813159|DEVICE|Remote Ischaemic Conditioning (RIC)|The RIC protocol will comprise inflation of the automated RIC device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
41311483|NCT04813159|DEVICE|Sham-control|The sham protocol will comprise low-pressure inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff used in the active arm. The sham control protocol will be repeated daily for the next 2 days.
41311484|NCT00863837|DRUG|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
41311485|NCT00863837|DRUG|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
41311486|NCT03425942|BEHAVIORAL|Internet Cognitive Behavioral Therapy for insomnia (ICBT-i)|This intervention lasts for five weeks. The intervention is internet-based and mainly consists of the most potent CBT technics i.e. sleep restriction and stimulus control. Weekly feedback is provided by master students supervised by clinical psychologists.
41470317|NCT01783652|BEHAVIORAL|Intervention group|Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
40794265|NCT06512779|OTHER|Control Group|sleep hygiene education
40794266|NCT06512779|PROCEDURE|Surgical Intervention|Surgical Intervention includes uvulopalatopharyngoplasty (UPPP) and transoral robotic surgery (TORS). UPPP involves the removal of the uvula and tonsils, while TORS consists of the removal of the uvula, tonsils, and adipose tissue at the base of the tongue.
40794267|NCT06512779|OTHER|Oropharyngeal Training (face-to-face)|Participants will attend face-to-face oropharyngeal training sessions with a therapist in the lab, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
40794268|NCT06512779|OTHER|Oropharyngeal Training (telerehabilitation)|Participants will attend online oropharyngeal training (telerehabilitation) sessions with a therapist, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
40794269|NCT06512779|DEVICE|Continuous Positive Airway Pressure|Participants will use Continuous Positive Airway Pressure (CPAP) throughout the intervention period.
40794270|NCT02840305|OTHER|Evaluation of visual function|
40794271|NCT02840305|OTHER|Magnetic Resonance Imaging|
40794272|NCT04729933|DEVICE|V-Wave Shunt Placement|After the MitraClip Placement and after final screening, the existing transseptal puncture used for MitraClip placement is used to place the V-WAVE Shunt device.
40794273|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
40794274|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
41150341|NCT02792296|OTHER|Project: EVO Monitor|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
41150342|NCT02961816|DRUG|Palifermin|Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
40794277|NCT00194467|DRUG|valganciclovir|900 mg once a day for 8 weeks
40794278|NCT00194467|DRUG|placebo|matching placebo, once a day for 8 weeks
40794279|NCT02360852|DRUG|A4250|A4250 once daily
40794280|NCT03495141|BEHAVIORAL|Supervision/Coaching|Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee
40794281|NCT06555341|BEHAVIORAL|Experimental: Six Thinking Hats Group|"2. Subcutaneous insulin administration was explained with the traditional training model.~3. The Six Thinking Hats technique and how it is used was then explained in detail to the students. Any points that were not fully understood were explained again so that the technique was thoroughly reinforced.~4. The researchers had made hats from different coloured card. All the students wore all the hats in turn and were asked the questions related to that colour hat as stated above (semi-structured questionnaire 1-6).~5. The responses given by the students to the questions were audio-recorded. Each interview lasted 30 mins."
40999642|NCT05472558|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
40999643|NCT04431791|DRUG|Regorafenib|oral regorafenib
40999644|NCT04431791|DRUG|Fruquintinib|oral fruquintinib
41150343|NCT02961816|DRUG|Panobinostat|20 mg by mouth daily from Day -9 to -2.
41150344|NCT02961816|DRUG|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
40794282|NCT06555341|BEHAVIORAL|Other: Video Group|"2. Subcutaneous insulin administration was explained with the traditional training model.~3. Then by scanning the QR code from the nursing practice skills textbook(Aylaz \&amp; Yakıncı, 2024), the researchers provided the link for the students to watch the insulin application video.~4. Without mentioning hat colours or the Six Thinking Hats method to this group, the questions on the semi-structured questionnaire were asked, and the interviews, each lasting 30 mins, were audio-recorded.~5. After completing the video training, the mid-test data were collected by applying the Subcutaneous Insulin Application Skill Level Observation Form during administration of insulin to a dummy."
40794283|NCT02564588|DRUG|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
41150345|NCT02961816|DRUG|Busulfan|"Busulfan test dose administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK."
41150346|NCT02961816|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
40794284|NCT02564588|DRUG|Placebo|Placebo once daily
40794285|NCT04277546|DRUG|Brazikumab Maintenance Dose|Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
41150347|NCT02961816|DRUG|Rituximab|375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
41150348|NCT02961816|DRUG|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
41150349|NCT02961816|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
41150350|NCT02961816|DRUG|Glutamine|Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
41150351|NCT02961816|OTHER|Oral Cryotherapy (ice chips)|Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
41150352|NCT02961816|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
41150353|NCT02961816|BIOLOGICAL|Stem Cell Infusion|Stem cells administered by vein on Day 0.
41150354|NCT02961816|DRUG|G-CSF|G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
41150355|NCT01726634|OTHER|Elastic Tapping|
41150356|NCT04462653|DEVICE|Wearable Dynamic ECG Recorder|use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation
41150357|NCT04462653|DEVICE|12-lead ECG recordings|use a 12-lead ECG recordings to record heart rate and atrial fibrillation
41150358|NCT01182506|BEHAVIORAL|Cogmed Working Memory Training Program|"Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.~The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home."
41150359|NCT01996098|DRUG|6-month Icotinib|125 mg three times daily (375 mg per day) by mouth for 6 months
41150360|NCT01996098|DRUG|12-month icotinib|125 mg three times daily (375 mg per day) by mouth for 12 months
41150361|NCT01543009|OTHER|Emla + Local Warming|In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
41150362|NCT06291597|OTHER|Vaping|Participants use their vaping products at their own discretion and their intake is monitored via questionnaires.
41150363|NCT04232475|OTHER|1 minute of stair climbing and descending|1 minute of stair climbing and descending
41150364|NCT04232475|OTHER|3 minute of stair climbing and descending|3 minute of stair climbing and descending
41150365|NCT04232475|OTHER|10 minute of stair climbing and descending|10 minute of stair climbing and descending
41150366|NCT02982070|BEHAVIORAL|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
41150367|NCT02497547|DRUG|Oxytocin|
41150368|NCT02497547|DRUG|Placebo|
41150369|NCT06355271|PROCEDURE|Fentanyl 1|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and no fentanyl
41150370|NCT06355271|PROCEDURE|Fentanyl2|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 10 mcg of of fentanyl
41150371|NCT06355271|PROCEDURE|Fentanyl 3|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 20 mcg of fentanyl
41150372|NCT05583474|DRUG|OPC-1085EL|one drop for each eye, once per day
41150373|NCT05583474|DRUG|0.005% Latanoprost|one drop for each eye, once per day
41150374|NCT05008315|OTHER|Myofascial abdominal diaphragm release|Myofascial abdominal diaphragm release
41150375|NCT05008315|OTHER|Direct focused scar release technique|Direct focused scar release technique
41150376|NCT05008315|OTHER|Direct manipulations to visceral structures|Direct manipulations to visceral structures
41150377|NCT05008315|OTHER|pelvic anatomy education|pelvic anatomy education
41150378|NCT05008315|OTHER|sham|sham
41470318|NCT04648150|DEVICE|Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms|Evaluation of a millimeter wave emission bracelet -type medical device for improving Parkinson's disease symptoms: multicenter, double-blind randomized controlled trial
40794286|NCT04277546|DRUG|Brazikumab Induction Dose|Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
40794287|NCT02039765|DRUG|Brimonidine tartrate|
40794288|NCT00267306|DRUG|Visilizumab|
40794289|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
40794290|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
40794291|NCT04300660|OTHER|neuropathic pain after thoracic surgery|analysis of perioperative factors implicated in the onset of postoperative pain after chest surgery and the incidence of neuropathic pain
40794292|NCT02956746|BIOLOGICAL|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
40794293|NCT02956746|BIOLOGICAL|Imovax|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
40794294|NCT02956746|BIOLOGICAL|RabAvert|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
41311487|NCT03425942|BEHAVIORAL|Internet Applied Relaxation Techniques (IART-i)|This intervention lasts for five weeks. The intervention is internet-based and consists of different common applied relaxation exercises and treatments. Weekly feedback is provided by master students supervised by clinical psychologists.
41311488|NCT03768791|OTHER|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
41311489|NCT03768791|OTHER|SCS is switched on|Spinal cord stimulator is on
41311490|NCT05393817|DRUG|caffeine citrate|caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)
41311491|NCT05518734|DRUG|VX-708|Solution for intravenous (IV) administration.
41311492|NCT05518734|DRUG|Itraconazole|Solution for oral administration.
41311493|NCT05518734|DRUG|Midazolam|Solution for oral administration.
41311494|NCT05518734|DRUG|Placebo|Placebo matched to VX-708 for IV administration.
41311495|NCT00617318|DIETARY_SUPPLEMENT|Pomegranate|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
41470319|NCT04117945|BIOLOGICAL|Cetuximab|Given IV
41470320|NCT04117945|DRUG|Irinotecan|Given IV
41470321|NCT04117945|BIOLOGICAL|Panitumumab|Given IV
41470322|NCT04117945|DRUG|Regorafenib|Given PO
41470323|NCT05390398|BEHAVIORAL|Behaviour change guided lifestyle intervention|Participants in the intervention group receive personalized coaching from a lifestyle coach on adhering to the World Cancer Research Fund cancer prevention guidelines. The lifestyle coach is specialized in behaviour change techniques and uses these as the core of the lifestyle coaching. For each participant behavioural determinants will be assessed and targeted with specific applicable behaviour change techniques.
40794295|NCT02956746|BIOLOGICAL|HyperRAB ST (human rabies immune globulin)|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
40794296|NCT05536882|DRUG|Benzoyl peroxide|See arm description
40794297|NCT05536882|DRUG|Adapalene Gel|See arm description
40794298|NCT01881009|DEVICE|Hybrid Closed-loop System|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
40794299|NCT01881009|DEVICE|Sensor-augmented pump|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
40794300|NCT00788060|DRUG|Everolimus (RAD001)|5mg per day, continuously
40794301|NCT00788060|DRUG|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
40794302|NCT02100930|BIOLOGICAL|Anti-GD2 3F8 Monoclonal Antibody|
40794303|NCT02100930|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
40794304|NCT02100930|DRUG|oral isotretinoin|
40794305|NCT03133494|OTHER|ABG analysis|ABG analysis was performed and compared between two groups
40794306|NCT01367379|PROCEDURE|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
40999645|NCT04738773|DRUG|Naltrexone|On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per day or as much as tolerated by the patient.
40999646|NCT04738773|DRUG|Placebo|Placebo
41311496|NCT00617318|DIETARY_SUPPLEMENT|Placebo|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
41470324|NCT00986024|BEHAVIORAL|aerobic exercise|carried out 3 times per week for 12 weeks
40794307|NCT01367379|OTHER|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2\~4 times/month)
40794308|NCT05415969|OTHER|CKD-aP|Identification of CKD-aP prevalence and severity among patients on dialysis.
40794309|NCT03149159|DRUG|Nivolumab|Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
40794310|NCT03149159|DRUG|Ipilimumab|Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
40794311|NCT03149159|RADIATION|Steriotactic radiation therapy|The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
40794312|NCT02212366|DEVICE|Active TDCS|Active Stimulation
40794313|NCT02212366|DEVICE|Sham TDCS|Sham Stimulation
40794314|NCT06354348|DIAGNOSTIC_TEST|USG, Grip strength, Chair stand test (CST)|Anterior thigh muscle thickness was measured with USG Grip strength was measured with an electronic hand dynamometer Chair stand test (CST) was performed while participants were asked to stand up and sit down from a chair - without arm rest, for five times as quick as possible, with their arms crossed over their chests.
40794315|NCT02134301|DRUG|Oritavancin|
40794316|NCT06491225|BIOLOGICAL|GTE001 injection|GTE-001 injection to treat Advanced lung adenocarcinoma
40794317|NCT04369456|OTHER|blood sample|a blood sample is taken on Covid-19 kidney transplant patients with moderate symptoms
40794318|NCT04098705|OTHER|Introduction of the World Health Organization Triage Scale|"The intervention will comprise implementation of a new triage and patient flow system facilitated through staff training and clinical redesign.~The three-tier World Health Organization Triage Scale (WHOTS) will be used as the triage instrument. This tool, developed collaboratively by the WHO, International Committee of the Red Cross (ICRC) and Médecins Sans Frontières (MSF), incorporates features of the South African Triage Scale but has been modified for application in a wide variety of RL settings. WHOTS documents are provided in the research protocol."
40794319|NCT06511479|BEHAVIORAL|MIND-BP|8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.
40794320|NCT06511479|BEHAVIORAL|BOOST|The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.
40794321|NCT02705482|BIOLOGICAL|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
40794322|NCT02705482|BIOLOGICAL|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
40794323|NCT02705482|BIOLOGICAL|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
40794324|NCT04115774|DRUG|bisphosphonates|Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
40794325|NCT02084498|DEVICE|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
41311497|NCT04190953|OTHER|Twin block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion
41470325|NCT00986024|BEHAVIORAL|strength training|carried out 3 times per week for 12 weeks
41470326|NCT06611150|DRUG|Nab-paclitaxel|All participants enrolled in the study will be treated with nab-paclitaxel during radical radiotherapy following induction chemotherapy. The doses are increased progressively (180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m²).
40794326|NCT02084498|BEHAVIORAL|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
40794327|NCT04820062|OTHER|Content Validity|For the validity of built, it is generally advisable to include a ratio of 100 participants for 30 questionnaire items. In order to have a suitable questionnaire, we will limit ourselves to 30 items which will be the size of our questionnaire. It was therefore planned to include 100 participants The selection of experts will be based on experience in this area, knowledge and availability. It will be a rescimant physician and an infectious disease doctor. Each expert will be invited in isolation to comment on the items in the questionnaire
41311498|NCT04190953|OTHER|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement
41311499|NCT03850782|DRUG|Bimatoprost (SR)|"Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.~Fellow Eye: Standard of care or Bimatoprost SR."
41311500|NCT05400005|OTHER|Dietary protein|"Intervention of the study include consuming a higher protein diet. Depending on the group allocation, this is done by asking the subjects to follow My Healthy Plate diet and consumption of 20g of protein isolates (casein or soy)."
41311501|NCT02572258|OTHER|Nutritional cookie|
41311502|NCT03054948|DRUG|SMOFLipid|SMOFlipid is a lipid emulsion formed using soybean oil, medium chain triglycerides, olive oil, and fish oil.
41311503|NCT03054948|DRUG|Standard therapy|In most cases standard therapy will be IntraLipid.
41311504|NCT01098838|DRUG|LCL161|
41311505|NCT04350229|DRUG|Drug omission|Drug omission. In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.
41311506|NCT04350229|OTHER|Control group|No drug omission. In the control group, dexamethasone will not be omitted in the second application of paclitaxel.
41311507|NCT03358693|DRUG|Ustekinumab|Subject receives Ustekinumab open-label as per guidelines
40794328|NCT05657938|DEVICE|Wearable Device|The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.
41311508|NCT03358693|DRUG|Infliximab|Subject receives Infliximab open-label as per guidelines
41311509|NCT03358693|DRUG|Secukinumab|Subject receives Secukinumab open-label as per guidelines
41311510|NCT03358693|DRUG|Dupilumab|Subject receives Dupilumab open-label as per guidelines
41311511|NCT03358693|DRUG|Brodalumab|Subject receives Brodalumab open-label as per guidelines
41311512|NCT03358693|DRUG|Ixekizumab|Subject receives Ixekizumab open-label as per guidelines
41311513|NCT03358693|DRUG|Baricitinib|Subject receives Baricitinib open-label as per guidelines
40794329|NCT05657938|OTHER|Duchenne Video Assessment (DVA)|The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
40794330|NCT04202666|DEVICE|convex skin barrier|Total 300 patients and grouping in 1:1 ratio.(1)peristomy skin complication (30 mins) (2)life quality stomy care (3-5 mins) (3)stomy appliance satisfaction (3-5 mins)
40794331|NCT02845986|PROCEDURE|Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
41311514|NCT03358693|DRUG|Abrocitinib|Subject receives Abrocitinib open-label as per guidelines
41311515|NCT03358693|DRUG|Upadacitinib|Subject receives Upadacitinib open-label as per guidelines
41311516|NCT03358693|DRUG|Tralokinumab|Subject receives Tralokinumab open-label as per guidelines
41311517|NCT03898869|DIAGNOSTIC_TEST|Intraoperative NIRS monitoring|Near infrared spectroscopy non invasively used to register changes in tissue oxygen amount during endovascular revascularization
41311518|NCT05437341|BIOLOGICAL|bi-4SCAR PSMA/CD70 T cells|Infusion of bi-4SCAR PSMA/CD70 T cells at 10\^6 cells/kg body weight via IV
41311519|NCT03544268|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
41311520|NCT03544268|DRUG|Definity|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed). Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
41311521|NCT01113398|DRUG|AMG 102|AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
40794332|NCT02845986|DRUG|oxaliplatin|oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
41470327|NCT03880149|DIETARY_SUPPLEMENT|Omega-3|Each omega-3 capsule contains 600 mg, including 400 mg EPA + 200 mg Docosahexaenoic acid (DHA) and 400 IU of vitamin E for 5 omega-3 capsules. Omega-3 dosage: 1 g per 15 kg body mass
40999647|NCT05243095|OTHER|Computer assited, game-based cognitive training|"After recording the demographic information of the participants, the Stroop Test was applied to evaluate attention. After the stages of the test were explained to the participants in detail, they were shown once in practice.~The training group received 20 minutes of cognitive training every day for 8 weeks. No training was applied to the control group. Groups were evaluated at baseline and after 8 weeks."
40999648|NCT01172951|OTHER|Oral glucose tolerance test|75g anhydrous glucose powder mixed with 100mls water
40999649|NCT01172951|OTHER|Oral lipid tolerance test|150ml drink composed of 2 commercially available high fat products
40999650|NCT00624806|BEHAVIORAL|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
40999651|NCT00624806|BEHAVIORAL|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
40999652|NCT05366439|DRUG|AT-752|Parallel Assignment
40999653|NCT05366439|DRUG|Placebo Comparator|Parallel Assignment
40999654|NCT00449644|DRUG|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
40999655|NCT00449644|DRUG|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
40999656|NCT00449644|DRUG|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
40999657|NCT03673163|DRUG|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.
40999658|NCT03673163|DRUG|Control|Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
40999659|NCT04275596|DRUG|2QR complex|Application of topical gel containing 2QR complex on the anal wound until complete wound healing
40999660|NCT04275596|DRUG|Placebo|Application of topical placebo on the anal wound until complete wound healing
40999661|NCT05920434|OTHER|randomized controlled study|randomized controlled study,no drugs or devices were administered to the participants.
40999662|NCT04536727|BEHAVIORAL|Fit & Strong!|The 8-week intervention will consist of the Fit \& Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content
40999663|NCT04536727|BEHAVIORAL|Wait list|Participants randomized to the wait list group receive the 8-week Fit \& Strong! intervention after the intervention group has competed it and after the wait list group has provided their post-outcomes.
40999664|NCT03330938|BEHAVIORAL|CBI and Resilience|A combination of CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring) + Resilience strengthening (Identifying resilient strengths and potentialities, plus Imagination and projection into the future).
41150379|NCT02592434|DRUG|CP-690,550 (tofacitinib)|"During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet \[BID\] or solution \[BID\]):~5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects \>=40 kg."
41150380|NCT02592434|OTHER|placebo|matching placebo tablet or solution for tofacitinib
41311522|NCT01113398|DRUG|Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
41311523|NCT00478725|DRUG|GW786034, oral|oral, 800 mg
41311524|NCT00478725|DRUG|GW786034, IV|IV, 5 mg
41311525|NCT00478725|DRUG|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
41311526|NCT04504032|DRUG|Rivaroxaban|Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.
40999665|NCT03330938|BEHAVIORAL|Cognitive-behavioral Intervention|Only CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring).
40999666|NCT01598792|BIOLOGICAL|ADXS11-001|Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).
40999667|NCT04145778|OTHER|6-minute walk test|The 6-minute walk test is performed as part of routine practice for patients with BMDS to assess patients' overall endurance. In order to compare patients' global endurance with controls, this walking test will also be offered to 50 of the healthy subjects already recruited in the study.
41150381|NCT04568304|BIOLOGICAL|Toripalimab Injection|Toripalimab Injection 240 mg iv infusion on Day 1 of each 3-week cycle. The cumulative duration of Toripalimab Injection is up to 2 years.
41311527|NCT04504032|DRUG|Placebo|Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.
41311528|NCT00077376|BIOLOGICAL|trastuzumab|Given IV
41311529|NCT00077376|DRUG|ixabepilone|Given IV
41311530|NCT00077376|DRUG|carboplatin|Given IV
41311531|NCT00077376|OTHER|laboratory biomarker analysis|Correlative studies
41470328|NCT03880149|OTHER|Placebo|Medium-chain triglyceride (MCT) and vitamin E
41470329|NCT02512614|OTHER|Antimicrobial Hand Towel|Novel antimicrobial hand towel.
41311532|NCT02408055|DRUG|TA-8995|
41311533|NCT00184249|PROCEDURE|Bipolar radiofrequency ablation|Ablation using CE marked bipolar ablation devices
41311534|NCT01524367|DRUG|saline|We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
41311535|NCT01524367|DRUG|Dexmedetomidine|We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
41311536|NCT04895943|PROCEDURE|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
41311537|NCT04895943|PROCEDURE|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
41311538|NCT03095924|OTHER|News items with spin|Interpretation of news items with spin
41311539|NCT03095924|OTHER|News items without spin|Interpretation of news items without spin
41311540|NCT03408951|OTHER|Recording|The patient cutaneous ECG is recorded, to later be comparatively analysed by an expert and by the ISSD detection algorithm
40999668|NCT00153400|BEHAVIORAL|Enhanced Lifestyle Intervention|Three face-to-face counseling sessions for nutrition and physical activity. Used a Spanish culturally tailored materials. These interventions were delivered by community health workers (CHWs) who are trained.
40999669|NCT02199405|OTHER|Massage of chiropractic and adjusting cervical curvature|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
41311541|NCT02569411|OTHER|Financial Incentive|money
41470330|NCT06273787|OTHER|diaphragmatic release|diaphragmatic myofascial release for 1 months 3 sessions per week
41470331|NCT03553875|DRUG|Memantine Hydrochloride|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
41470332|NCT03553875|DRUG|Placebo|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
41470333|NCT03379155|OTHER|Internet-based self-help program|The intervention provided is based on the principles of cognitive behavioral therapy (CBT) (Bachem \& Maercker, 2013). The manual integrates a variety of approaches validated as treatments for PTSD, anxiety disorders, or depression; the selection focuses on exercises which are intended to target the main symptoms of AjD, namely preoccupations (e.g. constant rumination, excessive worry about the stressor) and failure to adapt (e.g. sleep disturbance, difficulties concentrating, loss of interest in previously enjoyable activities).
41470334|NCT04301518|OTHER|Multimodal intervention strategy|"* Once weekly nurse support~* 200 mg/daily micronized progesterone as vaginal suppository~* 81 mg/daily low dose aspirin~* two transvaginal ultrasounds~* cerclage placement if cervical length is less than or equal to 10 mm prior to 24 weeks gestation"
41470335|NCT03082651|OTHER|Alternating run training load|Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period
40999670|NCT02199405|OTHER|Sishi Daoyin|Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
41311542|NCT00585923|DEVICE|Fixed hole C-Tek™ Plate|Fixed hole C-Tek™ Plate
41311543|NCT00585923|DEVICE|Slotted hole C-Tek™ Plate|Slotted hole C-Tek™ Plate
41311544|NCT05346913|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
41470336|NCT03082651|OTHER|Alternating footwear|Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
41311545|NCT05062941|OTHER|Conventional physiotherapy|Conventional therapy (CT) included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation, 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and exercises.
41470337|NCT03082651|OTHER|Constant training|Runners will be assigned identical training sessions over a 7-day period.
41470338|NCT03082651|OTHER|Constant footwear|Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
40794333|NCT01722994|DEVICE|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
40999671|NCT02199405|OTHER|conventional massage|Conventional massage , 15 minutes, three times one week for 4 weeks
40999672|NCT02199405|OTHER|Cervical traction|
40999673|NCT02731729|DRUG|ipilimumab|
40999674|NCT02731729|DRUG|nivolumab|
40999675|NCT04366622|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
41150382|NCT04568304|DRUG|Gemcitabine Hydrochloride for Injection|"Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
41311546|NCT05062941|DEVICE|High-intensity laser therapy (HILT)|"HILT stimulates oxidation of mitochondria and ATP creation by delivering high energy output inside the tissues and with this photochemistry effect, metabolism and blood circulation is increased resulting HILT to cause quick absorption of edema and removal of exudates.~HILT (BTL 6000, BTL Industries, Inc., USA) application was to the shoulder area in the analgesic mode of the device at a frequency of 25 Hz with a power of 10 W and a dosage of 12 j/cm2 for 2 minutes: 5 sessions a week for 3 weeks and 15 sessions in total."
41311547|NCT01029431|DEVICE|AirQ Intubating Laryngeal Airway|After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted \& the evaluation described below will be conducted. The first LMA will then be removed \& the other device inserted \& assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment \& before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, \& inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
41311548|NCT05015205|OTHER|Muscle Energy Technique|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The muscle was positioned in position and patient was asked to apply 20% force isometrically and hold the isometric contractions for 7-10 seconds. Then the patient was asked to relax for about seconds. On exhalation, therapist takes muscle to new restriction barrier. Hold this position for 30 seconds at the end barrier as an end-stretch with 3 repetitions.
41470339|NCT06234748|RADIATION|Radiation|"Patients will undergo 2 phases of RT replanning:~1. Based on 2-week DCE-MRI low BV tumor subvolume, patients will have a PTVboost1 that will start to receive 2.5Gy/day with fraction 16. PTVboost1=(persistent lowBVsubvolume_2 wks+ MTV3_2 weeks)+ 3mm margin.~2. Based on 4-week FDG-PET MTV3, patients with have a PTVboost2 cone down that will receive 2.5Gy/day starting with fraction 23. PTVboost2=(LBV_2 wks + MTV3_4wks)+ 3mm margin~3. Thus, the tumor subvolumes that are included in the boost from fx16-35 will receive 86 Gy EQD2 (80Gy physical dose) and the FDG-avid subvolumes which start boost at 2 weeks but are not persistently avid at 4 wks will receive 76Gy EQD2 (74Gy physical dose)."
40999676|NCT06244069|DIAGNOSTIC_TEST|Temporal arterial biopsy|Collection of 30 ml of peripheral blood in ethylenediaminetetraacetic acid (EDTA) tubes performed at baseline, 6 months, 12 months and in case of flare before month 12. In addition, the temporal artery specimen (at least 5 mm in length) exceeding that used for clinical activity (at least 10 mm in length in accordance with current clinical recommendations) will be digested to use for research purposes (about protocols for collecting, processing, storing and sending biopsy, refer to Standard Operating Procedures, SOP).
40999677|NCT06244069|DIAGNOSTIC_TEST|Whole exome sequencing|"Patients with CHIP will be identified and characterized by using whole exome sequencing from the peripheral blood samples. M-CHIP will be further characterized by:~i) clone dimension as defined by Variant Allele Fraction (VAF); ii) mutations in specific genes such as DNMT3A, Tet methylcytosine dioxygenase 2 (TET2), Additional Sex combs (ASXL1), or Janus kinase 2 (JAK2); iii) multiple mutations.~L-CHIP will be further characterized by:~i) clone dimension as defined by the VAF; ii) mutations in specific genes such as Dual Specificity Phosphatase 22 (DUSP22), FAT atypical cadherin 1 (FAT1), (Histone-lysine N-methyltransferase 2D (KMT2D); iii) multiple mutations; iv) co-occurrence of mutations heralding M- and L-CHIP."
41470340|NCT06234748|DRUG|Platinum based chemotherapy|Standard of care therapy, weekly, with either Cisplatin or Carboplatin
41470341|NCT04474093|OTHER|Zirconium-reinforced glass ceramics(ZRGC),Lithium disilicate glass ceramics(LGC), Resin infiltrated glass ceramics(RIGC)|
41150383|NCT04568304|DRUG|Cisplatin for Injection / Carboplatin Injection|"Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
41311549|NCT05015205|OTHER|Postural Correction Exercises|: Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. Hip flexors and back extensors were stretched while hip extensors and abdominals were strengthened. Seated hip flexion used to stretch back extensors while lunge position used to stretch hip flexors. The abdominals were strengthened by using curl up exercises while hip extensors were strengthened by resisted contractions in prone lying.
40794334|NCT01722994|DEVICE|Chromic Gut Sterile absorbable Suture (Ethicon)|
40794335|NCT00276068|DRUG|topical lidocaine + oral desipramine, and/or placebo|
40794336|NCT05183074|DEVICE|MR-linac|1.5-Tesla MR-linac based SBRT
40794337|NCT03192293|DRUG|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans"
40794338|NCT00794846|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
40794339|NCT00794846|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
40794340|NCT05424965|OTHER|no intervention|no intervention
40794341|NCT04451135|DIAGNOSTIC_TEST|Electroencephalographic (EEG)|EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
40794342|NCT04451135|DIAGNOSTIC_TEST|Closed loop acoustic stimulation (CLAS)|Closed loop acoustic stimulation will be enabled on the DREEM headband on a subset of study participants. The device delivers stimulation in phase with the upstroke of the EEG slow wave (STIM) to boost slow oscillation activity. The timing of this stimulus augments the expression of subsequent slow waves.
40794343|NCT04451135|DIAGNOSTIC_TEST|Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)|The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
40794344|NCT04451135|DIAGNOSTIC_TEST|Ictal Electroencephalographic (EEG) Measurements|A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
40999678|NCT06244069|DIAGNOSTIC_TEST|Single cell transcriptomics|The investigators will identify actively inflamed arterial biopsies from three treatment-naïve patients without CHIP, and three treatment-naïve patients with CHIP driven by the most relevant gene mutation. Arterial wall Cluster of Differentiation (CD) 45+ leukocytes will be isolated after digestion of arterial tissue and characterized by single cell transcriptomics, with a specific focus on wall infiltrating T cells and macrophages and their subsets (eg: Vascular dendritic cells, Th1, Th2, Th17, Treg, M1- and M2-like,...). Frequencies of these subsets and their genetic expression will be compared between wall-infiltrating leukocytes from GCA patients with or without CH, focusing on histological events supposed to be pathogenic in GCA, or known to be dysfunctional in CHIP.
41150384|NCT04568304|DRUG|Placebo|Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.
41311550|NCT05152472|DRUG|Atezolizumab 1200 mg|(Intravenous administration)
41311551|NCT05152472|DRUG|Imatinib 400 MG|(Per os)
41311552|NCT00357526|DRUG|OCPs|
41311553|NCT00357526|DEVICE|vaginal ring|
41311554|NCT03046628|DEVICE|TcPO2|
40794345|NCT04451135|DIAGNOSTIC_TEST|Post-Ictal Electroencephalographic (EEG) Suppression Measurements|A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
40794346|NCT04451135|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Following EEG preprocessing of DREEM sleep recordings, SWA will be quantified using a custom-written MATLAB module as the average of total power spectral estimates within the 0.5-4 Hz frequency band in one minute intervals, during the first cycle of N3 sleep.
40794347|NCT00244868|OTHER|counseling intervention|
40794348|NCT00244868|OTHER|educational intervention|
40794349|NCT01022970|DRUG|QAX576 placebo|
41150385|NCT02080117|PROCEDURE|kidney transplantation, living or deceased donor|
41150386|NCT03480945|DIAGNOSTIC_TEST|serotonin|Endothelium-dependent dilatation
41150387|NCT03169530|OTHER|Alcohol|\~15 gm daily of beer, wine, or spirits for \~6 years
41311555|NCT03046628|DEVICE|Green laser (at 532nm) and a fast camera|
41470342|NCT04661449|OTHER|Comprehensive lifestyle intervention|Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).
40794350|NCT01022970|DRUG|QAX576|
40794351|NCT01396356|PROCEDURE|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
40794352|NCT05059093|DIAGNOSTIC_TEST|Classification and segmentation deep learning models|Models that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
41150388|NCT03997409|OTHER|Dietary Intervention|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.
41150389|NCT01082354|DRUG|recombinant somatropin|as per standard practice
41150390|NCT03721900|DRUG|SHX-001 Active low dose|ketamine transdermal patch
41150391|NCT03721900|DRUG|Placebo|transdermal patch
41150392|NCT03721900|DRUG|SHX-001 Active High dose|ketamine transdermal patch
41311556|NCT04646980|DIETARY_SUPPLEMENT|Biobran/MGN-3|Biobran/MGN3 is defined by the Medicines and Healthcare products Regulatory Agency (MHRA) as a food supplement. Biobran/MGN3 is manufactured by hydrolyzing rice bran with the enzymatic extract of medicinal Shiitake mushrooms. Enzyme hydrolysis of rice bran produces arabinoxylane, a hemi-cellulose compound, which constitutes the active ingredient of biobran/MGN3.
41150393|NCT06090318|DRUG|Milademetan|260 mg once daily orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.
40794353|NCT04867083|DRUG|ARV bitherapie|"1. Dolutégravir 50mg / Lamivudine 300mg per day~2. Dolutégravir 50mg / Rilpivirine 25mg per day~3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day"
40794354|NCT03109743|BEHAVIORAL|Sisters-GPS: Group Clinical Visits|Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
41150394|NCT06090318|DRUG|Atezolizumab|1680mg administered every 4 weeks
41150395|NCT04399798|DRUG|Baricitinib|4 mg/day for 7 days
41150396|NCT02633345|DIETARY_SUPPLEMENT|Probiotic tablets|Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
41150397|NCT02633345|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
41150398|NCT03873922|OTHER|Ketogenic diet intervention|Ketogenic, really low carbohydrate containing (15-20 g/day), meals will be offered to the participants.
41150399|NCT02539602|BEHAVIORAL|The Need to Know students received the N2K curriculum as described previously|
41150400|NCT04586049|DEVICE|MRI|Participants will undergo an MRI scan while participating in a breathing test to measure brain blood flow.
41150401|NCT04586049|DEVICE|Transcranial Doppler Ultrasound|Participants will undergo a TCD scan while participating in a breathing test to measure brain blood flow.
41150402|NCT04586049|OTHER|Sympathetic Nerve Activity|Participants will undergo sympathetic nerve activity testing while participating in a breathing test.
41150403|NCT04923230|BEHAVIORAL|Cannabis Actions and Practices Resource for Parents|The Cannabis Actions and Practices (CAP) resource is a parent-focused approach to help MM parents address marijuana use and attitudes by their adolescents. CAP includes information about the effects of marijuana on adolescent behavioral health, brain development, and social functioning. CAP also integrates motivational strategies to foster The CAP intervention focuses on building parenting skills and teaching strategies to: (1) limit adolescent exposure to cannabis products and parent cannabis use at home, (2) improve parent communication about their MM use, expectations about youth marijuana use, and attitudes about the potential harms of adolescent cannabis use, (3) improve monitoring, and (4) increase positive reinforcement for youth abstinence. Parents meet with an interventionist for two individual 75-minute sessions involving presentations, discussions, and behavioral rehearsal of key parenting skills.
41150404|NCT00028509|PROCEDURE|management of therapy complications|
41150405|NCT05165303|DRUG|lidocaine with propofol|different concentrations of lidocaine added to propofol varying from
41150406|NCT06037109|DEVICE|Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test|Previously collected urine samples will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
41150407|NCT02812706|DRUG|Isatuximab SAR650984|Pharmaceutical form: solution Route of administration: intravenous
41150408|NCT06276946|RADIATION|standard radiotherapy|radiotherapy planning goal is to restrict the mean parotid dose is equal to or less than 14Gy.
41150409|NCT06276946|RADIATION|experimental radiotherapy|radiotherapy planning goal is to restrict the parotid duct dose is equal to or less than 14Gy
41150410|NCT02984787|PROCEDURE|3D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
41150411|NCT02984787|PROCEDURE|2D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
41150412|NCT02416973|DEVICE|Provant|
41150413|NCT01264484|DEVICE|Advantage Prosthetic Heart Valve|All patients eligible for this study are treated with an Advantage prosthetic heart valve
41150414|NCT03802578|BEHAVIORAL|HAND EXERCISE|
41150415|NCT00002840|DRUG|lomustine|
41150416|NCT00002840|DRUG|procarbazine hydrochloride|
41150417|NCT00002840|DRUG|vincristine sulfate|
41150418|NCT00002840|RADIATION|radiation therapy|
41150419|NCT05413811|DRUG|5 Fluorouracil (5 FU) Cream|Intravaginal topical chemotherapy, 5-fluorouracil cream
41150420|NCT05413811|DRUG|Placebo|Intravaginal topical placebo cream
41470343|NCT02045524|OTHER|Deep muscle injection|
41470344|NCT02045524|OTHER|Sub-Q Injection|
40794355|NCT03109743|BEHAVIORAL|Control: One-on-one Adherence Counseling|For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
40794356|NCT05648877|DEVICE|Ureteroscope|Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
41311557|NCT04646980|OTHER|Placebo|Placebo, with same appearance and taste as Biobran/MGN-3, was given to control subjects at a dose of 500 mg everyday for 3 months
40794357|NCT02148263|DEVICE|senofilcon A|
40794358|NCT06425653|OTHER|Exercise Program|"In the intervention group in addition to the standard protocol, an exercise program intervention was applied and after the initial interview the Exercise Program DVD was provided through mobile phone. All patients were evaluated 4 times: at baseline, at the 4th week (first visit), at the 8th week (second visit) and at the 12th week (final visit) after randomization"
41311558|NCT01822041|DRUG|ARN-509|Single oral dose of 240 mg ARN-509
41311559|NCT02662777|DEVICE|Eso-SPONGE® vacuum treatment|
40794359|NCT04941469|DEVICE|Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types."
40794360|NCT04941469|DEVICE|Plain off-the-counter foot orthosis (Medical grade foot orthosis)|The control device for this study would be the plain original Formthotics (Original Dual Hard).
40794361|NCT00389376|DRUG|Placebo|Placebo
40794362|NCT00389376|DRUG|Silymarin|140 mg every 8 hours
40794363|NCT00389376|DRUG|Silymarin|280 mg single dose
40794364|NCT00389376|DRUG|Silymarin|280 mg single dose + every 8 hours
40794365|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
41150421|NCT04380688|DRUG|Acalabrutinib|Acalabrutinib administered orally
41150422|NCT03875794|OTHER|Osteopathic Manipulation|Using osteopathic manipulation as an intervention to increase milk supply in lactating women.
41150423|NCT06585007|RADIATION|Radiotherapy|Progression-directed therapy (stereotactic body radiation therapy)
41311560|NCT03280641|DRUG|Dabigatran Etexilate 110mg|Dabigatran Etexilate 110mg, BID
41311561|NCT03280641|DRUG|Warfarin Sodium|Target INR:1.6-3.0
41311562|NCT04288479|BEHAVIORAL|Single high-intensity interval training session|10 minutes warming up at low-to-moderate intensity, 8x30 seconds high intensity interval training with fetal heart rate measurement after each 30 second work-bout, 2 minutes recovery at low-to-moderate intensity. Continuous monitoring of maternal heart rate.
41311563|NCT05525338|DRUG|Alectinib|In case of an alectinib plasmaconcentration Cmin \<435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
41311564|NCT03053427|DRUG|Placebo|Oral administration
41311565|NCT03053427|DRUG|Gabapentin enacarbil|Oral administration
40794366|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
40794367|NCT00389376|DRUG|Silymarin|280 mg every 8 hours
40794368|NCT00389376|DRUG|Silymarin|700 mg single dose + every 8 hours
40794369|NCT00470262|DRUG|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
40794370|NCT00470262|DRUG|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
40794371|NCT02748876|OTHER|His-Ventricular (HV) optimisation|Optimisation of atrioventricular pacing interval
40794372|NCT00410969|DEVICE|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
40794373|NCT05246878|DRUG|EDP-235|Oral administration
40794374|NCT05246878|DRUG|Placebo|Placebo to match EDP-235, oral administration
40794375|NCT00699413|DRUG|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
41150424|NCT06585007|PROCEDURE|metastasectomy|Progression-directed therapy (metastasectomy)
41150425|NCT01877720|DEVICE|noninvasive respiratory support with NAVA mode and PSV|
41150426|NCT00000922|DRUG|Indinavir sulfate|
41150427|NCT00000922|DRUG|Abacavir sulfate|
41150428|NCT00000922|DRUG|Nelfinavir mesylate|
41311566|NCT00002833|BIOLOGICAL|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
41311567|NCT00002833|DRUG|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
40794376|NCT00699413|DRUG|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste."
41470345|NCT06613061|OTHER|Breathing exercise|"The researcher has a breathing exercise certificate. In our study, the breathing exercise application consists of three stages: box breathing, sigh breathing and diaphragm breathing.~Patients will be asked to continue the breathing exercise application for 2 weeks and will be reminded to do the breathing exercises. Box and sigh breathing will be done 3 times a day (morning, noon and evening) every day for 2 weeks. Diaphragm breathing exercise will be applied for 2 minutes in the first week and 4 minutes in the second week."
40794377|NCT05740046|DEVICE|INTORUS|INTERVENTION PROTOCOL WITH INTORUS
40794378|NCT01321853|OTHER|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
40794379|NCT01321853|OTHER|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
40999679|NCT04018937|DRUG|Alemtuzumab|Alemtuzumab will be administered by either subcutaneous (SQ) injection or IV. A test dose of alemtuzumab, 3 mg, is administered on the first day. If the test dose is tolerated, administration of three treatment doses will begin within 24 hours. The three treatment doses will be administered on consecutive days. On the first day, 10 mg/m2 will be given, 15 mg/m\^2 the second and 20 mg/m\^2 the third. Alemtuzumab will be started between Days -22 and -20, but all doses (test dose and three treatment doses) should be completed by Day -18.
40999680|NCT04018937|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for five days (Days -7 to -3).
40794380|NCT01253083|BEHAVIORAL|mobility training with dynamic body weight support|
40794381|NCT03980782|OTHER|Music Therapy|Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
40999681|NCT04018937|DRUG|Melphalan|Melphalan will be administered at 140 mg/m\^2 IV on Day -3 following fludarabine administration.
40999682|NCT04130295|OTHER|Wearable intensive nerve stimulator|The wearable device consists of 2 leads that provide biphasic, with alternating lead phase, asymmetrical rectangular current at a pulse duration of 0.28 msec, a randomly varying pulse frequency between 60-100 Hz, with a maximum intensity of 100mA.
40999683|NCT02259153|BEHAVIORAL|Changes in cholesterol metabolism|
41150429|NCT00000922|DRUG|Efavirenz|
41150430|NCT00000922|DRUG|Nevirapine|
40794382|NCT01946659|BEHAVIORAL|Adherence to Sleep Apnea Treatment|A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
40794383|NCT01946659|OTHER|Standard Care Group|The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
40999684|NCT02259153|OTHER|Lean red meat diet|
41150431|NCT00000922|DRUG|Lamivudine|
41150432|NCT00000922|DRUG|Stavudine|
41150433|NCT00000922|DRUG|Didanosine|
41150434|NCT03524092|DRUG|Mirikizumab SC|Administered SC
41150435|NCT03524092|DRUG|Mirikizumab IV|Administered IV
41150436|NCT03524092|DRUG|Placebo SC|Administered SC
41150437|NCT01770509|DEVICE|NMBM|Daily application of NMBM in addition to compression therapy
41150438|NCT01770509|OTHER|Compression garments|Compression garments
41150439|NCT02987088|DRUG|Sodium Nitrite|
41150440|NCT05417555|DEVICE|Low-Intensity Focused Ultrasound Pulsation (LIFUP)|Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)
41150441|NCT02187120|DRUG|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
41150442|NCT02187120|DRUG|Placebo|
40794384|NCT05153226|DRUG|Cyclophosphamide|50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
40794385|NCT05153226|BIOLOGICAL|ATG|10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
40794386|NCT04522050|DRUG|Gemcitabine combined with cisplatin induction chemotherapy|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m², d1) every 3 weeks for 2 cycles before radiotherapy. And then intensity modulated radiotherapy (IMRT) is given a total dose of GTVnx 70Gy, GTVnd 66Gy, CTV1 60Gy and CTV2 54Gy for 33 times in total, concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. The patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
40999685|NCT02259153|OTHER|Fat red meat diet|
41150443|NCT04422509|BIOLOGICAL|lanadelumab|single dose, or two doses administered iv
41150444|NCT04422509|OTHER|regular care|no lanadelumab administration, treated according to regular care
41470346|NCT05815849|DIETARY_SUPPLEMENT|Olive oil|0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group
40999686|NCT00409383|DRUG|Genasense® (oblimersen)|Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
41470347|NCT03474328|DEVICE|AlcoChange|Smartphone app and breathalyser
40999687|NCT00409383|DRUG|Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
41470348|NCT06452329|DRUG|Nivolumab|As prescribed by treating physician
41470349|NCT02430207|PROCEDURE|temporary pacing femoral vein|Temporary pacing via femoral or subclavian vein
41470350|NCT02430207|PROCEDURE|temporary pacing subclavian vein|
41470351|NCT01957345|OTHER|Blood punction|"T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)~signalisation test is made by flow cytometry~Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.~Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested."
41470352|NCT04122781|DEVICE|Novel K-wire fixation devices|The patients received surgery using novel K-wire fixation devices
41470353|NCT02672540|DRUG|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
41470354|NCT02672540|DRUG|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
41470355|NCT04266873|DEVICE|AffloVest|Form of High Frequency Chest Wall Oscillation mimicking manual techniques on a patients thorax to assist with secretion clearance. Delivered for 30 minutes, twice a day
41470356|NCT00739973|DRUG|Placebo|
41470357|NCT00739973|DRUG|Aliskiren 150 mg tablet|
41470358|NCT00739973|DRUG|Aliskiren 300 mg tablet|
41150445|NCT01876719|DRUG|AR08|
41150446|NCT01876719|DRUG|Placebo|
41150447|NCT00108355|DRUG|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
41150448|NCT00108355|DRUG|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
41150449|NCT00108355|DRUG|Midodrine|Midodrine oral tablet at 10 mg three times a day.
41150450|NCT00108355|DRUG|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
41150451|NCT00108355|DRUG|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
41470359|NCT00739973|DRUG|Amlodipine 5 mg capsule|
41470360|NCT00739973|DRUG|Amlodipine 10 mg capsule|
41470361|NCT00739973|DRUG|Aliskiren/amlodipine 150/5 mg tablet|
41470362|NCT00739973|DRUG|Aliskiren/amlodipine 150/10 mg tablet|
40999688|NCT00409383|DRUG|Temodar® (temozolomide)|Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
41150452|NCT00108355|DRUG|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
41470363|NCT00739973|DRUG|Aliskiren/amlodipine 300/5 mg tablet|
41470364|NCT00739973|DRUG|Aliskiren/amlodipine 300/10 mg tablet|
41470365|NCT06494280|DRUG|programmed intermittent Bolus epidural analgesia|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
41470366|NCT06494280|DRUG|continuous epidural infusion|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
41470367|NCT06073899|OTHER|Leg Extension Exercise|Participants will perform a concentric quadriceps contraction into terminal knee extension with weight equivalent to 65% of a1-repetition maximum.
41470368|NCT02339090|DRUG|Somavaratan|Somavaratan will be administered per dose and schedule specified in the arm description.
41470369|NCT02339090|DRUG|rhGH|rhGH will be administered per dose and schedule specified in the arm description.
41470370|NCT02443545|DRUG|Deferiprone|
41470371|NCT05077956|DIAGNOSTIC_TEST|Cerebrospinal and Blood Serum Semaphorin 4A Levels|Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.
40794387|NCT04522050|DRUG|concurrent chemoradiotherapy with gemcitabine|followed by concurrent gemcitabine chemoradiotherapy
40999689|NCT03096665|DIAGNOSTIC_TEST|blood test|Point of care blood analysis obtained from skin puncture
40999690|NCT02855749|PROCEDURE|ultrasound-guided percutaneous tracheostomy|to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
40999691|NCT03462316|BIOLOGICAL|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
40999692|NCT01342510|DRUG|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
40999693|NCT01342510|DRUG|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
40999694|NCT01342510|DRUG|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
40999695|NCT01342510|DRUG|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
40999696|NCT01855295|DIETARY_SUPPLEMENT|Protein Supplement|During the treatment phase, study subjects are advised to increase protein intake to 1.2 g/kg/day for 12 weeks. In addition to any protein supplementation the participant is on, supervised supplementation on each dialysis session is provided. Each participant receives 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
40999697|NCT01285648|PROCEDURE|Cpap|This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
40999698|NCT02753062|DRUG|bendamustine, rituximab|subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
40999699|NCT01733914|PROCEDURE|Acupuncture|Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
41150453|NCT00108355|PROCEDURE|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
41150454|NCT02119572|BEHAVIORAL|peer support|
41150455|NCT02119572|OTHER|usual education lectures|
41150456|NCT02516371|OTHER|lymphocyte|To evaluate the subpopulation of lymphocytes in cancer patients
41150457|NCT03367845|BEHAVIORAL|Control|Parents receive 8 phone contacts (1 per week) that do not focus on material in the sensitivity and couples communication intervention.
41311568|NCT00002833|DRUG|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
41150458|NCT03367845|BEHAVIORAL|Sensitivity Intervention|4 home visits take place. Mothers and fathers are video recorded with their infant (separately) for approximate 10-15 minutes at the beginning of each visit. The recorded situations are natural (e.g., playing together, bathing the baby, mealtime, etc.) and the family coach (interventionist) is not actively involved in the parent-child interaction. A different theme is covered across the four intervention sessions. For each parent-infant interaction recording, the family coach reviews the recordings between visits and provides feedback to parents in the following intervention session. The exception to this is that video of parent-child interactions during the lab pre-test is used for material at the first home visit. Each session takes approximately 90 minutes. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
41311569|NCT00002833|DRUG|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
41311570|NCT00002833|DRUG|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
41311571|NCT00002833|DRUG|Idarubicin|IV Days -6, -5 and -4.
41311572|NCT00002833|DRUG|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
41311573|NCT00002833|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
41470372|NCT04507594|PROCEDURE|Lung lobectomy OR esophagus cancer resection|Lunge lobectomy (total) Resection of esophagus cancer
41470373|NCT04810078|BIOLOGICAL|Nivolumab and rHuPH20|Specified dose on specified days
40794388|NCT05895305|COMBINATION_PRODUCT|Paclitaxel-Coated Pulmonary Balloon Catheter|Subjects with benign airway stenosis will be treated by Airiver pulmonary DCB at index procedure
40794389|NCT03135431|PROCEDURE|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
40999700|NCT01733914|OTHER|Control|Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
40999701|NCT05310110|DRUG|10% lidocaine spray|10% lidocaine spray 3 puff for the throat before induction
41150459|NCT03367845|BEHAVIORAL|Couples' Intervention|The psycho-educational inter-parental conflict prevention curriculum is a 4-session program that takes place in the families' homes. Each session lasts approximately 90 minutes and involves discussion and practice of four themes pertinent to improving conflict process, communication, and emotional security in the family: Conflict Overview, Interparental Conflict and Children, Stresses of Parenting, and Emotional Security. The family coach scaffolds and supports the couples' development of constructive conflict behaviors. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
41311574|NCT04123717|DRUG|Intravenous Ibuprofen|The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
41311575|NCT00004363|DRUG|chlorpropamide|
41311576|NCT00004363|DRUG|desmopressin|
41150460|NCT03367845|BEHAVIORAL|Sensitivity and Couples' Intervention|This group receives both the Sensitivity and Couples' Intervention in their home. There are 8 home visits (4 for Sensitivity and 4 for Couples Intervention). Because of COVID-19, we now conduct remote visits using Zoom.
41150461|NCT05082441|DRUG|Liposomal bupivacaine|Exparel mixed with bupivacaine to be infiltrated in the subcutaneous region of the wound instead of plain bupivacaine
41150462|NCT05082441|DRUG|Bupivacaine Hydrochloride|plain bupivacaine subcutaneous injection as standard of care control
41150463|NCT05673421|OTHER|Exergaming Training|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks
41470374|NCT04810078|BIOLOGICAL|Nivolumab|Specified dose on specified days
41470375|NCT03829215|DEVICE|CAERVest cooling device|The CAERVest device will be filled and placed on the supine patient's chest immediately after return of spontaneous circulation. After admission to the emergency department, the device will be removed, when a temperature below 34°C is reached.
40794390|NCT03135431|PROCEDURE|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
40794391|NCT02713334|BEHAVIORAL|survey|
40794392|NCT02713334|BEHAVIORAL|semi-structured interview|
40794393|NCT06219915|DRUG|Carbidopa 25 mg|Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
40794394|NCT06219915|DRUG|Carbidopa-Levodopa 25/100 mg|Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
40794395|NCT06219915|DRUG|Placebo 1|Participants will take one 25mg placebo tablet 3 times a day for 10 days.
40794396|NCT06219915|DRUG|Placebo 2|Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
41470376|NCT00206245|DRUG|AZD0865|
41470377|NCT00855764|DRUG|Paclitaxel|Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
41311577|NCT02178176|BEHAVIORAL|Education, encouragement, card sort|"Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.~We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process."
41311578|NCT02178176|BEHAVIORAL|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
41470378|NCT03728023|DRUG|AZD4205|SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
41470379|NCT03728023|DRUG|Placebo|Single dose in SAD and once daily for 14 days
41470380|NCT03399006|DEVICE|2D ultrasound|Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position \& carried out for measurement of fetal CRL and diagnosis of any major fetal defects
41470381|NCT03399006|DEVICE|Doppler Ultrasound|"measurement of UtA-PI \& UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated."
41470382|NCT03399006|DEVICE|3D ultrasound|"3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters."
41470383|NCT04904484|DEVICE|iZephyr hood|Assessment of an aerosol containment device
41470384|NCT00709306|DEVICE|UV-Detect Photos|UV-Detect Photos
41470385|NCT00709306|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing
41470386|NCT00709306|BEHAVIORAL|Education|Education
41470387|NCT01471834|DEVICE|BAROSTIM NEO System|
41470388|NCT01471834|DRUG|Medical Management|
41470389|NCT03358095|DEVICE|Tannenbaum Fr 10 stent or WallFlex stent|A plastic or metallic endoprosthesis is placed to the biliary ducts.
41470390|NCT01337726|BEHAVIORAL|Combined Psychotherapy and Illness Management|Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.
41470391|NCT01337726|BEHAVIORAL|Illness Management Only|Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
41470392|NCT00760786|DRUG|Intensive lipid lowering plus Omega3-fatty acid|Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
41470393|NCT00760786|DRUG|Moderate lipid lowering plus Omega3-fatty acid|atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
41311579|NCT05040789|BIOLOGICAL|CoVLP formulation|"The Coronavirus-Like Particle (CoVLP) COVID-19 Vaccine is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs).~The 3.75 µg dose of CoVLP will be administered with the adjuvant AS03 (manufactured by GlaxoSmithKline)."
41470394|NCT00760786|DRUG|Intensive lipid lowering plus placebo|atorvastatin 40mg qd
41470395|NCT00760786|DRUG|Moderate lipid lowering plus placebo|atorvastatin 10mg qd
41470396|NCT03123029|DRUG|Venetoclax|Venetoclax will be administered orally.
41470397|NCT00265044|BEHAVIORAL|Provider Education|
41470398|NCT00265044|BEHAVIORAL|Hypertension Alert|
41470399|NCT00265044|BEHAVIORAL|Patient Education|
41470400|NCT03215459|DEVICE|Cardiopulmonary Exercise Test|Cardiopulmonary Exercise Test
41470401|NCT05673993|BIOLOGICAL|Telitacicept 80 mg|Telitacicept 80 mg subcutaneously once a week.
41470402|NCT05673993|BIOLOGICAL|Telitacicept 160 mg|Telitacicept 160 mg subcutaneously once a week.
40999702|NCT05310110|DRUG|Placebo of lidocaine spray|Normal saline spray 3 puff for the throat before induction
41470403|NCT05673993|DRUG|Placebo|Subjects will be given subcutaneous placebo once a week.
41470404|NCT06614608|DRUG|5% ASKC200|5% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
41470405|NCT06614608|DRUG|1% ASKC200|1% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of1% for this study.
41470406|NCT05923970|DIAGNOSTIC_TEST|Serology for antibody levels - Baseline|Measurement of rubella IgG antibody levels at baseline
41470407|NCT05923970|DIAGNOSTIC_TEST|Serology to assess cell mediated immune (CMI) response - Baseline|Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.
41470408|NCT05923970|DIAGNOSTIC_TEST|Serology for antibody levels - Post third dose of MMR vaccine|Measurement of rubella IgG antibody levels post third dose of MMR vaccine
40794397|NCT02014662|OTHER|Eccentric exercise|Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
40794398|NCT02446821|DEVICE|VeraCept|IUD placement of VeraCept
40999703|NCT05310110|DRUG|Cisatracurium|Intravenous cisatracurium 0.12 mg/kg during induction
41150464|NCT05673421|OTHER|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb.Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
41311580|NCT03219593|DRUG|Apatinib mesylate tablets|Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
41311581|NCT05924776|BIOLOGICAL|Plasmodium immunotherapy|Inoculation 1-5 × 10\^6 Plasmodium vivax once
41311582|NCT03069469|DRUG|Vimseltinib|Colony-stimulating factor 1 receptor (CSF1R) inhibitor
41311583|NCT03187912|DRUG|Riboflavin|Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
41311584|NCT05159388|DRUG|PRS-344/S095012|PRS-344/S095012 Monotherapy
41311585|NCT01111201|BEHAVIORAL|questionnaires|The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
41311586|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
41311587|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation
41470409|NCT05923970|DIAGNOSTIC_TEST|Serology to assess CMI - Post third dose of MMR vaccine|Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.
41470410|NCT05470595|DRUG|Atezolizumab|Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
41470411|NCT05799716|DRUG|IVIG|0.5g/Kg
41470412|NCT05695391|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|LR769
41470413|NCT06309914|DIETARY_SUPPLEMENT|Placebo|Subjects will consume one capsule of the Placebo twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
40794399|NCT04399200|DEVICE|Treatment according to standard care recommandation|SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)
40794400|NCT03235453|OTHER|Binary rhythm|The binary rhythm intervention will be performed using the dance modalities, Forró, Merengue and Bolero. It will occur twice a week for 12 weeks with 45 minutes of sitting.
40794401|NCT03235453|OTHER|Quaternary rhythm|The quaternary rhythm intervention will be performed using the modalities of dance, Tango, Salsa, Zouk. It will occur twice a week for 12 weeks with 45 minutes of sitting.
41311588|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
40999704|NCT05310110|DRUG|Placebo of cisatracurium|Intravenous normal saline during induction
41311589|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
40794402|NCT02944838|BEHAVIORAL|Senior Change Makers Advocacy Program|see description
40794403|NCT02944838|BEHAVIORAL|Senior Change Makers Physical Activity Program|see description
40794404|NCT03805061|OTHER|'aerobic exercise'|The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed a period of; 8 weeks, 3 days a week, 30-45 minutes each patient.
40794405|NCT03805061|DEVICE|'isokinetic exercise'|Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low exercise and exercise was applied for 5-10 minutes to cool down at the end of the study. were included in a rehabilitation program that they would apply for 3 days per week for 8 weeks.The measuring of isokinetic muscle strength, CSMI Humac Norm isokinetic dynamometer's commonly used angular velocities of 60 ° and 180 ° / sec was used.
40794406|NCT02565693|DRUG|Apixaban|
40794407|NCT02565693|DRUG|Aspirin|
40794408|NCT02565693|DRUG|Carbasalate calcium|
40794409|NCT02565693|DRUG|Clopidogrel|
40794410|NCT02565693|DRUG|Dipyridamole|
40794411|NCT02565693|OTHER|No antithrombotic treatment|
40794412|NCT05334316|DRUG|Dexamethasone|Administered intravenously or orally based on daily CRP values and CRP corticosteriod dosing algorithm
40794413|NCT00238082|DRUG|HFA-134A Beclomethasone DIpropionate (QVAR)|
40794414|NCT00002237|DRUG|Peldesine|
40794415|NCT03415425|OTHER|Current Version of the Influenza Alert|Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.
40794416|NCT03415425|OTHER|Alternate Modifications of the Influenza Alert|Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
40794417|NCT03620032|DRUG|Nimotuzumab|humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)
40794418|NCT03620032|DRUG|Vinorelbine|Chemotherapy
40794419|NCT03620032|OTHER|Radiotherapy|RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS
40794420|NCT02779777|DRUG|Tipifarnib|Oral tablet
40794421|NCT05309967|OTHER|GLUMA DESINSITIZER|GLUTARALDEHYDE
40794422|NCT05309967|OTHER|PLACEBO|DESTILLED WATER
40794423|NCT02678962|DEVICE|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
40794424|NCT02678962|DEVICE|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
41311590|NCT03515434|PROCEDURE|ESP Block|ESP block will be performed at the finishing of surgery under spinal anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 2-3 cm lateral to T10 spinous process. The erector spinae muscles will be identified superficial to the tip of T10 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
40794425|NCT02678962|DEVICE|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
40794426|NCT02678962|DEVICE|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
40794427|NCT02678962|DEVICE|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
40794428|NCT02678962|DEVICE|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
40794429|NCT00502580|BEHAVIORAL|Interview|Interview taking about 10 minutes to complete.
40794430|NCT00809926|DRUG|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
40794431|NCT00809926|DRUG|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
40794432|NCT03464526|DRUG|Orvepitant|Tablet, once daily, oral
40794433|NCT03464526|DRUG|Placebo|Tablet, once daily, oral
40794434|NCT01880190|OTHER|Ringer's Lactate|
40794435|NCT01880190|OTHER|HES 130/0.4 and Ringer's Lactate|
40794436|NCT03894696|DRUG|Direct Acting Antivirals|follow up chronic HCV patients recieving DAAs to detect anxiety and depression
40794437|NCT02025634|DRUG|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
40794438|NCT02025634|DRUG|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
40794439|NCT06221410|OTHER|Alternative teaching method: Funny Scenario-Based Education|"A humorous scenario is written and performed by students as part of this alternative educational intervention. The engaging approach facilitates both a deeper understanding of complex medical terminology and adds a sense of humor and fun to the learning process.~Approximately 5 to 10 students will participate in each small group. A group size will be determined based on the voluntary interest and willingness of the students. These dynamic teams will provide students with opportunities to collaborate, enhance peer interaction, and cultivate soft skills such as communication and teamwork, all while having fun together."
41311591|NCT03515434|PROCEDURE|TAP Block|TAP block will be performed at the finishing of surgery under spinal anesthesia. A linear ultrasound transducer will be placed to lateral aspect of abdomen. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane between transversus abdominis and internal oblique muscles..A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
41311592|NCT03515434|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
41311593|NCT02352792|RADIATION|radiochemotherapy with 70 Gy|
41311594|NCT02352792|RADIATION|radiochemotherapy with 77 Gy|
41311595|NCT00740168|DRUG|bevacizumab treatment|single infusion 10 mg/kg
40794440|NCT06221410|OTHER|Alternative teaching method: Mind-mapping Education|As part of an alternative educational intervention, Mind-mapping Education encourages students to visually map out information, creating a graphic representation of their ideas and knowledge. Using such mind maps, students can see the connections and hierarchies in the information they are learning because they have a central idea with branches that denote related concepts, facts, and details.
41470414|NCT06309914|DIETARY_SUPPLEMENT|Enovita Grape Seed Extract|Subjects will consume one capsule of Enovita twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
40794441|NCT02085421|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
40794442|NCT05484466|DRUG|ZM-H1505R|There are three groups in this study. ZM-H1505R will be used in group A and Group B ，Subjects can use it for 48 weeks Group A: 30 subjects； ZM-H1505R 50 mg QD +ZM-H1505R placebo； Group B: 30 subjects； ZM-H1505R 100 mg QD
40794443|NCT05484466|OTHER|ZM-H1505R placebo|There are three groups in this study. ZM-H1505R will be used in group A and Group C ，Subjects can use it for 48 weeks Group A: 30 subjects；ZM-H1505R 50 mg +ZM-H1505R placebo 50mg QD ； Group C: 30 subjects；ZM-H1505R placebo 100mg QD
40794444|NCT05484466|COMBINATION_PRODUCT|Baraclude|All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks
40794445|NCT05427123|OTHER|Medication or psychosocial treatment|Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
40794446|NCT05323604|OTHER|Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
40794447|NCT05042401|DRUG|SHR-1703|SHR-1703 low dose
40794448|NCT05042401|DRUG|placebo|placebo low dose
40794449|NCT05042401|DRUG|SHR-1703|SHR-1703 high dose
40794450|NCT05042401|DRUG|placebo|placebo high dose
40794451|NCT03752203|DRUG|Sodium Fluorescein|Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
40794452|NCT03752203|DEVICE|Microscopic Resection|Resection will proceed with the use of a surgical microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
40794453|NCT03130725|PROCEDURE|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
40794454|NCT03130725|PROCEDURE|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
40794455|NCT01310946|OTHER|Database|Database
40794456|NCT00803738|DRUG|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
41311596|NCT02389673|DEVICE|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
41311597|NCT02498561|PROCEDURE|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
41311598|NCT02498561|PROCEDURE|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
40794457|NCT00803738|DRUG|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
40794458|NCT00076089|DRUG|Roflumilast|
40794459|NCT05496985|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
40794460|NCT06104007|DEVICE|Genoss® DCB|This study includes patients with coronary in-stent restenosis (ISR) who have undergone percutaneous coronary intervention (PCI) according to standard treatment protocols using the Genoss® DCB and have agreed to participate in the clinical research. The decision on which drug-coated balloon (DCB) to use during PCI is entirely based on the patient's condition and the characteristics of the coronary lesions identified through angiography. Thus, it's not possible to determine in advance to use the Genoss® DCB before the procedure, nor can the number of drug-coated balloon catheters to be used during the procedure be known or decided upon beforehand.
40794461|NCT02492308|PROCEDURE|SVF-MSC induction|"Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD"
40794462|NCT02492308|DRUG|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
41311599|NCT02498561|PROCEDURE|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
41311600|NCT02498561|PROCEDURE|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
40794463|NCT05242341|BEHAVIORAL|application(APP) teaching|Teaching the use of the APP
40794464|NCT01486355|BIOLOGICAL|Measles vaccine|Edmonston-Zagreb measles vaccine
40794465|NCT03015155|PROCEDURE|Infusion of Cold Saline into Local Infarction Myocardium.|Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
40794466|NCT04758286|PROCEDURE|Emergency surgical procedures|COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately
40794467|NCT02303210|DEVICE|hearing aid NaidaUP|Standard Power Hearing instruments including different frequency lowering techniques
40794468|NCT02303210|DEVICE|hearing aid NaidaSP|Standard Power Hearing instruments including different frequency lowering techniques
40794469|NCT00296218|DRUG|Irbesartan|
40794470|NCT01616212|OTHER|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
40794471|NCT01616212|OTHER|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
40794472|NCT01616212|OTHER|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
40794473|NCT01616212|OTHER|Drug Education for adolescents|Drug Education for adolescents
41157040|NCT05756361|BEHAVIORAL|Family-Based Treatment for T1D|"Our FBT curriculum, which has been delivered successfully in the specialty and primary care settings, has 3 components: 1. Meal planning including quality of carbohydrates and glycemic index for both parents and children while ensuring that youth have a balanced meal plan with adequate amounts of carbohydrates for optimal growth. Our FBT has a focus on Food Literacy including healthy food selection and sourcing of affordable healthy food, food preparation and preplanning, social engagement tailoring the meal plan to the needs to the family in socio cultural appropriate way and also feasibility based on logistics and economic aspects; 2. Physical activity (PA) component with shaping strategy to allow for a progressive shaping of easy PA starting, if needed, with as little as with 10 minutes of walking/day and strategies to incorporate PA in daily routines, family, and social activities; 3. Extensive behavioral component which has been shown to be very powerful in obesity treatment"
41311601|NCT01617187|DRUG|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
41311602|NCT01617187|DRUG|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
41311603|NCT01617187|DRUG|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
40794474|NCT05280821|DIETARY_SUPPLEMENT|daily ferrous sulfate|Daily intake of 100 mg ferrous sulfate capsules for 3 months
40794475|NCT05280821|DIETARY_SUPPLEMENT|alternate day ferrous sulfate|Alternate day intake of 100 mg ferrous sulfate capsules for 6 months
40794476|NCT00348959|BEHAVIORAL|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.~Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
40794477|NCT02827760|DIETARY_SUPPLEMENT|Synergy1|Inulin type fructans
40794478|NCT02827760|DIETARY_SUPPLEMENT|Maltodextrin|
40794479|NCT02859831|OTHER|water samples|
40794480|NCT02069873|BEHAVIORAL|16-Week Group Treatment|Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
40794481|NCT03516578|OTHER|Cardiac magnetic resonance imaging|
40794482|NCT01360814|PROCEDURE|quality-of-life assessment|Ancillary studies
40794483|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive multidisciplinary structured intervention
40999705|NCT05310110|DRUG|Propofol|The dosage of intravenous propofol for the first subjects was predetermined for each arm, and the dosage for the subsequent subjects would be determined according to the response of the previous subjects using the Dixon's up-and-down method with a step size of 0.25 mg/kg. If the subjects had no movement and stable hemodynamic status during and after the laryngeal mask airway (LMA) placement, the predetermined dosage of propofol for the subsequent subject would be decreased by 0.25 mg/kg. On the other hand, if the subjects had obvious movement, failure to LMA placement, and significant hemodynamic changes, the predetermined dosage of propofol for the subsequent subject would be increased by 0.25 mg/kg.
41311604|NCT01617187|DRUG|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
41311605|NCT05385042|DIETARY_SUPPLEMENT|Sangobion and Thiamine Hydrochloride|"Prophylactic dietary supplements: 1 capsule of Sangobion + separate Thiamine Hydrochloride tablet 100mg per day for 12 weeks.~Then non-anaemic pregnant women will continue with prophylactic nutritional supplements until delivery."
41311606|NCT05385042|DIETARY_SUPPLEMENT|Sangobion, Thiamine hydrochloride and Vitamin B12|"Treatment dietary supplements: 3 capsules of Sangobion + separate Thiamine Hydrochloride tablet 100mg, Vit B12 100mcg per day for 12 weeks.~If experience a therapeutic increase of 3% Haematocrit within 28 days (responders), they will continue with prophylactic nutritional supplements until delivery.~If no affect in Haematocrit level within 28 days (non-responders; defined by trimester of diagnosis), they will be investigated for their serum ferritin and if this is low (\<15ng/mL) intravenous (iv) iron supplement (Venofer®) will be provided. The dose will be calculated for the individual concerned (required iron dose (mg) = (2.4 x (target Hb of 11g/dL (Ht 33%) x pre-pregnancy weight (kg) +1000mg for replenishment of stores). Doses will be administered by slow iv infusion 200 mg per dose (maximum of 3 doses per week).~Following treatment they will continue with prophylactic nutritional supplements."
41311607|NCT04768335|BEHAVIORAL|cognitive experiments' session|The aim of this unique session of cognitive experiments is to study the links between source memory deficits and externalization abilities in healthy control subjects. Results of this Arm 2 will be compared to those of Arm 1.
41311608|NCT00793819|DRUG|silodosin|α1-adrenergic antagonist
41311609|NCT02634931|DRUG|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
40794484|NCT01360814|OTHER|questionnaire administration|Ancillary studies
40794485|NCT01360814|OTHER|counseling intervention|Receive multidisciplinary structured intervention
40794486|NCT01360814|BEHAVIORAL|exercise intervention|Receive multidisciplinary structured intervention
40794487|NCT01360814|OTHER|educational intervention|Receive multidisciplinary structured intervention
40794488|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive standard care
40794489|NCT01360814|PROCEDURE|standard follow-up care|Receive standard care
40794490|NCT05749367|DRUG|Ropivacaine + saline solution|SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.
40794491|NCT05749367|DRUG|Saline solution + Ropivacaine|SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
40794492|NCT06003218|DRUG|Dexmedetomidine-esketamine combination|Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
40794493|NCT06003218|DRUG|Remifentanil|Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
40794494|NCT06003218|DRUG|Oxycodone|Oxycodone will be injected intravenously 10-15 min before puncture.
40794495|NCT03391986|DEVICE|SEIRIN® Pyonex™ Acupuncture Needles|Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
40794496|NCT03391986|PROCEDURE|12 mm Plasters|"12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix"
40794497|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 25 μg|Two injections of the study vaccine were administered 28 days apart.
40794498|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 100 μg|Two injections of the study vaccine were administered 28 days apart.
40794499|NCT02676895|BIOLOGICAL|Menveo|One injection of Menveo was administered in subjects in the Control Group.
40794500|NCT02676895|BIOLOGICAL|Boostrix|One injection of Boostrix was administered in subjects in the Control Group.
40794501|NCT01194219|DRUG|Apremilast|
40794502|NCT01194219|DRUG|Placebo|Identical matching placebo
40794503|NCT01194219|DRUG|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
40794504|NCT02832102|PROCEDURE|Standard treatment of SCCHN patients|The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
41311610|NCT05674500|OTHER|Educational Training on standardized coaching language|The faculty trainer participants in training groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The training video will demonstrate the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction).
40794505|NCT00585637|DRUG|Vitamin D|Taken orally every day for three months
40999707|NCT04862156|DEVICE|Normothermic Machine Perfusion (NMP)|Storage and transportation of the donated liver using the OrganOx metra device.
40999708|NCT02166190|PROCEDURE|Radiofrequency Ablation using EndoHPB Probe|Radiofrequency Ablation using EndoHPB Probe
40999709|NCT02166190|PROCEDURE|Stenting only|Stenting only
40999710|NCT04441333|DEVICE|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum
40999711|NCT03993938|DEVICE|PVI measurement|Masimo Radical-7® probe to be attached to patient's finger along with standard ASA monitors at the start of procedure. After placement of arterial line, stroke volume variation (SVV) and pulse pressure variation (PPV) to be recorded along with pleth variability index (PVI) every 5 minutes. Intraprocedure left atrial pressure (LAP) (v-wave and mean) to be recorded prior to and after MitraClip deployment. Data to be analyzed - age, sex, BMI; Preprocedure ejection fraction (EF), pulmonary artery pressure (PAP), rhythm, mitral regurgitation severity; heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) every 5 minutes; SVV, PPV, PVI every 5 minutes; LAP prior to mitraclip deployment; LAP after mitraclip deployment
40999712|NCT00462319|BEHAVIORAL|Education, weight reduction and physical exercise|
40794506|NCT00585637|DIETARY_SUPPLEMENT|Placebo|Placebo pill taken once daily for 3 month
40794507|NCT01640015|OTHER|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
40794508|NCT04695353|PROCEDURE|Telemedicine: Virtual visits (videoconferences, texts)|Patients will receive clinical care by using telemedicine (virtual visits)
40999713|NCT05719363|DEVICE|Inogen Rove 6 Portable Oxygen Concentrator|"The Inogen Rove 6 POC is designed to provide a flow of high-purity oxygen. Inogen Rove 6 is a highly versatile and robust concentrator which offers patients the option to use up to 6 different flow settings.~The unit weighs just under 5 pounds. Utilizing an Intelligent delivery technology, the unit can provide patients with required oxygen therapy on a 24/7 basis. The Inogen Rove 6 POC will be used for patients with chronic heart failure as an investigational device. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the patient."
40794509|NCT04973358|OTHER|buccotherm mouthwash|twice a day for 14 weeks
40794510|NCT04973358|OTHER|placebo mouthwash|twice a day for 14 weeks
40794511|NCT01484145|DRUG|Terbinafine HCl|4% w/w terbinafine HCL gel, single dose,
40794512|NCT03190798|DRUG|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets."
40794513|NCT03190798|DRUG|Placebo|Placebo for Canagliflozin
41470415|NCT06309914|DIETARY_SUPPLEMENT|Mirtoselect Bilberry Extract|Subjects will consume one capsule of Mirtoselect twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
41470416|NCT06309914|DIETARY_SUPPLEMENT|Virtiva Plus Ginko Biloba Extract|Subjects will consume one capsule of Virtiva Plus twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
40794514|NCT04295837|OTHER|ABLE|Home-based occupational therapy compensatory programme addressing activities of daily living
40794515|NCT04295837|OTHER|Usual Care|Standard occupational therapy
40794516|NCT02476604|BEHAVIORAL|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
40794517|NCT06512155|DRUG|Pregabalin|Start taking 75mg bid of pregabalin two days before surgery, and take 150mg bid of pregabalin from one day before surgery to three days after surgery
41470417|NCT05499234|DRUG|Dolantin|If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
40794518|NCT06512155|DRUG|Zolpidem|Take zolpidem 10mg qn from two days before surgery to three days after surgery
40794519|NCT02315040|DEVICE|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
40794520|NCT02315040|OTHER|Standard Intrauterine Insemination|standard intrauterine insemination procedure
40794521|NCT02870985|DEVICE|Coronary Stent|
40794522|NCT06049147|DRUG|MBF-015 4 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
40794523|NCT06049147|DRUG|MBF-015 16 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
40794524|NCT06049147|DRUG|Placebo|Hard gelatin capsules filled with cellulose microcrystalline
40794525|NCT00988156|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
41470418|NCT05499234|DRUG|Paracetamol|If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
41470419|NCT01102452|DIETARY_SUPPLEMENT|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
40794526|NCT00988156|DRUG|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
40794527|NCT05524077|PROCEDURE|Ablation|"Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.~Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation."
40999714|NCT06065761|OTHER|Comprehensive ED heart failure management tool|The investigators plan a regional implementation of an electronic health record-based heart failure decision support tool across 21 EDs of Kaiser Permanente Northern California (KPNC).
40999715|NCT05764213|BEHAVIORAL|Listening to Women & Pregnant and Postpartum People|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services.
40999716|NCT05157932|BEHAVIORAL|Talk test prescription|Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on the Talk test method.
40794528|NCT05524077|DRUG|Anti-arrhythmic Drugs (AADs)|"Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose \<300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be \<2% (VANISH trial)."
40794529|NCT00286091|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
40794530|NCT00286091|BIOLOGICAL|Placebo|Same volume subcutaneous injection
40794531|NCT04781556|OTHER|No intervention|All patients treated between 01/01/2017 and 12/31/2018 in the Fracture sector will be screened through the computerized medical file. For patients who meet all the eligibility criteria, the information note, study questionnaire and a stamped envelope will be sent to them by post. Without feedback from him within 30 days of this submission, the patient is considered not to have objected to the study. The patient's information as well as his non-objection will be recorded in his medical file.
40999717|NCT05157932|BEHAVIORAL|CPET prescription|Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on their CPET results completed at baseline
40999718|NCT00497172|DEVICE|CYPHER Sirolimus-eluting stent|drug-eluting stent
40999719|NCT00497172|DEVICE|Bx SONIC bare metal stent|bare-metal stent
40999720|NCT05155384|OTHER|Pain Neuroscience Education|main topics of pain neuroscience education; neurophysiology of the nervous system, protective mechanism of pain, acute pain formation and chronic pain, factors that increase/reduce pain, central sensitization mechanism, neuroplasticity and treatment strategies in chronic pain.
41311611|NCT05674500|OTHER|Educational Training on goal setting|The faculty trainer participants in the control groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The video will be a 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices.
41470420|NCT01102452|DIETARY_SUPPLEMENT|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
40794532|NCT06094608|DEVICE|Morning light treatment|Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.
40794533|NCT06094608|BEHAVIORAL|Treatment-as-usual|Participants will not make modifications to their activities or sleep schedule.
40794534|NCT02229708|BEHAVIORAL|Healthy Lifestyle Group|
40794535|NCT00000792|DRUG|Hypericin|
40794536|NCT01470131|DRUG|Masitinib|Masitinib 6 mg/kg/day
40999721|NCT05155384|OTHER|Relaxation exercises|Relaxation exercises are a training based on deep relaxation techniques and visual imagery. Relaxation exercises will be applied at the end of the training sessions.
40999722|NCT05155384|OTHER|Cognition target exercise|Cognition target exercises are a time-based approach that is not symptom-conditioned (not based on fatigue or pain). It includes functional and dynamic exercises.
40999723|NCT05155384|OTHER|Pelvic floor stretching exercises|Pelvic floor stretching exercises; consists of stretching exercises involving the pelvic floor muscles and surrounding group muscles (such as piriformis, hamstring, adductor group muscles and lumbar extensors).
40999724|NCT05155384|DEVICE|Transcutaneous electrical nerve stimulation|It will be used with superficial electrodes attached to the suprapubic region of the patients for 20 minutes in each session.
40999725|NCT02196324|DRUG|serlopitant|NK1 receptor antagonist
40999726|NCT02196324|DRUG|Placebo|Placebo
40999727|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
41157041|NCT06311448|DRUG|Single target immunomodulation|Single target immunomodulation compromise of drugs which very specifically target cytokines, chemokines or specific receptors, which are involved in the pathofysiology of COVID-19. For instance, tociluzimab (IL-6 receptor blocker), Anakinra (IL-1 receptor blocker), Eculizimab (Complement inhibitor C5), etc.
41157042|NCT06311448|DRUG|Standard of care|Standard of care during COVID-19 pandemic including steroids.
41311612|NCT02997384|OTHER|Information|information of women about their risk of breast cancer and the screening methods recommended for them
41311613|NCT04030780|DIETARY_SUPPLEMENT|spore-forming probiotic|spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks
40794537|NCT01470131|DRUG|Placebo|Matching placebo
40794538|NCT01470131|DRUG|Bortezomib|Standard therapy (cycles of bortezomib)
40794539|NCT01470131|DRUG|Dexamethasone|Standard therapy (cycles of dexamethasone)
40794540|NCT06005012|DRUG|Semaglutide|Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).
41311614|NCT04030780|OTHER|Placebo|similar capsules administered twice daily
41311615|NCT02087384|BIOLOGICAL|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
41311616|NCT02087384|DRUG|Placebo|injection of 0.9% saline
40794541|NCT06005012|DRUG|Placebo|Placebo
40794542|NCT03184883|PROCEDURE|single conventional denture|mandibular conventional denture with soft liner
40794543|NCT03184883|PROCEDURE|single flexible denture|mandibular flexible compete denture
40794544|NCT05922007|OTHER|Validation of the Questionnaire|Validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ)
40794545|NCT05922007|OTHER|Prospective quantitative study - questionnaire survey|A questionnaire survey will be carried out using the questionnaire set three times
40794546|NCT02020798|OTHER|Dietary Intervention|
40794547|NCT04494828|DRUG|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
40794548|NCT04494828|DRUG|Normal saline group|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
40999728|NCT04411433|DRUG|Favipiravir (3600 mg + 1600 mg)|"Drug: Favipiravir (3600 mg + 1600 mg) Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
41311617|NCT00862849|DRUG|Insulin Lispro|
41311618|NCT00862849|DRUG|Regular Human Insulin|
41311619|NCT00862849|DRUG|rHuPH20|
41311620|NCT05255913|DRUG|Nanosilver|preventive material for arresting caries
41311621|NCT05255913|DRUG|Silver diamine fluoride|preventive material for arresting caries
41311622|NCT02753829|PROCEDURE|Cardiovascular rehabilitation program using Kinect of Xbox|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
41311623|NCT02753829|PROCEDURE|Cardiovascular rehabilitation program using paper manual|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
41311624|NCT02753829|OTHER|Educational component|It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
41311625|NCT05764018|DIETARY_SUPPLEMENT|Caffeine|Negligible amount of maltodextrin in flavoured drink solution containing 6 mg/kg body mass caffeine provided 45 minutes before exercise
40794549|NCT04532840|DEVICE|cryotherapy (Gymna Cryoflow ICE-CT)|Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.
40999729|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
40999730|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
40999731|NCT04411433|DRUG|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
40999732|NCT04411433|DRUG|Hydroxychloroquine combined with Azithromycin|"Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
40999733|NCT02541071|BEHAVIORAL|Stress Film|
40999734|NCT02541071|DRUG|Yohimbine|
41311626|NCT05764018|OTHER|Hypoxia|Participants will be breathing from a hypoxic gas mixture (13% O2) for the duration of the exercise bout. This will simulate an altitude of approximately 3500 m.
41311627|NCT05764018|OTHER|Placebo|Negligible amount of maltodextrin in flavoured drink solution provided 45 minutes before exercise.
41311628|NCT05764018|OTHER|Normoxia|Participants will be breathing from ambient air (\~21% O2) for the duration of the exercise bout. This will provide no hypoxic stimulus as the laboratory is located relatively near sea level (295 m)
41311629|NCT02276716|DIETARY_SUPPLEMENT|Phosphatidylserine|Phosphatidylserine will be titrated starting at 300mg/day dose for two months to 600mg/day dose for 2 months, then 800 mg/day dose for a final 2 month period.
41311630|NCT02012608|DRUG|Glutamine|Oral glutamine for subjects undergoing breast conserving therapy
41311631|NCT02012608|DRUG|Placebo|For subjects undergoing breast conserving therapy
41311632|NCT01769079|DRUG|Nitrate|Two arms: placebo and nitrate
40794550|NCT04532840|OTHER|Exercising, Positioning and splinting, Pressure Therapy and Massage|Exercising, Positioning and splinting, Pressure Therapy and Massage
40794551|NCT00890435|OTHER|questionnaire administration|
41311633|NCT01769079|DRUG|Placebo|
41311634|NCT04228120|BEHAVIORAL|self-regulation programme|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
40794552|NCT00890435|PROCEDURE|psychosocial assessment and care|
40794553|NCT04922853|DRUG|Capox chemotherapy|oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals
40794554|NCT03238703|DRUG|Anastrozole|Given PO
40794555|NCT03238703|DRUG|Exemestane|Given PO
40999735|NCT02541071|DRUG|Clonidine|
40999736|NCT02541071|DRUG|placebo|
41157043|NCT04613219|DRUG|Tofacitinib 5 MG [Xeljanz]|Treatment with Tofacitinib
41157044|NCT00908245|PROCEDURE|Control|Surgery without preconditioning surgery
41157045|NCT00908245|PROCEDURE|Preconditioning ischemia|Surgery with a preconditioning ischemia
41157046|NCT04057937|DRUG|Apremilast|Apremilast
41157047|NCT04057937|DRUG|Placebo|Placebo
41157048|NCT05815771|PROCEDURE|Micro fragmented adipose tissue mixed with bone marrow stem cells|mixture of stem cells
40794556|NCT03238703|OTHER|Laboratory Biomarker Analysis|Correlative studies
40794557|NCT03238703|DRUG|Letrozole|Given PO
40794558|NCT03238703|OTHER|Quality-of-Life Assessment|Ancillary studies
40794559|NCT03238703|OTHER|Questionnaire Administration|Ancillary studies
40794560|NCT03238703|DRUG|Tamoxifen Citrate|Given PO
40794561|NCT03238703|DRUG|Toremifene Citrate|Given PO
41150465|NCT01730261|BEHAVIORAL|Online Emotional Regulation Treatment|Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
41150466|NCT05741866|DEVICE|Chlorhexidine gluconate impregnated bordered polyurethane dressing|"PIVCs will be dressed and secured at the participating sites~* RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing.~* QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
41311635|NCT03095521|DRUG|Angal, lozenges [menthol],|Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
41311636|NCT03095521|DRUG|ANTI-ANGIN® FORMULA|"0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution."
41311637|NCT01794481|PROCEDURE|Resistance Exercise Training (RET)|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
41311638|NCT04167306|DRUG|Varenicline Tartrate 1 mg b.i.d|Capsules for oral use
41311639|NCT04167306|DRUG|Bupropion Hydrochloride 150 mg b.i.d|Capsules for oral use
41311640|NCT04167306|OTHER|Placebo for varenicline|Capsules for oral use
40794562|NCT03375931|BEHAVIORAL|Prayer|If the patient wishes to pray, the anesthesiologist will pray for one minute before anesthesia.
40794563|NCT03375931|BEHAVIORAL|non-prayer|If the patient does not want to pray, the anesthesiologist does anesthesia without praying.
40794564|NCT05534477|DEVICE|Verily Clinical Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
40794565|NCT05534477|DEVICE|Vivalink ECG Patch|The Vivalink ECG Patch is a continuously recording ECG monitor and will be used as a reference device for measuring participants' pulse rate, pulse rate variability, and pulse rate coverage. The Vivalink ECG Patch is a medical device manufactured by VivaLNK Inc. and has been cleared by the FDA.
40794566|NCT05534477|DEVICE|Modus StepWatch 4|Modus StepWatch 4 is an ankle-worn wearable medical device, and will be used as a reference device for measuring participants' ambulatory time and daily step count. The Modus StepWatch 4 is FDA listed.
40794567|NCT01530646|BEHAVIORAL|Weight loss|-750kcal/d
40794568|NCT01530646|DIETARY_SUPPLEMENT|Soy|2 x 25g/d SPC
40794569|NCT01530646|DIETARY_SUPPLEMENT|Whey|2 x 25g/d WPI
41311641|NCT04167306|OTHER|Placebo for bupropion|Capsules for oral use
41311642|NCT02565771|OTHER|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
41311643|NCT06119724|PROCEDURE|Bipolar enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using bipolar
40794570|NCT03687775|OTHER|Stability assessment|Qualitative and quantitative stability assessment
40794571|NCT04757571|DRUG|Paroxetine|Paroxetine 20 mg tablet plus standard therapy
40794572|NCT04757571|DRUG|Placebo|Placebo tablet plus standard therapy
40794573|NCT06062381|PROCEDURE|Abdominal Massage|"The intervention period will be 3 days for intervention group. These patients will receive 20 minutes of abdominal massage twice a day, and the interval between two massages will be 2 hours. The outcome variable variable gastric residual volume will be measured every day, before the intervention and 1 hour after the second massage. the GRV will be measured in ml (via feeding syringe) and marked on checklist.~The abdominal massage technique will consist of five steps based on tensegrity principle.~The lubricant gel will be used to facilitate the massaging. The patient's position will be supine while going through abdominal massage. The angle between the bed and the patient's head will be 30 to 45 degrees, and the patient's legs will be placed on a pillow. This condition will help to relax the abdominal muscles."
40794574|NCT02508363|BEHAVIORAL|questionnaires|
40794575|NCT00142337|DRUG|Zidovudine (ZDV)|Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.
40794576|NCT00142337|DRUG|Didanosine (ddI)|250 mg ddI-EC (400 mg if body weight \>60 kg) once daily, starting at the onset of labor and for one month postpartum
40794577|NCT01101672|PROCEDURE|Single port laparoscopic colectomy|Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
40794578|NCT01101672|PROCEDURE|Conventional laparoscopic colectomy|Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
40794579|NCT02983292|DEVICE|PyroTITAN™ HRA|Humeral Resurfacing
40794580|NCT00000553|DRUG|simvastatin|
40794581|NCT00000553|DRUG|niacin|
40794582|NCT00000553|DRUG|antioxidants|
40794583|NCT02593903|DRUG|Septra|
40794584|NCT00930917|DEVICE|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
40794585|NCT00930917|DEVICE|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
40999737|NCT06418386|PROCEDURE|manual saline IA|"* The procedural tooth is anesthetized and isolated with rubber dam. The tooth and adjacent rubber dam will be disinfected with tincture of iodine solution, All carious tissue will be removed by hight speed handpiece, distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min ,The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium),using manual k file starting with #15 and irrigation with normal saline~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
41150467|NCT05741866|DEVICE|Standard bordered polyurethane dressing|"PIVCs will be dressed and secured as per standard practice at the participating sites~* RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing.~* QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
41311644|NCT06119724|PROCEDURE|Thulium laser enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using thulium laser
41311645|NCT00668304|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg once orally daily
41150468|NCT05494099|PROCEDURE|endoscopic maxillary mega-antrostomy|a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy.
41311646|NCT06121557|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
41311647|NCT06121557|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
41470421|NCT03216109|BEHAVIORAL|Weekly telephone symptom assessment|Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
41470422|NCT06274788|DRUG|Omegaven® (fish oil triglycerides) Injectable Emulsion|"Pediatric patients Pediatric patients with new-onset PNAC~Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion Dose, frequency and duration is a decision of the Investigator"
40794586|NCT00930917|OTHER|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
40794587|NCT04169178|DRUG|HLX55|A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
40794588|NCT00394758|PROCEDURE|CO2 laser surgery|
40794589|NCT00394758|PROCEDURE|ultrasonic surgical aspiration|
40794590|NCT02605356|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|
40794591|NCT02605356|DRUG|Placebo|
40794592|NCT02605356|DRUG|Bortezomib|
40794593|NCT02605356|DRUG|Dexamethasone|
40794594|NCT01397227|BIOLOGICAL|Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
40794595|NCT01397227|BIOLOGICAL|Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
40794596|NCT01397227|BIOLOGICAL|Placebo|Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
40794597|NCT06011317|DRUG|EDG-7500|EDG-7500 is administered orally once daily
40794598|NCT06011317|DRUG|Placebo|Placebo is administered orally once daily
40794599|NCT03463837|OTHER|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%, ENDS for 5-days in confinement
40794600|NCT03463837|OTHER|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, ENDS for 5-days in confinement
40794601|NCT03463837|OTHER|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, ENDS for 5-days in confinement
40794602|NCT03463837|OTHER|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, ENDS for 5-days in confinement
41311648|NCT06121557|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
41470423|NCT03776734|OTHER|Cryotherapy application|Effects of 5-10- 20 minutes cold application on quadriceps muscle
41470424|NCT04622046|DRUG|ALXN2060|ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
40794603|NCT03463837|OTHER|Combustible cigarette|Exclusive use of combustible cigarette for 5 days in confinement.
40794604|NCT03463837|OTHER|Smoking Cessation|No smoking for 5-days in confinement.
40794605|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250mcg administered s.c. every other day
40794606|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|500mcg administered s.c. every other day
40794607|NCT00099502|DRUG|Copaxone|20 mg administered s.c. once daily.
40794608|NCT03560583|DRUG|Metoclopramide|Metoclopramide 10 mg BID
40794609|NCT03560583|DRUG|Placebo Oral Tablet|Placebo 10 mg BID
41150469|NCT05494099|PROCEDURE|Endoscopic Modified Medial Maxillectomy|In this approach, the maxillary sinus is operated upon, while the inferior turbinate and nasolacrimal duct are preserved.
40794610|NCT00414076|DRUG|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
40794611|NCT03722381|DRUG|Amlodipine Besylate|Pharmacokinetics
40794612|NCT01595529|DRUG|Cefixime|Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.
40794613|NCT01595529|DRUG|Cephalexin|Cephalexin 50mg/kg/day in 3 divided doses
40794614|NCT01595529|OTHER|Placebo|Placebo to match the other four active treatments
40794615|NCT01595529|DRUG|Trimethoprim/Sulfamethoxazole|8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.
40794616|NCT06338930|OTHER|Remote monitoring|The intervention group will enroll in the remote monitoring programme. In the standard of care patients visit the outpatient clinic every six months. Patients in the control group will remain in the six-monthly follow-up programma, whereas patients in the intervention group will only visit the outpatient clinic two-yearly. The latter group will be monitored remotely via questionnaires, calprotectin analysis (using CalproSmart) and blood analyses. An IBD nurse will evaluate all incomming data and undertake action if necessary.
40794617|NCT04071431|OTHER|Result masking|"The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
40794618|NCT00689897|PROCEDURE|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
40794619|NCT00689897|PROCEDURE|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
40794620|NCT01162473|DIETARY_SUPPLEMENT|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
41157049|NCT05815771|PROCEDURE|Bone Marrow stem cells aspirate|stem cells
41311649|NCT06121557|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|In the dose-escalation portion, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
41311650|NCT06121557|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
40794621|NCT01162473|DRUG|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
40794622|NCT01162473|OTHER|Food Challenge|
40794623|NCT04861272|BEHAVIORAL|Survey|Online survey
40794624|NCT03186105|OTHER|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days .
40794625|NCT00104988|DRUG|temozolomide|75 mg/m\^2/day PO daily for 6 weeks followed by a 2-week break
40794626|NCT00104988|DRUG|thalidomide|200 mg/day PO daily
40794627|NCT04082650|DRUG|vitamin D|4000IU per day
40794628|NCT04082650|OTHER|Placebo|The same doses with vitamin D
40794629|NCT02018484|PROCEDURE|Unicompartmental Knee Replacement|
40794630|NCT02517398|DRUG|MSB0011359C|Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
40794631|NCT05863390|BEHAVIORAL|McKenzie exercise|routine simple McKenzie exercise
41311651|NCT06121557|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a dose of 200mg (3mg/kg for participants whose weight is below 50kg) IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
40794632|NCT05863390|DIAGNOSTIC_TEST|Trochanteric belt|Trochanteric belt with conventional physical therapy
40794633|NCT00358059|BEHAVIORAL|Behavioral Family Systems Therapy for Diabetes|
41311652|NCT06121557|DRUG|Chemotherapeutic drug, ADC or PARP inhibitor|Another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor will be administered at investigator's discretion.
41311653|NCT06242067|DRUG|Trifluridine/tipiracil|patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).
41311654|NCT00834704|DRUG|PEGPH20|PEGylated recombinant human hyaluronidase
41311655|NCT02522832|OTHER|Titre 1|Virus infection
41311656|NCT02522832|OTHER|Titre 2|Virus infection
41311657|NCT02522832|OTHER|Titre 3|Virus infection
41311658|NCT06269679|DIAGNOSTIC_TEST|CBCT|Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF.
41311659|NCT04651725|OTHER|Exercises|Patients were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
40794634|NCT00755807|DRUG|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
40794635|NCT00755807|DRUG|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams \[mg\] QD for 12 weeks).
40794636|NCT05733637|OTHER|No intervention|There will be no intervention apply to study participants.
40794637|NCT00375427|DRUG|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
40794638|NCT02383862|OTHER|Feedback Group|The intervention will consist of feedback provided to clinicians in the form of patients' baseline PROMIS scores
40794639|NCT03313635|DIAGNOSTIC_TEST|Men presenting with low-T|Evaluation of prealbumin levels.
40794640|NCT04847570|OTHER|Music session|Non-clinical intervention only, and no change to clinical care or treatment. Participants will have 10 minutes of undisturbed rest, followed by a supervised music-listening session of up to 40 minutes, ending with another 10-minute rest period.
40794641|NCT01720303|DRUG|repaglinide|2 mg (tablets) before each main meal
40794642|NCT01720303|DRUG|isophane human insulin|Injection s.c. (under the skin) at bedtime
40794643|NCT01720303|DRUG|insulin|Injection s.c. (under the skin) twice daily
41150470|NCT05494099|PROCEDURE|Modified endoscopic pre-lacrimal approach|The approach involves making a curved mucosal incision on the lateral nasal wall just anterior to the head of the inferior turbinate. The nasal mucosa was then undermined off the lateral nasal wall. The maxillary sinus was entered with a chisel, and the medial bony wall of the maxillary sinus removed.
41311660|NCT04944888|DRUG|Eliglustat|Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).
40794644|NCT00149539|DRUG|Buprenorphine/naloxone|
40794645|NCT05082766|DRUG|enhanced DefenAge 8-in-1 BioSerum|DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
40794646|NCT03592771|BEHAVIORAL|THRIVE App|Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
40794647|NCT03592771|BEHAVIORAL|Tailored Feedback Messages|Participants receive weekly tailored feedback messages and/or images based on their baseline survey responses and use of the app during the 6-month intervention phase. Some tailored feedback includes links to symptom-specific educational materials and coping strategies for participants who report low-severity symptoms. Message categories are tailored to participant's responses to the app and baseline survey.
41157050|NCT06329661|DRUG|Cyclosporine ophthalmic solution, 0.1%|Colorless and clear opthalmic solution containing 0.1% Cyclosporine
41470425|NCT06015113|DRUG|Disitamab Vedotin plus pyrotinib or naratinib|"Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days.~Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days.~Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days."
40794648|NCT05945381|COMBINATION_PRODUCT|GIC on MIH|Subjects will be seated in a dental chair set-up using standard infection control guidelines. Then the study and its objectives will be explained to the patients and their caregivers. The tooth will be cleaned with a prophylactic paste and brush for complete debris and plaque removal. The tooth will then be dried with a cotton roll, as the patient doesn't tolerate the air-drying (which is the case in SCASS 2 and 3). Moisture control will be kept with cotton roll, the tooth is then sealed with a hard setting glass-ionomer cement (IonoStar Plus, VOCO, Germany) followed by an application of a surface coat (Easy Glaze, VOCO, Germany) for moisture and dehydration protection after sealant application. The distributed questionnaire will include questions regarding the attitude of the child's caregiver to the idea and their estimation of the child's fair regarding dental visit.
40794649|NCT05140135|BEHAVIORAL|Recovery Oriented Cognitive Therapy (CT-R)|The CT-R that will be implemented in the present study will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. In CT-R, clinicians use techniques to engage the patient in the adaptive mode, which includes cognitions, affects, motivation, and behaviors that are activated when the individual is engaged in personally meaningful activities.
41470426|NCT05602779|DEVICE|tVns Program|Participants will use the Neuvana Xen device 30 minutes a day for 3 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.
41470427|NCT05602779|OTHER|Phone App Program|Participants will have access to a specially designed phone app in order to play a game designed for this study. Approximately half of the participants will be able to connect with a fellow participant who is matched as their peer for social support.
41470428|NCT05602779|COMBINATION_PRODUCT|tVNS and Phone App Program|Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.
40794650|NCT05140135|OTHER|Treatment as Usual|All patients enrolled in the study who are randomized to the continued care as usual condition will continue to receive the treatments from their physician/treatment team at the Community Mental Health Center; however, they will not receive the adjunctive CT-R treatment.
40794651|NCT06056206|RADIATION|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list.
40794652|NCT05524636|DEVICE|Exercise with peripheral magnetic stimulation of the abdominal wall muscles|8-week exercise program with peripheral magnetic stimulation, focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
40794653|NCT05524636|OTHER|Exercise of the abdominal wall muscles|8-week exercise program focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
40794654|NCT01799486|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
41470429|NCT05602779|OTHER|Enhanced Treatment as Usual|Participants will have access to our program's phone app so the can play the game and will be called weekly to complete risk assessments.
40794655|NCT01799486|DRUG|Enecavir|0.5 mg monotherapy supplied in tablets.
40794656|NCT01799486|DRUG|Adefovir|10 mg monotherapy supplied in tablets.
41470430|NCT04657250|BEHAVIORAL|Smoking cessation + quitline linkage text messages|Smoking cessation text messages will provide behavioral skills and support for quitting smoking. Quitline linkage text messages will include contact information for the quitline, option to be contacted by the quitline and active referral to the quitline upon setting a Quit Date.
40794657|NCT02733822|DRUG|Naloxone|
40794658|NCT04906031|DRUG|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
41311661|NCT04944888|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor (physician decided).
41311662|NCT05297500|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-12)
41470431|NCT04657250|BEHAVIORAL|Passive quitline referral|Single text message with contact information for the Quitline
41470432|NCT06163092|OTHER||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
41470433|NCT00141141|DRUG|Atorvastatin|
41470434|NCT00141141|DRUG|Simvastatin|
40794659|NCT05531006|OTHER|retrospective cohort study|retrospective patient file review
40794660|NCT02229786|DRUG|Buscopan® plus|
40794661|NCT02229786|DRUG|Buscopan®|
41311663|NCT03224975|OTHER|fMRI|During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
41311664|NCT05217992|OTHER|Genetic assessment (hemophilia testing)|Determination of carrier ship of hemophilia with molecular tests
41311665|NCT00080366|DRUG|1-Octanol|
40794662|NCT02229786|DRUG|Paracetamol|
40794663|NCT02229786|DRUG|Placebo|
40794664|NCT02953561|DRUG|Avelumab|Given IV
40794665|NCT02953561|DRUG|Azacitidine|Given SC or IV
40794666|NCT02953561|OTHER|Laboratory Biomarker Analysis|Correlative studies
40794667|NCT06116032|DIAGNOSTIC_TEST|Methylation Cytometry|Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
40794668|NCT04068077|DEVICE|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
40794669|NCT01456793|BEHAVIORAL|Teen Options to Prevent Pregnancy (T.O.P.P.)|Telephone-based care coordination and mobile contraceptive services
40794670|NCT02961270|DRUG|Icotinib|Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
40794671|NCT05985837|DEVICE|KalobaGOLA spray (1)|Oral spray, 2-4 spray, till 8 times per day
40794672|NCT05985837|DEVICE|KalobaGOLA spray (2)|Oral spray, 2-4 spray, till 4 times per day
40794673|NCT05985837|DEVICE|KalobaGOLA tablets|1 tablets, 6 times per day
40794674|NCT00315952|DRUG|Exubera|
40794675|NCT06199908|DRUG|AMT-562|Administered AMT-562 for injection intravenously
40794676|NCT03448016|RADIATION|[C-11]|Radiolabel
40794677|NCT03448016|DRUG|NOP-1A|Tracer
40794678|NCT05844163|OTHER|observation|observation
40794679|NCT02122497|PROCEDURE|abdominal aortic surgery|
40794680|NCT03763695|OTHER|Measures for the VAP prevention in the PICU|Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.
40794681|NCT03763695|OTHER|Evaluation of VAP incidence before the protocol introduction|evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
40794682|NCT05079802|DRUG|Double antibiotic paste mixed with chitosan nanoparticles|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with chitosan nanoparticles gel
40794683|NCT05079802|DRUG|Double antibiotic paste mixed with propylene glycol|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
40794684|NCT00768261|DRUG|Memantine (Namenda®)|Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
40794685|NCT00768261|DRUG|Donepezil (Aricept®)|5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
40794686|NCT03410719|OTHER|Hi GI|subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be \<55 (Low-GI group) or \>70 (Hi-GI group).
40999738|NCT06418386|PROCEDURE|manual neem IB|"* The procedural tooth is anesthetized and isolated with rubber dam. The tooth and adjacent rubber dam will be disinfected with tincture of iodine solution~* . All carious tissue will be removed by high speed hand piece~  , distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min 19 The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using manual file and irrigation with neem leaf extract 100%~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
41157051|NCT06329661|DRUG|Saline solution, 0.6%|Colorless and clear sodium chloride solution (0.6%)
41470435|NCT02527239|OTHER|Prospective observational study|Prospective observational study collecting data during a clinic vist including measurement of respiratory muscle strength, respiratory failure, lung function, physical performance and blood testing for enzymes related to Pompe's disease and muscle function.
40794687|NCT01232439|DRUG|opioid receptor kappa antagonist|"Starting dose of 2 mg, administered orally, once.~The potential dose range for this study is 0.2 mg to 30 mg"
40999739|NCT06418386|PROCEDURE|manual sodium hypochlorite IC|"* adjacent rubber dam will be disinfected with tincture of iodine solution~* . All carious tissue will be removed by hight speed hand piece~* distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min 19 The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using manual file and irrigation with 1% sodium hypochlorite~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
40999740|NCT06418386|PROCEDURE|rotary saline IIA|"* shaping and cleaning done with using AF baby fanta files open file:#17 taper 08,then #20 taper 04 ,yellow then #25 taper 04 red , then #30 taper 04 blue . the files activated with torque 2 and speed 350 . Irrigation with normal saline~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then restored with glass inomar and stainless steel crown"
40999741|NCT06418386|PROCEDURE|rotary neem IIB|"* The procedural tooth is anesthetized and isolated with rubber dam as mentioned~* All carious tissue will be removed by high speed hand piece ,distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using AF baby fanta files SAME AS METION BEFORE ,and irrigation with 100%neem extract~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
40999742|NCT06418386|PROCEDURE|rotary sodoium hypochlorite IIC|"* The procedural tooth is anesthetized and isolated with rubber dam as mentioned~* All carious tissue will be removed by hight speed hand piece,distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using AF baby fanta files SAME AS MENTION BEFORE , and irrigation with 1% sodium hypochlorite~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
40999743|NCT04953533|OTHER|no intervention|
40999744|NCT03561493|OTHER|zumba exercise|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one hour in length and a recovery period of at least 48 h was taken between classes. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced. The Zumba sessions will be supervised by three certiﬁed Zumba instructors, each responsible for regular sessions per week.
41150471|NCT04061967|OTHER|Sending of screening summon.|"2019-2021 - A Cobas PCR Female swab sample packet will be sent. Response rates (participation) will be measured.~2022 and onwards - A FLOQSwab and corresponding sample tube for analysis on the BD COR platform will be sent."
41150472|NCT00337922|DRUG|Lamivudine / Abacavir Sulfate|
41150473|NCT06030999|DIETARY_SUPPLEMENT|Study product A (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
41150474|NCT06030999|DIETARY_SUPPLEMENT|Study product B (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
41150475|NCT06030999|DIETARY_SUPPLEMENT|Study product C (placebo)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
41150476|NCT05667688|DRUG|Tinlarebant (LBS-008)|A single dose of Tinlarebant (LBS-008) will be administered to each study participant on study Day 1.
41150477|NCT02721628|PROCEDURE|Epi-keratoplasty|Femtosecond laser assisted Epi-keratoplasty
41150478|NCT02721628|PROCEDURE|Collagen Cross-Linking|Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
41150479|NCT02721628|DEVICE|Femtosecond laser|Use in the epic-keratoplasty surgery
41157052|NCT03729544|BEHAVIORAL|On-screen computerized decision support alert|On-screen electronic alert during the outpatient clinical encounter that notifies him or her that the patient should be screened for CTEPH
41157053|NCT06425445|PROCEDURE|Measurement of maximal expiratory pressures during forced static expiratory maneuvers sustained over 5 seconds|Participants perform forced static expiratory maneuvers sustained over a five second period
41311666|NCT03305094|PROCEDURE|Blood pressure cuff inflation|Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
41311667|NCT00212303|BEHAVIORAL|Exercise training for 6 months|Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
41470436|NCT04576715|BEHAVIORAL|TEaM Intervention|"Multi-setting mTBI (mild traumatic brain injury) Evaluation and Management Intervention incorporates provider education and information technology support systems, based on the best available evidence and tailored to a specific environment (acute care setting vs primary care clinic). Facilitates linkages between providers (ED/UC to primary care) and systems (healthcare to school).~* Provider Training Modules: Training includes decision-making support alerted by positive triage screening and concussion-specific eMR template~* Management based on current best practices (however, may have additional education from the provider training)~* Return to school letters~* Primary Care Follow Up"
40794688|NCT04571060|DRUG|Zavegepant|One dose of zavegepant
40794689|NCT04571060|DRUG|Placebo|One dose of matching placebo
41470437|NCT04576715|BEHAVIORAL|Standard of Care|"Continue with CHOA current best practices for mTBI:~* No TEaM Provider training (but will be offered to all providers at end of study)~* Will not be trained on utilization and implementation of the concussion screening alert and eMR template"
41470438|NCT04417751|BEHAVIORAL|Cognitive Stimulation|The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 45 minutes and they will be developed according to the following structure: welcoming and greeting the participants (5 minutes); reality orientation therapy (10 minutes), cognitive stimulation \[CS\] activity (25 minutes); return to calm and closure of the session, and session evaluation (5 minutes). CS sessions will be conducted in an individual intervention format. The intervention sessions will include several activities based on different non-pharmacological therapies (e.g., reminiscence therapy, reality orientation therapy, cognitive training) whose effectiveness in older adults with neurocognitive disorders has been scientifically proven. All individual CS sessions will be conducted by one therapist (clinical psychologist) with more than five years of experience in CS.
41470439|NCT00360737|BIOLOGICAL|Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)|Biological/Vaccine NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from pooled plasma obtained from horses that have been immunized against one of seven botulinum antitoxins (A-G). .
41470440|NCT02176278|OTHER|Telephone Reminder|Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
40794690|NCT02969915|BEHAVIORAL|Incentives|Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
41150480|NCT03939793|BEHAVIORAL|IMPaCT Community Health Worker|"Once a CHW receives notification of a struggling patient, the CHW will visit the patient at their home within 1-2 days to initiate the IMPaCT intervention.~1. Elements of the standard IMPaCT intervention: During the first home visit, the CHW will use an in-depth semi-structured interview guide to get to know patients holistically and assess for unmet socioeconomic needs. This allows patients to express goals in line with their own needs and preferences. These individualized goals will become the basis for tailored action plans. The CHW will then provide hands-on, tailored support for the remainder of the 24-week study period to help patients achieve their goals.~2. Additional elements to help patients cope with failure: In this study, we will test a refined version of IMPaCT that incorporates two behavioral techniques for coping with failure: positive affect induction and attribution retraining."
41311668|NCT02588027|DRUG|Ibuprofen|Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
41311669|NCT02588027|DRUG|Placebo|Pharmacy formulated placebo
41311670|NCT05439694|DRUG|Tranexamic acid|have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
41311671|NCT05425875|PROCEDURE|Bronchoalveolar lavage using wall mount suction|BAL will be performed using wall mount suction with a pressure \<100 mmHg
41470441|NCT02176278|OTHER|Doctor-Nurse Follow Up|Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c\<7%, BP\<130/80 mmHg, LDL-C\<1.8 mmol/l, triglyceride\<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
41470442|NCT02176278|OTHER|Personalized Risk Report for Patient Empowerment|Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
41470443|NCT04845646|DRUG|ASC41|5mg/tablet
41470444|NCT04845646|DRUG|Itraconazole|200mg/capsule
41470445|NCT04845646|DRUG|Phenytoin|300mg/capsule
41470446|NCT02615184|DRUG|Dexlansoprazole|Dexlansoprazole capsules
41470447|NCT02861027|PROCEDURE|PPTHA|The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
41150481|NCT03939793|BEHAVIORAL|Digital health monitoring with financial incentives|Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.
41150482|NCT03939793|OTHER|Usual Care|Usual Care
40794691|NCT02969915|BEHAVIORAL|Integrated Care Centers|ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
40794692|NCT04934696|DRUG|BMS-986166|Specified dose on specified days
40794693|NCT04934696|DRUG|Oral contraceptive|Specified dose on specified days
41150483|NCT04729361|GENETIC|CGH array analysis|CGH array analysis
41150484|NCT00139971|DRUG|gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6|
41311672|NCT05425875|PROCEDURE|Bronchoalveolar lavage using manual suction|A 50-mL syringe will be used to apply suction through the working channel of a bronchoscope
41311673|NCT05425875|PROCEDURE|Bronchoalveolar lavage using manual suction with rubber tubing|A 50-mL syringe with an attached rubber tubing will be used to apply suction through the working channel of a bronchoscope
41311674|NCT02550314|DRUG|fiblast,gelatin sponge,fibrin glue|
41311675|NCT03348111|DEVICE|Air-polishing device|Air abrasion using the Air-Flow Master Piezon® with erythritol and Chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally
40794694|NCT05860907|DRUG|Huaier Granule|10g each time, three times a day
40794695|NCT05075733|OTHER|Survey|Survey was sent to all the Americas Hepato-Pancreato-Biliary Association's members
40794696|NCT06513923|DRUG|Remimazolam|In Remimazolam group, the induction dose of remimazolam is 0.3 mg/kg based on previous studies, the maintenance of anesthesia is 0.3-0.7 mg/kg/hr.
40794697|NCT06513923|DRUG|Flumazenil|Immediately after the cessation of remimazolam infusion in PACU(PACU, Postanesthesia care unit), the nurses who are blind to the anesthesia management were asked to administer the flumazenil.
40794698|NCT06513923|DRUG|Propofol|For propofol group, the induction of propofol is 1.5-2.0 mg/kg, followed by the maintenance of propofol infusion with 6-8 mg/kg/hr throughout the surgical procedure.
40794699|NCT04380909|BEHAVIORAL|Internet-based self-help|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
40794700|NCT04380909|BEHAVIORAL|Internet-based self-help after 3 weeks|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
40794701|NCT03353038|DEVICE|3D printed pillbox|The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
40794702|NCT05756920|DRUG|ABL301|SAD: Participants will receive a single dose of ABL301 IV infusion, MAD: Participants will receive multiple doses of ABL301 IV infusion
40794703|NCT05756920|DRUG|Placebo|SAD: single Placebo IV infusion, MAD: multiple Placebo IV infusion
40794704|NCT02296710|PROCEDURE|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
40794705|NCT04481607|DRUG|TQB3454|TQB3454 tablets is a small molecule oral drug.
40794706|NCT01053507|DRUG|sumatriptan/naproxen sodium|Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
40794707|NCT01053507|DRUG|Placebo|Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
40794708|NCT02343601|DEVICE|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
40794709|NCT05490277|DEVICE|Active Vibrotactile coordinated reset|Participants will receive active vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
41311676|NCT02065622|DRUG|Adalimumab|
41311677|NCT02065622|OTHER|Placebo|
40794710|NCT05490277|DEVICE|Sham vibrotactile coordinated reset|Participants will receive sham vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
40794711|NCT01469481|DRUG|PF-04991532|a single oral dose of \[14C\]PF-04991532 (450 mg/100 uCi suspension)
40794712|NCT03474263|BIOLOGICAL|Biologic: IC14 (monoclonal antibody against human CD14)|IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
40794713|NCT03926949|OTHER|Parenteral Nutrition|Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
40794714|NCT03926949|OTHER|Standard Nutrition Care|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
40794715|NCT00579423|BIOLOGICAL|QS21|"* Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~* Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~* Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient."
40794716|NCT05088434|DIETARY_SUPPLEMENT|Anaerobically Cultivated Human Intestinal Microbiota (ACHIM)|One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Vallingby, Sweden), containing 30 x 109 colony forming unit (CFU) of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.
41150485|NCT00139971|DRUG|UFT 250mg/m2, daily for 1 year|
41311678|NCT05902429|DRUG|Cladribine 10 mg oral tablet|Cladribine tablets (Mavenclad®, Merck KGaA, Darmstadt, Germany) will be given according to the label with a cumulative dose of 3.5 mg/kg body weight distributed over 2 years as one treatment course of 1.75 mg/kg per year. Each treatment course will consist of 2 weeks of treatment, one at the beginning of the first month and one at the beginning of the second month of the respective year of treatment. Each treatment week will consist of 4 or 5 days in which the participant will receive 10 mg or 20 mg (1 or 2 tablets, respectively) as a single daily dose, depending on body weight, according to the tables available in label. Upon completion of the two treatment courses, no further courses will be required in years 3 and 4.
41311679|NCT01694576|DRUG|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
41311680|NCT01826422|DIETARY_SUPPLEMENT|EPA and DHA|Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.
40999745|NCT05603923|BEHAVIORAL|Lumen Coached PST Intervention.|Lumen Intervention Orientation. Participants in the Lumen intervention arm attend a Lumen orientation visit (60 minutes) during which they will be given a Lumen intervention tutorial and receive a study iPad, configured to limit access to only the Lumen intervention enabled on the device. Before leaving, participants are scheduled for the first PST session with Coach Lumen. At the end of each PST session, participants are prompted to schedule their next session with Coach Lumen. They receive automated reminder notifications 1 day prior to their next session, on the session day, and have the opportunity to make up missed sessions. As needed, Lumen intervention orientations can be done remotely.
40999746|NCT05603923|BEHAVIORAL|Human Coached PST Intervention.|Participants in the human coached PST arm will serve as active treatment controls given the demonstrated efficacy of human coached PST in depression and anxiety. They will complete 8 PST sessions with a human coach; first session in-person and remaining sessions via videoconferencing (i.e., Zoom preferred; with phone calls allowed) on the same 4 weekly and then 4 biweekly schedule as that for Lumen participants. Participants will receive a study iPad to use for their PST sessions via zoom. Participants also complete the PHQ-9 and GAD-7 during each session. Participants will receive a certificate of completion.
41150486|NCT04715919|DIAGNOSTIC_TEST|Chest Computed Tomography|Evaluation of Lung Structure
41150487|NCT04715919|DIAGNOSTIC_TEST|Pulmonary Function Tests|Respiratory Capacity
41150488|NCT04715919|OTHER|Six Minutes Walk Test|Exercise Capacity
41150489|NCT04715919|OTHER|Quality of Life|Physical disability assessment tool
41150490|NCT06196710|DEVICE|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto the vessels.
41150491|NCT06196710|DEVICE|Hemo-clipping|Contact thermocoagulation using a 3.3mm probe, hemo-clips, or both. The use of the bipolar device involves firm mechanical compression and coagulation for about 8 seconds.
41150492|NCT03786003|PROCEDURE|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
41150493|NCT03786003|PROCEDURE|Thoracotomy|Standard thoracotomy
41150494|NCT01272388|DRUG|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
41150495|NCT01272388|DRUG|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
41150496|NCT01540474|BIOLOGICAL|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
41150497|NCT01540474|BIOLOGICAL|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
41150498|NCT01540474|BIOLOGICAL|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
41150499|NCT01540474|OTHER|Controlled group-Challenged Only: no vaccination|The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
41150500|NCT02177058|OTHER|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
41150501|NCT02177058|OTHER|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
41150502|NCT05959382|DEVICE|Dental Loupe|Magnification aid
41311681|NCT01826422|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
41311682|NCT02457182|OTHER|Mindfulness-based Stress Reduction (MBSR)|
41311683|NCT02457182|OTHER|Usual medical therapy|
41311684|NCT03383718|PROCEDURE|Revascularisation|Percutaneous coronary intervention or coronary artery bypass surgery
41311685|NCT03383718|OTHER|Optimal Medical Treatment/OMT|Standard of care in stable coronary artery disease or after acute myocardial infarction.
41150503|NCT05959382|DEVICE|Dental Operation Microscope|Magnification aid
41150504|NCT05659745|OTHER|VM-02|VM-02 is a personal care product for vaginal health.
41150505|NCT05659745|DIETARY_SUPPLEMENT|Commercial Oral Probiotic Competitor|Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.
41150506|NCT05659745|OTHER|VM-02 Placebo|VM-02 Placebo is a personal care product placebo for vaginal health.
41470448|NCT02861027|PROCEDURE|FES and PPTHA|The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
41157054|NCT00003924|BIOLOGICAL|recombinant interferon alfa|
41311686|NCT04385914|OTHER|COVID positive via testing|Following pregnancy outcomes whether they are COVID positive or negative
41311687|NCT04347226|DRUG|BMS-986253|BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).
41311688|NCT06166914|DRUG|Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml)|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml).
40794717|NCT05088434|DIETARY_SUPPLEMENT|Donor fecal microbiota transplantation|Only 60 ml of sterile 0.9% normal saline were added to a stool specimen, collected from the respective donor, with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
40794718|NCT05088434|DIETARY_SUPPLEMENT|Placebo|Only 60 ml of sterile 0.9% normal saline were added to the patient's own stool specimen with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
41311689|NCT06166914|DRUG|Placebo|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline.
40794719|NCT01292122|DEVICE|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
41311690|NCT04359082|DIETARY_SUPPLEMENT|CocoaVia supplement|CocoaVia is a dietary supplement that has concentrated bioflavanols of 225 mg flavanols per pill along with 30 mg theobromine and 10 mg caffeine
40794720|NCT06448130|DRUG|Henagliflozin 5mg|Henagliflozin 5mg + lifestyle intervention
40794721|NCT06448130|DRUG|Henagliflozin 10mg|Henagliflozin 10mg+ lifestyle intervention
40794722|NCT06448130|DRUG|Placebo|Placebo+ lifestyle intervention
40999747|NCT05603923|BEHAVIORAL|Optional (delayed) Lumen Coached PST (Waitlist control).|Waitlist control participants will only complete assessments during the 18-week trial period. At the end of their 18-week assessment, they will have the option to complete 8 PST sessions on their assigned iPads.
40999748|NCT00456716|DRUG|sorafenib|400mg po bid
40999749|NCT02606591|PROCEDURE|Electroencephalograph|EEG performed at beginning and end of school year.
40999750|NCT02606591|BEHAVIORAL|Cognitive Tests|During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
41311691|NCT04359082|OTHER|Placebo Pill|Placebo pill has no bioflavanols with 30 mg theobromine and 10 mg caffeine
41311692|NCT00751114|DRUG|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
41311693|NCT00751114|DRUG|Sitagliptin|Oral administration. 100 mg film-coated tablets.
41311694|NCT00751114|DRUG|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
41311695|NCT01108497|PROCEDURE|Bone Marrow Aspiration|
41311696|NCT03009201|DRUG|Doxorubicin Hydrochloride|Given IV
41311697|NCT03009201|OTHER|Laboratory Biomarker Analysis|Correlative studies
41311698|NCT03009201|OTHER|Pharmacological Study|Correlative studies
41311699|NCT03009201|DRUG|Ribociclib|Given PO
41311700|NCT03478319|DRUG|ACE-2494 or placebo|Recombination fusion protein
41311701|NCT01583998|BEHAVIORAL|e-MBC|antidepressant treatment
41311702|NCT01728883|DEVICE|Home vision monitoring using myVisionTrack®|Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
41311703|NCT00002545|DRUG|carmustine|
40999751|NCT02606591|OTHER|Hair Sample|Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
40999752|NCT05766332|OTHER|Clinical Evaluation|Undergo clinical evaluation
41311704|NCT00002545|RADIATION|low-LET photon therapy|
41311705|NCT00354263|BIOLOGICAL|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
41311706|NCT00354263|BIOLOGICAL|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
41311707|NCT05915234|DEVICE|Crushed ice|Each participant will receive two active devices and one sham comparator in a crossover design.The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of crushed ice. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
41470449|NCT04449458|BEHAVIORAL|Positively Me|12 session smoking cessation intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
41157055|NCT00761618|PROCEDURE|Intrapleural catheter (IPC) drained|IPC drained daily (Group 1) or 3 times per week (Group 2)
41311708|NCT05915234|DEVICE|Frozen peas|Each participant will receive two active devices and one sham comparator in a crossover design. The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of frozen peas. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
41157056|NCT00761618|PROCEDURE|IPC Placement|IPC placed in chest cavity to drain excess fluid
41311709|NCT05915234|DEVICE|Room temperature gel|Each participant will receive two active devices and one sham comparator in a crossover design. The sham comparator device used consists of an opaque bag with an external plastic cover and an aluminum interior filled with 80 grams of ultrasound gel at room temperature. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed.
40794723|NCT03375086|DRUG|APX3330|APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
40794724|NCT00194077|DRUG|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
41311710|NCT04412382|DIAGNOSTIC_TEST|NETosis markers|"NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.~Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed."
41470450|NCT04449458|BEHAVIORAL|Positively Living|12 session healthy living intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
40794725|NCT00194077|DRUG|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
40794726|NCT04739930|PROCEDURE|Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group
41470451|NCT06612944|DRUG|Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation|"1.1 AZA + BCL2 Inhibitor (Preferred Regimen) Subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; BCL2 inhibitor (VEN): 400 mg per day orally for one week (if combined with a CYP450 inhibitor, reduce to 100 mg per day).~1.2 AZA (DEC) + DLI For patients with TP53 mutations or those who do not respond to VEN, subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; decitabine at 5 mg/m² per day for 5 consecutive days, with a 28-day cycle (preferred for those with TP53 mutations). For patients without the option for DLI, regimen 1.1 is recommended.~DLI: Begins 3 months post-transplantation, starting with a dose of 1×10\^5 CD3+ T lymphocytes for haploidentical transplants, with doses increasing every 4-6 weeks to 5×10\^5 CD3+ T lymphocytes, 1×10\^6 CD3+, and 5×10\^6 CD3+ T lymphocytes; for full-matched transplants, the starting dose is 5×10\^5 CD3+ T lymphocytes with dose escalations as above to 1×1"
40794727|NCT04739930|PROCEDURE|Control group incision|0.5cm sham incision over the iliac crest
40794728|NCT06261008|BEHAVIORAL|TI group|CRC screening is arranged by referring the participants to the government-subsidized population-based CRC screening program. Our center is a PCP clinic offering FIT screenings under the Program. Colonoscopy is arranged if the FIT result is positive. Participants are instructed to repeat FIT at any PCP clinic 2 years after receiving a negative result. Based on the 34% local FIT screening adherence rate under SC and the assumption of improved FIT adherence to 49% after interactive TI, a minimum sample size of 332 subjects (166 per group) is required to achieve a statistical significance of p\<0.05 and power of 80%. Assuming that 10% of the subjects will drop out, be lost to follow-up, or have incomplete chatbot conversations, the required sample size is rounded up to 370 (185 per group)
40794729|NCT03088644|DRUG|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
40794730|NCT03088644|DRUG|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
40794731|NCT05521347|BEHAVIORAL|caffeine|we employed a randomized crossover design to divide participants into a caffeine trial (CAF) and a placebo trial (PL). The CAF group took capsules with 3 mg/kg of caffeine, whereas the PL group took a placebo capsule. After a 1-h rest, the Stroop task, visual search ability test, and the shooting ability test were conducted.
40999753|NCT05766332|OTHER|Electronic Health Record Review|Medical records reviewed
40999754|NCT01867593|DEVICE|C-11 methionine PET|
40999755|NCT02559869|DRUG|[18F] GE-180|PET Tracer Ligand
40999756|NCT03496688|PROCEDURE|Sinus floor augmentation|
40999757|NCT04727658|RADIATION|Radiosurgical thalamotomy on GammaKnife|fractional radiosurgical thalamotomy on an accelerator (3 sessions of 50 Gy at the isocenter )
40999758|NCT01508780|DEVICE|St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)|All subjects will have OCT and IVUS imaging during their right heart catheterization.
40999759|NCT01508780|DEVICE|Boston Scientific Intravascular Ultrasound|All subjects will have OCT and IVUS imaging during their right heart catheterization.
41157057|NCT00761618|RADIATION|Chest X-Ray|Chest X-Rays at 3 and 6 month follow up visits
40794732|NCT00033046|DRUG|Modafinil|
40794733|NCT02562846|OTHER|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
41150507|NCT02832453|BEHAVIORAL|Lifestyle|The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
41150508|NCT02832453|BEHAVIORAL|Aerobic interval training|The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .
41150509|NCT02832453|BEHAVIORAL|Traditional continous training|The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
41470452|NCT05701618|OTHER|Psychologically Informed Education Video Series|A short three video series (5-8.5 minutes each) provides psychologically-informed education at an age-appropriate level to address kinesiophobia, pain catastrophizing, and fear-avoidance beliefs.30 Participants will view the three-part education video series on an iPad at their first visit (video 1), one week (video 2), and three weeks (video 3).
40794734|NCT01670669|DRUG|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
40794735|NCT04538300|DIAGNOSTIC_TEST|Abramowitz Emesis Score|Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.
41150510|NCT02206607|DRUG|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
41150511|NCT02206607|DRUG|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
41470453|NCT05701618|OTHER|Anatomy and biomedical education videos|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
40794736|NCT04538300|DIAGNOSTIC_TEST|Degree of nausea|Degree of postoperative nausea was evaluated.
40794737|NCT04538300|DIAGNOSTIC_TEST|Observer's Assessment of Alertness/Sedation Scale|Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.
40794738|NCT04538300|DIAGNOSTIC_TEST|Patient Satisfaction|Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
40794739|NCT04538300|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
40794740|NCT04538300|OTHER|Chewing Peppermint gum|Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
40794741|NCT01882387|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
40794742|NCT01027962|OTHER|ICBT Program|Intensive Computerized Brain Training.
40794743|NCT00480831|DRUG|bevacizumab|Intravenous repeating dose
40794744|NCT00480831|DRUG|carboplatin|Intravenous repeating dose
40794745|NCT00480831|DRUG|paclitaxel|Intravenous repeating dose
40794746|NCT00480831|DRUG|placebo|Intravenous repeating dose
40794747|NCT00480831|DRUG|PRO95780|Intravenous repeating dose
40794748|NCT04884763|DRUG|Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments|Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
40794749|NCT04884763|DRUG|Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments|Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
40794750|NCT03766464|DIAGNOSTIC_TEST|Evaluation of TMD and pain sensitivity|Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.
40794751|NCT03766464|DIAGNOSTIC_TEST|Evaluation of SB|The presence or absence of SB will be diagnosed by Polysomnography
40794752|NCT03766464|DIAGNOSTIC_TEST|Evaluation of AB|A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
40794753|NCT01518725|DIETARY_SUPPLEMENT|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
40794754|NCT01518725|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
40794755|NCT01834599|DEVICE|cerebral oximetry|tissue saturation measurement in pregnant women
40794756|NCT01010451|PROCEDURE|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
40794757|NCT01010451|PROCEDURE|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
41150512|NCT02206607|DRUG|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
41311711|NCT05728086|OTHER|Group art therapy|The intervention is a manualised programme of group art therapy based on a bio-psychosocial therapeutic model. The programme is made up of six 60 - 90-minute art therapy group sessions facilitated by an experienced HCPC (Health and Care Professions Council) registered Art Therapists trained in the intervention.
41470454|NCT05148078|OTHER|PROMISE (Pediatric Radiation Oncology with Movie Induced Sedation Effect)|Pediatric Radiation Oncology with Movie Induced Sedation Effect (PROMISE) is an interactive, incentive-based movie system that integrates with a video surveillance gating module (VisionRT) to help keep a child's attention and prevent him or her from moving during radiation treatment. This technology is being studied as an alternative sedation solution for pediatric patients needing radiation treatment. As part of the trial, patients will be attempted to have CT simulation scan and first radiation treatment(s) using PROMISE, with general anesthesia on standby should PROMISE be unsuccessful. If PROMISE is unsuccessful for a given patient, then standard of care general anesthesia will be used for that patient's radiation treatment and PROMISE will be reattempted at physician discretion with anesthesia on standby.
41470455|NCT04491695|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 71.5 hours.
41311712|NCT00914602|DRUG|Sinemet 25-100 Oral Tablet|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
41150513|NCT02206607|DRUG|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
41311713|NCT00914602|DRUG|XP21279|Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
41311714|NCT00914602|DRUG|Carbidopa Pill|
41311715|NCT02712372|DRUG|AZD4831|AZD4831 1-50 mg/g oral suspension
41311716|NCT02712372|DRUG|AZD4831 placebo|AZD4831 placebo oral suspension
41470456|NCT04491695|DRUG|Oral antiplatelet|Aspirin, clopidogrel or other antiplatelet drugs. Loading dose will be considered if the patients is not on antiplatelet therapy.
41470457|NCT06360029|BEHAVIORAL|LvL UP|"The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant."
41470458|NCT06360029|BEHAVIORAL|LvL UP + MI|"After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle)."
40794758|NCT04408391|OTHER|Brain MRI scan|Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner
40794759|NCT01544101|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
40794760|NCT01544101|DIETARY_SUPPLEMENT|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
41311717|NCT05201586|OTHER|Conditional Cash Transfer|CCTs will be given to participants in the form of a pre-loaded debit card.
40794761|NCT01407952|DEVICE|HydroCoil Embolic System|HydroCoil Embolic System
41150514|NCT03915535|DIETARY_SUPPLEMENT|Eicosapentaenoic acid + Docosahexaenoic acid|Monoglyceride Omega-3 fish oils
41311718|NCT05201586|OTHER|Semi-structured interviews|Research team will conduct semi-structured interviews exploring how social determinants of health and social needs impact health. Participants will be asked to set a health goal. 6 months after the initial interview, the team will interview the patients again and evaluate whether that health goal was achieved.
41311719|NCT04922749|BEHAVIORAL|MULTI+|MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
41311720|NCT02168868|DIAGNOSTIC_TEST|Blood draw|A blood sample (5 mL) will be collected.
41311721|NCT02168868|DIAGNOSTIC_TEST|Stool Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a stool sample at home.
41311722|NCT02168868|DIAGNOSTIC_TEST|Urine Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a urine sample at home.
40794762|NCT01407952|DEVICE|Control (bare platinum coils)|bare platinum coils
41150515|NCT03915535|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|Monoglyceride Omega-3 fish oil
41150516|NCT03960437|DRUG|Etelcalcetide|Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
41311723|NCT01944969|DRUG|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
41311724|NCT05137119|DRUG|Cefazolin|Cefazolin
41311725|NCT05137119|DRUG|Penicillin|benzylpenicillin
41311726|NCT05137119|DRUG|Clindamycin|Clindamycin
41470459|NCT06360029|BEHAVIORAL|Comparison|Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
41470460|NCT06097702|DRUG|BX-001N Part 1|Dosage form- IV bolus Dosage- In the five cohorts, each participant receives a single IV bolus administration in one of the five doses based on body weight and followed up for 7 days.
41470461|NCT06097702|DRUG|BX-001N Part 2|Dosage form- IV bolus Dosage- In the three cohorts, each participant receives a single IV bolus administration for 7 sequential days in one of the three doses based on body weight and followed up for 14 days.
41470462|NCT06097702|DRUG|Placebo|Participants will receive matching placebo across Part 1 and 2 of the study.
41470463|NCT06601751|OTHER|Neurobic Exercise Program|6 weeks to improve cognitive function, memory and overall brain health by introducing non-routine activities that require participants to utilise their multiple senses and remember sequences and patterns. Each activity would be performed 2-3 times/ session, for recalling the observation period set at 1 minute and at the end of the 9th week, the memory retention effect will be measured.
41470464|NCT06601751|OTHER|Traditional Brain Exercise|activities like calculation or memory games. These exercises will be conducted in 2 days/week for 60-minute sessions in 6 weeks. The memory retention effect will be measured at the end of the 9th week. It is intended to be the baseline for comparing the effectiveness of a neurobic exercise program.
41470465|NCT03122717|DRUG|Gefitinib|gefitinib is a EGFR inhibitor
41470466|NCT03122717|DRUG|Osimertinib|An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
41470467|NCT05426616|DEVICE|collagen membrane (Creos Xenoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After having made multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied. An individualized collagen membrane is attached on top using membrane fixation pins. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved.
41470468|NCT05426616|DEVICE|titanium reinforced d-PTFE membrane (Creos Syntoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied.A titanium reinforced d-PTFE membrane is attached on top using membrane fixation pins. Care is taken to leave a distance of at least 1 mm between the membrane and neighboring teeth. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved. The membrane is removed after 9 months, prior to implant placement.
41470469|NCT01996423|DIETARY_SUPPLEMENT|Vitamin D3|
41311727|NCT05137119|DRUG|Vancomycin|Vancomycin or Daptomycin
41311728|NCT05137119|OTHER|Effectiveness of early switch to oral antibiotics|This involves testing a strategy rather than individual antibiotic agents
41311729|NCT05137119|RADIATION|Whole body FDG PET/CT Imaging|Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.
41311730|NCT06426199|DRUG|Chitosan-Hyaluronate Gel Mixture|The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Chitosan-Hyaluronate Gel Mixture into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
40794763|NCT01669694|OTHER|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
40794764|NCT05921591|DRUG|IRL201104|Lyophilised powder for reconstitution for IV dosing
40794765|NCT05921591|DRUG|Placebo|Matching placebo for IRL201104
40794766|NCT06469190|DRUG|KN5501|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
41311731|NCT06426199|DRUG|Hyaluronic Acid|The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Hyaluronic acid into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
41311732|NCT00649376|DRUG|Fexofenadine Tablets 180 mg|180mg, single dose fasting
41470470|NCT01996423|DIETARY_SUPPLEMENT|Placebo|
41470471|NCT02304978|BIOLOGICAL|Group CRC|blood samples
41470472|NCT02304978|BIOLOGICAL|Group control|Blood samples
41470473|NCT03977168|PROCEDURE|Application of circumferential pelvic compression (CPC) device|Application of circumferential pelvic compression (CPC) device used at any time within 24 hours of injury
41470474|NCT06028646|DEVICE|Dynamic Airway CT scan (DA-CT)|Patient will be asked to perform movements during the scan.
41470475|NCT00003430|DRUG|L-778,123|
41470476|NCT02139618|DRUG|Methyl Aminolevulinate (MAL)|
41470477|NCT02139618|DRUG|Placebo|
41470478|NCT00913796|DRUG|Potassium citrate|2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
41470479|NCT00913796|DRUG|Potassium chloride|370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
41470480|NCT05467826|DRUG|Sofosbuvir/Velpatasvir + Ribavirin|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
40794767|NCT05953298|DEVICE|Electrical impedance tomography (EIT)|Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level
40794768|NCT03686930|DRUG|Cohort 1 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
40794769|NCT03686930|DRUG|Cohort 2 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
41311733|NCT00649376|DRUG|Allegra® Tablets 180 mg|180mg, single dose fasting
41470481|NCT05467826|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
41470482|NCT05545618|DIAGNOSTIC_TEST|CCTA and 18F-FDG-PET/CT|18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days
41470483|NCT04147819|DRUG|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
40794770|NCT03686930|DRUG|Cohort 3 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
40794771|NCT03686930|DRUG|Placebo (for FP-045 oral solution)|Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
40999760|NCT03414463|BEHAVIORAL|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
41311734|NCT04274166|DRUG|secukinumab 150 mg (2 injections per dose|secukinumab 150 mg (2 injections per dose
41311735|NCT02106455|DRUG|Sodium risedronate|Sodium risedronate tablets
41470484|NCT04147819|DRUG|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).
41470485|NCT00065117|DRUG|ZD6126|
41470486|NCT00065117|DRUG|Placebo|
41470487|NCT00065117|DRUG|5-fluorouracil|
41470488|NCT00065117|DRUG|leucovorin|
41470489|NCT00065117|DRUG|oxaliplatin|
41470490|NCT05197777|DEVICE|tDCS associated to functional activities|The intervention will start by a pretest on the first day (day 0, baseline record). Tdcs will be applied associated functional task from an experimental workstation, consisting in a hairdressing dummy head fixed to a telescopic table, adjustable to each individual's height. Elbow angles will be adjusted in a static position with a manual goniometer (60 degrees). The task will be performed in a standing position inside a 1m2 perimeter during 30 minutes, undergoing repetitive movements. Performing a repetitive manual gesture. The cycle will be executed at a cadence of 30s/cycle with a metronome beat. The TCT - tDCS Stimulator Kit Research version, with 35 cm2 on M1 of the contralateral hemisphere for the rigth dominant hand. During the first 30 s of active tDCS, an initial period of ''ramping up'' is administered, in which the stimulator reaches the maximum programmed current (2 mA) to mimic cutaneous perceptions. A 2 mA intensity will be maintained during activity.
41470491|NCT05197777|OTHER|Conservative physiotherapy|Education and exercices for pain relief by usual tradicional physiotherapy in Hospital: walking, mobility, and transfert.
41470492|NCT06616818|OTHER|DASH-FV|12weeks of fruit and vegetable delivery to the home
41470493|NCT06616818|OTHER|nutrition counselling only|nutrition counselling as part of standard of care
41470494|NCT05095649|BIOLOGICAL|Regulatory T-cell enriched infusion|Enrichment of cluster of differentiation 25hi regulatory T cells from cluster of differentiation antigen 8 and/or cluster of differentiation antigen19 pre-depleted leukapheresis products.
41470495|NCT04083859|OTHER|mPATH-Lung|A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.
40794772|NCT05962216|DRUG|Brexpiprazole|Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders
41311736|NCT02117596|DRUG|Sirolimus|"1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
41311737|NCT03172520|DEVICE|APS electrode|The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.
40794773|NCT04746664|BEHAVIORAL|Nutritional counselling|Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
40794774|NCT02941770|BEHAVIORAL|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
40794775|NCT02941770|OTHER|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
41470496|NCT04083859|OTHER|Lung health video|Web-based video about guideline recommended exercise for lung health
40794776|NCT04310319|DIETARY_SUPPLEMENT|Sodiumchloride|Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
40794777|NCT04310319|DIETARY_SUPPLEMENT|Protein|Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
40794778|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (salt)|Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
40794779|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (protein)|Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
40794780|NCT01663766|DRUG|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
41311738|NCT03172520|DEVICE|Facial Nerve Monitor|The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
40794781|NCT00650052|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fasting
40794782|NCT00650052|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fasting
41311739|NCT02730338|BEHAVIORAL|High intensity aerobic and resistance training|
41311740|NCT02730338|BEHAVIORAL|Psychosocial support|
41311741|NCT03105700|DEVICE|Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.
41311742|NCT04774679|PROCEDURE|Endosonographic fine needle aspiration biopsy|An endoscopic ultrasound device will be inserted to the stomach and biopsy will performed with a needle
40794783|NCT05146219|DRUG|TY-9591 Tablets|TY-9591 Tablets 160mg/d
40794784|NCT00506454|DRUG|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
40794785|NCT00506454|DRUG|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
40999761|NCT02985632|DRUG|BMS-986141|
40999762|NCT01365390|OTHER|Data collection (Retrospective)|For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to \< 6 years) or since birth (for subjects aged \< 1 year) will be recorded in the electronic case report form.
41311743|NCT00001251|DRUG|Mafosfamide|
41470497|NCT06617793|BIOLOGICAL|rapcabtagene autoleucel (YTB323)|CAR-T cell suspension for intravenous infusion
41470498|NCT05593731|BIOLOGICAL|dental implants with melatonin gel|platelet rich fibrin membrane around dental implants
41470499|NCT00005086|DRUG|cisplatin|
41470500|NCT00005086|DRUG|docetaxel|
41470501|NCT00005086|DRUG|gemcitabine hydrochloride|
41470502|NCT00005086|DRUG|methotrexate|
41470503|NCT06417437|DRUG|SSRI|Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.
41470504|NCT06417437|DEVICE|rTMS|Patients will be treated targeting either the traditional brain region or new region.
41470505|NCT06417437|BEHAVIORAL|Neuro-Feedback|Patients under 18 years old will first be considered this treatment before other methods.
41470506|NCT06417437|BEHAVIORAL|Game Regulation|Patients will learn how to play several games that can supposedly regulate or affect negative emotions.
41470507|NCT04108962|DRUG|Fasenra, 30 Mg/mL Subcutaneous Solution|Anti-IL5 receptor alpha monoclonal antibody
41311744|NCT03499821|DEVICE|EDOF ICL|The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
41311745|NCT05249231|DRUG|Silver diamine fluoride|Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)
41470508|NCT00799942|DRUG|Neramexane mesylate|open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
41470509|NCT04938986|DIAGNOSTIC_TEST|IMMUNOSCORE®|recommendation for patient care according to the result of the IMMUNOSCORE®
41470510|NCT06616831|DEVICE|Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific Training|Each participant will complete 2 weeks, 3 times per week, task-specific training paired with transcutaneous auricular vagal nerve stimulation.
41470511|NCT04626544|DEVICE|Body-worn inertial sensors|The device typically includes accelerometers that capture body accelerations in three directions (anteroposteriorly, mediolaterally and vertically) and gyrometers that capture rotations (yaw, pitch and roll). The method of measuring gait using body-worn inertial sensors has been found reliable \[15\] and valid \[20\]. This project will use Opal sensors and the Mobility Lab software from the manufacturer APDM (https://www.apdm.com/wearable-sensors/).
41470512|NCT03059485|BIOLOGICAL|DC/AML Fusion Vaccine|The Dendritic Cell Fusion Vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells
41470513|NCT03059485|OTHER|Observation|Traditional care provided by the hospital.
41470514|NCT03217526|OTHER|Gait Training|Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
40794786|NCT06018077|BEHAVIORAL|Dietary İntake, Biochemical parameters, Antropometric measuruments|Nutritional status of individuals will be evaluated with a 24-hour retrospective food consumption record and food consumption frequency questionnaire. After 8-12 hours of fasting, body composition analysis will be performed and within the scope of anthropometric measurements, body weight, height length, BMI measurements will be taken. Then, venous blood will be taken from the participants C-reactive protein (CRP), albumin and chemerin level will be analyzed.
40794787|NCT03287193|BIOLOGICAL|Blood sample|for patient and its parents
41470515|NCT04157478|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
41470516|NCT04157478|RADIATION|Radiation therapy|Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.
40999763|NCT01365390|OTHER|Data collection (Prospective)|For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
40999764|NCT05092555|DIAGNOSTIC_TEST|Nasopharyngeal swap for Reverse transcription polymerase chain reaction|Nasopharyngeal swap and Blood sample is taken for doing previous tests and CT chest is done for all patients
40999765|NCT00116831|DRUG|Glipizide|oral anti-diabetic medication
40999766|NCT00116831|DRUG|rosiglitazone maleate|oral antidiabetic medication
40999767|NCT06311890|DRUG|N-chlorin e6 triglumine|a photodynamic therapy with chlorin-e6
41470517|NCT04157478|DRUG|Temozolomide|Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
41470518|NCT06617754|BIOLOGICAL|Biologic drugs|Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies
40794788|NCT03287193|GENETIC|high-throughput sequencing|exome or whole genome sequencing
40794789|NCT00196794|DRUG|Tolevamer potassium-sodium (GT267-004)|
40794790|NCT01007175|BIOLOGICAL|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
41470519|NCT02126384|DRUG|pneumovax vaccination|vaccination
41470520|NCT05531682|OTHER|Placebo|Subjects will receive several injections of Placebo
41470521|NCT05531682|DRUG|HB0017|Subjects will receive HB0017 in different dosing regimens
41470522|NCT06083090|PROCEDURE|Yogatherapy|The experimental arm will benefit from support by a physiotherapist trained in yoga, in a group for ten weeks with two weekly sessions of approximately 1 hour each. A new yoga program adapted for the axSPA will be implemented.
41150517|NCT02871453|DEVICE|Scalp Acupuncture Treatment|The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.
41470523|NCT06083090|PROCEDURE|Physiotherapy|The comparator arm will benefit from support by a physiotherapist, in groups for ten weeks at the rate of two weekly sessions of approximately 1 hour each. An already existing program adapted for the axSPA will be implemented.
41150518|NCT02871453|OTHER|Rehabilitation treatment|The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
41150519|NCT06226870|PROCEDURE|root canal tretment|traditional therapy
41150520|NCT06226870|PROCEDURE|biodentin VPT|Alternative therapy
41150521|NCT06226870|PROCEDURE|PRF|Alternative therapy
41150522|NCT01156922|DRUG|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~For up to 5 patients in the study, standard plasma exchange (one plasma volume, up to 5 treatments, during 1-2 weeks) will be performed 2-3 weeks prior to start of Rituximab therapy.~Amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
41150523|NCT00241475|DRUG|Gefitinib|
41150524|NCT03759262|DRUG|Cholecalciferol|A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.
41150525|NCT05680298|DRUG|Dupilumab|solution for injection, Subcutaneous injection
41150526|NCT04789616|DRUG|Maraviroc|Half of the participants will take maraviroc for a period of 8 weeks.
41150527|NCT04789616|BEHAVIORAL|Exercise Program|"All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for physiotherapy \& occupational therapy) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program."
41150528|NCT04789616|OTHER|Placebo|Half of the participants will take a placebo for a period of 8 weeks.
41150529|NCT04789616|DEVICE|Activity Sensor|"Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study."
41150530|NCT04789616|BEHAVIORAL|Motor Learning|Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 72 hours of the initial assessment (initial test and retention test).
41150531|NCT04422210|DRUG|Venetoclax|Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
41150532|NCT04422210|DRUG|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
41150533|NCT04422210|DRUG|Carboplatin|Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.
41311746|NCT05249231|DEVICE|Hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method
41311747|NCT01321502|DRUG|famciclovir|500 mg tablet
41470524|NCT04124029|DEVICE|No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.|No intervention will be used.
41311748|NCT02754830|DRUG|LY3303560 - IV|Administered IV
41311749|NCT02754830|DRUG|Saline Solution - IV|Administered IV
41311750|NCT02754830|DRUG|LY3303560 - SC|Administered SC
41311751|NCT04757727|OTHER|Decriptive study of EDB|data on EDB will be register
41311752|NCT05899387|PROCEDURE|Swap collection|"Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site."
41470525|NCT04124029|PROCEDURE|No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.|No intervention will be used.
40794791|NCT01007175|BIOLOGICAL|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
40794792|NCT01007175|BIOLOGICAL|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
40794793|NCT01007175|BIOLOGICAL|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
40794794|NCT01007175|BIOLOGICAL|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
40794795|NCT05789498|OTHER|In vitro stimulation of Pbmc with tumor antigen nanoparticles|PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.
40794796|NCT00652314|DEVICE|Thrombi-Gel|Applicaton of Hemostatic product during surgery
40794797|NCT00858351|BEHAVIORAL|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
40794798|NCT00858351|BEHAVIORAL|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
40794799|NCT06075134|PROCEDURE|Botox injection|Botox injection
40794800|NCT06075134|DEVICE|EMG|Quantitative Electromyography
40794801|NCT06075134|DRUG|Zinc Supplement|To increase efficacy of Botox
41311753|NCT05899387|PROCEDURE|Seroma punction|Puncturing of a seroma in case of occurence and clinical need
40794802|NCT06421480|OTHER|Detecting Risky Behaviors and Providing a Safe Environment in Patients Receiving Inpatient Treatment in a Psychiatric Clinic Using Machine Learning Model|Using machine learning, the computer will be trained to detect suicide and violent behavior. Cameras will be placed in patient rooms. These cameras will transfer the image to the computer. The computer will process these images and detect suicidal and violent behavior early. A warning will appear on the computer screen
40794803|NCT02509364|OTHER|No intervention|
40794804|NCT03730714|DRUG|"Local Anesthetic, Epinephrine and Morphine"|local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
40794805|NCT03730714|DRUG|"Local Anesthetic, Epinephrine, Morphine and Surgicel"|Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
40794806|NCT03730714|DRUG|"Normal Saline"|normal saline 0.9% to soak the surgicel according to the planned technique
40794807|NCT06339086|DRUG|Semaglutide Injection|"The subject will receive either a dose of semaglutide subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
40794808|NCT06339086|DRUG|Semaglutide Injection(Ozempic®)|"The subject will receive either a dose of Ozempic® subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
40794809|NCT06339086|DRUG|Metformin|"Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day.~Treatment duration 32 weeks."
41150534|NCT04422210|DRUG|Etoposide|Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.
41150535|NCT05431543|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
41470526|NCT06471127|BEHAVIORAL|Pseudoword learning paradigm task|Pseudoword learning is an experimental learning task by which participants view two novel objects (a target and a foil) and simultaneously hear an audio recording of the pseudoword name of one of the two objects. Participants must choose (via mouse click) which object corresponds to the word presented, immediately after which feedback is provided.
40794810|NCT01116388|OTHER|GFCF product with GFCF diet|"Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks."
40794811|NCT01116388|OTHER|product containing gluten and casein (milk protein) with GFCF diet|"Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks"
40794812|NCT02353013|DIETARY_SUPPLEMENT|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
41150536|NCT05431543|DRUG|Aceclidine ophthalmic solution|LNZ100- aceclidine ophthalmic solution
41150537|NCT05431543|DRUG|Vehicle proprietary ophthalmic solution|Proprietary Vehicle ophthalmic solution
41150538|NCT01199445|DIETARY_SUPPLEMENT|Triple fortified extruded tice (Fe, Zn and vitamin A)|Triple fortified extruded rice (Fe, Zn and vitamin A)will be mix at ratio of 1:50 with normal rice then give to children at school lunch meal for 60 days.
41311754|NCT05899387|PROCEDURE|Blood sampling|Blood sampling at defined time points according to protocol
40794813|NCT02353013|DIETARY_SUPPLEMENT|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
40794814|NCT03026296|BEHAVIORAL|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
40794815|NCT04279119|DRUG|ARQ-151- cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
40794816|NCT02501681|OTHER|priming solution during cardiovascular surgery|
40794817|NCT02575872|BEHAVIORAL|Exercise Intervention|Participate in physical activity behavioral intervention
40794818|NCT01474005|DEVICE|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
40794820|NCT03204604|DIETARY_SUPPLEMENT|Challenge A - low calorie Ensure®|Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
40794821|NCT03204604|DIETARY_SUPPLEMENT|Challenge B - Ensure® plus ketone esters (KE)|Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
41311755|NCT06054022|DEVICE|high flow nasal cannula|high flow nasal cannula provides heated and humidified gas to the airways via nasal prongs at a prescribed accurate fraction of inspired oxygen (FiO2) ranging from 0.21 to 1.0 and with a higher flow rate of up to 60 litres per minute
40794822|NCT03204604|PROCEDURE|PET Scan|Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of \[11C\]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using \[11C\]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post \[11C\]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
41311756|NCT06054022|DEVICE|nasoprong oxyen 2Litres per minute|nasoprong @L/min will deliver approximately a FiO2 of 0.3. subsequently, if incremental O2 is needed, patient will be provided with ventimask 40% and so forth
40794823|NCT03204604|BEHAVIORAL|Cognitive Testing - FCSRT|The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
40794824|NCT03204604|BEHAVIORAL|Story Recall|Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
40794825|NCT03204604|BEHAVIORAL|BVRT|Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
40794826|NCT03204604|BEHAVIORAL|CogState One Card Learning|The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
40794827|NCT04839250|PROCEDURE|heads-up method|3D surgical video system, which includes Alcon NGENUITY 3D visualization system (Alcon, Fort Worth, TX) and Leica M822 and M844 microscopes (Leica Microsystems, Wetzlar, Germany),can be used to perform head-up phacoemulsification combined with intraocular lens implantation surgery.
40794828|NCT04103281|OTHER|Sepsis|Sepsis patients in the ICU with a breathing tube
41311757|NCT03488121|BEHAVIORAL|Poster|Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
40794829|NCT01101958|DEVICE|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
41311758|NCT03488121|BEHAVIORAL|Thank-you Letter|Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
41470527|NCT01290835|RADIATION|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
41311759|NCT03590522|GENETIC|Ryanodine Receptor 2 gene expression|Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.
41311760|NCT00379197|DRUG|naltrexone|Naltrexone 50 mg will be orally taken once daily for 28 day (cycle 1), and continues once daily for another 28 days (cycle 2) without interval.
41470528|NCT01290835|RADIATION|stereotactic radiotherapy|
41470529|NCT05287399|DRUG|ASC61 200 mg 1|200mg of ASC61 orally once daily for cycles of 28 days
41470530|NCT05287399|DRUG|ASC61 200 mg 2|200 mg of ASC61 orally twice daily for cycles of 28 days
41470531|NCT05287399|DRUG|ASC61 300 mg|300 mg of ASC61 orally twice daily for cycles of 28 days
41470532|NCT05287399|DRUG|ASC61 400 mg|400 mg of ASC61 orally twice daily for cycles of 28 days
41311761|NCT00379197|PROCEDURE|PET scan|Patients will receive PET scan approximately one hour after being injected with 2-Deoxy-2-\[18F\]fluoro-D-Glucose (FDG). PET scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
41311763|NCT03212664|OTHER|exercise|physical therapy exercises
41311764|NCT02499341|DRUG|Tramadol|Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
41311765|NCT02499341|DRUG|Ketamine|Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
41311766|NCT00204997|PROCEDURE|Laparoscopic ovarian transposition|Laparoscopic ovarian transposition
41311767|NCT00131040|DRUG|Aprotinin|
41311768|NCT02670460|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
41311769|NCT01672606|DRUG|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
41311770|NCT03085641|DEVICE|Nasal high flow oxygen therapy|nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
41311771|NCT02568917|PROCEDURE|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
41311772|NCT02568917|PROCEDURE|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
41311773|NCT04037670|PROCEDURE|SASI bypass|Sleeve gastrectomy with single loop anastomosis between gastric antrum and ileum, 3 meters away from ileocecal junction
41311774|NCT02225873|OTHER|motor control exercises|Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles
41311775|NCT02225873|OTHER|muscle strength-endurance and proprioception|Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
41311776|NCT00306917|DEVICE|non-coated femoral hip stem|total hip replacement
41311777|NCT00306917|DEVICE|coated femoral hip stem|total hip replacement
41311778|NCT05274113|DRUG|Dexamethasone 4mg|4 mg of Dexamethasone will be given before surgery
41311779|NCT05274113|DRUG|Ropivacaine|Ultrasound guided supraclavicular block with ropivacaine will be given to patients before surgery
40999768|NCT06311890|PROCEDURE|acne removal surgery|acne removal surgery will be given before red light exposure
41311780|NCT05590741|BEHAVIORAL|Emotion Regulation Therapy via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
41311781|NCT05408312|BIOLOGICAL|Experimental Vaccine 1|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
41311782|NCT05408312|BIOLOGICAL|Experimental Vaccine 2|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
41470533|NCT05287399|DRUG|ASC61 600 mg|600 mg of ASC61 orally twice daily for cycles of 28 days
40794830|NCT01101958|DEVICE|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
41470534|NCT00707447|BEHAVIORAL|PREDIAS|Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
41470535|NCT00707447|BEHAVIORAL|Control|Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
41470536|NCT06120634|PROCEDURE|Open surgical method|After separating the preputial skin from glans and removing smegma, two artery clips were applied on the dorsal skin in the center to mark the skin to be divided. Crushing the skin for a couple of minutes, prior to incising, helps to reduce bleeding. The skin was cut about 2-3 mm short of the coronal sulcus. Similarly, 2-3 mm cuff of prepuce was circumferentially cut proximal to the corona. Using bipolar diathermy or catgut 4/0, frenular artery along with dorsal artery and vein of penis were coagulated or ligated respectively to achieve hemostasis. The skin and prepuce were approximated and sutured with catgut 4/0 at four places- ventral, dorsal, and two lateral points. Finally, a dressing with antibiotic ointment was applied to the wound.
40999769|NCT04995016|DRUG|Pembrolizumab|PD-1 inhibitor，Pembrolizumab 200mg IV, every 3 weeks.
41311783|NCT05408312|BIOLOGICAL|Experimental Vaccine 3|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
41470537|NCT06120634|PROCEDURE|Plastibell method|The prepuce was separated all around the glans, up to the coronal sulcus, and smegma was removed. A dorsal slit in the skin was made, after crushing the skin for a couple of minutes, long enough to accommodate the passage of an appropriate-sized plastibell. Once the distal edge of the bell snugly fit at or near the coronal sulcus, a ligature was applied and tightened around the sulcus on the bell. The extra preputial skin was cut with either scissors or a surgical blade, after breaking apart and discarding the handle of the plastibell. The urethral meatus was examined and its visibility was ensured prior to returning the baby boy to his parents. The baby was kept under observation for 30 minutes in the surgical ward and re-examined to ensure there was no hematoma or bleeding.
41470538|NCT03887988|PROCEDURE|"Primary early reconstruction"|Primary surgical reconstruction of the fracture within 3 weeks after injury
41470539|NCT03887988|OTHER|Nonsurgical|Nonsurgical treatment of fracture
41311784|NCT05408312|BIOLOGICAL|placebo|Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
41311785|NCT04762147|DRUG|paracetamol, the group P|The paracetamol was administered 30 minutes before the start of surgery for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
41311786|NCT04762147|DRUG|fentanyl, group-F administered as an active comparator|The fentanyl 2mcg/kg was administered at the time induction of anaesthesia for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
41470540|NCT03887988|PROCEDURE|"Primary delayed reconstruction"|Primary surgical reconstruction of the fracture more than 3 weeks after injury
41470541|NCT03887988|PROCEDURE|Secondary reconstruction|Second surgical reconstruction of the fracture after a primary reconstruction.
41470542|NCT05390125|OTHER|A team, proficiency based progression, simulation training programme|The training programme will consist of two components (i) a short online training course including video examples of high performing teams and also poor practice (ii) a ward-based team huddle simulation training and assessment programme. The design and shape of the training and assessment will be based on the development of robust metrics. The design of the metrics and programme will centre around use in the acute hospital setting but will be readily adaptable to the obstetric, paediatric setting. The process of validating the metrics and building the online and simulation course involves the review of videotapes of safety huddle performance.
41470543|NCT02367625|DEVICE|CryoPop|The new CryoPop device will be compared to standard cryotherapy
41470544|NCT02367625|DEVICE|MedGyn MGC 200|Standard cryotherapy
41470545|NCT01459263|DEVICE|ClariVein|Using the ClariVein device, the GSV will be occluded.
41470546|NCT04983602|OTHER|Comprehensive Geriatric Assessment arm|The intervention will involve a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.,
41470547|NCT04983602|OTHER|EDPLUS|EDPLUS involves a 6 week physiotherapy led community based intervention involving 3 home visits and weekly telephone support.
41470548|NCT06616324|DEVICE|Virtual Reality|Participants in the intervention group will undergo ESWL according to standard treatment but with the addition of Virtual Reality and ANC-headphones as a supplement.
41470549|NCT06256835|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
41470550|NCT06256835|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
41311787|NCT03157973|OTHER|Education intervention|eHealth tool and standardized nurse-led follow-up.
41311788|NCT02546674|DRUG|Nilotinib|A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.
41311789|NCT04811469|DRUG|CBP-174|CBP-174 oral solution, given once
41311790|NCT04811469|DRUG|Placebo|Placebo oral solution, given once
41470551|NCT01157715|BIOLOGICAL|intravitreal injection of KH902|
41470552|NCT00982631|DRUG|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
41470553|NCT02564848|PROCEDURE|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
41470554|NCT05458037|PROCEDURE|Speed of tenaculum application|Fast or slow closure of the tenaculum for application to the uterine cervix
41470555|NCT06614309|OTHER|Acute Placebo Visit|The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.
41470556|NCT06614309|OTHER|Acute Progressive Carbon Dioxide|The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.
41470557|NCT06614309|OTHER|Acute Intermittent Hypoxia|The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.
41311791|NCT04813939|DEVICE|IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany)|Point of care assessment of bio-adrenomedullin concentration will be performed using the IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany) on the 1,3,5-day ICU stay in COVID-19 patients. The method used is a double monoclonal sandwich immunoassay to measure the concentration of C-terminal amidated, biologically active adrenomedullin (bio-ADM) in whole blood. Additional measurement of bio-ADM will be performed as standard monitoring in patients suspected of septic complications of the course of COVID-19.
41470558|NCT06614309|OTHER|Training: Progressive Carbon Dioxide Ramping|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the progressive CO2 ramp protocol of 60-minute sessions, which will include 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles, for every visit during the 14 days.
41470559|NCT06614309|OTHER|Training: Intermittent Hypoxic Exposure|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the intermittent hypoxia exposure protocol of 60-minute sessions, which will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air for every visit during the 14 days.
41470560|NCT06614309|OTHER|Training: Placebo Control|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days.
41311792|NCT05973994|DEVICE|intravascular lithotripsy with Shockwave coronary system|OCT acquistion is performed at baseline. Then the IVL catheter will be passed across the lesion over the guidewire. Atherectomy or cutting/scoring balloons is not permitted per protocol. The IVL procedure is considered successful when a residual stenosis \<50% by visual estimate after IVL alone is achieved. After IVL procedure, one OCT imaging acquisition must be performed. If the residual stenosis is ≥50% following IVL, noncompliant balloon dilatation will be performed prior to stenting and OCT images repeated accordingly. Subsequent stent implantation will be performed per local standard of care at the discretion of the operator. Following stent implantation, high pressure post-dilatation is recommended and OCT imaging acquisition must be performed to assess stent apposition for secondary end point.
41311793|NCT01406847|OTHER|Spinal Manipulation|High velocity low amplitude joint-biased intervention
41470561|NCT00476593|DRUG|Diclofenac|"Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
41470562|NCT00476593|DRUG|Dexamethasone|"Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.~Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
41470563|NCT00528268|DRUG|Sodium phenylbutyrate (NaPB)|The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.
41470564|NCT00436917|DRUG|zoledronic acid|zoledronic acid
41470565|NCT00436917|PROCEDURE|Letrozole as adjuvant therapy|standard care
40794831|NCT03797066|DRUG|ZEPATIER 50Mg-100Mg Tablet|Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA\> 800,000 iu/ml or baseline NS5A resistance.
40794832|NCT05373758|OTHER|Standard of Care treatment strategy|Management of virologic failure on TLD using the Standard of Care strategy
41470566|NCT04410575|OTHER|Standard Pharmacist Care|Standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians)
40794833|NCT05373758|OTHER|Individualized Care treatment strategy|Management of virologic failure on TLD using the Individualized Care strategy
40794834|NCT05373758|OTHER|Immediate Switch|Management of virologic failure on TLD using the Immediate Switch strategy
40794835|NCT04938284|DEVICE|PAS|Paired associative stimulation is a combination of non-invasive transcranial magnetic stimulation (TMS) and non-invasive peripheral nerve stimulation (PNS)
41470567|NCT04410575|OTHER|Reviewed Questionnaire tool results with participant|Pharmacist reviews results of the patient-administered PHQ-9 and/or GAD-7 questionnaire tool, at the scheduled follow-up appointment
41470568|NCT04410575|OTHER|Patient Clinical Assessment|Pharmacist conducts clinical assessment of the participant's major depressive disorder and/or generalized anxiety, which can include: appearance, current mood, sleeping patterns, mental health, medical history, social history, family history, relationship with others, suicidal ideation, previous suicide attempts or hospitalizations, current employment status
41470569|NCT04410575|OTHER|Psychotherapy Referral|Pharmacist initiates collaboration with physician to arrange referral for psychotherapy, including: psychologist, social worker, counsellor, psychiatrist
40794836|NCT04938284|DEVICE|VNS|Non-invasive vagus nerve stimulation delivered through cymba concha \& cymba cavum of the ear.
40999770|NCT04995016|DRUG|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
41150539|NCT03890692|PROCEDURE|flexible nasoendoscopy|"nasopharyngeal endoscopy : After washing nasal cavities with a sterile physiologic solution to remove secretions or scabs, and decongesting them with an oxymetazoline solution in the subjects with turbinate hypertrophy,~* Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\\ septum\\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists"
41150540|NCT05270889|DRUG|Tislelizumab+Zanidatamab|"Zanidatamab will be administered at a flat dose as follows:~* Subjects with body weight \<70 kg: 1800 mg IV on Day 1 of each 21-day cycle~* Subjects with body weight ≥70 kg: 2400 mg IV on Day 1 of each 21-day cycle Tislelizumab will be administered at a dose of 200 mg IV on Day 1 of each cycle."
41150541|NCT04117711|DRUG|AT-007|AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
41311794|NCT01406847|OTHER|Spinal Mobilization|Low velocity, large amplitude oscillating joint biased technique
41311795|NCT01406847|OTHER|Static Touch|The investigators maintains hand contact with both hands over the lumbar area of the participant
41311796|NCT02680886|DEVICE|Novosyn® Quick|Skin closure
41311797|NCT02003560|RADIATION|accelerated partial breast irradiation|9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
41311798|NCT02648958|DRUG|Dexmedetomidine|The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.
41311799|NCT02648958|DRUG|normal saline|The control group received the normal saline infusion
41311800|NCT04872816|DEVICE|Continuous airway positive pressure|The continuous airway positive pressure will be used as the gold-standard treatment for obstructive sleep apnea for 6 months
41311801|NCT03966105|DIAGNOSTIC_TEST|HE and Congo red staining|Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.
40794837|NCT05216939|OTHER|Flannel mask with ear loops|Participants will have a mask fit test and will wear a flannel mask with ear loops. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort and fit of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
41150542|NCT04117711|DRUG|Placebo|Matching placebo will be administered once in the morning before breakfast
41150543|NCT01252199|DRUG|cαStx1/cαStx2|cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
41150544|NCT01252199|DRUG|Placebo|Placebo administered over 1 hour + standard of care
41150545|NCT04761614|BIOLOGICAL|Bevacizumab|Given IVPB
41150546|NCT04761614|DRUG|Fluorouracil|Given IV
41150547|NCT04761614|DRUG|Leucovorin Calcium|Given IVPB
41150548|NCT04761614|DRUG|Oxaliplatin|Given IVPB
41150549|NCT04761614|DRUG|Riluzole|Given PO
41311802|NCT01457859|DRUG|Triclosan|Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
41311803|NCT01457859|OTHER|Conventional non-coated surgical sutures|Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
41311804|NCT00002207|DRUG|Stavudine|
41311805|NCT00002207|DRUG|Didanosine|
41311806|NCT01628250|PROCEDURE|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
41150550|NCT02671071|BEHAVIORAL|Quality of Life Questionnaire (QLQ)|The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.
41150551|NCT04049578|DRUG|Balovaptan|Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.
41150552|NCT02076802|BEHAVIORAL|physical exercises|
41150553|NCT04676763|DRUG|Substance P|Participants will receive Substance P
41150554|NCT04676763|DRUG|Normal Saline|Participants will receive normal saline as Negative control
41150555|NCT04676763|DRUG|Histamine|Participants will receive histamine as Positive control
41150556|NCT06585059|DRUG|TQB2928 injection + Almonertinib Mesilate Tablets|"TQB2928 is a recombinant fully humanized Immunoglobulin G4 (IgG4) monoclonal antibody that can promote tumor cell phagocytosis by macrophages and exert anti-tumor effects.~Almonertinib Mesilate Tablets is a third generation of EGFR-TKI targeting drug."
41311807|NCT01628250|PROCEDURE|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
41311808|NCT00742443|DRUG|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
41311809|NCT00742443|DRUG|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
41311810|NCT00742443|DRUG|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
41470570|NCT04410575|OTHER|Pharmacist initiated interim telephone follow-up with participant|Interim telephone follow-up conducted by the pharmacist since the last in-person follow-up \& a minimum of 1-2 weeks after the last in-person follow-up that involved a dose adjustment, prescribing of adjunctive medication, or discontinuation of therapy (Note: a telephone follow-up does not replace the scheduled in-person follow-up)
41470571|NCT04410575|OTHER|Communication update with physician after participant contact|Pharmacist provides communication update (fax or electronic charting) with the participant's physician after contact with the participant
40794838|NCT05216939|OTHER|Flannel mask with ties|Participants will have a mask fit test and will wear a flannel mask with ties. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
40794839|NCT05216939|OTHER|Twill mask with ear loops|Participants will have a mask fit test and will wear a twill mask with ear loops. While wearing the twill mask with ear loops, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
40794840|NCT05216939|OTHER|Twill mask with ties|Participants will have a mask fit test and will wear a twill mask with ties. While wearing the twill mask with ties, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
40794841|NCT00002108|DRUG|Lamivudine|
40794842|NCT00002108|DRUG|Zidovudine|
40794843|NCT00263432|PROCEDURE|Human allogenic chondrocytes|Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
40794844|NCT00442377|PROCEDURE|exposure to malaria sporozoites|
40794845|NCT06080074|DEVICE|Cardiohelp device (VA-ECMO)|In children receiving the Cardiohelp device for severe heart failure, participants will be consented to a systematic data collection to describe the safety and effectiveness of the device in children.
40794846|NCT00703963|DEVICE|INRatio monitor by Hemosense|Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
40794847|NCT00703963|OTHER|Usual Care|Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
40794848|NCT03246516|OTHER|Questionnaire|"Auto and hetero questionnaires:~* STAI Y B, State-Trait Anxiety Inventoriage~* Brief COPE~* RHHI-24, Revised Health Hardiness Inventory~* IPQ-R, Illness Perception Questionnaire"
40794849|NCT04005391|OTHER|Offer of Participant's Choice of Contraception Method|Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
40999771|NCT05937295|DRUG|Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) adjuvanted with the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).~Vaccination will take place every 4 weeks at the beginning of Cycle 1 and 2. A total of two vaccinations are planned.~After 11 months a booster vaccination can be applied depending on T-cell responses.~Immune checkpoint inhibition (ICI):~Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).~The anti-PD-L1 antibody Atezolizumab (TecentriqTM) 1680 mg will be applied every 4 weeks as a 30-minute infusion (60-minute first dose) starting on day 15 after the first vaccination. Anti-PD-L1 treatment will be continued after the end of vaccination phase throughout the complete study period until End of Treatment (EOT) or until disease progression or other reasons for study termination."
40999772|NCT03531216|OTHER|Rosemary essential oil|Topically-applied oil to both dorsal and palmar aspects of the hands
40999773|NCT03531216|OTHER|Placebo|Topically-applied oil to both dorsal and palmar aspects of the hands
40999774|NCT00152581|DRUG|Pegylated interferon-alfa2a (Pegasys); ribavirin|
40999775|NCT01275066|DRUG|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
40999776|NCT01275066|DRUG|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
40999777|NCT01275066|DRUG|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
40999778|NCT05972538|DEVICE|Osstell ( Osstell AB, Goteborg, Sweden).|Implant stability were assessed on 15, 30,60 and 90 days of prosthesis delivery
40999779|NCT05972538|DEVICE|periodontal probe (Vivacare, TPS, Vivadent, Schaan, Lichtenstein|Clinical evaluation included assessment of pocket depth, plaque index and bleeding on probing) around the implant abutments on 15, 30,60 and 90 days of prosthesis delivery
40999780|NCT05972538|OTHER|questionnaire for patient satisfaction|A questionnaire was used to evaluate patient satisfaction on 90 days at the end of follow up period.
40999781|NCT00287664|DRUG|terlipressin|
40999782|NCT03711162|DRUG|GLPG1690|GLPG1690, film-coated tablets for oral use.
40999783|NCT03711162|DRUG|Placebo|Matching placebo, film-coated tablets for oral use.
41311811|NCT05520268|BEHAVIORAL|Conventional music therapy (CMT)|CMT comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and led by a professional music therapist. For PWDs living in a care home, the CMT sessions are implemented as inpatient rehabilitation held at the care home. For PWDs living at home, the CMT sessions are implemented as outpatient rehabilitation held at a local day activity centre.
41470572|NCT04410575|OTHER|Medication Counselling and Educational Support|Pharmacist provides medication related counselling and educational support to participant
41470573|NCT04410575|OTHER|Non-medication Counselling|Pharmacist provides non-medication related counselling and educational support to participant
41470574|NCT04410575|OTHER|Identification of drug interaction|Pharmacist identification of drug interaction related to medication for major depressive disorder and/or generalized anxiety
40794850|NCT00005097|DRUG|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
40999784|NCT00368264|DRUG|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
40999785|NCT00368264|DRUG|placebo|azathioprine (2 mg/kg) plus four placebo infusions
40999786|NCT00111969|DEVICE|Celacade™ system|
40999787|NCT02450227|DIETARY_SUPPLEMENT|Spinach - Whole leaf (10 mg lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
40999788|NCT02450227|DIETARY_SUPPLEMENT|Spinach - Minced (10 mg/lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
40999789|NCT00002510|BIOLOGICAL|filgrastim|
40999790|NCT00002510|DRUG|cyclophosphamide|
40999791|NCT00002510|DRUG|etoposide|
40999792|NCT00002510|DRUG|mesna|
41150557|NCT05206916|PROCEDURE|cryotherapy|Cryotherapy at sites of vibration as origin of snoring and site of collapse for patients with obstructive sleep apnea syndrome
41150558|NCT02435498|OTHER|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
41150559|NCT02435498|OTHER|Video|The online video will contain the same information within the website.
40999793|NCT00002510|PROCEDURE|peripheral blood stem cell transplantation|
40999794|NCT00002510|RADIATION|radiation therapy|
40999795|NCT03861260|PROCEDURE|Rigid cystoscopy with urethral dilatation|Patients will have a general anaesthetic and a rigid cytoscopic examination of the bladder dilated with sterile water. The urethra will be dilated from FR20 in incremental diameter increases of 2 to French 32 if possible.
40999796|NCT03861260|PROCEDURE|Flexible cystoscopy and installation of Glycosaminoglycan layer replacement (laluril)|Patients will undergo flexible cystoscopy and intravesical installations of Hyaluronic acid (HA) + Chondroitin Sulphate (CS) (GAGs) weekly for 4 weeks and then at 8 weeks and 12 weeks.
40999797|NCT03240133|DRUG|BCX7353|oral liquid formulation
40999798|NCT03240133|DRUG|Placebo|oral liquid formulation to match BCX7353
40999799|NCT05206435|DRUG|Electronic Cigarette|Electronic Cigarettes are provided to replace tobacco cigarettes
40999800|NCT05206435|DRUG|Nicotine Lozenge|Nicotine Lozenges are provided to replace tobacco cigarettes
40999801|NCT05279586|DRUG|lactulose|all interventions are used in secondary prophylaxis in cirrhotic patients
40999802|NCT05279586|DRUG|colistin|all interventions are used in secondary prophylaxis in cirrhotic patients
40999803|NCT03005821|OTHER|Chinese pediatric massage therapy + usual care|
40999804|NCT03005821|OTHER|Sham massage therapy + usual care|
40999805|NCT01940926|DRUG|68Ga-BNOTA-PRGD2|Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
40999806|NCT00426283|DRUG|Flovent|1760 mcg daily
40999807|NCT00426283|OTHER|Placebo|Placebo
41311812|NCT05520268|BEHAVIORAL|Digital music rehabilitation (DMR)|DMR comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and implemented using a novel digital music content service called HILDA. In HILDA, there are a number of stand-alone musical programs hosted by a virtual presenter which the PWDs can follow and through which they can interact. The DMR sessions are moderated by an instructor (care home staff member or research assistant). For PWDs living in a care home, the DMR is implemented as live sessions held at the care home using a HILDA box connected to a TV screen and operated via a remote controller by the instructor. For PWDs living at home, the DMR is implemented as virtual sessions using a video communication platform that allows the instructor to stream and control the HILDA service and the participants to see and hear each other and interact.
41311813|NCT00169988|DRUG|risperidone|
41311814|NCT00169988|DRUG|sertraline-primary|
41311815|NCT02855684|DRUG|Insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41311816|NCT02855684|DRUG|Insulin glargine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41311817|NCT02855684|DRUG|Non-insulin antihyperglycemic drugs|"Pharmaceutical form: capsule/tablet~Route of administration: oral"
41311818|NCT02643186|DRUG|preoperative vaginal misoprostol|preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
41311819|NCT02643186|PROCEDURE|bilateral uterine artery ligation|bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
41311820|NCT02082145|DEVICE|NMES|Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
41311821|NCT06516939|DRUG|bFGF|Half-face randomized control
41311822|NCT06516939|DRUG|Bovine Basic Gel|Bovine Basic Gel
40999808|NCT05698264|DEVICE|concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
40999809|NCT05698264|DEVICE|concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
40999810|NCT02321462|DRUG|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
40999811|NCT02321462|DRUG|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
41311823|NCT05216406|DIETARY_SUPPLEMENT|5-HTP|CLEANMOOD is an organic 5-Hydroxytryptophan (5-HTP) ingredient.
41311824|NCT05216406|OTHER|Placebo|Maltodextrin capsule
41470575|NCT04410575|OTHER|Identification of drug adverse effect|Pharmacist identification of adverse effect related to medication for major depressive disorder and/or generalized anxiety
40999812|NCT06353880|OTHER|Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition.|Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition. Sperm quality parameters, including count, motility, and morphology, will be assessed through semen analysis. Additionally, hormonal profiles related to reproductive health will be evaluated.
40999813|NCT00856908|DRUG|AZD1656|Tolerable dose given twice daily
41150560|NCT02435498|OTHER|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
41470576|NCT04410575|OTHER|Identification of severe deterioration|Pharmacist identification of participant severe deterioration (i.e. suicide attempt)
40999814|NCT00856908|DRUG|Placebo|Tolerable dose given twice daily
40999815|NCT00162565|DRUG|beta-blocker treatment|beta-blocker treatment
40999816|NCT04780386|DRUG|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)
40999817|NCT04780386|DRUG|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)
40999818|NCT05678062|DIAGNOSTIC_TEST|Point-of-care ultrasound|An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
40999819|NCT05761379|DEVICE|Photobiomodualtion Therapy|low lever light therapy with laser semi-conductor at wavelength of 650nm
40999820|NCT05761379|DEVICE|Single vision spectacles for correction myopia|Provide the distance best corrected vision acuity of refractive error of myopia for all the groups
41150561|NCT03109600|BIOLOGICAL|Vi-DT (Bio Farma)|Typhoid Conjugate Vaccine
41311825|NCT03346447|OTHER|Artificial Fecal Enzyme|Artificial Fecal enzyme Trypsin/Chymotrypsin mixture
41311826|NCT03639051|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
41311827|NCT03639051|OTHER|Optimal Medical Care|Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
41311828|NCT03360539|BEHAVIORAL|Nurse-Family Partnership|
41311829|NCT01321931|DRUG|Nicotine|6 mg experimental Nicotine Replacement Therapy (NRT)
41311830|NCT01321931|DRUG|Nicotine|4 mg marketed Nicotine Fruit Gum (NFG)
41311831|NCT01321931|DRUG|Nicotine|4 mg marketed nicotine mint lozenge (NIQ)
41311832|NCT04195269|DRUG|Test Article|10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.
40794851|NCT00682279|DRUG|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
40794852|NCT05324592|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously."
40794853|NCT05324592|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~One dose(2mg) of the drug will be injected intravitreously."
40794854|NCT00781443|DRUG|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
40794855|NCT00781443|DRUG|placebo|Repeating subcutaneous injection
40794856|NCT05597540|DRUG|Short antibiotic treatment|7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
40794857|NCT05597540|DRUG|Usual antibiotic treatment|14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
40794858|NCT00348998|BIOLOGICAL|bevacizumab|
40794859|NCT00348998|DRUG|bicalutamide|
40794860|NCT00348998|DRUG|goserelin acetate|
40794861|NCT00348998|RADIATION|radiation therapy|
40999821|NCT02323854|DEVICE|Ablation|Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
40794862|NCT00175565|DRUG|inhaled fluticasone 500 mcg b.i.d.|
40794863|NCT00153595|DRUG|EWO1|
41311833|NCT04859478|DIAGNOSTIC_TEST|Dual energy / spectral portal venous chest computed tomography|Each patient undergoes an additional dual energy / spectral chest CT in addition to standard care CTPA. The intervention is performed immediately after standard care CTPA.
41311834|NCT01928121|OTHER|Care provided by AF expert program|
41311835|NCT06282471|BEHAVIORAL|Expressive Writing and Problem-Solving Therapy (EW+PST)|Participants will undergo a 6-week self-guided EW+PST. Participants will be provided with 6 printed journals (one for each week of the study) and instructed to write at least 2 entries per week.
41311836|NCT02096146|PROCEDURE|TMT Fusion plate|Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.
41311837|NCT02096146|PROCEDURE|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
41311838|NCT00463658|OTHER|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
40794864|NCT00860626|DRUG|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
40794865|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
40794866|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
40794867|NCT02351492|PROCEDURE|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
40794868|NCT02351492|PROCEDURE|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
40794869|NCT02351492|DEVICE|magnet resonance imaging|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
40794870|NCT02351492|DEVICE|catheter|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
40794871|NCT02261064|DRUG|Telmisartan/Amlodipine low dose|
40999822|NCT02323854|PROCEDURE|Surgical Resection|The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
41150562|NCT03109600|BIOLOGICAL|Vi polysaccharide vaccine|Vi polysaccharide vaccine
41311839|NCT01980121|DEVICE|Ultrasound|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
41311840|NCT00661245|DEVICE|TOGA|Transoral Gastroplasty (TOGA®) System for gastric stapling.
41311841|NCT00661245|DEVICE|Control|The control device (bougie dilator) is a FDA-cleared (Class II) device.
41311842|NCT06065358|PROCEDURE|Tumor biopsy|Patients with advanced suspected HGSOC will be considered eligible (FIGO stage from III C or greater). At the time of surgery, patients' disease extension will be assessed with the Fagotti score (PIV) and the Vizzielli score (VS). Only patients who are not considered operable in the first place, will be enrolled. Samples will be taken during surgery that will take place in the operating rooms of oncological gynaecology.
40794872|NCT02261064|DRUG|Telmisartan/Amlodipine high dose|
40794873|NCT02261064|OTHER|Japanese meal|
40999823|NCT02603432|BIOLOGICAL|Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
41150563|NCT03109600|BIOLOGICAL|Influenzae vaccine|1 dose of Influenzae vaccine
41150564|NCT03109600|BIOLOGICAL|Pneumococcal conjugate vaccine|1 dose of Pneumococcal conjugate Vaccine
41470577|NCT04410575|OTHER|Pharmacist-to-physician recommendation for medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist collaborates, discusses, and makes recommendations to physician re: treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
40794874|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
40794875|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium gluconate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
40794876|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
40794877|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
40794878|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
40794879|NCT06237712|DIETARY_SUPPLEMENT|Placebo caps|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
40794880|NCT00413673|PROCEDURE|PRK|PRK
40794881|NCT02232971|DRUG|Glucagon|Glucagon is given in three different doses according to three research days.
40794882|NCT02232971|OTHER|Isotonic saline solution|Placebo
40794883|NCT03497468|OTHER|Combined exercise training|Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities
40794884|NCT03497468|OTHER|Task-oriented training|Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
40794885|NCT05254353|PROCEDURE|Analyses of proximal and distal samples|Evaluate the difference between proximal and distal CSF samples
40794886|NCT05298059|RADIATION|Laser of low frequncy|Apply the laser at three points on each tooth.
40794887|NCT05298059|DRUG|CPP-ACPF|Apply MI paste plus for five minutes, in the vestibular surface os teeth. During this time patientes should be with closed mounth ad should not talk or to split.
40794888|NCT03277001|DRUG|Rivaroxaban|Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and \< 50 ml/min) po.
40794889|NCT03277001|DRUG|Enoxaparin|Enoxaparin 40mg IH
40794890|NCT04625400|DIAGNOSTIC_TEST|bronchoscope|Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
40794891|NCT02870062|OTHER|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
40794892|NCT02870062|OTHER|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
40794893|NCT04831476|OTHER|Patients with Benign Prostate Hyperplasia|patients with benign prostatic hyperplasia under fixed dose combΙnation treatment with dutasteride and tamsulosin
40794894|NCT06485726|DRUG|Valproic Acid 500 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
40794895|NCT06485726|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
40794896|NCT05709704|DIAGNOSTIC_TEST|Self-palpation via telehealth|This will be used to determine if the participant has the diagnosis
41150565|NCT04647409|OTHER|screening|The determination of the prevalence of NAFLD in a general population in Flanders, Belgium
40794897|NCT05709704|DIAGNOSTIC_TEST|Real-time Ultrasound|This will be used in a subgroup of participants to confirm/rule out a diagnosis
40794898|NCT03976050|DRUG|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
41470578|NCT04410575|OTHER|Pharmacist initiated medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist initiated alteration to treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
40794899|NCT03541278|PROCEDURE|MIT|periareolar intraparenchymal, high volume and ultrasonographic guidance
40794900|NCT03541278|PROCEDURE|IM-SLNB|IM-SLNB was performed for IMLN visualized patients
40794901|NCT03820336|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
40794902|NCT03820336|DIETARY_SUPPLEMENT|Control Oil|Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
40794903|NCT06287255|BEHAVIORAL|EIM+|The Exercise is Medicine (EIM) program involves a personalized exercise prescription and wellness coaching component. At the first 1:1 session, participants are provided with a Fitbit and onboarded with Fitabase, allowing for documentation of baseline health behaviors. Over the course of the program, the EIM fitness specialist reviews Fitbit data and progress towards goals, sending push notifications for encouragement and reminders. A personal training session is conducted, followed by sixteen group sessions including up to eight participants. The final session includes updating goals, incorporating Fitbits, and providing an updated exercise prescription. Upon program completion, participants will attend monthly webinars and health coaching sessions at 6- and 12-months post-program. The program aims to help individuals overcome barriers and maintain long-term exercise self-efficacy.
40794904|NCT06181838|PROCEDURE|Lesion extraction|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
40794905|NCT06181838|DRUG|Tretinoin|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
40794906|NCT00257946|PROCEDURE|Repair of CDH w/SIS Gold|
40794907|NCT00257946|PROCEDURE|Repair of CDH w/Alloderm|
40794908|NCT02455102|OTHER|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
40794909|NCT04343365|OTHER|Evolutionary Tumor Board (ETB)|The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
40794910|NCT03436901|DIAGNOSTIC_TEST|MRI with DWI vs CT|MRI with diffusion weighted imaging of thorax, abdomen, and pelvis without contrast agent vs. CT of thorax, abdomen, and pelvis with contrast agent
40794911|NCT02895516|DEVICE|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
40794912|NCT03344783|OTHER|PUFA and R-TFA|PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography
40794913|NCT01815424|DRUG|placebo|placebo BID for 16 weeks and then re-randomized into active groups
40794914|NCT01815424|DRUG|CP-690,550|CP-690,550 5mg BID for 52 weeks
40794915|NCT01815424|DRUG|CP-690,550|CP-690,550 10mg BID for 52 weeks
40794916|NCT05177419|DRUG|Lysergic Acid Diethylamide|100 micrograms LSD base
40794917|NCT05177419|DRUG|Lysergic Acid Diethylamide|Low dose of LSD base
40794918|NCT06183151|DEVICE|Entia Liberty System|See arm/group description
40999824|NCT02603432|OTHER|Best Supportive Care|BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
41311843|NCT03373552|DIAGNOSTIC_TEST|Platelet function assay|Platelet function assay
41470579|NCT03788915|BEHAVIORAL|Online dietetic lifestyle counseling|"The certified clinical dieticians provide individual therapy online and offline according to their patients' needs and based on information supplied via the website www.livalife.dk. The dietician generates a daily caloric reduction plan of approximately 1600-4800 KJ based on the patients' diet record. The dietary advice will be standardized and follow the dietary guidelines given at www.livalife.dk and the Danish Health Administration (Sundhedsstyrelsen)."
40794919|NCT03773666|DRUG|Durvalumab|Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
41311844|NCT01316601|DRUG|QAX567|
40794920|NCT03773666|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
40999825|NCT02603432|BIOLOGICAL|Following the planned interim analysis for this study: Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
40999826|NCT03588364|OTHER|Osteopathic Manipulation|Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
40999827|NCT04220411|DRUG|AR100DP1|topical ointment
40999828|NCT02693509|OTHER|GWTG Heart Failure program|Evidence based guideline recommended therapies and counseling prior to hospital discharge
40999829|NCT05069922|OTHER|Fresh Frozen Plasma|Fresh Frozen Plasma
40999830|NCT02563028|DEVICE|SightSaver Visual Stimulator|Evoked response photic stimulator
41311845|NCT06234618|OTHER|visual deprivation|A group of patients walking with eyes open and walking with visual deprivation.
41311846|NCT04217889|OTHER|Questionnaire|Short questionnaire that can be completed during the usual consultation.
40999831|NCT05946538|DIAGNOSTIC_TEST|SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel|The SARS-CoV-2, Influenza and RSV PCR test is multiplex-tandem polymerase chain reaction (MT-PCR) based on qualitive in vitro diagnostic testing for the detection and identification of pathogens in nucleic acid extracts.
40999832|NCT05946538|DIAGNOSTIC_TEST|BioFire Respiratory Panel 2.1|The BioFire Respiratory Panel 2.1 (RP2.1) is a PCR-based multiplexed nucleic acid test intended for use with the BioFire® FilmArray® 2.0 or BioFire® FilmArray® Torch Systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections.
40999833|NCT04682821|OTHER|Artificial intelligence assistant system|The intervention is the use of the artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
40999834|NCT02922270|OTHER|Peritoneal dialysis patients at the Istanbul Medical Faculty|The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
40999835|NCT01339390|BEHAVIORAL|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
40999836|NCT01339390|BEHAVIORAL|MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
40999837|NCT05455983|BIOLOGICAL|covid19 vaccines|different types of (COVID-19) vaccination
40999838|NCT05352828|DRUG|Nivolumab|Dose: 480 mg or 6 mg/kg Q4W
40999839|NCT05352828|DRUG|Autologous CD30.CAR-T|Dose: 2 x 10e8 cells/m2
40999840|NCT05352828|DRUG|Fludarabine|Dose: 30 mg/m2/day x 3 days
40999841|NCT05352828|DRUG|Bendamustine|Dose: 70 mg/m2/day x 3 days
41470580|NCT03788915|BEHAVIORAL|Usual care|Patients randomized to the control group will be offered to receive usual municipal secondary or tertiary preventive offers.
41470581|NCT06617403|OTHER|non|non
41470582|NCT06076941|OTHER|Education|"Before the training was given to the pregnant women in the experimental group who agreed to participate in the study, the Introductory Information Form, the Form for Assessing Pregnant Women's Behaviors Towards Oral and Dental Health, and the Form for Assessing Pregnant Women's Knowledge Levels Towards Oral and Dental Health were applied by face-to-face interview method. The application of the forms took 20-30 minutes. Then, a training time was planned on a suitable date for the pregnant women.~In order to ensure the effectiveness of the training, to answer the questions of the pregnant women effectively and to be able to direct them to the dentist in line with their needs, the training was applied in groups of maximum five people. Lecture, question and answer and demonstration methods were used in the training.~One month after the training, the necessary forms were applied to the pregnant women and the study was terminated."
41470583|NCT05021887|DRUG|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
40999842|NCT02261376|DRUG|DS-1971a|DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
40999843|NCT04534764|DEVICE|etafilcon A with cosmetic pattern|TEST
40999844|NCT04534764|DEVICE|1-Day Acuvue DEFINE Vivid Style|CONTROL
40999845|NCT04916184|OTHER|aerobic exercise|exercise training rehabilitation (aerobic exercise with/without strength training)
40999846|NCT04916184|OTHER|combined exercise|exercise training rehabilitation (aerobic exercise with/without strength training)
41470584|NCT05021887|DRUG|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
41470585|NCT02918331|DRUG|Daratumumab (16 mg/kg)|Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
41470586|NCT02918331|DRUG|Lenalidomide|Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
40999847|NCT02903186|BEHAVIORAL|SMS|This is an intervention using short mobile messages (SMS)
40999848|NCT06060392|DRUG|Semaglutide Pill|Patient will receive oral semaglutide
40999849|NCT03658083|PROCEDURE|Thoracotomy|Open surgery
40999850|NCT03658083|PROCEDURE|Robotic-assisted thoracic surgery|Minimally invasive surgery
40999851|NCT03198377|DEVICE|TENS: Randomized frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: randomized pattern (from 80 to 120 Hz) Pulse width 200 microseconds"
41150566|NCT04685434|OTHER|Shriners Hospital for Children Upper Extremity Evaluation|The interventions are evaluating tools for the functional performance of the upper extremity.
40999852|NCT03198377|DEVICE|TENS: Scan 6/6 of frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: Scan of frequency from 80 to 120 Hz in 6/6 mode (frequency sweep from 80 Hz to 120 Hz in 6 seconds and from 120 to 80 Hz in 6 secons) Pulse width 200 microseconds"
40999853|NCT03198377|DEVICE|TENS: Fixed frequency|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Fixed frequency at 100 Hz Pulse width 200 microseconds"
40999854|NCT03198377|DEVICE|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
40999855|NCT00338910|DRUG|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
40999856|NCT02885155|OTHER|Echocardiography|planned at regular intervals
40999857|NCT02885155|OTHER|Hemodynamic examinations (right cardiac catheterization)|planned at regular intervals
40999858|NCT00112242|BIOLOGICAL|Melan-A ELA + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
40999859|NCT00112242|BIOLOGICAL|Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
40999860|NCT00112242|BIOLOGICAL|Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
40999861|NCT00112242|BIOLOGICAL|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
40999862|NCT00112242|BIOLOGICAL|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
40794921|NCT06411613|OTHER|CC Program|The CC Program will be delivered through the existing HBPC infrastructure at VA Puget Sound Health Care System. Each HBPC team is comprised on a lead physician or nurse practitioner, nurse, pharmacist, nutritionist, social worker, psychologist, therapist, and chaplain. At a minimum, subsequent clinical encounters and assessments for each Veteran will be scheduled no less than on a quarterly basis and more often as needed based on the HBPC team's clinical judgment. On a monthly basis, the entire HBPC team will conduct MDC meetings to review each Veteran's medical plan. The Program aims to provide patient-centered, whole-person and team-based care, shared decision-making, active symptom management, advance care planning and end-of-life care.
40999863|NCT03364296|OTHER|Blood Samples|Blood sample retrieved for biological assessment and biobanking
40999864|NCT05611242|PROCEDURE|MT+CAS with IV-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added intravenous antiplatelet therapy.
40999865|NCT05611242|PROCEDURE|MT+CAS with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy.
40999866|NCT05611242|PROCEDURE|MT+CAT with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy
41150567|NCT01448447|DEVICE|Mammosite ML|34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
41150568|NCT01448447|DEVICE|Mammosite ML|5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
41150569|NCT01365546|BIOLOGICAL|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
40794922|NCT05147753|DRUG|Moxonidine|0.6 mg moxonidine daily
41150570|NCT02739841|OTHER|Ventilator hyperinflation|4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
41150571|NCT02739841|OTHER|Chest physical therapy|The patient will be received vibration and passive of the both upper extremity.
41150572|NCT06585319|DRUG|Collagen-polyvinylpyrrolidone|2 ml intramuscular q24 h
41150573|NCT06585319|DRUG|Pirfenidone 1200 mg|1,200 mg of oral q12 h
41470587|NCT02918331|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
40794923|NCT03673540|BEHAVIORAL|CBT+ application|Smartphone application that comprises electronic self-monitoring of food intake, eating disorder behaviors, and mood and ecological momentary interventions
40794924|NCT06273566|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the AdT-Physio, Brief Cope and GSES questionnaires in random order.
40794925|NCT00486356|DRUG|capecitabine|
40794926|NCT00486356|DRUG|carboplatin|
40794927|NCT00486356|DRUG|epirubicin hydrochloride|
40794928|NCT00486356|GENETIC|microarray analysis|
40794929|NCT00486356|GENETIC|polymorphism analysis|
40794930|NCT00486356|OTHER|pharmacological study|
40794931|NCT02584712|OTHER|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
40794932|NCT05532228|PROCEDURE|Adenotonsillectomy|adenotonsillectomy by cold dissection
40794933|NCT02079909|DRUG|T-817MA-H|224 mg or 448 mg T-817 MA once daily
40794934|NCT02079909|DRUG|T-817MA-L|224 mg T-817 MA once daily
40794935|NCT02079909|DRUG|Placebo|Placebo
40794936|NCT02514291|BEHAVIORAL|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
40794937|NCT02866162|GENETIC|High-throughput exome sequencing|
40794938|NCT00407602|DEVICE|Implant of Argus II Retinal Prosthesis|epiretinal implantation of device
40794939|NCT04895930|DRUG|Furmonertinib|80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).
40794940|NCT04895930|DRUG|Anlotinib|10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).
40794941|NCT00405730|DRUG|Nepafenac 1mg/ml eye drops, suspension|One drop in the study eye 3 times daily for 23 days
40794942|NCT00405730|DRUG|Ketorolac Trometamol 5 mg/ml eye drops, solution|One drop in the study eye 3 times daily for 23 days
40794943|NCT00405730|OTHER|Nepafenac vehicle eye drops|One drop in the study eye 3 times daily for 23 days
40794944|NCT03259243|DRUG|Bupivacaine Hydrochloride|0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
40794945|NCT04635150|BEHAVIORAL|Close Collaboration with Parents|Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
40999867|NCT02767427|DEVICE|Chlorhexidine Wipes|(Standard of Care) Chlorhexidine wipes are a commonly used pre-operative skin cleansing measure, designed to reduce bacterial load on the skin of the surgical site.
40794946|NCT02358993|DRUG|methenamine hippurate|A urinary antiseptic used for prevention of UTI
40794947|NCT02358993|DRUG|Ciprofloxacin|An antibiotic used for treatment and prevention of UTI
40794948|NCT02507596|BIOLOGICAL|Nano-crystalline hydroxyapatite silica gel|it is a type of synthetic bone graft.
40794949|NCT02507596|PROCEDURE|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
40794950|NCT05299177|DEVICE|InControl|Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
40794951|NCT00386620|BEHAVIORAL|Questionnaire|45 minute survey about health, pain and relationships
40794952|NCT00386620|BEHAVIORAL|Interview|Feedback on use of handheld computer electronic diaries (ED).
40794953|NCT00402324|DRUG|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
41470588|NCT04134754|OTHER|6% Carbon dioxide/50% oxygen/balance nitrogen mixture|In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you
41470589|NCT02084927|BIOLOGICAL|HBOT|HBOT of 2 ATA for 90 minutes, for 60 treatments
40794954|NCT00402324|DRUG|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
40794955|NCT00402324|DRUG|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
40794956|NCT05050292|OTHER|Personalized cognitive stimulation|"Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity."
40794957|NCT05050292|OTHER|Sham cognitive stimulation|"Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game."
40794958|NCT00581022|PROCEDURE|Polysomnography|Overnight Sleep Study
40794959|NCT02059629|DEVICE|Eluna pacemaker family|"New pacemaker generation with new functions, like wandless RF telemetry SafeSync"
40794960|NCT02059629|DEVICE|Sentus BP lead|over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
40794961|NCT02163577|BIOLOGICAL|burosumab|solution for SC injection
40794962|NCT02011568|OTHER|Therapeutic Hypothermia|
40794963|NCT03360682|DRUG|Lamivudine 300 MG|Lamivudine 300 MG/day (48 weeks)
40794964|NCT03360682|DRUG|Abacavir 600 MG|Abacavir 600 MG/day (48 weeks)
40794965|NCT03360682|DRUG|Dolutegravir 50 mg|Dolutegravir 50 MG/day (48 weeks)
40794966|NCT03360682|DRUG|Tenofovir Disoproxil 245Mg Tablet|Tenofovir 245 MG/day (48 weeks)
41470590|NCT04286919|BEHAVIORAL|A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students|A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
41470591|NCT05393323|OTHER|conventional physical therapy with distraction technique|Distraction will be at suboccipital level and patients will ask to assume a supine position with the head on the plinth. The therapist will use fingertips in both hands from digits 2 through 5, and cups the suboccipital region of the patient and supports the posterior skull. The therapist provides a light distraction to the posterior skull. Distraction will be applied for 10 min with pull for 10 sec and5 sec will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 minute with total intervention period of 4 weeks with 5 sessions per week.
41470592|NCT05393323|OTHER|conventional physical therapy with traction technique|In cervical traction, patients will ask to lie supine on the treatment table. Head will cradle by physiotherapist from chin and the occiput, and then the physiotherapist will apply traction force in 25 degree neck flexion. Traction will be applied for 10 minutes with pull for 10 sec and 5 sec rest will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 min with total intervention period of 4 weeks with 5 sessions per week. All outcome measurements will be assessed before treatment and then reassessed at the end of 4th week.
41470593|NCT05487560|DRUG|Esomezol Cap|Esomezol Cap, Once daily administered per the locally approved product information
41470594|NCT03068845|DEVICE|Drug-eluting balloon angioplasty (DEBA)|"DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
40794967|NCT03360682|DRUG|Emtricitabine 200 MG|Emtricitabine 200 MG/day (48 weeks)
40794968|NCT00986791|OTHER|GSP-A|6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)
40794969|NCT01899131|DEVICE|platform-switch tapered internal implants|Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
40999868|NCT02767427|OTHER|No intervention|Chlorhexidine wipes will not be used though it is a commonly used pre-operative skin cleansing measure.
40999869|NCT02948491|OTHER|Music therapy|Song that the mother sings to the child before birth, recording of the mother's voice.
40999870|NCT00907374|DRUG|benazepril|benazepril 10 mg orally once daily
41470595|NCT03068845|DEVICE|Conventional Balloon Angioplasty (CBA)|"CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
41470596|NCT04886557|PROCEDURE|L4-L5 decompression and dynamic instrumentation|All surgeries were performed by a senior surgeon using a traditional midline approach. Stability-preserving lumbar decompression with facet joint undercutting was performed to preserve the facet joints as much as possible. In cases of severe stenosis, a bilateral partial facetectomy (\< 25%) was performed for adequate decompression. Posterior tension of the supra- and inter-spinous ligaments was preserved at the most cranial level. Patients were encouraged to ambulate after drain removal and wear a soft lumbar orthosis for at least 3 months after the operation.
41470597|NCT00985231|DEVICE|PureVision Multi-Focal contact lenses|Contact lenses to be worn on a daily wear basis for 2 weeks.
40999871|NCT00907374|DRUG|benazepril|40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
41470598|NCT00985231|DEVICE|SofLens59 contact lens|Contact lenses to be worn on a daily wear basis for 2 weeks.
41470599|NCT06365684|DRUG|Sodium zirconium cyclosilicate|In the case of hyperkalemia patients will be treated with Sodium zirconium cyclosilicate to allow the continuation of potassium enriched diet. In case hyperkalemia arises in the control group, patients will be treated with Sodium zirconium cyclosilicate as well.
40794970|NCT00808522|DRUG|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
40794971|NCT04963023|OTHER|Physical examinations|BPCO physical examinations
41150574|NCT03293147|OTHER|HPLC-MS/MS-guided intervention|The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
41150575|NCT03293147|OTHER|Standard care|Standard care for hypertensive patients
40794972|NCT04963023|DIAGNOSTIC_TEST|blood test|blood test in order to study immunologic markers
40999872|NCT06394869|DIAGNOSTIC_TEST|Cxbladder Detect+|Cxbladder Detect+ is a lab developed, test that is using RNA and DNA biomarkers in the urine to assess the likelihood of the presence of urothelial carcinoma in the bladder.
41150576|NCT00155662|BEHAVIORAL|work-hardening program|
40999873|NCT05714488|DEVICE|blue halo coil catheter|device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
41150577|NCT00092378|DRUG|MK0966, rofecoxib|
41150578|NCT00092378|DRUG|Comparator: diclofenac sodium, placebo|
40794973|NCT04118075|DRUG|PT-CY-FK +/-ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
40794974|NCT04716686|DRUG|Niraparib|Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.
41470600|NCT02618226|DEVICE|Optic nerve ultrasound|Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
40794975|NCT05340946|PROCEDURE|general anaesthesia|intraoperative general anaesthesia followed by postoperative IV patient analgesia
40794976|NCT05340946|PROCEDURE|spinal anaesthesia|patient received spinal followed by continuous ultrasound guided femoral never block.
40794977|NCT04565912|DRUG|Sage extract mouthwash|Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.
40794978|NCT04565912|DRUG|Chlorohexidine based mouthwash|Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
40794979|NCT01971671|OTHER|no intervention.|
40794980|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
40794981|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
40794982|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
40794983|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
41150579|NCT03979144|BEHAVIORAL|Observational study|This was an observational study of a medical device, through the usability assessment, for the registration of a self-test for the immunodeficiency virus (HIV) screening.
41470601|NCT06204575|OTHER|Data collection|Data collection
41470602|NCT06331117|DIAGNOSTIC_TEST|Diagnostic test|Multiomics profiling
41470603|NCT06617117|OTHER|High-intensity combined exercise|The main part consisted of interval cycling exercise, comprising 5x2 min at the second ventilatory threshold interspersed with 4x2 min at the first ventilatory threshold, followed by 2-min unloading pedalling. Subsequently, participants completed resistance exercises (2 sets of 12 repetitions), targeting the same muscle groups of the moderate-intensity exercise, at an intensity of 80% of their 1 repetition maximum.
41470604|NCT06617117|OTHER|Moderate-intensity combined exercise|The main part of the exercise session consisted of an 18-min cycling continuous aerobic exercise at the first ventilatory threshold, followed by 2-min of unloading cycling. Subsequently, participants engaged in resistance exercises - 2 sets of 12 repetitions at 60% of their one repetition maximum. These resistance exercises were part of a machine-assisted circuit training program, encompassing Chest Press, Leg Curl, Low Row, Leg Press, Lat Pull-down, and Leg Extension.
41470605|NCT05058560|DRUG|Tislelizumab|tislelizumab, 200 mg IV Q3W, up to one year.
41470606|NCT05321823|DEVICE|iBreast device|The iBreast (iBE) device is an automated, battery powered, portable device designed to be used by community health nurses as a screening and triage tool. The iBE is designed to be used by a community health worker or lay person after appropriate training. In resource-limited settings, it potentially provides an easily accessible, low-cost method to assess the breast for findings that warrant further evaluation.
41470607|NCT05321823|OTHER|Clinical Breast Examination|The standard clinical breast examination (CBE) will be performed by the community health nurses in the selected primary health care centers where patients will present for screening or diagnostic workup in the intervention community
41470608|NCT05321823|DIAGNOSTIC_TEST|Breast ultrasound|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have ultrasound with or without ultrasound-guided breast biopsy if indicated by the radiologist using portable ultrasound tablets that will be brought to the intervention community.
41470609|NCT05321823|DIAGNOSTIC_TEST|Mammography|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have mammography done using a mobile mammography van that will be brought to the intervention community.
41470610|NCT06123481|PROCEDURE|Core Decompression|Standard core decompression procedure is performed by drilling into the necrotic bone of the femoral head. A sham bone marrow aspiration involves advancing a needle to the iliac crest (no bone penetration, no bone marrow aspiration) through a small skin incision.
41470611|NCT06123481|PROCEDURE|Core Decompression Procedure with Autologous Bone Marrow Aspirate Concentrate|This involves bone marrow aspiration, concentrating the bone marrow aspirate, and injecting 6 milliliters of bone marrow aspirate concentrate into the necrotic femoral head through an opening created by the core decompression.
41470612|NCT02193607|PROCEDURE|TVT-O|Artificial mesh belt is placed in the middle urethra to provide support to remain no leak
41470613|NCT02193607|PROCEDURE|Improved reconstruction pelvic surgery|Repair of severe pelvic organ prolapse with mesh.
41470614|NCT04407832|DEVICE|heat probe or hemoclip|for hemostasis
41470615|NCT04407832|DEVICE|heat probe or hemoclip|for hemostasis
41470616|NCT03090490|OTHER|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients
41470617|NCT03090490|OTHER|Maintenance treatment discontinuation|Maintenance antipsychotic medication to stabilized patients
41470618|NCT03471988|DRUG|AK1820|"Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557"
41470619|NCT03471988|DRUG|Voriconazole|"Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible.~Other Name : VFend"
41470620|NCT03134430|OTHER|Normal saline|Injection of Normal saline around peripheral nerve
41470621|NCT03134430|OTHER|peripheral Nerve block|Injection of local anesthetics around peripheral nerve
41470622|NCT05854706|DEVICE|Theta Burst Stimulation|Theta Burst Stimulation
41470623|NCT01566526|DRUG|dexamethasone intravitreal implant 0.7 mg|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
41470624|NCT00959322|DEVICE|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
41470625|NCT03010618|OTHER|Hall technique stainless steel crowns|Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
41150580|NCT01148017|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
41150581|NCT03803488|DEVICE|DropSafe safety pen needle|
41470626|NCT01812629|OTHER|Experimental Infant Formula|Infant formula to be fed ad libitum
41470627|NCT06475625|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
41470628|NCT06475625|DEVICE|Orsiro™ or Orsiro_Mission™ stent|Percutaneous coronary intervention with Orsiro™ or Orsiro_Mission™ stents
41470629|NCT05612139|DEVICE|JTIN implantation surgery|The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.
41470630|NCT06226077|BEHAVIORAL|sleep extension intervention|The sleep intervention aims to increase sleep duration by one-hour (15 minutes/week) over the course of 4-weeks using components from Cognitive Behavioral Therapy for Insomnia. More specifically, the intervention consists of psychoeducation, sleep extension, sleep hygiene, and stimulus control. Participants will meet with Dr. Wu or a trained staff member once a week over the course of 4-weeks via Zoom. The intervention will be adapted based on feedback from the community, knowledge gained during previous interviews.
41470631|NCT06226077|BEHAVIORAL|contact control intervention|The control condition is a contact-control intervention whereby participants will meet with Dr. Wu or a trained staff member once-week over the course of 4-weeks to receive education materials from the Healthy Homes intervention developed by the UT School of Public Health.
41470632|NCT00942331|BIOLOGICAL|Bevacizumab|Given IV
40794984|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg on the day prior to angiography
40794985|NCT00693069|DRUG|Clopidogrel|clopidogrel 600 mg on the day prior to angiography
41150582|NCT06264661|BEHAVIORAL|Effect of Cognitive Behavioral Therapy with Phototherapy in glycated hemoglobin, CLOCK genes and quality of life in patients with type 2 diabetes mellitus and insomnia|Clinical, quasi-experimental, pre-post, explanatory, non-probability sampling. Subjects were invited to participate in Hospital Juárez de México. They received eight sessions of Cognitive Behavioral Therapy in combination with phototherapy. The assessment was carried out with validated instruments for Mexican population and gene expression was evaluated by real-time PCR.
41470633|NCT00942331|DRUG|Cisplatin|Given IV
41470634|NCT00942331|DRUG|Gemcitabine Hydrochloride|Given IV
40794986|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
40794987|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
40794988|NCT00529243|DRUG|raltegravir|This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
40794989|NCT05238272|DEVICE|Transcranial random noise stimulation (tRNS)|There will be 20 minutes of stimulation (real tRNS or sham tRNS), 40 minutes of MT (unilateral or bilateral) and 30 minutes of functional task training.
40794990|NCT05238272|DEVICE|sham tRNS|the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds
40794991|NCT05238272|BEHAVIORAL|the unilateral MT|For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task.
40794992|NCT05238272|BEHAVIORAL|the bilateral MT|For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task. The activities practiced during MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen).
41470635|NCT00942331|OTHER|Laboratory Biomarker Analysis|Correlative studies
41470636|NCT00942331|OTHER|Placebo Administration|Given IV
41470637|NCT00311649|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|
41470638|NCT00030407|DRUG|Celecoxib|On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
41470639|NCT00030407|DRUG|Docetaxel|On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
41470640|NCT03348488|PROCEDURE|Ultrafiltration dose|Fixed high volume of ultrafiltration over an hour during dialysis
41470641|NCT05736484|BEHAVIORAL|Social Support Gamification|Participants sign a pre-commitment contract agreeing to try their best to achieve their daily step goal. Over the 26-week intervention period, participants are endowed 70 points (10/day) weekly and informed they will lose 10 points each day goal is not met. Points are replenished at start of each week. At the end of each week, if the participant has 40 points or more, they will advance a level, or drop a level if they have less than 40 points. The levels include blue (lowest), bronze, silver, gold, platinum (highest). Participants select a family member or friend as a support partner to receive weekly email on participants' progress (points, game level, and average step count). Participants will also work with a virtual health coach by attending group sessions organized by them with other participants through video calls once a month to discuss ways to motivate participants to increase their physical activity.
40794993|NCT02610972|DEVICE|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
40999874|NCT06248320|PROCEDURE|Sigh ventilation|Sigh breaths were delivered from intubation to extubation. Intervention primarily conducted in the following three stages: 1. From intubation to surgical opening of the chest cavity; 2. From the surgical closure of the chest cavity close and continue unit the operating room exiting; 3. From Intensive Care Unit (ICU) arrival to Spontaneous breathing trial (SBT) start.
40999875|NCT03675490|BEHAVIORAL|ABLE - exercise with interactive technology|Multicomponent exercise with interactive technology - consists of wearable sensors and a screen displaying interaction. When the person does the exercises it produces an arts-based response on the screen (e.g., digital painting).,
40999876|NCT05683119|OTHER|Exercise and blood draw|This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle \[MC\] and oral contraceptive pill \[OCP\] use, on aspects of exercise physiology and athletic performance in female athletes. This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes. The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
40999877|NCT00424151|DRUG|Rituximab|
40999878|NCT00006347|RADIATION|indium In 111 monoclonal antibody MN-14|
40999879|NCT00006347|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
41150583|NCT01239225|DEVICE|Abdominal ultra-sound|
41150584|NCT01239225|PROCEDURE|Abdominal ultrasound|
41311847|NCT04914078|DRUG|Mepolizumab 100 MG|The patients will treated with subcutaneous Mepolizumab at 100 mg every 30 days. Patients will be recruited among those eligible to Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco) guidelines who will accept to participate to the study. In particular inclusion criteria will be: severe (Step 4 and 5 GINA) asthma with at least blood eosinophilic count above 300 cells/mcl at least once in the previous year and ≥150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation. In addition, one of the following conditions will be required: 1) ≥2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year.
41470642|NCT04030663|DRUG|papaverine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
41470643|NCT04030663|DRUG|nitroglycerine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
41470644|NCT04030663|DRUG|xlyocaine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
41470645|NCT00668096|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
41470646|NCT00668096|DRUG|Placebo|Matching Placebo
41470647|NCT04437888|DRUG|Ketamine|Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers
41470648|NCT00144079|PROCEDURE|external beam radiotherapy|
41470649|NCT06616792|COMBINATION_PRODUCT|Dexamethasone phonophoresis|Ultrasound therapeutic device with the use of 0.4% Dexamethasone sodium phosphate gel for phonophoresis.
41470650|NCT06616792|DEVICE|Laser Acupuncture|low level laser therapy placed in contact with the skin perpendicular over the body acupoints (LI 4) - (LI 20) - (EX- HN5) - (GV 20) - (GV 24) - (ST3) - (ST 7) in both sides and on (EX-HN3) acupoint,
41470651|NCT06616792|OTHER|Traditional medication|Each participant in this group receive the traditional medication.
41470652|NCT00932594|PROCEDURE|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
41470653|NCT00932594|OTHER|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
41470654|NCT00412204|DRUG|tiotropium bromide|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
41470655|NCT00412204|OTHER|Placebo|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
41470656|NCT02101788|DRUG|Letrozole|Given PO
41470657|NCT02101788|DRUG|Paclitaxel|Given IV
41470658|NCT02101788|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
41470659|NCT02101788|OTHER|Quality-of-Life Assessment|Ancillary studies
41470660|NCT02101788|OTHER|Questionnaire Administration|Ancillary studies
41470661|NCT02101788|DRUG|Tamoxifen Citrate|Given PO
41470662|NCT02101788|DRUG|Topotecan|Given IV
41470663|NCT02101788|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
41470664|NCT04045808|OTHER|radiographic evaluations were done|For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.
41470665|NCT05889273|DRUG|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
40999880|NCT00563238|DRUG|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
40999881|NCT03932396|OTHER|Observational study|No intervention is planned outside of usual clinical practice. Only active screening for hepatotropic virus infection, mainly hepatitis C virus, HIV, and mental illness will be carried out. If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
41470666|NCT01965626|DRUG|Oseltamivir|Oseltamivir 75 mg twice per day, 10 consecutive days
41470667|NCT01965626|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
41470668|NCT04004845|DRUG|Cytotec|Misoprostol 25mcg vaginal
41470669|NCT04004845|DRUG|oxytocin|Oxytocin 10 IU/ml Solution for infusion
41470670|NCT04004845|DEVICE|Cervical Foley Balloon|Cervical Foley will be inflated to 80cc
41470671|NCT00707434|DEVICE|Guardian® blood-sugar monitoring device|The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
41470672|NCT05069233|OTHER|UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
41470673|NCT05483387|DEVICE|Treatment with HBS 2 Resorb Mg|Treatment of fractures, arthrodesis or pseudarthroses of small bones and bone fragments
41470674|NCT05583526|DRUG|Ritlecitinib|50 mg capsule
41470675|NCT05583526|DRUG|Placebo|Matching capsule
41470676|NCT01921231|DRUG|Hyperbaric Prilocaine 1%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
41470677|NCT01921231|DRUG|Hyperbaric bupivacaine 0.5%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
41470678|NCT06396507|DRUG|Permethrin Solution|permethrin 5 % solution
41470679|NCT06396507|DRUG|Sulfur|Sulfur 10%+ vaseline 90 % ointment
41470680|NCT01682642|DRUG|Zoladex|after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
41470681|NCT00752284|PROCEDURE|Coronectomy|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
41470682|NCT00752284|PROCEDURE|Total Excision|Total excision of lower third molar
41311848|NCT04423614|OTHER|Inspiratory Muscle Training|Inspiratory muscle training exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
41311849|NCT04423614|OTHER|Relaxation Breathing|Relaxation breathing exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
41311850|NCT01821820|OTHER|Pistachios|
41311851|NCT03510611|DRUG|Ensartinib with fed or fasting|The two groups of subjects were given an equal dose of Ensartinib capsules (225 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of Ensartinib.
41311852|NCT01953536|DRUG|Vintafolide 2.5 mg|During treatment, participants receive IV vintafolide 2.5 mg.
41311853|NCT01953536|DRUG|Paclitaxel 80 mg/m^2|During treatment, participants receive IV paclitaxel 80 mg/m\^2.
41311854|NCT01953536|DRUG|Etarfolatide|During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
41311855|NCT01953536|DRUG|Folic acid|During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
41311856|NCT01953536|DRUG|Premedication for Paclitaxel|During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
41311857|NCT04050098|DRUG|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
41311858|NCT04050098|DRUG|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
41311859|NCT04348591|BEHAVIORAL|Cognitive Restructuring|All participants will learn how to change their thinking in order to be less upset when confronted with stressors
41311860|NCT04348591|DEVICE|neurostimulation|all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions
41311861|NCT02476357|DEVICE|Harmonic scalpel|
40999882|NCT04985630|DIETARY_SUPPLEMENT|Mitopure|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
40999883|NCT04985630|DIETARY_SUPPLEMENT|Pomegranate Juice|100% Pomegranate juice
40999884|NCT05426837|BEHAVIORAL|Combatting Social Isolation|A brief, computerized psychoeducational intervention designed to target ways to cope with and address loneliness and social isolation in older adults modeled after our group's previous Building Stronger Allies (BSA) intervention.
40999885|NCT05426837|BEHAVIORAL|Health Education Training|Control condition where participants learn about healthy lifestyle behaviors.
40999886|NCT02694315|OTHER|Bishop score|calculation of modified Bishop score in numbers by digital vaginal examination
41311862|NCT01441921|DIETARY_SUPPLEMENT|Pistachios|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
41311863|NCT01441921|OTHER|control diet|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
41311864|NCT03025334|DEVICE|High-definition transcranial direct current stimulation|brain stimulation to increase neuronal excitability in the targeted regions
41311865|NCT05238961|DRUG|[18F]DPA-714|Investigational PET Tracer \[18F\]DPA-714
41311866|NCT01520415|DRUG|Bupivacaine|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
41311867|NCT01520415|DRUG|Saline|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
41311868|NCT04569331|PROCEDURE|Stimulation of efferent loop|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened.~This procedure consists of introducing through the light efferent loop ileostomy 250 ml of water with thickener every 48-hours during the first two weeks and once daily the thrid week with a Foley catheter. Patient will be provided with all the material and the procedure sheet for all the stimulation of the efferent loop sessions. This technique will be performed at patient's home until the day before the ostomy patient closure surgery."
41311869|NCT04569331|PROCEDURE|Rehabilitation pelvic floor|3 months after the closure of the ileostomy, you will be referred to the pelvic floor rehabilitation unit,where will start 15 individual sessions, 2 days a week (8 weeks of sessions), with reeducation of defecatory habits and hygienic-dietary measures, defecation record where assess stool consistency using the Bristol Scale and number of bowel movements that take place in 24 hours, muscle toning exercises (Exercises Kegel), Biofeedback (BF), rectal balloon work to improve sensitivity and accommodation, reeducation of the expulsive maneuver, and perineal block in situations hyperpressive.
41311870|NCT03488914|BEHAVIORAL|YMHP Intervention|
41311871|NCT03488914|BEHAVIORAL|Enhanced Treatment as Usual|
40999887|NCT02694315|OTHER|cervical length|measuring cervical length by trans-vaginal ultrasound
40999888|NCT04242888|OTHER|pragmatic manual therapies|three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.
40999889|NCT04444596|DIAGNOSTIC_TEST|Conjunctival swab and nasopharyngeal swab|Both conjunctival swab and nasopharyngeal swab for SARS-COV 2 are conducted in patients with COVID-19.
40999890|NCT04055688|DEVICE|Orbeye surgical videomicroscope|The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
40999891|NCT04055688|DRUG|5-Aminolevulinic Acid|5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
40999892|NCT06496841|DRUG|Transnasal Sphenopalatine ganglion block|The transnasal approach to the sphenopalatine ganglion block allows for non-invasive access to the sphenopalatine ganglion, which is located deep in the nasopharynx in a recess posterior to the middle turbinate. A long cotton swab is inserted posterior to the nasopharynx until it is properly seated, and 2 mL of 2% lidocaine is injected through the outer end of the swab and left for 30 minutes. Patients are monitored for any potential complications or adverse effects throughout the procedure and for a period of time afterwards.
41311872|NCT05100654|DRUG|Doxycycline|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
41311873|NCT05100654|DRUG|Ciprofloxacin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
41311874|NCT05100654|DRUG|Augmentin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
41311875|NCT05100654|DRUG|Bactrim|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
41311876|NCT05275738|DIETARY_SUPPLEMENT|Nicotinamide|Study tablets for nicotinamide are produced by Blackmores Ltd.
41311877|NCT05275738|OTHER|Placebo|Study tablets for placebo are produced by Blackmores Ltd.
41311878|NCT03378726|DIETARY_SUPPLEMENT|Micronutrients|Micronutrient powder is the current supplement provided by the Colombian Ministry of Health and Social Protection to children between 1 and 5 years of age.
41311879|NCT03378726|BEHAVIORAL|SPOON Group Counseling|SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.
41311880|NCT03378726|BEHAVIORAL|Interpersonal Counseling|SPOON interpersonal counseling is an innovative behavior change strategy in which participants will learn information via one-on-one sessions with the instructor.
40999893|NCT06496841|DRUG|Ultrasound-guided suprazygomatic sphenopalatine ganglion block|The ultrasound transducer is placed in the infrazygomatic area, above the maxilla, at approximately a 45 cephalad angle. With this transducer position, the ptrigopalatine fossa, bounded anteriorly by the maxilla and posteriorly by the pterygoid process, is visualized. A 25 gauge spinal needle is inserted 1 to 1.5 cm above the zygomatic arch and posterior to the posterior orbital rim and advanced through an out-of-plane approach to reach the pterigolapalatine fossa. After the aspiration test, 3 mL of 2% lidocaine is injected and the spread of the drug is monitored by ultrasound. Patients are monitored for possible side effects and complications.
40999894|NCT03476304|DEVICE|Endocrown restoration|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with resin composite in a cast and cemented with self adhesive cement
41311881|NCT03378726|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.
41311882|NCT03378726|BEHAVIORAL|Standard Counseling|Standard counseling refers to the counseling currently provided by health personnel to women and children in the selected intervention area of Colombia
41311883|NCT03682510|PROCEDURE|stepwise devascularization|stepwise devascularization begins with suture the placenta bed through uterine artery ligation, internal iliac artery ligation etc
41311884|NCT03682510|PROCEDURE|B-Lynch Transverse Compression Suture group|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side. After encircling the para-uterine vasculature, the needle then perforates the posterior side of the uterus behind the vascular bundle entering the uterine cavity."
41311885|NCT03682510|PROCEDURE|N&H sandwich technique|In the N\&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade.
41311886|NCT00426517|DRUG|Campath 1H|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days
41311887|NCT00426517|DRUG|Busulfan|Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder
41311888|NCT00426517|DRUG|Horse Anti-human Thymocyte Globulin (h-ATG)|Conditioning with h-ATG 40 mg/kg total dose over 4 days given intravenously
41311889|NCT00426517|DRUG|Total Body Irradiation (TBI)|TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder
41311890|NCT00426517|DRUG|Sirolimus or equivalent based on response|post Transplantation immunosuppressants
41311891|NCT02704676|OTHER|marker(CA-125)|measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
41311892|NCT04946019|COMBINATION_PRODUCT|Unity-based MR-Linac guided FSRT|The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.
41311893|NCT00607438|DRUG|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
41311894|NCT00607438|DRUG|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
41311895|NCT01669811|DRUG|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
41470683|NCT05612087|DEVICE|Confocal laser endomicroscopy|Confocal laser endomicroscopy at jejunum, duodenum and stomach
40999895|NCT03476304|DEVICE|Post retained composite restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a semi direct composite restoration will be cemented with self adhesive cement.
40999896|NCT03476304|DEVICE|Post retained ceramic restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a ceramic restoration will be cemented with self adhesive cement.
40999897|NCT01256112|BEHAVIORAL|Parent Supported Behavioral Intervention|Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.
40999898|NCT01256112|BEHAVIORAL|Nutrition/Activity Education (NAE)|
40999899|NCT01936935|OTHER|Low-fat dairy|2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
40999900|NCT01936935|OTHER|Sugar-sweetened beverages|2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
40999901|NCT05130203|BEHAVIORAL|MouvMat Exergaming|Sessions engaging with exergaming device.
40999902|NCT05130203|BEHAVIORAL|Standard Recreational Programming|Conducted by recreational therapists.
40999903|NCT01505127|DRUG|TAK-438|
41311896|NCT01669811|DRUG|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
41311897|NCT04143672|DEVICE|Electronic digital pressure algometer|"Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer."
41311898|NCT04143672|DIAGNOSTIC_TEST|Pain sensitivity questionnaire|Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
41311899|NCT04336592|BEHAVIORAL|Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)|Gathers patient preferences for non-pharmacological pain management strategies through medical record and inform clinicians (via prompts, orders, etc.) of these preferences and encourages conversation about these preferences throughout their routine pre- and post-surgical interactions with patients. Resources will be provided to bedside clinicians as they assist patients in identifying a personalized post-discharge pain management strategy.
41470684|NCT01118845|DRUG|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
41470685|NCT01118845|DRUG|Rituximab|The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
41470686|NCT00298740|DEVICE|Aventis U-400 Insulin|
41470687|NCT01332721|DRUG|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
40999904|NCT01505127|DRUG|Lansoprazole|
40999905|NCT01505127|DRUG|Amoxicillin|
40999906|NCT01505127|DRUG|Clarithromycin|
40999907|NCT01188694|DRUG|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
40999908|NCT01188694|BEHAVIORAL|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
40999909|NCT01188694|BEHAVIORAL|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
41470688|NCT05105659|DIAGNOSTIC_TEST|Wechsler IQ for Adults|IQ test that measures the cognitive functions and intelligence using a scale and consists of many subtests assessing verbal and non-verbal performance.
40999910|NCT02488681|DEVICE|Micra Pacemaker Implant|
40999911|NCT04078828|PROCEDURE|Pelvic floor Reconstruction|Pelvic floor Reconstruction after laparoscopic anterior resection and double-stapling technique anastomosis were finished.
40999912|NCT03179150|DIAGNOSTIC_TEST|Computed Tomography|CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
40999913|NCT00881192|PROCEDURE|IABP|preoperative IABP placement
40999914|NCT01959620|BEHAVIORAL|1-Session Exposure Therapy|One exposure therapy session lasting one hour
40999915|NCT01959620|BEHAVIORAL|3-Session Exposure Therapy|Three exposure therapy sessions lasting one hour each, delivered one week apart
40999916|NCT05085977|BIOLOGICAL|TARA-002|Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.
41150585|NCT05555121|DRUG|Progesterone Effervescent Vaginal Tablet|On the day of Frozen Embryo Transfer (FET), women will have a blood test to determine progesterone levels. Depending on the result of progesterone level, the participant will be assigned to either the Endometrin 100 mg TID dose or the Endometrin 200 mg TID dose
41150586|NCT00329186|DRUG|desvenlafaxine SR|
41150587|NCT00329186|DRUG|venlafaxine ER|
41150588|NCT04503889|DEVICE|Transauricular electrical vagal nerve stimulation|transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.
41150589|NCT04503889|DEVICE|taVNS sham|ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)
41311900|NCT01366066|DEVICE|Transcutaneous mechanical nerve stimulation|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
41470689|NCT05105659|DIAGNOSTIC_TEST|MAS (Memory assessment scale)|tool that uses verbal and the visual tasks to assess memory, recall and cognition. The MAS consists of 12 subtests based on the following 7 memory tasks: Verbal Span, List Learning, Prose memory, Visual Span, Visual Recognition, Visual Reproduction and Names-Faces.
41470690|NCT05105659|DIAGNOSTIC_TEST|Health-Related Quality of Life (HRQoL)|measures multiple aspects of the individual's life and the impact of the disease and treatment on the individual's life. It does so by assessing the individual's own views and perspective of the care and treatment they are receiving and whether consider it satisfactory or not.
41470691|NCT05105659|DIAGNOSTIC_TEST|Symptom check list 90|a well-known scale that is used to identify and assess psychological symptoms. It consists of a 90-item checklist having a 5-point rating scale.
41470692|NCT05105659|DIAGNOSTIC_TEST|Socioeconomic level|scale for measurement of socioeconomic status in health research in Egypt. The new socioeconomic status scale has 7 domains with a total score of 84. Intra-and inter-observer variability and the internal consistency of the scale were assessed.
41470693|NCT03988101|DRUG|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
41470694|NCT03988101|DRUG|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
40794994|NCT05561933|BEHAVIORAL|Healthy Minds Program Foundations Training|"The HMP was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on decades of research on well-being. The program is delivered through a smartphone application and consists of didactic (learns) and experiential (practice) components. Practice components involve contemplative practices such as mindfulness, loving-kindness, and gratitude practices. Each practice allows participants to choose duration (between 5-30 minutes). In addition to sitting style practices common in other meditation apps/programs, the HMP also provides instruction in active practices. Active practices engage the same skills as sitting practice, but focus on strengthening skills during daily routines. Learn components provide psycho-educational content about the science of well-being. HMP learns and practices are based on a four pillar model of well-being skills consisting of Awareness, Connection, Insight, and Purpose."
40794995|NCT05272722|DIAGNOSTIC_TEST|ECG,|Holter monitoring
40794996|NCT03320837|DIETARY_SUPPLEMENT|Infant formula|Breast milk substitute containing synbiotics
41470695|NCT04373382|BEHAVIORAL|Peer Resilience Champion|PRC is supplied to everyone and provides support to hospital staff during the COVID-19 pandemic in a stepped-wedge design.
41470696|NCT04373382|BEHAVIORAL|Enriched Survey Feedback|This intervention provides feedback based on answers to questionnaires to those in the Enriched Feedback arm of the study.
41470697|NCT02240186|DEVICE|Microprocessor Knee (MPK)|MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.
41470698|NCT02240186|DEVICE|Non-Microprocessor Knee (NMPK)|A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
41470699|NCT02105155|DRUG|Conversion at day 7 ± 3 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
41470700|NCT02105155|DRUG|Conversion at day 90±5 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
41470701|NCT02012231|DRUG|PLX8394|PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
41470702|NCT06616779|DEVICE|GlucoTab|Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal insulin algorithm is to maintain blood glucose (BG) within acceptable targets according to the predefined health status. For a limited time period after therapy start, three BG measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status. Nurses and nursing assistants will be trained in the use of the GlucoTab system.
41470703|NCT06616779|OTHER|Diabetes Treatment|Diabetes Standard Care
41470704|NCT01877460|OTHER|Dietary intervention|All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
40794997|NCT03320837|OTHER|Breast milk|Breast milk
41311901|NCT05662306|DRUG|Aripiprazole Lauroxil|1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.
41311902|NCT05662306|BEHAVIORAL|Computerized cognitive and functional skills training|Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.
41311903|NCT06504329|PROCEDURE|MCAT + subepithelial connective tissue graft|After the tunnel is prepared using the MCAT technique, a connective tissue graft harvested from the palate will be placed into the tunnel with guiding sutures and secured in place. The flap will be advanced coronally to cover the connective tissue, ensuring primary closure.
41470705|NCT05528861|DRUG|Lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
41470706|NCT05528861|OTHER|Placebo|Placebo
40794998|NCT00691457|DEVICE|Opti-Free contact lens solution|Solution
40794999|NCT00691457|DEVICE|ReNu Multiplus contact lens solution|Solution
40795000|NCT00691457|DEVICE|Clear Care contact lens solution|Solution
41470707|NCT03647124|DRUG|Lenalidomide|Specified dose on specified days
41470708|NCT01103479|BEHAVIORAL|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
40999917|NCT06164132|OTHER|Evaluation|Evaluation through PCOS Phenotypes, measurements of Body weight, height, waist and hip circumferences, Dual-energy X-ray absorptiometry, and Sonographic examination.
40999918|NCT02213211|DRUG|Artemether lumefantrine|
40999919|NCT06108505|OTHER|Lacticaseibacillus with oats|Subjects will receive 7.5 gr of oats containing Lacticaseibacillus
40999920|NCT06108505|OTHER|Plain oats|Subjects will receive 7.5 gr of plain oats
40999921|NCT03461224|RADIATION|accelerated hypofractionated RT|
40999922|NCT03461224|RADIATION|conventional fractionated RT|
41311904|NCT06504329|PROCEDURE|MCAT + enamel matrix derivate|Participants in the Experimental groups will receive Emdogain as part of the treatment protocol. Emdogain will be applied in gel form with a dosage of 0.15 ml. It will be administered in conjunction with the modified coronally advanced tunnel (MCAT) technique. Emdogain will be used as an enamel matrix derivative to promote periodontal tissue regeneration.
41311905|NCT06504329|PROCEDURE|MCAT + subepithelial connective tissue graft + enamel matrix derivative|As part of the treatment protocol, participants will receive Emdogain in addition to the connective tissue graft. Emdogain will be applied in gel form at a dosage of 0.15 ml. It will be used in conjunction with the Modified Coronally Advanced Tunnel (MCAT) technique. Emdogain, an enamel matrix derivative, will be used to support periodontal tissue regeneration.
41311906|NCT05900011|BEHAVIORAL|Quality of life questionnaire|Measurement of the quality of life of patients with eosinophilic esophagitis by the PedsQL questionnaire eosinophilic esophagitis module
41311907|NCT03691402|BEHAVIORAL|MCT-Silver|Metacognitive training for depression in later life (MCT-Silver) is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
41311908|NCT03691402|BEHAVIORAL|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
40795001|NCT06289894|DRUG|BRY805 injection|BRY805 will be administered via IV infusion every 3 weeks. , Six dose levels of 0.3, 1, 3, 9,18 and 30 mg/kg will be tested
41311909|NCT02825264|DEVICE|STARflo Implant|All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
41311910|NCT00005986|DRUG|busulfan|
41311911|NCT00005986|DRUG|cyclophosphamide|
41311912|NCT00005986|DRUG|filgrastim|
41311913|NCT00005986|DRUG|recombinant interferon alfa|
40795002|NCT05533944|OTHER|Simulation training in Boškoski-Costamagna ERCP Trainer|Coached simulation training in Boškoski-Costamagna ERCP Trainer, by participating in three intensive courses during the first three months of training, with a monthly basis
40795003|NCT02780934|OTHER|Pressure Dressing|Patients in this group will receive the standard post-operative bandage: a pressure dressing consisting of high absorbency gauze and retention tape.
40795004|NCT02780934|OTHER|Simple Adhesive Dressing|Patients in this group will receive the experimental bandage: a simple adhesive dressing consisting of a non adherent pad and transparent dressing.
40795005|NCT05859646|DIETARY_SUPPLEMENT|Probiotic use|Probiotics were used for 3 months and all participated patients were followed for 6 months.
40795006|NCT00851890|DRUG|ABT-333|50 mg capsules
40795007|NCT00851890|OTHER|Placebo for ABT-333|Capsule
40795008|NCT00851890|DRUG|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
40795009|NCT00851890|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
40795010|NCT01591434|DEVICE|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
40795011|NCT01591434|DEVICE|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
40795012|NCT02104791|DRUG|procalcitonin|In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
40795013|NCT01643642|OTHER|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
40795014|NCT01643642|OTHER|Treatment As Usual|Other: Treatment As Usual
40795015|NCT03191942|DEVICE|Modified ortho-k lenses|KETT MC lens
40795016|NCT03191942|DEVICE|Ortho-k lenses|KATT BeFree lens
40795017|NCT05568563|DRUG|Ethyl chloride|Ethyl chloride is an agent that is widely used in dental practice as the standard modality for pulp vitality tests .
40795018|NCT05568563|OTHER|Honey|Honey is a natural dietary product
40795019|NCT04748692|PROCEDURE|Local exercise therapy|The local exercise therapy group will focus on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients will train with the support of a physiotherapist. The physiotherapist gradually increases the intensity of the exercises improving muscle endurance. The exercises will be supplemented with mobilisations of the patellofemoral joint. Twice a week, patients train at home following a prescribed exercise program writing down their work-out in an exercise journal.
40999923|NCT03037528|BEHAVIORAL|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.
40999924|NCT03037528|BEHAVIORAL|positive affect informational materials|Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.
40999925|NCT03037528|BEHAVIORAL|mindfulness informational materials|Participants will be taught about mindfulness and mindful eating techniques.
40999926|NCT03037528|BEHAVIORAL|dietary tracking|Participants will be asked to track their diet consistently.
40999927|NCT03179085|BEHAVIORAL|Home-Based Kidney Care|All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
40999928|NCT04882007|DRUG|OSE-127|mAb antagonist to CD127 receptor (or IL-7Rα)
40999929|NCT04882007|DRUG|Placebo|Normal saline
40999930|NCT05300490|DRUG|Prednisolone|In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
40999931|NCT05082077|DEVICE|LIVERguard|The LIVERguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of livers during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the liver. The intended organ storage time for the LIVERguard is up to 16 hours.
40999932|NCT00730782|BIOLOGICAL|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
41470709|NCT01103479|BEHAVIORAL|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
41470710|NCT01714739|DRUG|Lirilumab|Specified dose on specified days.
40999933|NCT03338062|DIAGNOSTIC_TEST|Hepatobiliary Iminodiacetic Acid (HIDA) scan|HIDA scan was used as the planning scan for SBRT.
40999934|NCT05992792|BEHAVIORAL|App message|Participantes push App message cancer prevention from the recomendations ECAC. 2 SMS notifications (push) per week or frequency of app notifications per week.
40999935|NCT05992792|BEHAVIORAL|SMS message|Participants push SMS message cancer prevention from the ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
40999936|NCT05992792|BEHAVIORAL|Internet|Internet connection in their mobile phone and WI-Fi. Participants push message cancer prevention from the recomendations ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
40999937|NCT05992792|BEHAVIORAL|Whithout internet|Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
40999938|NCT00829322|DRUG|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
40999939|NCT00829322|DRUG|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
40999940|NCT04974970|DRUG|Peanut Immunotherapy|Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
41470711|NCT01714739|DRUG|Nivolumab|Specified dose on specified days.
41470712|NCT01714739|DRUG|Ipilimumab|Specified dose on specified days.
40999941|NCT03547713|BEHAVIORAL|Social feedback|Social feedback regarding performance of a public speech is delivered to participants
41470713|NCT06617312|DRUG|Cytisinicline|Targets α4β2 nicotinic acetylcholine receptors
41470714|NCT06617312|DRUG|Placebo Oral Capsule|Matched to active drug, cytisinicline
40999942|NCT03547713|BEHAVIORAL|Self-referential paradigm|Exposure to traits varying in valence (positive vs. negative) and social domain (power vs. affiliation)
40999943|NCT03547713|BEHAVIORAL|Reward vs. punishment task|Reception of monetary gains vs. losses
41470715|NCT05353036|OTHER|Survey|Survey assessing incidence, frequency, and type of illicit substance use
40999944|NCT03547713|BEHAVIORAL|Emotional reactivity task|Exposure to emotional faces vs. shapes
41311914|NCT00005986|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
41311915|NCT00005986|PROCEDURE|peripheral blood stem cell transplantation|
41470716|NCT03898531|PROCEDURE|hip prosthesis removed metal / polyethylene, simple mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a simple mobility The aim is to define the types of particles that cause the most tissue inflammation"
40999945|NCT05585970|DIAGNOSTIC_TEST|procalcitonin|The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens
40999946|NCT00928928|PROCEDURE|Open colectomy|Open colectomy. Epidural anaesthesia used
40999947|NCT00928928|PROCEDURE|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
40999948|NCT00161993|DRUG|Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution|
40999949|NCT00161993|DRUG|Gammagard S/D (Solvent/Detergent)|
40999950|NCT04033159|DRUG|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA
40999951|NCT02803918|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
40999952|NCT02803918|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
40999953|NCT02803918|DRUG|Basal Insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
40999954|NCT02803918|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
41311916|NCT00005986|PROCEDURE|radiation therapy|
41311917|NCT04761887|DRUG|Cool Ropivacaine Block|Ropivacaine is cooled.
41311918|NCT04761887|DRUG|Room Temp Ropivacaine Block|Room Temp Block
41311919|NCT01513226|OTHER|Cycled light|lights on at daytime, lights off at nighttime
41311920|NCT02260466|OTHER|a basal LV septum biopsy|During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
41311921|NCT00002434|DRUG|Trimetrexate glucuronate|
41311922|NCT00002434|DRUG|Leucovorin calcium|
40795020|NCT04748692|PROCEDURE|Spinal manual therapy|The spinal manual therapy group will be treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots will be used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment will include manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation will be conducted if a restriction of range of motion will be found in any of the regions. Patients will also be asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
40795021|NCT00075764|DRUG|anastrozole|Given orally
41311923|NCT04995471|BEHAVIORAL|In presence RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
41470717|NCT03898531|PROCEDURE|hip prosthesis removed metal / polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
41470718|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ polyethylene, simple mobility|"Patients are hospitalized in order to change for their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a simple mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
41470719|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation."
41470720|NCT03898531|PROCEDURE|Primary implanted hip prosthesis|"Patients are hospitalized in order to have a first hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The patients will be received a first prosthesis."
40795022|NCT00075764|DRUG|fulvestrant|Given intramuscularly
40795023|NCT03952767|OTHER|Digital Physical Measures and Survey Assessments|Data from at home and in clinic visits will assess physical function and survey data will be collected
40795024|NCT06402929|BEHAVIORAL|Honest Open Proud - College (HOP-C)|"The program consists of three weekly workshops that are two hours in duration. There is a fourth booster workshop (two hours in duration) one month following program completion. All workshops will be held over an online videoconferencing platform.~HOP-C is a group program led by trained peer facilitators who have lived mental illness experience. Major topics that the program covers are:~1. discussing different types of disclosure;~2. conducting a cost-benefit analysis of disclosing in different situations;~3. strategies to anticipate how certain people will respond to disclosure when deciding on who to disclose to;~4. disclosure via social media; and~5. a guided creation of participants' own disclosure narrative.~During the booster workshop, participants will be encouraged to reflect on their disclosure decisions, and periodically revisit their disclosure cost-benefit analysis in deciding if and when to disclose in the future."
40795025|NCT01611740|PROCEDURE|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|"Telemonitoring system prototype developed by INSERM U-642 with analysis of :~* the variability of the cardiac cycle duration ;~* the variability of respiratory cycle amplitude and duration ;~* and their relationships."
40795026|NCT05359315|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
40795027|NCT06140251|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients identified with heart failure (both reduced ejection fraction and preserved) who are on optimal standard therapy and are candidates for treatment with SGLT2 inhibition will be identified from local heart failure databases, and local heart failure clinics. Following signed, informed consent and screening, patients will be allocated a first appointment where baseline clinical assessment and biomarker analysis will be obtained along with commencement on a SGLT2 inhibitor. Repeat assessment will be performed following a minimum period of 26 weeks.
40795028|NCT00453869|OTHER|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
40999955|NCT05700552|BEHAVIORAL|skin to skin contact|For skin-to-skin contact (TTT), the newborn is placed naked on the mother's bare chest in the prone (prone) position, the newborn's abdomen and chest are in contact with the mother's skin, and the newborn's head is turned to the side so that the airway remains open.
41470721|NCT03898531|PROCEDURE|hip prosthesis removed metal/metal|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/metal. The aim is to define the types of particles that cause the most tissue inflammation"
40795029|NCT05547087|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.
40795030|NCT04920084|OTHER|Plant based meals|For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
40795031|NCT06090630|PROCEDURE|Diffusion Weighted Imaging|Undergo DWI-MRI
40795032|NCT06090630|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopic imaging
40795033|NCT02995512|DRUG|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
40795034|NCT05013346|OTHER|No intervention needed|No intervention required. Not a clinical trial
41311924|NCT04995471|BEHAVIORAL|In presence RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
41311925|NCT04995471|BEHAVIORAL|Tele-RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
41311926|NCT04995471|BEHAVIORAL|Tele-RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
41311927|NCT01593163|DRUG|Ibuprofen EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
41311928|NCT01593163|DRUG|Standard ibuprofen treatment|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
41311929|NCT06334042|DIAGNOSTIC_TEST|Serum Chromium Level|Measuring serum chromium levels from patients who admitted in intensive care unit.
41470722|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ceramic|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/ceramic. The aim is to define the types of particles that cause the most tissue inflammation"
41470723|NCT03457090|OTHER|Examination : a TCD and Trans-Thoracic Echocardiography|"Examination that involves the completion of a TCD and an TTE (Trans-Thoracic Echocardiography) :~* To reports clinical parameters at the time of the examination : ECG data: sinus rhythm, atrial or ventricular arrhythmia, state of consciousness, heart rate, O2 saturation~* To review of pharmacological parameters at the time of the examination : presence of sedation; presence, type and dose of catecholamines.~* To collect biological data from the day of the examination : Partial Pressure of O2, PaCO2 (partial pressure) and hematocrit~* To collect possible additional examinations : brain scan, EEG. These are non-invasive exams that do not require patient displacement. Only the samples taken by the medical team as part of the treatment will be analyzed."
41470724|NCT05858268|GENETIC|Whole-genome sequencing|Whole-genome sequencing
41470725|NCT01104428|DRUG|Placebo|granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
40795035|NCT01308645|DRUG|SB injection|Infusion SB injection of 21.87 ml/m\^2, IV route, 24 times for 4 months
40795036|NCT00094562|DRUG|Fish oil supplement|
40999956|NCT00916175|DIETARY_SUPPLEMENT|P1&P2|"* First period (4 weeks) intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from AG\&CC group, 4 weeks intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
40999957|NCT00916175|DIETARY_SUPPLEMENT|P1&CC|"* First period (4 weeks) intake food product P1\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from AG\&P2 group, 4 weeks intake food product P1\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
41470726|NCT01104428|DRUG|"ziying granules"|granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
41470727|NCT00458419|DRUG|naloxone versus placebo|10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
41470728|NCT00458419|DRUG|intravenous injection of normal saline or naloxone|Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
41470729|NCT06616584|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41470730|NCT06616584|BIOLOGICAL|Cemiplimab|Given IV
40795037|NCT01599598|BEHAVIORAL|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
41470731|NCT06616584|PROCEDURE|Computed Tomography|Undergo CT
41470732|NCT06616584|DRUG|Dexamethasone|Given PO
41470733|NCT06616584|DRUG|Docetaxel|Given IV
41470734|NCT06616584|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41470735|NCT06616584|BIOLOGICAL|Ramucirumab|Given IV
41470736|NCT01109576|BEHAVIORAL|DSL Workshop|A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
41470737|NCT01000688|DRUG|vildagliptin + acarbose|4 week treatment
41470738|NCT01000688|DRUG|acarbose + vildagliptin|4 week treatment
41470739|NCT05522218|DEVICE|Eluvia drug eluting stent|Eluvia drug eluting stent for peripheral arterial disease
41470740|NCT05592249|OTHER|Dual Task MC|Dual Task MC group will receive 60 minutes motor - cognitive dual task intervention 5 day per week for 6 weeks in clinic.
41470741|NCT05592249|OTHER|Dual Task MM|Dual Task MM group will receive 60 minutes motor - motor dual task intervention 5 day per week for 6 weeks in clinic.
41470742|NCT01675076|DRUG|Dabigatran|NOAC
40795038|NCT01599598|BEHAVIORAL|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
40795039|NCT02058004|PROCEDURE|Cricoid pressure|Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
40795040|NCT01585779|DEVICE|Contour 3D® implant for tricuspid valve repair|Tricuspid annuloplasty ring
40795041|NCT01585779|DEVICE|Tri-Ad® implant for tricuspid valve repair|Tricuspid annuloplasty ring
40795042|NCT06072625|DIETARY_SUPPLEMENT|Extra virgin organic olive oil (ULTRA PREMIUM)|Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
40795043|NCT06308744|BEHAVIORAL|Body-scan meditation|Participants listen to a 15-minute Body-Scan mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
40795044|NCT06308744|BEHAVIORAL|Mindful Breathing meditation|Participants listen to a 15-minute Mindful Breathing mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
40795045|NCT06308744|BEHAVIORAL|Loving Kindness meditation|Participants listen to a 15-minute Loving Kindness mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
40795046|NCT06308744|BEHAVIORAL|Mindful Walking|Participants listen to a 15-minute Mindful Walking mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
40795047|NCT06308744|BEHAVIORAL|Listening of a story|Participants listen to a 15-minute story. The audio track is embedded in the Qualtrics survey.
40795048|NCT04471376|DRUG|Sugammadex|Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
41311930|NCT02294409|BEHAVIORAL|Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis|All CBT sessions will be conducted in English or French by trained clinicians with the aid of a group CBT script that we have developed over the last two years. The script will provide a general outline for each session, remind the therapist about relevant CBT principles, and provide examples of topics and homework that may be useful in each session. This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring; iii) Exposure component; iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia. The latter module specifically examines stigmatization and self-stigmatization that are contributing factors to social anxiety. Each of the 13 group sessions consisting of 6-8 participants on average, will last for 1.5 hour each. One session per week will be provided for the 13-week period.
41311931|NCT02294409|BEHAVIORAL|Group Computer assisted cognitive remediation therapy|This group intervention has been developed by Dr. Bowie a co-applicant on the current proposal. This intervention involves completing cognitive training activities on a computer, documenting and attempting new strategies for solving problems, and doing 'bridging activities'. The target domains of cognition to be trained are processing speed, attention, memory and executive functions. The investigators will perform 13 weekly sessions of 1.5 hours. The software Brain Training Pro (http://www.scientificbraintrainingpro.fr), which has been used extensively in the field of schizophrenia, will be used. Each 1.5 hour session will be conducted with groups of 6-8 participants. The therapist's interventions, while minimal, are meant to emphasize the link between activities in the CACRT sessions and day-to-day activities that people do.
41311932|NCT02093234|BEHAVIORAL|mobile health care application|mobile health application for cell phones to assist patients in managing their diabetes.
41311933|NCT02093234|BEHAVIORAL|CHWs and mobile health care application|CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
41311934|NCT02093234|BEHAVIORAL|Community Health Worker (CHW)|CHWs assist patients in managing their diabetes in various ways.
40795049|NCT01227226|DRUG|Artificial tears|Instill one drop of artificial tears
40795050|NCT04858841|DRUG|Levetiracetam Oral Product|Administer levetiracetam powder once a day in eligible patients
40795051|NCT04858841|DRUG|Perampanel Oral Product|Administer perampanel powder once a day in eligible patients
40795052|NCT04858841|DRUG|Placebo|Administer placebo powder once a day in eligible patients
41311935|NCT06068075|OTHER|FoundationOne Liquid CDx|a FoundationOne liquid biopsy test kit will be sent to the laboratory of the subject's treating center, in addition to the paired cell stabilizing tube from the primary center
41311936|NCT02942316|DEVICE|Pupil dilation reflex measurement|"Pupillometry (PDR) at four standardized times perioperatively~* after induction, before opioid administration~* after opioid administration, steady state~* surgical incision~* end of procedure"
41311937|NCT03216317|BEHAVIORAL|Intervention Group|Isometric handgrip training consisting of four series
41311938|NCT00256087|DRUG|Probiotic Lactobacillus|
41311939|NCT00256087|OTHER|Lactose Powder|
40795053|NCT03741907|PROCEDURE|FAUCS|extraperitoneal cesarean with a paramedian left section
40795054|NCT03741907|PROCEDURE|MLC|Gold standard
40795055|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)|Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant
40795056|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)|Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant
40795057|NCT05508178|DRUG|Placebo|Norovirus vaccine (rNV-2v) vehicle without antigen
40795058|NCT03748589|DEVICE|laryngeal mask airway|i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
40795059|NCT02740244|DEVICE|active iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
40795060|NCT02740244|DEVICE|sham iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
40795061|NCT04909840|OTHER|Instructions oral hygiene with toothbrush plus dental floss|Instructions of oral hygiene with toothbrush plus dental floss
40795062|NCT04909840|OTHER|Instructions oral hygiene with toothbrush only|Instructions only with toothbrush
41150590|NCT03591328|DIAGNOSTIC_TEST|Coronary CT angiography|"Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings."
41311940|NCT02222038|OTHER|skin biopsy|
40795063|NCT05940389|DEVICE|Naso Alveolar Mold|The NAM appliance is constructed according to the Grayson technique \[8\] with the nasal stent added from the start. The adhesive paste is used to hold the alveolar plate in place and labial taping is used. Patients are followed each 2 to 3 weeks for the appliance to be relined and selectively ground to modify the pressure as needed.
40795064|NCT05940389|DEVICE|Taping with nasal elevator:|For the lip approximation, Airoplast tape is used which is water resistant transparent and coated with hypoallergic adhesive on one side. The nasal elevator is 3D printed from the design inspired by the Dynacleft nasal elevator. Patients will be followed each 2 to 3 weeks for any modifications or adjustments.
40795065|NCT03644498|OTHER|Non-Interventional|Non-Interventional
40795066|NCT05275088|DEVICE|Prizvalve® system|Transcatheter atrioventricular valve replacement
40795067|NCT00452075|DRUG|erlotinib|150mg daily
40795068|NCT00802620|PROCEDURE|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
40795069|NCT03117647|PROCEDURE|Mansoura-VV compression suture|two compression suture both are v shaped apex of each suture placed 2 cm below suture line of C.S and 3 cm from the lateral border of the uterus on the right and left side
40795070|NCT00821158|DRUG|Antioxidant|Antioxidant iv bolus
40795071|NCT00821158|OTHER|Placebo|Placebo tablet and iv
41311941|NCT00966758|PROCEDURE|Computed Tomography|1 low dose CT scan is taken
41311942|NCT00966758|PROCEDURE|Single Photon Emission Computed Tomography|1 SPECT scan is taken
41311943|NCT05181020|BEHAVIORAL|Maternal Voice Exposure|Main objective of this study is to determine if it is possible to expose preterm infant in a systematic manner to mother's voices before their feeds and to determine if this exposure results in an increase in their oral intake.
41311944|NCT01446601|DEVICE|Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )|The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
41311945|NCT04765137|DRUG|Atorvastatin Oral Tablet|Atorvastatin pill 40 mg to be taken every night
41311946|NCT05889507|PROCEDURE|Whole body hypothermia|Whole-body hypothermia (33.5±0.5°C) initiated within 6 hours of birth and continued for 72 hours. The rectal temperature will be maintained at 33.5±0.5°C using a servo-controlled cooling machine.
41311947|NCT05889507|PROCEDURE|Targeted normothermia|The rectal temperature will be maintained at 36.5±0.5°C using servo-controlled incubators for the first 80 hours and any hyperthermia will be treated with a standardised protocol.
40795072|NCT00821158|DRUG|Anti-inflammatory drug|Anti-inflammatory tablet
40795073|NCT05677477|OTHER|simulation training|A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
41150591|NCT01636700|DRUG|Tramadol 2mg/kg|2mg/kg
41311948|NCT05889507|OTHER|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
41150592|NCT01636700|DRUG|Saline solution|saline solution- 1 dose
41150593|NCT04543032|OTHER|sensorimotor training|Sensorimotor exercises progressed from stable surfaces to unstable surfaces, training gait in a line (tandem walk or walking straight) followed by gait including change in directions, gait without obstacles to gait with obstacles, change in the support base (feet apart and then together), physical exercises with eyes opened and closed, always respecting the functional capacity of each patient and progressively increasing the difficulty of each exercise. To help the training, cones, balance board, bars, mats and a mini-trampoline will be used. According to the patient progress, the exercises will be combined, generating circuits
41150594|NCT05465187|OTHER|Non applicable|Non applicable
41150595|NCT04320433|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will ingest 75g anhydrous glucose dissolved in a volume of 200mL of water (NUTER.TEC GLUCOS, Subra, Toulouse, France).
41470743|NCT01675076|DRUG|Rivaroxaban|NOAC
41470744|NCT01675076|DRUG|Apixaban|NOAC
40795074|NCT00104338|DRUG|FK778|
40795075|NCT01882712|DRUG|CD07805/47 Gel 0.5%|
40795076|NCT01882712|DRUG|CD07805/47 Gel Placebo|
40795077|NCT01312025|PROCEDURE|conventional laparoscopic cholecystectomy|
40795078|NCT01312025|PROCEDURE|modified laparoscopic cholecystectomy|
40795079|NCT04830306|BEHAVIORAL|Exercise|Completion of exercise in accordance with assigned protocol
40795080|NCT06133556|DRUG|MCBC regimen|using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
40795081|NCT06133556|DRUG|Bu/Cy regimen|control group, the standard conditioning regimen Busulfan/Cyclophosphamide
40795082|NCT02961504|BIOLOGICAL|HLCM051|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered
40795083|NCT02961504|BIOLOGICAL|Placebo|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered
40795084|NCT05729555|DRUG|Compound ibuprofen polyrelease tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
41311949|NCT05889507|DIAGNOSTIC_TEST|Follow up assessment at 2 years of age|The assessment will be carried out using the Bayley Scales of Infant and Toddler Development IV. In addition, all infants will have a detailed neurological examination, including Gross Motor Function Classification System (GMFCS) for cerebral palsy, vision, and hearing assessment. Babies who die or who cannot be assessed with the Bayley-IV due to severe disability will be allocated a Cognitive Scale Composite score one point below the basal test score. PARCA-R will be completed by the parents immediately.
41470745|NCT04546269|PROCEDURE|Fully-guided vs. conventionally guided implant placement|Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
41470746|NCT03355196|DRUG|LRX712|Ascending single dose on Day 1
41470747|NCT03355196|DRUG|Placebo|Ascending single dose on Day 1
41470748|NCT06616649|DEVICE|Spinal cord stimulator implant|Participants will receive intervention in the operating room setting
41470749|NCT06617416|DRUG|Cadonilimab (AK104)|AK104 ivgtt Q3W
40795085|NCT05729555|DRUG|reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON \& JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON \& JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time"
40795086|NCT02741986|OTHER|Risk estimation|"Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
40795087|NCT00534768|PROCEDURE|active debridement|debridement on 1st, 3-5th and 7th postoperative days
40795088|NCT00534768|PROCEDURE|control group|Postoperative debridement on 7th postoperative day
40795089|NCT06231407|BEHAVIORAL|Recovery Oriented CBTp Medication Management|The prescriber structures the medication appointment to elicit and focus on subjects long term, valued goals (aspirations). With this information the prescriber will develop a plan to increase daily activity to facilitate the aspiration's pursuit. Obstacles (psychotic symptoms, motivational problems) will be identified and a formulation developed with the individual. Psychosocial interventions will be implemented for the various obstacles alongside monitoring and implementing of medications. Across sessions, the prescriber will continue to implement and monitor psychosocial interventions.
40795090|NCT06231407|BEHAVIORAL|Treatment as Usual|Residents will conduct medication management appointments as normally conducted
40999958|NCT00916175|DIETARY_SUPPLEMENT|AG&P2|"* First period (4 weeks) intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P1\&CC group, 4 weeks intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
40999959|NCT00916175|DIETARY_SUPPLEMENT|AG&CC|"* First period (4 weeks) intake food product AG\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from P1\&P2 group, 4 weeks intake food product AG\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
40999960|NCT00916175|DIETARY_SUPPLEMENT|TA (concentrated 5:1 aloe vera gel)|"* First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
40999961|NCT00916175|DIETARY_SUPPLEMENT|P3|"* First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
40999962|NCT04584554|BEHAVIORAL|BETTER Transitional Care Intervention|Patient and family will receive pre- and post-discharge support and education from interventionist.
40999963|NCT05450887|DRUG|Obeticholic Acid Tablets（OCA）|Obeticholic Acid：Once a day (QD) by mouth (PO).
40999964|NCT05450887|DRUG|UDCA|UDCA：13\~15 mg/kg/day
40999965|NCT05450887|DRUG|Placebo|Placebo：Once a day (QD) by mouth (PO).
40999966|NCT05140031|OTHER|PNE4Adults|"It is a clear and concise program, that consists of a manual for the physiotherapist delivering the education and a board game to enhance engagement and participant involvement. It not only provides the physiotherapist with a clear how-to manual but also provides an easy and accessible way for the patient to grasp the difficult and complex concept of pain."
40999967|NCT02357069|DRUG|Enbrel|Etanercept
41470750|NCT06617416|DRUG|Sugemalimab|1200mg Q3W
41470751|NCT03767699|BEHAVIORAL|Medical Nutrition Therapy|MNT was offered every 2-4 weeks to all pregnant women with T2DM and GDM. Women. MNT is offered as a mandatory part of their prenatal visit and/or hospital stay. The MNT provides an individual food plan with the following recommendations: total calories should be calculated as 30 kcal/kg based on pregestational BMI for an ideal weight. Of the total energy intake 40-45% is provided by carbohydrates, a maximum of 40% is provided by lipids and the remaining percentage by proteins providing moderate-to-low glycemic index foods and fiber consumption, glucose self-monitoring, participating in 15-30 min of daily physical activity after prior authorization of the treating physician, and meeting the minimal energy requirements of pregnancy (never \< 1,500 kcal).
41470752|NCT00221234|BEHAVIORAL|Print materials, pedometers/logbooks|
41470753|NCT00221234|BEHAVIORAL|Print materials, pedometers/logbooks, telephone counselling|
40999968|NCT02357069|DRUG|LBEC0101|Etanercept
41311950|NCT06187116|OTHER|Physiotherapist consultation|The consultation with the PT is 40-45 minutes long according to usual care and includes patient history, assessment and management according to an assessment template. If the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to general practitioner (GP) for new tests/assessments/medication. If the patient is found to be appropriate for surgery, and wishes to undergo surgery, or if the PT in the study wants a second opinion, the patient is 4) referred for orthopaedic consultation for surgical consideration.
41470754|NCT06471309|DEVICE|Theta burst transcranial magnetic stimulation|The stimulation intensity of TBS was 80%RMT, with a total of 600 pulses, five times a week for two weeks. In the bilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the unilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the sham stimulation group, sham iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. When giving sham stimulation, put the coil vertically so that the coil is perpendicular to the patient's skull surface , it will not produce real therapeutic effect.
41470755|NCT06227910|DRUG|Vedolizumab|Vedolizumab IV infusion.
41470756|NCT06227910|DRUG|Upadacitinib|Upadacitinib over-encapsulated tablets.
41470757|NCT06227910|DRUG|Placebo|Upadacitinib matched placebo capsules.
41470758|NCT05235425|BEHAVIORAL|Standard NDPP|"Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's standard National Diabetes Prevention Program. It teaches a lower calorie, lower fat diet.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
40795091|NCT03744195|OTHER|Group I Experimental Kinesotaping|"For application of kinesotaping following procedure will be adopted:~1. The skin will be cleaned properly with alcohol~2. The first strip will be applied in Y-shape (15-20% stretch) surrounding the deltoid muscle to provide inhibition and muscle relaxation~3. A second strip (I-shape) will be applied for functional correction (50-75% stretch), passing over the supraspinatus, trapezius, glenohumeral joint and middle deltoid Daily Strengthening Exercises (3 sets / 10\~30 reps) Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval"
40795092|NCT03744195|OTHER|Group II conventional training group|Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval) Strengthening Exercises (3 sets / 10\~30 reps)
40795093|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)|"- Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
40795094|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)|"- Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
40795095|NCT00816010|BEHAVIORAL|telephone contact|for lifestyle and compliance counseling
40795096|NCT02565147|PROCEDURE|PPCI|PPCI for treatment of participants presenting with large STEMI.
40795097|NCT02565147|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.
40795098|NCT02565147|DRUG|Heparin|Heparin is an anticoagulant.
40795099|NCT04703192|DRUG|Valemetostat Tosylate|Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
40795100|NCT04911647|DEVICE|ERCP using plastic stent|Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
40795101|NCT04911647|DEVICE|ERCP using metal stent|Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
40795102|NCT01458548|DRUG|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
40795103|NCT01458548|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
40795104|NCT00244725|DRUG|Odiparcil|
40795105|NCT00244725|DRUG|Warfarin|
40795106|NCT00244725|DRUG|Coumadin|
40795107|NCT01008761|DRUG|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
40999969|NCT03336216|BIOLOGICAL|Cabiralizumab|specified dose on specified days
40999970|NCT03336216|DRUG|Nab-paclitaxel|specified does on specified days
40795108|NCT01008761|DRUG|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
40795109|NCT04732442|DIETARY_SUPPLEMENT|Immunonutrition|Impact Oral® Nestle, Switzerland
40795110|NCT04732442|DIETARY_SUPPLEMENT|Standard Oral Nutritional Support|Fortimel Compact Protein® Nutricia, United Kingdom
40795111|NCT00848835|DEVICE|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
40795112|NCT02357537|BEHAVIORAL|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
40999971|NCT03336216|DRUG|Onivyde|specified dose on specified days
40999972|NCT03336216|BIOLOGICAL|Nivolumab|specified dose on specified days
40999973|NCT03336216|DRUG|Fluorouracil|specified dose on specified days
41470759|NCT05235425|BEHAVIORAL|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's National Diabetes Prevention Program, adapted to teach a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
40999974|NCT03336216|DRUG|Gemcitabine|specified dose on specified days
40999975|NCT03336216|DRUG|Oxaliplatin|specified dose on specified day
40999976|NCT03336216|DRUG|Leucovorin|Specified dose on specified days
40999977|NCT03336216|DRUG|Irinotecan Hydrochloride|Specified dose on specified days
40999978|NCT02717988|DRUG|SKI-O-703 capsule|SKI-O-703 25 mg capsule or 200 mg capsule without excipient
40999979|NCT02717988|DRUG|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose
40999980|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2
40999981|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
40999982|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2
40999983|NCT02838264|DRUG|PF-06463922|Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2
40999984|NCT02838264|DRUG|Itraconazole|200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
40999985|NCT06082466|PROCEDURE|FRAMED Infrainguinal Venous Bypass|The harvested vein graft will be covered with a mesh.
40999986|NCT06082466|PROCEDURE|Conventional Autologous Bypass|The harvested vein graft will be used without a mesh coating.
40999987|NCT05539365|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given IT
40999988|NCT05539365|PROCEDURE|Biopsy|Undergo biopsy
40999989|NCT05539365|PROCEDURE|Computed Tomography|Undergo CT scan
40999990|NCT05539365|PROCEDURE|Leukapheresis|Undergo leukapheresis
40999991|NCT05539365|BIOLOGICAL|Pembrolizumab|Given IV
40999992|NCT05539365|OTHER|Quality-of-Life Assessment|Ancillary studies
40999993|NCT02933177|BEHAVIORAL|2 months control condition - 4 months chariot-flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities."
40795113|NCT02727816|DEVICE|filcon IV I (BC 8.6)|control lens
40999994|NCT02933177|BEHAVIORAL|4 months control condition-2 months chariot flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities."
40999995|NCT00403000|DRUG|dutasteride|Oral
40999996|NCT04904185|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2 is administered i.v. on day -4, -3 and -2
40999997|NCT04904185|DRUG|Fludarabine Phosphate|Fludarabine Phosphate 30 mg/m2 is administered on day -4 and -3
40999998|NCT04904185|BIOLOGICAL|Multiple Antigen Specific Endogenously derived T cells|Antigen specific, ex vivo expanded T cells derived from peripheral blood T cells
40999999|NCT04904185|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered on day -1 and on day 21. The medicine is administered over 30 minutes
41000000|NCT01895738|BEHAVIORAL|WrapAround Care|Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
41000001|NCT05090995|BEHAVIORAL|Behavioral Self-Management and Feedback|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, active self-monitoring of health and behavior using daily diaries, and the provision of personalized health feedback and advice.
41000002|NCT05090995|BEHAVIORAL|Behavioral Self-Management|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, and active self-monitoring of health and behavior using daily diaries.
41000003|NCT06060626|DRUG|Sedation using only Propofol.|Patients in whom only propofol will be administered during sedation.
41000004|NCT06060626|DRUG|Sedation using combination of Propofol and Fentanyl.|Patients in whom combination of propofol and fentanyl will be administered during sedation.
41000005|NCT04925063|DRUG|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
41000006|NCT04564612|DRUG|BIIB091|Administered as specified in the treatment arm
41150596|NCT00682344|DRUG|Levobupivacaïne|1,75mg/kg
41150597|NCT01057888|OTHER|Autodialer|Autodialer telephone calls
41150598|NCT01057888|OTHER|Letters|Mailed reminder letters
41000007|NCT04564612|DRUG|Rabeprazole|Administered as specified in the treatment arm
41000008|NCT04564612|DRUG|Itraconazole|Administered as specified in the treatment arm
41000009|NCT06045039|OTHER|Stent-balloon-stent (SBS) technique|Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique. The procedure of this technique is to implant the stent into the side branch at the 1\~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel. The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
41000010|NCT05312671|DRUG|Atezolizumab|Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)
41000011|NCT05312671|DRUG|Carboplatin|Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
41000012|NCT05312671|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
41000013|NCT05312671|DRUG|Etoposide|Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)
41000014|NCT05312671|PROCEDURE|Cystectomy|Cystectomy should be performed within 42 days after completion of last administered study therapy of induction phase (first 4 cycles of chemotherapy).
41000015|NCT03023033|BEHAVIORAL|mHealth messaging|SMS appointment reminders and health messaging via mobile phones
41000016|NCT03023033|BEHAVIORAL|Transport Payments|A payment scaled to reflect the cost of typical return transport fare for residents of the clinic catchment area
41000017|NCT03846258|DRUG|Low bicarbonate solution (22 mmol/L)|Participants randomized to this arm will be started on CRRT using Phoxillum as the replacement fluid.
41000018|NCT03846258|DRUG|High Bicarbonate solution (32 mmol/L)|Participants randomized to this arm will be started on CRRT using Prismasate as the replacement fluid.
41000019|NCT05377021|BEHAVIORAL|Lifestyle change|"In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention."
41000020|NCT00903617|DRUG|GSK256073|5 mg for 8 weeks
41000021|NCT00903617|DRUG|GSK256073|50 mg for 8 weeks
41000022|NCT00903617|DRUG|GSK256073|150 mg for 8 weeks
41000023|NCT00903617|DRUG|Placebo|placebo for 8 weeks
41000024|NCT00903617|DRUG|Niaspan|1500 mg for 8 weeks
41000025|NCT00903617|DRUG|GSK256073|x mg for 8 weeks based from data from Part A
41000026|NCT00903617|DRUG|GSK256073|optional dose based on data from Part A
41150599|NCT04056598|DIAGNOSTIC_TEST|Study of humoral immunity|Analysis: Surface antigen ELISA, recognition of living P. acnes bacteria via FACS, 16SRNA study of microbiome, SLST typing of P. acnes bacteria
41311951|NCT06187116|OTHER|Orthopaedic surgeon consultation|The consultation with the OS is 20-30 minutes long and includes medical history, assessment and management plan, all according to usual care. It the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to GP for new tests/assessments/medication. If the patient is found appropriate for surgery, and wishes to undergo surgery, the patient is 4) scheduled for surgery.
41311952|NCT02352805|DEVICE|ECLS/ECC|Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
41311953|NCT05371067|OTHER|Fructose respiratory test|Healthy volunteers will performed a fructose respiratory test in order to evaluate if they are or not fructose malabsorbing. The two population will be compared about their feelings and their micriobiote.
41311954|NCT02927340|DRUG|Lorlatinib|
41311955|NCT02145923|PROCEDURE|Peripheral blood stem cell mobilisation and collection|
41311956|NCT02145923|DRUG|High-dose chemotherapy|High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
41311957|NCT02145923|DRUG|Bone marrow derived allogeneic MMSCs infusion|
40795114|NCT02727816|DEVICE|filcon IV I (BC 8.7)|control lens
41000027|NCT06109584|DEVICE|Insertion of central venous catheter|Central venous catheter verified by ultrasound and then verified by radiography.
41000028|NCT05729334|DEVICE|Clinicgram Euclides|"Clinicgram Euclides is a software that allows automated calculation of the area of skin lesions using a mobile device. Three different photographs will be taken of the subject's skin lesion. The area of the skin lesion will be calculated using the photograph of the skin lesion, and:~* for EUCLIDES 2D, an external marker. The investigator will outline the skin lesion and the external marker in the photograph prior to the calculation of the skin lesion area.~* for EUCLIDES 3D, a two reference points selected by the investigator."
41000029|NCT06371417|DRUG|RAY121|Injection
41000030|NCT06438042|DEVICE|Use of a powered low air pressure motorised therapeutic mattress that combines the motorised and static technologies|Patients with a high risk of pressure injury, without pressure injury, lying more than 20 hours a day, will ly a on a XTECH®25 mattress
41000031|NCT03249285|DRUG|Peri|Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
41000032|NCT03249285|DRUG|HCTZ|Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
41000033|NCT02347748|BEHAVIORAL|Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
41000034|NCT02347748|BEHAVIORAL|Reading pre-extubation script|Patients will be read a comfort talk script before extubation
41000035|NCT02347748|BEHAVIORAL|Reading 2 scripts|"Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.~Patients will be read a comfort talk script before extubation"
41000036|NCT00423306|DRUG|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
41000037|NCT00258076|DRUG|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE|
41000038|NCT00969553|DRUG|BI 6727|Dose level 1
41000039|NCT01667666|DRUG|Nebulized hypertonic saline|The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
41000040|NCT02515942|DRUG|CLG561|
41470760|NCT06616181|DEVICE|Anodal tDCS over M1|The anode will be placed over the left M1 (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.
40795115|NCT02727816|DEVICE|ocufilcon D|test lens
40795116|NCT02727816|DEVICE|methafilcon A (BC 8.6)|control lens
40795117|NCT02727816|DEVICE|methafilcon A (BC 8.7)|control lens
40795118|NCT02727816|DEVICE|somofilcon A|test lens
40795119|NCT01047917|BEHAVIORAL|Meditation DVD|Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
40795120|NCT02386462|DRUG|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
40795121|NCT02386462|DRUG|Propofol|
40795122|NCT05475977|DIAGNOSTIC_TEST|MSCT chest|Multi slice Computed Tomography of the chest
40795123|NCT04802031|BIOLOGICAL|Rapid Infusion Isatuximab|Given IV
41000041|NCT02515942|DRUG|LFG316|
41311958|NCT02145923|PROCEDURE|Autologous peripheral blood stem cells infusion|
40795124|NCT00628459|DIETARY_SUPPLEMENT|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
40795125|NCT02882191|DRUG|LevoCept|placement of LevoCept IUD
40795126|NCT01088204|PROCEDURE|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
40795127|NCT01088204|PROCEDURE|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
40795128|NCT01107392|DRUG|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
40795129|NCT01107392|DRUG|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
40795130|NCT02381314|BIOLOGICAL|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
40795131|NCT03754556|DEVICE|Intrauterine device|Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
40795132|NCT01737983|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10\^10 colony-forming units) for 6 months.
40795133|NCT01737983|DIETARY_SUPPLEMENT|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
40795134|NCT05168046|BEHAVIORAL|Mindfulness based stress reduction|program of weekly mindfulness based stress reduction intervention during 2 months and practice during 3 months
40795135|NCT01322724|PROCEDURE|Warm vs Cool water|Body vs Room temperature water used during insertion of colonoscopy
40795136|NCT03974126|OTHER|40 grams of starch|40 grams of starch in form of white bread to be consumed within 15 minutes
40795137|NCT03974126|OTHER|80 grams of starch|80 grams of starch in form of white bread to be consumed within 15 minutes
40795138|NCT04307069|DRUG|Oxytocin|The drug wil be adminisrate for augmentation of labor at admission.
40795139|NCT03377595|DRUG|Exparel|TAP (Transversus Abdominis Plane) block
40795140|NCT03377595|DRUG|Exparel|Wound infiltration
40795141|NCT04196855|DRUG|Teriparatide|"Terrosa 20 micrograms/80 microliters solution for injection. Each dose of 80 microliters contains 20 micrograms of teriparatide.~One cartridge of 2.4 mL of solution contains 600 micrograms of teriparatide (corresponding to 250 micrograms per mL).~Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34-N-terminal amino acid sequence of endogenous human parathyroid hormone."
40795142|NCT03484039|BEHAVIORAL|Medication Adherence|Some subjects will be enrolled in a medication adherence course.
40795143|NCT03484039|BEHAVIORAL|Seizure Documentation|Some subjects will be enrolled in a seizure documentation course.
40795144|NCT03484039|BEHAVIORAL|Memory Improvement|Some subjects will be enrolled in a memory improvement course.
40795145|NCT03484039|BEHAVIORAL|Stress Management|Some subjects will be enrolled in a stress management course.
41000042|NCT02515942|DRUG|Sham injection|Empty syringe (without a needle) placed against the eye
41000043|NCT03551210|DRUG|Nemonoxacin|Solution for infusion, 500 mg (250 ml)
41000044|NCT03551210|DRUG|Nemonoxacin|Capsules, 250 mg
41000045|NCT03551210|DRUG|Tavanic|Solution for infusion, 500 mg (100 ml)
41000046|NCT03551210|DRUG|Tavanic|Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
41311959|NCT00091702|BIOLOGICAL|Cold-adapted live attenuated influenza vaccine (FluMist)|
41311960|NCT00091702|BIOLOGICAL|Inactivated influenza vaccine (IAIV)|
41311961|NCT01861938|BIOLOGICAL|Melanoma vaccine modified to express HLA A2/4-1BB ligand|
41311962|NCT00432952|BEHAVIORAL|Intake of rainbow trout from different feeding conditions versus a control poultry meal|
41311963|NCT01895816|DIETARY_SUPPLEMENT|coated tablet|this supplement contains 700 mg of 8 natural herbals: Citrus \& ZINGIBER OFFICINALE \& Onion \& Ocimum basilicum \& Cinnamomum zelanicum \& Citrullus lanatus \& Citrullus vulgaris \& Daucus carota
41311964|NCT06552806|DIETARY_SUPPLEMENT|SLAB51|One dose of SLAB51 is administered after arrival to high altitude, then three times a day approximately every 5 hours upon waking during Days 2 and 3, and a final dose the morning of Day 4 of acclimatization.
41311965|NCT05178056|DEVICE|Spinal Cord Epidural Stimulation|Spinal Cord Epidural Stimulation (scES) will be administered by a multi-electrode array (5-6-5 SpecifyTM electrode, MEDTRONIC, Minneapolis, MN, USA) previously implanted in the epidural space over the dorsum of the spinal cord.
41470761|NCT06616181|DEVICE|Anodal tDCS over DLPFC|The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC) (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.
41311966|NCT05178056|OTHER|Respiratory Training|Standard threshold Positive Expiratory Pressure Device and standard threshold Inspiratory Muscle Trainer (Respironics Inc., Cedar Grove, NJ) assembled together will be used for respiratory training sessions to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure treshold load.
41470762|NCT06616181|BEHAVIORAL|Exercise telerehabilitation|Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance training will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact.
41470763|NCT01640184|PROCEDURE|Parathyroidectomy|sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.
41470764|NCT01640184|DRUG|Active vitamin D|CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
41470765|NCT01640184|PROCEDURE|Ultrasonic ablation|CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.
41470766|NCT01839695|DEVICE|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
41470767|NCT06617702|BEHAVIORAL|A text message alcohol intervention focused on cognitive, behavioral, and peer influences|Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g.desire to get drunk), behavioral (e.g.alcohol consumption), and peer influences (e.g.peer pressure and support).
41470768|NCT06617702|BEHAVIORAL|A text message alcohol intervention focused on cognitive and behavioral influences|Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g. desire to get drunk) and behavioral (e.g. alcohol consumption) influences.
41470769|NCT01085448|OTHER|Core Stabilization|"The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.~Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
41470770|NCT05065437|OTHER|Active (Virtual reality and spinal stimulation)|Each session is 25 minutes; 5 minutes of setup, and 20 minutes of simultaneous spinal stimulation at the cervical level and immersive virtual experience/gameplay.
41470771|NCT03469817|DIAGNOSTIC_TEST|MRI|"Patients who are part of Arm 2 will undergo an MRI at their 1 year post-operative visit."
41311967|NCT01938690|DEVICE|Transcranial magnetic stimulation (TMS)|8 sessions of TMS followed by task specific training
41311968|NCT04259385|BEHAVIORAL|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
41311969|NCT04259385|BEHAVIORAL|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
41311970|NCT04387994|OTHER|Blood samples collection|Collection of blood samples from consenting subjects to evaluate circulating biomarkers concentrations.
41311971|NCT04848337|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
41311972|NCT04848337|DRUG|Lenvatinib|Lenvatinib 20 mg orally daily.
41311973|NCT01544803|BEHAVIORAL|eScreen|The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
41311974|NCT01544803|BEHAVIORAL|Alkoholhjalpen|An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
41311975|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|10 mg of iron per day for 8 months, either in the form of NaFeEDTA
41311976|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|10 mg of iron per day for 8 months, in the form of FeSo4
41311977|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|EDTA fortified biscuit on a daily basis for 8 months
41000047|NCT03551210|DRUG|Placebo (250 ml)|0.9% NaCl (250 ml), solution for infusion
41000048|NCT03551210|DRUG|Placebo (100 ml)|0.9% NaCl (100 ml), solution for infusion
41000049|NCT01907477|OTHER|Samples taken at the clinical hematology unit|
41000050|NCT00647127|DRUG|Buprenorphine|Buprenorphine: 20microg/h
41000051|NCT00647127|DRUG|Fentanyl|Fentanyl: 25microg/h
41000052|NCT00647127|DRUG|Placebo|Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
41000053|NCT05245422|OTHER|Infant Formula - Partially hydrolyzed protein|Partially hydrolyzed cow's milk protein
41000054|NCT05245422|OTHER|Infant Formula - Intact protein|Intact cow's milk protein
41000055|NCT00876304|DRUG|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
41000056|NCT00876304|DRUG|Placebo|Placebo capsules every 12 hours for 10 days
41000057|NCT00594061|DEVICE|Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation|Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
41000058|NCT05427396|DRUG|JS004|Usage and dosage: Inject 200mg once every 3 weeks
41000059|NCT05427396|DRUG|Toripalimab Injection|Usage and dosage: Inject 240mg once every 3 weeks
41000060|NCT01072695|DRUG|GS-9256|75 mg BID x 28 days
40795146|NCT05922228|OTHER|neural flossing with proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week contract relax technique of proprioceptive neuromuscular facilitation for 5 minutes, 10 repetitions ×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 10 minutes
41000061|NCT01072695|DRUG|GS-9190|40 mg BID x 28 days
41000062|NCT01072695|DRUG|Ribavirin|1000-1200 mg/day given BID
41000063|NCT01072695|DRUG|Peginterferon alfa-2a|180 ug q week
41311978|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|control biscuit on a daily basis for 8 months
41311979|NCT02033772|PROCEDURE|Thoracoscopic surgery|
40795147|NCT05922228|OTHER|Neural flossing without proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 5 minutes
41000064|NCT06483971|DIAGNOSTIC_TEST|Oral Isotretinoin|20 mg/kg/day that affects sebaceous glands and is used to treat severe acne Frequency: Once daily
41000065|NCT06483971|COMBINATION_PRODUCT|Antibiotics|250 mg on laternate day/3 months Frequency: Once or twice daily
41000066|NCT05132621|DIAGNOSTIC_TEST|Smear|A smear of the posterior vaginal fornix collected with a gynecological speculum.
41000067|NCT06021067|BIOLOGICAL|Death mesenchymal stem cell|A standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10\^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4\~6 weeks.
41000068|NCT06148922|OTHER|Brief Mental Health First Aid Workshop|a 2-hour workshop delivered by a registered nurse with a MHFA training certificate
41000069|NCT06148922|OTHER|Semi-structured interviews|One-to-one, face-to-face semi-structured interviews will be conducted by a research assistant. The duration would be around 30 minutes.
41000070|NCT04576533|BEHAVIORAL|walk out from operating room|After the surgery of laparoscopic colectomy or laparoscopic rectectomy surgery (Dixon technique), patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
41000071|NCT04111094|DIAGNOSTIC_TEST|No intervention|No intervention
41000072|NCT02235779|OTHER|Transbronchial lung cryobiopsy|
41000073|NCT06439979|BEHAVIORAL|RAYS Intervention|Developmental baseball leagues will be randomly assigned to RAYS vs. control. Outcomes include directly-observed child sun safety behaviors after controlling for environmental ultra-violet radiation (UVR), with parent-reported child sun protection and other related endpoints at 1 year.
41000074|NCT04625751|OTHER|CO2-enriched air|To assess cardiovascular reactivity
41000075|NCT04625751|OTHER|Meal response test|Meal response test to assess changes in splanchnic blood flow.
41000076|NCT04724421|DRUG|Voxelotor|tablet or powder for oral suspension
41000077|NCT00186667|PROCEDURE|high dose chemotherapy and autologous hematopoietic cell transplant|
41000078|NCT03913091|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
41000079|NCT03913091|DRUG|0.5% Bupivacaine HCL|0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
41000080|NCT03291210|OTHER|normal inspired oxygen fraction|receives inspired oxygen fraction of 0.3
41000081|NCT03291210|OTHER|high inspired oxygen fraction|receives inspired oxygen fraction of 0.8
41000082|NCT00203528|DRUG|divalproex sodium ER|
41000083|NCT00203528|DRUG|risperidone|
41000084|NCT01040585|DRUG|Linezolid|Treatment for VAP as indication approved and as physician criterium.
41000085|NCT04566796|DRUG|Sugammadex|give 2 mg/ kg as muscle reversal drug in premature infants
41000086|NCT04566796|DRUG|Neostigmine|give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
41311980|NCT03032081|OTHER|High intensity exercise|High intensity exercise, defined as an exercise intensity of \> 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
41311981|NCT03032081|OTHER|Moderate intensity exercise|Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
41470772|NCT04948671|OTHER|there will be no intervention, this is an observational study|this is an observational study
41470773|NCT03498924|DIAGNOSTIC_TEST|Measure of biomarkers in serum and endometrial tissue|Blood sample and endometrial sample
41311982|NCT03921255|OTHER|Cognitive Bias Modification|There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark \& Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark \& Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey \& Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
40795148|NCT02220192|PROCEDURE|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
40795149|NCT03061877|OTHER|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
40795150|NCT05954949|PROCEDURE|Adenomas detection rate with the different observation methods|Films performed in white light high definition, NBI and indigo-carmine dye, will be compared blindly to detecte number of adenomas with the different observation methods
40795151|NCT04458246|OTHER|Exercise training group|Online aerobic home-based exercise training, 3 times per week, during 3 months. The exercise program is composed by 3 levels (starter, intermediate and advanced) which be completed in the first, second and third month of intervention, respectively.
40795152|NCT02446769|DEVICE|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
40795153|NCT03134391|DRUG|Vapocoolant spray, EMLA|Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
40795154|NCT00908323|BIOLOGICAL|JS7 DNA vaccine|
40795155|NCT00908323|BIOLOGICAL|MVA/HIV62 vaccine|
40795156|NCT03005236|DRUG|ENVARSUS|Envarsus is a once-a-day oral formulation of tacrolimus.
40795157|NCT03005236|DRUG|Standard twice daily tacrolimus|Standard tacrolimus will include twice-daily formulations that are currently available.
40795158|NCT00322049|BIOLOGICAL|Tetravalent live attenuated dengue vaccine|"DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit)."
40795159|NCT00322049|BIOLOGICAL|Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine|Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
40795160|NCT05401344|DIAGNOSTIC_TEST|test strips,sponges and cold dry air test|Test strips were used to evaluated the degree of dry nose, sponges were used to obtain the nasal secretion and cold dry air test was used to making diagnosis of vasomotor rihinitis.
40795161|NCT03538886|PROCEDURE|Coronary artery bypass grafting (CABG)|Revascularization of LAD lesion by CABG
40795162|NCT03538886|PROCEDURE|Percutaneous coronary intervention (PCI)|Revascularization of LAD lesion by PCI
40795163|NCT06471959|DRUG|Psilocybin|Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.
40795164|NCT05859555|OTHER|Thematic quality circles - Deprescription|Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)
40795165|NCT04472481|DRUG|Ergocalciferol 1.25 mg tablet|weekly 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) given orally group II
40795166|NCT01270932|DRUG|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
41311983|NCT01563640|OTHER|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
41311984|NCT01563640|OTHER|washing|normal washing of school uniforms, without permethrin insecticide impregnation
40795167|NCT02553928|DRUG|Memantine (once daily)|
40795168|NCT02553928|DRUG|Memantine (twice daily)|
40795169|NCT03641807|OTHER|Acupuncture|Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.
41470774|NCT05540873|DRUG|YYB-103|Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
41470775|NCT05589350|OTHER|saturated fat intake|Intake of saturated fat from yogurt and animal butter daily for 4-week period
41470776|NCT04881162|DEVICE|NOVIS Transcarotid Neuroprotection System (NPS)|The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection
41311985|NCT05544422|OTHER|The Timed Up & Go Test and 30second Chair-Stand Test'|"Evaluation of the participants will be carried out in the following order; 1) traditional assessment, 2) tele-assessment, 3) post-test. In the final test, only tele-assessment of the tests will be made.~During testing sessions, the results of each TUG and 30s-CST trial will be recorded on a standard test paper. TUG and 30s-CST will be tested in two different ways, traditional and tele, as 2 sessions every other day. Participants will rest for five to ten minutes between trials and an hour between sessions. During the one-hour rest between two test sessions, participants will rest in a chair, wheelchair or bed. Assessors will not know the TUG and 30s-CST results scored by each other."
41311986|NCT05383729|OTHER|learning-curve-based training modality|It is an individual duration of simulation training that is based on the previous performance of FOB on a simulator.
41311987|NCT05383729|OTHER|fixed-training-time training modality|It is a training duration of 1 hour which is the dominant duration of simulator training in previous studies.\[1\]
41311988|NCT05667155|BIOLOGICAL|CB dualCAR-NK19/70|Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19/CD70 CAR and IL15
41311989|NCT05929924|DIETARY_SUPPLEMENT|Extra virgin olive oil|EVOO will be included in the participant's daily diet for 6 months
41470777|NCT01015924|PROCEDURE|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
40795170|NCT03641807|OTHER|Sham acupuncture|Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
40795171|NCT04200092|COMBINATION_PRODUCT|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
40795172|NCT04200092|COMBINATION_PRODUCT|1mg AZ-010|Subject will receive a single inhaled dose (1.0 mg) of AZ-010 or matching Staccato Placebo
40795173|NCT04200092|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3.0 mg) of AZ-010 or matching Staccato Placebo
40795174|NCT04200092|COMBINATION_PRODUCT|AZ-010 1mg|2-period, 2-treatment open-label crossover design
41311990|NCT01523119|DRUG|Ondansetron|Orally Disintegrating Tablets 8 mg
40795175|NCT04200092|DRUG|IV Granisetron 1mg|2-period, 2-treatment open-label crossover design
40795176|NCT03536481|DRUG|ensartinib capsules (test product)|Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals
41311991|NCT03136367|OTHER|Option Grid|The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
41311992|NCT03136367|OTHER|Picture Option Grid|The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
41311993|NCT00674830|BEHAVIORAL|professionally administered cognitive-behavioral therapy|professionally administered CBT-I consisting of six weekly sessions
41311994|NCT00674830|BEHAVIORAL|self-administered form of cognitive-behavioral therapy|self-administered CBT-I consisting of six short booklets and videotapes
41311995|NCT00674830|BEHAVIORAL|placebo|usual care
41311996|NCT04496791|DEVICE|RIC (Receiver in Canal) hearing aid/ hearing instrument (HI)|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
40795177|NCT03536481|DRUG|ensartinib capsules (reference product)|Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
40795178|NCT03626012|DRUG|BIIB078|Administered as specified in the treatment arm.
40795179|NCT03626012|DRUG|Placebo|Administered as specified in the treatment arm.
41311997|NCT02858154|OTHER|HFNC|All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
41311998|NCT02858154|OTHER|Low flow oxygen by nasal cannula|All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea
41311999|NCT02752568|PROCEDURE|endometrial scratch|midluteal endometrial scratch using Novak curette under general anesthesia in the cycle preceding stimulation
41312000|NCT02752568|PROCEDURE|assisted hatching|using Octax laser 20120644-laser 5452
41470778|NCT01015924|PROCEDURE|ESIN|Elastiv stable intramedullary nailing
41470779|NCT03928236|OTHER|Limited Intraoperative Benzodiazepine|policy for limited use of intraoperative benzodiazepine
40795180|NCT03012828|DRUG|Moxidectin|Moxidectin is a broad spectrum macrocyclic lactone endectocide
40795181|NCT03012828|OTHER|Placebo|
40795182|NCT03504891|DIAGNOSTIC_TEST|MRI prior to CRT Upgrade|We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.
40795183|NCT03504891|DIAGNOSTIC_TEST|MRI prior to de novo CRT|We will perform MRI prior to de novo CRT implants as the comparison group.
40795184|NCT01673646|DRUG|Pasireotide LAR|Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 \> ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.
40795185|NCT02406521|DRUG|Pazopanib|
40795186|NCT02406521|DRUG|Sorafenib|
40795187|NCT02406521|DRUG|Radium-223|
40795188|NCT06170190|BIOLOGICAL|IBI133|"IBI133:~The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the course of the study. Q3W"
40795189|NCT02781571|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
40795190|NCT02902445|BIOLOGICAL|rotavirus rapid screen test|According to routine care
40795191|NCT02902445|GENETIC|polymorphism exploration|from an oral swab collected after parents consent
40795192|NCT05124028|DRUG|Orelabrutinib|50mg po qd 6 weeks
40795193|NCT05582148|DEVICE|Hearing aids fitting|Fitting hearing aids and evaluating the results at 6 months
40795194|NCT05208008|OTHER|With service dog|No intervention
40795195|NCT02547103|OTHER|Chlorhexidine gluconate-soaked cloths|
40795196|NCT02547103|OTHER|Normal saline|
40795197|NCT02547103|OTHER|mupirocin ointment|
40795198|NCT04770688|DRUG|Osimertinib|Osimertinib, 80mg, QD, p.o.
40795199|NCT04770688|DRUG|Anlotinib|"(Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle."
41312001|NCT02752568|PROCEDURE|controlled ovarian hyperstimulation|using merional\&/ or fostimon doses individualized as judged by patient age \& ovarian reserve \& monitored by follicular size \& serum estradiol
41312002|NCT02985450|BIOLOGICAL|Engerix-B|Hepatitis B Vaccine
40795200|NCT00140712|DRUG|Ropinirole Immediate Release|Ropinirole Immediate Release
40795201|NCT03742570|BEHAVIORAL|CBBDQ|a questionnaire for childood bladder and bowel dysfunctions
40795202|NCT01178476|DEVICE|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
40795203|NCT03835481|DRUG|BI 730357|Film-coated tablet
40795204|NCT03835481|DRUG|Placebo to match BI 730357|Film-coated tablet
41000089|NCT05667233|OTHER|Resistance Training Program|Participants will undergo a high exertion machine-based resistance training protocol.
41000090|NCT00000946|BIOLOGICAL|HIV p24/MF59 Vaccine|
41000091|NCT00000946|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
41312003|NCT06553898|BIOLOGICAL|anti-BCMA/CD70 CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
41312004|NCT00547599|DRUG|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
41312005|NCT04650958|PROCEDURE|Deep brain stimulation|Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
41312006|NCT01866878|DEVICE|equipment rehabilitation stereognosis|
41312007|NCT01866878|DEVICE|TENS|
41312008|NCT02570763|DEVICE|Active tDCS stimulation|
41312009|NCT02570763|DEVICE|Sham tDCS stimulation|
41312010|NCT03562585|DIAGNOSTIC_TEST|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
41312011|NCT02142894|DEVICE|CST001|
41312012|NCT06473285|DRUG|Drug: Esketamine (Continuous infusion)|Continuous intravenous infusion of ketamine at a dose of 0.3mg/(kg · h). Collect resting state EEG and auditory event-related potential (ERP) before administration (baseline), 60 minutes after administration, 30 and 60 minutes after discontinuation.
41470780|NCT03928236|OTHER|Liberal Intraoperative Benzodiazepine|policy for liberal use of intraoperative benzodiazepine
40795205|NCT01123031|DRUG|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
40795206|NCT01123031|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
40795207|NCT04878601|OTHER|Home-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and ART initiation with a 30-day supply. Monthly home-based ART follow-up visits with male-specific messaging and 30-day supply distribution will take place for 3-months. At 4-months providers will provide assisted linkage to a nearby facility to join the facility-based ART program. Additional counseling will be provided.
40795208|NCT04878601|OTHER|Facility-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and assisted linkage to a nearby facility for facility-based ART initiation and continuation. Male clients will receive a 30-day supply each visit and return monthly.
40795209|NCT03188263|OTHER|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
40795210|NCT03188263|OTHER|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
41000092|NCT00000946|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
41000093|NCT00000946|BIOLOGICAL|rgp120/HIV-1 SF-2|
41000094|NCT00150046|DRUG|Everolimus|
41000095|NCT06092515|DIETARY_SUPPLEMENT|Fermented High Zinc Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from fermented high zinc wheat flour.~* The flatbreads will be prepared using traditional fermentation methods.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months."
41000096|NCT06092515|DIETARY_SUPPLEMENT|Unfermented High Zinc Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from unfermented high zinc wheat flour,~* The flatbreads will not undergo a fermentation process.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months."
41000097|NCT06092515|DIETARY_SUPPLEMENT|Post-Harvest Fortified Whole Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from whole wheat flour fortified post-harvest~* These fortified flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months."
41000098|NCT06092515|DIETARY_SUPPLEMENT|Low Zinc Whole Wheat Flour Flatbread (Control Group)|"* Participants in this group will serve as the control group.~* They will receive flatbreads made from whole wheat flour with a low zinc content~* These low zinc flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months. six days a week over the course of six months."
41000099|NCT02110316|OTHER|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
40795211|NCT00693446|DRUG|Sirolimus|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day."
41312013|NCT01546389|BIOLOGICAL|Sanaria™ PfSPZ Vaccine|30 subjects in 3 cohorts, 6 groups in different doses of PfSPZ vaccine via the intradermal route. Cohort 1 Medium Dose, Medium Aliquot: Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose). Cohort 2: Medium dose, Low Aliquot: Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose), Cohort 3: High Dose, Low Aliquot; Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose)
41312014|NCT01546389|DRUG|Chloroquine|Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
41312015|NCT05583981|OTHER|Interview|Participate in interview
41312016|NCT03714282|DEVICE|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform locomotor activities.
41312017|NCT03714282|DEVICE|Conventional gait training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
41312018|NCT03714282|OTHER|Healthy control group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
41312019|NCT01897961|OTHER|Anticorps anti-PLA2R1|
41312020|NCT02605447|DRUG|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
41470781|NCT05780450|DEVICE|Transcranial Direct Current Therapy (tDCS)|"Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential.~Each session lasts between 20 and 30 minutes, and approximately 10 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA.~The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment."
41470782|NCT04705116|BIOLOGICAL|COVID-19 vaccine|At least one dose of a COVID-19 vaccine.
41470783|NCT05823896|DRUG|Nirmatrelvir/ritonavir|300/100 mg tablet twice daily (q12h) administered orally for 15 days
40795212|NCT00693446|DRUG|Tacrolimus|"Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids."
40795213|NCT02542059|RADIATION|68Ga-exendin PET/CT|68Ga-exendin PET/CT
41000100|NCT00607763|DRUG|Micafungin (Mycamine)|IV
41000101|NCT05321394|DRUG|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
41000102|NCT05321394|DRUG|Tixagevimab Cilgavimab|"2 subsequent injections:~1. tixagevimab 300mg/3mL (100mg/mL)~2. cilgavimab 300mg/3mL (100mg/mL)"
41000103|NCT05321394|DRUG|Nirmatrelvir Ritonavir|300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
41000104|NCT03033407|OTHER|Tailored mobile coaching messages|Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.
41312021|NCT02605447|DEVICE|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
41312022|NCT02403830|DRUG|Methylnaltrexone|Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
41312023|NCT02403830|OTHER|Placebo|Placebo will be administered as a 0.9% sodium chloride iv injection
41312024|NCT02403830|DRUG|Morphine|After methylnaltrexone, patients will receive 5-mg intravenous morphine
41312025|NCT02403830|DRUG|Ticagrelor|After morphine administration, patients will receive a 180-mg ticagrelor loading dose
41312026|NCT04523194|OTHER|Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)|Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.
41470784|NCT05823896|DRUG|Placebo/ritonavir|100mg tablet twice daily (q12h) administered orally for 15 days
41470785|NCT06466798|DRUG|Nivolumab|Nivolumab infusions will be given intraventricularly once every other week for 12 weeks. Dosing will be based upon patient body weight.
41470786|NCT06466798|DRUG|Methotrexate|2 mg methotrexate infusions will be given intraventricularly daily for 4 consecutive days per week every other week for 12 weeks.
41470787|NCT06466798|DRUG|5-Azacytidine|10 mg 5-Azacytidine infusions will be given intraventricularly once weekly for twelve consecutive weeks.
41470788|NCT04480801|OTHER|Thermal Evaluation and Foot Care|Participants in the experimental group will be given foot care and thermal evaluation in the clinic and will be taught to the patient and / or their relatives. Thermal evaluation and foot care video will be uploaded to the patient and / or relative's phone.
41000105|NCT01892696|DEVICE|varying inspiratory flow waveforms|inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
41000106|NCT02795559|OTHER|Glucose|75g glucose dissolved in 300ml water
41000107|NCT02795559|OTHER|Inulin|75g glucose plus 24g inulin dissolved in 300ml water
41000108|NCT02795559|OTHER|Resistant starch|75g glucose plus 28g resistant starch in 300ml water
41312027|NCT01602926|PROCEDURE|conventional surgical technique - Chevron-type distal metatarsal osteotomy|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
41312028|NCT01602926|PROCEDURE|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
41312029|NCT01602926|PROCEDURE|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
41312030|NCT00000728|DRUG|Zidovudine|
41000109|NCT01158222|DRUG|sunitinib malate|Given orally
41312031|NCT00000728|DRUG|Aldesleukin|
41312032|NCT01836887|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
41312033|NCT01836887|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
41312034|NCT01836887|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
41312035|NCT02939937|DRUG|Phenytoin|100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
41312036|NCT02939937|DRUG|placebo|100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
41312037|NCT04255836|DRUG|Durvalumab|Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months
41312038|NCT04255836|DRUG|the first line chemotherapy for metastatic NSCLC|paclitaxel+carboplatin or pemetrexed+cisplatin
41312039|NCT04255836|RADIATION|stereotactic body radiotherapy (SBRT)|SBRT total doses of 50-60Gy/≤10F
41312040|NCT03237988|DRUG|CPI-444 Capsules|100mg Capsule
41312041|NCT03237988|DRUG|CPI-444 Tablets|100mg Tablets
41312042|NCT01651052|PROCEDURE|Heart Valve Surgery|Implant of an aortic valve, Model 11000
41312043|NCT02857114|OTHER|massage|
41000110|NCT03367143|DRUG|Lenalidomide|
41000111|NCT03367143|DRUG|Ifosfamide|
41000112|NCT03367143|DRUG|Carboplatin|
41000113|NCT03367143|DRUG|Etoposide|
41000114|NCT01164449|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
41312044|NCT02045212|DRUG|RPh201|SC injection twice a week during 13/26 weeks
41000115|NCT04593030|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
41000116|NCT04593030|DRUG|Apixaban|Apixaban dispensing claim is used as the exposure
41000117|NCT02350309|DRUG|Lemborexant 5 mg|Lemborexant 5 mg tablet.
41000118|NCT02350309|DRUG|Lemborexant 10 mg|Lemborexant 10 mg tablet.
41000119|NCT02350309|DRUG|Lemborexant-matched placebo.|Lemborexant-matched placebo tablet.
41150600|NCT01598688|OTHER|Blood collection immediately after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
41312045|NCT02045212|DRUG|Placebo|SC injection twice a week during 13/26 weeks
41000120|NCT02350309|DRUG|Flurazepam 30 mg|Flurazepam 30 mg capsule.
41000121|NCT02302651|DEVICE|MR guided High Intensity focused ultrasound|High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
41000122|NCT02945527|DRUG|Acetazolamide|As described above
41000123|NCT02945527|DRUG|Dexamethasone|As described above
41000124|NCT03786757|DRUG|Rivaroxaban|Rivaroxaban 2.5mg/BID will be applied for 24 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
41000125|NCT01577667|DEVICE|Intellivent; automatic mode implemented on a S1 ventilator|Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
41000126|NCT05669079|DRUG|decitabine|15 mg/m2 daily intravenously for consecutive 3 days
41000127|NCT05669079|BIOLOGICAL|umbilical cord blood|MNC ≥ 3\*108 cells; HLA compatibility ≥ 5/6
41312046|NCT01446952|DRUG|Vitamin E δ-Tocotrienol|The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
41312047|NCT06067412|DRUG|Levetiracetam|Efficacy in fits
41312048|NCT06067412|DRUG|Phenytoin|Efficacy in fits
41312049|NCT03191669|OTHER|Auto-questionnaire|Single Auto-questionnaire administered during or after a consultation/hospitalization
41312050|NCT03625427|DIETARY_SUPPLEMENT|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, administered as two 1-gram capsules per day. Packaged as single-serve packets containing 2 capsules for each daily dose.
41312051|NCT03625427|DIETARY_SUPPLEMENT|Palmitoleic acid, 500 mg (Dose 1)|Palmitoleic acid (POA) 1 gram capsules containing 500 mg POA
41312052|NCT03625427|DIETARY_SUPPLEMENT|Palmitoleic acid, 1,000 mg (Dose 2)|Palmitoleic acid (POA) taken as two 1 gram capsules each containing 500 mg POA
41312053|NCT06151366|OTHER|non interventional|non interventional
41312054|NCT05125536|OTHER|Music therapy|rutin
41312055|NCT02428530|OTHER|Questionnaires|Norbeck Social Support Questionnaire (NSSQ)
41312056|NCT05094921|OTHER|Aquatic Halliwick method|The Halliwick Concept is a detailed swimming programme based on the scientific principles of body mechanics and the properties of water intended to educate individuals with special needs to be water safe and to move independently in the water as much as possible (Lambeck \& Stanat 2001a).The programme consists of 10 specific progressive stages that are achieved without the use of floatation devices (Lambeck \& Stanat 2001b).
41312057|NCT05094921|PROCEDURE|Conventional physical therapy|Conventional selected exercise program for 60 minutes ,3 session per week for 3 successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises to improve postural control and correct spinal deformities (3) improving postural responses, (4) Flexibility exercises of the soft tissue (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
41312058|NCT00641524|PROCEDURE|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
41312059|NCT03038243|BIOLOGICAL|Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)|2.25 x 10\^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
41312060|NCT03038243|BIOLOGICAL|Shigella flexneri 2a whole cell (Sf2aWC) vaccine|2.25 x 10\^11 Sf2WC cells administered orally on Days 0, 28, and 56
41312061|NCT03038243|OTHER|Placebo|2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
41312062|NCT04105244|BEHAVIORAL|Resourcefulness Training©|The intervention includes self-help and help-seeking skills.
41000128|NCT05669079|DRUG|Granulocyte-colony stimulating factor|Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
41312063|NCT05929417|OTHER|END-IT intervention for the community setting|The intervention was described in the arm/group descriptions.
41312064|NCT04434820|DEVICE|External negative pressure dressing system (Yuwell 7E-A portable suction unit)|A portable suction unit that will deliver 125 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
41312065|NCT05388162|DEVICE|Mobile colposcope|It is a comparison trial - Comparing a standard colposcpoe with a smart-phone based colpsocpe.
41312066|NCT01339949|DEVICE|IRay|low voltage external beam radiosurgery
41312067|NCT01339949|DEVICE|IRay|low voltage external beam radiosurgery
41312068|NCT02928549|BEHAVIORAL|semi-structured interviews|
41312069|NCT00702585|DRUG|Org 36286|Org 36286 single-dose subcutaneous injection
41312070|NCT00702585|DRUG|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
41312071|NCT05255588|DEVICE|EarlyTect® CRC test|A highly accurate and sensitive real time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE/qMSP) for measuring SDC2 methylation in stool DNA to detect CRC.
41312072|NCT04096352|BEHAVIORAL|Direct Method|Learning effective vocal skills using speech therapy exercises and virtual reality simulations.
41312073|NCT04096352|BEHAVIORAL|Indirect Method|Information on voice function and voice hygiene.
41312074|NCT03483506|DRUG|BI 1467335|Film-coated tablet
41312075|NCT03483506|DRUG|BI 1467335 (C-14) intravenous solution|Intravenous solution
41312076|NCT05414305|DRUG|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
41312077|NCT04387136|DRUG|Sublingual Sufentanil|15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.
41312078|NCT03761719|OTHER|No intervention|No intervention
41312079|NCT02547116|DRUG|Rifampin|Addition of Rifampin to standard anti-Staphylococcal treatment regimen
41312080|NCT00193219|DRUG|Bevacizumab|5 mg/kg IV
41312081|NCT00193219|DRUG|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
41312082|NCT00193219|DRUG|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
41312083|NCT00193219|DRUG|Leucovorin|350 mg IV
41312084|NCT00193219|DRUG|Oxaliplatin|85 mg/m2 IV
41000129|NCT05669079|DRUG|Recombinant human thrombopoietin / thrombopoietin receptor agonist|Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
41000130|NCT05669079|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
41000131|NCT01192971|DRUG|Apatinib|apatinib p.o. once daily for 4 weeks
41312085|NCT01111539|DRUG|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
40795214|NCT03196596|OTHER|Computer simulation|In these patients, a computer simulation model will be obtained based on pre procedural CT
40795215|NCT04644510|DEVICE|Lung ultrasonography|Standardized eight-point Lung ultrasonography
40795216|NCT01555996|BEHAVIORAL|Early and Intensive Occupational Therapy|"Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit."
40795217|NCT01555996|BEHAVIORAL|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
40795218|NCT02825446|PROCEDURE|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
40795219|NCT02825446|PROCEDURE|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
40795220|NCT02141165|DEVICE|Diagnosis, autoCPAP, follow up.|comparison between the efficacy of two protocol
40795221|NCT01890265|DRUG|Pamrevlumab|Solution for infusion
40795222|NCT01890265|DRUG|Placebo|Solution for infusion
40795223|NCT01890265|DRUG|Sub-Study: Pirfenidone|Pirfenidone concomitant therapy will not be provided by the Sponsor.
40795224|NCT01890265|DRUG|Sub-Study: Nintedanib|Nintedanib concomitant therapy will not be provided by the Sponsor.
41312086|NCT01111539|DRUG|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
41312087|NCT01111539|DRUG|Blinded capsule|Blinded capsule administered orally, once daily.
41312088|NCT05371990|OTHER|Determination of Eating habits|Questionnaire
41312089|NCT05268315|BEHAVIORAL|Brief Psychoeducational Intervention|The 1-session psychoeducational intervention is divided into three brief modules. Topics that are covered include thinking, learning, emotional, and behavioral functioning as they relate to childhood cancer, educational and school supports, and the role of neuropsychological and school-based assessments.
41312090|NCT00355212|PROCEDURE|percutaneous ablation of hepatocellular carcinoma|
41312091|NCT00374374|BEHAVIORAL|Administration of probiotic|
41312092|NCT00495495|DEVICE|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
41312093|NCT00495495|DEVICE|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
41312094|NCT03054077|OTHER|iPad with downloaded games|iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
41312095|NCT01021605|DEVICE|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive or invasive ventilation and then the Hemolung RAS. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
41312096|NCT01480141|DRUG|BIBW 2992 (Afatinib)|Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
41312097|NCT01502982|DRUG|R-CHOEP14x6+HD-AraC+HD-Mtx|rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
41312098|NCT04510350|OTHER|Biomarkers analysis|Genetic analysis of regions of interest
40795225|NCT04951375|PROCEDURE|arthroscopic repair|arthroscopic repair
40795226|NCT00845247|OTHER|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
40795227|NCT02822742|DRUG|DE-117 ophthalmic solution|
41312099|NCT01971489|DRUG|Buparlisib|Given PO
41312100|NCT01971489|DRUG|Cisplatin|Given IV
41312101|NCT01971489|DRUG|Gemcitabine Hydrochloride|Given IV
41312102|NCT01971489|OTHER|Laboratory Biomarker Analysis|Correlative studies
41312103|NCT01971489|OTHER|Pharmacological Study|Correlative studies
41312104|NCT01971489|OTHER|Questionnaire Administration|Ancillary studies
41470789|NCT04480801|OTHER|Foot Care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. Foot care video will be uploaded to the patient and / or relative's phone.
41312105|NCT06280976|DRUG|Statin|high intensity statin (eg atorvastatin 80 mg daily)
40795228|NCT02822742|DRUG|Latanoprost ophthalmic solution 0.005%|
40795229|NCT04413214|DRUG|Carrimycin|The study involves three dose groups: 200mg, 400mg and 600mg. Three patients are planned for each dose group. Starting from the low dose group, the treatment to three patients in the 200mg dose group: 200mg of Carrimycin after meals every morning (po) for three weeks, and then discontinue for one week, the tolerance and efficacy evaluation will be performed after the 4 weeks. DLT will be recorded during the 4 weeks.
41000132|NCT00165490|DRUG|Cetuximab|Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.
41312106|NCT06280976|DRUG|Aspirin tablet|aspirin 81 mg po qd
41312107|NCT06280976|DRUG|Nexlizet|bempedoic acid-ezetimibe 180-10 mg po qd
41312108|NCT06280976|DRUG|LEQVIO|inclisiran SQ as per product insert
41312109|NCT06280976|DRUG|Vascepa|icosapent ethyl 2g PO BID
41312110|NCT06280976|DRUG|Jardiance|empagliflozin 10 mg PO QD
41312111|NCT06280976|DRUG|Colchicine|Colchicine 0.5 MG po qd
41312112|NCT00094887|DRUG|Nitric Oxide|Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
41312113|NCT00094887|DRUG|Placebo|Nitrogen gas will be delivered in the same manor as the experimental drug.
41312114|NCT02617732|DRUG|Tianqi capsule|"The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.~The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day"
41312115|NCT02617732|DRUG|placebo|"The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.~The placebo group patients are treated with placebo by oral, 5 pills three times a day"
41312116|NCT01970514|DEVICE|ARO Spinal System|The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
41312117|NCT05514652|DRUG|Low opioid anesthesia|Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine
41000133|NCT00165490|DRUG|Cisplatin|Given once per week on weeks 1, 2, 4,and 5.
41312118|NCT05524870|OTHER|Mobilization|Movement with mobilization plus exercise
41312119|NCT04086069|DEVICE|Sit-to-stand trainer|The sit-to-stand trainer device is an exoskeleton that enables standing-up movement resembling the movement of a healthy person. It consists of three sub-systems: a foldable chair, a lever for body orientation and a triggering mechanism. It includes a support for feet with adjustable height. The device offers partial support to the patient while standing up. The patient will exercise with the device for 10 sessions (one per day), standing up for up to 30 times per session.
41312120|NCT00008138|DRUG|carboplatin|pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles
41312121|NCT00008138|DRUG|paclitaxel|pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles
41000134|NCT00165490|DRUG|Irinotecan|Given once per week on weeks 1, 2, 4,and 5.
41312122|NCT00008138|PROCEDURE|debulking surgery|exploratory laparotomy, interval cytoreduction (to \< 1 cm residual)
41312123|NCT02628249|DIETARY_SUPPLEMENT|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
41312124|NCT02628249|DIETARY_SUPPLEMENT|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.
41312125|NCT02628249|DIETARY_SUPPLEMENT|Branched chain amino acids|Branched chain amino acids modeled after egg protein.
41312126|NCT02628249|DIETARY_SUPPLEMENT|Essential amino acids|Essential amino acids modeled after egg protein.
41312127|NCT02628249|DIETARY_SUPPLEMENT|Non essential amino acids|Non essential amino acids modeled after egg protein.
41312128|NCT02235987|DRUG|octreotide|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
41312129|NCT02235987|DRUG|DG3173|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
41470790|NCT01957150|DRUG|Fluticasone Furoate/Vilanterol|Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
41470791|NCT01957150|DRUG|Vilanterol|Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
41470792|NCT01660477|DRUG|Isavuconazole|oral
41470793|NCT01660477|DRUG|Lopinavir/ritonavir|oral
41000135|NCT00165490|DEVICE|Radiation therapy|Once daily for 28 treatments (5 1/2 weeks)
41000136|NCT00165490|PROCEDURE|Surgery|Surgery performed 4-8 weeks after chemoradiation therapy.
41000137|NCT00917891|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
41000138|NCT00917891|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
41000139|NCT00463359|DRUG|Imiquimod cream|
41150601|NCT01598688|OTHER|Blood collection five minutes after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
41312130|NCT06554028|DRUG|chemotherapy TP regimen combined with Tislelizumab|"Induction chemotherapy TP regimen combined with Tislelizumab for 3 cycles: Cisplatin 37.5mg/m2 d1-2 q3w, Docetaxel 37.5mg/m2 d1and d3 q3w,Tislelizumab 200mg d3 q3w.~•Response rate of primary tumor or lymph nodes is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If the primary lesion reaches CR/PR and the lymph nodes reach CR, chemoradiotherapy based on cisplatin is conducted. If the primary lesion reaches CR/PR and lymph node PR/PD, cervical lymph node dissection will be performed, followed by radiotherapy/concurrent chemoradiotherapy. If the primary lesion is SD/PD, regardless of the condition of the lymph nodes, primary lesion resection and lymph node dissection should be performed, followed by adjuvant radiation/chemoradiation.~Other Names:~Docetaxel Cisplatin Paclitaxel"
41000140|NCT00463359|PROCEDURE|curettage and cautery|
41000141|NCT03504358|PROCEDURE|Liver resection|Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.
41150602|NCT05776329|BEHAVIORAL|AIA-D|"The total energy contribution (1800 kcal/d) is 20% from protein, 25% from lipids, and 55% from carbohydrates. The recommendations include increasing protein intake primarily from plant sources, limiting the intake of red and processed meat, reducing refined sugar, and moderating dairy consumption. It also includes a list of locally produced and seasonal fruits and vegetables and a list of selected ingredients with anti-inflammatory properties to elaborate their foods. Participants will attend 3 motivational sessions of 1 h every two weeks. Besides nutrition and health, the motivational talks focused on the environmental impact of sustainability. Session 1: Planetary healthy diet. The inflammatory potential of diet. Explanation of the program. Session 2. Effect of ultra-processed food on health. Session 3. Healthy diets.~Follow-up information, recipes, and pictures of dishes that meet the given recommendations will be sent once a week through closed social media groups."
41150603|NCT05776329|BEHAVIORAL|CONV-D|"CONV-D is based on general healthy diet recommendations. The total energy contribution (1800 kcal/d) was 20% from protein, 25% from lipids, and 55% from carbohydrates.~Among the recommended food groups are fruits (5 times a day), vegetables (5 times a day), cereals (3 times a day), legumes (3 times a day), dairy products (2 times a day), food of animal origin (3 times per day).~Participants in the CONV-D group will attend one motivational and nutritional orientation session on day 1 of the intervention.~Session 1. Food and nutrition. Obesity and diet. General healthy diet recommendations. Delivery of material (table of food equivalents).~Follow-up information will be sent once a week through closed social media groups."
41312131|NCT01989234|DRUG|YKP10811|
41312132|NCT01989234|DRUG|Placebo|
41312133|NCT04179968|DRUG|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
41312134|NCT04179968|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
41000142|NCT04838314|PROCEDURE|regional analgesia|Peri operative regional analgesia by bilateral ESP catheter for 72h
41000143|NCT00222456|BEHAVIORAL|Sensitizing parents|
41000144|NCT05328830|OTHER|Instrument assisted soft tissue mobilization|Myofascial release technique will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity with the Graston technique®. The application will be at 450 angles for each muscle, 2 minutes, for a total of 6 minutes. The IASTM application will include sweep-fan-sweep strokes and cycle through each muscle for the specified time.
41000145|NCT05328830|OTHER|Foam Roller|Will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity using rigid Foam Roller. A total of 6 minutes will be applied to a person, 2 minutes for each muscle. Pressure intensity; According to the Visual Analog Scale, which is the point where pain will not be felt but moderate to severe discomfort will be felt, it will be done at a severity of 7/10.
41150604|NCT02502188|DRUG|CC-90005|
41150605|NCT02502188|DRUG|Placebo|
41150606|NCT01904253|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
41150607|NCT01904253|DRUG|Amrubicin (Japan)|Patients will receive treatment administered according to the country-specific approved prescribing information
41312135|NCT04922515|OTHER|Oral and rectal swabs for microbiome sequencing|Oral swabs and rectal swabs are collected non-invasively.
41000146|NCT04422145|BEHAVIORAL|Structured nurse led intervention programme|A diabetes research nurse, over a period of 12 months, provided a structured education programme to participants focussing on the avoidance of hypoglycaemia and the treatment of this if/when it occurred.
41000147|NCT04422145|OTHER|Standard care|Participants continue on their current diabetes care plan and are looked after by their usual diabetes care provider
40795230|NCT05946161|BEHAVIORAL|e-Health intervention to promote mental and sexual health of prostate cancer survivors|An online psychological intervention (e-Health app technology) specifically tailored to meet the needs of Portuguese men with prostate cancer was developed to promote participants' mental and sexual health. The intervention protocol was designed under the principles of Cognitive Behavior Therapy (CBT), featuring psychological and sexual health promotion strategies. The intervention program consists of 5 modules covering components of psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring and relapse prevention. The modules will be delivered online (using text, videos, and graphics) along with therapeutic guidance and support provided by a certified Clinical Psychologist, over a 6-week period.
40795231|NCT02019953|OTHER|Yoga|The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
41000148|NCT03709537|BEHAVIORAL|Mental Health Peer Workforce Support|"Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency."
41000149|NCT02916615|OTHER|High nitrate vegetables|vegetables naturally high in nitrate
41000150|NCT02916615|DIETARY_SUPPLEMENT|Low nitrate vegetables + nitrate|pill containing KNO3
41000151|NCT02916615|OTHER|Low nitrate vegetables|vegetables naturally low in nitrate
41000152|NCT00146718|DRUG|Amodiaquine and Sulphadoxine/Pyrimethamine|
41000153|NCT00755066|DRUG|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
41000154|NCT00755066|DRUG|Placebo|Placebo intranasal spray
41000155|NCT01122667|DRUG|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
41000156|NCT05239897|DEVICE|Continuous theta burst stimulation (cTBS)|Patients assessed for postoperative delirium will be treated by consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions.
41000157|NCT01364428|DRUG|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
41000158|NCT01364428|DRUG|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
41000159|NCT03837548|OTHER|Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
41000160|NCT03837548|OTHER|The other Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
41000161|NCT04638465|PROCEDURE|Transoral robotic surgery|Transoral resection with neck dissection
41000162|NCT04638465|DRUG|Cisplatin - Dose Level 1|6 Cycles of 40 mg/m2
41000163|NCT04638465|DRUG|Cisplatin - Dose Level 2|7 Cycles of 40 mg/m2
41000164|NCT04638465|RADIATION|Dose Level 1|60 Gy/6 weeks - 2 Gy/fraction, 5 fractions/week
41000165|NCT04638465|RADIATION|Dose Level 2|70 Gy/7 weeks - 2 Gy/fraction, 5 fractions/week
41000166|NCT03168672|DEVICE|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
41000167|NCT01514695|DRUG|Midazolam|Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
41000168|NCT01514695|DRUG|Fentanyl|100mcg intravenously given in 2mL syringe at start of procedure
41000169|NCT01514695|OTHER|Placebo|One dose of saline (2ml)
41000170|NCT05381584|PROCEDURE|laparoscopy|laparoscopy will be done under anesthesia for management for cases with blind vagina
41000171|NCT04743661|DRUG|Irinotecan|"Irinotecan is a semisynthetic water-soluble analog of camptothecin (a plant alkaloid isolated from Camptotheca acuminata). Irinotecan is available in single-dose amber glass vials in 40 mg (2 mL) and 100 mg (5 mL), 300 mg (15 mL), and 500 mg (25 mL).~Patients on Stratum 1 will be given irinotecan at 50 mg/m2/day IV on Days 1 through 5 of each chemotherapy course."
41000172|NCT04743661|DRUG|Temozolomide|"An orally administered alkylating agent, a second generation imidazotetrazine. A prodrug of MTIC, temozolomide spontaneously decomposes to MTIC at physiologic pH. Exerts its effect by cross-linking DNA. Temozolomide capsules are available in six different strengths (5, 20, 100, 140, 180, 250 mg). The capsules vary in size, color, and imprint according to strength. In the US, capsules are packaged in 5-count and 14-count bottles.~Patients on Stratum 1 will be given temozolomide at 150 mg/m2/dose PO on Days 1-5 of each chemotherapy course."
41000173|NCT04743661|DRUG|Bevacizumab|"Bevacizumab is a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody. Bevacizumab is supplied as a clear to slightly opalescent, sterile liquid ready for parenteral administration. Each 400 mg (25 mg/mL, 16 mL fill) glass vial contains bevacizumab with phosphate, trehalose, polysorbate 20, and Sterile Water for Injection.~Patients on Stratum 1 will be given bevacizumab at 10 mg/kg/day IV on Days 1 and 15 of each chemotherapy course, with the exception of the last course of Induction Chemotherapy (i.e., Course 2 or 4) where it will be administered on Day 1 only."
41150608|NCT01904253|DRUG|Topotecan (Japan/Europe)|Patients will receive treatment administered according to the country-specific approved prescribing information
41150609|NCT01469819|DRUG|Lubiprostone|24 mcg twice a day (BID) for 2 weeks.
41150610|NCT01446042|DRUG|Testosterone|Intranasal testosterone
41000174|NCT04743661|DRUG|Omburtamab I-131|"Omburtamab is a murine IgG1 monoclonal antibody (mAb) against B7-H3 (CD276) manufactured by in vivo growth of the hybridoma cell line without the use of animal-derived components. Omburtamab will be radiolabeled with iodine-131 at a designated radiolabeling facility. 131I-omburtamab is supplied as a sterile, injectable, radioactive product in a vial. Each supplied vial will contain enough radioactivity to prepare 50 mCi of 131I-omburtamab, formulated in 3.5-4 mL of solution. 131I-omburtamab should be administered via an intraventricular access device (i.e., Ommaya catheter or programmable VP shunt). Radioimmunotherapy consists of 56 days.~Patients on Stratum 1 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 8 and 36 of Radioimmunotherapy.~Patients on Stratum 2 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 1 and 29 of Radioimmunotherapy."
41000175|NCT04743661|DRUG|Liothyronine|Liothyronine (or equivalent) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. Liothyronine (or equivalent) will be administered at 25 µg PO, NG, or G-tube (if weight \< 25 kg) or 50 µg PO, NG, or G-tube (if weight ≥ 25 kg) daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
41150611|NCT01446042|DRUG|Testosterone|Intranasal testosterone
41150612|NCT04676672|DEVICE|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
41470794|NCT04333381|OTHER|Educational and organizational intervention|"Patients included after a systematic educational and organizational intervention for early diagnosis and care in myocardial infarction, aimed at emergency nurses of a tertiary Hospital capable in primary PCI.~1. The educational intervention will consist:~   Systematized educational intervention on acute myocardial infarction for emergency triage nurses will consist of theoretical and practical training through case presentations and clinical simulation.~2. The organizational intervention will consist:~   * Development and dissemination of an early diagnostic tool for acute myocardial infarction: STEMI infographics. It will be provided to all emergency nurses and emergency triage boxes~  * Update the STEMI hospital protocol and adapt it to the current clinical guidelines of the European Society of Cardiology (ESC)~  * Review organizational strategies and definition of new improvement measures~  * Audit the delays in STEMI~  * Periodic multi-disciplinary update sessions"
41470795|NCT04333381|OTHER|Common Practice|Common practice is based on care by emergency nurses who did not receive any systematized education of acute myocardial infarction led by interventional cardiology nurses. On the other hand, emergency management is based on Plan-Do-Study-Act methodology and in the historical sample some organizational improvement strategies did not exist or were beginning to be implemented
41470796|NCT01222949|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
41470797|NCT00291473|DRUG|CHP-HER2, CHP-NY-ESO-1|
41470798|NCT02749760|OTHER|Strengthening program|Strengthening programs may be established to target the stabilizers of the elbows
41470799|NCT02749760|OTHER|Exercise program|Exercise program may be established to target the stabilizers of the elbows.
41150613|NCT04389554|OTHER|Blood D-dimer assay|Blood samples will be taken from the patients and will be examined by the ELISA method.
41150614|NCT03980171|DRUG|Obinutuzumab|A flat dose of 1000mg IV will be given every cycle during induction. a cycle is 28 days.During maintenance 1000mg IV will be given every second cycle for upto 2 years.
41150615|NCT03980171|DRUG|Venetoclax|During dose escalation, the doses for venetoclax can be 400mg daily days 1-10, 800mg daily days 1-10, 400mg daily continuous or 800mg daily continuous. 6 cycles of treatment will be given during induction. Once the recommended phase 2 dose (RP2D) is established that dose will be used in dose expansion. A further 6 cycles of venetoclax will be given during maintenance if required based on response at the end of induction.
41150616|NCT03980171|DRUG|Lenalidomide|During dose escalation, the doses of lenalidomide can be 15mg for days 1-21 or 20mg for days 1-21. 6 cycles of treatment will be given during induction. During maintenance the dose of lenalidomide will be 10mg continuous for a further 6 cycles if required based on response at the end of induction.
41150617|NCT04874493|OTHER|Electronic Health Record Review|Review of medical records
41150618|NCT04874493|OTHER|Questionnaire Administration|Complete questionnaire
41150619|NCT00720629|DRUG|Visilizumab|3 mg/m\^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
41150620|NCT00720629|DRUG|Tacrolimus|0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
41150621|NCT00720629|DRUG|Methotrexate|15 mg/m\^2 intravenously (IV) on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
41150622|NCT00720629|DRUG|Antithymocyte globulin (ATG)|1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
41150623|NCT00720629|DRUG|Tacrolimus|0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
41150624|NCT00720629|DRUG|Methotrexate|15 mg/m\^2 IV on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
41150625|NCT03896971|DRUG|Combination of thrombopoietin mimetic and cyclosporin A|This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
41150626|NCT05794191|BIOLOGICAL|Vaccine Administration|PCV13 administration
41150627|NCT04370392|PROCEDURE|intraperitoneal local anaesthetic instillation|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.
41150628|NCT03111849|OTHER|sarcopenia|Prevalence of sarcopenia in hospitalized chronic obstructive patients
41150629|NCT00469352|DRUG|Ranibizumab|Ranibizumab as needed
41000176|NCT04743661|DRUG|SSKI|SSKI (potassium iodide) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. SSKI (potassium iodide) will be administered as 7 drops (\~0.35 mL) PO, NG, or G-tube daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
41312136|NCT01255826|PROCEDURE|Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP|After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher \& Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is \< 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
41000177|NCT04743661|DRUG|Dexamethasone|Dexamethasone will be given as premedication for 131I-omburtamab to prevent possible meningeal inflammatory reaction. Starting within 24 hours prior to each 131I-omburtamab injection, dexamethasone will be administered orally at 0.5 mg (if weight \< 15 kg) or 1 mg (if weight ≥ 15 kg) twice-daily doses for a total of 6 doses to alleviate infusion-related AEs: Two doses starting 24 hours pre-131I-omburtamab injection, two doses on the day of the injection (can be given before or after), and two doses 24 hours post-131I-omburtamab injection.
41470800|NCT00808509|BIOLOGICAL|adalimumab|40 mg every other week via subcutaneous injection
41000178|NCT04743661|DRUG|Antipyretic|An antipyretic (e.g., oral acetaminophen \[15 mg/kg, 650 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
41000179|NCT04743661|DRUG|Antihistamine|An antihistamine (e.g., IV diphenhydramine \[1 mg/kg, 50 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
41150630|NCT05809635|OTHER|Natural History Study|Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
41150631|NCT01682447|OTHER|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
41150632|NCT03537534|DRUG|Lidocaine Jet Injector|Applying Lidocaine following endourologic procedure
41150633|NCT03537534|DRUG|Placebos|Applying surgilube following endourologic procedure
41150634|NCT02327702|DRUG|Emtricitabine|emtricitabine were given to each patients at baseline till 48 weeks after delivery
41150635|NCT03274934|BEHAVIORAL|Experimental: face-to-face and online support group:|5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
41150636|NCT03274934|BEHAVIORAL|Experimental: only online support group:|5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
41150637|NCT03274934|BEHAVIORAL|Control|Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
41150638|NCT00376259|DRUG|telbivudine|600mg/day oral tablet for 96 weeks
41150639|NCT00376259|DRUG|adefovir dipivoxil|10 mg of adefovir by mouth once daily
41150640|NCT05358938|OTHER|Exercise|30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
41150641|NCT05358938|DRUG|Checkpoint Blockade, Immune|Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
41150642|NCT04617847|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.
41150643|NCT05615753|BEHAVIORAL|Acupuncture|All participants will receive a semi-standardized acupuncture protocol with additional points for patient's particular pain location,
41470801|NCT00808509|DRUG|methotrexate|At least 10 mg/week administered orally or subcutaneously
41470802|NCT06364254|DIETARY_SUPPLEMENT|Cannabidiol Capsules|300 mg of cannabidiol administered 2 hours before 2 mile run
41470803|NCT06503549|OTHER|Assessments|Only the current assessments will be made
41470804|NCT02608840|OTHER|Auditory stimulation during sleep|The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
41000180|NCT04743661|DRUG|anti-emetics|An anti-emetic (e.g., IV ondansetron \[0.25 mg/kg, 16 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
41000181|NCT03924258|DIAGNOSTIC_TEST|Iron status testing|Blood sample for iron status testing
41312137|NCT01255826|PROCEDURE|Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.|After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
41312138|NCT06161194|OTHER|Supervised group exercise therapy|Participants will participate in a 90 minutes supervised group exercise therapy program 2 times a week for 8 consecutive weeks.
41312139|NCT01838967|DRUG|C - V - C+V|Drug will be administered to according to C - V - C+V sequence for 3 period.
41312140|NCT01838967|DRUG|C - C+V - V|Drug will be administered to according to C - C+V - V sequence for 3 period.
40795232|NCT02019953|OTHER|Walking|The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
41000182|NCT04328974|PROCEDURE|lumbar CSF drainage|We have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter was inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter was practiced using the LiquoGuard® (Möller Medical GmbH \& Co KG, Fulda, Germany). ICP control strategies was initiated when ICP exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP was less than 15 mmHg \[14, 15\].
41312141|NCT01838967|DRUG|V - C - C+V|Drug will be administered to according to V - C - C+V sequence for 3 period.
41312142|NCT01838967|DRUG|V - C+V - C|Drug will be administered to according to V - C+V - C sequence for 3 period.
41312143|NCT01838967|DRUG|C+V - C - V|Drug will be administered to according to C+V - C - V sequence for 3 period.
41312144|NCT01838967|DRUG|C+V - V - C|Drug will be administered to according to C+V - V - C sequence for 3 period.
41312145|NCT01160341|DRUG|Testosteron|Testosteron 250mg injection per 3-4 weeks for 6 months
41312146|NCT00412698|DRUG|rimonabant|"Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant"
41312147|NCT00412698|DRUG|Placebo|Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
41470805|NCT02608840|OTHER|Sham Intervention|The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
41000183|NCT00420524|DRUG|Patupilone/EPO906|
41000184|NCT01770288|OTHER|Anaerobic wingate test|
41000185|NCT04632251|DEVICE|SENSEI®|SENSEI® laparoscopic tethered gamma probe is an intra-operative laparoscopic gamma probe system
41312148|NCT00648193|DRUG|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
41312149|NCT00648193|DRUG|Paxil® 40 mg Table|40mg, single dose fasting
41312150|NCT01093755|DRUG|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
41312151|NCT01093755|DRUG|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
41312152|NCT05837078|PROCEDURE|ridge splitting with implant placement|ridge splitting of mandibular denture followed by two implant placement
41312153|NCT01996904|PROCEDURE|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
41470806|NCT01918579|PROCEDURE|Patients will be tested by rapid POC CRP test|Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
41470807|NCT02137694|OTHER|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
41470808|NCT01355848|BEHAVIORAL|Brief Intervention for Suicidality|Focuses on behavioral elements of care, including building rapport, functional analysis, and crisis planning
41312154|NCT01996904|PROCEDURE|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
41000186|NCT05202847|PROCEDURE|pulsed radiofrequency ablation to modifined points group|Point 1 place 10mm higher than the boundary between Femur's medial epicondyle and shaft. The 2nd point is targeted 20mm above the patella. Point 3 is targeted 10mm above the femur lateral epicondyle and shaft boundary. At point 4, find the boundary position between the tibia epicondyle and the shaft in the AP view and move it superolateral by 10 mm to target the central part of the medial shaft of the tibia and perform the main touch. Point 5 targets the center of the fibular head.
41312155|NCT02905942|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
41312156|NCT02905942|DRUG|rhG-CSF|rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
41312157|NCT04905875|PROCEDURE|Prone Position|Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
41312158|NCT03046940|OTHER|Patient-centered style of communication|Different doctor-patient communication
41312159|NCT03046940|OTHER|Doctor-centered style of communication|Different doctor-patient communication
41312160|NCT00423085|DRUG|Rivastigmine transdermal patch|"Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm\^2 (4.5 mg), 5 cm\^2 (9 mg), 7.5 cm\^2 (13.5 mg), and 10 cm\^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."
41312161|NCT00423085|DRUG|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm\^2, 5 cm\^2, 7.5 cm\^2 and 10 cm\^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
41312162|NCT00489840|DRUG|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
41312163|NCT00489840|DRUG|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
41312164|NCT03147339|OTHER|AGEs restricted diet|Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
41312165|NCT05388591|OTHER|Musicotherapy|Music listening with the application Music Care (style of music chosen by the patient) during wound suturing
41312166|NCT03241563|DRUG|Sodium Deoxycholate|
41312167|NCT03241563|DRUG|Triamcinolone|Triamcinolone 40mg/ml
41312168|NCT00005612|BIOLOGICAL|filgrastim|
41312169|NCT00005612|DRUG|carboplatin|
41312170|NCT00005612|DRUG|cyclophosphamide|
41000187|NCT05202847|PROCEDURE|pulsed radiofrequency ablation to conventional points group|Under AP view X-ray fluoroscopy, enter the cannula into the tunnel view until reaching the bone, reaching the border of the shaft and epicondyle, then stop the cannula tip at the anterior 2/3 junction in the lateral view. A total of three target points are the boundary position between the femur medial epicondyle and the shaft, the boundary position between the femur lateral epicondyle and the shaft, and the boundary position between the tibia meidal epiconcyle and the shaft. Subsequent procedure will be proceed same as Arm 1
41312171|NCT00005612|DRUG|etoposide|
41312172|NCT00005612|DRUG|paclitaxel|
40795233|NCT02019953|OTHER|Healthy Lifestyles Education|Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
40795234|NCT04836611|PROCEDURE|1 blood sample|2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire
41312173|NCT00005612|DRUG|topotecan hydrochloride|
41312174|NCT00005612|PROCEDURE|peripheral blood stem cell transplantation|
41312175|NCT01881971|DRUG|Placebo|suger pill manufactured to mimic crestor pills
41312176|NCT01881971|DRUG|Rouvastatin calcium|
41312177|NCT00091845|DRUG|AVI-4020 Injection|
41312178|NCT04898738|OTHER|Alcohol based hand sanitizer|Provision of ABHS to randomly selected households
41312179|NCT04635072|DRUG|Stabilised Whole Rice Bran|Patients with mild Atopic Dermatitis (AD) will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, once a day. Patients with moderate disease will use SWRB as a cleanser. In addition, they will also use SWRB as an emollient.
41312180|NCT03279302|DRUG|Glepaglutide|Solution for injection
41312181|NCT06174363|DRUG|Maxigesic|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
41470809|NCT05583877|BEHAVIORAL|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
41470810|NCT05583877|BEHAVIORAL|Usual Care|Participants will receive usual care for DSMT.
41312182|NCT06174363|DRUG|0.9% saline solution|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
41470811|NCT06428695|BEHAVIORAL|one-hour dietary self-monitoring tool education session|access the impact of a one-hour dietary self-monitoring tool education session for participants in a calorie-restricted weight management program on their knowledge of the use of the tool to help them adhere to a calorie-restricted weight management program
41470812|NCT03287687|DRUG|Carbon dioxide (CO2) gas insufflation|CO2 gas use for insufflation during endoscopy instead of air insufflation
41470813|NCT03287687|DRUG|Air insufflation|Air insufflation is the standard of practice (used in the control arm)
41470814|NCT06082908|DIAGNOSTIC_TEST|Diagnostic test|Subjective and objective measurement will be performed in older adults.
41470815|NCT02507245|DRUG|Growth Hormone-Releasing Hormone|From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
41470816|NCT05872464|OTHER|Artificial saliva containing cumin and ginger extract|Artificial saliva containing cumin and ginger extract in spray bottle
41470817|NCT05872464|OTHER|Placebo|Placebo containing composition close to the test group without cumin and ginger extract in spray bottle
41470818|NCT03068884|DEVICE|Cathodal Transcranial direct current stimulation|Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
41470819|NCT03068884|DIETARY_SUPPLEMENT|L-Tyrosine|Administration of 2 grams tyrosine
41470820|NCT03068884|DEVICE|Transcranial direct current stimulation (sham)|Sham tDCS
41470821|NCT03068884|DIETARY_SUPPLEMENT|Cellulose (placebo)|Administration of 2 grams cellulose
41470822|NCT02788513|DRUG|BI 425809 dose 1|
41470823|NCT02788513|DRUG|BI 425809 dose 2|
41470824|NCT02788513|DRUG|BI 425809 dose 3|
41000188|NCT05785364|DEVICE|Mpact 3D metal MONOCER cup|adult patients requiring a total hip arthroplasty under 75 years old, will receive the Mpact 3D metal cup, as acetabular sheel device implanted
41470825|NCT02788513|DRUG|BI 425809 dose 4|
41470826|NCT02788513|DRUG|Placebo|
41470827|NCT06313060|DIETARY_SUPPLEMENT|Coca-cola|200 ml of Coca-Cola will be administered and must be ingested within a maximum of 10 minutes
41470828|NCT04299217|DIETARY_SUPPLEMENT|Zynamite®|Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain 60% of the polyphenol mangiferin. Zynamite® is classified as a food or food supplement and is available for purchase within the EU. Zynamite® is not associated with any significant deleterious side effects.
41000189|NCT02102633|DRUG|Dabigatran|Dabigatran 150 mg orally
41000190|NCT02102633|DRUG|Bosutinib|Bosutinib 500 mg orally
41000191|NCT02102633|DRUG|Dabigatran|Dabigatran 150 mg orally
41000192|NCT04555837|DRUG|Alisertib|Given PO
41150644|NCT06552897|PROCEDURE|Intervention 1: Adductor Canal Block (ACB)|"For the Interventions section, you should describe the specific procedures or treatments administered in each arm of your study. Here's how you might present the interventions:~Intervention 1: Adductor Canal Block (ACB) Name: Adductor Canal Block (ACB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block. Dose and Administration: 20 ml of 0.25% bupivacaine is injected to target the saphenous nerve within the adductor canal.~Objective: To provide analgesia to the anterior and medial aspects of the knee, preserving motor function to facilitate early mobilization."
41312183|NCT02506296|DRUG|DPPIV inhibitor -|Mixed Meal Tolerance Test with or without a DPPIV inhibitor
41312184|NCT02506296|DEVICE|Continuous glucose monitoring system.|participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
41470829|NCT04299217|OTHER|Placebo|Placebo comparator (carrier)
41470830|NCT06329791|DRUG|AZR-MD-001|AZR-MD-001 sterile ophthalmic ointment 0.5%
41470831|NCT06329791|OTHER|Vehicle|AZR-MD-001 Vehicle
41470832|NCT05250206|OTHER|Myopia control lens|Evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.
41470833|NCT05746819|OTHER|Aggressive antipyretics therapy of fever vs usual care in the Malaria RCT study|After clinical trial of the Malaria RCT study, this study will compare children allocated to aggressive antipyretic therapy vs. usual care on the prevalence of structural brain abnormalities after recovery from CNS malaria.
41470834|NCT02400515|OTHER|Exercise|This is a quasi-experimental study and the same group was evaluated before and after the exercise.
41000193|NCT04555837|BIOLOGICAL|Pembrolizumab|Given IV
41000194|NCT00508742|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
41000195|NCT00508742|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
41000196|NCT01530971|DRUG|Supplemental 3LPM oxygen via canula|Parturients will receive supplemental oxygen (3LPM) via nasal canula
41000197|NCT01391728|BEHAVIORAL|Active Lifestyle all your Life|"Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme Active lifestyle all your life with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves."
41000198|NCT01220479|BEHAVIORAL|Exercise training program|"Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive."
41000199|NCT02795390|DRUG|Chinese herbal medicine|
41000200|NCT02795390|DRUG|Placebo|
41312185|NCT06553677|PROCEDURE|Tunneled coronal advanced flap with connective tissue graft|Tunneled coronal advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites.
41000201|NCT01909661|OTHER|Damira/Celia peptide hydrolyzed casein|
41312186|NCT06553677|PROCEDURE|Coronally advanced flap with connective tissue graft|Coronally advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites
41312187|NCT06457035|DRUG|immunosuppressant|No intervention was performed in this retrospective cohort study.
41312188|NCT04316663|BEHAVIORAL|Well-Being Intervention|The main aim of the well-being intervention is to reduce levels of distress through the promotion of psychological well-being. Key components of the intervention are self-monitoring of instances of well-being and what leads to their interruption (i.e., thoughts and behaviors), cognitive restructuring of interfering thoughts, and homework assignments to address dysfunctional behaviors and increase exposure to optimal experiences. Participants will become aware of their functioning based on six different dimensions of psychological well-being (i.e., self-acceptance, positive relations with others, autonomy, environmental mastery, purpose in life, and personal growth), and will be guided in finding a balance within each dimension.
41312189|NCT04316663|BEHAVIORAL|Sleep Hygiene|The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.
41470835|NCT06375369|PROCEDURE|Digital health pathway for children with medical complexity requiring tracheostomy (DECIDE-T)|The intervention involves developing a standardized clinical pathway for these children requiring tracheostomy. The pathway comprises of a hospital to home directive, incorporating digital health solutions to support family, caregivers, and healthcare professionals. These digital supports include but are not limited to a Connect Care pathway, resources to aid families to make informed choices during the clinical decision-making process, education modules and high-fidelity simulations to enhance family/caregiver education, an online parental resource center and access to peer support (spanning from hospital to community) and a telehealth post discharge program.
41470836|NCT02377388|DRUG|sitagliptin OR saxagliptin|sitagliptin OR saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
41470837|NCT02377388|DRUG|placebo|placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
41470838|NCT00989209|DRUG|Botulinum Toxin Type A|All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.
41000202|NCT01909661|OTHER|Picot riz/Celia rice/Sanutri arroz|
41000203|NCT02989207|PROCEDURE|Trabeculectomy|The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
41000204|NCT02989207|DEVICE|Baerveldt tube surgery|All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
41000205|NCT02989207|DRUG|mitomycin-C|This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
41150645|NCT06552897|PROCEDURE|Intervention 2: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB)|"Name: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block followed by a selective tibial nerve block.~Dose and Administration:~Adductor Canal Block (ACB): 20 ml of 0.25% bupivacaine. Selective Tibial Nerve Block (STNB): 20 ml of 0.25% bupivacaine. Objective: To provide comprehensive analgesia to both the anterior and posterior aspects of the knee, aiming to enhance pain relief and reduce opioid consumption."
41150646|NCT00591188|DRUG|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
41150647|NCT06270004|OTHER|nonsurgical periodontal therapy|sonic scaler for scaling and polishing. Graces curettes numbers(1-2,3-4,5-6,7-8,9-10,11-12,13-14)for root surfaces debridement(RSD), instructions and motivation for dental arch
41150648|NCT03867487|DRUG|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
41470839|NCT00989209|PROCEDURE|myofunctional therapy|All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.
40795235|NCT05545592|OTHER|Low oestrogen dosage|From the second day of the menstrual cycle, femoston (estradiol tablets) were orally taken 2 mg q.d.. The endometrial thickness and serum oestrogen and progesterone levels were monitored on the 12th to 14th days of the menstrual cycle.
40795236|NCT03442556|DRUG|Carboplatin|Given IV
40795237|NCT03442556|DRUG|Docetaxel|Given IV
41150649|NCT03867487|DRUG|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
41150650|NCT06585358|OTHER|MIPD|This is a non-inverventional study
41150651|NCT04468633|DEVICE|Baerveldt 350 implant|The Baerveldt implant is an FDA-approved silicone, non-valved implant.
41150652|NCT04468633|DEVICE|Ahmed ClearPath 350 implant|The Ahmed ClearPath is a non-valved glaucoma drainage device.
41150653|NCT04525183|BEHAVIORAL|Enhanced Usual Care (EOC)|Educational materials
41150654|NCT04525183|BEHAVIORAL|REVITALIZE ACT Intervention|Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks
41470840|NCT05523570|DRUG|HNC364|2 subjects (both male and female) to receive 20 mg HNC364 intramuscular administration to evaluate the safety and tolerability of HNC364 injectable suspension. Then 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 20 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
41312190|NCT05278650|OTHER|Senior PharmAssist^TM Program Implementation|"Representatives from three diverse communities will participate in co-design workshops to refine the Senior PharmAssistTM (SPA) implementation toolkit, which will then be delivered to agency staff from these partnering communities through a series of learning collaborative sessions to facilitate implementation of SPA core components in each community.~Community champions will be trained to deliver a community-based program to deliver the core components of SPA:~1. Medication Therapy Management (MTM);~2. Medication co-payment assistance;~3. Tailored community referrals; and~4. Medicare insurance counseling"
41312191|NCT03321214|OTHER|Gluten Sensor Dose-Finding Intervention|"Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is \< 20 ppm or a wheat icon for \> 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants."
41312192|NCT05936034|OTHER|Patients suffering from chemotherapy-induced ototoxicity|"At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Control group: standard support; Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire."
41470841|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 40 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
41470842|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 60 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
41470843|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 80 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
41470844|NCT00604084|DRUG|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
41470845|NCT00604084|DRUG|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
41470846|NCT00519922|OTHER|Kinesthesia, Balance, and Agility (KBA) Exercise|"Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion \& agility, dynamic proprioception,functional strength \& endurance.~Kinesthesia \& Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability \& confidence in ADL activities.~Soft pads will be used to progress some of the kinesthesia \& balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads."
41470847|NCT00519922|OTHER|Standard LE Strength Training|Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal \& external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
41470848|NCT02080507|DEVICE|Active Neuronetics rTMS stimulator|In the active group, magnetic power output will be delivered to the subject through the coils.
41470849|NCT02080507|DEVICE|Inactive Neuronetics rTMS stimulator|In the inactive group, no magnetic power output will be delivered to the subject through the coils.
41470850|NCT02013752|DEVICE|Perineal protection device.|A device used to reduce perineal tears during delivery of the baby.
41470851|NCT04296955|OTHER|Motivational interview as a new health communication intervention|Same as intervention name
40795238|NCT03442556|OTHER|Laboratory Biomarker Analysis|Correlative studies
40795239|NCT03442556|DRUG|Rucaparib Camsylate|Given PO
40795240|NCT03442556|DRUG|Rucaparib|Given PO
41312193|NCT05936034|OTHER|Patients suffring from chemotherapy-induced ototoxicity wearing hearing aids|"At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Experimental group: standard treatment with hearing aids (wearing a hearing aid).~Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire."
41312194|NCT04703348|DIAGNOSTIC_TEST|Motor imagery Questionnaire - Revised Second (MIQ-RS)|"Patients fulfill a questionnaire measuring individuals capacities to realize mental imagery. For more facilities and less risk of bias, the MIQ-RS was written on an online version with questions recorded in audio format. No official cut-off exists but studies seem to prove that people with :~* a score less than 48/98 are unable to do motor imagery~* a score between 49 and 73/98 have disturbed motor imagery capacities~* a score more than 74/98 have normal motor imagery capacities."
40795241|NCT03091790|DEVICE|Synthetic Mesh|Synthetic mesh used during open ventral hernia repair
40795242|NCT03091790|DEVICE|Biologic Mesh|Biologic mesh used during open ventral hernia repair
40795243|NCT04801485|DIETARY_SUPPLEMENT|D-chiro inositol|Active group receives inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.
40795244|NCT04801485|DIETARY_SUPPLEMENT|Placebo|Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.
40795245|NCT02614339|DRUG|metformin|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
40795246|NCT02614339|DRUG|control|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
40795247|NCT00311025|PROCEDURE|intensive endurance, strength and balance exercises|
40795248|NCT00673231|DRUG|Dapagliflozin|tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
41312195|NCT04982159|OTHER|There is no intervention. This is an observational study.|There is no intervention. This is an observational study.
41312196|NCT03105206|PROCEDURE|Flexible Ureteroscopy|the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
40795249|NCT00673231|DRUG|Dapagliflozin|Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
40795250|NCT00673231|DRUG|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
40795251|NCT00673231|DRUG|Placebo|Placebo
40795252|NCT00673231|DRUG|Dapagliflozin|tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
40795253|NCT00673231|DRUG|Dapagliflozin|tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
40795254|NCT00964483|BEHAVIORAL|DASH diet|The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
40795255|NCT00964483|BEHAVIORAL|Delayed Intervention|"The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure."
40795256|NCT06045065|OTHER|Fresh tumor sampling|Patient samples will be collected during neurosurgical resection. .
40795257|NCT02777359|PROCEDURE|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
40795258|NCT01142076|DRUG|Xinju Xiaogao Prescription|treatment group
40795259|NCT01142076|DRUG|placebo|Therapeutic dose of 10%
40795260|NCT00447967|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
41150655|NCT05981586|OTHER|Plyometric strengthening exercises|Comparative effects 1
41312197|NCT03240393|DRUG|INC280|cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations
41312198|NCT00261170|DRUG|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
41312199|NCT00261170|OTHER|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
40795261|NCT00447967|DRUG|Oxaliplatin|Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles
40795262|NCT00447967|DRUG|Fluorouracil|Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
40795263|NCT00447967|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
40795264|NCT00447967|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
41150656|NCT05981586|OTHER|Isotonic strengthening exercises|Comparative effects 2
41312200|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
41312201|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
41312202|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
41312203|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
41312204|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
41312205|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
41470852|NCT06580327|DRUG|programmed intermittent Bolus epidural analgesia|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
40795265|NCT05096975|OTHER|Evaluation of the CBCL-A-A-A and HiPIC in children with ADHD and with ED or without ED|"The intervention involves the completion of two questionnaires by parents at child psychiatry unit of Montpellier University Hospital when children come to participate in a psychometric assessment or when parents or children participate in therapeutic group.~All parents completed Child Behavior Checklist (CBCL; Achenbach \& Rescorla, 2001), a 118-item questionnaire to measure emotional and behavior problems in 4 to 18-years-old children in the past six months and Hierarchical Personality Inventory for Children (HiPIC, Mervielde \& De Fruyt, 1999, a 144-item questionnaire to obtain a profile of the personality of 6 to 12-year-old children."
40795266|NCT05601583|DEVICE|Continuous Glucose Monitor (CGM)|FDA-cleared FreeStyle Libre Glucose Monitoring System manufactured by Abbott. Integrated continuous glucose monitoring system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts.
40795267|NCT00819000|DRUG|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
40795268|NCT04803864|DRUG|Roxadustat|Orally 100mg, 3 times per week for 2 weeks First dose administered immediately after successful PCI.
40795269|NCT05408273|DIAGNOSTIC_TEST|Blood samples and Microvascular function assessment evaluated through laser-Doppler flowmetry by the LASER speckle contrast analysis (LASCA) device|We enrolled 39 non-smokers, low CVR postmenopausal women, with less than 10 years of hypoestrogenism. Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated
40795270|NCT04461873|OTHER|Reiki|Reiki by touching
40795271|NCT04461873|OTHER|Sham Reiki|Sham reiki by gesturing and mimic imitation through touching
40795272|NCT06473298|OTHER|Visual Light Tracking|visual light tracking program consists of 10 tasks every task lasts for 6 minutes and may be repeated for the child especially in the first sessions to give him trials to him/her to understand the exercise.
40795273|NCT02337101|OTHER|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
40795274|NCT02337101|BEHAVIORAL|EUC + Early intervention programme|"All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion."
40795275|NCT03438708|DRUG|Axitinib Oral Tablet [Inlyta]|Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
41000206|NCT06286462|OTHER|Cancer Tracking System (CATSystem)|The CATSystem provider dashboard highlights patients with overdue services or those in need of outreach and sends automated, customized texts to support screening and treatment follow-up per national guidelines. Points of intervention and alerts include: cervical cancer screening and treatment counseling, initial and follow up cervical cancer screening per national guidelines, treatment for precancer and cancer, referral tracking and follow up. In addition, the CATSystem can securely store images of the cervix taken with colposcopes to allow for remote expert consultation if needed to correctly diagnose a patient or can be reviewed at clinical team meetings for input. Primary goals of the CATSystem are to increase rates of guideline-adherent cervical cancer screening/ rescreening and improve guideline-adherent treatment, referral, and follow-up rates of women with positive screens.
41312206|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
41312207|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
41312208|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
41312209|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
41312210|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
41312211|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
41312212|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
41312213|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
41312214|NCT02763072|DEVICE|Enlighten Laser|
41000207|NCT00389116|DRUG|gastrograffin|ingestion
41000208|NCT00389116|DRUG|water|oral water ingestion
41000209|NCT02127632|DEVICE|Endotracheal Tube|ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
41000210|NCT02127632|DEVICE|Laryngeal Mask Airway-Supreme|"Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson \& Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.~Other Names:~LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7"
41000211|NCT04360564|OTHER|Recurrent pregnancy loss|As described before.
41150657|NCT02916524|BEHAVIORAL|Semantic Feature Analysis (SFA)|SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
41312215|NCT02763072|DEVICE|Excel V Laser|
41470853|NCT06580327|DRUG|continuous epidural infusion|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
41470854|NCT03546647|DEVICE|Dailies Aqua Comfort Plus Toric|Daily disposable soft toric contact lens
41470855|NCT03546647|DEVICE|Dailies Aqua Comfort Plus Sphere|Daily disposable soft spherical contact lens
41470856|NCT03184012|DEVICE|NuSmile Zirconia crowns by NuSmile company|anterior carious teeth restored with Zirconia crowns
40795276|NCT01804049|DRUG|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
41000212|NCT05409027|DRUG|SPI-62|SPI-62 is supplied as 1 mg tablets for oral dosing.
41000213|NCT05409027|DRUG|Cortisone-d8|Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion
41000214|NCT00136149|PROCEDURE|Immediate implants|Immediate implants are used.
41000215|NCT01139528|PROCEDURE|Bouquet pinning of the 5th metacarpal bone|The fracture is reduced under general anesthesia and 2-3 K-pins are introduced in the medullar cavity to keep the fracture in the reduced position
41000216|NCT02608112|DRUG|Methotrexate|Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
41000217|NCT02608112|DRUG|Tocilizumab|Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
41000218|NCT02806050|DRUG|Palbociclib|all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression
40795277|NCT01804049|DRUG|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
41000219|NCT02806050|DEVICE|FES PET|all patients will have a FES PET at baseline
41000220|NCT02806050|DRUG|Letrozole|all patients will be treated with Letrozole daily until progression
41150658|NCT01807845|DIETARY_SUPPLEMENT|enriched skimmilk with VD|enriched skimmilk with VD
41150659|NCT01807845|DIETARY_SUPPLEMENT|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
41150660|NCT01807845|DIETARY_SUPPLEMENT|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk
41150661|NCT02618200|DEVICE|3D prostate ultrasound|
41312216|NCT00999856|DEVICE|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
41312217|NCT00999856|DEVICE|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
41312218|NCT00999856|DEVICE|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
41312219|NCT00999856|DEVICE|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
41000221|NCT04118309|BEHAVIORAL|Exercise|
41000222|NCT04118309|OTHER|Placebo|
41000223|NCT04297930|DEVICE|Paul Glaucoma Implant Surgery|This group of patients had glaucoma surgery with the Paul Glaucoma Implant
41000224|NCT04715399|OTHER|No intervention|No intervention
41000225|NCT04552691|DRUG|Pegunigalsidase Alfa|Pegunigalsidase alfa is a recombinant ERT (enzyme replacement therapy) used to treat Fabry disease (dosage: 1 mg/kg body weight every 2 weeks).
41000226|NCT01236755|DEVICE|single-vision glasses|Daily wear of glasses to correct vision in the first seven months of the study
41000227|NCT01236755|DEVICE|ortho-k lenses|Nightly wear of lenses to correct vision in day time in the second seven months of the study
41470857|NCT03184012|DEVICE|Composite resin strip crowns by 3M company|anterior carious teeth restored with Strip crowns
41470858|NCT03546829|DRUG|Vancomycin|125 mg, 4x daily for 5 weeks
41470859|NCT03546829|RADIATION|Precision hypofractionated radiation|Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression and will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.
41470860|NCT00176540|DRUG|dextromethorphan hydrobromide|
41470861|NCT05739734|DRUG|CRIS100|local application of CRIS100
41470862|NCT05091086|DRUG|Denosumab|Active comparator: persistent treatment of denosumab. Experimental: alternating treatment with zoledronate and denosumab
41470863|NCT05589259|PROCEDURE|Axillary Brachial Plexus Block plus Physiotherapy|"Participants will receive a single-shot axillary-approach brachial plexus block. For the procedure, a 22g or larger peripheral intravenous cannula will be placed, and skin will be sterilized with chlorhexidine. Using aseptic technique, the anesthesiologist will anesthetize the skin and tract with 5cc of 1% lidocaine using a 25g 1.5 needle. After this, a 50mm 21g Pajunk needle will be guided under ultrasound with an in-plane technique to anesthetize the median, ulnar, radial, and musculocutaneous nerves. Identification of the axillary artery, vein and surrounding vessels will be done to ensure an intravascular injection is avoided. Once proper location is confirmed, the anesthesiologist will aspirate to ensure the needle is not intravascular. Once aspiration is confirmed negative, bupivacaine 0.25% 1.5mg/kg (lean body weight) will be injected in divided doses.~30 minutes after placement of the block, the standardized physiotherapy protocol will begin."
40795278|NCT05372978|BEHAVIORAL|Cash transfer|Participants will receive a one-time unconditional cash transfer of $8,500.
40795279|NCT02018523|DRUG|Lenalidomide|lenalidomide 10mg/day orally until disease progression
40795280|NCT01798901|DRUG|HDAC inhibitor AR-42|Given PO
41150662|NCT04750447|DEVICE|XEN 63|The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.
41150663|NCT01817088|PROCEDURE|New targeting procedure without electrophysiology|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.
41470864|NCT05589259|PROCEDURE|Physiotherapy alone|"Participants in the EXP arm and the CON arm will complete the same physiotherapy program.~PHYSIOTHERAPY PROTOCOL The physiotherapy program will include manipulation with or without a block. The goal of manipulation is to break up adhesions, possibly overcoming microvascular dysfunction. After the manipulation, participants will take part in a 6-week program which will include a weekly one-hour session with a physiotherapist at the KHSC-CPC and a home exercise program (HEP). During each session, the physiotherapist will work with the participants to increase ROM and limb function using manual therapy, stretching, and strengthening exercises specific to the affected joint(s) and most importantly using GMI. At the end of each session, the physiotherapist will prescribe exercises to complete at home."
41470865|NCT06590376|OTHER|midwifery care based on swanson care theory|All stages in the Midwifery Care and Counselling Practitioner Guide for Couples Experiencing Pregnancy Loss, which was developed by the researcher and included care, education and midwife counselling consisting of eight interviews, four of which were face-to-face and four by telephone, were applied.
41470866|NCT04287868|BIOLOGICAL|PDS0101|PDS0101 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.
41470867|NCT04287868|BIOLOGICAL|M7824|M7824 will be administered at a flat dose of 1,200 mg intravenous (IV) (over 1 hour) once every 2 weeks.
40795281|NCT01798901|DRUG|decitabine|Given IV
41150664|NCT01817088|PROCEDURE|Classical neurosurgical procedure|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
41150665|NCT03800602|DRUG|Metformin|Given PO
41150666|NCT03800602|BIOLOGICAL|Nivolumab|Given IV
41150667|NCT03015428|OTHER|psychoeducation|Providing knowledge and skills development in family caregivers of people with dementia, through a structured psychoeducational programme
41150668|NCT01741207|DRUG|N-acetylcystein|Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
41150669|NCT00139659|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
40795282|NCT01798901|OTHER|laboratory biomarker analysis|Correlative studies
40795283|NCT01798901|OTHER|pharmacological study|Correlative studies
40795284|NCT05014373|COMBINATION_PRODUCT|Favipiravir + Standard of Care|"1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care"
40795285|NCT05014373|PROCEDURE|Standard of Care|Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
40795286|NCT05075018|OTHER|Observational|Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
40795287|NCT00385385|DRUG|Rifalazil|
40795288|NCT00346658|DRUG|magnesium|
40795289|NCT02340169|DRUG|Topicort® (desoximetasone) Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
41312220|NCT00999856|DEVICE|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
41312221|NCT04113382|DRUG|CLENPIQ|"CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL."
41312222|NCT04113382|DRUG|MIRALAX|MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol \[PEG\] 3350).
41312223|NCT02141802|BEHAVIORAL|Doubling standing time|Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
41312224|NCT02141802|BEHAVIORAL|control|Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
41312225|NCT06490419|DEVICE|Electrolipolysis|"Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, with physiological nutrient content: carbohydrates-50%, proteins-20%, fats-30% and fiber daily consumption of 30 - 40 g in dry form (grain and vegetables). Calorie distribution: breakfast-40%, lunch-40%, dinner-20%. Behavioral therapy to correct eating disorders: diary of food and lifestyle, motivational phone calls every week~Electrolipolysis:~the participants will receive electrolipolysis applied to abdomen, thigh and gluteal regions, 3 sessions/week, for 3 months, 60 minutes/session; 30 minutes on the abdomen and thigh and 30 minutes on gluteal region. the device will be set to cause a contraction for 4 seconds followed by a relaxation for 4 seconds with a pulse width of 400 microseconds and a frequency of 20 pulses per minute."
41312226|NCT06490419|DEVICE|ultrasound cavitation|"Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, as in the electrolipolysis group.~ultrasound cavitation (UC): The participants will be treated by UC on the abdomen for 30 minutes, two sessions per week for 3 months. From standing position, the abdominal area of each patient will be divided transversally into 3 parts; part I: from the xiphoid process to 3 cm above the umbilicus, part II: from 3cm above the umbilicus to 2 cm below the umbilicus and part III: from 2 cm below the umbilicus to the pubic bone. Vertically, each part will be divided into right and left segments in relation to the linea alba, forming a total of 6 abdominal segments.~The program of cavitation; frequency (40 kHz) will be chosen, the time will be adjusted at 30 minutes. The cavitational head will be, then, moved very slowly on each abdominal segment in a small circular movement for 5 minutes."
41312227|NCT01929655|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
41000228|NCT05585814|DRUG|Capecitabine|Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3weeks for 3 cycles
41312228|NCT02381496|DRUG|ACT-453859 1 mg|Capsule
41312229|NCT02381496|DRUG|ACT-453859 3 mg|Capsule
41312230|NCT02381496|DRUG|ACT-453859 10 mg|Capsule
41312231|NCT02381496|DRUG|ACT-453859 30mg|Capsule
41312232|NCT02381496|DRUG|ACT-453859 100 mg|Capsule
41470868|NCT04287868|BIOLOGICAL|NHS-IL12|NHS-IL12 will be administered at as dose of potentially de-escalating doses by subcutaneous (SC) injection every 4 weeks.
41470869|NCT01780376|PROCEDURE|whole-body vibration (WBV)|whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
41470870|NCT02549846|DRUG|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
41470871|NCT05965791|DIAGNOSTIC_TEST|Phalen's wrist flexion test|The Phalen's test will be performed at different wrist flexion angles from 0 to 90 degrees.
41470872|NCT02807779|DRUG|Dexamethasone infusion|Participants will receive dexamethasone infusion following plain balloon angioplasty
41000229|NCT05585814|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 3cycles
41000230|NCT05585814|DRUG|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 3 cycles
41000231|NCT05585814|DRUG|Pembrolizumab|Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles
41000232|NCT01677091|OTHER|Cervical vibration|Vibration of neck muscles during 10 minutes
41312233|NCT02381496|DRUG|ACT-453859 300 mg|Capsule
41312234|NCT02381496|DRUG|ACT-453859 800 mg|Capsule
41312235|NCT02381496|OTHER|Placebo|Matching ACT-453859 placebo capsule
41312236|NCT02381496|DRUG|Setipiprant 500 mg|Capsule
41312237|NCT02381496|DRUG|Setipiprant 1000 mg|Capsule
41312238|NCT02985502|OTHER|pancreatogenic diabetes|pancreatogenic diabetes
41470873|NCT02807779|DEVICE|Drug coated balloon|Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
41470874|NCT02807779|DEVICE|Plain balloon angioplasty|Participants will receive plain balloon angioplasty only
41470875|NCT02037282|DRUG|Anti-influenza IVIG|
41470876|NCT06165445|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm) or via more than two but smaller round electrodes over the target regions.
41470877|NCT06165445|DEVICE|multichannel transcranial direct current stimulation (tDCS)|In multichannel tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through more than two and smaller round electrodes over the target regions.
41000233|NCT01677091|OTHER|Prism adaptation|Prism adaptation during 10 minutes
41000234|NCT01677091|OTHER|Conventional rehabilitation|conventional rehabilitation
41000235|NCT00243308|DRUG|Serine proteinase-1 (Serp-1)|
41000236|NCT04932785|OTHER|Regular diet|Regular diet
41000237|NCT04932785|OTHER|Clear Liquid Diet|Clear Liquid Diet
41000238|NCT03131063|OTHER|Antibiotic plasma dosage|Measurement of the concentration of antibiotics administered as part of the routine care of intensive care patients
41000239|NCT01971346|DRUG|etanercept|100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
41312239|NCT05650931|PROCEDURE|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and pain modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
41312240|NCT05650931|PROCEDURE|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation.|SNS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites in the cervical thickening (C5-T1). Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
41312241|NCT05650931|PROCEDURE|EEG to search for phantom pain biomarkers|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) when patient's pain returns to its preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
41000240|NCT03715608|OTHER|Psychological Intervention|The patients in the intervention group received psychological counseling and corresponding medication after the operation. Psychotherapy was based on the clinical expertise of the psychosocial specialist from Peking University Sixth Hospital, who selected the most appropriate plan for each patient.
41000241|NCT03925324|BIOLOGICAL|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg
41000242|NCT03925324|OTHER|Placebo|1.5 mL/kg Lactated Ringer's Solution
41000243|NCT03880903|DRUG|normal saline and salbutamol|patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours
41000244|NCT03880903|DRUG|hypertonic saline and salbutamol|patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours
41000245|NCT03880903|DRUG|Hypertonic saline|patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours
41000246|NCT04377282|OTHER|Food-1|Cooked buckwheat
41000247|NCT04377282|OTHER|Food-2|Cooked couscous
41312242|NCT03695640|DRUG|Magnesium Sulfate|Addition of magnesium sulfate as an adjuvant to levobupivacaine
41312243|NCT03695640|PROCEDURE|continuous femoral nerve block|continuous nerve block with levobupivacaine for treatment postoperative pain
41312244|NCT02765633|DRUG|Cangrelor|
41000248|NCT04377282|OTHER|Food-3|Water
41000249|NCT01045564|BIOLOGICAL|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
41000250|NCT01794403|RADIATION|Extended Hypofractionation Radiotherapy|A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.
41000251|NCT01794403|RADIATION|Accelerated Hypofractionation Radiotherapy|A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
41000252|NCT00895791|DEVICE|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
41000253|NCT00895791|DEVICE|culotte stenting (Xience V)|implantation of stent
41000254|NCT04796246|OTHER|Leap Motion Controller|Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.
41000255|NCT04796246|OTHER|Conventional Physiotherapy|The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
41000256|NCT03778151|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
40795290|NCT02963883|OTHER|SVO2 group / control group|
41312245|NCT04321252|DRUG|KAE609|"* iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)"
41312246|NCT04321252|DRUG|Placebo|matching placeo for iv administration
41470878|NCT00006102|DRUG|becatecarin|
41470879|NCT02000531|DRUG|Erlotinib|150 mg oral dose of erlotinib given once daily
41470880|NCT02000531|DRUG|Chemotherapy|Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1 and gemcitabine (1250 mg/m\^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
41150670|NCT00139659|DRUG|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
41150671|NCT04453306|DRUG|Topiramate|topiramate 25mg is coated in tablets in an independent laboratory
41150672|NCT04453306|DRUG|Placebo|innocuous substance is coated in tablets in an independent laboratory
41150673|NCT04609579|DRUG|SNX281|SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm.
41312247|NCT05160558|DRUG|BIIB132|Administered as specified in the treatment arm
40795291|NCT04738175|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
41150674|NCT04609579|DRUG|pembrolizumab|pembrolizumab (KEYTRUDA®) will be administered as an intravenous infusion on Day 8 in Cycle 1 (28-day cycle) and on Day 1 of each 21-day cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs.
41150675|NCT04842227|PROCEDURE|Nerve block|"Step 1: A small amount of local anesthetic (3-5cc of 0.5% ropivacaine) is administered under ultrasound guidance in the area of the supraclavicular nerve at the base of the neck under sterile conditions. This provides dense anesthesia of the skin and eliminates the need to introduce larger quantities of local anesthetic directly to the skin around the incision (usually 20mL).~The second step involves introducing 10-15cc of 0.5% ropivacaine under ultrasound guidance into the compartment between the pectoralis major and minor muscles to anesthetize the medial and lateral pectoral nerves. NOTE: Usual care involves blind administration of local anesthetic diffusely to the tissues in this region without targeting any particular nerves, and requires larger volumes of anesthetic (40mL for the blind approach vs 10-15mL for the nerve block)."
41150676|NCT04803994|DRUG|Atezolizumab|1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)
41150677|NCT04803994|DRUG|Bevacizumab|15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)
41150678|NCT04803994|PROCEDURE|TACE|Locoregional therapy will be performed as a standard-of-care procedure
41150679|NCT05286242|BIOLOGICAL|COVID19 vaccine|All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.
41150680|NCT05543759|DIETARY_SUPPLEMENT|Ready-To-Use Therapeutic Food (RUTF)|"* SAM \[MUAC \<115mm or WHZ \<-3 or oedema (+/++)\] = Two 92g sachets RUTF/day (Approx. 1000 kcal/day).~* MAM \[MUAC 115mm\<125mm or WHZ \<-2\] = One 92g sachet RUTF/day (Approx. 500 kcal/day)."
41150681|NCT00416585|DRUG|isotretinoin (Roaccutane)|
41150682|NCT03512288|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
41150683|NCT03512288|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
41150684|NCT05758922|DRUG|AZ-3102 (Dose 1)|"Pharmaceutical form: capsule~Route of administration: oral"
41150685|NCT05758922|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
41150686|NCT05758922|DRUG|AZ-3102 (Dose 2)|"Pharmaceutical form: capsule~Route of administration: oral"
41150687|NCT02962609|OTHER|Semielevated Side-lying Position-ESL|The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
41312248|NCT05160558|DRUG|BIIB132-Matching Placebo|Administered as specified in the treatment arm
41312249|NCT06288958|OTHER|Quality of Life and social participation in Italian children with CP|CP-QOL and PEM-CY questionnaires are fulfilled by families of children.
41312250|NCT03365804|DEVICE|3D Printed Brace|All subjects' body shape will be scanned to generate sterolithography (STL) files for 3D printing.
41312251|NCT01892618|DRUG|Prevenar 13|13-valent pneumococcal conjugated vaccine
41470881|NCT00717782|PROCEDURE|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
41470882|NCT00717782|PROCEDURE|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
41470883|NCT03064243|DRUG|apatinib|apatinib 500mg po. qd.
41470884|NCT00914979|DEVICE|AngioSculpt|The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
41470885|NCT02538835|BEHAVIORAL|Metacognitive therapy|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.
41470886|NCT02538835|BEHAVIORAL|Mindfulness based cognitive therapy, group|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel \& Segal.
41000257|NCT01106456|BEHAVIORAL|All Nations Breath of Life (ANBL)|ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
41312252|NCT01892618|DRUG|Pneumovax|23-valent pneumococcal polysaccharide vaccine
41312253|NCT03508635|DRUG|CORT125134|Oral capsules
41000258|NCT01106456|BEHAVIORAL|Nontailored program (NT)|"The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current best practice recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence."
41000259|NCT01106456|DRUG|Pharmacotherapy|All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
41000260|NCT04565054|DRUG|Abemaciclib 50 MG; 150mg 1-0-1 per os|Experimental: Abemaciclib plus ET Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
41000261|NCT02644707|DIETARY_SUPPLEMENT|L-selenomethionine|The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
41000262|NCT02644707|OTHER|Placebo|The group will be randomized to receive placebo (control group) for 6 months
41000263|NCT03490370|DEVICE|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4|In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.
41000264|NCT03734471|DEVICE|Reactor Device|The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
41000265|NCT03734471|PROCEDURE|Tube thoracostomy|Traditional chest tube placement
41000266|NCT02142166|PROCEDURE|Biomarker in serum, liquor, micro-dialysate|Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
41150688|NCT02962609|OTHER|Semielevated Supine Position|The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
41150689|NCT01257386|DRUG|Asacol®|400mg tablets
41150690|NCT01257386|DRUG|Mesalazine|400mg tablets
41150691|NCT03247985|DEVICE|PROLENE Polypropylene Tacking Mesh|Prolene mesh is a polypropylene plastic mesh (10 x 15 cm) implant fixed with titanium tacks
41150692|NCT03247985|DEVICE|ProGrip Self-fixating Mesh|"ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open \& laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid micro grips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation"
41150693|NCT03910491|BEHAVIORAL|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE emphasizes the 3 Ps (Praise, Paraphrase, and Point-out-Behavior). The training initially focuses on parenting skills including giving attention to the child's positive behaviors and ignoring minor misbehaviors. The second phase of training includes teaching techniques for giving children effective commands to set age-appropriate limits. The PriCARE curriculum also includes trauma and stress education components in order to contextualize the use of these skills with the types of behaviors and problems demonstrated by many children who have experienced psychosocial adversity and chronic familial stress. Throughout the curriculum, caregivers are encouraged to practice the skills. PriCARE has been evaluated in the primary care setting and has shown promise. There have been limited studies on PriCARE for foster caregivers.
41150694|NCT06225050|DEVICE|CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)|PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
41312254|NCT03508635|DRUG|Matching Placebo of CORT125134|Placebo
41312255|NCT03508635|DRUG|Mifepristone|Active comparator
41312256|NCT03508635|DRUG|Prednisone|Challenge agent
41312257|NCT03508635|DRUG|Glucose|
41312258|NCT01017809|DRUG|Aprepitant|Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
41312259|NCT04365439|BIOLOGICAL|Blood plasma|Convalescent plasma after COVID-19
41312260|NCT04627116|DRUG|Tecarfarin|Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.
41312261|NCT00313950|BIOLOGICAL|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
41312262|NCT00313950|BIOLOGICAL|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
40795292|NCT04738175|DRUG|Placebo|Diluent solution
40795293|NCT01725802|DRUG|Levodopa/carbidopa solution for SC administration|
41312263|NCT00313950|BIOLOGICAL|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
41312264|NCT05201274|BEHAVIORAL|Baduanjin sequential therapy|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
41312265|NCT05201274|BEHAVIORAL|Aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located at home or cardiac rehabilitation centre lasting 3 months. The program is consistent with the current recommended guidelines of moderate-intensity exercises for MI.
40795294|NCT01725802|DRUG|Placebo|
40795295|NCT01309204|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
41000267|NCT02142166|PROCEDURE|Biomarker in serum and in liquor|Single analysis of biomarker in serum and liquor
41000268|NCT01399593|DRUG|Eculizumab|
41000269|NCT02852031|OTHER|Collaborative Learning Network|
41000270|NCT03217227|OTHER|Cardiovascular Magnetic Resonance Imaging with Exercise Bike|A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.
41000271|NCT03217227|PROCEDURE|Cardiac Catheterization|"It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.~A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.~In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries.~If there is no significant narrowing lesions, the interventionist may perform additional flow resistance measurements of the small vessels to further investigate the cause of angina"
41150695|NCT01461343|OTHER|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
41150696|NCT06142799|PROCEDURE|root canal treatment|The root canal completedwill be completed. Then randomly it will be decided if the planned and milled overlay is placed the same day or delayed one week
41312266|NCT01658696|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 2 x 10\^8 pfu heterologous prime-boost immunisation
40795296|NCT01309204|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
41000272|NCT03217227|OTHER|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
41000273|NCT03217227|DIAGNOSTIC_TEST|I123 MIBG Scintigraphy (Optional)|"The test studies the cardiac sympathetic signalling that may help to identify patients with high risks of adverse events. The scan consists of 2 acquisitions of images 3-4 hours apart.~For this study, only patients without clinically significant lesions (diagnosed via the cardiac catetherisation and have normal FFR results) will undergo this test."
41000274|NCT02040610|RADIATION|Hypofractionated Proton Therapy|
41000275|NCT05222113|DRUG|Remdesivir|The patients, based on their clinical condition, got remdesivir OR favipiravir at least five days of treatment. The WHO ordinal scale was used to assess patients' clinical progress in the first and second weeks.
41000276|NCT00448071|DRUG|MTR107|
41312267|NCT01658696|BIOLOGICAL|Rabies vaccine|2 x 2.5IU Verorab
41312268|NCT05235217|DRUG|Test product (T) 40 mg Hard Gelatin Capsules|Hard Gelatin Capsules products containing 40 mg Esomeprazole
41312269|NCT05235217|DRUG|Reference product (R) 40 mg Hard Gelatin Capsules|Reference product (R) 40 mg Hard Gelatin Capsules
40795297|NCT01309204|DRUG|Brinzolamide 1% ophthalmic suspension|
40795298|NCT01309204|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|
40795299|NCT00293930|DRUG|Tacrolimus|
40795300|NCT04683406|DRUG|ZSP1273 600 mg|3 X 200-mg tablet taken orally
40795301|NCT04683406|DRUG|Placebo to Oseltamivir|Placebo capsules matching oseltamivir2 X 75-mg
40795302|NCT04683406|DRUG|Oseltamivir(oral)|2 X 75-mg tablet taken orally
40795303|NCT04683406|DRUG|Placebo to ZSP1273|Placebo capsules matching ZSP1273 600 mg
40795304|NCT03990532|RADIATION|treatment group(phase I)|"Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine"
41000277|NCT04167774|DRUG|Camrelizumab|Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg (3mg/kg for underweight patients).
41000278|NCT04167774|DRUG|nb-Paclitaxel|nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.
41150697|NCT01763489|BEHAVIORAL|Applicability Assessment|assess the applicability of a trial using the ASSIST tool or the synopsis
41150698|NCT01995565|OTHER|PLR|
41312270|NCT05909605|DEVICE|sphygmomanometer|Comparison to the ultrasound sensor
41312271|NCT05909605|DEVICE|Arterial Line|Comparison to the ultrasound sensor
41312272|NCT00302718|BEHAVIORAL|Physician-level financial incentives|Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
41000279|NCT03125512|DEVICE|Night Shift positional device|Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.
41000280|NCT03125512|DEVICE|continuous positive airway pressure|Automated adjusting continuous positive airway pressure
41000281|NCT00205712|DRUG|Ketamine|Ketamine without dexmedetomidine
41000282|NCT00205712|DRUG|Dexmedetomidine|Ketamine plus dexmedetomidine
41000283|NCT00617682|BIOLOGICAL|PNCRM9|0.5 mL IM at 30-35 wks gestation
41000284|NCT00617682|BIOLOGICAL|Placebo comparator|Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
41000285|NCT02372669|DEVICE|Chitosan nerve tube in addition to gold standard therapy|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
41000286|NCT02372669|PROCEDURE|Gold standard Primary microsurgical repair|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
41000287|NCT03729531|PROCEDURE|Conventional vein harvesting technique|Long incision will be used to expose the vein, the perivascular tissue will be dissected carefully by scissors, to check for leakage, the vein will be distended by injecting saline.
41000288|NCT03729531|PROCEDURE|no-touch vein harvesting technique|The vein will be harvested by low-frequency electrotome, about 5mm surrounding tissue will be preserved with the vein, distention should be avoided, the vein will not be cut off until being anastomosed.
41000289|NCT05706688|PROCEDURE|Anesthetic technique (regional versus general)|Anesthetic technique (regional versus general)
41000290|NCT03292081|DEVICE|OFDI|PCI under OFDI guidance
41000291|NCT03292081|DEVICE|IVUS|PCI under IVUS guidance
41000292|NCT02811939|DRUG|Active Dronabinol|20 mg capsule of Dronabinol will be administered orally
41000293|NCT02811939|DRUG|Active Pregnenolone|1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)
41000294|NCT02811939|DRUG|Placebo Dronabinol|Control: Placebo pill (no active cannabinoids) administered orally
41000295|NCT02811939|DRUG|Placebo Pregnenolone|Control: Placebo given sublingually (under the tongue)
41000296|NCT00698269|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
41000297|NCT00698269|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
41000298|NCT00698269|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
41312273|NCT00302718|BEHAVIORAL|Practice-level financial incentives|Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
41312274|NCT00302718|BEHAVIORAL|Physician- and practice-level financial incentives|Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
41312275|NCT05512208|DRUG|Avutometinib (VS-6766) + defactinib|"Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).~Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle."
41312276|NCT05345886|BEHAVIORAL|Hippotherapy|Hippotherapy is a rehabilitation method entrusted to a paramedic or medical practitioner who uses the horse in his/her program treatment, in addition to conventional medical care.
41312277|NCT02437058|OTHER|preidictive model|
41000299|NCT04968899|DRUG|Neofordex®|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.
41000300|NCT04968899|DRUG|Intravenous immunoglobulins|IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
41000301|NCT00180024|DRUG|irbesartan (drug)|
41000302|NCT04649775|DEVICE|AirFLO2|Mask device
41000303|NCT04209179|DRUG|PCO371|PCO371 capsule
41000304|NCT04209179|DRUG|Placebo|Placebo capsule
41000305|NCT00855491|PROCEDURE|Phaco|AcrySof Single-Piece IOL
41000306|NCT01467232|BIOLOGICAL|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
41000307|NCT01467232|BIOLOGICAL|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
41000308|NCT05018715|DIAGNOSTIC_TEST|Machine learning model diagnosis|Machine learning model diagnosis
41000309|NCT02000375|DRUG|DHEA|DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
41000310|NCT04914728|PROCEDURE|mini-invasive lumbar arthrodesis|"* The mini-invasive posterior approach is performed using a trans-muscular Wiltse approach. Pedicle screws, neurological decompression and intersomatic cage placement are performed.~* The mini-invasive anterior approach is performed via a left retroperitoneal pararectal approach. After complete discectomy, an intersomatic cage stabilised by a screwed plate will be placed."
41000311|NCT00180856|PROCEDURE|Radiofrequency ablation|
41000312|NCT03323528|DRUG|Benzalkonium Chloride-Benzocaine Topical|Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
41000313|NCT03323528|DRUG|Placebo Oral Tablet|"Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
40795305|NCT03990532|RADIATION|treatment group (phase II)|Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
40795306|NCT02817776|DEVICE|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
40795307|NCT05407116|OTHER|NCI PRO-CTCAE Questionnaire / EORTC QLQ-C30 Questionnaire|"PROs data will be collected prospectively via electronic questionnaires (PRO-CTCAE™), which is a patient-reported outcomes measurement system created to assess symptomatic toxicity in patients of cancer clinical research. PRO-CTCAE items evaluate frequency, severity, interference, amount, presence/absence symptoms. Each symptomatic adverse effect is measured by 1-3 features. GI items included nausea, vomiting, flatulence, bloating of the abdomen, constipation, diarrhea, abdominal pain, and loss of control of bowel movements. Urinary symptoms include the urge to urinate suddenly, frequency, urine colour change, loss of urine control (leakage).~Patients will also self-report health-related quality of life (QoL) in real-time, electronic PRO questionnaires (EORTC QLQ CX24, EN 24, C30) about QoL. Question 29 and 30 ask the patients to rate their overall health and QOL respectively during the past week on a scale between 1-7, where one is equivalent to very poor and seven is excellent."
40795308|NCT05712265|DRUG|Miricorilant|Miricorilant 6 x 100 mg coated tablets
40795309|NCT05712265|DRUG|Fluvoxamine|Fluvoxamine 50 mg tablet
40795310|NCT00022295|DRUG|idronoxil|
40795311|NCT00776542|DRUG|Minocycline 100mg Tablets|
40795312|NCT00924794|PROCEDURE|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
40795313|NCT04231682|DRUG|Denosumab Injection|Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
40795314|NCT04231682|DRUG|Placebos|Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
40795315|NCT04833946|OTHER|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
40795316|NCT04833946|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
40795317|NCT03419637|OTHER|Mobile app|The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
40795318|NCT03578926|DEVICE|fanfilcon A toric lens|contact lens
40795319|NCT03578926|DEVICE|senofilcon A toric lens|contact lens
40795320|NCT03384186|DRUG|Danicopan Modified Release Prototype 1|Danicopan (400 milligrams \[mg\]) oral tablet.
40795321|NCT03384186|DRUG|Danicopan Modified Release Prototype 2|Danicopan (400 mg) oral tablet.
40795322|NCT03384186|DRUG|Danicopan Modified Release Prototype 3|Danicopan (800 mg) oral tablet.
40795323|NCT01741298|BEHAVIORAL|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
40795324|NCT01720875|DRUG|Vorinostat Velcade Dexamethasone|
40795325|NCT03080571|BIOLOGICAL|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
40795326|NCT03080571|OTHER|standard care|
40795327|NCT01876680|OTHER|Stretching and aerobic exercise|"Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
40795328|NCT01876680|OTHER|Strength training|"Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
41000314|NCT04043195|DRUG|Nivolumab|240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
41000315|NCT04043195|DRUG|Oxaliplatin|65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
41000316|NCT04043195|DRUG|Ipilimumab|1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
40795329|NCT03203577|PROCEDURE|Initiation of mechanical ventilation|In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
40795330|NCT02929199|OTHER|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
41000317|NCT05937048|BIOLOGICAL|Albumin|20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.
41000318|NCT05937048|OTHER|Standard of Care|Standard treatment that the patient would receive had they not been included in the trial.
41312278|NCT02622724|DRUG|Interferon beta-1a|Investigational drug
41312279|NCT02622724|DRUG|Placebo|Placebo for investigational drug
41312280|NCT01219517|OTHER|Polar body and embryo biopsy|2 polar bodies and all embryos will be biopsied prior to embryo transfer.
41312281|NCT01673503|DEVICE|Carl Zeiss Meditech VisuMax laser|Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
41312282|NCT01067508|OTHER|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
41312283|NCT06017583|DRUG|Tislelizumab|Tirellizumab was administered intravenously at 200mg/d1, 21 days per cycle, with at least 4 cycles completed.
41312284|NCT06017583|DRUG|Capecitabine|Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
41312285|NCT06017583|DRUG|Oxaliplatin|Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
41312286|NCT06017583|RADIATION|SIB-IMRT|The tumor and the related mesenteric region 1cm above and below were simultaneously integrated boost to 5600cGy with the intensity-modulated radiotherapy. The other dose for clinical target volume is 5000 cGy.
41312287|NCT06017583|RADIATION|IMRT|The whole dose of the clinical target volume is 5000 cGy with intensity-modulated radiotherapy.
41312288|NCT04614116|OTHER|External cooling|water-circulating cooling/warming sleeves connected to a medical cooling device (Hilotherm Clinic®, Hilotherm GmbH, Germany) will be placed around the subject's abdomen and lower back. Initially the temperature of the water will be set to 25°C. A mild cold stimulus will be applied by reducing the temperature of the circulating water by approximately 1°C every 2 minutes to a minimum of 10°C.
41312289|NCT04614116|DIAGNOSTIC_TEST|FDG PET/CT|o 75 MBq 18F-FDG will be injected through the intravenous line on the scanner manually (bolus injection) with a simultaneous start of dynamic FDG-PET/CT scan for 45 minutes and a partial body scan from head to the abdomen after 45 minutes. Total scan time 60 minutes.
41312290|NCT04614116|DIAGNOSTIC_TEST|13C-Glucose injection|0.5 g 13C-Glucose i.v. infusion over 5 minutes, after termination of FDG injection
41312291|NCT04548999|DRUG|Ocrelizumab|"The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (participants's body weight \<75 kg) or 1800 mg (participant's body weight \>/=75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion every 24 weeks.~During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total)"
41312292|NCT04548999|DRUG|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 milligram (mg) every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
41312293|NCT04548999|DRUG|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
41000319|NCT05094934|DRUG|NNC0385-0434 A 100 mg|All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
41000320|NCT05360836|OTHER|Conservative treatment via telerehabilitation|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks."
41000321|NCT05360836|OTHER|Conservative treatmen + motor imagery|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images."
41000322|NCT03667352|PROCEDURE|Unilateral Scalp Block|Scalp block is provided by injecting local anaesthetic in the scalp at specific areas to block 6 nerves which are responsible for sensory innervation of the scalp - Supraorbital and supratrochlear nerves, Zygomaticotemporal nerve, Auriculotemporal nerve, Greater and lesser occipital nerves.
41000323|NCT03667352|PROCEDURE|Transversus abdominis plane block|The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). It is usually accomplished by a single bolus injection into the transversus abdominis plane through the lumbar triangle of Petit and can be accomplished either by blind landmark based technique or alternatively under ultrasound guidance (as in this study).
41000324|NCT03667352|DRUG|Intravenous Fentanyl|Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
41000325|NCT02322554|BIOLOGICAL|Cellular and tissue based products|Procedure: Application of device or biological to wounds
41312294|NCT04548999|DRUG|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
41312295|NCT03408548|PROCEDURE|Scaling root planning|Periodontal treatment
41312296|NCT03408548|DIETARY_SUPPLEMENT|Probiotic|two lozenge per day containing Bifidobacterium animalis lactis HN019
41312297|NCT03408548|OTHER|Placebo|two lozenge per day not containing Bifidobacterium animalis lactis HN019
41312298|NCT00856479|DEVICE|Infuse Bone Morphogenic Protein (BMP) 2|"Infuse is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. Infuse may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention."
41312299|NCT00856479|PROCEDURE|iliac crest autograft|A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
41312300|NCT05962814|DEVICE|EarGenie MVP test|The EarGenie test consists of placing the EarGenie headgear on the infant and running the fNIRS tests via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation. Automatic analyses are run to determine whether the infant heard the sounds or discriminated between them. The infant will be in a natural sleep when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
41312301|NCT02961686|RADIATION|Patients affected by prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
41312302|NCT00786032|DEVICE|BCI Device|A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
41312303|NCT02673892|OTHER|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
40795331|NCT02929199|OTHER|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
40795332|NCT03147378|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
41000326|NCT00824863|DRUG|ketoconazole 2% foam|topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
41000327|NCT01190254|DRUG|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
41000328|NCT01190254|DRUG|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
41000329|NCT01190254|DRUG|placebo|asenapine-matched placebo tablets for sublingual administration
41000330|NCT01162382|DEVICE|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
41150699|NCT03500796|PROCEDURE|Platelet rich plasma clot implantation|Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane
41150700|NCT03500796|PROCEDURE|Wound closure with amniotic membrane|Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin
41150701|NCT03419806|DRUG|Infudopa i.v.|"Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa.~From patient 6 and onwards:~Infudopa IntraV, at 81% of the subject's individual pre-study daily Duodopa dose, will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The i.v. morning bolus is 110% of the hourly continuous dose delivered at the rate of 60 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer IntraV). The morning dose will not exceed 24 mL, corresponding to 240 mg levodopa. The maximum daily dose levodopa during i.v. administration is not allowed to exceed 3240mg (equal to 81% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
41150702|NCT03419806|DRUG|Infudopa s.c.|"A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h.~From patient 6 and onwards:~Two infusion needles will be placed on the abdomen for the s.c. infusion of Infudopa SubC in 86% of the the subject's individual pre-study daily Duodopa dose. The intervention is given as a continuous fixed infusion rate for 16h preceded by a morning bolus dose. The s.c. morning bolus is 155% of the hourly continuous dose delivered at the rate of 80 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer SubC). The morning dose will not exceed 30 mL. The maximum daily dose levodopa during s.c. administration is not allowed to exceed 3440mg (equal to 86% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
41312304|NCT03153735|DEVICE|CMDHA0101|Maximum injection dose : 22 ml
41312305|NCT03153735|DEVICE|PowerFill®|Maximum injection dose : 22 ml
41312306|NCT02375958|DRUG|PCA062|
40795333|NCT00719498|DRUG|Epo-alpha|
41000331|NCT04406064|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into study participants who have evidence of SARS-CoV-2 infection.
41000332|NCT03033017|OTHER|Blood Testing|
41000333|NCT05040633|DEVICE|BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))|Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
41000334|NCT05040633|OTHER|Standard Exercise Therapy|Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
41000335|NCT01965288|DEVICE|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
41312307|NCT04832919|BEHAVIORAL|Nurse-Community-Family Partnership Intervention|Nurses conduct home visits on a monthly basis for the first five months post-baseline. During visits, nurses emphasize the importance of infection control measures and, jointly with household members, develop and follow-up on the implementation of an infection control plan tailored to the unique circumstances of the household. Nurses deliver training on infection control skills necessary for optimal implementation of the plan. Nurses offer at-home SARS-CoV-2 testing to all members of the household. Nurses conduct triage, medical case management, monitoring, and follow-up of individuals identified to have COVID-19 or any other acute health emergencies. CHWs conduct visits on a bi-weekly basis for the first five months post-baseline. CHWs deliver healthcare information and medical mistrust counseling in a culturally relevant and linguistically appropriate fashion; and provide social support, navigate household members to social welfare/vocational/economic/psychosocial services.
40795334|NCT02522429|DEVICE|Low Intensity Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
40795335|NCT00196690|DRUG|Donepezil|
40795336|NCT00211172|BEHAVIORAL|Beta-blocker adherence after an AMI|The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
41000336|NCT01965288|DEVICE|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
41000337|NCT06329102|PROCEDURE|Surgical access|Complications by Clavien Dindo Number of lymph nodes. Disease free and Overall survival
41000338|NCT05009394|PROCEDURE|Targeted Muscle Reinnervation (TMR)|Surgical procedure used to rewire injured proximal nerves to motor nerves directly innervating an otherwise redundant target muscle.
41000339|NCT05009394|PROCEDURE|Regenerative Peripheral Nerve Interface (RPNI)|Surgical procedure where the the nerve is split into fascicles and wrapped in free muscle grafts.
41000340|NCT05009394|PROCEDURE|Standard neuroma treatment, neuroma excision, and muscle burying|Surgical procedure where the neuroma is excised and the nerve stump is buried in an adjacent deep muscle.
41000341|NCT00187746|DRUG|Adefovir dipivoxil|Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
41000342|NCT04198727|OTHER|DPD activity assessment|Phenotyping DPD with enzyme activity measure and uracil dosage
41000343|NCT04198727|DRUG|Capecitabine|Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of
41150703|NCT03419806|DRUG|LCIG (Duodopa)|"Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.~From patient 6 and onwards:~The pre-study daily Duodopa dose will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The morning bolus is 110% of the hourly continuous dose delivered at the rate of 40 ml/h. The morning dose will not exceed 15 mL, corresponding to 300 mg levodopa. The maximum daily dose levodopa is not allowed to exceed 4000mg."
41150704|NCT03974997|DIAGNOSTIC_TEST|Determination of the circulating serum concentration of cytoquine TWEAK|Blood samples (20 ml of blood on dry tube) by venipuncture at the bend of the elbow will be made at T0, then monthly for a period of 1 year . The sera will be isolated by centrifugation and then frozen at -80 degrees Assays of the soluble form of TWEAK and TNF will be performed by ELISA blot technique developed by the team.
41150705|NCT05707689|BEHAVIORAL|Entertainment gaming|If needed, gaming schedule will be tailored based on the participants' individual needs (working, studying, family issues) as long as the total gaming hours will be achieved. Participants are encouraged not to play video games during the study period. Participants' gaming interventions will be monitored carefully and recorded after each gaming session in specific gaming diary.
41150706|NCT01648699|DRUG|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
41150707|NCT06320509|BIOLOGICAL|Continuous measurement of uPO2 (both groups)|uPO2 is collected continuously for the first 5 days of admission or until discharge from intensive care or removal of the urinary catheter.
41312308|NCT04191421|BIOLOGICAL|Siltuximab|Given IV
41312309|NCT04191421|BIOLOGICAL|Spartalizumab|Given IV
41312310|NCT04039633|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
41312311|NCT04039633|PROCEDURE|Sham spinal cord stimulation|A pulse generator is implanted, but no spinal cord stimulation is provided
41312312|NCT01879956|OTHER|Craft Activities|There is no intervention method used to perform the task.
41017771|NCT04713384|DEVICE|Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games|20 sessions of playing therapeutic games using both arms while siting at a table at home. Arms hold either generic game controllers, or BrightBrainer therapeutic controllers. Sessions involve a variety of games that train motor and cognitive function in an integrative way. The games are rendered by the BrightBrainer system. Games adapt and are winnable, benefiting well-being (reducing depression). Each session may generate many hundreds of arm repetitions, finger movement and grasps, depending on session duration. Data on arm reach as well as game outcomes and vitals are uploaded to an secure server. These data allow researchers to remotely monitor compliance to protocol and longitudinal progress. Caregivers are present at each session, and provide feedback as well as subjective ratings of the system.
41312313|NCT01879956|BEHAVIORAL|OGI Method|metacognitive approach to assess executive functions.
40795337|NCT03461562|OTHER|Aerobic Exercise|Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
40795338|NCT04434430|DRUG|Gabapentin|Oral Gabapentin 600 mg
40795339|NCT04434430|OTHER|Placebo|Oral NaCl 500 mg
40795340|NCT04377958|DIAGNOSTIC_TEST|Serum biomarker testing|Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
41312314|NCT04839770|DEVICE|Axonpen system|"The Axonpen™ system, containing the Axonpen and the Axonmonitor, has been cleared for the illumination and visualization of intracranial tissue and fluids and the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum.~The Axonpen is a neuroendoscope integrated with suction (sourced from hospital vacuum) and irrigation (sourced from third-party saline infusion bag) functions. The Axonmonitor is used for view and storage of the endoscopic image. The Axonpen™ system is intended to optimize the procedure of minimally invasive neurosurgery for early ICH evacuation."
41312315|NCT01897922|OTHER|An investigational infant formula containing a probiotic source|
41312316|NCT01897922|OTHER|Control: Marketed routine infant formula|
41312317|NCT04720586|PROCEDURE|lower eyelid blepharoplasty , retractor plication and wedge resection|combined lower eyelid blepharoplasty , retractor plication and wedge resection
41312318|NCT04720586|PROCEDURE|lower eyelid blepharoplasty and retractor plication|combined lower eyelid blepharoplasty and retractor plication procedures
41312319|NCT01606761|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
40795341|NCT04646252|OTHER|Perfused Boundary Region of sublingual microvessels|Measurement of Perfused Boundary Region of sublingual microvessels to assess thickness of endothelial glycocalyx Measurement of Pulse Wave Velocity to quantify arterial stiffness
41000344|NCT04338464|BEHAVIORAL|Psychosocial therapy for South Asian women experiencing mood disorders|"The 12 week intervention has four major components:~* Relational theory (Belgrave, 2002) \& South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~* Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek \& Ehrenriech-May, 2012; Ritschel, Noriel \& Lindsay, 2015).~* Psychoeducation on mental health, sexual health, and substance use.~* Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support."
41000345|NCT01663415|DRUG|Enzalutamide|oral
41000346|NCT00291122|DRUG|celecoxib 400 mg BID|
41000347|NCT05686265|DRUG|Oxygen|Physiological intervention consisting of 1 hour of mild hypoxia (PaO2 9-10 kPa), 1 hour of mild hyperoxia (PaO2 13-14 kPa), and in healthy subjects also 1 hour of an inspired oxygen fraction of 100%.
41000348|NCT03774940|DIAGNOSTIC_TEST|peripheric blood count|preoperative peripheric blood count
41312320|NCT01606761|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
41312321|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
41312322|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
41312323|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
41312324|NCT01503060|BEHAVIORAL|Educational video - Active|The active video will instruct parents in techniques related to optimal infant soothing.
40795342|NCT05111197|RADIATION|SRT|"Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy are treated with SRT, in addition to their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.~A maximum of 3 Brain metastases treatable in stereotactic radiotherapy will be included among these hypermetabolic lesions.~Each lesion is treated with a total dose of 24 Gy delivered in 3 fractions of 8 Gy (isodose surface)."
41000349|NCT02150564|DEVICE|Sonowand|Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure
41000350|NCT02150564|PROCEDURE|Navigation|Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.
41000351|NCT00838201|DRUG|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
41000352|NCT00661700|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
41312325|NCT01503060|BEHAVIORAL|Educational Video - Sham|The sham video will provide general information about immunization immunization pain management.
40795343|NCT05111197|DRUG|Immunotherapy|Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
41312326|NCT01503060|DRUG|Sucrose Placebo (water)|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
41312327|NCT01503060|DRUG|Sucrose|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
41312328|NCT01503060|DRUG|Lidocaine Placebo|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
41312329|NCT01503060|DRUG|Lidocaine|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
40795344|NCT02113423|RADIATION|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT|3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID\*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID\*2F
41312330|NCT00632541|DRUG|Sorafenib|Sorafenib 200mg po daily
41312331|NCT00632541|DRUG|Bevacizumab|"Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks"
41312332|NCT00632541|OTHER|Imaging|Imaging every third cycle
40795345|NCT04549558|DIAGNOSTIC_TEST|Multimodal Ultrasound|Multimodal Ultrasound (Strain Ultrasound Elastography, Conventional Grey-Scale Ultrasound, Color-Doppler Ultrasound, and Ultrasound Guided Fine Needle Aspirate) on Axillary Lymph Nodes
40795346|NCT06370312|PROCEDURE|Trapeziectomy|Patients scheduled for trapeziectomy due to thumb basal joint osteoarthritis are invited to participate. Synovial fluid is aspirated before the joint is opened. Bone and cartilage are collected. Blood samples are obtained preop. Patients are measured with grip strength, pinch strength, range of thumb motion, body mass index, central obesity and blood pressure.
40795347|NCT00075855|DRUG|therapeutic testosterone|
40795348|NCT00075855|OTHER|placebo|
40795349|NCT01132846|OTHER|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
40795350|NCT01132846|DRUG|Nesiritide|"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
40795351|NCT01132846|DRUG|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
40795352|NCT00792090|OTHER|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
40795353|NCT00792090|OTHER|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
40795354|NCT05620056|DRUG|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs|medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
41000353|NCT00661700|DRUG|Placebo|10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
41000354|NCT02597556|DRUG|Albendazole|A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
41312333|NCT05315232|OTHER|survey and interview|qualitative assessment
41312334|NCT03489616|BIOLOGICAL|rhGM-CSF|rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.
40795355|NCT03340285|DIETARY_SUPPLEMENT|AkP06|first 2 weeks: Placebo + Diet then 4 weeks AkP06 two tablet/day before meals + Diet
40795356|NCT03340285|DIETARY_SUPPLEMENT|Placebo|first 2 weeks: Placebo + Diet then 4 weeks placebo two tablet/day before meals + Diet
40795357|NCT01819363|PROCEDURE|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
40795358|NCT04220580|OTHER|Blood samples|3 blood samples, two for RNA and one for metabolites are taken 5 minutes before a Cold Pressor Test and again 1 hour after the Cold Pressor Test.
40795359|NCT05929430|BEHAVIORAL|Mindfulness program|Six weeks mindfulness program. The program is explained in arm descriptions.
40795360|NCT05929430|BEHAVIORAL|Mindfulness program with Virtual Reality|Six weeks mindfulness program. The program is explained in arm descriptions.
41000355|NCT02597556|DRUG|Placebo|Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
41000356|NCT00215046|DRUG|Vinblastine|drug - dosage and frequency is based on size of patient and response to treatment.
41000357|NCT00215046|DRUG|Methotrexate|drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
41312335|NCT03489616|DRUG|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
41312336|NCT03489616|RADIATION|Local Radiotherapy|Radiotherapy promotes the release of tumor antigen
41312337|NCT03489616|DRUG|Single agent|Other chemotherapy drugs,such as Docetaxel, gemcitabine
41312338|NCT05665621|OTHER|Eight-week in-school strength and balance training program|Training program consisting of two 1-hour strength and balance training sessions per week.
41312339|NCT00679679|DRUG|Metformin|Metformin 750 mg BID for 4 months
41312340|NCT00679679|DRUG|Placebo|Diet counseling and exercise
41312341|NCT00610376|BEHAVIORAL|Preschool handwashing intervention program|This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
41312342|NCT00610376|BEHAVIORAL|Home component intervention|The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
41312343|NCT05835752|DRUG|RAY1225|Administered SC
41312344|NCT05835752|DRUG|Placebo|Administered SC
41312345|NCT05835752|DRUG|RAY1225|Administered SC
41312346|NCT05835752|DRUG|Placebo|Administered SC
41312347|NCT05835752|DRUG|RAY1225|Administered SC
41312348|NCT05835752|DRUG|Placebo|Administered SC
41312349|NCT00840944|DRUG|somatropin|somatropin 0.050 mg/kg/day
41312350|NCT00840944|DRUG|triptorelin|triptorelin 3.75 mg each month
41312351|NCT01320111|DRUG|Paclitaxel and Sorafenib|"intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15~AND~pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day"
41312352|NCT01320111|DRUG|Paclitaxel|intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
41312353|NCT04657952|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine \& adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.
41312354|NCT04657952|DRUG|Medical Treatment|Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.
41312355|NCT00104494|DRUG|Zinc acetate (20mg/d)|Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
41312356|NCT00100724|BIOLOGICAL|rPA102|
41470887|NCT02538835|BEHAVIORAL|Support groups|Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
41470888|NCT06616662|PROCEDURE|MAF|use mucosal advancement flap to treat PAF
41470889|NCT06616662|PROCEDURE|LIFT|use LIFT surgery for treating PAF
41470890|NCT02997137|DIETARY_SUPPLEMENT|BOT-01|"Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
40795361|NCT03159910|BEHAVIORAL|Shoulder-Café|Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
40795362|NCT03159910|BEHAVIORAL|Shoulder-Guidance|Home-based shoulder exercise and written counselling.
40795363|NCT01606904|BEHAVIORAL|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
40795364|NCT02567799|DRUG|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
40795365|NCT02567799|DRUG|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
40795366|NCT02567799|DRUG|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart."
40795367|NCT02567799|RADIATION|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
41000358|NCT02202447|DRUG|EC1169|"PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule."
41000359|NCT02202447|OTHER|EC0652|PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
41000360|NCT02212821|DRUG|Erythromycin|
41000361|NCT02212821|DRUG|Placebo|physiological saline
41312357|NCT00661401|BIOLOGICAL|gammaglobulin|They were administered a polyvalent, pasteurized liquid immune globulin subcutaneously (human 16% Beriglobin ®, Germany) with doses ranging from 57 to 132 mg/kg/week in order to maintain the same dosage they received by intravenous route monthly previous to this protocol. After a wash-out period (15 weeks) of the subcutaneous immunoglobulin administration, blood was collected every 4 weeks immediately before infusions. The infusions were administered using battery-powered ambulatory syringe drivers together with 10 or 20 ml syringe and infusions sets according to a pre-defined protocol (Gardulf et al, 2006).
41000362|NCT00811564|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
41470891|NCT02997137|OTHER|Placebo|"Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
41470892|NCT05789485|BEHAVIORAL|structured treadmill walking|Three doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered throughout treatment.
41470893|NCT03616002|OTHER|Hookah smoking|ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
41470894|NCT06039020|DRUG|Anti-human thymocyte immunoglobulin, equine|Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be slowly administered by intravenous drip infusion once daily. The duration of treatment should be 4 days.
41470895|NCT03684031|BEHAVIORAL|Cognitive Control Training|A computer-based flanker task that aims to reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
41470896|NCT03684031|BEHAVIORAL|Sham Cognitive Control Training Program|A placebo version of the computer-based cognitive control training. Designed to appear similar to the experimental task, but will not reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
40795368|NCT00187304|DEVICE|Aortic valve replacement|
41312358|NCT00153894|BEHAVIORAL|Strength training|One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
41312359|NCT00153894|BEHAVIORAL|Endurance training|Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
41312360|NCT01887587|DRUG|MLN9708|
41312361|NCT01887587|DRUG|Vincristine|
41312362|NCT01887587|DRUG|Doxorubicin|
41470897|NCT03286608|OTHER|observational study (no intervention)|Statistical association between adherence to a pattern of polyphenol intake and the risk to develop dementia and Alzheimer's disease over 12 years
41470898|NCT05994248|DEVICE|Enform Mesh|Use of absorbable mesh in umbilical hernia repair
41312363|NCT01887587|DRUG|Dexamethasone|
41470899|NCT05994248|DEVICE|Marlex|Use of non-absorbable mesh in umbilical hernia repair
41470900|NCT03081728|DEVICE|Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml|bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
41470901|NCT03081728|DRUG|IV diclofenac and IV paracetamol|iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
41470902|NCT05287503|DRUG|Ambroxol Hydrochloride|Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.
41470903|NCT05287503|DRUG|Placebo|Excipients
41470904|NCT05110131|DEVICE|Device for performing biopsy via electromagnetic navigation bronchoscopy|Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)
41312364|NCT00804258|DRUG|intraperitoneal chemotherapy|
41312365|NCT00804258|OTHER|educational intervention|
41312366|NCT00804258|OTHER|medical chart review|
41470905|NCT05436704|PROCEDURE|EUS-FNB|EUS-FNB
41470906|NCT06616038|OTHER|Data collection|Given the observational nature of the study, the intervention is a simple data collection
41000363|NCT00811564|DRUG|latanoprost 0.005%|1 drop of study medication taken once daily
41000364|NCT00842348|DRUG|lanreotide (Autogel formulation)|Autogel 120 mg
41000365|NCT02188238|OTHER|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
41000366|NCT06436846|OTHER|Biospecimen sample collection during standard-of-care surgery|Patients in this observational study are undergoing planned surgical resection of their retroperitoneal sarcoma as prescribed by their primary surgeon and treatment team. In addition to removal of the primary tumor, surgeons remove 4 samples of retroperitoneal fat and a sample of subcutaneous fat for further study at the time of the operation.
41000367|NCT03266328|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
41470907|NCT06616558|OTHER|Sunscreen SPF 70|Participants will topically apply sunscreen SPF 70
41470908|NCT06616558|OTHER|Sunscreen SPF 70|On the randomized side of the half-face, the product will be applied by a qualified technician
41000368|NCT04260958|OTHER|Exercise-based cardiac rehabilitation|The exercise program (remote/centre-based) will be standardized. An exCR-program is defined as at least 24 supervised sessions, with a total session length of 60 minutes, for at least 3 months, with possibility to complete missed sessions the 4th month. Each exercise session includes at least 20 min of aerobic exercise, intensity 13-17 on Borg´s rating of perceived exertion (RPE)-scale ≈ 60% - 85% of VO2max or 70 - 95% of maximal heart rate. In addition, each exercise session includes 1-3 sets of 8-10 upper and/or lower limb exercises in 10-15 repetitions, 40-80% of 1 repetition maximum. Attending ≥75% of the 24 sessions over a 4-month period will be considered as successful.
41000369|NCT06458894|BEHAVIORAL|Prerehabilitation|Home prerehabilitation was performed on the basis of routine preoperative preparation
41000370|NCT01564303|DRUG|Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine|to evaluate the effect of the above agents on Kidney functioning parameters
41017772|NCT01795508|BEHAVIORAL|PMTO|Parent Management Training, Oregon
41312367|NCT00804258|OTHER|questionnaire administration|
41470909|NCT03942419|DRUG|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered with a microdose dispenser
41470910|NCT03942419|DRUG|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered with a microdose dispenser
41470911|NCT03942419|DRUG|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered with a microdose dispenser
40795369|NCT06204588|PROCEDURE|control group: SFA only|Single flap approach
41312368|NCT00804258|PROCEDURE|assessment of therapy complications|
41312369|NCT00804258|PROCEDURE|end-of-life treatment/management|
41312370|NCT00804258|PROCEDURE|psychosocial assessment and care|
41312371|NCT00804258|PROCEDURE|quality-of-life assessment|
41312372|NCT03134508|OTHER|treated by antiTNFα|pregnant IBD women treated by antiTNFα
41312373|NCT03134508|OTHER|not treated by antiTNFα|pregnant IBD women not treated by antiTNFα
41312374|NCT05344144|OTHER|Emotional Freedom Technique|EFT was applied to pregnant women with a history of prenatal loss twice, one week apart, by the researcher. Between the two treatments, they were given personalized homework (on waking up in the morning and before going to sleep at night) for self-administration.
41470912|NCT01782755|DRUG|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
41470913|NCT01782755|OTHER|Placebo - Microcrystalline Cellulose|Placebo capsule, twice daily (containing Microcrystalline Cellulose)
41470914|NCT01647958|DEVICE|EsophyX System with SerosaFuse fasteners|Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication using the EsophyX System with SerosaFuse fasteners
41470915|NCT01647958|DRUG|PPI|Control Arm participants will take maximum standard dose of PPI during Initial Study period
40795370|NCT06204588|PROCEDURE|Test group 1: VCMX + Low level LASER therapy + Single flap approach|using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
40795371|NCT06204588|PROCEDURE|Test group 2: Low level LASER therapy + Single flap approach|Laser therapy in horizontal bone loss defects by single flap approach (SFA+LLLT).
40795372|NCT03755245|OTHER|[68Ga]Ga-DOTA-Siglec-9|Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
40795373|NCT01645774|PROCEDURE|10s injections duration|10s injections duration
41312375|NCT05344144|OTHER|Music|Music practice was applied to the pregnant women with a history of prenatal loss twice, one week apart, by the researcher. For one week after the first application, the music application was applied by the pregnant woman once a day/for 30 minutes, and the researcher was reminded by phone message.
41312376|NCT01488318|DRUG|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
40795374|NCT01645774|PROCEDURE|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
40795375|NCT01645774|PROCEDURE|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
40795376|NCT01645774|PROCEDURE|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
40795377|NCT03186092|OTHER|respiratory muscle training|The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.
40795378|NCT03186092|OTHER|sham muscle training|sham comparator
40795379|NCT05223023|OTHER|questionnaire|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
41312377|NCT01488318|DRUG|Dasatinib|Dasatinib 150 mg po
41312378|NCT03247660|OTHER|PFM training|See information included in arm/group descriptions.
41312379|NCT03247660|OTHER|HE|See information included in arm/group descriptions.
41312380|NCT03247660|BEHAVIORAL|Educational strategy|See information included in arm/group descriptions.
41312381|NCT02393118|DEVICE|BrainPort V200 Device|Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
40795380|NCT02295462|OTHER|Person-centered Care|Medication Review + Person-centered Care
40795381|NCT02295462|OTHER|Optimised Treatment|Medication Review only
41000371|NCT04872855|DEVICE|patient with knee arthroplasty|patient with HLS KneeTec cementless and hybrid fixation prosthesis
41312382|NCT00285974|DEVICE|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
40795382|NCT03180580|BEHAVIORAL|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
40795383|NCT00885183|PROCEDURE|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
40795384|NCT02508545|OTHER|perceived egocentric distance (PED) measurements|
40795385|NCT02508545|OTHER|Parabolic flight|
41000372|NCT05269693|OTHER|Brief Hope Intervention|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions
41000373|NCT00060996|DRUG|Remodulin® (treprostinil sodium) Injection|
41000374|NCT05318144|OTHER||
41000375|NCT05705622|OTHER|Oral mukositis nurse's education for patients|Education given to patients by nurses on the prevention, treatment and care of oral mucositis
41000376|NCT03876327|PROCEDURE|fecal microbial transplantation|Fecal microbiota transplantation (FMT) is a technique in which intestinal microbiota are transferred from a healthy donor to the patient, with as primary goal to introduce - or restore - a stable and 'healthy' microbial community in the gut.
41017773|NCT01795508|BEHAVIORAL|TAU|Other kinds of family training
41017774|NCT04771741|DRUG|Acetominophen|1,000 mg every 6 hours
41017775|NCT04771741|DRUG|Toradol|10 mg every 6 hours, days 0-3
41017776|NCT04771741|DRUG|Meloxicam|15 mg once daily, beginning post-op day 4
41017777|NCT04771741|DRUG|Cyclobenzaprine|10 mg every 8 hours
41017778|NCT04771741|DRUG|Lyrica|75 mg every 12 hours
41017779|NCT03849638|OTHER|Gait training with real time biofeedback|"Patients presenting asymmetry of the kinematic parameters of the step to the evaluation with sensorized treadmill, will undergo gait training program.~The training program consists of 20 session (1 session/day) of gait training. Daily gait training will last 30 minutes as distributed:~* 5 minutes of heating at a comfortable speed for the patient~* Three 5-minute sessions of gait training with biofeedback interspersed with a break of 5 minutes each."
41017780|NCT06272747|DRUG|XH-S003|IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
41017781|NCT06272747|DRUG|Placebo|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
41017782|NCT05622591|DRUG|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
41000377|NCT04244786|DEVICE|Transcranial direct current stimulation|tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
41312383|NCT05653739|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|MBSR is Mindfulness based intervention designed by Kabat-Zinn (1990) in order to deal with the stress and other psychological issues among individuals. This has been very effective intervention across different cultures . In this 8 week intervention participants will be given some home tasks to practice for at least 40 minutes a day.
41312384|NCT03389061|DRUG|sofosbuvir/velpatasvir tablet|Single-dose SOF/VEL as a whole tablet in a fasted state.
41312385|NCT03389061|DRUG|sofosbuvir/velpatasvir crushed|Single-dose crushed SOF/VEL in a fasted state.
41000378|NCT04244786|OTHER|No intervention|No intervention for participants who discontinued prior to randomization
41470916|NCT01422486|DRUG|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
41470917|NCT04340999|DIAGNOSTIC_TEST|Nerve conduction studies and Quantitative EMG ( MUNE and IPA)|"Nerve Conduction Studies: Electrophysiological method that tests the presence/absence of peripheral neuropathy.~MUNE: Electrophysiological technique that assess number of motor units. IPA: Electrophysiological method that assess interference pattern and hence, borderline cases of neuropathy/ myopathy"
41470918|NCT06298214|BEHAVIORAL|Her Health Program|Addition of a community health worker navigator to assist subject in navigating their health in the first year postpartum.
40795386|NCT04884503|DRUG|Clonazepam tablets|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
40795387|NCT04884503|DEVICE|tongue pads|wearing a tongue pad 3 times a day for 20 minutes for 4 weeks
40795388|NCT04064190|DRUG|Vactosertib(TEW-7197)/ Durvalumab|Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
40795389|NCT05621122|OTHER|This is an observational study|This is an observational study. The control group (omnivours) will be compared with all otgher groups
40795390|NCT04910386|DRUG|Envafolimab plus Gemcitabine&Cisplatin|Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision
40795391|NCT04910386|DRUG|Gemcitabine&Cisplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
41000379|NCT05297396|OTHER|Slow Tapering of Chronic Opioid Therapy|Clinically prescribed daily opioids reduced by no more than 10 morphine milligram equivalent per day (MMED) each month for 12 months
41000380|NCT03126799|DRUG|Erlotinib plus Bevacizumab|Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
41000381|NCT03126799|DRUG|Erlotinib|Erlotinib 150mg, po, daily, Q weeks
41312386|NCT04834973|DRUG|tigilanol tiglate|"Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
41470919|NCT04056052|BEHAVIORAL|Mind the Gap: Home Activity Only|The primary focus of the home activity program was based on collaborative parent-child cooking activities which the families undertook themselves at home. There were two key tasks: the first was to add one extra vegetable to the evening meal each day, the second was to select, prepare and cook one recipe from the cook book each week.
41470920|NCT04056052|BEHAVIORAL|Mind the Gap: Home Activity + cooking Workshop|The main purpose of these workshops was to provide hands-on successful food preparation and cooking experiences for the families and several opportunities to taste new vegetable-based recipes as well as promoting knowledge of cost and healthy eating. Children and their parents were then encouraged to take whatever was learned and apply it at home.
40795392|NCT04392674|DEVICE|the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
41000382|NCT04929652|DRUG|Surufatinib,Camrelizumab,Irinotecan,GM-CSF|"1. Dose climbing stage design (n=12) :~   Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed \> DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with \> developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；~2. Dose expansion phase design(n=36):~   1. Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;~  2. PD-1(Camrelizumab) : 200mg, iv,D1, 3w;~  3. Irinotecan: 200mg/㎡, iv, D1, 3w;~  4. GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w."
41150708|NCT04243005|PROCEDURE|Supramarginal resection|Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
41150709|NCT04243005|PROCEDURE|Conventional surgery|Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
41150710|NCT02585752|DEVICE|Noninvasive ventilation|Expiratory pressure modulation
40795393|NCT05229809|DRUG|Yiqi Wenyang Jiedu prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
41000383|NCT03135041|DIETARY_SUPPLEMENT|Fiber-containing dietary supplement|Effects of fiber-containing dietary supplement on weight loss during energy restriction
40795394|NCT05229809|DRUG|Simulation agent of Yiqi Wenyang Jiedu prescription|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
40795395|NCT04346147|DRUG|Imatinib tablets|Imatinib 400 mg QD oral
40795396|NCT04346147|DRUG|Baricitinib Oral Tablet|Baricitinib 4 mg QD oral
40795397|NCT04346147|OTHER|Supportive tratment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
40795398|NCT01545297|DRUG|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
40795399|NCT01545297|DRUG|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
40795400|NCT01545297|DRUG|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
40795401|NCT03836846|BEHAVIORAL|CBT Mobile App|TAU and the additional treatment of a Mental Health App (What's Up?). This app will be used to guide adolescents through cognitive behavioral therapy and acceptance commitment therapy techniques, as well as to assist in developing coping mechanisms to prevent readmission.
40795402|NCT03836846|BEHAVIORAL|Treatment as usual|TAU as per standard of care
41000384|NCT03135041|DIETARY_SUPPLEMENT|Placebo|Effects of placebo supplement on weight loss during energy restriction
41000385|NCT05905484|DRUG|Bemnifosbuvir (BEM)|A single dose of BEM will be administered.
41000386|NCT05905484|DRUG|Placebo|A single dose of matching placebo will be administered.
41000387|NCT05905484|DRUG|Moxifloxacin|A single dose of Moxifloxacin will be administered.
41000388|NCT01784783|BEHAVIORAL|HOPE Intervention|"If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.~Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session."
41000389|NCT01784783|BEHAVIORAL|INVITE Intervention|Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
41000390|NCT00419562|DRUG|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
41000391|NCT00419562|DRUG|Placebo|Placebo capsule designed to match active drug
40795403|NCT05361538|DEVICE|True circular microwave needle|Use true circular microwave needle for thermal ablation
40795404|NCT04878107|DRUG|Camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd
40795405|NCT04878107|DRUG|Apatinib|Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor
40795406|NCT04878107|DRUG|Docetaxel injection|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
40795407|NCT04878107|RADIATION|SBRT|Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.
40795408|NCT04878107|RADIATION|LDRT|low dose radation therapy
41000392|NCT01041872|DRUG|Propofol Astrazeneca plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
41000393|NCT01041872|DRUG|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
41000394|NCT01041872|DRUG|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
41000395|NCT01041872|DRUG|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
41000396|NCT01041872|DRUG|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
41000397|NCT01041872|DRUG|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
41017783|NCT05050643|OTHER|EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy
41150711|NCT02965352|DEVICE|Door handle device|To evaluate the cylindrical grip movement, it was used a door handle, which evaluated all the strength at the arc of motion
40795409|NCT06045273|BEHAVIORAL|Elders' Resilience Curriculum|The Elders' Resilience Curriculum (ERC) is a culturally grounded, school-based program taught by White Mountain Apache Tribe (WMAT) Elders to youth. It is designed to prevent suicide ideation and behaviors for American Indian youth
40795410|NCT00095472|DRUG|L-NMMA|
41312387|NCT04834973|DRUG|pembrolizumab|"Three weekly 200 mg intravenous pembrolizumab treatment.~Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy."
41312388|NCT03277300|DIETARY_SUPPLEMENT|dietary supplement|good dietary supplement for critically ill patients
41312389|NCT05290649|DIAGNOSTIC_TEST|clinical assessment|mini mental test, pulmonary function test, respiratory muscle strength test, trunk impairment scale, timed up and go test, barthel index
41312390|NCT01666418|DRUG|Pazopanib/Paclitaxel|
41312391|NCT02042339|DRUG|Hyperbaric oxygen|The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
40795411|NCT00095472|DRUG|Sodium Nitrite|
40795412|NCT05653401|DRUG|Magnesium sulfate and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
41312392|NCT02080689|OTHER|Decipher|
41312393|NCT01952457|DEVICE|Zilver PTX|
41000398|NCT03100708|PROCEDURE|PIPAC|"* Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.~* Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.~The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system."
41000399|NCT01557400|DRUG|Ataluren|Oral powder for suspension
41312394|NCT01952457|DEVICE|prosthetic bypass|
41470921|NCT02629250|PROCEDURE|SV maximization|When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR \<100 bpm, Hb \>8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV \>10% or blood loss \>250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
40795413|NCT05653401|DRUG|Lidocain and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
41000400|NCT05407246|DRUG|Hemay005|Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
41000401|NCT03903627|OTHER|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
41000402|NCT04508569|BEHAVIORAL|Big Decisions|Big Decisions is a promising teen pregnancy prevention intervention that consists primarily of abstinence-plus sexual health education curriculum. The intended dosage for students is 10 classroom-based sexual health lessons.
41470922|NCT02629250|PROCEDURE|supernormal DO2|Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
41312395|NCT01412658|DIETARY_SUPPLEMENT|Hydrolyzed milk protein mixture|Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
41312396|NCT01412658|DIETARY_SUPPLEMENT|Glycerol placebo|"Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.~A food diary is maintained daily."
41312397|NCT04729920|DEVICE|Mechanical insufflation/exsufflation device (MI-E)|download of device (MI-E) data and self-reported satisfaction with the device
41312398|NCT05582265|DRUG|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41312399|NCT05582265|DRUG|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41312400|NCT05582265|DRUG|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
40795414|NCT05653401|DRUG|Placebo and diclofenac|Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
40795415|NCT01145781|PROCEDURE|Cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
40795416|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 10 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
41312401|NCT05582265|PROCEDURE|Surgical resection|Standard of care
41312402|NCT05582265|DRUG|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41312403|NCT05582265|DRUG|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41312404|NCT05582265|RADIATION|Radiation|Recommended, standard of care
41000403|NCT04547062|DRUG|Tocilizumab|Administration of tocilizumab at day 8 of induction following a classical induction
41312405|NCT05582265|DRUG|Carboplatin (neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41312406|NCT05582265|DRUG|Carboplatin (adjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
41312407|NCT03284242|DRUG|Treg|Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
41312408|NCT05792670|PROCEDURE|Changing mechanic ventilatation parameters|The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg. Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
41312409|NCT05782179|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to alhydrogel as an adjuvant
41312410|NCT05782179|BIOLOGICAL|Placebo|Normal Saline 0.9 %
41312411|NCT06552598|DRUG|KD01(the recombinant oncolytic adenovirus)|"Phase Ia PART 1 (Dose Escalation Phase with Monotherapy): Subjects in each dose group will continue to undergo a 21-day assessment for Dose-Limiting Toxicity (DLT) after completing the first cycle of treatment (D1-5), totaling 26 days starting from D1.~Phase Ib PART 2 (Dose Expansion Phase with Monotherapy): Subjects will receive intratumoral injections, starting on D1. Further treatment will continue based on the patient's willingness, with a maximum of 5 administrations. The final administration will be followed by surgery 7-14 days later, until the patient is discharged."
41000404|NCT01076829|OTHER|Spice polyphenols|spice
41312412|NCT02351258|DEVICE|70% Isopropyl alcohol embedded caps|Protective cap on central lines
41312413|NCT02351258|OTHER|Usual Care|"This involves the Best Practice Central Line Maintenance Care Bundle which includes;~1. Daily assessment whether central line is needed~2. Central line Site Care~3. Central line Hub/Cap/Tubing Care"
41312414|NCT00258102|DRUG|Levofloxacin|
41312415|NCT06553066|DRUG|Deep neuromascular blockage|"maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)"
41312416|NCT06553066|DRUG|Moderate neuromascular blockage|maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2
41312417|NCT05480293|DRUG|Ranibizumab|ranibizumab，0.5mg,IVT
41312418|NCT05480293|DRUG|SCT510A|SCT510A，1.25mg,IVT
41312419|NCT03408652|DRUG|denosumab|Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
41000405|NCT02805530|OTHER|First line systemic treatment|Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
41312420|NCT01136421|DRUG|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
41312421|NCT01136421|DRUG|Magnesium Sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
41312422|NCT00645567|DEVICE|Unassisted Manual Transfer|No device assistance
41312423|NCT00645567|DEVICE|Standard Transfer Board|Flat surface board
41312424|NCT00645567|DEVICE|Glide n' Go|Flip down power lift chair
41312425|NCT00645567|DEVICE|Easy Reach lift|Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
41312426|NCT00645567|DEVICE|Ryno lift|Lift for the wheelchair
41312427|NCT03359694|DRUG|DT group|Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
41000406|NCT02805530|OTHER|Radical treatment|to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
41000407|NCT02805530|RADIATION|radiation therapy|Patients will receive dose and fraction regimen according to the metastatic site.
41000408|NCT02805530|OTHER|Chemoradiotherapy|Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
41000409|NCT03425617|DRUG|Tiotropium + Olodaterol|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose
41000410|NCT03425617|OTHER|PLACEBO|PLACEBO via Respimat® single dose
41000411|NCT00861107|BIOLOGICAL|AlloStim-7|intradermal injection once a week for 3 weeks
41000412|NCT00861107|PROCEDURE|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
40795417|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 20 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
40795418|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 10 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
40795419|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
40795420|NCT02968498|DIETARY_SUPPLEMENT|Oral glucose 20 g|White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
40795421|NCT02968498|DIETARY_SUPPLEMENT|Still water|Still water will be used. Water from the same source will be also used to dissolve investigational and control products.
40795422|NCT05596318|DEVICE|Digital CBT-I|The digital CBT-I program is called Sleepio (Big Health, Ltd). Digital CBT-I will be delivered by an animated therapist in six weekly sessions that are approximately 10-20 minutes each. Sessions can be accessed via website or app at a time that is convenient for the participant. Session content is based on standard, in-person CBT-I protocols, and includes sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education. The program is interactive, automated, and tailored to participant progress. Additionally, participants will receive supplemental CBT-I content tailored for prenatal and postpartum insomnia.
40795423|NCT05596318|DEVICE|Digital SHE|The digital SHE program was created by Big Health, Ltd and has a total of six sessions. The content for SHE includes education about sleep stages, sleep architecture, sleep cycles; education about importance of sleep for performance, mood, and health; recommendations for developing healthy sleep habits; recommendations for lifestyle factors that impact sleep; recommendations for creating a sleep-friendly bedroom.
41000413|NCT00861107|BIOLOGICAL|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
41000414|NCT00861107|BIOLOGICAL|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10\^8 cell dose and if no toxicity dose escalates to 10\^9 cell dose.
41000415|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SAPB
40795424|NCT00100958|DRUG|indole-3-carbinol|
41000416|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant
41000417|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
41000418|NCT05017610|DRUG|Liothyronine|Given PO
41000419|NCT05017610|DRUG|Lomustine|Given PO
41000420|NCT05017610|DRUG|Methimazole|Given PO
41000421|NCT02027844|BEHAVIORAL|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
41312428|NCT03359694|DRUG|ET group|Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
41000422|NCT02027844|BEHAVIORAL|parental presence|parental presence during inhalational induction of sevoflurane
41000423|NCT06482333|OTHER|Time for resumption of DOAC|Time for resumption of DOAC
41000424|NCT04134000|DRUG|Atezolizumab|1200 mg IV q3w until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
41312429|NCT03359694|DRUG|NX group|Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
41312430|NCT00948662|DRUG|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
41312431|NCT00948662|DRUG|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
41312432|NCT00948662|DRUG|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
40795425|NCT05605548|DRUG|MitoQ|MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
40795426|NCT05605548|OTHER|Placebo|"A look-alike inactive substance, a sugar pill"
40795427|NCT01480583|DRUG|GRN1005|550 mg/m2 IV every 3 weeks
40795428|NCT01480583|DRUG|Trastuzumab|2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
40795429|NCT01480583|DRUG|18F-FLT|5 mCi of 18F-FLT IV during Screening and during Cycle 1
41000425|NCT04134000|DRUG|BCG|1 or 1/2 instillation per week until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
41000426|NCT01879228|DRUG|Sitagliptin|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
41000427|NCT01879228|DRUG|Placebo|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
41150712|NCT02965352|DEVICE|Linear switch device|To evaluate the pulp-pulp pinch movement, it was used one linear switch, which evaluated all the strength at the motion displacement.
41312433|NCT04719065|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.
40795430|NCT05631171|BEHAVIORAL|Adhera® Fatigue Digital Program|"Adhera® Fatigue Digital Program, that includes an application and a smartwatch, is a digital health solution based on emotional and behavioral change techniques. Patient adaptative self-management content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 3 months to detect biometric and psychometric (patient-reported outcomes) information."
41312434|NCT01143168|BIOLOGICAL|autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells|First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.
41000428|NCT01450410|DRUG|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
41312435|NCT02389712|DRUG|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
41312436|NCT02389712|DRUG|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed \> 40mg.
41312437|NCT02819895|OTHER|A customized windows® software application|A customized windows® software application with the ability to send automated voice call, SMS and email reminder about due dates for childhood routine immunizations.
41312438|NCT00498238|DRUG|Levothyroxine|
41312439|NCT06281886|DRUG|Induction Immunotherapy-Toripalimab|Toripalimab 240mg iv. drip, Q3W, 2 cycles
41312440|NCT06281886|DRUG|Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin|Albumin-paclitaxel 260 mg/m2, administered on day 1, combined with cisplatin 25 mg/m2, administered on day 1,2,3.
41312441|NCT06281886|RADIATION|Radiotherapy|Thoracic radiotherapy at a total dose of 50Gy was delivered using the intensity modulated radiation therapy technique.
41312442|NCT06281886|DRUG|Apatinib|Oral apatinib 250mg once daily during induction therapy and concurrent chemoradiotherapy.
41470923|NCT04629599|BEHAVIORAL|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
41150713|NCT02965352|DEVICE|Door key device|To evaluate the pulp-side pinch movement, it was used a door key, which evaluated all the strength at the arc of motion
41150714|NCT01844908|PROCEDURE|Electroacupuncture|
40795431|NCT02598869|DRUG|Triamcinolone Acetonide|injection of triamcinolone acetonide
40795432|NCT01495039|DRUG|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
40795433|NCT00833469|DRUG|Escitalopram|Once daily by mouth
40795434|NCT05960045|DIETARY_SUPPLEMENT|Direct Milk antigen reintroduction|Direct milk antigen re-introduction milk according to ESPGHAN guidelines
40795435|NCT05960045|DIETARY_SUPPLEMENT|Milk ladder|B: Milk ladder according to the iMAP guideline which are 6 weeks of gradual reintroduction starting with baked milk not direct antigen
40795436|NCT04115124|BEHAVIORAL|Participatory Action Research|The research will employ a Participatory Action research quasi-experimental pre-post test study design .
41000429|NCT01450410|DRUG|Placebo|Placebo treatment will last for 12 weeks.
41000430|NCT04157062|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in memory and thinking.
41000431|NCT04388943|OTHER|Observation|Physiological Measurements Patient reported questionnaire Blood sampling
41150715|NCT04544514|DIAGNOSTIC_TEST|lung ultrasound|LUS was performed within first 20 to 30 minutes and repeated at 1, 2, 4 and 6 hours.
41150716|NCT01899183|PROCEDURE|Anti-reflux Surgery|Nissen Fundoplication; Collis Gastroplasty
41150717|NCT04836234|OTHER|Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum|Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum 65g 40 pieces
41150718|NCT05005572|OTHER|Payment adjustment for home dialysis and transplant|The ETC model makes two types of payment adjustments for facilities and managing clinicians, an adjustment to the reimbursement rate for home dialysis, and a performance adjustment. The first adjustment, Home Dialysis Payment Adjustment (HDPA), raises the reimbursement rate for home dialysis for the first three years of the program; the amount of increase is 3% in 2021, and reduces to 2% in 2022, and 1% in 2023. The second adjustment, Performance Payment Adjustment (PPA), is an increase or decrease in the reimbursement rate based on the home dialysis rate and the transplant rate attributable to the participating facility or clinician.
41150719|NCT00996905|DEVICE|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
41150720|NCT00996905|DEVICE|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
41150721|NCT01556087|BEHAVIORAL|Distress Tolerance|7 individual sessions aimed at increasing distress tolerance skills
41470924|NCT04629599|BEHAVIORAL|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
40795437|NCT06512077|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
41470925|NCT00489749|PROCEDURE|Protected early weightbearing/Achilles tendon surgery|
41470926|NCT04546048|BEHAVIORAL|Strength Exercise Training|The 8-week exercise-training program consisted of two 30-min sessions a day for 5 days/week and conducted by elastic exercise bands in 2-3 sets, 6-10 repetitions, with 1-2 min rest between sets (M. Deltoideus and M. Quadriceps are trained as major muscle groups). The 8-repetition maximum(8RM) is used to determine training loads with the rated perceived exertion(RPE) lower than 5-7 on the Modified Borg scale(MBS). The program consisted functional exercises by half squat to squat and sit-to-stand chair exercises. Exercise sessions were supervised twice daily during the 1st week, the 2nd week training included one supervised and one unsupervised daily sessions. The remaining 6-week training program conducted at home individually after discharge. Patients instructed for the ongoing 8-week training program and a patient-specific schedule delivered to subjects. Phone calls are provided weekly and training load is assessed while generating 4th week evaluations.
40795438|NCT04192266|DRUG|Estradiol|2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
40795439|NCT04192266|DRUG|Placebo oral tablet|2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
41470927|NCT02508259|DRUG|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
41470928|NCT02508259|DRUG|Saline|50 ml IV over 30 minutes
40795440|NCT06101004|DEVICE|CVA-Flow|CVA-FLOW Software Device is indicated for the detection of Stroke and LVO in patients with suspected stroke.
40795441|NCT04224233|OTHER|Home-based physical activity programme|iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.
40795442|NCT04224233|OTHER|Usual care|Participants will receive a leaflet with exercises and PA recommendations.
41470929|NCT01221831|DRUG|estetrol, P 1 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P1 tablet per day~* Days 25-28: two placebo tablets per day"
41470930|NCT01221831|DRUG|estetrol, P2 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P2 tablet per day~* Days 25-28: two placebo tablets per day"
40795443|NCT05117567|COMBINATION_PRODUCT|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
41470931|NCT01221831|DRUG|Estradiol valerate, dienogest and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-26: one tablet of Estradiol valerate/dienogest per day~* Days 26-28: one placebo tablet per day"
41470932|NCT03017352|DRUG|Exenatide|
41470933|NCT03017352|DRUG|Placebos|
40795444|NCT03096639|DEVICE|Diaphragmatic Pacing Therapy DPTS|Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
40795445|NCT02146053|DIETARY_SUPPLEMENT|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
40795446|NCT02146053|DIETARY_SUPPLEMENT|Placebo|placebo capsules: methyl cellulose
41000432|NCT06095375|DRUG|Regorafenib|Cohort A (Adjuvant/Maintenance Phase). The Adjuvant (Maintenance) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level-1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with adjuvant TMZ to evaluate the initial toxicity of regorafenib and TMZ Cohort B (Concomitant Phase) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level -1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with TMZ and RT.
41150722|NCT01556087|BEHAVIORAL|Health Education|7 individual sessions with didactic health education information
41150723|NCT03110640|BIOLOGICAL|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
41150724|NCT03110640|DRUG|Fludarabine|Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
41150725|NCT03110640|DRUG|Cyclophosphamide|Patients were given cyclophosphamide 500mg/m2/day on day -4.
41150726|NCT05845866|BEHAVIORAL|Modified Body Project|The Body Project, an evidence-based body image intervention developed for young women at risk for eating pathology, was adapted for use among adult women with high weight and shape concern and high body weight who want to lose weight.
41470934|NCT05556343|DRUG|MYK-224|Specified dose on specified days
41470935|NCT04887116|BEHAVIORAL|Virtual Reality Exposure Therapy|Ten ninety minute sessions of Virtual Reality Exposure Therapy twice a week for five weeks
41000433|NCT06095375|DRUG|Temozolomide|"Following a 3+3 design, in cohort A three patients will be administered temozolomide 150-200 mg/m2 for 5 consecutive days every 28 days until 6-12 cycles and regorafenib daily for 21 days, with a 1-week washout period at dose of 80 mg (level 1), 120 mg (level 2), or 160 mg (level 3) (regorafenib 40 mg- level -1). As a general rule, one cycle will last 28 days (day 1-28); however, in the event of treatment prolongation, the cycle period will be extended.~In cohort B,During concomitant therapy phase: temozolomide 75 mg/m2/die for 42 (max 49 days) consecutive days (concomitant with radiation therapy)."
40795449|NCT06035952|DIAGNOSTIC_TEST|3D topographical scan|Subjects will undergo a quick, radiation-free, no contact 3D scan using a smartphone.
41312443|NCT06281886|DRUG|Capecitabine|Oral capecitabine 1000 mg/m2, twice daily, on days 1-14, every 3 weeks, concurrently with radiotherapy
41312444|NCT05668260|DEVICE|Biodegradable Stent|A trans-anastomotic biodegradable internal stent (ARCHIMEDES™) will be placed between the main pancreatic duct (MPD) and the enterotomy in the jejunum just after the completion of the posterior suture of duct-to-mucosa. The biodegradable stent will then be shaped according to the angle of the jejunal loop in order to minimise the risk of displacement. The adequate length of the stent will be chosen according to the length of the jejunal loop.
41312445|NCT01360944|DRUG|LAS41004|once daily, topical, 100 microgram
40795450|NCT00969163|DRUG|testosterone gel|300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
41312446|NCT01360944|DRUG|reference|once daily, 100 microgram
41312447|NCT04897841|DRUG|Liposomal bupivacaine|20 mL prior to closing fascia, the active drug (bupivacaine) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.
41312448|NCT04897841|DRUG|Bupivacaine Hydrochloride|30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic
41312449|NCT04897841|OTHER|saline|post-surgical saline
41312450|NCT02296996|DRUG|Dabrafenib + Trametinib|
41312451|NCT01724125|OTHER|personal electronic medical record|
41312452|NCT06348407|DRUG|IgE monoclonal antibody|omalizumab
41312453|NCT03102177|DRUG|Administration of stable Isotope labeled levothyroxine|Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
40795451|NCT00969163|DRUG|Comparator: placebo|transdermal placebo gel for 6 weeks
40795452|NCT01564251|DRUG|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
40795453|NCT01564251|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.
41312454|NCT03773341|OTHER|research questionnaire|Patient personal data History taking clinical knee examination
41312455|NCT00649649|DRUG|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fed
41312456|NCT00649649|DRUG|Accupril® Tablets 40 mg|40mg, single dose fed
41312457|NCT05266794|DRUG|Alpha lipoic acid|20 patients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
41312458|NCT05266794|DRUG|Selenium|23 patients who received Selenium 200µg once daily with their routine therapy just a
41312459|NCT03951688|OTHER|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
41312460|NCT00598195|DRUG|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
41312461|NCT01072539|DRUG|tigecycline|As prescribed by physician in usual clinical practice
41312462|NCT04887103|OTHER|Hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
41312463|NCT03069846|DEVICE|Spectra-Scope|"The Spectra-Scope consists of the light collection module and the spectral analysis module.~The light collection module is attached to the handpiece of short pulse Nd:YAG laser, and the analysis module is placed on the laser.~Each potential skin cancer site, which has previously been identified as requiring biopsy, should be assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots must be made before the scheduled biopsy.~All potentially cancerous lesions (or lesions that would usually undergo complete biopsy of the lesion or require follow up within three months) should be sampled. The Spectra-Scope will not provide a diagnosis at the time of sampling. Sites should record the spectra reported for each laser shot in the CRF."
41312464|NCT00091143|BIOLOGICAL|gp100 antigen|
41312465|NCT00091143|BIOLOGICAL|incomplete Freund's adjuvant|
41312466|NCT00091143|BIOLOGICAL|keyhole limpet hemocyanin|
41312467|NCT00091143|DRUG|fludarabine phosphate|
41312468|NCT00091143|PROCEDURE|peripheral blood stem cell transplantation|
41312469|NCT05674344|DEVICE|Masimo Temperature device|Non-invasive temperature device
41312470|NCT04886999|BEHAVIORAL|Exploratory study on patient's perception of Asthma symptoms|To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
40795454|NCT04980625|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
40795455|NCT04980625|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
40795456|NCT02363777|PROCEDURE|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
40795457|NCT02363777|PROCEDURE|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
40795458|NCT01350050|DRUG|articaine|"Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.~In dentistry, articaine is used both for infiltration and block injections."
40795459|NCT01350050|OTHER|9% Sodium Chloride solution for injection|9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
40795460|NCT06395116|OTHER|Denture base material|Denture base material constructed with different techniques for completely edentulous populations
40795461|NCT03456219|OTHER|Normal protein diet|The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.
40795462|NCT03456219|OTHER|High-protein diet|The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
40795463|NCT03032419|BIOLOGICAL|IPV-Al SSI|3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
40795464|NCT03032419|BIOLOGICAL|IPV SSI|3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
40795465|NCT00562432|DEVICE|Plexisyl-AF|Plexisyl-AF implants
40795466|NCT00562432|OTHER|No Treatment|CABG without the experimental treatment
40795467|NCT01098253|BEHAVIORAL|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
41312471|NCT06447324|DEVICE|Fender Mate matrix system|Matrix Systems used for Restoration of Class II Cavities in Primary Molars
41312472|NCT06447324|DEVICE|T-band matrix|Matrix Systems used for Restoration of Class II Cavities in Primary Molars
40795468|NCT03815630|DRUG|pd-1 and dc-cik cells|Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
40795469|NCT02784158|DRUG|Brigatinib|Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC who are resistant or intolerant to a prior ALK inhibitor at a dose of 180 mg QD with a 7 day lead-in at 90 mg QD, continuously, with or without food.
40795470|NCT03947268|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced pelvic cancer.
40795471|NCT04308018|PROCEDURE|S2alar-iliac screws|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
40795472|NCT04308018|PROCEDURE|S1 screws|Caudal end of the instrumentation at S1
40795473|NCT01196013|DRUG|Clofarabine|Intravenous, 30 mg/m2, 52 mg/m2
40795474|NCT06554106|OTHER|Neuromuscular Electrical Stimulation Group|All patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises. In addition to the study group, NMES will be applied to the upper trapezius muscle for 30 minutes 5 days a week for 4 weeks. Neuromuscular Electrical Stimulation (NMES) applications will be performed with a Compex 3 (Compex Medical SA, Ecublens, Switzerland) model, portable and programmable electrostimulator unit in rehabilitation mode and under the supervision of an expert physiotherapist experienced in the device and application. The NMES program will be applied with a 4-channel device with a functional stimulation capacity of 120 mA, pulse duration 400 μs and pulse frequency 150 Hz.
40795475|NCT06554106|OTHER|Control Group|Patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises.
41150727|NCT05845866|BEHAVIORAL|Facts about obesity, myths about weight loss|This intervention is designed to help individuals prepare for weight loss and is focused on facts about obesity, myths about weight loss, and the importance of a varied diet.
40795476|NCT06014151|OTHER|questionnaires|we will use a quantitative and a qualitative approach. For the first one, a psychosocial approach on a large number (500 women and 500 men) of candidates to donation. Of course, gender and parenthood will be considered in the analyses, as in the previous study. We will use two questionnaires for this study: 1) the one that was validated for the previous study, including socio-demographic data, donors' motivations and representations, 2) the second exploring personality, the NEO-PR inventory, which was also used for the previous study.
41150728|NCT05845866|BEHAVIORAL|Lifestyle intervention for weight loss|This 24-week behavioral weight management program is based on the Look AHEAD and Diabetes Prevention Program manuals. It is designed to facilitate 7-10% weight loss of initial body weight through dietary and physical activity changes with use of behavioral strategies to support lifestyle changes over time.
41312473|NCT01047761|OTHER|Exercise|"3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity~Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises"
41312474|NCT04302103|BIOLOGICAL|RC18 160mg|subcutaneous injection
41312475|NCT04302103|BIOLOGICAL|RC18 240 mg|subcutaneous injection
41312476|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
41312477|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
41312478|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
41312479|NCT00808249|DRUG|Placebo|2 tablets taken twice a day for 28 days
41312480|NCT04811248|OTHER|telephone call for parents of patients|telephone call for parents of patients aged 6 years old
41000434|NCT06305533|DEVICE|LASER disinfection|In test group 1, the diode Laser will be used to disinfect the inner layer of the pockets and thus reducing the microbial load. Diode laser (Biolase, EpicX, BIOLASE, Inc, USA) settings will be as follows: wavelength: 940nm; power: 1W; 300μm uninitiated fibers; continuous radiation mode; and energy level: 80 J/s. The laser fibers then will be inserted into the pockets in such a way that they will be in contact with the soft tissue wall of the pockets and parallel to the root surface and then will be moved to the apical surface through a horizontal sweeping motion (1mm/s) while remaining in contact with the soft tissue wall of the pockets.
40795477|NCT04833335|OTHER|MRI perfusion sequence|Quantitative analysis
41312481|NCT06027931|PROCEDURE|Conservative Access Opening, Traditional Access Opening|Conservative Access Opening will be used and evaluated for cleaning ability versus Traditional Access Opening.
40795478|NCT02259725|DRUG|regorafenib|Given PO
41000435|NCT06305533|DEVICE|Photodynamic therapy|the second test group will receive additional adjunctive aPDT using a ICG photosensitizer activated with diode laser. In details, pockets will be irrigated by a syringe loaded with an ICG photosensitizer solution (Verdye, Diagnostic green, Germany) at a concentration of 5mg/ml. The ICG solution will be allowed to stay in the pockets for 2min, and washing out excess solution from the pockets before laser irradiation. Afterwards, a 300μm bulb optical fibre of the 810nm diode laser unit (QuickLase, United Kingdom) set at 300mw in pulsed mode (100ms ON/100ms OFF) will be inserted along the pocket and activated for 30s with continuous vertical movements from the bottom of the pocket to the gingival margin
41000436|NCT06305533|PROCEDURE|Root surface debridement|For all groups, sites with initial PPD 4-6 mm will be treated with RSD using area specific (Graecy) curettes.
41470936|NCT06340503|DEVICE|Research-grade accelerometer|Participants will be instructed to wear device for 7 days prior to each visit and to bring the device to each visit. Study staff will extract data from the device within 14 days after each appointment and return the device to patients by mail.
40795479|NCT02259725|OTHER|laboratory biomarker analysis|Correlative studies
41000437|NCT01217970|DRUG|Ibudilast 20mg|Ibudilast 20mg BID
41000438|NCT01217970|DRUG|Ibudilast 50mg|Ibudilast 50mg BID
41000439|NCT01217970|DRUG|Placebo oral tablet|
41000440|NCT02680821|PROCEDURE|ALL reconstruction (Anterolateral ligament)|
41000441|NCT02680821|PROCEDURE|ACL revision (Anterior cruciate ligament )|
41000442|NCT01522066|PROCEDURE|Perineural catheter|Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
41000443|NCT01522066|PROCEDURE|Single-shot block|Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
41000444|NCT01301222|DRUG|Inj. Octreotide|100 mcg subcutaneously for 5 days
41000445|NCT03331796|DEVICE|Active rTMS (Bilateral DLPFC)|TMS Stimulation Parameters for the active DLPFC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
41000446|NCT03331796|DEVICE|Active rTMS (Bilateral LPC)|TMS Stimulation Parameters for the active LPC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
41000447|NCT03331796|DEVICE|Placebo rTMS (Inactive)|For the Placebo rTMS (Inactive) group, the participant will wear scalp electrodes through which a low voltage, low electric current (2-20mA at no more than 100V) is passed to mimic the sensation of receiving actual rTMS. Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
40795480|NCT00148031|DRUG|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
40795481|NCT00148031|BEHAVIORAL|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
40795482|NCT00148031|BEHAVIORAL|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
40795483|NCT00148031|BEHAVIORAL|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
40795484|NCT04178928|DRUG|Levothyroxine|investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
40795485|NCT05553769|OTHER|Resistance training, detraining, retraining|Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
40795486|NCT05318300|DIETARY_SUPPLEMENT|tested formula with fiber|formula containing fibers
40795487|NCT05318300|DIETARY_SUPPLEMENT|Control|formula without fiber
40795488|NCT04247893|DEVICE|blood flow restriction|Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
41000448|NCT04217486|OTHER|Patient will be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will then be shown a photograph of their knee at 2 weeks postoperative.
41000449|NCT04217486|OTHER|Patient will not be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will not be shown a photograph of their knee at 2 weeks postoperative.
41000450|NCT01312584|DIETARY_SUPPLEMENT|Processed High-flavanol|
41312482|NCT04863924|DIAGNOSTIC_TEST|Liquid Biopsy|All patients will have a liquid biopsy with ctDNA molecular profiling
41470937|NCT06340503|OTHER|National Comprehensive Cancer Network (NCCN) Education Materials|The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprised of recommendations for the prevention, diagnosis, and management of malignancies across the continuum of care.
41470938|NCT06340503|DEVICE|Garmin Vivofit activity tracker|This device can automatically capture and classify different physical activities such as walking, running, biking, swimming and using an elliptical.
41312483|NCT01721031|PROCEDURE|DPNB|Patients receive DPNB 30min before extubation at the end of operation
40795489|NCT04247893|DEVICE|Photobiomodulation|Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.
40795490|NCT04247893|DEVICE|Placebo photobiomodulation|Placebo photobiomodulation - photobiomodulation device turned off.
40795491|NCT00005844|DRUG|oxaliplatin|
40795492|NCT03202433|DEVICE|Use of virtual reality lenses, with relaxing audio-visual contents|Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
41000451|NCT01883401|DIETARY_SUPPLEMENT|Freeze-dried strawberries|25g or 50g freeze-dried strawberries reconstituted in water
41470939|NCT06340503|OTHER|Exercise Consultation Calls|The intervention group will receive five monthly exercise consultation calls with an exercise coach in between clinical visits and be provided with an exercise log for their personal use
41312484|NCT01721031|DRUG|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
41312485|NCT05910541|BEHAVIORAL|Mindful breathing|30 minutes of mindful breathing session for 4 consecutive days, guided by investigators in addition to standard care.
41312486|NCT05910541|OTHER|Standard care (control)|Standard care such as pain control, oxygen supplement.
41312487|NCT04992039|OTHER|WHO HEARTS technical package|"Components of WHO HEARTS technical package are~1. Universal BP screening via A\&D arm-in BP device.~2. Training of Medical Officers and Nurses on BP measurement using standard techniques.~3. Training of the nurses on screening, registration data collection via the Simple mobile smart-phone digital clinical hypertension information application.~4. Use of a drug and dose specific hypertension treatment protocol.~5. Standardized inventory and procurement practice to ensure a reliable supply of protocol medications.~6. Training and support for team-based model of hypertension care delivery.~7. Access to the Simple data dashboard for program monitoring.~8. Standardized procedure for patient follow-up.~9. Community-based prescription refilling."
41312488|NCT02231294|DRUG|Sifrol®|
41470940|NCT06340503|OTHER|Interview|The interviews will be conducted by a trained Q-PRO interviewer and audio recorded. Interviews are expected to last approximately 30 minutes. Discussion will include acceptability of the PAI intervention, related tools, and clinical experiences and will help shape/inform refinements need for a larger efficacy trial
40795493|NCT01453452|BEHAVIORAL|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be \< 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
41000452|NCT01883401|DIETARY_SUPPLEMENT|Dietary fiber|4g or 8g dietary fiber blended in water
41000453|NCT00898976|OTHER|immunohistochemistry staining method|
41312489|NCT06320938|OTHER|Neuroscience-Based Pain Education Combined with Home Exercise Program|Neuroscience-Based Pain Education and Home Exercises will be applied.
41312490|NCT06320938|OTHER|Myofascial Induction Techniques Combined with Home Exercise Program|Myofascial Induction Techniques and Home Exercises will be applied.
41312491|NCT06320938|OTHER|Home Exercises Group|Home Exercises wiil be applied
41312492|NCT04936724|OTHER|Pictorial Warning Labels|Participants will be randomized to one of two conditions and will view 4 pictorial warning labels from the assigned group for an eye-tracking task.
41312493|NCT03973684|DEVICE|pdt experimental group|"G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated."
41312494|NCT03973684|OTHER|tongue scraper group|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
41470941|NCT06340503|OTHER|Physical Activity Index Assessment (Intervention Arm)|Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 1, 3, 6, 9 and 12 while on study
40795494|NCT01453452|BEHAVIORAL|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
41000454|NCT00898976|OTHER|laboratory biomarker analysis|
40795495|NCT01453452|OTHER|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
40795496|NCT01453452|PROCEDURE|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
40795497|NCT05748301|OTHER|AI Clinician|N/A - Study is observational study testing the feasibility of running the AI Clinician in real time.
41000455|NCT02658890|DRUG|BMS-986205|
41000456|NCT02658890|DRUG|Nivolumab|
41000457|NCT02658890|DRUG|Ipilimumab|
41000458|NCT04138407|OTHER|seated Tai Chi|Seated Tai Chi is a redesigned short form of traditional Tai Chi, can be practiced in a chair or wheelchair
41000459|NCT04138407|OTHER|Usual rehabilitation exercise|Regular rehabilitation exercise used in participating hospital
41000460|NCT04147065|DRUG|Duration of eradication regimen|14 day eradication regimen
41000461|NCT05523206|OTHER|No intervention|No intervention
41000462|NCT02839616|PROCEDURE|orthotopic liver transplantation|
41000463|NCT02825836|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
41000464|NCT02825836|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
41000465|NCT05098353|DRUG|Quetiapine|25-75 mg per day for 6 weeks
41312495|NCT03148431|DRUG|LY3002815|Administered IV
41312496|NCT03148431|DRUG|Placebo|Administered IV
41312497|NCT00777231|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
41312498|NCT01938963|BEHAVIORAL|Collaborations in Health (COACH)|Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
40795498|NCT04248712|DRUG|Famotidine|40 mg tab twice daily by mouth for 12 week duration
40795499|NCT04248712|DRUG|Loratadine|10 mg tab once daily by mouth for 12 week duration
40795500|NCT04248712|DRUG|Placebo|Contains no active ingredient
40795501|NCT03409952|DEVICE|LaseMD and DUAL 1927nm Laser|Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.
40795502|NCT03409952|DEVICE|LaseMD|Laser treatment of benign pigmented lesion using optimized treatment settings.
40795503|NCT00714506|BEHAVIORAL|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
40795504|NCT00714506|OTHER|Physical activity control|physical activity plus successful aging health education
40795505|NCT00109213|PROCEDURE|Lumbar Laminectomy with Instrumented Pedicle Screw Fusion|Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
40795506|NCT00109213|PROCEDURE|Lumbar Laminectomy|Removal of bone to decompress spinal nerves
41312499|NCT03509272|DEVICE|remote monitoring|"Intervention Description: Patients can participate in the study when they're 10 weeks pregnant. At 10 weeks: a NICCOMO, Maternal Venous Doppler Echography and Maltron measurement will be taken. This measurement will be repeated at 20 weeks of pregnancy, and 30 weeks of pregnancy when they're aberrant.~When the measurements are abnormal, the patients will be included in the remote monitoring study. The following protocol and devices will be applied:~Device What When Withings Wireless Blood Pressure Monitor Blood Pressure 2x/day Withings Pulse O² Activity Day and night Withings Smart Body Analyzer Weight~1x/day"
40795507|NCT03220646|DRUG|abemaciclib|abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
40795508|NCT03220646|DRUG|abemaciclib|200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
40795509|NCT06373900|PROCEDURE|wound closure|Group A wound will be closed with Polypropylene and Group B wound will be closed with Polyglactin 910 suture. both wound closure followed for healing, infection and scar formation till 30th post operative day.
40795510|NCT01671553|BEHAVIORAL|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
40795511|NCT01255839|DEVICE|Double Balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
40795512|NCT01255839|DRUG|Minprostin|The prostaglandin 2 minprostin (3mg) was applied vaginally
40795513|NCT02485509|DRUG|VM-1500/Placebo|VM-1500 or Placebo
40795514|NCT03292003|DEVICE|Journey II BCS Total Knee System|
40795515|NCT04740086|PROCEDURE|Calcium alginate hydrogel|"1. The external and internal fistulous orifice and fistulous tract were explored without applying any product, including hydrogen peroxide or povidone-iodine.~2. The seton was removed and FT cannulation was performed using a needle for cleaning with a gauze impregnated with saline.~3. Calcium chloride was applied through the EFO until it exits through the IFO, and then the IFO was obturated.~4. Alginate was applied, and the pressure at the IFO was stopped, until the alginate solution partial exits through the IFO.~5. The IFO was closed with a 3/0 braided resorbable suture.~6. The EFO was removed with an electric scalpel and closed with a 3/0 braided resorbable suture."
40795516|NCT04744220|OTHER|Yoga Training Program (exercises)|Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session. The patients will start with breathing exercises, then relaxation exercises, warm-up exercises, asanas (posture exercises) and finally the yoga training program will be completed with deep relaxation technique.
40795517|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
41000466|NCT06087458|BIOLOGICAL|VOY-101|VOY-101
41312500|NCT02679248|DIETARY_SUPPLEMENT|Neo40 Daily®|
41312501|NCT02679248|DIETARY_SUPPLEMENT|Placebo|
41312502|NCT04081597|DRUG|Star-101|Administered orally
41312503|NCT04081597|DRUG|Placebo|Administered orally
41312504|NCT04810234|DEVICE|transcutaneous vagal nerve stimulation (tVNS)|Cervical and auricular transcutaneous stimulation of the vagus nerve
40795518|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
40795519|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
40795520|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
40795521|NCT04058015|OTHER|Stress-induced hyperglycemia|Stress-induced hyperglycemia (SIH)was defined as a serum glucose ≥ 200 mg/dL in the patients without Diabetes mellitus.
40795522|NCT04058015|OTHER|Diabetic hyperglycemia|Diabetic hyperglycemia (DH) which indicated a serum glucose ≥ 200 mg/dL in patients with Diabetes mellitus.
40795523|NCT04058015|OTHER|Diabetic normoglycemia|Diabetic normoglycemia (DN), which was defined when there was a serum glucose \< 200 mg/dL in the patients with Diabetes mellitus.
40795524|NCT04058015|OTHER|Non-diabetic normoglycemia|Non-diabetic normoglycemia (NDN) indicating a serum glucose \< 200 mg/dL in patients who were absent of Diabetes mellitus.
40795525|NCT04466384|DEVICE|BIS|Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.
40795526|NCT02676648|BEHAVIORAL|Multicomponent online program|The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
41000467|NCT05781438|BEHAVIORAL|In-home standing and walking intervention|"Parents/legal guardians will be educated on and provided an activity booklet on intensive standing and walking play activities for their infant in a 9 by 9 foot body-weight support system (BWS). Activities include: squatting play at a couch or table, cruising along and between furniture, walking with a push toy or with one or two hands held, walking without support, and kicking and throwing a soft ball.~For 16 weeks, parents/legal guardians will be encouraged to implement the parent-led, intensive standing and walking intervention using BWS for at least 5 days/week for 30-60 min/day, with weekly telehealth calls and monthly home visits to coach parents in identifying key activities and progressing the program."
41000468|NCT01197469|DRUG|Tadalafil|Tadalafil 10mg once daily for 3 months
41470942|NCT06340503|OTHER|Physical Activity Index Assessment (Control Arm)|Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 6, 9 and 12 while on study.
40795527|NCT02676648|BEHAVIORAL|Breath meter|We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
40795528|NCT02676648|BEHAVIORAL|Text messages|We will send participants text messages, to support intervention adherence.
40795529|NCT02676648|BEHAVIORAL|Diet-appropriate foods and cookbooks|We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
40795530|NCT01098331|PROCEDURE|Radical Prostatectomy|
40795531|NCT01098331|PROCEDURE|Brachytherapy|
40795532|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 1 mg|Singel-dose; Subcutaneous
40795533|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 4 mg|Singel-dose; Subcutaneous
40795534|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 8 mg|Singel-dose; Subcutaneous
40795535|NCT04380051|BEHAVIORAL|sensory-tonic stimulation|sensory-tonic stimulation done by the parents to the child, five times a week during 15 minutes at each time
40795536|NCT04380051|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact left free for parents
40795537|NCT02357199|OTHER|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
41000469|NCT01197469|DRUG|Placebo|
40795538|NCT00094926|DRUG|Risperdal Consta|25, 37.5 or 50mg IM injections every 2wks for 52wks
40795539|NCT00094926|DRUG|placebo|matching placebo IM injections every 2wks for 52wks
40795540|NCT06187779|OTHER|Lower segment measurment|Lower segment measurement will be taken prior to induction with a balloon catheter (ATAD).
40795541|NCT03335904|OTHER|Hyperoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
41000470|NCT02268409|DRUG|luspatercept|subcutaneous injection
41000471|NCT02567006|BEHAVIORAL|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
41000472|NCT02567006|OTHER|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
41000473|NCT04985851|DRUG|durvalumab + anlotinib|Approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease.
41000474|NCT04985851|DRUG|Durvalumab|durvalumab
41470943|NCT06340503|OTHER|Health Surveys|Various health surveys will be completed to assess participant health and physical activities.
41470944|NCT01281787|DRUG|Metoprolol|Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
41470945|NCT01281787|DRUG|Losartan|Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
41470946|NCT00426530|DRUG|everolimus (RAD001)|
40795542|NCT03335904|OTHER|Hypoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
40795543|NCT03335904|OTHER|Repeated Hypoxic Apneas|Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
40795544|NCT03335904|OTHER|Hypoxic Sleep Study|Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
40795545|NCT03335904|DRUG|Losartan|Losartan, 50mg, BID
40795546|NCT03335904|DRUG|Placebo|Placebo, 50mg, BID
40795547|NCT00925665|DEVICE|Glidescope|Patients are to be intubated using the Glidescope technique
40795548|NCT00925665|DEVICE|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
40795549|NCT06274996|DRUG|Upadacitinib|Upadacitinib, a selective Janus kinase (JAK) inhibitor taken orally, is being assessed for its unique capacity to attenuate inflammatory pathways in IBD at a cellular level by selectively inhibiting JAK1, a pathway integral to inflammatory cytokine production. This study focuses on its use as monotherapy for Chinese patients unresponsive to conventional IBD treatments, such as aminosalicylates and corticosteroids. By centering on a demographic typically underrepresented in research, the study aims to provide new insights into dosing, treatment frequency, and duration, thus enhancing the understanding of Upadacitinib\&#39;s safety and efficacy. The retrospective analysis of patient data is anticipated to inform more personalized treatment approaches, potentially improving IBD management and patient quality of life.
40795550|NCT02648594|DEVICE|Hook wire CT guided|The intervention consist to place a CT-guided hook wire in lung patient
40795551|NCT00318240|DEVICE|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
40795552|NCT03430973|BEHAVIORAL|Videos|Videos depicting various aggressive driving and road rage behaviors.
40795553|NCT03430973|BEHAVIORAL|Bumper stickers|Bumper stickers hypothesized to increase or decrease aggressive driving.
41470947|NCT01265667|DRUG|CF101|orally q12h
41470948|NCT01265667|DRUG|Placebo|orally q12h
41470949|NCT00544817|RADIATION|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
41470950|NCT00544817|DRUG|Temozolomide|"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
41470951|NCT00544817|DRUG|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
41470952|NCT00931463|DRUG|raltegravir|400 mg raltegravir tablet taken every 12 hours
41470953|NCT00931463|DRUG|2N(t)RTI|2N(t)RTIs as prescribed
41470954|NCT00931463|DRUG|Ritonavir-boosted lopinavir|2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
41470955|NCT06617637|OTHER|Aerobic Based Virtual Reality Exercise Training|"With Aerobic Based Virtual Reality Exercise Training, participants will perform aerobic exercise training with the Xbox Kinect 360 game Your Shape Fitness Evolved 2012. Your Shape Fitness Evolved 2012 is a game that requires basic coordination and is designed to improve the fitness levels of individuals. The game is used as an entertaining aerobic training tool that includes many aerobic activities such as boxing, yoga, dancing, etc. with adjustable difficulty levels."
41000475|NCT04659785|DRUG|Fluzoparib|Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity
41470956|NCT06617637|OTHER|Traditional Aerobic Exercise Training|Using a treadmill, participants will be put through an exercise training consisting of a 10-minute warm-up at 0 degree incline, a 20-30-minute (by increasing the walking time by 5 minutes at the end of the first four weeks and the beginning of the last four weeks) walking at 40-80% of the heart rate reserve (moderate-vigorous intensity) and a 10-minute cool-down period. Treadmill walking levels will be changed if necessary to ensure the targeted exercise intensity.
41470957|NCT03207672|DRUG|E7389-LF|intravenous infusion
41000476|NCT04659785|DRUG|Apatinib|Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
41000477|NCT00872846|DEVICE|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
41000478|NCT01269697|DIETARY_SUPPLEMENT|Nutrof Total|2 capsules 2 times per day during 6 month
41470958|NCT01038037|DRUG|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
41470959|NCT01038037|DRUG|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
41470960|NCT01038037|DRUG|panitumumab|i.v. day 1: 9 mg/kg q3w
41000479|NCT01269697|DIETARY_SUPPLEMENT|Placebo Nutrof total|2 capsules 2 times per day during 6 month
41470961|NCT03844997|DRUG|Palcociclib|"Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell cancer lines. Palbociclib is experimental because it is not approved by the Food and Drug Administration (FDA).~Palbociclib will be supplied as capsules or tablets containing 125 mg equivalents of Palbociclib free base"
41000480|NCT01095588|DRUG|200 mg Avanafil|2 X 100mg tablets avanafil
41312505|NCT05261880|OTHER|Neural mobilization|Neural mobilization and bone are two common physical therapy interventions used for Carpal Tunnel Syndrome. Neural mobilization reinstates the plasticity of the nervous system and restoring the capacity of stretching.
41470962|NCT03844997|DRUG|CPX-351|CPX-351 (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration. CPX-351 is an investigational (experimental) drug that works as formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA).
41470963|NCT00945334|DRUG|Neomycin|500 mg po bid for 14 days
41470964|NCT00945334|DRUG|Placebo|placebo for 14 days tid
41470965|NCT00945334|DRUG|Rifaximin|550 mg po tid
41470966|NCT00881413|DRUG|Esomeprazole|Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
41000481|NCT01095588|DRUG|Placebo|2 tablets
41000482|NCT01071512|DRUG|Tysabri|Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
41312506|NCT05261880|OTHER|Scaphoid , hamate mobilization|Bone mobilization in Carpal Tunnel Syndrome involves gliding at scaphoid and hamate.
41312507|NCT04427917|DRUG|PF-06835919|PF-06835919 300 mg repeated doses
41470967|NCT00881413|DRUG|Pantoprazole|After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
41470968|NCT01485484|DEVICE|Optic imaging use near-infrared trans-illumination methods|Optic imaging use near-infrared trans-illumination methods
41470969|NCT06533280|DRUG|Part A, C and D: VH3739937 500 mg|Oral administration of VH3739937 in moderate fat/moderate calorie conditions
41470970|NCT06533280|DRUG|Part A: VH3739937 100 mg|Oral administration of VH3739937 in moderate fat/moderate calorie conditions.
41470971|NCT06533280|DRUG|Part A and C: Placebo|Oral administration of Placebo in moderate fat/moderate calorie conditions
41312508|NCT04427917|DRUG|Placebo|Placebo repeated doses
41470972|NCT06533280|DRUG|Part B: Treatment A|VH3739937, 500 mg(single dose given as 5 x 100 mg tablets). administered under moderate fat/moderate calorie conditions (reference)
41470973|NCT06533280|DRUG|Part B: Treatment B|VH3739937, 500 mg (single dose given as 500 mg tablet) administered under moderate fat/moderate calorie conditions (test)
41470974|NCT06533280|DRUG|Part B: Treatment C|VH3739937, 500 mg single tablet administered under fasted conditions.
41470975|NCT06533280|DRUG|Part B: Treatment D|VH3739937, 500 mg single tablet administered under low-fat/ low calorie conditions.
41470976|NCT06533280|DRUG|Part B: Treatment E|VH3739937, 500 mg single tablet administered under high-fat/ high calorie conditions.
40795554|NCT03430973|BEHAVIORAL|Alcohol-related cues|Case of beer or water on passenger seat.
40795555|NCT03430973|BEHAVIORAL|Music|Lyrics and tempo of music will be manipulated to increase or decrease aggressive driving.
40795556|NCT03430973|BEHAVIORAL|Roadside vegetation|The roadside will contain trash to increase aggressive driving, or vegetation to decrease aggressive driving. There is also a control group.
40795557|NCT03430973|BEHAVIORAL|Video game|Participants will play a racing or neutral video game before driving in the simulator.
40795558|NCT03400410|BEHAVIORAL|Education Arm|The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
40795559|NCT03293355|BEHAVIORAL|VPN|Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
40795560|NCT03009162|DRUG|Lasmiditan|200 mg, single oral tablet
40795561|NCT05429320|PROCEDURE|Local ablative therapy|In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT. In Part II of the study, patients will be randomized to standard of care (continuation of systemic therapy) vs. LAT to all sites of disease
40795562|NCT05429320|OTHER|Blood collection to assess for ctDNA|Participants will undergo ctDNA collection in conjunction with their standard of care therapy.
40795563|NCT06442410|DEVICE|DTM™ spinal cord stimulation therapy delivered via Intellis™ neurostimulator system|Along with the appropriate Conventional Medical Management treatment made by the Investigator, the subject will be trialed and implanted with an Intellis™ neurostimulator system using DTM™ SCS programming parameters.
40795564|NCT06442410|OTHER|Conventional Medical Management (CMM)|The CMM treatment can be modified at any moment by the investigators based on their clinical evaluation and local standard of care. They may also consists of one or more of the following treatments: medications, combined physical and psychological management, physical therapy, back rehabilitation program, spinal manipulation and spinal mobilization, traction, acupuncture, cognitive behavioral therapy, biofeedback, nerve blocks, radio frequency ablation, epidural steroid injections, transcutaneous electrical nerve stimulation, intradiscal electrothermal therapy, nucleoplasty, also called plasma disc decompression (PDD) or similar
40795565|NCT05491096|OTHER|Proprioceptive Neuromuscular Training|Proprioceptive exercises will be divided into three components. The first component will be comprised of standing on Foam with eyes open and eyes closed and passing any object from one subject to the other for 10 minutes. The second component consists of activity that will be performed in groups of two. Throwing and catching a ball will be performed while standing on foam for additional10 minutes. The third component, throwing and catching a ball, will be performed on trampoline to further challenge the balance system. After each set of 10-minute exercise, the subjects will be given two-minute resting periods. In the end, 10 minutes will be given for cooling down in which deep breathing exercises and static back extensor stretching exercises will be performed to avoid fatigue and to bring the heart rate back to the normal resting level.
40795566|NCT05491096|OTHER|Conventional Physical Therapy|Conventional treatment protocolconsists of a structured exercise protocol Each training session consisted of three parts, the first part included the main movements (warming up 10 minutes plus 5 minutes stretching exercises), the second part consisted of specific movements (exercises with theraband and physioball, 20 minutes), and the third part composed of cool down exercises (10 minutes).(22)Experimental treatment protocolwill be proprioceptive training program. PTP will be based on earlier studies, and will be carried out for eight weeks, with two 60-minute sessions per week. It will start with 10 minutes of Warm-up activities when the subjects will be advised to do light manual stretches and to step up and down on foam to get their body warmed up to have improve muscular flexibility. This will be followed by 30 minutes of proprioceptive exercises targeting lower extremities.
40795567|NCT02809443|BIOLOGICAL|GLS-5700|GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
40795568|NCT02283892|OTHER|Checklist|3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.
40795569|NCT02283892|OTHER|Conventional evaluation|Physician evaluation without the use of checklists
40795570|NCT02033681|PROCEDURE|"One-per-mil Tumescent Solution Injection"|"One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger."
40795571|NCT02033681|PROCEDURE|Saline Solution|Saline solution is injected into the tissue as a placebo control.
40795572|NCT02110186|DEVICE|Dynamic Stabilization|
40795573|NCT02110186|PROCEDURE|Discectomy|
40795574|NCT02110186|DEVICE|Instrumentation and fusion|
40795575|NCT02704949|RADIATION|1/4 fluoroscopy dose|Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
40795576|NCT02704949|RADIATION|Full-dose|Use of full fluoroscopy dose while ureteroscopy is being performed
40795577|NCT02366923|DEVICE|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
40795578|NCT02366923|DEVICE|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
41470977|NCT06533280|DRUG|Part D: Probe cocktail|Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.
40795579|NCT00889850|DRUG|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
40795580|NCT00889850|DRUG|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
40795581|NCT04550780|DRUG|Mepolizumab|The first administration of mepolizumab.
41470978|NCT03347357|DRUG|Tacrolimus|Tacrolimus was administered orally at a dose of 0.05 mg/kg/dose twice daily (bid) for children with nephrotic syndrome.
41470979|NCT06029582|DEVICE|VR headset|Virtual Reality Headset
41470980|NCT02733627|DRUG|BI 1467335|
41470981|NCT02733627|DRUG|Placebo|
41470982|NCT01985464|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
41000483|NCT03523546|OTHER|Cancer Episode Payment Model (CEM)|Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
41000484|NCT00015275|BEHAVIORAL|Cocaine-Related Disorders|
41000485|NCT02203864|BIOLOGICAL|BIBW2 component A|BIBW2 without IL-2 secreting cell line
41312509|NCT03902743|OTHER|Anticipatory Care Plan group|The Anticipatory Care Plan will be delivered by a trained nurse. At the initial visit, the nurse will conduct a hollistic assessment using the EasyCare Assessment Tool. Following this visit, the nurse will draft a strucutred summary report of the home visit to include patient goals, preferences for care, identified problems and action list. The nurse will then consult with a pharmacist to identify any potential inappropriate prescribing. The nurse will then meet with the participants GP and review and provide feedback. The nurse will then re visit participants and discuss the report and agree a support plan and actions for follow up.
41312510|NCT03984331|DEVICE|Fish skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
41312511|NCT03984331|DEVICE|Cadaver skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
41312512|NCT02917551|OTHER|7 days of adequate antibiotic treatment|
41312513|NCT02917551|OTHER|14 days of adequate antibiotic treatment|
41470983|NCT05470829|DRUG|ZM-H1505R|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"
41312514|NCT01472172|DEVICE|Cryobiopsy (Autoclavable cryoprobe 20416-032)|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
41312515|NCT02537379|DRUG|SOF|SOF 400 mg tablets administered orally once daily
41312516|NCT02537379|DRUG|COPE|COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
41312517|NCT05370313|BEHAVIORAL|Market Price Condition (control)|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Cigarette taxes increased across trials at the same magnitudes used in the tax conditions.
41312518|NCT05370313|BEHAVIORAL|Tobacco Parity Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
41312519|NCT05370313|BEHAVIORAL|Nicotine-Content Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier.
41470984|NCT05470829|OTHER|ZM-H1505R Placebo|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"
41470985|NCT05286840|DIAGNOSTIC_TEST|64Cu-SAR-bisPSMA|Diagnostic PET/CT imaging agent targeted for Prostate Specific Membrane Antigen (PSMA)
41470986|NCT04944316|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet
41470987|NCT04944316|BEHAVIORAL|Dietary intervention|Portion-controlled diet (compliant with ADA guidelines)
41470988|NCT06269913|OTHER|FeSC|Iron/yeast complex
41470989|NCT04592523|OTHER|No Intervention|This is a non-interventional study.
41470990|NCT00161681|DRUG|Levonorgestrel/Ethinyl Estradiol|
41470991|NCT00794417|DRUG|Aflibercept|Administered in combination with the other two interventions via intravenous infusion.
41470992|NCT00794417|DRUG|Pemetrexed|Administered in combination with the other two interventions via intravenous infusion.
41000486|NCT02203864|BIOLOGICAL|BIBW2 component B|BIBW2 with IL-2 secreting cell line
41000487|NCT02957175|OTHER|Immunophenotyping|Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
41000488|NCT03437122|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
41000489|NCT02915653|OTHER|Educational materials on a new diagnostic service|Educational materials on a new diagnostic service
41000490|NCT02244203|DRUG|BI 60732|
41000491|NCT02244203|DRUG|Placebo|
41470993|NCT00794417|DRUG|Cisplatin|Administered in combination with the other two interventions via intravenous infusion.
41470994|NCT02844010|OTHER|weighing|
41000492|NCT06368453|DEVICE|INSTI® HIV Self-Test|"Each participant will be provided with the INSTI® HIV Self-Test and asked to conduct self testing. The operator will observe the participant and record the subject's interpretation of the results. Subjects will perform the test without intervention from the operator.~The operator will then perform the comparator test and collect a fingerstick blood sample. In the event of a discrepant result between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject and sent for discrepancy testing."
41470995|NCT06533371|DIAGNOSTIC_TEST|Relationship between lung ultrasound and computed tomographic scan|"Ultrasonographic findings will be obtained with clinical machines. Additionally, US scans as acquired with the Ula-Op open research platform will also be gathered. For both scanners, 10seconds videos will be recorded and stored in each landmark.~To correlate LUS artefactual patterns with peripheral parenchymal changes evaluated by HRCT of the chest, all chest CT findings will be analysed by an image processing platform designed to provide visualization and quantification of areas with abnormal CT tissue density indicative of emphysema and air trapping. Post-processing image analysis will be performed on images by using automated detection of potential emphysema systems."
41470996|NCT06617533|OTHER|PCF model|PCF practices practices receive (1) a per-beneficiary-per-month prospective payment that depends on the average health of their attributed Medicare beneficiaries; (2) a Flat Visit Fee for primary care visits, subject to a geographic adjustment factor, and (3) a Performance-based Adjustment (PBA). The PBAs depend on practices' performance on several quality measures in addition to their performance in reducing beneficiaries' use of inpatient care or total cost of care, relative to national and regional benchmarks. Practices must meet a limited set of care delivery requirements and can use the PCF Model's flexible use of payments to invest in strategies that best suit their practices' unique patient population and resources. In return, practices take on limited financial risk in exchange for performance-based payments that reward participants that meet certain performance and quality benchmarks for selected outcomes.
41470997|NCT06617130|DIETARY_SUPPLEMENT|Corn soy bean blended flour porridge plus indispensable amino acid|"Protocol treatment will start within two weeks of enrollment to the study. Following the baseline study assessments, each participant will receive corn-soy bean blended flour porridge supplemented with IAAs (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) dosed at 12g/d and providing 1.5 times the estimated average requirement (EAR) for a healthy child (Intervention group). The porridge will provide 30% daily energy requirement. The study foods will be taken once daily by the child with at least three observed feeding sessions per week over the 4 weeks of the study to assess compliance.~Children in the control arm will receive corn-soy blended flour porridge without added amino acids."
41470998|NCT06069856|DIETARY_SUPPLEMENT|Iron Folic Acid Tablets with 60 mg of iron|IFA with 60 mg iron is an intervention group. IFA with 60 mg of iron will be taken orally once daily from the time of randomization
40795582|NCT04770558|OTHER|Interactive Exergame|The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
40795583|NCT05400850|OTHER|YOGA|Five different YOGA Asana's will made randomly
40795584|NCT06239883|OTHER|Voiding diary|The patients with diagnosed OSA will be asked to fill in the voiding diary.
40795585|NCT03266744|DIAGNOSTIC_TEST|Computerised Tomography|
40795586|NCT03266744|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|
41312520|NCT05370313|BEHAVIORAL|Harm-Reduction Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
41312521|NCT05370313|BEHAVIORAL|Modified Risk Tobacco Product (MRTP) Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier.
41312522|NCT04868591|OTHER|Single session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participant will not receive additional care by the APPT.
41312523|NCT04868591|OTHER|Multiple session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participants will receive five additional consultations with the APPT within a 12-week period. During the follow-up visits, the APPT will reassess the participants, provide further education and recommendations, review and modify the home exercise program and may provide other rehabilitation interventions.
41312524|NCT05745116|DEVICE|Notal Vision Home OCT|Optical Coherence Tomography (OCT) was originally developed in 1991 as a non-invasive imaging technology to generate cross-sectional imagery of ocular tissues in vivo1. Cross-sectional visualization of the retina has proven to be a valuable tool in the identification and assessment of structural abnormalities that are not visible with ophthalmoscopic or biomicroscopic examination. OCT has become eye care professionals' leading diagnostic tool in the detection, diagnosis and treatment of retinal diseases and conditions, including age-related macular degeneration (AMD), Diabetic Macular Edema (DME), and Retina Vein Occlusion (RVO). Notal Vision, Inc. (Manassas, VA) is developing a Home Optical Coherence Tomography (OCT) System to allow OCT images to be captured on an OCT device placed in the patients' homes for daily scanning of eyes diagnosed with DME. This Home OCT allows visualization of retinal fluid in the central 10 degrees and is currently for investigational use only.
41312525|NCT01414712|OTHER|Blood Drawing|Blood Drawing to measure circulating tumor cells counts.
41312526|NCT03449316|BEHAVIORAL|Inhaler technique education|Teaching of inhalers use with placebo devices in real training
40795587|NCT03266744|DIAGNOSTIC_TEST|Bone scan|
40795588|NCT03440801|DEVICE|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
40795589|NCT03440801|DEVICE|Xience|Durable-polymer everolimus-eluting stent Xience
40795590|NCT06197074|OTHER|Ultrasound assessment|The morphological characteristics of the quadriceps muscle of the participants will be assessed using ultrasound.
40795591|NCT01364129|PROCEDURE|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
41470999|NCT06069856|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization.
41471000|NCT06184295|DEVICE|TBI - Intervention Group|The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.
41471001|NCT06115863|OTHER|Early Cognitive Stimulation Interventions|early cognitive stimulation interventions refer to multi-dimensions of stimulative evidenced-based interventions, which are done during the first 24 hours from patient admission to the ICU. They are designed to stimulate cognitive function domains that are impacted by delirium such as attention, registration, recall, and language.
41471002|NCT06121258|OTHER|Educational video series|The intervention is a web-based educational video series that was developed using a patient-centered approach that discusses breast cancer treatment, sexual health side effects, and provides treatment and mitigation strategies for these side effects.
41471003|NCT03129230|PROCEDURE|free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.
41471004|NCT04785131|OTHER|Prune|daily consumption of 50 grams prune.
41471005|NCT00337974|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
41471006|NCT00337974|OTHER|Educational DVDs|
41471007|NCT04831138|PROCEDURE|MRI with ASL|"T0 (Week 0): MRI with ASL will be performed either for research alone or along with patient's standard of care imaging session including contrast-enhancement.~T1 (Day 7+-2): contrast-enhanced research MRI with ASL T2 (Day 14+-2): contrast-enhanced research MRI with ASL T3: MRI with ASL will be performed along with patient's standard of care imaging session.~T4: MRI with ASL will be performed along with patient's standard of care imaging session.~T5: MRI with ASL will be performed along with patient's standard of care imaging session."
40795592|NCT06555393|DIETARY_SUPPLEMENT|Egg White Powder|"Participants will consume a standardized breakfast (2 slices of 70 g whole wheat bread, 10 g of butter and 30 g of strawberry jam) followed by a smoothie containing the powder. The Egg White Powder will be incorporated in the standardized smoothie containing water, fruits and chocolate/strawberry syrup totaling 250 Kcal. The total calories of the breakfast will be adapted to the calorie needs of each participant to account for 20-25% of their daily calorie intake.~After a 9 h fast, blood will be taken before consumption of the standardized breakfast and smoothie (T= 0) and at 5, 10, 20, 30, 60, 90, 120, and 180 min after consumption of the smoothie. Participants will be given 15-25 minutes to eat their breakfast. Urine samples will be collected from participants before the smoothie consumption (0 h) and at 30 min, 90 min, 150 min, 6 hours, 12 hours, and 24 hours following consumption."
41471008|NCT03443193|OTHER|Exercise training|Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
41471009|NCT04138706|DRUG|Vancomycin|Extension of initial vancomycin regimen for the treatment of C. diff from 14 days to 28 days (i.e. an additional 14 days of vancomycin treatment)
41471010|NCT04138706|DRUG|Placebos|Initial vancomycin treatment (x14 days) will be followed by 14 days of placebo.
40795593|NCT00617097|DRUG|lidocaine|paracervical block with lidocaine
41000493|NCT05737472|DIETARY_SUPPLEMENT|High-protein RUTF|The high-protein RUTF is isocaloric to the standard RUTF. To have a higher protein quantity and quality, the recipe has greater proportions of milk powder plus whey protein and vegetable oil. A total of 15% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS )of the high protein, RUTF is 1.18 which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 1.19
41000494|NCT05737472|DIETARY_SUPPLEMENT|Standard RUTF|The standard RUTF was manufactured according to WHO recommendations, with at least 50% of protein-sourced dairy, mainly skim milk. A total of 10% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS) of the standard RUTF is 0.76, which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 0.86.
41312527|NCT03720821|BEHAVIORAL|Cognitive Training + fMRI|"Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training."
40795594|NCT00617097|DRUG|ketorolac and lidocaine|paracervical block with ketorolac and lidocaine
40795595|NCT03860831|DRUG|Ketamine + midazolam|Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
41312528|NCT05570045|DIETARY_SUPPLEMENT|Colos Gain|"Dietary Supplement: Colos Gain Colos Gain is a nutrient product made by VITADAIRY Dairy Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~Direction: Mix 5 spoons of Colos Gain (equal to 45 grams) with 180 ml of warm water (50˚C) which provides 210kcal (The energy density reaches 1kal/ml). Consume 2-3 glasses per day or follow the directions from the medical supervisors.~The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
41312529|NCT03052842|DRUG|C16G2 Strip|Antimicrobial Peptide
40795596|NCT01635998|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
40795597|NCT00910910|DRUG|Lenalidomide|"For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to \< 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first."
41312530|NCT03052842|OTHER|Placebo Strip|Placebo
41312531|NCT04507867|DIETARY_SUPPLEMENT|Nutritional support system (NSS)|"1. Combination of three B vitamins (B1, B6 and B12) Neurobion 10 mg solution for IM injection, One every 24 hours for the first 5 days.~2. Probiotics Saccharomyces boulardii CNCM I-745 Floratil. One morning and one evening 250 mg capsule during the first 6 days~3. One envelope of NSS-1 in the morning and one envelope in the afternoon mixed with 400 ml of water each, contain nutritional support system."
41312532|NCT04507867|OTHER|Conventional nutritional support designed by hospital nutritionists|Diet designed by the nutrition department according to comorbidities and intubation probability. Food will be established according to the provisions of the ISSEMYM Toluca Arturo Montiel Rojas Medical Center.
41312533|NCT02277899|OTHER|Communication regarding overweight status|Pediatrician-patient/parent communication regarding child's high weight status
41312534|NCT02277899|OTHER|Risk-factor assessment and counseling|Counseling regarding cardiovascular risk factor assessments/results.
41312535|NCT02277899|OTHER|Lifestyle behavior assessment and counseling|Counseling regarding diet and lifestyle changes to improve weight status.
41312536|NCT02277899|OTHER|Interval follow-up to readdress weight|Interval follow-up to readdress weight, prior to the next well-child visit one year later. Follow-up could include ongoing care through nutrition and/or an intensive weight-management program.
41312537|NCT02277899|OTHER|Patient-centered communication|Patient-centered communication will be scored as the ratio of patient to doctor-centered communication regarding weight topics. Means will be calculated for total and weight-communication-specific pediatrician, child, and parent-talk time, and patient, doctor, and the ratio of patient/doctor-centered communication scores. For the primary hypothesis, biomedical information-giving (for example, risk-factor communication) will be treated as patient-centered because the principal investigator's focus groups suggest that parents want this information, and prior research suggests that including biomedical-information giving improves the correlation of Roter's patient-centeredness measure with patient health status and satisfaction scores.
40795598|NCT00910910|DRUG|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
40795599|NCT02915627|DEVICE|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
41000495|NCT06122207|DIETARY_SUPPLEMENT|Probiotic|"* Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy:~  * Women: 1 capsule of probiotic per day for 12 weeks.~* Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months."
41000496|NCT06122207|DIETARY_SUPPLEMENT|Placebo|"* Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy:~  * Women:1 capsule of placebo per day for 12 weeks.~* Men: 1 capsule of placebo per day for 6-months."
41312538|NCT04673136|DEVICE|GI-GENIUS Medtronic|Colonoscopy assisted by GI-GENIUS device
41312539|NCT04673136|OTHER|Colonoscopy|Standard colonoscopy
41312540|NCT03970395|OTHER|Osteopathic manipulative therapy (OMTh)|The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.
41471011|NCT04143295|DRUG|Diiodothyropropionic acid|Drug Administration
40795600|NCT03198091|DRUG|Dun Ye Guan Xin Ning|Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
41000497|NCT05572619|DEVICE|1st Reading|The medical team visually checks the non-contrast CT without cELVO and diagnose the large vessel occlusion.
41000498|NCT05572619|DEVICE|2nd Reading|The medical team visually checks the non-contrast CT with assistance from the cELVO and diagnose the large vessel occlusion.
41312541|NCT03970395|OTHER|Light Touch Therapy (LTT)|The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.
41471012|NCT03811132|OTHER|Observation|There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.
40795601|NCT04981301|DRUG|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the convex probe will be covered with a sterile sheath and a 22G, 100 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles with the anterior approach, the needle will be punctured in the Petit triangle and 5 ml of saline will be injected into the anterolateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
40795602|NCT02453750|DRUG|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls \<10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls \>10%, the previous step will be repeated.
40795603|NCT02453750|DRUG|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
40795604|NCT06510179|OTHER|Toothbrushing|Patients brush their teeth using the technique instructed to them using the toothbrush provided.
40795605|NCT06199804|BEHAVIORAL|Toy Hygiene Training|The training was given to the mothers in 2 sessions (morning and afternoon), each lasting approximately 30 minutes, accompanied by the Toy Hygiene Guide. The sessions were presented face to face in the mother's room in the form of explaining, showing, question and answer and power point, at a time convenient for the mother and the child, outside the morning and afternoon treatment and care hours. After the first session was completed, an appointment was made with the mother for the afternoon session. In the second session, the information in the book that was not given in the first session was presented to the mothers face to face in the mother's room, outside the treatment and care hours, at a time convenient for the mother and the child. After the training was completed, a final five-minute discussion was held with the mothers in the form of a general question and answer session. The training book was given to the mothers in the experimental group on the first day.
40795606|NCT04638920|OTHER|No intervention|No intervention
41000499|NCT01627613|DRUG|AP301|"AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days."
41000500|NCT01627613|DRUG|Saline solution|Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
41312542|NCT03970395|OTHER|Repositioning therapy|"It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed."
41312543|NCT03835000|PROCEDURE|Orthopedic surgery|before and after surgery, patient will need medical imaging to asses their conditions
41312544|NCT03337594|DRUG|Pre-operative MRI with Dotarem|Dotarem® (gadoterate meglumine - Guerbet)
41312545|NCT03337594|DRUG|Pre-operative MRI with MultiHance|MultiHance® (gadobenate dimeglumine - Bracco)
41312546|NCT03337594|PROCEDURE|Surgery|Cardiac surgery
41312547|NCT02176590|BEHAVIORAL|Power PATH|PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
41312548|NCT02176590|OTHER|Head Start as usual|Standard Head Start programming (including classroom instruction, meals, and family services)
41312549|NCT00285103|DRUG|SPC2996|
41312550|NCT01069523|DRUG|Guanfacine Extended Release|Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.
41312551|NCT01069523|DRUG|Placebo|Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
41312552|NCT00004038|BIOLOGICAL|Ad5CMV-p53 gene|
41312553|NCT00004038|DRUG|chemotherapy|
41312554|NCT03164226|DEVICE|Digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain|To verify the contribution of digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
41312555|NCT00701727|DRUG|ezetimibe|1 tablet,10mg, once a day, for 7 weeks
41312556|NCT00701727|DRUG|Placebo|1 tablet, once a day, for 7 weeks
41312557|NCT05316090|PROCEDURE|Core stability exercises program|Strengthening to the trunk muscles
41312558|NCT05316090|PROCEDURE|Traditional physical therapy program|Neurodevelopmental training excercises
41312559|NCT02730442|DRUG|F901318|Administration of F901318 intravenously
41471013|NCT03028896|PROCEDURE|90° rotational technique|the LMA FlexibleTM was rotated counter-clockwise through 90°
41471014|NCT03009487|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
41312560|NCT02730442|DRUG|Fluconazole|Oral administration
40795607|NCT05237362|BEHAVIORAL|Saga Stories|Saga Stories in health talks consists of material for child healthcare nurses to use to facilitate the health talk with both the child and parent(s) and is complemented with take-home material. Every nurse will receive a large flip-chart with colourful pictures and text to facilitate their health talk at the 5-year check-up. The flip-chart will include information and questions regarding food, physical activity and sedentary behaviour, sleep, dental health, as well as bathroom habits. At the conclusion of the check-up the children will receive the book 'Saga Stories: Your amazing body and brain´ as well as games for the child to take home to promote healthy lifestyle behaviours (fruit and vegetable bingo and a physical activity fortune teller).
40795608|NCT03724279|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening."
40795609|NCT05163301|BEHAVIORAL|Relapse Prevention Intervention|2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
40795610|NCT01683136|DEVICE|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
40795611|NCT05383781|OTHER|Hip and Knee focused exercises|Exercises which improves muscle strength, ROM
40795612|NCT05383781|OTHER|Short foot exercise|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
40795613|NCT05111431|DRUG|Dexmedetomidine Hydrochloride Nasal Spray|"In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray."
40795614|NCT05111431|DRUG|Dexmedetomidine hydrochloride nasal spray blank preparation|"In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
40795615|NCT02432937|DRUG|Corever|Corever
40795616|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ H.|Vegan Capsules with active product, GutMagnific™ high dose
41000501|NCT01124604|DRUG|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
41312561|NCT03215654|OTHER|"EspaiJove.net mental health literacy program"|"The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context."
41312562|NCT06271447|OTHER|Traditional therapy|"All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.~Since the questionnaires to be used in the study are related to fear of movement and pain, neuroscience education will be included in the treatment program of the patients. Patients will be informed about proper posture and movement regarding fear of movement and pain avoidance behaviors."
41312563|NCT01702363|DRUG|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
41312564|NCT00239486|DRUG|Pramipexole|
41312565|NCT01717703|DIETARY_SUPPLEMENT|Water|
41471015|NCT03009487|DRUG|Olmesartan 40 mg, Rosuvastatin 20mg|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
40795617|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ L.|Vegan Capsules with active product, GutMagnific™ low dose
41312566|NCT01717703|DIETARY_SUPPLEMENT|Fruit drink|
41312567|NCT01717703|DIETARY_SUPPLEMENT|Cola|
41312568|NCT01717703|DIETARY_SUPPLEMENT|1% chocolate milk|
40795618|NCT04741841|DIETARY_SUPPLEMENT|Placebo|Vegan capsules identical to active product in taste and appearance but without probiotic
40795619|NCT02840435|BEHAVIORAL|Sit to Quit|Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
40795620|NCT02840435|BEHAVIORAL|Quit for Life|"Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills."
41471016|NCT03009487|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
40795621|NCT01125475|DEVICE|RebiSmart|Treatment with Rebif New Formulation using RebiSmart.
40795622|NCT00382317|DRUG|Iobitridol|
40795623|NCT03288454|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
40795624|NCT03288454|DRUG|Placebo|Saline for injection
40795625|NCT03288454|DRUG|Apixaban|Apixaban 10mg given twice daily (q12h)
40795626|NCT04755998|OTHER|Use of virtual reality glasses during vaccination applications in children|"To the experimental group:~Before the vaccine administration;~* Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student.~* Cartoons and virtual reality glasses that the student wanted to watch were prepared.~* While the nurse was preparing the vaccines, the student was put on virtual reality glasses and the distance settings of the lenses were adjusted and the cartoons he chose to watch during the vaccination applications started to be shown. Since virtual reality glasses can cause anxiety attacks manifested by nausea in some children, this was also tested beforehand. It took about two minutes to administer the vaccine and watch cartoons.~Those applied after the vaccine administration;~- Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student."
40795627|NCT00648921|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fasting
41000502|NCT01124604|DRUG|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
41312569|NCT04574609|DEVICE|Oncomfort® clinical virtual reality|"hypnotherapy arm, patients will receive in addition to the care provided by the usual :~* for PAC insertion: a 45-minute hypnotherapy session 2 hours before the procedure in a room of the outpatient surgery unit (UCA).~* during the entire duration of chemotherapy (and/or immunotherapy for HER2+ patients) : one hypnotherapy session before the first treatment and then every 3 weeks. One hypnotherapy session before the first treatment and then every 3 weeks. Thus, sessions will take place before each treatment for 3-week inter-course regimens and every 3 treatments for chemotherapy administered on a weekly. Each session will last 20 minutes."
41312570|NCT06006312|DIAGNOSTIC_TEST|fecal elastase-1 test|Personal information of the enrolled subjects will be collected and a fecal collection device will be distributed. Fecal elastase-1 levels will be measured after the fecal sample is collected.
41312571|NCT06006312|DIAGNOSTIC_TEST|72-hour fecal fat quantification|Enrolled subjects will eat a standard meal (100g of fat) daily for five consecutive days and collect stool samples for the last 72h. The fat content in the sample will be quantitatively detected and the fat absorption coefficient will be calculated.
41312572|NCT06006312|DIAGNOSTIC_TEST|blood sample test|The enrolled subjects will undergo oral glucose tolerance test and will be collected blood samples for measurement of plasma glucose, insulin level, C-peptide level, glycosylated hemoglobin and vitamin.
41312573|NCT03050671|DEVICE|Intermittent Pneumatic Compression, Rapid|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
40795628|NCT00648921|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fasting
41000503|NCT04466163|BEHAVIORAL|Schema Therapy and the Healthy Adult|The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen \& Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
41000504|NCT05210790|DRUG|Placebo|Placebo
41000505|NCT05210790|DRUG|Rusfertide|Experimental drug
40795629|NCT02054039|DEVICE|Incentive spirometry (IS)|Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
40795630|NCT02054039|DEVICE|Breath Stacking (BS)|Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
40795631|NCT04051749|PROCEDURE|Noncardiac Vascular Surgery|Noncardiac Vascular Surgery
40795632|NCT06418737|BEHAVIORAL|Sleep HygieneTraining|"Training Content~* Importance of Sleep: The vital importance of sleep for physical and mental health.~* Benefits of Adequate and Quality Sleep: The numerous benefits of sufficient and good quality sleep.~* Sleep Stages: The different stages of sleep and their characteristics.~* Sleep Hygiene: The concept of sleep hygiene and its importance for improving sleep quality.~* What to Do?~* What to Avoid for Better Sleep?"
40795633|NCT04709679|PROCEDURE|MicroPulse TransScleral CycloPhotoCoagulation|A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients
40795634|NCT06286449|OTHER|Spinal tap|A spinal tap is performed on all enrolled study participants that meet the eligibility criteria
41000506|NCT06184425|PROCEDURE|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 25-gauge pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
41000507|NCT06184425|PROCEDURE|Dural Puncture Epidural technique using pencil-point 27G Whitacre needle|- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 27-gauage pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
41000508|NCT03155009|DRUG|Alectinib|600 mg orally BID with food
41000509|NCT03063827|DRUG|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
41000510|NCT03063827|DIAGNOSTIC_TEST|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
41000511|NCT03012386|DRUG|Sildenafil Citrate in G allele carrier|chronic use of phosphodiesterase 5 inhibitor in G allele carrier
41000512|NCT03012386|DRUG|Sildenafil Citrate in non G allele carrier|chronic use of phosphodiesterase 5 inhibitor in Non G allele carrier
41471017|NCT04528576|DEVICE|Dragonfly mitral valve repair system|With transesophageal echocardiographic guidance,implanting clip using Dragonfly mitral valve repair system
40795635|NCT05396339|DRUG|IAE0972|IAE0972 is an investigational product
40795636|NCT04065698|DRUG|RV521|Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.
41000513|NCT01468766|OTHER|Supervised progressive resistance training|2x60 minutes per week for 12 weeks
40795637|NCT03439046|DRUG|Ribociclib|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
40795638|NCT03439046|DRUG|Letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
40795639|NCT03439046|DRUG|Alpelisib|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
40795640|NCT03439046|DRUG|Fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
40795641|NCT03320967|DIAGNOSTIC_TEST|Copeptin in plasma|Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.
40795642|NCT03199794|BIOLOGICAL|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
40795643|NCT05512481|DRUG|Camrelizumab|"NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year"
41312574|NCT03050671|DEVICE|Intermittent Pneumatic Compression, Slow|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
41312575|NCT00211588|DRUG|galantamine|
41312576|NCT05685576|DEVICE|Piezotomed ridge splitting and osseodensification|Ridge expansion using piezotomed ridge splitting and osseodensification
41312577|NCT01357915|PROCEDURE|Blood sampling|"Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."
41471018|NCT06460506|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
40795644|NCT06187220|DEVICE|Therapeutic Plasma Exchange (PEX)|Therapeutic plasma exchange with treatment sessions \>=1 replacing varying fractions of patient´s whole plasma with healthy donor plasma
40795645|NCT05011175|OTHER|Survey|Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
40795646|NCT01356498|BIOLOGICAL|pegloticase|8 mg intravenous infusion
40795647|NCT01999686|DRUG|DLBS3233|
40795648|NCT01999686|DRUG|Metformin XR|
40795649|NCT01999686|DRUG|Placebo metformin|Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
40795650|NCT01999686|DRUG|Placebo DLBS3233|Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
40795651|NCT00841243|DIETARY_SUPPLEMENT|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
40795652|NCT04212715|RADIATION|Pelvic SABR with intra-prostatic SABR|SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
41000514|NCT01468766|OTHER|Supervised progressive muscle relaxation training (Jacobson method)|2x60 minutes per week for 12 weeks
41000515|NCT04915391|DIAGNOSTIC_TEST|Skin biopsy and blood sample for inflammation markers, RNA and proteins|A skin biopsy will be performed at the baseline visit from which primary cell cultures of fibroblasts and keratinocytes will be obtained. Four to six weeks later a second biopsy on the scar will be performed and analyzed anatomically and pathologically. In addition, at the initial visit, blood samples will be drawn for analysis of inflammation markers, RNA and proteins.
41000516|NCT00006211|DRUG|Capravirine|
41000517|NCT00006211|DRUG|Nelfinavir mesylate|
41000518|NCT02667483|DRUG|DS-5141b|DS-5141b, Subcutaneous injection
41000519|NCT01537783|DRUG|Chlorhexidine gluconate|Scrubs applied once a day for 5 days
41000520|NCT01537783|DRUG|Mupirocin|Nasal mupirocin applied topically to both nostrils twice a day for 5 days
41312578|NCT01357915|BIOLOGICAL|GSK149203A|GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses
41471019|NCT06460506|DRUG|IVA|Granules for oral administration
40795653|NCT06288633|PROCEDURE|Ganglionated plexi ablation|"Through access in the femoral vein, a mapping or ablation-mapping catheter is inserted into the right atrium, and a three-dimensional reconstruction of the right atrium is performed using an electroanatomic mapping system. The inferior and superior vena cava, the coronary sinus are indicated.~Then a transeptal puncture is performed using a transeptal introducer and a needle for transeptal puncture under fluoroscopic control. A three-dimensional reconstruction of the left atrium is performed using an electroanatomic mapping system.~During or immediately after the creation of three-dimensional maps of both atria, areas of the typical concentration of ganglion plexuses (GP) are ablated using radiofrequency applications (30-50 Watts, 10-40 s each point). Ablated points are annotated on the three-dimensional map. GPs ablation zones are about 0.5 x 1.0 cm in size."
40795654|NCT06288633|DIAGNOSTIC_TEST|Electrophysiological study|Through access in the femoral vein, a diagnostic catheter is inserted in the area of the coronary sinus under fluoroscopic control. The effective refractory period (ERP) of the atria will be measured according to the method adopted in clinical practice, namely: using a ten-pole diagnostic electrode installed in the coronary sinus, a series of eight electrical pulses with the same amplitude and frequency is applied to the atrial myocardium. Then the ninth pulse is applied with a gradual decrease in the time interval until the absence of an atrial myocardium response to the pulse is registered. The cycle of an additional, ninth pulse, in which the atrial myocardium did not respond to an electrical impulse, is considered an atrial ERP.
40795655|NCT04684576|DEVICE|Permobil Explorer Mini|The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
40795656|NCT04684576|DEVICE|Modified Ride-On Car|Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
40795657|NCT05128071|DRUG|Progesterone|Randomized to 400 mg (200 mg twice daily) oral micronized progesterone daily
40795658|NCT05128071|DRUG|Placebo|Randomized to placebo twice daily
40795659|NCT01060904|DRUG|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
40795660|NCT01060904|DRUG|doxorubicin|25 mg/m2 IV every 2 weeks
40795661|NCT01060904|DRUG|vinblastine|6 mg/m2 IV every 2 weeks
40795662|NCT01060904|DRUG|dacarbazine|375 mg/m2 IV every 2 weeks
40795663|NCT01060904|DRUG|bleomycin|10 units/m2 IV every 2 weeks
40795664|NCT01060904|DRUG|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
40795665|NCT04727996|DRUG|Sitravatinib|120 mg will be administered orally once daily
40795666|NCT04727996|DRUG|Tislelizumab|200 mg will be administered intravenously (IV) once every 3 weeks
40795667|NCT03125499|OTHER|Previous treated with TPX-100|No intervention, only observational
40795668|NCT01791621|OTHER|Elimination/Challenge Diet|"An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.~The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team."
40795669|NCT00356070|DRUG|Strattera|
41150729|NCT06185101|BEHAVIORAL|STEP-UP|The STEP-UP chronic pain self-management intervention (Support, Training, and Education for Pain Self-Management - Using Podcasts) will feature an educational podcast series teaching core pain self-management skills. Podcasts will be supplemented by sessions with a Community Health Worker taking place at designated times over a 7-week period. The Community Health Worker will guide participants in a modified Patient Priorities of Care (PPC) approach to help them identify their values and priorities and develop goals that reflect these.
40795670|NCT05806346|DRUG|TXA administration|Tranexamic acid intravenous administration
40795671|NCT05806346|DRUG|Placebo administration|Placebo (normal saline) intravenous administration
40795672|NCT02172391|DRUG|Tiotropium inhalation powder capsules|
40795673|NCT02172391|DRUG|Placebo inhalation powder capsules|
40795674|NCT04965792|OTHER|Screening|Blood test
40795675|NCT02620033|BEHAVIORAL|Yoga therapy|
40795676|NCT03003754|BEHAVIORAL|High Intensity Training (HIT) + Resistance Training (RT)|Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.
40795677|NCT03003754|BEHAVIORAL|Control group|Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
40795678|NCT00068315|DRUG|bortezomib|Given IV
40795679|NCT00068315|DRUG|fludarabine phosphate|Given IV
40795680|NCT00068315|BIOLOGICAL|rituximab|Given IV
40795681|NCT03072043|DRUG|APR-246|Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
40795682|NCT03072043|DRUG|Azacitidine|Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m\^2.
40795683|NCT03190499|OTHER|Family based assessment|Family of the children will be assessed with questionnaires about their child health condition.
40795684|NCT04538599|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
40795685|NCT00041470|DRUG|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
40795686|NCT00041470|DRUG|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
40795687|NCT00041470|DRUG|Herceptin|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
40795688|NCT00041470|DRUG|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
40795689|NCT03017339|OTHER|Functional Exercise|
40795690|NCT03017339|RADIATION|Low Level Laser Therapy|
40795691|NCT03017339|RADIATION|Placebo Low Level Laser Therapy|Low Level Laser Therapy with the device off
40795692|NCT04707716|OTHER|conometric concept Acuris system|implant crown retention type using friction only
40795693|NCT04707716|OTHER|screw retention|screw retained implant crown
40795694|NCT04707716|OTHER|cementation|cement retained implant crown
41312579|NCT01875367|DRUG|Trastuzumab Injectable Solution|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
41312580|NCT01875367|DRUG|Trastuzumab Injectable Product|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
41312581|NCT01875367|DRUG|Trastuzumab Injection|Powder for concentrate for solution for infusion. 1 cycle
41312582|NCT06093217|DEVICE|Artificial Intelligence|AI technology will generate a report with relevant key slice imaging identifying the presence of an acute pulmonary embolism and RV:LV ratio measurements to the radiologist
40795695|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Non-obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
41150730|NCT05872958|DRUG|AZD3152|AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.
41150731|NCT05872958|OTHER|Placebo|Placebo is a matching volume of 0.9% sodium chloride, will be administered via IM injection or IV infusion, as per the assigned arms.
41150732|NCT03278808|DRUG|Chloroquine-Azithromycin (CQ/AZ)|Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
41150733|NCT03278808|DRUG|Chloroquine (CQ)|Chloroquine (CQ); 300 mg of CQ only given orally
41312583|NCT05734781|OTHER|Not Application as this is a qualitative study|Not Application as this is a qualitative study
41312584|NCT01945333|BEHAVIORAL|Cognitive remediation|Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
40795696|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Mild obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
41000521|NCT05736679|DEVICE|In2Care EaveTube|In2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer.
41000522|NCT02353767|PROCEDURE|Noninvasive evaluation of liver fibrosis and steatosis|Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
41312585|NCT04798391|DRUG|Dexamethasone|Steroids and analgesics
41312586|NCT01064193|PROCEDURE|biopsy|"The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:~* Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.~* Insert carefully the pipelle de Cornier® in the uterus through the cervix.~* Withdraw the piston to create a negative pression~* Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.~* Withdraw the pipelle de Cornier® when filled with tissue~* Reinsert internal piston to deposit sample in cup filled with a fixative."
41312587|NCT01064193|PROCEDURE|IVF|fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
41312588|NCT02155764|DEVICE|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
41471020|NCT04010916|OTHER|Group Preoperatively Adductor Canal Block|The ACB will be performed preoperatively before inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
41471021|NCT04010916|OTHER|Group Preoperatively Tourniquet Adductor Canal Block|The ACB will be performed preoperatively after inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
40795697|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Moderate obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
40795698|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Severe obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
40795699|NCT03271216|DEVICE|No intervention|no intervention
40795700|NCT05770297|DIETARY_SUPPLEMENT|Propolis|intervention will use propolis extract (liquid-based) with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given to intervention group
40795701|NCT05770297|OTHER|placebo|intervention will use placebo with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given control group
40795702|NCT01799343|OTHER|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
40795703|NCT03609502|BEHAVIORAL|behavioral training|the participants will be trained to perceive a non-native speech contrast
41312589|NCT02155764|DEVICE|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
41471022|NCT04010916|OTHER|Group Postoperatively Adductor Canal Block|The ACB will be performed postoperatively. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
41471023|NCT04955366|DRUG|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly
41471024|NCT04955366|DRUG|Abatacept|Abatacept is an immunosuppressive medication and will be given SQ at a dose of 125 mg s.c. weekly
40795704|NCT01065675|OTHER|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
40795705|NCT00939887|DRUG|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
41471025|NCT03291041|DRUG|Tasimelteon|capsule
41471026|NCT03291041|DRUG|Placebo|capsule
40795706|NCT04439864|DEVICE|MyIDEA|An educational tablet app that is customized to the patient based on the data in the Electronic Health Record.
41000523|NCT00850395|DRUG|maraviroc|No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
41312590|NCT02155764|DEVICE|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
41312591|NCT06521957|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
41312592|NCT05946759|DEVICE|Histolog Scanner|The PMPF study is collecting data that includes the use of the CE Mark IVD Histolog Scanner for the breast lumpectomy margin assessment.
41471027|NCT06236256|DEVICE|MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system|The MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system consists of the following devices: MiniMed 780G insulin pump, Guardian Link (4) transmitter and the Guardian Sensor (4). It is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed 780G system includes SmartGuard technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. Study participants will be connected to the system and glucose data will be collected throughout the 12 month study period.
41471028|NCT06236256|OTHER|MDI/CSII|Participants in the control group with continue their routine procedures that include eighter Multiple daily insulin injections (MDI) treatment or different kinds of Continuous subcutaneous insulin infusion (CSII) pumps depending on their treatment before the study. The participants will be connected to a standalone sensor at the start, middle and end of the study and glucose data will be collected.
40795707|NCT03387709|BEHAVIORAL|Pistachio-enriched diet|Composition of prescribed diets will be based on individual preferences, with the goal of consuming 1.5 oz of pistachios per day and increased energy expenditure. During the 4-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Pistachios will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
40795708|NCT03387709|BEHAVIORAL|General dietary guidance diet|During the 4-month group intervention, study subjects will participate group sessions, receive telephone, email and/or text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
41312593|NCT05564286|DRUG|Fosaprepitant|In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
41471029|NCT06021054|DRUG|Veligrotug (VRDN-001)|Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor
41471030|NCT06021054|DRUG|Placebo|5 IV infusions of placebo
41471031|NCT05367765|DRUG|Flumatinib|Flumatinib 600mg orally daily
41471032|NCT05367765|DRUG|Imatinib|Imatinib 400mg orally daily (Reference drug instructions)
41471033|NCT06021678|DRUG|EX103 injection|Administered as specified in the treatment arm.
41471034|NCT04549922|DRUG|ISIS 721744|1.2 mL of ISIS 721744 subcutaneous once after randomization
41471035|NCT04549922|DRUG|Normal Saline|1.2 mL subcutaneous
41471036|NCT00099268|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
41471037|NCT00099268|DRUG|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
41471038|NCT06429982|DRUG|Dexamethasone|Steroid five day treatment
41471039|NCT06429982|DRUG|Placebo|Placebo control group
41471040|NCT01684215|DRUG|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
41312594|NCT05564286|DRUG|tropisetron|All patients received tropisetron 5mg on day 1.
41312595|NCT05564286|DRUG|Dexamethasone|.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
41471041|NCT01684215|DRUG|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
41471042|NCT01684215|DRUG|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
41471043|NCT01684215|DRUG|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
41471044|NCT01684215|DRUG|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
41471045|NCT05924867|OTHER|plasma activated saline|The plasma activated normal saline used in the intervention was prepared by a self-made machine, and the safety of the plasma activated water produced by the machine has passed the national quality inspection.
41471046|NCT05924867|OTHER|Routine nursing|For postoperative incision infection group and infected ulcer group, conventional dressing change treatment was given, namely chlorhexidine disinfectant washing, drainage and bandaging; For the fat liquefaction group, conventional treatment was given, namely negative pressure suction.
41312596|NCT04859335|RADIATION|gammaknife radiosurgery|Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.
41312597|NCT00870831|OTHER|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
41471047|NCT04632706|DRUG|Ivermectin|Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study
41471048|NCT04632706|DRUG|Placebo|Matching Placebo to the Active IMP.
41471049|NCT00648245|DRUG|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered once per day for 21 days by nebulizer
41471050|NCT00648245|DRUG|BIO-11006 Inhalation Solution|150 mg of BIO-11006 administered once per day for 21 days by nebulizer
40795709|NCT04711239|DIAGNOSTIC_TEST|PGT-A / niPGT-A|PGT-A and niPGT-A will be performed using next generation sequencing (NGS) analysis for chromosome copy number variation (CNV). Embryo transfers will rely solely on the results of PGT-A for trophectoderm biopsies.
40795710|NCT05933967|DRUG|Orelabrutinib+R-CHOP|Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.
40795711|NCT05881681|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
40795712|NCT02377024|DIETARY_SUPPLEMENT|TF 600mg|
41000524|NCT02679911|DRUG|Loceryl NL|Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
40795713|NCT02377024|DIETARY_SUPPLEMENT|TF 1200mg|
40795714|NCT02377024|DIETARY_SUPPLEMENT|placebo|
40795715|NCT02955108|PROCEDURE|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
41000525|NCT02679911|DRUG|Ciclopirox NL|Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
41000526|NCT05949138|DEVICE|ECG-Less Cardiac CT using SmartPhase|"Administration of medications and biologic products (such as contrast agent administration, and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational workflow on an existing CT device that has regulatory clearance. The investigational workflow includes preforming the CT acquisition according to the hospital's usual care with the exception that the ECG signal which triggers the scan will be coming from an ECG simulator based on an estimate of the patient's heart rate, rather than through ECG leads connected to the subject. Clinically-indicated Cardiac CTs take approximately 30-60 minutes. No additional imaging is needed as part of the study."
41000527|NCT03118128|DRUG|Metformin|Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
41312598|NCT01984034|BEHAVIORAL|Educational Outreach Visits|The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.
40795716|NCT02955108|PROCEDURE|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
40795717|NCT01100333|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant hFSH prescribed according to prescriber's judgement
41000528|NCT03222843|DRUG|Hetrombopag Olamine|once daily
41000529|NCT03222843|DRUG|matching placebo|once daily
41000530|NCT01100099|DIETARY_SUPPLEMENT|Gluten challenge.|The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
41312599|NCT01984034|OTHER|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
40795718|NCT02535013|DEVICE|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
40795719|NCT03496064|OTHER|Successful reperfusion|Defined as modified Thrombolysis in Cerebral Infarction 2b/3
40795720|NCT03331991|BIOLOGICAL|influenza vaccine|exposure to influenza vaccine
40795721|NCT03021603|BEHAVIORAL|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
40795722|NCT05711160|DIAGNOSTIC_TEST|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
40795723|NCT05711160|DIAGNOSTIC_TEST|CBCT images|All patients have been undergoing CBCT scans for both jaws
40795724|NCT05711160|DIAGNOSTIC_TEST|IOS images|The patient's teeth have been dried with air syringe and scanned with the Intraoral scanner
41312600|NCT06372067|DEVICE|Intramedullary screw|Intramedullary (IM) screw fixation is a minimally invasive technique that provides rigid fixation of fractures, acting as an internal splint and load-sharing device. IM screw fixation may allow for early mobilization without the operative site morbidity of open reduction and its associated complications.
41471051|NCT00648245|DRUG|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
40795725|NCT03782259|DRUG|dapagliflozin|Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.
40795726|NCT03782259|OTHER|Placebo|Placebo
40795727|NCT05743712|OTHER|SMART-Wrap|This intervention, SMS (short message system)-based augmentation, seeks to improve the impact and approach of the Wraparound service model by utilizing SMS, which has been shown to increase treatment adherence and sustained engagement. This intervention will facilitate regular, repeated evaluation of intermediate outcomes through self-report assessments.
40795728|NCT04062864|DEVICE|Pupil size|Measures the diameter of pupil before and after painful stimuli
40795729|NCT02530476|DRUG|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
40795730|NCT02530476|DRUG|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
40795731|NCT02798744|DRUG|Empagliflozin|25mg once daily to be taken orally for the duration of the study (24 weeks)
40795732|NCT02798744|BEHAVIORAL|Diet|Daily energy restriction diet to be followed for the duration of the study (24 weeks)
40795733|NCT02798744|DRUG|Placebo|Placebo once daily for the duration of the study (24 weeks)
40795734|NCT05669040|OTHER|Pharmacological education|Inform the patient of the medication that is being taken and how it has to be taken; What is it for and the side effects and/or adverse reactions.
40795735|NCT05669040|OTHER|Training in the use of MyPlan Aplication|Review of the use of the aplication
40795736|NCT05669040|OTHER|Patient Experience|"* How do you feel?~* Sad feelings and frustration.~* Achievements day by day, think positive.~* Importance of interpersonal relationships.~* Explain activities to relax the mind"
40795737|NCT05711706|OTHER|Su Jok Application|Su Jok massage appplication
40795738|NCT04428255|DRUG|HBM9161 Dose A|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
40795739|NCT04428255|DRUG|HBM9161 Dose B|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
40795740|NCT04428255|DRUG|Placebo|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
40795741|NCT00610844|PROCEDURE|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
40795742|NCT05710003|BEHAVIORAL|breathing exercises|"A-breathing exercises: 20 times per hour. While setting down, deep breathing is taken from the nose while mouth is closed, breath holding for at least ten seconds, then slow maximal exhalation for at least 10 seconds.~B-Upper Limb Endurance Exercises (low weight and high repetition) : Study participants will be educated to perform upper limb exercises every 4 hours. Three exercises will be repeated 10×3 times with 1 minute rest in between.~Breathing exercise and upper limb endurance exercises is explained in the reminder in details"
40795743|NCT00097929|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
40795744|NCT02777450|PROCEDURE|lumbar facet block|injection of Levobupivacaine 0,25% and corticosteroids
41471052|NCT00648245|DRUG|Placebo|Placebo given once daily for 21 days by nebulizer
40795745|NCT03060915|DEVICE|Polysomnography|Patient's undergo a polysomnography
40795746|NCT03060915|DEVICE|Actigraphy|Patient's wear an actigraphy while doing the polysomnography
40795747|NCT02100423|DRUG|curcumin|Given PO
40795748|NCT02100423|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
41312601|NCT06372067|DEVICE|Kirschner wire|Kirschner wire (K-wire) fixation is a minimally invasive technique that provides non-rigid fixation of fractures. K-wires allow for fracture fixation with minimal soft tissue injury and preserved blood supply. However, patients require prolonged postoperative immobilization and are at risk of malunion and pin tract infection.
41312602|NCT01122628|DEVICE|ORIF with DVR-A locking plate|Size, length of plate and number os screws decided by operating surgeon
41471053|NCT00648245|DRUG|BIO-11006|125 mg BIO-11006 given twice per day for 21 days by nebulizer
41471054|NCT01478828|DRUG|Lovastatin|oral qd varying dose escalations/de-escalations
40795749|NCT02100423|OTHER|laboratory biomarker analysis|Correlative studies
40795750|NCT02100423|OTHER|pharmacological study|Correlative studies
40795751|NCT01487538|BEHAVIORAL|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
40795752|NCT01487538|BEHAVIORAL|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
40795753|NCT01487538|BEHAVIORAL|Discussion Boards|forum to exchange information and experiences
40795754|NCT01487538|BEHAVIORAL|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
40795755|NCT02141672|DRUG|Voclosporin High Dose|
40795756|NCT02141672|DRUG|Voclosporin Low Dose|
40795757|NCT02141672|DRUG|Placebo|
40795758|NCT05850442|DIAGNOSTIC_TEST|Questionary|Patients will be asked to fill Fibromyalgia Impact Questionary, WHO Short Quality of Life Questionary, McGill Pain Questionary and Beck Anxiety Questionary
40795759|NCT05604144|DEVICE|Cryoanalgesia (iovera°®)|iovera°® treatment will be administered via ultrasound guidance to 1-2 branches of the dorsal/digital/proper nerve/s that innervate the Morton's neuroma. The treatment will be completed one time per subject.
40795760|NCT06400628|BEHAVIORAL|Self-management education|The base line data will be taken and used as control, while the final result will be utilized as the case
40795761|NCT06351163|PROCEDURE|Laparoscopic reduction|A 1cm longitudinal transumbilical incision was made to insert a 5mm trocar for laparoscope placement. CO2 was injected at 10mmHg and a flow rate of 3L. Two 5-mm working trocars were inserted in the lower right and left abdomen under direct visualization, along with two grasping forceps. The ascending colon was manipulated to locate the intussusception mass. Atraumatic graspers were alternately utilized on the ascending colon to mobilize the intussusceptum, pushing it downward towards the cecum. The first visible part of the terminal ileum was grasped and pulled outward and downward, along with its mesentery, using the right grasper, while the left grasper pulled the intussusceptum's neck in the opposite direction. If resistance was encountered, the terminal ileum could be held with the left hand while the right grasper widened the intussusceptum's neck. After reduction, the intestines were examined for necrosis and possible lead points, followed by routine appendectomy and ileopexy.
40795762|NCT06351163|PROCEDURE|Transumbilical mini-open reduction|If laparoscopic reduction alone was unsuccessful or if bowel resection was required, the intussusceptum was fixed with grasping forceps and brought to the umbilicus for MOR. A 2cm transumbilical incision was created, and a skin retractor was inserted. The underlying fascia was longitudinally extended upward and downward along the linea alba. Upon division of the peritoneum, the actual opening could be expanded up to 5cm, while maintaining the skin incision at 2cm. If the initial incision site proved insufficient for exploration, lateral division of the rectus muscle around the umbilicus on both sides could be performed without cutting the skin, thereby enlarging the surgical field. Manual reduction of the intussusceptum was subsequently carried out, along with bowel resection and anastomosis as indicated.
40795763|NCT03366025|DIAGNOSTIC_TEST|Serum progesterone measure|Serum Progesterone will be measured in all donors on the day triggering at 8:00 am, 12:00 p, 16:00 pm and 20:00 pm
40795764|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
40795765|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
40795766|NCT00873275|BIOLOGICAL|bevacizumab|5mg/kg IV day 1 and 15 of each 28 day course of treatment
40795767|NCT00873275|DRUG|FOLFOX regimen|Leucovorin, 5-FU and Oxaliplatin
41000531|NCT03433664|DEVICE|CO2 laser|Fractional CO2 laser treatment using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping
41000532|NCT04488120|DEVICE|transcatheter closure of secundum atrial septal defects in patients|transcatheter closure of secundum atrial septal defects in patients
41000533|NCT01940120|DEVICE|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
41000534|NCT02578927|DIETARY_SUPPLEMENT|GT+Ex|In this session the volunteers ingested capsules with 2g of powder green tea before exercise
41000535|NCT02578927|DIETARY_SUPPLEMENT|PL+Ex|In this session the volunteers ingested capsules with 2g of placebo before exercise
41312603|NCT05500924|OTHER|Intervention group|5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging
41312604|NCT00204334|DRUG|darbopoeitin|
41312605|NCT02258867|DRUG|Placebo|Solution for subcutaneous injection
41312606|NCT02258867|DRUG|Gevokizumab|Solution for subcutaneous injection
41312607|NCT00171314|DRUG|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
41312608|NCT00171314|DRUG|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
41312609|NCT03570034|DEVICE|Obalon Balloon System|Obalon Balloon System with a moderate intensity Weight Loss Behavioral Modification Program
41312610|NCT01972009|PROCEDURE|Cardiac catheterisation|Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
41471055|NCT05571033|BEHAVIORAL|Spinal reflex conditioning|Each participant will serve as their own control. The intervention is 30 sessions. The first 6 sessions are baseline measures of reflexes. The remaining sessions will engage participants in learning how to decrease their reflex activity in their calf muscle on the more-affected leg. Each intervention visit will involve 20 trials in which participants do not get visual feedback about their performance, then 225 trials with visual feedback.
41000536|NCT02578927|DIETARY_SUPPLEMENT|Green Tea|In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
41000537|NCT03941535|DRUG|Vitamin K|Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
41312611|NCT04103398|COMBINATION_PRODUCT|TACE+sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
41312612|NCT04103398|PROCEDURE|TACE|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
41312613|NCT00103467|BIOLOGICAL|rPA102 Vaccine|
41312614|NCT01487096|DRUG|Teriflunomide|"film-coated tablet~oral administration"
41471056|NCT04285827|BIOLOGICAL|CSL889|Administered as an IV infusion
41312615|NCT01487096|DRUG|Placebo (placebo for teriflunomide)|"film-coated tablet~oral administration"
41312616|NCT02382341|DEVICE|BIOSURE™ HEALICOIL™ PK Interference Screw|Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
41312617|NCT02941913|DRUG|palonosetron|receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
41312618|NCT00504335|DRUG|BIO 300 Capsules|
41312619|NCT03635398|DEVICE|Sipnose device|SipNose's intranasal drug delivery platform uses an innovative mechanism that is suposed to improves efficacy, patient compliance and safety
41471057|NCT06307041|DEVICE|Dental floss+Gengigel|0.2% Hyaluronic Acid Gel-Impregnated Dental Flosses
40795768|NCT00873275|DRUG|fluorouracil|400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment
40795769|NCT00873275|DRUG|leucovorin calcium|400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
40795770|NCT00873275|DRUG|oxaliplatin|85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
40795771|NCT00873275|DRUG|ursodiol|Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.
40795772|NCT00873275|GENETIC|RNA analysis|Analysis on discard tissues
40795773|NCT00873275|GENETIC|gene expression analysis|Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial
40795774|NCT00873275|GENETIC|polymerase chain reaction|Analysis on discard tissues
40795775|NCT00873275|GENETIC|western blotting|Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
40795776|NCT00873275|OTHER|immunohistochemistry staining method|Performed on tumor blocks from the primary and the metastases from the patients on study
40795777|NCT00873275|OTHER|laboratory biomarker analysis|Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
40795778|NCT00873275|OTHER|pharmacological study|Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.
40795779|NCT00873275|PROCEDURE|positron emission tomography (PET)|Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.
40795780|NCT04779307|DRUG|Vedolizumab|Vedolizumab IV infusion.
40795781|NCT02220803|DRUG|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
40795782|NCT02220803|DEVICE|nasal Continuous Positive Airway Pressure (nCPAP)|
41000538|NCT00000540|DEVICE|defibrillators, implantable|
41000539|NCT02485028|DRUG|Dapoxetine 30mg tablet|
41000540|NCT02485028|DRUG|Mirodenafil 50mg tablet|
41000541|NCT02693574|DRUG|Clarithromycin|
41000542|NCT02693574|DRUG|Levofloxacin|
41000543|NCT04988256|DRUG|Cyclosporine|"Patients randomized to cyclosporine will be treated as mentioned under Arm/Group Description"
41000544|NCT04988256|DRUG|Methylprednisolone and Prednisone|All patients randomized to steroids will initially be treated with IV methylprednisolone and eventually started on an oral prednisone taper.
41000545|NCT00062465|DRUG|TwHF|
41000546|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus|SARS-CoV-2, intranasally, (1x10\^1 TCID50, 1x10\^2 TCID50 and 1x10\^3 TCID50 or higher, as necessary)
41312620|NCT03635398|DEVICE|MAD (Mucosal Atomization Device)|MAD (Mucosal Atomization Device)
41000547|NCT04865237|DRUG|Remdesivir|VEKLURY™
41000548|NCT05629013|BEHAVIORAL|After-Action Review|After-action reviews, or debriefs, are a relatively simple, inexpensive, and quick, tool to improve learning, performance, and the effectiveness of teams and individuals. After-action reviews are active self-learning processes wherein participants reflect on specific performance episode to actively engage in self-discovery and improve learning in a non-punitive/non-judgmental manner to result in enhanced performance. This proposal aims to apply the team effectiveness intervention of the after-action review (AAR) to the services intervention of the Child and Family Team (CFT) meetings currently used in the CWS.
41000549|NCT03821012|OTHER|in-hospital process optimization|
41000550|NCT03821012|OTHER|PPCI hospital-based regional STEMI transfer network construction|
41000551|NCT03821012|OTHER|the whole-city STEMI care network construction|
41312621|NCT03635398|DRUG|midazolam|oral administration of midazolam
41312622|NCT03201952|DRUG|Ursodeoxycholic Acid|Ileostomy administration of 300mg UDCA once
41471058|NCT06307041|DEVICE|Dental Floss|Dental Flosses
40795783|NCT00778167|BIOLOGICAL|cixutumumab|Given IV
40795784|NCT00778167|DRUG|erlotinib hydrochloride|Given PO
40795785|NCT00778167|OTHER|laboratory biomarker analysis|Correlative studies
40795786|NCT03228784|PROCEDURE|LASIK|
40795787|NCT05989438|OTHER|Orientations for families|"Guidance for parents will follow the guide/manual prepared by the researchers, in addition to verbal and video guidance. Once a week a reminder will be sent, and once a month researchers will contact you by phone for guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
41000552|NCT00021268|DRUG|tocladesine|
41000553|NCT02146638|DRUG|Morphine|
41000554|NCT02146638|DRUG|Fentanyl|
41000555|NCT04644614|DEVICE|Magnetic Stimulation - Armchair type|MS and Sham MS will be applied two days a week, 20 minutes a day, for 8 weeks, a total of 16 sessions.
41000556|NCT03507556|PROCEDURE|Triple paste and induced bleeding|
41000557|NCT03507556|DRUG|Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol|triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
41000558|NCT04817228|DRUG|EscharEx (EX-02 formulation)|EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.
41312623|NCT03201952|DRUG|Placebos|Ileostomy administration of 5cc saline placebo once
41471059|NCT03039036|PROCEDURE|Amniotomy|Artificially rupturing membranes
41000559|NCT00613509|BIOLOGICAL|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
41000560|NCT00613509|BIOLOGICAL|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
41000561|NCT05583396|DIAGNOSTIC_TEST|Acute exercise|The measurement will be repeated within one to seven days.
41000562|NCT04703452|OTHER|Indicators of central sensitisation|Indicators of central sensitisation, assessed by the Central Sensitization Inventory
41000563|NCT05217550|BEHAVIORAL|Veggie Brek|Offering vegetables to children at breakfast alongside their main breakfast food for three consecutive weeks (five days a week) between baseline and follow-up weeks where vegetables are also offered to children at breakfast alongside their main breakfast food for five days a week.
41000564|NCT01068938|DEVICE|three different perimeters: HFA, Octopus, MATRIX|visual fields
41000565|NCT02582099|DRUG|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
41000566|NCT02582099|DRUG|Normal saline nasal irrigation|Nasal wash with normal saline solution
41000567|NCT02439112|OTHER|Exercise|"8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly \>65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.~Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)"
41000568|NCT01221961|DEVICE|Masimo Radical-7|The Masimo device will be placed on one finger of the patient. To see whether or not the hemoglobin values recorded at the same time matches between the standard clinical practice (CSMC Lab and outside Lab) and the Masimo device
41000569|NCT03156010|DEVICE|Neuro Kinetics IPAS|Testing with PAS device
41000570|NCT03156010|DEVICE|Oculogica EyeBox|Testing with Oculogica EyeBox device
41312624|NCT06373042|DRUG|Intraarterial and intravenous tirofiban|Intraarterial and intravenous tirofiban after endovascular thrombectomy
41000571|NCT03156010|DEVICE|SyncThink EyeSync Device|Testing with SyncThink EyeSync device
41000572|NCT02626143|OTHER|Investigational nutrient-rich whey protein formula|
41000573|NCT02626143|OTHER|Cow's milk based formula|
41000574|NCT00394212|DEVICE|Transoral Suturing|suturing of anastomosis
41000575|NCT00394212|OTHER|Sham Endoscopy|suturing not performed
41000576|NCT05882227|BEHAVIORAL|video|The patients will receive the discharge information through the visualization of a video with discharge information extracted from the optimized hip prosthesis recovery program document; information for patients, relatives or caregivers. The video will consist of two parts: a first part where it will be explained what will happen in the next hours in the unit, the documentation that will be delivered at discharge and the pharmacological treatment. The second part will consist of a video explaining wound care at discharge, discharge recommendations, symptoms that may appear after surgery and alarm symptoms.
41000577|NCT05882227|BEHAVIORAL|Traditional information|"Patients will receive the information at discharge by means of the document entitled Optimized Hip Replacement Recovery Program; information for patients, relatives or caregivers, which will act as a control group."
41000578|NCT03041012|DRUG|Romidepsin|5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
41000579|NCT03041012|DRUG|3BNC117|30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
41000580|NCT03041012|DRUG|Antiretrovirals|Combination antiretroviral therapy
41000581|NCT00058825|BIOLOGICAL|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
41000582|NCT00058825|DRUG|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
41000583|NCT00058825|PROCEDURE|Stem Cell Transplant|Day 0: Donor stem cells infused.
41000584|NCT00058825|RADIATION|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
41000585|NCT00058825|DRUG|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
41000586|NCT00615056|DRUG|Bevacizumab (avastin)|Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
41000587|NCT00615056|DRUG|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
41000588|NCT00615056|DRUG|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
41000589|NCT00615056|DRUG|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
41000590|NCT00615056|DRUG|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
41000591|NCT00615056|DRUG|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
41000592|NCT00615056|DRUG|Bevacizumab (avastin)|Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
41000593|NCT00615056|DRUG|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
41312625|NCT06373042|DRUG|Intraarterial and intravenous placebo|Intraarterial and intravenous placebo after endovascular thrombectomy
40795788|NCT05989438|OTHER|Professional stimulation more orientations for families.|"Each session will last approximately 50 minutes, where the stimuli will be performed in: supine position; Ventral Decubitus; Seated; Four supports, kneeling/semi-kneeling and standing.~If the child no longer uses the posture or it is not an acquisition for the age group in which the baby is, the time will be distributed in order to contemplate the expected acquisitions for the age group in which the baby is. The stimuli will be performed based on the neuropsychomotor development, in order of progression and according to the corrected age of the baby.~The frequency of consultations may vary due to the different degrees of prematurity, and the stipulated initial frequency will vary between 1-8 times a month.~The orientations will also be provided to family members during consultations, and families will also perform stimuli at home according to written, verbal and video guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
40795789|NCT02366676|DRUG|hyaluronic acid and chondroitin sulphate|IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd\~5th month:once a month)
40795790|NCT04917367|PROCEDURE|exploratory surgery|"For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies."
40795791|NCT04751227|DRUG|Modafinil|100-200 mg oral daily for for Wakefulness in the Critical Care Units
40795792|NCT00265837|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
41000594|NCT02101502|OTHER|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
40795793|NCT00265837|PROCEDURE|allogeneic bone marrow transplantation|
40795794|NCT00265837|PROCEDURE|in vitro-treated bone marrow transplantation|
40795795|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids Supplementation|
40795796|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
40795797|NCT05623748|PROCEDURE|CTCs isolation/purification and cell number expansion|In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
40795798|NCT01224327|BIOLOGICAL|umbilical cord Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
40795799|NCT01224327|DRUG|Conserved therapy|Oral or intravenous administration
40795800|NCT03018535|DRUG|Rituximab|Rituximab,1 g IV, day 1 and day 15
41000595|NCT00445510|DRUG|GSK256066|
41000596|NCT01971658|DRUG|Thalidomide®|
40795801|NCT03018535|DRUG|Methylprednisolone|Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
40795802|NCT03018535|DRUG|Cyclophosphamide|Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
40795803|NCT03570242|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
40795804|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
40795805|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
40795806|NCT01009970|DRUG|Rituximab|375 mg/m2 day 1
40795807|NCT01009970|DRUG|Cyclophosphamide|750 mg/m2 day 2
40795808|NCT01009970|DRUG|Vincristine|1,4 mg/m2 (max 2 mg) day 2
40795809|NCT01009970|DRUG|Prednisone|40 mg/m2 day 2-6
40795810|NCT01009970|DRUG|Doxorubicin|50 mg/m2 day 2
40795811|NCT06027619|DRUG|Topical aminolevulinate (10% ALA gel)|10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
40795812|NCT06027619|DEVICE|Red light illumination|Illumination of red light of narrow spectrum of 635 nm with a light dose of approximately 37 J/cm2
40795813|NCT02078024|DRUG|IVM plus ALB|
40795814|NCT02078024|DRUG|IVM|
41000597|NCT01971658|DRUG|Cyclophosphamide|
41000598|NCT01971658|DRUG|Velcade®|
41000599|NCT01971658|DRUG|Dexaméthasone|
41000600|NCT01649258|DRUG|granisetron transdermal system|Given granisetron transdermal system patch
41000601|NCT01649258|DRUG|fosaprepitant dimeglumine|Given IV
41000602|NCT01649258|OTHER|laboratory biomarker analysis|Correlative studies
41000603|NCT00423969|DRUG|Galantamine|
41000604|NCT00423969|DRUG|Escitalopram|
41000605|NCT00003681|BIOLOGICAL|epoetin alfa|
41000606|NCT00003681|DRUG|amifostine trihydrate|
41000607|NCT02155738|DRUG|IV Acetaminophen|
41000608|NCT02155738|DRUG|IV normal saline|IV normal saline
41000609|NCT01664013|DRUG|Nuronox|Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
41000610|NCT02417051|BEHAVIORAL|Disaster Worker Resiliency Training|The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
40795815|NCT00008411|DRUG|Docetaxel|Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
40795816|NCT00008411|DRUG|Docetaxel|35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
40795817|NCT05651763|OTHER|Stimulation and exercise group|Exercise protocol + application of active direct current stimulation for 30 minutes.
40795818|NCT05651763|OTHER|Exercise and sham stimulation group|Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
40795819|NCT01766037|DEVICE|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
40795820|NCT01766037|BEHAVIORAL|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
40795821|NCT02001324|OTHER|Web-based data collection|
40795822|NCT02001324|OTHER|Paper-based data collection|
40795823|NCT02465476|PROCEDURE|telemedicine|treatment pathway organized by telemedicine
40795824|NCT06184685|DRUG|Sahasthara Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
40795825|NCT06184685|DRUG|Diclofenac Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
41000611|NCT05861791|DRUG|Fentanyl|opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug
41000612|NCT05861791|DRUG|ketorolac tromethamine with nefopam hydrochloride|non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug
41000613|NCT01090726|DEVICE|Storz videolaryngoscope|Storz videolaryngoscope being used for the actual intubation
41000614|NCT01090726|DEVICE|Airtraq|Airtraq being used for the actual intubation
41000615|NCT03852797|DRUG|Oxytocin|Oxytocin solution, 20nM concentration
41000616|NCT03852797|DRUG|Ketamine|Ketamine in solution, 10-4M to 10-7M
41000617|NCT03852797|DRUG|Propofol|Propofol in solution, 10-4M to 10-7M
40795826|NCT02208375|DRUG|Capivasertib|Given PO
40795827|NCT02208375|OTHER|Laboratory Biomarker Analysis|Correlative studies
41000618|NCT03852797|DRUG|Etomidate|Etomidate in solution, 10-4M to 10-7M
41000619|NCT02386696|OTHER|Ultrasound|Lung ultrasound examination on healthy volunteers
41000620|NCT00573027|PROCEDURE|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
41000621|NCT03149237|BEHAVIORAL|Couples-based services|Couples-based services, including treatment, counseling and peer mentoring in the community.
41000622|NCT03160833|DRUG|HMPL-453|oral administrative
41000623|NCT04517916|DEVICE|Zephyr Valve|Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.
40795828|NCT02208375|DRUG|Olaparib|Given PO
40795829|NCT02208375|OTHER|Pharmacological Study|Correlative studies
40795830|NCT02208375|DRUG|Vistusertib|Given PO
40795831|NCT01575808|DEVICE|GP1101|Endovascular stent graft implantation
40795832|NCT06554600|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
40795833|NCT06554600|DRUG|Polatuzumab Vedotin|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin on Day 2 of each cycle.
40795834|NCT06554600|DRUG|Bendamustine|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 70 mg/m2 Bendamustine on Days 2 and 3 of each cycle.
41000624|NCT02121587|BEHAVIORAL|Pain self-management course|This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
41000625|NCT03935633|DRUG|CN128 Tablets|Iron chelator， oral tablets
41000626|NCT02438748|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
40795835|NCT06554600|DRUG|Rituximab|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab on Day 1 of each cycle.
40795836|NCT00953953|DEVICE|Phillips ultrasound system|The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
40795837|NCT00755963|DRUG|estradiol valerate|Progynova® 21; 2mg/d
40795838|NCT00755963|DRUG|micronized progesterone|Utrogestan®; 200mg/d
40795839|NCT00755963|DRUG|placebo|maltodextrin
40795840|NCT06526312|BEHAVIORAL|SMS/Text (CAMPI)|Configurable Assessment Messaging Platform for Interventions (CAMPI) is a SMS text messaging platform to promote motivation and home practice.
40795841|NCT06526312|BEHAVIORAL|Fidelity Monitoring System (Lyssn)|Lyssn's HIPAA-compliant, cloud-based platform uses embedded speech-to-text transcription from audio recorded sessions for rapid assessment and easy session review for supervisors and interventionists,
40795842|NCT06526312|BEHAVIORAL|Family Check-Up 4 Health (FCU4Health)|An evidence-based, data-driven, individually tailored parenting intervention with evidence of effectiveness on child and family health behaviors and psychosocial well-being. The program includes three components: 1) a comprehensive family assessment, 2) feedback and motivation session, and 3) individually tailored follow-up support (including parent training modules from the Everyday Parenting curriculum and connection with community resources). Dosage and content of these follow-up sessions are driven by the results of the assessment and family interest. The assessment, feedback and motivation session, and follow-up support are repeated annually.
40795843|NCT02873455|OTHER|Short video clip including the circumstance of operation theater, and surgeon's interview|
40795844|NCT04326010|DEVICE|Surgery|THA surgery
40795845|NCT02843438|OTHER|Fluorescein angiography|
40795846|NCT02843438|OTHER|Dilated fundus examination|
40795847|NCT02843438|BIOLOGICAL|Toxoplasmosis serology|
40795848|NCT02843438|DRUG|Anti-toxoplasmosis treatment|
40795849|NCT02843438|DRUG|Anti-inflammatory treatments|
40795850|NCT02843438|OTHER|Puncture in anterior chamber|
40795851|NCT03067402|OTHER|Observation|Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
40795852|NCT03067402|DIAGNOSTIC_TEST|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
40795853|NCT05689489|OTHER|Puzzle Method|While preparing the puzzle to be used in the study, the puzzle preparation program will be used (Crossword Puzzle Maker). Students in the initiative group will be asked to solve a total of 6 puzzles, one puzzle each week. The answers to the prepared puzzles will cover the theoretical course topics of psychiatric nursing. In the puzzles, students will be expected to place their answers in the specified rows and columns. Students will be asked to solve puzzles individually. In addition, the answer to each puzzle will be found on the reverse on the back page. Students will be reminded that there is no time limit for solving the puzzles. Researchers will guide students while students solve puzzles.
40795854|NCT05689489|OTHER|Ongoing Education|Students in the control group will only take the theoretical course of psychiatric nursing.
40795855|NCT02655952|DRUG|Foxy-5|
40795856|NCT04907253|DRUG|Quercetin|500 mg twice daily
40795857|NCT04907253|DRUG|Placebo|twice daily
41000627|NCT00499135|OTHER|Computed Tomography|Correlative studies
40795858|NCT05340478|BEHAVIORAL|Intensive Transdiagnostic Cognitive Behavioral Therapy|cognitive behavioral treatment that addresses multiple anxiety problems simultaneously and delivered in a massed format over one weekend
40795859|NCT05985525|DEVICE|Skeletal muscle and cerebral NIRS (research device)|NIRS applied on skeletal muscle and brain on days 1, 3, and 8 of ICU admission. Monitoring applied for up to 24hrs on each day.
40795860|NCT02440139|DEVICE|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
41000628|NCT00499135|OTHER|Fluorothymidine F-18|Correlative studies
41000629|NCT00499135|OTHER|Laboratory Biomarker Analysis|Correlative studies
40795861|NCT01125410|DRUG|Dequalinium chloride|Vaginal tablet, 10mg, 1 tablet daily for 6 days
40795862|NCT01125410|DRUG|Clindamycin|vaginal cream, 2%, once daily for 7 days
40795863|NCT05712577|OTHER|Questionnaire|Rosenberg Self- Esteem scale
40795864|NCT05712577|OTHER|Questionnaire|Short Form 36 scale
40795865|NCT05712577|OTHER|Questionnaire|Coping orientation to the problems experienced - New Version in Italian
40795866|NCT05712577|OTHER|Questionnaire|Outcome Questionnaire - version 42.5
40795867|NCT04645992|DEVICE|active TENS|study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
40795868|NCT04645992|DEVICE|sham TENS|control group will be treated with the same protocol as the study group but with the TENS unit is off .
40795869|NCT04032886|OTHER|kinesio tape|This is a taping method used for correction of rounded shoulders.
41000630|NCT00499135|OTHER|Pharmacological Study|Correlative studies
41000631|NCT00499135|OTHER|Positron Emission Tomography|Correlative studies
41000632|NCT00499135|DRUG|Sunitinib Malate|Given PO
41000633|NCT04332289|OTHER|Heavy water experiment|3 times daily heavy water (deuterated-water) and mixed meal administration for one week
41000634|NCT00911261|DRUG|Oxymorphone Extended Release|"* Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~* Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~* Treatment will consist of up to 12 months of dosing with Oxymorphone ER."
40795870|NCT04032886|OTHER|exercise|Exercises include basic postural exercises.
40795871|NCT02942888|DIETARY_SUPPLEMENT|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
41000635|NCT01492452|OTHER|standardized guidelines for nursing|Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
41000636|NCT00831532|DRUG|Dimebon|Dimebon 5mg in healthy controls
41000637|NCT00831532|DRUG|Dimebon|Dimebon 5mg in mild hepatic impairment patients
41000638|NCT00831532|DRUG|Dimebon|Dimebon 5mg in moderate hepatic impairment patients
41000639|NCT00831532|DRUG|Dimebon|Dimebon 5mg in Severe Hepatic Impairment
41000640|NCT02114879|BEHAVIORAL|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
41000641|NCT02114879|BEHAVIORAL|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
41000642|NCT06298175|BEHAVIORAL|Self management training|The self-management training programme for the study group consisted of eight sessions. Each session lasted between 40 and 50 minutes and followed a structured format: a 5-minute introduction, a 5-minute summary of the previous session, and a 30-40 minute presentation on the session's topic. Training plan on cognition, emotion regulation and self-management was implemented
41000643|NCT06255652|DRUG|Cephradin|Velosef
41000644|NCT03357926|DIAGNOSTIC_TEST|24 hour Holter ECG Monitoring|24 hour Holter ECG Monitoring
41000645|NCT02376192|DEVICE|Initial MicroScan® (Microvision Medical) SDF Measurement|Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
41000646|NCT02376192|DRUG|Spinal Anesthesia- Bupivacaine|The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
41000647|NCT02376192|DEVICE|Comparative MicroScan® (Microvision Medical) SDF Measurement|A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
40795872|NCT02942888|DIETARY_SUPPLEMENT|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
41000648|NCT02376192|DRUG|Bolus Phenylephrine/Ephedrine Treatment|Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
41000649|NCT02376192|DRUG|Phenylephrine Infusion|Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
41000650|NCT01811095|OTHER|Training|"Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a completed score) on two non-consecutive attempts. For the Suturing skills (SymbionixTM): Horizontal suturing defect task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score."
40795873|NCT05750108|DEVICE|Parasym device (active, current (mA) < discomfort threshold)|Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
41000651|NCT05414643|OTHER|Standard care|No interventions were used, as this is an observational study.
41000652|NCT00571506|DRUG|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
41150734|NCT03278808|DRUG|atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
41312626|NCT06358937|DEVICE|Laser Assisted New Attachment Procedure using ND:YAG laser|A free running, pulsed, 1064 nm wavelength-specific ND:YAG laser will be used. A thin 300 μm laser fiber optic will be placed parallel to the root surface, allows easy access into deep periodontal pockets. The initial pass with the laser is known as Laser Troughing, and it is done with a micro-short duration pulse, with a 4.0 watt power, 150 μs duration in pulsed mode and 20Hz frequency. Ultrasonic scaler will be then used to remove calculus. The second pass is carried out with 650 μs pulse duration, 10-30 seconds for each tooth, 4.0 watt power and 20HZ frequency, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed. Relieving the occlusion is the last step of the LANAP protocol.
41312627|NCT06358937|DEVICE|Laser Assisted New Attachment Procedure using diode laser|"Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm attached with a power average set at 0.5-1.5 watt will be used.~The first pass laser troughing is done using a thin flexible fiber-optic cable 300 μm placed parallel to the root surface, attached with a power average set at 0.5-1 watt, in continuous mode. Ultrasonic scaler will be then used to remove calculus which present on the root surface. The second pass is carried out with 1-1.5 watt power in continuous mode, 10-30 seconds for each tooth, and, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed in order to enhance the healing"
41312628|NCT06358937|PROCEDURE|Scaling and Root Planing using ultrasonic and curettes|Scaling and root planing (SRP) using ultrasonic device at a moderate setting and with the appropriate tips and curettes will be also used where indicated and time spent in SRP on each tooth will not be restricted.
40795874|NCT05750108|DEVICE|Parasym device (sham, current (mA) = 0)|Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
40795875|NCT01704508|DRUG|Artemether-lumefantrine|
41000653|NCT00571506|DRUG|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
41000654|NCT03898349|OTHER|Annie text messaging system|Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
41000655|NCT03898349|OTHER|Annie text messaging system with Usual implementation|"Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls"
41000656|NCT03898349|OTHER|Annie text messaging system with Augmented implementation|"Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance"
41150735|NCT05283642|DIETARY_SUPPLEMENT|DCI|Oral supplementation with D-chiro-inositol once daily
41312629|NCT02128282|DRUG|CX-4945|API powder-in-capsule in 200 mg strength.
41312630|NCT02128282|DRUG|Cisplatin|25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
41471060|NCT03039036|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.
41471061|NCT03039036|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
41471062|NCT02808819|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
41471063|NCT02808819|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 8 weeks
41471064|NCT01915342|DEVICE|Focal muscular vibration|
41471065|NCT05828095|BIOLOGICAL|INO-6160, 2 mg|ID EP at month 0,1,3 and 6
41471066|NCT05828095|BIOLOGICAL|Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)|IM at month 3 and 6
41471067|NCT05388812|OTHER|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
41471068|NCT05388812|OTHER|Individual Placement and Support (IPS)|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
40795876|NCT01704508|DRUG|Dihydroartemisinin-piperaquine|
40795877|NCT06118424|BEHAVIORAL|deepfake video|The combination of the words deep and fake is called deepfake in the literature as deep learning. Deepfakes, which have recently become more widely known as a result of the shocking images and sound recordings of many people, from politicians to famous movie stars, are generally hyperrealistic videos in which people's faces and voices are used by other faces and voices without permission and manipulated digitally. Deepfakes rely on neural networks that analyze large data samples to learn to mimic a person's facial expressions, mannerisms, voice and tone. The process involves feeding a deep learning algorithm to exchange images of two people or faces.
41000657|NCT01982253|DRUG|Fasiglifam|Fasiglifam tablets
41000658|NCT01982253|DRUG|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
41000659|NCT04884711|OTHER|No Interventions. Participants will be using their everyday digital health technologies.|The investigators will be involving older people to understand the barriers \& facilitators of digital health technology adoption for homebound older people. In this process no interventions will be given by us.
41150736|NCT00578929|DRUG|Olopatadine Hydrochloride Nasal Spray 0.6%|Olopatadine HCl 1 or 2 sprays per nostril twice daily
41312631|NCT02128282|DRUG|Gemcitabine|1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
41312632|NCT01013896|BEHAVIORAL|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
41312633|NCT01013896|OTHER|Cystic Fibrosis Education|"Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group."
41471069|NCT04159181|OTHER|Lactulose|Oral solution lactulose (20g lactulose/200mL water).
41471070|NCT04159181|OTHER|Picoprep|Cathartic to accomplish an evacuation of the colonic content.
41471071|NCT04159181|OTHER|Placebo (water)|oral administration of Water (200mL).
41471072|NCT01856439|DRUG|ProSavin|Long term follow up of patients who received ProSavin in a previous study
41471073|NCT00115934|PROCEDURE|Blalock-Taussig pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
41471074|NCT00115934|PROCEDURE|Right ventricular to pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
41471075|NCT05276505|OTHER|Lavender Aromatherapy Tablet|Before the breast biopsy, aromatherapy tablets was adhered to the patient's shoulder in the waiting room and were asked to sniff
41471076|NCT06153355|DRUG|LY3839840|Administered orally.
41471077|NCT06153355|DRUG|Placebo|Administered orally.
41471078|NCT05004064|DRUG|Acalabrutinib|Patients will receive acalabrutinib 100mg twice daily for up to six 28 day cycles. Patients can receive 100mg once daily for cycle 1, day 1 to day 7, according to the investigator's discretion.
41312634|NCT02240537|DRUG|Sargramostim|Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
41471079|NCT05004064|DRUG|Rituximab|Patient will receive rituximab 375 mg/m2 IV on day 1 (+/- 3 days) of each cycle, for a maximum of 6 cycles
41471080|NCT04845620|DRUG|ARQ-151 Active|ARQ-151 Cream 0.05% - Active
41471081|NCT04845620|DRUG|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
41471082|NCT04670406|BEHAVIORAL|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
41471083|NCT06052787|DRUG|Cerebrolysin|Cerebrolysin, a mixture of free amino acids and low molecular weight peptides, has a neurotrophic factor-like activity with immediate pleiotropic neuroprotective activity and long-term multimodal effects on endogenous post-lesional regulation. Cerebrolysin has been suggested to exert beneficial effects on neurobehavioural functions, cognitive performance , and neuro-motor recovery , as part of initial therapy in severe and moderate acute TBI.
41471084|NCT06052787|DRUG|amantadine sulfate|The dopaminergic agonist amantadine enhances presynaptic dopamine release and inhibits dopamine reuptake, resulting in an increased amount of dopamine in the synaptic cleft. Amantadine may also increase the density of postsynaptic dopamine receptors and alter the conformation of these receptors. Amantadine acts as an NMDA receptor antagonist, blocking glutamate, an NMDA channel activator. This effect may be responsible for amantadine's possible beneficial effect soon after TBI
41471085|NCT02994394|DRUG|OPC-41061|
41471086|NCT02619682|DRUG|Ixazomib Citrate|Given PO
41471087|NCT02619682|OTHER|Laboratory Biomarker Analysis|Correlative studies
40795878|NCT01218217|DRUG|SQ109|SQ109 150 mg tablet
41312635|NCT02240537|DRUG|BB-MPI-03|Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
41312636|NCT02240537|DRUG|Montanide|"Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.~Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration."
41312637|NCT02467647|DRUG|Thalidomide|
41471088|NCT02619682|DRUG|Lenalidomide|Given PO
41471089|NCT02591563|OTHER|procedures|Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
41471090|NCT01761669|DRUG|Vitamin D|
41471091|NCT03416556|PROCEDURE|Mobilization to the glenohumeral joint|The treatment condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder. In particular, a Grade III AP glide to the humeral head with the arm positioned in 90º of glenohumeral abduction and full internal rotation was used. The posterior gliding force to the humeral head was applied maintaining the glide at right angles to the plane of movement and at a frequency of 2 Hz which was controlled by means of a metronome. The arm was returned to its original position between each set.
41471092|NCT03416556|PROCEDURE|The manual contact condition|During the manual contact condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition. However, a simulated posterior glide was performed but with minimal pressure actually applied. The number of repetitions and sets were as per the treatment condition.
41471093|NCT03416556|OTHER|No-contact condition|During the no-contact condition, the subject remained in the initial starting position thorough the entire session but there was no manual contact between the therapist and the participant. The total treatment time was the same as per the other conditions.
41471094|NCT00805402|OTHER|flow cytometry|flow cytometry
41471095|NCT03201978|DRUG|GSK2894512 1% CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
41471096|NCT03201978|DRUG|GSK2894512 MATCHING VEHICLE CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
41471097|NCT02062801|DRUG|Ephedrine|Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (\<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea
41471098|NCT02062801|DRUG|Placebo|Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
40795879|NCT01218217|DRUG|Rifampicin|Rifampicin 150 mg capsules
40795880|NCT01290042|DRUG|AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
40795881|NCT01290042|OTHER|Placebo for AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
40795882|NCT00004744|DRUG|immune globulin|
40795883|NCT05243979|RADIATION|DEXA scan|bone study
41312638|NCT02467647|DRUG|HLJDT|
41471099|NCT03576287|DRUG|Apremilast Oral Product|Apremilast
41312639|NCT04147832|OTHER|Alert to provider|Provider will receive an alert of sub-optimal patient attendance using 4 rules.
41312640|NCT03819764|BEHAVIORAL|Aerobic Exercise|Cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
41471100|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 1 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 60 mCi (2.22 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
41471101|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 2 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.33 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
41471102|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 3 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 135 mCi (4.99 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
41471103|NCT03018093|BIOLOGICAL|C-CAR-011|CD19-targeted chimeric antigen receptor T cells
41471104|NCT04226131|OTHER|Blood Draw|A study nurse will draw up to 150 mL of blood to measure erythrocyte sedimentation rate (ESR) and measures of immune cell function. ESR is a common hematology test that is a measure of inflammation.
41471105|NCT04226131|OTHER|Disease Activity (DAS-28) Assessment|Participants in the RA cohort will receive a 28-joint examination by the study physician to assess RA disease activity and report their overall health assessment.
41471106|NCT04226131|OTHER|Skeletal Muscle Mitochondrial Respiratory Capacity|Near-Infrared Spectroscopy (NIRS) will be used to measure oxidative capacity of forearm flexor digitorum profundus and medial gastrocnemius muscles using the PortaMon device (Artinis Medical Systems, The Netherlands). NIRS is a low-cost, non-invasive method that estimates muscle oxidative capacity by measuring oxygen consumption (mVO2) recovery kinetics via assessment of intramuscular oxy- and deoxy-hemoglobin concentration following a sequence of brief, rapid arterial cuff occlusions. NIRS measures mitochondrial oxidative function as the mVO2 recovery rate constant k. In the absence of blood flow, changes in muscle oxygenation occur via oxygen consumption alone. In persons without RA, this non-invasive approach is highly correlated with muscle respiratory capacity assessed via muscle biopsies using in situ permiabilized fiber bundles and the Oroboros O2k system.
41471107|NCT04226131|OTHER|Muscle Biopsy|After local anesthesia (xylocaine, 2%) is injected, a small incision will be made in the thigh. Four to six small pieces of muscle about the size of a pea will be surgically removed. The incision site will be closed using steri-strips and/or derma-bond, and a light dressing applied.
41471108|NCT04226131|OTHER|Body Composition|Body composition assessments include circumference measurements and the BOD POD®. Minimal waist circumference measurements will be taken using a tape measure.
41471109|NCT04226131|OTHER|Cardiopulmonary Exercise Test (CPET)|Cardiorespiratory aerobic capacity (VO2 peak), will be assessed using a maximal treadmill test protocol with cardiopulmonary gas exchange. Subjects will be asked to exercise on a treadmill to their perceived maximum ability and effort during which time they will have a mouthpiece in their mouth to determine maximal oxygen use/consumption through breathing. For safety purposes the subject will be monitored by electrocardiogram (ECG) and their blood pressure will be measured at rest and throughout the exercise phase of this test.
41471110|NCT04226131|OTHER|Strength Testing|Strength assessments will include dynamometry-assessed grip and quadriceps strength (Cybex HUMAC NORM, Comp Sports Med, Inc., Stoughton, MA) tests
41471111|NCT04226131|OTHER|Questionnaires|Measures include global health, pain, fatigue, physical function, self-efficacy for disease management and sleep.
40795884|NCT03329625|BEHAVIORAL|Pathways Triple P|Pathways Triple was developed by Matt Sanders and is a behavioral parent training intervention designed to treat child behavior problems and prevent child maltreatment.
41471112|NCT04226131|OTHER|Skeletal Muscle Biomechanical Property Assessment|Passive skeletal muscle stiffness and elasticity measurements of bilateral biceps brachii, flexor carpi radialis, vastus lateralis, and tibialis anterior using mechanical deformation with myotonometry using the MyotonPro device.
41471113|NCT03085225|DRUG|Combination of trabectedin with durvalumab|"Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).~Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial."
41000660|NCT04884711|OTHER|In depth Interviews|In-depth interviews will be conducted to gather lived experiences of homebound older people.
41150737|NCT00578929|DRUG|Vehicle|Vehicle 1 or 2 sprays per nostril twice daily
41312641|NCT03819764|BEHAVIORAL|Upper Extremity Repetitive Task Practice|Repetitive arm exercises
41312642|NCT06553430|BEHAVIORAL|aerobics exercises|Moderate-intensity aerobic exercise for 30-60 min 3 times per week for 12 weeks
41312643|NCT06127706|DEVICE|twin vaginal delivery simulation|skill test after formal lecture and simulation in group 1 and after digital learning only
41312644|NCT01057069|DRUG|Carboplatin and Paclitaxel|Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
41312645|NCT01057069|DRUG|Doxorubicin, cyclophosphamide|Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
41471114|NCT06425198|DRUG|BMS-986278|Specified dose on specified days
41000661|NCT04884711|OTHER|Focus Group Discussions|Focus Group Discussions will be used to create avenues to enhance dignity and human perspectives in digital designs for older people.
41312646|NCT01057069|DRUG|Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide|"One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion."
41471115|NCT06616116|DEVICE|Biosignal feedback|"1. Real-time neurofeedback guided mindfulness~   : Unlike standard mindfulness therapies, this intervention integrates real-time monitoring of brainwave activity (EEG). Participants in the experimental group receive immediate auditory feedback during their mindfulness sessions, which helps guide their practice and enhance engagement.~2. Tailored progress report In addition to real-time feedback, participants in the Mindfulness with biosignal feedback group receive detailed reports of their biosignal data (EEG and HRV) before, during, and after each session. These reports allow for deeper self-reflection and personalized adjustments to their mindfulness practice, which is not commonly provided in other mindfulness programs."
41471116|NCT06616116|DEVICE|Sham Comparator|Biosignal Monitoring (EEG and HRV) during Mindfulness without real-time feedback
41471117|NCT00685802|DRUG|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
41471118|NCT00685802|DRUG|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
41471119|NCT05882734|DRUG|M1774|In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
41471120|NCT05882734|DRUG|Cemiplimab|Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
41471121|NCT06470360|OTHER|Surgycal procedure|surgical technique
41471122|NCT00743509|DRUG|Cyclophosphamide and Sirolimus|"The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously"
41471123|NCT04554095|OTHER|Clinical data collection|Respiratory parameters, analytic values, lung ultrasound and echocardiography
41471124|NCT03243929|BEHAVIORAL|Translation of District Sun Safe Policies to Schools|Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.
41471125|NCT03243929|BEHAVIORAL|Attention Control|Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
41471126|NCT04954859|DRUG|Bepirovirsen|No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.
41471127|NCT04954859|DRUG|Placebo|No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.
41150738|NCT03902327|DIETARY_SUPPLEMENT|NAC group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + N - acetylocysteine supplementation (1600 mg /d, 400 mg x 4 times a day)(30 people).
41150739|NCT03902327|DIETARY_SUPPLEMENT|Control group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + placebo (4 times a day) (30 people).
41312647|NCT00374855|DRUG|PPAR alpha|
40795885|NCT03329625|BEHAVIORAL|Services as Usual|Families received family centered services and other parenting interventions as deemed appropriate by the child welfare case manager.
40795886|NCT03368196|DRUG|DS-8201a|An antibody drug conjugate
40795887|NCT05483959|OTHER|BIPAP mode/SIMV PC mode|BIPAP is a mode of ventilation recently used in ARDS
40795888|NCT06073080|OTHER|Protein Nutrition During Recovery|Dietary Protein Nutrition Distribution
41000662|NCT04238728|DEVICE|Silverlon|silver nylon dressing will be applied daily
41000663|NCT05791474|DRUG|ATI-2231|Provided by Aclaris Therapeutics, Inc.
41000664|NCT00344773|DRUG|Gefitinib|250mg tablet oral tablet once daily
41000665|NCT01881659|OTHER|HPV screening|Women who signed informed consent will be screened with HPV testing.
41150740|NCT06387576|BEHAVIORAL|Behaviorally informed pre-discharge iPad video scheduling|The iPad video scheduling process will occur prior to patient discharge from the hospital. This intervention harnesses behavioral principles, such as commitment (patient committing to scheduled appointment), social accountability (patients feeling more accountable after scheduling their appointment via the video visit), and social support (patients feeling more supported after engaging in this conversation with a scheduler via video).
41150741|NCT01753323|DRUG|KAF156|KAF156 was supplied as tablets for oral use.
41312648|NCT00374855|DRUG|Hydrochlorothiazide|
41312649|NCT00374855|DRUG|Placebo|
41312650|NCT00092066|DRUG|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks|
41312651|NCT04629612|PROCEDURE|Regional anesthesia|Regional anesthesia such as paravertebral block, pectoral block, superficial cervical plexus block, etc applies according to institution protocol
40795889|NCT03552107|DRUG|Lorcaserin|Treatment initiation with Lorcaserin
41000666|NCT01389180|BEHAVIORAL|Behavioral Drug and HIV Risk Reduction Counseling|BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
40795890|NCT01183429|DRUG|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. \*High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
40795891|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess myofibrillar protein synthesis rates|Amino acid dose = 0.25g/kg bodyweight
40795892|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance|Amino acid dose = 0.25g/kg bodyweight
41000667|NCT01389180|BEHAVIORAL|Educational Counseling|EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
41000668|NCT01389180|BEHAVIORAL|Treatment as Usual|TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
41000669|NCT00554671|OTHER|Algorithm driven medication titration|Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
41000670|NCT00554671|BEHAVIORAL|Monitoring|Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
41000671|NCT00554671|BEHAVIORAL|Group support|Peer support are provided in the group setting
41000672|NCT00554671|BEHAVIORAL|Self efficacy|Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
41150742|NCT06372756|DIAGNOSTIC_TEST|Deep learning image reconstruction|Deep learning image reconstruction (DLIR) is a newly developed artificial intelligence noise reduction algorithm in recent years. It trains massive high-quality FBP data sets to learn to distinguish noise and signal, so as to selectively reduce noise and reconstruct high-quality images with low-quality image data.
41312652|NCT01760824|DRUG|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
41312653|NCT01760824|DRUG|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
41312654|NCT04389749|DEVICE|CPM|CPM-continuous passive motion device.
41312655|NCT00523406|PROCEDURE|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
41312656|NCT04561245|DRUG|ALT-801|Injected subcutaneously (SC)
40795893|NCT02137447|DEVICE|Negative Pressure treatment|
41150743|NCT04640376|DRUG|Paracetamol Uniflash 125mg|Oromucosal solution 1.25 mL for buccal use
41150744|NCT04640376|DRUG|Panadol 500 MG Oral Tablet X1|Tablet masked in capsule
41150745|NCT04640376|DRUG|Panadol 500 MG Oral Tablet X2|Tablet masked in capsule
41150746|NCT04640376|DRUG|Placebo|Dummy treatment
41150747|NCT04855708|OTHER|Virtual visit|Patients randomized to this group will have a virtual 2-week post-operative visit
40795894|NCT01196897|DEVICE|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
40795895|NCT05721781|BEHAVIORAL|Oral Hygiene instruction|Participants will be instructed on the Modified Bass technique for toothbrushing: brushing with a soft bristled toothbrush held at a 45 degree angle to the gums and brushed in a circular motion. Participants will also be instructed to floss at least once per day using floss or another inter-dental device (e.g., floss pick).
40795896|NCT05721781|PROCEDURE|Dental Cleaning|Participants will receive a dental cleaning according to the current standard of care for routine dental cleanings.
40795897|NCT00845481|DRUG|Daivobet® ointment|Once daily application 6 days a week for 3 weeks
40795898|NCT00845481|DRUG|Betnovat® ointment|Once daily application 6 days a week for 3 weeks
40795899|NCT00845481|DRUG|Diprosalic ointment|Once daily application 6 days a week for 3 weeks
41000673|NCT03827278|DRUG|Voriconazole|"6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months"
41000674|NCT03348696|DRUG|Dexamethasone tapering dose|dexamethasone standard of care pre-medication + dexamethasone tapering dose
41150748|NCT04855708|OTHER|Office visit|Patients randomized to this group will have a in-person 2-week post-operative visit
41150749|NCT03612999|DEVICE|Dexcom continuous glucose monitor|Continuous glucose monitors (CGMs) record subjects glucose levels
41150750|NCT03612999|DEVICE|Fitbit activity tracker|Activity trackers will record subjects' physical activity, heart rate, and sleep.
41312657|NCT04561245|OTHER|Placebo|Injected subcutaneously (SC)
41312658|NCT00398385|DRUG|cisplatin|
41312659|NCT00398385|DRUG|gemcitabine hydrochloride|
41312660|NCT00398385|PROCEDURE|adjuvant therapy|
41312661|NCT00398385|PROCEDURE|conventional surgery|
41312662|NCT00398385|PROCEDURE|neoadjuvant therapy|
40795900|NCT00845481|DRUG|Dermovat ointment|Once daily application 6 days a week for 3 weeks
40795901|NCT00845481|DRUG|Elocon ointment|Once daily application 6 days a week for 3 weeks
40795902|NCT00845481|DRUG|Daivobet® ointment vehicle|Once daily application 6 days a week for 3 weeks
40795903|NCT05447390|DIAGNOSTIC_TEST|Handgrip strength test|The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
40795904|NCT03443856|DRUG|Nivolumab and Ipilimumab|Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
40795905|NCT03443856|OTHER|chemotherapy|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
40795906|NCT02198859|DRUG|Lithium Carbonate|
40795907|NCT05475028|OTHER|RRBS|Reduced Representation Bisulfite Sequencing
40795908|NCT04211285|DIAGNOSTIC_TEST|e-GAB|android application for comprehensive geriatric assessment
40795909|NCT04211285|DIAGNOSTIC_TEST|standard physician performed CGA|CGA by an experienced geriatrician blinded to the result of e-GAB
40795910|NCT01274598|BIOLOGICAL|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10\^10 CFU by mouth twice daily for 28 days
40795911|NCT04047615|OTHER|Exercise|An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
40795912|NCT05052463|OTHER|electrolyte imbalance analysis|ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
40795913|NCT01457404|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
40795914|NCT01457404|BEHAVIORAL|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
40795915|NCT01279811|OTHER|Crossover of vasopressors|"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."
40795916|NCT00348478|BEHAVIORAL|water and health education program to improve hygiene|
40795917|NCT00216918|DRUG|Atomoxetine Hydrochloride|
40795918|NCT04852055|BEHAVIORAL|Advance Care Planning Video|Clinical assistants determine who is the correct person to receive the informational materials. If the patient is the correct recipient, clinicians will send the informational materials to the patient at the assisted living center. If the proxy is the correct recipient, the clinical assistant will determine whether or not the proxy is using the existing online portal. If the proxy is using the portal, the informational materials will be sent electronically. If the proxy does not access the portal, the informational materials will be sent to their residences.
40795919|NCT01279044|BEHAVIORAL|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
40795920|NCT01279044|BEHAVIORAL|Standard HIV testing with information only|Standard HIV testing with information only
40795921|NCT00662831|DRUG|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
40795922|NCT00662831|DRUG|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
40795923|NCT02680340|PROCEDURE|Total Hip Arthroplasty|Patients who had a primary THA between 2002 and 2005
40795924|NCT04583124|OTHER|ATENTO-B|Patients will perform therapeutic exercise and vagal activation techniques before medical treatment and will follow the usual care after medical treatment.
40795925|NCT04583124|OTHER|ATENTO-T|Patients will perform therapeutic exercise and vagal activation techniques throughout medical treatment and will follow the usual care after medical treatment.
40795926|NCT02413944|PROCEDURE|ACTH stimulation test|ACTH stimulation test
40795927|NCT04615624|DRUG|Furosemide|Furosemide, a loop diuretic
40795928|NCT04615624|OTHER|Placebo|Normal saline
40795929|NCT03657784|DRUG|P03277|Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
40795930|NCT05096143|DRUG|Sacubitril/valsartan|Participants who were prescribed with Sacubitril/valsartan
40795931|NCT05096143|DRUG|ACEi/ARB|Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
40795932|NCT05404191|DEVICE|low level laser therapy|"Low level laser therapy will be performed for 30 min 3 times per week for 8 weeks on the wound area.~Wound area was irradiated by a red 655 nm light, 150 mW, 2 J/cm2 at the bed of the wound."
40795933|NCT02947802|OTHER|Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages|In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.
40795934|NCT02947802|OTHER|Control condition|In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
40795935|NCT01274234|DEVICE|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
41000675|NCT03348696|DRUG|Dexamethasone physician choice|Dexamethasone standard of care pre-medication + dexamethasone physician choice
41150751|NCT03612999|BEHAVIORAL|Subjects record daily activity|Subjects will record their daily activities, either on paper or on a secure texting app.
41000676|NCT02983006|BIOLOGICAL|DS-8273a|"* Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~* Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"
41471128|NCT02970552|DRUG|Vaginal Progesterone|200 mg micronized vaginal progesterone suppository
41471129|NCT02970552|DRUG|Placebo|Indistinguishable placebo vaginal suppository
41471130|NCT03635268|OTHER|Data collection|Sociodemographic, medical and hospital, on ambulatory care consumption data.
41471131|NCT01765517|DIETARY_SUPPLEMENT|Probiotics|Administration of probiotics daily for 26 weeks and compared to placebo
41471132|NCT01765517|DIETARY_SUPPLEMENT|Placebo|Administration of placebo daily for 26 weeks and compared to probiotics group
41471133|NCT03864042|DRUG|losartan|taken orally
41471134|NCT03864042|DRUG|dextromethorphan|taken orally
41471135|NCT03864042|DRUG|caffeine|taken orally
41471136|NCT03864042|DRUG|omeprazole|taken orally
41471137|NCT03864042|DRUG|midazolam|taken orally
41471138|NCT03864042|DRUG|rosuvastatin|taken orally
41471139|NCT03864042|DRUG|bupropion immediate release (IR)|taken orally
40795936|NCT02634775|OTHER|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
41000677|NCT02983006|BIOLOGICAL|Nivolumab|5 mg/kg IV Q 3 weeks
41000678|NCT03424837|BEHAVIORAL|ASCENT|"ASCENT includes the following components:~* Survivorship care plan created through the ASCENT tool~* Online tool which assesses health care needs and facilitates receipt of care~* A national-level navigator who helps the participant to access support services~* Periodic reminders for the participant to pursue recommended survivorship care"
41000679|NCT04664504|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy Radiotherapy|50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d.
41000680|NCT04664504|RADIATION|Short-course Radiotherapy|25Gy in 5 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
41150752|NCT03612999|BEHAVIORAL|Subjects record psychological state|Subjects will record their psychological state, either on paper or on a secure texting app.
40795937|NCT03298698|DRUG|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
40795938|NCT03298698|DRUG|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
40795939|NCT02089009|OTHER|Retinal imaging|Retinal imaging by using non-mydriatic camera devices
40795940|NCT02089009|OTHER|Vessel measurements|Vessel measurements based on the taken images by the use of a specialized software
41312663|NCT00358995|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
41471140|NCT03864042|DRUG|encorafenib|taken orally
41471141|NCT03864042|DRUG|binimetinib|taken orally
41471142|NCT03864042|DRUG|modafinil|taken orally
41471143|NCT02326363|BEHAVIORAL|Mindfulness Based Relapse Prevention (MBRP)|Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.
41471144|NCT02326363|BEHAVIORAL|Twelve-Step Facilitation Intervention (TSF)|"The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
41471145|NCT06346106|GENETIC|Male Rett|This study does not have an intervention. Participants of this study must be parents or caregivers to boys with Rett syndrome.
41471146|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
41471147|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
41471148|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
41471149|NCT06269809|PROCEDURE|Temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Temporary clipping of the uterine arteries and the utero-ovarian ligaments using laparoscopic clips/bulldog clamps, during robotically assisted myomectomy.
41471150|NCT06269809|PROCEDURE|No temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Robotically assisted myomectomy, for which no temporary clipping of the uterine arteries and the utero-ovarian ligaments
41312664|NCT00358995|BEHAVIORAL|Stress Management Therapy (SMT)|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
41312665|NCT02507193|PROCEDURE|Open reduction internal fixation|An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
41312666|NCT02507193|PROCEDURE|Intermedullary Nail|An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
41312667|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells -iv low dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 1x10\^6
41150753|NCT04383834|DEVICE|NobelActive® TiUltra™ implants and On1™ Base/Xeal™ along with On1 components|"The NobelActive® TiUltra™ implant is an ultra-hydrophilic multi-zone anodized implant surface. NobelActive® TiUltra™ features a gradual change in topography, from a minimally rough non-porous nanostructured implant collar to a moderately rough porous apex: more than roughness. NobelActive® TiUltra™ collar features surface chemistry and topography that promote early osseointegration and are designed to support bone stability. In addition, the Protective Layer preserves the pristine surface chemistry and hydrophilicity.~The second new product is the Base/Xeal™ new surface, which is covered by a titanium oxide layer, created by electrochemical anodization of a titanium machined component, resulting in a yellow hue nano-structured surface."
41312668|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells -iv middle dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 3x10\^6
41312669|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells - iv high dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 10x10\^6
41312670|NCT05228106|DIAGNOSTIC_TEST|[68Ga]-PSMA-617|The intervention consists of an intravenous injection of the radiopharmaceutical \[68Ga\]-PSMA-617 and a physiological saline flush, followed 60-90 minutes later by a PET/CT image acquisition.
41312671|NCT02781454|DRUG|Mexiletine|
41312672|NCT02781454|DRUG|Placebo|
41312673|NCT04314596|OTHER|Cross Training Course|One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.
41312674|NCT04314596|DIETARY_SUPPLEMENT|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
41312675|NCT00847938|DRUG|neostigmine|0.04 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
41312676|NCT00847938|DRUG|neostigmine|0.02 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
41312677|NCT00847938|DRUG|neostigmine|0.01 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
41312678|NCT00670397|DRUG|HPPH|IV
41312679|NCT04465396|DRUG|Teduglutide|Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.
41312680|NCT04465396|DEVICE|Syringe Injection|Teduglutide was administered using syringe.
41312681|NCT04465396|DEVICE|Pen injector|Teduglutide was administered using pen injector.
41312682|NCT01892319|DRUG|insulin detemir|Patients will be treated according to routine clinical practice at the discretion of the treating physician
41312683|NCT01892319|DRUG|other injectable antidiabetic treatment regimens|Patients will be treated according to routine clinical practice at the discretion of the treating physician
41312684|NCT01000727|DRUG|Darapladib 160 mg|Lp-PLA2 inhibitor
41312685|NCT01000727|DRUG|Placebo|Placebo administered
41312686|NCT01000727|OTHER|Standard Therapy|Guideline mandated therapy for individual's condition
41312687|NCT01626352|DRUG|Bendamustine|Patients will receive as an IV infusion bendamustine 90 mg/m\^2 Days 1 and 2 of Cycles 1 through 6.
41000681|NCT04664504|RADIATION|Local dose increase of Short-course Radiotherapy|25Gy in 5 fractions to the of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. And 4Gy in 1 fractions to the PGTV of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
40795941|NCT02089009|OTHER|Change in vessel diameters|Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
41312688|NCT01626352|DRUG|Ofatumumab|Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6
41312689|NCT05528874|DIETARY_SUPPLEMENT|Same intervention for both groups: glycaemic index assessment of 3 biscuits recipes|Following International standards ISO 26642 guidelines, subjects (at fasting) will have their glycemia measured and after will consume a solution containing 50g of glucose and 100g of water. In the following 2 hours, glycemia and other blood parameters will be taken 6 times (at 15, 30, 45, 60, 90, and 120 minutes). This protocol is repeated twice within 3 months. After these 2 days, with the same methods, they will come to our clinic to test 3 different recipes of biscuits (characteristics are presented on request). Subjects and investigators are not blinded to these biscuits characteristics.
40795942|NCT03623698|DRUG|Nebulised hypertonic saline|Nebulised hypertonic saline used for a period of at least 12 months
40795943|NCT00532311|DRUG|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
40795944|NCT00532311|DRUG|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
40795945|NCT02348580|BEHAVIORAL|Child centered teaching of life-skills|The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
40795946|NCT04055272|BEHAVIORAL|Mobile text messaging intervention|Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
40795947|NCT03813875|DRUG|Fentanyl|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0\~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
40795948|NCT03813875|OTHER|Bispectral index (BIS) and analgesia nociception index (ANI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
40795949|NCT03813875|DRUG|alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
41000682|NCT04664504|DRUG|Consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses\*3 weeks per course.
41000683|NCT04664504|DRUG|Adjuvant chemotherapy|2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses\*3 weeks per course
41000684|NCT04664504|PROCEDURE|TME|Total mesorectal excision
41150754|NCT05023304|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
41150755|NCT05023304|DRUG|Topical Prednisolone|Standard of care topical drop treatment
41150756|NCT06351397|BEHAVIORAL|Mixed Reality (MR)|"Mixed Reality simulation of medical crisis scenarios.~MR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario"
41312690|NCT05528874|DIETARY_SUPPLEMENT|Crossover: Recipe 4 before recipe 5|"After the assessment of fasting parameters, subjects will consume recipe 4 (chocolate biscuits) and perform a 180 min curve with blood taken at 15, 30, 45, 60, 90, 120, and 180 minutes. In this case, both investigators and patients are blinded to the presence of an additional non-nutritive, non-toxic and without taste encapsulated bitter compound (artemisia absinthium), that could be present in recipe 4 or recipe 5. On the second day (with at least a week gap), patients will consume recipe 5. Questionnaires and a food diary will also be requested for subjects for lunch and dinner."
41312691|NCT05528874|DIETARY_SUPPLEMENT|Crossover: Recipe 5 before recipe 4|Same as previous group, but starting with recipe 5
41312692|NCT00743600|OTHER|ultrasound of painful shoulder|Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.
41312693|NCT00743600|OTHER|ultrasound|Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.
41312694|NCT00262080|DRUG|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
40795950|NCT03813875|DRUG|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0\~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
41000685|NCT01041625|DRUG|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
41000686|NCT03302728|DRUG|Lenalidomide 15mg|At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
41000687|NCT03302728|DRUG|Brentuximab Vedotin 1.8 mg/Kg|At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
41000688|NCT02218333|DIETARY_SUPPLEMENT|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
41000689|NCT02218333|DIETARY_SUPPLEMENT|Placebo|
41000690|NCT00924872|OTHER|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
41000691|NCT05358275|DEVICE|surgical cutting guide with piezo|3D planned lid surgery
41000692|NCT05358275|OTHER|control|ordinary cyst enucleation
41000693|NCT06408467|OTHER|aMMP-8 diagnostic test|40 patients
41312695|NCT00262080|DRUG|Phosphate Buffer Saline (PBS),|given as three 1mL subcutaneous injections.
41312696|NCT05947747|DRUG|EXO-CD24|Twice a day for 5 days, dose 10\^10
41000694|NCT02269462|DRUG|Efavirenz|600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
41000695|NCT02269462|DRUG|Nevirapine|200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
41017784|NCT05050643|OTHER|EBQI-LC|A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.
41017785|NCT02642913|DRUG|Enzalutamide|
41017786|NCT02642913|DRUG|Enzalutamide with Sorafenib|
41150757|NCT06247761|DEVICE|Skin closure at end of hand surgery|skin closure with vicryl rapide suture
41150758|NCT01810406|PROCEDURE|CSE with 10 ml EVE|Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
41150759|NCT01810406|PROCEDURE|CSE without EVE|Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
41150760|NCT04086576|DEVICE|Alcohoot|Alcohoot branded smartphone-paired breathalyzer
41150761|NCT04086576|DEVICE|BACtrack Mobile Pro|BACtrack Mobile Pro branded smartphone-paired breathalyzer
41017787|NCT06165744|DEVICE|UNITY VCS|Investigational device used during anterior and posterior segment ophthalmic surgery.
41017788|NCT06165744|PROCEDURE|Eye surgery|Eye surgery performed with UNITY VCS
41150762|NCT04086576|DEVICE|DRIVESAFE Evoc|DRIVESAFE Evoc branded smartphone-paired breathalyzer
41150763|NCT04086576|DEVICE|BACtrack Vio|BACtrack Vio branded smartphone-paired breathalyzer
41150764|NCT04086576|DEVICE|Drinkmate|Drinkmate branded smartphone-paired breathalyzer
41150765|NCT04086576|DEVICE|Floome|Floome branded smartphone-paired breathalyzer
41150766|NCT04086576|DEVICE|Intoxilyzer 240|Intoxilyzer 240 police grade breathalyzer
41312697|NCT05947747|OTHER|Placebo|Twice a day for 5 days
41312698|NCT05675891|OTHER|Supplemental Feeding System Group|The body weight is measured in the morning fasting on the day when oral feeding is decided, 3 feeding between 08-16:00 are carried out with the supplemental feeding system, The amount of food prepared is recorded, Heart rate, oxygen saturation, respiratory rate and early feeding skill score are recorded before, during and after feeding, When the feeding is finished, the total amount of food taken by the baby and the feeding time are recorded, The rate of food intake (%) and the amount of food received per minute are calculated and recorded, Infants who can take 80% of the amount of food given at each meal by being fed orally for 8 meals two days in a row are considered to have switched to full oral feeding.
40795951|NCT03813875|DRUG|sevoflurane|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0\~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
40795952|NCT03813875|DRUG|midazolam|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0\~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
40795953|NCT00175760|PROCEDURE|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
40795954|NCT00200707|PROCEDURE|Intracoronary injection of autologous bone marrow mononuclear cells|
40795955|NCT06502522|OTHER|Whole-body electrical stimulation|"Symmetrical biphasic current, pulse width of 400 μs, frequency of 75 Hz, contraction time of five seconds and rest time of 10 seconds. The intensity will be individually adjusted to the patient's maximum tolerance limit to reach the motor threshold and the volunteer will be instructed to achieve a score of 7 on the modified BORG scale to ensure a moderate-intense effort. The session time will be 16 minutes, resulting in a total of 64 contractions per session. The progression of overload will only occur with an increase in the intensity of all muscle groups during the sessions.~Concomitantly with the electrical stimuli, the volunteer will perform exercises for the upper, lower limbs and trunk. After performing neuromuscular electrical stimulation, the patient will remain in the supine position to receive sensory stimulation throughout the body. The parameters used will be: frequency of 20 Hz and pulse width of 400 μs for 44 minutes."
40795956|NCT04803175|DRUG|Sacubitril-Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
40795957|NCT04803175|DRUG|Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
40795958|NCT04573790|PROCEDURE|eFONA|Surgical Tracheotomy
40795959|NCT02038946|DRUG|Nivolumab|
40795960|NCT05879393|DIETARY_SUPPLEMENT|OMNi-BiOTiC® Active|Multistrain probiotic
40795961|NCT05879393|OTHER|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
41312699|NCT05248971|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is an evidence-based treatment method for children and adolescents who have been exposed to trauma and experience posttraumatic stress symptoms. The treatment model has a family and caregiver focus, and non-offending caregivers are included in the treatment. TF-CBT is normally provided through 8-12 treatment sessions.
40795962|NCT00302744|DRUG|Psilocybin (drug)|Capsule (.2 mg/kg).
40795963|NCT00302744|OTHER|Niacin|Active Placebo
40795964|NCT00302744|DIAGNOSTIC_TEST|MRI|MRI required for study inclusion for purpose of ruling out metasteses to brain
40795965|NCT02334072|DEVICE|Laryngeal mask classical application|Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
40795966|NCT02334072|DEVICE|I-gel laryngeal mask application|I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
40795967|NCT02334072|DEVICE|Cobra laryngeal mask application|Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
40795968|NCT02334072|DEVICE|Supreme laryngeal mask application|Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
40795969|NCT02334072|DEVICE|Proseal laryngeal mask application|Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
40795970|NCT04859348|OTHER|routine physical therapy|G- A 36 participants received only routine treatment for GDM which includes insulin therapy and diet control guided by gynecologist and routine physical therapy which includes walk for 1 hr with proper warm up and cool down periods, three times in a week from 20-24 weeks of gestation to till delivery.
40795971|NCT04859348|OTHER|routine physical therapy and antenatal exercises|G- B 36 participants receive routine therapy (insulin therapy and diet control) and Aerobic and strengthening Exercises for 3 days a week, for 2 weeks 6 sessions under the supervision of physiotherapist and remaining was performed at home. Exercise was started from 15 min and reach to 30 mins gradually.10-15-minute warm-up, cool-down period was included by using ACOG Guideline. Aerobic exercise includes a brisk walk and strengthening exercise were performed with hold for 5 seconds and 10 repetitions. Exercise should stop if they experience any signs of dizziness, dyspnea, amniotic fluid leaking or vaginal bleeding. Confidentiality and blindness ensure by random allocation.
40795972|NCT05310123|DIETARY_SUPPLEMENT|AC-11|6-months of treatment with AC-11
41150767|NCT05979987|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
41312700|NCT06153082|DIAGNOSTIC_TEST|ROTEM|In ROTEM group if CT EXTEM \>80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM \<35 and MCF FIBTEM \<8 CRYO or Fibrinogen concentrate, if MCF EXTEM\<35 and MCF FIBTEM \>8 Platelet, CL LY\>50 Trenaxemic acid
40795973|NCT04438759|DEVICE|Oncomfort, commercially available Virtual Reality headset|Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform 93/42/EEC and 2007/47/EEC
40795974|NCT05679960|DIAGNOSTIC_TEST|Urine PolypDx machine Versus Colonoscopy|"1. Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~2. Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups"
40795975|NCT02554799|DRUG|MMV390048 formulation A|MMV390048 formulation A, tablet
40795976|NCT02554799|DRUG|MMV390048 formulation B|MMV390048 formulation B, tablet
40795977|NCT01735383|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
40795978|NCT01735383|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
40795979|NCT06435988|BEHAVIORAL|Training in the pecha kucha technique|Providing labor training to pregnant women with the Pecha Kucha technique
40795980|NCT04062981|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
40795981|NCT03238274|DEVICE|Sofia 2 Lyme FIA testing|IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
40795982|NCT04808713|BEHAVIORAL|Treatment|The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
40795983|NCT05748509|OTHER|Surface EMG activations|We will try to find out which of the exercises such as pressing the back back, waist extension on the balance ball, lumbar extension in the active prone position, Superman exercises have better lumbar extensor muscle activations. Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
40795984|NCT03276832|DRUG|Imiquimod|Applied cutaneously
40795985|NCT03276832|PROCEDURE|Biopsy|Undergo biopsy
40795986|NCT03276832|BIOLOGICAL|Pembrolizumab|Given IV
40795987|NCT03276832|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40795988|NCT03276832|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40795989|NCT03276832|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40795990|NCT05698615|BEHAVIORAL|Chess training|"The chess training, which takes place as a measure for CRT with the children and adolescents, is carried out by the concept of the Munich Chess Academy. The concept applied here, Chess according to the King's Plan, represents a holistic concept. Especially prepared for children and adolescents, theoretical aspects are illustrated in games and exercises."
40795991|NCT05009576|OTHER|silver alginate|silver alginate hydrofiber dressing
40795992|NCT05009576|OTHER|VAC dressing without silver alginate|vaccum assisted dressing
40795993|NCT03091387|DIAGNOSTIC_TEST|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
40795994|NCT02735057|DRUG|Carboplatin|
40795995|NCT05317650|OTHER|Multi-gravitational suspension-based therapy (M-Gravity)|Multi-gravitational suspension-based therapy (M-Gravity) is a comprehensive discipline based on the principles of non-gravity, which serves to increase the quality of life and holistic health of the individual with the rehabilitation content of non-pressure inversion therapy.
40795996|NCT04469088|OTHER|Dry needling|Twenty-three patients with TJD will be allocated in Dry Needling Group. They will receive 3 sessions of dry needling separated for 4 days. This treatment will consist of puncturing the active myofascial trigger points (PGM) of the aforementioned muscles. Sterile acupuncture needles of 0.26 mm in diameter by 40 mm in length, guided with a plastic cannula of the Ener-qi brand, will be used. The area will be cleaned with alcohol and a deep puncture of the PGM will be performed, triggering local spasm responses. Needle through the muscle following the technique described by Hong (Hong et al. 1994). After the procedure, the area is compressed with cotton for 90 seconds.
40795997|NCT04469088|OTHER|Manual Therapy Treatment|Twenty-three patients will be allocated in Manual Therapy (MT) Group for three sessions during 30 minutes. MT treatment will consist in the application of neuromuscular techniques of the temporal, masseter and sternocleidomastoid muscles and Jones techniques in the external pterygoid muscle. Neuromuscular techniques are performed with the index and major fingers to apply a transverse friction with enough pressure to feel vertical fibers of each muscle or produce a medium discomfort level. To perform the Jones technique on the external pterygoid muscle, the patient will be asked to open the mouth and deviate the jaw slightly towards the treated side in order to make room for the finger to be located between the upper jaw and the coronoid process. Once the trigger point is located, we press to trigger the pain and we look for neurological silence and we maintain the pressure for 90 seconds. Over time, we slowly withdraw the pressure and return to the position passively.
40795998|NCT01813201|DRUG|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
40795999|NCT01813201|DRUG|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
40796000|NCT02727595|DEVICE|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
40796001|NCT01461746|DRUG|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
40796002|NCT01461746|DRUG|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
40796003|NCT01461746|RADIATION|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
40796004|NCT06227312|DEVICE|LADY 1 Pro, New Life Balance|whole-body vibration training on the platform
40796005|NCT06227312|OTHER|exercises|calf raises and modified drop jumps
41000696|NCT03951246|OTHER|Cognitive and Motor Training|"In the first phase of the trial, all participants (patients and healthy children) will complete cognitive and motor functions assessment.~Then the sample of patients who have cognitive/motor impairment will be randomized to an either Intervention or Control group.~In the second phase of the trial, survivors in the Intervention Group will receive 6 sessions of cognitive and motor training during two weeks, and survivors in Control Group will undergo .....~After this treatment phase, motor and cognitive functions assessment will be conducted in all patients once again.~In the third phase, the Control Group will be provided the active intervention (i.e. 6 sessions of cognitive and motor training during two weeks), while the Intervention Group engages in passive reading.~After this, motor and cognitive functions assessment will be carried out in all patients once again."
41000697|NCT04415541|BEHAVIORAL|Psychodynamic Psychotherapy|Intensive psychotherapy that is psychodynamically oriented.
41000698|NCT04415541|BEHAVIORAL|Usual Care|Conventional treatment offered in the community.
41000699|NCT05992506|DIAGNOSTIC_TEST|POD risk estimation using PEUMA|A software will analyze intraoperative EEG recording for the estimation of a POD Risk Index
41000700|NCT01997268|DRUG|Placebo|Corn Oil
41000701|NCT01997268|DRUG|SC401B 2 capsules|
41312701|NCT06153082|DIAGNOSTIC_TEST|Thromboelastography|Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°.
41312702|NCT04504370|DRUG|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
40796006|NCT01970644|RADIATION|Gamma knife radiosurgery|Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
40796007|NCT06043180|PROCEDURE|Transcatheter aortic valve implantation|Intervention on aortic valve for severe aortic stenosis
40796008|NCT01295138|DRUG|Lactulose|Lactulose liquid. 15mls twice daily
41000702|NCT01997268|DRUG|SC401B 4 capsules|
41000703|NCT01997268|DRUG|SC401B 6 capsules|
41000704|NCT01886248|DRUG|Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU|
41150768|NCT05979987|BEHAVIORAL|Persuasion via anecdote|The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message prompts patients to click on a link to read the story about the patient.
41150769|NCT05979987|BEHAVIORAL|Persuasion via anecdote without link|The message will contain a link to an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message won't contain a link to the story, but it will briefly describe the story.
41000705|NCT05180435|BEHAVIORAL|Family Meals|A family-based multicomponent lifestyle modification intervention with the goal to increase the frequency of family meals and meet physical activity recommendations.
41000706|NCT05180435|BEHAVIORAL|Standard|A family-based multicomponent lifestyle modification intervention with the goal to increase the consumption of fruits and vegetables and and meet physical activity recommendations.
41000707|NCT03470337|DRUG|Phlogenzym|Bromelain / Trypsin / Rutoside
41000708|NCT03470337|OTHER|Placebo|
41000709|NCT06138626|BEHAVIORAL|Alert|An alert that appears when anesthetic fresh gas flow is excessive
41000710|NCT04952870|OTHER|Inhaled NO|Newborn or young infants (\< 3 months) receiving inhaled NO as part of their treatment for severe respiratory failure
41000711|NCT04952870|OTHER|routine care|Patients treated for respiratory failure
41000712|NCT00913744|DRUG|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
41000713|NCT00913744|DRUG|Sham injection|Sham injection
41000714|NCT03073096|PROCEDURE|LVA at time of nodal dissection|Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
41000715|NCT05390268|BEHAVIORAL|Mobile app-assisted behavioral treatment|"The app-assisted training group have access to a newly developed app in which they are taught how to handle tics. A new app session is released at each new treatment session and the content of the app videos is comparable to the information and training at face-to-face individual treatment, as defined by the manual Niks to Tics\["
41000716|NCT00393679|DRUG|amodiaquine-artesunate (ASAQ)|A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
41000717|NCT00393679|DRUG|dihydroartemisinin-piperaquine (DHAPQ)|DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
41000718|NCT00393679|DRUG|artemether-lumefantrine (AL)|Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
41000719|NCT00393679|DRUG|Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)|"Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
41000720|NCT04733963|DRUG|Fruquintinib Plus Capecitabine|Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
41312703|NCT04504370|DRUG|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
41312704|NCT01757613|DRUG|AK 3012|cutaneous use twice a day
41000721|NCT04733963|DRUG|Bevacizumab Plus Capecitabine|Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
40796009|NCT02991898|BIOLOGICAL|Infusion of Treg|"Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion."
41000722|NCT02076412|DRUG|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
40796010|NCT01119066|RADIATION|total body irradiation|dose of 1375-1500 cGy
41150770|NCT05979987|BEHAVIORAL|Persuasion via research|This message will mention that research has shown promptly closing health gaps saves lives.The message will contain a link to an official website that supports the statement.
41150771|NCT02023099|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
41312705|NCT06270355|PROCEDURE|Risk based screening|Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.
40796011|NCT01119066|DRUG|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
40796012|NCT01119066|DRUG|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
40796013|NCT01119066|DRUG|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
40796014|NCT01119066|DRUG|Melphalan|70mg/m2/day x 2
41150772|NCT02023099|DRUG|Placebo|Tablet
41312706|NCT00314652|DRUG|Buprenorphine transdermal delivery system|
41471151|NCT03274037|DIAGNOSTIC_TEST|Device for mechanical excitation by pressure waves|"The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.~The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece~The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields."
40796015|NCT01119066|DRUG|Fludarabine|25mg/m2/ day x 5
40796016|NCT01119066|DRUG|Clofarabine|20mg/m2/ day x 5 (or, for children \<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
40796017|NCT01119066|PROCEDURE|(CliniMACS) T-cell depleted PBSC Transplant|
40796018|NCT00202215|BEHAVIORAL|Chrysalis Day Program|
40796019|NCT04512820|DEVICE|TRUCLEAR tissue removal system|evacuation of POC using the TRUCLEAR tissue removal system
40796020|NCT04054921|DRUG|PTG-300|PTG-300 is a hepcidin Mimetic
40796021|NCT03965104|BEHAVIORAL|Hypertension Canada Professional Certification Program: HC-PCP|The HC-PCP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
40796022|NCT06322550|BEHAVIORAL|cover story|After agreeing to participate, migraine patients were randomly given the briefing information and therefore their group allocation. Patients received the cover stories via the allocated flyer with study information and also by the physician from the outpatient clinic. Fifty percent of patients (Migraine as Patients \[MP\]) received the information that they will take part in a migraine study (compared to healthy controls) and that this study would investigates migraine associated dizziness by watching a visual stimulus (roller coaster video). The protocol for the intervention was standardized and identical for all participants. The other 50% (Migraine as Healthy \[MH\]) received the information that this study was in cooperation with the University's vertigo Department and that they will take part as controls since they were healthy apart from their migraine.
41000723|NCT02076412|DRUG|Placebo|Placebo tablet PO bid (morning and evening)
41000724|NCT02131480|DRUG|Doxorubicin|60 mg/m²
41000725|NCT02131480|DRUG|Trabectedin|1,1 mg/m²
41150773|NCT05229549|OTHER|GOLIKE PLUS 3-16|PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
41150774|NCT05229549|OTHER|Free AAs|It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
41150775|NCT01671371|OTHER|Point-of-Care Ultrasound|Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
41150776|NCT03872661|DRUG|IBI308|IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles.
41150777|NCT03872661|DRUG|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg on day 1 of each 21-day cycle for 4 cycles.
41150778|NCT03872661|DRUG|Pemetrexed|Pemetrexed was given 500 mg/m\^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles.
41150779|NCT03872661|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles.
41312707|NCT00465855|COMBINATION_PRODUCT|Hyperbaric Oxygen (HBO2) - 3 sessions|"Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods."
41471152|NCT05386394|DEVICE|Active tDCS + Language Therapy|Active tDCS stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 milliamps (mA)/cm2; estimated total charge 0.048 Coulombs (C)/cm2) in a ramp-like fashion for a maximum of 20 minutes. Language therapy will be conducted in conjunction with stimulation and will target oral and written naming.
40796023|NCT00843258|DEVICE|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
40796024|NCT02827344|BIOLOGICAL|blood sample collection for CTC and MDSC analysis|"* Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~* Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~* Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
41471153|NCT05386394|DEVICE|Sham tDCS + Language Therapy|During sham stimulation, current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Language therapy targeting oral and written naming will be administered during sham tDCS stimulation.
40796025|NCT04136548|DRUG|Fentanyl|Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
40796026|NCT04136548|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
40796027|NCT00301145|BEHAVIORAL|smoking cessation intervention|
40796028|NCT00301145|DRUG|varenicline|
40796029|NCT00301145|OTHER|counseling intervention|
40796030|NCT00301145|OTHER|internet-based intervention|
40796031|NCT04058899|DRUG|Dexmedetomidine|sedative and might be analgesic drug
40796032|NCT04058899|DRUG|Nalbuphine|agonist antagonist narcotic
40796033|NCT04058899|DEVICE|infusion pump|infusion pump for titration of fluid containing drug infusion
40796034|NCT04594629|DRUG|Nitroglycerin|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
40796035|NCT04594629|DRUG|PGI2|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
40796036|NCT01833494|DRUG|PA21|
40796037|NCT05449912|OTHER|Collection of environmental exposure data|noise pollution air pollution proximity and accessibility to green spaces, blue spaces
40796038|NCT00326001|DEVICE|Gold tip catheter|Radiofrquency ablation using gold tip catheter
40796039|NCT00326001|DEVICE|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
40796040|NCT05332392|DEVICE|INVSENSOR00040|Noninvasive wearable health monitoring device
40796041|NCT05363722|DRUG|IBI310（0.5mg/kg）|IBI310 0.5mg/kg IV d1 Q6W
40796042|NCT05363722|DRUG|IBI310（0.3mg/kg）|IBI310 0.3mg/kg IV d1 Q6W
40796043|NCT05363722|DRUG|sintilimab|sintilimab 200 mg IV d1 Q3W
41000726|NCT03160053|DEVICE|NB-UVB|NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
41471154|NCT01741467|BEHAVIORAL|RT-CGM|Dexcom Seven+
40796044|NCT05363722|DRUG|bevacizumab|bevacizumab 15 mg/kg IV d1，Q3W
40796045|NCT03700840|DEVICE|Interdental brushes|interdental brush at 4 sites and PCR analysis
41000727|NCT01234233|PROCEDURE|duration of preoperative active warming|"duration of prewarming by forced air warming"
40796047|NCT05281237|DEVICE|AveCure 16 Gauge Flexible Microwave Ablation Probe|Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
40796048|NCT05801848|DIAGNOSTIC_TEST|[18F]NaF PET/CT scan|Patients will have their lower back scanned using \[18F\]NaF PET/CT
40796049|NCT05547919|RADIATION|18F-PSMA PET/CT|Patients with metastasized gastrointestinal tumors, that exhibit histological PSMA expression, receive an additional 18F-PSMA PET/CT to routine imaging.
40796050|NCT02254044|DRUG|bivatuzumab mertansine|
40796051|NCT03482986|BEHAVIORAL|Dietary habits plan|Patients will be given a personalized plan regarding their diet.
41000728|NCT05932446|DRUG|LY3819469|Administered SC.
41000729|NCT02203812|DRUG|Probiotic Arm|Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
41000730|NCT02203812|DRUG|Placebo Arm|Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
41000731|NCT02617550|DRUG|Vericiguat (BAY1021189)|Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
41312708|NCT00465855|COMBINATION_PRODUCT|Hyperbaric Oxygen (HBO2) - 1 session|"During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods."
41471155|NCT02190279|DRUG|18F DCFBC|Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
40796052|NCT04976790|BEHAVIORAL|Chinese Tuina therapy|Firstly, the patient is in the prone position, and the doctor use the method of rolling or kneading the Bladder meridians on both sides of the spine. The waist will be focused on to manipulate preferentially and then using the same technique on the patient's back, buttocks and lower limbs. Secondly, the physician will perform the manipulation on the patient's waist and the posterolateral side of the lower limbs by pressing, kneading, plucking. The doctors press the acupoints, including Mingmen(DU04),Shenshu(BL23),Yaoyangguan(DU03),Huantiao(GB30), Weizhong(BL40),Chengshan(BL57),and Ashi points, with the elbow or the thumb to achieve Deqi sensation. Thirdly, the The doctor uses the method of pressing acupoints, including Tianshu(ST25),Qichong(ST30),Chongmen(SP12),Daimai(GB26),Jingmen(GB25) on both sides. Fourthly, the patient is required to face the doctor in a lateral position for pulling manipulation on the both sides of lumbar vertebrae.
40796053|NCT04976790|DRUG|Flurbiprofen Cataplasms group (FCG).|One Flurbiprofen Cataplasm was applied to the left and right sides of the waist, twice daily, for 14 days
40796054|NCT04156334|PROCEDURE|Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia|QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
40796055|NCT05290662|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
40796056|NCT05290662|DRUG|Cyclophosphamide/Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
40796057|NCT04490213|OTHER|Allevyn, Aquacel and Tegaderm, Mediskin|Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.
40796058|NCT03522935|DRUG|Elafin|Elafin subcutaneous.
40796059|NCT03522935|DRUG|Placebo|Placebo subcutaneous.
40796060|NCT03684837|DIETARY_SUPPLEMENT|Vitamine D supplementation|a vitamine D dose for week
40796061|NCT03684837|OTHER|chronic exercise in whole body vibration (WBV)|exercise in WBV during 03 months, e times per week
40796062|NCT05600361|DRUG|hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy|In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
40796063|NCT04931797|BEHAVIORAL|video decision aid|advance care planning video decision aid
40796064|NCT04931797|BEHAVIORAL|control arm ACP information sheet|control arm ACP information sheet
40796065|NCT00334737|DRUG|Darbepoetin Alfa Injection|darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
40796066|NCT00334737|DRUG|erythropoietin alfa injection|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
40796067|NCT00334737|DRUG|sham injection|sham injection other names: not applicable
41000732|NCT02617550|DRUG|Placebo|Placebo for 14 +/-3 days given as 1 or 2 tablets \[o.d.\].
41471156|NCT02190279|DRUG|Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)|
40796068|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 1.
40796069|NCT03974932|DRUG|Ibuprofen|NSAID.
40796070|NCT03974932|DRUG|Acetaminophen|Analgesic.
40796071|NCT03974932|DRUG|Celecoxib|NSAID.
40796072|NCT03974932|DRUG|+/- Bupivacaine HCl|Local anesthetic.
40796073|NCT03974932|DEVICE|Luer Lock Applicator|Applicator for instillation.
40796074|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 2.
40796075|NCT03170570|DEVICE|intensity-modulated radiotherapy|IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
40796076|NCT02704975|DEVICE|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
40796077|NCT02704975|DEVICE|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
40796078|NCT01356862|DRUG|PASIREOTIDE|One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
40796079|NCT01356862|DRUG|PLACEBO|ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
40796080|NCT02439307|DRUG|Rifaximin|1200 mg of rifaximin for 2 weeks.
40796081|NCT02439307|DRUG|Placebo|Placebo for 2 weeks
40796082|NCT03274947|DEVICE|Cerebellar TMS|Cerebellar transcranial magnetic stimulation
41000733|NCT02617550|DRUG|Nitroglycerin|0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat \[trough\] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat \[peak\] or placebo) on day 13, day 27 and day 41
41000734|NCT02727920|DIETARY_SUPPLEMENT|Energy drink|
41000735|NCT02727920|OTHER|Placebo|placebo drink
41017789|NCT00967408|DRUG|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
41312709|NCT00053261|PROCEDURE|management of therapy complications|
41000736|NCT01129141|PROCEDURE|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
41000737|NCT01129141|PROCEDURE|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
41000738|NCT04961034|PROCEDURE|kasai portoenterostomy|surgical creation of stoma between porta hepatis and jejunal loop
41000739|NCT04499586|COMBINATION_PRODUCT|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Raltitrexed: 3mg/m2 per week. Irinotecan : 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) per week. Radiation: 45-55Gy/25-30Fx
41000740|NCT02239809|PROCEDURE|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
41000741|NCT02239809|PROCEDURE|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. Patients of the placebo group will be implanted with a lead in the V1 branch of the trigeminal nerve, but will not receive stimulation.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to placebo stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
41000742|NCT04830527|BEHAVIORAL|EMA prompting for patients|"EMA prompting will consist of the delivery of the PHQ-4 and PANAS questionnaires, as well as basic identification, therapy motivations and expectations, location, current activity and social interactions.~These prompts will be presented to patients during a 7 day period, 5 times per day."
41000743|NCT04830527|BEHAVIORAL|PDF Reports for therapists|After the patients' EMA data is collected, a previously designed R script will summarize and transform the data into a brief and graphic report for therapists in the experimental arm of the study. These reports are intended to provide detailed information about the patients' mood, anxiety levels, positive and negative affects, as well as crossed data such as mood according to location, anxiety according to activity, etc.
41000744|NCT03416400|OTHER|Oocyte vitrification|Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.
41000745|NCT05817136|DIAGNOSTIC_TEST|Eko DUO|Acquisition of a single-lead ECG via patients self-examine themselves twice a week for 12 months.
41000746|NCT02782416|OTHER|Examination of latent tuberculosis|
41000747|NCT04047264|PROCEDURE|Microdialysis|Undergo microdialysis
41000748|NCT02581384|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
40796083|NCT03274947|DEVICE|Sham cerebellar TMS|Sham cerebellar transcranial magnetic stimulation
41000749|NCT00869739|BEHAVIORAL|telephone-based intervention|
41000750|NCT00869739|OTHER|educational intervention|
41000751|NCT00869739|OTHER|partner-assisted coping skills training|
41000752|NCT00869739|OTHER|questionnaire administration|
41000753|NCT00869739|PROCEDURE|psychosocial assessment and care|
41000754|NCT00869739|PROCEDURE|quality-of-life assessment|
41312710|NCT06020027|BEHAVIORAL|Water is K'é|Four-month multi-level, family-based intervention that is grounded in Navajo culture and promotes individual knowledge, motivation and skills; social norms; and environmental changes (access to drinking water). At minimum, the enrolled child and primary caregiver will attend monthly sessions, with an open invitation to other family members. Families will also receive social media posts and develop a family access plan by selecting strategies (if needed) to boost their confidence in their water sources at home. ECE sites will also develop a tailored access plan, selecting strategies to increase confidence in water offered at the ECE site, and implement their access plan with study team support.
41312711|NCT00651404|DRUG|Ezetimibe|oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
41000755|NCT00004066|BIOLOGICAL|filgrastim|
41000756|NCT00004066|DRUG|docetaxel|
41000757|NCT00004066|DRUG|gemcitabine hydrochloride|
40796084|NCT02951234|OTHER|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
40796085|NCT02951234|OTHER|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
40796086|NCT02420184|DEVICE|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
41312712|NCT00651404|DRUG|Placebo|oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
41312713|NCT03791359|OTHER|CardioPulmonary Resuscitation|Whether the victim received CPR as per standard protocol.
41312714|NCT00352755|PROCEDURE|Surgical debulking with peritonectomy|
41471157|NCT06317389|OTHER|Questionnaires|Patients will benefit of supervision by the ONCORAL team in the usual way and their intervention will be limited to completing questionnaires.
40796087|NCT02420184|OTHER|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
40796088|NCT04253210|OTHER|psychological|Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).
40796089|NCT05429580|DRUG|Tranexamic acid|given intravenous tranexamic acid
40796090|NCT05429580|OTHER|5% Dextrose|given placebo.
40796091|NCT05445258|DEVICE|InnoCath AB® hyper-compliant balloon catheter|endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)
40796092|NCT01084291|BIOLOGICAL|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
40796093|NCT01084291|OTHER|Placebo injection|Subcutaneous injection of placebo
40796094|NCT03917875|BEHAVIORAL|Personalized feedback intervention|The novel integrated PFI will be developed and modeled from past PFIs targeting hazardous drinking. Participants will view feedback on the computer screen. The computer program/algorithm will determine the proper normative feedback to participants.
40796095|NCT03492502|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|"Consenting allo- SCT patients with acute steroid-resistant GI-related GVHD grade III-IV will receive autologous FMT by nasogastric tube. Standardized stool suspension will be given once a day for two consecutive days.In order to prevent aspiration, patients will be kept in a 45ᵒ upright position for four hours. Participants will fast the night before and be treated with proton pump inhibitors prior to each FMT.~In cases where complete response was not obtained within 7 days after autologous FMT, patients may be eligible for another trail of autologous FMT or to switch to other pharmacological interventions. Stool samples will be collected before and after the intervention for microbial analyses."
40796096|NCT00369850|OTHER|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
41000758|NCT04300569|OTHER|Non-interventional|No intervention will be administered.
41000759|NCT05161065|DEVICE|Cardiologs|Apple Watch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
41000760|NCT04036942|PROCEDURE|Ablation of the gastroesophageal junction with hybrid argon plasma|In the management group with argon plasma hybrid after marking 270 degrees of the esophagogastric junction, submucosal elevation and argon plasma burn of the marked and elevated area is performed.
41000761|NCT04036942|PROCEDURE|mucosectomy with band of the gastroesophageal junction|In the management group with mucosectomy after marking 270 degrees of the esophagogastric junction, a submucosal elevation of the marked area is performed to subsequently perform ligation and resection with a hot snare below the ligation area.
41000762|NCT03957434|OTHER|Physiotherapy|Education, pelvic floor muscle exercises with biofeedback and home exercises.
41017790|NCT00967408|DRUG|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
41150780|NCT03872661|PROCEDURE|Thoracic surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
41150781|NCT03312972|RADIATION|HDR Brachytherapy|HDR Brachytherapy implant, deliver 1 to 2 fractions, Up to 30 Gray (Gy) to target lesion
41150782|NCT00216788|DRUG|Esomeprazole (Nexium) 40 mg/day|
41312715|NCT00352755|DRUG|Intraperitoneal 5FU|
41312716|NCT00352755|DRUG|FOLFOX|
41312717|NCT03137121|DRUG|Olanzapine|Olanzapine is used as an anti-emetic.
41312718|NCT03137121|OTHER|Placebo|The placebo is a non-anti-emetic.
41312719|NCT01820078|DRUG|Experimental arm|Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
41312720|NCT01820078|OTHER|Comparator Arm|Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
41471158|NCT04224194|COMBINATION_PRODUCT|Adalimumab|Combined product as Drug is delivered through an autoinjector pen on which real-life patient handling experience is assessed.
41471159|NCT03244982|DRUG|Fluorescein Na 10% Inj 500mg|Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
41471160|NCT03244982|DRUG|Fluorescein Na 10% Inj 250mg|Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
40796097|NCT00369850|PROCEDURE|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
40796098|NCT00369850|PROCEDURE|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
40796099|NCT06315972|DRUG|clemastine (8 mg/day)|add-on clemastine (8 mg/day) + aerobic exercise training
40796100|NCT06315972|DRUG|Placebo|add-on placebo + aerobic exercise training
40796101|NCT01939522|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (PCV13)|
40796102|NCT00004846|DRUG|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
41017791|NCT00967408|OTHER|Rehabilitative treatment|Rehabilitative treatment
41017792|NCT01114841|DRUG|Tazarotene Foam|"Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
41150783|NCT06495463|DRUG|Trifluridine/tipiracil|"Trifluridine/tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~(choose one combination) : oxalipatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days."
41150784|NCT02188784|DRUG|Polysaccharide Iron Complex 150 mg|Oral Iron
41312721|NCT00165841|DRUG|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
41312722|NCT05689138|OTHER|Oral and Fecal Sample Collection|No interventions
41312723|NCT02345252|DRUG|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
41312724|NCT02345252|DRUG|FTC/RPV/TDF Placebo|Tablets administered orally once daily
41312725|NCT02345252|DRUG|FTC/RPV/TDF|200/25/300 mg FDC tablets administered orally once daily
40796103|NCT05176340|OTHER|Specific Thematic Nursing Care Action Modules (STNC-AM)|"The STNC-AM platform that investigators present here is an educational program that integrates education and coaching.~The nurse coaching component was based on the STNC-AM platform. This online platform can guide nurses' health education for the comprehensive care of stroke patients. Nurses can use an iPad and enter the STNC-AM platform website, where they can directly access the Care Action Module."
40796104|NCT01598714|DEVICE|Darco shoe|Darco shoe
40796105|NCT01598714|DEVICE|Podalux shoe|Podalux shoe
40796106|NCT01598714|DEVICE|Standard dressing shoe|Standard dressing shoe
40796107|NCT03469622|DEVICE|EndoRings|EndoRings-assisted colonoscopy
40796108|NCT03469622|DEVICE|Standard colonoscopy|Standard colonoscopy without any additional devices
40796109|NCT02168101|DRUG|MLN9708|"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg."
40796110|NCT01995526|DRUG|Insulin Peglispro|
40796111|NCT03971162|DRUG|3+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
40796112|NCT03971162|DRUG|6+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
41312726|NCT02345252|DRUG|FTC/RPV/TAF Placebo|Tablets administered orally once daily
41312727|NCT05522673|DRUG|11(R)-rolipram|Injected IV followed by PET scanning
41312728|NCT00356863|BEHAVIORAL|Increasing awareness to cardiac rehabilitation programs|Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
41312729|NCT06244940|DIAGNOSTIC_TEST|Whole Genome Sequencing (WGC) from subject samples|Perform whole genome sequencing (WGS) on fetuses with prenatally detected congenital heart disease (CHD) who meet inclusion criteria. Assess diagnostic yield of WGS in CHD and effect of prenatal versus postnatal phenotype on diagnostic yield.
41312730|NCT04606654|OTHER|Handgrip strength training without Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contract his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training.
41312731|NCT04606654|OTHER|Handgrip strength training with Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contracts his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training. However, for one of the limbs the pneumatic blood pressure cuff will be placed on the upper arm, 4 cm proximal to the ante-cubital fossa. The decision which arm would receive the occlusion during training will be randomized to avoid a dominant or non-dominant hand bias. During experimental group training blood pressure cuff will be partially inflated (80 mmHg) to ensure venous occlusion. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training while the cuff remained inflated.
40796113|NCT02138812|DRUG|BAY1161909|Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
40796114|NCT02138812|DRUG|Paclitaxel|75 mg/m\^2 (initial dose escalation) or 90 mg/m\^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
40796115|NCT01346943|DEVICE|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
41000763|NCT00774631|PROCEDURE|Mild induced hypothermia (32-34°C)|"Mild Induced hypothermia:~Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 \[6, 48\]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods."
40796116|NCT04774068|DRUG|Parsaclisib|Given PO
40796117|NCT04774068|DRUG|Romidepsin|Given IV
40796118|NCT00055926|DRUG|CP-724,714|
40796119|NCT01266278|OTHER|Dynamic ultrasound|Measurement of the size of the subacromial space with dynamic ultrasound.
40796120|NCT01266278|OTHER|FASTRAK|Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
40796121|NCT01266278|OTHER|Assessment of shoulder posture by measuring|Assessment of shoulder posture by measuring several angles and distances.
41312732|NCT06020339|OTHER|The midwife-led continuous care model (MLCC)|"Continuity of midwife-led care has been defined as care in which the midwife is the leading professional in the planning, organization and delivery of care given to a woman from the initial assessment of the pregnant woman to the postpartum period.~ELSBM; It is the same midwife or midwife group providing the care and counseling needed by the woman during pregnancy, childbirth and postpartum period. In this care model, the midwife is the leading health care specialist who is responsible for planning and arranging the care given to women in the antenatal, natal and postnatal period. MLCC is woman-centered and is based on the idea that pregnancy and childbirth are normal life events.~This care model includes education, counseling and care according to the needs of the woman. It promotes vaginal delivery as a normal process and advocates minimal interventions. Continuity of midwifery-led care is associated with superior outcomes for women and infants than other models of care."
41312733|NCT03477617|OTHER|Intraoperative Hemodynamic Algorithm|Anesthesiologists are instructed to use the study's algorithm to manage intraoperative hypotension in response to the cardiac output monitor values.
41312734|NCT03477617|COMBINATION_PRODUCT|Usual hemodynamic management|Anesthesiologists are instructed to manage intraoperative hypotension based on their usual clinical care, without information from cardiac output monitor
41312735|NCT04914377|DRUG|TQ Formula/Tab|TQ Formula will be administered as an oral dose daily. The dose planned in this study is 3 g per day (3 500mg capsules to be taken twice daily).
41312736|NCT05009316|OTHER|Questionnaires|Online-based questionnaires
41312737|NCT01238315|BIOLOGICAL|HuCNS-SC|Surgery to implant human CNS stem cells
41312738|NCT04271475|DRUG|Macitentan|Participants will receive Macitentan film-coated tablets orally od.
41312739|NCT04271475|DRUG|Placebo|Participant will receive matching placebo tablets orally od.
41312740|NCT02731118|DIETARY_SUPPLEMENT|Salovum|AF-enriched egg yolk
41312741|NCT02731118|DIETARY_SUPPLEMENT|Placebo|egg yolk
41312742|NCT06310096|OTHER|TLF fascial stretching exercise|"Relaxed lumbo-pelvic upright sitting with arms in neutral anatomical position (O'Sullivan et al., 2006). The subjects had to bend both knee flexed 90. The feet of the Participant lied flat on the ground. Trunk was in aligned position and the angle between upper body and lower body was 90. Seated position led to caudal tensioning of the pTLF via stretching of the gluteus maximus (GM)~Seated position with passive arms elevation Seated position with passive caudal stretching of TLF through thigh elevation. The subjects had to bend both hips while keeping their feet onto a stool (30 cm high) so to pull the GM and the TLF"
41312743|NCT06310096|OTHER|conventional physiotherapy program.|hotpack, ultrasound ,Tens
41312744|NCT06220630|OTHER|Breast cancer|Male patients who were microscopically diagnosed as primary breast cancer.
41312745|NCT03571321|DRUG|Ruxolitinib|"Participants will receive one of 3 doses \[taken by mouth\] (30 mg, 40 mg, or 50 mg) depending on when they are enrolled to the study.~Remission consolidation regimen:~* Days 1-14 and 29-43~Interim maintenance regimen:~* Days 1-14 and 29-43~Delayed Intensification regimen:~* Days 1-14 and 29-43"
41312746|NCT03571321|DRUG|Cyclophosphamide|"Remission consolidation regimen:~* 1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29~Delayed Intensification regimen:~* 1000 mg/m2 IV on Day 29"
41312747|NCT03571321|DRUG|Cytarabine|"Remission consolidation regimen:~* 75 mg/m2/day IV or subcutaneously (SC) on Days 1-4 (i.e., 4 doses), 8-11, 29-32, and 36-39~Delayed Intensification regimen:~* 75 mg/m2/day IV or SC on Days 29-32 and 36-39"
41312748|NCT03571321|DRUG|Mercaptopurine|"Taken by mouth.~Remission consolidation regimen:~* 60 mg/m2 on Days 1-14 and 29-42~Maintenance Therapy:~* 75 mg/m2 on Days 1-84"
41312749|NCT03571321|DRUG|Vincristine|"Remission consolidation regimen:~* 1.5 mg/m2 (maximum 2 mg) IV once per week on Days 15, 22, 43, and 50~Interim maintenance regimen:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 11, 21, 31, and 41~Delayed Intensification regimen:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 8, 15, 43, and 50~Maintenance Therapy:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 29, and 57"
41312750|NCT03571321|DRUG|Pegaspargase|"Remission consolidation regimen:~* 2500 IU/m2 given by intramuscular (IM) injection or IV on Days 15 and 43~Interim maintenance regimen:~* 2500 IU/m2 IM or IV on Days 2 and 22~Delayed Intensification regimen:~* 2500 IU/m2 IM or IV on Day 4 (OR Day 5 OR Day 6) AND Day 43."
41312751|NCT03571321|DRUG|Rituximab|"For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only.~Remission consolidation regimen:~* 375 mg/m2 IV on Days 1, 8, 29 and 36~Interim maintenance regimen:~* 375 mg/m2 IV on Days 1 and 11~Delayed Intensification regimen:~* 375 mg/m2 IV on Days 1 and 8"
41312752|NCT03571321|DRUG|Methotrexate (Intrathecal Administration)|"Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal \[IT\] administration).~Remission consolidation regimen:~* 15 mg on Days 1, 8, 15, and 22~Interim maintenance regimen:~* 15 mg on Days 1 and 31~Delayed Intensification regimen:~* 15 mg on Days 1, 29, and 36~Maintenance Therapy:~* 15 mg on Day 1~* 15 mg on Day 29 (First 4 courses only)"
41000764|NCT00774631|PROCEDURE|local recommendations and guidelines|"Investigational procedure:~This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.~Controls will receive standard care and will be also be deeply sedated for 48 hours."
41150785|NCT02188784|DRUG|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
41150786|NCT02301117|DRUG|TAS-102|
41150787|NCT05332522|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
41150788|NCT04984980|DRUG|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
41312753|NCT03571321|DRUG|Methotrexate (Intravenous Administration)|"Interim maintenance regimen:~* 100 mg/m2 IV on Days 1, 11, 21, 31, and 41"
41312754|NCT03571321|DRUG|Dexamethasone|"Taken by mouth or given by IV infusion.~Delayed Intensification regimen:~* 10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21~Maintenance Therapy:~* 6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61"
41312755|NCT03571321|DRUG|Doxorubicin|"Delayed Intensification regimen:~* 25 mg/m2 IV on Days 1, 8, 15"
41312756|NCT03571321|DRUG|Thioguanine|"Taken by mouth at least 1 hour after evening meal.~Delayed Intensification regimen:~* 60 mg/m2 on Days 29-42"
41312757|NCT03571321|DRUG|Methotrexate Oral Product|"Taken by mouth.~Maintenance Therapy:~* 20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)~* Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given\]"
41471161|NCT04821752|BEHAVIORAL|Avoidance Education|Reduction of environmental toxins exposure from the diet will be achieved by switching to organic foods. Reduction of residential and occupational exposure to toxins from household cleaning products, cosmetics, personal care products, and other sources will be achieved by switching to safer products or avoidance of the toxic exposure.
41471162|NCT04579315|OTHER|Intervention group; NNRD group|The intervention is a whole food approach, meaning that the participants in the intervention group receives all daily food elements that they should consume
40796122|NCT04185077|DRUG|Bivalirudin|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
40796123|NCT04185077|DRUG|Heparin|a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
40796124|NCT06003192|OTHER|Universal Opt-out HIV Screening|Using a tablet device, offering universal opt-out HIV screening to adolescents seeking care in a pediatric emergency department.
40796125|NCT00383331|DRUG|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
40796126|NCT00383331|DRUG|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
40796127|NCT04442633|DRUG|Glutamine Cap/Tab|Glutamine Capsules: One capsule three times daily on an empty stomach for one month
41000765|NCT04007172|PROCEDURE|neural therapy|Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
41000766|NCT04007172|DEVICE|Physical Therapy|Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
41150789|NCT05955768|PROCEDURE|Disposable cervical dilator stick combined with lidocaine hydrochloride injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing lidocaine hydrochloride. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
41150790|NCT05955768|PROCEDURE|Disposable cervical dilator stick combined with normal saline injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing normal saline. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
41150791|NCT04929483|DRUG|BIO89-100|Subcutaneous injection
41312758|NCT03531333|PROCEDURE|ultrasound guided surgery.|during surgery, the neurosurgeon will acquire ultrasound guided images (fused with the standard neuronavigation system) to evaluate the progress of tumor resection.
41312759|NCT01783717|DRUG|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
41312760|NCT06131125|OTHER|Plyometric training exercises|This includes plyometric training exercises thrice a week for 6 weeks
41312761|NCT06131125|OTHER|Explosive strength training exercises|this includes explosive strength training exercises thrice a week for 6 weeks
41471163|NCT03407612|DEVICE|Continuous Passive Motion|CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.
41471164|NCT06353191|OTHER|Non-Interventional Study|Non-interventional study
41471165|NCT01803269|DRUG|topotecan hydrochloride|Given IV
41471166|NCT01803269|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
41471167|NCT05421273|DEVICE|Spinal cord stimulation using passive recharge burst stimulation|Passive recharge burst is marked by a recharge pattern that passively compensates for charge differences.
41471168|NCT05421273|DEVICE|Spinal cord stimulation using active recharge burst stimulation|Active recharge burst is characterized by negative pulses that directly compensate for charge differences.
40796128|NCT04442633|DRUG|Miconazole Oral gel|Miconazole oral gel: applied three to four times daily for three weeks
40796129|NCT04442633|DRUG|Kenacort in orabase|Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
40796130|NCT01147159|OTHER|Extracts of allergens|Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
41312762|NCT03177980|DRUG|Fentanyl|The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
41312763|NCT03177980|DRUG|Fentanyl and clonidine|In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
41312764|NCT05298696|DRUG|Cilostazol|Cilostazol 100 mg twice daily
41312765|NCT05298696|DRUG|Placebo|Placebo twice daily
41312766|NCT05108519|OTHER|Electronic Health Record Review|Medical records are reviewed
41312767|NCT06013605|BEHAVIORAL|Walking Exercise and Leg Straightening|Participants performed the exercise on the day agreed upon with the researcher. Respondents did walking exercises 3 times per week for 4 weeks with a duration of 10 minutes of warm-up, 30 minutes of walking exercises, and 10 minutes of cooling down. Respondents also did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
41312768|NCT06013605|BEHAVIORAL|Leg Straightening|Respondents did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
41312769|NCT06308640|DEVICE|Insertion of the device intraorally|"* The distalizer appliance will be checked for adaptation intraorally, the two bands of the maxillary first molars will be fitted in their accurate position on the teeth.~* The screw insertion will be carried out with the patient under local anesthesia.~* They will be placed inside the two eyelets of the anterior arms of the screw in the appliance"
41312770|NCT05632627|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to improvements in cognition, TBI-related symptoms, pain, sleep, depression, anxiety, and peripheral markers of inflammation and oxidative stress.
40796131|NCT00682929|DRUG|Inhaled Cannabis|Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
40796132|NCT00682929|DRUG|Oral THC|Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
41000767|NCT04602858|DEVICE|Reactive Balance Training|Reactive balance training involves the use of the Trip and Slip walkway that is able to expose participants to unpredictable trips and slips. Trips and slips will occur at random location on the walkway and times within the gait cycle, with the participants receiving 3-monthly retraining sessions along with an educational booklet.
41000768|NCT04602858|OTHER|Control|The control intervention will be receiving an educational booklet as part of standard care. The education component will target a variety of fall risk factors and provide strategies to mitigate these risk factors.
41000769|NCT05645822|OTHER|Screen&treat|Study participants will be tested with an RDT to prove the presence of antibodies against Trypanosoma brucei gambiense. Should the RDT be positive, they will be offered the 10-day treatment with fexinidazole, and an additional blood sample will be taken for the post hoc confirmation of the disease.
41000770|NCT01076985|DRUG|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
41000771|NCT03011359|OTHER|Optimizing B.I (New) PCA mode|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 6 hr: 1.5 - 3.5 ml, 6-24 hr: 1 - 3 ml, 24 hr \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 3.5 ml (or 0.5 ml).
41150792|NCT04929483|DRUG|Placebo|Subcutaneous injection
41150793|NCT02426424|DEVICE|Watchpat|WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
41000772|NCT03011359|OTHER|Conventional PCA mode|(Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
41000773|NCT02859649|BEHAVIORAL|neuropsychological test|neuropsychological test
41000774|NCT00082433|DRUG|Ixabepilone + Capecitabine|Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
41000775|NCT00082433|DRUG|Capecitabine|Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
41150794|NCT02426424|DEVICE|CPAP|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
41150795|NCT04618575|DRUG|Ursodeoxycholic acid combined with total glucosides of paeony|Ursodeoxycholic acid combined with total glucosides of paeony
41312771|NCT05632627|DRUG|Placebo|Placebo arm
41312772|NCT01104558|DRUG|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
41312773|NCT06063252|BEHAVIORAL|NISMA|"The intervention NISMA is a nine-month intervention and consisted of four individual sessions and two group sessions. The theoretical frame is Social Cognitive Theory, along with Acceptance and Commitment Therapy (ACT), to support the enhancement of self-efficacy. It involves four individual face-to-face sessions with a nurse and two group sessions (5-7 patients) with a nurse, an occupational therapist (OT), and a physiotherapist (PT), with the nurse being the facilitator. Every session has a specific topic and, in every session, a person-centered approach was used to address current problems and secure relevance.~Participants in the control group receive usual care, and the intervention group receives both usual care supplemented with the intervention."
41312774|NCT05178251|PROCEDURE|appendectomy|appendectomy for acute appendicitis
40796133|NCT00682929|DRUG|Oral Placebo|Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
41312775|NCT05210205|DIETARY_SUPPLEMENT|EAA|EAA-enhanced protein snack bars
41312776|NCT05210205|DIETARY_SUPPLEMENT|Energy Dense|Energy dense snack bars (same calories in a smaller volume of food)
41312777|NCT05210205|DIETARY_SUPPLEMENT|Control|Low energy dense snack bars (same calories in a greater volume of food)
41312778|NCT04556617|DRUG|PLX2853|PLX2853 tablets
41312779|NCT04556617|DRUG|Olaparib|Olaparib tablets
41312780|NCT04556617|DRUG|Abiraterone acetate|Abiraterone acetate tablets
41312781|NCT04556617|DRUG|Prednisone|Prednisone (or equivalent) tablets
41312782|NCT03074994|DRUG|Peri-articular TXA (15 mg/kg)|combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL
41312783|NCT03074994|DRUG|Intraarticular TXA 2 g (40 mL)|inject separate from multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 75 mL)
41312784|NCT03074994|PROCEDURE|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area|(Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
41312785|NCT03074994|PROCEDURE|TXA 40 mL inject into intraaricular knee capsule|after multimodal local anesthetic infiltration (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to tourniquet deflation
41312786|NCT05055167|DRUG|Envafolimab|single agent, 300mg Q3W IH until disease progressed
41312787|NCT05075148|OTHER|radiology|Interventional radiology for aneurysmal bone cyst ( percutaneous alcoholization, vascualr embolisation)
40796134|NCT00682929|DRUG|Inhaled placebo|Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
40796135|NCT04633135|DEVICE|Philips stove|Philips Smokeless stove HD4012LS
40796136|NCT04633135|DEVICE|Gyapa stove|Wood stove made in Ghana
40796137|NCT02572297|OTHER|video-EEG|Registration of seizures during video-EEG
41150796|NCT04618575|DRUG|Ursodeoxycholic acid only|Ursodeoxycholic acid only
41150797|NCT02067000|BEHAVIORAL|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
40796138|NCT04570878|PROCEDURE|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
40796139|NCT04570878|PROCEDURE|Control|No regional block is provided at the end of surgery.
41150798|NCT01529372|DEVICE|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
41150799|NCT02159456|OTHER|Continuous enteral feeding via infusion pump|
41150800|NCT02159456|OTHER|Intermittent enteral feeding via gravity-based infusion|
41150801|NCT05274906|OTHER|Randomized, cross-over controlled feeding trial testing a Healthy Eating Index 2015 (HEI-2015) diet with and without red and processed meat|Healthy Eating Index-2015 (HEI-2015) with or without red/processed meat (HEI-2015-M)
41150802|NCT01733199|OTHER|questionnaires|Summons of patients and filling questionnaire.
41150803|NCT05327725|OTHER|Fatigue Reduction Diet|Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol.
41150804|NCT00427544|DRUG|PRA-027|
41150805|NCT02602002|DRUG|Remifentanil|IV
41150806|NCT02602002|DRUG|Placebo|Placebo
41150807|NCT02877745|OTHER|Stratification, no intervention|
41150808|NCT03761849|DRUG|RO7234292|Intrathecal injection
41150809|NCT03761849|DRUG|Placebo|Intrathecal injection
41150810|NCT02465944|DRUG|FFP104|Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
41150811|NCT02465944|DRUG|Placebo|Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
41150812|NCT01113541|DRUG|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
41150813|NCT03341858|OTHER|no intervention-strictly observational|
41150814|NCT00194961|DRUG|Recombinant Human Growth Hormone|
41150815|NCT00865033|DRUG|Metformin HCL Tablets, 1000 mg Sandoz|
41150816|NCT00865033|DRUG|Glucophage 1000 mg|
41150817|NCT06361576|DRUG|Nivolumab|As per product label
41150818|NCT04625023|OTHER|Observational|Retrospective cohorts and Prospective observation of standard clinical practice
41150819|NCT02031055|DRUG|TAS-102 with a light tracer dose of [14C]FTD|A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 μg) of \[14C\]FTD administered as an oral solution on Day 1 (mass balance part)
41150820|NCT02031055|DRUG|TAS-102 with a light tracer dose of [14C] TPI|A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 μg) of \[14C\]TPI administered as an oral solution on Day 1 (mass balance part)
41150821|NCT02031055|DRUG|TAS-102 tablets|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
41150822|NCT03877133|DEVICE|Near-infrared spectroscopy|Regional oxygen saturation probe is applied to the skin near the kidney bilaterally and is connected to the regional oxygen saturation monitor.
41150823|NCT03296007|BEHAVIORAL|Mindfulness Meditation|A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
41150824|NCT04651348|DRUG|Recombinant Humanized Monoclonal Antibody MIL95|"PART A :The patients confirming to the eligibility criteria will be assigned to the 4 dose groups (0.1mg/kg, 0.3mg/kg, 0.8mg/kg, 1.0mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL95 every week on Day 1 for a maximum of Twelve weeks.~PART B:One recommended dose as a priming dose will be selected from 4 dose groups(0.1mg/kg、0.3mg/kg、0.8mg/kg、1.0mg/kg) based on results of PART A. Each patient will receive a priming dose of MIL95 on Day 1 Cycle 1.The patients will be assigned to the 5 maintenance dose groups (3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 45mg/kg, respectively) based on the sequence of inclusion. The maintenance dose was given on Day 8,15,22 Cycle 1 and on Day 1,8,15,22 Cycle 2+. Each cycle was 28 days."
41000776|NCT04352751|OTHER|convalescent plasma|"* Plasmapheresis, 900 - 1000 mL each time.~* Standard apheresis plasma collection protocol using Haemonetics MCS+ intermittent blood flow system or Terumo Optia, Cobe-Spectra, Trima or Fresenius continuous flow system to be used.~* Isovolumic saline replacement should be done.~* Each donor can donate convalescent plasma again after an interval of every 2 weeks"
41000777|NCT03414346|OTHER|Exclusively ice pack|Each subject will receive an experimental intervention of exclusively 500 grams of crushed ice. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
41000778|NCT03414346|OTHER|Ice pack added 10% of water|Each subject will receive an experimental intervention of ice pack added to 50 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
41000779|NCT03414346|OTHER|Ice pack added 100% of water|Each subject will receive an experimental intervention of ice pack added to 500 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
41000780|NCT01861496|DRUG|LiPlaCis|LiPlaCis IV every 3 weeks on day 1, day 8
41000781|NCT01725191|OTHER|Laboratory Biomarker Analysis|Correlative studies
41000782|NCT01725191|OTHER|Pharmacological Study|Correlative studies
41000783|NCT01725191|DRUG|Tivantinib|Given PO
41000784|NCT01719185|DRUG|Phentermine and B12|
41000785|NCT01719185|DRUG|Phentermine|
41000786|NCT01786265|DRUG|Abiraterone Acetate|Given PO
41000787|NCT01786265|DRUG|Bicalutamide|Given PO
41000788|NCT01786265|DRUG|Degarelix|Given via injection
41000789|NCT01786265|DRUG|Flutamide|Given PO
41000790|NCT01786265|DRUG|Goserelin Acetate|Given via injection
41312788|NCT04425772|DRUG|FNC+Standard of Care|FNC + Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
41312789|NCT04425772|DRUG|FNC dummy tablet+Standard of Care|FNC dummy tablet+ Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
41312790|NCT02341118|GENETIC|BRCA genetic data|Two blood samples will be taken which is part of the standard of care. Tumor samples will be obtained from previous biopsy or surgery prior to this study for DNA testing
41312791|NCT00121511|DRUG|Efudex (5-fluorouracil)|
41000791|NCT01786265|DRUG|Leuprolide Acetate|Given via injection
41312792|NCT03664622|DRUG|Ketamine|Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.
41312793|NCT03664622|DRUG|Morphine|a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
41312794|NCT05836363|PROCEDURE|Ascending aorta replacement|The aneurysmatic ascending aorta tract is replaced with a tubular dacron prosthesis
41471169|NCT02676791|DRUG|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
41471170|NCT01584895|BEHAVIORAL|Cardiac Rehabilitation|A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
41471171|NCT04060511|DRUG|HS-10342|HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
41471172|NCT02096822|BEHAVIORAL|Facilitated tucking + non-nutritive sucking|
41000792|NCT01786265|DRUG|Nilutamide|Given PO
41000793|NCT01786265|DRUG|Prednisone|
41000794|NCT04213456|DIETARY_SUPPLEMENT|Nutritional Sport Formula|Powder added to water,high protein and multi vitamins and minerals
41000795|NCT04213456|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
41000796|NCT04686864|BEHAVIORAL|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
41000797|NCT02022228|DRUG|triptorelin|0.2 mg triptorelin, ih
41312795|NCT04901533|PROCEDURE|O-A-A|patient is supine, and the therapist stands on the side to be manipulated. The cranial hand of the therapist globally grasps the patient's skull and turns the patient's neck on that same side. The caudal hand is placed on the patient's face. The technique is performed by an impulse in pure rotation on the side that the cervical region is rotated, with a helical movement.
41312796|NCT04901533|PROCEDURE|cranial listening|The patient is in the supine position, and the therapist sitting at the head of the patient. The therapist places his hands on the head of the patient, the thumbs touch each other, without touching the vault cranial. A perception of the cranial rhythm is carried out passively.
41312797|NCT04568941|BEHAVIORAL|Vacuum-Assisted Biopsy|Vacuum-Assisted Biopsy
41312798|NCT04568941|BEHAVIORAL|Core Needle Biopsy|Core Needle Biopsy
41471173|NCT02096822|OTHER|non-nutritive sucking|
41471174|NCT05089929|DEVICE|Endoflip 2.0|FLIP topography (Endoflip 2.0) analysis will be performed on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.
40796140|NCT04892472|DEVICE|NovoTTF-200T|All patients enrolled in this group will receive TTFields treatment, delivered for at an average of least 18 hours a day using NovoTTF-200T concomitant with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.
41000798|NCT02022228|DRUG|hCG|1000 IU hCG, im
41150825|NCT02919865|DEVICE|MR perfusion imaging|"MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.~Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.~All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery."
41150826|NCT03458494|OTHER|Mediterranean Diet|Participants will receive meals traditionally consumed in Mediterranean countries
40796141|NCT04892472|DRUG|Pembrolizumab (MK-3475) 200 mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
40796142|NCT02821156|DRUG||Inhaled Nitric Oxide with monitoring by EZ-KINOX device
40796143|NCT06386926|OTHER|Electro Therapy|radial shockwave 3 sessions one session per week for four consecutive weeks ,receive Ultrasound phonophoresis using diclofenac Na+ 12 session, 3 sessions per week and conventional physical therapy modalities in the form of 3 sessions every week for 8 weeks
40796144|NCT01138696|OTHER|Questionnaires|KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
40796145|NCT01138696|OTHER|RX|X-rays and clinical investigation of the knee 20 years after surgery
40796146|NCT05656222|DRUG|VIA combination treatment|a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
40796147|NCT06343272|DIETARY_SUPPLEMENT|EAA supplementation|"The experimental group will receive the mixture (Amino-Ther® PRO, Professional Dietetics, Milan) composed of (in mg): L-leucine 1200, l L-isine 900, L-threonine 700, L-isoleucine 600, L-valine 600, L-cystine 150, L histidine 150, L-phenylalanine 100, L-methionine 50, L-tryptophan 50, vitamin B6 0.85, vitamin B1 0.70, citric acid 409, acidomalic 102.5, succinic acid 102.5.~1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days There are: proteins 0.00 g, carbohydrates 2.1 g, fats 0.00 g"
40796148|NCT06343272|OTHER|Isocaloric placebo|The control group will take 25g of maltodextrins daily with the same methods as the treated group: 1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days
40796149|NCT05013021|OTHER|Sprint Interval Training|"The Sprint Interval Training (SIT) training consists of 3 successive blocks of 5 training sessions each. The sessions are 24 to 48 hours apart.~. One block lasts two weeks. After the end of one block, the following block begins the day after.~The Sprint Interval Training lasts 6 weeks.~Each session consists of a series of sprints, the number of which varies from 8 to 14. Thus a session will last from 30 to 45 min approximately~So, the time frame of this study is Baseline, Block 1, Block 2 and Block 3 (Not in day or week or month)"
40796150|NCT02886910|OTHER|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
40796151|NCT02886910|OTHER|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
40796152|NCT01453036|PROCEDURE|23S rRNA point mutation test of Helicobacter pylori|mutation test group\>\> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group \>\> no intervention
40796153|NCT01453036|PROCEDURE|UBT test & Gastroenterology with biopsy c silver stain|UBT test \& Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group \>\> intervention
41000799|NCT02022228|DRUG|hCG|500IU hCG, im
41000800|NCT02377089|DEVICE|Trigeminal Nerve Stimulation|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
41150827|NCT03458494|OTHER|Low-fat diet|Participants will receive meals with a low content of total fat.
41150828|NCT00648271|DRUG|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
41150829|NCT00648271|DRUG|Lopressor® Tablets 50 mg|1x50mg, single dose fed
41312799|NCT04568941|BEHAVIORAL|Intraoperative Excisional Biopsy|Intraoperative Excisional Biopsy
41312800|NCT02200471|DEVICE|VeinViewer|
41312801|NCT00074724|PROCEDURE|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
41312802|NCT00074724|DRUG|Modern medical management|Therapies with evidence-based recommendations.
41312803|NCT00074724|DEVICE|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
41312804|NCT00074724|DRUG|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
41312805|NCT02815293|DRUG|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
41471175|NCT05089929|PROCEDURE|High Resolution Manometry|All patients undergoing routine evaluation for gastroesophageal reflux disease will undergo high resolution manometry (HRM) testing.
41312806|NCT02815293|DRUG|Vehicle|1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
41312807|NCT01160952|DRUG|itraconazole|the two groups are defined by different treatment duration
41000801|NCT02377089|DEVICE|Placebo|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
41000802|NCT03164967|BIOLOGICAL|Bivigam|
41000803|NCT00314236|DEVICE|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
41000804|NCT00314236|PROCEDURE|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
41000805|NCT04659746|DEVICE|MejoraCare|mHealth solution to support remote monitoring of symptoms and patient empowerment through education.
41000806|NCT05164900|PROCEDURE|pterygium excision with sutures fixed conjunctival auto-graft|Pterygium excision with vicryl 8/0 fixed conjunctival auto-graft under local anesthesia. During the follow up period, indicators of ocular irritation were assessed.
41000807|NCT05675553|DEVICE|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, and explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants. The treatment framework is semi-structured through human-computer interaction. The forms of interaction include inquiries, statements, recommendations summaries, and knowledge assessments.
41471176|NCT03870477|DEVICE|THP Hip Fracture Plating System with telescoping lag screws|The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
41150830|NCT02041897|PROCEDURE|EUS-FNA|Only one puncture will be performed. First the fluid will be aspirated out for biochemical analysis and cytology. Then the tissue will be aspirated out from the solid part of the lesion for pathology.
41150831|NCT00098514|DRUG|talotrexin ammonium|
41312808|NCT00647868|DRUG|testosterone|Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
41471177|NCT03925935|BIOLOGICAL|AB-205|Engineered human umbilical vein endothelial cells
41471178|NCT03629028|DIAGNOSTIC_TEST|Residual myometrium thickness|The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
41150832|NCT01837199|DRUG|Metronidazole plus Amoxicillin|All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
41150833|NCT03050372|DEVICE|LFMS - Active|A non-invasive form of brain stimulation administered from a device resembling a bird cage. The device covers the top part of the head for the duration of stimulation (in the current study, 20 minutes)
41312809|NCT00000585|DRUG|penicillin|
41471179|NCT03629028|DIAGNOSTIC_TEST|Niche Presence|The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6 to 9 months by saline infusion sonography.
41471180|NCT03629028|DIAGNOSTIC_TEST|Adjacent myometrium thickness|The myometrium will be closed by single or double layer during cesarean and adjacent myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
41471181|NCT03629028|DIAGNOSTIC_TEST|Niche Measurements (depth of niche, width of niche, length of niche)|The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6 to 9 months by saline infusion sonography.
41471182|NCT00319787|DRUG|Iressa|
41471183|NCT02333188|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
41471184|NCT02333188|DRUG|Leucovorin Calcium|Given IV
41471185|NCT02333188|DRUG|Irinotecan Hydrochloride|Given IV
41471186|NCT02333188|DRUG|Fluorouracil|Given IV
41471187|NCT02333188|OTHER|Laboratory Biomarker Analysis|Correlative studies
41000808|NCT05675553|OTHER|treatment as usual|Both groups will receive treatment as usual, including medication, exercise, and psychological education.
41000809|NCT00899691|GENETIC|protein expression analysis|
41000810|NCT04189458|OTHER|Multimodal exercise program|Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (30 min), cool-down (5 min), and finishing ritual (5 min). At the initial stage, the activation of different muscle groups will be performed. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities and will privilege IPS. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation - physical fitness (strength, balance and agility) - alternating with exercises mainly focused on cognitive stimulation - CF (planning ability, solving-problems, IPS, attention and DT performance). At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants sign an attendance sheet regarding the session, including perceived exertion (Borg Scale) and satisfaction (Caregiver Treatment Satisfaction questionnaire).
41471188|NCT03451604|OTHER|preoperative assessement|All data concerning study, involved in normal care of patient for his anesthesia (non interventional study), where included in anonymous computerized database by anesthesiologist during pre operative clinic.
41471189|NCT04201470|OTHER|Blood withdrawal|Measurement of serum neurofilaments light chain and GFAP
41471190|NCT04201470|OTHER|MRI|Cervical and cerebral MRI without contrast injection
41471191|NCT04201470|OTHER|Neurologic / neuropsychologic tests - Patients|EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)
41471192|NCT04201470|OTHER|Neurologic / neuropsychologic tests - Controls|NHPT, T25FW, CSCT
41471193|NCT06212674|PROCEDURE|PVI + LAAO|Treatment with a complex procedure of PVI + LAAO
41471194|NCT06212674|PROCEDURE|LAAO|Tratment with LAAO procedure
40796154|NCT06354530|DRUG|anlotinib|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: anlotinib 8 mg/day orally (from days 1 to 14 in a 21-day cycle) for 2 cycles"
41312810|NCT03916172|BEHAVIORAL|The Open Door Approach to Parenting Teenagers (APT)|APT works on a one-to-one or couple basis. It offers 6 weekly 50-minute appointments with an optional 7th review session. The practitioners delivering the intervention have qualifications in psychology, or significant experience of working with adolescent populations, and have undertaken training and supervision in the model. Its aim is to help the parent manage the parenting of their teenager more effectively and establish a more balanced relationship by eliciting their views, feelings, and understanding of their teenager and their relationship, discussing their parental identity and role, carefully examining communication, responses, and information giving, and supporting appropriate boundary making. This is achieved through a collaborative development of strategies, psychoeducation and behavioural experiments.
41312811|NCT05012852|DEVICE|VagiVitalAC|In the Pilot part, the single intervention used is VagiVitalAC treatment for 30 days. In the randomized part, patients in the Interventional arm are treated with VagiVital AC for up to 90 days.
41312812|NCT03214692|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
41312813|NCT00283530|PROCEDURE|Tumor biopsy|
41312814|NCT05855928|DIAGNOSTIC_TEST|Mime Therapy|electrical stimulation with the MIME therapy and protocol
41312815|NCT05855928|DIAGNOSTIC_TEST|PNF Technique|electrical stimulation with the PNF technique with the routine physical therapy
41312816|NCT04949906|DRUG|Raise serum brain granules|Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
41312817|NCT04949906|DRUG|No nourishing serum brain granules are used|No nourishing serum brain granules are used
41312818|NCT04436874|DEVICE|endoscopy|transplant infusion of feces from healthy donors into affected subjects
41312819|NCT02586987|DRUG|Selumetinib|Selumetinib oral
41312820|NCT02586987|DRUG|MEDI4736|MEDI4736 IV
41312821|NCT02586987|DRUG|Tremelimumab|Tremelimumab, IV
41312822|NCT06378294|PROCEDURE|Mastectomy|Adjuvant postmastectomy radiotherapy
41471195|NCT06212674|DRUG|NOAC|NOAC treatment
41471196|NCT00891072|DRUG|R-(-)-gossypol acetic acid|Given orally
41471197|NCT00891072|DRUG|paclitaxel|Given IV
41471198|NCT00891072|DRUG|carboplatin|Given IV
41471199|NCT00891072|OTHER|pharmacological study|Correlative studies
41471200|NCT02073136|OTHER|Diet with phosphate containing additives|
41150834|NCT03050372|DEVICE|LFMS - Sham|A simulation of the LFMS-Active intervention, using the same device that produces a sound similar to the sound made by the device during the active treatment, for a similar duration (in the current study, 20 minutes)
41150835|NCT00204100|DEVICE|Surface Functional Electrical Stimulation|
41471201|NCT02073136|OTHER|Diet without phosphate containing additives|
41471202|NCT06361095|BEHAVIORAL|Traditional Attention Bias Modification|Each ABM trial begins with a central fixation cross for 1500ms, followed by a pair of POFA or IAPS stimuli (see Figure 3). POFA pairs will be presented for 3000ms, while IAPS pairs will be presented for 4500ms (due to the increased image complexity of IAPS images relative to POFA images). Longer stimulus duration times were selected based on evidence that attention biases for sad stimuli are prolonged in depression. Following offset of the images, either a single or double asterisk probe appears in the location of one of the images and will remain until a participant response or 10,000ms. In active ABM, the probe had an 80% probability of appearing in the location of the neutral stimulus. Investigators selected 80% rather than 100% to allow for computing attention bias during training and to facilitate task engagement. At the end of each ABM session, participants are provided feedback regarding their task performance relative to their last five sessions in a visual format.
41150836|NCT04653987|PROCEDURE|Percutaneous biliary drainage|
41150837|NCT04909593|DEVICE|Spinal Cord Stimulation|Spinal cord stimulation at varied electrode, pulse width, frequency and amplitude parameters
41312823|NCT06456541|OTHER|Experimental Extensively Hydrolyzed Formula|Experimental powder formula
41000811|NCT05683288|OTHER|IASTM|IASTM will be applied to the upper trapezius and sternocleidomastoid muscles of the participants for 90 seconds, with a frequency of 60 beats per minute.
41150838|NCT00218075|DRUG|Levodopa|
41150839|NCT00218075|DRUG|Carbidopa|
41150840|NCT00218075|BEHAVIORAL|Clinical Management|
41150841|NCT00218075|BEHAVIORAL|Relapse Prevention Therapy|
41150842|NCT00218075|BEHAVIORAL|Contingency Management|
41150843|NCT02545426|OTHER|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
41312824|NCT06456541|OTHER|Placebo Extensively Hydrolyzed Formula|Placebo powder formula
41312825|NCT05673473|RADIATION|scoliosis radiographs|Low dose fluoroscopic imaging technique for scoliosis x-rays
41312826|NCT06283784|OTHER|Yovis Capsules|Subjects will assume the active treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
41312827|NCT06283784|OTHER|Placebo|Subjects will assume the placebo treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
40796155|NCT06354530|RADIATION|Thoracic radiotherapy|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Thoracic radiotherapy RT once daily (from cycle 1 \[C1D1\], 41.4Gy/23Fx, 1.8Gy daily, for 4.6 weeks, 5 days/week)"
40796156|NCT02540512|PROCEDURE|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
40796157|NCT02540512|DEVICE|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
41000812|NCT05683288|OTHER|Myofascial Release|Basic movements will be performed for 3 minutes in the rectus capitis, sternocleidomastoideus, hyoid region and upper trapezius regions.
40796158|NCT02540512|PROCEDURE|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
40796159|NCT02540512|DRUG|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
41000813|NCT05683288|OTHER|250W infrared application|For 15 minutes, 250W infrared application will be applied on the cervical region from a distance of 50 cm
40796160|NCT02540512|DRUG|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
41000814|NCT05683288|DEVICE|TENS|TENS will be applied for 20 minutes at 80Hz frequency, with a current transit time of 150ms.
41000815|NCT05683288|OTHER|Home exercise|Cervical strengthening and stretching exercises five days a week will given
41000816|NCT05804383|DRUG|BMS-984923|Capsules
41000817|NCT05804383|DRUG|Placebo|Capsules
41000818|NCT02508636|DRUG|Enzalutamide|Given orally
40796166|NCT01886235|PROCEDURE|Diagnostic Microscopy|Undergo intravital microscopy
40796167|NCT01886235|DRUG|Fluorescein Sodium Injection|Given IV
41000819|NCT02508636|DRUG|Leuprolide|Given via intramuscular injection
41000820|NCT02508636|RADIATION|Intensity-Modulated Radiation Therapy|A total dose of 45 Gy in 25 fractions of 1.8 Gy each.
41000821|NCT04091503|DRUG|Intranasal Modified Temozolomide|"Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated"
41000822|NCT03995381|OTHER|Decision aids|Shared decision making with decision aids
41000823|NCT01195805|DRUG|Spironolactone|1 tablet twice a day for 28 days
41000824|NCT01195805|OTHER|Placebo|1 tablet twice a day for 28 days
41000825|NCT01195805|DRUG|Amiloride|1 tablet twice a day for 28 days
41000826|NCT06127082|DEVICE|Echocardiography|Do echocardiography to obese patient
41000827|NCT01968018|DRUG|Tramadol HCI/acetaminophen|Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
41000828|NCT01093196|DRUG|Melphalan, Prednisone, Lenalidomide|"Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period \[different doses according to the age of patients (65-75 or \>75 years old);oral Prednisone for 4 days followed by a 24 day rest period.~Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.~ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD)."
41000829|NCT01093196|DRUG|Cyclophosphamide, Prednisone, Lenalidomide|Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period \[day 21 to 28\]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
40796168|NCT01886235|OTHER|Laboratory Biomarker Analysis|Correlative studies
40796169|NCT01886235|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40796170|NCT03614598|PROCEDURE|Insertion of LMA-UNIQUE(TM) device|LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
40796171|NCT03614598|PROCEDURE|Insertion of LMA-SUPREME(TM) device|LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
40796172|NCT03614598|PROCEDURE|Insertion of I-GEL(R) device|I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
40796173|NCT00222755|BEHAVIORAL|Disease Management|Self-management, care management, guidelines
40796174|NCT03901625|DEVICE|Manual Toothbrush|A manual toothbrush is used to clean teeth surfaces.
40796175|NCT03901625|DEVICE|Dental floss|A dental floss is used to clean inter-proximal areas.
40796176|NCT03901625|DEVICE|Waterjet|A waterjet is used to clean inter-proximal areas.
40796177|NCT03901625|DEVICE|Electric Toothbrush|An electric toothbrush is used to clean teeth surfaces.
41150844|NCT00518596|DIETARY_SUPPLEMENT|Probiotic supplementation (Lactobacillus plantarum)|GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
41000830|NCT01093196|DRUG|Lenalidomide, dexamethasone|Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
41000831|NCT03132051|DRUG|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
41000832|NCT04594850|BIOLOGICAL|Cellgram-ED|Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.
40796178|NCT00434993|DRUG|Albuterol Sulfate|"Albuterol sulfate, USP, solution for inhalation will be diluted as follows:~* The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.~* The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
40796179|NCT00434993|PROCEDURE|Mini-Bronchoalveolar Lavage (BAL)|The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
40796180|NCT00434993|DRUG|Placebo|"Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
40796181|NCT06291311|OTHER|Cold physical Plasma|The treatment is administered by either the supervising specialists or assistant doctors at the University Women's Hospital, under their supervision and authorization. It's important to note that the NIPP treatment is designed to be relatively brief, with a duration not exceeding 10-20 minutes.
40796182|NCT06291311|OTHER|Control group|A potential natural healing of the HPV infection will be anticipated
40796183|NCT06285032|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|Individuals will participate in a series of eight, 1hour weekly group sessions delivered by a study interventionalist who is a licensed social worker (see personnel list) using a HIPAA-compliant videoconferencing platform (Zoom). Each group will consist of 6-10 participants and participants randomized to this intervention will select between a series of date/time options. The investigators plan to run four groups with staggered start times. All participants will receive digital copies of the workbook for this intervention and each session, they will be given assignments to practice the strategies they learn during the intervention.
40796184|NCT06285032|BEHAVIORAL|Social Navigation Group|Those in the social navigation intervention, will meet with a navigator weekly through a virtual visit (HIPAA-compliant videoconferencing or phone call based on patient preference) over the course of 8 weeks. Each virtual visit will last approximately 30 minutes with a longer initial intake visit lasting 60 minutes. During the intake visit, the navigator will complete a patient narrative and an inventory of the patient's existing social network, former social network and interests. Using this, the navigator will work with the patient to develop an action plan to promote, establish or re-establish social connections. The action plan will be referenced and refined throughout the course of the 8 weeks. They will suggest specific social activities and connect patients to resources such as, community-based organizations or local social groups matched to individual participant interest to assist with social connection
40796185|NCT06285032|BEHAVIORAL|Controlled Group|Those randomized to the control group will receive usual care from their primary care clinician. At the conclusion of the study (after the final outcomes are collected), they will be offered a list of possible community-based organizations for social connection.
41000833|NCT01424553|OTHER|Prevention and follow-up of the patients pulmonary parameters|Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
41000834|NCT03161483|DRUG|CC-220|CC-220
41000835|NCT03161483|OTHER|Placebo|Placebo QD PO
41017793|NCT01114841|DRUG|Vehicle Foam|"Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
41000836|NCT05832671|PROCEDURE|Erector Spinae muscle block|In the ESB group, the patient will be placed in the lateral position. The site of surgery is upward. After skin preparation using 10% povidone-iodine, a high-frequency linear ultrasound transducer will be placed over the ipsilateral site of surgery 1-2 cm lateral to the spine at the T10 level, counting upward from the sacrum. After identifying the erector spinae muscles and transverse process, a needle will be inserted with an in-plane technique in the craniocaudal direction
40796186|NCT03580538|OTHER|resistive exercise with elastic tube|performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
41000837|NCT05832671|PROCEDURE|caudal block|In the CB group, patients will be placed in a lateral position. An ultrasound transducer is first placed transversely at the midline to obtain a transverse view of the 2 cornua, the sacrococcygeal ligament, sacral bone, and sacral hiatus. At this position, the ultrasound transducer will be twisted to 90° to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the 2 cornua and on visualization of the frog sign (the 2 sacral cornua identified as 2 hyperechoic reverse U-shaped structure) the needle will be inserted into the sacral canal under direct real-time longitudinal visualization. After negative aspiration for blood or cerebrospinal fluid, bupivacaine (0.25%) 2.5 mg/kg will be injected over a one minute period while observing an ultrasound longitudinal image.
40796187|NCT02118454|BEHAVIORAL|Daily IVR Calls Intervention|
40796188|NCT02118454|BEHAVIORAL|Weekly IVR Survey Only|
40796189|NCT03035864|DRUG|rhNGF|Eye Drop 20 μg/mL
40796190|NCT03035864|OTHER|Vehicle|Vehicle Eye Drop
40796191|NCT05257421|DEVICE|shockwave machine|shockwave therapy. 2000 impulses will be applied, 1000 on the TrPs and 1000 surrounding it, with Energy level up to 2,5 bars and frequency of 10Hz
40796192|NCT05257421|OTHER|leg and back exercises|"the exercise program will include 5 exercises that focuses on the back and lower limbs. These exercises are:~* Bridge~* Plank~* Squat~* Push-ups~* Back extension Each exercise will be done for 3-5 sets."
40796193|NCT05257421|COMBINATION_PRODUCT|shockwave and exercises|both types of interventions will be applied for the patient
40796194|NCT00288015|BIOLOGICAL|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
40796195|NCT00002552|BIOLOGICAL|filgrastim|
40796196|NCT00002552|BIOLOGICAL|sargramostim|
40796197|NCT00002552|DRUG|carmustine|
40796198|NCT00002552|DRUG|cyclophosphamide|
40796199|NCT00002552|DRUG|cytarabine|
40796200|NCT00002552|DRUG|etoposide|
41000838|NCT03238911|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
41000839|NCT03238911|DRUG|Ferric carboxymaltose|"Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial.~Ferric carboxymaltose was administered as 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg)."
41000840|NCT01325779|DRUG|heparin|subcutaneous heparin 5000 units every 8 hours
41000841|NCT01325779|DRUG|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
41000842|NCT01024296|DEVICE|Port Close|Device for applying loop suture to close surgical site
41150845|NCT04295499|DEVICE|soft (hydrophilic) contact lens|The intervention is a daily wear soft contact lens
40796201|NCT00002552|DRUG|leucovorin calcium|
40796202|NCT00002552|DRUG|methotrexate|
40796203|NCT00002552|DRUG|perfosfamide|
40796204|NCT00002552|DRUG|therapeutic hydrocortisone|
40796205|NCT00002552|PROCEDURE|allogeneic bone marrow transplantation|
40796206|NCT00002552|PROCEDURE|autologous bone marrow transplantation|
40796207|NCT00002552|PROCEDURE|in vitro-treated bone marrow transplantation|
40796208|NCT00002552|PROCEDURE|peripheral blood stem cell transplantation|
40796209|NCT00002552|PROCEDURE|syngeneic bone marrow transplantation|
40796210|NCT00002552|RADIATION|radiation therapy|
40796211|NCT05831904|DEVICE|whole-body vibration|After attaching the surface electromyography(EMG) to bilateral hip girdle muscles, participants will walk and jump at their comfortable speed. After investigator record the muscle activation values, participants will be asked to stand on the vibration device. While the whole-body vibration is applied, the hip girdle muscles activation values will be recorded accordingly via sEMG.
40796212|NCT03132961|OTHER|Infrasound exposure|All cohorts will receive an identical infrasound exposure of equal time duration, varying only the order in which the testing is performed. To simulate the frequencies generated by a common source of environmental infrasound (wind turbines), recordings measured at a full-scale research wind turbine at the University of Minnesota will be utilized to create an infrasound stimulus. The resultant sound file consists of the fundamental frequency at approximately 0.7 Hz, equal to the blade passage rate, plus the harmonic overtones of the fundamental frequency. The presentation level is 85 dB SPL. The stimulus will be presented in a sound field.
40796213|NCT04536051|BIOLOGICAL|ChAdOx1 nCoV-19 single dose + paracetamol|Single dose of ChAdOx1nCOV19 vaccine, 5x10\^10 vp + paracetamol
40796214|NCT04536051|BIOLOGICAL|MenACWY single dose + paracetamol|Single dose of MenACWY + paracetamol
40796215|NCT04536051|BIOLOGICAL|ChAdOx1 nCoV-19 two dose + paracetamol|Two dose of ChAdOx1 nCoV-19 vaccine, 5x10\^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10\^10 vp), 4-12 weeks apart + paracetamol
40796216|NCT04536051|BIOLOGICAL|MenACWY prime & saline placebo boost + paracetamol|MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol
40796217|NCT03086408|DEVICE|THRIVE|active nasal oxygen delivery system
40796218|NCT03086408|DEVICE|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
40796219|NCT03058198|DIAGNOSTIC_TEST|89Zr-ABT806 PET|Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
40796220|NCT05562557|BEHAVIORAL|Motivational Enhancement|To encourage intrinsic motivation to engage in fatherhood activities
40796221|NCT05562557|BEHAVIORAL|HERO Dads Fatherhood Program|Fatherhood engagement curriculum to increase awareness, knowledge, and skills for parenting and co-parenting
40796222|NCT05562557|BEHAVIORAL|Contingency Management|To reinforce healthy behaviors, including attendance at services
40796223|NCT05562557|BEHAVIORAL|Case Management|Referrals to treatment, social services, and employment services
40796224|NCT00996957|BIOLOGICAL|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
40796225|NCT06235463|OTHER|Osteopathic Pedal Pump|Participants randomized to this condition will receive 5 minutes of myofascial release to the thoracic inlet and 5 minutes of the pedal pump technique.
40796226|NCT06235463|OTHER|Light Touch Treatment|Participants randomized to receive the sham treatment will receive light touch from the operator on the base of the neck and the balls of the feet. This light touch is meant to mimic the pedal pump through touching the same areas of the body but without palpating so that no lymphatic fluid is removed from the lower limbs.
41150846|NCT01810640|PROCEDURE|Percutaneous Liver Biopsy|Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
40796227|NCT06015360|PROCEDURE|Fat Graft|Fat grafting
40796228|NCT04961281|DRUG|Dexmedetomidine|injection of Dexmedetomidine ( 10 microgram/kg) + 10 cc saline injection nearby median nerve as hydro-dissection
41150847|NCT04907877|DIETARY_SUPPLEMENT|Probiotic|Probiotic will be taken 1 time a day before breakfast for 28 days.
41312828|NCT04958616|DIAGNOSTIC_TEST|Skin prick test.|Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive \[9\]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
41312829|NCT01791114|OTHER|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
41312830|NCT01791114|OTHER|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
41312831|NCT01791114|OTHER|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
41312832|NCT01791114|OTHER|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
41312833|NCT01791114|OTHER|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
40796229|NCT04961281|DRUG|Triamcinolone|injection of triamcinolone ( 40 mg) + 10 cc saline injection nearby median nerve as hydro-dissection
40796230|NCT02574767|BEHAVIORAL|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet \& Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
40796231|NCT02574767|DIETARY_SUPPLEMENT|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
40796232|NCT02574767|BEHAVIORAL|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet \& PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
41150848|NCT04907877|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken 1 time a day before breakfast for 28 days.
41150849|NCT05145088|BEHAVIORAL|submaximal exercise testing according to ACSM guidelines|For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate
41312834|NCT01791114|OTHER|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
40796233|NCT02574767|DIETARY_SUPPLEMENT|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
41000843|NCT05128175|DRUG|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
40796234|NCT04667676|DEVICE|acupoint TENS|TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
40796235|NCT03663569|DRUG|Spiolto® Respimat®|Drug
40796236|NCT00078806|DRUG|Etanercept|Administered by subcutaneous injection twice a week
41312835|NCT01791114|OTHER|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
40796237|NCT00078806|DRUG|Placebo|Administered by subcutaneous injection twice a week
40796238|NCT04994639|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
40796239|NCT04383028|PROCEDURE|MELD algorithm use to aid in the planning of SEEG electrode trajectories|"During the routine SEEG planning meetings, the planning of SEEG trajectories, including the number and location of electrodes, will follow the usual clinical pathway and be planned according to the expertise of the attending neurosurgeon, neurophysiologist and neurologist at the multidisciplinary team meeting. Once the trajectories have been planned, anonymised scans for each patient (linked to them via a unique study ID) will be run through the MELD classifier and the top 3 MELD identified lesion clusters will be considered for further implantation.~These top 3 MELD classifier identified clusters will then be merged with the existing clinical plan to assess if each of the clusters are already being sampled by an SEEG electrode. If there is already an electrode in each lesion, no adjustments will be made. If there are clusters that are not being recorded from, and it is technically possible, extra electrodes (up to 3) will be added to record from these additional locations."
41000844|NCT04705285|DEVICE|Erbium Yag Laser|Subjets in the laser arm will undergo 2 sessions of vaginal erbium-yag laser, separated by a month
41000845|NCT04705285|BEHAVIORAL|Pelvic Floor Training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist
41000846|NCT03430804|OTHER|Bishop score calculation of modified Bishop score in numbers by digital vaginal examination|Measurement of cervical length by transvaginal ultrasound and digital examination of Bishop score in 320 parturients undergoing labour induction at term
41000847|NCT00343733|DRUG|OraVescent Fentanyl|
41000848|NCT00125866|BEHAVIORAL|Flavonoid rich or flavonoid depleted chocolate drink|
41312836|NCT01132989|DRUG|Lenalidomide|Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated Creatinine Clearance (by Cockcroft-Gault) Starting Lenalidomide Dose 60 ml/min 25mg daily on Days 1-21 of each 28-day cycle 30 and \< 60 ml/min 10mg daily on Days 1-21 of each 28-day cycle
41000849|NCT05203471|OTHER|integrated care model|The investigators are piloting an integrated care model for rural patients with diabetic foot ulcers. The model uses two tools to promote collaboration between providers: a care algorithm and a referral checklist. The care algorithm will be used by rural primary care providers to guide integrated care addressing glycemic control, vascular disease, wound care, and infection. The referral checklist will be used by rural schedulers who place referrals to urban specialists. It prompts schedulers to fax appropriate supporting documents (e.g. notes, labs, vascular testing results) with the referral request.
41000850|NCT01449578|DRUG|Dexpramipexole|Oral Tablet at varying doses
41312837|NCT06227338|DRUG|Indocyanine green|"Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg)."
41000851|NCT01449578|DRUG|Dexpramipexole Placebo|Oral tablet at varying doses
41312838|NCT04054349|OTHER|Low FODMAP diet|The low FODMAP diet group reduced the intake of FODMAP(fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)
41312839|NCT04202718|DIAGNOSTIC_TEST|VitalPatch Device|The VitalPatch® is an IRB (791130) and FDA approved wearable device that allows for the constant monitoring of biometric measurements and may have utility in the health management of individuals at high-risk for poor health outcomes and in the detection or prevention of adverse events within settings where more traditional telemetry monitoring devices are not currently in use.
41312840|NCT00353496|DRUG|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
41312841|NCT00353496|DRUG|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
41312842|NCT04255784|DEVICE|Active iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
41312843|NCT04255784|DEVICE|Sham iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
41312844|NCT05080959|DRUG|CPL-01|Subjects will receive a single dose
40796240|NCT03053557|BEHAVIORAL|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
40796241|NCT04875455|DEVICE|POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
40796242|NCT01862406|OTHER|Label|Participants were presented with either a generic label or a brand-name label
40796243|NCT05897073|BEHAVIORAL|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
40796244|NCT05897073|BEHAVIORAL|Exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
40796245|NCT05897073|BEHAVIORAL|Time-restricted eating plus exercise intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
40796246|NCT00995098|DIETARY_SUPPLEMENT|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
40796247|NCT00995098|DIETARY_SUPPLEMENT|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
41000852|NCT04113499|PROCEDURE|Direct Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~For endoscopic necrosectomy, in patients allocated to direct endoscopic necrosectomy group, endoscopic necrosectomy is performed during the same session as the index endoscopic drainage. It is performed using a therapeutic gastroscope and various accessories (see below for further details) for 90 to 120 minutes."
41150850|NCT06386575|OTHER|control group; Patients who received physiological saline|All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the control group will be given 40 milliliters of physiological saline during the suprainguinal fascia iliaca block.
41312845|NCT05080959|DRUG|Naropin 150 MG Per 20 ML Injection|Subjects will receive a single dose
41312846|NCT05080959|DRUG|Placebo|Subjects will receive a single dose
41312847|NCT05657704|DRUG|The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype|Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
41312848|NCT02425007|DEVICE|Incentive spirometry|
41312849|NCT03054467|DRUG|Caduet 10Mg-20Mg Tablet|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
41312850|NCT03054467|DRUG|NorvasC® 10 mg Tablets|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
41312851|NCT00296725|DRUG|Fluoxetine|Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.
41312852|NCT00296725|DRUG|Imipramine|Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. \*All increases only if tolerated.
41312853|NCT01830296|DRUG|Remifentanil+morphine|Morphine, Remifentanil+Morphine
41312854|NCT00948818|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
41312855|NCT00948818|DRUG|Matching placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
41312856|NCT04143620|PROCEDURE|Procedure|Triple procedure
41312857|NCT03195855|OTHER|Manual therapy / joint mobilisations|Manual therapy is a common form of treatment employed usually by physiotherapists, in order to help increase range of motion of a specific joint region by restoring the arthrokinematic accessory gliding and rolling movement that is associated with normal joint movement. The hypothesised mechanism of action for this is that improvements of gliding and rolling will normalise osteokinematic rotation and consequently enable the normalisation of active movements. Another possible mechanism of action of mobilisations includes increasing the extensibility of the noncontractile capsular and ligamentous tissues. The effectiveness of passive accessory gliding techniques to increase joint ROM has been widely explored in the literature; with some studies revealing an increase in ankle dorsiflexion and others no change in ankle dorsiflexion. However, the subjects taking part in these studies were people without diabetes and mostly people with ankle sprains or ankle instability.
41471203|NCT06361095|BEHAVIORAL|Gamified Attention Bias Modification|Each trial consists of the fixation stage, facial cue stage, and response stage. At the fixation stage, an image appears (a colorful medallion) for 500 ms. The fixation appears randomly within a fixed rectangular field on the user's smartphone screen, and is always at the midpoint between the two face cues that will appear in the next stage. Next, after the cue disappears, two animated faces appear on the screen, one happy and one sad, with a 1000ms duration. Immediately after they disappear, a target probe (a trail) appears in the location of the happy face cue. The path remains (up to 3 seconds) until participants respond by tracing it starting from the point at which the face cue disappeared. They are instructed to quickly but accurately trace the path with their finger and receive visual and haptic feedback during tracing to indicate they are tracing accurately, followed by the path disappearing.
41471204|NCT06361095|BEHAVIORAL|Sham Attention Bias Modification|Sham attention bias modification designed to match the active ABM condition in all respects except for the shifting attention away from negative stimuli in active attention bias modification.
41471205|NCT04600024|DIAGNOSTIC_TEST|Ultrasound guided diagnostic injection|4 cc lidocaine %2 injection into the piriformis muscle was performed for the diagnosis of piriformis syndrome. It was performed by the ultrasound-guidance to increase the accuracy of the injection.
41471206|NCT04300023|BEHAVIORAL|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
41471207|NCT01295086|DRUG|Docetaxel|42, 51 or 60 mg/m² day 1 every 3. week
40796248|NCT01559337|PROCEDURE|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
40796249|NCT06207552|GENETIC|BBM-F101 injection|The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.
40796250|NCT02474303|DRUG|Truvada|Demonstration Study
41312858|NCT00976950|DRUG|Tipranavir|
40796251|NCT02656966|DEVICE|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
40796252|NCT03343678|DRUG|Venetoclax|Venetoclax given alone and then in combination with BI 836826
40796253|NCT03343678|DRUG|BI 836826|Venetoclax given in combination with BI 836826
40796254|NCT03715725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Administration according to clinical practice
40796255|NCT03715725|DRUG|Apixaban (Eliquis)|Administration according to clinical practice
40796256|NCT03715725|DRUG|Dabigatran etexilate (Pradaxa)|Administration according to clinical practice
41000853|NCT04113499|PROCEDURE|Step-up Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~In patients allocated to the step-up endoscopic interventions group, endoscopic necrosectomy is not performed at the time of the index intervention, however it is performed when clinically indicated during the follow-up period (6 months from index intervention)."
41000854|NCT01787578|DRUG|Sobetirome|50 mcg or 100 mcg once-daily oral
41312859|NCT00976950|DRUG|ritonavir|low-dose
41312860|NCT04007055|DIAGNOSTIC_TEST|Point of care screening for HPR|HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234
41471208|NCT01295086|DRUG|Oxaliplatin|100 mg/m² day 1 every 3. week
41471209|NCT01295086|DRUG|Capecitabine|1250 mg/² continuously
41471210|NCT01295086|DRUG|Trastuzumab|Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
41471211|NCT01836614|DRUG|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
41471212|NCT01731249|BIOLOGICAL|Placebo|10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
41471213|NCT01731249|BIOLOGICAL|Birch pollen allergen extract|Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
41471214|NCT00850226|BEHAVIORAL|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
40796257|NCT03715725|DRUG|Warfarin (Marevan)|Administration according to clinical practice
41000855|NCT01428193|DRUG|Flutamide|Subjects weighing \> 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day.
41000856|NCT01428193|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
41000857|NCT01428193|DRUG|estrace|0.5-1 mg once a day for seven days
41312861|NCT04007055|DRUG|Ticagrelor 90mg|Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
41312862|NCT02095236|BEHAVIORAL|organ motion|Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
41312863|NCT04587453|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to human interleukin-13 (IL-13) and blocks the interaction with IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
41471215|NCT00850226|BEHAVIORAL|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
41471216|NCT05690815|DRUG|Descovy|Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.
41000858|NCT04145895|OTHER|Postoperative activity restrictions|Recommendations for return to full activity including return to school, sports, exercise, etc.
41000859|NCT01924169|DRUG|Lenalidomide|"5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.~If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years."
41150851|NCT06386575|OTHER|suprainguinal fascia block; Patients receiving local anesthetic|All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the sfıb group will be given 40 milliliters of 0.25 % bupivacaine during the suprainguinal fascia iliaca block.
40796258|NCT01679938|BEHAVIORAL|primary obesity prevention|"1. Training of child care providers.~2. Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~3. Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~4. Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
40796259|NCT04414553|BEHAVIORAL|Community Active and Healthy Families|"Community-AHF will consist of eight, semimonthly 2-hour group appointments. Community-AHF sessions will target two areas: 1) Practical information regarding importance of healthy behaviors, and 2) Problem-solving skills to overcome barriers to improving diet and increasing physical activity and other related healthy behaviors. Each session covers specific objectives, includes a number of complementary activities and provides participants with take-home materials to facilitate behavior change.~Community-AHF will be delivered by a nurse and a Community Health Worker (CHW) trained by a consultant nutritionist and study investigators. The CHW will contact families between group sessions to discuss challenges and successes regarding lifestyle changes."
40796260|NCT01574820|DRUG|placebo tablet|placebo tablet for 6 months
41150852|NCT00525200|DRUG|5-Fluoruracil, Cisplatinum|"5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21"
41150853|NCT00525200|DRUG|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
41312864|NCT04587453|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
41150854|NCT01827202|OTHER|RAS blockade discontinuation|In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
41150855|NCT01827202|DRUG|Aliskiren|
41312865|NCT04587453|OTHER|Topical corticosteroids (TCS)|TCS administered as needed.
40796261|NCT01574820|DRUG|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
40796262|NCT02204046|DRUG|BIWA 4|
40796263|NCT02014259|DRUG|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
40796264|NCT00330304|DRUG|Isoniazid|isoniazid 10mg/kg orally, daily, for study period
40796265|NCT00330304|DRUG|Cotrimoxazole|Cotrimoxazole given 3 times a week or daily, orally, for study period
41312866|NCT02517593|GENETIC|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40%).
40796266|NCT00330304|DRUG|isoniazid|Isoniazid, 10mg/kg daily for study period
40796267|NCT00330304|OTHER|placebo|Placebo tablet identicle in appearance to intervention: isoniazid table
40796268|NCT03367403|DRUG|Donanemab|Administered IV
40796269|NCT03367403|DRUG|Placebo|Administered IV
40796270|NCT03367403|DRUG|LY3202626|Administered orally
41150856|NCT01827202|DRUG|Candesartan|
41000860|NCT01924169|BIOLOGICAL|Influenza Vaccine|Administered as injection yearly, during the fall/winter season.
41471217|NCT01765751|PROCEDURE|Manual Cervical Distraction|Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
41312867|NCT04568317|BEHAVIORAL|Space from Depression|This is a 7-module internet-based CBT program. The structure and content of the modules follow evidence-based CBT principles; they are structured to incorporate quizzes, videos, psychoeducational content and interactive tools, personalised homework suggestions and summaries. One of the interactive tools is the mood monitor, where users are encouraged to monitor their mood and reflect on several factors that might had influenced it. Clients are allocated to a psychological wellbeing practitioner (PWP). The PWP is responsible for monitoring and guiding the client's progress throughout the intervention. Over the course of the 8 week supported intervention period, on 6 separate occasions the PWP will review participants progress, leaving feedback for them and responding to the work they have completed. The basic share level allows PWP is to view users' goals for the week, key messages and progress points. Each PWP will provide post-session feedback of between 10 and 15 minutes per session.
41471218|NCT06483737|DRUG|Human albumin infusion at a modified dosage|Participants receive intravenous infusion of human albumin at different dosages according to the serum albumin level.
41471219|NCT06483737|DRUG|Human albumin infusion at a routine dosage|Participants receive intravenous infusion of human albumin according to the current clinical practice.
41471220|NCT06483737|DRUG|Lactulose|All participants will receive standard treatment of overt HE according to the current practice guideline.
41471221|NCT06483737|DRUG|Rifaximin|All participants will receive standard treatment of overt HE according to the current practice guideline.
41471222|NCT06483737|DRUG|Ornithine Aspartate|All participants will receive standard treatment of overt HE according to the current practice guideline.
41471223|NCT06483737|DRUG|Branched-Chain Amino Acids|All participants will receive standard treatment of overt HE according to the current practice guideline.
41471224|NCT06483737|DRUG|Arginine|All participants will receive standard treatment of overt HE according to the current practice guideline.
41471225|NCT06483737|DEVICE|plasma exchange|All participants will receive standard treatment of overt HE according to the current practice guideline.
41471226|NCT03992547|OTHER|Robot-assisted Gait Training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern.
41471227|NCT02283671|BIOLOGICAL|Tolerogenic Dendritic cells loaded with myelin peptides|Somatic-cell therapy medicines application
41471228|NCT04071054|DIAGNOSTIC_TEST|Carnation Ambulatory Monitor (CAM)|7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
41150857|NCT04026022|DRUG|Fentanyl Transdermal System|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.
41000861|NCT01924169|BIOLOGICAL|Pneumovax Vaccine|Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
41150858|NCT04026022|DRUG|Placebo|Placebo plaster in the ER or PACU
41000862|NCT01051128|DEVICE|Prometra Programmable Implantable Pump System|The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
41150859|NCT04787692|BEHAVIORAL|Opioid and Benzodiazepine Naive-patients|Duration of treatment : 1 month Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, Cognitive behavioral therapy(CBT), Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
41312868|NCT04568317|DEVICE|Mood Monitor watch app|"The Mood Monitor watch app will allow in-the-moment self-report of patients' mood and automated monitoring of their sleep and activity level. This data will be integrated into the existing Mood Monitor tool within the participant's Space from Depression program. During the intervention, prompts to record mood data will appear on the watch app; participants will be encourage to choose the frequency and time ranges to receive prompts. The watch app main screen will provide a daily and weekly visualisation of participant's mood, bedtime, hours slept and steps count, and visual cues on their progress. Participants will receive encouragement prompts to reward frequent and consistent self-report of mood over time and a good sleep hygiene. Finally, the app Tips to Stay Well feature will allow participants to go through a list of lifestyle-related tips extracted from the Space from Depression program."
41312869|NCT00923234|DRUG|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
41312870|NCT00923234|DRUG|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
41312871|NCT02910544|DIETARY_SUPPLEMENT|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
41312872|NCT06106633|DEVICE|TriNaV|Assess Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization Via Pressure-Enabled Drug Delivery With the TriNav Infusion System
41312873|NCT06250517|DEVICE|EVLP|The right lung will be perfused for 3h with EVLP
41312874|NCT06250517|DEVICE|Cold preservation|The left lung will be cold preserved as usual protocol
41312875|NCT05194124|DRUG|Setmelanotide 20mg weekly|1:1 randomization in the double blind period, followed by open label
41471229|NCT05850052|OTHER|Conventional direct laryngoscopy using a Macintosh blade|Examine a patient's airway to aid placement of tracheal tube with ease.
40796271|NCT06517368|DEVICE|MRI, Ultrasound|The patients will undergo both B-mode and sonoelastographic examinations in the supine and lateral decubitus position and will perform during breath-holding after deep inspiration. The elastogram was displayed over the B-mode image in a color scale: red (greatest strain, softest tissue component), green (average strain, intermediate tissue component), and blue (no strain, hardest tissue component) Patients will be examined by MRI with diffusion images and ADC values.
41471230|NCT05850052|DEVICE|McGrath videolaryngoscope for rapid sequence endotracheal intubation|Visualize a patient's airway to aid placement of tracheal tube with ease.
40796272|NCT00298298|BIOLOGICAL|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
41150860|NCT04787692|BEHAVIORAL|Opioid and Benzodiazepine Tolerant-patients|Duration of treatment : 6 months Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, CBT, Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
41150861|NCT02005484|DRUG|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
41150864|NCT05697393|DEVICE|Shaker Pressure Band|
41150865|NCT06204237|DRUG|[89Zr]Zr-DFO-APAC|All participants will receive a single i.v. injection of \[89Zr\]Zr-DFO-APAC 15 MBq (Megabecquerel).
41312876|NCT05194124|DRUG|Placebo daily|1:1 randomization in the double blind period
41312877|NCT05194124|DRUG|Setmelanotide 30mg weekly|1:1 randomization in the double blind period, followed by open label
41312878|NCT05194124|DRUG|Setmelanotide 2mg daily|1:1 randomization in the double blind period
41312879|NCT05194124|DRUG|Setmelanotide 3mg daily|1:1 randomization in the double blind period
41312880|NCT05194124|DRUG|Placebo weekly|1:1 randomization in the double blind period
41471231|NCT02295813|BIOLOGICAL|FBF001|
41471232|NCT02295813|DRUG|Placebo|
41150866|NCT06204237|RADIATION|PET/CT scan|The IMP administration will be followed by whole-body PET/CT scanning (day 1), and repeated PET/CT scans on days 3 and 7.
41150867|NCT06136325|PROCEDURE|Obsidian RFP anal fistula surgery|Anal fistula closure with instillation in the fistula tract and the inner ostium of Obsidian RTF®
41150868|NCT02457078|DIETARY_SUPPLEMENT|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
41150869|NCT02457078|DIETARY_SUPPLEMENT|Control Supplement|Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
41471233|NCT02244424|BEHAVIORAL|Tools for Teen Moms|"The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities (challenges) for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life."
41471234|NCT00977431|DRUG|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
41471235|NCT00977431|PROCEDURE|Radiotherapy|Day 1 to day 42
41471236|NCT00977431|DRUG|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
41471237|NCT00977431|PROCEDURE|Radiotherapy|Day 1 to day 42
41312881|NCT05624775|BEHAVIORAL|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will cook and engage virtually (with video and sound on) from their home kitchens via the digital platform. Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($20 per class = $100 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions. Recipes will provide enough food for a family of four. clinic patients
41312882|NCT03162497|DRUG|Azithromycin|Azithromycin 15mg/g eyedrops
41471238|NCT00977431|DRUG|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
41471239|NCT00605917|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration."
41471240|NCT04615312|DRUG|a CDK4 / 6 inhibitor and a MEK inhibitor|Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose
41471241|NCT05162729|BEHAVIORAL|Game-like online working memory training|Participants in the WM group will be receiving two types of WM training tasks (two mini-games) in each session. Half of the training time will be spent on playing a game that requires visual-spatial WM, and the other half of the training time will be spent on playing a game that demands verbal WM. In both the games, the participant is asked to remember the pictures or audios (numbers) presented, and then recall them and select them on the screen.
41471242|NCT05162729|BEHAVIORAL|Game-like online social emotional training|"Participants in the SE group will be also receiving two types of SE training tasks in each session, to match with the ones in the WM training. There are two mini-games for training.~To match with the spatial-visual WM training, participants in the SE group will be asked to first look at a picture that depicts a daily social scenario (i.e., a child who fell down and hurt himself), and then to choose an emotion that the child in the picture may feel from four options of facial emotions displayed on the screen. The other mini-game, with the aim to match with the auditory WM training, will first tell a short story of a social scenario (i.e. David accidentally fell down and got hurt), and then will ask the child to choose the emotion that the character in the story may feel from the four options displayed on the screen. Each mini game lasts for about 7 minutes in each training session."
41471243|NCT02418455|DRUG|UX003|solution for intravenous infusion
41150870|NCT04228068|OTHER|Rehabilitation Program|"PT visits (two visits): The first visit will happen within a week of discharge. During this visit, the PT will assess participants, tailor the program to their needs, and coach them in carrying out the exercises at home. The last visit will be 12 weeks after the first. During this visit, the PT will reassess the participants and make adjustments to the program. The participants will be encouraged to continue exercising beyond the 12 weeks.~The PTA will visit the participants' homes with the PT and will conduct additional solo visits every other week (i.e. 7 PTA visits in total, in 1st week and at 2, 4, 6, 8, 10, and 12 weeks). The PTA will facilitate and progress the exercise program as prescribed and directed by the PT and help in delivering the education component of the program."
41150871|NCT04228068|OTHER|Pain self management|In addition to the exercise program, the intervention group will receive a pain self-management support tailored by the PT to the participants' needs.
41150872|NCT04228068|OTHER|Conventional care|The control group will receive the usual care provided by the healthcare system.
41312883|NCT03162497|DRUG|Doxycycline|Doxycycline 100 mg per os
41471244|NCT04204226|BEHAVIORAL|Social Worker|The social worker will discuss the clinician's recommendations for needed services and how to access the services. The family will be provided the social worker's contact information and be encouraged to reach out with more questions or if more information is needed.
41150873|NCT00100945|DRUG|gefitinib|
41150874|NCT06244888|BEHAVIORAL|Intervention Targeting Stress and Emotion Regulation|This intervention involves learning and practicing relaxation exercises and setting aside time for pleasurable activities.
41312884|NCT00757926|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
41312885|NCT00757926|OTHER|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
41312886|NCT03666975|DEVICE|LIV 30 Hz|LivMD LIV platform
41312887|NCT03360136|BEHAVIORAL|Multi-professional CBT-rehabilitation|"See Detailed description"
40796273|NCT01772550|DEVICE|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
40796274|NCT01772550|DEVICE|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
41000863|NCT04695132|BEHAVIORAL|Illness Management and Recovery treatment programme|The Illness Management and Recovery treatment programme is a psychosocial treatment aimed at attaining illness management skills and promoting a sense of personal recovery amongst patients with serious mental illness. The original treatment protocol has been translated to Swedish and adapted to a forensic mental health setting. The treatment consists of ten chapters containing information and practical exercises relating to topics relevant for mental health and mental health recovery. These topics include medication use, stress reduction, problem solving, recovery goals and navigating the forensic mental health system. Participants are assigned practical homework and tasks to be completed outside of treatment sessions. Group sessions are conducted to present and discuss treatment material. Individual sessions are used to rehearse treatment content, personalize the treatment and review progress in achieving tasks agreed upon in the group setting.
41000864|NCT05369351|DRUG|Standard treatment+mirabegron|In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
41000865|NCT05369351|OTHER|Standard treatment|Standard treatment
41000866|NCT02253212|DEVICE|SonoCloud|SonoCloud : dose escalation
41312888|NCT02787642|DRUG|Olaparib|Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.
41312889|NCT02787642|RADIATION|Concomitant Radiotherapy|Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
41312890|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) low dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) low dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
41000867|NCT02253212|DRUG|Carboplatin|Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
41000868|NCT02908113|BEHAVIORAL|collection data|
41000869|NCT02908113|BEHAVIORAL|IRM|
41000870|NCT02800330|DRUG|Esomeprazole 40mg concomitantly|During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
41000871|NCT02800330|DRUG|Esomeprazole 40mg before|During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
41000872|NCT02800330|DRUG|Regorafenib 160mg or 120mg|Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
41000873|NCT06123546|OTHER|Patient oriented discharge summary|"The intervention consists of three components: the patient-oriented discharge summary (PODS), the teach-back technique and the involvement of caregivers.~The PODS will be completed with participants over the course of the hospitalisation as teaching content related to the six sections of information is delivered. Participants will take the PODS home at discharge to use it as a reference for relevant and individualized discharge information in the post-discharge period.~Healthcare providers will receive a training refresher on the teach-back technique and will be reminded to use it when they deliver discharge teaching during participants' hospital stay.~Involvement of caregivers will include early identification by the healthcare provider responsible for patient admission of a caregiver who will provide care at home, at least one teaching session during hospitalization and the review of the PODS the day of discharge."
41000874|NCT03342664|DEVICE|Artemis + Medical Management|Subject will receive best MM in addition to the MIS procedure with Artemis.
41000875|NCT03342664|OTHER|Best Medical Management Alone (MM)|Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.
41000876|NCT03037788|DRUG|WO3979|Application of cream to each axilla
41312891|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) middle dose formulation vaccine|2 doses of 0.15 ml each of RSV (GSK3389245A) middle dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
41312892|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) high dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) high dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
41312893|NCT02927873|DRUG|Placebo|2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
41000877|NCT03037788|DRUG|WO3970|Application of cream to each axilla
41000878|NCT03037788|DRUG|WO3992|Application of cream to each axilla
41000879|NCT03037788|DRUG|Placebo (WO3988)|Application of cream to each axilla
41000880|NCT01749579|DRUG|Propofol|Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
41312896|NCT03365479|DRUG|Iloprost|Single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
41312897|NCT00679731|DRUG|ABT-874|200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
41312898|NCT00679731|DRUG|Methotrexate|5.0 to 25 mg weekly
41312899|NCT06376266|COMBINATION_PRODUCT|nutritional supplements|a daily supplement of branched-chain amino acids combined with medium-chain triglycerides
41312900|NCT05912309|BEHAVIORAL|Time Restricted Eating (TRE)|Participants will be required to reduce their eating time window to ≤ 8 hours/day. Women can choose when to begin eating, but the last meal should be completed before or at 20:00 hours (concentrating the eating window towards the active phase confers higher cardiometabolic health benefits). Our preliminary results suggest that this eating window is feasible and safe. Participants will receive dietary advice regarding the daily amount of high quality protein and meal-specific protein quantities. All the participants will attend a lifestyle education program based on Mediterranean diet and WHO physical activity recommendations every two weeks.
41312901|NCT05912309|BEHAVIORAL|Exercise|Sport sciences specialists will design, supervise and monitor the concurrent exercise intervention following the 2020 WHO recommendations. The program will be tailored to the participant's ability and health, and will be focused on a gradual increase to levels that are safe. Resistance training: 3 times/week designed to manage, attenuate and even prevent the loss of skeletal muscle tissue and function. The exercise sessions will be scheduled within or immediately after their eating window in order to maximize muscular muscle protein synthesis. Morning and afternoon training schedules will be offered to participants.
41471245|NCT04204226|BEHAVIORAL|Autism Behavioral Health Navigation (ABHN)|The goal of the ABHN intervention is to ensure access to recommended community behavioral health services, decrease parent stress levels, and/or improve child sleep and activity levels in order to reduce disruptive behaviors. Navigators will check-in at least weekly by telephone, email, or text message (as per family preference) during the first 4 weeks of the intervention and at least every 2 weeks for the remainder of the intervention or until ABHN and family agree that all goals and action steps in the Family Care Plan are completed.
41471246|NCT04204226|BEHAVIORAL|Social work + ABHN|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN
41471247|NCT04204226|BEHAVIORAL|Social work + ABHN + CAP|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN+Complex Autism Program (CAP)
41471248|NCT02083419|DEVICE|LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
41000881|NCT01749579|DRUG|Midazolam|Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
41000882|NCT01749579|DRUG|Fentanyl|Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
41000883|NCT00969293|DRUG|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."
41000884|NCT02663635|DEVICE|Safe'N'Sound|
41000885|NCT03533062|DRUG|botulinum toxin A|botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months
41000886|NCT01939587|DRUG|PBF-680 5 mg|
41150875|NCT06244888|BEHAVIORAL|Intervention Targeting Motivation and Self-efficacy for Weight Management|This intervention involves identifying values related to weight, lifestyle, and health; identifying barriers to value-consistent living; exploring the consequences of letting barriers drive behavior; and 4) setting goals that are small, specific, attainable, and values-consistent.
41312902|NCT05912309|BEHAVIORAL|Caloric Restriction|Individualised intensive behavioural intervention weight loss program including CR, exercise training and lifestyle education designed according to the current guidelines. CR will be tailored to participants (objectively assessed). Diet will provide 600 kcal/day less than the individual energy requirements based on measured resting energy expenditure (indirect calorimetry) and multiplied by an activity factor obtained by accelerometry. Experienced nutritionists will design personalized and balanced CR diet, and will train the participants through the food exchange system to follow the treatment. In those cases in which the CR compromised a protein intake of at least 1.2 g/kg/day, the macronutrient percentage distribution will be modified prioritizing achieving this minimum protein intake.
41312903|NCT04134585|OTHER|semi-structured interviews|Semi-structured interviews will be performed to determine representations of physical activity, reluctance/motivation to participate in physical activity sessions and facilitators who can help them overcome these barriers.
41312904|NCT05390424|DIAGNOSTIC_TEST|Blood collection using Dried Blood Spot|Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
41000887|NCT01939587|DRUG|PBF-680 20 mg|
41000888|NCT01939587|DRUG|Placebo|
41000889|NCT02659020|DRUG|Olaratumab|Administered IV
41000890|NCT02659020|DRUG|Gemcitabine|Administered IV
41150876|NCT06244888|BEHAVIORAL|Intervention for Normalization of Eating|This intervention involves dietary self-monitoring with the goal of staying within a calorie goal ranging from 1,200 kcal/day to 1,800 kcal/day. Participants are also provided with meal planning tools and encouraged to addresses hunger and cravings by promoting feelings of satiety via consumption of foods that are high in volume but low in calories.
41000891|NCT02659020|DRUG|Docetaxel|Administered IV
41000892|NCT02659020|DRUG|Placebo|Administered IV
41000893|NCT02188576|DRUG|high dose TXA|
41000894|NCT02188576|DRUG|Low dose TXA|
41312905|NCT05251454|PROCEDURE|Brain Stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase).
41312906|NCT04144452|OTHER|Patient Education Session|The intervention of Patient Education will be designed individually according to the patient's need who have undergone lumbar microdiscectomy procedure through MIS. The basic purpose of the educational session will be to inform the participants about their pre operative and current back condition and discuss methods to care for their back. The session will be given for one hour and face to face interaction will be ensured twice a week. Initially the post operative education plan and instructions will be formulated, reviewed and finalized by the operating surgeon.
41150877|NCT06244888|BEHAVIORAL|Intervention Targeting Physical Activity and Sleep|This simple intervention prompts participants at the start of the day to schedule up to 30 minutes of moderate-to-vigorous intensity physical activity; brisk walking is encouraged. Participants also set a bedtime and wake time and are encouraged to set a reminder alarm to ensure at least 8 hours of sleep.
41312907|NCT04144452|OTHER|Therapeutic Exercise plus educational session|Therapeutic exercises include strength and endurance training and mat exercises. Strengthening exercises of the trunk extensors will be initiated first and then endurance exercises will be targeted. Mat exercises will be performed to strengthen the back and lower musculature. Treatment will be given twice a week for almost three months. Individualized educational sessions will be performed in the same way as conducted in the other group. Progression of the exercises and the rest periods will be incorporated according to the status of patient.
41312908|NCT06089161|OTHER|Standard of Care|Participants in this group will receive standard of care treatment for sleep apnea.
41312909|NCT06089161|BEHAVIORAL|Personalized OSA Treatment|Participants in this group will receive standard of care treatment plus the personalized treatment that consists of videos approximately three minutes long, virtual, accessed through web based application, that the participant watches weekly. The purpose of the video is tailored educational content for sleep apnea.
41471249|NCT00642421|DRUG|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
41471250|NCT00642421|DRUG|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
41471251|NCT06461793|RADIATION|Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients|this researcher performed biodegradable material injection during radical radiotherapy in combination with hormone therapy in high - risk prostate cancer patients. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
41471252|NCT02118168|OTHER|No intervention|No intervention is foreseen in this Observational Study
41471253|NCT01196117|DEVICE|14 days of placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
41471254|NCT01196117|DEVICE|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
41471255|NCT05939804|DEVICE|TENS|TENS will be applied to the experimental group on the 0th and 1st days after the surgery, and the pain assessment at the time of movement/rest before and after the procedure will be made by the researcher.
41471256|NCT06416852|DRUG|18F-Alfatide Injection|A single dose of (0.1\~0.15）±0.015 mCi/kg IV injection of 18F-Alfatide. The patients will be intravenously injected with 18F-Alfatide Injection and undergo PET/CT scan at 60 min±10 min after the injection.
41000895|NCT04859868|DEVICE|Galvanic Vestibular Stimulation|Low electrical currents to the vestibular system, to induce the realistic sensation of motion (i.e., the g-forces that occur during flight) as well as null out motion perception.
41000896|NCT06290310|DEVICE|EIT|continuous electric impedance tomography measurement
41150878|NCT00525915|DRUG|5-Fluorouracil|"Arm A = 250 mg/m\^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m\^2 IV over 48 hours on days 1 and 15."
41150879|NCT00525915|DRUG|Oxaliplatin|"Arm A: 40 mg/m\^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m\^2 IV on Day 1 and 15"
41150880|NCT00525915|RADIATION|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
41150881|NCT00525915|PROCEDURE|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
41150882|NCT03424187|DIETARY_SUPPLEMENT|chickpea|"all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea"
41150883|NCT03894033|DEVICE|Ascyrus Medical Dissection Stent (AMDS)|The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
41000897|NCT06290310|DEVICE|patient-ventilator asynchrony assessment|patient-ventilator asynchrony assessment by flow/time curve and machine learning
41000898|NCT00038922|DRUG|rhIL-11|
41000899|NCT04648865|DRUG|LY3537031|Administered SC.
41000900|NCT04648865|DRUG|Placebo|Administered SC.
41000901|NCT00199290|DRUG|Trafermin (genetical recombination)|
41312910|NCT01561560|DEVICE|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
41312911|NCT01561560|DEVICE|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
41312912|NCT05574335|DRUG|Siplizumab|Weekly siplizumab doses for a total of 12 weeks
41312913|NCT01051986|PROCEDURE|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
41312914|NCT01051986|PROCEDURE|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
41312915|NCT00000639|DRUG|Itraconazole|
41312916|NCT00000639|DRUG|Flucytosine|
41312917|NCT00000639|DRUG|Fluconazole|
41312918|NCT00000639|DRUG|Amphotericin B|
41312919|NCT03911336|DRUG|Group A - test:Tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
41312920|NCT03911336|DRUG|Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
41312921|NCT03911336|DRUG|Group C - Control 2: tooth extraction and intake of a Non-Nsaid|Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
41312922|NCT05098158|OTHER|Non-pharmacological pain treatment|Participant selects from telehealth consultation on massage therapy, yoga therapy, chiropractic and physical therapies.
41312923|NCT06243341|DIETARY_SUPPLEMENT|Lepidium meyenii (MACA)|The MACA supplement is derived from a concentrated 6:1 blend of black, red, and yellow MACA root compounds, with an 80:15:5 ratio respectively.
41312924|NCT00377611|BIOLOGICAL|Fluarix™|
41150884|NCT04288414|DIAGNOSTIC_TEST|functional near-infrared spectroscopy|Functional near-infrared spectroscopy (fNIRS) is a non-invasive method that can evaluate the brain function by measuring the change in brain metabolic activity and hemodynamics during a given task with near-infrared spectroscopy.
41150885|NCT00237718|DRUG|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
41150886|NCT00237718|DRUG|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
41150887|NCT00237718|DRUG|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
41150888|NCT00237718|DRUG|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
41150889|NCT06538727|OTHER|Osteopathic Manipulation Treatment - Scapular Release|First, the patient will be positioned in the supine position. The physician or trained fellow will then place his/her hands on the medial border of the scapula on the affected side. From the paraspinal fascia to the medial border of the scapula a lateral traction is added along with a superior to inferior traction and additionally an inferior to superior traction. The shoulder will be used as an additional fulcrum by having the shoulder in the forward flexion position at 90 degrees and then adduction of the humerus to aid in addition movement of the scapula by moving the upper arm into adduction and abduction in a rhythmic motion. The treatment with a rhythmic and/or static traction in the motions described above and manual movement of the scapula will be done for a maximum of 15 minutes.
41150890|NCT05879822|DRUG|INCB099280|Administered as specified in the treatment arm description
41150891|NCT05222178|DRUG|HMI-103|HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
41150892|NCT01982266|DEVICE|GRADION™ Hip Total Cartilage Replacement (TCR)™|
41150893|NCT01176747|DRUG|BDP/formoterol NEXT DPI|Single inhalation of radiolabelled BDP/formoterol 100/6 µg NEXT DPI (4 puffs giving a total dose of 400 µg BDP + 24 µg formoterol)
41150894|NCT04287361|OTHER|Efficacy of intravenous clonazepam|Efficacy of intravenous clonazepam
41150895|NCT00612521|DRUG|Adenosine|For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
41150896|NCT03656926|DRUG|Liposomal Cyclosporine A|This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
41150897|NCT03656926|DRUG|Standard of Care|Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator
41150898|NCT05820542|OTHER|miller laryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
41150899|NCT05820542|OTHER|McGrath MAC videolaryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
41150900|NCT04468607|DRUG|BLYG8824A|BLYG8824A will be administered at a flat dose independent of body weight.
41312925|NCT06188559|DRUG|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).
41312926|NCT05552534|OTHER|STIR PROTOCOL|"Screening, STIR protocol (screening, brief intervention, incentive to download the tobacco info service application, delivery of the tobacco-info-service brochure, initiation of a nicotine patch made by the trained emergency nurse or doctor) then three consultations face-to-face or remotely with a member of the team addictionology at 7 days, 1 and 3 months."
41312927|NCT00027456|DRUG|Leptin A-100|
41312928|NCT03649321|DRUG|Bemcentinib|200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
41312929|NCT03649321|DRUG|Nab-paclitaxel|25 mg/m\^2 Day 1 /8 every 21 days or 28 days.
41471257|NCT06416852|DRUG|18F-FDG Injection|A single dose of 5～10mCi IV injection of 18F-FDG. The patients will be intravenously injected with 18F-FDG Injection and undergo PET/CT scan at 40 min±10 min after the injection.
41471258|NCT05650086|DEVICE|Thermalytix|One-time Thermal imaging is performed for this cohort.
41471259|NCT00004150|DRUG|fluorouracil|
40796275|NCT04531956|OTHER|Diagnostic decision aid s-decided|The intervention will consist of implementing a patient decision aid (PtDA) in general practice. The patient decision aid will be developed in line with the systematic development process specified by the International Patient Decision Aids Standards (IPDAS)
40796276|NCT02158767|BIOLOGICAL|Allogenic T cell-depleted hematopoietic stem cell transplantation|Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells
41471260|NCT00004150|DRUG|leucovorin calcium|
41471261|NCT00004150|PROCEDURE|adjuvant therapy|
40796277|NCT00705874|DRUG|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
40796278|NCT00705874|DRUG|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
41000902|NCT00797082|DEVICE|MRI|MRI = Myocardial Perfusion Stress
41000903|NCT00797082|DEVICE|MPS|MPS = Myocardial Perfusion Scintigraphy
41000904|NCT01220271|DRUG|LY2157299|Administered orally
41312930|NCT03649321|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days
41312931|NCT03649321|DRUG|Cisplatin|Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days
41471262|NCT05684224|BEHAVIORAL|Dynamic accommodation|Dynamic accommodation will be tracked using the Tobii Glasses
41471263|NCT05631535|OTHER|Intensive lifestyle change program with a very-low-energy diet|The intervention will consist of two phases. In the first phase, the participants receive weekly visits for two months. During these visits, a nutritionist will take the participants' weight and abdominal circumference measurements, and each one will receive a meal plan with a very low-energy diet (800 kcal/d). The second phase will implement in the third and fourth months, and nutritional counseling will continue to be provided every week in the third and biweekly in the fourth month. In this second phase, a gradual reintroduction to low-energy dietary meal plans (1200-1800 kcal/d) will perform. In addition, a specially adapted Diabetes Prevention Program for a very low-energy diet will implement.
41471264|NCT05631535|OTHER|Intensive lifestyle change program with a low-energy diet|The structure (frequency of nutritional counseling, number of sessions, time of sessions, etc.) in this group will be the same as that of the intervention group, and a modified Diabetes Prevention Program will also provide. From the beginning of the study will recommend meal plans with a low-energy diet (1200-1800 kcal).
41471265|NCT00512837|BEHAVIORAL|Mobile phone technology|
41471266|NCT04227938|DRUG|ALPN-101|A single dose of ALPN-101 will be administered via intravenous infusion.
41312932|NCT04755712|DRUG|Rachianesthesia|Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
41312933|NCT04755712|DRUG|Sodium Chloride Injection|"Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2)."
41312934|NCT04755712|DRUG|Morphine|Morphine via pump (patient controlled analgesia)
41312935|NCT04343313|DEVICE|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
41471267|NCT04532177|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|fractionated linear accelerator based SBRT to 40 Gy in 5 fractions
41471268|NCT06616207|DRUG|Placebo|Placebo (Double distilled water matched in color and taste) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
41471269|NCT06616207|DRUG|Povidone-iodine solution|Povidone-iodine solution will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
41471270|NCT06298318|OTHER|vodka|1g/kg body weight
41471271|NCT06298318|OTHER|water|equal amount of non-alcoholic beverages with the same taste and colour but without alcohol
41471272|NCT05704972|OTHER|the operating room environment risk|in determining the risks they face in the operating room environment.
41471273|NCT06617390|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
40796279|NCT00705874|DRUG|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
40796280|NCT00705874|DRUG|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
41000905|NCT01220271|DRUG|Radiation|Administered as approved
41000906|NCT01220271|DRUG|Temozolomide|Administered orally
41000907|NCT04349722|DRUG|Hyoscine Butylbromide|Intervention is given once a participant is in established labor
41000908|NCT04349722|OTHER|Placebo|Intervention is given once a participant is in established labor
41000909|NCT05513378|DEVICE|Needle guide|Please see the arm/group description
41000910|NCT05504629|BEHAVIORAL|Concurrent training order 1|atag
41471274|NCT02230111|BEHAVIORAL|Energy restriction plus CDR|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.
41471275|NCT02230111|BEHAVIORAL|Energy restriction without CDR|Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
41471276|NCT00523289|DRUG|Bupivacaine|Dosage: 150mg at once for anesthesia induction
41471277|NCT00523289|DRUG|Ropivacaine|Single dose of ropivacaine, 150mg
41471278|NCT06614959|DEVICE|Oscillatory Positive Expiratory Pressure (OPEP) Therapy|The smart OPEP device is a standard OPEP device equipped with an additional detachable sensor that collects diagnostic information on the total elapsed time of OPEP use, the pressure generated during use, frequency and amplitude of pressure oscillations, respiratory information (inhalations/exhalation number/time), and sum of all oscillations with a pressure over 1 centimeter of water (cmH2O), all of which will inform the duration and quality of home use.
41471279|NCT01044394|DRUG|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
41471280|NCT05871606|DRUG|iNO|Inhaled Nitrous Oxide
41312936|NCT05071560|OTHER|Combined exercise training|"Before the intervention, these women will undergo an evaluation of cardiorespiratory fitness, functional fitness, psychological status and a physiatry assessment. A consent form is signed before the start.~The physical exercise intervention was planned based on the recommendations of the American College of Sports Medicine for cancer survivors (ACSM 2019), with two supervised combined training sessions (mobility, aerobic training, strength and flexibility training) planned, and one unsupervised aerobic training session per week, interspersed with at least one rest day in between, for 8 weeks. The intensity will be individualized and defined based on the initial assessment. The structure of the training plan was based on the FITT-VP principles (frequency, intensity, time, type, volume and progression) recommended by the ACSM (2019)."
41471281|NCT01758146|DRUG|Tamoxifen|20 mg once daily for 5 years
41312937|NCT02860845|DEVICE|Boric acid and probiotics|Vaginal capsules administered once a day during 7 days.
41471282|NCT01758146|DRUG|Letrozole|Letroz, Femara, Letronat
41312938|NCT02860845|DRUG|Antibiotic (Clindamycin)|Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
41312939|NCT02860845|DRUG|Antifungal (Clotrimazole)|Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.
41312940|NCT04533958|DEVICE|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
41312941|NCT05338957|DRUG|MRG002+HX008|Administrated intravenously
41471283|NCT06004180|DRUG|Lu AF28996|Hard capsule, orally, per schedule specified in the arm description.
41471284|NCT05424133|OTHER|High frequency chest wall oscillation|High frequency chest wall oscillations at 13-15Hz oscillating frequency for 20 minutes twice a day for 4 weeks.
41471285|NCT05424133|OTHER|Active cycle of breathing|Active cycle of breathing technique and it will performed twice a day for 4 week intervention period for 20 minutes
41471286|NCT05589038|OTHER|Baby Wash/Shampoo|Parent participant will bathe the baby participant with the baby wash/shampoo at least 3 times per week, but no more than once daily.
41471287|NCT05589038|OTHER|Baby Lotion|Parent participant will use the baby lotion on baby participants at least once daily.
41471288|NCT06132620|DRUG|Femoston|"Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment."
41471289|NCT06132620|DRUG|Qingxin Zishen Decoction|Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
41471290|NCT01216098|BEHAVIORAL|Doula support|A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
41471291|NCT05838456|DEVICE|Viz.AI software|Viz.AI software performs artificial intelligence-based automated detection of large vessel occlusions and alerts the AIS care team.
41471292|NCT02574715|DRUG|Levonorgestrel (Jaydess, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
41471293|NCT05352282|PROCEDURE|Serratus Anterior Plane Block|SAPB will be done preoperative before induction of anesthesia under songraphic guidance and aseptic conditions with the patient in the lateral position, with the side of the surgical side up and the upper limb hanging over the patient's head. The ribs will be then counted, and when the 5th rib is identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane. The ribs, pleura, overlying serratus muscle and latissimus dorsi muscle will be identified, and the needle will be advanced cephalic in-plane until the tip reaches the plane between the serratus anterior and latissimus dorsi. Afterward, 2 mL dextrose 5% will be injected; then, 30 mL of bupivacaine 0.25% will be injected in the plane between the serratus anterior and latissimus dorsi.
41000911|NCT05504629|BEHAVIORAL|RT+ET|aetaer
41000912|NCT05016388|OTHER|Collaborative Multidimensional Model (CMD)|The teams enrolled in the CMD intervention will have a 22-hour training that integrates current knowledge of depression with skills for the management of functional variables, interpersonal, social, emotional regulation, and history of biographical adversity from childhood considering the trauma informed care paradigm. After the training, the PHC teams will implement the depression treatment according to a collaborative model.
41312942|NCT04752124|OTHER|Exercise Therapy|High intensity speed based interval treadmill training
41000913|NCT05016388|OTHER|Standard Model (SM)|The teams enrolled in the SM intervention will have a 22-hour training that integrates the current national clinical guide for Depression in Chile. This guide offers a staggered treatment according to the severity of the depression. After the training, the PHC teams will implement the depression treatment according to the SM.
41000914|NCT03367312|DRUG|Hyperpolarized 129Xenon gas|Hyperpolarized 129Xenon gas XeMRI scans will provide 3D images of ventilation and gas exchange pre, post, and 2-4 hours post inhaled prostacyclin treatment. Subjects will inhale HP 129Xe from the dose delivery bags with each scan and then move into the scanner and undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will undergo several MRI scans after inhalation of HPXe. This will occur as three scans at the three different time points (pre, post, and 2-4 hours post) of inhaled prostacyclin treatment.
41000915|NCT04090593|OTHER|Patient Education 101: Mobile Health Education Tool|Intervention is interactive, mobile (tablet-or-smart-phone delivered), educational module that patients engage with during hospital admission.
41000916|NCT02787252|DEVICE|Implant procedure, Freedom Spinal Cord Stimulation System|A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
41312943|NCT04752124|OTHER|conventional therapy|conventional physical therapy
41312944|NCT04163640|OTHER|intra-ovarian platelet rich plasma injection|patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
41312945|NCT05243394|OTHER|Gamified virtual reality treadmill gait training with tDCS|Progressive treadmill gait training in a gamified virtual reality environment with tDCS
41000917|NCT00326664|DRUG|Cediranib Maleate|Given orally
41471294|NCT05352282|PROCEDURE|Lumbar Intrathecal Fentanyl Injection|Patients will receive 25 microgram intracthecal fentanyl immediately preoperative.
41471295|NCT06214611|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy in the head and neck region
41471296|NCT01021267|DRUG|Saw palmetto berry extract|1x daily 1 capsule containing 320mg lipophilic extract
41471297|NCT00811434|DRUG|Lactulose|1.5cc/kg/day po for three months
41471298|NCT00811434|DRUG|placebo|1.5 ml sugar water/kg day for three months
41471299|NCT02617641|BEHAVIORAL|TAVIEenM@RCHE|The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
41471300|NCT02617641|BEHAVIORAL|Publicly available websites|"* Le Programme de marche (Institut de Cardiologie de Montréal)~* L'activité physique (Institut de Cardiologie de Montréal)~* L'activité physique (Fondation des maladies du cœur et de l'AVC)~* Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)~* Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)"
41471301|NCT00734942|OTHER|support service|"* professional partners for communication~* befriending with other families concerned~* information and education (about illness, symptoms, first aid, caring)~* free-time activities and time out~* homework assistance~* administrative advise~* support for everyday life"
41471302|NCT01470196|DRUG|Dexamethasone|20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
41000918|NCT03588481|DEVICE|DESyne X2|Novolimus-eluting stent
41000919|NCT05440292|DEVICE|Transcranial magnetic stimulation|For each stimulation day, low-frequency (1 Hz) ,1800 pulses(intensity of 100% resting motor threshold(RMT), duration 30 min) rTMS stimulation were delivered on the hotspot of unaffected hemisphere(Hotspot-rTMS Group) and the motor task activation poin of unaffected hemisphere(fMRI-rTMS Group). rTMS which guided by individualized navigation delivery 5 days a week for 4 weeks.
41000920|NCT01686646|DRUG|paracetamol + caffeine|paracetamol with caffeine
41000921|NCT01686646|DRUG|paracetamol|paracetamol
41312946|NCT05243394|OTHER|Gamified virtual reality treadmill gait training|Progressive treadmill gait training in a gamified virtual reality environment
41312947|NCT05243394|OTHER|Treadmill gait training|Progressive treadmill gait training
41312948|NCT05997017|DRUG|nab-sirolimus|Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients
41312949|NCT03550638|DEVICE|Coil system(Ton-bridgeMT)|1. It consists of a push system with a development mark, and a Detachable platinum-tungsten alloy coil which is connected to the push system. It can be used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
40796281|NCT00705874|DRUG|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
41471303|NCT01470196|DRUG|Carfilzomib|20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
40796282|NCT00705874|DRUG|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
40796283|NCT00705874|DRUG|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
40796284|NCT01943786|DRUG|FOLFIRI + Cetuximab|Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
40796285|NCT04490525|DEVICE|Telerehabilitation|Blood pressure (iHealth Neo/BP5s), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), and tablet (iPad Air 2).
41150901|NCT05746845|BIOLOGICAL|Blood sample|"Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)"
40796286|NCT05294484|DRUG|Indapamide 1.5 MG SR|the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
41312950|NCT03550638|DEVICE|Axium Detachable Coil(Medtronic)|2. It is made up of a push system with a development mark, a platinum-tungsten alloy embolized coil connected to the push system and a manual release device for releasing the coil from the distal end of the push system. It is mainly used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
41312951|NCT02207595|DRUG|UCB5857|"* Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use"
41471304|NCT01470196|DRUG|Rituximab|375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
40796287|NCT06186583|DRUG|Pimicotinib（ABSK021）|A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
41471305|NCT06616129|DIAGNOSTIC_TEST|Geriatric assessment|At the clinic further information on the somatic, social, psychological and functional domain will be gathered by the nurse and two validated tests to map the vulnerability and resilience of the patient will be used; the Cognitive Impairment Test and the timed Up and Go Test.
40796288|NCT00187538|BEHAVIORAL|Dietary|dietary
40796289|NCT00902850|DEVICE|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
40796290|NCT00902850|DEVICE|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
40796291|NCT03400358|OTHER|uterocervical angle|the angle between cervical canal and anterior uterine wall is measured sonographically.
40796292|NCT03246581|DRUG|Tiotropium|inhalation
40796293|NCT03896854|BIOLOGICAL|CART-19|CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19 cells/kg).
41312952|NCT02207595|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use"
40796294|NCT01949766|DRUG|Glycerol phenylbutyrate|
40796295|NCT00395499|DRUG|Risperidone|
40796296|NCT05024253|DRUG|Tranexamic acid injection|. TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only activate fibrin-bound plasminogen and produce plasmin responsible for cleaving fibrin molecule and dissolving the blood clot)
40796297|NCT05024253|OTHER|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
40796298|NCT01294137|DEVICE|ventilatory polygraphy|
40796299|NCT03501901|DIAGNOSTIC_TEST|Antibiotic susceptibility test|
40796300|NCT01467466|DRUG|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
41000922|NCT02809430|DEVICE|Continuous Positive Airway Pressure|Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.
41312953|NCT03151148|BIOLOGICAL|TMT Lotion|TMT product and Vegetable glycerin-Cetaphil®
41150902|NCT03756896|DRUG|Carfilzomib|Given IV
41150903|NCT03756896|DRUG|Dexamethasone|Given PO
41150904|NCT03756896|DRUG|Pomalidomide|Given PO
41150905|NCT05623761|DRUG|BUCCOTHERM® Sensitive Gums with Fluoride|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums with Fluoride twice daily for 1 month.
41312954|NCT03151148|DRUG|Placebo Lotion|Cetaphil® moisturizing lotion and vegetable glycerin
41312955|NCT05290142|OTHER|Digital Training with Coaching (DT-C)|An identical digital training course and helpline will be available for the participants in this group. In addition to receiving the same digital training resources as the DT group, participants in DT-C will receive weekly individualized telephone calls from a coach who will motivate them and troubleshoot towards course completion. The focus will be on clarifying learning objectives and redirecting participants to relevant materials rather than providing new learning opportunities. Participants will also be able to send text messages to coaches with queries related to course content, progress and technical difficulties. Coaches will reply to participants' messages within one working day and send reminders about upcoming telephone sessions, as well as prompts if the participant has not logged into the course for 3 consecutive days.
41000923|NCT06115928|DEVICE|Virtual reality|Participants will perform cardiac rehabilitation with hardware-type technology consisting of a PICO 4® head mounted display (HMD) headset and the software TREADMILL XR®.
41000924|NCT03467633|BEHAVIORAL|High-intensity interval training|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the UOHI prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
41312956|NCT05290142|OTHER|Self-Guided Digital Training|Participants will be enrolled in a digital training course that addresses non-specific counselling skills and skills specific to an evidence-based problem-solving intervention. The course will be available offline and online on a smartphone app (called 'Sangath Training') as well as a website (https://training.sangath.in/login/index.php) that can be accessed through an internet-enabled device. The training will be delivered through didactic lectures, role-play demonstrations, and recommended readings spread across 16 modules. Participants will be provided with automated feedback on their learning through self-assessment quizzes after each module. Modules will be available sequentially and unlocked after accessing all content in the preceding module, over a period of 4 weeks. Technical helpline: Participants will also have an option to message a centralized helpline for assistance with accessing and navigating the digital interface.
41312957|NCT04922619|DEVICE|tonotopy based fitting then default fitting|Cochlear implant with default fitting then tonotopy based fitting
41312958|NCT04922619|DEVICE|default fitting then tonotopy based fitting|Cochlear implant with tonotopy based fitting then default fitting
41312959|NCT04861961|PROCEDURE|DS vs. SADI-S vs. OAGBP|Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.
41471306|NCT06616129|OTHER|Shared decision-making conversation|"The nurse and nurse practitioner together will talk with the patient and their partner about possible treatment options as well as patients' expectations, preferences and their life in general.~During the conversation the OPT (Outcome Prioritization Tool) will be used to clarify the most important goals of treatment for the patient. The OPT exists of four universal treatment goals rated on a visual analogue scale from 0 to 100. The goals represented are: life extension, maintaining independence, reducing pain and reducing other symptoms. The goals will be explained and the patient will be asked to rate each outcome according to the trade-off principle meaning that two outcomes cannot be rated equally."
41471307|NCT01625481|DEVICE|Seal-V|Seal-V is applied adjunctively to cover the suture lines.
41471308|NCT01143649|DEVICE|transcranial direct current stimulation (tDCS)|Subjects will be stimulated at 1 mA for 40 minutes.
41471309|NCT01143649|PROCEDURE|constraint induced movement therapy (CIMT)|
41471310|NCT01143649|DEVICE|transcranial alternating current stimulation (tACS)|Subjects will be stimulated at 15Hz for 20 minutes.
41471311|NCT03889834|PROCEDURE|Autologous Blood Transfusion|Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days
41000925|NCT03318991|PROCEDURE|Laser prostatectomy|Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.
41000926|NCT01619033|DRUG|BF2.649|single dose 20 mg
41000927|NCT01050738|PROCEDURE|Position of catheter|Position of catheter for administration of local anestesia.
41471312|NCT03889834|OTHER|No transfusion|no transfusion
41471313|NCT04947501|DRUG|Cyclophosphamide|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.~\*\*\*\*\*\*\* Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
41000928|NCT01859715|DRUG|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
41000929|NCT01859715|DRUG|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
41312960|NCT00511342|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
41312961|NCT00511342|DRUG|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
41312962|NCT04260659|DRUG|Dexmedetomidine Hydrochloride [Dexdor]|Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.
41312963|NCT04260659|DRUG|Remifentanil [Ultiva]|Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.
41312964|NCT04260659|DRUG|Ketamine [Ketalar]|Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.
41312965|NCT04260659|DRUG|Lidocaine [Xylocaine 2%]|Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.
41312966|NCT04260659|DRUG|Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]|Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.
41471314|NCT04947501|DRUG|Topotecan|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
41471315|NCT04947501|DRUG|Vincristine|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
41471316|NCT04947501|DRUG|Doxorubicin|"Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
41471317|NCT04947501|DRUG|Ifosfamide|Administration of ICE - cycle 2 Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs.
41471318|NCT04947501|DRUG|Etoposide|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs."
41471319|NCT04947501|DRUG|Carboplatin|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs."
41471320|NCT04947501|DRUG|Mesna|"Administration of CTV - cycles 1 and 4 Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Administration of ICE - cycle 2 Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.~Administration of CDV - cycle 3 Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion."
41471321|NCT05315245|OTHER|AGI|no intervention, only observation
41471322|NCT02404077|DRUG|Clonidine|
41000930|NCT01859715|DRUG|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
41312967|NCT04260659|DRUG|Fentanyl [Fentanyl WZF]|Rescue dosis of 100 mcg iv will be administered if hypertension \> 140/90 mmHg or tachycardia \> 120min occurs. If necessary rescue dosis may be repeated.
41312968|NCT02399592|DRUG|Bevacizumab|10 mg/kg q3w
41312969|NCT02399592|DRUG|Tocotrinol|300 mg tid
41312970|NCT00772382|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
41312971|NCT02247284|DEVICE|RNFL and BMO-MRW SD-OCT|Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
41312972|NCT04141852|DEVICE|Implantation of VasQ device|"The VasQ external support device (Laminate Medical Technologies, Israel) is a novel Nitinol implant, externally surrounding and supporting the vein and hugging the artery near the junction site, without being in contact with the blood flow."
41312973|NCT02406547|DEVICE|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
41312974|NCT02406547|DEVICE|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
41312975|NCT03796182|DRUG|Metformin|Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.
41312976|NCT03796182|DRUG|PF-04965842|PF 04965842 100 mg tablets
41471323|NCT01637831|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
41312977|NCT04975971|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
41471324|NCT06460961|BIOLOGICAL|MK-6837|IV Infusion
41312978|NCT05428800|BEHAVIORAL|Progressive Relaxation Exercises|Progressive muscle relaxation (PMR) is a relaxation technique that tenses and relaxes muscles in an unprompted, regular, and consecutive manner until the whole body is relaxed.
41312979|NCT04116476|DRUG|MT-7117|Single Dose of MT-7117
41312980|NCT04696458|DIETARY_SUPPLEMENT|Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483)|Probiotic Capsules in blister packets of capsules containing the probiotic intervention contain a combination of three strains of lactic acid bacteria: two Lactobacillus plantarum (CECT7484 and CECT7485) and one Pediococcus acidilactici (CECT7483).
41312981|NCT04696458|OTHER|Placebo Comparator: Placebo|Placebo Capsules in blister packets of capsules containing the inert (controlled) non-interventional treatment.
41471325|NCT06460961|BIOLOGICAL|Pembrolizumab|IV Infusion
41471326|NCT04311151|PROCEDURE|own seizures visualization|At the hospital discharge, patients
41471327|NCT06276699|PROCEDURE|1.Isometric exercise 2.combined conservative treatment|Exercise programs will be taught to patients with details by an experienced physiotherapist at the beginning of the study. Cervical Traction Patient will sit upright posture on a chair. Mechanical traction will be applied. It includes placement of a halo device around the neck, then the harness will be attached to the machine that applies traction force through-out the treatment, the device is controlled by the control panel. Intermittent mechanical traction will be applied for 10 minutes in which pull for 10 seconds and 5 seconds rest will be applied. Neural mobilization will be carried out using Butler's approach. The subject will be positioned in supine, and the median nerve will be mobilized using a slider.
41471328|NCT00455026|DRUG|remifentanil|target effect site concentration during induction
41471329|NCT04075552|BEHAVIORAL|Pre Meal Presentation|Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.
41471330|NCT04075552|BEHAVIORAL|Pre Meal Presentation + Modeling|"Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model."
41471331|NCT04075552|BEHAVIORAL|Pre Meal Presentation + Token Economy|Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
41471332|NCT02221596|DIETARY_SUPPLEMENT|vitamin D|50,000IU/wk of vitamin D3
41000931|NCT06173206|DRUG|SP (Macleods Pharmaceuticals Ltd)|Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
41312982|NCT02235116|OTHER|Survey|
41312983|NCT03873402|BIOLOGICAL|Nivolumab|Specified dose on specified days
41312984|NCT03873402|BIOLOGICAL|Ipilimumab|Specified dose on specified days
41312985|NCT03873402|OTHER|Ipilimumab placebo|Specified dose on specified days
41312986|NCT01287533|DRUG|Ibandronate|monthly dosage of ibandronate 150mg
41312987|NCT01287533|DRUG|Placebo|monthly dosage of placebo
41471333|NCT02221596|OTHER|aerobic training|7 days of treadmill training during the 13th week of study
41312988|NCT00835107|DRUG|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
41471334|NCT02004184|DRUG|maintenance pemetrexed|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
41471335|NCT02004184|DRUG|pemetrexed at progression|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
41471336|NCT04919382|BIOLOGICAL|Atezolizumab|Given IV
41471337|NCT04919382|DRUG|Temozolomide|Given PO
41471338|NCT04027881|BEHAVIORAL|Sit Together and REad|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
41471339|NCT05551702|BEHAVIORAL|CBT-txt|Cognitive Behavioral Therapy delivered via automated text messaging.
41312989|NCT00835107|DRUG|placebo|placebo comparator, oral capsules, BID, for one month
41312990|NCT01691872|DRUG|Retigabine|Retigabine
41312991|NCT01222572|RADIATION|Stereotactic boost|
41312992|NCT01222572|RADIATION|Conventional RT|
41312993|NCT01222572|DRUG|Etoposide|
41312994|NCT01222572|DRUG|Cisplatin|
41312995|NCT02497872|PROCEDURE|Biliary stone removal|Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
41312996|NCT03832920|OTHER|Analgesia Nociception Index|A monitor of nociception for patients under general anesthesia
41471340|NCT04963608|DRUG|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
41471341|NCT00506506|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily x 48 hours
40796301|NCT01467466|DRUG|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
41312997|NCT06082557|DRUG|T60c injection|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and TROP2-CAR (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion."
40796302|NCT01467466|DRUG|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
40796303|NCT01467466|DRUG|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
41000932|NCT06173206|DRUG|SPAQ (Guilin Pharmaceuticals)|Children will receive 500mg sulfadoxine plus 25mg pyrimethamine as one tablet, and 153mg amodiaquine (as hydrochloride) as one tablet on Day 0, and Children will 153mg amodiaquine (as hydrochloride) as one tablet on days 1 and 2.
41000933|NCT06173206|DRUG|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
41312998|NCT00646841|DRUG|Doxazosin gastrointestinal therapeutic system (GITS)|4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
41312999|NCT06191887|BIOLOGICAL|Autologous BAFFR-targeting CAR T Cells|Given IV
40796304|NCT01442337|DRUG|ASP8597|one time IV dose
40796305|NCT01442337|DRUG|Placebo|one time IV dose
40796306|NCT02056444|DRUG|Tranexamic Acid|
40796307|NCT03235921|DRUG|Nitroglycerin patch 5mg|application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
40796308|NCT03235921|OTHER|placebo|no drug given to the control group
40796309|NCT02423525|DRUG|Afatinib|
40796310|NCT03483792|BIOLOGICAL|Plasma dosage|4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
40796311|NCT03483792|GENETIC|placental biopsy|Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
40796312|NCT01752556|PROCEDURE|diagnosis and therapeutic decision|A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
40796313|NCT01752556|PROCEDURE|diagnosis and therapeutic decision|A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
40796314|NCT04644276|DEVICE|Mask with Mask Adhesive/Arm 1|Patients will be randomized to Arm1 if they receive the mask adhesive and mask on the first study night then the mask without the mask adhesive on the second study night.
41313000|NCT06191887|DRUG|Bendamustine|Given IV
41313001|NCT06191887|PROCEDURE|Biopsy|Undergo biopsy
41313002|NCT06191887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41313003|NCT06191887|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy/aspirate
41313004|NCT06191887|PROCEDURE|Computed Tomography|Undergo CT scan
40796315|NCT04644276|DEVICE|Mask without Mask Adhesive / Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then the mask adhesive with the mask on the second study night.
40796316|NCT00314873|DRUG|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
41000934|NCT01414569|DRUG|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
41000935|NCT01140425|DRUG|PF-00232798|600 mg oral solution once daily x 7 days
41000936|NCT01140425|DRUG|PF-00232798|300 mg oral solution once daily x 7 days
41000937|NCT01140425|DRUG|Placebo|Oral solution once daily x 7 days
41313005|NCT06191887|DRUG|Cyclophosphamide|Given IV
40796317|NCT02552095|DEVICE|Triathlon PKR|
41000938|NCT01140425|DRUG|Moxifloxacin|400 mg tablet single dose
41000939|NCT04784286|OTHER|Telemedicine 30-day post-op visit|Consented subjects randomized to the telemedicine visit arm will do their 30-day post-op visit via secure telemedicine video application through the Center of Connected Care. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
41000940|NCT04784286|OTHER|In-Person 30-day post-op visit|Consented subjects randomized to the in-person visit arm will physically come to a clinical visit with the bariatric surgery midlevel providers. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
41000941|NCT00006916|BIOLOGICAL|bleomycin|
41000942|NCT00006916|DEVICE|Ommaya reservoir|
41313006|NCT06191887|PROCEDURE|Echocardiography|Undergo echocardiography
41313007|NCT06191887|DRUG|Fludarabine|Given IV
41471342|NCT00506506|DRUG|Placebo|
41313008|NCT06191887|PROCEDURE|Leukapheresis|Undergo leukapheresis
41313009|NCT06191887|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41313010|NCT06191887|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41471343|NCT01949714|PROCEDURE|Removal of adrenal tumor|
41000943|NCT00006916|RADIATION|radiation therapy|60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
41313011|NCT03011580|DIETARY_SUPPLEMENT|Fultium-D3|Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
41313012|NCT03011580|DIETARY_SUPPLEMENT|Placebo|3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
41000944|NCT05430828|DRUG|Repatha (evolocumab); Praluent (alirocumab)|Dosage form: Injection
41313013|NCT04895163|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy performed for acute appendicitis
41313014|NCT06068322|OTHER|Exercise training on a stationary bicycle|"Training is performed two to three times per week for a total of 30 sessions using a group format.~Both regimens start with a five-minute warm-up and ends with a five-minute cool-down, performed at an intensity corresponding to 30% of the maximal work rate achieved during a CPET (i.e., max aerobic power \[MAP\]) with a self-selected pedalling cadence of 50-70 revolutions per minute (RPM).~All exercise sessions will be held and supervised by an experienced health care professional, i.e. physiotherapists or other health professional.~The different types of exercise training is described under the specific arm.~Following the first 12-week training period, participants with COPD will enter a 21-month maintenance phase. They will continue to exercise using the same training modality (HIIT or MICT) as during the first 12-weeks but can select between three different settings to continue their training: Home, Outpatient, or Mix setting."
41313015|NCT06539247|COMBINATION_PRODUCT|Motor Relearning Program with Electrical Muscle Stimulation (MRA + EMS)|This arm will receive a 30-minute motor relearning program focused on improving foot drop and gait patterns and Electrical Muscle Stimulation (EMS) for Targeted Activation (10 minutes) with 40 mA (default) adaptive, considering both intensity and duration for safe foot lift during walking.
41313016|NCT06539247|COMBINATION_PRODUCT|Proprioceptive Neuromuscular Facilitation Technique with Electrical Muscle Stimulation (PNF + EMS)|"This arm will receive a 30-minute intervention combining Proprioceptive Neuromuscular Facilitation (PNF) techniques and EMS. The program will consist of:~PNF Techniques for Neuromuscular Facilitation (20 minutes) and Electrical Muscle Stimulation (EMS) for Muscle Response Enhancement (10 minutes): Similar to Arm 1, EMS will be applied to the affected ankle dorsiflexors for 10 minutes with the same parameters."
41313017|NCT00448916|DRUG|Pregabalin|Orally-administered pregabalin
41313018|NCT00980343|DRUG|vismodegib|Given orally
41313019|NCT00980343|PROCEDURE|therapeutic conventional surgery|undergo surgery
41313020|NCT00980343|OTHER|laboratory biomarker analysis|correlative studies
41313021|NCT00980343|OTHER|pharmacological study|correlative studies
41313022|NCT02913352|PROCEDURE|Latarjet procedure|Open anterior glenoid bone graft from coracoid process
41313023|NCT02913352|PROCEDURE|Modified Eden-Hybinette|Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
41313024|NCT05125107|DEVICE|Quantitative Flow Ratio derived PPG and dQFR/ds|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)"
41313025|NCT03991364|OTHER|Constant gait speed group|The speed of the robot-assisted gait treatment is constantly applied for 5 times a week for 2 weeks.
41313026|NCT03991364|OTHER|Increasing gait speed group|The speed of the robot-assisted gait treatment is gradually increase for 5 times a week for 2 weeks.
41313027|NCT06296433|OTHER|VR rehabilitation|VR software application containing education, exergames, therapeutic exercises and relaxation sections.
40796318|NCT01813695|PROCEDURE|Preemptive genotyping in medical record|
41150906|NCT05623761|DRUG|BUCCOTHERM® Sensitive Gums Fluoride-Free|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums Fluoride-Free twice daily for 1 month.
41313028|NCT06296433|OTHER|VR video application|VR software application that plays 2D nature videos
41313029|NCT04937582|DIAGNOSTIC_TEST|Cognitive assessment|Complete cognitive and psychological assessment
41313030|NCT04937582|DIAGNOSTIC_TEST|Imaging|"Brain MRI~Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)"
41313031|NCT04937582|DIAGNOSTIC_TEST|Routine care|"Electroencephalogram (EEG)~Optional: polysomnography, lumbar puncture"
41313032|NCT04937582|OTHER|Psychiatric evaluation|Psychiatric consultation if necessary
41313033|NCT04937582|OTHER|Psychiatric evaluation|Psychiatric consultation if necessary (before the end of their participation in the study)
41313034|NCT01648452|BIOLOGICAL|NT-501 CNTF-releasing implant|20 ng/day released into the eye
41471344|NCT06022367|DIAGNOSTIC_TEST|Head Turn Activation Technique|Participant sat upright with head turned to the side through 45 degrees. They are presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
41471345|NCT06022367|DIAGNOSTIC_TEST|Head Raise Activation Technique|Participant assumes caloric test position (30 degrees from horizontal) with head raised. Participant is presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
41150907|NCT01469429|OTHER|placebo|Receive lozenge placebo PO
41150908|NCT01469429|OTHER|laboratory biomarker analysis|Correlative studies
41150909|NCT01469429|OTHER|questionnaire administration|Ancillary studies
41150910|NCT01469429|DRUG|chemoprevention|Receive LBR lozenge PO
41150911|NCT01469429|DRUG|chemoprevention|Receive LBR Saliva Substitute PO
41000945|NCT02421133|OTHER|Transitional care program.|"During the patient's stay in hospital, the transition nurse creates a transitional care file including information about the patient (inpatient medical and nurse care plan, medications), the discharge plan, and the contact information of the relevant primary care providers. She notifies the patient's primary care physician of the date of the discharge to home, of the potential medical problems and of the discharge care plan; a primary care physician visit is planned the month following the discharge.~The day of the hospital discharge: meeting with the patient to review the follow-up recommendations. The transition nurse verifies that the medications are prescribed accordingly with the discharge plan, that the patient and his caregiver understand the prescription and are informed with the planned appointments and the biological monitoring.~During 4 weeks after the hospital discharge: follow-up by the transition nurse once a week, alternately by telephone and home visit."
41150912|NCT01469429|OTHER|placebo|Receive Saliva Substitute placebo PO
41313035|NCT03513965|BEHAVIORAL|Symptoms as Positive Signals Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. However, Symptoms as Positive Signals Mindset families are additionally encouraged to think of symptoms as a positive signal that their immune system is becoming increasingly desensitized to their allergen. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
41471346|NCT04372849|OTHER|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
41471347|NCT04372849|OTHER|Placebo|Single dose of placebo solution as nasal spray
41471348|NCT03714555|DIAGNOSTIC_TEST|Safety Laboratories|Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis
41471349|NCT03714555|OTHER|AE Assessment|Assessment of Adverse Events (AE)
41471350|NCT03714555|OTHER|Physical Exam|Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
40796319|NCT01813695|PROCEDURE|Genotyping not included in electronic medical record|
40796320|NCT05135039|DRUG|Canagliflozin|Canagliflozin 100mg/day/patient
40796321|NCT05135039|DRUG|Placebo|Placebo 100mg/day/patient
41150913|NCT00562926|PROCEDURE|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
41150914|NCT02884219|DRUG|Ibuprofen|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
41150915|NCT02884219|OTHER|Expectative Management|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
41150916|NCT02884219|DRUG|Indomethacin|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
41150917|NCT03787693|BEHAVIORAL|VR - Virtual Reality|Subjects in the experimental group will perform the split-belt task in a VR environment
41150918|NCT02829099|DRUG|JNJ-64457107|JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
41471351|NCT03714555|OTHER|Concomitant Medication Review|Prior and Concomitant Medication Review
41471352|NCT03714555|DIAGNOSTIC_TEST|Tumor Imaging|Tumor CT or MRI
41471353|NCT03714555|DRUG|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
40796322|NCT02044224|DRUG|Dexmedetomidine|"Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).~Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.~Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required"
40796323|NCT05745610|DRUG|Shen Hai Long Capsule|3 times/day (9 capsules/day) for 12 weeks
40796324|NCT05745610|DRUG|Sheng Jing Capsule|3 times/day (12 capsules/day) for 12 weeks
41471354|NCT03714555|DRUG|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
41471355|NCT03714555|DRUG|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
40796325|NCT04019964|DRUG|Nivolumab|Nivolumab 480mg intravenously every 4 weeks
41471356|NCT06173596|DRUG|ALXN2080|Participants will receive ALXN2080 orally.
41471357|NCT06173596|DRUG|Itraconazole|Participants will receive Itraconazole orally.
41471358|NCT06173596|DRUG|Fluconazole (AxMP)|Participants will receive Fluconazole orally.
41471359|NCT06173596|DRUG|Carbamazepine (AxMP)|Participants will receive Carbamazepine orally.
41471360|NCT03998319|DRUG|Tenecteplase (1/3 systemic weight based dose)|50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
41471361|NCT03998319|OTHER|Sterile water for injection (WFI)|Placebo comparative arm.
41471362|NCT05967416|BIOLOGICAL|SIRPant-M|Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection
40796326|NCT04903574|BEHAVIORAL|NEAT!2 sedentary behavior app|This is a smartphone app that reminds you to stand up if you've been sitting for at least 30 minutes.
40796327|NCT04903574|OTHER|Pregnancy smartphone app|This is a commercially available general pregnancy smartphone app
40796328|NCT01453491|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
40796329|NCT02217813|DRUG|Tafamidis|20 mg of current commercial formulation
40796330|NCT02217813|DRUG|Tafamidis|20 mg of new formulation
41313036|NCT03513965|BEHAVIORAL|Symptoms as Side Effects Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
41000946|NCT02421133|OTHER|standard care program|The patients will be discharged according to the usual care plan of each participating hospital. The medical team does a medical and geriatric assessment of the patients according to the recommendations. The communication of information to the primary care providers (nurse, primary care physician...) is left to the discretion of the medical teams of the discharging hospitals, according to their habits of work.
41000947|NCT00358527|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
41313037|NCT03030911|DRUG|Dexmedetomidine|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
41313038|NCT03030911|DRUG|Midazolam|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
41000948|NCT00358527|OTHER|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
41000949|NCT04023877|DRUG|E2027|E2027 oral capsule.
41313039|NCT03030911|DRUG|Fentanyl|The drug will be administered in both groups
41471363|NCT05967416|RADIATION|External-beam radiotherapy (XRT)|Radiotherapy given by external beam
41471364|NCT03851588|OTHER|Placebo|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.
41471365|NCT03851588|DRUG|Dolutegravir 50 mg|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
40796331|NCT01583114|DRUG|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
41471366|NCT05735418|DIETARY_SUPPLEMENT|GI Biome #7|It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10\^8 CFU/day.
41471367|NCT05735418|DIETARY_SUPPLEMENT|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
40796332|NCT01583114|DRUG|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
41000950|NCT03402438|DRUG|Fulacimstat (BAY1142524)|single oral dose of 25 mg immediate-release tablet BAY1142524
41313040|NCT03030911|DEVICE|Indirect calorimetry|The device will be used for measurement of basal metabolic rate
41313041|NCT00954317|PROCEDURE|epidural placed low|epidural placed low
41313042|NCT00954317|PROCEDURE|high epidural|high epidural
41471368|NCT01997294|DRUG|Sequential therapy of atorvastatin|80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
41471369|NCT02400476|DRUG|Neratinib|
41471370|NCT02400476|DRUG|Loperamide|
41471371|NCT02400476|DRUG|Colestipol|2 g twice daily with or without food for one 28 day cycle
41000951|NCT03063996|PROCEDURE|peripheral IV access procedure|standard of care guided IV access into peripheral vein excluding IJ
41000952|NCT03063996|PROCEDURE|Peripheral IJ access procedure|standard of care guided IV access into IJ
41000953|NCT01224886|BEHAVIORAL|Physical activity|Supervised exercise intervention
41000954|NCT03496142|PROCEDURE|Transperineal prostate biopsy|Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
41000955|NCT03496142|PROCEDURE|Transrectal prostate biopsy|Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
41000956|NCT03592615|PROCEDURE|cataract surgery|Cataract surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than cataract, e.g., treatment for lens dislocation. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating astigmatism.
41000957|NCT03592615|PROCEDURE|Corneal refractive surgery|Corneal refractive surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than refractive error, e.g., treatment for corneal scar. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating severe astigmatism.
41313043|NCT06364982|DIAGNOSTIC_TEST|Two contiguous dental implants placed with less ≤ 3mm from each other.|Implant Placement of 2 contiguous dental implants with less ≤ 3mm from each other.
41313044|NCT06364982|DIAGNOSTIC_TEST|Two contiguous dental implants placed with > 3mm from each other.|Implant Placement of 2 contiguous dental implants with \> 3mm from each other.
41313045|NCT02391350|BEHAVIORAL|Education and re-assurance|Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
41313046|NCT02391350|PROCEDURE|Physical Therapy|Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
41471372|NCT02400476|DRUG|Budesonide|9 mg extended release tablets once daily with or without food for 28 days
41471373|NCT00892281|DRUG|doxycycline (Oracea®) 40 mg modified release as monotherapy|Take once daily in the morning
41471374|NCT00892281|DRUG|doxycycline (Oracea®) 40 mg modified release as add-on therapy|Take once daily in the morning
40796333|NCT03330678|DIETARY_SUPPLEMENT|Probiotic (VSL#3)|Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
41000958|NCT05930665|DRUG|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin|Cadonilimab 10mg/kg intravenous (IV) every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks + Carboplatin AUC 5 IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Cadonilimab 10mg/kg IV every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks
41000959|NCT02205593|BEHAVIORAL|Control|Regular follow-up and treatment WITHOUT behavioural intervention
40796334|NCT03356353|DRUG|Sildenafil Citrate|20 mg tablets
40796335|NCT05214430|OTHER|3 months exclusive enteral nutrition after surgery|patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.
40796336|NCT01063062|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
41471375|NCT00258778|DRUG|Human Glucocerebrosidase (prGCD)|
40796337|NCT01063062|DRUG|Methotrexate|methotrexate as per standard of care in clinical practice.
40796338|NCT05449041|DEVICE|Bulbicam|Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size
40796339|NCT00964951|BIOLOGICAL|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
40796340|NCT00964951|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
40796341|NCT01665911|DRUG|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
40796342|NCT01665911|DRUG|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
41000960|NCT05530122|BIOLOGICAL|infliximab, adalimumab, golimumab, vedolizumab, ustekinumab|
41000961|NCT02619695|DRUG|Fastjel|2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
41000962|NCT02965612|DEVICE|Injex|administration of Specific Immunotherapy (ITS) with car pressure injector without a needle
40796343|NCT01665911|DRUG|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
41000963|NCT02965612|PROCEDURE|SCIT|administration of Specific Immunotherapy (ITS) via traditional subcutaneous
41000964|NCT03409471|DEVICE|Flocked Swab|At the colposcopy clinic, vaginal self-sample will be collected with the Flocked Swab (Noble Bioscience, Inc., Korea).
41000965|NCT03409471|DEVICE|Cervical Brush|Physician collected cervical sample will be collected also at the colposcopy center with the Cervical Brush (Noble Bioscience, Inc., Korea).
40796344|NCT01665911|DRUG|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
40796345|NCT01665911|OTHER|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
40796346|NCT03805854|DEVICE|10 Hz tACS of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
40796347|NCT03805854|DEVICE|10 Hz tACS of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
40796348|NCT03805854|DEVICE|80 Hz tACS of the bilateral somatosensory cortex|80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
41000966|NCT03409471|DIAGNOSTIC_TEST|HPV assay|The hrHPV assay used, will be the Roche Cobas® 4800 HPV test, Anyplex™ II HPV HR detection kit and Realtime HPV HR-S Detection kit.
41000967|NCT02583581|DEVICE|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
41000968|NCT02583581|DEVICE|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
41000969|NCT02927457|DRUG|GSK2646264 1%|A cream for topical application with a concentration of 1% GSK2646264.
41000970|NCT02927457|DRUG|Placebo|Subjects will receive matching Placebo topically.
41000971|NCT04977258|OTHER|Treadmill aerobic exercise without water intake|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
41000972|NCT04977258|OTHER|Treadmill aerobic exercise with water intake of a predetermined amount.|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
41150919|NCT02623101|DEVICE|Reflectance confocal microscopy|Non-invasive imaging of the lesion
41313047|NCT03164512|DRUG|Oral or vaporized cannabidiol|Acute drug exposure
41471376|NCT04924244|OTHER|Music Therapy|We will play music of the subject's choice of genre during the procedure.
41471377|NCT04924244|OTHER|No Music|No music will be played during the subject's interventional procedure
41000973|NCT04977258|OTHER|Treadmill aerobic exercise with water intake according to the desire to drink|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
41000974|NCT05030142|PROCEDURE|Mechanical Thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
41471378|NCT06238661|DIAGNOSTIC_TEST|Urology visit with Risk Calculator and MRI|Patients with PSA ≥3 ng/ml will undergo urology visit with risk calculator and MRI assessment of the prostate
40796349|NCT03805854|DEVICE|80 Hz tACS of the prefrontal cortex|80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
40796350|NCT03805854|DEVICE|Sham stimulation of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
40796351|NCT03805854|DEVICE|Sham stimulation of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.
40796352|NCT01481350|DRUG|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
40796353|NCT04396795|DRUG|Autologous Platelet Rich Plasma|Each injection session will consist of a total of 5 mL PRP infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum.
40796354|NCT04396795|OTHER|Saline solution|Each injection session will consist of a total of 5 mL saline solution infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum
40796355|NCT02318836|DRUG|Lofexidine Hydrochloride (HCl) tablets|Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
41000975|NCT05030142|DRUG|Best medical treatment alone|Best medical treatment alone (usual care)
41000976|NCT01346267|PROCEDURE|Real Acupressure Band|Acupressure wristband
41313048|NCT03164512|DRUG|Placebo|Placebo capsule/vapor
41471379|NCT04043819|DRUG|PSC-01|PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
41471380|NCT01469507|DEVICE|Chondroitin sulfate and sodium hyaluronate|3 weekly injections
40796356|NCT00984776|OTHER|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
40796357|NCT00530634|DRUG|cisplatin|
40796358|NCT00530634|DRUG|gemcitabine hydrochloride|
40796359|NCT00530634|GENETIC|gene expression analysis|
40796360|NCT00530634|GENETIC|reverse transcriptase-polymerase chain reaction|
40796361|NCT00530634|OTHER|immunohistochemistry staining method|
40796362|NCT00530634|PROCEDURE|adjuvant therapy|
40796363|NCT00530634|PROCEDURE|conventional surgery|
40796364|NCT00530634|RADIATION|radiation therapy|
40796365|NCT04013269|DEVICE|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
40796366|NCT06302803|BEHAVIORAL|Intermittent fasting plus time-restricted eating|Participants in the mTRE group will be instructed to eat during a window of 8 h (8 am to 4 pm) 5 days and fast (approximately 500-600 kcal per day) 2 days per week.
40796367|NCT06302803|BEHAVIORAL|Calorie restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on eating time.
41000977|NCT01346267|PROCEDURE|Placebo Acupressure Band|Sham wristband
41000978|NCT03718611|DRUG|BR9001|BR9001 is a test drug as generic
40796368|NCT00157963|DRUG|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
40796369|NCT05445921|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.
40796370|NCT06503627|PROCEDURE|bladder flap dissection|bladder flap dissection during caesarean section
40796371|NCT02840942|BEHAVIORAL|Coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills."
41313049|NCT01006720|DRUG|Sugammadex|"Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)"
41313050|NCT01006720|DRUG|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
41313051|NCT01006720|DRUG|Saline|Saline 0.9% (Saline)
41313052|NCT01237808|DRUG|Cytarabine|in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).
41471381|NCT01469507|DRUG|Hyaluronan|3 weekly injections
41313053|NCT01237808|DRUG|Etoposide|first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).
41313054|NCT01237808|DRUG|All-trans retinoic acid (ATRA)|in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.
41313055|NCT04507620|DEVICE|cervical neck collar|devices used for cervical immobilization
41000979|NCT03718611|DRUG|BR900A|BR900A is a reference drug
41000980|NCT06207539|DRUG|hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
41000981|NCT06207539|DRUG|misoprostol under the generic name of misotac tablets|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
41000982|NCT06140095|DRUG|Evolocumab|See arm description
41000983|NCT03151759|RADIATION|Neoadjuvant radiotherapy|Neoadjuvant radiotherapy prior to rectal cancer surgery
41313056|NCT00014378|DRUG|Chinese Herb Huanglian (Coptis chinesis)|Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
41313057|NCT01293149|DRUG|Ropivacaine|ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
41313058|NCT01293149|DRUG|Clonidine|clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
41313059|NCT04156932|PROCEDURE|uterine artery closure|Interruption the uterine blood flow by closing the uterine artery at its cervical-isthmic part or at its origin.
41313060|NCT05008705|DIETARY_SUPPLEMENT|Protein supplementation|Patients will receive diary 2 doses of the protein supplement
41313061|NCT05008705|DEVICE|Neuromuscular electrostimulation.|Patients will receive diary sessions of neuromuscular electrostimulation.
41313062|NCT05008705|DIETARY_SUPPLEMENT|Placebo (isocaloric supplement)|Patients will receive diary 2 doses of the isocaloric supplement
41313063|NCT05008705|DEVICE|Sham for neuromuscular electrostimulation.|Patients will not receive neuromuscular electrostimulation.
41313064|NCT00471445|DRUG|ketamine/amitriptyline NP-H cream|Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
41313065|NCT00471445|OTHER|placebo|Applied topically
41313066|NCT03001154|BEHAVIORAL|Face-to-face Virtual Reality Exposure Therapy|In session, systematic, hierarchical exposure to feared stimuli with therapist.
41313067|NCT03001154|BEHAVIORAL|Internet-administered Virtual Reality Exposure Therapy|Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program
41313068|NCT03001154|OTHER|Waiting-list|Weekly assessments of public speaking
41313069|NCT01684475|DRUG|CJH1 (CLR4001)|
41313070|NCT04753242|OTHER|Online survey questionnaire|Self-developed questionnaire based on relevant literature, own experience and consultation with participating professional societies. The survey contains 25 questions on structural and process variables regarding psychosocial care structures that psychosocial C\&L services have established in acute hospitals in the context of the COVID-19 pandemic, the implementation and use of COVID-19-related services for patients, relatives and staff, special challenges, as well as needs and wishes for the future. Thereby the survey is aiming at the creation of a data basis for improving the structural and process quality of psychosocial care services through psychosocial C\&L services in the context of pandemics, especially the COVID-19 pandemic.
41313071|NCT05984797|OTHER|Integrated Short-term Palliative Rehabilitation|"Participants will be offered up to 3 manualised sessions (face to face and/or remotely, via telephone or video-conference) delivered by an expert rehabilitation practitioner (physiotherapist, occupational therapist,).~Core components focus on (i) self-management of symptoms, (ii) physical activities and fitness, and (iii) social participation. Delivery of rehabilitation intervention components will include explicit use of behaviour change techniques including goal setting and action planning to focus on outcomes that are meaningful for the person, their family, and clinicians."
40796372|NCT02840942|BEHAVIORAL|Non-coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only."
41000984|NCT06229080|DEVICE|NexGel|When a planned perfused area includes three or more Couinaud segments and more than 50% of the target area is non-tumorous liver, short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver. The embolization particles will be prepared by mixing one vial of the particles with 5 mL of iodinated contrast agents and intra-arterially delivered with a microcatheter 2.0-Fr or larger. After confirming the disappearance or substantial reduction of liver parenchymal staining of the embolized area on angiography, radioembolization using Y90 glass or resin microspheres will be conducted. Digital subtraction angiography will be performed 30 minutes after the transient embolization to identify recanalization of the transiently embolized hepatic arteries.
41000985|NCT02739269|OTHER|Serum AMH measurement|Serum AMH is measured one month before the IVF treatment
41313072|NCT01759498|DIETARY_SUPPLEMENT|HYDRO|
41313073|NCT01759498|DIETARY_SUPPLEMENT|ACTIVE|
41313074|NCT01759498|DIETARY_SUPPLEMENT|HYDRO 2|
41313075|NCT06553846|DRUG|Lutetium [177Lu]-FAP-75|Lutetium \[177Lu\]-FAP-75 will be administrated per dose level in which the patients are assigned.
41313076|NCT03683706|BEHAVIORAL|LTP in My Own Way Plus|LTP in My Own Way Plus is a 12-session integrated intervention-Learning through Play in My Own Way Plus Cognitive Behaviour Therapy (CBT). LTP in My Own Way is the extension of the parent education program called 'Learning Through Play' developed by Toronto Public Health (1993) revised by The Hincks-Dellcrest Centre (2000). LTP aims for the healthy growth of young children (birth to 6 years) using the stages of development incorporating Piaget's theory of cognitive development and Bowlby's theory of attachment. The objective of this program is to strengthen parent-child attachment by encouraging parental involvement and teaching parents how to use play activities to enhance their children's development. Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.
40796373|NCT02867228|OTHER|changes in ventilator settings|Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
41313077|NCT03368131|DRUG|Trastuzumab|intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle
41313078|NCT03368131|DRUG|Capecitabine|825\~1000mg/m2 bid d1-14
41313079|NCT03368131|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
41313080|NCT03368131|RADIATION|Radiotherapy|45 Gray (unit) Gy/25f （1.8Gy/f/d，5 f/w）
40796374|NCT04973995|BEHAVIORAL|several physical examinations|By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
41000986|NCT02739269|OTHER|AFC measurement|Early follicular phase AFC is measured one month before the IVF treatment
41000987|NCT01853033|BIOLOGICAL|ABT-122|Injection
41000988|NCT01853033|BIOLOGICAL|Placebo|Placebo Injection
41313081|NCT04501198|DEVICE|moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine|"1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. Xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. The Xiusheng Decoction should be taken twice a day. Traditional exercises will be taken for 35\~40 minutes everyday, 7 times a week. The intervention of Xiusheng Decoction and traditional exercises will be conducted for 8 weeks. All patients will be instructed to follow a good living habits which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
41313082|NCT04501198|DEVICE|Moxibustion combined with lifestyle intervention.|"1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
41313083|NCT04501198|DEVICE|lifestyle intervention|All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
41313084|NCT01133431|DRUG|CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
41313085|NCT01133431|DRUG|CKD-501 placebo tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
41313086|NCT03474406|OTHER|follow up system and multimodality approach|To provide a new service system for cancer pain in pain clinic by early detecting red flag sign to consult other departments, early alleviating severe pain, following patients intensively by telephone call and giving pain education
41313087|NCT04891991|DRUG|Intravitreal infliximab|1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.
41313088|NCT04891991|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy
41313089|NCT05025735|DRUG|Dapagliflozin 10Mg Tab|"Hyperglycemia is an expected effect of PI3K inhibitors given the pivotal role of PI3K in mediating the response to insulin in multiple tissues. Blocking insulin signaling by p110α inhibitors leads to glycogen breakdown in the liver along with decreased glucose uptake in peripheral tissues. The resulting hyperglycemia causes a compensatory response of increase insulin secretion by the pancreas.~If concurrent treatment with dapagliflozin can abrogate the alpelisib induced hyperglycemia and subsequent rebound hyperinsulinemia it may significantly improve the therapeutic efficacy of alpelisib."
41313090|NCT02205606|DRUG|HGP0816 5mg|P.O.
40796375|NCT01343836|OTHER|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
41150920|NCT02623101|PROCEDURE|Punch biopsy|Obtaining a skin sample of the suspicious lesion under local anesthetics
40796376|NCT01343836|OTHER|Saline|Intratendinous saline injection with eccentric exercises
41000989|NCT00974571|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
41000990|NCT00974571|DRUG|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
41000991|NCT00974571|DRUG|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
41000992|NCT02194868|BIOLOGICAL|Recipients|"1. Adult recipient:~   * collected 20 ml pre-transplant~  * collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,~  * collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360~2. Children recipients~   * collected residual blood pre-transplant~  * collected residual blood on day 20 post-transplant at engraftment for cell phenotype,~  * collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT"
41150921|NCT02623101|PROCEDURE|Surgical excision|Excision of the basal cell carcinoma lesion under local anesthetics
41150922|NCT00762502|DEVICE|senofilcon A toric contact lens|soft contact lens
41150923|NCT00762502|DEVICE|balafilcon A toric contact lens|soft contact lens
41150924|NCT06106568|PROCEDURE|EOB-MRI|Retrospective analysis for pancreatic cancer patients who had a record of EOB-MRI in the Medical Data Vision (MDV) database in Japan
41150925|NCT06106568|PROCEDURE|Surgery|Retrospective analysis for pancreatic cancer patients who had a record of any surgery for the pancreatic cancer in the Medical Data Vision (MDV) database in Japan
41313091|NCT02205606|DRUG|HGP0816 10mg|P.O.
41313092|NCT02205606|DRUG|HGP0816 20mg|P.O.
41313093|NCT02205606|DRUG|HCP1306 5/10mg|P.O.
41313094|NCT02205606|DRUG|HCP1306 10/10mg|P.O.
41313095|NCT02205606|DRUG|HCP1306 20/10mg|P.O.
40796377|NCT04456478|PROCEDURE|pH at 7.38 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
41313096|NCT03170479|DIETARY_SUPPLEMENT|Vitamin D|Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.
41313097|NCT03170479|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
41313098|NCT06473493|DRUG|Alverine|180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
41313099|NCT02726932|OTHER|No intervention, merely observational|
40796378|NCT04456478|PROCEDURE|pH at 7.22 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
40796379|NCT02516397|DIETARY_SUPPLEMENT|Omnia|12weeks of treatment
40796380|NCT02516397|DIETARY_SUPPLEMENT|Placebo|12weeks of treatment
41150926|NCT06106568|PROCEDURE|Open-close Laparotomy|Retrospective analysis for pancreatic cancer patients who had a record of an open-close laparotomy in the Medical Data Vision (MDV) database in Japan
41150927|NCT05599516|BIOLOGICAL|LIBP-Rec-Vaccine|Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm
41150928|NCT05599516|BIOLOGICAL|BIBP-Rec-Vaccine|Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm
41150929|NCT05599516|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
41150930|NCT03579680|BEHAVIORAL|ADT ORDER CHECK ATTESTATION (OR)|Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior.
41150931|NCT03579680|BEHAVIORAL|PROVIDER SCRIPT (SC)|The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior.
41150932|NCT02232919|DEVICE|Deep Brain Stimulation|"If subjects qualify with respect to protocol requirements, the Medtronic Activa system will be implanted with the leads placed bilaterally in the VMH.~Adjustment of DBS parameters at the three months visit will be performed to improve efficacy when the goal of 3% body weight loss mark was not achieved during this period of continuous stimulation. Subjects will be seen monthly after discharge throughout the study period. At visits, safety will be assessed through blood/urine tests, blood pressure measurements, verbal interviews with the subjects and family, quarterly formal psychiatric tests as well as QOL scales.~The determination of efficacy will be the within-group percent change in weight at the end of the DBS treatment period compared to baseline."
41150933|NCT03403556|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
41150934|NCT03403556|DRUG|Monorova|Rosuvastatin 20mg qd for 24 weeks
41150935|NCT05016674|DEVICE|LipoLife system|Abdominal Laser-Assisted Liposuction
41150936|NCT06585579|DEVICE|Mucogyne Ovule|In Mucogyne group, patient will receive 2 boxes of Mucogyne® ovule. 24 hours after intervention, the patient will apply Mucogyne® ovule, 1 ovule per day for 10 days, to be repeated as needed (for practices' homogenisation, after the 10th day, it is recommended to apply one ovule every second day, until EOS visit)
41150937|NCT02332421|DEVICE|modified dentoalveolar distractor|Here, the modified distractor is going to be used when retracting the canine.
41150938|NCT03887715|DEVICE|Vagus Nerve Stimulation (VNS)|VNS is an implantable device that delivers stimulation to the vagal nerve.
41150939|NCT05798754|PROCEDURE|Loss of resistance (LOR) technique|The thoracic epidural space will be identified by the loss of resistance (LOR) technique
41313100|NCT04092244|DIAGNOSTIC_TEST|CTHRC1 biomarker|its a biomarker detected in the serum of the patients
41313101|NCT06200740|DEVICE|Sonara|web application facilitating asynchronous observation of methadone dosing
41150940|NCT05798754|DEVICE|CompuFlo® technology|The thoracic epidural space will be identified by the CompuFlo® technology
41150941|NCT03534141|DEVICE|Esophageal cooling/warming device|The EnsoETM (formerly known as Esophageal Cooling Device) is a non-sterile multilumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while allowing gastric decompression and drainage. It is placed in a manner identical to a standard orogastric tube, which is standard equipment for liver transplant surgery. It is removed at the end of surgery. Control of the patient's temperature is achieved by connecting the EnsoETM to an external heat exchanger (Gaymar Medi-Therm III or similar system). The Medi-Therm III is a standard device used in operating rooms for warming patients with a conductive table warming pad. The Medi-Therm III circulates temperature-controlled water through a closed-loop system via the two outer lumens of the EnsoETM. Water temperature ranges from 4°C - 42°C.
41150942|NCT03534141|OTHER|Mild hypothermia|Cooling will be initiated after induction of anesthesia and maintained throughout the anhepatic phase of liver transplantation. In all feasible cases the surgeon will cover the peritoneal surface over the right kidney, which is exposed during the operation, with ice-cold sponges to enhance cooling of the renal parenchyma. After blood flow is completely restored to the liver, the esophageal cooling device and other standard measures (forced-air, fluid, and table warmers, plus a heated anesthesia circuit) will be used to actively re-warm the patient (expected warming rate ≥ 1 deg C/hour). The goal is to achieve normothermia by case end.
40796381|NCT02010593|DRUG|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-\[\[4-\[(2,4,6-trimethylphenyl)amino\]-2- pyrimidinyl\]amino\]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
40796382|NCT02010593|DRUG|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
40796383|NCT00060710|DRUG|CP-461|
41150943|NCT03534141|OTHER|Normothermia|After induction of anesthesia, the esophageal cooling/warming device and standard warming measures will be used to maintain normothermia throughout the operation.
41150944|NCT01424176|DRUG|Dexpramipexole (dose 1)|
41150945|NCT01424176|DRUG|Dexpramipexole (dose 2)|
41313102|NCT00062114|BIOLOGICAL|rituximab|
41313103|NCT00062114|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
41313104|NCT02497157|DRUG|Oxaliplatin (L-OHP)|
41471382|NCT06457048|OTHER|Stroke Unit|The stroke unit at the University Teaching Hospital is a 12-bed unit on the general medical wards staffed by neurologists and nurses specifically trained in stroke care. This intervention includes new protocols and clinical practice guidelines that were developed by multiple stakeholders in Zambia to standardize stroke care, with a focus on early and consistent mobilization of patients with stroke, minimizing use of urinary catheters, provision of deep vein thrombosis prophylaxis, formal assessment of swallowing and assignment of modified diets as needed, and appropriate initiation of secondary prevention medications for stroke. Nurses and doctors working in this unit were trained on the new stroke unit protocols and are asked to follow these protocols in caring for patients with stroke admitted to the Stroke Unit.
40796384|NCT04105686|OTHER|Control Infant Formula|Ready to feed infant formula, feed ad libitum
40796385|NCT04105686|OTHER|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
40796386|NCT05703724|DEVICE|AI algorithm for the detection of glaucoma|The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
40796387|NCT01219101|DRUG|clomiphene citrate with ethinyl esteradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
40796388|NCT01219101|DRUG|clomiphene citrate with plasebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
41313105|NCT02497157|DRUG|Irinotecan hydrochloride hydrate (CPT-11)|
41313106|NCT02497157|DRUG|Continuous intravenous infusion of fluorouracil (CIV 5-FU)|
41313107|NCT02497157|DRUG|Levofolinate calcium (l-LV)|
41313108|NCT02497157|DRUG|Bevacizumab (Bmab)|
41313109|NCT04248192|BIOLOGICAL|DD HST-NEETs|HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
41313110|NCT06256783|DRUG|Baozhu Keli|Once enrolled, participants will be administrated Baozhu Keli
41313111|NCT05557955|OTHER|Breathing test|Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.
41313112|NCT03976115|DRUG|DDO-3055|Oral
41313113|NCT03976115|DRUG|Placebos|Oral
41313114|NCT01963208|DRUG|ganaxolone|200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
41313115|NCT01963208|DRUG|Placebo|placebo
41000993|NCT02194868|BIOLOGICAL|Donors|"1. Adult donors :~   * collected 20 ml of blood, (if possible before granulocyte colony-stimulating factor (GCSF) administration)~  * collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.~2. Children donors samples~   * collected residual blood~  * 2ml of bone marrow (bottom of tube)"
41000994|NCT03068975|DRUG|Alvimopan|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
41000995|NCT03068975|DRUG|Placebo|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
40796389|NCT05716867|BIOLOGICAL|Measurement of salivary cystatin S protein levels in saliva|The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls
41000996|NCT01005004|BIOLOGICAL|HuCNS-SC cells|intracerebral transplantation
41000997|NCT03493828|PROCEDURE|TAP block using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
41000998|NCT03493828|PROCEDURE|TAP block using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
41000999|NCT03493828|PROCEDURE|TAP block using Normal Saline|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
41001000|NCT03548012|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
40796390|NCT05535023|DRUG|SAR444245|Given by vein (IV)
40796391|NCT05535023|DRUG|Cemiplimab|Given by vein (IV)
40796392|NCT01960283|DRUG|Methotrexate (Novatrex ®) + anti-H1|"Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group."
40796393|NCT01960283|DRUG|Placebo + anti-H1|"Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group."
40796394|NCT05799703|DEVICE|electrical stimulation device|the device has 2 channels ,4 electrodes with multiple ems programs
40796395|NCT05799703|OTHER|kinesio taping|kinesio tape a therapeutic tape that's applied strategically to the body to provide support, lessen pain, reduce swelling, and improve performance
41001001|NCT02419846|OTHER|Educational Intervention|Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
41001002|NCT02419846|PROCEDURE|digital rectal examination|Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
41001003|NCT02419846|OTHER|Pre-test administration|15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
41001004|NCT02419846|OTHER|Survey Administration|Survey will be administered at the end of the program for participants to assess their experience
41313116|NCT03248245|OTHER|LOG-model|"Besides the LOG-manual, school owners and leaders receive economic compensation and the intervention team will supervise the implementation. School-owners, school leaders and teachers will participate in dialogue-seminars at the municipal level and the school level respectively. The aim is to discuss and agree on the goal and content of the work and discuss the experiences from the implementation. The main arena for discussing and practical implementation will be in local collaborating teams or resource teams in each school. The resource teams at schools will consist of various interprofessional competences in addition to the school leader. The main method in the LOG-model is the interchange and feedback process between the discussion of measures and the execution of these measures."
41313117|NCT03248245|OTHER|TAU|Ordinary practices related to interprofessional team collaboration
41313118|NCT00607568|DRUG|Atomoxetine|"atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II."
40796396|NCT03551613|DIETARY_SUPPLEMENT|honey supplementation|honey supplementation
41313119|NCT00972127|DRUG|Neramexane|25 mg or 2x25mg tablets
40796397|NCT04407156|OTHER|acute kidney injury|AKI in COVID positive cases
41001005|NCT02419846|OTHER|Prostate-specific antigen measurement|PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
40796398|NCT01191515|DEVICE|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
40796399|NCT03879928|DRUG|Single ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
40796400|NCT03879928|DRUG|Multiple ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as MAD doses
40796401|NCT03879928|DRUG|Food effects of FM101|The study drug (FM101) will be administered orally under fasted condition and fed condition.
40796402|NCT04784793|OTHER|App-based group|"Participants received home exercise programs by a postural alignment exercise mobile app we developed.~The postural alignment app included 3 main emerged themes were recorded as self-assessment, neck/shoulder, and upper back-specific exercise content, and motivational notifications.~Participants can evaluate themselves in the application thanks to the self-assessment, receive motivational notifications during the day, and exercise reminders on the days determined by them. They can apply the exercise program with the formed exercise content videos.~The exercise program consists of combined exercises that postural alignment plus exercises of neck spinal stabilization, stretching, and strengthening of neck/shoulders/upper back regions.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
40796403|NCT04784793|OTHER|Control group|"Participants received home exercise programs as a paper handout.~The exercise program was the same for app-based and control groups.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
40796404|NCT01253369|DRUG|Pazopanib|
40796405|NCT04085146|PROCEDURE|Individualized optimal positive end-expiratory pressure|Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
40796406|NCT04085146|PROCEDURE|Conventional positive end-expiratory pressure|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
40796407|NCT03826459|PROCEDURE|Non-Locking Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running \& non-locking technique. The second layer cannot be of a locking technique.
40796408|NCT03826459|PROCEDURE|Locked Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running \& locking technique. The second layer can be locking or non-locking.
41001006|NCT02419846|OTHER|Post test administration|Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
41001007|NCT02559388|DRUG|Montelukast|
41001008|NCT02559388|DRUG|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
41001009|NCT03026621|DIETARY_SUPPLEMENT|Lignite Extract|"The study design is a double-blind case-control trial, whereby half of the participants will be cases and will be asked to take 5mL 'Restore' mineral supplement three times each day. The other half of the participants will be controls and will be asked to take 5mL of a placebo three times each day. Both the study leader and the participants will be blinded to who receives Restore and who receive placebo."
41001010|NCT03026621|OTHER|Herbal tea|This is an herbal tea that will look like the control
41150946|NCT02538055|BEHAVIORAL|Living Healthy|This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.
41313120|NCT02288624|DIETARY_SUPPLEMENT|Processed orange juice|3 different formulation of edible orange drinks
41313121|NCT03300752|BEHAVIORAL|BREATHE Intervention|PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.
41313122|NCT03300752|BEHAVIORAL|Control Intervention|PCP will provide discussion of healthy lifestyles.
40796409|NCT04783311|BIOLOGICAL|EuCorVac-19|Two intramuscular doses (0.5mL per dose) at 3-week interval
40796410|NCT04783311|OTHER|Normal Saline|Two intramuscular doses (0.5mL per dose) at 3-week interval
40796411|NCT01624961|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
40796412|NCT03900728|DEVICE|Auriculotherapy with needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
40796413|NCT03900728|DEVICE|Auriculotherapy with beads|A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
40796414|NCT03900728|DEVICE|Placebo Adhesive disks|Single-use adhesive disks without needles or beads.
40796415|NCT02148068|PROCEDURE|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
40796416|NCT03336086|COMBINATION_PRODUCT|weight loss program|A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
40796417|NCT03777046|BEHAVIORAL|Standard of Care (SOC)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
40796418|NCT03777046|BEHAVIORAL|SOC with Psychology Therapy (CBT)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
40796419|NCT05156437|DRUG|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin
41313123|NCT04702217|OTHER|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists with special interest in POTS.
40796420|NCT05156437|DRUG|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
41313124|NCT03645772|OTHER|Exercise intervention|12-week progressive training intervention
41471383|NCT06250751|BEHAVIORAL|Behavioral Exercise Training (BET) intervention|Introduce and refine concept of exercise and cardiovascular health by initiating walking or cycling and provide behavioral counseling sessions to foster support for adoption and maintenance of exercise, and to troubleshoot barriers. During the first two weeks, the study team will meet with participants twice per week (virtually) to introduce the intervention, familiarize men with the exercise program, exercise logs, resistance bands for strength training. Contact will drop to once per week during weeks 3-8 (total=10 contacts in weeks 1-8). Behavioral counseling will be delivered by the PI or the study coordinator for 30-40 minutes prior to 20-30 mins of an individual or group-based strength training class.
40796421|NCT01504893|PROCEDURE|Protective one lung ventilation|Low tidal volume, PEEP and alveolar recruitment maneuver
40796422|NCT05947916|DEVICE|Real-time Continuous Glucose Monitoring System|The intervention group wore real-time CGM (120 cases) to monitor blood glucose, and was required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.
40796423|NCT01423695|DRUG|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
40796424|NCT05842408|DRUG|DA-5212|Test drug: DA-5212
40796425|NCT05842408|DRUG|DA-5212-R|Control drug: DA-5212-R
40796426|NCT05140772|DRUG|Dipeptiven|IV administration daily for 7 days
40796427|NCT05140772|DRUG|normal Saline|IV administration daily for 7 days
40796428|NCT05016024|DEVICE|Colilen IBS|Patients will take Colilen IBS in First or Second Period
40796429|NCT05016024|OTHER|Placebo|Patients will take PlaceboS in First or Second Period
40796430|NCT03804242|BEHAVIORAL|Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience|This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
41313125|NCT05494541|OTHER|Crizanlizumab|Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.
41471384|NCT05338476|DRUG|Midazolam|Administered orally.
41471385|NCT05338476|DRUG|Selpercatinib|Administered orally.
41313126|NCT01752582|DEVICE|BuMA stent|About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
40796431|NCT00643890|GENETIC|Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus|One-time bilateral administration of rAAV-GAD at 1X10\^12 vector genomes in 35 uL.
40796432|NCT04348812|BEHAVIORAL|ABMT|mobile attention bias modification training for anxiety, using the app Personal Zen
40796433|NCT04348812|OTHER|Transcranial direct current stimulation|Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
41313127|NCT01752582|DEVICE|EXCEL stent|About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
41313128|NCT03545698|OTHER|Avizia Telehealth Platform|Avizia will be utilized as a communication tool between home-based caregivers (family members, formal caregivers, or informal caregivers) and the House Calls care management team.
41313129|NCT06484439|DRUG|Ketorolac|10 mg PO q 6h scheduled
41313130|NCT06484439|DRUG|Oxycodone|5 mg PO PRN
40796434|NCT00690794|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
40796435|NCT00690794|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
41313131|NCT06484439|DRUG|Acetaminophen|650 mg q 6h scheduled
41313132|NCT06484439|DRUG|Ibuprofen|600 mg PO scheduled q6h
41471386|NCT01945619|BIOLOGICAL|Trivirus-Specific CTLs|Patients will receive up to 2 x 10\^7 CHM-CTL/m2 as a single infusion and may receive up to 4 additional infusions at intervals of at least 2 weeks.
40796436|NCT04834908|BIOLOGICAL|Equine COVID-19 Antiserum|Equine COVID-19 antiserum is a polyclonal antibody and it contains Equine COVID-19 immune globulin G.
40796437|NCT04834908|DRUG|Standard of care|Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
40796438|NCT03381664|DRUG|AVP-923|capsule
40796439|NCT04994665|PROCEDURE|sleeve gastrectomy|The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed
40796440|NCT04994665|PROCEDURE|sleeve gastrectomy with omentopexy|After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature
40796441|NCT04848467|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine (CVnCoV)|Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.
40796442|NCT04848467|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.
40796443|NCT04848467|OTHER|Placebo|One intramuscular injection as normal saline \[0.9% NaCl\].
40796444|NCT03775499|DIETARY_SUPPLEMENT|Intervention 1 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
40796445|NCT03775499|OTHER|Intervention 1 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
41313133|NCT06484439|DRUG|Hydrocodone|5 mg hydrocodone PO PRN q6h
41313134|NCT00547638|DEVICE|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
41313135|NCT00547638|DEVICE|cyanoacrylate|Topical Skin Adhesive
41313136|NCT03482323|BEHAVIORAL|Exercise|Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.
41001011|NCT03389711|COMBINATION_PRODUCT|DMARD´s and multidisciplinary treatment|"At study enrollment, medical history, disease-specific autoantibodies, ACR 1987 classification criteria for RA were applied. Medical evaluations were standardized and included at least 66 swollen and 68 tender joint counts, acute reactant-phase determinations , patient and physician reported outcomes, comorbidity established by record review, and treatment assessments (name, dose and schedule of all drug they were taking) along with an evaluation of persistence, at six-month intervals.~Patients were evaluated by a single rheumatologist every two months during the first two years of follow-up, and every two, four or six months thereafter.~Also the following scores: Michigan Hand Outcome Questionnaire (MHQ), Disabilities of the Arm, Shoulder and Hand Outcome Measure (DASH),Mayor Depressive Episodes (MDE) was defined using the Mini International Neuropsychiatric Interview and the severity of depressive symptoms was assessed with the Beck Depression Inventory (BDI-II)."
41001012|NCT04019041|DRUG|bermekimab|bermekimab 2 mL (200 mg/mL) pre-filled syringe
40796446|NCT03775499|DIETARY_SUPPLEMENT|Intervention 2 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
40796447|NCT03775499|OTHER|Intervention 2 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
40796448|NCT04294381|BEHAVIORAL|Decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
40796449|NCT05253755|BIOLOGICAL|DBI-001|Topical application of DBI-001 gel on skin affected with atopic dermatitis.
40796450|NCT05253755|BIOLOGICAL|Aqueous gel|Topical application of aqueous gel on skin affected with atopic dermatitis.
40796451|NCT02595866|DRUG|Antiretroviral Therapy|Given PO
40796452|NCT02595866|PROCEDURE|Biopsy|Undergo biopsy
40796453|NCT02595866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40796454|NCT02595866|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40796455|NCT02595866|BIOLOGICAL|Pembrolizumab|Given IV
40796456|NCT02595866|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40796457|NCT00066612|DRUG|irinotecan hydrochloride|Irinotecan will be given 250 mg/m\^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
40796458|NCT02072252|BEHAVIORAL|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
40796459|NCT04194892|BIOLOGICAL|Pegilodecakin|Administered SQ
40796460|NCT05911958|DRUG|SHR-A1811 for injection|SHR-A1811 for injection
41001013|NCT04019041|DRUG|placebo|placebo 2 mL pre-filled syringe
41001014|NCT03060772|DRUG|Pioglitazone|Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
41001015|NCT01737567|OTHER|Bright Narrow Band Imaging.|Using Bright Narrow Band Imaging to detect colonic adenomas.
41001016|NCT01737567|OTHER|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
41001017|NCT00191503|DRUG|Pemetrexed|
41001018|NCT00191503|DRUG|Gemcitabine|
41001019|NCT04345952|BEHAVIORAL|Calm Meditation Mobile App|The Calm Meditation Mobile App will be used to deliver the meditation intervention to study participants. The Calm app is downloaded onto the participant's smartphone.
41001020|NCT04227522|DRUG|Rucaparib|A starting dose of 600 mg Rucaparib is taken twice daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
41001021|NCT04227522|DRUG|Placebos|Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
41313137|NCT03482323|BEHAVIORAL|Tai-Chi|Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.
40796461|NCT03786926|DRUG|HMPL-689|HMPL-689 is a PI3Kδ inhibitor
40796462|NCT06120686|OTHER|Biofeedback method|Study group - implementing a conventional therapy program supplemented additionally with visual and auditory biofeedback training on a dynamic balance platform
40796463|NCT06120686|OTHER|Conventional therapy program|Control group - rehabilitation management aimed at improving cognitive and motor functions in children with mild intellectual disabilities.
40796464|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
41001022|NCT02233010|OTHER|The level of NGAL after pre op,post op 4hr, post op 12hr|
41313138|NCT03746964|PROCEDURE|Cardiac MRI|Preoperative cardiac MRI
41313139|NCT03746964|OTHER|in-vitro elasticity tests|in-vitro elasticity tests performed on a segment of ascending aorta collected during surgery
41313140|NCT05691634|PROCEDURE|MRI|Patient with a tatoo will perform an MRI. The possible symptoms during the MRI or after MRI will then be described (duration, type,...).
41313141|NCT05691634|OTHER|Likert scale questionnaire|The patient will appreciate his feeling after MRI on a Likert scale (from 1 to 5)
41313142|NCT01005511|DEVICE|Grindcare|Active treatment
41471387|NCT05380921|DEVICE|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
40796465|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
40796466|NCT04780802|PROCEDURE|The balloon catheter is placed at the various arterial feeders of the tumor|use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
40796467|NCT03044275|OTHER|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
40796468|NCT03044275|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
40796469|NCT01018654|BEHAVIORAL|Standard Cognitive Behavioral Treatment|Standard CBT for Substance Abuse
40796470|NCT01018654|BEHAVIORAL|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
41001023|NCT02310919|DRUG|Low dose hCG plus FSH co-trigger|Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
41001024|NCT02310919|DRUG|Standard dose of hCG|Standard dose of hCG (10,000 or 5,000 IU) trigger
41313143|NCT01005511|DEVICE|Grindcare - inactive|Placebo treatment
41313144|NCT03405493|BEHAVIORAL|Wake and Light Therapy|Participants will be helped to change the pattern sleep by depriving participants of sleep for one night. On Day 1 participants will be supported to stay up all night and the following day at the Hospital. Participants can go to bed by 5pm at home on Day 2. Participants will need to get up by about 1am and return to the hospital to be supported to stay awake. Participants will then go to bed at 7pm on Day 3. Participants will be asked to sleep until 3am and then stay awake at home until bed at 9pm on Day 4. Participants will then get up by 5am on Day 5 and stay awake until 11pm to resume a normal sleep routine waking by 7am on Day 6. Participants will also be given a light box to use each morning. For the light box, participants will be asked to sit about one foot away from a light box. You will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes. Participants may continue to have treatment as usual.
41471388|NCT05380921|DEVICE|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
41471389|NCT05528302|OTHER|Tech-CBT intervention|The Tech-CBT intervention is a manualised package that incorporates Cognitive Behavioural Therapy methods.
41471390|NCT02824640|BEHAVIORAL|Patient Navigation|The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
40796471|NCT02691416|DRUG|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
40796472|NCT02691416|DRUG|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
40796473|NCT00125814|DRUG|Interferon alfa-2b|
40796474|NCT00125814|PROCEDURE|Structured treatment interruptions|
40796475|NCT00886860|DRUG|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
40796476|NCT00886860|DRUG|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
40796477|NCT05592990|DRUG|NGI226|NGI226 MP
40796478|NCT05592990|DRUG|Placebo|Placebo MP
40796479|NCT02673983|PROCEDURE|Endoscopic full-thickness biopsy|
41001025|NCT05522465|DRUG|Prednisone|Prednisone 4mg/kg.d, d1-4
41313145|NCT03405493|BEHAVIORAL|Sleep and Light Therapy|Participants will be given information and advice on how to get a good night's sleep. Participants will be also given a light box to use in the morning for 1 week. For the light box, participants will be asked to sit about one foot away from a light box. Participants will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes when you get up. Participants may continue to have any treatment as usual (for example medication or talking therapies).
41313146|NCT01442532|DRUG|JNJ-38518168 (30 mg)|Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
41313147|NCT01442532|DRUG|JNJ-38518168 (10 mg)|Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
41001026|NCT05522465|DRUG|Dexamethasone|Dexamethasone 0.6mg/kg.d, d1-4
41313148|NCT01442532|DRUG|JNJ-38518168 (3 mg)|Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
41313149|NCT01442532|DRUG|Placebo|Form=tablet, route=oral use, for 14 days
41313150|NCT01442532|DRUG|Midazolam and JNJ-38518168|Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
41313151|NCT02929849|DIETARY_SUPPLEMENT|300 mg SC|Salacia (T1) capsule given with breakfast (mixed meal tolerance test)
41471391|NCT02824640|BEHAVIORAL|modified Directly Observed Therapy|Subjects will be observed taking medications, a minimum of 5 times a week for those enrolled in the OAT setting, and a minimum of 3 times a week for those enrolled in the community health clinic setting.
40796480|NCT03233139|DRUG|Cemiplimab|Patients will be administered cemiplimab as per protocol. For Cohort A Only, patients with confirmed progressive disease may opt to receive up to 4 cycles of platinum doublet chemotherapy in addition to cemiplimab per investigator's judgement.
41001027|NCT05691231|DEVICE|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
40796481|NCT03233139|DRUG|Ipilimumab|To be administered per protocol
41001028|NCT02530424|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
41150947|NCT02538055|BEHAVIORAL|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
41313152|NCT02929849|DIETARY_SUPPLEMENT|500 mg SC|Salacia (T2) capsule given with breakfast (mixed meal tolerance test)
41313153|NCT02929849|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given with breakfast (mixed meal tolerance test)
41313154|NCT03116373|OTHER|mandible fixation|Intubation device will be fixed on mandible
41313155|NCT03116373|OTHER|Maxilla fixation|Intubation device will be fixed on maxilla
41313156|NCT03053596|DEVICE|DEB-TACE using anthracyclin loaded LifePearl™|The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.
41313157|NCT03874624|DIAGNOSTIC_TEST|two-dimensional speckle tracking|Analysis of myocardial left atrial strain using two-dimensional speckle tracking echocardiography.
41313158|NCT01689376|DRUG|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
41313159|NCT01032993|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks
41313160|NCT01032993|OTHER|Placebo|Placebo (three chewable tablets) 2 times daily for 4 weeks
41471392|NCT02409940|BIOLOGICAL|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
41471393|NCT02198924|DRUG|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
41471394|NCT02198924|DRUG|placebo|control patients are supplied with the corresponding placebo with the same instructions.
41471395|NCT03769506|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|Use of ASP-1929 PIT therapy
41471396|NCT03769506|DRUG|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
41471397|NCT04836351|OTHER|Concentrated rehabilitation for patients with persistent symptoms post COVID-19|3+ 1-2 days concentrated rehabilitation for patients with persistent symptoms post COVID-19 with a mobile application follow-up and physical consultations at 3 months post intervention.
41471398|NCT04196452|DRUG|Ipilimumab|Specified dose on specified days
40796482|NCT03233139|DRUG|Platinum-doublet chemotherapy|To be administered per protocol
40796483|NCT03233139|DRUG|Gemcitabine|To be administered per protocol
40796484|NCT03233139|DRUG|Pemetrexed|To be administered per protocol
40796485|NCT03233139|DRUG|Paclitaxel|To be administered per protocol
41001029|NCT02530424|DRUG|Pertuzumab|Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
41001030|NCT02530424|DRUG|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
41001031|NCT02530424|DRUG|Fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
41001032|NCT04169867|BIOLOGICAL|Collection of stool samples|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
41001033|NCT03578081|DRUG|Palonosetron Hydrochloride|Given IV
41001034|NCT03578081|DRUG|Ondansetron Hydrochloride|Given IV or PO
41001035|NCT03578081|DRUG|Dexamethasone|Given PO
41001036|NCT03578081|DRUG|Fosaprepitant Dimeglumine|Given IV
41001037|NCT03578081|DRUG|Olanzapine|Given PO
41150948|NCT03966014|DRUG|EM-amoxicillin 3 x 10 days|Patients will receive amoxicillin 500 milligram tid for 10 days
41150949|NCT03966014|DRUG|EM-amoxicillin 3 x 14 days|Patients will receive amoxicillin 500 milligram tid for 14 days
41471399|NCT01906424|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
41471400|NCT02250924|DIETARY_SUPPLEMENT|Caffeine|caffeinated gum
41471401|NCT02250924|OTHER|Gum|Chewing gum
40796486|NCT03233139|DRUG|Fianlimab|To be administered per protocol
40796487|NCT04901806|DRUG|PBI-200|PBI-200 will be administered orally over continuous 28-day cycles
40796488|NCT04713410|DRUG|Prednisolone|Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
40796489|NCT05353114|OTHER|3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).|The 3D foot scan becomes a movile app that recommends a specific size and model of therapeutic footwear according to the measurements
40796490|NCT00510445|DRUG|Imetelstat Sodium (GRN163L)|"The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle."
40796491|NCT02440204|PROCEDURE|Intubation|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
41001038|NCT03578081|OTHER|Placebo|Given IV
41001039|NCT01159964|BIOLOGICAL|Immunotherapeutic GSK2302032A, different formulations|Intramuscular administration
41471402|NCT02250924|BEHAVIORAL|wear silicone bracelet|Subjects will put on bracelet to correspond with times for chewing gum
41471403|NCT04622124|DRUG|Placebo|
40796492|NCT02440204|DRUG|Remifentanil|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
41150950|NCT03966014|DRUG|EM-amoxicillin 2 x 14 days|Patients will receive amoxicillin 500 milligram bid for 14 days
41150951|NCT03966014|OTHER|Controls|No intervention.
41150952|NCT06003881|DRUG|Pozelimab|Subcutaneous (SC) administration
41150953|NCT03472859|DEVICE|PHOTOLASE|This is the investigational yellow laser (PHOTOLASE)
40796493|NCT02440204|DRUG|Sevoflurane|The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
40796494|NCT00430989|OTHER|Nitrous Oxide|General anaesthesia with the inclusion of Nitrous Oxide at 70%
41001040|NCT01494610|DRUG|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
41001041|NCT01494610|DRUG|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
41001042|NCT02404350|BIOLOGICAL|Secukinumab|Anti IL-17a monoclonal antibody
41001043|NCT03514121|BIOLOGICAL|FPA150|A monoclonal antibody against B7-H4
41001044|NCT03514121|BIOLOGICAL|Pembrolizumab|An anti-PD1 antibody
41001045|NCT03321669|PROCEDURE|Capsule endoscopy|Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
41001046|NCT01665274|DRUG|Capecitabine|Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
41150954|NCT03472859|DEVICE|KTP|This is the traditional green laser (KTP)
41150955|NCT03635047|BIOLOGICAL|AL002|Single-doses of AL002 in up to 9 dose-escalating cohorts
41001047|NCT01665274|DRUG|Oxaliplatin|Oxaliplatin IV infusion, 130mg/m² d1, q3w
41150956|NCT03635047|OTHER|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients
41150957|NCT03959735|OTHER|High Intensity Interval Training (HIIT)|HIIT is a type of exercise involving alternating short bursts of high intensity exercise with recovery periods of rest or light exercise.
41150958|NCT04453137|BIOLOGICAL|Adalimumab originator|Subcutaneous injection every other week
41150959|NCT04453137|BIOLOGICAL|Adalimumab biosimilar|Subcutaneous injection every other week
41150960|NCT05556772|PROCEDURE|Biospecimen Collection|Collection of blood; urine; cervical, anal, vaginal samples
41150961|NCT05556772|OTHER|Interview|Attend interview
41150962|NCT03788941|PROCEDURE|left atrial appendage closure and catheter ablation|"Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation."
41471404|NCT04622124|DIETARY_SUPPLEMENT|fasted vs. high-fat meal|
41471405|NCT04622124|DRUG|Placebo|
41471406|NCT02451306|DRUG|Quetiapine|See information in arm description.
41471407|NCT02451306|DRUG|Placebo|See information in arm description.
41471408|NCT01872845|DRUG|Pravastatin 40mg|Pravastatin 40mg PO daily for 1year from the day of BES implantation
41471409|NCT01872845|DRUG|Rosuvastatin|Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
41001048|NCT01665274|PROCEDURE|D2 resection|D2 resection
41313161|NCT01063816|DRUG|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
41313162|NCT01063816|DRUG|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
41313163|NCT01063816|DRUG|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
40796495|NCT00430989|OTHER|No Nitrous Oxide|General anaesthesia with no use of Nitrous Oxide
40796496|NCT04037891|DRUG|rVA576|"19 Patients with moderate to severe AKC. the study includes two parts: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.~Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial."
40796497|NCT04037891|OTHER|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
41150963|NCT02589678|BIOLOGICAL|Tdap - IPV Vaccine|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
41150964|NCT02589678|BIOLOGICAL|MMR Vaccine|A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
41150965|NCT03588676|OTHER|Melatonin|5mg Melatonin
41150966|NCT03588676|OTHER|Placebo|5mg Placebo capsule
41150967|NCT05872906|DEVICE|Acupuncture|A 1.5-inch needle of 34 gauge (CASOON stainless steel acupuncture needles) is inserted. The physician will then locate the de qi location of the test subjects and elicit a de qi response accompanied by muscle twitch.
41150968|NCT03581253|OTHER|"Facial disability Index (FDi)"|questionnaires regarding to quality of life
41150969|NCT03581253|OTHER|"Facial Clinimetric Evaluation (FaCE)"|questionnaires regarding to quality of life
41313164|NCT03752606|BIOLOGICAL|TACHOSIL GROUP|
41313165|NCT05312931|OTHER|OSCE|Students undergo OSCE (objective structured clinical exams). It means students will perform CPR for 2 min and their success rate will be monitored.
41313166|NCT06025123|DEVICE|Early transnasal evaporative cooling with the RhinoChill device|Early prehospital transnasal evaporative cooling followed by systemic hypothermia to 33 degrees Celsius for 24 hours and fever control for 72 hours
41313167|NCT02900924|DEVICE|BioMimics 3D Stent|
41313168|NCT04821973|DEVICE|Radius PPG Tetherless Pulse Oximetry (Masimo)|continuous monitoring by a portable, wireless and stand-alone device
41313169|NCT04821973|DEVICE|usual monitoring|usual nurse respiratory monitoring
41313170|NCT04218916|DRUG|Rhodiola Rosea Capsules|0.28g per capsule, 0.56g once (2 capsules), three times a day
41313171|NCT04218916|DRUG|Placebo|2 placebo capsules once, three times a day
41313172|NCT06124547|DRUG|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
41001049|NCT06104501|DEVICE|RadiHeart|The participants' blood pressure will be measured multiple times by both the mercury sphygmomanometer and RadiHeart, by using the same arm sequential method.
41001050|NCT05326139|DRUG|Tranexamic acid|TA-soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
41001051|NCT05326139|OTHER|Isotonic saline|Isotonic saline -soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
41001052|NCT06405139|DRUG|Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine|Nanoliposomal irinotecan 60mg/m2; Oxaliplatin 85 mg/m2; Capecitabine 800 mg/m2 twice daily, day 1 to 7; repeated every two weeks.
41001053|NCT02674412|DRUG|Buspirone|
41001054|NCT02674412|DRUG|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
41001055|NCT01955070|OTHER|Multimedia Presentation for Ketamine sedation|PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
41001056|NCT05618106|OTHER|variations of the low FODMAP diet|"Cross-over of 3 interventions in IBS patients:~1. Low Polyol diet~2. Low FOS+GOS diet~3. Low FODMAP diet"
41001057|NCT03592433|BEHAVIORAL|I Can PIC|Participants will be shown (on a computer or via email link) a website called I Can PIC. I Can PIC provides health insurance education, suggests ways to learn about the costs of cancer care and follow-up, shows resources to help offset the high costs of care, and helps individuals estimate (based on national data) how much they might spend on health insurance in the upcoming year.
41001058|NCT01813318|DRUG|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
41001059|NCT01813318|DRUG|Placebo|Subjects receiving placebo will be dosed similarly to the acamprosate group.
41001060|NCT04602572|BEHAVIORAL|Lifestyle course.|Pharmacotherapy
41001061|NCT04602572|PROCEDURE|Bariatric surgery.|Sleeve gastrectomy or gastric bypass.
41001062|NCT03080259|BEHAVIORAL|Stimulant Diversion Prevention (SDP)|provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
41001063|NCT05823558|DIAGNOSTIC_TEST|Lomber Muscle Thickness Measurement|Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.
41001064|NCT05851729|OTHER|Kegal exercises with postural correction|Kegal exercises with postural correction
41001065|NCT05851729|OTHER|Kegal exercises without postural correction|Kegal exercises without postural correction
41001066|NCT00310908|DRUG|Tramadol Hcl|Active Comparator
41001067|NCT05324163|DRUG|X0002 Spray|X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
41001068|NCT05324163|DRUG|Celecoxib capsules|X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
41001069|NCT05324163|DRUG|placebo|X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
41001070|NCT02237846|BIOLOGICAL|Human umbilical cord tissue-derived mesenchymal stem cells|
41001071|NCT04371380|DRUG|Cabotegravir Tablets|Cabotegravir tablets will be white to almost white oval shaped film coated tablets with a unit dose of 30 mg and will be administered orally.
41150970|NCT02035488|DRUG|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
41313173|NCT04662216|PROCEDURE|Scaling and root planing|Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes).
41001072|NCT04371380|DRUG|Rilpivirine Tablets|Rilpivirine tablets will be off-white, round, biconvex film coated tablets with a unit dose of 25 mg and will be administered orally.
41001073|NCT04371380|DRUG|Cabotegravir extended release suspension for injection (long-acting)|Cabotegravir long-acting will be a sterile white to slightly pink suspension containing 200 mg per mL of GSK1265744 as free acid for administration by intramuscular injection.
41001074|NCT04371380|DRUG|Rilpivirine extended release suspension for injection (long-acting)|Rilpivirine long-acting will be a sterile white suspension containing 300 mg per mL of rilpivirine as the free base for administration by intramuscular injection.
41001075|NCT02119546|OTHER|Aerobic exercise|Aerobic exercise and dual-task training
41001076|NCT02119546|OTHER|Stretch exercise|Stretch exercise \& sitting balance
41001077|NCT01879566|OTHER|No intervention will be done. The study is observational|
41001078|NCT05363735|OTHER|Ultrasound Elastography|Patients will be examined by ultrasound elastography.
41001079|NCT05756764|DRUG|Semaglutide|Medication for weight loss
41001080|NCT05756764|DRUG|Phentermine-Topiramate combination|Medication for weight loss
41150971|NCT06164119|OTHER|manual treatment with osteopathic techniques and nutritional treatment|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet)
41150972|NCT06164119|OTHER|manual treatment with osteopathic techniques|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques)
41150973|NCT06164119|OTHER|nutritional treatment|nutritional treatment (personalized Mediterranean Diet)
41001081|NCT05756764|DRUG|Phentermine|Medication for weight loss
41001082|NCT05756764|DRUG|Tirzepatide|Medication for weight loss
41001083|NCT05756764|DRUG|Topiramate|Medication for weight loss
41001084|NCT05756764|DRUG|Diethylpropion|Medication for weight loss
41001085|NCT05756764|DRUG|Naltrexone/Bupropion|Medication for weight loss
41001086|NCT05756764|DRUG|Liraglutide|Medication for weight loss
41001087|NCT02526407|BEHAVIORAL|Singing|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
41001088|NCT02526407|BEHAVIORAL|Group play|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
41001089|NCT03950518|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules, 12mg/d
41001090|NCT03950518|DRUG|Arginine hydrochloride|AHC,12mg/d AH,40g/d
41313174|NCT04662216|PROCEDURE|"Scaling and root planing + Perisolv +Hyadent BG gels"|"Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes), Perisolv gel will adjectively be applied to all pockets with probing depth(PD) ≥ 5 mm, which will be inserted into periodontal pockets before and during SRP (2 times). The nozzle will be placed in the pocket mesially, lingually, distally and bucally. Afterwards, all teeth will be polished and all treated pockets will be filled with hyaluronic acid gel (Hyadent BG)."
41313175|NCT06372821|DRUG|NIO752|Antisense oligonucleotide
41313176|NCT06372821|OTHER|Placebo|Saline
41471410|NCT03332251|DEVICE|Posture Correction Girdle|Participants will be invited to undergo a fitting session of posture correction girdle. After the fitting, participants will join a 6-month wear trial of the posture correction girdle. Participants are required to wear the girdle for 8 hours a day and the compliance will be recorded by a logbook daily. Participants will be invited to undergo assessments before the wear trial, after the trial of 3 months, and after the trial of 6 months. The measure outcomes of the assessment include 1) ultrasound scanning image, 2) 3D body scan, 3) electromyography signal, 4) garment pressure, and 5) questionnaire.
40796498|NCT03838211|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
40796499|NCT03838211|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
40796500|NCT03559517|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
40796501|NCT03559517|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
41471411|NCT01297816|DRUG|placebo|100mg,BD, fo three month
40796502|NCT05163314|DRUG|Soticlestat|Soticlestat mini-tablets or tablets
40796503|NCT04809493|PROCEDURE|Conventional dialysis treatment|Conventional dialysis treatment
40796504|NCT04809493|PROCEDURE|Isonatremic dialysis treatment|Isonatremic dialysis treatment
40796505|NCT01097096|BIOLOGICAL|CAD106|150μg and 450μg doses were reconstituted and administered via intramuscular injection
40796506|NCT01097096|BIOLOGICAL|Placebo|Identical placebo to CAD106 administered via intramuscular injection
40796507|NCT01097096|BIOLOGICAL|Alum|An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106
40796508|NCT01097096|BIOLOGICAL|MF59|An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106
40796509|NCT01496053|DIETARY_SUPPLEMENT|AndoSan|AndoSan 30 ml x 2 for 21 days
40796510|NCT01496053|DIETARY_SUPPLEMENT|Sugar Extract|Sham comparator
40796511|NCT05077839|DRUG|Trifluridine/Tipiracil|Trifluridine/tipiracil was approved in the third-line treatment of advanced colorectal cancer. Its efficacy in the first-line treatment was unknown.
40796512|NCT05358626|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody testing|IgG Antibody testing for previous exposure to SARS-CoV-2
40796513|NCT00931125|DRUG|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
40796514|NCT00931125|PROCEDURE|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
41471412|NCT01297816|DRUG|Minocycline|100mg
40796515|NCT01229046|DRUG|Ticarcillin-clavulanic acid|5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
40796516|NCT06149676|DRUG|Saccharomyces Boulardii 250 MG [Florastor]|All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin
40796517|NCT04538118|BEHAVIORAL|Shoulder disability|"Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
40796518|NCT04538118|DEVICE|Shoulder Range of Motion|"Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
40796519|NCT04538118|BEHAVIORAL|Pain Intensity|"Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
40796520|NCT05841719|OTHER|Screening test|Capillary blood sampling by finger-prick devices and second confirmatory venous sampling when needed.
40796521|NCT04701060|DRUG|Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w|preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
40796522|NCT02229825|DRUG|Duloxetine|Capsule
40796523|NCT02229825|DRUG|Placebo|Capsule
40796524|NCT01202890|DRUG|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
41313177|NCT00677690|OTHER|neuromuscular electrical stimulation (NMES)|NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.
40796525|NCT01202890|DRUG|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
40796526|NCT05080439|OTHER|Diacutaneous Fibrolysis|Application of diacutaneous fibrolysis in teres major
40796527|NCT05080439|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
41313178|NCT00677690|OTHER|Sham electrical stimulation|Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
41313179|NCT01858155|DRUG|Melatonin|
41471413|NCT05992987|DIAGNOSTIC_TEST|Adenosine deaminase serum level|Adenosine deaminase will be measured by enzymatic (clorometric / kinetic) method (Diazyme laboratories, San Diego, California, USA).
40796528|NCT00049257|DRUG|carboplatin|Administered Day 1 of each cycle. AUC=6.
40796529|NCT00049257|DRUG|paclitaxel|administered Days 1, 8, and 15 of each cycle. 100mg/m2
40796530|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-in technique|This method consists of inserting the needle with the stylet-in, then only remove the stylet once the desired depth is achieved and CSF flow is expected. If no CSF comes back, the stylet is replaced before continuing to advance the needle until the subarachnoid space is entered. This is the technique generally used in our emergency department and will serve as the control treatment group.
40796531|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-out technique|This method consists of inserting the needle through the epidermis and the dermis, which is estimated as a 0.5 to 1 cm length in children, then remove the stylet before progressing through the other structures until the subarachnoid space is entered. This approach will be used in the experimental technique group.
40796532|NCT00135330|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
40796533|NCT00135330|DRUG|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
40796534|NCT04449107|BEHAVIORAL|Android based mobile phone application|An android based mobile application will be developed. The application will have features and capacity for text messages, voice messages, pictorial messages and video messages. The content of the messages will be according to the findings of Paigham e sehat project and the four messages domains would be educational, reminder, religious and adverse effects. In addition, pictorial and video messages would be used as per freely available through EPI programme Pakistan.
40796535|NCT02073812|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
40796536|NCT00287001|DEVICE|Cold air cooling|
41313180|NCT00059215|DRUG|Prasugrel (CS-747)|Administered orally
40796537|NCT05190978|DEVICE|Acellular Dermal Matrix|Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
41313181|NCT00059215|DRUG|Clopidogrel|Administered orally
40796538|NCT05190978|PROCEDURE|Reconstruction without ADM|Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
41313182|NCT01534234|DEVICE|PARADYM RF SONR|SonR CRT Optimization
40796539|NCT04710498|DRUG|Atezolizumab|Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
40796540|NCT03444545|DEVICE|Capnodynamic method|"Expired carbon dioxide is measured with a mainstream infrared sensor (Capnostat-3, Respironics Inc, Wallingford, CT, USA) and gas flow analysed with the flow sensor incorporated in the ventilator (Servo-i, Maquet Critical Care, Solna, Sweden) which was connected to a computer where all the mathematical analysis is carried out with a software written in Matlab™ (The Mathworks Inc, Natick, MA, USA).~Instead of a fixed ratio between inspiration and expiration, three breaths out of every nine are prolonged with a 3-4 seconds longer expiration creating small changes in end- expiratory CO2"
41001091|NCT03950518|DRUG|levamisole|AHC,12mg/d AH,40mg/d LM,150mg/d
41471414|NCT05992987|DIAGNOSTIC_TEST|IgE antibodies serum level|Level of IgE will be measured by electrochemiluminesence immunoassay (ECLIA, automatic cobase immunoassay, Roche Diagnostics GmbH, Mannheim, USA).
41313183|NCT01534234|DEVICE|PARADYM RF SONR|Echocardiography Optimization
41313184|NCT04895605|DEVICE|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
41313185|NCT04895605|DEVICE|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
41313186|NCT01885078|DRUG|Baricitinib|Administered orally
41313187|NCT01885078|DRUG|Placebo|Administered orally
40796541|NCT03444545|DEVICE|Transpulmonary thermodilution|Each cardiac output measurement comprises an average of three thermodilutions performed successively one after another. TPTD is performed with a PiCCO2 monitor (Pulsion Medical Systems SE, Feldkirchen, Germany)
40796542|NCT04172350|OTHER|iCareBreast|The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
40796543|NCT04172350|OTHER|Routine care|Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
40796544|NCT05976152|DRUG|dl-3-butylphthalide|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
40796545|NCT05976152|DRUG|dl-3-butylphthalide placebo|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
41313188|NCT02723110|OTHER|4 Hour Frequently Sampled Oral Glucose Tolerance Test|Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
41001092|NCT04067362|OTHER|food containing dietary fiber|commercially available chicory root flour and chicory root fiber
41001093|NCT01978314|DEVICE|75 mg / 6 mL VFI™|Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
41001094|NCT01914224|BEHAVIORAL|dietary education of low sodium and high potassium consumption|
41001095|NCT01914224|BEHAVIORAL|dietary education of low sodium consumption only|
41001096|NCT05724849|DRUG|Venlafaxine|See arm/group description.
41001097|NCT05724849|DRUG|Placebo|See arm/group description.
41001098|NCT03966716|DEVICE|Arthroplasty|Patients with an undisplaced femoral neck fracture receive a hemi or total hip arthroplasty depending on each hospital's routine for patient age and mobility.
41001099|NCT03966716|DEVICE|Internal Fixation|Patients with an undisplaced femoral neck fracture undergo a closed reduction and internal fixation with 2-3 screws or pins, or sliding hip screw device. Type of fixation depends on each hospital's routine.
41001100|NCT05401838|BEHAVIORAL|Group Brief Cognitive-Behavioral Therapy (G-BCBT)|G-BCBT comprises 12, 90 minute sessions organized in three phases: (1) emotion regulation, (2) cognitive flexibility, and (3) relapse prevention. The first session will be a tailored individual session focusing on person-specific crisis response planning and developing the participant's suicide mode. Sessions 2 through 5 feature treatment goal setting, followed by teaching skills in stimulus control, mindfulness, relaxation, a reasons for living task, and survival kit. Sessions 6 through 10 provide opportunities for improving cognitive flexibility via cognitive-behavioral exercises such as ABC worksheets, challenging questions, patterns of problematic thinking worksheets, coping cards, and activity planning. The third phase of treatment focuses on relapse prevention, and encompasses the last two sessions of treatments where group participants demonstrate mastery of the skills learned in treatment and practice successfully navigating a future stressful situation.
41313189|NCT02723110|OTHER|Isoglycaemic Clamp|Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
41313190|NCT05259267|BEHAVIORAL|Online Group Therapy for PTG|Online Group Therapy for PTG consists of eight sessions. Each sessions have specific themes. First session: psychoeducation, normalization of the experiences and emotions. Second session: emotion regulation skills. Third session: awareness of the negative thoughts that make patients worried, anxious, feared. Forth session: restructuring of the thoughts and practicing mindfulness technics. 5. session: practicing of self-disclosure skills 6. session: creating a breast cancer story with balancing losses and gains. 7. session: sharing of the effects of breast cancer on life and developing new life priorities 8. session: making life meaning and developing new life goals.
41313191|NCT05259267|BEHAVIORAL|Online Support Group|Online support groups also consist of eight sessions. 1. session: introducing the program and learning the expectancies 2. session: sharing what is known about breast cancer 3. session: risk and protective factors for breast cancer 4. session: sharing side effects of surgical operation and treatments 5. session: sharing the reactions of family, close friends 6. session: patient-doctor relationship and also sharing the challenges and facilitators of healthcare system 7. session: sharing the current position in the treatment and of what has been done for improvement 8. session: sharing the reliable information sources for breast cancer and close
40796546|NCT05744778|OTHER|Dry needling|In addition to the physical therapy and exercise program, the dry needling group will consist of patients who have had 3 sessions of dry needling applied to the trigger points in the trapezius muscle, 5 days apart.
40796547|NCT05744778|OTHER|Physical therapy and rehabilitation|The physical therapy and rehabilitation group will consist of patients who will be applied the same exercise program together with the same physical therapy applications (superficial heat (infrared lamp), transcutaneous electrical nerve stimulation (TENS) and therapeutic ultrasound (TUS)) 5 sessions per week for 3 weeks.
40796548|NCT01248728|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
40796549|NCT01248728|DIETARY_SUPPLEMENT|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
40796550|NCT03326635|OTHER|Frailty in elderly (≥70 y) patients in ICU|Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
40796551|NCT04170998|DRUG|Evogliptin 5mg|Participants receive Evogliptin 5mg orally once a day
41313192|NCT00004929|BIOLOGICAL|MUC-2-KLH vaccine|
40796552|NCT04170998|DRUG|Evogliptin Placebo|Participants receive placebo to match Evogliptin 5mg orally once a day
40796553|NCT04170998|DRUG|Dapagliflozin 10mg|Participants receive Dapagliflozin orally once a day
40796554|NCT04170998|DRUG|Metformin ≥ 1000mg|Metformin are administered at the same dose and formulation.
40796555|NCT03007420|DRUG|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
40796556|NCT03007420|DRUG|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
40796557|NCT05957458|DEVICE|Airdoc device of red light for Myopia|This light is Narrow-Band, Long-Wavelength Lighting with three different illumination (400lux, 800lux, 1200lux) or irridiance (1.2mW, 0.6mW, 0.37mW) respectively. And the wavelength is 650nm. It allows biocular therapy.
40796558|NCT01689987|DRUG|Cyclophosphamide|Given IV
40796559|NCT01689987|DRUG|Dexamethasone|Given PO
40796560|NCT01689987|DRUG|Hydroxychloroquine|Given PO
40796561|NCT01689987|OTHER|Laboratory Biomarker Analysis|Correlative studies
41313193|NCT00004929|BIOLOGICAL|QS21|
41313194|NCT05875558|PROCEDURE|M-TACE|Lipiodol combined with microspheres
40796562|NCT01689987|OTHER|Pharmacological Study|Correlative studies
40796563|NCT01689987|DRUG|Sirolimus|Given PO
41313195|NCT06134791|OTHER|No intervention|No intervention
41313196|NCT03548038|OTHER|taste test|All subjects will complete a procedure to determine their taste sensitivity to sweet tastants.
40796564|NCT01248572|DEVICE|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
41471415|NCT06473402|DIAGNOSTIC_TEST|Muscle Strength Test|Hamstring muscle strength of the participants was measured with a dynamometer (Microfet 2, Hoggan Health Industries, HHD) with the knee flexed at 90 degrees. After the physiotherapist fixes and positions the dynamometer 5 cm proximal to the calcaneus with a belt, the participant will be asked to accelerate to maximum isometric strength by trying to bring his heel closer to his hip against this resistance. The isometric strength of the hamstring muscle will be measured in Newtons (N) by being asked to wait at maximum force level for three seconds. Measurements were made in 2 repetitions and the highest value was noted. There will be a 30-second rest period between attempts.
41471416|NCT06473402|DIAGNOSTIC_TEST|Hamstring Flexibility|The Sit and Reach Test will be administered to evaluate flexibility. Measurements will be made with a test stand with a length of 35 cm, a width of 45 cm and a height of 32 cm. The measurement of the participant who cannot reach the zero point of the sole of the foot on this tripod will be recorded as minus (-), while the measurement of the participant who can pass the zero point will be recorded as plus (+). Participants will be seated in a long sitting position with the soles of their feet resting on the testing apparatus, and the measurement will begin with their knee joints fully extended. While leaning his body forward, he will be asked to lie forward as far as he can, with his hands in front of his body, without bending his knees. The test will be repeated 2 times and the best value will be recorded in cm.
41471417|NCT06473402|DIAGNOSTIC_TEST|Knee Range of Motion|Joint range of motion measurement of the participants was made with a universal goniometer. Degree was used as the measurement unit. The measurement was made in the prone position. The pivot point of the goniometer is placed on the lateral epicondyle of the femur, and the fixed arm is kept parallel to the lateral midline of the femur, while the movable arm will follow the fibula. The joint range of motion of the participants was measured before and after manual therapy. AAOS (American of Orthopedic Surgeons) was taken as the reference value.
41471418|NCT06473402|DEVICE|Percussion Therapy|A percussion massage device was used in the study. Massage application was applied to the Hamstring muscle, adhering to optimal standards. During the application, a wide round head, which is the most preferred by clinical professionals, was used and 30 Hz, which is considered as the average application speed, was used. The application was applied for a total of 6 minutes, 2 minutes for each part of the muscle. Applications have been made many times on every part of the muscle, from the starting point to the ending point.
40796565|NCT02295228|OTHER|No intervention|There are no interventions. This is an observational trial.
41001101|NCT05401838|BEHAVIORAL|Dialectical Behavior Therapy (DBT) Skills Group|DBT comprises 24 weekly group therapy sessions each lasting 90 minutes. DBT sessions include worksheets and skills practice activities. The DBT protocol entails three phases as follows. Phase I (8 weeks) covers a two-week mindfulness orientation and a six-week distress tolerance module. Distress tolerance skill building includes paired muscle relaxation, distraction, and radical acceptance. Phase II (nine weeks) entails a two-week mindfulness module followed by seven weeks of emotion regulation skill building. Emotion regulation content includes a model of describing emotion and a pleasant events checklist. Phase III (7 weeks) includes two-week mindfulness and orientation module, followed by five weeks of interpersonal effectiveness training. Interpersonal effectiveness training approaches include clarifying goals in interpersonal situations, guidelines for keeping relationships, and self-respect. Mindfulness, cutting across modules, addresses review of concepts such as Wise Mind.
41001102|NCT00738972|DRUG|valsartan|80 mg valsartan. Duration: 12 months. Tablets
41001103|NCT00738972|DRUG|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
41313197|NCT01575405|DRUG|Rectal formulation (RF) of tenofovir 1% gel|The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
40796566|NCT06345261|DRUG|DiphenhydrAMINE 50 Mg/mL Injectable Solution|injection of Diphenhydramine 50 Mg/mL
40796567|NCT06345261|DRUG|Saline|injection of saline
40796568|NCT03774771|DRUG|Cinacalcet|Capsule for oral administration
40796569|NCT03774771|DRUG|Placebo|Capsules for oral administration
40796570|NCT04094493|DRUG|vit D|preoperative intra muscular vit D injection
40796571|NCT00923351|DRUG|Tumor Purged/CD25 Depleted Lymphocytes|
41001104|NCT00738972|DRUG|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
41001105|NCT00738972|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
41001106|NCT05515848|OTHER|No intervention|There is no intervention in this retrospective study.
41001107|NCT01726257|DEVICE|Nellix System|Subjects in this study will receive a Nellix Endovascular Sealing System as part of their intervention.
41001108|NCT05520008|OTHER|Game-based exercise|Patients in the active group will put on a sensor connected to a tablet to play a game-based foot/ankle exercise twice a day for 5 minutes for four weeks.
41001109|NCT03857087|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
41001110|NCT03857087|PROCEDURE|Magnetic Resonance Imaging (MRI)|Given PET/MRI
40796572|NCT00923351|BIOLOGICAL|Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
40796573|NCT00923351|DRUG|rhIL-7|rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
40796574|NCT00923351|BIOLOGICAL|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
40796575|NCT00887159|DRUG|Cisplatin|Given IV
40796576|NCT00887159|BIOLOGICAL|Cixutumumab|Given IV
40796577|NCT00887159|DRUG|Etoposide|Given IV
40796578|NCT00887159|OTHER|Laboratory Biomarker Analysis|Correlative studies
40796579|NCT00887159|DRUG|Vismodegib|Given PO
40796580|NCT04437550|OTHER|Exercise|high intensity exercise = 15 x 60 s sprints at 85% velocity of VO2max (vVO2max) with 60 s walking at 20% vVO2max or moderate intensity exercise = walking at 60% vVO2max
40796581|NCT02329977|OTHER|standard barium meal examination|All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
40796582|NCT01465880|OTHER|Part A|Smoking abstinence, smoking 2 and 4 cigarettes
40796583|NCT04465604|OTHER|Wearing surgical face mask sprayed with hypertonic saline|The inner surface of a standard surgical face mask will sprayed by 10 to 15 ml of HTS (6% w/v Saline solution prepared by adding 6 gram NaCl to 100 ml of water if not commercially available) and allowed to air dry. The participant will wear the face mask for 20-30 minutes every 6 hours until discharge, intubation for mechanical ventilation or death. A new HTS sprayed mask will be worn by the participant every 24 hours. The data items will be collected on daily basis
40796584|NCT00213941|DEVICE|Echocardiography|
40796585|NCT00375505|DRUG|Zoledronic acid|
40796586|NCT00375505|DRUG|Placebo|Placebo
41313198|NCT01575405|DRUG|Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy) propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
41313199|NCT01575405|DRUG|Universal HEC Placebo Gel Formulation|The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
40796587|NCT03683420|BEHAVIORAL|Music Therapy|The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
40796588|NCT02998684|DEVICE|Active Transcranial Direct Current Stimulation|
40796589|NCT02998684|DEVICE|Sham Transcranial Direct Current Stimulation|
40796590|NCT02998684|BEHAVIORAL|PEERS Social Skills Training|14 weekly social skills training sessions for all participants
41150974|NCT05971186|DRUG|Ibuprofen 400 mg|Dosage Form: Tablet Dosage: 1 tablet of Ibuprofen (400 mg) Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption
41150975|NCT05971186|OTHER|Young Coconut Water|Dosage Form: Liquid (coconut water) Dosage: 330 ml (milliliters) of young coconut water Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
40796591|NCT00240812|DRUG|ibuprofen; pseudoephedrine HCl|
40796592|NCT01413295|DRUG|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
40796593|NCT01413295|OTHER|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
40796594|NCT02064049|DRUG|Sofosbuvir/velpatasvir|The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
40796595|NCT03150290|OTHER|Indirect Calorimetry.|REE measurement
40796596|NCT03150290|DEVICE|18-FDG-PET|18-FDG-PET
40796597|NCT03475446|DEVICE|real anodal tDCS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.
40796598|NCT03475446|DEVICE|real tACS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.
40796599|NCT03475446|DEVICE|sham tES healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.
40796600|NCT03475446|DEVICE|real anodal tDCS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.
40796601|NCT03475446|DEVICE|real tACS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.
40796602|NCT03475446|DEVICE|sham tES MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.
40796603|NCT03475446|DEVICE|real anodal tDCS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.
40796604|NCT03475446|DEVICE|real tACS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.
40796605|NCT03475446|DEVICE|sham tES AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.
40796606|NCT04475419|PROCEDURE|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)|covering the affected molar with preformed metal crown cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
40796607|NCT01735734|DEVICE|Air cooling to CM site|
40796608|NCT02662426|DRUG|Lingdancao granules|4 packs per time (3g/pack), three times per day
40796609|NCT02662426|DRUG|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
40796610|NCT02662426|DRUG|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
41150976|NCT05971186|OTHER|Dark Chocolate Bar|Dosage Form: Solid (dark chocolate bar) Dosage: 35 grams of 70% dark chocolate Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
41313200|NCT04994821|DEVICE|transcranial direct current stimulator (tDCS)|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
41001111|NCT03857087|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET/MRI
41313201|NCT04994821|BEHAVIORAL|Cognitive Reappraisal|Emotion regulation therapy
41313202|NCT00434512|BIOLOGICAL|HIV vaccine 732461|
41001112|NCT00733720|DRUG|Suboxone|4/1mg, 8/2mg 16/4mg
41313203|NCT00310388|DRUG|Retigabine (INN), Ezogabine (USAN)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
41471419|NCT06473402|OTHER|Manual Therapy Technique|Anterior and posterior innominate muscle energy techniques were performed on patients. In the anterior technique, the patient lay on their back with their leg on the diagonal shoulder. The clinician flexed the hip and knee, placed their hand on the back thigh, and instructed the patient to push, resulting in hip extension. After eight seconds, the patient inhaled and exhaled. The clinician then increased hip flexion and applied pressure against a new barrier. In the posterior technique, the patient lay on their side in the modified sims position. The clinician held the leg with their caudal hand and placed the hypothenar edge of their cranial hand on the right SIPS. The patient then pulled the leg towards themselves, applying equal counterforce for eight seconds before inhaling and exhaling. Finally, the clinician extended the leg and pushed it against a new barrier.
41150977|NCT02525744|DRUG|LY900014|Administered SC
41471420|NCT00497588|PROCEDURE|surgery|
41471421|NCT00497588|RADIATION|radiotherapy|
40796611|NCT02662426|DRUG|analogous Lingdancao granules|4 packs per time, three times per day
41001113|NCT04319939|OTHER|Assist Control Mode and Pressure Support Mode Mechanical Ventilation|Diaphragm ultrasound measurements (end expiration and peak inspiration thickness) will be performed in assist control mode and pressure support mode mechanical ventilation in each participant. The participant will thus serve as his/her own control for these interventions.
41150978|NCT02525744|DRUG|Insulin Lispro (Humalog)|Administered SC
41150979|NCT05361954|DRUG|STI-1386|Second generation oncolytic virus
41150980|NCT04931199|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The standard of care procedures for children with clinically elevated anxiety, depression, and PTSD is traditional CBT from their mental health provider.
41313204|NCT04345926|DRUG|Propofol|Stepped propofol concentration after 20 min of LOS
41150981|NCT04931199|BEHAVIORAL|CBT+App|Participants receive CBT as usual enhanced with a simple, HIPAA compliant, web-based application to help mental health providers implement homework during CBT with children with elevated PTSD, anxiety, and/or depression, and their caregivers. The three major components of the app help providers to (1) Practice interactive, digitized CBT exercises with patients in-session; (2) Remind patients to practice CBT exercises for homework, and (3) Review homework during the next session.
41150982|NCT05550584|DEVICE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE).|In the THRIVE group, dedicated Optiflow THRIVE nasal cannulas will be positioned for 100% high flow oxygen therapy at an initial flow of 30 L/min. After induction of anesthesia and throughout the procedure the flow of oxygen will be increased to 70 L/min.
41313205|NCT04345926|DEVICE|Electroencephalogram recording|Acquisition of EEG activity
41471422|NCT05399485|DRUG|Rimegepant|Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12
41471423|NCT05399485|DRUG|Placebo|Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
41471424|NCT03063216|PROCEDURE|intraocular lens implantation|1）Pediatric cataract patients with intraocular lens implantation and those without intraocular lens implantation；2）Traumatic cataract patients with intraocular lens implantation and those without intraocular lens implantation
40796612|NCT02880228|DRUG|Dexamethasone|Given PO
40796613|NCT02880228|OTHER|Laboratory Biomarker Analysis|Correlative studies
40796614|NCT02880228|DRUG|Lenalidomide|Given PO
40796615|NCT02880228|BIOLOGICAL|Pembrolizumab|Given IV
40796616|NCT03697161|DRUG|OV101 (gaboxadol)|OV101 (gaboxadol)
40796617|NCT06398002|OTHER|Dialysate calcium 1.50 mmol/L|Increased dialysate calcium of 1.50 mmol/L (as compared to standard dialysate calcium of 1.25 mmol/L)
40796618|NCT05844202|DRUG|Alveavax-v1.2|BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19
41001114|NCT05300165|DIETARY_SUPPLEMENT|Beer|A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
41001115|NCT02699944|DEVICE|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
41150983|NCT05550584|DEVICE|LMA|Mechanical ventilation performed by a laringeal mask
41313206|NCT02792322|DEVICE|Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device|Patient's will be having TORS surgery in a seated position
41313207|NCT03783052|DEVICE|SmartPill in fasted state|SmartPill administration in fasted state
41313208|NCT03783052|DEVICE|SmartPill in fed state|SmartPill administration in fed state
40796619|NCT05844202|DRUG|Janssen Ad26.COV2.S|COVID-19 vaccine by Janssen / Johnson \& Johnson
40796620|NCT04469023|DRUG|TS-142|Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
41313209|NCT03783052|OTHER|Aspiration|Aspiration of gastrointestinal samples in fasted and fed state
41313210|NCT03783052|OTHER|Gastric emptying scintigraphy|Gastric emptying scintigraphy in fed state
41313211|NCT05524740|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for improvement of the structure of facial muscles.
41313212|NCT01199250|OTHER|Laboratory Biomarker Analysis|Correlative studies
41313213|NCT06432556|GENETIC|scRNAseq|A blood test tube (only for scRNAseq, 2 tubes of 10 ml per patient)
41313214|NCT06432556|PROCEDURE|two Skin biopsies|2 skin biopsies from a lesional area
41313215|NCT06432556|PROCEDURE|one Skin biopsies|1 skin biopsies from a lesional area
41313216|NCT01478152|OTHER|Drug-like Medical Device: Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
40796621|NCT04257643|OTHER|aquatic based exercise.|exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention
41313217|NCT00874679|DRUG|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
41313218|NCT01999946|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
41313219|NCT05386654|DEVICE|imPulse™ Tor System|Self-directed blood pressure data capture
41001116|NCT05325567|PROCEDURE|Mini open incision CTR|two techniques commonly used for carpal tunnel release are being compared to determine if one vs. the other provides superior patient outcomes.
41001117|NCT05548023|DEVICE|The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent|The Angiolite stent is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design and a high overexpansion capacity that might overcomes some of these challenges in LMCA PCI. The ANGIOLITE randomized trial confirmed the non-inferiority of the Angiolite stent against the conventional DES
41001118|NCT03101904|DIETARY_SUPPLEMENT|Beetroot Juice|
41001119|NCT03101904|DIETARY_SUPPLEMENT|Placebo|
41001120|NCT02901951|BIOLOGICAL|Engerix-B|Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.
41001121|NCT04102358|PROCEDURE|Medial approach infraclavicular block with single injection|infraclavicular blocks performed with single injection
41001122|NCT04102358|PROCEDURE|Medial approach infraclavicular block with triple injection|infraclavicular blocks performed with triple injection
41001123|NCT03010787|DRUG|V565|single ascending dose of V565
41001124|NCT03010787|DRUG|V565|Multiple dose
41001125|NCT03010787|DRUG|Placebo|Single and multiple dose
41001126|NCT03010787|DRUG|V565|Open-label single dose
41001127|NCT03010787|DRUG|V565|Open-label single ascending dose
41001128|NCT05978232|BEHAVIORAL|NAVAH|Patient navigator program that aims to inform African-American prostate and breast cancer patients about their treatment options, specifically radiotherapy
41001129|NCT02381418|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
41001130|NCT00656006|DRUG|Albuferon|
41001131|NCT00656006|DRUG|Ribavirin|
41001132|NCT04772534|BIOLOGICAL|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
41001133|NCT03681457|DRUG|LJN452|Dose A single dose
41001134|NCT00370253|DRUG|Terlipressin|1mg/4 h per day
41001135|NCT00370253|DRUG|Noradrenalin|0,1 mcg/kg/min
41001136|NCT01399359|BEHAVIORAL|Counseling session|
41001137|NCT01399359|OTHER|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
41001138|NCT01399359|OTHER|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
41001139|NCT01399359|OTHER|online questionnaire|
41001140|NCT00486122|DRUG|Atomoxetine Hydrochloride|
41001141|NCT00486122|DRUG|Placebo|
41001142|NCT06221696|DIETARY_SUPPLEMENT|Active Fiber Supplement Group|Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
41001143|NCT06221696|OTHER|Placebo Group|Three daily packets of placebo powder, taken 30 minutes before each main meal.
41001144|NCT06445179|PROCEDURE|Total Laparoscopic Hysterectomy|"The standard procedure for performing total hysterectomy will also follow the Querleu and Morrow classification system, which divides the procedure into four types based on the extent of resection:~* Type A: minimum resection of paracervix.~* Type B: transection of the paracervix and the ureter.~* Type C: Transection of paracervix at the junction with the internal iliac vascular system~* Type D: Laterally extended resection. Furthermore, bilateral ureterolysis will be performed with the option of bilateral concomitant salpingo-oophorectomy."
41001145|NCT06445179|DEVICE|Ureterolysis|unilateral or bilateral ureterolysis with or without bilateral adnexectomy
41471425|NCT01301924|DRUG|Meglumine antimoniate|"Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:~High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine."
41313220|NCT04402008|DRUG|Poziotinib Once Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
40796622|NCT04257643|OTHER|land-based exercise.|land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles \[14\]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
41313221|NCT04402008|DRUG|Poziotinib Twice Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
41313222|NCT04402008|DRUG|Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
41313223|NCT06087224|OTHER|Teleneonatology|Real-time, two way, audio-video telemedicine connection between the neonatologist located in the regional neonatal intensive care unit (NICU) and the physician located at the community hospital.
41471426|NCT05468372|DRUG|Posaconazole 600 mg followed by posaconazole 300 mg once daily|Posaconazole will be given as a delayed release tablet, the dose would be 600 mg in two divided doses on day 1, followed by 300 mg once a day from then on. If a subject vomits within 15 minutes of posaconazole tablet administration, the dosing should be repeated as soon as possible, following appropriate antiemetic treatment. The drug will be administered after a meal.
41471427|NCT05468372|DRUG|Liposomal Amphotericin B|"All study subjects will be administered intravenous liposomal amphotericin B \[5 mg/kg/day infusion in 5% dextrose solution\] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment."
41313224|NCT00310570|DEVICE|Circumferential thermoplastic thimble splint|
41313225|NCT00310570|DEVICE|"dorsal aluminium foam Mexican Hat splint"|
41313226|NCT00310570|DEVICE|stack splint (control)|
41313227|NCT00003817|DRUG|dolasetron mesylate|
41313228|NCT00003817|DRUG|granisetron hydrochloride|
41471428|NCT02965664|DRUG|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
41471429|NCT02965664|DRUG|Placebo|Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
40796623|NCT01094834|DRUG|DWP05195|tablets, oral administration, multiple administration
41001146|NCT02375672|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
41313229|NCT00003817|DRUG|ondansetron|
41313230|NCT00003817|DRUG|tropisetron|
41313231|NCT00003817|PROCEDURE|quality-of-life assessment|
41313232|NCT04392206|DRUG|Adipose Derived Mesenchymal Stem Cells|The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution
41313233|NCT01838174|DRUG|ACTHAR Gel (ACTH)|15 days of daily injections
41313234|NCT01838174|DRUG|IV methylprednisolone (steroids)|3 days of intravenous methylprednisolone followed by 11 days of oral taper
41471430|NCT05910528|DRUG|RO7790121|RO7790121 will be administered during the Induction, Maintenance and OLE period.
41471431|NCT05341804|BEHAVIORAL|cognitive and balance dual task training|a cognitive and balance dual task training program involving the Internet of Thing technique software - Cognitive and Balance training Simultaneously software
41471432|NCT05341804|BEHAVIORAL|balance training|Includes static balance, dynamic balance and strength training
41471433|NCT03809637|DRUG|Pemetrexed, cisplatin|Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
41471434|NCT01660022|DRUG|100mg OZ439 single oral dose|100mg OZ439 oral suspension single dose
41471435|NCT01660022|DRUG|Placebo|Placebo
41471436|NCT01660022|DRUG|300 mg OZ439 single oral dose|300mg OZ439 oral suspension single dose
41471437|NCT01660022|DRUG|160mg Piperaquine single oral dose|160 mg Piperaquine tablet
41471438|NCT01660022|DRUG|480mg Piperaquine single oral dose|480 mg Piperaquine tablet
41471439|NCT01660022|DRUG|1440mg Piperaquine single oral dose|1440 mg Piperaquine tablet
41313235|NCT05693090|DRUG|Tipifarnib|Oral administration
41313236|NCT05693090|DRUG|Osimertinib|Oral administration
41313237|NCT00075244|DRUG|Replagal|
41313238|NCT00501046|DRUG|Placebo|9g /day (3 times a day)
41313239|NCT00501046|DRUG|AST-120|9g /day (3 times a day)
41471440|NCT01660022|DRUG|800 mg OZ439 single oral dose|800mg OZ439 oral suspension single dose
41471441|NCT02269631|BEHAVIORAL|Legume diet group|about 1 1/2 cups of legumes included in lunch and dinner meals
41471442|NCT02269631|BEHAVIORAL|Control diet group|no legumes in lunch or dinner meals
41471443|NCT02269631|DEVICE|Smartpill|to assess how long food takes to pass through the digestive system
41471444|NCT02269631|OTHER|legumes|about 1 1/2 cups of legumes included in lunch and dinner meals
41313240|NCT02572895|DIETARY_SUPPLEMENT|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
41313241|NCT01464463|BEHAVIORAL|CBT - active|Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
41471445|NCT05976724|OTHER|TENS, exercise|"TENS: The patients were sat in a chair positioned next to a treatment table. The hand to be treated was placed on the treatment table with the forearm in the supine position. Electrodes were then placed on the transverse carpal ligament and palmar surface of the hand. Conventional TENS was applied, with the current transition time set to 50-100 µs, and performed at a frequency of 100 Hz for a period of 20 minutes at an amplitude that did not cause muscle contraction or any feeling of numbness or tingling.~The supervised exercises were performed by the patients in a seated position. Strengthening exercises were performed with both hands by means of Digi-Flex hand exerciser (IMC Products Corp, Hicksville, New York), modeling mass and elastics. The patients were tasked with performing these exercises 10 times in each session and three times daily."
40796624|NCT02594228|BEHAVIORAL|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
40796625|NCT02594228|BEHAVIORAL|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
40796626|NCT00500565|DRUG|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
40796627|NCT00500565|DRUG|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
40796628|NCT06422325|DEVICE|MPC closed-loop system in insulin only mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer insulin continuously for managing blood sugar.
40796629|NCT06422325|DEVICE|MPC closed-loop system in insulin/pramlintide mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer both insulin and pramlintide continuously for managing blood sugar. The system will deliver pramlintide in a fixed ratio to insulin at 6 mcg of pramlintide delivered for every 1 unit of insulin.
40796630|NCT05802472|OTHER|Polyphenolic beverage from extract of Vachellia farnesiana|During Visit 2. A single infusion of the polyphenolic extract was administered orally. The dose (1.2 mg/kg body weight) of lyophilized extract, which was diluted in water, was calculated considering each participant's weight.
40796631|NCT05802472|OTHER|Placebo|During Visit 2. 250 ml of single potable water was administered orally.
40796632|NCT01846299|OTHER|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
40796633|NCT01846299|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
40796634|NCT03183752|DRUG|Metformin|500 mg metformin three times daily
40796635|NCT03183752|DRUG|Placebo|500 mg placebo three times daily
40796636|NCT01234480|DEVICE|BD SurePath Plus Pap test|BD SurePath Plus Pap test
40796637|NCT01234480|DEVICE|BD SurePath Pap test|BD SurePath Plus Pap test
41313242|NCT01464463|BEHAVIORAL|CBT - euthymic|Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
41313243|NCT01464463|BEHAVIORAL|CBASP|"Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.~Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship."
40796638|NCT01234480|PROCEDURE|colposcopy with biopsy/ECC|Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher
40796639|NCT01234480|DEVICE|HPV DNA test|digene HC2 HPV DNA test
41001147|NCT02375672|DRUG|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion"
41313244|NCT04169061|DRUG|Acthar|Acthar gel for subcutaneous injection
41313245|NCT03284255|DEVICE|study group|study group in which patient will accept the treatment of Bioresorbable Coronary Stent
41313246|NCT03284255|DEVICE|control group|control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
41313247|NCT04204655|DIAGNOSTIC_TEST|BIA|Bioelectrical Impedance Analysis
41313248|NCT05197673|BEHAVIORAL|Theory of planned behaviours (TPB) based intervention|Intervention group will receive TPB-based education program to improve workers' attitude toward SARS-CoV-2 and raise their intention to vaccination and virus testing. The intervention will be implemented at the baseline with measurements repeated at the 3rd month, 6th month and 9th month. The standardized mode of intervention includes face-to-face/online seminar (depends on the COVID-19 situation), message via mobile phone, promotion pamphlet, etc.
41313249|NCT05819736|OTHER|Monitoring|Monitoring
41313250|NCT00235651|DRUG|Amphotericin B|
41313251|NCT00885417|DRUG|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
41313252|NCT04195100|DRUG|Pilocarpine Ophthalmic Solution|"1. low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day~2. high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day"
41313253|NCT02654574|OTHER|IADL administration by phone|The administration of IADL questionnaire by phone consists of a collection of answers given by the caregiver during the interview with the research nurse, trained for this procedure. This method of procurement will be standardized with a listing support for the phone interview to obtain the same conditions for collection of data from a caregiver to another. Questions will be asked in the same order than the questionnaire collected with the reference procedure i.e. face-to-face interview at the Memory Clinic. The IADL questionnaires in paper format used during the ace-to-face interview and by phone will be identical.
41001148|NCT01020058|PROCEDURE|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
41313254|NCT05394584|BEHAVIORAL|Cognitive Stimulation Therapy|Cognitive stimulation therapy is a non-pharmacological intervention for people with dementia at mild to moderate stages. Group cognitive stimulation therapy is a 14-session intervention delivered twice every week for 7 weeks. In each session, mentally stimulating activities are conducted around a specific themed, such as current affairs, word association, categorising objects, and number game. Each group consists of eight people with similar levels of cognitive impairment, facilitated by two group leaders who lead the activities according to 18 key principles of the therapy, including new associations, opinions rather than facts, implicit learning, and person-centred.
41313255|NCT02498756|BIOLOGICAL|Cytokine-induced killer cells|CIK cells are transferred every 3 months for 1 year.
41313256|NCT02498756|DRUG|Ipilimumab|Ipilimumab are delivered every 3 weeks for one year
41001149|NCT05210686|OTHER|subgingival re-instrumentation|subgingival re-instrumentation (control)
41313257|NCT00519493|PROCEDURE|Suture|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
41313258|NCT00519493|DEVICE|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
41001150|NCT02457325|DRUG|Surgery with 2%Articaine first, then Surgery with 4% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
41001151|NCT02457325|DRUG|Surgery with 4%Articaine first, then Surgery with 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
41313259|NCT02836535|BEHAVIORAL|qualitative interviews|
41313260|NCT02860806|DRUG|JNJ-63623872|3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
41313261|NCT02860806|DRUG|Placebo|Intravenous infusion of matching placebo.
41313262|NCT03259490|DRUG|Empagliflozin/linagliptin/metformin HCl|Once daily
41313263|NCT03259490|DRUG|Empagliflozin|Once daily
41313264|NCT03259490|DRUG|Linagliptin|Once daily
41001152|NCT01578928|DRUG|SOM230|
41313265|NCT03259490|DRUG|Metformin HCl|Once daily
41313266|NCT04118114|DRUG|PRL3-zumab|IV administration every 2 weeks
41313267|NCT05093257|DIAGNOSTIC_TEST|Laboratory investigations for control|"1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry"
41313268|NCT05093257|DIAGNOSTIC_TEST|Laboratory investigations for patients|"1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. Anti-nuclear antibodies test by immunoflourescence for ITP patients.~6. Bone marrow aspiration (for diagnosis of ITP).~7. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry."
41001153|NCT03674866|DRUG|Insulin degludec|Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.
41001154|NCT01627938|DRUG|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
41001155|NCT01627938|DRUG|Placebo plus Mitoxantrone (MX)|MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
41313269|NCT03579550|PROCEDURE|office hysteroscopic metroplasty intervention arm|One group will be performed hysteroscopic metroplasty Second group will be undertaken to six months spontaneous coitus and three cycles of COH/IUI
41313270|NCT06298461|DRUG|KleanLyte|Laxative for colonoscopy bowel preparation
41313271|NCT06298461|DRUG|Bi-PegLyte|Laxative for colonoscopy bowel preparation
41313272|NCT06224881|DRUG|Ascorbic acid|2 gm every 8hrs for 4 days
41313273|NCT05081024|PROCEDURE|Biopsy|Undergo biopsy
41313274|NCT05081024|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or tissue samples
41313275|NCT05081024|OTHER|Electronic Health Record Review|Medical records are reviewed
41313276|NCT05466266|DEVICE|ICE|All patients received ICE examination.
41001156|NCT06420154|BIOLOGICAL|anti-CD19-CAR-T cells|"The subjects received infusions of anti-CD19 CAR-T cells following completion of lymphodepleting preconditioning chemotherapy.~Dosage：1×10\^5 cells/Kg; 3×10\^5 cells/Kg; 1×10\^6 cells/Kg~frequency：single infusion"
41313277|NCT05466266|DEVICE|TEE|All patients received TEE examination.
41313278|NCT02047630|DRUG|Generic latanoprost|
41471446|NCT05976724|OTHER|Mulligan mobilisation|Each participant was tested with sustained manual glides in each of the possible directions during active wrist flexion and extension from the seated position. For the lateral glide, the therapist stabilises the lateral aspect of the distal radius using the first web-space. And glides the proximal row of carpal bones laterally (towards the thumb) using the first web-space of the other hand, following the joint line. For the medial glide, the therapist stabilises the medial aspect of the distal ulna using the first web-space. And glides the proximal row of carpal bones medially (away from the thumb) using the first web-space of the other hand, following the joint line.
41471447|NCT06617624|OTHER|MRI|Healthy volunteer will have a non-injected cardiovascular MRI
41313279|NCT02047630|DRUG|Brand-name latanoprost|
41471448|NCT06617624|OTHER|MRI Contrast|Patients will have the gadolinium injected cardiovascular MRI
41471449|NCT06013930|BEHAVIORAL|External Qigong|External Qigong will be facilitated by a seasoned Qigong practitioner. The Qigong practitioner will assist participants in learning how to use the healing powers of their bodies to decrease feelings of anxiety and/or depression
41471450|NCT06013930|BEHAVIORAL|Mindfulness Meditation|Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a meditation designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.
41001157|NCT04382248|OTHER|Smartphone App|An app for monitoring medications, blood pressure, exercise, healthy eating
41313280|NCT05653297|DEVICE|Vacuum-Assisted Closure|NPWT (MEDWAY GROUP VAC) will be applied on post traumatic raw areas until the wound is ready for reconstruction, Then it will be applied over skin graft after coverage
41313281|NCT01056341|DRUG|Propranolol|Propranolol (1 or 3 mg/kg/day for 3 or 6 months)
41471451|NCT06013930|OTHER|Psychoeducation|In the psychoeducation arm, participants will receive information related to managing anxiety and/or depression through a recorded presentation. Participants will learn about stress-management techniques to help reduce symptoms of anxiety and/or depression. They will also receive information on resources that could be helpful in treating anxiety and/or depression.
41471452|NCT04495751|DIETARY_SUPPLEMENT|Muscadine grape extract|Four pills twice daily
41471453|NCT04495751|DRUG|Placebo|Four pills twice daily.
41471454|NCT04495751|OTHER|Quality of Life Assessment|Ancillary studies
41471455|NCT04495751|OTHER|Questionnaires|Ancillary studies
41001158|NCT04382248|BEHAVIORAL|Tailored education|in-person coaching
41471456|NCT04495751|OTHER|Participant Feedback|Ancillary studies
41313282|NCT01056341|DRUG|Placebo|Treatment with placebo for 6 months
41313283|NCT04585217|PROCEDURE|Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid)|"Plain gut suture (6-0 fast absorbing plain gut \[Sharpoint Express gut TM\]) and polypropylene suture (6-0 polypropylene \[Ethicon Prolene TM\]) will be used to close blepharoplasty incisions. Each patient will have one eyelid using plain gut suture and the other eyelid with polypropylene suture. Each subject will be randomized as to laterality."
41313284|NCT04479917|DRUG|TPN171H|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
41471457|NCT02488668|DEVICE|Surface Electrical Stimulation|Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
41471458|NCT06143956|DRUG|LY3305677|Administered SC. ISA specific interventions will be listed in the ISA.
41001159|NCT02656641|BEHAVIORAL|Continuous Client Feedback|Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
41313285|NCT04479917|DRUG|placebo|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
41471459|NCT06143956|DRUG|LY3841136|Administered SC. ISA specific interventions will be listed in the ISA.
41471460|NCT06143956|DRUG|Tirzepatide|Administered SC. ISA specific interventions will be listed in the ISA.
40796640|NCT05453071|OTHER|Cognitive Exercise Therapy Approach (BETY)|BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
40796641|NCT06006936|BEHAVIORAL|Coping with Infertility Self-Help Program|"The CWI program consists of seven 10-minute videos, each with accompanying homework assignments.~The first module, cognitive restructuring, includes instructions on challenging extreme or unhelpful automatic thoughts. The second module, challenging negative core beliefs, includes looking for patterns in thinking that illustrate core beliefs. The third module features behavioural activation techniques and emphasizes the importance of regular pleasure and skill-based activities. The fourth module highlights coping with grief and factors that contribute to grief, such as individual differences in grieving style. The fifth module supports strengthening relationships through responding to requests for affection and outlines several common relationship mistakes. The sixth module demonstrates how to identify and use values to make decisions and guide behaviour. The seventh module summarizes how thoughts, actions, and interactions can contribute to well-being when experiencing infertility."
40796642|NCT01005641|DRUG|exemestane|25 mg daily
40796643|NCT01005641|DRUG|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
40796644|NCT04042597|DRUG|Anlotinib Hydrochloride|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
40796645|NCT01222988|DIETARY_SUPPLEMENT|Optifast Products|Optional Optifast products offered once every other week X 6 months; then monthly.
40796646|NCT04356846|DRUG|LP-108 tablet|Taken orally within 30 minutes after a meal at the designated dose, once daily.
40796647|NCT00644072|DRUG|SNX-5422|
40796648|NCT06421506|PROCEDURE|Less invasive surfactant administration during high flow nasal cannula treatment|Surfactant distilled through a small tube inserted into the windpipe via the mouth whilst the baby is awake and supported with HFNC.
40796649|NCT02872597|DRUG|Ipratropium|
40796650|NCT02872597|DRUG|0.9% Sodium Chloride|
40796651|NCT02872597|DRUG|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
40796652|NCT02872597|DRUG|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
41471461|NCT06143956|DRUG|Placebo|Administered SC. ISA specific interventions will be listed in the ISA.
40796653|NCT00039039|DRUG|carboplatin|
40796654|NCT00039039|DRUG|chemotherapy|
40796655|NCT00039039|DRUG|cisplatin|
40796656|NCT00039039|DRUG|paclitaxel|
40796657|NCT00039039|RADIATION|radiation therapy|
40796658|NCT01370941|DIETARY_SUPPLEMENT|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
40796659|NCT01370941|DIETARY_SUPPLEMENT|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
40796660|NCT01118780|DRUG|Duloxetine|Administered by mouth, daily for 10 weeks
40796661|NCT01118780|DRUG|Placebo|Administered by mouth, daily for 10 weeks
41471462|NCT06615232|BEHAVIORAL|Vaginal washing cessation|Participants will attend weekly small group (\~10 women per group) sessions that are structured using the transtheoretical model of behavioral change to promote vaginal washing cessation.
41001160|NCT02656641|BEHAVIORAL|Continuous Self Feedback|Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
41471463|NCT06615843|DEVICE|Participants will receive post-emergency gynecological follow-up at home using a connected health app|The app will facilitate data collection and communication, including logging of vital signs, symptoms (such as pain, bleeding, and vomiting), and uploading of test results. Medical professionals will review the health data twice daily and provide care instructions through instant messaging. The app will also alert the medical team of any urgent updates or deviations from expected health patterns
41017794|NCT06313372|DIAGNOSTIC_TEST|Respiratory oscillometry|This a Delphi study where we are obtaining expert opinion and input on the use of respiratory oscillometry (a diagnostic respiratory test) in the assessment and management of patients with asthma or chronic obstructive pulmonary disease. The participants are respiratory specialists/pulmonologists. They are sharing their insights into the clinical use of respiratory oscillometry via a series of online surveys. The Delphi process is used in an attempt to achieve consensus as to how respiratory oscillometry is used in clinical practice. As such there is no intervention being used on the study participants, but they are sharing insights on how the respiratory test is used in their clinical practice in order to obtain consensus on this use.
41150984|NCT03614351|DIETARY_SUPPLEMENT|Protein (PROT)|Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.
40796665|NCT01295944|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
40796666|NCT01295944|DRUG|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
40796667|NCT02860234|DRUG|Oxaliplatin|
40796668|NCT02860234|DRUG|Capecitabine|
40796669|NCT02860234|RADIATION|intensity modulated radiotherapy|
40796670|NCT02860234|PROCEDURE|DRE-Endoscopy-MRI-CEA|
40796671|NCT02860234|PROCEDURE|Nonoperative Management|
40796672|NCT02860234|PROCEDURE|Local Excision|
40796673|NCT02860234|PROCEDURE|Total Mesorectal Excision|
40796674|NCT02860234|BEHAVIORAL|Quality of Life Questionnaires|
40796675|NCT05002933|DRUG|Insulin glargine 300 U/ml|Solution for injection Subcutaneous injection
40796676|NCT02176200|DRUG|Berodual® Respimat®, low inspiratory flow rate|
40796677|NCT02176200|DRUG|Berodual® Respimat®, medium inspiratory flow rate|
40796678|NCT02176200|DRUG|Berodual® Respimat®, high inspiratory flow rate|
40796679|NCT02176200|DRUG|Berodual® HFA-MDI, low inspiratory flow rate|
41150985|NCT03614351|OTHER|Control (CONT)|Instructed not to alter their diet based on the app, and to continue to eat as they normally would.
40796680|NCT02176200|DRUG|Berodual® HFA-MDI, medium inspiratory flow rate|
40796681|NCT02176200|DRUG|Berodual® HFA-MDI, high inspiratory flow rate|
40796682|NCT02031003|DIETARY_SUPPLEMENT|Infant formula|Infant formula
40796683|NCT04165460|OTHER|Psychoeducation|Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
40796684|NCT04165460|OTHER|Relaxation|Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
40796685|NCT04165460|OTHER|Cognitive Restructuring|Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.
40796686|NCT04165460|OTHER|Solving Problems|To generate alternative solutions to practical problems based on the model described by Nezu.
40796687|NCT00753727|DRUG|Sunitinib malate|Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
40796688|NCT00753727|RADIATION|Radiotherapy|Preoperative radiotherapy consisting of external beam radiotherapy at a dose of 50.4 Gy given in 28 fractions, five days a week, over five weeks and 3 days to the planning target volume.
40796689|NCT01798095|BIOLOGICAL|Aplisol@ PPD material|Determine equivalency of materials
40796690|NCT01798095|BIOLOGICAL|Reference Standard|Reference standard material for comparison to newly produced materials.
41001161|NCT04173143|DEVICE|Craniocervical flexion training with pressure biofeedback|Total 15 patients participated in this training group. Session was performed thrice in a week. Each session was givenfor approximately 20minutesPatients were asked to lie in supine hook lying position. After that Pressure biofeedback unit's air bag was clipped together and folded in three and positioned behind the neck just below the occiput. Patients were advised to perform Craniocervical flexion and practiced head nodding action to progressively target (reach the incremental targets) and hold the 5 pressure levels for 10 second between 22 mm Hg and 30 mmHg. A 2 minute second rest period was provided between each level. Minimum performance requirement was 26 mm Hg while ideal performance targets are 28 and 30 mm Hg... Patient will be re-assessed for all baseline variables after 4 weeks of training
41001162|NCT04173143|OTHER|Craniocervical flexion training without pressure biofeedback|Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
41001163|NCT00324831|DRUG|autologous immunoglobulin idiotype-KLH conjugate vaccine|
41001164|NCT00324831|DRUG|cyclophosphamide|
41001165|NCT00324831|DRUG|doxorubicin hydrochloride|
41001166|NCT00324831|DRUG|prednisone|
41001167|NCT00324831|DRUG|rituximab|
41001168|NCT00324831|DRUG|sargramostim|
41001169|NCT00324831|DRUG|vincristine|
41001170|NCT00324831|PROCEDURE|Intervention/procedure|
41001171|NCT00324831|PROCEDURE|antibody therapy|
41001172|NCT00324831|PROCEDURE|biological therapy|
41001173|NCT00324831|PROCEDURE|chemotherapy|
41001174|NCT00324831|PROCEDURE|colony-stimulating factor therapy|
41001175|NCT00324831|PROCEDURE|cytokine therapy|
41001176|NCT00324831|PROCEDURE|monoclonal antibody therapy|
41001177|NCT00324831|PROCEDURE|non-specific immune-modulator therapy|
41001178|NCT00324831|PROCEDURE|therapeutic procedure|
41150986|NCT03613454|DEVICE|Splenic artery embolization with vascular embolic coils|Splenic artery embolization with vascular embolic coils
40796691|NCT00783653|DRUG|Sunitinib|25 mg or 37,5 mg daily dose until DLT
40796692|NCT00550342|DRUG|rituximab|375 mg/m2 intravenously for 4 doses
41001179|NCT00324831|PROCEDURE|tumor cell derivative vaccine|
41001180|NCT00324831|PROCEDURE|vaccine therapy|
41150987|NCT03613454|DEVICE|Splenic artery embolization with vascular embolic plugs|Splenic artery embolization with vascular embolic plugs
41150988|NCT06484660|PROCEDURE|Minimally Invasive Approach In The Mucosal Advancement Flap Technique|Surgical treatment of complex perianal fistula. Less tissue damage. Electrocoagulation source with 75% lower power. Better de-epithelialization of the intra-sphinteric tract. More precise closure of orifice. More consistent mucosal flap
40796693|NCT03443089|DRUG|Test formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
41001181|NCT03984786|BEHAVIORAL|Assessment Interview|An interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization immediately after the initial telephone screen, where the interviewer will use the AUD section of the SCID-5.
41001182|NCT03984786|BEHAVIORAL|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
41001183|NCT03984786|BEHAVIORAL|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).
41150989|NCT04417907|DRUG|Perampanel 1 week titration|Healthy adults will take 2mg perampanel PO QD for one week followed 4mg perampanel PO QD for five weeks.
41001184|NCT00554437|BEHAVIORAL|UW Falls Prevention Program|The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
41001185|NCT00873548|DEVICE|PFNA-Asia|"The operation is performed under regional or general anesthesia and involves the following main steps:~1. Positioning of the patient~2. Definition of the CCD-angle~3. Fracture reduction~4. Determination of the nail diameter~5. Incision~6. Insertion of the device"
41001186|NCT06423235|DRUG|regular dose of JiRui® Prunella oral liquid|Take 10ml twice a day
41001187|NCT06423235|DRUG|2x regular dose of JiRui® Prunella oral liquid|Take 20ml twice a day
41001188|NCT06423235|DRUG|regular dose of placebo|Take 10ml twice a day
41001189|NCT06423235|DRUG|2x regular dose of placebo|Take 20ml twice a day
41001190|NCT03425929|DRUG|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin.
41001191|NCT03425929|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
41001192|NCT00094874|PROCEDURE|Acupuncture|
41001193|NCT03382106|DRUG|Sildenafil 20 MG|Sildenafil, 20mg three times daily for 3 month period.
41001194|NCT03382106|DRUG|Placebo Oral Tablet|Placebo manufactured to look like Sildenafil 20 MG
41001195|NCT03382106|DIAGNOSTIC_TEST|Pulse wave velocity|Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.
41150990|NCT04417907|DRUG|Perampanel 2 week titration|Healthy adults will take 2mg perampanel PO QD for two weeks followed 4mg perampanel PO QD for four weeks.
41150991|NCT04417907|DRUG|Perampanel 4mg|Healthy adults will take 4mg perampanel PO QD for six weeks
41150992|NCT04417907|DRUG|Placebo|Healthy adults will take 2mg placebo PO QD for six weeks
41150993|NCT03094520|DEVICE|tDCS|Transcranial direct current stimulation (tDCS)
41001196|NCT03382106|DIAGNOSTIC_TEST|Carotid artery compliance and stiffness|An echocardiogram is done by using a probe placed on the skin.
41001197|NCT03382106|DIAGNOSTIC_TEST|Pressure wave reflection|Carotid pulse measurement taken using a tonometer probe
41001198|NCT00524446|DIETARY_SUPPLEMENT|Milk-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
41001199|NCT00524446|DIETARY_SUPPLEMENT|Soy-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
41001200|NCT00524446|DIETARY_SUPPLEMENT|Maize-soy flour|Counseling + Vitamin A as for ST_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
41001201|NCT03530475|DIAGNOSTIC_TEST|ultrasound and doppler|"• Ultrasound examination (2D gray scale and color doppler )~1. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion."
41313286|NCT02526719|PROCEDURE|Nipple Delay surgery|The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
41001202|NCT04242056|DRUG|18F-PM-PBB3|"18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets."
41001204|NCT00588445|DRUG|Gefitinib|"Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.~Patients who have had at least a minor response to gefitinib therapy preoperatively (\> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.~Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy."
41001205|NCT03458533|PROCEDURE|Bariatric surgery|
41001206|NCT03458533|BEHAVIORAL|Diet and lifestyle changes|
41001207|NCT05079464|OTHER|tDCS|All participants randomized to tDCS will receive active tDCS
41001208|NCT05079464|OTHER|Exercise|Participants will exercise at Toronto Rehab.
41001209|NCT05079464|OTHER|Sham stimulation|The same procedure for tDCS will be used for the sham condition, except without active current.
41001210|NCT05079464|OTHER|Treatment as usual|Exercise education/ treatment as usual will include routine advice about physical activity.
41001211|NCT01388829|DRUG|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
41150994|NCT03094520|DEVICE|sham-tDCS|sham stimulation
41150995|NCT03144076|OTHER|RSBY Health Insurance|RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
41150996|NCT05313477|DRUG|Ergocalciferol Capsules|Depend on initial 25(OH) vitamin D level If \<10ng/mL, 60000U of Ergocalciferol capsules per week If 10-19.9ng/mL, 40000U of Ergocalciferol capsules per week If \>20 ng/mL, 20000U of Ergocalciferol capsule per week
41001212|NCT01388829|DRUG|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
41001213|NCT02789176|OTHER|Surveys|Regarding development, epilepsy, and family impact
41001214|NCT02789176|OTHER|EEG|
41150997|NCT05313477|DRUG|Calcium carbonate|1000mg of Calcium carbonate daily
41150998|NCT00003778|DRUG|dolastatin 10|
41150999|NCT01066897|DRUG|Pramipexole|Patients will received increasing dose of pramipexole
41151000|NCT00197262|DRUG|GW685698X Aqueous Nasal Spray|
41313287|NCT00780052|DRUG|c-myb AS ODN|Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
41001215|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - TBW training|The investigators will use a temporal order judgment (TOJ) with a visual (light) cue and a motion (yaw rotation, y-translation) cue. The relative timing of the motion onset and the light are varied and subjects indicate which occurred first by pressing a button after the motion ends. The TOJ task will generate a psychometric curve and the PSS (point of subjective simultaneity) and TBW (temporal binding window) are calculated. Then training focuses on SOAs (stimulus onset asynchronies) near the TBW borders (e.g., PSS +/- 0.5xTBW), starting from 50 ms outside the TBW and moving randomly towards the PSS. The goal of the training is to narrow the TBW -- training trials will be provided for 30 min and after each response the subject is told if their response was right or wrong. After training, the TOJ task is repeated to determine how the TBW has changed. Sham training will be the same as the actual training except that verbal feedback of response accuracy will not be provided.
41001216|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - PSS training|After the PSS and TBW are calculated with the standard TOJ paradigm, 100 training trials are provided where the SOA is set to \[PSS - 200 ms\], with the goal of shifting the PSS more negative. Then the TOJ task will be repeated but every 10 testing trials will be followed by 10 training trials (SOA = PSS - 200), and this pattern will be repeated 10 times to 100 more training trials interspersed with the Post TOJ data. Subjects will respond after all trials and testing and training will not be distinguished. After this is completed, the new PSS and TBW are calculated. Sham PSS training will be identical to the above except that the 'training' period will consist of random SOAs rather than a series of fixed SOAs.
41001217|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - PSS adaptation with VI stimulation|The adaptation will utilize the same approach used in non-implanted patients. The investigators will provide a repeated, fixed SOA with either the CI or VI leading the other stimulus by 220 ms. After the training period, which will match the number of stimuli pairs provided to our normal vestibular-auditory control subjects undergoing PSS adaptation, the TOJ study is repeated to recalculate the PSS and TBW.
41471464|NCT02999451|DEVICE|snare-assisted POEM|"POEM is performed by using a snare which is retracted into the sheath to expose the tip, leaving a 1-2mm length for operation.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a snare in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a snare.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a snare.~4. The mucosal incision is closed with endoclips."
41471465|NCT02999451|DEVICE|knife-assisted POEM|"POEM is performed by using a conventional endoscopic knife.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a knife in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a knife.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a knife.~4. The mucosal incision is closed with endoclips."
41471466|NCT02342249|DRUG|VX-787 300 mg|A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
41471467|NCT02342249|DRUG|VX-787 600 mg|A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.
41017795|NCT03604718|BIOLOGICAL|Beltavac® Polymerized with Alternaria alternata|Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice
41017796|NCT02871843|DRUG|RRx-001 dose escalation with TMZ + RT|Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
41017797|NCT02871843|RADIATION|Radiation|Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)
41017798|NCT02871843|DRUG|Fixed dose Temozolomide (75 mg/m2)|Oral temozolomide 75 mg/m2 daily for 6 weeks
41017799|NCT02871843|DRUG|TMZ Maintenance|TMZ maintenance at 150-200 mg/m2
41017800|NCT03861468|OTHER|Care pathway|Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
41017801|NCT04901884|DRUG|PET/MR with 18F-FDG|(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
41017802|NCT04166149|DIAGNOSTIC_TEST|dd-cfDNA Blood Test|The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.
41017803|NCT01639209|PROCEDURE|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
41017804|NCT01639209|PROCEDURE|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
41017805|NCT00999349|DRUG|Silymarin (LEGALON)|Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
41017806|NCT00999349|DRUG|Placebo|
41017807|NCT00774787|DRUG|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
41017808|NCT00003335|BIOLOGICAL|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
41017809|NCT00003335|DRUG|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
41017810|NCT00003335|DRUG|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
41017811|NCT00003335|DRUG|melphalan|melphalan IV for three days on days -4 to -2
41017812|NCT00003335|DRUG|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
41017813|NCT00003335|PROCEDURE|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
41001218|NCT04196933|BEHAVIORAL|Chronic Motion-modulated Stimulation|To provide 8 hours of 'physiologic' CI and VI inputs during normal activities, the investigators will employ standard motion-modulated stimulation with the VI. This requires pre-adaptation to a 200 pps tonic stimulation rate (to emulate the push-pull design of the native vestibular system allowing modulating stimulation upward or downward with opposite directions of motion). The three electrodes are connected to the head-mounted prosthetic circuit, which consists of three angular velocity sensors (one aligned with the sensitive axis of each canal) such that head rotations in the plane of the given canal modulate the stimulation rate of the corresponding electrode, upward (for ipsi) or downward (for contralateral) head rotations, thereby simulating normal canal-mediated modulations.
41001219|NCT03616912|DRUG|Baricitinib|Administered orally.
41471468|NCT02342249|DRUG|Oseltamivir 75 mg|A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
41001220|NCT03616912|DRUG|Placebo|Administered orally.
41001221|NCT00578175|BIOLOGICAL|Priorix-Tetra™ (MMRV vaccine 208136)|One subcutaneous injection.
41001222|NCT00578175|BIOLOGICAL|ProQuad®|One subcutaneous injection.
41001223|NCT00578175|BIOLOGICAL|Havrix®|Two intramuscular injections.
41001224|NCT00578175|BIOLOGICAL|Prevnar®|One intramuscular injection.
41001225|NCT00886431|OTHER|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
41001226|NCT03422341|DEVICE|Comparison between GenePOC CR and Reference Method|The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.
41001227|NCT02619890|OTHER|Brain Glioma Registry|
41001228|NCT03221933|BIOLOGICAL|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses
41001229|NCT03221933|BIOLOGICAL|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided dose
41001230|NCT03999411|DRUG|Nicoderm C-Q Transdermal Product|6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
41001231|NCT03999411|BEHAVIORAL|Adherence to Antiretroviral Therapy Counseling|Brief counseling on adhering to antiretroviral therapy with self-help materials.
41313288|NCT04780958|OTHER|Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.|Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube.In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA)
41313289|NCT00930605|DRUG|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
41471469|NCT02342249|DRUG|Placebo|Subjects will receive matching placebo of Oseltamivir
41001232|NCT03999411|BEHAVIORAL|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and 2 follow-up phone calls.
41313290|NCT00930605|DRUG|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
41313291|NCT04791683|OTHER|sexaul counseling|Sexual counseling includes interviews about sexual problems in couples who are in the process of infertility treatment and suggestions for solving these problems.
41471470|NCT05260021|DRUG|Tirzepatide Dose 1|Administered SC
41313292|NCT03501745|BEHAVIORAL|WeChat|Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
41471471|NCT05260021|DRUG|Tirzepatide Dose 2|Administered SC
41471472|NCT05260021|DRUG|Placebo|Administered SC
41471473|NCT04865484|PROCEDURE|Surgical resection|Surgical resection of fibrostenotic area (\>4cm)
41471474|NCT04865484|PROCEDURE|Endoscopic stricturotomy|Endoscopic stricturotomy of fibrostenotic area (≤4cm)
41471475|NCT04865484|PROCEDURE|Strictureplasty|Strictureplasty of fibrostenotic area (≤4cm)
41471476|NCT02151175|DEVICE|LIFUP|
41001233|NCT03999411|BEHAVIORAL|"Crave-to-Quit app"|"Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention."
41001234|NCT03999411|BEHAVIORAL|"vDOT emocha app"|"Video Directly Observed Therapy (vDOT) smartphone app (emocha) that allows participants to take a video of themselves taking medication to ensure adherence."
41017814|NCT00003335|RADIATION|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
41017815|NCT04363281|OTHER|preoperative questionnaire|"1. Three questions to predict acute pain:~   * Verbal numeric score Anxiety 0-10~  * Anticipated postoperative pain level~  * Anticipated analgesic requirements~2. Speilberger STATE-TRATE inventory index~3. Pain Catastrophizing Scale"
41017816|NCT04363281|OTHER|PACU questionnaire|parturients will be approached and requested to fill out a questionnaire regarding intraoperative pain, medication consumption, anxiety and nausea.
41017817|NCT04363281|OTHER|Postoperative questionnaire|Parturients will be approached at 24 hours postpartum and questioned regarding anxiety levels and medication consumption and requested to fill out the OBSQOR 11 questionnaire at 24 hours postpartum.
41017818|NCT04363281|OTHER|Postoperative questionnaire- Obstetrician|The attended obstetrician will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
41017819|NCT04363281|OTHER|Postoperative questionnaire- anesthesiologist|he attended anesthesiologist will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
41017820|NCT01228240|DRUG|Metformin|
41001237|NCT02086942|DRUG|Bortezomib|Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.
41001238|NCT02086942|DRUG|cyclophosphamide|Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
41001239|NCT02086942|DRUG|Dexamethasone|Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
41001240|NCT00749463|DRUG|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
41001241|NCT00749463|DRUG|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
41001242|NCT05826782|BIOLOGICAL|Proxeed Plus 2*1 A arm|Proxeed plus 2 x daily sachets (2\*1) three mounths
41001243|NCT05826782|BIOLOGICAL|Placebo|Placebo 2 x daily sachets (2\*1) three mounths
41001244|NCT04425330|OTHER|physiotherapy exercises|The evidence on the effectiveness of physical therapy in children with myelomeningocele is limited. The International Classification of Functionality, Disability and Health for Children and Youth is a useful tool to assist therapists in analyzing problems about the focus of the intervention. The evidence in physical therapy practice for individuals of all ages with neurological disorders, focuses on 5 Ps: prevention, prediction, participation, personalized and plasticity. Thus, neurological physiotherapists must perform the care with a focus on preventing the patient's disabilities, predicting the ideal response of an intervention, through measures of results of the movement system. In addition, it is of paramount importance that the goal of rehabilitation is that people with neurological disabilities are fully included and participate in life activities that are important to them and that their care is personalized. All of these measures facilitate the process of positive plasticity.
41001245|NCT04425330|OTHER|PBM|Photobiomodulation occurs from the application of low intensity light such as low intensity laser and light emitting diode (LED). The therapeutic effectiveness of phototherapy is based on the absorption of photons by photoreceptors or chromophores. Studies on the experimental model of spinal cord injury have shown that both wavelengths have the potential to be an effective and non-invasive means of therapy, promoting axonal appearance, increased concentration of glial cells and nerve connections, in addition to functional and sensitive. The findings of a clinical trial involving individuals diagnosed with spinal cord injury demonstrate that PBM exerted positive effects on motor function, especially during isotonic contraction of stimulated muscles assessed by electromyography, and there was a recovery in sensory perception and muscle strength.
41471477|NCT06369649|DEVICE|Coolsense and Buzzy|Before the procedure, the independent observer, parent and child will be informed by the researcher about the method that will be used in the selected group and the scales that they will score. For children and parents in each group, a standard approach will be applied. Single blinding (participants) will be used in the research and the researchers will not have information about the other group. Cold application will be applied to children in group number one (Coolsense group). Coolsense, which does not contain any chemicals, provides cold application with the metal piece on its tip. In group number two (Buzzy group), vibration and cold application will be applied to the children. Buzzy is a handheld device with a bee-shaped motor that creates a small cold pad and vibration in the area in contact with the skin surface. Group number three (control group) will continue the standard procedure of the clinic and no different application or approach will be applied.
41471478|NCT01631682|DRUG|Propranolol|40mg single pill
41471479|NCT01631682|BEHAVIORAL|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
41471480|NCT01631682|DRUG|Mifepristone|1800mg, 9 tablets
41471481|NCT01631682|DRUG|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
41001246|NCT04425330|OTHER|SHAM PBM|SHAM PBM
41017821|NCT05394337|DRUG|Atezolizumab|Given by vein (IV)
40796694|NCT03443089|DRUG|Reference formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
40796695|NCT02151903|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
41017822|NCT05394337|DRUG|Tiragolumab|Given by vein (IV)
41017823|NCT06358079|PROCEDURE|Re-infusion of unwashed shed blood|Use of an isolated cardiotomy circuit for re-infusion of unwashed shed blood during off-pump coronary artery surgery
41017824|NCT03014752|OTHER|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
41017825|NCT03014752|OTHER|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
41017826|NCT00804297|DRUG|Octreotide (drug)|
41017827|NCT06288867|PROCEDURE|Arthroscopic Labral Repair|Patients with Hip Labral tears will be treated with labral repair
41017828|NCT06288867|PROCEDURE|Arthroscopic Labral Debridement|Patients with Hip Labral tears will be treated with labral debridement
41017829|NCT05392556|DIETARY_SUPPLEMENT|Probiotic|Cerebiome (Lallemand Health Solutions): probiotic supplement containing Bifidobacterium longum R0175, Lactobacillus helveticus R0052, and maltodextrin. Dosing: Oral, 3.6 g/d containing 3x10\^9 CFU/d (powder form)
41017830|NCT05392556|DIETARY_SUPPLEMENT|Prebiotic|Bimuno-GOS (Clasado Biosciences): Dosing: Oral; 3.6 g/d containing 2.75 g active GOS/d (powder form)
41017831|NCT05392556|OTHER|Placebo|Maltodextrin 3.6 g/d (powder form)
41001247|NCT02243878|RADIATION|Stereotactic radiotherapy (16 Gray or Sham)|Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.
41001248|NCT02243878|DRUG|0.5 mg ranibizumab|Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
41001249|NCT00207142|DRUG|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
41001250|NCT00207142|DRUG|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
41001251|NCT03608488|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 50.000 IU/per week, for 8 weeks
41001252|NCT03608488|OTHER|Exercise|Core stability, balance exercises
41001253|NCT06424054|OTHER|eChemoCoach|the eChemoCoach is an electronic questionnaire which is accessible for patients via the secured electronic health portal (EHP) of the EHR, which is CE-certified. By utilizing the eChemoCoach, patients (for this project we focus on breast cancer patients) have the ability to complete a questionnaire on a daily basis, when experiencing side effects. The eChemoCoach has the potential to evaluate the severity of adverse effects based on the CTCAE criteria and triage them, mimicking the decision-making process of a HCP through computer adaptive testing (CAT). Upon completing the questionnaire, the eChemoCoach translates the responses for each specific side effect into corresponding CTCAE grades. The tool then promptly offers patients personalized advice, tailored to their individual condition.
41001254|NCT00543764|OTHER|pathway|Comparison of pre and post pathway
41001255|NCT04586179|OTHER|Aerobic (treadmill) Exercise|"Individuals begin walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion (RPE) greater than 18.5."
41001256|NCT04586179|OTHER|Dynamic (Agility) Exercise|"Participants will begin in a center circle with equidistant cones 2.5 meters away. After the administrator presents a card, the participant touches a corresponding cone and returns to the starting position. Cards will be presented in increasing frequency in synchrony with a metronome application until exercise termination criteria are identified.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion greater than 18.5."
41313293|NCT03709134|DIAGNOSTIC_TEST|Genomic Markers (CTC/ctDNA)|This is a non-interventional study.
41313294|NCT00032994|BEHAVIORAL|Behavior Therapy|
41313295|NCT02701803|DEVICE|Parkinson's KinetiGraph™ logger|Logger is recording device which records the movement and acceleration of upper extremity
40796696|NCT02919163|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
40796697|NCT01004536|DEVICE|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
41001257|NCT00366990|BEHAVIORAL|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics with a focus on lowering sodium intake.
41001258|NCT00366990|BEHAVIORAL|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics.
41001259|NCT06331793|DEVICE|Active AlgoCare|Device that emits Pulsed Electromagnetic Fields
41313296|NCT03938441|OTHER|Intermittent Fasting|"The version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies.~On fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories.~Furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day."
40796698|NCT01004536|OTHER|no treatment|left untreated during the study period
40796699|NCT01916824|DRUG|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
40796700|NCT00348738|DRUG|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of \>14g/dl, \<15g/dl is reached or until the end of the radiation therapy.
41001260|NCT06331793|DEVICE|Non-active AlgoCare|Device that doesn't emit Pulsed Electromagnetic Fields
41001261|NCT02132585|PROCEDURE|Speckle tracking echocardiography|
41001262|NCT00856024|BIOLOGICAL|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
41017832|NCT06202885|DRUG|Immunotherapy|Immunotherapy
41017833|NCT06142955|DEVICE|MAGSTIM Rapid2 TMS system|The device will administer TMS pulses in bursts at fixed intervals for a total of 600 pulses over 190 seconds after first assessing the participants motor threshold (MT). During the sham stimulation condition, the TMS coil will be tilted 90° tangential to the scalp during the administration so that the orientation is not biologically active and will not elicit a muscle contraction. This sham condition will look and sound just like real TMS.
41017834|NCT05068440|DRUG|Zanubrutinib|administered orally as capsules
41017835|NCT04040972|OTHER|Compassion Focussed Therapy|Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
41017836|NCT00727389|BEHAVIORAL|Physiotherapy|Exercise two days a week for six month
41001263|NCT00856024|DRUG|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
41001264|NCT05019222|DRUG|Sevoflurane based inhalation anesthesia|Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.
41001265|NCT05019222|DRUG|Remimazolam based total intravenous anesthesia|Remimazolam group will be inducted with remiamazolam at 6 mg/kg/h and maintained with remimazolam at 0.5-1.5 mg/kg/h and TCI Minto model of remifentanil for general anesthesia.
41001266|NCT00402675|PROCEDURE|Timing of percutaneous coronary intervention|Immediate, early or selective invasive angiography
41001267|NCT01894269|DRUG|Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.|In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
40796701|NCT02805634|OTHER|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
41001268|NCT06022185|DIAGNOSTIC_TEST|Web Based Training on E-health Literacy, Digital Literacy and Healthy Lifestyle Behaviors.|"In the trainings planned for elderly individuals, digital literacy and e-health literacy levels will be improved, knowledge and awareness levels of elderly individuals will be increased and they will be provided with information in this direction. healthy lifestyle behaviors.~Personal information form, E-Health Literacy Scale, Acquisition and Confirmation of Health Information in Digital Environment Scale, Healthy Lifestyle Behaviors Scale-II will be used in the research."
41001269|NCT00787774|DRUG|resume raltegravir|resume raltegravir after 16 weeks of stopping
41471482|NCT03888521|BEHAVIORAL|Resound Relief smartphone app|The intervention is a smartphone app which has been developed to include a wide range of sounds and techniques aimed at reducing the impact of tinnitus.
41471483|NCT06127017|PROCEDURE|splinting dental implants with titanium bar|splinting of dental implants will be done in the placebo comparator group by welding a titanium bar intraorally to the temporary sleeves attached to the implants.
40796702|NCT02805634|DEVICE|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
40796703|NCT03441022|DEVICE|Amiigo Watch Only|Subjects will be asked to wear a wrist band with capabilities to detect their heart rate or rhythm on the basis of PPG on either wrist around the time of their cardioversion procedure. Data will be acquired from the wrist band at the same time as the electrocardiogram (ECG) monitor to which subjects are hooked up for the purposes of the cardioversion.
41001270|NCT05665881|DRUG|Ephedrine|vasopressor
41001271|NCT05665881|DRUG|Phenylephrine|vasopressor
41001272|NCT05665881|DRUG|Norepinephrine|vasopressor
41001273|NCT06482931|OTHER|Quality of life questionnaires|Patients will be asked to fill in two quality of life questionnaires: PACT-Q and EQ-5D-5L.
41001274|NCT03751085|DEVICE|AW frame|AW stereotactic frame for intracranial lesion biopsy
41001275|NCT06122142|DEVICE|Transfluthrin - delivery by paid study personnel|Passive emanator with formulated transfluthrin, SR product will be delivered by paid study personnel
41001276|NCT06122142|DEVICE|Transfluthrin - delivery by voucher system|Passive emanator with formulated transfluthrin, voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.
41151001|NCT01286870|DEVICE|Mentor Becker 25 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
41151002|NCT01286870|DEVICE|Mentor Becker 50 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
41151003|NCT05455554|DIAGNOSTIC_TEST|Flowmet-D|Flowmet-D is a non-invasive device that measures blood flow.
41151004|NCT05455554|DIAGNOSTIC_TEST|ABI|ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
41151005|NCT01495754|OTHER|coffee|Comparison of different amounts of coffee
41151006|NCT00580047|DRUG|Zoledronic Acid|4mg IV Annually
41151007|NCT00580047|COMBINATION_PRODUCT|Calcium with vitamin D|1200 mg Calcium with 800 International Units of vitamin D
41151008|NCT00580047|DRUG|Alendronate|70mg weekly
41151009|NCT05320068|DRUG|Oral Vancomycin|A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.
41471484|NCT06127017|PROCEDURE|splinting dental implants with PEEK bar|in the active comparator group ,the PEEK bar will be attached to the temporary sleeves using flowable composite resin material.
41471485|NCT03829007|DIAGNOSTIC_TEST|PD-L1 imaging|89Zr-durvalumab injection followed by a PET/CT scan 5 days after injection
41471486|NCT03829007|DRUG|Durvalumab|Durvalumab treatment is initiated after the PET/CT scan in a fixed dose of 1500 mg iv q4w
41313297|NCT01490749|DRUG|RAD001|Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
41313298|NCT01490749|DRUG|XELOX|Patients will receive two cycles of XELOX.
41313299|NCT01490749|DRUG|Carboplatin|Given on a 3 weeks on and 1 week off schedule.
41313300|NCT01490749|RADIATION|Radiation|1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
41313301|NCT02237976|BEHAVIORAL|Self-hypnosis|
41313302|NCT02237976|BEHAVIORAL|Routine practice|
41313303|NCT03134651|DEVICE|Monitoring brain function|
41313304|NCT03134651|DRUG|propofol|
41313305|NCT02392494|DRUG|MK-1075|MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
41313306|NCT02640352|DIETARY_SUPPLEMENT|Probi Defendum|
41313307|NCT02640352|DIETARY_SUPPLEMENT|Placebo|
41313308|NCT01955850|BEHAVIORAL|Cognitive behavioral treatment for insomnia|Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
41313309|NCT03739476|DRUG|Quetiapine 25 milligrams capsule|Compare the incidence of postoperative delirium.
41313310|NCT03739476|DRUG|Placebo oral capsule|Compare the incidence of postoperative delirium.
41313311|NCT05942157|OTHER|Therapeutic Drug Monitoring (TDM)|Upon randomization and before the bacterial culture results are known, blood sampling will be obtained from the patient during the morning round of initial empiric antibiotic administration. PK/PD target analysis based on the clinical susceptibility breakpoints of Enterobacterales (the most prevalent organism family of DT-GNB infections in our setting) will be performed and a dosage recommendation will be communicated to the primary ID clinician. Antibiotic dosing adjustments (if any) will be made within 8 - 24 hours of the blood sampling by the Primary / Infectious Diseases clinician. In case of inappropriate dosing, where the PK/PD target is not achieved or exceeded with antibiotic side effects observed, the dosage will be increased or decreased, respectively.
41313312|NCT04673617|DRUG|AB-101|NK cell therapy
41313313|NCT04673617|DRUG|Rituximab|Anti-CD20 antibody therapy
41313314|NCT04673617|DRUG|Interleukin-2|Immune cytokine
41313315|NCT04673617|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
41313316|NCT04673617|DRUG|Fludarabine|Lymphodepleting chemotherapy
41313317|NCT04673617|DRUG|Bendamustine|Chemoimmunotherapy
41313318|NCT05145478|DEVICE|Shockwave Intravascular Lithotripsy (IVL)|Eligible patients with atherosclerotic lesions in the femoral artery who either have claudication or critical limb ischemia will receive endovascular treatment in addition to be treated with Shockwave Intravascular Lithotripsy (IVL) technology.
41313319|NCT01362218|DRUG|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
41313320|NCT01362218|DRUG|Simvastatin, ramipril, acetylsalicylic acid|A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
41313321|NCT02426593|DEVICE|IMED-4|Non-invasive novel lung hydration status sensor.
41001277|NCT06122142|DEVICE|Transfluthrin - delivery by village health teams|Passive emanator with formulated transfluthrin, village health teams will distribute SR products.
41001278|NCT02284503|DRUG|Rosuvastatin|The subjects will receive intensive Rosuvastatin before and after PCI
41313322|NCT04892758|DRUG|Formoterol fumarate 10 mcg|Formoterol fumarate 10 mcg dispensing claim is used as the reference group.
41313323|NCT04892758|DRUG|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID dispensing claim is used as the exposure group.
41313324|NCT04880538|PROCEDURE|Endoscopic procedure|Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.
41313325|NCT06431243|DRUG|A group Purinostat Mesylate 6mg/m2|Purinostat Mesylate 6mg/m2 + EM 25mg
41313326|NCT06431243|DRUG|A group Purinostat Mesylate 8.4mg/m2|Purinostat Mesylate 8.4mg/m2 + EM 25mg
41471487|NCT02994290|DRUG|HPV vaccine|After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
41313327|NCT06431243|DRUG|A group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2 + EM 25mg
41313328|NCT06431243|DRUG|A group Purinostat Mesylate 15.0mg/m2|Purinostat Mesylate 15.0mg/m2 + EM 25mg
41313329|NCT06431243|DRUG|B group Purinostat Mesylate 6.0mg/m2|Purinostat Mesylate 6.0mg/m2 + Tislelizumab 200mg
41313330|NCT06431243|DRUG|B group Purinostat Mesylate 8.4 mg/m2|Purinostat Mesylate 8.4mg/m2 + Tislelizumab 200mg
41313331|NCT06431243|DRUG|B group Purinostat Mesylate 11.2 mg/m2|Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg
41313332|NCT06431243|DRUG|B group Purinostat Mesylate 15.0 mg/m2|Purinostat Mesylate 15.0mg/m2 + Tislelizumab 200mg
41313333|NCT03190226|PROCEDURE|L-PRF membranes|split-mouth design, randomized L-PRF membranes vs. free gingival graft
41313334|NCT03190226|PROCEDURE|Free Gingival Graft|split-mouth design, randomized L-PRF membranes vs. free gingival graft
41313335|NCT03627910|DIETARY_SUPPLEMENT|symbiotic|Feed supplementation
41313336|NCT03627910|DIETARY_SUPPLEMENT|zinc and arginine|Feed supplementation
41471488|NCT02994290|BEHAVIORAL|Inpatient Postpartum HPV Immunization Quality Improvement Program|"The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed."
41471489|NCT03658187|DIETARY_SUPPLEMENT|Placebo|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
41471490|NCT03658187|DIETARY_SUPPLEMENT|IP|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
41471491|NCT01343875|PROCEDURE|tear of the distal tendon in the biceps muscle|
41471492|NCT05613036|DRUG|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)|\[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 1)
41471493|NCT05613036|DRUG|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)|\[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 2)
41471494|NCT05613036|DRUG|BI 907828|BI 907828
41471495|NCT02244749|OTHER|skin specimen|skin specimen
41471496|NCT06274424|BEHAVIORAL|The Friends Program|A group CBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions.
41471497|NCT04690569|DIAGNOSTIC_TEST|MeMed BV|The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.
41313337|NCT01095575|DRUG|normal saline 3 ml, morphine 3mg|On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
41471498|NCT00890942|DRUG|naloxone|naloxone 0.4mg.(1 ml) intramuscular
41001279|NCT04240145|DEVICE|MSCT Abdomen|Visceral fat volumetry using MSCT and it's relation to NASH
41001280|NCT05400616|PROCEDURE|Microbiome Transplant|A raw microbiome, is collected from a donor without any sinonasal health problems, as a nasal lavage.
41471499|NCT00890942|DRUG|normal saline|normal saline 1 ml IM
41471500|NCT00759278|PROCEDURE|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
41151010|NCT05320068|DRUG|Placebo|A blinded capsule that contains no vancomycin every 6 hours during 10 days.
41151011|NCT02543294|DEVICE|Echocardiograms|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
41151012|NCT02543294|DEVICE|Electrocardiogram|Electrocardiogram performed at baseline.
41471501|NCT05274048|DRUG|Neratinib Pill|Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
41471502|NCT05274048|DRUG|Fam-Trastuzumab Deruxtecan-Nxki (TDxD)|standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
41471503|NCT05486299|PROCEDURE|Robotic assisted single-port general surgery|Robot assisted single-port rectal resection, colectomy, partial gastrectomy, appendectomy and cholecystectomy via the single-port configuration
41471504|NCT01522950|DRUG|Nebivolol|5 mg daily or 10 mg daily
41471505|NCT01522950|DRUG|atenolol|25 mg daily or 50 mg daily
40796704|NCT03441022|DEVICE|Amiigo Watch + BodyGuardian|Subjects will be sent home after the cardioversion with a 30 day heart monitor called the BodyGuardian. This device continuously monitors their heart rate and rhythm and they will wear this on the chest. Subjects will also wear the wrist monitor over the same 30 day period.
41471506|NCT01522950|DRUG|placebo|one tablet daily
41471507|NCT00772616|DRUG|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
41471508|NCT00772616|DRUG|Sufentanil|dosage according to usual criteria
41471509|NCT04627831|DRUG|CE-Iohexol|Captisol-Enabled™ Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
41471510|NCT04627831|DRUG|Iohexol|Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
41471511|NCT01701973|DRUG|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
41471512|NCT01701973|DRUG|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
40796705|NCT06138808|OTHER|Stereoelectroencephalography (SEEG)|Participants will under Stereoelectroencephalography (SEEG) as part of standard of care. This is not assigned by the protocol.
41001281|NCT05400616|PROCEDURE|Placebo|Normal saline.
41001282|NCT01308307|DEVICE|photorefraction|photorefraction is a name of device.
41151013|NCT02543294|BEHAVIORAL|Symptom Questionnaire|Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
41151014|NCT02543294|BEHAVIORAL|Telephone Follow-Up|Telephone follow-up by study staff at months 3 and 5.
41151015|NCT01016730|DRUG|Bortezomib|Given IV
41151016|NCT01016730|OTHER|Laboratory Biomarker Analysis|Correlative studies
41151017|NCT01016730|OTHER|Questionnaire Administration|Ancillary studies
41001283|NCT04237428|BIOLOGICAL|CD19 CAR-T cells infusion|"Biological: CD19 CAR-T cells infusion Biological: CD19 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD19 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD19 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD19 CAR-T cells are infused into patients for one time, the number of infused CD19 CAR-T cells are 0.5-4×10\^6/kg."
41001284|NCT04505891|BEHAVIORAL|Education|Kidney health education will be delivered prior to discharge by trained nurse educators.
41313338|NCT00621452|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
41313339|NCT00621452|DRUG|cyclophosphamide|Given IV
41313340|NCT00621452|BIOLOGICAL|aldesleukin|Given subcutaneously
41313341|NCT00621452|GENETIC|polymerase chain reaction|Correlative studies
41313342|NCT00621452|GENETIC|gene rearrangement analysis|Correlative studies
41313343|NCT00621452|PROCEDURE|lymph node biopsy|Optional correlative studies
41313344|NCT00621452|BIOLOGICAL|genetically engineered lymphocyte therapy|Receive genetically modified T cells
41313345|NCT00621452|PROCEDURE|bone marrow aspiration|Optional correlative studies
41313346|NCT00621452|OTHER|flow cytometry|Correlative studies
41313347|NCT00621452|OTHER|laboratory biomarker analysis|Correlative studies
41313348|NCT00621452|OTHER|enzyme-linked immunosorbent assay|Correlative studies
41313349|NCT03861195|PROCEDURE|laparoscopic surgery|patients affected by uterine diseases that undergo treatment
41313350|NCT00643591|OTHER|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
41313351|NCT04570657|BIOLOGICAL|MEDI3506|Participants will receive multiple doses of MEDI3506 at dose level 1 or dose level 2
41313352|NCT04570657|DRUG|Placebo|Participants will receive multiple doses of placebo
41313353|NCT02841787|BEHAVIORAL|iCBT for late life depression|
41313354|NCT04551573|DRUG|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
41313355|NCT04551573|DRUG|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
41313356|NCT05018117|DRUG|Nicotine gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
41001285|NCT04505891|BEHAVIORAL|Education and follow-up|In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
41001286|NCT03879889|DRUG|Nicotine patch|Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
41151018|NCT05478200|BEHAVIORAL|physical exercise|Group A (physical exercise, combined with pain education and healthy lifestyle habits), will receive an intervention programme consisting of 3 sessions per week for 12 weeks (total of 36 sessions). Each week there will be one face-to-face session, followed by 2 home sessions, (12 face-to-face and 24 home sessions). The sessions will include cardiovascular exercises, 2 days a week we will work on strength13 and 1 day a week we will work on mobility and exercises to improve movement control, both before the cardiovascular effort14 . Each session will include a light warm-up (at the beginning of the session) and a cool down (at the end).
41313357|NCT05018117|OTHER|Placebo gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
41313358|NCT03015922|DRUG|Lenalidomide or Pomalidomide|Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
41313359|NCT03015922|BIOLOGICAL|REOLYSIN|Patients will receive Reolysin alongside either lenalidomide or pomalidomide
41313360|NCT03419052|BEHAVIORAL|Speed of processing training|Speed of processing training is provided by the Internet-based BrainHQ program from Posit Science, Inc. BrainHQ contains five different speed training modules (Hawk Eye, Visual Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) which tap time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory.
41313361|NCT03419052|BEHAVIORAL|MIND foods|"The MIND diet (created by the Rush Aging \& Memory group) specifically emphasizes foods high in polyphenols such as berries, nuts, cocoa, black beans, olive oil, and green leafy vegetables. Participants select these foods from the digital study application and receive them through home delivery."
41471513|NCT01701973|DRUG|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
41313362|NCT03419052|BEHAVIORAL|Cognitive training control|Control training is provided by the Internet-based BrainHQ program from Posit Science, Inc.These are inert games such as tic-tac-toe, connect 4, battleship, etc.
41313363|NCT03419052|BEHAVIORAL|Control foods|Foods contain low polyphenols. Participants select these foods from the digital study application and receive them through home delivery.
41313364|NCT04994444|DRUG|Nicoderm CQ 21Mg/24Hr Transdermal System|Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
41313365|NCT02305654|PROCEDURE|ILND - Inguinal Lymph Node Dissection|Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.
41313366|NCT02305654|DRUG|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
41313367|NCT02305654|DRUG|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
41313368|NCT02305654|DRUG|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
41313369|NCT02305654|RADIATION|Intensity modulated radiation treatment (IMRT)|Treatment with very high energy X-rays (radiotherapy).
41313370|NCT02305654|PROCEDURE|Prophylactic PLND - pelvic lymph node dissection|Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.
41471514|NCT01701973|DRUG|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
41001287|NCT04115943|OTHER|Treatment protocol for neck pain|The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.
41001288|NCT04115943|OTHER|Protocol for release of tongue muscles|. The aim is the relaxation of the suprahyoid muscles (mylohyoid, geniohyoid, digastric and stylohyoid) as well as the cervical fascia of the anterior region and soft tissues of the region of the pharynx and larynx.
41001289|NCT00881946|DRUG|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
41313371|NCT05307445|DEVICE|Photobiomodulation with Bioptron Hyperlight Therapy|The Bioptron® Device provides polarized visible polychromatic noncoherent light with 90 W; light wavelength = 480-3400 nm; degree of polarization = 95%; specific power = 40 mW/cm2; energy density = 2.4 J/cm2. The duration of each treatment session was 10 min. Bioptron light was positioned 10 cm from the oral mucosa and a mouth opener was positioned for the entire duration of the session. Two weekly sessions during the first 4 weeks of treatment were applied.
41313372|NCT06399731|DEVICE|High-frequency (10Hz) rTMS|High-frequency (10 Hz) rTMS targeting the left DLPFC, based on fMRI-peak activation during performance of the Tower of London task, at 110% resting motor threshold intensity, corrected for scalp-cortex distance at the target location, for a total of 3000 pulses per session, using 30 trains of 10 seconds with 30-second inter-train intervals (total duration: 20 minutes), using neuronavigation to record the pulse location.
41313373|NCT06399731|DEVICE|Anodal tDCS|Anodal high-definition tDCS. The anode will be placed at the F3 EEG location, coordinates registered using neuronavigation on the first intervention session on-site, and cathodes at Fp1, Fz, C3 and F7, in a ring surrounding the anode, using π cm2 circular stimulation electrodes, stimulating the left DLPFC at 2 mA intensity for a duration of 20 minutes, 15 s ramp up and 15 s ramp down. After an initial on-site instructional tDCS session, the tDCS intervention will be delivered at home, in part remotely-supervised via MS Teams.
41313374|NCT02575573|OTHER|Factors influencing resuscitation decisions of patients|
41001290|NCT04837092|DRUG|FR104|FR104 treatment administration at day 0, day 14 then every 28 days until month 12
41001291|NCT01746212|PROCEDURE|One-level or two-level anterior lumbar interbody fusion|Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
41001292|NCT01746212|BIOLOGICAL|InQu Bone Graft Extender and Substitute mixed with BMAC|Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
41001293|NCT01746212|DEVICE|Synthes Spinal Instrumentation|Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
41001294|NCT05394675|DRUG|DS-9606a|Intravenous infusion
41001295|NCT03303404|DEVICE|Ambulatory (24-hour) Blood Pressure|Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
41313375|NCT02575573|OTHER|Factors leading to not asking patients about resuscitation preference|
41313376|NCT06196957|COMBINATION_PRODUCT|pursed lip breathing|pursed lip breathing
41313377|NCT02796391|DRUG|Very Low Nicotine Content (VLNC) Cigarettes|"Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm."
41001296|NCT03789552|DRUG|T89 capsule|T89 capsules (75mg)
41001297|NCT03789552|DRUG|Placebo capsule|Placebo capsules (0mg)
41001298|NCT04943731|DEVICE|Provox Life|Phase 1: Like for like transition, Phase 2: Provox Life day/night regimen
41001299|NCT01367769|OTHER|No intervention|There will be no intervention in this study.
41001300|NCT01904708|OTHER|Acute Moderate Intensity Exercise|Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
41001301|NCT01510119|DRUG|Hydroxychloroquine|
41001302|NCT01510119|DRUG|RAD001|
41001303|NCT00233623|DRUG|Iressa (Gefitinib)|
41001304|NCT00233623|DRUG|Irinotecan|
41001305|NCT00233623|DRUG|5Fluorouracil|
41313378|NCT02796391|BEHAVIORAL|One on One Counseling|All participants will receive One on One Counseling.
41313379|NCT05692648|BEHAVIORAL|Supine position group|These neonates were placed in supine position, fed every 2 hours in accordance with routine clinical practice, and then returned to supine position.
41313380|NCT05692648|BEHAVIORAL|Hourly position change group|"Infants in this group were repositioned every hour based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours."
41471515|NCT01701973|DRUG|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
41313381|NCT05692648|BEHAVIORAL|Control Group (2-hour position change)|Neonates in this group were repositioned every 2 hours as routine practice based on the time of phototherapy initiation. Phototherapy was started with neonates in supine position. In the second period, the neonate was placed in the prone position after routine feeding was performed.
41001306|NCT00233623|DRUG|Leucovorin|
41001307|NCT01110421|DRUG|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
41001308|NCT01110421|DRUG|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
41001309|NCT01110421|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
41001310|NCT01110421|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
41001311|NCT01110421|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
41001312|NCT01895673|OTHER|Gadolinium|All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
40796706|NCT01784367|DEVICE|vv-ECCO2R (Novalung GmbH, Germany)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
41313382|NCT01575197|BIOLOGICAL|Human Rotavirus Vaccine|Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 \& 10 weeks of age, 10 \& 14 weeks of age, or 6, 10, \& 14 weeks of age, depending on study arm assignment.
41001313|NCT03941210|OTHER|Detection of molecular Biomarkers|MicroRNA expression profile analysis by flow cytometry
41001314|NCT03200925|OTHER|"Jumping into Kangaroo Care - a video created by the Ohio Department of Health"|The video is 8 minutes and 52 seconds in length. The video discusses the benefits and logistics of Kangaroo Care from professional's perspectives and from new mother's perspectives.
41001315|NCT04209309|DEVICE|repetitive transcranial magnetic stimulation|
41313383|NCT04507477|BIOLOGICAL|Rituximab|For EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours.
41313384|NCT03571841|BEHAVIORAL|Group Session|The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan
41313385|NCT03571841|BEHAVIORAL|Telephone Booster|One month following the group session, women will receive a telephone booster session (\<15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.
41313386|NCT06368089|OTHER|Inspiratory muscle training (IMT) group|The IMT group receives inspiratory muscle training of 50%MIP, 6 breaths/set 10 sets/day for 7 days combined with conventional chest physiotherapy including; percussion, vibration, postural draining, positioning, and passive range of motion.
41313387|NCT06368089|OTHER|Early mobilization (EM) group|The ER group received active exercise in sitting, standing, and marching 30 minutes/day for 7 days with conventional chest physical therapy
40796707|NCT01282385|DRUG|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
40796708|NCT01282385|DRUG|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
40796709|NCT01844297|DRUG|TDF+3TC+EFV|
41313388|NCT04809389|BIOLOGICAL|DelNS1-nCoV-RBD LAIV|Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2
41313389|NCT04809389|BIOLOGICAL|Matching placebo|0.9% NaCl solution
41313390|NCT01021852|DRUG|MK-6096|MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
41313391|NCT01021852|DRUG|Dose-matched Placebo to MK-6096|Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
41471516|NCT01784198|DIETARY_SUPPLEMENT|Protein Intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
41471517|NCT05363995|BEHAVIORAL|i-Sleep & BioClock Intervention|"The 'i-Sleep \& BioClock' intervention aims at improving sleep and the biological clock among university students. It is incorporates evidence-based techniques such as cognitive behavioural therapy for insomnia (CBTi). The intervention has a duration of 5 weeks and consists of five modules:~1. psychoeducation on insomnia, sleep hygiene and the biological clock,~2. stimulus control and sleep restriction therapy,~3. worrying and relaxation exercises,~4. cognitive therapy to change dysfunctional thoughts about sleep, and~5. summary module, relapse prevention, and plan for the future.~The intervention is supported by e-coaches who give personalized written feedback. Students will fill in a sleep \& light exposure diary daily."
41471518|NCT01726127|OTHER|Broccoli and Brussels Sprouts|
41471519|NCT01726127|DIETARY_SUPPLEMENT|Cruciferous Complete|
41471520|NCT01726127|OTHER|Placebo|
41471521|NCT02087891|BEHAVIORAL|Web-based Stress Management Program (WSM)|The intervention, developed by the Cleveland Clinic, is an 8-week online, interactive, educational program based on mindfulness meditation. Briefly, each week subjects are introduced to the (1) weekly audio introduction to the mindfulness theme or particular meditation technique of the week, (2) weekly audio meditation techniques for relaxation, (3) daily articles providing scientific evidence and merits of meditation, and (4) bi-weekly email reminders. The introductory talks and meditation exercises were also provided on compact discs (CD) in mp3 format.
41471522|NCT02087891|BEHAVIORAL|Group Support (WSMg1)|Subjects will meet once per week for 1 hour during the 8-week duration and practice 2-minutes of deep breathing exercises, listen to 10-minutes audio recording of the weekly lesson and practice 20-30 minutes guided meditation exercise. The remainder of the time will be used to foster sharing experiences and answering specific questions related to the weekly lesson.
41471523|NCT02087891|BEHAVIORAL|Clinical Expert Support (WSMg2)|A clinical psychologist will replace the non-expert facilitator during 4 group support sessions.
41471524|NCT06058221|DEVICE|simultaneous videolaryngoscopy|Two specialists perform tracheal intubation, one using a video laryngoscope to expose the vocal cords and the other using a fiberoptic bronchoscope.
41471525|NCT06058221|DEVICE|supraglottic airway|After inserting the supraglottic airway, the specialist performs intubation using a fiberoptic bronchoscope through the supraglottic airway.
41471526|NCT02385201|DEVICE|Senza|Spinal Cord Stimulation
41001316|NCT02531412|DRUG|Spironolactone|After a major surgery event a time 0, 24h and 48h
41001317|NCT02531412|DRUG|Placebo|After a major surgery event a time 0, 24h and 48h
41313392|NCT01913808|DRUG|Ferric carboxymaltose|Single intravenous dose ferric carboxymaltose
41313393|NCT01913808|DRUG|ferrous glycine sulphate|Daily oral dose of 100 mg iron (ferrous glycine sulphate)
41313394|NCT04597619|OTHER|Novel Nonopioid Pathway|The novel nonopioid pathway consists of preoperative counseling, postoperative standardized orders and standard of care adjunctive and analgesic medications, specialized discharge instructions and written patient instructions regarding medications and activity.
41471527|NCT03167502|OTHER|eccentric work|patient will follow 2 eccentric trainings per week during 6 weeks
41471528|NCT03167502|OTHER|concentric work|patient will follow 2 concentric trainings per week during 6 weeks
41471529|NCT05725902|DRUG|Etavopivat|The study intervention is etavopivat (400 mg), administered orally and once daily (QD)
41471530|NCT02387567|DRUG|Lidocaine|Paraspinal block with 3ml lidocaine injection at 1%.
41001318|NCT00955266|DRUG|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
41001319|NCT00955266|DRUG|Placebo|Normal saline, 50cc delivered over 5 minutes
41001320|NCT04372602|DRUG|Duvelisib|-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.
41001321|NCT04372602|PROCEDURE|Peripheral blood draw|"* First 10 patients enrolled~* Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29"
41313395|NCT01982773|BEHAVIORAL|Virtual Hope Box Smartphone App|Smartphone app
41313396|NCT01982773|BEHAVIORAL|Enhanced Treatment as Usual|Printed materials
40796710|NCT03531164|OTHER|kAYAK ERGOMETER GROUP|Kayak ergometer training for 30 min 5 times a week for 6 weeks. The training includes a warming (pre charge) during 3 minutes, a training (charge) characterised by 3-5 intervals with medium to high intensity during 2-4 minutes and pauses of 1-2 minutes between active phases and 2 minutes of cooling down (post charge) to complete 30 minutes of training.
40796711|NCT03531164|OTHER|CONTROL GROUP|Proprioceptive neurofacilitation exercises focused in trunk control during 30 minutes 5 times a week for 6 weeks.
40796712|NCT00349349|DRUG|ofatumumab|Intravenous infusion
41001322|NCT04372602|DRUG|Placebo|-Provided by Verastem
41001323|NCT03083496|DRUG|Potassium Oxalate 5%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
41001324|NCT03083496|DRUG|Potassium Oxalate 10%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
41001325|NCT05599178|OTHER|Ultrasound examination in early labor|Combined trans-abdominal and trans-perineal ultrasound examination
41001326|NCT03569371|DRUG|INCB054707|INCB054707 administered once daily orally with water without regard to food for 8 weeks.
41313397|NCT02299141|DRUG|Nintedanib|
41313398|NCT04825379|DEVICE|bioactive composite|Cention N
41313399|NCT04825379|DEVICE|posterior composite|G-ænial Posterior
41001327|NCT03214809|DIAGNOSTIC_TEST|ultrasound protocol|after first assessment and treatment by the MET team, an Multi-organ ultrasound protocol will be run by the MET doctor
41001328|NCT04143451|BIOLOGICAL|Vaxigrip tetra|quadrivalent influenza vaccine
41001329|NCT04143451|BIOLOGICAL|Fluzone high-dose|high-dose trivalent influenza vaccine
41001330|NCT04143451|DRUG|Aldara 5% Topical Cream|imiquimod cream
41313400|NCT02562248|OTHER|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
41313401|NCT02562248|OTHER|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
41471531|NCT02387567|DRUG|Sham Lidocaine|Sham injection, without lidocaine.
41471532|NCT02387567|OTHER|Standard treatment|Standard treatment only, without lidocaine or sham injection.
41471533|NCT03752398|BIOLOGICAL|XmAb®23104|Monoclonal bispecific antibody
41471534|NCT03752398|BIOLOGICAL|Yervoy® (ipilimumab)|Monoclonal antibody
41001331|NCT04143451|DRUG|Aqueous cream BP|inactive aqueous cream
41001332|NCT06221228|BEHAVIORAL|Audio-visual assisted Flipped Classroom (FC) CAPD Training Programme|"FC CAPD programme is a one-week individual intervention, which consists of five sessions (8-hours each).~Pre-class audio-visual tutorials will be provided for self-study prior to face-to-face (F2F) sessions. Six instructional videos, each dedicated to a specific procedure, are accessible for preview and repeated viewing as needed. Such flexibility allows the patients to revise at their own preferred time and pace.~Participants will be asked to take note of any issues or difficulties they encounter while watching the video.~A CAPD education booklet will be prepared and distributed to the patients at the beginning of the F2F training session.~Take-home exercises will allow participants to revise the materials covered in the videos and consolidate their learning."
41001333|NCT02877628|OTHER|Pharmacokinetic-pharmacodynamic model in liver transplantation|Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination
41001334|NCT05272982|DIAGNOSTIC_TEST|Thoracic fluid content by electrical cardiometry group|Thoracic fluid content will be measured using electrical cardiometry device (ICON ® Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). The ICON device will be connected to four electrocardiogram electrodes which will be placed over patients' skin after cleaning with alcohol at the neck below the left ear, just above the left clavicular midpoint, and two electrodes at left mid-axillary line one at the level of the xiphoid process, and the other electrode 5 cm below this point. The thoracic fluid content will be observed for 30 s and the average of the highest and lowest values will be recorded.
41001335|NCT05272982|DIAGNOSTIC_TEST|Ultrasound examination group|The 12-region technique for lung assessment will be performed using Philips ® (CX50 - Extreme edition) equipped with phased array transducer. B-line will be defined as laser like vertical hyperechoic artefact which extends between the pleural line and the bottom of the screen and moves with respiratory movements. Two types of B-lines will be evaluated.
41313402|NCT03809832|DIAGNOSTIC_TEST|Microbiological sampling|An microbiological sampling of the ventilator humidifier will be performed.
41313403|NCT01113021|DEVICE|Photon stimulation by low level laser therapy|
41313404|NCT01218789|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
41313405|NCT05688410|OTHER|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
41471535|NCT06084169|DEVICE|Intra Ocular Lens (IOL) Implant|Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye
41471536|NCT04935788|DIETARY_SUPPLEMENT|milk protein|milk protein supplement
41313406|NCT05688410|BEHAVIORAL|Psychotherapy Pain and Addiction (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
41471537|NCT04935788|DIETARY_SUPPLEMENT|micellar casein|micellar casein supplement
41471538|NCT04935788|DIETARY_SUPPLEMENT|pea protein|pea protein supplement
41471539|NCT04935788|DIETARY_SUPPLEMENT|milk/pea protein blend|milk/pea protein supplement
41471540|NCT01766791|OTHER|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM
41471541|NCT01766791|OTHER|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - \< 75 1RM
41471542|NCT01766791|OTHER|HIT-exercise with protein|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM and Protein Supplementation
41471543|NCT01766791|OTHER|Control|control group, no intervention, maintenance of physical activity
41471544|NCT01941888|DRUG|Propofol|
41471545|NCT01941888|DRUG|Midazolam|
41471546|NCT01941888|DEVICE|Target Controlled Infusion|
41471547|NCT00277407|PROCEDURE|NAET with acupressure and/or chiropractic procedures|
41471548|NCT01553201|DRUG|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
41471549|NCT01553201|DRUG|Placebo|Saline, 4cc, one time intramuscular administration
41001336|NCT06333327|DEVICE|Pulmonary vein isolation with the multielectrode radiofrequency balloon catheter|Pulmonary vein isolation with the multielectrode radiofrequency balloon catheter
41313407|NCT02097758|DEVICE|Transcatheter device closure|"Closure of atrial septal defect with device~* choosing device size with 3D image and the formula~* we do not use sizing balloon for choosing of the device size"
40796713|NCT04224103|DRUG|Inhaled nitric oxide|"Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation."
40796714|NCT06554561|DRUG|Pomalidomide|3-5mg d1-d14 for 4-6 cycles, every 21 days as induction/consolidation chemotherapy, Then 3-5mg d1-d14 for 12 cycles, every 28 days as maintenance treatment.
40796715|NCT06554561|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 4-6 cycles will be prescribed.
40796716|NCT06554561|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 4-6 cycles will be prescribed.
40796717|NCT00147992|PROCEDURE|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
40796718|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 150mg at 0 Day 1, Day 8, Day 15
40796719|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 300mg at 0 Day 1, Day 8, Day 15
41001337|NCT04146480|DIAGNOSTIC_TEST|F18-NaF PET/CT|"The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5. Upon completion of the scan, will be released without any restrictions."
41001338|NCT01457599|PROCEDURE|Computertomography-guided marking of colorectal liver metastases|Computertomography-guided marking of colorectal liver metastases
41313408|NCT01711684|DRUG|Diphenylcyclopropenone (DPCP)|Topical application of study drug
41313409|NCT01647659|DRUG|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
41313410|NCT01647659|DRUG|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
41313411|NCT03117062|OTHER|occlusal reduction|relief of occlusion following endodontic treatment
40796720|NCT05980065|DRUG|Placebo|Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15
40796721|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 600mg at 0 Day 1, Day 8, Day 15
40796722|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 900mg at 0 Day 1, Day 8, Day 15
40796723|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 1200mg at 0 Day 1, Day 8, Day 15
40796724|NCT05874505|DRUG|Adalimumab|Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15
40796725|NCT05874505|DRUG|Tocilizumab|Tocilizumab 162 mg subcutaneous each week for 15 weeks
40796726|NCT00626886|DRUG|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
40796727|NCT00626886|DRUG|placebo collagen sponge|collagen
40796728|NCT01605422|OTHER|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
40796729|NCT02855658|DRUG|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
40796730|NCT02855658|DRUG|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
41001339|NCT00849368|DRUG|Azathioprine / Allopurinol|"Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets"
41001340|NCT03921710|DRUG|CAPA-IVM|Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin \[SAGE, Denmark\] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.
41313412|NCT04397718|DRUG|Degarelix|Degarelix is an FDA-approved drug for prostate cancer
41313413|NCT04397718|OTHER|Saline|09% Saline
41313414|NCT06516185|DEVICE|direct-printed aligner|Patients will be treated with direct-printed aligners until dental alignment is achieved.
41313415|NCT06516185|DEVICE|thermoformed aligner|Patients will be treated with thermoformed aligners until dental alignment is achieved.
41313416|NCT05840419|DEVICE|Laparoscopic appendectomy|Laparoscopic appendectomy with Airseal or with standard insufflation
41313417|NCT05081648|PROCEDURE|CT MuST|Multiple Single Cannulation Technique (MuST): Experimental technique
41471550|NCT06424717|DRUG|Avelumab|Participants will be administered Avelumab intravenously (IV).
41471551|NCT06424717|DRUG|Tuvusertib|Participants will be administered Tuvusertib orally.
41313418|NCT05081648|PROCEDURE|Rope-ladder cannulation technique|Standard cannulation technique( Rope-ladder)
41471552|NCT03239977|BEHAVIORAL|Online Social Intelligence Training|The SII consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that SII is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
41471553|NCT03239977|BEHAVIORAL|Attention Control (AC)|A placebo condition delivered online to both custodial grandmothers and their adolescent grandchild which presents health-related information only.
41471554|NCT05025280|OTHER|Adolescent/Adult Sensory Profile Questionnaire|"The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking."
41471555|NCT06456424|BIOLOGICAL|Phage therapy|Bacteriophage cocktail consisting of phages BP13 and J1P3
41471556|NCT06334419|DRUG|Gaboxadol|Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)
41471557|NCT06334419|DRUG|Placebo|Two placebo capsules
41471558|NCT02268539|PROCEDURE|ablation|Ablation ranging from 20-25 watts / 30-45 seconds
41471559|NCT03677219|OTHER|Educational Video|The educational video is a 2 minute video depicting a live lumbar puncture on an infant interwoven with animations of the relevant anatomy.
41471560|NCT05085795|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
41471561|NCT00538655|DRUG|modafinil|400mg vs. 200mg (PO) daily
41471562|NCT06587464|OTHER|No Intervention|This is a non-interventional study.
41471563|NCT00026052|DRUG|riluzole|
41471564|NCT03662308|DEVICE|Heated Vest|Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature
41471565|NCT03662308|DEVICE|Non-Heated Vest|A similarly insulated (compared to the experimental vest), but non-heated vest
41471566|NCT02656082|DRUG|Etanercept|Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
40796731|NCT05648344|BEHAVIORAL|WW|"WW assigns foods to a point value calculated through a proprietary algorithm that accounts for the food's caloric value, saturated and unsaturated fat, sugar, fiber, and protein. Members are encouraged to track their food and beverage intake, with the goal of staying within their personal points targets assigned based in an individual's sex, age height, weight, goals, and activity. The program also has Zero Point Foods (list of healthy foods with no point value) and can be eaten freely. In addition to the personal points, participants will be asked to attend WW coach-led virtual workshops conducted over Zoom, engage with peer- support, and WW-trained behavior change experts via 24/7 chat."
40796732|NCT05648344|BEHAVIORAL|Control|Usual care with information from myplate.gov
41001341|NCT03921710|DRUG|Standard-IVM|Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
41001342|NCT02142686|DEVICE|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
41001343|NCT02142686|DEVICE|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
41001344|NCT02142686|DEVICE|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
41001345|NCT06071455|OTHER|Platelet-rich fibrin|injected distal to the canine on the experimental side.
41001346|NCT06071455|OTHER|Vitamin D3|injected distal to the canine on the experimental side.
41001347|NCT03907683|BEHAVIORAL|Short Message with Text and Optional Image|"Messages can be up to 256 characters of text and with or without an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
40796733|NCT00598923|DRUG|topiramate|100 mg twice per day for 3 months
40796734|NCT00598923|DRUG|topiramate|100 twice per day for 6 days after loading dose of phenytoin
41001348|NCT03272451|PROCEDURE|culprit vessel intervention|ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
41001349|NCT03272451|PROCEDURE|traditional approach|single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
41001350|NCT04906785|DRUG|CKD-385|Test Drug
40796735|NCT00598923|DRUG|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
41001351|NCT04906785|DRUG|D744|Reference Drug
41001352|NCT06061393|DRUG|Venofer 200 MG Per 10 ML Injection|treat anemia with venofer up to 5 doses
41001353|NCT06061393|DRUG|Ferinject|ferinject 500 mg, once a week for 2 weeks
41001354|NCT02845752|DRUG|Stiolto Respimat|Oral inhalation spray
41001355|NCT02845752|DRUG|Placebo Respimat|Oral inhalation spray
41313419|NCT01658579|DRUG|HOE901-U300 (new formulation of insulin glargine)|
41313420|NCT01658579|DRUG|Lantus (insulin glargine)|
41313421|NCT00579501|DRUG|Trabectedin|Trabectedin 1.5 mg/m\^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
41313422|NCT00579501|DRUG|Dexamethasone|Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
41001356|NCT03811795|OTHER|ECG monitoring with a Kardia Mobile monitor|The participants in the study will undergo a total of two follow-up visits after ablation (approximately 3 and 6 months) with a 12-lead electrocardiogram at each visit. An assessment of rhythm will be performed with daily transmissions as well as subject-activated event recordings for symptoms with the Kardia Mobile smartphone based monitor. The Kardia Mobile System is an FDA-cleared, clinical grade mobile ECG monitor coupled with a smartphone app that is able to record a single-lead ECG and securely transmit the tracings to the study investigators via the Kardia Pro commercial (HIPPA compliant) remote monitoring service for clinicians.
41001357|NCT00721695|DRUG|OMS302|OMS302 Irrigation Solution
41313423|NCT04678011|PROCEDURE|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.
41313424|NCT02547636|OTHER|Observational study|No intervention will be used in this study.
40796736|NCT02374060|DRUG|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
41001358|NCT00721695|DRUG|OMS302-PE|OMS302-PE HCI Irrigation Solution
41001359|NCT00721695|DRUG|Vehicle|Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
41001360|NCT04160793|DEVICE|Genital Nerve Stimulation|Implantation the vaginal way a stimulation's electrode to the dorsal nerve of the clintoris in local anesthesia
41001361|NCT00206453|DRUG|Taxotere|Chemotherapy IV
41001362|NCT04974658|PROCEDURE|Inter-semispinal plane block|Ultrasound Inter-semispinal plane block in block group
41001363|NCT00587379|DRUG|Atorvastatin|40 mg atorvastatin pill daily
41001364|NCT00587379|DRUG|placebo|40 mg pill per day
41313425|NCT00028561|DRUG|ixabepilone|Given IV
41313426|NCT00028561|DRUG|carboplatin|Given IV
41313427|NCT00028561|OTHER|laboratory biomarker analysis|Correlative studies
41313428|NCT00028561|OTHER|pharmacological study|Correlative studies
40796737|NCT02374060|DRUG|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
40796738|NCT02374060|DRUG|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
40796739|NCT03583359|DEVICE|Radiesse (+)|Radiesse (+) for jawlines.
41001365|NCT02946060|OTHER|Audiobooks|iPods with audiobooks
41001366|NCT02946060|OTHER|Tempo-pace synchronized playlists|Playlists with or without RAS
41001367|NCT02946060|OTHER|Usual Care|iPods containing either a silent track or white noise
41001368|NCT01418937|BIOLOGICAL|CervarixTM (GSK580299)|Three intramuscular injections
41001369|NCT05354128|DRUG|Thrombolytic|Standard intravenous thrombolysis.
41001370|NCT05354128|PROCEDURE|percutaneous coronary stenting|Percutaneous coronary stenting
41313429|NCT04569916|RADIATION|radiotherapy|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
41313430|NCT04569916|DRUG|irinotecan liposome|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
41313431|NCT04569916|DRUG|apatinib|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
41313432|NCT04569916|DRUG|PD-1 antibody|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
41313433|NCT05671601|DIAGNOSTIC_TEST|Automatic picture recognition|A machine that processes photographs automatically taken
41313434|NCT05671601|DIAGNOSTIC_TEST|Manual Assessment Group|Manual recognition of pictures
41001371|NCT03738371|OTHER|In situ simulation|Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
41001372|NCT02244580|DEVICE|MammaTyper™|MammaTyper™ kit is a molecular in vitro diagnostic test for the quantitative detection of the ribonuclease acid (RNA) expression status of the genes for estrogen receptor (ESR1), progesterone receptor (PGR), human epidermal growth factor receptor 2 (HER2) and proliferation antigen KI 67.
41001373|NCT02476968|DRUG|Olaparib|"Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.~Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.~Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water."
41001374|NCT04049656|DEVICE|HFVI|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
41313435|NCT05508672|OTHER|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI)|We will equip CCeSCI with both core eHealth features and provider-side intervention. Patients assigned to the intervention group will receive a series of online interactive and personalization technologies, including an algorithm-based video curriculum with auto-texting, backstage monitoring system etc. Besides, the patients will also have the face-to-face meetings with community health workers. Provider-side intervention includes training for community workers, WeChat group discussion, and performance-based incentives. The training aims to provide essential skills for community workers so that they can provide face-to-face meetings with smokers during the first 3 months of quitting to prevent or revert relapse in a timely and proactive manner.
41001375|NCT01926795|PROCEDURE|Short leg cast|
41001376|NCT01926795|PROCEDURE|No Immobilization|
41001377|NCT01262885|DRUG|GSK2251052|500 mg tablet, dose levels detailed in Arm description
41001378|NCT01262885|DRUG|Placebo|matching placebo tablet
41001379|NCT04792112|BEHAVIORAL|Decision support tool|Decision support tool for late preterm antenatal corticosteroids
41001380|NCT05906862|DRUG|AMT-253|Administered intravenously
41001381|NCT03411876|DEVICE|Oxymizer® pendant nasal cannula|Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.
41001382|NCT03411876|DEVICE|conventional nasal cannula|Supplemental oxygen is provided by a conventional nasal cannula.
41001383|NCT01352312|DRUG|Bendamustine|Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
41001384|NCT01352312|DRUG|Pentostatin|Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
41313436|NCT05508672|OTHER|"Traditional smoking is harmful education"|"In the control group, the participants will receive traditional smoking is harmful education video, which is recorded by the clinical physicians."
41001385|NCT01352312|DRUG|Ofatumumab|Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
41001386|NCT01374308|BIOLOGICAL|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
41001387|NCT01374308|DRUG|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
41313437|NCT01530438|OTHER|MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research|"At T0 and T9 or 12 monts, are performed :~* Imaging : fMRI at rest and anatomical MRI~* Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ..."
41313438|NCT02669862|DRUG|A-101 Solution 40|
41313439|NCT02669862|DRUG|A-101 Solution 45|
41313440|NCT02669862|DRUG|Vehicle Solution|
40796740|NCT01896778|PROCEDURE|Hyperthermia Treatment|Undergo B-WARM
41001388|NCT06190808|DIAGNOSTIC_TEST|Dexcom G7 Continuous Glucose Monitor|Continuous glucose monitor
41001389|NCT00414388|DRUG|Sorafenib|400mg twice daily
41313441|NCT05067062|DIETARY_SUPPLEMENT|New Zealand blackcurrant extract|Capsules taken daily or intermittent
41313442|NCT01766882|BEHAVIORAL|Lower sodium intervention|"1. Lower sodium intervention:~1. Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately \>180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.~2. Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants."
41313443|NCT01766882|OTHER|Progressive Challenge to Post Dialysis Weight|The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
41313444|NCT02518308|BEHAVIORAL|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
41313445|NCT04044092|OTHER|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
41313446|NCT04044092|OTHER|ELDOA stretching exercise|Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
41313447|NCT03282708|OTHER|Fresh stool collection|"One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
41471567|NCT04333017|DEVICE|Percutaneous radiofrequency ablation of parietal endometriosis|Treatment is carried out under local anaesthesia after surgical asepsis, in interventional radiology room. Radiofrequency needles are inserted percutaneously under ultrasound guidance. Number of needles depends on the size of lesion (1 or 2 or 3 needles). In case of proximity between lesion and peritoneum, artificial ascites can be performed. Treatment is carried out in accordance with device's instructions for use (thyroid nodules treatment algorithm), with a gradual increase in power every 5 minutes, without exceeding the maximum authorised power (depending on number and length of needles). State of coagulation is monitored under visual ultrasound control of ablation area (diffusion of Co bubbles), until a decrease in effective power is obtained. Several ablation zones are performed on the same nodule with overlapping of the different impacts. An ice pack is applied to the treated area. An analgesic PO treatment of step 1 and/or 2 is prescribed for 5 days.
41471568|NCT06176196|DRUG|VX-548|Tablets for oral administration.
41471569|NCT06176196|DRUG|Placebo|Tablets for oral administration.
41471570|NCT03670732|OTHER|continuous positive airway pressure|Continuous positive airway pressure is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
41471571|NCT03670732|OTHER|nasal intermittent positive pressure ventilation|NIPPV is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
41471572|NCT05643716|BEHAVIORAL|Aerobic Exercise|The aerobic exercise intervention is described in the Aerobic Exercise Arm description.
41471573|NCT04006938|BEHAVIORAL|Single Bout ('S')|Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast
41471574|NCT04006938|BEHAVIORAL|Multiple Bout ('M')|Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
41471575|NCT03496883|BIOLOGICAL|Recombinant Activated Factor VII (rFVIIa)|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
41313448|NCT05098548|PROCEDURE|angioplasty|using a balloon to stretch open a narrowed or blocked artery. However, most modern angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into the artery during the procedure. The stent is left in place permanently to allow blood to flow more freely .
41471576|NCT03496883|BIOLOGICAL|Placebo|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
41471577|NCT00841152|DEVICE|Bioactive glass|Surgical implantation
41471578|NCT00841152|DEVICE|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
41471579|NCT00841152|PROCEDURE|Autograft|Surgical transplantation from iliac crest
41471580|NCT00841152|PROCEDURE|Allograft (frozen femoral head)|Surgical transplantation
41471581|NCT02586363|DRUG|Baraclude Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
41471582|NCT02586363|DRUG|Cavir Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
41471583|NCT02586363|DRUG|Cavir Tab. 0.5mg, high fatty meal|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
41471584|NCT04174716|DRUG|IDX-1197|Until progression or unacceptable toxicity develops
40796741|NCT01896778|OTHER|Laboratory Biomarker Analysis|Correlative studies
40796742|NCT04213469|BIOLOGICAL|PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells|Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1
41471585|NCT03041207|BEHAVIORAL|Development and implementation of an antibiotic guideline|A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
41471586|NCT04194437|DEVICE|OCS Liver System|The OCS Liver System will be used to preserve, optimize and assess livers from DCD donors.
41471587|NCT06185972|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
41471588|NCT06185972|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
41471589|NCT01632384|BEHAVIORAL|Abstain from smoking for 24 hours|Compare smoking satiation to 24 hour smoking abstinence
41471590|NCT06617676|DEVICE|Transcutaneous tibial nerve stimulation|Two electrodes will be place over the tibial nerve over the medial ankle. The electrical stimulation will be turned up to patient tolerance at a sensory level only.
40796743|NCT04899726|DEVICE|Rectoscope (P201630551)|Rectoscope (P201630551) allows the identification of the distal section margin in oncological rectal surgery.
41471591|NCT05281926|DRUG|Poly ICLC|IT Poly-ICLC injection (1.0 mg) at Day 1 of weeks 0, 1 and 2. IM Poly-ICLC (20 μg/Kg) at Day 1 and Day 3 of weeks 3, 4, 5 and 6.
41471592|NCT05202288|BIOLOGICAL|Ervebo|Administration of r-VSV-ZEBOV vaccine
41471593|NCT05202288|DRUG|Inmazeb|Administration of Inmazeb
41471594|NCT00702208|DEVICE|Delphi Screener|Self-sampling device for cervical vaginal lavage
41471595|NCT03485846|DRUG|Narlaprevir|100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily
41471596|NCT03485846|DRUG|Ritonavir|100 mg, tablets, taken as 100 mg per os daily
41471597|NCT03485846|DRUG|Daclatasvir|60 mg, tablets, taken as 60 mg per os daily
40796744|NCT01698203|DRUG|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
40796745|NCT01698203|DRUG|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
40796746|NCT01698203|DRUG|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
40796747|NCT05424835|DRUG|SHR-A1811|SHR-A1811
40796748|NCT05424835|DRUG|Pyrotinib in combination with Capecitabine.|Pyrotinib in combination with Capecitabine.
41313449|NCT01991405|DEVICE|Computerized Working Memory Training.|"Auditive and visual Working Memory tasks, administrated on a computer under guidance. 5 x 45 minutes per week, for 5 weeks. The intervention group will train at an adaptive level that is not to difficult nor to easy, which is hypothesized as optimal for learning and training effect. The placebo group will train with a sham program that is fixed (non-adaptive in difficulty level), but otherwise identical."
41313450|NCT06129396|OTHER|Aerobic exercise|The aerobic exercise consists of: (1) 5 min warm-up exercise, (2) 20 min aerobic exercise with HR at target zone (one research assistant will be onsite to monitor whether the HR is around the range of moderate intensity), and (3) 5 min cool-down exercise.
41313451|NCT06129396|OTHER|Video-watching|The video-watching group will be asked to watch a nature documentary for 30 mins
41313452|NCT05372341|OTHER|descriptive|posotcovid patients will be elective surgery postoperative outcomes
41471598|NCT06471543|DRUG|RN0361|solution
41471599|NCT02291367|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
41471600|NCT02291367|DRUG|Cymbalta®|60 mg capsule of Eli Lilly and Company
41471601|NCT05409352|BEHAVIORAL|Self-administered acupressure|Participants will receive training of self-acupressure on the 5 standard acupoints by a trained traditional Chinese medicine (TCM) practitioner, have return-demonstration, be assessed by the practitioner with the use of a competency checklist, and be instructed to perform self-acupressure on the standard acupoints once a day. A follow-up visit will be conducted to reinforce learning, in which participants will demonstrate the acupressure technique while the practitioner observes and provides feedback, including suggestions for technique adjustments if necessary. The practitioner will recommend 2 additional acupoints from the list of optional acupoints based on the patients' sensitivity to acupoint stimulation and preference. Daily duration of self-practice will range from 8-10 minutes depending on the semi-individualized protocol (5 standard + 2 optional acupoints).
41471602|NCT05409352|BEHAVIORAL|Aerobic exercise|Participants will receive verbal and written information from a trained exercise specialist about the specific advice of the desired exercise frequency (3x/week), duration (30 min each time), and intensity (moderate determined by rating of 12 to 14 on the Borg Rating of Perceived Exertion scale). The exercise specialist will demonstrate how to perform walking at moderate intensity indoors and outdoors, followed by return-demonstration of the patient. Education on safety precautions and walk schedule planning will be provided. Competency check will be performed to assess participants' ability to self-monitor and self-regular exercise intensity using Borg Scale. One week after the start of the program, the exercise specialist will conduct a 1-hour follow-up visit to supervise the patient's walking session and assess whether there is any additional advice needed.
41471603|NCT04376359|PROCEDURE|hyperbaric oxygen therapy|Hyperbaric oxygen therapy is the patient put in airtight oxygen tank, by increasing the air pressure in the environment (1.5 to 3.0) under atmospheric pressure, to give 100% oxygen, the patient treatment time is approximately 60 minutes to 120 minutes in this way, can achieve the purpose of greatly increase the oxygen partial pressure in the organization, so as to achieve reverse brain edema, reduce lipid peroxidation, inhibiting leukocyte hyperactivity, rebuild the blood brain barrier.
41313453|NCT05355727|OTHER|Clinical decision support tool recommended outcome|The PROSAIC-DS tool will take the variables and produce a suggested outcome. It will supply supporting evidence and best practice for its recommendations
41471604|NCT04904055|OTHER|Value-based Formulary|Prescription drug formulary tiers informed by estimated value
41471605|NCT04906837|DIAGNOSTIC_TEST|Trans aortic valve implantation|Measurement of the membranous septum on the pre TAVI scanner and the valve implantation height
41471606|NCT05306197|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
41471607|NCT05306197|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
41471608|NCT05306197|BEHAVIORAL|Non-Contingent Feedback Training|Participants listen to a musical track they chose with no operant conditioning.
41471609|NCT03701711|DRUG|Lenalidomide|"Dose Escalation~Patients in the dose escalation phase will receive oral treatment with:~Lenalidomide: 10, 15, or 25 mg on Days 1-21 of every 28-day cycle Dexamethasone: 20mg on Days 1,8,15 and 22~Starting doses of Lenalidomide will be assigned at the time of registration.~Dose Expansion~Once the MTD has been established or determined, 8 additional patients will be treated at the MTD of lenalidomide at the same schedule as above. Dexamethasone will be given at the same dose as in the dose escalation portion of the study."
41471610|NCT01754376|DRUG|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
41471611|NCT01754376|DRUG|Vemurafenib|Tablets given twice daily.
41471612|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily for one month.
41471613|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
41471614|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
41471615|NCT04624659|DRUG|Etavopivat Tablets Low dose|200 mg once daily
41471616|NCT04624659|DRUG|Etavopivat Tablets High dose|400 mg once daily
41313454|NCT00726817|DRUG|Butyrate|
41471617|NCT04624659|DRUG|Placebo Tablets|Placebo once daily
41471618|NCT04624659|DRUG|Etavopivat Tablets|Selected dose once daily
41471619|NCT01757899|DRUG|Methylprednisolone Arm|Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
41471620|NCT01757899|DRUG|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc \[methylprednisolone + diluting fluid\], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
41471621|NCT01869426|DIETARY_SUPPLEMENT|VSL#3 drops|
41471622|NCT01869426|DIETARY_SUPPLEMENT|VSL#3 drops placebo|
41471623|NCT05471609|DRUG|levodopa/carbidopa oral formulation A|Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
41313455|NCT01040208|DRUG|flibanserin 50 mg to 100 mg qhs|50 to 100mg qhs
41313456|NCT01040208|DRUG|flibanserin 100 mg qhs|100mg qhs
41471624|NCT05471609|DRUG|levodopa/carbidopa oral formulation B|Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
41471625|NCT05471609|DRUG|levodopa/carbidopa oral formulation C|Outer sachet 50mg CD/200mg LD and inner sachet 50mg CD /200mg LD
40796749|NCT06431191|PROCEDURE|lateral raw|lateral raw repair for full tear rotator cuff combined microfracture procedure, without medial raw
40796750|NCT06431191|PROCEDURE|double raw|double raw repair for full tear rotator cuff combined microfracture procedure
41313457|NCT01040208|DRUG|placebo 2 tablets qhs|50 mg placebo
41313458|NCT01012505|OTHER|adding pad with maternal milk in hte incubator|"2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.~stopping intervention and for other 2 days recording infants data and taking saliva cortisol"
41471626|NCT00679250|DRUG|levocetirizine|5 mg once nightly before visit
41471627|NCT00679250|DRUG|placebo to levocetirizine|1 tablet once nightly before visit
41471628|NCT02079337|DRUG|Rocuronium|
41471629|NCT02079337|DRUG|sugammadex|
41471630|NCT02079337|DRUG|placebo|
41471631|NCT01765270|DRUG|Saxagliptin|one 5-mg saxagliptin tablet daily
41471632|NCT01765270|DRUG|Placebo|5mg placebo tablet daily
41471633|NCT02997657|BEHAVIORAL|Positive Psychotherapy|Exercises designed to boost moods, positive behaviors, and positive cognitions.
41471634|NCT02997657|BEHAVIORAL|Standard smoking cessation counseling|Counseling designed to provide support and problem solving for smoking cessation
41471635|NCT03381937|OTHER|speech trial|speech trial during different ventilation conditions
41471636|NCT05919745|DRUG|Ibuprofen 600 mg|Preoperative delivery of ibuprofen per os.
41471637|NCT05919745|DRUG|Placebo|Preoperative delivery of placebo per os.
41001390|NCT03001570|DRUG|Cetuximab plus Radiotherapy|Standard dose of a curative radiotherapy treatment is 70Gy given with conventional fractionation (2G daily) in an overall length of 7 weeks. In this study, the fractionation has been modified accordingly Cetuximab pharmacokinetics. Cetuximab will be administered with standard schedule: charge dose of 400mg/mq a week before the beginning of concurrent treatment, then weekly doses of 250mg/mq intravenous for 7 administration. This schedule to obtain the same biological efficacy on tumour with lower toxicity on healthy tissues.
41313459|NCT02662985|DRUG|AIN457 (secukinumab)|"Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections."
41313460|NCT02662985|DRUG|Placebo|Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
41313461|NCT00657852|DRUG|Disodium pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
41001391|NCT02049242|PROCEDURE|triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
41313462|NCT00657852|DRUG|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
41313463|NCT02407041|DRUG|GR-MD-02|IV infusion
41471638|NCT05919745|DRUG|Acetaminophen|Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
41471639|NCT05255952|PROCEDURE|Electrical stimulation|Electrical stimulation of the cardiac plexus
41471640|NCT04910828|OTHER|Common foods of varying glycemic indices|Examples of foods of varying glycemic index to be tested include bread, rice, breakfast cereals, starchy vegetables, legumes, fruit and dairy products.
41471641|NCT00700817|DRUG|liraglutide|1.2 mg once daily, subcutaneous (under the skin) injection
41471642|NCT00700817|DRUG|sitagliptin|Tablets, 100 mg daily
41471643|NCT00700817|DRUG|metformin|Tablets, minimum 1500 mg daily
41001392|NCT02049242|PROCEDURE|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
41471644|NCT00700817|DRUG|liraglutide|1.8 mg once daily, subcutaneous (under the skin) injection
41471645|NCT04528888|DRUG|Enoxaparin|Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
41471646|NCT04528888|DRUG|Methylprednisolone|Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
41471647|NCT04528888|DRUG|unfractionated heparin|Patients in this group will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
41001393|NCT05720325|DRUG|Dupilumab|Dupixent is an interleukin-4 receptor alpha antagonist
41001394|NCT05720325|OTHER|House Dust Mites (HDM)|House Dust Mites used to challenge subjects using an aeroallergen challenge chamber
41313464|NCT00838916|BIOLOGICAL|albiglutide|albiglutide weekly injection
41313465|NCT00838916|DRUG|insulin glargine|insulin glargine
41313466|NCT02366754|DEVICE|rTMS|Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.
41471648|NCT05107128|DRUG|SAGE-718|Oral capsules.
40796751|NCT06377384|OTHER|FLIGHT Intervention|Personalized and multimodality intervention focusing upon modifiable lifestyle factors, environmental modifications, and transdisciplinary clinical care.
41313467|NCT02366754|DEVICE|Placebo rTMS|The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
41471649|NCT05107128|DRUG|Placebo|SAGE-718-matching oral capsules.
41471650|NCT04260321|DEVICE|AI|Artificial intelligence colonoscopy
41471651|NCT00050882|DRUG|GM-611|
41471652|NCT02371993|DIETARY_SUPPLEMENT|Choline|
41471653|NCT02371993|OTHER|Placebo|
41471654|NCT00637091|DRUG|Cetuximab, irinotecan|cetuximab, irinotecan
41471655|NCT06472180|PROCEDURE|Glass ceramic sectional veneer|partial laminate veneer
41313468|NCT00364494|PROCEDURE|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht\<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht\>25% bleed or not
40796752|NCT04816981|DEVICE|EBUS-Elastography|Patients undergoing LN staging for lung cancer with EBUS-TBNA will have digital images and biopsy of every LN obtained in accordance with standards of care. Prior to the lymph node biopsy by EBUS-TBNA, elastography will be performed. The relative strain of tissues in the scanned area of the LNs will be displayed as a colour map, with stiffer areas in blue and softer tissue in red. Elastography and B-mode images will be displayed side by side and images recorded and saved onto an external drive for analysis. Elastography images will be fed to the NeuralSeg algorithm which has a network architecture similar to the standard U-Net for image segmentation. The automatically identified regions of interest will be overlaid onto the EBUS Elastography images to extract the LN stiffness measurements. After overlaying, NeuralSeg will determine the proportion of the LN area within 9 previously defined stiffness thresholds.
41001395|NCT05720325|OTHER|Placebo|Inert placebo administered to placebo arms of study.
41001396|NCT00909948|OTHER|Fludarabine and total body irradiation|The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
41001397|NCT00909948|RADIATION|Total body irradiation|Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
41313469|NCT03440255|DEVICE|Transcutaneous Vagus Nerve Stimulation|"TaVNS will be applied by the TENS 7000 device. The stimulation was set according the group of treatment: (GAD: 20Hz-80µs), (CP: 5Hz-200 µs), (IBS: 3Hz-250µs).~The current intensity was individually established under the pain threshold .The stimulus generates an continous asymmetric biphasic waveform. Ear clip electrodes were plugged in the concha area of the left ear. The stimulation will last 30 min per session (total=8)"
41313470|NCT00733382|DRUG|dexamethazone|injection form, 8 miligram, injected once
41313471|NCT02503631|DEVICE|Stool Sample Collection Kit|Stool sample collection kit
41313472|NCT06552299|OTHER|Laypersons|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
41313473|NCT06552299|OTHER|Health-Care Providers|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
41313474|NCT01341379|DRUG|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
41313475|NCT06366828|OTHER|retrospective|follow up
41471656|NCT06472180|PROCEDURE|Glass ceramic laminate veneer|Glass ceramic laminate veneer
41471657|NCT04897191|OTHER|Age|Determination of age-dependence
41001398|NCT02330796|DRUG|Bucillamine|Bucillamine Tablets
41001399|NCT02330796|DRUG|Colchicine|
41001400|NCT03676842|COMBINATION_PRODUCT|FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB|Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB
41001401|NCT00245765|DRUG|Certolizumab Pegol|"* Pharmaceutical Form: solution for injection in pre-filled syringe~* Route of Administration: subcutaneous use"
41001402|NCT00245765|OTHER|Placebo|Matching Placebo to Certolizumab Pegol
41001403|NCT04185233|OTHER|Games on an iPad|Many games will be programmed on the iPad and organized by age. The child will choose one game and play it during all the procedure time.
41313476|NCT02602938|DRUG|Aspirin|Take aspirin (100mg) orally once a day for 2 months
41313477|NCT02987348|DRUG|exenatide once weekly|patients received exenatide once weekly treatment under their standard care, no intervention was given by the study investigator
41313478|NCT02987348|DRUG|exenatide twice daily|patients with exenatide twice daily treatment under their standard care, no intervention was given by the study investigator.
41313479|NCT02987348|DRUG|basal insulin|patients with basal insulin treatment under their standard care, no intervention was given by the study investigator
41313480|NCT02366663|RADIATION|90-Yttrium Ibritumomab tiuxetan|0.4 mCi/kg given IV
41471658|NCT06616259|DRUG|mCapOX plus Cetuximab|"mCapOX plus Cetuximab Induction therapy：Capecitabine 1000mg/m2 po, bid, D1-7 + Oxaliplatin ivgtt 85mg/m2, D1 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy."
41001404|NCT04185233|DRUG|Nitrous Oxide|Nitrous oxide will be provided to the child by a mask 3 minutes before the intervention and during all this one.
41001405|NCT04657497|DRUG|FOY-305|Specified Dosage and Duration of Treatment
41001406|NCT04657497|DRUG|Placebo|Specified Dosage and Duration of Treatment
41313481|NCT02366663|DRUG|Carmustine|Given IV
41001407|NCT03366064|BIOLOGICAL|Pemetrexed and donor-derived NK cell infusion|Patients are administered with donor-derived NK cells one week after pemetrexed infusion
41313482|NCT02366663|DRUG|Etoposide|Given IV
41313483|NCT02366663|DRUG|Cytarabine|Given IV
41313484|NCT02366663|DRUG|Melphalan|Given IV
41151019|NCT05478200|OTHER|Manual therapy|Group B will receive a treatment based on passive analgesic techniques consisting of manual therapy, electrotherapy (interferential currents) and thermotherapy (microwaves). This treatment will be carried out in two weekly sessions (over eight weeks) of 40 minutes each, consisting of 15 minutes of manual therapy (of the lumbopelvic musculature), 10 minutes of electrotherapy (interferential current in the lumbar region) and thermotherapy (10 minutes local in the lumbar region).
41313485|NCT02366663|PROCEDURE|Autologous Hematopoietic Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplantation (ASCT)
41313486|NCT02366663|BIOLOGICAL|Rituximab|Given IV
41313487|NCT04668001|DEVICE|Near-Infrared Transcranial Photobiomodulation|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
41313488|NCT04668001|DEVICE|Sham Transcranial Photobiomodulation|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
41313489|NCT00360919|BEHAVIORAL|cheese ingestion|"On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese.~Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals.~At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal."
41313490|NCT01518712|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
41471659|NCT06616259|DRUG|mFOLFOX6 plus Cetuximab|"mFOLFOX6 plus Cetuximab Induction therapy：Oxaliplatin ivgtt 85mg/m2, D1 + Leucovorin ivgtt 400mg/m2, D1 + Fluorouracil iv bolus 400mg/m2, D1 + Fluorouracil 2400mg/m2 continuous infusion for 46-48h + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy."
41471660|NCT01857206|BIOLOGICAL|Mammalian cell based flu vaccine|
41471661|NCT01857206|BIOLOGICAL|Egg based flu vaccine|
41471662|NCT00468871|DRUG|fluocinolone acetonide intravitreal implant|surgical intravitreal implant of fluocinolone acetonide
41471663|NCT00468871|DRUG|corticosteroids and immunosuppressants|Systemic corticosteroids alone or combined with immunosuppressants
40796753|NCT06089733|DRUG|Part A ABSK201 and Itraconazole|Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.
40796754|NCT06089733|DRUG|Part A ABSK201 and Rifampicin|Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
40796755|NCT02466425|DRUG|SHP465|12.5mg and 25mg capsules (one capsule daily)
40796756|NCT02466425|DRUG|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
40796757|NCT00440492|DRUG|PLA-695|
40796758|NCT06361004|DEVICE|Deep Brain Stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (GPi, amGPi, pvGPi, Cm-Spv-Voi, Cm-Voi, NA-ALIC, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
40796759|NCT01840813|DRUG|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
40796760|NCT01840813|DRUG|Normal saline|It is a placebo group
40796761|NCT03920501|BEHAVIORAL|Tele-Critical Care|Daily multidisciplinary rounds with a board certified physician through tele-critical care focusing on: 1) diagnosis; 2) active problems; and 3) therapeutic goals. In addition, the management of health care quality indicators will be conducted by a specially trained (Science of Improvement) board-certified intensive care physician.
41151020|NCT03727334|BEHAVIORAL|Online Spatial Navigation Training|Participants complete training tasks that test their spatial navigational abilities, cognitive map formation, and pattern separation. These training tasks involve map drawing, vector mapping, proximity judgments, and navigating with blocked routes.
41151021|NCT00313963|DRUG|Magnesium Sulfate|Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
41471664|NCT01644487|DEVICE|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
41471665|NCT01644487|DEVICE|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
41471666|NCT05002114|DRUG|Cannabidiol|Topical CBD cream - special formulation
41471667|NCT05002114|OTHER|Placebo|Not the drug
41471668|NCT03987555|OTHER|Blood draws|Blood draws for serum and peripheral blood mononuclear cell isolation collected throughout treatment course
41471669|NCT03987555|OTHER|QLQ-CIPN20 Survey|20-item self-reported survey for participant reported symptoms related to chemotherapy-induced peripheral neuropathy
41471670|NCT03987555|OTHER|PR-CTCAE Survey|124-item survey addressing chemotherapy-induced peripheral neuropathy concerning severity of the numbness and tingling and the degree these symptoms interfere with daily activities.
40796762|NCT05881486|DRUG|Ondansetron 8mg|8 mg Ondansetron+100 ml normal saline
41471671|NCT02503475|OTHER|Real-Time fMRI|"Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:~(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements."
41313491|NCT01518712|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
41471672|NCT02503475|BEHAVIORAL|CBT or MBSR|CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
41471673|NCT02503475|DEVICE|Acupuncture|Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
41471674|NCT02622659|DRUG|Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
40796763|NCT05881486|DRUG|Fosaprepitant 150 mg|150 mg fosaprepitant +100 ml normal saline
41001408|NCT03751215|PROCEDURE|Cataract surgery|During cataract surgery the patient is implanted with the monofocal IOL Clareon in one eye and the monofocal IOL AcrySof in the contralateral eye
41001409|NCT05723016|OTHER|preimplantation genetic test for aneuploidies (PGT-a)|preimplantation genetic test for embryo aneuploidies after IVF
41313492|NCT02899117|OTHER|Yoga|There are 4 yoga sessions completed with a certified instructor during cancer treatment
41471675|NCT02622659|DRUG|Xiaoer Jiebiao Oral Liquid|"1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day"
41471676|NCT00872326|PROCEDURE|Autologous Bone Marrow Mononuclear Cells|Infusion \> 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
41471677|NCT05952453|DRUG|Carboplatin|neoadjuvant treatment , followed by surgery, then maintenance chemotherapy
41151022|NCT00313963|DRUG|Normal Saline|Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
41471678|NCT05952453|DRUG|olaparibp, embro|maintenance chemotherapy : olaparib, pembro
41471679|NCT02095340|OTHER|Positive Interpretation Bias Training|
41471680|NCT02095340|OTHER|Neutral Interpretation Bias Training|
41471681|NCT05966311|DEVICE|Percutaneous Ultrasound Gastrostomy|Ultrasound guided placement of gastrostomy tube using the PUMA-G Pediatric System
41471682|NCT06386419|DRUG|inclisiran|Inclisiran sodium 300 mg SC. Three single doses of inclisiran sodium will be administered to the participants on Day 1, Day 90, and Day 270, respectively
40796764|NCT03759639|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
40796765|NCT01245686|BEHAVIORAL|Lifestyle and medication intervention|The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
41001410|NCT06072937|DEVICE|IntelliStent|Staged implantation of IntelliStent. The system comprises a nitinol self-expanding stent with a hollow element delivered over-the-wire into the main pulmonary artery or its left and right branches, using an 18 Fr transfemoral introducer sheath. The stent consists of two sections, one with a larger diameter and one with a smaller diameter, available in 6 sizes suitable for vessel sizes ranging from 20mm to 30 mm. Additional smaller sizes are currently under development.
41001411|NCT04854915|BEHAVIORAL|LOOP + mHealth technology assisted exercise counselling|Participants will complete a 3 month exercise and physical activity intervention supported by mHealth technology
40796766|NCT01013324|DRUG|XL147 (SAR245408)|dosed as capsules taken orally daily
41001412|NCT04854915|BEHAVIORAL|LOOP Only|Participants will complete the LOOP @ Alder Hey programme
41001413|NCT03662438|OTHER|Home-based physiotherapy program|The home-based physiotherapy program will consist of a total of 2 home visits by a physiotherapist which will be scheduled at the start and midpoint of the 10-week program. The visit will include activity education, goal setting and establishment of a home exercise regimen in patient's own home and community environment). Participants will be contacted weekly via telephone to provide encouragement for patient on the program, enquire about compliance to the exercise program and safety (e.g. falls and healthcare utilisation).
41151023|NCT05340283|PROCEDURE|physiotherapy|Patients received physiotherapy treatment at home for a certain period of time. Data were collected on the assessments made at the beginning and at the end of the physiotherapy treatment.
41151024|NCT02215447|DRUG|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
41151025|NCT02215447|DRUG|Carboplatin|
41313493|NCT05944991|OTHER|Olive oil message|Message of olive oil 2 times daily
40796767|NCT05576298|BIOLOGICAL|Insulin degludec injection, RD15003|single dose, s.c. injection
41313494|NCT02209311|PROCEDURE|Oral mucosa biopsy|
41001414|NCT03662438|DEVICE|Prescription of a Portable Oxygen Concentrator (POC) device|Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device \[Philips SimplyGo Mini\] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
41001415|NCT04307628|OTHER|Walnut|Study participants will eat 2 ounces of walnuts each day.
41001416|NCT04307628|OTHER|Nut-Free|Study participants will not eat nuts.
41151026|NCT06502678|BIOLOGICAL|Fcr blocker of autoantibodies|in vitro assays, combined with multi-omics approach and in vitro experimental models, will gain insights into the pathogenesis of Systemic Sclerosis (SSc)dissecting the consequences of treatment with Fcblocker on functional and phenotypic cell behavior. Healthy microvascular endothelial cells, fibroblasts and monocytes will be challenged with serum and autoantibodies prior to or upon treatment with Efgartigimod in order to assess both the prevention and the recovery capacity of the FcR blocker. The putative modulatory effect of Efgartigimod on vascular remodeling, endothelial-to-mesenchymal transition, fibroblast-to-myofibroblasts transition and monocyte behavior will be evaluated in in-vitro consolidated assays. Integrated Omics analyses will support and complement the in vitro findings by unveiling potential prognostic signatures and by identifying specific treatment-related profiles that might guide the modulation of the drug usage in order to maximize its beneficial effect
41151027|NCT05943535|DRUG|Placebo|Placebo administered QID
41151028|NCT05943535|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
41313495|NCT02209311|PROCEDURE|Sinus lift with implantation of tissue engineered construction|
41313496|NCT02209311|DEVICE|Dental implant|
41313497|NCT05833321|DIAGNOSTIC_TEST|Sarcopenia diagnostic test|"measurement of impedance and physical tests (hand grip dynamometer, walking test), SEFI nutritional intake questionnaire"
41313498|NCT01476384|DIETARY_SUPPLEMENT|Glucose|Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
41313499|NCT01476384|DIETARY_SUPPLEMENT|Placebo|250 ml water
41313500|NCT04799236|DRUG|Group 1: Miltefosine|Miltefosine 50 mg pill will be administered po every 8 hours with food, during 28 days
41313501|NCT04799236|DRUG|Group 2: Pentavalent Antimony|will be administered by IV infusion diluted in 150 ml of DWD5% over 20 minutes
41313502|NCT04799236|DRUG|Group 3: Liposomal amphotericin B|3 amps (150 mg) will be administered by IV infusion iver 2 hours every other day for a total of 15 doses.
41471683|NCT04030013|OTHER|group education|All patients of group 1 and 2 will receive intensive education for 3-4 months, then refreshment session every 3 months for 2 years. Initially, patient data will be collected through 3 types of forms: patient identification form, metabolic control parameters form and diabetes self-care scale questionnaire; then every 6 months metabolic parameters and diabetes self-care scale questionnaire will be reassessed.
41471684|NCT03115606|DEVICE|C-Mac D Blade|Videolaryngoscope
41313503|NCT04538092|OTHER|Enhanced Recovery After Surgery Protocol|The investigators have developed an Enhanced Recovery After Surgery protocol for complex spine surgery at UNC. This study will help elucidate the effects of multiple interventions tailored to help patients recover from complex surgery.
40796768|NCT05576298|BIOLOGICAL|Insulin degludec, Tresiba|single dose, s.c. injection
40796769|NCT00243945|DRUG|Rotigotine|
40796770|NCT02786212|DRUG|Dexmedetomidine|
41001417|NCT04296981|OTHER|video-based patient information|explanatory video (8 minutes) concerning communication, stroke issues and stages of the continuum of care
41313504|NCT04686019|OTHER|Inspiratory muscle training (IMT)|"IMT and conventional neurorehabilitation - treatment as usual. The intervention group will add-on IMT sessions exercising at 30 % of MIP. MIP is measured by instructing the patient to perform five forceful inspirations against an occluded mouthpiece (Power Breath). The best score is multiplied by 0.3 to determine the resistance. IMT is performed with IMT Threshold flute with the calculated resistance. During the measurement with Power Breath the patient sits straight up and uses nose clip. The patient can receive help to hold the Power Breath if necessary.~One session of IMT with IMT threshold flute consists of 2 times 15 inspirations in normal breathing rhythm (5-10 min). Patients in the intervention group perform 2 sessions a day (morning and evening), training is performed prior to a meal, 7 days a week for 3 weeks."
41313505|NCT01642524|BIOLOGICAL|hypertonic saline mixed Dextran|single dose administered intravenously
41001418|NCT02409836|DRUG|Marketed Dentifrice|Marketed Dentifrice
41001419|NCT02409836|DRUG|Marketed Flavored Dentifrice|Hawaiian Punch Flavored
41313506|NCT01642524|BIOLOGICAL|Saline solution|placebo - saline solution
41313507|NCT03916471|DEVICE|Solyx™ SIS System|Single-incision sling system
41313508|NCT03916471|DEVICE|Obtryx™ II System (Halo)|Transobturator Mid-urethral Sling System
41313509|NCT05511831|DRUG|Ketotifen Fumarate|Ketotifen treatment for 3 months, 1 mg each time, 1-2 times a day according to the patient's tolerance
41001420|NCT02409836|DRUG|Marketed Flavored Dentifrice|Bubble Gum Flavored
41001421|NCT02876965|PROCEDURE|Muscle Stretching|Subjects completed one stretching session on the main muscle groups of the body weekly.
41001422|NCT02876965|PROCEDURE|Physical Exercise|Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.
41001423|NCT01398111|DRUG|Glycopyrrolate + Formoterol|glycopyrrolate pMDI + formoterol pMDI
41001424|NCT01398111|DRUG|Glycopyrrolate|glycopyrrolate pMDI
41001425|NCT01398111|DRUG|Formoterol|formoterol pMDI
41151029|NCT05943535|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
41471685|NCT03115606|DEVICE|Fastrach LMA|Laryngeal mask airway
41471686|NCT01672047|DRUG|Vitamin D2|25（OH）D level \<12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， \>116.75nmol/L stopped.
40796771|NCT02786212|DRUG|Normal Saline|
41001426|NCT01398111|DRUG|Placebo|placebo pMDI
41151030|NCT01304953|DRUG|Group P+P|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
40796772|NCT04444739|OTHER|radiographic data collection|From existing radiological Images (upright standing X-ray and supine MRI of the lumbar spine), specific radiographic parameters will be extracted
40796773|NCT04648917|DRUG|Caffeic acid|40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)
40796774|NCT04404790|DRUG|Anfibatide 5 IU/60kg|5 IU/60kg IV administration of Anfibatide with 5 minutes
40796775|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.002 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
40796776|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.004 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
40796777|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.008 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
40796778|NCT04404790|DRUG|Anfibatide 7 IU/60kg|7 IU/60kg IV administration of Anfibatide with 5 minutes
40796779|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.002 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
40796780|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.004 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
40796781|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.008 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
40796782|NCT06396702|OTHER|EASE-SOT|EASE integrates supportive counseling and trauma-focused cognitive behavioral therapy (CBT) (EASE-psy) with systematic physical symptom screening and triggered referral to supportive care to manage moderate to severe physical symptoms (EASE-phys) using electronic patient reported outcome measures (ePROMs). The intervention duration is 8 weeks. Based on individual preference, EASE-psy may be administered in person or virtually via Microsoft Teams. Based on individual preference, participants may receive ePROMs either on tablets or to their personal electronic devices via email, while at the hospital ward and in clinics, ensuring easy access and administration of these tools.
40796783|NCT05231759|DEVICE|L'DISQ|
40796784|NCT05451589|BEHAVIORAL|RESET|RESET consists of 7 weekly group phone sessions led by Community Health Workers, along with an accompanying podcast series.Topics will include positive psychology, physical activity, social connection, eating well, relaxation, and more. There will be one individual session with the Community Health Worker to screen for unmet social needs and to offer connections to resources as needed. In the group sessions, participants will set goals incorporating positive activities and strategies to improve daily functioning. Up-to-date information related to COVID-19 prevention and treatment will be provided.
40796785|NCT05451589|BEHAVIORAL|Wellness Check Control|"After completing the baseline survey, control group participants will be mailed an educational packet consisting of information about COVID-19 prevention and treatment, as well as essential community resources. Control group participants will also be invited to take part in a wellness check telephone session with a Community Health Worker, about a half-hour long, at which a social needs screener will be administered, and any needed referrals will be made. After completing the 8-month follow up, they will have the opportunity to participate in the full intervention."
40796786|NCT03644225|DEVICE|Measurment with Aspirational Medical Device|The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.
40796787|NCT03644225|DEVICE|Measurment with Cutometer MPA 580|The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
40796788|NCT01331746|DRUG|APD515|20 mg oromucosal-oral administration qds for 7 days
40796789|NCT01331746|DRUG|Placebo|qds for 7 days
40796790|NCT02521038|DRUG|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
40796791|NCT01405703|OTHER|xrays|xrays from 2 week postop to 5 year postop
40796792|NCT05092386|BIOLOGICAL|Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine|The investigational vaccine was manufactured by Sinovac Research \& Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.
41313510|NCT05511831|DRUG|standard treatment|Standard treatment methods will be determined according to the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2019) \[19\], including primary PCI, dual antiplatelet, anticoagulation, ACEI/ARB/ARNI, β-receptor blockade drugs, statins, etc.
41313511|NCT05425485|BEHAVIORAL|Multi-component intervention|Web-based strategy with processes, materials, and patient and doctor education formats.
41313512|NCT00213928|DRUG|Horse Chestnut Seed Extract|Control (no intervention) vs Horse Chestnut Seed Extract
41313513|NCT03424889|DRUG|Xylometazoline|Nasal administration of Xylometazoline
41313514|NCT03424889|DRUG|Saline|Nasal administration of 0.9% Saline
41471687|NCT01767610|DRUG|micronized fenofibrate 160mg|
40796793|NCT05092386|BIOLOGICAL|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)|The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.
40796794|NCT05092386|BIOLOGICAL|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)|The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.
40796795|NCT04119752|DIETARY_SUPPLEMENT|Curcumin powder|10g of curcumin powder
40796796|NCT04119752|DIETARY_SUPPLEMENT|Placebo|1g of sucralose
40796797|NCT01564823|DRUG|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
40796798|NCT01564823|DRUG|Metronidazole|Metronidazole 250 mg/8h 3 months
40796799|NCT01564823|DRUG|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
40796800|NCT01564823|DRUG|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
41471688|NCT01767610|DRUG|pitavastatin Ca 2mg|
41313515|NCT04254783|DRUG|Risankizumab|Intravenous (IV) infusion
40796801|NCT01027559|DRUG|Sertraline|Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.
41151031|NCT01304953|DRUG|Group P+T|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
41151032|NCT01304953|DRUG|Group S+P|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
41313516|NCT04254783|DRUG|Cytochrome P450 (CYP) Substrates|Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol
41313517|NCT03270150|DEVICE|BTL-899|BTL-899
41313518|NCT05678075|BEHAVIORAL|Whole-food plant-based nutrition education|Participants will receive an educational intervention regarding the benefits of a whole food plant-based diet and how to incorporate more plant-based foods into their diets. The intervention will last 6 weeks.
41313519|NCT02462941|DRUG|Adenosine|Testing escalating doses of adenosine in pediatric heart transplant patients
41313520|NCT02462941|PROCEDURE|Cardiac catheterization|(non-experimental) standard procedure
41313521|NCT04182698|DRUG|Simultaneous chemoradiotherapy for An Luo|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
41313522|NCT04751903|BEHAVIORAL|oral motor stimulation|Oral motor stimulation (OMS) is defined as the sensorial stimulation of cheek, lip, jaw, upper-lower gum, internal cheek, tongue and soft palate that affects the physiology of oropharyngeal mechanisms and develops feeding functions.It took 15 minutes to apply the OMS by lightly touching their cheeks, lips, gums, and tongue with fingertips for the first 12 minutes, followed by letting the infant suck on a pacifier for the remaining 3 minutes. OMS used as an alternative or supplementary early intervention strategy to develop oral feeding skills in preterm infants.
41313523|NCT04914832|BIOLOGICAL|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus vaccine expressing the SARS-CoV-2 S surface glycoprotein.
41313524|NCT01594138|OTHER|Standardized questionnaires and a ubiquitous questionnaire|Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
41313525|NCT00127530|DRUG|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
41151033|NCT01304953|DRUG|Group S+T|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
41471689|NCT01767610|DRUG|micronized fenofibrate 160mg plus pitavastatin Ca 2mg|
41151034|NCT05324527|OTHER|Hand Massage|Hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
41151035|NCT06379321|DEVICE|Triathlon Hinge Knee (THK) System|Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use
41151036|NCT03379311|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
41151037|NCT03586739|PROCEDURE|endovascular angioplasty using covered stents|Primary endovascular angioplasty using one or several covered stents
41151038|NCT03586739|PROCEDURE|endovascular angioplasty using bare metal stents|Primary endovascular angioplasty using one or several bare metal stents
41151039|NCT03586739|DEVICE|Duplex-scan|a Duplex-scan will be performed during patient follow up.
41151040|NCT03586739|DEVICE|computerized tomography scan (CT-scan)|"a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up."
41151041|NCT03586739|DEVICE|digital angiography|In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
41313526|NCT00127530|DRUG|Placebo|sugar pill, twice a day (b.i.d.)
41313527|NCT00347763|PROCEDURE|10% permethrin in water applied as low volume spray|
41313528|NCT00642655|DRUG|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
41313529|NCT00135837|DRUG|Verteporfin for injection|
41313530|NCT02225444|OTHER|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
41313531|NCT00815906|DRUG|SBI-087|IV, Single dose
41313532|NCT00815906|DRUG|SBI-087|IV, Single dose
41313533|NCT00815906|DRUG|SBI-087|SC, Single dose
41313534|NCT00815906|DRUG|SBI-087|SC, Single dose
41471690|NCT02244294|DRUG|FLOMAX® capsules|
41471691|NCT02244294|DRUG|Placebo capsules|
41471692|NCT06358950|DRUG|ALKS 2680|Oral tablet of ALKS 2680 for once daily administration
41471693|NCT06358950|DRUG|Placebo|Oral tablet containing matching placebo for once daily administration
40796802|NCT01027559|BEHAVIORAL|Cognitive Behavioral Therapy|Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
40796803|NCT05808582|DRUG|chidamide，fulvestrant|chidamide combined with fulvestrant
41151042|NCT03586739|OTHER|Short Form-36 (SF-36) questionnaire|The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
41151043|NCT06286956|DEVICE|Treatment of rectal lesions with UNI-VEC|Polyp resections
41151044|NCT05466968|DRUG|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
41151045|NCT05466968|DRUG|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
41313535|NCT02559713|DRUG|Vedolizumab|Vedolizumab IV infusion
41313536|NCT05267912|PROCEDURE|Biopsy|We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.
41151046|NCT03522688|DRUG|Dexmedetomidine|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.
41151047|NCT03522688|DRUG|Normal saline|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
41151048|NCT00330135|DRUG|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
41151049|NCT00330135|DRUG|placebo injection|placebo injection - 1 injection
41151050|NCT04915456|DRUG|Systemic Steroid (Prednisolone)|Systemic steroids (Prednisolone) additive to topical steroids (Mometasone fuorate) in a postoperative setting after FESS
41151051|NCT04915456|OTHER|Placebo|Placebo additive to topical steroids in a postoperative setting after FESS
41151052|NCT05430347|COMBINATION_PRODUCT|Neoadjuvant therapy: TCbHPy|Pyrotinib combined with docetaxel, carboplatin and trastuzumab (TCbHPy) for neoadjuvant therapy of HR+/HER2+ breast cancer
41151053|NCT05430347|COMBINATION_PRODUCT|Neoadjuvant therapy: TCbHP|Pertuzumab combined with docetaxel, carboplatin and trastuzumab (TCbHP) for neoadjuvant therapy of HR+/HER2+ breast cancer
41151054|NCT00847847|PROCEDURE|Anconeus Muscle biopsy|Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
41151055|NCT02137928|DRUG|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
41151056|NCT02137928|DRUG|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
41151057|NCT04869384|OTHER|Reminders and feedback to improve adherence|Subjects will receive reminders and feedback to improve their adherence.
41151058|NCT04869384|OTHER|No reminders and feedback to improve adherence|Subjects will not receive reminders and feedback to improve their adherence.
41151059|NCT02375932|BEHAVIORAL|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
41151060|NCT02375932|BEHAVIORAL|Usual Care Control|Patients continue to receive usual care from their primary care provider
41151061|NCT03154827|DRUG|BL-8040|Subjects will receive maintenance treatment consisting of subcutaneous (SC) injections of BL-8040 on Days 1, 2 and 3 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
41151062|NCT03154827|DRUG|Atezolizumab|Subjects will receive maintenance treatment consisting of intravenous (IV) infusion of Atezolizumab on Day 2 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
41151063|NCT00639639|BIOLOGICAL|tetanus toxoid|Given by injection
41151064|NCT00639639|BIOLOGICAL|therapeutic autologous dendritic cells|Given intradermally
41151065|NCT00639639|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
41151066|NCT02286297|DEVICE|McGRATH® MAC|video-laryngoscopy-1
41151067|NCT02286297|DEVICE|AirTraq|video-laryngoscopy-2
41151068|NCT02286297|DEVICE|GlideScope|video-laryngoscopy-3
41151069|NCT02286297|DEVICE|Miller|Direct laryngoscopy
41151070|NCT01343147|OTHER|Microwave diathermy|Deep tissue heating via microwave diathermy
41151071|NCT01343147|OTHER|Superficial hyperthermia|Superficial heating via hot pack application
41151072|NCT06585475|BEHAVIORAL|Structured training according to premenstrual syndrome symptom map|A symptom map consisting of evidence-based practices for coping with PMS symptoms was created. An educational content based on this map was prepared and applied to women with PMS to evaluate whether it was effective compared to the control group.
41151073|NCT03054194|DRUG|E2730|capsules
41151074|NCT03054194|DRUG|Placebo|capsules
41471694|NCT06617065|DRUG|Addition of 1 mL of 50% dextrose solution to the usual local anesthetic solution of choice for each patient.|"The principal investigator will use a palpation-guided approach to select the injection sites. Injection solutions will be prepared by the assisting nurse. For each patient, 1 mL of a 50% dextrose solution (Pfizer Canada ULS, Kirkland, Québec) will be added to the usual local anesthetic solution of choice.~Solutions contain either 0.3% Ropivacaine, 1% Procaine, 0.5% Lidocaine, 0.25% Bupivacaine, or a mixture of 0.25% Bupivacaine and 2% Lidocaine in a 9:1 ratio."
41471695|NCT00021216|DRUG|bortezomib|Given IV
41471696|NCT00021216|OTHER|laboratory biomarker analysis|Correlative studies
41471697|NCT00021216|OTHER|pharmacological study|Correlative studies
41471698|NCT04825002|DIAGNOSTIC_TEST|Urinary multimarker sensor|We will develop a urinary multimarker sensor, able to measure trace amounts of biomarkers from naturally voided urine.
41471699|NCT02165514|PROCEDURE|Lunar iDXA x-ray scan|Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
41471700|NCT02775578|PROCEDURE|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
41471701|NCT02775578|PROCEDURE|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
41471702|NCT02775578|PROCEDURE|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
41471703|NCT01020526|DRUG|pregabalin|Oral capsule 75-450 mg/day
41471704|NCT05693571|BEHAVIORAL|Valera Smart Phone Application and Care Manager Dashboard|Valera mobile health application will provide educational materials around mental health and Systemic Lupus Erythematosus (SLE) and the ability to connect to a SLE care team via a care manager.
41471705|NCT03100890|OTHER|Preoperative training (hospital)|Preoperative hospital training
41471706|NCT03100890|OTHER|Preoperative training (home)|Preoperative in-home training
41471707|NCT06130787|BIOLOGICAL|Blood and bone marrow sample|"Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12.~An optional bone marrow sample will be taken during the myelogram performed at diagnosis.~Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36"
41471708|NCT00025129|DRUG|laromustine|
40796804|NCT01144416|BIOLOGICAL|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
40796805|NCT01144416|BIOLOGICAL|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
41313537|NCT00217867|BEHAVIORAL|Animated character intervention with telephone follow-up|Animated character will teach the discharge plan before discharge, then this teaching will be reinforced by computerized telephone system.
40796806|NCT01144416|DRUG|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
40796807|NCT01144416|DRUG|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
40796808|NCT01906411|DIETARY_SUPPLEMENT|Dopamine depletion vs. Balanced aminoacid drink|
41151075|NCT02800135|DRUG|Furosemide|1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
41313538|NCT03520816|OTHER|Burn Physiotherapy Protocol|It consisted of parameters such as early mobilisation and ambulatory training, chest physiotherapy, and both active and passive normal joint movement exercises.
41313539|NCT00706667|DRUG|Ferinject ®|iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
41313540|NCT03230344|PROCEDURE|open flap debridement|open flap debridement simultaneously with root canal treatment
41313541|NCT03230344|PROCEDURE|open flap debridement|open flap debridement and delayed root canal treatment
41471709|NCT00267163|DRUG|donepezil|
41313542|NCT03529383|DEVICE|Connected device|Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.
41471710|NCT00267163|DRUG|Placebo|
41471711|NCT02729779|OTHER|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
41471712|NCT02729779|OTHER|Aerobic Group|Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
41471713|NCT05978739|DRUG|Orelabrutinib High dose|Orelabrutinib will be administered as 3 tablets once per day
40796809|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using bupivacaine|while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of 0.25% bupivacaine with adrenaline 1:400,000 will be administered in increments bilaterally.
40796810|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using normal saline|Sham Block will be done while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of normal saline 0.9 % will be administered bilaterally.
40796811|NCT00428181|BEHAVIORAL|Brief alcohol intervention|Brief alcohol intervention
40796812|NCT00428181|BEHAVIORAL|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
41313543|NCT03529383|BEHAVIORAL|Therapeutic education|"Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~* a 1-hour individual session of educational diagnosis to assess their needs and establish a contract of objectives,~* two educational sessions of 1h30 each using tools, in group of 10 patients maximum to improve their daily practice of physical activity,~* a 1-hour individual session of educational assessment to evaluate whether their objectives were reached."
41313544|NCT00575094|DRUG|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
40796813|NCT03666520|OTHER|Clinical Decision Support prompted to the clinician to convert drug.|This study is designed to further research the conversion of Intravenous medications to oral medications in patients in an inpatient setting whenever it is appropriate and safe. We have chosen eight medications to research in this study. These medications were chosen because large difference in cost between an intravenous (IV) dose of this medication versus an oral (PO) dose of this medication exist. This study aims to further evaluate the appropriateness and safety of converting IV medications to PO medications for hospitalized patients through a pilot clinical trial.
40796814|NCT05594485|DEVICE|Carebot AI CXR|Carebot AI CXR is a deep learning-based software that assists radiologists in the interpretation of chest radiographs in posterior-anterior (PA) or anterior-posterior (AP) projections. The solution with artificial intelligence automatically detects abnormality based on visual patterns for the following findings: atelectasis, consolidation, cardiomegaly, mediastinal widening, pneumoperitoneum, pneumothorax, pulmonary edema, pulmonary lesion, bone fracture, hilar enlargement, subcutaneous emphysema, and pleural effusion.
40796815|NCT00437268|DRUG|enzastaurin|1125 milligrams (mg) loading dose, then 500 mg orally, daily, of each 21-day cycle until progressive disease
40796816|NCT00437268|DRUG|irinotecan|300 milligrams per square meter (mg/m\^2) intravenously on Day 1 of each 21-day cycle until progressive disease
40796817|NCT00437268|DRUG|cetuximab|400 mg/m\^2, intravenously on Day 1, 250 mg/m\^2 on Day 8, Day 15 Cycle 1 then 250 mg/m\^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
40796818|NCT05744856|BEHAVIORAL|Self-care with informal support|"The detailed content of the self-care with informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
40796819|NCT02063984|BEHAVIORAL|Intensive Outpatient Treatment (IOP) + Contingency Management (CM)|Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
40796820|NCT02063984|BEHAVIORAL|Working Memory Training|25 computer-delivered sessions of neurocognitive training
40796821|NCT06550206|BEHAVIORAL|Children's stranger wariness response to strangers|Children will see two strangers, one from a familiar racial background and one from an unfamiliar racial background. Familiar race stranger will be from the same racial background as the child's caregiver and unfamiliar race stranger will not.
40796822|NCT02231528|DEVICE|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
40796823|NCT02231528|DEVICE|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
41471714|NCT05978739|DRUG|Orelabrutinib Low dose|Orelabrutinib will be administered as 1 tablet once per day
41471715|NCT04776746|DRUG|trofinetide|Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).
41471716|NCT01010815|PROCEDURE|Colonoscopy biopsy|Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
41471717|NCT01010815|OTHER|stool collection|Stool will be collected from participants at study entry
41471718|NCT01010815|PROCEDURE|colonoscopy biopsy|colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
41471719|NCT01010815|OTHER|stool collection|stool will be collected from participants 2 times during study - at active phase and inactive phase
41313545|NCT05545579|OTHER|circuit trainng|Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes. The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
41471720|NCT04923126|DRUG|Mirdametinib|By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28
41471721|NCT06216171|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy
41471722|NCT06216171|RADIATION|image guided radiotherapy without online adaptation|image guided radiotherapy without online adaptation
41471723|NCT05636995|DIAGNOSTIC_TEST|Aldosterone/Renin Ratio|Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.
41471724|NCT05794087|OTHER|Clean Air|Subjects will be exposed to clean air for 3 hours.
41471725|NCT05794087|OTHER|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
41471726|NCT05447806|DEVICE|Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support|This prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing.
41471727|NCT01552369|DRUG|Valganciclovir|Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
41471728|NCT04126954|OTHER|Serum PTH concentrations results|To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
41471729|NCT00108979|DRUG|Escitalopram|
41471730|NCT01593072|DRUG|AVI-7537|"Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV~The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
41471731|NCT01593072|OTHER|Normal Saline Solution (NSS)|Normal Saline Solution (NSS)
41471732|NCT05999279|BEHAVIORAL|Survey|Developed questionnaire to assess the literacy of patients + another survey to assess their preferences regarding traditional versus digital pharmaceutical care
41471733|NCT03614494|DRUG|Piroxicam 40 mg|Additional co-treatment
41471734|NCT03614494|DRUG|Levonorgestrel 1.5mg|Standard treatment
41471735|NCT03875690|DRUG|Injection of methylprednisolone|Patients will receive 20mg/kg IV of methylprednisolone at the time of anaesthetic induction. Methylprednisolone will be infused in a ready-to-use 50 mL bag of sodium chloride 0.9% during 30 minutes at anaesthesic induction.
41471736|NCT03875690|DRUG|Injection of sodium chloride|patients in the placebo group will receive 50 mL of sodium chloride 0.9% in a ready-to-use bag during 30 minutes at anaesthesic induction.
41471737|NCT03875690|BIOLOGICAL|Blood samples|electrolyte panel and glycemia performed within the first 24 hours after surgery.
41471738|NCT06258161|PROCEDURE|Spinal Fusion|Realignment and fusion of adult spinal deformity
41471739|NCT06258161|OTHER|No intervention|No intervention for control group.
41151076|NCT05028322|DRUG|IMIQUIMOD cream|Cream to apply before intra-dermal vaccine injection
41151077|NCT05028322|BIOLOGICAL|HEPATITIS B SURFACE ANTIGEN|HBV Vaccine
41151078|NCT00266136|DRUG|Cytarabine|see protocol
41151079|NCT00266136|DRUG|Thioguanine|see protocol
41151080|NCT00266136|DRUG|Daunorubicin|see protocol
41151081|NCT00266136|DRUG|Cyclophosphamide|see protocol
41151082|NCT00266136|DRUG|G-CSF|see protocol
41151083|NCT00266136|PROCEDURE|Autologous stem cell transplantation|for details see protocol
41313546|NCT05545579|OTHER|trunk stabilization techniques|The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
41313547|NCT04649073|BIOLOGICAL|OPC-415|OPC-415 (up to 1×10\^7cells/kg) On 2 days
41313548|NCT01674244|BEHAVIORAL|Integrative Exercise|
41313549|NCT01674244|BEHAVIORAL|Monitor Only Waitlist|
41313550|NCT03718052|PROCEDURE|Early valve surgery (EVS)|Early valve surgery (EVS) within 72 hours of randomization
41313551|NCT03718052|PROCEDURE|Conventional Care|Conventional care according to the 2015 European guidelines.
41471740|NCT06184594|OTHER|eNav|The eNav toolkit is a digital navigation toolkit that includes a website and text messaging support. The website includes information, motivational support, decisional support and cues to action (e.g., ability to request a CRC screening test). The eNav tool also includes text-messaging based navigation (e.g., reminders, instructions to complete the screening test).
41471741|NCT06184594|OTHER|Standard of Care|Standard of care procedures for selecting their CRC screening test.
41471742|NCT05178108|OTHER|Real-time MRI of swallowing|"The examination recording a total of 9 sequences of less than 30 seconds will be performed, in transverse section (passing through the epiglottis), frontal section, in the plane of the posterior pharyngeal wall, and in median sagittal section.~Each bolus of 20 ml will be administered in full, in one go, using a syringe. It is kept in the mouth for a few seconds and swallowed on demand.~The semi-liquid bolus of 20 ml comes from the mixture of 198 ml of pineapple juice to 10 gr of Nutilis Powder (NUTRICIA), food thickener containing neither gluten, nor lactose.~Ingredients: Dextrin-maltose, thickeners (modified starch (corn), tara gum, xanthan gum, guar gum).~* 3 sequences with no food~* 3 sequences with ingestion of a liquid bolus of 20 ml (pineapple juice) mouth closed~* 3 sequences with ingestion of a semi-liquid bolus of 20 ml (pineapple juice + Nutilis Powder) mouth closed"
41471743|NCT06109857|OTHER|Non-Interventional Study|Non-interventional study
41471744|NCT04167384|OTHER|Product A|Usual brand (UB) filtered, combustible cigarette
41471745|NCT04167384|OTHER|Product B|Nicorette® Mint 4 mg nicotine lozenge
41471746|NCT04167384|OTHER|Product C|CSD1903-11, a hard nicotine lozenge, 2 mg nicotine
41471747|NCT04167384|OTHER|Product D|CSD1903-11, a hard nicotine lozenge, 4 mg nicotine
41471748|NCT04167384|OTHER|Product E|CSD1903-11, a hard nicotine lozenge, 8 mg nicotine
41471749|NCT04167384|OTHER|Product F|CSD1903-12, a soft nicotine lozenge, 2 mg nicotine
41471750|NCT04167384|OTHER|Product G|CSD1903-12, a soft nicotine lozenge, 4 mg nicotine
41471751|NCT04167384|OTHER|Product H|CSD1903-12, a soft nicotine lozenge, 8 mg nicotine
41471752|NCT05375890|OTHER|no intervention|Narcolepsy patients in Russia gathered according to criteria.
41471753|NCT00392782|BIOLOGICAL|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
41471754|NCT00392782|DRUG|fludarabine phosphate|Fludarabine 40 mg/m\^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m\^2).
41471755|NCT00392782|DRUG|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
40796824|NCT04777006|BEHAVIORAL|Problem Management Plus|"PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term problem management rather than problem solving to emphasize that many problems encountered by individuals living in adverse circumstances may not be solvable. The plus in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4"
41313552|NCT06390631|DEVICE|Continuous Positive Airway Pressure|Patients with COPD were recruited to breath under the atmosphere pressure and different levels of CPAP (4, 6, 8 and 10 cm H2O).
41313553|NCT02612961|OTHER|3mL of normal saline from the pink sodium chloride bullet|
41313554|NCT02612961|OTHER|Sham Comparator of 3mL normal saline|
41001427|NCT00322010|PROCEDURE|early PT OT|"1. Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).~2. Sessions began with active assisted and active range of motion exercises in the supine position.~3. If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.~4. Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. The session progresses to transfer training, and finally pre-gait exercises and ambulation.~6. Progression of activities is dependent on patient tolerance and stability.~7. Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged."
41001428|NCT05423067|PROCEDURE|bilateral permanent occlusion of uterine arteries|bilateral permanent Occlusion of uterine arteries through abdominal route
41151084|NCT00266136|PROCEDURE|Allogeneic stem cell transplantation|for details see protocol
41471756|NCT00392782|PROCEDURE|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
41471757|NCT00392782|RADIATION|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
41001429|NCT02886052|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|
41001430|NCT02886052|OTHER|Active control|
41471758|NCT06596642|DRUG|Luspatercept|As per product label
41471759|NCT00801294|DRUG|BIBF 1120 and BIBW 2992|
41471760|NCT06616376|OTHER|Anti-Embolism Stocking|To prevent patients undergoing TKA surgery from being affected by one another, the patients were hospitalized in separate rooms, and the orthopedic clinic team was made aware of the situation. The patients in the control group were told not to remove their socks until the sutures were removed after the operation, whereas the patients in the experimental group were told to remove their socks on the 10th day after the operation, so the patients had no idea which group they were in.
41313555|NCT05896618|DEVICE|TPA|1. Group I (TPA group).In which patients will receive Transpalatal arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
41471761|NCT04916613|DRUG|Darolutamide 300 mg|600 mg po, b.i.d.
41471762|NCT04916613|DRUG|Placebo|po, b.i.d.
41471763|NCT04916613|DRUG|Androgen deprivation therapy|Use according to local standard of care
41471764|NCT05664217|DRUG|NKTR-255 at 1.5 µg/kg|NKTR-255 at 1.5 µg/kg
41471765|NCT05664217|DRUG|NKTR-255 at 3.0 μg/kg|NKTR-255 at 3.0 μg/kg
41471766|NCT05664217|DRUG|NKTR-255 at 3.0/6.0 μg/kg|NKTR-255 at 3.0/6.0 μg/kg
41471767|NCT05664217|OTHER|Placebo Comparator|Commercially available 0.9% Sodium Chloride Solution for Injection (USP)
41313556|NCT05896618|DEVICE|Nance appliance|2. Group II (Nance group).In which patients will receive Nance holding arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
41313557|NCT03896789|OTHER|PEGASUS Program for Care|This is in essence a checklist of pediatric guidelines to follow for participants who meet inclusion criteria. Site staff will receive training in how to implement this pathway into their usual care.
41313558|NCT04903119|DRUG|Nilotinib 100mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 100mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
41313559|NCT04903119|DRUG|Nilotinib 200mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 200mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
41313560|NCT04903119|DRUG|Nilotinib 300mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 300mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
41471768|NCT00521482|DRUG|Temozolomide|
41471769|NCT00521482|DRUG|Temozolomide plus Thalidomide|
41471770|NCT02340689|OTHER|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
41471771|NCT00256529|PROCEDURE|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
41151085|NCT05243498|OTHER|Assessment of the Allogenomic Mismatch Score (AMS)|Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient. Roughly, the exome of the donor is aligned to the exome of the recipient, allowing to count the number of variations that will generate a peptide present in the recipient but absent in the donor.
41313561|NCT04903119|DRUG|Nilotinib 400mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 400mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
41313562|NCT04903119|DRUG|Dabrafenib|All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.
41313563|NCT04903119|DRUG|Trametinib|All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.
41471772|NCT03991442|DRUG|Fimasartan/Amlodipine|Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
41471773|NCT02419924|DEVICE|"the Bottom's Up"|A modified toilet seat that supports the perineum, preventing excessive pelvic floor descent and laxity which can cause constipation.
41151086|NCT05243498|OTHER|Assessment of the optimised Allogenomic Mismatch Score (AMS)|Optimised Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient, encountering only peptides that can be presented by the donors' MHC (using another layer of algorithm, NetMHCpan).
41151087|NCT04827602|OTHER|Drug allergy label status in electronic health records|Registered drug allergy labels in primary care and hospital electronic medical charts
41151088|NCT02606617|DRUG|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
41471774|NCT02262858|DRUG|Telmisartan and HCTZ|
41471775|NCT02262858|DRUG|Telmisartan|
41471776|NCT02262858|DRUG|HCTZ|
41471777|NCT03146273|DIETARY_SUPPLEMENT|Multivitamins|"After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins."
41471778|NCT00607295|DRUG|clino-san vaginal lubricant|Clino-san 2ml vaginal application 3 times per week for 12 weeks
41471779|NCT00968500|BEHAVIORAL|Questionnaires/Interviews|"Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer."
41471780|NCT03187028|BEHAVIORAL|Diet Only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
41471781|NCT03187028|BEHAVIORAL|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling.
41471782|NCT03027011|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
41471783|NCT03027011|PROCEDURE|Control|Control group without remote ischemic preconditioning
41313564|NCT04873024|DEVICE|cMAP Flow V 2.0|"Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment."
41313565|NCT04370717|OTHER|telehealth consultation|"A telehealth consultation will be scheduled and conducted without modifications from the routine clinic protocol. The case report will include ICD-10 code and plan of care.~After one week, patients will receive an electronic satisfaction survey. An in-person follow-up and/or procedural visit will be subsequently scheduled. During this visit, the same physician will complete physical examination, document the diagnosis and proceed with either the same or modified plan of care. The research coordinator will enter diagnostic and procedural codes in the case report form."
41313566|NCT02293018|DRUG|0.75% (w/w) MTC896 Gel Once Daily|
41313567|NCT02293018|DRUG|0.75% (w/w) MTC896 Gel Twice Daily|
41313568|NCT02293018|DRUG|1.5% (w/w) MTC896 Gel Once Daily|
41313569|NCT04104906|OTHER|motor control training|The volunteers of the motor control group will initiate the exercises on a stable and rigid basis. These will be progressed with adding an unstable base as the volunteer gains motor learning (between the fourth and fifth week of the protocol). For the motor control group, two sets of 10 repetitions will be performed keeping in isometry for ten seconds each repetition.
41313570|NCT04104906|OTHER|The exercise group|the protocol of strengthening and will have five elastic bands with different resistances available (extra-light, light, moderate, strong and extra-strong) for elbow flexion exercises progression, medial rotation and lateral rotation of the shoulder and scapular retraction.
41313571|NCT02084836|OTHER|Functional Magnetic Resonance Imaging|
41313572|NCT00321425|PROCEDURE|brachial plexus block|
41471784|NCT00401167|DRUG|memantine|Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
41471785|NCT02130778|DRUG|Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline|infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
41313573|NCT00321425|PROCEDURE|ultrasound guidance|
41471786|NCT02130778|OTHER|500 ml 0.9% saline|infusion of saline
41471787|NCT04575714|OTHER|Data record|Data record
41471788|NCT00384293|DRUG|Comparator: niacin (+) laropiprant (MK0524A)|niacin (+) laropiprant (2 g) po qd.
41471789|NCT00384293|DRUG|Comparator: placebo|niacin (+) laropiprant (2 g) placebo po qd.
41471790|NCT02061176|PROCEDURE|Transanal Haemorrhoidal Dearterialization|
41471791|NCT02061176|PROCEDURE|Open Haemorrhoidectomy|
41313574|NCT00321425|PROCEDURE|electrical nerve stimulation|
41313575|NCT03772561|DRUG|AZD5363+Olaparib+Durvalumab|Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities.
41313576|NCT05149248|BIOLOGICAL|Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]|HPV vaccination in an alternative schedule for MSM of 1 dose (M0).
41313577|NCT05149248|BIOLOGICAL|Two dose|HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6)
41001431|NCT00378066|DRUG|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
41001432|NCT06456281|DIAGNOSTIC_TEST|A noninvasive cfDNA multi-omics assay|Peripheral venous blood samples will be collected from pancreatic cancer patients, individuals with precancerous lesions, and healthy controls. Subsequently, cfDNA will be extracted and subjected to low-pass whole genome sequencing (LP-WGS) and hybrid capture-based targeted methylation sequencing (TMS).
41313578|NCT05149248|OTHER|Control group|HPV vaccination at 12 months
41313579|NCT05149248|BIOLOGICAL|2 dose vaccination over 6 month|2-dose HPV vaccination regimen over a 6-month period (M0,6)
41313580|NCT00760604|PROCEDURE|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
41313581|NCT02607358|OTHER|blood sampling for HOTPR-testing|All subjects are tested for responderstatus using the VerifyNow System
41313582|NCT00132821|DRUG|Bupropion|Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)
41313583|NCT00132821|DRUG|Transdermal Nicotine Patch|21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
41313584|NCT00132821|DRUG|Placebo Bupropion|Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
41313585|NCT00132821|DRUG|Placebo transdermal nicotine patch|21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
41471792|NCT01220609|DRUG|Ixabepilone|Given IV
41471793|NCT01220609|OTHER|Laboratory Biomarker Analysis|Correlative studies
41471794|NCT00498342|DRUG|N-acetylcysteine|
41471795|NCT05744401|DRUG|AL002|Administered via intravenous (IV) infusion
41471796|NCT06605625|BIOLOGICAL|Influenza vaccination|one annual dose of inactivated influenza vaccine
41471797|NCT06605625|BIOLOGICAL|SARS-CoV-2 vaccine|dose of SARS CoV2 vaccine
41471798|NCT06605625|BIOLOGICAL|Zoster Vaccine Recombinant|first and/or second vaccination for shingles (Herpes zoster)
41471799|NCT04908202|DRUG|Deucravacitinib|Specified dose on specified days
41471800|NCT04908202|OTHER|Placebo|Specified dose on specified days
41471801|NCT00412737|DRUG|Oseltamivir|Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
41471802|NCT00412737|DRUG|Placebo|Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
41471803|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
41001433|NCT00712465|DRUG|AZD1305|Extended Release tablet, repeated administration
41001434|NCT00712465|DRUG|Digoxin|Tablet, repeated administration
41001435|NCT02170584|DRUG|BIBR 953 ZW IV|
41001436|NCT02170584|DRUG|BIBR 1048 MS tablet|
41151089|NCT02606617|DRUG|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
41313586|NCT02551198|DRUG|HAPREP®|"Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc)~: : PEG-Asc(500mLx2 times q30min)\[PM 7-9, the day before colonoscopy\] + PEG-Asc(500mLx2 times q30min)\[AM 5-7, the day of colonoscopy\]"
41471804|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
41313587|NCT02551198|DRUG|SUCLEAR®|Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)\[PM 7-9, the day before colonoscopy\] + OSS(1b/177mL)\[AM 5-7, the day of colonoscopy\]
41001437|NCT02170584|DRUG|BIBR 1048 MS oral solution|
41001438|NCT02170584|DRUG|BIBR 953 ZW IV Placebo|
41313588|NCT04224428|DRUG|Fexofenadine Pill|fexofenadine tablets 60 mg once daily will be taken for six months
41001439|NCT06216392|BIOLOGICAL|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
41151090|NCT03331276|OTHER|BBN|BBN to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
41313589|NCT04224428|DRUG|Placebo oral tablet|lactose oral tablet
41313590|NCT05938777|BEHAVIORAL|Non-Stage-Matched Intervention|The proposed intervention will be non-Stage-Matched that uses different Processes of Change as strategies to change the physical exercise behavior.
41313591|NCT02581111|DRUG|Naloxone|Naloxone 8-mg IV bolus
41313592|NCT02581111|DRUG|Normal saline|
41313593|NCT00748553|DRUG|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
41313594|NCT00748553|DRUG|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
41313595|NCT00446446|DRUG|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
41001440|NCT06216392|BIOLOGICAL|placebo|0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
41001441|NCT02094716|DRUG|Permethrin Foam 4%|Topical application, whole-body treatment
41001442|NCT02094716|DRUG|Permethrin Foam 5%|Topical application, whole-body treatment
41001443|NCT02094716|DRUG|Vehicle Foam|Topical application, whole-body treatment
41001444|NCT06291558|OTHER|Exercise|The first 5 minutes of heating in the exercise program are planned to be implemented for 8 weeks, and the last 5 minutes are a cooling period. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. As respiratory exercise, diaphragmatic respiratory exercise will be applied to heating and cooling peryots with 5 repetitions. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, and hip exercise. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
41001445|NCT05974904|OTHER|high-sensitivity C-reactive protein to albumin ratio|High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.
41151091|NCT03331276|OTHER|Brand|Brand to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
41313596|NCT05883553|DEVICE|Usability and added value of device within sexual activity|Participants and there partners will be asked to use the device over the course of 4 months, during which both will provide answers to questionnaires on quality of relation and sexual life, and detailed questions on the usability and the added value of the used device during sexual activity along with overall satisfaction with the device.
40796825|NCT04777006|DRUG|Antidepressant Therapy|"Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 \< 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care."
40796826|NCT03383250|DIETARY_SUPPLEMENT|Normal meal|
40796827|NCT00751959|DRUG|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
40796828|NCT00751959|DRUG|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
40796829|NCT00124072|DRUG|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
40796830|NCT00124072|DIETARY_SUPPLEMENT|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
40796831|NCT00124072|DRUG|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
40796832|NCT00124072|DRUG|Placebo|Placebo vitamin B12/folic acid tablet once daily
40796833|NCT00040742|DIETARY_SUPPLEMENT|ginger|Given orally
40796834|NCT00040742|OTHER|placebo|Given orally
40796835|NCT02831855|DRUG|CP-690,550|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
40796836|NCT02831855|DRUG|Methotrexate|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
41001446|NCT04618055|DEVICE|NiTiDent Tuah Porous NiTi Dental Implants|A newly developed NiTiDent Tuah porous NiTi cylindrical bone level dental implant measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations produced by Nitium Technology Sdn Bhd.
41001447|NCT04618055|DEVICE|Control Dental Implant Systems|A market approved bone level dental implant systems measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations
41151092|NCT03366233|OTHER|Mental fatigue|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task. The Stroop task requires inhibition and sustained attention on controlled processes.
41151093|NCT03366233|OTHER|Control|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content.
41151094|NCT06584617|DEVICE|Berovenal®|Easy to spread, water-washable, light brown, turbid hydrogel in tube containing 30 g of hydrogel and closed with a plastic screw cap.
40796837|NCT02831855|DRUG|Placebo|During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
40796838|NCT01206140|OTHER|Laboratory Biomarker Analysis|Correlative studies
40796839|NCT01206140|DRUG|Selumetinib|Given PO
40796840|NCT01206140|DRUG|Temsirolimus|Given IV
40796841|NCT06449404|OTHER|7T-MRI scaning|7T-MRI scaning
40796842|NCT06093308|DRUG|Deuremidevir Hydrobromide Tablets|Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning
40796843|NCT02946177|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
40796844|NCT02946177|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
40796845|NCT05701839|PROCEDURE|face mask ventilation|In participants with face mask ventilation, oxygen inhaled through face mask at a flow rate of 5 L/min.
40796846|NCT05701839|PROCEDURE|nasopharyngeal tube ventilation|In participants with nasopharyngeal tube ventilation, oxygen inhaled through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min.
40796847|NCT05701839|DEVICE|oxygen saturation monitoring|In participants with oxygen saturation monitoring, assist ventilation through face mask will be performed when oxygen saturation drops to 95%, it lasts for another 10 seconds when oxygen saturation restores to 100%.
40796848|NCT05701839|DEVICE|oxygen reserve index monitoring|In participants with oxygen reserve index monitoring, assist ventilation through face mask will be performed when oxygen reserve index drops to 0.1, it lasts for another 10 seconds when oxygen reserve index restores to 0.1.
41151095|NCT06584617|DEVICE|NU-GEL Hydrogel with Alginate|Transparent, easy to spread and water-washable hydrogel in ampoule (concertina pack) containing 25 g or 15 g of hydrogel and closed with a plastic cap.
41151096|NCT02820298|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
41471805|NCT05646706|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
41001448|NCT06058195|PROCEDURE|Quadratus lumborum plane block|QLB (quadratus lumborum plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
41001449|NCT06058195|PROCEDURE|Transverse abdominis plane block|TAPB (transverse abdominis plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
41151097|NCT05483192|DIETARY_SUPPLEMENT|Oral Dyglomera|"Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.~Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin."
41313597|NCT01885858|BEHAVIORAL|Indigenous profile|Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
41313598|NCT01885858|BEHAVIORAL|Mestizo profile|Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
41313599|NCT05825209|DRUG|Food-Grown Magnesium|1 daily dose of 2 capsules equivalent to 80mg food-grown magnesium (40mg per capsule)
41313600|NCT05825209|DRUG|Microcrystalline cellulose|1 daily dose of 2 capsules containing microcrystalline cellulose
41313601|NCT00383721|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
41313602|NCT00383721|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
41313603|NCT00383721|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
41471806|NCT03302377|BEHAVIORAL|physical activity counseling & Fitbit|Participants will receive individual counseling \& guidance in goal setting, then will receive a Fitbit wrist monitor and guidance in personalizing the Fitbit features
40796849|NCT05878873|BEHAVIORAL|Split-belt Treadmill|Split-belt treadmill training, where the speed of each leg is controlled independently has been shown to create gait adaptation where the coordination of each leg is altered, creating improved gait symmetry for people with walking impairments.
41151098|NCT00296504|DRUG|fosamprenavir (GW433908)|
41151099|NCT00296504|DRUG|ritonavir|
41151100|NCT01815255|DRUG|tenofovir (TDF)|
41151101|NCT05820451|DEVICE|Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed left sided hemodynamic support devices (Impella) will be included.
41313604|NCT00383721|DRUG|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
41313605|NCT00383721|DRUG|Placebo|Placebo MDI twice a day for 26 weeks
41313606|NCT01889966|DRUG|Sildenafil|oral Sildenafil 3 x 20 mg for 90 days
41313607|NCT04415216|DEVICE|percutaneous coronary intervention|Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
41313608|NCT06330597|DIAGNOSTIC_TEST|Echocardiography and lung ultrasound|All patients will undergo non-invasive echocardiogram and lung ultrasound at times of assessment of hemodynamic parameters as needed by usual clinical management.
41313609|NCT01324622|DEVICE|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
41313610|NCT01324622|PROCEDURE|laminectomy|standard procedure
41313611|NCT01980706|DRUG|Baclofen|Baclofen is a GABA-B agonist
41313612|NCT01980706|DRUG|Placebo|Pill containing no pharmacologically active substance.
41313613|NCT02145741|DRUG|Xentuzumab, low dose, every week (qw)|Patient to receive low dose of Xentuzumab IV
41313614|NCT02145741|DRUG|Xentuzumab, middle dose, qw|Patient to receive middle dose of Xentuzumab IV
41471807|NCT00329628|DRUG|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
41471808|NCT00329628|DRUG|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
41471809|NCT04641247|DRUG|Niraparib|Niraparib tablets or capsules will be given once a day via the oral route.
41471810|NCT04022031|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
41471811|NCT04028154|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
41471812|NCT04028154|PROCEDURE|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
41001450|NCT06058195|PROCEDURE|Intravenous analgesia|IVA (Intravenous analgesia): These patients will be administered 1000 mg paracetamol intravenously in the preoperative waiting room in the operating room approximately 20-30 minutes before induction of anaesthesia. No block procedure will be performed. Patients will not be given any analgesic medication before awakening from anaesthesia.
41313615|NCT02145741|DRUG|Xentuzumab, high dose, qw|Patient to receive high dose of Xentuzumab IV
41313616|NCT02431468|DRUG|Bryostatin 1|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
41313617|NCT02431468|OTHER|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.
40796850|NCT05878873|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS is a form of nerve stimulation that stimulates at a frequency below motor threshold, targeting activation of sensory receptors, such as muscle spindles. Electrodes that create this stimulation will be placed on the skin superficial to the muscle bellies of the tibialis anterior and rectus femoris.
41313618|NCT04199208|OTHER|Prehabilitation and Immunonutrition|See study synopsis
41313619|NCT04199208|OTHER|Standard Care Arm|Standard care as per the daily routines of the Hospital at which the study takes place
41313620|NCT04969497|DRUG|"Treatment A: M207 3.8 mg MiniMac"|"Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups"
41313621|NCT04969497|DRUG|"Treatment B: M207 3.8 mg MACAP"|"Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups"
40796851|NCT03423303|DIAGNOSTIC_TEST|Prostate cancer screening|Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
40796852|NCT05487690|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries. to help to reduce intra-operative radiation.
40796853|NCT05487690|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
40796854|NCT03402191|DRUG|L-arginine|l-arginine for thalassemia with pulmonary hypertension
40796855|NCT03402191|DRUG|Sildenafil|Sildenafil for thalassemia with pulmonary hypertension
40796856|NCT04047368|PROCEDURE|Rotablation|Percutaneous Coronary Intervention using Rotablation
40796857|NCT04047368|PROCEDURE|Coronary Lithoplasty|Percutaneous Coronary Intervention using Lithoplasty
40796858|NCT00358319|DRUG|Karenitecin|
40796859|NCT00358319|DRUG|Valproic Acid|
41001451|NCT05830630|DRUG|Bupivacaine methylene blue|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
41001452|NCT05830630|DRUG|bupivacaine saline|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
41001453|NCT00692770|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
41001454|NCT00692770|DRUG|Placebo|Placebo 2 tablets twice daily (BID)
41151102|NCT05820451|DEVICE|Impella RP with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed right sided hemodynamic support devices (Impella) will be included.
41151103|NCT05527054|OTHER|Diuretics|Inpatients using diuretics
41151104|NCT03768986|BEHAVIORAL|Standard referral for HIV testing|Participants receive standard referral for HIV testing in the community.
40796860|NCT05663177|DRUG|Almonertinib and metronomic oral vinorelbine|Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
41001455|NCT05102188|COMBINATION_PRODUCT|Assessment of sleep and related factors|Eligible participants will be invited to fill out several forms and wear a watch-like device on their wrist (an accelerometer) for 7 days to assess their sleep habits. They will also be asked to sleep at home with a watch-like device attached to a sleeve which covers their index finger (an oximeter) for one night to assess whether they may have a sleep problem like sleep apnea.
41151105|NCT03768986|BEHAVIORAL|Online risk reduction training|Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
41151106|NCT03768986|BEHAVIORAL|Reinforcement|Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
41151107|NCT03928171|OTHER|Intra-abdominal pressure during laparoscopy|Insufflation pressure of the abdomen during laparoscopy
41151108|NCT02917993|DRUG|Itacitinib|In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
41313622|NCT04969497|DRUG|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
41313623|NCT02499003|DRUG|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
41471813|NCT06616402|DEVICE|prototype prosthetic group|"These 3 sessions will commence only upon successful completion of the prosthesis safety and reliability tests conducted in the preceding sessions.~For each module combination, a session will be conducted to assess motor performance through the acquisition of spatiotemporal parameters and energy efficiency parameters of gait. Motor performance will be evaluated using functional assessment tests and data will be recorded during the following activities:~* parallel bar walking on flat ground~* parallel bar walking on an inclined surface~* treadmill walking with a safety harness~* stair climbing/descending with a handrail~* standing up and sitting down from a chair within parallel bars At the end of each session, satisfaction questionnaires (ad hoc questionnaire) will be completed. At the end of the experiment, a usability scale for the devices (ad hoc System Usability Scale) will be completed.~Each session is expected to last approximately 2.5 hours."
41471814|NCT04778306|PROCEDURE|Transoral Laser Surgery|Remove of the laryngeal tumour via diode laser
41313624|NCT01313806|DEVICE|Resonator|Treatment group vs. Placebo group
41313625|NCT01313806|DEVICE|Placebo|Inactive Resonator Device
41313626|NCT05499702|BEHAVIORAL|Caloric Restriction|"Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from Nutritional Guidelines after Bariatric Surgery. Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake"
41471815|NCT05009368|DRUG|Drug: Treatment A|CTL0901, single dose, daily, repeated oral administration for 4 days
41471816|NCT05009368|DRUG|Drug: Treatment B|CTL0902, single dose, daily, repeated oral administration for 7 days
40796863|NCT04008303|PROCEDURE|Migraine surgery|Surgical decompression of neuromuscular structures causing migraine headaches.
40796864|NCT02227030|DRUG|BIIB 722 CL solution|
40796865|NCT02227030|DRUG|BIIB 722 CL tablet|
40796866|NCT02227030|DRUG|Placebo solution|
40796867|NCT02227030|DRUG|Placebo tablet|
40796868|NCT04401150|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
41471817|NCT05009368|DRUG|Drug: Treatment C|CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days
40796869|NCT04401150|DRUG|Control|Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
40796870|NCT02202915|BEHAVIORAL|Behavioral Checklist|
40796871|NCT03332199|OTHER|Psycho-educational intervention|The total program, consisting of three intervention sessions, was given over a period of 3 weeks. The one face-to-face session of an-hour's duration was provided within a week of the chemotherapy cycle following recruitment. Two booster sessions of 20-30 minutes were then conducted by phone at one-week intervals after the first intervention session.
40796872|NCT02003976|PROCEDURE|Medial Opening Wedge High Tibial Osteotomy (HTO)|A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
40796873|NCT02003976|OTHER|Non-Surgical Treatment Program|A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
40796874|NCT02195700|DRUG|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
41001456|NCT02940171|PROCEDURE|Early Excision of full thickness burn|first excision surgery of full -thickness burn performed within 48 hours from burn injury
41001457|NCT02940171|PROCEDURE|Late Excision of full thickness burn|first excision surgery of full -thickness burn performed after 48 hours from burn injury
41001458|NCT06351579|OTHER|Control|This is an observational (registry) study for data collection only. No device or intervention will be used in this study.
41001459|NCT05040581|BEHAVIORAL|1-Day CBT-Based Workshop for Preventing PPD|The intervention is a 6-hour long CBT-based workshop. The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning.
41001460|NCT05423821|OTHER|Anesthesia efficacy in patients undergoing MRI|atropine will be administered when bradycardia develops, oxygen will be given if hypoxia develops
41001461|NCT05324878|OTHER|Training|Social workers/nurses participants are agreeing to participating in the training program (3 sessions of 2 hours over a period of six weeks - one session every 2 weeks), follow up training sessions (occurring monthly), mentorship calls with social worker faculty on the project team, recording one conversation between social worker and a patient for quality improvement purposes, and completing evaluation of the project interventions (5-minute questionnaire after each education session, 15-minute questionnaire at end of participation in project).
40796875|NCT02195700|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks.
40796876|NCT04460794|BEHAVIORAL|Ballet-inspired workouts|8 weeks, delivered by volunteers with a self-directed resource package
40796877|NCT04460794|OTHER|Usual care|Usual care and general recommendations on basic stretching and leg exercises for stroke survivors
41151109|NCT02917993|DRUG|Osimertinib|Osimertinib 80 mg once daily (QD)
41313627|NCT05499702|DRUG|Hyperglycemic clamp|Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism
41313628|NCT03630978|PROCEDURE|Liver resection|Major or minor, open or laparoscopic liver resection
41313629|NCT05598294|PROCEDURE|Mobilization recommendations|Standard mobilization recommendations will be given to all patients, and feedback will be given to the intervention group to increase the number of steps 4 times a day according to the daily targeted number of steps.
41471818|NCT04823507|DEVICE|BIOFLEX DUO+|"* Data scores will be collected for patients who initially underwent the Workplace Post-Injury 1 test of the ImPACT® test system prior to PBM treatment.~* Patients were treated with photobiomodulation using the BIOFLEX® DUO+ system that utilized a 180 bulb Light Emitting Diode (LED) array followed by laser probes. Both delivery methods were applied to the cervical spine and the cranium, and both entailed the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided three times per week on alternating days with weekends off for 4 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for treatment of the cervical spine.~* Data scores will be collected for a second ImPACT® test using the Workplace Post-Injury 2 test.~* Results of the Post-Injury 1 test and the Post-Injury 2 test will be compared."
41001462|NCT02366832|PROCEDURE|Cryoablation|Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
41001463|NCT02366832|DEVICE|17g Galil Medical Ice Sphere cryoablation needle|Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.
41471819|NCT06617000|BIOLOGICAL|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
41471820|NCT06504147|DRUG|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.
41001464|NCT02123199|DRUG|Indacaterol (Onbrez®) /QAB149|
41001465|NCT03023085|DRUG|BLI4700|BLI4700 bowel preparation
41471821|NCT06208423|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
41471822|NCT00084799|BIOLOGICAL|monoclonal antibody hu3S193|
41471823|NCT06020482|OTHER|Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity|The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.
41001466|NCT03695731|PROCEDURE|cold induced activation of brown adipose tissue|cold exposure wearing a cold life jacket
41001467|NCT05772533|PROCEDURE|Serratus anterior plane block|The latissimus dorsi muscle between the midaxillary line and the posterior axillary line will be located under ultrasound guidance. The needle will be inserted into the plane from top to bottom until the serratus anterior surface, and the injectate will be slowly administered.
41001468|NCT05772533|PROCEDURE|PENG block|"Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed Between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
41001469|NCT03243812|BIOLOGICAL|Blood sampling|Blood sampling will be performed to assess hematological and hemorheological parameters
41001470|NCT03243812|OTHER|Maximum Voluntary Contraction (MVC) test force|Maximum Voluntary Contraction (MVC) test force will be performed before and after a localized muscle endurance test
41001471|NCT03243812|OTHER|Localized muscle endurance test|Subject will perform 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
41313630|NCT05874453|OTHER|eye care protocol|The lower conjunctiva of the eye to be treated is opened, 1-2 drops of gel are applied, the eye is closed. Cleaning eye secretions is done with sterile distilled water. A gel containing trehalose, hyaluronic acid and carbomer will be applied every 2-4 hours in accordance with intensive care eye care protocol. In order to determine the exposure keratopathy, staining with Fluorescein Sodium will be performed by the ophthalmologist on days 0, 5 and 10, and a blue light pen will be used for evaluation. In order to determine the degree of dry eye, the Schirmer I test will be performed on the 0th and 10th days
41313631|NCT03939806|DRUG|Oxytocin|To be given to Oxytocin group following the clamping of the umbilical cord
41001472|NCT03243812|OTHER|Self-paced six-minute walk test|Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society
41001473|NCT03862664|PROCEDURE|Collection of data|The investigators will retrieve retrospectively the medical record of donors who underwent hepatic lobectomy for liver transplantation
41001474|NCT02129803|DEVICE|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
41313632|NCT03939806|DRUG|Carbetocin|To be given to Carbetocin group following the clamping of the umbilical cord
41313633|NCT03957655|BIOLOGICAL|SHED group|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12
41313634|NCT00950079|DRUG|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
41313635|NCT00950079|DRUG|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
41471824|NCT03365544|OTHER|Time-restricted eating|Groups will be required to only ingest calories in their designated 8 hour eating window.
41471825|NCT00101413|DRUG|Sorafenib (Nexavar, BAY43-9006)|BAY43-9006 400 mg bid X 28 day cycles \[Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
41471826|NCT04372290|OTHER|Product A|Usual brand (UB) filtered, combustible cigarette
41471827|NCT04372290|OTHER|Product B|Nicorette® White Ice Mint 2 mg nicotine gum
41471828|NCT04372290|OTHER|Product C|CSD1904-01, a nicotine pouch, 2 mg nicotine
41471829|NCT04372290|OTHER|Product D|CSD1904-02, a nicotine pouch, 4 mg nicotine
41471830|NCT04372290|OTHER|Product E|CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
41001475|NCT02129803|DEVICE|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
41001476|NCT01157533|DRUG|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
41151110|NCT01514630|DRUG|Creatine monohydrate|Five grams of creatine monohydrate will be administered for eight weeks.
41471831|NCT02136303|DIETARY_SUPPLEMENT|S1: Dosage-dependency|kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
40796878|NCT03625869|DEVICE|PiCSO|After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
41471832|NCT02136303|OTHER|S2: Kale extract versus kale purée|
41471833|NCT02136303|OTHER|S3: Kale extract: AMD-patients|
41471834|NCT05621187|DEVICE|Pamira ICD lead family|Implantation, measurements and follow-up schedule
41471835|NCT01008514|PROCEDURE|adjuvant therapy|
40796879|NCT04077424|BIOLOGICAL|Fluzone-High Dose Quadrivalent|Seasonal influenza vaccination with FDA approved vaccines for this age group.
40796880|NCT04077424|BIOLOGICAL|Fluad|Adjuvanted (MF59) inactivated influenza vaccine
40796881|NCT04077424|BIOLOGICAL|Flublock|Recombinant hemagglutinin vaccine
40796882|NCT05743127|DEVICE|3D-Printed Hyrax Expander|This is a type of maxillary expander that is designed on a computer and printed in metal using 3D printers and is used to expand the upper jaw.
40796883|NCT05743127|DEVICE|Conventional Laboratory Fabricated Hyrax Expander|This is a type of maxillary expander that is made by hand in an orthodontic laboratory and is used to expand the upper jaw.
41471836|NCT01008514|RADIATION|accelerated partial breast irradiation|
40796884|NCT04706780|OTHER|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
40796885|NCT00136695|DRUG|anastrozole|1 mg QD
40796886|NCT04206631|DRUG|Doxycycline Capsule|Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
40796887|NCT04206631|PROCEDURE|Comedone extraction|Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
40796888|NCT00393991|DRUG|Fluticasone propionate/formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
41001477|NCT04259112|PROCEDURE|high pressure|High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
41001478|NCT04259112|DRUG|deep neuromuscular block|Deep neuromuscular block is defined as PTC 1-2.
41001479|NCT04259112|PROCEDURE|low pressure|Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.
41001480|NCT04259112|DRUG|moderate neuromuscular block|Moderate neuromuscular block is defined as TOF twitch 1-2.
41001481|NCT01461772|RADIATION|Radiation therapy|pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
41471837|NCT01008514|RADIATION|intracavitary balloon brachytherapy|
41151111|NCT05951556|DEVICE|Use of BCI|Clients will utilize BCI with training to communicate wants and needs
41151112|NCT04890158|OTHER|Prone positioning for a total of 6 hours daily|Prone positioning for 6 hours daily
41471838|NCT03118219|OTHER|Positive adjustment coping intervention|see arm description
41471839|NCT03118219|OTHER|Brainteaser|see arm description
41471840|NCT04063319|OTHER|High-fidelity simulation|The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
41471841|NCT06311669|PROCEDURE|iliac vein stenting|patients will undergo left common iliac vein stenting according to diameter measurements using balloon-mounted stents.
40796889|NCT00393991|DRUG|Fluticasone propionate 100|Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
40796890|NCT00393991|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
40796891|NCT00393991|DRUG|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
40796892|NCT02474576|PROCEDURE|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
40796893|NCT05388604|DEVICE|RF device|The entire defined treatment area will then be treated by delivering adjacent pulses with minimal overlap of 10% or less. Parameters may be adjusted throughout the treatment in order to increase subject comfort.
40796894|NCT05388604|DEVICE|Microneedling device|"Test spots may be performed prior to the first treatment. Test spots may be performed prior to the first treatment. It will follow a similar procedure to treatment but only in an inconspicuous place, such as behind the ear, in an area no larger than 2in x 2in.~The tip will be placed in contact with the skin, and parameters may be adjusted throughout the treatment and will determined by the Clinician."
40796895|NCT00463138|BEHAVIORAL|Crisis intervention|
41001482|NCT01461772|DRUG|Carboplatin|carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
41001483|NCT01461772|DRUG|Cisplatin|Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
41001484|NCT02986620|GENETIC|IDH mutation test performed at diagnosis or relapse until January 31st, 2019.|Observation of the test result.
41313636|NCT02428452|BEHAVIORAL|Social ABCs parent-mediated intervention program|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
41313637|NCT01253044|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
40796896|NCT03060993|DRUG|Cannabis|Patients will be administered cannabis (THC/CBD) in vaporized form.
41001485|NCT05175066|DRUG|Bisoprolol|For patients who were candidates to start therapy with anthracycline, bisoprolol was administrated as explained before to determine the effect of this drug on the reduction of anthracycline-induced cardiomyopathy.
41001486|NCT05175066|DRUG|Placebo|Tablets with similar shape and size and color to bisoprolol were given to the patients whom undergone chemotherapy with anthracyclines to compare the effects between two groups.
41001487|NCT01371097|OTHER|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
41001488|NCT03943563|DIAGNOSTIC_TEST|Dixon sequences acquisition|Dixon sequences acquisition
41001489|NCT03383328|DRUG|NSAID + prednisolone, preoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
41471842|NCT06311669|PROCEDURE|pelvic vein embolization|embolization of pelvic veins by injection of left ovarian vein or parauterine veins pelvic escape points using sandwich technique of detachable or pushable coils and polidocanol 3 %.
41471843|NCT02023840|DRUG|metronidazole gel|
41001490|NCT03383328|DRUG|NSAID + prednisolone, postoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
41001491|NCT03383328|DRUG|NSAID, preoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
41151113|NCT01476137|DRUG|GSK1120212|MEK inhibitor
41151114|NCT01476137|DRUG|GSK2110183|AKT inhibitor
41001492|NCT03383328|DRUG|NSAID, postoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
41001493|NCT03383328|DRUG|Drop-less surgery|A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
41001494|NCT04804462|DEVICE|Virtual Reality Meditation|After donning the VR headset, participants will be able to use a handheld controller to choose from several virtual outdoor settings, three types of meditation, and three session lengths. After choosing their desired option, participants will experience virtual reality meditation in the desired virtual location, of the desired meditation type, and for the allotted duration chosen.
41001495|NCT00645333|DRUG|MK-0752, Docetaxel, Pegfilgrastim|MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
41001496|NCT03438890|DEVICE|Warm saline|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
41001497|NCT03438890|DEVICE|anti-fog agent|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
41001498|NCT03438890|DEVICE|chlorhexidine|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
41001499|NCT03007511|DEVICE|Fidmi enhanced enteral feeding device|Fidmi enhanced enteral feeding device is intended to provide nutrition to a patient directly into the stomach through a stoma. The Fidmi PEG device would be investigated in this study on patients suffering from dysphagia, who are scheduled for PEG procedure in order to improve surgical initial insertion, device replacement and removal.
41001500|NCT06076694|DRUG|TNP-2198|Group A, TNP-2198 capsules 400mg(4 capsules),BID, 14days Group B, TNP-2198 capsules 600mg(6 capsules),BID, 14days Group C , TNP-2198 capsules 600mg(6 capsules),TID, 14days Group D, TNP-2198 capsules 600mg(6 capsules),TID, 7days
41313638|NCT01253044|BEHAVIORAL|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
41313639|NCT03925961|OTHER|Preoperative education|The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.
40796897|NCT03060993|DRUG|Placebo|Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
41313640|NCT01490268|DRUG|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
41313641|NCT01490268|DRUG|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
41471844|NCT02023840|PROCEDURE|ultrasonics|
41471845|NCT02023840|PROCEDURE|erythritol|
41471846|NCT02023840|DRUG|placebo|
41471847|NCT06428513|BEHAVIORAL|HCTP|10 weekly 1-on-1 30-minute tele-sessions via Zoom, delivered by a certified health coach. At baseline assessment including full medical history, medications, lifestyle practices, self-reported health status, psychosocial status, and other relevant information will be taken. At the first session, participants identify their health vision and 3-month health goals. At subsequent meetings, participants review their progress towards reaching the prior week's goals and identify goals for the next week. An individualized action plan will be formulated to help each participant achieve their goals. The action plan will focus on important lifestyle practices (physical activity/exercise training, correct nutrition, weight management, tobacco cessation, and stress management. Patients can request further health care advice felt necessary for their progress, and will be referred to health care professionals in the rehabilitation hospital that provide care for lung transplantation candidates.
40796898|NCT04544644|DRUG|AK104+anlotinib|AK 104 is given by intravenous infusion and anlotinib is given by oral.
40796899|NCT06023121|DIAGNOSTIC_TEST|Measurement of levels of an exosome-based liquid biopsy signature|Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature
41151115|NCT00002401|DRUG|Indinavir sulfate|
41151116|NCT00002401|DRUG|Delavirdine mesylate|
41313642|NCT03800862|DEVICE|CT-FFR and CTP|Those who agree to participate will be scheduled to have the CT-FFR and CTP performed within sixty days of the initial Coronary CTA procedure. A CTA will be performed at rest for FFR. The patient will then take approximately a 30 min break. Regadenoson will then be administered and the dynamic CT procedure will be done for perfusion.
41313643|NCT02771652|BEHAVIORAL|e-training|The e-training intervention is a home-based aerobic and resistance training program. Resistance training was prescribed twice weekly for a period of 12 weeks. No special equipment was necessary except an elastic exercise band or a large gymnastic ball. In addition, endurance training was to be carried out once a week. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. The form of activity for the endurance training was freely selected, duration (between 10-60 min) was adjusted to individual fitness levels. Therapists aimed at eliciting a BORG Feedback of between 11 (fairly light) and 16 (hard). The exercise training was home-based and supervised via the internet. Participants continued exercise training for another 12 weeks after the 3month assessment.
41471848|NCT04180371|DRUG|BT5528|Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.
41471849|NCT04180371|DRUG|Nivolumab|Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.
41001501|NCT06076694|DRUG|Rabeprazole Sodium|Group A,Group B,Control group: Rabeprazole sodium enteric-coated tablets 20 mg, BID, 14days Group C :Rabeprazole sodium enteric-coated tablets 20 mg, TID, 14 days Group D : Rabeprazole sodium enteric-coated tablets 20 mg, TID, 7 days
41001502|NCT06076694|DRUG|Amoxicillin|Group A,Group B,Control group: Amoxicillin capsules 1g, BID, 14days Group D : Amoxicillin capsules 1g, TID, 7 days
41001503|NCT06323252|DIETARY_SUPPLEMENT|MastihaOil|1 soft gel capsule of Mastiha oil every day for 3 months
41313644|NCT02771652|OTHER|Control|After the initial assessment on entry, those assigned to the control group were instructed to maintain their previous physical activity behaviour. After waiting three months, they received the same e-training intervention as the intervention group had received from the start.
41001504|NCT06323252|BEHAVIORAL|nutritional counsel|nutritional counsel
41313645|NCT00288860|BEHAVIORAL|Telephone monitoring|Three months of biweekly telephone monitoring and support
41313646|NCT00288860|OTHER|Treatment-As-Usual|Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
41001505|NCT02423616|OTHER|Healthy individuals|INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
41313647|NCT03953261|DRUG|Curcumin supplement|Intervention is 2 grams of curcumin supplement per day
41313648|NCT04136613|DEVICE|Copper Intra uterine contarceptive device ( Cu-T 380A)|Insertion of the Cu-T 380A during cesarean delivery immediately after placental removal.
41313649|NCT01621672|DRUG|Revlimid|10 mg/day in the morning same time each day
41313650|NCT05528224|OTHER|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"OCD patients will take part in four structured online lessons for 6 weeks. Lesson one: Psychological Health Education, including the knowledge about OCD, SUDs and other related information.~Lesson two: Exposure and Response Prevention (ERP), including the knowledge about ERP, exposure item list and other related information.~Lesson three: Practice of Exposure and Response Prevention. Patients are asked to perform ERP practice based on what they have learned previously: practice at least once a day, a day about one hour all together. On this basis, in the main study, patients with severe obsessive and compulsive symptoms(Y-BOCS≥24) will be provided with extra therapist-guided ICBT: twice a week, about an hour one time. While in the pilot study, non-responders at week 3(YBOCS score reduction rate\<25%) will be provided with extra therapist-guided ICBT.~Lesson four: Practice retrospection and relapse prevention."
41313651|NCT05528224|OTHER|Cognitive Behavioral Group Therapy (CBGT)|OCD patients will be asked to come to Shanghai Mental Health Center to take part in the offline CBT group. Each group will be treated for 6 weeks, twice a week for 2 hours each time. The treatment was supervised by an experienced CBGT therapist. The structure of the course basically corresponds with the SC-ICBT group.
41313652|NCT05528224|DRUG|conventional medical treatment (TAU)|"In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual."
41471850|NCT06239961|BEHAVIORAL|Social Connection|6 weekly Behavioral Activation Intervention calls with a 1 hour duration for each call.
41471851|NCT06239961|BEHAVIORAL|Nutritional Coaching|4 weekly nutritional coaching calls with a Registered Dietician with a 1 hour duration for each call.
41471852|NCT06239961|BEHAVIORAL|Physical Activity Coaching|4 weekly physical activity coaching sessions with a 1 hour duration for each call.
41471853|NCT00024349|DRUG|fluorouracil|
41313653|NCT04311177|DRUG|Losartan|Losartan; 25 mg daily; oral administration
41313654|NCT04311177|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
41313655|NCT00396149|BIOLOGICAL|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
41313656|NCT00396149|BIOLOGICAL|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
41313657|NCT01317667|BIOLOGICAL|RVEc|
41471854|NCT00024349|DRUG|mitomycin C|
41471855|NCT00024349|RADIATION|radiation therapy|
41471856|NCT06616883|DRUG|DA-5221_01|single dose administration (DA-5221_01 one tablet once a day)
41001506|NCT02167256|DRUG|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
41471857|NCT06616883|DRUG|DA-5221_01-R1 + DA-5221_01-R2|single dose administration (DA-5221_01-R1 one tablet once a day + DA-5221_01-R2 one tablet once a day)
41471858|NCT03389256|DRUG|Apatinib|Apatinib mesylate tablets 250 mg qd po, if the patient can tolerate the toxic side effects, adjust the dose to 500mg qd po after 1 week.
41001507|NCT02167256|DRUG|AZD0530 125mg daily|Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
41001508|NCT02167256|DRUG|Placebo|50% of patients will receive placebo treatment for the duration of the study.
41001509|NCT05297539|OTHER|Point light display|Visualization of point-light human actions
41001510|NCT02282956|DRUG|Ropivacaine 0,75%|Ropivacaine injection
41001511|NCT02282956|PROCEDURE|posterior tibial nerve block|ultrasound guided posterior tibal nerve block
41001512|NCT02282956|DRUG|morphine and droperidol|i.v PCA
41471859|NCT03389256|DRUG|EGFR-TKI|Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po
41471860|NCT03509714|DIETARY_SUPPLEMENT|Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)|2 Pills to be taken orally per day during their entire menstrual cycle
41471861|NCT03509714|DIETARY_SUPPLEMENT|rice flour (Placebo)|250 mg rice flour (Placebo)
41001513|NCT02540954|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|A dose of 2 mg aflibercept injected intravitreally
40796900|NCT01760499|DRUG|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
41001514|NCT00275210|DRUG|Oxaliplatin (SR96669)|
41001515|NCT05626946|OTHER|Observation|Observation
41001516|NCT02434835|DRUG|[14C]KWA-0711|
41001517|NCT03480997|COMBINATION_PRODUCT|Albuterol Sulfate and Ipratropium Bromide|
41313658|NCT04875338|DRUG|plate-rich plasma|1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), , while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
41313659|NCT04875338|DRUG|saline (0.9 NACI)|1 ml saline (0.9 NACI) while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
41001518|NCT03480997|COMBINATION_PRODUCT|Albuterol Sulfate|
41001519|NCT02886390|DEVICE|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
41001520|NCT03339609|DIAGNOSTIC_TEST|Uroflow|Isolated uroflow measurement
41001521|NCT03339609|DIAGNOSTIC_TEST|Uroflow/EMG|Uroflow measurement with superficial EMG testing of the pelvic floor
41001522|NCT03339609|DIAGNOSTIC_TEST|US|Ultrasound of post void residual urine
41001523|NCT01828372|OTHER|additional blood withdrawals|Blood withdrawals by either venous puncture or placement of permanent venous catheter.
41001524|NCT02106728|BEHAVIORAL|Multi-Family Therapy|Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
41313660|NCT04875338|DRUG|betametazon|1 ml betametazon while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
41313661|NCT02695524|OTHER|Scapula-focused exercises|
41313662|NCT02695524|OTHER|Motor control exercises|
41001525|NCT02106728|BEHAVIORAL|Supportive Family Therapy|Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
41001526|NCT04208906|DEVICE|Masimo O3|"After anesthesia induction, a masimo O3 sensors are attached to the forehead (ScO2) and the sole of the foot (StO2). About 0.4 ml blood samples are obtained from arterial line and central venous line at three epochs before and after cardiopulmonary bypass (total 6 times)~* T1: before cardiopulmonary bypass (CPB), fraction of inspired oxygen (FiO2) 0.2~* T2: before CPB, FiO2 0.5~* T3: before CPB, FiO2 0.8~* T4: after CPB, FiO2 0.8~* T5: after CPB, FiO2 0.5~* T6: after CPB, FiO2 0.2~Hemoglobin oxygen saturation values are confirmed in each sample (arterial sample: SaO2, venous sample: SvO2). Each O3 values (ScO2 and StO2) are compared to the values of SvO2, 0.7 × SvO2 + 0.3 × SaO2."
41313663|NCT00448760|DRUG|Docetaxel|Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
41001527|NCT03929965|DRUG|Anlotinib|Anlotinib
41001528|NCT01787084|DEVICE|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
41001529|NCT03365206|OTHER|Questionnaire on practices and knowledge in terms of oral hygiene|Questionnaire on practices and knowledge in terms of oral hygiene during a dental consultation
41001530|NCT02801318|PROCEDURE|Polysomnography|
41001531|NCT06122090|DRUG|Bimatoprost|Bimatoprost will be delivered with laser
41001532|NCT06122090|DRUG|Saline|Saline control will be delivered with laser
41001533|NCT02144740|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
41001534|NCT02144740|DIETARY_SUPPLEMENT|Placebo|A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
41001535|NCT02048020|DRUG|paclitaxel|Given IV
41001536|NCT02048020|DRUG|carboplatin|Given IV
41001537|NCT02048020|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
41001538|NCT02048020|PROCEDURE|quality-of-life assessment|Ancillary studies
41313664|NCT00448760|DRUG|Floxuridine|Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
40796901|NCT01760499|PROCEDURE|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
41001539|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
41001540|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
41001541|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
41001542|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
41001543|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
41001544|NCT01959542|DEVICE|MRI|
41001545|NCT01959542|OTHER|PSA Blood Test|Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
41001546|NCT01231581|DRUG|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
41001547|NCT01231581|DRUG|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
41001548|NCT01231581|DRUG|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
41001549|NCT03948373|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
41001550|NCT00261742|DRUG|Penicillin versus cefuroxim per os|
41001551|NCT00732810|DRUG|SCH 727965|SCH 727965 50 mg/m\^2 IV on Day 1 of each 21 day cycle until disease progression.
41001552|NCT00732810|DRUG|Capecitabine|Capecitabine 1250 mg/m\^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
40796902|NCT01498692|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
41001553|NCT00732810|DRUG|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
41001554|NCT05888168|PROCEDURE|CABG|All participants in the study will undergo the standard procedure of CABG. Continuous electrocardiogram monitoring and electrocardiography were used to identify the cardiac rhythm.
41001555|NCT04907032|DRUG|Mirabegron 50 MG|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
41001556|NCT04907032|DEVICE|Posterior Tibial Nerve Stimulation (PTNS)|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
41001557|NCT03510117|BEHAVIORAL|Mindfulness|Mindfulness
41001558|NCT00749983|DIETARY_SUPPLEMENT|Creatine supplementation|
41001559|NCT00749983|DIETARY_SUPPLEMENT|Dextrose supplementation|
41001560|NCT05248516|DIETARY_SUPPLEMENT|Simplified dose of ready-to-use therapeutic food (RUTF)|"In the simplified arm all children receive the same dose: 1 sachet of RUTF/day. This until discharge from treatment.~Recovery from treatment will be defined as WAZ\>= -3 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
41001561|NCT05248516|DIETARY_SUPPLEMENT|Standard dose of ready-to-use therapeutic food (RUTF)|"In the standard arm, children will receive different doses of RUTF depending on their WHZ category and weight.~1. children with a WHZ\<-3 will receive the equivalent of 200kcal/kg/d of RUTF until discharge.~2. children with a WHZ between -3 and -2 will receive 1 sachet (500kcal) of RUTF per day until discharge.~3. children with a WHZ\>=-2 will receive no nutritional treatment.~Recovery from treatment will be defined as WHZ\>= -2 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
41001562|NCT05248516|DIETARY_SUPPLEMENT|No nutritional treatment|no nutritional treatment will be provided to children in the control arm.
41001563|NCT01427088|DEVICE|CR Technology, TAMAS for repetitive TMS|repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
41001564|NCT01411163|DRUG|Creatine monohydrate|Up to 30 grams daily creatine monohydrate
41001565|NCT05546684|OTHER|footbath|footbath for patients before sleeping
41001566|NCT02850003|DRUG|IDP-120 Gel|Gel
41001567|NCT04767009|DRUG|PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)|Patients will receive PD-1/PD-L1 inhibitors for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1/PD-L1 inhibitors will be administrated as an intravenous(IV) infusion.
41151117|NCT00002401|DRUG|Lamivudine|
41313665|NCT00448760|DRUG|Leucovorin|Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
41313666|NCT00448760|DRUG|Oxaliplatin|Intravenously, 85 mg/m2, over 2 hours, 2 cycles
41313667|NCT00448760|GENETIC|Microarray analysis|Analysis of tumor for pathologic response to protocol therapy
40796903|NCT02649920|DEVICE|Cervical ripening balloon|
40796904|NCT02649920|DRUG|Dinoprostone|
41151118|NCT00002401|DRUG|Zidovudine|
41151119|NCT06009770|DEVICE|"medical device Homing (TecnoBody); medical device Icone (Heaxel)"|Rehabilitation activities for PD and MS will be aimed at improving motor performance and balance using a task-oriented approach with Homing system technology; post-stroke patients will perform a home-based upper limb rehabilitation with the iCONE robotic device for robot-assisted neurorehabilitation of the upper limb.
41151120|NCT06009770|BEHAVIORAL|Usual Care|Standard motor exercise training aimed at muscle mobilization and strengthening (MS and PD groups) or to mobilize and enhance motor control of upper limb functions (post-stroke group)
41151121|NCT00340184|DRUG|paclitaxel, carboplatin|
41313668|NCT00448760|GENETIC|reverse transcriptase-polymerase chain reaction|Analysis of tumor for pathologic response to protocol therapy
41313669|NCT00448760|PROCEDURE|Conventional surgery|Surgical removal of tumor for correlative studies
41313670|NCT06365515|DRUG|Levodopa administration|To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019). Maximum plasma concentration of Madopar occur \~60 minutes after drug administration. Participants will start the Effort Allocation Task 45 minutes after Levodopa administration.
41313671|NCT06365515|DRUG|Placebo administration|Placebo tablets will be administered as the placebo-controlled condition.
41471862|NCT05540379|DEVICE|Virtual Reality Training|Training the obstetrics and Gynecologist Residents on Virtual endoscopic simulation and skills acquisition
41471863|NCT06292975|OTHER|Supervised Vigorous intensity aerobic interval exercise|7-weeks course of aerobic and resistance exercise, delivered 2 weeks before neoadjuvant radiotherapy (NART), 1 week of NART and 4 weeks post NART.
41471864|NCT04741529|BEHAVIORAL|Healthy Minds Program app|"The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Drs. Richard Davidson and Cortland Dahl. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has \>100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.~Participants in this study will receive 2 weeks of training in the Connection module of HMP."
41471865|NCT04830917|OTHER|Immobilization type for mallet injury|Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury
41471866|NCT03705949|DRUG|Sodium Hyaluronate 0.1% drops|Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
41471867|NCT03705949|DRUG|Sodium Hyaluronate 0.2% drops|Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
41471868|NCT00678327|BIOLOGICAL|bleomycin sulfate|Given IV
41471869|NCT00678327|BIOLOGICAL|filgrastim|Given subcutaneously
41471870|NCT00678327|BIOLOGICAL|pegfilgrastim|Given subcutaneously
41471871|NCT00678327|DRUG|cyclophosphamide|Given IV
41471872|NCT00678327|DRUG|dacarbazine|Given IV
41001568|NCT04767009|RADIATION|SBRT|Patients with oligo-residual NSCLC after effective treatment with PD-1/PD-L1 inhibitors will be treated with curative-intent SBRT of residual lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1/PD-L1 inhibitors will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
41001569|NCT02702401|BIOLOGICAL|Pembrolizumab|IV infusion
41001570|NCT02702401|DRUG|Placebo|0.90% w/v sodium chloride IV infusion
41313672|NCT01919918|DRUG|Muscle Contraction with Metabolite Solution Administration|Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
41471873|NCT00678327|DRUG|doxorubicin hydrochloride|Given IV
41471874|NCT00678327|DRUG|etoposide|Given IV
41471875|NCT00678327|DRUG|prednisolone|Given orally
41471876|NCT00678327|DRUG|procarbazine hydrochloride|Given orally
41471877|NCT00678327|DRUG|vinblastine sulfate|Given IV
41471878|NCT00678327|DRUG|vincristine sulfate|Given IV
40796905|NCT01034982|DRUG|AZD9668|20 mg
41471879|NCT01359579|DRUG|varespladib methyl|Single oral 500 mg dose
40796906|NCT01034982|DRUG|AZD9668|60 mg
40796907|NCT02410642|PROCEDURE|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
40796908|NCT02601638|OTHER|Demographics and Health History Questionnaire|
40796909|NCT02601638|OTHER|Pre-Class Laryngectomy Survey|
40796910|NCT02601638|BEHAVIORAL|Counseling session with speech pathologist|
40796911|NCT02601638|BEHAVIORAL|Total Laryngectomy Preoperative Education Class|
41001571|NCT02702401|OTHER|Best Supportive Care|Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
41151122|NCT00441571|DRUG|177Lu-CYT-500|
41151123|NCT01846988|DEVICE|crossover treatment (REMstar Auto A-Flex)|All subjects will use same device with 4 week crossover of settings of APAP and CPAP
41151124|NCT02178878|GENETIC|Progress, Pain|Progress, Pain
41151125|NCT01684345|DRUG|Placebo|Solution for subcutaneous injection
41151126|NCT01684345|DRUG|Dose 1 gevokizumab|Solution for subcutaneous injection
41151127|NCT01684345|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
41151128|NCT02301104|DRUG|TAS-102|
41151129|NCT00158561|DRUG|sulfadoxine-pyrimethamine and chlorproguanil-dapsone|
41151130|NCT02375607|DEVICE|Algometer|Algometer performed patients
41151131|NCT05347524|OTHER|Baseline blood draw and blood-based biomarkers analyses|Baseline blood draw and blood-based biomarkers analyses
41151132|NCT03663699|BEHAVIORAL|Exergaming|free access to the exergaming platform PlayPulse for 24 weeks
41471880|NCT05902468|DRUG|Ursodeoxycholic acid|ursodeoxycholic acid 500 mg orally twice daily for 12 weeks
41471881|NCT04703543|DEVICE|Pilot evaluation study on use PSMA and Cu-PET/CT|This study aims at assessing the detection rate of both PSMA and Cu-PET/CT on tissue relapse, study whether this method is equivalent to mpMR
41471882|NCT01974882|OTHER|Ice pack|Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
41471883|NCT05717270|PROCEDURE|Two-layered suture repair|The ruptured Achilles tendon will be sutured in two-layer.
41471884|NCT05863559|BEHAVIORAL|Super Chef: Family Fun in the Kitchen!|Two-phase intervention: in the online phase, a professional chef will demonstrate cooking strategies to help families modify existing recipes to be consistent with the Mediterranean Dietary pattern. Effective food parenting practices will also be integrated into the intervention. The intervention is guided by theory - Family Systems, Social Cognitive, and Self Determination - and gamification techniques. At the end of the online phase, dyads will set a goal to use the cooking strategy and make a plan to facilitate goal attainment. In the home phase, the dyad will work together to use the plan to meet the goal. Dyads can also participate in bonus activities. Prior to viewing the next session, dyads will report whether the goal was attained and any bonus activities completed. Collectively, this will determine level of Super Chef status the family achieves at the end of the program (Session 4).
41471885|NCT06230627|OTHER|Home-Based Rehabilitation rogram|The intervention is distinguished from others in that it applies to patients' homes and the trial was followed up in the middle of complex conditions of the COVID-19 Pandemic. Also, the challenge was represented by the HBRP applied to patients with SCIs after 4-5 years of rehabilitation interruption.
41471886|NCT05196100|DEVICE|Amparo confidence socket|Confidence socket involves thermoplastic material being moulded onto the patient's residual limb and a socket is produced in a single session. The socket can be remoulded to adjust to changes in residual limb volume.
41471887|NCT00172068|DRUG|Zoledronic acid + Calcium/Vitamin D|
41471888|NCT06193031|DRUG|C16TR|Administered as inhalation using a Philips Micro device inhaler.
41313673|NCT03806179|DRUG|10 MBq/kg Betalutin|10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
41313674|NCT03806179|DRUG|15 MBq/kg Betalutin|15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
41313675|NCT03361319|DRUG|Vargatef|small molecule triple kinase inhibitor
41313676|NCT03361319|DRUG|Abraxane|Paclitaxel formulated as albumin bound nanoparticles
41313677|NCT03361319|OTHER|placebo|Placebo in place of Ninedanib
41471889|NCT06193031|DRUG|Placebo|Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.
41471890|NCT06193031|DRUG|Tyvaso®|Administered as inhalation.
41471891|NCT00895037|DRUG|ReFacto AF (Moroctocog alfa)|Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
41471892|NCT04598360|PROCEDURE|Heart-Lung-Machine|blood sample before and during a single Heart-Lung-Machine procedure
41471893|NCT02319057|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
41471894|NCT02319057|DRUG|ORM-12741 IR|Immediate release formulation of ORM-12741
41471895|NCT02319057|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
41471896|NCT06427369|OTHER|Radioconjugate|1241-hJAA-F11 IV administration
41471897|NCT06427369|PROCEDURE|Positron Emission Tomography|PET/CT Imaging
41001572|NCT04563091|DEVICE|Hemodialysis with online HFR|"1. Hemodialytic therapy using 240-minute online HFR on Flexya® hemodialysis machine (Medtronic, Mirandola, Italy). The blood flow from vascular access will be maintained at values \> 250 ml/minute, the flow of dialysis fluid will be 500 ml/minute. Weight loss during dialytic treatment will be prescribed according to the patient's clinical needs.~2. Assess potassium (intra and extra cellular), sodium, bicarbonatemia, calcemia, urea, blood sugar values and ECG every 30 minutes during dialysis and every 60 minutes after dialysis.~3. Body impedance analysis at time 0 at 240 minutes, after 60 minutes after the end of dialysis and after 7 hours after the end of dialysis.~4. Use of the Natrium sensor (Medtronic, Mirandola, Italy) during HFR dialytic treatment."
41313678|NCT05140954|DRUG|co-formulated 25mg TAF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC
41313679|NCT03209635|DIETARY_SUPPLEMENT|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
41313680|NCT03209635|DIETARY_SUPPLEMENT|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
41313681|NCT01098461|BIOLOGICAL|albiglutide|subcutaneous injection of albiglutide
41313682|NCT01098461|BIOLOGICAL|placebo|subcutaneous injection of placebo to match albiglutide
41313683|NCT02657551|DRUG|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
41313684|NCT03034759|OTHER|individualized insulin sensitivity index (ISind)|"The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads."
41471898|NCT06427369|PROCEDURE|Computed Tomography|PET/CT Imaging
41471899|NCT06427369|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|FDG PET/CT Imaging
41471900|NCT06427369|PROCEDURE|Biospecimen Collection|Blood sample collection imaging
41471901|NCT04013698|OTHER|PEEP level 5 cmH2O|PEEP level set for 45 minutes
41471902|NCT04013698|OTHER|PEEP level 15 cmH2O|PEEP level set for 45 minutes
40796912|NCT02601638|OTHER|Day of Hospital Discharge Laryngectomy Survey|
41313685|NCT05394740|DRUG|Regorafenib|"90 mg administered orally, once daily for 21 consecutive days followed by 7 days off~\*Repeat every 4 weeks as Regorafenib therapy"
41313686|NCT05394740|DRUG|Nivolumab|CohotA:360 mg administered intravenously, every 3 weeks \*Administered on the same day as CapeOX therapy Cohort B: 240 mg administered intravenously, every 2 weeks \*Administered on the same day as FOLFOX therapy
41471903|NCT06590467|DEVICE|Amplatzer™ Occlusion Devices|The Amplatzer™ Occluders are devices intended for the occlusion of multiple septal heart defects.
41471904|NCT06590467|DEVICE|Epic™ Surgical Tissue Heart Valve devices|The Epic™ valves are indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic/mitral heart valve. It may also be used as a replacement for a previously implanted aortic/mitral prosthetic heart valve.
41471905|NCT04922450|DRUG|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/3weeks)
41471906|NCT04922450|DRUG|Albumin Paclitaxel|Albumin Paclitaxel(260mg/m²),every 3 weeks
41471907|NCT04922450|DRUG|Cisplatin|Cisplatin（80mg/m²）, every 3 weeks
41471908|NCT05565261|DEVICE|complete denture|Bite force was measured with a bite force measuring device. Quality of life and patient satisfaction were evaluated with questionnaires.
40796913|NCT02601638|OTHER|Day of Discharge Practicum|
40796914|NCT02601638|OTHER|Laryngectomy Education Study Exit Survey|
40796915|NCT03699397|DIAGNOSTIC_TEST|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. To do this, the investigators will use the WaveguardTM dry electrode EEG cap and compatible eegoTM amplifier, developed by ANT Neuro B.V. Netherlands and both CE marked as medical devices in the European Union (see appendices 1 and 2). Both products will be used within the intended use as described in the user manuals. The dry electrode cap is put on the patients head and records the EEG signal for several minutes; the amplifier is used to amplify the EEG signal and reduce artefacts.
40796916|NCT01632592|DRUG|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
41313687|NCT05394740|DRUG|CapeOX|"For Cohort A only~* Capecitabine 1,000 mg/m\^2 administered orally, twice daily (Days 1 to 14 continuous dosing of CapeOX therapy)~* Oxaliplatin 130 mg/m\^2 administered intravenously (Day 1 of CapeOX therapy) \*Repeat every 3 weeks as CapeOX therapy"
41313688|NCT05394740|DRUG|FOLFOX regimen|"For Cohort B only~* Leucovorin 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy)~* Fluorouracil 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) and 1,200 mg/m2 administered intravenously (Days 1 to 2 of FOLFOX therapy)~* Oxaliplatin 85 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) \*Repeat every 2 weeks as FOLFOX therapy"
41471909|NCT00876356|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
40796917|NCT01632592|DRUG|Placebo|placebo given by injection 2mg subcutaneously daily
40796918|NCT01895400|DRUG|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
40796919|NCT01895400|DRUG|Placebo|Take placebo drug 1T bid po medication for 8 weeks
40796920|NCT01084577|DEVICE|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
40796921|NCT01084577|DEVICE|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
40796922|NCT05828719|PROCEDURE|Percutaneous coronary intervention|"Revascularization indication~1. Diameter stenosis \>90% by visual assessment~2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)~3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.~   * Left main artery~  * Proximal to mid left anterior descending artery~  * Proximal left circumflex artery in left dominant coronary arterial system~  * Proximal to distal right coronary artery in right dominant coronary arterial system"
40796923|NCT05336929|OTHER|Roy adaptation model-based nursing education|
41313689|NCT04949555|OTHER|Primary congenital glaucoma evaluation|long term evaluation of primary congenital glaucoma management
41313690|NCT01062620|DRUG|AXL1717|Phase I study with increasing dosage and treatment duration
41471910|NCT00876356|DIETARY_SUPPLEMENT|Olive oil|Olive oil 4.5g/day x 12 weeks
41471911|NCT01396382|RADIATION|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography (PET). Efficacy of the 68Ga-DOTATATE PET scan was assessed and compared to 111In-Pentetreotide scan and to scans with CT and/or MRI. Safety and toxicity were also assessed with pre-injection and post-imaging vital signs, pulse oximetry on room air, 12 lead ECGs, and blood laboratory tests, including tumor markers, liver and renal functions and blood counts, and direct patient questioning. Late delayed tumor markers, liver and renal functions and blood counts were assessed when available.
41471912|NCT00418522|DRUG|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
41471913|NCT00418522|DRUG|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
41471914|NCT05644886|BEHAVIORAL|FP Training and Technical Support|Same as in Intervention arm description
41471915|NCT04007471|OTHER|Anonymous survey|Anonymous questionnaire to determine the prevalence of dysmenorrhea of adolescent girls, to assess the severity of dysmenorrhea, how girls experience their menses, the consequences on daily living activities or at school, and how they manage their pain.
41471916|NCT00729131|DRUG|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
41471917|NCT04248517|OTHER|mHealth Intervention|Participants will download the app onto their smartphone and complete ecological momentary assessements
41471918|NCT01303068|DEVICE|13C urea breath test Kit|20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas
41471919|NCT00966381|OTHER|Exercise and weight loss intervention|randomized control trial, stratified by parity
41471920|NCT04594005|DRUG|abemaciclib+paclitaxel|"Phase 1b: About 3-6 patients enrollment is expected at dose level 1, -1 and -2. Dose reduction will be preceded with 3 patients/cohort until the first DLT with 4 weeks' observation. The recommend phase 2 dose (RP2D) will be defined.~level1: abemaciclib 100mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level-1: abemaciclib 100mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks level-2: abemaciclib 50mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks~Phase2: At the RP2D dose level in phase I part, we will expand phase 2 study."
41471921|NCT04425122|DIAGNOSTIC_TEST|Upper endoscopy|Upper endoscopy would be performed. Biopsy would be taken from oesophageal cancer tissue and adjacent non-cancerous mucosa
41471922|NCT04425122|DIAGNOSTIC_TEST|Upper endoscopy|Upper endoscopy would be performed. Random biopsy would be taken from normal non-cancer esophageal mucosa.
40796924|NCT00399568|DRUG|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
41471923|NCT02792218|DRUG|Ofatumumab subcutaneous injection|Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
41471924|NCT02792218|DRUG|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
40796925|NCT00399568|DRUG|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
40796926|NCT05360251|DEVICE|PDL(595nm)|One subject was treated with pulsed dye laser (Vbeam platinum, 595 nm, Candela Corporation): energy dosages of 9-11 J/cm2, pulse durations of 10/20 ms, and spot size of 7 mm.
40796927|NCT05360251|DEVICE|IPL(DPL)|One subject was treated with IPL(delicate Pulsed Light, Dye-VL, Alma Lasers Corporation): energy dosages of 8.4-10.6 J/cm2, pulse durations of 10/12 ms, and spot size of 10×30 mm.
40796928|NCT05360251|DEVICE|IPL(M22 590)|One subject was treated with IPL(M22 590, 590-1200nm, Lumenis Limited): energy dosages of 15-18 J/cm2, pulse durations of 3-4 ms, pulse delay of 30-40 ms, and spot size of 15×35 mm.
40796929|NCT05360251|DEVICE|IPL(M22 vascular)|One subject was treated with IPL(M22 vascular, 530-650nm and 900-1200nm, Lumenis Limited): energy dosages of 9-17 J/cm2, pulse durations of 4-6 ms, pulse delay of 20-40 ms, and spot size of 15×35 mm.
41001573|NCT01998048|PROCEDURE|Latarjet|A diagnostic arthroscopy is performed before the Latarjet operation in general anaesthesia. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeons' decision by inserting 1 to 2 more suture anchors according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect. Thereafter an open Latarjet operation is performed using standard techniques described by Walch or de Beer. A deltopectoral incision is used. The coracoid process is osteotomized and ventrally prepared to bleeding bone. The coracoid process is then transferred through the middle of the subscapularis and re-attached on to the freshened neck of the glenoid, just medial to the joint line with two screws and washers, according to the surgeon's preference.
41471925|NCT02792218|DRUG|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
41471926|NCT02792218|DRUG|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
40796930|NCT06080763|PROCEDURE|Physical Therapy Management|Physical therapy management is a routine intervention provided by physical therapists at Mahidol University's Physical Therapy Center for individuals with knee osteoarthritis.
40796931|NCT02036580|BIOLOGICAL|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
40796932|NCT02036580|BIOLOGICAL|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
41471927|NCT06102824|DRUG|Organoid-guided treatment|The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
40796933|NCT02036580|OTHER|Placebo|
40796934|NCT02460068|DRUG|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
41313691|NCT06439563|DRUG|JP-1366 10 mg|JP-1366 10 mg, tablet, orally once a day for up to 24 weeks
41313692|NCT06439563|DRUG|Lanston Capsule 15 mg|Lanston Capsule 15 mg orally once a day for up to 24 weeks
40796935|NCT02460068|DRUG|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
40796936|NCT02460068|DRUG|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
41313693|NCT06439563|DRUG|JP-1366 10 mg placebo|JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks
41313694|NCT06439563|DRUG|Lanston Capsule 15 mg placebo|Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
40796937|NCT03571750|BEHAVIORAL|Building Stronger Allies|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
40796938|NCT03571750|BEHAVIORAL|Health Education Training|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
40796939|NCT02018536|DRUG|GSK2336805 30 mg|A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
40796940|NCT02018536|DRUG|GSK2336805 60 mg|A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
40796941|NCT02018536|DRUG|GSK2336805 120 mg|A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
40796942|NCT02018536|DRUG|TMC435 150 mg (Treatment A)|1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
40796943|NCT02018536|DRUG|GSK2336805 60 mg (Treatment B and part of Treatment C and D)|2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
40796944|NCT02018536|DRUG|TMC435 100 mg (part of Treatment C)|1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
41313695|NCT03143868|BEHAVIORAL|Exercise Modality|The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
41313696|NCT04325594|PROCEDURE|Cardiac catheterization|Catheterization of the right and left heart cavities
41313697|NCT04325594|BIOLOGICAL|Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells|After performing cardiac catheterization, selective coronary angiography will be performed abruptly to assess the condition of the coronary canal by access through the right radial or common femoral artery on the right after 70 U/kg of heparin iv. Then 20 ml of the finished suspension (1×10(7) umbilical cord-derived mesenchymal stromal cells diluted in 20 ml of heparinized saline) will be administrated into the mouth of the left coronary artery (LCA) without occlusion of the vessel with a balloon catheter and without stopping the coronary blood flow. Cell injection will be carried out using a standard 6 Fr catheter for selective coronary angiography with perfusion for 10 minutes at a volume rate of 2 ml/min, thereby introducing 1×10(6) cells per minute
41313698|NCT05422352|DIETARY_SUPPLEMENT|Carnosine|Patients who will receive carnosine supplementation 500mg capsules (Now foods) in combination with Vitamin B complex (B1+B6+B12, 150 mg+100 mg+1 mg, respectively, Neurovit, European Egyptian Pharm. Ind., Egypt), two tablets per day
40796945|NCT02018536|DRUG|TMC435 150 mg (part of treatment D)|1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
41313699|NCT06233734|DEVICE|The Lokomat (Hocoma, Zurich, Switzerland).|The Lokomat is a device which can be used to implement robot-assisted gait training safely within disabled stroke populations. The robot-assisted gait training group will receive training via the Lokomat. Involvement in the study will not influence the duration or frequency of robot-assisted gait training sessions they receive. The amount of training they receive via the Lokomat will be determined (as per standard care) by the care team at the stroke ward.
41471928|NCT06102824|DRUG|Taxane|Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w
41313700|NCT02852148|DEVICE|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
41471929|NCT06102824|DRUG|Capecitabine|1000-1250mg/m2, PO, bid, days1-14, q3w
40796946|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)|The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
40796947|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training (RAS)|The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.
41471930|NCT06102824|DRUG|Gemcitabine|800-1200mg/m2, IV, days 1, 8, q3w
40796948|NCT03838614|BEHAVIORAL|Muscle power training (MPT)|The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.
40796949|NCT03838614|OTHER|Controls|Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
40796950|NCT03964168|DRUG|Biologic Agent|Patients who discontinued a bioloic agent
40796951|NCT05542498|BEHAVIORAL|Mindfulness|Training is focused on learning and applying the principles of R.A.I.N. (Recognize, Allow, Investigate, Non-identify) in the context of physics learning.
40796952|NCT05542498|BEHAVIORAL|Relaxation|Training is focused on learning and applying relaxation practices (e.g., progressive muscle relaxation, guided imagery) in the context of physics learning.
40796953|NCT05719779|DEVICE|Ronco-Onco and MAD|Comparison of active over a neutral mandibular advacement oral appliance to assess tolerance and efficacy in oropharyngeal cancer individuals in managing snoring and sleep apnea following radiotherapy of oropharynx.
40796954|NCT04628702|BEHAVIORAL|tablet training|1.5 year training period
40796955|NCT00400855|DRUG|Fluticasone propionate|Study drug
40796956|NCT01642056|DRUG|EPI-743|This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
40796957|NCT01642056|DRUG|Placebo|
40796958|NCT00288886|BEHAVIORAL|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
40796959|NCT00288886|BEHAVIORAL|Control arm|Routine residential treatment and orientation to continuing care.
41471931|NCT06102824|DRUG|Vinorelbine|20-35mg/m2, IV, days 1 and 8, q3w
41471932|NCT06102824|DRUG|Eribulin|1.4mg/m2, IV, days 1 and 8, q3w
41471933|NCT06102824|DRUG|Anthracycline|Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
41471934|NCT06102824|DRUG|Carboplatin|Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w
41471935|NCT06102824|DRUG|Utidelone|30mg/m2, IV, once per day on days 1-5, q3w
41471936|NCT06102824|DRUG|Trastuzumab deruxtecan|5.4mg/kg, IV, q3w
41471937|NCT06102824|DRUG|Sacituzumab govitecan|10mg/kg, IV, days 1 and 8, q3w
41471938|NCT01891812|DRUG|Nitrous oxide 50%|
40796960|NCT03125330|BEHAVIORAL|Professional coaching|Professional coaching is provided by the Principal Investigator via video conference.
40796961|NCT00626782|DRUG|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
40796962|NCT00626782|DRUG|Mitomycin (MMC)|Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
40796963|NCT04079231|DRUG|Brolucizumab|Intravitreal Injection
41151133|NCT01502605|DRUG|5-Aminolevulinic Acid|A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
41151134|NCT01818453|BEHAVIORAL|Computerized self-help program for depression|For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
41151135|NCT00841945|DRUG|rituximab|RITUXIMAB 375 MG/M² IV DAY 1 or each course
40796964|NCT04079231|DRUG|Aflibercept|Intravitreal injection
40796965|NCT03587896|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
40796966|NCT00373646|DRUG|Thalidomide, Pharmion|200 mg p.o. daily
40796967|NCT03857932|PROCEDURE|Participants receive SLNB as well as non SLNs resection|Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
40796968|NCT03503396|BEHAVIORAL|BAC Driving Feedback/Warning|Participants will receive a warning at a set BAC limit, indicating they are too impaired to drive.
40796969|NCT03503396|BEHAVIORAL|No Feedback|Participants will receive no information about BAC, but will still complete study assessments and provide breath samples during drinking sessions.
41001574|NCT01998048|PROCEDURE|Bankart|An arthroscopic Bankart operation is performed in general anaesthesia according to current practise (Provencher 2010). The intra-articular findings are recorded and the anteroinferior labrum and the IGHL are mobilized until subscapular muscle fibers can be seen. The IGHL complex is then re-attached to the freshened neck of the glenoid with 2 to 3 suture anchors according to surgeon's preference to re-create labral bumper and capsular tension. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeon's decision by inserting 1 to 2 more suture anchors, according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect.
41001575|NCT05439408|DRUG|Dasatinib ASD 100 mg|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation
41001576|NCT05439408|DRUG|Dasatinib 140 MG [Sprycel]|SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets
41001577|NCT05230212|OTHER|Pecan Breakfast Shake|The pecan breakfast shake contains 68 grams of blended raw pecans. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
40796970|NCT03221465|BEHAVIORAL|Self-monitoring of physical activity with incentives|Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
40796971|NCT03221465|BEHAVIORAL|Usual care and self-monitoring of physical activity|Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
40796972|NCT01771991|DRUG|Topical Sodermix Dismutase in the form of Sodermix (SOD)|Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
40796973|NCT01771991|DRUG|Placebo|Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
40796974|NCT06307990|GENETIC|NGS sequencing|analysis of candidate genes for RTHs syndromes, transporters defects or gene involved in thyroid hormone metabolism. Whole exome sequencing (WES) in a minority of cases
40796975|NCT06307990|DIAGNOSTIC_TEST|serological tests|assessment of T4, T3 and other TH metabolites (LC-MS) in serum and dried blood spots
40796976|NCT02709577|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
40796977|NCT02709577|OTHER|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
41001578|NCT05230212|OTHER|Cream Breakfast Shake|The cream breakfast shake contains 138 grams of heavy whipping cream. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
41151136|NCT00841945|DRUG|doxorubicin|doxorubicin 50 mg / m² iv day 1 of each course
41471939|NCT05288166|DRUG|Abemaciclib|Administered orally.
40796978|NCT02536716|PROCEDURE|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
40796979|NCT02536716|PROCEDURE|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
40796980|NCT02515968|DRUG|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
40796981|NCT02515968|DRUG|Propofol|
40796982|NCT01720589|DIETARY_SUPPLEMENT|Melt (test oil)|
40796983|NCT01720589|DIETARY_SUPPLEMENT|Corn oil (control)|
40796984|NCT01596855|DRUG|FG-4592|TIW dosing, capsule
40796985|NCT01596855|DRUG|Epoetin Alfa|TIW
40796986|NCT06214676|DEVICE|OCT angiography|Detection of microvascular changes in patients with primary open angle glaucoma by using Optical Coherence Tomography Angiography
40796987|NCT03520296|OTHER|Questionnaire|Questionnaire evaluating well-being in relation to diet and nutrition
40796988|NCT05127408|PROCEDURE|Interventional Endoscopy|correct defects of the gastrointestinal tract.
40796989|NCT04224441|DRUG|Chlorpromazine Pill|The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide
40796990|NCT02209792|DRUG|Placebo|
40796991|NCT02209792|DRUG|BIBR 796 BS, 5 mg|
40796992|NCT02209792|DRUG|BIBR 796 BS, 20 mg|
40796993|NCT01143909|OTHER|omitting FFP transfusion before an intervention|In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
41001579|NCT01009099|OTHER|breathing retraining|breathing retraining using a metronome
41001580|NCT01009099|OTHER|exercise training|treadmill exercise training
41001581|NCT02888327|DRUG|AL-794|
41001582|NCT02888327|DRUG|Oseltamivir|
41001583|NCT02888327|DRUG|Digoxin|
41001584|NCT02888327|DRUG|Midazolam|
41001585|NCT02888327|DRUG|Pitavastatin|
41001586|NCT02888327|DRUG|JNJ-63623872|
41001587|NCT04226482|DEVICE|New Device|Laparoscopic appendectomy using new ultrasonic shears.
41001588|NCT04226482|DEVICE|Used Device|Laparoscopic appendectomy using reprocessed ultrasonic shears.
41001589|NCT02464202|OTHER|stereolithography tooth replica|Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
41001590|NCT02467556|DRUG|Morphine, memantine|Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
41151137|NCT00841945|DRUG|vincristine|VINCRISTINE 1?4 MG/M² IV ON DAY 1
41151138|NCT00841945|DRUG|prednisone|Prednisone 40 mg/m² DAy 1 to day 5
41151139|NCT00841945|PROCEDURE|radiotherapy|radiotherapy : total dose = 40 GY (5 fractions by week)
41151140|NCT02374476|DEVICE|Bipolar Ablation|Patients will undergo bipolar ablation if unipolar ablation unsuccessful
41471940|NCT05288166|DRUG|Abiraterone|Administered orally.
41471941|NCT05288166|DRUG|Prednisone or Prednisolone|Administered orally.
41313701|NCT01965236|DIETARY_SUPPLEMENT|sodium chloride|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
40796994|NCT05944588|OTHER|Pulmonary Ultrasound|2 pulmonary ultrasound exams, one before respiratory weaning test, and one other at the end of the respiratory weaning test, before extubation
40796995|NCT03451487|DRUG|Panadol®|Acetaminophen 500mg Tablet
40796996|NCT03451487|DRUG|SafeTynadol®|Acetaminophen 500mg Tablet
40796997|NCT05010070|BEHAVIORAL|diet and lifestyle program|See description of main arm.
40796998|NCT06196151|BEHAVIORAL|Antenatal training|"Training hours: Training will be completed in a total of three weeks and six hours, two hours each week.~Method: The training will be given online via Zoom application. The training will consist of a total of three weeks and six hours, two hours each week. Informed Voluntary Consent Form will be obtained from individuals in both groups. Pregnant women in both the control and intervention groups will be asked to fill out the Women's Introductory Information Form. The data of the intervention group will be filled out before the first Antenatal education lesson and after all six-hour Antenatal education lessons are completed. The data of the control group will be filled in parallel with the intervention group.~Group to receive the training: Healthy pregnant women who are at the 20th gestational week at the earliest will be included in the training. Trainings will be carried out in closed groups."
40796999|NCT05253742|OTHER|No intervention - the investigators are evaluating a new image acquisition method on an MRI scanner|The investigators will evaluate the performance of a modified MRI acquisition method against an existing method in fetal imaging in volunteers
40797000|NCT02835703|PROCEDURE|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
40797001|NCT04548427|DRUG|CKD-352|Eye Drop
40797002|NCT04548427|DRUG|Diquafosol Sodium 3%|Eye Drop
40797003|NCT06470620|DIAGNOSTIC_TEST|pelvic floor muscle assessment|no intervention will be performed - several diagnostic assessments tools
40797004|NCT03115411|DEVICE|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
41313702|NCT01965236|DIETARY_SUPPLEMENT|Placebo|
41313703|NCT00484536|DRUG|CDP323|250 mg capsules, 500 mg bid (1000 mg/day)
41313704|NCT00484536|DRUG|placebo|capsules, once daily
41471942|NCT05288166|DRUG|Placebo for Abemaciclib|Administered orally.
41471943|NCT02264535|DRUG|0.1mg/ml Ginkgolides Meglumine Injection|
40797005|NCT05027347|DIAGNOSTIC_TEST|plasma circulating tumor DNA|A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
40797006|NCT04281420|DRUG|ATG-019|ATG-019 30 mg QoD×3 is selected as the staring dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
41313705|NCT00484536|DRUG|CDP323|250 mg Capsules, 500 mg, once daily
40797007|NCT04281420|COMBINATION_PRODUCT|ATG-019 + Niacin ER|ATG-019 60 mg is selected as starting dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle. And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
40797008|NCT02998671|BIOLOGICAL|CJM112|
40797009|NCT02998671|OTHER|Placebo|
40797010|NCT01515579|DRUG|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
40797011|NCT01515579|DRUG|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
40797012|NCT01833858|DRUG|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
40797013|NCT01833858|DRUG|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
40797014|NCT05924581|OTHER|Clinical assessment of spinal stiffness|"The clinical stiffness tests will be applied twice to the same patient by the same operator to verify intra-operator variability and twice by two operators at the same time to verify inter-operator variability.~The verification of diagnostic accuracy with respect to the radiographic reference standard will be carried out retrospectively by using the data already available and systematically collected in electronic format during medical visits and physiotherapy sessions."
40797015|NCT05582356|DIETARY_SUPPLEMENT|Carbohydrate group (Group OC)|Carbohydrate group (Group OC)
40797016|NCT05582356|DIETARY_SUPPLEMENT|Placebo group (Group OP|Placebo group (Group OP
40797017|NCT01823107|DEVICE|Meso BioMatrix Device|
40797018|NCT05320484|OTHER|Clinical Pilates Exercises|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
41313706|NCT02526758|DRUG|beclomethasone|
41313707|NCT02526758|DRUG|formoterol|
41313708|NCT02526758|DRUG|budesonide|
41313709|NCT02247674|PROCEDURE|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
41471944|NCT02264535|DRUG|1mg/ml Ginkgolides Meglumine Injection|
41471945|NCT02264535|DRUG|5mg/ml Ginkgolides Meglumine Injection|
41471946|NCT02067767|DRUG|Abacavir/Lamivudine/Dolutegravir|"At Day 1 (D1):~* group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;~* group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1."
41471947|NCT02334241|DEVICE|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
41471948|NCT02334241|DEVICE|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
41471949|NCT00030524|DRUG|gefitinib|
41471950|NCT01163084|DRUG|Goserelin Acetate|Given SC
41471951|NCT01163084|OTHER|Laboratory Biomarker Analysis|Correlative studies
41471952|NCT01163084|DRUG|Leuprolide Acetate|Given IM
41471953|NCT01163084|DRUG|Vismodegib|Given PO
41471954|NCT05340192|DRUG|Octreotide 1 MG/ML|100 mcg (1 ml) of Octreotide
41471955|NCT03400280|OTHER|Best practice algorithm for postoperative care|See arm/group description
41471956|NCT00745134|DRUG|Capecitabine|Given PO
41471957|NCT00745134|DIETARY_SUPPLEMENT|Curcumin|Given PO
40797019|NCT05320484|OTHER|Classic Posture exercise|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
40797020|NCT00848887|BIOLOGICAL|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
40797021|NCT02089932|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."
40797022|NCT02089932|DRUG|Placebo|
40797023|NCT05985798|DRUG|Sin-Bev-TACE|Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.
40797024|NCT05985798|DRUG|Len-TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated on demand.
41313710|NCT03609658|BEHAVIORAL|Nurse Navigator Pathway|In the Nurse Navigator Pathway, nurse navigators are being used as leverage to: approach qualified patients to initiate advance care planning discussions, schedule advance care planning visit with patients' primary care provider to further discuss advance care planning and to mail advance care planning resources to patients after their initial advance care planning discussion.
41313711|NCT03609658|BEHAVIORAL|Usual Care|In the Usual Care arm, there is no approach by nurse navigators to initiate advance care planning discussions and it does not have a structure advance care planning visit. Therefore, no further action is required for the patients who were randomly assigned to the usual care arm.
41313712|NCT04900480|OTHER|Direct access to publicly subsidized physiotherapy|This pilot project introduces temporary exemption on the legal required GP referral for public subsidy for treatment in general physiotherapy.
41313713|NCT00625521|DRUG|ASF 1096 0.5 % cream applied twice daily|
41313714|NCT00625521|DRUG|Cream vehicle for ASF 1096 cream applied twice daily|
41313715|NCT02492997|DEVICE|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
41471958|NCT00745134|OTHER|Laboratory Biomarker Analysis|Correlative studies
41471959|NCT00745134|OTHER|Pharmacological Study|Optional correlative studies
40797025|NCT03585725|DRUG|Ribavirin|"Ribavirin is FDA-approved oral medication for antiviral indications. Ribavirin will be obtained commercially for this trial.~Treatment will be administered on an outpatient basis. Ribavirin should be administered with food."
40797026|NCT05968248|PROCEDURE|MLR-DBS|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously. Device: MLR-DBS devices~(1) DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); (2) Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); (3) Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
40797027|NCT05968248|PROCEDURE|Conventional rehabilitation group|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.The latter will receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
40797028|NCT02644252|DRUG|Day 1: Cisplatin 75 mg/m2|
40797029|NCT02644252|DRUG|Day 1: Vinorelbine 25 mg/m2|
40797030|NCT02644252|DRUG|Day 8: Capsule vinorelbine 50 mg/m2|
40797031|NCT02644252|DRUG|Day 1: Carboplatin AUC=5|
40797032|NCT02644252|DRUG|Day 1: Vinorelbine 30 mg/m2|
40797033|NCT02644252|DRUG|Day 8: Capsule vinorelbine 60 mg/m2|
40797034|NCT02644252|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily until progression|
40797035|NCT02644252|DRUG|Placebo 1 capsule x 3 daily until progression|
41471960|NCT00745134|OTHER|Placebo|Given PO
41471961|NCT00745134|OTHER|Quality-of-Life Assessment|Ancillary studies
41471962|NCT00745134|RADIATION|Radiation Therapy|Undergo radiation therapy
41471963|NCT01863056|OTHER|Sit-Stand Desk|Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
41471964|NCT04855448|DEVICE|Micro Hand S robot and da Vinci robot|The surgeries are performed with the Micro Hand S robot and da Vinci robot
41471965|NCT04855448|DEVICE|da Vinci robot|The surgeries are performed with the da Vinci robot
41313716|NCT02492997|OTHER|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
41471966|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily from the time of randomization until delivery.
41471967|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
41471968|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
41471969|NCT04572139|DIAGNOSTIC_TEST|Pituitary stimulation test|Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH
41471970|NCT01381263|BEHAVIORAL|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
41471971|NCT01381263|OTHER|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
41471972|NCT01119807|DEVICE|Intravenous access during OHCA|First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.
41471973|NCT01119807|DEVICE|Humeral IO insertion|First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.
41471974|NCT01119807|DEVICE|TIbial IO insertion|First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
41471975|NCT06468696|PROCEDURE|Suturing the cervical linea alba during endoscopic thyroid surgery.|Suturing the cervical linea alba during endoscopic thyroid surgery.
41471976|NCT06468696|GENETIC|Performing transcriptome sequencing|Performing transcriptome sequencing
41471977|NCT05403619|DIAGNOSTIC_TEST|Diagnostic test|Cardiac Ultrasound in order to explore the causes of shortness of breath
41471978|NCT06102499|DEVICE|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded
41471979|NCT01613378|OTHER|No intervention|No intervention administered in this study
41471980|NCT04373629|BEHAVIORAL|attentional modulation|Attentional instructions when viewing faces will be given
41471981|NCT04373629|OTHER|perceptual modulation|Faces will be presented of varying durations
41471982|NCT04373629|OTHER|naturalistic viewing|Faces will be viewed without specific instructions
41471983|NCT04692025|DRUG|ASC41 tablet|Oral tablet
41471984|NCT00442546|DRUG|pregabalin|150 milligram (mg)/ day (double blind)
41471985|NCT00442546|DRUG|pregabalin|300 mg/day (double blind)
41313717|NCT01096043|DRUG|Placebo|An infusion of an identically appearing solution of sugar water will be intravenously administered.
41313718|NCT01096043|DRUG|Strata 1 CXL-1020|Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
41471986|NCT00442546|DRUG|Placebo|Placebo
40797036|NCT03761589|BEHAVIORAL|AFL Intervention|The AFL intervention consisted of two 90-minute sessions per week for 12 months for both children and parents. The child physical activity sessions, held separately from the parent sessions, aimed to achieve 60 minutes of moderate-to-vigorous physical activity during each session through structured play activities, athletic drills, and sport exercises. Child dietary behaviors were taught through educational activities in small groups. For the parent program, behavior modification techniques were used to guide parents toward changing their own and their child's behavior. Take-home materials for self-monitoring of behaviors were used for both the child and the parent in order to reinforce concepts discussed in class.
41313719|NCT01096043|DRUG|Strata 2 CXL-1020|One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
41313720|NCT01096043|DRUG|Strata 3 CXL-1020|A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
41313721|NCT03427905|PROCEDURE|Lipoaspiration|Procedure: Lipoaspiration of fat and processing for the isolation of SVF Procedure: Transplantation
41471987|NCT00465231|DRUG|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
41471988|NCT00465231|DRUG|preservative free saline|10mL saline solution
41471989|NCT03082235|DRUG|E6742|gelatin capsules
41471990|NCT03082235|DRUG|Placebo|gelatin capsules
41471991|NCT05802446|OTHER|Real-time fMRI Neurofeedback|Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant. With this feedback on brain activity, subjects can learn to control the activity of selected brain areas. Trial after trial, participants develop their individual strategies to voluntarily regulate the signal. The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback. By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.
41471992|NCT06616623|BIOLOGICAL|Atezolizumab|Given IV
41471993|NCT06616623|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
41471994|NCT06616623|PROCEDURE|Computed Tomography|Undergo CT
41471995|NCT06616623|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41471996|NCT06616623|DRUG|Vismodegib|Given PO
41471997|NCT00092950|BEHAVIORAL|Physical activity|
41471998|NCT03997786|DRUG|Tildrakizumab|Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
41471999|NCT03997786|DRUG|Placebo|(Weeks 0 to 16)
41472000|NCT03997786|DRUG|Tildrakizumab|(Weeks 16 to 52)
41313722|NCT03427905|PROCEDURE|Transplantation|Procedure: Lipoaspiration of fat and processing for the isolation of SVF and culture for the obtention of ADSCS Procedure: Transplantation
41313723|NCT00849121|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
41313724|NCT00849121|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
41313725|NCT01142284|DRUG|Cilostazol, Probucol|"Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID"
41313726|NCT05120999|DEVICE|Train of four measurement|Use of either TetraGraph or TOFScan to measure the neuromuscular blockade
41313727|NCT02504268|DRUG|Abatacept|
41472001|NCT03997786|DRUG|Tildrakizumab|at every 12 weeks in open label fashion till 5 years (240 weeks).
41472002|NCT03997786|DRUG|Tildrakizumab|(Weeks 0 to 16)
41472003|NCT03997786|DRUG|Etanercept|(Weeks 0 to 16)
40797037|NCT03761589|BEHAVIORAL|Wait-List Control|Families that were randomly assigned to the wait-list control group were asked not to change their normal physical activity or dietary behaviors for the duration of the 12-week waiting period. They were asked to participate in the baseline and 12-week evaluations and then they were enrolled to receive the 12-week intervention.
40797038|NCT05934110|DRUG|EMP16-120/40|"EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID)."
40797039|NCT05934110|DRUG|MR orlistat 120 mg|"MR orlistat 120 mg is the same as EMP16-120/40 but without the acarbose component in matching oral capsules.~Dosage:. week 1-2: 60 mg MR orlistat (1 capsule per day), week 3-4: 60 mg MR orlistat (1 capsule TID), week 5-26: 60 mg MR orlistat (2 capsules TID)."
40797040|NCT05934110|DRUG|Conventional orlistat 120 mg,|"Orlistat in its conventional form will be Alli® 60 mg during week 1 to 4 and Xenical® 120 mg from week 5 and onwards in matching oral capsules.~Dosage:~week 1-2: 60 mg conventional orlistat (1 capsule per day), week 3-4: 60 mg conventional orlistat (1 capsule TID), week 5-26: 120 mg conventional orlistat plus placebo (1 capsule of each TID)."
41472004|NCT03997786|DRUG|Placebo|(Weeks 16 to 52)
41472005|NCT03480672|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|intravenous application, 12 months, in 3-week cycle (q3w) 200 mg
41001591|NCT02467556|BEHAVIORAL|Psychological intervention|To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
41001592|NCT02467556|OTHER|Physiotherapy intervention|Graded motor imagenary with group and individual weekly sessions with daily practices at home.
41151141|NCT00333554|DIETARY_SUPPLEMENT|DHA Treatment|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
41472006|NCT03480672|OTHER|adjuvant radiochemotherapy|adjuvant radiochemotherapy with cisplatin
41472007|NCT00567476|DRUG|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
41472008|NCT00567476|DRUG|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent
41472009|NCT00567476|DRUG|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
41472010|NCT00567476|DRUG|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
41472011|NCT06595108|RADIATION|Stereotactic body radiotherapy|Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and they should begin stereotactic radiotherapy to one or more but not more than five sites for primary cancer and/or metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.
41472012|NCT02695719|DRUG|Placebo|Lubiprostone placebo-matching capsules
41472013|NCT02695719|DRUG|Lubiprostone|Lubiprostone capsules
41472014|NCT04157517|DRUG|Modakafusp Alfa|Modakafusp alfa intravenous infusion.
41472015|NCT04157517|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
41151142|NCT00333554|DIETARY_SUPPLEMENT|Placebo for DHA|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
41151143|NCT06407193|OTHER|MRI and scintigraphy|Gastric emptying measured with MRI and scintigraphy
41151144|NCT01169571|DRUG|Dexmedetomidine|
41151145|NCT03379909|DRUG|Metformin|Metformin orally at doses up to 1500 mg twice daily for 3 months.
41151146|NCT03288480|DRUG|PT-112|This is a single arm study
41151147|NCT01769352|DRUG|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
41151148|NCT04143100|OTHER|Survey|For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.
41472016|NCT06573970|DRUG|Atomoxetine|Atomoxetine is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD), and executive dysfunction. Dispensing of blinded medication (40mg to 80mg ATX or placebo) will begin at randomization and will be dispensed at weeks 2, 4, 8, and 12. The initial dose of ATX is 40mg or placebo and will be given for one week, the dose will be titrated to 80mg if tolerated in the second week through week 12.
41151149|NCT00316589|BIOLOGICAL|IMVAMUNE (MVA-BN)|2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
41313728|NCT02504268|DRUG|Methotrexate|
41313729|NCT02504268|OTHER|Abatacept Placebo|
41313730|NCT02504268|OTHER|Methotrexate Placebo|
41313731|NCT02745132|OTHER|Neuropsychological evaluation and Brain MRI|"This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times.~Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
41313732|NCT03580382|DRUG|Trametinib daily Until PD|1.0 mg daily
41313733|NCT03580382|DRUG|CDX-3379 (ERBB3 antibody)|15mg/kg IV Q3W
41313734|NCT05732844|DEVICE|Intervention group with Enna pelvic ball|"The home guideline for placement of the vaginal spheres will be as described in next:~st-2nd week 15 minutes, 1 time a day nd-4th week 30 minutes, 1 time a day 4th-8th week 1 hour, 1 time a day 8th-12th week 2 hours, 1 time a day 12th-16th week 3 hours, 1 time a day"
41313735|NCT05732844|OTHER|Control group|According to the PERFECT score, a daily home guideline for the performance of PFMT will be requested three times a day, two types of exercises (endurance and strength), and eight repetitions of each.
41151150|NCT03999398|PROCEDURE|Percutaneous coronary intervention (PCI)|Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
41472017|NCT06573970|DRUG|Placebo|placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.
41472018|NCT06147531|BIOLOGICAL|Delayed Cold-Stored Buffy Coat Platelets|To prepare cold-stored platelets, blood banks will transition conventional room temperature platelets up to 4 days after collection (with agitation) to cold-storage (at 1-6 C without agitation) for a minimum of 1 day (24 hours) and a maximum of 10 days after collection (for a total shelf life of ≤ 14 days after collection). Thus, cold-stored platelets will be produced and stored the same way as room temperature platelets up until their transition to cold-storage, ensuring similar products differing only in storage conditions and expiration date (as cold-stored platelets will have an expiration date beyond the current 5 days for pathogen inactivated platelets or 7 days for bacterially cultured platelets). Pathogen reduced platelets will be used for the pilot study (Canada is transitioning in 2022-23 to pathogen-reduced platelets and one site has already transitioned).
41472019|NCT06147531|BIOLOGICAL|Room Temperature Buffy Coat Platelets|Room temperature stored platelets are prepared from donor whole blood, which is centrifuged to collect the buffy coat layer containing platelets. Seven ABO matched buffy coats from male and/or female donors are pooled in 280 ml of platelet additive solution and split into a single dose after pathogen inactivation, resulting in a product with a final platelet count of approximately 1300 x 109. Pathogen inactivated platelets (shelf-life of 5 days, with recent Health Canada approval for an extension of the shelf-life to 7 days), will be used as Canada is transitioning in 2022-23 to pathogen-inactivated platelets and one site has already transitioned.
41472020|NCT02874014|RADIATION|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes|
41472021|NCT01128582|DRUG|Rozerem (ramelteon)|dosage= take 1 tablet(8 MG) 20 min. before bedtime
41472022|NCT01128582|DRUG|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
41472023|NCT05767047|DRUG|Apremilast|Oral tablets or liquid suspension
41472024|NCT06433206|OTHER|no intervention|no intervention
41472025|NCT05724446|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).
41313736|NCT01325324|DEVICE|measurement of intraocular pressure|Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
41313737|NCT06441136|OTHER|PhoRTE Program|Speech therapy program guided by a speech language pathologist. This program includes in person or virtual visits and at home exercises.
41472026|NCT05724446|DRUG|Prednisolone acetate ophthalmic suspension, 1%|Microfine sterile ophthalmic suspension of dense and whitish appearance.
41472027|NCT06617442|PROCEDURE|Pulmonary vein isolation|First pulmonary vein isolation performed for atrial fibrillation.
41472028|NCT04213209|DRUG|Brentuximab Vedotin (Genetical Recombination)|Brentuximab Vedotin Intravenous Infusion
41313738|NCT06441136|OTHER|University of California Los Angeles (UCLA) Loneliness Scale|A questionnaire measuring levels of loneliness.
41313739|NCT06441136|OTHER|Social Disconnectedness Scale|A questionnaire that asks about social network size and the frequency of social activities attended.
40797041|NCT05934110|DRUG|EMP16-60/20|"Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)"
40797042|NCT05934110|DRUG|Placebo|"Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)"
41313740|NCT06441136|OTHER|Patient Health Questionnaire 9|A questionnaire measuring levels of depression.
41313741|NCT06441136|OTHER|Aging Voice Index|A questionnaire of patient-reported voice outcome measures designed to capture the quality of life impact of dysphonia in older adults.
41313742|NCT06441136|OTHER|The Edmonton Frail Scale|A questionnaire that measures frailty levels.
41313743|NCT06441136|OTHER|Vocal Effort Scale|A picture based questionnaire scale that asks the subject to rate their perceived effort when using their voice.
41313744|NCT06441136|OTHER|Montreal Cognitive Assessment|A screening tool used to test for cognitive impairment.
41313745|NCT06441136|OTHER|Voice Handicap Index-10|A questionnaire used to measure quality of life impact of dysphonia.
41313746|NCT06441136|OTHER|Voice Problem Impact Scales|A 4 question survey that captures impact of voice on four domains - work/daily activities, social life, home, and overall quality of life.
41472029|NCT04037982|PROCEDURE|laparoscopic pancreaticoduodenectomy|During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.
41472030|NCT04037982|PROCEDURE|Open pancreaticoduodenectomy|During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
41472031|NCT00457210|PROCEDURE|Brain Radiotherapy/Stereotactic Radiosurgery|
41472032|NCT01652976|DRUG|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
41472033|NCT01652976|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
41472034|NCT04497272|OTHER|COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
41472035|NCT04366180|DIETARY_SUPPLEMENT|Probiotic|The probiotic group will received one capsule with Lactobacillus K8 per day (3x10\^9 cfu/day) during 2 months
41001593|NCT05414903|BEHAVIORAL|Dynamic Visual Acuity|"First, participants will report the direction of the open portion of a Landolt C (right, left, up, or down) with the head still. Ten targets at 5 acuity levels (LogMAR -0.3, 0, 0.3, 0.7, 1.0, corresponding to Snellen visual acuity of 20/10, 20/20, 20/40, 20/100, 20/200) will be identified. Next, a rate sensor will be placed on the subject's head in the plane of the horizontal canals and htDVA will be measured. The Landolt C will be presented automatically when the examiner has moved the subject's head \> 150˚/sec. htDVA scores will be the LogMAR at which the subject fails to correctly identify 50% of the visual targets or reaches a LogMAR of -0.3. The overall htDVA score is calculated by subtracting the head still LogMAR from the htDVA LogMAR. htDVA scores will be calculated for right and left head movements separately."
41313747|NCT06441136|OTHER|Cough Severity Index|A 10 question survey asking to rate severity of cough.
41313748|NCT06441136|PROCEDURE|Laryngoscopy|Nose is anesthetized and a flexible endoscope is passed to visualize the larynx at rest and during sustained vowel production (/i/) for 3-5 seconds. This will be used to measure bowing index and normalized glottal gap of the vocal folds.
41472036|NCT04366180|DIETARY_SUPPLEMENT|Control|The control group will received one placebo capsule per day during 2 months
41472037|NCT03446365|BEHAVIORAL|ASMAS|A high school peer led group intervention for middles school students targeting asthma education and asthma management practices.
41313749|NCT06441136|OTHER|Acoustic, perceptual, and aerodynamic assessments|Participants will complete voice recording tasks including sustained vowel production, six standard sentences, and 20 seconds of natural conversational speech. This will be used to measure CAPE-V rating, Cepstral peak prominence, fundamental frequency, signal-to-noise ratio, voice type components, mean flow rate, subglottal pressure, and vocal efficiency.
41313750|NCT00004993|DRUG|Parathyroid hormone (hPTH 1-34)|
41313751|NCT03712501|BEHAVIORAL|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
41313752|NCT04935060|BEHAVIORAL|A guide to inform the process of delivering the outcomes of a dementia assessment|The guide provides information that informs the approach taken to assessing people for dementia. It aims to guide clinicians. patients and their companions to think about how the diagnostic process is carried out, taking into account patient preferences, particularly around how they would like diagnostic decisions to be communicated to them.
41313753|NCT04935060|BEHAVIORAL|Usual Care|Clinicians conduct the dementia assessment as per standard protocols
41472038|NCT03446365|BEHAVIORAL|Asthma education plus child health|Health educator led intervention focused on asthma education and other child health topics.
41472039|NCT02521818|OTHER|Modified Atkins Diet|
41472040|NCT02521818|OTHER|NIA Diet for Seniors|
41472041|NCT04977609|BEHAVIORAL|VR+MUSIC|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
41472042|NCT04977609|BEHAVIORAL|VR|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
41472043|NCT04977609|BEHAVIORAL|TAU|Traditional post-stroke upper limb motor rehabilitation under the supervision of a physical therapist, for 0 daily sessions of 30 minutes, over 2 weeks.
41472044|NCT03273023|DEVICE|Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System|Promus PREMIERTM Stent System
41472045|NCT05732259|OTHER|Percussion therapy|Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest.
41472046|NCT05732259|OTHER|Manual Myofascial Release technique|Manual myofascial release technique for 90 sec continuous.
41472047|NCT02546050|DRUG|Metformin|
41313754|NCT03395275|BEHAVIORAL|Quantitative Sensory Tests|"Three testing modalities will be utilized for this study:~1. Hot threshold test: The hot threshold method we will be utilizing has been described in the literature with good reproducibility and reliability. We will be using a similar system and have reproduced the program using a non-invasive device.~2. Cold threshold test: the same non-invasive device will be used to test cold detection and pain threshold levels. This method is previously described.~3. Pressure threshold: Mechanical testing (pressure pain threshold) will be assessed utilizing an algometer. We have used this method in a previous study and published results."
41313755|NCT03395275|BEHAVIORAL|surveys|surveys including anxiety, depression, pain behavior, fatigue, pain interference, physical function, sleep disturbance, self-efficacy, satisfaction roles
41313756|NCT05962242|RADIATION|Radiation Therapy|External Beam Radiation to Head and Neck
41313757|NCT02476591|BEHAVIORAL|Charge Transparency|"Providers caring for patients in the Charge Transparency cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs"
41313758|NCT05442294|BEHAVIORAL|Juego de Llaves|The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values
41313759|NCT06290271|OTHER|Intracranial artery flow pattern|the cerebral blood flow patterns observed after the occluded artery has been recanalized.
41313760|NCT00786136|DRUG|rosuvastatin|rosuvastatin
41313761|NCT01908959|BEHAVIORAL|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
41313762|NCT05882890|OTHER|cranio sacral therapy|Manual treatment of 5 grams on the whole airwaysystem, the throat, the neck, the meninges, the craniel , nerve sleeves, the visceral cranium, the soft tissue in the mouth
41313763|NCT05926258|DRUG|Chloroprocaine 3% eye gel|ocular surface anesthesia
41313764|NCT05926258|DRUG|Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops|ocular surface anesthesia
41313765|NCT02985268|DEVICE|MitraClip|The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus \[degenerative MR\] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
41472048|NCT01729026|OTHER|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
41472049|NCT01489618|BIOLOGICAL|PPS|POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE
41472050|NCT01489618|BIOLOGICAL|PnCJ PPS|PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
41472051|NCT02914769|DRUG|Ayahuasca|patients will receive a single dose of ayahuasca.
41472052|NCT02914769|DRUG|placebo|patients will receive a single dose of a passive placebo.
41472053|NCT03983798|OTHER|Simulation training in psychiatry|"Each participant will complete 6 hours of psychiatric simulation training, dealing with mood disorders, anxious disorders, eating disorders, borderline disorders, substance abuse and schizophrenia. Simulation training will be supplemented by brief lecture on concept map and portfolio at the beginning of the first hour.~Curriculum integration of simulation training in psychiatric course assure that each pathology studied is supplemented by a one-hour lecture and 1 to 3 hours clinical cases and MCQ training. A part of the medical students are supplemented by clinical practice ; whereas the other won't benefit from clinical practice."
41313766|NCT02985268|DRUG|Optimal Medical Therapy|Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
41313767|NCT02985268|DEVICE|CRT-D|Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
41313768|NCT00001261|DRUG|Gamma Globulin|
41313769|NCT01404026|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm\^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
41313770|NCT04161274|PROCEDURE|Traditional method: Electrosurgery|"The patient will be prepared before this technique by removing all metal objects in his possession. The area should be disinfected with a local antiseptic, leaving the area aseptic. Afterwards, perilesional infiltrated local anaesthesia (subcutaneous or intradermal) will be applied. Once the area has been anaesthetised, excision is made with scissors cutting through the most proximal part of the skin tag pendulum and the lesion is coagulated with the handle or knife of the electrocoagulator (previously regulated with the intensity in coagulation mode). The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight."
41313771|NCT04161274|PROCEDURE|Traditional method: Cryotherapy|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. for a few minutes the tip of an Adson forceps will be introduced in a container with liquid nitrogen until freezing. It will then be applied to the most proximal part of the skin tag pendulum until it is observed that the frostbite has reached the base of the lesion and the surface becomes whitish, with a halo of 1-3 mm. When this happens, it will be excise above the frost part in the pendulum. After application, it is disinfected with povidone- iodine and covered with a protective dressing of sterile occlusive gauze plaster. It will then form an eschar. Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight.
41472054|NCT04701034|DRUG|Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)|infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
41472055|NCT04701034|DRUG|Prednisolone Tablets|5 mg before ET and 10 mg after ET until gestational week 8+0
41472056|NCT04701034|DRUG|Human Albumin Solution|Infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
40797043|NCT00924677|PROCEDURE|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
40797044|NCT00924677|PROCEDURE|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
40797045|NCT05302895|DEVICE|All-in-one health monitoring device|The staff will use the new monitoring device to carry out the health monitoring on every day during the 12-week period. After each round of health monitoring by the traditional and the new devices, the staff will need to fill in log sheets designed by HKU to document the time consumed for the entire process.
40797046|NCT00245453|DRUG|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
40797047|NCT00245453|DRUG|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
40797048|NCT00245453|DRUG|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
41472057|NCT04701034|DRUG|Placebo tablet|1 tablet before ET and 2 tablets after ET until gestational week 8+0
40797049|NCT02310737|PROCEDURE|sharp incision|The fascia will be opened with a sharp scissors in cesarean section
40797050|NCT02310737|PROCEDURE|blunt incision|Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
40797051|NCT05107063|DRUG|Pravastatin|Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
40797052|NCT04192045|OTHER|Survey|A survey will be used at 24 hours and 30 days to assess the quality of recovery
40797053|NCT00422188|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
40797054|NCT00422188|DRUG|Placebo|Administered via intralipomal injection.
41472058|NCT06555783|DRUG|ALKS 2680|Oral tablet containing ALKS 2680
40797055|NCT05706207|DRUG|HB0030 injection|0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
40797056|NCT05706207|DRUG|HB0030 injection|0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
40797057|NCT05706207|DRUG|HB0030 injection|1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
41472059|NCT06555783|DRUG|Placebo|Oral tablet containing placebo for once daily administration
41472060|NCT04615533|OTHER|Frail older adults, assessment|Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinnetti Balance and gait sacale
41472061|NCT05918822|DRUG|Maribavir Commercial Tablet Formulation|Maribavir commercial tablet.
41472062|NCT05918822|DRUG|Maribavir Pediatric Powder-for-oral Suspension Formulation|Maribavir pediatric powder-for-oral suspension.
41313772|NCT04161274|PROCEDURE|Traditional method: Silver nitrate|"The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag cutting through the most proximal part of the skin tag pendulum, then cauterized with the tip of the silver nitrate rod, trying not to apply in the perilesional zone.~The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or solar rays."
41472063|NCT05918822|DRUG|Rabeprazole|Rabeprazole tablet.
41472064|NCT03536494|BEHAVIORAL|Review the use of mirabegron and its discontinuation|"A structured intervention was designed consisting of four major sections:~* General practitioners: information and training with written material and patient-centred prescribing.~* Specialized hospital care: information regarding the intervention for urologists and gynaecologists.~* Management support with the definition of a structured strategy.~* Monthly monitoring of the intervention."
41001594|NCT05414903|BEHAVIORAL|Reading Outcomes|"The TOSWRF will be used to assess reading fluency. Children get 3 minutes to identify as many words as possible by drawing boundaries between successive unrelated words.~The TOSCRF will be used to assess reading fluency. Children are allowed 3 minutes to identify as many contextually related words as possible by drawing boundaries between successive words.~The TILLS will be used to assess reading comprehension. Each subject will read a short passage and answer 3 yes/no questions assessing reading comprehension.~A computer based MNREAD Test will be used to assess reading acuity, critical print size and Reading Accessibility Index.~During the TILLS and MNRead test, eye tracking (Eye Link 1000+ eye tracker) will be used to record fixation duration, saccade length, regression frequency, and total time spent."
41313773|NCT04161274|PROCEDURE|Moist healing environment method|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag by cutting through the most proximal part of the pendulum of the skin tag, later it will be disinfected with chlorhexidine and thin hydrocolloid dressing will be placed. Indications to the patient: the project participant will be told not to touch the dressing until the next control after 3 days with the research team. In case of incidents with the dressing (fall of the dressing), the patient will be given a replacement dressing for this purpose and be able to restore it immediately. It is recommended not to expose the area to the solar rays
41001595|NCT05414903|BEHAVIORAL|Static Visual Acuity|"The subject's head will be in a headrest. Static visual acuity will be assessed in 9 domains (3 levels of visual target complexity x 3 levels of presentation complexity). The 3 levels of visual target complexity are identifying: 1) colors, 2) the direction of the open prongs of the Landolt C (right, left, up, or down), which does not require alphabet knowledge, and 3) single letters (C, D, H, K, O, N, S, R, V, and Z; NIH Toolbox, Li 2014)). The 3 levels of presentation complexity are identifying: 1) 1-visual optotype, 2) a successive row of 5 visual optotypes flashed for 3 seconds (Hillman 1999), and 3) successive rows of optotypes in paragraph form as quickly as possible (i.e., rapid automatized naming). Outcome parameters will be %-correct at each acuity level and reaction time. Fixation duration, saccade length, saccade frequency, regression frequency, and total time spent will be collected via an eye tracker (Eye Link 1000+ eye tracker \[SR Research, EyeLink, Ontario, Canada\])."
41313774|NCT01479959|DEVICE|Eole 3 ventilator - Resmed|positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
41472065|NCT02593396|DRUG|Bupropion hydrochloride sustained-release|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
41472066|NCT02593396|DRUG|placebo|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
41472067|NCT05840276|DEVICE|Cryoneurolysis|The VISUAL-ICE uses a combination of argon and helium, to create a highly localized cold zone with temperatures between -20 and -100°C. A probe will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization to accurately determine the location of the nerve and to account for adjacent neurovascular structures and variations in anatomical structures. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Cryoneurolysis at each target site requires 2 freeze cycles with a duration of 3 mins, and with thaw cycles between 20-40 seconds.
41472068|NCT05840276|OTHER|Sham|A sham needles will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Sham will simulate cryoneurolysis at each target site for 2 freeze cycles with a duration of 3 mins, and also simulate thaw cycles between 20-40 seconds. No temperature changes will actually occur although the experience and sounds will be similar to cryoneurolysis
41001596|NCT04522037|OTHER|No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups|Respiratory rate is analyzed with the scope (approved by the French national medical authorities)
41001597|NCT04619706|DRUG|FSD201|Tablets for oral administration.
41472069|NCT06274047|DRUG|Apalutamide|Given by PO
41001598|NCT04619706|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
41001599|NCT04619706|OTHER|Standard of Care for Covid-19|Standard of care for Covid-19 as determined by site PI
41313775|NCT03229083|OTHER|Carevive software|In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.
41313776|NCT04685070|DRUG|HS-10296 (Almonertinib)|Neoadjuvant treatment stage: HS-10296 110mg, qd, po, 4 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: HS-10296 110mg, qd, po, up to 48 weeks (including neoadjuvant stage). PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
41313777|NCT01393756|DRUG|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
41313778|NCT02312076|DRUG|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
41313779|NCT02144558|OTHER|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
41313780|NCT00001735|PROCEDURE|Gene therapy|
41313781|NCT01969799|DRUG|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
41472070|NCT06274047|DRUG|Androgen Deprivation Therapy|Given by PO
41001600|NCT02696369|DRUG|2% lidocaine HCl with epinephrine 1:200,000|
41001601|NCT02696369|DRUG|2% lidocaine HCl with epinephrine 1:80,000|
41472071|NCT03680716|DRUG|Ropivacaine injection|Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).
41472072|NCT03680716|DRUG|Ropivacaine injection|Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).
41472073|NCT04403399|DRUG|Varenicline|Initial 0.25 mg oral dose of varenicline administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final 0.5 mg BID oral varenicline administered for the remaining 3 weeks.
41472074|NCT04403399|DRUG|Placebo|Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
41313782|NCT01969799|DRUG|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
41313783|NCT01949727|OTHER|AIM 2: Pulmonary Rehabilitation|Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
41472075|NCT01885351|BEHAVIORAL|MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
41001602|NCT00694980|DRUG|placebo|Intravenous and subcutaneous escalating doses
41001603|NCT00694980|DRUG|rhuMAb Beta7|Intravenous and subcutaneous escalating doses
41001604|NCT00489853|DRUG|budesonide/formoterol Turbuhaler 320/9µg|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
41001605|NCT00489853|DRUG|formoterol Turbuhaler 9µg|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
41001606|NCT00489853|OTHER|Placebo|Placebo, 1 inhalation twice daily
41001607|NCT02262481|DRUG|dydrogesterone|
41001608|NCT02262481|DRUG|placebo|
41001609|NCT04516616|DRUG|Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)|PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
41001610|NCT04350151|BEHAVIORAL|no intervention|no intervention
41001611|NCT05718635|DIAGNOSTIC_TEST|coloured duplex|colored duplex to locate numbers sites and size of perforators.
41001612|NCT05718635|PROCEDURE|supra facial dissection|flap raising in supra facial plane
41001613|NCT02969928|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
41001614|NCT02969928|DRUG|Clarithromycin|Administration of Clarithromycin 500mg bid for 7 days
41001615|NCT02969928|DRUG|Amoxicillin|Administration of Amoxicillin 500mg tid for 7 days.
41001616|NCT02969928|DRUG|Metronidazole|Administration of Metronidazole 400mg tid for 7 days.
41001617|NCT05960396|BEHAVIORAL|Diet intervention|investigators use different diet intervention to observe the changes of biochemical indicators, body composition, Gut microbiota, metabonomics, etc. for patients with MAFLD during different periods
41313784|NCT03755284|OTHER|Sacral Massage|● In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour.
41472076|NCT01885351|BEHAVIORAL|MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
41472077|NCT02930629|DEVICE|Train-of-Four (TOF) Watch|"For patients, on arriving in PACU after having had muscle relaxants during general anaesthesia~* Two ECG electrodes will be placed 4 cm apart over the path of the ulnar nerve of the wrist after cleaning the skin with alcohol swabs.~* The TOF force transducer will be placed on the volar aspect of the thumb.~* The TOF Watch leads will be attached to the ECG electrodes.~* A TOF stimulus will be applied: four twitches at 2Hz (every 0.5 seconds), each twitch lasting 0.2ms, and at a current of 50 mA. As far as possible, this will be done when patients are still slightly drowsy from the effects of anaesthesia.~* Two TOF ratio will be elicited (two sets of four twitches 15 seconds apart), and an average of the two taken"
41313785|NCT04342182|BIOLOGICAL|Convalescent plasma|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
41472078|NCT02405572|OTHER|infant formula|infant formulas
41472079|NCT02923414|DEVICE|Standard escalating shocks|125 J, 150 J, 200 J
41472080|NCT02923414|DEVICE|High energy shock protocol|360 J, 360 J, 360 J.
41472081|NCT02720133|BIOLOGICAL|biochemical parameters|"patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.~All these tests should be practice before, during and after Ramadan fasting for comparison."
41472082|NCT05301686|PROCEDURE|Patients with Cyclop lesion|Arthroscopy with resection of Cyclop formation
41472083|NCT03489226|DIETARY_SUPPLEMENT|Capsimax|Capsimax
41472084|NCT03489226|DIETARY_SUPPLEMENT|Placebo|Placebo
41472085|NCT03489226|OTHER|Meal|Meal
41472086|NCT02427984|OTHER|Metal ions dosage and evaluation of local/systemic reaction|"Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
41472087|NCT02427984|OTHER|Noise registration and metal ions determination|"Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of range of noise"
41472088|NCT02427984|OTHER|Metal ions dosage, evaluation of local/systemic reaction, noise registration|"Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
41001618|NCT04139928|DIETARY_SUPPLEMENT|Picometer-ionic form of magnesium chloride|Single-dose (300 mg) of the picometer-ionic form of magnesium chloride
41001619|NCT04139928|DIETARY_SUPPLEMENT|Magnesium citrate or magnesium oxide|Single-dose (300 mg) of magnesium citrate or magnesium oxide
41472089|NCT00980889|DEVICE|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
41472090|NCT00980889|DEVICE|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
41472091|NCT06387979|OTHER|Non-Interventional Study|Non-Interventional Study
41472092|NCT06383390|DRUG|Retatrutide|Administered SC
41472093|NCT06383390|DRUG|Placebo|Administered SC
41472094|NCT00992095|DRUG|buprenorphine hydrochloride|single dose 8 mg sublingual tablet
41001620|NCT04139928|DIETARY_SUPPLEMENT|Placebo|Placebo
41472095|NCT03572842|OTHER|quantiferon monitor test|different blood test with quantiferon monitor
40797058|NCT05706207|DRUG|HB0030 injection|3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
40797059|NCT05706207|DRUG|HB0030 injection|10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
41001621|NCT01230931|DEVICE|Vitagel|Vitagel (by Stryker) is a topical surgical hemostat spray that results in coagulation. The components are as follows: autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors; this is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.
41313786|NCT02560831|BEHAVIORAL|Therapeutic exercise and Pompage|Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.
41313787|NCT02560831|BEHAVIORAL|Educational lectures|Educational lectures in four meetings for 12 weeks (Control Group)
41472096|NCT02941588|PROCEDURE|Non-cardiac surgery|Any surgery with general anesthesia except cardiac surgery
41472097|NCT05655455|BEHAVIORAL|walking group: 1.group|In the study, walking attempt will be applied (2 x40 min/week and 6 weeks in total) to the 1st intervention group (n:15) in a gym. It will be given by a specialist in public health nursing. (first researcher)
41472098|NCT05655455|BEHAVIORAL|dance and movement therapy group: 2.group|In the study, dance and movement therapy will be applied (2 x40 min/week and 6 weeks in total) to the 2nd intervention group (n:15) in a gym. It will be given by a specialist in psychiatric nursing.
41313788|NCT02595047|PROCEDURE|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
41313789|NCT04223700|PROCEDURE|Ultrasound imaging & fluoroscopic confirmation|The researchers use ultrasound to scan the left and right sides of the paravertebral sagittal imaging to identify trapezius, semispinalis, erector spinae muscle, transverse process and rhomboid muscle. The radiopaque marker is attached respectively to the skin of the inferior margin of the rhomboid muscle on the left and right thoracic spinal spines. Then, as the first step for the scheduled nerve block to the patient, thoracic vertebra level verification using C-arm is performed. At this time, left and right level of the transverse process of thoracic spine marked with the radiopaque marker are confirmed and recorded.
41313790|NCT00734344|DRUG|Raltegravir|Raltegravir 400 mg. BID
40797060|NCT05706207|DRUG|HB0030 injection|20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
40797061|NCT05706207|DRUG|HB0030 injection|30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
40797062|NCT05706207|DRUG|HB0030 injection|40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
41001622|NCT01230931|PROCEDURE|Standard of care|Standard of care for hemostasis in acetabular surgery includes electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing.
41313791|NCT00734344|DRUG|Efavirenz|600 mg once daily
41313792|NCT00734344|DRUG|Emtricitibine|200mg once daily
41313793|NCT00734344|DRUG|Tenofovir disoproxil once daily|300mg once daily
41313794|NCT00734344|DRUG|Tenofovir disoproxil twice daily|300mg twice daily
41313795|NCT01795898|DRUG|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
41313796|NCT06073652|OTHER|Control 1st age starter infant formula|A standard bovine milk-based term infant formula.
41472099|NCT00865098|DRUG|Cetuximab|Patients receive Cetuximab at an initial dose of 400 mg/m\^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m\^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
41472100|NCT00900016|GENETIC|protein expression analysis|
41472101|NCT00900016|GENETIC|western blotting|
41472102|NCT00900016|OTHER|immunohistochemistry staining method|
41472103|NCT00900016|OTHER|immunologic technique|
41472104|NCT00900016|OTHER|laboratory biomarker analysis|
41472105|NCT01269476|DRUG|SNX-001|3.6, 7.2, or 10.8 mg single dose or t.i.w.
41472106|NCT01269476|DRUG|Placebo|Same volumes and frequency as active.
41472107|NCT05247333|OTHER|Minor ailment service|The service had several components: agreed standard operational procedures between community pharmacists and primary care physicians for 31 minor ailments, IT based consultation protocol and training before and during the study for the pharmacists. Practice change facilitators were used to confirm the fidelity of the intervention.
41472108|NCT00724620|BIOLOGICAL|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
41472109|NCT00724620|DRUG|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
41472110|NCT03753776|DRUG|Placebo pills of Radium bromatum|Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
41472111|NCT03753776|DRUG|Radium bromatum pills|Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
40797063|NCT03870464|DIAGNOSTIC_TEST|CT-scans extended|CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.
40797064|NCT03870464|DIAGNOSTIC_TEST|MRI scan of the brain|MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.
41001623|NCT03583996|COMBINATION_PRODUCT|HepQuant SHUNT Liver Diagnostic Test|One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate
41001624|NCT03172936|DRUG|MIW815|MIW 815 (ADU-S100) is a STING agonist
41001625|NCT03172936|BIOLOGICAL|PDR001|PDR001 is an anti-PD-1 antibody
41313797|NCT06073652|OTHER|Experimental 1st age starter infant formula|Same content as Control formula plus supplemented with a HMO blend and a probiotic
41313798|NCT02958397|BIOLOGICAL|Anti-CD33-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD33-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
41313799|NCT03065634|BEHAVIORAL|Return to work and living healthy after head and neck cancer|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions. The individual sessions aim to improve work ability, quality of life and psychological well-being
41472112|NCT03753776|DRUG|Radium bromatum/Apis mellifica/Belladonna placebo pills|Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
41313800|NCT03065634|BEHAVIORAL|socio-legal counseling|"Non-manualized socio-legal counseling~two socio-legal counseling sessions delivered by a social worker"
41313801|NCT06552338|OTHER|Observational|No intervention. Study is observational
41313802|NCT04637945|DIETARY_SUPPLEMENT|ACRB|Product will be consumed once daily, preferably with breakfast.
41313803|NCT04637945|OTHER|Placebo|Product will be consumed once daily, preferably with breakfast.
41313804|NCT01397552|DRUG|Dexamethasone|10 mg/mL injected into lumbar spine, one level, one injection
41313805|NCT01397552|DRUG|methylprednisolone acetate|80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
41472113|NCT03753776|DRUG|Radium bromatum/Apis mellifica/Belladonna pills|Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
41472114|NCT00755378|DRUG|AZD8529|Oral
41472115|NCT00755378|DRUG|Placebo|Oral
41472116|NCT06616506|DEVICE|newly-invented AI model|Apply newly-invented AI models to assist in determining surgical plans and outcome prediction.
41472117|NCT00332267|PROCEDURE|Endotoxin infusion, Normobaric hypoxia|
41472118|NCT05722028|PROCEDURE|hysteroscopy|Surgical hysteroscopy without anaesthesia for removal of uterine polyp / retained products of conception.
41472119|NCT01748955|DRUG|Paroxetine CR for Major Depressive Episode|Dosage will be 25mg every day for 2 weeks, then 37.5mg every day for 2 weeks, and then optional increase to 50mg every day for the remainder of treatment.
41472120|NCT01748955|DRUG|Bupropion XL for Major Depressive Episode|Dosage will be 150mg every day for 2 weeks, then 300mg every day for 2 weeks, and then optional increase to 450mg every day for the remainder of treatment.
41472121|NCT05116059|DRUG|Amphotericin B colloidal dispersion（ABCD）|The dosage and course of ABCD were determined by clinicians, and this study was registered according to clinical practice
41472122|NCT01975194|DRUG|Rosuvastatin|Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
41313806|NCT05933252|OTHER|Augmented reality (AR)|an app on an iPad every 15 minutes
41313807|NCT05411640|OTHER|Aerobic exercise with Blood flow restriction|Experimental group will be given aerobic exercises with blood flow restriction training. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. . Arterial occlusion of 60% will be achieved by Blood Flow Restriction apparatus. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
41313808|NCT05411640|OTHER|Aerobic exercise without Blood flow restriction|Active Comparator group will be given aerobic exercises. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
41472123|NCT06598293|BEHAVIORAL|PRO-CTCAE, Pain NRS|The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a PROM developed to systematically and objectively reflect patients' experiences and perceptions of therapeutic drugs in toxicity evaluation and adverse event reporting. PRO-CTCAE can be used to monitor patients' symptoms and side effects, support therapeutic decision-making, facilitate communication among medical staff, implement patient-centred care, and screen for health conditions.
41472124|NCT02779751|DRUG|Abemaciclib|Administered orally
41472125|NCT02779751|DRUG|Pembrolizumab|Administered IV
41001626|NCT01112293|DRUG|GC1008|GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
41313809|NCT05411640|OTHER|Patient Education and dietary modification|Participants will individually instruct to reduce total energy intake and increase physical activity, aiming at a 5% reduction in body weight. The participants will be given pamphlets providing general information on pre diabetes and dietary modifications. Total intervention protocol for the group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
41472126|NCT02779751|DRUG|Anastrozole|Administered orally
41472127|NCT06355830|DIAGNOSTIC_TEST|Orthoptic assessment (Outcome measure)|The protocol image assessment is non-invasive and includes retinal imaging by Color Fundus photography (CFP), Spectral Domain Optical Coherence Tomography (SD-OCT), OCT-Angiography (OCT-A) using Spectralis OCT, with OCT Angiography Module (Heidelberg Eng. GmbH, Germany).
41472128|NCT06616532|DRUG|PM8002|Following a predefined dose and date.
41472129|NCT06616532|DRUG|Paclitaxel|175mg/m2 via IV infusion on Day 1 Q3W
41472130|NCT06616532|DRUG|Topotecan|1.25mg/m2/day via IV infusion on Days 1-5 Q3W
41472131|NCT00918918|DIETARY_SUPPLEMENT|Alcohol + orange juice|100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
41472132|NCT00918918|DIETARY_SUPPLEMENT|Orange juice|200 mL orange juice
41472133|NCT06617507|OTHER|Group 1|The Modified Ashworth Scale (MAS), The Gillette Functional Assessment Questionnaire (FAQ) and The Edinburgh Visual Gait Score (EVGS) were applied to the participants.
41472134|NCT01345526|DEVICE|Reconval K1 Cream|
41472135|NCT01345526|DEVICE|Reconval Cream|
41472136|NCT01658202|DRUG|V0116 transdermal patch (Test treatment )|
41472137|NCT01658202|DRUG|Nicotine transdermal patch (Reference Treatment )|
41472138|NCT05699759|DRUG|K8|Subjects will have the treatment administered intravitreally (one eye only) using an injector system on a 24-gauge needle to deliver a cylindrical, 3 mm long, drug eluting pellet containing 300 µg of K8. Participants will be followed for 168 days (24 weeks).
41472139|NCT02070757|DRUG|Ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
41313810|NCT03771417|BEHAVIORAL|Exercise Intervention|The use of exercise to improve muscle and cardiometabolic health in older adults.
41001627|NCT03736850|DRUG|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
41313811|NCT05986032|DIAGNOSTIC_TEST|Respiratory Oscillometry|Measurement of respiratory system reactance by respiratory oscillometry
41313812|NCT00494871|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL \[creatinine clearance\] \>= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
41313813|NCT00494871|DRUG|Warfarin|Participants orally administered a warfarin potassium tablet (INR \[international normalized ratio\] target was 1.6-2.6 for patients \>70 years and 2.0-3.0 for patients \<70 years)
41472140|NCT02070757|DRUG|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
41472141|NCT05954819|OTHER|Planned patient education|Patients in the experimental group will be given about 30 minutes of patient education. After the training, a Patient Education Booklet containing Myocardial Infarction and Diabetes Education will be presented to the patients. Control group patients will not be given any training other than the hospital routine.
41472142|NCT06422884|DRUG|ENV-101|oral tablet, dosed once a day
41472143|NCT06422884|DRUG|Placebo|oral tablet, dosed once a day
41472144|NCT02487082|DRUG|Melatonin and Donepezil|10 weeks of active study medication in Group A during Phase 1 \& Phase 2. 5 weeks of active study medication in Group B during Phase 2.
41472145|NCT02487082|OTHER|Placebo|For both groups: 5 weeks of Placebo in the Run-In Phase. For Group B: an addition 5 weeks of Placebo in Phase 1.
41472146|NCT02396082|BEHAVIORAL|MIND-S Intervention|MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education
41472147|NCT02396082|OTHER|Augmented Usual Care|Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
41472148|NCT03022539|RADIATION|Repeat CT scan|
41313814|NCT00494871|DRUG|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
41472149|NCT01253317|DRUG|rhIGF-1|1) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
41472150|NCT00184119|PROCEDURE|Psychiatric Intensive Care Unit|
41472151|NCT00184119|PROCEDURE|Care in whole acute unit|psychiatric acute care as usual
41472152|NCT06021470|BEHAVIORAL|Cognitive rehabilitation intervention|The intervention comprises a five-week group-based cognitive rehabilitation intervention delivered by a clinical neuropsychologist, with home activities tailored to each stroke survivor's identified goals. Sessions involve four patients and are delivered once per week lasting 2.5 hours with breaks.
41472153|NCT06176625|BEHAVIORAL|Communication Signage|Signage regarding effective communication strategies posted on door to patient's room.
41472154|NCT06176625|BEHAVIORAL|Amplifier Use|Patient is provided amplification device and signage regarding effective communication strategies with reminder to utilize the amplification device posted on door to patient's room.
41472155|NCT06617715|BIOLOGICAL|Sinovac PCV13|One dose of Sinovac PCV13 (0.5 mL) is administered intramuscularly.
41313815|NCT00494871|DRUG|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
41472156|NCT06617715|BIOLOGICAL|Prevnar®|One dose of Prevnar® (0.5 mL) is administered intramuscularly.
41472157|NCT03214302|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
41472158|NCT00510315|OTHER|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
41001628|NCT04700696|BEHAVIORAL|Peer Recovery Support|Weekly visits with peer who has lived experience related to child welfare and addiction
41001629|NCT04700696|BEHAVIORAL|Family Treatment Drug Court with Medications for Opioid Use Disorders (MOUD)|Incentivized to participate in Family Treatment Drug Court with option for Medications for Opioid Use Disorders (MOUD)
41313816|NCT02220348|DRUG|linaclotide|
41313817|NCT00696462|DEVICE|forced-air warming|forced-air warming device
41313818|NCT00082758|BIOLOGICAL|hu14.18-Interleukin-2 fusion protein|Given IV
41472159|NCT03902002|DRUG|Omaveloxolone 50 mg capsules|Capsules containing 50 mg of omaveloxolone
41472160|NCT05854459|OTHER|HIIT and Nordic Curl exercise program|The training program in the HIIT+NC group was divided into the following parts: i) warm-up (10 minutes); ii) HIIT (25 minutes) consisting of a circuit of eight exercises; iii) Nordic curl exercise (10 mintues); and iv) stretching.
41313819|NCT05851339|OTHER|SF- 36 Questionnaire|applicants will fill health related quality of life SF-36 Questionnaire after PCNL or RIRS
41313820|NCT02134327|DRUG|Combination of Dexmedetomidine with Midazolam|
40797065|NCT03870464|OTHER|Prospective registration of irAEs|irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.
41313821|NCT00449111|DRUG|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
40797066|NCT03870464|BEHAVIORAL|Quality of Life questionnaires|Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
41313822|NCT02397694|DRUG|BIC|75 mg tablet administered orally once daily
41313823|NCT02397694|DRUG|F/TAF|200/25 mg FDC tablet administered orally once daily
41313824|NCT02397694|DRUG|DTG|50 mg tablet administered orally once daily
41313825|NCT02397694|DRUG|BIC Placebo|Tablet administered orally once daily
41313826|NCT02397694|DRUG|DTG Placebo|Tablet administered orally once daily
41313827|NCT02397694|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily
41472161|NCT05854459|OTHER|HIIT-only program|The HIIT group performed the same exercises in the warm-up, HIIT and stretching sections as the HIIT+NC group, however, they did not perform the NC eccentric exercises.
41472162|NCT01135628|OTHER|Auxiliary Treatment|Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months
41472163|NCT01135628|DIETARY_SUPPLEMENT|Hyperproteic and fiber-rich diet|Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
41472164|NCT01135628|DRUG|Nitazoxanide|Nitazoxanide tablets 400 mg, bid, orally for 6 months
41472165|NCT00109486|DRUG|GW685698X|
41472166|NCT03550534|DRUG|Calcium Carbonate|Calcium carbonate was obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
41472167|NCT03550534|DRUG|Placebo oral capsule|Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
40797067|NCT01739608|OTHER|Invitation to screening|Invitation to screening
40797068|NCT03088787|DEVICE|Nexfin measuremtents|There will be only observational recordings, no interevntion
41001630|NCT04700696|BEHAVIORAL|Relational Skill Building based on the Nurturing Parenting Program (NPP)|Home-based parenting support
41001631|NCT05714111|OTHER|Radiology evaluations and interventions|Diagnostic and interventional radiology procedures
41313828|NCT01552824|PROCEDURE|CYSTO|Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
41313829|NCT01552824|PROCEDURE|Vesico-amniotic shunt|In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
41313830|NCT04743700|PROCEDURE|Piezocision|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome. These piezocisions will be performed on the buccal cortical bone only, 2-3mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle . The exact location of incision will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added and then 5mm incision is given in gingiva and overlying mucoperiosteum in a vertical line apically to expose the underlying bone.
41313831|NCT04743700|PROCEDURE|Micro-osteoperforations|Three MOPs mesial and three MOPs distal to canine(in a vertical line) with the help of minisrew implant driver (fig.2). These MOPs will be performed on the buccal cortical bone only, 2-3 mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and no flap will be raised. The exact location of first MOP will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added. The location of second MOP at 5mm apically in a vertical line and third MOP at 5 mm apically to second MOP
41313832|NCT03939351|DIAGNOSTIC_TEST|OCT-angiography and SD-OCT|Performing an OCT-angiography and SD-OCT examination
41472168|NCT03968731|OTHER|Zocular Eyelid System Treatment|Zocular products contain okra-infused Zocusome micelles that gently lift and clear the oil, debris, and residue on eyelid margins. THerefore, the ZEST treatment is expected to improve signs and symptoms of Meibomian gland dysfunction (MGD) and reduce Contact lens discomfort associated with MGD.
41472169|NCT01402154|BIOLOGICAL|EPISPOT detection of the number of circulating cells|EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
41472170|NCT01402154|BIOLOGICAL|CellSearch detection of the number of circulating, functional, prostate cells|CellSearch detection of the number of circulating, functional, prostate cells per unit blood
41472171|NCT02323802|BEHAVIORAL|educational group intervention|
41472172|NCT02323802|BEHAVIORAL|prescriptive diet|
41472173|NCT04661826|DRUG|Oncofid-P-B|Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
41472174|NCT03492970|BIOLOGICAL|Hourly dosing of the nychtemeral secretion of melatonin|Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS
41472175|NCT00426179|DRUG|Imatinib|
41472176|NCT00708708|DRUG|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
41472177|NCT04500548|PROCEDURE|Biospecimen Collection|Undergo collection of tissue samples
41472178|NCT04500548|BIOLOGICAL|Ipilimumab|Given IV
41313833|NCT04407455|DIAGNOSTIC_TEST|Karaduman Chewing Performance Scale|For chewing evaluation, children will be asked to bite and chew a standardized biscuit. Each chewing evaluation will be scored according to the KCPS.
41313834|NCT03420326|BEHAVIORAL|Frailty status assessment|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status
41313835|NCT00022971|BIOLOGICAL|Apolizumab|Apolizumab IV on Day 1. Administer weekly for 4 weeks
41313836|NCT00022971|BIOLOGICAL|Rituximab|Rituximab IV 24-36 hours after Apolizumab ends. Administer weekly for 4 weeks
41313837|NCT04754165|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
41313838|NCT05852678|OTHER|cohort|The Cantabria Cohort will recruit 40,000-50,000 residents aged 40-69 years at baseline
41313839|NCT04153617|DIETARY_SUPPLEMENT|Control honey|Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
41313840|NCT04153617|DIETARY_SUPPLEMENT|Modified honey with soluble fiber and polyphenols|Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
41313841|NCT06056349|DRUG|Midazolam oral solution|Buccal administration
41472179|NCT04500548|BIOLOGICAL|Nivolumab|Given IV
41472180|NCT02776553|OTHER|Nutritional consultation|Dietary advice will be provided at the beginning of the study and individually tailored to the participant's usual eating habits plus amino acid supplement including 10 grams of branched-chain amino acids
41472181|NCT02776553|BEHAVIORAL|Physical training program|Physical activity prescription will target ≥10,000 steps/day, taking into account all activities performed throughout the day, although the increment in activity should be no less than 3000 steps/day above the baseline.
41472182|NCT02776553|BEHAVIORAL|Behavioral modification therapy|The behavior modification theory will be applied in the form of a structured set of cues and questions between investigator and participant at each visit in order to provide individually tailored counseling to enhance internal motivation and facilitate behavior change toward physical activity and dietary improvement that are adaptable to each participant's usual habits.
41313842|NCT06056349|DRUG|ClonazePAM Oral Product|Orodispersable
41313843|NCT06056349|OTHER|Usual medication/ traditional|Medication that is usually used in the emergency department
41313844|NCT02984852|DRUG|Darunavir (DRV)|Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
41313845|NCT02984852|DRUG|Cobicistat (COBI)|Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
41313846|NCT02984852|DRUG|Emtricitabine (FTC)|Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).
41313847|NCT02984852|DRUG|Tenofovir Alafenamide (TAF)|Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).
41313848|NCT06175962|BEHAVIORAL|TRAINING AND EXERCISE|"Menopause health training will take place in 2 sessions each week and will be completed in 4 sessions. Each session duration is 45 minutes. Baduanjin exercise training will take place in 2 sessions per week, each session lasting 30 minutes. It will be completed in 8 sessions in total. Relaxing music will be played during the Baduanjin exercise and relaxation will be encouraged. During the Baduanjin exercise, proper posture, conscious breathing and focus of the mind will be prioritized. While the movements are being implemented, their symbolic meanings will be explained to the participants. Women will be asked to perform baduanji 3 times a week for 8 weeks.~During this process, reminder messages will be sent to women via WhatsApp."
41472183|NCT03917511|BEHAVIORAL|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
41472184|NCT03917511|BEHAVIORAL|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
41472185|NCT05057052|DRUG|Sintilimab|Sintilimab plus regorafenib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
41472186|NCT05057052|DRUG|Regorafenib|Regorafenib will be initiated on day 14 after cryoablation. Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
41001632|NCT01871363|RADIATION|chemoradiation|"* radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~* bevacizumab: at dose 5 mg/kg on days -1, 15, 31.~* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
41001633|NCT06343844|DIAGNOSTIC_TEST|cardiac imaging to assess left ventricular volumes and function|non-invasive cardiac imaging (echocardiography and MRI)
41001634|NCT05489315|DEVICE|Positioning with peanut ball|If participants are randomly selected to receive a peanut ball, the intent is for the patient to remain on the peanut ball during their labor progression.
41313849|NCT00947752|DRUG|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
41313850|NCT00947752|DRUG|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
41313851|NCT04233359|PROCEDURE|Local anesthetic thoracoscopy|Procedure to obtain histological biopsies of the parietal pleura on awake, fastening patients.
41313852|NCT04233359|PROCEDURE|US-guided pleural biopsy|In local anesthesia, a closed needle biopsy is performed Ultrasound guided of the parietal pleura at the place of deepest fluid recess in the intrathoracic space. A pigtail catheter French 7-16 is placed afterwards for fluid drainage.
40797069|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 3 months|Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
40797070|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 6 months|Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
41472187|NCT05057052|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
41472188|NCT05329285|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Alternative treatment
40797071|NCT05870969|BEHAVIORAL|Liver cancer surveillance annually|Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
40797072|NCT01465438|DRUG|Adalimumab|Adalimumab 40 mg every other week
40797073|NCT02327585|BEHAVIORAL|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
40797074|NCT00733733|DRUG|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
40797075|NCT03679676|DRUG|Omalizumab|Omalizumab is injected every 2 to 4 weeks
40797076|NCT03679676|DRUG|Dupilumab|"Dupilumab is injected every 2 weeks~combination, or placebo."
40797077|NCT03679676|OTHER|Placebo|Placebo is injected every 2 to 4 weeks
40797078|NCT02674113|DRUG|regional anesthesia bupivacaine|a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
40797079|NCT02674113|DRUG|regional anesthesia placebo|subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
40797080|NCT05174546|DIAGNOSTIC_TEST|T2 magnetic resonance|Samples for assessment by the T2MR will be collected once daily in occasion of any consecutive febrile episode during neutropenia when blood cultures are ordered as per standard of care. T2 magnetic resonance will be run according to manufacturer's instructions
40797081|NCT00506467|PROCEDURE|Vibration Response Imaging|Lung function test performed using the VRI system immediately before or after the standard lung function test.
41472189|NCT06616272|OTHER|Cervical rehabilitation|"* Manual joint mobilization (Grades I-V) of painful and restricted cervical spine segments.~* Supine manual cervical traction to stretch and mobilize the cervical spinal tissues.~* Manual soft tissue mobilization of the cervical, upper thoracic and/or shoulder muscles.~* Passive stretching of hypertonic muscles and active strengthening of hypotonic muscles.~* Motor-control and isometric exercises to activate the deep neck flexors."
40797082|NCT03533959|DRUG|Alirocumab|the administration of Alirocumab at least 75mg every 2 weeks
40797083|NCT04340388|DRUG|Dolutegravir 50 MG|15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
40797084|NCT04340388|DRUG|Antiretroviral/Anti HIV|15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
40797085|NCT02944721|GENETIC|Genetical analyses|
40797086|NCT02944721|OTHER|Chronic pain identification questionnaires|
40797087|NCT02944721|OTHER|Neurophysiological and psychophysical evaluations|
40797088|NCT02944721|OTHER|Quality of life questionnaires|
40797089|NCT04092803|OTHER|Virtual Reality|The system includes a VR headset with VR software already loaded in to it.
40797090|NCT00657137|DRUG|apricoxib + lapatinib + capecitabine|"apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
40797091|NCT00657137|DRUG|placebo + lapatinib + capecitabine|"placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
40797092|NCT03162133|OTHER|Baduanjin exercise|
40797093|NCT03450239|OTHER|MRI|MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
40797094|NCT01887964|OTHER|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
40797095|NCT01887964|OTHER|Control flour|Wheat flour without resistant starch (type-4)
40797096|NCT04404673|PROCEDURE|Evaluation of urinary and sexual dysfunction after rectal resection|Comparison among the 4 different surgical approaches for urinary and sexual function
40797097|NCT02186782|DRUG|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
40797098|NCT02186782|DRUG|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
40797099|NCT06513130|OTHER|Geriatric assessment in the 7 days following ICU discharge.|ICU survivors will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following ICU discharge.
40797100|NCT06513130|OTHER|No geriatric assessment in the 7 days following ICU discharge.|No geriatric assessment in the 7 days following ICU discharge.
40797101|NCT00886327|PROCEDURE|Colonic capsule endoscopy|
40797102|NCT02497222|DRUG|RNS60|
41313853|NCT05071352|DRUG|Nefopam|Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
41313854|NCT05071352|DRUG|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.|In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
40797103|NCT02497222|DRUG|Normal Saline|
40797104|NCT02307240|DRUG|CUDC-907|CUDC-907 oral with meals.
40797105|NCT01789086|DRUG|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
41313855|NCT04515043|DRUG|INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.|blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine
41313856|NCT04446026|DRUG|teneligliptin|teneligliptin 20mg PO qd for 24weeks
40797106|NCT01789086|DRUG|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
40797107|NCT02453698|DRUG|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, \& Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
40797108|NCT02453698|OTHER|Placebo|Lactose Placebo
40797109|NCT03352999|PROCEDURE|Fast track access to vaECMO|"ROHCA must be witnessed with onset of bystander CPR and an immediate call to Emergency Dispatch. Furthermore, to minimize any loss of time, all qualified geographical locations are directly incorporated in the regulation software of the center for medical emergency control.~Patients suitable for vaECMO implantation were identified as early as possible by the Medical Dispatcher at the Emergency Call Dispatch Center.~Bystanders pursued CPR until Mobile Intensive Care Unit (MICU) arrival. OHCA was considered refractory after 10 min of CPR initiating the transport by MICU to the hospital such that the vaECMO intervention could be performed. The resuscitation was pursued during the transfer to hospital. An automated chest compression device was used in order to minimize interruption periods.~The intensivists and cardiac surgeons stood ready to implant the vaECMO surgically in the catheterization laboratory where a percutaneous coronary intervention was subsequently performed."
41313857|NCT04446026|DRUG|Placebo|teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks
41313858|NCT05465031|DRUG|Sacubitril-valsartan|Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.
41313859|NCT00286390|PROCEDURE|Acupuncture|
41313860|NCT03505138|DEVICE|Group intervention|"GROUP 1 (telematic group):~These patients will have a tablet connected via internet (Telefónica-e-Health). They have to measure their lung function, temperature, pulse oxymetry and symtoms questionnaire every week. The device (tablet) asks them about possible COPD exacerbation. If the patient has an exacerbation, the device offers them a treatment for this exacerbation and it begins a following of this exacerbation until resolution, every day.~The pneumologists will receive an alert in other tablet when the patients have an exacerbation or worsening of their diseases.~The period of monitoring is 1 year."
41472190|NCT06616272|OTHER|Standard Concussion Care|"Standard Concussion Care interventions are individualized to each patient and their adjudicated profile(s)/moderating factor(s) and may include any/all of the following:~* Behavioral regulation~* Vestibular rehabilitation~* Oculomotor rehabilitation~* Exertion rehabilitation~* Pharmacological management~* Behavioral sleep intervention~* \*Cervical spine rehabilitation (the variable of interest in this study)~* Psychotherapy"
41472191|NCT00903552|BIOLOGICAL|Influenza VLP Vaccine|
40797110|NCT02669394|BEHAVIORAL|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
40797111|NCT02669394|BEHAVIORAL|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
41313861|NCT03505138|OTHER|health care system|"GROUP 2 (conventional group or control group) Patients with a COPD exacerbation can go to their family physicians or emergency services and these physicians will establish a treatment and a monitoring of these exacerbation (conventional group).~The period of monitoring is 1 year."
41313862|NCT01782794|OTHER|Data collection|Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
41313863|NCT05483621|DRUG|Beta-hCG|Treatment of spermatogenesis
41313864|NCT04895098|DRUG|statin and ezetimibe combination therapy|Receiving statins (atorvastatin/rosuvastatin or others) in combination with ezetimibe 10mg/day in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
41313865|NCT04895098|DRUG|statin monotherapy|Receiving statins (atorvastatin/rosuvastatin or others) as monotherapy in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
41313866|NCT03348852|DEVICE|Transcranial direct current stimulation|Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
41313867|NCT06361264|COMBINATION_PRODUCT|Karanahan|During the preparatory stage, a tumor sample from participant is harvested intraoperatively. The primary culture is obtained from this tumor tissue sample. Repair cycle time is estimated, and the day when tumor cells are synchronized at the cell cycle G2/M phase is identified. The schedule of administering cyclophosphamide and DNAmix complex composite preparation is calculated according to the resulting time points. According to the elaborated regimen, the participant receives 4 intravenous cyclophosphamide injections at the dose of 300 mg/m2 in combination with 4 injections of 1-12 mg of DNAmix administered into prominent tumor nidi and lymph depots. The participant receives from 2 to 6 courses of therapy. The interval between courses is 21 days.
41472192|NCT00903552|BIOLOGICAL|Placebo|phosphate-buffered saline (PBS)
41472193|NCT04184999|DRUG|dexamethasone intraocular suspension, 9%|single dose intracameral corticosteroid
41472194|NCT04184999|DRUG|Prednisolone Acetate 1% Oph Susp|topical ophthalmic steroid drop
41472195|NCT02148913|DRUG|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
41472196|NCT02148913|DRUG|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6
41472197|NCT02148913|DRUG|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5
41472198|NCT02148913|DRUG|Cohort 3b: Carfilzomib 27 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
41472199|NCT01264913|BEHAVIORAL|sleep extension & circadian alignment|Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
41313868|NCT05727085|OTHER|All pregnant women with a twin pregnancy and the offspring|No intervention
41313869|NCT02699242|DEVICE|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
41001635|NCT05489315|OTHER|Traditional positioning|If participants are randomly selected to NOT receive a peanut ball, the intent is for the patient to undergo traditional positioning/use wedge pillows during their labor progression.
41472200|NCT02384291|DEVICE|Alpha-Bio GRAFT Natural Bovine Bone|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
41313870|NCT05413005|COMBINATION_PRODUCT|ECP regular-intensity arm|"* Weeks 1-8: Once every 2 weeks: weeks 1, 3, 5, 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Once per month: weeks 9, 13 (cryo-ECP bags infused once-a-week)~* Weeks 17-24: One: week 17 (cryo-ECP bags infused every two weeks)"
41472201|NCT02384291|DEVICE|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
41472202|NCT05792319|DIAGNOSTIC_TEST|24 hour copper in urine and liver function test|sampling 24 hour copper in urine and liver function test
41472203|NCT04593342|DEVICE|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
41472204|NCT04593342|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
41472205|NCT06525857|OTHER|LTOT|Patients with newly prescribed LTOT will be monitored for physiological changes
41313871|NCT05413005|COMBINATION_PRODUCT|ECP accelerated-intensity arm|"* Weeks 1-8: Once every week: weeks 1- 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Cryo-ECP bags infused once-a-week~* Weeks 17-24: Cryo-ECP bags infused every two weeks"
41313872|NCT05413005|BIOLOGICAL|T1DM standard of care|"The standard of care is defined as per the DOH Standards for diagnosis, management and data reporting for diabetes in combination with the DOH recommended NICE guidelines Type 1 diabetes in adults: diagnosis and management (NG17)"
41313873|NCT02300428|DIETARY_SUPPLEMENT|oral iron|BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
41313874|NCT01573507|OTHER|sodium lactate infusion|3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
41313875|NCT04574063|BEHAVIORAL|Lifestyle intervention to reduce breast cancer risk|Women will be educated about lifestyle factors which increase breast cancer risk. They will also be guided through an online goal setting process.
41313876|NCT00231244|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|CYPHER Sirolimus-Eluting Coronary Stent
41313877|NCT05830188|BEHAVIORAL|Coping and Resilience Intervention for Adolescents|It is a school-based resilience enhancement program to help adolescents build skills of positive coping and social support to minimize negative coping and distress by sharing, identifying, and discussing their feelings, thoughts, and actions regarding problems and stressful events.
41472206|NCT05653635|RADIATION|Simultaneous-integrated boost with IMRT|Simultaneous-integrated boost guided by FDOPA-PET
41472207|NCT01294566|DRUG|GSK1322888|1 mg, 5 mg or 25 mg capsule
41472208|NCT01294566|DRUG|Placebo|matching placebo capsules
41472209|NCT03297294|DRUG|EMA401|capsules, oral
41472210|NCT03297294|DRUG|Placebo|Placebo to EMA401 capsules, oral
41472211|NCT05951348|PROCEDURE|Delayed cord clamping for 30 seconds|waiting for 30 seconds after delivery of the fetus or milking of the cord in the direction of the fetus 10 times in time frame 10-15 seconds
41472212|NCT04380649|DEVICE|New headset prototype|creation of a new headset prototype for using the P300 Speller, comfortable to use in everyday life by people with disabilities.
40797112|NCT01464645|DEVICE|Modular Revision Hip System|Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
41001636|NCT02455310|BEHAVIORAL|Educational activities to improve dementia care|The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
41001637|NCT02502266|DRUG|Cediranib|Given PO
41001638|NCT02502266|DRUG|Cediranib Maleate|Given PO
41001639|NCT02502266|PROCEDURE|Computed Tomography|Undergo CT
41001640|NCT02502266|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41001641|NCT02502266|DRUG|Olaparib|Given PO
41001642|NCT02502266|DRUG|Paclitaxel|Given IV
41001643|NCT02502266|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
41001644|NCT02502266|OTHER|Questionnaire Administration|Ancillary studies
41001645|NCT02502266|DRUG|Topotecan|Given IV
41001646|NCT02502266|DRUG|Topotecan Hydrochloride|Given IV
41001647|NCT01933048|DRUG|FluMist|FluMist Intranasal Vaccine
41001648|NCT00983580|DRUG|Aspirin|Given PO
41001649|NCT00983580|DRUG|Eflornithine|Given PO
41472213|NCT02919111|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
41313878|NCT05830188|OTHER|Printing materials of Coping and Resilience Intervention for Adolescents|Printing materials for the CERIA sessions will be given to school counselors who provide school counseling programs in the control group.
41313879|NCT04955002|OTHER|No intervention|No intervention
41313880|NCT03201146|DRUG|Apatinib|Doses to be determined following the completion of Phase I of the study.
41313881|NCT03201146|DRUG|AP or AC|Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
41313882|NCT03201146|DRUG|Apatinib 250mg|250mg/d,q.d.,p.o.every 21 days.
41313883|NCT03201146|DRUG|Apatinib 500mg|500mg/d,q.d.,p.o.every 21 days.
41313884|NCT03201146|DRUG|Apatinib 750mg|750mg/d,q.d.,p.o.every 21 days.
41313885|NCT02723591|DRUG|Tacrolimus|Oral Capsule
41313886|NCT02723591|DRUG|Tacrolimus immediate release|Oral Capsule
41313887|NCT04108013|DRUG|SHR-1210|In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
41313888|NCT04108013|DRUG|Carboplatin and Paclitaxel-albumin|In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
41313889|NCT01458314|OTHER|Daily NIV during rehabilitation|Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
41313890|NCT01458314|OTHER|Rehabilitation without NIV|Training in patients without NIV adoption
41313891|NCT01700517|OTHER|Spinal anesthesia|spinal anesthesia
41472214|NCT06481098|DRUG|HM15275|HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
41001650|NCT00983580|OTHER|Laboratory Biomarker Analysis|Correlative study
41001651|NCT00983580|OTHER|Placebo|Given PO
41001652|NCT00983580|OTHER|Telephone-Based Intervention|Ancillary studies
41001653|NCT03026257|DEVICE|Lotrafilcon B contact lenses with added wetting agent|Silicone hydrogel contact lenses
41001654|NCT03026257|DEVICE|Samfilcon A contact lenses|Habitual silicone hydrogel contact lenses
41001655|NCT03026257|DEVICE|POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent|Multi-purpose disinfecting solution for contact lens care
41001656|NCT03026257|DEVICE|Hydrogen peroxide-based contact lens solution with added wetting agent|Solution for contact lens cleaning and disinfecting
41001657|NCT03026257|DEVICE|Senofilcon C contact lenses|Habitual silicone hydrogel contact lenses
41313892|NCT01700517|OTHER|Femoral nerve block|Femoral nerve block
41313893|NCT01700517|OTHER|sciatic nerves block|sciatic nerves block
41313894|NCT02570529|DRUG|Albis®|The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
41472215|NCT06481098|DRUG|Placebo of HM15275|A sterile, matching solution supplied in pre-filled syringes.
41472216|NCT05099523|PROCEDURE|taking arterial blood sample through the injector|taking blood samples from patients applied with different oxygen concentrations
41472217|NCT05198765|BEHAVIORAL|BMI-CDS|The BMI-CDS is a sophisticated point of care shared decision support tool for patients with type 2 diabetes and high BMI. The intervention is built on existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and updated CDS all subsequent primary care office, video, and phone encounters.
41001658|NCT03026257|DEVICE|Senofilcon A contact lenses|Habitual silicone hydrogel contact lenses with a replacement pair issued after 2 weeks
41001659|NCT03026257|DEVICE|Comfilcon A contact lenses|Habitual silicone hydrogel contact lenses
41001660|NCT03026257|DEVICE|Habitual Multi-Purpose Solution (HMPS)|Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
41001661|NCT02501980|BIOLOGICAL|Biomarker testing and Ultrasonography|
41001662|NCT02915614|PROCEDURE|Pulmonary rehabilitation|3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
41001663|NCT00006484|DRUG|carboplatin|
41001664|NCT00006484|DRUG|paclitaxel|
41001665|NCT00006484|DRUG|tirapazamine|
41001666|NCT06249282|PROCEDURE|Biopsy|Undergo biopsy
41001667|NCT06249282|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41001668|NCT06249282|DRUG|Carfilzomib|Given IV
41001669|NCT06249282|PROCEDURE|Computed Tomography|Undergo CT
41001670|NCT06249282|PROCEDURE|Echocardiography|Undergo ECHO
41001671|NCT06249282|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41001672|NCT06249282|DRUG|Sotorasib|Given PO
41001673|NCT05633706|DEVICE|fluid biopsy capsule|Collection of a fluid biopsy from the small intestine via ingestible capsule
41001674|NCT03913143|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
41001675|NCT03913143|OTHER|Sham|Sham-Procedure (no experimental drug administered)
41313895|NCT02570529|DRUG|Placebo|The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
41313896|NCT01362946|BEHAVIORAL|Reward-Emphasized Treatment|Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized
41313897|NCT01362946|BEHAVIORAL|Standard Treatment|Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
41313898|NCT05785390|DRUG|NP-101|NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
41313899|NCT05785390|OTHER|Placebo|Identical placebo
40797113|NCT05849350|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
41001676|NCT02978742|BEHAVIORAL|Adaptive Recovery Record App|Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
41001677|NCT02978742|BEHAVIORAL|Standardized Coaching|Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
41001678|NCT04126291|BEHAVIORAL|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
41001679|NCT04365699|DRUG|AT-001|Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team
41001680|NCT06182358|DRUG|Lotilaner ophthalmic solution, 0.25%|XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days
41001681|NCT06182358|DRUG|Vehicle control|Vehicle of XDEMVY administered topically twice a day for approximately 43 days
41001682|NCT01640366|DEVICE|PICO|Single-use Negative Pressure Wound Therapy System
41001683|NCT03764722|DRUG|Levosimendan|"The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP \<90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months."
41001684|NCT04369248|OTHER|hepassocin|hepassocin levels in polycystic ovary syndrome
41151151|NCT05415644|DRUG|hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets|"High-specification group: subject preparation: HRX0701 (50 mg/1000 mg) 1 tablet (to be taken after a meal); Reference preparation: 1 tablet of retagliptin phosphate (50 mg), 2 tablets of metformin hydrochloride (Glucophage®) (500 mg), taken twice after meals.~Low Specification Group:~Preparation: HRX0701 (50 mg/850 mg) 1 tablet (taken after a meal); Reference: 1 tablet of retagliptin phosphate (50 mg), 1 tablet of metformin hydrochloride (Glucophage®) (850 mg), taken twice after meals."
41313900|NCT02456870|OTHER|Overfeeding|Consumption of 40% excess calories for 7 consecutive days
41151152|NCT05415644|DRUG|hrx0701 tablets|"High specification group HRX0701 (FDC) tablets (50 mg / 1000 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).~Low-spec group HRX0701 (FDC) tablets (50 mg / 850 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach)."
41151153|NCT03595826|DRUG|Neurostimulant pharmaceutical drugs|The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
41151154|NCT00144937|DRUG|Stepwise therapy for dyslipidemia, hypertension and diabetes|
41313901|NCT00539916|BEHAVIORAL|Regular orange juice consumption|600 mL /day.
41313902|NCT05521217|DIAGNOSTIC_TEST|MyotonPRO|"Evaluation of biomechanics and viscoelastic properties of posture muscle in children with Spinal Muscular Atrophy.~The biomechanical and viscoelastic properties of the posture muscle in children with Spinal Muscular Atrophy. will be measured with the MyotonPRO device."
41313903|NCT04051151|BEHAVIORAL|Gameficiation|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game platform via Way to Health. This game will include wearing a Fit Bit device, setting a daily step goal, and point deductions for failure to meet this step goal throughout the following 4 weeks. Participants will move up or down specified levels each week depending on how many days they met their step goal.
41313904|NCT02521961|OTHER|Informational Intervention|Watch a Chair-robics DVD
41313905|NCT02521961|OTHER|Informational Intervention|Receive community resource booklet
40797114|NCT05849350|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
40797115|NCT06216327|BEHAVIORAL|household safety intervention|This intervention includes a household safety intervention that is delivered by an interventionist with specific training in facilitating lethal means safety discussions, and the provision of no-cost safety devices for medications and firearms.
40797116|NCT03346187|DRUG|Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)|Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)
40797117|NCT03346187|DRUG|Test drug(CKD-337)|CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
40797118|NCT05100355|PROCEDURE|Physiological serum injection|In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray
40797119|NCT05100355|PROCEDURE|Contrast agent injection|In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray
41472218|NCT05947526|PROCEDURE|Oocyte pick-up|With the needle, transvaginally USG-guided oocyte pick-up procedure is going to be performed
41472219|NCT00288665|DEVICE|Export catheter (Medtronic)|
41472220|NCT02111122|DRUG|Sodium Oxybate|
41472221|NCT02111122|DRUG|Placebo|
41472222|NCT05933473|PROCEDURE|Percutaneous coronary intervention|percutaneous intervention to oseal LAD with or without LM stenting
41472223|NCT04291508|DRUG|Intravenous Acetaminophen (room temperature)|Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs \< 50 kg) every six hours for 5 days (20 doses)
41472224|NCT04291508|DRUG|Intravenous Vitamin C (refrigerated)|Vitamin C given intravenously at the dose of 50 mg/kg every six hours for 5 days (20 doses)
41472225|NCT04291508|DRUG|5% Dextrose (room temperature)|Placebo (identical appearing room temperature 5% dextrose solution) infused every six hours for 5 days (20 doses)
41472226|NCT04291508|DRUG|5% Dextrose refrigerated|Placebo (identical appearing refrigerated 5% dextrose solution) infused every six hours for 5 days (20 doses)
41472227|NCT01669031|OTHER|Practice program|Each practice session (simulated visual field test on computer) takes 3-15 minutes
41472228|NCT00698087|BIOLOGICAL|MPL-Adjuvanted recombinant hepatitis B vaccine|Intramuscular injection, 2 or 3 doses, 2 different formulations
41472229|NCT00698087|BIOLOGICAL|Engerix™-B|Intramuscular injection, 2 or 3 doses
41472230|NCT06617039|DRUG|Remifentanil and ciprofol|R group will be started with remifentanil 0.5ug/kg and ciprofol 0.4 mg/kg.
41472231|NCT06617039|DRUG|esketamine 0.3mg/kg and ciprofol|Anesthesia induction was initiated by esketamine 0.3mg/kg, followed by ciprofol 0.2-0.4mg/kg.
41472232|NCT06617039|DRUG|esketamine 0.5mg/kg and ciprofol|Anesthesia induction was initiated by esketamine 0.5mg/kg, followed by ciprofol 0.2-0.4mg/kg.
41472233|NCT06617039|DRUG|Ciprofol|Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.
41472234|NCT01553747|DRUG|Eluxadoline|Oral tablets twice daily
41472235|NCT01553747|DRUG|Placebo|Oral tablets twice daily
41472236|NCT01665651|DRUG|Yougui granules|Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
41472237|NCT01665651|DRUG|Zuogui granules|Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
41001685|NCT04021264|DRUG|Ropivacaine-Sufentanil|Local anesthetic injection
41001686|NCT04021264|DRUG|Dextrose 5|Sham injection
41001687|NCT04197570|DRUG|Opioid Anesthetics|see arm/group description
41151155|NCT00144937|BEHAVIORAL|Dietary recommendations|
41001688|NCT04197570|DRUG|Non Opioid Analgesics|see arm/group description
41001689|NCT05994716|OTHER|Telemonitoring|"A) Monthly completion data on the web platform: 1) SCCAI for Ulcerative colitis and Harvey-Bradshaw index for Crohn disease. 2) IBD disk questionnaire to evaluate disease dynamics. 3) General blood test.~B) Possibility of online consultation with a gastroenterologist upon request via chat or phone call.~C) Access to educational information about IBD, necessary lifestyle changes, dietary recommendations;~D) monthly phone call will be made to each patient from the intervention group to answer any questions or concerns they may have and to interview them according to the checklist."
41001690|NCT00449293|BEHAVIORAL|standard cognitive behavioral therapy|Standard therapy to help participants with smoking cessation.
41001691|NCT00449293|BEHAVIORAL|Mindfulness Based Cognitive Therapy|A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
41001692|NCT06344819|PROCEDURE|Acupuncture|Acupuncture involves insertion of thin filiform needles (gauze 30-40) at certain points on the body.
41151156|NCT00144937|BEHAVIORAL|Increase in physical activity|
41151157|NCT00144937|BEHAVIORAL|Smoking cessation|
41151158|NCT03378895|BEHAVIORAL|online questionnaire|Risk assessment identified by online questionnaire
41472238|NCT01665651|DRUG|Yougui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
41472239|NCT01665651|DRUG|Zuogui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
41313906|NCT02521961|OTHER|Quality-of-Life Assessment|Ancillary studies
41313907|NCT02521961|OTHER|Questionnaire Administration|Ancillary studies
41313908|NCT02521961|PROCEDURE|Support Group Therapy|Attend support group sessions
41313909|NCT06211530|DEVICE|SpO2 Sensor Testing|Participants participating in this study will be connected to eight (8) Portrait Mobile P-SA01PL/P-SP01PL prototype sensors provided by GEHC and two reference monitors, Nellcor N-600X V 1.6.0.0 and a forehead sensor, used as standard operating procedures at the site. Data will be collected using the Portrait Hub patient monitor. The participants are exposed to a desaturation protocol that sequentially decreases the SpO2 in a stepwise fashion. The goal is to achieve six stable oxygenation plateaus between 100 and 70% SpO2, while recording simultaneous SpO2 readings from the prototype and reference devices. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.
41313910|NCT01865435|GENETIC|cord blood sample|
41313911|NCT05102396|DRUG|Topical oxybutynin spray|Participants will receive topical oxybutynin spray (10%).
41313912|NCT05102396|DRUG|Topical placebo spray|Participants will receive topical placebo spray.
41313913|NCT05102396|DRUG|Oral oxybutynin|Participants will receive oxybutynin (tablets).
41313914|NCT00556218|BEHAVIORAL|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
41313915|NCT00556218|BEHAVIORAL|No Meditation|No meditation; usual care.
41313916|NCT05471245|DEVICE|Magic Touch SCB by Concept Medical Inc.|PCI with drug-coated balloon
41313917|NCT04620915|BEHAVIORAL|High-level construal|"In the high-level construal condition, participants will be sent messages asking them to consider why they are quitting (What are your main reasons for quitting?) and to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014). The corpus for this condition is 100 messages composed by a large independent sample of mTurk workers who are smokers and validated by a team of RAs trained to 0.8 reliability on ratings of high-level construal. To meet criteria for inclusion, a message must be rated as significantly closer to high-level (vs. low-level) on a rating scale of construal level.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
41313918|NCT04620915|BEHAVIORAL|Down-regulation of craving for cigarettes|"In the down-regulation of craving condition, participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences). The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability on ratings of plausibility AND effortful cognitive inhibition or control.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
41472240|NCT01525576|BEHAVIORAL|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
40797120|NCT01926951|DEVICE|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
40797121|NCT02623205|DRUG|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
41151159|NCT05711745|PROCEDURE|Calf myofascial technique|A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
41472241|NCT05571072|OTHER|Opioid calculator|Our research group previously created an Opioid calculator that can be used to predict the number of opioids needed post-operatively based on patient health history and characteristics.
41472242|NCT05571072|OTHER|Standard opioid prescription|Patients will receive prescription for post-operative opioids based on what the attending surgeon usually provides.
41472243|NCT01355718|DRUG|repaglinide|The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
41472244|NCT04239482|DIETARY_SUPPLEMENT|L-arginine + Nitrate / Nitrite|Longer-term supplementation (8 weeks)
41472245|NCT04239482|DIETARY_SUPPLEMENT|Placebo|Longer-term supplementation (8 weeks)
41472246|NCT06316713|BEHAVIORAL|One MORE (Spanish Adaptation)|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into two, 1-hour segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Participants will also be guided through a mindful pain management practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The second segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, as well as learning to focus on increasing the positive emotions that can attenuate pain with mindful savoring.
41472247|NCT04341272|DEVICE|Intermittent Pneumatic Compression Device (FDA approved)|Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
41472248|NCT05069155|BEHAVIORAL|Gamification|Each participant signs a pre-commitment contract agreeing to try their best to achieve their daily step goal. Each week over the 12 week intervention period, participants are endowed 70 points (10/day). Participants are informed they will lose 10 points for each day the step goal is not met. Points are replenished at the start of the week. At the end of the week, if the participant has 40 points or more, he/she will advance one level, or drop one level if they have less than 40 points. The levels include: blue (lowest), bronze, silver, gold, platinum (highest). Each participant begins in the middle (silver). Each participant will also select a spouse, family member, or friend that they see often to serve as a supportive sponsor that receives a weekly email participants progress including points, game level, and average step countThis supportive sponsor will help to enhance social incentives to motivate the individual towards his or her goal.
41472249|NCT05307406|BIOLOGICAL|Experimental|Participants will receive a single IV infusion in a double blind manner
41472250|NCT04808349|OTHER|no intervention|no intervention
41472251|NCT05546242|DRUG|Cabotegravir/Rilpivirine|injectable long-acting cabotegravir 600mg + long-acting rilpivirine 900mg administered every 2 months
41151160|NCT02650453|PROCEDURE|Deep venous reconstruction|PTA \& stenting with/without endophlebectomy and/or arteriovenous fistula creation
41151161|NCT01412398|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in CAPD who have received Fosrenol for hyperphosphatemia
41151162|NCT05112172|OTHER|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
41151163|NCT02662023|DRUG|Bolus|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.
41151164|NCT02662023|DRUG|Basal|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.
40797122|NCT02623205|DRUG|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
40797123|NCT00236288|DRUG|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
41151165|NCT02701595|DRUG|Amoxicillin|amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients \>70kg)
41472252|NCT05546242|DRUG|Antiretroviral|Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
41472253|NCT06295744|RADIATION|Radiation Therapy|WBI with SIB delivered over 5 fractions
40797124|NCT04888416|BEHAVIORAL|I-STROM|I-STROM is a combination of the following implementation strategies: (a) initial and ongoing training, (b) learning collaboratives/knowledge sharing meetings, and (c) outcome measure champions
40797125|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
41313919|NCT04620915|BEHAVIORAL|Up-regulation of goal energization|"In the up-regulation of goal energization condition, participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking. These messages will name a specific core value that the participant rated in the top three (of 19) during the baseline session, and will draw a connection between quitting and the core value. For example, a message for a person who nominated family as one of her top three core values might read, Quitting will help you model a healthy lifestyle for your family. This intervention is grounded in robust theory and evidence supporting Self-Affirmation Theory. The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability in correctly identifying to which core value the message is tied.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics."
41313920|NCT03998917|DIAGNOSTIC_TEST|Discrimination of neuromuscular alterations protocol|Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
40797126|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
41313921|NCT02225574|DRUG|MEK-162|"Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
41313922|NCT02225574|DRUG|Nilotinib|"Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle."
41313923|NCT02225574|BEHAVIORAL|Questionnaires|Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
41313924|NCT01794819|DEVICE|C-reactive protein test|Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
41313925|NCT02276235|DEVICE|Catgut embedding group|"An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
41313926|NCT02276235|DEVICE|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
41313927|NCT05941351|PROCEDURE|flap fixation|flap fixation using running or interrupted sutures
41313928|NCT00396240|DRUG|Rosuvastatin|
41151166|NCT02701595|PROCEDURE|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
41151167|NCT04301609|DIETARY_SUPPLEMENT|Active|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
41313929|NCT00396240|PROCEDURE|Initiatives to improve compliance|
41313930|NCT01562366|DEVICE|Topaz|Radiofrequency micro debridement with Topaz will be used to treat the gluteal tendons following standard of care procedure
41313931|NCT01562366|PROCEDURE|Iliotibial band release and trochanteric bursectomy|Standard of Care: An iliotibial band release and trochanteric bursectomy will be performed.
41313932|NCT04366752|OTHER|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in ICU until the day of patient discharge
41313933|NCT04366752|OTHER|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in ICU until the day of patient discharge
41313934|NCT02172521|DRUG|Tiotropium bromide|Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
41313935|NCT03468699|COMBINATION_PRODUCT|Autologous BMMC transplantation|Stem cell transplantation
41472254|NCT01246362|DRUG|Control|Given placebo
41472255|NCT01246362|DRUG|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
41472256|NCT00458107|DRUG|SCA-136|
40797127|NCT00570778|DRUG|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
40797128|NCT00570778|DRUG|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
40797129|NCT00570778|DRUG|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
41151168|NCT04301609|DIETARY_SUPPLEMENT|Placebo|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
41472257|NCT06616701|BEHAVIORAL|Follow up call|As part of the standard of care, caregivers of youths who present to the hospital with suicidal risk receive a follow up call approximately 5-10 business days after the hospital discharge to assist them with any challenges they may encounter in accessing mental health care, including medication access. The intervention group will receive a call 5 days after discharge. The non-intervention group will receive a call 10 days after discharge.
41472258|NCT05524311|DRUG|Baricitinib|Oral tablets (2 mg) will be used For children \> or = 6 years: 4 mg once a day (2 x 2 mg) during the 24 weeks-period study For children \< 6 years: 2 mg once a day during the 24 weeks -period study
41472259|NCT05524311|BIOLOGICAL|pharmacokinetics study|additionnal blood sampling at week 4, 8, 12, and 24
41472260|NCT05524311|BIOLOGICAL|dosage of cytokines|additionnal blood sampling at weeks 0, 4 and 24
41472261|NCT05524311|BIOLOGICAL|transcriptomic analysis|additionnal blood sampling at weeks 0, 4 and 24
41472262|NCT05524311|BEHAVIORAL|Parent version of the Child Health Questionnaire (CHQ)|Evaluate by parents at each visits
41472263|NCT05524311|BEHAVIORAL|Childhood Health Assessment Questionnaire|Evaluate by parents at each visits
41472264|NCT05524311|BIOLOGICAL|Pregnancy test|Urine pregnancy test at V4 A dosage of bHCG with current biological analysis is done at each visit (except V4)
40797130|NCT01148901|DRUG|Infliximab|Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
41472265|NCT03352375|DEVICE|Orotracheally intubation|Interventions used for airway safety and ventilation during surgical procedures
41151169|NCT02798861|DEVICE|Fibroscan 402/530|Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.
41001693|NCT06344819|OTHER|Sham Acupuncture|During sham acupuncture, the point on the participant's thigh 6 inches proximal to the ST36 acupuncture point is gently tapped with an acupuncture needle guide tube and an acupuncture needle is taped flat to the skin. This point is not on any acupuncture meridian or point.
41313936|NCT05122195|OTHER|Compression therapy|Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.
41313937|NCT02090192|PROCEDURE|WBV training|
41001694|NCT00688480|DRUG|Placebo|1 capsule, orally for 9 months
41001695|NCT00688480|DRUG|Allopurinol|Allopurinol 300 mg once/day orally, 9 months
41001696|NCT00998634|DRUG|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
41001697|NCT05795894|BEHAVIORAL|STAI-Y|Situational Anxiety and Trait Anxiety Inventory
41313938|NCT02090192|PROCEDURE|PRT training|
41151170|NCT00781209|PROCEDURE|Irradiation plus Stereotactic Radiosurgery|"Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:\<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy."
41313939|NCT04206527|BEHAVIORAL|Training of AHSAs on PCC for FP|ASHAs provided with training on FP methods and counseling plus PCC for FP
41313940|NCT04206527|BEHAVIORAL|Enhanced FP training|Participation in an enhanced FP training including PCC
41472266|NCT03352375|DEVICE|Laryngeal Mask Airway|Interventions used for airway safety and ventilation during surgical procedures
41472267|NCT01216410|DRUG|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
41472268|NCT01216410|DRUG|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
41472269|NCT01216410|DRUG|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
41472270|NCT00108576|DRUG|Divalproex|anticonvulsant; mood stabilizer
41472271|NCT00108576|OTHER|placebo|Look-a-like placebo
41472272|NCT05368558|DRUG|Cariprazine|Oral Capsule
41472273|NCT05368558|DRUG|Placebo|Oral Capsule
41472274|NCT03311308|DRUG|Pembrolizumab Injection [Keytruda]|200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
41472275|NCT03311308|DRUG|Metformin|500 mg, by mouth, twice a day for nine weeks.
41472276|NCT01357434|BEHAVIORAL|Fast Food Restaurant|Participants will purchase a meal at Subway and McDonald's, on different days.
41472277|NCT03808870|DRUG|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
41472278|NCT06412302|OTHER|Whey Protein+Resistance Training|WP group received 25g protein on one scoop of Whey Protein Isolate (Iso100 Dymatize) with 8 weeks of resistance training 3 days a week.
41151171|NCT04371471|DIAGNOSTIC_TEST|STC-19 score|Score calculated by an algorithm using a vital sign (systolic blood pressure) and biomarkers (complete blood count with differential)
41313941|NCT01814488|PROCEDURE|allogeneic transplant|"Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.~The conditioning regimen in standard use is:~Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;~Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;~Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.~Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if \<40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice."
41001698|NCT05795894|BEHAVIORAL|BDI scale|• Beck Depression Inventory scale
41151172|NCT04028128|DIETARY_SUPPLEMENT|Cocoa group|Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
41313942|NCT03522272|DEVICE|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with cetylpyridinium chloride
41313943|NCT03522272|DEVICE|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with water
41313944|NCT03522272|OTHER|Conventional denture hygiene|Mechanical cleaning of denture with a soft toothbrush and liquid detergent
41313945|NCT04273399|OTHER|High-impact exercise intervention|"* Twelve-week high-impact exercise intervention~* Majority home based sessions, some supervised sessions~* Three exercise sessions per week~* Between 50 - 100 jumps per session~* Progressive jumping exercises to increase mechanical loading"
41313946|NCT04273399|OTHER|Acute response to high-impact exercise|"* First session of twelve-week high-impact exercise session used to assess the acute physiological response to one session of high-impact exercise in both Crohn's disease and healthy controls~* One supervised session of high-impact exercise~* Bloods to assess acute inflammatory and bone turnover response post-exercise"
41313947|NCT05900193|DIETARY_SUPPLEMENT|TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test|Participants drank a glucose beverage for an oral glucose tolerance test along or with admixture with the TAS1R2/3 agonist sucralose or the TAS1R2/3 antagonist lactisole.
41313948|NCT00361127|DRUG|isotonic saline infusion|
41313949|NCT01892098|DIETARY_SUPPLEMENT|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
41313950|NCT01892098|DIETARY_SUPPLEMENT|Placebo|Cellulose pill given as placebo
41313951|NCT05086289|DRUG|LY3526318|Administered orally
41313952|NCT05086289|DRUG|Placebo|Administered orally
41313953|NCT01665521|OTHER|HEART Pathway|During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
41313954|NCT01605344|DRUG|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
41313955|NCT01605344|DRUG|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
41313956|NCT01147575|DIETARY_SUPPLEMENT|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH the groups were switched for another 6 months (period 2).
41313957|NCT01147575|DIETARY_SUPPLEMENT|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without placebo the groups were switched for another 6 months (period 2).
41313958|NCT03721185|COMBINATION_PRODUCT|Dr.K. Treatment|Overweight and obesity treatment response
41151173|NCT04028128|DIETARY_SUPPLEMENT|Placebo group|The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
41001699|NCT05795894|BEHAVIORAL|M.I.N.I.Kid|"Suicidal risk module of the Mini-International Neuropsychiatric Interview child/adolescent version"
41001700|NCT05795894|BEHAVIORAL|PCL-5|Post-traumatic Check List Scale
41001701|NCT02273843|DRUG|High-dose vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
41001702|NCT02273843|DRUG|Conventional-Dose Vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
41151174|NCT03138616|DRUG|vitamin D|take 1600 units of vitamin D daily for nine months
41151175|NCT03713437|DIAGNOSTIC_TEST|Measurement of differentially methylated insulin DNA|A serum sample will be drawn to measure differentially methylated insulin DNA.
41151176|NCT04285476|DIAGNOSTIC_TEST|Signature of microRNA for patients with bethesda classification 3, 4 or 5|If the cytology results are Bethesda 3, 4 or 5, then a miRNA analysis will be performed.
41313959|NCT06411223|BEHAVIORAL|Collaborative drug therapy management model|CDTM+ is an interdisciplinary approach to patient care in which clinicians collaborate with pharmacists to provide and manage patient drug therapy.
41313960|NCT06411223|DRUG|Cabotegravir/Rilpivirine|Long-acting injectable treatment prescribed to treat HIV-1 infection in people 12 years and older and who weigh at least 77 lbs (35kg), to replace their current HIV-1 medicines when their healthcare provider determines they meet certain requirements.
41313961|NCT04746183|DRUG|CST-2: EIDD-2801|"CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
41313962|NCT04746183|DRUG|CST-2: Placebo|CST-2 Phase II: Placebo will be administered orally, twice daily (BID) for 10 doses (5 or 6 days).
41313963|NCT04746183|DRUG|Nitazoxanide|"CST3A \& CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
41472279|NCT06412302|OTHER|High protein yogurt+Resistance Training|PY group received 24.6g protein on two High Protein yogurts (Lonco Leche) with 8 weeks of resistance training 3 days a week.
41313964|NCT04746183|DRUG|VIR-7832|"CST-5: Phase I, Single doses of VIR-7832 will be administered by intravenous (IV) infusion over 1 hour. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated, with escalation guided by emerging safety data and decision by the SRC.~Phase II: As per Phase I, with the dose determined by the recommended phase II dose."
41472280|NCT06430918|OTHER|physical examination, questionnaires and inventories|Questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
41472281|NCT03081910|GENETIC|Autologous CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"
41472282|NCT03081910|GENETIC|Allogeneic CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"
41472283|NCT01253928|DRUG|Pioglitazone|45mg qd for 4 months
41472284|NCT01634412|DRUG|SL TNX-102 2.4 mg at pH 3.5|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
41472285|NCT01634412|DRUG|SL TNX-102 2.4 mg at pH 7.1|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
41472286|NCT01634412|DRUG|Cyclobenzaprine Tablet|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
41472287|NCT01634412|DRUG|Cyclobenzaprine IV|1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
41472288|NCT05208879|BIOLOGICAL|Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only)|"Carotenoid status will be determined by measuring plasma and erythrocyte concentrations of lutein and zeaxanthin obtained during an annual blood draw. These molecules will be analyzed by high performance liquid chromatography.~The oxidative stress markers will be measured, in the blood sample already collected, thanks to specific assay kits: Erythrocyte reduced glutathione, Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Plasma and erythrocyte malondialdehyde, Plasma vitamin C, Plasma oxidized cholesterol, F2-isoprostanes.~This study does not result in any change in patient management, but requires the collection of an additional volume of blood (14 ml of study-specific blood) during the annual blood draw performed as part of routine patient follow-up."
41472289|NCT05208879|OTHER|Characterization, evaluation and comparison of macular pigment density|The macular pigment optical density (OD) will be determined by an additional photograph during the fundus usually performed for annual follow-up through two-wavelength autofluorescence imaging. Indeed, the measurement of the optical density consists of an additional post-examination analysis of additional retinal images obtained during the fundus performed for the patients' ophthalmologic follow-up.
41472290|NCT04407299|BEHAVIORAL|self-administered structured questionnaire|It was designed as a self-administered questionnaire with closed questions (yes/no questions, rating scale and multiple choice questions) and some open ended questions.
41472291|NCT01392326|DRUG|Secukinumab (75 mg)|Secukinumab (75 mg)
41472292|NCT01392326|DRUG|Secukinumab (150 mg)|Secukinumab (150 mg)
41472293|NCT01392326|DRUG|Placebo Comparator|Placebo Comparator
41472294|NCT01249014|OTHER|Warmed fluids|IV fluids warmed by a Belmont fluid warmer
41472295|NCT01249014|OTHER|Fluid warmer and warming blanket|Warm are blown into a Bair hugger warming blanket covering the patient
41151177|NCT05893225|DRUG|Metformin Hydrochloride 850 mg Oral Tablet|Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.
41472296|NCT01249014|DEVICE|Belmont fluid warmer|Belmont fluid warmer used to warm fluids
41472297|NCT01249014|DEVICE|Bair hugger warming blanket|Bair hugger warming blanket laid on body
41472298|NCT06136650|DRUG|Opevesostat|Administered orally
41001703|NCT00107458|DRUG|valproic acid|
41001704|NCT03998007|DEVICE|IRIS System|A QEEG based pain biomarker that scales with the patient reported NRS
41151178|NCT05893225|DRUG|Placebo|Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.
41313965|NCT04746183|DRUG|VIR-7831|CST-5 Phase II: A 500 mg dose of VIR-7831 will also be given by IV infusion over 1 hour.
41313966|NCT04746183|DRUG|CST-5: Placebo|CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour
41472299|NCT06136650|DRUG|Dexamethasone|Administered orally
41472300|NCT06136650|DRUG|Fludrocortisone acetate|Administered orally
41472301|NCT06136650|DRUG|Hydrocortisone|Administered orally or IM as a rescue drug
41151179|NCT00771238|DEVICE|P500 Mattress|Study mattress
41151180|NCT01810328|OTHER|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
41472302|NCT06136650|DRUG|Abiraterone acetate|Administered orally
41472303|NCT06136650|DRUG|Prednisone acetate|Administered orally
41472304|NCT06136650|DRUG|Enzalutamide|Administered orally
41472305|NCT03767517|OTHER|Active Intervention|Half of the patients will receive tele-consult program. Tele-consult intervention includes: initial consult and 2 follow up contacts. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
41313967|NCT04746183|DRUG|Favipiravir|CST-6: Multiple doses of IV Favipiravir will be administered by intravenous (IV) infusion over 1 hour. Dosing regimen will be every 12 hours for 7 days duration. The starting dose will be 600mg (BID), and dose escalations to 1200mg (BID), 1800mg (BID) and 2400mg (BID) are anticipated as well as a de-escalation dose of 300mg (BID) if necessary, with de-escalation and escalation guided by emerging safety data and decision by the Safety Review Committee (SRC).
40797131|NCT05845619|BEHAVIORAL|Enhanced virologic monitoring|"The pilot intervention will include the following components:~1. More frequent viral load collection: Participants who enroll in the first 3 months of the pilot study period will be eligible for a 3-month follow-up visit and will have viral load assessed again at that time.~2. Rapid return of viral load results: Mentor mothers (peer counselors) will be trained to return viral load results to patients. Viral loads will will be processed with GeneXpert point of care technology.~3. Enhanced viral load counseling: Mentor mothers will reinforce adherence with all patients with undetectable levels via scripted messaging to reward and encourage healthy behavior. For those with any detectable levels, mentor mothers will be trained to provide targeted counseling with scripted messaging according to viral load level (undetectable, low-level viremia (50-1000), high viral load (\>1000))."
41001705|NCT05846620|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
41001706|NCT03030027|BEHAVIORAL|Connecting Through Caregiving|The Connecting Through Caregiving intervention focuses on reappraisal exercises on intergeneration relationships in caregiving, involving the following: 1) enhancing self-awareness of the caregiver, 2) developing interpersonal empathy for the care-recipient, 3) help-seeking in caregiving, 4) balancing self-care and caring and 5) negotiating action plans.
41001707|NCT03030027|OTHER|Basic Skills Building|Skill building involves: 1) monitoring activities, 2) pleasant event scheduling, 3) communicating with the care recipient, 4) communicating with family members and 5) review implementation
41001708|NCT01321788|DRUG|TINZAPARIN|Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
41151181|NCT01810328|OTHER|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
41151182|NCT04562571|OTHER|Charter & patient information leaflets|Public commitment charter, non-prescription pad, information leaflet in case of antibiotic prescription
41151183|NCT00938041|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
41151184|NCT03825614|BEHAVIORAL|training|plates and therapeutic exercises applied on young adults
41151185|NCT04885478|OTHER|Immune response monitoring , blood samples|"In both cohorts:~-SARS-CoV-2 IgG and IgM antibodies, ( Nucleocapside, Spike) in 8 visits during a year.~Infected HCW:~* Cytokines and T-Cell determination at baseline, 30, 60,180 days, 365 after positive test ( RT-PCR or SARS-CoV-2 antibodies )~* Covid-19 Symptoms, clinical monitoring"
41151186|NCT04213625|OTHER|Surgeon Personal Background|"Experimental group will receive an information sheet with their surgeon's educational and personal background.~Personal Background~* Favorite outdoor activity/form of exercise~* Favorite hobby~* Family information (children, pets)~* Single sentence about how the clinician conceptualizes excellent patient care"
41151187|NCT02949622|BEHAVIORAL|Multimodal intervention program|"The intervention is structured as follows:~Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)"
41151188|NCT02949622|OTHER|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
41151189|NCT00212979|OTHER|non intervention study|
41151190|NCT00471562|BIOLOGICAL|therapeutic angiotensin-(1-7)|sequentially increasing doses 50-1000 mcg/kg
41151191|NCT05776745|BEHAVIORAL|Speech|Patients read specific words and sentences
41151192|NCT05776745|DEVICE|Stereoelectroencephalography|Using stereoelectroencephalography to record the Intracranial EEG of the patient
41151193|NCT00719056|DRUG|Teicoplanin|The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
41151194|NCT00719056|DRUG|β-lactams or ciprofloxacin|Multiple doses for up to six consecutive days
41151195|NCT01765439|DIETARY_SUPPLEMENT|VSL#3 (Original De Simone formulation)|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
41313968|NCT04746183|DRUG|Molnupiravir|Molnupiravir 800mg Twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required.
41313969|NCT04746183|DRUG|Paxlovid|Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days. The dose of Paxlovid® will be fixed for all cohorts.
41313970|NCT00000875|DRUG|Indinavir sulfate|
41313971|NCT00000875|DRUG|Diphenhydramine hydrochloride|
41313972|NCT00000875|DRUG|Lymphocytes, Activated|
41313973|NCT00000875|DRUG|Lamivudine|
40797132|NCT01849393|OTHER|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
40797133|NCT04174157|OTHER|Prospective observational registry|This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
41313974|NCT00000875|DRUG|Zidovudine|
41313975|NCT00000875|DRUG|Acetaminophen|
41313976|NCT00000875|DRUG|Aldesleukin|
40797134|NCT04174157|DRUG|Zolgensma|Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
41313977|NCT01025817|DRUG|Everolimus and tacrolimus|"Everolimus:~* Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets~* Dose: 1.5 mg per day~* Frequency: 0.75 mg twice daily~Tacrolimus:~* Dose adjusted to maintain specific blood levels"
41313978|NCT01025817|DRUG|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
41313979|NCT04511468|DIETARY_SUPPLEMENT|Zinc, Chromium, Vitamin C, and Copper Supplementation|Combination of mineral and vitamin supplementation that consist of Zinc, Chromium, Vitamin C, and Copper
41313980|NCT04511468|BEHAVIORAL|Standard healthy lifestyle intervention|Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.
41313981|NCT04511468|OTHER|Placebo|Placebo with inactive ingredients
41313982|NCT02432248|DRUG|Dehydroepiandrosterone|75mg/day, PO for 90 days
40797135|NCT02317601|DRUG|methylprednisolone sodium succinate|Single dose Intravenous
40797136|NCT02317601|DRUG|placebo saline|
40797137|NCT03116035|OTHER|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
40797138|NCT03116035|OTHER|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
41313983|NCT02432248|OTHER|placebo(medical starch)|75mg/day, PO for 90 days
41313984|NCT02049749|BEHAVIORAL|Immediate CARE|CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
41313988|NCT00154141|DRUG|Fibrin sealant (FS2)|
41313989|NCT00513097|BEHAVIORAL|Smoking Prevention Program|Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.
40797139|NCT02096250|OTHER|NaFeEDTA|
40797140|NCT02096250|OTHER|Ferrous fumarate|
40797141|NCT02096250|OTHER|NaFeEDTA + ferrous fumarate|
40797142|NCT01393210|DIETARY_SUPPLEMENT|low calorie diet plus beta-glucan|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
40797143|NCT01393210|OTHER|low-calorie diet|low-calorie diet only for 12 weeks.
40797144|NCT01212965|DRUG|Selenium|400 μg once a day for 6 months by mouth
40797145|NCT00268944|BIOLOGICAL|Myozyme|20 mg/kg qow
40797146|NCT05129163|BEHAVIORAL|Exercise|The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
40797147|NCT05129163|BEHAVIORAL|Nutrition activities|The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
40797148|NCT02180204|DRUG|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
40797149|NCT02180204|DRUG|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
40797150|NCT03825640|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
41001709|NCT01321788|DRUG|PLACEBO|Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
41313990|NCT00513097|BEHAVIORAL|Focus Group|A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.
41313991|NCT00513097|BEHAVIORAL|Survey|On-line evaluations and questionnaires
41313992|NCT03256474|OTHER|Multimodal Therapy|Drugs, external applications like chest wraps, inhalations
41313993|NCT06238245|DRUG|Cyclophosphamid|ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg/kg, day -5; 2.5 mg/kg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and mismatched unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg/kg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.
41313994|NCT02085213|DRUG|Glyceryl Trinitrate|
41313995|NCT02085213|DRUG|Matched Placebo|Matched placebo
41313996|NCT00011479|DRUG|Abacavir sulfate|
41313997|NCT01258530|DRUG|over-encapsulated oseltamivir|75 mg once
41313998|NCT01258530|DRUG|oseltamivir|75 mg once
41313999|NCT01319643|DRUG|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
41314000|NCT05658354|OTHER|Computerized cognitive program|BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.
41314001|NCT00764478|DRUG|Asenapine|asenapine tablet, 5 mg sublingually BID for 21 days
41314002|NCT00764478|DRUG|Asenapine|asenapine tablet, 10 mg sublingually BID for 21 days
41314003|NCT00764478|DRUG|Placebo|placebo sublingual tablet, administered BID for 21 days
41314004|NCT03034408|DRUG|Nalmefene|
41472306|NCT03767517|OTHER|Usual Care|Half of the patients will receive usual care. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
41472307|NCT00002262|DRUG|Tumor Necrosis Factor|
41472308|NCT03989531|BIOLOGICAL|Adrecizumab|Drip infusion over 60 minutes
41472309|NCT03989531|DRUG|Placebo|Drip infusion over 60 minutes
41001710|NCT01807052|OTHER|laboratory biomarker analysis|Correlative studies
41001711|NCT01398566|BEHAVIORAL|SuperBetter play|average 10 min of game play per day for 6 week period
40797151|NCT02342860|OTHER|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~* Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~* Software: operations and maintenance (O\&M) training for teachers, hygiene training, and basic hygiene package."
40797152|NCT03573752|OTHER|outpatient management for promontofixation by laparoscopy|postoperative H8 exit after laparoscopic promontofixation
41001712|NCT01970683|DIETARY_SUPPLEMENT|VSL #3 BID|
41001713|NCT01139281|DRUG|Ginkgo Biloba Extract (GBE761)|The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
41314005|NCT03034408|DRUG|Baclofen|
41314006|NCT03034408|DRUG|Placebo Oral Capsule|
41314007|NCT05872594|DIAGNOSTIC_TEST|Online questionnaire|data will be collected remotely on the online platform Qualtrics
41314008|NCT06197932|OTHER|Routine exercise and running training|impact of a 4-week running training program on physical performance variables in a control group comprising 15 participants. The control group exclusively underwent running training, and measurements were taken for variables such as the strength of the big toe of both right and left feet using a hip and toe dynamometer (measured in kilograms). Additionally, assessments included vertical jump height and horizontal jump distance (both measured in centimeters), balance using the Y-balance test, and agility via the T-test. All measurements were conducted with standardized equipment, both before and after the training period. se physical performance indicators.
41314009|NCT06197932|OTHER|Big Toe Strengthening Exercise|impact of a 4-week intervention involving toe-strengthening exercises and concurrent running training on 15 participants. Pre-assessment measurements included big toe strength, vertical and horizontal jump heights, Y-balance for balance, and T-tests for agility. Following pre-assessment, participants followed a structured toe-strengthening protocol, performing 15 repetitions in three sets twice a day for three weeks. Post-intervention measurements, using the same units and instruments, aim to reveal the effects of the intervention on specified physical variables. This research provides insights into the potential benefits of combining toe-strengthening exercises with running training for enhanced physical performance.
41314010|NCT02697084|OTHER|anal cancer|Anal cancer patients with TEP TDM
41001714|NCT01139281|DRUG|Placebo|The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
41472310|NCT05259085|DRUG|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
41472311|NCT06304714|OTHER|Patients suffering from envenomation by Bothrops|"For research purposes, the investigator will collect six additional tubes of blood during a venipuncture. This additional volume of blood will be used for research analysis.~The total volume drawn will be within the maximum volume of blood that can be drawn based on body weight.~Venous sampling is planned as part of routine care and the additional blood volumes collected are not significant. This is a low risk procedure due to the small amount of extra blood taken (25,5 ml)."
41472312|NCT06369506|DIAGNOSTIC_TEST|GTmeasurement|GT was measured from the point corresponding to the base of the gingival sulcus and 1 mm and 2 mm apical to this point. If the GT was ≤1 mm, it was considered a thin phenotype, and if it was \>1 mm, it was considered a thick phenotype.
41472313|NCT03764735|DRUG|Low Dose - SkQ1|SkQ1 Low dose ophthalmic solution
41472314|NCT03764735|DRUG|High dose - SkQ1|SkQ1 High Dose ophthalmic solution
41472315|NCT03764735|DRUG|SkQ1 (Vehicle)|Vehicle for SkQ1 ophthalmic solution
41472316|NCT02971982|DRUG|rituximab /Dexamethasone/cyclophosphamide|rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
41472317|NCT02971982|DRUG|Velcade/Dexamethasone/cyclophosphamide|Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
41472318|NCT00237419|DRUG|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
41472319|NCT04234464|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol single dose
41472320|NCT04234464|COMBINATION_PRODUCT|Placebo metered-dose inhaler|Placebo inhalation aerosol single dose
41001715|NCT03887039|OTHER|clinical examination|clinical examination for all the oral findings
40797153|NCT03573752|OTHER|questionnaire|Each patient will complete a questionnaire on the experience of management, both in terms of pain management, anxiety and overall satisfaction.
40797154|NCT01288170|DRUG|Nebcinal Tobi|
40797155|NCT01288170|DRUG|Tobi Nebcinal|
41001716|NCT03561181|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
41001717|NCT03561181|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
41001718|NCT04182581|BIOLOGICAL|BCMA/CD19 Dual-Target CAR-T|BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.
41001719|NCT00542750|DRUG|N-Acetylcysteine|N-Acetylcysteine 1200 mg twice daily for four weeks
41472321|NCT03659084|DRUG|EXJADE|The patient having given his consent, will begin the Exjade at 10 mg / kg per day if the ferritin level reached 1000 ng / ml at 6 months after allograft, for a minimum duration of three months and up to 6 months. The iron parameters will be evaluated at 3, 6, 9, 12, 18 and 24 months after the beginning of the exjade treatment. The evaluation of the disease will be carried out according to the practices of the center. It is recommended to have a washout period of one week between stopping the ciclosporin and the beginning of treatment by exjade.
41472322|NCT02762617|DRUG|Tenofovir disoproxil fumarate intravaginal ring|The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
41472323|NCT02762617|DRUG|Placebo intravaginal ring (IVR)|The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
41472324|NCT06198530|BEHAVIORAL|cognitive training in NLCs|In the nurse-led clinics(NLCs) training group, CCT was given twice a week during 1-6 months and once a week during 7-12 month in nursing clinic. There is 60 minutes at a time.
41472325|NCT06198530|BEHAVIORAL|cognitive training in home|In the home-based training group, CCT was given four times a week during 1-6 months and twice a week during 7-12 month in nursing clinic. There is 30 minutes at a time. Nurses teach patients to acquire and carry out CCT at home during hospitalization. Nurses set the daily reminder function at 9:00am through training system.
41472326|NCT06198530|BEHAVIORAL|cognitive training in tradition|In the traditional training group, the Home Cognitive Training Manual for Alzheimer's Disease compiled by our research team was distributed.
40797156|NCT06311773|DEVICE|Boomerang Catheter|The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.
41001720|NCT06437210|DIETARY_SUPPLEMENT|Viusid Oral Solution|Patients in the experimental intervention group will be administered Viusid Oral Solution (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
41001721|NCT06437210|DIETARY_SUPPLEMENT|Placebo|Patients in the experimental intervention group will be administered Placebo (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
41151196|NCT00987155|DEVICE|Ergometry|MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
41151197|NCT02447380|DRUG|AZD6094|AZD6094 600MG qd
41151198|NCT02447380|DRUG|Docetaxel|Docetaxel 60 mg/m2
40797157|NCT04354948|BEHAVIORAL|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
40797158|NCT04354948|BEHAVIORAL|No pain (Hypotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
40797159|NCT05266846|DRUG|Pembrolizumab injection|Pembrolizumab 20mg ivgtt once every 21day Platium based Chemotherapy ivgtt once every 21day Bevacizumab 15mg/kg ivgtt once every 21day
40797160|NCT06039215|OTHER|Ventilatory adjustments by nurses|Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
40797161|NCT02671006|OTHER|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
41001722|NCT00003217|BIOLOGICAL|filgrastim|
41001723|NCT00003217|DRUG|cyclophosphamide|
41001724|NCT00003217|DRUG|cytarabine|
41151199|NCT02454647|DRUG|Induction chemotherapy|
41151200|NCT02454647|RADIATION|Radiotherapy with concurrent chemotherapy|
41151201|NCT02454647|PROCEDURE|Salvage surgery|
41151202|NCT03145142|PROCEDURE|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds
41151203|NCT03145142|PROCEDURE|Delayed Cord Clamping|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
41001725|NCT00003217|DRUG|dexamethasone|
41001726|NCT00003217|DRUG|doxorubicin hydrochloride|
41001727|NCT00003217|DRUG|methotrexate|
41001728|NCT00003217|DRUG|vincristine sulfate|
41151204|NCT02430597|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.
41151205|NCT02430597|DEVICE|NanoKnife|
41151206|NCT05118737|DRUG|Colchicine|colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
41151207|NCT03556345|DRUG|RC48-ADC|2.5 mg/kg IV every 2 weeks
41314011|NCT03447613|PROCEDURE|surgery|All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.
41314012|NCT02367534|PROCEDURE|umbilical vein catheterization|A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
41314013|NCT04881578|OTHER|continuous cardiac monitoring before and after transcatheter PFO closure|Data will be assessed from patients with cryptogenic stroke and planned PFO occlusion who undergo the contemporary ICM protocols to search for silent AF
41314014|NCT06536764|OTHER|Progressive Muscle Relaxation Exercises|Progressive muscle Relaxation exercises will be performed by this group.Advise women to sit in chair. The therapist's voice will then instruct them to contract and release different muscle groups. They will practice tensing a muscle group until they feel the slight contraction and then release it, simultaneously contracting and relaxing all other muscle groups.Practice will progress in the same manner, starting with the muscles in the feet, then the calf, thigh, gluteal muscles, abdomen, chest, hands, forearms, arms, shoulders, neck, face, and finally the forehead muscles .
41314015|NCT06536764|OTHER|Conventional Therapy(Hot pack,TENS,Patient Education)|Conventional therapy including hot pack and TENS will be applied for 10 minutes each. Meanwhile, patients will be given education to ease back pain and improve sleep.
41314016|NCT01758666|DRUG|Methotrexate,Calcium folinate|
41472327|NCT00101842|DRUG|Pemetrexed|
41472328|NCT00101842|DRUG|Gemcitabine|
41472329|NCT00101842|DRUG|Platinol|
40797162|NCT05798546|BIOLOGICAL|Neo-T|Patients will recive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
40797163|NCT05798546|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.
40797164|NCT05798546|DRUG|Fludarabine|Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.
40797165|NCT05798546|DRUG|Interleukin-2|500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
40797166|NCT03939338|OTHER|Treg levels and CMR results|This is an observational study. Exposure: Different Treg levels and CMR results.
40797167|NCT06400823|OTHER|VR+TENS|"During the invention, patients will be in VR scenarios and play task-oriented games, interacting with elements that appear in the virtual world, to improve mobility and functional independence of the upper limbs.~The task-oriented games will target different components depending on the disability of the patient."
40797168|NCT06400823|OTHER|Conventional rehabilitation|Patients will perform conventional upper-limb stroke rehabilitation. The movement performed will be comparable with the movement performed in the VR+TENS group
40797169|NCT01251718|DRUG|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
40797170|NCT03440515|DRUG|Prednisone|Prednisone treatment for severe skin rash induced by imatinib
41472330|NCT01429831|DRUG|Aripiprazole|starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
41472331|NCT02408445|DRUG|testosterone cypionate 200mg/ml|Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
41472332|NCT05434130|BEHAVIORAL|High Dose Exercise|The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (\>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
41472333|NCT06586151|BEHAVIORAL|Transcendent Health|Gender-inclusive HIV prevention program: Text messaging-based program that lasts 5 months. Content includes information, motivation and behavioral skills about how to prevent HIV, as well as information about healthy and unhealthy romantic relationships, and navigating issues related to one\&#39;s gender.
41472334|NCT06586151|BEHAVIORAL|Text Messaging with Information|Text messaging-based program that lasts 5 months. Content includes information about HIV prevention and aspects of a healthy adolescent lifestyle (e.g., self-esteem).
40797171|NCT03038971|BIOLOGICAL|Dose Level 1|Short and Tall Ragweed Mix
40797172|NCT03038971|BIOLOGICAL|Dose Level 2|Short and Tall Ragweed Mix
41472335|NCT02731963|DRUG|Polyethylene glycol|Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
41472336|NCT01049412|DRUG|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
40797173|NCT03038971|BIOLOGICAL|Placebo|Saline with 0.4% Phenol
40797174|NCT05679661|DIETARY_SUPPLEMENT|immunonutrition|Patients in the intervention group will receive additional immunonutrition supplementation, which is oral intake of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery.
40797175|NCT05679661|BEHAVIORAL|oral chlorhexidine decontamination|Patients in the intervention group will receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
40797176|NCT02526953|DRUG|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
40797177|NCT02526953|DRUG|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
40797178|NCT02526953|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
40797179|NCT02526953|DRUG|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
41472337|NCT01049412|DRUG|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
40797180|NCT02526953|DRUG|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
40797181|NCT02526953|RADIATION|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
41472338|NCT04526899|BIOLOGICAL|BNT111|IV injection
41472339|NCT04526899|BIOLOGICAL|Cemiplimab|IV infusion
41472340|NCT05545306|DIETARY_SUPPLEMENT|+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
40797182|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
40797183|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
40797184|NCT01389726|BEHAVIORAL|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
40797185|NCT01389726|BEHAVIORAL|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
41001729|NCT04589325|DRUG|Ixekizumab|"Ixekizumab will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Ixekizumab will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
41001730|NCT04589325|DRUG|Placebo|"Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
41472341|NCT05545306|DIETARY_SUPPLEMENT|fasting|Fasting for at least 24 hours
41472342|NCT05545306|DIETARY_SUPPLEMENT|-50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-50% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
41472343|NCT05545306|DIETARY_SUPPLEMENT|+150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+150% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
41472344|NCT05545306|DIETARY_SUPPLEMENT|+200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+200% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
41472345|NCT05545306|DIETARY_SUPPLEMENT|-25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
40797186|NCT01389726|BEHAVIORAL|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader \& 1 peer leader over the course of 11 weeks.
40797187|NCT03083665|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablets~* Route of administration: Oral use"
41151208|NCT05714774|DEVICE|HIFU treatment of prostate cancer|HIFU treatment using Focal One (EDAP TMS) combined with the acquisition of additional ultrasound images before, between, and after HIFU shots will be performed.
41151209|NCT01078571|BIOLOGICAL|adalimumab (HUMIRA®)|The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
41151210|NCT04528680|DEVICE|Sonication for opening of blood-brain barrier|Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles
41151211|NCT04528680|DRUG|Chemotherapy, albumin-bound paclitaxel|Intravenous infusion of ABX over 30 minutes
41151212|NCT04528680|DRUG|Chemotherapy, carboplatin|Intravenous infusion of carboplatin over 30 minutes
41151213|NCT01133678|DRUG|Everolimus|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel (175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus 5 mg PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
41151214|NCT01133678|DRUG|Placebo|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
41151215|NCT03973437|DEVICE|Artificial inteligence associated ulcerative colitis severity scoring system|Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
41314017|NCT05343806|DRUG|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
41314018|NCT05343806|DRUG|Magnesium Sulfate|Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
41314019|NCT04209647|OTHER|REHIT Exercise|"-Start with warm-up period --\> %50 of maximum work rate, 3 minutes~One Exercise Cycle consists of:~* 15 seconds exercise period: %100 of maximum work rate~* 15 seconds recovery period: %50 of maximum work rate~Total Duration: 10 minutes"
41314020|NCT04209647|OTHER|Continuous Aerobic Exercise|At %50 of maximum heart rate, 30-60 minutes aerobic exercise
41314021|NCT00710034|OTHER|Oral tobacco|Snus
41314022|NCT00710034|DRUG|Nicotine Gum|4 mg Nicotine gum
41314023|NCT01630096|DRUG|Nu-Lytely|Bowl prep solution.
41314024|NCT02569619|BEHAVIORAL|Activity Intervention|
41314025|NCT02569619|BEHAVIORAL|Healthy Diet Intervention|
41472346|NCT05545306|DIETARY_SUPPLEMENT|+150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
41472347|NCT02210052|DEVICE|Radiofrequency cannula|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
40797188|NCT03083665|DRUG|Brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 25 mg tablets and 50 mg tablets~* Route of administration: Oral use"
41314026|NCT00792233|OTHER|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
41314027|NCT01773096|DRUG|Methylnaltrexone|Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
41314028|NCT01773096|DRUG|Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax|Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
41314029|NCT00738543|OTHER|WHOLE GROUP OF 48 VOLUNTEERS|Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
41314030|NCT04600050|OTHER|usual care and exercise education|Provide exercise training materials after the education of exercise and health to enable home-based exercise
41314031|NCT04600050|OTHER|Eccentric exercise|Under the face-to-face supervisor, the eccentric exercise using a flywheel, and the self-directed home-based eccentric overload exercise using an elastic band are performed.
41314032|NCT04091230|DEVICE|TRUSbx|Trans Rectal UltraSound guided Prostate Biopsy
41314033|NCT04912037|DEVICE|artificial intelligence assistance system|the artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed, and feedback the overspeed percentage.
41314034|NCT05949606|DRUG|SI-B001|Administration by intravenous infusion
41314035|NCT05949606|DRUG|SI-B003|Administration by intravenous infusion
41314036|NCT05192174|BIOLOGICAL|NIB101|NIB101
41314037|NCT03990519|DRUG|JNJ-26366821|Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
41314038|NCT03990519|DRUG|Placebo|Participants will receive sodium chloride injection as placebo on Day 1.
41314039|NCT05760820|BEHAVIORAL|SES Children (SES Mini & SES Nxt)|"SES Children (SES Mini \& SES Nxt) is a digital intervention aiming to develop children's self-efficacy and ability to overcome the challenges that come with a divorce and major life crises, thereby reducing the negative impacts of these on children's overall mental health and wellbeing. The intervention formatted to specific age groups between the ages of 3 and 17, and is relevant to all children whose parents have split up, regardless of whether they experience a higher or lower degree of conflict between the parents, a or higher or lower degree of strain from the judicial divorce.~The intervention covers a variety of topics, including when my parents fight, a bonus family, packing the overnight bag, to live in two places, and children's rights."
41314040|NCT04116450|PROCEDURE|Glaucolight illuminated microcatheter.|To study circumferential trabeculotomy for congenital glaucoma using Glaucolight illuminated microcatheter.
40797189|NCT05657535|DEVICE|Low-intensity continuous ultrasound stimulator|Stimulation 5 minutes, 3 times a day for 4 weeks on the knee
40797190|NCT06156878|COMBINATION_PRODUCT|Anti-EGFR and PD-1 inhibitor arm|Drug: PD-1 inhibitor and anti-EGFR monoclonal antibody The patients will receive radiotherapy (66-70.4Gy) combined with PD-1 inhibitor (every 3 weeks) and anti-EGFR monoclonal antibody (every 1 week). The specific treatment description is included in arm description.
40797191|NCT06246422|DRUG|Tranexamic Acid 500 MG|Local instillation of 500 mg tranexamic acid in 20 ml normal saline in the gall bladder bed
40797192|NCT06246422|DRUG|Normal saline|Local instillation of 20 ml normal saline in the gall bladder bed
41001731|NCT01333488|DEVICE|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
41001732|NCT01333488|DRUG|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
41314041|NCT03303040|OTHER|Electrical stimulation of hemidiaphragm|Electrical impulses
40797193|NCT05965245|BEHAVIORAL|Suubi-Mhealth|Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.
40797194|NCT02808325|DRUG|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
41314042|NCT01226355|DEVICE|stent|"NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.~Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd."
40797195|NCT02808325|DRUG|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
40797196|NCT03260855|OTHER|Questionnaires/Scales|Scale of Fear of Cancer Recurrence Inventory, Hospital Anxiety and Depression Scale, Evaluation of stress and life quality.
41472348|NCT05091216|OTHER|Traditional Chinese Medicine mouthwash|The mouthwash used in this test is based on the records of past traditional Chinese medicine classics and the existing antibacterial experimental evidence. The selected medicinal materials are honeysuckle, scutellaria, peppermint, licorice, and rhizome.
41472349|NCT05091216|OTHER|Dilute 50 times of Traditional Chinese Medicine mouthwash|Dilute 50 times of traditional Chinese medicine mouthwash.
40797197|NCT03260855|OTHER|Human blood sample|The intervention is based on blood test.
40797198|NCT01380678|DRUG|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
40797199|NCT01380678|DRUG|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
40797200|NCT02039167|DEVICE|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
41001733|NCT05098535|OTHER|Visual Aid|"The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual description stating the anticipated risk.~For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS."
41151216|NCT03973437|DEVICE|Conventional human scoring|Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
41151217|NCT04103333|PROCEDURE|Lumbar Puncture|Administered as specified in the treatment arm.
40797201|NCT04587206|DRUG|CKD-348|QD, PO
41151218|NCT04103333|PROCEDURE|Blood Collection|Administered as specified in the treatment arm.
41472350|NCT05022368|DEVICE|LabraGuard|Protection of the lips and the oral commissure during transoral procedures
41472351|NCT01099631|BIOLOGICAL|Salmonella typhimurium|Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.
41472352|NCT00136760|DRUG|Bupropion|Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
41472353|NCT00136760|DRUG|Contingent reinforcement plus placebo|contingent reinforcement plus placebo (3 weeks)
41472354|NCT00136760|DRUG|non-contingent reinforcement plus bupropion|non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
41472355|NCT00136760|DRUG|Non-contingent reinforcement plus placebo|Non-contingent reinforcement plus placebo
40797202|NCT04587206|DRUG|CKD-828, D097, D337|QD, PO
40797203|NCT03798639|BIOLOGICAL|Ipilimumab|Given IV
40797204|NCT03798639|BIOLOGICAL|Nivolumab|Given IV
40797205|NCT03798639|RADIATION|Radiation Therapy|Receive radiation therapy
40797206|NCT00940290|OTHER|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
40797207|NCT04633395|OTHER|Music|The participant can choose between 5 different soothing playlists
40797208|NCT04633395|BEHAVIORAL|Sleep hygiene|These are behavioural guidelines to help establish a better sleep pattern
40797209|NCT00005987|DRUG|carmustine|
40797210|NCT00005987|DRUG|cyclophosphamide|
40797211|NCT00005987|DRUG|dexamethasone|
40797212|NCT00005987|DRUG|etoposide|
40797213|NCT00005987|DRUG|filgrastim|
41472356|NCT00504803|PROCEDURE|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
41472357|NCT02194569|DRUG|Citrate|
41472358|NCT06484985|DRUG|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
40797214|NCT00005987|DRUG|mitoxantrone hydrochloride|
40797215|NCT00005987|DRUG|recombinant interferon alfa|
40797216|NCT00005987|DRUG|sargramostim|
40797217|NCT00005987|PROCEDURE|bone marrow ablation with stem cell support|
40797218|NCT00005987|PROCEDURE|peripheral blood stem cell transplantation|
40797219|NCT00005987|PROCEDURE|radiation therapy|
40797220|NCT04491903|PROCEDURE|REBOA|Endovascular balloon occlusion of the aorta
40797221|NCT03936907|DRUG|OWCP Orally Disintegrating Tablet|Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
41001734|NCT05098535|OTHER|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
41001735|NCT02752009|PROCEDURE|Axillary Lymph Node Sampling Clip|
41314043|NCT04747483|OTHER|Extension Oriented Treatment Approach|"The EOTA intervention involves three components.~The first component is a series of active extension- oriented exercises:~Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension The second component of the EOTA is subject education. Subjects are educated to maintain the natural lordosis of the lumbar spine while sitting, and are instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension. The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
40797222|NCT03936907|DRUG|Sativex|Sativex® Oromucosal Spray
41001736|NCT02518477|OTHER|exercise|progressive resistance training
40797224|NCT04875468|OTHER|TheraCem self-adhesive resin cement|MDP, calcium and fluoride releasing cement for dental zirconia crowns
40797225|NCT04875468|OTHER|Multilink adhesive resin cement|(non MDP, non-calcium and fluoride releasing cement)
40797226|NCT01062789|DEVICE|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
40797227|NCT06482827|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
40797228|NCT06482827|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2004 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
40797229|NCT04221503|DRUG|Niraparib|Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.
41314044|NCT04747483|OTHER|EOTA+ Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
40797230|NCT04221503|DEVICE|Optune|"Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells."
40797231|NCT04221503|PROCEDURE|Planned surgical resection|Surgery of supratentorial glioblastoma (GBM).
40797232|NCT01461499|DRUG|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
40797233|NCT01461499|DRUG|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
40797234|NCT04381052|DRUG|Clazakizumab|Dose is 25mg intravenously over 30 minutes.
40797235|NCT04381052|OTHER|Placebo|Intravenously administered over 30 minutes.
40797236|NCT01618240|OTHER|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
40797237|NCT01618240|OTHER|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
40797238|NCT04294940|OTHER|Wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients"
41001737|NCT01257204|DRUG|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
41001738|NCT01257204|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
41314045|NCT00292448|DRUG|Ba 679 BR Respimat|
41314046|NCT00292448|DRUG|Tiotropium (Spiriva) inhalation capsule 18 ug|
41472359|NCT06196944|BEHAVIORAL|Augmentative Alternative Communication|Traditional Method
41472360|NCT06196944|OTHER|Augmentative Alternative Communication Device|Augmentative Alternative Communication Device 3 session for 40 minutes
41472361|NCT06443255|DRUG|Cociane hydrochloride 4%|2 mL of 4% cocaine
41472362|NCT06443255|DRUG|Lidocaine 4%|1.5 mL of 4% lidocaine
41472363|NCT06443255|DRUG|Xylometazoline 0.1%|0.5 mL of xylometazoline 0.1%
41472364|NCT06443255|DRUG|Saline 0.9%|2 mL of saline 0.9%
41472365|NCT00170144|DRUG|Branchamin 4%|
41472366|NCT00368563|DRUG|Helioblock SX|
40797239|NCT04294940|OTHER|Use the mobile application CardiCare™ and wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients~* wear their smartphone everyday and use the mobile application CardiCare™"
40797240|NCT03551834|OTHER|Conventional scleral patch graft glaucoma implantation|conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
40797241|NCT03551834|OTHER|New surgical method (short tunnel small flap technique)|a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
40797242|NCT04372550|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
41151219|NCT02338778|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
41151220|NCT02338778|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
41314047|NCT03336827|BEHAVIORAL|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
41314048|NCT03336827|BEHAVIORAL|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
41314049|NCT03496363|DIAGNOSTIC_TEST|TSH , T4|Thyroid stimulating hormone
41314050|NCT03061370|PROCEDURE|Esophagectomy or Gastrectomy|Surgical resection
40797243|NCT04372550|OTHER|Standard of Care|Standard of care rehabilitation
40797244|NCT01489501|PROCEDURE|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
40797245|NCT02149355|OTHER|teeth molding|teeth molding in patients suffering from congenital fourth nerve palsy
41001739|NCT01257204|DRUG|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
41314051|NCT01953328|DRUG|Atorvastatin|Administered orally once a day
41472367|NCT00523328|DRUG|BG9924|dosage administered as per Biogen-idec protocol
40797246|NCT00122616|BIOLOGICAL|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
40797247|NCT00122616|DRUG|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
40797248|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
40797249|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
40797250|NCT05954208|OTHER|Vısual Arts Group Therapy Based On Watson's Human Care Model|VAGT-WHCM was applied to the intervention group, consisting of six sessions, lasting 90 minutes on average, once a week in three groups.
40797251|NCT05954208|OTHER|Ongoing treatment|The control group participated only in the routine follow-up, treatment and practices in the institution.
40797252|NCT03268408|BEHAVIORAL|Baby Newsletter|eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
40797253|NCT03634098|DEVICE|new quantitative imaging techniques with contast products|magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue
41001740|NCT01257204|DRUG|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
41001741|NCT02994862|OTHER|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
41001742|NCT02994862|OTHER|Conventional Bonding|Normal Bonding Protocol
41001743|NCT01624428|DRUG|Varenicline|1 mg bid varenicline titrated over a 2 week period
41001744|NCT01624428|DRUG|Placebo|1 mg bid placebo titrated over a 2 week period
41151221|NCT04201847|DIAGNOSTIC_TEST|Serum test|Serum Fetuin A and fetuin B
41151222|NCT00002761|BIOLOGICAL|filgrastim|
41314052|NCT01953328|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
41314053|NCT01953328|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
41314054|NCT04729582|BIOLOGICAL|Primary human muscle stem cells (Satori-01)|Primary human muscle stem cells are isolated from patient's muscle tissue and expanded ex-vivo. They are injected into the urethral sphincter region as a one-time autologous treatment.
41472368|NCT05966987|COMBINATION_PRODUCT|Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin|laser and platelet rich fibrin
41472369|NCT06306092|BEHAVIORAL|Sleep on Schedule|Sleep education at school
41001745|NCT02630784|PROCEDURE|Non-Invasive Ventilation with Homecare ventilator|
41001746|NCT02630784|PROCEDURE|Non-Invasive Ventilation with ICU ventilator|
41001747|NCT05547321|DRUG|OMTX705|The investigational product is OMTX705 administered as monotherapy.
41314055|NCT04729582|OTHER|Placebo|Placebo is the injection solution without muscle stem cells.
41314056|NCT05580055|DIAGNOSTIC_TEST|Affinity|Blood Analyser
41314057|NCT06350058|BIOLOGICAL|Inactivated rotavirus vaccine (low dose)|The protein content of each dose is 2.5 μg. The antigen content shall not be less than 2000U, and each person shall receive one dose of 0.5ml.
41314058|NCT06350058|BIOLOGICAL|Inactivated rotavirus vaccine (high dose)|The protein content of each dose is 5 μg. The antigen content shall not be less than 4000U, and each person shall receive one dose of 0.5ml.
41314059|NCT06350058|BIOLOGICAL|Placebo|Aluminum hydroxide adjuvant.
41472370|NCT06306092|BEHAVIORAL|Technology restriction|Reduction of electronic media use before bedtime
41472371|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Knowledge Intervention|Counseling scripts assessing and addressing vaccination-related knowledge gaps
40797254|NCT03634098|DIAGNOSTIC_TEST|blood sample|extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data
40797255|NCT03634098|DIAGNOSTIC_TEST|second generation tests|second generation tests NIT-NASHr et NIT-A2F2
40797256|NCT04124094|DRUG|Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
40797257|NCT04124094|DRUG|Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|2 inhalations in one study period
41151223|NCT00002761|BIOLOGICAL|recombinant interferon gamma|
41314060|NCT02812433|DRUG|Sildenafil|sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
40797258|NCT04124094|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
41151224|NCT00002761|DRUG|busulfan|
41151225|NCT00002761|DRUG|cyclophosphamide|
41151226|NCT00002761|DRUG|cyclosporine|
41314061|NCT02812433|DRUG|Ora-Blend|Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
41472372|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Reminders|Reminders of upcoming vaccination due dates, sent to the mother's mobile phone
41472373|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Incentives|Conditional incentives for timely vaccination, tailored to each child's vaccination schedule
41472374|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Service notifications|Service notifications (e.g., related to stockouts or service non-availability), sent to the mother's mobile phone
41472375|NCT06609434|PROCEDURE|Radiofrequency ablation|This study is the first to apply radiofrequency ablation to multiple recurrent intrahepatic lesions of colorectal cancer liver metastases.
41472376|NCT03543852|BEHAVIORAL|SurvivorLink|SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
40797259|NCT02415049|OTHER|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
40797260|NCT02415049|OTHER|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
40797261|NCT00002081|DRUG|Zidovudine|
40797262|NCT00002081|DRUG|Zalcitabine|
40797263|NCT00034671|DRUG|Posaconazole oral suspension|
40797264|NCT01656707|BEHAVIORAL|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
41151227|NCT00002761|DRUG|cytarabine|
41151228|NCT00002761|DRUG|idarubicin|
41151229|NCT00002761|PROCEDURE|peripheral blood stem cell transplantation|
41151230|NCT05490368|DEVICE|Bed mattress sensor system|The new sensor pad can detect any bed-exit activities, including stirring, sitting up, leaving, and out-of-bed. Audible message and alert to care staff can be customised in each participant. Whenever the system detects a change of bed-exit activity, an audible message will be played in the control box next to the resident's bed reminding the resident not to leave and that a care staff shall arrive shortly. Care staff at the nurse station will simultaneously receive the alert, as a sound and a visual figure on the dashboard, with the location and body position of the resident, and be prompted for a rapid and appropriate response. Care staff are allowed to customise each resident's alert settings, including time to alert and notification method.
41314062|NCT00972829|DRUG|Rosuvastatin|Rosuvastatin 10 or 20 milligrams once or twice a week
41314063|NCT00972829|DRUG|Ezetimibe|Ezetimibe 5 or 10 milligrams
41314064|NCT06553508|PROCEDURE|Trochanteric bursa repaired|As a routine procedure in our centre, the trochanteric bursa is left unrepaired after a hip arthroplasty.
41314065|NCT06553508|PROCEDURE|Trochanteric bursa unrepaired|For the experimental arm, the trochanteric bursa is repaired after a hip arthroplasty. The conventional joint closure is performed after reduction and then the bursa is retrieved and repaired.
41314066|NCT00434863|DRUG|botulinum toxin type A|
41314067|NCT01930812|PROCEDURE|NaF PET/CT Imaging|Diagnostic imaging test that is considered investigational
41314068|NCT01930812|PROCEDURE|99mTc-medronate whole body bone scan with SPECT|99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
41314069|NCT01930812|DRUG|18F-Sodium Fluoride (NaF)|A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
41314070|NCT02066194|PROCEDURE|Electroacupuncture|
41314071|NCT01648543|PROCEDURE|lumbar sympathetic ganglion block|
41314072|NCT06286436|OTHER|Dual-task training|The intervention will consist of three different tasks that participants have to carry out while performing mental calculations (counting backwards from 100 by ones, twos, and threes). The three tasks will be as follows: grouping blocks of different colours into groups according to colour; picking up beans with a spoon and carrying them to a specific place; opening and closing a bottle cap with the affected hand. The total duration of the intervention will be 12 sessions, divided into three days per week for four weeks.
41001748|NCT05547321|DRUG|Pembrolizumab|The investigational product is OMTX705 administered in combination with pembrolizumab.
41151231|NCT05248269|PROCEDURE|Radiofrequency thermocoagulation|The 2 pertinent contacts connect to Radiofrequency thermocoagulation lesion-generator equipment (Cosman G4 with Ad-tech electrodes), expressly modified for use with SEEG electrodes. The following parameters will be adopted: current power 3 W within 180 seconds and current intensity (usually approximately 25 mA) variable according to impedance.
41314073|NCT06110299|DIAGNOSTIC_TEST|air injection|delination of the ureter and pelvis by injecting air under C-ARM
41314074|NCT06126874|OTHER|Patient Education|Individuals in both study groups will be provided with patient education through verbal and visual presentations. In the content of patient education; information about the importance of the research topic and the content of the study through anatomical models and short animations, lifestyle recommendations for urinary incontinence symptoms (avoiding bladder irritants such as alcohol, caffeine, tea, spicy foods, acidic foods and chocolate, regulating water / fluid consumption, recommendations for attention to bowel regularity and increasing physical activity levels) and recommendations for sexual functioning (coitus positions that facilitate erection, recommendations for reshaping the sexual schema, recommendations for the physical dimension of sexual health) will be given.
41314075|NCT06126874|OTHER|Pelvic Floor Muscle Training|In PFMT, voluntary maximal and submaximal contractions for strength and endurance training of pelvic floor muscles will be taught and individuals will continue PFMT as a home exercise program. In the first 2 weeks of PFMT, individuals will perform 3 sessions of exercise per day. In each 2-week control, the number of sessions will be increased by 1 session and PFMT application will be completed with 5 sessions per day in the study.
41472377|NCT00601757|BEHAVIORAL|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
41472378|NCT00601757|BEHAVIORAL|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
41472379|NCT04459676|DRUG|Standard of Care (SOC) + ANG-3777|Standard of Care (SOC) + ANG-3777
40797265|NCT01656707|BEHAVIORAL|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
41151232|NCT02700386|COMBINATION_PRODUCT|Adjuvant Hypofractionated Radiation|Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
41151233|NCT00850954|OTHER|Informational Intervention|Receive information on secondhand smoke and supporting smoker in quitting
41151234|NCT00850954|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation materials based on TTM
41151235|NCT00850954|OTHER|Survey Administration|Ancillary studies
41151236|NCT05597033|BEHAVIORAL|Exercise|walking and handgrip exercise
41151237|NCT05597033|BEHAVIORAL|Control|seated rest
40797266|NCT03283488|DRUG|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
41001749|NCT03267862|OTHER|there was no intervention|patients were observed during routine care on separate times when their eye pressure was different on one day from another.
41151238|NCT00355771|DRUG|Levocetirizine|Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
41151239|NCT00355771|DRUG|Placebo|1 tablet OD in the morning for 8 weeks
41151240|NCT03649659|DRUG|Silver Diamine Fluoride|SDF will be applied twice during the study
41472380|NCT04459676|DRUG|Standard Of Care (SOC) + Placebo|Standard Of Care + Placebo
41001750|NCT00792610|BIOLOGICAL|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
41001751|NCT01381861|BIOLOGICAL|Carotuximab (TRC105)|Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
41001752|NCT01088009|DRUG|lamivudine|patients in this arm will receive oral lamivudine 100mg,daily for 24 weeks; if patients with HBV DNA higher than 1000 copies/ml at week 24, add on adefovir to week 104; otherwise, keep lamivudine monotherapy to week 104
41151241|NCT03649659|DRUG|Placebo|This is being compared to the SDF and will also be applied twice
41151242|NCT00427245|DRUG|cyclophosphamide|
41151243|NCT00427245|DRUG|goserelin acetate|
41151244|NCT00427245|PROCEDURE|adjuvant therapy|
41151245|NCT00427245|PROCEDURE|fertility assessment and management|
41151246|NCT00427245|PROCEDURE|neoadjuvant therapy|
41151247|NCT02200016|PROCEDURE|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
41151248|NCT02200016|PROCEDURE|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
41151249|NCT02200016|DEVICE|B Braun Contiplex S catheter|
41472381|NCT05209997|OTHER|Source document data collection|Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be colected in the study.
40797267|NCT03283488|DRUG|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
41472382|NCT02533284|DRUG|Magnesium Sulfate|preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
41472383|NCT02533284|DRUG|bupevecaine|US guided TAP using Bupevecaine 0.25 %
41472384|NCT02533284|DRUG|saline|US guided TAP using placebo (saline)
41472385|NCT00478452|BIOLOGICAL|DC-Ova|
41472386|NCT00478452|BIOLOGICAL|DC Ova with Cyclophosphamide|
40797268|NCT01248988|OTHER|Synflorix™ Data collection|Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
40797269|NCT02483858|DRUG|PQR 309|Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
41472387|NCT06029270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41472388|NCT06029270|PROCEDURE|Bone Scan|Undergo bone scan
40797270|NCT05141175|DEVICE|Hypertension medication algorithm|The algorithm is configured to align medication choices based on the hemodynamic findings from the ICG readings. This decision support tool was created so as to organize these medications based on their mechanism of action and is consistent with the evidence-based treatment of hypertension.
40797271|NCT05141175|DEVICE|Impedance Cardiography|The ICG system provides a printed report that indicates whether a person's hemodynamic state is predominantly one that is vasoconstricted, hyperdynamic, or mixed
40797272|NCT04928885|BEHAVIORAL|Wits Workout Program|12 week, one hour per week multi-modal, interactive training.
40797273|NCT04928885|OTHER|Control Group that receives intervention after the study|The control group will not receive the intervention during study period but will take baseline, 3 mos and 6 mos surveys. They will complete the workshop after the study period is over.
40797274|NCT06144294|OTHER|Whole-Body Hyperthermia|The Clearlight dome sauna is portable infrared sauna consisting of two lightweight domes and an infrared heating pad. The sauna will be used to deliver the intervention to the participant and the sauna session will end as soon as (1) an internal body temperature of 38.5 C (101.3 F) is reached for two consecutive minutes or, (2) 140 minutes have passed.
40797275|NCT06144294|DIAGNOSTIC_TEST|fMRI|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain.
41001753|NCT01088009|DRUG|lamivudine|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
41001754|NCT01088009|DRUG|lamivudine, adefovir|patients in this arm will receive oral lamivudine 100mg daily and adefovir 10mg for 104 weeks
41001755|NCT03166280|DRUG|Sofosbuvir 400 mg|treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day
41472389|NCT06029270|DRUG|Carboplatin|Given IV
41472390|NCT06029270|DRUG|Cisplatin|Given IV
40797276|NCT03183063|DEVICE|4DCT and SPECT/CT|Each patient will receive two 4DCT followed by SPECT/CT.
40797277|NCT03183063|DEVICE|4DCT with BiPAP and SPECT/CT|Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT
41001756|NCT03166280|DRUG|Daclatasvir 60 mg/day|treatment for hepatitis c by Daclatasvir 60 mg/day
41001757|NCT00500422|DRUG|Doxil|Starting dose of 20 mg/m\^2 IV over 2 hours on Day 1, 21 day cycle
41001758|NCT00500422|DRUG|Gemcitabine|500 mg/m\^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
41001759|NCT00500422|DRUG|Velcade|Starting dose of 0.7 mg/m\^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
41472391|NCT06029270|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41472392|NCT06029270|DRUG|Gemcitabine|Given IV
41472393|NCT06029270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41001760|NCT04385602|DRUG|Intratracheal dexmedetomidine|Thirty minutes before the end of the surgery, Dex (0.5μg/kg diluted and mixed in 1ml saline in a medical spray bottle) will be sprayed down the intratracheal tube
41472394|NCT06029270|BIOLOGICAL|Nivolumab|Given IV
41472395|NCT06029270|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41472396|NCT06029270|BIOLOGICAL|Relatlimab|Given IV
41472397|NCT02409186|DRUG|Nimotuzumab|400mg/w，d1, week 1-7
41472398|NCT02409186|RADIATION|radiotherapy|Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
41472399|NCT02409186|DRUG|chemoradiotherapy Paclitaxel|45 mg/m2, d1, week 1-7
41472400|NCT02409186|DRUG|chemoradiotherapy Cisplatin|20 mg/m2, d1, week 1-7
41472401|NCT02409186|OTHER|placebo|400mg/w，d1, week 1-7
41472402|NCT01279382|BEHAVIORAL|Hypnotherapy (HYP)|Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
41472403|NCT01279382|BEHAVIORAL|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
41472404|NCT01279382|OTHER|Care as usual (CON)|CON was given to a subgroup of patients as control intervention in IBS treatment
41472405|NCT01920984|DRUG|intravitreal injection of 1.25 mg of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
41472406|NCT01874977|BEHAVIORAL|Pedometer|Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
41314076|NCT06126874|OTHER|Aerobic Exercise Training|Aerobic exercise training will be planned 3 days a week, 1 day on the routine clinic day with a treadmill ergometer and 2 days as a home program in the form of brisk walking outside the clinic (e.g. outdoors or in a suitable environment).The intensity of aerobic exercise training will be planned according to the Maximal Heart Rate (MHR) method and Modified Borg Scale (MBS). In the first 2 weeks in the clinic, training will be started with 50 min (+10 min warm-up and cool-down) at 60% of the MHR, the exercise intensity will be increased by 5% every 2 weeks, and the program will be terminated by providing exercise training at 85% of the MHR in the 10th-12th week. Patients will be asked to adjust the intensity of aerobic exercise outside the clinic to correspond to the 12-14 (slightly difficult) degree of perceived fatigue according to the MBS.
40797278|NCT03183063|DEVICE|4DCT with CTA in suspected PE|Each patient will receive 4DCT before or after CTA for suspected PE
40797279|NCT04719481|DRUG|Pravastatin Sodium 80 MG|daily oral administration of 80mg
40797280|NCT04719481|DRUG|Placebo|daily oral administration
40797281|NCT01211977|DRUG|XOMA 052|
40797282|NCT03902015|DEVICE|Nuance Phone case|"participants will receive a phone (iPhone) with the Nuance Phone case and a designated app required for the use of the device. Participants will first undergo hearing test via the app, and afterwards (in case they are not excluded based on hearing status), will receive a introduction on how to use the app and the device. Before starting the clinical trial, children will undergo three adjustments days in which they will practice using the device in school. During this period the researchers will make sure that the participants are adapting to the use of the device, and in any case there is a problem, will be able to contact a representative of Nuance Hearing who will be available to support technical issues."
40797283|NCT02250131|PROCEDURE|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery \> 280 mL/min/m2
40797284|NCT04015570|BIOLOGICAL|High Volume Plasma Exchange|PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
40797285|NCT04015570|OTHER|Standard Medical Treatment|Standard Medical Treatment (Albumin+High caloric diet)
40797286|NCT04306458|PROCEDURE|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
40797287|NCT04306458|DEVICE|daVinci Xi system|robot assisted minimally invasive esophagectomy
40797288|NCT04704297|DRUG|Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.|We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
40797289|NCT04704297|DRUG|Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.|Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
40797290|NCT04704297|DRUG|Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.|60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
40797291|NCT00924612|DRUG|Oral testosterone undecanoate (containing 300 mg T)|
40797292|NCT04723498|DIAGNOSTIC_TEST|screening questionnaire|Fill in screening questionnaire
40797293|NCT01959178|DEVICE|LD127025 MF|At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
40797294|NCT01959178|DEVICE|Air Optix Aqua MF|At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
40797295|NCT06451367|OTHER|neuromuscular programm|neuromuscular programm during 12 weeks (3 times a week, 10 minutes each time)
40797296|NCT04916977|OTHER|FD patients|Patients with Fabry disease diagnosis
40797297|NCT02977364|DRUG|HS-10241|
40797298|NCT01934907|OTHER|Washing of packed RBC by normal saline|
40797299|NCT05947838|PROCEDURE|Circulating tumoral DNA directed neoadjuvant therapy arm|Given by IV (vein)
41151250|NCT05323643|DEVICE|Ultrasound|"musculoskeletal US will be performed using commercially -available equipment, with high frequency linear -array transducers and a standard gel interface. The higher frequency transducers provide better spatial resolution, while the lower frequency transducers provide a greater depth of tissue penetrance. Colour Doppler US is also performed in most cases as it plays an important role in supporting and confirming diagnoses, by providing valuable information about the pathophysiology of the abnormality.~The patients will be seated with hands placed on a table, to permit examination of both volar and dorsal aspects, in longitudinal and transversal axis. Examination of the hands and fingers usually requires a large amount of transmission gel, in order to avoid compression and to permit dynamic evaluation. When acute trauma with skin lesions is investigated, sterile transmission gel, or sterile acoustic standoff pads can be used"
41151251|NCT04252794|PROCEDURE|Splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
40797300|NCT03499860|DIAGNOSTIC_TEST|Passive Leg Raising Test|A passive leg raising test is performed in all patients included in the study
40797301|NCT06292195|OTHER|Exposure|Maternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels)
40797302|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
40797303|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
40797304|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
40797305|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
40797306|NCT04224831|COMBINATION_PRODUCT|Source of growth factors: autologous platelet-rich plasma (aPRP) + repetitive electromagnetic stimulation for iontophoresis|"Autologous platelet rich plasma is containing many types of growth factors (GFs) such as epithelial growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF).~Repetitive high frequency electromagnetic stimulation (rEMS) creates a stimulated focus in the tissue by increasing blood flow and platelets at the capillary level. Electromagnetic stimulation along with growth factors has shown synergetic effects toward enhanced epithelial integrity and neural functions. With the addition of possible iontophoresis effects in the rEMS, the passage of the various active molecules can be augmented at the tissue level thereby increasing the widespread effect of the GFs in the damaged choroidal and outer retinal microenvironment."
40797307|NCT05710731|OTHER|Use of simulation in urinary catheterization training|To train students on urinary catheterization by using one of 3 different simulation methods.
41314077|NCT06126874|OTHER|Resistance Exercise Training|Resisted exercise training will be planned 2 days a week, 1 day in the clinic and 1 day outside the clinic as a home program, and 12 different exercises for large muscle groups with dumbbells and weight sets, resistance bands (therabands) will be used in the training. These exercises are leg press, leg extension, leg curl, squat, seated row, lateral pull down, biceps curl, triceps extension, dumble fly, lateral raises, bench press and abdominal crunch. Exercises will be performed with free weights (dumbbells), resistance bands (therabands) or body weight.
40797308|NCT04808791|DRUG|Irinotecan|"Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor."
40797309|NCT04808791|DRUG|Oxaliplatin|"Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent."
40797310|NCT04808791|DRUG|TAS 102 (Trifluridine/Tipiracil)|"Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor"
40797311|NCT04192669|DEVICE|Heart rate monitoring|The heart rate will be recorded and calculated by a heart rate monitor (Polar H10, Finland) located on the chest. The recording is done over a period of 5 minutes, the patient being in a sitting position, without any particular stimulus, in a quiet room. The recording is transferred via the HRV Logger application. Any ectopic beats and artifacts are automatically identified and replaced by values interpolated by the investigator, if necessary. The Kubios HRV Premium Software is used for all calculations.
40797312|NCT05962684|OTHER|ERAS|Implementation of ERAS protocol in elective craniotomy patients
40797313|NCT04227626|DEVICE|GlucoSTAT|Closed-loop blood glucose control using intravenous insulin and dextrose
41001761|NCT04385602|DRUG|Saline Solution|Thirty minutes before the end of the surgery, 1ml saline in a medical spray bottle will be sprayed down the intratracheal tube
41001762|NCT01385475|BEHAVIORAL|RT|8 week RT Intervention
41472407|NCT01874977|BEHAVIORAL|Educational materials|"Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment."
40797314|NCT03993886|DEVICE|CorBand|The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
40797315|NCT03993886|OTHER|Activity Monitor|commercially available accelerometer to be worn on wrist
40797316|NCT03993886|OTHER|Bioimpedance spectrometer|Commercially available bioimpedance monitor.
40797317|NCT03993886|OTHER|ECG|Commercially available electrocardiogram machine
40797318|NCT03993886|OTHER|respiratory rate sensor|Commercially available respiratory rate sensor.
40797319|NCT02761473|OTHER|skin biopsy|A skin biopsy will be obtained from a typical UP lesion in affected patients
41001763|NCT03821506|DEVICE|Dynamic Light|Dynamic Lighting system
41001764|NCT03821506|DEVICE|Usual care|Standard lighting system
41001765|NCT06132607|DEVICE|Preoperative 3D lung reconstruction created with open-source software|Preoperative 3D lung reconstruction created with open-source software 3D Slicer
41472408|NCT01874977|BEHAVIORAL|Step count goals|Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
41001766|NCT01290848|BEHAVIORAL|Take TIME Health Campaign|"1. Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.~2. Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.~3. Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children."
40797320|NCT02761473|OTHER|blood draw|Blood will be obtained from subjects, parents and unaffected siblings
40797321|NCT05373095|BEHAVIORAL|PKC (adapted adherence counseling) and Conditional Cash Transfers|The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (\~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically \<$1.
40797322|NCT03747796|OTHER|Supine position|The children will be placed in the supine position after ingestion of a standard volume of clear fluid
40797323|NCT03747796|OTHER|Semi-sitting position|The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
40797324|NCT00418600|DRUG|Hectorol® (doxercalciferol capsules)|Hectorol capsules at 1.0 times current injection dose
40797325|NCT00418600|DRUG|doxercalciferol capsules, Hectorol®|Hectorol capsules at 1.5 times current injection dose
41151252|NCT04252794|OTHER|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
41314078|NCT03337139|BEHAVIORAL|Gold Standard Behavior Therapy for Weight Loss|Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
41314079|NCT03337139|BEHAVIORAL|Standard Remote Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by participant self-report. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
41314080|NCT03337139|BEHAVIORAL|Digital Data Sharing Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
41151253|NCT01270347|DRUG|MP-376 (Levofloxacin Solution for Inhalation)|MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
41151254|NCT01270347|DRUG|TIS (Tobramycin Inhalation Solution)|Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
41151255|NCT05198323|DRUG|LT3001 Drug Product|Administered by intravenous infusion
41151256|NCT05198323|DRUG|Placebo|Administered by intravenous infusion
40797326|NCT00418600|DRUG|doxercalciferol capsules, Hectorol® capsules|Hectorol capsules at 2.0 times current injection dose
40797327|NCT05263570|DRUG|Standard Therapy|Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
40797328|NCT02658552|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
40797329|NCT05688592|PROCEDURE|PET-CT|"This is a before-and-after study (not a clinical trial)~* in the case of fungemia, 2 weeks after the initial staging 18F-FDG PET-CT.~* in the case of focal IFIs, 2-4 and 12 weeks after the initial staging 18F-FDG PET-CT"
41151257|NCT03568630|DIAGNOSTIC_TEST|Mixed Meal Tolerance Test|The goal of the test is to determine hormone secretion from the pancreas and small intestine in response to the mixed meal.
41151258|NCT03568630|DIAGNOSTIC_TEST|Hemoglobin A1c|This test provides the average level of blood glucose over the last 3 months.
41151259|NCT03568630|DIAGNOSTIC_TEST|Other exploratory blood biomarkers|Other exploratory blood biomarkers including cell free DNA and other markers in development
41151260|NCT03313544|DRUG|Nivolumab|NIVOLUMAB
41151261|NCT03313544|DEVICE|MRI|Cardiac MRI 6 MONTHS
41151262|NCT03313544|BIOLOGICAL|BLOOD SAMPLES|biological (BNP and troponin)
41151263|NCT03313544|DEVICE|trans-thoracic echocardiography|1, 3 and 6 months
41151264|NCT01170871|DRUG|Ixabepilone|
41151265|NCT01170871|DRUG|Pemetrexed|
41151266|NCT04168593|PROCEDURE|Acupuncture|20 min of Acupuncture section follow by 10 min of cupping around the knee
41151267|NCT04893993|DRUG|Thiamine|Tablets. 300mg/tablet. Dosage depends on gender and weight
41151268|NCT04893993|DRUG|Placebo|Tablets. Same number of tablets as Thiamine
41314081|NCT05010629|DRUG|9-ING-41|Intravenous infusion
41314082|NCT05010629|DRUG|Carboplatin|Intravenous infusion
41314083|NCT03497234|DIAGNOSTIC_TEST|Perilynx Analyzer to measure AF and VF fluid|Hologic developed a rapid in-vitro diagnostic system composed of an analyzer and cassettes to identify women with intra-amniotic infection.
41314084|NCT03081286|PROCEDURE|Liposuction|Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
41472409|NCT06229119|DEVICE|Implantable Collamer Lens|The EVO ICL lens is intended to be placed entirely within the posterior chamber directly behind the iris and in front of the anterior capsule of the human crystalline lens. When correctly positioned, the EVO ICL lens functions as a refractive element to optically reduce moderate to high myopia with or without astigmatism.
41472410|NCT03245307|DRUG|Apatinib|Apatinib at a dosage of 750mg will be administered daily from day 9 of phase A
41472411|NCT03245307|DRUG|Nifedipine GTIS|Nifedipine at a dosage of 30mg will be administered at day 1 and day 14 of phase A
41472412|NCT03245307|DRUG|Warfarin Potassium|Nifedipine at a dosage of 3mg will be administered at day 3 and day 16 of phase A
41472413|NCT02123420|DEVICE|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|"Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J\&J International, St-Stevens-Woluwe, Belgium)."
40797330|NCT04017780|DEVICE|Single-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
40797331|NCT04017780|DEVICE|Double-Limb Intensive Care Unit ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
40797332|NCT04017780|DEVICE|Double-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
40797333|NCT06385379|DEVICE|WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system|The WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system, the aortic extension stent graft system and the branch stent system.
41314085|NCT03081286|PROCEDURE|Fat graft|The harvested lipoaspirate is injected at the site of pain.
41472414|NCT01685359|DRUG|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
41472415|NCT06399861|DEVICE|Incubator ambient relative humidity (RH) of 70%|The incubator will be set to an ambient relative humidity (RH) of 70%.
41472416|NCT06399861|DEVICE|Incubator ambient relative humidity (RH) of 90%|The incubator will be set to an ambient relative humidity (RH) of 90%.
41472417|NCT06615791|BEHAVIORAL|FIT FIRST Teen|High intensity sports drills and games.
41472418|NCT03540849|DRUG|Brentuximab Vedotin (Bv)|HL patients who are eligible for the study, will receive maintenance Bv. The first Bv dosage will be administered three months after allo-SCT (day 90) at the dosage of 1.8 mg/kg every 21 days for 12 cycles. post allo-SCT maintenance Bv for Hodgkin lymphoma
41472419|NCT01007279|DRUG|ROSUVASTATIN|40 mg before procedure
41472420|NCT04862962|DRUG|Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose|Oral Tablets 10 mg/10 mg or 20 mg/10 mg
41314086|NCT03081286|PROCEDURE|Sham graft (saline injection)|Saline will be injected at the site of pain instead of fat
41314087|NCT04627298|BEHAVIORAL|educational video game for preteens to support HPV vaccination|An educational video game developed for 11-12 year olds to increase interest in and decision to pursue HPV vaccination.
41314088|NCT04172909|OTHER|LEGO Bricks MRI|LEGO Bricks model MRI (A model of the MRI machine and adjacent control room made out of LEGO bricks) will be used by the child life specialist to prepare the child for MRI
41314089|NCT04172909|OTHER|Mock MRI tube|Mock MRI tube will be used by the child life specialist to prepare the child for MRI
41472421|NCT01445418|DRUG|AZ2281 + Carboplatin|Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.; Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
41472422|NCT01602016|DRUG|Folinic Acid and placebo|Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
41472423|NCT01602016|DRUG|Folinic Acid|capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
41472424|NCT01185379|DIETARY_SUPPLEMENT|Efalex active 50+|4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.
40797334|NCT05315934|OTHER|Upper body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the arm-crank ergometer.
40797335|NCT05315934|OTHER|Lower body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the cycle ergometer.
41472425|NCT01185379|DIETARY_SUPPLEMENT|DHA rich fish oil|4 x 500 mg DHA rich tuna oil to be taken daily for 6 months
41472426|NCT01185379|DIETARY_SUPPLEMENT|Placebo|4 x 500 mg capsules to be taken daily for 6 months
40797336|NCT02871349|DRUG|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
41314090|NCT04496440|OTHER|Contracture Correction Therapy|Non-drug and non-surgical treatment of contracted knee capsules
41314091|NCT04478149|DEVICE|SafelyYou|technology to detect and prevent falls
41314092|NCT04478149|OTHER|Control|technology present but not activated
41472427|NCT01719887|DEVICE|Conservative treatment|Conservative treatment with functional brace.
41314093|NCT00066664|GENETIC|proteomic profiling|
41472428|NCT01719887|PROCEDURE|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
41472429|NCT01719887|OTHER|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
40797337|NCT02871349|DRUG|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
40797338|NCT02871349|DEVICE|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
40797339|NCT02944708|DRUG|Conventional chemotherapy|
40797340|NCT02944708|DRUG|Maintenance chemotherapy 1|
40797341|NCT02944708|DRUG|Maintenance chemotherapy 2|
40797342|NCT01941381|PROCEDURE|Tympanometry|All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
40797343|NCT00574392|DEVICE|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
40797344|NCT05464771|PROCEDURE|Surgery for hip and knee replacement|Elective inpatient surgery for hip and knee replacement
40797345|NCT00318279|DEVICE|Surgical simulator to practice vascular anastomosis|
40797346|NCT01564212|OTHER|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
40797347|NCT01564212|OTHER|laminar airflow with surgical drapes|
40797348|NCT01564212|OTHER|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
40797349|NCT01564212|OTHER|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
40797350|NCT02317198|DRUG|Clopidogrel|
41472430|NCT05102019|DEVICE|Arm 1: treatment with Neovasc Reducer|Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
41472431|NCT05102019|OTHER|Arm 2 (control): Implantation procedure with no device implanted|No device is implanted
40797351|NCT02317198|DRUG|Ticagrelor or Prasugrel|
40797352|NCT04894019|DEVICE|Continuous invasive blood pressure monitoring|Continuous invasive blood pressure monitoring using an arterial catheter
40797353|NCT04894019|DEVICE|Intermittent non-invasive blood pressure monitoring|Intermittent non-invasive blood pressure monitoring using upper-arm cuff oscillometry
40797354|NCT04565340|OTHER|Mode of delivery, maternal and neonatal outcomes/complications|Mode of delivery, maternal and neonatal outcomes/complications
41472432|NCT05102019|DEVICE|Arm 3 (unblinded, non-randomized): Single arm registry|Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
41472433|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under citrate predilution|blood gas analysis of blood on different sample points and dialysis fluid
41472434|NCT03314363|DEVICE|filter replacement|Using local protocol: stop and disconnect CRRT, replace filter and reconnect and restart CRRT.
40797355|NCT05999578|OTHER|Hypnosis|Hypnosis support before, during and at the end of cardiac MRI exam
40797356|NCT06343545|BEHAVIORAL|Standard of Care|Standard of Care provided by enrolling hospitals
40797357|NCT06343545|BEHAVIORAL|Rehabilitation|An implementation bundle of measures to improve outcomes in intensive care unit, hospital, and after hospital discharge, including rehabilitation at home performed through telemedicine.
40797358|NCT03470194|OTHER|Interpretation Modality: In Person|Use of In-Person interpretation support for LEP participant during clinical appointment
41314094|NCT04667234|DRUG|AMG 510|Administered as an oral tablet.
41314095|NCT06359743|PROCEDURE|Quadratus Lamborum versus superior hypogatric|Ultrasound Guided Quadratus Lumborum Block versus Laparoscopic Superior Hypogastric Plexus Block for Postoperative Analgesia after Laparoscopic Hysterectomy
40797359|NCT03470194|OTHER|Interpretation Modality: Telephonic|Use of telephonic interpretation support for LEP participant during clinical appointment
41001767|NCT04472936|PROCEDURE|Single catheter approach|Single venous femoral access will be obtained and the ablation will be performed similar to Group A. After the ablation line is over, we will confirm CTI block using the PRI. During atrial pacing (10 V, 1.5 ms) at a stable cycle length (range 500-700ms) from the tip of the ablation catheter with a sweep speed of 300mm/s, the ablation catheter will be placed first at 5 o'clock (medial to CTI line), then at 7 o'clock (lateral to CTI line), and finally at 9 o'clock position, and the corresponding PRIs will be measured for each pacing site. CTI block is assumed when: (i) the PRI at 7 o'clock is \>80ms longer than that at pacing sites of 5, and (ii) the PRI at 9 o'clock is shorter than the PRI at 7 o'clock.
41314096|NCT03241472|DRUG|Letrozole|oral tablets 5 mg
41314097|NCT03241472|DRUG|Clomiphene Citrate plus N acetyl cystine|Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg
41314098|NCT02732340|PROCEDURE|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
41472435|NCT03314363|DEVICE|IC|monitor patients during the whole study period with indirect calorimetry
41472436|NCT03314363|DRUG|NaCl predilution|Replace citrate predilution with NaCl
41472437|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under NaCl predilution|repeat blood gas analysis of blood on different sample points and dialysis fluid
41472438|NCT03314363|DRUG|double ultrafiltration|double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
41472439|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under citrate predilution and double ultrafiltration rate|repeat blood gas analysis of blood on different sample points and dialysis fluid
40797360|NCT05877937|OTHER|Supportive care (Watching a comedy movie)|A 10.1 inch Android tablet (2 pieces) and disposable earplugs for each patient were used in the study. A comic film archive was created in line with the recommendation and consultancy of department of state conservatory and performing arts. In this regard, the officials of the Conservatory stated that they had no standardized comedy films specific to society and emphasized that the standardization of art limits art activities. Therefore, there should be no limitations for art. In the film archive cre-ated according to their suggestions, there were a total of five comedy movies, including three Turkish comedies, one foreign romantic comedy, and one foreign Turkish-dubbed family comedy. The original/licensed versions of the movies in this archive were ob-tained and uploaded to the tablet. The movies lasted 90-120 minutes (as long as the av-erage duration of IV treatment). The patients selected the movie that they would watch during the treatment.
40797361|NCT01977729|DRUG|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S\<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
40797362|NCT01977729|BEHAVIORAL|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
41314099|NCT01114373|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
40797363|NCT03036852|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
41472440|NCT03314363|DIETARY_SUPPLEMENT|pause and restart nutritional therapy|pause parenteral and enteral nutrition before indirect calorimetry is performed. and restart after first blood analysis for vitamine status
41472441|NCT03314363|DIAGNOSTIC_TEST|evolution of vitamin and trace elements|blood analysis for vitamin and trace elements. Perform this blood analysis after restart of CRRT but before restart of nutritional therapy, 30 minutes after restart of nutritional therapy and 24h after restart of nutritional therapy.
41472442|NCT02690935|DRUG|2LALERG|Homeopathic drug
41472443|NCT02690935|DRUG|Placebo|Placebo
41472444|NCT01897168|DEVICE|No intervention|
41472445|NCT03691688|DRUG|Aspirin 100 mg|Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion
41472446|NCT03691688|DRUG|Clopidogrel 75mg|Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
41472447|NCT03297567|BEHAVIORAL|verbal guidance and a booklet|Patients allocated to the intervention group will receive verbal instruction from the researchers on the importance and benefits of movement during hospital stay, as well as what they should do to increase the level of physical activity. These patients will receive the same guidelines through a playable, easy-to-understand and inexpensive booklet developed by the researchers themselves in PowerPoint 2016 (Microsoft) in order to remedy any doubt or forgetfulness during the hospitalization period
41472448|NCT02958852|DRUG|Letrozole|
41472449|NCT02958852|DRUG|Letrozole and atorvastatin|
41472450|NCT02958852|DRUG|Fulvestrant|Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
41314100|NCT01114373|DRUG|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
41314101|NCT04144855|DRUG|TQB3474 injection|This is a kind of heat shock protein (HSP90) inhibitor.
41314102|NCT05570318|DRUG|Polyethylene Glycols|To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.
41314103|NCT05570318|DEVICE|Low volume trans anal irrigation|To be administered rectally on a daily basis throughout the study period (6 weeks) along with an adjusted dose of polyethylene glycols
41314104|NCT02156960|DRUG|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
41314105|NCT02156960|DRUG|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
41314106|NCT02156960|DRUG|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
41472451|NCT05896215|DRUG|KNP2002|Dairy topical administration for 12 weeks
41472452|NCT05896215|DRUG|Placebo of KNP2002|Dairy topical administration for 12 weeks
41472453|NCT00192673|DRUG|PEG-asparaginase|
41472454|NCT00707564|DEVICE|HemCon Dental Dressing|The HemCon Dental Dressing is an oral wound dressing made of chitosan
41472455|NCT00707564|DEVICE|Gauze with pressure|Gauze with pressure
41472456|NCT03297619|BEHAVIORAL|Mindfulness and Acceptance Workbook for Social Anxiety and Shyness|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
41472457|NCT03297619|BEHAVIORAL|The Shyness and Social Anxiety Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period (with some chapters omitted).
41314107|NCT04214730|COMBINATION_PRODUCT|NK combined with Chemotherapy|Patients will receive 4 cycles of NK treatments combined with Chemotherapy within 8 months
41314108|NCT04214730|DRUG|Chemotherapy|Patients will only receive Chemotherapy.
41472458|NCT01525654|BEHAVIORAL|Peer Support Program|Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
40797364|NCT01336712|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m\^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
40797365|NCT02869581|OTHER|Data collection|
41001768|NCT04472936|PROCEDURE|Traditional approach|Double venous femoral access will be obtained. A duodecapolar catheter will be positioned in the right atrium around the tricuspid valve annulus (TVA) to record activation sequence around the tricuspid annulus. An ablation catheter will be positioned using fluoroscopic guidance in the central CTI, 6 o'clock in a left anterior oblique view. The distal ablation electrode position will then be adjusted toward or away from the TVA, based on the ratio of atrial and ventricular electrogram amplitudes with an optimal ratio of 1:2 or 1:4 at the TVA. After the ablation catheter is positioned, it will be very slowly withdrawn during ablation toward the inferior vena cava while radiofrequency energy is applied continuously. CTI block will be evaluated after ablation by determining the right atrial activation sequence during pacing from the low lateral right atrium and coronary sinus ostium.
41001769|NCT00225836|DEVICE|OVA (TENS apparatus)|
41001770|NCT03307733|BEHAVIORAL|walking and behavour change techniques|a Fitbit pedometer with individualised step targets and partaking in a closed Facebook group
41472459|NCT02845726|OTHER|Stent examination, urinary analysis, USSQ questionnaire|
41472460|NCT06461117|OTHER|Beetroot Juice|Beetroot juice (8 mmol NO3-) consumption before training at 6 days
41472461|NCT06461117|OTHER|Plesabo Drink|Plesabo drink (0,6 mmol NO3-) consumption before training at 6 days
41472462|NCT02558465|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Treatment parameters following the summary of product characteristics and the physician's decision
41472463|NCT03151564|DIAGNOSTIC_TEST|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
41472464|NCT03151564|DIAGNOSTIC_TEST|Computed Tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
40797366|NCT01111383|DRUG|tobramycin|"300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 on cycles of 4 weeks duration during the 48-week period."
40797367|NCT05723692|BIOLOGICAL|ALTB-268|monoclonal antibody
41001771|NCT01465464|DRUG|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
41314109|NCT01289626|DRUG|lanthanum carbonate|FOSRENOL® will be administered orally in a dose of 1500- 3750 mg daily in divided doses with meals. Dose escalation will be utilized to a target dose of 3750 mg daily or as designated by clinician over a 4-week period from start of study. The drug will be administered for 12 weeks.
41314110|NCT01289626|DRUG|Lanthanum for calciphylaxis|Lanthanum use in calciphylaxis
41314111|NCT00750165|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
41314112|NCT06279312|DIETARY_SUPPLEMENT|Placebo drink|consume 1 drink per day for 4 weeks
41314113|NCT06279312|DIETARY_SUPPLEMENT|Adaptogen Elixir drink|consume 1 drink per day for 4 weeks
40797368|NCT05723692|OTHER|Placebo|formulation buffer
40797369|NCT06032559|BEHAVIORAL|MORE|MORE plus TAU
40797370|NCT06032559|BEHAVIORAL|SMP|SMP plus TAU
41314114|NCT02867345|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
41314115|NCT02867345|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
40797371|NCT06032559|OTHER|TAU|TAU only
40797372|NCT03925272|PROCEDURE|Collection of samples (blood, stool, etc.)|
41314116|NCT02867345|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
40797373|NCT03925272|GENETIC|Genetic determinants analysis|
40797374|NCT03925272|PROCEDURE|Sample obtained after surgery performed in the context of care|
41472465|NCT03151564|DIAGNOSTIC_TEST|Deep Learning Image Reconstruction (DLIR)|Participants to receive standard-of-care imaging without the artificial intelligence software and imaging technique.
40797375|NCT00235222|DRUG|stavudine|
41472466|NCT05990504|DEVICE|ultrasound real-time guidance combined with Dural Puncture Epidural Labor Anagesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
41472467|NCT05990504|DEVICE|ultrasound real-time guidance combined with Epidural Labor Anagesia|Epidural is a traditional labor analgesia technique.
41001772|NCT01465464|DRUG|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
41314117|NCT01434641|OTHER|low-dose stress MPI SPECT|novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
41472468|NCT05379556|DIAGNOSTIC_TEST|Assessment of andrological profile of LO-COCO-ANDRO male patients|"Assessment of serum prolactin (PRL), luteininzing hormone (LH), follicle stimulating hormone (FSH), 17β-estradiol, testosterone. Physical examination with measurement of body weight, height, body mass index, waist and hip circumference. Andrological physical examination with evaluation of testis volume with Prader orchidometer, testicular consistency and lesions, varicocele. Scrotal ultrasound performed in longitudinal, transverse and oblique scans using a high frequency linear probe with grayscale and color-doppler; transrectal prostate ultrasound performed with transverse, longitudinal and oblique scans using an end fire probe; basal penile ultrasound will be performed in longitudinal and transverse scans using a high frequency linear probe with grayscale and color-doppler; dynamic penile ultrasound performed as described for basal penile ultrasound after intra-cavernous infiltration of 10 mcg of prostaglandin-E1 (PGE1)."
41472469|NCT05379556|DIAGNOSTIC_TEST|Assessment of reproductive function of LO-COCO-ANDRO male patients|Semen samples will be collected on site by masturbation directly into a sterile plastic container after 3-5 days of sexual abstinence. The sample will be analyzed according to World Health Organization (WHO) 2010 guidelines. Semen samples will be stored for biochemical and molecular evaluations.
41472470|NCT05379556|DIAGNOSTIC_TEST|Assessment of sexual function of LO-COCO-ANDRO male patients|Validated questionnaires to assess the prevalence of male sexual disorders, namely erectile dysfunction with International Index of Erectile function 15 (IIEF-15), premature ejaculation with premature ejaculation diagnostic tool (PEDT), hypoactive sexual desire disorder with andrological structured interview on erectile dysfunction (ANDRO-SIEDY). Patients will be also interviewed to evaluate lifestyle habits.
40797376|NCT02923531|DRUG|X4P-001|X4P-001 will be administered as per the dose and schedule specified in the arm.
40797377|NCT02923531|DRUG|Nivolumab|Nivolumab will be administered as per the dose and schedule specified in the arm.
40797378|NCT02469701|DRUG|nivolumab and ablation|
40797379|NCT00842283|OTHER|skin tissue sample|skin tissue sample
40797380|NCT04171908|OTHER|Conventional therapy|Conventional Physical therapy for the upper limb
40797381|NCT04171908|OTHER|semi-inversive tech|Conventional Physical therapy for the upper limb plus Semi-inversive tech
40797382|NCT04424394|DEVICE|DualStim Therapy|6 DualStim Therapies over a period of 7 weeks.
40797383|NCT04424394|BIOLOGICAL|Umbilical cord-derived Wharton's Jelly|2 intracavernosal injections over a period of 7 weeks.
40797384|NCT04424394|OTHER|Saline|2 intracavernosal injections over a period of 7 weeks.
40797385|NCT06331039|OTHER|PFMT|PFM exercises were done. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
40797386|NCT06331039|OTHER|PFMT+Otago|It were done by combining Otago exercises and PFM exercises. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
40797387|NCT04259437|OTHER|High Protein, Energy Dense Nutritional Supplement|Ready to drink oral supplement
40797388|NCT03520686|DRUG|N-803 + Pembrolizumab|"The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~* Pembrolizumab (200 mg intravenous infusion \[IV\])~* N-803 (15 μg/kg subcutaneously \[SC\])"
40797389|NCT03520686|DRUG|N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab|"The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV)~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)~Day 8:~* Nab-paclitaxel (100mg/m² IV)~Day 15:~* Nab-paclitaxel (100mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)"
41151269|NCT05157464|DRUG|Losartan|Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.
41151270|NCT03785418|BEHAVIORAL|Multicomponent Risk Factor Modification|Healthy eating, regular exercise and behavioural therapy.
41151271|NCT01038128|DRUG|Memantine|Drug: Memantine, 10-40 mg daily
40797390|NCT03520686|DRUG|N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~* N-803 (15 μg/kg SC)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)"
40797391|NCT03520686|DRUG|Pembrolizumab|"Drug: Pembrolizumab~The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)"
40797392|NCT03520686|DRUG|Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab|"The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)~* Pembrolizumab (200mg IV)~Day 8:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Day 15:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)"
40797393|NCT03520686|DRUG|Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)"
40797394|NCT03520686|DRUG|N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab|The treatment plan for the experimental arm of Cohort D will consist of repeated 6-week cycles for a maximum of 18 cycles (approximately 2 years). Nab-paclitaxel and Carboplatin will only be administered in cycle 1.
40797395|NCT02445105|BEHAVIORAL|Autism Navigator Enhanced Practice|Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
41151272|NCT00729261|PROCEDURE|extubation|Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.
41151273|NCT00729261|PROCEDURE|continued intubation|patients remain intubated until their Glasgow coma scores improve to greater than 8.
41151274|NCT06072352|OTHER|Perineal cleansing using chlorhexidine acetate solution|Perineal cleansing using chlorhexidine acetate solution
41151275|NCT06072352|OTHER|Normal saline|Perineal cleansing using normal saline
41151276|NCT01874470|DEVICE|renal denervation|
41151277|NCT01874470|OTHER|standard medication|
41151278|NCT03782545|DEVICE|Cutera truSculpt Device|The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
41151279|NCT04405089|DEVICE|Device: Active Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with 2 milliamperes (mAmps) of anodal stimulation applied to the right prefrontal cortex for total of 26 minutes.
41151280|NCT04405089|DEVICE|Device: Sham Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
41151281|NCT05237856|DEVICE|Capnometry Monitorization|After spinal anesthesia, a non-invasive nasal cannula will be applied to the patient, ETCO2 and IPI values will be continuously measured and recorded from this cannula with a capnometry device.
41151282|NCT00821093|DRUG|Indacaterol 150 µg|Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
41151283|NCT00821093|DRUG|Salmeterol 50 µg|Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
41151284|NCT00821093|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
41151285|NCT00821093|DRUG|Placebo to salmeterol|Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
41151286|NCT05778266|DIETARY_SUPPLEMENT|L-citrulline|oral supplementation of pure L-citrulline (6 g) for twelve weeks
41151287|NCT05778266|DIETARY_SUPPLEMENT|Carboxymethyl cellulose|oral supplementation of Carboxymethyl cellulose (6 g) as a placebo, for twelve weeks
41151288|NCT05778266|OTHER|High Intensity Intervals Training|participants will have sessions 3 days a week for twelve weeks
41151289|NCT02948686|OTHER|Self-Etching Application Strategy|In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
41314118|NCT02757781|BEHAVIORAL|Community of Practice|The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
40797396|NCT02445105|BEHAVIORAL|Family Engagement plus Autism Navigator|Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
40797397|NCT03352232|COMBINATION_PRODUCT|HBOT and OMT|Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at increased atmospheric pressure. Osteopathic manipulative therapy (OMT) is used for myriad ailments including contractures, pain, spasticity. Patients in intervention arms will receive hyperbaric oxygen therapy at 2ATM (atmospheres) for 90minutes daily for up to 6weeks. In addition, they will receive osteopathic manipulative therapies twice a week during the same treatment phase.
40797398|NCT05044650|DIETARY_SUPPLEMENT|KOVIR capsule combined with background treatment|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
40797399|NCT03271242|OTHER|Systematic implementation support|Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
40797400|NCT03271242|OTHER|No implementation support|No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
40797401|NCT04432649|BIOLOGICAL|4SCAR-276|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
40797402|NCT05136222|OTHER|Intervention polysomnography|Please refer to 'Arms: Intervention' section.
40797403|NCT05136222|OTHER|Sham polysomnography|Please refer to 'Arms: Control' section.
40797404|NCT00648427|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
40797405|NCT00648427|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
40797406|NCT00104728|DRUG|ZD1839|
40797407|NCT01532921|PROCEDURE|Tricuspid valve repair|
41001773|NCT00728377|BEHAVIORAL|Physical activity|Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.
41001774|NCT00728377|BEHAVIORAL|Heath & Wellness|The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
41001775|NCT05516576|DEVICE|endomina®|Endoscopic gastroplasty
41001776|NCT04089540|PROCEDURE|New intubation method|
41001777|NCT04089540|PROCEDURE|Conventional intubation method|
41001778|NCT04238624|DRUG|Dabrafenib|Participants will receive dabrafenib 150 mg orally twice a day
41001779|NCT04238624|DRUG|Trametinib|Participants will receive trametinib 2 mg orally once a day
41314119|NCT04699071|DRUG|pembrolizumab and lenvatinib|"All patients will receive oral lenvatinib daily plus intravenous pembrolizumab 3-weekly.~A cycle is 21 days. Allowances will be made for stepwise dose reductions of lenvatinib due to treatment-related toxicities.~Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, (CTCAE) Version 5.0.~Patients are planned to continue therapy until disease progression, intolerable toxicity, or withdrawal of patient consent."
41314120|NCT00483275|DRUG|Alfacalcidol|
41314121|NCT00483275|BEHAVIORAL|Balance, gait and strength training|
41314122|NCT00483275|BEHAVIORAL|Patient education|
41314123|NCT01079429|GENETIC|Genetic study of DNA copies|Gene expression profiling, DNA copy number variation
41314124|NCT03767296|DRUG|Ephedrine Hydrochloride 3 MG/ML|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, .....(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease \< 20%)"
41314125|NCT03767296|DRUG|Phenylephrine|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,...(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease \< 20%)"
41314126|NCT02099942|DEVICE|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|"The V8 device can be used for BAV as follows:~* as stand-alone intervention~* as a bridge to transcatheter aortic valve replacement (TAVR)~* as a bridge to surgical aortic valve replacement (SAVR)~* as an intraprocedural predilatation prior to TAVR"
40797408|NCT01532921|PROCEDURE|Left-sided heart surgery|Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned
40797409|NCT01532921|DEVICE|Contour 3D Tricuspid Annuloplasty Ring|Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair
41472471|NCT05379556|DIAGNOSTIC_TEST|Assessment of olfactory function of LO-COCO-ANDRO male and female patients|"Brief interview to collect patient's anamnesis relative to olfactory function, with particular reference to hypo / anosmia and hypo/ageusia onset timeline, duration and regression.~Interview for the self-assessment of chemosensory skills and for the evaluation of quality of life in relation to olfactory dysfunction.~Sniffin 'Sticks test for the evaluation of odor threshold (T), odor discrimination (D) and odor identification (I) (TDI score)."
40797410|NCT03949452|OTHER|Subcostal Transversus Abdominis Plane catheter|"Prior to surgery, an ultrasound guided unilateral Subcostal Transversus abdominis plane bolus dose (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) will be given on the same side of the surgical incision.~At the end of surgery, A Transversus abdominis plane catheter will be inserted unilaterally by surgeon during wound closure. Then postoperatively, Transversus abdominis plane infusion of a solution mixture prepared in multiple 50 cm syringes each syringe contain 20 ml bupivacaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivacaine is 0.2%). This solution mixture will be infused through Transversus abdominis plane catheter at a rate of 6 ml/hour for 72 hours postoperatively."
40797411|NCT03949452|OTHER|Epidural catheter|"Prior to surgery, we will site an epidural catheter in the thoracic T7-T9 region, and inject an epidural bolus dose same as described above (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) for intra operative analgesia.~Postoperatively, patients will receive epidural infusion of the solution mixture (same as described above) prepared in multiple 50 cm syringes each syringe contain 20 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivaccaine is 0.2%). This solution mixture will be infused epidurally at a rate of 6 ml/hour for 72 hours (3 days) postoperatively."
40797412|NCT01888783|OTHER|Tactile acuity measured by 2PD and the GOT|"For a detailed description of the methods see outcome measures"
41314127|NCT06019936|DRUG|MT2004 Capsule|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
41314128|NCT06019936|DRUG|MT2004 Capsule Placebo|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
40797413|NCT04052750|BEHAVIORAL|SMS follow-up|In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
41314129|NCT04019652|DRUG|CS-3150|Single, oral administration; 10-mg or 40-mg dose
41314130|NCT04019652|DRUG|Moxifloxacin|Single, oral administration; 400 mg-tablet
41001780|NCT00327704|DRUG|albumin|albumin 20% 100 ml/8 hours for 3 days
41314131|NCT04019652|DRUG|Placebo matching moxifloxacin tablet|Placebo tablets matching moxifloxacin tablets
41472472|NCT06330350|OTHER|Qualitative interview|Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.
41472473|NCT00004079|DRUG|SarCNU|Given PO
41472474|NCT00004079|OTHER|pharmacological study|Correlative studies
41472475|NCT00004079|OTHER|laboratory biomarker analysis|Correlative studies
41001781|NCT00327704|DRUG|saline|saline 100 ml/8hours for 3 days
41314132|NCT04019652|DRUG|Placebo matching CS-3150|Placebo tablets matching CS-3150 tablets
41001782|NCT06441383|OTHER|Pittsburgh Sleep Quality Index|"The the Pittsburg Sleep Quality Index (PSQI) questionnaire is a standardized tool for the subjective assessment of sleep. Sleep is described according to 7 components: subjective sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disorders, medication use and daytime dysfunction. The sum of the scores for these 7 components gives an overall score of 21 points maximum.~The presence of sleep disorders will be defined according to the results of the PSQI, with a value above 5 defining the presence of sleep disorders."
41001783|NCT06336369|DIAGNOSTIC_TEST|analyzing brown adipose tissue, body composition and metabolic health|cooling procedure, PET-CT imaging, MR imaging, blood sampling, indirect calorimetry, thermograpy, impedance analysis
41314133|NCT01367301|DRUG|paclitaxel|Given IV
41314134|NCT01367301|DRUG|carboplatin|Given IV
41314135|NCT01367301|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
41314136|NCT01367301|RADIATION|brachytherapy|Undergo HDR brachytherapy
41314137|NCT01367301|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
41314138|NCT01367301|OTHER|laboratory biomarker analysis|Correlative studies
41314139|NCT06027073|BIOLOGICAL|omalizumab|adding omalizumab to anti asthmatic therapy
41472476|NCT04044560|BIOLOGICAL|blinatumomab|Continuous intravenous infusion
41472477|NCT06617663|BEHAVIORAL|EMDR|Eye Movement Desensitization and Reprocessing (EMDR) is a therapy designed to alleviate the distress associated with traumatic memories.
41472478|NCT06617663|BEHAVIORAL|ACT|Acceptance and Commitment Therapy (ACT) is an action-oriented approach to psychotherapy that stems from traditional behavior therapy and cognitive behavioral therapy. Clients learn to stop avoiding, denying, and struggling with their inner emotions and, instead, accept that these deeper feelings are appropriate responses to certain situations and should not prevent them from moving forward in their lives. The ACT Your Way method is specifically designed for young people.
41472479|NCT04923516|OTHER|Dosage of Delta-aminolevulinic acid and Porphobilinogen|Results of dosages of Delta-aminolevulinic acid and Porphobilinogen which are performed in accordance with the current practice will be recorded
41314140|NCT02343276|DRUG|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
41314141|NCT02343276|OTHER|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
41314142|NCT02626572|DRUG|S47445 5mg|S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
41314143|NCT02626572|DRUG|S47445 15mg|S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
41001784|NCT03844126|OTHER|Transition classes|90 minutes spent with patients and their families (separately) to review the changes and challenges associated with healthcare transition and help alleviate some of the barriers traditionally associated with this process.
41314144|NCT02626572|DRUG|S47445 50mg|S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
41314145|NCT02626572|DRUG|Placebo|Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
41472480|NCT05785806|BEHAVIORAL|Skin to skin contact and co-parenting theory course|On the day before delivery, pregnant women and their husbands attend a course on the theory of skin contact and co-parenting to explain the role and importance of skin contact ; to understand the knowledge of co-parenting and parenting care ; to learn the communication method and future parenting plan based on the theory of co-parenting, and to learn the operation of skin contact with newborns after delivery.
41472481|NCT05785806|BEHAVIORAL|Skin to skin contact instruction manual and co-parenting theory brochure|According to reading and analyzing the literature on skin contact, summarize the content of skin contact operation guidance ; read and analyze the relevant literature of co-parenting theory, and summarize the theoretical knowledge and practical operation methods of co-parenting. Pregnant women and their spouses can check in time.
41001785|NCT05551143|OTHER|LiftKit|"The LiftKit contains 7 tools that could assist EMS providers when lifting/moving patients. These tools are:~1. Simple Strap - A sling to lift a seated patient~2. Strap and slide stick - A strap system for raising a supine patient to a sitting posture.~3. Slip Preventer- An envelope that goes over the patients feet with high friction straps for the EMS providers to stand on that prevent the patient from sliding forward when lifted.~4. Drag Straps - straps with handles that can be clipped on tarps used to drag patients~5. The Binder Lift - a vest with handles that allow EMS providers to easily get hold of patient they need to lift.~6. Patient Turning Straps - a way to log-roll a patient that in on the floor while in a standing posture.~7. The ELK - an inflatable seat cushion that can raise a patient who in the floor to chair level"
41001786|NCT05437978|OTHER|"Cap Sport Santé 83 program"|"In Var department (France), the  Maison Sport-Santé 83  has set up a program called Cap Sport Santé 83 to support patients who received a prescription to practice APA regularly. This program helps long-term illnesses patients to restart physical activity by considering their pathology. The Cap Sport Santé 83 program is composed of 5 stages which aim to encourage adherence to APA practice by relying on the medical prescription system. Throughout the process, the patient is supervised and supported by the program's coordinator."
41001787|NCT03445624|DRUG|Infliximab|follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy
41001788|NCT01849211|DRUG|rocuronium|
41001789|NCT00357370|DRUG|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
41001790|NCT00357370|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
41001791|NCT06208241|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
41314146|NCT01449552|DRUG|Tranexamic acid|the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
41314147|NCT01449552|PROCEDURE|Drain clamping|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
41314148|NCT01449552|OTHER|Drain clamping and tranexamic acid|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
41314149|NCT01449552|OTHER|No clamp and placebo|The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
40797414|NCT03120663|DRUG|amoxicillin-clavulanic acid|"During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.~Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² ."
40797415|NCT05006989|OTHER|Blueberry Powder|Administered 10 grams/day
40797416|NCT05006989|OTHER|Placebo Powder|Administered 10 grams/day
40797417|NCT00230776|DRUG|pregabalin|
40797418|NCT00230776|DRUG|placebo|
40797419|NCT05600985|PROCEDURE|FS-LASIK|Laser-assisted in situ keratomileusis, commonly referred to laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hypermetropia, and astigmatism.
40797420|NCT05580263|BEHAVIORAL|aerobic exercise|The main AE program will be designed and controlled for at least moderate intensity of heart rate reserve (HRR) lasting 30 minutes. The goal of intensity will be set at least 40% of HRR during the first two weeks, and then progressively increase the targeted intensity at the end of 16 weeks with 60% HRR. The motions will design by involving core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).
40797421|NCT05580263|BEHAVIORAL|resistance exercise|"In the process, the participants will be instructed by resisting the weight smoothly, and peaking at hold. RE prescription consist of 2-4 sets with 10-15 repetitions per set with a rest interval of 1-2 minutes between sets to improve muscular fitness.~The first two weeks will start with two sets of 10-15 repetitions and then gradually progress on four sets of 15 repetitions at the end of 16 weeks. The total duration of RE will lasting around 15 minutes."
40797422|NCT00517010|DRUG|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
41314150|NCT05142540|PROCEDURE|blood and saliva samples will be taken|"For serology, 8 ml of blood and 1.5 ml saliva samples will be taken at every visit.~For testing cellular immunity, additional 24 ml of blood will be drawn at visits 1 and 2."
41314151|NCT05554471|DEVICE|MYNX CONTROL™ Venous Vascular Closure Device 6F-12F|Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.
41314152|NCT00438399|DRUG|C. propionate - Corticosteroid 1|Twice daily application
41314153|NCT00438399|DRUG|C. propionate- Corticosteroid 2|Twice daily application
41314154|NCT00438399|DRUG|C. propionate -Corticosteroid 3|Twice daily application
41314155|NCT00438399|DRUG|Corticosteroid 1- C. propionate|Twice daily application
41314156|NCT00438399|DRUG|Corticosteroid 2 - C. propionate|Twice daily application
41314157|NCT00438399|DRUG|Corticosteroid 3 - C. propionate|Twice daily application
41314158|NCT01261806|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Enhances nurturance, following the lead, and calming behaviors
41314159|NCT01261806|BEHAVIORAL|Developmental Education for Families|Attention control: Enhances parents understanding of developmental milestones
41314160|NCT05765695|PROCEDURE|Radiofrequency ablation performed with a 19 gauge STARmed needle.|The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.
41314161|NCT02864940|DEVICE|Lumosity|A web-based cognitive training platform that includes games designed with the purpose of improving the user's cognitive abilities
40797423|NCT00426868|OTHER|Direct injection of ADRCs into the Left Ventricle|Dose escalation
40797424|NCT00426868|OTHER|Direct injection of placebo into the Left Ventricle|
40797425|NCT06472323|PROCEDURE|PRF+PRP, PRF|Under CT guidance, the trocar then was inserted through the ipsilateral foramen ovale to the Gasserian ganglion of the patient. After puncturing the foramen ovalis, remove the cannula needle core and connected with RF electrode (PMK-21-100, Baylis, Canada) and the RF generator. Electrical stimulation was carried out at 50 Hz to determine the sensory threshold and at 2 Hz to determine the motor threshold. The RF generator was set to the manual PRF mode with a standard setting of 42°C, the UP knob was turned to increase the output voltage until the maximum voltage (bearable without causing pain in conscious patients)was reached; 120 s, 2 times. After removing the RF electrode in the combined treatment group, 2ml of LP-PRP mixture was injected slowly into the Gasserian ganglion and mandibular nerve and PRF group only receive PRF treatment.
40797426|NCT03586024|DRUG|Pembrolizumab|dose of pembrolizumab will be 200 mg IV every 3 weeks
40797427|NCT00000673|DRUG|Ganciclovir|
40797428|NCT05296551|OTHER|Motor Task|A visuomotor task is presented where an individual must match their knee to an ellipse that moves up and down on a screen, resulting in a marching-in-place motion at a specified frequency.
40797429|NCT05296551|OTHER|Cognitive-motor dual-task|"While performing the Motor Task intervention, letters of different colors and orientation randomly appear one at a time on the screen. During the Cognitive-motor dual-task, individuals are instructed to count the number of times that either 1 (simple cognitive task), or 2 (complex cognitive task) characters appear on the screen during the motor task."
40797430|NCT02516995|DEVICE|Functional magnetic resonance imaging|
40797431|NCT02516995|DEVICE|Ultrasound|
41314162|NCT02864940|DEVICE|Crossword puzzle|This game offers a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also includes optional help features such as filling in an unknown letter or word.
41314163|NCT00002511|RADIATION|low-LET photon therapy|
41314164|NCT04127734|PROCEDURE|The efficacy of various interventions for anastomotic leakage after rectal cancer resection are investigated|Investigated interventions comprise conservative, radiological, endoscopic and surgical (including stoma formation) interventions
41314165|NCT00123916|DRUG|Benznidazole|Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
41472482|NCT05785806|BEHAVIORAL|Daily face-to-face skin to skin contact guidance during hospitalization|After delivery, face-to-face skin-to-skin contact guidance and co-parenting communication and practice were given to the parturient and her husband on a daily basis during hospitalization. Establish a daily fixed skin contact duration target, and the specific operation is freely allocated by both parents.
40797432|NCT02997865|BEHAVIORAL|Stepped care for depression|Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
40797433|NCT04452747|PROCEDURE|Vaginal Dinoprostone system (Propess®)|Labour will be induced using the vaginal Dinoprostone system (Propess®) as a first strategy
40797434|NCT04452747|PROCEDURE|Dilatation balloon|Labour will be induced using a cervix dilatation balloon as a first strategy
40797435|NCT01580709|PROCEDURE|Multiple brushings|Seven consecutive brush samples for cytology.
40797436|NCT01580709|PROCEDURE|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
40797437|NCT03899233|DEVICE|Fractional CO2 laser|Low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond
40797438|NCT03899233|DRUG|Tranexamic acid intradermal microinjections|Tranexamic acid 500mg/5ml ampules
40797439|NCT03265145|DRUG|Stiolto Respimat|Duration - 12 months
40797440|NCT03265145|DRUG|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
40797441|NCT03265145|DRUG|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
40797442|NCT03265145|DRUG|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
40797443|NCT00006459|DRUG|gemcitabine hydrochloride|
40797444|NCT00006459|DRUG|paclitaxel|
40797445|NCT00985608|DRUG|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
40797446|NCT00985608|DRUG|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
40797447|NCT02318368|DRUG|Ficlatuzumab|
41001792|NCT00677807|DRUG|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
41001793|NCT00677807|DRUG|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
41001794|NCT00417794|DRUG|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
41314166|NCT00123916|DRUG|Placebo|a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
41314167|NCT00238303|DRUG|vorinostat|Given orally
41314168|NCT00238303|PROCEDURE|conventional surgery|Patients undergo surgery to remove tumor
40797448|NCT02318368|DRUG|Erlotinib|
40797449|NCT02318368|DRUG|placebo|
40797450|NCT02695017|DEVICE|Iso inertial|
40797451|NCT02695017|DEVICE|Conventional machine|
40797452|NCT06298903|OTHER|Hip Activation|Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.
40797453|NCT06298903|OTHER|Hip activation + Single leg balance|"Hip activation HEP: Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.~Single leg balance: variety of single leg balance exercises with different upper extremity and lower extremity positions to provide different balance stimuli. Weeks are alternated performing these exercises with eyes open and eyes closed."
40797454|NCT03649438|DRUG|131 I-Metaiodobenzylguanidine|"* Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~* Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~* Dose of \> 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available."
41001795|NCT00417794|DRUG|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
41001796|NCT01594593|BEHAVIORAL|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
41001797|NCT02736656|DRUG|SPN-812|
40797455|NCT03649438|DRUG|Potassium Iodide|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
40797456|NCT03649438|DRUG|G-csf|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
40797457|NCT00725946|DRUG|Iodine-124|
40797458|NCT00725946|RADIATION|PET/CT with Iodine-124|
40797459|NCT05523557|BEHAVIORAL|Urban Training|1) one-to-one motivational interview for a maximum of 1h; 2) exercise following a dossier containing various maps of Urban Training walking trails, previously used in patients with COPD with a recommendation of doing a minimum of 1 circuit/day; or in case of living faraway from Urban Training walking trails, the instructions will be to walk at least 30 minutes per day ⩾5 days per week, at a pace reaching a dyspnoea Borg scale score of 4 -6; 3) a FitBit Inspire (FitBit, San Francisco, United States) to obtain direct feedback on the step count and intensity of PA; and 4) a motivational follow-up visit, in group, once per month during the follow-up period.
41001798|NCT02450214|DRUG|Saline|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
41001799|NCT02450214|DRUG|Ketamine|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
41314169|NCT01188564|DRUG|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
41314170|NCT01188564|DRUG|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
40797460|NCT02078050|OTHER|Phrenic nerves magnetic stimulations|
40797461|NCT00770562|DRUG|rituximab|
40797462|NCT00770562|DRUG|Dexamethasone|
40797463|NCT06378333|PROCEDURE|patients who underwent coronary angiography|All patients included in the ICAR project (Montpellier - Nîmes) benefit from a consultation at one year (12+or - 2 months), as they are systematically reviewed in our department: data will therefore be collected in the patient's medical record. Clinical biological parameters and events during the hospital phase are also collected in the patient's computerized record. Normal patient management remains unchanged.
40797464|NCT01501890|DRUG|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
40797465|NCT01501890|DRUG|Placebo|0.9% NaCl
41472483|NCT05785806|BEHAVIORAL|Online punching skin to skin contact|Share common parenting related knowledge, daily skin contact reminders, emphasize mutual recognition and mutual support of parents, and conduct WeChat follow-up every two weeks to understand the physical and mental status of both parties and the growth of infants.
40797466|NCT01350258|DRUG|Fludarabine|Part of the conditioning regimen
40797467|NCT01350258|DRUG|Thiotepa|Part of the conditioning regimen
40797468|NCT01350258|RADIATION|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
40797469|NCT01350258|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
40797470|NCT01350258|DRUG|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
40797471|NCT01350258|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
40797472|NCT01816776|DEVICE|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
40797473|NCT01816776|DEVICE|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
40797474|NCT05930847|DEVICE|Digital Game Application|The digital game contains brief information about the respiratory system adapted to children, and it is a game whose duration can be adjusted manually to follow the treatment process of the patient, taking into account the ½ ratio in the inhalation and exhalation process in the clinic.
40797475|NCT05930847|DRUG|Use of medication for asthma|The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
40797476|NCT04671563|DRUG|Tenofovir Disoproxil Fumarate 300 MG|One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
40797477|NCT00735553|DRUG|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
40797478|NCT00735553|DRUG|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
41001800|NCT02450214|DRUG|Ketamine + magnesium|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
41472484|NCT05785806|BEHAVIORAL|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
40797479|NCT00735553|DRUG|Placebo|Two placebo capsules orally daily for up to four months
40797480|NCT04807608|OTHER|Usability Assessment|A survey will be administered to the subject at the end of the 6th week of product usage related to the wearable device and the related software platform's usability. Survey items will include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.
40797481|NCT00003730|DRUG|fluorouracil|
40797482|NCT00003730|DRUG|vinorelbine tartrate|
40797483|NCT06093269|BIOLOGICAL|Blood samples|"For all subjects (short kinetics):~* Pre-injection of cefazolin~* Start of next dialysis~* Two hours after start of subsequent dialysis~* End of next dialysis, before cefazolin administration~Only in hospitalized subjects (rich kinetics):~* 30 minutes, 1h and 2h after cefazolin injection, to describe the cefazolin peak and possible post-dialysis rebound~* 12h, 24h and 36h after cefazolin injection, to better describe cefazolin elimination and distribution"
40797484|NCT00236964|DRUG|Iron Sucrose + Erythropoietin|
40797485|NCT00236964|DRUG|Ferrous Sulfate + Erythropoietin|
41472485|NCT06327217|RADIATION|Bilateral hip x-ray|Patients will be asked to visit the clinic for a bilateral hip x-ray, in order to evaluate the degree os osteoarthritis.
40797486|NCT02931409|PROCEDURE|Optimal PEEP|Optimal PEEP determined by Cstat during PEEP titration procedure.
40797487|NCT02931409|PROCEDURE|Standard PEEP|Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
41001801|NCT01858012|BEHAVIORAL|Moderate alcohol cessation|patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement
41001802|NCT00136487|DRUG|Celecoxib|
41001803|NCT02311751|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
40797491|NCT06377280|DEVICE|Navina Mini|CE-marked Navina Mini, released on the market May 2023
40797492|NCT00325507|BIOLOGICAL|TroVax|TroVax 1 x 10E9 TCID 50mL
40797493|NCT00325507|DRUG|IL-2|IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6
41001804|NCT04249804|DRUG|Magnesium Sulfate 1000 MG|intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering
41314171|NCT01415856|DEVICE|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
40797494|NCT04645511|PROCEDURE|Balloon sinuplasty of maxillary sinuses|A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.
40797495|NCT04645511|PROCEDURE|Sham surgery|"The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides."
40797496|NCT05731635|DIAGNOSTIC_TEST|plantar pressure values|Walking enables for extremely accurate and pointwise ground response force measurement because to plantar pressure measurement (pedobarography). It allows for the objective comparison and evaluation of the dynamic pressure put on the ground by the foot in contact with it. It is often used in clinics to assess foot mechanics and associated disorders that affect the foot sole. Additionally, plantar pressure analysis is useful for identifying, treating, and monitoring conditions that impact the lower extremity's axial alignment.
40797497|NCT00003262|BIOLOGICAL|bleomycin sulfate|
40797498|NCT00003262|BIOLOGICAL|filgrastim|
40797499|NCT00003262|DRUG|Stanford V regimen|
40797500|NCT00003262|DRUG|doxorubicin hydrochloride|
40797501|NCT00003262|DRUG|epirubicin hydrochloride|
40797502|NCT00003262|DRUG|etoposide|
40797503|NCT00003262|DRUG|mechlorethamine hydrochloride|
40797504|NCT00003262|DRUG|prednisone|
40797505|NCT00003262|DRUG|vinblastine sulfate|
40797506|NCT00003262|DRUG|vincristine sulfate|
41314172|NCT01415856|DEVICE|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
41314173|NCT02112916|DRUG|Bortezomib|Given IV
41314174|NCT02112916|DRUG|Cyclophosphamide|Given IV
41314175|NCT02112916|DRUG|Cytarabine|Given IT, IV, or SC
41314176|NCT02112916|DRUG|Daunorubicin|Given IV
41314177|NCT02112916|DRUG|Daunorubicin Hydrochloride|Given IV
41314178|NCT02112916|DRUG|Dexamethasone|Given PO or IV
41314179|NCT02112916|DRUG|Doxorubicin|Given IV
41314180|NCT02112916|DRUG|Doxorubicin Hydrochloride|Given IV
41314181|NCT02112916|DRUG|Etoposide|Given IV
41314182|NCT02112916|DRUG|Hydrocortisone Sodium Succinate|Given IT
41314183|NCT02112916|DRUG|Ifosfamide|Given IV
40797507|NCT06374927|DEVICE|Rehabilitation Gaming System (VR-based mobile application)|The study intervention includes using the mobile phone technology RGSapp. This application integrates sensor data for delivering patient-tailored VR and AR-based training via gamified exercises for cognitive training.
40797508|NCT01463423|RADIATION|iSABR, 25 Gray in 1 fraction for small peripheral tumors|Radiotherapy procedure for participants with small peripheral tumors ≤ 10 cc.
40797509|NCT01463423|RADIATION|iSABR, 50 Gray in 4 fractions for medium peripheral tumors|Radiotherapy procedure for participants with medium peripheral tumors \> 10 cc and ≤ 30 cc.
40797510|NCT01463423|RADIATION|iSABR, 54 Gray in 3 fractions for large peripheral tumors|Radiotherapy procedure for participants with large peripheral tumors \> 30 cc.
40797511|NCT01463423|RADIATION|iSABR, 40 Gray in 4 fractions for small central tumors|Radiotherapy procedure for participants with small central tumors ≤ 10 cc.
40797512|NCT01463423|RADIATION|iSABR, 50 Gray in 4 fractions for medium central tumors|Radiotherapy procedure for participants with medium central tumors \> 10 cc and ≤ 30 cc.
41314184|NCT02112916|DRUG|Leucovorin Calcium|Given PO or IV
41314185|NCT02112916|DRUG|Mercaptopurine|Give PO
40797513|NCT01463423|RADIATION|iSABR, 60 Gray in 8 fractions for large central tumors|Radiotherapy procedure for participants with large central tumors \> 30 cc.
40797514|NCT04901663|DRUG|Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG|Orally twice daily for 2 weeks
40797515|NCT04901663|DRUG|Vonoprazan 20 MG; Amoxicillin 1000 MG|Orally twice daily for 2 weeks
40797516|NCT03842774|DIETARY_SUPPLEMENT|Exract of Gelidium elegans|Exract of Gelidium elegans will be given to the test group.
40797517|NCT03842774|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be given to the test group.
40797518|NCT03051295|OTHER|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
40797519|NCT06110949|DEVICE|Triaxial accelerometry|A group of patients will be controlled with triaxial accelerometer (GENEActiv watch) on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction, in order to collect raw data regarding patient mobility (duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity) during the admission (from the admission day to discharge).
41314186|NCT02112916|DRUG|Methotrexate|Given IT, IV, or PO
41314187|NCT02112916|DRUG|Pegaspargase|Given IV
41314188|NCT02112916|RADIATION|Radiation Therapy|Undergo radiation therapy
41314189|NCT02112916|DRUG|Thioguanine|Given PO
41314190|NCT02112916|DRUG|Vincristine|Given IV
41314191|NCT02112916|DRUG|Vincristine Sulfate|Given IV
41314192|NCT01167465|OTHER|Moussik Diaper Rash Mousse|To be used as instructed
41314193|NCT01167465|OTHER|Desitin Creamy Ointment|To be used as instructed
41314194|NCT05743140|DIAGNOSTIC_TEST|CaIMR|Investigators diagnose CMD with CaIMR. Investigators use OCT and OCTA to analyze the fundus microcirculation quantitatively.
41314195|NCT01590862|DEVICE|Deep Brain Stimulator|Medtronic Deep Brain Stimulation device turned on and off
41314196|NCT04482868|PROCEDURE|Percutaneous screw fixation through K-wire-assisted reduction and maintenance|Percutaneous screw fixation for acute scaphoid fractures through K-wire-assisted reduction and maintenance
41314197|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (60µg/per protein)|two doses of 60µg/0.6ml per dose
41314198|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (30µg/per protein)|two doses of 30µg/0.6ml per dose
41314199|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (15µg/per protein)|two doses of 15µg/0.6ml per dose
41314200|NCT04021394|DIAGNOSTIC_TEST|CellSearch CTC platform|epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs
41314201|NCT04021394|DIAGNOSTIC_TEST|Parsortix CTC platform|EMT-independent platform
41314202|NCT05682586|BIOLOGICAL|umbilical cord mesenchymal stem cells|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
41314203|NCT05682586|DRUG|paxlovid|Participants will receive standard dose of paxlovid therapy, which contains 300mg namatevir and 100mg litonavir twice a day for a total course of 5 days.
41314204|NCT05398120|BEHAVIORAL|Skills Group|Adolescents and young adults with a CHR syndrome ages 13-18 will complete feasibility and outcome measures while participating in a weekly skills group for 6 months.
41314205|NCT00150670|DRUG|TS-1 and cisplatin|TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.
41314206|NCT00150670|DRUG|TS-1|TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
41314207|NCT01608724|DRUG|Saxagliptin|oral, 5 mg once a day (Q.D.)
41314208|NCT03503214|DIAGNOSTIC_TEST|In vitro determination of non-carbonic buffer power|In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide
41314209|NCT03503214|DIAGNOSTIC_TEST|Classic description of acid-base status|Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.
41314210|NCT03924141|BEHAVIORAL|Training in de-escalation|Will receive one hour of de-escalation training
41314211|NCT00699101|DEVICE|Conture Multi-Lumen Balloon|Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
41314212|NCT03294408|DIAGNOSTIC_TEST|multimodal imaging|
41314213|NCT05117125|DIAGNOSTIC_TEST|Heparin-binding protein|Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
41314214|NCT05117125|DIAGNOSTIC_TEST|Interleukin-26|Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
41314215|NCT05117125|DIAGNOSTIC_TEST|Microbiome|Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
41314216|NCT05117125|DIAGNOSTIC_TEST|Bacterial transcriptome|Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
41314217|NCT05117125|DIAGNOSTIC_TEST|Proteome|Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
41314218|NCT00236119|DRUG|CEP-701 20mg|Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.
41314219|NCT00236119|DRUG|CEP-701 40mg|Dosages of oral CEP-701 40mg will be given twice daily.Escalation to the next higher dosage, CEP-701 60mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 2 will continue on the 40mg dosage until study completion.
41314220|NCT00236119|DRUG|CEP-701 60mg|Dosages of oral CEP-701 60mg will be given twice daily. Escalation to the next higher dosage, CEP-701 80mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 3 will continue on the 60mg dosage until study completion.
41314221|NCT00236119|DRUG|CEP-701 80mg|Dosages of oral CEP-701 80mg will be given twice daily. Patients who have moved to Cohort 4 will continue on the 80mg dosage until study completion.
41314222|NCT06084338|RADIATION|stereotactic ablative radiotherapy|Metastasis directed
41314223|NCT06084338|DRUG|Pluvicto|PSMA targeted radiopharmaceutical therapy
41314224|NCT06084338|DRUG|topical testosterone|Topical testosterone 1.62% gel
41314225|NCT01023412|DIETARY_SUPPLEMENT|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
41314226|NCT03443843|DRUG|loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)|Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
41314227|NCT03443843|DRUG|Placebo tablet|Placebo tablet orally
41314228|NCT03443843|DRUG|Fluticasone Propionate|Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
41314229|NCT03443843|DRUG|Placebo spray|Placebo Nasal Spray, 2 sprays per nostril
41314230|NCT00992784|BIOLOGICAL|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
41314231|NCT00992784|BIOLOGICAL|FluarixTM|Single dose, intramuscular injection
41314232|NCT02106988|RADIATION|Radiation Therapy|Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
41314233|NCT02106988|DRUG|Dexamethasone|40 mg by vein Days 1-3 in a 21 day cycle.
41314234|NCT02106988|DRUG|Etoposide phosphate|67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
41314235|NCT02106988|DRUG|Ifosfamide|1 g/m2 by vein on Days 1-3 of a 21 day cycle.
41314236|NCT02106988|DRUG|Mesna|0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
41314237|NCT02106988|DRUG|Carboplatin|200 mg/m2 by vein on Day 1 of a 21 day cycle.
41314238|NCT02310828|DRUG|Acetium|Capsule for oral administration contains L-cysteine 100mg
41314239|NCT02310828|DRUG|Placebo|A placebo capsule matching Acetium for oral administration.
41314240|NCT03587480|PROCEDURE|TME+LLND|patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)
41314241|NCT03587480|PROCEDURE|TME+nCRT|patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)
41314242|NCT01798940|DRUG|Torrent's Pioglitazone|
41472486|NCT06327217|OTHER|Questionnaires|Patients will be asked to complete questionnaires on function, quality of life and pain (the modified Harris Hip Score (mHHS), Hip Outcome Score (HOS), the World Health Organisation Quality of Life Questionnaire (WHOWOL) and Visual Analogue Scale (VAS) for pain). One question will be asked: 'How satisfied are you with the results of the surgery?' on a 10-point scale.
40797520|NCT06453382|BEHAVIORAL|Behavioural change modification, Screening, NCD related knowledge practice and attitude|The investigators will provide periodic training regarding the control and prevention of NCDs to the stakeholders. The investigators will provide WHO-Package of Essential Non-Communicable Diseases (PEN) protocol training to the stakeholders involved in healthcare service delivery. The investigators will equip the government healthcare facilities with the equipment needed for the screening of NCDs. For the stakeholders who are not directly involved with healthcare service delivery, the investigators will train them about the 5 NCDs (diabetes, hypertension, chronic respiratory disease, cancer, and mental illness) and the 5 NCD risk factors (unhealthy diet, inadequate physical activity, tobacco cessation, alcohol cessation, and air pollution). The investigators will also share information, education, and communication (IEC) materials with the stakeholders, and then they will share the information with the community.
40797521|NCT01485276|PROCEDURE|DBS Surgery|
40797522|NCT02244307|DRUG|alpha-adrenergic blocker|
40797523|NCT05551351|DIAGNOSTIC_TEST|Cardiac CT with photon counting detector|Cardiac CT including the coronary arteries. The cardiac CT is performed in routine care for the included patients.
40797524|NCT01826539|PROCEDURE|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
40797525|NCT04029428|DRUG|90Y-DOTATATE|Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
40797526|NCT04029428|DRUG|(177Lu-DOTAOTyr3)Octreotate|Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
40797527|NCT04029428|DRUG|90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)|Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
40797528|NCT03995095|OTHER|Therapeutic interview: kibo protocol|The kibo protocol is a therapeutic interview designed to address the spiritual needs of patients at the end of life.
40797529|NCT04791657|PROCEDURE|Appendectomy|Surgical treatment for appendicitis
41314243|NCT05668468|DIETARY_SUPPLEMENT|Bifidobacterium adolescentis IVS-1 capsule|Daily Bifidobacterium adolescentis IVS-1 capsule containing up to 6x10 ninth cfu per capsule or daily cellulose capsule
41472487|NCT04490473|OTHER|survey work|Survey forms will be sent to individuals online. Information about the study will be given to individuals with the informative text at the beginning of the questionnaire form. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
41001805|NCT00768729|DRUG|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
41001806|NCT00768729|DRUG|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
41001807|NCT00140075|DRUG|Epirubicin with Cyclophosphamide, followed by a Taxane|"Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
41314244|NCT05668468|OTHER|Placebo cellulose capsule|Daily cellulose capsule
41314245|NCT02814357|OTHER|Control (market standard)|
41314246|NCT02814357|OTHER|wheat flour|
41314247|NCT02814357|OTHER|chickpea flour|
41314248|NCT02814357|OTHER|guar gum|
41314249|NCT02814357|OTHER|barley|
41314250|NCT02140203|OTHER|Yoga Training|one-year experimental training (three times per week and one hour per session)
40797530|NCT02402530|DRUG|Placebo|Matching placebo administered as intravenous infusion.
40797531|NCT02402530|DRUG|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
40797532|NCT05580601|DRUG|CIML-NK Cells|"The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of:~* Cytokine-Induced Memory-Like NK cells (CIML-NK cells)~* Human Serum Albumin~* Plasmalyte~The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested."
40797533|NCT00027144|BIOLOGICAL|Heat Shock Protein 70 HSP70|
40797534|NCT00650663|DRUG|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
40797535|NCT00650663|DRUG|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
40797536|NCT01738685|BEHAVIORAL|Behavioral Intervention.|
40797537|NCT01738685|OTHER|Nutritional Education.|
40797538|NCT00044369|PROCEDURE|Varicocele repair|
41314251|NCT03128216|PROCEDURE|Blind Local Anesthetic infiltration|Patients of this group received blind local anesthetic infiltration on surgical site. Local anesthetic infiltration are performed by surgeon.
41314252|NCT03128216|PROCEDURE|Transversals Fascia Block|Patients of this group received ultrasound guided omolateral Transversals Fascia Block.
40797539|NCT05466552|PROCEDURE|PCI procedure|During the PCI procedure, use of ECMO/Impella 5.0 is allowed hemodynamic instability (bail- out).
41314253|NCT03128216|PROCEDURE|Spinal Anesthesia|Patients of this group received Spinal Anesthesia
40797540|NCT02890745|DRUG|Empagliflozin|
40797541|NCT02890745|DRUG|Placebo|
40797542|NCT05912595|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of tissue oxygenation and frequent MS symptoms following a single session of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for one month (3 sessions per week) on tissue oxygenation and MS related symptoms."
40797543|NCT02339844|DRUG|Aripiprazole|6 weeks of individual doses of aripiprazole
40797544|NCT05511506|OTHER|aqueous humor collection|Once the laser procedures were finished, the patient was transported to another surgery operating bed. Before the eyeball was opened, 100-200 μL of aqueous humor was obtained from the anterior chamber via an ultra-thin needle through the paracentesis site of cornea.
40797545|NCT03612063|DEVICE|Fitbit Iconic HR and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
40797546|NCT03612063|DEVICE|Fitbit Iconic HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
40797547|NCT03612063|DEVICE|Garmin Vivosmart HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
40797548|NCT03612063|DEVICE|Fitbit Iconic HR and Apple Watch III|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
40797549|NCT03612063|DEVICE|Apple Watch III and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
40797550|NCT03612063|DEVICE|Apple Watch III and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
40797551|NCT02881411|OTHER|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
40797552|NCT02881411|OTHER|Fibromyalgia coping skills programme|Exercise, education programme
40797553|NCT01308255|DRUG|Infliximab|"Prior to week 26~* Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)~* Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.~* Folic acid 5 mg daily except the day methotrexate is taken~Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity"
40797554|NCT01308255|DRUG|Methylprednisolone|Steroid
41314254|NCT03128216|DRUG|Ropivacaine|Local anesthetic used for local infiltration and Transversals fascia block
40797555|NCT01308255|DRUG|Methotrexate|All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
40797556|NCT01308255|DIETARY_SUPPLEMENT|Folic acid|All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
40797557|NCT05596539|OTHER|Data collection|Collection data from diagnostic Data collected following to medical exam as part of care
40797558|NCT06174012|DRUG|Sodium Fluoride|Sodium fluoride was applied before radiotherapy, at 3 months, 6 months, and 12 months after radiotherapy.
41001808|NCT00140075|DRUG|Epirubicin with a Taxane|"Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
41001809|NCT01331694|DRUG|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
41001810|NCT01331694|DRUG|tiotropium|patients initiating treatment with tiotropium
41001811|NCT01331694|DRUG|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
41001812|NCT01750580|DRUG|Lirilumab|
41001813|NCT01750580|DRUG|Ipilimumab|
41314255|NCT03128216|DRUG|Bupivacaine|Local anesthetic used for Spinal Anesthesia
41314256|NCT06214351|OTHER|Use of mobile midwifery application|Pregnant women in the experimental group will have a mobile midwifery application installed on their smartphones. The pregnant woman will be able to reach the research midwife 24/7. With the informative content and algorithm mechanism in the application, she will be able to provide individual care and detect early signs of danger, enabling her to seek medical attention.
41314257|NCT02130479|BEHAVIORAL|Contingency Management-Family Engagement|
41314258|NCT02130479|BEHAVIORAL|Treatment as Usual|
41314259|NCT05191823|DRUG|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
41314260|NCT05191823|DIETARY_SUPPLEMENT|Placebo|400 mg corn oil per day for 6 months
41314261|NCT01094730|DEVICE|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
41472488|NCT06467331|OTHER|Hippotherapy|Hippotherapy, also known as horse-assisted therapy, is a form of animal-assisted therapy. It consists of regularly scheduled sessions designed to enhance functionality in individuals' lives and contribute to their overall health improvement.
41472489|NCT03010852|BEHAVIORAL|Focused incentive spirometer education and monitoring|
41472490|NCT04411823|DEVICE|EndoFLIP measurement|EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern under FDA cleared indication. It is performed during endoscopy.
41001814|NCT00696956|DEVICE|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
41001815|NCT00696956|DEVICE|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
41001816|NCT00794196|BEHAVIORAL|Pharmaceutical care program for antidepressant treatment|The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
41314262|NCT01094730|DEVICE|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
41314263|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -IV|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct -intravenous (i.v.) arm
41314264|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -intra-hepatic artery|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: intra-hepatic artery (i.a.) arm
41314265|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -Intratumoral Injections|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: Intratumoral Injections (i.t.) arm
41314266|NCT00214968|DRUG|Modafinil|maximum dosage 400 mg/day (4 tablets)
41314267|NCT00553137|DRUG|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
41314268|NCT00553137|DRUG|fluconazole|150 mg fluconazole tablets once daily for 14 days
41314269|NCT00084812|DRUG|cisplatin|
41314270|NCT00084812|DRUG|safingol|
41314271|NCT00747396|OTHER|Foster Care Placement|A group of children living in institutions in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and trained in Romanian. Before placement, foster parents visited their children to begin developing a relationship with the child. Hired foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Foster parents were invited to participate in a support group organized by social workers. Project social workers consulted weekly with US staff experienced in dealing with young children in foster care.
41314272|NCT05068193|DRUG|BR2008-1 (R)|After fasting at least 10 hours, two tablets of BR2008-1 will be administered orally with 150mL of water around 8 a.m.
41001817|NCT00184262|BEHAVIORAL|ERP cognitive therapy|15 exposure and response prevention (ERP) sessions in 3 months with a cognitive therapy rationale
41001818|NCT00184262|BEHAVIORAL|ERP behavioral therapy|15 exposure and response prevention (ERP) sessions in 3 months with a behavioral therapy rationale
41314273|NCT05068193|DRUG|BR2008 (T)|After fasting at least 10 hours, one tablet of BR2008 will be administered orally with 150mL of water around 8 a.m.
41314274|NCT06281782|OTHER|topical retinoids and platalet rich plasma|We will analyse both monotherapy with a topical retinoid alone and combination therapy with a topical retinoid and platelet-rich plasma (PRP) to elucidate their role in acne treatment and provide possible recommendations for their use.
41314275|NCT05102149|DRUG|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively;
41314276|NCT05102149|DRUG|Vildagliptin|Vildagliptin: 50 mg each time, orally in the morning and evening respectively;
41314277|NCT05102149|DRUG|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
41314278|NCT05102149|DRUG|Vildagliptin matched placebo|One tablet each time, orally in the morning and evening respectively;
41314279|NCT02935114|DRUG|37% Carbamide Peroxide|"* no Gingival dam protection (as manufacturer´s instruction)~* 37% Carbamide Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
41314280|NCT02935114|DRUG|35% hydrogen Peroxide|"* Gingival dam protection (as manufacturer´s instruction)~* 35% Hydrogen Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
41314281|NCT01557218|OTHER|Cucumber snack|Three 300-g bowls of vegetables per table: three of cucumber slices
41314282|NCT01557218|OTHER|Pepper snack|Three 300-g bowls of vegetables per table: three of yellow pepper strips
41314283|NCT01557218|OTHER|Tomato snack|Three 300-g bowls of vegetables per table: three of grape tomatoes
41314284|NCT01557218|OTHER|Vegetable variety snack|Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
41314285|NCT01557218|OTHER|Apple snack|Three 300-g bowls of fruits per table: three of apple wedges
41314286|NCT01557218|OTHER|Peach snack|Three 300-g bowls of fruits per table: three of peach slices
41314287|NCT01557218|OTHER|Pineapple snack|Three 300-g bowls of fruits per table: three of pineapple half-rings
41472491|NCT05752292|BEHAVIORAL|Standard Health Information|Standard health information about postpartum screening and lifestyle programs for diabetes prevention
41472492|NCT05752292|BEHAVIORAL|Values Affirmation (VA)|Interactive prompts to reflect on core personal values
41472493|NCT05752292|BEHAVIORAL|Tailored Risk Information (TRI)|Interactive prompts to provide tailored information on risk factors for type 2 diabetes
41472494|NCT05752292|BEHAVIORAL|Motivational Interviewing-based (MI)|Interactive prompts based on principles of motivational interviewing
41472495|NCT05752292|BEHAVIORAL|Action planning (AP)|Interactive prompts to problem solve challenges
41472496|NCT06607718|OTHER|Resistance Training|Resistance training for elderly patients in the acute care unit.
40797559|NCT01966354|PROCEDURE|Ultrasound-guided Internal jugular venous approach|"The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane)."
40797560|NCT00634140|DRUG|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
40797561|NCT00634140|DRUG|Placebo|placebo for 4-6 weeks
40797562|NCT03799952|BEHAVIORAL|Zoomers on the Go Exercise Program|60 minute exercise class involving resistance and aerobic training activities, as well as flexibility and balance activities. An educational handout is offered at the end of every class, relating to health behaviour.
40797563|NCT03372720|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
40797564|NCT03372720|OTHER|Questionnaire Administration|Ancillary studies
41314288|NCT01557218|OTHER|Fruit variety snack|Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
40797565|NCT03372720|PROCEDURE|Sham Intervention|Undergo sham laser therapy
41314289|NCT02760017|DRUG|B. forficata|
41314290|NCT02760017|DRUG|Placebo|
41314291|NCT02163993|DRUG|Galcanezumab|Administered SQ
41314292|NCT02163993|DRUG|Placebo|Administered SQ
41314293|NCT04220632|DRUG|Itacitinib|at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
40797566|NCT01632852|BIOLOGICAL|CSL362|"CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362."
40797567|NCT00243867|DRUG|Taxoprexin|6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes
40797568|NCT03146663|DRUG|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
40797569|NCT03146663|DRUG|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
40797570|NCT05820841|DRUG|R-miniCHOP + Acalabrutinib|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5)~* Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8.~Cycles repeated every 3 weeks"
40797571|NCT05820841|DRUG|R-miniCHOP|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks"
40797572|NCT05284500|PROCEDURE|Pediatric cardiac surgery with cardiopulmonary bypass|All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database
40797573|NCT01530503|DRUG|capecitabine and mitomycin|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
40797574|NCT01530503|DRUG|Capecitabine|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
41314294|NCT04220632|DRUG|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
41314295|NCT04220632|DRUG|Methylprednisolone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
41314296|NCT04237740|DRUG|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
40797575|NCT05070793|BEHAVIORAL|Culturally adapted interpersonal psychotherapy|Individual psychotherapy based on Brief Interpersonal Psychotherapy, culturally adapted for transgender and nonbinary individuals.
40797576|NCT03351868|GENETIC|Gene-modified autologous stem cells|Infusion for 5x10\^6\~1x10\^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
40797577|NCT06523764|DRUG|tegoprazan|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
40797578|NCT06523764|DRUG|Minocycline|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
40797579|NCT06523764|DRUG|bismuth potassium citrate|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
40797580|NCT06523764|DRUG|Esomeprazole 40mg|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
41314297|NCT06530303|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
41314298|NCT06530303|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
41314299|NCT06530303|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
41314300|NCT06530303|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
41314301|NCT06530303|DRUG|Pembrolizumab|Intravenous (IV) infusion
41314302|NCT06380361|DEVICE|BioSpy System|One arm only - in all eligible study patients, the study device will be used. In patients with suspicion of lung cancer a bronchoscope will be inserted to navigate to the lesion where a biopsy sample will be taken for histology analysis. In the current trial, the device will be used to perform electrophysiological measurements in the lesion during bronchoscopic biopsy procedure.
41314303|NCT04376606|PROCEDURE|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
40797581|NCT06523764|DRUG|Amoxicillin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
40797582|NCT06523764|DRUG|clarithromycin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
40797583|NCT01928290|DRUG|Irinotecan|
40797584|NCT01928290|DRUG|Trastuzumab|
40797585|NCT01928290|DRUG|Oxaliplatin|
41472497|NCT06607718|DIETARY_SUPPLEMENT|Oral Nutritional Supplementation|To receive two daily packs of a hypercaloric and hyperproteic oral nutritional supplement for 3 months.
41472498|NCT06607718|OTHER|Control Group|No intervention
40797586|NCT01928290|DRUG|Leucovorin|
41314304|NCT04376606|PROCEDURE|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
41001819|NCT06105385|OTHER|Suboccipital Myofascial Release Technique|With the patient in a supine position, the therapist sits behind the patient with his or her forearms on the treatment table. The therapist places his fingers between the occiput and axis, with his fingers in semi-flexion (2nd, 3rd and 4th fingers), and continues to hold his hands on the occiput until relaxation is achieved in the suboccipital muscles. A light traction is applied at the end of the technique. Average application time is 4-5 minutes.
41314305|NCT04376606|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
41314306|NCT05216848|OTHER|Wijma Delivery Expectancy Questionnaire|Simple questionaire identifying the level of fear of childbirth in pregnancy
41472499|NCT03610919|DRUG|Nasal Sprays|Intranasal administration of 24 international units per dose.
40797587|NCT01928290|DRUG|Fluorouracil|
40797588|NCT04560686|DRUG|Bintrafusp Alfa|Given IV
40797589|NCT04560686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41001820|NCT05263427|DEVICE|TOCONAUTE|"This study will be carried out during delivery. The will be placed on the mother's abdomen to capture fetal and maternal heart rate as well as the uterine contractions in parallel of the cardiotocograph.~For each of the participants, the TOCONAUTE will remain on the mother's abdomen till childbirth. This procedure will not affect the usual care of the patient."
41001821|NCT00577083|DEVICE|Cap-fitted colonoscopy|Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
41001822|NCT03621228|DEVICE|MindfulGarden|MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
41001823|NCT06262841|DEVICE|Piezosurgery|Piezosurgery used as an osteotomy device
41001824|NCT06262841|DEVICE|Conventional burs|Conventional burs used as an osteotomy device
41001825|NCT02445027|DEVICE|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
41314307|NCT05216848|OTHER|Clinical data collection|Collection of the standard clinical data during hospitalization
41314308|NCT05515822|DRUG|Oxycodone Hydrochloride|The doses were calculated according to the ideal body weight. Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
41472500|NCT03164837|DRUG|68Ga-NOTA-RM26|Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
41472501|NCT01275560|DRUG|Metronidazole|Metronidazole,per os,500mg, 3 per day during 10 days
41472502|NCT01275560|DRUG|CArbosylane|
41472503|NCT04596306|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
40797590|NCT03822637|DRUG|n-acetylcystine + albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
40797591|NCT03822637|DRUG|0.9% saline + albuterol|Normal saline is a placebo agent and Albuterol is a bronchodilator.
40797592|NCT03001193|DRUG|DF 01|
40797593|NCT03001193|DRUG|Oxytocin|
40797594|NCT03001193|DRUG|Placebo|
40797595|NCT01957293|DRUG|Salbutamol|single oral administration, 4 mg
40797596|NCT01957293|DRUG|Placebo|single oral administration
40797597|NCT01565408|DRUG|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
40797598|NCT01565408|DRUG|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
40797599|NCT00407615|DEVICE|Flex Pad/Static Magnet|
40797600|NCT05754411|DRUG|[14C]STI-1558|Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.
40797601|NCT03789656|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
40797602|NCT00727545|OTHER|iron bisglycine chelate|
40797603|NCT00727545|OTHER|placebo|
40797604|NCT03975335|BEHAVIORAL|Health education|In this health education intervention, emphasis is given on evoking adolescents' internal desire to change, supporting self-efficacy to be changed, guiding self-regulatory ways along with facilitating desired changing process by empowering them with choices and skills.
40797605|NCT03975335|OTHER|Carrier Guidance|Carrier opportunities and counselling
40797606|NCT06380725|DEVICE|Transcranial alternating current stimulation(real stimulation)|Real tACS is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of weak current to the brain by means of electrodes placed in the skull.
41314309|NCT05515822|DRUG|Dezocine|Dezocine was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
40797607|NCT06380725|DEVICE|Transcranial alternating current stimulation(sham stimulation)|Transcranial alternating current stimulation (sham-stimulation) is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of a weak current to the brain by means of electrodes placed in the skull. The subjects felt the same as the real stimulus when receiving the sham-stimulus treatment, but the sham-stimulus did not have the current stimulation.
40797608|NCT03785353|BEHAVIORAL|PNE lecture|A translated (from English to Spanish) lecture on Pain Neuroscience Education
41314310|NCT05515822|DRUG|Esketamine and Oxycodone|Esketamine was administered 5min before skin incision, and Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
41314311|NCT01763021|DRUG|PCI-32765|PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
40797609|NCT02628405|DRUG|Carboplatin|Given IV
40797610|NCT02628405|DRUG|Etoposide|Given IV
40797611|NCT02628405|DRUG|Ifosfamide|Given IV
40797612|NCT02628405|OTHER|Laboratory Biomarker Analysis|Correlative studies
40797613|NCT02628405|DRUG|Lenalidomide|Given PO
40797614|NCT02628405|BIOLOGICAL|Rituximab|Given IV
40797615|NCT02204423|PROCEDURE|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
40797616|NCT03835182|DEVICE|Ultrasound group|Ultrasound 1 MHz, 1.5 W/cm2 for a total of 10 min applied to the lower back
40797617|NCT03835182|DEVICE|Short wave diathermy group|SWD frequency of 27.12MHz applied in continuous mode (thermic) applied to the lower back for twenty minutes
40797618|NCT03835182|OTHER|Control group|superficial heat, analgesic physical modality and exercise only
40797619|NCT03396497|DRUG|LYC-55716|Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.
41001826|NCT02188485|BEHAVIORAL|ENGAGE|Up to 10 sessions delivered in the home.
41314312|NCT01763021|DRUG|Rifampin|Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
41314313|NCT04117178|DRUG|Donepezil|Adjustment of treatment with donepezil according to serum level.
41314314|NCT04117178|DRUG|Memantine|Adjustment of treatment with memantine according to serum level.
41314315|NCT04117178|DIAGNOSTIC_TEST|Measurement of serum level of anti-dementia drug|"Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month."
41314316|NCT04224896|DIAGNOSTIC_TEST|UPPER ENDOSCOPY|UPPER ENDOSCOPY
40797620|NCT03396497|DRUG|Pembrolizumab|Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
40797621|NCT00408265|BEHAVIORAL|Contingency Management|
40797622|NCT04929353|OTHER|Systematic symptom assessment|"* Systematic symptom assessment~* Conventional symptom assessment"
40797623|NCT03772795|OTHER|Orthodontic Alignment|"Group 1:- Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
40797624|NCT03772795|OTHER|Orthodontic Alignment|Group 2: Teeth alignment using clear aligners.
40797625|NCT04114071|BEHAVIORAL|TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women|See arm description
40797626|NCT04308655|OTHER|Interview|Semi-structured interviews
40797627|NCT04308655|OTHER|Surveys|Validated surveys on pain, fear, anxiety, depression, beliefs
40797628|NCT02594007|DEVICE|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
40797629|NCT02594007|DEVICE|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
40797630|NCT02594007|DEVICE|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
41151290|NCT02948686|OTHER|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
41314317|NCT00139425|BEHAVIORAL|Disease Management Assessment|
40797631|NCT00156104|DRUG|Asenapine|5 mg BID
40797632|NCT00156104|DRUG|Asenapine|10 mg BID
40797633|NCT00156104|DRUG|Haloperidol|4 mg BID
40797634|NCT00156104|OTHER|Placebo arm|
40797635|NCT06293534|DIAGNOSTIC_TEST|TSH,T3,T4|Diagnosis of the psychiatric disorders among study group will be assessed and recorded and history of Electroconvulsive therapy (ECT) also will be recorded , physical examination for signs that suggests actual thyroid disease such as unexplained bradycardia or tachycardia, hypothermia , goiter or non palpable thyroid among study group will be assessed
40797636|NCT04721158|DEVICE|Continuous glucose monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
40797637|NCT02596256|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
40797638|NCT02596256|DRUG|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
40797639|NCT02386787|DEVICE|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
40797640|NCT03398941|DRUG|Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide|Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
40797641|NCT03374358|DRUG|Raltegravir|The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .
41314318|NCT03398369|DIAGNOSTIC_TEST|CMR/CTA Guidance for CRT|The intervention is the use of CMR and CTA to determine the optimal pacing site in the left ventricle for cardiac resynchronization therapy (CRT) and guide left ventricular lead placement.
41314319|NCT00473837|DRUG|Chloroquine|This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
41314320|NCT00473837|DRUG|Placebo|The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
41314321|NCT04485091|COMBINATION_PRODUCT|20% TCM and PBM|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will start shortly after the observation of frosting level I, which characterizes an exfoliation of superficial depth. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs. For the PBM, a LED device with an irradiance of 10 milliwatts per square centimeter (mW/cm²) in continuous operation mode and a wavelength of 660 nm will be used. It will provide an energy density of 4 J/cm² within 400 seconds of irradiation.
41314322|NCT04485091|OTHER|20% TCM and PBM placebo|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will be simulated soon after the observation of frosting level I. The patient will not be aware of the simulation of the procedure. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs.
41314323|NCT04619264|DRUG|Papacarie|First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
41314324|NCT04619264|PROCEDURE|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque and then isolated with cotton rolls to promote a dry environment. Caries was removed using a sharp excavator and the cavity was cleaned using a small wet cotton pellet and dried with a dry cotton pellet.
41314325|NCT04863417|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 2000 cm2 Body Surface Area
41314326|NCT04863417|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 4000 cm2 Body Surface Area
41314327|NCT03415763|DRUG|Capecitabine|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
41314328|NCT03415763|DRUG|mFOLFOX6 or CAPOX|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
41472504|NCT00202839|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program
41472505|NCT00202839|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program
41472506|NCT00202839|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program
41472507|NCT00202839|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program
41472508|NCT00451152|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
40797642|NCT05944068|BEHAVIORAL|midfulness training|For this study we chose for a mindfulness based intervention. Mindfulness is defined as the ability to notice and observe details about one's present internal and external environment with the goal of non-judgemental and non-elaborative awareness of cognitions, emotions and physical sensations. The goal of the mindfulness intervention will be to teach patients a way of coping with negative emotions without acting on them, letting patients take control of their disease related behaviour and come to better disease acceptance. Where medical treatments fail to take away all disabling symptoms, psychological interventions like mindfulness could offer patients a coping method through which symptoms are experienced as less disabling and patients regain their quality of life. This research may further strengthen the need for a multidisciplinary approach in patients with Crohn's disease.
40797643|NCT00270751|PROCEDURE|1 apical pleurectomy|
40797644|NCT00270751|PROCEDURE|2 pleural abrasion + minocycline pleurodesis|
40797645|NCT04500392|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device#the flow is up to 60L/min
41472509|NCT00451152|OTHER|Anecortave Acetate Vehicle|Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
41472510|NCT01280344|DRUG|Saline Solution for Injection|Intravenous (IV)
41472511|NCT01280344|DRUG|Ipamorelin|Intravenous (IV)
41472512|NCT03512912|DEVICE|transcutaneous electrical calf muscle stimulation + supervised walking therapy|transcutaneous electrical calf muscle stimulation + supervised walking therapy
41472513|NCT06616246|BEHAVIORAL|HealthyLifetime|HealthyLifetimeTM \[HL\] seeks to intervene early in the aging process when individuals have the best chance for longer-term benefits of changing their health behavior, staving off functional decline, and minimizing the onset or exacerbation of chronic conditions.
41472514|NCT02491996|BEHAVIORAL|desire satisfaction-targeted intervention for disordered gamblers|This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
41472515|NCT00810602|PROCEDURE|reduced intensity, related donor stem cell transplant|"Fludarabine /Busulfan(FluBu2)regimen~Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant."
41472516|NCT00810602|DRUG|tacrolimus (standard GVHD prophylaxis)|Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
40797646|NCT04500392|DEVICE|Regular nasal cannula|Oxygen is supplied with a regular nasal cannula #the flow is up to 6L/min
40797647|NCT02434549|DRUG|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
40797648|NCT02434549|DRUG|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
40797649|NCT04265248|DEVICE|Virtual Reality Headset|The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.
41472517|NCT00810602|DRUG|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
41472518|NCT00810602|DRUG|vorinostat|"Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.~Dose escalation/ de-escalation~Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher \[probably or definitely related to the drug\] then vorinostat dose will be escalated to 200 mg PO BID.~If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.~If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study."
41472519|NCT06425367|DIAGNOSTIC_TEST|Antibiotic susceptibility testing|antibiotic susceptibility testing is performed on MHR-SIR or MH medium depending on randomization
41472520|NCT03176784|DRUG|Varenicline|0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
41472521|NCT03176784|DRUG|Nicotine patch|14 mg and 7 mg nicotine patches used. See arms for specific durations.
40797650|NCT04265248|BEHAVIORAL|Exercise|The subjects will perform evidence-based exercises for the neck.
40797651|NCT04168164|OTHER|aquatic therapy|The exercises of Ai Chi were performed in a specific order, until completion of the total possible movements.
40797652|NCT04168164|OTHER|Dry land therapy|sessions including exercises for gait, trunk mobility and exercises involving the upper and lower limbs
41472522|NCT03176784|OTHER|Placebo Patch|Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
40797653|NCT04168164|OTHER|Combined therapy|alternate sessions of therapy on dry land and aquatic therapy with Ai Chi
40797654|NCT05175131|DRUG|Mebeverine+Simethicone|fixed-dose combination, film-coated tablets, 135 mg + 80 mg
40797655|NCT05175131|DRUG|Mebeverine|Duspatalin®, coated tablets 135 mg
41314329|NCT05005988|BEHAVIORAL|Actions for Empowered Maternal Neonatal Care|"The intervention includes three 30-minute face-to-face sessions:~Session 1. Recognizing prematurity and the NICU environment: includes definitions of prematurity, characteristics of premature infants, equipment and dynamics of NICU care. Mothers are encouraged to identify their own and contextual resources that can help empower them.~Session 2. Identifying the care of a premature baby: aspects related to the kangaroo method, feeding, thermoregulation, among others, are presented. Knowledge is presented as an empowerment resource.~Session 3: Preparation for the return home. Aspects related to the discharge process and transition to home are described. Includes information on the transition home, warning signs, emergency situations, physical burden, and recognition of sources of personal and professional support.~Session on admission to the out-of-hospital kangaroo program: presents the dynamics of the kangaroo program, as well as the goals in the new care setting."
41314330|NCT03624517|DRUG|Octreotide|Octreotide infusion for 24-hours in patients with bleeding esophageal varices.
41314331|NCT02054143|PROCEDURE|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
41314332|NCT02054143|DRUG|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) during the whole operation.
41314333|NCT04061252|DRUG|KHK4827|brodalumab 210mg Q2W, SC
41314334|NCT04061252|DRUG|Placebo|Q2W, SC
40797656|NCT05175131|DRUG|Simethicone|Espumisan® capsules 40 mg
41314335|NCT01691352|PROCEDURE|Wick dressing|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
41314336|NCT01691352|PROCEDURE|No Wick|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
41314337|NCT04520022|DRUG|Human Umbilical Cord Blood-derived Mesenchymal Stem Cells|3.0 x 106 cells/kg, IV, Total of 3 doses every 2weeks
41314338|NCT00376987|DIETARY_SUPPLEMENT|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
41314339|NCT01419704|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
41314340|NCT05431049|PROCEDURE|Percutaneous nephrolithotomy surgery (PNL)|Percutaneous nephrolithotomy (PNL) surgery was performed in all arms of the study to remove the renal stones. This surgery was performed with 2 anesthesia methods, CSEA and GA. These formed the groups of the study.
41314341|NCT01151046|DRUG|MM-121|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
41314342|NCT01151046|DRUG|Placebo|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
41314343|NCT01151046|DRUG|Exemestane|Exemestane (25 mg) administered orally once per day
41314344|NCT05683652|DEVICE|TRAINING BOOKLET|Cancer patients in the intervention group, who will receive immunotherapy for the first time, will be given face-to-face training with the prepared training booklet and followed up by phone. Patients who received immunotherapy after the 1st, 2nd and 3rd cycles, respectively, will be called by phone. The researcher's phone number will be given to the intervention group patients and they will be told that they can call 24/7 if they experience any symptoms. The telephone interview form created by the researcher will be used during the monitoring by telephone.
41314345|NCT03813745|OTHER|early denudation|COCs will be denudated in 30 min after oocyte retrieval
41314346|NCT03813745|OTHER|late denudation|COCs will be denudated 2 hr after oocyte retrieval
41314347|NCT00707655|DRUG|Zalutumumab|Eight weekly infusions
40797657|NCT02688192|BEHAVIORAL|Exercise Intervention|Participate in fitness program
40797658|NCT02688192|BEHAVIORAL|Internet-Based Intervention|Engage in private social support messaging and Use the mobile app
40797659|NCT02688192|DEVICE|Monitoring Device|Wear an electronic accelerometer
40797660|NCT02688192|OTHER|Quality-of-Life Assessment|Ancillary studies
40797661|NCT00709176|BEHAVIORAL|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
40797662|NCT00709176|BEHAVIORAL|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
40797663|NCT00684710|DRUG|PAZ-417|
40797664|NCT00684710|DRUG|Placebo|
40797665|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.
40797666|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
40797667|NCT05272397|DRUG|Methylphenidate 20 Mg Oral Tablet|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
40797668|NCT05272397|DRUG|Placebo|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
40797669|NCT05272397|BEHAVIORAL|Language Task|The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
40797670|NCT05272397|BEHAVIORAL|Rest Recording|Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
41472523|NCT03176784|OTHER|Placebo Pill|Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
41472524|NCT00432055|DRUG|Botulinum toxin type A (Botox)|
41472525|NCT00432055|DRUG|placebo (saline)|
40797671|NCT05272397|BEHAVIORAL|Go/No-Go Task|A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall \& Smith (2011) will be employed.
41314348|NCT02723266|BEHAVIORAL|STOPPING-GDM|Educational counseling and skills building Intervention
41314349|NCT04178252|OTHER|mask|investigators will add eye mask to standard treatment
41314350|NCT04178252|OTHER|headset|investigators will add headset to standard treatment
41314351|NCT04178252|OTHER|standard drug|investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes
41314352|NCT04350866|OTHER|Expert Recommendations for Implementing Change (ERIC) bundle of strategies|"* Develop a formal implementation blueprint/checklist~* Conduct educational meetings; Develop \& distribute educational materials~* Organize implementation meetings~* Audit and provide feedback~* Facilitation~* Increase demand with marketing to patients~* Promote adaptability~* Involve patients and family; Use their feedback; Prepare them to be active participants"
41472526|NCT01923194|DRUG|Highly Purified Urofollitropin|for Injection
41472527|NCT01923194|DRUG|Recombinant Human Follitropin Alfa|for Injection
40797672|NCT05272397|BEHAVIORAL|Processing Speed|A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
41151291|NCT02948686|OTHER|Self Etching with Extended time Application Strategy|In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
41151292|NCT02948686|OTHER|Self Etching with Extended layers number Strategy|In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
41151293|NCT05385991|BIOLOGICAL|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
41314353|NCT04121429|OTHER|Observation|No intervention will be performed
41314354|NCT02017236|DRUG|Volitinib|600mg Volitinib ,single dose,oral
41314355|NCT04005950|DEVICE|Scalpel Bougie technique|ScalpelCric Set
41314356|NCT04005950|DEVICE|modified Scalpel Bougie technique|ScalpelCric Set plus speculum
41314357|NCT04045236|OTHER|Registry|Data collection
41314358|NCT04095806|OTHER|Stroke (exposure)|stroke case definition (exposure) listed in inclusion/exclusion criteria section
41314359|NCT05992415|OTHER|Intervention Using Patient Navigators|Consented participants referred to ophthalmology from the 9 developments randomized to the Intervention Arm will receive ongoing support from patient navigators to assist with all aspects of follow-up eye care, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
41314360|NCT05992415|OTHER|Usual Care Without Patient Navigators|Consented participants referred from the 5 developments randomized to the Usual Care Arm 2 who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1-year period.
41314361|NCT01714817|BIOLOGICAL|BMS-188667|
41472528|NCT04514497|PROCEDURE|Biopsy|Undergo tumor biopsy
41472529|NCT04514497|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41472530|NCT04514497|PROCEDURE|Computed Tomography|Undergo CT
41472531|NCT04514497|DRUG|Elimusertib|Given PO
41472532|NCT04514497|DRUG|Irinotecan Hydrochloride|Given IV
41472533|NCT04514497|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41472534|NCT04514497|DRUG|Topotecan Hydrochloride|Given IV
41472535|NCT00418067|DEVICE|Endeavor|Zotarolimus-eluting stent
41472536|NCT00418067|DEVICE|Cypher|Sirolimus-eluting stent
41472537|NCT00418067|DEVICE|Taxus Liberte|Paclitaxel-eluting stent
41472538|NCT06105164|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher."
40797673|NCT05272397|BEHAVIORAL|Operation Span|In the operation span task, participants are instructed to solve math operations (e.g., (1\*2) +1=?) as soon as possible and then remember a single letter. This to-be-remembered letter is followed by either another math-word combination or a recall screen, which will show up at the end of each set. When the recall screen is presented, participants have to recall all the letters in the correct order they were presented. The experimental trials contain three sets at each set size (i.e., the number of math-word pairs), with set sizes ranging from 3 to 7 items. This results in a total of 75 sets with 75 letters and 75 math problems. The order of set sizes is random for each participant. Participants' operation span will be evaluated by the total number of letters recalled in the correct serial position regardless of whether the entire trial was recalled correctly.
40797674|NCT05272397|BEHAVIORAL|Reading Span|Participants are instructed to judge whether a presented sentence makes sense or not. After each sentence, a to-be-remembered letter will be shown on the screen, which is followed by either another sentence-word combination or the final recall screen. The set size ranges from 3 to 7 items. At the end of each set of sentences, participants will be required to recall all the letters in the current set in order. There will be a total of 75 letters and 75 sentence judgements. The order of the set sizes will be at random for each participant. Participants' performance will be evaluated by calculating the total number of correctly recalled letter sets.
40797675|NCT05272397|BEHAVIORAL|Barratt Impulsiveness Scale|The Barratt impulsiveness scale (BIS-11) will be used in the experiment to measure participants' trait impulsivity. Participants will be required to rate themselves on 30 items that are related to attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness.
40797676|NCT03114111|DRUG|aminolevulinic acid (ALA)|
41314362|NCT01714817|DRUG|Mycophenolate mofetil|
40797677|NCT03114111|DRUG|Placebo|
41157058|NCT06632925|PROCEDURE|Catheter ablation|"The catheter ablation strategy is the same as the current treatment approach in patients with AF, according to the consensus of catheter ablation of AF. All procedures will be performed under local sedation or general anesthesia depending on the operator, and each patient will undergo an electrophysiological study and substrate mapping in the fasting state with adequate pre-ablation anticoagulation and transesophageal echocardiography to rule out LA thrombus. All antiarrhythmic drugs except amiodarone will be discontinued for at least 5 half-lives before the procedure.~Step I: Substrate mapping before ablation, Step II: Pulmonary vein isolation (PVI), Step III: Post-ablation mapping in SR immediately after ablation, Step IV: Inducibility after ablation, Step V: Remmaping 30 minutes after ablation"
41314363|NCT01714817|DRUG|Prednisone|
41314364|NCT01714817|BIOLOGICAL|Placebo matching with BMS-188667|
41314365|NCT03284008|OTHER|Manual manoeuver + stretching|Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.
41314366|NCT03284008|OTHER|stretching exercise|Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
41314367|NCT01643759|DRUG|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
41314368|NCT01924052|DRUG|CGRP|Calcitonin-gene-related-peptide (CGRP)
41314369|NCT05810961|BIOLOGICAL|efgartigimod IV|infusion of efgartigimod
41314370|NCT05810961|OTHER|placebo|infusion of placebo
41314371|NCT01948141|DRUG|nintedanib|Given PO
40797678|NCT04381624|OTHER|Exercise program|exercise program in 12 sessions, of approximately one hour, distributed in 3 sessions per week during a month
40797679|NCT03792555|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
40797680|NCT03792555|DRUG|Placebo|Placebo, capsules, once daily by mouth
40797681|NCT05679596|DIETARY_SUPPLEMENT|ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate|Provided twice a day between meals.
40797682|NCT05679596|DIETARY_SUPPLEMENT|carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)|Provided twice a day between meals.
41472539|NCT06105164|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
41472540|NCT03609242|BEHAVIORAL|STOP-HPV bundle intervention|This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
40797683|NCT02229981|DRUG|ABC294640|
40797684|NCT04608292|DIAGNOSTIC_TEST|Single-voxel MRS|Diagnostic test is a single voxel MRS scan
40797685|NCT04608292|DIAGNOSTIC_TEST|Multi-voxel MRSI|Diagnostic test is a multi-voxel MRS imaging scan
41001827|NCT01561066|PROCEDURE|Autologous platelet-rich fibrin glue (PRFG)|"1. Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.~2. PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings."
41314372|NCT06082648|DEVICE|Transcranial magnetic stimulation|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla.Stimulation group: Intermittentpulse transcranial magnetic stimulation (iTBS) will be performed with : the cluster consists of 3 pulses, the intra-cluster frequency is 50Hz, the intercluster frequency is 5Hz, the interval is 8.2s for every stimulus. There are 20 cycles and a total of 600 pulses. Each intervention time is 3min11s, and the stimulation intensity is set as 80% resting state motion threshold. The intervention will be performed once a day for 2 weeks.
41472541|NCT05550831|PROCEDURE|Radiofrequency|Peripheral ablation of affected Morton´s Neuroma nerve endings by thermal dissipation by an electrode.
41472542|NCT03608306|OTHER|Resin-modified glass ionomer|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
41472543|NCT03608306|OTHER|Bulk-fill glass hybrid restorative|It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
41472544|NCT03192852|OTHER|dental bleaching|dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel
41472545|NCT03192852|PROCEDURE|Gingivoplasty|gengivoplasty will be realized to in illuminated tissue an no illuminated tissue to morphometrically evaluate the tissue
41472546|NCT02565017|BEHAVIORAL|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
41472547|NCT06612034|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
41472548|NCT06358274|OTHER|Thru-hiking|planning to embark on the Colorado Trail
40797686|NCT04608292|DIAGNOSTIC_TEST|Magnetization Transfer Imaging|Diagnostic test is a set of magnetic transfer weighted images
40797687|NCT04608292|OTHER|Alcohol ingestion|Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
40797688|NCT04608292|DEVICE|ClearMate|Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
40797689|NCT04608292|DIAGNOSTIC_TEST|Blood sampling|Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.
40797690|NCT01104402|DEVICE|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
40797691|NCT04239261|DIETARY_SUPPLEMENT|SBI|Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily
40797692|NCT04239261|DIETARY_SUPPLEMENT|Placebo|Hydrolyzed gelatin 10.0 g once daily
40797693|NCT00483678|OTHER|counseling intervention|
40797694|NCT00483678|OTHER|questionnaire administration|
40797695|NCT00483678|PROCEDURE|psychosocial assessment and care|
40797696|NCT00839280|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
40797697|NCT00839280|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
41001828|NCT01561066|DRUG|Octreotide|subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
41001829|NCT05479812|DRUG|WTX-124|Investigation Product Monotherapy
41314373|NCT06082648|DEVICE|Sham Transcranial magnetic stimulationt|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla. Patients on the Sham stimulation group will be interfered with the stimulation coil perpendicular to the skull, so that they will hear the sound of machine without having therapeutic effects. The parameters will be the same as those in the stimulation group.
41314374|NCT03106194|OTHER|case management|
41001830|NCT05479812|DRUG|pembrolizumab|Investigation Product in combination with approved therapy
41001831|NCT05689840|PROCEDURE|Receiving inpatient surgical intervention|Receiving inpatient surgical intervention in Peking Union Medical College Hospital
41001832|NCT01620580|BEHAVIORAL|Self-management|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3"
41001833|NCT01620580|BEHAVIORAL|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills \& adherence to renal diet and fluid restriction without discussing any intervention with the group.
41001834|NCT03076424|OTHER|no intervention used|Patients will be giving a blood sample after 8 hours of fasting.
41314375|NCT03314181|DRUG|Dexamethasone|Infusion; Intravenous (IV), or Tablet; Oral
41314376|NCT03314181|DRUG|Daratumumab|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
41314377|NCT03314181|DRUG|Venetoclax|Tablet; Oral
40797698|NCT06245005|DEVICE|Brain exercise gameplay on a portable electronic device|Feasibility is defined as a 70% completion rate for at least 3 of the six brain exercise games in study participants from which a 'first gameplay score' can be determined. Investigators will also assess level of satisfaction with the brain exercise intervention and barriers to playing in the busy preoperative clinical settings as evaluated by a patient-centered questionnaire (Discharge Survey).
41314378|NCT03314181|DRUG|Bortezomib|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
41314379|NCT03829865|DIAGNOSTIC_TEST|High resolution esophageal manometry|High resolution esophageal manometry will be performed to eligible subjects willing to participate in the study
41314380|NCT03971084|OTHER|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
41314381|NCT03971084|OTHER|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
40797699|NCT05561439|OTHER|Dosimetric monitoring|Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
41314382|NCT01935362|DIETARY_SUPPLEMENT|Citrus supplement|
41314383|NCT01935362|DIETARY_SUPPLEMENT|Placebo|
41314384|NCT00370695|DEVICE|Precision Spinal Cord Stimulation System|Stimulation turned on from implant throughout the Study
41314385|NCT00960934|DRUG|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
41314386|NCT00960934|DRUG|Placebo|Dose-matched oral placebo to MK-5442
41314387|NCT00960934|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
40797700|NCT04102904|OTHER|Observational|Patients will be asked to donate a semen sample which will be analysed and compared with their eventual diagnosis.
40797701|NCT02252640|BIOLOGICAL|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
40797702|NCT02252640|BIOLOGICAL|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
41001835|NCT02319538|PROCEDURE|Total thyroidectomy performed|Surgery combined with standard thyroxine treatment
41001836|NCT05516082|DEVICE|Lens A|DDH contact lens for 15 minutes
41001837|NCT05516082|DEVICE|Lens B|DDSH contact lens for 15 minutes
41001838|NCT00461695|BIOLOGICAL|Vaccination against TBEV (FSME Immun CC)|Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
41001839|NCT03044197|DEVICE|MRI/ultrasound transperineal prostate biopsy|3-6 targeted biopsy cores from each prostate region of interest
41001840|NCT03044197|DEVICE|transrectal ultrasound-guided prostate biopsy|12 systematic biopsy cores
41001841|NCT00462956|DRUG|Tykerb|lapatinib 1500mg daily
41157059|NCT00584376|DRUG|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
41157060|NCT00584376|DRUG|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
41314388|NCT00960934|DIETARY_SUPPLEMENT|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
41314389|NCT01536119|BEHAVIORAL|Coparenting Breastfeeding Support Intervention|The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
41314390|NCT04252612|DRUG|Pramlintide|SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.
41314391|NCT05539105|PROCEDURE|Double tract reconstruction|Double tract reconstruction would be applied after radical proximal gastrectomy.
40797703|NCT02252640|BIOLOGICAL|ChAd63 ME-TRAP (5 x 10^10 vp)|
40797704|NCT02252640|BIOLOGICAL|MVA ME-TRAP (2 x 10^8 pfu)|
40797705|NCT01925768|DRUG|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
40797706|NCT01925768|DRUG|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
40797707|NCT03818763|BIOLOGICAL|Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII|"Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (≥0.6BU).~The infusion volume of transduced cells will not exceed 20 ml/kg body weight."
41314392|NCT05539105|PROCEDURE|Gastric conduit reconstruction|Gastric conduit reconstructionn would be applied after radical proximal gastrectomy.
41472549|NCT05773534|DIAGNOSTIC_TEST|MSOT|Similar as the conventional sonography, the MSOT transducer head is placed on the skin of the examined person above the target organ. But instead of sound waves, energy is applied to the tissue via laser light, leading to constant changes of minimal expansions and contractions (thermoelastic expansion) of different tissue components or molecules. The same transducer head that releases the laser flashes can also detect the emitted ultrasound waves. In the newly configured device (Acuity Echo, iThera Medical GmbH, Munich, CE-certified), an extended spectrum of laser light can be used, enabling among others the derivation of values corresponding to hemoglobin and its oxygenation levels. As hemoglobin concentration and oxygenation status are markers for perfusion, MSOT-based imaging of these parameters could be a highly sensitive and reliable method to analyze muscle perfusion.
40797708|NCT03122145|DRUG|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
41001842|NCT01397695|DRUG|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
41001843|NCT00593307|OTHER|high GI|high GI and high carb breakfast
41001844|NCT00593307|OTHER|Low GI|low GI, high carb breakfast
41001845|NCT00593307|OTHER|Low GI Low Carb|low GI low carb breakfast
41001846|NCT00593307|OTHER|High GI Low carb|high GI low carb breakfast
41314393|NCT05539105|PROCEDURE|Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after radical proximal gastrectomy.
41314394|NCT05508438|DEVICE|Transfemoral mitral-valve repair|Transfemoral mitral-valve repair
41001847|NCT03139890|OTHER|High-fat (HF-LC-LP) milkshake|During this experimental day, men will receive a high-fat milkshake
41001848|NCT03139890|OTHER|High-carbohydrate (LF-HC-LP) milkshake|During this experimental day, men will receive a high-carbohydrate milkshake
41001849|NCT03139890|OTHER|High-protein (LF-LC-HP) milkshake|During this experimental day, men will receive a high-protein milkshake
41314395|NCT04727502|DRUG|Duloxetine|duloxetine
41001850|NCT03912727|DIETARY_SUPPLEMENT|Alpha-Lipoic acid plus renal replacement therapy|Alpha lipoic acid (ALA) is a vitamin-like antioxidant
41001851|NCT03912727|OTHER|renal replacement therapy|standard renal replacement therapy
41001852|NCT00405548|DRUG|BNP (nesiritide)|
41001853|NCT00405548|DRUG|Placebo|
41151294|NCT04221308|DEVICE|Single port laparoscopic systems|The first assistant handles the scope from the patient's right side. The second assistant, who is positioned between the legs of the patient, inserts a uterine manipulator (Rumi System; Cooper Surgical, CT). At the beginning of the surgery, a 1.5 to 2.5 cm vertical incision is made within the umbilicus using the open Hasson approach. After the bottom retractor ring of the wound retractor component of the Octo-Port is inverted (DalimSurgNet, Seoul, Korea), it is inserted through the incision deep in the peritoneum. Carbon dioxide is insufflated through the gas valve of the Octo-Port to maintain intra-abdominal pressure at 10 to 12 mm Hg. Through the 10 mm channels of the Octo-Port, a 10 mm, 30° rigid laparoscope is introduced. Rigid laparoscopic instruments are introduced through the 5 mm channels of the Octo-Port. The utero-ovarian ligament or infundibulopelvic ligament, uterine vessels, and uterine ligaments are transected by using the 5 mm LigaSure vessel sealer device
41314396|NCT04727502|DRUG|Pregablin|Pregablin
41314397|NCT04377334|BIOLOGICAL|MSC|infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells
41314398|NCT01192750|OTHER|immunohistochemistry staining method|
41314399|NCT01192750|OTHER|laboratory biomarker analysis|
41314400|NCT01192750|OTHER|medical chart review|
41314401|NCT02035150|DIETARY_SUPPLEMENT|Oatmeal|A breakfast consisting of oatmeal
41314402|NCT02035150|DIETARY_SUPPLEMENT|Frosted Flakes|A breakfast consisting of Frosted Flakes and milk
41314403|NCT02035150|DIETARY_SUPPLEMENT|No Breakfast|A breakfast consisting of plain water
41472550|NCT06616467|BEHAVIORAL|Tummy Time for the prevention of childhood obesity|"A cognitive-behavioral intervention aimed at mothers of infants is presented that aims to increase the practice of TT and maintain a healthy weight in the infant, called \&#34;Tummy Time for the prevention of childhood obesity\&#34;, within the intervention modifiable variables are involved that directly impact the expected results such as: the knowledge and beliefs of the mothers, infant temperament, parental self-efficacy and self-efficacy for the practice of TT.~The intervention lasts 12 weeks from the first contact with the participants and consists of eight sessions broken down as follows: the first session is presented in a face-to-face format with expository, audiovisual and demonstrative means; sessions two, four, five and seven are provided through a text message with use WhatsApp® and the use of visual media. Sessions three, six and eight are delivered via telephone call with the aim of offering feedback on the doubts generated up to that point."
40797709|NCT03122145|DEVICE|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
41314404|NCT01766570|OTHER|Uncontrolled nutritional intervention with a supplemental beverage|Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
41314405|NCT01766570|OTHER|Placebo|
41314406|NCT06259773|DIAGNOSTIC_TEST|knee stability test (DYNEELAX)|Each knee was tested under a force 120 Newtons in a posterior to anterior direction to create anterior tibial translation at 20 degrees knee flexion. Side-to-side difference of anterior/posterior tibial translation (mm) was measured from radiographs. Measurement of rotation and translation by DYNEELAX was also recorded.
40797710|NCT00133159|BIOLOGICAL|Grass MATAMPL|
40797711|NCT04307368|OTHER|FODMAP diet|8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
41314407|NCT05851586|PROCEDURE|Supervised exercise + home exercise program|The supervised exercise + home exercise program group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist. They will also be provided with two supervised exercise sessions per month delivered in a group setting in order to ensure proper performance of the home exercise programs.
40797712|NCT04307368|OTHER|Elimination-rotational diet|During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
41001854|NCT04698356|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed in order to train each individual at their own level and to make the task challenging. A short-term memory component was also added to the original training paradigm, to enhance the cognitive skills of our participants. To provide maximal speech-in-noise benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate this in young, normal-hearing adults (18-30 years) by studying our outcome measure (speech reception threshold) for the different sentence-scenarios and test-retest sessions.
41001855|NCT05111977|DEVICE|Vibrant capsule|A capsule delivering mechanical vibrations
41314408|NCT05851586|PROCEDURE|Home exercise program only|The home exercise program only group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist, without any supervised guidance on exercise performance.
40797713|NCT04307368|OTHER|Classic diet|8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
41001856|NCT00164242|DRUG|Galantamine|
40797714|NCT04548700|DRUG|Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle."
41001857|NCT00983554|DRUG|Anastrazole|Arimidex 1mg daily
41001858|NCT00983554|DRUG|Testosterone|Testim 10g daily
41001859|NCT00983554|DRUG|Dutasteride|Avodart 2.5mg daily
41001860|NCT00983554|DRUG|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
41001861|NCT00062569|BEHAVIORAL|Bathing Support Intervention (BSI)|Bathing Support Intervention - Review of caregiver current practices and perceptions and care recipient behavioral symptoms associated with bathing with pattern analysis based on observation; skill building for bathing and communication techniques; coaching for implementation
41314409|NCT04813536|OTHER|the Standard Shiftwork Index questionnaire|"1. Biographical information: This includes personal data (e.g., age, sex, marital status, and domestic situations), shift details (e.g., shift start and end times), organization of shiftwork, and general job satisfaction~2. Sleep and fatigue: Measures the effect of shiftwork on perceived sleep quality and quantity and fatigue"
41314410|NCT04813536|OTHER|complete blood picture|5ml blood to estimate changes of total leucocytic count, Hemoglobin, eosinophilic, monocyte
40797715|NCT04548700|DRUG|Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day."
41314411|NCT04813536|OTHER|lipid profile|5ml blood to estimate changes of plasma triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and HDL-C
41314412|NCT05617404|DIAGNOSTIC_TEST|CT scan|Polytrauma patients with thoracic CT-scan
41314413|NCT05084794|PROCEDURE|Internal fixation|Fixation of posterior malleolus with either plate or screws.
41314414|NCT02063919|OTHER|the mucosal microbiome in the biopsy specimen was analysed|
41314415|NCT00901147|DRUG|panobinostat and bortezomib|oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
41314416|NCT00873769|DRUG|Inhaled Loxapine 10 mg|Staccato Loxapine 10 mg, single dose
41472551|NCT06185595|OTHER|Beverage. Incomplete block where each participant will complete 3 of the 6 possible glycerol-sodium blends in random order.|9.3 oz (273 ml) aliquot of one of the study beverages every 15 min for a total of 28 oz (828 ml) over a 45-min period, followed by 15 min of rest. Flavored water matched for sweetness, color. flavor, but cannot be matched for saltiness. All sodium-containing drinks will include a base blend of other electrolytes (potassium 15 mmol/L, magnesium 8 mmol/L, and calcium 5 mmol/L).
41472552|NCT06468748|DRUG|Semaglutide|During the first visit, participants will be taught how to self-administer the pen injector by medical staff. Participants will also be provided instructions for self-administering injections and a compliance log to track adherence to the treatment, and additional information about each injection (date, time, injection site)
41472553|NCT04679142|DRUG|Baclofen Tablets|Enrolled patients will receive treatment and evaluations for their disease as determined by their physicians in accordance with local standard of care. Visits will be scheduled by their physician according to patient-specific needs and national clinical practice.
41472554|NCT06617208|DEVICE|Neuropixel probe recording|Neuropixel recordings captures neuronal activity at the single-neuron level across the layers of the cortex.
40797716|NCT03456349|DRUG|HTL0018318|HTL0018318
40797717|NCT03456349|DRUG|Placebo|Placebo
40797718|NCT04947345|DRUG|Remimazolam Besylate|Remimazolam Besylate are used as sedatives for subjects in this arm.
41001862|NCT00062569|BEHAVIORAL|Caregiver reminiscence with coaching|"BSI plus Reminiscence - BSI as above plus caregiver interview to ascertain pleasant long-term memories (e.g. stories, pictures, music) developed into a crib sheet for caregiver use conversationally prior to and during the bath"
41001863|NCT00922571|PROCEDURE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
41001864|NCT00922571|DEVICE|FS Laser System|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
41001865|NCT06109428|DRUG|HTX-011|400 mg
40797719|NCT04947345|DRUG|Propofol|Propofol are used as sedatives for subjects in this arm.
40797720|NCT04839653|DRUG|Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h|The oral paste will be applied topically on the oropharyngeal mucosa q6h.
40797721|NCT04839653|DRUG|Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h|The suspension will be administered through the nasogastric tube q6h.
41314417|NCT04822272|DEVICE|MRI thermometry|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
41314418|NCT05668312|OTHER|Tele-prehabilitation|Preoperative tele-rehabilitation using a virtual reality system.
41314419|NCT05668312|OTHER|Standard prehabilitation|Preoperative home-based rehabilitation delivered with a printed booklet for the Con-O subjects and no intervention for the Con-Y subjects.
41314420|NCT02548572|DEVICE|Transcorneal Electrical Stimulation using Okustim device|"The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device)."
40797722|NCT04839653|DRUG|Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd|Patients who do not receive systemic antibiotics for other reasons will get a short course of systemic antibiotic
40797723|NCT01104545|DRUG|MK-3614|
40797724|NCT01104545|DRUG|Comparator: Placebo|
40797725|NCT02807389|DRUG|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
41001866|NCT06109428|DRUG|Bupivacaine Hydrochloride|125 mg
41001867|NCT06109428|DRUG|Ibuprofen|400 mg
41001868|NCT06109428|DRUG|Acetaminophen|1 g
41001869|NCT06109428|DEVICE|Luer lock applicator|Applicator for instillation
41001870|NCT00658281|PROCEDURE|CBCT Scan|Cone Beam Computed Tomography (CBCT) scan performed once a week.
41001871|NCT00658281|PROCEDURE|OBI KV Imaging|On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
41314421|NCT02909998|OTHER|Blood sample|Conservation at the end of the blood sample
41314422|NCT01303809|OTHER|Enhanced Recovery After Surgey for Sleeve Gastrectomy|"Intraoperative:~1. Pre-op carbohydrate loading~2. No pre-op GIK while NBM~3. Pre-medication~4. Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg~5. Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics~6. Fluid restriction~7. Standardised method of anaesthesia~8. Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites~9. 10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure~Postoperative:~1. Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively~2. Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1~3. Post operative oxygenation~4. Incentive spirometry~5. Drains (e.g. IDC) removed in recovery~6. Full mobilisation 4-8 hours post op)~7. Early Follow up"
41314423|NCT02065310|OTHER|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 \& 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."
41151295|NCT04001582|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
41314424|NCT03308981|DEVICE|REThink therapeutic online game|The REThink therapeutic online game has seven levels. Each level has various degrees of complexity, which increase as the player progresses in the game. The scenario of the game was developed based on the REBT model, such that it focuses on: a. identifying the emotional and behavioral reactions; b. identifying cognitive processes; c. identifying the relation between cognitive processes and emotions and behavioral reactions; d. changing irrational cognitions into rational cognitions; e. building problem solving skills; f. building relaxation skills and g. building happiness skills.
41314425|NCT03308981|OTHER|REBE group|In the Rational-Emotive-Behavioral Education (REBE) group participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
41314426|NCT05463042|BEHAVIORAL|Intermittent Hypoxia|During the intermittent hypoxia session, participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle.
41151296|NCT06059963|DEVICE|Signal-C™|Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).
41314427|NCT05463042|BEHAVIORAL|Normoxia (sham)|During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.
41314428|NCT00650091|DRUG|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
41314429|NCT00650091|DRUG|Placebo|Participants will receive placebo each day.
41314430|NCT02859493|DEVICE|Saccharomyces cerevisiae|
41314431|NCT02859493|DEVICE|Placebo|
41314432|NCT01268423|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomy within the first 4 days of mechanical ventilation.
41151297|NCT02521428|OTHER|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
41314433|NCT01268423|PROCEDURE|Prolonged translaryngeal intubation|Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
41314434|NCT05293652|OTHER|Iontophoresis|Hydrocortisone iontophoresis
41472555|NCT02785627|OTHER|Comprehensive bone health assessment|Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
41472556|NCT05871333|DRUG|Losartan 50mg Tab|Losartan 50 mg oral tablets
41472557|NCT05445076|BIOLOGICAL|anti-TRBV9 monoclonal antibody, low dose|infusion
40797726|NCT00292071|DRUG|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
41314435|NCT05293652|OTHER|Phonophoresis|Hydrocortisone Phonophoresis
41314436|NCT05293652|OTHER|traditional PT program|Ultrasound and deep friction massage
41472558|NCT05445076|BIOLOGICAL|anti-TRBV9 monoclonal antibody, high dose|infusion
41472559|NCT05445076|OTHER|placebo|infusion
41472560|NCT00305916|PROCEDURE|Multislice spiral computed tomography coronary angiography|
41472561|NCT00305916|PROCEDURE|conventional coronary angiography|
41472562|NCT04177641|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
41001872|NCT03376178|COMBINATION_PRODUCT|lidocaine and ropivacaine injection through catheters|injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
41001873|NCT03282552|DEVICE|Nasal Cannula High Flow Oxygen|Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
41001874|NCT01225445|DRUG|Ramipril|2.5 mg daily
41151298|NCT01211717|DIETARY_SUPPLEMENT|Branched Chained Amino Acids|Two doses of the Branched Chained Amino Acid supplement will be taken. The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise. The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used. This dose will be divided in half and administered at the two specified occasions. The ratio of isoleucine, leucine, and valine will be 1:2.5:1 respectively
41151299|NCT01211717|OTHER|Cellulose Placebo mix|The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise. This dose will be divided in half and administered at the two specified occasions.
41151300|NCT02286427|DEVICE|Amniotic Membrane|
41151301|NCT00487253|DRUG|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
41151302|NCT00487253|DRUG|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
41151303|NCT03320941|DRUG|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally daily.
41151304|NCT03320941|DRUG|Placebo|Placebo will be supplied as tablets to be taken daily orally.
41314437|NCT02527655|BEHAVIORAL|Choice-Based Physical Activity and Active Transportation|
41314438|NCT06303947|DEVICE|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
41472563|NCT04177641|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
41001875|NCT00758628|DRUG|Bromefenac|Bromfenac BID 3 months
41001876|NCT00758628|DRUG|Blink|Blink BID for 3 months
40797727|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
41001877|NCT01261858|DEVICE|Kryptonite|osteoconductive biologic bone cement to be applied upon sternal closure
41001878|NCT05435378|DRUG|Vitamin B3 100 MG Oral Tablet|After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
41001879|NCT05435378|DRUG|vitamin B9|After the non surgical treatment and the oral hygiene instructions the systemically administered vitamin B9 capsules will then given to the patients under the previously mentioned dosage.
41001880|NCT05435378|DRUG|Placebo|After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
41314439|NCT06303947|DEVICE|Nasogastric tube|The group is given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
41472564|NCT06615934|OTHER|Aerobic and resistance exercise|"From the first day of transplantation in the ICU until 10 days after transfer to the ward or discharge from the hospital, if needed, the patients of the group will undergo respiratory physiotherapy once a day. The process of this program includes patient assessment, clinical decision-making, and implementation of therapeutic interventions.~The interventions of the therapeutic exercise group are divided into three phases:~1. From the time the patient enters the ICU until the time of extubation;~2. From the time of extubation to the time of transfer to the ward;~3. Duration of the patient's stay in the ward."
41314440|NCT06303947|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
41472565|NCT06615934|OTHER|Respiratory physiotherapy|The participants of this group will receive respiratory physiotherapy daily after transplant until discharge.
41472566|NCT01344382|BEHAVIORAL|Community Reinforcement and Family Training|The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.
41472567|NCT01344382|BEHAVIORAL|Al-Anon Facilitation|Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
41472568|NCT03860207|BIOLOGICAL|Humanized 3F8 Bispecific Antibody|Phase I Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.
41472569|NCT03860207|OTHER|Blood draw|In cycle 1, blood is drawn for PK studies.
41472570|NCT04052698|DRUG|Wilate|"Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute."
41472571|NCT06610474|BEHAVIORAL|"Use of the online Talk to Nathan about Prostate Cancer decision aid"|This decision aid is publicly available at this website in both English or Spanish: https://www.cdc.gov/prostate-cancer/talk-to-nathan/index.html
41472572|NCT06610474|BEHAVIORAL|Use of a standard prostate cancer screening decision aid|The standard decision aid is available here and will be used in either English or Spanish: https://massclearinghouse.ehs.state.ma.us/PROG-CANC/CA1382kit.html
41314441|NCT06109441|BIOLOGICAL|ALTB-268|ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.
41314442|NCT04309669|DRUG|TOT'HEMA|three ampoules per day during 12 weeks
41314443|NCT02214316|OTHER|Hypertonic Saline|
41151305|NCT05712889|DRUG|VIP236|VIP236 will be administered by IV infusion once every 3 weeks.
41314444|NCT03604510|PROCEDURE|Electroencephalographic recordings|24 hours of electroencephalographic recordings (EEG-Holter) of prefrontal activity of Tourette's syndrome (TS) patients in ecological conditions.
41314445|NCT05249816|BIOLOGICAL|NVX-CoV2373|A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant
41472573|NCT06610474|BEHAVIORAL|Use of standard prostate cancer education materials|The standard education materials are available from the National Cancer Institute (NCI) website in English or Spanish: https://www.cancer.gov/types/prostate/patient/prostate-screening-pdq
41151306|NCT00834483|DEVICE|Knotless suture for wound closure|Angiotech Quill SRS
41151307|NCT00834483|DEVICE|Layered traditional wound closure (monocryl)|Layered traditional wound closure (monocryl)
41151308|NCT05774418|BIOLOGICAL|BNT162b2 COVID-19 Vaccine|BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
41314446|NCT05249816|BIOLOGICAL|BBIBP-CorV vaccine|BBIBP-CorV vaccine administered per manufacturer instructions.
41472574|NCT05171764|DEVICE|Additional Gemstone Spectral Imaging (GSI) cardiac scan|After the subject undergoes the clinically prescribed cardiac Computed Tomography (CT) scan for their diagnostic purposes, the investigational Gemstone Spectral Imaging (GSI) scan will be conducted following the diagnostic CT scan utilizing the same contrast administration.
41472575|NCT04309526|DRUG|NCO-48 Fumarate|NCO-48 Fumarate
41472576|NCT04309526|DRUG|Placebo|Placebo
41472577|NCT06279806|OTHER|Mobile health application use|"Women will be asked to use the app for at least 8 weeks. In order to monitor the usage, the researcher will monitor whether the women log in to the Information and Counseling section from the admin panel. Women who do not log in to the Information and Counseling section will be removed from the study at this stage. A weekly reminder will be sent to women via the mobile application. The questions asked by the participants through the question-and-answer section of the mobile health application will be examined every day and answered by the researcher between 10:00-11:00 every morning and 22:00-23:00 every evening. Likewise, the content shared by women in the forum section of the mobile application will be checked daily by the researcher and content that is harmful to women will be removed."
41472578|NCT06279806|OTHER|Information of the breast cancer survivor period booklet|Women in the control group will be given information of the breast cancer survivor period booklet.
41151309|NCT01532024|OTHER|Microdose of NAP|Delivery of NAP at microdose (\<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
41151310|NCT00977340|BEHAVIORAL|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
41314447|NCT00139685|DRUG|Depo-Provera Contraceptive Injection - DP150CI|
41314448|NCT05194046|DRUG|JP-1366 20mg 1capsule|will be orally administered
41314449|NCT05194046|DRUG|Amoxicillin 500Mg Cap|Amoxicilin 500Mg 2 capsules will be orally administered
41314450|NCT05194046|DRUG|Clarithromycin 500Mg Tab|Amoxicilin 500Mg 1 tablet will be orally administered
41314451|NCT06015802|OTHER|diagnosed and treated reasonably according to the clinical guidelines and clinical pathways|The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.
41314452|NCT01426399|DRUG|LC15-0444|LC15-0444 50mg qd (8 days once daily)
41314453|NCT01426399|DRUG|Metformin|Metformin 1000 mg bid (8 days twice daily)
41314454|NCT01426399|DRUG|LC15-0444+Metformin|LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
41314455|NCT00394238|PROCEDURE|Ultrasonographic imaging|
41151311|NCT00977340|BEHAVIORAL|confrontation|Confrontation
41151312|NCT00977340|BEHAVIORAL|imagination|Imagination
41151313|NCT01870687|DRUG|20mg VAC BNO 1095 FCT|
41314456|NCT04533815|BEHAVIORAL|LOCK sleep intervention|Nursing home staff are trained to use a collaborative problem-solving approach to sleep quality improvement using front-line huddling
41151314|NCT01870687|DRUG|Placebo|
41151315|NCT03694249|DRUG|Ifetroban Sodium|Given by mouth
41151316|NCT03694249|OTHER|Placebo|Given by mouth
41151317|NCT02714998|DRUG|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
41151318|NCT02714998|PROCEDURE|salpingectomy|Laparoscopic unilateral salpingectomy
41151319|NCT03195699|DRUG|TTI-101|Oral capsule
41151320|NCT03195699|DRUG|TTI-101|Oral tablet
41151321|NCT01292005|DRUG|Pentoxifylline|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
41151322|NCT01292005|DRUG|Placebo|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
41151323|NCT04601090|OTHER|ICU treatment|This is an observational study, so all patients will undergo a variation of ICU treatment, and we will record that information (e.g., time on ventilator, time in ICU, SAPS score at admission)
41151324|NCT03771469|OTHER|Sleep study|Sleep study
41314457|NCT01238133|DRUG|Carboplatin|Given IV
41314458|NCT01238133|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
41314459|NCT01238133|OTHER|Laboratory Biomarker Analysis|Correlative studies
41314460|NCT01238133|DRUG|Paclitaxel|Given IV
41314461|NCT01238133|OTHER|Pharmacological Study|Ancillary studies
41314462|NCT01238133|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41314463|NCT02782871|DEVICE|Pneupac VR1|A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
41314464|NCT02792010|DEVICE|Hip cartilage MRI|Hip cartilage MRI
41314465|NCT03497026|DEVICE|Robotic Bronchoscopy Platform|Eligible patients will undergo the robotic bronchoscopy for evaluation of suspected lung nodules.
41314466|NCT05342467|DRUG|Gemeprost 1 Mg Vaginal Pessary|Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
41314467|NCT05342467|DRUG|Dinoprostone 3 mg|Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
41314468|NCT00797069|OTHER|standard nutritional product (medical food)|once during crossover
41314469|NCT00797069|OTHER|nutritional product for diabetes (medical food)|once during crossover
41314470|NCT00797069|OTHER|diabetes specific experimental nutritional product (medical food)|once during crossover
41314471|NCT02681055|DRUG|MN-001|MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
41314472|NCT03075176|DEVICE|Wavefront optimized LASIK|Wavefront optimized laser vision correction
41314473|NCT03075176|DEVICE|Wavefront optimized Photorefractive Keratectomy|Wavefront optimized laser vision correction
41314474|NCT03075176|DEVICE|Topography-guided LASIK|Topography-guided laser vision correction
41314475|NCT03075176|DEVICE|Topography-guided Photorefractive Keratectomy|Topography-guided laser vision correction
41314476|NCT04689594|COMBINATION_PRODUCT|CLS2702C/CLS2702D|"CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month; transplantation and assessment period, 6 months \[24 weeks\]); follow-up period, 6 months \[24 weeks\]) Other Names: •Human (autologous) oral mucosal cell sheet~•Transplantation device"
41314477|NCT05876858|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
41314478|NCT05876858|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
41472579|NCT06463977|OTHER|Survey|The study consisted of a 3 × 3 online factorial experiment employing a survey instrument hosted via Qualtrics presenting describing three patient vignettes. The three patient vignettes varied by various clinical characteristics including age, gender, performance status, smoking history, extent of disease, symptoms and molecular status. Each patient had advanced non-small cell lung cancer (aNSCLC). Each vignette had two parts: Part 1 described the case history for one of the three patients, after which prognostic estimates and medical decision-making was assessed (i.e. 1, 2, 3). Part 2 immediately followed and described the same vignette from the same patient with added information from a hypothetical ML predictive algorithm (i.e. A, B, C). The order of the vignettes in each survey was randomized with regard to presentation strategies for the ML risk predictions, so that there were 6 versions of the survey to which each participant was randomized.
41151325|NCT00417989|DEVICE|MiniMed Paradigm REAL-Time System|Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
41151326|NCT04362111|DRUG|Anakinra|The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days
41001881|NCT05435378|PROCEDURE|full mouth non surgical periodontal treatment|full mouth scaling and debridement will be done by the primary investigator using ultrasonic scaler and periodontal curettes. After the non surgical treatment patients will be given oral hygiene instructions where they will be instructed to brush twice daily and shown how to brush using the horizontal scraping technique they will also be instructed to use the dental floss and shown how to use it.
41001882|NCT02242838|DRUG|Telmisartan|
41151327|NCT04362111|DRUG|Normal saline|The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
41151328|NCT00658177|DRUG|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
41314479|NCT03288493|BIOLOGICAL|P-BCMA-101 CAR-T cells|"P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated."
41314480|NCT03288493|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
41314481|NCT06310577|DEVICE|Leak-free bronchoscope adapter|Bronchoscopy using both a standard adapter and a leak-free adapter will be performed.
41001883|NCT02507635|DRUG|Levocetirizine|administration of Levocetirizine 5 mg/day for 4 weeks
41001884|NCT02507635|DRUG|Desloratadine|administration of Desloratadine 5 mg/day for 4 weeks
41001885|NCT02617316|OTHER|Barefoot|barefoot running test was 20 minutes.
41001886|NCT02617316|OTHER|In shoes|In shoes test was 20 minutes.
41151329|NCT00658177|DRUG|Placebo|Matching placebo
41001887|NCT01660828|OTHER|remote ischemic preconditioning (RIPC)|RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
41151330|NCT05439720|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime. The total dose is 75g of ketone ester.
41151331|NCT05439720|DIETARY_SUPPLEMENT|Placebo|Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.
41151332|NCT05439720|BEHAVIORAL|Exercise|A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime
41151333|NCT05151016|DRUG|mifepristone|Mifepristone tablets, 10mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks
41314482|NCT05349058|DRUG|Immune Checkpoint Inhibitors|Patients receive Immune Checkpoint Inhibitor as per oncology protocol
40797728|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
40797729|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
40797730|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
40797731|NCT01608737|DRUG|BI 201335|BI 201335 once daily low dose for 24 weeks
40797732|NCT04499027|DIAGNOSTIC_TEST|Lung ultrasound scan|"12 hours postoperatively using a convex ultrasound probe LUS will be performed by an experienced radiologist according to standardized protocols. For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines will be identified. Each one will be divided into upper and lower halves, making a sum of 6 different quadrants for each side: anterior superior, anterior inferior, lateral superior, lateral inferior, posterior superior, posterior inferior.~For each quadrant a score will be assigned based on B lines which are defined as comet like artifacts indicating subpleural interstitial edema as follows:~(0) normal aeration: A lines with lung sliding or fewer than two isolated B lines; (1) moderate loss of lung aeration: well-defined, multiple B lines ; (2) severe loss of lung aeration: multiple coalescent B lines; and (3) complete loss of lung aeration or lung consolidation."
40797733|NCT01973231|DRUG|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
40797734|NCT01973231|DRUG|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
40797735|NCT01047137|BEHAVIORAL|Psychological Stress Intervention|Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.
40797736|NCT01047137|BEHAVIORAL|General Supportive Therapy|There is no focus on stress intervention.
40797737|NCT02675933|BEHAVIORAL|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
40797738|NCT00610792|DRUG|bortezomib|1.3 mg/m2 on Days 1, 4, 8 \& 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
40797739|NCT00610792|DRUG|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
40797740|NCT02388165|BIOLOGICAL|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
40797741|NCT02388165|OTHER|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
40797742|NCT05388227|OTHER|Pole Walking|Group training sessions will be offered at the participating independent living/retirement communities. Training sessions will be held either indoors or outdoors, 2-3 times a week, for 20-60 min/session, over 12 weeks.
40797743|NCT03576781|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
40797744|NCT03576781|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
41151334|NCT05151016|DRUG|Triptorelin Acetate|dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
41314483|NCT01461512|DRUG|heme arginate administration|heme arginate 1 mg/kg body weight 24 hours prior to ischemia
41151335|NCT05430607|BEHAVIORAL|Running therapy|A 9-week running program.
41151336|NCT01025921|DRUG|colistin (Tadim)|500.000 units of inhaled colistin three times daily for 10 days
41151337|NCT01025921|OTHER|inhaled normal saline|inhalation of 2,5cc Normal Saline via nebulisation
41151338|NCT05304884|COMBINATION_PRODUCT|combined oxygen-ozone and corticosteroid|Subacromial injection using Ultrasound
41151339|NCT04267393|DRUG|BMS-986263|Specified dose on specified days
41151340|NCT04267393|OTHER|Placebo|Specified dose on specified days
41151341|NCT01024829|RADIATION|Radiotherapy|Radiotherapy
41314484|NCT01461512|DRUG|Placebo administration|NaCl isotonic
41314485|NCT01281852|DRUG|Cisplatin|Given IV
41314486|NCT01281852|OTHER|Laboratory Biomarker Analysis|Correlative studies
40797745|NCT03576781|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
40797746|NCT03576781|DEVICE|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
40797747|NCT04346186|DIAGNOSTIC_TEST|IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2
40797748|NCT04346186|DIAGNOSTIC_TEST|Elisa-test for IgM and IgG to SARS-CoV-2|Elisa-test for IgM and IgG to SARS-CoV-2
41151342|NCT02054000|DRUG|Tirofiban|Intracoronary administering of Tirofiban
41151343|NCT02054000|OTHER|Placebo|Intracoronary serum physiologic
41151344|NCT04792541|OTHER|HY containing gel; GUM® Afta Clear Gel, Sunstar|
41151345|NCT04792541|OTHER|saline solution|
41151346|NCT02363933|DRUG|Perampanel|Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures
41314487|NCT01281852|DRUG|Paclitaxel|Given IV
40797749|NCT03303053|DRUG|Cholestyramine Powder 4g|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
41314488|NCT01281852|DRUG|Veliparib|Given PO
41314489|NCT01588353|DRUG|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
41314490|NCT02658994|BEHAVIORAL|Thinking Healthy Program Peer Delivered Plus|
41314491|NCT02658994|OTHER|Enhanced Usual Care|
41151347|NCT00857311|BIOLOGICAL|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
41314492|NCT02701686|BEHAVIORAL|quit immediately (QI)|advise to quit immediately using the AWARD model
41314493|NCT02701686|BEHAVIORAL|cut down to quit (CDTQ)|advise to reduce cigarette consumption and quit eventally using the AWARD model
41314494|NCT04281342|DRUG|Aprocitentan 25 mg|Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
41314495|NCT04281342|DRUG|Aprocitentan 100 mg|Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
41314496|NCT04281342|DRUG|Matching placebo|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.
41314497|NCT04281342|OTHER|Moxifloxacin control to establish assay sensitivity|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.
41314498|NCT01523561|BEHAVIORAL|dance group|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
41314499|NCT02953782|DRUG|Magrolimab|Administered intravenously
41314500|NCT02953782|DRUG|Cetuximab|Administered intravenously
41314501|NCT06011291|DRUG|SYH2051 tablets|Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.
41314502|NCT06011291|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Radical or adjuvant radiotherapy
41314503|NCT06066203|DRUG|GNC-035|GNC-035 was administered by intravenous infusion for 2 h-4 h, once a week ( IV, QW ), 3 weeks as a cycle.
41314504|NCT04180800|OTHER|Lubben Social Network Scale - 6|One short oral interview to complete the Lubben Social Network Scale in auto-survey, translated in French. It contains 6 questions on 30 points, higher scores are associated with more social engagement, lower scores, specifically under 12/30, are associated with social isolation.
41314505|NCT03331094|PROCEDURE|Surgery with graft|arthrodesis with autologous bone graft and using pedicular ilio-sacred EUROS ® screw
41314506|NCT03331094|PROCEDURE|surgery without graft|arthrodesis without bone graft using pedicular ilio-sacred EUROS ® screw
41314507|NCT05830513|DEVICE|Virtual Reality|Women will be randomly allocated to undergo OPU either with the use of virutal reality (group A) or the control group with standard treatment, without analgesia(group B). The participants of group A will wear the Oculus Quest 2 and will be surrounded by a virtual world. They will see objects flying towards themselves. They will be able to interact with the virtual world by hand controllers and can try to catch the objects.
41314508|NCT03490357|PROCEDURE|Control - Transversus Abdominus Plane Block|Abdominal fascial plane block - regional anesthesia
41314509|NCT03490357|PROCEDURE|Quadratus Lumborum Block|Abdominal fascial plane block - regional anesthesia
41314510|NCT04046406|DEVICE|MR neurography-guided cryoanalgesia|Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
41314511|NCT00377910|DRUG|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
41314512|NCT02637726|DRUG|Propofol : TCI Schnider|Target controlled infusion using schnider model for propofol
41314513|NCT02637726|DRUG|Propofol : TCI Kataria|Target controlled infusion using Kataria model for propofol
41472580|NCT06078540|OTHER|USeeBP|"USeeBP is a low risk mobile medical app that proposes to do no more than:~* Help patients (i.e., users) self-manage their disease or conditions without providing specific treatment or treatment suggestions;~* Provide patients with simple tools to organize and track their health information;~* Provide easy access to information related to patients' health conditions or treatments;~* Help patients document, show, or communicate potential medical conditions to health care providers;"
41151348|NCT00857311|BIOLOGICAL|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
41472581|NCT04238637|DRUG|Durvalumab|Durvalumab IV (intravenous Infusion)
41472582|NCT04238637|DRUG|Tremelimumab|Tremelimumab IV (intravenous Infusion)
41472583|NCT05683496|DRUG|lonigutamab|subcutaneous injection
41472584|NCT05683496|DRUG|Placebo|subcutaneous injection
41151349|NCT00857311|BIOLOGICAL|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
41151350|NCT00857311|BIOLOGICAL|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
41314514|NCT02637726|DRUG|Propofol : TIVA|Total intravenous anesthesia without use of a pharmokinetic model
41314515|NCT02637726|DEVICE|EEG Monitoring|Maintaining a bispectral index between 45 and 55
41314516|NCT02637726|DRUG|Remifentanil|Remifentanil at discretion of the anesthesiologist
41314517|NCT04817072|OTHER|Blood sample|Blood sample (20mL) for pro-inflammatory cytokines assay
41314518|NCT04371952|DRUG|Doxycycline|comparison of doxycycline 200 mg/day to placebo
41314519|NCT04371952|DRUG|Placebo|Placebo : lactose, 380 mg/gélule
41314520|NCT04786548|DRUG|Celecoxib|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.
41314521|NCT05059548|OTHER|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
41314522|NCT02266082|OTHER|No intervention|There is no intervention in this study.
41001888|NCT04654533|OTHER|COSC|"COSC is professional development program for early childcare providers adapted from the Circle of Security-Parenting (COSP) model. It is a manualized intervention that leverages research on attachment relationships combining psycho-education with a mentalization-based approach. The model uses pre-produced video vignettes of secure and problematic caregiver-child interactions to illustrate how caregivers' may struggle in meeting children's' attachment needs.~Participants are invited to reflect on how they meet and perhaps still not meet the needs of the children in their care with a particular focus on the challenging or 'difficult' children.~The COSP manual has been translated into Danish (Cooper, Hoffman and Powel, 2020, translated by Pedersen, Kronendorf von Wowern, Lier, \& Smith-Nielsen), and the additional COSC material has been translated into Danish for the purpose of this study."
41001889|NCT00344383|DRUG|Norgestimate/Ethinyl Estradiol tablet|
41001890|NCT00006482|DRUG|cisplatin|
41314523|NCT02486211|DRUG|Amantadine|100mg twice per day for 7 days at 0600 and 1200
41314524|NCT02486211|DRUG|Placebo|Placebo comparator
41472585|NCT05040126|DRUG|Linezolid|"Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system.~Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks.~Participants will be followed for 48 weeks after the end of treatment"
41314525|NCT03004469|DRUG|P-3074|
41314526|NCT03004469|DRUG|Finasteride|
41314527|NCT03004469|DRUG|P-3074 Vehicle|
41314528|NCT03004469|DRUG|Finasteride Placebo|
41314529|NCT03629418|DRUG|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
41472586|NCT05040126|DRUG|Bedaquiline|Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms
41001891|NCT00006482|DRUG|gemcitabine hydrochloride|
41001892|NCT03296306|DRUG|Treatment duration of cisplatin based chemotherapy|"* GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks~* GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks~* MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks~* HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks"
41001893|NCT01423448|OTHER|bulletin board|An asynchronous online bulletin board for people with experience of depression
41001894|NCT04114253|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
41001895|NCT05865288|DRUG|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with the nursing staff supervising for proper administration of substance, after training and guiding the patient, and for supervision of side effects.
41001896|NCT03080103|PROCEDURE|Laparoscopic or Open appendectomy|Laparoscopic three-port or single-port appendectomy; or conventional McBurney laparotomic appendectomy; or open appendectomy performed through midline incision
41314530|NCT03629418|DRUG|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
41314531|NCT02260856|DEVICE|Tantalum Beads & Injector|To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
41314532|NCT02260856|PROCEDURE|Percutaneous Drill Epiphysiodesis|
41314533|NCT02260856|PROCEDURE|Percutaneous Screw Epiphysiodesis|
41314534|NCT02317536|DIETARY_SUPPLEMENT|Carnipure Product 1|
41314535|NCT02317536|DIETARY_SUPPLEMENT|Carnipure Product 2|
41314536|NCT02317536|OTHER|Placebo|Placebo
41314537|NCT00637715|DRUG|Alfuzosin|
41314538|NCT03904641|RADIATION|aPDT|For aPDT, PapacarieMblue (Fórmula e Ação) will be used. It will be left for 5 minutes in the cavity. The carious tissue will be removed and the application of the PapacarieMblue will be repeated. The tissue will then be irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ.
41314539|NCT03904641|PROCEDURE|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
41472587|NCT05040126|DRUG|Pretomanid|Pretomanid is administered as one tablet once a day for 26 weeks in all three arms
41472588|NCT01885182|DRUG|Oxycodone/Naloxone|
41472589|NCT01885182|DRUG|Oxycodone|
41314540|NCT04212858|GENETIC|zinc-finger protein 217 gene|search for zinc-finger protein 217 gene in myeloma patients
41314541|NCT00700531|DEVICE|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
41314542|NCT00700531|PROCEDURE|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
41314543|NCT03414008|DRUG|BI 1291583|Single dose
41472590|NCT01264640|DRUG|Aspirin and Clopidogrel|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
41472591|NCT04529772|DRUG|acalabrutinib|Investigational Product
41472592|NCT04529772|DRUG|placebo|Placebo comparator
41472593|NCT04529772|DRUG|Prednisone|Investigational Product
41472594|NCT04529772|DRUG|Rituximab|Investigational Product
41314544|NCT03414008|DRUG|Matching placebo: Tartaric acid|Single dose
41314545|NCT03901807|DEVICE|Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge|TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
41472595|NCT04529772|DRUG|Cyclophosphamide|Investigational Product
41472596|NCT04529772|DRUG|Vincristine|Investigational Product
41472597|NCT04529772|DRUG|Doxorubicin|Investigational Product
41472598|NCT06267872|BIOLOGICAL|CD4BS CH505M5 Pr-NP1|A ferritin NP expressing 8 copies of an HIV-1 Env protein trimer. To be administered intramuscularly (IM).
41472599|NCT06267872|BIOLOGICAL|CH505TF chTrimer|A stabilized chimeric SOSIP Env trimer protein with the N-terminal sequence of CH505 TF gp120 Env transplanted into the BG505 SOSIP sequence. To be administered IM.
41472600|NCT06267872|BIOLOGICAL|3M-052-AF (labeled as AP 60-702)|An aqueous formulation (AF) of the small molecule imidazoquinoline immune response modifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.
41314546|NCT02059213|DRUG|Ibrance|
41314547|NCT02059213|DRUG|Bicalutamide|
41314548|NCT02059213|DRUG|Zoladex|
41314549|NCT02059213|DRUG|Lupron Depot|
41314550|NCT02979730|OTHER|Core Lab Test|For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
41314551|NCT02979730|OTHER|ED Point of Care Test|For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
41472601|NCT06267872|BIOLOGICAL|Aluminum Hydroxide Suspension (Alum)|Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg) along with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.
41472602|NCT06267872|BIOLOGICAL|ACU-026-001-1 (labeled as empty LNP)|An AF consisting of 4 lipid components.
41472603|NCT02751827|OTHER|Blood sample|"One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics~One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic"
41314552|NCT00100412|DRUG|Graded dobutamine infusions|
41314553|NCT00100412|DRUG|Graded phenylephrine injections|
41314554|NCT00100412|BEHAVIORAL|Psychosocial challenge involving socioevaluative public speaking|
41314555|NCT02136121|DEVICE|da Vinci Sp Surgical System - Robotic|robotic assisted laparoscopic single-port system
41314556|NCT00555048|BIOLOGICAL|alemtuzumab|
41314557|NCT00555048|DRUG|busulfan|
41314558|NCT00555048|DRUG|cyclophosphamide|
41314559|NCT00555048|DRUG|methotrexate|
41314560|NCT00555048|DRUG|tacrolimus|
41314561|NCT00555048|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41472604|NCT06136416|OTHER|Questionnaire for Non-dystrophic myotonias|Patients will have to complete the questionnaire created specifically for their pathology, as well as an evaluation grid of the same questionnaire to assess its relevance and good understanding
41472605|NCT00005026|DRUG|carboplatin|
41472606|NCT00005026|DRUG|paclitaxel|
41314562|NCT00555048|PROCEDURE|peripheral blood stem cell transplantation|
41314563|NCT05807386|BEHAVIORAL|Home-based exercise programme|A 12 week, online delivered, home-based exercise programme.
41314564|NCT04260828|DRUG|Aspirin 100mg|Daily active drug administered orally for 3 months.
41314565|NCT04260828|OTHER|Placebo|Sugar pill administered orally for 3 months.
41314566|NCT03309592|DRUG|Ambrisentan Pill|Will be administered as stated in Arm/Group Descriptions
41314567|NCT03309592|DRUG|Tadalafil Pill|Will be administered as stated in Arm/Group Descriptions
41314568|NCT03107676|OTHER|trunk extensors endurance training|endurance training
41314569|NCT02065596|DRUG|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
41472607|NCT00005026|DRUG|topotecan hydrochloride|
41472608|NCT02646917|PROCEDURE|Aesthetic Microneedling Treatment|Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
41472609|NCT01453621|OTHER|Computerized clinical decision support|Intervention sites will receive decision support regarding whether patient meets very low risk criteria for clinically-important traumatic brain injury based on the PECARN prediction rules.
41472610|NCT04953416|DEVICE|1565nm non ablative fractional laser|The ResurFX module contains Erbium:Glass Fiber Laser Technology with wavelength of 1565 nm, which is transferred to the ResurFX handpiece via a fiber.
41472611|NCT04008537|DEVICE|Ring gantry kV-CBCT combined with linear accelerator|Each imaging session will be less than one hour, and is expected to take no more than 15 minutes.
41472612|NCT02846883|BIOLOGICAL|1 million MSCs/kg|Intravenous infusion of 1 million allogeneic MSCs/kg.
41472613|NCT02846883|BIOLOGICAL|3 million MSCs/kg|Intravenous infusion of 3 million allogeneic MSCs/kg
41472614|NCT02846883|DRUG|Placebo|Intravenous infusion of Plasmalyte A (placebo)
41472615|NCT05516992|DRUG|SB-01 For Injection|Intradiscal injection
41472616|NCT05516992|DRUG|Sham Needle|Sham needle placement
41472617|NCT03123887|OTHER|salvage therapy|VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other
41472618|NCT04253353|DRUG|tafamidis|61 mg capsule
40797750|NCT03303053|DRUG|Prednisolone|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
41314570|NCT02065596|PROCEDURE|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
41314571|NCT03904524|BEHAVIORAL|SET-to-Meet|The overall objective of this study is to pilot test, in advance of a larger randomized trial, a scalable, nurse-led intervention to ensure timely interdisciplinary family meetings are held on behalf of critically-ill ICU patients who cannot participate in discussions about their care.
41314572|NCT00306774|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
40797751|NCT03303053|DRUG|Standard treatment|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
41314573|NCT00306774|DIETARY_SUPPLEMENT|Placebo|Placebo capsule per day for 2 years
41314574|NCT01397448|DRUG|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
41314575|NCT01397448|DRUG|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
41314576|NCT01397448|DRUG|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
41314577|NCT03615469|DEVICE|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
41314578|NCT03615469|DEVICE|Neuromuscular electrical stimulation|When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
41001897|NCT03080103|DRUG|Antibiotic-first therapy|Patients treated with antibiotics as first-line approach
41001898|NCT02270866|DEVICE|TNM(trademark) - thermoneuromodulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
41314579|NCT00934427|DRUG|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
41314580|NCT00934427|DRUG|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
41314581|NCT02152670|DRUG|Methylphenidate|
41314582|NCT02152670|DRUG|Alpha Methyl Para Tyrosine (AMPT)|
41472619|NCT04253353|DRUG|rosuvastatin|10 mg tablet
41472620|NCT06609161|DRUG|Tedizolid Phosphate Oral Formulation 1 (Reference)|Formulation 1 (FM1) powder for oral suspension.
40797752|NCT05139745|DEVICE|BTL-899|BTL-899 treatment
40797753|NCT02424500|DEVICE|d-Nav|Insulin dosage is adjusted as required
40797754|NCT02424500|DEVICE|Blood Glucose Monitoring System|Insulin dosage is adjusted as required
40797755|NCT03556670|BEHAVIORAL|Total Worker Health|The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
40797756|NCT03556670|OTHER|Control|Usual practice control
40797757|NCT05028699|OTHER|Snack|Participants will consume 32 g of a common bean baked snack per day for 28 days during the intervention stage.
41001899|NCT01512953|DRUG|Lansoprazole|Lansoprazole 30 mg once a day
41001900|NCT02334228|BEHAVIORAL|In SHAPE Lifestyles|In SHAPE Lifestyles is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
40797758|NCT01491061|DRUG|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
40797759|NCT01491061|DRUG|Placebo|os, two doses 12 hours apart prior to PCI
40797760|NCT01805687|DRUG|Zileuton extended release|
40797761|NCT03050450|DRUG|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
41314583|NCT02152670|OTHER|[11C]PHNO|
40797762|NCT03050450|DRUG|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
41001901|NCT02334228|BEHAVIORAL|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
41001902|NCT01715818|DRUG|Placebo|matching aleglitazar placebo tablet orally daily
41314584|NCT02152670|OTHER|[11C]raclopride|
41314585|NCT00490659|DRUG|gemcitabine|
41314586|NCT00490659|DRUG|cisplatin|
41314587|NCT00490659|PROCEDURE|radical surgery|
41314588|NCT00490659|PROCEDURE|chemoradiotherapy|
41314589|NCT01999166|RADIATION|radiography (X-ray)|
41314590|NCT01999166|GENETIC|DNA sampling|
41314591|NCT01948388|DRUG|corticotrophin 80 units|Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin
41314592|NCT02319096|OTHER|Whole body vibration therapy|Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
41314593|NCT04695106|DRUG|Ticagrelor|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months.
41314594|NCT04695106|DRUG|Dabigatran Etexilate|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
41314595|NCT04695106|DRUG|Aspirin|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
41001903|NCT01715818|DRUG|aleglitazar|150 mcg orally daily
41001904|NCT04583813|DRUG|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
41314596|NCT04695106|DRUG|Clopidogrel|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
41472621|NCT06609161|DRUG|Tedizolid Phosphate Oral Formulation 2 (Test)|Formulation 2 (FM2) powder for oral suspension.
41314597|NCT00002212|DRUG|Bexarotene|
41472622|NCT01859767|DRUG|[123I]MNI-672 SPECT|Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
41472623|NCT01909128|DIETARY_SUPPLEMENT|fermented milk|fermented milk with Lactobacillus CBA-L74
41472624|NCT01909128|DIETARY_SUPPLEMENT|fermented rice|fermented rice wit Lactobacillus CBA-L74
41472625|NCT06617377|OTHER|advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan|advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan (estimated total scanning time = 45 min for all centers except for Toulouse = 60min) will be acquired at least after 72h from complete withdrawal of sedation in normothermia condition (between Day 1 and Day 7 after inclusion).
41472626|NCT04923711|BEHAVIORAL|Moderate intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 60-69% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 50-59% reserve heart rate or the heart rate at the anaerobic threshold."
41472627|NCT04923711|BEHAVIORAL|High intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 70-85% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 60-70% reserve heart rate or the heart rate at the anaerobic threshold."
41472628|NCT05217589|OTHER|Funny/Amusing Video Clips|Participants watch 5-7 minutes of video clips that are funny/amusing in nature
41472629|NCT05217589|OTHER|Horror/Scary Video Clips|Participants watch 5-7 minutes of video clips that are scary in nature
40797763|NCT03050450|DRUG|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
40797764|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
40797765|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
41314598|NCT00235690|PROCEDURE|Blood draws|PK samples obtained around a clinical dosing of colistin
41314599|NCT00235690|OTHER|Blood draw|PK blood samples will be obtained around a clinical dosing of colistin
41314600|NCT03159377|DEVICE|Ultra low dose chest CT|Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
41314601|NCT03258346|OTHER|Inertial Load Cycling Training|Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
41314602|NCT03258346|DIETARY_SUPPLEMENT|Pomegranate Juice|Subjects will consume 8oz of pomegranate juice daily for duration of study.
40797766|NCT05392673|OTHER|KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)|Artificial liver scavenges inflammatory factors.
40797767|NCT02406573|DEVICE|Crest® Sensi-Stop™ Strips|
41001905|NCT04583813|OTHER|Placebo|Empagliflozin matching placebo, once daily, for 24 months
41001906|NCT02150668|BEHAVIORAL|Homework, Organization, and Planning Skills (HOPS) Intervention|
41151351|NCT05793827|BEHAVIORAL|Adapted Hatha Yoga|Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation
40797768|NCT00595881|DEVICE|Bedside emergency ultrasound|Ultrasound will be performed on the lesion in question.
40797769|NCT05708573|DRUG|Rosuvastatin|In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).
40797770|NCT05708573|DRUG|ALXN2040|In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
40797771|NCT00154817|PROCEDURE|radiotherapy|
41001907|NCT02150668|BEHAVIORAL|Homework Support Intervention (HSI)|
41001908|NCT05361681|OTHER|Electromagnetic Field Exposure|All participants were exposed to the electromagnetic field of 4-5 different high power charging systems, charging 4-5 different, commercially available full electric cars
41001909|NCT01690767|DRUG|2% lidocaine gel|Children \< 7 kg and \> 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
41001910|NCT01690767|DRUG|Health Care Lubricating Jelly|Non-medicinal lubrication gel
41001911|NCT01462669|DRUG|50mg Ezogabine/retigabine|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
41001912|NCT01462669|DRUG|100mg Ezogabine/retigabine|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
41001913|NCT01462669|DRUG|200mg Ezogabine/retigabine|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
41001914|NCT01462669|DRUG|400mg Ezogabine/retigabine|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
41001915|NCT05159245|DRUG|Alectinib|ALK
41314603|NCT03258346|DIETARY_SUPPLEMENT|Placebo|Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
41314604|NCT01195363|DRUG|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
41314605|NCT01195363|DRUG|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
41314606|NCT03586245|DIETARY_SUPPLEMENT|Ferric pyrophosphate|57 Iron isotopically labeled FePP powder.
41151352|NCT05793827|BEHAVIORAL|Low-Impact Exercise|This includes low-intensity exercise, which is matched to the estimated metabolic costs of yoga, 2.5 Metabolic Equivalent of Task (MET). Sessions include warm up, cool down, and five, 10-minute exercise stations, (e.g., walking, balance, resistance bands, weight-bearing exercise, and core work). Control exercise will be prescribed between 2.0 to 3.0 METs, equating to 30 to 40% heart rate reserve. Heart rate zones are calculated for each participant and monitored to ensure proper intensity
41314607|NCT03586245|DIETARY_SUPPLEMENT|Aspiron|58 Iron isotope intrinsically labeled Aspergillus oryzae.
41314608|NCT03586245|DIETARY_SUPPLEMENT|Ferrous sulfate|57 Iron isotopically labeled FeSO4 powder.
41314609|NCT04738825|BEHAVIORAL|Contingency Management with stepped care to PrEP adherence and support services (CoMPASS)|"Participants will receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12 will be stepped up to receive PrEP adherence and support services (n=5)."
41314610|NCT03029481|DRUG|Ganitumab|The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clinical progression or decision to move to an alternate therapy.
41314611|NCT00403312|BEHAVIORAL|Smoking Cessation Behavioral Program|
41314612|NCT00403312|DRUG|Nicotine Patch|
41314613|NCT00403312|BEHAVIORAL|Physical Activity|
41314614|NCT03497260|DIETARY_SUPPLEMENT|Fructose|Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
40797772|NCT04614012|OTHER|treated with hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
40797773|NCT00888706|BEHAVIORAL|Control Condition|The group participated in the usual nursing home activities and routines.
40797774|NCT00888706|BEHAVIORAL|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
41001916|NCT05159245|DRUG|Cobimetinib|MEK1, MEK2
41001917|NCT05159245|DRUG|Vismodegib|Hedgehog
41001918|NCT05159245|DRUG|Trastuzumab+Pertuzumab|HER2
41001919|NCT05159245|DRUG|Entrectinib|NTRK/ ROS1, ALK
41001920|NCT05159245|DRUG|Atezolizumab|PD-L1
41001921|NCT05159245|DRUG|Vemurafenib|BRAF V600
41001922|NCT05159245|DRUG|Regorafenib|KIT/BRAF, RET
41001923|NCT05159245|DRUG|Apalutamide|AR
41001924|NCT05159245|DRUG|Abemaciclib|CDK4/6
41001925|NCT05159245|DRUG|Tepotinib|MET ex14
41001926|NCT05159245|DRUG|Dabrafenib|RAF
41001927|NCT05159245|DRUG|Trametinib|MEK1, MEK2
41001928|NCT05159245|DRUG|Dabrafenib+Trametinib|RAF, MEK1, MEK2
41001929|NCT05159245|DRUG|Pemigatinib|FGFR2
41001930|NCT03740425|PROCEDURE|Blood Transfusion|Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)
41001931|NCT04289116|BEHAVIORAL|We Test|This design tests the added benefits of adjunct intervention components delivered prior to receipt of CHTC-Assertive Communication Training (ACT) videos viewed by the couple separately and individually delivered Motivational Interviewing-based Communication Skills Training (MI-CST). These target the development of communication skills necessary to participate fully in HIV prevention and sexual safety discussions inherent to CHTC.
41001932|NCT04289116|BEHAVIORAL|IHTC|Individual HIV Testing and Counseling
41001933|NCT01417403|DRUG|hydroxychloroquine|Given PO
41314615|NCT03497260|OTHER|Plain water|Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
41314616|NCT04753814|DIAGNOSTIC_TEST|Diagostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.
41314617|NCT04881201|PROCEDURE|blood sample|blood sample
41314618|NCT01728753|DRUG|Placebo|Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
41314619|NCT01728753|DRUG|Favipiravir|1200 mg TID on Day 1, then 600 mg TID on Days 2-5
41314620|NCT01728753|DRUG|Favipiravir|2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
41314621|NCT01728753|DRUG|Favipiravir|1800 mg BID on Day 1, then 800mg BID for Days 2 5
41314622|NCT04597281|OTHER|Lifestyle intervention|The intervention group, will receive education on Mediterranean lifestyle (Mediterranean diet and physical activity promotion), combined with the provision of extra-virgin olive oil and fish, in order to be consumed at least 3 times per week. Physical activity sessions with a physical activity monitor will also be offered for free to the children (2 sessions of 60 minutes of moderate-vigorous physical activity, per week)
41314623|NCT03195504|DEVICE|HFNC|High flow nasal oxygen (60 l) under GA
41314624|NCT03195504|DEVICE|CON (control)|Standard oxygen (10-15 l) under GA
41314625|NCT00532961|DRUG|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
41314626|NCT00532961|DRUG|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
41314627|NCT05838651|DEVICE|MinerOss® X Plug|A xenograft composed of 80% bovine cancellous particulate and 20% bovine Type I collagen.
41314628|NCT05838651|DEVICE|Striate+ Membrane|A non-crosslinked collagen covering used to keep bacteria out and hold the bone graft in place.
41001934|NCT01417403|RADIATION|radiation therapy|Undergo radiotherapy
41001935|NCT01642238|DRUG|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
41001936|NCT01642238|DRUG|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
41151353|NCT01989156|OTHER|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
41314629|NCT00972842|DRUG|Vorinostat, Lenalidomide|"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles~Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"
41314630|NCT06069011|OTHER|Interdisciplinary management|assessment and treatment in an interdisciplinary model
41314631|NCT06069011|OTHER|usual care|assessment and treatment in usual care model
41314632|NCT01551134|PROCEDURE|Fundoplication|Primary fundoplication
41314633|NCT01551134|PROCEDURE|Fundoplication|Primary fundoplication
41314634|NCT03512977|PROCEDURE|sphenopalatine ganglion block|the intervention will be performed on sitting position. Lidocaine 2% viscous (0.5ml) will be apply on cotton swab sticks and one will be gently inserted into nostril, along the floor of the nose. Stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab stick will be left undisturbed for 20 minutes.
41314635|NCT03512977|DRUG|conservative treatment|Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline
41314636|NCT04822857|DIAGNOSTIC_TEST|AMH|The group was divided according to the level of Anti-Müllerian Hormone
41314637|NCT01595165|PROCEDURE|Ultrasound guided subcostal TAP block|Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
41314638|NCT01595165|PROCEDURE|Placebo Ultrasound guided subcostal TAP block|Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
41314639|NCT01452555|BEHAVIORAL|Video or In-Person Presentation|Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
41314640|NCT01079533|BEHAVIORAL|Stepped CRCS Interventions|"In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS."
41001937|NCT01573780|DRUG|Smac mimetic TL32711|Given IV
41001938|NCT01573780|DRUG|gemcitabine hydrochloride|Given IV
41001939|NCT01573780|OTHER|laboratory biomarker analysis|Correlative studies
41001940|NCT01573780|OTHER|pharmacological study|Correlative studies
41001941|NCT01573780|PROCEDURE|biopsy|Optional correlative studies
41001942|NCT00658112|DRUG|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
41001943|NCT00013663|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
41001944|NCT00013663|DRUG|Aldesleukin|
41472630|NCT05217589|OTHER|Thrilling/Suspenseful Video Clips|Participants watch 5-7 minutes of video clips that are thrilling/suspenseful in nature
41472631|NCT01257581|DRUG|creatine|creatine monohydrate powder
41472632|NCT01257581|DRUG|tamoxifen|Tamoxifen citrate capsules
41472633|NCT04563520|DRUG|aPCC-emicizumab|Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI.
41472634|NCT04563520|DRUG|FEIBA|"FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia patients with inhibitors for: control and prevention of bleeding episodes, perioperative management, routine prophylaxis to prevent or reduce the frequency of bleeding episodes. If there is less than a good' response in bleed event at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with a max dose of no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days."
41472635|NCT04563520|DRUG|rFVIIa|rFVIIa is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents with hemophilia with inhibitors.
41001945|NCT04333810|DEVICE|Whoop strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep duration, resting heart rate, heart rate variability, activity (calories).
41001946|NCT02550327|DRUG|Nab-paclitaxel|125 mg/m2
41001947|NCT02550327|DRUG|Gemcitabine|1000 mg/m2
41001948|NCT02550327|DRUG|Cisplatin|25 mg/m2
41151354|NCT01989156|OTHER|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
41151355|NCT01989156|OTHER|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
41472636|NCT02518217|BEHAVIORAL|Weight Loss Apps|Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.
41472637|NCT02518217|BEHAVIORAL|ShapeUp Empower|Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.
41472638|NCT02518217|BEHAVIORAL|Financial Incentives for Engagement|Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
41472639|NCT05093881|BIOLOGICAL|Cellgram-LC|Patients who had administered Cellgram-LC in PMC-P-07 study
41472640|NCT05234814|OTHER|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.|"Fire dragon pot moxibustion treatment The main acupuncture points are as follows: Fengchi, Jianjin, Dazhui, Feiyu, Xinyu, Ganyu, Piyu, Shenyu, etc (all acupuncture points are positioned according to the national standard: GB/T12346-2006).~Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
41472641|NCT05234814|OTHER|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy|"Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
41472642|NCT05942976|OTHER|ULTRASOUND|10 enthesis areas will be evaluated in 20 minutes with ultrasound.
41472643|NCT05081245|DRUG|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
41472644|NCT05081245|DRUG|ML-004 Placebo|Participants will receive matching placebo once daily.
41001949|NCT02550327|DRUG|Anakinra|100 mg
41001950|NCT03081585|BEHAVIORAL|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
41001951|NCT05590585|DRUG|dupilumab|Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
41001952|NCT05590585|OTHER|Topical emollient (moisturizer)|Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
41001953|NCT04603729|DRUG|Dexamethasone 2 MG/ML|Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants
41001954|NCT04603729|DRUG|Methylprednisolone Injection|methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
41001955|NCT06223646|BIOLOGICAL|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
41001956|NCT04185168|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone (as 2 tablets)
41314641|NCT01079533|BEHAVIORAL|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
41314642|NCT04638712|OTHER|Microbiopsy sample|before and after chemotherapy
41314643|NCT04638712|OTHER|Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level|before and after chemotherapy
41314644|NCT01196650|DRUG|IN 10 003 formulation A|
41314645|NCT01196650|DRUG|IN 10 003 formulation B|
41314646|NCT01196650|DRUG|Placebo capsules|
41314647|NCT05518175|DEVICE|Traditional laparoscopy|Utilizes three or four 5 mm ports for access and retrieval.
41314648|NCT05518175|DEVICE|Single site laparoscopy|One port is placed via a 2 to 3 cm umbilical/fascia incision to accommodate the Gelpoint device, where several laparoscopic instruments are used. With this technique, there is a single incision, hidden in the umbilicus a
41314649|NCT05518175|DEVICE|V-Notes surgery|One port placed trans-vaginally via a 2-3 cm vaginal incision with no abdominal scars
41314650|NCT04148599|DRUG|dexmedetomidine infusion|a loading dose of 1µg/kg of dexmedetomidine (precedex) made to 50 ml using normal saline will be given over 10 minutes followed by infusion of dexmedetomidine with a dose of 0.5µg/kg/hour till the end of surgery.
41314651|NCT04148599|DRUG|lidocaine infusion|a loading dose of 1.5 mg/kg of lidocaine made to 50 ml using normal saline and given over 10 minutes followed by infusion of lidocaine with a dose of 1.5 mg/kg/hour till the end of surgery.
41314652|NCT04148599|DRUG|Placebos|50 ml of normal saline given over 10 minutes followed by saline infusion intraoperatively at a rate of 10 ml/hour till the end of surgery.
41001957|NCT04185168|OTHER|control|2 tablets of placebo
41001958|NCT05225103|BEHAVIORAL|SAFETY-Acute intervention|The trauma-informed brief suicide intervention based on the SAFETY-A (single crisis session in addition to follow-up caring contacts). Delivered in addition to usual care in facilities.
41001959|NCT00000796|DRUG|Cycloserine|
41001960|NCT00000796|DRUG|Ethionamide|
41001961|NCT00000796|DRUG|Capreomycin sulfate|
41001962|NCT00000796|DRUG|Aminosalicylic acid|
41001963|NCT00000796|DRUG|Streptomycin sulfate|
41001964|NCT00000796|DRUG|Ethambutol hydrochloride|
41001965|NCT00000796|DRUG|Amikacin sulfate|
41001966|NCT00000796|DRUG|Isoniazid|
41001967|NCT00000796|DRUG|Pyrazinamide|
41001968|NCT00000796|DRUG|Pyridoxine hydrochloride|
41001969|NCT00000796|DRUG|Levofloxacin|
41001970|NCT00000796|DRUG|Rifampin|
41001971|NCT00000796|DRUG|Clofazimine|
41001972|NCT03508856|DRUG|Ingenol Mebutate (Picato®) 0.015% gel|
41001973|NCT03863028|OTHER|Simulation training|It is not a randomized trial - all three groups are exposed to simulation training.
41001974|NCT05651464|DRUG|Vancomycine|Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
41001975|NCT03495232|DEVICE|Zimmer Biomet Persona total knee system|Product manufactured by Zimmer Biomet used to replace the knee joint.
41001976|NCT01504321|DRUG|Moxonidine|0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
41001977|NCT01504321|DRUG|Placebo|Encapsulated lactose powder
41001978|NCT05987865|BEHAVIORAL|Neurofeedback training|Features related to PD symptoms will be extracted from the brain recordings in real-time and used to drive a visual cursor on a computer screen placed in front of the participant, while the participant will be asked to try to control the cursor by regulating their brain signals.
41001979|NCT03523117|DRUG|Ferric carboxymaltose|Intravenous iron
41314653|NCT00608439|DRUG|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
41314654|NCT00608439|OTHER|Placebo|"Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52."
41314655|NCT01621724|GENETIC|WT1 TCR-transduced T cells|"Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells"
41001980|NCT03523117|DRUG|Ferrous Sulfate|oral iron therapy
41001981|NCT06274710|BEHAVIORAL|ODYSSEE-KH|Automated digital counselling program
41001982|NCT04385784|OTHER|Balance exercise program.|Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.
41001983|NCT04385784|OTHER|Home-based exercise program.|Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
41001984|NCT00916474|DRUG|telaprevir|
41001985|NCT00323973|DRUG|Bisoprolol|10 mg qd
41001986|NCT06277804|DRUG|LTC004 in Combination With Cyclophosphamide and Fludarabine|LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable
41151356|NCT04205045|DIAGNOSTIC_TEST|Lactose Breath Test|Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.
41472645|NCT04764630|DRUG|Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min
41472646|NCT04764630|DRUG|Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
41001987|NCT00820742|DRUG|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
41001988|NCT05561972|DEVICE|injectable multifractional intercalated hyaluronic acid [Armonia®, Regenyal, Italy]|Armonia® 2 ml was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
41001989|NCT03525197|DIETARY_SUPPLEMENT|Whey protein-based supplement|High quality protein supplement to be consumed twice daily
41001990|NCT03525197|DIETARY_SUPPLEMENT|Collagen protein-based supplement|Lower quality protein supplement to be consumed daily
41001991|NCT01660893|DRUG|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
41001992|NCT01660893|DRUG|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
41001993|NCT01660893|DRUG|Placebo|3 unilateral intranasal sprays per dose
41001994|NCT04845607|DRUG|Amiodarone Injection|Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
41001995|NCT02312232|DRUG|levodopa, carbidopa, ODM-104|
41001996|NCT03767218|COMBINATION_PRODUCT|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from the late follicular phase of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH \> 10 IU/L, till day of trigger.
41001997|NCT03767218|COMBINATION_PRODUCT|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
41001998|NCT05167162|DIAGNOSTIC_TEST|State-Trait Anxiety Questionnaire|"The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~1. Not at all~2. Little~3. Sometimes~4. Almost always~5. Always"
40797775|NCT00888706|BEHAVIORAL|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
40797776|NCT00888706|BEHAVIORAL|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
41001999|NCT05167162|DIAGNOSTIC_TEST|Rating of Perceived Exertion|"The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~1. No pain~2. Little pain~3. Moderate~4. Severe~5. Very strong~6. Unbearable"
41002000|NCT05167162|DIAGNOSTIC_TEST|Motor coordination tests|"The motor coordination tests are divided into three:~1. Jumping with 2 feet together.~2. Throwing 2 balls from a given distance and space.~3. Proprioception turns"
41314656|NCT00773565|DIETARY_SUPPLEMENT|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
41314657|NCT01869166|BIOLOGICAL|CART-EGFR|
41314658|NCT03096002|BEHAVIORAL|Lifestyle change|The 3-week lifestyle change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 3-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the lab). The supervised session will include brief behavioral counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
41314659|NCT01850862|OTHER|Collective group exercise program in patients with KOA|
41314660|NCT01850862|OTHER|Orientation (without exercise)|Orientation about osteoarthritis disease but without any exercise program
41314661|NCT03565848|PROCEDURE|Mesenteric vascular and nerve sparing surgery in laparoscopic segmental colorectal resection|Laparoscopic segmental colorectal resection performed by dissecting adherent to the intestinal wall with mesenteric vascularization and innervation entirely preserved.
41314662|NCT01797965|DRUG|BIIB019 (Daclizumab)|Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
41314663|NCT06322524|DEVICE|Gamma sensory flicker|participants were exposed to flicker stimulation through a light and sound device, the flicker was 40 Hz.
41314664|NCT02336412|OTHER|SMS reminder|Daily SMS medication reminder
41314665|NCT04047758|DRUG|Palbociclib + Letrozole|(1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment \[3 weeks on (days 1-21) and 1 week off (days 22-28)\], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
41314666|NCT04047758|DRUG|Letrozole|Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
41314667|NCT05271396|OTHER|Clinical Assessment|The demographic information and clinical findings of the participants were recorded. Mandible movements evaluation with a digital caliper. The Visual Analogue Scale (VAS) to measure the severity of pain at rest and during activity. Cervical lordosis and shoulder posture assessment, Fonseca Anamnestic Index for TMD severity classification. Spirometric measurement to evaluate respiratory functions of all participants and intraoral pressure measurement to determine respiratory muscle strength.
40797777|NCT02216916|DRUG|HM781-36B|
41002001|NCT05167162|PROCEDURE|Physiotherapeutic intervention|Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.
41002002|NCT05167162|OTHER|Data Analysis|The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
41002003|NCT00360074|DRUG|Thyroxin, Triiodothyronine|
41002004|NCT01344369|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/0.035 mg Chewable Tablets
41314668|NCT01727050|DEVICE|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
41314669|NCT01727050|DEVICE|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
41314670|NCT03583372|DRUG|Vibegron|single daily dose 75 mg
41314671|NCT03583372|DRUG|placebos|placebo to match vibegron (experimental drug) and tolterodine (active comparator)
41314672|NCT03583372|DRUG|Tolterodine Tartrate ER|single daily dose of 4 mg
41314673|NCT03353753|DRUG|DCC-2618|Oral KIT/PDGFRA kinase inhibitor
41314674|NCT03353753|DRUG|Placebo Oral Tablet|Placebo
41314675|NCT04377061|DIAGNOSTIC_TEST|Evaluation of anemia|Evaluation of anemia in NCWS patients, and in CD and IBS controls, with both retrospective and prospective method.
41314676|NCT04693442|OTHER|taking of blood, urine and blood samples and objective scar assessment|blood, urine and skin tissue sampling \& scar assessment questionnaires
41472647|NCT04764630|DRUG|Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
41472648|NCT01118026|DRUG|ABVD|doxorubicin 25 mg/m\^2 IV bleomycin 10 units/m\^2 IV vinblastine 6 mg/m\^2 IV dacarbazine 375 mg/m\^2 IV
40797778|NCT02615418|DEVICE|NIBS system for evaluation and treatment utilizing non invasive brain stimulation|
40797779|NCT05695794|OTHER|the group with a bed head height of 45 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving a 45 degree head height to 30 patients determined by Randomizer.org.
40797780|NCT05695794|OTHER|the group with a bed head height of 30 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving 30 degrees of bed head height to 30 patients determined by Randomizer.org.
41472649|NCT01118026|DRUG|BEACOPP|bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4 mg/m\^2 IV on Day 8 procarbazine 100 mg/m\^2 orally on Days 1-7 prednisone 40 mg/m\^2 orally on Days 1-14
41472650|NCT01118026|RADIATION|radiation therapy|
41472651|NCT00209287|BEHAVIORAL|Observe patients with inactive ulcerative colitis|Observe patients with inactive ulcerative colitis
41472652|NCT01854086|OTHER|Questionnaires about compliance and persistence with bisphosphonates treatment|
41472653|NCT04817215|DRUG|ORMD-0801|Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
41472654|NCT00809237|DRUG|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
41472655|NCT04601233|DRUG|XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector|Self injection testosterone treatment
41472656|NCT03166124|DRUG|LY900014|Administered SC
41472657|NCT03166124|DRUG|Insulin Lispro|Administered SC
41472658|NCT04100824|PROCEDURE|stellate ganglion block by transcranial doppler|stellate ganglion block is a block of sympathetic ganglion
41314677|NCT04430660|OTHER|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.
41314678|NCT04430660|DEVICE|Continuous glucose monitoring|Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.
41314679|NCT02311699|BEHAVIORAL|Intervention to reduce IPV and HIV|The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two-hour session per group of participants.
41314680|NCT06155760|DRUG|Prednisolone|10mg of prednisolone plus standard medical therapy for 60 days
41314681|NCT06155760|OTHER|Standard Medical therapy|IV Albumin, Diuretics, Multi vitamins as per clinicians decision
41314682|NCT06155760|DRUG|Placebo|Placebo
41314683|NCT06167499|OTHER|Diabetes Therapeutic Education conducted by nurses|"Individual consultations with the therapeutic education IDE, who will help the patient to achieve the therapeutic objectives set before the medical consultation.~Once the objectives have been set, the IDE will set up individual workshops and subsequently assess the patient's learning and its impact on his or her care. These workshops can include equipment demonstrations and practical exercises, explanations of treatment adaptation protocols, and dietary or sexual advice."
41472659|NCT04100824|DRUG|Nimodipine|Nimodipine 60mg every 4h
41472660|NCT04798482|DRUG|Dexmedetomidine|Patients will undergo the usual anal manometry study, with no adjuvant medications, per routine practice currently in the gastrointestinal unit. Following completion of manometry, 0.5 mcg/kg DEX will be administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Manometry measurements will be followed for 15 minutes in response to DEX.
41472661|NCT01913379|DRUG|MDV3100|Oral
41472662|NCT01913379|DRUG|Gemfibrozil|Oral
41472663|NCT01913379|DRUG|Itraconazole|Oral
41472664|NCT05840094|DRUG|18F-FDG|18F-FDG is injected intravenously with a dose of 0.1mCi/kg.
41472665|NCT05840094|DEVICE|MR STIR|The overall scanning time of MR is about 13min.
40797781|NCT00633087|DRUG|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
40797782|NCT05824663|DRUG|HBM1020|Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
41002005|NCT01344369|DRUG|FEMCON® Fe|0.4 mg/0.035 mg Chewable Tablets
41314684|NCT01259973|DRUG|Risperidone|1 single dose of 2.5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
41314685|NCT01259973|DRUG|Placebo|1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
41002006|NCT00470288|PROCEDURE|bladder flap during cesarean section|
41314686|NCT01259973|DRUG|Haloperidol|1 single dose of 5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
41314687|NCT00775502|DRUG|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
41472666|NCT05840094|PROCEDURE|EBUS-TBNA|Puncture about 20 times, 3 stitches in each group of enlarged lymph nodes, 1 stitch in the anterior, middle and posterior parts respectively
41472667|NCT04837079|OTHER|Clinical observational study|Clinical observational study
41472668|NCT04741152|PROCEDURE|Pancreatic resection|Different pancreatic resections
41472669|NCT01443377|BIOLOGICAL|Panitumumab|Intravenous (IV), Panitumumab 6 mg/kg BW q2w d1-d57 (5 times total); begin on day 1 (run-in-phase) and subsequent application on days 15, 29 43 and 57.
41472670|NCT06557278|BIOLOGICAL|AlloStim|experimental immunotherapy to prime for checkpoint inhibitor
41472671|NCT06557278|DRUG|Bavencio|anti-PDL1 checkpoint inhibitor
41472672|NCT05501808|PROCEDURE|cerasmart|the patient received a crown made of cerasmart ceramic
41472673|NCT05501808|PROCEDURE|enamic|the patient received a crown made of enamic ceramic
41472674|NCT06615752|DRUG|green tea and quercetin + docetaxel|green tea and quercetin supplements in combination with docetaxel infusion
41472675|NCT06615752|DRUG|Placebo + docetaxel|Placebo will be given along with docetaxel chemotherapy
41472676|NCT01289951|DRUG|Raltegravir 400 mg/12hours|
41472677|NCT01289951|DRUG|Raltegravir 400 mg/12hours|
40797783|NCT02812238|DIETARY_SUPPLEMENT|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
40797784|NCT02812238|DRUG|Placebo|Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
40797785|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
40797786|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
40797787|NCT01780844|DRUG|ASKP1240|intravenous infusion
40797788|NCT01780844|DRUG|Tacrolimus|intravenous or oral
40797789|NCT01780844|DRUG|Mycophenolate Mofetil (MMF)|intravenous or oral
40797790|NCT01780844|DRUG|Basiliximab|intravenous
41314688|NCT00240552|DRUG|fosamprenavir|
41314689|NCT00240552|DRUG|Telzir®|
41314690|NCT01758965|OTHER|PPI|monotherapy of PPI
41314691|NCT01758965|OTHER|H2RA and surgicel|combination therapy of H2RA and surgicel
41314692|NCT02594397|OTHER|acupoints combination 1|
41314693|NCT02594397|OTHER|acupoints combination 2|
41314694|NCT02594397|OTHER|sham acupoints combination|
41314695|NCT00578799|DIETARY_SUPPLEMENT|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
41314696|NCT00578799|DIETARY_SUPPLEMENT|placebo|placebo capsules (potato starch
41314697|NCT02179528|DRUG|Etoposide|
41314698|NCT04061681|BEHAVIORAL|Behavioral Intervention (BIPAMS)|This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
41314699|NCT03335852|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
41314700|NCT05016869|DRUG|fruquintinib plus capecitabine|"Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W"
41314701|NCT02276521|BIOLOGICAL|Cervarix®|All groups will received one dose of Cervarix® vaccine
41314702|NCT03866252|DRUG|LSD|LSD administration per os
41314703|NCT04511026|DRUG|Lymphoseek|Radioactive diagnostic agent
41314704|NCT04511026|DEVICE|Single Photon Emission Computed Tomography (SPECT)|Imaging test
41314705|NCT04511026|DRUG|Indocyanine Green (ICG)|Cyanine dye used in medical diagnostics manufactured by Akorn Inc.
41314706|NCT04511026|DEVICE|Neoprobe Gamma Detection System NPB11L(Model1102)|Neoprobe Gamma Detection System NPB11L(Model1102) made by Devicor Medical Products, Inc.
41314707|NCT04028999|DEVICE|Evaluate the effects of the EO31 shoulder sling in adults post-stoke|Investigator want to evaluate the efficient of the EO31 shoulder sling in adults post-stroke. The EO31 shoulder sling is made-to-measure shoulder pads for upper limb after cerebrovascular accident
41314708|NCT06357260|DRUG|Pregabalin and Carbamazepine|Carbamazepine+pregabalin with fixed dose of pregabalin 75mg BD and carbamazepine being titrated as per patients's need
41314709|NCT06357260|DRUG|Carbamazepine|Carbamazepine with dose of Carbazmaepine being titrated as per patients's need
40797791|NCT01780844|DRUG|Methylprednisone|Intravenous
40797792|NCT01780844|DRUG|Prednisone|Oral
40797793|NCT03172299|DRUG|Aflibercept Injection|Intravitreal injection of aflibercept 40mg/mL will be done on patients. The injections will be performed on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, injections will be performed every 3 months for a period of 21 months.
40797794|NCT03172299|DRUG|False injection|A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.
40797795|NCT05017389|DIAGNOSTIC_TEST|Griffiths development scales|Griffiths development scales Chinese Edition (gds-c) was used to evaluate the development levels of children up to 6 years and WISC for children more than 6 years.
41314710|NCT00574431|OTHER|Data Collection|Collection of patient data before implementation of a nutritional management protocol
41314711|NCT00574431|OTHER|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
41314712|NCT02055430|PROCEDURE|percutaneous nephrostomy insertion|The 1st arm was drained by PCN. This was performed under general anesthesia (GA) and fluoroscopic guidance.
41314713|NCT02055430|PROCEDURE|bilateral double J ureteric stent|The 2nd arm was drained by bilateral JJ . This was performed under general anesthesia (GA) and fluoroscopic guidance.
41314714|NCT02055430|PROCEDURE|Definitive stone management|(shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.
41314715|NCT06411249|DRUG|Belimumab (GSK1550188)|GSK1550188 will be administered subcutaneously.
41314716|NCT05509218|BEHAVIORAL|Mobile-delivered personalized feedback|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided on how their most recent behavior (e.g., drinks last night, drinking days so far this week) compare/contrast with personal goals. Participants will then choose whether to receive additional feedback in any of 7 areas: blood alcohol concentrate on, high risk behaviors, consequences of drinking, caloric intake, spending, how drinking compares to peers, and safe drinking strategies. All participants will receive feedback on drinks consumed, and then be asked to choose at least one additional topic for feedback (following each drinking day). In addition to day-level feedback, an aggregate feedback report on drinking patterns and related behaviors will be delivered twice, once at the end of each 2-week period. Once again, they will have the option to view feedback across the range of topics noted above.
41314717|NCT00389103|BIOLOGICAL|MVA (smallpox vaccine)|0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
40797796|NCT00625391|DRUG|Placebo|500 mg medicinal starch pills daily
41151357|NCT04205045|OTHER|Gut permeability test|A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.
41472678|NCT06051604|DEVICE|Mi-Helper|The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
40797797|NCT00625391|DRUG|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
40797798|NCT00625391|DRUG|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
40797799|NCT00625391|DRUG|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
40797800|NCT01642901|DRUG|Zoledronic acid|5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
41002007|NCT01790334|OTHER|Ultrasonography|
41002008|NCT01709695|DRUG|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
41002009|NCT01709695|DRUG|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
41002010|NCT04537728|BEHAVIORAL|My Healthy Brain Version 2|multimodal lifestyle intervention incorporating mindfulness skills, behavioral principles, and recent research on brain disease risk factors
41002011|NCT04847674|DRUG|TEV-53275 Dose A|subcutaneous (sc) injection
41002012|NCT04847674|DRUG|TEV-53275 Dose B|subcutaneous (sc) injection
41002013|NCT04847674|DRUG|Placebo|Matching subcutaneous (sc) placebo injection
41002014|NCT02582853|PROCEDURE|Lumbar puncture|Lumbar puncture for spinal fluid
41002015|NCT02582853|PROCEDURE|Blood Sample|Blood sample
41151358|NCT04205045|OTHER|Milk Test|Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).
41151359|NCT01445379|DRUG|Ipilimumab|Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
41002016|NCT02679586|DEVICE|Diffusion weighted MRI|
41002017|NCT04331392|BEHAVIORAL|Spatial Navigation Intervention|"The 16-week intervention is completed daily, 5 days/week, remotely from home on a designated study website. Each week participants learn a new city through navigation tasks which increase in difficulty day-to-day and have a total of 4 levels of difficulty, with the goal of being able to independently navigate the city by the end of the week via Google Street View. Participants complete end-of-day multiple-choice tasks, testing what they learned with 3 types of allocentric questions: 1) predicting the next street/landmark, 2) distance judgement and 3) vector mapping. Participants also complete a map placement task, which involves reporting the locations of all studied landmarks/streets.~Participants are presented with auditory rewards in the forms of short audio clips about landmarks, written encouragement in the form pop-ups (e.g., Good work, keep it up!), and coffee card rewards based on adherence to the intervention (e.g.,$5 bi-weekly if 100% of intervention is completed)."
41002018|NCT04331392|BEHAVIORAL|Educational Videos|The 16-week active control, remote video intervention is completed daily, 5 days a week by participants on a designated website. Participants placed in the active control group are trained on educational topics by watching videos of Ted Talks, to control for the effects of generalized environmental enrichment of the same dose as targeted navigation training. For each day of training, participants are asked to select between an option of 2 possible videos, watching a total of three videos per day. To ensure compliance and sufficient attention to the videos, at the end of each video, participants are asked to rate 5 aspects of the content (relevance, interest, comprehensibility, complexity, informative), and speaker (persuasiveness, quality of delivery, facial expression, convincingness, captivation), on a scale of 1 (lowest) to 5 (highest). Additionally, as with remote navigation participants, they are given written and monetary rewards.
41151360|NCT04532333|DRUG|Bivalirudin 250 MG Injection|Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
41151361|NCT04532333|DRUG|Heparin|Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
41151362|NCT03967119|DEVICE|Patient monitoring|Arterial blood pressure, pulse oxygen saturation, and cardiac output/stroke volume are monitored with invasive arterial catheter, pulse oxymetry, and esophageal doppler in all participants. Some dynamic variables including SVV and PPV are automatically calculated in each monitor. PWV is manually calculated in a printed plethysmographic waveform. Plethysmographic waveform amplitude (PW) is measured on a beat-to-beat basis as the vertical distance between peaks and preceding valley troughs in the waveform. The maximum PW (PWmax) and minimum PW (PWmin) are determined manually over the same respiratory cycle, and PWV is calculated. PWV=(PWmax-PWmin)/\[(PWmax+PWmin)/2\].
41472679|NCT02084368|PROCEDURE|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS
41472680|NCT02084368|PROCEDURE|Combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8\~10mg at L2-3 or L3-4.
40797801|NCT01642901|DRUG|normal saline 0.9%|Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
40797802|NCT01875081|BIOLOGICAL|Livercellgram|"Livercellgram~* Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20\~25℃~  * Injection Method: Directly inject into liver through hepatic artery"
41002019|NCT00134381|DRUG|Green Tea|Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
41314718|NCT04109235|OTHER|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
41472681|NCT02084368|DRUG|Ropivacaine|Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.
41472682|NCT02084368|DRUG|Bupivacaine|Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8\~10mg.
41472683|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
41472684|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
41472685|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
41472686|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
41472687|NCT01373879|BIOLOGICAL|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
41472688|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
41472689|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
41472690|NCT01373879|BIOLOGICAL|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
41472691|NCT04829760|DIETARY_SUPPLEMENT|Psyllium|Participants will consume 10 grams of fiber from psyllium in two doses each day for 8 weeks
41472692|NCT04829760|DIETARY_SUPPLEMENT|Coarse wheat bran|Participants will consume 10 grams of fiber from coarse wheat bran in two doses each day for 8 weeks
41472693|NCT04829760|DIETARY_SUPPLEMENT|Maltodextrin|Participants will consume maltodextrin in a volume equivalent to the psyllium intervention (\~2 tablespoons) in two doses each day for 8 weeks
41472694|NCT04647617|BEHAVIORAL|Quantitative weight -bearing and report exercise sign data every weekly|keep their normal live style
41472695|NCT04235972|OTHER|Follow-up consultation|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
41472696|NCT03360357|PROCEDURE|Guided drills|"These residents will perform 5 set of exercises:~1. Needle Dance (Learning to manipulate the suture)~2. Loopy Loop (Learning to place needle through a loop)~3. Slalom Course (Passing the needle and suture through 5 rings right handed and left handed)~4. Dense Matter (Passing the needle through dense material without losing control of the needle)~5. Respect for tissue (Passing the needle through flimsy material without tearing)"
41472697|NCT06043622|OTHER|Optical coherence tomography angiography|Optical coherence tomography angiography
41472698|NCT06043622|OTHER|ophthalmological exam|ophthalmological exam
41472699|NCT04188548|DRUG|LY3484356|Administered orally
41472700|NCT04188548|DRUG|Abemaciclib|Administered orally
41472701|NCT04188548|DRUG|Everolimus|Administered orally
41472702|NCT04188548|DRUG|Alpelisib|Administered orally
41472703|NCT04188548|DRUG|Trastuzumab|Administered intravenously
41472704|NCT04188548|DRUG|Aromatase Inhibitor (AI)|Anastrozole or Exemestane or Letrozole administered orally (physician choice)
41472705|NCT04188548|DRUG|Pertuzumab|Administered intravenously
40797803|NCT05891015|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
41002020|NCT00134381|DRUG|Placebo|Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
41002021|NCT03299842|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
41002022|NCT01113125|DRUG|Betamethason-17-valerate and fusidic acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
41472706|NCT06616636|DRUG|Azacitidine|Given by IV
41472707|NCT06616636|DRUG|Rezatapopt|Given orally with food
41472708|NCT06616636|DRUG|Venetoclax|Given by mouth
40797804|NCT06290492|DEVICE|transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes
40797805|NCT06290492|DEVICE|sham transcranial direct current stimulation|Sham tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
40797806|NCT02544750|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
40797807|NCT04826263|OTHER|Home Exercise Program|All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.
40797808|NCT04826263|OTHER|Low-Level Laser Therapy (LLLT)|Patients in the LLLT group will receive gallium-aluminum-arsenide (Ga-Al-As) low-level laser treatment with Chattanooga Vectra Genisys Transport model (Chattanooga Group) with a wavelength of 850 nm and a power of 100 mW. The LLLT treatment will be applied 3 times a week, a total of 10 sessions. A maximum energy density of 5.6 j/cm2 will be reached by delivering a continuously increasing dose of energy to each tender spot for one minute. The LLLT will be performed with patients in the prone position and will be applied to 5 points on the plantar fascia by positioning the laser head perpendicular to the treatment area.
41002023|NCT01113125|DRUG|Fusidic Acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
41151363|NCT02072889|OTHER|Neck Angle|Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated
41151364|NCT06585176|OTHER|No intervention|This concerns a natural history study. No interventions will be used.
41472709|NCT01358799|DEVICE|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
41002024|NCT04431037|DIETARY_SUPPLEMENT|Early oral feeding/Enhanced recovery after surgery protocols|Early oral feeding refers to NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
41002025|NCT01384435|DRUG|KPS-0373|
41151365|NCT06456788|BIOLOGICAL|MMR vaccination|MMR vaccination status
41151366|NCT00040729|GENETIC|mutation analysis|
41002026|NCT01384435|DRUG|KPS-0373|
41002027|NCT01384435|DRUG|KPS-0373|
41002028|NCT01384435|DRUG|KPS-0373|
41002029|NCT01384435|DRUG|Placebo|
41151367|NCT04698499|OTHER|Swallowing exercise from home|Treatment Arm A will consist of using pen and paper to complete the exercises. This is considered standard care. Treatment Arm B will consist of using Mobili-T to complete the exercises.
41472710|NCT05143203|OTHER|Self-hypnosis training|Self-hypnosis training will be conducted in two phases and the evaluation of effectiveness of the training will be measured using GAD7, PHQ9 and PROQOL questionnaires
41472711|NCT00147160|DRUG|Temozolomide, Cisplatinum|
41472712|NCT03395639|DRUG|Edoxaban|Edoxaban 15 mg or 30 mg tablets for participants 12 to \<18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
41472713|NCT03395639|DRUG|Standard of Care (SOC)|Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
41472714|NCT00020267|DRUG|interleukin-2|
41002030|NCT03976427|BEHAVIORAL|Guided Imagery|The guided imagery exercise asks participants to think about positive associations with healthy foods and imagine their future healthy selves.
41002031|NCT02259933|DRUG|KUC 7483 CL|
41002032|NCT02259933|DRUG|Placebo|
41002033|NCT01572038|DRUG|Docetaxel|Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
41002034|NCT01572038|DRUG|Nab-paclitaxel|Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
41002035|NCT01572038|DRUG|Paclitaxel|Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
41002036|NCT01572038|DRUG|Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.
41002037|NCT01572038|DRUG|Trastuzumab|Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
41002038|NCT02888899|BEHAVIORAL|Biofeedback|
41002039|NCT02888899|DRUG|Loperamide|
41002040|NCT02888899|DRUG|Stool bulking agent (sterculia or ispaghula husk)|
41002041|NCT02888899|OTHER|PTNS|
41002042|NCT00294164|DRUG|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
41002043|NCT00294164|DRUG|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
41002044|NCT00637195|BIOLOGICAL|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)|Intramuscular administration, 3 doses.
41002045|NCT00637195|BIOLOGICAL|Engerix™|Intramuscular administration, 4 doses.
41002046|NCT06259331|DRUG|SPN-812 (600mg, QD)|Viloxazine ER
41002047|NCT02030171|OTHER|functionnal reeducation|Specific functionnal reeducation for chronic low back pain
40797809|NCT04826263|OTHER|Extracorporeal Shockwave Therapy (ESWT)|Patients in the ESWT group will receive treatment with a radial ESWT system (EMS Swiss Dolor Clast), which transforms kinetic energy into a shock wave, which is then applied to the target tissue with pressure varying from 1 to 10 bar and penetrating up to 40 mm. The ESWT treatment will be administered to the patients once a week for three weeks, for a total dose of 2000 mJ/mm2 pulse per application. ESWT will be applied to the patients in prone position with their foot inverted. Ultrasound gel will be applied to the patient's heel The area of tenderness will be palpated and 1000 shock wave impulses were applied to this area, and 1000 pulses will be applied over the plantar fascia.
40797810|NCT04541693|DEVICE|Full revision|Both cup and stem require revision
40797811|NCT04541693|DEVICE|Cup revision|Only the cup requires revision
40797812|NCT04541693|DEVICE|Stem revision|Only the stem requires revision
40797813|NCT02970136|DEVICE|OraQuick Swab|OraQuick for oral fluid HIV antibody testing
40797814|NCT02970136|DEVICE|Fecal Immunochemical Test|Fecal Immunochemical stool test specific for human hemoglobin
40797815|NCT02970136|DEVICE|OraQuick Fingerstick|Patients will be tested for Hepatitis C infection using a fingerstick
40797816|NCT02970136|OTHER|Standard Screening Tests|Patients will be navigated to a local health center for standard screening tests
40797817|NCT02970136|DEVICE|HPV Self-Sampling Test|Patients will be using swab to check for HPV infection
40797818|NCT02970136|OTHER|Home Based Screening Tests|Patients will provided screening tests and instructed by Community Health Worker on how to perform home screening tests
40797819|NCT06177262|BEHAVIORAL|cognitive behavioral therapy|Cognitive behavioral therapy for eating disorders.
40797820|NCT03915444|DRUG|nab-Paclitaxel + Cisplatin + Gemcitabine|"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL\* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."
40797821|NCT06018207|DRUG|Midazolam oral solution|"The ED50 dose of midazolam oral solution for hypnosis is studied using an up-and-down sequential allocation while waiting for surgery and general anesthesia in preoperative room.~The starting dose is 6 mg and the step size is 1 mg. The interval sequential dose is varied by 1 mg based on the hypnosis response of the previous patient after one hour.~Definition of successful hypnosis by taking midazolam oral solution:~The polysomnograph (PSG) not only shows stage N2 within 30 minutes, but also shows stage N3 within an hour; or else, definition of unsuccessful hypnosis.~The procedure is as follows: (1) The first subject is given 6mg of midazolam oral solution; (2) If succeed, the second subject takes 4mg; (3) If not succeed, the second subject takes 8mg; (4) Until seven sequence reversal inflection points."
40797822|NCT05519111|DRUG|Dronabinol|Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)
40797823|NCT05519111|DRUG|Placebo|placebo equivalent
40797824|NCT05143905|DRUG|AZD7503|Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
41151368|NCT02551926|BEHAVIORAL|mobile text messages|
41151369|NCT02551926|BEHAVIORAL|virtual community|
41314719|NCT04109235|OTHER|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4\&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
41314720|NCT00118729|DRUG|GW685698X Aqueous Nasal Spray|
41314721|NCT00305253|DEVICE|Non-pneumatic Anti-shock Garment (NASG)|In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
41472715|NCT00020267|DRUG|MAGE-12 peptide vaccine|
41472716|NCT00020267|DRUG|Montanide ISA-51|
41472717|NCT04442724|PROCEDURE|Fiducial marker placement|placement of 24k gold fiducial markers surrounding the tumor site, at time of primary or re-staging bladder tumor resection
41472718|NCT04442724|DIAGNOSTIC_TEST|Multiparametric MRI (mpMRI)|In this study, mp-MRI is defined as MRI that includes T1 \& T2 weighted sequences, diffusion weighted sequences, and Dynamic contrast enhanced (DCE) MRI sequences.
41472719|NCT04788537|BEHAVIORAL|Training to Understand and Navigate Emotions and Interactions (TUNE In)|A three-part cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings.
40797825|NCT05143905|DRUG|Placebo|Randomised participants will receive placebo by SC injection
40797826|NCT03732716|DIAGNOSTIC_TEST|blood pressure measurement|Intervention: Each patient's supine and standing blood pressure measurements will be recorded
40797827|NCT03075306|BEHAVIORAL|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
40797828|NCT06375395|DEVICE|Active tACS Device|Transcranial Alternating Current Stimulation
41151370|NCT02551926|BEHAVIORAL|brochures|
41151371|NCT02551926|OTHER|Usual care|
41151372|NCT02551926|DEVICE|mobile phone|
41151373|NCT04445246|DRUG|Inhaled ILOPROST|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.
41151374|NCT05929222|RADIATION|Radiotherapy|Involved-Site Radiation Therapy 24Gy
41151375|NCT05929222|OTHER|Radiotherapy plus Obinutuzumab|Involved-Site Radiation Therapy 24Gy followed by Obinutuzumab 1000mg flat dose 4 doses weekly plus addition 4 doses every 3 weeks
41151376|NCT01874717|OTHER|Conscious sedation for dental care|
41151377|NCT01874717|DRUG|midazolam|
41314722|NCT05006521|DRUG|KN-002|KN-002 dry powder inhaler
41314723|NCT00199134|DRUG|Letrozole|Size of the tumor is followed
41002048|NCT04004728|PROCEDURE|1064 Nd:YAG laser|1064 laser - 135J 25ms spot 3mm GLicose - 75% - 3 ml
41002049|NCT04514601|OTHER|Standard Operating Protocol|This was a written protocol on how the handover process should be conducted.
41002050|NCT05909371|OTHER|exercise|Application of two different exercises to liver transplant individuals.
41002051|NCT05984355|OTHER|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential application and captors which suggest a Walking itinerary
41314724|NCT01165151|BEHAVIORAL|behavioral weight loss program|weekly, group-based lifestyle weight loss program
41314725|NCT03377010|OTHER|Dietary intake -Food Frequency Questionnaire|Dietary intake will be assessed using 2014 full-length food frequency questionnaire. The Block 2014 questionnaire combines a full-length food frequency questionnaire with a brief physical activity screening tool. The food and beverage list includes 127 items in the past 1 month, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
41314726|NCT03377010|OTHER|Receptivity to Participating in Diet Interventions|Study participants will rate their interest in learning more about dietary interventions to stay healthy using items developed specifically for this study. The items will be rated on a 3-point Likert-type scale from 3 (extremely interested) to 1 (not at all interested).
41314727|NCT01864798|DRUG|Denosumab|
41314728|NCT01204255|DRUG|lorazepam|Given topically
41314729|NCT01204255|DRUG|diphenhydramine hydrochloride|Given topically
41314730|NCT01204255|DRUG|haloperidol|Given topically
41314731|NCT01204255|OTHER|questionnaire administration|Ancillary studies
41314732|NCT01204255|OTHER|laboratory biomarker analysis|Correlative studies
41314733|NCT02300896|OTHER|Group-based exercise training during hospitalization|Exercise training. Individual program training 5 days a week during hospitalization
41314734|NCT02141646|BEHAVIORAL|Motivational Interviewing|The main goals of motivational interviewing are to engage clients, elicit change talk, and evoke motivation to make positive changes from the client.
41314735|NCT02141646|BEHAVIORAL|Behavioral Skills Training|Behavioral Skills Training (BST) is a training package that utilizes instructions, modeling, rehearsal, and feedback in order to teach a new skill.
41314736|NCT06007339|DEVICE|PerQseal ELITE|"The term PerQseal Elite used singularly refers to the closure system comprising the closure device and Introducer. These individually are referred to as: PerQseal Elite VCD or PerQseal Elite closure device and/or PerQseal Elite Introducer."
41314737|NCT05755334|DRUG|Ropivacaine|Administration of Ropivacaine
41314738|NCT03016546|BEHAVIORAL|BEST-maCARE|Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
41314739|NCT03016546|BEHAVIORAL|Attention Control Condition|The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
41314740|NCT04284020|BEHAVIORAL|Therapeutic educational program|See arm/group descriptions
41314741|NCT04284020|OTHER|PFMT|See arm/group descriptions
41314742|NCT04284020|OTHER|TTNS|See arm/group descriptions
41314743|NCT00330525|DRUG|sibutramine|
41314744|NCT05963048|DRUG|Rituximab|IV infusion 1000 mg
41002052|NCT03554291|DRUG|Famotidine 20 MG|Famotidine 20 mg capsule taken daily for 24 weeks.
41002053|NCT03554291|OTHER|Placebo|Placebo capsule taken daily for 24 weeks.
41002054|NCT00577512|DRUG|DTPACE|"* Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~* Thalidomide 200 mg by mouth (PO) Days 1-7~* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~* Adriamycin 15 mg/m2 Days 1-4~* Cyclophosphamide 600 mg/m2 Days 1-4~* Etoposide 60 mg/m2 Days 1-4"
41002055|NCT01127750|DRUG|FTY720|
41002056|NCT04216862|OTHER|Exercise|Different type of exercises for treatment of Forward Head Posture
41002057|NCT03680274|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
41002058|NCT03680274|OTHER|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
41002059|NCT04123496|DEVICE|rTMS|Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
41002060|NCT05449925|PROCEDURE|Injectable PRF and Microneedling|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
41002061|NCT01236404|DRUG|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
41002062|NCT01236404|DRUG|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
41151378|NCT01294358|DRUG|Gemcitabine|Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
41151379|NCT03160859|OTHER|Control|Unsedated colonoscopy with water exchange (WE) where the residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water is removed predominantly during insertion.
41002063|NCT06353490|DEVICE|Infrared Forehead Thermometer (GE-TF03)|Infrared Forehead Thermometer (GE-TF03) is an investigational device intended to measure body temperature on the forehead. GE-TF03 took three measurements for each subject.
41151380|NCT03160859|DEVICE|Study method|Unsedated colonoscopy with water exchange (WE + cap) and the addition of a cap fitted to the colonoscope.
41314745|NCT05963048|DRUG|IL6 inhibitor|6 mg/kg I V infusion monthly
41314746|NCT06017947|PROCEDURE|Music care|20 min music listening during transportation to hospital
41314747|NCT02021448|OTHER|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
41314748|NCT04257955|BEHAVIORAL|Interview and evaluation of Engagement|(i) the completion of the scheduled outpatients visit (ii) filling of the PHE-Scale® questionnaire by the patient to investigate the level of engagement and (iii) the completion of a semi-structured interview to assess the rate of understanding of the information received from the doctor.
41314749|NCT05838300|DEVICE|Warm humidified CO2|Participants will receive warm (37°C) and humidified (95%) CO2.The humidification and warming device to be used is AlwaysPneumo® AP 50/30 InsuflowPort® (Lexion Medical, FDA approved) which is a specialized port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source
41314750|NCT05838300|DEVICE|Dry CO2|Participants will receive standard cold (19-21 °C) and non-humidified (0%) CO2 insufflation with Airseal Insufflator
41314751|NCT00691262|DRUG|tacrolimus ointment|transdermal
41314752|NCT02517827|DEVICE|Atherectomy and paclitaxel-coated balloon angioplasty|Directional atherectomy and paclitaxel-coated balloon angioplasty (optional with stentimplantation) of the common femoral artery
41314753|NCT02517827|PROCEDURE|Open, surgical endarterectomy|open, surgical endarterectomy of the common femoral artery
41314754|NCT02695706|DEVICE|Laboratoires Mercurochrome Reparador|Developed for the treatment of damaged or fragile skin.
41314755|NCT01123577|OTHER|Home Blood Pressure Monitor Group|Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
41472720|NCT05453786|DRUG|SID1903|Single oral administration of SID1903 after an overnight fast
41314756|NCT01682499|DRUG|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
41314757|NCT04365998|DEVICE|BUBOLight® Device|1 session of phototherapy with BUBOLight® device during 4 hours.
41314758|NCT02289482|DRUG|GSK2838232 PIB (SDD)|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
41314759|NCT02289482|DRUG|GSK2838232 PIB (API)|GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
41314760|NCT02289482|DRUG|Placebo|Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
41472721|NCT05453786|DRUG|SID1903-R1/SID1903-R2|Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
41472722|NCT00002194|DRUG|Erythromycin|
41472723|NCT00002194|DRUG|Nevirapine|
41472724|NCT00002194|DRUG|Clarithromycin|
41002064|NCT06353490|DEVICE|Infrared Ear Thermometer (GE-TE06)|Infrared Ear Thermometer (GE-TE06) is an investigational device intended to measure body temperature in the ear canal. GE-TF06 took three measurements for each subject.
41002065|NCT06353490|DEVICE|Electronic Thermometer (MT-B321FB)|Electronic Thermometer (MT-B321FB) is an investigational device intended to measure body temperature on the temporal artery. MT-B321FB took three measurements for each subject.
41002066|NCT06353490|DEVICE|Electronic Thermometer (MT-B231)|Electronic Thermometer (MT-B231) is a reference device that measured axillary temperature one time for each subject.
41002067|NCT02099214|DEVICE|3Tesla cardiac MRI|
41002068|NCT02099214|DEVICE|Electrocardiogram (EKG)|
41002069|NCT02099214|BIOLOGICAL|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
41002070|NCT02099214|BIOLOGICAL|Pregnancy test|Beta-hCG
41002071|NCT02099214|DEVICE|Echocardiography at rest|Transthoracic echocardiograph
41002072|NCT02099214|BIOLOGICAL|Urinary pregnancy test|
41002073|NCT02099214|DEVICE|3Tesla abdominal MRI|
41002074|NCT01972672|DRUG|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
41002075|NCT05091307|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as an IM injection.
41002076|NCT05091307|OTHER|Placebo|Placebo will be administered as an IM injection.
41002077|NCT05091307|BIOLOGICAL|Influenza Vaccine|Influenza vaccine high and standard dose will be administered as IM injection.
41002078|NCT05393375|OTHER|No intervention|No intervention
41002079|NCT01310322|DRUG|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
41002080|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
41002081|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
41002082|NCT01310322|DRUG|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
41002083|NCT04360577|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).
41002084|NCT03492697|DRUG|PF-06882961 Immediate Release Tablet|Immediate Release Tablet
41002085|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (long)|Controlled Release tablet (long)
41002086|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (short)|Controlled Release tablet (short)
41002087|NCT03492697|DRUG|PF-06882961 Immediate Release Solution|PF-06882961 Immediate Release solution
41002088|NCT02333916|OTHER|overfeeding + exercise pre-training|
41472725|NCT06614660|OTHER|Metabolism genomics and imaging genomics|Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\&#39;s blood specimen was collected to collect metabolism genomics and imaging genomics.
41002089|NCT02333916|BEHAVIORAL|fitness training|
41002090|NCT02333916|OTHER|overfeeding + exercise post-training|
41002091|NCT05685472|BIOLOGICAL|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
41314761|NCT02289482|DRUG|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
41314762|NCT00808730|PROCEDURE|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
41314763|NCT05047159|DEVICE|rTMS|"Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex."
41472726|NCT02979457|BEHAVIORAL|Awareness of degree of worry|degree of worry is a definition made for this project. It is roothed in coping psychology but has been influenced by the construct of self-rated health. Will blinding of DOW have an effect on triage outcome.
41314764|NCT05047159|DEVICE|light therapy|Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.
41314765|NCT05047159|DEVICE|ECT|The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.
41472727|NCT06064825|OTHER|2 year follow-up of neurodevelopment using a parental questionnaire|A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
41472728|NCT02403739|OTHER|No Intervention|No Intervention
41472729|NCT02265406|DRUG|Anti-Infective Agents|
41002092|NCT00495716|DRUG|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
41472730|NCT02265406|DRUG|Placebo|
41472731|NCT02997878|BIOLOGICAL|Orbcel-C|Selected Mesenchymal Stromal Cells derived from human umbilical cord
41472732|NCT06474299|DRUG|Varenicline|0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (at least 8 hours apart) for 4 days prior to the TQD. On the 8th day (the TQD), participants will increase to their target maintenance dose of a 1 mg pill twice daily
41472733|NCT06474299|DRUG|Nicotine patch|Following package inserts starting on the TQD, participants who smoke \>10 cigarettes per day at baseline will be given 8 weeks of 21 mg nicotine patches, followed by 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Participants who smoke ≤10 cigarettes per day at baseline will be given 10 weeks of 14 mg nicotine patches followed by 2 weeks of 7 mg patches.
41472734|NCT06474299|BEHAVIORAL|Dual Focused Cessation Counseling|Dual Focused Cessation Counseling will focus on quitting both smoking and vaping. Specifically, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places such as the car or at specific times of day) prior to quitting and to practice cessation coping strategies (e.g., distraction techniques, getting social support).
40797829|NCT06375395|DEVICE|Sham tACS Device|Placebo Device that simulates active tACS treatment
40797830|NCT02678403|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
41002093|NCT00495716|DRUG|acyclovir|400 mg acyclovir orally twice daily for 1 year
41002094|NCT04347395|PROCEDURE|Respiratory Bundle & Prevention|The respiratory care bundle intervention comprised of: bed tilt, swallow screen, mouth wash and vaccinations. The bed tilt was a 30-degree whole bed-up positioning both day and night throughout the hospital stay and is shown in Figure 1. Swallow screen was undertaken within 48 hours of admission. Chlorhexidine mouth wash was prescribed initially four times daily. The protocol was amended to twice daily chlorhexidine mouth wash in August 2017 due to poor compliance with four times daily administration. Mouthwash administration was monitored in the intervention group only and deemed non-compliant if missed more than 3 times during the admission. Pneumococcal and influenza vaccination was offered at discharge or within 2-4 weeks post discharge, at no charge to the patient. Post discharge advice was to use pillows in bed to minimize the time the patient laid flat and to avoid lying down for an hour after meals.
41151381|NCT04928235|DIAGNOSTIC_TEST|Thermal Imaging as Diagnostic Adjunct|Thermal images of the participants lower extremities will be taken and skin surface temperature values will be provided to the healthcare provider for review during the emergency department encounter.
41314766|NCT05047159|DEVICE|MST|A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram \[EEG\] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.
41314767|NCT05047159|DRUG|drug therapy|There is no restriction on the choice of therapeutic drugs.
41314768|NCT03700788|DRUG|Chlorhexidine|2% Chorhexidine (intracranial; remains in canal until removal at next visit)
41314769|NCT03700788|DRUG|Calcium Hydroxide|Calcium Hydroxide (intracranial; remains in canal until removal at next visit)
41314770|NCT06092853|OTHER|Gingival crevicular fluid (GCF) and serum samples|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
41314771|NCT04296526|BEHAVIORAL|Exercise Prescription|To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.
41314772|NCT04296526|BEHAVIORAL|Exercise Education|To organize sessions for how to proper exercise.
41472735|NCT06474299|BEHAVIORAL|Smoking Focused Cessation Counseling|Smoking Focused Cessation Counseling will focus on quitting smoking and using ENDS as a harm reduction strategy (i.e., using ENDS as a substitute for cigarettes).
41472736|NCT06474299|OTHER|Counseling Intensity: 1 Session|Participants assigned to one session will complete a single, 15-20 minute, in-person session at Visit 2 (1 week pre-TQD).
41472737|NCT06474299|OTHER|Counseling Intensity: 4 Sessions|Participants assigned to intensive counseling will have four, 15-20-minute sessions, one in-person at Visit 2 and then 3 phone sessions: 1 day post-TQD and Weeks 1 and 2.
41472738|NCT03336879|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
41472739|NCT00002006|DRUG|Zidovudine|
41472740|NCT00002006|DRUG|Sargramostim|
41472741|NCT04344197|OTHER|global survey|surgery questionnaire
41472742|NCT04638270|BIOLOGICAL|anti-CD19 FasT CAR-T cells|Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion.
41472743|NCT03791294|DRUG|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
41472744|NCT01749358|BEHAVIORAL|Accelerated Skill Acquisition Program (ASAP)|A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
41314773|NCT04296526|BEHAVIORAL|Social Support|Supports such as peer influence or reminder phone messages
41472745|NCT01749358|BEHAVIORAL|Active Monitoring|This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
41472746|NCT01111214|OTHER|no intervention|There is no intervention. This is a non interventional study.
41472747|NCT01922219|BEHAVIORAL|Cognitive Behavioral Therapy|14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
41472748|NCT04225286|OTHER|Human breast milk|Intranasal human breast milk
41472749|NCT01897623|OTHER|ultrasound of aorta|
41472750|NCT01034852|PROCEDURE|Totally Thoracoscopic Maze|Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
41002095|NCT00806884|OTHER|Physiotherapy Musculoskeletal Treatment|Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
41314774|NCT06289400|DEVICE|Magnetic field application|The applicator (Size: 15x15 cm) has placed 1-3 cm above the skin surface at the painful area. During the treatment, treatment has applied with ready-made protocols included in the device.
41314775|NCT06289400|OTHER|Conventional treatment|Within the scope of conventional treatment, hotpack application, transcutaneous electrical stimulation (TENS), interferential current and ultrasound treatment modalities will be applied. In addition, strengthening exercises will be applied to the muscles around the hip and knee and stretching exercises will be applied to the short muscle groups.
41314776|NCT06389188|PROCEDURE|RHB Group|The RHB-group were treated with passive manual therapy (P-MT) by soft tissue mobilization, massage and muscular stretching of the anterior and posterior cervical muscles; active therapeutic exercises (A-TE); and oculo-cervical exercises (OC-E). Patients received a total of 20 sessions of 30 minutes each during 4 weeks
41314777|NCT00503490|DRUG|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
41314778|NCT00503490|DRUG|placebo|BID
41314779|NCT04313361|OTHER|No intervention|No drug will be administered as part of this study.
41314780|NCT01477372|BEHAVIORAL|Supervised exercise program|Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
41472751|NCT03858127|OTHER|Collection of urine sample|Collection of urine sample for measurement of LH and FSH
41472752|NCT03858127|OTHER|Examination of genitalia|Examination of genitalia
41472753|NCT03858127|OTHER|Video messaging|Short video of infant recorded at home by the parents
41314781|NCT02843646|DEVICE|Walk Aide training|
41314782|NCT01273389|DRUG|CNTO 136|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
41314783|NCT01273389|DRUG|Placebo|Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
41314784|NCT02797548|DRUG|Aspirin only|Aspirin only during surgery
41314785|NCT02797548|DRUG|No antiplatelet therapy|No antiplatelet therapy will be during surgery
41472754|NCT05265065|BIOLOGICAL|Tozinameran - Standard Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose."
41472755|NCT05265065|BIOLOGICAL|Tozinameran - Fractional Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose."
41472756|NCT01032460|DEVICE|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
41472757|NCT01032460|DEVICE|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
41472758|NCT01032460|DEVICE|intubate with the Airtraq device|intubate with the Airtraq device
41002096|NCT00806884|OTHER|Control group measurements|None other than control group measurements
41002097|NCT00709371|DRUG|Zonisamide SR placebo/ bupropion SR placebo|2 placebo combination tablets twice daily for 16 weeks (maintenance period)
41002098|NCT00709371|DRUG|Zonisamide SR placebo/ bupropion SR 360 mg/day|2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
41002099|NCT00709371|DRUG|Zonisamide SR 120 mg/day/ bupropion SR placebo|2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
41002100|NCT00709371|DRUG|Zonisamide SR 360 mg/day/ bupropion SR placebo|2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
41002101|NCT00709371|DRUG|Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
41002102|NCT00709371|DRUG|Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
41472759|NCT01677208|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
40797831|NCT02678403|DEVICE|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
41002103|NCT00482079|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
41002104|NCT00482079|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
41002105|NCT05321862|DRUG|[68Ga]Ga-PentixaFor|Tomography by Emission of Positons (PET) with the radiopharmaceutic \[68Ga\]Ga-PentixaFor
41002106|NCT01303575|BEHAVIORAL|HIV, STI and Pregnancy Prevention Curriculum|"A complete internet-based, It's Your Game...Keep It Real Intervention Program"
41002107|NCT01303575|BEHAVIORAL|Control Curricula|A computer-based, science education program that does not contain elements of sexual health education
41002108|NCT06237153|DRUG|Triamcinolone Acetonide extended release suspension|Active steroid
41002109|NCT04482296|DRUG|SSRI with Zinc Sulfate|Zinc sulfate (30 mg) once daily for 8 weeks SSRI
41002110|NCT00838227|DRUG|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
41002111|NCT00323414|DRUG|Polyunsaturated fatty acid (Opti-EPA)|Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
40797832|NCT02749201|DEVICE|Gastrisail|Light Intensity and gastric wall thickness assessment
41002112|NCT00323414|DRUG|Placebo|Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
41002113|NCT04871295|BEHAVIORAL|Noom Healthy Weight|Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
41002114|NCT01596764|DRUG|Loperamide placebo|200 ml apple juice
41002115|NCT01596764|DRUG|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
41002116|NCT01596764|DEVICE|Colon Transit|5 capsules containing radio-opaque markers of different shapes, respectively
41002117|NCT01596764|DRUG|Sulfasalazine|Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
41002118|NCT01596764|DRUG|Placebo of MNTX and NLX|Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
41314786|NCT03769935|DRUG|cis Platinum, etoposide, S1|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
41002119|NCT01596764|DRUG|Naloxone|Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
41314787|NCT05725421|PROCEDURE|Donor Radical and Partial Nephrectomy|Donor participants will undergo laparoscopic radical nephrectomy (RN) . Donor kidney then will undergo cold perfusion and ex-vivo partial nephrectomy (PN) with cold ischemia. During PN, careful inspection of tumor will be performed to ensure it is well-encapsulated. If any infiltrative features (versus well encapsulated tumor) are noted intraoperatively then transplant will not be performed. Multiple surgical margins will be sent (either frozen section or standard with priority). If final margins are positive or concerning, then transplant will not be performed. Biopsies of the tumor will be performed and sent to pathology (either frozen section or standard with priority).
41314788|NCT05725421|PROCEDURE|Kidney Transplantation|The donor kidney will remain on ice while pathologic analysis is performed, and transplant recipient surgery is initiated (if pathologic analysis satisfactory). Cold ischemia with delay for pathology will have minimal functional impact in this setting based on extensive prior experience with renal transplantation where kidneys are routinely kept hypothermic for several hours prior to transplantation.
41314789|NCT05725421|PROCEDURE|Laparoscopic Radical Nephrectomy|Radical nephrectomy consists of the removal of the kidney together with the perirenal fat and regional lymph nodes. The transperitoneal approach allows early control of the renal vessels.
41314790|NCT03677895|DRUG|Hyaluronic Acid|Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
41002120|NCT01596764|DRUG|Methylnaltrexone|Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
41002121|NCT03053895|PROCEDURE|CSDH - Bedside twist drill technique|For patients randomized to bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic
41472760|NCT01677208|PROCEDURE|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
41002122|NCT03053895|PROCEDURE|CSDH - Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
41002123|NCT01907828|DEVICE|Renal Artery Ablation|Renal artery denervation using the EnligHTN™ Renal Denervation System
41002124|NCT01907828|DEVICE|Cardiac Ablation|Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
41002125|NCT00231348|DRUG|Nefazodone|
41002126|NCT00934739|DRUG|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
41002127|NCT00934739|DRUG|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
41002128|NCT04736238|PROCEDURE|Arthroscopy surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. Establish an anteromedial channel at the inner side of the tibial anterior tibial tendon at the level of the tibiotalar joint, and establish an anterolateral channel at the lateral angle of the talus. Exploring and clearing the ankle joint and dealing with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then observe the lateral sulcus through the anterior medial channel, clean the synovium in the lateral sulcus, and explore the anterior talofibular ligament. A double-line anchor was inserted into the fibula side stop of the anterior talofibular ligament through the anterolateral channel. The anterior talofibular ligament was sutured using an outside-in technique in the anterior inferior safety zone of the distal end of the fibula. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
41151382|NCT05873816|DEVICE|ProtEmbo - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
41151383|NCT05873816|DEVICE|Sentinel - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
41314791|NCT03013205|PROCEDURE|Intraarticular triamcinolone injection|triamcinolone 10mg/mL
41314792|NCT03013205|PROCEDURE|Intraarticular Xylocaine injection|Xylocaine 1% 4ml
41472761|NCT01677208|DRUG|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
41002129|NCT04736238|PROCEDURE|BrostrÖm surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. The first ankle arthroscopy is performed to deal with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then, open surgery was performed, and an arc incision was made at the anterior edge of the lateral malleolus to the tip of the fibula. After separating the subcutaneous tissue, the anterolateral joint capsule and talofibular ligament are exposed. A double-line anchor was placed at the fibular side stop of the anterior talofibular ligament. Tighten and suture the anterior talofibular ligament, anterolateral joint capsule, and extensor support belt with an anchor band. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
41002130|NCT05395962|DRUG|Carboplatin|treatment with bleomycin and carboplatin in association with electroporation
41002131|NCT05395962|DRUG|Bleomycin|treatment with bleomycin in association with electroporation
41002132|NCT01307566|DEVICE|Continuous Positive Airway Pressure CPAP|CPAP treatment
41002133|NCT05583903|OTHER|Virtual Reality Software|The ReCognition virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
41151384|NCT05085015|OTHER|Functional Exercise Training Group|"Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. The training will be given on the treadmill Treadmill Technogym. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end."
41314793|NCT03013205|PROCEDURE|Coracohumeral ligament triamcinolone injection|triamcinolone 10mg/mL
41314794|NCT03013205|PROCEDURE|Physiotherapy|
41314795|NCT03671382|BEHAVIORAL|Communication Training Program and Patient Prompt Sheet|The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
41314796|NCT03775096|DRUG|Carvedilol|At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
41472762|NCT05730712|PROCEDURE|Biopsy|Undergo biopsy
41472763|NCT05730712|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
41472764|NCT05730712|PROCEDURE|Computed Tomography|Undergo CT
41472765|NCT05730712|PROCEDURE|Echocardiography|Undergo ECHO
41472766|NCT05730712|DRUG|Enzalutamide|Given PO
41472767|NCT05730712|DRUG|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
41472768|NCT05730712|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41002134|NCT03493490|DRUG|Neodolpasse|Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
41151385|NCT05085015|OTHER|Home Exercise Training Group|Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. They will walk at least 30 minutes, 3 days a week for 8 weeks at outdoor. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end.
41151386|NCT00275678|PROCEDURE|Blood stem cell versus bone marrow transplant|"1. Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI.~2. Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state and at least 120 mg/kg cyclophosphamide.~3. Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of least 120 mg per m2 and a melphalan dose of at least 140 mg per m2.~4. Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG. Institutional standards should be followed for targeting plasma levels."
41151387|NCT04431739|DEVICE|MRI including conventional MRI, DWI with multiple ADC values|The utility of apparent diffusion coefficient obtained in diffusion-weighted MR imaging for the differentiation between benign and malignant vertebral lesions
41151388|NCT04100564|DEVICE|Supraglottic airway device|Initial advanced airway management with a supraglottic device
41151389|NCT04100564|OTHER|Standard airway management|Initial advanced airway management with standard care method
41151390|NCT01531478|OTHER|Unique medical visit of the study|"The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.~After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia)."
41151391|NCT02347839|PROCEDURE|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
41151392|NCT02873442|PROCEDURE|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
41314797|NCT01954472|BEHAVIORAL|Enhanced portfolio plus structured exercise|"Foods on the dietary portfolio plan will contribute 9g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1g plant sterol/1000 kcal diet (in sterol margarine), 22.5g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese), and additional sources of plant protein from pulses (eg. Lentils, chickpeas, beans, etc) and 22.5g almonds or equivalent of other nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: The physical activity/exercise program is based on the program used at the Quebec Heart and Lung Institute."
41314798|NCT01954472|BEHAVIORAL|High fiber diet plus routine exercise|"Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce meat consumption, choose low fat dairy products and a control margarine.~Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided."
41314799|NCT00432094|DRUG|carboplatin|Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes
41314800|NCT00432094|DRUG|etoposide|600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
41314801|NCT00432094|DRUG|ifosfamide|2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
41151393|NCT02873442|BIOLOGICAL|Precision Cells|"DC cell suspension (1×107 DC+ physiological saline~+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
41151394|NCT02825849|BIOLOGICAL|Intrauterine infusion of platelet rich plasma|Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.
41314802|NCT00432094|DRUG|paclitaxel|225 mg/m\^2 intravenous over 3 hours on Day -7.
41314803|NCT00432094|DRUG|thiotepa|150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
41314804|NCT00432094|PROCEDURE|autologous hematopoietic stem cell transplantation|Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)
41314805|NCT00432094|DRUG|Mesna|2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
41002135|NCT03493490|DRUG|Diclofenac|Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
41002136|NCT03493490|DRUG|Placebo|Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
41002137|NCT04270500|BEHAVIORAL|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
41002138|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg|
41002139|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg|
41002140|NCT02667938|DRUG|HGP1201|
41472769|NCT05730712|OTHER|Questionnaire Administration|Ancillary studies
41472770|NCT01215071|PROCEDURE|limited lymphadenectomy|Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
41472771|NCT01215071|PROCEDURE|extended lymphadenectomy|Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
41472772|NCT04350008|DEVICE|Renamic Neo programmer device, including software; PK-222-L ECG cable|Patients were enrolled either for implantation including subsequent pre-hospital discharge or for a follow-up visit only. ICM patients were included for follow-ups only. Implants were programmed and interrogated by using the investigational devices.
41472773|NCT06595147|BEHAVIORAL|Structured Exercise Training|Participants will complete 12-weeks of supervised, structured moderate-to-high intensity aerobic and resistance training three times per week.
41472774|NCT06595147|BEHAVIORAL|Group-based Yoga and Stretching|Participants will complete 12-weeks of supervised group-based yoga and stretching once per week.
40797833|NCT01871545|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
40797834|NCT05077540|DRUG|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
40797835|NCT05077540|DRUG|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
40797836|NCT04981964|PROCEDURE|Exercise training|both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles
40797837|NCT02378077|PROCEDURE|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
40797838|NCT02378077|PROCEDURE|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
40797839|NCT02378077|DIETARY_SUPPLEMENT|Fish Oil Supplement|Fish Oil supplementation for three months.
40797840|NCT00127491|PROCEDURE|Placement of an esophageal balloon measurements|In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
40797841|NCT00127491|OTHER|Low tidal volume ventilation|Low tidal volume ventilation strategy (ARDSnet)
41472775|NCT03899649|DRUG|SOC|Standard of Care treatment
40797842|NCT00127491|OTHER|Transpulmonary pressure-directed ventilation (EPVent)|Transpulmonary pressure-directed ventilation using measurements from the esophageal balloon.
40797843|NCT03302910|OTHER|Short Stay Unit|Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.
40797844|NCT03302910|OTHER|Standard of Care|Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.
41151395|NCT03886688|DRUG|HEC53856|oral administration
41472776|NCT03899649|DEVICE|NanoKnife System|Irreversible Electroporation
41472777|NCT00380549|DIAGNOSTIC_TEST|Blood ion levels|Blood ion levels or the levels of cobalt and chromium ions in the blood and urine will be analyzed.
41472778|NCT06315517|OTHER|Conventional lactose-free cow's milk|"Participants will receive conventional lactose-free cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
41002141|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg placebo|
41002142|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg placebo|
41002143|NCT02667938|DRUG|HGP1201 placebo|
41151396|NCT03886688|DRUG|placebo|oral administration
41472779|NCT06315517|OTHER|Nonconventional (A2) cow's milk|"Participants will receive nonconventional (A2) cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
41002144|NCT05794256|OTHER|No interventions are planned|No interventions are planned
41002145|NCT03439371|OTHER|HLA-mismatched micro-transplantation after induction chemotherapy|HLA-mismatched micro-transplantation after induction chemotherapy
41002146|NCT02272413|DRUG|BI 695502|
41314806|NCT00432094|BIOLOGICAL|filgrastim|Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
41002147|NCT02272413|DRUG|Avastin|
41002148|NCT01469468|DRUG|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
41002149|NCT01469468|DRUG|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
41314807|NCT01348425|DEVICE|Longer Zilver PTX Stents|Treatment with at least one 100 mm or longer Zilver PTX stent
41314808|NCT01348425|DEVICE|Shorter Zilver PTX Stents|Treatment with Zilver PTX stents 80 mm or shorter only
41314809|NCT04305886|OTHER|Discussion Guide|Written list of prompts to facilitate discussion
41314810|NCT02557360|DIETARY_SUPPLEMENT|S-adenosyl-L-methionine|Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
41314811|NCT00852189|DRUG|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
41314812|NCT00852189|DRUG|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
41314813|NCT00852189|DRUG|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
41314814|NCT01782456|OTHER|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
41314815|NCT01449201|DRUG|PF-00299804|45 mg P.O. Daily (28-day treatment as one treatment cycle)
41472780|NCT06315517|OTHER|Nonconventional (A2) lactose-free cow's milk|"Participants will receive nonconventional (A2) lactose-free cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
41472781|NCT05190523|DRUG|ASC42 5 mg|5 mg of ASC42 tablets orally once daily for 12 weeks.
41472782|NCT05190523|DRUG|ASC42 10 mg|2 x 5 mg of ASC42 tablets orally once daily for 12 weeks.
41472783|NCT05190523|DRUG|ASC42 15 mg|15 mg of ASC42 tablets orally once daily for 12 weeks.
41002150|NCT03897790|OTHER|Transcranial Doppler (DTC)|Evaluation of Vasoconstrictor Vasoreactivity with Transcranial Doppler
41002151|NCT02273648|DEVICE|Drug Eluting Stent (DES)|Percutaneous Coronary Intervention
41002152|NCT02405416|PROCEDURE|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
41002153|NCT02405416|PROCEDURE|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
41002154|NCT02405416|PROCEDURE|Portal triad clamping|Portal triad are clamped in hepatectomy.
41002155|NCT04359368|OTHER|collection of patient data|Data collection (history, clinical presentation, medication, complications, laboratory testing) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs.
41002156|NCT00006125|DRUG|doxorubicin hydrochloride|
41002157|NCT00006125|DRUG|topotecan hydrochloride|
41002158|NCT02755376|BIOLOGICAL|Cartistem(TM)|ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.
41002159|NCT02755376|BIOLOGICAL|hyaluronic acid|ACL reconstruction and injection of hyaluronic acid under arthroscopy.
41002160|NCT02755376|PROCEDURE|ACL reconstruction only|ACL reconstruction only without any injection under arthroscopy
41002161|NCT02188615|PROCEDURE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
41002162|NCT02188615|DRUG|Cisplatin|only Radical Chemoradiotherapy
41002163|NCT02188615|DEVICE|Mckeown MIE|only Mckeown MIE using thoracoscopy and laparoscopy
41002164|NCT03196011|OTHER|TKR with mechanical alignment method|TKR implanted using traditional mechanical alignment methods
41002165|NCT03196011|OTHER|TKR with alternative alignment method|TKR implanted using alternative alignment methods
41002166|NCT05199480|DRUG|Tobacco flavored liquid type 1|A commercially available cartridge-based device with tobacco flavored liquid.
41002167|NCT05199480|DRUG|Tobacco flavored liquid type 2|A commercially available cartridge-based device with tobacco flavored liquid.
41151397|NCT03266003|OTHER|Electronic DOT|"Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded)."
41151398|NCT03266003|OTHER|In-person DOT|A trained person is in the physical presence of patients as anti-TB drugs are ingested.
41314816|NCT01429792|DRUG|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
41314817|NCT01429792|DRUG|ribavirin [Copegus]|standard treatment, orally daily
41472784|NCT05190523|DRUG|Placebo|Placebo tablets orally once daily for 12 weeks.
41472785|NCT03998709|DRUG|Somatostatin|Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study
41472786|NCT03998709|OTHER|Dextrose|intravenous glucose will be used to raise fasting glucose in people with NFG / NGT
41472787|NCT03998709|DRUG|Insulin|insulin will be used to lower fasting FFA and glucose in people with IFG / IGT
41472788|NCT03998709|OTHER|Intralipid|intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT
41472789|NCT02639728|OTHER|Regular Coffee|Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
40797845|NCT01901614|PROCEDURE|LALAK|"1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
41151399|NCT00965393|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
41151400|NCT00965393|DRUG|Placebo|Systemic infusion of placebo (saline)
41472790|NCT02639728|OTHER|Decaffeinated coffee|Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
41472791|NCT02639728|OTHER|Warm water|Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
41472792|NCT06502652|OTHER|hippotherapy|A hippotherapy simulator is a horse riding simulator exercise machine, mimicking a horse's gait and recreating the horseback riding experience within the safety of a therapy clinic. Child with down syndrome will be seated on the stimulator for 10-15 minutes every session. The patient's pelvis moves softly, rhythmically, and repetitively when riding this action is comparable to what the human pelvis does when walking normally
41472793|NCT06502652|OTHER|balance training|The therapist modified the railing height to suit each child, ensuring the children were standing erect on the treadmill. Treadmill training completed under three conditions in 1-min training cycles. For 15 s of each minute the child could hold on to the railings with both hands, for the next 15 s with one hand, and finally with no hands on the handrails for 30 s. Each child repeated this procedure 20 Times and cool down for 5 minutes
41472794|NCT05650424|OTHER|Abdominal massage training|please refer to group description
41472795|NCT03399994|DEVICE|device implantation during coronary angioplasty|device implantation during coronary angioplasty
41151401|NCT00965393|DRUG|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
41314818|NCT01908517|BEHAVIORAL|HPV Vaccine Electronic Reminders|The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
41472796|NCT01909934|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion
41472797|NCT05518032|PROCEDURE|Biopsy|Undergo biopsy
41472798|NCT05518032|BIOLOGICAL|Pembrolizumab|Given IV
41472799|NCT05518032|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Given intratumorally
41314819|NCT00789958|DRUG|capecitabine|"Adjuvant chemotherapy: 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT"
41314820|NCT00789958|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, IV, Days 1 \& 8 of each cycle
41472800|NCT00003098|OTHER|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
41002168|NCT04320940|DRUG|Phenobarbital Sodium Injection|The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
41314821|NCT00789958|RADIATION|3-dimensional conformal radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
41314822|NCT00789958|RADIATION|intensity-modulated radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
41002169|NCT05256121|OTHER|AD Risk factors balance|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants by phone every 3-4 weeks to inquire about risk factors data. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
41314823|NCT04558788|DIAGNOSTIC_TEST|Immunohistochemistry on intestinal biopsies|Immunohistochemistry will be performed on human intestinal biopsies
41314824|NCT01493986|DRUG|Ropivacaine|Dosage. Onset time
41472801|NCT00003098|OTHER|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
41472802|NCT01672359|DIETARY_SUPPLEMENT|Ginkgo Synergy® and Choline|3 tablets 2 times per day with breakfast and dinner over 6 months
41472803|NCT01672359|DIETARY_SUPPLEMENT|OPC Synergy® and Catalyn|3 tablets 2 times per day with breakfast and dinner over 6 months
41472804|NCT01672359|DIETARY_SUPPLEMENT|Placebo|
41472805|NCT06164028|OTHER|cognitive interview|Participants will take part in a semi-structured qualitative interview (\~1 hour).
41472806|NCT05721651|DRUG|Fruquintinib+PD-1|"This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib（4mg orally, once daily for 3 wks on/1 wk off ）combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.~PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;"
40797846|NCT01901614|PROCEDURE|IEK|"1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
40797847|NCT01901614|DRUG|Retrobulbar Block or General Anesthesia|
41314825|NCT05522894|DRUG|AK104|10mg/kg IV every 3 weeks (Q3W)
41314826|NCT05522894|DRUG|Cisplatin|75mg/m2 IV every 3 weeks (Q3W)
41314827|NCT05522894|DRUG|Paclitaxel|175mg/m2 IV every 3 weeks (Q3W)
41314828|NCT05208203|OTHER|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
41472807|NCT03919487|PROCEDURE|Back to back colonoscopy|After first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed.
41472808|NCT01353846|OTHER|observation natural cycle|The patients natural reproductive cycle will be observed and compared to the second arm.
41472809|NCT01353846|DRUG|Agonist GnRH; estradiol Valerate; progesterone|Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
41472810|NCT05699291|OTHER|Sentinel node detection technique|Patients cared for by a surgeon for histologically proven breast cancer and for whom an indication for detection of the sentinel lymph node is posed.
41472811|NCT06469619|BEHAVIORAL|Music listening|Listening to music of one's choice one hour daily.
41472812|NCT06026631|PROCEDURE|Lipidomic analysis for breast cancer patients|Lipidomic analysis for breast cancer patients
41472813|NCT00201916|PROCEDURE|5250 cGy/20 fractions over 28 days|see above
41472814|NCT00201916|PROCEDURE|6600 cGy/33 fractions over 45 days|see above
40797848|NCT01901614|DEVICE|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
40797849|NCT01901614|DRUG|Topical Anesthesia|
40797850|NCT01901614|DEVICE|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
40797851|NCT02165943|DEVICE|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
40797852|NCT03519724|DRUG|Sugammadex|Reversal of deep NMB
41314829|NCT03363412|DEVICE|PTFE-covered stent grafts|Creation of a small diameter intrahepatic shunt between portal and hepatic veins.
41314830|NCT04881240|BIOLOGICAL|CD19-CAR(Mem) T-cells|Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion
41314831|NCT04881240|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
41314832|NCT04881240|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.
40797853|NCT03519724|DRUG|Neostigmine|Reversal of moderate NMB
40797854|NCT02967549|DEVICE|NAVA|NAVA delivered by the Servo-n ventilator (Maquet)
40797855|NCT02967549|DEVICE|PAV|PAV delivered by the Stephanie ventilator (Stephan)
40797856|NCT05331053|DRUG|Atorvastatin|Simvastation acts as a systemic LOX inhibitor.
40797857|NCT03393897|OTHER|Trans oesophageal echocardiography|Transoesophageal echocardiography : it's a standard practice for this patient
40797858|NCT03393897|OTHER|Trendelenburg test|Trendelenburg test : it's a standard practice for this patient
40797859|NCT05833009|DEVICE|Acupuncture|All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
40797860|NCT04362800|OTHER|MRI|MRI at baseline and J90
40797861|NCT04362800|OTHER|Electro-Encephalography-High Density|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
40797862|NCT04362800|OTHER|3D and EMG analysis|3D and EMG analysis at baseline and J90
40797863|NCT04362800|OTHER|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
40797864|NCT03198481|BEHAVIORAL|Patient-Centered Counseling Video|Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.
40797865|NCT03198481|BEHAVIORAL|Physician Counseling Video|Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
40797866|NCT05053074|DEVICE|Nasal High Flow (NHF)|Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.
40797867|NCT04283955|DRUG|High-dose MTX based chemotherapy|Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6\~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7\~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
41151402|NCT03838159|DRUG|Paclitaxel|"Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected."
41151403|NCT03838159|DRUG|Carboplatin|Carboplatin must be administered at the end of the Paclitaxel infusion
41314833|NCT04881240|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.
41314834|NCT04881240|DEVICE|CliniMACS|A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.
41314835|NCT04881240|PROCEDURE|Leukapheresis|Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.
41314836|NCT05464862|DRUG|Popliteal Plexus Block with 10 ml|Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml
41472815|NCT01936311|BEHAVIORAL|Self-management goal elicitation|The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
41472816|NCT04081441|DEVICE|Inyenyeri clean cookstove and fuel system|The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp
40797868|NCT03180333|DRUG|PNA|
40797869|NCT03180333|DRUG|PNA placebo|
40797870|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
40797871|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
40797872|NCT00749788|DRUG|Placebo|Matching placebo tablets, oral, 30 minutes after the start of the morning meal
40797873|NCT05339399|OTHER|oxytocin augmentation|Only observation of the outcome
40797874|NCT00191399|DRUG|Olanzapine|
40797875|NCT00191399|DRUG|Fluoxetine|
40797876|NCT04588220|OTHER|Obstetric ultrasound and fetal-maternal assessment|melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
41314837|NCT05464862|DRUG|Popliteal Plexus Block with 20 ml|Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml
41314838|NCT05464862|DRUG|Popliteal Plexus Block with 30 ml|Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml
40797877|NCT02205268|PROCEDURE|Near infrared spectroscopy neurofeedback training|
40797878|NCT05018598|DRUG|Administration via pressurized metered dose inhaler (pMDI)|CHF5993 pMDI
40797879|NCT05018598|DRUG|Administration via pressurized metered dose inhaler (pMDI)|CHF1535 pMDI or CHF5993 pMDI
41314839|NCT05464862|DRUG|Femoral Nerve Block|Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.
41314840|NCT05464862|DRUG|Sciatic Nerve Block|Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
41314841|NCT05378516|OTHER|no intervention|no intervention
41314842|NCT06552416|DRUG|MT-401-OTS|MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.
40797880|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
40797881|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
40797882|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
40797883|NCT02427139|DEVICE|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
41002170|NCT05180903|OTHER|X-tra base & GrandioSO reinforced by Ribbond|The missing peripheral tooth structure will be built up via 2-mm wedge-shaped a universal hybrid resin composite, GrandioSO . Then the polyethylene fibers will be wetted with an unfilled resin first . After removing the excess resin, fibers will be covered with a very thin layer of flowable composite X-tra base . After that, fibers will be bonded immediately against the peripheral missing walls and cured for 20 seconds. Then a bulk-fill flowable resin composite lining X-tra base will be applied in approximately 4 mm thick in bulk increments as needed to fill the cavity 2 mm short of the occlusal cavosurface and each increment will be light cured for 20 s. The remaining occlusal part of the cavity will be restored with a universal hybrid resin composite, GrandioSO . The shade of the composite will be selected according to the teeth to be restored. All cavities will be restored with open-sandwich technique (Deliperi, et al. 2017).
41002171|NCT03910218|BEHAVIORAL|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring, PrEP eligibility screening,PrEP/nPEP services (labs, medication), healthcare planning/coordination, MI counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
41314843|NCT04850716|OTHER|non-intervention|non-intervention
41314844|NCT00110318|PROCEDURE|Manual therapy and therapeutic exercise|
41314845|NCT00110318|PROCEDURE|Corticosteroid injections|
41314846|NCT01876394|OTHER|Coconut Oil|Shake with 50 g Coconut oil
41314847|NCT01876394|OTHER|Canola Oil|Shake with 50 g Canola oil
41314848|NCT01876394|OTHER|Grapeseed Oil|Shake with 50 g Grapeseed oil
41314849|NCT01876394|OTHER|Chia Oil|Shake with 50 g Chia oil
41314850|NCT01876394|OTHER|Butter|Shake with 50 g Butter
41314851|NCT06400316|DIETARY_SUPPLEMENT|Amino Acid Supplement|The intervention lasts 4-week following the rheumatoid arthritis flare. It requires twice daily consumption of amino acid supplements alongside the breakfast and lunch time meals.
41314852|NCT04912570|PROCEDURE|Manual Thrombus Aspiration|Manual thrombus aspiration using one of the FDA approved aspirators will be done.
41314853|NCT04912570|PROCEDURE|Standard PCI|Standard PCI according to the most recent guidelines
41314854|NCT02062463|DRUG|Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX|SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 μg)
41314855|NCT02062463|DRUG|SYMBICORT TURBOHALER budesonide and formoterol fumarate|SYMBICORT® TURBOHALER® (200/6 and 400/12 μg)
41314856|NCT01869751|DRUG|Prucalopride|Treatment with prucalopride for slow-transit constipation
41314857|NCT02165033|DRUG|Budesonide/Procaterol 180/10 X 4 puffs|Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
41314858|NCT02430428|DEVICE|Carl Zeiss Meditec VisuMax Femtosecond Laser|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
41314859|NCT00530556|DRUG|zolpidem|
41314860|NCT03225716|DRUG|Ulocuplumab|Ulocuplumab is a type of protein called an antibody that attacks CXCR4
41314861|NCT03225716|DRUG|Ibrutinib|Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
41314862|NCT00946881|DRUG|WST 11 -mediated -VTP|The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
41314863|NCT04669041|DRUG|Rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
41314864|NCT04669041|DRUG|SPC ezetimibe/rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
41314865|NCT04669041|DRUG|Rosuvastatin active capsule|Pharmaceutical form:Capsule Route of administration: Oral
41314866|NCT04669041|DRUG|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
41314867|NCT04669041|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
41472817|NCT04081441|BEHAVIORAL|I-ACT (Individual, Agency-Centered Training) workshop|The I-ACT (Individual, Agency-Centered Training) empowerment workshop consists of behavioral exercises drawn primarily from positive psychology, that provide the tools to foster a growth mindset by allowing participants to understand the link between their thoughts, beliefs, and past actions to their future actions. Conducted in a workshop setting, this locally adapted version of the I-ACT curriculum consists of two days for women and a 1 day workshop for their male partners (as applicable)
41472818|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group I: 10 patients will be treated with Lysis and lavage
40797884|NCT04833660|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a safe, noninvasive, and effective therapeutic intervention that uses an electromagnetic coil applied to the scalp to produce a magnetic field. rTMS induces changes in cortical excitability at the stimulation site and transsynaptically at distant areas. Cortical excitability is increased by high-frequency (≥5 Hz) stimulation and is decreased by low-frequency (1 Hz) stimulation. The application of high-frequency unilateral rTMS to the motor cortex in patients is reported to have a potential to control various types of pain, such as neuropathic pain, fibromyalgia, and musculoskeletal origin pain (myofascial pain syndrome, shoulder pain, and lower back pain).
41314868|NCT02278640|DEVICE|Harmonic ACE®+7 Shears|Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
41314869|NCT04528797|DRUG|Levothyroxine|
41314870|NCT04528797|DRUG|Methylprednisolone|
41472819|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group II: 10 patients will be treated with operative arthroscopy
41472820|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group III: 10 patients will be treated with operative arthroscopy + discopexy
41472821|NCT00717496|OTHER|Telephone Support Intervention to Improve Breastfeeding|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. Both groups will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
41472822|NCT02985398|BIOLOGICAL|ALD403 (Eptinezumab)|
41472823|NCT06615908|DRUG|Psilocybin|See treatment arm description.
40797885|NCT03840044|OTHER|Cold air exercise test|Subjects will perform a submaximal 90 minutes exercise test in a controlled cold air environment (-5°C, 60% relative humidity) in a climate chamber with evaluation pre§/during\*/post§ of heart rate (HR)§\* and blood pressure (BP)§\*, spirometry§\*, PNIF§, FeNO§, electrocardiogram (ECG)§\*, body \& exhaled air temperature§\*, capsaicin cough threshold test§, histamine bronchial challenge test§, and sampling of nasal fluid§, induced sputum§, and venous blood§.
40797886|NCT03665766|DRUG|Cycloserine,Tacrolimus|
41002172|NCT03910218|BEHAVIORAL|Usual Care|Participant will receive usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling, substance use treatment referrals, PrEP/nPEP referrals
41002173|NCT03633981|OTHER|clinical examinations|"Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery:~* right and left pupillometry (3 times)~* BIS values~* right and left NIRS values~* right and left transcranial Doppler~* neurological clinical examination"
41472824|NCT00638833|DRUG|Memantine|Memantine 30 mg/day (20-10-0)
41472825|NCT00638833|DRUG|Placebo|Placebo pills
41002174|NCT03633981|OTHER|neurological assessment when a neurological event occurs|"next neurological event:~* seizures~* pupillary asymmetry~* myoclonias~* brain stem reflex abnormalities~* osteotendinous reflex abnormalities"
41002175|NCT03633981|OTHER|mortality assessment|to 28 days
41002176|NCT06358456|DRUG|Artificial tear|Application of low viscosity artificial tears (Artelac EDO). The active ingredient is hypromellose (1.92 mg per 0.6 ml container).
41002177|NCT06358456|OTHER|No artificial tears|Before artificial tear application, 2 baseline measurements were taken of the cornea without any intervention
41002178|NCT01483196|PROCEDURE|ultrasound imaging|Undergo TCD
41002179|NCT01483196|OTHER|questionnaire administration|Complete neurocognitive questionnaires
41314871|NCT05412472|DRUG|GC4419|45 mg IV infusion of GC4419 over 60 minutes.
41314872|NCT03323918|OTHER|ImPACT|Teaching parents to train social communicative skills as outlined in arm description.
41314873|NCT03323918|OTHER|TAU|TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
41314874|NCT01376726|BIOLOGICAL|Sub C gp140 Vaccine|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
41314875|NCT01376726|BIOLOGICAL|MF59C.1 Adjuvant|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
41314876|NCT00864422|BEHAVIORAL|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
41472826|NCT04144426|BEHAVIORAL|Normal diet|Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times
41472827|NCT04144426|BEHAVIORAL|Modified diet|Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
40797887|NCT02408679|PROCEDURE|Blood sampling|One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
41002180|NCT01483196|PROCEDURE|assessment of therapy complications|Undergo TCD
41002181|NCT01483196|PROCEDURE|quality-of-life assessment|Ancillary studies
41002182|NCT01483196|PROCEDURE|magnetic resonance imaging|Undergo MRI
41002183|NCT04060329|BEHAVIORAL|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
40797888|NCT02408679|OTHER|Predictive questionnaire for vitamin D insufficiency|The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
40797889|NCT02964273|DRUG|Tolvaptan|Tolvaptan spray-dried, immediate release tablets
41002184|NCT05041790|DRUG|Choline Alfoscerate|Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
41002185|NCT05041790|DRUG|Placebo|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
41002186|NCT01489072|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
41002187|NCT01489072|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
41002188|NCT02538926|DRUG|Asparaginase|Given IM or IV
41002189|NCT02538926|DRUG|Cyclophosphamide|Given IV
41002190|NCT02538926|DRUG|Doxorubicin Hydrochloride|Given IV
41002191|NCT02538926|DRUG|Etoposide|Given IV
41002192|NCT02538926|DRUG|Imatinib Mesylate|Given PO
41002193|NCT02538926|OTHER|Laboratory Biomarker Analysis|Correlative studies
41002194|NCT02538926|DRUG|Prednisone|Given PO
41002195|NCT02538926|BIOLOGICAL|Rituximab|Given IV
41002196|NCT02538926|DRUG|Vincristine Sulfate|Given IV
41002197|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months
41002198|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months
40797890|NCT02964273|DRUG|Tolvaptan Matching-placebo|Tolvaptan matching-placebo tablets
40797891|NCT01032187|DRUG|Meglumine antimoniate|20mg/kg/day IV for 20 days
41002199|NCT01263288|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
41002200|NCT04911738|OTHER|Virtual Reality , immersion in a virtual titlted room|The immersion in virtual reality will be based on the HTC VIVE® device and the software developed by the Virtualis Society.
41002201|NCT01391481|DRUG|Perfluorocarbon|Vaporized PFC Inhalation 100ml/8h for 5 days
41151404|NCT03838159|DRUG|Nivolumab|"Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~The administration of nivolumab infusion must be completed within 24 hours of preparation."
40797892|NCT01032187|DRUG|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
41002202|NCT01391481|DRUG|Sterile Water for Injection|Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
41002203|NCT06158022|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
41002204|NCT06158022|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
41002205|NCT03164798|PROCEDURE|Conventional inpatient rehabilitation|comprehensive inpatient rehabilitation for 2 weeks
41002206|NCT01856790|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
41002207|NCT01856790|DRUG|liraglutide|Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
41002208|NCT05181111|DEVICE|Wearable Sensor|The sensor measures vital signs including heart rate and respiratory rate, posture and level of physical activity.
41002209|NCT05181111|OTHER|Usual Care|Usual Care Monitoring
41002210|NCT01791361|OTHER|Other|No intervention other than routine medical care
41002211|NCT06173466|DRUG|Liposomal bupivacaine|Liposomal bupivacaine 133mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
41002212|NCT06173466|DRUG|Bupivacaine Hydrochloride combined with dexamethasone|Standard bupivacaine combined with dexamethasone 4mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
41002213|NCT02696551|OTHER|Medical education|
41002214|NCT02165930|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
41151405|NCT06427395|DRUG|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program
41151406|NCT01535196|DRUG|Vigantol oil and MCT oil|Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
41151407|NCT06328322|PROCEDURE|Percutaneous Coronary Intervention in Left Main Artery Disease|To investigate and assess the effectiveness and safety of percutaneous coronary intervention in left main coronary artery disease in sitting of acute coronary syndromes.
41151408|NCT01398345|BEHAVIORAL|Exercise and Respiratory Training|Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
41151409|NCT00191984|DRUG|pemetrexed|400 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
41472828|NCT06615947|DEVICE|Robotic gait training|"RAGT group, will be trained 3-times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly. Training intensity will be monitored and standardized using the Borg Rating of Perceived Exertion scale, and will progress from 'fairly light' to 'somewhat hard'.~Progression will occur by increasing the number of steps in each session and decrease the level of assistance.~Participants will be secured with the appropriately sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5-minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern."
40797893|NCT06522568|BEHAVIORAL|MyMammogram|An online breast cancer screening decision aid
40797894|NCT06522568|OTHER|Provider communication|Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment
40797895|NCT01941654|RADIATION|preemptive local ablative therapy|
40797896|NCT01941654|DRUG|Oral TKI|
41314877|NCT00864422|BEHAVIORAL|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
41314878|NCT01257919|DRUG|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
41314879|NCT01257919|DRUG|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
41314880|NCT04540302|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
41314881|NCT04540302|DEVICE|PTA|Target lesion treated with standard percutaneous transluminal angioplasty (PTA)
40797897|NCT04087031|OTHER|control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
40797898|NCT04087031|OTHER|virtual reality games|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Tymo system (Tyromotion, Austria), a wireless static and dynamic platform, for evaluating and rehabilitating posture.
40797899|NCT04087031|OTHER|robotic treadmill|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Walker View (TecnoBody, Italy) a treadmill equipped with a sensorized belt with eight load cells and a 3D camera
40797900|NCT01755975|DRUG|Romidepsin|Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
40797901|NCT01755975|DRUG|Lenalidomide|Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.
40797902|NCT01825512|DRUG|Deferiprone|Deferiprone 80 mg/mL oral solution
41002215|NCT02165930|DRUG|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
41151410|NCT00191984|DRUG|irinotecan|180 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
41151411|NCT04547504|DRUG|Pembrolizumab|Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.
41151412|NCT04547504|DRUG|Pembrolizumab and Chemotherapy drugs|"An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~* Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~* Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~* Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~* Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop."
41151413|NCT00005908|DRUG|Docetaxel - Dose A|Dose A-Cohort 1 Docetaxel 75 mg/m\^2 intravenous day 1
41151414|NCT00005908|DRUG|Anastrozole|1 mg orally daily for five years
41151415|NCT00005908|DRUG|cyclophosphamide|600 mg/m\^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
41151416|NCT00005908|DRUG|Docetaxel - Dose B|Dose B - Cohort 2 Docetaxel 60 mg/m\^2 intravenous day 1
41151417|NCT00005908|DRUG|Doxorubicin hydrochloride|60 mg/m\^2 will be administered as a slow intravenous push on day 1
41151418|NCT00005908|DRUG|Tamoxifen Citrate|20 mg/day orally for five years
41151419|NCT00005908|DRUG|Capecitabine - Dose B|Dose B - Cohort 2 capecitabine 937.5 mg/m\^2 orally twice daily day 2-15
41151420|NCT00005908|DRUG|Capecitabine - Dose A|capecitabine 1000 mg/m\^2 orally twice daily day 2-15 for 4 cycles
41151421|NCT01370161|PROCEDURE|TIPS treatment|"1. A 8 mm Fluency stent will be used. The aim will be to reduce the portal pressure gradient (PPG) below to 12 mm Hg or 25-75% of baseline.~2. Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices.~3. After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted."
41151422|NCT01370161|DRUG|Medical treatment|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
41151423|NCT02152995|PROCEDURE|Computed Tomography|Undergo iodine I-124 PET/CT
41151424|NCT02152995|OTHER|Iodine I 124|Undergo iodine I-124 PET/CT
41151425|NCT02152995|RADIATION|Iodine I-131|Given PO
41151426|NCT02152995|OTHER|Laboratory Biomarker Analysis|Correlative studies
41151427|NCT02152995|OTHER|Pharmacodynamic Study|Correlative studies
41151428|NCT02152995|PROCEDURE|Positron Emission Tomography|Undergo iodine I-124 PET/CT
41151429|NCT02152995|DRUG|Trametinib|Given PO
41151430|NCT03392688|OTHER|kujala patellofemoral pain scale|Kujala patellofemoral pain scale was used to evaluate knee functions of the PFP subjects.
41151431|NCT03392688|DIAGNOSTIC_TEST|Surface EMG|The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
41151432|NCT03392688|OTHER|Q angle measurement|Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
41151433|NCT05945823|DRUG|Futibatinib|TAS-120 20 mg tablets, oral; once daily
41151434|NCT05945823|DRUG|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
41151435|NCT05945823|DRUG|Cisplatin|80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy
41151436|NCT05945823|DRUG|5-FU|"4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy."
41314882|NCT01019486|DRUG|Regadenoson myocardial perfusion imaging|Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
41314883|NCT01019486|DRUG|Regadenoson MRI myocardial blood flow|CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
41314884|NCT05811767|OTHER|Health Examination|The study is a cross-sectional study and therefore there is no intervention. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
41314885|NCT01373866|DEVICE|MagPro X100 repetitive Transcranial Magnetic Stimulation|"Target defined using both fMRI during hallucinations occurence and tractography.~Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session"
40797903|NCT01825512|DRUG|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
41151437|NCT05945823|DRUG|Oxaliplatin|85 mg/m\^2 Q2W via IV infusion, as part of mFOLFIRINOX or mFOLFOX6 chemotherapy. 2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.
41151438|NCT05945823|DRUG|Leucovorin|400 mg/m\^2 Q2W as part of mFOLFIRINOX or mFOLFOX6 chemotherapy.
41151439|NCT05945823|DRUG|Levoleucovorin|200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
41151440|NCT05945823|DRUG|Irinotecan|150 mg/m\^2 Q2W as part of mFOLFIRINOX chemotherapy.
41151441|NCT03841227|DEVICE|Active-tDCS|Active home-based tDCS applied at home. 5 days a week for 4 weeks.
41151442|NCT03841227|DEVICE|Sham-tDCS|Sham home-based tDCS applied at home. 5 days a week for 4 weeks.
41151443|NCT05444777|DRUG|Ketamine Hydrochloride|Ketamine was given prior to wound closure.
41151444|NCT04950010|BEHAVIORAL|High-Intensity Interval Training|HIIT is a type of training in which short periods of high-intensity anaerobic exercise (1-4 minutes at 80-95% of VO2peak) are alternated with less intense aerobic recovery periods (1-3 minutes at 50-60% VO2peak). Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise (i.e., number and intensity of intervals) increases across weeks. Intervals will progress from a heart rate corresponding with 75% VO2peak in Week 1 to 90-95% VO2peak in Weeks 5-8. Sessions will be \~30 minutes in length. Indoor cycling is the primary mode of exercise.
41151445|NCT04950010|BEHAVIORAL|Moderate-Intensity Exercise|Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Indoor cycling is the primary mode of exercise. Sessions will include moderate-intensity cycling that progresses from a heart rate corresponding with 55-60% VO2peak for 30 minutes in Week 1 to 65-70% VO2peak for 45-50 minutes in Weeks 5-8.
41151446|NCT04503551|DRUG|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
41151447|NCT04503551|DRUG|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
40797904|NCT04393038|DRUG|ABX464|ABX464 50mg QD for 28 days + Standard of Care
40797905|NCT04393038|DRUG|Placebo|Placebo 50mg QD for 28 days + Standard of Care
41151448|NCT05939349|OTHER|Produce Prescription Group|"Participants will receive vouchers equal to $40/household/month, with an additional $5/month per additional household member, for the purchase of fresh fruits and vegetables during the six-month intervention period. The vouchers will be administered in the form of a restricted Mastercard debit card.~A variety of nutrition education options will be offered throughout the intervention period and participation will be tracked. The Nutrition education options will include a periodic newsletter to participants that will include nutrition and diabetes prevention and management opportunities available through Griffin Hospital Population Health Team, the local health department, program and education opportunities available through the Registered Dietitians, local offerings by SNAP-Education and The Expanded Food and Nutrition Education Program."
41314886|NCT01373866|DEVICE|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
41002216|NCT02165930|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
41002217|NCT02165930|DRUG|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
41002218|NCT04122573|DIAGNOSTIC_TEST|Coronary angiography|Acute chest pain patients, suspected acute coronary syndrome, are diagnosed by coronary angiography.
41002219|NCT04122573|DIAGNOSTIC_TEST|CT angiography of aorta|Acute chest pain patients, suspected acute aortic dissection, are diagnosed by gold standard of CTA.
41002220|NCT04122573|DIAGNOSTIC_TEST|CT angiography of pulmonary arteries.|Acute chest pain patients, suspected acute pulmonary embolism, are diagnosed by gold standard of CTA.
41002221|NCT04122573|DIAGNOSTIC_TEST|Electrocardiogram|All patients with acute chest pain will subject to ECG examination within 10 minutes of admission, which can quickly screen ST-segment elevation myocardial infarction.
41002222|NCT04122573|DIAGNOSTIC_TEST|Cardiac Troponin|Dynamic changes of cardiac troponin I and/or T will be used in the diagnosis of acute myocardial infarction
41314887|NCT01881841|BEHAVIORAL|cMET|Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
41314888|NCT01935336|DRUG|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
41314889|NCT03060330|PROCEDURE|Modified Laparoscopic Ventral Mesh Rectopexy|This group will undergo modified laparoscopic ventral mesh rectopexy alone
41314890|NCT03060330|PROCEDURE|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection|This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
41314891|NCT02289404|DRUG|NVP-1203|Oral
41314892|NCT02289404|DRUG|NVP-1203|Oral
41314893|NCT06219434|BEHAVIORAL|Mindfulness Relaxation|Participate in mindfulness program
41002223|NCT04495088|DRUG|mFOLFOX (neoadjuvant)|neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
41002224|NCT04495088|DRUG|XELOX (neoadjuvant)|neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
41314894|NCT06219434|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
41314895|NCT06219434|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41314896|NCT06219434|OTHER|Questionnaire Administration|Ancillary studies
41002225|NCT04495088|DRUG|mFOLFOX (adjuvant)|adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
41002226|NCT04495088|DRUG|XELOX (adjuvant)|adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
41002227|NCT04495088|DRUG|Capecitabine (adjuvant)|adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
41002228|NCT04495088|DRUG|"infusional 5-FU/FA AIO regimen (adjuvant)"|adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
41002229|NCT04495088|DRUG|"infusional 5-FU/FA de Gramont (adjuvant)"|adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
41314897|NCT03007017|PROCEDURE|Deceased donor nephrectomy, prior to cross clamp of donor aorta|"The investigators will perform a prospective investigation of organ recoveries during which the left kidney will be removed prior to cessation of cardiac activity. The second kidney will be removed in the standard fashion. To do this, investigators will adopt techniques used in living donor kidney transplantation. Specifically, a specialized vascular stapler will be used to divide the renal artery at the level of aorta, followed by the vein, at the level of the vena cava. As such, no cuff of abdominal aorta or vena cava will be present on the target kidneys. Once removed from the body, just as is done for living donor kidney transplantation, the kidneys will be immediately flushed. As this ex-vivo flush is already performed for cadaveric kidney transplantation, there should be no additional cost for performing this portion of the procedure. Approximately 15 minutes of additional surgical dissection (prior to stopping the heart) will be required under the proposed study."
41314898|NCT03007017|PROCEDURE|Deceased donor nephrectomy, standard of care|The investigators will remove the right kidney in the stand of care procedures for cadaveric kidney transplantation
41472829|NCT06615947|OTHER|tRHB|"Participants randomize to receive a tRHB, will be trained 3 times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly.~A standardized protocol based on the usual clinical practice of physiotherapy in people with multiple sclerosis will be follow, according to patient characteristics, to design the sessions based on the patient objectives to be achieved, choosing the type of specific exercises to be performed based on the patient's condition and with the possibility of adapting them to their evolution during the twenty-four sessions."
41002230|NCT04270825|BEHAVIORAL|Group CBT with IPT|Group treatment designed to target relationships with both possessions and people.
41002231|NCT01076907|OTHER|Warm water|Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
41002232|NCT01076907|OTHER|Control|Air will be used instead of warm water for unsedated colonoscopy.
41314899|NCT03309267|PROCEDURE|Intercostal block|Intercostal block +patient controlled analgesia
41314900|NCT03309267|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
41314901|NCT03991884|DRUG|Etoposide|Given IV
41314902|NCT03991884|DRUG|Doxorubicin|Given IV
41314903|NCT03991884|DRUG|Vincristine|Given IV
41472830|NCT02917252|OTHER|3-hydroxybuturate|Drink of ketone bodies
41472831|NCT02917252|OTHER|Placebo|Drink of saline
41472832|NCT04375709|OTHER|Physical exercise|The intervention consists out of combined aerobic and strength exercise supervised and guided by specialized physical therapists; additional methods like functional electrical stimulation or oxygen supplementation are added during the main training if indicated.
41472833|NCT04375709|BEHAVIORAL|Education sessions|Sessions include information on physical activity (behaviour), coping with stress and anxiety, dyspnoe, or fatigue; Professional support is given in case of risk for nutritional deficits or post-traumatic stress; sessions are conducted by medical specialists or specialized physiotherapists. All sessions are individually-tailored. In case of nutrition or psychological issues individual sessions are guided by specific health-professionals.
41472834|NCT06615765|OTHER|Acupuncture|"Acupuncture sessions will use sterile, disposable stainless-steel needles (0.3 mm × 40 mm and 0.3 mm × 75 mm). Each session has two phases:~Supine Position:~* Needles (0.35 mm × 75 mm) are inserted into ST25, ST15, and SP14, reaching the abdominal muscle layer.~* Needles (0.30 mm × 40 mm) are inserted into CV12, CV4, ST36, ST37, and SP6.~* Electroacupuncture (EA) at ST25, SP15, and ST36 uses a continuous 5 Hz wave, 0.1 to 2.0 mA.~Prone Position:~* Needles are inserted into BL32, BL33, and BL35 with precise angles and depths.~* EA at BL32, BL33, and BL35 uses a continuous 5 Hz wave, 2.0 to 6.5 mA. Sessions occur three times a week for the first 4 weeks, then twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions."
41002233|NCT05973916|OTHER|Comprehensive intervention|"cleaning of patients' rooms will be subjected to a comprehensive intervention, consisting of: 1) a patient's unit commando team for daily and for terminal cleaning, 2) all lights in patients' room are VYV led lights, and 3) in each room, a QleanAir Scandinavia® filtering machine will be placed."
41002234|NCT00006095|DRUG|irinotecan hydrochloride|
41002235|NCT00006095|DRUG|vincristine sulfate|
41002236|NCT05581316|DIAGNOSTIC_TEST|Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center.|This patients who were included in this study were assessed for four weeks from the first day of hospitalization and taken to the treatment program. All patients who use peripheral venous catheters in this group.
41002237|NCT01556204|PROCEDURE|Robotic surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
41002238|NCT01556204|PROCEDURE|Laparoscopic Surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
41002239|NCT01687491|DRUG|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
41002240|NCT01687491|DRUG|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
41002241|NCT05810116|DRUG|Levagen+|Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
41002242|NCT05810116|DRUG|Microcrystalline cellulose|Daily dose of 1-2 capsules (1 capsule containing 350mg)
41002243|NCT04295603|OTHER|Toucher Massage (TM) on the feet|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes (according to current Geneva Hospital practice) on the foot area. At least four sessions will be delivered and spread over two weeks. The TM will be provided by the care team. The training time for the workers corresponds to 2 times 2 hours. In order to be as close as possible to a standardized session, practitioners will benefit from an intervention guide.
41002244|NCT04295603|OTHER|Homedics HM MP RELEX 90 device|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes. The use of the Homedics device is no more a common treatment than the practice of Touch-Massage. TM involves a therapeutic relationship between caregiver and patient. It is for this reason that we need a comparator that should allow us to keep the aspect of the massage while decreasing the aspect of the therapeutic relationship and therefore offer us an adequate comparator."
41002245|NCT01514552|OTHER|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
41002246|NCT01514552|OTHER|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
41002247|NCT06496802|OTHER|no intervention|no intervention
41002248|NCT01556542|DEVICE|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
41002249|NCT01556542|DEVICE|nitinol stent implantation|nitinol stent implantation
41002250|NCT06301100|OTHER|Dual energy CT after routine simulation|Dual energy CT after routine simulation
41314904|NCT03991884|DRUG|Prednisone|Given PO or IV
41314905|NCT03991884|DRUG|Cyclophosphamide|Given IV
41314906|NCT03991884|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
40797906|NCT06351423|BEHAVIORAL|Forest Bathing (FB)|"The forest bathing (FB) intervention will be comprised of four 2-hour sessions held in a country park on four consecutive weekends during the daytime. The FB sessions will cover 1-2 kilometers per forest visit. Participants will convene at the country park entrance. An FB guide will provide a briefing and commence the forest trip. Following 20 minutes for participants to slow down and share their experiences, they will be invited to mindfully center themselves using their five senses for another 20 minutes. Subsequently, the participants will be afforded 20 minutes to wander along a designated forest path, followed by another 20 minutes during which they will be encouraged to stroll in a designated area to help foster a deep connection with the forest.~Participants will have a 20-minute interval between each activity to share their experiences. A tea ceremony will be held at the end of each FB session."
41002251|NCT01791738|PROCEDURE|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
41002252|NCT04152512|BEHAVIORAL|Questionnaire administration|Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
41002253|NCT05529212|PROCEDURE|ischemic reperfusion injury|ischemic reperfusion injury is a pathological process in which the ischemic myocardium is restored to normal perfusion, but the tissue damage is progressively aggravated when the coronary artery supply is completely blocked after cardiopulmonary bypass surgery and then recanalised at a certain time.
41002254|NCT02029651|DEVICE|E-glove system|Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke
41002255|NCT02029651|PROCEDURE|Conventional occupational therapy|conventional occupational therapy
41151449|NCT05988385|DEVICE|Positive airway pressure|Positive airway pressure (PAP) therapy is a sleep apnea treatment that uses a stream of compressed air to support the airway during sleep. With PAP therapy, a mask is worn during sleep and a portable machine gently blows pressurized room air from into your upper airway through a tube connected to the mask. This positive airflow helps keep the airway open, preventing the collapse that occurs during apnea, thus allowing normal breathing.
41314907|NCT03355794|DRUG|ribociclib|Oral capsule or liquid formula
40797907|NCT06351423|BEHAVIORAL|MIND diet|The participants will undertake four three-month nutrition programmes consisting of four nutrition counselling sessions in an activity room at each participating community centre. All intervention sessions will be conducted by a registered nutritionist. In the nutrition sessions, the participants will learn to modify their diet to meet the MIND diet guidelines. The MIND diet promotes 10 healthy food groups and limits five unhealthy food groups (Morris et al., 2015a; Arjmand et al., 2022). As a reference, a 7-day sample menu will be provided which meets the required number of servings per day.
40797908|NCT01531582|DRUG|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
40797909|NCT01821092|PROCEDURE|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
40797910|NCT01821092|DEVICE|osseointegrated implant|Osseointegrated Implant Insertion
40797911|NCT00002028|DRUG|Didanosine|
40797912|NCT06554782|DEVICE|manual u-shaped toothbrush|manual u-shaped toothbrush with bristles angled 45 degrees to brush upper and lower teeth at the same time
40797913|NCT02108756|DRUG|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
41151450|NCT05988385|DEVICE|Oral appliance therapy|Oral appliance therapy involves the use of a dental appliance or oral mandibular advancement device that prevents the tongue from blocking the throat and/or advances the lower jaw forward. These devices help keep the airway open during sleep.
41472835|NCT06615765|OTHER|Sham acupuncture|Sterile, disposable stainless-steel needles (0.30 mm × 25 mm) will be used. After skin sterilization, needles will be inserted into the same points as the acupuncture group but to a shallow depth of 2 to 3 mm and lightly manipulated for blinding. Paired alligator clips will be attached to the same points, but the sham EA apparatus will have no current output, though it mimics the active EA apparatus in appearance and sound. Sham sessions will follow the same schedule as the acupuncture group: three times a week for the first 4 weeks and twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions.
41472836|NCT06484322|BEHAVIORAL|Strategies Empowering Activities in Everyday life (SEE 2.0)|SEEs internet-based intervention process begins with supporting the client to explore the need of and readiness for changes in everyday life. Thereafter, the client is supported to self-analyse their engagement in activities in everyday life along with use of management strategies in everyday life. Next, the client takes on web- modules including short educational movies with subsequent analyses and reflections. The modules aim to support the development of self-management by improving the knowledge of how strategies and changes in daily activities can prevent disabilities and contribute to improved health. After that, the focus is on establishing an activity plan with goals and activity-based management strategies to promote an active everyday life. The clients' implementation of the plan is supported through follow-up meetings. During the whole intervention process, the client is regularly supported by an occupational therapist through feedback and online guiding dialogues.
41472837|NCT00706992|BIOLOGICAL|ALVAC-MART-1 vaccine|Given subcutaneously
40797914|NCT02108756|DRUG|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
40797915|NCT04054206|DRUG|MN-166|MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
41151451|NCT05988385|DEVICE|Positional therapy|A NightShift Sleep Positioner (Advanced Brain Monitoring) is a neck vibration device, FDA approved to treat positional sleep apnea. The device detects patient supine position and delivers a small vibratory signal to the back of the neck to prompt position change.
41314908|NCT03355794|DRUG|Everolimus|Oral tablets or dispersible tablets
41314909|NCT04157985|DRUG|Continue PD-1/PD-L1 Inhibitors treatment|Continued treatment with PD-1/PD-L1-1 inhibitor
41314910|NCT04157985|OTHER|Discontinue PD-1/PD-L1-1 inhibitor|Discontinued treatment with PD-1/PD-L1-1 inhibitor
41472838|NCT00706992|BIOLOGICAL|MART-1:26-35(27L) peptide vaccine|Given subcutaneously
41472839|NCT00706992|BIOLOGICAL|Aldesleukin|Given subcutaneously
40797916|NCT03166462|OTHER|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
41472840|NCT00706992|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Given intravenously (IV)
41472841|NCT00706992|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously
41472842|NCT04987255|OTHER|Free visit|The persons with sedentary (healthy) in this group will have to visit the museum freely (without a guide) for a period of 75 minutes.
41472843|NCT04987255|OTHER|Guided visit|The persons with sedentary (healthy) in this group will have to visit the museum with a guide for a period of 75 minutes.
40797917|NCT02466035|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
40797918|NCT01050023|DEVICE|Provant Device (Wound Therapy System)|Twice daily application of the active Provant device to the wound for twelve (12) weeks.
40797919|NCT01050023|DEVICE|Provant Device - Inactive|Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
40797920|NCT05445219|DIAGNOSTIC_TEST|RespirAct|The RespirAct device is an automated breathing circuit that uses a gas bladder to control and deliver CO2 to measure cerebrovascular reactivity
40797921|NCT05809323|OTHER|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 12 weeks all patients will return for re-assessment.
41151452|NCT03109899|BEHAVIORAL|Sex Pro mobile Application|Mobile mHealth app that provides HIV risk assessment, home HIV/STI testing options, and PrEP uptake support for young Black MSM.
41472844|NCT04987255|OTHER|Guided visit (stroke)|The persons with motor disability after stroke in this group will have to visit the museum with a guide for a period of 75 minutes.
41472845|NCT02281682|DRUG|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
41472846|NCT02281682|DRUG|5-fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
41472847|NCT02281682|DRUG|Ingenol mebutate|during 3 (consecutive) days once daily. Prior to treatment: curettage
41472848|NCT02281682|PROCEDURE|methylaminolevulinate photodynamic therapy|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
41472849|NCT05983159|DRUG|Alpelisib|Oral alpha-specific PI3-kinase inhibitor
41472850|NCT05983159|DRUG|Mirdametinib|An investigational oral MEK inhibitor
41472851|NCT01385826|DRUG|Anti-tumor necrosis factor alpha monoclonal antibody|The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
40797922|NCT05809323|OTHER|Control Group|Patients in the control group will be instructed to continue with baseline physical activities over the duration of the study and be given instructions on the use of the activity tracker. At the end of 12 weeks all patients will return for re-assessment.
40797923|NCT04368013|PROCEDURE|Extended sampling and procedures|The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
40797924|NCT00000407|BEHAVIORAL|Vocational counseling intervention|
40797925|NCT00000407|BEHAVIORAL|Reading materials for control participants|
40797926|NCT00000407|BEHAVIORAL|Standard of care|No education or behavioral intervention
40797927|NCT04342949|BEHAVIORAL|quality of life|To observe the difference of quality of life
41472852|NCT01385826|DRUG|placebo|Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
41472853|NCT06552104|BEHAVIORAL|ACUPRESSURE APPLI ACUPRESSURE APPLICATION|Pre-test data were collected from participants who met the inclusion criteria and volunteered to participate in the study by researcher BI in the LDP rooms during the latency period of labor. Post-test data were obtained by the same researcher 16 hours after the cesarean section. Data were obtained using the Personal Information Form, Episiotomy Evaluation Form (EEF), Visual Analog Scale (VAS), and Spielberger Manual for State-Trait Anxiety Inventory (STAI).
41472854|NCT04802408|COMBINATION_PRODUCT|Shampoo and saline|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
41472855|NCT04802408|COMBINATION_PRODUCT|Saline and Listerine|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
41472856|NCT04802408|COMBINATION_PRODUCT|Shampoo and Listerine|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
41472857|NCT04802408|COMBINATION_PRODUCT|Saline and Saline|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
41472858|NCT01087021|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
41472859|NCT06584357|OTHER|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of AD. Some of the samples will be stored for future analysis.
41472860|NCT06584357|RADIATION|MK6240|Each participant will be assessed using either one of two radioactive tau PET tracers: Flortaucipir or MK6240. Flortaucipir is FDA approved while MK6240 is not and is being used in this study as an investigational radioactive drug.
40797928|NCT03462641|DRUG|Flumazenil|1mg in 10cc normal saline
41314911|NCT03075748|DEVICE|TAAA Debranching Stent Graft System|The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
41314912|NCT02337595|BIOLOGICAL|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
41314913|NCT02213302|DRUG|placebo administration|
41314914|NCT02213302|DRUG|midazolam intravenous administration|
41314915|NCT01260935|PROCEDURE|Laparoscopic Hill Repair|With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
41314916|NCT01260935|PROCEDURE|Laparoscopic Nissen Repair|With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
41314917|NCT05059951|DRUG|Immune checkpoint inhibitor|Chemotherapy follow the guild line.
41314918|NCT01722487|DRUG|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
41314919|NCT01722487|DRUG|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
41314920|NCT00315705|DRUG|clofarabine|Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
40797929|NCT03462641|DRUG|Placebo|10 cc normal saline
40797930|NCT01843166|DRUG|Premarin vaginal cream|2g at bedtime twice weekly
41002256|NCT02347527|BEHAVIORAL|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
41314921|NCT00315705|DRUG|Etoposide|Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
41472861|NCT03026907|DRUG|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
41472862|NCT03026907|DRUG|Azathioprine|Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
40797931|NCT01843166|DRUG|Placebo cream|2g at bedtime twice weekly
40797932|NCT03743714|OTHER|yoga treatment; flexibility, balance and strength exercises.|yoga treatment including flexibility exercises, balance exercises, and strength exercises.
41002257|NCT02347527|BEHAVIORAL|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
41002258|NCT00040885|BIOLOGICAL|infliximab|
40797933|NCT05232214|DEVICE|Biometry|Only one eye from each patient will be included in the study. All patients included in the study will undergo biometric measurements in a random fashion with the three devices (IOLMaster 700, Argos and Anterion Heildelberg). Each patient will be measured three times with each device
40797934|NCT03873298|DRUG|Inhaled nitric oxide|Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
40797935|NCT02144571|BEHAVIORAL|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
40797936|NCT01174979|DRUG|Caroverin|treatment with eardrops 2 times for 48 hours
40797937|NCT04414813|BIOLOGICAL|Human Amniotic Epithelial Stem Cells|Stereotactic transplantation of hAESCs for participants with PD.
40797938|NCT03775824|DRUG|MTX start|Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
41151453|NCT05464199|OTHER|Neurofeedback training|"Self-administered neurofeedback treatment using headset and tablet-based application, designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own brain EEG signals associated with activity in brain networks related to pain perception and pain modulation.~Visual feedback will be provided onscreen representing the participant's real time EEG activity measured by the headset. Each session will be split into five blocks of five minutes each, with a one-minute rest period in between, in order to avoid fatigue and allow the participant to move around and adjust their position. After each rest block, participants will be asked if they are ready to proceed and when ready, the next block can be started. After the end of the session (5 blocks) the participant will then be asked to perform a post-session eyes-open EEG recording, similar to the eyes-open baseline taken at the start of the session."
41151454|NCT02797795|DRUG|NEV801|Dose Escalation
41151455|NCT01631825|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
41002259|NCT00040885|DRUG|docetaxel|
41002260|NCT00040885|OTHER|placebo|
40797939|NCT03775824|DRUG|TNF start|Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
40797940|NCT00529438|DRUG|Bardoxolone methyl|
40797941|NCT02100254|BEHAVIORAL|behavioral intervention|View personal narrative informational video
40797942|NCT02100254|BEHAVIORAL|behavioral intervention|View fact-based informational video
41314922|NCT00315705|DRUG|Cyclophosphamide|Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
41314923|NCT01714752|PROCEDURE|measure of left ventricular and diastolic pressure at exercise|
40797943|NCT02225704|DRUG|Radium-223 and enzalutamide|
41002261|NCT04361162|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
41472863|NCT06612203|DRUG|Debio 0123 and Sacituzumab govitecan|Debio 0123 will be administered orally during 6 days of each 21-day cycle in combination with 10 mg/kg of Sacituzumab govitecan administered intravenously on D1 and D8 of each 21-day cycle until documented disease progression, death, unacceptable toxicity, or discontinuation from the study treatment for any other reason, whichever occurs first.
41472864|NCT00003396|BIOLOGICAL|anti-thymocyte globulin|
41472865|NCT00003396|BIOLOGICAL|graft-versus-tumor induction therapy|
41472866|NCT00003396|DRUG|cyclophosphamide|
41472867|NCT00003396|DRUG|melphalan|
41472868|NCT00003396|PROCEDURE|peripheral blood stem cell transplantation|
40797944|NCT03880370|BEHAVIORAL|Questionnaires / scales|EVA, ROLAND MORRIS, OWESTRY and Global Questionnaire of Physical Activity (GPAQ)
40797945|NCT03880370|DIAGNOSTIC_TEST|Ultrasound imaging|Rectus abdominis dominant side \& non-dominant side external oblique dominant side \& non-dominant side internal oblique dominant side \& non-dominant side transversus abdominis dominant side \& non-dominant side lumbar multififidus l4-l5-s1 gluteus medius dominant side \& non-dominant side
40797946|NCT03880370|DIAGNOSTIC_TEST|FLEXIBILITY|weight-bearing lunge hip lateral rotation straight leg raise fingertip to floor test
41002262|NCT04361162|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
41314924|NCT02580994|DRUG|Pembrolizumab|IV infusion at the dose of 200 mg on day 1 every 3 weeks
41314925|NCT02580994|DRUG|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
41314926|NCT03677817|DRUG|Lidocaine|regimen of lidocaine administration of 1,5 mg/kg, IV bolus, followed by continuous infusion at 3,0 mg/kg/h
41314927|NCT03677817|DRUG|NaCl 0,9%|IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
41314928|NCT05212155|BEHAVIORAL|family-based behavioral treatment (FBT)|Individual and group treatment of parent/child dyads to improve dietary choices, minimize sedentary behaviors, increase physical activity levels, and identify social support environments that reinforce healthy lifestyle choices.
41314929|NCT05833685|OTHER|no intervention|no intervention
41472869|NCT00003396|RADIATION|radiation therapy|
41472870|NCT03581188|DEVICE|Patient-led surveillance|Usual care plus reminders, ASICA instructional videos, a mobile dermatoscope, an app that facilitates store-and-forward teledermatology, and fast-tracked unscheduled clinic visits.
41472871|NCT03581188|BEHAVIORAL|Clinician-led surveillance|Usual care (scheduled clinician visits)
41472872|NCT03717519|DIAGNOSTIC_TEST|Measurement of platelet count at diagnosis|Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment
41472873|NCT01933919|DRUG|Fluvoxamine maleate|Film-coated tablet containing 25 mg of fluvoxamine maleate
41472874|NCT01933919|DRUG|Placebo|Placebo tablet matching to fluvoxamine maleate
41002263|NCT04361162|RADIATION|Radiation|3D Conformal Radiotherapy to shrink or kill tumors
41151456|NCT02800512|PROCEDURE|Robotic sacrocolpopexy|Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
41472875|NCT03482167|DRUG|Niagen®|250 mg capsules (4 capsules daily)
41472876|NCT03482167|OTHER|Placebo|placebo
41472877|NCT05123729|BEHAVIORAL|Crowdsourced campaign package|COVID-19 prevention intervention developed using a crowdsourcing process.
41472878|NCT05123729|BEHAVIORAL|Standard information|Standard informational videos promoting the adoption of health-protective behaviors and COVID-19 testing
41472879|NCT06188507|DRUG|GSK4347859|GSK4347859 will be administered
41472880|NCT06188507|DRUG|Placebo|Placebo will be administered
41472881|NCT00880087|PROCEDURE|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
41472882|NCT00880087|PROCEDURE|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
41472883|NCT00809315|OTHER|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
41472884|NCT00809315|BEHAVIORAL|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
41314930|NCT05626517|DIAGNOSTIC_TEST|Ocular Imaging|The retinal photography will be acquired from macula-centre and an optic-disc centre for both left and right eye after their cardiac assessment. Patient will be required to focus at a target inside the machine for approximately 5 to 10 seconds, with a flash followed at the end when eye image is captured. Based on patients' eye conditions, additional or less images may be taken. This allows a snapshot of both retinal and coronary vessels at a single point in time, no mydriatic drops will be used. Participants will be given the option to undergo mydriatic photographs of the retina at SNEC/SERI depending on participant eye condition. For mydriatic photograph, images will be obtained after pupil dilation and graded for presence and severity of diabetic retinopathy according to the modified ETDRS system and other retinal abnormalities by trained graders.
41314931|NCT05626517|OTHER|Questionnaires|3 to 4 questionnaires will be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire) to investigate the correlation between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and outcomes.Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function (IIEF) questionnaire. Participants have the option to not complete the whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
41314932|NCT04058054|DEVICE|KeraStat® Cream|Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
41314933|NCT04058054|DEVICE|KeraStat Gel|Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
41472885|NCT05506878|DEVICE|NSS-2 BRIDGE|"NBD® will be applied to either the right or left ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.~Once the device is placed, subjects will be asked to perform a pinch test throughout the duration of their time wearing the device. To perform the pinch test subjects must pinch down on the electrodes and ground to ensure the electrodes are still placed in their designated locations and have not come loose."
41472886|NCT05506878|DEVICE|Sham NSS-2 BRIDGE|Sham NBD® will be applied to either the left or right ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.
41472887|NCT04894071|DRUG|QA102|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
41472888|NCT04894071|DRUG|Placebo|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
41472889|NCT01682629|OTHER|Debriefing Script|"A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration."
41472890|NCT01682629|OTHER|High Physical Realism Simulation|"High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups."
41472891|NCT03447886|OTHER|Phone interview|Collecting clinical and socio-demographic information.
41314934|NCT04058054|DEVICE|Biafine|Administered 0.025 gm of Biafine per subject on day 1 of the study.
41314935|NCT04058054|DRUG|Histamine|Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
41314936|NCT04058054|DRUG|Saline (0.9% NaCl)|Administered 1 drop of saline per subject on day 1 of the study.
41314937|NCT02675153|DRUG|Rapamycin|Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.
41314938|NCT01078701|BIOLOGICAL|GHB11L1|GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
41314939|NCT01078701|BIOLOGICAL|Placebo|SPGN buffer
41314940|NCT03277144|DEVICE|TST-TriStaple(3lines stapler)Technology|Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
41314941|NCT03277144|OTHER|other conventional techniques|Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
41314942|NCT00057460|DRUG|Talampanel|
40797947|NCT03880370|DIAGNOSTIC_TEST|FUNCTIONAL TESTS|Star excursion balance test (sebt) prone bridging test Side bridging test Modified biering-sørensen
41472892|NCT05894564|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
41002264|NCT02825303|OTHER|Workplace consisting of two height-adjustable desks|Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader
41472893|NCT05894564|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
41472894|NCT06616909|BEHAVIORAL|ACP GAME|,Using board games as an activity intervention, a tool for discussion between elderly people with lung cancer and potential agents
41002265|NCT06007014|DRUG|Chiglitazar sodium|tablets 48mg/ day administered for 18 weeks
41002266|NCT06007014|DRUG|Chiglitazar placebo|tablets 48mg/ day administered for 18 weeks
41151457|NCT02800512|PROCEDURE|high uterosacral ligament suspension|Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
41151458|NCT01849185|OTHER|Food supplement|
41472895|NCT06616909|BEHAVIORAL|acp manual|acp manual
41314943|NCT03611517|BEHAVIORAL|Sexual rehabilitation programme|The intervention consists of 4 patient/couple sessions (each max. 60 minutes) scheduled at 1, 3, 6 and 12 months post-RT. Patients treated with RTBT have an additional session 2 months post RT. If preferred, one extra session of 30 minutes can be scheduled between 6 and 12 months after RT. The intervention includes (1) education on the specific cancer diagnosis and treatment, (2) education on the importance of regular dilation for prevention of vaginal stenosis (if indicated), (3) discussing and resolving potential fears and experienced barriers to performing vaginal dilation (if indicated) and sexual activity,(4) promoting couples' mutual coping and support processes and (5) specific sexual therapy techniques to address sexual and body image concerns.
41314944|NCT04373239|PROCEDURE|Assisted Reproductive Technology|Assisted reproductive technology includes IVF and IVF+ICSI.
41314945|NCT05353101|DRUG|Cyclosporine 0.05% eye drops|Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC
41314946|NCT05353101|DRUG|Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%|Corticosteroids can inhibit the release of mast cells, block the chemotaxis of inflammatory cells, and reduce the number of mast cells and eosinophils in the conjunctiva. At the same time, it can inhibit phospholipase A2 and quickly alleviate symptoms and signs.
40797948|NCT01188902|DIETARY_SUPPLEMENT|walnut|walnut consumption 48 g/d
40797949|NCT00814580|DRUG|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
40797950|NCT00814580|DRUG|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
40797951|NCT04981847|BEHAVIORAL|Dietary Intervention Meetings|Participants will attend classes once per week for 3 months.
40797952|NCT00587808|PROCEDURE|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
41314947|NCT01504386|PROCEDURE|TAP block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
41314948|NCT01504386|PROCEDURE|Placebo TAP block|Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
41314949|NCT05116514|OTHER|Case management|"Regular and personalized follow-up by a case manager using a case management approach, updated every 3 months"
40797953|NCT01294111|BEHAVIORAL|Tai Chi training|Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
40797954|NCT02508584|BIOLOGICAL|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
40797955|NCT03456258|DIAGNOSTIC_TEST|Complete blood count|To measure hemoglobin difference and serum ferritin levels .
40797956|NCT02620800|DRUG|5FU|5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump
40797957|NCT02620800|DRUG|nab-paclitaxel|nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
40797958|NCT02620800|DRUG|bevacizumab|bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
40797959|NCT02620800|DRUG|calcium leucovorin|calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15
40797960|NCT02620800|DRUG|oxaliplatin|oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15
41151459|NCT00215943|DRUG|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
41314950|NCT00316381|PROCEDURE|Autologous bone marrow-derived stem cells|
41314951|NCT00698789|DRUG|INCB019602|5 mg of INCB019602 in AM with placebo administration in PM
41314952|NCT00698789|DRUG|INCB019602|20 mg in AM with placebo administration in PM
41151460|NCT00215943|DRUG|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
41151461|NCT00215943|DRUG|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
41151462|NCT00215943|DRUG|vincristine|As outlined in VAD Treatment Arm
41314953|NCT00698789|DRUG|INCB019602|5 mg in PM with placebo administration in AM
41314954|NCT00698789|DRUG|INCB019602|20 mg in PM with placebo administration in AM
40797961|NCT04910152|DRUG|BRD4 Inhibitor PLX51107|Given PO
41314955|NCT00698789|DRUG|INCB019602|7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
41314956|NCT00698789|DRUG|Placebo|Placebo administration in AM or PM depending on treatment arm dosing regimen.
41314957|NCT00698789|DRUG|Metformin|Stable dose metformin monotherapy
40797962|NCT03998514|DRUG|CB4211 Dose 1|Administered by subcutaneous injection
40797963|NCT03998514|DRUG|CB4211 Dose 2|Administered by subcutaneous injection
40797964|NCT03998514|DRUG|CB4211 Dose 3|Administered by subcutaneous injection
41314958|NCT01893658|DRUG|Omalizumab|administration of a single dose together with the standard treatment
41314959|NCT01893658|DRUG|Prednisone|standard treatment
40797965|NCT03998514|DRUG|CB4211 Dose 4|Administered by subcutaneous injection
40797966|NCT03998514|DRUG|CB4211 Dose 5|Administered by subcutaneous injection
40797967|NCT03998514|DRUG|CB4211 Dose 6|Administered by subcutaneous injection
41151463|NCT00215943|DRUG|adriamycin|As outlined in VAD Treatment arm
41151464|NCT00005843|DRUG|tipifarnib|
41151465|NCT03239353|DRUG|Entecavir|Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
41151466|NCT02547025|DRUG|rabeprazole+3 antibiotics|(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
41314960|NCT02231450|DRUG|Lu AE58054 encapsulated film-coated tablets|
41314961|NCT04831515|DEVICE|Lens A|daily disposable soft contact lens - test lens
41314962|NCT04831515|DEVICE|Lens B|daily disposable soft contact lens - control lens
41314963|NCT04709302|BIOLOGICAL|COVID-19|Patients diagnosed with a COVID-19 infection
41314964|NCT04709302|BIOLOGICAL|HIV|Patients diagnosed HIV-positive
41314965|NCT04709302|DRUG|ART|Patients on ART
40797968|NCT03998514|DRUG|CB4211 Dose TBD|Administered by subcutaneous injection
40797969|NCT03998514|DRUG|Placebo|Administered by subcutaneous injection
40797970|NCT02998879|DRUG|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
40797971|NCT01811069|PROCEDURE|Head up|30˚ reverse trendelenburg body position
40797972|NCT00977639|PROCEDURE|Pathwork TOO test|
41314966|NCT00799344|DEVICE|Catania Stent|coronary stent implantation
40797973|NCT02298309|OTHER|Test-and-Treat TB|
40797974|NCT01236261|OTHER|Non intervention|Non interventional study
41314967|NCT05844956|DRUG|DZD8586|Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
40797975|NCT03252041|DEVICE|MRI|Magnetic Resonance imaging modalities and sequences in pelvic congestion syndrome
41314968|NCT00484965|PROCEDURE|Coronary stenting|
40797976|NCT00720967|PROCEDURE|Open Heart Surgery (OHS)|General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
40797977|NCT00720967|PROCEDURE|Intraoperative Modified Ultrafiltration (MUF)|Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP \>75 mmHg, CVP \> 12 mmHg, Htc \> 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at \~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
40797978|NCT00720967|PROCEDURE|Hemodialysis (HD)|Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs \< 75 kg, and 4 hours if \> 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
41314969|NCT04759014|OTHER|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life
41314970|NCT01833104|BEHAVIORAL|Presence - Perspective - Affect|"PRESENCE: Cultivate attentional skills \& interoceptive body awareness. 2 exercises: Breathing Meditation \& Body Scan.~PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, \& other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation \& Perspective Dyad.~AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad."
41314971|NCT01833104|BEHAVIORAL|Presence - Affect - Perspective.|As specified above however the order is interchanged between the cohorts TC1 and TC2.
41314972|NCT01833104|BEHAVIORAL|Affect|"AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad."
41314973|NCT02694094|DIETARY_SUPPLEMENT|Modified Atkins or Ketogenic Diet|Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for \> 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
41314974|NCT05189158|DIAGNOSTIC_TEST|Hypercapnic hyperoxic ventilatory response|"The hypercapnic ventilatory response (HCVR) described by Read in 1967 (Read's rebreathing method) is a clinical way to assess the central and peripheric sensitivity to CO2, using a small bag (4-6 l) to achieve prompt equilibrium between the apparatus compartments and the lungs.~By rebreathing a hyperoxic mixture with an initial composition of 70% O2, 7% CO2 and 23% N2, this equilibrium is assumed to be achieved after 15 seconds of rebreathing, when the relationship between VE and PetCO2 has become linear."
41314975|NCT05189158|DIAGNOSTIC_TEST|Hypoxic eucapnic ventilatory response|The hypoxic eucapnic ventilatory response (HOVR) is a clinical way to assess the peripheric chemosensitivity to O2, using a small bag (4-6 l) to rebreathe a gas mixture initially composed of 20% O2, 0% CO2 and Δ% N2. Eucapnia is achieved by the activation of a CO2 reabsorption cell during the course of the test.
41314976|NCT01519063|DRUG|Naltrexone and memantine first|Naltrexone 50mg memantine 20mg
41314977|NCT01519063|DRUG|Naltrexone and Placebo first|Naltrexone 50 mg Placebo
41314978|NCT01634321|DRUG|Luphere depot 3.75mg(Leuprolide acetate 3.75mg)|
41151467|NCT02547025|DRUG|rabeprazole+bismuth+2 antibiotics|(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
41151468|NCT02547025|DRUG|rabeprazole+amox+tetr+levo|(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
41314979|NCT04089813|DRUG|Metformin|Patients use metformin to control blood sugar
41151469|NCT06183944|OTHER|Hierarchical clustering methods|Hierarchical clustering methods will be used to form homogeneous groups of patients based on their data at diagnosis: presence or absence of symptoms, clinical and biological data, and presence or absence of favouring factors. Patient evolution at 6 months can fall into categories: stable, aggravation or progress, which are determined by events such as recurrence, hemorrhage, functional sequelae or death.
41314980|NCT05014048|DIETARY_SUPPLEMENT|Vitamin D3|20 mikrog vitamin D3 daily
41314981|NCT05014048|DIETARY_SUPPLEMENT|Placebo|Placebo
41314982|NCT02029352|DRUG|Sinecatechins 10%|
41314983|NCT02029352|DRUG|Placebo|Composition, apart from the active substance, is otherwise identical to the investigational medical product.
41314984|NCT00664300|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
41314985|NCT03340181|OTHER|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.
41314986|NCT03280433|OTHER|Aortic valve replacement|
41472896|NCT03661606|OTHER|Simulated Altitude Chamber|"Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.~Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with altitude change of 3000 meters. At the chamber site, subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow up phone call to check on subjects will then be done on day 5 before closing the study."
41472897|NCT05752916|DRUG|rhTNK-tPA|Recombinant human TNK tissue-type plasminogen activator. Patients will receive intravenous rhTNK-tPA (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
41472898|NCT05752916|DRUG|Antiplatelet Agents|Patients will receive single antiplatelet therapy-choice at the discretion of the clinician. Aspirin will be the choice of most physicians, some will choose clopidogrel.
41472899|NCT05246696|OTHER|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
41472900|NCT05519657|OTHER||
41472901|NCT02464488|OTHER|Plasma drug concentrations|Measure of plasma concentrations of the anticoagulant drug taken by the patient
41472902|NCT02443584|OTHER|pharmacogenetic testing|pharmacogenetic testing for anti-depressant/anti-psychotic medications
41472903|NCT03716531|RADIATION|IORT|IORT works by delivering radiation therapy to the tumor while reducing the amount of healthy tissue exposed to the radiation therapy
41472904|NCT01304381|OTHER|Integrated care|Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
41472905|NCT01304381|OTHER|Integrated care|One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
41151470|NCT03623308|OTHER|Fiber cereal|Whole grain and bran cereal
41314987|NCT03097796|DRUG|PUL-042|PUL-042 Inhalation Solution
41314988|NCT04312438|DIAGNOSTIC_TEST|oral food challenge with cow's milk proteins|in children with diagnosed Cow's Milk Allergy open oral food challenge test with cow's milk protein (milk formula in children up to 3 yo, cow,s milk after 3 yo) will be carried out
41314989|NCT01884857|DRUG|Metoprolol Succinate ER Tablets 50 mg|1\* 50 mg tablet once a day
41314990|NCT01884857|DRUG|'TOPROL-XL®' ER Tablets 50 mg|1 \* 50 mg tablet per day
41314991|NCT06483165|OTHER|BE FAST Educational video|A 1-minute educational video format using BE FAST. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
41151471|NCT00666913|OTHER|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
41314992|NCT06483165|OTHER|F.A.S.T. Educational Video|A 1-minute educational video format using F.A.S.T. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
41151472|NCT00267956|DRUG|CNTO 1275 63 mg|The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
41151473|NCT00267956|DRUG|Placebo|The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
41151474|NCT00843245|OTHER|No intervention|No intervention
41151475|NCT02293278|BEHAVIORAL|Physical Activity Intervention|The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
41151476|NCT06490497|OTHER|Interview|individual interviews semi-directive
41151477|NCT05842278|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
41151478|NCT05842278|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
41151479|NCT05842278|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
41151480|NCT05842278|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
41151481|NCT05842278|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
41151482|NCT05413954|OTHER|Control|Control group ate snacks composed of dried vegetables, one classical egg yolk and 2.3g of sunflower oil during 10 weeks
41151483|NCT05413954|OTHER|Test|Tes group ate snacks composed of dried vegetables, one test egg yolk naturally enriched in rumenic acid, docosahexaenoic acid and punicic acid, 0.34g of pomegranate seed oil and 2.26g of olive oil during 10 weeks
41151484|NCT01879735|DRUG|11C-CSar|PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
41151485|NCT01879735|DRUG|ICG|Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
41151486|NCT02054442|DRUG|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
41151487|NCT02054442|DRUG|Methotrexate|
41151488|NCT03373188|BIOLOGICAL|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
41151489|NCT03373188|BIOLOGICAL|Ipilimumab|Given IV
41151490|NCT03373188|BIOLOGICAL|Nivolumab|Given IV
41151491|NCT03373188|PROCEDURE|Surgery|Undergo therapeutic conventional surgery
41151492|NCT04967092|DRUG|Modified Xiao-Feng Powder + Antiallergics|Modified Xiao-Feng Powder granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
41151493|NCT04967092|OTHER|Placebo + Antiallergics|Placebo granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
41151494|NCT00964756|GENETIC|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
41151495|NCT00964756|DRUG|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
41151496|NCT02732899|DRUG|Sirolimus|
41151497|NCT02732899|DRUG|EYLEA|
41151498|NCT06153836|PROCEDURE|Neurotization Procedure|Undergo placement of nerve graft
41151499|NCT06153836|OTHER|Questionnaire Administration|Ancillary studies
41151500|NCT06153836|PROCEDURE|Subcutaneous Mastectomy|Undergo standard of care NSM
41151501|NCT02008539|DRUG|MSC_apceth_101|
41151502|NCT02814461|DRUG|Axitinib|Axitinib (dose escalation): for total 8 weeks during and after RT, with starting dose of 1mg BID. According to the rule of traditional 3 + 3 design, 3-level axitinib dose escalation will be conducted: 1mg BID (level - I), 2mg BID (level - II) and 3mg BID (level - III).
41151503|NCT02814461|RADIATION|Radiation|Radiotherapy (RT) dose (fixed strength for normal liver): 37.5 to 67.5 Gy in 15 fractions (2.5 to 4.5 Gy per fraction) to liver tumor(s) (e.g. portal vein thrombosis, tumors with size ≥3 cm, or recurrent/refractory tumors). The final prescribed dose is based on an upper limit of mean liver dose of 18 Gy for all plans. (Daily Entecavir 0.5-1mg or Telbivudine 600mg is recommended for patients with positive hepatitis B during and 3 months after RT.)
41002267|NCT05686512|BEHAVIORAL|Step-by-Step|"The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given. See Figure 1 for a schematic representation of the stepped care approach, and Table 2 for an overview of session content.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)"
41002268|NCT05686512|BEHAVIORAL|Cool Kids|"The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (120 minutes)"
41314993|NCT04771052|OTHER|COVID Rehabilitation Program for the Elderly (CORE)|In the intervention unit, two teams (core team: physiotherapists and service healthcare workers; specialized team: occupational therapist, registered dietician, social worker) are dedicated to the patients hospitalized in COVID-19 unit. To prevent malnutrition, caused by disease-associated inflammation, the Nutrition as Medicine program (prescribed small doses (30 or 60 mL; 2 kcal/mL) of oral nutrition supplement dispensed with medication pass, 1 to 4 times a day), has been systematically implemented (collective prescription). To improve muscle strength, balance and tissue oxygenation and concomitantly reduce immobilization and risk of falls, each patient has a private pedal exerciser, resistance elastic bands and free weights to perform a progressive, monitored and individualized rehabilitation program thrice a day.
41472906|NCT05466344|DEVICE|Herbst Group|"1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured leaving an extended part of the plate in the oral cavity which contain the soldered ball housing.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.~4. Cementation of upper Herbst splint with connecting the telescopic piston through fitting of the plunger into the tube bilaterally.~5. When reactivation of the telescopic piston is needed, extension rings are used."
41472907|NCT05466344|DEVICE|TFBC Group|"1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.~5. Finally follow finishing steps for each patient."
41002269|NCT04362917|OTHER|There is no intervention|There is no intervention
41002270|NCT02066012|OTHER|dysmetabolic iron overload syndrome|
41314994|NCT03932682|BIOLOGICAL|QIVc|QIVc is a quadrivalent vaccine and contains 2 influenza type A strains and 2 influenza type B lineages recommended by World Health Organization (WHO) for inclusion in the quadrivalent vaccine formulation for the influenza season corresponding to the season of conduct of study.
41472908|NCT01353807|DIETARY_SUPPLEMENT|Fish oil|4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
41472909|NCT01353807|DIETARY_SUPPLEMENT|Olive oil|4 1-g gelatine capsules with virgin olive oil
41472910|NCT05841147|DRUG|Tirofiban|Intravenous administration of tirofiban
41002271|NCT04473651|DRUG|Lu AG06479|capsules, orally (Part A and B)
41151504|NCT05566626|DEVICE|Hyperspectral retinal image|Hyperspectral image of both eyes
41472911|NCT05841147|DRUG|normal saline|Intravenous administration of normal saline
41472912|NCT06227624|DRUG|Oral zinc sulfate and standard phototherapy|study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy
41472913|NCT01519102|DEVICE|Dual Hormone closed-loop system|The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
41472914|NCT02159937|OTHER|Blood sampling by vena punction.|In vitro tests will be performed after blood sample collection from metastatic cancer patients
41472915|NCT04134026|DRUG|HIF-PHI|Drug will be dosed orally three times a week.
41472916|NCT04134026|DRUG|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
41002272|NCT04473651|DRUG|Placebos|Placebo - capsules, orally (Part A only)
41002273|NCT04723199|DEVICE|Electrocautetery LAMS|Electrocautetery LAMS
41002274|NCT01192152|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
41002275|NCT01192152|DRUG|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
41002276|NCT01192152|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
41002277|NCT01505192|DEVICE|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
41151505|NCT05566626|DRUG|Mydriacyl Ophthalmic Product|Mydriatic drops before retinoscopy
41157061|NCT05554042|DIAGNOSTIC_TEST|Kintsugi Voice Device|The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.
41314995|NCT03932682|BIOLOGICAL|Comparator|Meningococcal Group C Polysaccharide Conjugate Vaccine (MenC vaccine, Neisvac-C)
41472917|NCT00574067|DRUG|Buprenorphine +OTP|Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
41472918|NCT00574067|DRUG|Buprenorphine +CHC|Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
41472919|NCT00574067|DRUG|Counseling +OTP|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
41002278|NCT05103228|DRUG|Follitropin Alfa|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
41002279|NCT05103228|DRUG|Follitropin delta|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
41002280|NCT05103228|DRUG|human menopausal gonadotropin|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
41002281|NCT05180136|DIETARY_SUPPLEMENT|Rice bran extract group|Rice bran extract 1,000 mg/day for 8 weeks
41002282|NCT05180136|DIETARY_SUPPLEMENT|Control group|Placebo 1,000 mg/day for 8 weeks
41002283|NCT00816868|DRUG|erlotinib in combination with capecitabine|Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
41002284|NCT03672695|COMBINATION_PRODUCT|S 64315 (also referred as MIK665) and venetoclax|"The treatment combination period can only begin after the planned dose of venetoclax is reached. Depending on the administration dosing schedule, the combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) during which the patient continues to receive venetoclax daily. Once the planned dose of both drugs is reached the schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.~S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 250 mg once a week might be explored.~Venetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy."
41002285|NCT04116645|OTHER|genital and rectal swab|6. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
41002286|NCT01930292|DRUG|Part A: Debio 1143|Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
41002287|NCT01930292|DRUG|Paclitaxel|Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
41002288|NCT01930292|DRUG|Carboplatin|Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
41002289|NCT01930292|DRUG|Part B: Debio 1143|RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
41002290|NCT00189735|DRUG|FK778|
41002291|NCT05728346|DRUG|Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers|stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers
41157062|NCT05971017|DIETARY_SUPPLEMENT|Control Group|Lettuce without any biostimulation was assigned to each participant belonging to the control group which ate 100gr every day for 15 days
41314996|NCT03825094|DEVICE|DyeVert™ Contrast Reduction Systems|Osprey Medical DyeVert™ Contrast Reduction Systems (DyeVert Systems) provide fluid pathway resistance modulation such that excess contrast media (CM) (i.e. CM that is not needed for diagnostic or therapeutic purposes) is minimized in the patient's vasculature and total contrast media volume (CMV) reduction occurs, while maintaining adequate image quality.
41314997|NCT05831618|OTHER|Interactive Visuo-Vestibular training|Dynamic motor activitites aimed to enhance the visuo-vestibular interaction and the sensorial reweighting will be performed for the Interactive Visuo-Vestibular training group.
41314998|NCT05831618|OTHER|Vestibular rehabilitation training|Dynamic motor activitites aimed to enhance vestibular reflexes will be performed for the vestibular rehabilitation group
40797979|NCT01487486|DRUG|IVF Antagonist Protocol|"1. Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~2. Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle \>14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~3. hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval."
40797980|NCT01791491|DRUG|Belatacept|Single intravenous infusion of belatacept, 7.5 mg/kg
40797981|NCT03263325|OTHER|Discarded urine sample|Collection of discarded urine during surgery and following surgery
40797982|NCT02308592|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important."
40797983|NCT02308592|BEHAVIORAL|Standard Resource Sheet|"Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization."
41002292|NCT04625608|DRUG|Paracetamol|Standard care of 3 ml/kg water, plus 15 mg/kg oral paracetamol suspension, a minimum of 1 hour prior to the induction of general anaesthesia.
41002293|NCT04625608|OTHER|Standard care|Standard care of 3.6 ml/kg water, a minimum of 1 hour prior to the induction of general anaesthesia.
41002294|NCT05196919|BIOLOGICAL|XT-150|XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.
41002295|NCT05196919|BIOLOGICAL|Placebo|Phosphate-buffered saline for injection
41002296|NCT00134212|DRUG|Dopexamine and norepinephrine|
41002297|NCT00134212|DRUG|Epinephrine|
41314999|NCT05360420|DIAGNOSTIC_TEST|Immediate CEUS|Subjects will receive CEUS examination immediately for the suspicious lesion detected by US.
41157063|NCT05971017|DIETARY_SUPPLEMENT|Biostimulated group|Intervention biostimulated group 100gr of biostimulated lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 15 days
41315000|NCT00393913|DEVICE|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
41315001|NCT03136952|DEVICE|NIRS frontal and occipital|NIRS frontal and occipital on pediatric population during general anesthesia
41315002|NCT02608034|DRUG|Itraconazole|Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
41315003|NCT02608034|DRUG|Rifampin|Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
41315004|NCT02608034|DRUG|Vemurafenib|Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.
41315005|NCT02853006|BIOLOGICAL|Blood and respiratory fluids sampling|In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
41315006|NCT02853006|PROCEDURE|Biopsy|
41315007|NCT02853006|PROCEDURE|Excised tissues|
41315008|NCT01492283|OTHER|OGTT|50g waterfree glucose dissolved in 300 ml water consumed over 5 min.
41315009|NCT01492283|OTHER|IIGI|iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose
41315010|NCT03466021|DRUG|Liraglutide|Initially 0.6 mg daily, increasing weekly with 0.6 mg, until 3.0 mg is reached.
41315011|NCT03466021|DRUG|Placebo|Matching injection
41315012|NCT04717141|OTHER|Selective nerve block|"D0 :~* Information, collection of consent, inclusion,~* Clinical and instrumental evaluation,~* Realization of the selective nerve block,~* Post-selective nerve block clinical and instrumental re-evaluation,~* Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~- Clinical and instrumental post-botulinum toxin injection evaluation."
41315013|NCT05175937|DEVICE|smartphone APP based remote monitoring|smartphone APP to monitor remotely patients implanted with ICD
41315014|NCT05175937|DEVICE|bedside transmitter based remote monitoring|bedside transmitter to monitor remotely patients implanted with ICD
41315015|NCT05611359|PROCEDURE|Thermal Ablation|Thermal hepatic ablation Combined with Chemotherapy
41315016|NCT05611359|DRUG|Chemotherapy|Chemotherapy
41315017|NCT05628584|COMBINATION_PRODUCT|High FODMAP diet with metformin|Controlled High FODMAP diet (15g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
41315018|NCT05628584|COMBINATION_PRODUCT|Low FODMAP diet with metformin|Controlled low FODMAP diet (3g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
41315019|NCT03698513|DRUG|BMS-986177|BMS-986177 capsule
41315020|NCT03698513|OTHER|Placebo (for BMS-986177)|BMS-986177 placebo match capsule
41315021|NCT03698513|DRUG|Clopidogrel|Clopidogrel tablet
41315022|NCT03698513|DRUG|Aspirin|Aspirin tablet
41315023|NCT01934894|DRUG|cabazitaxel|
41315024|NCT01934894|DRUG|lapatinib|
41315025|NCT02049801|DRUG|MEK inhibitor MEK162|Given PO
41315026|NCT02049801|DRUG|idarubicin|Given IV
41315027|NCT02049801|DRUG|cytarabine|Given IV
41315028|NCT02049801|OTHER|pharmacological study|Correlative studies
41315029|NCT02049801|OTHER|laboratory biomarker analysis|Correlative studies
41315030|NCT05073965|DIETARY_SUPPLEMENT|Vitamin D|Subjects were assigned to receive a 1000IU vitamin D supplement dose
41315031|NCT05073965|OTHER|Placebo|Subject were assigned to receive a placebo
41315032|NCT01076634|DRUG|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
41315033|NCT01076634|DRUG|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
40797984|NCT01754246|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
41315034|NCT00796094|OTHER|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
41472920|NCT00574067|DRUG|Counseling +CHC|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
41472921|NCT00925756|DRUG|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
41472922|NCT02858726|DRUG|CR845 0.5 mcg/kg|IV medication delivered three times/week
41151506|NCT05567848|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with functional MRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses per session. Sessions will be separated by an interval of 50 minutes (up to a total of 8 per day)."
41472923|NCT02858726|DRUG|CR845 1 mcg/kg|IV medication delivered three times/week
41472924|NCT02858726|DRUG|CR845 1.5mcg/kg|IV medication delivered three times/week
41472925|NCT02858726|DRUG|Placebo|IV medication delivered three times/week
40797985|NCT02382731|BEHAVIORAL|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.
40797986|NCT02382731|BEHAVIORAL|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
40797987|NCT03869567|DEVICE|cone beam CT|Just after thrombectomy, a cone beam CT will be done, while patient is on angiography table, in order to determine if hemorrhage image is due to contrast accumulation or blood-brain barrier disruption.
40797988|NCT02622295|BEHAVIORAL|Single-session electrically induced exercise|A single session of electrically induced exercise to the quadriceps and hamstring muscle groups of people with paralysis.
41315035|NCT00002717|DRUG|cisplatin|
41315036|NCT00002717|DRUG|paclitaxel|
41315037|NCT03734367|BEHAVIORAL|Emotional abilities training program|A randomized controlled trial that evaluates the effectiveness of a program of emotional skills on metabolic control to be assessed through the glycosylated hemoglobin (HbA1c), healthy lifestyle habits and wellbeing in adolescents with type 1, Diabetes Mellitus
41151507|NCT06241677|DRUG|alteplase or tenecteplase|Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given
41315038|NCT03637907|OTHER|Not applicable - no intervention.|No intervention is performed, just a CT with a new detector and comparison with the same patients older image.
41315039|NCT05503134|BIOLOGICAL|Universal Donor Natural Killer Cells|Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
41315040|NCT00062699|DRUG|Zemplar (paricalcitol injection)|
41315041|NCT00062699|DRUG|Calcijex|
41315042|NCT02292316|BEHAVIORAL|gait and cognitive assessments|several tests are given in each domain
41315043|NCT02292316|BIOLOGICAL|blood sample|routine analyses in rheumatology such blood count and 25OH-D
41315044|NCT02292316|OTHER|osteodensitometry|Looking for osteoporosis
41315045|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 2% Twice a day|nasal spray
41315046|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 3% Twice a day|nasal spray
41315047|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 4% Twice a day|nasal spray
41315048|NCT01277341|DRUG|Placebo Nasal Spray|nasal spray
41315049|NCT00679068|DRUG|Bosentan|62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
41315050|NCT04748406|DEVICE|Extracorporeal Shock Wave Therapy(ESWT)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied.
41315051|NCT04748406|OTHER|Peloid therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week
41315052|NCT04748406|OTHER|Home Workout Program|Patients will be given a home exercise program consisting of eccentric strengthening exercises and stretching exercises, which are planned to increase resistance every week. The patients will be taught strengthening exercises for forearm pronation-supination with wrist extensors and a home exercise program will be started 3 sets of 10 repetitions per day.
41315053|NCT04748406|OTHER|Cold application|At the beginning of each treatment, gel ice packs are wrapped with a moist towel and placed around the elbow joint for 15 minutes. will be applied.
41315054|NCT01778127|BEHAVIORAL|Activity Monitor|Measurement of physical activity.
41315055|NCT01778127|BEHAVIORAL|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
40797989|NCT02622295|BEHAVIORAL|Electrically-induced exercise training|Multiple sessions of electrically induced exercise to the quadriceps and hamstring muscle groups for up to 3 years in people with paralysis.
41151508|NCT02236299|PROCEDURE|Right Coronary Artery Percutaneous Coronary Intervention|
41151509|NCT02236299|OTHER|saline placebo infusion|30 minute placebo infusion used as a comparator to the GLP-1 infusion
41151510|NCT02236299|OTHER|GLP-1 Infusion|30 minute infusion GLP-1
41315056|NCT01778127|BEHAVIORAL|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
41315057|NCT02237157|DRUG|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
41315058|NCT05784337|DEVICE|Mi-thos® Transcatheter Mitral Valve Replacement System|Transcatheter Mitral Valve Replacement
41315059|NCT02358369|DRUG|Bimatoprost|Bimatoprost sustained release Ocular Insert
41315060|NCT02358369|DRUG|Timolol 0.5%|BID drops OU, 0.5% ophthalmic solution
41315061|NCT02358369|DEVICE|Placebo Ocular Insert|Placebo ocular insert OU.
41315062|NCT02358369|DRUG|Placebo Eye Drops|Placebo eye drops BID OU.
41315063|NCT03077763|DRUG|Sodium Nitrite|
41315064|NCT04935047|OTHER|Multilingual Support|Multilingual Support is a classroom intervention, which is designed to be delivered in classes of adult learning of a new language. The intervention involves the use of a language assistant, who is at minimum independent user (B1) in the language to be learned (in this case Norwegian), according to the language proficiency scale of the Common European Framework of Reference (CEFR) for languages, learning, teaching, assessment (Little, 2006). The language assistant will be in the classroom for seven hours a week, collaborating with the teacher in providing language training. In classrooms where participants have different primary languages, the language assistant(s) must cover all languages represented in the classroom.
41315065|NCT01401465|DRUG|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
41315066|NCT01401465|DRUG|mometasone|200 mcg mometasone aqueous nasal spray once daily
41315067|NCT06463548|DRUG|irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection (70mg/m2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
41315068|NCT06463548|DRUG|Capecitabine|Capecitabine (850 mg/m2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle.
41315069|NCT06463548|DRUG|Lenvatinib|Lenvatinib (8 mg) will be administered orally in a 2-week treatment cycle, once a day from day 1 to day 14 of each cycle
41315070|NCT01361919|PROCEDURE|Feedback During CPR Training and Testing|"Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool."
41315071|NCT01361919|PROCEDURE|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
41315072|NCT01361919|PROCEDURE|Feedback during CPR Training Not Testing|Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
41315073|NCT00581906|RADIATION|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1\^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) \& group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite \& will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st \& 2nd weeks of treatment \& the 2nd intra-treatment DCE-MRI is recommended between the 3rd \& 4th weeks of treatment.
41315074|NCT03314220|BEHAVIORAL|preoperative preparation|Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
41472926|NCT05402306|OTHER|Treatment group|Group metacognitive therapy, mainly with attention training technique over two weeks.
41472927|NCT06026813|DEVICE|test pressure alternating shoes|test pressure alternating shoes
40797990|NCT03102450|DRUG|Benzalkonium Chloride Spermicide Cream|"One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.~Duration of treatment : 6 months (12 months optional)"
41151511|NCT04143802|DRUG|LY3437943|Administered SC
41151512|NCT04143802|DRUG|Dulaglutide|Administered SC
41151513|NCT04143802|DRUG|Placebo|Administered SC
40797991|NCT05312411|BIOLOGICAL|SCRI-E2CAR_EGFRtv1|Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)
41151514|NCT01263223|DRUG|LY2216684|Administered orally
41151515|NCT01263223|DRUG|Placebo|Administered orally
41151516|NCT02625636|DRUG|SAR438544|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41151517|NCT02625636|DRUG|placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41151518|NCT02625636|DRUG|r-glucagon|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41151519|NCT01256645|OTHER|blood transfusion|application of single units of red blood cell transfusions
41151520|NCT05472233|PROCEDURE|Suture removal after Coronally Positioned Flap|Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
41315075|NCT05950347|DEVICE|Active Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
41315076|NCT05950347|DEVICE|Sham Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
41315077|NCT01159626|DRUG|PF-03463275|Oral single 20 mg dose as two 10mg controlled release tablets
41315078|NCT01159626|DRUG|PF-03463275|Oral single 40 mg dose as four 10mg controlled release tablets
41315079|NCT01159626|DRUG|PF-03463275|Oral single 60 mg dose as six 10mg controlled release tablets
41315080|NCT01159626|DRUG|Placebo|Oral single dose as matching placebo
41315081|NCT01159626|DRUG|PF-03463275|Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
41315082|NCT01159626|DRUG|Placebo|Oral multiple doses as matching placebo for 7 days
41315083|NCT01911845|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
41315084|NCT01911845|DRUG|ABT-333|Tablet
41315085|NCT01911845|DRUG|Ribavirin (RBV)|Tablet
41315086|NCT01797510|BEHAVIORAL|Web Based Health Coaching|
41315087|NCT04793763|OTHER|traditional therapeutic exercises|group A will receive traditional exercises
41315088|NCT04793763|OTHER|traditional therapeutic exercises and McKenize technique|Group B will receive traditional therapeutic exercises and McKenize technique
41315089|NCT04793763|OTHER|traditional therapeutic exercises and deep neck flexor exercises|Group C receive traditional therapeutic exercises and deep neck flexor exercises
41315090|NCT06105424|PROCEDURE|Lung Permeability Assessment|A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.
41315091|NCT02612389|OTHER|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
41315092|NCT00414778|DRUG|LHT344|
41315093|NCT04550221|BEHAVIORAL|Shauriana|The components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions. The four in-person health education and coaching sessions will be delivered once per week, by trained peer facilitators who identify as GBMSM. These sessions will focus on the following topics: sexual health basics (understanding how HIV and STIs are transmitted, prevented, and diagnosed/treated), relationships (types of relationships we have, characteristics of healthy relationships, communication skills), stress and coping (understanding mental health challenges, adaptive and maladaptive coping strategies), and healthy sexuality and empowerment (understanding sexual orientation and gender identity, challenging stereotypes about GBMSM, making sexual choices).
41472928|NCT02380313|DRUG|Afuresertib|White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
41472929|NCT02380313|DRUG|Enzalutamide|Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
40797992|NCT05312411|DRUG|UB_TT170|Bispecific small molecule adapter formulated with phosphate buffered saline
40797993|NCT04742530|BEHAVIORAL|Fasted Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after a 7-hour period of fasting. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
40797994|NCT04742530|BEHAVIORAL|Fed Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
40797995|NCT04742530|BEHAVIORAL|Fed Morning Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 10:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
41472930|NCT02380313|DRUG|Abiraterone|White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
40797996|NCT04072835|DRUG|Etripamil NS|Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
40797997|NCT02846792|BIOLOGICAL|Nivolumab|Given IV
41472931|NCT02380313|DRUG|Prednisone|Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
40797998|NCT02846792|DRUG|Plinabulin|Given IV
40797999|NCT01229683|PROCEDURE|Interscalene Nerve Block|Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
40798000|NCT05690347|BEHAVIORAL|Back At work After Surgery (BAAS)|see protocol
40798001|NCT04381299|OTHER|autologous platelet rich plasma|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
40798002|NCT04381299|OTHER|saline solution|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
41002298|NCT06188442|DRUG|DoxyODPrEP|Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex
41002299|NCT06188442|DRUG|DoxyPEP|Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
40798003|NCT01527240|DRUG|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
40798004|NCT01527240|DRUG|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
40798005|NCT03275090|DRUG|Smoflipid ®|
40798006|NCT03742479|DEVICE|Restylane® Silk|Injectable Hyaluronic Acid (HA)
40798007|NCT05052944|DEVICE|Cochlear implantation|Patients who receive cochlear implant for single-sided deafness
40798008|NCT04729153|DRUG|DAAD Compound|Sofosbuvir , Daclatasvir and ribavirin
40798009|NCT05594771|PROCEDURE|epidural needle|the loading dose for labor analgesia administrated via epidural needle before the catheter insertion
40798010|NCT05594771|PROCEDURE|epidural catheter|the loading dose for labor analgesia administrated via epidural catheter
41002300|NCT05993676|BEHAVIORAL|MeT4VeT mobile phone app: control|The control/ sham comparator arm of the Mental Health Toolkit for Veterans (MeT4VeT) smart phone app contains only signposting information around support services available to military veterans
41002301|NCT05993676|BEHAVIORAL|MeT4VeT mobile phone app: intervention|"The Mental Health Toolkit for Veterans (MeT4VeT) smart phone app has been developed through careful and close collaboration with military veterans and key providers of veterans' mental healthcare services. The aim of this app is to provide both a degree of education to support military veterans' understanding of mental health and foster self-recognition and management of mental health symptoms whilst also encouraging those who need it to seek more formal support.~The elements of the app have been chosen for inclusion as they represent the intersection between:~1. Core components of cognitive behavioural therapy, the theoretical framework underwriting the app~2. Behaviour change constructs"
41002302|NCT05540366|OTHER|Physical therapy combined with aerobic exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike.
41002303|NCT05540366|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)
41472932|NCT01638858|DRUG|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
41472933|NCT02809820|DRUG|Carvedilol|Patients randomized to this group will receive carvedilol at the highest dose tolerated
41472934|NCT02809820|DRUG|Metoprolol|Patients randomized to this group will receive metoprolol at the highest dose tolerated
41472935|NCT00725478|DRUG|Piribedil|
40798011|NCT00241176|DRUG|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS \& CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
40798012|NCT01324050|BEHAVIORAL|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
40798013|NCT01324050|BEHAVIORAL|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
40798014|NCT01995500|DEVICE|BioNIR|drug-eluting stent
40798015|NCT01995500|DEVICE|Resolute|drug-eluting stent
40798016|NCT01696799|DRUG|Econazole Nitrate|
40798017|NCT01696799|DRUG|placebo|
40798018|NCT05628870|DRUG|HRS-1358|HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.
40798019|NCT00002811|DRUG|liposomal T4N5 lotion|
40798020|NCT05356988|BEHAVIORAL|Physical activity experiment|The Physical Activity (PA) group will have access for one year to the PA website to help increase aerobic and strength training activities.
41002304|NCT05595408|DRUG|Adjuvant chemotherapy|cisplatin/carboplatin-gemcitabine 4-6 cycles
40798021|NCT05356988|BEHAVIORAL|Balance and flexibility control|The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure around stretching and balance exercises.
40798022|NCT02236572|DRUG|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~* Anastrozole 1 mg~* Letrozole 2.5 mg~* Exemestane 25 mg"
40798023|NCT03930381|OTHER|ASTHMAXcel App|ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
40798024|NCT01541735|DRUG|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
40798025|NCT01541735|DRUG|placebo|Placebo 40 mg dose.
40798026|NCT02725476|BIOLOGICAL|XmAb5871|
41002305|NCT05595408|DRUG|adjuvant immunotherapy|immunotherapy for one year
41315094|NCT05363683|PROCEDURE|Squat Biofeedback|The intervention group will complete bilateral squats with each limb on a separate portable force plate. They will receive real-time visual feedback on a 32-inch screen during all squats. Biofeedback conditions will be progressed from simplest (ground reaction force only) to most complex (ground reaction force plus center of pressure). This intervention will be included in additional to standard care post-operative physical therapy.
40798027|NCT05746091|PROCEDURE|wrist arthroscopy|Arthroscopic Partial Trapeziectomy with Hematoma Distraction in Basal Thumb Arthritis
40798028|NCT04672980|DRUG|RTX-321|RTX-321 monotherapy
40798029|NCT01422941|DEVICE|CAVU Attune Device|The CAVU Attune device is used with LAGB.
40798030|NCT05619120|DRUG|Mexiletine|Mexiletine (150mg, bid, po) is given to patients who have been divided into Mexiletine group.
40798031|NCT05619120|OTHER|Conventional therapy|Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
41002306|NCT00660348|DRUG|morphine sulfate|This is morphine given in the traditional methods.
41002307|NCT00660348|DEVICE|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
41002308|NCT05926167|DIAGNOSTIC_TEST|blood tests drawn days 1, 8, 22 and 90 of the study|Blood tests related to Factor VIII activity that are not a part of standard of care
41002309|NCT05371600|DRUG|Midazolam|midazolam IV at 0.04 mg/kg
41002310|NCT05371600|OTHER|Saline|an equal volume of saline IV
41315095|NCT05363683|PROCEDURE|Standard Care|Standard care post-operative physical therapy
41315096|NCT01000194|DIETARY_SUPPLEMENT|High fat meal|A high fat milkshake containing 55g of fat
41315097|NCT00006454|DRUG|carboplatin|
41315098|NCT00006454|DRUG|paclitaxel|
41315099|NCT00006454|DRUG|topotecan hydrochloride|
41315100|NCT03886142|PROCEDURE|radiofrequency|radiofrequency of the genicular nerves
41315101|NCT03886142|PROCEDURE|platelet rich plasma injection|intra articular injection of platelet rich plasma
41315102|NCT02193256|DRUG|Varenicline|Titrated over 1 week to a maximum dose of 2mg/day
41315103|NCT02193256|DRUG|Prazosin|Titrated over 3 weeks to a maximum dose of 8mg/day
41315104|NCT02193256|DRUG|Placebo|
41315105|NCT01665248|OTHER|18-F Sodium Fluoride Uptake in Positron emission tomography|
41315106|NCT05646446|BEHAVIORAL|REACH Program|The REACH program addresses alcohol use, sexual assault risk, and experiences relating to harm among bisexual women.
41315107|NCT05699772|BEHAVIORAL|Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI)|The GLB-TBI was modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB) by a group of stakeholders using a community based participatory research approach. The GLB-TBI is modified for people with Traumatic Brain Injury and addresses their unique weight loss and healthy lifestyle needs.
41315108|NCT05699772|BEHAVIORAL|Brain Health Group (BHG)|The BHG was developed by researchers and clinicians at Baylor Scott \& White Institute for Rehabilitation.
40798032|NCT01108328|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
40798033|NCT04599491|DEVICE|Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'|Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.
40798034|NCT04599491|DEVICE|Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'|Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.
40798035|NCT01160393|DEVICE|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
40798036|NCT01458743|DRUG|Ceftaroline|60-minute single intravenous dose of 600 mg of Ceftaroline on Days 1 and 8; 60-minute intravenous dose of 600 mg of Ceftaroline twice per day on Days 3-7.
40798037|NCT01458743|DRUG|Ceftaroline|Single intravenous dose on Days 1 and 9. Intravenous three times per day on Days 2-8.
40798038|NCT01448889|DRUG|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
40798039|NCT01448889|DRUG|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
40798040|NCT03019757|RADIATION|DaTscan|A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT
41315109|NCT06423287|DIETARY_SUPPLEMENT|Lactobacillus plantarum LP-KFY04|Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks' trial.
41472936|NCT03142659|OTHER|registry-no intervention|registry-no intervention After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide
41472937|NCT01039454|DRUG|GSK598809 Capsules|GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
40798041|NCT03019757|RADIATION|F18-AV-45|A brain scan to to measure the extent of amyloid deposition
40798042|NCT03019757|RADIATION|FDG-PET|a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
40798043|NCT03019757|GENETIC|APOE genotype|10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
40798044|NCT03019757|PROCEDURE|Polysomnogram|Overnight sleep study
40798045|NCT03019757|BEHAVIORAL|Clinical Assessment|Clinical assessments include cognitive, behavioral, and motor evaluations
40798046|NCT03757624|PROCEDURE|shrinkage|shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
40798047|NCT02546726|BEHAVIORAL|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
40798048|NCT02546726|BEHAVIORAL|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
40798049|NCT05529082|OTHER|Opioid Attitudes|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
40798050|NCT05529082|OTHER|Beliefs survey|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
40798051|NCT01926444|DRUG|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
40798052|NCT01460810|OTHER|1000CsK Silicon Oil Tamponade|Details covered in arm description
40798053|NCT00083460|DRUG|PS-341|Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
40798054|NCT00083460|DRUG|Thalidomide|In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
40798055|NCT00083460|DRUG|Dexamethasone|A dose of 20mg for cylces 3-8.
40798056|NCT04644198|BIOLOGICAL|Convalescent Plasma Infusion|250 mls of convalescent plasma on day 1 \& 2.
41315110|NCT06423287|OTHER|Take placebo in addition to the limited diet.|Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks'trial.
41315111|NCT02320695|DRUG|Saline|
41315112|NCT02320695|DRUG|Isopropyl Alcohol|
41315113|NCT02320695|DRUG|Pain Relieving Cream|
41315114|NCT02320695|DRUG|Antibiotic/Pain Relieving Ointment|
41315115|NCT02320695|DRUG|Original Ointment|
41315116|NCT02320695|DRUG|Pain Relief Ointment|
41315117|NCT03517917|OTHER|Tumour tissue collection|Collection of tumour tissue and blood
41315118|NCT03926767|OTHER|Pain Neuroscience Education (PNE)|A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
41315119|NCT03926767|OTHER|Orofacial Manual Therapy|A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
41315120|NCT03926767|OTHER|Orofacial Exercises|Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
40798057|NCT02782234|BEHAVIORAL|Contract management|
40798058|NCT04454346|DEVICE|Double Foley Catheter For Ripening The Unfavorable Cervix|New method
40798059|NCT01811589|DEVICE|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
40798060|NCT01811589|OTHER|Free-hand|Ventricular catheter placement without a guidance (free-hand)
41315121|NCT03926767|OTHER|Neck Motor Control Exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
41315122|NCT02357641|OTHER|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
41472938|NCT01039454|DRUG|GSK598809 Placebo Capsules|Treatment of substance dependence and potentially other impulse control disorders.
40798061|NCT02424058|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
41315123|NCT01596959|PROCEDURE|Radiofrequency ablation utilising the ECI contact software|irrigated radiofrequency ablation to the right atrium using the ECI contact data
41472939|NCT03485482|DRUG|Bisoprolol|bisoprolo 5 mg tablets
41315124|NCT01596959|PROCEDURE|Radiofrequency ablation without the use of ECI contact data|irrigated RF ablation without the use of ECI contact data
41315125|NCT01417065|DRUG|Temsirolimus|Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
41315126|NCT00230529|DRUG|infliximab|
41472940|NCT03485482|DRUG|Ivabradine|Ivabradine 10 mg tablet
41472941|NCT03485482|DRUG|combination of Ivabradine and bisoprolol|combination of 10 mg ivabradine and 5 mg bisoprolol
40798062|NCT02424058|BEHAVIORAL|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
40798063|NCT03301779|DEVICE|Hemanext Red Blood Cell Processing System|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
40798064|NCT06365658|DIAGNOSTIC_TEST|Psychological assessment|Psychological assessment of memory, learning and language
40798065|NCT00265486|DRUG|Recombinant human Erythropoietin|Adm 100 U/kg sc 1 hour before completing exercise in protocol
40798066|NCT05226832|PROCEDURE|40mg Triamcinolone Injections in the Bladder|Patients will undergo a standard of care cystoscopy with non-standard of care solumedrol injections in the clinic. Subjects will have lidocaine jelly instilled into their bladder for 5 minutes prior to injection cystoscopy. Injections will be performed using a 17fr flexible cystoscope in the outpatient setting. There will be 10 intravesical Injections of 1cc of 40mg solumedrol diluted to 10cc with injectable normal saline. The needle will penetrate the bladder at a depth of 2-3mm using a Laborie endoscopic single use needle, about the length of a pencil tip. The patient may experience discomfort with cystoscopy and injections. Any procedure complications will be noted based on the Clavien-Dindo Classification Index, discussed in the safety section. This is estimated to take 30 minutes.
40798067|NCT04358146|OTHER|Experimental Infant formula|Exclusive formula feeding with the new infant formula thickened with fibers
41315127|NCT03746223|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses as maintenance
41315128|NCT03746223|DRUG|Rituximab|Rituximab：375mg/m2 intravenous infusion d1, every 28 days for 1 cycle. 6 cycles will be prescribed as protocol
41315129|NCT03746223|DRUG|Lenalidomide|25mg Qd, oral , d1-21 in 28-day cycle in the induction phase and maintenance phase.
41315130|NCT04182256|DEVICE|MS|Magnetic Spiderman (MS) is a novel surgical instrumentIt. It consists of a circular neodymium iron boron magnet packed in a stainless-steel case with a spring and a jagged clamp, which gives it a spider-like appearance.
41315131|NCT02871193|DRUG|Ropivacaine|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml
41315132|NCT02871193|DRUG|Dexamethasone|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg
41315133|NCT02871193|OTHER|saline|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
41315134|NCT02619318|BEHAVIORAL|Balancing Everyday Life (BEL)|
41315135|NCT02619318|BEHAVIORAL|Care as usual (generally standard occupational therapy)|
41315136|NCT00395837|BEHAVIORAL|Aerobic exercise|
41472942|NCT03800225|PROCEDURE|Repair|Anterior ligament repair with internal brace.
41002311|NCT05311371|OTHER|Breathing exercise group|"The exercise was applied in accordance with the Guideline on Breathing Exercise for Reducing Nausea and Vomiting prepared by the researcher in accordance with the literature. In addition, the researcher has a breath coaching certificate. The guideline include the application steps of breathing exercise. First, the researcher will demonstrate to the patients the practice of breathing exercise in accordance with the guideline. In the next step, patients they will be asked to do this application on themselves. The training is planned to take about 15-20 minutes for each patient. This guide will be given to patients after the training. They will be asked to do this breathing exercise correctly and effectively in accordance with the guideline for at least 5 min in case of sensation of nausea and vomiting for 14 days. The researcher will follow up the patients for 14 days by visiting room them every day."
41002312|NCT05311371|OTHER|Control group|No intervention
41002313|NCT01112384|DRUG|SB939|Given orally 3 times per week
41002314|NCT02174835|DRUG|AVP-786|
41151521|NCT00761241|DRUG|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
41002315|NCT02174835|DRUG|AVP-923|
41151522|NCT00761241|BIOLOGICAL|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
41002316|NCT04380311|DEVICE|Tacrolimus Dosing Support Tool|The tacrolimus dosing support tool is based on a population pharmacokinetic model that incorporates patient specific factors including age, renal function, and concomitant medications.
41002317|NCT01514396|DEVICE|Surgiseal|surgical glue
41002318|NCT04679077|OTHER|Cytocam-IDF imaging device|Observation of the microcirculation
41002319|NCT00324064|PROCEDURE|GHRH/arginine stimulation testing|GHRH(Geref) 1mcg/kg IVP followed by Arginine 10% solution 0.5mg/kg (maximum of 30 Gm) infused over 30 minutes. Labs drawn 6 times over 2 hours.
41002320|NCT00717769|DRUG|SUN13834|Low dose, orally 3 times a day (tid) for 28 days of SUN13834
41002321|NCT00717769|DRUG|Placebo|Placebo, orally (tid) for 28 days of SUN13834
41002322|NCT00915512|DRUG|Paliperidone extended-release (ER)|Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
41151523|NCT00761241|RADIATION|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
40798068|NCT04358146|OTHER|Infant formula thickened with locust bean gum|Exclusive formula feeding with the formula thickened with locust bean
40798069|NCT06038292|RADIATION|DXA Scan|DEXA (dual x-ray absorptiometry) Scans which measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip, the spine and the bones of the hands and can easily diagnose osteoporosis.
41002323|NCT01965808|DRUG|LY2157299|Administered orally
41002324|NCT03755388|DEVICE|Episealer|Placing Episealer device
41002325|NCT00450710|PROCEDURE|ileal interposition with a sleeve gastrectomy|
41002326|NCT04623580|DEVICE|Surgical inguinal or femoral hernia repair|Surgical inguinal or femoral hernia repair (primary or mesh)
41002327|NCT02008500|OTHER|placebo mouthwash|15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
41002328|NCT02008500|OTHER|Herbal Mouthwash|15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
41002329|NCT02008500|OTHER|Non Herbal Mouthwash|15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
41002330|NCT04027166|DRUG|Methadone|Methadone will be administered before study procedures
41002331|NCT04027166|DRUG|Methadone|Methadone will be delayed (4 hours) until the end of the procedures
41002332|NCT02791620|DEVICE|a nanofractional radiofrequency device|A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
41002333|NCT01582997|DRUG|GSK2118436|Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
41002334|NCT04886011|COMBINATION_PRODUCT|placebo gel|just methyl cellulose gel was applied to the ulcer
41002335|NCT04886011|COMBINATION_PRODUCT|camel whey protein gel|camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
41002336|NCT01449526|DEVICE|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
41002337|NCT01449526|DEVICE|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
41151524|NCT00761241|PROCEDURE|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
41315137|NCT04020146|OTHER|Gingival biopsies|Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.
40798070|NCT04329806|DRUG|Moxonidine 0.2 MG|Moxonidine 0.2 MG twice daily
41002338|NCT04433468|DEVICE|RIPC|The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.
41002339|NCT03914742|DRUG|PARP Inhibitor BGB-290|Given PO
41315138|NCT01717664|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
41315139|NCT00516633|BEHAVIORAL|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
41315140|NCT01144234|BEHAVIORAL|Invitation letter for male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
41472943|NCT06151067|DIAGNOSTIC_TEST|High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testing|High-Resolution Manometry Upper-GI endoscopy pH-Impedance testing
40798071|NCT04329806|DRUG|Amlodipine 5 MG|Amlodipine 5 MG twice daily
41002340|NCT03914742|DRUG|Temozolomide|Given PO
41151525|NCT04486742|BEHAVIORAL|Itch CBT|Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.
41151526|NCT06465433|DRUG|Tafasitamab|Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
40798072|NCT04981106|OTHER|Elastic Band Exercise|"The participants were asked to do exercise 4 times a day with a minimum of 2 hours interval between the sessions. The participants were instructed to avoid elastic band exercise 1 hour before or after the meals in order to prevent a physical impairment and to adopt a moderately progressive approach in order to prevent lower extremity pain after exercise and to increase the sense of success and confidence.~Through phone calls, researchers asked the participants in intervention group if they do the elastic band exercises at home and if they had any difficulty while doing these exercises, as well as the reasons if they haven't done the exercises. When the participants in control and intervention groups returned to hospital after 4 weeks, the knee joint movement, lower extremity strength, knee joint pain, quality of life, kinesiophobia, and depression levels and physical functions of these groups were compared."
40798073|NCT00988052|DRUG|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
41002341|NCT03914742|PROCEDURE|Therapeutic Conventional Surgery|resection surgery
41002342|NCT04697979|OTHER|Questionnaire|"Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary."
41002343|NCT05256238|OTHER|comprehensive supervised exercise program (CSEP)|"The CSEP starts as soon as possible after cancer diagnosis and lasts for 12 weeks:~* week 1-6 (during cancer treatment): 2 supervised sessions at the exercise room of the University Hospital Leuven in connection to the radiotherapy treatment session and one additional session at home. Patients will receive equipment to perform the program at home, e.g. weights, therabands,...~* week 7-12 (after cancer treatment): 1 supervised session at the exercise room of University Hospital Leuven in connection to the follow-up consultations (once a week) with the oncologist and two additional sessions at home~* maintenance program (from week 13), patients will exercise at home with a monthly teleconsultation"
41002344|NCT06190561|DRUG|PF-07940367|Participants to receive a single dose of PF-07940367 product II 150 mg by mouth
41002345|NCT06190561|DRUG|PF-07940367|Participants to receive a single dose of PF-07940367 product I 150 mg by mouth
41002346|NCT03196752|PROCEDURE|laryngeal handshake|palpate for the cricothyroid membrane using the laryngeal handshake technique
41002347|NCT03196752|OTHER|simple palpation|conventional
41002348|NCT01897675|PROCEDURE|Incision and Drainage with packing (wick) placement|
41151527|NCT05727878|DRUG|KPI-012|KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells
41151528|NCT05727878|DRUG|KPI-012 Vehicle|KPI-012 formulation with no active drug
41151529|NCT03664271|BEHAVIORAL|in-clinic video intervention|Video with information about eczema and eczema treatment, to be watched in clinic and at home
41315141|NCT01144234|BEHAVIORAL|Information letter|In this arm the pregnant women got an information letter
41315142|NCT00002903|DRUG|docetaxel|
41315143|NCT01231360|OTHER|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
41315144|NCT01231360|OTHER|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
41315145|NCT01483898|BIOLOGICAL|Ixmyelocel-T|On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
41472944|NCT04529395|OTHER|Blending of essential oils|The mixture of essential oils will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
41472945|NCT04529395|OTHER|Apricot vegetable oil|The apricot vegetable oil will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
41472946|NCT00860691|PROCEDURE|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
41472947|NCT00860691|PROCEDURE|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
40798074|NCT02041390|OTHER|SMS reminder|Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
40798075|NCT02041390|OTHER|Conventional reminder|After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
40798076|NCT05260138|OTHER|Gentle Body message|The intervention group received gentle body massage twice/day and position change from supine to lateral every two hours under the phototherapy for three consecutive days in addition to routine NICU care.
40798077|NCT05260138|OTHER|Routine NICU Care|received the conventional NICU care of infants undergoing phototherapy. Phototherapy was given by single Blue LEDs emitting light in a narrow spectrum (450-470 nm). Initially, phototherapy lamps were checked and adjusted at the height of 30 cm from the neonates who were kept naked in the incubator/crib except for the reproductive organs with shielded eyes. The neonates were positioned supine under the phototherapy. The treatment was given continuously, except while feeding and nursing for 30 minutes every 3 hours. The neonates' skin was cleaned with warm water without applying any sorts of ointments oils or creams. They were also observed for signs of dehydration.
41002349|NCT01897675|PROCEDURE|Abscess drainage with loop placement|
41002350|NCT00259090|DRUG|Fulvestrant|500 mg intramuscular injection
41002351|NCT00259090|DRUG|Anastrazole|oral tablet
41002352|NCT05114304|OTHER|Evaluation of co-morbid psychiatric disorders|"Added scales :~* Mini Internationnal Neuropsychiatric Interview~* Fagerström test~* DSM-5 Scale~Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics~Expired carbon monoxide for patients using nicotine substitutes"
41151530|NCT03664271|BEHAVIORAL|at home video intervention|Video with information about eczema and eczema treatment, to be watched at home only
41151531|NCT03444155|DIETARY_SUPPLEMENT|Natural Panmol-B-Complex|Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) - Synthetic Vitamin B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
41315146|NCT01483898|OTHER|Placebo|On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
41315147|NCT05126706|BEHAVIORAL|Digital lifestyle management|Digital lifestyle management for Weight Loss Control after Thyroidectomy
41315148|NCT03719326|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist for oral use
40798078|NCT02399124|DEVICE|PROSENSE™|single arm, open label, PROSENSE™ treatment
40798079|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of gastric tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of gastric tumor."
41002353|NCT06485271|DRUG|Camrelizumab|200mg,iv,d1,Q2W/Q3W
41002354|NCT06485271|DRUG|apatinib|250mg,qd
41002355|NCT06485271|DRUG|chemotherapy|Standard treatment
41002356|NCT03549702|DRUG|Povidone iodine 1% solution|irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure
41002357|NCT04133493|DEVICE|Kerecis Omega3 Wound|"The intervention group will receive, in addition, a fish skin graft (KerecisTM Omega3 Wound) secured with Steristrips, sutures or staples, covered with a nonadherent dressing (Adaptic, Systagenix, Yorkshire, UK or equivalent), the product bolstered down to the wound bed with a foam dressing (HydraFoam, DermaRite) and hydrogel as needed to retain adequate moisture balance and padded with stretch gauze and self adherent wrap as needed.~The wound will be dressed by the site investigator 1 day a week."
41151532|NCT03444155|DIETARY_SUPPLEMENT|Synthetic Vitamin B-Complex|Synthetic Vitamin B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85µg) - Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
41315149|NCT03719326|DRUG|IPI-549|IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use
41315150|NCT03719326|DRUG|Pegylated liposomal doxorubicin (PLD)|Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
41315151|NCT03719326|DRUG|nanoparticle albumin-bound paclitaxel (NP)|NP is a microtubule inhibitor for intravenous (IV) use
41315152|NCT04489485|BEHAVIORAL|Teen Depression Module used for care|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, and treatment using the Teen Depression Module and offered a depression chabot. Suicide screening will be conducted.
41151533|NCT04770909|BEHAVIORAL|Incentives for dietary self-monitoring and weight loss|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
41472948|NCT00860691|OTHER|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
40798080|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of colorectal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of colorectal tumor."
40798081|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of bladder tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples ,urine sample，blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the three types of samples of the patients respectively, and the DNA sequencing results of the three types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA ,urine ctDNAand tissue gDNA for the gene detection of bladder tumor."
40798082|NCT01185951|DRUG|Polidocanol|Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks
40798083|NCT01185951|DEVICE|Focused extracorporeal shock wave therapy|Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks
40798084|NCT01185951|DRUG|Topical NO|Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
40798085|NCT01185951|BEHAVIORAL|Painful eccentric training in Achilles tendinopathy|Painful eccentric training for Achilles tendinopathy on a stair single-stance with 6x15 repetitions per leg and day over at least 12 weeks
41002358|NCT04133493|DEVICE|Fibracol|The Standard of Care Group will receive Fibracol covered with DSD. Change three times per week
41002359|NCT01506531|PROCEDURE|silo for gastroschisis|silo placed around abdominal contents in gastroschisis patients
41002360|NCT01506531|PROCEDURE|Primary closure of gastroschisis|Primary closure of gastroschisis, if possible
41151534|NCT04770909|BEHAVIORAL|Incentives for dietary self-monitoring|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
41151535|NCT04770909|BEHAVIORAL|Incentives for weight loss|Participants can earn up to $300 during the trial for achieving weight loss
40798086|NCT01185951|BEHAVIORAL|Painful eccentric training for patella tendinopathy on 25° decline board|Painful eccentric training for patella tendinopathy on a 25° decline board single-stance with 6x15 repetitions per leg and day over at least 12 weeks
40798087|NCT01185951|BEHAVIORAL|Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar|Painful eccentric training for elbow tendinopathy using a green coloured Thera-Band Flex-Bar with painful supination and pronation with 6x15 repetitions per day over at least 12 weeks
40798088|NCT05892497|OTHER|Tecartherapy|The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.
41002361|NCT02376946|DEVICE|ActiPatch(TM)|Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
41002362|NCT02376946|DEVICE|Placebo|Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
41002363|NCT03391973|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
41002364|NCT04891848|OTHER|inflammation|inflammatory values in complete blood count (CBC)
41002365|NCT01730183|OTHER|Bone marrow derived stem cells|Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
41002366|NCT06026904|DEVICE|transcutaneous auricular vagus nerve stimulation|taVNS was developed as a non-invasive variant of VNS where the vagus nerve is stimulated through the skin of the auricle, which has become a promising avenue for research and, potentially, treatment of various disorders. Commonly, taVNS is applied via the ear targeting the auricular branch of the vagus nerve, where the stimulation elicits far-field potentials. In line with preclinical studies, acute taVNS enhances invigoration of effort and response inhibition capability.
41002367|NCT01876264|PROCEDURE|Extended resection|
41002368|NCT01876264|PROCEDURE|Conventional resection|
41151536|NCT06029595|DRUG|Experimental: CHF6001 3200 μg|800 μg/actuation - 2 inhalations of CHF6001 800 μg twice daily (BID) total daily dose 3200 μg
41151537|NCT06029595|DRUG|Placebo Comparator: CHF6001 Placebo|2 inhalations of CHF6001 matching placebo BID
41151538|NCT04374435|PROCEDURE|MKTP with Surgical blade|In this procedure, the donor skin will be harvested with a surgical blade and the donor skin will be dissociated
41151539|NCT04374435|DEVICE|MKTP with Negative Pressure Instrument|In this procedure, the investigator uses a negative pressure instrument to create a few blisters on the donor skin and use the blisters for grafting after cell dissociation.
41315153|NCT03773926|DEVICE|Neuro-feedback therapy|The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
41472949|NCT02382926|OTHER|Capacitive ECG and contactless heart and breathing rate measurements via camera|During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
40798089|NCT05415423|BEHAVIORAL|Developing an objective measure of experienced pain|"At the beginning of each study, participants are randomly allocated into one of two groups.~Within each group all participants are exposed to the same painful stimulus. One group experiences a painful stimulus of higher intensity compared to that of the other group. The painful stimuli are physically identical for every subject within the same group and within the standard of previous pain research.~Participants are then asked to evaluate the painful stimulus they just received according to a self-reported scale (NRS, VAS, gLMS, NRS-MB). Participants are also asked to decide multiple times whether they prefer a larger amount of money and experience the same or more painful stimulus they received before or a smaller amount of money and no (or a less) painful stimulus. The smaller amount of money is progressively increased across choices until it matches the larger amount, similar to multiple price-list methods (MPL) which are standard in economics."
40798090|NCT04219449|DIAGNOSTIC_TEST|PT|measuring PT drawn on citrated blood sample
40798091|NCT04219449|DIAGNOSTIC_TEST|Protein C|measuring protein C drawn on citrated blood sample
40798092|NCT04219449|DIAGNOSTIC_TEST|Platelet aggregation by ADP and arachidonic acid|measuring platelet aggregation drawn on citrated blood sample
40798093|NCT01034501|DEVICE|sham procedure|non activated laser tip
41002369|NCT04401891|BEHAVIORAL|Formal pre-operative education|One group of patients will receive formal pre-operative education prior to surgery from an occupational or physical therapists while the other group of patients will only receive routine education in the MD office.
41002370|NCT06333795|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Treatment is given as capsules.
41002371|NCT06333795|PROCEDURE|Placebo|Treatment is given as capsules.
41002372|NCT06106971|DRUG|Sodium tetradecyl sulfate|Subjects receive sodium tetradecyl sulfate via balloon-occluded retrograde transvenous obliteration at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding.
40798094|NCT01034501|DEVICE|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
41002373|NCT06106971|DRUG|Cyanoacrylate|Subjects receive endoscopic cyanoacrylate injection at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding then receive repeated endoscopic cyanoacrylate injection at 1-month intervals until obliteration of gastric varices.
41002374|NCT05371314|DIAGNOSTIC_TEST|P/FP ratio|PaO2/FiO2 X PEEP, SpO2/FiO2 X PEEP
41002375|NCT03435549|BEHAVIORAL|Remote monitoring|Patients given an activity tracker to wear for 6 weeks after LEJR replacement surgery. For 2 weeks after surgery, they will also receive a daily text messages asking what their pain is on a scale of 0 to 10. They will be asked to reply to the text with their pain score. They will also be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days.
41002376|NCT03435549|BEHAVIORAL|Remote monitoring plus goal setting and social support|Patients given activity tracker to wear for 6 weeks after LEJR surgery. For 2 weeks after surgery, they will receive a daily text messages asking what their pain is on a scale of 0 to 10 and asked to reply by text. They will be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days. Patients will be asked to identify a a friend or family member to act as support partner. The study will share progress updates with support partner and contact this individual if patient stops wearing the activity tracker for over 3 days. This partner will also be able to provide supportive messages to help encourage them to reach their activity goals.
41002377|NCT00364780|DRUG|XL647|XL647 will be administered orally as a single agent. XL647 will be supplied as 50 mg tablets. Subjects in the Intermittent 5 \& 9 cohort will receive XL647 at a dose of 350 mg on a 5 days on and 9 days off cycle every 2 weeks for 8 weeks. Subjects in the Daily Dosing cohort will receive XL647 administered daily as a single oral dose of 300 mg. In the absence of progressive disease (PD) and unacceptable XL647-related toxicity, subjects may continue to receive XL647 treatment on their assigned dosing schedule for up to 1 year on this study. Subjects who reach 1 year of treatment with no evidence of disease progression may, with the concurrence of the investigator and the sponsor, continue to receive therapy.
41315154|NCT02604927|DIETARY_SUPPLEMENT|Beta-alanine|
41315155|NCT02604927|DIETARY_SUPPLEMENT|Dextrose|
41315156|NCT01635634|OTHER|Cupping therapy|Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
41315157|NCT05973006|BIOLOGICAL|NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine|Coformulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg antigen and 100 µg adjuvant per mL. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg Matrix-M adjuvant.
41472950|NCT00682552|PROCEDURE|A cervico-vaginal cervical smear|12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
41472951|NCT03549455|BEHAVIORAL|Exposure Therapy and Self Distancing|Weeks 1 and 2 will be introductory sessions (background, rationale, motivational enhancement); Weeks 3 \& 4 will have Exposure therapy with Self-Distancing; Weeks 5 \& 6 will have Exposure therapy only; Weeks 7 \& 8 will have Exposure therapy with Self-Distancing;
41472952|NCT04940702|OTHER|Focal Vibration|"Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.~The exercise is the same than traditional training group."
40798095|NCT01230190|DIETARY_SUPPLEMENT|Ecologic ® Panda II|"Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1\*10\^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals."
40798096|NCT01230190|DIETARY_SUPPLEMENT|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
41002378|NCT03099551|DEVICE|Group using manual toothbrush Curaprox 5460 Ultra Soft|Manual toothbrush usage with Bass technique twice a day during 2 minutes
41151540|NCT04374435|DEVICE|Suction blister grafting without cell dissociation|In this procedure, an automated suction blister device will be used to create micro domes and these micro domes will be used directly for grafting without dissociation.
41151541|NCT04653571|OTHER|CASPR2 encephalitis|Defining the initial clinical symptoms and those leading to the diagnosis of CASPR2 antibody associated encephalitis. For that, we will investigate the initial cognitive status, the initial neuropsychological investigations the clinical presentation of the first seizures, and the prodromes assessed by patients at the beginning of their disease. We will also look at the initial EEG records, in order to acknowledge whether the initial cognitive symptoms may be due to unseen seizures.
41472953|NCT04940702|OTHER|Blood Flow Restriction|Training with Blood Flow Restriction, the restriction is in the proximal part of the lower limb. The exercise is the same than traditional training group.
40798097|NCT06291337|DRUG|Inhibition of Sweet Taste by Ibuprofen Oral Rinses|Participants rinse the mouth with ibuprofen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
41472954|NCT04940702|OTHER|Traditional Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
41472955|NCT04714281|DEVICE|Dialyser|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
41151542|NCT03336684|BEHAVIORAL|Patient education|Rheumatoid arthritis patients will be provided with disease education literature
41151543|NCT00138645|BEHAVIORAL|MicroDiet|MicroDiet
40798098|NCT06291337|DRUG|Inhibition of Sweet Taste by Naproxen Oral Rinses|Participants rinse the mouth with naproxen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
40798099|NCT01445613|DEVICE|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
40798100|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy with AI|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders. The Eleos Health platform provides real-time data that optimizes this therapy and helps the provider tailor the intervention to the specific client.
40798101|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders.
40798102|NCT04620616|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
40798103|NCT04620616|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
40798104|NCT04620616|OTHER|Subject Usual Brand ENDS|Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
40798105|NCT00770627|DIETARY_SUPPLEMENT|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
40798106|NCT04954300|OTHER|no intervention|No intervention
41151544|NCT00138645|BEHAVIORAL|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet but will be instructed not to use meal replacements
41472956|NCT00004481|PROCEDURE|genetic testing|
40798107|NCT05976568|DRUG|QL1706|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
40798108|NCT05976568|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
40798109|NCT05976568|DRUG|Oxaliplatin injection|85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
40798110|NCT05976568|DRUG|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
40798111|NCT05976568|DRUG|Sintilimab|200 mg administered as IV infusion on Day 1 of each 21-day cycle
40798112|NCT01872975|RADIATION|regional nodal XRT|
40798113|NCT01872975|RADIATION|chestwall XRT|
40798114|NCT01872975|RADIATION|WBI|
40798115|NCT02584062|PROCEDURE|no-touch fluid-air exchange|
40798116|NCT02584062|PROCEDURE|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
40798117|NCT05070312|BIOLOGICAL|MEDI3506|MEDI3506
40798118|NCT05070312|DRUG|Placebo|Placebo
40798119|NCT03046446|DRUG|FX006 32 mg|Single intra-articular injection
40798120|NCT02479204|DRUG|ACT-334441 2 mg|capsule containing ACT-334441 at a strength of 2 mg
40798121|NCT02479204|DRUG|ACT-334441 4 mg|capsule containing ACT-334441 at a strength of 4 mg
41002379|NCT03099551|DEVICE|Group using sonic toothbrush Edel White|Sonic toothbrush usage twice a day during 2 minutes
41002380|NCT03072173|DRUG|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
41002381|NCT03072173|DRUG|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
41151545|NCT05611476|BEHAVIORAL|Cognitive Muscular Therapy for low back pain|Psychologically informed physiotherapy which used biofeedback training to reduce muscle overactivity and improve postural control
41151546|NCT05438511|BEHAVIORAL|Focus group|A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.
41472957|NCT00000745|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
41472958|NCT00000745|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
41472959|NCT05241418|DIAGNOSTIC_TEST|Atrial 3D late gadolinium enhancement|We will use cardiac MRI to take a picture of the atria. This picture will be used to identify scar tissue within the atria.
41315158|NCT05973006|BIOLOGICAL|Prototype/XBB.1.5 Bivalent Vaccine (5 µg)|A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 50 µg Matrix-M adjuvant.
41472960|NCT02963584|OTHER|decision aid|The related information about CTO and PCI procedures will be told to the patients thoroughly.
41472961|NCT06164275|PROCEDURE|Biopsy|Undergo tumor biopsy
41472962|NCT06164275|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41472963|NCT06164275|PROCEDURE|Computed Tomography|Undergo CT scan
41472964|NCT06164275|DRUG|Dacarbazine|Given IV
41472965|NCT06164275|DRUG|Doxorubicin|Given IV
41472966|NCT06164275|PROCEDURE|Echocardiography|Undergo echocardiography
41472967|NCT06164275|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
41472968|NCT06164275|BIOLOGICAL|Pembrolizumab|Given IV
41472969|NCT06164275|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41472970|NCT06164275|DRUG|Vinblastine|Given IV
41472971|NCT04675775|OTHER|Medically-tailored meals (MTM)|After the run-in baseline period participants will be expected to consume the meals and protein supplements meals between approximately Weeks 4 - 11 of the study. Additionally, participants will complete surveys before, during and after the meals.
41472972|NCT04675775|DIETARY_SUPPLEMENT|Protein supplements|"A daytime and nighttime protein supplement will be provided after the baseline visit and should be consumed daily at home during the same study days as MTM. The daytime protein supplement is a protein bar (ZonePerfect or Perfect Bar). The nighttime supplement is a protein powder or liquid that can be dissolved in either water or milk.~This is provided to participants with ProCel Vanilla Whey Protein powder which provides 15 grams of protein per serving or the ProCel LiquaCel liquid protein supplement mango, grape, watermelon and/or lemon flavors which provides 16g of protein per serving."
41472973|NCT04675775|BEHAVIORAL|Nutrition education handout|A standardized nutrition education handout containing instructions on following a high-protein and sodium restricted diet (depending on the presence of ascites) will be given as part of Standard of Care.
41315159|NCT00994656|DEVICE|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
41315160|NCT05014295|OTHER|Accessing personal medical records online via online portals|The participants will receive details on accessing personal medical records online via online portals, for each of the major hospital systems
41315161|NCT00987922|DEVICE|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
41315162|NCT03711994|OTHER|Alkantis|cold therapy pack placed on the wound post operatively
41315163|NCT00118508|DRUG|risedronate (including placebo)|risedronate 35mg weekly
41315164|NCT05738902|OTHER|Assessment of compliance to ERAS.|Assessment of compliance to ERAS in postoperative day 2 (POD2) using five indicators based on ERAS items and association with postoperative complications up to 30 days after discharge.
41315165|NCT04073940|BEHAVIORAL|Targeted Ballet Program|All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
41315166|NCT01200615|BEHAVIORAL|Wording of the explenation on side-effects as part of the informed consent.|Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.
41315167|NCT03901261|PROCEDURE|Neuro-imaging, Lumbar puncture|Optional Lumbar Puncture will be performed at inclusion visit Optional Neuro-Imaging (MRI (Magnetic Resonance Imaging) will be performed within 3 months after inclusion visit
41315168|NCT00734734|BIOLOGICAL|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
41315169|NCT03110146|DEVICE|EnSite Precision|Ablation procedure
41315170|NCT02983630|OTHER|Penicillin allergy testing|The standard protocol for testing for penicillin hypersensitivity, including initial skin testing with prick and intradermal evaluation followed by oral challenge if skin testing is negative.
41315171|NCT03497429|DRUG|Niraparib|Niraparib capsule
41315172|NCT00269737|DRUG|Fentanyl Transdermal Therapeutic System (TTS)|
41472974|NCT01239472|DRUG|Everolimus|Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
41472975|NCT03746002|DRUG|Metolazone 60 minutes prior to furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
41472976|NCT03746002|DRUG|Metolazone concurrently with furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
41472977|NCT00791986|DEVICE|ULB , LB|"ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks."
41472978|NCT00780260|BEHAVIORAL|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
41472979|NCT05630703|BEHAVIORAL|Mindfulness-based Attention Training in IBS|The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
40798122|NCT02479204|DRUG|Placebo|ACT-33441-matching placebo
40798123|NCT02479204|DRUG|Atenolol|film-coated tablet containing atenolol at a strength of 50 mg
40798124|NCT02479204|DRUG|Diltiazem ER|film-coated tablet containing diltiazem at a strength of of 120 mg
41472980|NCT05630703|OTHER|Low FODMAP Diet|Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format
40798125|NCT03850093|DRUG|Gabapentin1200 mg|patients received 1200mg gabapentin 2 hrs preoperative
40798126|NCT03850093|DRUG|bisoprolol 2.5mg|patients received 2.5mg bisoprolol 2 hrs preoperative
40798127|NCT03850093|DRUG|placebo|patients received oral placebo 2 hrs preoperative
41315173|NCT05138406|OTHER|Graded Motor Imagery|The graded motor imaging program will be set to 2 weeks each component. Participants will receive lateralization for the first 2 weeks, motor imagery for 2 weeks, and mirror therapy for 2 weeks. At the same time, standard rehabilitation will be applied for 6 weeks. Treatments will begin 24-48 hours after surgery. Treatments will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
41315174|NCT05138406|OTHER|Standard Rehabilitation|Standard rehabilitation consisting of cold therapy, stretching and strengthening exercises will be applied. Treatment will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
41315175|NCT02193815|DRUG|PF06263276|4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
41315176|NCT02193815|OTHER|Vehicle|Active ingredient-free vehicle to 4% solution
41315177|NCT02193815|DRUG|2%Tofacitinib Ointment|Daily Dosage: approximately 4 mg tofacitinib
41315178|NCT02193815|OTHER|Vehicle|Active ingredient-free vehicle to 2% Ointment
41315179|NCT02193815|DRUG|Daivonex|Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
41315180|NCT02193815|DRUG|Daivonex Ointment|Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
41315181|NCT00931476|DRUG|somatropin|
41315182|NCT00931476|DRUG|placebo|
41315183|NCT02456181|BEHAVIORAL|JumpMath|
41002382|NCT05433779|DEVICE|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
41472981|NCT00505648|DRUG|Tegeline®|2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
41472982|NCT05743049|OTHER|Obtaining blood for analysis of various circulating biomarkers|4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
41472983|NCT05693818|OTHER|Clinical Limping Evalution|"Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp).~If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided."
41002383|NCT02665975|BEHAVIORAL|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
40798130|NCT03394742|BEHAVIORAL|Peer support|Peer support persons are breast cancer survivors, who were educated to give peer support. They contacted participants by telephone.
41472984|NCT02117388|BEHAVIORAL|Sleep Restriction|Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
40798131|NCT06174155|OTHER|physical therapy treatment|The control group will receive the physical therapy program and conduct five times per week over four consecutive weeks under the supervision of a physical rehabilitation specialist. The primary focus of the program was to improve scar malleability, lengthen muscles and tendons, enhance joint mobility, and to restore functionality. Each session lasted almost for 45 minutes and consisted of therapeutic paraffin application; deep tissue massaging (5 minutes); stretching exercises; active ROM exercises.
40798132|NCT06174155|OTHER|Botulinum toxin-A injection in addition to physical therapy program|Two injection procedures will be used. The first is an EMG-guided BTX-A administration (Botox®, Allergan PLC, Dublin, Ireland) that will be localized to the motor endplate zone of the wrist flexors, radial and ulnar deviators. The second is a meso-injection procedure, where the BTX-A will be injected subdermal, intradermal, and into the scar (around the periphery and into the center).
41472985|NCT02117388|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
41472986|NCT02117388|BEHAVIORAL|Combined Therapy|Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
40798133|NCT06174155|OTHER|shock wave therapy in addition to physical therapy program|After wound and skin graft healing (\~ 90 days post-surgery), the unfocused shockwave will be applied to the site of burn injury on the volar aspect of the hand of the subjects and will allocate to the shock wave therapy intervention arm. The treatment will be delivered using a portable shockwave device (Zimmer enPuls, EMS physio Ltd, Germany).
41002384|NCT02665975|BEHAVIORAL|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
41315184|NCT04736706|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
41315185|NCT04736706|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
41315186|NCT04736706|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
41315187|NCT04736706|DRUG|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
41315188|NCT05855317|OTHER|Blood sample|Additional blood samples will be taken on a catheter, used for standard care.
41315189|NCT04151355|DRUG|Atorvastatin 20mg|atorvastatin (20 mg once daily)
41315190|NCT02232087|DRUG|Salmeterol|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
41315191|NCT02232087|DRUG|fluticasone propionate|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
40798134|NCT05598853|DRUG|intrathecal nivolumab and intrathecal ipilimumab|Patients shall be treated with a fixed dose of intrathecal nivolumab and increasing doses of intrathecal ipilimumab. From cycle 2, patients will receive systemic nivolumab/ipilimumab in addition to intrathecal treatment. Systemic nivolumab/ipilimumab corresponds to the current standard of care for non-small cell lung cancer and for melanoma patients.
40798135|NCT04661111|DEVICE|Hymovis® ONE (32 mg/4 ml)|Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
40798136|NCT04773288|OTHER|Live feedback during handwashing|Live feedback provided during handwashing on display
40798137|NCT03978611|DRUG|Relatlimab|Specified dose on specified days
40798138|NCT03978611|DRUG|Ipilimumab|Specified dose on specified days
40798139|NCT01853891|OTHER|dim light at night|
41002385|NCT01942629|OTHER|their will be no intervention in any of the groups, the study is retrospective|
41315192|NCT04667806|BEHAVIORAL|Questionnaires|Use questionnaires ( SF36 questionnaire (generic score) and St Georges's questionnaire (specific score))
41315193|NCT02489006|DRUG|Olaparib|
41315194|NCT02489006|DRUG|Platinum-based Chemotherapy|Chosen by the study doctor, per standard of care.
41315195|NCT01202721|DRUG|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg
41315196|NCT01202721|DRUG|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg.
41472987|NCT03199313|DRUG|Sutezolid|Sutezolid supplied as tablets and matching placebo for oral administration.
41472988|NCT03199313|DRUG|Placebo|Matching Sutezolid placebo
40798140|NCT03705559|DRUG|Vaporized Marijuana|Active Marijuana or Placebo, administered through vaporizer
40798141|NCT03705559|DRUG|Opioid Agonist|Active Opioid Agonist or Placebo, administered intranasally
40798142|NCT04961346|DEVICE|Ultrapro® mesh|large-pore, lightweight polypropylene mesh
40798143|NCT04961346|DEVICE|Premilene® mesh|small-pore, heavyweight polypropylene mesh
40798144|NCT02069977|DRUG|Aripiprazole|
40798145|NCT04014894|DRUG|ET019003-T Cells|Fludarabine 25 mg/day on day -5, -4 and -3; Cyclophosphamide 250 or 300 mg/day on day -5, -4 and -3; ET019003-T Cells on day 0.
41002386|NCT03302481|OTHER|liver biopsy|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
41315197|NCT05667792|DEVICE|Microsoft Kinect 360|Balance and trunk proprioception games will be selected and played for the children to be included in the treatment. Children will play these games with their own body movements.
41472989|NCT06049680|DRUG|SMOFlipid® (lipid injectable emulsion)|"SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated."
41472990|NCT02227459|DRUG|ND-L02-s0201 Injection|
40798146|NCT02291133|PROCEDURE|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
40798147|NCT02291133|DEVICE|Cliniporator Vitae®|"Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization."
40798148|NCT02291133|DRUG|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
41002387|NCT04498962|DRUG|Danzhu Fuyuan Granule|Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.
41315198|NCT05667792|OTHER|Pediatric Rehabilitation|Bobath therapy
41315199|NCT02902744|DRUG|ILUVIEN®|Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
41002388|NCT03865329|BEHAVIORAL|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
41002389|NCT00613028|DRUG|Temo + Avastin|Patients have progressed/had gr3/\> toxicity related to etoposide, with no had progression/gr 3/\> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
41002390|NCT00613028|DRUG|VP-16 + Avastin|Patients have progressed/had gr3/\> toxicity related to temozolomide, but have not progressed/gr3/\> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
41002391|NCT05669443|DEVICE|conventional PEEP|Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.
41315200|NCT04621006|DIAGNOSTIC_TEST|Continuously assessment of disease activity|Continuous measures of disease activity and activity in the contact activation system.
41315201|NCT00694954|DEVICE|Diagnostic Test - Given Imaging Pillcam|"Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.~Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)"
41315202|NCT00694954|OTHER|Diagnostics|Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
41472991|NCT04314544|DRUG|TILD|one 1 mL injection of study medication
41472992|NCT04314544|DRUG|matching placebo injections|one 1 mL injection of placebo
40798149|NCT01328028|OTHER|Testing of archived cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
40798150|NCT01328028|OTHER|Data collection|Log sheet
40798151|NCT03765216|DRUG|2L Polyethylene Glycol (PEG)|Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
40798152|NCT03765216|DRUG|4L Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
40798153|NCT01976702|BEHAVIORAL|Enhanced Behavioral Skills Training|
40798154|NCT01681667|DRUG|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
40798155|NCT00995436|DEVICE|Extraoral anchorage|Extra oral anchorage
40798156|NCT00995436|DEVICE|Miniscrews|Intraoral skeletal anchorage using mini screws
40798157|NCT00995436|DEVICE|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
40798158|NCT00001040|DRUG|Saquinavir|
40798159|NCT00001040|DRUG|Zidovudine|
40798160|NCT00001040|DRUG|Zalcitabine|
40798161|NCT01460706|DRUG|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
40798162|NCT04867369|DRUG|Bupivacaine 20mL 0.5%|Patients in both groups will receive an interscalene nerve block with 20 mL 0.5% bupivacaine.
41151547|NCT05438511|BEHAVIORAL|Organizational Readiness for Implementing Change|measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.
40798163|NCT04867369|DRUG|Bupivacaine 20mL 0.25%|Participants in the Pecs II block group will receive a Pecs II fascial plane block with 20 mL 0.25% bupivacaine.
40798164|NCT04867369|DRUG|Bupivacaine up to 15mL 0.25%|The Surgical infiltration group patients will receive local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.
40798165|NCT01794624|BEHAVIORAL|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
40798166|NCT01794624|BEHAVIORAL|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
40798167|NCT04736576|DEVICE|Wearable device|As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
40798168|NCT04945473|PROCEDURE|Endoscopic placement of additional sutures|A new endoscopic suture will be performed in case of a BMI≥30 or total weight loss (TBWL) less than 10%, and relaxation of gastric tubulization during the regular endoscopic follow-up after 6 months from the ESG. The same endoscopic suture technique of the primary ESG will be applied.
40798169|NCT01740258|RADIATION|Radiation Therapy|
40798170|NCT01740258|DRUG|Temozolomide|
41002392|NCT05669443|DEVICE|optimized PEEP|Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
41151548|NCT00324363|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
40798171|NCT01740258|DRUG|Bevacizumab|
40798172|NCT02869126|PROCEDURE|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"* During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~* Stress conventional acquisition with D.SPECT camera 20 min after injection~* 60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~* double isotope acquisition 5 min after thallium-201 injection~* injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~* rest conventional acquisition 20 min later"
40798173|NCT02869126|DRUG|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy"
40798174|NCT02869126|DRUG|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy"
40798175|NCT00594607|DEVICE|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
40798176|NCT00594607|DEVICE|Fx8 (Fresenius)|Polysulphone dialysis membrane
40798177|NCT00272831|DRUG|Cilostazol|Cilostazol 100 mg twice daily
40798178|NCT00272831|DRUG|Placebo|1 tablet twice daily
40798179|NCT00325130|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|"Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6."
40798180|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
40798181|NCT00325130|BIOLOGICAL|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
40798182|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
40798183|NCT00325130|BIOLOGICAL|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
40798184|NCT06228482|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
41472993|NCT06068777|DRUG|Rosmary|inhale two drops of rosemary oil, from a gauze, for 3 minutes before the procedure of extraction of a primary molar
40798185|NCT00371202|PROCEDURE|keratoplasty|
40798186|NCT04822818|DRUG|BEVA+SOC|Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
40798187|NCT04822818|DRUG|SOC|patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
40798188|NCT05370027|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Vagus nerve stimulation will be applied with the Vagustim device for 20 (10+10) minutes, with a biphasic frequency, a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current intensity where the participant feels the current comfortably.
40798189|NCT01841021|DRUG|Brentuximab vedotin|Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
40798190|NCT03851627|DRUG|Testosterone Undecanoate|1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter
40798191|NCT03851627|DRUG|Placebo|Placebo Arm
41315203|NCT00325286|DRUG|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
41315204|NCT05912920|PROCEDURE|gastric band|gastric band
41315205|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC Solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
41315206|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC Solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
41315207|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
41472994|NCT06068777|DRUG|Lemongrass Oil|inhale two drops of lemongrass oil, from a gauze, for three minutes before the procedure of extraction.
41472995|NCT03694808|DRUG|Fluad Vaccine|single adjuvanted dose (AD) intramuscular injection
41472996|NCT03694808|DRUG|Fluzone HD Vaccine|single high dose (HD) intramuscular injection
40798192|NCT02487758|PROCEDURE|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
40798193|NCT04216849|BIOLOGICAL|human umbilical cord mesenchymal stem cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
40798194|NCT04216849|OTHER|saline|Saline solution containing human serum albumin will be infused to the control group
40798195|NCT03047811|OTHER|TCR - T cell therapy|Low dose group: 1 x 10 \^8 /kg T cell total reinfusion. High dose groups: 10 x 10 \^ 8 / kgT cell total reinfusion.
40798196|NCT00229697|DRUG|Gefitinib|
40798197|NCT00229697|DRUG|Tamoxifen|
40798198|NCT01282255|DRUG|NNC109-0012|The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
40798199|NCT01282255|DRUG|placebo|The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
40798200|NCT06430242|DEVICE|Tele rehabilitation|In the active group, one of the co-investigators will install and demonstrate the use of the mobile app (Rehab App) on participants' mobile phone and explain the use of the software. The participants will be followed up for the duration of their enrolment in the e-health and tele-rehabilitation service, which can last up to 2 months.
40798201|NCT06430242|OTHER|Exercise|Participants in the control group will get the usual treatment from the clinical staff and in-person education, and they will be supervised by one of the assigned research team members every week.
40798202|NCT01232127|DRUG|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
40798203|NCT01232127|DRUG|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
40798204|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
40798205|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
40798206|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
40798207|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
40798208|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
40798209|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
40798210|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
40798211|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
41002393|NCT05827497|DRUG|Baricitinib 2 MG|baricitinib 2 mg once daily
41002394|NCT05827497|DRUG|Methotrexate 25mg|25mg daily
41151549|NCT00324363|DRUG|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
40798212|NCT00475553|OTHER|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
40798213|NCT00475553|OTHER|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
40798214|NCT06285565|COMBINATION_PRODUCT|Nurse-led telephone coaching intervention with home telemonitoring of vital signs|In addition to standard care, the intervention group will receive a nurse-led supportive programme that involves a pre-discharge educational meeting and 6-month telephone coaching sessions. Patient's caregivers will also be invited to participate. After discharge, patients will be asked to measure their vital signs, daily. In case of alteration, the nurse will ascertain the presence of congestion symptoms and decide to reinforce the recommendations for self-management, request a specialist medical consultant, or refer to the emergency services
41472997|NCT06231459|DRUG|Evolocumab|Evolocumab 140 mg was administered intramuscularly every two weeks at the discretion of their physiciansm according to LDLc response. Clinical-demographic and anthropometry data were collected during a direct interview. Blood sample was processed to obtain glycated hemoglobin complete blood count and serum lipids. Likewise, flow cytometry was used to characterize baseline circulating M1-, M2-macrophages and monocytes. Multiplexing of plasma samples was used to compare plasma fraktaline, IL-1, IL-4, IL-6, IL-8, IL-10, MCP-1 and TNF-alpha. Endpoints consisted of: 1) lower serum lipids; 2) modification of pro-inflammatory mediators (neutrophils, lymphocytes, NtLR, soluble pro-inflammatory cytokines).
41472998|NCT03839277|DEVICE|Endocuff Vision|Endocuff Vision is attached to the tip of colonoscope before intubation.
41472999|NCT00031811|DRUG|raloxifene|
40798215|NCT03563755|OTHER|Cognitive Bias Modification|CBM-Attention (CBM-A) will be used with the aim of ameliorating negative cognitive biases in attention by redirecting attention towards positive social stimuli (accepting faces). Similarly CBM-Interpretation (CBM-I) will be used to ameliorate negative interpretation bias, by reinforcing benign outcomes of ambiguous social scenarios. Implementation intentions will be used to guide participants in planning new ways to face difficult social situations involving the risk of social rejection/criticism. Participants will continue to receive their usual treatment.
40798216|NCT05296746|DRUG|Ribociclib (neoadjuvant)|Ribociclib 600 mg/day + letrozole during neoadjuvant phase.
40798217|NCT05296746|DRUG|Chemotherapy (adjuvant)|Adjuvant chemotherapy. 3 regimens are permitted.
40798218|NCT05296746|DRUG|Ribociclib (adjuvant)|Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
40798219|NCT03628105|BEHAVIORAL|CR Before Exposure|"Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger \& Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study."
40798220|NCT03628105|BEHAVIORAL|CR After Exposure|Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
40798221|NCT04303013|BEHAVIORAL|Meditation|Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
40798222|NCT04303013|OTHER|Standard of Care|Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
40798223|NCT05290506|DRUG|Dipeptidyl-Peptidase IV Inhibitors|All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
40798224|NCT04351399|OTHER|questionnaire assesment|The questionnaire will ask questions around their socio-demographic characteristics,quality of life, painful, using analgesic , since they are in quarantine
41473000|NCT00031811|PROCEDURE|quality-of-life assessment|
41473001|NCT02614963|DRUG|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
41473002|NCT02614963|DRUG|placebo|Irritable bowel syndrome patients treated with placebo
41473003|NCT02341521|DRUG|OC000459|Taken orally for 8 days
41473004|NCT01597219|PROCEDURE|Reduced intensity haplodentical stem cell transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 \& +4
40798225|NCT04748679|BEHAVIORAL|Worry Intervention|The worry intervention is weekly individual therapy with a trained therapist
40798226|NCT04748679|BEHAVIORAL|Befriending|The worry intervention is weekly individual therapy with a trained therapist
40798227|NCT00001901|DRUG|Etanercept|
40798228|NCT06091124|DRUG|Adebrelimab|Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
40798229|NCT06091124|DRUG|Etoposide|Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
40798230|NCT06091124|DRUG|Cisplatin|Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
40798231|NCT06091124|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed within 4-6 weeks after completion of last dose
40798232|NCT02697760|RADIATION|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
40798233|NCT00758940|DEVICE|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
40798234|NCT00438360|DRUG|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
40798235|NCT00438360|DRUG|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
41315208|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
41473005|NCT01597219|PROCEDURE|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 \& -2 Stem cell transplant day 0
41473006|NCT00920894|DIETARY_SUPPLEMENT|plant stanol ester|the effect of plant stanol esters on plasma lipids
40798236|NCT00822159|DEVICE|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
40798237|NCT00352469|DRUG|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
40798238|NCT04678362|DRUG|Talazoparib + Avelumab|Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
40798239|NCT05320354|DIAGNOSTIC_TEST|Microbial ID test|In addition to the standard of care procedure for patients suspected for a periprosthetic joint infection, the MID-test will be performed using the residual synovial fluid. Individual test results of the MID-test are not reported back to the participating sites in order to not interfere with the sites' standard of care approach.
40798240|NCT03244709|DRUG|Tocilizumab|Intravenous Tocilizumab followed by subcutaneousTocilizumab
40798241|NCT05800353|PROCEDURE|YAG vitreolysis|"A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician.~Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye."
41473007|NCT03585426|DRUG|Vancomycin|Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
41473008|NCT02596386|PROCEDURE|sialometry|potassium evaluation
41473009|NCT02596386|PROCEDURE|blood test|potassium evaluation
41473010|NCT05723419|PROCEDURE|axillary block using 5 ml local anesthetics|ultrasoud guided axillary block
41473011|NCT00956787|DRUG|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
41473012|NCT04744454|DRUG|Isauvuconazole group|Patients who are treated with Isavuconazole according to its protocol label.
41473013|NCT00798382|OTHER|soy protein formula|ad lib for 0-35 days of age
40798242|NCT02526212|BEHAVIORAL|G-BMT|The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
41002395|NCT06375005|DRUG|Telitacicept|Telitacicept is fusion protein comprising a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept binds to and neutralizes the activity of two cell-signalling molecules, B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing the development and survival of plasma cells and mature B cells. Telitacicept will be subcutaneously injected at a dose of 160mg per week, lasting for 48 weeks.
41002396|NCT06375005|DRUG|Mycophenolate Mofetil|All patients will receive background therapy with Mycophenolate Mofetil (MMF), administered orally at a dose of 0.5g twice daily for 48 weeks.
41002397|NCT00044343|DRUG|lapatinib|
41315209|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
41473014|NCT00798382|OTHER|Commercially available soy formula|ad lib for 0-35 days of age
41473015|NCT00798382|OTHER|Soy formula experimental #2|ad lib for 0-35 days of age
41473016|NCT02220725|BIOLOGICAL|Andexanet|
41473017|NCT02220725|OTHER|Placebo|
41473018|NCT06617273|DEVICE|Ophthalmosurgical handpiece with active anterior chamber pressure sensing and regulation|Cataract surgery in patients with diabetic retinopathy using active anterior chamber pressure sensing and regulation
41473019|NCT02713815|RADIATION|repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day
41473020|NCT02713815|RADIATION|sham repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
41473021|NCT00114231|DRUG|capecitabine|
41473022|NCT00114231|DRUG|oxaliplatin|Given IV
41473023|NCT00114231|PROCEDURE|neoadjuvant therapy|Undergo surgery
41473024|NCT00114231|RADIATION|radiation therapy|Undergo radiotherapy
41473025|NCT06233357|DRUG|treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)|IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight
41473026|NCT00992212|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
41473027|NCT06079879|DRUG|Bomedemstat|Oral Capsule
41473028|NCT06079879|DRUG|Anagrelide|Oral Capsule
41473029|NCT06079879|DRUG|Busulfan|Oral Tablet
41002398|NCT00012051|BIOLOGICAL|filgrastim|
41002399|NCT00012051|BIOLOGICAL|rituximab|
41002400|NCT00012051|DRUG|carmustine|
41002401|NCT00012051|DRUG|cisplatin|
41002402|NCT00012051|DRUG|cytarabine|
41002403|NCT00012051|DRUG|dexamethasone|
41002404|NCT00012051|DRUG|etoposide|
41002405|NCT00012051|DRUG|ifosfamide|
41002406|NCT00012051|DRUG|melphalan|
41002407|NCT00012051|DRUG|methotrexate|
41002408|NCT00012051|PROCEDURE|bone marrow ablation with stem cell support|
41002409|NCT00012051|PROCEDURE|peripheral blood stem cell transplantation|
41002410|NCT00012051|RADIATION|radiation therapy|
41002411|NCT00223106|DEVICE|Vaginal Sling|
41315210|NCT00254293|DRUG|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
41315211|NCT01984879|OTHER|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
41315212|NCT04636008|DRUG|Sintilimab|Sintilimab+Hypofractionated radiotherapy
41315213|NCT04636008|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy
41473030|NCT06079879|DRUG|Interferon alfa/pegylated interferon alfa|Subcutaneous Solution
41473031|NCT06079879|DRUG|Ruxolitinib|Oral Tablet
40798243|NCT02526212|BEHAVIORAL|Treatment as usual|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
41315214|NCT03811171|DEVICE|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.
41002412|NCT03216850|DEVICE|Sublingual microcirculation assessment|Non-invasive investigation of the endothelial glycocalyx in the sublingual microcirculation.
41315215|NCT05591794|OTHER|Aerobic and resistance exercises|Participants in the study group will be given an aerobic exercise program on the treadmill for 8 weeks, 2 days a week, 20 minutes at a rate of 60-80% of the target heart rate. Participants will work on the treadmill for 20 minutes at 60-70% of the target heart rate for the first four weeks, and at 70-80% of the target heart rate for the last four weeks. Resistance exercises will consist of exercises that will work large muscle groups with rubber bands. According to Borg, the resistance exercises to be applied will be three sets of 10 repetitions for each movement at an RPE of 11-12 during the first four weeks, and 3 sets of 15 repetitions at the same RPE for the last four weeks, 2 times a week for 20 minutes.
41315216|NCT05591794|DIETARY_SUPPLEMENT|Diet program|Initially, participants will be educated on healthy eating habits through one-on-one dietitian consultation. A personalized calorie-restricting diet will be given. According to this program, the daily energy intake of the individual will be reduced to provide 0.5-1.0 kg of body weight loss per week.
41315217|NCT05591794|OTHER|Regular walking program|Regular walking will be recommended as 30 minutes/5 days or 50 minutes/3 days per week.
41315218|NCT02512744|PROCEDURE|Decannulation protocol.|Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
41315219|NCT02512744|DEVICE|High flow conditioned oxygen therapy|High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
41315220|NCT00101491|BEHAVIORAL|Health Communication DVD video|Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
41315221|NCT01916993|DRUG|NBI-98854 50 mg capsule|
41473032|NCT05777824|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy
40798244|NCT02526212|DRUG|Buprenorphine|All participants will continue to receive maintenance treatment with buprenorphine-naloxone
41002413|NCT04804709|DRUG|Panobinostat 15 MG|After each instance of opening the BBB using specific parameters of focused ultrasound in the specific number of tumor sites (one, two, or three), the subjects will receive oral Panobinostat (15 mg/m\^2).
41002414|NCT04804709|DEVICE|Focused Ultrasound with neuro-navigator-controlled sonication|"The purpose of this study is to evaluate the feasibility of opening the BBB safely using specific parameters of focused ultrasound in progressive/recurrent diffuse midline gliomas in one, two, or three tumor sites. The trial will follow a 3+3 Number of Tumor Sites (NOTS) escalation scheme. The number of tumor sites in reference to here is the number of openings in the blood-brain barrier using Focused Ultrasound (FUS). Subjects will start the first cycle of the treatment arm with 1 tumor site and move on to incrementing NOTS levels if no dose-limiting toxicities (DLTs) are observed."
41002415|NCT00353678|DRUG|YM150|
41151550|NCT04246099|OTHER|Post-operative care|"Retrospective collection of clinical data recorded in the electronic medical record.~The following variables were continuously recorded in the institutional database: age, gender, body weight, height, personal medical history, American Society of Anesthesiologists (ASA) score, type of thoracic surgery, the duration of surgery, duration of anesthesia (from intubation to extubation), the duration of PACU stay, the need for morphine titration, epinephrine, norepinephrine.~For data at day 30, the vast majority of patients were included in the enhanced recovery program and as such benefited from a consultation at 1 month with a coordination nurse who collected data on post-operative pain in a standardized manner.~All data was extracted from investigators institutional database and collected by a physician who was not involved in the care of the study patients."
41315222|NCT05049837|OTHER|Group Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
41315223|NCT05049837|OTHER|Group Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
41315224|NCT05049837|OTHER|Group Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples
41315225|NCT05049837|OTHER|Group Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
41315226|NCT05049837|OTHER|Group Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
41473033|NCT05777824|RADIATION|postoperative radiaotherapy|postoperative radiotherapy (60Gy or 50Gy)
41002416|NCT03430752|OTHER|questionnaires|Participants were asked to respond to the questionnaires including the Chinese version of the Paediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0), the Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC), the Chinese version of Rosenberg self-esteem scale, the Chinese version of the Herth Hope Index (HHI) and the Chinese version of Resilience Scale for Children (RS10).
41002417|NCT05370404|OTHER|Prescription by surgical team|The surgical team prescribes medications to the patient
41002418|NCT05370404|OTHER|Recommendation by surgical team|The surgical team recommends the patient to take over-the-counter medications
41002419|NCT05179733|DRUG|six courses of zanubrutinib, rituximab and lenalidomide|Patients in ZR2 group will receive 6 cycles of zanubrutinib 160mg bid, day 1-21, orally, lenalidomide 25mg qd, day 2-11, orally, rituximab 375mg/m², day 1, intravenously, every 21 days.
41002420|NCT05179733|DRUG|six courses of rituximab combined with low-dose CHOP|Patients in R-miniCHOP group will receive rituximab 375 mg/m² on day 1, cyclophosphamide 400 mg/m², doxorubicin 25 mg/m², and vincristine 1 mg on day 2, and prednisone 40 mg/m² on days 2-6, every 21 days.
41315227|NCT05049837|OTHER|Group Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
41315228|NCT06512623|DEVICE|Hemoadsoprtion|The hemoadsorption treatment will be performed during the entire duration of the CPB. Blood flow within the cartridge will be measured.
41315229|NCT02808741|DRUG|F901318 SDD|Pharmacokinetics area under curve
41315230|NCT02808741|DRUG|F901318 IR|Pharmacokinetics area under curve
41002421|NCT02507414|OTHER|Blood samples|15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.
41002422|NCT02507414|OTHER|Measurement of microcirculation|Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
41002423|NCT02507414|OTHER|Head down tilt|"At three different time points the participants will be head down tilted in 20 degrees.~End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)"
41002424|NCT01289808|DRUG|Glucose 25%|1ml of glucose 25% once
41002425|NCT01289808|DRUG|Glucose 25%|1ml glucose once per os
41002426|NCT01451346|DIETARY_SUPPLEMENT|B. Infantis 35624|One sachet daily for 12 weeks
41151551|NCT04161872|DRUG|Uricemin|Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine
41151552|NCT04161872|DRUG|Placebo|Placebo
41151553|NCT05855499|DEVICE|CPtcube, CPTpatch|This study investigates the effectiveness of a system for reproducible application of cold plasma on larger areas and observes the effect of a 4-week additional plasma treatment on wound healing of large chronic wounds.
41151554|NCT03962270|DEVICE|shock wave device|The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
41151555|NCT06358040|DEVICE|Opioid-Dispensing Device|Addinex Opioid-Dispensing Device
41151556|NCT06358040|OTHER|App|Addinex App
41151557|NCT06358040|OTHER|Standard Opioid Pill Bottle|Standard Opioid Pill Bottle
41151558|NCT06511830|DIAGNOSTIC_TEST|Dental Monitoring images|Dental Monitoring is a series of intraoral photos that will be taken and assessed to determine the subject's dental plaque levels
41151559|NCT04800978|BIOLOGICAL|BAVC-C+Durvalumab|"* Durvalumab Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for infusion after dilution.~* BVAC-C BVAC-C will be supplied in cyclic olefin co-polymer vials containing 1x10⁸ cells of suspension at a concentration of 5x10⁷ cells/mL infusion"
41151560|NCT00083122|DRUG|cisplatin|Given IV
41151561|NCT00083122|DRUG|alvocidib|Given IV
41151562|NCT00083122|DRUG|cisplatin/flavopiridol|Given IV
41151563|NCT06270849|OTHER|Questionnaire|The questionnaire to assess severity of LUTS in women.
41151564|NCT04851444|DRUG|SI-F019|Single dose is administered IV.
41151565|NCT04543942|DRUG|Alcohol|Alcohol will be administered by IV infusion (60mg%).
41151566|NCT04543942|DRUG|Saline|Saline is administered as the placebo
41151567|NCT00787345|OTHER|simulation based training|simulation based training in aseptic techniques that included specified AT categories
41151568|NCT02217891|BEHAVIORAL|Semi-structured interview|Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, \& qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits \& harms of tumor genomic profiling; 2) interest in \& perceived benefits \& harms of incidental findings arising from tumor genomic profiling; 3) anticipated process \& needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, \& those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; \& 6) implications of \& concerns about incidental findings for family.
41151569|NCT06584747|DIAGNOSTIC_TEST|PET scan|18F-FDG PET scans will be performed to assess cerebral vascular reserve. For exams involving stimulation with Acetazolamide (DIAMOX®), the radiopharmaceutical injection (18F-FDG or 99mTc-HMPAO) will start exactly 15 minutes after the Acetazolamide (DIAMOX®) injection.
41151570|NCT06104059|DEVICE|Nociception level index (NOL™)|If a NOL value \>25 persists for \>1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.
41002427|NCT05551806|BEHAVIORAL|Internet-based self-help cognitive behavioural therapy|The online CBT-I course will consist of an introductory module, followed by 6 weekly modules, incorporating the key CBT-I components, including sleep hygiene education, stimulus control, sleep restriction, relaxation training, and cognitive therapy.
41002428|NCT05878548|PROCEDURE|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture
41002429|NCT03800719|BEHAVIORAL|AWARD advice|"At baseline, brief smoking cessation advice following AWARD model will be delivered to subjects within about 2 to 5 minutes:~* Ask about smoking history and habit~* Warn about the risks of smoking using a leaflet~* Advise to quit smoking as soon as possible and use nicotine replacement therapy (NRT) or SC services~* Refer subjects to free smoking cessation services in Hong Kong if they agree~* Do it again: smokers who have tried to quit but relapsed will be encouraged to quit again and those who have reduced smoking will be advised to further reduce or quit smoking"
41002430|NCT03800719|BEHAVIORAL|Health warning leaflet|At baseline, an A5-sized leaflet will be given to subjects, which includes information about risks of smoking, pictures of smoking-related diseases, and smoking cessation services provided in Hong Kong.
41002431|NCT03800719|BEHAVIORAL|Active referral to smoking cessation (SC) services|At baseline, subjects will be encouraged to seek smoking cessation services in Hong Kong. If subjects agree, their contact information will be sent to the preferred service providers for a quick appointment and follow-up.
41002432|NCT03800719|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of pre-set 26 messages will be sent to subjects through WhatsApp 12 weeks after baseline to remind the quit date and to encourage abstinence. Messages are tailored based on subjects' sociodemographic characteristics and smoking habit following Social Cognitive Theory and Transtheoretical Model. Messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. The schedule will be adjusted according to the quit date and also smokers' requests. The format of regular messages will mainly be text-based but also include pictures, animations and videos.
41315231|NCT02808741|DRUG|F901318 IR Fasting|Pharmacokinetics area under curve
41315232|NCT02808741|DRUG|F901318 IR Fed|Pharmacokinetics area under curve
41315233|NCT02472691|DRUG|Lenalidomide|Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
41315234|NCT02472691|DRUG|Azacitidine|Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
41315235|NCT02472691|BIOLOGICAL|Donor Lymphocyte Infusions|DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10\^6 CD3/kg (1st DLI), 1-5x10\^6 CD3/kg (2nd DLI) and 5-15x10\^6 CD3/kg (3rd DLI).
41315236|NCT01248910|BEHAVIORAL|Alpine Skiing|
41315237|NCT05164406|PROCEDURE|Blood salvage therapy|In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
41315238|NCT05985122|DIAGNOSTIC_TEST|C3NEF assay|This assay will consist of a dual test, detecting C3 convertase binding C3NEF autoantibodies and measuring the functional consequence by complement alternative pathway (AP) activity using two distinct ELISA designs: C3NEF detection assay and AP activity assay.
41315239|NCT05509153|DRUG|NAC|1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
41315240|NCT05509153|DRUG|Placebo|Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
41315241|NCT03051724|OTHER|Telematic follow up|Follow-up of OSA patients through automatic CPAP with data transmission (Dreamstation; Philips Respironics), a 24-hour voice mailbox available for questions or problems, and an Internet-connected (4G) tablet with a friendly mobile application for simple questionnaires.
41315242|NCT01422811|BEHAVIORAL|Multicomponent strategy to reduce avoidable length of stay|"The strategy comprises two integrated components:~1. Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;~2. Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team."
41315243|NCT01422811|OTHER|No intervention|No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
40798245|NCT02783547|DRUG|SyB C-1101 and Azacytidine|"This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.~SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up."
40798246|NCT05082012|DEVICE|Treatment of Hallux Valgus|Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated subject duration will be 2 years post index procedure.
40798247|NCT05934591|BEHAVIORAL|Community Wise|The intervention received by each group will be Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
40798248|NCT00389545|PROCEDURE|Intracoronary infusion of autologous bone-marrow derived stem cells|
41315244|NCT05864183|DIAGNOSTIC_TEST|HbA1c|HbA1c will be measured for all patients to minimize the risk of developing diabetes or its complications .
41315245|NCT05864183|DIAGNOSTIC_TEST|lipid profile|lipid profile will be measured for all patients to minimize the risk of developing diabetes or its complications .
41315246|NCT05864183|DIAGNOSTIC_TEST|CBC|CBC will be measured for all patients to minimize the risk of developing diabetes or its complications
41315247|NCT05864183|DIAGNOSTIC_TEST|Alb/cr ratio|Alb/cr will be measured for all patients to minimize the risk of developing diabetes or its complications
41315248|NCT05864183|DIAGNOSTIC_TEST|serum creatinine .|serum creatinine will be measured for all patients to minimize the risk of developing diabetes or its complications
41315249|NCT05864183|DIAGNOSTIC_TEST|CRP|CRP will be measured for all patients to minimize the risk of developing diabetes or its complications
41315250|NCT05864183|DIAGNOSTIC_TEST|urine analysis|urine analysis will be measured for all patients to minimize the risk of developing diabetes or its complications
41315251|NCT05864183|DIAGNOSTIC_TEST|ECG|ECG will be done for all patients to minimize the risk of developing diabetes or its complications
41315252|NCT05864183|DIAGNOSTIC_TEST|fundus examination|fundus examination will be done for all patients to minimize the risk of developing diabetes or its complications
40798249|NCT02807220|DRUG|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
40798250|NCT03162796|DRUG|Guselkumab|Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
40798251|NCT03162796|DRUG|Placebo|Participants will receive matching placebo as SC injection.
41315253|NCT06371014|DRUG|Ondansetron oral membrane|A new oral film formulation of ondansetron was used to replace traditional tablets in the treatment of antiemetic chemotherapy
41315254|NCT05640674|DRUG|Ibuprofen|Non-opioid
41315255|NCT05640674|DRUG|Hydrocodone/acetaminophen|Opioid
41315256|NCT05640674|DRUG|Acetaminophen|Non-opioid
40798252|NCT03694340|OTHER|Re-programming of cochlear implant|New MAP based on behavioral T- and C-levels
40798253|NCT01437111|DRUG|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
40798254|NCT01875393|DRUG|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
40798255|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
41151571|NCT06104059|OTHER|Fentanyl|Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.
41151572|NCT04013347|PROCEDURE|Rectal Resection|Low Anterior Resection and Abdominoperineal Resection
41315257|NCT04766138|DEVICE|Fecobionics|Fecobionics is a new device to be inserted through the anal canal into rectum for studying defecation
41315258|NCT03720730|OTHER|EMA|"The mobile application (EMA) combines an explicit data collection with an implicit one.~For the explicit data collection with Memind application, patients will have to answer specific questionnaires about sleep, appetite and social factors. Some of the questions will be asked on regular basis, at the same time everyday, while others will be asked randomly during the day (between 9 a.m and 9 p.m).~The implicit data collecting will be carried out using smartphone sensors (application eB2)."
41315259|NCT01965912|DRUG|Kuvan®|Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
41315260|NCT05807178|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
41315261|NCT05807178|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
41315262|NCT04281745|BIOLOGICAL|CORETOX Inj|Clostridium botulinum type A (Hall group); a lyophilized white power for injection with a colorless transparent vial. colorless transparent solution when dissolved with saline.
41315263|NCT01890070|DIETARY_SUPPLEMENT|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
41315264|NCT01890070|DIETARY_SUPPLEMENT|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
41473034|NCT02591212|BEHAVIORAL|Green Dot|Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
41473035|NCT02591212|BEHAVIORAL|Wellness Initiatives for Student Empowerment|Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
41473036|NCT06372925|DRUG|atorvastatin|20mg atorvastatin PO
40798256|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
40798257|NCT02193009|BEHAVIORAL|SipSmarter|6-month behavioral trial
40798258|NCT02193009|BEHAVIORAL|MoveMore|6 month behavioral trial
40798259|NCT03349138|DEVICE|Conventional Therapy|
40798260|NCT03349138|DEVICE|Robotic Glove|
40798261|NCT03349138|DEVICE|Electrical Stimulation|
40798262|NCT04670263|DEVICE|Tear Film Imager|Tear Film Imager recording
40798263|NCT03685903|DEVICE|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
41473037|NCT06372925|PROCEDURE|IVUS/OCT|performed the IVUS/OCT at baseline and Day 360
40798264|NCT06005558|DRUG|Normal saline|100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.
40798265|NCT06005558|DRUG|Methylene Blue low dose|A bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
40798266|NCT06005558|DRUG|Methylene Blue high dose|A bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
40798267|NCT01581528|GENETIC|gene expression analysis|
40798268|NCT01581528|OTHER|cell culture procedure|
40798269|NCT01581528|OTHER|flow cytometry|
40798270|NCT01581528|OTHER|laboratory biomarker analysis|
40798271|NCT01581528|OTHER|metabolic assessment|
41473038|NCT06372925|DRUG|inclisiran|Inclisiran 284mg SC
41473039|NCT02624167|DRUG|NW-3509A|Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
40798272|NCT02008149|OTHER|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
40798273|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
40798274|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
40798275|NCT04057924|OTHER|abstention from CIN2 treatment and surveillance for at least 2 years|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
40798276|NCT01779336|DRUG|PL225B|"* Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~* This 21 day administration will define a treatment cycle.~* Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified."
40798277|NCT02263326|DRUG|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
41315265|NCT01890070|DIETARY_SUPPLEMENT|Red wine|Italian Organic Red Wine
40798278|NCT02263326|DRUG|lamivudine|300 mg tablet by mouth once daily for 48 weeks
40798279|NCT02263326|DRUG|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
40798280|NCT02483429|DEVICE|VRT Care|The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
40798281|NCT04725045|DEVICE|Boston Scientific: Study tool computer|compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
40798282|NCT00565396|DRUG|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
40798283|NCT01949571|DRUG|Mirtazapine (REMERON, Schering-Plough-Organon)|During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
41151573|NCT02648659|DRUG|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
41315266|NCT01890070|DIETARY_SUPPLEMENT|Olive Oil|Italian Organic Olive Oil
41315267|NCT01890070|DIETARY_SUPPLEMENT|Wild mixed greens|Italian organic wild mixed greens
41315268|NCT01890070|DIETARY_SUPPLEMENT|Chestnut|Italian Organic Chestnut
41315269|NCT01890070|OTHER|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
41473040|NCT02624167|DRUG|Placebo|Patients will be given oral dose of matching Placebo
41002433|NCT03800719|BEHAVIORAL|Psychosocial support and referral to SC services through IM|Personalized interactive text or voice conversation will be provided by trained smoking cessation advisors through WhatsApp for 3 months after baseline. Advisors will periodically proactively send messages to subjects to initiate the conversation (e.g. asking recent progress of smoking cessation) and deliver evidence-based advice. Advisors will also actively refer subjects, if they have expressed the need, to smoking cessation services providers. A standard operation algorithm for advisors used in the pilot feasibility trial will be modified for the use.
41002434|NCT03800719|BEHAVIORAL|Message on general health delivered by short message service (SMS)|After baseline, regular messages using SMS will be sent to subjects with similar frequency to Intervention group. The messages include information on general health and reminders on follow-up surveys and biochemical validation for quitting.
41002435|NCT03400033|DRUG|Daprodustat tablets|Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
41002436|NCT03400033|DRUG|Matching placebo tablets|Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
41002437|NCT03400033|DRUG|Epoetin alfa vials|Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
41002438|NCT03400033|DRUG|Saline vials or bags|0.9% sodium chloride saline vials or bags administered by the IV route.
41151574|NCT02648659|DRUG|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
41151575|NCT02648659|DRUG|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
41151576|NCT02648659|DRUG|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
41151577|NCT00203788|BEHAVIORAL|Individual Placement and Support|Supported education/employment
41151578|NCT00203788|BEHAVIORAL|Workplace Fundamentals Module|Group skills training on job/school topics
41315270|NCT03363711|OTHER|AYA STEPS|a mobile health application
41315271|NCT03534063|GENETIC|CYP2D6-guided opioid therapy|Using a standardized consult note, recommendations were made to avoid tramadol, hydrocodone, codeine, and oxycodone in PMs, IMs, and UMs and to use an alternative opioid (e.g. morphine, hydromorphone) or non-opioid (e.g. NSAID). Consideration of tramadol as the first-line opioid will be recommended for NMs.
41473041|NCT02836301|BEHAVIORAL|Control ending - Uplifting|The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
41473042|NCT02836301|BEHAVIORAL|Negative Consequences Ending|A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots...a missed opportunity.
41002439|NCT04741165|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
41002440|NCT04741165|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
41002441|NCT04741165|DRUG|Lenvatinib|Administered orally once a day during each 21-day cycle
41151579|NCT00203788|BEHAVIORAL|Brokered Vocational Rehabilitation|Vocational rehabilitation through traditional separate state-funded agency
41151580|NCT00203788|DRUG|Oral risperidone|Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
41151581|NCT00203788|BEHAVIORAL|Skills training group|Group social skills training that did not focus primarily on work situations
41151582|NCT02255526|DEVICE|BodyGuardian|BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
41151583|NCT00401791|BEHAVIORAL|Exercise|"* Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period~* Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer."
41151584|NCT04271956|BIOLOGICAL|Tislelizumab|Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg
41151585|NCT04271956|DRUG|Zanubrutinib|Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
41151586|NCT04271956|DRUG|Sonrotoclax|"Cycle 1: Sonrotoclax Start Ramp-up to 320 mg QD po Days 1-2 Sonrotoclax 2 mg (2 tabl. at 1mg) Days 3-4 Sonrotoclax 5 mg (1 tabl. at 5mg) Days 5-6 Sonrotoclax 10 mg (2 tabl. at 5mg) Days 7-8 Sonrotoclax 20 mg (1 tabl. at 20mg) Days 9-10 Sonrotoclax 40 mg (2 tabl. at 20mg) Days 11-12 Sonrotoclax 80 mg (1 tabl. at 80mg) Days 13-14 Sonrotoclax 160 mg (2 tabl. at 80mg) Days 15-16 Sonrotoclax 320 mg (4 tabl. at 80mg)~Cycle 2-6: Day 1-21 Sonrotoclax 320 mg QD po"
41315272|NCT05491694|DRUG|Toripalimab|Toripalimab 240mg
41315273|NCT05491694|DRUG|Epirubicin|90mg/m2，IVD，q3w
41315274|NCT05491694|PROCEDURE|High Intensity Focused Ultrasoun|HIFU treatment at lesion site
41315275|NCT05491694|DRUG|Cyclophosphamide|600mg/m2，IVD，q3w
41315276|NCT05491694|DRUG|Carboplatin|AUC 5，IVD，q3w
41315277|NCT05491694|DRUG|Nab-paclitaxel|260mg/m2，IVD，q3w
40798284|NCT06040684|DIAGNOSTIC_TEST|Level of antibodies|The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.
40798285|NCT05761288|BEHAVIORAL|Intraoperative microbreaks and exercises|"Intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. Intervention exercises include: chest and shoulder opener elbows in pockets, chin tuck, neck rotation, squat with truncal rotation (chair pose with prayer), and forward bend."
40798286|NCT00880269|DRUG|Panobinostat/LBH589|
40798287|NCT03545087|DRUG|Lanabecestat|Administered orally
40798288|NCT03545087|DRUG|Iohexol|Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
40798289|NCT04646746|DIETARY_SUPPLEMENT|100% wheat|100 g of bread backed with 100% wheat
40798290|NCT04646746|DIETARY_SUPPLEMENT|50% nude barley and 50% wheat|100 g of bread backed with 50% nude barley and 50% wheat
40798291|NCT04646746|DIETARY_SUPPLEMENT|75% nude barley and 25% wheat|100 g of bread backed with 75% of nude barley and 25% wheat
40798292|NCT04646746|DIETARY_SUPPLEMENT|50% gene-modified high-amylose barley and 50% wheat|100 g of bread backed with 50% gene-modified high-amylose barley and 50% wheat
40798293|NCT05457842|DRUG|pudexacianinium chloride|Intradermal injection
40798294|NCT03403530|DRUG|IgM rich Immunoglobin|the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
40798295|NCT06547333|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
40798296|NCT06547333|DRUG|Placebo|Placebo
40798297|NCT02534025|PROCEDURE|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
40798298|NCT03328468|OTHER|Breathing Exercise|Breathing exercise for stroke patients
40798299|NCT03873727|BIOLOGICAL|Prevenar13 (PCV13) and Pneumovax (PPS23)|One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12
41002442|NCT01434290|RADIATION|36.25 Gy IMRT|36.25 Gy in 5 fractions of 7.5 Gy twice a week over 15-17 days. A minimum of 72 hours and a maximum of 96 hours will separate each treatment. IMRT or similar techniques that use inverse treatment planning or protons are required.
41002443|NCT01434290|RADIATION|51.6 Gy IMRT|51.6 Gy in 12 fractions of 4.3 Gy 5 days a week over 16-18 days. IMRT or similar techniques that use inverse treatment planning or protons are required.
41151587|NCT06111183|BIOLOGICAL|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
41151588|NCT06111183|OTHER|Placebo|Placebo is topically applied on chronic wounds and covered by wound dressing.
40798300|NCT03873727|BIOLOGICAL|Placebo / Pneumovax (PPS23)|One dose of Placebo at Month 0 and one dose of PPS23 at Month 12
40798301|NCT03873727|BIOLOGICAL|Blood sample|an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
40798302|NCT02715830|PROCEDURE|Angioplasty of distal arteries|angioplasty of the arteries bellow-the-knee
40798303|NCT05906680|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
40798304|NCT02830854|OTHER|Molecular Hydrogen|
40798305|NCT05085041|BEHAVIORAL|Multi-Component eHealth Intervention, namely Healthy Online Parental Education (HOPE)|The investigators will provide 8 sessions of a multi-component education intervention to the participants in the intervention group. Each session will address parental nutrition knowledge, self-efficacy, and attitudes around feeding, parental modeling of healthy foods, and skill development to increase success in making behavioral changes. The intervention curriculum will be informed by Social Cognitive Theory to help parents guide young children to engage in healthy eating behaviors through modeling (Curriculum Design). The investigators will deliver the intervention using multicomponent to enhance and maximize the learning experiences of the participants for successful behavior changes. The intervention will be comprised of instructional videos, text messages with key information, online cooking activities, and telephone consultation (Modality).
40798306|NCT03012191|DRUG|Gentamicin Sulfate|Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
40798307|NCT03731052|DRUG|188-0551 Spray|Topical Spray containing active drug
40798308|NCT03731052|DRUG|Vehicle Spray|Topical Spray containing no active drug
40798309|NCT04643366|DRUG|Chemotherapy|Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)
40798310|NCT04643366|RADIATION|Radiation Therapy|Pelvic Intensity-modulated radiation therapy (IMRT)
40798311|NCT00343499|DRUG|valsartan|
40798312|NCT01229007|BIOLOGICAL|Biostate|1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
41002444|NCT04781634|BIOLOGICAL|CD19 and CD22 targeted prime CAR-T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
41002445|NCT00964392|PROCEDURE|Atrial fibrillation ablation|Radiofrequency ablation
41002446|NCT00261924|DEVICE|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
41002447|NCT02790346|PROCEDURE|arthrodesis talonavicular|
41002448|NCT02790346|PROCEDURE|tendon gestures|
41002449|NCT01171716|OTHER|Meal Patterning|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
40798313|NCT00368680|DEVICE|Early Bubble CPAP|
41002450|NCT00848328|BIOLOGICAL|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
41002451|NCT00848328|DRUG|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
41002452|NCT03876730|OTHER|ICF CP Core Set|Core set
41002453|NCT01769885|DRUG|tivozanib|Given PO
41002454|NCT01769885|PROCEDURE|therapeutic conventional surgery|Undergo nephrectomy
41002455|NCT02476838|PROCEDURE|Hand Transplantation|microvascular VCA transplant
41002456|NCT02003625|DRUG|GCSF|
41002457|NCT02003625|DRUG|meloxicam|
41002458|NCT02003625|DRUG|Placebo|
41002459|NCT04426617|PROCEDURE|Ultrasound Guided Transversus Abdominis Plane Block|The patient will lie in the supine position. The transducer will be placed in the axial plane on the mid-axillary. transversus abdominis muscle will be visualized. A skin wheel using 3 ml of lidocaine 1 % is made 2 to 3 cm medial to the medial aspect of the transducer and the 22 gauge is inserted in-plane pointing laterally. Then Injection of local anaesthetic mixure in the right plane.
41002460|NCT00685932|DEVICE|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
41002461|NCT00885547|DRUG|tripterygium wilfordii (TW)|90 mg/d for 6 months
41002462|NCT05923424|DRUG|REGN17092|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
41002463|NCT05923424|DRUG|Matching Placebo|Single ascending IV or SC administration per the protocol
41002464|NCT00094965|DRUG|Oxaliplatin (SR96669)|oxaliplatin in combination with FOLFOX4
41002465|NCT02313753|BEHAVIORAL|CLASP|
41002466|NCT02313753|BEHAVIORAL|SAFE|
41002467|NCT03999307|RADIATION|Low-Level Laser Therapy (LLLT)|LLLT will be applied in this group
41002468|NCT03999307|PROCEDURE|Flapless Corticopunture|Small holes in the cortical bone will be achieved using 1-mm diameter round surgical Tungsten bur
41002469|NCT03999307|OTHER|Control|Typical orthodontic treatment with no LLLT or flapless corticopuncture
41002470|NCT05799092|DIAGNOSTIC_TEST|Invasive coronary angiography|As alternative to non-invasive functional testing, invasive coronary angiography will be performed.
41151589|NCT04673305|OTHER|Cognitive Assessment, Cytokine dosage|Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
40798314|NCT01742299|DRUG|imatinib mesylate|Imatinib will be provided as 100 mg and 400 mg tablets taken orally once daily unless other wise instructed by investigator
41151590|NCT06577376|DRUG|DP303c|DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker
40798315|NCT00739310|DEVICE|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
40798316|NCT04898348|DRUG|KBL697|3 capsules twice a day dosing of KBL697
40798317|NCT04898348|DRUG|Placebo|3 capsules twice a day dosing of Placebo
40798318|NCT03212508|DEVICE|RAM cannula and Hudson prongs|Measuring intraoral pressure using two different nasal interface for applying nasal continuous positive airway pressure
40798319|NCT01869634|DRUG|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
40798320|NCT01527591|BIOLOGICAL|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
40798321|NCT01591408|DEVICE|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
40798322|NCT02210988|OTHER|acupuncture|Intervention with acupuncture
41002471|NCT05799092|DIAGNOSTIC_TEST|Non-invasive functional test|Standard non-invasive functional testing will be performed.
41002472|NCT00099463|PROCEDURE|Blood Test|
41002473|NCT00099463|PROCEDURE|Urine Test|
41002474|NCT00099463|PROCEDURE|Physical Exam|
41002475|NCT00099463|DRUG|Vaccine|
41002476|NCT00099463|DRUG|VRC-SRSDNA015-00-VP|
41002477|NCT05961566|DEVICE|Use of collagen matrix after subepithelial connective tissue graft harvest|A collagen matrix is placed under the overlying flap after the subepithelial connective tissue graft harvesting.
41002478|NCT02084628|DRUG|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole \[mmol\]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent \[%\] solution) manually.
41002479|NCT03106207|PROCEDURE|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
41002480|NCT01268384|DRUG|Gemcitabine plus Capecitabine|Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
41315278|NCT02887833|OTHER|Clinical biomarker (thermal sensory testing)|Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
40798323|NCT04314245|OTHER|Active Comparator: Pathology|Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.
40798324|NCT04314245|OTHER|Active Comparator: Clinical Diagnosis|Routine clinical diagnosis and treatment of benign disease of the urinary system
40798325|NCT04314245|OTHER|Active Comparator: Clinical diagnosis|Routine urine test and imaging diagnostic techniques, such as B-ultrasound.
40798326|NCT04314245|OTHER|Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay|A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.
40798327|NCT03910725|OTHER|Electrocardiographic imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
40798328|NCT02457650|DRUG|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
40798329|NCT02457650|DRUG|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
41473043|NCT02836301|BEHAVIORAL|Unresolved Ending|In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
41002481|NCT04667403|OTHER|Telemedicine|"In addition to his standard follow-up, the patient benefits from a home follow-up of his pain for 6 months from his inclusion in the study.~The patient has to log on via the application, every week. to fill in the questionnaire to evaluate the pain over the past week.~The questionnaire consists of 4 questions to which the patient answers using a numerical scale from 0 to 10.~If the patient's pain is not controlled, the patient can log on in emergency mode as many times as he or she deems necessary.~A nurse path coordinator will be informed of each connection. Depending on the type of alert received, she may initiate a telephone consultation with the oncologist or pain specialist:~* If necessary within 24 hours of the connection if it is a weekly connection,~* Systematic within 3 hours if it is an emergency connection or if the data entered at the time of the weekly connection requires medical intervention."
40798330|NCT02457650|BIOLOGICAL|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
40798331|NCT03415581|DRUG|Intranasal Oxycodone|Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.
40798332|NCT03415581|BEHAVIORAL|Cue Session|During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
40798333|NCT05410496|DRUG|Tenofovir Alafenamide 25 MG|To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
40798334|NCT04313075|DRUG|Leronlimab|Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
41151591|NCT06577376|DRUG|Simmitinib tablets|A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)
40798335|NCT04475562|DEVICE|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
40798336|NCT03389412|DRUG|Desmopressin|The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).
40798337|NCT03389412|DEVICE|Conditional alarm|Eight weeks of treatment.
41151592|NCT06577376|DRUG|Irinotecan liposomes|A chemotherapy
41151593|NCT06577376|DRUG|Paclitaxel or docetaxel or irinotecan|Paclitaxel or docetaxel or irinotecan is used as a control.
41151594|NCT01642888|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
41151595|NCT01642888|BIOLOGICAL|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
41151596|NCT03322449|OTHER|Animal Diet|during one week participants will receive food products enriched in animal products and with high content of fat and protein
41151597|NCT03322449|OTHER|Plant Diet|during one week participants will receive plant products enriched in fiber and complex carbohydrates
41002482|NCT04383821|DEVICE|Double-Trunk Mask|The DTM (oxygen delivery system) is worn by the patient for 30 minutes.
41002483|NCT04383821|DEVICE|Non-Rebreather mask|The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
41315279|NCT05384223|BEHAVIORAL|RRFT (Risk Reduction through Family Therapy)|RRFT is an adaptation and integration of existing empirically-supported interventions with similar theoretical rationales targeting similar populations, particularly Multisystemic Therapy principles (MST)for adolescent SUP and Trauma Focused-Cognitive Behavioral Therapy (TF-CBT) components for PTSD in youth. RRFT consists of seven primary components: Psychoeducation and Engagement, Coping, Family Communication, Substance Use, PTSD, Healthy Dating and Sexual Decision-Making, and Revictimization Risk Reduction.
41473044|NCT00684567|RADIATION|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
41473045|NCT00684567|DRUG|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
40798338|NCT06368284|PROCEDURE|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident between January 2017 and December 2023, managed and followed up in France
40798339|NCT04706312|OTHER|stem cells|hAMSCs injection via venous in the dorsum of hand
41002484|NCT02769702|DRUG|Acthar|Acthar 80 IU SC twice a week
41002485|NCT04010266|DEVICE|RelieVRx headset|RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain
41002486|NCT04010266|DRUG|multi-modality pain management|combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
41002487|NCT01466946|BEHAVIORAL|semi-structured interviews|Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin \& Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
41002488|NCT03127969|OTHER|Fluidotherapy treatment|fluidotherapy and joint protection and exercise
41002489|NCT03127969|OTHER|Joint protection and exercise|joint protection and exercise
41002490|NCT05074433|DRUG|casirivimab+imdevimab|Co-administered sequentially subcutaneous (SC)
41002491|NCT05074433|DRUG|Placebo|Administered SC
41002492|NCT00117858|PROCEDURE|Anodal DC polarization of left prefrontal cortex|
41002493|NCT01719692|DRUG|Rituximab|
41002494|NCT00113256|DRUG|Rubitecan|
41002495|NCT04078776|OTHER|No intervention|There is no intervention in this study
41002496|NCT01667640|RADIATION|sector irradiation|"Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.~A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.~Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.~Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.~Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported."
40798340|NCT00037440|GENETIC|Polymorphisms measured|
40798341|NCT06091436|DRUG|GenSci094|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.
40798342|NCT06091436|DRUG|Placebo RecFSH / follitropin alfa|powder-injection, but without the active ingedient, SC injection . Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
41002497|NCT01667640|RADIATION|whole brain irradiation|"For whole brain radiation the entire brain, the base of the skull and the meninges are included.~Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.~The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented."
41315280|NCT05384223|BEHAVIORAL|ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)|Encompass is currently a research to practice treatment for adolescents with co-occurring substance use disorders and mental health problems and is used as the standard treatment in the target study settings.
41315281|NCT01427283|DRUG|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
41473046|NCT01067716|DEVICE|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
40798343|NCT06091436|BIOLOGICAL|Biological: RecFSH / Follitropin alfa (Days 1 to 7)|Daily SC injections with 150IU or 225IU recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
40798344|NCT06091436|DRUG|Placebo GenSci094|Pre-filled syringe containing an identical solution when compared to GenSci094. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
40798345|NCT06091436|BIOLOGICAL|RecFSH / Follitropin alfa (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.
40798346|NCT06091436|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
41315282|NCT01427283|DRUG|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
41315283|NCT01427283|DRUG|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
41315284|NCT04970524|PROCEDURE|Comparison of conventional free gingival graft versus partial free gingival graft|"Conventional free gingival graft was applied to the area of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
41315285|NCT04970524|PROCEDURE|Comparison of conventional free gingival graft versus partial free gingival graft|"Partially de-epithelialized free gingival graft was applied to the other region of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
41315286|NCT05912959|OTHER|photo biostimulation|the intervention is a type of wavelength around 820 nm. this method of treatment is totally safe. yet, it has many therapeutic effects on the cellular level as well as tissue and organ level. during treatment with laser, the patient does not feel any specific sensation.
41473047|NCT01730560|OTHER|Treatment A|"The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.~The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month)."
41473048|NCT01730560|OTHER|Treatment B|"Placebo treatment using the same computer-based training task, but including only the ramp phase.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month)."
41473049|NCT02534233|DEVICE|CryoBalloon|Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
41473050|NCT04072549|BEHAVIORAL|Free Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
41473051|NCT06613087|OTHER|Foot bath|In the foot bath application, the feet will be kept in water at a constant temperature of 38-40 °C for about 20 minutes. During this time, the water temperature will be checked with a thermometer at intervals. Foot bath applications will be performed for 3 days, on the 2nd, 3rd and 4th days of hospitalization.
40798347|NCT06091436|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
40798348|NCT06091436|DRUG|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.
40798349|NCT00306839|PROCEDURE|standardized Lichtenstein technique|
40798350|NCT05739396|OTHER|core stabilization|The treatment session lasted one hour with short breaks of around 10 minutes and will be conducted three times per week for twelve successive weeks
40798351|NCT00149240|BIOLOGICAL|Botulinum toxin type A|
40798352|NCT06070389|DEVICE|Sansa device|The Sansa device will be used during a single overnight polysomnography study.
40798353|NCT02346227|DRUG|AV2|"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."
41315287|NCT05768841|BEHAVIORAL|mental health issues|survey on mental health issues in endurance athletes
41315288|NCT01105221|DEVICE|Acupuncture|Participants, allocated to this group, will have twelve times of acupuncture treatment in four weeks. Seventeen acupuncture points, which are both BL2, GB14, TE23, Ex1, ST1, GB20, LI4, LI11 and single GV23, will be selected and disposable 0.20\*30mm acupuncture needles(Dongbang Co., Korea) will be inserted on these points. Strong 'deqi' sensation will be induced by twisting acupuncture needles and retained for 20 minutes before removed.
41315289|NCT01105221|DRUG|Refresh Plus|Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose). They should use artificial tear in both eyes at least once a day for four weeks.
41315290|NCT02776410|BEHAVIORAL|Consumer reactions to tailored messages sent via app|The intervention will take 1 month. Participants from the Intervention group will receive tailored messages every 2-3 days with a push notification. Additionally, interaction with the participants via the use of app is foreseen.
41315291|NCT01240655|DRUG|LCL161|
41315292|NCT01240655|DRUG|Paclitaxel|
41473052|NCT03263793|BEHAVIORAL|Choral (group) singing therapy sessions|Choral (group) singing therapy sessions will be conducted once weekly and daily home practice exercises will be assigned. All vocal exercises are based on principles that have been successful in other intensive Parkinson Disease vocal exercise programs.
41473053|NCT03130348|DRUG|Bortezomib|Given SC
41473054|NCT03130348|DRUG|Dexamethasone|Given PO
41473055|NCT03130348|DRUG|Ibrutinib|Given PO
41473056|NCT03130348|OTHER|Laboratory Biomarker Analysis|Correlative studies
41473057|NCT06483256|DIAGNOSTIC_TEST|radiographic control|Radiographic study with standard projections (AP and LL) is used to assess any signs of anchor loosening and/or presence of heterotopic ossifications (which can restrict movement and is one of the main complications).
41473058|NCT04062994|BEHAVIORAL|Nudge to reduce intraoperative hypotension|Providers will be alerted if their patients are at high risk of hypotension or at increased risk of sequelae from hypotension. Intraoperatively, if patients have more than 10 minutes of hypotension an alert will be displayed on the screen.
41473059|NCT00988208|DRUG|Lenalidomide|25 mg lenalidomide orally once each day on Days 1-14
41473060|NCT00988208|DRUG|Docetaxel|75 mg/m2 intravenous docetaxel on Day 1
41473061|NCT00988208|DRUG|Prednisone|5 mg prednisone orally twice daily on each day of the treatment cycle
41473062|NCT00988208|DRUG|Placebo|Oral placebo once each day on Days 1-14 of the treatment cycle
41473063|NCT02067702|PROCEDURE|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
41473064|NCT05677087|BEHAVIORAL|PREPARE Nutrition Education Module|The Perinatal Remote Education for Pandemic Resilience (PREARE) program is a 6-week intensive program aimed at increasing maternal and infant dietary diversity as well as maternal health literacy. Modules that will be completed in the program include education on early initiation of breastfeeding, food groups and the benefits of a balanced diet, appropriate meal frequency for mother and infant, and appropriate sources of health information. Information on personal hygiene and COVID-19 hygiene protocols as well as danger signs during pregnancy are included in the module to improve maternal knowledge on safety protocols and pregnancy complications.
41473065|NCT05303935|DRUG|Quetiapine 50 MG|A single dose of 50mg of quetiapine taken at bedtime for one night.
41473066|NCT05303935|DRUG|Placebo|A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
41473067|NCT05493761|DRUG|Denosumab|60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
41473068|NCT05493761|DRUG|Alendronate Sodium|70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
41473069|NCT03514186|BEHAVIORAL|Speech and Language Therapy|"Includes:~* one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~* one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~* one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~* one hour in a conversation group that emphasizes multimodality communication"
41473070|NCT03633552|DRUG|Temozolomide|The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
40798354|NCT02346227|DRUG|Placebo|"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."
41315293|NCT01922284|BIOLOGICAL|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
40798355|NCT05077982|DIAGNOSTIC_TEST|Spirometry|Spirometry to assess lung function
41315294|NCT01922284|BIOLOGICAL|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
41315295|NCT01922284|BIOLOGICAL|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
41315296|NCT01922284|BIOLOGICAL|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
41315297|NCT05902013|DEVICE|laryngoscopy|laryngoscopy for nasotracheal intubation
41315298|NCT01426607|DEVICE|AMO|
41315299|NCT03978182|DEVICE|accelerated deep rTMS|A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
41315300|NCT00778986|DEVICE|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
41315301|NCT02472119|DIETARY_SUPPLEMENT|rusks made of wheat flour enzymatically treated|100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
41473071|NCT04924374|DIETARY_SUPPLEMENT|Microbiota Transplant plus anti PD1 therapy|"Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (\>30g/day).~anti PD1 therapy every 2-3 weeks"
41473072|NCT04924374|DRUG|anti PD1 therapy|anti PD1 therapy every 2-3 weeks
40798356|NCT05077982|DIAGNOSTIC_TEST|6-minute walk|Exercise tolerance
40798357|NCT05777668|RADIATION|Volumetric modulated radiotherapy|
40798358|NCT05684692|DRUG|Siltuximab|A chimeric immunoglobulin G mAb, via intravenous infusion.
40798359|NCT05684692|DRUG|Erenumab-Aooe|Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
40798360|NCT05684692|DRUG|Siltuximab Matching Placebo|Dextrose 5% in water, via intravenous infusion.
40798361|NCT05684692|DRUG|Erenumab-Aooe Matching Placebo|0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
40798362|NCT02816268|OTHER|Pulmonary vein isolation|
40798363|NCT06026605|DRUG|WTX212A|WTX212A infusion once every 21 days
40798364|NCT05328869|OTHER|Relaxation training|Relaxation training will be performed under the supervision of a physiotherapist. The training is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
40798365|NCT05328869|OTHER|No intervention|No intervention will be applied. The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
40798366|NCT04941430|DIAGNOSTIC_TEST|Magnetic Resonance Imaging using 7 Tesla MRI|Undergo 7T MRI
40798367|NCT04424459|DRUG|opioid withdrawal|The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
40798368|NCT00056576|DRUG|Zonisamide|
40798369|NCT00117780|DRUG|insulin detemir|
40798370|NCT00117780|DRUG|insulin aspart|
40798371|NCT05908357|OTHER|Exergaming|Use of the exergame XboX 360 series with kinect sensor
40798372|NCT05908357|OTHER|Booklet|Use of the booklet with instructions of exercises to be done at home with tele-health through whatsapp app.
41473073|NCT02641002|DRUG|CC-90002|Monoclonal Ab to CD47
41473074|NCT03808584|OTHER|Physiotherapy|4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
41473075|NCT05530473|DEVICE|capsular tension ring|To insert a capsular tension ring during the cataract surgery
41473076|NCT01579760|DRUG|Aflibercept every 2 months|2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
41473077|NCT01579760|DRUG|Aflibercept monthly|2.0mg aflibercept intravitreal injections every month (M0-11)
41473078|NCT05698706|DEVICE|TOOsonix System ONE-M|Selected BCC sites will be treated using high intensity focused ultrasound
40798373|NCT01281384|OTHER|Advanced Imaging|
40798374|NCT01281384|OTHER|Standard Imaging|
40798375|NCT03470740|BEHAVIORAL|rheumatoid arthritis self-management program|The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
40798376|NCT06243328|DEVICE|negative wound pressure therapy|nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister
40798377|NCT03752996|DEVICE|ACURATE TF™ Aortic Valve System|Transcatheter Aortic Valve Implantation
40798378|NCT04320212|PROCEDURE|lumber epidural analgesia|the lumber epidural analgesia will be given after induction of general anesthesia.
40798379|NCT04320212|PROCEDURE|erector spinae analgesia|the erector spinae analgesia will be given after induction of general anesthesia.
40798380|NCT05645796|OTHER|Adopted contrast media amount by using different approaches|Using different contrast media approaches recommended by literature to explore the impact on the contrast enhancement in chest CT
40798381|NCT00633178|BEHAVIORAL|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
40798382|NCT00633178|BEHAVIORAL|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
40798383|NCT03619577|BEHAVIORAL|Sequential training|For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
40798384|NCT03617718|DRUG|Glycine Buffer|Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
40798385|NCT05822947|OTHER|Active manual therapy|Soft tissue mobilization of the lumbar paraspinal musculature (3 to 4 minutes).
40798386|NCT05822947|OTHER|Control manual therapy|Light touch and a breathing exercise (3 to 4 minutes).
41002498|NCT00804336|DRUG|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
41473079|NCT02371421|DRUG|Allopurinol|
40798387|NCT02509936|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
40798388|NCT02509936|DIETARY_SUPPLEMENT|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
40798389|NCT06335069|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI|All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.
40798390|NCT00922402|PROCEDURE|Intensive insulin infusion|"The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.~In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase."
40798391|NCT01048242|DRUG|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
40798392|NCT01048242|DRUG|Placebo|placebo
40798393|NCT04662775|BEHAVIORAL|HERizon Project|"1. Participants were asked to complete 3x30-minute physical activity sessions each week \& record their sessions using a logbook. They were given the choice of different types of home-based virtual exercise. 2. Behaviour change support calls - participants were allocated an Activity Mentor (trainee sport and exercise psychologists, was supervised by a HCPC-registered Psychologist). Participants had seven weekly videocalls. Each call was based on a pre-planned session outline and was goal orientated, participant centred and focused on physical activity. 3. No reply SMS - Participants received 3 standardised text messages each week, aimed at providing physical activity -related facts, encouragement and study information."
40798394|NCT01151384|DRUG|LE-DT|Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
40798395|NCT05626179|DRUG|[14C] IBI351|The oral formulation of \[14C\] IBI351 was formulated as a suspension for subjects to take orally in drinking water under fasting conditions
41315302|NCT02472119|DIETARY_SUPPLEMENT|rusks made of wheat flour not enzimatically modified|100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
40798396|NCT03601065|OTHER|Videos of polyps, resection of polyps|Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
40798397|NCT00023933|DRUG|iodine I 131 monoclonal antibody CC49-deltaCH2|Given IV
40798398|NCT05625295|OTHER|data collection protocol in clinical history|collection of data from the clinical history according to the established protocol
40798399|NCT02188940|BEHAVIORAL|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
40798400|NCT02188940|BEHAVIORAL|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
40798401|NCT02188940|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
40798402|NCT02188940|OTHER|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
40798403|NCT02188940|OTHER|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~\*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
40798404|NCT02512289|DEVICE|tDCS (ELDITH) and RAT (REAplan)|Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
41002499|NCT00804336|DRUG|RAD001|Given orally once a day
41315303|NCT02472119|DIETARY_SUPPLEMENT|Gluten-free diet|gluten-free diet
41315304|NCT02034357|OTHER|Neurocognitive function|Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
41315305|NCT02034357|OTHER|Sleep evaluations|Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
41315306|NCT03522701|BEHAVIORAL|CBTI|Refer to the arm description
41315307|NCT04914741|DRUG|Rituximab|Rituximab 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
41315308|NCT04914741|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
41315309|NCT04914741|DRUG|Doxorubicin|Doxorubicin 50mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
40798405|NCT03110211|PROCEDURE|Physical Therapist Evaluation|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a physical therapist.
40798406|NCT03110211|PROCEDURE|Primary Care Physician|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a primary care physician.
40798407|NCT02601430|OTHER|BOLD-MRI|A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
40798408|NCT03213132|BEHAVIORAL|SHUTi (Sleep Health Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
40798409|NCT03213132|BEHAVIORAL|Patient Education|Educational website containing information on insomnia
40798410|NCT03794427|OTHER|unilateral lumbosacral nerve block|Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
40798411|NCT03794427|OTHER|Spinal anesthesia|Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
40798412|NCT03794427|OTHER|Placebo at the spinal anesthesia level|Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
41151598|NCT02705456|PROCEDURE|Tooth Brushing HA|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
40798413|NCT03794427|OTHER|Placebo at lumbosacral level|Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
40798414|NCT02570724|DRUG|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
40798415|NCT02570724|BIOLOGICAL|blood patch|
40798416|NCT02755662|DEVICE|Mandibular Retention Device|
40798417|NCT02505022|DRUG|Pharmacotherapy|Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
40798418|NCT02505022|BEHAVIORAL|Behavioral treatment|Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
40798419|NCT00002124|DRUG|Delavirdine mesylate|
40798420|NCT00002124|DRUG|Lamivudine|
41315310|NCT04914741|DRUG|Vincristine|Vincristine 1.4mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
40798421|NCT00002124|DRUG|Zidovudine|
40798422|NCT00161616|DRUG|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
40798423|NCT04416334|DRUG|Colchicine plus symptomatic treatment (paracetamol)|Colchicine plus symptomatic treatment (paracetamol).
40798424|NCT04416334|DRUG|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
40798425|NCT00113633|BEHAVIORAL|Intervention Subjects|The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
41315311|NCT04914741|DRUG|Prednisolone|Prednisolone 100mg orally on Days 1-5 of every 21-day cycle
41315312|NCT04914741|DRUG|Glofitamab|Glofitamab will be administered by IV infusion as per the schedule specified in the respective arm
41315313|NCT04914741|DRUG|Polatuzumab vedotin|Polatuzumab 1.8mg/kg administered by IV infusion on Day 1 of every 21-day cycle
40798426|NCT00780143|DRUG|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
40798427|NCT03481842|BIOLOGICAL|Linifanib|in a minimally sufficient therapeutic dose
40798428|NCT03481842|DRUG|BIBW2992|in a minimally sufficient therapeutic dose
40798429|NCT03481842|DRUG|Axitinib|in a minimally sufficient therapeutic dose
40798430|NCT03770741|OTHER|Modify cardio-respiratory support to avoid cerebral hypoxia|modification of cardio-respiratory support based on an evidence-based treatment guideline
40798431|NCT03770741|OTHER|Treatment as usual|Monitoring and treatment according to local guidelines and practice
40798432|NCT00708591|DRUG|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
41151599|NCT02705456|PROCEDURE|Tooth Brushing FL|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
41151600|NCT04485975|DEVICE|Therapeutic plasma exchange|Therapeutic plasma exchange filtrates plasma and decreases thyroid hormone concentration in the blood
41151601|NCT04521647|DRUG|Nicotine|Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use
41473080|NCT06106451|BEHAVIORAL|Standard of Care plus Enhanced Patient Education|Patients in this arm will receive a pamphlet explaining the benefits of cardiac rehabilitation. This pamphlet will be given in addition to standard of care patient education. The research team will also call the patient at four specified time points to provide additional information.
41315314|NCT01614665|DRUG|Tacrolimus|Participants receive an initial total daily dose of tacrolimus depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 2 doses in the morning and the evening. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus doses are taken orally twice a day in the morning and evening and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
41473081|NCT06106451|BEHAVIORAL|Motivational Interviewing Intervention|Patients in this arm of the study will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
41473082|NCT06106451|BEHAVIORAL|Home-Based Activity Program plus Motivational Interviewing Intervention|Patients in this arm will be evaluated on postoperative day 1 by a physical therapist on the study team. After the evaluation, the physical therapist will use the information from the evaluation to make a tailored home-based physical activity program for the patient. The patient will begin the home-based physical activity program on the day of their 1-month post-operative cardiology clinic appointment. In addition to the home-based activity program, patients will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
41473083|NCT00921037|PROCEDURE|Erbium-YAG laser vaporization|spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz
41473084|NCT04492852|PROCEDURE|Polypropylene (PROLENE) sutures|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
41473085|NCT04492852|PROCEDURE|Staple Sutures|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
41473086|NCT06044194|DRUG|L-arginine and liposomal vitamin C|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group) or an oral supplement of Placebo once a day for 3 months (control group)
41473087|NCT06390124|DRUG|Platelet Derived Growth Factor (PDGF)|Reconstructive therapy of advanced peri-implantitis-related defects with anorganic bovine bone and allograft combined with PDGF
40798433|NCT00708591|DRUG|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
40798434|NCT05129657|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
40798435|NCT05129657|OTHER|Product B|P1012914, A nicotine pouch product with 4 mg of nicotine
40798436|NCT05129657|OTHER|Product C|P1012915, A nicotine pouch product with 8 mg of nicotine
41473088|NCT02280720|PROCEDURE|Stenting using Optimax™|
41473089|NCT02280720|PROCEDURE|Stenting using PROMUS Element™ Plus|
41473090|NCT02839668|DRUG|Lidocaine|Continuous infusion of lidocaine
41473091|NCT02839668|DRUG|Sevoflurane|maintenance of hypnosis during anaesthesia with sevoflurane
41473092|NCT02839668|DRUG|TIVA-TCI|maintenance of hypnosis during anaesthesia with sevoflurane
41473093|NCT02839668|DRUG|Acetaminophen|administration of 1 g acetaminophen for postoperative analgesia
41473094|NCT02839668|DRUG|Tramadol|administration of tramadol for postoperative analgesia
41473095|NCT02839668|DRUG|Neostigmine|A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
41473096|NCT02839668|DRUG|Atropine|A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
41473097|NCT02839668|DEVICE|BIS|For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
40798437|NCT05129657|OTHER|Product D|P1012919, A nicotine pouch product with 12 mg of nicotine
40798438|NCT05129657|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
40798439|NCT01277705|BIOLOGICAL|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
41473098|NCT05927779|DRUG|TFX06 tablet|TFX06 tablet taken orally
40798440|NCT01277705|BIOLOGICAL|Boostrix™|Intramuscular, single dose
40798441|NCT01277705|BIOLOGICAL|GSK Biologicals' IPV vaccine|Intramuscular, single dose
40798442|NCT01277705|BIOLOGICAL|Revaxis®|Intramuscular, single dose
40798443|NCT01591837|BIOLOGICAL|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
40798444|NCT02511795|DRUG|AZD1775|"AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
41002500|NCT06481202|BIOLOGICAL|Complarate®|The test drug Complarate® was administered as an intravenous infusion at a single dose of 8 mg/kg.
41002501|NCT06481202|BIOLOGICAL|Actemra®|The reference drug Actemra® was administered as an intravenous infusion at a single dose of 8 mg/kg.
41151602|NCT00276016|DRUG|phenylephrine|immediate-release 12 mg capsules for oral administration
41151603|NCT00276016|DRUG|pseudoephedrine|60 mg immediate-release tablets for oral administration
41151604|NCT00276016|DRUG|placebo|placebo capsules
41151605|NCT02001207|OTHER|Salivary cortisol test|
41151606|NCT03096496|OTHER|QoL questionnaires|Quality of life questionnaires
41002502|NCT02813343|DEVICE|BlueStar app|BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.
41002503|NCT02635191|DRUG|Tailored Group|All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
41002504|NCT02635191|DRUG|Standard group|All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
41002505|NCT00122720|DRUG|Darbepoetin Alfa|
41002506|NCT05243212|BIOLOGICAL|CAR-BCMA|CAR-BCMA T-cells are genetically modified autologous T-cells directed to the B-cell maturation antigen (BCMA). CAR-BCMA T-cells identify and eliminate BCMA-expressing malignant plasma cells. Upon binding to BCMA-expressing cells, the CAR transmits a signal to promote T cell expansion, activation, persistence and elimination of malignant plasma cells.
41002507|NCT00594464|DRUG|Rotigotine|"2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery."
41002508|NCT02990793|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/ECG resonance therapy (MeRT) treatment that is tailored specifically to each participant's EEG intrinsic alpha frequency (IAF). rTMS is applied at the participant's IAF.
41002509|NCT02990793|DEVICE|Sham MeRT Treatment|rTMS coil does not emit magnetic stimulation.
41151607|NCT01324011|BEHAVIORAL|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
41151608|NCT00399659|DRUG|Tegaserod|
40798445|NCT02511795|DRUG|Olaparib|"AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
41151609|NCT03287947|DRUG|nintedanib|Oral nintedanib, taken twice daily
41151610|NCT00293332|BIOLOGICAL|bevacizumab|Neoadjuvant therapy with 15 mg/kg, IV on Day 1 of each 21 day cycle for the first 2 cycles.
41151611|NCT00293332|DRUG|carboplatin|Neoadjuvant therapy, AUC 6, IV on day 1 of each 21 day cycle for 3 cycles.
41151612|NCT00293332|DRUG|docetaxel|Neoadjuvant therapy, 75 mg/m2, IV on day 1 of each 21 day cycle for 3 cycles.
41151613|NCT00293332|PROCEDURE|conventional surgery|Standard surgery after 3 cycles of neoadjuvant therapy with docetaxel, carboplatin, and bevacizumab. Bevacizumab is given for the first 2 cycles only.
41151614|NCT03221634|BIOLOGICAL|Pembrolizumab|IV infusion
41151615|NCT03221634|BIOLOGICAL|Daratumumab|IV infusion
41151616|NCT05018871|BIOLOGICAL|autologous adipose derived mesenchymal stem cells|cultured autologous adult adipose derived mesenchymal stem cells
41151617|NCT01862224|DRUG|JNJ-38518168|JNJ-38518168 30 mg once daily, Week 0 to Week 52.
41151618|NCT01862224|DRUG|Placebo|Matching placebo once daily (Week 0 to Week 12).
41151619|NCT01862224|DRUG|Methotrexate|All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
41473099|NCT01602172|BEHAVIORAL|Brief Alcohol Intervention|3 part intervention: Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
40798446|NCT02384044|DEVICE|Crest® Sensi-Stop™ Strips|
40798447|NCT02384044|DEVICE|Colgate® Sensitivity Relief Pen|
40798448|NCT03021655|BEHAVIORAL|Adventure-based intervention group|One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.
40798449|NCT03021655|BEHAVIORAL|WhatsApp intervention group|A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.
40798450|NCT03021655|BEHAVIORAL|Control group|Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
40798451|NCT00245388|DRUG|Muraglitazar|
41151620|NCT04229706|DRUG|High dose Xiang Ju Ru Pi Ning capsule|xingjurupining capsule,8 capsule,tid,3 months.
41151621|NCT04229706|DRUG|Low dose Xiang Ju Ru Pi Ning capsule|xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.
40798452|NCT02968446|DIETARY_SUPPLEMENT|4 placebo|subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills
40798453|NCT02968446|DIETARY_SUPPLEMENT|4 Vitamin D|subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)
41315315|NCT01614665|DRUG|Tacrolimus prolonged release|Participants receive an initial total daily dose of tacrolimus prolonged release depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 1 dose. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus prolonged release doses are taken orally once a day in the morning and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
41315316|NCT01623531|DRUG|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
40798454|NCT02968446|DRUG|Valchlor|Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
40798455|NCT01650831|DEVICE|Modified BreathID|A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
40798456|NCT06095934|OTHER|neo-antigen vaccine|anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy
41315317|NCT03825523|OTHER|iART|After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
41315318|NCT03825523|OTHER|cART|After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
41315319|NCT02344407|BIOLOGICAL|VSVG-ZEBOV|The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
40798457|NCT03447405|DEVICE|Dino Egg|DINO EGG speakers, a NICU-safe and developmentally appropriate music player that delivers parent's voice to the bedside of NICU infants. The device passed NCH NICU-safe products committee and has been used in the clinical setting delivering clinical music therapy services (available at bedside to play parents' voice).
40798458|NCT00179062|DRUG|olanzapine versus risperidone|Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
40798459|NCT03528876|DRUG|FOLFOX and FOLFIRI|a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
40798460|NCT04600726|OTHER|no intervention|no interventioni
40798461|NCT06467786|DRUG|Irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection combined with platinum
41151622|NCT04229706|DRUG|Xiang Ju Ru Pi Ning capsule placebo|xiangjurupining capsule,8 capsule,tid,3 months.
41151623|NCT00308009|PROCEDURE|Vaginal Repair for prolapse, TVT procedure|"1. TVT at the time of Vaginal Repair~2. TVT 3 months after Vaginal Repair"
41151624|NCT00308009|PROCEDURE|TVT and Prolapse surgery|"1. TVT at the time of Prolapse surgery~2. TVT 3 months after Prolapse Surgery"
41151625|NCT01283971|DRUG|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
41151626|NCT01283971|DRUG|adalimumab|Adalimumab 40 mg SC every 2 weeks.
41151627|NCT01283971|DRUG|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
41151628|NCT01283971|DRUG|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
41151629|NCT01283971|DRUG|methotrexate|Methotrexate 10-25 mg weekly.
41151630|NCT01283971|DRUG|folate|Folate at least 5 mg weekly.
41151631|NCT03188978|DRUG|Atorvastatin 40mg|one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
41151632|NCT03188978|OTHER|Placebo|one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
41151633|NCT01615523|OTHER|MRI, EEG and cognitive testing|Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
41151634|NCT03521076|DEVICE|Virtual Reality|Participants will have the opportunity to choose a game or relaxation experience to utilize during a botulinum toxin injection to distract from pain and anxiety during one visit. Virtual Reality will not be available during the other visit. AppliedVR has a number of games and relaxation experiences available for participants to chose from.
41151635|NCT01923870|DRUG|Androxal 25 mg|
41151636|NCT01874522|DRUG|TAS-102 tablets|"Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met."
41151637|NCT01874522|DRUG|TAS-102 oral solution|60 mg/dose, orally, up to 2 single doses separated by 1-week washout
41151638|NCT03865862|OTHER|Experimental|The athletes will perform an intervention of 4 weeks, with two weekly sessions, in which the intervention will be performed during the training, with these sessions lasting 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series. This intervention will be performed adding 50% of his OR as external load during the first two weeks, 55% of his MR during the third week, and 60% of his MR in the fourth week of the intervention. During the exercise you can help the physiotherapist who will accompany you to perform the concentric phase without load.
41151639|NCT03865862|OTHER|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 squat repetitions on a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a 15-second rest between series. The subjects of this group will perform the protocol using only their own weight as a load.
41002510|NCT02478138|PROCEDURE|Sentinel lymph node mapping|Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
41002511|NCT02478138|DRUG|Indocyanine Green (ICG)|
41002512|NCT02478138|DEVICE|near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)|
41002513|NCT05198570|OTHER|Pharmacokinetic analysis|Population pharmacokinetic analysis of plasma concentrations of aciclovir obtained during routine therapeutic drug monitoring
41002514|NCT00743912|DRUG|rifaximin|550 mg TID
41002515|NCT02180516|DRUG|Meloxicam|
41002516|NCT02180516|DRUG|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
41002517|NCT01166828|BEHAVIORAL|TELLEPUPPS|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
41002518|NCT01015352|DRUG|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
41002519|NCT01015352|DRUG|Epoetin beta|"Epoetin beta : 60000U weekly SQ injections~NeoRecormon®"
41002520|NCT01723228|DRUG|Rasagiline|
41002521|NCT01723228|DRUG|Placebo|
41002522|NCT01565135|BEHAVIORAL|Multimodal Vaccine Program|"Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~* Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~* Practice-based reminder/recall~* Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback"
41002523|NCT00578942|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45."
41002524|NCT02646696|OTHER|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
41473100|NCT01602172|OTHER|Lifestyle brochures|Set of educational brochures/brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have.
41002525|NCT02832869|OTHER|short message service based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
41002526|NCT02832869|OTHER|Wechat based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
41002527|NCT02848976|OTHER|Re-training to effort (RE)|The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
41002528|NCT00075335|DRUG|AMD3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
41002529|NCT00555984|DRUG|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
41002530|NCT00555984|DRUG|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
41002531|NCT01590407|DRUG|ALS-002200|ALS-002200
41002532|NCT01590407|DRUG|Placebo|Placebo
41002533|NCT04107480|PROCEDURE|Endoscopic trans-sphenoidal adenoma resection|"Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group.~Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice."
41002534|NCT04107480|DRUG|Dopamine Agonists|"The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care."
41002535|NCT06375057|PROCEDURE|laparoscopic cholecystectomy|A blood sample is taken the day after surgery
41002536|NCT00247728|DRUG|PI-88|Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks
40798462|NCT06057597|PROCEDURE|Laparoscopic OAGB|It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
40798463|NCT06057597|PROCEDURE|Laparoscopic RYGB|A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
40798464|NCT00816491|DEVICE|conventional white light colonoscopy|conventional white light colonoscopy
40798465|NCT00816491|DEVICE|FICE (Fujinon Intelligent Chromoendoscopy)|chromoendoscopy
40798466|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
40798467|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
40798468|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
40798469|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
40798470|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
40798471|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
40798472|NCT06164964|DIAGNOSTIC_TEST|study of higher cognitive functions|"General objective: increase knowledge about neural correlates:~of the cognitive processing of stimuli of a social nature; of decision-making processes in the context of individual choice; of the influence of the social context on individual decision-making processes."
40798473|NCT05101733|DIAGNOSTIC_TEST|Nasal provocation|Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device
40798474|NCT05101733|DIAGNOSTIC_TEST|Skin-Prick Test|Skin-Prick-Test is administered to determine an allergy against Alternaria
40798475|NCT05101733|DIAGNOSTIC_TEST|Blood draw|For further analysis
40798476|NCT05101733|DIAGNOSTIC_TEST|Collection of nasal secretion|Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray
40798477|NCT02509468|DRUG|Sirolimus|"* each patient will be followed during a 12-month-period~* each patient will start by an observational period and end being treated by sirolimus~* at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period"
40798478|NCT04098887|RADIATION|Lattice stereotactic body radiation therapy|For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV_2000 and PTV_6670, respectively).
41002537|NCT04518007|DEVICE|hyperbaric oxygen therapy|"The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sago l Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel."
40798479|NCT03797963|DEVICE|PBM+ACB|Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone
40798480|NCT03797963|DEVICE|ABB+ACB|Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone
40798481|NCT05810909|DIETARY_SUPPLEMENT|amorphous calcium carbonate/ Placebo|The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)
40798482|NCT00290992|DRUG|rasburicase (SR29142)|
40798483|NCT03201575|DEVICE|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
40798484|NCT03201575|DEVICE|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
40798485|NCT03311581|DRUG|Propofol|Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.
40798486|NCT03311581|DEVICE|Sevoflurane|sevoflurane inhalation 2\~4%
40798487|NCT05064501|DIAGNOSTIC_TEST|spirometry|Lung function test: pre and post bronchodilator spirometry
40798488|NCT05064501|OTHER|Asthma control test|Asthma control test
40798489|NCT00255723|DRUG|carboplatin|Given IV
41002538|NCT05374499|DRUG|Liposomal bupivacaine|Dosage: 3 mL Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
41002539|NCT05374499|DRUG|0.5% bupivacaine with 1:100,000 epinephrine|Dosage: 3 mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine (2:1 ratio of saline to standard bupivacaine) Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
41473101|NCT06260020|BEHAVIORAL|Comprehensive module for management of sleep disorders[Behavioral and pharmacological therapy]|"Development of module by Delphi method:components of Module include Behavioural intervention Modifying stimulus by change in location,using bedtime stories. Giving schedules to activities which interfere with sleep before bedtime. Using a bedtime pass to allow child to make a prefixed number of requests for parental attention while in bed.~Giving sleep items like cuddle toys to replace parental presence. Gradually delaying the bedtime so the child feels urge to sleep. Sleep hygiene by providing suitable environment to sleep, proper bedtime routine, sleep wake schedules Providing rewards for following good bedtime routine as positive reinforcement. Pharmacological intervention Sleep disorders due to underlying ENT, pulmonary conditions, to be treated as per standard protocol Usage of melatonin if required for sleep onset difficulty An 80%agreement over an intervention will be included in the module"
41473102|NCT05892484|DEVICE|Thermal Imaging|Thermal Imaging device used to evaluate fracture in those presenting with proposed wrist fracture in the emergency department.
41473103|NCT05892484|DIAGNOSTIC_TEST|X-RAY|Routine X-RAY
40798490|NCT00255723|DRUG|etoposide|Given IV
40798491|NCT00255723|DRUG|ifosfamide|Given IV
41473104|NCT01066117|OTHER|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
41473105|NCT02358850|DRUG|Norco (Hydrocodone and Acetaminophen)|Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days
41473106|NCT02358850|DRUG|Percocet (Oxycodone and Acetaminophen)|Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
41473107|NCT02358850|DRUG|Dilaudid (hydromorphone)|Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
41473108|NCT02358850|DRUG|Tylenol (Acetaminophen)|Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
41473109|NCT03965624|DRUG|Ninlaro|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
41473110|NCT06616727|DRUG|SNC109|SNC-109 CAR-T Cells, first dose from 5×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
40798492|NCT00879723|DIETARY_SUPPLEMENT|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
40798493|NCT02094209|DEVICE|SmartFix|AO Fracture Monitor attached postoperatively to a connection rod of the external fixator. The device continuously measures deformation of the fixator frame due to weight bearing for up to 4 months by means of a strain gauge.
40798494|NCT06479291|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
41473111|NCT03543345|DIAGNOSTIC_TEST|echocardiography study|"Patients with right coronary artery occlusion lesion will be subjected to:~* Written consent.~* Complete history.~* Complete physical examination.~* Trans-thoracic echocardiography assessment of the right ventricular function before PCI to the RCA~* Follow up Trans-thoracic echocardiography assessment of the right ventricular function four weeks after the PCI."
41473112|NCT04474782|DIAGNOSTIC_TEST|There is not an intervention|There is not an intervention
41473113|NCT02023008|PROCEDURE|yoga therapy|Undergo integral yoga intervention with videoconferencing
41473114|NCT02023008|OTHER|internet-based intervention|Undergo integral yoga intervention with videoconferencing
41473115|NCT02023008|OTHER|questionnaire administration|Ancillary studies
41473116|NCT02842463|OTHER|2 times : 6-minute stepper test with a rest of 20min between each test.|
41473117|NCT00455442|DRUG|Mifepristone|
41473118|NCT06617494|OTHER|Pain modulation testing|During the visit, noxious heat stimuli will be applied bilaterally to the face and distant body sites as part of conditioned pain modulation (CPM) testing. The test stimuli will be individually tailored to be moderately painful, while the conditioning stimulus will vary in intensity: moderately painful, non-painful, and sham heat. Participants will also record daily TMD pain intensity ratings for seven days before and after the visit.
41473119|NCT05514236|OTHER|Virtual Reality Therapy|"Participants will be given the virtual reality device (a headset) with immersive video content for use during the hysteroscopy. Designated moving objects with sound will be broadcasted on the screen to the participant in this group.~Participant can adjust the volume of the sound according to her comfort."
40798495|NCT06479291|DRUG|Eltrombopag|Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
40798496|NCT03899025|RADIATION|CT|CT = computed tomography of the hand/wrist HRpQCT = high resolution peripheral quantitative CT scan of the hand/wrist
40798497|NCT04797455|BEHAVIORAL|DBT-Based Parenting Intervention|The intervention will consist of 4 individual telehealth parent sessions, to be completed within one month after the teen discharges from the inpatient hospital or within one month of linkage to care whatever comes first . Sessions will be 60-90 minute in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 4.
40798498|NCT04797455|BEHAVIORAL|Treatment as usual|No parenting intervention provided beyond standard practices on the adolescent psychiatric inpatient unit.
40798499|NCT05848466|DRUG|BAT8010 for Injection|Intravenous
40798500|NCT04061824|DRUG|Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))|In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.
40798501|NCT04061824|DRUG|Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)|In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
40798502|NCT04313777|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
40798503|NCT04313777|DEVICE|Virtual therapeutic support|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.
41473120|NCT05514236|OTHER|Music Therapy|"Participants will be given a headphone playing either classical light music or 'POP' songs according to their option during the hysteroscopy.~Participant can adjust the volume of the music according to her comfort."
40798504|NCT04313777|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
40798505|NCT00003065|BIOLOGICAL|filgrastim|
41002540|NCT04330742|DRUG|lactated ringers|the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.
41002541|NCT06466174|DIETARY_SUPPLEMENT|Placebo 1 to Probiotic A|42 day Crossover study design between Placebo 1 and Probiotic A (n = 25)
41473121|NCT00515034|DRUG|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
41473122|NCT00515034|DRUG|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
41473123|NCT00515034|DRUG|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
41002542|NCT06466174|DIETARY_SUPPLEMENT|Probiotic A to Placebo 1|42 day Crossover study design between Probiotic A and Placebo 1 (n = 25)
41002543|NCT06466174|DIETARY_SUPPLEMENT|Placebo 2 to Probiotic B|42 day Crossover study design between Placebo 2 and Probiotic B (n = 25)
41002544|NCT06466174|DIETARY_SUPPLEMENT|Probiotic B to Placebo 2|42 day Crossover study design between Probiotic B and Placebo 2 (n = 25)
41002545|NCT00382811|DRUG|phenoxodiol|400mg phenoxodiol three times daily in 28 day cycles.
41002546|NCT00382811|DRUG|carboplatin|AUC=2 weekly in 28 day cycles
41002547|NCT00382811|DRUG|placebo|every 8 hours daily in 28 day cycles
41002548|NCT03250546|PROCEDURE|transplant from a haplo-identical donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
41002549|NCT03250546|PROCEDURE|transplant from a non related donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
41002550|NCT00938483|OTHER|Nutramigen Lipil (Infant formula)|
41002551|NCT02979743|BEHAVIORAL|Occupational therapy|
41002552|NCT02979743|OTHER|Occupational therapy puls acupuncture and massage methods|
41002553|NCT03250468|BEHAVIORAL|CBT-I|Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
41002554|NCT05233410|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
41002555|NCT05233410|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
41002556|NCT02126969|RADIATION|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
41002557|NCT02126969|DRUG|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
41002558|NCT03026465|DEVICE|Polymer-free stent|PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)
41002559|NCT03026465|DEVICE|Biodegradable-polymer stent|PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
41002560|NCT05611086|DRUG|N-Acetylcysteine|Subjects in treatment group will be given capsules containing 600 mg of NAC
41002561|NCT05611086|DRUG|Placebo|subjects in the control group will be given capsules containing placebo (lactose)
41002562|NCT03325686|DIETARY_SUPPLEMENT|vitamin D supplement|D; received 50,000 IU of vitamin D supplement weekly
41002563|NCT03325686|OTHER|Placebo|placebo
41002564|NCT05991102|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
41315320|NCT02344407|BIOLOGICAL|ChAd3-EBO Z|The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
41002565|NCT05190120|PROCEDURE|Femoral Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
41002566|NCT05190120|PROCEDURE|Adductor Canal Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
41002567|NCT05190120|DRUG|preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine|
41002568|NCT05190120|DRUG|Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.|
40798506|NCT00003065|DRUG|paclitaxel|
40798507|NCT00003065|DRUG|topotecan hydrochloride|
41002569|NCT00735371|DRUG|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
41002570|NCT00735371|DRUG|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
41002571|NCT00735371|DRUG|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
41002572|NCT00735371|DRUG|Placebo|Placebo will be identical to test product.
41315321|NCT02344407|BIOLOGICAL|Placebo|
41473124|NCT00515034|DRUG|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
41473125|NCT02130531|DRUG|Emixustat HCl Tablet|Tablet for oral administration
41473126|NCT02130531|OTHER|Placebo Tablet|Tablet for oral administration
41002573|NCT04498793|BIOLOGICAL|Tislelizumab|On Day 1 of the last seven cycles in the neoadjuvant and each cycle in the adjuvant phases of the study for a total of 21 cycles; intravenous (IV) infusion.
41002574|NCT04498793|DRUG|Nab paclitaxel|On Days 1 and 8 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
41002575|NCT04498793|DRUG|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
41002576|NCT04498793|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
41002577|NCT04498793|DEVICE|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
41002578|NCT04853225|OTHER|Prospective observational cohort study|Prospective observational cohort study
41002579|NCT06199570|BEHAVIORAL|Adapted Stress Management Program|Participants will receive a 15-minute orientation session in-person or remotely to introduce the program and to receive the study materials, including the instructional sheet, small booklet, and study tablet that will be used to promote practice of stress management exercises and for completing study assessments. They will complete self-guided web modules with stress management activities/skills on tablet devices, and will rate the modules' acceptability and perceived helpfulness. After visiting each module, they will be asked to practice at least one skill daily. In a 1-week pre-scan call, they will be reminded about the skills, make a plan for using them, and troubleshoot questions about using the materials. Participants will attend scans and scan result appointments with their oncologist as usual. In a 1-week post-scan phone call, the stress management plan will be revisited for new concerns.
41002580|NCT06199570|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care includes a resource list, tablet for study assessments, and reminder calls.
41002581|NCT02479711|OTHER|composite restoration|The tooth will be isolated with cotton rolls and the caries will be removed. Enamel and dentin conditionings were performed with a self-etching adhesive system (Adhese One F, Ivoclar Vivadent, Liechtenstein). Bulk fill composite (Tetric EvoCeram® , Ivoclar Vivadent, Liechtenstein) will be injected in a single bulk increment of less than 4 mm to fill the preparations. The material was condensed with a flat instrument. Once set, it will be polished with finishing cups (Enhance® , Dentsply , Milford, USA). An interproximal strip will be used to finish the final contour.
41002582|NCT02479711|OTHER|glass ionomer cement|The tooth will be isolated wit cotton rolls and the caries will be removed. The dentist will mix and handle the materials in accordance with the manufacturers' instructions. The material was condensed with a flat instrument. Once set, it will be polished. An interproximal strip will be used to finish the final contour. G-Coat Plus (GC, America) will be applied to the surface and margins of the restoration.
41002583|NCT00365326|BIOLOGICAL|Catheter-based intracoronary injection|This Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO.
41002584|NCT06162494|BIOLOGICAL|Recombinant Zoster Vaccine|After giving consent, participants will be given first dose of vaccine. Participants will be brought back 30-60 days post-vaccine for follow up testing and second dose of vaccine
41002585|NCT06226727|DRUG|BR1019|One tablet administered alone
41002586|NCT06226727|DRUG|BR1019-1|One tablet administered alone
41002587|NCT06226727|DRUG|BR1019-2|One tablet administered alone
41002588|NCT03534856|BEHAVIORAL|Mindfulness meditation|Short guided mindfulness meditations were provided on an MP3 player.
41002589|NCT04483024|DIETARY_SUPPLEMENT|Collagen hydrolysate and chicken extract|One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
41002590|NCT06159972|DEVICE|EndoFLIP|EndoFLIP is a small balloon catheter that is inserted through the endoscope at the time of endoscopy.
41002591|NCT02214121|DRUG|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
41002592|NCT02214121|DRUG|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
41473127|NCT06423157|OTHER|Intervention|The intervention period will last 6 weeks, with a periodicity of 2 weekly sessions of 20 minutes each. All interventions will take place at the Palacio de los Deportes de Murcia. All interventions will be carried out by the same physiotherapist, following the same protocol. The intervention of the experimental group will consist of a protocol using plyometric and stability exercises.
41473128|NCT05556226|DRUG|ABBV-154 Dose Formulation A|Subcutaneous Injection
41002593|NCT06496126|DEVICE|Cerasmart 270 (GC Coop, Tokyo, Japonya)|Hybrid Ceramic Block
41002594|NCT06496126|DEVICE|EverX Flow (GC Coop, Tokyo, Japonya)|Fiber Reinforced Composite Resin
41002595|NCT06496126|DEVICE|: G-CEM ONE (GC Coop, Tokyo, Japonya)|Universal Self Adhesive Resin Cement
41002596|NCT06496126|DEVICE|G-Premio Bond (GC Coop, Tokyo, Japonya)|Universal Adhesive
41002597|NCT06496126|DEVICE|G-ænial A'CHORD|Conventional Composite Resin
41002598|NCT03880851|RADIATION|Plan adaptation of Radiation Treatment in case of anatomical changes|Image guided radiotherapy is given to 60Gy in 20 fractions. Intervention: Radiation treatment plan adaption in case of volume changes of target volume or not meeting OAR constraints due to volume changes.
41002599|NCT00482755|DRUG|sunitinib malate|
41002600|NCT00482755|OTHER|immunohistochemistry staining method|
41002601|NCT00482755|OTHER|laboratory biomarker analysis|
41002602|NCT00482755|OTHER|pharmacological study|
41473129|NCT05556226|DRUG|ABBV-154 Dose Formulation B|Subcutaneous Injection
41002603|NCT00482755|PROCEDURE|needle biopsy|
41002604|NCT00482755|PROCEDURE|neoadjuvant therapy|
41002605|NCT04720365|DEVICE|play-based rehabilitaion|usual re-education treatment by their physiotherapist
41002606|NCT04971564|OTHER|Blood sampling|Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion
41002607|NCT04138615|DRUG|Morphine|Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
41002608|NCT04138615|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
41002609|NCT03143270|DRUG|Drug Eluting Bead Transarterial Chemoembolization|Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
41002610|NCT03143270|DRUG|Nivolumab|All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
41002611|NCT03801616|DEVICE|Virtual Reality|Virtual Reality in controlling pain
41002612|NCT04637958|DEVICE|THA|Total hip arthroplasty
41002613|NCT00169143|DRUG|Rituximab + ACVBP regimen plus Pegfilgrastim|
41002614|NCT00169143|PROCEDURE|Autologous stem cell transplant|
41002616|NCT00807534|DRUG|ipratropium bromide|ipratropium bromide nebulization
41002617|NCT00807534|DRUG|placebo|placebo nebulization
41002618|NCT00807534|BEHAVIORAL|constant rate step test|nebulization of 500ug
41473130|NCT05765799|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (dedicated consultation, information posters, explanatory video, information form, etc.).
40798508|NCT05965076|PROCEDURE|Glycine Perio Flow|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss and glycine perio-flow.
40798509|NCT05965076|BEHAVIORAL|Angled Toothbrush|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and an angled toothbrush.
41002619|NCT00807534|BEHAVIORAL|constant rate shuttle walk test|nebulization of 500ug
41002620|NCT01125215|DRUG|0.75% capsaicin nanoparticle cream|0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks
41002621|NCT01125215|DRUG|Placebo|Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
41002622|NCT04492891|DRUG|Cyclosporine|2.5 mg/kg PO BID 7 days
41002623|NCT04492891|OTHER|Standard of Care Treatment|Standard of Care Treatment, N= 25 Patients, 7 days
41473131|NCT01358084|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
41002624|NCT06022016|GENETIC|For each person (index case or related) included in this study:|"* an health questionnaire will be completed in order to gather information on the participant's medical history and lifestyle.~* a saliva sample will be taken (if applicable) so that a genetic analysis can be performed."
41002625|NCT01748253|DRUG|Telmisartan-amlodipine tablet administration group (morning)|Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
41002626|NCT01748253|DRUG|Telmisartan-amlodipine tablet administration group (bedtime)|Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
41002627|NCT00231101|DRUG|Quetiapine|
41002628|NCT04628312|OTHER|Static footprint|The static footprint will measure the plantar pressures and surface area of the back of the foot, midfoot and forefoot. Subjects were instructed to stand barefoot on the force platform, participants were instructed to remain in a relaxed standing posture with feet shoulder-width apart and positioned 30 degrees from the midline.
41002629|NCT05326503|DIETARY_SUPPLEMENT|Meal matrix with polyphenol supplement (PPS)|Test meal with polyphenol supplement
41002630|NCT05326503|DIETARY_SUPPLEMENT|Meal matrix with placebo|Test meal with placebo (maltodextrin) supplement
41002631|NCT05326503|DIETARY_SUPPLEMENT|No meal matrix with PPS|Test drink with polyphenol supplement
41002632|NCT05326503|DIETARY_SUPPLEMENT|No meal matrix with placebo|Test drink with placebo (maltodextrin) supplement
41002633|NCT04917276|DIAGNOSTIC_TEST|Circulating tumor cell|Detecting CTC in different time points of treatment (like PR, PD, pre and post-operation)
41002634|NCT05164458|DRUG|IBI 308 injection|IBI308 IV 200mg Q3W Day1
41002635|NCT05164458|DRUG|IBI 389 Injection|IBI 389 IV Q2\~Q3W Day 1
41002636|NCT01862172|OTHER|Additional MRI|
41002637|NCT02959281|OTHER|Providing caring physicians with hemodynamic variables|NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
41002638|NCT05054738|BEHAVIORAL|Combined Recovery Program|A six-session treatment group designed to explore goals, values, and personal strengths about making a change for overall quality of life, health and well-being combined with skill building designed for helping to live a more stable life in their own home that will include money management for financial success and home maintenance.
41002639|NCT05054738|BEHAVIORAL|Stable & Able (S&A)|A 90-day Home Telehealth program designed to help maintain skills to stay sober.
41002640|NCT03748199|DRUG|POL6014|"DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)"
41002641|NCT03748199|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
41002642|NCT04095507|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
41002643|NCT03007394|DRUG|Lorcaserin|Lorcaserin Capsule
41002644|NCT03007394|DRUG|Placebo Oral Capsule|sugar pill to mimic lorcaserin 10mg capsule
41002645|NCT04203550|PROCEDURE|Intraoperative irrigation|Operation with irrigation
41002646|NCT04203550|PROCEDURE|No irrigation|Operation without irrigation
41002647|NCT01825408|DRUG|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
41002648|NCT01825408|DRUG|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
41002649|NCT01825408|DRUG|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
41002650|NCT01801787|DEVICE|tDCS|active vs. sham tDCS left hemisphere
41002651|NCT06362148|DIAGNOSTIC_TEST|Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay|Blood sampling for circulating tumor DNA analysis at baseline, cycle 2 day 1, cycle 3 day 1, mid-treatment, end of induction/end of treatment, 100 day follow-up, 6 month, 12 month, 18 month and 24 month follow-up. Blood sampling will also be done in case of relapsing/refractory disease at any point prior to the abovementioned time points.
41002652|NCT06362148|DIAGNOSTIC_TEST|18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)|FDG-PET/CT performed at baseline, mid-treatment, end of induction/end of treatment and 6 month, 12 month, 18 month and 24 month follow-up.
41002653|NCT06391788|PROCEDURE|thoracoscopic Morrow surgery|minimally invasive trans-mitral Morrow septal myectomy
40798510|NCT05965076|PROCEDURE|Standard Professional Oral Hygiene|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss.
41002654|NCT06391788|PROCEDURE|modified Morrow surgery|median open modified enlarged Morrow septal myectomy
41002655|NCT03791658|OTHER|The 12-question TAI|The 12-question TAI (Test for the Adherence to Inhalers) yields a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious).
41473132|NCT01358084|DRUG|Placebo|Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
41473133|NCT01358084|OTHER|Best Supportive Care|Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
40798511|NCT05965076|BEHAVIORAL|Standard Domiciliary Oral Hygiene|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and a standard toothbrush.
41002656|NCT03791658|OTHER|Information from patients file|Depending on which arm or group specific information will be gathered from the patients file after informed consent.
41002657|NCT03791658|OTHER|The Asthma Control Test (ACT)|An international validated questionnaire on the symptoms an asthmatic experiences and the disease control in the patient. Only for the Asthmatics arm of the study
41002658|NCT03791658|OTHER|The COPD Assessment Test (CAT)|An international validated questionnaire on the symptoms a COPD-patient experiences and the disease control in the patient. Only for the COPD arm of the study
41002659|NCT01371656|DRUG|levofloxacin|Given PO or IV
41002660|NCT02674022|DIETARY_SUPPLEMENT|Prenatal supplement|Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
41002661|NCT05996861|BEHAVIORAL|ICU sleep protocol|"Adjusting sound intensity, as well as reducing noise: efforts will be made to minimize staff conversation volume during the night.~Earplugs will be offered, along with the provision of eye masks for lucid patients, and thermal comfort adjustments will be made, such as providing blankets and/or adjusting room temperature.~Dimming of lights starting from 10 PM. Reduced circulation of external services between 11 PM and 6 AM, and rationalization of sample collections and/or patient transfers between beds during the 11 PM to 6 AM interval.~Optimization of analgesics for better pain control; optimization of medication use during wakefulness when clinically feasible; adjustment of intervals for capillary blood glucose measurement; maintaining and/or resuming the use of chronic sleep medications. If the patient has been unable to sleep, a hypnotic medication will be offered.~Other considerations include suggesting ventilatory support measures for selected patients."
41002662|NCT02743572|OTHER|iron sucrose-1|iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d
41002663|NCT02743572|OTHER|iron sucrose-2|iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d
41002664|NCT02743572|OTHER|iron sucrose-3|iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d
41002665|NCT02743572|OTHER|iron sucrose-4|iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
41002666|NCT01686412|DEVICE|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
41002667|NCT04060407|DRUG|CD24Fc|CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
41002668|NCT04060407|DRUG|Ipilimumab|Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4.
41002669|NCT04060407|DRUG|Nivolumab|Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.
41002670|NCT04157946|DIAGNOSTIC_TEST|CT|"Patients with ARDS were included. We excluded patients with emphysema, asthma, pneumothorax, or serious conditions of instability: oxygen saturation ≤ 88%; severe shock, ventricular arrhythmia, or myocardial ischemia.~To allow comparison between groups, patients were ventilated in volume control under similar conditions of tidal volume (TV; 6 ml/kg-PBW), plateau pressure (PPlat 30 cmH2O), respiratory rate (18 bit/min) and constant flow. PEEP was adjusted to reach objective PPlat.~Transpulmonary pressures (TP) were measured and a chest CT scan performed during an expiratory and inspiratory pause. Global and regional volumes of lungs were measured using specific software (Volume Analysis Software,Toshiba, Japan). Three regions were identified: basal (from the diaphragm to the carina), middle (from the carina to the aortic arch) and apical (above the aortic arch)."
41002671|NCT04364529|OTHER|The pit crew model|The pit crew model
41002672|NCT02456610|BIOLOGICAL|CMV/EBV specific CTLs|Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
41002673|NCT06258148|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
41002674|NCT06258148|DRUG|Placebo|Placebo, SC, once a week
41002675|NCT04091646|DRUG|Roflumilast Foam 0.3%|Roflumilast foam for topical application.
41002676|NCT04091646|DRUG|Vehicle foam|Vehicle foam for topical application.
41002677|NCT03719313|DRUG|Lonafarnib|Lonafarnib (LNF) 50 mg BID
41002678|NCT03719313|DRUG|Ritonavir|Ritonavir (RTV) 100 mg BID
41002679|NCT03719313|DRUG|PEG IFN-alfa-2a|PEG IFN alfa-2a 180 mcg QW
41002680|NCT03719313|DRUG|Placebo Lonafarnib|Placebo
41002681|NCT03719313|DRUG|Placebo Ritonavir|Placebo
41002682|NCT01209910|OTHER|Water|Subjects in this arm will be able to drink water with some conditions.
41002683|NCT02182375|DRUG|BI 201335 NA|
41002684|NCT02182375|DRUG|Raltegravir|
41002685|NCT01690390|DRUG|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
41002686|NCT01690390|DRUG|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
41002687|NCT03532464|DRUG|azithromycin|The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
41002688|NCT03532464|DRUG|doxycycline|The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
41002689|NCT01032135|BEHAVIORAL|Motivational Interviewing|2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
41002690|NCT01032135|BEHAVIORAL|Telephone counseling|one telephone counseling session per week for 10 weeks.
41002691|NCT01032135|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Counseling|One CBT session per week, for 10 weeks.
41002692|NCT01032135|DRUG|medication management|Prescription for naltrexone
41002693|NCT01032135|BEHAVIORAL|Intensive OutPatient Therapy|Return to IOP, group therapy 3 times weekly for about three hours a day.
41002694|NCT05660694|DRUG|Triamcinolone|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
41151640|NCT02637947|DEVICE|catheter ablation using magnetic navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.
41002695|NCT05660694|DRUG|Pentoxifylline with Vitamin E|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
41002696|NCT02382016|DRUG|Macitentan|Macitentan film-coated tablet 10 mg once daily.
41002697|NCT02382016|OTHER|Placebo|Matching placebo tablet once daily.
41002698|NCT03291613|OTHER|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
41002699|NCT05672121|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
41002700|NCT06481722|OTHER|cerebral palsy|no intervention
41002701|NCT05005390|DEVICE|TTIP ventilation|In TTIP ventilation, an endotracheal tube is inserted via the nostril or oral cavity and subsequently advanced until the tip of the tube reaches approximately the level of the glottis.
41002702|NCT05005390|DEVICE|Mask Ventilation|In mask ventilation, a mask is placed over the nose and mouth.
41002703|NCT03164499|BEHAVIORAL|Individual counselling on lifestyles|Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.
41002704|NCT03164499|BEHAVIORAL|Additional group counselling on lifestyles|"Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.~Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment."
41151641|NCT02637947|DEVICE|catheter ablation using manual navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
41002705|NCT02703636|DRUG|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
41002706|NCT01254799|DRUG|Doxycycline|100 mg Doxycycline capsules twice daily for 5 days
41002707|NCT01254799|DRUG|Placebo|Placebo capsules twice daily for 5 days
41002708|NCT04522024|PROCEDURE|Epicardial focal cryoablation|Epicardial focal cryoablation on the left atrium around right upper pulmonary vein area
41002709|NCT04522024|PROCEDURE|Mei Mini Maze procedure|Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side
41002710|NCT02677792|BEHAVIORAL|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
41315322|NCT04946799|BEHAVIORAL|Low-intensity training combined with blood flow restriction (LI-BFR)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve), with compression belts attached on both thighs, during exercise the belts are inflated with 50% of the participant's arterial occlusion pressure. Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. The compression belt is deflated during the rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
41315323|NCT04946799|BEHAVIORAL|High-intensity aerobic exercise (HI)|Participants (n=20) receives high intensity aerobic exercise intervention on a cycle ergometer (at 70% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
41473134|NCT01168687|DRUG|Levetiracetam (Keppra)|"Group A: Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days."
41473135|NCT01168687|DRUG|Placebo|
41473136|NCT00518882|DRUG|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
41002711|NCT02353091|DEVICE|Remote Microphone Hearing Aids|The ear receivers connect wirelessly with the microphone being worn by the teacher within a range of 25m.
41002712|NCT01563068|DRUG|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
41002713|NCT00302133|DRUG|Naltrexone hydrochloride|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks
41002714|NCT00302133|OTHER|Placebo|Placebo arm
41002715|NCT06325150|DEVICE|Light emitting glasses|Assess the capacity of 20 min use of AYO light emitting glasses on different outcomes
41002716|NCT04763499|OTHER|freeze dried strawberry powder|approximately 24 strawberries that have been freeze dried into a powder
41002717|NCT04216875|PROCEDURE|Best Practice Diabetes Management in Primary Care|Practice adherence to best practice guidelines treating diabetes patients in different primary care practices is shown in this before- and after observational study
41473137|NCT00518882|DRUG|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
41473138|NCT06616597|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg/ day
41473139|NCT06616597|DRUG|Dexamethasone|Dexamethasone 0.5mg/day
41473140|NCT06616597|DRUG|Metronidazole|Metronidazole 1500mg/ per day
41473141|NCT01360827|DRUG|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
40798512|NCT04033614|DEVICE|Fasciotens-Abdomen|The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
40798513|NCT00093262|DRUG|clevidipine|
40798514|NCT00093262|DRUG|placebo|
41002718|NCT01618357|RADIATION|Radiation|Patients will receive radiation therapy at a dose of 2.35 Gy per fraction to the breast and regional nodal region for 16 fractions to a total dose of 37.5 Gy. Treatments will be given Monday through Friday. Radiation therapy will start on day 1 of Veliparib.
41002719|NCT01618357|PROCEDURE|Lumpectomy/Mastectomy|Resection of breast cancer.
41002720|NCT01618357|DRUG|Veliparib|Pills to be taken twice a day during radiation and for one week after completion of radiation for a total of 29 days.
40798515|NCT05250921|PROCEDURE|Corticision|Corticision will be performed to enhance teeth alignment.
41002721|NCT00283439|BIOLOGICAL|AMG 531|"Planned Cohorts:~1. 100 mcg,~2. 300 mcg,~3. 700 mcg,~4. 1000 mcg;~   Optional Cohorts:~5. cohort expansion,~6. schedule change,~7. new dose"
41002722|NCT01885390|DEVICE|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
41002723|NCT06425471|DEVICE|KARL STORZ fetoscope arm|The type of fetoscope used in utero(either straight or curved or both ) will depend on the location of the placenta. The fetoscope will be used to cauterize abnormal blood vessels that cause twin-to-twin transfusion syndrome (TTTS)
41002724|NCT00829296|DRUG|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
41002725|NCT00829296|DRUG|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
41002726|NCT04210635|OTHER|ZEN cart|essential oils + relaxing music + dim light
41002727|NCT00210314|DRUG|high dose methotrexate|
41002728|NCT00210314|DRUG|high dose cytarabine|
41002729|NCT00210314|RADIATION|radiotherapy|
40798516|NCT05250921|DEVICE|Conventional fixed appliance|No surgical intervention is going to be applied to the patients in this group.
40798517|NCT01243008|DRUG|Application of SHB001|"* Cohort 1: Application of SHB001 on the skin of right thigh~* Cohort 2:~  1. Application of SHB001 on the skin of right thigh~ 2. punch biopsies of treated skin areas"
40798518|NCT02026947|DRUG|Sodium Benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
40798519|NCT02026947|DRUG|Placebo|
40798520|NCT03937388|OTHER|Cochlear stimulation strategy including time-fixed gaps|Investigation of the impact of time-fixed gaps (zero-stimulation periods) in the cochlear stimulation strategy on speech performance and hearing quality.
41151642|NCT06021834|OTHER|rehabilitation|The subjects will be invited to attend the program three times per week.
41151643|NCT04673071|OTHER|Thread Embedding Acupuncture (TEA)|"TEA in 1 month for 4 months The six TEA points used in this study are GV20, BL15, BL18, ST40, GV14 and GB34.~Acupuncture point Procedure Baihui (GV20) oblique insertion toward nose, 3cm Both Xin Shu (BL15) perpendicular insertion, 3cm Both Gan Shu (BL18) perpendicular insertion, 3cm Both Fenglong (ST40) perpendicular insertion, 3cm Dazhui (GV14) perpendicular insertion, 3cm Both Yanglingquan (GB34) perpendicular insertion, 3cm"
41151644|NCT04673071|OTHER|Sham-TEA (STEA)|STEA in 1 month for 4 months All procedure of Sham-TEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
41151645|NCT01411176|DRUG|Menthol|20 mL NPO-11 in a prefilled plastic syringe
41151646|NCT01411176|DRUG|Placebo|The placebo is included same additives as active comparator.
41151647|NCT02167334|DEVICE|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
41151648|NCT02167334|PROCEDURE|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
41151649|NCT04466293|BEHAVIORAL|Choice Architecture|"1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach. This will be adapted to the country context and may include a pre-printed prescription pad (Mozambique), adaptations in clinical stationary (Zimbabwe), or adaptations to an electronic prescribing system (Malawi).~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
41002730|NCT03289728|OTHER|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with \< moderate ischemia will receive medical treatment only (MT)."
41002731|NCT03289728|PROCEDURE|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
41002732|NCT04546958|DIETARY_SUPPLEMENT|Whey protein supplements|Nutritional counseling and whey protein supplements for 3 months
41002733|NCT04546958|OTHER|Nutritional counseling|Nutritional counseling by dietitians for 3 months
41002734|NCT00404352|DRUG|RNF|Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
41002735|NCT00404352|DRUG|RNF|Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
41002736|NCT00404352|DRUG|Placebo|Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
41002737|NCT00007033|DRUG|magnesium gluconate|
41002738|NCT00007033|DRUG|magnesium sulfate|
41002739|NCT01442363|DRUG|BLI-1300 low dose|topical ointment
41002740|NCT01442363|DRUG|BLI-1300 high dose|topical ointment
41002741|NCT01442363|DRUG|placebo|topical ointment
41002742|NCT00769847|PROCEDURE|Endoscopic strip craniectomy|Surgery
41002743|NCT01252290|DRUG|Lovaza™|4 capsules daily for 6 months
41002744|NCT01446731|BIOLOGICAL|mRNA transfected dendritic cell|"Autologous monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.~5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration)."
41002745|NCT01446731|DRUG|Docetaxel|Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
41002746|NCT05228782|OTHER|HOW R U? Intervention|HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.
41002747|NCT02984384|DRUG|Acetylsalicylic acid|The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
41002748|NCT02984384|DRUG|Low Molecular Weight Heparin (LMWH)|The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
41002749|NCT06207058|DRUG|Baloxavir Marboxil|Subjects testing positive for influenza will receive a dose of Baloxavir Marboxil orally, according to the dosing indicated in the package insert.
41002750|NCT05252533|DRUG|Ustekinumab|This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.
41002751|NCT05112666|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Clinical Practice Research Datalink (CPRD) GOLD and Aurum Hospital Episode Statistics (HES)-linked datasets in UK.
41002752|NCT05112666|DRUG|other DOACs|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
41002753|NCT05112666|DRUG|LMWH|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
41315324|NCT04946799|BEHAVIORAL|Low intensity exercise (LI)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
41002754|NCT04943965|DIAGNOSTIC_TEST|Ultrasound imaging|"The intervention is non-invasive, chest wall, echocardiographic image acquisition in the cardiac operating room prior to a scheduled cardiac surgery. Echocardiographic images will be taken at three, key, timepoints in the operating room prior to cardiac surgery:~1. Pre-induction.~2. Post-induction / Pre-PAC~3. Post-induction / Post-PAC"
41002755|NCT01140763|DEVICE|Sysmex's 5-blade lymph node cutter|"A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either reference histopathology or test histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin \& eosin (H\&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed."
41002756|NCT03913949|DRUG|APG-2575|Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
41002757|NCT03611569|DRUG|Lu AF82422|Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose
41002758|NCT03611569|DRUG|Placebo|placebo - concentrate for solution for infusion, single dose
41002759|NCT03973346|OTHER|Risk screening tool exposure|Risk screening tool is available to providers
41002760|NCT05624099|DRUG|camrelizumab|200mg intravenous drip d1q3w
41002761|NCT05624099|DRUG|Paclitaxel drugs|150mg/m2 d1 q3w
41002762|NCT05624099|DRUG|Platinum drug|Cisplatin, carboplatin, nedaplatin and other platinum drugs
41002763|NCT05624099|RADIATION|Radiation|Dose: 5040cGy/28f
41002764|NCT03955042|DRUG|Pemetrexed|Pemetrexed 900 mg/m\^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
41002765|NCT03521258|DEVICE|Dehydrated Human Amnion/Chorion Membrane|
40798521|NCT03353987|BEHAVIORAL|Cognitive training|"Procedure~1. A therapist will go through the daily routine of the participants at home before starting the intervention~2. Selections of exercise items based on familiar items/ activities at home~3. Given a memory logbook with list of household items, names and numbers and newspaper cuttings from the previous week~4. Taught on how to perform the exercises~5. Perform at least one hour per day~6. Both spatial and visual memory strategies will be used for memory training: simple mnemonics, associations, visualisations, rhymes~7. Advised to follow-up with the therapist to review on the progress and compliance of exercises weekly~8. The difficulty of the exercise will be adjusted weekly~List of exercises:~1. Memorizing a set of lists, household items, names and numbers~2. Summarising the contents of newspaper cuttings within a set of time~3. Searching and listing sets of words from newspaper cuttings"
40798522|NCT05211674|OTHER|quantified analysis of postural control during activities of daily living|functional tests that reproduce tasks of daily living (timed up and go test with and without dual cognitive task, modified Glittre ADL test)
40798523|NCT02789358|OTHER|Conventional cryotherapy dosage|Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
40798524|NCT02789358|OTHER|Experimental cryotherapy dosage|"cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds"
40798525|NCT02789358|DEVICE|Arctic Front Advance ST Cryoenergy Balloon Catheter|Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
40798526|NCT02789358|DRUG|Adenosine triphosphate|12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
40798527|NCT02789358|DEVICE|nECG platform Nuubo®|30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
40798528|NCT03715140|DRUG|Crucumin|Evaluation of the effect of Crucumin in patients with osteoarthritis
40798529|NCT03715140|DRUG|Placebo|Placebo
40798530|NCT02758600|OTHER|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
41002766|NCT03521258|PROCEDURE|Flap-Based Reconstructive Surgery|Standard of Care surgical intervention
41002767|NCT00275158|DRUG|L-Arginine Supplementation|
41315325|NCT04676464|DIAGNOSTIC_TEST|Ultra- sound|Ultrasound assessment of quadricep muscle layer thickness QMLT within 72hrs of initial CT scan
41315326|NCT05143957|DRUG|sapablursen|Sapablursen will be administered by SC injection.
41315327|NCT02750904|BEHAVIORAL|Experimental plus Nicotine Replacement Therapy|"Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.~Includes four in person and four phone visits.~Therapy information is withheld to protect the integrity of the study."
40798531|NCT00482040|DEVICE|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
40798532|NCT02630069|DRUG|CDP-choline|CDP-choline 500mg once a day for 12 weeks
40798533|NCT02630069|DRUG|Placebo|Placebo 500mg once a day for 12 weeks
40798534|NCT02630069|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy 1 session/2 weeks for 12 weeks
41002768|NCT00180375|DEVICE|Prizm, Vitality, Renewal|Follow-up during 2 years
41002769|NCT05850650|OTHER|Application of a collagen sponge after surgical extraction of impacted 3rd molar|Application of a collagen sponge after surgical extraction of impacted 3rd molar
41002770|NCT05850650|OTHER|No collagen sponge application after surgical extraction of impacted 3rd molar|No collagen sponge application after surgical extraction of impacted 3rd molar
41002771|NCT04902495|OTHER|MTA Pro Root|pulp therapy
41151650|NCT01112163|DEVICE|Enhanced external counter pulsation|While an individual is undergoing ECP, they have pneumatic stockings (also known as cuffs) on their legs and are connected to telemetry monitors that monitor their heart rate and rhythm.The cuffs should ideally inflate at the beginning of diastole and deflate at the beginning of systole. During the inflation portion of the cycle, the calf cuffs inflate first, then the lower thigh cuffs and finally the upper thigh cuffs. Inflation is controlled by a pressure monitor, and the cuffs are inflated to about 300 mmHg.
41315328|NCT02750904|BEHAVIORAL|Control plus Nicotine Replacement Therapy|Includes four in-person and four phone visits
41315329|NCT05790473|DIAGNOSTIC_TEST|Artificial Intelligence|Development of AI algorithm for early detection of fetal brain anomalies in the first trimester of pregnancy
41002772|NCT04902495|OTHER|MTA HP Repair|pulp therapy
41002773|NCT04902495|OTHER|Biodentine|pulp therapy
41002774|NCT03142880|COMBINATION_PRODUCT|hyperbaric ropivacaine|We change the density of ropivacaine solution to make it into an marginally hyperbaric state or into an commonly hyperbaric state.and we hypothesized that the marginally hyperbaric ropivacaine will get a similar efficacy to commonly hyperbaric solutions but a more steadily hemodynamic status.
41002775|NCT01297868|OTHER|exercise|
41002776|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 500 mg/day for 4 weeks.
41002777|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1000 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 10000 mg/day for 4 weeks.
41002778|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 1500 mg/day for 4 weeks.
41002779|NCT06404203|OTHER|Plasebo|Volunteers will receive a soft vegan gelatin capsule containing lactose in a dose of 1500 mg/day for 4 weeks.
40798535|NCT04005469|DRUG|Treprostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
41002780|NCT01728025|DRUG|Ranolazine|
41002781|NCT00843713|DRUG|raltegravir|For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
41002782|NCT00843713|DRUG|Placebo|For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
41002783|NCT02897128|OTHER|Observational Only - Transcutaneous Oxygen Measurement|The transcutaneous oxygen at your surgical site will be measured at three time points prior to your surgery.
41002784|NCT00347724|DRUG|Tramadol HCl ER|
41002785|NCT00075829|PROCEDURE|One Autologous Transplant|Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive \~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) \> 500/mm3 for two days.
41315330|NCT03115476|DRUG|ingenol disoxate gel 0.018%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
41473142|NCT01360827|DRUG|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
41002786|NCT00075829|PROCEDURE|Non-Myeloablative Allogeneic Transplant|Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
41002787|NCT00075829|PROCEDURE|Second Autologous Transplant|Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
41002788|NCT00075829|DRUG|Thalidomide|Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
41002789|NCT00075829|DRUG|Dexamethasone|Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
41315331|NCT03115476|DRUG|ingenol disoxate gel 0.037%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
41002790|NCT00075829|BEHAVIORAL|Observation|One year of observation post-transplants.
41002791|NCT03571087|DRUG|HL140 5/10|"1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
41002792|NCT03571087|DRUG|HL140 10/10|"1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
41002793|NCT03571087|DRUG|HL140 20/10|"1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
41002794|NCT03571087|DRUG|Rosuvastatin 5mg → HL140 5/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~   * HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
41002795|NCT03571087|DRUG|Rosuvastatin 10mg → HL140 10/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~   * HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
41315332|NCT03115476|OTHER|Vehicle gel|Vehicle to ingenol disoxate gel with no active ingredient
41002796|NCT03571087|DRUG|Rosuvastatin 20mg → HL140 20/10|"1. Treatment(W0\~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
41002797|NCT03960502|DRUG|AG-881|Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of \[14C\]AG-881.
41002798|NCT03960502|DRUG|[13C315N3]AG-881|Single IV microdose of approximately 100 μg.
41002799|NCT01544712|PROCEDURE|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
41002800|NCT01544712|PROCEDURE|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
41002801|NCT02385799|DRUG|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
41002802|NCT02385799|DRUG|Sertraline|Active medication
41002803|NCT00957203|DRUG|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
41002804|NCT00395239|DRUG|inhaled corticosteroid|Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
41002805|NCT02547662|DRUG|Dexamethasone|Given PO
41002806|NCT02547662|DRUG|Ixazomib Citrate|Given PO
41315333|NCT01642836|BEHAVIORAL|MMM|"1. a theory-based community team sports program designed specifically for overweight and obese children,~2. a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~3. a primary care provider behavioral counseling intervention linked to the community and home interventions."
41315334|NCT01642836|BEHAVIORAL|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~1. notification of primary care providers about metabolic measures and blood pressure~2. state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
41315335|NCT01393171|DEVICE|Polypropylene mesh (Polyform by Boston Scientific)|Site-specific cystocele repair with polypropylene mesh augmentation
41002807|NCT02547662|OTHER|Laboratory Biomarker Analysis|Correlative studies
41315336|NCT01393171|PROCEDURE|Porcine Dermis (Pelvicol by CRBard)|Site-specific cystocele repair with porcine dermis augmentation
41315337|NCT01393171|PROCEDURE|Anterior Colporrhaphy|Anterior vaginal prolapse repair with suture.
41002808|NCT02547662|DRUG|Pomalidomide|Given PO
41002809|NCT05351346|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
41002810|NCT05351346|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
41002811|NCT05351346|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
41315338|NCT05427344|OTHER|Water exercise group|Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi.
40798536|NCT01527877|DRUG|BKM120|"Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed."
40798537|NCT05031117|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Technique at L4-5 interspace using Tuhoy needle (18G) then epidural catheter (20G) inserted, then 15ml 0.5% Bupivacane and 50ug fentanyl given.
40798538|NCT05031117|PROCEDURE|25G Dural Puncture Epidural Technique|25G pencil point spinal needle will be inserted at L4-5 interspace through the tuhoy needle
40798539|NCT02934841|DRUG|Conbercept|
40798540|NCT02934841|DRUG|sham|
40798541|NCT05754398|BEHAVIORAL|six independent and interconnected educational training sessions|"Each of the six components will be offered each month for six consecutive months. Each session will last approximately 30 to 40 minutes.~All the six sessions will be delivered through a face-to-face approach."
40798542|NCT05227495|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
40798543|NCT05227495|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
40798544|NCT02931643|OTHER|High fat challenge breakfast|In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
40798545|NCT02931643|OTHER|High fat challenge breakfast with mixed-spices|In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
40798546|NCT01110525|DRUG|AZD1981|4X100 mg per oral, twice daily for 28 days
40798547|NCT01110525|DRUG|Neovletta 21/28|Once daily with (21) or without (28) pause for bleeding.
41002812|NCT05351346|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
41002813|NCT05351346|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
41315339|NCT05427344|OTHER|Land exercise group|Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land.
41315340|NCT05427344|OTHER|Control group|Control group who will not perform additional physical activity or receive any extra treatments.
41315341|NCT04389580|DRUG|Drug: Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen"
41315342|NCT04389580|DRUG|Aerosolized Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen"
40798548|NCT01110525|DRUG|Placebo AZD1981|4X100 mg per oral, twice daily for 28 days
40798549|NCT06125171|DRUG|Tucidinostat, Apatinib|"Tucidinostat:~age≥18years, 30mg, po., biw, q4w; age≥10years，\<18years，0.5mg/kg, biw, q4w~Apatinib:~BSA≥1.2m\^2, 500mg, qd, q4w BSA\<1.2m\^2, 250mg, qd, q4w"
41002814|NCT05351346|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
41002815|NCT05351346|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
41002816|NCT05351346|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
41002817|NCT01482767|DRUG|Pegylated-Interferon Alfa 2b (PEG-IFN)|1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
41002818|NCT01482767|DRUG|Ribavirin (RBV)|800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
41002819|NCT01482767|DRUG|Boceprevir (BOC)|800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
41002820|NCT03126994|DEVICE|PhysioWave Cardiovascular Analyzer|Measurement of Pulse Wave Velocity, Pulse Rate, Body Weight and BMI
41002821|NCT03126994|DEVICE|AtCor XCEL PWA & PWV|Measurement of Pulse Wave Velocity and Pulse Rate
41315343|NCT04228692|PROCEDURE|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.
40798550|NCT04747236|DRUG|Azacytidine|Azacytidine, 300 mg po daily on Days 1-14
40798551|NCT04747236|DRUG|Romidepsin|Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
41002822|NCT03126994|DEVICE|Detecto SOLO|Measurement of Body Weight and BMI
41002823|NCT01519856|DRUG|piribedil (Clarium)|oral tablets, 50 mg
40798552|NCT04747236|DRUG|Belinostat|Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
40798553|NCT04747236|DRUG|Pralatrexate|Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
40798554|NCT04747236|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
40798555|NCT01662557|BEHAVIORAL|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
40798556|NCT01662557|OTHER|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
40798557|NCT01746381|DEVICE|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
40798558|NCT01060748|BIOLOGICAL|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
40798559|NCT01060748|BIOLOGICAL|Placebo|Placebo
40798560|NCT01930604|DRUG|Botox (onabotulinumtoxinA)|
40798561|NCT01930604|DRUG|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
40798562|NCT01930604|DRUG|NaCl (placebo)|
40798563|NCT05989672|BIOLOGICAL|HSVTI Formulation 1|This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F1 Group.
40798564|NCT05989672|BIOLOGICAL|HSVTI Formulation 2|This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F2 Group.
40798565|NCT05989672|BIOLOGICAL|Placebo|This intervention will be administered intramuscular as 2 doses to Placebo group.
40798566|NCT04830215|DRUG|Brexpiprazole|Oral brexpiprazole tablets as adjunctive therapy to ADT
41002824|NCT03892811|OTHER|Three study conditions|Continuous fluoroscopy (at 30 frames/second) will be used for intermittent periods to capture 10 swallows in the initial sucking sequence of each of three study conditions: 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple.
41002825|NCT03829046|DRUG|Placebo|12 weeks of treatment
40798567|NCT01258556|DIETARY_SUPPLEMENT|Yogurt supplemented with L. rhamnosus fiti|200 ml of L. rhamnosus fiti at 10\*9 cfu/ml daily for 30 days.
40798568|NCT01258556|DIETARY_SUPPLEMENT|Yogurt not supplemented with a probiotic strain.|200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
40798569|NCT03137680|BEHAVIORAL|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
40798570|NCT01322854|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
40798571|NCT01715688|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
41002826|NCT03829046|DRUG|Evolocumab|12 weeks of treatment
40798572|NCT01715688|DRUG|Saline|Administration of saline in the endotracheal tube cuff
40798573|NCT05592327|PROCEDURE|Citric acid abutment|The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
40798574|NCT00600106|DRUG|1/10 NA/EE|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
40798575|NCT00600106|DRUG|Placebo|1 mg placebo
40798576|NCT06471699|DEVICE|Continous Glucose Monitoring|The aim is to examine if the use of CGM will give the participants a significant support to implement lifestyle improvements in individuals with new on-set type 2 diabetes
40798577|NCT06471699|OTHER|Self monitoring blood glucose|Capillary testing as in standard procedure
40798578|NCT04775355|PROCEDURE|Biospecimen Collection|Undergo collection of stool and urine
40798579|NCT04775355|OTHER|Electronic Health Record Review|Medical records are reviewed
40798580|NCT04775355|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
40798581|NCT04775355|OTHER|Questionnaire Administration|Complete questionnaires
40798582|NCT03312790|DEVICE|Tasks|Augmented reality device Real condition
40798583|NCT04589572|PROCEDURE|XLIF|the XLIF procedure, a minimally invasive procedure that approaches the spine from the lateral via the space between the 12th rib and the highest point of the iliac crest.
40798584|NCT04589572|PROCEDURE|PLIF|open posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) are used to treat degenerative diseases of the spinal column.
40798585|NCT03576014|BIOLOGICAL|BD03|BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2\~4 weeks after the transplant.
40798586|NCT03955328|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
41315344|NCT04228692|DEVICE|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
41315346|NCT03180489|DRUG|Dapagliflozin Tablet|Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
41315347|NCT03180489|DRUG|Placebo Tablet|Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
41315348|NCT00907582|PROCEDURE|autologous hematopoietic cell transplantation|"Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3."
41315349|NCT03816410|PROCEDURE|LAA amputation|complete surgical amputation of the left atrial appendage
41315350|NCT06461611|BEHAVIORAL|Health Diary Program|The health diary is constructed based on the theory of health action process approach, which is used to plan and clock for self-management behaviors of adolescent patients during fixed orthodontic treatment.
41315351|NCT06461611|BEHAVIORAL|Traditional Health Education|Traditional health education is that the nurse orally teaches the patient about fixed orthodontic knowledge, and the patient obtains a paper information.
41315352|NCT03298191|DRUG|Magnesium Sulfate|Those women will be given Magnesium Sulfate for tocolysis
41315353|NCT03298191|DRUG|Ritodrine|Those women will be given Ritodrine for tocolysis
41315354|NCT03298191|DRUG|Calcium Channel Blockers|Those women will be given Calcium Channel Blockers for tocolysis
41315355|NCT02461836|DRUG|Gemcitabine|Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
41315356|NCT02461836|RADIATION|SBRT|Protocol: 5 Gy/d, for 5 consecutive days
41315357|NCT02038218|DRUG|4-Demethyl-4-cholestryloxycarbonylpenclomedine|"This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
41315358|NCT00651976|DRUG|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
41002827|NCT04260815|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.
41315359|NCT00651976|OTHER|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
40798587|NCT00056173|DRUG|GTI-2040|
40798588|NCT04959227|OTHER|Sema activity|sema activity 3 days a week for at least a year
40798589|NCT05544201|DEVICE|High-definition transcranial current stimulation|High-definition transcranial current stimulation (HD-tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
40798590|NCT01109615|DRUG|Pemetrexed|400 mg/m2 on day 1 of a 3 weeks cycle
41002828|NCT00348556|DRUG|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
41002829|NCT02571543|DRUG|Ibuprofen|Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
41002830|NCT06193902|BIOLOGICAL|LEU011|Immunotherapy
41002831|NCT01720069|DRUG|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
41002832|NCT02239536|PROCEDURE|hot snare polypectomy|hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
41315360|NCT00651976|PROCEDURE|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
41315361|NCT00005060|DRUG|Taxotere-Cisplatin-5FU|Preoperatively
41315362|NCT00005060|DRUG|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
41315363|NCT04017442|DRUG|Preservative Free Morphine|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
41315364|NCT04017442|DRUG|Saline|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
40798591|NCT01109615|DRUG|Gemcitabine|1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
41002833|NCT02239536|PROCEDURE|hot snare polypectomy after saline injection|hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
41002834|NCT00273728|DRUG|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
41002835|NCT02202928|BIOLOGICAL|DC-CIK|8×10\^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.
41002836|NCT02202928|RADIATION|Radiotherapy|45\~50 Gy in 25-28 fractions.
41002837|NCT02202928|DRUG|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
41002838|NCT06517147|DEVICE|Cryogenx cooling|During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.
41315365|NCT01184404|DRUG|Bosentan|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
41002839|NCT06517147|DEVICE|Regular cooling|During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.
41315366|NCT04251689|DRUG|Mannitol|Mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
41315367|NCT04251689|DRUG|Placebo|0.9% normal saline 100 ml
41315368|NCT00064350|DRUG|Sorafenib|"Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death."
41315369|NCT00064350|DRUG|Placebo|Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
41315370|NCT02295735|DEVICE|Mepilex® Border Sacrum and Mepilex® Border Heel|
41315371|NCT01671722|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
41315372|NCT01305213|BIOLOGICAL|Bevacizumab|Given IV
41315373|NCT01305213|DRUG|Fosbretabulin Tromethamine|Given IV
41315374|NCT01305213|OTHER|Laboratory Biomarker Analysis|Correlative studies
41315375|NCT00729313|DRUG|Lanreotide microparticles|
41315376|NCT00729313|DRUG|Placebo|
41315377|NCT05341674|OTHER|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.
41315378|NCT01695850|DRUG|MZRW|Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
41315379|NCT01695850|DRUG|Senna|Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
41002840|NCT05338190|DRUG|Combination of Rituximab with subcutaneous belimumab|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
41315380|NCT01695850|DRUG|placebo|The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
41315381|NCT00622869|DRUG|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
41002841|NCT05338190|DRUG|Combination of Rituximab with subcutaneous placebo|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
41002842|NCT03272919|OTHER|Arm 1: Investigational INF|INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain.
41002843|NCT03272919|OTHER|Arm 2: standardized muscle stretching and strength|subjects will receive a standardized program of muscle stretching and strengthening exercise under the supervision of treating physical therapist.
41002844|NCT03510156|BEHAVIORAL|Behavior analytic treatment|Function-based treatment
41002845|NCT05147896|DRUG|Semaglutide Oral Tablet|Semaglutide Oral Tablets will be introduced to the active arm as per protocol for regular therapy introduction.
41315382|NCT00622869|DRUG|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
41315383|NCT00622869|DRUG|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
41002846|NCT02062762|BEHAVIORAL|Online-MBSR|8 week mindfulness based stress reduction online
41315384|NCT00622869|DRUG|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
41315385|NCT00622869|DRUG|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
41473143|NCT06093087|PROCEDURE|SAIF|The patient was placed in a prone position under general anesthesia. Using a C-arm X-ray machine and a positioning plate for navigation, the target position on the vertebral body was located one the surface of the body. The puncture needle core was withdrawn after puncturing, and a guide needle was inserted. After removing the puncture needle sleeve, a hollow bone cement screw was screwed into the anterior column of the vertebral body through the guide needle. Subsequently, bone cement was injected into the appropriate position through the bone cement screw to restore the vertebral height
41473144|NCT06093087|PROCEDURE|BKP|The patient was placed in a prone position after general anesthesia. Using a C-arm X-ray machine and a positioning plate for guidance, the target position on the vertebral body was located from the surface of the body. A puncture needle sleeve was inserted into the vertebral body. A PKP balloon was then inserted to perform vertebral restoration. After removing the balloon, an appropriate amount of bone cement was injected to ensure even distribution within the vertebral body. Vertebral height augmentation and restoration will then be achieved.
41473145|NCT06331234|OTHER|Vena cava inferior diameter|he VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.
41473146|NCT02008708|BEHAVIORAL|Livestock Microfinance|Participants randomized to the microfinance group receive the pig loan.
40798592|NCT02455804|DEVICE|Stenting procedure|All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
40798593|NCT03402594|DEVICE|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
40798594|NCT03402594|DEVICE|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
40798595|NCT05631340|OTHER|Discharge education|Researcher's newly prepared discharge education supported by a booklet and mobile app
41002847|NCT02062762|BEHAVIORAL|Expressive Writing Online|Online distributed expressive writing intervention as active control
41002848|NCT01607983|DRUG|inhaled nitric oxide|20 parts per million (ppm) of inhaled nitric oxide
41315386|NCT00622869|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
41473147|NCT02008708|OTHER|Delayed Control Group|Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
41315387|NCT03374384|OTHER|No drug intervention|This study will be performed in Al-Arish Central Hospital and will include all patients from 2 months up to 18 years of age with seizures admitted to Al-Arish Central Hospital
41315388|NCT05641948|OTHER|MRI scan|Participants will undergo brain MRI scan at 3 intervals
41315389|NCT02556593|RADIATION|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
41315390|NCT02556593|RADIATION|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
40798596|NCT00583752|BIOLOGICAL|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
40798597|NCT03073083|PROCEDURE|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon
40798598|NCT03073083|PROCEDURE|Pattella tendon autograft|ACL reconstruction surgery with patella tendon
41002849|NCT03856762|DIETARY_SUPPLEMENT|traditional Jiangnan diet|traditional Jiangnan diet supplement from Monday to Friday for six months
41315391|NCT02556593|DRUG|erlotinib|erlotinib 150mg daily
41315392|NCT05990036|OTHER|Sports vision enhancement training curriculum|A curriculum of 8 sports vision training procedures applied during women's collegiate softball team training. The training protocol consists of once weekly training sessions, 45 minutes in duration.
41315393|NCT01124448|BIOLOGICAL|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
41315394|NCT01124448|BIOLOGICAL|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
41315395|NCT03311399|OTHER|SSI Screening Tool used in home visits by CHWs|Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Following the screening, the sCHWs will use the cell phone to photograph the surgical wound and record the GPS location of the visit.
41315396|NCT03311399|OTHER|SSI Screening Tool used via phone call follow-up|Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone.
41315397|NCT00652431|DRUG|Vytorin + Niaspan|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
41315398|NCT00652431|DRUG|Vytorin|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
41315399|NCT00652431|DRUG|Niaspan|Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
41315400|NCT01457001|DRUG|25-OH-D vitamin|
41315401|NCT02812446|OTHER|IAI infection|
41315402|NCT02812446|OTHER|Staphylococcus aureus nasal carriage infection|
41315403|NCT01228942|DEVICE|COXEN analysis for chemotherapy prediction|Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
41473148|NCT00855075|DEVICE|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
41473149|NCT01747122|DEVICE|Wound catheter|Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
41473150|NCT01747122|DEVICE|Epidural|
41473151|NCT00727519|DIETARY_SUPPLEMENT|Pomegranate juice|
41473152|NCT00727519|DIETARY_SUPPLEMENT|Placebo|
41315404|NCT05353166|DRUG|REGN5381|Single dose administered via IV infusion
41315405|NCT05353166|DRUG|Matching Placebo|Single dose administered via IV infusion
41315406|NCT01044680|DIETARY_SUPPLEMENT|NUTRIOSE|17 grams of NUTRIOSE consumed twice daily for 12 weeks
41315407|NCT01044680|DIETARY_SUPPLEMENT|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
41315408|NCT05008588|BIOLOGICAL|Conditioned Medium|Intranasal of 3 cc of conditioned medium each, for 3 days in a row
41315409|NCT05008588|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
41315410|NCT05008588|PROCEDURE|Neurologic and Neutrophic Drugs|Such as clopidogrel, piracetam, citicoline
41315411|NCT03060083|OTHER|Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)|Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
41473153|NCT01678651|PROCEDURE|Stimulation with human FSH|Human FSH
41473154|NCT01678651|PROCEDURE|Stimulation with recombinant FSH|Recombinant FSH
41473155|NCT03329534|OTHER|Gluten free diet|A month long gluten free diet
41002850|NCT03856762|DIETARY_SUPPLEMENT|Mediterranean diet|Mediterranean diet supplement from Monday to Friday for six months
41002851|NCT03856762|DIETARY_SUPPLEMENT|Current Shanghai diet|current Shanghai diet supplement from Monday to Friday for six months
41315412|NCT03060083|OTHER|Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)|Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
41315413|NCT01693133|OTHER|Standard of Care: Moist Wound Therapy and Offloading|Standard of Care: Moist Wound Therapy and Offloading
41315414|NCT01693133|OTHER|EpiFix plus Standard of Care|Weekly application of EpiFix and Standard of Care
41315415|NCT05432674|COMBINATION_PRODUCT|Digital Fall Prevention|Exercises delivered through a tablet and remote motivational calls
41315416|NCT04300491|OTHER|Suspension walking training|Physiotherapy session, objective wlaking with body weight support using a specific device
41315417|NCT00039442|DRUG|Capecitabine|Given orally
41315418|NCT00039442|OTHER|Laboratory Biomarker Analysis|Correlative studies
41315419|NCT04853524|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
41315420|NCT04853524|DRUG|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)|A combination of BIC, FTC and TAF will be administered orally.
41473156|NCT02704195|PROCEDURE|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
41473157|NCT02704195|PROCEDURE|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
41473158|NCT05494216|OTHER|PICSI|Sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
41473159|NCT05494216|OTHER|MACS|Sperm selection using MACS for selecting sperm with lower DNA fragmentation index
41473160|NCT06497075|DRUG|Albendazole 400mg|Single oral dose of Albendazole 400mg tablet
41473161|NCT06497075|DRUG|Ivermectin 3 MG|Generic ivermectin 3mg tablets given as a single oral dose of 200ug/kg using a dose-pole (height categories: 90-119 cm: 1 tablet , 120-140 cm: 2 tablets, 141-158 cm: 3 tablets or \> 158 cm: 4 tablets)
41473162|NCT04027257|BEHAVIORAL|Sit Together and Read (STAR)|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
41473163|NCT04768894|PROCEDURE|Second transurehral resection of bladder tumour|Remove of the bladder tumour as endoscopically
41473164|NCT04414137|OTHER|Description of eosinophilic pneumonia due to daptomycine|Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection
41002852|NCT01323075|PROCEDURE|Truncal block|Patients will have a truncal block during hand or wrist surgery.
41002853|NCT01504334|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
41002854|NCT01504334|DRUG|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
41315421|NCT04658381|GENETIC|Genetic analysis|Patient exome sequencing will be performed by Illumina technology on the NextSeq 550 sequencer. Briefly, the exons of the genes are selected by capture and are amplified by PCR simultaneously, in a single reaction, and then sequenced by Illumina technology. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana.
40798599|NCT03073083|PROCEDURE|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon
40798600|NCT05421169|DIAGNOSTIC_TEST|diastolic hyperemia-free ratio (DFR)|diastolic hyperemia-free ratio uses the mean Pd/Pa calculated over the period in diastole defined as that during which arterial pressure is negatively sloped and below the mean arterial pressure
41002855|NCT02818595|DEVICE|electroencephalogram (HR-EEG)|
41002856|NCT02818595|DEVICE|Near Infra Red Spectroscopy (NIRS)|
41002857|NCT00347295|DRUG|Brotizolam|
41002858|NCT00347295|DRUG|Estazolam|
41002859|NCT04999046|DEVICE|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.
41002860|NCT05111132|DIAGNOSTIC_TEST|Fluid challenge (cristalloïd, NaCl 0,9%)|A fluid challenge according to group will be administrated by infusion pump
41315422|NCT04658381|PROCEDURE|Ophthalmologic exam|Standard ophthalmologic assessment (measurement of visual acuity, measurement of intraocular pressure, slit lamp examination), OCT-B scan, OCT-Angiography, Adaptive optics
41315423|NCT01709136|DRUG|Sirolimus|Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
41473165|NCT01559935|DRUG|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
41473166|NCT01559935|DRUG|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
41473167|NCT01559935|DRUG|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
41473168|NCT01559935|DRUG|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
40798601|NCT02412189|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
41002861|NCT04803929|BIOLOGICAL|anti-ILT3 CAR-T|Autologous T cells genetically modified with anti-ILT3 CAR
41002862|NCT00379496|PROCEDURE|Antidepressants|
41002863|NCT00379496|PROCEDURE|acupuncture|
41315424|NCT02307071|DEVICE|Cefaly Kit Arnold|Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
41315425|NCT00472355|DRUG|apomorphine|
41473169|NCT01559935|DRUG|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
40798602|NCT02412189|DRUG|Norepinephrine|Norepinephrine therapy to maintain preanesthesia blood pressure
40798603|NCT05121298|DRUG|upadacitinib 15mg/day|Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) ≤3.2 at 12 weeks, and a DAS28-CRP of \<2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.
40798604|NCT01693250|BEHAVIORAL|fitbit Ultra|Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
40798605|NCT01693250|BEHAVIORAL|Pedometer|adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
40798606|NCT02400970|OTHER|malignant cells|
40798607|NCT02281227|PROCEDURE|skin compression|skin compression with an indicator for determination of needle entry point
41473170|NCT01559935|DRUG|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
41473171|NCT04417049|DRUG|Pentoxifylline 400 MG|All patients will be provided with pentoxifylline 400 mg to be orally ingested twice daily for 8 weeks.
41473172|NCT00139724|DRUG|tolterodine extended release capsule|
40798608|NCT00454740|DRUG|solifenacin succinate|Oral
40798609|NCT01628523|OTHER|For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.|Mechanical ventilation via an endotracheal tube or tracheostomy tube
40798610|NCT04983693|BEHAVIORAL|Dementia-friendly Worship Service|Key elements of dementia-friendly worship services include familiar hymns, prayers and bible stories and short sermons. Participants can attend the worship services either in person or through online video streaming. Participant dyads should watch the six worship services together, over a span of 6 to 8 weeks.
40798611|NCT04868097|PROCEDURE|cervix biopsy|large loop electrosurgical cervix biopsy
41151651|NCT06646068|OTHER|Philips 66 with CBL|Each team is given six minutes to brainstorm ideas or solutions to specific clinical cases. This technique is applied during case-based learning sessions to enhance clinical judgment and critical thinking skills among nursing students.
41473173|NCT04651192|OTHER|Combat Exposure|Soldiers will be exposed to combat as part of their routine military service. The ROTC students will not be exposed to combat.
40798612|NCT02053922|DRUG|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
40798613|NCT02053922|DRUG|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . \[Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada\] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
40798614|NCT02053922|DRUG|Misoprostol|Misoprostol (200 mcg Tablet) \[Misotac, Sigma Pharmaceutical Industries, SAE, Egypt\] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
40798615|NCT00942370|DEVICE|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:~* EMG and MMG Signals of rectus abdominis of the abdomen,~* Respiratory flow,~* An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
41002864|NCT03840395|DEVICE|Pharyngeal Electrical Stimulation (PES)|The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
41002865|NCT05278429|DEVICE|Myosuit robotic device|The Myosuit is a partially soft, exoskeleton-type, wearable robot that supports the synergistic extension of the hip and knee joints.
41002866|NCT02340533|PROCEDURE|hysteroscopic endo-myometrial biopsy|
41151652|NCT03360227|DEVICE|implantation of cardiac devices|implantation of cardiac devices
41315426|NCT02848339|DRUG|aspirin|aspirin desensitization
41315427|NCT04966884|DRUG|JAK Inhibitor|"1. Prednisone 0.8-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. Tofacitinib 5 mg twice daily for 12 months."
41315428|NCT01511107|DRUG|Amoxicillin-Clavulanate, 10 days|Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-10
41315429|NCT01511107|DRUG|Amoxicillin-Clavulanate, 5 days|"Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-5~Plus~Placebo Days 6-10"
41315430|NCT05502471|DIAGNOSTIC_TEST|Zonulin|Serum zonulin level
41473174|NCT02577341|DRUG|Nimotuzumab|Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.
41151653|NCT06056219|DEVICE|Mirror therapy|30 minutes' mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise of less-affected upper extremity using a mirror box
41151654|NCT06056219|DEVICE|Virtual reality-based mirror therapy with rhythmic skill training|30 minutes' virtual reality-based mirror therapy with rhythmic skill training included musical exercises involving virtual drums playing with less-affected upper extremity, and synchronized virtual drums playing and singing activity
41315431|NCT05502471|DIAGNOSTIC_TEST|Occludin|Serum occludin level
41473175|NCT02577341|DRUG|docetaxel and cisplatin|Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
41473176|NCT02577341|RADIATION|daily RT to the chest|Patients received daily RT to the chest
41473177|NCT05244018|DRUG|Vitamin D3 tablets|Vitamin D3 tablets 50,000 IU units
41473178|NCT05244018|DRUG|Vitamin D tablets|Vitamin D tablets 5000 units as daily requirements
41473179|NCT03284502|DRUG|HM95573, cobimetinib|Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib
41473180|NCT03284502|DRUG|HM95573, cetuximab|Regimen: twice daily (BID), continuous dosing for HM95573
41473181|NCT03284502|DRUG|HM95573, cobimetinib|Regimen: Recommended dose (RD) and schedule selected based on the data of safety, tolerability, pharmacokinetics, and anti-tumor activity tested in Stage 1
41473182|NCT03284502|DRUG|HM95573, cetuximab|Regimen: Expansion dose of HM95573 selected based on the data of safety and tolerability tested in Stage 1b
41473183|NCT02946606|DRUG|GX-H9|Human growth hormone
41473184|NCT02946606|DRUG|Genotropin|Human growth hormone
41473185|NCT00094367|DRUG|Abacavir/Lamivudine|
41002867|NCT02340533|DEVICE|ultrasound|two dimensional trans-vaginal ultrasonography
41002868|NCT00398853|DIETARY_SUPPLEMENT|chromium picolinate 1000 mcg daily vs placebo|chromium picolinate 1000 mcg daily vs placebo
41151655|NCT06056219|OTHER|Task-oriented training|20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient
41151656|NCT02896153|OTHER|Questionnaire|
41151657|NCT03467802|BIOLOGICAL|enamel matrix derivative|Enamel matrix derivative (EMD), sold under the brand name Emdogain®, is an amelogenin derivative of embryonal porcine enamel and is FDA approved for application to root surfaces to treat recession defects. Amelogenins comprise the majority of the proteins in EMD while others such as tuftelin, ameloblastin and amelin make up the remainder. EMD is thought to mimic the role of proteins crucial to cementogenesis and root development, which may promote new gingival attachment to exposed roots. The properties of EMD may favor early healing of the soft tissue and stimulate angiogenesis.
41151658|NCT03467802|DEVICE|Porcine collagen matrix|Mucograft® is a bi-layered grafting material composed of Type I and III collagen. It is derived from veterinary certified pigs, sterilized by gamma irradiation and has a low antigenicity in conjunction with good biocompatibility. The material is approximately 2.5-5mm thick and is indicated for root coverage, increasing keratinized tissue, covering of implants placed immediately and alveolar ridge reconstruction. A compact outer layer contributes to protection, structure and allows for better control during suturing; while the inner layer is thick, porous and spongy in nature, providing a suitable environment for early vascularization and promotion of cellular in-growth.
41151659|NCT04677985|COMBINATION_PRODUCT|Menthol based topical analgesic|Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.
41151660|NCT01560962|DRUG|povidone iodine|over the counter (OTC) 5% povidone iodine (PI)
41151661|NCT01560962|OTHER|No Intervention|
41151662|NCT01560962|DRUG|Azithromycin|
41151663|NCT01560962|DRUG|tobramycin-dexmethasone|
41151664|NCT01560962|OTHER|warm soaked eyelid wash|
41151665|NCT00070161|DIETARY_SUPPLEMENT|EGb761|
41151666|NCT00070161|DRUG|donepezil hydrochloride|
41151667|NCT00070161|PROCEDURE|cognitive assessment|
41151668|NCT00481156|BEHAVIORAL|Cognitive Remediation|
41151669|NCT00481156|BEHAVIORAL|Cognitive Behavioral Social Skills Training|
41151670|NCT00481156|OTHER|Retest in Health Controls|Pre/Post test performance and neuroimaging only
41151671|NCT02074865|BIOLOGICAL|biological samples|
41473186|NCT05707455|OTHER|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
41473187|NCT00592202|DEVICE|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
41473188|NCT02752802|DEVICE|Diagnostic Coronary Angiogram|Diagnostic angiographic procedure with the use of the DyeVert System.
41473189|NCT04418531|BIOLOGICAL|Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria .
41473190|NCT00847743|DIETARY_SUPPLEMENT|Tart Cherry Juice|8 fl.oz. twice per day
41473191|NCT00147849|BEHAVIORAL|mailing of printed educational materials|
41473192|NCT00147849|BEHAVIORAL|a combination of interactive educational meetings, educational outreach visits, and reminders|
41473193|NCT00147849|BEHAVIORAL|identification of local opinion leaders and establishment of local consensus processes|
41473194|NCT03980301|DIAGNOSTIC_TEST|ultrasound|screening of pregnant women with hepatitis c virus received treatment in first trimester for congenital anomalies
41473195|NCT05312086|OTHER|MRI|"Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes.~Performing MRI does not require the injection of contrast products or radiopharmaceuticals."
41473196|NCT03476031|DIAGNOSTIC_TEST|renal biopsy|needle biopsy will be taken from the kidney tissue then, diagnosed
41002869|NCT00398853|OTHER|Placebo|Placebo
41002870|NCT03643965|DRUG|Nefecon|Nefecon 16 mg for daily administration by mouth for 9 months.
41002871|NCT03643965|DRUG|Placebo oral capsule|Placebo capsules for daily administration by mouth for 9 months.
41002872|NCT01470846|PROCEDURE|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
41151672|NCT00852345|DRUG|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
41473197|NCT02327793|DRUG|Nitroglycerin|
41473198|NCT02327793|DRUG|Labetalol|
41473199|NCT01774825|DIETARY_SUPPLEMENT|IQP-CL-101|2 softgels twice a day
41473200|NCT01774825|OTHER|Placebo|2 softgels twice a day
41315432|NCT06433518|DRUG|recombinant hCG|"Experimental Group: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm.~Control Group: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.~All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.~The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.~Primary and secondary outcomes will be compared between the two groups."
41315433|NCT03936517|DRUG|Prednisolone|Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
41315434|NCT03936517|DRUG|Hydrocortisone|Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
41315435|NCT00580944|PROCEDURE|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
41315436|NCT01755195|DRUG|Cabozantinib|Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
41315437|NCT01941524|DRUG|Poractant alfa instillation|aEEG and NIRS monitoring during poractant alfa instilation
41315438|NCT01941524|DRUG|Beractant instillation|aEEG and NRs monitoring during beractant instillation
41315439|NCT03670394|DIAGNOSTIC_TEST|Capillary Refill|We are measuring capillary refill to assess it's correlation with dehydration in children
41315440|NCT01478399|DRUG|PB1023 Injection|90 mg Dose
41315441|NCT01930526|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
41315442|NCT02539355|OTHER|Diet A|12-week diet
41315443|NCT02539355|OTHER|Diet B|12-week Diet
41315444|NCT01595659|BEHAVIORAL|Passenger|Driving with risk accepting or risk averse passenger
41473201|NCT02219308|PROCEDURE|Paracervical Block (PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.~IUD placement then proceeds"
41473202|NCT02219308|PROCEDURE|No Paracervical Block (Sham PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blanching, indentation, or pain.~IUD placement then proceeds"
41151673|NCT04479176|PROCEDURE|Transnasal Sphenopalatine Ganglion Block|In transnasal approach, several authors described the traditional technique using sterile 10cm cotton tipped applicators that are dipped in the chosen anesthetic and then advanced along the superior border of the middle turbinate, until it reaches the posterior wall of the nasopharynx. Some other techniques had described dripping one or two ml of the anesthetics into the nostril.
41151674|NCT03441789|DRUG|Enstilar|Enstilar foam applied to affected areas daily
41473203|NCT04025138|OTHER|Neuromuscular tests in isometric mode|"Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~* Voluntary maximum forces plantar flexors and knee extensors~* Electrically evoked forces~* ElectroMyoGraphic activity (EMG)~* Three-Modality Evoked Potentials (TMEPs)"
41002873|NCT01470846|PROCEDURE|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
41002874|NCT00974714|DRUG|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
41151675|NCT03441789|DRUG|Vehicle|vehicle foam applied to affected areas once daily
41151676|NCT03441789|DRUG|Otezla|Otezla 30mg
41151677|NCT04955886|DRUG|Surufatinib(HMPL-012)|Surufatinib(250mg) will be orally administered within 1 hour after breakfast once a day (QD) , Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Until disease progression, death, intolerable toxicity or other protocol specified end-of-treatment criteria is met .
41151678|NCT06181266|DRUG|ZH9|ZH9 is a live attenuated S. enterica serovar Typhi ZH9 \[Ty2 ΔaroC ΔssaV\]), a differentiated novel microbial immunotherapy.
41151679|NCT01863888|DRUG|teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
41151680|NCT01863888|DRUG|cholestyramine|Pharmaceutical form:powder Route of administration: oral
41151681|NCT01863888|DRUG|charcoal|Pharmaceutical form:granule Route of administration: oral
41151682|NCT00685659|OTHER|Intensive Outpatient Treatment|9 hours of group counseling per week for 2-3 months
41151683|NCT00685659|OTHER|Adaptive telephone-based counseling|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included
41151684|NCT00685659|OTHER|Adaptive telephone-based counseling plus incentives|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
41151685|NCT00689520|DRUG|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
41151686|NCT00689520|DRUG|acenocoumarol|tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
41151687|NCT06585683|DIAGNOSTIC_TEST|Clinical Evaluation at Day 4|Participants will undergo an abbreviated physical exam, assessment of concomitant medications, and reassessment for signs/symptoms of TB
41151688|NCT06585683|DIAGNOSTIC_TEST|Laboratory Evaluation at Day 4|Peripheral blood samples, including serum, PBMC, and whole blood, are collected from participants. A tongue swab is also collected from each participant.
41151689|NCT06585683|DIAGNOSTIC_TEST|Clinical Evaluation at week 26|Participants will undergo another complete physical exam and have their medical (including TB) history, potential TB signs/symptoms, and concomitant medications reassessed. Chest radiography will be obtained for all participants. An assessment of TB outcomes will also be performed.
41002875|NCT00974714|OTHER|placebo|oral placebo 2 g twice a day for 14 weeks
41002876|NCT00116558|DEVICE|Early NIPPV|Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).
41002877|NCT00116558|DEVICE|Standard NIPPV|Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).
41002878|NCT04855643|DEVICE|home-based active tDCS|Anode and cathode electrodes will be placed over the left and right dorsolateral prefrontal cortexes, respectively, with the use of the Omni-Lateral-Electrode system. Caregivers will set up and administer tDCS for participants with ADRD at home. tDCS will be applied for 30 min at an intensity of 2mA, with 30 s ramping up and down. All sessions will be remotely supervised by trained research staff.
41002879|NCT04855643|DEVICE|home-based sham tDCS|For sham stimulation, electric current will be applied only in the first 30s tDCS. All sessions will be remotely supervised by trained research staff.
41002880|NCT01874834|OTHER|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
41002881|NCT03732053|OTHER|GPR Intervention Research group|The research intervention consisted in the reappointment of three GPR therapeutic postures.
41002882|NCT03814954|DRUG|Salbutamol|At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
41002883|NCT03814954|DRUG|Epinephrine|At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
41002884|NCT03090100|DRUG|Guselkumab|Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
41002885|NCT03090100|DRUG|Placebo|Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
41002886|NCT03090100|DRUG|Secukinumab|Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
41002887|NCT00810953|DRUG|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
41315445|NCT06087042|DIAGNOSTIC_TEST|serum and unstimulated salivary samples|"Participants were told to cease smoking, eating, or drinking before the collection of samples by about half an hour. Obtaining the sample was done by demanding the individual to swallow then incline his head forward to expectorate saliva in a sterile tube for about 3 min. Afterwards the samples were coded by serial numbers then stored at -20°C until being assessed.~Under aseptic circumstances and using plain tubes, 5ml peripheral venous blood samples were collected from all participants by standard venipuncture. Samples were transported to biochemistry laboratory and centrifuged followed by filtration of the clarifying supernatant and then stored at -20ºC"
41151690|NCT06585683|DIAGNOSTIC_TEST|Laboratory Evaluation at week 26|Peripheral blood samples, including serum, PBMC, and whole blood, will be collected. Participants not previously identified as living with HIV will undergo HIV diagnostic testing, while participants living with HIV will have their HIV viral load and CD4+ T-cell count measured.
41002888|NCT01224249|DIETARY_SUPPLEMENT|Fish and shellfish|Intake of 1000 grams of fish and shellfish per week for six months.
41315446|NCT02418533|DRUG|menotropin|Menopur is used for controlled ovarian stimulation (COH)
41315447|NCT02418533|DRUG|Recominant Follicle Stimulating Hormone (rFSH)|Gonal-f is used for controlled ovarian stimulation (COH)
41315448|NCT03508765|DIAGNOSTIC_TEST|Structural Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
41473204|NCT04025138|DEVICE|Transcranial Magnetic Stimulation (TMS)|Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
41473205|NCT04025138|OTHER|Neuromuscular fatigue assessment test|Neuromuscular fatigue assessment test in dynamic mode will be assessed by the Force/Velocity Profile (FVP) measure: 2 sprints of 8 seconds on a cycle ergometer.
41002889|NCT03855735|BEHAVIORAL|TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)|The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.
41002890|NCT04001842|OTHER|Surgical reconstruction of the mandible using an axially vascularized bone construct|Surgically reconstructing defects of the mandible using reconstruction plate and Titanium mesh filled with an artificial bone substitute to form a bone construct. This construct will be vascularized at the same operation using a vein graft from the forearm. The vein graft will be microsurgically connected to an artery and vein within the facial/neck region to provide a vascular supply to the construct (arterio venous loop)
41002891|NCT02739191|DEVICE|PICO, Smith & Nephew|Direct application of negative pressure wound therapy following Foot and Ankle surgery
41002892|NCT01889680|DRUG|5-FU|400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
41002893|NCT01889680|DRUG|LV|400 mg/m2 IV day 1 every 14 days until disease progression
41002894|NCT01889680|DRUG|ziv-aflibercept|4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
41002895|NCT01889680|DRUG|mFOLFOX6|5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
41002896|NCT02995785|OTHER|simulation-based training|simulation-based training:The first aid skill simulation training with discussion and debriefing(75-min) and TMS online lecture(15-min).
41002897|NCT02995785|OTHER|traditional training|traditional training:Give TMS online lecture(15-min).
41002898|NCT03938142|OTHER|Filling in an online survey regarding goalsettings|Patients are asked to fill in an online survey regarding their individual goalsettings.
41002899|NCT01363596|OTHER|Creighton Model System in conjunction with Natural Procreative Technology (NPT)|Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
41315449|NCT03508765|DIAGNOSTIC_TEST|Functional Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
40798616|NCT06017960|OTHER|Dry needling + usual care|"Participants assigned to the dry needling group will receive a weekly session for four weeks of ultrasound-guided dry needling in the inner gastrocnemius muscle with disposable stainless-steel needles, according to the depth of the muscle to be treated. For the realization of the technique, the diagnostic criteria of the Dry Needling in Hypertonia and Spasticity technique (DNHS®) developed by Herrero et al. will be applied adapted to the characteristics of the study, as well as the procedure for its application.~The ultrasound guidance will be the same ultrasound device than in the assessments. This ultrasound-guided intervention allows to guarantee the safety of the approach, to have the certainty in the location of the target structure and to see the responses of local spasm. During the application of the technique, patient will not look at the ultrasound screen to ensure the blindness of the patient to the group allocated."
41002900|NCT03423732|DRUG|CardioCell|"Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion."
41315450|NCT03508765|BEHAVIORAL|Digit Span subtest|Evaluates auditory attention and working memory
41315451|NCT03508765|BEHAVIORAL|Brief Test of Attention|Assesses selective auditory attention
41315452|NCT03508765|BEHAVIORAL|Trail Making Test (Parts A & B)|Assesses visual scanning, graphomotor speed, and setshifting
41315453|NCT03508765|BEHAVIORAL|Auditory Consonant Trigrams Test|Assesses attention and susceptibility to interference
41315454|NCT03508765|BEHAVIORAL|Controlled Oral Word Association Test|A timed test of verbal fluency.
41315455|NCT03508765|BEHAVIORAL|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall.
41315456|NCT03508765|BEHAVIORAL|The Center for Epidemiological Study-Depression|assesses perceived depression
41315457|NCT03508765|BEHAVIORAL|The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4|A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue
41315458|NCT03508765|OTHER|Blood draw|Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.
41315459|NCT06419517|DEVICE|EMG-triggered ES|The ES treatment protocol consisted of daily endovaginal electrostimulation sessions for four weeks. We used a portable unit EVOSTIM ®, which allowed us to use different frequencies and length of impulse and a probe Perisphera ® The average current intensity was adjusted according to the sensation of discomfort in each patient.
41315460|NCT06419517|OTHER|Pelvic Floor Muscle Training|Standardization of the supervised PFMT To achieve standardization of supervised PFMT treatments, a written protocol for the physiotherapeutic examinations and PFMT program will be provided to the physiotherapists (or nurse or midwife) delivering the treatments (See Additional file).
41315461|NCT05385497|OTHER|Aerobic Exercise|Participants will perform a 30-minute exercise protocol (5 minutes warm-up and cool-down each and 20 minutes moderate intensity exercise) on a StepOne™ recumbent stepper
41315462|NCT05385497|DEVICE|Virtual Reality|Participants will interact with the virtual environment and view the gaming environment on a flat-screen TV placed in front of them at a suitable distance. The participants will play four games (50 repetitions/game divided into three blocks with 1-2 minutes rest between blocks), with the order of the games randomized in every session.
41315463|NCT04995328|OTHER|Radiation Care Gel|The investigational medical product of this study is a hydrogel, Radiation Care® gel which increases moisturizing and it can be applied to the target areas including skin folds and creases.
41002901|NCT03423732|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
41151691|NCT00896389|PROCEDURE|Salt loading|Subjects will arrive at the Amish Research Clinics after overnight fasting. After taking height, weight, BP, and body temperature, subjects will receive 2 liters (L) of 0.9% sodium chloride (NaCl) saline over 4 hours while their blood pressure is monitored every 15 minutes. Blood pressure will be taken every 15 minutes during this procedure. Blood and urine samples will be collected from all subjects pre- and post-infusion.
41315464|NCT01441115|PROCEDURE|Radiation Therapy|
41315465|NCT01441115|DRUG|ECI301|
41315466|NCT03808038|OTHER|None- Observational Study|None- Observational Study
41315467|NCT03001843|DRUG|Ketamine|Anesthesia of only Ketamine
41315468|NCT03001843|DRUG|Narcotics|The narcotic group will receive no ketamine but rather a more standard anesthetic
41315469|NCT03001843|BEHAVIORAL|pain scale|0-10 pain scale. 0 = no pain and 10 = worst pain
41315470|NCT04108585|PROCEDURE|HFO therapy|HFO therapy from mechanical ventilation
41315471|NCT04108585|PROCEDURE|CPAP therapy|CPAP therapy from mechanical ventilation
41315472|NCT03432052|PROCEDURE|centralization|Wrist centralization involves aligning the distal ulna with the middle finger metacarpal and passing a large Kirschner wire or a small Steinmann pin through the middle finger metacarpal, carpus, and ulna for temporary stability. This is followed by soft tissue balancing in order to counteract the volar and radial directed force vectors consisting of reefing the ulnocarpal wrist capsule and transferring the extensor carpi ulnaris muscle distally and flexor carpi ulnaris muscle dorsally on the wrist.
41315473|NCT01680978|DRUG|aleglitazar|150 mcg orally daily, 6 weeks
41315474|NCT01680978|DRUG|placebo|orally daily, 6 weeks
41315475|NCT05614713|PROCEDURE|Selected physical therapy program|Gait training and balance training
41315476|NCT05614713|PROCEDURE|Modified physical therapy program to increase sensory input|Gait training and balance training using sensory stimulating matts
41315477|NCT00002344|DRUG|Azithromycin|
41315478|NCT01500018|DRUG|TC-5214|Single oral dose of 2 mg
41315479|NCT01500018|DRUG|TC-5214 Placebo|Single oral dose
41315480|NCT01500018|DRUG|Ketamine|Single oral dose of 100 mg
41315481|NCT01500018|DRUG|Phentermine|Single oral dose of 45 mg
41315482|NCT01500018|DRUG|TC-5214|Single oral dose of 8 mg
41315483|NCT01500018|DRUG|TC-5214|Single oral dose of 16 mg
41473206|NCT04025138|OTHER|treadmill|2 sessions of treadmill will be realized: 8 and 10 km.h-1 for level running and 7 km.h-1 with 10% slope for graded running.
41315484|NCT01500018|DRUG|Phentermine|Single oral dose of 90 mg
41315485|NCT05506553|DEVICE|Intervention arm - Eyhance Toric II Intraocular Lens|Bilateral cataract extraction and insertion of Eyhance Toric II Intraocular Lens
41473207|NCT04025138|BIOLOGICAL|Blood sample|Blood sample will be realized to measure hemorrheologic and hematologic parameters.
41473208|NCT04025138|BIOLOGICAL|Urinary sample|Urinary sample will be realized to measure hemorrheologic and hematologic parameters.
41473209|NCT02501551|DRUG|regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
41473210|NCT02931292|PROCEDURE|Laparoscopic sleeve gastrectomy|"Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained."
41473211|NCT04065568|DEVICE|DISKO-tool|The training program will be based on the initial assessments of functioning and disability and the patients' performance of the test exercises. Type and number of exercises per session, level of difficulty and number of repetitions (including proportion of repetitions to the right and left side of the body) will be set. The set training program is thereafter introduced and evaluated during the first follow-up by video communication with the patients.
41473212|NCT05082363|COMBINATION_PRODUCT|C4d evaluation in lupus nephritis in serum and renal tissue|C4d plasma levels were analyzed by a unique assay specifically detecting C4d arising from complement activation and C4 plasma levels were quantified with competitive ELISA. SLE patients in activitity with and without lupus nephritis In patient with lupus nephritis we will evaluate the C4d after developing remission in the form of reduction of proteinurea less than .5g/g measured as PCR as complete response and less than50% reduction in proteinurea in partial response according to KIDGO guide line Percutaneous renal biopsies were performed in SLE and non-SLE patients under ultrasonographic guidance. 10% formalin-fixed tissue was embedded in paraffin. Four μm-thick sections were stained with hematoxylin and eosin (H\&E), periodic acid-Schiff (PAS), periodic acid methenamine silver (PAM), masson-trichrome and polyclonal rabbit anti-human C4d antibody, Renal biopsy specimens of SLE patients were assessed using the most recent modification of the World Health Organization (WHO)
41473213|NCT00111956|DRUG|Etanercept|
41473214|NCT00111956|DRUG|Placebo|
41473215|NCT06042127|PROCEDURE|POEM-F|POEM-F would be performed as described in the arms section
41473216|NCT06042127|PROCEDURE|Conventional POEM|Anterior POEM performed as described in the arms section
41473217|NCT03085368|DRUG|lapatinib/herceptin|Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
41473218|NCT06371872|PROCEDURE|total transfixing injury to the rotator cuff|develop an appropriate prescription strategy with a view to improving patients' quality of life in the short, medium and long term in this condition
41473219|NCT05742919|DRUG|NNC0194-0499|Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
41473220|NCT05742919|DRUG|NNC0194-0499|Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
41473221|NCT05742919|DRUG|NC0194-0499|Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
41473222|NCT02588079|BEHAVIORAL|Internet-based cognitive behavioral therapy|
41002902|NCT05233436|DRUG|PF-07265028|PF-07265028 will be administered orally
41315486|NCT05506553|DEVICE|Control Arm - Alcon IQ Toric Intraocular lens|Bilateral cataract extraction and insertion of Alcon IQ Toric Intraocular Lens
41002903|NCT05233436|BIOLOGICAL|Sasanlimab|Administered subcutaneously
41315487|NCT01405313|DEVICE|Modified Adaptive Servoventilation Device|The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
41315488|NCT01405313|DEVICE|Conventional Adaptive Servoventilation device|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
41473223|NCT02459717|OTHER|Probiotics and prebiotic|Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
41473224|NCT02459717|OTHER|Placebo|Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
41473225|NCT05287152|DEVICE|titanium tacks or pins|using tacks or pins made of titanium 2.5 mm diameter and 4mm length for free gingival graft fixation.
41473226|NCT05754229|DEVICE|AI-assisted colonoscopy|The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
41473227|NCT01337765|DRUG|BEZ235 + MEK162|
41473228|NCT05543694|DRUG|Bupivacaine Hydrochloride|Subjects will receive a dose of bupivacaine as described in the arm section of this trial
41473229|NCT02181296|DRUG|ropivacaine|
41473230|NCT05060731|DRUG|Oral iron supplementation|Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.
41473231|NCT05060731|DRUG|Intravenous iron supplementation|One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.
41473232|NCT04468906|PROCEDURE|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat LHBT lesions.
41473233|NCT04468906|PROCEDURE|"Self-locking T Tenotomy"|"Self-locking T Tenotomy describes the surgical procedure that will be performed to treat LHBT lesions."
40798617|NCT06017960|OTHER|Sham dry needling + usual care|"Participants assigned to this group will receive the same assessments, the same number of sessions, and the sham dry needling at the same site as the dry needling group, but with a sham intervention, where the needle is dropped through the guide tube and touch the skin. The patient will not feel anything, or at most that the needle touches the skin, since it does not get into the subcutaneous cell tissue, as placebo interventions were performed in similar studies. The context will be simulated in its entirety, using the same ultrasound and disposable needles for the intervention.~Both groups will continue their daily motor rehabilitation treatment during the 4 weeks, which consists of strength training, balance, motor control, gait training, and mass practice oriented to tasks of intensity and duration appropriate to each patient, allowing the fastest possible clinical improvement, as recommended by clinical practice guidelines."
40798618|NCT05918016|DIAGNOSTIC_TEST|Routine cranial ultrasounds|we will use the routine cranial ultrasounds
41315489|NCT06170801|BEHAVIORAL|Kiesler Circle Training (KCT)|Kiesler Circle Training is a transdiagnostic modular group treatment, which comprises a baseline module and four additional independent modules (nonverbal communication, verbal communication, conflict training and empathy and corrective interpersonal experiences). KCT is based on a heuristic model to explain and anticipate interactions developed by Donald Kiesler and other representatives of the interpersonal theory. The circumplex model arranges the variety of interpersonal behaviors in terms of a circular continuum allocated on two orthogonal axes: The vertical axis addresses interpersonal control (agency), the horizontal axis addresses interpersonal communion. The model further allows illustrating complementary action tendencies to anticipate other's reactions and to guide own behavior to achieve interpersonal goals. KCT is designed for increasing the awareness of such interpersonal action tendencies and for improving interpersonal behavioral flexibility.
41315490|NCT06170801|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is based on the interrelationships of thoughts, actions and feelings. Presumably, individual CBT will address intrapersonal therapeutic foci such as behavioral activation, identification of dysfunctional thoughts, overcoming fears by exposure, etc. Individual CBT may also include interpersonal functioning as therapeutic foci. Disorder-specific treatment manuals are available for all diagnoses included in the study. Of note, state-of-the-art CBT does not necessarily mean, that individual CBT-sessions strictly adhere to a manual. However, because both study sites are CBT training institutes, which guarantee supervision at least every four hours, it can be estimated that state-of-the-art CBT is realized.
41315491|NCT05762874|DRUG|Ruxolitinib|JAK inhibitor
41315492|NCT06022978|PROCEDURE|Submucosal Saline Injection|Inject 3-5 mL of saline into the submucosa within 10 minutes using a single-use 22G mucosal needle. The puncture point is located 0.5 cm from the edgeof the lesion, and the saline injection is stopped when the esophageal mucosa is elevated by approximately 1 cm.
41473234|NCT06617767|OTHER|Reiki|The Reiki group received distant Reiki application to their energy centers for 20 minutes, once a day, for 4 consecutive days, by researchers with Reiki Stage II training under the guidance of a researcher with the Usui Reiki Master \& Teacher degree.
41151692|NCT00896389|DRUG|Hydrochlorothiazide (HCTZ)|We will perform short-term HCTZ intervention on the same 120 subjects. After overnight fasting and having their height, weight, and BP measured, subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. Ambulatory blood pressure will be measured and blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will repeat the 7-day HCTZ intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
41151693|NCT02939859|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
41151694|NCT02939859|DEVICE|Centricyte 1000|Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF
41151695|NCT02939859|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
41151696|NCT01961934|DRUG|Sodium Acetate C11 PET/CT Imaging|
41151697|NCT03734172|DIAGNOSTIC_TEST|Sample collection|Specimen collection
41151698|NCT00000499|DRUG|chlorthalidone|
41151699|NCT00000499|DRUG|reserpine|
41151700|NCT00000499|DRUG|hydralazine|
41151701|NCT00000499|DRUG|metoprolol|
41151702|NCT04847908|OTHER|Single high-intensity interval exercise intervention|Study participants perform a single bout of exercise on a cycle ergometer (high-intensity interval exercise intervention) within the first and third cycle of chemotherapy. Following a 2 minute warm-up, the interval protocol comprises 10 intervals à 15 seconds with high intensity and 60 seconds low intensity in-between. Blood samples are taken at t0 pre-exercise (after a 10 minute rest) and at t1 immediately post-exercise via central catheter (Hickman/port).
41151703|NCT01622088|DRUG|Dexpramipexole|Oral tablet 150 mg given twice daily (BID)
41151704|NCT03296423|BIOLOGICAL|Vaccination|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
41151705|NCT03296423|BIOLOGICAL|Placebo|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
41151706|NCT03094143|PROCEDURE|Aortic valve intervention|The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.
41151707|NCT04554199|DEVICE|Flexible partial denture|removable partial dentures (RPDs) were fabricated using thermoplastic resins (flexible RPDs). EEG and MMSE were evaluated before denture delivery and after one month of denture wear.
41151708|NCT00925327|OTHER|Corneal collagen cross-linking with riboflavin/UVA light|Corneal collagen cross-linking with riboflavin/UVA light
41151709|NCT05407844|OTHER|Community Health Worker (CHW) based palliative care|Those in the intervention group will receive support from a dedicated CHW trained in motivational interviewing, components of palliative care communication, and social determinants of health.
41315493|NCT06022978|PROCEDURE|Blue laser Imaging and Magnifying Endoscopy|It is a new system for image-enhanced endoscopy using laser light. By clicking a button on the endoscope only , endoscopists can electronically stain and magnify the digestive tract lesions. This system can help endoscopists observe leisons more clearly and improve diagnosic accuracy.
41315494|NCT01604057|DRUG|ZT-034 Low Dose Nasal Spray|Nasal Spray
41315495|NCT01604057|DRUG|ZT-034 Mid Dose Nasal Spray|Nasal Spray
41315496|NCT01604057|DRUG|ZT-034 High Dose Nasal Spray|Nasal Spray
41315497|NCT01604057|DRUG|Teriparatide|20 mcg subcutaneous daily
41315498|NCT01604057|DRUG|Placebo|Nasal Spray
41315499|NCT02290054|PROCEDURE|Control|Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
41315500|NCT02290054|PROCEDURE|Treated|Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles.
41315501|NCT02290054|PROCEDURE|Intra-venous anesthesia|
41315502|NCT00979446|BEHAVIORAL|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
41315503|NCT00979446|BEHAVIORAL|Self-directed|Received study materials but no phone coaching
41315504|NCT03830814|PROCEDURE|Echocardiography|Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
41315505|NCT01694420|DRUG|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
41315506|NCT06179615|OTHER|surface hardness test for denture teeth|surface hardness test of denture teeth at insertion then after 6 months of use
41473235|NCT05601960|OTHER|anti-acne dermocosmetic|Topical application once daily for 2 months
40798619|NCT02487147|OTHER|Free Air Portable Air Powered Respirator|The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.
40798620|NCT02487147|OTHER|N95 Respirator|The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
40798621|NCT05233501|PROCEDURE|low level laser therapy|adjunctive application of low level laser therapy to non-surgical periodontal treatment
40798622|NCT05233501|PROCEDURE|non-surgical periodontal treatment|standart periodontal therapy
40798623|NCT06552845|DIAGNOSTIC_TEST|LGE-MRI Scan|Participants will receive LGE-MRI scan before catheter ablation and 3 months after catheter ablation
40798624|NCT05631314|PROCEDURE|operative treatment|Operative treatment can consist of open reduction and volar and/or dorsal plating or closed reduction and fixation with K-wires, external fixateur.
40798625|NCT05631314|PROCEDURE|non-operative treatment|Non-operative treatment will consist of immobilization in a below the elbow cast for 4-6 weeks with or without prior closed reduction.
40798626|NCT00048945|DRUG|PEGASYS|
40798627|NCT04501601|DIETARY_SUPPLEMENT|Fruit and vegetable solid drink|weight loss program supplement
41473236|NCT00504478|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 supplement will be given in addition to high complex carbohydrate diet.
41473237|NCT00504478|OTHER|high complex carbohydrate diet|
41473238|NCT01800435|DRUG|aPCC, aPCC + TXA|Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
40798628|NCT03743545|OTHER|low speed drilling without irrigation|comparing between conventional implant placement drilling speed with irrigation and experimental arm (low speed without irrigation)
40798629|NCT04474197|DRUG|VX-864|Tablets for oral administration.
40798630|NCT04474197|DRUG|Placebo|Placebo matched to VX-864 for oral administration.
40798631|NCT01557101|PROCEDURE|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
41315507|NCT06179615|OTHER|wear resistance of denture teeth measurement|2D, Vertical wear, 3D Volumetric wear were measured for denture teeth
41315508|NCT03811717|OTHER|FAST+EX|Participants will perform 2-hours of low-intensity arm exercise (8 x 15 min bouts of arm ergometer exercise separated by 10 min of rest) during an 8-hour fast.
41315509|NCT03811717|OTHER|FAST|Participants will complete an 8-hour fast.
41315510|NCT04758429|DEVICE|Machine-learning Algorithm|System technology/Software
41315511|NCT06048406|COMBINATION_PRODUCT|Health education|The intervention group will receive a health education intervention focused on influenza vaccination literacy, while the control group will continue with their standard school health education without any additional intervention. An influenza vaccination health education including topics such as the importance of influenza vaccination, benefits of vaccination, and vaccination methods, will be developed and reviewed by an expert group. The package for the intervention group will include educational activities, distribution of promotional materials, vaccination services, and distribution of vaccination souvenirs.
41315512|NCT01147081|BIOLOGICAL|BEGRIVAC|126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)
41315513|NCT02517151|DRUG|Ferric carboxymaltose|
41315514|NCT02517151|DRUG|Placebo|
41315515|NCT02961712|BIOLOGICAL|NK cells|single intravenous injection of NK cells (0.9\~1\*10\^9)
41315516|NCT02961712|BIOLOGICAL|amniotic epithelial cells|single intrathecal injection of amniotic epithelial cells
41315517|NCT00343291|BIOLOGICAL|Cetuximab|Administered intravenously
41315518|NCT00343291|BIOLOGICAL|Bevacizumab|Administered intravenously
41315519|NCT00343291|DRUG|Paclitaxel|Administered intravenously
41315520|NCT00343291|DRUG|Carboplatin|Administered intravenously
41473239|NCT01800435|DRUG|rFVIIa, rFVIIa + TXA|NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
41473240|NCT05909917|OTHER|Half-Day First Responder Training|Participants in both study arms will undergo a half-day first responder training course designed for laypeople. The course will consist of five curricular categories: scene management, airway and breathing, hemorrhage control, fracture management, and victim transport. Course material will not differ between in-person and virtual arms, however the method of information dissemination will vary.
41473241|NCT02309424|DIETARY_SUPPLEMENT|Vinegar|0,50mmol vinegar (6% acetic acid)
41473242|NCT02309424|OTHER|Placebo|50 ml water
41473243|NCT03901391|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole Exome Sequencing
41473244|NCT03443518|PROCEDURE|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark for Psoas Compartment Block (PCB)
41315521|NCT06373172|OTHER|virtual simulation-based education program|"We used vSim® for Nursing - Nursing Medical-Surgical as the virtual simulation-based education program. Four modules were included: (a) acute myocardial infarction, (b) diabetes mellitus, (c) transfusion, and (4) asthma. Each module learning sessions was conducted based on scenarios, which consisted of five steps: Suggested reading, Pre-simulation quiz, vSim, Post-simulation quiz, and Guide reflection questions. For each module, the intervention was performed for two hours. The participants attended four module learning sessions and received eight hours of training. Debriefing using guided reflection questions were completed in the form of a team reflection, followed by an instructor-learner discussion and feedback for 20 minutes of each module."
41315522|NCT02344420|PROCEDURE|Echocardiography|"The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.~Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization."
41315523|NCT02344420|BEHAVIORAL|Minnesota Living Heart Failure Questionnaire (MLHF)|MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
41315524|NCT02344420|PROCEDURE|Six minute walk test|The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
41315525|NCT02344420|BEHAVIORAL|Self assessment score|patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
41315526|NCT00718757|DRUG|Dexamethasone|5 doses given on Days 6-10
41315527|NCT00718757|DRUG|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
41315528|NCT00718757|DRUG|Vincristine|"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~\* Patients \< 1 year of age or \< 10kg in weight: Vincristine 0.05 mg/kg"
41315529|NCT00261326|DRUG|simvastatin|80 mg once daily
41315530|NCT00261326|DRUG|placebo|calcium tablets once daily
41315531|NCT03192072|DIAGNOSTIC_TEST|Host Gene Expression|comparison to retrospective clinical adjudication
41473245|NCT03443518|PROCEDURE|Local Anesthesia infiltration|Lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration.
41473246|NCT03443518|DRUG|Normal saline 0.9% IV infusion|Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).
41473247|NCT03443518|DRUG|Remifentanil infusion|Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
41473248|NCT06122233|BEHAVIORAL|Pulmonary Fibrosis self-management package and smartphone application|"The pulmonary fibrosis package includes modules on understanding treatment options for pulmonary fibrosis, managing medication and side effects, understanding and accessing clinical trials, managing shortness of breath, managing fatigue and mood, managing co-existing conditions, the role and importance of pulmonary rehabilitation and regular physical activity, role of oxygen therapy, smoking cessation advice and support, accessing community support, and communicating with others when living with pulmonary fibrosis.~The RE-BUILD app is used as a tool for data collection and to help participants self-monitor their disease over time. Participants enter their health data, including baseline conditions, medications and diagnosis, pulmonary function results and supplementary oxygen use. It also tracks air quality data close to the participant as well as physical activity level (step count). The app also has links to ILD-related educational resources."
41473249|NCT00868296|DRUG|pantoprazole|
41473250|NCT03246906|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
41473251|NCT03246906|DRUG|Cyclophosphamide|Given IV
41473252|NCT03246906|DRUG|Cyclosporine|Given PO
41473253|NCT03246906|DRUG|Mycophenolate Mofetil|Given PO
41473254|NCT03246906|DRUG|Sirolimus|Given PO
41315532|NCT01743872|PROCEDURE|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
40798632|NCT01557101|PROCEDURE|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
41315533|NCT01743872|PROCEDURE|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
41002904|NCT01783951|BIOLOGICAL|DC-CIK|Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
41473255|NCT03358043|DEVICE|mechanical ventilation|Consecutive intubated pateints receiving mechanical ventilation with a PaO2/FiO2≤300 mmHg on positive end-expiratory pressure (PEEP) of 5 cmH2O or more and FiO2 of 0.3 or more.
41473256|NCT06360757|DIAGNOSTIC_TEST|NeuMoDx SARS-CoV-2 Assay|The NeuMoDx™ SARS-CoV-2 Assay is an automated, in vitro nucleic acid amplification test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal (NP) swabs in transport medium obtained from symptomatic individuals suspected of COVID-19 infection. The NeuMoDx SARS-CoV-2 Assay as performed on the NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System incorporates automated RNA extraction to isolate target nucleic acids from the specimen and real-time reverse transcription PCR targeting two conserved regions of the SARS-CoV-2 genome.
41473257|NCT01567241|OTHER|clinical hypnosis or relaxation music|25 minute tape recording
41473258|NCT01305876|BEHAVIORAL|yoga intervention|yoga session 2 x week over 3-1/2 months
40798633|NCT02344121|RADIATION|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
40798634|NCT02291783|DRUG|HTL0009936|Single dose
40798635|NCT02291783|DRUG|HTL0009936 placebo|Placebo single dose
40798636|NCT01506557|DIETARY_SUPPLEMENT|cholecalciferol|dose 800 IU/day for 6 month
40798637|NCT01506557|DIETARY_SUPPLEMENT|placebo|oil capsules
40798638|NCT02974140|DEVICE|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
41315534|NCT01743872|PROCEDURE|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
41315535|NCT01743872|PROCEDURE|Heparinized Normal Saline Injection|Media #4: Heparinized Normal Saline (Heparin NS) will be hand injected using 20 mL (2 U/mL) in antegrade fashion.
41473259|NCT05659524|OTHER|Nasal saline irrigation|"The following nasal care recommendations have been approved by the study protocol committee for patients randomized to the treatment arm with saline irrigations:~* Postoperative days 1 through 3: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily.~* Postoperative day 3 to week 12: patients will begin twice daily sinus irrigation rinse (e.g., NeilMed Sinus Rinse). They will perform 240 mL sinus rinses BID. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative."
41473260|NCT00078481|DRUG|Idebenone|
41473261|NCT00377078|DRUG|recombinant human lactoferrin|
41473262|NCT02113371|BEHAVIORAL|Intervention|
40798639|NCT02974140|PROCEDURE|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
40798640|NCT00601614|DRUG|temozolomide|
40798641|NCT00601614|DRUG|vandetanib|
41315536|NCT00900172|BIOLOGICAL|bevacizumab|
41315537|NCT00900172|DRUG|carboplatin|
41315538|NCT00900172|DRUG|paclitaxel|
41315539|NCT00900172|GENETIC|gene expression analysis|
41315540|NCT00900172|GENETIC|polymerase chain reaction|
41315541|NCT00900172|GENETIC|polymorphism analysis|
41315542|NCT00900172|OTHER|laboratory biomarker analysis|
41315543|NCT01554839|BEHAVIORAL|"Family of Heroes"|One hour online educational tool
41473263|NCT02480426|DEVICE|CT-image guidance|TIPS creation is performed under the guidance of 3D CT-image.
41473264|NCT02480426|DRUG|CO2 portograms guidance|TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
41473265|NCT05518916|OTHER|Nonfarmacology method|Yakson Method and Swaddling
41315544|NCT01554839|BEHAVIORAL|Baseline and Follow up Surveys|Baseline and follow up questionaires completed online
41473266|NCT04274582|DIETARY_SUPPLEMENT|chokeberry extract|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
41473267|NCT05418075|OTHER|Psychotherapy|If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.
41473268|NCT00190580|DRUG|valsartan|valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs
40798642|NCT00601614|OTHER|immunoenzyme technique|
41315545|NCT03093961|DEVICE|IASD implant|Single arm for implant
41315546|NCT02780765|DEVICE|heated humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)
41473269|NCT00190580|DRUG|Conventional antihypertensive drugs|Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
41473270|NCT03743090|DIAGNOSTIC_TEST|Polysomnography.|A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
41473271|NCT05833152|PROCEDURE|total knee arthroplasty|To observe the postoperative functional outcome of patients with knee extension lag at different angles
41473272|NCT03224520|BEHAVIORAL|Recommender CTHC|Enhanced Messaging
41473273|NCT03224520|BEHAVIORAL|Standard CTHC|Standard Messaging
41473274|NCT03224520|OTHER|Peer Recruitment|Tools to facilitate smokers' recruiting their peers
41473275|NCT03224520|OTHER|Standard Online Recruitment|Search Engine and Social Media Advertisements
41473276|NCT04526652|DRUG|Dexmedetomidine|Evaluating anxiety score in both arms
41473277|NCT04526652|DRUG|Placebo|Evaluating anxiety score in both arms
41473278|NCT03304782|OTHER|Fitbit activity tracker|Wearable device that records the number of steps a person takes throughout the day
41473279|NCT06603181|OTHER|conventional treatment|exercise and splint
41473280|NCT06603181|OTHER|phonophoresis|exercise, splint and phonophoresis
41473281|NCT06603181|OTHER|extracorporeal shock wave therapy|exercise, splint and ESWT
40798643|NCT00601614|OTHER|laboratory biomarker analysis|
40798644|NCT01094977|DRUG|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
40798645|NCT01094977|DRUG|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
40798646|NCT01094977|DRUG|Saline Placebo|
40798647|NCT02365610|DRUG|GWP42006|
40798648|NCT02365610|DRUG|Placebo Control|
41315547|NCT02780765|DEVICE|mist humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
41315548|NCT03448978|BIOLOGICAL|Descartes-08|autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
41315549|NCT03448978|DRUG|Fludarabine|intravenous fludarabine
41315550|NCT03448978|DRUG|Cyclophosphamide|intravenous cyclophosphamide
40798649|NCT01732510|DRUG|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
40798650|NCT01732510|DRUG|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
41315551|NCT06364865|DEVICE|laparoscopic procedure|Not applicable, subject requiring procedure will have a laparoscopic procedure performed according to the institutions standard of care procedures. There are no clinical procedures performed on the subject as part of this registry study. Surgeon will answer questionnaires regarding use of the device upon completion of the laparoscopic procedure.
41315552|NCT01897181|DEVICE|Hearing aids|Using hearing aids for 12 months
40798651|NCT03742310|DRUG|Vitamin D|Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
41315553|NCT01498237|DEVICE|Photoacoustic endoprobe|The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
41315554|NCT01498237|PROCEDURE|Photoacoustic endoscopy|Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
41315555|NCT02482441|DRUG|OMP-131R10|There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
41315556|NCT02482441|DRUG|FOLFIRI|Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
41315557|NCT00551538|DRUG|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
41315558|NCT00551538|DRUG|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
41315559|NCT03756740|OTHER|telerehabilitation and physical therapy|subject will receive the LBP exercises as a video to his/her mobile or e-mail
40798652|NCT00150215|DRUG|PF-00184562|
40798653|NCT00150215|DRUG|Olanzapine|
40798654|NCT02311036|OTHER|Comprehensive Rehabilitation|Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
40798655|NCT00584818|DRUG|PB127 for Injectable Suspension|"Stages 1 \& 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.~Stage 3 - will utilize infusion rate and dose established in Stages 1 \& 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
40798656|NCT04823728|GENETIC|Autoimmune encephalitis and paraneoplastic neurological syndromes|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
41002905|NCT01783951|DRUG|S-1|The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
41002906|NCT01783951|DRUG|Cisplatin|Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
41002907|NCT04144166|DEVICE|capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
41151710|NCT06415071|OTHER|No intervention|Exposures of interest would be clearly defined according to a specific research question and identified from the database
41151711|NCT06155123|DRUG|Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)|Monthly or quarterly mAbs administration for a year
41315560|NCT03756740|OTHER|control|subjects will receive the LBP exercises as printed pictures on paper
41315561|NCT02685891|OTHER|Playing tones during deep sleep|Playing tones time locked to slow waves (Duration:50ms, volume: 50dB)
41315562|NCT02685891|OTHER|sham condition|in the sham condition, no tones will be played
41315563|NCT04183699|DIAGNOSTIC_TEST|Prostate biopsy|MRI-targeted + systematic random prostate biopsy
41315564|NCT06011330|DRUG|Fruquintinib combined with anti-PD-1 antibodies|Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).
41315565|NCT06167642|DRUG|Ofatumumab|Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
41315566|NCT03072641|DIETARY_SUPPLEMENT|ProBion Clinica|
41315567|NCT01370057|DEVICE|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
41315568|NCT06402812|OTHER|Interview|A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.
41315569|NCT05829616|DRUG|QLS12004|Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
41315570|NCT01999855|OTHER|Phoniatric tests|
41315571|NCT03121833|DRUG|Endostar|Recombinant Human Endostatin Injection
41315572|NCT03121833|DRUG|Placebo|500ml 0.9% sodium chloride
41315573|NCT03121833|DRUG|AIM regimen / GT regimen|"Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)"
41315574|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Pre-filled syringe, 0.5mL dose volume
41315575|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intramuscular injection, 0.5mL dose volume
41315576|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intradermal injection, 0.2mL dose volume
41473282|NCT06045520|BEHAVIORAL|Information-Motivation-Behavioral Skills Model|1.-2.Meeting:Regarding the information component of the IMB model; Answers given by the adolescents to the epilepsy knowledge test, the topics on which the adolescent wants to get information will be agreed with the adolescent and an education training will be created.3.,4.,5.-6. Meeting:Personal motivation, which is the first step of the motivation component; A meeting will be held regarding the obstacles to the disease, attitudes and behaviors towards the disease. In order to strengthen social support systems, a one-session seizure management training will be planned with a person chosen by the adolescent from his parent or friend group.7-8. Meeting:Seizure self-efficacy and treatment compliance will be evaluated in the behavioral skills component. During training, achievable goals will be set to ask the adolescent to provide personal feedback, ask open-ended questions, engage in reflective listening, and increase personal and social motivation to comply with medical recommendations
41473283|NCT03258879|PROCEDURE|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
41473284|NCT03258879|PROCEDURE|Dural puncture epidural|DPE group: Dural puncture performed, but no medication will be injected intrathecally.
41473285|NCT02014441|DRUG|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10\^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10\^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
41473286|NCT04625062|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, participants view a dynamic display of the speech signal in the form of a real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants were cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency.
41473287|NCT04625062|BEHAVIORAL|Motor-based treatment|Motor-based articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract were used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
41473288|NCT00638794|DEVICE|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
40798657|NCT01282242|DRUG|IV rt-PA|open-label
40798658|NCT03861416|DRUG|L-arginine 1.4% 500 ml|Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
40798659|NCT03861416|DRUG|L-arginine 1.4% 250 ml + placebo 250 ml|Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
40798660|NCT03861416|DRUG|Placebo solution|Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
40798661|NCT04111796|OTHER|nature based solution for stress reduction|participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
41315577|NCT06142461|DEVICE|PharmaJet Stratis® Needle-Free Injection System|0.5mL dose injection
40798662|NCT00205153|BEHAVIORAL|Pharmacy TEAM monitoring and counseling|Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
40798663|NCT03079687|DRUG|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
40798664|NCT05597358|RADIATION|High Intensity Laser Therapy (HILT)|Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.
41315578|NCT06142461|DEVICE|PharmaJet Tropis® Needle-Free Injection System|0.1mL dose injection
41315579|NCT06282900|OTHER|University students|A cross-sectional study (Level IV evidence) will be conducted at the university (Acibadem University, Turkey). All students at the university will be invited to respond to a self-administered online survey. The survey will be prepared via Google Forms.
41315580|NCT05100316|OTHER|Screening Platform|Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study.
40798665|NCT05597358|RADIATION|Sham High Intensity Laser Therapy|Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
40798666|NCT04300504|OTHER|observational study|observational study
40798667|NCT00050830|DRUG|CI 1033|
40798668|NCT06403553|DIAGNOSTIC_TEST|Fecal Calprotectin|Fecal Calprotectin measurement on days 1and 3
40798669|NCT02201329|DRUG|Azacitidine|Azacitidine (subcutaneous)
40798670|NCT02201329|DRUG|Volasertib|Volasertib escalating doses (intravenous)
41151712|NCT04457011|DRUG|High dose Susu Xiao'er Zhike Granules 1 bag|High dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 20.25 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
40798671|NCT01500252|DEVICE|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
40798672|NCT01500252|DEVICE|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
40798673|NCT00799227|DRUG|Dexamethasone|700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System at Day 1 in the study eye.
40798674|NCT06436222|DEVICE|HVNI|Preterm infants with gestational age (GA) less than 32 weeks or birth weight less than 1500 grams. The infant has moderate respiratory distress (Downe score ≤ 6) detected within 24 hours after birth.
40798675|NCT00470002|DRUG|Somatropin|
40798676|NCT04858607|DIAGNOSTIC_TEST|Blood sample|Serology, immune status, T cell immunity, and T cell aging.
40798677|NCT04858607|DIAGNOSTIC_TEST|Saliva sample|Antibody tests
40798678|NCT06205563|BEHAVIORAL|high-intensity interval training|High-intensity interval training (to significantly faster breathing, a significant increase in breathing depth, a significant increase in heart rate, sweating, and the need to stop exercising and adjust your breathing before you can speak; Energy expenditure (METy ≥6.00 in children) : Participants randomly assigned to HIIT will perform a 10-minute warm-up at 60-70% of their maximum heart rate (HRmax). After this, they will walk, run, or bike at 85-95% of their maximum heart rate for four sessions of four minutes each, with three minutes of active recovery (50-70% of their maximum heart rate) in between. The participants were given a five-minute cooling-off period at the end, for a total of 40 minutes of exercise. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
40798679|NCT06205563|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training (rapid breathing, rapid heart rate, slight sweating, but still able to talk easily; Energy expenditure (children METy) 3.00 to 5.99) : Participants randomly assigned to the MICT group will walk, run, or cycle continuously for 40 minutes at 60-70% HRmax. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
40798680|NCT05768958|OTHER|Exercise|45 min exercise bout performed on bicycle ergometer. The exercise bout will consist of a 10 min warm-up period at 40 % Watt max followed by 4 cycles of 4 min at 85 % Watt max and 3 min at 50 % Watt max. A cool-down period (7 min) will be performed at 40 % Watt max.
40798681|NCT05768958|OTHER|Control|45 min rest during the same time period as the exercise bout on exercise study visits.
40798682|NCT04314024|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
40798683|NCT04616313|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
41002908|NCT01816464|BIOLOGICAL|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.~The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe."
41002909|NCT02189421|DEVICE|ultra-slim upper endoscope|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
41315581|NCT04653818|DRUG|Velpatasvir/Sofosbuvir|sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.
41315582|NCT00607958|DRUG|tipranavir/ritonavir (dose reduction)|tipranavir/ritonavir 500/100 BID
41315583|NCT04346264|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design only a diagnostic testing|Only a diagnostic test (serum blood and antibody measurement) is planned
41315584|NCT04939025|PROCEDURE|Multi-interventional program|"1. Preoperative oral antibiotics and antibiotic enema of the rectal stump prior to the surgery~2. Routine and tailored lengthening measures of the mesentery~3. Intraoperative control of pouch vascularization using ICG~4. Early diagnosis and active assessment of the integrity of the anastomosis.~   1. Routine CRP-measurements at day 4 and 6 (after removal pouch catheter) in the non-diverted pouches with CT-scan with rectal contrast if any suspicion on a leak (elevated or rise in CRP. symptoms).~  2. Routine CRP-measurements at day 4 in the diverted pouches with endoscopy 10-14 days after pouch creation.~5. Endosponge vacuum assisted closure (EVAC) of the anastomotic defect aiming to close the defect within 10-14 days after diagnosis.~6. MRI assessment of the pouch after stoma closure preferably at one year to rule out chronic sepsis mimicking pouchitis or Crohn's disease."
41473289|NCT04241133|BEHAVIORAL|The UnProcessed Pantry Project (UP3)|UP3 uses the Social-Ecological Model to target multiple levels, including the food supply in the rural study location (community level), the food environment at the food pantry (environmental level), and participant dietary intake (individual level). It is hypothesized that UP3 will improve access to minimally processed foods and decrease access to ultra-processed foods at the food pantry, which will improve overall dietary quality of individuals as measured by the Healthy Eating Index-2015 compared to baseline and to the control group. Demographic and food security data will characterize the population. Psychosocial factors will be collected to understand changes in knowledge, attitudes, and perceptions about processed foods. Biomarkers of health data (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to determine the feasibility of measuring potential short-term health effects alongside UP3.
41473290|NCT01911104|BEHAVIORAL|Exercise|10 weeks of aerobic exercise
41473291|NCT04451928|DIAGNOSTIC_TEST|Serum sample analysis|Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels
41473292|NCT00010166|DRUG|gemcitabine hydrochloride|
41473293|NCT00010166|PROCEDURE|adjuvant therapy|
41473294|NCT00010166|RADIATION|radiation therapy|
41473295|NCT00897949|DRUG|rizatriptan benzoate (MK0462)|Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
41473296|NCT00897949|DRUG|Comparator: placebo|Placebo to rizatriptan
41473297|NCT01098994|DIETARY_SUPPLEMENT|Vitamin E|Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
41473298|NCT01098994|OTHER|Dummy pills|Daily placebo administration for 8 weeks
41315585|NCT03296865|DEVICE|Kinesio taping|"We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed."
41315586|NCT00005847|BIOLOGICAL|recombinant interferon alfa|
41473299|NCT02843659|DRUG|BMS-931699|Specified dose on specified days
41473300|NCT02843659|DRUG|BMS-986142|Specified dose on specified days
41473301|NCT02843659|DRUG|Placebo|Specified dose on specified days
41151713|NCT04457011|DRUG|Middle dose Susu Xiao'er Zhike Granules 1 bag|Middle dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 10.12 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
41315587|NCT00005847|DRUG|estramustine phosphate sodium|
41315588|NCT00005847|DRUG|isotretinoin|
41315589|NCT00005847|DRUG|mitoxantrone hydrochloride|
41473302|NCT01514825|DRUG|YM150|oral
41315590|NCT00005847|DRUG|paclitaxel|
41315591|NCT00005847|DRUG|vinorelbine ditartrate|
41473303|NCT01514825|DRUG|Placebo|oral
41473304|NCT02754024|PROCEDURE|Total shoulder arthroplasty (TSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
41473305|NCT02754024|PROCEDURE|Hemi shoulder arthroplasty (HSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
41473306|NCT02754024|DEVICE|Eclipse™ (Arthrex Inc., Naples, FL, USA)|stemless humeral head implant
41473307|NCT04265950|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
41473308|NCT00455416|DRUG|Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))|1000mgx5 daily
41473309|NCT00455416|DRUG|Selenium (L-Selenomethionine),|100mcgx2 daily
41473310|NCT00455416|DRUG|Garlic extract (Allicin)|6 garlic pearls daily
41315592|NCT03440853|BEHAVIORAL|TASCCI|TASCCI is a stepped-care collaborative care approach of pharmaco- and/or behavioral-therapy for a 12 week period. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference. A trained behavioral therapist will deliver weekly video conferencing sessions during dialysis treatment.
41473311|NCT00455416|DRUG|Pomegranate juice (ellagic acid)|Pomegranate juice 100%, 660ml /495 ml every second day.
41473312|NCT00455416|DRUG|Grape juice (resveratrol, quercetin)|Merlot grape juice 100%, 660ml /495 ml every second day
41473313|NCT00455416|DRUG|Green Tea (Epigallocathechin gallate)|Green Tea. 2 cups daily
40798684|NCT04616313|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
41151714|NCT04457011|DRUG|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 1.01 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
41151715|NCT01955720|DRUG|BI 655075|
41151716|NCT01955720|DRUG|BI 655075|
41151717|NCT01955720|DRUG|Placebo|
41151718|NCT01955720|DRUG|BI 655075|
41151719|NCT01955720|DRUG|Placebo|
41151720|NCT01955720|DRUG|Placebo|
41151721|NCT01955720|DRUG|Placebo|
41473314|NCT06529939|DRUG|Psilocybin|"Individuals will be given 15 milligrams (mg) of psilocybin orally, and will be asked to lay flat in a functional magnetic resonance imaging (fMRI) brain scanner. The following scans will be collected: anatomical and resting state; while they watch a scrambled film clip; while they watch an intact film clip; while they perform a mental imagery task; while they listen to two pieces of music.~Participants will then be given two questionnaires: one assessing their overall plot comprehension, and the other asking about their experience in the scanner. They will then be asked to perform a series of visual illusions tasks, and following, play a variety of web-based games assessing their cognitive function. After this, they will be interviewed by one of the study researchers about their overall experience before/during/after the scan."
40798685|NCT04616313|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
41151722|NCT01955720|DRUG|BI 655075|
41151723|NCT03527758|DEVICE|Flo TracIQ with HPI software|Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.
41151724|NCT04332991|DRUG|Hydroxychloroquine|"Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course."
41151725|NCT04332991|DRUG|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
41151726|NCT02713217|OTHER|Usual Care|This condition is defined as usual care occurring within Community Based Outpatient Clinics (CBOCs), which typically does not involve substantial integration of mental health care and primary care.
41315593|NCT03440853|OTHER|Technology Delivered Health Education Intervention|The Technology Delivered Health Education Intervention will deliver weekly video conferencing sessions to deliver online educational material from the National Kidney Foundation. These sessions will be delivered by a care coordinator.
41315594|NCT00051545|DRUG|Seocalcitol|
41315595|NCT06286358|DIAGNOSTIC_TEST|Kinocardiography|Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes
41315596|NCT03079349|OTHER|Medical Education|All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
41315597|NCT03079349|OTHER|Medical Intervention|All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
41315598|NCT03464123|OTHER|Standard cardiopulmonary resuscitation|Standard Advanced Life Support based on guidelines 2015, including mechanical chest compression device
40798686|NCT04616313|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity
40798687|NCT04616313|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
41315599|NCT06362499|DEVICE|Experimental Group|After the initial assessment, all volunteers will receive a POWERbreathe® classic light resistance device (POWERbreathe®, Nsc, Brazil), to carry out the training, and will be individually guided on how to use it and how to complete the protocol. They will perform a trial session to familiarize themselves with the device that will not be considered for analysis. Every week, volunteers will receive a telephone call from researcher 2, who will not participate in the evaluation, to confirm whether the exercise with the POWERbreathe® will be performed appropriately at the recommended frequency, intensity, and duration and whether there are any questions regarding the protocol. At the end of each week, participants will receive a video call from researcher 2 to adjust the device according to G1's weekly load progression.
41315600|NCT00747838|PROCEDURE|Minimally Invasive Maze Procedure|Minimally Invasive Surgical Correction of Atrial Fibrillation.
41315601|NCT00929734|DRUG|Rosuvastatin|10mg tablets, once daily in three months
41315602|NCT00929734|DRUG|Placebo|1 tablet, once daily in three months
41315603|NCT02326207|DEVICE|Infant Ventilator Circuit Dual Heated with Autofeed Chamber|
41315604|NCT03493685|DRUG|sparsentan|Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily
41315605|NCT03493685|DRUG|Irbesartan|target dose of 300 mg daily
41315606|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus Cisplatin)|"Participants will receive one of the following Gemcitabine-based systemic therapy alone:~Gemcitabine 1000mg/m2 and Cisplatin 25 mg/m2, each administered on Days 1 and 8 every 3 weeks (q3w)~Duration: 3 months (in addition to 3 months previously received)"
41315607|NCT06214572|RADIATION|RT|"Participants will receive radiation therapy in addition to systemic therapy Hypofractionated external image guided radiation to a dose of 40-55Gy in 10 sessions (up to 60Gy in 15 sessions) over 2-3 weeks.~This is followed by systemic therapy as in the Systemic therapy alone arm."
40798688|NCT04616313|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
40798689|NCT04616313|OTHER|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
41151727|NCT02713217|OTHER|Blended Telemedicine-Based Integrated Care|"This condition involves exposure to a blended collaborative care model that includes care management for depression and alcohol disorders and virtual co-location of doctoral-level mental health providers with prompt access through tele-video or telephone communication."
40798690|NCT01688245|BEHAVIORAL|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
40798691|NCT01688245|BEHAVIORAL|SMS Assessments|Weekly post-weekend drinking outcome assessments
40798692|NCT00164658|BEHAVIORAL|Familial risk assessment and personalized prevention messages|
40798693|NCT03102515|DRUG|USG-TAP block|
40798694|NCT03102515|DRUG|CIC|
40798695|NCT03306472|DRUG|Megestrol Acetate 40 MG|Progesterone Agonist
40798696|NCT03306472|DRUG|Megestrol Acetate 160 MG|Progesterone Agonist
40798697|NCT03306472|DRUG|Letrozole|Aromatase Inhibitor
40798698|NCT06341595|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1, 4-6 cycles
40798699|NCT06341595|RADIATION|Extraperitoneal radiation therapy|Radiotherapy using extraperitoneal radiation therapy, once a day, 5 times a week, 1.8-2 Gy/f, a total of 45-50.4 Gy (lymph node lesion radiation dose of 60-66 Gy)
40798700|NCT06341595|DRUG|Oxaliplatin|oxaliplatin: 130mg/m\^2, D1, Q3W, 4-6 cycles
40798701|NCT06341595|DRUG|S-1|S-1: 40mg/m\^2, bid, d1-14, 4-6 cycles
40798702|NCT02236273|BEHAVIORAL|Conventional text message reminder|Receipt of conventional text message notifying when due for next dose
40798703|NCT02236273|BEHAVIORAL|Enhanced text message reminders|Receipt of enhanced text messages notifying when due for next dose coupled with educational information
41151728|NCT01642771|DRUG|5-Fu/epirubicin/CTX following Docetaxel|Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
41151729|NCT01642771|DRUG|Docetaxel/capecitabine followed by XEC|Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
41315608|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus oxaliplatin)|"Gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 IV infusion on days 1 and 8 q2w.~Duration: 3 months"
41315609|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)|"Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 each administered on Days 1 and 8, q3w.~Duration 3 months Durvalumab (12 months)"
41315610|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)|Gemcitabine 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel 100 mg/m2, on days 1 and 8, q3w Duration: 3 months
41315611|NCT00669916|BIOLOGICAL|AIN457|single infusion of 3 mg/kg
41315612|NCT00669916|DRUG|Placebo|single infusion of placebo
41315613|NCT00188266|DRUG|cisplatinum combined with infusional fluorouracil (5 FU)|Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
41315614|NCT00050791|DRUG|Leptin|Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
41315615|NCT00050791|BEHAVIORAL|Very Low Calorie Diet|placebo injections
41315616|NCT00330863|DRUG|Risperidone microspheres|Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
40798704|NCT01712581|OTHER|Magnetic Resonance Imaging|
40798705|NCT04909034|DRUG|MS-20|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
40798706|NCT04909034|DRUG|Placebo|Oral solution without active ingredients
40798707|NCT04009018|OTHER|Perioperative Satisfaction Scale in Regional Anesthesia|This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
40798708|NCT03674970|DRUG|Nicotine Film|"Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting."
40798709|NCT00003587|DRUG|carboplatin|AUC=5.5 day 1 every 21 days X 3
40798710|NCT00003587|DRUG|cisplatin|IV cisplatin 100 mg/m\^2 day 1 every 21 days X 3
41315617|NCT00330863|DRUG|Risperidone|Target dose is 4 mg/day.
41315618|NCT00330863|DRUG|Olanzapine|Target dose is 15 mg/day.
41315619|NCT00330863|DRUG|Quetiapine|Target dose is 600 mg/day.
41315620|NCT00330863|DRUG|Ziprasidone|Target dose is 120 mg/day.
41315621|NCT00330863|DRUG|Aripiprazole|Target dose is 20 mg/day.
40798711|NCT00003587|DRUG|docetaxel|IV docetaxel 75 mg/m\^2 day 1 every 21 days X 3
40798712|NCT00003587|DRUG|gemcitabine|IV gemcitabine 1,000 mg/m\^2/day, days 1 and 8 every 21 days X3
40798713|NCT00003587|DRUG|paclitaxel|IV paclitaxel 225 mg/m\^2/day, day 1 every 21 days X 3
40798714|NCT00003587|DRUG|vinorelbine|IV vinorelbine 25 mg/m\^2/day, days 1 and 8 every 21 days X 3
40798715|NCT03444103|DRUG|Clazakizumab / Clazakizumab|Humanized monoclonal anti-IL-6 antibody
40798716|NCT03444103|DRUG|Placebo / Clazakizumab|0.9% Saline
40798717|NCT00003421|BIOLOGICAL|bleomycin sulfate|
40798718|NCT00003421|DRUG|ABVD regimen|
40798719|NCT00003421|DRUG|chlorambucil|
40798720|NCT00003421|DRUG|dacarbazine|
40798721|NCT00003421|DRUG|doxorubicin hydrochloride|
40798722|NCT00003421|DRUG|etoposide|
40798723|NCT00003421|DRUG|prednisolone|
40798724|NCT00003421|DRUG|procarbazine hydrochloride|
40798725|NCT00003421|DRUG|vinblastine sulfate|
40798726|NCT00003421|DRUG|vincristine sulfate|
40798727|NCT00003421|RADIATION|radiation therapy|
40798728|NCT02298868|DRUG|Baclofen|
40798729|NCT01262560|DRUG|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
41315622|NCT00330863|DRUG|Paliperidone|Target dose is 6 mg/day.
41315623|NCT01309438|DRUG|Rivaroxaban (normal renal function)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
41315624|NCT01309438|DRUG|Rivaroxaban (mild and moderate renal impairment)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
41002910|NCT03758742|BEHAVIORAL|High-Fruit Diet|Participants will consume a diet rich in whole fruit. During Phase I (Weeks 1-4; supervised controlled feeding), participants will gradually increase the amount of whole fruit they consume, eventually reaching 50% of calories from whole fruit. In Phase II (Week 5-12; supervised controlled feeding), participants will consume a whole fruit-rich, eucaloric diet that provides 50% of calories in the form of whole fruit. The non-fruit portion of the diet will be styled as a Mediterranean Diet. Participants will be required to approximately keep their weight stable during Phases I and II. In the Follow-Up Phase (Months 4-12; free-living), participants will be instructed to continue consuming at least one-third of their diet as whole fruit and to make healthy food choices.
41002911|NCT06228430|DRUG|Acyclovir 800 mg Tablet|Acyclovir 800 mg Tablet (Test Drug)
41002912|NCT06228430|DRUG|Zovirax™ 800 mg Tablet|Zovirax™ 800 mg Tablet (Reference Drug)
41002913|NCT00523185|DRUG|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
41315625|NCT01309438|DRUG|Erythromycin (normal renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
41315626|NCT01309438|DRUG|Erythromycin (mild and moderate renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
41315627|NCT04825236|OTHER|MyVoice:CF|"Participants will be given access to MyVoice:CF, a web-based decision aid (DA). This tool includes information about fertility, genetics, parenting, pregnancy, and breastfeeding within the context of cystic fibrosis (CF). The tool includes interactive elements designed to give users the ability to assess and reflect on their own reproductive goals and experiences and promote self-efficacy to engage in shared decision-making with their CF and women's health providers.~Upon completion of use of the decision aid, a summary sheet is generated based on the user's interaction with the tool. This summary is supplied to the provider prior to the next appointment."
41315628|NCT02769806|PROCEDURE|MRI|
41315629|NCT02298478|BEHAVIORAL|NO-FEAR Airlines|"NO-FEAR Airlines is a computer program that allows people who are afraid to fly to be exposed to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines divides the flight process into six sequential stages: (1) flight preparation, (2) a series of activities immediately prior to flying on the day of the flight, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway and landing, (6) sequence with images and auditory stimuli related to plane crashes."
41473315|NCT06529939|OTHER|Placebo|"Individuals will be given a placebo orally, and will be asked to lay flat in a functional magnetic resonance imaging (fMRI) scanner. The following scans will be collected: anatomical and resting state; while they watch a scrambled film clip; while they watch an intact film clip; while they perform a mental imagery task; while they listen to two pieces of music.~Participants will then be given two questionnaires: one assessing their overall plot comprehension, and the other asking about their experience in the scanner. They will then be asked to perform a series of visual illusions tasks, and following, play a variety of web-based games assessing their cognitive function. After this, they will be interviewed by one of the study researchers about their overall experience before/during/after the scan."
41473316|NCT00004490|DRUG|sodium dichloroacetate|
41473317|NCT00517543|DRUG|GW856553|
41473318|NCT05991596|BEHAVIORAL|Psychodramatic psychotherapy|"The psychodramatic psychotherapy will include a total of 14 meetings during a 6 months period and they will be held in presence (or remotely in case of COVID-19 government restrictions) as follows:~* 1 individual motivational interview;~* 1 weekly group session lasting 2 hours for 1 month (total 4 meetings);~* 1 group session every 15 days lasting 2 hours, for 5 months (total 10 meetings).~Patients will also receive the pharmacological treatment usually recommended for vitiligo."
41473319|NCT05991596|BEHAVIORAL|Self-help activities|"The self-help activities will include:~* 1 individual motivational interview;~* 1 weekly, 2 hours group meeting, for 1 month (total 4 meetings);~* 1 group meeting lasting 2 hours every 15 days, for 5 months (total 10 meetings).~Patients will also receive pharmacological treatment usually recommended for vitiligo."
41473320|NCT06617338|DIAGNOSTIC_TEST|CT scan unilateral knee|Intervention given to the Active Comparator arm
41473321|NCT06617338|DIAGNOSTIC_TEST|CT scan bilateral knee|Intervention given to the Experimental Arm
41473322|NCT02397213|DRUG|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.
40798730|NCT01262560|DRUG|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
41002914|NCT00523185|DRUG|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
41002915|NCT04982666|OTHER|Whole-Food, Plant-Based Diet|This diet is focused on nutritional needs with natural, minimally-processed plant foods.
41002916|NCT04982666|OTHER|FODMAP Diet|An elimination diet of fermentable, oligosaccharides, disaccharides, monosaccharides and polyols
41002917|NCT06416865|DRUG|AJU-C52L, AJU-C52|"AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.~AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks."
41002918|NCT06416865|DRUG|C52R1L, C52R1M|"C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.~C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks."
41002919|NCT04152122|DIAGNOSTIC_TEST|The dynamic stereopsis test|The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.
41002920|NCT00712296|DRUG|ASHMI 4|4 capsules orally twice a day
41473323|NCT02397213|DRUG|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
41473324|NCT05506358|DIAGNOSTIC_TEST|High performance liquid chromatography|High performance liquid chromatography (HPLC) using the D10 System by Bio-Rad Laboratories will be used as the gold standard test.
41473325|NCT05506358|DEVICE|Automated sickling test|The standard sickling test using 2% sodium metabisulphite will be augmented using an automated microscope (such as Octopi) and machine learning, and will be used as one of the low-cost tests.
40798731|NCT01262560|DRUG|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~1. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~2. Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
40798732|NCT03689608|OTHER|Intermittent Fasting (IF)|Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
40798733|NCT03689608|OTHER|Daily Restriction (DR)|Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
40798734|NCT03689608|OTHER|standard care (SC)|Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.
40798735|NCT02223052|DRUG|CC-486|Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
40798736|NCT02223052|DRUG|Vidaza|75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
40798737|NCT02819986|BEHAVIORAL|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
40798738|NCT05797051|DIAGNOSTIC_TEST|Microscopic hyperspectral imaging system|Microscopic hyperspectral imaging system
40798739|NCT00277810|DRUG|lecozotan SR (SRA-333)|one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
40798740|NCT00422877|DRUG|Taxoprexin|DHA-paclitaxel
40798741|NCT00718575|PROCEDURE|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
41151730|NCT00466856|DRUG|octreotide acetate|"Lung/liver Ratio Dose of SIR-Spheres~* \<10% Administer full dose of SIR-Spheres~* 10% to 15% Reduce dose of SIR-Spheres by 20%~* 16% to 20% Reduce dose of SIR-Spheres by 40%~* \>20% Do not give SIR-Spheres"
40798742|NCT02110849|RADIATION|Proton|Proton Therapy for Prostate Cancer
40798743|NCT04792788|PROCEDURE|Weaning from mechanical ventilation|Cross over study: 3 periods of 40 minutes in ventilation mode (NAVA or PSV); to register ventilator traces and cardiopulmonary parameters during the last 10 minutes of each period.
40798744|NCT01283438|DEVICE|Barricaid|Annular closure device
40798745|NCT01283438|DEVICE|Standard of Care|Standard Limited discectomy
40798746|NCT00897780|BEHAVIORAL|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
40798747|NCT01321255|DRUG|FDC|FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
40798748|NCT01321255|DRUG|Separately drugs, simvastatin, aspirin and ramipril|Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
40798749|NCT01018173|DRUG|placebo|sc weekly
40798750|NCT01018173|DRUG|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
40798751|NCT01756573|DRUG|Dexamthsone|
40798752|NCT01756573|DRUG|Bupivacaine|
40798753|NCT00143624|DRUG|Rosiglitazone maleate|See Detailed Description.
40798754|NCT00143624|DRUG|Placebo|See detailed description.
40798755|NCT03544905|DRUG|CYH33 for tablet|1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
41473326|NCT05506358|DIAGNOSTIC_TEST|HbS solubility test|Standard HbS solubility test currently used in Nepal (e.g. Sicklevue) will be used as one of the low-cost tests
40798756|NCT03498131|DRUG|3 mg Melatonin|3 mg melatonin once each day
40798757|NCT03498131|DRUG|5 mg Melatonin|5 mg Melatonin once each day
40798758|NCT02524236|DRUG|Botox injection in the prostate|transrectal access of prostatic injection
40798759|NCT01999244|BEHAVIORAL|Self-monitoring skills|
40798760|NCT01999244|BEHAVIORAL|Technology|
40798761|NCT01999244|BEHAVIORAL|Interventionist Contact|
40798762|NCT05737823|BEHAVIORAL|Carers-ID online support programme|The Carers-ID online programme, which consists of ten modules which cover topics including: promoting resilience, reducing anxiety, managing stress, accessing local supports, managing family conflict and information for siblings who are carers.
40798763|NCT05737823|BEHAVIORAL|Carers-ID online support programme - Wait-list control|The same programme as above delivered to the wait-list control after the T2 follow-up data has been collected.
40798764|NCT03282344|DRUG|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
41473327|NCT05506358|DEVICE|HemoTypeSC|A point-of-care lateral flow assay, HemoTypeSC (https://www.hemotype.com/), will be used as one of the low-cost tests
40798765|NCT03282344|DRUG|Nivolumab|360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
40798766|NCT05096117|DRUG|ASP8062|ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
40798767|NCT05096117|DRUG|Placebo|1 x per day for 6 weeks
41002921|NCT00712296|DRUG|ASHMI 12|12 capsules orally twice a day
41002922|NCT00712296|DRUG|Placebo|Placebo 6 capsules twice a day
41002923|NCT03171350|DIAGNOSTIC_TEST|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
41002924|NCT02361710|PROCEDURE|frozen embryo transfer|comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
41002925|NCT04977323|OTHER|TICK-B group|These interventions will use as distraction techniques.
41002926|NCT02583932|DRUG|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
41151731|NCT00466856|RADIATION|yttrium Y 90 resin microspheres|radiation
41151732|NCT00687128|BEHAVIORAL|Low-intensity treadmill exercise|Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
41151733|NCT00687128|BEHAVIORAL|Moderate-intensity treadmill exercise|Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
41315630|NCT03294928|OTHER|progressive increasing of PEEP level.|"four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.~Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).~Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).~Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry."
41473328|NCT05506358|DEVICE|Sickle SCAN|A point-of-care lateral flow assay, Sickle SCAN (https://www.biomedomics.com/products/hematology/sicklescan/), will be used as one of the low-cost tests
41473329|NCT05506358|DEVICE|Gazelle Hb Variant Test|A portable electrophoresis machine, Gazelle diagnostic device (https://hemexhealth.com/), will be used as one of the low-cost tests
41473330|NCT02498249|DEVICE|low level laser therapy|Will be performed irradiation with low-intensity laser in upper trapezius muscle
40798768|NCT02364037|BEHAVIORAL|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
40798769|NCT02364037|BEHAVIORAL|Contraceptive Education Session|Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
40798770|NCT02364037|DEVICE|Cost Support for IUDs and implants|Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
40798771|NCT00460655|DRUG|GSK1358820|botulinum toxin type A
40798772|NCT00460655|DRUG|Placebo|Placebo
40798773|NCT03215628|DIAGNOSTIC_TEST|TCEUS|Intravenous sulphur hexafluoride microbubbles
41002927|NCT02583932|BEHAVIORAL|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
41151734|NCT00687128|BEHAVIORAL|Non-aerobic stretching exercise|Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
41151735|NCT00768911|DRUG|CT-322|"Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week"
41315631|NCT00839878|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
41151736|NCT00768911|DRUG|Temozolomide|"75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met"
41151737|NCT00768911|PROCEDURE|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
41315632|NCT03217773|PROCEDURE|ESD|Refer to arm description
41473331|NCT02498249|DEVICE|Placebo low level laser therapy|Will be not performed irradiation with low-intensity laser in upper trapezius muscle
41473332|NCT02430415|DEVICE|laryngoscope-assisted lightwand intubation|laryngoscope-assisted lightwand intubation
41002928|NCT03070353|DRUG|Dextran 40|Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
41151738|NCT00575900|BEHAVIORAL|dietary intervention|12 weeks of dietary intervention
41151739|NCT02884336|OTHER|No intervention|
41151740|NCT06058156|DRUG|SAR444656 (KT-474)|Oral Tablet
41151741|NCT06058156|DRUG|Placebo|Oral Tablet
41151742|NCT03191526|DRUG|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks.
41151743|NCT03191526|DRUG|Placebo (saline)|Intravenous injection every 12 weeks.
41151744|NCT00291863|DRUG|Simvastatin|
41315633|NCT03217773|PROCEDURE|TAMIS|Refer to arm description
41473333|NCT02430415|DEVICE|traditional lightwand intubation|traditional lightwand intubation
41473334|NCT01258088|DRUG|AN2728 Ointment|5mg/cm2, BID
41473335|NCT01258088|DRUG|AN2728 Vehicle|5mg/cm2 BID
41473336|NCT06365294|PROCEDURE|Rescue extracranial stenting|Rescue extracranial stenting in tandem occlusions
41473337|NCT06224855|DRUG|DXC006|"Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose."
41315634|NCT05869539|DRUG|Combination of Tumor-infiltrating lymphocyte transfer with ANV419|"The study uses a personalized IMP (investigational medicinal product), i.e. TIL product in combination with ANV419.~Day 0: Autologous TIL: (minimum 5 x 10\^9 and up to 2x 10\^11 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion. Actual body weight will be used to calculate the dose of ANV419.~Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to calculate the dose of ANV419."
41315635|NCT00954837|PROCEDURE|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
41315636|NCT04102735|DEVICE|Under-the-nose facemask|Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.
41315637|NCT04102735|DEVICE|Over-the-nose facemask|Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
41151745|NCT02849509|DRUG|Pradaxa (dabigatran)|Pradaxa (dabigatran etexilate)110mg or 150mg
41151746|NCT02849509|DRUG|Vitamin K antagonist|Vitamin K antagonist or Pradaxa
41151747|NCT05747352|OTHER|closed-loop hybrid insulin administration|observational non-interventional study
41315638|NCT02670330|DRUG|SD-101-6.0 cream|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
41315639|NCT00325650|DRUG|Rimonabant|Tablet, oral administration
41315640|NCT00325650|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
41315641|NCT03899532|DEVICE|Remote Ischemic Conditioning|Standard manual blood pressure cuff
41315642|NCT03899532|OTHER|No-Remote Ischemic Conditioning|No-Remote Ischemic Conditioning
41315643|NCT06466928|PROCEDURE|Total pancreatectomy|Surgical removal of the entire pancreas
41315644|NCT04989504|OTHER|Best Practice|Receive standard of care
41315645|NCT04989504|DEVICE|Wound Dressing Material|Apply Mepitel Film
41315646|NCT04989504|OTHER|Quality-of-Life Assessment|Ancillary studies
41473338|NCT02087176|DRUG|AZD1775|AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
41473339|NCT02087176|DRUG|AZD1775 Placebo|Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
40798774|NCT06533384|DRUG|As per the germline BRCA1/2 mutation status, the selection of either Fluzopalil or capecitabine in combination with Camrelizumab is made for adjuvant therapy.|As per the germline BRCA1/2 mutation status, the selection of either Fluzopalil or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
40798775|NCT06200168|DEVICE|Electroacupuncture|"The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz."
41315647|NCT04989504|OTHER|Questionnaire Administration|Ancillary studies
41315648|NCT00033033|DRUG|Reserpine|
41315649|NCT04202653|DRUG|ETV|entecavir 0.5 mg qd
41315650|NCT04202653|DRUG|TQ-A3334|TQ-A3334 po qw
41315651|NCT04202653|DRUG|TQ-B2450|TQ-B2450 q3w iv
41315652|NCT01321840|PROCEDURE|Specific Autoregulation Therapy (SART)|Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
41315653|NCT05027516|DRUG|Rocephin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection
41315654|NCT05027516|DRUG|Azithromycin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
41473340|NCT02087176|DRUG|Antimitotic Agent|The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
41315655|NCT01255891|RADIATION|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
41315656|NCT02066753|PROCEDURE|Mild therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature between 32-34°C.
41315657|NCT03553602|RADIATION|HDR Brachytherapy + EBRT + STAD|"HDR Brachytherapy implant: 2 fractions of 12 Gy to the prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET- positive lesions.~6 months hormonal therapy(LHRH agonist and anti-androgen\[until end of radiotherapy\])"
41315658|NCT05203276|DRUG|Envafolimab|300mg，SC，Q3W，d1
41315659|NCT05203276|DRUG|Endostar|210mg，CIV，Q3W，d1-3
41473341|NCT02087176|DRUG|pegfiligrastim|Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
41002929|NCT04454372|OTHER|demographic and clinical data obtained from hospital's electronic medical record.|This retrospective observational study. . Demographic and severity data will include age, sex, SAPS 3 and SOFA scores at admission, nutritional risk determined by NRS-2002 and commodities. Clinical and laboratory data on arrival at the ICU including PaO2 / FIO2, blood count and PCR D-dimer, ferritin, fibrinogen, DHL. Drug interventions including use of hydroxychloroquine, corticosteroids, heparin, tocilizumab. Characteristics of invasive and non-invasive respiratory support, use of prone position and ECMO and vasoactive drugs. The main complications, acute kidney injury requiring renal replacement therapy, secondary infectious complications will be documented as well as the outcomes.
41315660|NCT04550611|OTHER|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
41002930|NCT01806896|DRUG|PF-02545920|"* Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Treatment for 28 days."
41315661|NCT04550611|OTHER|plasma exchange|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
41473342|NCT05592093|DRUG|Korean red ginseng capsule (marketed product in Korea)|Korean red ginseng capsule (marketed product in Korea) KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time.
41473343|NCT05592093|DRUG|Korean red ginseng capsule(placebo)|"KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group.~The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time."
41315662|NCT00574119|DRUG|spironolactone|spironolactone 50 mg daily for 6 months
41315663|NCT05166759|DEVICE|Doppler ultrasound|Pulmonary artery pressure and right heart function will be assessed using Doppler ultrasound
41002931|NCT01806896|DRUG|Placebo|"- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
41002932|NCT01806896|DRUG|PF-02545920|"* 5mg dose~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days."
41002933|NCT01806896|DRUG|Placebo|"* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days."
41002934|NCT02734888|OTHER|No drug or device, only a test. The test is called a PET/CT|A single PET/CT scan will be performed
41002935|NCT03464864|DRUG|Treprostinil Inhalation Powder|Single ascending dose
41002936|NCT04257682|DRUG|Bupivacaine|Bupivacaine is a long-lasting dense sensory-motor block that can last up to four hours. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 6.75 mg to 8.25 mg for the knee, and 7.5 mg to 9 mg for the hip.
41315664|NCT00754728|DEVICE|JACTAX DES|Drug Eluting Stent
41315665|NCT00844064|DRUG|AP 12009|"Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles"
41315666|NCT06504485|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
41315667|NCT01940510|DRUG|RO5424802|Single dose without (Day 1) and with (Day 17) co-administration of rifampin
40798776|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
40798777|NCT06200168|DEVICE|Sham electroacupuncture|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation."
41002937|NCT04257682|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic that is known for its differential sensory-motor block. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 9 mg to 11 mg for the knee, and 10 mg to 12 mg for the hip.
41002938|NCT04257682|DRUG|Mepivacaine|Mepivacaine is an intermediate-acting local anesthetic producing shorting and motor-sparing blocks. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 40 mg to 50 mg for the knee, and 45 mg to 55 mg for the hip.
41002939|NCT03657888|BEHAVIORAL|Family Club Denmark (FCD)|Participation in Family Club Denmark
41315668|NCT01940510|DRUG|rifampin|Multiple doses Days 8-16 and Days 17-20
41315669|NCT05800106|DRUG|Sunitinib malate capsules generic product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
41315670|NCT05800106|DRUG|Sunitinib malate capsules reference product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
41315671|NCT05605041|DEVICE|Headspace|Headspace is an app that allows users to practice mindfulness through guided meditation
41473344|NCT02761213|DRUG|Oral sulfate solution (OSS)|Oral sulfate solution (OSS)
41473345|NCT02761213|DRUG|2-L PEG/Asc|Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
41473346|NCT01297322|OTHER|Manual compression|Standard of Care
41473347|NCT01297322|DEVICE|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
41002940|NCT03657888|OTHER|Wait-list control|Participants on the waiting list
41002941|NCT01838005|BEHAVIORAL|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
41315672|NCT03529136|BIOLOGICAL|UC-MSC|Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
41315673|NCT01380444|PROCEDURE|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
41473348|NCT00398684|DRUG|Single dose nevirapine to the mother and to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
41473349|NCT00398684|DRUG|Single dose nevirapine to the mother and placebo to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
41473350|NCT00398684|DRUG|Single dose placebo to the mother and to the child|One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
41473351|NCT03176524|DRUG|BioChaperone® glucagon formulation 1|Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
41473352|NCT03176524|DRUG|BioChaperone® glucagon formulation 2|Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
41473353|NCT03176524|DRUG|GlucaGen® HypoKit®|Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
41315674|NCT01380444|PROCEDURE|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
41315675|NCT00609219|BIOLOGICAL|autologous EBV specific CTLs|"30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 2 x 10\^7 cells/m2~Group Two:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 1 x 10\^8 cells/m2~Group Three:~Day 0 - 1 x 10\^8 cells/m2 Day 14 - 2 x 10\^8 cells/m2"
41315676|NCT00738374|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
41315677|NCT00738374|DRUG|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
40798778|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
40798779|NCT02840318|OTHER|Compassion Intervention|See arm description
40798780|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
40798781|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
40798782|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
40798783|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
40798784|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
40798785|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
40798786|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
40798787|NCT00436046|BIOLOGICAL|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
41002942|NCT05418452|DRUG|Metformin|metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects
41002943|NCT03759756|OTHER|AI presentation|AI presentation means the automatic diagnosis information of AI and AI presentation means it is visible in the group.
41002944|NCT03759756|OTHER|no AI presentation|AI presentation means the automatic diagnosis information of AI and no AI presentation means it is invisible in the group.
41002945|NCT02456922|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
41002946|NCT06065826|OTHER|Assessment|All subjects will be assessed for FHP by taking a lateral view picture to calculate the CVA using the Kinovea software. Each subject with FHP will be examined for myofascial trigger points done by the therapist finger to palpate bilaterally on tender nodules in masticatory and neck muscles. Then using a pressure algometer, the PPT value will be scored for each trigger in each muscle bilaterally. Masticatory muscle endurance will be measured by asking the subject to bite on load sensor for as long as the subject can until exhaustion. Using a stopwatch, the time will be recorded in seconds. Using the craniocervical extension endurance test, the subject will lie prone with their head unsupported and with a bubble inclinometer attached to their head. Using a stopwatch, time in seconds will be recorded to test how long the subject can sustain the neck in neutral position. Finally, a smartphone addiction scale will be answered by the subject to identify how much they are addicted to its use.
40798788|NCT00436046|BIOLOGICAL|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
40798789|NCT02689414|PROCEDURE|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
41002947|NCT04193176|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
41002948|NCT04193176|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
41002949|NCT00481442|DRUG|Phenylephrine|
41315678|NCT02999568|OTHER|Physical exercise|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
41315679|NCT01225471|BIOLOGICAL|CDCA1|CDCA1-A24-56 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. This peptide conjugated with Montanide ISA 51 as an adjuvant.
41315680|NCT04897282|DIAGNOSTIC_TEST|UCRI|Biomarker panel and algorithm
41315681|NCT06186752|BEHAVIORAL|MyIBD|MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.
41315682|NCT02909569|DRUG|INCB039110|All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
41315683|NCT03522350|DEVICE|EmbryoScope|Standard of care arm
41315684|NCT03522350|DEVICE|EmbryoScope+|Experimental arm
41315685|NCT06071299|BEHAVIORAL|FCC|Children evaluated for abusive injuries. Caregiver offered meeting with IPV advocate during visit (survivor-centered care, immediate access to services; continued engagement with advocate for ongoing needs). Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
41315686|NCT06071299|BEHAVIORAL|CCC|Children evaluated for abusive injuries. Medical provider offers IPV resources to caregiver. Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
41315687|NCT01750632|PROCEDURE|Orchiectomy|The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.
41315688|NCT02912598|DEVICE|Mallinckrodt™ Endobronchial Tube|
41315689|NCT02912598|DEVICE|Fuji Uniblocker™|
41473354|NCT06055608|DRUG|Sirolimus|Participants in Group 1 will transition to sirolimus therapy on day 14 (+/- 5 days) - weight \<40 kg will receive 3mg/m\^ 2, with maintenance dose of 1 mg/m\^2 divided BID - weight \>= 40kg will receive 6mg/m\^ 2, with maintenance dose of 2 mg daily
41473355|NCT06055608|BIOLOGICAL|Belatacept|Belatacept will be administered as an intravenous infusion over 30 minutes. The belatacept dose for the study is 10 mg/kg on post-operative day (POD) 1, 5, 14, 28, 56, 84 for the first 3 months, followed by 5 mg/kg every 4 weeks (+/-4 days), starting on month 4 until month 24
41473356|NCT06055608|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil-MMF will be initiated at 600 mg/m\^2 BID until tacrolimus is at therapeutic levels, then 450 mg/m\^2 BID
41473357|NCT06055608|DRUG|Tacrolimus (Group1)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels. Participants in Group 1 will be transitioned to sirolimus 2-4 weeks post-transplant
41002950|NCT01972269|DRUG|Bupivacaine-fentanyl|0.125% bupivacaine-fentanyl 5mcg/mL
41002951|NCT01972269|DRUG|Lidocaine|2% lidocaine
41002952|NCT05262205|OTHER|measuring depth of anesthesia and its relation to the globe|measuring feasibility of BIS monitor in detecting depth of anesthesia in pediatric population and whether it will be beneficial as a tool for helping anesthesiologist in maintaining central globe alignment
41002953|NCT03848845|DRUG|belantamab mafodotin|belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
41002954|NCT03848845|DRUG|Pembrolizumab|Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
41002955|NCT02069522|OTHER|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
41002956|NCT02069522|OTHER|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
41315690|NCT02912598|DEVICE|ETView VivaSight™-SL+EB|
41315691|NCT02912598|DEVICE|COOK© Arndt Endobronchial Blocker|
41315692|NCT05804006|OTHER|Conventional physiotherapy followed by HIIT-REC program|The experimental protocol will be preceded by 30 minutes of conventional physiotherapy followed by 15 min the rest period; then the HIIT-REC procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload at 50 rpm for weeks 1-2 and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (4 to 6 repetitions). The training intensity will progress similarly by 5% peak workload two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5
41315693|NCT04612153|OTHER|Epidemiologic|Epidemiologic study. Observational, transverse study
41315694|NCT03141372|DEVICE|Void Trial using Foley catheter|A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
41315695|NCT05877651|BIOLOGICAL|MASCT-I injection|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
41315696|NCT01933165|DEVICE|LipiView|
41315697|NCT06079775|DRUG|Xeruborbactam Oral Prodrug|Experimental
41315698|NCT06079775|DRUG|Ceftibuten|Experimental
41315699|NCT06079775|DRUG|Xeruborbactam Oral Prodrug Placebo|Placebo Comparator
41315700|NCT06079775|DRUG|Ceftibuten Placebo|Placebo Comparator
41473358|NCT06055608|DRUG|Anti-Thymocyte Globulin (ATG)|Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function
41473359|NCT06055608|DRUG|Tacrolimus (Group 2)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels
41473360|NCT00920114|BIOLOGICAL|blood sample|
41315701|NCT00192036|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
41315702|NCT00192036|DRUG|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
41315703|NCT00192036|RADIATION|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
41315704|NCT03119844|OTHER|Exercise|The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.
41315705|NCT03119844|OTHER|Placebo Phototherapy|Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
41315706|NCT03119844|OTHER|Active Phototherapy|Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
41315707|NCT04311619|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein per injection
41315708|NCT04311619|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
41315709|NCT02010437|DRUG|Sodium Tetradecyl Sulphate (STS)|
41315710|NCT06013995|DRUG|BMS-986326|Specified dose on specified days
41315711|NCT06013995|OTHER|Placebo for BMS-986326|Specified dose on specified days
41315712|NCT02571751|DEVICE|UNIGEL Silicone Gel-Filled Breast Implant|
41315713|NCT01907984|DRUG|Diclofenac|
41315714|NCT01907984|DRUG|Midazolam|
40798790|NCT02689414|PROCEDURE|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
41315715|NCT00676936|DRUG|Methylprednisolone|Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
41315716|NCT00676936|DRUG|Placebo|Custom made capsules, Lactose, administered twice daily, intervention period 7 days
41315717|NCT04777721|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
41315718|NCT04981574|OTHER|Massage and stretching on neck area and thoracic thrust manipulation|"1. Twenty (20) minutes massage in the neck area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the neck area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching will be made on the trapezius superior, musculus levator scapulae and sternocleidomastoideus holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
41315719|NCT04981574|OTHER|Massage and stretching on low back area and thoracic thrust manipulation|"1. Twenty (20) minutes massage in the low back area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the low back area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching activities will be: cat-cow pose, lower back stretches and knee twist holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
41315720|NCT03309787|BEHAVIORAL|eHealth|Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
41315721|NCT01825655|DRUG|Cetirizine|
41315722|NCT01825655|DRUG|Placebo or sugar pill|
41315723|NCT06108869|OTHER|ABT Online Programme|"When the study begins, participants meet each week on Microsoft teams for a 6 week period. Each session will last approximately 1 hour. There will be a maximum of six other participants and two facilitators present at each session. Each session will consist of:~* A short ABT practice~* An educational component related to the development of our ABT practice~* A group discussion on the week's topic and how it relates to you and your diagnosis"
41315724|NCT06108869|OTHER|Delayed Control group|Participants will still meet as a group for first two weeks, before beginning with the ABT practice.
40798791|NCT00475592|DEVICE|Esophageal Capsule Endoscopy|
40798792|NCT00475592|DEVICE|Upper Gastrointestinal Endoscopy|
40798793|NCT00593177|DRUG|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
41315725|NCT01991938|DRUG|VS-5584|
41473361|NCT00258375|DRUG|custirsen sodium|
41473362|NCT00258375|DRUG|docetaxel|
40798794|NCT05726318|DRUG|Antibiotics|Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoaxole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
40798795|NCT00909441|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
40798796|NCT05774015|DIETARY_SUPPLEMENT|Magnesium Oxide tablet 500 mg|To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level
41315726|NCT05294211|DEVICE|M•care™ System|The M•care™ System will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
41315727|NCT05294211|DEVICE|Cardiotocography (CTG)|A standard of care CTG device will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
41315728|NCT05392894|PROCEDURE|Haploidentical stem cell transplantation|Stem cell transplant from bone marrow or peripheral blood from haploidentical donor using standard nationally approved transplant procedure.
41315729|NCT05392894|OTHER|Standard medical care|Standard medical care may include any currently available therapies for SCD patients. These may or may not include regular elective transfusion therapy or medications such as hydroxycarbamide.
41315730|NCT06101082|BIOLOGICAL|Intravenous infusion anti-HER2-CAR-T cell|Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10\^6 CAR-T cells/kg, 3×10\^6 CAR-T cells/kg, and 1×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
41315731|NCT05775744|OTHER|Tight postpartum blood pressure control|The standard of care for patients with pregnancy induced hypertension is to start antihypertensive therapy if blood pressures are consistently over 150/100 mm Hg. There is no established standard of care for titrating blood pressure medication in the postpartum period for those with chronic hypertension and the approach to these patients varies by institution. The intervention in this study will be to start antihypertensive medications at a lower blood pressure cutoff, which is commonly used in the non-pregnant patient population to more tightly control blood pressure. Remote patient monitoring may be considered standard of care. The blood pressure targets chosen for this study are considered to be standard of care for non-pregnant people.
41315732|NCT05869552|OTHER|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management. The intervention will consist of an initial session with the youth focusing on accessing mental health care plus case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to three months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
41315733|NCT05869552|OTHER|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 3 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training and support on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 3 months.
41315734|NCT02453009|DRUG|Docetaxel|Pharmaceutical form:solution Route of administration: intravenous
41315735|NCT02453009|DRUG|Prednisone|Pharmaceutical form:tablet Route of administration: oral
41315736|NCT02453009|DRUG|Enzalutamide|Pharmaceutical form : soft gelatin capsules Route of administration: oral
41315737|NCT00503880|BIOLOGICAL|filgrastim|subcutaneously one day prior to treatment
41315738|NCT00503880|DRUG|clofarabine|single IV dose over 1 hour daily for 5 days
41315739|NCT00503880|DRUG|cytarabine|subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
41473363|NCT01330667|DIETARY_SUPPLEMENT|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
41473364|NCT01096979|DRUG|LIPO-102|subcutaneous injection
40798797|NCT05221567|BEHAVIORAL|Psychotherapy|Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)
41473365|NCT01096979|DRUG|Placebo|Placebo
41473366|NCT04461210|DIAGNOSTIC_TEST|Thermographic Imaging and Mechanical Pain Assessment|Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera
41473367|NCT03715686|PROCEDURE|wire localization|Pathologically proven positive axillary lymph node will be clip-marked before the initiation of neoadjuvant chemotherapy. After the completion of neoadjuvant chemotherapy, a wire will be placed to localize the clip-marked node before surgery. During surgery, a standard sentinel lymph node biopsy will be performed as well as the removal of the wire localized node. ALND will be performed in all participants.
41473368|NCT05184699|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Patients with psoriatic disease will be randomized to receive food supplement Endocalyx for 4 months.
41473369|NCT05184699|DIETARY_SUPPLEMENT|Placebo|Patients with psoriatic disease will be randomized to receive placebo for 4 months.
40798798|NCT01947283|BEHAVIORAL|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
41473370|NCT02168725|DRUG|briciclib|
40798799|NCT01947283|BEHAVIORAL|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
41002957|NCT02258204|DRUG|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
41002958|NCT02258204|DRUG|Placebo|
41473371|NCT00356824|DRUG|Amodiaquine|200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
41473372|NCT00356824|DRUG|Artesunate|50 mg oral tablet taken daily for 3 days under direct supervision at study clinic
41315740|NCT00503880|GENETIC|microarray analysis|Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
41315741|NCT00503880|PROCEDURE|biopsy|bone marrow biopsy
41315742|NCT02705508|DRUG|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
41002959|NCT04270981|DRUG|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C|960 mg (4 × 240 mg capsules)of acoziborole in oral and fasted condition
41315743|NCT02705508|DRUG|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
41315744|NCT02705508|DRUG|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
41315745|NCT02705508|RADIATION|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
41002960|NCT03584269|DEVICE|NIV Device + LTOT|Respiratory assistance by a facial mask without intubation or tracheotomy
41315746|NCT03498287|DEVICE|Study Device|Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).
41315747|NCT03498287|DEVICE|Sham Device|Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). \*Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
41315748|NCT02692456|DEVICE|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
41315749|NCT02692456|DEVICE|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
41315750|NCT02056834|DEVICE|chronOS Inject|chronOS Inject is used as bone void filler in internal fixation of proximal tibial fractures
41315751|NCT02217228|DEVICE|Sebacia microparticles and laser|
41315752|NCT02217228|DEVICE|Vehicle suspension and laser|
41315753|NCT02217228|DEVICE|Sebacia microparticles without laser|
41315754|NCT02999880|PROCEDURE|Polychromatic layering|Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
41315755|NCT02863367|DRUG|Apatinib|Apatinib：500 mg，po，qd, d1-14, every 3 week
41002961|NCT03584269|DEVICE|LTOT|Long term oxygenatory tyherapy without NIV
41002962|NCT03246113|DRUG|Cannabis|Cannabis cigarettes provided by NIDA that contain high levels of CBD (4.8%) and low levels of THC (3.23%). Patients will smoke one-half (1/2) to two (2) cannabis cigarettes prior to receiving chemoradiation.
41002963|NCT03246113|DRUG|Temozolomide|Oral alkylating agent with demonstrated antitumor activity.
41002964|NCT03246113|RADIATION|Radiation Therapy|standard fractionation radiotherapy of 60 Gy in 30 treatments with temozolomide.
41002965|NCT00776646|DRUG|hydrochlorothiazide 50 mg tablet|
41002966|NCT00122941|DIETARY_SUPPLEMENT|multiple micronutrients|
41002967|NCT00745914|DRUG|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
41002968|NCT00745914|DRUG|Placebo comparator|Placebo comparator
41002969|NCT01334658|PROCEDURE|Phacoemulsification cataract surgery|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
41315756|NCT02863367|DRUG|Gemcitabine|Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
41315757|NCT05534204|PROCEDURE|Silk suture|Patients with bilateral impacted lower third molars will have operations for both sides. On one side for primarily closure after operation silk suture will be used.
41315758|NCT05534204|PROCEDURE|Polyester suture|Patients with bilateral impacted lower third molars will have operations for both side. On one side for primarily closure after operation polyester suture will be used.
41315759|NCT05868096|OTHER|Structured holistic thinking course(2 hr)|The holistic thinking curriculum was designed as a structured program using mind maps, case-based discussions, and clinical observations to integrate physical, psychological, social, and spiritual aspects.
41315760|NCT05868096|OTHER|Clinical practice training|there is no holistic thinking curriculum.Using the holistic thinking case study form - introductory version self-study
41315761|NCT02864966|DEVICE|Condom|This study involves testing a condom, however the device will not be used as intended. The device will be destroyed to make the test patches required for this safety study.
41315762|NCT01481168|DEVICE|Pacemaker implantation (Medtronic)|DDD+/-R pacing
41315763|NCT01481168|DEVICE|Pacemaker implantation (Medtronic)|ODO pacing
41315764|NCT01481168|DEVICE|Implantable Loop Recorder (Medtronic)|Loop recorder implantation
41315765|NCT00589979|DRUG|Lidoderm (Lidocaine 5% Patch)|Topical Patch
41315766|NCT00589979|DRUG|Placebo Patch|Topical Patch
41315767|NCT04317352|PROCEDURE|MVR|Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
41315768|NCT03220711|DEVICE|confocal endomicroscope|"This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies."
41315769|NCT03220711|DRUG|Fluorescein|Fluorescent dye used for imaging contrast only.
41473373|NCT02396277|PROCEDURE|Immobilization|This is not an intervention study; but the patients are subjected to immobilization with a cast as part of a regular clinical treatment for distal radius fracture.
41473374|NCT04472858|DRUG|Donafenib|dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.
41473375|NCT04472858|DRUG|CS1001|CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days
41473376|NCT00442754|BIOLOGICAL|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
41473377|NCT02483338|BEHAVIORAL|Assessment of pain|Assessment of pain using FASS but without using this score to manage pain
41473378|NCT02697539|OTHER|AmF/SnF2|AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
40798800|NCT03249324|BEHAVIORAL|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
40798801|NCT03249324|OTHER|Usual Care|Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
40798802|NCT03279887|DIAGNOSTIC_TEST|Lung Ultrasound|
40798803|NCT04114708|DIAGNOSTIC_TEST|Anterior cruciate ligament Reconstruction (ACLR)|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autograft.
40798804|NCT04114708|DIAGNOSTIC_TEST|ACLR with lateral extra-articular tenodesis (LET)|All LETs will be performed in a standardized fashion using the modified Lameire technique. All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
40798805|NCT04601259|COMBINATION_PRODUCT|Orkla Corn Plaster with salicylic acid|Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
40798806|NCT04601259|DEVICE|Orkla Corn Protector|Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
40798807|NCT04338607|PROCEDURE|Subtalar (Talocalcaneal) arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
40798808|NCT04338607|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
40798809|NCT00708136|BEHAVIORAL|water based training program to improve balance|
41002970|NCT01334658|DRUG|Glucose-bicarbonate-Ringer Lactate (GBRL)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
41473379|NCT02697539|OTHER|mHA|microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
41473380|NCT03253094|DRUG|Fluconazole|Oral Antifungal comparator
41473381|NCT03253094|DRUG|SCY-078|Investigational Antifungal
41473382|NCT06011382|DEVICE|Advanced Molar Distalization Appliance (amda®)|AMDA is a prefabricated device anchored to the palate by miniscrews and it is a noncompliance appliance for maxillary molar distalization
41473383|NCT06011382|DEVICE|Buccal mini-implants|Buccal mini-implants for maxillary molar distalization
41473384|NCT04077242|DIAGNOSTIC_TEST|"Hysteroscopic Fallopian tube assessment using the Parryscope technique"|A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present \[10\]. At least 30 seconds of observation per ostia is performed if patency is not observed.
41473385|NCT04077242|DIAGNOSTIC_TEST|"Hysteroscopic Fallopian tube assessment using the Tubal flow technique"|"a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
41315770|NCT04654091|PROCEDURE|Cryoteraphy with liquid nitrogen|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of cryotherapy with liquid nitrogen will be carried out using CryoPen b® (HO Equipment, Hhislenghien-Belgium). To analyze the homogeneous application in all the patients in the study, perform 2 applications of 15 seconds per session, with an interval of 30 seconds between each application, such and as manufacturers recommend. The number of sessions in which the product is applied will be a maximum of 5, following the procedure of previous studies."
41315771|NCT04654091|PROCEDURE|Nitric-zinc complex|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of nitric acid-zinc complex with Verrutop® (Isdin, Barcelona-Spain) will be carried out. The preparation is applied by making small touches with the applicators included in the product.~The number of sessions in which the product is applied will be a maximum of 5, following the recommendations of the manufacturers in the product data sheet."
41315772|NCT00583440|BEHAVIORAL|12-step facilitation|12 weekly individual 12-step facilitation sessions
41315773|NCT00583440|BEHAVIORAL|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
40798810|NCT05684445|OTHER|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
40798811|NCT02134561|BEHAVIORAL|psychological interview|
40798812|NCT02134561|RADIATION|MRI|This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
40798813|NCT02134561|OTHER|cognitive tests|
41315774|NCT05270850|PROCEDURE|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
41315775|NCT05270850|PROCEDURE|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula
41315776|NCT00709358|OTHER|Detection of microbial DNA in blood by SeptiFast®|"The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.~Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours."
41315777|NCT00709358|OTHER|detection of microbial DNA in blood by blood culture|A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
41473386|NCT06217796|COMBINATION_PRODUCT|MydCombi|A single metered spray administered with the MydCombi dispenser
40798814|NCT02134561|OTHER|neurological tests|
40798815|NCT06279949|BEHAVIORAL|Provider training|Clinics randomized to a condition involving provider training will receive training on state-specific laws regulating minors' access to confidential HIV testing.
40798816|NCT06279949|BEHAVIORAL|Clinic protocols|Clinics randomized to a condition involving the implementation of new clinic protocols to support confidential care provision will receive training on navigating the new protocols.
40798817|NCT04800575|DEVICE|semi-permeable film|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
40798818|NCT04800575|DEVICE|sterile gauze and tape|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
40798819|NCT05031299|BEHAVIORAL|Standard care|Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.
40798820|NCT05031299|BEHAVIORAL|Health-promotion application for self-management|Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
40798821|NCT05031299|DEVICE|Wearables and devices|Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
40798822|NCT03449563|COMBINATION_PRODUCT|Open TPVB|In Group E,the thoracic paravertebral block was performed under the direct vision with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
40798823|NCT03449563|COMBINATION_PRODUCT|Ultrasound-guided TPVB|In Group U, thoracic paravertebral block was performed on the operated side under ultrasound guidance with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
40798824|NCT03449563|OTHER|placebo|In Group G,patients were just received Patient-controlled intravenous analgesia after the surgery.
40798825|NCT05813184|DRUG|Antibiotics|Any antibiotic therapy administered \> 7 days
40798826|NCT03138317|BIOLOGICAL|PRP|This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
40798827|NCT03138317|BIOLOGICAL|Plasma|This group will receive a knee injection with 6 ml of plasma.
40798828|NCT03138317|BIOLOGICAL|Placebo|This group will receive a knee injection with 6 ml saline solution.
40798829|NCT02785783|DEVICE|Standard colonoscopy|
40798830|NCT02785783|DEVICE|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
40798831|NCT04560816|DRUG|ALXN1840|ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
40798832|NCT04560816|DRUG|Placebo|Placebo will be administered orally.
40798833|NCT04560816|DRUG|Moxifloxacin|Moxifloxacin (400 milligrams) will be administered orally.
41315778|NCT01527227|OTHER|questionnaires|The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
40798834|NCT02463396|BEHAVIORAL|MBCT for ADHD|
40798835|NCT02236325|BEHAVIORAL|DBT Brief Suicide Intervention|Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.
40798836|NCT02236325|BEHAVIORAL|Relaxation Training|Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
40798839|NCT04051294|DIETARY_SUPPLEMENT|Commercial kombucha tea|Commercially-available kombucha tea.
41002971|NCT01334658|DRUG|Balanced Salt Solution (BSS®)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
41002972|NCT00286416|DRUG|omalizumab (Xolair)|
41315779|NCT05887947|OTHER|Electronic Cigarette Nicotine Concentration Order 1.8% 5% 1.8%|"At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
40798840|NCT04051294|DIETARY_SUPPLEMENT|Brewed kombucha tea|Kombucha tea brewed
41002973|NCT00983216|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.
40798841|NCT04051294|OTHER|Control: Tea|Tea brewed in our lab.
41002974|NCT00983216|DRUG|Ketoconazole|one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19
40798842|NCT04051294|OTHER|Control: Water|Tap water
40798843|NCT05620810|BEHAVIORAL|neuropsychiatric symptoms|neuropsychiatric symptoms
40798844|NCT06254092|PROCEDURE|tourniquet binding of cervical|The procedure will be performed by surgeons with rich experience in clinical work
40798845|NCT02489149|OTHER|Multi-sector interventions|"* Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~* For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~* For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~* Helping families to have more knowledge about your citizen rights."
41473387|NCT01082887|OTHER|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
40798846|NCT02489149|OTHER|Control|Placebo Comparator: Conventional approach of current public food and nutrition policies.
41315780|NCT05887947|OTHER|Electronic Cigarette Nicotine Concentration Order 1.8% 5% 5%|"At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
41315781|NCT05887947|OTHER|Electronic Cigarette Nicotine Concentration Order 5% 1.8% 1.8%|"At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
40798847|NCT01142050|BIOLOGICAL|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
40798848|NCT01223339|DRUG|Ertugliflozin|Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
40798849|NCT01223339|DRUG|Placebo|Placebo tablets to Ertugliflozin administered in the fasted state
40798850|NCT01223339|DRUG|Ertugliflozin|Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
40798851|NCT01223339|DRUG|Placebo|Placebo tablets administered once daily in the fed state for 7 days
40798852|NCT05131334|DEVICE|auriStim, for auricular vagal stimulation|For auricular vagal stimulation we used auriStim (AU0115, Multisana GmbH, Vienna, Austria). Using a green light-emitting diode (LEDs) flashlight, blood vessels in the cymba conchae of the left ear side were detected. Minimal invasive needles (penetrating 1-2mm) were placed close to the vessel-bifurcation to provide efficient stimulation of the auricular branch of the vagus nerve. The built-in microchip controls monophasic volt pulses of 1 ms, with alternating polarity, a frequency of 1 Hz and an amplitude of 4V. Stimulation lasted for 72h in total with alternating on/off periods of three hours. Thereafter, the device was removed, and patients continued their therapy consisting of anti-withdrawal medication.
40798853|NCT01483235|BEHAVIORAL|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
40798854|NCT01483235|BEHAVIORAL|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
40798855|NCT03940989|OTHER|HABIT-ILE|Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
40798856|NCT05568160|DRUG|Vasopressin|The infusion is started at 5 ml hr-1, increased in increments of 1 ml hr-1 every 5 minutes to reach a maximum target rate of 30 ml hr-1
40798857|NCT05568160|DRUG|Norepinephrine|The infusion is started at 5 ml h-1, increased in increments of 1 ml h-1 every 5 minutes to a maximum target rate of 30 ml h-1
40798858|NCT05568160|OTHER|Collection of clinical data|At D1, D2, D7, D30 or D60 and D90
41315782|NCT05887947|OTHER|Electronic Cigarette Nicotine Concentration Order 5% 1.8% 5%|"At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
41315783|NCT04083898|BIOLOGICAL|Isatuximab|Isatuximab will be administered on a 28-day cycle
40798859|NCT05568160|OTHER|Quality of Life Questionnaire EQ-5D|At the anesthesia consultation, discharge from intensive care, D7, D30 and D90
40798860|NCT03274011|DRUG|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
40798861|NCT04373148|OTHER|There is no intervention|There is no intervention
40798862|NCT05434793|DEVICE|RJ-LASER, LASERPEN®; Reimers & Janssen, Germany|The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
40798863|NCT05689918|OTHER|No intervention|No intervention
40798864|NCT00004573|DRUG|ganciclovir|
40798865|NCT05640050|OTHER|Audit Implementation|The feasibility of establishing and implementing an acceptable and robust audit system with community representation at secondary health facilities to improve maternal and perinatal outcomes. The implementation phases follow the standard World Health Organization (WHO) audit system.
41315784|NCT04083898|DRUG|Bendamustine|Bendamustine will be administered on a 28-day cycle as follows
41315785|NCT04083898|DRUG|Prednisone|Prednisone will be administered on a 28-day cycle as follows
41315786|NCT04824417|DRUG|Itraconazole 200 mg|Control
41315787|NCT04824417|DRUG|Voriconazole 200mg|Comparator
40798866|NCT02441907|DRUG|aflibercept|
40798867|NCT00057759|DRUG|sildenafil citrate|
40798868|NCT00057759|OTHER|Placebo|Placebo
40798869|NCT02689206|DRUG|GSK1278863|GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
40798870|NCT02689206|DRUG|GSK1278863 matching Placebo|GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
40798871|NCT06058663|PROCEDURE|Angiography|Undergo mapping angiography
41002975|NCT00983216|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
41315788|NCT02130154|OTHER|18-FDG PET CT scan and 123I-MIBG SPECT scan|
40798872|NCT06058663|PROCEDURE|Biopsy|Undergo biopsy
40798873|NCT06058663|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40798874|NCT06058663|PROCEDURE|Computed Tomography|Undergo CT
40798875|NCT06058663|BIOLOGICAL|Durvalumab|Given IV
40798876|NCT06058663|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40798877|NCT06058663|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40798878|NCT06058663|BIOLOGICAL|Tremelimumab|Given IV
40798879|NCT06058663|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Receive transarterial Y90 radioembolization
40798880|NCT01373255|PROCEDURE|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
41315789|NCT04227392|DEVICE|vaginal radiofrequency|2 sessions of vaginal radiofrequency therapy with 3 week interval. A session last 20 minutes.
41315790|NCT01954251|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
41315791|NCT01954251|BIOLOGICAL|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
41315792|NCT04622085|DEVICE|ANIMERS Chiara LA|20mg/SciVision Biotech Inc.
41315793|NCT04622085|DEVICE|JUVÉDERM VOLUMA®|20mg/Allergan, Inc.
41315794|NCT03517306|OTHER|No Interventions|No Interventions
41002976|NCT02705690|DEVICE|iOS Balance Application|"We have designed an iOS application and a belt. The application uses accelerometer data to calculate postural sway. Steps:~The phone is kept stable against the lower back of the participant using the belt.~The iOS application gives instructions to user to adopt the correct stance (eg: Standing Unsupported, legs side by side) Once the stance is adopted, the application turns on the accelerometer in the phone to sample acceleration along x (media lateral) and z (anterior posterior) axis.~These displacements from the mean are used to calculate the Root Mean Square of a person which acts a proxy score for Postural Sway. (Postural sway is defined as the phenomenon of constant displacement and correction of the position of the center of gravity within the base of support)"
41315795|NCT01867814|PROCEDURE|Pneumoperitoneum|Pneumoperitoneum 15 mmHg and 10 mmHg
41002977|NCT03996200|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
41002978|NCT01479803|PROCEDURE|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
41002979|NCT05492396|DEVICE|Standard gluteus medius repair with Tapestry Biointegrative implant|Patients will undergo standard gluteus medius repair utilizing augmentation.
41002980|NCT02501603|DRUG|afatinib|Afatinib 40mg daily oral administration
41002981|NCT02501603|DRUG|paclitaxel|Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
41315796|NCT03099980|BIOLOGICAL|secukinumab|secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections
41315797|NCT00847756|OTHER|questionnaire|Identification of risk factors
41473388|NCT05296876|PROCEDURE|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to perform CEA for patients. All patients will be assessed by SSPC evaluation system before CEA. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA and the type of CEA can be selected as conventional, eversion or a shunt or patch based on the discretion of the surgeon.
41002982|NCT03808168|DRUG|Nivolumab|Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
41002983|NCT05156580|OTHER|No intervention|This is an observational study without any intervention
41002984|NCT01321775|DRUG|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|"Neo-adjuvant doses (12 weeks):~Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.~Adjuvant doses:~Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)"
41315798|NCT00847756|PROCEDURE|blood sample|venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
41002985|NCT04970758|OTHER||no intervention
41002986|NCT03794843|DRUG|Nimodipine Injection|Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
41002987|NCT03794843|DRUG|Nimodipine Injection (II)|Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
41002988|NCT04729166|BEHAVIORAL|Structured education and follow-up|This structured educational material was developed by the authors on the basis of the literature. Interventions of the study were carried out in the 32nd-42nd week of pregnancy, 3rd-7th day postpartum, and at the 1st month. At first stage, a 15-20-minute education was given to the pregnant women in the study group in the breastfeeding room of the facility, educational booklets were distributed. The main emphasis parts of the education were repeated with a standard summary information form at each follow-up.
41315799|NCT00847756|PROCEDURE|collection of middle ear fluid|During routine surgery middle ear fluids are collected per patient.
41315800|NCT00847756|PROCEDURE|nasopharyngeal swab|A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
41315801|NCT03617003|DRUG|WST11 mediated vascular targeted phototherapy (VTP)|All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.
41315802|NCT03617003|PROCEDURE|Endoscopy|Endoscopy of the bladder
41473389|NCT01694017|DRUG|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
41473390|NCT01694017|DRUG|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
41473391|NCT03650959|OTHER|Method of learning simple interrupted sutures with instrument tie|Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.
41473392|NCT05918757|OTHER|Protein dose 1.5 g/kg/day|Administration of 1.5 g of protein/kg/day via enteral/parenteral nutrition
41002989|NCT00690963|PROCEDURE|Radiotherapy|Dose excalation based on normal tissue toxicity using 5 dose bins ranging from 56.8 Gy/ 27 fractions to 67.3 Gy in 27 fractions.
41315803|NCT05638763|DRUG|Dasatinib Pill|Patients will receive half pill of dasatinib 50mg (25mg/day, orally) for one year
41315804|NCT05638763|DRUG|Ketoconazole Pill|Patients will receive ketoconazole 200mg two times a day, orally, for one year.
41315805|NCT01422590|DRUG|Sitagliptin|Single oral administration of sitagliptin 100 mg
41315806|NCT01422590|DRUG|Mitiglinide|Single oral administration of mitiglinide 10 mg
41315807|NCT01422590|DRUG|Sitagliptin, Mitiglinide|Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
41473393|NCT05918757|OTHER|Protein dose 1.0 g/kg/day|Administration of 1.0 g of protein/kg/day via enteral/parenteral nutrition
41315808|NCT02252692|DRUG|Enalapril|oral administration
41473394|NCT02394639|OTHER|video-EEG monitoring|
41473395|NCT05550376|OTHER|Registry|Non-interventional registry
41473396|NCT05862272|DRUG|Relugolix Combination Tablet|A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.
41473397|NCT04960319|DEVICE|Intravascular Lithotripsy|Coronary Angiography. When the anatomic inclusion criteria are met, traverse the lesion with a guidewire. If traversal fails, assign the subject to the registry. After wire traversal has been documented by cine angiography, angiographic, OCT-defined or balloon expansion criteria are met, subject is enrolled. Blood sample for Troponin (hs TnT) baseline measurement has to be taken. The subjects will be randomized in a 1:1 fashion to treatment with either IVL or RA.
41002990|NCT02610699|OTHER|Conventional otoscope|The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
41002991|NCT02610699|OTHER|Smartphone otoscope|The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
41473398|NCT05274672|DRUG|Nitrofurantoin|Prophylactic postoperative antibiotic use
41473399|NCT05274672|DRUG|Cephalexin|Prophylactic postoperative antibiotic use
41473400|NCT05274672|DRUG|Sulfamethoxazole Trimethoprim Combination|Prophylactic postoperative antibiotic use
41473401|NCT05274672|DRUG|Ciprofloxacin|Prophylactic postoperative antibiotic use
41002992|NCT04268420|DRUG|FMP013|Falciparum Malaria Protein-13
41002993|NCT04268420|DRUG|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
41002994|NCT03595410|OTHER|Recurrence laryngeal cancer|Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
41002995|NCT01922024|DEVICE|LRT55 Testing|Testing on the Unyvero LRT55
41002996|NCT05417932|BIOLOGICAL|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
41002997|NCT05126927|BIOLOGICAL|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
41151748|NCT06279780|DIETARY_SUPPLEMENT|very low-calorie diet|Subjects undergo two cycles of a very-low-calorie diet (VLCD) for 6 weeks each, alternating with a hypocaloric diet (12 weeks). The dietetic intervention consists of a VLCD using a liquid formula (Optisource Plus, Nestlé S.A., Vevey, Switzerland), providing 52.8 g protein, 75.0 g carbohydrates, 13.5 g fat, 11.4 g fiber, and essential vitamins and minerals based on Recommended Dietary Allowances (RDA). This formula supplies 2738 kJ/day (654 kcal/day), replacing the participants' three daily meals. Following this and before the second VLCD cycle, a dietician performs an individualized nutritional assessment to calculate the resting energy expenditure, and personalized hypocaloric diets were prepared, reducing 500 kcal for each individual on their daily caloric expenditure, maintaining the recommended intake of each of the macronutrients (55% carbohydrates, 30% fats and 15% proteins) for 12-weeks.
41151749|NCT02746783|DRUG|Single dose MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
41151750|NCT02746783|DRUG|Double dose of MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
41151751|NCT05200299|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)
41151752|NCT05200299|DRUG|mFOLFOX6 OR CapeOx|"mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)"
41151753|NCT05450159|BEHAVIORAL|ROADskills program|Participants in the intervention arm of the study will watch a 30-minute personalized video on their driving that uses information compiled from a GPS device that will be installed in their vehicle during their baseline visit.
41151754|NCT05450159|BEHAVIORAL|Healthy Aging|Participants in active comparator arm of the study will watch a 30-min video and receive a written brochure that provide tips for maintaining a healthy lifestyle in later life, including the importance of community mobility.
41151755|NCT01871597|DEVICE|Pulmonary Artery Energy Seal|Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
41151756|NCT01550783|OTHER|Cervical Papanicolaou Test|Undergo standard of care Pap test screening
41151757|NCT01550783|OTHER|Cytology Specimen Collection Procedure|Undergo home-based HPV screening
41151758|NCT01550783|OTHER|Questionnaire Administration|Ancillary studies
41151759|NCT01550783|PROCEDURE|Screening Method|Undergo standard of care Pap test screening
40798881|NCT04397367|DRUG|Ruxolitinib 10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
40798882|NCT04397367|DRUG|Ruxolitinib 5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
41002998|NCT04412330|OTHER|ICU Recovery + Physical Therapy|Physical therapy interventions will be supervised by a physical therapist (\>20 years of experience in ICU and pulmonary rehabilitation). Potential interventions include endurance/aerobic training (treadmill training, upper and lower extremity ergometer, and recumbent step machine), upper and lower extremity resistance strength training, balance training, functional movement training, and education. If the interventions are providing in the home environment the exercises will be completed through Zoom, video communications app. Home-based interventions will include seated and standing exercise including resistance exercises (such as lifting small weights) and endurance (e.g. marching or stepping in place, repetitive sit-to-stand training). Physical therapist will provide verbal instructions for motivation and adherence to exercise interventions.
41002999|NCT02506816|DRUG|Olaparib|Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
41003000|NCT05652296|DEVICE|External Ventricular Drainage (EVD)|EVD of Cerebral Spinal Fluid from the lateral ventricles of the brain
41003001|NCT04449367|PROCEDURE|ultrasound guided erector spinae plane block|bilatral block given to patients under general anaesthesia for thoracic spine sugery to contorl post operative pain
41003002|NCT06273176|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
41003003|NCT06273176|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
41003004|NCT06273176|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
41003005|NCT05625035|DRUG|Lianhua Qingwen capsules|Lianhua Qingwen capsules: 4 capsules once, three times daily
41003006|NCT00003075|DRUG|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
41003007|NCT00003075|OTHER|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
41003008|NCT03013543|DRUG|Setmelanotide|RM-493 QD SC injection
41003009|NCT00123188|PROCEDURE|Ultrasound and Biopsy|Transvaginal ultrasound and Endometrial Biopsy
41003010|NCT05277311|DRUG|LongShengZhi capsule|LongShengZhi capsules, orally, 5 capsules each time, three times a day.
41003011|NCT05277311|DRUG|LongShengZhi capsule placebo|LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
41003012|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
41151760|NCT01550783|PROCEDURE|Screening Method|Undergo home-based HPV screening
41151761|NCT02211599|OTHER|15% protein|Meal to provide 15%en from protein.
41151762|NCT02211599|OTHER|30% protein|Meal to provide 30%en from protein.
41151763|NCT02211599|OTHER|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
41151764|NCT01848483|BEHAVIORAL|AIDS EPC Package plus MI|"1. Motivational Interviewing: In MI session #1, the nurse will set the agenda \& ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 \& 4, the nurse will also introduce advance care planning.~2. EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic \& conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation \& coordination of care."
41473402|NCT05274672|PROCEDURE|Holmium Laser Enucleation of prostate|Endoscopic transurethral Holmium Laser enucleation of enlarged prostate followed by morcellation of prostatic tissue
41473403|NCT03318887|DRUG|Sofosbuvir/daclatasvir with or without ribavirin|Direct-acting antiviral treatment for hepatitis C virus infection
41473404|NCT01386502|BIOLOGICAL|p53: 264-272 peptide|
41473405|NCT01386502|DRUG|CT-011|
40798883|NCT04397367|DRUG|Ruxolitinib 5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
41473406|NCT03172052|DRUG|streptokinase|• Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is \>100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
41473407|NCT03172052|DRUG|MESNA (2-mercaptoethane sulfonate Na)|• Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
41473408|NCT03172052|DEVICE|Medical thoracoscopy|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
41473409|NCT03172052|DEVICE|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
40798884|NCT04397367|DRUG|Ruxolitinib 2.5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
40798885|NCT01058681|DIETARY_SUPPLEMENT|effect of metabolic variations on LH pulsatility|"Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia."
40798886|NCT05088330|DRUG|Daratumumab|treatment with D-VRD in NDMM
40798887|NCT01967797|BEHAVIORAL|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes \& team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners \& teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
40798888|NCT06216041|DRUG|IMM-H014|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
40798889|NCT06216041|DRUG|Placebo|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
40798890|NCT06216041|DRUG|IMM-H014 ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
40798891|NCT06216041|DRUG|Placebo ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
40798892|NCT05002985|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
40798893|NCT03969290|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
40798894|NCT03969290|DEVICE|Etafilcon A contact lenses|Daily disposable contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
40798895|NCT01375816|DRUG|FOLFIRI 1-Bevacizumab|
40798896|NCT01375816|DRUG|fluorouracil|
40798897|NCT01375816|DRUG|irinotecan hydrochloride|
40798898|NCT01375816|DRUG|leucovorin calcium|
41473410|NCT05533099|OTHER|Observational study|Observational study of a device implanted in a previous clinical study
41473411|NCT01914523|DEVICE|Macintosh|Laryngeal exposure and tracheal intubation using that device
40798899|NCT01375816|DRUG|liposome-encapsulated irinotecan hydrochloride PEP02|
40798900|NCT01375816|DRUG|Bevacizumab|
40798901|NCT06353152|DRUG|Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection|single-/multiple-dose infusion
40798902|NCT06336434|DRUG|CAB LA 600mg|600mg (3mL) IM Injection
40798903|NCT06336434|DRUG|RPV LA 900mg|900mg (3mL) IM Injection
40798904|NCT06336434|DRUG|CAB LA 400mg|400mg (2mL) IM Injection
40798905|NCT06336434|DRUG|RPV LA 600mg|600mg (2mL) IM injection
40798906|NCT01270880|DRUG|Hsp90 inhibitor STA-9090|Given IV
41473412|NCT01914523|DEVICE|King Vision|Laryngeal exposure and tracheal intubation using that device
41473413|NCT01914523|DEVICE|Glidescope|Laryngeal exposure and tracheal intubation using that device
41473414|NCT01914523|DEVICE|AirTraq|Laryngeal exposure and tracheal intubation using that device
41473415|NCT00858013|DRUG|Nateglinide|Nateglinide 90\~120mg three times a day
40798907|NCT01270880|OTHER|laboratory biomarker analysis|Correlative studies
40798908|NCT01270880|GENETIC|polymerase chain reaction|Correlative studies
40798909|NCT01270880|OTHER|enzyme-linked immunosorbent assay|Correlative studies
40798910|NCT01270880|GENETIC|RNA analysis|Correlative studies
40798911|NCT01270880|OTHER|spectrophotometry|Correlative studies
41473416|NCT00858013|DRUG|Glimepiride|Glimepiride 1\~2mg once a day
41473417|NCT01269450|DRUG|micronized progesterone 200 mg (Utrogestan)|micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
41473418|NCT01269450|DRUG|placebo|placebo 200mg vaginal tablets
41473419|NCT03331159|DEVICE|NanoBone|Cage was filled with nanocrystalline hydroxyapatite embedded in a silica gel matrix
41003013|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
41003014|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
41003015|NCT02036099|OTHER|Driving in Mild Dementia Decision Tool|
41473420|NCT03331159|DEVICE|Homologous Bone|Cage was filled with homologous bone
41473421|NCT03727737|DEVICE|Repetitive Transcranial magnetic Stimulation|RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
41473422|NCT02577224|OTHER|Patient-initiated treatment|Please see Intervention Arm
41473423|NCT03562949|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
41473424|NCT03562949|DRUG|Reference Product|QVAR® 40 mcg (Beclomethasone Dipropionate HFA)
41473425|NCT03562949|DRUG|Placebo|Placebo Product
41473426|NCT04941131|DRUG|Chlorhexidine digluconate, povidone iodine|This is a mouth wash that can be used over the counter.
41473427|NCT03034161|DEVICE|Thermal imaging|Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.
41473428|NCT05175924|OTHER|Nanpharmacological method|Virtual Reality
41473429|NCT01571726|DRUG|Fluciclatide|7mCi
41473430|NCT00272506|DRUG|inhaled corticosteroid|
41473431|NCT00272506|DRUG|long-acting beta2-agonist|
41473432|NCT03276676|DRUG|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine|Multi-tracer PET exams of \[18F\]FLT and \[18F\]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
41473433|NCT04464109|PROCEDURE|Evisceration with orbital implantation|Evisceration will be performed. Alloplastic orbital implant will be inserted either posterior to the sclera or partly within the scleral canal.
41473434|NCT04059549|BEHAVIORAL|PartnerCHESS|"Patients randomized to the PartnerCHESS group will receive all A-CHESS services plus the following services from ABCT:~Urge discussion. Daily EMAs will track preconditions for relapse (urges), review urge reduction options on PartnerCHESS, and encourage discussions between partners on the causes of and ways to reduce urges.~Homework checklist. Tracks which interventions the couple is using/practicing, along with resources to help.~Relapse plan. Monitoring and reminders of steps planned for relapse prevention. Reminders. Reminders to notice something positive in partner, of reasons to stay sober, to take meds, etc.~Trigger identification and removal. During set-up, patient and partner enter triggers. PartnerCHESS will quiz couples on upcoming trigger events and remind them of ways to address each."
41473435|NCT04059549|BEHAVIORAL|A-CHESS|A-CHESS control group
41473436|NCT06099990|DRUG|dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets|dalpiciclib+ abiraterone+ prednisone
41473437|NCT06099990|DRUG|placebo; abiraterone acetate tablets; prednisone tablets|placebo+abirarerone+prenisone
41473438|NCT01279252|DRUG|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
40798912|NCT01270880|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
40798913|NCT01270880|GENETIC|gene expression analysis|Correlative studies
40798914|NCT01864681|DRUG|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
40798915|NCT01864681|DRUG|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
40798916|NCT04884750|BEHAVIORAL|ECA-ACE Vaccination Promotion Intervention|A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
41003016|NCT00885833|DRUG|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
41003017|NCT02995291|DRUG|OraVerse|1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.
41473439|NCT04691375|DRUG|PY314|Dose of PY314 as a single agent given in a standard 3+3 design.
40798917|NCT00575107|OTHER|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
41473440|NCT04691375|DRUG|Combination Therapy: PY314 + Pembrolizumab|Dose of PY314 alone and given in combination with pembrolizumab
41473441|NCT00333723|DRUG|Rosiglitazone|
41473442|NCT01685593|DEVICE|abdominal binder|
40798918|NCT00575107|OTHER|Exercise|Standard training of leg extension
40798919|NCT01403779|RADIATION|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
41003018|NCT02995291|DRUG|Saline Water (Control)|1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.
41003019|NCT06137443|DEVICE|Balance Training|Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
41003020|NCT01330758|DRUG|AZD8931|40 mg AZD8931 wet granulation tablet formulation
41003021|NCT01330758|DRUG|AZD8931|40 mg AZD8931 roller compacted tablet formulation
41003022|NCT04964453|DRUG|Placebo|Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
41003023|NCT04964453|DRUG|BI 474121|Healthy subjects were given a single dose of BI 474121 as a uncoated tablet(s) taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
40798920|NCT05650463|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
41003024|NCT01503827|RADIATION|WBRT|A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
41003025|NCT00829881|DRUG|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
41003026|NCT00829881|DRUG|Placebo Capsule|A single placebo capsule
41003027|NCT01414335|DIETARY_SUPPLEMENT|amino acid composition|one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
41003028|NCT01414335|OTHER|Placebo|placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
41003029|NCT04909086|PROCEDURE|Standard physical Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle stretching, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
41003030|NCT04909086|PROCEDURE|Closed Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of seated leg press and partial squat exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
41003031|NCT04909086|PROCEDURE|Open Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of Quadriceps seated strengthening and Hamstring curl-up exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
41003032|NCT00397982|BIOLOGICAL|Bevacizumab|Given IV
40798921|NCT05436522|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
40798922|NCT05436522|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
40798923|NCT00661726|DRUG|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
41003033|NCT00397982|OTHER|Laboratory Biomarker Analysis|Correlative studies
41473443|NCT01685593|OTHER|no binder|
40798924|NCT04974905|PROCEDURE|retrograde access for re-canalization of infra-inguinal arterial occlusive disease|after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
40798925|NCT02272036|PROCEDURE|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
40798926|NCT02272036|DEVICE|mobile phone|SMS received by mobile phone
40798927|NCT02702609|DEVICE|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
41003034|NCT00397982|DRUG|Temsirolimus|Given IV
41003035|NCT00397982|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection
41473444|NCT05363982|DEVICE|Transcranial Photobiomodulation (tPBM)|"Transcranial Photobiomodulation (tPBM) is a novel treatment approach based on application of an invisible, non-ionizing electromagnetic wave that results in metabolic modulation in tissues targeted. This intervention consists of exposing bilaterally the frontal brain to the electromagnetic wave that penetrates the skin and skull into brain tissue, is non-invasive and minimally dissipated as thermal energy.~Other Names:~Niraxx G1 Headband"
41473445|NCT05363982|DEVICE|Placebo/ Sham|The sham treatment will consist of applying all the procedures for the delivery of tPBM, but will not deliver light.
41473446|NCT01158326|DRUG|Resfenol|"Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours."
41473447|NCT01158326|OTHER|Placebo|10 ml of oral placebo every 6 hours for 48 hours
41473448|NCT06616064|BEHAVIORAL|personalised feedback and brief motivational|personalised feedback and brief motivational
41473449|NCT06616064|OTHER|routine lifestyle advice|routine lifestyle advice
41473450|NCT06616064|OTHER|questionnaire CliniCAP|questionnaire CliniCAP
41473451|NCT06285240|DRUG|MK-1167|1 mg and 5 mg oral capsules
41473452|NCT06285240|DRUG|Donepezil|10 mg oral tablets
41473453|NCT06285240|DRUG|Placebo|MK-1167 matching placebo administered oral capsules
41473454|NCT02172352|DRUG|Ba 679 BR low dose|
41473455|NCT02172352|DRUG|Ba 679 BR middle dose|
41473456|NCT02172352|DRUG|Ba 679 BR high dose|
41473457|NCT02172352|DRUG|Placebo inhalation powder|
41473458|NCT03803111|BEHAVIORAL|Initial exercise training|Initial exercise training program
41473459|NCT03803111|DRUG|Initial FCM|Initial intravenous iron supplementation (FCM)
41473460|NCT03803111|DRUG|Subsequent FCM|Subsequent intravenous iron Supplementation (FCM) after 2 months
41473461|NCT03803111|BEHAVIORAL|Subsequent exercise training|Subsequent exercise training program after 2 months
41473462|NCT03171441|DIAGNOSTIC_TEST|nailfold videocapillaroscopy|non-invasive nailfold videocapillaroscopy
41473463|NCT03171441|DIAGNOSTIC_TEST|inflammatory biomarkers|blood sample collection to asses leptin and C-reactive protein
41473464|NCT00778882|DRUG|VM106|Autologous hematopoietic stem cells with MT-gp91 retroviral vector
41473465|NCT04214665|DRUG|Alpha Lipoic acid 600 mg HR film coated tablets|
41473466|NCT00346164|DRUG|doxorubicin hydrochloride|Given IV
41473467|NCT00346164|OTHER|clinical observation|Patients undergo observation
41473468|NCT00346164|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
41003036|NCT00691496|BEHAVIORAL|Behavioral intervention to reduce sexual risk among African-American men who have sex with men|5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
41003037|NCT04419116|PROCEDURE|tibial preservation bone cut|tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.
41003038|NCT00637039|DRUG|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
41473469|NCT00346164|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
41473470|NCT00346164|DRUG|ifosfamide|Given IV
41473471|NCT01978899|BEHAVIORAL|Immediate Weight Loss Program Group|Participation in 15-week Healthy Living Program.
41473472|NCT01978899|BEHAVIORAL|Delayed Weight Loss Program Group|Participation in 15-week Healthy Living Program following 15-week wait period.
41473473|NCT01935479|DRUG|AK159|transdermal administration of teriparatide acetate
41473474|NCT01935479|DRUG|MN-10-T|subcutaneous administration of teriparatide acetate
41473475|NCT01935479|DRUG|Placebo|Placebo AK159
41473476|NCT04334928|DRUG|Emtricitabine/tenofovir disoproxil|Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.
41473477|NCT04334928|DRUG|Hydroxychloroquine|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.
41473478|NCT04334928|DRUG|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil
41473479|NCT04334928|DRUG|Placebo: Hydroxychloroquine|Placebo: Tablets similar in appearance to Hydroxychloroquine
41473480|NCT04596124|DEVICE|fitostimoline plus|randomized controlled multicentric study
41473481|NCT00388934|DEVICE|Drug eluting stent|percutaneous intervention with implantation of drug eluting coronary stent
41473482|NCT02804282|COMBINATION_PRODUCT|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
41473483|NCT03736187|DRUG|Cephalexin|Giving cephalexin and metronidazole in one group \&cephalexin alone in another group
41473484|NCT01729988|PROCEDURE|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
41473485|NCT06617091|DRUG|GRAdHIVNE1 Vaccine|This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
41473486|NCT06617091|OTHER|Placebo|This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
41473487|NCT03690167|OTHER|Concentrated Growth Factor (CGF)|CGF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for CGF)
41473488|NCT03690167|OTHER|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for A-PRF)
41473489|NCT03690167|OTHER|Control|Nothing applied after extraction
41473490|NCT05265221|PROCEDURE|Endoscopic submucosal dissection|ESD was performed under conscious sedation. For sedation, midazolam and/or propofol were administered intravenously, with cardiorespiratory monitoring. Initially, indigo carmine dye was sprayed onto the tumor to clarify the margin. Then, markings were made 10 mm outside the tumor margin using argon plasma coagulation. After marking, a mixture of sodium hyaluronate with indigo carmine and epinephrine was injected into the submucosa outside the marking dots. Circumferential mucosal incision and submucosal dissection were performed using a Dual and/or IT knife. During the procedure, immediate bleeding was treated by Coagrasper. After ESD, chest and abdominal plain radiography were performed routinely for detection of gastric perforation.
41473491|NCT02457819|DRUG|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
40798928|NCT02702609|DEVICE|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
40798929|NCT05733741|DRUG|Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)|"For each patient, one eye was treated with preservative-free Benoxinate hydrochloride 0.4%.~The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Benoxinate hydrochloride 0.4% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
40798930|NCT05733741|DRUG|Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).|"The other eye was treated with preservative-free Sodium hyaluronate 0.2%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Sodium hyaluronate 0.2% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
40798931|NCT00128024|DRUG|lipid-lowering treatment|
40798932|NCT05657080|DEVICE|Cytosponge-TFF3|Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
40798933|NCT01239277|OTHER|protein|20g protein
40798934|NCT01239277|OTHER|protein and carbohydrate|20g protein and 20g carbohydrate
40798935|NCT01239277|OTHER|protein and leucine|20g protein, 2.5g leucine
40798936|NCT03154515|DRUG|Ingavirin|
40798937|NCT03154515|DRUG|Placebo|
40798938|NCT03078439|OTHER|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.~A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
40798939|NCT00140153|DRUG|testosterone gel (Androgel)|
40798940|NCT04737356|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory as well as self-determination therapy for low self-esteem among adolescents.
40798941|NCT05087433|OTHER|Progressive Relaxation Exercises|The trainer performed the PRE exercise online with the nurses. The video recording of the progressive relaxation exercises was shared with the nurses participating in the study on WhatsApp groups. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month. The PRE application was reminded daily from the WhatsApp group for the nurses to apply regularly to the sessions and not to disrupt the sessions. Nurses shared the messages stating that they were doing the PRE application on a daily basis for four weeks on WhatsApp groups.
40798942|NCT05937386|DRUG|AGMB-129|Oral capsule
40798943|NCT05937386|DRUG|MDZ|Pre-filled oral syringes
40798944|NCT02729116|DRUG|Sitafloxacin|Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.
40798945|NCT02729116|DRUG|Ertapenem|Patients are given IV ertapenem for 14 days
40798946|NCT02253433|OTHER|Enhanced Clinic Care|The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
40798947|NCT02253433|OTHER|Enhanced Clinic Care + Home Intervention|The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
41473492|NCT06446388|DRUG|QLS31905|Administered as an intravenous infusion.
40798948|NCT04359862|DRUG|Sevoflurane|25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
40798949|NCT04359862|DRUG|Propofol|25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
40798950|NCT00581399|DEVICE|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
40798951|NCT00581399|DEVICE|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
40798952|NCT02782351|BIOLOGICAL|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
40798953|NCT01631487|DRUG|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
40798954|NCT01631487|DRUG|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
40798955|NCT01631487|DRUG|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
40798956|NCT01631487|DRUG|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
40798957|NCT04626284|PROCEDURE|Heart Transplantation|Heart Transplantation
40798958|NCT00485563|BIOLOGICAL|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
40798959|NCT00485563|BIOLOGICAL|GPI-0100|3.0 mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
40798960|NCT00485563|DRUG|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks for the first two treatment cycles and then 3 days per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
40798961|NCT00485563|DRUG|Interleukin-2|7.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 2.5 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
40798962|NCT00485563|DRUG|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
40798963|NCT00224120|DRUG|Silodosin|8 mg daily for 12 weeks
40798964|NCT00224120|OTHER|Placebo|One capsule daily for 12 weeks
40798965|NCT03067519|OTHER|Fast track surgery|early feeding and mobilization after surgery
40798966|NCT03067519|OTHER|Conventional management|Management per the primary surgeon
40798967|NCT04145544|DEVICE|Implantation of the ArtiFascia®|"Following are the general instructions for use for the ArtiFascia®:~* Cut the ArtiFascia® to the required shape under aseptic conditions~* Apply ArtiFascia® to the damaged area~* Suture the ArtiFascia® in place~* Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results."
40798968|NCT04145544|DEVICE|Implantation of other commercial suturable dural substitute|Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
40798969|NCT01643408|DRUG|asparaginase Erwinia chrysanthemi|
40798970|NCT03587428|DRUG|Zinc-A toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
40798971|NCT03587428|DRUG|Zinc-B toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
41473493|NCT06446388|DRUG|Oxaliplatin|130 mg/m2, intravenous infusion, D1, up to 8 cycles.
41473494|NCT06446388|DRUG|Capecitabine|1000 mg/m2, oral, bid, D1-D14
41473495|NCT06446388|DRUG|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.
41473496|NCT06446388|DRUG|Cisplatin|25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.
41003039|NCT06455280|DRUG|Siplizumab|Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.
41003040|NCT03098511|DIAGNOSTIC_TEST|Neurological Diagnostic Evaluation|"Clinical Data:~* Demographic data~* Daily data (clinical exams, laboratory data)~* Drug administration~* Additional clinical or ancillary neurological determination test~Diagnostic Intervention:~* CT-Perfusion~* CT-Angiography reconstructions~Reference Standard:~- Clinical Neurological Exam~Blood Samples (Pharmacokinetics, Inflammatory \& Nanovesicles Parameters):~* At the time of patient enrolment~* 6 hours after patient enrolment~* At the time of the clinical neurological exam~Secondary Outcome measures at 6 months:~* extended Glasgow Outcome Scale (GOSe)~* modified Rankin Scale (mRS)"
41003041|NCT03270917|PROCEDURE|Parenchymal preserving postero-superior liver segment resection|Parenchymal preserving liver segment resection of one or two of the postero-superior liver segments (4A, 7 or 8).
41003042|NCT05410626|DRUG|prolong-release methylphenidate|This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.
41003043|NCT02504697|OTHER|Biosamples from airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
41003044|NCT01278459|DRUG|Atorvastatin|4 week treatment, 20mg/day taken orally in tablet form
41003045|NCT06062043|BEHAVIORAL|Brief ACT with CPP Education Treatment|The Brief ACT with CPP Education treatment provides women veterans with new ways of responding to difficult thoughts and emotions related to pain while also encouraging them to engage in meaningful life activities. The CPP educational component includes information about pathology, risk factors, health outcomes, and treatment that are specific to women's biological and reproductive functioning. Treatment content has been further tailored to reflect the cultural experiences of women veterans (including discussions on the interplay between military culture, perceived social norms, and gender role expectations).
41003046|NCT01592188|BEHAVIORAL|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
41003047|NCT01592188|BEHAVIORAL|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
41473497|NCT06446388|DRUG|QL1706|5 mg/kg, intravenous infusion,D1
41473498|NCT06446388|DRUG|Chemotherapy drug|Standard chemotherapy recommended by guidelines.
40798972|NCT03587428|OTHER|Mineral water|Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 \[generally 7\] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
40798973|NCT00817323|PROCEDURE|Dietary amino-acid depletion|See detailed description
40798974|NCT00651014|DRUG|Ezetimibe|oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
41003048|NCT02771262|OTHER|Pulmonary Rehabilitation|
41003049|NCT01908569|OTHER|MACS|The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
41473499|NCT02372591|DRUG|Buprenorphine|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
41473500|NCT02372591|DRUG|Hydromorphone|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
41473501|NCT02372591|DRUG|Placebo|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
40798975|NCT00651014|DRUG|Placebo|oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
40798976|NCT00148993|BIOLOGICAL|Tumor Cell Vaccine|
40798977|NCT03800537|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
41473502|NCT03836482|DEVICE|Selective Cytopheretic Device|Treatment will be delivered for 6 hours a day for up to 6 consecutive days.
41473503|NCT02688296|DEVICE|Fibulock|Fibulock intramedullary implant will be used to repair fibula fractures
41473504|NCT03684681|BEHAVIORAL|Peer Navigator Intervention|A peer navigator delivers an intervention to current drug users and uses their own training and real- life experiences to help people meet their goals.
41473505|NCT03684681|BEHAVIORAL|Social Work Intervention|A hospital social workers uses their own previous training to help people meet their goals.
41473506|NCT05253222|DIAGNOSTIC_TEST|retrograde image by colonic TET|"Delivery of contrast fluid by colonic TET Each participant will receive one delivery of 200 ml contrast fluid by colonic TET to the distal portion of the lesion.~One group will be taken CT investigation, another group will be taken X-ray fluoroscopy.~Imaging parameters will be collected and evaluated."
41473507|NCT05183412|DEVICE|The Sedakit Oncomfort VR glasses (30-minutes Aqua program)|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone. The patients watch a VR underwater view of the ocean while listening to speeches to induce relaxation and meditation.
41473508|NCT05183412|PROCEDURE|Ultrasound-guided regional nerve block and hand surgery without VR glasses|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are NOT subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone.
41473509|NCT05183412|PROCEDURE|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Ultrasound-guided regional nerve block and hand surgery with VR glasses
41473510|NCT05393063|DRUG|AK127|Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）
41473511|NCT00004988|DRUG|VNP20009|
41473512|NCT01098110|DRUG|Asenapine 5 mg|Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
40798978|NCT06520696|BEHAVIORAL|MILC application|Eligible Hispanic participants in their third trimester will be recruited for the study. Intervention group will receive standard WIC services plus the MILC application. Standard WIC support includes on-site lactation consultation, bilingual peer counseling, weekly peer support meetings, free breast pump, and enhanced food package for BF mothers. If a participant has trouble with breastfeeding, she will be referred to a home-visiting breastfeeding peer counselor in the area. Participants will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months along with demonstrating breastfeeding via MILC app. Participants will send in 1 BF video per month using the MILC app to verify continued BF and fill out monthly self-report to verify EBF. Participants in the incentive group will receive escalating monthly points as incentives for every additional month of continued BF and EBF.
41003050|NCT01908569|OTHER|NO MACS|The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
41003051|NCT00501202|DRUG|placebo|twice daily for 4 weeks
41003052|NCT00501202|DRUG|RWJ-333369 (carisbamate)|200 mg tablet twice daily for 4 weeks
41003053|NCT01358318|OTHER|Satiety|Single consumption of snack bars to determine satiety and food intake at next meal.
41003054|NCT04895384|DEVICE|Edwards ClearSight and Masimo SET|Placement of Edwards ClearSight and Masimo SET on the patient intraoperatively.
41003055|NCT03978364|DRUG|Azacitidine combined HHT|Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days
41003056|NCT03978364|DRUG|Azacitidine regimen|Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
41003057|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
41003058|NCT01541826|DIETARY_SUPPLEMENT|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
41003059|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
41003060|NCT00297037|DRUG|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
41003061|NCT02882321|DRUG|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
41473513|NCT01098110|DRUG|Asenapine 10 mg|Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
41473514|NCT01098110|DRUG|Placebo|A matching placebo of asenapine sublingual tablet not containing asenapine
41003062|NCT02882321|OTHER|Pharmacological Study|Correlative studies
41003063|NCT00898703|OTHER|flow cytometry|
41003064|NCT00898703|OTHER|immunoenzyme technique|
41003065|NCT00898703|OTHER|laboratory biomarker analysis|
41003066|NCT03802448|COMBINATION_PRODUCT|Study group|"Each pregnant woman in the study group received myofascial release technique, 3 sessions/week for 4 weeks. a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
41003067|NCT03802448|DEVICE|Control group|A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
41315809|NCT04250012|BEHAVIORAL|Internet-based ACT intervention|The Internet-based ACT intervention included a 10-week web-based program consisting of five modules with different themes that the participants were instructed to process during the course of two weeks. The program was based on the processes of ACT and included themes such as life values, mindfulness, defusion, self-as-context acceptance and self-compassion. The content of each module consisted of text, video, exercises with audio files, and homework assignments. In addition, the participants filled in a diary with exercises in paper format. The intervention included also three remote meetings (à 45 minutes) via a videoconferencing tool doxy.me conducted by a psychologist. The remote meetings took place at the beginning, after 4 weeks, and at the end of the intervention.
41473515|NCT05403957|OTHER|TID video|"Main intervention: A video introducing the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 6 screenshots from the video and 6 true or false questions."
41473516|NCT05403957|OTHER|TID worksheet|"Main intervention: A worksheet using pictures and texts to introduce the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 8 pictures from the TID worksheet in the main intervention and 6 true or false questions."
41003068|NCT02609022|BIOLOGICAL|CV-MG01|"3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose."
41473517|NCT05403957|OTHER|SSB worksheet|"Main intervention: A worksheet using pictures and texts to introduce the beverage industry's marketing tactics to attract children and adolescents to drink SSBs and the health risks of SSBs.~Booster intervention: 8 pictures from the SSB worksheet in the main intervention and 6 true or false questions."
41473518|NCT05540652|BEHAVIORAL|Mindfulness-Based Queer Resilience (MBQR)|"Mindfulness-based Queer Resilience (MBQR) is an internet delivered group-based, LGBTQ affirmative mindfulness program designed to address minority stress and promote mental and sexual health among young adult gay, bisexual, and queer men. The intervention group will meet once a week for up to 2.5 hours for nine weeks. Participants will receive free training in meditation, mindful movements, and in directing mindfulness-based skills towards enhancing things like stress recovery, sleep, resilience, cognitive performance and social relationships. MBQR was adapted from the Mindfulness-Based Stress Reduction program. Customization of the curriculum was developed by queer researchers and teachers, with input from the LGBTQ community."
41473519|NCT01030211|PROCEDURE|Platelet transfusion|4 units of platelets for patients with platelet count \<20x10\^3/uL
41473520|NCT01030211|OTHER|Supportive care|Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
41473521|NCT01891305|DRUG|VT-1161|
40798979|NCT06520696|BEHAVIORAL|Usual care|"Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program and will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months. Participants in the control group can receive financial compensation for the completion of assessments. This is necessary to maximize retention and adherence to the monthly assessment schedule, provide comparable remuneration as the incentive group, and minimize demoralization of control group participants following treatment assignment. All participants are informed of the differential group procedures during the randomization consent process. In addition to the follow-up assessment, control group will also complete a monthly self-report on BF status (both for EBF and any BF). For attention control purposes in this group, participants will be referred to a mobile app for tracking the baby's milestones called Baby Connect."
40798980|NCT05802420|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
41003069|NCT02609022|BIOLOGICAL|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
41003070|NCT01067768|OTHER|Daily review|"Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.~The attending physician decides withdraw or no withdraw the urinary catheter"
41003071|NCT01521611|RADIATION|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
41473522|NCT01891305|DRUG|placebo|
41315810|NCT04250012|BEHAVIORAL|Psychoeducation|The psychoeducation group received a self-help booklet and a link to a web-based wellness training program. The program included exercises with MP3 audio files. No personal support during the 10-week intervention was provided.
40798981|NCT03371576|DEVICE|intraocular lenses|
40798982|NCT06417827|DIAGNOSTIC_TEST|SP patients-actors|SP Actors employed by MesserMSR, the Israeli Center for Medical Simulation, trained to simulate symptoms of psychiatric illnesses.
40798983|NCT06417827|DIAGNOSTIC_TEST|Patients|Patients (n=150) examined in the psychiatric division and emergency room (ER) of Sheba Medical center. Or people who applied following an advertisement on social networks.
40798984|NCT06417827|DIAGNOSTIC_TEST|Control group- patients|Control group (n=50) Patients who came to the ER at the hospital due to physical complaints, and no psychiatric history.
40798985|NCT05681572|DRUG|Midazolam|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
40798986|NCT05681572|DRUG|Dexmedetomidine|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
40798987|NCT05681572|DRUG|Placebo|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
40798988|NCT01864148|DRUG|BIIB033|
40798989|NCT01864148|OTHER|Placebo|
40798990|NCT01864148|DRUG|Avonex|
40798991|NCT04351607|DIETARY_SUPPLEMENT|Oleovital® Eisen Forte|60 mg daily oral Supplementation for 3 to 6 weeks
40798992|NCT00422643|DRUG|Sodium hyaluronate (hyaluronic acid)|
40798993|NCT06202352|BEHAVIORAL|Meditation and Yoga|The yoga and meditation intervention will use a 60-minute vinyasa yoga class once a week, followed by a guided yoga instruction booklet that takes an average of 30 minutes to read. The intervention will be carried out in the last eight weeks of the spring semester, when hospital practices are most intense and before the final exams. Posttest forms will be filled out the week of final exams. The time devoted to meditation will be increased every week for the last two weeks, starting with 5 minutes and gradually increasing to 20 minutes in the eighth week.
40798994|NCT04517344|OTHER|Initial Flow Rate|Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min
40798995|NCT05541627|GENETIC|AB-1001 Gene Therapy|One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene
41003072|NCT04165668|OTHER|Exposure: First on scene|To be first on scene for resuscitation at the suspected out-of hospital cardiac arrest, before EMS and first responders (fire and police services)
41003073|NCT01563575|OTHER|fast-track implementation process|Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
40798996|NCT02523092|DRUG|Acthar gel|Acthar gel given IM or SQ as per package insert
41003074|NCT04528446|RADIATION|Dual-energy X-ray absorptiometry|DXA whole body, hip, spine, and radius at baseline, and 12-month visit.
41003075|NCT04528446|RADIATION|High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)|HR-pQCT of the radius and tibia at baseline, and 12-month visit.
40798997|NCT02525484|DRUG|Pirfenidone|Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
40798998|NCT04166578|DRUG|lignocaine|The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
40798999|NCT04166578|PROCEDURE|Phacoemulsyfication|Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
40799000|NCT04166578|PROCEDURE|Intraocular lens implantation|An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
40799001|NCT04166578|BEHAVIORAL|Visual Analog Scale for Pain|VAS for Pain is a new tool developed to assess the pain in quantitative terms.
40799002|NCT04166578|BEHAVIORAL|Brief Pain Inventory-short form|BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
40799003|NCT04166578|DIAGNOSTIC_TEST|Best corrected visual acuity measurment|Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
40799004|NCT04166578|DIAGNOSTIC_TEST|Slit-lamp biomicroscopy|Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
40799005|NCT01803880|DEVICE|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
40799006|NCT01803880|DEVICE|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
41003076|NCT04528446|OTHER|Blood draw and Urine collection|The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.
41003077|NCT04528446|OTHER|Questionnaires|Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
41003078|NCT03395314|DRUG|Ketamine|1 single dose of IV ketamine
41003079|NCT03395314|DRUG|Midazolam|1 single dose of IV midazolam
41003080|NCT01435291|DRUG|Advagraf Capsule|"Other Names:~* FK506E~* MR4~* tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
41003081|NCT01435291|DRUG|Prograf Capsule|"Other Names:~* FK506E~* MR4~* tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
41003082|NCT05857124|DEVICE|Vielight Neuro RX Gamma active device|The Vielight Neuro RX Gamma active device is a home-use photobiomodulation (PBM) device designed to deliver near-infrared (810 nm) light (or photons) to the brain/scalp and nasal tissues.
41003083|NCT05857124|DEVICE|Vielight Neuro RX Gamma sham device|The Vielight Neuro RX Gamma sham device is a home-use device similar to the Vielight Neuro RX Gamma active device, but acting as a sham.
41003084|NCT01637688|DIETARY_SUPPLEMENT|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
41003085|NCT05930678|PROCEDURE|No ventilation with face mask|During the period of apnea (in general anesthesia), the patient did not help with face mask
41003086|NCT05930678|PROCEDURE|Ventilation with face mask|During the pperiod of apnea (in general anesthesia), the patient did help with face mask
41003087|NCT06484153|DRUG|Pirfenidone|Two doses of pirfenidone (200 mg,tid,po;500 mg,tid,po) were set up. Using the 3+3 design, the DLT observation period is 28 days.
41003088|NCT06484153|DRUG|Fruquintinib|3mg, orally, qd
41003089|NCT06484153|DRUG|Pembrolizumab|200mg iv every 3 weeks
41473523|NCT02315547|DRUG|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline \[16\]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
41473524|NCT00474604|PROCEDURE|diffusion-weighted magnetic resonance imaging|A scan will be performed.
41315811|NCT00623467|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
41315812|NCT00593840|RADIATION|Intensity modulated radiation therapy|
41315813|NCT00390416|DRUG|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
41315814|NCT06509724|RADIATION|Conventional Fractionated IMRT|"* Dose: 1.8-2.0 Gy per session, total 25-28 sessions (40-50.4Gy)~* Chemotherapy: Weekly, total 5-6 sessions"
41315815|NCT06509724|RADIATION|Hypofractionated IMRT|"* Dose: 2.5 Gy per session, total 16 sessions (40Gy)~* Chemotherapy: Weekly, total 3 sessions"
41315816|NCT04923620|DRUG|cetuximab+mFOLFOX6|cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
41315817|NCT04923620|RADIATION|short-course radiotherapy|25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6
41315818|NCT01860534|BEHAVIORAL|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
41315819|NCT03514069|DRUG|ruxolitinib|Starting dose ruxolitinib 10 mg twice daily
41315820|NCT03514069|RADIATION|radiation|60gy for 6 weeks
41473525|NCT00474604|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
41473526|NCT00474604|PROCEDURE|magnetic resonance spectroscopic imaging|A scan will be performed.
41473527|NCT03612739|BIOLOGICAL|NKR-2 CAR-T Cells|"The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5."
41473528|NCT02170831|DRUG|BIBR 1048 MS low|
41315821|NCT03514069|DRUG|temozolomide|75mg/m2
41315822|NCT06180759|DRUG|Intravenous infusion of DMT|A dose rate of 1.2 mg/min will be administered
41315823|NCT06180759|DRUG|Intravenous infusion of ketamine|A dose rate of 1.0 mg/min will be administered
41315824|NCT06180759|DRUG|Intravenous infusion of placebo|A Placebo (saline infusion) will be administered.
41315825|NCT02236949|BEHAVIORAL|Pain Practice Change Booster Intervention|See experimental arm for a description of the intervention
41315826|NCT03299855|OTHER|Passation of neuropsychological test|Passation of MoCA and MMS tests associated with neuropsychological test
41315827|NCT02500394|PROCEDURE|Ionosteril|biomarker guided volume substitution with Ionosteril
41315828|NCT03227965|BIOLOGICAL|Immune cells population assesment|T lymphocytes population description through blood, urine and faeces samples
41473529|NCT02170831|DRUG|BIBR 1048 MS medium 1|
41473530|NCT02170831|DRUG|BIBR 1048 MS medium 2|
41473531|NCT02170831|DRUG|BIBR 1048 MS high|
41473532|NCT02170831|DRUG|BIBR 1048 MS placebo|
40799007|NCT06442904|OTHER|Digital education program|The approximately six hours long digital education program will be available for three months and implies further education in intraoral radiographic examinations.
40799008|NCT05084079|DRUG|CSII with formula-based initial insulin regimen|Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
40799009|NCT05084079|DRUG|CSII with weight-based initial insulin regimen|TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
41003090|NCT04642729|PROCEDURE|Fresh Corneal Lenticule Implantation using Relex-Smile Surgery|Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
41003091|NCT05121584|PROCEDURE|Placement of an anterior crown restoration as a final restoration|Placement of an anterior crown restoration as a final restoration
41003092|NCT03325907|DEVICE|navigational template|The navigational template was created based on computed tomography data using three-dimensional technology.
41003093|NCT01080313|OTHER|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
40799010|NCT06368414|DRUG|Asciminib|that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation
41315829|NCT03616327|DEVICE|MATRx in-lab, MATRx plus|The MATRx remotely controlled mandibular positioner (RCMP) consists of temporary dental trays connected to an extra-oral linear actuator that protrudes the mandible. MATRx is used during polysomnography, where sleep and cardio-respiratory variables are recorded during sleep. The position of the mandible is controlled remotely by a sleep technologist, who moves the mandible while monitoring cardio-respiratory variables. The test determines if mandibular protrusion eliminates pharyngeal obstruction and the required protrusion. The MATRx plus is used in the home. Like the RCMP, the patient sleeps with the motorized mandibular positioner (MP) in place. However, the MP's position is controlled by a computer, making it a feedback controlled mandibular positioner (FCMP). The FCMP detects apneas and hypopneas in real time. Using this information, the controller decides when to move the mandible and by how much. The test predicts of therapeutic outcome with OA and provides a target protrusion.
41473533|NCT06214754|PROCEDURE|PCI|The subjects underwent immediate coronary angiography after Percutaneous transluminal coronary angioplasty to evaluate the success rate of instruments, and immediate coronary angiography after PCI to evaluate the success rate of clinical treatment
41473534|NCT03013881|BIOLOGICAL|UB-921|150 mg/vial
41473535|NCT03013881|BIOLOGICAL|Herceptin|440 mg/vial
41473536|NCT04681196|OTHER|patients shifted to nasal mask after persistent OSA with oronasal mask|In this group were selected OSA patients exhibiting persistent obstructive events and paradoxical obstruction with oronasal masks during CPAP , that were fully recovered (no more OSA detected) with the shift to nasal one
40799011|NCT03248167|DRUG|Cannabidiol|600 mg daily
40799012|NCT03248167|DRUG|Placebos|This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
40799013|NCT04566952|DRUG|Anlotinib|Anlotinib will be treated with its minimum dose that is orally 8 mg daily on days 1-14 of a 21-days cycle.
40799014|NCT04566952|DRUG|Olaparib|Olaparib will be treated with a total daily dose of 450 or 300mg.
41003094|NCT00413725|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
41003095|NCT00413725|OTHER|Placebo|Placebo
41003096|NCT02977234|DRUG|Isoamyl 2-Cyanoacrylate|
41003097|NCT05274256|PROCEDURE|implant placement with simultaneous soft tissue augmentation|implant placement with simultaneous soft tissue augmentation using De-epithelialized free gingival graft and immediate temporization in the maxillary aesthetic zone .
41003098|NCT04242108|DIAGNOSTIC_TEST|Deep learning algorithm based on AS-OCT scans|The OCT scans of study subjects would be imported into the algorithm. Automated classfication of angle width and detection of synechia would be performed by the algorithm. The diagnostic performance of the algorithm would be compared with gonioscopy records.
41003099|NCT01588912|DRUG|Telbivudine|If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
41003100|NCT01588912|DRUG|Tenofovir|If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
41003101|NCT01588912|DRUG|Entecavir|Maintain the entecavir through the study period
41003102|NCT06096415|DRUG|ABX-101 1mg|ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
41003103|NCT06096415|DRUG|ABX-101 2mg|ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
41003104|NCT01841814|RADIATION|Bone densitometry.|
41003105|NCT03092180|DRUG|Intravenous Infusion|Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
41003106|NCT05503719|PROCEDURE|Surgical wound closed with an absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with an absorbable suture according to their respective study group.
41003107|NCT05503719|PROCEDURE|Surgical wound closed with a non-absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with a non-absorbable suture according to their respective study group.
41003108|NCT00649064|DRUG|Ziprasidone|Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
41003109|NCT04501731|OTHER|Transcranial Magnetic Stimulation (TMS)|With the TMS session we gather information about nerve fibres from the brain to the hand. It will last around 2 hours and 30 minutes.
41003110|NCT04501731|OTHER|Magnetic Resonance Imaging (MRI)|With the MRI scan we will gather information about the brain structure and function. This will last around 30 minutes.
41003111|NCT04501731|OTHER|Motor assessment|"The motor assessment includes a pegboard game, a grab the alien nose game and measure of your maximum grip force. In total it will last around 30 minutes."
41003112|NCT04501731|OTHER|Questionnaires|Feasibility, tolerability of such intervention as well as quality of life of PFT survivors will be assessed thanks to questionnaires.
41003113|NCT04618120|OTHER|Virtual reality-based exercise|"Virtual reality-based exercises with Microsoft Xbox 360 Kinect and breathing exercises.~Patient education"
41003114|NCT04618120|OTHER|Exercise|Shoulder range of motion, stretching, posture and breathing exercises. Patient education
41003115|NCT05071703|DRUG|Trilaciclib|"* Carboplatin combined with Etoposide (ES-SCLC patients)~* plus Topotecan (second/third line ES-SCLC patients)"
41003116|NCT02390583|BEHAVIORAL|CBT treatment of internet dependence|CBT treatment of internet dependence
40799015|NCT04113356|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
40799016|NCT06549166|OTHER|Experimental: VR and exercise|Participants will perform a 20-minute exercise program consisting of neck joint mobility exercises, neck and scapulothoracic muscle strengthening exercises, and stretching exercises. Then, for the next 20 minutes, they will engage in active neck movements using the Oculus Quest2 headset with the Ocean Rift game.
40799017|NCT06549166|OTHER|Sham Comparator: exercise|The control group will perform a 40-minute same neck exercises.
41003117|NCT02390583|BEHAVIORAL|CBT treatment of sleep disorders|CBT treatment of sleep disorders
41003118|NCT00363454|DRUG|Triciribine Phosphate Monohydrate|8 Cycles @ 28 days. Level 1: 15 mg/m\^2; Level 2: 25 mg/m\^2; 35 mg/m\^2; 45 mg/m\^2.
41003119|NCT02588924|OTHER|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
41315830|NCT04326023|DRUG|PARP Inhibitors|olaparib, rucaparib, niraparib, talazoparib, veliparib
41315831|NCT03269890|PROCEDURE|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks once before surgery per side
41315832|NCT03269890|PROCEDURE|US-intermediate cervical plexus block|15 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml once before surgery per side.
41003120|NCT02588924|OTHER|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
41003121|NCT04911725|DEVICE|Elastic Compression Prototype|Elastic Compression device - No medical, surgical or laboratory procedure is implied in the use of the IMD.
41003122|NCT04582851|OTHER|some risk factors correlated with TMD|exposure factors causing TMD
41003123|NCT02014675|DEVICE|SD01 ICD lead|
41003124|NCT02686346|DRUG|Brentuximab Vedotin|"Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
41003125|NCT02686346|DRUG|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
41003126|NCT02686346|DRUG|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
41003127|NCT02686346|DRUG|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
41003128|NCT01616186|DRUG|Everolimus and sorafenib|"* Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing~* Everolimus and sorafenib are dosed continuously~(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)"
41003129|NCT01616186|DRUG|Sunitinib monotherapy|"Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing~(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)"
41003130|NCT06210087|OTHER|Spontaneous pushing technique|Pregnant women selected for the experimental group were trained on spontaneous pushing technique in the first stage of labor. During the second stage of labor, the women were encouraged and supported in this direction.
41003131|NCT03031171|BEHAVIORAL|Screening patient navigation|The program offered assistance with scheduling, paperwork, arranging transportation, answering questions and providing education about screening and colorectal cancer.
41003132|NCT03031171|BEHAVIORAL|Non-Navigated|Randomly matched sample of non-navigated clinic patients
41315833|NCT03288324|DRUG|Tofacitinib|Tofacitinib 5 mg twice daily
41315834|NCT06281145|BEHAVIORAL|Heart-rate variability biofeedback intervention|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
41315835|NCT06190743|OTHER|Prevention events organized by participating centers|Cardiovascular disease primary prevention events organized by centers participating in the study where capillary sampling will be performed on subjects to quantify plasma levels of cardiovascular risk factors and validated questionnaires will be administered
41315836|NCT03935607|DIAGNOSTIC_TEST|Transvaginal sonography|Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
40799018|NCT01539070|BEHAVIORAL|Eating and physical activity counseling|"The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity."
41003133|NCT06155617|OTHER|Upper Extremity Rehabilitation|Pain management, ROM, Edema Management, Desensitization, Strengthening, Functional Tasks
41315837|NCT03600948|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
41003134|NCT00053794|DRUG|perifosine|
41003135|NCT01336686|DRUG|Arhalofenate|Arhalofenate 400 mg once daily for 4 weeks
41315838|NCT03304470|DRUG|ATx201 2% Cream|Anhydrous Cream
41315839|NCT03304470|DRUG|ATx201 Cream Vehicle|Anhydrous Cream
41315840|NCT01921946|DRUG|Fimasartan|
41315841|NCT01921946|DRUG|Rosuvastatin|
41315842|NCT01750944|PROCEDURE|Ankle first|"1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPA-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPT-LR are re-measured."
41315843|NCT01750944|PROCEDURE|Toe first|"1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPT-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPA-LR are re-measured."
41315844|NCT04658472|DRUG|SAR445088 (IV)|Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)
41315845|NCT04658472|DRUG|SAR445088 (SC)|Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
41315846|NCT01872091|OTHER|cryotherapy by immersion|
41315847|NCT01872091|OTHER|Control group|
41473537|NCT04423159|BIOLOGICAL|OCV Vaccine|2 doses of OCV were administered to all enrolled participants 1st dose administered at baseline and second dose administered 28 days post 1st dose.
41003136|NCT01336686|DRUG|Arhalofenate|Arhalofenate 600 mg once daily for 4 weeks
41003137|NCT01336686|DRUG|Placebo comparator|Matching placebo once daily for 4 weeks
41003138|NCT01336686|DRUG|Colchicine|0.6 mg colchicine daily for flare prophylaxis
41315848|NCT04580251|PROCEDURE|Targeted axillary dissection|The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
41315849|NCT03136770|DIETARY_SUPPLEMENT|CK-30|Compound K 600 mg
41315850|NCT03136770|DIETARY_SUPPLEMENT|Red ginseng extracts|Red ginseng extracts 2.94 g
41315851|NCT06136312|DEVICE|Multi4|TURBT procedure performed with the Multi4 instrument in local anesthesia
41315852|NCT06350565|DRUG|Dexamethasone|This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions. During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.
41315853|NCT00303758|DRUG|cisplatin|
41315854|NCT00303758|DRUG|fluorouracil|
41315855|NCT00303758|DRUG|gemcitabine hydrochloride|
41315856|NCT00303758|DRUG|leucovorin calcium|
41315857|NCT04972734|BIOLOGICAL|premature newborns developing a NEC|weekly Blood sample and daily Stools sample during 12 weeks + Blood and stool sample during NEC
41315858|NCT04972734|BIOLOGICAL|premature newborns without NEC|weekly Blood sample and daily Stools sample during 12 weeks
41315859|NCT04237324|PROCEDURE|Treatment one side BLE by NAFL|One side of the patient face underwent treatment using the ResurFX module of M22 (Lumenis Co., Yokneam, Israel) randomly.
41315860|NCT04237324|PROCEDURE|Treatment another side BLE by FMR|One side of the patient face underwent treatment using FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
41315861|NCT00280150|BIOLOGICAL|bevacizumab|Given IV
41315862|NCT00280150|DRUG|carboplatin|Given IV
41315863|NCT00280150|DRUG|erlotinib hydrochloride|Given orally
41315864|NCT00280150|DRUG|paclitaxel|Given IV
41315865|NCT00280150|RADIATION|3-dimensional conformal radiation therapy|Given 5 days a week for 7 weeks
41315866|NCT02822534|DRUG|SP2086|the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
41315867|NCT04095754|PROCEDURE|Head-Up Position|Anti-Trendelenburg Position
41473538|NCT05788575|PROCEDURE|surgery|any surgery that an inpatient has undergone
41473539|NCT02332408|RADIATION|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
41473540|NCT02332408|RADIATION|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
41473541|NCT01991288|PROCEDURE|SNB Saphenous Nerve Block|Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
41003139|NCT01353378|DRUG|dexmedetomidine|Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
41315868|NCT04095754|DRUG|Dexmedetomidine|Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1
41315869|NCT04095754|DRUG|Induction and maintenance of anaesthesia|"Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim."
41473542|NCT01991288|PROCEDURE|NSNB Non Saphenous Nerve Block|All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
41003140|NCT06308991|OTHER|Yakson touch|Yakson touch method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The Yakson method continued for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes).
41003141|NCT06308991|OTHER|Gentle Human Touch|Gentle Human Touch (GHT) method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The GHT method continued for 15 minutes.
41315870|NCT05562024|BIOLOGICAL|T cell injection targeting B7-H3 chimeric antigen receptor|The subjects will be administered once.
41315871|NCT03102216|DIAGNOSTIC_TEST|iSTAT|iSTAT troponin, INR, CG4+ and Chem8
41315872|NCT03102216|DIAGNOSTIC_TEST|CBC|Complete Blood Count
41473543|NCT01046630|DRUG|AZD6765|single infusion
41473544|NCT01046630|DRUG|Ketamine|single infusion
41473545|NCT01046630|DRUG|Placebo|single infusion
41473546|NCT01338714|OTHER|Compound Herbal Formula (RHD-1)|100 ml/per day
41473547|NCT01338714|OTHER|dilute RHD-1|100 ml/per day
41473548|NCT04599621|DIAGNOSTIC_TEST|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10),Collection of blood samples to determine the level of uric acid|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10) All study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA). All participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method.
41473549|NCT02667678|BIOLOGICAL|Cohort HIVOL, patients infected by HIV|Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
41315873|NCT03102216|DIAGNOSTIC_TEST|ECG|ElectroCardioGram
41315874|NCT03102216|DIAGNOSTIC_TEST|Lodox|Low dose x-ray
41315875|NCT05144243|DRUG|Venetoclax|Tablet: Oral
41315876|NCT05144243|DRUG|Azacitidine|Subcutaneous Injection (SC)
41315877|NCT00945074|OTHER|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
41473550|NCT00343434|BEHAVIORAL|behavioral dietary intervention|
41473551|NCT00343434|BEHAVIORAL|exercise intervention|
41003142|NCT06308991|OTHER|Routine care|Infants in the Routine care will be applied swaddling. It will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.
41315878|NCT00945074|OTHER|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
41315879|NCT00945074|OTHER|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
41473552|NCT00343434|DIETARY_SUPPLEMENT|soy isoflavones|
41473553|NCT00343434|DIETARY_SUPPLEMENT|soy protein isolate|
41473554|NCT00343434|OTHER|counseling intervention|
41473555|NCT00343434|OTHER|educational intervention|
41473556|NCT00343434|PROCEDURE|psychosocial assessment and care|
41473557|NCT00343434|PROCEDURE|quality-of-life assessment|
41473558|NCT05172102|OTHER|breathing exercise, Aerobic exercises|6 min of quiet breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).
41473559|NCT05414864|DRUG|Ramelteon (RozeremR)|8mg daily
41473560|NCT05414864|BEHAVIORAL|sleep hygiene|sleep behavioral guidelines
41473561|NCT03028064|OTHER|blood taking|in this cohort study, we will take blood to examine the platelet function
41473562|NCT05482204|OTHER|Low Climate Impact label|Menu labels indicating low climate impact on chicken, fish, and vegetarian food items on a simulated online fast food menu.
41473563|NCT05482204|OTHER|High Climate Impact label|Menu labels indicating high climate impact on beef food items on a simulated online fast food menu.
41473564|NCT02508116|GENETIC|CYP2C19 genotyping|The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 \*2, \*3, and \*17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
41003143|NCT03761732|BEHAVIORAL|Islamic Trauma Healing|6 session behavioral intervention program designed to reduce PTSD and related symptomatology
41003144|NCT03548766|BIOLOGICAL|Homologous Blood Transfusion|Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
41003145|NCT03548766|BIOLOGICAL|Autologous Blood Transfusion|Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
41151765|NCT01848483|OTHER|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
41151766|NCT00293085|DRUG|Docetaxel|
41315880|NCT03296787|DRUG|TAK-954|TAK-954 intravenous infusion.
41473565|NCT02715232|DRUG|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
41473566|NCT02715232|DRUG|Lynestrenol|2-3 tablets/day, if menstruation still occurs
41315881|NCT03154151|BEHAVIORAL|Online Cognitive-Behavioral Therapy|Each participant will complete writing assignments focusing on how their experiences during the 9/11 attacks or the WTC recovery effort continue to affect their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
41003146|NCT06000865|BEHAVIORAL|Action video game training|20 sessions of AVG over 10 weeks (45 minutes per session, 2 sessions per week)
41003147|NCT06000865|BEHAVIORAL|Conventional physical training|20 sessions of physical training over 10 weeks (45 minutes per session, 2 sessions per week)
41003148|NCT03688672|DEVICE|Apioc Contact Lens Design|Novel soft contact lens design.
41473567|NCT02715232|DRUG|Cyproterone Acetate|25mg daily
41473568|NCT02715232|DRUG|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
41473569|NCT02715232|DRUG|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
41473570|NCT04491578|BEHAVIORAL|"ACP programme Have a Say"|Each dyad of participants will receive a 4-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 2 group-based sessions and 2 dyadic discussions. One hour for each session. The group-based sessions are nurse-led, in which dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are led by trained ACP facilitator. Dyads of participants will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
41473571|NCT00024388|DRUG|DHA-paclitaxel|
41473572|NCT03057002|DIAGNOSTIC_TEST|Hyperpolarized 13C-Pyruvate|All subjects will be observed for myocardial hyperpolarized \[1-13C\]pyruvate flux during magnetic resonance spectroscopic imaging.
41473573|NCT04500132|DRUG|EC-18|EC-18 QD
41473574|NCT04500132|DRUG|Placebo EC-18|Placebo EC-18 QD
41473575|NCT05563181|BEHAVIORAL|Control bar code label|Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
41473576|NCT05563181|BEHAVIORAL|Warning label|"Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
41473577|NCT05563181|BEHAVIORAL|Informational campaign poster about added-sugar warning labels|Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.
41473578|NCT06168318|DRUG|VH4004280 Formulation A|Oral administration of VH4004280 Formulation A in fasted or fed conditions.
41151767|NCT00293085|DRUG|Docetaxel|"Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
41151768|NCT05844280|PROCEDURE|BFR+NMES at therapeutic level|This group will receive therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic.
41473579|NCT06168318|DRUG|VH4004280 Formulation B|Oral administration of VH4004280 Formulation B in fasted or fed conditions.
41473580|NCT06168318|DRUG|VH4004280 Formulation C|Oral administration of VH4004280 Formulation C in fasted or fed conditions.
41473581|NCT06168318|DRUG|VH4004280 Formulation D|Oral administration of VH4004280 Formulation D in fasted or fed conditions.
41473582|NCT06168318|DRUG|VH4004280 Formulation E|Oral administration of VH4004280 Formulation E in fasted or fed conditions.
41473583|NCT06043791|RADIATION|1.5 Tesla magnet MR arthrography|MR arthrogram is an invasive procedure where the patient's joint is injected with a mixture of dilute gadolinium, iodinated contrast medium, local anesthetic, and saline solution followed by imaging with 1.5 Tesla MRI.
41473584|NCT06043791|RADIATION|3 Tesla magnet non-contrast MRI|3T MRI uses very powerful magnets that produce a 3-tesla magnetic field. A 3-tesla magnetic field is twice as powerful as the fields used in conventional high-field MRI scanners, and as much as 15 times stronger than low-field or open MRI scanners. This results in a clearer and more complete image. Studies have shown that it is highly sensitive and specific in detecting labral and cartilage pathology
41473585|NCT03810573|DEVICE|NB1|rhNELL-1/DBX
41473586|NCT04221126|DEVICE|TMFI|Tixel rapidly transfer thermal energy by a metallic pyramid tip that enable skin contact through integrated pulsed movements. The rapid heating dehydrates he epidermis and superficial dermis and creates micropores with no coagulative damage of surronding tissue.
41473587|NCT04221126|DRUG|ALA cream|ALA compounded in a cream
41473588|NCT04221126|DRUG|ALA gel|ALA compounded in a gel
41473589|NCT01677013|OTHER|BMMCT|Bone marrow mononuclear cell transplantation via selective catheterization
41473590|NCT04959383|OTHER|Low complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept low for this group.
41473591|NCT04959383|OTHER|Moderate complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept moderate for this group.
41473592|NCT04959383|OTHER|High complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept high for this group.
41473593|NCT04959383|OTHER|Control Group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. This group will receive exergame balance training on Wii fit. Participants in this group will play Soccer Heading, Ski Slalom, Ski Jump, Table Tilt, Tightrope Walk, Balance Bubble, Penguin Slide and Snowboard Slalom game.
41473594|NCT04520776|DEVICE|BAGUERA®C Cervical Disc Prosthesis|surgery
41473595|NCT04520776|DEVICE|Mobi-C® Cervical Disc|surgery
41473596|NCT03275584|DRUG|N-13 ammonia intravenous injection|"Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging"
41473597|NCT02044432|OTHER|ginger compress|Kidney ginger compress
41315882|NCT03154151|BEHAVIORAL|Online Supportive Therapy|Each participant will complete writing assignments focusing on problems and stressors that are currently affecting their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
41315883|NCT02024191|DIETARY_SUPPLEMENT|Glutamine|
41473598|NCT05022563|DRUG|Parenteral anticoagulant|Parenteral anticoagulant only
41473599|NCT05022563|DRUG|Warfarin|Warfarin-based
41473600|NCT05022563|DRUG|Apixaban|Apixaban
41473601|NCT05022563|DRUG|Rivaroxaban|Rivaroxaban
41473602|NCT05022563|DRUG|Dabigatran|Dabigatran
41473603|NCT05022563|DRUG|Edoxaban|Edoxaban
41473604|NCT03558620|PROCEDURE|mask ventilation|mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)
41473605|NCT00793741|DRUG|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
41473606|NCT04403516|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.
41473607|NCT04403516|DRUG|Prednisolone Acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
41473608|NCT02906865|OTHER|Proximal hamstring tendons repair|Proximal hamstring tendons repair
41473609|NCT05736224|DRUG|Sunscreen|The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and trans-resveratrol.
41473610|NCT05736224|OTHER|UV Light|UV light to the correct sites, and the Multiport 610 solar simulator used to deliver 1 MED UVR to the appropriate subsites.
41473611|NCT05688397|DIETARY_SUPPLEMENT|Experimental 1|L. gasseri oral capsule once a day (1 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
40799019|NCT02674464|BEHAVIORAL|Provider Audit-Feedback, Stratified by Race and Ethnicity|Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. The RICH LIFE Project provides the health systems with the logic to build practice and provider level hypertension (HTN) dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as \<140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
41003149|NCT00757835|DRUG|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
41003150|NCT00757835|DRUG|latanoprost/timolol fixed combination drops|once in the evening
41003151|NCT01966926|BEHAVIORAL|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
41003152|NCT00654069|DRUG|Placebo|2 tablets every 6 hours for 48 hours
41003153|NCT00654069|DRUG|Acurox 5/30 mg|2 tablets every 6 hours for 48 hours
41003154|NCT00654069|DRUG|Acurox 7.5/30|2 tablets every 6 hours for 48 hours
41003155|NCT05500365|PROCEDURE|Catheter ablation therapy|Pace mapping procedure performed during catheter ablation therapy
41003156|NCT00190801|DRUG|pemetrexed|
41003157|NCT00190801|DRUG|cisplatin|
41003158|NCT01823874|PROCEDURE|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
41003159|NCT02682316|OTHER|dry gauze|
41473612|NCT05688397|DIETARY_SUPPLEMENT|Experimental 2|L. gasseri and L. crispatus oral capsule once a day (1.5 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
41473613|NCT05688397|DIETARY_SUPPLEMENT|Placebo|One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
41473614|NCT03483311|OTHER|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1
41151769|NCT05844280|PROCEDURE|BFR+NMES at sub therapeutic level|This means that the BFR tourniquet and the NMES device will be at such low settings as to not create the treatment effect but subject will have the equipments on their thigh during exercise
41151770|NCT02383121|DRUG|Midodrine|Not appliciable
41151771|NCT02980198|BIOLOGICAL|IFN-Kinoid|IM administration
41151772|NCT02980198|OTHER|Placebo|IM administration
41151773|NCT02980198|OTHER|ISA 51|adjuvant
41003160|NCT02682316|DEVICE|The Prevena Incision Management System|
41003161|NCT05273268|OTHER|Personalized nutrition|Personalized nutrition based on individual traits delivered through mobile device app.
41003162|NCT05273268|OTHER|Generalized nutrition|General nutrition guidelines currently used by USDA.
41003163|NCT01921829|DRUG|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
41003164|NCT00072150|DRUG|bortezomib|Given IV
41003165|NCT03781076|BEHAVIORAL|Sleep Intervention|The study therapist will outline the biopsychosocial model of mTBI recovery, highlighting the shift from biological injury to behavior (especially sleep behavior) as key driver of symptoms. The intervention will then apply well-established strategies from the pediatric psychology and insomnia literatures, encouraging conjoint problem-solving by parent and youth with the shared goal of maximizing nocturnal sleep. These include: pre-planning, problem-solving, development of a positive routine, commitment to sleep-promoting behaviors, self-monitoring, and positive reinforcement. The therapist will also teach a brief, self-guided pre-sleep relaxation exercise that has been used in insomnia treatment to maximize the benefit of additional sleep opportunity.
41003166|NCT05761275|PROCEDURE|Elective cystectomy|Adnexal cyst removal for presumed benign adnexal pathology.
41003167|NCT05761275|PROCEDURE|Elective oophorectomy|Ovarian removal for presumed benign adnexal pathology.
41003168|NCT05761275|PROCEDURE|Elective salpingectomy|Tubal removal for presumed benign adnexal pathology.
41003169|NCT05761275|PROCEDURE|Elective tubal sterilization|Tubal obstruction as a definitive contraceptive method (tubal cauterization with or without sectioning, partial or total removal of both tubes, or obstruction with small clips/ligatures).
41151774|NCT06256003|DEVICE|UC-A|Mobile app digital therapy
41151775|NCT06256003|DEVICE|UC-N|Mobile app digital therapy
41151776|NCT05208021|BEHAVIORAL|Intervention group (Motivational Interviewing)|The Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program were applied to the experimental group, which consisted of 6 sessions and lasted an average of 60-120 minutes. Sessions were held in the form of individual interviews due to the pandemic and social distance conditions.
41151777|NCT05420701|PROCEDURE|TEE|Patients in the surgical arm (LAAC) will be arranged to do TEE, which is not considered standard of care.
41151778|NCT05285696|DRUG|CSB-111|\[68Ga\]-NOTA-hGZP is a PET imaging agent.
41151779|NCT01348763|DRUG|Maraviroc|Maraviroc 150 mg daily
41151780|NCT01348763|DRUG|Truvada|daily until 10. day then stop
41151781|NCT01348763|DRUG|Darunavir|daily until 10. day then stop
41151782|NCT03096262|BEHAVIORAL|Output-Focus Condition|Users are asked to tag more, and force feedback is exerted the more points the user has
41151783|NCT03096262|BEHAVIORAL|Input-Focus Condition|Users are asked to tag more and force feedback is exerted based on the number of images the user has analyzed.
41473615|NCT04392557|DRUG|Metformin / alogliptin Oral Product|850 or 1000 mg/ 12.5 mg every 12 hours for 12 months
41473616|NCT04392557|DRUG|Metformin / Pioglitazone Pill|(850 mg/15 mg every 12 hours) for 12 months
41473617|NCT04392557|DRUG|triple therapy|Metformin / Alogliptin/ Pioglitazone
40799020|NCT02674464|BEHAVIORAL|Blood Pressure Measurement Standardization|"All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures."
40799021|NCT02674464|BEHAVIORAL|System Level Leadership Intervention|"This System-Level Leadership intervention aims to create a learning network through an inter-organizational approach to promote health equity and reduce CVD disparities. Elements of the system-level leadership intervention, then, include: 1) an introductory session during the kick-off event (baseline); 2) a quarterly 1 hour content call with a presentation on leading for equity and discussion among system-level leaders, community organization leaders, and interested practice champions in the CC/Stepped care arm conducted via conference call/webinar; and 3) monthly coaching calls for the system and practice level leaders, CMs, and CHWs in the CC/stepped care arm to discuss the interventions, while they are actively engaged in the intervention phase."
40799022|NCT02674464|BEHAVIORAL|Collaborative Care Team Intervention|The collaborative care intervention creates a collaborative care team that, at a minimum, consists of PCP, nurse, or social worker care manager, and community health worker. The collaborative care team develops the medical management plan in partnership with patients; 2) uses care coordination to maximize interaction of the patients' PCPs with other care providers addressing medication management, patient self-management, and psychosocial support on a regular, consistent basis; and 3) determines patient access to CHW support and subspecialty consultations.
41151784|NCT00540761|DEVICE|OFDI imaging|Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
40799023|NCT02674464|BEHAVIORAL|Community Health Worker Referral|"As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants"
40799024|NCT02674464|BEHAVIORAL|Specialist Care Consultation|"As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care"
40799025|NCT05760027|OTHER|Plyometric exercise|The group of athletes will perform plyometric stability exercises and their usual exercise for 30 days.
41151785|NCT03671499|BEHAVIORAL|Social Cognitive Theory based text messages|Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
41151786|NCT03369119|DRUG|Montelukast 4 Mg Oral Granule|
41473618|NCT02663882|BEHAVIORAL|self control practice - smoking related task|participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
41473619|NCT02663882|BEHAVIORAL|self control practice - non-smoking related task|participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
41473620|NCT00036647|DRUG|Tarceva (erlotinib HCl, OSI-774 )|
41473621|NCT02847208|OTHER|self-report written questionnaire|The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.
41473622|NCT05900830|OTHER|play therapy|A combined program based on physical and occupational therapy techniques within a play context
41473623|NCT05900830|OTHER|common educational methods|the child will receive his education in a passive manner
41473624|NCT02201459|DRUG|Nilotinib (Tasigna ®), capsules of 150 mg|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
41473625|NCT02201459|DRUG|Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)|"* Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and~* Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation."
41473626|NCT00686439|DRUG|adalimumab|subcutaneous injection 40mg on alternate weeks
41473627|NCT00686439|DRUG|adalimumab|subcutaneous injection 40mg every other week
41473628|NCT03442959|OTHER|Data record|characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)
41473629|NCT00296491|DRUG|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
41473630|NCT00296491|DRUG|montelukast (MON)|montelukast capsule
41473631|NCT00296491|DRUG|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
41473632|NCT00296491|DRUG|placebo nasal|vehicle placebo nasal spray
41473633|NCT00296491|DRUG|ADVAIR DISKUS|ADVAIR DISKUS
41151787|NCT03369119|DRUG|Placebos|
41151788|NCT01648491|PROCEDURE|Muscle Biopsy|Biopsy of thigh muscle to obtain stem cell core.
41151789|NCT01648491|BIOLOGICAL|Injection of autologous stem cells|After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
41151790|NCT04282200|DRUG|Ketorolac|intravenous ketorolac 30 mg every 6 hours
41315884|NCT00570531|DRUG|Bevacizumab|Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.
40799026|NCT05760027|OTHER|Regular exercise|The group of athletes will perform their usual exercise for 30 days.
40799027|NCT05018195|PROCEDURE|Excise adipose tissue|Perform partial omentectomy to obtain one 5\*5 cm omental fat and excise one 3\*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery
41473634|NCT00296491|DRUG|placebo capsule|placebo capsule
41473635|NCT00296491|DRUG|placebo DISKUS|placebo DISKUS
41473636|NCT00006399|DRUG|Donepezil|
41473637|NCT00006399|DRUG|Estrogen|
41473638|NCT00006399|DRUG|Progesterone|
41473639|NCT02116517|DIETARY_SUPPLEMENT|green tea extract|500 mg three times per day
41473640|NCT02116517|DIETARY_SUPPLEMENT|Placebo|cellulose 500mg three times a day for 6 weeks
41473641|NCT01566279|DRUG|Everolimus|All patients will receive everolimus 10mg q.d.
41473642|NCT02336620|DRUG|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
41473643|NCT02336620|DRUG|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
41473644|NCT02647528|DEVICE|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
41473645|NCT02647528|DEVICE|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
41473646|NCT06531824|DRUG|BI 690517|BI 690517
41473647|NCT06531824|DRUG|Placebo matching BI 690517|Placebo matching BI 690517
41473648|NCT06531824|DRUG|Empagliflozin|Empagliflozin
41473649|NCT06615895|BEHAVIORAL|Telehealth home activity|Several course activities with diverse sensory modalities are provided a week. Caregivers or caretakers need to help children participate in the course content and implement relevant suggestions at least 3-5 times a week for six weeks. The research will be conducted on an online platform. Course announcements, reminders and confirmation of work execution, through caregivers\&#39; feedback records, urge caregivers to engage in parent-child games related to sensory integration and integrated into life at home. Such high-frequency, short-term sensory activities will be adapted to the equipment available at home. It will mainly focus on movement planning, bilateral integration/crossing the midline, vestibular system , visual perception, visual-motor integration, eye movements, core strength activities and Activities focused on balance ability.
41473650|NCT04208269|OTHER|postcard campaign|Post card sent to parent only
41473651|NCT04208269|OTHER|Health Information Technology system|Accessed by adolescent and provider only
40799028|NCT05538377|OTHER|Focal Vibration|This group will receive a multicomponent exercise program based on specific literature for effective training. In addition, this group will perform the strength and endurance exercises with focal vibration on the vastus internus, externus and biceps femoris. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
40799029|NCT05538377|OTHER|Control Group|This group will receive the same multicomponent exercise program than the other group based on specific literature for effective training. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
40799030|NCT02068677|OTHER|Sympathetic response|Sympathetic response will be defined as change in heart rate by \>10 bpm and change in BP \<10mmHg.
41151791|NCT00547300|DRUG|Metoprolol ER|Metoprolol ER once daily, oral administration
41473652|NCT06094998|DIAGNOSTIC_TEST|hemogram examination|It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART. Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
41473653|NCT03474029|DRUG|Rifapentine daily for 6 weeks|600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
41473654|NCT03474029|DRUG|Rifapentine and Isoniazid weekly for 12 weeks|"Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RPT 900 mg once-weekly for persons weighing \> 50 kg. For persons weighing \< 50 kg, the following doses will be given: weight \> 25-32 kg - RPT 600 mg; weight \> 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max)."
41473655|NCT03474029|DRUG|Rifampin and Isoniazid daily for 12 weeks|"Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*.~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max)."
41473656|NCT03474029|DRUG|Rifampin daily for 16 weeks|"Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg."
41151792|NCT00547300|DRUG|Nebivolol|Nebivolol once daily, oral administration
41473657|NCT05108116|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS 3D recontruction of the lower limb and pelvis will be performed.
41473658|NCT05477719|DEVICE|Wearing of specific compression stockings|The patient will wear specific compression stockings prevent the accumulation of fluids during the day in the lower part of the body and thus limiting the nocturnal drainage effect from the lower part of the body to the upper part of the body
41473659|NCT05692999|DRUG|Pembrolizumab 200 mg Q6W|Pembrolizumab 200mg Q6W
41315885|NCT00570531|DRUG|Paclitaxel|Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.
41315886|NCT00570531|DRUG|Cisplatin|Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.
41315887|NCT00570531|DRUG|5-Fluorouracil|Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.
41315888|NCT00570531|RADIATION|Radiation Therapy|Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.
41315889|NCT00570531|PROCEDURE|Esophagectomy|Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
41315890|NCT02137759|RADIATION|Standard Radiation Therapy|Radiation therapy to 60 Gy
40799031|NCT02068677|OTHER|no sympathetic response|no Sympathetic response will be defined as change in heart rate by \<10 bpm and change in BP \<10mmHg.
40799032|NCT06287242|OTHER|spinal manipulation|High velocity, low amplitude (HVLA) manipulation of the cervical or thoracic spine
40799033|NCT01541007|DRUG|Cabazitaxel|25 mg/m2 every three weeks
41003170|NCT04487327|OTHER|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
41315891|NCT02137759|DRUG|Standard Temozolomide|Temozolomide given orally
41315892|NCT02137759|DRUG|Belinostat|Belinostat dose to be determined, given intravenously over 30-45 minutes
41315893|NCT04623463|BEHAVIORAL|Physical activity intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
41315894|NCT02990897|BEHAVIORAL|clinical decision support message|The intervention patient's physician is shown an estimate of the patient's 5 year risk of ESRD with a link for further information.
41315895|NCT03064958|OTHER|Herbs and spices|Mix of commonly used herbs and spices
41315896|NCT03064958|OTHER|High fat meal|Meal containing 1000kcal and 45g fat
41315897|NCT01656317|OTHER|Early multidisciplinary rehabilitation|"Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist."
41315898|NCT03991559|DRUG|Manganese Chloride|Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle
41315899|NCT03991559|DRUG|Anti-PD-1 antibody|Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle
41315900|NCT03991559|COMBINATION_PRODUCT|Systemic therapy|Whether and which should be given depends on the treatment regimen before enrollment.
41315901|NCT00041769|PROCEDURE|Therapeutic Drug Monitoring (TDM)|
41315902|NCT01963754|DEVICE|Dental Implants in Posterior Mandible|Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
41315903|NCT01963754|DRUG|Subperiosteal 1:100.000 Articaine 4% epinephrine|Administration of subperiosteal anesthesia for implant placement
40799034|NCT01541007|DRUG|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
40799035|NCT00082368|DRUG|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
40799036|NCT00082368|DRUG|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
40799037|NCT02277691|DRUG|TAK-536TCH tablet|TAK-536TCH tablets
40799038|NCT02277691|DRUG|TAK-536CCB tablet|TAK-536CCB tablets
40799039|NCT02277691|DRUG|HCTZ 12.5 mg tablet|HCTZ tablets
40799040|NCT05257395|DRUG|XZP-3287+ Letrozole/Anastrozole|XZP-3287 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
40799041|NCT05257395|DRUG|Placebo + Letrozole/Anastrozole|Placebo 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
40799042|NCT03072394|DRUG|Local anesthetic|Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
40799043|NCT03072394|DRUG|local anaesthetic injection|Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
40799044|NCT00092820|DRUG|MK0653, ezetimibe|
40799045|NCT00092820|DRUG|Comparator: placebo|
41315904|NCT01963754|DRUG|Loco-regional 1:100.000 Articaine 4% epinephrine|Administer loco-regional anesthesia for implant placement in posterior mandible
40799046|NCT03863379|DIAGNOSTIC_TEST|whole body DXA|Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
40799047|NCT01539122|DEVICE|Zimmer TM Glenoid|The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
40799048|NCT01539122|DEVICE|Cemented Glenoid|A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
40799049|NCT05441215|DRUG|nirmatrelvir|nirmatrelvir/ritonavir
40799050|NCT05441215|DRUG|ritonavir|nirmatrelvir/ritonavir
40799051|NCT00585988|DEVICE|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
40799052|NCT00585988|DEVICE|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
40799053|NCT05474287|PROCEDURE|SJOV|SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV were as follows: driving pressure (DP) 15 psi; respiratory rate (RR) 20 bpm; inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply, 100% oxygen.
40799054|NCT05474287|PROCEDURE|HFNO|HFNO is conducted. Oxygen supplementation is delivered at 35 liters min-1 with a fraction of inspired oxygen (FiO2) of 100%.
40799055|NCT05273814|DRUG|Tislelizumab|Tislelizumab intravenous infusion 200mg d4
41003171|NCT03712410|BEHAVIORAL|PISCES|The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
41151793|NCT02144116|OTHER|Dance-movement therapy|The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.
41151794|NCT02144116|OTHER|Control group|Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
41151795|NCT06460103|DEVICE|"Placement of a Straumann® Bone Level Tapered implant SLActive® (hydrophilic surface)"|"Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLActive® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation."
41315905|NCT01507844|DEVICE|positive ventilation|10 minutes of increased 4,7,12 positive pressure ventilation
41315906|NCT04904003|OTHER|Rehabilitation Intervention|Strength, flexibility, endurance, balance, mobility, (self-efficacy)
41315907|NCT03338114|DRUG|FLX-787-ODT (orally disintigrating tablet)|Oral Disintegrating Tablet
41315908|NCT06134713|DRUG|cryotherapy with sterile saline at 2.5ºC|In the cryotherapy (experimental group), final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept refrigerated at 2.5ºC and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
41315909|NCT06134713|DRUG|control with sterile saline at room temperature|In the control group, final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept at room temperature and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
41315910|NCT04109872|DRUG|Lenalidomide|Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
41315911|NCT03136133|DIETARY_SUPPLEMENT|Active protein drink|Fish protein from cod to be used for man after Heavy excercise to restitute
41315912|NCT00965406|DRUG|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
41315913|NCT05357326|DRUG|Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
41315914|NCT05357326|DEVICE|Orthokeratology|wear orthokeratology at night while sleeping
40799056|NCT05273814|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
40799057|NCT05273814|DRUG|Bevacizumab|Pemetrexed intravenous infusion 7.5mg/kg，d1
40799058|NCT04789473|GENETIC|Polygenic Risk Score Generation|PRS will be calculated for gestational diabetes risk using both cohorts, participants wont have results returned to them during the study.
40799059|NCT00294671|DRUG|diflunisal|given twice daily for 24 months
40799060|NCT00294671|OTHER|placebo|an inactive substance given twice daily for 24 months
40799061|NCT05145751|OTHER|Simple inflammatory biomarkers measurement|In patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection the values of simple inflammatory biomarkers such NLR will be measured
40799062|NCT01000298|DRUG|Placebo|liquid placebo medication given twice per day for 7 days
40799063|NCT01000298|DRUG|Amoxicillin|liquid amoxicillin given twice per day for 7 days
40799064|NCT01000298|DRUG|Cefdinir|liquid cefdinir given twice per day for 7 days
40799065|NCT00232999|DRUG|Nebulized IVX-0142|
41003172|NCT03002168|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.
41003173|NCT03002168|DIETARY_SUPPLEMENT|Placebo|Placebo tablets identical in appearance to the active comparator
41315915|NCT05357326|DRUG|Atropine Sulfate 0.04% Eye Drop|use one drop into subconjunctiva
41315916|NCT04353336|DRUG|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine
41315917|NCT04777214|DEVICE|Repetitive Transcranial Magnetic Stimulation|Active TMS will be at 90% motor threshold
40799066|NCT01260688|DRUG|cediranib maleate|Given orally
40799067|NCT01260688|DRUG|dasatinib|Given orally
40799068|NCT04242576|DEVICE|Right Left Judgement|It is an application by Noigroup (Neuro Orthopedic Institute), adapted to different devices.
40799069|NCT04242576|OTHER|Action Observation|Videos of cervical movements.
40799070|NCT04242576|BEHAVIORAL|Exercise|Evidence based exercises for the neck.
40799071|NCT01413711|DRUG|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
40799072|NCT00330980|DRUG|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
40799073|NCT00330980|DRUG|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
41315918|NCT04777214|DEVICE|Sham TMS|Sham TMS will be administered
41315919|NCT03116308|DRUG|Opicapone (OPC)|50 mg OPC capsules; oral route
41473660|NCT05692999|DRUG|Pemetrexed 500 mg/m^2 Q3W|Pemetrexed 500 mg/m\^2 Q3W
41473661|NCT05692999|DRUG|Pembrolizumab 200 mg Q3W or 400 mg Q6W|Pembrolizumab 200 mg Q3W or 400 mg Q6W
41003174|NCT03002168|RADIATION|Triolein radiolabeled with 100 microcuries of 3^Hydrogen|A MicroCurie (µCi) is a measure of radioactivity.
41003175|NCT03002168|RADIATION|Tripalmitin radiolabeled with 20 microcuries of 14^Carbon|A MicroCurie (µCi) is a measure of radioactivity.
41003176|NCT00249470|BEHAVIORAL|Abstinence & Work|Participants in the Abstinence \& Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
41003177|NCT00249470|BEHAVIORAL|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
41003178|NCT02152410|DEVICE|acupuncture|Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)
41003179|NCT02152410|DRUG|Morphine|bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS\> 30).
41003180|NCT00876473|PROCEDURE|CPAP system|"Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange~CPAP systems:~Continuous high-flow CPAP with fixed value PEEP valve~Continuous high-flow CPAP with Boussignac valve~Demand flow CPAP supplied by ventilator"
41003181|NCT04655716|DRUG|Sodium Bicarbonate 150Meq/L/D5W Inj|Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.
41003182|NCT00819416|DRUG|5% albumin|5% albumin for the first 7 days of care in the ICU
41003183|NCT00819416|DRUG|Normal Saline|Normal Saline for the first 7 days of care in the ICU
41003184|NCT00481728|DRUG|Tolterodine|Single dose per patient as determined by protocol.
41003185|NCT00481728|PROCEDURE|Filling cystometry|This is a procedure.
41003186|NCT00481728|PROCEDURE|Intravesical neurostimulation|This is a procedure.
41003187|NCT06483035|DEVICE|Intensive Visual Stimulation (IVS)|The IVS system initially makes a video-recording of the intact body part (arm or leg) executing a set of specific movements. These video recordings will be digitally reversed and projected onto a large screen in front of the patient. On the screen, the patient will monitor an intact, life-like extremity in place of the amputated extremity. This digital extremity will then execute the recorded movements in a pre-planned manner. Simultaneously, the patient will follow the digital virtual limb moving on the screen with his/hers amputated arm/leg, which is hidden below the screen. Hence, IVS therapy comprises elements of both movement perception, motor planning, motor execution and visual feedback of two intact limbs moving which are distinctive from classical Mirror-Therapy.
41003188|NCT06483035|OTHER|Usual Care (UC)|"After allocation to UC, the participants continue with their normal treatment as prescribed by their medical doctor. All control participants are offered to complete IVS treatment after the end of the study period. The participants in the control group will therefore be placed on a fictitious waiting list during the study period."
41003189|NCT01054638|DRUG|HAART Treatment|"Using pharmacy records, identify all patients with HAART dispensing during baseline \& follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past \& non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), \& Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline \& follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs."
41003190|NCT00189046|BEHAVIORAL|driving and laboratory tests|
41003191|NCT00697346|DRUG|Alisertib|Alisertib (MLN8237) PIC or ECT
41003192|NCT01358617|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
41003193|NCT01013233|BEHAVIORAL|cognitive training|cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
41003194|NCT01013233|OTHER|control group|no intervention
41003195|NCT04814290|OTHER|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 [SF-36]).|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 \[SF-36\]).
41151796|NCT06460103|DEVICE|"Placement of a Straumann® Bone Level Tapered implant SLA® (hydrophobic surface)"|"Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLA® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation."
41151797|NCT02028650|BIOLOGICAL|the first donor's stem cell|HLA-matched stem cell infusion
41151798|NCT02028650|BIOLOGICAL|the second donor's stem cell|HLA-mismatched, the second donor's stem cell infusion
41315920|NCT03110419|OTHER|Physical Exercise|The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
41315921|NCT05937217|OTHER|myofascial induction and direct scar release techniques|Manual therapy techniques used to reduce chronic lower transverse abdominal scars pain and improve quality of life of the affected women
41473662|NCT05735964|DRUG|Indocyanine green|Intravenous and endoluminal dosing
41003196|NCT00649337|PROCEDURE|Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography|"AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.~The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed."
41003197|NCT05374265|OTHER|Cardiovascular Magnetic Resonance Scan|Patients will receive a baseline CMR scan to detect viability within 7 days of index admission
41003198|NCT00614913|RADIATION|Proton radiation therapy|A total dose of 63 Gy will be delivered in 15 equally divided daily fractions over a 3 week coarse as an out-patient.
41003199|NCT04264468|COMBINATION_PRODUCT|neoadjuvant chemotherapy|This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
41003200|NCT01385124|DRUG|Oral Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
41003201|NCT00219674|BEHAVIORAL|Group I: Video training|"Participants will receive the AED with a video that provides instructional training."
41003202|NCT00219674|BEHAVIORAL|Group II: Video training + enhanced self-efficacy (SE)|Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.
41003203|NCT00219674|BEHAVIORAL|Group III: In-person training + enhanced SE|Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.
41003204|NCT00219674|BEHAVIORAL|Group IV: In-person training + enhanced SE + support|Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
41003205|NCT00836875|DRUG|Voriconazole|"All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (\<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing \<50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension."
41003206|NCT04116710|BIOLOGICAL|HS-110 (viagenpumatucel-L)|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
41003207|NCT04116710|BIOLOGICAL|HS-130|Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
41003208|NCT00009919|DRUG|semaxanib|Given IV
41003209|NCT06149416|DEVICE|Experimental Masimo RD SET SpO2 Adhesive Sensors|Masimo RD SET SpO2 Adhesive Sensors, Adult (4000 Adt), Adult \& Neonate (4003 Neo)
41003210|NCT04887662|OTHER|Fermented vegetable|Participants will be asked to consume 100 g of fermented vegetables per day, at least 5 days per week, for 8 weeks
41003211|NCT00547703|DRUG|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
41003212|NCT00547703|DRUG|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
41003213|NCT02155335|DRUG|Prefilled Syringe delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using prefilled syringe
41151799|NCT03528161|OTHER|Measurement of hypersensitive troponin|"Telephone follow-up at one month, 3 months and 6 months by a clinical research technician. Collection of serious adverse events, reports of hospitalization.~The hypersensitive troponin assay will be recently proposed in a short-term risk stratification score after syncope (30 days), the canadian syncope risk score. If hypersensitive troponin benefits from interesting performances it needs to be evaluated prospectively, as measured only in 47.9% of syncope in this study. Hypersensitive troponin could be a prognostic marker of early serious adverse cardiovascular events in syncope."
41151800|NCT00016978|DRUG|FOLFOX regimen|
41151801|NCT00016978|DRUG|fluorouracil|
40799074|NCT00330980|DRUG|Placebo|Participants will receive placebo for 6 months.
41003214|NCT02155335|DRUG|Smartject Device delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using Smartject Device.
41003215|NCT03145441|DEVICE|CytoSorb®|CytoSorb® is a biocompatible, high adsorptive polymer indicated in conditions where cytokine levels are extremely elevated.
41003216|NCT03812965|DRUG|Botulinum toxin type A|2 units/point of botulinum toxin type A
40799075|NCT01901289|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
40799076|NCT01140594|PROCEDURE|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
40799077|NCT01140594|PROCEDURE|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
41003217|NCT05763888|OTHER|No drug will given|No intervention will be given to the subject
41003218|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
41003219|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
41003220|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
41003221|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
41003222|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
41003223|NCT05799950|DEVICE|AcrySof single-piece IOL|Acrylic single-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
41003224|NCT05799950|DEVICE|AcrySof multi-piece IOL|Acrylic multi-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
41003225|NCT03277261|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
41003226|NCT03277261|DRUG|Teriflunomide|Film-coated tablets administered orally.
41151802|NCT00016978|DRUG|leucovorin calcium|
41151803|NCT00016978|DRUG|oxaliplatin|
40799078|NCT00620373|DEVICE|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
40799079|NCT00620373|DEVICE|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
40799080|NCT00620373|DRUG|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
40799081|NCT05293600|DRUG|Placebo|Placebo capsule 30 min before bedtime
40799082|NCT05293600|DRUG|Acetazolamide|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
40799083|NCT05293600|DRUG|Trazodone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
40799084|NCT05293600|DRUG|Atomoxetine and eszopiclone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
40799085|NCT04789954|BIOLOGICAL|Eptacog alfa, activated|A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
41003227|NCT03277261|DRUG|Oral Placebo|Administered orally.
41151804|NCT06076525|BEHAVIORAL|Multidirectional Perturbations for Balance Control Assessment (60 perturbations)|The intervention involves exposing participants to a series of 60 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by 5 epochs to assess motor flexibility. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
41315922|NCT05937217|DEVICE|therapeutic ultrasound|Ultrasound petron (model SM 500) specifications: output frequency:1Mhz, output power:5W/cm², power intensity:5 degree (0.8-1.2-1.6-2.0-2.5), time intensity:5-30(step by 5 min) . It will be applied for both groups for 10 minutes
40799086|NCT00107900|DRUG|DU-176b|
40799087|NCT01618058|DRUG|No Investigational Product|"This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants"
40799088|NCT01360424|DRUG|Teriparatide|Daily administration of teriparatide 20 ug s.c. for 24 months
40799089|NCT00269750|DRUG|OROS® oxybutynin or Ditropan®|
41003228|NCT03277261|DRUG|IV Placebo|Administered as an IV infusion.
41003229|NCT00578500|PROCEDURE|ovarian transplantation|Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
41003230|NCT00371943|PROCEDURE|band ligation|
41003231|NCT02501096|DRUG|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
41003232|NCT02501096|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
41473663|NCT04859387|OTHER|set of pragmatic shoulder technique|Group A received pragmatic intervention which includes Pectoralis major and minor stretch, AC joint mobilization, rotator cuff facilitation for subscapularis and infraspinatus, serratus anterior stretch, thoracic manipulation and posterior capsular stretch.
41473664|NCT04859387|OTHER|traditional physical therapy|Group B received traditional interventions which includes modalities such as TENS and hot pack, soft tissue mobilization, joint mobilization, stretching and strengthening etc. other than pragmatic intervention
41473665|NCT03500367|DRUG|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
41473666|NCT04832048|OTHER|Therapeutic physical exercise|"The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.~Intensity was be determined by Maximum Heart Rate (HRF)."
41473667|NCT04832048|OTHER|No physical exercise|No programmed physical exercise
41473668|NCT05686759|BIOLOGICAL|Undiluted I.V.-Hepabig inj(GC5103)|undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
41473669|NCT05686759|BIOLOGICAL|Diluted I.V.-Hepabig inj(GC5103)|Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
41473670|NCT04415684|DEVICE|Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
41473671|NCT04415684|DEVICE|No Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
41473672|NCT04936919|DEVICE|BroadBand Light|Treatment arm will receive Broadband light treatment
41473673|NCT03528473|OTHER|Exercise|"The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.~Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.~Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines."
41473674|NCT01286558|DRUG|40 mg telmisartan|once daily
41473675|NCT01286558|DRUG|5 mg amlodipine|once daily
41473676|NCT01286558|DRUG|5 mg amlodipine|once daily
41473677|NCT01286558|DRUG|80 mg telmisartan|once daily
40799090|NCT03150745|PROCEDURE|3- Cervical Pap smears|Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure
41003233|NCT06113952|DEVICE|Sharps bin to collect used needles/injections|Enrolled participants will be provided with a Smart Sharps Bin. The bin will collect used needles over a period of 12 months starting from enrollment.
41315923|NCT04717076|BEHAVIORAL|App-based nutritional concept and fitness tracking|The App-based nutritional concept based on menu plan, which are personalized according to participants age, gender, physical activity. The App is coupled with a Smartwatch to encourage and track physical activity over the study period.
41315924|NCT04717076|BEHAVIORAL|Nutritional concept with individual nutritional counselling|Nutritional concept based on personalized menu plans and individual nutritional counselling every four weeks (4 times during the study)
41315925|NCT04717076|BEHAVIORAL|Nutritional concept without individual nutritional counselling|Nutritional concept based on personalized menu plans
41315926|NCT05479409|RADIATION|Neoadjuvant radiotherapy|radiation therapy combined with chemotherapy prior to surgery
41315927|NCT05720442|DRUG|Tangweian Recipe|The Tangweian recipe is a combination of several Chinese herbs
41473678|NCT03024931|OTHER|observational study|No intervention
41473679|NCT03472742|DRUG|Mesenchymal Stem Cell|As this is a follow-up and an observation study, ADR-001 was administered in the previous study, not in this study.
41003234|NCT00684606|DRUG|Oxytocin IV|5 miu/1000ml Glu/Saline
41003235|NCT03181542|DEVICE|Infrared illumination|Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
41003236|NCT00436943|DRUG|nicotine replacement therapy and bupropion|3-6 months
41315928|NCT05720442|DRUG|Mosapride Citrate|The mosapride citrate tablets will be administrated.
41315929|NCT00418964|PROCEDURE|Single bundle hamstring|Single bundle hamstring
41003237|NCT00436943|BEHAVIORAL|smoking cessation counseling and referrals|Organizational counseling and referrals
41003238|NCT00009048|DRUG|EMD 128130|
41003239|NCT00009048|DRUG|IV Levodopa|
41473680|NCT06583850|OTHER|The Neck Disability Index|The Neck Disability Index (NDI) is the most widely used self-report tool to assess neck pain status, and provides information not only about pain experiences but also about a person\&#39;s functional status. The NDI consists of 10 questions related to pain, functional activities, self-care, and quality of life that are measured on a 6-point scale (0, no disability; 5, full disability). The numeric score for each item is summed for a score ranging from 0 to 50; 0-4 points are defined as no disability, 5-14 points as mild disability, 15-24 points as moderate disability, 25-34 points as severe disability and above 35 points as complete disability.
41473681|NCT06583850|OTHER|Visual analog scale (VAS)|A 10 cm VAS numbered from 0 to 10 was used for the assessment. 0 indicates no pain and 10 indicates unbearable pain. Participants were asked to mark a point between 0-10 according to their pain status
40799091|NCT03150745|PROCEDURE|Colposcopic examination|"0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).~e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination"
40799092|NCT03150745|PROCEDURE|Office hysteroscopy|0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
40799093|NCT00647244|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil 245 mg oral tablet once daily
41157064|NCT05138432|BEHAVIORAL|Fruit and Vegetable Prescription Voucher|Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.
41315930|NCT00418964|PROCEDURE|Double bundle hamstring|Double bundle hamstring
41315931|NCT00418964|PROCEDURE|Bone patellar tendon bone|Bone patellar tendon bone
41315932|NCT03434704|DRUG|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine"|Thiotepa iv 5 mg/kg/bid (total dose TD 10 mg/kg) day -3,-2; Treosulfan iv 14g/mq/day (TD 42 g/mq) as a single daily dose day -6, -5, -4; Fludarabine iv 30 mg/m2 (TD 150 mg/m2) day -6, -5, -4, -3, -2. Thiotepa TD 5 mg/kg and treosulfan TD 36 g/mq dose reduction according to age \> 65 years.
41315933|NCT03434704|PROCEDURE|PBSC graft|(target 4-8 × 106 CD34+ cells/kg patient body weight)
41315934|NCT03434704|DRUG|GvHD prophylaxis|"Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.~Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28. Cyclophosphamide 50 mg/kg i.v. day +3+4. Mesna: \>80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5."
41315935|NCT03434704|DRUG|Primary antifungal prophylaxis|Posaconazole delayed-release tablet \[available in 100 mg tablets\]: 300 mg twice daily on the first day followed by a maintenance dose of 300 mg once a day, starting on the day 0 to day 85.
41315936|NCT03711019|DEVICE|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
41315937|NCT03711019|DEVICE|RUL-UB ECT|"In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
41315938|NCT03711019|DEVICE|Bitemporal ECT|"Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
41315939|NCT01293032|PROCEDURE|Neoadjuvant Therapy|Undergo neoadjuvant therapy
41473682|NCT06583850|OTHER|Pittsburgh Sleep Quality Index|Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-report questionnaire
41473683|NCT06583850|OTHER|Cervical Range of Motion Assessment|Active Cervical Range Of Motion was measured with a universal goniometer in all three planes of motion in the cervical region: lateral flexion (frontal plane), axial rotation to both right and left sides (horizontal plane), and flexion-extension (sagittal plane).
41473684|NCT04073017|DIETARY_SUPPLEMENT|Enterade®|Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks
40799094|NCT00647244|DRUG|Abacavir|Abacavir 300 mg oral tablet twice daily
40799095|NCT04695470|DRUG|Fruquintinib and Sintilimab|"fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w"
40799096|NCT05442723|PROCEDURE|On-Pump CABG|coronary artery grafting by using cardiopulmonary bypass machine
40799097|NCT05442723|PROCEDURE|Off-Pump CABG|coronary artery grafting by beating heart technique
40799098|NCT01304615|BEHAVIORAL|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
40799099|NCT01304615|BEHAVIORAL|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
41003240|NCT04292730|DRUG|Remdesivir|Administered as an intravenous infusion
41151805|NCT06076525|BEHAVIORAL|Multidirectional Perturbations for Balance Control Assessment (150 perturbations)|The intervention involves exposing participants to a series of 150 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by seven epochs. The first five epochs will deliver multidirectional perturbations to assess modifiability of motor flexibility, followed by a sixth epoch to test generalization to novel perturbation directions while walking. Finally there will be a seventh epoch of perturbations while standing to test generalization from walking balance control to standing balance control. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
41151806|NCT02998658|DEVICE|Vaginal cuff closure using barbed sutures|Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
41003241|NCT04292730|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
41003242|NCT01364090|DRUG|Pegylated interferon alfa 2b|Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
41003243|NCT01364090|DRUG|Ribavirin|Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
41151807|NCT02998658|DEVICE|Vaginal cuff closure using conventional sutures|Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
41003244|NCT03034993|BEHAVIORAL|Text Messaging|"Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response."
41003245|NCT05967962|BEHAVIORAL|The Trauma Film Paradigm|"Trauma film paradigm is a well-known, validated and established procedure that produces reactions similar to those generated by trauma, and that is often used in research to predict susceptibility for peritraumatic and posttraumatic reactions. In this study the trauma film paradigm will be utilized to simulate combat exposure. The two groups of participants will undergo the trauma film paradigm by watching 16 min traumatic combat scenes vs. non-traumatic movie scenes, respectively. Participants will be given standardized instructions (i.e., ''Imagine you are present at the scene; Do not close your eyes)."
41003246|NCT05967962|BEHAVIORAL|non-traumatic (neutral) film|non-traumatic (neutral) film
41003247|NCT04782908|DEVICE|Transcatheter tricuspid valve edge-to-edge repair|Transcatheter tricuspid valve edge-to-edge repair is an interventional approach to treat severe tricuspid regurgitation. Under general anesthesia a clip delivery system is forwarded through the vena femoralis and right atrium in the right ventricle. A clip is deployed to clamp the tricuspid valve and reduce tricuspid valve regurgitation.
41003248|NCT06450548|OTHER|Parametric acquisition|Parametric acquisition for 18F-FDG PET/CT and 68GA-PSMA PET/CT with 24 h at 15 days of interval
41003249|NCT00196950|BIOLOGICAL|Meningococcal (vaccine)|
41003250|NCT02190799|BIOLOGICAL|Convalescent plasma|Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
41003251|NCT04889625|DEVICE|senofilcon A C3|Test Lens
41003252|NCT04889625|DEVICE|Dailies Total 1® Multifocal Contact Lenses|Control Lens
41003253|NCT01103934|DRUG|Vitamin D3|4000 IU once daily
41003254|NCT01103934|DRUG|Placebo|Placebo taken once daily
41003255|NCT01103934|DRUG|Fluticasone Propionate|200 mcg daily, intranasal
41003256|NCT03305510|DIAGNOSTIC_TEST|vitamin D is below 20ng/ml|
41003257|NCT02694419|DEVICE|Doppler evaluation|Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
41003258|NCT01933906|DRUG|P1101|
41151808|NCT01256814|BEHAVIORAL|SystemCHANGE-HIV|SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
41315940|NCT01293032|PROCEDURE|Therapeutic Conventional Surgery|Undergo therapeutic conventional surgery
41473685|NCT04073017|OTHER|Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)|Ancillary studies
41315941|NCT01293032|OTHER|Laboratory Biomarker Analysis|Correlative studies
41315942|NCT01293032|GENETIC|Gene Expression Analysis|"Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a Recurrence Score (RS)."
41315943|NCT01293032|DRUG|Systemic Chemotherapy|Undergo chemotherapy
41315944|NCT01293032|DRUG|Tamoxifen Citrate|Undergo hormonal therapy
41315945|NCT01293032|DRUG|Aromatase Inhibition Therapy|Undergo hormonal therapy
41315946|NCT06406686|PROCEDURE|Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter|Durable block across the cavotricuspid isthmus by radiofrequency ablation.
41473686|NCT05307159|DIETARY_SUPPLEMENT|bean protein supplement|They will have a snack with bean protein for 21 days Participants will follow their usual diet, which will be quantified and evaluated.
41473687|NCT00678626|DRUG|CP-751,871|Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
41473688|NCT00678626|DRUG|Docetaxel|Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
41473689|NCT06400108|OTHER|Dementia Moves|"Dementia Moves: Dementia Moves is a multicomponent exercise program that can be individually tailored to the abilities of LTC residents with more advanced dementia and focuses on moderate- to high-intensity strength and balance activities with an aim to improve ADLs. Individualized strategies are implemented throughout the intervention to support and promote participation of individuals with more advanced dementia.~Each exercise will be individually prescribed for each participant by the physiotherapists (PT) at the beginning of the program. The intensity of the exercise will be adjusted throughout the program by the PT to ensure the target intensity of moderate to high intensity balance and strength exercises. The intervention will be provided face to face in groups of 4 residents with the PT, PTA, and three volunteers. Though the intervention is delivered in a group setting, the specific exercises that the participants complete are individualized based on their abilities."
41473690|NCT03748394|BEHAVIORAL|Work-directed rehabilitation|Each participant starts with a meeting together with an occupational therapist or a physical therapist, focusing on the participant's resources and obstacles for functioning well at work. A plan is designed and carried out over 8 weeks, including 1-4 different treatment modules of occupational and physical therapy, to support the person's ability to function at work
40799100|NCT01304615|BEHAVIORAL|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
41151809|NCT02020551|DRUG|Lidocaine Spray|
41315947|NCT03608891|DEVICE|Computer guided patient specific 3D titanium plate|CBCT or CT scan will be done preoperatively and dicom files will be imported to mimics software to design and print the patient specific 3D titanium plate.
41473691|NCT03748394|BEHAVIORAL|Physical activity|In a meeting with a physical therapist, each participant receives advice on physical activity to support mental health, according to national recommendations. The participant is offered to train at a local gym during 8 weeks.
41151810|NCT02020551|DRUG|Placebo|
41151811|NCT04047862|DRUG|Ociperlimab|Administered as an intravenous (IV) injection
41151812|NCT04047862|DRUG|Tislelizumab|Administered as an IV injection
41151813|NCT04047862|DRUG|Pemetrexed|Administered in accordance with local guidelines, prescribing information/summary of product
41151814|NCT04047862|DRUG|Paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
41151815|NCT04047862|DRUG|Nab paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
41151816|NCT04047862|DRUG|Carboplatin|Administered in accordance with local guidelines , prescribing information/summary of product
41151817|NCT04047862|DRUG|Cisplatin|Administered in accordance with local guidelines , prescribing information/summary of product
41151818|NCT04047862|DRUG|Etoposide|Administered in accordance with local guidelines , prescribing information/summary of product
41151819|NCT04047862|DRUG|5fluorouracil|Administered in accordance with local guidelines , prescribing information/summary of product
41151820|NCT04047862|DRUG|Oxaliplatin|Administered in accordance with local guidelines , prescribing information/summary of product
41151821|NCT04047862|DRUG|Capecitabine|Administered in accordance with local guidelines , prescribing information/summary of product
41315948|NCT03608891|DEVICE|Conventional titanium miniplates|In this group two miniplates of titanium Mini-System 2.0 mm will be used. The plate has profile height 1.0 mm whereas the screw length varies according to the site of the plate. According to Champy osteosynthesis lines for fixation of the posterior mandibular fracture ,the first plate will be placed at the inferior border from the buccal side, using bicortical screws engaging the buccal and lingual cortices to achieve rigid fixation, while the second plate will be placed at about 5mm superior to the inferior plate in the subapical region, using monocortical screws engaging only the buccal cortex to avoid injuring the teeth roots.
41315949|NCT01378936|BEHAVIORAL|MI plus IOC group intervention|45 minute Motivational Interview plus 16 session IOC intervention
41315950|NCT01378936|BEHAVIORAL|Motivational Interview only|45 minute Motivational Interview session
41315951|NCT01519284|DRUG|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
41473692|NCT04385095|DRUG|SNG001|SNG001 via inhalation
41473693|NCT04385095|DRUG|Placebo|Placebo via inhalation
41003259|NCT00992810|PROCEDURE|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
41003260|NCT00992810|PROCEDURE|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
41003261|NCT01401933|DRUG|Linifanib|QD on Days 1 and 13
41003262|NCT01401933|DRUG|Rifampin|QD on Days 5-16
41003263|NCT00621218|DRUG|tretinoin gel 0.05%|Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
41003264|NCT00621218|DRUG|vehicle|Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
41003265|NCT00234195|DRUG|bupropion extended release (Wellbutrin XL)|
41003266|NCT03129516|BEHAVIORAL|Determining Imaginary levels|Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
41003267|NCT00367068|DRUG|baclofen, intrathecal|
41003268|NCT00367068|DEVICE|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
41003269|NCT05638646|OTHER|Intervention group|Practice standard for clinical diagnosis and treatment of chronic obstructive pulmonary disease
41003270|NCT05638646|OTHER|control group|Maintain current treatment
41003271|NCT02776228|DRUG|Brotizolam|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
41003272|NCT02776228|DRUG|placebo|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
41003273|NCT01041716|OTHER|None - Observational study|None - Observational study
41315952|NCT01519284|DRUG|Entacapone|Entacapone 200 mg
40799101|NCT01030952|DRUG|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
41003274|NCT01574703|DRUG|placebo|All dosing to have taken place per study A3051123
41003275|NCT01574703|DRUG|varenicline tartrate|All dosing to have taken place per study A3051123
41003276|NCT01574703|DRUG|bupropion hydrochloride|All dosing to have taken place per study A3051123
41003277|NCT01574703|DRUG|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
41003278|NCT06075680|PROCEDURE|Non-Surgical Periodontal Treatment|The primary goal of nonsurgical periodontal therapy is to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and result in improvement in the clinical signs and symptoms of active disease
41003279|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) in water|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) in water containing 0,41 g of tested protein/kg of body weight.
41315953|NCT01519284|DRUG|Placebo|placebo (four times a day)
41315954|NCT01519284|DRUG|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
41315955|NCT01519284|DRUG|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
41315956|NCT01519284|DRUG|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
41003280|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) within meal|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) within a meal containing 0,41 g of tested protein/kg of body weight.
41003281|NCT06381869|DIETARY_SUPPLEMENT|Whey protein in water|After selection and randomization, the subjects will consume per os whey protein in water containing 0,41 g of tested protein/kg of body weight.
41003282|NCT06381869|DIETARY_SUPPLEMENT|Whey protein within meal|After selection and randomization, the subjects will consume per os whey protein within a meal containing 0,41 g of tested protein/kg of body weight.
41003283|NCT03231306|DRUG|Binimetinib|Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
41003284|NCT04725435|BEHAVIORAL|Kangaroo care|Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes.
41003285|NCT04725435|BEHAVIORAL|Facilitated Tucking Position|"Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure."
41151822|NCT06376006|BEHAVIORAL|EMR STAT - Survey|Surveys are completed before and after Advanced Fellow Training.
41315957|NCT01828918|GENETIC|microRNAs|
41315958|NCT06412419|DIAGNOSTIC_TEST|Magnifying Endoscopy and Endoscopic Ultrasonography|The acquired magnifying endoscopy and endoscopic ultrasonography images were shared with artificial intelligence for machine learning, diagnostic modeling and optimization. In the real world evaluation phase, the high-risk population of early esophageal cancer who planned to undergo esophageal electronic endoscopy were prospectively enrolled. The artificial intelligence-assisted diagnosis system was used for prediction before surgery, and the postoperative pathological results were used as the gold standard to diagnose by grouping.
41315959|NCT00332800|DRUG|Nutritional Supplementation|
41315960|NCT01089829|OTHER|Foot examination|"Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system"
41315961|NCT02922192|DRUG|TNF-α antagonists, non-TNFs, DMARD non-biologics|Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
40799102|NCT01030952|DRUG|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
40799103|NCT00631813|DRUG|Prucalopride|0.5 mg bid
40799104|NCT00631813|DRUG|Prucalopride|1 mg bid
40799105|NCT00631813|DRUG|Prucalopride|2 mg bid
40799106|NCT00631813|DRUG|Placebo|bid
41315962|NCT05523765|DRUG|Brepocitinib|Oral Brepocitinib
41315963|NCT06409091|DEVICE|Medium weight or Heavy weight mesh|Patients received a hernia repair with one of the two groups
41315964|NCT06090344|OTHER|Traditional video format|6 x 3 minute videos designed in the same format as traditionally found on the internet
41315965|NCT06090344|OTHER|Evidence-informed video format|6 x 3 minute videos designed in the format recommended by advice in the literature
41315966|NCT02072772|BEHAVIORAL|Positively Smoke Free group treatment|See Arm Description
41315967|NCT02072772|BEHAVIORAL|Standard Care|See Arm Description
41315968|NCT02542436|OTHER|No intervention|No intervention administered in this study
41315969|NCT06319001|OTHER|Low-volume high intensity exercise|This intervention will consist of 10 x 10-second interval sprints on a stationary bicycle interspersed with 50-second breaks between repetitions. The cycle resistance will be adjusted to the level equaling the highest power output, which will be determined during warm-up sprints.
41315970|NCT06319001|OTHER|Combined intermittent sauna and cold water bath (sauna+cold bath).|This intervention will consist of 3x10 min bouts in the dry sauna interspersed with 2x 60 seconds of cold water immersion up to the neck.
41315971|NCT00887146|DRUG|concomitant temozolomide (TMZ)|75 mg/m\^2, orally daily
41315972|NCT00887146|RADIATION|radiotherapy|
41315973|NCT00887146|DRUG|procarbazine|Days 8-21: 60 mg/m\^2 orally
41315974|NCT00887146|DRUG|adjuvant temozolomide (TMZ)|150 or 200 mg/m\^2 orally
41315975|NCT00887146|DRUG|CCNU|Day 1: 110 mg/m\^2 orally
41315976|NCT00887146|DRUG|vincristine|Days 8 and 29: 1.4 mg/m\^2 IV
41315977|NCT00446485|DRUG|Ginkgo biloba standardized extract 24/6|tablets, 120 mg/day (60 mg two times daily) during 6 months
41315978|NCT00446485|DRUG|Ginkgo Biloba standardized extract 24/6|tablets, 60 mg/day during 6 months
41315979|NCT00446485|DRUG|placebo|placebo during 6 months
41315980|NCT01905150|DRUG|G-FLIP|G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin
41315981|NCT01905150|DRUG|G-FLIP-DM|G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
41315982|NCT01905150|DIETARY_SUPPLEMENT|Vitamin C|High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
41315983|NCT00115765|DRUG|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
41315984|NCT00115765|DRUG|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
41315985|NCT00115765|DRUG|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
41315986|NCT00115765|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
41315987|NCT05108480|OTHER|Experimental group|This study followed the protocol designed for patients with hemophilic knee arthropathy. For its implementation, a 30-cm long15-cm diameter foam roller was used, and a ball 22 cm in length and 8 cm in diameter. The total duration of the intervention was 15 minutes, with 7 sessions per week over a period of 8 weeks. The physiotherapist who supervised the intervention followed up on all patients by telephone on a weekly basis to check for the absence of haemarthrosis during the intervention and to detect the possible need for protocol adaptations depending on the clinical situation of each patient. Each patient was individually provided with instructions as to how perform the exercises during the pretreatment evaluation, customizing the program if necessary. All patients had access to a mobile application, designed ad hoc for the research study (He-Foam®), where they could learn about the exercises through demonstration videos.
41315988|NCT03483766|DEVICE|Robotic Functional Rehabilitation system|The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.
41315989|NCT01371487|DRUG|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
41315990|NCT03258047|COMBINATION_PRODUCT|CAR-T|CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells.
41315991|NCT00999219|DRUG|FK199B|oral
41315992|NCT00999219|DRUG|Zolpidem|oral
41315993|NCT03589820|OTHER|artificial liver support system|Patients will receive the treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine. The volume of fresh frozen plasma used in plasma exchange is 2000 millilitre. The time for continuous hemodiafiltration is about 8 hours.
41315994|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 20J|120W Lumenis Holmium:YAG laser 20J
41315995|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 40 J|120W Lumenis Holmium:YAG laser 40J
41315996|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 60 J|120W Lumenis Holmium:YAG laser 60J
41315997|NCT01650792|DRUG|Aspirin|
41315998|NCT02815176|OTHER|Blood sampling|Sampling the blood including DNA to investigate the thrombotic profile
41315999|NCT00228969|DRUG|RWJ-333369|
41316000|NCT05602610|OTHER|No intervention|No intervention
40799107|NCT02653443|BIOLOGICAL|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
41316001|NCT01866761|PROCEDURE|Periodontal treatment|
41473694|NCT05412524|BEHAVIORAL|reading|Mothers and, if desired, mother's partner will read to preterm infant as frequently and as much as they are able to. Reading is the intervention. The variable of interest is parents' and infants' change in salivary oxytocin receptor gene methylation (OXTRm) over time.
40799108|NCT02653443|BIOLOGICAL|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
41003286|NCT04460222|PROCEDURE|Rotational Thromboelastometry to guide blood product transfusion pre invasive procedure|"Rotational Thromboelastometry will be performed pre procedure and blood component will be transfused if~* EXTEM CT more than 80 sec then FFP will be transfused at 15 ml/kg MCF less than 35 mm then Platelet will be transfused at 10 ml/kg~* FIBTEM MCF less than 7 mm then Cryoprecipitate will be transfused at 5 ml/kg"
41473695|NCT02620059|BEHAVIORAL|Lifestyle Intervention|The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
41003287|NCT04460222|PROCEDURE|Conventional transfusion methods to guide blood product transfusion pre invasive procedure|Transfusion will be given If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg
41316002|NCT06098196|DRUG|Aminophyllin|Patients will be observationally included in the Elveld TCI or Schnider TCI group and recevied or not Aminiophylline bolus. The TCI model, such as the aminophylline delivery or not, is chosen at anesthesiologist's discretion, as suggested in literature
41316003|NCT00005848|DRUG|chemotherapy|
41316004|NCT00005848|DRUG|tipifarnib|
41316005|NCT05044585|OTHER|Remote Automated Monitoring System|The subject will be monitored with conventional monitoring devices as well as the MultiSense patch.
41316006|NCT03155295|OTHER|Physical reality simulation|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. These models are constructed at the Laboratory for Simulation-based Translational Research at the Department of Urology. Group 1 urologists will rehearse the minimally-invasive partial nephrectomy (MIPN) surgery using these patient-specific models.
41316007|NCT03155295|OTHER|Virtual reality simulation|The DaVinci surgical skills simulator system uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. All urologists have already completed a basic robotic skills curriculum. Group 2 urologists will complete a refresher module on the virtual reality simulator.
41316008|NCT04758858|OTHER|Insulin treatment optimization with participant's usual diet|Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
41316009|NCT04758858|DEVICE|Abbott's FreeStyle Libre|During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
41316010|NCT04758858|OTHER|Three-day food journal|Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
41316011|NCT04758858|OTHER|Medical visit|During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
41316012|NCT04758858|OTHER|Blood pressure measurements|Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
41316013|NCT04758858|OTHER|Anthropometric parameters measurements|Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
41473696|NCT06332313|PROCEDURE|erector spina plane block|ESP block is a method used to provide postoperative analgesia by injecting local anesthetic between the erector spinae muscle and the transverse process of the vertebra under ultrasound guidance, targeting the dorsal and ventral rami of thoracic and abdominal spinal nerves. The aim of this randomized controlled study is to observe whether there is a difference in tramadol consumption within 24 hours after surgery between patients who undergo RIRS operations at T11 level with different volumes of ESP blocks performed under ultrasound guidance before general anesthesia induction.
41473697|NCT06615804|BIOLOGICAL|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It's primarily used to treat depression, especially in patients who haven't responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits
41473698|NCT04838028|PROCEDURE|TEP|Laparoscopic totally extraperitoneal mesh repair of groin hernia
41473699|NCT04838028|PROCEDURE|TAPP|Laparoscopic transabdominal mesh repair of groin hernia
41473700|NCT04750382|DRUG|HX008+Cisplatin+Gemcitabine|Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m\^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m\^2, Day 1, Day 8, Q3W for up to 6 cycles
40799109|NCT04148703|OTHER|Follow up post Pacemaker implantation in office|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by in-office follow-up
41316014|NCT04758858|OTHER|Indirect calorimetry test|Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
41316015|NCT04758858|OTHER|Well-being questionnaire|Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
41316016|NCT04758858|OTHER|Diet appreciation questionnaire|Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
41316017|NCT04758858|DEVICE|Pedometer (PiezoRxD)|Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
41316018|NCT04758858|OTHER|Hepatic imaging (MRI)|Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
41316019|NCT04758858|OTHER|Glucagon efficiency test|The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
41473701|NCT04625192|PROCEDURE|Trephine osteotomy|"* Using a trephine on a straight implant handpiece (at approximately 1800 rpm) with copious irrigation to avoid overheating the bone, a round bone cut will be made 4 -5 mm above the crest of the alveolar ridge.~* The trephine is positioned perpendicular to the lateral wall, removing the outer cortex with a very gentle touch to avoid tearing the schneiderian membrane."
41473702|NCT00963079|PROCEDURE|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
40799110|NCT04148703|OTHER|Follow up post Pacemaker implantation by home monitoring|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by home monitoring
40799111|NCT00763191|OTHER|examination of ocular movements|
40799112|NCT00763191|OTHER|MATTIS test|
40799113|NCT00763191|OTHER|UPDRS test|
40799114|NCT00763191|OTHER|CRST test|
40799115|NCT06269692|DEVICE|MRI screening|Cardiac Magnetic Resonance imaging for the quantification of the infarct intramural scar
40799116|NCT06269692|DEVICE|Implantable Loop Recorder|Inplantation of the Implantable Loop Recorder (ILR) for the patients assigned to the experimental group
40799117|NCT06269692|DEVICE|Implantable Cardioverter Defibrillator|Inplantation of the Implantable Cardioverter Defibrillator (ICD) for the patients assigned to the control group, according to the current guidelines
40799118|NCT04349358|OTHER|FDG and FCH PET/CT|"* during the initial myeloma check-up : FDG and FCH PET/CT exams (maximum 21 days after inclusion)~* just before maintenance treatment, respecting a minimum interval of 2 weeks after the last course of chemotherapy : FDG and FCH PET/CT exams"
40799119|NCT06271681|DRUG|15-valent pneumococcal conjugate vaccine|FDA approved pneumococcal vaccines 15 valent conjugate vaccine administered at enrollment
40799120|NCT06271681|DRUG|23-valent pneumococcal polysaccharide vaccine|23 valent pneumococcal vaccine administered 8 weeks after initial 15 valent pneumococcal conjugate vaccine
41003288|NCT05449028|DRUG|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
41003289|NCT05449028|DRUG|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
41003290|NCT05449028|DRUG|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
41003291|NCT05449028|DRUG|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
41316020|NCT04758858|OTHER|Body composition : Dual Energy X-ray absorptiometry (DEXA)|Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
41003292|NCT05449028|DRUG|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
41003293|NCT04710251|DEVICE|Speedometer|We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
41003294|NCT06200675|OTHER|Compassion-based intervention|Participants assigned to this intervention will be asked to engage in one brief compassion-focused exercise, where they will be asked to be asked to connect to their inner compassionate self. They will be asked to stay connected to that feeling while rereading what they wrote about their feelings of shame and imagining it was someone else who wrote it. Participants will then be asked to write a compassionate response to themselves. Participants will then be asked to reread this response while remaining connected to their compassionate self.
41316021|NCT04758858|OTHER|Blood tests|Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
41316022|NCT04758858|OTHER|Stool sample collections (optional)|Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
41473703|NCT00963079|PROCEDURE|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
41473704|NCT04683237|DRUG|Liraglutide Injection|Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.
41003295|NCT06200675|OTHER|Logic-based intervention|Participants assigned to this intervention will be asked to engage in one brief (10-15 minute) online logic-based exercise that was adapted from a CBT thought record. Participants will be asked to reread what they wrote about their feelings of shame and chose a thought central to their shame to use for this exercise. Participants will be asked to generate evidence for and against their chosen thought, and then generate a more balanced thought. After the exercise, participants will be asked to reread their newly generated more balanced thought.
41003296|NCT06200675|OTHER|Placebo control condition|"Participants assigned to this intervention will be asked to listen to an audio recording of The Hobbit and then re-read what they wrote about their feelings of shame. They will then be asked to write a reflection about the thoughts and feelings arising from doing so. They will then be asked to re-read what they wrote in this reflection."
41003297|NCT01133691|DIETARY_SUPPLEMENT|clear fluid, light breakfast|clear fluid 7 ml/kg, breakfast consisting of yoghurt, muesli, mild
41003298|NCT05262907|DEVICE|Transthoracic Echocardiogram or Cardiac MRI|Non-invasive imaging of the heart to evaluate structure and function.
41003299|NCT05262907|DEVICE|Ventripoint Echocardiogram|Non-invasive ultrasound of the heart to evaluate structure and function through 3D imaging.
41003300|NCT02310178|PROCEDURE|Bariatric surgery|all of the current bariatric surgeries are allowed in this prospective cohort study
41003301|NCT00197327|DRUG|Epidural bupivacaine (0.25% versus 0.0625%)|
41003302|NCT05439603|DRUG|ANC-501|Five 10 mg capsules per day
41003303|NCT04515303|OTHER|Diverse Intervention Participation in DASH|A qualitative examination of barriers and facilitators of the DASH dietary pattern, and quantitative investigation of the types of recruitment methods effective for black adults entering a digital DASH-promoting intervention.
41003304|NCT04464681|DRUG|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
41003305|NCT04464681|DRUG|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
41003306|NCT00271479|BIOLOGICAL|A, C, Y, W135 meningococcal polysaccharide vaccine|
41003307|NCT02880982|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
41003308|NCT02880982|OTHER|Placebo|Weekly oral placebo softgel capsule
41003309|NCT01347437|BEHAVIORAL|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team-is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
41003310|NCT01302392|DRUG|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \[Days 1, 2, 8, 9, 15, 16\] for individual subjects).
41003311|NCT01302392|DRUG|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
41003312|NCT00062582|DRUG|Roflumilast|
41003313|NCT00579826|DRUG|Letrozole|Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
41151823|NCT04878861|BEHAVIORAL|Training in the blind field|Participants will complete visual training at two locations in the blind field. These two locations of training will be determined at the baseline study visit (0 months) and will be located within the perimetry-defined blind field. The training programme involves discriminating the direction of motion in a small circle of moving dots. The computer software and a chin-rest will be loaned to each participant to complete training at home. Participants will perform 300 trials at each location in their blind field, 5 days a week for at least 24 weeks (40-60 minutes in total). The computer programme will automatically generate a record of participant performance after each home training session.
41473705|NCT04683237|DRUG|Megestrol Acetate 160 MG|160mg po qd
41473706|NCT04301245|OTHER|Educational program|"The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment."
41473707|NCT03750656|DRUG|Hyoscyamine|Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent
41003314|NCT00579826|DRUG|Placebo|Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
41003315|NCT00754182|DEVICE|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
41003316|NCT00754182|DEVICE|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
41003317|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
41003318|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
41003319|NCT04888975|DEVICE|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
41003320|NCT00763074|BEHAVIORAL|Standard life style modification for type 2 diabetes|"Two session of education for exercise and diet.~----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30\~35kcal/day"
41003321|NCT00763074|BEHAVIORAL|Diet restriction|"Education for diet and exercise every 2 weeks~----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day"
41003322|NCT00763074|BEHAVIORAL|Exercise|"Education for diet and exercise every 2 weeks~----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day"
41003323|NCT00763074|BEHAVIORAL|Diet and exercise|"Education for diet and exercise every 2 weeks~----------- Exercise education like as exercise group and diet education like as diet group"
41151824|NCT01236963|DRUG|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indications
41151825|NCT01236963|DEVICE|Dental Floss|
41151826|NCT01446822|DEVICE|Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
41151827|NCT01446822|DEVICE|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
41151828|NCT01512355|DRUG|Dexmedetomidine|After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
41151829|NCT01512355|DRUG|placebo group|normal saline_02mcg/kg/hr
41151830|NCT04716283|OTHER|Validated questionnaire : The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS)|"The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score.~The Epworth Sleepiness Scale (ESS) is a scale intended to measure daytime sleepiness .The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities."
41151831|NCT06265441|PROCEDURE|Group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance in which the adductor canal is identified and 20 ml of 0.25% bupivacaine will be injected|The patients in group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance (SonoSite™, Inc., Bothell, WA 98021, USA) in which the patients are placed in the supine position with the arms resting comfortably across the chest and the affected lower extremity is externally rotated. Adductor canal was identified beneath the sartorius muscle and 22-gauge 90-mm spinal needle is inserted from anterolateral to posteromedial direction at a point approximately at the junction between the middle and distal third of the thigh on the anteromedial femur, this location is called mid adductor canal, then 20 ml of 0.25% bupivacaine is injected in the canal
41151832|NCT06265441|PROCEDURE|Group B will receive adductor canal block under ultrasound guide 20 ml bupivacaine 0.25% and IPACK block under direct visualization of ultrasound of 20 ml bupivacaine 0.25%|The patients in Group B will receive ACB as described above then IPACK block, in which the patients are placed in a supine position and knee is placed in position of 90° flexion. A low-frequency ultrasound probe is positioned in the popliteal crease 1 finger breadth above the patella, and a spinal needle is inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle is placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.25% bupivacaine is injected while the needle is being withdrawn after negative aspiration.
41151833|NCT01827800|BEHAVIORAL|eHealth weight loss intervention|This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
41151834|NCT05262504|DEVICE|İntraocular lens implantation|Each participant underwent bilateral sequential cataract surgery and bilateral implantation of a novel non-diffractive EDOF IOL (n=26) or a trifocal IOL (n=26). The interval between the first and second-eye surgeries was 1 to 3 weeks. The patients selected the IOL model after they were fully informed regarding the advantages and disadvantages of each IOL, by their surgeon. Their degree of interest in greater spectacle freedom at far, intermediate, and near distances, as well as their daily activities such as frequency of night driving or reading habits were discussed. The possibility of photic disturbances was described and explained as well.
41151835|NCT04707287|OTHER|No Intervention|No intervention used. This is observational study
41151836|NCT01498406|DIETARY_SUPPLEMENT|vitamin D|The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (\<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (\>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
41151837|NCT04203199|DEVICE|Real rTMS to the mPFC using H7 Coil|This will be delivered with the Brainsway H7 coil system; 1200 pulses with the H7 coil helmet. Blinded using active/sham operator cards.
41151838|NCT04203199|DEVICE|Real rTMS to the dlPFC using H1 Coil|This will be delivered with the Brainsway H1 coil system; 3000 pulses with the H1 coil helmet. Blinded using active/sham operator cards.
41151839|NCT02316145|BEHAVIORAL|Habilitation (Internet-based support and coaching)|Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
41151840|NCT05795309|DEVICE|Hybrid Automated Insulin Delivery|Consists of an insulin pump and real-time continuous glucose monitoring (CGM)
41151841|NCT01014013|DRUG|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
41473708|NCT03750656|DRUG|Tamsulosin|Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent
41316023|NCT04758858|OTHER|Hypoglycemia journal|During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
41473709|NCT00777933|DRUG|tacrolimus|
41473710|NCT00777933|DRUG|cyclosporine|
41473711|NCT05251506|DEVICE|laser lancing device or lancet for blood glucose level measurement|Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.
41473712|NCT04880382|DRUG|ICI treatment discontinuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter
40799121|NCT06004258|OTHER|Painless Vaccination|"Structural adaptation of the vaccination areas and cozy decoration (colorful room, mobiles to hang on the ceiling) Nursing uniforms decorated with children's pictures Introduction of toys, stuffed animals, stamps and reward stickers, drawings and crayons, soothing music in the background~Antalgic measures by age ranges:~0-6M (FLACC scale) Breastfeed for two minutes if infant is breastfeeding Glucose 33% or 50% or if rotavirus vaccination, on mother's pacifier or gloved finger (non-nutritive sucking) Comfort between vaccinations 6-15M (FLACC scale) Position infant sitting on guardian's lap facing forward Distraction techniques: stuffed animals, toys, audiovisual devices 3-6Y (Wong-Baker scale) Involve child, explain Child sits on tutor's lap facing forward Distraction techniques: audiovisual devices, drawings 6-14Y (VAS scale)Always seated. Distraction method: audio-visual devices, breathing"
40799122|NCT00282087|DRUG|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
40799123|NCT01149083|PROCEDURE|Biopsy|Undergo biopsy
40799124|NCT01149083|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40799125|NCT01149083|DRUG|Carboplatin|Given IV
40799126|NCT01149083|PROCEDURE|Computed Tomography|Undergo CT
40799127|NCT01149083|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40799128|NCT01149083|DRUG|Veliparib|Given PO
40799129|NCT01956747|PROCEDURE|venapunction|
40799130|NCT01956747|PROCEDURE|bone marrow punction|
41003324|NCT06328790|OTHER|Multidisciplinary Rehabilitation Training|34 Patients will attend the in-person 5-day rehabilitation program (2 h/day) followed by a 12-weeks telemedicine program (1 h/week).
41151842|NCT01014013|DRUG|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
41473713|NCT04880382|DRUG|ICI treatment continuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity
40799131|NCT00712686|DRUG|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
40799132|NCT00712686|DRUG|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
40799133|NCT04753346|OTHER|Physical Activity Level|International Physical Activity Questionnaire
40799134|NCT04753346|OTHER|Anxiety and Depression Assessment|Hospital Anxiety and Depression Scale
40799135|NCT04753346|DIAGNOSTIC_TEST|Exercise Capacity|6 Minute Walk Test
40799136|NCT04753346|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry
40799137|NCT04753346|DIAGNOSTIC_TEST|Cardiopulmonary Fitness Level|Cardiopulmonary Exercise Test
40799138|NCT04753346|OTHER|Cognitive Assessment|Montreal Cognitive Assessment
40799139|NCT03378544|BEHAVIORAL|mhGAP|The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity
40799140|NCT05088759|BEHAVIORAL|Alert|The alert-based CDS will consist of an on-screen electronic dialogue box that will notify the clinician that the patient is at increased risk for cardiovascular events and is not at LDL-C goal according to current evidence-based clinical practice guidelines. The clinician will have the opportunity to proceed to an order template through which ezetimibe or a PCSK9 inhibitor can be prescribed. The clinician could also elect to learn more about current evidence-based clinical practice guideline recommendations for LDL targets. Finally, the clinician could elect to proceed without ordering more intensive lipid-lowering therapy or reading the guidelines but would have to provide a rationale for not prescribing ezetimibe or a PCSK9 inhibitor.
41151843|NCT00676663|DRUG|entinostat|Entinostat 5 mg tablet orally once per week
41151844|NCT00676663|DRUG|exemestane|Exemestane 25 mg tablet orally once daily
41151845|NCT00676663|DRUG|Placebo|Placebo-matching entinostat tablet orally once per week
41151846|NCT00714688|DRUG|prolonged release (PR) OROS methylphenidate 54 mg|18+36mg once daily for 13 weeks
41151847|NCT00714688|DRUG|prolonged release (PR) OROS methylphenidate 72 mg|2x36mg once daily for 13 weeks
41151848|NCT00714688|DRUG|Placebo|2xplacebo once daily for 13 weeks
41151849|NCT06317311|BIOLOGICAL|Dostarlimab|Dostarlimab is administered via intravenous (IV) infusion at a dose of 500 milligram (mg) for first 6 cycles (each cycle is of 21 days) followed by 1,000 mg from cycle 7 (each cycle is of 42 days)
41151850|NCT06317311|DRUG|Carboplatin|Carboplatin is administered IV at a dose of Area under the concentration time curve (AUC) 5 milligram\*millilitre/ minute (mg•mL/min) for cycles 1 to 6 (each cycle is of 21 days)
41151851|NCT06317311|DRUG|Paclitaxel|Paclitaxel is administered IV at a dose of 175 milligram per meter square (mg/m2) for cycles 1 to 6 (each cycle is of 21 days)
41151852|NCT00255515|DRUG|Quetiapine fumarate|oral
41151853|NCT00255515|DRUG|conventional treatment for schizophrenia|various standard therapies
41151854|NCT03644186|DRUG|Paclitaxel|Chemotherapy plus HER2 Blockade
41151855|NCT03644186|DRUG|Trastuzumab|Chemotherapy plus HER2 Blockade
41151856|NCT03644186|DRUG|Pertuzumab|Chemotherapy plus HER2 Blockade
41151857|NCT03644186|DRUG|Palbociclib|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
41151858|NCT03644186|DRUG|Letrozole|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
41151859|NCT03644186|DRUG|Trastuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
41151860|NCT03644186|DRUG|Pertuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
41473714|NCT05683210|BEHAVIORAL|Cup feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The feeding process was completed at the end of 30 minutes even if the infant did not take all of the food. The infant was followed up for 30 minutes after the end of feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
41473715|NCT05683210|BEHAVIORAL|Bottle feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. During the feeding period, heart rate and oxygen saturation were continuously recorded. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The infant was followed up for 30 minutes after the end of the feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
41473716|NCT02156921|OTHER|App-based training|
41473717|NCT06357923|DIAGNOSTIC_TEST|dosage|Presence of mutation on the gene panel and Frequency of allele variation
41473718|NCT03416491|DRUG|KW-136|KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.
41473719|NCT03416491|DRUG|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
41473720|NCT05810025|BEHAVIORAL|RealRisks|RealRisks is a web-based patient-centered decision aid (DA) designed to improve: 1) accuracy of breast cancer risk perceptions; 2) chemoprevention knowledge, and 3) informed choice. The DA includes audio and modules about breast cancer risk (including interactive games on risk communication) and chemoprevention. Through RealRisks, the investigators will collect information on breast cancer risk factors to calculate a patient's BCSC breast cancer risk score and also factors that influenced decision-making about chemoprevention through the preference elicitation game. RealRisks generates an action plan for patients summarizing their personalized breast cancer risk profile and preference elicitation for chemoprevention. Of note, the tool is designed for patients with varying levels of health literacy and numeracy and is available in English and Spanish.
41473721|NCT03345264|BEHAVIORAL|Online, interactive self-help program|Participants will receive access to the program, which provides: In-depth information specific to cancer sites and treatments, guidance on medical options for cancer-related sex or fertility problems, personalized goal-setting with progress tracking and relapse prevention, self-help exercises on overcoming sexual, relationship, and dating problems, videos of survivors' stories, and video vignettes with actors.
41473722|NCT01130779|DRUG|Erlotinib (TARCEVA®)|Erlotinib 150mg/day, everyday
41473723|NCT00489164|DEVICE|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
41473724|NCT00052416|DRUG|thalidomide|
41473725|NCT04231123|PROCEDURE|PENG Block with local anesthetic|After induction of general anesthesia, PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
41473726|NCT04231123|PROCEDURE|PENG Block with 0,9% saline|After induction of general anesthesia, PENG block with 20 ml of 0,9% saline will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
41316024|NCT04758858|OTHER|Ketone journal|During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
41473727|NCT03020784|DRUG|Placebo|Placebo
41003325|NCT06328790|BEHAVIORAL|Cross-sectional study on patients with FMD and patients with structural/organic diseases|Each subject will undergo behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and interoceptive domains.
41316025|NCT04758858|OTHER|Adherence to the diet (Keenoa)|During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
41473728|NCT03020784|DRUG|PF-06818883|Treatment
40799141|NCT03528655|OTHER|Decision aid|Decision aid is a tool that helps pregnant women become involved in decision making on choosing rooming-in or separation care. Decision aid provides information about the options and outcomes, and by clarifying personal values.
41003326|NCT06328790|BEHAVIORAL|Cross-sectional study on patients with FMD and healthy controls (HC)|Each subject will undergo a set of behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and
41003327|NCT00292357|PROCEDURE|Application of autologous bone marrow|
41003328|NCT04860310|PROCEDURE|Endometrial biopsy|Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.
41003329|NCT05716035|DRUG|Tocilizumab Injection|Participants will receive IV tocilizumab
41003330|NCT00858871|DRUG|Brivanib|Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
41003331|NCT00858871|DRUG|Placebo|Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
41003332|NCT00858871|DRUG|Sorafenib|Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
41003333|NCT00858871|DRUG|Placebo|Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
41003334|NCT06440031|BEHAVIORAL|CaMaPi|CaMaPi is a manually assisted brief psychological intervention that is based on the principles of Cognitive Behaviour Therapy (CBT). The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the suicidal ideation and self-harm attempt using virtual stories of four young people to be delivered in 8-10 sessions for over three months
41003335|NCT06440031|OTHER|TAU|Treatment as Usual (TAU) is routine care, such as diagnosis, assessment, psychotherapy, monitoring and any form of intervention (e.g., medication prescription) available at the collaborating service.
41003336|NCT05981638|OTHER|group WM|Patients were given 5ml/kg dose of water and patients were mobilized.
41151861|NCT06407973|DEVICE|OMNI Surgical System|The OMNI Surgical System is 510(k) cleared and indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma
41151862|NCT06407973|DRUG|Latanoprost plus adjunctive glaucoma medication|"* Latanoprost ophthalmic solution (0.005%) is a topical prostaglandin F2 analog used in the treatment of Glaucoma.~* An adjunctive topical glaucoma medication of a different class as selected by the Investigator"
41151863|NCT04871932|BIOLOGICAL|Recently Vaccination|
41151864|NCT06585436|PROCEDURE|partial caries removal|removal of all cavity caries except last layer related to the pulp
41151865|NCT00942799|DRUG|Genz-644282 (28-day dosing schedule)|Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
41151866|NCT00942799|DRUG|Genz-644282 (21-day dosing schedule)|The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
41151867|NCT00515879|DRUG|D-cycloserine|50 mg
41151868|NCT00515879|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions aim to help participants become more comfortable with social situations.
41151869|NCT00515879|DRUG|Placebo|Same dosage as active pill
41151870|NCT00672100|DRUG|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
41316026|NCT03694041|DRUG|SAD: APX-115|Drug: APX-115 SAD APX-115 SAD for 1day
41316027|NCT03694041|DRUG|SAD: Placebo|Drug: Placebo Placebo for 1day
41151871|NCT00672100|DRUG|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
41316028|NCT03694041|DRUG|MAD: APX-115|Drug: APX-115 MAD APX-115 MAD repeatedly administered.
41316029|NCT03694041|DRUG|MAD: Placebo|Matching study drug will be repeatedly administered.
41316030|NCT03694041|OTHER|Food effect: fasted and fed|A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
41316031|NCT03694041|OTHER|Metabolic probe with or without APX-115|A metabolic probe will be administered with and without APX-115.
41316032|NCT01134757|BIOLOGICAL|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
41151872|NCT00672100|DRUG|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
41151873|NCT06192537|BEHAVIORAL|A role-playing exercise by utilizing an obesity suit in a simulation scenario|All participants will be asked to wear an obesity simulation suit (Unisex obesity Simulation suit, Erler-Zimmer, Germany) and to participate in a standardized scenario that simulates meetings between a person with obesity and a 'registered dietitian'. The 'registered dietitian' will be presented by a professional role-player and the scenario will encompass different levels of weight bias through dialogue and the use of inappropriate equipment.
41151874|NCT05195034|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
41151875|NCT05195034|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
41151876|NCT01237509|DEVICE|Hypo device|
41151877|NCT06181123|OTHER|Cardiorespiratory Assesments|The following were evaluated to make comparisons between the two groups: Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
41316033|NCT03407508|DIETARY_SUPPLEMENT|Comparison of Diets|Okinawan-based Nordic Diet and Control Diet
41316034|NCT04815304|DIAGNOSTIC_TEST|peripheral lymphocytes subsets|The data were collected during the first and the second wave of epidemic in COVID-19 patients with acute respiratory distress syndrome. At the moment of hospitalization, at the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans (lung ultrasound score, diaphragmatic thickness and motion), arterial blood gas analysis parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation ), and pain assessed by using numeric rating scale. Macroscopic and microscopic hypopharynx and larynx damages were also evaluated by video-laryngoscopy and light miscoscopy.
41316035|NCT03925818|DRUG|Bismuth Subcitrate Potassium|Pylera capsules
41316036|NCT03925818|DIETARY_SUPPLEMENT|Gastrus|Gastrus 1 tablet
41003337|NCT05981638|OTHER|group WR|Patients were given 5ml/kg dose of water and patients were rest.
41003338|NCT05981638|OTHER|Group AR|Patients were given 5ml/kg dose of apple juice and patients were rest.
41003339|NCT05981638|OTHER|Group AM|Patients were given 5ml/kg dose of apple juice and patients were mobilized.
41003340|NCT02007356|BIOLOGICAL|IFN-γ positive selected T-cells|
41003341|NCT00358202|DRUG|cefepime|cefepime hydrochloride 1gm IM q24h
41003342|NCT00358202|DRUG|ceftriaxone|ceftriaxone 1 gm IM q24h
41003343|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 10 micrograms|Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months
41003344|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 100 micrograms|Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
41003345|NCT01226719|DRUG|Panitumumab|6 mg/kg, 60-90 minute IV infusion every 2 weeks
41003346|NCT01226719|DRUG|Oxaliplatin|85 mg/m2, 2-hour IV infusion every 2 weeks
41003347|NCT01226719|DRUG|Irinotecan|125 mg/m2, 1-hour IV infusion every 2 weeks
41003348|NCT01226719|DRUG|Leucovorin|200 mg/m2, 2-hour IV infusion every 2 weeks
41003349|NCT01226719|DRUG|5-Fluorouracil|3200 mg/m2 IV, 48-hour continuous infusion every two weeks
41316037|NCT02756975|DEVICE|coaxial prostate biopsy|In this method, a larger introducing needle is needed for the puncture. The introducing needle is placed over the perineum. The biopsy needle is inserted throughout the introducing needle.Then, the direction of the biopsy is changed by tilting the coaxial needle. The investigator needs to puncture the prostate capsule only once for sampling at each each side of the prostate (right and left sides).
41003350|NCT03364088|PROCEDURE|Spinal anesthesia with tourniquet|Operation is done under spinal anesthesia and surgical tourniquet is used.
41003351|NCT03364088|PROCEDURE|Spinal anesthesia without tourniquet|Operation is done under spinal anesthesia and without the use of surgical tourniquet.
41003352|NCT03364088|PROCEDURE|General anesthesia with tourniquet|Operation is done under general anesthesia and surgical tourniquet is used.
41003353|NCT03364088|PROCEDURE|General anesthesia without tourniquet|Operation is done under general anesthesia and without the use of surgical tourniquet.
41003354|NCT03364088|DRUG|Oxycodone by patient-controlled analgesia (PCA)|PCA device (CADD Legacy PCA Pump, Smiths Medical, Kent, UK) is programmed to give intravenous oxycodone in doses of 0.04 mg/kg (ideal body weight). The minimum time between doses is set to 10 minutes and no more than 4 doses per hour are allowed.
41003355|NCT01398891|OTHER|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
41003356|NCT00152217|DRUG|TS-1 (S-1)|80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
41003357|NCT00152217|PROCEDURE|Surgery|Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
41003358|NCT01387204|DRUG|GSK1120212|The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
41473729|NCT03203772|OTHER|Immersive Virtual Reality|Participants will engage in virtual visualization therapy in an immersive virtual reality environment
41473730|NCT04571892|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
41473731|NCT01057927|DRUG|OC000459|OC000459 capsules 2x100mg BID for 28 days
41003359|NCT01507285|DRUG|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
41003360|NCT01507285|DRUG|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
41003361|NCT03858387|DRUG|Meropenem|"This group is composed of 52 critically ill patients, meropenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2.5 h, 2.5-4 h, 4-8 h or 4-12 after meropenem administration."
41003362|NCT03858387|DRUG|Imipenem|"This group is composed of 50 critically ill patients, imipenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h or 4-12 after imipenem administration."
41003363|NCT05689385|OTHER|eHealth-based cardiac rehabilitation|"The 12-wk case manager-led eHCR program includes:~1. Individualized exercise prescription according to the results of cardiopulmonary exercise test.~2. At least one session of in-person physical therapy to familiarize participants with the process of exercise training before the initiation of telerehabilitation.~3. Telerehabilitation: a 30-minute moderate aerobic exercise training with remote monitoring and instruction using video conferencing. (Frequency: twice per week in the first 4 weeks, once per week in the 5th-8th week, once every 2 weeks in the 9th-12th week)~4. Additional self-exercise to achieve the target volume of 150-minute moderate aerobic exercise and 2 sessions of resistance training per week.~5. Patient education for secondary prevention delivered regularly via a communication app on the smartphone.~6. Weekly follow-up call from a case manager via phone call or communication app."
41003364|NCT05483946|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - for each participant, a pre-defined number of measurements will be conducted per leg and forearm
41151878|NCT00346359|BIOLOGICAL|anti-thymocyte globulin|
41151879|NCT00346359|DRUG|busulfan|
41151880|NCT00346359|DRUG|fludarabine phosphate|
40799142|NCT03848130|OTHER|Mulligan Knee Taping with Home Exercises|Each patient in group I i.e. taping group with home exercises was given 40 minutes session. Each session started in sitting or lying position with leg extended and mulligan tape was used. Taping was started in the middle of patella, at the level of superior aspect of patella and pulled the tape medially and fixed the tape at medial border. This tilts the lateral border of patella away from femur and produced skin wrinkling. Besides this, home exercises such as quads isometrics and self stretchings \& ROMs were also guided. This session was repeated three times a week for one month (Total 12 sessions/ one month).
40799143|NCT03848130|OTHER|Lateral wedge insoles with Home Exercises|Each patient in group II i.e. lateral wedge insole with home exercises group was given 20-minute session. In each session, Lateral wedge insoles of 7mm made of silicon or ledos material were advised and home exercises in the same way. This session was repeated once a month but evaluations were obtained after a complete week for one month. (Total 4 sessions/one month)
40799144|NCT03848130|OTHER|Traditional Physiotherapy with Home Exercises|Each patient in group III i.e. traditional physiotherapy with home exercises group was given 40 to 45-minute session. Each session started in lying position. In each session, therapeutic ultrasound with 1.5MHz frequency and continuous mode for 7 minute was given. Then passive stretchings of the following muscle groups was done; calf, hamstring, quadriceps, hip flexors and hip adductors \& abductors and followed by strengthening exercises manually and with quadriceps bench. Home exercises were guided in the same way. This session was repeated 3 to 4 times a month. (Total 12 to 16 sessions/ one month)
40799145|NCT00867958|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
40799146|NCT05545787|PROCEDURE|Cold snare endoscopic mucosal resection|During CS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The polyp and 1-2mm of surrounding mucosa will then be closely snared and transected mechanically.
40799147|NCT05545787|PROCEDURE|Hot snare endoscopic mucosal resection|During HS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The snare will be placed around the lesion, and then cautery will be applied using the electrosurgical generator.
40799148|NCT00048022|DRUG|Dual Integrin Antagonist|
40799149|NCT04642118|PROCEDURE|Pulmonary recruitment maneuver|Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
40799150|NCT05156710|DRUG|BIVV020 (SAR445088)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
40799151|NCT05156710|DRUG|Intravenous immunoglobulin (IVIg)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
40799152|NCT05156710|DRUG|Rituximab or biosimilar|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
40799153|NCT05156710|DRUG|Antithymocyte globulin (ATG)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
40799154|NCT05156710|DRUG|Tacrolimus|Pharmaceutical Form: Tablet Route of Administration: Oral
40799155|NCT05156710|DRUG|Mycophenolate|Pharmaceutical Form: Tablet Route of Administration: Oral
40799156|NCT05156710|DRUG|Corticosteroids|Pharmaceutical Form: Vary Route of Administration: Vary
40799157|NCT04130438|DRUG|Nebivolol|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
40799158|NCT04130438|DRUG|Diltiazem|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
40799159|NCT04130438|OTHER|Placebo|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
41003365|NCT04110067|OTHER|Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)|Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser
41003366|NCT05272930|DRUG|Dienogest|Assessment of fibromyalgia effects after the use of dienogest
41003367|NCT01200875|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|One ultrasound-guided intratendinous or intramuscular PRP injection
41003368|NCT01200875|PROCEDURE|Platelet-Rich Plasma (PRP)|One ultrasound-guided PRP injection
41003369|NCT01497210|DEVICE|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
41316038|NCT02756975|DEVICE|noncoaxial prostate biopsy|"In this method, there is no introducing needle. Biopsy needle is inserted repeatedly for each tissue sampling (at least fourteen times). A smaller biopsy needle is used for the puncture in this method.~The main disadvantage of the coaxial technique is that a larger introducing needle is needed for the puncture (12). On the other whand, the advantage of noncoaxial method is that the needle is within the prostate for only a few seconds to document needle position with ultrasonography before firing"
41316039|NCT01983410|BEHAVIORAL|The risk assessment questionnaire|
41316040|NCT01983410|OTHER|Blood specimens|
41316041|NCT01983410|OTHER|tumor tissue samples will be requested|
41316042|NCT03783728|DRUG|Rifapentine 600 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
41316043|NCT03783728|DRUG|Isoniazid 900 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
41316044|NCT03783728|DRUG|Pyridoxine 50 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
41316045|NCT03870126|OTHER|Flavored beverage|Consume one beverage at the beginning of each visit of the cross-over sequence
41316046|NCT00937794|BEHAVIORAL|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
41473732|NCT01057927|DRUG|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
41473733|NCT01290237|DRUG|vancomycin hydrocloride|see description of study arms
40799160|NCT02125838|DEVICE|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
41003370|NCT00859170|DEVICE|Accordion device|an antiretropulsion device
41003371|NCT01868633|DRUG|Dexamethasone|
41003372|NCT01868633|DRUG|Placebo|
41003373|NCT03251248|DRUG|MSB11455|Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
41003374|NCT03251248|DRUG|Neulasta|Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
41316047|NCT00937794|OTHER|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
41316048|NCT03546790|DRUG|Marijuana|Marijuana smoked via blunts with different cigar wrappers
41316049|NCT01353144|DRUG|aspirin|aspirin, 100 mg, qd x 8 weeks
41316050|NCT03188432|DRUG|Carboplatin|Given IV and IP
41316051|NCT03188432|OTHER|Quality-of-Life Assessment|Ancillary studies
41316052|NCT03188432|OTHER|Questionnaire Administration|Ancillary studies
41316053|NCT03188432|PROCEDURE|Cytoreductive Surgery|Undergo CRS
41316054|NCT01968954|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
41316055|NCT01968954|OTHER|Placebo|subcutaneous injection, every 2 weeks for 12 months
41316056|NCT01153191|PROCEDURE|Normal saline pressurized irrigation|same
41316057|NCT01153191|DRUG|sub-q gentamicin|2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
41316058|NCT02541006|DRUG|Tiotropium 18 mcg|tiotropium 18 mcg once a day
41316059|NCT06010355|PROCEDURE|Discussion|Participate in focus groups
41003375|NCT04538066|DRUG|Bryostatin 1|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
41003376|NCT04538066|OTHER|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
41316060|NCT06010355|OTHER|Media Intervention|Watch culturally appropriate video
41316061|NCT06010355|OTHER|Interview|Undergo interview
41316062|NCT06010355|OTHER|Media Intervention|Watch culturally appropriate video
41316063|NCT06010355|OTHER|Test|Complete test
41316064|NCT02210104|DRUG|Ipilimumab|Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
41316065|NCT02210104|DRUG|Cyclophosphamide|300 mg/m2 administered intravenously 2 days prior to T cell infusion.
41003377|NCT01844635|DRUG|Thymoglobulin|
41003378|NCT01072851|BEHAVIORAL|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
41316066|NCT02210104|BIOLOGICAL|CD4+ T cells|Antigen-specific CD4+ T cells administered at a dose of 10\^10 cells/m\^2 on Day 0.
41316067|NCT04816149|BEHAVIORAL|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
40799161|NCT02125838|DEVICE|Endotracheal Tube|ETT
40799162|NCT02613663|PROCEDURE|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
41151881|NCT00346359|DRUG|methotrexate|
41473734|NCT00003531|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41151882|NCT00346359|DRUG|tacrolimus|
41151883|NCT00346359|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41151884|NCT00346359|PROCEDURE|peripheral blood stem cell transplantation|
41151885|NCT01755598|BIOLOGICAL|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
41151886|NCT01755598|BIOLOGICAL|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
41151887|NCT03204318|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
41151888|NCT03204318|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
41151889|NCT03204318|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
41151890|NCT03204318|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
41151891|NCT02161393|BEHAVIORAL|Physical Activity Intervention|The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.
41151892|NCT02161393|BEHAVIORAL|Pulmonary Rehabilitation Programme|This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
41151893|NCT04061317|OTHER|Frailty Assessment|"We will use validated measures to determine existence of frailty prior to interventional cardiac procedures (PRISMA-7, Edmonton and FRIED Frailty Index). We will repeat the measures at 6 weeks and 6 months post procedure. We will also collect clinical data to assess any links between frailty and clinical outcomes.~We are also keen to understand the effects of health-related quality of life on frailty and will be collecting generic data via the SF-36 and EQ5-D."
41151894|NCT04436835|BEHAVIORAL|Psychotherapy|Undergo ART
41151895|NCT04436835|OTHER|Questionnaire Administration|Ancillary studies
41151896|NCT01843699|DRUG|Topiramate flexible dosage|
41151897|NCT01843699|DRUG|Placebo matching tablets|
40799163|NCT02613663|PROCEDURE|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
40799164|NCT04378101|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
40799165|NCT01633255|DRUG|18F-Fluciclatide|
41473735|NCT04455971|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a form of meditation that increases bodily awareness during structured, partnered female genital stimulation over a 15-minute period.
40799166|NCT04294459|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
40799167|NCT04294459|DRUG|Acetaminophen (paracetamol) or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
41151898|NCT01843699|BEHAVIORAL|4-session gambling cognitive restructuring|
41151899|NCT03321188|PROCEDURE|HIPEC|HIPEC with cisplatin
41151900|NCT03321188|DRUG|Carboplatin|Adjuvant IV chemotherapy
41151901|NCT03321188|DRUG|Paclitaxel|Adjuvant IV chemotherapy
40799168|NCT04294459|DRUG|Ranitidine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
40799169|NCT04294459|DRUG|Diphenhydramine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
40799170|NCT04294459|DRUG|Methylprednisolone or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
40799171|NCT04294459|DRUG|Montelukast or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
40799172|NCT00785187|DEVICE|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
40799173|NCT04984343|RADIATION|Radiation Therapy|"Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have \>72 hours between beginning of each fraction."
40799174|NCT03885154|DRUG|Valproic Acid (VPA)|IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
40799175|NCT03885154|DRUG|Dihydroergotamine (DHE)|0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
40799176|NCT05689450|OTHER|Data collection: Amikacin concentration|Blood samples for the measurement of the concentration and calculation of the AUC of amikacin are collected 60 min (+/-30 min) and 8 h (+/-1 h) after the beginning of amikacin infusion. The blood collection after the start of the amikacin infusion will be repeated during every subsequent amikacin administration, but max. during 3 consecutive days.
40799177|NCT01819207|OTHER|blood test by thromboelastography|
40799178|NCT02277249|DRUG|Digoxin (transvaginal administration)|"Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
40799179|NCT02277249|DRUG|Digoxin (transabdominal administration)|"Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
40799180|NCT06323850|BEHAVIORAL|Intervention Phase|After participants have been enrolled, they will be assigned to one of the trainer-pairs and will work with them to schedule the first two sessions. Most clients will be able to schedule one virtual session per week and one ride along session per week for the first five weeks, with the remaining three weeks allotted to practice ride-along sessions and module repetition (as needed). The additional time also provides a buffer if subjects are unavailable for a week during the intervention phase.
40799181|NCT06323850|BEHAVIORAL|Virtual Training Sessions|Virtual sessions will take place over Zoom each session lasting 20-30 minutes. Each of the five virtual sessions will be aligned with the five online modules. For each module, exercises are built in to test comprehension. If the participant does not complete an exercise accurately, the lead trainer will explain why the response was incorrect and prompt them to repeat the video modeling exercise. The support training partner will take notes to support the formative assessment process and complete fidelity checks.
40799182|NCT06323850|BEHAVIORAL|Ride-Along Training Sessions|The first ride-along session will be the baseline session for assessing level of independence (number of cues needed) and safety. The participant will have up to 8 ride-along sessions to reach full independence (no cues needed) and full marks on the safety assessment. The lead trainer will provide the cues as needed to complete each step of the Rideshare process.
40799183|NCT02676674|DRUG|Dose 1|Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
40799184|NCT02676674|DRUG|Dose 2|Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
40799185|NCT03075280|PROCEDURE|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
40799186|NCT00771927|DRUG|Lacosamide|Vimpat was used as per site routine practices, and in-line with the marketing authorization.
40799187|NCT00832598|RADIATION|[18F]FACBC PET and [18F]FLT PET imaging|\[18F\]FACBC PET and \[18F\]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
40799188|NCT03169868|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
40799189|NCT05200416|DEVICE|Heylo|Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
40799190|NCT05200416|DEVICE|Standard of Care|Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
40799191|NCT03545308|DRUG|Rocuronium|Dose: 1 mg/kg
40799192|NCT04621266|BEHAVIORAL|Online Home-based peer support|Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
40799193|NCT01234038|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
41003379|NCT01072851|BEHAVIORAL|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
41003380|NCT01072851|BEHAVIORAL|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
41003381|NCT02513524|PROCEDURE|Direct Observed Therapy test|There is one group only, all of whom will undergo direct observed therapy testing
41473736|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot A|
41003382|NCT03689361|COMBINATION_PRODUCT|MRI|Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion).
41316068|NCT04816149|BEHAVIORAL|Treatment for Relationships and Safety Together (TR&ST)|TR\&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
41003383|NCT03689361|DIAGNOSTIC_TEST|MRI control|MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion)
41003384|NCT03689361|OTHER|telephone consultation|telephone consultation
41003385|NCT01991171|OTHER|Kinesio Taping|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
41003386|NCT04182035|OTHER|patient-tailored therapy|The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
41003387|NCT04182035|OTHER|Non-patient tailored therapy: generalized exercise program|The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
41003388|NCT04182035|OTHER|Education|Education considering neck pain information
41316069|NCT04865250|DRUG|Atezolizumab 1200 mg abs day 1 q22 (iv)|Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)
41316070|NCT00680290|PROCEDURE|Exercise|Exercise x 8 weeks
41316071|NCT06106646|DIETARY_SUPPLEMENT|No active intervention in this protocol (previously randomized to Vitamin C)|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
41316072|NCT06106646|OTHER|No active intervention in this protocol (previously randomized to Placebo)|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
41003389|NCT05973747|DRUG|Calcium Gluconate|Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.
41003390|NCT05973747|DRUG|Calcium chloride|0.5 grams of calcium chloride, infused intravenously over 10 minutes upon umbilical cord clamping
41316073|NCT03863236|DIETARY_SUPPLEMENT|regular diet|The control group (group 1) will continue their regular diet.
41316074|NCT03863236|DIETARY_SUPPLEMENT|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
41003391|NCT02809703|OTHER|Survey Questions|Subjects will receive surveys via direct mail. They will be given the opportunity to opt in to receive a phone call regarding quality of life.
41003392|NCT02150174|BEHAVIORAL|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
41003393|NCT04534842|DRUG|SYNB1618|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
41003394|NCT04534842|DRUG|SYNB1934|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
41003395|NCT02346240|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/ mL~* Route of Administration: Subcutaneous use"
41003396|NCT02346240|BIOLOGICAL|Etanercept|"* Active Substance: Etanercept~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 50 mg / mL~* Route of Administration: Subcutaneous use"
41316075|NCT01173796|PROCEDURE|catheter ablation|perimitral flutter ablation by blocking the mitral isthmus
41316076|NCT01173796|PROCEDURE|catheter ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
41316077|NCT05963295|DIAGNOSTIC_TEST|toxoplasma igG|Dignosis of toxoplasma
41003397|NCT02346240|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
41151902|NCT03323814|DEVICE|Slow-wave optimization|employing sensory stimulation to enhance slow waves
41151903|NCT05106023|DRUG|SHR-1701|SHR-1701 combined with temozolomide
41151904|NCT05106023|DRUG|Temozolomide|SHR-1701 combined with temozolomide
41151905|NCT03239171|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
41316078|NCT01288508|DIETARY_SUPPLEMENT|Supra Fiber|2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days
40799194|NCT01234038|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
40799195|NCT01234038|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
40799196|NCT01234038|DRUG|Paclitaxel|200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
40799197|NCT01234038|DRUG|Carboplatin|AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
40799198|NCT02413996|DEVICE|Kinetec® knee continuous passive motion (CPM )|CPM of the knee
40799199|NCT02413996|BEHAVIORAL|Functional activities|Stairs, walking
41003398|NCT02643524|BEHAVIORAL|Nutrition and Exercise Counseling|Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.
41473737|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot B|
40799200|NCT02413996|OTHER|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS)
40799201|NCT02413996|OTHER|traditional rehabilitation|exercise therapy through a traditional rehabilitation training made by physiotherapists
40799202|NCT02000024|BEHAVIORAL|Weight Watchers|"The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk."
40799203|NCT02000024|BEHAVIORAL|National Diabetes Education Program|
40799204|NCT04922372|COMBINATION_PRODUCT|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
41003399|NCT02643524|BEHAVIORAL|Control|Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
41003400|NCT02777125|DEVICE|Metered Dose Inhaler|A metered dose inhaler (MDI) is a small hand held pressurized canister device that contains both a medication, in this case albuterol, and a propellant. Pressing the device delivers 90mcg of albuterol. The MDI is attached to a spacer device, which is a one way holding chamber which allows the medication to be delivered over a series of breaths.
41151906|NCT03239171|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
41151907|NCT03530345|DRUG|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
41151908|NCT03530345|DRUG|Placebo|Glass vials with matching placebo.
41151909|NCT01119534|DRUG|Guaiacol, eucalyptol, menthol and camphor suppository|2 times per day
41316079|NCT01288508|DIETARY_SUPPLEMENT|Psyllium|1 tablespoon of fiber taken with 8 oz water twice a day for 30 days
41316080|NCT03579524|PROCEDURE|Erector Spinae Plane Block|At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
41316081|NCT03579524|PROCEDURE|Serratus Anterior Plane Block|At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
41316082|NCT06188195|DRUG|Dexamethasone|ACS intervention were used in the experimental group
41316083|NCT01861054|DRUG|Reparixin|1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
41316084|NCT05328856|DEVICE|Hansgrohe prototype|Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out with a mixing function for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds
41316085|NCT04173052|DEVICE|Testis' shocker|The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
41316086|NCT05907993|DRUG|Ibuprofen 800 mg|Intravenous Ibuprofen versus intravenous Ketorolac for postoperative pain relief
41316087|NCT00328965|DRUG|Lacidipine|Lacidipine 2, 4, 6mg
41316088|NCT05632224|DRUG|Aprepitant|The drug is given 1 hour before the start of the surgery
41316089|NCT05632224|DRUG|Granisetron|The drug is given 10 minutes before the patients's extubation
41473738|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot C|
41151910|NCT01119534|DRUG|guaiacol suppository|2 times per day
41151911|NCT01119534|DRUG|Guaifenesin syrup|4.19 mL - 4 in 4 hours
41003401|NCT02777125|DEVICE|Breath Actuated Nebulizer|The breath actuated nebulizer (BAN) device is a device that converts liquid medication, in this case albuterol, into an aerosol. It consists of a mouthpiece, a medication reservoir, and connective tubing that attaches to a compressor. This BAN device delivers medication when the patient takes a breath, but it can be attached to a mask and set to continuous nebulization for patients that are not able to coordinate their breaths.
41003402|NCT04615559|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
41003403|NCT03793907|DEVICE|FitBit|Wear Fitbit
40799205|NCT05148936|OTHER|COVID-19 Testing Home-based (Aim 1)|Implementation of Antigen and PCR testing at participant homes
41003404|NCT03793907|OTHER|Quality-of-Life Assessment|Ancillary studies
41003405|NCT03793907|OTHER|Questionnaire Administration|Ancillary studies
41003406|NCT03793907|OTHER|Resistance Training|Complete strength training
41003407|NCT03793907|BEHAVIORAL|STEPS to Enhance Physical Activity|Complete a walking program
41003408|NCT03314467|DIAGNOSTIC_TEST|polysomnography|"* classical polysomnography~* non invasive measurement of blood pressure~* blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes"
41003409|NCT02967250|DRUG|ursodeoxycholic acid|Subjects will be provided \~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over \~2 weeks to a stable dose for 4 weeks.
41316090|NCT05310513|OTHER|Whether the patient needs to be admitted to the ICU|According to ICU admission or not, patients were grouped into ICU group and NOT-ICU group.
41316091|NCT02793323|OTHER|Superficial cervical nerve block|A nerve stimulator is used to guide superficial cervical blockade to relieve shoulder pain.
41316092|NCT02793323|OTHER|NSAID|100 mg (100 ml) intravenous NSAIDs (Profenid)
41316093|NCT02793323|OTHER|General anesthesia|General anesthesia is induced with 1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen
41003410|NCT05856838|DEVICE|NovaSure ablation|Ablation of the endometrial tissue using the NovaSure device
41003411|NCT05575648|OTHER|10 meter walk test|To assess the dual task performance of children 10 meter walk test will be used.
41003412|NCT05466227|OTHER|Implementation of Modified Valsalva maneuvre|"Modified Valsalva maneuvre:~* Patient is attached to 12-lead ECG monitoring~* The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe~* Patient's legs are elevated (45°) for 15 seconds~* Afterwards, the patient is placed back in an upright position~* If not efficient, this maneuver can be repeated up to two times"
41003413|NCT04999111|BIOLOGICAL|Ad26.COV2.S|Participants will receive IM injection of Ad26.COV2.S.
41003414|NCT00124215|BIOLOGICAL|GI-5005|Heat-killed yeast cell transfected with NS3-Core fusion protien.
41316094|NCT02793323|OTHER|IV placebo|100 ml IV saline
41316095|NCT02793323|OTHER|Placebo superficial cervical nerve block|Superficial cervical nerve block containing 5 ml saline
41003415|NCT00356551|BEHAVIORAL|Family Spirit curriculum|
41003416|NCT00264641|DRUG|Human insulin|Hyperinsulinaemic induced hypoglycaemia
41316096|NCT03348241|DRUG|Gum Arabic|Gum acacia, also known as Gum Arabic is exuded from acacia trees; mainly from Acacia Senegal (gum Hashab or Kordofan gum) which was used in this study.
40799206|NCT05148936|OTHER|COVID-19 Testing Mobile (Aim 1)|Implementation of Antigen and PCR testing at mobile test sites
40799207|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 1 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - active outreach
40799208|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 2 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - baseline outreach
41151912|NCT04113902|BEHAVIORAL|Health Education|the adolescent girls and their mothers who participated in the intervention group were given health education twice in the first interview and in the fifth week. Follow-up continued for 12 weeks. The adolescent girls and their mothers in the control group received routine clinical practice. The effects of health education were evaluated with Human Papilloma Virus Knowledge Scale and Health Belief Model Scale for Human Papilloma Virus and its Vaccination.
40799209|NCT00512850|DIETARY_SUPPLEMENT|Folic acid|Intervention group 1g folic acid per day
41003417|NCT05543785|DRUG|Ketorolac|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
41151913|NCT01854372|DRUG|R-HCVAD and R-MC|
41151914|NCT02465606|DRUG|Lebrikizumab|Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.
41316097|NCT03348241|DRUG|Chemotherapy|Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.
41316098|NCT03348241|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
41316099|NCT02979301|DRUG|Tamoxifen|5 mg or 10 mg tamoxifen per day for 30 days.
41316100|NCT04171648|OTHER|Roasted Peanut Treatment|The subjects will consume 2 ounces or \~48 grams of roasted in shell peanuts a day for two weeks.
41316101|NCT04171648|OTHER|Boiled Peanut Treatment|The subjects will consume 2 ounces or \~48 grams of boiled peanuts a day for two weeks.
41316102|NCT00111150|DRUG|Tenofovir Disoproxil Fumarate 300 mg daily|
41316103|NCT05508685|OTHER|HIIT and Cognitive Reassessment|Participants will receive 40 minutes of high-intensity interval training focusing on the upper and lower limbs associated with a cognitive reassessment strategy during the exercises.
41316104|NCT05508685|OTHER|HIIT group|Participants will receive high-intensity interval training, lasting 40 minutes, focusing on upper and lower limbs.
41316105|NCT05508685|OTHER|Emotional regulation strategy group|Participants will be instructed to cognitively reassess the negative emotions they feel or do not feel during the practice of the exercises. Participants will receive instructions on how to reassess.
41316106|NCT05508685|OTHER|placebo group|Participants in this group will not receive any intervention. Only pre and post experiment will be evaluated.
41316107|NCT02640144|DRUG|Sodium Hyaluronate 1%|Intra articular knee injection following arthroscopy
41316108|NCT02640144|DRUG|Placebo|Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.
40799210|NCT00512850|OTHER|Placebo|One placebo pill per day
40799211|NCT03380637|OTHER|ultrasound|Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
41316109|NCT03659370|OTHER|Fumigation|use Fumigation to increase the improvement of osteoarthritis of knee
41151915|NCT02465606|DRUG|Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)|Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
41151916|NCT05567029|DRUG|Risankizumab Dose A|Prefilled Syringe
41151917|NCT05567029|DRUG|Risankizumab Dose B|Prefilled Syringe
41151918|NCT00523133|DRUG|naltrexone|50 mg naltrexone daily for 3 months
41151919|NCT00523133|DRUG|naltrexone|50 mg of naltrexone daily for 6 months
41151920|NCT00523133|BEHAVIORAL|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
41151921|NCT00523133|BEHAVIORAL|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
41316110|NCT03659370|OTHER|Acupuncture|Acupuncture
41316111|NCT04806516|DEVICE|Summit RC+S System with ECoG Paddles|"Summit RC+S System with ECoG Paddles consists of:~* Olympus RC+S implantable pulse generator (IPG), Model B35300R: 2 per subject x 5 subjects = 10 units~* Extension Leads, Model 37087: 2 per subject X 5 subjects = 10 units~* DBS Leads, Model 3387: 2 per subject X 5 subjects = 10 units~* Patient Therapy Manager (PTM), Model 4NR009: 1 per subject x 5 subjects = 5 units~* Recharge Therapy Manager (RTM), Model 97755: 1 per subject x 5 subjects = 5 units~* Clinician Telemetry Module (CTM), Model 4NR011: 1 per subject x 5 subjects = 5 units~* Research Lab Programmer (RLP), Model 4NR010: 1 unit~* Research Software Development Kit (RDK), Model 4NR013: 2 units~* Subdural Quadripolar Paddle Lead, Model 09130: 2 per subject x 5 subjects = 10 units"
41316112|NCT04806516|OTHER|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
40799212|NCT03472495|DRUG|Diltiazem Oral Product|Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)
40799213|NCT03472495|DRUG|Diltiazem Injectable Product|Diltiazem Continuous Infusion Titrated
41003418|NCT05543785|OTHER|Control|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 50 ml normal saline without drugs will be injected
41003419|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
41003420|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
41003421|NCT02665871|BIOLOGICAL|placebo|
41003422|NCT02665871|BIOLOGICAL|placebo|
41151922|NCT04868734|BEHAVIORAL|Supportive Psychotherapy|Supportive Psychotherapy give to patient with Acute Coronary Syndrome
41151923|NCT01766414|DRUG|C1-esterase inhibitor|intravenously
41151924|NCT01766414|DRUG|Endotoxin|intravenously
41316113|NCT03834662|DRUG|AVID200|A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
41473739|NCT00489099|BIOLOGICAL|V232 Current Process Hepatitis B Vaccine|
41316114|NCT06169930|OTHER|This was an observational study without any intervention|This was an observational study without any intervention
41316115|NCT00466583|DRUG|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
41316116|NCT04803968|OTHER|bicycle ergometer and arm ergometer exercise|"After the bicycle ergometer training is completed, there will be a 15-minute break for blood pressure measurement of the patients.~Then the combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.~For this, the patient will sit upright in front of the height-adjustable arm ergometer stand (Lode Angio Arm Ergometer with Automat) with the fulcrum of the handle at shoulder height.~The arm endurance training group will work for a total of 20 minutes, at 60% of the peak workload and at 50 rpm."
41316117|NCT04803968|OTHER|bicycle ergometer exercise|All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training (Lode Corival Cpet Ergoline type: 960900 serial number: 20160094, Netherlands). The exercise protocol for the lower extremities will consist of a total of 40 minutes, including an 8-minute warm-up phase and an 8-minute cool-down phase. Exercise intensity, on the other hand, will be arranged as recommended in the European Society of Cardiology (ESC) 2020 guideline for chronic heart failure patients, at a workload corresponding to 70-80% of peak oxygen consumption (VO2peak), with a turnover rate of 60 cycles / min.
41316118|NCT03000374|DRUG|Panitumumab|Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
41316119|NCT03000374|DRUG|5Fluorouracil|Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
41316120|NCT03000374|DRUG|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
41473740|NCT05338372|BEHAVIORAL|Two days forest therapy|Participants attend two days (with a break day in between) of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
41473741|NCT05338372|BEHAVIORAL|Three days forest therapy|Participants attend three days of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
41473742|NCT03456024|OTHER|Questinnaire|
41473743|NCT00918463|DRUG|dasatinib|100 mg daily dosing
41003423|NCT04760210|OTHER|Control Group|Treatment for this group is conventional physical therapy along with the bed rest.
41003424|NCT04760210|OTHER|Decompression Group|Treatment for this is conventional physical therapy along with the spinal decompression.
41151925|NCT01690871|DRUG|BEZ235|Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
41151926|NCT06559072|DRUG|Atorvastatin|On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days
41151927|NCT06584578|OTHER|Whole-Body Electromyostimulation|Participants were included in tree exercise programs (Yoga, Pilates, WB-EMS) by an expert trainer 2 days a week for 12 weeks. At the same time, an active control group conducted a weekly diet counseling for 12 weeks by an expert dietician.
41151928|NCT06584578|OTHER|Pilates|Pilates exercise twice weekly for 12 weeks
41151929|NCT06584578|OTHER|Tai Chi|Pilates exercise twice weekly for 12 weeks
41151930|NCT06584578|OTHER|Nutritional counseling|Nutritional counseling for 12 weeks
41316121|NCT03000374|DRUG|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
41316122|NCT04350190|DRUG|Apatinib mesylate tablet|The dose of apatinib mesylate tablets is 250mg, oral, qd, continuous administration, 4 weeks (28 days) as an observation cycle.
41316123|NCT04350190|DRUG|PD-1|The dose of PD - 1 is 200 mg/ time, intravenous injection, q2w, 4 weeks (28 days) for an observation period.
41473744|NCT00768118|DIETARY_SUPPLEMENT|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
41473745|NCT00768118|GENETIC|electrophoretic mobility shift assay|
41473746|NCT00768118|OTHER|laboratory biomarker analysis|
41473747|NCT06341049|PROCEDURE|Intraperitoneal local anasthetic application + local anesthetic wound infiltration|For Group Intraperitoneal local anasthetic+ loal anesthetic wound infiltration, after the birth of the newborn and placenta, the uterus is taken out and closed, the blood accumulated in the pelvis is carefully wiped with surgical towels, and after complete hemostasis is achieved, sterilely prepared 20 ml 0.5% bupivacaine + 20 ml 2% lidocaine +1 A total of 40 ml of solution containing 200,000 epinephrine will be given to the surgeon. 10 ml of this solution will be instilled into all four quadrants of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer will be sutured or left open, depending on the surgeon's preference. 10 ml will be infiltrated around the edges of the rectus aponeurosis, and the remaining 20 ml will be infiltrated subcutaneously into the wound area.
41473748|NCT06341049|PROCEDURE|Intrathecal morphine application|Group Morphine will be given 11.2 mg hyperbaric bupivacaine + 15 µg fentanyl + 150 µg morphine into the spinal space.
41003425|NCT04760210|OTHER|ELDOA|Treatment for this is conventional physical therapy along with the ELDOA.
41003426|NCT02751177|GENETIC|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|Mutation in plasma DNA vs tumor tissue
41003427|NCT06137456|DEVICE|Exoskeletal robotic therapy for walking.|Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.
41003428|NCT06137456|OTHER|Conventional exercise therapy|Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.
41316124|NCT04875403|OTHER|Inspiratory muscle trainning|linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).
41316125|NCT04875403|OTHER|Exercise|exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate
41316126|NCT00258206|BIOLOGICAL|rituximab|
41316127|NCT00258206|DRUG|cyclophosphamide|
41316128|NCT02725827|OTHER|EmbryoGlue (Vitrolife)|A hyaluronan-enriched embryo transfer medium
41316129|NCT02725827|OTHER|Control medium|The usual embryo transfer medium used in the study centres.
41316130|NCT03333330|DRUG|Visipaque 320 and SonoVue|"Intervention is related to the administration of contrast agents:~Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS"
41316131|NCT01703611|OTHER|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
41316132|NCT01703611|OTHER|Usual Nutrition Care|Usual nutrition care in India
41316133|NCT01968720|DRUG|CAT-2003|
41316134|NCT01968720|DRUG|Placebo|
41316135|NCT00868452|DRUG|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
41473749|NCT06341049|PROCEDURE|Quadratus lumborum block tip 1 application|In Group Quadratus lumborum block, Quadratus lumborum block type I, a total of 40 ml of a solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200,000 epinephrine will be applied bilaterally under ultrasound guidance.
41473750|NCT01404052|DEVICE|Transcranial Direct Current Stimulation|Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
41473751|NCT02270424|DRUG|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
41473752|NCT02270424|DRUG|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
41473753|NCT02270424|DRUG|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
41473754|NCT02270424|DRUG|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
41473755|NCT02270424|DRUG|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
41316136|NCT00868452|DRUG|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
41316137|NCT01597037|BEHAVIORAL|Script training|90 minutes/day, 6 days a week; includes 3 weeks of training
41316138|NCT04246593|OTHER|Mobile Market program implementation|"Mobile Market program implementation includes utilizing a Veggie Van model which sells reduced cost locally-grown produce in communities with barriers to accessing fresh F\&Vs because of availability, cost, or lack of produce preparation skills.The Veggie Van visits sites that already serve the target market (e.g., lower-income housing communities, community health centers, community colleges). While Mobile Market programs vary in their model and operation, we believe that the three components of Veggie Van's success are it's share model, price reductions (incentives), and educational component"
41316139|NCT03700632|OTHER|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
41316140|NCT04883658|DRUG|CKD-348(2)|QD, PO
41316141|NCT04883658|DRUG|CKD-828, D097, D337|QD, PO
41316142|NCT00917306|DRUG|PEP005 Gel|0.05% two day treatment
41316143|NCT04222933|DEVICE|Motorized cryotherapy|application of motorized cryotherapy after ACL reconstruction
41316144|NCT04222933|DEVICE|Classical cryotherapy|application of an ice bag
41316145|NCT01044420|DRUG|mFOLFIRI|mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
41316146|NCT01807195|OTHER|contrast medium usage|
41316147|NCT05165979|OTHER|Hospitalization due to COVID-19|Hospitalization due to COVID-19
41316148|NCT00077519|DRUG|tipifarnib|
41316149|NCT00077519|RADIATION|radiation therapy|
40799214|NCT06554340|BEHAVIORAL|Home-based aerobic training|The aerobic training will focus on large, dynamic movements of the lower extremities using leg cycling ergometry on an upright cycle ergometer installed in the participant's homes and will progress in duration (10-40 minutes) and intensity (50-70% VO2 peak) over the 3-month intervention period. All participants will start exercise at 50% of VO2peak for 10-min as determined by the exercise test, for the first week, to individualize the exercise prescription. Progression will initially target duration with weekly progressions of 5 min to 30 min of exercise, followed by progression of intensity by 5% per week until 70% is attained, based on patient tolerance of the increased work.
41316150|NCT01632735|BEHAVIORAL|Mobile Continuing Care|Behavioral: Mobile Texting 12-week intervention. Delivers daily Recovering monitoring, self-management feedback, and education/social support
41316151|NCT00819585|DRUG|Canakinumab|Canakinumab was supplied in glass vials as a lyophilized powder.
41316152|NCT00819585|DRUG|Colchicine|0.5 mg capsule orally once daily for 16 weeks.
40799215|NCT05365958|BEHAVIORAL|HIV Podcast for Heterosexual African American Adults|"The video podcast will deliver HIV prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
41003429|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
41151931|NCT06338254|OTHER|percussion massage therapy|Pregnant women included in this group received a total of 12 sessions of percussion massage therapy, applied to their bilateral lower extremities for four weeks. Percussion massage was applied to both extremities at separate times for 5 minutes each with the Hypervolt device. (Fig. 2) Four muscles in total were focused on; These muscles are medial gastrocnemius, lateral gastrocnemius, peronus longus, and tibialis anterior. Percussion massage was applied in the longitudinal direction of the muscle, from distal to proximal and back to distal, going from posterior to anterior muscle groups. Percussion massage started on the medial side and ended on the lateral side for each muscle. Equal pressure and duration were applied to each muscle.
41151932|NCT02406040|OTHER|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
41151933|NCT03127618|DRUG|Lorlatinib|
41151934|NCT05789927|PROCEDURE|Assessment of the microbial exposome|The assessment of the microbial exposome will be carried out by the deployment of 4 dust collectors (1 per season) at the patient's home. The evaluation of the endogenous myco-microbiome will be carried out by analyzing patient sputum obtained during follow-up visits or during routine care in the event of an exacerbation.
41151935|NCT06054178|DRUG|Fluorescein Sodium|Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg
41151936|NCT02523443|OTHER|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
41151937|NCT02523443|OTHER|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
41151938|NCT05619445|OTHER|Whole Liquid Egg|Subjects will consume 2 fluid ounces of whole liquid eggs per day for 120 days.
41151939|NCT05619445|OTHER|Plant-based Egg Substitute|Subjects will consume 2 fluid ounces of liquid plant-based egg substitute (JUST eggs) per day for 120 days.
41151940|NCT03450018|DRUG|SLC-0111|Oral SLC-0111
41151941|NCT03450018|DRUG|Gemcitabine Injection|1000 mg/m\^2 IV
41316153|NCT00819585|DRUG|Allopurinol|100-300 mg orally once daily for 24 weeks.
41316154|NCT00819585|DRUG|Placebo Matching Canakinumab|Subcutaneous injection.
41316155|NCT00819585|DRUG|Placebo Matching Colchicine|Capsule orally once daily for 16 weeks.
41316156|NCT04275050|DRUG|TQB3303|TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
41316157|NCT01140854|PROCEDURE|Lumbar spine surgery|(non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
41316158|NCT01140854|OTHER|Neurologic/neuropsychometric examinations|To measure postoperative cognitive dysfunction.
41316159|NCT04395352|DEVICE|Endocuff Vision (ECV)|Detachable disposable (single-use) device that fits over the distal colonoscope end.
41316160|NCT05835245|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
41316161|NCT05835245|DRUG|Sintilimab|a PD-1 immune check inhibitor
41316162|NCT05835245|DRUG|Lenvatinib|Lenvatinib capsules
41316163|NCT01818388|DEVICE|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest.
40799216|NCT01208324|DRUG|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
41003430|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
41003431|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
41003432|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
40799217|NCT01208324|DRUG|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
40799218|NCT01208324|DRUG|Placebo Patch|placebo
40799219|NCT01208324|DRUG|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
40799220|NCT04916561|DIAGNOSTIC_TEST|RT-PCR|Detection of Covid-19 in bone, articular fluid and muscle samples using RT-PCR
40799221|NCT05710796|BEHAVIORAL|Difference in gender, response to disease, diagnostic test values|Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
40799222|NCT06044233|DRUG|STI-1558|STI-1558 test preparation and reference preparation
41003433|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
41003434|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
41003435|NCT03951922|BEHAVIORAL|Horticultural activity|Therapeutic horticulture activities are plant-related activities that include but not limited to digging, watering, planting, weeding, trimming, fertilizing, mulching, harvesting, learning about organic farming, and exploring options to incorporate horticulture into daily activities
41151942|NCT01125735|DEVICE|MIST Therapy|The MIST Therapy System is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (noncontact). The system generates and propels the therapeutic MIST Therapy towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon, the acoustic pressure wave, drives them toward the wound.
40799223|NCT04508933|DEVICE|Extravascular Lung Water Index|Measurement of the EVLWI
40799224|NCT04508933|DEVICE|Pulmonary Vascular Permeability Index|Measurement of the PVPI
40799225|NCT01391689|DIETARY_SUPPLEMENT|diindolylmethane|Given PO
40799226|NCT01391689|DIETARY_SUPPLEMENT|placebo|Given PO
40799227|NCT02322580|DRUG|etanercept|
40799228|NCT02346903|DRUG|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
41003436|NCT05279521|BEHAVIORAL|pulmonary rehabilitation exercise|The lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
41003437|NCT00724516|DEVICE|Novel Breast Compression Paddle|Instead of using the regular wire localization mammography compression paddle, a new breast compression paddle will be used. The new breast compression paddle is similar to a tennis racquet. It consists of crossing plastic strings that are strung tightly in a frame. The needle/wire can be inserted anywhere between the strings.
41003438|NCT03494036|DIETARY_SUPPLEMENT|Synbiotic|capsule
40799229|NCT03653234|DEVICE|TV-based Assistive Integrated Service|"TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice."
40799230|NCT04648488|OTHER|Experimental early mobilisation|early activ assisted exercises treatment
40799231|NCT04648488|OTHER|Aktive comparator standrad treatmnet|standard treatment with a plaster 3 weeks and then active assisted exercises
40799232|NCT02713113|DRUG|sugammadex reversal of neuromuscular blockade|
40799233|NCT05225077|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.
40799234|NCT06085716|BEHAVIORAL|Psychoeducational Intervention|Participants in the PI group will complete the educational sessions only.
40799235|NCT06085716|DRUG|Open Label Placebo|This group will only take placebo capsules every day.
40799236|NCT06085716|BEHAVIORAL|Psychoeducational Intervention+Placebo|This group will take the placebo capsules every day, as well as completing the educational sessions.
40799237|NCT00256464|BEHAVIORAL|Multi-component Yoga Intervention|
40799238|NCT05710133|OTHER|food|alectinib-d6 will be administered with breakfast on day 1 to determine the food-effect
40799239|NCT05710133|OTHER|fast|alectinib-d6 will be administered after an overnight fast of minimal 10 hours on day 9 to determine the food-effect
40799240|NCT06280638|OTHER|Virtual stent-guided incremental optimization strategy (VIOS)|"PCI is performed according to strategy recommended by Imaging-Heart Team based on VIOS protocol."
40799241|NCT06280638|OTHER|Standard angiographic strategy|PCI is performed based on international guidelines, local protocols and practice.
40799242|NCT01144169|DRUG|Hydroxychloroquine (HC)|Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
41316164|NCT02531789|OTHER|Observation|C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
41316165|NCT03267992|BEHAVIORAL|COPD Co-Pilot AIR App|App. For COPD symptoms after Coil procedure
41316166|NCT02011867|DEVICE|Cork Electrode|
41316167|NCT04640207|DEVICE|Facial skin treatment|Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
40799243|NCT05894304|DEVICE|Suspension system|suspended from the handles of the straps by either their hands or feet while the non-suspended pair of extremities are in contact with the ground leading to muscle activation due to unstable base of support
41003439|NCT03494036|DIETARY_SUPPLEMENT|Placebo|capsule
41316168|NCT03633565|DRUG|Sildenafil (Phosphodiesterase inhibitors)|tablet 25mg
41316169|NCT03633565|DRUG|Prednisolone (Steroids)|tablet 20 mg
40799244|NCT05894304|OTHER|Scapular training exercises|Scapular muscle strength by resistance
40799245|NCT03190135|BEHAVIORAL|BOKS: 2 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
40799246|NCT03190135|BEHAVIORAL|BOKS: 3 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
40799247|NCT03263988|DEVICE|ConCardiac|All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
40799248|NCT01037335|DRUG|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
40799249|NCT06068946|BIOLOGICAL|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist
40799250|NCT06068946|BIOLOGICAL|Placebo|Placebo comparator
40799251|NCT05849675|DRUG|Pitolisant 17.8 MG [Wakix]|Single dose pitoliosant (36mg)
41316170|NCT03633565|PROCEDURE|Mesenchymal stem cell transplantation|stem cell transplantation intramuscular
41316171|NCT00369395|DRUG|volociximab|Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
40799252|NCT05849675|DRUG|Placebo|Single dose placebo
40799253|NCT04445207|BIOLOGICAL|Convalescent Plasma|One to two 200 mL units of Convalescent plasma per infusion, up to 6 total units within a 3-week period.
41316172|NCT04237818|DIETARY_SUPPLEMENT|Placebo drink|consume 2 bottle (30 mL) per day for 56 days
41151943|NCT01125735|OTHER|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
40799254|NCT05281627|OTHER|Emergency Laparotomy|All patients undergoing Emergency Laparotomy
40799255|NCT02016495|DIETARY_SUPPLEMENT|Magnesium plus alpha-lipoic acid|
40799256|NCT02016495|DRUG|Placebo|
40799257|NCT01817842|BEHAVIORAL|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
40799258|NCT01817842|BEHAVIORAL|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
41316173|NCT04237818|DIETARY_SUPPLEMENT|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|consume 2 bottle (30 mL) per day for 56 days
41316174|NCT06019910|OTHER|Snus with or without tobacco|At baseline, participants have used the intervention daily for at least 30 days. They will then cease usage of the intervention abruptly. After 3 weeks, they may continue to abstain from the intervention or relapse at their own discretion.
41316175|NCT05430711|DRUG|Dinoprostone|After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
41151944|NCT01586910|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
40799259|NCT01817842|BEHAVIORAL|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
40799260|NCT06154148|PROCEDURE|Sustained Diagonal Flexion positioning|This position is a semi reclined positioning, the infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infant's head turns toward the mother's face and is located between the nipple and the clavicule. Their arms and legs are flexed,in a naturally adopted asymmetrical tonic neck posture, according to the infant's term and comfort. The infant is naked and positioned inside the mother's clothes.
40799261|NCT06154148|PROCEDURE|Traditional prone position|The infant is placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
40799262|NCT03299478|OTHER|Will look for immune infiltration|
40799263|NCT03130517|DRUG|intravenous immunoglobulin|giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm
40799264|NCT01786382|DRUG|PPI-668|
41003440|NCT04212585|DIAGNOSTIC_TEST|Serology test|"Serology for Helicobacter pylori (immunoglobulin G for all sites, immunoglobulin M optional, immunoglobulin A optional) will be collected from all participants. 90 samples (immunoglobulin G, immunoglobulin M and immunoglobulin A) at least needed from each site.~Stool antigen for Helicobacter pylori"
41151945|NCT01586910|PROCEDURE|Surgical Aortic Valve Replacement (SAVR)|
41473756|NCT02270424|DRUG|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
41151946|NCT01586910|DEVICE|Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)|
41151947|NCT05724576|BIOLOGICAL|OmniMSC-AMI|10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10\^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10\^7 OmniMSC-AMI, n=5).
41151948|NCT02068079|DRUG|Vemurafenib and Trientine|
41151949|NCT03054792|DRUG|18F-FAZA (F18-Fluoroazomycin Arabinoside)|Intravenous administration of a hypoxia marker, 18F- Fluoroazomycin arabinoside (FAZA), before a PET-MR imaging in order to identify areas of lower oxygen content on samples of a tumour.
40799265|NCT01786382|DRUG|Midazolam|
40799266|NCT01786382|DRUG|Omeprazole|
40799267|NCT01786382|DRUG|Telaprevir|
40799268|NCT00780767|DEVICE|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
40799269|NCT04242628|OTHER|Facebook course|The intervention consists of the attendance to a course on Facebook and Social Networking Sites use
40799270|NCT04242628|OTHER|Lifestyle Course|The intervention consists of the attendance to a course on lifestyle education and brain functioning in older people
41003441|NCT04036656|DRUG|SYHA136 0.5 mg|oral tablet
41003442|NCT04036656|DRUG|SYHA136 1 mg|oral tablet
41316176|NCT04243356|BEHAVIORAL|Nurse Encounter Group|Nurses in this group will meet with former ICU patients in a post ICU clinic visit. This will be a structured meeting for approximately 15 minutes with the nurse and former patient. The encounter will be observed by a member of the research team. Surveys will be completed before and after the visits. Additionally, nurses will be interviewed 4-7 days after meeting with their former patients.
41003443|NCT04036656|DRUG|SYHA136 2.5 mg|oral tablet
41003444|NCT04036656|DRUG|SYHA136 5 mg|oral tablet
41003445|NCT04036656|DRUG|SYHA136 10 mg|oral tablet
41316177|NCT04243356|OTHER|Nurse control group|This group will complete surveys.
41316178|NCT00410449|DRUG|Alpha tocopherol|
41316179|NCT04858880|RADIATION|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.
41316180|NCT01819311|BEHAVIORAL|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
41316181|NCT01819311|BEHAVIORAL|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
41316182|NCT05405036|OTHER|simulated patient|In the last month of the Measurement and Evaluation course in Physiotherapy, a simulated patient session will be held four times (with disease in the cervical-lumbar-shoulder and knee region). Students will be evaluated by the methods they learned about patients. 10 days before and after the simulated patient sessions, the questionnaire will be applied in Turkish for validity and reliability, and then the questionnaire will be repeated after the simulated patient sessions are over, and the effect of the smile patient sessions on the perceived communication skills of the patient will be examined.
41316183|NCT05780346|OTHER|TGNB-CARE (Connecting and Reflecting Experience)|12 session 60-minute mentalizing-focused parenting group with approximately 6 caregivers, facilitated by a mental health clinician
41316184|NCT05171582|PROCEDURE|Surgery 1 (Test group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the test group will be full-filled either with bovine bone substitute with hyaluronic acid (Cerabone plus). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
41003446|NCT04036656|DRUG|SYHA136 20 mg|oral tablet
41003447|NCT04036656|DRUG|SYHA136 35 mg|oral tablet
41003448|NCT04036656|DRUG|SYHA136 50 mg|oral tablet
41003449|NCT04036656|DRUG|Placebo matching SYHA136 0.5 mg|oral tablet
41003450|NCT04036656|DRUG|Placebo matching SYHA136 1 mg|oral tablet
41003451|NCT04036656|DRUG|Placebo matching SYHA136 2.5 mg|oral tablet
41003452|NCT04036656|DRUG|Placebo matching SYHA136 5 mg|oral tablet
41003453|NCT04036656|DRUG|Placebo matching SYHA136 10 mg|oral tablet
41003454|NCT04036656|DRUG|Placebo matching SYHA136 20 mg|oral tablet
41003455|NCT04036656|DRUG|Placebo matching SYHA136 35 mg|oral tablet
41003456|NCT04036656|DRUG|Placebo matching SYHA136 50 mg|oral tablet
41151950|NCT03054792|DIAGNOSTIC_TEST|Blood Oxygen Level Dependent [BOLD] MRI|BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
41151951|NCT03054792|DIAGNOSTIC_TEST|Diffusion-Weighted [DW] MRI|DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
41151952|NCT03054792|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy [MRS]|MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
41151953|NCT05121649|OTHER|Video streaming|Video streaming as a supplement to telephone during emergency calls for dispatchers at EMCCs
41151954|NCT01995149|BEHAVIORAL|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
41151955|NCT03751280|DEVICE|PEAR-004|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
41151956|NCT03751280|DEVICE|Sham|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
41151957|NCT06226896|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily plus RAS inhibitor
41473757|NCT02270424|DRUG|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
41473758|NCT01749748|PROCEDURE|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
41473759|NCT01408225|PROCEDURE|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
41473760|NCT00146406|BEHAVIORAL|Project Connect|
41316185|NCT05171582|PROCEDURE|Surgery 2 (Control group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the control group will be full-filled either with bovine bone substitute (Cerabone). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
41316186|NCT03335956|DRUG|CORT125281, 40mg, fasted|CORT125281 is supplied as capsules for oral dosing
41316187|NCT03335956|DRUG|Prednisone 25mg, fasted|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
41316188|NCT03335956|DRUG|Placebo oral capsule, fasted|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
41316189|NCT03335956|DRUG|Pioglitazone 15mg Tablet|"Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered"
41316190|NCT03335956|DRUG|Placebo oral capsule, fed|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
41473761|NCT06433635|DRUG|Cariprazine|"1. Cariprazine monotherapy outperformed placebo in improving depressive symptoms in most large randomized control trials (RCT). Pooled data showed higher remission rates (30.2%) with cariprazine (1.5 mg and 3 mg/day) compared to placebo (20.9%). Its efficacy extends to bipolar I depression, including mixed features and anxiety.~2. Common adverse effects include nausea (8%) and akathisia (7%). Somnolence and sedation were slightly more common with cariprazine than placebo.~3. Results from a large RCT evaluating cariprazine for bipolar disorder maintenance treatment (NCT03573297) are awaited. An open-label trial reported reduced manic symptoms over 16 weeks.~4. Cariprazine is a D3-preferring partial agonist for D3 and D2 receptors. It antagonizes 5-HT2A and 5-HT2B receptors and partially agonizes 5-HT1A receptors. Affinity for 5-HT1C and histamine 1 receptors is low to moderate."
41473762|NCT06433635|DRUG|Aripiprazole/Escitalopram combination|"1. 40-70% of bipolar patients use antidepressants, often with antipsychotics or mood stabilizers. Aripiprazole lacks efficacy in bipolar depression but is used for mania. Escitalopram, studied alongside mood stabilizers, showed some efficacy.~2. Aripiprazole in bipolar depression trials led to higher rates of akathisia, insomnia, nausea, fatigue, and impulse control disorders. Escitalopram's is generally safe but adverse effects include nausea, diarrhea, insomnia, dry mouth, ejaculatory dysfunction and dizziness.~3. Aripiprazole monotherapy in bipolar I patients reduced relapse rates and delayed relapse time, but not for depressive episodes.~4. Aripiprazole acts as a partial agonist at D2, D3, 5-HT1A, and 5-HT2C receptors, with antagonistic effects on α1 and possibly H1 receptors. Escitalopram is highly selective for the serotonin transporter, with no significant activity at other receptors."
41316191|NCT03335956|DRUG|Prednisone 25mg, fed|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
41316192|NCT03335956|DRUG|CORT125281, 120mg, fasted|CORT125281 is supplied as capsules for oral dosing
41316193|NCT03335956|DRUG|CORT125281, 360mg, fasted|CORT125281 is supplied as capsules for oral dosing
41316194|NCT03335956|DRUG|CORT125281, 720mg, fasted|CORT125281 is supplied as capsules for oral dosing
41316195|NCT03335956|DRUG|CORT125281, 360mg, fed|CORT125281 is supplied as capsules for oral dosing
41316196|NCT03335956|DRUG|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
41316197|NCT03335956|DRUG|CORT125281, 120mg|CORT125281 is supplied as capsules for oral dosing once daily
41316198|NCT03335956|DRUG|CORT125281, 180mg|CORT125281 is supplied as capsules for oral dosing twice daily
41316199|NCT03335956|DRUG|CORT125281, 240mg|CORT125281 is supplied as capsules for oral dosing twice daily
41316200|NCT03335956|DRUG|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing once daily
41316201|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal"
41473763|NCT06433635|DRUG|Quetiapine|"1. Both immediate and extended-release quetiapine monotherapies showed superiority over placebo in acute BD depression across three 8-week randomized trials, confirmed by meta-analysis. Quetiapine exhibited significantly higher remission rates (52.8%) compared to placebo (34.7%) and improved various aspects of life, including quality of life, clinical global impression, sleep, functioning, and anxiety.~2. Common adverse events of quetiapine include sedation, hypotension, increased appetite, weight gain, dyslipidemia, and elevated glucose levels, particularly in a population already at risk.~3. Four studies examined quetiapine's maintenance effects in patients with manic, mixed, or depressive episodes. Overall, quetiapine prolonged the time to recurrence for both depressive and manic episodes."
41473764|NCT06433635|DRUG|Lurasidone|"1. Lurasidone, either alone or with lithium/valproate, proved more effective than placebo for acute BD depression in two 6-week randomized trials. Remission rates were significantly higher with lurasidone monotherapy (40.9%) and in combination (50.3%) compared to placebo (24.7% and 35.4% respectively). Lurasidone also improved anxiety, quality of life, and disability.~2. Common mild adverse events included nausea, headache, akathisia, somnolence, sedation, dry mouth, and vomiting. Weight gain, dyslipidemia, and increased glucose levels were not observed.~3. In a 6-month double-blind discontinuation study post-acute treatment response, lurasidone combined with lithium/valproate prolonged time to depressive episode recurrence compared to placebo (hazard ratio: 0.68). Although not statistically significant due to low placebo recurrence and shorter follow-up, it hints at maintenance efficacy."
41473765|NCT02252523|DRUG|Dexmedetomidine|
41473766|NCT02712437|BEHAVIORAL|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
41473767|NCT05631249|DRUG|Sotorasib 120Mg Tab|Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up
41473768|NCT04685694|DRUG|Misoprostol|sl 800 mcg misoprostol
41473769|NCT05887219|DRUG|Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) for 6 months
40799271|NCT00810771|BEHAVIORAL|Standard Information|A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
40799272|NCT00810771|BEHAVIORAL|Preference-tailored Information|A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
40799273|NCT01119196|OTHER|Icodextrin dialysate|use of alternate SOC dialysate
40799274|NCT04809519|OTHER|Integrative Nursing based Multimodal Interventions for Uncontrolled Hypertensives|In this study, multimodal interventions including yoga, meditation, and breathing techniques, compliance training for hypertension treatment, and home blood pressure measurement training will be applied to the experimental group.
40799275|NCT04809519|OTHER|Ongoing treatment|The ongoing health service of the control group will continue. In addition, the control group will be directed to a specialist doctor and standard brochures prepared by the Ministry of Health for hypertensive individuals will be given.
41003457|NCT03027466|BEHAVIORAL|Self-affirmation induction|Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
41003458|NCT00924911|DRUG|GSK1322322|Four different formulations of 1000mg of GSK1322322
41003459|NCT00924911|DRUG|GSK1322322|GSK1322322 1000mg
41151958|NCT05750121|BEHAVIORAL|E-health enhanced motor-cognitive training|The intervention group will implement physical activity (aerobic exercise and resistance training) and cognitive training (CogniFit) intervention with the e-health components (persuasive technology). The intervention period will last for 12 weeks, with three 90 minutes sessions (60 minutes of physical activity and 30 minutes of cognitive training) per week.
41003460|NCT02963493|DRUG|Melphalan flufenamide (Melflufen)|
41151959|NCT05315076|OTHER|thoracic Manipulation Posterior anterior and conventional therapy|A high-velocity, end range force directed to both sides of the respective zygapophyseal joint as indicated by the segmental examination. This procedure will be performed for a maximum of two attempts. When a cracking sound occurred, the therapist will move on to the next segmental restriction from an upper level to a lower level.
41151960|NCT05315076|OTHER|Muscle Energy Technique (PIR) and conventional treatment|sustain the Isometric contraction for 7-10 and hold the breath. Then the patient will be asked to breathe out and relax while the therapist stretches further up to the neck barrier and hold this for 30 seconds.3 to 5 repetition
41151961|NCT03391778|BIOLOGICAL|ADP adoptive cell therapy|No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
41473770|NCT05887219|DRUG|Group B Azelaic Acid 20 % Cream for 6 months|Group B was managed with topical 20% azelaic acid (daily at night) for six months.
41473771|NCT04187209|DEVICE|Use of the Atalante exoskeleton|A session includes a stand-up, walks over a distance of 10 meters, exercises with or without the assistance of the exoskeleton, U-turns and a sitting.
41473772|NCT04025684|OTHER|Oral B Indicator 123|Manual toothbrush (medium bristle stiffness; compact head, UK market).
41473773|NCT04025684|OTHER|Dr Best Original|Manual toothbrush (medium bristle stiffness; regular head, German market)
41473774|NCT04025684|OTHER|Dr Best Multi Expert|Manual toothbrush (medium bristle stiffness; compact head, German market)
40799276|NCT01848067|DRUG|Alisertib|Given PO
41316202|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily"
41316203|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily"
41316204|NCT04744701|DIAGNOSTIC_TEST|Hemochron Signature Elite Whole Blood Microcoagulation System|Bedside test of Activated Partial Thromboplastin Time
41316205|NCT02566252|DRUG|PUL-042 Inhalation Solution|PUL-042
41316206|NCT02566252|DRUG|Cromolyn Sodium|Pre-treatment
41316207|NCT02566252|DRUG|Albuterol sulfate|Pre-treatment
41316208|NCT01844830|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Intranasally administered regional anesthetic
41473775|NCT04025684|OTHER|parodontax Interdental|Manual toothbrush (soft bristle stiffness; compact head, German market)
41473776|NCT03433755|DRUG|evolocumab|Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.
41473777|NCT03433755|DRUG|placebo|Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
41003461|NCT02963493|DRUG|Dexamethasone|IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.
41003462|NCT05983718|DEVICE|Surgical Guide|For this case, after the patient is given anesthesia, the guide will be placed on the teeth. All the drillings will be performed through the guided path. There will be no need for raising flap according to flapless surgery. At the end of the operation, the operation site will be checked and hemostasis will be provided. The operator will record the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
41003463|NCT05983718|PROCEDURE|Guide-pin-assisted Freehand surgery|The regular protocol of the implant surgery will be followed. Before the surgery begins, the patient will be given anesthesia to ensure they are comfortable and pain-free during the procedure. Doctors will go through the digital planning to understand the desired angulation. Then the bony bed will be prepared raising flap from targeted area. Then a guide-pin will be inserted by drilling and through radiographic image the direction will be confirmed. Following the hole of the guide-pin, the implant will be inserted. At the end of the operation, the raised flap will be sewn and hemostasis will be provided. The operator records the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
41003464|NCT01839448|BIOLOGICAL|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
41151962|NCT06585709|DEVICE|Active repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS will be delivered with a MagVenture MagPro X100 rTMS device with a Cool-B65-AP coil. rTMS will be applied to a personalized treatment target within the Left-Dorsolateral Prefrontal Cortex using a Localite Neuronavigation device.
41151963|NCT06585709|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS in an identical fashion to the active-rTMS condition will be delivered via the built-in e-sham system in the MagVenture device.
41151964|NCT01121497|DRUG|Physostigmine|Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
41151965|NCT05493605|PROCEDURE|Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope|The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.
41151966|NCT03199170|DRUG|Intrathecal morphine|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia
41151967|NCT03199170|DRUG|Bilateral Quadratus Lumborum Block|0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine
41316209|NCT01844830|DRUG|Placebo|Inactive ingredients supplied in identical nasal sprayer
41316210|NCT01933256|DRUG|HIP2B|
41316211|NCT01933256|DRUG|Placebo|
41316212|NCT04962503|DRUG|Afamelanotide|Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.
41316213|NCT02821455|PROCEDURE|Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
41316214|NCT04942938|DEVICE|Neubie|The Neubie is a direct current neuromuscular electrical stimulation device. This system uses an exponential wave pattern to mimic the natural pattern neurologically to lengthen fibers of the sarcomere and engage force velocity of muscle with minimized protective co-contraction of nearby muscle groups. The golgi tendon and muscle spindles code for joint position and muscle/tendon stretch with 66% of fibers being intrafusal. Impacting these structures has direct impact on reticulospinal tract fibers and proprioceptive central fibers modulation of levels of spasticity. The Neubie direct current is designed to improve positioning of these stretch receptors.
41316215|NCT00048399|DRUG|Fludarabine|
41316216|NCT00048399|DRUG|CAMPATH 1H|
41316217|NCT00048399|DRUG|FK506|
41316218|NCT00048399|PROCEDURE|Stem Cell Transplantation|
41316219|NCT02251444|PROCEDURE|outpatient rehabilitation program|
41316220|NCT02251444|PROCEDURE|physical therapy|
41316221|NCT01670409|RADIATION|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
40799277|NCT01848067|DRUG|Abiraterone acetate|Given PO
40799278|NCT01848067|DRUG|Prednisone|Given PO
40799279|NCT05948527|DEVICE|high flow nasal canula|administration of high flow nasal canula at initial flow 35 liters per minute and Fio2 (fraction of inspired oxygen of 50%) with titration to reach oxygen saturation of 88-92%.
41003465|NCT04675424|DEVICE|ANSwatch|"ANSwatch wrist sphygmomanometer and the specific database from monitors in ICUs may be a feasible way to predict outcome among ICU patients. Two measurements will be obtained:~1. Pulse diagnosis: Pulse diagnosis done on radial artery is recorded by traditional Chinese medicine physician and ANSwatch wrist sphygmomanometer at the same time.~2. Heart rate variability: Heart Rate Variability represents significant information on autonomic nervous system (ANS)'s regulating function and balance status."
40799280|NCT01671709|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
41003466|NCT05049148|OTHER|Platelet count in excised tumors|Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.
40799281|NCT00456755|DRUG|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
40799282|NCT00456755|OTHER|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
40799283|NCT02374788|BEHAVIORAL|Pedometer intervention|Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
41003467|NCT00145509|DRUG|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
41003468|NCT00145509|DRUG|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
41003469|NCT04732637|DIAGNOSTIC_TEST|"Test At Home's Proprietary Lollipop Buccal Cavity Swab"|"Self-collected Test At Home's proprietary Lollipop Buccal Cavity Swab with VTM."
41003470|NCT03087370|OTHER|No intervention|No intervention
40799284|NCT02374788|BEHAVIORAL|Group meetings|Participants receive 12 group meetings over two years' time.
40799285|NCT02374788|BEHAVIORAL|Individual consultations|Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
40799286|NCT05856929|OTHER|no Intervention|no intervention
41003471|NCT02761811|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
41003472|NCT03517709|OTHER|Primary Care Physician Management of blood pressure|"* You will receive a 30-minute education session about your blood pressure medications and the need to take them every day.~* Your primary care physician will make recommendations on your optimal target blood pressure range and medication recommendations. ."
41003473|NCT03517709|DEVICE|Withings Smart Blood Pressure Monitor|We will use the Withings Smart Blood Pressure Monitor for daily blood pressure measurements.
41003474|NCT05962411|OTHER|Dress in Professional Attire|"Adolescents pretend to be adult e-cigarette buyers by dressing in professional attire."
41003475|NCT04915781|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
41003476|NCT02549157|PROCEDURE|Pelvic Floor Muscle Training|
40799287|NCT06268184|DIETARY_SUPPLEMENT|D3 LAB SYRUP|omega 3 suplementation
40799288|NCT06268184|DIETARY_SUPPLEMENT|placebo syrup|placebo syrup contains purified water, glycerin, xanthan gum, tween 80, methyl paraben, propyl paraben, sorbitol solution70% and apple flavor.
40799289|NCT02479958|PROCEDURE|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
40799290|NCT02479958|PROCEDURE|Tooth drying|The tooth was dried with air jet.
41003477|NCT01412866|BEHAVIORAL|EDSS with CO feedback and health checklist|Web-based electronic decision support system with CO feedback and health-checklist
41003478|NCT01412866|BEHAVIORAL|EDSS with health checklist feedback alon|Web-based electronic decision support system (EDSS) with health-checklist feedback alone (without CO feedback)
41003479|NCT00006012|BIOLOGICAL|filgrastim|
41003480|NCT00006012|DRUG|amifostine trihydrate|
41003481|NCT00006012|DRUG|cisplatin|
41003482|NCT00006012|DRUG|etoposide|
41003483|NCT00006012|DRUG|paclitaxel|
41003484|NCT00006012|DRUG|topotecan hydrochloride|
41316222|NCT01670409|DRUG|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
41003485|NCT00006012|RADIATION|radiation therapy|
41003486|NCT02296112|DRUG|trametinib|Given PO
41003487|NCT02296112|OTHER|laboratory biomarker analysis|Correlative studies
41003488|NCT02296112|OTHER|pharmacological study|Correlative studies
41003489|NCT01454934|DRUG|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
41003490|NCT01454934|DRUG|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"* Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~* Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~* Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~* Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
41003491|NCT04890392|DRUG|PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)|S-1: 40\~60mg Bid，d1\~14, q3w. Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w. PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w. Stage I: PD1 inhibitor + SOX regimen (q3W) . Stage II: PD1 inhibitor + SOX regimen (q3W) Stage III: PD1 inhibitor + SOX regimen (q3W) . Efficacy evaluation,then followed by surgery.
41003492|NCT00676442|DRUG|PN400|naproxen/esomeprazole
41003493|NCT03821558|OTHER|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.
41003494|NCT00218348|DRUG|Dextro-Amphetamine Sulfate|
41003495|NCT00847275|OTHER|Exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
41151968|NCT03199170|DRUG|Intrathecal morphine with bilateral Quadratus Lumborum Block|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
41151969|NCT05448950|DEVICE|VIG Continued Access Study|Small skin incisions will be made for tunneling the graft under the skin in a standard manner. The VIG device is provided pre-loaded within a customized catheter-based delivery system for over-the-wire delivery. The VIG is inserted through an introducer sheath placed in the target vein so that the 'vessel end' of the VIG is deployed within the vein, and the 'graft end' extends out of the vein for connection to the graft. Delivery and deployment will be performed under fluoroscopic guidance. The VIG will be deployed first, connected to the AVG, then the graft and VIG will be flushed and clamped. The arterial anastomosis will then be created using a standard suturing method.
41151970|NCT06050837|OTHER|No intervention|No intervention
41316223|NCT03657667|PROCEDURE|Ureteroscopy|Endoscopic removal of kidney stones
41316224|NCT02496481|BEHAVIORAL|Motivational Interviewing|Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
41316225|NCT02496481|BEHAVIORAL|Tailored brochure|Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
40799291|NCT02479958|PROCEDURE|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
41003496|NCT00847275|OTHER|Geriatric follow-up|"250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
41151971|NCT04123938|OTHER|Pea Protein|Soluble pea protein
41151972|NCT04123938|OTHER|Whey Protein|Whey protein concentrate
41151973|NCT04123938|OTHER|Maltodextrin|Non-protein isocaloric comparator
41003497|NCT01088646|DEVICE|PillCam® Express Capsule Endoscopy Delivery System|"The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.~Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.~The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free."
41003498|NCT02047617|DEVICE|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
41003499|NCT02047617|DEVICE|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
41003500|NCT03759067|DRUG|clopidogrel 75mg|clopidogrel once daily 75mg
41003501|NCT03759067|DRUG|Clopidogrel 300 mg|clopidogrel 300mg reloading
41003502|NCT03759067|DRUG|clopidogrel 600mg|clopidogrel 600mg loading
41003503|NCT03372512|DIAGNOSTIC_TEST|Bioimpedance spectroscopy|Fluid overload will be assessed by bioimpedance spectroscopy
41003504|NCT00989833|DRUG|budesonide|400 yg x 1
41003505|NCT00989833|DRUG|terbutaline|0.4 mg as-needed
41151974|NCT05104957|OTHER|Dynamic tape|The experimental group will use a special dynamic patch made of cotton, coated with a hypoallergenic acrylic heat-activated adhesive arranged in sinusoidal-shaped layers. The tape will be applied using the muscle technique with a Y-shaped cut patch directly to the dried and non-greased skin. The application will be performed in a standing position, with the participant's lower extremities straight. The therapist will place the beginning of the tape (the base) on the participant's sacrum and then, asking them to bend 45 degrees forward, tape the tails of the tape along the spine on the extensor muscles of the lumbar region, without changing the tension of the tape, keeping the base in the initial position.
41151975|NCT05104957|OTHER|Sham tape|In the control group, a plain paper patch will be used to conduct the study, which, like the dynamic patch, will be applied using the same form of tape cutting and the same application technique. The entire method of applying the patch will also take place in the participant's standing position with forward bending. The paper patch will be placed at the levels from the L3 segment to the sacrum, along the spine on the lumbar extensor muscles.
41316226|NCT01429077|DRUG|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
40799292|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
41003506|NCT00989833|DRUG|budesonide/formoterol|160/4.5 yg as-needed
41003507|NCT01458899|DRUG|TC-5214|Oral tablets, single 4mg dose
41003508|NCT05758740|BEHAVIORAL|E-health enhanced behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, a conventional behavioural change intervention will begin following a standardized intervention implementation manual and the physical activity amount will be logged by the participants using a logbook. Physical activity counselling will be conducted by a trained research assistant face-to-face at the elderly community centre. Each counselling session lasts for one hour and is once per week for 12 weeks.
41003509|NCT05758740|BEHAVIORAL|Conventional behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, e-health enhanced behavioural change intervention will begin following a standardized intervention implementation manual and using participants' own smartphones installed with two Apps (i.e., Samsung Health and WhatsApp). The physical activity amount will be logged by the smartphone using Samsung Health. Physical activity counselling will be conducted by a trained research assistant remotely using a smartphone. The remote counselling sessions totally last for accumulatively 1 hour per week for 12 weeks.
41003510|NCT02248090|DRUG|AZD9496|AZD9496
41003511|NCT02248090|DRUG|AZD9496|If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
41003512|NCT02863835|OTHER|EIT|All participants will have continuous monitoring of EIT whilst self venting
41003513|NCT02863835|OTHER|Salbutamol nebulisation and with CPAP|All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
41003514|NCT02143115|PROCEDURE|Optical colonoscopy|Examination of the colon with a colonoscope
41316227|NCT01429077|DRUG|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
41316228|NCT03638661|DIETARY_SUPPLEMENT|vegetable (canola, flaxseed) derived n-3 fatty acid|vegetable (canola, flaxseed) derived n-3 fatty acid was used for fat source.
41316229|NCT03638661|DIETARY_SUPPLEMENT|soybean oil|soybean oil used formula
41316230|NCT03713931|DIAGNOSTIC_TEST|PUMA Score questionnaire|"Every patient who meet the criteria for active search (older than 40 years, smokers or ex-smokers of more than 10 pack-years who attend the usual care in the first level of care) will be scored with the PUMA´s questionnaire in an application and electronic database (RedCap) specially designed for the active search of cases.~Patients with PUMA´s score ≥ 5, and without exclusion criteria for spirometry will be referred to perform spirometry at the institution"
41316231|NCT03628417|PROCEDURE|Calcium Electroporation|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
41316232|NCT03628417|PROCEDURE|Bleomycin based electrochemotherapy|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
41316233|NCT04399512|PROCEDURE|Nonsurgical root canal treatment|Nonsurgical root canal treatment will be given
41316234|NCT01132677|DEVICE|Hylan G-F 20 (Synvisc One)|Single IA injection of 6cc's. Injections will be administered as outlined on the company label.
41316235|NCT01132677|DRUG|Methylprednisolone (Corticosteroid)|Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
41316236|NCT00150059|DRUG|Pimecrolimus Cream 1%|
41316237|NCT01906866|DRUG|Circadin 2/5/10 mg|Circadin 2/5/10 mg. Active arm
41316238|NCT01906866|DRUG|Placebo|Control arm
41003515|NCT02143115|RADIATION|CT-Colonography|A computerized X-ray that may find out if there are polyps or cancers and also pictures the contents of the abdomen and pelvis
40799293|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
41003516|NCT05354375|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.
41003517|NCT05692661|RADIATION|proton plus carbon ion radiotherapy|CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels \[10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx \].
41003518|NCT05968846|DRUG|Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)|124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is a a novel iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging that has been shown to bind systemic amyloid deposits of diverse types in all organs, including the heart. The peptide binds amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.
41316239|NCT04597255|DEVICE|Holographic optical coherence tomography|Descriptive wavefront analysis with holographic optical coherence tomography
41316240|NCT01787643|OTHER|Height-Adjustable Desk Intallation in Office|
41316241|NCT05798689|COMBINATION_PRODUCT|Probiotic administration and gluten|Probiotic preparation including multi-species strains of Lactobacillus and Bacillus. The probiotic was administered at baseline and interrupted after 32 days. At the same time the other arm received placebo. Gluten was provided after 10 days of gluten free diet in increasing amounts
41316242|NCT05798689|COMBINATION_PRODUCT|Placebo administration and gluten|The placebo was administered at baseline and interrupted after 32 days. At the same time the other arm received probiotic. Gluten was provided after 10 days of gluten free diet in increasing amounts
41316243|NCT04529421|BEHAVIORAL|Online instruction|For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.
40799294|NCT01644669|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
41003519|NCT00518804|BEHAVIORAL|Functional Behavioural Skills Group and Parent Training|
41316244|NCT04529421|BEHAVIORAL|In-person instruction|For some courses and groups of students, instruction is primarily offered in-person, on campus (or elsewhere).
40799295|NCT03557957|OTHER|Targeted correction of plasma sodium levels|Targeted correction of hyponatremia
41003520|NCT04263818|PROCEDURE|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for|"Carrying out the endoscopic procedure planned for the patient with the dedicated colonoscope which has magnetic coils over the entire length of the insertion tube. These magnetic coils generate a pulsed magnetic field at low frequency. These pulses are transmitted to an external receiver, refreshed at 15 images per second, then relayed to the processor to generate a 3D representation of the colonoscope next to it of the endoscopic image. There is no additional risk to the patient compared to current practice.~Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for."
40799296|NCT03557957|OTHER|Standard care|Standard care of hyponatremia
40799297|NCT05366127|OTHER|IGA score|IGA score will be assessed by 2 blinded investigators
41316245|NCT02156492|DRUG|Evacetrapib|Administered orally.
41316246|NCT02156492|DRUG|Simvastatin|Administered orally.
41316247|NCT02156492|DRUG|Atorvastatin|Administered orally.
40799298|NCT05366127|OTHER|BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)|BPDAI will be assessed by 2 by 2 blinded investigators
40799299|NCT04244695|DRUG|Dexamethasone Oral|To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
41003521|NCT06382233|DIAGNOSTIC_TEST|Identification of Diagnostic Biomarkers|Urinary single-cell and EVs screening to stage the intrarenal injury and repair processes in UPJO babies and identification of the whole blood gene expression profiling of babies with unilateral UPJO. Data deriving from patients with unilateral UPJO will be compared with data deriving from controls.
41003522|NCT06019156|BEHAVIORAL|Exercise video distribution of Metaverse|Participants received a 10-minute exercise video each week with a load of about 4 to 8 metabolic equivalents of task (METs) in the metaverse space, for eight videos delivered to encourage exercise.
41003523|NCT06019156|BEHAVIORAL|Exercise video distribution of YouTube|Participants view exercise videos with the same content as the metaverse group.
41003524|NCT03340129|DRUG|Ipilimumab|Ipilimumab 3mg per kg every 3 weeks for 4 doses
41003525|NCT03340129|DRUG|Nivolumab|Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
41316248|NCT00199758|DRUG|cisplatin|
41316249|NCT00199758|DRUG|Gemcitabine|
41003526|NCT03340129|RADIATION|Stereotactic Radiotherapy|The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.
41003527|NCT03340129|OTHER|Salvage therapy|Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
41316250|NCT00199758|DRUG|Taxol|
41316251|NCT02299063|DRUG|Dexmedetomidine|A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
40799300|NCT01769664|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
40799301|NCT01769664|DRUG|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
41003528|NCT01147653|BIOLOGICAL|Autologous UCB Reinfusion|Autologous umbilical cord blood (UCB) reinfusion
41003529|NCT01147653|OTHER|Placebo|Placebo
41003530|NCT00534690|PROCEDURE|One-Lung ventilation|Low Vt, High PEP
41003531|NCT00534690|PROCEDURE|One-Llung ventilation|High Vt, low PEP
40799302|NCT01769664|DRUG|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
40799303|NCT05506072|OTHER|Blood flow restriction therapy|Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
41003532|NCT04219865|DRUG|Group 1: Compound Edaravone/Placebo Injection|Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min
41316252|NCT02299063|DRUG|0.9% NaCl|
41316253|NCT03508141|DRUG|Fibrinogen Concentrate|Experimental
41316254|NCT03508141|DRUG|Cryoprecipitate|Comparator
41316255|NCT02675894|DEVICE|cooled-wet electrode|RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.
41316256|NCT02675894|DEVICE|separable clustered electrode|RFA is performed using separable clustered electrode in switching monopolar mode.
41316257|NCT02671942|DRUG|Roflumilast|
41316258|NCT02671942|DRUG|Placebo|
41316259|NCT05506592|OTHER|dermatological product|cosmetic shampoo
41316260|NCT02201381|DRUG|Metabolic treatment|While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
41316261|NCT03090373|DEVICE|UroShield|The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
41316262|NCT04357119|PROCEDURE|One-anastomosis gastric bypass|"Laparoscopic single anastomosis gastric bypass is reported to be a safe alternative to LRYGB, showing comparable efficacy in weight reduction and resolution of metabolic complications with reduced surgical complications.~The advantages with this technique as claimed by those speaking in favor of it are many: fewer sites for leakage and internal hernia, easier and faster to learn and perform, easy to reverse and revise, and with results at least comparable with the result following standard Roux-en-Y gastric bypass (RYGB).~The length of the biliopancreatic limb in single anastomosis gastric bypass as reported by Rutledge is fixed 200 cm starting at the duodenojejunal junction, neglecting the length of the common limb.~Because of deficient data regarding the effect of common limb length on the outcome of LSAGB, so a clinical trial shall add new knowledge regarding sufficient weight loss, rate of complications and the need for revision."
41316263|NCT04595396|PROCEDURE|Laparoscopic Gastric Bypass|The LGBP was performed using a classic Roux-en-Y procedure. Briefly, a gastric pouch of 30-50 cc was constructed with an antecolic calibrated gastro-jejunal anastomosis (mechanical anastomosis using a 2.5 mm load). The biliary and alimentary limbs measured ≈70 cm and ≈150 cm, respectively, and the jejuno-jejunal anastomosis was also performed in a latero-lateral fashion (mechanical anastomosis using a 2.5 mm load). Mesenteric defects were closed with running non-absorbable sutures and the omentum was divided in every case
41316264|NCT02159261|DRUG|BAY98-7071_EE20/DRSP/L-5-MTHF|Patients treated by Physicians under approved local prescriptions
41316265|NCT06243822|DRUG|Ketamine|ketamine is initiated at 0.5 mg/kg/h and titrated by 0.25 mg/kg/h every 15 minutes to a maximum dosage of 4 mg/kg/h to achieve appropriate sedation.
41316266|NCT06243822|DRUG|Propofol|Propofol is initiated at 0.3 to 0.6 mg /kg/hr. and titrated by 0.3 to 0.6 mg/kg/h every 5 to 10 minutes up to a maximum dosage of 4.5 to 4.8 mg/kg/hr. to achieve appropriate sedation.
41473778|NCT05500092|DRUG|Nivolumab|Patients randomized to the Nivolumab + Platinum Doublet Chemotherapy only arm will receive three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) with sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
41473779|NCT05500092|RADIATION|(8gy x 3)|sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
41473780|NCT05500092|DRUG|Platinum Doublet|Standard of care doublet platinum therapy
41473781|NCT06334861|BIOLOGICAL|Herpes Zoster adjuvanted recombinant vaccine|patients will receive two doses of vaccine with an interval between the first and second dose of 2 months
41003533|NCT04219865|DRUG|Group 2: Compound Edaravone/Placebo Injection|Compound Edaravone 60mg-1200mg (containing edaravone 60 mg and 2-aminoethanesulfonic acid 1200 mg) / placebo single intravenous infusion for 30min
41003534|NCT04219865|DRUG|Group 3: Compound Edaravone/Placebo Injection|Compound Edaravone 90mg-1800mg (containing edaravone 90 mg and 2-aminoethanesulfonic acid 1800 mg) / placebo single intravenous infusion for 30min
41316267|NCT06163560|DEVICE|"Smartphone app Happy Baby HK"|"Happy Baby HK will provide developmental stage, developmental aspects, parenting videos and cartoon images created for new mothers."
41003535|NCT04219865|DRUG|Group 4: Compound Edaravone/Placebo Injection|Compound Edaravone 120mg-2400mg (containing edaravone 120 mg and 2-aminoethanesulfonic acid 2400 mg) / placebo single intravenous infusion for 30min
41003536|NCT04219865|DRUG|Group 5: Compound Edaravone/Placebo Injection|Maximum tolerated dose of drug / placebo for a single intravenous infusion for 30 minutes three times a day at an interval of 8 h until the last dose on the morning of Day 3, after which the sequential test drug 30 mg-600 mg / placebo will be administered daily from Day 3 night Intravenous infusion, 30 minutes at 12-hour intervals until morning on Day 7
41003537|NCT04070300|BEHAVIORAL|Interval exercise|Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.
41316268|NCT06163560|DEVICE|Family Health Service parenting booklet|The parenting booklet is publicly available and provides brief caretaking tips for mothers with children under 3 years of age.
41316269|NCT00748085|DEVICE|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
41316270|NCT01996748|DRUG|DF277|Two administrations daily for 7 days
41316271|NCT01996748|DRUG|Placebo|Two administrations daily for 7 days
41316272|NCT02486887|DEVICE|telemonitoring of weight, pulse and blood pressure|
41316273|NCT00545987|DEVICE|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
41003538|NCT01109082|PROCEDURE|posterior spine fusion|vertebrae are fused to straighten a spinal curve
41003539|NCT00232908|DRUG|ARV regimen|As prescribed
41003540|NCT00232908|DRUG|enfuvirtide [Fuzeon]|90mg sc bid for 12 weeks
41316274|NCT00545987|DEVICE|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
41316275|NCT00789191|DRUG|insulin detemir|The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
41473782|NCT02563418|DEVICE|Eye-tracking|
41473783|NCT04126486|OTHER|Zio®XT Monitor|A Zio® XT monitor will be affixed to the participant's chest
41473784|NCT02737592|DEVICE|"Trojan Simply Pleasure Personal Lubricant"|silicone base without sensate
41473785|NCT06326177|PROCEDURE|Spine Posture Assessment|Spine posture will be assessed with double inclinometer method. After determining landmarks for each assessment, inclinometers will be placed and degree will be noted. Both degree which are obtained with different inclinometers will be used to summed up for determining postural alteration degree. Cervical, thoracal, thoracolumbar and lumbar spinal postures will be used. Spine postures are going to be expressed as, cervical lordosis degree, thoracal kyphosis degree, thoracolumbar posture degree and lumbar lordosis degree. Landmarks for cervical lordosis are C2 and C7, for thoracal kyphosis are T1 and T12, for lumbar lordosis are T12 and S1, for thoracolumbar posture C7 and S1.
41316276|NCT00789191|DRUG|sitagliptin|The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
40799304|NCT05506072|OTHER|Standard Physical Thearapy|"Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training."
41003541|NCT05289596|BEHAVIORAL|Sleep Healthy Using the Internet (SHUT-i)|SHUTi is a six session, 6-8 week cognitive behavioral therapy for insomnia program over the internet. The online, self-paced program offers illustrations, graphics, videos and built-in algorithms offering brief sleep diaries, personalized sleep window recommendations, education from sleep experts, peer stories about insomnia, and skills to help participants relearn proper sleep dynamics and increase sleep efficiency.
41316277|NCT00789191|DRUG|metformin|Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
41316278|NCT00789191|DRUG|sulphonylurea|Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
41003542|NCT04138875|DRUG|Rituximab|Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a \>10% change in weight dosing will be readjusted.
41316279|NCT05157399|DEVICE|Otoband|Participants with Dizziness and Vertigo will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
40799305|NCT03626064|BEHAVIORAL|Smoking Cessation Counselling|One on one smoking cessation counselling with a certified mental health nurse
41316280|NCT05157399|DEVICE|Placebo Device|Participants with Dizziness and Vertigo will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
41316281|NCT02723136|DEVICE|Smartphone Application|Smartphone application developed by internists and engineers. Will be made available on iOS(R) and Android(R) operating systems.
41316282|NCT04054843|DIAGNOSTIC_TEST|Afamin|Plasma maternal afamin levels
41316283|NCT04263948|DEVICE|Picado system internet platform and connected objects|The system will monitor the circadian rhythms, physical activity, sleep, symptoms and body weight of patients with advanced pancreatic cancer during one week before (baseline) and six weeks after the 1st course of standard mFOLFIRINOX. The reach of preset thresholds for several parameters that are automatically computed will trigger alerts toward approved health professionals, and their responses will be traced.
41316284|NCT03988608|DRUG|Eltrombopag 25 mg|film-coated tablets containing 25 mg of eltrombopag free acid in each tablet
41316285|NCT00744016|DRUG|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
41003543|NCT04138875|DRUG|Brentuximab Vedotin|Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
41003544|NCT04138875|DRUG|Bendamustine|Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
41316286|NCT00744016|DRUG|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning
41316287|NCT04362449|COMBINATION_PRODUCT|Shortened hydration time and dispensary of Akynzeo|Hydration is reduced to 1 hour and 40 minutes and Akynzeo is administered as an oral drug instead of Ondansetron being given as an IV before chemotherapy.
41316288|NCT04362449|COMBINATION_PRODUCT|Standard of care|Hydration remains at around 6 hours and 30 minutes due to no oral fluids being consumed prior to treatment and normal saline being administered for 90 minutes before cisplatin and then for 2 hours after cisplatin and before gemcitabine administration
41316289|NCT06087952|OTHER|Randomised treatment advice (discontinue vs continue after 3 months)|Randomisation to continue or discontinue anticoagulant therapy in 1:1 ratio stratified on risk category of L-TRRiP and VTE-BLEED score
41316290|NCT06087952|DIAGNOSTIC_TEST|VTE-BLEED score|Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score
41316291|NCT06087952|DIAGNOSTIC_TEST|L-TRRiP score|Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score
41316292|NCT06087952|OTHER|Advise to continue anticoagulant treatment after 3 months|Advise to continue anticoagulant treatment after 3 months for patients with high VTE recurrence and low bleeding risk
41316293|NCT06087952|OTHER|Advise to discontinue anticoagulant treatment after 3 months|Advise to discontinue anticoagulant treatment after 3 months for patients with low VTE recurrence risk
41316294|NCT06429423|BEHAVIORAL|Acute exercise low intensity|"A 15-minute exercise on low intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state."
41316295|NCT06429423|BEHAVIORAL|Acute exercise moderate intensity|"A 15-minute exercise on moderate intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state."
41316296|NCT03016026|PROCEDURE|ERAS|Undergo an ERAS program
41316297|NCT02829866|DEVICE|AMIStem-H|
41316298|NCT02787330|BEHAVIORAL|Control Group|Sessions will not be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
41316299|NCT02787330|BEHAVIORAL|Experimental Group|The experimental group will be detailed, session by session, in the manual written for this purpose. It addresses on topic per session (respecting each other, medical information about cancer, family relationships, sibling's fears and feelings, relationship between siblings, relationships at school, generating hope.
41316300|NCT04659434|DRUG|Sintilimab|"Patients receive sintiliman+R-GemOx three weeks for a cycle, detailed as follows:~Combination therapy~* Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 4 cycles~* R-GemOx: Rituximab 375mg/m2, d1; Gemcitabine 1000mg, d2; Oxaliplatin 100mg/m2, d2; every 3 weeks for a cycle, 4 cycle as protocol specified.~Monotherapy:~-Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 8 cycles"
41316301|NCT05674201|COMBINATION_PRODUCT|Propofol-Dexmedetomidine|Propofol-Dexmedetomidine AND Propofol-Remifentanil
41316302|NCT00111917|DRUG|Infliximab|anti-TNF
41316303|NCT00111917|OTHER|Placebo|Placebo infusion
41003545|NCT02418468|DRUG|Indacaterol|Indacaterol 150µg capsules for inhalation daily
41151976|NCT05076955|DRUG|vancomycin-tobramycin-itraconazole|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
41003546|NCT02418468|DRUG|Placebo|Matching placebo indacaterol capsules for inhalation daily
41151977|NCT00036309|DRUG|Duloxetine Hydrochloride|
41151978|NCT06385418|DRUG|Colonic local administration of fluorouracil with enhanced adhesion|Fluorouracil is administered via the colon as an injectable solution at a dose of 500 mg per day for 6 days, along with poloxamer 407 and poloxamer 188 used as thermosensitive hydrogel to enhance adhesion.
41151979|NCT00521807|PROCEDURE|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
41151980|NCT02099656|DRUG|Lebrikizumab|Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
41151981|NCT02099656|DRUG|Placebo|Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
41003547|NCT06469008|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
41151982|NCT02099656|DRUG|Inhaled corticposteroids (ICS)|Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
41151983|NCT02099656|DRUG|Second Asthma Controller Medication|Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
40799306|NCT03626064|DRUG|Nicotine Replacement Therapy|Access to a range of nicotine replacement therapy: nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler
40799307|NCT04893317|DEVICE|Ablation in the ventricles with the Adagio Medical VT Cryoablation System|The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias
40799308|NCT03950544|DRUG|Fosfomycin|Fosfomycin and meropenem
40799309|NCT03950544|DRUG|Tigecycline|Tigecycline and meropenem
40799310|NCT03950544|DRUG|Polymyxin B|Polymyxin B and meropenem
40799311|NCT04683146|DRUG|Hand antisepsis with Propanolol- 1 60%.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later"
40799312|NCT04683146|DRUG|Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later."
40799313|NCT04810364|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
40799314|NCT02705846|OTHER|Observation of treatment outcomes via Questionnaire|Collection of treatment data from participants
40799315|NCT04389710|DRUG|Convalescent Plasma|One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
40799316|NCT03581149|DRUG|Sodium Picosulfate/Magnesium Citrate Laxative|● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
40799317|NCT03581149|DRUG|2L polyethylene glycol/ascorbic acid|"* First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~* Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet."
40799318|NCT05844735|DRUG|SAR441566|Tablet
40799319|NCT05844735|DRUG|Placebo|Tablet
40799320|NCT05844735|DRUG|Ciprofloxacin|Tablet
40799321|NCT02250508|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
40799322|NCT02250508|BIOLOGICAL|Haemate P® (Human Coagulation Factor VIII)|
40799323|NCT06242990|BEHAVIORAL|Y-PATH NI|"The Y-PATH NI intervention provides a whole of school approach with student, teacher, parent and guardian components. Student components: Y-PATH resources delivered by physical education teachers (6 lesson plans, resource cards to use as teaching prompts), student handbook. Posters are also displayed in the sports hall/ PE department.~Teacher components: Teachers will receive online and in-person training to deliver the Y-PATH programme. This component also targets all non-specialist PE teachers and includes workshops, information leaflets, development of a physical activity promotion charter and a step challenge.~Parent/guardian components: Information session and leaflets distributed across the intervention period."
40799324|NCT00062491|DRUG|Karenitecin (BNP1350)|Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
40799325|NCT02994485|DRUG|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
40799326|NCT05100771|OTHER|Pediatric brain MRI|Routine brain MRI with automated quantitative information (brain volumetry and T1 relaxometry)
41003548|NCT03348358|BEHAVIORAL|quiet music|playing quiet music during labor
41003549|NCT03348358|BEHAVIORAL|Rhythmic music|playing rhythmic music during labor
41151984|NCT06195150|OTHER|Blood collection|15ml of blood are harvested before surgery
40799327|NCT02082444|OTHER|Skipping lunch|
40799328|NCT00150111|DRUG|Methimazole|
40799329|NCT00150111|DRUG|Rituximab|
40799330|NCT00150111|BIOLOGICAL|Immunization with various vaccines|
40799331|NCT02591537|DEVICE|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
40799332|NCT04447235|DRUG|Placebo|Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
41003550|NCT03348358|BEHAVIORAL|control|No music during labor
41003551|NCT00006890|DRUG|prednisone|Prednisone 50mg on alternate days
41003552|NCT00006890|DRUG|thalidomide|THALIDOMIDE 200 mg qhs
41003553|NCT04249128|DIETARY_SUPPLEMENT|Vegetarian Collagen|Collagen is a protein made up of amino-acids, which are in turn built of carbon, oxygen and hydrogen.
40799333|NCT04447235|DRUG|Ivermectin|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
40799334|NCT04447235|DRUG|Losartan|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
40799335|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
40799336|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
40799337|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
40799338|NCT00391053|BIOLOGICAL|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
40799339|NCT05561101|OTHER|Caregivers burden|Assessment of caregiver burden after admision at Emergency Department of their elderly relative
41316304|NCT01611129|BEHAVIORAL|Internet-based counseling|Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI \& CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
41316305|NCT05419271|PROCEDURE|home hemodialysis session with 9L internal convection|home hemodialysis session with 9L internal convection
41316306|NCT03198780|OTHER|Breathing Awareness|Participants will use a pulse-oximeter and biofeedback app to guide them through pursed-lip breathing training.
40799340|NCT02200926|OTHER|Loaded breathing training|7 days/weeks, for 8 weeks
40799341|NCT02200926|OTHER|Unloaded breathing training|7 days/week, for 8 weeks
40799342|NCT02200926|OTHER|Placebo|7 days/week, for 8 weeks
40799343|NCT03687294|DEVICE|enzyme linked immunosorbent assay (ELISA)|ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
40799344|NCT00922376|DEVICE|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
41003554|NCT04249128|DIETARY_SUPPLEMENT|Keratin|Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.
41003555|NCT04249128|DIETARY_SUPPLEMENT|Ceramides|Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.
41003556|NCT04249128|DIETARY_SUPPLEMENT|Astaxanthin|is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.
41003557|NCT03298828|BIOLOGICAL|CD19 CAR and PD-1 knock out engineered T-cells|A single dose of 1 x 10\^6/kg CD19 CAR transduced and PD-1 knock out engineered T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
41151985|NCT02639234|BIOLOGICAL|Vigil™|Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10\^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.
41151986|NCT02639234|DRUG|Nivolumab|Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
41003558|NCT03298828|BIOLOGICAL|CD19 CAR T-cells|A single dose of 1 x 10\^6/kg CD19 CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
41151987|NCT00928876|DRUG|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
41151988|NCT00928876|DRUG|Placebo|placebo s/c daily for four weeks
41151989|NCT00165035|DEVICE|CoStar Paclitaxel Drug Eluting Coronary Stent System|Drug eluting stent
41151990|NCT00165035|DEVICE|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent|Drug eluting stent
41151991|NCT06584721|OTHER|Anti-pronation taping (Low dye taping) + Conventional therapy|"They would be receiving treatment as follow:~Anti-pronation taping (Low dye taping) Applied on alternate days. 3 days / week for 4 weeks.~Conventional Therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsxset1, 10sec hold) 3sessions/ week."
41151992|NCT06584721|OTHER|Short Foot Exercises + Conventional PT|"They would be receiving treatment as follow:~Short foot exercises are used to reduce the foot pronation: Frequency: 30 reps x 1 set, 30 sec hold and 10 sec relaxation for 4 weeks. 3 session/ week).~Short foot Exercises includes a four-week plan, 1- Shortening of foot in Anterior-posterior direction, 2- Increase medial longitudinal arch, 3- Balanced loading in standing, 4- Approximating Head of first, second meta-tarsal and calcaneus with patient in standing (single leg).~Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsx1set, 10sec hold) 3sessions/ week."
41151993|NCT04554316|DEVICE|Steri-strip|Steri-Strips (3M Health Care, St. Paul, Minn) are a commonly used means of covering surgical incisions following many operations. Use of adhesive surgical tape over incisions maintains epidermal approximation in primary skin closure while limiting exposure to the environment, theoretically improving cosmesis and limiting risk of infection.
41151994|NCT06010368|DRUG|Tranexamic acid injection|In TXA group (n=75): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.
41316307|NCT03744130|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|"1. administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~2. visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~3. administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~4. the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~5. the original DICOM loop is sent to a work station"
41316308|NCT01889628|DIETARY_SUPPLEMENT|Liquid-based Nutritional Formulae and liquid glucose|
41316309|NCT02227108|DRUG|Moxetumomab Pasudotox|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
41316310|NCT04144075|BEHAVIORAL|Mindful Self-Compassion Program|It is a protocolized training program in mindfulness and self-compassion skills. It has a duration of 8 weekly group sessions of about two hours and 45 minutes and a silent retreat of 4 hours.
41316311|NCT04144075|BEHAVIORAL|Cognitive Behaviour Therapy Group|It is a control intervention designed for the development of a control group suitable for comparison with experimental groups.
41316312|NCT04144075|OTHER|Treatment as usual|It is variable according to the clinical and personal characteristics of the patient, the most common components will be described.
41003559|NCT00196781|BEHAVIORAL|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
41316313|NCT04409652|PROCEDURE|Head on bed|During emergence, head is kept on bed without pillow.
41473786|NCT06326177|PROCEDURE|Spine Movement Assessment|Spine movement will be assessed via using bubble inclinometer in terms of degree. Bony landmarks will be spotted like done in spine posture assessment after that full spinal flexion and extension wanted in order to record degrees in inclinometers at the end range. As a result the difference between two inclinometer will give the motion of that segment. Lumbar and thoracolumbar spinal movement will be assessed with this method. For thoracal and cervical range of motion values will be recorded separately without substruction from both inclinometer. Thoracal rotation range of motion will be assessed with two landmarks and will be recorded separately according to landmark. Thoracolumbar range of motion will be assessed with two substruction of degrees. Landmarks for cervical range of motion are vertex and C7, for thoracal range of motion are T1 and T12, for lumbar range of motion are T12 and S1, for thoracolumbar range of motion C7 and S1.
40799345|NCT00703846|DRUG|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
40799346|NCT03409081|DRUG|gilteritinib|oral
40799347|NCT02045888|DEVICE|ADRCs prepared by investigational Celution Device|ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
41316314|NCT04409652|PROCEDURE|Head on pillow|During emergence, head is kept on pillow.
41316315|NCT05216068|DIAGNOSTIC_TEST|NGS|Based on the next generation sequencing (NGS), WES can identify single nucleotide variants (SNVs) and small variants.
41316316|NCT02068131|DRUG|Novaferon|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
41316317|NCT02068131|DRUG|Capecitabine|The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
41316318|NCT01005446|DEVICE|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
41316319|NCT03111264|BEHAVIORAL|CHAMP|"The CHAMP only group intervention is based on Food Friends \& Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills."
41316320|NCT03111264|BEHAVIORAL|CHAMP+|The CHAMP+ component is comprised of a curriculum of parenting, wellness, physical activity, and feeding in the home environment. The CHAMP+ intervention will span over the course of the CHAMP intervention.
40799348|NCT02045888|BIOLOGICAL|Placebo|Placebo is visually matched solution
41003560|NCT00196781|BEHAVIORAL|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
41003561|NCT02735070|DRUG|Resfenol|Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
41003562|NCT02735070|DRUG|Coristina d|Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
41003563|NCT01466270|DRUG|donepezil hydrochloride|Given PO
41003564|NCT01466270|DRUG|Placebo|Given PO
41316321|NCT01736254|DRUG|Evacetrapib|
41003565|NCT02474199|BIOLOGICAL|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
41316322|NCT01736254|DRUG|Gemfibrozil|
40799349|NCT05342324|DIAGNOSTIC_TEST|Optical coherence tomography angiography|To evaluate the vessel density in choriocapillary vascular networks, using optical coherence tomography angiography
40799350|NCT02501148|DEVICE|carotid artery stenting|Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
40799351|NCT02286804|DEVICE|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
41003566|NCT02474199|DRUG|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
41003567|NCT02474199|DRUG|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
41003568|NCT02474199|DRUG|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
41003569|NCT02474199|PROCEDURE|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
41003570|NCT00997503|DEVICE|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
41003571|NCT00997503|DRUG|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
41003572|NCT00997503|DRUG|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
41003573|NCT00997503|DRUG|aspirin|"Oral, as prescribed by physician through end of study.~."
41003574|NCT00326612|DRUG|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
41003575|NCT00326612|DRUG|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
41003576|NCT02611258|DRUG|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
41003577|NCT00136292|DRUG|daptomycin|
41316323|NCT00970957|DRUG|Avastin Intravitreal Injection|Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
41316324|NCT00970957|DRUG|Sham Avastin Intravitreal Injection|Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
41316325|NCT05107349|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
41316326|NCT05797454|PROCEDURE|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the lesion
41316327|NCT05797454|PROCEDURE|Wire-guided localization|Positioning guide wire in the center of the lesion
41003578|NCT00633191|DRUG|Anti-pseudomonas IgY gargle|Gargle (solution), \> 5FKU, every night after toothbrushing, life-long
41316328|NCT02491502|DEVICE|Echopulse|HIFU Under ultrasound guidance
40799352|NCT05159687|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine
40799353|NCT05159687|DRUG|Placebo|Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
41151995|NCT06010368|DRUG|Oxytocin|the oxytocin group (n = 75): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
41151996|NCT04004923|PROCEDURE|Monopolar hysteroscopy|Unipolar resectoscopes are used in this group and the distention fluid is mannitol
41316329|NCT04913415|OTHER|Low Suction Strategy of Chest Tube Management|A digital chest tube will be set to a low pressure mode (-8mmHg) during recovery after minimally invasive lung resection.
41316330|NCT04913415|OTHER|Standard Suction Strategy of Chest Tube Management|A digital chest tube will be to the standard suction mode (-20mmHg) during recovery after minimally invasive lung resection.
40799354|NCT00834600|DRUG|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg
40799355|NCT00834600|DRUG|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
40799356|NCT04299152|COMBINATION_PRODUCT|Stem Cell Educator-Treated Mononuclear Cells Apheresis|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
40799357|NCT03804892|DIAGNOSTIC_TEST|Body Composition|Participants undergo a 5 minute body scan to determine their body composition.
40799358|NCT03804892|DIAGNOSTIC_TEST|Maximal aerobic fitness test|Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
40799359|NCT03804892|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will undergo an OGTT to determine insulin sensitivity.
40799360|NCT03804892|OTHER|Muscle biopsy|Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
40799361|NCT03804892|OTHER|Blood samples|Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
40799362|NCT05302973|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
40799363|NCT05302973|OTHER|Aerobic exercise|30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
40799364|NCT00000788|DRUG|Methadone hydrochloride|
40799365|NCT00000788|DRUG|Fluconazole|
40799366|NCT01500785|DRUG|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
40799367|NCT01500785|DRUG|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
40799368|NCT02388464|DRUG|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
40799369|NCT02388464|DRUG|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
40799370|NCT02388464|DRUG|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
40799371|NCT02388464|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
40799372|NCT04850924|OTHER|evaluation psychological trauma|9 classes of symptoms to be evaluated
40799373|NCT02368600|BEHAVIORAL|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
40799374|NCT03574766|BEHAVIORAL|Meditation|Daily meditation
40799375|NCT05889780|OTHER|Food pantry referrals|Clients receive food for up to 21 meals per person in the household each month.
40799376|NCT05889780|OTHER|No-prep, ready-to-eat meals|12 nutritious no-prep, ready-to-eat meals are provided each month.
40799377|NCT05889780|OTHER|Vouchers|A $75 voucher is provided each month and participants are instructed to use the voucher to purchase food or transportation to food retailers.
40799378|NCT00137488|DEVICE|imaging and angiogenic profiles|Image tumor angiogenesis by DCE-MRI using 1.5- or 3-T MRI instruments (13,14,15) pre-and postoperatively (before biopsy or surgery).
40799379|NCT05271734|DEVICE|Lid retractor placement|Insertion of a lid retractor to find out if the corneal limbus is exposed in 360 degress
40799380|NCT02391311|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
41003579|NCT00838565|DRUG|Placebo|intravenous infusion on three consecutive months
40799381|NCT06503822|DEVICE|Long peripheral venous catheter|In this study, patients eligible for admission were subjected to peripheral vein long catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data were collected.
40799382|NCT06503822|OTHER|Control group (Short peripheral venous catheter)|In this study, the patients eligible for admission will undergo peripheral venous short catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data will be collected.
40799383|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
41003580|NCT00838565|DRUG|dose level 1|intravenous infusion on three consecutive months
41003581|NCT00838565|DRUG|dose level 2|intravenous infusion on three consecutive months
40799384|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
41003582|NCT00838565|DRUG|dose level 3|intravenous infusion on three consecutive months
40799385|NCT04221893|RADIATION|Radiation Therapy (RT)|Undergo radiation therapy
40799386|NCT04512001|DRUG|MSB11456|Participants will receive MSB11456 subcutaneously, once a week.
41003583|NCT00838565|DRUG|dose level 4|intravenous infusion on 3 consecutive months
41003584|NCT01963390|DRUG|Testosterone Therapy|In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
41003585|NCT06484608|DRUG|Isotonic Saline with Dextrose|This clinical trial involves two interventions for maintaining fluid therapy in neonates post-surgery. The first intervention, isotonic saline with dextrose, involves administering 0.9% saline solution combined with 5% dextrose. This isotonic solution aims to maintain serum sodium levels within the normal range and minimize the risk of hyponatremia and hypernatremia in postoperative neonates. The second intervention, hypotonic saline with dextrose, involves administering 0.45% saline solution combined with 5% dextrose. This hypotonic solution is being compared to the isotonic solution to evaluate its effectiveness in maintaining electrolyte balance.
41003586|NCT01856543|OTHER|Eucerin|
41003587|NCT01856543|OTHER|Mometasone Furoate 0.1%|
41003588|NCT02839499|DEVICE|RU sleeping®|Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.
41003589|NCT02839499|OTHER|autonomy scale (ADL and AGGIR)|autonomy data
41003590|NCT02839499|OTHER|various activity scale (IADL)|activity of life data
40799387|NCT04512001|DRUG|EU-approved RoActemra|Participants will receive EU-approved RoActemra® subcutaneously, once a week.
41003591|NCT02366078|BEHAVIORAL|SMART|Paced breathing meditation with cognitive training
41003592|NCT05254262|PROCEDURE|Elderly surgical patients|Patients who needs elective or emergency surgery for any reason
41003593|NCT00994331|PROCEDURE|Percutaneous coronary intervention|non surgical procedure to open blocked coronary arteries
41003594|NCT01878604|GENETIC|Gene analysis|Gene analysis
41003595|NCT01878604|OTHER|Historical data of lipid-lowering drug administration|Collecting historical data of lipid-lowering drug administration
41003596|NCT01878604|OTHER|Historical data of plasma lipids, xanthoma changes|Collecting historical data of plasma lipids and xanthoma changes
41003597|NCT01440348|PROCEDURE|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
41003598|NCT03029624|DEVICE|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
41003599|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (NH formulation)|Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation
41151997|NCT04004923|PROCEDURE|Bipolar hysteroscopy|Bipolar resectoscopes are used in this group and the distention fluid is serum physiologic
41151998|NCT05558241|DEVICE|High-resolution micro-ultrasound|In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
41151999|NCT03852875|OTHER|Education|Same
41152000|NCT03852875|OTHER|Control|Same
41316331|NCT03892746|DEVICE|Active tDCS + task oriented practice|Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.
41316332|NCT03892746|DEVICE|Sham tDCS + task oriented practice|Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
41316333|NCT04419818|BEHAVIORAL|Virtual Reality|Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Participants will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action.
41316334|NCT02357953|OTHER|Measurement of cardiac index|
41316335|NCT01928485|OTHER|active surveillance|Undergo active surveillance
41316336|NCT01928485|DRUG|Sunphenon|Given PO
41316337|NCT01928485|OTHER|laboratory biomarker analysis|Correlative studies
41316338|NCT01928485|OTHER|Questionnaire Administration|Ancillary studies
41316339|NCT05883085|DRUG|Anlotinib hydrochloride|Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
41316340|NCT01895452|DRUG|ALKS 9072, Low Dose|Intramuscular injection, given monthly
41316341|NCT01895452|DRUG|ALKS 9072, High Dose|Intramuscular injection, given monthly
41316342|NCT05524493|DIAGNOSTIC_TEST|Structural MRI|We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2\*-weighted sequences
41316343|NCT05524493|DIAGNOSTIC_TEST|Quantitative MRI|We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).
41316344|NCT05524493|DIAGNOSTIC_TEST|Diffusion MRI|We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.
41316345|NCT05524493|DIAGNOSTIC_TEST|fMRI|We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.
41316346|NCT05524493|DIAGNOSTIC_TEST|MR Spectroscopy|We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
41316347|NCT01490762|DRUG|Technosphere Insulin Inhalation Powder using the Gen2C inhaler|Inhalation Powder
41316348|NCT01490762|DRUG|Regular Human Insulin|Subcutaneous injection
41003600|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (SH formulation)|Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation
41003601|NCT02957890|BIOLOGICAL|Placebo|Round 2 (May): 0.5mL normal saline
41003602|NCT02313610|DRUG|Qinbudan|Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
41003603|NCT02313610|DRUG|Qinbudan Placebo|Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
41152001|NCT03802513|OTHER|Physical Therapy|Individualized physiotherapy including exercises to be performed by the Veteran at home.
41152002|NCT03332589|DRUG|E6201|E6201 formulated in cyclodextrin for IV administration.
41152003|NCT03332589|DRUG|E6201 plus dabrafenib|E6201 formulated in cyclodextrin for IV administration. Dabrafenib capsules for oral administration.
40799388|NCT05829005|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
40799389|NCT04444271|DRUG|Mesenchymal stem cells|1. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care
40799390|NCT04444271|OTHER|Placebo|100 ml of normal saline will be given intravenously to control arm
40799391|NCT01743612|PROCEDURE|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
41316349|NCT05602012|BEHAVIORAL|Mindfulness based cognitive counseling group|Intervention: The sessions were conducted by the researchers who received training in the field of Mindfulness Based Cognitive Therapy. Sessions are structured as follows; 'Awareness and autopilot, living in our minds, tidying up the dispersed mind, recognizing the unpleasant/version, allowing, ways to take care of oneself, turning to face difficulties, being stuck in the past, living in the present?'
41316350|NCT03539861|DEVICE|Hemodialysis|Each patient will receive two hemodialysis treatments while on this study. The first hemodialysis treatment will be standard of care hemodialysis. The second treatment will be the experimental hemodialysis treatment using the Selective cytopheretic device.
40799392|NCT01743612|PROCEDURE|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
40799393|NCT01488461|GENETIC|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
40799394|NCT02623777|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
41316351|NCT06534814|DIAGNOSTIC_TEST|AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM)|The AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM) intervention involves the development and application of an advanced artificial intelligence (AI) system specifically designed to enhance the identification and characterization of lymph node metastasis in patients diagnosed with gastric cancer.
41003604|NCT00849966|DRUG|Celebrex suspension|"Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
41003605|NCT00849966|DRUG|Placebo|"Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
41003606|NCT00368589|DRUG|atorvastatin|
41152004|NCT01975259|DRUG|Oral Glucose Tolerance test (75g 2-hour)|A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution \& have glucose levels recorded up to every 30 mins for 2hours
41152005|NCT01975259|DRUG|Modified Oral Glucose Tolerance Test (50g 4-hours)|A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution \& have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
41316352|NCT06441851|PROCEDURE|Videolaparoscopic Partial Nephrectomy|Videolaparoscopic partial nephrectomy
40799395|NCT02623777|DIETARY_SUPPLEMENT|Short chain fatty acids|Short chain fatty acids administered
40799396|NCT00130104|PROCEDURE|Transthecal Metacarpal Block|
41003607|NCT00011089|DRUG|Tenofovir disoproxil fumarate|
41003608|NCT03775668|DRUG|1 µCi of 14C-AAI101 + 500 mg AAI101|Single dose open label
41003609|NCT04067284|BEHAVIORAL|Nutrition education|"Nutrition Education on~* Continued breastfeeding until two years of age~* Food groups~* Balanced diet~* Introduction to locally available nutritious and low-cost foods~* Amount and frequency of complementary feeding~* Safe water, and~* Handwashing with soap before feeding"
41003610|NCT04067284|DIETARY_SUPPLEMENT|Homemade yogurt supplementation|The homemade yogurt supplementation will start a week after beginning of 6 months of age once the child is introduced to solid foods of the mother's choice. The yogurt will be supplied to the mothers every day at time of feeding.
41316353|NCT06441851|PROCEDURE|Robot-assisted Partial Nephrectomy|Robot-assisted partial nephrectomy
41003611|NCT04067284|OTHER|Usual care|No intervention/ control group
40799397|NCT02226588|DRUG|Misoprostol|
40799398|NCT03389698|DEVICE|GRASP Dynamic Contrast-Enhanced (DCE) MRI|Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.
40799399|NCT03389698|DEVICE|3T Brain Scan|Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.
40799400|NCT03389698|DRUG|Gadolinium-based Contrast Agent (GBCA) for MRI|Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.
40799401|NCT04366830|DRUG|Remestemcel-L|Participants will receive remestemcel-L in two infusions of 2 x 10\^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).
41152006|NCT01975259|DRUG|Matched isoglycemic clamp|A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test. This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test. The same blood tests will be performed at the same time points as the modified glucose tolerance test
40799402|NCT02284815|DIETARY_SUPPLEMENT|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
40799403|NCT03085134|OTHER|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
40799404|NCT03085134|OTHER|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
40799405|NCT03599778|DRUG|Apatinib|XELOX + apatinib's MTD
40799406|NCT03073811|DIETARY_SUPPLEMENT|Protein enhanced nutrition intervention|Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.
40799407|NCT03073811|OTHER|Education Control|provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
40799408|NCT03154255|BEHAVIORAL|Mediterranean-Style Diet Educational Training|"The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
40799409|NCT05801146|DRUG|Botulinum Toxin Type A Injection [HG102]|Single administration, Day 0, 20 units
40799410|NCT05801146|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
40799411|NCT06333002|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, Extreme Gradient Boosting, Support Vector Machine and Multilayer Perceptron.
40799412|NCT02013778|DRUG|HCQ|
40799413|NCT02651324|DRUG|Ketamine|
40799414|NCT02651324|OTHER|Placebo|
40799415|NCT02973139|OTHER|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
40799416|NCT02973139|OTHER|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
40799417|NCT01479244|BIOLOGICAL|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
40799418|NCT01479244|BIOLOGICAL|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
40799419|NCT00868972|PROCEDURE|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
40799420|NCT00868972|DEVICE|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
40799421|NCT04322409|DEVICE|Neuromuscular Electrical Stimulation|"5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of on time, and 50 seconds off, with 10 cycles being performed each session."
40799422|NCT04322409|DEVICE|Transcutaneous Electrical Nerve Stimulation|5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
41152007|NCT01975259|DRUG|Hyperglycemic clamp with concurrent GLP-1 infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
40799423|NCT01454505|DRUG|AL-53817 nasal spray solution|Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.
40799424|NCT01454505|OTHER|Vehicle nasal spray|Inactive ingredients used as placebo comparator during Stage A and Stage B.
40799425|NCT05078931|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks for up to 35 cycles
40799426|NCT05078931|DRUG|Lenvatinib|Lenvatinib 20mg will be administered orally daily.
40799427|NCT02349659|DEVICE|Implantation with the commercially available Axium neurostimulator|
40799428|NCT04786821|BEHAVIORAL|Standard Exercise Training|Participants will receive interventions by an exercise specialist for up to 30 minutes based on the participant's tolerance. The exercises used in control group will depend on the individual and their abilities as evaluated in the baseline assessment session. Possible exercises include arm crank, recumbent cycle, and chair exercises. These sessions will be delivered by a member of the research team.
40799429|NCT04786821|DEVICE|Phoenix Exoskeleton suit|Participants will aim to walk wearing the Exoskeleton for up to 30 minutes. Based on the participant's tolerance, the duration of walking can be shorter and can be split into shorter intervals to achieve more activity. Over the sessions, based on the participants' tolerance, gradually the duration of walking can be increased with shorter breaks. This will be delivered by a research physiotherapist.
40799430|NCT00847899|DRUG|AR9281|AR9281 taken in BID dosing regimen for 28 days
41473787|NCT06326177|PROCEDURE|Core Muscle Endurance Assessment|Core muscle endurance is divided into three components. Trunk anterior flexion test will be used to assess anterior core region endurance. Lateral plank test will be used to determine lateral core muscle endurance. Trunk posterior extensor test will be used to determine endurance of the posterior core musculature. All of these test are calculated in predetermined positions according to literature with static contractions. Maximum duration of maintaining that position is needed. In trunk anterior flexion test participant will sit with 60 degree inclination from the ground while making contact with their feet when hips and knees are flexed. In lateral plank test participants should place their elbow to ground and lift their hip while feet are in contact with ground in side lying position. In trunk extensor endurance test participants will lie prone to the bed while maintaining contact with their ASIS and lower extremity. The upper body should stay outside of the bed.
40799431|NCT00847899|DRUG|AR9281|AR9281 taken in TID dosing regimen for 28 days
40799432|NCT00847899|DRUG|Placebo|Placebo taken in BID dosing regimen for 28 days
40799433|NCT00847899|DRUG|Placebo|Placebo taken in TID dosing regimen for 28 days
40799434|NCT04539054|DIETARY_SUPPLEMENT|ENGN Shred|ENGN Shred is a multi-ingredient pre-workout supplement.
41152008|NCT01975259|DRUG|Hyperglycemic Clamp with concurrent GIP infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
40799435|NCT04539054|DIETARY_SUPPLEMENT|Nutricost caffeine powder|Caffeine powder.
40799436|NCT04539054|DIETARY_SUPPLEMENT|Crystal Light|Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
40799437|NCT04900246|PROCEDURE|Visual Inspection|"The examiners will evaluate the surfaces included in the study independently and without knowledge of the results of the other examiner, after prophylaxis, using a mouth mirror and a WHO probe or Ball point. The evaluations will be carried out in a dental chair with the aid of a reflector. The teeth will be examined moist, and afterwards, they will be dried for 5 seconds with the use of a triple syringe.~For visual inspection, the International Caries Detection and Assessment System (ICDAS) evaluation system will be used. Complete ICDAS has seven categories, the first for healthy teeth (code 0) and the next two for limited enamel caries, white/brown stain (codes 1 and 2). The following two categories (codes 3 and 4) are considered to be caries that extend to the enamel without exposed dentin. And the two remaining categories (codes 5 and 6), are considered caries with exposed dentin."
40799438|NCT04900246|RADIATION|BWX Radiographic Assessment|Participants will be radiographed with a digital X-ray device (DIOX-602, Micro Imagem, Indaiatuba, Brazil) with a regulation of 60 kV and 2 mA and exposure time of 0.10s. The technique used will be the interproximal/bitewing (BWX), with the FIT T1 Digital Sensor (external dimensions: 36.7mm x 24.3mm/sensitive area dimensions: 30.0mm x 20.0mm - 600mm²) and the sockets will be standardized with use of Han-Shin radiographic positioners (Jon, São Paulo, Brazil).
40799439|NCT04900246|DEVICE|Assessment of the iTero Element 5D scan|For scanning, the iTero 5D (Align Technology) equipment featuring NIRI Technology will be used. The Infrared Imaging Technology (NIRI) is a diagnostic tool that allows the detection of interproximal and occlusal caries in several stages, from the initial enamel caries to lesions in the amelo-dentin junction, without the use of ionizing radiation. Infrared is the region of the electromagnetic spectrum between 0.7 and 2.0 micrometers (µm). The iTero Element 5D imaging system uses wavelength light (= 850 nm) in an electromagnetic spectrum that, in interaction with the hard tooth tissue, provides additional data on its structure.
40799440|NCT00714662|DEVICE|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
40799441|NCT00091663|DRUG|Tarceva (erlotinib HCl)|
40799442|NCT03823105|DEVICE|OHR Tracker and PulseWatch|Category A (ClinO). Medical study with CE-marked medical devices to photoplethysmographic measure heart rate, heart rate variability, and pulse wave and accelerometric data
40799443|NCT03745872|BEHAVIORAL|Knowledge Assessment|Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.
40799444|NCT06030973|BEHAVIORAL|Filling in an online survey|Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.
40799445|NCT00442533|DRUG|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
40799446|NCT03987711|DRUG|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
40799447|NCT03987711|DRUG|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
40799448|NCT03987711|OTHER|No oral anticoagulation|No oral anticoagulation
40799449|NCT06139614|BEHAVIORAL|PERSIST|PERSIST is adapted from empirically validated treatment of negative affect and low positive emotion. Skills Training 1 includes content across 4 sessions on 1) understanding emotions, 2) present-moment emotional awareness, 3) cognitive flexibility, and 4) countering avoidant and emotion-driven responses. Skills Training 2 includes content across 4 sessions on a) translating values to action, b) lower barriers to action, c) countering avoidance, and d) maintaining actions that support personal resilience. The classes will occur every other Wednesday, resulting in a 16-week intervention period.
40799450|NCT03604497|BEHAVIORAL|beacon alerts|alerts via unidirectional communication from beacons to smartphones when smartphones are approaching pedestrian crossing at activated intersection
40799451|NCT03604497|BEHAVIORAL|no alerts retention|no alerts will appear, but we will measure retention of behavior learned during the active intervention stage
40799452|NCT04532346|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug. hydroxychloroquine has been reported to improve the clinical status of chILD cases wtih genetic causes. The exact mechanism of action of hydroxychloroquine is unknown. In additon to having anti-inflammatory properties, hydroxychloroquine has been shown to affect intracellular processing of surfactant protein.
40799453|NCT01759342|BEHAVIORAL|Aerobic exercise|
40799454|NCT01759342|BEHAVIORAL|Resistance exercise|
40799455|NCT01759342|BEHAVIORAL|Flexibility and postural exercise|
40799456|NCT01759342|BEHAVIORAL|Balance exercise|
40799457|NCT05170477|PROCEDURE|apical patency|In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration.
40799458|NCT05170477|PROCEDURE|Non-apical surgery|in Gp B apical patency will not be maintained. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration
40799459|NCT04482439|DEVICE|Vivity Extended Depth of Focus intraocular lens (IOL)|Bilateral implantation of the Vivity lens after cataract surgery, with slight myopia planned in the non-dominant eye.
40799460|NCT03886194|PROCEDURE|interventional treatment in pulmonary|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
41316354|NCT06402669|OTHER|Packed Red Blood Cell Administration|Difference in occurrence of mortality in patients transferred versus directly admitted who have packed red blood cell administration in the first four hours of arrival to the hospital.
41473788|NCT06326177|PROCEDURE|Scapular Dyskinesia|Scapular dyskinesia will be assessed with scapular dyskinesia test. Dumbbells which are 1,5kg will be used in the testing setting. Participant will perform full shoulder abduction for 5 times while examiner assesses the movement quality by ranking it as subtle dyskinesis, obvious dyskinesis and no dyskinesis according to the movement of the scapula. After that participant will perform 5 repetitions of shoulder flexion.
40799461|NCT01773967|DRUG|LGG|LGG 10\^10 cfu PO BID X 5 days
40799462|NCT01773967|DRUG|micro-crystalline cellulose|1 capsule PO bid x 5 days
40799463|NCT04700085|DEVICE|ReMotion Knee|The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
41316355|NCT03296293|OTHER|PEEP at 5cmH2O|Effect of PEEP at 5cmH2O on ICP
40799464|NCT01596712|DRUG|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
40799465|NCT01596712|DRUG|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
40799466|NCT05256888|BEHAVIORAL|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
40799467|NCT05256888|BEHAVIORAL|Healthy lifestyle education|Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks
41003612|NCT02151448|BIOLOGICAL|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
41003613|NCT02151448|DRUG|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
41316356|NCT03296293|OTHER|PEEP at 10cmH2O|Effect of PEEP at 10cmH2O on ICP
41316357|NCT03296293|OTHER|PEEP at 15cmH2O|Effect of PEEP at 15cmH2O on ICP
41316358|NCT02683694|DEVICE|iOCT|the number of subjects that can be peeled without dye are assessed
41316359|NCT01185249|PROCEDURE|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
41316360|NCT04726293|DIETARY_SUPPLEMENT|Mango|Mango beverage -1 cup fresh mango equivalent, twice a day for 4 weeks
41316361|NCT04726293|DIETARY_SUPPLEMENT|Control|control beverage 1 cup, twice a day for 4 weeks
41316362|NCT02006264|DRUG|TDF Intravaginal Ring|The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
41316363|NCT02006264|DRUG|Placebo Intravaginal Ring|The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
40799468|NCT05671406|BEHAVIORAL|Sensor-controlled digital game|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid hospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal Hypertension health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
40799469|NCT05671406|BEHAVIORAL|Sensor only|Real-time behaviors of physical activity will be tracked by an off-the-shelf sensor and app (Withings). This group will also be provided with standardized evidence-based Hypertension educational material. However, the data from the Withings sensor will not be routed to the SCDG.
40799470|NCT01490216|DRUG|lisdexamfetamine|20mg q.d. to 70mg b.i.d
40799471|NCT05699018|DIAGNOSTIC_TEST|eLIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elastometry ≥ 8 kPa and \< 15 kPa)
40799472|NCT01113177|DEVICE|Distraction splint therapy|After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
40799473|NCT06137885|BEHAVIORAL|Cardiac rehabilitation|Cardiac rehabilitation is a comprehensive model of care involving prescribed exercise, medication management, lifestyle modification, and psychosocial counseling to help people with heart diseases resume and enhance their psychosocial and vocational status.
40799474|NCT06137885|OTHER|Active post-market surveillance of devices|Active post-market surveillance of devices is an essential and ongoing process that involves systematic monitoring and assessment of medical devices once they are available on the market. It involves continuous data collection and analysis, early detection of issues, risk assessment, compliance with regulatory requirements, adaptive decision-making, and transparent communication with healthcare professionals and patients.
40799475|NCT06137885|OTHER|Multi-omics approach to precision medicine|Multi-omics analysis refers to the collective analysis of extensive biological data from multiple omics sources to gain a holistic understanding of an individual's health status, disease susceptibility, and response to therapies. By considering a broad spectrum of genetic and molecular information, multi-omics precision medicine aims to deliver more accurate diagnoses, predict disease risks, select optimal treatment options, and monitor therapeutic responses with a high degree of specificity, ultimately improving patient outcomes and minimizing adverse effects.
40799476|NCT06137885|OTHER|The prescription pattern analysis|The prescription pattern analysis refers to the systematic examination and evaluation of the types, dosages, frequencies, and trends in medications prescribed to patients with cardiovascular conditions. By scrutinizing prescription patterns, researchers and healthcare professionals can identify prevalent medications, assess adherence to treatment guidelines, uncover potential gaps or areas for improvement in patient care, and gain insights into the evolving landscape of cardiovascular therapies.
40799477|NCT03051464|PROCEDURE|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
40799478|NCT03051464|RADIATION|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
40799479|NCT03051464|RADIATION|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
40799480|NCT01713647|DRUG|Amlodipin, losartan, HCTZ|
40799481|NCT01320345|DRUG|Fenofibrate|145 mg tablet of fenofibrate administered once daily for 36 months.
40799482|NCT01320345|DRUG|Inert lactose placebo|Insert lactose tablet matching active tablet administered once daily for 36 months.
40799483|NCT06129461|BEHAVIORAL|Single-session acceptance-based online workshop targeting food cravings as predictors of loss of control and binge eating in pregnancy|Participants in the intervention will learn acceptance-based strategies for reducing the adverse impact of food cravings on eating behaviors. Unlike control-based strategies, acceptance-based strategies do not attempt to change the content or frequency of thoughts; rather, they foster willingness to acknowledge and experience uncontrollable thoughts, urges, and emotions as what they are - nothing more, nothing less. Acceptance-based approaches have demonstrated efficacy in reducing the adverse impact of food cravings on eating behaviors in non-pregnant samples.
40799484|NCT02997696|DRUG|ONO-4474|
40799485|NCT02997696|DRUG|Placebo matching ONO-4474|
40799486|NCT02192892|DIETARY_SUPPLEMENT|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
40799487|NCT02192892|DIETARY_SUPPLEMENT|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
40799488|NCT02192892|DIETARY_SUPPLEMENT|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
40799489|NCT02192892|DIETARY_SUPPLEMENT|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
41003614|NCT02151448|DRUG|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
41316364|NCT00921882|PROCEDURE|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
41316365|NCT05783193|DRUG|TGIR (Traditional Gastrointestinal Remedy)|TGIR botanical formulation
41316366|NCT05783193|DRUG|Placebo|Placebo capsules
40799490|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
40799491|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
40799492|NCT02192892|DIETARY_SUPPLEMENT|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
40799493|NCT02192892|DIETARY_SUPPLEMENT|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
40799494|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge flour|Porridge from commercial porridge flour
40799495|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge bar|Porridge from commercial porridge bar
41316367|NCT06394518|DRUG|TNP-2092 for injection|The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)
41316368|NCT06394518|DRUG|placebo|The placebo for TNP-2092 active drug
41316369|NCT04385615|OTHER|Fasting Mimicking Diet|Participants will be requested to follow three cycles (of 5 day each), for three consecutive months, of a Fasting Mimicking Diet, a plant-based, low-calorie, low-protein, low-carbohydrate, high-unsaturated fat diet. For the remaining 25 days of each month, participants should continue with their habitual eating habits.
41316370|NCT05796505|BEHAVIORAL|ADVANCE Steering Committee interventions|Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
40799496|NCT02192892|DIETARY_SUPPLEMENT|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
40799497|NCT01720004|OTHER|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
40799498|NCT04266392|DRUG|[18F]-DCFPyl Ligand|To assess the performance of \[18F\]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
40799499|NCT03979469|DRUG|Ketamine, dexmedetomidine|Patients will receive non-opioid analgesics, such as dexmedetomidine, ketamine perioperatively
40799500|NCT03979469|DRUG|fentanyl, remifentanil|Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
40799501|NCT01919073|BEHAVIORAL|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
40799502|NCT01919073|BEHAVIORAL|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
40799503|NCT00159679|DRUG|Pregabalin|
40799504|NCT01769950|OTHER|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
40799505|NCT05135585|OTHER|Blood sample collection|Blood sample collection at 1 month and 6 months after vaccination
41316371|NCT01357304|BEHAVIORAL|Group treatment and PAR|Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
41316372|NCT03823092|DIAGNOSTIC_TEST|polarization sensitivity|test of polarization vision as described in Study Description
40799506|NCT05135585|OTHER|Questionnaires|data collection (health data, vaccination data, etc.)
41316373|NCT05133193|DRUG|three kinds of antibiotics|All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
40799507|NCT00855777|DRUG|etoricoxib|etoricoxib 120 mg/day for 3 days
40799508|NCT00855777|DRUG|ibuprofen|ibuprofen 1,800 mg/day for 3 days
41473789|NCT06326177|PROCEDURE|Shoulder Strength|Shoulder strength will be assessed via usage of microfet hand held dynamometer. Isometric shoulder strength will be calculated in supine lying position while participant holding their arm at side with 90 degree elbow flexion. After that participant will apply maximal contraction towards external rotation while examiner resists that motion in order to prevent any motion with dynamometer. Eccentric shoulder strength will be assessed in sitting position. Participant will hold their shoulder at 90 degrees of abduction with 90 degree external rotation. Also elbow should be in 90 degree flexed position. After that examiner will give force towards neutral rotation while holding the arm. Participant will resist this motion eccentrically until neutral rotation is reached. Velocity of the shoulder should be same throughout all motion due to creation of isokinetic environment.
40799509|NCT06461286|DRUG|PYC-001|Single Group Assignment
40799510|NCT00107432|DRUG|sorafenib tosylate|Given orally
41152009|NCT01975259|DRUG|Hyperglycemic clamp with placebo infusion|"An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).~After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving."
40799511|NCT00107432|OTHER|laboratory biomarker analysis|Correlative studies
40799512|NCT00439595|DEVICE|Hemocue 210 meter|Diagnostic device
40799513|NCT00439595|DEVICE|Copack HBCS|
40799514|NCT03582046|DEVICE|Abdominal Perfusion Pressure (APP)|Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
40799515|NCT03582046|DEVICE|Mean Arterial Pressure (MAP)|Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
40799516|NCT01670279|DRUG|Brexpiprazole|up to 3mg oral dose once daily
40799517|NCT01670279|DRUG|Placebo|
41152010|NCT01975259|OTHER|Liquid Meal Test (Carbohydrate-rich)|A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
41316374|NCT04417504|OTHER|MobFood breakfast kit|Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood_PPS4.
41316375|NCT04417504|OTHER|Control isocaloric breakfast|White bread, butter and milk.
41316376|NCT04429685|DRUG|Ketamine|Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline
41316377|NCT04429685|DRUG|Saline (placebo)|Saline (placebo)
41316378|NCT03386656|DRUG|Amchafibrin|Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
41316379|NCT03386656|OTHER|Saline Solution|Placebo
41316380|NCT02513784|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
41316381|NCT04556370|DRUG|Normal saline|Normal saline infusion simultaneous with subarachnoid block
41316382|NCT04556370|DRUG|Norepinephrine|Different infusion dose of norepinephrine simultaneous with subarachnoid block
40799518|NCT00535535|DIETARY_SUPPLEMENT|Fructose|Fructose, 0.5 g/kg
40799519|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
40799520|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
40799521|NCT02141230|DRUG|Alli® 60 mg|Participants purchasing Alli®
40799522|NCT02936869|BEHAVIORAL|Performance-based monetary incentives|
40799523|NCT05595070|PROCEDURE|Haematopoietic stem cell transplantation|Haematopoietic stem cell transplantation (HSCT) is widely used in the treatment of malignant and non-malignant conditions to reconstitute the immune system secondary to cytotoxic conditioning regimens. These regimens, consisting of chemotherapy with or without total body irradiation, cause severe immunosuppression prior to, during and after HSCT. Immune reconstitution takes place by infusion of stem cells either harvested from the patient (autologous HSCT) or from a donor (allogeneic HSCT).
40799524|NCT00127452|DIETARY_SUPPLEMENT|margarine spread|Daily use of margarine spread (approximately 20 grams) during 40 months
40799525|NCT00191568|DRUG|Gemcitabine|
40799526|NCT00191568|DRUG|Oxaliplatin|
40799527|NCT00191568|PROCEDURE|Radiotherapy|
40799528|NCT05894356|OTHER|Study chart review|Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly
40799529|NCT03162744|BEHAVIORAL|Post-suicidal crisis interview|Protective factor exploration during post-suicidal crisis interview
41003615|NCT02151448|BIOLOGICAL|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
41003616|NCT00710320|PROCEDURE|Covered and uncovered anesthesia induction|"We hypothesize that the core temperatures of:~1. the covered group during induction of general anesthesia will be greater by 0.5ºC than the uncovered group during induction of general anesthesia.~2. both groups, covered and uncovered, will be equal during surgery and post-operatively. In other words, due to the active warming procedures during surgery and post-operatively in the PICU, core temperatures of the uncovered group will catch up to the covered group."
41152011|NCT01975259|OTHER|Liquid Meal Test (Fat-rich)|A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
41473790|NCT03244475|DEVICE|TES|"The EEG interface device is the J\&J Engineering I-330 C2. IASIS is delivered via the 4 EEG leads with respect to the Common Neck Reference. During each session, 2 electrodes are attached to the participant's left and right mastoids, while the remaining 2 electrodes are moved to various locations on the scalp to record EEG signals. All 4 electrodes are involved in applying weak electric current pulses back to the brain. The feedback signal consists 2 types of narrow pulse trains, both with 150mV in amplitude.~The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a waveform that provides tES to the brain delivered at a frequency of 4Hz, 40Hz, and 77.5Hz at 0 to 15mA peak current. Evidence shows this waveform, at these frequencies, results in improved clinical outcomes for anxiety and pain. We hypothesize that repeated TES treatments serve to stimulate long-term neurochemical changes."
41316383|NCT03268694|BEHAVIORAL|Working Memory Task|"Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.~N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily."
41152012|NCT01975259|OTHER|Liquid Meal Test (Mixed)|A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
41316384|NCT03268694|BEHAVIORAL|Reward Learning Task|Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
41316385|NCT03268694|BEHAVIORAL|Facial Emotion Recognition Task|On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
41316386|NCT02527122|DIAGNOSTIC_TEST|Allergen extracts|
41316387|NCT05391568|OTHER|Real Dry Needling|"Needle will be placed at trapezius muscle. Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
41473791|NCT01561794|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|"(1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.~2) Hospital-acquired pneumonia (HAP): For the patient with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days."
41473792|NCT06052020|DRUG|Alirocumab|alirocumab (75 mg every 2 weeks)
41473793|NCT06052020|DRUG|Atorvastatin|Atorvastatin 20-40mg
41473794|NCT00466895|DRUG|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
41473795|NCT04403763|DRUG|AGN-241622|Topical eye drop
41316388|NCT05391568|OTHER|Sham Dry Needling|"Sham needle will be placed at trapezius muscle. Simulated Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
41473796|NCT04403763|DRUG|Vehicle|Topical eye drop
41473797|NCT05290779|PROCEDURE|selective lumbar nerve root injection|selective lumbar nerve root steroid injection for treatment of radicular pain.
41473798|NCT02947620|DRUG|Metformin/Atorvastatin 1500mg/40mg, QD|
41473799|NCT02947620|DRUG|Metformin 1500mg, QD|
41473800|NCT02947620|DRUG|Atorvastatin 40mg, QD|
41473801|NCT03471208|DEVICE|Dynamic Navigation Assisted Implant Surgery|Implant surgery using dynamic navigation assistance
41473802|NCT03471208|PROCEDURE|Freehand Implant Surgery|Dental implant surgery via conventional freehand
41473803|NCT01358149|OTHER|cocoa-based food|single intake of cocoa-based food
41473804|NCT01358149|OTHER|cocoa-based food|Single intake of cocoa-based food
41473805|NCT01397955|DRUG|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
41003617|NCT03588637|OTHER|No intervention|No intervention
41003618|NCT04334460|DRUG|BLD-2660|BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.
41003619|NCT01703793|DRUG|Test Product 49778|
41316389|NCT03428802|OTHER|Laboratory Biomarker Analysis|Correlative studies
41316390|NCT03428802|BIOLOGICAL|Pembrolizumab|Given IV
40799530|NCT02534012|DRUG|Paravertebral block|Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
41316391|NCT00373490|DRUG|Vorinostat|600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.
40799531|NCT02534012|DRUG|General anesthesia|Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
40799532|NCT02534012|PROCEDURE|Major abdominal surgery|
40799533|NCT04293276|DRUG|Pyrotinib|Pyrotinib Tablets
40799534|NCT04293276|DRUG|SHR6390|SHR6390 Tablets
40799535|NCT06089031|DIAGNOSTIC_TEST|Coronary Function Test|Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
41003620|NCT01703793|DRUG|Test Product 10156|
41316392|NCT00373490|DRUG|Vorinostat|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
41473806|NCT05981495|DEVICE|NanoDetect-TB|This study of the NanoDetect-TB investigational device will test plasma and serum samples from TB suspects. There is no intervention for the subjects and there will be a single visit blood draw.
41473807|NCT04776057|OTHER|catarct surgery with toric intra ocular lenses|rotation stability of toric intraocular lenses between sitting or routine settings (sitting, going around) after cataract operation
40799536|NCT00604318|DRUG|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
40799537|NCT01184703|OTHER|Low GI food|Comparison of carbohydrates in diabetic patients
41152013|NCT01975259|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days. The device uses a small plastic tube to record the glucose level from interstitial fluid \& every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
41316393|NCT04243252|BEHAVIORAL|Healthy Pantry Program|Food pantries will receive the Healthy Pantry Program online training, which will be completed by at least one pantry staff member and teaches pantry staff a novel traffic-light nutrition labeling system, a multilingual healthy recipe database, and how to use those and other behavioral economic strategies to implement simple interventions in the food pantry to promote client selection of healthier options. Onsite support by a registered dietitian is included.
40799538|NCT03903549|DRUG|[18F]P17-059|Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning
40799539|NCT05421923|DRUG|SR1375 capsules|Ascending single and multiple doses of SR1375 orally
40799540|NCT05421923|OTHER|Placebo|Ascending single and multiple doses of Placebo orally
40799541|NCT03635164|DRUG|Durvalumab|Patients will receive one dose of neoadjuvant durvalumab 1500 mg approximately 3-6 weeks prior to standard of care surgery. It will be given concurrently with the first dose of radiation (RT). Patients will receive up to six doses of durvalumab and radiation post-operatively.
40799542|NCT03635164|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The starting RT dose level will be given as 6 Gy for 2 fractions (12 Gy total) every other day over approximately one week to sites of gross disease only to minimize exposure to normal tissue. If toxicity develops and surgery is delayed by more than 8 weeks (qualifying as a DLT), the radiation dose will be dropped per protocol for the next set of patients. If this dose is tolerated, the dose will be increased to 6 Gy for 3 fractions (18 Gy total) for the next 3 patients.
41003621|NCT01703793|DRUG|Vehicle (placebo)|
41003622|NCT03732911|BEHAVIORAL|Intervention|Participants will receive the following intervention bundle (1) educational materials about child development and developmental monitoring checklists; (2) age and language appropriate picture books; and (3) two tailored text messages per week for a 6-month period.
41003623|NCT05092659|BEHAVIORAL|Patient interview|Each patient included will be interviewed 3 times : before surgery, 3 and 6 months after surgery
41003624|NCT05925491|DRUG|Pembrolizumab|Pembrolizumab administration in combination with chemotherapy for 3 cycles, followed by standard of care
41003625|NCT05925491|DRUG|Cisplatin|Cisplatin 75mg/mq in combination with pembrolizumab 200 mg and docetaxel 75 mg/mq every three weeks (Q3W) for 3 courses.
41316394|NCT04243252|OTHER|Waitlist Control|Normal food pantry use for duration of the 9-month study period. Control pantries will have access to the Healthy Pantry Program after study is completed.
41316395|NCT02733406|OTHER|Target Controlled Infusion|
41316396|NCT02733406|OTHER|Velocity Controlled Infusion|
41316397|NCT00234416|DRUG|Gefitinib|
41316398|NCT00234416|DRUG|Gemcitabine|
41473808|NCT05158140|BIOLOGICAL|V110|Single intramuscular (IM) dose of 0.5 mL V110, a pneumococcal polysaccharide vaccine (PCV), containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
41473809|NCT05158140|BIOLOGICAL|V114|Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F
41473810|NCT05158140|BIOLOGICAL|mRNA-1273|Single IM dose of 50 μg/0.25 mL mRNA-1273
40799543|NCT03635164|PROCEDURE|Standard of Care Therapy|Patients will proceed to surgical resection 3-6 weeks after radiation as recommended by the ENT surgeon.
40799544|NCT02345408|DRUG|CCX872-B|Tablets (oral administration)
40799545|NCT01101893|DRUG|Raltegravir|raltegravir 400mg q12h x 5 days (Reference Treatment)
40799546|NCT01101893|DRUG|GSK2248761|GSK2248761 200mg q24h x 5 days (Reference Treatment)
41316399|NCT04158089|BEHAVIORAL|Babies and Moms connected through Love, Openness, and Opportunity (BLOOM)|"Participants will be randomly assigned into one of two groups for the BLOOM intervention; the control group will receive treatment as usual. Participants assigned to the treatment group will receive texted attachment exercises to complete from home. The intervention will take place over a 2-week period. Participants in the Attachment Exercises group will receive a text every day with an activity designed to increase feelings of attachment (e.g., read a children's book; sign a nursery rhyme; picture giving your baby a baby; tell your baby a story, etc.)."
41316400|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate
41316401|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate + GOS|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and GOS (3g)
40799547|NCT01101893|DRUG|GSK2248761 + Raltegravir|GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
40799548|NCT03772548|DIAGNOSTIC_TEST|MRI|We will examine acute (\<4 weeks post SCI) to chronic (\>6 months post SCI) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
40799549|NCT03772548|DIAGNOSTIC_TEST|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
40799550|NCT05970536|OTHER|Apple vinegar or EDTA 17%|Application of each chelating agent for 5 minutes for dentin conditioning followed by placement of MTA on the pulp chamber.
40799551|NCT02350075|PROCEDURE|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
41316402|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate + HMOs|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and HMOs (2'-FL (2g) + LNnT(1g))
41152014|NCT06585696|DRUG|CU-20101 treatment for Moderate to Severe Glabellar Striae|"Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36)."
41152015|NCT01107717|DRUG|metformin\pioglitazone\exenatide|metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c \< 6.5%
41152016|NCT01107717|DRUG|metformin, glyburide and glargine|subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c \< 6.5%
41316403|NCT05931744|DRUG|Budesonide|after application of topical vasoconstrictor packs into both nasal cavities, using 1 cc 28 gauge needle sterile syringe, one pack of budesonide ampule 0.5 mg/2ml was injected into visible polyps on both cavities 1 ml in each cavity weekly for 5 consecutive weeks
41316404|NCT05931744|DRUG|Prednisone|patients given oral prednisone 1 mg/ kg with max. dose 70 mg/d divided into two doses for 3 days then tapered gradually for two weeks
41316405|NCT05931744|DRUG|Saline|saline intrapolyp injection
41316406|NCT02867449|BEHAVIORAL|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
41316407|NCT02867449|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
41316408|NCT05152017|BIOLOGICAL|Flu-M Quadro [inactivated split influenza vaccine] with preservative|solution for intramuscular injection, 0.5 ml
41316409|NCT05152017|BIOLOGICAL|Flu-M Quadro [inactivated split influenza vaccine] without preservative|solution for intramuscular injection, 0.5 ml
41316410|NCT05152017|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
40799552|NCT02350075|DEVICE|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
41316411|NCT03303092|DRUG|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
41316412|NCT03303092|DRUG|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
41316413|NCT03303092|DRUG|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
41316414|NCT00602719|DRUG|Zolpidem|
41316415|NCT00467025|DRUG|AMG 386|3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
41316416|NCT00467025|DRUG|Sorafenib|400 mg PO BID
41316417|NCT00467025|DRUG|AMG 386 placebo IV|AMG 386 placebo IV
40799553|NCT03978741|DEVICE|Yōni.Fit Test Device|The Yōni.Fit Test Device is a silicone pessary.
40799554|NCT03978741|DEVICE|Yōni.Fit Comparator Device|The Yōni.Fit Comparator Device is a silicone pessary with a different configuration.
40799555|NCT05303506|DIAGNOSTIC_TEST|serum ferritin and AST|observiational study
40799556|NCT00632775|DRUG|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
40799557|NCT00632775|DRUG|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
40799558|NCT02006108|DRUG|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
40799559|NCT02006108|OTHER|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
40799560|NCT04974827|DRUG|Camrelizumab|200mg/3weeks
40799561|NCT04974827|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
41316418|NCT03482141|DEVICE|Whole Exome Sequencing (WES)|The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.
41316419|NCT04510194|DRUG|Metformin|Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.
41473811|NCT05158140|BIOLOGICAL|Placebo for V110|Single IM dose of 0.5 mL placebo for V110
41473812|NCT05158140|BIOLOGICAL|Placebo for V114|Single IM dose of 0.5 mL placebo for V114
40799562|NCT01505036|OTHER|SMARTCARE service|U-Healthcare service
40799563|NCT01074476|DIETARY_SUPPLEMENT|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
40799564|NCT01074476|OTHER|Placebo|Placebo tablets, twice per day for 3 months
40799565|NCT00606411|DRUG|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
41003626|NCT05925491|DRUG|Docetaxel|Docetaxel 75 mg/mq in combination with pembrolizumab 200 mg and cisplatin 75 mg/mq every three weeks (Q3W) for 3 courses.
41473813|NCT04814459|OTHER|HOP-UP-PT Program|Interventions provided to EG participants included; (1) the Otago Exercise Program (OEP) which is a well-established exercise program with evidence that it reduces falls among community-dwelling older adults, (2) motivational interviewing (MI) to optimize positive health behaviors, and (3) home and environmental modification recommendations aimed at safety. Participants were provided with and educated on the use of a wrist-worn activity tracker and an automated BP monitor unit. Finally, when follow up items were identified (e.g., orthostatic hypotension, community exercise classes), these referrals were made and documented.
41473814|NCT01397981|BEHAVIORAL|Gait retraining|Changing the kinematics of walking
41152017|NCT05711017|DRUG|Huashibaidu granule|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the Huashibaidu group will receive Huashibaidu granule two times a day for five consecutive days (day 1\~5).
41473815|NCT03220113|COMBINATION_PRODUCT|Dexamethasone, Lidocaine, Thiamine cohort|Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
41473816|NCT05982249|DEVICE|Hypnosis|Patients will be given earphones to hear a hypnotic script that was recorded by Dr. Zahi Arnon, a psychologist specializing in hypnosis after observing about ten BM examinations at the hematology institute. The length of the recording is about 7 minutes.
41473817|NCT05982249|DEVICE|Virtual reality (VR)|Patients will be connected to a VR device that will transmit to the patient's choice a 3D screen and soothing noise for about 7 minutes.
40799566|NCT02901249|DRUG|sertraline|
40799567|NCT02901249|DRUG|Nortriptyline|
41152018|NCT05711017|DRUG|Placebo|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the placebo group will receive placebo two times a day for five consecutive days (day 1\~5).
41152019|NCT03921164|PROCEDURE|Trans-oesophageal Doppler|"As required by the standard of care of the interventional neuroradiology procedure, the neuroradiologist also cannulates the femoral artery. At the end of the procedure, during catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.~Descending aortic velocity is measured with a transesophageal Doppler CardioQ-ODM+ (Deltex Medical, Chichester, UK) in order to construct the VP Loop in descending thoracic aorta."
41152020|NCT03921164|PROCEDURE|Trans-thoracic echocardiography|Estimation of ventricular diastolic pressure by measuring mitral and aortic flow gradients by echocardiography (EPIQ G7 Philips© or similar) Determination of left ventricular volumes during the cardiac cycle by echocardiography (3D EPIQ G7 Philips© or similar).
41473818|NCT02996019|DRUG|Etrolizumab|Etrolizumab will be administered at a dose of 105 milligrams (mg).
40799568|NCT02901249|DRUG|Lithium|
40799569|NCT04788485|DRUG|Diosmectite|use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates
40799570|NCT03034005|DRUG|Budesonide|1600 ug inhaled daily for 6 weeks
40799571|NCT00971581|DRUG|FDC KETOPROFEN+OMEPRAZOLE|Ketoprofen + Omeprazole FDC once daily for 4 weeks
40799572|NCT03957668|DRUG|PEG 3350|PEG 3350 17 g once daily for 14 days
40799573|NCT03957668|DRUG|Lactulose|Lactulose 10 g once daily for 14 days
41003627|NCT05925491|DRUG|Carboplatin|Carboplatin AUC 5 alternative to Cisplatin if toxicities occur.
41473819|NCT02996019|DEVICE|Auto-Injector (AI)|The pre-filled AI will be used to administer etrolizumab.
41473820|NCT02996019|DEVICE|Prefilled Syringe With Needle Safety Device (PFS-NSD)|The PFS-NSD will be used to administer etrolizumab.
40799574|NCT04262882|BEHAVIORAL|Multilevel Family Planning Intervention|"The intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community."
40799575|NCT04262882|BEHAVIORAL|Time and attention matched control|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (hand-washing, food preparation) following an intervention manual that was developed for community groups in Uganda."
40799576|NCT03066206|DRUG|Poziotinib|Given PO
40799577|NCT00989846|OTHER|biomarker|measuring serum-biomarkers
40799578|NCT00301262|DRUG|Viagra (Sildenafil citrate)|
40799579|NCT06291493|DIAGNOSTIC_TEST|Fingerstick blood draw|Capillary blood specimen collected from two separate fingerstick blood draws.
40799580|NCT01540526|DRUG|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
41003628|NCT06095466|DEVICE|Echocardiographic assessment|M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
41003629|NCT06095466|DIAGNOSTIC_TEST|Histopathology and Immunohistochemistry|"In patients who do not survive, we will take a trucut core biopsy from the ventricular myocardium, using ultrasound guidance. Cardiac tissue slices preserve the heterogeneous structure and multicellularity of the myocardium and allow its functional characterization. However, in this protocol, only those patients who consent to autopsy or those who consent to most mortem biopsy will be sampled for cardiac histology in CCM. Thus samples for histology and immunohistopathology will be available in only a few patients.~For the immunohistochemistry study, the sections will be collected on the poly-L-lysine covered slides and dried in a thermostat, at 37°C, for 24 hours, for increasing the adherence of the biological material to the histological slide."
41003630|NCT01393743|DRUG|Perampanel|
41316420|NCT04510194|DRUG|Placebo|placebo; appearance and size are exact matching to the three study drugs.
41316421|NCT04510194|DRUG|Fluvoxamine|An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14
41316422|NCT04510194|DRUG|Ivermectin|An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days
41316423|NCT02807363|DRUG|Leuprolide Oral Tablet 4-mg QD|4-mg Leuprolide oral tablet once daily for 28 consecutive days.
41316424|NCT02807363|DRUG|Leuprolide Oral Tablet 4-mg BID|4-mg Leuprolide oral tablet twice daily for 28 consecutive days.
41316425|NCT02807363|DRUG|Leuprolide Depot|3.75 mg intramuscular depot injection
41003631|NCT01393743|DRUG|Placebo comparator|
41152021|NCT03921164|PROCEDURE|Applanation tonometry|"Measurements using the SphygmoCor radial tonometer (AtCor Medical, Pty Ltd, Sydney, Australia), the most widely used tonometer in clinical research for non-invasive central pressure measurement and pulse wave analysis. The central blood pressure is then estimated using a validated radial-aortic transfer function.~The tonometer requires prior calibration by mean (MAP) and diastolic (PAD) blood pressure measured with the conventional brachial cuff as validated in the literature."
41316426|NCT02807363|DRUG|Leuprolide Oral Tablet 10-mg BID|10-mg Leuprolide oral tablet twice daily for 28 consecutive days.
41316427|NCT03956225|DEVICE|Systane iLux® Dry Eye System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
41316428|NCT03956225|DEVICE|LipiFlow® Thermal Pulsation System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
41316429|NCT01974726|OTHER|ET Stress test|Performed in pressure chamber. For subjects with intact tympanic membranes, chamber pressure increased from ambient to +2500 daPa (+2000 daPa for children). At that pressure and then at down-stepped pressures of 250 daPa/steps to a chamber pressure of -1500 daPa (or a passive ET opening), the subject will swallow to attempt to open the ET as detected by sonotubometry and/or a change in ear canal pressure. ET passive opening and closing pressures will then be determined. In ears with a non-intact tympanic membrane, a small volume probe connected to a pressure transducer will be placed in the ear canals and the procedure repeated with continuous recording of ME pressure. ET opening is recorded as a change in ME pressure toward local ambient.
41316430|NCT01974726|OTHER|Sonotubometry|Microphones are placed in the ear canals and covered with ear protectors. A nasal probe placed in one nostril introduces a white noise to the nasopharynx and the subject is asked to swallow. The test system identifies the sound frequency best transmitted through an open ET (if the test is positive, i.e. ET opens) and the procedure is repeated with the nasal sound pressure delivered at that frequency. The probe is then placed in the contralateral nostril and the procedure repeated. The microphone signals from both ear canals are continuously outputted and recorded. A positive ET opening is defined as a 5 dB increase above baseline during any of the 4 swallows and can be semi-quantified as the area under the baseline-adjusted ear canal sound pressure-time curve. The test is designed to measure the presence or absence of muscle-assisted ET openings during swallowing at local ambient pressure.
40799581|NCT01948219|DEVICE|ENTegral Artificial Larynx implant|
40799582|NCT02052661|BIOLOGICAL|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
40799583|NCT02488135|DEVICE|Floseal Hemostatic Matrix|Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.
40799584|NCT02488135|PROCEDURE|Traditional Nasal Packing|Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.
40799585|NCT02457689|BIOLOGICAL|GTU®-MultiHIV B Clade Vaccine|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
40799586|NCT02457689|OTHER|Sodium chloride BP|For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
40799587|NCT05068830|DRUG|ExPlas|"ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max \>50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.~The transfusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
40799588|NCT05068830|DRUG|Octaplasma|"Octaplasma is defined as a Investigational Medicinal Product. Octaplasma is human pooled plasma produced by Octapharma (Lachen, Switzerland). The transfusion volume will be 200 mL at every time point .~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
40799589|NCT05068830|DRUG|Saline|"Saline is provided by the hospital pharmacies in Central Norway. The infusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
40799590|NCT04754971|OTHER|psycho-education program|Psychoeducation Practice 1 day per week, 60-90 min. sessions will take 8 weeks. At the end of the training, the final test will be applied to the experimental and control group. 3rd and 6th month follow-up measurements are planned to be carried out intermittently at the end of the month.
40799591|NCT00140179|DRUG|valnoctamide|
40799592|NCT02408172|DRUG|Amlodipine|Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
40799593|NCT02408172|DRUG|metoprolol|Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
40799594|NCT04737434|DEVICE|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave deliver or not to participants during sleep.
41316431|NCT01974726|OTHER|Forced Response Test (FRT)|The FRT requires a non-intact tympanic membrane and uses an instrument consisting of an ear canal probe coupled serially to a differential pressure transducer, via a valve to a flow sensor and via a second valve to a variable-speed constant-flow pump. The probe is sealed in the ear canal and both valves are opened. The pump is set to deliver a constant flow of 11 ml/min which increases ME pressure to passively open the ET. This is followed by a decrease in ME pressure to steady state pressure and flow conditions. The subject is asked to swallow which either transiently increases (further ET dilation) or decreases (ET constriction) the transET flow. The pump is turned off causing the ET to close at a residual ME pressure. This procedure is repeated at flow rates of 23 and then 46 ml/min.
40799595|NCT04737434|DEVICE|electromagnetic field with no wave|electromagnetic field with no wave
40799596|NCT06553586|OTHER|Data collection|"Data of the proposed study will be collected from two main sites, namely they:~1. All emergency departments of health service outlets received the concerned victims of RTAs in Riyadh Region throughout the last five years (2019-2023). The records and documents of these hospitals will be reviewed and the researcher will determine and pick up the victims of RTAs only and record them in a relevant form designed to fit with the proposed study.~2. The General Administration of Traffic in Riyadh Region."
40799597|NCT05891535|PROCEDURE|Robot assisted radical cystectomy without mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
40799598|NCT05891535|PROCEDURE|Robot assisted radical cystectomy with mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
40799599|NCT05130385|DEVICE|High-resolution optical coherence tomography (High-Res-OCT)|Imaging with high-resolution optical coherence tomography
40799600|NCT05130385|DEVICE|Standard spectral domain OCT (SD-OCT)|Imaging with standard spectral domain OCT
40799601|NCT06464731|PROCEDURE|EVT|Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines. This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on. The EVT regimen and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to the local guidelines.
40799602|NCT04656808|BEHAVIORAL|Guilt Focused Intervention|Psychotherapy, group intervention
40799603|NCT04656808|BEHAVIORAL|Cognitive behavioral therapy|Psychotherapy, group intervention
40799604|NCT01930422|DEVICE|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
40799605|NCT01930422|DEVICE|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
40799606|NCT01602601|DRUG|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
41473821|NCT04846647|BEHAVIORAL|unexplained hypophoshatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
40799607|NCT01602601|DRUG|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
40799608|NCT05745337|DRUG|As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)|Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
41152022|NCT03167645|DRUG|Human albumin|Substitution according to pre-specified dosage
41473822|NCT05290337|DRUG|zanubrutinib|BTK inhibitor
40799609|NCT02046837|BEHAVIORAL|Supervised 1:1 exercise|The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
40799610|NCT02046837|BEHAVIORAL|Supervised group exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
41316432|NCT01974726|OTHER|Inflation Deflation Test (IDT)|The IDT requires a non-intact tympanic membrane and uses the FRT instrument. ME pressure is increased to 250 daPa (ref ambient), the valves to the flow sensor and pump closed and the subject is asked to swallow repeatedly at a natural interval while monitoring ME pressure until further swallowing fails to change ME pressure. The procedure is repeated with an applied under-pressure of -250 daPa. The outcome variable is the percent pressure change (%reduction) at test end. The test measures the muscle-assisted tubal openings under minor stress (ME under-pressure) and facilitative (ME over-pressure) conditions, and can detect a patulous/semi-patulous ET by an inability to maintain applied ME over and/or under-pressures between swallows.
40799611|NCT02046837|BEHAVIORAL|Home-based exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
40799612|NCT03719001|DRUG|Phenylephrine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure
40799613|NCT03719001|DRUG|Dexmedetomidine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
41152023|NCT04323111|PROCEDURE|metzenbaum's technique|surgical procedure for correction of caudal end nasal septal deviation
40799614|NCT03719001|DRUG|Clevidipine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
40799615|NCT03719001|OTHER|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)
40799616|NCT03719001|OTHER|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.
40799617|NCT03719001|DRUG|Calcium Chloride|CaCl will be administered to increase blood pressure and plasma calcium concentration
40799618|NCT05003973|BEHAVIORAL|home-based anti-resistance exercise|It is a 12-week, middle-level, home-based, anti-resistance exercise. Exercise was recommended 1-2 times per day for 15-20 mins per session.
40799619|NCT05003973|BEHAVIORAL|usually care|The leaflet of the lymphedema self-care, including skin care and manual lymphatic drainage
40799620|NCT00292045|BIOLOGICAL|NY-ESO-1 protein/CpG 7909|Patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) as an adjuvant administered intradermally every 3 weeks for 4 doses (i.e., 12-week cycle).
41152024|NCT04832724|GENETIC|RGX-314|RGX-314 is a recombinant adeno-associated virus gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
40799621|NCT02110433|DEVICE|Placebo group|patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations
40799622|NCT02110433|DEVICE|Cordiva System (R)|Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
40799623|NCT02110433|DEVICE|BNP heartcheck|Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP \< 100 pg/ml or remaining stable (\< 30% increase).
40799624|NCT03645941|BEHAVIORAL|Facebook Group|The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.
40799625|NCT04033822|PROCEDURE|cholecystectomy|If patients are randomized to the intervention arm of the study; said patient will undergo corrective cholecystectomy surgery to correct cholecystitis as soon as possible with a goal of surgery within 6 hours of diagnosis.
40799626|NCT03694769|OTHER|Semi-structured interview|One-hour interview with researcher
40799627|NCT03694769|OTHER|Drop attack diary|Diary of any drop attacks experienced within an 8 week period
40799628|NCT05371158|BEHAVIORAL|Online intervention|The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
41003632|NCT05677620|RADIATION|Pharyngeal Computed Tomography|To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
40799629|NCT01308814|DRUG|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
40799630|NCT01308814|DRUG|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
40799631|NCT04574180|OTHER|Dental Crown|Pediatric size dental crown; restore damaged tooth to its normal shape, size, and function.
40799632|NCT02016716|DRUG|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
41003633|NCT05677620|DRUG|Drug-Induced Sleep Endoscopy (Propofol)|The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
40799633|NCT02016716|DRUG|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
40799634|NCT02016716|DRUG|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
40799635|NCT02016716|DRUG|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
41316433|NCT01974726|OTHER|Maneuver Sequence|The sequence consists of the Toynbee, Valsalva, Sniffing and Continuous Pressure Test (CPT). The test system consists of ear canal and nasal pressure probes. For the Toynbee test the subject pinches both nostrils (without constricting the nasal probe) and swallows; for the Sniffing test, the subject performs a series of forcible sniffs that must achieve a nasopharyngeal pressure of at least -400 daPa; for the Valsalva test the subject pinches both nostrils and forcibly blows against the closed nose to achieve a nasopharyngeal pressure of at least 400 daPa, and for the CPT the subject breathes through his/her mouth in a relaxed manner for 2 minutes.
41316434|NCT01974726|OTHER|9-Step Test|This test requires an intact tympanic membrane. Middle ear (ME) pressure is recorded by tympanometry before and after application of a 300 daPa over-pressure to the ear canal and then before and after application of a 300 daPa under-pressure to the ear canal. Between steps, the subject is asked to swallow in an attempt to open the ET and change ME pressure. A positive test is indicated by a minimum 10 daPa change in ME pressure after a given swallow and excellent muscle-assisted ET opening is indicated by an initial change to a more negative ME pressure after a swallow, followed by a return to 0 daPa, a positive ME pressure and a return to 0 daPa for sequential swallows. The test is designed to measure the presence/absence of active ET openings during swallowing at ambient pressures.
41316435|NCT01974726|OTHER|Tubomanometry|The test system is commercially available and can test ears with and without an intact tympanic membrane. Pressure sensors are inserted bilaterally into the ear canals and sealed. A controlled air-flow is introduced into the nose and nasopharynx and the subject swallows. ET openings are detected as a change in ME pressure measured directly as a pressure pulse in the ear canal for ears with a non-intact tympanic membrane or indirectly as a change in ear canal pressure caused by tympanic membrane displacement in ears with intact tympanic membranes. The outcome is the detection of a pressure change in the ear canal during swallowing which is indicative of a muscle-assisted tubal opening.
41316436|NCT01974726|OTHER|Videoendoscopic assessment of ETF|The subject's nose is topically anesthetized and decongested with 4% lidocaine and 0.05% oxymetazoline. If ventilation tubes are present, probes are sealed in the ear canal(s)and a pressure of 200 daPa is applied to the ME(s) to assess ET opening. If tympanic membranes are intact, microphones for sonotubometry are placed in the ear canals. Then, an endoscope attached to a video camera is introduced into the ipsilateral nasal cavity and focused on the ET orifice. For sonotubometry, the sound source probe is placed in the contralateral nostril. The subject is asked to swallow, vocalize and perform a series of mandibular movements. Signals from the video camera and pressure transducer or sonotubometry microphones are continuously recorded. The data are studied to document dilation of the nasopharyngeal ET orifice during swallowing and to rule in or out an anatomical or functional nasopharyngeal abnormality as the cause of a diagnosed ET dysfunction.
40799636|NCT05206214|PROCEDURE|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver. . Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
40799637|NCT05206214|PROCEDURE|Mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver. Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
40799638|NCT01063608|BIOLOGICAL|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
41316437|NCT01974726|OTHER|Pressure chamber ET test|Performed in pressure chamber. Pressure increased to create middle-ear underpressure, then subject is asked to swallow several times. Middle-ear pressures are then measured by tympanometry. This is repeated with decreased chamber pressure, creating a middle-ear overpressure.
41316438|NCT01284270|OTHER|Cardiac MRI|Cardiac MRI
41316439|NCT05010525|DRUG|ATG-016|48 patients enrolled, orally, each 3 week (21-day) a cycle
40799639|NCT03267784|BIOLOGICAL|allo-APZ2-DFU|Suspension of ABCB5-positive mesenchymal stem cells
41152025|NCT04100148|DEVICE|SyncAV programmed ON|For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.
41152026|NCT04100148|DEVICE|Fixed AV delay|For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.
41152027|NCT04514289|DRUG|Indocyanine green solution|Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.
41152028|NCT00860899|DRUG|clonidine, levobupivacaine|One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine \[Catapres®, Boehringer Ingelheim, Germany\], 7 mL of 0.25% levobupivacaine \[Chirocaine®, Abbott S.p.A., Italy\] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
41152029|NCT03196180|DRUG|Imiquimod|Given intravaginally
41152030|NCT03196180|DRUG|Topical Fluorouracil|Given intravaginally
41152031|NCT03734588|GENETIC|SPK-8016|adeno-associated viral vector
41003634|NCT05677620|DEVICE|Mandibular Advancement Device|A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.
41003635|NCT01263548|DRUG|lisdexamfetamine dimesylate|Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
41003636|NCT02961699|DEVICE|Transpose ® RT System|adipose-derived stem cell therapy
41003637|NCT02961699|OTHER|debridement/dressing of wound|standard of care debridement and wound dressing
41003638|NCT00000707|DRUG|Pentamidine isethionate|
41003639|NCT02993679|PROCEDURE|reconstruction of the ACL and anterolateral ligament|reconstruction of the ACL and anterolateral ligament
41003640|NCT04527861|PROCEDURE|Single-incision Laparoscopic Surgery|In this group，the surgery is performed through a single incision. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
40799640|NCT05210088|DRUG|Hypoxia, intermittent|"The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored."
40799641|NCT05210088|OTHER|Normoxia|The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
40799642|NCT05828615|OTHER|Group A|"Close your eyes and exhale through your left nostril fully and slowly, once you have exhaled completely, release your right nostril and place your ring finger on the left nostril.~Breathe in deeply and slowly from the right side. Make sure your breath is smooth and continuous. Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
40799643|NCT05828615|OTHER|Group B|"The position of the woman should be relaxed and comfortable e.g., crock lying, sitting, standing position. Place one hand on chest and other on stomach and close eyes to relax and focus on breathing. Slowly breathe in through nose with your closed mouth.Breathe out through your nose and try to use as small effort as possible and make your breaths slow, relaxed and smooth.~Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
40799644|NCT02791035|DRUG|Oral administration of Ipragliflozin|
40799645|NCT00020098|PROCEDURE|evaluation of cancer risk factors|
40799646|NCT01471769|BEHAVIORAL|Pain management video|6-minute video
40799647|NCT01471769|BEHAVIORAL|Falls Prevention Video|6-minute video
40799648|NCT01861704|DEVICE|Lyric|Extended wear hearing instrument
40799649|NCT01861704|DEVICE|Lyric2|Extended wear hearing instrument
40799650|NCT03268889|DRUG|Chidamide|Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
41003641|NCT04527861|PROCEDURE|Conventional Laparoscopic Surgery|In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
40799651|NCT03411018|OTHER|Mechanical ventilation exposure|
40799652|NCT03550391|DRUG|Memantine|20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg per week. Memantine should start at 5 mg, and then increased in 5 mg increments at the following schedule, depending on the patient's response and tolerance:
40799653|NCT03550391|RADIATION|Hippocampal-avoidant (HA-WBRT) Radiotherapy|30Gy in 10 fractions
40799654|NCT03550391|PROCEDURE|Stereotactic Radiosurgery (SRS)|18-20 or 22 Gy in single fraction
41003642|NCT01569529|BEHAVIORAL|Online advertisement|Internet advertisement with messages tailored for young adult smoker's motivated to quit
41003643|NCT02920983|DEVICE|somofilcon A|contact lens
41003644|NCT02920983|DEVICE|nelfilcon A II 2|contact lens
41003645|NCT02920983|DEVICE|omafilcon A ll 2|contact lens
41003646|NCT00122343|DRUG|ridaforolimus|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
41003647|NCT05595317|DEVICE|Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. In the non-immersive virtual reality application, Microsoft Kinect Xbox 360 Adventures games will be applied at the light level exercise level under the supervision of a physiotherapist. The participant will play a game in which he stands in a standing boat in a boat going on a flowing river and has to overcome obstacles by jumping, crouching and stepping left and right (River rush game).
41316440|NCT05663242|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
41316441|NCT05663242|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
41152032|NCT05974371|OTHER|emotional context similarity|On Day 1, all participants will encode AB neutral word pairs (e.g., Pencil - Car) shown with positive, negative, or neutral images. On Day 2, all participants will encode AC neutral words pairs (e.g., Pencil - Book) alongside images of either the same or different valence. The emotional similarity of AB (Day 1) and AC (Day 2) image contexts (i.e., the independent variable) will consist of the following conditions: positive-positive, positive-negative, negative-negative, negative-positive, neutral-neutral, neutral-positive, and neutral-negative.
41316442|NCT05283863|DEVICE|High-frequency stimulation|Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
41316443|NCT05283863|DEVICE|Sham Stimulation|Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
40799655|NCT04482777|DRUG|Corticosteriod for treated patients|Drug given to some patients with autoimmune disease
40799656|NCT01032070|DRUG|erlotinib|oral
40799657|NCT01032070|DRUG|etoposide|oral
40799658|NCT03567967|BEHAVIORAL|Fruit and vegetable voucher|Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
40799659|NCT06119971|DEVICE|ACUPRESSURE|Acupressure using disposable devices consisting of a metal microbead and an adhesive material.
40799660|NCT02107625|BEHAVIORAL|Diet A i.e. Low FODMAP diet|
40799661|NCT02107625|BEHAVIORAL|Diet B, i.e. Traditional IBS diet|
40799662|NCT01496287|DEVICE|Tube Delivery System (TDS)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
40799663|NCT00003566|PROCEDURE|videothoracoscopy|
40799664|NCT03565250|OTHER|self understanding interview|semi-structured interview designed for assessment of identity according to Damon \& Hart's 7-dimension develomental model
40799665|NCT06180616|DRUG|Tirzepatide|"Tirzepatide will be self-administered subcutaneously by study participants via an injection. The drug will be taken weekly following the schedule: 4 weeks at 2.5 mg QW, 4 weeks at 5.0 mg QW, 4 weeks at 7.5 mg QW, 4 weeks at 10.0 mg QW, 4 weeks at 12.5 mg QW, 12 weeks at 15 mg QW.~Modification of study drug will be performed if the participant is experiencing significant side effects and cannot tolerate the higher dosage of the study drug. In this instance, the study drug dosage will be reduced to the previously tolerated dosage and held at this dose for a further 4 weeks. One further attempt at dose escalation will be undertaken after 4 weeks, at the discretion of the participant and the study investigator. If recurrent side effects are experienced by the participant, the study drug will be returned to the previously tolerated dosage, and the prescription continued at this dosage for the remainder of the study."
40799666|NCT05330390|DRUG|Levetiracetam|Epilepsy, treatment with levetiracetam
40799667|NCT06496308|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
40799668|NCT06496308|DRUG|Bendamustine|Bendamustine IV will be administered as per the schedule specified in the respective arm.
40799669|NCT06496308|DRUG|Rituximab|Rituximab IV will be administered as per the schedule specified in the respective arm.
40799670|NCT06496308|DRUG|Venetoclax|Venetoclax PO will be administered as per the schedule specified in the respective arm.
40799671|NCT01049204|DRUG|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
40799672|NCT01049204|DRUG|placebo|Placebo twice daily for 24 weeks
40799673|NCT00761384|DRUG|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
40799674|NCT03953248|DRUG|L-Carnitine|
41152033|NCT05599230|DRUG|Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening|Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.
40799675|NCT02676700|BEHAVIORAL|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
40799676|NCT02676700|BEHAVIORAL|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
40799677|NCT00967694|DRUG|Nitrous oxide|Nitrous oxide sedation by inhalation
40799678|NCT03956992|OTHER|Mouth gel|Stop using the mouth gel
40799679|NCT00001335|DRUG|ADR-529|
41152034|NCT02394509|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
41152035|NCT00647387|DEVICE|Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)|Device
41152036|NCT01516710|PROCEDURE|Open liver resection|Patients will be operated with open liver resection for colorectal metastasis
41152037|NCT01516710|PROCEDURE|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
41152038|NCT06129656|OTHER|Routine diagnostics|Data collection of routine diagnostics
41152039|NCT06129656|OTHER|Routine treatment|Data collection of routine treatment
41152040|NCT01493947|DRUG|Ivermectin 1% cream|Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
41152041|NCT01493947|DRUG|Metronidazole 0.75% cream|Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
41152042|NCT03489837|DRUG|Levotuss|oral taken
41316444|NCT00019721|BIOLOGICAL|MART-1 antigen|
40799680|NCT00001335|DRUG|Topotecan|
40799681|NCT00001335|DRUG|G-CSF|
40799682|NCT00799630|DIETARY_SUPPLEMENT|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
40799683|NCT01746355|PROCEDURE|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
40799684|NCT02319460|BIOLOGICAL|Kcentra®|Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.
40799685|NCT02319460|BIOLOGICAL|Plasma|
40799686|NCT06125067|PROCEDURE|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
40799687|NCT06125067|PROCEDURE|Fascia Iliaca Compartment Block|Fascia Iliaca Compartment Block is performed with the patient in a supine position. A high-frequency (6-14 MHz) linear ultrasound probe is positioned transversely to locate the femoral artery in the inguinal crease. The hyperechoic femoral nerve is usually visualized lateral to the femoral artery, between the iliopsoas and fascia iliaca. The probe is manoeuvred in a cranial and caudal direction to capture high-quality images of the femoral nerve and fascia iliaca. Identification of the triangular-shaped sartorius muscle and anterior superior iliac spine (ASIS) is achieved by lateral movement of the probe. Post-skin disinfection, the needle tip is directed just beneath the fascia iliaca. Local anaesthetic is administered following negative pressure aspiration into the area. The local anaesthetic spreads towards the femoral nerve medially and towards the iliac process laterally.
40799688|NCT06125067|PROCEDURE|iPACK Block|During the iPACK procedure, the patient assumes a supine position with the lower extremity flexed at the knee and abducted at the hip (in frog-leg position). The ultrasound transducer is placed in the lower third of the medial thigh, and then pushed backward and downward to visualize the gap between the popliteal artery and the femoral shaft, straight above the femoral condyles. After ensuring that the needle tip is placed 2 cm beyond the lateral border of the artery, local anaesthetic solution is administrated in divided doses to infiltrate the tissue space. The needle is then withdrawn after confirming negative aspiration.
40799689|NCT05959655|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
41003648|NCT05595317|DEVICE|Sham Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. As a sham application, the participants will sit in a chair in front of the screen and try to prevent the balls sent from the opposite direction by using their upper extremities while their bodies are fixed with the help of a belt, under the supervision of a physiotherapist (Rally ball game).
41003649|NCT01256593|DRUG|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
41152043|NCT02093078|BEHAVIORAL|CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
41316445|NCT00019721|BIOLOGICAL|aldesleukin|
41316446|NCT00019721|BIOLOGICAL|gp100 antigen|
41316447|NCT00019721|BIOLOGICAL|incomplete Freund's adjuvant|
41316448|NCT04765748|DEVICE|Cytosorb|Cytokine filter, which can be used intraoperatively while using a heart lung machine
41316449|NCT00567541|DEVICE|Battery Powered Microneuromodulator (BBPM)|The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
41316450|NCT05447598|OTHER|Nurse-led remote monitoring program|Symptoms of disease progression, clinical parameters, medication adherence and follow-up needs will be reported by patients or with support from relatives or homecare nurses 2-4 times/months over a three months period using a digital platform. Telephone monitoring is planned for patients who are not able to comply with the digital platform. In addition, an individualized self-treatment plan for diuretics and lifestyle advice will be prepared, preferably together with relatives at the outpatient clinic. Participants will also have access to a website with written information and videos about HF and self-management. Finally, a pillbox will be delivered to facilitate drug adherence.
41316451|NCT05447598|OTHER|Usual care treatment|Usual care treatment and follow-up care at the outpatient clinic and in primary care
41316452|NCT03120481|OTHER|no intervation|no intervention
41316453|NCT00003219|DRUG|perillyl alcohol|
41316454|NCT02375204|DRUG|paclitaxel|IV
41316455|NCT02375204|DRUG|ifosfamide|IV
41316456|NCT02375204|DRUG|cisplatin|IV
41316457|NCT02375204|DRUG|pegylated G-CSF|IV
40799690|NCT06005532|DRUG|Adalimumab|Adalimumab injection 40 mg / 0.8 ml
40799691|NCT06005532|DRUG|Humira|Adalimumab injection 40 mg / 0.4 ml
40799692|NCT00025792|DRUG|Pramipexole|
41316458|NCT02375204|DRUG|G-CSF|IV
41316459|NCT02375204|DRUG|carboplatin|IV
41316460|NCT02375204|DRUG|etoposide phosphate|IV
41316461|NCT02375204|PROCEDURE|stem cell reinfusion|surgical procedure
41316462|NCT03785795|DEVICE|Uncertain diagnosis of true labor|Multichannel EMG of uterine bioelectrical signals will be recorded using area sensors. The output of the synchronization calculations will be correlated with the time to delivery
41316463|NCT02158702|DRUG|Pomalidomide and Dexamethasone|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
41316464|NCT03617367|BIOLOGICAL|daxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
41157065|NCT04691336|BEHAVIORAL|Educational and Training with counselling|The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
41316465|NCT02841319|OTHER|Virtual Reality Exercises using Hand Tutor|Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
40799693|NCT01781793|OTHER|Room air|Humidified room air (21% oxygen) will be inspired
40799694|NCT01781793|OTHER|Hyperoxia|60% oxygen will be inspired
40799695|NCT06495320|OTHER|Rational drug use education|Rational Drug Use Education Program for Parents: The training program consists of 30 minutes. The training program will be delivered to parents in the form of a 30-minute training session with a powerpoint presentation, using the face-to-face education model. Interactive education methods that enable parents' participation will be used. In addition, in order to increase the permanence of education, the educational content will be given to parents in the form of an educational booklet.
40799696|NCT00705250|DRUG|bendamustine hcl|Patients will receive bendamustine 120mg/m\^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is \> 1000/ul and the platelet count is \> 75,000/ul.
40799697|NCT02406469|DIETARY_SUPPLEMENT|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
40799698|NCT03915990|DIAGNOSTIC_TEST|umbilical and middle cerebral artery Doppler|Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
41316466|NCT00413062|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
41316467|NCT00413062|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
40799699|NCT06260449|PROCEDURE|Surgical removal|Removal of the granuloma
40799700|NCT05037695|DRUG|empagliflozin 25 MG|empagliflozin 25mg - daily
40799701|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 1|Stage I- Cohort I: (2mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo) -
40799702|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 2|Stage I- Cohort II: Dose 2 (4mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo)
40799703|NCT03388216|BIOLOGICAL|Drug: INM004- Repeated dose|Stage II: Either 3 doses of 2 mg/kg or 4 mg/kg will be administered every 24 hs. The ratio is 5:1 (investigational product : placebo).
40799704|NCT03388216|OTHER|Placebo|A placebo infusion will be administered at the same infusion rate as the Drug arm
40799705|NCT02533544|DRUG|tenofovir disoproxil fumarate|
40799706|NCT01738815|DRUG|Valproic Acid|500 mg orally, once daily for up to 30 days
40799707|NCT04493424|DRUG|Spesolimab|Spesolimab
40799708|NCT03983720|OTHER|Evaluation of degree chronic fatigue.|Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
40799709|NCT03983720|OTHER|Questionnaires|"* Fatigue Severity Scale (FSS)~* Modified Fatigue Impact Scale (MFIS)~* Godin Leisure-Time Exercise Questionnaire (GLTEQ)~* Scale of life quality of multiple sclerosis (SEP-59)~* Center for Epidemiologic Studies Depression (CES-D)~* Pittsburgh Sleep Quality Index (PSQ-I)"
40799710|NCT03983720|BIOLOGICAL|Blood sample|Blood sample will be realized to evaluate anemia and inflammations.
40799711|NCT03983720|OTHER|Cardiopulmonary evaluation|Cardiopulmonary evaluation will be realized with a cycle ergometer.
40799712|NCT03983720|DEVICE|Capacity of muscular oxygen extraction|Measure the capacity of muscular oxygen extraction with a cycle ergometer.
40799713|NCT03983720|DEVICE|Sleep assessment|Sleep assessment will be measured by actigraphy during 15 days.
40799714|NCT03983720|DEVICE|Metabolic fatigue|Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
40799715|NCT03983720|OTHER|Neuromuscular evaluation|"Neuromuscular evaluation will be measured by the composite of the results of:~* Fatigue test~* Measure of voluntary isometric force~* Surface electromyography~* Peripheral nerve stimulation~* Transcranial Magnetic Stimulation (TMS)~* Perceived fatigue~* Cognitive fatigue~* Thermoregulation"
40799716|NCT01823198|BIOLOGICAL|Aldesleukin|Given SC
40799717|NCT01823198|BIOLOGICAL|Allogeneic CD56-positive CD3-negative Natural Killer Cells|Given IV
40799718|NCT01823198|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplant
40799719|NCT01823198|DRUG|Busulfan|Given IV
40799720|NCT01823198|DRUG|Fludarabine Phosphate|Given IV
40799721|NCT01823198|OTHER|Laboratory Biomarker Analysis|Correlative studies
40799722|NCT01823198|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
40799723|NCT01823198|OTHER|Pharmacological Study|Correlative studies
40799724|NCT03116906|DRUG|BI 685509|to be given for a total of up to 15 days
40799725|NCT03116906|DRUG|Placebo|to be given for a total of up to 15 days
40799726|NCT01489865|DRUG|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
40799727|NCT01156025|DRUG|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
40799728|NCT01156025|DRUG|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
40799729|NCT05470985|DRUG|Ozanimod|Specific dose on specific days
40799730|NCT02673099|PROCEDURE|HDF online|Hemodialysis by the HDF online method
40799731|NCT05082519|BEHAVIORAL|IDEAL2 Intervention|Intervention of diet and exercise to improve outcomes for ALL patients
40799732|NCT00348101|DRUG|Combined therapy with enoximone and esmolol|
40799733|NCT03376711|BEHAVIORAL|Online Peer Support Program|"The online peer support program will entail: 1) Informational links; 2) A discussion forum (open to all participants and allowing for asynchronous contact between caregivers \& peer mentors); 3) A weekly live chat; 4) Private messaging (audio, video, and text options); and 5) Ask-a-mentor (A short video/blurb profiling each caregiving mentor will be posted including details such as gender, age, duration of care, relationship to care-recipient, and illness that care-recipient suffers from). Caregiving participants can then self-match to a peer mentor they feel is best-positioned to address their support needs."
40799734|NCT02594930|PROCEDURE|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
40799735|NCT06221943|BEHAVIORAL|Group-based Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in a group setting.
40799736|NCT06221943|BEHAVIORAL|One-on-one Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in an one-on-one setting
40799737|NCT06221943|BEHAVIORAL|ASD Diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
40799738|NCT05369962|DEVICE|Ultrasound|Ultrasound measurements of the Qcsa
40799739|NCT05579847|OTHER|mHealth Smart Phone Application|The mHealth interactive application consists of educational intervention geared towards eligible patients who are receiving Nivolumab/ Pembro with Axitinib/Cabozantinib/Lenvatinib. These patients commonly experience immune-related side effects, higher rate of fatigue, high blood pressure, and palmar-plantar erythrodysesthesia. The educational intervention will consist of multiple modules covering relevant information on treatment and adverse events and provided over a six-week period through an mHealth platform. This educational intervention includes a patient-friendly algorithm for early detection and management of the most common adverse events in patients with advanced renal cell carcinoma receiving combination immunotherapy.
40799740|NCT05579847|BEHAVIORAL|eHEALS digital literacy test|"The eHEALS digital literacy test is an 8-item measure of eHealth literacy developed to measure the participants combined knowledge, comfort and perceived skills at finding, evaluating and applying electronic health information to health problems. The test is measured with a 5-point Likert scale with response options ranging from strongly disagree to strongly agree. Total scores of the eHEALS are summed to range from 8 to 40, with higher scores representing higher self-perceived eHealth literacy."
40799741|NCT05579847|BEHAVIORAL|Weekly Quiz|Participants will take a weekly true/false quiz to assess knowledge of their diagnosis, expected outcome and treatment associated adverse effects at baseline and longitudinally. Each quiz will be administered at the beginning of the week before the weekly educational content is available, then the same quiz will be administered after the educational content is reviewed by the patient. Each quiz will be scored based on the number of correct answers.
40799742|NCT05579847|BEHAVIORAL|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|"The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) comprises 30 single questions, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact) scales assess symptoms. No item occurs in more than one scale.~Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient)."
40799743|NCT05579847|BEHAVIORAL|Patient Post Intervention Survey|The Patient Post Intervention Survey is a 7 question survey to help determine the effectiveness of the mHealth app. 3 questions are open fields for patient feedback, and 4 questions ask how often the app was used, how often the educational module was used and if the patient found it useful.
41003650|NCT04434885|OTHER|Clinical and imaging examination of symptoms and signs suggestive of axial involvement|Clinical and imaging examination including X-rays and magnetic resonance imaging of sacroiliac joints and spine
40799744|NCT03544424|OTHER|No intervention|No intervention
41003651|NCT03688412|DEVICE|Cook lead extraction devices|The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
41003652|NCT04140461|DRUG|Amphotericin B|The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.
41003653|NCT04140461|DRUG|Flucytosine|The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.
41003654|NCT00003694|DRUG|omacetaxine mepesuccinate|Given IV
40799745|NCT00000401|DRUG|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
40799746|NCT02672189|BEHAVIORAL|EVA-Online|Internet-based cognitive behavioral therapy
40799747|NCT00769223|OTHER|medical chart review|
40799748|NCT00769223|OTHER|questionnaire administration|
40799749|NCT00769223|PROCEDURE|quality-of-life assessment|
40799750|NCT00769223|RADIATION|brachytherapy|
40799751|NCT00769223|RADIATION|radiation therapy|
40799752|NCT02289911|OTHER|Didactic training in the FAST|Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
40799753|NCT06526182|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
40799754|NCT04520152|DEVICE|FreeFlowMedical Lung Tensioning Device|Bronchoscopic lung tensioning device implantation
40799755|NCT03233828|BIOLOGICAL|Aldesleukin|500,000 IU in 0.1mL
40799756|NCT03233828|OTHER|Saline|0.1 mL of sterile saline solution (0.9% m/v)
41003655|NCT00003694|DRUG|cytarabine|Given IV
40799757|NCT01628484|OTHER|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
40799758|NCT01628484|OTHER|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
40799759|NCT01628484|OTHER|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
40799760|NCT03370419|BEHAVIORAL|Treatment|Lifestyle intervention fostering the development of behavioral automaticity (habit strength) or dietary and physical activity behaviors.
40799761|NCT03370419|BEHAVIORAL|Usual care|Usual care
40799762|NCT05971368|PROCEDURE|thoracic paravertebal block|"o Group A: Patients will receive ultrasound guided thoraxic paravertebral block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~A high-frequency linear ultrasound probe will be placed between transverse processes from the T4 level (the level of port introduction) in the paramedian plane while patients is in the lateral decubitus position. The transverse processes, superior costotransverse ligaments, and pleura will be well visualized. The block needle (22 gauge) will be advanced until it crosses the superior costotransverse ligament. The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) in the thoracic paravertebral space. Depression of the pleura will be observed as a result of the spread of local anesthetic."
40799763|NCT05971368|PROCEDURE|serratus anterior muscle block|"Group B: Patients will receive ultrasound guided serratus anterior muscle block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~While the patient is in the supine position, a high-frequency linear ultrasound probe will be placed horizontally on the mid-axillary line at the level of 4th or 5th ribs on the side of the block. The serratus anterior, latissimus dorsi, and intercostal muscles will be identified. The block needle (22-gauge) will be advanced below the serratus anterior muscle (SAM) towards the fifth rib (using in-plane technique). The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) between the SAM and the rib. It will be observed that the solution of local anesthesia will spread between the SAM and the rib."
41003656|NCT00003694|OTHER|laboratory biomarker analysis|Correlative studies
41157066|NCT05924048|OTHER|Reducing the Oxygen Concentration From 5% to 2%|Effect of Reducing the Oxygen Concentration From 5% to 2% in arm 1.
40799764|NCT05962645|DRUG|Vapendavir|This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
40799765|NCT03533699|DRUG|Propranolol|
40799766|NCT03533699|DRUG|Placebo Oral Tablet|oral tablets with no active drug
40799767|NCT02628041|RADIATION|Permanent Iodine-125 seed implant|"Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure."
40799768|NCT02628041|RADIATION|High-Dose-rate Prostate Brachytherapy|"High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed."
40799769|NCT02429804|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
40799770|NCT02429804|DRUG|Fludeoxyglucose F-18|Given IV
40799771|NCT02429804|DRUG|Fluorine F 18 Sodium Fluoride|Given IV
40799772|NCT02429804|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
40799773|NCT02429804|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
41003657|NCT01182493|DEVICE|Insulin Pump (Medtronic Minimed Paradigm® VEO)|The pump delivers insulin as specified by the patient
41003658|NCT00688766|DRUG|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
41003659|NCT00688766|DRUG|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
41157067|NCT06350591|OTHER|Immobilization|single-leg immobilization
41157068|NCT06350591|OTHER|Resistance training|Leg extension and leg press; 3 sets of 8-12 reps
41157069|NCT01533181|OTHER|Laboratory Biomarker Analysis|Correlative studies
41157070|NCT01533181|DRUG|Linsitinib|150 mg given orally (PO) twice a day (BID)
41003660|NCT00688766|OTHER|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
41003661|NCT01544530|OTHER|Cold isotonic fluid and central venous hypothermia catheter|20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
41003662|NCT00855309|DRUG|acyclovir sodium|Given IV
40799774|NCT06287541|PROCEDURE|Urine biomarker -Guided without reTURBT|Participants will proceed without reTURBT
41003663|NCT03592121|DRUG|AB-101|Apply approximately 1 hour prior to sexual activity
41003664|NCT03592121|DRUG|Placebo|Apply approximately 1 hour prior to sexual activity
41003665|NCT05022758|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|One of NOAC (Non-vitamin K antagonist oral anticoagulants)
41003666|NCT05022758|DRUG|Warfarin|One of OAC (Oral anticoagulation therapy)
41003667|NCT03892980|DEVICE|Nipple-Sparing Mastectomy|Nipple-sparing mastectomy using da Vinci Surgical Systems.
41003668|NCT02367599|DRUG|Vitamin D Supplement|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
41003669|NCT04672005|DRUG|Folfirinox alternating with Gemcitabine-nab-Paclitaxel|modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
41003670|NCT02189057|OTHER|AssureRx GeneSight genotyping results|
41003671|NCT02189057|OTHER|Treatment as usual|
41003672|NCT02355327|DEVICE|Laselle Kegel Exerciser|Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.
41003673|NCT02355327|BEHAVIORAL|Pelvic floor muscle exercises|Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
41003674|NCT00749931|DEVICE|MarginProbe|Device use to assess margin status of the excised specimen surface.
41003675|NCT00749931|PROCEDURE|Lumpectomy|Standard of care lumpectomy procedure
41003676|NCT02577965|PROCEDURE|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
41003677|NCT02577965|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
41003678|NCT01024543|DRUG|Angiotensin II|Angiotensin II
41003679|NCT01024543|DRUG|Phenylephrine|Phenylephrine
41003680|NCT01024543|DRUG|Placebo|
41003681|NCT03706807|OTHER|Mindfulness-Based Intervention|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
41003682|NCT03706807|OTHER|Cognitive Stimulation|A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
41003683|NCT04409821|BEHAVIORAL|Tele-delivered psychological intervention|The intervention consists of two (or one, if preferred by caregivers) weekly tele-sessions during the ICU stay, lasting up to 30 minutes, and two sessions in the month after discharge from or death in the ICU. Sessions will be conducted via phone-calls or video-conferencing. Therapists will 1) validate caregivers' subjective experience, 2) normalize and psychoeducate about emotional reactions, and 3) offer emotion regulation drawing on contemporary cognitive treatment packages of decentering, acceptance and emotion tolerance. Sessions for bereaved caregivers will include psycho-education about grief, assessment of risk for adverse outcomes and information about available support, if needed. The intervention will be performed based on an intervention manual. The content of the intervention will be continually adapted and tailored to the needs of the participating caregivers by involving all caregivers in co-creating the intervention trough brief post-session interviews.
40799775|NCT05046717|DEVICE|ADAMTS13 Activity Assays|"In this study the measurement of ADAMTS13 activity will be assessed with three different commercial kits:~1. HemosIL AcuStar ADAMTS13 Activity Assay (Instrumentation Laboratory, Bedford, Massachusetts, United States)~2. ELISA, DG-EIA ADAMTS13 Activity (Diagnostic Grifols®, Spain)~3. FRETS-VWF73 for ADAMTS13 Activity Assay~Three kits will be used with all patients."
40799776|NCT03672812|DRUG|Liraglutide|liraglutide 3mg 6/6 hours
41003684|NCT02932904|DRUG|Vortioxetine|Vortioxetine Overencapsulated Tablet
41003685|NCT02932904|DRUG|Paroxetine|Paroxetine Overencapsulated Tablets.
41003686|NCT02932904|DRUG|Placebo|Vortioxetine Placebo-matching Capsules.
41003687|NCT00782262|DIETARY_SUPPLEMENT|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
41003688|NCT00616850|PROCEDURE|Continuous femoral catheter block|A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
41003689|NCT00616850|DRUG|Lidocaine|Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
41003690|NCT00616850|OTHER|Preservative free normal saline|Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
41003691|NCT05886569|DEVICE|DIGIPREDICT Physiopatech|Application of the DIGIPREDICT Physiopatch investigational device
41157071|NCT01533181|OTHER|Pharmacological Study|Correlative studies
41003692|NCT03111654|DIAGNOSTIC_TEST|Compare the risk of a vascular event|"Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events."
41003693|NCT02263066|BIOLOGICAL|BAY14-2222_Kogenate-FS FVIII|Depends on Doctor's decision
41473823|NCT01491308|OTHER|Red blood cells transfusion|This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
41473824|NCT06227702|OTHER|Fluid management according to Venous Excess Ultrasound (VExUS) Score|Management of furosemide intravenous infusion according to VeXus results
41473825|NCT00149149|OTHER|Zinc Carnosine coadministered with Indomethacin|
41473826|NCT00149149|OTHER|Placebo coadministered with Indomethacin|
41003694|NCT04035304|OTHER|Mindfulness Coach|"Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises."
41003695|NCT03974230|OTHER|Collection of datas|Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
41003696|NCT03974230|BIOLOGICAL|blood sample|Blood sample will be performed (genetic analyses).
41003697|NCT03974230|OTHER|slit lamp examination|Slit lamp examination will be performed.
41003698|NCT01600586|DEVICE|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
41003699|NCT03799484|DRUG|Botulinum toxin type A|Botulinum toxin type A will be administered to both sides
41003700|NCT03799484|DRUG|2.5% lidocaine/2.5% prilocaine|2.5% lidocaine/2.5% prilocaine will be applied to one side of the forehead
41003701|NCT03799484|DEVICE|petrolatum ointment|petrolatum ointment will be applied to one side of the forehead
41473827|NCT02262559|DRUG|BIBR 277 tablet|
41473828|NCT02262559|DRUG|BIBR 277 capsule|
41473829|NCT06035484|OTHER|Seat height|Seat height of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
41003702|NCT05539807|BEHAVIORAL|Mindful Eating Conscious Living|"MECL is a 8 week mindfulness-based group intervention. Each session is of 2.5-3 hours duration. During the sessions, theories about eating-related difficulties in general are presented, participants are guided in mindfulness practices and participants who want to share their experiences in the group can do so. Topics include: (1) What is mindfulness, why and how can we use mindfulness in relation to eating (2) slowing down, taking breaks and noticing different types of hunger (e.g. physical hunger and the hunger for comfort - heart hunger) (3) working with satiety and satisfaction (4) becoming aware of patterns associated with one's eating behaviors, (5) awareness of feelings and bodily sensations (6) Food and mood (7) craving, and finally (8) working with heart hunger and emotional eating. Six to 10 participants participated in each group."
41003703|NCT02659215|DEVICE|Hyalofast|Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
41157072|NCT01533181|DRUG|Topotecan Hydrochloride|1.5 mg/m\^2 intravenously (IV) or 2.3 mg/m\^2 orally (PO)
41473830|NCT06035484|OTHER|Seat inclination|Seat inclination of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
41473831|NCT01838187|RADIATION|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
41473832|NCT01838187|DRUG|Vorinostat|180 mg/m2 orally once daily on days 0 to +13
41473833|NCT03181048|PROCEDURE|Periacetabular osteotomy|The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.
41473834|NCT03181048|PROCEDURE|Periacetabular osteotomy with hip arthroscopy|An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
41473835|NCT01362426|DRUG|paliperidone palmitate|Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
41473836|NCT04737850|DRUG|Hetrombopag|Thrombopoietin receptor agonist
41473837|NCT04737850|DRUG|Placebo|Placebo with no active pharmaceutical ingredient
41003704|NCT02659215|PROCEDURE|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
41003705|NCT04671810|BIOLOGICAL|Elizaria®|Elizaria® will be prescribed by the Physician according to the actual SMPC.
41003706|NCT05827627|OTHER|simulation|Midwifery student directing the birth of a fetus with frank breech presentation.
41003707|NCT06484777|DRUG|SHR-9539 for injection|SHR-9539 for dose escalation/dose extension
41003708|NCT00797953|DRUG|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
41003709|NCT02386943|DRUG|Sitagliptin|100mg po once.
41003710|NCT02386943|DRUG|Saxagliptin|5mg po once.
41003711|NCT02386943|DRUG|Blank control|No medication is taken.
41003712|NCT03949829|DIAGNOSTIC_TEST|Cardiovascular CT|Cardiac and cardiovascular non-contrast and contrast CT
41003713|NCT01640730|DRUG|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
41003714|NCT06072547|OTHER|Access to all varieties of on! 4mg nicotine pouches (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original)|Access to all varieties of on! 4mg nicotine pouch products (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original), throughout the trial.
41003715|NCT06072547|OTHER|Access to Original on! 4mg nicotine pouches|Access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
41003716|NCT06072547|OTHER|Non-Flavored then complete flavor on! nicotine pouches|Access to non-flavored (i.e., Original) on! 4mg nicotine pouch products during the first 3 weeks and then access to all varieties (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original) of on! 4mg nicotine pouch products during the rest of the trial
41003717|NCT01170728|DEVICE|Coloplast Virtue® Male Sling|The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
41003718|NCT03516669|DRUG|Clarithromycin|Twenty patients receive intraluminal clarithromycin eradication of H. pylor.
41152044|NCT03953378|OTHER|Multi-parametric Flow Cytometry analysis on patients and healthy donors samples|"Collection of venous blood (16 mL) and synovial fluid (when available) samples, for each patient, at inclusion and in the frame of the usual medical follow-up at 3 months and between 6 and 12 months, before the onset of MTX (untreated patients) or during the course of MTX treatment (MTX-treated patients).~Collection of anonymous healthy donors blood samples, age- and sex-matched, obtained from the Etablissement Français du Sang.~Multi-parametric Flow Cytometry analysis was performed on these samples to assess CD73 expression on total memory T cells and within T helper lymphocyte subsets, their cytokine production and AMPase functions. For FoxP3 intracellular staining, cells were treated using the FoxP3 Fixation and Permeabilization kit (Life Technologies), according to manufacturer instructions. Stainings were analyzed on a LSR-Fortessa™ (BD Biosciences) with conserved settings throughout the entire study and data were analyzed using FlowJo™ Software (Tree Star v10.4)."
41316468|NCT05584930|OTHER|Collection of blood sample|"* Visit 1 : At inclusion (day 1 of chemotherapy treatment)~* Visit 2 : Onset of aplasia~* Visit 3a : day 1 of the 1st febrile aplasia~* Visit 3b : day 3 of the 1st febrile episode~* Visit 3c : day 8 of the 1st febrile episode~* Visit 4a : second febrile episode (after 7 days)~* Visit 4b : day 3 of the second febrile episode (after 7 days)"
41316469|NCT03935165|DRUG|Indocyanine Green|"0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green®~- Indocyanine Green is administered Intravenously"
41316470|NCT06043141|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
41003719|NCT03516669|DRUG|Amoxicillin, Clarithromycin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
41003720|NCT03580603|OTHER|Visualization tool|Visual representation of past microbiological culture data
40799777|NCT06519240|RADIATION|18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography (18F-FDG PET CT)|Each participant will prepare for their study PET CT by following an initial 18 hour of zero carbohydrate diet followed by another 18 hours of fasting (water allowed). After confirming preparation, each study participant will have a single rest rubidium and 18F-FDG PET CT scan.
41003721|NCT00360334|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
41003722|NCT00360334|DRUG|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
41152045|NCT02592486|BIOLOGICAL|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
41003723|NCT03762655|DEVICE|Neuro-Spinal Scaffold|"The investigational product (Neuro-Spinal ScaffoldTM or Scaffold) is a porous bioresorbable polymer scaffold comprised of a synthetic biomaterial, poly(lactic-co-glycolic acid)-b-poly(L-lysine) (PLGA-PLL). The Scaffold is cylindrical in shape (3 mm diameter) and is available is three lengths (6 mm, 8 mm, 10 mm) for optimal fit in the intraspinal lesion cavity.~Based upon pre-clinical testing, the Scaffold is expected to be resorbed from the site of implant within 4 to 8 weeks."
41003724|NCT03072212|OTHER|Observational study|No intervention
41003725|NCT01524770|BIOLOGICAL|Dulaglutide|Administered by subcutaneous (SC) injection
41003726|NCT00853177|PROCEDURE|MEOPA inhalation|N2O of 50% and 50% O2
41003727|NCT00853177|PROCEDURE|xylocaine|Ampoule-bottle of 20 ml
41003728|NCT04831775|BEHAVIORAL|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice and will be held over 8 weeks. The classes will be taught by a GRA. Classes 1 \& 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 \& 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. Each online class will follow the same format: (1) introduction/revisiting content from the previous class; (2) review of progress on computer exercises; (3) practicing cognitive strategies in class; and (4) a weekly topic. The GRA will also prescribe exercises for the following weeks.
41003729|NCT04831775|BEHAVIORAL|Brain Games|The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Participants will only need a computer, smart phone, or tablet with Internet access to securely log onto the website. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on.
41003730|NCT03405142|DRUG|Panitumumab-IRDye800|Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is \< 1/12 of the therapeutic dose.
41003731|NCT03405142|DRUG|Lymphoseek|Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
41316471|NCT06043141|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
41316472|NCT06043141|DIAGNOSTIC_TEST|Pressure pain threshold|Pain pressure threshold (PPT) is used to measure deep muscular tissue pain sensitivity.
41316473|NCT06483490|OTHER|This is a cross-sectional, non pharmacological study|Measurement of immune checkpoint levels, mitochondrial dysfunction, pollutant concentrations and G-quadruplex levels and their correlation in all enrolled subjects.
41473838|NCT05031247|OTHER|Wellbeing Program|The community navigator program was developed during a three-phase community-based participatory research project that aims to examine emotional/mental health needs and address access to mental health services among immigrants and refugees from Muslim-majority countries.
41473839|NCT03519282|DEVICE|comfilcon A multifocal toric lens|contact lens
41003732|NCT06251856|BEHAVIORAL|lymphedema education program|On post-op day 2, patients will receive Symptom Management Model-Based Lower Extremity Lymphedema Training. Brochures will be introduced and delivered to the patient.
41003733|NCT04905251|DRUG|Mifepristone-Misoprostol|Non interventional design.
41152046|NCT02592486|BIOLOGICAL|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
41152047|NCT02326493|DEVICE|Cardiac Resynchronization Therapy|A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
41152048|NCT03845517|DRUG|Placebo|Placebo
41152049|NCT03845517|DRUG|PF-06700841 15 mg|PF-06700841 15 mg
41152050|NCT03845517|DRUG|PF-06700841 30 mg|PF-06700841 30 mg
41152051|NCT03845517|DRUG|PF-06700841 45 mg|PF-06700841 45 mg
41152052|NCT00992654|DRUG|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
41152053|NCT05934370|OTHER|Home-Based Environmental Interventions (HEI)|"Housing Specialist will conduct an environmental home assessment to identify asthma triggers.~• The participant will receive the following Breath Easy at Home Kit Products:~* HEPA filtered upright vacuum cleaner~* HEPA-filtered air purifier~* Hypoallergenic latex free mattress and pillow covers~* Healthier household cleaners~* Non-toxic pest control devices for rodent control~* Safe products to locate and kill roaches."
41152054|NCT01090856|PROCEDURE|Pre-dilation side branch|Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
41152055|NCT02239666|OTHER|NIS|This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
41152056|NCT04717375|DRUG|SAR444881|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
41152057|NCT04717375|DRUG|Pembrolizumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
41152058|NCT04717375|DRUG|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
41152059|NCT04717375|DRUG|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
41152060|NCT04717375|DRUG|Pemetrexed|Pharmaceutical form: Powder for concentrate for solution for infusion or concentrate for solution for infusion; Route of administration: Intravenous
41157073|NCT05800483|BEHAVIORAL|Healium|web-based platform to elicit patients' preferences about prostate cancer treatment and designed for low health literature populations
41473840|NCT03519282|DEVICE|omafilcon A Multifocal Toric Lens|contact lens
41473841|NCT01048463|DRUG|Nutriall|The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
41473842|NCT01048463|DRUG|LDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
41003734|NCT05873569|BEHAVIORAL|Mothers and Babies Virtual Group Intervention|The Mothers and Babies Virtual Group (MBVG) intervention is a 10-session intervention built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and are led by a trained MBVG facilitator.
41003735|NCT03780153|OTHER|No intervention|Observation study. No intervention
41003736|NCT00379470|DEVICE|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
41473843|NCT01048463|DRUG|Placebo|The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
41473844|NCT01048463|DRUG|HDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
41473845|NCT01048463|DRUG|Chemotherapy|Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
41473846|NCT06200584|DRUG|Risperidone|Antipsychotic Agent
41473847|NCT06200584|DRUG|Olanzapine|Antipsychotic Agent
41473848|NCT06200584|DRUG|Quetiapine|Antipsychotic Agent
41473849|NCT06200584|DRUG|Risperidone and Vitamin D and Vitamin E|vitamin
41473850|NCT06200584|DRUG|Olanzapine and Vitamin D and Vitamin E|vitamin and Antipsychotic agent
41473851|NCT06200584|DRUG|Quetiapine and Vitamin D and Vitamin E|Vitamin and Antipsychotic agents
41473852|NCT01028911|DRUG|PF-03654746|PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
41003737|NCT04222738|DIETARY_SUPPLEMENT|GINOFF1|The intervention lasted for six weeks and consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day.
41003738|NCT04188262|COMBINATION_PRODUCT|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
41003739|NCT00670228|DRUG|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
41003740|NCT00670228|DRUG|Insulin Glulisine (Apidra)|"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
41152061|NCT03964545|BEHAVIORAL|neurofeedback|Patients are instructed to reduce amygdala activation by means of down-regulating the EFP. An auditory feedback interface is used with the instruction to down-regulate volume of a jingle, reflecting intensity of EFP.
41003741|NCT00670228|DRUG|Standard Therapy|Standard insulin therapy titrated to blood sugar control
41003742|NCT04307485|DRUG|Ticagrelor|90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT
41003743|NCT03982329|DEVICE|navigated repetitive transcranial magnetic stimulation|
41003744|NCT03982329|PROCEDURE|physical therapy|
41003745|NCT02300324|DIETARY_SUPPLEMENT|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
41003746|NCT02300324|DIETARY_SUPPLEMENT|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
41152062|NCT05834647|DRUG|Prilocaine 2%|50 mg prilocaine 2% (2.5 mL volume) before undergoing cystoscopy procedure
41152063|NCT05834647|DRUG|Hyperbaric Lidocaine 5%|50 mg Hyperbaric Lidocaine 5% (1.0 mL volume) before undergoing cystoscopy procedure
41152064|NCT01198899|OTHER|blood sampling|Blood sampling will be used.
41473853|NCT01028911|DRUG|Placebo|"Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator."
41473854|NCT04836520|DRUG|SHR6390+anatrozole|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
41473855|NCT02568007|DRUG|Cyproheptadine|
41473856|NCT02971722|DRUG|JY09|2mg/1ml/bottle
41473857|NCT02971722|DRUG|Placebo|1ml/bottle
41473858|NCT06118502|BEHAVIORAL|Switching to a different medication|Participants will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again at week 4.
41473859|NCT06118502|BEHAVIORAL|Continued use of the same medication|Participants will receive four additional weeks of the same medication (varenicline or NRT) with instructions to try to quit again at week 4.
41473860|NCT06118502|BEHAVIORAL|Switching to a harm reduction tobacco product|Participants will receive four weeks of e-cigarette products with instructions to switch completely at Week 8
41473861|NCT05601778|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
41473862|NCT05601778|DRUG|placebo|the placebo comparator of study
41473863|NCT04618978|PROCEDURE|PSG and actigraphy recording|"Gold standard: electromyographic recording of tibialis anterior muscle during full night polysomnography (PSG).~The new generation actigraphs devices Actiwatch will be combined to PSG as a screening tool: MotionWatch will be placed on the dorsum of feet to record)."
41003747|NCT02300324|DIETARY_SUPPLEMENT|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
41003748|NCT03587610|BIOLOGICAL|Remedial vaccination|"* if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~* if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
41003749|NCT06355258|DRUG|Troxerutin|Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
41003750|NCT06355258|DRUG|Placebo|Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
41003751|NCT06355258|DRUG|placebo + low molecular weight heparin|4000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
41003752|NCT06355258|DRUG|troxerutin + low molecular weight heparin|4000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
41316474|NCT04253041|BEHAVIORAL|Effects of Instagram Exposure on Lifestyle Satisfaction|Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
41316475|NCT05415852|DEVICE|Laser|Laser
41003753|NCT02849548|DRUG|suvorexant|First in class orexin antagonist approved by the FDA for the treatment of insomnia
41003754|NCT02849548|OTHER|placebo|Pill with inactive ingredients
41003755|NCT00615563|BEHAVIORAL|NO BI Drug administered|
41003756|NCT03867513|OTHER|Multimodal imaging|All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.
41003757|NCT05982535|DEVICE|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
41003758|NCT00093457|DRUG|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
41003759|NCT00779675|BIOLOGICAL|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
41003760|NCT02547129|DEVICE|Static Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
41316476|NCT03400137|DIAGNOSTIC_TEST|Increasing of intraocular pressure (IC)|intraocular pressure will be increased using an ophthalmodynanometer
41316477|NCT06033950|DRUG|Finerenone|Oral finerenone.
41316478|NCT06033950|DRUG|Placebo|Matching oral placebo.
41316479|NCT04717193|DRUG|Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine|Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
41003761|NCT02547129|DEVICE|Articulating Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
41316480|NCT04717193|PROCEDURE|Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine|Infiltration of local anesthetic at incision sites.
41003762|NCT01595360|DRUG|Placebo|It is applied directly to the bleeding site after tooth extraction
41003763|NCT01595360|DRUG|TT-173|It is applied directly to the bleeding site after tooth extraction
41003764|NCT02052739|DRUG|SAGE-547|Solution for injection for IV infusion
41316481|NCT03627858|DRUG|beclomethasone / formoterol / glycopyrronium|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
41316482|NCT03314714|PROCEDURE|Acute bout of endurance exercise|Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
41316483|NCT05108220|DIETARY_SUPPLEMENT|Cannabidiol (CBD)- containing consumer products|Oils or capsules containing CBD which could be purchased commercially within the U.S.
41316484|NCT01354353|DRUG|LY2140023|Administered orally
41316485|NCT01354353|DRUG|Aripiprazole|Administered orally
41316486|NCT00747617|DRUG|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
41316487|NCT01379495|BEHAVIORAL|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
41316488|NCT01018719|DEVICE|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
41316489|NCT05739877|DRUG|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
41316490|NCT05739877|DRUG|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
41316491|NCT01702662|DEVICE|Photopill treatment|2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
41003765|NCT04187196|DRUG|Propofol|Propofol will be given at an initial dose of 0.8 mg/kg followed by 20 mg every minute after 2 minutes, if adequate sedation is not achieved
41003766|NCT04187196|DRUG|Methohexital|Methohexital will be given at an initial dose of 0.5 mg/kg, followed by 10 mg every minute after 2 minutes, if adequate sedation is not achieved
41003767|NCT03950128|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|"This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The skills followed the ABCDE acronym. ABCDE stands for awareness, breathing, checking in with your feelings and thoughts, describing your experience, and expressing what you want to change. Students learned about the skills and had opportunities to practice them as well."
41003768|NCT03950128|BEHAVIORAL|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions. The selected materials covered (a) what dating abuse is, (b) the pattern of abuse and, (c) technology and dating abuse. The curriculum is interactive and includes handouts, activities, and discussion.
41003769|NCT03341130|DEVICE|Mandibular Repositioning Splint|The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.
41003770|NCT03341130|DEVICE|Mandibular Advancement Oral Appliance|Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
41003771|NCT04281381|DIAGNOSTIC_TEST|Cross-sectional imaging|MRI with gadolinium contrast will be the imaging modality of choice. In patients with contraindications to MRI who instead undergo baseline evaluation by CT scan, tumor evaluation will be by serial CT scans with IV contrast throughout the study period.
41003772|NCT03061539|DRUG|Nivolumab & Ipilimumab|"Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent"
41003773|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
40799778|NCT03786224|BEHAVIORAL|Contingency Management|Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
41316492|NCT03896113|DRUG|Celecoxib 200mg capsule|Patient confirmed with endometrial cancer will received twice daily 200 mg Celecoxib, 15 days before the surgery.
41003774|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
41003775|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
41003776|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
41003777|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
41003778|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
41316493|NCT04419324|DEVICE|transoral flexible endoscope with magnifying narrow band imaging|To use an esophago-gastroscopy endoscope (OGD) with Narrow Band Imaging (NBI) passed transorally and retroflexed into the nasopharynx to view the nasopharynx with increased magnification and clarity for the diagnosis of nasopharyngeal carcinoma.
40799779|NCT03198767|DRUG|LIK066|LIK066 50 mg tablets. Open-label, bulk, blister-pack.
41316494|NCT00134225|DEVICE|Muscle Pattern Recognition (MPR)|
40799780|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 50%|50% carbohydrate in breakfast meal
40799781|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 25%|25% carbohydrate in breakfast meal
40799782|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 8%|8% carbohydrate in breakfast meal
40799783|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 0%|0% carbohydrate in breakfast meal
40799784|NCT03198767|DIETARY_SUPPLEMENT|Psyllium|Powder 6 grams
40799785|NCT03198767|DIETARY_SUPPLEMENT|Calcium carbonate|Liquid 1 gram (4 mL equivalent sugar free)
40799786|NCT02641756|OTHER|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
41003779|NCT01395940|DRUG|KLH-2109|
41316495|NCT05917210|BEHAVIORAL|Standard TB-EC|Standard TB-EC by healthcare workers
41316496|NCT05917210|BEHAVIORAL|Peer navigation strategy for TB-EC|multi-component, peer-navigation strategy for TB-EC
41316497|NCT03709524|DEVICE|Airtraq + fiberoptic|video laryngoscope with a monitor
41316498|NCT03709524|DEVICE|Airtraq|video laryngoscope with a monitor
41473864|NCT00965016|PROCEDURE|hypothermia|Core temperature --\> 34.9℃ within 30 min --\> 33.5℃ within 120min --\> 33℃for 24 H Decrease temperature in 0.9℃/hour
40799787|NCT01162954|DRUG|DA-6034|
40799788|NCT01162954|DRUG|Placebo|
40799789|NCT04177004|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
41003780|NCT01395940|DRUG|KLH-2109|
41003781|NCT04050111|BIOLOGICAL|Stromal-vascular fraction|Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
41316499|NCT03709524|DEVICE|Nasotracheal Airtraq + styletted tube|video laryngoscope with a monitor
41003782|NCT00805766|DRUG|TA-650|(1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
41003783|NCT01464515|DEVICE|H-Coil Deep TMS|this group will receive high frequency treatment of deep TMS with 10Hz
41003784|NCT01464515|DEVICE|SHAM Coil TMS|this group will receive SHAM treatment of deep TMS
41003785|NCT03790826|DEVICE|cystoscopy|Comparison of bladder mucosa via cystoscopy.
41003786|NCT02972528|BIOLOGICAL|Platelet Lysate|Direct injection of allogenic Platelet Lysate
41003787|NCT02972528|BIOLOGICAL|Platelet Poor Plasma|Direct injection of allogenic Platelet Poor Plasma
41003788|NCT00144586|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks
41003789|NCT06277115|DEVICE|Continuous positive airway pressure (CPAP)|Nocturnal continuous positive airway pressure therapy is the gold standard treatment for symptomatic OSA. It provides positive pressure via a nasal or oronasal mask to prevent upper airway collapse during sleep.
41003790|NCT00581958|OTHER|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
41003791|NCT06267612|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
41003792|NCT00208377|DEVICE|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
41003793|NCT06391866|OTHER|extracorporeal circulation|extracorporeal circulation during cardiosurgical operation
41473865|NCT05914545|DRUG|FZ-AD004|"Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles."
41473866|NCT02669160|DEVICE|PC Innowalk|
41473867|NCT02669160|DEVICE|Conventional passive stander|
41473868|NCT02285348|PROCEDURE|Lumbar puncture|Lumbar puncture is done according to general practice
41473869|NCT04654897|DRUG|[14C]-NT-814|120 mg radioactive labeled elinzanetant (\[14C\]-NT-814) oral suspension containing NMT (not more than) 5.6 MBq (megabecquerel) \[14C\].
40799790|NCT04177004|DRUG|Cyclophosphamide|Given IV
41003794|NCT03806582|DRUG|Norepinephrine|intervention with norepinephrine to reach a MAP of 85 mmHg
41003795|NCT06442735|OTHER|intrapartum ultrasound|In IPUS group, the patient's labor was observed by intrapartum ultrasound.
41003796|NCT06442735|OTHER|vaginal examination|In VE group, the patient's labor was observed by vaginal examination.
41003797|NCT02410720|OTHER|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
41473870|NCT06616298|OTHER|Assessing and Listening to Individual Goals and Needs (ALIGN)|Assessing and Listening to Individual Goals and Needs (ALIGN). ALIGN utilizes the skills of palliative care social workers (PCSWs) trained in family and systems-level theory to address changing preferences for care, family distress, and to facilitate communication across care transitions to improve care aligned with preferences.3 The intervention is implemented virtually in community SNFs and follows patients for 45 days after SNF discharge to reflect real-world patient flow.
41473871|NCT01343069|PROCEDURE|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
41473872|NCT01095523|PROCEDURE|Laparotomy+ HIPEC +/- CRS|
41473873|NCT03618329|OTHER|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
41473874|NCT05391659|DEVICE|deep learning|a form of artificial intelligence (AI), has been introduced for automated analysis of images
41473875|NCT05391659|DIAGNOSTIC_TEST|remote grading of fundus images|referrable cases identified by DR AI tool will be remotely graded by a human
41473876|NCT05391659|DIAGNOSTIC_TEST|gold standard|examination by ophthalmologist
41473877|NCT00373425|DRUG|Erlotinib|150 mg tablet
40799791|NCT04177004|DRUG|Etoposide|Given IV
40799792|NCT04177004|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FTBI
40799793|NCT04177004|DRUG|Goat Milk|Given human lysozyme goat milk PO
40799794|NCT04177004|BIOLOGICAL|Palifermin|Given IV
41003798|NCT02410720|OTHER|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
41473878|NCT00373425|DRUG|Placebo|Placebo tablet
41473879|NCT04473716|DRUG|Toripalimab|Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22
40799795|NCT04177004|DRUG|Sirolimus|Given PO
40799796|NCT04177004|DRUG|Tacrolimus|Given IV and PO
40799797|NCT04234386|RADIATION|GammaPod Radiation|The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.
40799798|NCT03702062|DIAGNOSTIC_TEST|6 Minute Walk Test Smart phone Application|The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
41003799|NCT02410720|OTHER|Explanation of paper and application instructions|The research fellow will explain instructions to patients
41003800|NCT02410720|OTHER|Picoprep solution|
41003801|NCT00284531|DRUG|Daclizumab|
41003802|NCT06457594|OTHER|Questionnaire|EORTC QLQ-INFO25 EORTC QLQ - H\&N43 and EORTC QLQ-C30
41473880|NCT04473716|DRUG|Paclitaxcel|Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22
41473881|NCT04473716|DRUG|Cisplatin|Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22
41473882|NCT04473716|PROCEDURE|Radical surgery|Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.
41473883|NCT04473716|RADIATION|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.
41473884|NCT03653026|DRUG|Placebo|Tablet for oral administration
41473885|NCT03653026|DRUG|Upadacitinib|Tablet for oral administration
41316500|NCT06461546|DRUG|Imlifidase|"* Imlifidase (POD0, pre-transplantation), imlifidase, 0.25 mg/kg over a period of 15 minutes, prior to transplantation.~* Dose Adjustment Criteria~FC-XM screening and single antigen will be performed after 6 hours of imlifidase infusion, It will take 3 hours to obtain the results, respectively:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - 2nd Imlifidase infusion will be required (imlifidase dose: 0.25mg/Kg).~FC-XM screening and single antigen will be performed after 2 hours of the 2nd Imlifidase infusion:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - The scheduled kidney transplant will be canceled."
41003803|NCT03202004|DRUG|GSK2894512 1% cream|1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
41003804|NCT03202004|DRUG|Vehicle cream|Vehicle cream will be provided in tubes labeled in compliance with country requirements.
41003805|NCT00706836|DRUG|Pregabalin 50mg|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
41003806|NCT00706836|DRUG|Pregabalin 200 MG|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
40799799|NCT04426175|DEVICE|2D and 3D cutting method using a low energy Femtosecond laser LDV Z8 for LASIK flap cutting|2D and 3D cutting methods were randomly used in same subjects
40799800|NCT00817765|DRUG|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
41003807|NCT00706836|DRUG|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
41003808|NCT00401011|DRUG|Perifosine|"Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks."
41003809|NCT00401011|DRUG|Bortezomib|Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
41003810|NCT00401011|DRUG|Dexamethasone|Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
41003811|NCT03422991|OTHER|Blood sampling and Quality of life questionnaire.|Blood sampling and Quality of life questionnaire.
41003812|NCT04666090|DRUG|Carillizumab|administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.
41003813|NCT04666090|PROCEDURE|Esophagectomy|Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma
41003814|NCT04666090|OTHER|Samples|Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use
41003815|NCT01470391|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with Ropivacaine
41003816|NCT01470391|PROCEDURE|Femoral Nerve Block|US-guided Femoral Nerve Block with Ropivacaine
41003817|NCT03102918|DRUG|Cannabidiol|Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
41003818|NCT03102918|DRUG|Placebo|Participants will receive placebo over a 6-week treatment period.
41003819|NCT06467266|DIAGNOSTIC_TEST|Acute Haemodynamic Study|Multisite temporary pacing
41316501|NCT05359406|COMBINATION_PRODUCT|a combination therapy including tislelizumab|"For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx. Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w, i.v). For patients with RAS or BRAF mutation, chemotherapy adopts FOLFOX+BEV plan. For patients without RAS or BRAF mutation, chemotherapy adopts FOLFIRI+CET plan.~Patients will be followed for safety during the study. The safety follow-up period is defined as 90 days after the last dose of tislelizumab. Safety related data will be collected from the time of signing the informed consent until the end of the safety follow-up period or the start of new therapy."
41316502|NCT01733901|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
41316503|NCT01733901|PROCEDURE|PCI|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
41316504|NCT00234572|DRUG|Lanreotide (Autogel formulation)|
41316505|NCT05225220|DEVICE|Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)|Electrode clip will be placed on the left ear.
41316506|NCT00510224|DRUG|Sandostatin|Sandostatin 30mg intramuscular every 28 days
41003820|NCT02252627|DRUG|Administration of phenylephrine|Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
41003821|NCT02252627|OTHER|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
41003822|NCT02252627|OTHER|Contrast enhanced ultrasound scan|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
41152065|NCT03508882|DRUG|Botulinum Toxin Type A 100Unit/Vial (Product)|Botulinum Toxin Type A 100Unit/Vial (Product) comes as a dry powder and is routinely reconstituted with Saline Solution for Injection
41003823|NCT02252627|DRUG|Administration of ephedrine|Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
41003824|NCT03766178|DRUG|Nimotuzumab + SHR-1210|"SHR-1210: 200 mg/time, intravenous injection, q2W continuous medication, a course of treatment needs 28 days. The cumulative longest medication period is 2 years.~Nimotuzumab: 200 mg/time, intravenous injection, administered on the 1st and 8th days of each cycle, every 2 weeks is one cycle."
41003825|NCT04447092|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)
41003826|NCT04447092|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)
41003827|NCT04447092|DRUG|Pembrolizumab|Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)
41003828|NCT04447092|DRUG|Oxaliplatin|Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)
41003829|NCT04447092|DRUG|Leucovorin|Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
41003830|NCT04447092|DRUG|Irinotecan|Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)
41003831|NCT04447092|DRUG|5FU|5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
41003832|NCT00159588|DRUG|Betablockers or other preventive drugs based on primary headache type|Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
41003833|NCT01888497|DRUG|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
41003834|NCT01888497|DRUG|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
41003835|NCT01888497|DRUG|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
41003836|NCT01888497|DRUG|Placebo|Oral, prior to bedtime on the night before performance testing
41003837|NCT05605262|DRUG|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
41316507|NCT00695240|DEVICE|Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
41316508|NCT04158986|BEHAVIORAL|Nurse-driven post-discharge intervention|"Home visits based on the concepts of Family Nursing:~The participants will receive three home visits by a nurse who is trained in the Family Nursing principles during the first 12 weeks after discharge.~The home visits will comprise of:~* Filling in the Chronic Liver Disease Questionnaire.~* Therapeutic conversations including drawing and review of genogram and eco-map.~* Information about- and help to initiate contact to relevant municipal offers.~* Evidence-based information based on the patient's current problems or symptoms, base-line knowledge and receptiveness.~Follow-up telephone calls:~• After the first 12 weeks participants will be followed-up by telephone monthly during the following 12 weeks.~Pamphlet:~• All participants will receive a pamphlet with brief information regarding preventive measures and early signs of decompensation as well as relevant contact details. The pamphlet will be handed out before discharge"
40799801|NCT00817765|DRUG|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
40799802|NCT00817765|DRUG|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
40799803|NCT05068323|DIAGNOSTIC_TEST|Digital electroencephalography (EEG) for an hour (16 channels)|Digital electroencephalography (EEG) for an hour (16 channels)
40799804|NCT02572505|DRUG|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
40799805|NCT06468891|OTHER|Incontinence Symptom Severity Index|"* The ISSI consists of eight items that assess different aspects of urinary incontinence symptoms, including emptying difficulties, nocturia, daytime frequency, stress incontinence, urge incontinence, leakage with activity, and pad use.~* Each item is scored on a scale of (0 to 3) or (0 to 4), depending on the severity of the symptom. Higher scores indicate more severe symptoms.~* The total ISSI score is obtained by summing the scores of all eight items, resulting in a range of 0 to 32 or 0 to 40, depending on the version used.~* The severity of urinary incontinence symptoms can be categorized based on the total ISSI score"
41003838|NCT06019416|BEHAVIORAL|culturally tailored mindfulness-positive psychological intervention|"This 3-week culturally tailored mindfulness-positive psychological intervention instructs techniques to enhance positive emotions and meditation exercise lasting approximately 30 minutes. The culturally tailored mindfulness-positive psychological intervention consists of four modules: 1) noticing positive events, 2) amplifying positive events, 3) gratitude, and 4) mindfulness and meditation. This 3-dimensional software includes gamification features, including a virtual living room, Japanese garden, art gallery, and meditation garden.~A private office and/or space was utilized to implement the culturally tailored mindfulness-positive psychological intervention for older Korean Americans/immigrants, provided by the recruitment sites such as non-profit organization and church. The private room at the sites had a desktop (or laptop) computer, a virtual reality device (Oculus Quest 2), a chair, and a desk."
41316509|NCT00455130|DRUG|Inhaled mannitol|
41473886|NCT04805619|DEVICE|Biomime Morph, a tapered drug eluting stent (DES) with hybrid design|Biomime Morph DES is a cobalt-chromium stent, with strut thickness of 65 µm, a hybrid cell design (closed cells in the extremity and open cells in the middle) and a conic shape, where the proximal part of the stent is 0.5 mm larger than the distal part (Table 1). In addition, the Biomime Morph elutes Sirolimus from a biodegradable polymer matrix.
41003839|NCT03537118|PROCEDURE|Fluoroscopic + Ultrasound Guidance|Fluoroscopic Guidance Alone
41003840|NCT05498558|OTHER|No intervention.|No intervention.
41003841|NCT00802022|DEVICE|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
41003842|NCT00994448|DRUG|Bupropion SR 150mg tabs|Bupropion SR 150mg tabs (Zyban) twice daily
41003843|NCT00994448|DRUG|Placebo tablets|One placebo tablet twice daily
41003844|NCT00534235|PROCEDURE|Decompression|Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain
41003845|NCT00534235|DEVICE|Posterolateral Fusion and Implantation of Pedicle Screws|
41473887|NCT05717244|DEVICE|2WIN-S|Determining pupil diameter by 2WIN-S
41473888|NCT05717244|DEVICE|OPD|Determining pupil diameter by OPD
40799806|NCT06468891|OTHER|Force platform|"Use the provided software or tools to analyze the recorded force data, including Step Cycle Duration (ms), Time of Contact (ms), Swing Duration (ms), Single Step Duration (ms), Double Support Duration (ms), Initial Contact (ms) , Loading Response (ms), Mid Stance (ms), Terminal Stance (ms), Step Cycle Length, Half Step Length for left and right lower limbs.~* Interpret the data to draw conclusions about the forces exerted during the subject's movements or activities."
40799807|NCT06468891|OTHER|The STT three-dimensional motion analysis (3DMA) system|The STT three-dimensional motion analysis (3DMA) system (STT Systems Company, Zuatzu Business Park, Easo Building, 2nd Floor, San Sebastián, Spain) was used for the assessment of spatiotemporal characteristics of gait. It is an indoor optical system that consists of four cameras, fifteen markers, and computer software for automatic three-dimensional motion capture and analysis. CLINICAL 3DMA V.6.11 is professional software with highly accurate marker tracking. The STT Helen Hayes protocol was used for the gait analysis in this study.
40799808|NCT00740441|DRUG|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
40799809|NCT04506593|OTHER|no intervention|
40799810|NCT02520388|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
40799811|NCT02520388|DRUG|Placebo|
40799812|NCT01713582|DRUG|OTX015/Birabresib|OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
40799813|NCT04105192|DIETARY_SUPPLEMENT|dietary supplement consumption|Consumption of the product under study for 84 days, plecebo or experimental product
40799814|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
40799815|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
40799816|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
40799817|NCT03184662|OTHER|HIPA|"inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.~First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months"
40799818|NCT03184662|OTHER|Counseling PA|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
40799819|NCT01643265|DIETARY_SUPPLEMENT|Whey Milk Protein|20 grams of Whey Milk Protein
40799820|NCT01643265|DIETARY_SUPPLEMENT|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
41316510|NCT06386809|DEVICE|TAVNS|TAVNS is a recently introduced treatment involving transcutaneous electrical stimulation of the auricular branch of the vagus nerve with VAGUSTIM device.
40799821|NCT02147197|DRUG|Ulipristal acetate (UPA)|UPA tablet
40799822|NCT02147197|DRUG|Placebo|Matching placebo tablet.
40799823|NCT04359524|DIETARY_SUPPLEMENT|Vitamin D3 (1200 IU/30µg)|
41316511|NCT06386809|OTHER|Exercise program|Rocabado 6x6 exercises will be applied in our study. Rocabado exercise, which is the most commonly used exercise method in the literature, is a set of exercises for the craniocervical and craniomandibular system.
41316512|NCT01791699|DRUG|Moxonidine|
41316513|NCT01791699|DRUG|Placebo|
41316514|NCT05893069|DRUG|Oxandrolone|oral oxandrolone for 12 weeks
41473889|NCT01828645|DIETARY_SUPPLEMENT|Carbohydrate plus whey protein enriched drink|The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
41473890|NCT05365152|DIETARY_SUPPLEMENT|Meal Replacement|Meal Replacement
41473891|NCT04022824|OTHER|OSA|Patients with OSA (apnea hypopnea index ≥15) based on sleep study
41003846|NCT00534235|DEVICE|Implantation of coflex Interlaminar Technology|
41473892|NCT04022824|OTHER|Non-OSA|Patients without OSA (apnea hypopnea index \<15) based on sleep study
41473893|NCT02948790|DEVICE|Neuristim|Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode
41473894|NCT02948790|DEVICE|Cochlear implant|Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode
40799824|NCT04359524|DIETARY_SUPPLEMENT|Placebo|Placebo oil capsule
40799825|NCT05570721|BEHAVIORAL|Trier Social Stress Test|The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.
40799826|NCT01534351|DRUG|Finasteride|Finasteride 5 mg oral tablet taken once daily.
40799827|NCT01534351|DRUG|Tamsulosin|Tamsulosin 0.2 mg oral capsule taken once daily.
40799828|NCT01534351|DRUG|Finasteride-matching placebo|Matching placebo to finasteride 5 mg oral tablet taken once daily.
40799829|NCT01534351|DRUG|Tamsulosin-matching placebo|Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
41316515|NCT05893069|DRUG|Placebo|oral placebo for 12 weeks
41316516|NCT02947022|DRUG|Calcium DTPA|"On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
41003847|NCT00000439|DRUG|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
41003848|NCT05365438|DRUG|Omega 3-Atorvastatin|Atmeg 2 capsules with 1 pack of Omethyl cutielet
41003849|NCT05365438|DRUG|Omega 3-Atorvastatin|Atmeg 2 capsules
41003850|NCT05365438|DRUG|Atorvastatin-Ezetimibe|ezetimibe/atorvastatin 10/20 mg
41003851|NCT02827058|DEVICE|G25 pencil point needle|
41003852|NCT02827058|DEVICE|G27 pencil point needle|
41003853|NCT00838266|DRUG|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
41003854|NCT00838266|OTHER|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
41003855|NCT02561130|DRUG|insulin glargine|Dose is titrated to achieve fasting normoglycemia
41003856|NCT02561130|DRUG|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
41003857|NCT02561130|DRUG|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
41003858|NCT02561130|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
41003859|NCT02703571|DRUG|ribociclib|Combination treatment with LEE and TMT
41003860|NCT02703571|DRUG|Trametinib|Combination treatment with LEE and TMT
41003861|NCT04648930|DRUG|Xolair|There was no treatment allocation. Patients administered Xolair by prescription that started before inclusion of the patient into the study were enrolled.
41316517|NCT02947022|DRUG|Zinc DTPA|"On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
41316518|NCT00995670|DRUG|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
41316519|NCT00995670|DRUG|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
41473895|NCT05202041|OTHER|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio \> 0.80, then no PCI revascularization of target blood vessels will be carried out.
41473896|NCT05202041|OTHER|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
41473897|NCT06004869|BEHAVIORAL|Ecological momentary assessments/interventions with cognitive behavioural therapy for insomnia (EMA/I CBT-I)|an integrated system based on an existing multicomponent cognitive behavioural therapy for insomnia (CBT-I) and EMA app
41003862|NCT05853133|OTHER|Erector Spinae Plane Block|Group E (ESP block), before the operation, the ESP block will be applied to the patients in the prone position under sedation by same anesthesiologist. ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level. All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
41003863|NCT05853133|OTHER|Wound Infiltration|Group W, at the end of the operation,wound infiltration will be administered under general anesthesia in supine position by same surgeon. Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each). All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
41003864|NCT06019975|DIAGNOSTIC_TEST|FDG-PET|Brain FDG-PET
41003865|NCT03869593|GENETIC|Sample analysis|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
41003866|NCT03856437|BEHAVIORAL|HPV vaccination messages|Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
41003867|NCT03862391|DRUG|Analgesics|while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.
41003868|NCT03862391|DRUG|Antiemetics|while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
41316520|NCT00995670|DRUG|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
40799830|NCT06390046|PROCEDURE|Intubation|Comparing videao laryngospy with traditional laryngoscopy
40799831|NCT06390046|DRUG|TIVA versus Inhalation|comparing TIVA with genera anesthesia with inhalation agent
41473898|NCT06004869|BEHAVIORAL|Self-help cognitive behavioural therapy for insomnia|An mobile app that delivers CBT-I content.
41473899|NCT04186559|DRUG|Topical Pentoxifylline Gel (Vehicle +PTX)|Patients will be given 1 tube containing 20 ml of topical PTX gel (containing 1,000mg of PTX) to be applied no fewer than four times per day with complete consumption of the entire tube each day.
41473900|NCT04186559|DRUG|Topical Placebo Gel (Vehicle)|Patients will be given 1 tube containing 20 ml of topical placebo gel to be applied no fewer than four times per day with complete consumption of the entire tube each day.
41473901|NCT06616142|DRUG|[18F]CETO tracer|PET/CT with para-chloro-2-\[18F\]fluoroethyl-etomidate (\[18F\]CETO) has a high specificity for the steroidogenic enzymes CYP11B1 and CYP11B2, present in the adrenal cortex, and has more favourable tracer characteristics compared to \[11C\]metomidate. Results obtained with this novel tracer seem promising, but its potential value in the subtyping of PA needs to be further established.
41473902|NCT06616142|DRUG|Dexamethasone oral|Pre-treatment of dexamethasone prior to 18F CETO PET/CT scan
41473903|NCT06616142|PROCEDURE|Adrenal vein sampling|Adrenl vein sampling
41473904|NCT00929981|DRUG|Tablet Methylprednisolone (4 or 16 mg)|Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
40799832|NCT00091741|DRUG|Etanercept (Enbrel)|
40799833|NCT00284505|DRUG|thalidomide|
40799834|NCT02077777|DRUG|Mesalazine|Mesalazine cpr 800 mg t.i.d. for 3 months
40799835|NCT05159739|GENETIC|Blood Draw or Saliva/Cheek Cell Sample:|Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
40799836|NCT00666653|DRUG|pramipexole|
41003869|NCT04525612|DIAGNOSTIC_TEST|68Ga-BNU-PSMA|Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.
41003870|NCT02533271|RADIATION|Short-course radiotherapy with neoadjuvant chemotherapy|Short-course radiotherapy with 4 cycles of neoadjuvant chemotherapy
41003871|NCT02533271|RADIATION|Long-term chemoradiotherapy|Standard chemoradiotherapy
41316521|NCT00995670|DRUG|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
41316522|NCT05150834|OTHER|This is observational study|We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
41316523|NCT06402968|DRUG|Clevidipine Injection|Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
40799837|NCT05195645|DRUG|Abatacept 250 MG|Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
40799838|NCT02840188|OTHER|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
41316524|NCT06402968|DRUG|Alternate IV Antihypertensive Regimen|"The alternate IV antihypertensive regimen would be the institutional standard management at designated non-clevidipine hospitals. It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour."
41316525|NCT04894812|OTHER|Neurodevelopmental technique|"1. st month: postural maintenance; exercises with weight on forearms and hands, in sitting, crawling, semi-kneeling and standing positions with support from therapist.~2. nd month: balance and corrective reactions; using CP ball and tilt board.~3. rd month: ambulation training; appropriate to motor development level (crawling, creeping, walking in a semi-kneeling position and walking between parallel bars)."
41316526|NCT01769261|OTHER|eligible, Internet|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
41473905|NCT03005067|DRUG|Carbomer 980 (1146A)|Test product containing carbomer 980 gel
41473906|NCT03005067|OTHER|Placebo|Reference product containing vehicle without carbomer 980 gel
40799839|NCT01788397|BEHAVIORAL|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
41003872|NCT04347486|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2
41003873|NCT04347486|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2
41003874|NCT04347486|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2
41003875|NCT04347486|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
41003876|NCT03851016|BEHAVIORAL|Life Story Book|Life story Book is intended to allow a person the opportunity to reminisce chronologically through their life and capture their life stories into a book.
41473907|NCT01959490|BIOLOGICAL|trastuzumab|Given IV
41473908|NCT01959490|BIOLOGICAL|Pertuzumab|Given IV
41473909|NCT01959490|DRUG|docetaxel|Given IV
41473910|NCT01959490|DRUG|carboplatin|Given IV
41473911|NCT01959490|DRUG|doxorubicin|Given IV
41473912|NCT01959490|DRUG|cyclophosphamide|Given IV
41473913|NCT01959490|DRUG|paclitaxel|Given IV
41473914|NCT01959490|DRUG|Bevacizumab|
41473915|NCT06416969|DRUG|Somatostatin|Intravenous infusion 200 ug/hr for 2 hours, 100 ug/hr for 30 minutes
41473916|NCT06416969|DRUG|Epinephrine|Intravenous infusion
41003877|NCT03851016|BEHAVIORAL|Usual Care|Three weeks of Usual Care with no visits from research team
41003878|NCT05140577|OTHER|Maximal voluntary isometric strengthening|The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds
41003879|NCT02117037|OTHER|blood sample|
41003880|NCT00739752|BEHAVIORAL|Non-Framed-Offered|Subjects received information only and are offered the vaccine.
41003881|NCT00739752|BEHAVIORAL|Non-Framed-Recommended|Subjects receive information only and are recommended the vaccine.
41003882|NCT00739752|BEHAVIORAL|Gain-Framed-Offered|Subjects receive gain-framed messages and are offered the vaccine.
41003883|NCT00739752|BEHAVIORAL|Gain-Framed-Recommended|Subjects receive gain-framed messages and are recommended the vaccine.
41003884|NCT00739752|BEHAVIORAL|Loss-Framed-Offered|Subjects receive loss-framed messages and are offered the vaccine.
41003885|NCT00739752|BEHAVIORAL|Loss-Framed-Recommended|Subjects receive loss-framed messages and are recommended the vaccine.
41003886|NCT01440322|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
41003887|NCT01440322|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
41003888|NCT05385939|OTHER|Observational|This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.
41003889|NCT00431457|DEVICE|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
41003890|NCT00431457|PROCEDURE|amygddohyppocampertomy|Resective surgery
41003891|NCT02895399|OTHER|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
41316527|NCT01769261|OTHER|eligibles, telephone|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
41473917|NCT00165386|PROCEDURE|Magnetic Resonance Imaging|
40799840|NCT02552173|RADIATION|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
41003892|NCT01404091|DRUG|LY2940094|Administered orally
40799842|NCT05508542|BEHAVIORAL|Progressive relaxation exercises|Personal information form, Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be applied to the pregnant women at the first interview. Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. Afterwards, the Relaxation Exercises CD will be played and the exercises will be performed with the patient along with the CD. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.
41003893|NCT05874180|DRUG|DW6013|"Drug: DW6013 Single oral administration of DW6013 in fed condition~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition"
41003894|NCT02433834|DRUG|Glycopyrronium MDI|GP MDI
40799843|NCT03267979|OTHER|Video-pupillometer|Video-pupillometer will be performed. In this study data will be collected and analyzed.
41003895|NCT02433834|DRUG|Serevent Diskus 50 μg|
41003896|NCT02433834|DRUG|Placebo|
41003897|NCT01849588|DRUG|Sorafenib|
41003898|NCT06093724|DIAGNOSTIC_TEST|Static and dynamic perineo-pelvic MRI|Static and dynamic perineo-pelvic MRI before surgery, and at 6 and 24 months after surgery.
40799844|NCT03267979|OTHER|Electrocardiogram|Electrocardiogram will be performed. In this study data will be collected and analyzed.
41003899|NCT00539838|DRUG|Prednisone|Oral repeating dose
41003900|NCT00539838|DRUG|Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)|Oral repeating dose
41003901|NCT00539838|DRUG|Methylprednisolone|Intravenous repeating dose
41003902|NCT00539838|DRUG|Ocrelizumab|Intravenous repeating dose
41003903|NCT00539838|DRUG|Placebo|Intravenous repeating dose
41003904|NCT00086580|BIOLOGICAL|FluCAM [Fludara + Campath]|"Phase A: Escalating Doses of alemtuzumab (Campath) Alone~Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.~Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.~Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.~Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.~Phase B: FluCAM~Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m\^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity."
41003905|NCT00086580|BIOLOGICAL|fludarabine phosphate|Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m\^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
41003906|NCT05176093|BIOLOGICAL|Engensis|Lyophilized biologic to be reconstituted containing Engensis
41003907|NCT05176093|OTHER|Placebo|Injectable Liquid
41003908|NCT00980551|DRUG|subtenon Carboplatin|Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
41316528|NCT01769261|OTHER|non eligibles|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
41003909|NCT00980551|DRUG|Topotecan Hydrochloride|Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
41316529|NCT01904734|DRUG|Clomiphene|Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
41316530|NCT00176241|DRUG|gemcitabine|2000-3000mg/m2 IV on days 1 \& 15
41316531|NCT00176241|DRUG|paclitaxel|150 mg/m2 IV on days 1 \& 15
41316532|NCT00176241|RADIATION|radiation|50-80 cGy on days 1,2,15,16
41473918|NCT00165386|PROCEDURE|Bone Marrow Biopsy|
41003910|NCT00980551|DRUG|Vincristine|Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
41003911|NCT00980551|DRUG|Filgrastim|Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
41316533|NCT01868776|DRUG|buffered lidocaine|
41473919|NCT00021489|DRUG|Abacavir sulfate|
41473920|NCT00021489|DRUG|Mycophenolate mofetil|
41473921|NCT01651611|BEHAVIORAL|Motivational interviewing|The TTA will use motivational interviewing (MI) techniques to assess the participant's motivation and readiness to quit, suggest plans, and assist the participant in selecting a method of treatment.
41316534|NCT01868776|DRUG|nonbuffered lidocaine|
41473922|NCT01651611|BEHAVIORAL|Smoking cessation counseling|The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
40799845|NCT02097719|DRUG|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
40799846|NCT02097719|DRUG|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
41003912|NCT03458130|DRUG|AG10|TTR stabilizer
41003913|NCT03458130|DRUG|Placebo Oral Tablet|Nonactive control
41003914|NCT02615951|OTHER|blood sampling|Blood sample retrieval for biological and genetic analysis and comparison
41003915|NCT05318638|DEVICE|Soft robotic glove|The soft-robotic glove used in the study is the Carbonhand system (Bioservo Technologies, Sweden). It is a CE-marked medical device and it consists of a glove that supports finger flexion via sewn-in tendons and a control unit housing the actuators that pull on the tendons and the batteries. The grip support is activated by applying very light pressure on sensors in the fingertips of the glove, and de-activated by releasing the pressure on the sensors.
41003916|NCT00952094|DRUG|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
40799847|NCT02097719|DRUG|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
41003917|NCT04490993|DRUG|APL-1202 in combination with Epirubicin|"* Induction period: APL-1202 is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, APL-1202 is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
40799848|NCT02097719|DRUG|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
40799849|NCT02323126|DRUG|EGF816|EGF816 150 mg once daily (QD) administered orally as a capsule
40799850|NCT02323126|DRUG|INC280|INC280 400 mg twice daily (BID) administered orally as a tablet
40799851|NCT02323126|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion
40799852|NCT00851292|DEVICE|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
41152066|NCT03508882|DRUG|Saline Solution for Injection|The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
41152067|NCT04946656|PROCEDURE|sphenopalatine ganglion block|The sphenopalatine ganglion will be blocked with bupivacaine for this study
41316535|NCT06009224|OTHER|ERAS perioperative management|"* Epidural analgesia~* Fluid balance~* Other items are the same as conventional"
41316536|NCT01161082|DRUG|REGN727(SAR236553)|subcutaneous
41316537|NCT01146249|OTHER|Balance assessment under sensory stimulation|Balance assessment under sensory stimulation
41316538|NCT00684125|DEVICE|Blake Drains (Blake drain, Ethicon USA)|19F Blake drain located in the posterior pericardial cavity
41473923|NCT01651611|BEHAVIORAL|Navigation to smoking cessation resources|The TTA will assist participants in obtaining NRT and getting connected to smoking cessation counseling services, such as the Smokers' Quitline and clinic-based programs.
41473924|NCT01651611|BEHAVIORAL|Social support|Meetings with the TTA will be a source of social support for the participant as they attempt to quit or stay quit.
41473925|NCT03361124|DRUG|Oxytocin|Administration of additional 20 mU Oxytocin
41473926|NCT01826916|DRUG|DX-88 (ecallantide)|solution for injection 10 mg/mL
41473927|NCT02369718|OTHER|Listening to 12 Fournier's lists of words|Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.
40799853|NCT03618771|DEVICE|Total knee arthroplasty|Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.
41316539|NCT00684125|DEVICE|Standard mediastinal drainage|Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
40799854|NCT03435120|OTHER|No intervention|No intervention
40799855|NCT03995745|BEHAVIORAL|Medication adherence and financial incentives|Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
40799856|NCT02859285|OTHER|Placebo vulvar cream|
41003918|NCT04490993|DRUG|Placebo in combination with Epirubicin|"* Induction period: placebo is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, placebo is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
40799857|NCT02859285|OTHER|Estradiol vulvar cream|
40799858|NCT00907322|DRUG|Dimebon|Oral tablet; 20 mg Dimebon, single dose
40799859|NCT00907322|DRUG|Dimebon|Oral tablet; 40 mg Dimebon, single dose
41003919|NCT00084669|DRUG|venlafaxine|
41003920|NCT00084669|DRUG|zolpidem tartrate|
41003921|NCT00084669|PROCEDURE|management of therapy complications|
41316540|NCT03736954|BEHAVIORAL|positive suggestion|humanization of critical care experience with positive reframing of hospital course on daily basis to eligible participants
41316541|NCT04782193|BIOLOGICAL|CD19 and CD22 targeted prime CAR- T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
40799860|NCT00907322|DRUG|Dimebon|Oral tablet; 60 mg Dimebon, single dose
40799861|NCT00907322|DRUG|Dimebon|Oral tablet; placebo, single dose
40799862|NCT04457791|BEHAVIORAL|Personalized dietary advice|Via an self-developed website and algorithm, participants will receive digital personalized dietary advice to increase dietary fiber intake, aiming to reduce constipation complaints. The advice is personalized on phenotype (habitual diet, gender)
41003922|NCT04415099|OTHER|Muscle fatigue protocol|"Tibialis posterior was fatigued using 2 exercises:~1. Unilateral heel raise exercise~2. Close chain resisted foot adduction exercise"
41003923|NCT02254707|DRUG|BILB 1941 ZW|
41003924|NCT02254707|DRUG|Placebo|
41003925|NCT01863472|DEVICE|HeartLight(TM) Laser Balloon|With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
41003926|NCT01863472|DEVICE|irrigated radiofrequency current ablation|The irrigated radiofrequency current ablation is used for pulmonary vein isolation
41003927|NCT00096512|DRUG|sorafenib tosylate|Given orally
40799863|NCT03680833|PROCEDURE|Sentinel node detection in cervical cancer|The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
41003928|NCT00096512|OTHER|laboratory biomarker analysis|Correlative studies
41003929|NCT00430092|DRUG|Difluprednate|
41003930|NCT00430092|DRUG|Difluprednate|
41003931|NCT00430092|DRUG|Placebo|
41003932|NCT04489030|OTHER|Magnifying narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
41003933|NCT00832403|OTHER|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
41003934|NCT01421784|OTHER|cine MRI|Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
41003935|NCT06273228|BEHAVIORAL|Family Check-Up Online|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers.
41003936|NCT01391065|RADIATION|MR PET Guided Brachytherapy|
41003937|NCT01347190|BIOLOGICAL|CR002 Liquid API|A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
41316542|NCT02451436|BEHAVIORAL|Sleep and Media Use Intervention|
40799864|NCT03572959|DRUG|0.1 % topical triamcinolone acetonide|0.1 % topical triamcinolone acetonide preparation was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application.
41003938|NCT01347190|BIOLOGICAL|Placebo|A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
41003939|NCT03569670|DEVICE|Posterior stabilized all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.
41003940|NCT03569670|DEVICE|Cruciate retaining all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
41003941|NCT00002417|DRUG|Amprenavir|
41316543|NCT02451436|BEHAVIORAL|Study Skills Control Group|
41316544|NCT00878215|DEVICE|Explorer Liver Image Guided System|
41316545|NCT00878215|DEVICE|Explorer Liver Passive Tracking|
41316546|NCT00878215|PROCEDURE|Liver surgery|-Standard of care
41316547|NCT00878215|PROCEDURE|Liver abalation|-Standard of care
41316548|NCT00012012|DRUG|Amifostine trihydrate|Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
41316549|NCT00012012|DRUG|Cisplatin|Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m\^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
41316550|NCT00012012|RADIATION|Intracavitary brachytherapy|For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
40799865|NCT03572959|DEVICE|SIROIaser|"Oral Lichen Planus lesions were irradiated with a 970-nm diode laser with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly (once every third day) for two months until the resolution of signs for a maximum of ten sessions."
41473928|NCT02369718|OTHER|Listening to 48 Fournier's lists of words|48 disyllable Fournier's lists of words are presented to the subjects (6 SNR\*2 coding strategies\*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
40799866|NCT01479751|DRUG|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
40799867|NCT01479751|DRUG|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
40799868|NCT01479751|DRUG|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
40799869|NCT01814865|DRUG|Abiraterone Acetate|1000 mg PO OD x 2 weeks
40799870|NCT01814865|DRUG|Prednisone|5 mg PO OD x 2 weeks
40799871|NCT01814865|DRUG|Aromatase Inhibitor|1 mg PO OD x 2 weeks
40799872|NCT05358262|DEVICE|Airvo|Fisher \& Paykel's AIRVO 2 is a humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases to spontaneously breathing patients through a variety of interfaces including nasal cannula. Flow can be delivered from 2 to 60 LPM
40799873|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
40799874|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
40799875|NCT06521385|DEVICE|Makani Science Respiratory Monitoring System|Subjects monitored by the Makani Science Respiratory Monitoring System
40799876|NCT03493061|DRUG|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
40799877|NCT03493061|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
40799878|NCT03493061|DRUG|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
40799879|NCT00783835|DRUG|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
40799880|NCT02136004|DEVICE|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
40799881|NCT05202899|DRUG|sugammadex|The use of sugammadex
40799882|NCT06386055|BEHAVIORAL|Active exercise|The intervention group will be provided with training courses for 3 months.
40799883|NCT02342847|OTHER|N/A (non-interventional study)|
40799884|NCT05919784|BEHAVIORAL|Cognitive behavioural therapy|The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
40799885|NCT01835977|DEVICE|Irreversible Electroporation (Nanoknife)|
41473929|NCT03223454|BIOLOGICAL|hAECs|hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
41473930|NCT03223454|BIOLOGICAL|biological amnion|Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
40799886|NCT02547246|DEVICE|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
40799887|NCT02547246|DEVICE|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
40799888|NCT03066960|PROCEDURE|Radiofrequency neurotomy|RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
40799889|NCT03066960|PROCEDURE|Sham treatment|Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
40799890|NCT03657134|DIAGNOSTIC_TEST|CoVa-2 Monitoring System|Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
40799891|NCT02023580|BEHAVIORAL|Video treatments|"The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 \& 10) Support of HIV disclosure and perceived responsibility."
40799892|NCT05503706|OTHER|1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo|dandruff shampoo
40799893|NCT06024109|DEVICE|Closure of the Vaginal Cuff after Total Hysterectomy|Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
41473931|NCT00594113|OTHER|Touch 2 Screen|"Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior"
41473932|NCT00594113|OTHER|Touch screen intervention|Touch screen intervention
41473933|NCT05801302|DEVICE|Foam rolling (shorter volume)|A single intervention will be performed (3 sets of 30 seconds, with between-sets intervals of 30 seconds).
40799894|NCT00659386|DRUG|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
40799895|NCT00241072|DRUG|valsartan|24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)
40799896|NCT00574041|DRUG|Interferon beta-1a|injected, once a week
40799897|NCT01441947|DRUG|Cabozantinib|Part of combination arm
40799898|NCT01441947|DRUG|Fulvestrant|part of combination arm
40799899|NCT05130684|DRUG|Nivolumab|adding nivolumab to conventional neoadjuvant CRT
41003942|NCT03703635|DEVICE|intracranial balloon angioplasty|A balloon (recommending the Neuro RX and Neuro LPS Intracranial Balloon Dilation Catheter \[Sinomed Inc., Tianjin, China\]) is navigated by the microwire to the lesion of the target artery.
41003943|NCT03703635|DRUG|aggressive medical management|Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/80-90 mmHg and LDL lower than 70 mg/dl or 1.8mmol/L.
41003944|NCT03881137|OTHER|Geriatric assessment with management|"A multicomponent intervention, carried out in cooperation between hospital and community services, based on a geriatric assessment (GA) followed by individually adapted measures targeting identified needs.~The GA and the start of the intervention will be handled by a PhD student (geriatrician) or project cancer nurse at start of RT. Pre-planned guidelines will be followed. Contribution from relevant hospital professionals will be sought according to needs. Then the intervention will be offered in the primary health care taking advantage of existing services, e.g. home care, rehabilitation services, exercise groups etc. A community-based coordinating nurse will follow the patients with weekly contacts throughout RT and to end of intervention 8 weeks post-RT. To ensure that each patient's intervention is properly adjusted to changing needs, repeated clinical assessments will be performed by the end of RT and 4 weeks post-RT."
41003945|NCT01541930|DRUG|GK567|Once or twice daily, for 14 days, up to 30 g per day
41003946|NCT00529386|DRUG|Botox|300 units
41003947|NCT03261583|OTHER|Thoracis Surgery - Common care|Observational study. It is only a matter of collecting clinical data.
41003948|NCT06227507|BEHAVIORAL|Front-of-package label|Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.
41003949|NCT01735656|DEVICE|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
41003950|NCT03467269|DIAGNOSTIC_TEST|Brush sign|presence of a brush sign in MRI image in acute cerebral ischaemia
41473934|NCT05801302|DEVICE|Foam rolling (longer volume)|A single intervention will be performed (3 sets of 60 seconds, with between-sets intervals of 30 seconds).
41473935|NCT02299219|BEHAVIORAL|Taking Charge: Managing Cancer Online|"n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French."
41473936|NCT02299219|BEHAVIORAL|Standard Medical Care and Cancer Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments."
40799900|NCT01463696|DRUG|MK-8242|10 mg, 100 mg and 150 mg capsules
40799901|NCT04328545|DEVICE|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
40799902|NCT04328545|DEVICE|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
40799903|NCT04328545|DEVICE|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
40799904|NCT03763812|PROCEDURE|Endovascular Aneurysm Repair (EVAR)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
40799905|NCT03763812|PROCEDURE|Endovascular Aneurysm Sealing (EVAS)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
41473937|NCT04975893|BIOLOGICAL|mRNA-1647|No investigational product will be administered during the Primary Extension Phase or to the participants in the Observational Group.
41473938|NCT04975893|OTHER|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
41473939|NCT04892316|DIAGNOSTIC_TEST|Diagnostic test|The training dataset was used to train the model, which was validated and tested by the other two datasets.
41003951|NCT03670810|DRUG|Lasmiditan|Administered orally.
41003952|NCT03670810|DRUG|Placebo|Administered orally.
41003953|NCT02356783|DEVICE|Pedometer|Wireless pedometer
41003954|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 1 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
41473940|NCT05883397|OTHER|HBOT|Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.
41473941|NCT05883397|OTHER|Hippocampal training|Hippocampal training: This will combine physical and cognitive training. Training will be given 3 times per week, prior to the next HBOT, and more than 20 hours after the last HBOT session.
41003955|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 2 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
41316551|NCT00012012|RADIATION|External beam radiation therapy|Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
41316552|NCT00798655|DRUG|Panitumumab|"Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.~The panitumumab dose will be calculated based on the subject's actual weekly body weight"
41316553|NCT00798655|DRUG|Cisplatin|Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
41316554|NCT00798655|RADIATION|Radiation Therapy|"Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.~Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day."
41316555|NCT05562284|PROCEDURE|intra-arterial thrombolysis|IAT introduces rt-PA directly into the ophthalmic circulation by super-selective microcatheterization.
41473942|NCT02316158|OTHER|Web-based support|Comparison between the efficacy between webb-based support and informational support
41316556|NCT05562284|OTHER|conservative treatments|conservative treatments
41316557|NCT02831842|DRUG|Anti-EGFR-Containing Regimen|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
41473943|NCT03396874|DRUG|68Ga-PSMA|"PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
41473944|NCT02668042|BIOLOGICAL|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
41473945|NCT03030326|BEHAVIORAL|heart rate variability biofeedback|Patients learn to increase heart rate variability by breathing at the resonance frequency of the cardiovascular system, at approximately 6 breaths/min, varying among people.
41473946|NCT06289829|DRUG|remifentanil of the assigned dose|Ambu Auragain will be inserted after general anesthesia is induced with remimazolam and remifentanil. Each patient will be assigned with a certain dose of remifentanil, according to whether the previous patient's LMA insertion process was successful or not.
41003956|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 3 - Without Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps.~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
41003957|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 3 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
41003958|NCT03857633|DIAGNOSTIC_TEST|Peripheral Whole Blood Samples|20ml EDTA whole blood samples - collected sequentially during study - max 8 time points
41003959|NCT02611492|DRUG|Nilotinib|400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
41003960|NCT02611492|DRUG|Methotrexate|1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
41003961|NCT02611492|DRUG|Aracytine (Ara C)|Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
41316558|NCT02831842|DRUG|Bevacizumab-containing regimen|Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
41316559|NCT02831842|DRUG|Chemotherapy|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
41316560|NCT01806376|DRUG|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
41316561|NCT03298152|PROCEDURE|CERASMART Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks
41316562|NCT03298152|PROCEDURE|Emax Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using Emax material
41316563|NCT00288834|BEHAVIORAL|dysphagia rehabilitation|
41316564|NCT01518244|DRUG|Brinzolamide/timolol maleate fixed combination|
41316565|NCT01172834|BEHAVIORAL|Health Coaching|A manual-driven group Health Coaching intervention. Once a week for 3 months.
41316566|NCT02704494|DRUG|Resveratrol|Resveratrol 500mg daily
41316567|NCT02704494|DRUG|Placebo|Placebo 1 capsule daily
41316568|NCT02704494|DRUG|Losartan|Losartan 12.5mg daily
41003962|NCT02611492|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
41003963|NCT02611492|DRUG|Depomedrol|40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
41003964|NCT02611492|DRUG|Dexamethasone|40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
40799906|NCT06133855|RADIATION|Pulsed electromagnetic field|The experimental group will be treated with an ASA magnetic field device (Automatic PMT Quattro Pro) at a frequency of 50 Hz in addition to the traditional physical therapy program. Each session will consist of 20 minutes of the patient lying prone and exposed to low-intensity 20-gauss PEMF.
41003965|NCT02611492|DRUG|Vincristine|2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
41003966|NCT02611492|DRUG|Imatinib|300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
41003967|NCT02611492|DRUG|6 Mercaptopurine (6MP)|60 mg/m2 per os, D1 to D14, interphase
41003968|NCT05437289|DRUG|AZD7442 IM|In cohort 1, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) administered sequentially as direct gluteal IM injections.
41003969|NCT05437289|DRUG|Placebo IM|In cohort 1, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
41003970|NCT05437289|DRUG|AZD7442 IM|In cohort 2, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) administered sequentially as direct gluteal IM injections.
41003971|NCT05437289|DRUG|Placebo IM|In cohort 2, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
41003972|NCT05437289|DRUG|AZD7442 IV|In cohort 3, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
41003973|NCT05437289|DRUG|Placebo IV|In cohort 3, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
41003974|NCT05437289|DRUG|AZD7442 IV|In cohort 4, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
41003975|NCT05437289|DRUG|Placebo IV|In cohort 4, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
41316569|NCT04433624|OTHER|Group (B)|Group (B) (n=15): will receive The bilateral ESP blocks were performed by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the erector spinae muscle and the transverse processes of the lumbar vertebrae
41316570|NCT01959399|DRUG|ASP015K|oral tablet
41316571|NCT01959399|DRUG|Rosuvastatin|oral tablet
41316572|NCT03095716|OTHER|laparoscopic surgery|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
41316573|NCT02323321|DEVICE|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
41473947|NCT06289829|DEVICE|Ambu Auragain for airway management|Ambu Auragain, a type of laryngeal mask airway, will be inserted into every patient after general anesthesia has been induced.
40799907|NCT06133855|OTHER|traditional physical therapy program|"A traditional physical therapy program will include~Infrared radiation for 20 minutes per session for 3 sessions per week for 4 weeks~Ultrasonic: 1 MHz; continuous mode of application: 1.5 w/cm2 for 5 minutes; 3 sessions per week for 4 weeks.~stretching exercises for the hamstring, calf muscles, and back muscles. 3 sessions per week for 4 weeks~Strengthening exercises for back and abdominal muscles."
40799908|NCT05561816|DRUG|Hydroxymethylquinoxalindioxyde|Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
41003976|NCT02296814|DRUG|Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
41003977|NCT02296814|DRUG|Placebo for Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
41003978|NCT05325463|PROCEDURE|conventional lung recruitment|The recruitment maneuver will be performed by pressure controlled mode maintaining a steady airway pressure of 15 cmH2O, with 5 cmH2O increments in positive end-expiratory pressure (PEEP) until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 sec. The peak airway pressure will be maintained for 10 sec or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings.
41003979|NCT05325463|PROCEDURE|ultrasound- guided lung recruitment|The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area was visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit was 40 cmH2O.
41003980|NCT05055674|BEHAVIORAL|Motherly app|The Motherly app is organized in four different modules: 1) Library: a collection of brief texts on several topics related to health and pregnancy, 2) Health: journeys with varying degrees of interactivity designed to teach and engage participants in well-established psychological techniques (behavioral activation, cognitive restructuring, emotion regulation, stress management techniques, mindfulness and meditation, sleep hygiene techniques), 3) Pregnancy and motherhood: a module to help mothers keep track of their health care visits, medical exams, and their childrens' development, and 4) Profile: a module allowing participants to keep track of activities and goals completed in the Health module journeys, and to assess depression and anxiety symptoms with brief questionnaires, with results displayed graphically in a timeline and in the the form of short feedback texts.
41152068|NCT01580462|OTHER|Observational study|"Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded."
41316574|NCT06145685|PROCEDURE|Minimally invasive non-surgical periodontal therapy|Minimally invasive non-surgical periodontal therapy
41316575|NCT06145685|PROCEDURE|Conventional non-surgical periodontal therapy|Conventional non-surgical periodontal therapy
41473948|NCT01820858|DRUG|Paclitaxel|175 mg/m(2), intravenously (IV)
41473949|NCT01820858|DRUG|Paraplatin (Carboplatin Injection)|AUC=5, IV
41473950|NCT01820858|RADIATION|Pelvic Radiation|45-50 Gy
41003981|NCT05055674|BEHAVIORAL|COMVC app|The COMVC displays over 30 brief psychoeducational videos on several topics related to general mental health, such as depression, anxiety, stress, sleep, problem solving techniques, among others. Psychoeducation is limited to video only (no interactivity). The content of these videos was developed by clinicians, researchers, and professors from the Psychiatry Department of the Medical School of the University of Sao Paulo and from the Federal University of Rio Grande do Sul. Mental health monitoring is delivered by means of brief questionnaires assessing depression and anxiety symptoms, which can be filled at users' discretion. Users' responses are displayed graphically in a timeline and they receive short feedback texts based on assessment results.
41003982|NCT01193491|DRUG|IPI-493|Capsules, ascending dose, multiple schedules
41003983|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL QD: RAL 800 mg/24 hs
41003984|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL BID 400 mg/12 hs
41003985|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL BID to QD
41003986|NCT02944318|BEHAVIORAL|The Movement Program|The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
41003987|NCT06406738|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform newborn first-care.
41003988|NCT02131584|OTHER|Questionnaire Administration|Ancillary studies
41003989|NCT02131584|DRUG|Ruxolitinib Phosphate|Given PO
40799909|NCT05561816|DRUG|Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium|Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
41003990|NCT01218516|BIOLOGICAL|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
41003991|NCT01218516|OTHER|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
41003992|NCT01218516|DRUG|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].
41003993|NCT01218516|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 will be administered intravenously.
41003994|NCT01218516|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously.
41473951|NCT01820858|RADIATION|Vaginal Brachytherapy 1|5 Gy, 3 times
40799910|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 3.2 mg/m² dose."
40799911|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 1.6 mg/m² dose"
40799912|NCT00613548|PROCEDURE|CABG alone|CABG alone
40799913|NCT00613548|PROCEDURE|CABG + Mitral repair|CABG + Mitral repair
41003995|NCT01218516|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered intravenously.
41003996|NCT02544529|DRUG|Echothiophate Iodide 0.03% Ophthalmic Solution|one drop to each eye three times per week for 18 weeks
41003997|NCT02544529|DRUG|Carboxymethylcellulose Sodium (0.5%)|one drop to each eye three times per week for 18 weeks
41003998|NCT00228345|PROCEDURE|Optical coherence tomography,Fluorescein angiography|
41003999|NCT03499392|OTHER|psychological tests|psychological tests psychological interviews
41004000|NCT02299050|DRUG|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
41316576|NCT00935519|DEVICE|4th generation ceramic bearing composite ceramic bearing|THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
41473952|NCT01820858|RADIATION|Vaginal brachytherapy 2|5 Gy, 2-4 times
41316577|NCT05738499|OTHER|Character strengths-based structured treatment and education programme (CSSTEP)|This CSSTEP intervention included both psychological and educational contents, and the intervention type was psycho-educational intervention. The implementation process lasted for three weeks. CSSTEP mainly includes two main components. The first part is character strengths-based intervention. The second part is educational intervention, which is structured treatment and education programme for stroke patients. The two components were combined and optimized on the basis of theoritical and empirical evidences, and then this kind of complex intervention suitable for Chinese clinical stroke patients was obtained.
41316578|NCT05738499|OTHER|Structured treatment and education programme (STEP)|The STEP programme is aimed at the treatment needs of stroke patients, considering the education level and cultural background of patients, screening important health education content, and planning and grading of patients' education. The intervention consisted of three educational sessions, focusing on patients' daily life, post-stroke rehabilitation and secondary prevention.
41316579|NCT04092816|BEHAVIORAL|FAMILY Intervention|The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials.
41316580|NCT01206478|DRUG|Amitriptyline|Amitriptyline 1 mg/kg once daily at bedtime.
41316581|NCT01206478|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
41316582|NCT01206478|DRUG|Megestrol|At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
41316583|NCT00835419|DRUG|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
41316584|NCT04410198|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
40799914|NCT05961111|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
40799915|NCT00678938|BEHAVIORAL|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
40799916|NCT00678938|BEHAVIORAL|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
40799917|NCT05271253|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia.
40799918|NCT05271253|DRUG|bupivacaine|0.25% bupivacaine is injected in the caudal epidural space
40799919|NCT05271253|DRUG|normal Saline|injection of normal Saline
40799920|NCT03985462|BIOLOGICAL|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
40799921|NCT01420913|DRUG|Pregabalin|Pregabalin 300mg a day
40799922|NCT02627443|DRUG|Berzosertib|Given IV
40799923|NCT02627443|DRUG|Carboplatin|Given IV
40799924|NCT02627443|DRUG|Gemcitabine Hydrochloride|Given IV
40799925|NCT02627443|OTHER|Laboratory Biomarker Analysis|Correlative studies
40799926|NCT02627443|OTHER|Pharmacological Study|Correlative studies
40799927|NCT04193904|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
40799928|NCT04193904|RADIATION|Hypofractionated Preoperative Radiation|Radiation will be delivered as 30Gy/10 fractions over two weeks.
40799929|NCT04607434|DRUG|Ocotillol Type Ginsenoside Derivatives|Peripheral blood PMN of patients with ARDS were taken. The neutrophils isolated from peripheral blood of ARDS patients were incubated with different doses of OCT glycine derivatives (20,50,100 UM) for 20 h
40799930|NCT01924039|BEHAVIORAL|Brief Motivational Enhancement Therapy|The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
41316585|NCT02951390|OTHER|High-definition white-light endoscopy|The intervention is do not perform chromoendoscopy
41316586|NCT02178501|DIETARY_SUPPLEMENT|Omega-3 PUFA|comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
41473953|NCT05171673|DRUG|Licart™ (diclofenac epolamine) topical system|The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
40799931|NCT01924039|OTHER|treatment as usual|Treatment as usual includes case management as well as psychiatric appointments.
40799932|NCT02443246|DRUG|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
40799933|NCT02443246|DRUG|Placebo|
40799934|NCT03569787|DIAGNOSTIC_TEST|MRI Pituitary|Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
40799935|NCT00077714|DRUG|Paliperidone ER|
40799936|NCT02236234|BIOLOGICAL|HPV vaccine|HPV vaccine
41473954|NCT02458092|BIOLOGICAL|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
41473955|NCT02458092|BIOLOGICAL|Rabipur|Rabipur is a licensed rabies vaccine.
41473956|NCT05302479|OTHER|COMPASS 31 questionnaire|A 31 question questionnaire that measures autonomic symptoms.
41473957|NCT06611176|DRUG|Local levobupivacaine|submucosal injection of levobupivacaine during esophageal esad
41473958|NCT03658863|PROCEDURE|endoscopic ultrasound|Evaluation of bile ducts with endoscope with special ultrasonographic function
41473959|NCT03658863|PROCEDURE|intraoperative cholangiography|evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy
41473960|NCT03658863|PROCEDURE|ERCP|evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum
41473961|NCT03658863|DEVICE|Ultrasound endoscope|Endoscope with built-in ultrasound function
41473962|NCT00493779|PROCEDURE|Blood Collection|4 weeks
41473963|NCT02036450|DEVICE|Implantable loop recorder (Medtronic Reveal LINQ(TM))|The patients in the experimental arm receive an implantable loop recorder (Medtronic Reveal LINQ(TM)) with continuous monitoring, and are followed by daily automated remote transmissions. New arrhythmia episodes are reviewed daily by an experienced medical doctor. If AF lasting ≥6 minutes is detected and confirmed by at least two senior cardiologists, OAC is initiated. Decision about specific type of OAC, and possible further clinical work-up or treatment, is left to the treating physician and the patient. The remote monitoring continues until end of service of the device, patient withdrawal or other end-of-study.
41473964|NCT02112279|BIOLOGICAL|Donor microbiota applied via colonoscopy.|"B. Preparation of donor sample 1. Instillation via Colonoscopy~1. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.~Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe."
41473965|NCT02788799|OTHER|Standard 12-Lead ECG|Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.
41316587|NCT04498819|BEHAVIORAL|Wearable Activity Trackers, Exercise Prescription and Virtual Care|"The intervention is merging wearable activity trackers and tailored aerobic exercise prescriptions into the PCDSP's virtual STAND (a biweekly, evidence based, lifestyle medicine) program.~Participants will wear activity trackers for a week to collect baseline step data (used to create tailored step prescriptions). Biweekly, new step prescriptions will be tailored to each participant based on the previous two week's step count data. The intervention will add onto STAND classes by using activity tracker data into the class discussion for learning opportunities, as well as goal setting and action planning. The day of class, participants will receive a summary email new prescription and encouragement to continue to work hard, using the previous weeks' data to reinforce motivation. The activity tracker will provide instant feedback about step goals, sedentary behaviour and exercise minutes. Individual calls every other week will ensure adherence to exercise regime."
41316588|NCT01916707|DRUG|Dosing of enoxaparin for VTE prophylaxis|
41316589|NCT00424528|DRUG|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
41316590|NCT00424528|DRUG|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
41316591|NCT00424528|DRUG|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
41316592|NCT00424528|DRUG|Placebo|Placebo inhalation solution and placebo inhalation powder
41473966|NCT02788799|OTHER|Posterior ECG Leads|Recording posterior ECG leads (V7, V8 and V9) in addition to standard 12-lead ECG for identifying STEMI involving left cirumflex coronary artery.
41316593|NCT05630170|DEVICE|AI-ECG|A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.
41316594|NCT04706429|DRUG|Trientine|Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.
41473967|NCT04330911|PROCEDURE|Aerobic Exercise|Exercise loading is determined by increasing the heart rate. This loading calculated by Karvonen formulas (maximum %80 of Heart Rate)
41473968|NCT06155773|PROCEDURE|Highly viscous glass ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
41473969|NCT06155773|PROCEDURE|Low shrinkage Flowable Composite (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
41473970|NCT06155773|PROCEDURE|Resin Modified Glass Ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
40799937|NCT01637532|DRUG|tocilizumab and interferon alpha 2-b|"During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg"
41473971|NCT06155773|PROCEDURE|Bioactive Ionic Resin (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
41473972|NCT06504498|DEVICE|0.5 mm-thick Duran® clear aligner|0.5 mm-thick clear aligner was used for orthodontic treatment.
41473973|NCT06504498|DEVICE|0.75 mm-thick Duran® clear aligner|0.75 mm-thick clear aligner was used for orthodontic treatment.
41473974|NCT00915837|DRUG|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
41473975|NCT00915837|DRUG|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
41473976|NCT01643226|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
41473977|NCT01643226|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
41473978|NCT01643226|DEVICE|KXL System|30 mW/cm2
41473979|NCT04509999|DRUG|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily
41473980|NCT04509999|DRUG|Placebo|Placebo as formulated by mouth daily
41316595|NCT04706429|DRUG|Placebo|Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.
41316596|NCT01021813|DRUG|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
41316597|NCT01021813|DRUG|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
41473981|NCT01758419|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
41473982|NCT02883478|DEVICE|UV-X 1000 (3 mW/cm²)|Ultraviolet-A (UVA) irradiation for 30 minutes at 3 milliwatt/cm² (mW/cm²).
41316598|NCT05644379|DRUG|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
41473983|NCT02883478|PROCEDURE|UV-X 2000 (9 mW/cm²)|Ultraviolet-A (UVA) irradiation for 10 minutes at 9 mW/cm².
41473984|NCT02883478|DRUG|riboflavin with hydroxypropyl methylcellulose|Drops of riboflavin with hydroxypropyl methylcellulose will be applied in the eye for 20 minutes before ultraviolet-A(UVA) irradiation and every 2 minutes during UVA irradiation
41473985|NCT00005075|PROCEDURE|high-intensity focused ultrasound ablation|
41473986|NCT02440516|OTHER|Early treatment group|Physical- and occupational Therapy
41316599|NCT05644379|DRUG|Regorafenib|Regorafenib 80mg, po, orally once daily
41316600|NCT05202769|OTHER|Video filming|Video clips taken using RGB and thermal imaging cameras under varying conditions of lighting, movement and procedures taking place.
41473987|NCT02440516|OTHER|Late treatment group|Waiting list - then Physical- and occupational Therapy
41473988|NCT05139277|DIAGNOSTIC_TEST|CONVIVO system|Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Again this will only be in regions that would normally be resected or sampled in routine clinical care. Following image acquisition, a neuropathologist present in the operating room, will review and capture each image.
41316601|NCT03810209|DRUG|Magnesium Sulphate|adding magnesium sulphate to local anaesthetic in SAP Block
41316602|NCT03810209|DRUG|Normal saline|adding normal saline to local anaesthetic in SAP block
41316603|NCT02326467|DRUG|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
40799938|NCT01637532|DRUG|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
40799939|NCT03822143|DIAGNOSTIC_TEST|Ultrasound|Use of ultrasound device to diagnosis anemia in a fetus
41316604|NCT06525545|PROCEDURE|early mobilizzation of the ankle|perform flexion-extension exercises of the operated ankle
41316605|NCT03379012|DRUG|Testosterone undecanoate and sunitinib or pazopanib|Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
41316606|NCT01030458|DRUG|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
41316607|NCT01030458|DRUG|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
41316608|NCT02587624|PROCEDURE|catheter ablation|Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.
41316609|NCT03089216|PROCEDURE|Combined Bleaching(2x20)|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
41316610|NCT03089216|PROCEDURE|Combined Bleaching(2x20) with arginine|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
41316611|NCT03089216|PROCEDURE|Combined Bleaching (1x20)|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
41473989|NCT05139277|OTHER|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
41473990|NCT06342024|OTHER|Pistachio group|Participants will be giving 1.5 ounces of pistachios to consume during the 6-month trial.
41152069|NCT02169245|OTHER|Dietary control of protein and fiber intake at breakfast|Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
41316612|NCT03089216|PROCEDURE|Combined Bleaching(1x20) with arginine|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
41473991|NCT00135382|DRUG|Videx EC|
41473992|NCT00135382|DRUG|Epivir|
41473993|NCT00135382|DRUG|Sustiva|
41473994|NCT04847596|OTHER|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
41473995|NCT04847596|OTHER|Covid-19 vaccine|Prospective observational cohort study. There is no treatment allocation. Participants will obtain the COVID-19 FDA approved Emergency Use mRNA vaccine through their HCP (private insurance) or appropriate federal, state or local program.
41473996|NCT04162353|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
41473997|NCT06308172|PROCEDURE|Hysterotomy closure|Hysterotomy closure is done in either one of two ways. Single layer closure consists in a single layer, unlocked suture. Double layer closure consists in a double layer, unlocked suture.
41473998|NCT03212794|BEHAVIORAL|Recovery coach|The recovery coach will support the subjects in the following areas: 1) monitor and manage symptoms, 2) patient education and self-management, and 3) enlisting community and social supports. Encouragement to continue treatment will be a primary focus of the recovery coach. In addition, the coach will conduct weekly sessions on various topics and offer personal insights and facilitate a discussion.
41316613|NCT03089216|DRUG|8% arginine and calcium carbonate|using during all the treatment.
41316614|NCT00362791|BEHAVIORAL|"Enhanced HIV/STD Counseling: 4 face-to-face, interctive counseling sessions based on the Theory of Reasoned Action & Health Belief Model"|
41316615|NCT00362791|BEHAVIORAL|"Brief Counseling (aka client-centered counseling): 2 brief, face-to-face interactive sessions targeted a patient-identified risk behavior"|
41316616|NCT00362791|BEHAVIORAL|"HIV Prevention Education: 2 brief, didactic sessions informing the patient about HIV/STD prevention strategies"|
41316617|NCT05550818|OTHER|High Ultra Processed Food Diet|Participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
41473999|NCT03382431|DRUG|PC786|Repeat doses
41474000|NCT03382431|DRUG|Placebo/vehicle|Repeat doses
41474001|NCT01273857|PROCEDURE|Autologous cardiac progenitor cell transplantation|Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
41474002|NCT01273857|PROCEDURE|staged shunt procedure|Norwood-Glenn, Glenn, or Fontan procedure will be applied
41474003|NCT03250455|DIAGNOSTIC_TEST|CTA CTP|CT Angiography myocardial CT Perfusion
41474004|NCT03250455|DIAGNOSTIC_TEST|CTA|CT Angiography
41474005|NCT01944384|DRUG|aldactone|aldactone 25 mg for 6 months
41474006|NCT03648619|DIAGNOSTIC_TEST|Semi whole-body MRI|Single semi-automatic, semi whole-body MRI protocol (Dot engine)
41474007|NCT06469112|DEVICE|Vibration|The device was used to provide vibration with the participants in this group. This device, designed as a combination of cold application and local vibration to reduce pain experienced during invasive procedures, is frequently chosen for all age groups.
41474008|NCT06469112|OTHER|Placebo|The device was used with participants in this group. The device, at room temperature, was placed by the researcher 5cm proximal to the injection site before the injection was performed. With participants in this group, the device was placed on the procedure site, but no vibration was made. The device was held on the participants for one minute before the injection and throughout the procedure, with the vibration switched off.
41474009|NCT04082936|DRUG|imvotamab|Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
41316618|NCT05550818|OTHER|No Ultra Processed Food Diet|Participants will be provided and consume a diet containing no UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
41152070|NCT00214162|BEHAVIORAL|Comprehensive Health Enhancement Support System|Full CHESS
41316619|NCT01213368|DRUG|DRONEDARONE (SR33589)|"Pharmaceutical form: tablets~Route of administration: oral"
41316620|NCT01213368|DRUG|placebo|"Pharmaceutical form: tablets~Route of administration: oral"
41316621|NCT04585295|DIETARY_SUPPLEMENT|Betaine|50 mg/kg Betaine consumed twice daily for 7 days.
41316622|NCT04585295|DIETARY_SUPPLEMENT|BCAA Big 6|1 level scoop (\~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.
41316623|NCT04585295|DIETARY_SUPPLEMENT|Placebo|50 mg/kg Placebo consumed twice daily for 7 days.
41316624|NCT00202397|DRUG|Riluzole|capsule-shaped 50 mg tablets bid for 8 weeks
41316625|NCT00202397|OTHER|placebo|capsule-shaped tablet bid for 8 weeks
41316626|NCT05263817|BIOLOGICAL|CD19/BCMA CAR T-cells|Each subject receive CD19/BCMA CAR T-cells by intravenous infusion
41474010|NCT05899920|DIAGNOSTIC_TEST|Blood samples will be taken for pharmacokinetics and pharmacogenetics|To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
41474011|NCT03879096|OTHER|Therapeutic Exercise and Education|Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.
40799940|NCT04504539|BIOLOGICAL|mOPV|mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1
41152071|NCT00214162|BEHAVIORAL|computer with internet|computer with internet use x 1 year
41152072|NCT00349661|DRUG|impact on VASP test|
41152073|NCT01165944|DRUG|Pramlintide|Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
41316627|NCT03948126|OTHER|Questionnaire about geophagia (knowledge about soil/clay consumption and knowledge of the health effects of geophagy)|
41316628|NCT01693055|DEVICE|UltheraTM 100 shots|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
41316629|NCT00190983|DRUG|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
41316630|NCT04284943|PROCEDURE|Long limb Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 150 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 50 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
41316631|NCT04284943|PROCEDURE|Conventional Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 20 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 30-45 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
41316632|NCT04284943|PROCEDURE|Billroth II reconstruction after subtotal gastrectomy|The duodenum will be transected approximately 2 cm distal to the pylorus and anastomosis will be performed between the gastric remnant and a loop of jejunum chosen approximately 20 cm distal to the ligament of Treitz (Length of afferent loop)
41316633|NCT02058758|DEVICE|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
41152074|NCT01666171|DRUG|metformin hydrochloride|
41316634|NCT04157868|DRUG|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
41316635|NCT04157868|DRUG|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
41152075|NCT01666171|OTHER|clinical observation|
41152076|NCT01666171|OTHER|diagnostic laboratory biomarker analysis|
41152077|NCT01666171|OTHER|imaging biomarker analysis|
41152078|NCT01666171|OTHER|medical chart review|
41152079|NCT01666171|PROCEDURE|digital mammography|
41152080|NCT06365177|OTHER|Physical consultation|"The subject enters a room where the therapist is present. A chair is placed against a wall in the same room.~Once again, the therapist suggests repeating the test. During the test, the therapist sits opposite the patient, at the same distance as the computer used during the teleconsultation."
41474012|NCT00909584|DRUG|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
41474013|NCT02153892|DEVICE|GDS Accucinch System|Percutaneous Coronary Intervention
41474014|NCT01955512|DRUG|Clopidogrel|Clopidogrel 75mg daily for 7 days
41474015|NCT01955512|DRUG|Placebo|Matched placebo
41474016|NCT03669575|DIETARY_SUPPLEMENT|omega 7|Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
41474017|NCT03669575|DIETARY_SUPPLEMENT|Placebo|Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
41474018|NCT00138957|PROCEDURE|Laparoscopic parastomal hernia repair with mesh|
41474019|NCT00176631|DIETARY_SUPPLEMENT|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
40799941|NCT04504539|BIOLOGICAL|bOPV|bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3
41316636|NCT00353964|DRUG|rEV131|
41316637|NCT00353964|DRUG|Prenisolone sodium phosphate 1.0%|
41316638|NCT00353964|DRUG|rEV131 vehicle|
41316639|NCT03677310|DRUG|3% Sodium Chloride|3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
41316640|NCT03677310|DRUG|Normal Saline|Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
41316641|NCT02915952|DEVICE|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
41316642|NCT02915952|OTHER|Conventional Sutures|Conventional Sutures will be used for surgical wound closure in C-Section Surgery
41316643|NCT06146335|PROCEDURE|Kono-S anastomosis (KSa)|antimesenteric functional end-to-end handsewn anastomosis connecting small intestine and colon after surgery
41316644|NCT06146335|PROCEDURE|Side-to-side anastomosis (SSa)|side-to-side anastomosis connecting small intestine and colon after surgery
41316645|NCT04004559|OTHER|No interventions|As this is a patient registry, there are no interventions.
41316646|NCT05400473|OTHER|Therapeutic exercise|This group will consist of 30 participants. A program consisting of specific therapeutic exercises for the cervical region will be applied.
41316647|NCT05400473|OTHER|Photobiomodulation|Photobiomodulation will be applied on the cervical region. To perform the photobiomodulation protocol, a low power infrared laser therapy unit will be used.
41316648|NCT04111172|BIOLOGICAL|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Given as intramuscular injection
41316649|NCT02938052|BEHAVIORAL|PP-based health behavior intervention|The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
41316650|NCT03486210|BEHAVIORAL|Food preference|The study will take place in two phases. A first phase will consist in the validation of translations and the selection of images on 20 healthy volunteers and 20 health professionals specialized in nutrition. They will have to fill a form with images of food and evaluate to what extend they think the pictures represent what we can eat in France. This step will adapt the questionnaire to our country.
41316651|NCT03486210|OTHER|Psychological assesment|"Phase performed with patients fasting for at least 2 hours before the different tests. The FLPQ will be compared between a group of patients suffering from unoperated obesity (OCt), a group of patients operated on a sleeve gastrectomy (OSl) and a group operated by a bypass (OBy) between 6 and 24 months post-surgery, randomized for the 6 combined tests (2 categories). The award can be made in 2 sessions of at least 3 of the 6 tests combined. Each test combines 2 of the 11 categories. The test will consist of 96 pairs of 16 food images presented on a computer screen in color. Participants will be invited to choose the food they most want to eat, by pressing the corresponding computer button (choices saved by counting the frequency scores in E-prime).~The level of hunger will be evaluated by an Analogical Visual Scale, ranging from 0 to 10.~Patients should also complete 3 self-questionnaires used routinely (Binge Eating Scale, The Yale Food Addiction Scale, The UPPS-P short version)."
41316652|NCT01237106|OTHER|IVM|all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
41316653|NCT02557854|DRUG|Doxorubicin HCl liposomal injection|50mg IV every 4 weeks
41316654|NCT02557854|DEVICE|Philips Sonalleve MR-HIFU Hyperthermia|Hyperthermia to 42C for 30 minutes every 4 weeks
41316655|NCT05476185|BEHAVIORAL|READY4Life Programming - classroom instruction|The intervention group receives 16 hours of classroom instruction.
41474020|NCT00176631|DRUG|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
41474021|NCT03523247|BEHAVIORAL|whole food, plant based diet|whole food, plant based diet featuring vegetables, fruits, legumes, whole grains, seeds, and nuts
41474022|NCT04574128|PROCEDURE|No retransfusion of cardiotomy blood|No retransfusion of cardiotomy blood via heart- and lung mashine
41004006|NCT02829749|DEVICE|NeoChord beating heart mitral valve implantation|The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
41474023|NCT05587972|OTHER|survey|Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic PRO surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks.
41474024|NCT02262195|OTHER|Elevated levels of carboxyhemoglobin|Comparison of pulse co-oximeters
41474025|NCT04329299|DIAGNOSTIC_TEST|blood-based biomarkers analyses|Analyses of H. pylori antibodies/pepsinogen levels, micro RNAs (miRNAs) or blood-based protein markers levels in participants' blood samples
41474026|NCT06218121|DIAGNOSTIC_TEST|Instrumental and Functional Tests that Assess Functional Capacity|The correlation between all functional, ultrasound, nutritional, and psychological variables will be analyzed. Through GLIM diagnosis, anthropometric data (weight, height, BMI) as well as analytical data including inflammation information (CRP and albumin) will be used to reach a diagnosis that allows comparison/correlation with the rest of the variable parameters.
40799942|NCT04504539|BIOLOGICAL|Full dose IPV|FIPV (full dose injectable polio vaccine)
40799943|NCT04504539|BIOLOGICAL|fractional IPV|fIPV (fractional dose injectable polio vaccine)
41004007|NCT02829749|PROCEDURE|Control|traditional mitral valve repair performed under cardiac arrest
41004008|NCT05160428|BIOLOGICAL|COVID-19 vaccination|different types of covid-19 vaccinations.
41004009|NCT03139916|DRUG|Temozolomide|Temozolomide causes cell death and shrinks and kills the cancer cells
41316656|NCT01667393|DEVICE|IDEV SUPERA Stent|
41004010|NCT03139916|DRUG|Bavituximab|Bavituximab may activate (cause) the immune system to attack the cancer cells
41004011|NCT03139916|RADIATION|Radiation|Radiation causes cell death and shrinks and kills the cancer cells.
41004012|NCT04464642|DRUG|Methotrexate|Methotrexate 25 mg subcutaneous is given in group A
41316657|NCT01667393|DEVICE|Percutaneous Transluminal Angioplasty|
41474027|NCT00975741|DEVICE|OXIMAX|
41474028|NCT00975741|DEVICE|ASMANEX TWISTHALER|
41004013|NCT04464642|DRUG|Tofacitinib|tofacitinib 10 mg given in group B
41316658|NCT04674618|DEVICE|US-assisted nusinersen administration|Ultrasound identification of intervertebral space (L2-L3 or L3-L4)
41316659|NCT00656734|BIOLOGICAL|MDX 1411|MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
41316660|NCT04742426|OTHER|WHO recommended PPE|Uses polycarbonate safety spectacles, fluid-resistant (Type IIR) surgical mask and disposable surgical gown. No head or foot cover.
41474029|NCT05755087|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41474030|NCT05755087|PROCEDURE|Computed Tomography|Undergo CT
41474031|NCT05755087|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41316661|NCT04742426|OTHER|Super-safe setup|Uses surgical cap, FFP3 respirator covered by surgical mask, face shield, whole-body suit (Tyvec), 3 pairs of gloves typed to suit sleeves and disposable foot cover.
41474032|NCT05755087|DRUG|Tegavivint|Given IV
41474033|NCT06199713|DIAGNOSTIC_TEST|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography|research scan 3-4 weeks after start of immunotherapy
41474034|NCT00148720|DRUG|Capecitabine|Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
41474035|NCT02432118|PROCEDURE|Lumpectomy|Undergo lumpectomy
41474036|NCT02432118|OTHER|Questionnaire Administration|Ancillary studies
41474037|NCT02432118|PROCEDURE|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
41474038|NCT04512326|PROCEDURE|Total or Subtotal colectomy|Total or subtotal colectomy (emergent or elective) with primary anastomosis (ileorectal or ileosigmoid)
41474039|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
41474040|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
41474041|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
41474042|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
41474043|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
41474044|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
41474045|NCT00467987|DRUG|androgel|androgel 1%
41316662|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (<3-day postpartum)|Single dose 200,000 IU vitamin A supplementation at \<3-day and placebo supplementation at 6-wk postpartum.
41316663|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (6 wk postpartum)|Placebo supplementation at \<3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
41474046|NCT00467987|DRUG|placebo|placebo
41474047|NCT01352182|DRUG|Pioglitazone hydrochloride|Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
40799944|NCT00918606|DRUG|LIPO-102|LIPO-102
40799945|NCT00189579|DRUG|Herceptin|
40799946|NCT03391557|DIAGNOSTIC_TEST|UE|All patients were examined by enhanced chest computed tomography (CT), the B-mode ultrasound and endobronchial ultrasound (EBUS)guided elastography before EBUS-TBNA. Each lymph node was assessed by describing the characteristics of the CT image (short diameter, texture, shape, boundary, mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and ultrasound elastography (image type, grading score, strain rate, blue area ratio).
41004014|NCT01281748|DRUG|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
41152081|NCT06365177|OTHER|Teleconsultation|"Prior to the test, the investigator should carry out a mock test with a volunteer from the facility, for example, to ensure wifi, sound and image functionality.~The patient enters a room where a computer equipped with a webcam is set up on a desk. The teleconsultation has already started when the patient enters the room. No recordings are made.~A chair is placed at a distance from the desk, with the backrest against a wall. The chair faces the computer. The desk or table where the computer is located is about 3 meters from the participant, ensuring that the webcam can frame the patient's entire body during the test.~With the consultation already underway, the investigator can direct the patient to sit in the chair against the wall. The investigator will make sure that the patient hears the instructions given.~Once the patient is seated on the chair, the therapist explains the test procedure and shows it once to make sure the subject understands it."
41316664|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (<3-day and 6 wk postpartum)|200,000 IU vitamin A supplementation, both at \<3-day and 6-wk postpartum
41474048|NCT02406794|DRUG|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
41152082|NCT01754545|DRUG|Octaplas infusion and placebo (group 1)|Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
41152083|NCT01754545|DRUG|Octaplas infusion and placebo (group 2)|Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
41152084|NCT00735228|DEVICE|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
41152085|NCT05417568|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
41152086|NCT05417568|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
41152087|NCT01142154|DRUG|Prodarsan|Prodarsan TID, oral solution, 6-8 days
41474049|NCT06050876|PROCEDURE|Laparoscopic cholecystectomy for gallbladder volvulus|Laparoscopic cholecystectomy for volvulus of gallbladder
41474050|NCT06123026|DRUG|Cabergoline|1mg oral cabergoline given to participants once
41474051|NCT06123026|DRUG|Placebo|1 encapsulated placebo tablet given to participants after procedure
41474052|NCT04629274|PROCEDURE|Blood sampling|The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interval between these 2 samples.If the results obtained with the 2 initial samples would be of interest to the Sponsor, the patient will be asked to come back for additional samplings with a maximum of 6 additional blood draws
40799947|NCT01169701|DRUG|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
40799948|NCT01169701|DRUG|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
40799949|NCT01169701|DRUG|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
40799950|NCT01018017|DRUG|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
41316665|NCT02043223|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation, both at \<3-day and 6-wk postpartum.
40799951|NCT01018017|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
40799952|NCT00068263|RADIATION|radiation therapy|
41004015|NCT01281748|OTHER|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
41004016|NCT00394030|DRUG|GSK716155 subcutaneous injections|GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
41004017|NCT04355962|DRUG|Sevoflurane|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
41004018|NCT04355962|DRUG|Intravenous drug|Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
41004019|NCT05447078|DIETARY_SUPPLEMENT|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
41004020|NCT05447078|DIETARY_SUPPLEMENT|Placebo|Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.
41004021|NCT03577431|BIOLOGICAL|arTreg-CSB|"Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10\^6 total cells. If a minimum arTreg-CSB dose of 1 to \< 2.5 x 10\^6 cells, the product will be infused. If the dose obtained after product manufacture is \< 1 x 10\^6 cells, the product will not be infused. When the dose obtained after product manufacture is \> 125 x 10\^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10\^6 cells, and ≥ 2.5 to 125 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes."
41004022|NCT03577431|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion."
41474053|NCT04945018|BIOLOGICAL|HS-001 CS|Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension
41474054|NCT04945018|DEVICE|HS-001-D needle, HS-001-D Adaptor|Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors
41474055|NCT02212340|DRUG|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
41474056|NCT02212340|DRUG|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
41004023|NCT03577431|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
41004024|NCT03577431|DRUG|mesna|Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.
41474057|NCT02588547|DRUG|Granisetron|IV granisetron 1 mg before spinal anethesia
40799953|NCT03836872|DEVICE|Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
40799954|NCT02075294|DRUG|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
40799955|NCT04535102|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin is an ADC designed for the targeted delivery of MMAE(mono-methyl auristatin E), a potent microtubule inhibitor to lymphoma cells expressing CD79b. MMAE has a mechanism of action that is similar to that of vincristine.
41004025|NCT03577431|DRUG|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
41004026|NCT02581774|OTHER|normal delivery tracking|normal delivery tracking
41474058|NCT02588547|DRUG|Granisetron|IV granisetron 0.7 mg before spinal anethesia
40799956|NCT00395070|BIOLOGICAL|Allovectin-7®|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
41004027|NCT04966676|DIAGNOSTIC_TEST|cfDNA blood test|Blood sample will be taken for cfDNA testing
41004028|NCT04966676|DRUG|Nivolumab|Antineoplastic agent
41004029|NCT04966676|DRUG|Ipilimumab|Antineoplastic agent
41004030|NCT04966676|COMBINATION_PRODUCT|Platinum-based Chemotherapy|May include carboplatin with gemcitabine, or paclitaxel or pemetrexed
41004031|NCT03149250|DIAGNOSTIC_TEST|Aggregometry, Monitoring of plasmatic hemostasis|Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
41004032|NCT04935476|DRUG|Dapsone 85 mg PO BID|Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.
41004033|NCT04935476|DRUG|Placebo 85 mg PO BID|Placebo oral tablet, twice daily for 21 days.
41004034|NCT05058313|DEVICE|Photobiomodulation|Six weekly photobiomodulation sessions (PBMT) using the MILTA ™ GYNECO vaginal probe.
41316666|NCT00000196|DRUG|Naltrexone|
41474059|NCT02588547|DRUG|Sodium chloride|IV 2 ml 0.9 sodium chloride before spinal anethesia
41474060|NCT01834898|DRUG|Controlled-release oxycodone|Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
41474061|NCT01117467|OTHER|Simulation scenario|Students performing their scenario will be paired, not solo
40799957|NCT00395070|DRUG|Dacarbazine (DTIC)|1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
41316667|NCT03312712|RADIATION|PET/CT scan|"PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.~Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.~After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.~18F-FDG will be administered intravenously at a dose of approximately 200 MBq.~Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs."
41474062|NCT01117467|OTHER|Simulation scenario|Students will perform their simulation scenario solo and receive feedback within the group
41474063|NCT06403683|DIAGNOSTIC_TEST|WaLIDD score / Insomnia Severity Index (ISI) / International Physical Activity Questionnaire (Short-form) / Six-Minute Walk Test|Case control trial study
41474064|NCT02986035|OTHER|ECA cream|
41474065|NCT05993598|OTHER|hippotherapy|Evaluation parameters were applied to 30 children with special needs at the beginning of the session. After the evaluation, each group was given a 30-minute hippotherapy session in the manege area. During the practice, the child simply sat on the horse. The horse was asked to maintain its balance by adapting to the oscillations it creates while walking on the sand. Immediately after the 30-minute application, the initial evaluations were made again. As a result, it was investigated whether hippotherapy applied on different sitting surfaces in children with special needs had an effect on sitting balance and walking speed.
40799958|NCT00395070|DRUG|Temozolomide (TMZ)|150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
40799959|NCT00915759|DEVICE|ProKera|ProKera placed in non-dominant eye after PRK
40799960|NCT00915759|DEVICE|Bandage contact lens|Bandage contact lens placed in dominant eye, the current standard after PRK
40799961|NCT02314156|DRUG|Telapristone Acetate|Given transdermally
40799962|NCT02314156|OTHER|Placebo|Given PO
40799963|NCT02314156|DRUG|Telapristone Acetate|Given PO
40799964|NCT02314156|OTHER|Placebo|Given transdermally
40799965|NCT02314156|OTHER|Laboratory Biomarker Analysis|Correlative studies
41474066|NCT03493321|OTHER|PRF with Theracal|using the PRF which is a new technique with an bioactive material which is the Theracal to evaluate its effect upon the radicular pulp tissue
40799966|NCT02314156|OTHER|Questionnaire Administration|Ancillary studies
40799967|NCT00090961|OTHER|educational intervention|
41152088|NCT06306599|DIAGNOSTIC_TEST|S-Detect for Thyroid|"Deep learning based program on Samsung ultrasound machines designed to do real-time semi-automated analysis of thyroid nodules. The ultrasound operator freezes a transverse image of the patient's thyroid nodule and activates S-Detect. The operator selects the nodule on the screen, and the program automatically draws a region of interest. Then S-Detect gives a dichotomous diagnosis of either Possibly benign and Possibly malignant. In addition, it measures the nodule and characterises it with a lexicon based on EUTIRADS."
41004035|NCT01638962|DRUG|Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)|The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
41004036|NCT01638962|OTHER|Neuromuscular exercise|The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
41152089|NCT02513979|DRUG|Angiotensin type II receptor antagonists|Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
41316668|NCT03312712|OTHER|LPS Challenge|In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.
41316669|NCT03312712|OTHER|Saline Challenge|In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.
41474067|NCT02853864|DRUG|0.0 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0 ng/ml
41474068|NCT02853864|DRUG|0.4 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4 ng/ml
41474069|NCT02853864|DRUG|0.6 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6 ng/ml
41474070|NCT02853864|DRUG|0.8 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8 ng/ml
41474071|NCT02853864|DRUG|Propofol|The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
40799968|NCT00090961|OTHER|supervised exercise program|
40799969|NCT00021567|DRUG|Interferon Gamma for Aerosol|
40799970|NCT00763295|OTHER|T-Spot.TB test|diagnostic test
40799971|NCT02654821|BIOLOGICAL|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
40799972|NCT02654821|PROCEDURE|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
40799973|NCT02654821|PROCEDURE|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
40799974|NCT00978419|DRUG|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
40799975|NCT00978419|DRUG|Placebo|Placebo administered every day for up to 28 days
40799976|NCT04496908|PROCEDURE|amniotomy|Artificially rupturing membranes
40799977|NCT04496908|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline.
41316670|NCT03312712|DIAGNOSTIC_TEST|Blood and urine sampling|For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
41316671|NCT02484612|BEHAVIORAL|acute exercise|
41316672|NCT03630484|OTHER|Expiratory Rib Cage Compression|Compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
41316673|NCT03630484|OTHER|Compression + Ventilator Hyperinflation|Mechanical ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same. In Expiratory Rib Cage Compression associated with ventilator hyperinflation, thoracic compression maneuver was performed at the end of inspiration, at the exact moment of cycling.
41474072|NCT02784678|PROCEDURE|closed reduction group|Patients in the experimental group will undergo C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws. In the experimental group, fractures will be reduced and internally fixed with fully threaded headless cannulated compression screws of appropriate lengths (Acutrak plus; Acumed Inc., Beaverton, OR, USA) under C-arm fluoroscopic guidance to restore the radial inclination and ulnar deviation of the distal radius.
41474073|NCT02784678|DEVICE|open reduction group|Patients in the control group will undergo open reduction and internal fixation with a titanium plate (Ningbo Cibei Medical Treatment Appliance Co., Ltd., Ningbo, China).
41474074|NCT00972907|DRUG|Nifedipine coated suppositories|12 mg Nifedipine coated suppositories BID
41004037|NCT02579746|BEHAVIORAL|DASHNa-CC|The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.
41004038|NCT02579746|BEHAVIORAL|usual care|education booklet, encouragement of physician visit, use of public health resources if needed
41474075|NCT02765672|BEHAVIORAL|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
41004039|NCT03270046|PROCEDURE|Water enema|Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
41004040|NCT03298750|PROCEDURE|Resection of ovarian tissue and mechanical stimulation|"he women will undergo a surgical laparoscopy during which one of the two technique will ensue.~1. One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.~2. A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.~The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.~These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.~Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).~Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory."
41004041|NCT02928510|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
41004042|NCT02928510|PROCEDURE|Colonoscopy|Undergo colonoscopy
41004043|NCT02928510|PROCEDURE|Colposcopic Biopsy|Undergo colposcopic biopsy
41004044|NCT02928510|DRUG|Idelalisib|Given PO
41004045|NCT02928510|OTHER|Laboratory Biomarker Analysis|Correlative studies
41004046|NCT02928510|OTHER|Pharmacological Study|Correlative studies
41004047|NCT02928510|PROCEDURE|Physical Examination|Undergo physical examination
41004048|NCT02928510|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
41004049|NCT01505686|PROCEDURE|MRI scan|MRI scan with a 1,5 T MRI scanner
41004050|NCT02794272|DEVICE|tDCS|
41316674|NCT00788697|DRUG|SonoVue-enhanced ultrasound|Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
41316675|NCT00788697|OTHER|Unenhanced ultrasound|-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
40799978|NCT04496908|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg.
40799979|NCT06552975|OTHER|Infection|Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.
40799980|NCT02398136|DRUG|Ketamine|
40799981|NCT02398136|DRUG|Midazolam|
41004051|NCT02794272|DEVICE|sham-tDCS|
40799982|NCT02940899|OTHER|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
41004052|NCT00620594|DRUG|BEZ235|
41004053|NCT02552316|DEVICE|NB-UVB Phototherapy|
41004054|NCT04488328|OTHER|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)
41004055|NCT02456324|DEVICE|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
41004056|NCT02456324|DEVICE|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
41316676|NCT03431324|BEHAVIORAL|Episodic Future Thinking about Mating Opportunities|"Participants who complete the mating-EFT intervention will be instructed to write about three positive mating-related events that would occur within the course of one year if you successfully quit smoking now. Participants will then be asked to close their eyes and imagine the events that they listed as specifically and vividly as possible (e.g., to imagine the setting and the sequence of the events, as well as the persons and objects that would be present. A period of one minute will be allotted for participants to mentally pre-experience each event.~The general-EFT intervention will be structured similarly to, with the key exception of being instructed to write about and imagine three positive life events."
41316677|NCT03431324|BEHAVIORAL|Targeted Mating-EFT Intervention|"This intervention is identical to the Episodic Future Thinking about Mating Opportunities intervention with the exception that in Arm 2 the aim will be to determine whether the Mating-EFT intervention is especially effective when administered to individuals who are single or highly motivated to seek a mate."
41316678|NCT03941236|DRUG|dasiglucagon|Glucagon analog
41316679|NCT01042613|PROCEDURE|Cannulation using Accuvein device|If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
41316680|NCT01042613|PROCEDURE|Standard Cannulation method|If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
41316681|NCT03307954|DEVICE|Ekso Therapy (Exoskeleton Suit)|
41316682|NCT03307954|OTHER|Usual Physiotherapy|
41316683|NCT05216991|OTHER|TetraGraph on dominant hand|Using standard of care TetraGraph device on dominant hand
41316684|NCT05216991|OTHER|TetraGraph on non-dominant hand|Using standard of care TetraGraph device on non-dominant hand
41474076|NCT02765672|OTHER|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
40799983|NCT04314700|DEVICE|OCT- based investigational imaging device|Excised breast lumpectomy tissue will be imaged and images reviewed on an investigational Wide-Field OCT (WF-OCT) device.
40799984|NCT06433154|PROCEDURE|Arthroscopic surgery|Arthroscopic treatment (lysis and lavage) of internal derangement of the temporomandibular joint.
40799985|NCT03548896|PROCEDURE|Post extraction socket|\*\*Dental implant will be placed 3 months after tooth extraction
40799986|NCT03042650|BEHAVIORAL|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
41004057|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 12.5 mcg|1 dose of 0.5 mL
41004058|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 5.0 mcg|1 dose of 0.5 mL
41316685|NCT03386578|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily
41316686|NCT03386578|BEHAVIORAL|Behavioral HIV risk reduction package|HIV risk reduction package, including cohort-appropriate SMS messages. Participants in the PrEP Comparison Component: Cohort 1 will also receive enhanced adherence support, including two-way SMS messaging and tailored counseling with near-real time drug level feedback.
41316687|NCT05138549|DRUG|Astaxanthin|12 mg oral astaxanthin supplement
41316688|NCT05138549|OTHER|Placebo|Oral placebo identical to astaxanthin supplement
41316689|NCT04198324|PROCEDURE|Closure of the uterus with endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed with suturing the endometrium.
41316690|NCT04198324|PROCEDURE|Closure of the uterus without endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed without suturing the endometrium.
41316691|NCT01467648|DRUG|Doripenem|"(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
41474077|NCT02765672|BEHAVIORAL|Propensity for Angry Driving Scale|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
41474078|NCT02765672|BEHAVIORAL|Community Integration Questionnaire|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
41474079|NCT02765672|BEHAVIORAL|Satisfaction with Life|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
40799987|NCT03042650|BEHAVIORAL|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
40799988|NCT00002509|BIOLOGICAL|filgrastim|
40799989|NCT00002509|DRUG|carboplatin|
40799990|NCT00002509|DRUG|cyclophosphamide|
40799991|NCT00002509|DRUG|etoposide|
40799992|NCT00002509|DRUG|mesna|
40799993|NCT00002509|PROCEDURE|autologous bone marrow transplantation|
41004059|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 1.25 mcg|1 dose of 0.5 mL
41004060|NCT01193907|BIOLOGICAL|Vi-polysaccharide vaccine|1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide
41004061|NCT03548584|DRUG|Brexpiprazole|Oral tablets
41004062|NCT03548584|OTHER|Placebo|Oral tablets
41004063|NCT00353366|BIOLOGICAL|Rotarix|Two doses of the oral vaccine
41316692|NCT01467648|DRUG|Doripenem|"(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
41474080|NCT02765672|BEHAVIORAL|Fitness-to-Drive Screening Measure (FTDS)|Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
41316693|NCT04413643|DEVICE|Noninvasive Ventilation|The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 \>45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.
40799994|NCT00002509|PROCEDURE|peripheral blood stem cell transplantation|
40799995|NCT01553682|BEHAVIORAL|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
40799996|NCT01553682|BEHAVIORAL|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
40799997|NCT04894838|PROCEDURE|Distal gastric bypass|Distal gastric bypass, revisonal surgery after failed RYGB
41004064|NCT00353366|OTHER|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
41004065|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
41004066|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
41316694|NCT01070602|PROCEDURE|anterior (more central) corneal paracentesis incision|3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
41316695|NCT04003337|OTHER|Morpho-kinetics selection with time-lapse (Embryoscope) evaluation|Embryos in group B will be selected in blastocyst stage according to morpho-kinetics criteria before the embryo transfer
41316696|NCT00423735|DRUG|Dasatinib|Given PO
41316697|NCT00423735|OTHER|Pharmacological Study|Correlative studies
41316698|NCT00119730|DRUG|Fludarabine|Given on days 1-3 of each 28-day cycle
40799998|NCT06026072|OTHER|CLAD-V SCORE|the CLAD-V score is measured by the doctor during the emergency take care. After 7 days the patient will be call back to compare the prediction of CLAD-V score and the reality of surgical intervention or no.
40799999|NCT00419211|BEHAVIORAL|Exercise|Tailored exercise program
40800000|NCT02644096|OTHER|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
40800001|NCT02342288|PROCEDURE|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
41004067|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
41004068|NCT00409292|DRUG|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
41004069|NCT02273219|DRUG|AEB071|Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
41004070|NCT02273219|DRUG|BYL719|Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
41004071|NCT02867540|OTHER|MRI enterography|
41004072|NCT04948138|DIETARY_SUPPLEMENT|Glutamine oral supplementation|Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
41004073|NCT03978975|BEHAVIORAL|Food intake|"For all those session, subjects will take a standardized breakfast (570kcal) three hours before experimental session.~Control session (CON): subject will stand sited without any activity during 40 min.~Subjects will be submitted to three aquatic cycling exercise session:~* session 27°C :aquatic cycling at 27°C without water jet during 40 min~* session 27°C+ water jets : aquatic cycling at 27 °C with water jets during 40 min~* session 18°C : aquatic cycling at 187°C without water jet during 40 min Every exercise session will be set at 70% of theorical maximal heart rate During each session, oxygen consumption and carbon dioxide production will be analysed with gas analysis system. Appetite and hunger sensation will be measured with a specific scale at different time point of each day of experimental session. Thirty minutes after the end of each experimental session subjects will have a buffet meal for lunch time."
41004074|NCT03581110|DIAGNOSTIC_TEST|computed tomography|noncontrast-enhanced chest computed tomography
41004075|NCT05558293|PROCEDURE|Scaling and root planing|Full mouth or quadrant SRP
41004076|NCT06175143|BIOLOGICAL|GR2002 injection|TSLP monoclonal antibody
41004077|NCT01332617|DRUG|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|"1. Simvastatin 80 mg PO daily starting day -2 through day 10.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8."
41316699|NCT00119730|DRUG|Mitoxantrone|Given on day 1 of each 28-day cycle
41316700|NCT00119730|DRUG|Rituximab|Given on day 1 of each 28-day cycle
41316701|NCT00119730|DRUG|Zevalin|After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
41004078|NCT02697162|DEVICE|Antiseptic-coated catheter|Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride
41004079|NCT02697162|DEVICE|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
41474081|NCT02765672|PROCEDURE|Simulated Driving Evaluation|This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
41316702|NCT00939224|DEVICE|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
41316703|NCT01757782|DRUG|Oral Sildenafil|Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be \<10% of previous value and SpO2 was not increasing \>5 of previous value) and blood pressure remained stable
41474082|NCT02765672|PROCEDURE|Driving Safety Education|This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional
41316704|NCT01757782|DRUG|Placebo (distilled water)|Distill water oral
41474083|NCT02765672|PROCEDURE|Occupational Therapy Driving Intervention (OT-DI)|This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.
41474084|NCT02765672|PROCEDURE|On-road driving test|This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5
41474085|NCT02765672|PROCEDURE|Driving triggers evaluation|The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
41474086|NCT02502734|DRUG|Fluticasone furoate|FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
41474087|NCT02502734|DRUG|Placebo|Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
41474088|NCT02502734|DRUG|Salbutamol|Salbutamol will be provided as a inhaler.
41474089|NCT04778618|DRUG|Antithymocyte Globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg). Antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (days -5 and -2). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate
41474090|NCT00406588|DRUG|Levodopa (Pardoprunox)|12-42mg
41474091|NCT00406588|DRUG|Placebo Comparator|Placebo
41004080|NCT02697162|DRUG|Octenidine chloride|Antiseptic
41004081|NCT01023165|PROCEDURE|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
41004082|NCT04377607|OTHER|File scanning|RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
41004083|NCT05210127|PROCEDURE|Scarf osteotomy for Hallux Valgus deformity|An experiment of foot muscle strength and activation, during gate phases after hallux valgus correction with the use of core foot system protocol
41004084|NCT03610243|BEHAVIORAL|Self-administered acupressure|Two 2-hour one-on-one training sessions in patient-centered self-administered acupressure will be provided by trainers in the first week (4 hours) in the patient's home or at the university, depending on his/her preference. From the second to fourth weeks of the intervention, participants will engage in 15 minutes of self-administered acupressure twice a day (for a total of 10.5 hours over the 3 weeks). They will log the frequency of self-practice in a diary and be encouraged to undertake self-practice beyond the 4-week intervention. At weeks 2, 3, and 4, a 1-hour follow-up visit will be conducted by the same team of trainers to reinforce learning and self-practice (for a total of 3 hours over the 3 weeks).
41004085|NCT02271633|DIETARY_SUPPLEMENT|Sodium nitrate|
41152090|NCT02791009|OTHER|Cardiovascular Magnetic Resonance Imaging (CMRI)|CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
41152091|NCT02791009|OTHER|Electrocardiogram (ECG)|ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
41152092|NCT02791009|OTHER|Blood Sample Collection|Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
41152093|NCT02791009|OTHER|Clinical Assessment|Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
41474092|NCT06368752|BIOLOGICAL|GIP[3-30]NH2|GIP\[3-30\]NH2 is the naturally occurring shorter (truncated) variant of GIP\[1-42\]. GIP\[3-30\]NH2 also stimulates the GIP receptor and therefore acts like a GIP receptorantagonist
41474093|NCT06368752|OTHER|Saline|Sodium chlorid with 0,5% human serum albumin.
41152094|NCT02791009|OTHER|Cardiovascular Ultrasound (CVUS)|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
41316705|NCT05651893|BEHAVIORAL|re-examination|During colonoscopy, the left colon was examined a second time in the forward view.
41316706|NCT05651893|BEHAVIORAL|extended withdraw time|During colonoscopy, the left colon was examined with double basic withdrawal time in the forward view.
41316707|NCT00355849|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 52 weeks
41316708|NCT00355849|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 52 weeks
41316709|NCT03524105|BEHAVIORAL|Program for Parents (Parenting Program)|Program for Parents (Parenting Program) is implemented by a mental health professional and offered to groups of \~15 parents during the school day and during after school hours. The Program for Parents includes 2-hour sessions provided weekly over a 4-month period. The Program for Students (Friends School Social Emotional Learning Program) is implemented by classroom teachers in the classroom with 90 minute lessons and activities once a week for 14 weeks
41316710|NCT03524105|BEHAVIORAL|Thrive Professional Learning|Professional Learning is delivered to teachers in groups of 20-40 4 times a year over a two-year period. Professional Learning is delivered to leaders in groups of 20 - 40 three times a year over the same two-year period.
41316711|NCT01170117|DRUG|Olanzapine|Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.
41316712|NCT01170117|DRUG|Placebo|Control Group will receive placebo pill
41316713|NCT05326217|OTHER|Aerobic exercise|The aerobic exercise :In this study, the exercise intensity is set based on the subject's maximum heart rate, and the target heart rate is adjusted according to the literature to reach 60-90% of the maximum heart rate. A gradual increase of intermittent exercise will be designed for current exercise prescription. In terms of exercise frequency and time, there will be two times interventions per week for at least 60 minutes per time (including warm-up and cool down exercises).
41316714|NCT05326217|OTHER|Resistant exercise|The resistant exercise : muscular endurance (15-20RM) and muscular hypertrophy (8-12RM) are applied to main exercise intensity. The intensity is gradually adjusted according to the state of each subject, and the intervention is performed twice a week (50 minutes per time).The target muscles of resistance training include quadriceps femoris, biceps femoris, calf muscles, core muscles (including pelvic floor muscles), back muscles, pectoralis major, biceps/triceps and other muscle groups.
41316715|NCT05543460|PROCEDURE|MARPE with Corticopunctures|Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency aided with corticopunctures made along the mid-palatal suture
41316716|NCT05543460|DEVICE|MARPE|Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency
41316717|NCT03585322|DRUG|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
41316718|NCT03589885|DRUG|Placebo 2 mL auto-injector|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
41316719|NCT03589885|DRUG|Placebo 1 mL prefilled syringe|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
41316720|NCT03589885|DRUG|Secukinumab 2 mL auto-injector|2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
41474094|NCT03463018|DIETARY_SUPPLEMENT|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)
41474095|NCT03463018|DIETARY_SUPPLEMENT|Placebo|Placebo tablet containing matching excipients to the active intervention
41474096|NCT00251914|DRUG|Esomeprazole|
41474097|NCT02825576|DRUG|Sugammadex|Sugammadex 2mg/kg given for reversal agent
41474098|NCT02825576|DRUG|Neostigmine/Glycopyrrolate|Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent
40800002|NCT02342288|PROCEDURE|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
40800003|NCT03560102|DEVICE|Philips Sonalleve® MR-HIFU Breast Therapy System|The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
40800004|NCT05171374|DRUG|Dabrafenib|Observational stusy. No intervention is planned
40800005|NCT05171374|DRUG|Trametinib|Observational stusy. No intervention is planned
40800006|NCT01894724|DEVICE|NeuroSave device|
40800007|NCT06391008|RADIATION|Stereotactic radiotherapy|Targeting primary lung lesions and irradiable mediastinal lymph nodes, stereotactic large segment radiotherapy was performed to complete the prescribed dose, PTV (planned target area): 5Gy x 3f
40800008|NCT06391008|DRUG|Evoximab|Evoximab (20mg/kg, Q3W)
41152095|NCT02791009|OTHER|Cognitive Test|To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
40800009|NCT06391008|DRUG|Pemetrexed|Pemetrexed (500mg/m2, Q3W)
40800010|NCT06391008|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 260 mg/m2, Q3W
40800011|NCT06391008|DRUG|Carboplatin|Carboplatin (AUC5, Q3W)
40800012|NCT01865318|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin)
40800013|NCT00771706|DRUG|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
40800014|NCT00771706|DRUG|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
40800015|NCT06235593|BEHAVIORAL|Self-care Intervention|"The intervention will focus on self-care behavior of people with chronic diseases according to two distinct periods (through a longitudinal study - follow-up nursing interventions):~(i) baseline; and (ii) 4 months;"
40800016|NCT03712176|BEHAVIORAL|Lifestyle alteration|Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
40800017|NCT03516175|DEVICE|High flow transnasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange
40800018|NCT03516175|DEVICE|Pre oxygenation using tight fitting facemask|100% oxygen via a tight fitting facemask
40800019|NCT00286624|BIOLOGICAL|Allogeneic Islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
41316721|NCT03589885|DRUG|Secukinumab 1 mL prefilled syringe|2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
40800020|NCT00286624|DRUG|Everolimus|Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
40800021|NCT00286624|DRUG|anti-thymocyte globulin|A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
40800022|NCT00286624|DRUG|Cyclosporine|Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
40800023|NCT05464238|OTHER|Exercise rehabilitation|The initial phase of exercise training will be closely monitored and will be based on a three-weeks in-hospital stay to adjust and teach the exercise training which will be continued at home for 12 more weeks. In-hospital stays will be arranged country specific and hospitalization time may range. The rehabilitation program comprises of interval ergometer training (20 minutes 5 days per week), dumbbell training (30 minutes 5 days per week), respiratory therapy (30 minutes 5 days per week), mental training and guided walks for 2-5 times/week.
41152096|NCT02615041|DRUG|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
41316722|NCT05127070|DEVICE|Neotree|The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.
41474099|NCT05715476|PROCEDURE|cesarian surgery|The same anesthesia protocol will be applied to the patient group at each altitude. In the sitting position, the spinal space was entered with a 25 gauge Quincke-tipped needle from the L4-5 space and a drop of CSF will be dripped onto the pH paper. Immediately afterwards, 12 mg of 0.5% hyperbaric bupivacaine will be given. The color formed on the pH paper will be noted. Sensory block level will be tested with pinprick test and motor block level will be evaluated with Modified Bromage scale. The number and duration of spinal anesthesia applications, the time of occurrence of sensory block in the T6 dermatome, the time to reach each score of the MB scale, the duration of the operation, the highest level of sensory block and anesthetic complications will be recorded. Sensory block time and motor block time of the patients followed in the service will be recorded.
41474100|NCT00692146|DRUG|AZD1386|Oral solution fixed dose (95 mg given orally on two occasions)
41474101|NCT00692146|DRUG|Placebo|Oral solution fixed dose (95 mg given orally on two occasions)
40800024|NCT05464238|OTHER|Standard treatment|Standard treatment during study duration
41004086|NCT02271633|DIETARY_SUPPLEMENT|Beetroot juice|
41004087|NCT02271633|DIETARY_SUPPLEMENT|Spinach|
41004088|NCT02271633|DIETARY_SUPPLEMENT|Rocket salad|
41004089|NCT05954481|OTHER|Stress echocardiography|After a rest trans thoracic echocardiography (usual follow-up), eligible patients will have a stress ultrasound echocardiography on a dedicated cycle ergometer
41004090|NCT03000582|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
41152097|NCT02615041|DRUG|Meropenem|"1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
41152098|NCT02615041|DRUG|Meropenem|"2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
41316723|NCT02721251|BEHAVIORAL|Exercise|16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
41474102|NCT05327855|DRUG|OPL-0301 Dose 1|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
41004091|NCT03000582|DIETARY_SUPPLEMENT|Creatine nitrate-1|Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
41474103|NCT05327855|DRUG|OPL-0301 Dose 2|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
41474104|NCT05327855|DRUG|Placebo|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
41474105|NCT00345215|BEHAVIORAL|High Sodium Diet|250-350 mmol
41474106|NCT00345215|BEHAVIORAL|Low Sodium Diet|25-35 mmol
41474107|NCT00707421|DRUG|ketorolac acetate|
41474108|NCT00707421|DRUG|fluorometholone|
41474109|NCT00707421|DRUG|artificial lacrimal tears|
40800025|NCT03820986|BIOLOGICAL|Pembrolizumab|IV infusion
40800026|NCT03820986|DRUG|Lenvatinib|Oral capsule
40800027|NCT03820986|DRUG|Placebo for lenvatinib|Oral capsule
40800028|NCT01207609|PROCEDURE|Laparoscopic Gastric Plication|The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
40800029|NCT05179278|OTHER|Post-surgical nurse follow-up|Follow-up face-to-face consultation or follow-up telephone consultation a month after the intervention and telephone consultation at one year
40800030|NCT00014443|DRUG|thalidomide|
40800031|NCT00014443|DRUG|topotecan hydrochloride|
40800032|NCT02905539|DRUG|Iron Isomaltoside 1000|
40800033|NCT02905539|DRUG|Ferric Carboxymaltose|
40800034|NCT00182078|DRUG|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
40800035|NCT00182078|DRUG|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
41474110|NCT01793818|BIOLOGICAL|Tat Oyi|Three injections in the arm
41474111|NCT03056079|DRUG|Intravitreal aflibercept|Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
40800036|NCT06064006|DRUG|NNC0487-0111|NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
40800037|NCT06064006|DRUG|Placebo (NNC0487-0111)|Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
40800038|NCT05062694|OTHER|Survey|It will be created a questionnaire to investigate, among Italian physiotherapists, their clinical approach to the patient with Central Sensitisation
41004092|NCT03000582|DIETARY_SUPPLEMENT|Creatine nitrate-2|Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
41004093|NCT03000582|DIETARY_SUPPLEMENT|Placebo|Placebo (6.5 g dextrose)
41004094|NCT00002882|BIOLOGICAL|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
41004095|NCT00002882|BIOLOGICAL|Recombinant Interferon Alfa (IFN-A)|"IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5"
41004096|NCT00002882|DRUG|Cisplatin|IV Days 1-4
41004097|NCT00002882|DRUG|Dacarbazine|IVPB on day 1
41004098|NCT00002882|DRUG|Vinblastine|IVPB on days 1-4
41004099|NCT00002882|PROCEDURE|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
41004100|NCT03265626|BEHAVIORAL|Intervention 1: Comprehensive preventive intervention|aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
41004101|NCT03265626|BEHAVIORAL|Intervention 2: Awareness creation and community mobilization|Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
41004102|NCT03265626|OTHER|available standard care|The standard care will be maintained but no other additional intevvenion designed by this study
40800039|NCT01653587|DEVICE|Percutaneous coronary intervention|Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
40800040|NCT05086900|OTHER|Non-interventional Cross-sectional Patient Reported Outcome Measure Development|Development of Patient Reported Outcome Measure
40800041|NCT02661737|DEVICE|YVOIRE volume s|
40800042|NCT05365516|OTHER|Implementing medical safety huddles|These short, virtual huddles are led by a huddle leader and occur on a weekly or once every two week basis. Each site will be adapting the Medical Safety Huddles for their context and workflow to specifically engage physicians.
40800043|NCT00536718|GENETIC|gene expression analysis|
40800044|NCT00536718|GENETIC|molecular diagnostic method|
40800045|NCT00536718|GENETIC|polymorphism analysis|
41004103|NCT00177437|BEHAVIORAL|home testing kit|
41316724|NCT02721251|BEHAVIORAL|Weight Loss|16 week. the goal is 10% weight loss.
41316725|NCT02721251|BEHAVIORAL|Exercise + Weight Loss|Combined exercise and weight loss components of the other arms
41316726|NCT00000150|PROCEDURE|Subfoveal Choroidal Neovascularization Removal|
41316727|NCT02176395|DRUG|Danhong injection|40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
40800046|NCT00536718|GENETIC|protein expression analysis|
40800047|NCT00536718|OTHER|medical chart review|
40800048|NCT00536718|OTHER|questionnaire administration|
40800049|NCT04198766|DRUG|INBRX-106 - Hexavalent OX40 agonist antibody|The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
40800050|NCT04198766|DRUG|pembrolizumab 200 mg|pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
41004104|NCT01768390|OTHER|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
41316728|NCT02176395|PROCEDURE|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
41316729|NCT02176395|DRUG|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
41316730|NCT02139995|BEHAVIORAL|RBC transfusion based on different protocols|transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
41316731|NCT06379802|BEHAVIORAL|Individualized physical activity and diet|Precision health
41316732|NCT01081821|DRUG|single dose NJ-39758979/ matching placebo|Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
40800051|NCT04198766|DRUG|pembrolizumab 400 mg|pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
40800052|NCT04198766|DRUG|Carboplatin AUC-5|carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
41004105|NCT01768390|OTHER|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
41004106|NCT01163409|PROCEDURE|exercise training|exercise training comprises aerobic and strength training
41004107|NCT01163409|PROCEDURE|acupuncture|acupuncture involves two sessions per week, during 14 weeks.
41316733|NCT01081821|DRUG|multi-dose JNJ-39758979 /matching placebo|JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
41316734|NCT01308723|DRUG|RO5323441|escalating doses iv
41316735|NCT01308723|DRUG|RO5323441|iv every 2 weeks
41316736|NCT01308723|DRUG|sorafenib|400 mg orally twice daily to once every other day
40800053|NCT04198766|DRUG|Carboplatin AUC-6|carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
40800054|NCT04198766|DRUG|Pemetrexed 500 mg/m2|pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles
40800055|NCT04198766|DRUG|Cisplatin 75mg/m2|cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
40800056|NCT04198766|DRUG|Paclitaxel 200mg/m2|paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
41004108|NCT01163409|PROCEDURE|Exercise, Acupuncture and Fibromyalgia|Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
41316737|NCT01892397|DEVICE|Optune (NovoTTF-100A)|
41316738|NCT03740412|BEHAVIORAL|Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls|The intervention has multiple components in order to reduce sedentary behaviour, namely: incorporating individualised feedback on sitting time, education about sedentary behaviour, individualised goal-setting and environmental modification according to each participant's own behavioural patterns and capabilities, motivational interviewing, and biweekly phone calls.
41316739|NCT02656758|BEHAVIORAL|intensive Executive function training|Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
41316740|NCT04944329|PROCEDURE|Hip fracture surgery|Hip fracture surgery
41316741|NCT05065996|DIAGNOSTIC_TEST|Aortic MRI + 4D flow MRI|Together with routine aortic MRI specific 4D flow MRI sequence will be done.
41316742|NCT00000567|PROCEDURE|high-frequency ventilation|
41316743|NCT02159469|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels
41316744|NCT03144323|BEHAVIORAL|Reminders|"Four reminders will be set on the patient's mobile phone's Calendar-type app, saying Don't forget to wear your elastics, at 08:00, 13:00, 17:00 and 22:00."
41316745|NCT05072665|DEVICE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
41316746|NCT03587818|OTHER|person-centred communication|The intervention aimed to actively make use of a person-centred approach to support patients undergoing CRC surgery to be prepared for surgery, discharge and recovery in relation to CRC. This was accomplished through person-centred communication, which was based on a standardized dialogue tool with tailored written information material (component I), in combination with an approach for professionals to facilitate person-centred communication (component II) in consultations.
41474112|NCT04339426|DRUG|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
41474113|NCT02950142|OTHER|CPOE with order sets for lab testing|CPOE including series of recommended tests ordered per indication
41004109|NCT00354445|DRUG|pegaptanib sodium (Macugen)|
41004110|NCT04062916|OTHER|BSGE pelvic pain questionnaire and VAS scores|Patients were evaluated using the BSGE pelvic pain questionnaire in terms of pre-operative and post-operative pain assessment in order to determine the effects of endometriosis surgery on the quality of life. The patients were asked to indicate their levels of dyspareunia, dysmenorrhea, and chronic pelvic pain on a VAS on the pelvic pain questionnaire.
41004111|NCT00003256|DRUG|alvocidib|
41004112|NCT00914030|OTHER|Neuropsychological evaluation|Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
41152099|NCT05586308|BEHAVIORAL|Text-massaging suport|Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
41316747|NCT02854904|DRUG|Dexmedetomidine intervention|Immune effect of alpha-2 agonist to arthrodesis. Dexmedetomidine as a immune control anesthesic in patients undergoing to arthrodesis. Alpha-2 agonist to general anaesthesia.
41316748|NCT02854904|DRUG|Placebo|Placebo controlled
41316749|NCT03363217|DRUG|Trametinib|Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
41316750|NCT00183950|DRUG|Noscapine|
41316751|NCT02417909|OTHER|questionnaires about quality of life|all teenagers included in the trial and their parents must complete the questionnaires given of them the day of enrollment.
41316752|NCT04985331|DEVICE|W-GenZD|"W-GenZD is a program that delivers evidence based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent."
41316753|NCT03385382|DRUG|Dexamethasone intravitreal implant 0.7 mg|Intravitreal Implant of dexamethasone
41004113|NCT01127503|DRUG|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day \[2000 mg/day if metyrosine\]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
41152100|NCT05586308|BEHAVIORAL|Financial incentive|"1. Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase)~2. Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22).~3. A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample"
41316754|NCT03385382|DRUG|Ranibizumab Injection|Injection of ranibizumab
41316755|NCT01989182|DEVICE|Spiration Valve System|
41316756|NCT01989182|OTHER|Medical Management|
41316757|NCT01814683|DRUG|Primaquine|14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
41316758|NCT01814683|DRUG|Primaquine|7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
41316759|NCT01814683|DRUG|Placebo|14 days placebo.
41316760|NCT02862548|DRUG|TAF|Tablet administered orally
41316761|NCT02862548|DRUG|TDF|Tablet administered orally
41316762|NCT02862548|DRUG|Other approved antivirals|Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice
41474114|NCT02950142|OTHER|CPOE without order sets for lab testing|CPOE only
41474115|NCT03077529|DIETARY_SUPPLEMENT|Galacto-oligosacchride|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
41474116|NCT03077529|DIETARY_SUPPLEMENT|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
41474117|NCT00308360|DRUG|Risperidone, divalproex|
41004114|NCT01127503|DRUG|Placebo|Placebo capsules were identically matched to Metyrosine.
41004115|NCT06264388|DRUG|DB107-RRV|Patients will undergo surgery to remove as much of the high-grade glioma (HHG) tumor as possible and will receive combination intravenous (IV) and adaptive repeat intratumoral delivery of DB107-RRV in the vein (IV) and in the walls of the cavity that remains where tumor is removed.
41316763|NCT04836819|DRUG|Lidocain|IV lidocaine infusion (2 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 1 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
41316764|NCT04836819|DRUG|Ketamine|IV ketamine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
41316765|NCT04836819|DRUG|Dexmedetomidine|IV dexmedetomidine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
41004116|NCT06264388|DRUG|DB107-FC|Patients will start taking DB107-FC three times by mouth every day for a period of seven days, which is one cycle of treatment. A cycle of treatment is medication taken on a set schedule with periods of rest in between. Patients will wait five weeks before taking the next seven day course of DB107-FC. The first dose of DB107-FC will be taken at the hospital or clinic; afterward, patients will take the doses of DB107-FC at home. Patients will take DB107-FC for up to 12 months after surgery.
41004117|NCT00699010|DRUG|Acurox 5/30mg taken first|followed by oxycodone 5mg with 48 hour washout
41004118|NCT00699010|DRUG|Oxycodone 5mg taken first|followed by Acurox 5/30mg with 48 hour washout
41316766|NCT04812418|DIETARY_SUPPLEMENT|Noctesia|3 tablets every day at bedtime with a large glass of water
41474118|NCT01668121|DRUG|Symbicort Turbohaler|
41474119|NCT01668121|DRUG|Budesonide/formoterol Easyhaler|
41474120|NCT02078921|DRUG|Sodium Nitrate|
41474121|NCT02078921|DRUG|Placebo|
41474122|NCT02904499|DRUG|Dabigatran|
41474123|NCT05082324|OTHER|Adapted physical activity|Patient participates in an adapted physical activity program for 3 months, with 2 one-hour sports sessions per week
41474124|NCT05117047|PROCEDURE|liver resection|After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
41004119|NCT04156815|RADIATION|1,565nm NAFL|1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
41004120|NCT04156815|DRUG|Oral isotretinoin|Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
41316767|NCT04812418|DIETARY_SUPPLEMENT|Placebo|3 tablets every day at bedtime with a large glass of water
41474125|NCT05435586|OTHER|Web Based Breastfeeding Education and Counseling with Digital Game Support|The educational content prepared by the researcher on the web page will be integrated into the game program designed with the gamification technique. In this designed program, users will be notified at appropriate times to enter the system and play games from the link sent via e-mail. After the users have finished the game, they will fill the scale in the relevant week and will only be able to exit the system in that way.
41474126|NCT01839370|DEVICE|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
40800057|NCT04198766|DRUG|Nab paclitaxel 100mg/m2|Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4
40800058|NCT02342782|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
40800059|NCT02342782|DRUG|Carmustine|Given IV
40800060|NCT02342782|DRUG|Etoposide|Given IV
40800061|NCT02342782|DRUG|Cytarabine|Given IV
41004121|NCT04156815|OTHER|Pricking blood therapy|Pricking blood therapy (PBT) is a modified acupuncture strategy that is adapted to treat inflammatory related diseases. It has been shown to be effective in treatment of many chronic and acute inflammatory conditions including vasomotor rhinitis, acute herpes zoster and acute gouty arthritis,suggesting a potential efficacy for AV as well. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
40800062|NCT02342782|DRUG|Melphalan|Given IV
40800063|NCT02342782|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
40800064|NCT02342782|OTHER|Laboratory Biomarker Analysis|Correlative studies
40800065|NCT02342782|OTHER|Pharmacological Study|Correlative studies
40800066|NCT05730868|PROCEDURE|myofascial release|Soft tissue release will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
41316768|NCT04363437|DRUG|Colchicine|People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.
41316769|NCT04363437|DRUG|Usual Care|COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.
40800067|NCT05730868|PROCEDURE|muscle energy technique|Muscle energy Technique will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
40800068|NCT05730868|PROCEDURE|MFR & MET|combination of myofascial release and muscle energy technique will be performed on the trapezius, suboccipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
41004122|NCT01947400|OTHER|Hospitalists|AIDET Training
41004123|NCT00101101|DRUG|Cyclophosphamide|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
41004124|NCT00101101|DRUG|Doxorubicin|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
41316770|NCT04324918|DRUG|HCP1102|The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
41316771|NCT04324918|DRUG|HGP1408|The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
41316772|NCT03493867|DEVICE|Vitaliti|Measurements recorded by the Vitaliti device will be compared to the recordings from the arterial catheter.
40800069|NCT05730868|PROCEDURE|conventional therapy|traditional physical therapy devices are used to relieve pain and spam. this will include a hot pack, ultrasound, and TENS (Transcutaneous electrical nerve stimulation)
40800070|NCT02949050|BIOLOGICAL|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
40800071|NCT02949050|BIOLOGICAL|SCIT|Treatment group consists of patients who completed \> 1 year of SCIT while control group patients did not undergo SCIT
40800072|NCT03148275|OTHER|Questionnaire Administration|Ancillary studies
40800073|NCT03148275|DRUG|Trametinib|Given PO
41316773|NCT00870818|DIAGNOSTIC_TEST|Blood samples for safety|serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
41316774|NCT00870818|BEHAVIORAL|Patient reported outcome questionnaires|EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
41316775|NCT00870818|DIAGNOSTIC_TEST|Analysis of T-cell subsets|CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
40800074|NCT01384552|OTHER|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
40800075|NCT01384552|OTHER|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
40800076|NCT04166370|OTHER|Control|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
41316776|NCT06261931|DIAGNOSTIC_TEST|Diagnostic assessment|patient with sponiloarthritis who comes to the clinic Hospital for clinical evaluation of disease. Assessment instrumental evaluation of the axial involvment t, with x-ray of the spine and pelvis every 5 years, and MRI of the spine and pelvis every 2 years.
40800077|NCT04166370|OTHER|Strengthened (Services and SBCC)|"Strengthening referrals to health services- Needed improvements to existing health referral networks will be assessed, identified and implemented. Peer leaders will refer PLW to nearby service delivery points.~Improving quality of health/nutrition services- Health-related service providers will be trained and supervised on nutrition best practices.~SBCC- Primarily target PLW. Delivered using traditional and digital channels. Text/voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for these messages. Female community nutrition promoters will also be deployed; delivering SBCC during group meetings and in health facilities. Mothers' groups will be established, and will be led by peer leaders, mentored in the delivery of messages on nutrition behavior."
41004125|NCT00101101|DRUG|Vincristine|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
41004126|NCT00101101|DRUG|Prednisone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
41004127|NCT00101101|DRUG|Dexamethasone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
41316777|NCT06261931|DIAGNOSTIC_TEST|Diagnostic assessment|peripheral involvement, with joint ultrasound at baseline, at 3 months from the start of a new therapy, and therefore in the event of reactivation of the disease
41316778|NCT06082752|PROCEDURE|Massage session|Participants in the intervention group are provided with the 5-minute massage session in the medial and lateral gastrocnemius muscle (dominant leg).
41316779|NCT05985434|PROCEDURE|Surgical treatment|decompression with or without stabilization; stabilization only; debulking; en bloc resection
41316780|NCT01760993|DRUG|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
41316781|NCT02370017|BIOLOGICAL|ANKL(Ex vivo-expanded NK cell enriched lymphocytes)|add ANKL in 3rd and 4th course in case of stable response after two initial courses
41316782|NCT01644942|OTHER|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
41316783|NCT03503682|RADIATION|standard treatment|3000 cGy in 10 daily fractions
41316784|NCT03503682|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
41316785|NCT01107405|DRUG|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
41316786|NCT01107405|DRUG|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
41316787|NCT01107405|DRUG|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
41316788|NCT01107405|DRUG|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
41316789|NCT01107405|DRUG|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
41316790|NCT01767519|BIOLOGICAL|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
41316791|NCT01767519|DRUG|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
41316792|NCT01767519|DRUG|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
41316793|NCT01767519|DRUG|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
41316794|NCT00152074|BEHAVIORAL|Reduce salt intake|
41474127|NCT03124290|OTHER|paced auditory serial addition test (PASAT)|A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
41474128|NCT01120769|DRUG|Acetaminophen|single dose
41474129|NCT01120769|DRUG|Placebo|single dose
41316795|NCT05294822|PROCEDURE|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|Islet transplantation was completed using percutaneous transhepatic portal vein puncture. After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
41316796|NCT02432040|DRUG|Atorvastatin|Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia
41316797|NCT02432040|DRUG|Placebo|Placebo tablets, made to look like the interventional drug
40800078|NCT04166370|OTHER|Strengthened (Services and SBCC) + CCT|Will include all components of the strengthened intervention and participants will receive monthly cash transfers, which is about 25% of monthly consumption expenditure among poor rural households in Bangladesh. Cash transfers will begin when a woman enrolls (at any time during her pregnancy or until 2 months after giving birth). The monthly transfer will continue until a child is 12 months of age, thereby supporting mothers during the critical period of complementary food introduction. The transfer is contingent on having had a minimum of 4 ANC visits and monthly participation in mother's group SBCC sessions.
41316798|NCT01841918|BIOLOGICAL|Avian Flu Vaccine|
41316799|NCT01705197|DRUG|Avanafil 100 or 200mg|This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
41474130|NCT04366596|DEVICE|Angioplasty with paclitaxel eluting balloon|The patients will be treated with renal artery angioplasty using paclitaxel eluting balloon
41316800|NCT04815551|DRUG|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
40800079|NCT00548626|PROCEDURE|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
41316801|NCT04815551|DRUG|Placebo|Placebo is sterile liquid for IV infusion.
41316802|NCT00570752|OTHER|Placebo|
41316803|NCT00570752|DRUG|BMS-582949|
41316804|NCT00570752|DRUG|Atorvastatin|
41316805|NCT00570752|DRUG|Statin|
41316806|NCT03827668|DRUG|PF-06650833 alone|In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
41316807|NCT03827668|DRUG|PF-06651600 alone|In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
41316808|NCT03827668|DRUG|PF-06650833 together with PF-06651600|In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
41474131|NCT04366596|DEVICE|Angioplasty with plain old balloon|Angioplasty with plain old balloon
41316809|NCT03915236|DEVICE|MON4STRAT Strategy|Meropenem infusion guided by daily Therapeutic Drug Monitoring (adjusted in order to reach predetermined PK/PD targets) using MON4STRAT device.
41316810|NCT03915236|OTHER|Control group|Meropenem 1 gram infused every 8 hours over 30 minutes, consistent with standard-of-care treatment and published guidelines. Meropenem doses will be modified according to SmPC recommendations.
41316811|NCT00286130|DRUG|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
41316812|NCT00286130|DRUG|FOLFOX 6|"FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
41316813|NCT00286130|DRUG|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
41316814|NCT06101524|PROCEDURE|Free gingival unit, free gingival greft|The free gingival graft and the free gingival unit taken from the upper jaw palatal mucosa were sutured to the lower jaw anterior region.
41316815|NCT02275598|DRUG|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
41474132|NCT04360395|BEHAVIORAL|Gait Therapy|The therapeutic gait training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints.
41316816|NCT02275598|DRUG|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
41316817|NCT02986685|DRUG|Trimebutine Maleate|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage ,then oral trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily were administered to the experimental arm for 4 weeks.
40800080|NCT00548626|PROCEDURE|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
40800081|NCT04891718|BIOLOGICAL|MVC-101|Intratumoural microdose injection by the CIVO device.
40800082|NCT04891718|BIOLOGICAL|Nivolumab|Intratumoural microdose injection by the CIVO device.
40800083|NCT04891718|COMBINATION_PRODUCT|MVC-101 + Nivolumab|Intratumoural microdose injection by the CIVO device.
40800084|NCT01723046|DEVICE|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
40800085|NCT05965050|DIAGNOSTIC_TEST|Myofascial Release Technique|myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.
40800086|NCT05965050|OTHER|Ultrasound Therapy|Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms
40800087|NCT04514627|DEVICE|Auricular percutaneous neurostimulation|The BRIDGE/PENFS device manufactured by Key Electronics, consists of a battery activated generator and wire harness that connects to the generator. Four leads are also attached to the generator, each with a sterile 2 mm, titanium needle. The BRIDGE device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The PENFS device generator has a battery life of 5 days and delivers almost continuous stimulations throughout the 120 hours.
41004128|NCT00101101|BIOLOGICAL|Autologous Tumor Cell-Based Vaccine|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
41004129|NCT00101101|DRUG|IL-2|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
41004130|NCT02163291|DRUG|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
41152101|NCT05586308|BEHAVIORAL|Media literacy|Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.
41152102|NCT02388399|PROCEDURE|Device|Optical coherence tomography to evaluate plaque morphology and vulnerable features (ex\> cap thickness, spotty calcification)
41152103|NCT02388399|PROCEDURE|Device|Resting and hyperemic pressure pullback tracing will be done with motorized pullback system.
41152104|NCT03866109|DRUG|Temferon|Genetically modified HSPCs
41152105|NCT00695149|PROCEDURE|Transplantation of bone marrow stromal cell|
41152106|NCT06474442|GENETIC|BD111 Injection (investigational new drug)|BD111: intrastromally injection, single-dosing RP2D (TU/eye), specified injection volume is 0.15mL.
41152107|NCT06474442|COMBINATION_PRODUCT|Triple-drugs therapy of HSV-1 stromal keratitis|"Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks."
41152108|NCT05223452|DEVICE|UltraSound|we use prob that admit some of radiation to patient to see the organs inside the abdomen
41152109|NCT01697592|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
41152110|NCT01697592|DRUG|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
41152111|NCT00229190|PROCEDURE|Nasal lavage|
41152112|NCT00229190|PROCEDURE|Allergy skin testing|
41152113|NCT00229190|PROCEDURE|Peak nasal inspiratory flow|
41316818|NCT02986685|DRUG|rabeprazole|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage,and rabeprazole 20mg once daily was administered to other arm for additional 4 weeks.
41474133|NCT03518216|BEHAVIORAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a remotely delivered tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be interactive with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist support. The intervention is delivered through a HIPAA compliant video platform.
41474134|NCT00854373|DRUG|Bravelle(follicle stimulating hormone)|One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
40800088|NCT06024616|BEHAVIORAL|TARANG|"TARANG is aimed to empower young women to navigate newly formed relationships, improve women's awareness of sexual reproductive health, and challenge inequitable gender norms, with an aim to reduce unintended pregnancies and increase use of family planning. The TARANG intervention for newly married women will include 14 group sessions delivered by trained moderators from Vikalp. It will cover three overarching themes, including norms, empowerment, and sexual and reproductive health and wellbeing.~Four light-touch sessions for mothers-in-law and one in-person session for husbands of newly married women will be conducted. For husbands, TARANG will include one 2-hour group session within the first month of the intervention, followed by regular and moderated content delivery via videos and take-home exercises over WhatsApp groups. Vikalp will conduct door-to-door listing, and a research team from NEERMAN will recruit households into the study depending on the eligibility criteria."
40800089|NCT01421238|BEHAVIORAL|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
41316819|NCT01265420|BIOLOGICAL|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
40800090|NCT03358355|DRUG|unacelyated ghrelin|We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
40800091|NCT04311970|DEVICE|EsoCheck|All patients with known diagnosis of EoE will be administered the EsoCheck device prior to standard of care endoscopy
41316820|NCT02495740|BEHAVIORAL|Commuting to work|Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
40800092|NCT02972346|DRUG|ACTH|routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
40800093|NCT00742222|RADIATION|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
41316821|NCT04473144|DRUG|Ulinastatin|In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
40800094|NCT00742222|RADIATION|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
40800095|NCT05263180|BIOLOGICAL|EMB-09|EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.
41316822|NCT02031822|PROCEDURE|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
41316823|NCT03828149|COMBINATION_PRODUCT|Drug:OP0201|Drug: OP0201
41316824|NCT03828149|COMBINATION_PRODUCT|Drug: Placebo|Drug: Placebo
41474135|NCT00854373|OTHER|Saline ( placebo)|1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
41474136|NCT01747382|PROCEDURE|Renal denervation|
40800096|NCT04189796|DIETARY_SUPPLEMENT|Cheese|Daily oral intake of cheese
40800097|NCT02297815|DRUG|Broad-spectrum antibiotics|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
41152114|NCT00229190|PROCEDURE|Acoustic rhinometry|
41316825|NCT04237402|OTHER|Hair follicles sampling|The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
41316826|NCT01471704|DRUG|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
41316827|NCT01471704|DRUG|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
40800098|NCT02297815|DRUG|Narrow-spectrum antibiotics|Amoxicillin, Penicillin
40800099|NCT03972462|DRUG|NPC-12G Gel 0.2%|Period 1
40800100|NCT03972462|DRUG|Rapamune® 2 mg tablet|Period 2
40800101|NCT05349968|DRUG|Lipovirtide for injection|Multiple dosing of Lipovirtide
41316828|NCT01471704|DRUG|50 mg dose of INX-08189 and 240 mg verapamil HCL ER|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
41316829|NCT05684952|DRUG|Shenlingcao Oral Liquid|Shenlingcao oral liquid (200ml/bottle) is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
41474137|NCT03990116|PROCEDURE|Lateral|Posture lateral kangaroo care
40800102|NCT03026816|DEVICE|Epidural Spinal Cord Stimulation|epidural spinal cord stimulator
40800103|NCT04660695|DEVICE|EUS-guided gastroenterostomy|Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
40800104|NCT01707680|OTHER|SOC|Patient are given standard of care
40800105|NCT04257968|DIAGNOSTIC_TEST|Ultrasonography|carotid ultrasonography (IMT and elastography)
41152115|NCT00229190|PROCEDURE|Nasal examination|
41152116|NCT00229190|PROCEDURE|Quality of Life Questionnaire|
41152117|NCT00229190|PROCEDURE|Physical examination|
41152118|NCT03380143|BEHAVIORAL|Wellness Landscape Intervention|Community and organization systems intervention targeting youth population physical activity
41152119|NCT03380143|BEHAVIORAL|Standard Practice|Community development intervention
41316830|NCT05320692|DRUG|TACE+Camrelizumab+Apatinib mesylate|TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.
41316831|NCT05320692|PROCEDURE|TACE|TACE Alone.
41316832|NCT06209814|DEVICE|Conventional denture|Patients in this group received conventional maxillary and mandibular complete dentures. The patients used these dentures for 45 days. Then, the conventional maxillary denture was replaced by open faced denture with soft acryl resin wing.
41474138|NCT03990116|PROCEDURE|Prone|Posture prone kangaroo care
41316833|NCT06209814|DEVICE|Maxillary open-faced denture|Patients in this group received a maxillary open faced denture with soft acryl resin wing and a conventional mandibular complete denture. The patients used these dentures for 45 days. Afterward, the maxillary open-faced denture was replaced by one with a conventional construction.
41316834|NCT04627142|DRUG|BI 1701963|Tablet
41316835|NCT04627142|DRUG|Camptosar®|Solution for infusion
41316836|NCT00208494|DEVICE|Total Hip Replacement|Total hip replacement
40800106|NCT04257968|DIAGNOSTIC_TEST|MRI|MRI of carotid artery and brain
40800107|NCT04257968|DIAGNOSTIC_TEST|Neuro Psychological Assessment Battery|Hopkins Verbal Learning Test Digit Span WAIS-IV Stroop Color Word test Trail Making Test Brixton Spatial Anticipation Test Fluency letter (B-D-H) Fluency animal naming Symbol Digit Substitution WAIS-IV
40800108|NCT04257968|DIAGNOSTIC_TEST|Questionaires|Cognitive Failures, Depression, Anxiety, Fatigue, Speech handicap, fear for recurrence, Quality of Life.
40800109|NCT04075747|DRUG|CPX-351|Up to 2 induction and 2 consolidation courses will be offered
40800110|NCT04075747|DRUG|Venetoclax|Will be administered over specified duration during induction and consolidation courses
40800111|NCT04075747|DRUG|Midostaurin|Will be administered over specified duration during induction and consolidation courses
41316837|NCT00208494|DEVICE|Total hip replacement|Total hip replacement
41316838|NCT04872335|OTHER|Gong's Mobilization|Group A received Gong's mobilization and common treatnent (TENs,Hot pack and cervical stretches). Gong's mobilization which is concurrent application of Apophyseal joint gliding and end range passive physiological movements while the subject's cervical postures are passively Neutral in order to induce Normal Cervical Extension. The Subjects in Group A were treated three times in a week for 4 weeks.
40800112|NCT04075747|DRUG|Enasidenib|Will be administered over specified duration during induction and consolidation courses
40800113|NCT02510469|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
40800114|NCT06311955|RADIATION|Carbon ion radiotherapy|The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
41316839|NCT04872335|OTHER|Gradually Graded Exercise Therapy|"The Subjects in Group B were received Exercise Therapy and common treatment (TENs, Hot pack and cervical stretches) three times in a week continue for 4 weeks . Each exercise session will take 30 min. It will be consisted of 5 min warm-up exercises, 20 min stabilization exercises, 5 min cool-down, and stretching exercises including neck and shoulder girdle muscles.~The aim of Exercise program was to create a neutral spine and activate deep muscles of the cervical spine. The patients were educated to maintain neutral spine during the exercises and throughout the day as much as possible.~Scapulothoracic stabilization exercises were included_ specific exercises for the muscles affecting scapular orientation related to neck pain. The subjects were educated to maintain the positions and contractions during the exercises including scapular retraction, eccentric scapular retraction, and combined scapular retraction with shoulder lateral rotation, forward punch, and dynamic hug."
40800115|NCT06311955|OTHER|combined with platinum-based regimen|combined with platinum-based regimen
40800116|NCT02731820|DIETARY_SUPPLEMENT|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
40800117|NCT02731820|DIETARY_SUPPLEMENT|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
40800118|NCT02731820|DIETARY_SUPPLEMENT|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
40800119|NCT02731820|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
40800120|NCT03375645|DRUG|Any oral opioid|Emergency department patients who receive a prescription for an oral opioid
40800121|NCT04074070|OTHER|Ultrasound examination|Ultrasound examination of joints, tendons and entheses.
40800122|NCT05842434|DEVICE|Felix|Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
40800123|NCT05209620|DRUG|ICP-022|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
41152120|NCT05016778|DRUG|GPRC5D-CAR-T|After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.
41316840|NCT05654766|DIAGNOSTIC_TEST|Flow cytometry|Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.
41316841|NCT05654766|DIAGNOSTIC_TEST|Platelet aggregation and plasma coagulation|Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).
41316842|NCT04721067|DEVICE|SHUTi|SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones. It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.
41474139|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
41474140|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
41474141|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
41316843|NCT04721067|BEHAVIORAL|Sleep Education/Hygiene|A research assistant (RA) will deliver the active control procedures. During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices. To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider. We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.
41316844|NCT00430313|PROCEDURE|Electro-Stimulation of Yongquan (K1) Acupoint|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
41316845|NCT00430313|PROCEDURE|Electro-Stimulation of Yongquan (K1) Acupoint|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
41316846|NCT00845546|DRUG|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
41316847|NCT05484180|OTHER|training and counseling supported guided imagery application|After the preparation process, as a nursing attempt to the individuals in the experimental group; Training and consultancy supported guided imagery based on the health promotion model will be implemented. This initiative; It will take a total of 12 weeks, including 6 weeks of training program and 6 weeks of counseling program and guided imagery.
41316848|NCT03337555|DEVICE|McGrath|McGrath videolaryngoscope
40800124|NCT05209620|DRUG|Pemetrexed|Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).
40800125|NCT04539613|DRUG|HPFSH & HMG|. Various gonadotropin preparations
40800126|NCT05286476|COMBINATION_PRODUCT|Whole Body Vibration|vibration was administered for 1min, with a rest interval of 1min between each vibration set repeating 10 vibrations, with a frequency of 30 Hz and an amplitude of 0-2 mm and a speed of 50 m /s,18 and these sessions lasted for 6 weeks 3 days a week. whole-body vibration was induced by a noninvasive oscillation platform
40800127|NCT05286476|OTHER|pelvic floor exercises and static abdominal exercises in addition to diet instructions|"During the low abdominal hollowing with instructed pelvic floor co-contraction test subjects were instructed with the standard command: 'Breathing normally, and keeping your back still, gently lift and tighten your pelvic floor. Now gently draw in your low tummy as well and hold it'. Pelvic floor facilitates transversus abdominis thickness.~subject in supine lying with her arms crossed over the diastasis for support. And subject has to draw or pull the abdomen inwards so that there elicits an isometric contraction of abdominal muscles and repeated this for 5-7 times."
40800128|NCT01247454|BEHAVIORAL|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
40800129|NCT01247454|BEHAVIORAL|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
40800130|NCT01247454|BEHAVIORAL|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
40800131|NCT02514811|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
40800132|NCT03130907|DEVICE|Placement of ureteral stent|will randomize groups to either receive a postoperative ureteral stent or not.
40800133|NCT00080834|DRUG|DJ-927|
41316849|NCT03337555|DEVICE|Pentax|Pentax videolaryngoscope
41316850|NCT03337555|DEVICE|Macintosh|Macintosh direct laryngoscope
41474142|NCT06615869|DRUG|Molnupiravir|Oral Administration.
40800134|NCT04415294|DIAGNOSTIC_TEST|Critical flicker frequency|Measure the critical flicker frequency as a screening test for hepatic encephalopathy using a portable self administered device
40800135|NCT03981094|DRUG|BMS-986278|suspension
40800136|NCT03981094|DRUG|Pirfenidone|capsule
40800137|NCT03388801|OTHER|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
41004131|NCT01760148|DRUG|interferon alpha 2b|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
41316851|NCT01794013|BEHAVIORAL|Parent training|All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.
41316852|NCT01794013|BEHAVIORAL|Routine care|routine care
41316853|NCT06409702|DRUG|Carfilzomib|"Induction:~ASCT：20mg/56mg/m2 ,D1,8,15，C2-4; non ASCT: 20mg/36mg/m2 ,D1,8,15，C2-4;~Consolidation:~ASCT: 56mg/m2 ,D1,8,15，C5-6; non ASCT: 36mg/m2 ,D1,8,15，C5-8;~Maintenance:~ASCT: 70mg/m2 ，D1，15; non-ASCT：56mg/m2 ，D1，15 After consolidation therapy, if MRD negativity is sustained for more than 1 year, carfilzomib will be discontinued"
41474143|NCT04779229|BEHAVIORAL|Parent Activation|Parent Activation (PA) is comprised of concrete social learning theory steps (i.e., direct instruction, modeling, practice opportunities, and reinforcement) that aim to enhance a parent's confidence, knowledge, and ability to manage his/her child's health. PA is applicable across a range of conditions, including behavioral and psychiatric problems, and it can be delivered by varied providers, including paraprofessionals.
41004132|NCT03324763|OTHER|stool sampling|A stool sample will be collected to perform the H. pylori antigen test
41004133|NCT00424905|DRUG|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
41152121|NCT05662878|OTHER|Assessment of Hand Strength and Spasticity|Assessment of Hand Strength and Spasticity
41316854|NCT06409702|DRUG|Daratumumab|"28d/Cycle~Induction:~16mg/kg, D1,8,15,22，C 2-3，16mg/kg, D1,15, C4;~Consolidation:~ASCT: 16mg/kg/d, D1,15,C5-6; non ASCT: 16mg/kg/d, D1,15,C5-8;~Maintenance:~16mg/kg, D1,monthly After consolidation therapy, if MRD negativity is sustained for more than 1 year, daratumumab will be discontinued"
41316855|NCT06409702|DRUG|Lenalidomide|"28d/Cycle~Induction:~25mg qd d1-21 C2-C4;~Consolidation:~ASCT: 10mg d1-21，C5-6; non ASCT: 25 mg d1-21，C5-8;~Maintenance: 10mgqd D1-21~After consolidation therapy, if MRD negativity is sustained for more than 1 year, lenalidomide monotherapy will be maintained until disease progression"
41316856|NCT06409702|DRUG|Dexamethasone|"28d/Cycle~Induction:~ASCT：40mg qd, po/iv，D1,8,15,22，C2-4; non ASCT:20mg qd, po/iv，D1,8,15,22，C2-4;~Consolidation:~ASCT: 40mg qd, po/iv，D1,8,15,22，C5-6; non ASCT:20mg qd, po/iv，D1,8,15,22，C5-8"
41474144|NCT04779229|BEHAVIORAL|Usual Services|This intervention refers to the typical techniques that JPOs employ to monitor the juveniles on their caseloads (e.g., regular meetings with youth and parents to ensure the youth is following conditions of probation and issuing swift sanctions \[community service; detention\] if conditions are not being followed).
41004134|NCT02438228|OTHER|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
41474145|NCT00982891|DRUG|Opioid (morphine sulphate) in low dose|individualized titration
40800140|NCT03550443|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
40800141|NCT03550443|DRUG|Placebo|Capsules containing an inert placebo
41474146|NCT02346682|DRUG|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
40800142|NCT05311514|BIOLOGICAL|Allogeneic platelet lysate eye drops|Eye drops
40800143|NCT01268540|DEVICE|FY-60AD|Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
40800144|NCT01268540|DEVICE|NHT15, NHT30, & NHT53|Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
41004135|NCT04512911|PROCEDURE|Endocardial ablation|Endocardial ablation of VT
41152122|NCT02946788|DRUG|Minocycline|BPX-01 1 or 2% topical gel will be applied to face once daily
41152123|NCT04786431|OTHER|Blood collection for lipid profiling by LC-MS|Blood withdrawal
41152124|NCT04816539|DEVICE|TetraGraph|Use of two monitoring devices of neuromuscular function during surgery
41152125|NCT06261567|DRUG|Biologic treatment|Patients receiving treatment with any biologic treatment for severe asthma which is approved within the UK NHS. These include omalizumab, mepolizumab, reslizumab, benralizumab and/or dupilumab
41152126|NCT01356121|DRUG|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
41152127|NCT01356121|DRUG|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
41152128|NCT01746199|DRUG|cotrimoxazole daily prophylaxis|
41316857|NCT06409702|DRUG|VRD for first-cycle induction therapy|"Induction:~C1, 28d/cycle Bortezomib(V）:1.3 mg/m2，H，d1、4、8、11； Lenalidomide(R)：25mg，po. qd d1-14; Dexamethasone(D)：20 mg，po/iv，D1，2, 4，5, 8，9, 11,12。"
41316858|NCT02581566|DRUG|Intrathecal Dexmedetomidine|Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
41316859|NCT02581566|DRUG|Intraarticular Dexmedetomidine|Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
41474147|NCT04632524|DRUG|MgSO4|Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.
41474148|NCT01884402|DRUG|Peginterferon alfa-2a|Treatment as usual clinical practice
41474149|NCT01884402|DRUG|Ribavirin|Treatment as usual clinical practice
41474150|NCT05394766|OTHER|Omada Hypertension Program|The Omada Program: an online program that offers comprehensive lifestyle self-management support for hypertension.
40800145|NCT04522882|DEVICE|Actimetry|Actimetry will be performed at home to measure physical activity, sleep duration and patient chronotype for 7 days.
40800146|NCT04522882|OTHER|Questionnaires|Patients will complete food and medication intake questionnaires for 7 days.
40800147|NCT04522882|OTHER|Glucose level and insulin administration|Continuous subcutaneous glucose level (measured by continuous glucose monitor (CGM)) and the insulin doses delivered by the insulin pump will be collected for 7 days .
40800148|NCT02956252|PROCEDURE|Spinal anesthesia|Spinal anesthesia was used in patients who underwent LC
41004136|NCT04512911|PROCEDURE|Endocardial- Epicardial ablation|Epicardial ablation of VT in addition to endocardial ablation
41004137|NCT04512911|DRUG|Antiarrhythmic medications|Addition of anti arrhythmic medication or dose increase
41152129|NCT01746199|DRUG|sulphadoxine-pyrimethamine|Intermittent preventive sulphadoxine-pyrimethamine treatment
41152130|NCT02558816|DRUG|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199
40800149|NCT02956252|PROCEDURE|General anesthesia|General anesthesia was used in patients who underwent LC
40800150|NCT03272386|OTHER|Observational study|Completing a questionnaire
41004138|NCT03350503|DEVICE|AcrySof IQ Toric A-code IOL|Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
41004139|NCT03350503|PROCEDURE|Cataract surgery|Removal of cataractous lens and implantation of IOL
41004140|NCT04340882|DRUG|Docetaxel|Given IV
41004141|NCT04340882|BIOLOGICAL|Pembrolizumab|Given IV
41004142|NCT04340882|BIOLOGICAL|Ramucirumab|Given IV
41004143|NCT00610493|DRUG|Bevacizumab|5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle
41004144|NCT00610493|DRUG|Temsirolimus|5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle
41004145|NCT00610493|PROCEDURE|Additional Blood Drawn|2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.
41004146|NCT00610493|PROCEDURE|Biopsy|First tumor biopsy during screening visit and Second at the end of Cycle 1
41004147|NCT00610493|PROCEDURE|DCE-MRI Scan|DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
41004148|NCT03696524|DEVICE|tunneled pleural catheter|Placement of a tunneled pleural catheter through the chest wall into the pleural space to drain the patient's chronic pleural effusion. The catheter is an indwelling device that will be drained from home three times per week by nursing care, the patient, or patient's family.
41004149|NCT01831232|DRUG|pravastatin sodium|Given PO
41004150|NCT01831232|DRUG|idarubicin|Given IV
41004151|NCT01831232|DRUG|cytarabine|Given IV
41004152|NCT01831232|OTHER|laboratory biomarker analysis|Correlative studies
41004153|NCT00862784|BIOLOGICAL|IMC-1121B (ramucirumab)|8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
41004154|NCT00862784|DRUG|Oxaliplatin|85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
41004155|NCT00862784|DRUG|Folinic acid|400 mg/m² intravenous infusion over 2 hours on Day 1
41004156|NCT00862784|DRUG|5-FU|400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
41004157|NCT00862784|DRUG|5-FU|2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
41004158|NCT01454726|OTHER|Diaoshi Jifa therapy plus the Western medical treatment.|Diaoshi Jifa treatment
41004159|NCT01454726|OTHER|drug|the Western medical treatment alone.
41004160|NCT02757079|DRUG|NPC-15|NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
41004161|NCT02337244|DEVICE|Zimmer Persona Total Knee System|No Intervention
41004162|NCT02821962|BEHAVIORAL|Sedentary prompts from a VTAP device|
41004163|NCT04507932|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.
41004164|NCT00094653|DRUG|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses
41004165|NCT00094653|BIOLOGICAL|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
41004166|NCT06441734|DIAGNOSTIC_TEST|cbc serum ferritin serum iron|by using sample of blood to do cbc and serum ferritin and serum iron during 1year
41004167|NCT05626881|DRUG|PRP|"It will include patients with melasma treated with PRP sessions every two weeks for three months. 10 ml of venous blood will withdraw by means of a wide bore needle and a vacutainer containing an anticoagulant (Acid citrate dextrose).~Double centrifugation will be done. First centrifugation, will be done for 10 minutes. After the first centrifugation, three layers will be seen , Second centrifugation will be done for 10 min, after which the platelets separate and form a grayish pellet at the bottom of the tube and the rest will be platelet-poor plasma. About 1 ml of this platelet-poor plasma will be decanted off and the platelet pellet will be resuspended in the remaining plasma to get PRP. With 10 ml blood, about 1-1.5 ml of PRP will be obtained.~PRP is injected intralesionally at the site of melasma using a 30 G hypodermic needle through an insulin syringe."
41004168|NCT05626881|DRUG|sylimarin cream|Silymarin was manufactured with concentration of 1.4%
41004169|NCT02470728|OTHER|New Clinical Pathway|
41316860|NCT02581566|DRUG|Bupivacaine|Intrathecal Bupivacaine
41474151|NCT02187107|DRUG|TMC114|300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange
41004170|NCT04155515|DRUG|TG-2349|TG-2349 400mg
41004171|NCT04155515|DRUG|DAG181|DAG181 200mg
41004172|NCT04155515|DRUG|Ribavirin|Ribavirin 1000mg/1200mg
41474152|NCT02187107|DRUG|rtv|100 mg tablet of Norvir®
41474153|NCT03138824|PROCEDURE|SPIES assisted TURBT|SPIES assisted TURBT of NMIBC
41316861|NCT02694627|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
41004173|NCT00973791|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
40800151|NCT04550520|DIAGNOSTIC_TEST|Glucagon|Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
40800152|NCT04550520|DIAGNOSTIC_TEST|Placebo|As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
40800153|NCT00293813|DRUG|Alendronate|Alendronate 70 mg PO QW
40800154|NCT00293813|DRUG|Denosumab|denosumab 60 mg SC q 6 mos
40800155|NCT00293813|DRUG|Placebo|Placebo for alendronate and placebo for denosumab
40800156|NCT02551380|DRUG|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
40800157|NCT02551380|OTHER|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
40800158|NCT04299828|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the role of immune cells in coagulopathy.
40800159|NCT04277481|OTHER|10 minute cold pack|10 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
40800160|NCT04277481|OTHER|12 minute cold pack|12 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
41004174|NCT00973791|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
41004175|NCT02881294|DRUG|SUVN-G3031|
40800161|NCT04277481|OTHER|15 minute cold pack|15, min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
40800162|NCT04277481|OTHER|20 minute cold pack|20 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
40800163|NCT01420224|OTHER|Commercial airline flight|Normal scheduled passenger flight
40800164|NCT05237063|BIOLOGICAL|Blood and urine samples|Additional Blood and urine samples will be collected at inclusion, 1, 3 and 5 years follow up visits
40800165|NCT05345405|BEHAVIORAL|Dyadic CARE|Dyadic CARE involves two telehealth sessions with a clinician, the survivor, and a supporter of the survivor's choice. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
41004176|NCT03816631|DRUG|Pimodivir|Participants will receive single oral dose of Pimodivir 600 mg (2\*300 mg tablets) under fasted condition on Day 1.
41004177|NCT00127140|DRUG|vorinostat|
41004178|NCT00192075|DRUG|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
41004179|NCT00192075|DRUG|avastin|5 milligrams per kilogram (mg/kg)
41316862|NCT00057590|BEHAVIORAL|Care manager outreach and monitoring|
41474154|NCT03138824|PROCEDURE|WLI assisted TURBT|White Light Imaging (WLI) assisted TURBT for treatment of NMIBC
41474155|NCT05748483|DRUG|Atogepant|Oral Tablet
41474156|NCT05748483|DRUG|Placebo for Atogepant|Oral Tablet
41474157|NCT05748483|DRUG|Topiramate|Oral Capsule
41316863|NCT03585192|OTHER|Skin Group|"1. If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~2. A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life."
41316864|NCT03585192|OTHER|Warmer Group|"1. Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~2. If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life."
41316865|NCT05136846|DRUG|Carboplatin|Given IV
41316866|NCT05136846|BIOLOGICAL|Durvalumab|Given IV
41316867|NCT05136846|DRUG|Paclitaxel|Given IV
41316868|NCT05136846|DRUG|Papaverine|Given IV or SC
40800166|NCT05345405|BEHAVIORAL|Supporter-Only CARE|Supporter-only CARE involves two telehealth sessions with a clinician and a supporter of the survivor's choice, without the survivor present. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
40800167|NCT01061723|DRUG|Sarilumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
40800168|NCT01061723|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
40800169|NCT03427593|GENETIC|FACS analyses|FACS analyses
40800170|NCT03427593|GENETIC|Target Sequencing by NGS ( Next-generation sequencing)|Target Sequencing by NGS ( Next-generation sequencing)
40800171|NCT03427593|GENETIC|Whole Exome Sequencing|Whole Exome Sequencing
41316869|NCT05136846|RADIATION|Radiation Therapy|Undergo RT
41316870|NCT05136846|DRUG|Pemetrexed|Given IV
41316871|NCT04315610|OTHER|Access to mobile phone application|Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application. After discharge, assessments using the application are performed if necessary.
41316872|NCT04315610|OTHER|Treatment as usual|Active comparator group, based on traditional information and follow-up.
41316873|NCT05123898|PROCEDURE|Soft tissue augmentation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Ostem dental implant (Osstem Implant Co., Ltd.)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly"
41316874|NCT01345344|BEHAVIORAL|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
41474158|NCT05748483|DRUG|Placebo for Topiramate|Oral Capsule
40800172|NCT04894539|DEVICE|DS5 electrical stimulator|TENS
40800173|NCT00800696|PROCEDURE|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
40800174|NCT04727450|BEHAVIORAL|Cognitive training|Involves participants engaging in selected games which require thinking skills to be played in a group of 2-4 people.
41316875|NCT01345344|BEHAVIORAL|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
41316876|NCT03656120|DRUG|0.2mg group|Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
41316877|NCT03656120|DRUG|0.5mg group|Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
41316878|NCT03656120|DRUG|placebo control group|Participants only take placebos for 12 weeks during the research.
41316879|NCT02473003|BEHAVIORAL|high intensity exercise|high intensity exercise 80-90%
41316880|NCT02473003|BEHAVIORAL|low/medium intensity exercise|low/medium intensity exercise 40-50%
41316881|NCT02473003|BEHAVIORAL|Behavioral medicine strategies|Motivational and self-regulatory behavioral medicine support strategies
41474159|NCT03326986|DRUG|MK-7252|1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
41474160|NCT03326986|DRUG|Placebo|Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
41474161|NCT02921503|OTHER|mobile topical corticosteroid app|app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
41316882|NCT04417725|OTHER|Not applicable - this is a non-interventional, observational study.|Not applicable - this is a non-interventional, observational study.
40800175|NCT04727450|BEHAVIORAL|physical training|"Involves learning of preselected routines of line dancing taught by a line dance instructor."
41474162|NCT05881642|PROCEDURE|Prostate and seminal-sparing Cystectomy|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
41316883|NCT00301028|BIOLOGICAL|Cetuximab|Beginning weekly dose 400 mg/m\^2 IV over 1-2 hours, and 250 mg/m\^2 weeks 2-6.
41004180|NCT00192075|DRUG|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
41316884|NCT00301028|DRUG|Carboplatin|AUC 2 weekly for 6 courses.
41316885|NCT00301028|DRUG|Paclitaxel|135 mg/m\^2 weekly for 6 courses.
41316886|NCT00301028|PROCEDURE|Conventional Surgery|Following induction in second part of study.
41316887|NCT00301028|RADIATION|Radiation Therapy|Following induction in second part of study.
41316888|NCT01832012|OTHER|Multimedia|AHA specific BLS refresher video, 7 minutes in length.
40800176|NCT04727450|BEHAVIORAL|Combination of cognitive and physical training (CCPT)-BIGMAP|BIGMAP is a program engaging participants in specially designed cognitive/memory games together with physical training (Fu \& Chow, 2019).
41474163|NCT05881642|PROCEDURE|Conventional Radical Cystoprostatectomy|According to the consensus standard program, remove the accessory tissues including the bladder,prostate and seminal vesicles
41004181|NCT00192075|DRUG|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
41004182|NCT04124107|DEVICE|multiparametric MRI and 68Ga-PSMA PET/MRI|All participants will undergo multiparametric MRI examination. If mpMRI is unfavorable for prostate cancer, participants will undergo 68Ga-PSMA PET/MRI examination
41004183|NCT04124107|PROCEDURE|Prostate biopsy|Participants with unfavorable mpMRI but favorable 68Ga-PSMA PET/MRI will undergo both 68Ga-PSMA PET/MRI-ultrasound-fusion targeted biopsy and transperineal ultrasound guided 12-core systematic biopsy
41004184|NCT02223767|DEVICE|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and intertrial interval (ITI) of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
41004185|NCT02223767|DEVICE|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
41004186|NCT05949190|DIETARY_SUPPLEMENT|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline)|Balanced energy protein supplement with added DHA/EPA/choline, micronutrients
41004187|NCT05949190|DIETARY_SUPPLEMENT|M-RUSF (Maternal Ready-to-Use Supplementary Food)|Balanced energy protein supplement with added micronutrients
41316889|NCT01832012|OTHER|Hands-on practice|Hands-on BLS CPR practice on a Laerdal BLS manikin.
41316890|NCT05078073|DEVICE|Hyperbaric oxygen therapy|Patients with aGVHD treated with HBOT every two days
41474164|NCT04104984|DEVICE|transvaginal ultrasound|a transvaginal ultrasound is done to patient to determine cervical length
41474165|NCT04104984|DRUG|Progesterone Vaginal Suppository|a progesterone vaginal suppository to prevent preterm labour
41474166|NCT04104984|PROCEDURE|cervical cercalage|Mcdonald's cervical cercalage . a stitch taken around the cervix to prevent preterm labour
41474167|NCT04104984|OTHER|digital vaginal exam|vaginal examination to detect short cervix
40800177|NCT04454320|OTHER|INTUSSUSCEPTION IN CHILDREN|the seasonal variation and management outcomes of childhood intussusception.
40800178|NCT05527782|DRUG|modified TPF|modified TPF: modified docetaxel-cisplatin-fluorouracil followed by concurrent chemoradiotherapy
40800179|NCT05527782|OTHER|Quality of life assessment (QoL)|Quality of life assessment with questionnaires: EORTC QLQ-C30 and QLQ H\&N-35
40800180|NCT00600275|DRUG|BGT226|
40800181|NCT03726658|DRUG|AGN-241751|AGN-241751 is supplied in tablet form
40800182|NCT03726658|DRUG|Placebo|Placebo is supplied in tablet form
41004188|NCT05949190|DRUG|Azithromycin|1g dose
41004189|NCT05949190|DRUG|Albendazole|400mg dose
41004190|NCT05949190|DRUG|Sulfadoxine pyrimethamine|Monthly, 1,500/75mg dose
41316891|NCT04389398|DEVICE|pocket compression fixation belt|Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.
41316892|NCT02596152|OTHER|mini-trampoline|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
41316893|NCT02596152|OTHER|Nordic Walking|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
41316894|NCT01785810|DRUG|Maraviroc 300 mg|Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
41316895|NCT03209440|BEHAVIORAL|Dignity Therapy - Nurse Led|The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
41316896|NCT03209440|BEHAVIORAL|Usual care|Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.
41474168|NCT04104984|DEVICE|abdominal ultrasound|use abdominal ultrasound to measure cervical length
41474169|NCT04104984|DRUG|Tocolytic Agents|a medication is given to prevent uterine contraction
41474170|NCT05865392|BEHAVIORAL|Move physical activity support program|The Move program includes four intervention components: 1) 3, 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) access to an online fitness membership, and 4) weekly mental guided imagery sessions. Participants will be asked to build up their physical activity levels up to 150 minutes/week. They will receive an online fitness center membership during this entire 12-week program.
41474171|NCT01524302|DRUG|Ceftaroline|600 mg Q12h
40800183|NCT03030352|BEHAVIORAL|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
40800184|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (200 µg/kg) oro-dispersible minitablets
41004191|NCT05949190|BEHAVIORAL|Cognitive behavioral therapy|Novel program developed for illiterate end-users
41004192|NCT05949190|OTHER|Insecticide-treated mosquito net|Bed net to prevent malaria
41004193|NCT02665416|DRUG|Selicrelumab|Selicrelumab will be provided as concentrate for solution to be administered via SC injection
41004194|NCT02665416|DRUG|Vanucizumab|Vanucizumab will be provided as solution to be administered via IV infusion.
41316897|NCT03209440|BEHAVIORAL|Dignity Therapy - Chaplain Led|The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
41474172|NCT01524302|DRUG|Levofloxacin|750 mg QD
41474173|NCT00766831|DRUG|Hydromorphone|Participants will receive hydromorphone OROS (8 milligram \[mg\] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
41474174|NCT04119219|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
41474175|NCT03261362|DIETARY_SUPPLEMENT|Branched-chain amino acids reduced intake|
41474176|NCT00003014|DRUG|carboplatin|
41474177|NCT00003014|RADIATION|radiation therapy|
41474178|NCT02946684|DRUG|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
41474179|NCT02946684|DRUG|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
41474180|NCT01522079|PROCEDURE|Air stacking manuever|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
41474181|NCT00497250|DRUG|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
40800185|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (400 µg/kg) oro-dispersible minitablets
40800186|NCT01915537|DRUG|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX\>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
40800187|NCT01915537|DRUG|Classic DMARDs treatment group|"Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time."
40800188|NCT04014751|OTHER|Symptom Monitoring Intervention|This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
40800189|NCT03896061|DEVICE|Laparoscopic sleeve procedures|Laparoscopic sleeve procedures with powered stapler
40800190|NCT00260832|DRUG|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m\^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
41316898|NCT00985556|DRUG|capecitabine|Given orally
41316899|NCT00985556|DRUG|oxaliplatin|Given IV
40800191|NCT00260832|DRUG|Dacogen (decitabine) only|20mg/m\^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
40800192|NCT05151692|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
41474182|NCT00497250|DEVICE|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
41474183|NCT05146726|OTHER|BARMER anemia treatment|BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.
41474184|NCT05146726|OTHER|NON-BARMER anemia treatment|Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability\> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)
41004195|NCT02665416|DRUG|Bevacizumab|Bevacizumab will be administered via IV infusion.
41004196|NCT00343057|OTHER|Patients' questionnaire|
41474185|NCT00528684|BIOLOGICAL|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
41004197|NCT04519658|DRUG|CIN-107|CIN-107 tablets by mouth once daily
41004198|NCT04519658|DRUG|Placebo|placebo tablets by mouth once daily
41316900|NCT00985556|DRUG|tegafur-gimeracil-oteracil potassium|Given orally
41474186|NCT00063882|RADIATION|Brachytherapy (100/110)|100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.
41474187|NCT00063882|RADIATION|Brachytherapy (125/145)|125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.
40800193|NCT04841785|DIAGNOSTIC_TEST|mailer-based finger-prick|All participants in the antibody measurement study will be sent a mailer-based finger-prick set. The sets will be sent to the home address of the patient, including a return envelope. After collecting and returning the samples SARS-CoV-2 antibodies will be analysed quantitatively at the laboratory.
41004199|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
41004200|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
41152131|NCT05094947|PROCEDURE|intermittent catheterization|clean intermittent catheterization with catheter Nelaton
41152132|NCT05094947|PROCEDURE|trial without catheter|catheter Foley
41152133|NCT05094947|DRUG|alpha-blockers|tamsulosin, alfuzosin, doxazosin, silodosin
41316901|NCT02568345|DRUG|sugammadex ED90|"The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.~In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg."
41316902|NCT04497298|BIOLOGICAL|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
41474188|NCT00063882|RADIATION|External Beam Radiation Therapy|Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
41004201|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
41004202|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
41004203|NCT04587193|DEVICE|Robotic-assist gait training device|PD participants will walk while wearing a robotic-assist gait training device
41004204|NCT05138939|OTHER|Red wine A|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
41004205|NCT05138939|OTHER|Red wine B|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
41152134|NCT02610413|OTHER|Laboratory Biomarker Analysis|Correlative studies
41152135|NCT06453304|DRUG|Calcium Hydroxide|Intracanal medication
41152136|NCT06453304|DRUG|Leddermix|Intracanal medication
41152137|NCT06453304|DRUG|Glycirrhizin|Intracanal medication
41152138|NCT01015794|DRUG|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
41152139|NCT01015794|DRUG|ephedrine hydrochloride|single dose of 1 mg/kg body weight
40800194|NCT04790669|PROCEDURE|Daily adjustable progressive resistance exercises (DAPRE)|Daily adjustable progressive resistance exercises (DAPRE) In Group A, 11 participants were received Conventional physiotherapy treatment in addition to DAPRE technique by leg extension machine. In DAPRE technique, four sets of exercises were performed. The first two sets of exercise consisted of ten and then six repetitions, per- formed against one-half and three-fourths of the previously established working weight. Working weight is the amount of weight a patient uses during an individual session. The full working weight was used on the third set, and the patient performed as many repetitions as possible. After performing each of the third and fourth sets, patients rested for 1 min.6 weeks (3 sessions per week)• Hot pack: 10 min• Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
41004206|NCT05138939|OTHER|Control|8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
41004207|NCT05091268|BEHAVIORAL|Exercise|"All participants will attend a four-hour pain education session including gynecologist, psychologist, sexologist, and physiotherapist at Akershus University Hospital.~The education will be held twice, with half of the participants at the time. The training group will then attend a 60 minutes weekly group training session led by a physiotherapist with specialist training in women's health over a period of four months. In addition, participants will perform a progressive home exercise program performed daily over the same period. The focus will be general strength training using own body weight and cardiovascular fitness (walking, low-impact aerobic exercise), stretching, and relaxation"
41004208|NCT01180738|BEHAVIORAL|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
41316903|NCT04497298|BIOLOGICAL|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
41316904|NCT04497298|BIOLOGICAL|One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo
41316905|NCT04497298|OTHER|Placebo|Physiological saline solution (0.9% NaCl)
41316906|NCT04186468|OTHER|ICU follow-up clinic|The intervention aims at improving health-related quality of life and will contain three components: information, consultation and networking. More information will be available for the participants from the intensive care stay onwards, e.g. an information brochure, and during the entire follow-up period, e.g. by contacting the outpatient clinic via telephone. Participants will be invited to visit the ICU follow-up clinic at least once during the first six months after discharge from ICU. During the visits, participants will be screened for symptoms of PICS and, if required, referred to specialists for further treatment. The aim of the networking part is to improve the exchange between the health sectors and disciplines, e.g. through a special referral letter from the ICU follow-up clinic, and thus to provide a network of outpatient care providers for the former ICU patients.
41316907|NCT00073814|DRUG|Levalbuterol tartrate MDI|levalbuterol MDI 90 mcg QID
41316908|NCT00073814|DRUG|racemic albuterol MDI|racemic albuterol MDI 180 mcg QID
41474189|NCT05260723|BEHAVIORAL|Behavioral: Sit Less|The Sit Less arm uses habit formation, social cognitive theory, and motivational interviewing techniques to support behavior change and includes: 1) 7 health coaching sessions to set personalized goals and review progress; 2) wearing an activPAL (thigh worn accelerometer that measures sitting time); 3) intervention tools to support behavior change (e.g., standing desk, wrist worn monitor).
41474190|NCT06085937|DRUG|Ketamine|Patients will receive 0.2mg/kg of IV ketamine
41474191|NCT03956589|DRUG|Orkambi|Open label of Orkambi treatment during 3 months
41474192|NCT00256776|DRUG|Velcade (Bortezomib)|
41004209|NCT01180738|BEHAVIORAL|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
41004210|NCT02759068|BEHAVIORAL|sounds and odors|presentation of sounds and odors
41004211|NCT03287388|PROCEDURE|No Rocuronium|Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
41474193|NCT00256776|DRUG|Thalidomide|
41004212|NCT03287388|DRUG|Rocuronium (moderate NMB)|Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
41474194|NCT00256776|DRUG|Dexamethasone|
41474195|NCT01569347|OTHER|Interviews|Interviews
41474196|NCT01569347|OTHER|Blood sample|Blood sample
41474197|NCT01569347|OTHER|Hair sample|Hair sample
41474198|NCT06092190|DEVICE|EMG|Electrodiagnostic testing (electromyography and nerve conduction velocity) can objectively verify the tibial nerve dysfunction. Electrodiagnosis rests upon demonstrating impaired tibial nerve conduction across the tarsal tunnel in context of normal conduction
41474199|NCT00134329|PROCEDURE|Filling out a questionnaire on the possible occurrence of erectile dysfunction|
40800195|NCT04790669|PROCEDURE|Close kinetic chain exercises (CKC).|Close kinetic chain exercises (CKC). In Group B, 11 participants was received Conventional physiotherapy treatment in addition to close kinetic chain exercises. Close kinetic chain exercises for extensor lag was seated leg press, double or single one third knee bend, step up and down exercise, wall slide with weight. Treatment time was 30 minutes and three session per week was applied on alternate day for up to 6 weeks. Pre interventional readings will be taken at baseline \& post interventional readings at 6th week. 6 weeks (3 sessions per week) • Hot pack: 10 min • Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
40800196|NCT02936518|PROCEDURE|Lingual frenotomy and/or maxillary labial frenectomy|
40800197|NCT04998500|BIOLOGICAL|Growth hormone, saline and GH receptor blockade (Pegvisomant)|This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.
41316909|NCT00073814|DRUG|Placebo|Placebo MDI QID
41316910|NCT00469638|PROCEDURE|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
41474200|NCT05037773|BEHAVIORAL|Intervention targeting parental reminiscing style|8-session intervention (i.e., 1 session/week) targeting 3 main aspects of parental reminiscing: the promotion of child participation, the structure of discussions about the past and the content addressed during these discussions. Different learning techniques are used: psychoeducation, modeling and supervised practice.
40800198|NCT02092636|OTHER|NIR/US Diagnostic Group|Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
40800199|NCT02092636|OTHER|NIR/US Neoadjuvant Chemotherapy Group|Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
40800200|NCT02092636|OTHER|NIR/US Process Validation Group|Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
41474201|NCT02747004|DRUG|Abemaciclib|Administered orally
40800201|NCT00851552|BIOLOGICAL|rituximab|Given IV
40800202|NCT00851552|DRUG|bortezomib|Given IV
40800203|NCT00851552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
40800204|NCT00851552|GENETIC|gene expression analysis|Correlative Study
40800205|NCT00851552|GENETIC|polymerase chain reaction|Correlative Study
40800206|NCT00851552|GENETIC|polymorphism analysis|Correlative Study
40800207|NCT00851552|GENETIC|proteomic profiling|Correlative Study
40800208|NCT00851552|OTHER|flow cytometry|Correlative Study
41316911|NCT00469638|PROCEDURE|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
41474202|NCT02747004|DRUG|Tamoxifen|Administered orally
41474203|NCT02747004|DRUG|Prophylactic Loperamide|Administered orally
41474204|NCT06308835|OTHER|questionnaires|BREF(Batterie d'efficience Frontale), SDMT (Symbol Digit Modalities Test), TMT (Trail making test), Empans verbaux et BNT (Boston naming Test)
41474205|NCT01629394|DRUG|Sugammadex|Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
40800209|NCT00851552|OTHER|laboratory biomarker analysis|Correlative Study
40800210|NCT03472820|OTHER|Diet Recommendations|Specific dietary guidelines will be outlined for participants.
40800211|NCT03472820|OTHER|Lifestyle Recommendations|Participants are encouraged to average a minimum of 7 hours of sleep per night.
40800212|NCT03472820|OTHER|Exercise Recommendations|Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.
40800213|NCT03472820|OTHER|Stress Management Recommendations|Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.
40800214|NCT03472820|OTHER|PhytoGanix (tropical fruit flavor)|Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.
40800215|NCT03472820|OTHER|UltraFlora Intensive Care|Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
41316912|NCT03963934|OTHER|Program on a nurse-led telephone 6-month-follow-up for uncontrolled hypertensive women: a patient-tailored intervention|Implementation of personalized support: The accompaniment includes 7 telephone interviews for 6 months (understanding the antihypertensive treatment, identifying the brakes and the levers when taking medication, organizing the treatment taking, making the home blood pressure)
41316913|NCT02359695|DRUG|Growth Hormone|A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
41316914|NCT06483763|OTHER|SmokerFace App from the Education Against Tobacco (EAT) program|The SmokerFace App utilizes photo-aging technology that requires users to take a selfie. This selfie is processed by the software to generate four images depicting the consequences of smoking (or not smoking) one pack a day over both a one-year and 15 years. The app provides explanations of these smoking beauty-reducing visual outcomes and educates users about the aesthetic impacts of smoking, along with potential health consequences.
41474206|NCT01629394|DRUG|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
41474207|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
40800216|NCT06093542|DRUG|AZD7053|Randomised participants will receive AZD7503 subcutaneously.
41004213|NCT03287388|DRUG|Rocuronium (deep NMB)|Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
41004214|NCT04552366|BIOLOGICAL|Ad5-nCoV|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
41474208|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg ( ideal body weight )
40800217|NCT06093542|DRUG|Placebo|Randomised participants will receive placebo subcutaneously.
40800218|NCT01636336|OTHER|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
40800219|NCT01636336|OTHER|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
40800220|NCT02585986|DIETARY_SUPPLEMENT|Probiotic|daily intake of 1 capsule probiotic
40800221|NCT02585986|DIETARY_SUPPLEMENT|Placebo|daily intake of 1 capsule containing placebo
40800222|NCT03621904|DRUG|Hormonal Antineoplastics|Hormonal therapy used for treatment in endometrial cancer patients
40800223|NCT00444483|BEHAVIORAL|Structured diabetes teaching and treatment program|
40800224|NCT06264908|BEHAVIORAL|Integrated self-management programme|"8 weeks integrated management programme with three educational sessions. Group therapy sessions (6-8 participants per group) delivered by occupational therapists and rheumatology nurses.~1. Disease pathology and Pain management~2. Joint protection and stretching exercise~3. Psychosocial education~4. Aids prescription Each session will consist of education session, exercise session and group sharing sessions."
41004215|NCT02983071|DRUG|G1T38|
41004216|NCT02983071|DRUG|Fulvestrant|
41004217|NCT04287907|DEVICE|Monitor Group|Use of colorimetric end tidal CO2 to guide provider during provision of mask ventilation, where colour change indicates effective breaths
41152140|NCT00930644|DRUG|teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 24 months
41152141|NCT05219747|OTHER|Mucoadhesive film containing Acmella oleracea extract|Participants will apply a mucoadhesive film containing Acmella oleracea extract on labial mucosa of lower lip by themselves at least for 2 hours
41152142|NCT05219747|OTHER|Mucoadhesive film without Acmella oleracea extract|Participants will apply a mucoadhesive film on labial mucosa of lower lip by themselves at least for 2 hours
41152143|NCT03856645|DRUG|OKG-0301|OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
41152144|NCT00574106|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
41152145|NCT05513261|DIAGNOSTIC_TEST|High definition colonoscopy (standard colonoscopy) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply the standard colonoscopy without computer-aided colonoscopy (polyDeep)
41152146|NCT05513261|DIAGNOSTIC_TEST|PolyDeep assisted high definition colonoscopy (CAD system) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply polyDeep assisted high definition colonoscopy (CAD system).
41152147|NCT04641234|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
41152148|NCT05614843|DEVICE|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
41152149|NCT05614843|DEVICE|Sham placebo|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
41152150|NCT00110279|BIOLOGICAL|H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
41152151|NCT02785822|DRUG|hMG-HP|Ovarian stimulation with hMG-HP (150 IU / day)
41152152|NCT02785822|DRUG|hFSH-HP|Ovarian stimulation with hFSH-HP (150 IU / day)
41152153|NCT00449033|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
41152154|NCT00449033|DRUG|Placebo|Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
41152155|NCT00449033|DRUG|Gemcitabine|Chemotherapy component; Gemcitabine 1250 mg/m\^2 IV
41152156|NCT00449033|DRUG|Cisplatin|Chemotherapy component; Cisplatin 75 mg/m\^2 IV
41152157|NCT03440580|DEVICE|BOOSTH|BOOSTH as a serious game is used as a tool to motivate children to perform more PA. BOOSTH uses the combination of a smartphone game and a pedometer that assesses daily PA by measuring steps/day. The BOOSTH activity monitor is a wrist-worn activity monitor that is able to provide online feedback on the child's PA levels. Moreover, BOOSTH is a reward-based game as a child is given incentive to increase their PA level, in order to acquire activity points which later can be used to unlock levels and progress in the BOOSTH game.
41152158|NCT05309356|OTHER|ACCEPT Decision Intervention|The intervention consists of the CPM (ACCEPT) that is integrated with a decision aid, together called the ACCEPT Decision Intervention (ADI). The ADI will provide physicians with a quantification of the exacerbation risk for each patient and the corresponding treatment recommendation, as well as information about the benefits and risks of different inhaled therapies to discuss with the patients. The intervention also includes a 1-page take-home pamphlet on evidence-based risk behaviour factor modification for COPD, tailored to the treatment recommendation.
41152159|NCT05309356|OTHER|Comparator|The patient will receive the physician-recommended treatment for COPD (usual care). All physicians will be provided refresher training on the Canadian Thoracic Society COPD guidelines during the phase in period (month 1).
41152160|NCT03174470|DEVICE|TENS Stimulator|Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
41152161|NCT04214808|DRUG|AD-208|Dutasteride 0.2mg
41474209|NCT01629394|DRUG|Sugammadex|Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)\]
41004218|NCT03689764|OTHER|interactive video game-based exercise|Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
41316915|NCT06483763|OTHER|The use of standardized school-based educational module|This module is designed to promote a tobacco- and nicotine-free environment and is validated by at least three experts in related fields (27). The intervention will be customized to fit the Omani sociocultural context and will be administered in the classrooms of respective schools by the same team of trained medical students
41316916|NCT03357913|OTHER|Lung transplantation|To estimate the incidence of non-respiratory co-morbidities after lung transplantation between 2004 and 2014 in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region
41316917|NCT03182465|DIAGNOSTIC_TEST|Value of ProCalcitonin|The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.
41316918|NCT03145194|DRUG|Ticagrelor|2 x 90mg Ticagrelor tablets
41316919|NCT03145194|OTHER|Placebo|2 x matching placebo tablets
41474210|NCT01629394|DRUG|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
41474211|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
41474212|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50μg/kg ( ideal body weight )
40800225|NCT03279159|OTHER|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
41004219|NCT03689764|OTHER|no intervention|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
41004220|NCT06031571|PROCEDURE|dry cupping massage|Dry cupping is a form of massage therapy that involves using Hijamat cups without skin injury while applying suction and then performing circular and transverse movements
41004221|NCT06031571|PROCEDURE|Myofacial release|Myofascial release is a form of manual therapy using hands-on techniques to regain tissue extensibility and elasticity
41004222|NCT01495845|OTHER|Pharmacogenomics testing for clopidogrel responsiveness|Patients must come to the pharmacy for all visits. At the 1st visit, the patient will provide consent, a complete list of medications, a complete pre-study questionnaire, a copy of their insurance card, and a buccal swab (collected by the pharmacist). The swab will be sent to the testing facility for genotypic testing of CYP2C19. Upon receipt of the results of the results, the pharmacist will propose an intervention to the prescriber based on the patient's indication for clopidogrel and the identification of certain genetic variations atCYP2C19. All patients will be asked to return to the pharmacy for explanation of the results and implementation of any changes approved by the prescriber and to complete a follow-up questionnaire. After the visit to explain the results of testing, the patient's insurance will be billed electronically for a medication therapy management visit; patients without insurance will not be billed. Patients may opt out of billing to insurance at any time.
41004223|NCT01194024|OTHER|Standard of Care|bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
41004224|NCT01344447|DRUG|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of approx. 0.1mmol/kg
41004225|NCT00096044|BIOLOGICAL|rituximab|IV
41004226|NCT00096044|DRUG|lenalidomide|Oral
41004227|NCT03671902|DEVICE|Fluid shift|We are using lower body negative and positive pressure to create a fluid shift in the body. This study is investigating if there are changes in phonocardiographic parameters related to changes in blood volume caused by this fluid shift
41004228|NCT05508412|BEHAVIORAL|CancerPEP|CancerPEP
41004229|NCT01550874|BEHAVIORAL|Physical activity behavior-change counselling|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and (ii) get feedback about performance toward goals.
41316920|NCT03488251|DRUG|MT-3724|MT-3724 will be administered.
41316921|NCT03488251|DRUG|Gemcitabine|Gemcitabine will be administered.
41316922|NCT03488251|DRUG|Oxaliplatin|Oxaliplatin will be administered.
41316923|NCT04700852|DEVICE|Puressentiel protective nasal spray|provocative nasal test with grass pollen and nasal lavage
41316924|NCT00257491|DRUG|Telmisartan|
41316925|NCT00257491|DRUG|Telmisartan/HCTZ|
41316926|NCT03337152|DRUG|primaquine|Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
41316927|NCT03337152|DRUG|chloroquine + primaquine|Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
41316928|NCT02004912|OTHER|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
41316929|NCT02806466|PROCEDURE|Fiberoptic bronchoscopy|
41316930|NCT02417467|OTHER|Nicotine E-Cigarette|
41316931|NCT02417467|OTHER|Non-Nicotine E-Cigarette|
41316932|NCT02417467|BEHAVIORAL|Counseling|
41474213|NCT02972021|DEVICE|High-flow nasal cannula|
41474214|NCT05604937|OTHER|Shi's traumatology osteopathic manipulation|Patients receive treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments. The manipulation intervention has mainly two steps: First, doctors perform soft-tissue manipulation on neck and shoulders to relax for 10 min; Second, doctors perform manipulation to reconstruct atlantoaxial joint. The strength of manipulation is based on the patient's tolerance. Do not use too much force.
41474215|NCT05604937|DRUG|Merislon|Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to patients of the control group, for 2 weeks, 6mg a day, three times a day.
40800226|NCT03279159|OTHER|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
40800227|NCT02029456|DRUG|25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours|
40800228|NCT00296049|DRUG|daptomycin|
40800229|NCT00296049|DRUG|vancomycin|
40800230|NCT05533307|DIAGNOSTIC_TEST|observational analysis of mediolateral episiotomy with arizona sexuel function scoring after 3 months of normal vaginal birth|ASEX (ARİZONA SEXUEL FONCTİON SCORİNG) TEST
41316933|NCT02389140|OTHER|Trigger point release|Trigger point therapy
41316934|NCT02389140|OTHER|Ultrasound|sham ultrasound
40800231|NCT01463163|DRUG|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
40800232|NCT01463163|DRUG|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
40800233|NCT02405247|OTHER|Patient Reported Outcome (PRO)|Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
40800234|NCT05369377|DRUG|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
40800235|NCT05369377|DRUG|Eltrombopag|eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
40800236|NCT02221635|PROCEDURE|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
40800237|NCT02221635|DRUG|Risperidone|Risperidone (2-4 mg) was took orally.
40800238|NCT02339532|DRUG|FEC100|"3 cycles of FEC 100 administered IV q3w~* 5-Fluorouracil (5-FU) 500 mg/m²~* Epirubicin 100 mg/m²~* Cyclophosphamide 500 mg/m²"
40800239|NCT02339532|DRUG|Docetaxel|TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV
41004230|NCT03602937|DIETARY_SUPPLEMENT|Renastep|Renastep is a ready-to-use, high energy, low volume liquid renal specific feed that can be administered enterally via tube or oral consumption.
41152162|NCT04214808|DRUG|Avodart Soft Capsule 0.5mg|Dutasteride 0.5mg
41316935|NCT02404883|OTHER|Online Decision-Aid Tool|
41316936|NCT04121520|OTHER|Questionnaire|"1. Comprehensive perioperative assessment~2. Questionnaire administration"
41316937|NCT04325776|DRUG|AL2846|AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
41316938|NCT04325776|DRUG|Zoledronic Acid Injection|Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
41316939|NCT00832546|DRUG|Placebo|
41316940|NCT00832546|DRUG|Oral NGX426 (Powder in solution)|
41316941|NCT00903747|DRUG|prucalopride|2-10 mg prucalopride
41316942|NCT00903747|DRUG|moxifloxacin|400 mg moxifloxacin (Group 2a)
40800240|NCT02339532|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
40800241|NCT02339532|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
40800242|NCT02339532|DRUG|Carboplatin|CARBOPLATIN AUC 6 IV q3w
40800243|NCT02982772|OTHER|Combination Therapy|"Brief behavioral intervention~The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks."
40800244|NCT02982772|OTHER|Standard Care Intervention|"Brief Behavioral Intervention~The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.~Standard Flavored Gums for 10 weeks"
40800245|NCT02501967|OTHER|COMET|The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
40800246|NCT05905224|DEVICE|Invisalign 7-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 7-day wear protocol
40800247|NCT05905224|DEVICE|Invisalign 3-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 3-day wear protocol
41152163|NCT01100593|PROCEDURE|length of IV catheter|Subjects will be randomized to one of two IV catheter lengths
40800248|NCT04925219|BEHAVIORAL|Remotely supervised exercise programme|Electronic walking log Fortnightly video/telephone calls with physiotherapist
40800249|NCT04925219|BEHAVIORAL|Self-directed exercise|Electronic walking log and instructions to exercise 4 times per week.
40800250|NCT00531440|DRUG|Everolimus (RAD001)|
41152164|NCT00788671|OTHER|Laboratory Biomarker Analysis|Correlative studies
41152165|NCT00788671|DEVICE|Levonorgestrel-Releasing Intrauterine System|Undergo placement of a levonorgestrel-releasing intrauterine system
41316943|NCT00903747|DRUG|placebo|placebo (Group 2b)
41316944|NCT02622100|DEVICE|Bioresorbable Vascular Scaffold|
41316945|NCT04696874|PROCEDURE||All testes were fixed to the ipsilateral sub-dartos pouch. All epididymides and vasa deferentia were carefully examined, and any observed anomalies were recorded.
41316946|NCT00539253|DRUG|gadobenate dimeglumine (MultiHance)|The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
41341769|NCT02891772|PROCEDURE|ultrasonographic measurement of corrected flow time(FTc) in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
40800251|NCT02434653|OTHER|Monitoring hemoglobin levels following anemia associated symptoms|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
40800252|NCT02434653|OTHER|Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
40800253|NCT01440114|DRUG|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
40800254|NCT01440114|DRUG|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
41316947|NCT04020094|COMBINATION_PRODUCT|MVA-BN-Brachyury|"Cycle= 21 days. Neoadjuvant Therapy: Treatment will be given for 2 neoadjuvant cycles. MVA-BN-Brachyury will be administered as intratumoral injection on Day 1 of each of 2 neoadjuvant cycles. PROSTVAC-V will be administered as a subq injection on Day 1 of Cycle 1 (the first neoadjuvant cycle) and PROSTVAC-F will be administered as a subq injection on Day 1 of Cycle 2 (the second neoadjuvant cycle). Atezolizumab will be given as an infusion on Day 1 of each 2 neoadjuvant cycles.~MVA-BN-Brachyury will be injected intratumorally into the prostate. Injections will target PI-RADS 4 and 5 lesions.~Surgery: Patients will undergo SOC radical prostatectomy Adjuvant Therapy: Systemic treatment with atezolizumab and PROSTVAC-F will be reinitiated between 3 to 8 weeks after surgery and will continue for an additional 6 cycles. PROSTVAC-F will be given as a subq injection on Day 1 of each cycle. Atezolizumab will be given as an infusion on Day 1 of each cycle."
40800255|NCT06549504|DRUG|AG2202T|AG2202T Single-dose
40800256|NCT06549504|DRUG|AG2202R|AG2202R Single-dose
40800257|NCT00400218|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
40800258|NCT01198704|OTHER|search of factors predicting tumor recurrence|Morphological, chronological, anatomy-pathological and molecular search
40800259|NCT01562392|DIETARY_SUPPLEMENT|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
40800260|NCT01562392|DIETARY_SUPPLEMENT|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
40800261|NCT01673854|DRUG|Ipilimumab|
40800262|NCT01673854|BIOLOGICAL|Vemurafenib|
40800263|NCT05974384|DEVICE|No Music|No listening to music while intervention is carried out
40800264|NCT05974384|DEVICE|Music|Listening to music while intervention is carried out
40800265|NCT00333411|DRUG|BIRT 2584 XX|
40800266|NCT00333411|DRUG|Placebo|
41004231|NCT00378014|DRUG|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
41004232|NCT00378014|DRUG|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
41316948|NCT04779671|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 30 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
41474216|NCT05983666|DIAGNOSTIC_TEST|Ultrasound Oesophageal Intubation|Ultrasound Oesophageal intubation detection
40800267|NCT03612128|OTHER|control group|Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
40800268|NCT03612128|OTHER|intervention group|Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
40800269|NCT00100568|DRUG|Efavirenz|600 mg tablet taken orally daily
40800270|NCT00100568|DRUG|Lamivudine/zidovudine|150mg lamivudine/300mg zidovudine tablet taken orally twice daily
40800271|NCT05739006|DRUG|BCD-201|up to 8 treatment cycles
40800272|NCT05739006|DRUG|Keytruda|up to 8 treatment cycles
41152166|NCT00788671|OTHER|Quality-of-Life Assessment|Ancillary studies
40800273|NCT01681186|DRUG|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
40800274|NCT01681186|DRUG|LY2940680 Tablet (Test)|Administered orally as a tablet
40800275|NCT01681186|DRUG|Lansoprazole|Administered orally as a capsule
40800276|NCT01681186|DRUG|Placebo Capsule(s)|Administered orally as a capsule(s)
40800277|NCT02836717|DEVICE|sacral nerve modulation|electric stimulation of the sacral nerve using an implanted electrode and stimulator
40800278|NCT04300205|DEVICE|High intensity LED light device|Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months
40800279|NCT04300205|DEVICE|Sham LED light device|Participants have the light treatment moved off their wound after masking
40800280|NCT06365255|OTHER|questionnaires|filling in questionnaires
40800281|NCT01014767|DRUG|Carboplatin|"Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3"
40800282|NCT01014767|DRUG|Cisplatin|Cycles 1 \& 2: 70 mg/m²/d IV over 6 hours on day 4
40800283|NCT01014767|DRUG|Cyclophosphamide|"Standard Arm, Cycle 1: 1 g/m\^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 \& 5: 1 g/m\^2 IV over 1 hour on day 2 and 3"
40800284|NCT01014767|DRUG|Dactinomycin|Cycles 1 \& 2: 45 µg/kg/day (max. 2 mg), IV on day 1
40800285|NCT01014767|DRUG|Doxorubicin|Cycles 1 \& 2: 25 mg/m²/day IV over 12 hrs on days 1-3
40800286|NCT01014767|DRUG|Etoposide|"Standard Arm (1), Cycles 1 \& 2:~100 mg/m2 IV over 1 hour on days 1-5~All Arms, Cycles 4-6:~100 mg/m2 IV over 1 hour on days 1-5"
40800287|NCT01014767|DRUG|Irinotecan|"Temozolomide Irinotecan arm (4), Cycles 1 \& 2:~50 mg/m2/day x 5 days as 1 hour IV infusions"
41474217|NCT04785157|BIOLOGICAL|serology testing profiles description|SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF)
41474218|NCT04785157|BIOLOGICAL|immune response characterization|systemic and central immune response characterization , associated to the assessment of CNS damage biomarkers (peripheral blood and CSF)
41474219|NCT04785157|OTHER|in vivo brain PET-TSPO acquisitions|in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia)
41474220|NCT04785157|OTHER|brain MRI assessment|structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity)
40800288|NCT01014767|DRUG|Leucovorin|Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
40800289|NCT01014767|DRUG|Methotrexate|5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
40800290|NCT01014767|DRUG|Temozolomide|150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
40800291|NCT01014767|DRUG|Vincristine|"Standard Arm (1), Cycles 1 \& 2 : 1.5 mg/m\^2 IV over 15 minutes on day 5~Doxorubicin/cisplatin arm (2), Cycles 1 \& 2: 1.5 mg/m\^2/day (max. 2 mg), i.v. on days 8, 15~For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5"
40800292|NCT01510990|DRUG|Gefitinib|gefitinib 250mg/day daily
40800293|NCT01378650|DRUG|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
40800294|NCT01378650|DRUG|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
40800295|NCT05487677|DEVICE|BioBrace Augmentation|During shoulder replacement surgery, the subscapularis (rotator cuff muscle) is sometimes repaired back again. This will be stitched and augmented with a BioBrace. The Biobrace is a biocomposite scaffold meaning both synthetic and biologic, compared to other traditional implants that are either synthetic or biologic. The stitch in the BioBrace group will be anchored to and reinforced by this material.
40800296|NCT05487677|PROCEDURE|Standard Repair with Sutures|During shoulder replacement surgery, the Subscapularis (rotator cuff muscle) is sometimes repaired back again. This is usually repaired with stitches per standard of care treatment.
40800297|NCT04234347|PROCEDURE|Intravenous access method|Comparing long and short axis approach to USGPIV access.
40800298|NCT01547351|OTHER|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
40800299|NCT00521729|PROCEDURE|Exposure to Cold Temperature|
40800300|NCT02831127|OTHER|short message service group|Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
40800301|NCT02831127|OTHER|conventional group|After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
40800302|NCT01415583|DRUG|Dexamethasone|0.5mg/kg (max dose 20mg)
41316949|NCT04779671|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
41316950|NCT02767453|PROCEDURE|Wound drainage|Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
41474221|NCT04785157|BEHAVIORAL|neurocognitive assessment|multi-domains neurocognitive assessment
41474222|NCT01380249|DRUG|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
41474223|NCT00810888|DRUG|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
41474224|NCT00810888|DRUG|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
41474225|NCT01358539|BEHAVIORAL|Pain education|Patients receiving pain education
41474226|NCT04034355|DRUG|Calmangafodipir (5 µmol/kg)|PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a solution in 20 mL single dose glass vials.
41474227|NCT04034355|OTHER|Placebo|Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a solution in 20 mL single dose glass vials.
41474228|NCT02717078|OTHER|Diet Therapy|The intervention for both study groups will be a change in diet.
41474229|NCT03836924|DRUG|Perampanel|Perampanel tablets.
40800303|NCT04094324|BEHAVIORAL|Questionnaires|4 questionnaires will be answered via iPads
40800304|NCT04169204|DIAGNOSTIC_TEST|Measurement of microcirculation|As a simple clinical test, every patient will receive the assessment capillary refill time and mottling-score. Additionally, repetitive measurements of lactate will be done. The SDF-camera (MicroVision Medical®, Amsterdam, Netherlands) will measure sublingual microcirculation at different time points (Admission and 24h).
40800305|NCT06121076|OTHER|SDM-EBP training|A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.
40800306|NCT02700620|BEHAVIORAL|Internet-delivered CBT|Guided internet treatment
41004233|NCT00378014|DRUG|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
41316951|NCT02767453|PROCEDURE|Total Shoulder Arthroplasty|"Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA."
41316952|NCT03751592|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
41004234|NCT04531410|DIETARY_SUPPLEMENT|linoleic acid supplementation|Oils given daily at morning meal with extra enzymes
41316953|NCT01848639|DRUG|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
41316954|NCT01848639|DRUG|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
41316955|NCT04448262|OTHER|data collection|collection of data about bronchial and systemic inflammation, quality of life, lung function
41316956|NCT04005196|DIAGNOSTIC_TEST|EEG|Data recording will continue up until a maximum of 120 hours after emergence from sedation or at CVICU discharge. This study period is informed by baseline data from our institution where the median duration of delirium following emergence from coma was 2 days, allowing sufficient time to capture transitions from coma to wakefulness with and without delirium. EEG recordings will be divided in to epochs corresponding to coma, wakefulness, and delirium if present.
41316957|NCT01583452|OTHER|Chewing Gum|The use of chewing gum as a preventive measure for post-operative ileus
41316958|NCT03292952|DRUG|KP415 oral capsule|Daily dose
41316959|NCT03292952|DRUG|Placebo oral capsule|Daily dose
41316960|NCT03544554|BEHAVIORAL|a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model. Within the scope of the counseling and training program|The intervention group was provided with a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model.
41316961|NCT00088569|DRUG|0-15 Water|
41316962|NCT03379506|DRUG|EBR/GZR FDC Tablet|Participants who are 12 to \<18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
41004235|NCT04531410|DIETARY_SUPPLEMENT|oleic acid supplementation|Oils given at morning meal with extra enzymes
41004236|NCT00799617|DRUG|AndroGel® (testosterone gel)|Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
41004237|NCT00799617|DRUG|Placebo|Testosterone levels will be measured at regular intervals.
41316963|NCT03379506|DRUG|Placebo|Placebo tablet matched to EBR/GZR FDC tablet.
41316964|NCT03379506|DRUG|Grazoprevir Oral Granules|Participants 3 to \<12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.
41004238|NCT05255458|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
41004239|NCT05255458|DRUG|Placebo|Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
41316965|NCT03379506|DRUG|Elbasvir Oral Granules|Participants 3 to \<12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
41316966|NCT05405595|DRUG|ADG126|ADG126 and Pembrolizumab (KEYTRUDA®) combination treatment both will be dosed until progressive disease (PD), intolerable toxicities, withdrawals of consent, or up to 35 cycles.
41316967|NCT03910647|DRUG|pantoprazole|effect of this drug on renal function
41316968|NCT00442013|DRUG|Lansoprazole|Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.
41316969|NCT00442013|DRUG|Matching placebo|Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
41316970|NCT00423241|DEVICE|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
41474230|NCT04508699|OTHER|semantic learning|Experimental semantic learning from linguistic context task
41004240|NCT04087122|DEVICE|Esophageal warming device (Attune Medical, Chicago, IL|Prospective, single center pilot stud
41316971|NCT00423241|DEVICE|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
41004241|NCT00204256|DRUG|Iron sucrose|
41004242|NCT01228929|OTHER|Environmental Chamber Condition Change Intervention|For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.
41474231|NCT03442010|OTHER|Detection of adverse drug events|Detection of adverse drug events
41004243|NCT05605665|DRUG|low-dose interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once twice a week, for 12 weeks.
41004244|NCT05605665|DRUG|rapamycin|Rapamycin 0.5ml was taken orally once per day
41004245|NCT01067703|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
41004246|NCT01067703|PROCEDURE|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
41004247|NCT03941522|OTHER|Early discharge from hospital|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
41004248|NCT05817396|BEHAVIORAL|Promotion of Physical Activity-related Health Competence (PAHCO)|"Intervention for the curriculum content PAHCO at nursing schools in Bavaria"
41004249|NCT02321696|DEVICE|Acupuncture|
41004250|NCT02321696|OTHER|Physiotherapy and eccentric exercise|
41004251|NCT02321696|OTHER|Watchful waiting and eccentric exercise|
41004252|NCT02321696|OTHER|eccentric exercise|
41004253|NCT06183359|OTHER|SIP|compare the SIP group versus the ACT group
41004254|NCT00104533|DEVICE|Magnets|
41004255|NCT00581074|BEHAVIORAL|diet (grapefruit or grapefruit juice)|weight loss diet
41004256|NCT01899599|DRUG|PankoMab-GEX|start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
41004257|NCT01899599|DRUG|Placebo|start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
41004258|NCT03696654|PROCEDURE|adenotonsillar surgery|when indicated, adenotonsillar surgery for SDB treatment
41004259|NCT01073865|DRUG|ZD9393 (Zoladex) 10.8 mg|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
41316972|NCT00011713|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
41316973|NCT02471001|BIOLOGICAL|Blood samples|Two additional blood samples will be taken from in-situ catheters during heart surgery.
41316974|NCT02851433|DRUG|total anaesthesia and postoperative inhaled sedation with Sevoflurane|
41004260|NCT01073865|DRUG|ZD9393 (Zoladex) 3.6 mg|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
41004261|NCT04341974|DIAGNOSTIC_TEST|Serum creatinine|Will be described: 1) the number of patients actually screened with postoperative serum creatinine and 2) the number of patients actually screened with the same parameter at the long-term after surgery
41004262|NCT02342704|DRUG|natalizumab|Administered as specified in the treatment arm
41004263|NCT02342704|DRUG|fingolimod|Administered as specified in the treatment arm
41004264|NCT06391463|OTHER|Carriage of MRB ou BC|Study of the epidemiology of the carriage of BMR and BC germs in patients in the neonatology department
41316975|NCT02851433|DRUG|total intravenous anaesthesia with Propofol.|
41474232|NCT01123096|PROCEDURE|Cough Stress Test|A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.
41474233|NCT01123096|OTHER|24 Hour Pad Test|The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
41004265|NCT04974775|DIAGNOSTIC_TEST|Blood collection|Sampling on admission to ICU (all patients)
41004266|NCT04974775|DIAGNOSTIC_TEST|Blood collection, serial sampling|"Additional sampling to admission samples in~1. the Cardiac Arrest group after 12 and 48 hours~2. the Covid-19 group on day 2 and 7 while in the ICU~3. the Covid-19 group after 3 and 12 months."
41004267|NCT04001569|DRUG|AZD8186 in combination with paclitaxel|"Phase 1b is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D will be determined based on the MTD and toxicity profiles.~In phase 2 part, RP2D from the phase 1b part will be applied.~* AZD8186 ( )mg po bid, 5 days on, 2 days off~* Paclitaxel ( )mg/m² on D1,8,15 every 4 weeks"
41004268|NCT02836171|DRUG|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
41474234|NCT00000202|DRUG|Buprenorphine|
41004269|NCT02836171|DRUG|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
41004270|NCT03568942|DRUG|Gepotidacin|Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
41004271|NCT06332521|OTHER|Acoustic signal analysis method|Evaluate at birth in 2 characterized populations of babies born at term or prematurely, the correlation between bioacoustic characteristic of a cry specific to each baby, with the neurodevelopmental data at 2 years.
41004272|NCT03769272|PROCEDURE|Measurement of electrical delay during LV lead placement|Measurement of electrical signal in the heart during implantation of CRT, by positioning the lead in different places in the heart.
41004273|NCT04845737|OTHER|sympathetic skin response measurement|"Sympathetic skin response(SSR) was studied with upper and lower extremity hand and foot recording of all participants, and amplitude and latency values will be recorded. SSR measurement will be made at room temperature of 25 ºC, while the patients are resting in the supine position. 6 mm silver disc electrodes will be used as the recording electrode.~The relationship between the patients' vitamin D levels and inflammatory response markers and their sympathetic skin responses will be investigated by statistical analysis."
41004274|NCT00043693|BEHAVIORAL|Family Intervention for Dual Diagnosis|The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
41316976|NCT03824548|OTHER|this is non-intervention study, there is no intervention drug or device in this study.|this is exactly a non-interventional study, no intervention during the whole study.
41316977|NCT00718289|OTHER|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
41474235|NCT05816200|DEVICE|Low-Level Light Therapy|Punctual applications of infrared laser (L2) (power of 100mW, 808 nm, 6 joules of energy/60 seconds) in the affected region, keeping one centimeter of distance between the points, until the entire area of the complaint was irradiated. being held one session per week, totaling eight weeks of treatment at the end of the study.
40800307|NCT01295307|DRUG|Clofarabine|Induction and consolidation therapy / conditioning therapy with Clofarabine
41004275|NCT00043693|BEHAVIORAL|Family psychoeducation program|The family psychoeducation program consists of 6 weekly sessions.
41004276|NCT06502288|DRUG|625 mg of amoxicillin with combined clavulanic acid tablet|The intervention group must take 625 mg of amoxicillin with combined clavulanic acid tablets three times a day after meals for 7 days following extraction.
41316978|NCT00718289|OTHER|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
41316979|NCT03882346|COMBINATION_PRODUCT|LifeLiver|LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.
41316980|NCT05291598|DRUG|IV meloxicam|Participants will be administered meloxicam 30 mg IV push pre-operatively.
41316981|NCT05291598|DRUG|Ketorolac|Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.
41316982|NCT02709928|DRUG|TD-0714|
41316983|NCT02709928|DRUG|Placebo|
41316984|NCT03106506|PROCEDURE|Connective tissue graft|Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
41474236|NCT05816200|DEVICE|Transcutaneous Electric Nerve Stimulation|Using a device at a frequency of 50 Hertz with intensity modulated according to the patient's comfort ranging from 1 - 4 (pulse amplitude) with a duration of 25 minutes per session, with one session per week, totaling eight weeks of treatment at the end of the study. The device's self-adhesive electrodes were fixed on the participant's face, following the path of the trigeminal nerve branch on the side affected by pain and/or burning.
41474237|NCT02560779|DRUG|Carotuximab (TRC105)|Bi-weekly iv TRC105 (15 mg/kg) will be given with 400mg sorafenib twice daily in the phase 1B portion of the study. Weekly iv TRC105 (10 mg/kg) will be given with 400mg sorafenib twice daily in the phase 2 portion of the study.
41474238|NCT02560779|DRUG|Sorafenib|400 mg of sorafenib will be given twice daily.
41004277|NCT05112198|DEVICE|Use of Noona web- based symptom tracking tool|Noona patient reported outcome (PRO) platform tool that summarizes symptoms and distress
41004278|NCT06132022|OTHER|Mandala|Mandala work is one of the non-pharmacological approaches and is used to support patients and caregivers in various diseases. Mandala is a method that anyone can apply based on coloring a circular shape.
41316985|NCT06329999|DRUG|CMGV|"Initial treatment induction therapy: CMG+Vineclavone regimen Mitoxantrone liposomes 15mg/m2, iv, d1; Cytarabine 10mg/m2, H, q12h, d1-7; G-CSF starts at 5ug/kg, H, d0, WBC ≥ 30 × 109/L, stop G-CSF; Vinecla 100mg, 2200mg, 3400mg, d4-10. Every 4 weeks is a cycle, for a total of 2 cycles. For patients with CR/CRI/MLFS/PR in the first cycle, repeat this regimen for consolidation treatment once (the second course of treatment is Vineclavone 400mg d1-7).~Follow up treatment: Patients who meet the transplantation criteria will undergo hematopoietic stem cell transplantation, while those who do not undergo transplantation will continue to receive CMG+Vineclavone consolidation for 4-6 courses."
40800308|NCT03954886|DEVICE|Plus powered optical lens|A plus powered optical lens will be placed in front of one eye.
40800309|NCT05482425|OTHER|Autologous facial fat graft injection|Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
40800310|NCT04191304|BIOLOGICAL|Benralizumab|Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
40800311|NCT04191304|BIOLOGICAL|Placebo|Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
40800312|NCT04748328|PROCEDURE|ACL Reconstruction surgery and Rehabilitation Treatment|ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
40800313|NCT04930913|DIAGNOSTIC_TEST|Three-dimensional Ultrasound|women suspected of having adhesions will perform 3D US
40800314|NCT02994082|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
40800315|NCT02994082|BEHAVIORAL|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
40800316|NCT02994082|BEHAVIORAL|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
40800317|NCT02994082|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
40800318|NCT02994082|DRUG|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
41316986|NCT05585086|OTHER|Peppermint Oil Inhalation|Peppermint oil will be given by diluting 1/10 in wheat oil so that it does not cause skin irritation. Application; by inhalation method, 2 cc lavender essential oil + 100 cc water (2%) will be in the form of two drops for 20 minutes. Since the effectiveness of essential oils decreases over time and the desired dose cannot be applied at the same time; Peppermint oil will be applied to the individual for a total of 5 times every 30 minutes.
41004279|NCT06132022|OTHER|Routine care|The clinic's routine information will be given to the caregivers of the control group.
40800319|NCT02994082|DRUG|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
41004280|NCT05360563|OTHER|Home-based physical training|Patients allocated to this group will participate in a 16-week home-based physical training program, structured in three weekly sessions of aerobic and muscle strengthening exercises (which also have components that stimulate flexibility and balance). A third of the weekly physical training sessions will be supervised via telemedicine (with video call) by a clinical exercise specialist, but all patients will have illustrated exercise booklets and a full-time remote support service available for the remaining sessions (via text or voice messages).
41004281|NCT06481059|RADIATION|Head and Neck cancer post-radiotherapy|Head and Neck Cancer patients who received radiotherapy after 6 months
41004282|NCT01466192|DRUG|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
41316987|NCT04719676|OTHER|Core strength training using unstable surface|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on unstable surface"
41316988|NCT04719676|OTHER|The stable surface would be gym floor.|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on stable gym Floor"
41316989|NCT00456729|DRUG|Metronidazole|
41004283|NCT01466192|DRUG|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
41004284|NCT01466192|DRUG|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
41004285|NCT03640065|DRUG|freeze-dried probiotic sachets|"* The participants will be instructed to consume the sachets as follow, each sachet powder is mixed with 10 ml of water in a measuring cup, then swish the mixture in the mouth for one minute before swallowing.~* This procedure will be repeated once daily for the following 4 weeks.~* 4 weeks supply will be given to the participants."
41004286|NCT03640065|DIETARY_SUPPLEMENT|fermented dairy product ( yogurt)|"* The participants will be instructed to consume the yogurt once daily regularly for the following 4 weeks.~* 4 weeks supply will be given to the participants with instruction to store the yogurt in refrigerator at home"
41004287|NCT01219725|BEHAVIORAL|Exercise training|6 months of moderate intensity exercise training 3 times per week
41004288|NCT06440070|PROCEDURE|Loop Carpal Tunnel Release|Under the guidance of ultrasound, needles are inserted above and below the transverse carpal ligament, respectively, to form a loop around the ligament. Finally, the ligament is cut by pulling the looped thread.
41004289|NCT06442501|OTHER|routine care|routine care
41004290|NCT02572050|PROCEDURE|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
41004291|NCT03377712|DEVICE|optoelectronic plethysmography|Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations
41004292|NCT03377712|DEVICE|diaphragmatic ultrasound|Evaluates the diaphragmatic mobility through images, simple and non-invasive use
41004293|NCT03377712|DEVICE|Postural evaluation|Evaluates the patient's posture through photos and filming, rapid examination, simple and non-invasive
41004294|NCT03377712|DEVICE|Pain evaluation|by means of questionnaires
41004295|NCT03377712|DEVICE|Evaluation of the function|through questionnaires
41316990|NCT00456729|PROCEDURE|Blood tests|
41316991|NCT02115113|DRUG|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
41316992|NCT02115113|DRUG|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
41004296|NCT03377712|DEVICE|Functional capacity assessment|Evaluated through the six-minute walk test, where the patient walks along a 30-meter corridor, simple, fast and safe assessment
41004297|NCT03377712|DEVICE|Quality of life assessment|through questionnaire
41004298|NCT01530126|BIOLOGICAL|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
41004299|NCT01530126|BIOLOGICAL|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
41004300|NCT01530126|BIOLOGICAL|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
41004301|NCT01166308|RADIATION|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
41004302|NCT01166308|RADIATION|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
41004303|NCT01944059|DRUG|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
41004304|NCT01944059|OTHER|Placebo (l-alanine)|Theramine like placebo comparator
41316993|NCT01091987|BEHAVIORAL|Non-pharmacological approach of insomnia|education on sleep, sleep hygiene, stimulus control, cognitive techniques
40800320|NCT02994082|DRUG|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
40800321|NCT02994082|DRUG|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
40800322|NCT02994082|DRUG|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
40800323|NCT02994082|DRUG|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
40800324|NCT02994082|DRUG|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
41316994|NCT00141557|DRUG|esterified estrogens 1.25mg and methyltestosterone 2.5mg|ESTRATEST® administered orally QD
41316995|NCT00141557|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
41316996|NCT02207478|PROCEDURE|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
41004305|NCT00000403|DRUG|Doxycycline|
41316997|NCT02207478|PROCEDURE|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
41316998|NCT06468865|DEVICE|Continuous glucose monitor (Dexcom® G7)|Continuous glucose monitors measures glucose levels in the interstitial fluid every 5 minutes
41316999|NCT03051087|DRUG|Ganirelix acetate|
41317000|NCT00750555|DRUG|Erlotinib|150 mg per day orally until disease progression occurs, up to a maximum of 12 months
40800325|NCT02994082|BEHAVIORAL|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
40800326|NCT02994082|BEHAVIORAL|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
40800327|NCT00540241|DRUG|Pemetrexed|in-label use
40800328|NCT03809078|DRUG|68Ga RM2|PET radiopharmaceutical
40800329|NCT03809078|DRUG|68Ga-PSMA-11|PET radiopharmaceutical
40800330|NCT03809078|DEVICE|Investigational PET scanner coils and software|GE Healthcare non-approved PET scanner coils and software
40800331|NCT03500016|OTHER|High intensity interval training|See under arm description.
41004306|NCT00052728|DRUG|tamoxifen citrate|
41004307|NCT00052728|DRUG|tipifarnib|
41004308|NCT04576104|PROCEDURE|Biopsy|Undergo biopsy
41004309|NCT04576104|DRUG|Extended Release Metformin Hydrochloride|Given PO
41004310|NCT04576104|DRUG|Megestrol Acetate|Given PO
41004311|NCT04576104|OTHER|Questionnaire Administration|Ancillary studies
41004312|NCT02752295|BEHAVIORAL|stress-coping week|The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.
41317001|NCT00671814|DRUG|TR-701|TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
41317002|NCT00671814|DRUG|linezolid|Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.
41317003|NCT00671814|DRUG|placebo|Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
41317004|NCT06114394|PROCEDURE|UPV/EHU technique (Aguirre-Zorzano et al 2017)|"The UPV/EHU technique (Aguirre-Zorzano et al., 2017) begins with the elevation of the full thickness flap (FTF) in the palate and an intrasulcular incision performed with a number 12 blade, preserving the papillae in the interproximal spaces. Then, the FTF is dissected with a 15c blade, holding the flap with tissue forceps, leaving the epithelium and a thin layer of the connective tissue in the flap, so that the underlying connective tissue can be harvested. After that the flap is sutured."
41317005|NCT06114394|PROCEDURE|Single incision technique (Huerzeler & Weng 1999)|The CTG is harvested with the single incsion technique described by Huerzeler \& Weng in 1999.
41317006|NCT04101487|OTHER|Cash Transfer|Monthly cash transfers
41317007|NCT04101487|OTHER|Cash Transfers and Nutrition Education|Cash transfers every month and structured nutrition education provided at household level by community health assistants based on a nutrition education handbook
41317008|NCT05402436|OTHER|A diagnosis of atypia as part of the English screening programme|An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA
40800332|NCT01439659|BEHAVIORAL|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
40800333|NCT01439659|DIETARY_SUPPLEMENT|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
41004313|NCT02752295|BEHAVIORAL|additional two days follow-up weekend|A two-days follow-up which recapitulates previous treatment elements.
41004314|NCT02256891|DEVICE|PRFM|
41004315|NCT02256891|PROCEDURE|Double Row|
41004316|NCT01211028|BIOLOGICAL|Expanded autologous ASCs|Drug: Expanded autologous adipose-derived adult stroma/stem cells
41004317|NCT03791866|OTHER|Nutrition|Enteral nutrition
41004318|NCT05924035|DEVICE|HBOT|HBOT treatment on a multiplace chamber (OXYHeal Hyperbaric Oxygen Chamber), 100% oxygen at 2.0 atmospheres for 90 minutes - on 4 consecutive days within 3 hours of completion of exercise training (as soon as practically possible). This will occur during week 2 of data collection.
41004319|NCT01865825|RADIATION|Esophageal Barium Xray|"•Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.~We will have patients complete the Mayo Dysphasia Questionnaire-30 day."
41152167|NCT02332122|PROCEDURE|Sputum induction|Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is \>= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.
41152168|NCT02332122|PROCEDURE|Skin prick test|Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (\>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of \>= 3mm is a positive result.
40800334|NCT00119028|PROCEDURE|Depression Care Quality Improvement Implementation|We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
40800335|NCT05327075|OTHER|questionnaire|it is in the form of questionnaire and scoring tool
41004320|NCT00632697|DRUG|pentoxifylline|800 mg daily for six months
41004321|NCT00632697|DRUG|placebo|
41152169|NCT02332122|OTHER|Questionnaires|MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire
41152170|NCT00054730|DRUG|CX516 (Ampalex®)|
41152171|NCT03563131|DEVICE|Persona® total knee arthroplasty|Insertion of the cemented or uncemented Persona® total knee arthroplasty
41152172|NCT01951105|DRUG|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
41317009|NCT04703127|DRUG|Tadalafil and Combined Dapoxietine|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
41317010|NCT04703127|DRUG|Dapoxietine and Combined Lidocaine 5% Spray|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
41317011|NCT04621669|DRUG|SHR3680|240 mg
41317012|NCT04621669|DRUG|digoxin|0.25 mg
41317013|NCT04621669|DRUG|Rosuvastatin calcium|10 mg
41317014|NCT04621669|DRUG|metformin hydrochloride|500 mg
41317015|NCT02598466|DRUG|Abatacept|
41317016|NCT03335618|OTHER|Activity Monitoring and Symptom Coaching|Triggered check-ins by study personnel to keep participants on track to meet fitness goals
40800336|NCT02886507|DIETARY_SUPPLEMENT|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
40800337|NCT02886507|DIETARY_SUPPLEMENT|Placebo|The placebo capsules contain microcrystalline cellulose.
40800338|NCT05551793|DRUG|Dupilumab|Dupilumab: 300mg SC injections
40800339|NCT05551793|DRUG|Placebo|Placebo: SC injections of equivalent volume
41317017|NCT03335618|OTHER|Passive Activity Monitoring|Passive step tracking without check-ins
41317018|NCT06085261|BEHAVIORAL|home-based telerehabilitation group|Participants will download the web application in their smartphones in the hospital's outpatient clinic and learn to use the sports wristwatch. Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises. The initial aerobic exercise prescription for walking will be set at 80% of the speed walked during a 6-minute walk test (6MWT) and progressed each 4-week according to patient assessments. Resistance training for the arms and legs will utilize elastic bands, while respiratory training will utilize portable breathing trainer. During each training session, participants will be asked to follow the videos in the web application, wearing the sports wristwatch recording their exercise intensity. At the end of every training session, training data could be uploaded to the web platform automatically, which will be checked by staff in hospital.
41317019|NCT06085261|BEHAVIORAL|center-based traditional rehabilitation group|"Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment.~The initial aerobic exercise prescription for cycling will be set at 60% of the peak oxygen uptake (VO2) on a cardiopulmonary exercise test (CPET). Resistance training and respiratory training are similar to the telerehabilitation group."
41317020|NCT01418053|DRUG|caraway oil|essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
41317021|NCT01418053|DRUG|Olive oil|1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
41474239|NCT04462484|BEHAVIORAL|videoconference|The intervention is a person-directed, individual, primary occupational intervention. It will be carried out via videoconference in six sessions of 45 minutes (on a weekly basis). Through guided dialogue, individual difficulties and opportunities of each subject will be examined in order to gain self-awareness of personal characteristics (strengths, limitations, maximum workload capacity) in their particular set of job demands and resources. Participants are encouraged to adopt the set of self-care strategies in each dimension, adapting them to their specific context. Activities will be carried out in Spanish by the researcher.
41474240|NCT03226171|DRUG|Dose-adjusted SK-1403|SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
40800340|NCT06414343|OTHER|Observational - no intervention|Observational - no intervention
40800341|NCT03680196|DRUG|medication Botulinum A injection.|In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
41004322|NCT03926234|OTHER|Four-level Chinese Emergency triage scale|a four-level category system, i.e. life-threatening (Level I), emergent (Level II), urgent (Level III) and semi-urgent (Level IV) . This system contains critical indicators (cardiac arrest, shock, and apnea), high risk indicators (ACS and DKA), single objective indicators (SBP, RR, HR, and SpO2) and MEWS (synthesis indicator). According to patients' health care problems, patients are rated by nurses into one of the four mentioned levels.
41317022|NCT03403894|BEHAVIORAL|Asking caregivers in their practice|A questionary is given to caregivers
41317023|NCT00434122|DRUG|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
41474241|NCT04243096|BEHAVIORAL|Exercise-based Physical Therapy|Exercises for pain modulation, strengthening, and neuromuscular control
41474242|NCT04978844|BEHAVIORAL|IWOTCH|Arm 1
41474243|NCT04978844|BEHAVIORAL|Dyadic therapy|Arm 2
41474244|NCT03352752|DEVICE|HTC Vive|Wearing VR helmet before operation
41474245|NCT03352752|OTHER|Without HTC Vive|Wearing a blindfold before operation
41474246|NCT01027767|DEVICE|Molecular Breast Imaging|Molecular Breast Imaging
41004323|NCT02531165|DRUG|Fentanyl|Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
41004324|NCT02531165|DRUG|Morphine|Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
41004325|NCT02531165|DRUG|Ticagrelor|Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
41474247|NCT00653159|DEVICE|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
41004326|NCT02531165|DRUG|Aspirin|500 mg loading dose orally (or intravenously), followed by 100 mg od
41004327|NCT02531165|DRUG|Unfractioned Heparin|5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.
41004328|NCT02531165|PROCEDURE|Primary PCI|Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
41004329|NCT00701129|BIOLOGICAL|Alglucosidase Alfa|Administered as IV infusion.
41004330|NCT00701129|DRUG|Methotrexate|Administered subcutaneously.
41004331|NCT00701129|DRUG|Rituximab|Administered as IV infusion.
41004332|NCT03412916|BEHAVIORAL|GetActive|GetActive is a comprehensive, multimodal treatment that was designed to increase quality of life, resiliency and ability to cope with medical symptoms and stress. This program is rooted in the elicitation of the relaxation response, a non-judgmental state of focused attention and increased awareness.
41317024|NCT00434122|DRUG|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
41317025|NCT00996021|DRUG|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
41317026|NCT00996021|DRUG|Placebo Suspension|Placebo is a liquid with no drug in it.
41317027|NCT00996021|DRUG|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
41317028|NCT03390712|DRUG|Paliperidone Palmitate|Monthly injections
41317029|NCT03390712|DRUG|Risperidal Consta|Bi-weekly injection
41317030|NCT03390712|DRUG|Antipsychotic|Any oral antipsychotic prescribed to be taken on a regular basis prior to the initiation of a long-acting injectable antipsychotic.
41317031|NCT00282269|PROCEDURE|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
41317032|NCT04810299|OTHER|Aromatherapy|Aromatherapy; It is one of the complementary therapy methods defined as the therapeutic use of essential oils obtained from parts of plants such as root, seed, leaf, flower, shell with appropriate methods.
41317033|NCT04810299|OTHER|Classical foot massage|Classical foot massage; It is defined as a massage technique based on the principle of systematic relaxation
41317034|NCT02895256|DRUG|Any treatment for cluster headache|
41317035|NCT04197544|PROCEDURE|endoFAVI|EndoFAVI creation to patients that require vascular access for hemodialysis.
41317036|NCT04301921|OTHER|Traditional punkcture site and No anticoagulation|Traditional punkcture site and No anticoagulation
41317037|NCT04301921|OTHER|Traditional punkcture site and ACT-guided anticoagulation|Traditional punkcture site and ACT-guided anticoagulation
41004333|NCT03412916|BEHAVIORAL|Get Active with Fitbit|The GetActive Program for Pain with a Digital Monitoring Device (GetActive Fitbit) is identical to the GetActive with the addition of a FitBit for recording of physical activity.
41004334|NCT05595993|DRUG|Cilostazol|Study participants will be allocated to receive oral administration of 200 mg cilostazol.
41004335|NCT05595993|DRUG|Placebo|Study participants will be allocated to receive oral administration of placebo.
41004336|NCT03369938|OTHER|exercise training intervention|structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)
41004337|NCT03467425|DRUG|FF/UMEC/VI|FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
41004338|NCT03467425|DRUG|Inhaled Corticosteroid|Inhaled Corticosteroid (ICS) as prescribed by the physician.
41004339|NCT03467425|DRUG|LAMA|LAMA as prescribed by the physician.
41004340|NCT03467425|DRUG|LABA|LABA as prescribed by the physician.
41004341|NCT03467425|DRUG|COPD rescue medications|Rescue medications for COPD will be prescribed and obtained according to usual practice.
41004342|NCT01387607|DRUG|pregabalin|Pregabalin capsule, 300-450mg/day, twice daily
41004343|NCT01387607|DRUG|placebo|Placebo, twice daily
41004344|NCT03606681|DRUG|Calcium Hydroxide|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
41004345|NCT03606681|DRUG|Mineral Trioxide Aggregate|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.
41004346|NCT03606681|DRUG|TheraCal LC|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
41004347|NCT03065556|DRUG|188-0551 Solution|Topical solution containing active drug
41317038|NCT01044238|DRUG|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
41317039|NCT01044238|DRUG|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
41474248|NCT00653159|DEVICE|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
41474249|NCT04678401|RADIATION|Radiation|Total Myeloid and Lymphoid Irradiation (TMLI) delivered through Radiation Oncology institutional standards
41474250|NCT04678401|DRUG|Fludarabine|Given intravenously -10 to -6 days prior to hematopoietic stem cell transplant (HSCT)
41474251|NCT04678401|DRUG|Thiotepa|Given intravenously on day -10 and day- 9 prior to hematopoietic stem cell transplant (HSCT)
40800342|NCT05962619|PROCEDURE|arthrocentesis alone|The procedure is done under general anesthesia. The patient is seated inclined at a 45 degree angle with the head turned to contralateral side. The points of needle insertion on the skin, are as follow: a line is drawn from the middle of the tragus to the outer canthus of the eye. The posterior entrance point is located along the canthotragal line, 10 mm from the middle of the tragus line and 2 mm below, the anterior entrance point is placed 10 mm further forward along the line and 10 mm below it . A needle connected to a 10 ml syringe with the Ringer's lactate solution is then inserted into the superior compartment (posterior point), and solution is injected . Another needle is then inserted into the area of articular eminence to enable the free flow of solution through the superior compartment. During the lavage, the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions
40800343|NCT05962619|PROCEDURE|arthrocentesis with hyaluronic acid injection|in this group Once arthrocentesis is completed, an ampule of sodium HA (Hyalgan 1 ml) is connected to the needle in situ And 0.5 ml injected into the superior joint space. Pressure dressing is placed in site of injection. so We use arthrocentesis hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction
41004348|NCT03065556|DRUG|Vehicle Solution|Topical solution containing no active drug
41317040|NCT02648724|DRUG|Sym015|Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
41317041|NCT05184309|OTHER|ConventioanalExercises|Wand exercises and shoulder wheel exercises to increase the range of motion of the shoulder joint with 10 repetitions will be applied in CEG. Finger ladder exercises will be performed in the abduction and flexion position with 5 repetitions, holding the endpoint for 5 seconds. Stretching exercises with 5 repetitions will be applied in all directions for the limitation of movement, holding it for 20 seconds at the endpoint. Individuals performed conventional exercises twice a week for 6 weeks.
41474252|NCT04678401|DRUG|Cyclophosphamide|Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)
41474253|NCT04678401|DRUG|Mesna|Given intravenously with Cyclophosphamide on day -8 and day -7 prior to hematopoietic stem cell transplant (HSCT)
41474254|NCT04678401|BIOLOGICAL|Treg-enriched donor cell|Given intravenously -4 day prior to hematopoietic stem cell transplant (HSCT)
41474255|NCT04678401|BIOLOGICAL|Unmodified donor T Cell|Given intravenously -1 day prior to hematopoietic stem cell transplant (HSCT)
41474256|NCT04678401|PROCEDURE|CD34+ Haplo Peripheral Blood Stem Cell|CD34+ Haplo Peripheral Blood Stem Cell Transplantation
41474257|NCT03856515|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - With Nicotine)
41474258|NCT03856515|OTHER|Questionnaire Administration|Ancillary studies
41474259|NCT03856515|DEVICE|Electronic Cigarette|Electronic Cigarette - with Nicotine
40800344|NCT06293716|DRUG|CVL237 tablets|CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
41474260|NCT03856515|DEVICE|Electronic Cigarette|Electronic Cigarette -without Nicotine
41474261|NCT04060914|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg plus aspirin for 12 months
41474262|NCT04060914|DRUG|Ticagrelor 90mg/60mg|1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
41474263|NCT04060914|DRUG|Clopidogrel 75mg|Clopidogrel 75mg plus aspirin for 12 months
41474264|NCT01433887|DRUG|48-weeks course|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
41474265|NCT01433887|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
41004349|NCT00715793|DRUG|Decitabine|"In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle."
41004350|NCT00715793|DRUG|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
41474266|NCT01433887|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
41474267|NCT01433887|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
41474268|NCT06300827|OTHER|Structured digital-based training|The eight week intervention will be delivered in 15 different sessions, each session lasting 40 minutes. It is expected that the seventh week session will last approximately 150 minutes. The control group is expected to continue with their daily lives.
41474269|NCT05934773|DEVICE|KineAssist robotic treadmill|"A formal standardization procedure will be used. Prior to testing, the participant's weight, height, age, blood pressure, and resting heart rate will be recorded. Each session will take place over a 1 hour period. All of our participants will have 1 evaluation sessions prior to the training sessions (overground) and 1 evaluation sessions at the end of the training sessions (overground).~Each participant will have the training sessions up to 3 times each week. The total number of training sessions would be 12-16 sessions (based on duration of stay) of robotic treadmill training for, distributed equally over each specific training modality (Endurance x 4, Strength x 4, Speed x 4, and Dynamic Balance x 4)."
41474270|NCT04372719|DRUG|H3N2|
41474271|NCT00285519|DRUG|Doxazosin (drug)|
41474272|NCT01230892|DRUG|Nebivolol|10 mg PO qday
40800345|NCT06293716|DRUG|CVL237 placebo tablets|CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
40800346|NCT01131806|DRUG|fluticasone/ salmeterol 125/25 mcg/puff|fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks
41004351|NCT00715793|PROCEDURE|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
41004352|NCT02199418|DRUG|Paclitaxel|
41004353|NCT02199418|DRUG|Cisplatin|
41004354|NCT02153866|BIOLOGICAL|rotavirus vaccine|3ml/dose, oral
41004355|NCT02153866|BIOLOGICAL|measles-rubella vaccine|0.5ml per dose, subcutaneous injection
40800347|NCT01131806|DRUG|fluticasone/ salmeterol 250/25 mcg/puff|fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
41004356|NCT02153866|BIOLOGICAL|measles-mumps-rubella vaccine|0.5ml per dose, subcutaneous injection
41004357|NCT01920815|OTHER|No interventions|
41004358|NCT06533189|DEVICE|Enhanced Diffusion Software|Application of specific sequences with the use of Enhanced Diffusion Software during Patient MRI
41474273|NCT01230892|DRUG|Atenolol|100 mg PO qday
41474274|NCT04031092|DEVICE|Wearable tech with feedback|An armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone.
41004359|NCT00892164|DEVICE|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
41004360|NCT00892164|DEVICE|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
41004361|NCT03431116|RADIATION|ultrasound|to detect the placental site
41004362|NCT01527552|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
41004363|NCT03952169|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
41004364|NCT03952169|OTHER|Placebo controls|placebo with a similar appearance to probiotics supplement
41004365|NCT06469255|OTHER|Diet Treatment|4 weeks low calorie diet treatment
41317042|NCT05184309|OTHER|Serious games|A Serious game program will be applied to the individuals twice a week for 6 weeks in this group. Armrotate, Uball, Balance Surf and Balance Adventure games will be developed by Becure company for shoulder rehabilitation. These games developed for shoulder rehabilitation will be applied to individuals under the supervision of a physiotherapist. Each game will be played for 10 minutes, for a total of 40 minutes.
41317043|NCT00037635|DRUG|AMG 073|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
41317044|NCT00037635|DRUG|Placebo|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
41317045|NCT01453309|PROCEDURE|Cell Saver|Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.
41004366|NCT04233281|OTHER|Kori tofu|16.5 gram Kori-tofu mixed in a high carbohydrate test meal
41004367|NCT04233281|OTHER|Whey protein|high carbohydrate test meal with whey protein, matched in macronutrient content
41004368|NCT05358496|DIAGNOSTIC_TEST|Data collection|Clinical data collection
41004369|NCT05137795|DRUG|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
41004370|NCT05137795|DRUG|Placebo|Normal Saline Inhalation
41004371|NCT05137795|DEVICE|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
41004372|NCT03668652|DEVICE|Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)|"HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO"
41004373|NCT03668652|PROCEDURE|Radical prostatectomy|"Prostatectomy arm:~Robot assisted or open retropubic prostatectomy"
41004374|NCT00164450|DRUG|Rifapentine + isoniazid once weekly for 3 months|
41004375|NCT02164552|DIETARY_SUPPLEMENT|Vitamin D3 pills|Dietary supplement
41317046|NCT01453309|PROCEDURE|No Cell Saver|Cell Saver will not be available during surgery
41004376|NCT02164552|OTHER|Placebo pills|Placebo pills similar in appearance and shape but without vitamin D
41004377|NCT02980965|DRUG|letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel|Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
41004378|NCT02980965|DRUG|fluorouracil, epirubicin, cyclophosphamide, docetaxel|Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
41152173|NCT01951105|DRUG|Carbidopa/Levodopa|"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
41317047|NCT04209777|DRUG|Probiotic Blend Chewable Tablet|Lactobacillus-reuteri probiotics were used as an experimental drug.
41317048|NCT04209777|DRUG|Antibiotics|Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.
41317049|NCT03446430|DEVICE|PWV measurement by LDV|PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
41317050|NCT03222076|BIOLOGICAL|Ipilimumab|Given IV
41474275|NCT04031092|DEVICE|Wearable tech without feedback|An armwrist device measuring physical activity level, no reporting back to the user.
41474276|NCT04031092|BEHAVIORAL|Rehabilitation program|traditional inpatient rehabilitation program.
41474277|NCT06405542|BEHAVIORAL|EX-CIPN|"The 10-week intervention includes:~Individualized Exercise Program: Each participant will receive an individualized progressive exercise program that includes cardiovascular and strength training as well as balance and desensitization exercises and will be adjusted to the needs of the patient.~Remote Monitoring: Fitbit™ devices will be used to monitor patients' physical activity over the duration of the program. Fitness trackers can promote behaviour change and allows for self-monitoring and feedback to the participant.~Remote Person-to-Person Clinical Support: Participants will have scheduled remote check-ins and health coaching sessions with their assigned RKin over Microsoft Teams (MSTeams) on weeks 2, 3, 4, 6, and 8 of the intervention. During these calls, the RKin will review, adapt, and progress the exercise program as needed, discuss and develop goals for the following week, and identify potential barriers and solutions in achieving their goals."
41317051|NCT03222076|BIOLOGICAL|Nivolumab|Given IV
41317052|NCT03325556|DRUG|Placebo|Placebo, tablets, once daily by mouth
41317053|NCT03325556|DRUG|Pimavanserin 34 mg|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth
41317054|NCT03325556|DRUG|Pimavanserin 20 mg|Pimavanserin 20 mg total daily dose, tablets, once daily by mouth
41317055|NCT00507416|DRUG|Bortezomib|Bortezomib bolus intravenous (IV) injection
41317056|NCT00507416|DRUG|Dexamethasone|Dexamethasone for oral administration
41317057|NCT00507416|DRUG|Melphalan|Melphalan for oral administration
41317058|NCT00507416|DRUG|Prednisone|Prednisone for oral administration
41317059|NCT00507416|DRUG|Thalidomide|Thalidomide for oral administration
41317060|NCT04674839|DRUG|MS-20|fermented soymilk product
41317061|NCT04674839|OTHER|Placebo|No active ingredient
41317062|NCT02297542|BIOLOGICAL|Flu Vaccine|
41317063|NCT03103906|OTHER|Cream (Test product)|Moisturizing cream with SPF (Sun protecting factor) 20
41317064|NCT03103906|OTHER|Cleanser (Reference Product)|Moisturizing facial cleanser
41317065|NCT03103906|OTHER|Sunscreen (Reference Product)|SPF 50 sunscreen
41474278|NCT05735002|DIAGNOSTIC_TEST|13C-butyrate breath test|breath test
40800348|NCT04002050|BEHAVIORAL|Cognitive Behavioural Therapy with Mindfulness Course|The Cognitive Behaviour Therapy with Mindfulness (CBTm) Course for Public Safety Personnel is a brief psychoeducational course consisting of 5 classes (90 minutes each) occurring on a weekly basis. The CBTm course addresses the fundamentals of CBT and provides participants with practical strategies for managing stress (such as relaxation strategies, cognitive restructuring, goal setting, behavioural activation, and exposure therapy).
40800349|NCT04166773|DRUG|Tirzepatide|Administered SC
40800350|NCT04166773|DRUG|Placebo|Administered SC
40800351|NCT04021485|OTHER|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~* Standardized neurological exam~* Morphometric measurements including height, weight, head circumference~* Blood pressure measurement~* Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~* Social Relativeness, using Social Relativeness Scale parental questionnaire,~* Parental stress using PSI questionnaire"
40800352|NCT00140296|BEHAVIORAL|Contraceptive counseling|
40800353|NCT04879108|OTHER|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Transcutaneous Electrical Nerve Stimulation was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy and Rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
40800354|NCT04879108|OTHER|Physiotherapy Rehabilitation|"Physiotherapy and Rehabilitation was performed for 5 days after surgery, twice a day, for 30 min, 5 day a week after thoracic surgery. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
40800355|NCT04107740|DRUG|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
40800356|NCT04107740|DRUG|Placebo|BID, 10mg per day, for 24 weeks
40800357|NCT00465452|DRUG|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
40800358|NCT03127917|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline capsules given at 6 g/day
40800359|NCT03127917|OTHER|Placebo|Maltodextrin capsules given as placebo
40800360|NCT06138600|DRUG|Cabotegravir Injection [Apretude]|White to slightly pink free flowing suspension suspension for injection contained in a brown coloured vial. Each vial is for single use and does not require dilution prior to administration.
40800361|NCT06138600|DRUG|Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)|TDF/FTC is currently available as standard of care for PrEP in the public sector as per the department of health guidelines.
40800362|NCT05740631|DRUG|Ocaliva|Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
41152174|NCT01951105|DRUG|Placebo|Take two placebo capsules three times a day for 12 weeks.
41152175|NCT03759405|BIOLOGICAL|iPS differentiated cardiomyocytes|Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
41317066|NCT05231174|OTHER|A self-evlaution tool based on Large Language Model|"Following the baseline assessment, participants will be guided to use a self-evaluation tool independently to assess their risk of diabetic retinopathy (DR). This tool is a fusion of a conversational AI system based on LLM and an existing logistic diagnostic model.~The AI system is designed to collect clinical variables, including age, duration of diabetes, Body Mass Index (BMI), and insulin usage. Additionally, clinical test data such as mean arterial pressure, HbA1c, serum creatinine, and microalbuminuria will be extracted from a local dataset using the patient's name and ID. Once collected, these data will be transmitted to a server-based diagnostic model for further analysis to determine the presence of DR."
41317067|NCT00900913|DRUG|ropivacaine (Naropin)|intravenous infusion 1 mg/kg bw
41317068|NCT06342102|PROCEDURE|PENG + LFCN block|The PENG block was performed under ultrasound guidance. After skin disinfection, the needle was advanced between the psoas tendon and pubic ramus where 20 mL of 0.5% ropivacaine were injected. The LFCN block was performed following the PENG block.10 ml of 0.5% ropivacaine were injected near the nerve into the fat-filled flat tunnel (FFFT) located at the level of the superior anterior iliac spine and lateral to the sartorius muscle.
41474279|NCT05723198|DRUG|Baricitinib|Administered orally
41474280|NCT05723198|DRUG|Placebo|Administered orally
41474281|NCT01730040|DRUG|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
41474282|NCT01730040|DRUG|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
41474283|NCT01730040|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
41474284|NCT01730040|DRUG|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
41474285|NCT01730040|DRUG|Placebo|Placebo for alirocumab and ezetimibe.
41474286|NCT05744700|DIETARY_SUPPLEMENT|Inulinase|Participants will consume one capsule containing 1,000 INU inulinase, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
41152176|NCT01545271|DRUG|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
41152177|NCT01545271|DEVICE|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
41152178|NCT05476783|DRUG|TB006|Clear to slightly opalescent, sterile solution for injection
40800363|NCT05740631|DRUG|Placebo|Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
41317069|NCT06342102|PROCEDURE|FIC block|FICB was performed under ultrasound guidance. The needle was advanced above the fascia iliaca and 20 mL of 0.5% ropivacaine were injected
41317070|NCT06446206|DRUG|Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib|Adebrelimab plus paclitaxel, carboplatin and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab.
41317071|NCT05678946|OTHER|Integrated face-to-face rehabilitation and telerehabilitation|Kela´s integrated face-to-face rehabilitation and telerehabilitation services for family caregivers include two 5-day periods of face-to-face rehabilitation and a 12-week telerehabilitation period between them. It is for those over the age of 18 who work as family caregivers on a daily basis and need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. The service, provided free of charge, is carried out in a Finnish rehabilitation centre and online over a period of 8 months, and it is implemented by a multidisciplinary team of rehabilitation experts. During the 12-week telerehabilitation period, the service providers utilise The Own Path, an acceptance and commitment therapy -based guided web intervention found beneficial for older Finnish family caregivers (Lappalainen et al. 2021). Telerehabilitation is independent of time and place.
41317072|NCT05678946|OTHER|Social Holidays|MTLH's Social Holidays for family caregivers are 5-day holidays in a Finnish hotel, spa, sports institute, or rehabilitation centre. The theme, content, and level of available assistance in Social Holidays vary, and the rehabilitation concept is lighter than that of Kela's rehabilitation services. Social Holidays include full-board accommodation and holiday activities, e.g. lectures, group discussions, instructed exercise, and a pampering treatment. MTLH organises Social Holidays for family caregivers as well as family caregivers and care recipients. The participants cover their travel expenses and pay a fixed sum of €125. Other than that, Social Holidays are provided free of charge. Social Holidays are intended for family caregivers who need recreational activities, rest, and peer support.
41341770|NCT02490241|DRUG|Lithium|Patients taking lithium as a mood stabilizer during pregnancy are eligible to participate in the study. Their dose and serum concentration levels of lithium will be monitored throughout pregnancy and up to three months postpartum.
41341771|NCT05963555|DEVICE|NovoThor|Following the baseline block (first four weeks), participants will use the NovoThor device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
40800364|NCT01095081|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
40800365|NCT05182658|DRUG|Empagliflozin 10 MG|The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
40800366|NCT05182658|DRUG|Placebo|The proposed intervention will be administration of placebo for a period of 12 months. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
40800367|NCT05937256|PROCEDURE|Quadratus lumborum block type III|Patients will be placed in lateral decubitus position with the side of the target stone facing up. After sterilization and draping of the skin, using US probe the block will be applied targeting the fascial plane between the quadratus lumborum and psoas major muscles (anterior aspect of the quadratus lumborum). After 20 min, sensory blockade will be evaluated with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients will be transferred to ESWL Room.
40800368|NCT05937256|PROCEDURE|Erector spinae plane block|Patients will be placed in the lateral decubitus position according to the selected site. After sterilization and draping of the skin, using US probe, the block will be applied in the plane deep to the erector spinae muscles and superficial to the transverse process. After 20 min, sensory blockade will be assessed with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients is transferred to ESWL Room.
40800369|NCT06163573|BIOLOGICAL|N-TEC|Implantation of an autologous tissue engineered cartilage graft in the patellofemoral joint for treatment of osteoarthritis.
40800370|NCT06163573|BIOLOGICAL|Platelet rich plasma|"Injection of an autologous Conditioned Plasma ACP® on the basis of one injection per week for three consecutive weeks.~Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks."
40800371|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
40800372|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
40800373|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
40800374|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
40800375|NCT05007418|BIOLOGICAL|STI-1492|Anti-CD38 A2 KOKI DAR T cells
40800376|NCT00190229|DRUG|Cyclophosphamide|Cyclophosphamide
40800377|NCT05960643|OTHER|Training and application in breast modeling|BSE application skill evaluation form will be evaluated out of 100 points. The form includes 7 skills: carefully reviewing the model, using three types of pressure, massage, hand position, performing three types of movement, examining each breast for five minutes, and detecting the nodule in the model. A high score is interpreted as a high level of skills.
40800378|NCT05960643|OTHER|Control|No intervention will be made against people in this group.
40800379|NCT03241277|PROCEDURE|Non surgical periodontal treatment|Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
40800380|NCT04396548|DRUG|Midodrine Oral Product|Patients will receive oral 10 mg tablet of midodrine with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine.
40800381|NCT04396548|DRUG|Inert tablet containing sugar (placebo)|: Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
41317073|NCT05678946|OTHER|Face-to-face rehabilitation|Kela's rehabilitation services for family caregivers and the care recipients include three 5-day periods of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation centre over a 10-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation services for family caregivers and the care recipients are provided free of charge. The service is intended for persons over the age of 18 who work as family caregivers on a daily basis with or without family caregiver support and who need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation.
41004379|NCT02277496|BEHAVIORAL|Toolkit Intervention|The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
41004380|NCT02646579|PROCEDURE|Spinal and Peripheral Dry Needling|Participants will be positioned lying flat and the relevant spinal level will be treated using a Seirin L- type 50 mm needle. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
41317074|NCT05577091|GENETIC|Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.|"Intratumoral or intraventricular administration via Ommaya reservoir.~Dose level 0: 1×10\^7 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients.~Dose level 1: 1×10\^8/ 5×10\^6 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients. The dose of Dose level 1 will refer to the adverse effect of Dose level 0. When dose-related side effects occurred in 2 patients in the Dose level 0, the dose should be reduced to 5×10\^6 cells.~In Dose levels 0 and 1, the second dose will be infused 28 days after the first dose, and the subsequent doses will be administered weekly.~Dose level 2: 5×10\^7 autologous Tris-CAR-T cells, weekly administered, maximum 8 weeks, 4 patients. If the results of Dose levels 0 and 1 suggested that dose-related toxic side effects could have occurred in the 1×10\^7cells dose, the researcher would re-determine the dosage of the multidose clinical exploration study."
41317075|NCT04486963|DRUG|Sanhuangjingshimingwan|Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
41317076|NCT04486963|DRUG|Sanhuangjingshimingwan Placebo|Sanhuangjingshimingwan Placebo,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
41317077|NCT02242227|DRUG|Salmeterol xinafoate|
41317078|NCT02242227|DRUG|Serevent® Diskus®|
41317079|NCT02242227|DRUG|Placebo (HandiHaler®)|
41317080|NCT02242227|DRUG|Placebo (Diskus®)|
41317081|NCT05779579|DRUG|HS-10517 Dose 1|HS-10517 Dose 1+Ritonavir
41317082|NCT05779579|DRUG|HS-10517 Dose 2|HS-10517 Dose 2+Ritonavir
41317083|NCT05779579|DRUG|HS-10517 Dose 3|HS-10517 Dose 3+Ritonavir
41317084|NCT05779579|DRUG|HS-10517 Dose 4|HS-10517 Dose 4+Ritonavir
41317085|NCT05779579|DRUG|Placebo|Dose level A of placebo
41317086|NCT01086150|PROCEDURE|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
41317087|NCT01086150|DRUG|Lidocaine 5% patches|Subject will apply patches to affected area QD for 12 hours then remove.
41317088|NCT05834907|BEHAVIORAL|Circle of Security Parenting|"COS-P is an attachment-based, home visiting intervention intended to supporting parents in serving as a secure base from which their children can explore the world, and to which their children can return in times of distress (Bowlby, 1988). Such secure base parenting increases the likelihood of children's secure attachment. COS-P also targets parental responses to children's expression of their needs (e.g., crying), and is designed to help parents understand the ways in which their own (parental) dysregulated emotional, physiological, and behavioral responses to children's emotions and behaviors can limit their responsiveness to their children's attachment needs."
41474287|NCT05744700|DIETARY_SUPPLEMENT|Maltodextrin placebo|Participants will consume one capsule containing maltodextrin, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
40800382|NCT03714984|OTHER|Pre operative exercise|After randomization participants will be allocated in two groups. The educational pelvic floor intervention group will receive two months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction.
40800383|NCT03714984|OTHER|Control Group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
40800384|NCT00163241|DRUG|celecoxib|
40800385|NCT06094244|DRUG|Atorvastatin|Doses of atorvastatin of up to 20 mg/d.
40800386|NCT06094244|DRUG|Rosuvastatin|Doses of rosuvastatin of up to 10 mg/d.
40800387|NCT06094244|OTHER|No drugs|No drugs
40800388|NCT00298441|DRUG|chondroitin sulfate-iron colloid|
40800389|NCT01717196|OTHER|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
40800390|NCT02057640|DRUG|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
40800391|NCT02057640|DRUG|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
40800392|NCT02057640|DRUG|MLN9708|4mg on day 1, 8, 15, 28
41004381|NCT02646579|PROCEDURE|Peripheral Dry Needling|Participants will be positioned lying flat and the relevant peripheral points will be treated using a Seirin L- type 50 mm needle. The peripheral treatment site(s) will be determined by the physical therapist's palpation of active or latent trigger points or tender points. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
40800393|NCT05538949|DRUG|EB-203|"* Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~* Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8."
40800394|NCT05538949|DRUG|Placebo|Placebo 1Drop, QD / Day1, BID / Day5\~Day8.
40800395|NCT03790813|DIAGNOSTIC_TEST|Intervention 1|Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.
40800396|NCT03790813|DIAGNOSTIC_TEST|Intervention 2|MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.
40800397|NCT00828802|DRUG|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
40800398|NCT02793973|DEVICE|shoe lifts|
40800399|NCT01877525|PROCEDURE|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
40800400|NCT05657249|DIAGNOSTIC_TEST|Non-contrast focused MRI|non-contrast liver MRI focusing on HCC surveillance in a short scan time.
40800401|NCT01099748|DRUG|Methadone|Methadone 50 - 150 mg QD (Day 1)
40800402|NCT01099748|DRUG|Lersivirine + Methadone|Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
40800403|NCT02070328|OTHER|Registry|
40800404|NCT03423238|OTHER|Exercise|Each exercise session lasts for 60 to 90 minutes and consists of 5-10 minutes of warm-up and cool-down activity; up to 30 minutes of aerobic exercise using a variety of modalities (e.g., walking laps on a track, cycle ergometry, treadmills, stair climbers); and 15-20 minutes of upper and lower body resistance exercises using Thera-Bands. An exercise physiologist creates an individualized plan
40800405|NCT03423238|BEHAVIORAL|Health Education|Group education classes conducted by an exercise physiologist and/or dietitian are designed to provide support and general information on healthy lifestyle behaviors. Topics include risk factor control, diabetes, hypertension, lipids, medications, aerobic exercise, strength training and flexibility, weight control, reading food nutrition labels, eating out, holiday eating, intimacy, stress, relaxation, cardiac symptoms, and cardiac interventions.
41004382|NCT00132015|DRUG|tanespimycin|
41004383|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
41004384|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
41004385|NCT00308711|DRUG|Misoprostol vaginal insert 100 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
41474288|NCT06601621|COMBINATION_PRODUCT|electroacupuncture+ self-acupressure|"Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi; is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2/10Hz for 30 minutes. self-acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi; for three minutes."
41474289|NCT06601621|COMBINATION_PRODUCT|sham electroacupuncture + sham self-acupressure|"Sham electroacupuncture: The sham electroacupuncture shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi; sensation. Sham self-acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi."
41474290|NCT06121791|OTHER|Normal values of abdominal level muscle areas of Turkish children|age, sex, L3-L4 LEVEL: Psoas muscle area, Paraspinal muscle area, Abdominal muscle area, L4-L5 LEVEL: Psoas muscle area, Paraspinal muscle area, Abdominal muscle area
40800406|NCT03423238|OTHER|Exercise Compliance|Multiple behavioral management strategies to create a positive exercise environment and promote adherence and retention will be utilized. These include promptly contacting participants who miss a session, scheduling makeup sessions, and offering individual counseling sessions to discuss strategies to promote attendance and limit obstacles to participation.
40800407|NCT03423238|DIETARY_SUPPLEMENT|Calorie-Restricted Diet|Diet plans will provide a caloric deficit of 500 kcals per day. The lowest calorie level permitted will be 1,100 kcals for women and 1,200 kcals for men. The calorie distribution goal will be 15-20% from protein, \<30% from fat, and 45-60% from carbohydrates. Participants will consume 2 meal replacements per day (Premier Protein shakes and bars); provided by the study)), along with one meal composed of traditional foods (500-750 kcals, low in fat, high in vegetables), and 1-3 snacks as needed (e.g., cereal bar, fruit, or vegetable, providing 100-150 kcals each). For the meal, patients will follow a weekly menu plan and recipes provided by the study. The food plan will be tailored to individual preferences and energy needs.
41004386|NCT00308711|DRUG|Misoprostol vaginal insert 50 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
41004387|NCT00308711|DRUG|Dinoprostone vaginal insert (Cervidil)|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
41317089|NCT05834907|BEHAVIORAL|Little Talks|Little Talks is an early literacy home visiting intervention developed for low-income, racial and ethnic minority infants and toddlers, and has been tested in Early Head Start contexts (Manz et al., 2016; Manz et al. 2017). Little Talks uses book sharing to promote early literacy and has been adapted in both English and Spanish. The intervention utilizes modular treatments during home visits, teaching parents how to facilitate language interactions with their children through book sharing. Age appropriate books are given to parents to share with their children during the intervention.
41317090|NCT02916095|DRUG|Kanitinib|Oral administration of Kanitinib tablets.
41317091|NCT02702011|DRUG|empagliflozin medium dose|
41317092|NCT02702011|DRUG|empagliflozin low dose|
41317093|NCT02702011|DRUG|empagliflozin high dose|
41317094|NCT02702011|DRUG|placebo|
41317095|NCT06460636|OTHER|progressive muscle relaxation therapy|Participants will undergo progressive relaxation exercises, including muscle tension and release with deep breathing, held for 5 seconds each. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall
41317096|NCT06460636|OTHER|aquatic therapy|participants will receive aquatic therapy. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall.
41474291|NCT03056768|BEHAVIORAL|Multidomain intervention|1-year multidomain health promotion (physical, cognitive, nutritional intervention)
41474292|NCT03056768|BEHAVIORAL|Active control|Health promotion activities provided by local health bureau.
41004388|NCT00025883|DRUG|Metreleptin|Drug treatment
41317097|NCT02152592|DRUG|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
41317098|NCT02152592|DRUG|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
41317099|NCT00003225|DRUG|amifostine trihydrate|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
41317100|NCT00003225|DRUG|irinotecan hydrochloride|"10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles"
41317101|NCT01322646|DEVICE|CarChipPro|On board driving monitor
40800408|NCT03423238|BEHAVIORAL|Behavioral Modification|During months 1-3, participants will attend weekly individual behavioral counseling sessions with the study registered dietitian (RD); individual sessions will be held twice per month during months 4-6. The sessions will focus on self-monitoring, portion control, mindful eating, coping with negative thoughts, eating at regular times, and stress management. The RD will review individual progress, solve problems, answer questions, and set weight loss goals.
40800409|NCT03423238|OTHER|Weight-Loss Compliance|Participants will be asked to record their food and beverage intake in daily logs which will be reviewed weekly by the RD to verify compliance to the diet. Body weight will be measured weekly to ensure that participants are losing weight at an appropriate rate. If a participant is not meeting weight loss goals, energy intake will be modified accordingly to produce the desired rate of weight loss.
40800410|NCT03423238|OTHER|Dietary Counseling|Participants have one meeting with the Rehab dietitian upon starting.
40800411|NCT01545869|PROCEDURE|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
40800412|NCT05918133|DRUG|PM8002|IV infusion
40800413|NCT05918133|DRUG|nab-paclitaxel|IV infusion
40800414|NCT06479512|DEVICE|ultrasonography to measure the index of the caval aorta and non-invasive pulse oximetry for perfusion index|Inferior vena cava and aortic diameter measurements will be made by ultrasonography and perfusion index determination using non-invasive pulse oximetry
40800415|NCT01212887|BIOLOGICAL|MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|
40800416|NCT01212887|BIOLOGICAL|aldesleukin|
40800417|NCT01212887|DRUG|cyclophosphamide|
40800418|NCT01212887|DRUG|fludarabine phosphate|
40800419|NCT01212887|OTHER|laboratory biomarker analysis|
40800420|NCT01212887|OTHER|pharmacological study|
40800421|NCT04098653|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
41004389|NCT02657811|DEVICE|Miri, Benchtop Multi-room incubator|Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.
41004390|NCT02657811|DEVICE|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.
41004391|NCT02657811|DEVICE|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
41004392|NCT01847391|DRUG|GS-6615|GS-6615 tablet(s) administered orally once daily
41004393|NCT01847391|DRUG|Placebo|Placebo tablet(s) to match GS-6615 administered orally once daily
41004394|NCT02485912|BIOLOGICAL|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
41004395|NCT02485912|BIOLOGICAL|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
40800422|NCT04098653|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
40800423|NCT04098653|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
40800424|NCT04148066|DIAGNOSTIC_TEST|ctDNA blood sample|every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.
40800425|NCT03909906|DRUG|Euphytose®|(50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)
40800426|NCT03909906|DRUG|Placebo Oral Tablet|Placebo comparator
41004396|NCT00600756|DRUG|Quetiapine XR|Oral, once daily, tablets of 400 mg to 800 mg
41004397|NCT00600756|DRUG|Risperidone|Oral, once daily, tablets of 2 mg to 6 mg
41004398|NCT02927028|OTHER|Chewing|"On the first visit, the random nut treatments will include chewing walnuts, almonds and pistachios. The chewing conditions will include: 1) 5 g nuts alone, 2) 5 g nuts with 5 ml water, 3) 5 g nuts with 5 ml apple juice, 4) 5 g nuts with 5 g plain yogurt, 5) 5 g nuts with 5 g sweet yogurt.~On visits 2 and 3 the treatments of either 28 g of walnuts or walnut butter will be presented."
41004399|NCT04454450|DIAGNOSTIC_TEST|PET/MRI|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.
41004400|NCT04454450|DIAGNOSTIC_TEST|Contrast enhanced CT|Standard of care contrast enhanced CT
41317102|NCT01322646|BEHAVIORAL|Driver's Education|10 Session License to Learn Program.
40800427|NCT01731340|DIETARY_SUPPLEMENT|Calcium Citrate|750mg
40800428|NCT01731340|OTHER|Low Dietary Calcium|450 mg
40800429|NCT01731340|OTHER|High Dietary Calcium|1200 mg
40800430|NCT03944564|BEHAVIORAL|Sitting|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
40800431|NCT03944564|BEHAVIORAL|Static standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
40800432|NCT03944564|BEHAVIORAL|Dynamic standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
41317103|NCT01322646|BEHAVIORAL|STEER Program|8-session behavioral parent training and teen social skills/communication training program
41317104|NCT01322646|OTHER|Driving Simulator Practice|Practice Driving on a driving simulator
41317105|NCT01480492|DRUG|Telbivudine|600mg,1/d,one year
41317106|NCT00702156|DRUG|Bisoprolol|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
41474293|NCT04039048|DEVICE|cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.
41004401|NCT04347304|DIETARY_SUPPLEMENT|Dark chocolate (20 grams) per day providing 508 mg of polyphenols|subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
41004402|NCT04347304|DIETARY_SUPPLEMENT|white chocolate (20 grams) with no polyphenols|subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
41004403|NCT05242081|DRUG|S-ketamine|S-ketamine 0.5mg/kg for induction and 0.2mg/kg/h for maintenance
41474294|NCT04039048|DEVICE|Sham cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
41474295|NCT04039048|OTHER|Balance training|Balance training will be performed through the Biodex Balance System for 20 minutes.
41004404|NCT05242081|DRUG|Sufentanil|Sufentanil 0.2-0.3μg/kg for induction and remifentanil 0.05-0.15μg/kg/min for maintenance
41004405|NCT00793364|DIETARY_SUPPLEMENT|Stanol ester spread|Stanol ester spread 20 g every day
41004406|NCT00793364|DIETARY_SUPPLEMENT|Placebo spread|Placebo spread 20 g every day
41004407|NCT00793364|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet every day
41004408|NCT05187416|DIAGNOSTIC_TEST|two-dimensional shear wave elastography|Preoperative ultrasound elastography examination
41004409|NCT01485458|PROCEDURE|Early surgery|Surgery within 24 hours after admission
41004410|NCT01485458|PROCEDURE|Delayed surgery|Surgery more than 2 weeks after injury
41004411|NCT05851560|DRUG|Oxidized regenerated cellulose(ORC)|Investigate the antiadhesive effect of multiple antiadhesive barriers in thyroid surgery
41004412|NCT05851560|DRUG|Hyaluronic acid(HA)|Hyaluronic acid(HA)
41004413|NCT05159843|BEHAVIORAL|Therapeutic education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
41004414|NCT01038271|OTHER|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
41004415|NCT01038271|OTHER|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
41004416|NCT05410327|OTHER|Chokeberry (Aronia melanocarpa) juice|A water-infused chokeberry (Aronia melanocarpa) juice will be used as the intervention. The brand being used is called 'Superberries'.
41004417|NCT03818022|PROCEDURE|Cryoneurolysis (Iovera)|Cryoneurolysis performed by radiology department 1 week prior to total knee arthroplasty
41004418|NCT06423716|DRUG|Duloxetine|60mg duloxetine given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
41004419|NCT06423716|DRUG|Placebo|Placebo given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
41004420|NCT01559311|DEVICE|CRT-P OFF|CRT Pacemaker
41004421|NCT01559311|DEVICE|CRT-P ON|CRT Pacemaker
41004422|NCT01559311|DEVICE|DDDR|Dual-chamber, rate-modulated pacemaker
41004423|NCT00981006|PROCEDURE|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
41004424|NCT02684227|DRUG|Carboplatin|Given IV
41004425|NCT02684227|DRUG|Enzalutamide|Given PO
41004426|NCT02684227|OTHER|Laboratory Biomarker Analysis|Correlative studies
41004427|NCT02684227|DRUG|Paclitaxel|Given IV
41004428|NCT02684227|OTHER|Pharmacological Study|Correlative studies
41004429|NCT04300972|DIAGNOSTIC_TEST|Body/weight adaption|contrast media dose is adapted to weight and body type
41317107|NCT00702156|DRUG|Placebo|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
41317108|NCT05658185|BEHAVIORAL|MIDITRA|"The psychological treatment protocol will be implemented over 10 group sessions of face-to-face psychological treatment with patients. The treatment sessions will have the following objectives and themes:~* Adjustment to the disease:~* Self-esteem/self-concept:~* Coping with fear:~* Emotional self-regulation:~* Social area and enjoyment:~* Decision making and problem solving:~* Communication and listening skills:"
41004430|NCT04300972|DIAGNOSTIC_TEST|Standard dose|a fixed amount of contrast media is used, independently of weight and body type
41004431|NCT05473533|DRUG|Placebo|Placebo; formulated as solution for inhalation without active substance.
41004432|NCT05473533|DRUG|PRS-220|PRS-220; formulated as solution for inhalation.
41004433|NCT01100411|DEVICE|Air Optix Aqua|Contact lens material: Lotrafilcon A
41317109|NCT05444478|PROCEDURE|Microwave ablation|only microwave ablation for tumor
41317110|NCT05444478|DRUG|Lenvatinib|lenvatinib (80 mg for body no more than 60kg，120 mg for body weight \>60 kg)
41317111|NCT02907320|DRUG|CYCLO 3 ® FORT|
41317112|NCT02907320|DRUG|MPFF|
41317113|NCT02907320|DRUG|placebo CYCLO 3 ® FORT|
41317114|NCT02907320|DRUG|placebo MPFF|
41317115|NCT00731263|DRUG|AZD8055|Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
41317116|NCT05913141|OTHER|Drug screen with PDO/PDO-TIL/PDOTS|Drug screen with patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture system, or patient-derived organotypic tissue spheroids.
40800433|NCT06091293|BEHAVIORAL|Narrative Intervention for Long COVID-19 (NICO)|The NICO intervention was delivered by a licensed psychotherapist asynchronously over a 3 month time period.
40800434|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, iron and B12 in Whey Protein|Chocolate Flavored Whey Protein Isolate Powder with (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
41317117|NCT02421744|BEHAVIORAL|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
40800435|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Rice Protein|Chocolate Flavored Rice Protein Isolate with (200mg Lactoferrin, 6mg Iron, 5.2 ug B12)
40800436|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Maltrodextrin|Chocolate Flavored (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
41317118|NCT02421744|BEHAVIORAL|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
40800437|NCT04797689|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
40800438|NCT04797689|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
40800439|NCT01794507|DRUG|ABT-199|ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
40800440|NCT01794507|DRUG|bortezomib|Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
40800441|NCT01794507|DRUG|dexamethasone|Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
41317119|NCT04193852|DRUG|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Coated Tablets
41317120|NCT04193852|DRUG|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Coated Tablets
41317121|NCT06379867|DRUG|HSK3486|0.4 mg/kg, IV bolus administration
41317122|NCT06379867|DRUG|Placebo|IV bolus administration
41317123|NCT06379867|DRUG|Moxifloxacin|0.4 g, Oral administration with 240 mL
41317124|NCT02779673|OTHER|Yoghurt drink containing plant stanol as esters|
41474296|NCT01303237|DRUG|Cetuximab + RT|Cetuximab initial dose 400 mg/m² on week 1; Cetuximab maintenance dose 250 mg/m² continued for 7 weeks plus concomitant RT
40800442|NCT06288308|DIAGNOSTIC_TEST|fibronigin to albumin ratio|"To investigate the association of fibrinogen to albumin ratio (FAR) with LN in different classes.~b. Secondary (subsidiary):~To prove the possible role of FAR as a novel diagnostic biomarker to predict LN progression"
40800443|NCT04497363|DEVICE|Brainsonix Pulsar 1002|Each participant will undergo 8 consecutive weekly sessions (each session is 10 minutes long) of focused ultrasound with the Brainsonix Pulsar 1002 device.
41004434|NCT01100411|DEVICE|Biofinity|Contact lens material: Comfilcon A
41004435|NCT01100411|DEVICE|Proclear|Contact lens material: Omafilcon A
41004436|NCT01100411|DEVICE|Acuvue Oasys|Contact lens material: Senofilcon A
41004437|NCT01100411|DEVICE|Acuvue 2|Contact lens material: Etafilcon A
41317125|NCT02779673|OTHER|Yoghurt drink without plant stanol as esters|
41317126|NCT04940442|BEHAVIORAL|Outreach|Active: Outreach offering FIT or colonoscopy. Sequential: Outreach offering FIT first, and then offering colonoscopy to those still unscreened
41317127|NCT00667251|BIOLOGICAL|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
41317128|NCT00667251|DRUG|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
41317129|NCT00667251|DRUG|lapatinib ditosylate|1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).
41317130|NCT00667251|DRUG|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
41317131|NCT02541474|OTHER|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
41317132|NCT02494739|OTHER|Yogurt enriched with polyphenols|Yogurt enriched with polyphenols extracted from grape seeds
41317133|NCT02494739|OTHER|Yogurt not enriched with polyphenols|Yogurt not enriched with polyphenols
41004438|NCT01100411|DEVICE|Purevision|Contact lens material: Balafilcon A
41317134|NCT04959552|DEVICE|FreeStyle Libre 2|The FreeStyle Libre 2 Flash Glucose Monitoring
41317135|NCT01692353|OTHER|Subject's usual brand (UB) tobacco product|For SMK: UB of cigarettes; For MSC: UB of moist snuff
41317136|NCT00078559|DRUG|Alemtuzumab|30mg intravenous infusion on days 0 (transplant), 1, and 2
41317137|NCT00078559|DRUG|Sirolimus|2mg/day orally within 24-48 hrs post-transplant, and adjusted to achieve blood levels of 8-12 ng/mL for 1 year
41317138|NCT00078559|DRUG|Tacrolimus|2mg orally twice daily, on days 1-60
41474297|NCT06516913|DEVICE|Syringe Pump|Used to administer buffer solution with hyaluronic acid SC
41004439|NCT03225612|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is delivered by a percutaneous transcatheter procedure. The Trialign PTVAS procedure utilizes catheters and wires to deliver up to two sets of pledgeted sutures across the tricuspid annulus near the septal/posterior and the posterior/anterior commissures. Each set of implants is pulled together to plicate the posterior tricuspid annulus.
41004440|NCT01247090|DRUG|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU \* 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
41317139|NCT00078559|PROCEDURE|Kidney transplant|Kidney transplant with primary cadaveric or non-HLA-identical living donor kidney (0-3 HLA-antigen mismatch)
41317140|NCT00078559|DRUG|Methylprednisolone (or equivalent)|250 mg intravenous infusion 60 minutes prior to first dose of alemtuzumab
41317141|NCT00078559|DRUG|Acetaminophen|650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
40800444|NCT03814967|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
41317142|NCT00078559|DRUG|Diphenhydramine|25 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
41474298|NCT03653624|OTHER|No intervention|No intervention is involved int his study. Fully anonymised blood pressure data will be collected from the vital signs monitors in the operating room.
40800445|NCT01268046|DRUG|Estradiol oral capsule|1 oral capsule (1 mg estradiol) administered daily for one month
40800446|NCT01268046|DRUG|transderman estrogen patch|transdermal estrogen patch (50 mcg/day) for one month
40800447|NCT01268046|DRUG|trasdermal placebo patch|transdermal placebo patch with patch change every 84 hr for one month
40800448|NCT01268046|DRUG|placebo oral capsule|placebo oral capsule administered daily for one month.
40800449|NCT06188598|BEHAVIORAL|Time-restricted eating|Eating is restricted to an 8-hour window that is the same each day (e.g., 10am - 6pm)
41474299|NCT04352270|OTHER|AD printed educational materials|Printed educational materials in Spanish and English about coping with Atopic Dermatitis, specifically geared towards children and parents will be given to participants.
40800450|NCT02597452|DEVICE|intelligent Breast Exam, iBE|A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.
40800451|NCT00811291|DIETARY_SUPPLEMENT|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
40800452|NCT00811291|DIETARY_SUPPLEMENT|calcium|according to protocol
40800453|NCT05089552|OTHER|1-WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale|WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale The WHOQOL-BREF is composed of 26 self-administered items. Using a 5-point Likert response scale ranging from 1 (very dissatisfied/very poor) to 5 (very satisfied/very good), family caregivers were asked to rank each item accordingly. Caregivers were asked to respond to the items indicating their assessment of QOL during the preceding 2 weeks, Ohaeri and Awadalla developed and tested the Arabic version of the WHOQOL-BREF among an Arab population in Kuwait. The translated Arabic WHOQOL-BREF has considerable reliability and validity indices . As reported in the Kuwaiti study, a satisfactory (≥0.7) Cronbach's alpha was reported for the full questionnaire and the domains
41004441|NCT01247090|DRUG|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU \* 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
41004442|NCT01247090|DRUG|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
41317143|NCT00078559|DRUG|Trimethoprim (TMP)/Sulfa (Bactrim, Septra)|1 double strength tablet 3 times a week from day 1 through 1 year post-transplant.
41317144|NCT00078559|DRUG|Valgancyclovir|Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance
41317145|NCT00078559|DRUG|Acyclovir|400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.
40800454|NCT05089552|OTHER|SCL-90-R(Symptoms Checklist-90-Revised) Arabic version scale|"developed by Derogatis et al. and El-Behairy. established the validity and reliability of the Arabic version.SCL-90-R is a 90-item self-report symptom inventory, and reflect the psychologic symptom pattern of psychiatric and medical patients. Each item of the 90 is rated on a five-point scale of distress (0-4), ranging from not at all to extremely.Under usual circumstances, SCL-90-R requires between 12 and 15 minutes to be completed.SCL-90-R is a measure of the current psychologic symptom status. It is not a measure of personality, except indirectly, in that certain personality disorders may manifest a characteristic profile on the primary symptom dimensions."
40800455|NCT05089552|OTHER|addiction severity index|a semi-structured interview that takes approximately 45 minute. developed to evaluate treatment outcome in substance abusers. The instrument focuses on seven areas that are typically affected in the lives of substance abusers: medical status, employment, drug use, alcohol use, legal status, family/social status, and psychiatric status. Information regarding frequency, duration, and severity of problems in these seven areas is collected for both lifetime and recent (past 30 days) history. The ASI provides two types of scores: severity and subjective ratings of the client's need for treatment, and composite scores of problem severity during the prior 30 days. Specific alcohol-related questions include total lifetime years of use, money spent on alcohol, and number of days that alcohol problems are experienced.
40800456|NCT00000870|DRUG|Indinavir sulfate|
40800457|NCT00000870|DRUG|Lamivudine|
40800458|NCT00000870|DRUG|Stavudine|
40800459|NCT00000870|DRUG|Zidovudine|
40800460|NCT00000870|DRUG|Didanosine|
41004443|NCT06008613|DEVICE|3D Holographic Guidance, Navigation, and Control (3D GN&C)|"Using electromagnetic (EM) guidance and tracking to precisely place a Cook Zenith Flex AAA bifurcated stent graft during EVAR. EM guidance and tracking is enabled using a system consisting of:~1. experimental 3D guidance, navigation, and control (3D-GNC) software developed by Centerline Biomedical, Inc., integrated with the company's FDA-cleared Intra-Operative Positioning System (IOPS),~2. FDA-cleared compatible sensorized guidewires added to the Cook Zenith Flex delivery system, and~3. 3D visualization on the IOPS mobile cart monitor and 3D holographic visualization overlaid on the patient during the procedure using a head mounted display (HMD), the Microsoft HoloLens 2."
41004444|NCT05652166|OTHER|telephone interview|telephone call to parents to know the information given following the ingestion of foreign body by their child
41004445|NCT06202742|BEHAVIORAL|cognitive behavioral therapy for insomnia|Online meeting, weekly for 8 weeks, to deliver CBTI by psychologist/ psychiatrist
41317146|NCT00078559|DRUG|Pentamidine|300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa
41317147|NCT00078559|DRUG|Clotrimazole|10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)
41317148|NCT00078559|DRUG|Nystatin|500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
41317149|NCT04853043|DRUG|Cetuximab|Cetuximab will be administered every 2 weeks (14 days). The initial dose of 500 mg/m2 is to be administered by IV infusion over 120 minutes on the first day of the treatment. In the absence of infusion reactions, subsequent doses are to be administered over 60 minutes biweekly. Each cycle will be defined as 14 days of treatment.
41317150|NCT05856825|PROCEDURE|Robot-assisted radical cystectomy|Robot-assisted radical cystectomy
40800461|NCT00000870|DRUG|Aldesleukin|
40800462|NCT04984395|DIAGNOSTIC_TEST|Post-treatment CT-guided bone marrow biopsy|At post-treatment, 12 +/- 3 weeks after initiating treatment, patients will undergo a CT guided bone marrow biopsy of the same lesion as baseline.
40800463|NCT02959294|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
40800464|NCT02959294|DEVICE|Centricyte 1000|Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF
40800465|NCT02959294|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
41004446|NCT06202742|BEHAVIORAL|Health education|Online meeting, weekly for 8 weeks, to deliver general health knowledge
41004447|NCT04809909|PROCEDURE|Peripheral stimulation of acupuncture points (PSAP)|Electrode leads will be implanted at Bladder 25-bilateral (BL25), the acupoint commonly used for relief of chronic Low Back Pain in standardized acupuncture.
41474300|NCT04352270|OTHER|AD educational videos|Short, educational videos in English and Spanish about coping with Atopic Dermatitis, specifically geared towards children and parents will be developed. There will be Spanish and English versions of the videos, minimal text, comprehensive language, animations, and it will be administered via user friendly platforms or websites.
41474301|NCT05802199|DIAGNOSTIC_TEST|Hepatic fat fraction and hepatic fibrosis|"All patients underwent measurement of UDFF for hepatic fat fraction and auto-pSWE for hepatic fibrosis.~All patients underwent measurement of MRI-PDFF for hepatic fat fraction and MRE for hepatic fibrosis as reference standard."
41004448|NCT04809909|PROCEDURE|Peripheral nerve field stimulation (PNFS)|Electrode leads will be implanted at the region of pain.
41004449|NCT04777539|OTHER|At-home natalizumab treated MS patient|"MS patient who are treated with natalizumab in at-home hospitalization (HAD) setting / according at-home hospitalization program"
41317151|NCT05321485|OTHER|MedicijnWijs|"The mobile phone app MedicijnWijs will guide the participants with their azathioprine therapy during 6 weeks. Information about azathioprine is given as well as general information about IBD, specified to disease modality (Crohn's Disease and Ulcerative Colitis). Contact details of the patient's pharmacy are listed, questions about the patient's symptoms are asked, and push notifications are added to remind the patients to take their medication.~At the beginning of the 6-weeks guidance, two validated questionnaires that are translated and validated in Dutch will have to be filled in: the MARS-5 and the IBD-KID2. After 6 weeks, the participants have to fill out the same questionnaires again to assess potential changes in the scores compared to baseline. Also, a number of questions will be asked to assess the ease of use of MedicijnWijs."
41004450|NCT01438970|DEVICE|ALFApump system|The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
41004451|NCT00895739|BIOLOGICAL|alemtuzumab|
41004452|NCT00895739|DRUG|cyclosporine|
41004453|NCT02448875|DEVICE|CyPass Micro-Stent|Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
41004454|NCT02448875|DEVICE|Viscoelastic|Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
41004455|NCT06247033|DEVICE|Tibial Nerve Stimulation with TENS device|Tibial nerve stimulation was applied with TENS device transcutaneously and electrodes were positioned in medial part of the ankle. Negative transcutaneous electrode was positioned 3 centimeter posteriorly to the medial malleol. And positive transcutaneous electrode was positioned 10 centimeter above the negative electrode.
41004456|NCT06247033|BEHAVIORAL|Pelvic muscle training exercise with bladder training|Control group was followed with sham tibial nerve stimulation, which were performed by after starting electric current with TENS device, current were decreased and completely shut off. Sham stimulation was also applied for 6 weeks, 2 times in a week, 30 minutes. All patients were followed for PFTE and BT according to given standard schedule.
41004457|NCT03479866|OTHER|Dietary intervention|To carry out an interventional dietary study using standardised meals to predict for an individual their metabolic response to certain foods using the gut microbiome and their metabolic profile. Responses will include post-prandial appetite, levels of satiety, circulating glucose, insulin, ketone bodies and lipid levels.
41317152|NCT02542917|DEVICE|IBDoc home test for faecal calprotectin|IBDoc home test for faecal calprotectin
40800466|NCT00861757|DRUG|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
40800467|NCT00861757|DRUG|Placebo|PO, QD (30 min after meal) for 12 weeks
40800468|NCT00861757|DRUG|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
40800469|NCT00422448|GENETIC|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
40800470|NCT04717271|OTHER|Movement Guidance Group|"Participants of the MVG will received kinesthetic stimuli by manual assistance of the physiotherapist, which has the intention of guiding and improving the quality of movement during XBOX Kinect training for balance and gait.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
40800471|NCT04717271|OTHER|No Movement Guidance Group|"Participants of the NO-MVG will not received kinesthetic stimuli by manual assistance of the physiotherapist during XBOX Kinect training for balance and gait.~They will perform the exercises without any manual correction. Although, the physiotherapist will be present during all session to ensure their safety.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
40800472|NCT04733118|DRUG|Trastuzumab and Pertuzumab (FDC SC) and T-DM1|"Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen.~After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC.~Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report:~* Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles~* Cohort B: T-DM1 ± ET for 10 cycles~* Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1."
40800473|NCT00768846|DEVICE|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
41474302|NCT03336918|DRUG|Lithium|"Open-label lithium treatment for Bipolar Disorder Subjects~Healthy Controls only repeat testing - no intervention"
41474303|NCT02575339|DRUG|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
41474304|NCT02575339|DRUG|MLN0128 (RP2D)|"Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."
41474305|NCT02575339|DRUG|Sorafenib|"Phase II Arm B:~Sorafenib administered at 400mg PO BID daily"
41317153|NCT06012045|BEHAVIORAL|Enhanced Cue Exposure Therapy|The E-CET will consist of six weekly sessions and will be delivered by a clinical psychology trainee in person. The first session will be used to introduce the rationale and procedures of E-CET to the participant to establish therapeutic alliance, agreement on treatment goals and tasks, and to collect information on idiosyncratic CS-US expectancies to be targeted in exposures. In this session, questions will be asked specifically to assess idiosyncratic CS-US expectancies related to the four categories: positive reinforcement, craving/drive reduction, mood regulation, and disinhibition. An exhaustive list of all idiosyncratic NEE-triggering cues and CSUS expectancies will be generated from this session. These cues and CS-US expectancies will be targeted in the following exposure sessions and in homework exposures with the goal to cover as many of them as possible during the 6-week treatment.
41317154|NCT06012045|BEHAVIORAL|Behavioral Lifestyle Intervention|It consists of six weekly sessions of behavioral counseling integrating behavioral strategies for making changes related to diet and exercise. These behavioral strategies will include education about healthy and balanced diets, and ways to attain the minimum level of physical activity for wellbeing (150 minutes moderate-to-vigorous exercise per week), goalsetting, problem-solving, coping, and relaxation. A manualized protocol developed by the PI's team for previous studies in the local community will be used.
41317155|NCT05038748|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
41317156|NCT05038748|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
41317157|NCT05600647|DEVICE|Electromagnetic Field therapy with an exercise program|"1. The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. the patient was lying on the mattress in a supine position.~2. the exercise program included postural correction strengthening exercises, stretching, proprioception and balance training"
41317158|NCT05600647|OTHER|exercise program|the exercise program included postural correction, strengthening exercises, stretching, proprioception and balance training
41317159|NCT02124707|DRUG|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
41317160|NCT02124707|DRUG|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
41317161|NCT02124707|DRUG|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
41317162|NCT00848250|DRUG|Angiotensin Converting Enzyme Inhibitor|Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
41317163|NCT00848250|OTHER|No ACE Inhibitor|Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
41317164|NCT04380974|PROCEDURE|OCTA plus OCT guided 3+PRN regimen|"For the OCTA plus OCT guided 3+PRN regimen, we recorded patients' data after retreatment by 3 monthly intravitreal injections of anti-VEGF drug. Subsequent reinjections were given as needed according to the changes in patients' visual acuity, activity of PCV lesions shown by OCTA and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, OCTA and OCT.~In case of BVN increased or polypoidal lesion progressed on OCTA scans, persistent subfoveal or perifoveal fluid, macular intraretinal edema on OCT scans, or visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
41317165|NCT04380974|PROCEDURE|OCT guided 3+PRN regimen|"For the OCT guided 3+PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Anti-VEGF drugs. Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, and OCT.~In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
41317166|NCT04380974|DRUG|Anti-VEGF drug|Conbercept or other anti-VEGF drugs
41341772|NCT05963555|DEVICE|VieLight|Following the baseline block (first four weeks), participants will use the VieLight device 2-3 times per week for 20 minute sessions and may be completed at home.
41474306|NCT04553991|PROCEDURE|Ultrasound guided QL block|20 mL of 0.25% bupivacaine was applied bilaterally at the anterolateral border of the QL at its junction with transversalis fascia
41474307|NCT04553991|PROCEDURE|Ultrasound guided TAP block|20 mL of 0.25% bupivacaine was applied bilaterally in the TAP
40800474|NCT00768846|DEVICE|Xience V Stent|Everolimus-eluting Xience V Stent
40800475|NCT06162312|OTHER|Antenatal perineal massage|Participants at 34-35 weeks of gestation were received training in self-perineal massage and performed a daily 5-minute massage using water-based jelly until delivery to compare with standard obstetric care on postpartum morbidities
40800476|NCT00983333|DEVICE|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
41004458|NCT00958776|DRUG|Peramivir+SOC|"* Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~* Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
41317167|NCT02168894|PROCEDURE|Acupuncture|"Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment."
41317168|NCT02168894|PROCEDURE|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
41317169|NCT02168894|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
40800477|NCT03458325|COMBINATION_PRODUCT|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
40800478|NCT04010656|PROCEDURE|PVR-based self-catheterization|Home self-catheterization based on standard of care
40800479|NCT04829526|OTHER|data collection|Retrospective extraction of demographic, clinical, laboratory, and electrophysiological data from the digital medical records
40800480|NCT03497273|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
41004459|NCT00958776|DRUG|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
41317170|NCT02932332|OTHER|High-flow Oxygen|Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
41317171|NCT02932332|OTHER|Low-flow Oxygen|Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
41317172|NCT02932332|OTHER|High-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
41317173|NCT02932332|OTHER|Low-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
41341773|NCT05963555|DEVICE|ZeroBody|Following the baseline block (first four weeks), participants will use the Zerobody device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
40800481|NCT03497273|DRUG|Corticosteroid|Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
40800482|NCT06436612|RADIATION|Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy|stereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.
41341774|NCT00666380|BIOLOGICAL|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
41474308|NCT04239118|COMBINATION_PRODUCT|Complex endoscopic treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets|Complex endoscopic bleeding ulcers treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
40800483|NCT00118248|DRUG|tanespimycin|Given IV
40800484|NCT06173024|BIOLOGICAL|TAK-577|TAK-577 as IV injection at dose calculated based on the participant's body weight.
40800485|NCT05664503|OTHER|Assigned Interventions STOMA-M|The training, which includes information on stoma care, maintenance of daily life activities, and complication management, was given to the patients in the experimental group via the STOMA-M.
40800486|NCT00636103|DRUG|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
40800487|NCT00636103|OTHER|Placebo|"Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
41004460|NCT03490266|PROCEDURE|Robotic Repair|The surgeon will be utilizing a robotic system to repair the hernia.
40800488|NCT05462717|DRUG|RMC-6291|Oral tablet once or twice a day
40800489|NCT02160249|BEHAVIORAL|Community-based rehabilitation|
40800490|NCT02160249|OTHER|Facility based care|
40800491|NCT00285155|DRUG|Bupropion|
40800492|NCT02140606|DRUG|Cafusertib Hydrochloride|Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
41004461|NCT03490266|PROCEDURE|Laparoscopic Repair|The surgeon will be repairing the hernia laparoscopically.
41004462|NCT04521491|DRUG|FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).|FOLFOX4 (OXA 85 mg/m2 intravenously \[IV\] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
41004463|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 1
40800493|NCT00295009|DEVICE|ProDisc|Total disc replacement with ProDisc
40800494|NCT00295009|PROCEDURE|Spinal Fusion|A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
41004464|NCT00957437|DRUG|AZD1305|ER formulation 1, bid for 5 days
41004465|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 2
41004466|NCT01800071|DRUG|MVA-EBNA1/LMP2 vaccine|
41317174|NCT04972916|OTHER|Patient navigation-based tobacco harm reduction intervention|At the first intervention interview, the patient navigators will educate participants about the benefits of quitting, introduce smoking cessation resources, motivate participants to link with treatment, help participants attend smoking cessation treatments, and assess barriers that prevented them from being able to consider smoking cessation. The cessation treatment resources will be discussed include PennState Health Smoking Cessation Clinic, Pennsylvania Quitline, or visiting their primary care provider (PCP) to discuss cessation, prescription medications, and/or nicotine replacement therapy. A follow-up call will be made 1 month later to further assist and motivate to use tobacco treatment services, and assess interim tobacco treatment engagement outcome.
41317175|NCT00955292|DRUG|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
41317176|NCT00165646|DRUG|E3810|E3810 5mg: once daily orally for 4 weeks
41317177|NCT00165646|DRUG|E3810|E3810 10mg: once daily orally for 4 weeks
40800495|NCT02182778|DRUG|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
40800496|NCT02182778|DRUG|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
40800497|NCT00332579|DRUG|Naltrexone|daily
41474309|NCT04239118|PROCEDURE|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents
41474310|NCT00321594|DRUG|belinostat|Given IV
41474311|NCT01817192|DRUG|Adjuvant Chemotherapy|Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
40800498|NCT00332579|DRUG|Placebo|daily
40800499|NCT04811755|BEHAVIORAL|Surgical timing from ED admission to surgery|the impact of delay of time between patient admission to ED and surgery for source control on 90-d mortality and postoperative outcomes in patients with gastrointestinal perforation with or without septic shock
40800500|NCT02738541|DRUG|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
41004467|NCT04388579|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
41317178|NCT00165646|DRUG|Placebo|Placebo: once daily orally for 4 weeks
41317179|NCT02754544|PROCEDURE|Direct Electrocortical Stimulation|Undergo direct electrocortical stimulation
41317180|NCT02754544|OTHER|Electrocorticography|Undergo electrocorticography
41474312|NCT01817192|OTHER|Radiographic surveillance|Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.
41474313|NCT01817192|OTHER|14-Gene Prognostic Assay|This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.
41474314|NCT05813379|COMBINATION_PRODUCT|exosime injection|Treatment- exosome injection
41474315|NCT04341259|DRUG|Ipatasertib|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD) as described above.
41474316|NCT02052791|DRUG|nusinersen|Administered by intrathecal (IT) injection
41474317|NCT01456741|PROCEDURE|EBNA with ROSE|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence with rapid on-site evaluation~B) if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
41474318|NCT01456741|PROCEDURE|standard EBNA|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence.~B)if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
41474319|NCT00719979|BEHAVIORAL|Behavioral intervention (iCBT + TeleCoach)|TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.
40800501|NCT02738541|DRUG|PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE|PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
40800502|NCT03254628|OTHER|Helping Mothers Survive - Bleeding After Birth training|One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.
41317181|NCT02591004|DRUG|Magesium sulphate|\*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins \& 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
41317182|NCT02591004|DRUG|Nifedipine|\*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
41317183|NCT02591004|RADIATION|Doppler on fetal middle cerebral artery|both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
41317184|NCT01354041|BEHAVIORAL|Acceptance and Commitment Therapy|Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
41317185|NCT06179030|DIAGNOSTIC_TEST|serum samples|The serum samples were taken from the patients at the 3rd month (switch point)
41317186|NCT06179030|DRUG|dexamethasone implant versus ranibizumab|dexamethasone implant versus ranibizumab will be studied as a secondary outcome
41004468|NCT02460770|DRUG|Autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
41004469|NCT06237166|BEHAVIORAL|mylovia|Participants will receive access to the digital health intervention mylovia in addition to TAU.
41004470|NCT02304224|OTHER|eye masks|eye masks from 21:00 to 6:00 each night during admission
41004471|NCT02627612|BEHAVIORAL|Pro Vetus|Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
41004472|NCT02627612|BEHAVIORAL|Team Red, White, and Blue (TM RWB)|TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
41317187|NCT05715268|DEVICE|WeB|"Participants will be given WeB devices and trained on the use of these devices for home therapy, including the associated mobile applications. Participants will be given home programs and given a schedule to use the WeB devices at home on their own time. At their standard visit participants will have their WeB device use checked and progressed as the therapist deems appropriate.~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
41474320|NCT00719979|BEHAVIORAL|Internet-based cognitive behavioral therapy (I-CBT)|I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.
41474321|NCT00719979|BEHAVIORAL|Treatment as usual / Wait-list control|TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
41474322|NCT05878379|BEHAVIORAL|Dietary Iron Program|"Teachers Lesson 1: Discuss about causes, prevention and effects of anemia and ID, dietary iron, dietary enhancers and inhibitors of iron absorption, and school lunch menu Lesson 2: Participate in and observe how to teach children in an iron curriculum~Caregivers Lesson 1: Presentation and group talk about causes, prevention, and effects of anemia and ID, dietary iron, and dietary enhancers and inhibitors of iron absorption Lesson 2: Discuss benefits and barriers of changing to an iron-rich meal at home Lesson 3: Cooking class for preparing an iron-rich meal at home (2 times) Lesson 4: Home visit~Children Lesson 1: Group talk about causes and effects of anemia and ID Games: Where are you from? Lesson 2: Presentation and group talk about dietary iron, and dietary enhancers and inhibitors of iron absorption, and iron-rich food Games: What is the winner? Assignment: Market assignment Lesson 3: Cooking class (2 times)"
41474323|NCT03040752|DRUG|Nifedipine 20 Mg|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
41474324|NCT03040752|DRUG|Ritodrine Oral Tablet|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor
41474325|NCT00093184|DRUG|Angiomax (bivalirudin) anticoagulant|
41474326|NCT05356936|DIETARY_SUPPLEMENT|Vitamin K2 (MK-7)|Participants will receive Vitamin K2 (MK-7) daily by mouth.
41474327|NCT05356936|DIETARY_SUPPLEMENT|Vitamin D3|Participants will receive Vitamin D3 daily by mouth.
41474328|NCT05828082|PROCEDURE|Biopsy|Undergo biopsy
41474329|NCT05828082|PROCEDURE|Biospecimen Collection|Correlative studies
41474330|NCT05828082|PROCEDURE|Computed Tomography|Undergo CT
41474331|NCT05828082|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41474332|NCT05828082|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI or PET/CT
41474333|NCT05828082|DRUG|Tuvusertib|Given PO
41474334|NCT05828082|PROCEDURE|Ultrasound Imaging|Undergo U/S
41474335|NCT05220553|DEVICE|PROLIMB Prosthesis|Participants will be given the PROLIMB prosthesis to test in the lab and to use in their daily lives
41474336|NCT05976347|DRUG|Fluoxetine 20 MG|Fluoxetine 20 mg once daily
41474337|NCT05976347|DRUG|Duloxetine 30 MG|Duloxetine 30 mg once daily
41474338|NCT05976347|OTHER|Observation|Referral to behavioral health and resources for addressing depressive symptoms
41474339|NCT00002829|BIOLOGICAL|Recombinant Interferon Alfa|Daily
41474340|NCT00002829|DRUG|Cyclophosphamide|Infused intravenously over 2 hours daily on Day -7 and -6.
41474341|NCT00002829|DRUG|Etoposide|Administered intravenously on Day -8
41004473|NCT03666169|OTHER|Survey|Survey
41474342|NCT00002829|DRUG|Mesna|Beginning 1 hour after initiation of the cyclophosphamide treatment.
41474343|NCT00002829|PROCEDURE|Bone Marrow Transplantation|Infusion on Day 0.
41474344|NCT00002829|RADIATION|Radiation Therapy|Total body irradiation is received on days -4, -3, -2 , and -1.
41004474|NCT04164147|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior Cruciate Ligament sacrificing or retaining implant
41004475|NCT04164147|DIAGNOSTIC_TEST|CT scan|CT scans of the affected knee joint before and after the surgical procedure
41004476|NCT04164147|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
41474345|NCT01079819|DRUG|BMS-708163|Capsule, Oral, 50 mg, once daily, 1 Day
41474346|NCT01079819|DRUG|BMS-708163|Capsule, Oral, 125 mg, once daily, 14 Days
41474347|NCT01079819|DRUG|Placebo|Capsule, Oral, 0 mg, One daily, 1 Day
41474348|NCT01079819|DRUG|Placebo|Capsule, Oral, 0 mg, One daily, 14 Day
41474349|NCT02056067|BEHAVIORAL|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
41317188|NCT05715268|OTHER|Standard pelvic floor physical therapy|"Baseline will consist of a standard PFPT evaluation. Regular visits (tele-video visits or in-person depending on the patients preference) will be scheduled every week for the first 4 weeks and then every other week at the discretion of the therapist. A total of 8-10 visits will be scheduled over the 12 weeks of the study. Participants will be given home exercise programs (as per standard PFPT).~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
41317189|NCT06241287|BEHAVIORAL|Better Living with Non-memory led Dementia programme|an 8-week duration 6-module educational programme covering the following topics: 1) Welcome to the programme and what to expect from it; 2) Understanding the disease; 3) How to provide better support for the person with dementia; 4) How to look after the caregiver's own mental health; 5) Where to find additional sources of support, and 6) An introduction to the value of support groups. At the end of modules 2, 3, and 4, participants will be asked to complete a real-life task to put in practice skills learned in the specific module (e.g., approaching a friend and explaining the disease in lay terms). The first session (onboarding) will be facilitated via Zoom by one of the members of the research team. Up to 3 total interactions between facilitators and participants will be offered to support participants' engagement with the programme. All course modules will be printable using the pdf download button on the programme's page.
41474350|NCT02056067|BEHAVIORAL|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
40800503|NCT03254628|OTHER|Helping Babies Breathe|One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag \& mask device.
40800504|NCT03254628|BEHAVIORAL|Mentor|A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
40800505|NCT03254628|BEHAVIORAL|Phone|District trainers telephone clinical mentors and encourage them to lead practice sessions.
40800506|NCT03254628|DRUG|oxytocin and misoprostol|This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
40800507|NCT03254628|DEVICE|Newborn bag and mask|All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
40800508|NCT01415297|DRUG|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
41004477|NCT04164147|DEVICE|one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and NexGen PS total knee implant|Participant are randomly allocated to receive one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and the NexGen PS total knee implant for treatment of end-stage knee osteoarthritis.
41004478|NCT03309280|OTHER|Duration of intubation|Time between intubation in the operating room and exhumation in the Intensive Care Unit.
41004479|NCT03309280|DIAGNOSTIC_TEST|Evolution of the renal function|Evolution of the renal function in the next two days
41317190|NCT06241287|OTHER|Waiting list|Signposting individuals to the publicly available Rare Dementia Support website. The control group will further receive access to the Better Living with Non-memory led Dementia programme after completing the collection of measures at 6 months.
41317191|NCT00469404|DRUG|Buprenorphine|
41317192|NCT05795010|OTHER|MRD test|ctDNA detection based on tumor whole exon sequencing
41317193|NCT00831441|DRUG|Apixaban|Tablets, Oral, 5 mg, twice daily, until study end
41317194|NCT00831441|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, until study end
41004480|NCT01514318|DEVICE|Revelation Hip Stem (Revelation)|Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
41004481|NCT05979103|BEHAVIORAL|Listening to Reggae Music and told the stereotype|Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks. Each day, we will send them a playlist to listen to.
41004482|NCT05979103|BEHAVIORAL|Listening to Nature Sounds|Participants in this group will NOT be told the stereotype for the audio they are listening to. They will listen to nature sounds over the 4 weeks. Each day, we will send them a playlist to listen to.
41004483|NCT01100008|PROCEDURE|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
41004484|NCT03535220|COMBINATION_PRODUCT|Protease Inhibitors|Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
41004485|NCT01703637|DRUG|Sitagliptin|"* before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy"
41317195|NCT01434381|BIOLOGICAL|Pfs25-EPA/Alhydrogel|
41317196|NCT00983840|OTHER|Family Eats|8-session web-based program on healthy eating for African American families
41317197|NCT03653403|DRUG|IDP-126 Gel|Component A
41317198|NCT03653403|DRUG|Control Gel|gel
40800509|NCT00920361|DRUG|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
40800510|NCT03081663|PROCEDURE|Quads-Sparing Approach|Quadriceps-sparing mid-vastus approach for total knee arthroplasty
40800511|NCT03081663|PROCEDURE|Medial Para-Patellar Approach|Medial para-patellar approach for total knee arthroplasty
40800512|NCT00935506|DRUG|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
40800513|NCT00935506|DRUG|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
40800514|NCT03040739|OTHER|use of O'ARM imaging system|use of O'ARM imaging system
40800515|NCT02853552|DRUG|Misoprostol|800mcg misoprostol taken sublingually
41004486|NCT01703637|DRUG|Vildagliptin|"* before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy"
41317199|NCT02211976|DRUG|Bisacodyl|
41317200|NCT02211976|DRUG|Simeticone|
41317201|NCT04333121|OTHER|weight|we can monitoring the growth of the infants by weight gain degree
41317202|NCT03558555|DRUG|Acetaminophen IV Soln|1000mg of IV acetaminophen
41317203|NCT03558555|DRUG|Oral Acetaminophen|oral acetaminophen 975mg pills
41474351|NCT05147636|PROCEDURE|Extubation with PEEP|No aspiration within the 3 minutes before extubation and extubation with 10cmH2O PEEP
41474352|NCT05147636|PROCEDURE|Endotracheal Aspiration|Aspiration during cuff deflation
41474353|NCT04686994|DRUG|ASC 41|Oral tablets
41474354|NCT04686994|DRUG|ASC 41 Placebo|Oral tablets
41474355|NCT02456649|DEVICE|MarginProbe|Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to \< 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as \< 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
41474356|NCT03752554|PROCEDURE|segmental resection|All cases will undergo surgery under general anesthesia. The mandibular lesion will be segmentally resected. The cuts will be performed with the aid of the prefabricated digital template. The neurovascular bundle will be separated and protected. Then reconstruction will be performed
41474357|NCT03176368|OTHER|Coconut Oil|Coconut Oil
41474358|NCT04893122|OTHER|COVID-19 pandemic|Study focuses on the impact of the COVID-19 pandemic on emergency attendances and admissions.
41474359|NCT06309316|BEHAVIORAL|Person-centred care (PCC)|In addition to usual care, patients will receive PCC through physical visits, telephone and through a web-based platform for 15-months. Primary outcome is after 3 month (we expect the need of support is largest in the beginning) but the intervention will continue for the period of care 12-18 months, increasing transferability to regular care.
41474360|NCT03191708|DIAGNOSTIC_TEST|Fractional Flow Reserve (FFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
41474361|NCT00307931|BIOLOGICAL|Certolizumab pegol|"certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.~Treatment duration: 12 weeks."
41474362|NCT00088387|DRUG|Divalproex|
40800516|NCT03855046|DRUG|IncobotulinumtoxinA 50 U Intramuscular Powder for Solution|"Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution."
41004487|NCT01703637|DRUG|Saxagliptin|"* before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~* before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy"
41004488|NCT03026712|DEVICE|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
41317204|NCT03558555|DRUG|Placebo Pills|placebo match to acetaminophen
41317205|NCT03558555|DRUG|Saline|Intravenous saline
41004489|NCT03026712|DEVICE|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
41004490|NCT02139566|BEHAVIORAL|Video consent (high-tech)|Consent provided by an animated video with captions
41317206|NCT02664532|OTHER|Miller group|Miller blade was used for laryngoscopy
41317207|NCT02664532|OTHER|Macintosh group|Macintosh blade was used for laryngoscopy
41317208|NCT03451500|DRUG|carbidopa-levodopa|See previous
41317209|NCT05265130|DRUG|YiQiFuMai|YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.
41317210|NCT05265130|DRUG|0.9% Normal Saline 250ml|0.9% Normal Saline 250ml IV, about 40 drops per min.
41317211|NCT03198754|DEVICE|PEI Experimental Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
41317212|NCT03198754|DEVICE|Comparison Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
41317213|NCT01669941|DRUG|IPTp-SP|3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
41317214|NCT01669941|DRUG|IPTp-DP|At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
41474363|NCT00088387|DRUG|Lithium|
41474364|NCT03605823|DEVICE|Express Mini shunt|Implantation of Express Mini shunt through pars plana in vitrectomized eyes
41474365|NCT04815395|DRUG|Oxytocin|Administration of oxytocin (24IU) orally
41474366|NCT04815395|DRUG|Oxytocin|Administration of oxytocin (24IU) intranasally
40800517|NCT03855046|PROCEDURE|Lateral subcutaneous sphincterotomy.|The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.
41317215|NCT01669941|DRUG|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
40800518|NCT05351840|DRUG|LivaloV|Treatment A, Tablet, Oral, QD for 7 Days
40800519|NCT05351840|DRUG|A|Treatment B, Tablet, Oral, QD for 10 Days
40800520|NCT05351840|DRUG|LivaloVA|Treatment C, Tablet, Oral, QD for 7 Days
40800521|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 2 of Cycles 3-6
40800522|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 1 of Cycles 3-6
40800523|NCT02243371|DRUG|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6
40800524|NCT02243371|BIOLOGICAL|GVAX|5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
40800525|NCT02243371|DRUG|CY|200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2
40800526|NCT00694577|RADIATION|Partial Breast Irradiation using 32 Gy / 8 fractions|32 Gy-8 Treatments, 4 Treatment Days
40800527|NCT00694577|RADIATION|Partial Breast Irradiation using 36 Gy / 9 fractions|36 Gy- 9 Treatments, 4 1/2 Treatment Days
40800528|NCT00694577|RADIATION|Partial Breast Irradiation using 40 Gy /10 fractions|40 Gy-10 Treatments, 5 Treatment days
40800529|NCT02492191|DEVICE|Smartphone app Recovery Assessment by Phone Points (RAPP)|An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
40800530|NCT04509011|DEVICE|Fluobeam® LX|Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
40800531|NCT02590276|BEHAVIORAL|characterization|
40800532|NCT05151510|PROCEDURE|Trigger point injection with 1% lidocaine|Previously discussed in prior section.
40800533|NCT05151510|DRUG|Lidocaine patch 5%|Will place lidocaine patch onto skin overlaying point of maximal tenderness
41317216|NCT01592409|DRUG|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
41317217|NCT01592409|DRUG|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
41474367|NCT04815395|DRUG|Placebo|Administration of placebo orally
41474368|NCT02172677|BEHAVIORAL|Episodic memory task|
41474369|NCT02172677|DEVICE|fMRI|
41474370|NCT02152735|PROCEDURE|Cleaning the uterine cavity|These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
41474371|NCT00275275|DRUG|Requip PR|Requip 24-Hour once a day for one month
40800534|NCT02173483|PROCEDURE|Quadriceps graft|
40800535|NCT02480413|OTHER|Accuracy of an algorithm and the pediatric emergency tape.|No intervention
40800536|NCT05628285|DEVICE|Sentio 1|Sound processor
40800537|NCT05833230|OTHER|Intensive Day Monitoring|During intake, a research assistant will demonstrate how to place the Heart Rate Variability monitor and provide instructions on completing the saliva samples at home. Participants will wear the Heart Rate Variability monitor for three consecutive, randomly selected days twice (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. All participants will complete a total of 6 such days during the study.
40800538|NCT04796272|OTHER|Adapted and individualized physical training program|Physical training program adapted and individualized according to each patient in this group
40800539|NCT04796272|OTHER|traditional training program|Same training program for all patients in this group
40800540|NCT00399217|DEVICE|Subcutaneous Implantable Defibrillator (S-ICD) system|
40800541|NCT00399217|DEVICE|ICD|
40800542|NCT04044196|PROCEDURE|Rotator cuff repair|Rotator cuff repair performed arthroscopically
40800543|NCT03173989|DEVICE|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
40800544|NCT03173989|BEHAVIORAL|Orientation|Orientation for home.
40800545|NCT00479102|DRUG|Ferripel-3 - iron polysaccharide complex for prevention|
40800546|NCT04384705|OTHER|research specific blood sample|"* one blood sample before the epidemic phase~* one blood sample during epidemic phase~* one blood sample after epidemic phase"
40800547|NCT03297684|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
41004491|NCT02139566|BEHAVIORAL|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
41474372|NCT00275275|DRUG|Mirapex|All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
41004492|NCT02139566|BEHAVIORAL|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
40800548|NCT05285761|BEHAVIORAL|Provision of extended information on the conduct of complementary feeding|"Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child."
41004493|NCT02139566|BEHAVIORAL|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
41317218|NCT00642746|DRUG|Erlotinib|"Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage."
41317219|NCT00642746|DRUG|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
41317220|NCT00642746|DRUG|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
41317221|NCT00642746|DRUG|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
41317222|NCT00642746|DRUG|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
41317223|NCT00893048|DRUG|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
41317224|NCT00893048|DRUG|Placebo Oral Tablet|Placebo
41317225|NCT00348842|PROCEDURE|Newcastle Virus|
41317226|NCT03306485|OTHER|Correlating the number of reflux episodes detected on 1-h post prandial esophageal high resolution manometry combined and those detected on ambulatory 24-h pH-impedance monitoring performed on PPI|Esophageal high resolution impedance manometry (HRIM) consists of introducing a transnasal probe to record esophageal contractility (manometry), bolus transit (impedance) but also the occurrence of reflux episodes. Ambulatory 24-h pH-impedance monitoring consists of recording the occurrence of reflux episodes by introducing a transnasal catheter into the esophagus. After inserting the transnasal HRIM probe and the pH-impedance catheter, both HRIM and 24-h pH-impedance recordings are started. The patient is instructed to eat a meal that induces reflux symptoms (the patient brings his own meal). One hour the end of the meal, the HRIM probe is removed. The patient is discharged at home and the 24-h pH-impedance monitoring is continued. The patient is coming back 24-h after catheter insertion to stop the pH-impedance recording and remove the catheter.
41317227|NCT01165593|OTHER|There is no intervention that is a part of this study.|There is no intervention that is a part of this study. Imaging data is gathered as part of normal care.
41317228|NCT02452801|DRUG|ALKS 5461|Single dose, given orally
41317229|NCT00895193|OTHER|Apple pectin|Apple pectin 2000mg
41317230|NCT00895193|DRUG|Aspirin 325 mg|Aspirin 325 mg
41317231|NCT00895193|OTHER|Placebo|Placebo
41317232|NCT00675103|DRUG|pegloticase 8 mg i.v.|pegloticase 8 mg i.v. every 2 weeks for 24 weeks
41474373|NCT04733248|OTHER|Kinesiotaping group|"* HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHING EXERCISES(10 reps 3sets) hold for 2 sec~* Apply KINESO- TAPE on upper trapezius (from I-O for Inhibition purpose)~HOME PLAN OF EXPERIMENTAL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec (In neck flexion, In neck extension, In side bending) In experimental group kinesiotape was applied on upper trapezius from insertion to origin for inhibition purpose. As it had increased the functional status of the patient. Post -intervention assessment was taken on 1 st, 2nd and 3rd visit."
41474374|NCT04733248|OTHER|stretching group|"* HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHINGS EXERCISES (10 reps 3sets) hold for 2 sec 5.9HOME PLAN OF CONTROL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec In neck flexion In neck extension In side bending Post-intervention assessment was taken on 1 st, 2nd and 3 rd visit"
41004494|NCT02139566|BEHAVIORAL|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
41004495|NCT02734316|OTHER|endoscopic procedure|Evaluation of adverse events in patients on DOACs undergoing GI endoscopy
41004496|NCT00005770|DEVICE|Acupuncture|
41004497|NCT00366392|DEVICE|Optical Aids|
41004498|NCT04524312|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant
41317233|NCT02471911|DRUG|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
41317234|NCT02471911|DRUG|Rituximab|IV Rituximab 375 mg/m2 on D1
41317235|NCT02471911|DRUG|Etoposide|IV Etoposide 100 mg/m2 on D1-3
41317236|NCT02471911|DRUG|Carboplatin|IV Carboplatin AUC 5 on D2
41317237|NCT02471911|DRUG|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
41317238|NCT02471911|DRUG|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
41317239|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone
41317240|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 with dinutuximab, filgrastim, teceleukin combination
41004499|NCT04524312|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
41004500|NCT04524312|DEVICE|NexGen Ps or Bioimplanti K-MOD implant|Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.
41317241|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 with nivolumab combination
41317242|NCT05902819|BEHAVIORAL|Imagery|Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.
41317243|NCT05902819|DRUG|Minocycline|Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.
41317244|NCT05902819|DRUG|Placebo|Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.
41317245|NCT01568424|DEVICE|CentriMag RVAS placement|Patients will be treated with a CentriMag RVAS
41317246|NCT00375635|PROCEDURE|mFPSA treatment|
41317247|NCT00878631|DRUG|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
41317248|NCT00878631|DRUG|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
41004501|NCT02320890|DEVICE|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
41004502|NCT02320890|DEVICE|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
41317249|NCT03985748|DEVICE|BAN|Inhaled bronchodilators will be delivered using an AeroEclipse® II Breath Actuated Nebuliz (BAN)
41474375|NCT05387148|DRUG|Cannabidiol (CBD)|Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.
41004503|NCT00945984|PROCEDURE|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
41004504|NCT01459172|OTHER|limonene containing massage oil|daily massage application to the breast for 4 weeks
41004505|NCT01150695|OTHER|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
41004506|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine \[approximately 1x10\^9 colony forming units (cfu)/mL\] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
41004507|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10\^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
41004508|NCT05404269|DEVICE|AGC mode|Automated Gas Control mode at Maquet FLOW-i anesthesia machine
41004509|NCT03883204|DRUG|Aripiprazole|Initial dose: 10 mg.
41004510|NCT03883204|DRUG|Risperidone|Initial dose: 2 mg.
41004511|NCT00262067|DRUG|Bevacizumab|Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
41004512|NCT00262067|DRUG|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody.
41317250|NCT03985748|DEVICE|SN|Inhaled bronchodilators will be delivered using a Standard Nebulizer (SN)
41317251|NCT00877669|PROCEDURE|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
41317252|NCT00877669|PROCEDURE|Holmium Laser Enucleation of the Prostate|HoLEP using 100W Ho:YAG laser
41474376|NCT05387148|DRUG|Placebo|The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
41474377|NCT04824859|BEHAVIORAL|Behavioral|eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team
41152179|NCT03684434|BEHAVIORAL|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
41317253|NCT03543306|DRUG|daborafenib plus trametinib|Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
41317254|NCT05250830|DEVICE|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
41317255|NCT05250830|DEVICE|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
41317256|NCT04573127|OTHER|descriptive study|Retrospective analysis of existing data collected as a part of the regular follow-up
41317257|NCT05436899|OTHER|LapSim training|Complete 4 courses, each of 12 weeks, of virtual reality simulation on LapSim surgical simulator.
41317258|NCT05436899|OTHER|LapSim exam|Completed at the beginning and at the end of each of the 4 courses the corresponding exam task.
41474378|NCT06293326|DRUG|bi-layer calcium carbonate tablet (BAY1180654)|Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
41317259|NCT00264849|DRUG|Omalizumab|Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
40800549|NCT05285761|BEHAVIORAL|Provision of current official information on complementary feeding|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
41317260|NCT00264849|OTHER|Optimized asthma therapy|Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
41317261|NCT05242445|DRUG|Cetrelimab|Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.
40800550|NCT02485639|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants received vaccine intramuscularly (IM) on Day 0.
41317262|NCT05242445|DRUG|Placebo|Placebo will be administered via SC injection or as an IV infusion.
41317263|NCT01831206|PROCEDURE|Collagen cross-linking|"Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.~Standard treatment arm will receive only standard medication."
41474379|NCT06293326|DRUG|Immediate release calcium carbonate tablet (BAY1180654)|Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
41474380|NCT00001108|DRUG|Ritonavir|
41474381|NCT00001108|DRUG|Nelfinavir mesylate|
41474382|NCT00001108|DRUG|Saquinavir|
40800551|NCT02334020|OTHER|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
40800552|NCT04528550|BIOLOGICAL|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection.
41152180|NCT03684434|BEHAVIORAL|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
41152181|NCT03743922|DRUG|Calciferol|calciferol capsule
41317264|NCT05594108|DIAGNOSTIC_TEST|ultrasonography|transabdominal ultrasonography
41317265|NCT02130258|DEVICE|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
41317266|NCT02130258|PROCEDURE|Epidural Steroid Injection (ESI)|Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.
41317267|NCT04629898|BEHAVIORAL|multi-task in the real world and virtual reality video sport games|This was a 2-staged intervention study. The 1st stage intervention uses multitasks in the real world including stepping exercise, ball-kicking activity and bean-bag tossing activity. The 2nd stage intervention used video sport games conveyed by Xbox Kinect. Tennis and golf games were selected.
41317268|NCT00592553|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the respective arms.
41317269|NCT00592553|DRUG|Placebo|Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
41317270|NCT01208038|DRUG|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
41317271|NCT05435742|BIOLOGICAL|SON-080|Recombinant human interleukin-6 (rhIL-6)
41317272|NCT02266615|GENETIC|Biobanking of biomaterial for future genetic research.|
41317273|NCT00126178|BIOLOGICAL|HSPPC-96|
41317274|NCT02601066|DEVICE|Electrophysiological Study and ECG holter monitor|Electrophysiological Study and ECG holter monitor implantation
40800553|NCT04528550|DRUG|Placebo|Included patients will receive the same amount of saline through lumbar injection.
40800554|NCT05083611|OTHER|GraMI|The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
40800555|NCT01264692|DRUG|ACT-280778|10 mg once daily for 28 ± 2 days
40800556|NCT01264692|DRUG|Placebo|Placebo oral capsules matching ACT-280778
41152182|NCT03743922|DRUG|Placebo|placebo capsule
41317275|NCT02855450|DRUG|rhNGF|Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
41317276|NCT02855450|DRUG|Vehicle|Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
41474383|NCT00001108|DRUG|Nevirapine|
41474384|NCT00001108|DRUG|Lamivudine|
41474385|NCT00001108|DRUG|Stavudine|
41474386|NCT00001108|DRUG|Didanosine|
41474387|NCT02597582|PROCEDURE|Neck dissection|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
41474388|NCT05711342|BEHAVIORAL|Aggression|"The intervention consists of 10 lessons:~1. Motivation - where are you now?~2. Where do you want to go?~3. Circle of aggression.~4. Thoughts.~5. Emotions.~6. Bodily sensations.~7. Techniques for self-control.~8. Asking for help.~9. Assertiveness.~10. Relapse-prevention. Each lesson consists of multiple components, i.e. written text, assignments and videos with therapists and/or experts by experience. After each lesson, the therapist sends written feedback on the assignments to the patient. Because 'Aggression' is a blended intervention, each lesson is briefly discussed in an in-person treatment session. Generally, participants work on one lesson per week."
41474389|NCT05711342|BEHAVIORAL|Treatment as usual|In-person aggression treatment as usual (TAU), as delivered by the organization. This refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient. The main focus of treatment as usual should lie on aggression regulation.
40800557|NCT01264692|DRUG|Amlodipine|10 mg once daily for 28 ± 2 days
41317277|NCT06175065|DRUG|RLS-0071|RLS-0071, will be administered as an IV infusion 10 mg/kg. Planned infusion duration is 8 minutes.
41317278|NCT06175065|DRUG|Placebo|Placebo control (commercial sterile saline), will be administered as an IV infusion. Planned infusion duration is 8 minutes.
41317279|NCT05109819|RADIATION|Esophagus sparring radiotherapy treatment|A radiotherapy plan for metastatic spinal cord compression is conducted with specific constrains sparring the esophagus.
41317280|NCT01303380|DRUG|Canakinumab|
41317281|NCT04212286|DIAGNOSTIC_TEST|Diagnostic CEUS and EOB-MRI|Undergo Sonovue-CEUS and EOB-MRI
41317282|NCT03326830|DEVICE|High-flow nasal oxygen|oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher\&Paykel, New-Zealand).
40800558|NCT03511014|DEVICE|Microcurrent|Micrucurrent will be apply
41317283|NCT03326830|DEVICE|Standard oxygen therapy|Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
41317284|NCT03107455|DEVICE|MitraClip|MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet
41317285|NCT03786237|DRUG|Rigosertib Oral Capsules / Rigosertib Intravenous|"Patients will take Rigosertib either as oral capsules or will get intravenous infusions depending on the needs of the patients.~Oral Capsules:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg) in the morning and in the afternoon, total of 1120mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter."
40800559|NCT06353048|PROCEDURE|fixation of tibial plateau fractures|fixation of tibial plateau fractures by screws only versus plate and screws
40800560|NCT06149221|DEVICE|NTAP|Cold plasma is generated and applied to the scalp area, which was previously soaked with normal saline
40800561|NCT02518165|DIETARY_SUPPLEMENT|Proprietary spearmint extract|Water extracted spearmint extract
40800562|NCT02518165|OTHER|Placebo|Microcrystalline Cellulose
40800563|NCT02684617|BIOLOGICAL|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
40800564|NCT02684617|DRUG|dinaciclib|dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
40800565|NCT05570656|DEVICE|XSENS-Awinda|"The participant wears inertial sensors X-Sens that measure the kinematic data and the amplitude of joint movements during different movements (flexion and extension of the spine, walking, picking up an object on the ground, tying their shoelaces, getting up from a chair... ) Each movement will be repeated 3 times.~Participants will also have self-questionnaires to complete (BASDAI and BASFI).~The exams are carried out on one day."
40800566|NCT00656058|DRUG|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
40800567|NCT00513084|BEHAVIORAL|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
40800568|NCT05780008|BEHAVIORAL|Eat My ABCs|"The Eat My ABCs curriculum incorporates senses into learning (hear, see, smell, taste) and includes two sessions/week: 1) healthy eating learning; and 2) mindful food taste-testing activities to expose children to the one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty.~Child Letter to Parents. Every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home.~Program Cookbook. The investigators have developed a targeted program cookbook for low-income families. The program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets. In addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home."
40800569|NCT06203938|DEVICE|Transcranial infrared light stimulation|Trancranial infrared light stimulation administered via light-emitting diodes
40800570|NCT06203938|DEVICE|Sham|Identical to TILS, but with lights off
41317286|NCT05738694|DRUG|Axitinib plus Toripalimab|Preoperative treatment with axitinib will be given for 3 months, 5 mg twice daily, orally. Preoperative treatment with Toripalimab will be given for 4 cycles (3 weeks considered one cycle), 240 mg, Q3W.
41317287|NCT05738694|PROCEDURE|nephrectomy|nephrectomy
41317288|NCT04903964|OTHER|family-centered nutrition education|There is a training program prepared by the researcher to increase the nutritional knowledge of mothers with children aged 0-3. The definition and importance of nutrition in the session, respectively, adequate and balanced nutrition, insufficient and unbalanced nutrition damages, grouping of nutrients, feeding 0--6 months old baby, feeding premature baby, breastfeeding, situations to be considered while breastfeeding, starting additional foods, 9-12 monthly baby nutrition, 1-3 years old child nutrition and nutritional nutrition support.
41317289|NCT05429177|DRUG|QY101 ointment or vehicle|QY101 ointment or vehicl topical applied to skin
40800571|NCT01680354|PROCEDURE|ReLEx|
40800572|NCT01680354|PROCEDURE|LASIK|
40800573|NCT00005947|BIOLOGICAL|sipuleucel-T|Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
40800574|NCT00005947|BIOLOGICAL|Placebo|Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
41317290|NCT05836519|OTHER|Survey Navicular Drop test, International Physical Activity Questionnaire (IPAQ) Short Form, 6-minute walk test, Foot Function Index (AFI), SF-36 quality of life questionnaire, Modified borg scale|Pulse oximetry will be used to measure the oxyhemoglobin value of the participants, and a sphygmomanometer will be used for blood pressure and heart rate measurements.
41317291|NCT00311181|DEVICE|Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)|Patients that are indicated for an ICD or CRT-D receive one of these devices.
41474390|NCT01695096|OTHER|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
41152183|NCT02195219|PROCEDURE|open reduction internal fixation|MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.
41317292|NCT01089582|OTHER|No intervention|
41317293|NCT00423618|RADIATION|radiotherapy|radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
41474391|NCT01695096|OTHER|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
41474392|NCT03452618|DIAGNOSTIC_TEST|diagnosis variables|"The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~* Age of the patient~* Sex~* Presence of bulbar involvement or not~* Time from onset of first symptoms to diagnosis of ALS~* Score ALSFRS-R~* Presence of another underlying respiratory pathology (COPD, asthma ...)~* FVC measurement (Forced vital capacity)~* PaCO2 measurement~* Measure SNIP (Sniff nasal inspiratory pressure)~* Measure of Pimax (Pressure inspiratory maximal)~* Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)"
41474393|NCT00919984|DRUG|IP chemotherapy|IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
41474394|NCT03439579|BEHAVIORAL|Home weight loss program|Patient remote self-monitoring of diet, activity, and weight with clinician feedback provided remotely based on self-monitored data.
41474395|NCT06340906|OTHER|Electroacupuncture|EA at 10 standardized acu-points that were chosen for their therapeutic effects: Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6), Shenmen (HT7), Hegu (LI4) bilateral, Zusanli (ST36), Sanyinjiao (SP6), Zhaohai (KI6), Taichong (LR3) bilateral, Tian Shu (ST25) bilateral.
41474396|NCT00933959|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
41474397|NCT00933959|BEHAVIORAL|Sleep Hygiene|Treatment as usual
41317294|NCT05597059|DIAGNOSTIC_TEST|Machine Learning Prediction|Machine Learning Prediction
40800575|NCT03440463|BEHAVIORAL|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
40800576|NCT03440463|BEHAVIORAL|Norms-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare.
40800577|NCT03440463|BEHAVIORAL|Norms-plus-Strategies booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare. These booster emails will also contain reminders of strategies they can use to protect themselves from alcohol-related harm, both ones they've reported using in the past and others they might consider using in the future.
40800578|NCT05231850|DRUG|Tislelizumab|All eligible patients receive received 200 mg Tislelizumab intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
41317295|NCT04908917|DEVICE|Portable Air Cleaner with a HEPA Filter|A novel intervention using a portable air cleaner with HEPA filter to treat mildly high BP to potentially reduce the cardiovascular effects of PM2.5. Leave the PAC running with the HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
41317296|NCT04908917|DEVICE|Portable Air Cleaner without a HEPA Filter|Leave the PAC running without a HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
40800579|NCT01473199|DEVICE|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
40800580|NCT03731104|DEVICE|Near InfraRed Spectroscopy assessment|"Regional Cerebral Oxygen saturation (rScO2 ) values will be collected for all patients during the procedure using a 2-wavelength (730-810 nm) cerebral oxymeter (monitor INVOS 5100C®, Medtronics). Two transducers will be placed on both fronto-parietal sides of the patient's head.~To assess the balance between oxygen delivery and consumption, the Fractional cerebral Tissue Oxygen Extraction (FTOE) will be calculated as this ratio: FTOE=\[SpO2-rScO2\]/SpO2.~Data will be collected for a period of 3 hours starting from the beginning of catecholamine treatment."
40800581|NCT03731104|DEVICE|Transcranial Doppler Ultrasound assessment|"Transcranial Doppler ultrasound will be performed for all patients during the procedure using a VIVID S-5 (General Electric®) echograph. All examinations will be performed by a single trained operator. A 3 MHz probe will be placed on left and right temporal window to detect signal from the middle cerebral artery. 2 measures will be performed for each side to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
40800582|NCT03731104|DEVICE|Cardiac output assessment|"Transthoracic echocardiography will be realized for all patients during the procedure using a transthoracic ultrasound device (VIVID S-5, General Electric®) with a 3 to 6 MHz probe. All examinations will be performed by a single trained operator.~Two echocardiographic views will be examined to assess cardiac output : the two-chamber long-axis view to measure sub-aortic diameter (d), and the four-chamber view to measure the Left ventricular outflow tract velocity time integral (LVOT VTI). Cardiac output (Qc) will then be calculated taking account these parameters and heart rate with this formula : Qc = \[π x d2 x VTI x HR\] / 4 2 measures will be performed to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
41317297|NCT05246176|DEVICE|nephrostomy set|insertion of the nephrostomy set through the skin to obtaining good external drainage of bile in case of malignant obstructive jaundice.
40800583|NCT01042587|OTHER|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
40800584|NCT01042587|OTHER|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
41152184|NCT02195219|OTHER|sling rest and early functional recovery|Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
41152185|NCT00014508|BIOLOGICAL|sargramostim|
41152186|NCT00014508|DRUG|cyclophosphamide|
41152187|NCT00014508|DRUG|cyclosporine|
41152188|NCT00014508|DRUG|fludarabine phosphate|
41317298|NCT02170649|DRUG|BIA 2-093|
41317299|NCT01142609|BEHAVIORAL|eGet|eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
41474398|NCT03050697|DEVICE|HARMONI® Modular Toric Intraocular Lens|Two-component system consisting of a base and a separate toric optic
41474399|NCT03050697|PROCEDURE|Cataract extraction with intraocular lens (IOL) implantation|Cataract removal via manual phacoemulsification, followed by HMTIOL implantation
41474400|NCT05307133|OTHER|Sleeve Gastreextomy|The aim of the present study is to elucidate whether serum levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.
41474401|NCT06616233|DEVICE|Remote Ischaemic Conditioning with exercise|Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm). During the cuff deflation phase, participants will undergo handgrip exercise at 20-30% of their maximal voluntary contraction for 3 minutes. There will be a total of 4 cycles of exercise.
41474402|NCT06616233|DEVICE|Other: Remote Ischaemic Conditioning|Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm).. There will be a total of 4 cycles.
41317300|NCT01413841|DRUG|Nasal oxygen|3 l oxygen
41317301|NCT01413841|DRUG|Regular nasal air|3 l nasal air
41317302|NCT01252342|DRUG|Oxytocin|10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
41317303|NCT01252342|DRUG|Saline|10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
41474403|NCT06094049|OTHER|Preference test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using flour fortified with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food.
41474404|NCT06094049|OTHER|Triangle test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using unfortified flour and fortified-flour with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food and who will be blinded to the flour type.
40800585|NCT01908491|DEVICE|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
40800586|NCT01908491|DEVICE|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15\~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
40800587|NCT02021890|BEHAVIORAL|Dance program|two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
40800588|NCT02021890|BEHAVIORAL|Self-selected physical activity|gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
40800589|NCT01404143|PROCEDURE|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
40800590|NCT01404143|PROCEDURE|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
40800591|NCT05607173|DRUG|Fexinidazole (HOE239)|Route of administration: oral; pharmaceutical form: tablet
40800592|NCT01384565|DRUG|G-CSF+EPO|"Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses)."
41004513|NCT00262067|DRUG|Chemotherapy|"The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle"
41004514|NCT01397175|DEVICE|Biolimus-eluting stent|Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
41152189|NCT00014508|DRUG|melphalan|
41152190|NCT00014508|PROCEDURE|peripheral blood stem cell transplantation|
41317304|NCT02303951|DRUG|Vemurafenib|Run-In: Day 1-21 960 mg bid orally, Day 22-28 720 mg bid orally Triple-Treatment (week 5 ongoing): 720 mg bid orally
41317305|NCT02303951|DRUG|Cobimetinib|Run-In: Day 1-21 60 mg od orally Triple-Treatment (week 5 ongoing): 60 mg od 21/7 orally (3 weeks on drug, 1 week off)
41317306|NCT02303951|DRUG|Atezolizumab|Triple-Treatment (week 5 ongoing): 840 mg Q2W i.v
41317307|NCT06443476|PROCEDURE|Tenting abutment technique|To evaluate a novel method using a designed tenting abutment to reduce number of surgeries and the edentulous healing period is shortened. In addition, to prevent vertical and horizontal collapse of the bone graft and minimizes resorption of the bone graft during the healing the atrophic posterior mandible.
41317308|NCT06443476|PROCEDURE|Tent pole technique|using the Tent pole technique to gain bone vertical and horizontal loss
41317309|NCT02089620|DRUG|Yasmin|will be used every 21 days for three months by the patient
41317310|NCT02089620|DIETARY_SUPPLEMENT|Calver|Calver will be given daily for 3 months
41317311|NCT02089620|DRUG|Placebo 1|Patients will receive a daily placebo similar in size and structure to calvar.
41317312|NCT02089620|DRUG|Placebo 2|Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
41317313|NCT03532672|OTHER|Acute Fasting|The volunteers will fast overnight (10 hours) and breakfast will be offered (bread, butter, ham and industrialized fruit juice). The participants will fast for another 10 hours during daily activities.
41317314|NCT05004142|DRUG|FCN-437c+Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
41317315|NCT05004142|DRUG|FCN-437c+Letrozole+Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
41317316|NCT04829292|BEHAVIORAL|Supportive therapy and CBT|In this open trial participants are first offered supportive therapy followed by CBT
41317317|NCT00654784|DRUG|idebenone|idebenone 450 mg/day (150 mg three times a day)
41317318|NCT00654784|DRUG|placebo|
41317319|NCT00180141|DRUG|Elidel-Creme|
41317320|NCT04307836|DEVICE|Renal Denervation|Renal Denervation: DENEX system
41317321|NCT04215523|DRUG|Dapagliflozin|Dapagliflozin dispensing claim for any dose is exposure
41317322|NCT04215523|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim for any dose is reference
41474405|NCT03261479|DIAGNOSTIC_TEST|Thermal image|We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
41474406|NCT03224247|PROCEDURE|Transverse cutting|Transverse cutting and/or pulling.of lower uterine segment during lower cesarean section extending the uterine incision laterally.
41474407|NCT03224247|PROCEDURE|vertical splitting|vertical splitting of lower uterine segment during lower cesarean section making the direction of traction up and downward instead of being laterally and we suppose that this will allow the tissues to split along their natural arrangement, decreasing the probability of extension of the wound into the uterine vessels, thus; decreasing blood loss; operative time and maternal recovery.
41474408|NCT02675959|DRUG|Defibrotide|defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
41004515|NCT01397175|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
41004516|NCT01397175|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
41004517|NCT06243133|DRUG|clopidogrel for 90 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
41004518|NCT06243133|DRUG|clopidogrel for 30 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
41004519|NCT05373511|OTHER|"3D/4D spine and posture analysis DIERS FORMETRIC 4D ,The Biodex Balance System SD-"|"3D/4D spine and posture analysis DIERS FORMETRIC 4D for postural analysis assessment~,The Biodex Balance System SD- for balance assessment"
41004520|NCT00667238|BEHAVIORAL|Questionnaire|
41004521|NCT05425290|BEHAVIORAL|Single-session emotion regulation training|The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
41004522|NCT04759625|OTHER|Novel biscuit enriched with mushroom powder containing 3g of β-glucans|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
41004523|NCT04759625|OTHER|Placebo biscuit|Daily consumption of placebo biscuit
41004524|NCT06242210|OTHER|pursed lip|pursed lip breathing technique for group A through videos on smart phones and a brochure given to patients. Each session takes 15-20 minutes until researchers ensure that patients understand how to perform exercises and re-demonstrate them. • Each group applied it twice per day for a period of 4 weeks. Telephone follow-up was used for patients in both groups
41317323|NCT03598738|DRUG|Esomeprazole 40mg|Esomeprazole 40mg oral tablet, once a day
41317324|NCT02892565|OTHER|Blood sample|
41317325|NCT05678192|DRUG|oral menopausal hormone therapy|Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg
41317326|NCT05678192|DRUG|transdermal menopausal hormone therapy|Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg
41317327|NCT01578057|DRUG|tasimelteon|20mg, once
40800593|NCT01384565|DRUG|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
40800594|NCT00932438|DEVICE|LC beads loaded with Irinotecan|Chemoembolization using LC beads loaded with 100mg Irinotecan
41317328|NCT01578057|DRUG|Ethanol|0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
41317329|NCT01578057|OTHER|Placebo tasimelteon|once
41317330|NCT01578057|DRUG|Placebo ethanol|A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
41317331|NCT00731848|DIETARY_SUPPLEMENT|pomegranate liquid extract|Pomegranate liquid extract, 8 oz per day, for 52 weeks
41317332|NCT03986775|DIETARY_SUPPLEMENT|isomaltulose|replacement of sucrose with low-glycemic isomaltulose
40800595|NCT00932438|DRUG|Oxaliplatin|Oxaliplatin 85 mg/sqm, IV infusion every two weeks
41317333|NCT03986775|DIETARY_SUPPLEMENT|sucrose|conventional beverage with sucrose
41317334|NCT04543955|DRUG|Telotristat (Low-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 750mg per day (250mg TID) for 20 months.
41317335|NCT04543955|DRUG|Telotristat (High-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 1500mg per day (500mg TID) for 20 months.
41317336|NCT00052884|BIOLOGICAL|filgrastim|
41474409|NCT03182894|DRUG|Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
41474410|NCT02510014|DRUG|SUBOXONE sublingual film|SUBOXONE (buprenorphine sublingual film) is used for induction therapy on Days -14 to -12. Participants then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to starting the Treatment Period.
41474411|NCT02510014|DRUG|RBP-6000|Injections administered subcutaneously every 28 days on alternate sides of participant's abdomen starting at 300 mg. Subsequent doses of RBP-6000 could be adjusted down to 100 mg with the possibility of adjusting back up to 300 mg based on the medical judgment of the investigator. De novo subjects receive up to 12 injections and roll-over subjects receive up to 6 injections.
41474412|NCT01606059|DRUG|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
41474413|NCT01606059|DRUG|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
41474414|NCT05022134|BEHAVIORAL|CHOICE-AYA|Adapted contraceptive counseling specific to AYA experiencing homelessness
41474415|NCT01566019|PROCEDURE|Tumoral biopsy|Every enrolled patient undergoes tumoral biopsy
41474416|NCT04574115|DEVICE|Omega Refractive Capsule with an FDA approved Intraocular Lens|Omega refractive capsule in conjunction with an FDA approved Intraocular Lens
41474417|NCT04574115|DEVICE|FDA approved Intraocular Lens|FDA approved Intraocular Lens
40800596|NCT00932438|DRUG|Leucovorin|Leucovorin 200 mg/sqm, IV infusion every two weeks
41004525|NCT06242210|OTHER|Stacked Breathing|The technique will be administered to the patient under supervision for 10 minutes, and the patient will be instructed to use this trained exercise in his daily routine as per needed
41004526|NCT03900299|PROCEDURE|oncoplastic breast surgery|oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
41004527|NCT02620098|OTHER|Size Matters Handwriting Program|The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
41004528|NCT00643370|OTHER|CT scan of the chest under deep inspiration breath hold|computed tomography scan of the chest under dep inspiration breath hold conditions
41004529|NCT00772551|DRUG|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
41004530|NCT00772551|DRUG|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
41004531|NCT04332328|DIETARY_SUPPLEMENT|Diet|Group of diet types
41152191|NCT03316248|OTHER|visual feedback|in the study group, subjects were applied for example prosthetic weight bearing exercises in front of the mirror. They watched their reflected image while doing exercises.
41317337|NCT00052884|DRUG|amifostine trihydrate|
41317338|NCT00052884|DRUG|melphalan|
41474418|NCT00669981|BEHAVIORAL|Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)|CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.
41474419|NCT06177847|DEVICE|BIS|In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided
41474420|NCT06610461|DEVICE|HFNO-Treatment|The investigated intervention is the application of HFNO throughout a high-risk upper GI-endoscopy. Concentration of oxygen is 100%. Prior to induction, flow rate is set to 20 l/min and increased to 30 l/min if tolerated by the patient. After induction of anesthesia, flow rate is increased to 60 l/min and maintained throughout the anesthesia.
41317339|NCT00052884|PROCEDURE|bone marrow ablation with stem cell support|
41317340|NCT00052884|PROCEDURE|peripheral blood stem cell transplantation|
41317341|NCT05821621|OTHER|no intervention|observational study : there is no intervention
41317342|NCT00743457|DEVICE|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
41474421|NCT06263101|OTHER|Biochemical testing of abdominal drainage fluid|Drainage fluid was collected from patients on the first and third postoperative days to test the levels of three biochemical tests (albumin, lactate dehydrogenase \[LDH\], adenosine deaminase \[ADA\]).
41474422|NCT06263101|OTHER|Cytological examination of abdominal drainage fluid|Cytological examination of abdominal drainage fluid on the first postoperative day and the third postoperative day, calculation of neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), prognostic nutritional index (PNI)
40800597|NCT00932438|DRUG|5-Fluorouracil|5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
41474423|NCT06263101|OTHER|Peripheral blood cytology tests|Peripheral blood cytology tests on the first postoperative day and the third postoperative day, calculation of Neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet lymphocyte ratio (PLR), systemic immunoinflammatory index (SII)
41152192|NCT03316248|OTHER|usual prosthetic rehabilitation|prosthetic weight bearing and balance exercises were applied to the control group for 9 sessions.
41474424|NCT01011075|DRUG|Imatinib mesylate|Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
41004532|NCT01393769|DRUG|Melphalan|The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
41317343|NCT01028833|OTHER|Power mobility|Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
41317344|NCT06552715|DEVICE|Placement of resorbable HAp-based composite|The resorbable HAp-based composite device will be immersed in a saline solution for 15 minutes, allowing it to transition from a rigid state to a flexible and deformable one (Fig. 1). Subsequently, the device will be shaped appropriately on the resin model, ensuring proper placement within the bone defect to be regenerated. Patients will receive antibiotic prophylaxis of 1 g amoxicillin, 1 hour before the procedure (or 300 mg clindamycin in case of penicillin allergy). Before the surgical procedure, patients will rinse with 2% chlorhexidine for one minute to reduce the bacterial load in the oral cavity. For the surgical procedure, under local anesthesia with Articaine and Adrenaline 1:100000, mucoperiosteal flaps will be raised. The pre-shaped resorbable device will then be adapted to the defect and fixed with osteosynthesis screws, used according to clinical practice for this type of intervention. Finally, the flaps will be sutured to ensure primary intention closure.
41317345|NCT00104078|DRUG|MYO-029|
41317346|NCT00001940|DRUG|Voriconazole|
41317347|NCT03722784|DEVICE|Invigor A (test)|silicone hydrogel lens
41317348|NCT03722784|DEVICE|Invigor B (control)|silicone hydrogel lens
41317349|NCT02723292|BEHAVIORAL|TOP|
41317350|NCT02723292|BEHAVIORAL|Control intervention|
41317351|NCT04613102|DRUG|AVCN583601 (3% Cannabidiol cream)|Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).
41317352|NCT02035982|DRUG|Cholinesterase Inhibitor|"For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency."
41317353|NCT02035982|DRUG|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
41317354|NCT01569425|OTHER|Dietary intervention|High Calorie breakfast and high calorie dinner
41317355|NCT01585935|DRUG|SMOFLIPID|target dose: 3g/kg/d
41317356|NCT01585935|DRUG|INTRALIPID|target dose: 3g/kg/d
41317357|NCT01956240|PROCEDURE|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
41317358|NCT01956240|PROCEDURE|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
41317359|NCT04119427|DEVICE|ultrasonic therapeutic apparatus 1|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
41317360|NCT04119427|DEVICE|ultrasonic therapeutic apparatus 2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
41317361|NCT01278017|DRUG|ceftriaxone|ceftriaxone ,parenteral route, 50mg/kg/day divided twice
41317362|NCT00016393|DRUG|ixabepilone|
41317363|NCT02513368|DEVICE|augmentation procedure with Bio-Oss® and Bio-Gide®|soft tissue management using GBR procedure
41474425|NCT01011075|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
41474426|NCT02781935|PROCEDURE|DW-MRI|DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.
41004533|NCT04277091|OTHER|High-intensity interval training|Arm-cranking exercise
41317364|NCT02513368|PROCEDURE|augmentation procedure with connective tissue graft|soft tissue management using the bilaminar technique
40800598|NCT00932438|DRUG|Bevacizumab|Bevacizumab 5 mg/kg given at the discretion of the treating physician
40800599|NCT05451004|OTHER|Lymphatic Mapping with SPECT-CT|Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
41004534|NCT04277091|OTHER|Moderate-intensity continuos training|Arm-cranking exercise
41004535|NCT01650363|OTHER|Acupuncture, homeopathy, osteopathy- and reflexology|a combination of the above mentioned treatments
41004536|NCT01650363|DRUG|Homeopathic placebo medication|2-3 mm small spheric suger pils
40800600|NCT05451004|RADIATION|Ipsilateral and Contralateral Neck|Radiotherapy
40800601|NCT00795444|DRUG|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
40800602|NCT01457664|DRUG|Placebo|Placebo to RO4995819 once daily for 14 days
41317365|NCT06159166|DRUG|Mirdametinib|This study is designed to assess Mirdametinib safety and efficacy in two phases: phase 1 tests the safety of up to four dose regimens of Mirdametinib, administered continuously or intermittently (3 weeks on/1 week off) to identify up to two recommended phase 2 doses. Phase 2a of the study will test the safety and efficacy of the recommended phase 2 dose(s) in adults with NF1 and cNF. The following dosing strategy will be assessed in participants ≥ 18 years old with NF1 and a minimum of 12 measurable cNF who desire systemic treatment of their cNF due to disfigurement, pain or itching. Each treatment cycle in this study is 28 days.treatment cycle in this study is 28 days.
41317366|NCT00240539|PROCEDURE|Blood sampling|A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.
41317367|NCT02930616|DEVICE|Patients in Group 1 will receive pCLE at first and WLE 2 months later|
41317368|NCT02930616|DEVICE|patients in Group 2 will receive WLE at first and pCLE 2 months later.|
41317369|NCT05197478|OTHER|Mini Nutritional Assessment ,Pıtsburg Sleep Qualıty Scale, Short Physical Activity Survey|"To evaluate the lifestyle before being infected with COVID 19, physical activity, nutrition and sleep habits were questioned.~To evaluate sleep habits; Pitsburg Sleep Quality Scale (PSQS) Nutritional habits: Mini Nutritional Assessment(MNA) Scale For the evaluation of physical activity; International Brief Physical Activity Questionnaire"
41317370|NCT01679093|DRUG|ondansetron|ondansetron: 4 mg intravenous administration afer the induction of anesthesia.
41474427|NCT04083352|DIETARY_SUPPLEMENT|Pruvit Ketomax Ketone Salt|6-week supplementation with ketone salts
41004537|NCT05111366|DRUG|TQB2450 injection|TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
41004538|NCT05111366|DRUG|Anlotinib hydrochloride capsules|Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.
41004539|NCT02453295|BEHAVIORAL|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
41004540|NCT01018459|BIOLOGICAL|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.
41004541|NCT01018459|DRUG|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
41004542|NCT04099667|DRUG|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
41004543|NCT04099667|DRUG|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
41004544|NCT04099667|DRUG|Phase 2; Placebo|Intramuscular injections on Day 1
41004545|NCT04099667|DRUG|Phase 3; MYOBLOC|Intramuscular injections on Day 1
41004546|NCT04099667|DRUG|Phase 3; Placebo|Intramuscular injections on Day 1
41004547|NCT01147991|BIOLOGICAL|EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|
41004548|NCT01147991|OTHER|laboratory biomarker analysis|
41474428|NCT04083352|DIETARY_SUPPLEMENT|Placebo|Placebo was taken for 6-weeks and was calorie and flavor matched to the ketone salt supplement.
41474429|NCT03534193|OTHER|Molly Center Diabetes Care Guide (Paper-based)|Diabetes education with Registered Nurse in addition to Paper based education modules
41474430|NCT03534193|OTHER|Tablet based interactive diabetes education modules|Molly Center Standard Diabetes Education plus access to interactive diabetes education modules through bedside tablet.
41004549|NCT01147991|OTHER|pharmacological study|
41004550|NCT01828034|DRUG|Gemcitabine|
41004551|NCT01828034|DRUG|Cisplatin|
41004552|NCT01828034|DRUG|MEK162|
41004553|NCT00614796|BEHAVIORAL|Coach, using a stepcounter with exercise counseling|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
41004554|NCT00028756|DRUG|doxorubicin hydrochloride|Given IV
41004555|NCT00028756|DRUG|gemcitabine hydrochloride|Given IV
41004556|NCT00028756|DRUG|vinblastine sulfate|Given IV
41004557|NCT00028756|DRUG|methotrexate|Given IV
41004558|NCT00028756|DRUG|cisplatin|Given IV
41004559|NCT00028756|BIOLOGICAL|filgrastim|Given SC
41004560|NCT03069625|BEHAVIORAL|Sit-to-stand test|CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
41004561|NCT03069625|BEHAVIORAL|6-Minute Walk Test|CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
41004562|NCT05625763|DIAGNOSTIC_TEST|sonoclot signature analysis|Investigate the value of global hemostasis studies (Sonoclot signature analysis) in cases of pre-eclampsia and if there a correlation between it and the specific traditional assays of hemostasis.
41004563|NCT03411473|BIOLOGICAL|AGEN1884 in combination with pembrolizumab|AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations
41004564|NCT02903667|DEVICE|Bone grafting|
41152193|NCT02312609|DRUG|Minocycline hydrochloride|extended release tablets 135 mg
41004565|NCT02239250|DEVICE|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
41004566|NCT03890679|DIAGNOSTIC_TEST|rapid whole genomic sequencing (rWGS)|rWGS and NewbornDx are genomic sequencing platforms
41004567|NCT02788734|OTHER|Web-based survey|This study protocol consists of one anonymous survey. Each participant can complete only one survey. The survey will take approximately 25 minutes to complete. The survey is designed to identify items that best reflect the symptom severity and functional status in patients with CTS and CMT. A unique link to the survey will be included in an email invitation distributed to all adult CMT or HNPP patients self-registered in the RDCRN INC Contact Registry. Upon clicking the link, the participant will be directed to the IRB-approved online consent form. Upon providing consent, the participant will be directed to the online survey.
41317371|NCT01679093|DRUG|Droperidol|droperidol: 1.25 mg intravenous administration after the induction of anesthesia.
41317372|NCT01679093|DRUG|Dexamethasone|dexametasone: 4 mg intravenous administration after the induction of anesthesia.
41317373|NCT00844649|DRUG|Albumin-bound paclitaxel (ABI-007)|ABI-007 125 mg/m\^2 administered by intravenous infusion
41317374|NCT00844649|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
41317375|NCT06553183|PROCEDURE|immersive virtual reality|Exercise based on virtual reality video games. Immersive type will be used.
41317376|NCT06553183|PROCEDURE|traditional physicaltherapy|pneumatic compression, exercise and skin care
41317377|NCT03716986|DIAGNOSTIC_TEST|MRI Oxygen Saturation Map|Calculation of the oxygen saturation map of gliomas cases
41474431|NCT05619159|DEVICE|microscopic pathological evaluation|description of moesin expression between endometrial hyperplasia and endometrial carcinoma
41474432|NCT04918160|OTHER|Exposure to the FICS annual meeting (June 9-11 2021, Paris Congress Center)|The study will compare COVID-19 screening nasal antigenic self-test (Boiron Auto Test Covid Nasal) positivity at D7 and COVID-19 symptoms in the 21 days between participants to the FICS annual meeting held in June 9-11 2021 in the Paris Congress Center (conference attendees / exposed) and healthcare professionals who did not attend the meeting (controls / not exposed).
41474433|NCT05015374|DIETARY_SUPPLEMENT|Astaxanthin|350 mg/capsule (2mg Astaxanthin)
41474434|NCT05015374|DIETARY_SUPPLEMENT|Placebo|Placebo
41474435|NCT03994367|OTHER|High animal protein isolate|Increased dietary protein content from animal protein isolates
41004568|NCT04685564|DRUG|RBD1016|"Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission."
41004569|NCT04685564|DRUG|Placebo|the same as RBD1016
41004570|NCT05488899|DIAGNOSTIC_TEST|Half iodine Spectral CT|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 keV.
41317378|NCT02808312|DRUG|Cilofexor|Tablet(s) administered orally in a fed state on Day 1
41317379|NCT02525419|BEHAVIORAL|Weight Loss Phase|High Protein, Intermittent Fast, Low Calorie Diet
41317380|NCT02525419|BEHAVIORAL|HP-IF|High Protein, Intermittent Fast
41474436|NCT03994367|OTHER|High animal protein whole food|Increased dietary protein content from animal protein whole food
41474437|NCT03994367|OTHER|High plant protein isolate|Increased dietary protein content from plant protein isolates
41474438|NCT03994367|OTHER|High plant protein whole food|Increased dietary protein content from animal protein whole food
41474439|NCT01865929|DEVICE|Robotic hysterectomy|Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
41474440|NCT01865929|PROCEDURE|Vaginal or laparoscopic hysterectomy|Benign hysterectomy performed by traditional minimal invasive procedures.
41474441|NCT03020719|DRUG|Oral Glutathione|Oral Glutathione oral powder
41317381|NCT02525419|BEHAVIORAL|HH|Heart Healthy
41317382|NCT02679209|BIOLOGICAL|Demineralized bone matrix in putty form|it is a type of bone graft from human cadavers.
41317383|NCT02679209|BIOLOGICAL|Amnion chorion membrane|A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
41317384|NCT02395497|BIOLOGICAL|Monoclonal Antibody (Humanized Anti-CD52)|
41317385|NCT02395497|DRUG|Tacrolimus|
41317386|NCT02395497|PROCEDURE|Penile Allotransplantation|
41317387|NCT05672966|BIOLOGICAL|Human papillomavirus (HPV) Vaccine|0.5mL, Intramuscular
41317388|NCT05672966|BIOLOGICAL|Placebo|0.5mL, Intramuscular
41474442|NCT03020719|DRUG|Placebo|Placebo oral powder
41004571|NCT05488899|DIAGNOSTIC_TEST|Standard iodine conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kv Polychromatic CT acquisition.
41317389|NCT04381663|PROCEDURE|conservative treatment|conservative treatment for patients with cervical spine stenosis without myelopathy
41317390|NCT04381663|PROCEDURE|surgical treatment|surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy
41317391|NCT06396663|OTHER|Rapid Opioid de-escalation|"Option 1: 10% - 50% decrease/day until opioids discontinued (≤ 10 days). For Fentanyl patches in decrements of 12 mcg/hr.~Option 2: Stop all opioid medication completely"
41317392|NCT06396663|OTHER|Gradual Opioid de-escalation|Option 1: 20% - 50% decrease/weekly until opioids discontinued Option 2: 10% - 20% decrease/weekly until 30 mg daily. Then reduce by 5% - 10% everyday.
41317393|NCT06396663|OTHER|Continuation of opioids|Continue on opioids and review in 1 weeks time.
41317394|NCT01274741|BEHAVIORAL|Creating Change (CC)|Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format. The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
41317395|NCT01274741|BEHAVIORAL|Seeking Safety (SS)|Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD. It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders. In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
41317396|NCT02208024|RADIATION|Stereotactic Body Radiation Therapy|
41474443|NCT05386524|DRUG|sintilimab|sintilimab 200mg, ivgtt，d1
41004572|NCT04334499|OTHER|Sample collection from tissue discard|Collection of vitreous humor tissue and venous blood from subjects undergoing ocular surgery that may provide vitreous humor discarded tissue.
41004573|NCT01280773|DEVICE|NAVA|Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
41004574|NCT02558998|OTHER|Survey|
41317397|NCT02025491|DRUG|Liposomal Amphotericin B|Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
41317398|NCT05454202|DEVICE|ANI|Pain measurement during care procedures in palliative care
41474444|NCT05386524|DRUG|bevacizumab biosimilar|bevacizumab biosimilar 15mg/kg，ivgtt d1
41474445|NCT05386524|DRUG|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 30mg/m2 d1，q3w
41004575|NCT04334642|OTHER|A mindfulness based intervention|It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
41004576|NCT02635464|BIOLOGICAL|hUC-MSCs+Injectable collagen scaffold+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
41317399|NCT04427436|OTHER|No Intervention|No Intervention
40800603|NCT01457664|DRUG|RO4995819|RO4995819 doses once daily for 14 days
41317400|NCT00789269|DRUG|rhubarb|14 days of rhubarb
41317401|NCT00789269|DRUG|placebo|14 days of placebo
41317402|NCT05071729|DRUG|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant on Day 1.
41317403|NCT01478438|DEVICE|Novilase Interstitial Laser Therapy|Image guided Interstitial Laser Ablation of breast tumors
41317404|NCT02863939|DEVICE|Single photon emission computed tomography myocardial perfusion imaging|a novel cadmium-zinc-telluride (CZT) SPECT camera
41317405|NCT02863939|OTHER|exercise|
41317406|NCT05824637|DEVICE|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
41317407|NCT05824637|DIAGNOSTIC_TEST|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
41317408|NCT01740388|DRUG|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
41317409|NCT01740388|DRUG|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
41474446|NCT00112294|DRUG|Paclitaxel (Taxane)|IV, 225 mg/m\^2
41474447|NCT00112294|DRUG|Docetaxel (Taxane)|IV, 75 mg/m\^2
41474448|NCT00112294|DRUG|Carboplatin|AUC=6, q 3 weeks (6 cycles maximum)
41474449|NCT00112294|DRUG|Cetuximab|Intravenous, 400 mg/m\^2, initial dose followed by 250 mg/m\^2, weekly starting on Week 2
41474450|NCT00987142|DRUG|CX501|Cultured chimeric skin
41474451|NCT00987142|DEVICE|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
41317410|NCT06467708|DEVICE|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS).
41317411|NCT00275925|DRUG|Oxcarbazepine|
41317412|NCT00039195|BIOLOGICAL|filgrastim|
41317413|NCT00039195|BIOLOGICAL|rituximab|
41317414|NCT00039195|DRUG|carboplatin|
41317415|NCT00039195|DRUG|cyclophosphamide|
41317416|NCT00039195|DRUG|doxorubicin hydrochloride|
41317417|NCT00039195|DRUG|etoposide|
41317418|NCT00039195|DRUG|ifosfamide|
41317419|NCT00039195|DRUG|prednisone|
41317420|NCT00039195|DRUG|vincristine sulfate|
41317421|NCT00039195|PROCEDURE|peripheral blood stem cell transplantation|
41004577|NCT02635464|BIOLOGICAL|hUC-MSCs+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
41474452|NCT01052324|DRUG|Remifentanil|After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5\~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
41474453|NCT02284347|DEVICE|Electromagnetic Sinus Dilation System (NuVent™)|NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
41474454|NCT01980160|DEVICE|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
40800604|NCT03493672|DIAGNOSTIC_TEST|Objective measurement of physical activity and fitness|Physical activity and fitness will be assessed objectively with a smartphone
41004578|NCT02635464|PROCEDURE|CABG|Patients underwent CABG alone.
41004579|NCT00684853|DRUG|bevacizumab|1.25 mg of bevacizumab intravitreal
41004580|NCT00684853|DRUG|vetaporfin|full fluence of vetaporfin
41004581|NCT04436523|DEVICE|Blood flow restriction (Delfi Personalized Tourniquet System)|The Delfi Personalized Tourniquet System will be utilized to apply the blood flow restriction protocol.
41317422|NCT00039195|RADIATION|radiation therapy|
41317423|NCT04248790|BEHAVIORAL|mobile app to improve adherence to PrEP self-management|Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.
41341775|NCT05923151|PROCEDURE|The cranial-caudal mixed medial approach|"Expose the fusion fascia of Transverse colon mesocolon and stomach, and cut the gastrocolic ligament. The mesentery of Transverse colon was dissociated from the medial side to the lateral side along the gastroepiploic vessels to expose the branches of Henle's trunk and the right colon vessels. The dorsal mesentery of the small intestine is cut along the yellow white line, and free cephalically along the Toldt space to separate the posterior space of the Ascending colon and the anterior space of the pancreas and duodenum behind the Transverse colon. The right colon blood vessels were dissected along SMV from the projection of ileocolic blood vessels, and the blood vessels were cut off by high ligation, and the lymph nodes at the root of Mesentery were cleared. Through a small incision in the middle of the abdomen, the right colon and mesentery were completely removed to complete digestive tract reconstruction."
41341776|NCT01279967|DRUG|ADI-PEG 20|36.8mg/m2 based on BSA, weekly treatment for 6 months
41341777|NCT05645276|DRUG|AK129 IV infusion|AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
41341778|NCT02111707|DRUG|Rectal indomethacin 100mg one time before or after ERCP|Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
41341779|NCT00257868|DRUG|Rivastigmine prevention of delirium|
41474455|NCT01980160|DEVICE|Unactivated Nometex Device|
41474456|NCT04351841|OTHER|arabinogalactan|A beverage will be prepared by thoroughly mixing the 15 g of arabinogalactan with water and Crystal Light flavoring
41474457|NCT04351841|OTHER|maltodextrin|A beverage will be prepared by thoroughly mixing the 15 g of maltodextrin with water and Crystal Light flavoring
41474458|NCT01037582|DRUG|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
41341780|NCT01942304|PROCEDURE|Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation|
41474459|NCT01037582|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
41474460|NCT01037582|DRUG|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
40800605|NCT03045614|OTHER|No intervention|No intervention
40800606|NCT06422221|DRUG|Clindamycin|Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation
41004582|NCT04436523|OTHER|Standard rehabilitation|Post-operative physical therapy as guided by a standardized protocol for patients undergoing meniscus repair.
41341781|NCT01942304|PROCEDURE|Anorganic bovine bone mineral in direct sinus augmentation|
41341782|NCT01261494|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
41341783|NCT01261494|DRUG|Placebo|hard gelatin capsules,oral administration,4 capsules per day before breakfast
41474461|NCT01037582|DRUG|placebo|Subjects will be randomized to receive a single dose of placebo.
41474462|NCT01037582|DRUG|NN9924 (s.c.)|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
41474463|NCT01037582|DRUG|NN9924 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
41474464|NCT03993327|BIOLOGICAL|Iodine I 124 Monoclonal Antibody M5A|Given IV
41474465|NCT03993327|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41474466|NCT04671537|DRUG|Preloading with crystalloid fluid|crystalloid fluid at 10 ml/kg of ideal body weight was administered intravenously in 30 min before the BCP for patients
41474467|NCT00911755|PROCEDURE|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
41474468|NCT00911755|PROCEDURE|Endotracheal Intubation|
41004583|NCT02613533|OTHER|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
41004584|NCT01679275|OTHER|measuring cerebral oxygenation|
41152194|NCT04743453|DRUG|Dapagliflozin|Dapagliflozin 10 mg: Study drug will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
41152195|NCT04743453|DRUG|Placebo|Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
40800607|NCT06422221|DRUG|Doxycycline|Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
41152196|NCT00557154|DEVICE|ultrasound|ultrasound used to identify target vein
41152197|NCT00557154|DEVICE|standard technique for venipuncture|routine equipment
41152198|NCT06585345|BIOLOGICAL|CD7 CAR-T cell|Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (1-100)x10\^6 CD7 CAR-T cells/kg\]
41152199|NCT05569265|PROCEDURE|Intraoperative hemodynamic management|Goal directed Hemodynamic therapy
41152200|NCT05844150|DRUG|PM8002|IV infusion
41152201|NCT05844150|DRUG|Platinum|IV infusion
41152202|NCT05844150|DRUG|Atezolizumab|IV infusion
41152203|NCT05844150|DRUG|Etoposide|IV infusion
41152204|NCT03992599|PROCEDURE|Laparoscopic modified complete mesocolic excision|First, complete kocherization may be required to clear possible tumor spread if the tumor is infiltrating or adhering to the duodenum or perinephric fat tissue. Second, if the tumor is locally advanced, the entire prerenal soft tissue behind Gerota's fascia may need to be cleared, especially for tumors growing toward the posterior. The third difference of mCME with the conventional CME involves the tailored resection of the mesocolon and ileal mesentery according to tumor location. After identifying the root of the middle colic artery, the site of the vascular ligation depends on the location of the tumor. When the tumor is located in the cecum and ascending colon, only the right branch of the middle colic artery is ligated. If the tumor was present in these latter sites, the root of the middle colic artery is ligated.
41152205|NCT04825210|BEHAVIORAL|Integrated Behavioral Health - Prevention|IBH-P consists of 15-30 minute visits with mothers as part of the 1, 2, 4, and 6 month well-child visits. The intervention is delivered by doctoral level pediatric psychologists that are an integrated member of the primary care team.
41152206|NCT04825210|BEHAVIORAL|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|Bright Futures curriculum will be delivered by the pediatrician as part of the 1, 2, 4 and 6 month well-child visits.
41152207|NCT00329771|OTHER|No intervention: We are testing for the presence of allodynia|We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
41152208|NCT02599077|DRUG|Dienogest|patients assigned to this treatment receive 2 milligrams per day
41152209|NCT02599077|DRUG|Levonorgestrel|patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
41152210|NCT04655014|OTHER|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
41152211|NCT01595724|DRUG|Visanne (Dienogest, BAY86-5258)|Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
41152212|NCT02395406|DEVICE|Orotracheal intubation with Totaltrack|
41152213|NCT02395406|DEVICE|Orotracheal intubation with Airtraq|
41152214|NCT02278822|OTHER|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
41152215|NCT02278822|OTHER|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
41152216|NCT04891263|PROCEDURE|Suture-Septoplasty|Patients receive suture-septoplasty for repair of nasal septal deviation.
41152217|NCT04891263|DEVICE|Surgical suture|Suture used for closure during septoplasty surgery.
41317424|NCT05845918|BEHAVIORAL|PRISEM CEP|Participants in PRISEM CEP will undergo assessment and goal setting during the intake process to ensure that the program meets their needs. All participants partake in lifestyle programs in individual or group-based in-person activities that address cognitive, physical, social, and functional independence, education, and well-being goals.
41317425|NCT05845918|BEHAVIORAL|PRISEM Remote|"Participants will attend 1-hour sessions weekly for 12 weeks (12 sessions) then biweekly for 8 weeks (4 sessions) and 1 session in the last month (1 session). Sessions will be group-based and will cover the following topics: 1) Program Overview, 2) Get Active, 3)Track Activity, 4) Eating Well, 5) Track Food, 6) Get More Active, 7) Energy In, Energy Out, 8) Eating to Support Health Goals, 9) Manage Stress, 10) Eat Well Away From Home, 11) Managing Triggers, 12) How to Stay Active, 13) Take Charge of Thoughts, 14) Get Back on Track, 15) Get Support (from friends and family), and 16) Staying Motivated. Sessions will include a brief presentation of the topic, followed by an introduction to tools and strategies to practice. This is a facilitated program with participants driving the direction and acting as peer support to one another."
41317426|NCT02043405|BEHAVIORAL|Weight loss and exercise training intervention|Combined weight loss and exercise training intervention
41317427|NCT02043405|BEHAVIORAL|Weight loss Only Intervention|Weight loss Only Intervention
41317428|NCT05462613|OTHER|quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
41317429|NCT05462613|PROCEDURE|Blood sample|Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
41317430|NCT05462613|DRUG|Regorafenib|"- Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
41317431|NCT05462613|DRUG|Metronomic chemotherapies|"* Capecitabine: 625mg/m²/orally twice daily continuously during the first two months~* Cyclophosphamide: 50 mg per os, daily, for two months"
41317432|NCT05462613|DRUG|Aspirin|75 mg orally and daily during two months
41317433|NCT05462613|DRUG|Bevacizumab|5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
41317434|NCT05462613|DRUG|FOLFIRI or FOLFOX|every 2 weeks according to investigator practice
41317435|NCT00135486|BIOLOGICAL|MenC-TT|
41474469|NCT06615700|DRUG|NA-931|NA-931 is a quadruple receptor agonist for weight loss
41474470|NCT06615700|DRUG|Placebo|Placebo of NA-931
41474471|NCT06403072|DIAGNOSTIC_TEST|The Gynecologic Imaging-Reporting and Data System (GI-RADS)|The Gynecologic Imaging-Reporting and Data System (GI-RADS) using ultrasound
41474472|NCT04660955|OTHER|No Intervention - Observational study with MRI|90 minute MRI of the knees
41474473|NCT00007761|BEHAVIORAL|Bipolar Disorder Program|
41004585|NCT05596760|BEHAVIORAL|Jumpstart Guide|The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families in the outpatient setting. The intervention's goal is to prompt clinicians to provide, during a scheduled (non-urgent) clinic visit, standard of care which includes a discussion with patients (and/or their LNOKs) about their goals of care. It is designed to promote and guide these discussions for older adults with memory problems through suggestions and tips on the Jumpstart Guide.
41004586|NCT05207020|DEVICE|Glycemia estimated by exhaled air analyzer|Measurement of volatile compounds in the air exhaled by the volunteer on 3 different MIBs (3 breaths in total) at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
41474474|NCT00007761|BEHAVIORAL|Usual (psychiatric) Care|
41474475|NCT01704937|DRUG|Fecal Microbiota Transplant (FMT)|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube"
41474476|NCT05904249|OTHER|Internet Based Synchronized Telerehabilitation|"Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching"
41474477|NCT05904249|OTHER|Face-to-Face Rehabilitation|"Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching"
40800608|NCT01765036|DRUG|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
41004587|NCT05207020|BEHAVIORAL|Questionnaire|The questionnaire focuses on the methods and feelings of the blood glucose self-monitoring that he is currently carrying out, a first feedback on user experience on the operation of the prototype and the collection of his expectations for a future commercial device
41317436|NCT00135486|BIOLOGICAL|Hib-MenC-TT|
41317437|NCT05753098|DRUG|estrogen therapy|oral estradiol valerate
41317438|NCT05753098|DRUG|Sildenafil|PDE5 inhibitor
41317439|NCT05753098|DRUG|Clomiphene Citrate 50mg|used for ovulation induction
41317440|NCT06190405|DIAGNOSTIC_TEST|Hemoglobin A1c|Patients with a HbA1c \<5.7% will be considered a normal test, and they will continue their routine prenatal care, including GDM screening at 24-28 weeks. Patients with a HbA1c ≥5.7% and ≤6.4% will be diagnosed with early GDM. Patients with a HbA1c ≥6.5% will be diagnosed with pregestational diabetes. Patient diagnosed with early GDM or pregestational diabetes will be treated as per usual clinical protocol for gestational/pregestational diabetes.
41317441|NCT06190405|DIAGNOSTIC_TEST|Risk-based screening by ACOG with two-step GTT|Patients will be assessed for risk factors for GDM as per ACOG. Patients with a negative screen will continue routine care, including GDM screening at 24-28 weeks. Patients with a positive screen will undergo a two-step GTT screening. Patients with a 1-h GTT \<135 mg/dL will continue with routine care, including GDM screening at 24-28 weeks. Patients with a 1-h GTT ≥185 mg/dL and \<200 mg/dL will be diagnosed with early GDM. Patients with a 1-h GTT ≥200 mg/dL will be diagnosed with pregestational DM. Patients with a 1-h GTT ≥135 mg/dL and \<185 mg/dL will undergo a fasting 3-h GTT. Patient will be diagnosed with early GDM by Carpenter and Coustan criteria. Patients will be diagnosed with pregestational DM if their fasting glucose value is ≥126 mg/dL. If patients pass the 3-h GTT, they will continue routine care, including GDM screen at 24-28 weeks with a 3-h GTT. Patient diagnosed with early GDM/pregestational DM will be treated as per usual clinical protocol for GDM/pregestational DM.
41474478|NCT06522269|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
41474479|NCT06522269|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
41474480|NCT02592772|OTHER|Reduced Nicotine Non-Menthol (RNC)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.
41474481|NCT02592772|OTHER|Reduced Nicotine Menthol (RNC-Men)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.
41317442|NCT05847244|DRUG|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner)
41474482|NCT02592772|OTHER|Conventional Nicotine Non-Menthol (CN)|Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
41474483|NCT05068960|DRUG|Liposomal bupivacaine|Addition of liposomal bupivacaine to the interscalene block for extended pain control following total shoulder arthroplasty
41474484|NCT05068960|DRUG|Bupivacaine|Interscalene block with bupivacaine for pain control following total shoulder arthroplasty
41474485|NCT01396421|DRUG|OPC-34712 [Brexpiprazole] High Dose|Higher dose, tablet, once daily, for six weeks
41152218|NCT04299698|BEHAVIORAL|lifestyle|Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.
41317443|NCT03741296|PROCEDURE|Single stage revision|One-stage exchange hip joint replacement surgery
41317444|NCT03741296|PROCEDURE|Two-stage revision|Two-stage exchange hip joint replacement surgery
41474486|NCT01396421|DRUG|Experimental: OPC-34712 [Brexpiprazole] Middle Dose|Middle dose, tablet, once daily, for six weeks
41474487|NCT01396421|DRUG|Experimental: OPC-34712 [Brexpiprazole] Low Dose|Lower dose, tablet, once daily, for six weeks
41474488|NCT01396421|DRUG|Placebo|Placebo, once daily, for six weeks
41474489|NCT05380323|DRUG|LY3541105|Administered SC.
41474490|NCT05380323|DRUG|Placebo|Administered SC.
41474491|NCT00072072|DRUG|celecoxib|
41004588|NCT05207020|BIOLOGICAL|Veinous glycemia|Measurement of the veinous glycemia at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
41004589|NCT05207020|BIOLOGICAL|Capillary glycemia|7-step capillary glycemia measurement: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
41152219|NCT03059056|DRUG|Empagliflozin 25mg|Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
41474492|NCT00072072|DRUG|erlotinib hydrochloride|
41474493|NCT01245036|DRUG|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.\<50 kg and 600 mg/day if wt. \>50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
41474494|NCT00004294|GENETIC|human glucocerebrosidase gene into autologous peripheral blood stem cells|
41474495|NCT00303667|BIOLOGICAL|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
41474496|NCT00303667|BIOLOGICAL|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10\^7 cells/kg.
41474497|NCT00303667|DRUG|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
41474498|NCT00303667|DRUG|fludarabine phosphate|Administered intravenously (IV) 40 mg/m\^2 on Days -18 through -14
41004590|NCT05207020|BIOLOGICAL|constitution biological collection|Sampling for storage of serum at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
41152220|NCT06585280|OTHER|No intervention|No intervention
41152221|NCT03991325|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
41152222|NCT02762500|DRUG|LYC-30937-EC|
41152223|NCT02762500|DRUG|Placebo|
41004591|NCT05207020|BIOLOGICAL|Blood sample|Single blood sample before mealtimes for HbA1C molecular analysis
41474499|NCT00303667|PROCEDURE|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
41317445|NCT04733846|OTHER|data collection|Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma
41317446|NCT03832153|PROCEDURE|thrombus aspiration|Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
41317447|NCT04197986|DRUG|Infigratinib|Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
41004592|NCT05207020|OTHER|Test meal|taking a test meal before the various blood sugar measurements
41317448|NCT04197986|DRUG|Placebo|Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
41317449|NCT04094766|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
41317450|NCT02070406|DRUG|cyclophosphamide|Given IV
41474500|NCT00303667|RADIATION|total body irradiation|Administered on Day -13, 200 cGy two times.
41004593|NCT04787939|BEHAVIORAL|Early Feeding|Subjects will be permitted to drink liquids by mouth on the first day after surgery. Outcomes related to their care, wound healing, and quality of life will be followed for 30 days after surgery.
40800609|NCT05753254|OTHER|Firefighting training exercises with no fire|The participants will be performing firefighting equivalent work in a clean environment, without fire (no ambient temperature, soot or smoke).
40800610|NCT05753254|OTHER|Firefighting training exercises under wood fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under wood fire conditions.
40800611|NCT05753254|OTHER|Firefighting training exercises under gas fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under gas fire conditions.
40800612|NCT00742131|DRUG|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.
41004594|NCT00783042|DRUG|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
41004595|NCT00783042|DRUG|Placebo|Tablet, oral, once daily for 1 month (double blind)
41004596|NCT02499393|DRUG|Magnesium Sulfate|intravenous infusion of magnesium sulphate
41004597|NCT04512274|DEVICE|Test Article|Omeza Collagen Matrix
41004598|NCT00500370|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
41004599|NCT00500370|DRUG|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
41004600|NCT02915029|OTHER|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
41317451|NCT02070406|DRUG|fludarabine phosphate|Given IV
41317452|NCT02070406|BIOLOGICAL|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV
41474501|NCT00303667|BIOLOGICAL|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
41474502|NCT00303667|DRUG|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
41474503|NCT00303667|DRUG|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
41474504|NCT00303667|DRUG|fludarabine phosphate|Administered intravenously (IV) 35 mg/m\^2 on Days -18 through -14
41317453|NCT02070406|BIOLOGICAL|dendritic cell vaccine therapy|NY-ESO-1157-165 peptide pulsed DC vaccine given ID
41317454|NCT02070406|BIOLOGICAL|aldesleukin|Given SC
41317455|NCT02070406|RADIATION|fludeoxyglucose F 18|Correlative studies
41317456|NCT02070406|PROCEDURE|positron emission tomography|Correlative studies
41474505|NCT05227131|DRUG|Margetuximab|Margetuximab (15 mg/kg) will be administrated by intravenous infusion on Day 1 of each cycle.
41474506|NCT05227131|DRUG|Tucatinib|Tucatinib (300 mg) will be administrated orally twice daily (every 12 hours) continuously in 21-day cycles.
41474507|NCT05227131|DRUG|Capecitabine|Capecitabine (1000 mg per square meter of body-surface area) will be administrated orally twice daily on days 1 to 14 of each 21-day cycle
41317457|NCT02070406|OTHER|laboratory biomarker analysis|Correlative studies
41317458|NCT02623595|RADIATION|Stereotactic body radiotherapy|A type of radiation therapy
41474508|NCT04257214|BEHAVIORAL|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
41317459|NCT02623595|DRUG|rhGM-CSF|Immune modulating agents
41317460|NCT03170583|DEVICE|St. Jude Medical Tendril MRI™ lead|pacemaker, leads
41474509|NCT03099629|BEHAVIORAL|inspiratory muscle training|inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
41317461|NCT06262893|PROCEDURE|Shoulder arthroscopy blocks|Effect of dexamethasone adjuvant in combined supraclavicular block and suprascapular block versus Interscalene block in patients undergoing shoulder arthroscopy.
41317462|NCT04081376|DRUG|Hydromorphone Hydrochloride|4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
41317463|NCT06195826|PROCEDURE|Gravity infusion|hysteroscopic myomectomy with the gravity infusion method
41317464|NCT06195826|PROCEDURE|Pump infusion|hysteroscopic myomectomy with the pump infusion method
41317465|NCT02598518|BEHAVIORAL|Integrating Combined Therapies|Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
41474510|NCT01449045|DRUG|IPTc+CCM|Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
41474511|NCT01449045|DRUG|Community Case Management with artemether-lumefantrine (AL)|Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
40800613|NCT00729911|PROCEDURE|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
40800614|NCT00729911|DRUG|Amiodarone|Taken orally on a daily basis.
40800615|NCT05371834|DEVICE|Microwave Treatment (Swift System)|"Localized microwave energy applied to the wart lesion. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).~For common warts (usually hands, elbow, knees): Treatment starts at 6W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeated on the same wart as is tolerable (3-5 repetitions).~For plantar warts: Treatment starts at 8W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeat on the same wart as is tolerable (3-5 repetitions).~Less power for a longer time will result in a more gradual temperature rise. Higher power for a shorter time will result in a more immediate temperature rise."
40800616|NCT05371834|DEVICE|Cryotherapy|Local application of Cryotherapy. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).
40800617|NCT02015949|DRUG|Methylphenidate|Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
41317466|NCT02598518|BEHAVIORAL|Standard Care|Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
41317467|NCT00946569|DRUG|JNJ39758979|Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
41317468|NCT00946569|DRUG|Placebo|Participants will receive matching placebo once daily orally for 12 weeks.
41317469|NCT04580823|DIETARY_SUPPLEMENT|Fasting with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan.
41317470|NCT04580823|DIETARY_SUPPLEMENT|Post-Prandial with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan and they will have a liquid meal 20 minutes before the scan.
41317471|NCT02446353|DRUG|Apetrol ES / Megace|Sequences of administered drugs
41317472|NCT03001583|BEHAVIORAL|Education program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
41317473|NCT03001583|BEHAVIORAL|Education program WITHOUT cooking lessons|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
41317474|NCT06485986|OTHER|DBS on/off|DBS will be turned on and off for experimental periods to compare the effect of DBS on behaviour.
41317475|NCT04341012|DIAGNOSTIC_TEST|Collection of breath sample|Analysis of volatile organic compounds in breath
41317476|NCT00383214|DRUG|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
41317477|NCT00383214|OTHER|Placebo|Intravenous
41317478|NCT03886025|OTHER|Anodal transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
41317479|NCT03886025|BEHAVIORAL|Cognitive training|Iowa Gambling Task will be used for cognitive training
41317480|NCT03886025|OTHER|Sham transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
41474512|NCT00279539|GENETIC|Vascular Endothelial Growth Factor (VEGF1)|
41474513|NCT04909541|OTHER|CEGSSS-Canadian Endourology Group Stent Symptom Score|Patient with ureteral stent complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
41317481|NCT01206452|DRUG|Prednisone|60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
41317482|NCT01206452|OTHER|Placebo|60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
41004601|NCT04516265|PROCEDURE|neurodevelopmental treatment|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
41004602|NCT04516265|PROCEDURE|video-based trunk training|Games developed for the use of children with cerebral palsy will be used for trunk training.
41317483|NCT01206452|PROCEDURE|Ablation Procedure|Atrial Fibrillation (AF) ablation
41317484|NCT04156828|DRUG|Copanlisib|Given IV
41317485|NCT04156828|DRUG|Gemcitabine|Given IV
41317486|NCT04156828|DRUG|Carboplatin|Given IV
41317487|NCT04156828|DRUG|Dexamethasone|Given PO
41317488|NCT04156828|BIOLOGICAL|Rituximab|Given IV
41317489|NCT04156828|BIOLOGICAL|Pegfilgrastim|Given SC
41317490|NCT02919124|DEVICE|Echoclip|An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
41317491|NCT03766802|BEHAVIORAL|Wearable watch training group.|3 orientation session Watch notifies 3/week for exercise
41317492|NCT03766802|BEHAVIORAL|Mobile application training group.|"3 orientation session App notifies 3/week for exercise~Benefits of app:~Cheaper Trackable and notifiable if patients don't exercise."
41317493|NCT03766802|BEHAVIORAL|Supervised exercise training group|3/week training supervised by a physical therapist
41317494|NCT01023438|OTHER|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
41317495|NCT01023438|OTHER|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
41317496|NCT03730194|DIETARY_SUPPLEMENT|Melatonin|Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime
41474514|NCT05943041|DRUG|GB104(Level 1)|One capsule QD oral administration for 28 days
41004603|NCT04516265|PROCEDURE|Video-based trunk training will apply with Theratogs|Video-based trunk training will apply with Theratogs
41474515|NCT05943041|DRUG|GB104(Level 2)|Three capsules QD oral administration for 28 days
41474516|NCT05943041|DRUG|GB104(Level 3)|Five capsules QD oral administration for 28 days
41474517|NCT03404401|DRUG|BLI4700|Oral bowel preparation
41474518|NCT03404401|DRUG|Polyethylene glycol bowel preparation|Oral bowel preparation
40800618|NCT02015949|DRUG|Placebo|Twice daily placebo tablet for two weeks
41004604|NCT02965443|DRUG|Dapagliflozin 10 mg + Saxagliptin 5 mg|24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg
41317497|NCT03730194|BEHAVIORAL|Bedtime Bank|The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.
41317498|NCT01954069|DEVICE|Semi-quantitative pregnancy test|
41474519|NCT04021355|OTHER|Oral sodium supplementation|Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.
41474520|NCT01529658|PROCEDURE|Renal hypothermia|"Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.~When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery."
41474521|NCT00149526|BEHAVIORAL|Shared Decision-Making|
40800619|NCT02693080|DEVICE|CAPP-Seq|Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
40800620|NCT02693080|DRUG|Isovue-200|Contrast agent
40800621|NCT02693080|RADIATION|Computed Tomography Perfusion Imaging|
40800622|NCT03465579|DIAGNOSTIC_TEST|pelvic MRI|multi-parametric pelvic MRI
40800623|NCT03465579|DIAGNOSTIC_TEST|68Ga-PSMA PET/CT|68Ga-PSMA PET/CT
41317499|NCT01692912|OTHER|Intensive Care|Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28\<2.6
41317500|NCT05846295|OTHER|ESTIMATE|An online educational module consisting of a video tutorial and feedback during a questionnaire
41317501|NCT04375241|OTHER|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
41317502|NCT06118346|BEHAVIORAL|Female-Specific Cognitive Behavioral Therapy (FS-CBT)|FS-CBT is a unique 12-session weekly group CBT treatment designed for women Veterans with AUD and/or risky drinking, and provides (1) AUD interventions, (2) general female-specific content, (3) female-Veteran content, (4) wellness and self-care, and (5) a novel 24/7 social support for abstinence discussion mobile app.
41317503|NCT06118346|BEHAVIORAL|Usual Care|Usual care means that participants will receive brief alcohol counseling and have access to available treatments for AUD at the VA.
41317504|NCT05415150|DRUG|Thrombolytic Agent|Subjects may receive one or more of the treatment options
41317505|NCT04982510|DEVICE|complete denture|3D printed complete denture
41317506|NCT04234126|PROCEDURE|ERCP|Routine ERCP for CBD stone with the gallbladder in situ, the chronic gallbladder status was defined as gallbladder wall thickness≥4mm, chronic cholecystitis, polyps,crudely or calculus .
41317507|NCT00644254|PROCEDURE|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
41317508|NCT04084132|PROCEDURE|Pulmonary valve replacement|Surgical implantation of an adult-sized (≥ 18 mm) homograft or Contegra graft as right ventricle-to-pulmonary artery conduit under cardiopulmonary bypass through a sternotomy.
41474522|NCT02389101|OTHER|68Ga-DOTANOC PET/CT; Diffusion weighted MRI|PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
41317509|NCT03166865|BIOLOGICAL|Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Allogeneic UC-MSCs 1 x 10\~7 diluted on 5 mL of Platelet Rich Plasma
41004605|NCT02965443|DRUG|Placebo 1 10 mg + Placebo 2 5 mg|24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
41317510|NCT03166865|OTHER|Hyaluronic acid|intra-articular injection of Hyaluronic Acid
41317511|NCT00057395|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
41317512|NCT00645294|DRUG|Adefovir dipivoxil|0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
41317513|NCT00645294|DRUG|Adefovir Dipivoxil|0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
41317514|NCT00645294|DRUG|Adefovir Dipivoxil|ADV 10 mg on Day 1
41317515|NCT05207306|PROCEDURE|Type of interfascial plane block|"In the M-TAPA group, after finding the right 10th costal cartilage using ultrasound guidance, a anesthesiologist inject 0.375% ropivacaine 15ml into the lower aspect of the chondrium. Perform left M-TAPA in the same way.~In the subcostal TAPB group, a anesthesiologist inject 0.375% ropivacaine 15ml into end of right rectus abdominis muscle using ultrasound guidance. Perform left subcostal TAPB in the same way."
41317516|NCT01224587|DRUG|D1000078|Oral, one single dose
41317517|NCT01224587|DRUG|D1000082|Oral, one single dose
41317518|NCT01224587|DRUG|D1000083|Oral, one single dose
41317519|NCT01224587|DRUG|D1000085|Oral, one single dose
41317520|NCT03689413|DRUG|Sugammadex 200 MG in 2 ML Injection|1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
41317521|NCT04050501|DEVICE|non-invasive Vagus Nerve Stimulator|Two stimulations of two minutes each will be applied in the neck every 15 minutes in the first 3 hours. Thereafter two stimulations will be applied every 8 hours over the next 5 days or until discharge, whichever occurs first. The stimulation side in the neck will be the radiological side of the stroke.
41317522|NCT04839991|DRUG|CB307|Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
41317523|NCT06081673|DRUG|Penpulimab injection|Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).
41317524|NCT06081673|DRUG|cisplatin|Cisplatin :75mg/m2, D1, IV(21 days/cycle)
41317525|NCT06081673|DRUG|albumin-paclitaxel|albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)
41317526|NCT01566058|DEVICE|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
41317527|NCT01566058|OTHER|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
41474523|NCT00932945|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
41474524|NCT01321281|DIETARY_SUPPLEMENT|AquaCal|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg)."
41317528|NCT02982538|BEHAVIORAL|Extended Training in Prolonged Exposure Therapy for PTSD|Extended training in Prolonged Exposure consists of a 4-day PE workshop, followed by expert PE consultation on 2 training cases. PE consultation consists of weekly telephone calls with expert PE therapists at the University of Pennsylvania, who will review video-recordings of providers PE sessions and provide feedback. Consultation is considered complete if the consultant has reviewed a minimum of 12 video-recorded sessions across 2 training cases, and has provided feedback on all of the crucial elements of PE (e.g., rationale, imaginal exposure, in vivo exposure, processing).
41317529|NCT02982538|BEHAVIORAL|Standard Training in Prolonged Exposure Therapy for PTSD|Standard training in PE consists of a 4-day professional workshop on Prolonged Exposure Therapy. This is similar to the standard training approach that has been used to train providers in delivery of PE in the Army.
41317530|NCT01309841|DRUG|NKTR-118|12.5 mg oral tablet once daily
41317531|NCT01309841|DRUG|NKTR-118|25 mg oral tablet once daily
41317532|NCT01309841|DRUG|Placebo|Oral tablet once daily
41317533|NCT05578482|DRUG|Dicloxacillin Oral Capsule|Randomized to either systemic dicloxacillin \& elocon or placebo \& elocon
40800624|NCT06521827|RADIATION|short course radiotherapy|short course palliative radiotherapy
41004606|NCT00401765|DRUG|CNTO 328|Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.
41317534|NCT05578482|DRUG|Elocon 0.1 % Topical Cream|Both groups are treated with elocon for five days.
41317535|NCT06527456|OTHER|participation of the general practitioner|participation of the general practitioner in encouraging cervical cancer screening
41317536|NCT01022567|PROCEDURE|Appendicectomy|Standard appendicectomy
41317537|NCT01022567|DRUG|Ertapenem|ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
40800625|NCT03076489|OTHER|First Visit|blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home
41004607|NCT00401765|DRUG|Docetaxel|Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
41317538|NCT00109304|BIOLOGICAL|VEE 3526|
41317539|NCT06347341|DIETARY_SUPPLEMENT|Clinical study comparing a gluten-containing diet to a gluten-free diet|The study includes a basal period of 2 weeks, 2 test periods of a maximum duration of 1 week and a wash-out period of 2 to 3 weeks.
41317540|NCT00046176|DRUG|abacavir/lamivudine|
41317541|NCT00046176|DRUG|abacavir|
41317542|NCT00046176|DRUG|lamivudine|
41317543|NCT02705118|DEVICE|Automatic Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.
41317544|NCT02705118|DEVICE|Manual Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
41474525|NCT01321281|DIETARY_SUPPLEMENT|AquaPT|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract."
41004608|NCT02410811|OTHER|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
41004609|NCT06034054|OTHER|nursing counceling|"* Providing an educational booklet containing information about pastry, verbally explaining the content of the prepared educational booklet.~* Answering the information and questions that the patient needs in addition, and receiving contact information in October.~* Monthly calls will be made to patients 6. providing information that the same tests will be performed again per month, if necessary, this monthly call counseling by reaching out without waiting indicating what they can receive."
41317545|NCT03792451|DRUG|Pegvaliase|Treated with pegvaliase for one or more years or followed an unrestricted diet for 6 or more months while being treated with pegvaliase.
41317546|NCT00419913|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA 25 mg tid
41317547|NCT06512194|DRUG|Psilocybin|The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of synthetic psilocybin.
41474526|NCT03842852|PROCEDURE|Inguinal hernia repair|The grupo one underwent open repair and laparoscopic repair
40800626|NCT03076489|OTHER|on-line questionnaires|The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.
41004610|NCT01416883|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
41004611|NCT05340153|DRUG|Artemether-Lumefantrine Drug Combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
41004612|NCT05340153|DRUG|Dihydroartemisinin-Piperaquine drug combination|Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
41004613|NCT03571919|DRUG|Lidocaine infusion|Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr
41004614|NCT03571919|DRUG|Saline infusion|Intravenous bolus of saline and then infusion
41004615|NCT04601051|BIOLOGICAL|NTLA-2001|A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
41004616|NCT02126540|DEVICE|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
41004617|NCT00397800|BIOLOGICAL|rituximab|
41004618|NCT00397800|DRUG|cyclophosphamide|
41004619|NCT00397800|DRUG|fludarabine phosphate|
41004620|NCT00397800|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
41004621|NCT01440946|DRUG|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
41004622|NCT01440946|DRUG|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
41317548|NCT06512194|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|For both the active and sham taVNS procedure, participants will be provided with, and trained on, use of a taVNS device that applies gentle stimulation to the left ear.
41474527|NCT00221962|DRUG|Aripiprazole|Open label
41474528|NCT05025579|OTHER|Aerobic Exercise|"Since up in 2 min 10 repetitions active joint movement (while seated knee flexion and extension the ankle plantar and dorsal flexion , standing the hip flexion , extension the , abduction and adduction ) , treadmill for 3 minutes, 0.5 m / sec speed walk with and to adapt both warming bike 5 minutes, RPE ( Rating of Perceived exertion discoverable by exertion rate) will be 2/10 in a way was built.~As aerobic exercise, the first week will be RPE 4/10 for 10 minutes, the second week with RPE 4/10 12 minutes, the third week with RPE 4/10 14 minutes, the fourth week with RPE 4/10, 16 minutes, the fifth week with RPE 5/ 2 0 will be as 18 minutes sixth week RPA 10.6 will form was done 20 minutes of exercise .~Cooling period in the RPE 2.10 will be the 5 minute turning cycling, 5 min active range of motion exercises and stretching was done."
41474529|NCT01995721|BIOLOGICAL|4-valent HPV vaccine|Vaccination with 4-valent HPV vaccine in months 0., 2., 6.
40800627|NCT03076489|DEVICE|fMRI|a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
40800628|NCT02103062|DRUG|ABI-007|
41004623|NCT06288516|DRUG|Benralizumab 30 mg/ml|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks
41004624|NCT02995252|OTHER|Blood draws|
40800629|NCT05151159|OTHER|immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3|
41004625|NCT02995252|DRUG|Tenofovir Alafenamide|25 mg tablet, once a day by mouth.
41004626|NCT02995252|OTHER|Knowledge Index Questionnaire|
41004627|NCT02995252|OTHER|Liver transient elastography (FibroScan)|Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
41152224|NCT01972373|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure
41152225|NCT01972373|DEVICE|NIR fluorescence endoscopy|48-72 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum
41152226|NCT06546566|OTHER|Video Game-Based Breathing Exercises|The video game-based breathing exercises program will consist of 5 breathing games included in the BreathingLabs game kit and each game will be performed in 2 sets of 10 repetitions. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
41152227|NCT06546566|OTHER|Conventional Breathing Exercises|The conventional breathing exercises program will consist of routine breathing exercises. Breathing exercises will be given 2 times a day, 5 repetitions, 2 sets. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
41317549|NCT06512194|DEVICE|Sham taVNS|For both the active and sham taVNS procedure, participants will be provided with, and trained on, use of a taVNS device that applies gentle stimulation to the left ear.
41317550|NCT06512194|OTHER|Treatment as Usual|Treatment as usual consists of an integration 1-day, 1-week, and 2-weeks post-psilocybin dosing.
40800630|NCT06190470|DRUG|Cannabis|Cannabis product is from the extraction of the powdered, dried and mature pistillate inflorescences of Cannabis sativa L. containing THC 30mg/ml.
40800631|NCT06190470|DRUG|Placebo|Placebo is similar to Cannabis product but do not contain THC.
40800632|NCT01843673|PROCEDURE|computed tomography|Undergo FBCT
41317551|NCT00111475|DRUG|Romiplostim|Administered by subcutaneous injection
41317552|NCT00111475|DRUG|Placebo|Administered by subcutaneous injection
41317553|NCT05439863|DEVICE|transcatheter heart valve|patients with severe aortic valve disease underwent transcatheter heart valve
41317554|NCT03013244|BEHAVIORAL|The Body Project: More Than Muscles|Participants complete a variety of activities designed to counter internalization of the lean, muscular body ideal for men.
41317555|NCT01350960|DRUG|SPC5001|3 weekly SC injections
41317556|NCT01350960|DRUG|Saline 0.9%|3 weekly SC injections
41317557|NCT01350960|DRUG|SPC5001|3 weekly SC injections
40800633|NCT01843673|PROCEDURE|cone-beam computed tomography|Undergo dual CBCT
41317558|NCT01350960|DRUG|SPC5001|3 weekly SC injections
41317559|NCT01350960|DRUG|SPC5001|3 weekly SC injections
41317560|NCT01350960|DRUG|SPC5001|3 weekly SC injections
41474530|NCT02194023|DRUG|Placebo: PCB|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
40800634|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian kV OBI
41474531|NCT02194023|DRUG|0.12%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
41474532|NCT02194023|DRUG|0.03%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
41474533|NCT02194023|DRUG|PAT|Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
40800635|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
40800636|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian MV OBI
41474534|NCT02860182|OTHER|measure the elastic properties of aortic wall|
40800637|NCT01843673|PROCEDURE|electronic portal imaging|Undergo EPID imaging
40800638|NCT01843673|RADIATION|image-guided adaptive radiation therapy|Undergo IGART
41152228|NCT01827176|OTHER|Recurrent Acute Rhinosinusitis|Clinical Characteristic of Recurrent Acute Rhinosinusitis
41152229|NCT03647709|OTHER|opioids|dosage frequency and duration
41152230|NCT03750175|OTHER|Plasma circulating DNA analysis|Clinical utility of ctDNA analysis for treatment decision
41317561|NCT02713763|DRUG|Sunitinib|Sunitinib 37.5 mg/day
41317562|NCT04979949|BIOLOGICAL|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
41317563|NCT04979949|BIOLOGICAL|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
41152231|NCT05993832|OTHER|input cue|The object is labelled with 1) gaze only; 2) novel label only; or 3) conflicting gaze and novel label
40800643|NCT05619094|OTHER|Corrective exercise program|"Strengthening exercises for deep cervical flexor muscles and shoulder retractors.~Stretching exercises for cervical extensors and pectoral muscles."
40800644|NCT03776318|DRUG|Long-Term Safety Follow-up|STX-015-18-01 long-term safety follow-up
40800645|NCT02788032|OTHER|EnergieShake oral supplement|The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
40800646|NCT01734798|RADIATION|Radiation|
40800647|NCT01734798|DRUG|gemcitabine and cisplatin|
40800648|NCT01734798|OTHER|Radiotherapy and Drug|
40800649|NCT02739386|BIOLOGICAL|Ipilimumab|Intravenous monoclonal antibody injection
40800650|NCT04370587|BIOLOGICAL|T3011|T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
40800651|NCT04370587|COMBINATION_PRODUCT|T3011 + pembrolizumab|T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
40800652|NCT02794896|DRUG|High dose propofol, fentanyl and sevoflurane|Deep Anesthesia
40800653|NCT02794896|DRUG|Low dose propofol, fentanyl and sevoflurane|Shallow Anesthesia
41152232|NCT03300661|BEHAVIORAL|Mediterranean Style|After completion of a Food Frequency Questinnaire (FFQ) and the International Physical Activity Questionnaire (IPAQ), patients enrolled in the study undergo a personalized educational intervention by a registered dietician. During the intervention the dietician advice about the main errors in diet and physical activity (by FFQ and IPAQ) and chooses three aims in diet modification and one aim in physical activity improvement. Patients adherence is assessed by the same dietician every three months, using FFQ and IPAQ, and futher supports are provided. Total intervention lenght is twelve months.
41152233|NCT00043368|DRUG|PF-3512676|PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
41152234|NCT02246647|DIAGNOSTIC_TEST|Permeability measurement|Saccharide excretion was compared between IBS-C and healthy volunteers
41152235|NCT02246647|PROCEDURE|Esophagogastroduodenoscopy|Duodenal biopsies were collected from IBS-C and healthy volunteers
41152236|NCT02246647|PROCEDURE|Flexible sigmoidoscopy|Colonic biopsies were collected from IBS-C and healthy volunteers
41152237|NCT00591084|DRUG|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
41152238|NCT00591084|DRUG|placebo|infusion placebo (group B)once a day and continued for 14 days
41474535|NCT03316326|DRUG|Tegafur-gimeracil-oteracil potassium|40 mg bid, D1-14
41474536|NCT03316326|DRUG|Oxaliplatin|85 mg/m2, D1
41474537|NCT03316326|DRUG|Irinotecan|150 mg/m2, D8
41474538|NCT04882137|BEHAVIORAL|Education plus Coaching|Providers in Intervention group will receive standard education (1.5 hr CME), a tip sheet on how to manage side effects for quick reference and a number to directly reach a provider experienced with managing etonogestrel side effects with questions regarding how to manage side effects.
40800654|NCT06314854|OTHER|Running water sound|Running water sound for experimental group Standard care for control group
40800655|NCT00451958|DRUG|Degarelix 80 mg / Degarelix 80 mg|
41317564|NCT01594294|DEVICE|AOSEPT® Plus contact lens solution|Hydrogen peroxide-based cleaning and disinfection system
41317565|NCT01594294|DEVICE|ReNu MultiPlus® contact lens solution|Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
41317566|NCT01594294|DEVICE|Etafilcon A contact lenses|Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
41317567|NCT01594294|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
41317568|NCT01594294|DEVICE|COMPLETE® MPS Easy Rub® Formula contact lens solution|PHMB 0.0001% and poloxamer 0.05% multipurpose solution
41317569|NCT01841957|PROCEDURE|ISBCS|same-day cataract surgery
41317570|NCT01841957|PROCEDURE|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
41317571|NCT02311309|OTHER|Control|Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration \>8 g/dL.
41317572|NCT02311309|OTHER|Unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration \< 8 g/dL.
41317573|NCT05412537|OTHER|MI|How to motivate people
41317574|NCT05412537|OTHER|CAU|consult as usual
41317575|NCT03431701|OTHER|Chlorhexidine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains chlorhexidine. A sponge soaked with chlorhexidine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
41317576|NCT03431701|OTHER|Iodine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains iodine. A sponge soaked with iodine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
41317577|NCT03431701|OTHER|Antibiotics|All participants will receive a single body mass index (BMI) based antibiotic dose of cefazolin or clindamycin within 30 minutes prior to the incision.
41317578|NCT02638896|DRUG|etanercept (Half-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .
41317579|NCT02638896|DRUG|etanercept (Full-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.
41317580|NCT02638896|DRUG|Sulfasalazine|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.
41317581|NCT02638896|DRUG|Celecoxib|Celecoxib (0.4g/d) will be the background therapy.
41317582|NCT00671216|DRUG|GSK233705|Subjects will receive 200 (mcg) microgram once daily as a single dose
41317583|NCT00671216|DRUG|GW642444|Subjects will receive 50 mcg once daily as a single dose
41317584|NCT00671216|DRUG|GSK233705 and GW642444|Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
41317585|NCT00671216|DRUG|Placebo|Placebo matching study medication will be inhaled by subjects
41317586|NCT00405821|DRUG|Acyclovir|400mg twice daily for 24 months
41317587|NCT00405821|DRUG|Placebo|Placebo tablet twice daily for 24 months
41317588|NCT04488224|DEVICE|Nano-X Patient Rotation System|"The Nano-X prototype is a horizontal patient rotation system that immobilises participants while being rotated on the horizontal axis.~This device will be used to rotate patients horizontally while cone-beam Computed Tomography (CBCT) projections are acquired."
41317589|NCT04488224|RADIATION|Conventional CBCT scan|A conventional cone-beam Computed Tomography (CBCT) scan is acquired on standard radiotherapy machinery.
41317590|NCT04488224|OTHER|Psychometrically validated questionnaires|The Claustrophobia Questionnaire (CLQ), Short Form State/Trait Anxiety inventory (STAI) and Fast Motion Sickness (FMS) questionnaires administered. CLQ only once before the first session, STAI and FMS both before and after each Nano-X CBCT session.
41317591|NCT04101760|DRUG|Long-acting granulocyte colony stimulating factor|Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy
41317592|NCT04101760|DRUG|Short-acting granulocyte colony stimulating factor|Patients will accept short-acting granulocyte colony stimulating factor followed regular or prophylactic patterns
41317593|NCT01961843|DRUG|Abiraterone|Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.
41317594|NCT01961843|DRUG|Prednisone|Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.
41317595|NCT01987388|OTHER|High Intensity Exercise|While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.
41474539|NCT00589849|PROCEDURE|T-wave Alternans|T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
41474540|NCT00522444|DRUG|Nebulized Magnesium Sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
41474541|NCT00522444|OTHER|Nebulized normal saline|standard of care
41004628|NCT02995252|PROCEDURE|Liver Biopsy|40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
41004629|NCT05621564|DRUG|pre-operative therapy|pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
40800656|NCT00451958|DRUG|Degarelix 160 mg / Degarelix 160 mg|
40800657|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 80 mg|
41317596|NCT01987388|OTHER|Low Intensity Exercise|While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.
41317597|NCT01987388|OTHER|High Carbohydrate Beverage|Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.
41317598|NCT01987388|OTHER|High Fat Beverage|Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.
40800658|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 160 mg|
41004630|NCT04150224|DRUG|PBTZ169 640 mg OD|Two administrations once a day with a wash-out period: food effect
41004631|NCT04150224|DRUG|PBTZ169 640 mg BiD|Twice a day fasted; 1 day of administration
41004632|NCT04150224|DRUG|PBTZ169 960 mg SD|Once a day fasted
41004633|NCT04150224|DRUG|PBTZ169 1280 mg SD|Once a day fasted
41004634|NCT04150224|DRUG|PBTZ169 1280 mg MD|Once a day after meal, 14 doses
41317599|NCT01319110|DRUG|Coenzyme Q10|Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
41317600|NCT01319110|DIETARY_SUPPLEMENT|Placebo|Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
41317601|NCT05866653|DRUG|lidocaine transdermal patch|The topical pain-relieving treatment 5% lidocaine transdermal patch has been registered in the USA since 1999
41317602|NCT02785952|BIOLOGICAL|Ipilimumab|Given IV
41317603|NCT02785952|OTHER|Laboratory Biomarker Analysis|Correlative studies
41317604|NCT02785952|BIOLOGICAL|Nivolumab|Given IV
41317605|NCT02785952|OTHER|Quality-of-Life Assessment|Ancillary studies
41004635|NCT02227485|DRUG|Punica granatum Pleniflora (Golnaar) mouth rinse|"All the patient in intervention group use 10 ml of Golnaar mouth rinse for 2 minutes every night for 2 weeks."
41004636|NCT02227485|DRUG|Chlorhexidine (0.2%)|All the patient in control group use 10 ml of chlorhexidine (0.2%) for 2 minutes every night for 2 weeks.
41004637|NCT02227485|PROCEDURE|Tooth bleaching|Tooth bleaching for both groups one time after using mouth rinses.
41474542|NCT01174524|DRUG|gestoden 60 mcg|gestoden 60 mcg, once a day, administered in 24/4 regimen.
41474543|NCT01174524|DRUG|ethinylestradiol 15 mcg|ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
41474544|NCT05146349|OTHER|Minnesota RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an control group that is not.
40800659|NCT00404378|DRUG|ketoconazole|Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
40800660|NCT00404378|DRUG|casopitant 100 mg|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
40800661|NCT00404378|DRUG|Casopitant 50 mg|Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
41004638|NCT00751816|DRUG|systemic chemotherapy|
41004639|NCT00751816|OTHER|survey administration|will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.
41004640|NCT00751816|PROCEDURE|adjuvant therapy|
41004641|NCT00751816|PROCEDURE|management of therapy complications|
41004642|NCT00751816|PROCEDURE|musculoskeletal complications management/prevention|
41004643|NCT00751816|PROCEDURE|physical therapy|weekly visits coordinated with adjuvant treatment as part of standard care
41004644|NCT00751816|RADIATION|radiation therapy|
40800662|NCT01520649|DRUG|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
40800663|NCT01520649|DRUG|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
41004645|NCT02534831|PROCEDURE|Soft tissue manual therapy protocol|The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
41004646|NCT06409624|OTHER|No intervention is planned as part of the study|No intervention is planned as part of the study
41317606|NCT02785952|OTHER|Questionnaire Administration|Ancillary studies
41317607|NCT01195831|DRUG|Xamiol® gel|Once daily application
41317608|NCT01195831|DRUG|Calcipotriol scalp solution|Twice daily application
41317609|NCT00456794|DRUG|Istradefylline (KW-6002)|
41317610|NCT00114270|DRUG|letrozole|
41317611|NCT00114270|DRUG|zoledronic acid|
41474545|NCT01682148|BIOLOGICAL|Botulinum toxin type A|
41317612|NCT00866268|DEVICE|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
41474546|NCT05365659|DRUG|IKS03|IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
41474547|NCT00005090|BIOLOGICAL|bleomycin sulfate|10 U/m\^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
41474548|NCT00005090|DRUG|carmustine|150/m\^2 on days -6 to -4 (4-6 days before transplant).
41474549|NCT00005090|DRUG|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
41474550|NCT00005090|DRUG|dacarbazine|375 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
41474551|NCT00005090|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
41474552|NCT00005090|DRUG|etoposide|60 mg/kg on day -4 (4 days before transplant).
41474553|NCT00005090|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
41474554|NCT00005090|PROCEDURE|peripheral blood stem cell transplantation|2 x 10\^6 CD34+ blood mononuclear cells/kg of actual body weight
41004647|NCT06381349|DIAGNOSTIC_TEST|Gastric Alimetry test|Gastric Alimetry test will be performed within 30-days prior to G-POEM procedure. It's results will not inform clinical management in this observational study.
41004648|NCT02553421|DEVICE|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
41004649|NCT04788914|DIETARY_SUPPLEMENT|Active bamboo charcoal± probiotics|Active bamboo charcoal 2g, TID probiotics 0.8g
41004650|NCT00001180|DRUG|Ovine Corticotropin-Releasing Hormone (oCRH)|
41004651|NCT00098111|DRUG|azathioprine|
41152239|NCT00591084|DRUG|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
41152240|NCT02628613|DRUG|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
41152241|NCT02628613|DRUG|Paclitaxel plus Epirubicin|standard neoadjuvant chemotherapy
41152242|NCT06022406|BIOLOGICAL|FMT capsules|Formulation: 80-100g of healthy donor stool processed, frozen and encapsulated in gelatin capsules (modified Kao et al, 2017).
41152243|NCT06022406|BIOLOGICAL|Placebo capsules|Formulation: microcrystalline cellulose, for equivalence in weight and color, will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.
41152244|NCT00125619|BEHAVIORAL|Locomotor training|This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
41152245|NCT00213915|DRUG|12 g of L-arginine glutamate during 6 weeks twice a day|
41152246|NCT02121808|PROCEDURE|NIPPV|"Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)"
41152247|NCT02121808|PROCEDURE|Tidal volume|Tidal volume spontaneous ventilation, no assistance.
41152248|NCT05321576|PROCEDURE|Erector spinae plane block (ESPB) technique without opioid use|Local anesthetic injection to the erector spinae muscle plane at T5 level on the operation side.
41152249|NCT01523678|DRUG|Filgrastim|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
41152250|NCT01523678|DRUG|Paclitaxel|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
41152251|NCT01523678|DRUG|Carboplatin|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
41152252|NCT05805033|OTHER|Mucointegration|Placement of abutment on a dental implant to study mucointegration
41152253|NCT06092879|OTHER|Asciminib|There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled
41152254|NCT04736602|DRUG|Triptorelin pamoate 15mg|Intramuscular injection (IM)
41317613|NCT00866268|DEVICE|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
41317614|NCT02932189|DEVICE|Inspiratory muscle training|For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
41317615|NCT05627700|DEVICE|AVL200 IOL|The AVL200 is an intraocular lens surgically implanted in the eye after cataract surgery.
41474555|NCT04995120|DRUG|chemotherapy TP regimen combined with Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
40800664|NCT04492241|DRUG|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.
40800665|NCT04492241|DRUG|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.
40800666|NCT06516991|DEVICE|Temporal Interference Stimulation|"Specific electrode sites are customized for the subject through magnetic resonance scanning, the deep nucleus cluster to be stimulated-nucleus accumbens is calibrated through electric field simulation before treatment, and the stimulation target can be accurately positioned by stimulating the specific electrode sites of the subject during treatment.~During the treatment period, all subjects were treated with a fixed time interference stimulation (TI) device at a frequency of 30 minutes twice a day, 5 days a week, for a total of 10 treatments. The output current intensity during treatment is 3.64 mA+4.36 mA."
40800667|NCT04812782|DIETARY_SUPPLEMENT|EVOO supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO
41474556|NCT03185182|DRUG|Ioflupane I123|"185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .~The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution."
40800668|NCT04812782|DIETARY_SUPPLEMENT|Butter supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter
40800669|NCT00683930|DRUG|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
40800670|NCT00683930|DRUG|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
40800671|NCT00683930|DRUG|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
41474557|NCT04888676|PROCEDURE|Class II Restoration|A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm
41474558|NCT02910414|DRUG|Dehydrated alcohol|Dehydrated Alcohol Injection, USP is used in the study.
41474559|NCT02910414|DEVICE|Peregrine System Kit (Sham Procedure)|Pre-procedural diagnostic renal angiography only, performed for confirmation of anatomical eligibility prior to randomization
40800672|NCT04312867|BEHAVIORAL|Project STRONG|Project STRONG is a 6-module web-based, dyadic intervention for middle school boys and their parents to complete. Its goal is primary prevention of adolescent dating violence by targeting parent-child communication and emotion regulation ability.
40800673|NCT04312867|BEHAVIORAL|Health Promotion|Health promotion is a 6 module web-based, health information program designed to provide health content similar to that provided in a middle school health class. This program is designed to mirror Project STRONG for time and delivery method.
40800674|NCT00564733|DRUG|carboplatin|Given IV
40800675|NCT00564733|DRUG|docetaxel|Given IV
40800676|NCT00564733|DRUG|gemcitabine hydrochloride|Given IV
40800677|NCT00564733|DRUG|paclitaxel|Given IV
40800678|NCT00564733|PROCEDURE|computed tomography|Undergo FDG PET/CT
40800679|NCT00564733|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
40800680|NCT00564733|RADIATION|fludeoxyglucose F 18|Given IV
40800681|NCT00564733|OTHER|imaging biomarker analysis|Correlative studies
40800682|NCT03029039|OTHER|Blood samples|Blood samples will be collected at inclusion.
40800683|NCT01876303|OTHER|laboratory biomarker analysis|Correlative studies
40800684|NCT01876303|OTHER|questionnaire administration|Ancillary studies
41004652|NCT03940365|DEVICE|Fetal Life tocometer device|The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
41317616|NCT01000779|DRUG|Propranolol|upto 320mg/day maximum
41317617|NCT01000779|DEVICE|multi band ligator for esophageal varices|to obliterate esophageal varices
41317618|NCT05890118|DRUG|Stelara|A commercial formulation of ustekinumab for SC control (0.5mg)
41317619|NCT05890118|COMBINATION_PRODUCT|RT-111 (0.5mg)|RaniPill capsule containing ustekinumab with a dose of 0.5mg
41317620|NCT05890118|COMBINATION_PRODUCT|RT-111 (0.75mg)|RaniPill capsule containing ustekinumab with a dose of 0.75mg
41317621|NCT00537264|OTHER|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
40800685|NCT02733549|OTHER|LFTs|"A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed."
40800686|NCT00002032|DRUG|Rifabutin|
41317622|NCT00537264|OTHER|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
41317623|NCT04023942|BEHAVIORAL|Weight maintenance intervention|Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
41317624|NCT02961517|OTHER|Questionnaire|Anonymous questionnaire collecting basic sociodemographic data about the participant and information regarding their preferences for the method of delivery format of patient education information
41317625|NCT02335580|DRUG|Somatostatin and its analogs|Somatostatin and/or octreotide will be intravenously infused.
41317626|NCT02335580|PROCEDURE|Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection|Endoscopic sclerotherapy, endoscopic variceal ligation, and/or endoscopic tissue glue injection will be performed based on the endoscopists' choice.
41317627|NCT02481336|OTHER|Questionnaires|EORTC CIPN20 and EQ-5D-3L
41474560|NCT00727077|BIOLOGICAL|IntronA (interferon alfa-2b; SCH 30500)|IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
41474561|NCT00727077|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
41474562|NCT01652729|DRUG|Exenatide once weekly suspension|
41474563|NCT01652729|DRUG|Sitagliptin|
41474564|NCT01652729|DRUG|Placebo|Placebo oral capsule once daily
41474565|NCT04693338|OTHER|Quality-of-Life Assessment|Ancillary studies
41474566|NCT04693338|OTHER|Questionnaire Administration|Ancillary studies
41474567|NCT04693338|OTHER|Supportive Care|Receive ICP tasks
41474568|NCT05375019|BEHAVIORAL|Positive discipline program|The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program
41474569|NCT05375019|BEHAVIORAL|active control group|free interaction group consisting of topics determined by the families.
41474570|NCT01872702|DRUG|malaria elimination using DP and low-dose primaquine|Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
40800687|NCT00193011|DRUG|Docetaxel|Docetaxel
40800688|NCT00193011|DRUG|Cyclophosphamide|Cyclophosphamide
40800689|NCT00193011|DRUG|Methotrexate|Methotrexate
41004653|NCT05826964|DRUG|AI+CDK4/6i|"Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
41004654|NCT05826964|DRUG|SERD+CDK4/6i|"Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
41004655|NCT05826964|DRUG|mTOR inhibitor + AI|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
41157076|NCT02747121|BEHAVIORAL|External inspection of health services|The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
41157077|NCT00484172|PROCEDURE|blood draws|
41474571|NCT03327714|BEHAVIORAL|Mindfulness and compassion|
41474572|NCT01796964|DRUG|ESBA1008 solution|For intravitreal (IVT) injection
41474573|NCT01796964|DRUG|Aflibercept|For intravitreal (IVT) injection
41474574|NCT04017559|BEHAVIORAL|Motivational Interviewing|A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
41474575|NCT03601624|DRUG|Pomalidomide|"1. Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~2. Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~3. Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
41474576|NCT03093935|DEVICE|StimRouter Neuromodulation System|The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
41474577|NCT00922259|BIOLOGICAL|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10\^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
41474578|NCT00172419|DRUG|Atorvastatin|Atorvastatin, 40 mg/day for 12 weeks
40800690|NCT00193011|DRUG|5-Fluorouracil|5-Fluorouracil
40800691|NCT02569424|BEHAVIORAL|Patient's position|Supine or Trendelenburg strict -20°)
40800692|NCT03357796|DRUG|LY03005|80 mg, oral tablets, single dose
40800693|NCT03357796|DRUG|Pristiq|50 mg, oral tablets, single dose
40800694|NCT03704844|OTHER|non applicable|non applicable
41474579|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate|1.2 g/kg/h
41474580|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
41474581|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
41474582|NCT04431414|OTHER|Sample collection|"* blood, nasal swab, nasal wash, and saliva~* optional stool swab"
41474583|NCT00705120|OTHER|Bone Marrow Cell Transplantation|
41474584|NCT00705120|RADIATION|Irradiation, Total Body|
41004656|NCT05826964|DRUG|mTOR inhibitor + SERD|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
41317628|NCT02481336|PROCEDURE|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
41317629|NCT02481336|GENETIC|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
41317630|NCT03285906|DRUG|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
41474585|NCT00705120|DRUG|Cyclophosphamide|
40800695|NCT00110435|DRUG|MK0653A, ezetimibe (+) simvastatin|
40800696|NCT00110435|DRUG|Duration of Treatment: 4 wk placebo run in then 6 wk active|
40800697|NCT00110435|DRUG|Comparator: atorvastatin|
40800698|NCT00652743|BIOLOGICAL|Pandemic influenza vaccine GSK1562902A|IM administration
40800699|NCT05312749|OTHER|progressive relaxation exercises|progressive relaxation exercises
40800700|NCT03834610|DRUG|L-arginine 5 gm oral caps|oral L-arginine 5 gm daily for 8 weeks
40800701|NCT03834610|DRUG|Tadalafil 10 MG|oral daily tadalafil 10mg for 8 weeks
40800702|NCT03834610|DIAGNOSTIC_TEST|serum testosterone level|measurement of serum testosterone level
40800703|NCT03834610|DIAGNOSTIC_TEST|HbA1C|measurement of HbA1C levels
41474586|NCT00705120|DRUG|Cyclosporin|
41004657|NCT05826964|DRUG|mTOR inhibitor + Selective estrogen receptor modulator|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
41004658|NCT05826964|DRUG|PI3K inhibitor + SERD|Participants will receive standard of care one PI3K inhibitor therapy (Alpelisib), in combination with SERD therapy (Fulvestrant) in Step 2 Arm 2 and Step 3. PI3K inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
41317631|NCT04876703|DEVICE|Multichannel Functional electrical stimulation|The Xcite system is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education.
41474587|NCT00705120|PROCEDURE|Mesenchymal Stem Cell Transplantation|
40800704|NCT03834610|DEVICE|penile doppler|penile doppler to measure the degree of erection and penile vasculature
40800705|NCT06057337|BEHAVIORAL|"Families with Pride (Familias con Orgullo)"|Families with Pride (Familias con Orgullo) aims to prevent the co-occurring epidemics of drug use and depression in Hispanic sexual minority youth. It focuses on improving parent support for the adolescent, parent acceptance of the adolescent, family functioning (e.g., communication), and decreasing stress and sexual minority stress. The program consists of 11 weekly, in-person sessions: 7 parent group sessions, 3 concurrent adolescent group sessions, both lasting two hours, 4 family sessions lasting 1 hour in either Spanish or English, depending on participant language preference. In the parent group sessions, parents come together to foster social support, family functioning, and increase parental support and acceptance for the adolescent. In the adolescent sessions, adolescents build skills in confronting and managing stressors related to being a sexual minority.
40800706|NCT02578134|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
40800707|NCT02578134|OTHER|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
40800708|NCT01800331|BEHAVIORAL|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
40800709|NCT06158464|OTHER|Functional Capacity Evaluation|In a FCE, an occupational therapist will evaluate a patient's ability to perform work-related tasks, using a battery of tests. Depending on the circumstances, he/she will for instance test fatigue, ask the patient to kneel, lift objects, or assess concentration. This assessment lasts ± 4 hours and includes physical tests and tests related to the (previous or reference) profession of the client. This means that an explicit match is made between the functional capacities of the patient (what is he/she capable of) and the demands of a certain job (what is he/she expected to do). Following this assessment, the occupational therapist will explain the results of this assessment to the patient. The evaluation will therefore take place during one or two visits.
40800710|NCT00256360|DRUG|dose dense with neulasta|
41157078|NCT00214071|BIOLOGICAL|Influenza vaccine|
41317632|NCT04876703|OTHER|Standard motor training|Standard motor training is the conventional rehabilitation treatment
41317633|NCT01604876|DEVICE|light therapy 30 min morning and evening, three months|"Light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] equipped with 3x36W Fluorescent bulbs (Osram 954), reflectors and a diffuser screen providing 10,000 lux at 30 cm eye level distance.~therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
41474588|NCT00705120|DRUG|Busulfan|
41474589|NCT03046719|DRUG|Bupivacaine 0,5%|Bupivacaine 0,5% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
41474590|NCT03046719|DRUG|NaCl 0,9%|NaCl 0,9% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
41474591|NCT05026931|OTHER|Foam rolling|Group A will be treated with foam rolling effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
41474592|NCT05026931|OTHER|Stretching exercises|Group B will be treated with stretching exercises effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
41474593|NCT06285812|DEVICE|OtoSight Middle Ear Scope|Subjects will be evaluated with the OtoSight Middle Ear Scope
41474594|NCT05644756|BEHAVIORAL|IMPACT Methods to Identify and Prioritize Determinants (Challenge I), Challenge and Match strategies to Prioritized Determinants (Challenge II)|IMPACT Center developed two methods for identifying determinants that involved providers, staff, and youth at community mental health centers in site visit 1: Rapid Ethnographic Assessment, Design Probes. Then, practice partners engage in a facilitated group activity to rate the criticality, chronicity, and ubiquity of the list of determinants in Site Visit 2. Finally, practice partners engage in a third site visit where they create Causal Pathway Diagrams that allow them to match strategies to prioritize determinants and create Implementation Plans.
41474595|NCT05941273|DEVICE|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
40800711|NCT05319808|OTHER|Manual therapy|Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
40800712|NCT05319808|DEVICE|Telehealth exercises|A novel, remote computer based cervical joint positioning exercise and cervical kinaesthetic exercise (CKE) program. A technical consultant monitors the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so subjects can be encouraged with a friendly reminder.
40800713|NCT05319808|OTHER|Non-computer based exercises|Home-exercises in the need of each subject (pragmatic approach) taught by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
41317634|NCT01604876|DEVICE|light therapy 30 min morning and evening, three months|"200 lux light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] To lower the intensity to 200 lux the bulbs are enwrapped with one layer of L299s neutral density filter (LEE Filters, Andover, UK).~Therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
41317635|NCT01523314|DRUG|dexamethasone - Cyclodextrin eye drops|The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
41317636|NCT01523314|OTHER|intravitreal Avastin injection +/- macular laser|The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
41317637|NCT02072720|DRUG|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
41317638|NCT05454722|DEVICE|ADEX Gel|Emollient Gel with added anti-inflammatory
41317639|NCT05796882|BEHAVIORAL|Whole Food Plant-Based Diet Ad Libitum|"Participants will follow a Low Fat Whole Food Plant-Based Diet Ad Libitum for 8 weeks. It consists of increasing the daily consumption of fruits and vegetables, including sources of vegetable protein such as legumes (beans, lentils, chickpeas, peas, etc), soybeans and their derivatives (tofu, textured soybeans, soymilk), and whole grains. (oats, wheat, rice, quinoa, corn), nuts and seeds high in omega-3 fatty acids (chia, flaxseed, hemp), and minimize processed foods, and foods high in saturated fat. Avoiding animal-sourced foods.~There will be no caloric restriction, however, visual support will be provided, in the form of a traffic light, to distinguish the frequency with which each type of food can be consumed"
41317640|NCT05796882|BEHAVIORAL|Nutritional Standard Care|Nutritional Consultation every month for 2 months. Recommendations on healthy eating and lifestyle will be given. Duration 8 weeks
41317641|NCT05553678|DRUG|Midazolam|Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.
41317642|NCT05553678|DRUG|Normal saline|Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.
41317643|NCT00255086|DRUG|Memantine|10mg Memantine
41317644|NCT00255086|DRUG|Placebo pill|10mg placebo pill
41317645|NCT01391819|OTHER|Data collection|Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.
41474596|NCT02057445|DRUG|EBV CTL's|Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
41474597|NCT02057445|OTHER|Peripheral Blood Donor|Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
41474598|NCT01841216|DEVICE|Lower Body Exercises with and without resistance|lower body exercises with and without resistance designed to activate the gluteal/hip musculature
41474599|NCT05433259|DEVICE|Overnight orthokeratology|Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.
41004659|NCT05826964|DRUG|PI3K inhibitor + AI|Participants will receive standard of care a PI3K inhibitor therapy (Alpelisib), in combination with an AI therapy (Letrozole) in Step 2 Arm 2 and Step 3. PI3K inhibitor + AI therapy administered as one of the available options for early switch from SERD+CDk4/6i therapy in administered in Step 1.
41004660|NCT05826964|DRUG|Chemotherapy|Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
41317646|NCT01391819|PROCEDURE|Blood sample collection|A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.
41317647|NCT00897325|OTHER|Cytology Specimen Collection Procedure|Correlative studies
41317648|NCT00897325|OTHER|Laboratory Biomarker Analysis|Correlative studies
41317649|NCT02335112|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
41317650|NCT02335112|DEVICE|NanoKnife|
41317651|NCT00444509|DRUG|GW685698X|GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
41317652|NCT00444509|DRUG|GW685698X containing magnesium stearate|GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
41317653|NCT04176744|OTHER|Uni- and bilateral magnetic phrenic nerve stimulation|Uni- and bilateral magnetic phrenic nerve stimulation using different coils, stimulation patterns (frequency, intensity, number of pulses) and locations (neck, chest).
41317654|NCT02221271|DRUG|NPB-01|
41317655|NCT00349752|BIOLOGICAL|certolizumab pegol 400 mg|Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
41474600|NCT04208126|DEVICE|ECMO|ECMO implantation immediately after ICU admission
41474601|NCT05772884|OTHER|Supervised Exercise Intervention|Exercise duration will be gradually increased as tolerated to 50 min/session, with intensity ramping up to 65-75% HRmax by week 3. On-site exercise sessions will occur along a pre-marked walking path, and a trained staff member will walk alongside the participant to monitor their heart rate. Speed will be manipulated to achieve desired intensity and to sustain heart rate in the target zone. Heart rate will be monitored and recorded via telemetry during the on-site exercise sessions. Step cadence (i.e., steps/minute) will also be monitored and recorded during the on-site sessions and discussed with participants as a way to understand and track their speed when completing off-site walking sessions on their own.
41474602|NCT04130178|DRUG|Nerve block|block of the digital nerves in rheumatoid arthritis patient
41474603|NCT04130178|DRUG|Saline injection|subcutaneous saline injection
41474604|NCT05827484|BIOLOGICAL|Autologous platelets rich plasma|30 ml of venous blood were drawn from the participant by means of venipuncture. The collected blood was mixed with 3 ml anti-coagulant acid citrate dextrose in the centrifugation sterile tube. The blood sample was then centrifuged using the centrifugation machine. 3 ml of PRP from the buffy coat layer were loaded in a 5 ml syringe. After local sterilization and draping of the site of injection and under US guidance the hematoma was aspirated from the injury site and the freshly prepared PRP was injected.
41474605|NCT05827484|COMBINATION_PRODUCT|Autologous platelets rich plasma + oral LOSARTAN administration|in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till day 30 after injury.
41474606|NCT06241859|DEVICE|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to maintain a sedation depth between 80-90 value, which corresponds to light sedation definition.
41474607|NCT06241859|DEVICE|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to monitor sedation depth.
41474608|NCT06364878|DIAGNOSTIC_TEST|In vivo confocal microscopy|The patients cornea will be examined non-invasively by IVCM
41474609|NCT06364878|DIAGNOSTIC_TEST|Tear film sampling|Patients tear film will be collected and stored at -80 degrees for analysis
41474610|NCT05886231|OTHER|music sound therapy|investigate the effects of music on intraoperative hemodynamic parameters, anesthesia depth, muscle relaxant consumption, analgesic consumption and pain and side effects (nausea, vomiting, tremor) in the early postoperative period in patients undergoing thyroidectomy operation under general anesthesia.
41474611|NCT01329224|OTHER|Measurement of platelet anti-aggregation|Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
41474612|NCT02332213|PROCEDURE|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
40800714|NCT05792982|BEHAVIORAL|12 hour fasting for 29 days|This study aims to determine the effects of fasting on serum FGF21 levels. For this reason, male adults who fasted during the Ramadan were included in the study.
41474613|NCT02332213|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
41474614|NCT02332213|PROCEDURE|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
41474615|NCT02332213|PROCEDURE|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
41474616|NCT02332213|PROCEDURE|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
41474617|NCT02332213|PROCEDURE|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
41474618|NCT02224066|DRUG|Ticagrelor 90 mg twice per day during three months following TAVI|
41474619|NCT02224066|DRUG|Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI|
40800715|NCT02544867|BEHAVIORAL|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
41474620|NCT05119660|DEVICE|Intermittent Theta Burst Stimulation|iTBS
41474621|NCT04815252|BEHAVIORAL|CHIME|CHIME is a professional development program to provide knowledge and skills for nurturing early childhood educator mindfulness, compassion and socio-emotional learning. CHIME is a manualized curriculum delivered by a trained facilitator. The intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Sessions can be delivered online or in-person.
40800716|NCT01127984|DRUG|tissucol|dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
41157079|NCT04387916|DRUG|KC1036|Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
41474622|NCT03052972|DRUG|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose
41474623|NCT03052972|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
41317656|NCT00349752|OTHER|Placebo|Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
41317657|NCT00918086|DIETARY_SUPPLEMENT|Vitamin D pill|Oral tablet taken for 16 weeks
41474624|NCT04594915|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics \[SmPC\]).
41474625|NCT03221231|DRUG|N-acetylcysteine|1200 mg/day, twice daily, N-acetylcysteine
41474626|NCT03221231|DRUG|Placebo Oral Tablet|twice daily, placebo
41474627|NCT03221231|OTHER|Magnetic Resonance Imaging|
41474628|NCT03221231|OTHER|Neurocognitive measures|
41474629|NCT03221231|OTHER|Neuro-inflammatory measures|
41474630|NCT05178914|PROCEDURE|Treatment adaptation|Patients will benefit from intensified treatment or de escalation treatment according to the result of the index of microcirculatory resistance
41317658|NCT00918086|DIETARY_SUPPLEMENT|Placebo|An inactive pill that looks and tastes like the Vitamin D pill
41317659|NCT04637971|OTHER|Coaching|Participants will receive 4 sessions of group coaching intervention within 6 weeks. Each session is in a group of 3-4 women and lasts for approximately 1.5 hours. The sessions will be conducted by experienced social workers.
41317660|NCT04637971|OTHER|Self-help tips plus telephone support|Participants will receive 4 self-help tips sent via SMS and 4 phone call from a social worker in 6-week of time. During the telephone call, the social worker will advise the client to make use of the tips we sent to her.
41317661|NCT03701217|DRUG|Eltrombopag|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents.
41317662|NCT05129995|OTHER|Passive heat treatment|Participants will be subjected to an 8-week (3 x pw) passive heat treatment, by means of infrared sauna bathing, intervention.
41474631|NCT00949988|DRUG|Dasatinib and Rituximab|"In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional"
41474632|NCT00792623|BIOLOGICAL|VarilrixTM|Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.
41474633|NCT03768284|OTHER|Saliva or buccal sample|Saliva or buccal sample
41474634|NCT02989298|OTHER|No intervention|Registration of all PD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals，which have signed the contract in China.
41474635|NCT02340221|DRUG|Taselisib|Taselisib 4 mg was administered as two tablets of 2 mg each as per the schedule specified in the respective arm.
41474636|NCT02340221|DRUG|Placebo|Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
41474637|NCT02340221|DRUG|Fulvestrant|Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
41317663|NCT03017482|DEVICE|Medtronic 670G|"This is an open labeled follow up of a clinical startup of a newly approved FDA closed loop insulin delivery system. It is essentially a prospective chart review of the clinically startup of a FDA closed loop system and has many elements of a quality improvement project with additional features of:~* Questionnaires about the utility and impact of the device~* Use of the device in children younger than the current FDA approval range"
41317664|NCT01241019|DRUG|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
41474638|NCT03829579|DRUG|Esketamine|Participants will self-administer esketamine nasal spray, under the supervision of the healthcare professional at the site of care. A starting dose of 56 milligram (mg) will be administered intranasally into each nostril on Day 1 with subsequent doses of 56 mg or 84 mg administered during Weeks 1-4 (2 treatment sessions per week). For participants who respond, treatment is continued as follows: 56 mg or 84 mg of esketamine nasal spray during Weeks 5-8 (once weekly), and Week 9 onwards (every 2 weeks or once weekly), with period re-evaluation to determine the need for continued treatment. Doses will be adjusted based on efficacy and tolerability to the previous dosing.
41474639|NCT00710749|DEVICE|Disposable device|Disposable urine flow meter
41474640|NCT00710749|DEVICE|Digital device|Digital urine flowmeter
41474641|NCT00710749|DEVICE|Clinic flow measurement|Clinic gold standard flow measurement
41474642|NCT05909202|DEVICE|Sham VR|Nature-based non-immersive VR program
41474643|NCT05909202|DEVICE|Active VR|Nature-based immersive VR program
41474644|NCT00468429|DRUG|Subconjunctival Bevacizumab|
41474645|NCT05945992|BEHAVIORAL|Emotion regulation|Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises
41474646|NCT05945992|BEHAVIORAL|Self-acceptance|Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.
41474647|NCT05945992|BEHAVIORAL|Mindfulness|Guided mindfulness-exercises, different meditation techniques like body scan, breathing meditation. Reflection and exchange within the group
41474648|NCT05945992|BEHAVIORAL|Resource activation|Exercises focusing on developing positive emotions and fostering personal strengths, based on the Positive Psychology movement of Martin Seligman, working on individual values, life goals and sense of life.
41474649|NCT05945992|BEHAVIORAL|Control component 1_social behaviors in groups|Control component for emotion regulation
41474650|NCT05945992|BEHAVIORAL|Control component 2_communication skills|Control component for self-acceptance
41474651|NCT05945992|BEHAVIORAL|Control component 3_stress management|Control component for mindfulness
41317665|NCT01784952|DIETARY_SUPPLEMENT|Dietary intervention|The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
40800717|NCT01127984|PROCEDURE|drainage system|application of vacuum drainage system
41317666|NCT06159829|BEHAVIORAL|experimental|intervention group used VR with a natural landscape and relaxing musical accompaniment during the upper endoscopy procedure.
41317667|NCT04448093|PROCEDURE|dental treatment|Dental treatment of adequacy of oral environment and assessment of quality of life and self-esteem through questionnaires comparing a group that received treatment with another that did not.
41317668|NCT01396902|BEHAVIORAL|Standard of care|You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
41317669|NCT01396902|BEHAVIORAL|Text Messaging|You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
41317670|NCT02918409|DRUG|Colistin|
41317671|NCT02918409|DRUG|Tobramycin|
41317672|NCT00879606|DRUG|ALT-836|In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
41317673|NCT00879606|DRUG|Placebo|In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
41317674|NCT05950659|DEVICE|Orpyx SI Sensory Insole System|The Orpyx SI Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading
41317675|NCT03169023|BEHAVIORAL|ScaleDown|-Participants receives behavioral prompts and daily feedback by text messaging with motivational instructions for specific dietary and behavior modifications
41317676|NCT03169023|BEHAVIORAL|Enhanced Usual Care Packets|-From the American Cancer Society Website
41317677|NCT03169023|OTHER|12-Item Short Form Health Survey|-Measures functional health and well-being from the patient's perspective
41317678|NCT03169023|OTHER|International Physical Activity Questionnaire short form|-7 item scale that measures a range of physical activity from vigorous to sedentary over the last 7 days
41317679|NCT03169023|OTHER|Multidimensional Body Self Relations Questionnaire - Appearance Subscales|-Gold-standard for the assessment of body image attitudes and contains 34 items
41317680|NCT03169023|OTHER|Cancer-Related Body Image Scale|-13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment
41317681|NCT03169023|OTHER|Patient Health Questionnaire 9-Item Version|-Widely used measure that assesses mood, including an item that screens for suicidality
41317682|NCT03169023|BEHAVIORAL|iOTA|-Washington University based intervention
41317683|NCT02616016|DEVICE|MRI Guided High Intensity Focused Ultrasound|Target treatment of bone metastases using High Intensity Focused Ultrasound
41317684|NCT04888351|OTHER|Comparison of complications between mastectomies with IBR and mastectomies without IBR|"Precocious complications (less than 3 months after surgery) are classified with Clavien's classification : hematoma, seroma, stitches, antibiotics, transfusion.~Tardive complications (after 3 months until 1 year) are more specifics : hematoma, seroma, tardive infections, asymmetry, removing of implant, breaking up of implant, skin necrosis, capsular contractures, implant loss, chronic pain."
41317685|NCT04888351|OTHER|To analyze variations of number of patients eligibles to IBR|Including patients with differents classic risk factors : T3, T4, tobacco, diabetes, overweight and obesity, hypertension, age over 70, thoracic irradiation in the past
41157080|NCT04883541|BEHAVIORAL|yoga and meditation|The pregnant women in the study group were given yoga and meditation classes, which included a total of twenty 10-week lessons, which were done by the researchers as 6-week birth preparation training, and with the onset of the birth action, birth processes were followed in the course of labour period yoga and meditation.
40800718|NCT02792309|BEHAVIORAL|MotherWise Program|Healthy Marriage or Relationship Education services for pregnant women.
41157081|NCT04883541|BEHAVIORAL|Birth preparation training|The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
41317686|NCT00229203|DRUG|Plitidepsin|3-hour infusion every 2 weeks alone or in combination with dexamethasone
41317687|NCT05133245|OTHER|Diagnostic study only|Diagnostic study only
41317688|NCT04000347|DRUG|2.5% benzoyl peroxide gel|2.5% benzoyl peroxide gel was given to patients for 2 weeks
41317689|NCT04000347|DRUG|5% benzoyl peroxide gel|5% benzoyl peroxide gel was given to patients for 2 weeks
41317690|NCT03092349|DEVICE|Vector optimisation|Evaluation of hemodynamically best LV Stimulation vector and device programming according to measurements
41317691|NCT03177265|BEHAVIORAL|Text messaging prior to first counseling call|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
41474652|NCT05945992|BEHAVIORAL|Control component 4_constructive conflict resolution|Control component for resource activation
40800719|NCT02520544|DEVICE|Accolade stem|Total hip replacement
40800720|NCT02520544|DEVICE|Accolade II stem|Total hip replacement
40800721|NCT02520544|DEVICE|Trident/Tritanium cup|Total hip replacement
40800722|NCT01977196|BIOLOGICAL|DPT/HepatitisB/Hib vaccine|DPT/HepatitisB/Hib vaccine (Bio Farma)
41474653|NCT00118378|DRUG|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
41474654|NCT00118378|DRUG|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
41474655|NCT05015335|DRUG|Adalimumab|ADA 40mg q2w
41474656|NCT05015335|DRUG|Methotrexate|MTX 10mg qw
41474657|NCT02154724|DEVICE|aDBS|The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.
41474658|NCT02154724|DEVICE|DBS|The aDBS s applied for two hous in DBS modality.
41474659|NCT02459418|DRUG|Afolia|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
41474660|NCT02459418|DRUG|US Gonal-f®|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
41474661|NCT01017419|BEHAVIORAL|Counseling|Informational Counseling provided after hearing aid fitting
41317692|NCT03177265|BEHAVIORAL|Text-to-Enhance|Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
41317693|NCT03177265|BEHAVIORAL|Mail Notice|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
41474662|NCT01161394|DRUG|Pioglitazone 15mg|
41474663|NCT01161394|DRUG|pioglitazone 30mg|
41474664|NCT01161394|DRUG|placebo|
41474665|NCT00384384|DRUG|oral 18B Glycyrrhetinic acid versus placebo|
41474666|NCT02710682|PROCEDURE|Mini-open surgery|"This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.~1. Skin disinfection; Local anesthesia (lidocaine 1%).~2. Skin incision, slightly anterior to lateral epicondyle.~3. Exposure of the plane between the tendon and fascia.~4. Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.~5. Excision of diseased tissue of the ECRB tendon.~6. ECRL tendon is sutured back to the fascia. The skin is closed.~7. Patient is monitored for 30 minutes after procedure."
41474667|NCT02710682|DEVICE|Ultrasound-guided Tendon fenestration|"This treatment will be administered by a fellowship-trained MSK radiologist.~1. Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.~2. Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.~3. Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.~4. Patient monitored for 30 minutes, before being discharged."
41474668|NCT01556152|DRUG|GRC 17536 (Medium Dose)|1 BD for 28 days
41474669|NCT01556152|DRUG|GRC 17536 (Low Dose)|1 BD for 28 Days
41317694|NCT03177265|BEHAVIORAL|Telephone Counseling|Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
41317695|NCT02020460|DEVICE|Subdural trial lead|
41317696|NCT02020460|DEVICE|Epidural trial lead|
41317697|NCT00178048|DRUG|paroxetine|
41317698|NCT00086944|BIOLOGICAL|oblimersen sodium|Given IV
41317699|NCT00086944|BIOLOGICAL|rituximab|Given IV
41474670|NCT01556152|DRUG|Placebo|Matching Placebo for 28 Days
40800723|NCT01117298|DRUG|Tadalafil|Tab Tadalafil, 20 mg alternate day for 8 weeks
40800724|NCT01117298|DRUG|Placebo|Tab Placebo every alternate day for 8 weeks
40800725|NCT03379948|DIAGNOSTIC_TEST|blood culture|blood culture to diagnose blood stream infection
41317700|NCT00086944|DRUG|ifosfamide|Given IV
41317701|NCT00086944|DRUG|carboplatin|Given IV
41317702|NCT00086944|DRUG|etoposide|Given IV
41317703|NCT00086944|BIOLOGICAL|filgrastim|Given SC
41004661|NCT05826964|DRUG|Oral SERD|Participants will receive standard of care oral SERD therapy (Elacestrant) in Step 2 Arm 2 and Step 3. Oral SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
41004662|NCT01105507|DRUG|canakinumab (company code: ACZ885D)|
41004663|NCT05609188|OTHER|Guaranteed Income|Monthly cash transfer of $500 per month for 12 months.
41317704|NCT00086944|BIOLOGICAL|pegfilgrastim|Given SC
41317705|NCT00086944|OTHER|laboratory biomarker analysis|Correlative studies
41317706|NCT03179436|BIOLOGICAL|Quavonlimab|Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
41474671|NCT00384475|DRUG|Ciclesonide Nasal Spray|
41474672|NCT01702077|PROCEDURE|Neurofeedback|
41474673|NCT01702077|PROCEDURE|Sham feedback|
41474674|NCT01983514|DRUG|8IU intranasal oxytocin|
41474675|NCT01983514|DRUG|24 IU intranasal oxytocin|
41474676|NCT01983514|DRUG|1 IU intravenous oxytocin|
41474677|NCT01983514|DRUG|Placebo|
41474678|NCT03519984|DRUG|Cytarabine|Given IV
41474679|NCT03519984|OTHER|Laboratory Biomarker Analysis|Correlative studies
41474680|NCT03519984|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
41474681|NCT03519984|DRUG|Vincristine Liposomal|Given IV
41474682|NCT05444322|DRUG|RD14-01 cell infusion|Autologous CAR T cells
41474683|NCT06139055|DRUG|GSBR-1290 (Capsule/Tablet)|Participants will receive GSBR-1290 oral capsules or tablets.
41474684|NCT06139055|DRUG|GSBR-1290|Participants will receive GSBR-1290 oral tablets.
41474685|NCT06139055|DRUG|Placebo|Participants will receive matching-placebo oral tablets.
41474686|NCT06139055|DRUG|Placebo (Capsule/Tablet)|Participants will receive matching-placebo oral capsules or tablets.
41317707|NCT03179436|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
41474687|NCT05281978|BEHAVIORAL|Decrease Sedentary Time + Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise; personalized step count goals to increase daily volume of physical activity and displacement of sedentary time
41474688|NCT05281978|BEHAVIORAL|Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise
41474689|NCT01940302|DIETARY_SUPPLEMENT|LEHEL multi-nutrients supplement|The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
41474690|NCT04577885|DRUG|SHR2554 and Rifampin|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
40800726|NCT00368745|DRUG|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
41474691|NCT00951626|BEHAVIORAL|exercise intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
41474692|NCT00951626|BEHAVIORAL|telephone-based intervention|"Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.~For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant."
41157082|NCT06089967|OTHER|Medical chart review|Clinical data for all enrolled patients will be abstracted from the electronic medical record. This will include but will not be limited to patient demographics, primary disease (site, histology, histologic grade, staging system used, staging, molecular markers), prior cancer treatment, immunotherapy received, time of onset, treatment received for irAEs, and disease response to treatment. Clinical data will be collected for up to one year after discontinuation of cancer immunotherapy treatment.
41474693|NCT00951626|DIETARY_SUPPLEMENT|dietary intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
41474694|NCT00951626|OTHER|educational intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
41474695|NCT00951626|OTHER|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
41474696|NCT00951626|PROCEDURE|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
41474697|NCT00951626|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
41474698|NCT00951626|PROCEDURE|assessment of therapy complications|Collected throughout the 12 month study period
41474699|NCT00951626|PROCEDURE|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
40800727|NCT00368745|DRUG|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
41157083|NCT02312362|PROCEDURE|Combined sclerotomy ab interno and phaco|
41157084|NCT02312362|PROCEDURE|Phacoemulsification with IOL implantation|
41474700|NCT00951626|PROCEDURE|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
41474701|NCT00951626|PROCEDURE|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
40800728|NCT00061035|BIOLOGICAL|Transgenic Lymphocyte Immunization Vaccine (TLI)|
41317708|NCT03179436|DRUG|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
41317709|NCT00899210|OTHER|laboratory biomarker analysis|
41317710|NCT00899210|PROCEDURE|cryosurgery|
41317711|NCT00899210|PROCEDURE|radiofrequency ablation|
41317712|NCT00899210|PROCEDURE|therapeutic conventional surgery|
41317713|NCT01217190|DRUG|Ondansetron (ODFS)|Test Article
41317714|NCT01217190|DRUG|Zofran (ODT)|Comparator
41317715|NCT05356741|DRUG|AMX-818|Administered as IV infusion
41317716|NCT05356741|DRUG|pembrolizumab|Administered as IV infusion
41317717|NCT03354702|OTHER|Aerobic|Aerobic exercise Patients performs 8 sessions of aerobic exercise (walking / running),with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
41317718|NCT03354702|OTHER|Stretching|Stretching Patients performs 8 sessions of stretching, with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
41317719|NCT02294318|BEHAVIORAL|HealthCall+Motivational Interviewing|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
41317720|NCT02294318|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
41317721|NCT01795586|DRUG|Eribulin|"Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.~Level 1: 0.9 mg/m\^2; Level 2: 1.1 mg/m\^2; Level 3: 1.4 mg/m\^2"
41317722|NCT01795586|DRUG|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
41317723|NCT03287752|DEVICE|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
41317724|NCT03287752|DEVICE|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
41317725|NCT03715959|PROCEDURE|Aspiration of Breast|Undergo NAF
41317726|NCT03715959|PROCEDURE|Biospecimen Collection|Undergo NAF
41317727|NCT00234208|PROCEDURE|Medical thoracoscopy|
41317728|NCT00234208|PROCEDURE|Simple chest tube drainage|
41317729|NCT03714906|PROCEDURE|Stellate ganglion block|Stellate ganglion block will consist of an injection of 0.25% bupivacaine placed under ultrasound guidance by a trained anesthesiologist in the pre-operative holding area prior to surgery.
41317730|NCT03548974|BEHAVIORAL|Treatment group 1|The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard). The exercise training was home-based and supervised via the internet.
41317731|NCT03548974|BEHAVIORAL|Treatment group 2|The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)
41317732|NCT03866148|DEVICE|Reveal LINQ|Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
41317733|NCT00054249|DRUG|T900607|
41317734|NCT00611221|PROCEDURE|Massage|Massage therapy by an RMT during labour
41317735|NCT00611221|PROCEDURE|Massage|Massage by anyone else, eg. husband, nurse, doula
41317736|NCT03849976|BEHAVIORAL|Therapeutic communication|Patients will be accompanied to the operating room by a stretcher bearer trained in therapeutic communication
41317737|NCT03518814|OTHER|Questionnaires|FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire
40800729|NCT01667497|DRUG|Fampridine SR|
41317738|NCT05960461|BEHAVIORAL|FMF (Families Moving Forward) Connect Pro|"FMF Connect Pro is a program supported by mental health providers to increase access to care for children (ages 3 to 12) with fetal alcohol spectrum disorders (FASD) and their families. FMF Connect Pro teaches and supports providers in 3 main activities:~1. Routine screening of prenatal alcohol exposure (PAE)~2. Apply DSM-5 diagnostic criteria for Neurodevelopmental Disorder Associated with Prenatal Alcohol Exposure (ND-PAE)~3. Support caregivers using the FMF Connect app~FMF Connect Pro involves a Provider Dashboard with several main sections:~* Learning - includes content and additional resources to support providers in learning how to screen PAE, diagnose ND-PAE, and support families using the FMF Connect app.~* Tools and Resources - includes: screening, diagnostic, and documentation templates; app tip sheets; workbooks; supporting articles, websites, and other resources~* Clients - providers can track clients' progress using the FMF Connect app"
41317739|NCT05960461|BEHAVIORAL|ECHO (Extension of Community Healthcare Outcomes) implementation.|Mental health providers participate in a 13-session tele-mentoring training program using the ECHO (Extension of Community Healthcare Outcomes) approach. Each session involves a brief didactic presentation and case-based learning using de-identified cases shared by participants. The curriculum teaches providers how to do FMF Connect Pro.
41317740|NCT05960461|BEHAVIORAL|Self-Directed Learning implementation.|Mental health providers complete 13 learning modules asynchronously on the FMF Connect Pro Dashboard. These modules include pre-recorded didactic content, brief exercises to assess learning, and additional resources. The curriculum teaches providers how to do FMF Connect Pro.
41317741|NCT03810001|BEHAVIORAL|Mechanical Stimulation|micromanipulation technique before insertion of the microinjection needle into the oocyte and expulsion of the spermatozoon
41317742|NCT00913133|DRUG|Desirudin|Desirudin SC 15mg q12h
41317743|NCT03670524|OTHER|Greenness as a therapeutic intervention|Greenness to be used as a therapeutic intervention
41317744|NCT03017365|OTHER|Stable Resistance Training|traditional machine-based resistance training
41317745|NCT03017365|OTHER|Unstable Resistance Training|free weight resistance training using unstable devices
41317746|NCT03017365|OTHER|Adductor/Abductor Resistance Training|machine-based adductor/abductor resistance training
41317747|NCT00004278|DRUG|ganciclovir|
40800730|NCT01667497|DRUG|Placebo|
40800731|NCT01687543|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
40800732|NCT01687543|OTHER|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
41317748|NCT02678663|PROCEDURE|Injection-assisted Cold Snare Polypectomy|Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
41317749|NCT02678663|PROCEDURE|Endoscopic Mucosal Resection|Resection of a polyp after blue-tinted saline injection using snare electrocautery
41317750|NCT01235286|PROCEDURE|remote ischemic preconditioning|"A standardized location for microcirculatory assessment was determined on the left leg of each participant between the proximal and distal third of a drawn line between the anterior superior iliac spine and the lateral aspect of the Patella.~The healthy subjects had to rest before starting data assessment in a horizontal position for 15 minutes. The probe was taped on the left upper leg in a standardized manner after localizing the measuring point. A blood pressure cuff was applied on the contralateral upper arm. Baseline data was assessed over 5 minutes before starting remote ischemia. Three circles of a five minute ischemia were applied at the contralateral right upper arm at suprasystolic levels. Parameters of microcirculation were assessed continuously over time. Microcirculation during the reperfusion phase was ascertained over 10 minutes after first and second remote ischemia and 15 minutes after the third remote ischemia."
41317751|NCT02322268|DIETARY_SUPPLEMENT|Cosmos Caudatus|15g of Cosmos caudatus consumed with lunch or dinner
41317752|NCT01836211|OTHER|Fast strategy|High sensitivity troponin T followed by computed coronary tomography angiography
41317753|NCT01836211|OTHER|Standard of care strategy|Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
41317754|NCT05369026|OTHER|Single leg immobilization|2 weeks of single-leg immobilization
41317755|NCT03411265|OTHER|self-administered, e-health application|"RETAIN is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT and its benefits when they started treatment. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
41317756|NCT04807036|DEVICE|Hypotension Prediction Index|HemoSphere Clinical Platform with Acumen Hypotension Prediction Index Feature
41317757|NCT04793386|DIAGNOSTIC_TEST|carotid ultrasound|Every time checking pulse, evaluate the carotid artery compressibility and pulsatility by ultrasound
41317758|NCT02791087|OTHER|Computed Tomography Angiography|The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
41317759|NCT02791087|OTHER|Intra-operative graft flow rate measurement|This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
41317760|NCT00422409|PROCEDURE|Endoscopic stenting|
41317761|NCT02496117|PROCEDURE|Electrical mapping, nerve stimulation checked renal denervation procedure|
41317762|NCT02496117|PROCEDURE|Electrial mapping, nerve stimulation guided renal denervation procedure|
41317763|NCT06160869|BEHAVIORAL|Acceptance and commitment therapy|"The psychoeducational intervention will consist of seven structured sessions aimed at introducing patients with primary psychosis to the principles and practices of Acceptance and Commitment Therapy (ACT). The primary focus of the intervention is to empower participants to effectively manage distressing thoughts and feelings while pursuing meaningful and valued life goals. Each session covers specific aspects of ACT.~Acceptance and commitment therapy will be adminitered in addition to treament as usual provided to patients."
41317764|NCT06160869|COMBINATION_PRODUCT|Treatment as usual|The treatment as usual (TAU) for all patients regardless of condition will consist of hospital treatment, including daily medication management sessions with a psychiatrist (e.g., antipsychotic and other medications as appropriate), community meetings, other group therapy, case management, occupational therapy, open air walks, discharge planning, physical examination, and other services (e.g., medical testing).
41317765|NCT06239506|OTHER|no intervention|no intervention
41317766|NCT01450956|DRUG|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
41317767|NCT01450956|OTHER|Control|Patients will receive only oxygen and air through oxygenator
41317768|NCT04015414|DRUG|Varenicline|191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling
41317769|NCT04015414|DRUG|Cytisine|185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
41317770|NCT05576155|DRUG|Compound 21|Compound 21 + Ringer's is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M
41317771|NCT05576155|DRUG|Compound 21 + losartan|Compound 21 + losartan (43 µM) is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M.
41474702|NCT00951626|PROCEDURE|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
41004664|NCT05609188|BEHAVIORAL|Peer learning circles|Participants can opt-in to attend peer learning circles (also called My Money Hour), which are discussion groups of 10-12 participants about financial topics co-led by a peer (Black youth) with experience in financial programming and an adult financial coach. My Money Hour sessions will be offered on-line multiple times throughout every month of the project, with rotating themes, to ensure that the 50-minute sessions are available different days of the week and times of the day.
41317772|NCT03889600|OTHER|REDD-CAT|After obtaining informed consent from a participant and gathering baseline data, the study RA will send a flag in the EMR to notify the nurse care manager that a patient has enrolled in the REDD-CAT pilot. The nurse care manager will then incorporate the administration of the REDD-CAT to the patient as part of standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
41474703|NCT05187858|DRUG|LNP3794|LNP3794 capsules administered orally once daily
41474704|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
41474705|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
41474706|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
41474707|NCT01477502|OTHER|individual homeopathic treatment|participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
41474708|NCT01477502|OTHER|standard treatment without homeopathy|participants receive standard UTI prophylaxis
40800733|NCT01183520|DIETARY_SUPPLEMENT|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
41157085|NCT05880459|DRUG|propofol and magnesium sulphate ,propofol and nalbuphine|"The patients will be randomly divided into 2 groups by using a computer-generated randomization tableAll patients will fast from solids for 8 h and from liquids for 2 h. After arrival at preoperative area an intravenous cannula will be placed in the peripheral vein of right hand for fluid infusion and medicine administration.~All of the patients will be interviewed by the patient sedation satisfaction assessment tool (PSSI) regarding their experience 1 hour after the operation."
41317773|NCT02943512|OTHER|Discharge day of procedure|Subjects will be discharged the day of the procedure if safe
41317774|NCT05147974|BEHAVIORAL|DOZE app|"Complete DOZE app: Delivering Online ZZZ's with Empirical support (DOZE) app plus a Consensus Sleep Diary (CSD).~The DOZE app, is a web-based app optimized for desktop, smartphone, or tablet use. It is a self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected applications that will allow tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log onto the sleep dairy (via automated alerts) once a day over a 10-week period to complete sleep diary entries, develop and track their goals, and receive sleep health education/tailored sleep health interventions.~1-week pre- and post- intervention, participants will complete a battery of baseline study questionnaires and have the option of using a Geneactiv actigraphy device along with a CSD."
41317775|NCT05364983|DEVICE|Juvene IOL|Cataract extraction and implantation of a posterior chamber IOL
41317776|NCT05364983|DEVICE|Tecnis® Monofocal (ZCB00, PCB00 or DCB00)|Cataract extraction and implantation of a posterior chamber IOL
41317777|NCT02279121|DEVICE|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
41317778|NCT02279121|DRUG|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
41317779|NCT03638882|BEHAVIORAL|Duolingo|Will learn Spanish using the commercially available Duolingo application. It is a computerized language training program.
41317780|NCT03638882|BEHAVIORAL|BrainHQ|Will use the commercially available Posit Science product Brain HQ. Brain HQ is a computerized adaptive cognitive brain training program.
41317781|NCT03638882|BEHAVIORAL|Passive Control|No Intervention.
41317782|NCT04628728|OTHER|Survey based on questionnaire (self-designed)|Participants are handed a questionnaire to asses comprehension of medical content provided in the referral letters.
41317783|NCT03205826|OTHER|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
41474709|NCT00042549|DEVICE|Extracorporeal Shock Wave Lithotripsy|
41474710|NCT00042549|DRUG|ursodiol|
41474711|NCT04722328|DIAGNOSTIC_TEST|CSF metagenomic next generation sequencing (mNGS)|TestCSF routine, biochemical, smear staining (Gram staining, acid fast staining, ink staining), culture and mNGS。
41474712|NCT04986852|DRUG|Olinvacimab|Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).
41474713|NCT06318039|OTHER|Novel program|Applying new training method; the Nordic hamstring exercise
41474714|NCT06318039|OTHER|Traditional program|Conventional rehabilitation training administered
41474715|NCT02631837|PROCEDURE|vNOTES hysterectomy|Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
41474716|NCT02631837|PROCEDURE|LSC hysterectomy|Surgical removal of the uterus by transabdominal laparoscopy
41004665|NCT05609188|BEHAVIORAL|Financial coaching|Participants can opt-in to receive financial coaching sessions with a trained financial mentor. Meetings will occur monthly and typically include six one hour sessions. The mentor will be responsive to individual needs, but will touch on the following priority areas: building credit (credit repair, improving credit scores, credit products); savings (emergency savings plans, savings habits and strategies, understanding savings accounts); money management (creating budgets, understanding income vs expense, assessing spending, making better financial decisions); financial products (credit building products, auto loans, credit cards); and long-term goals (home ownership, investments).
41004666|NCT06036069|OTHER|Conventional physical therapy|"* Standing with feet together while the therapist was sitting behind and manually locking the child knees.~* Step standing with the therapist behind the child.~* High step standing and trying to keep balanced. The child stood on exercise mattress.~* Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~* Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction."
41004667|NCT02658279|DRUG|Pembrolizumab|
41004668|NCT01308190|DRUG|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
41004669|NCT01308190|RADIATION|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
41004670|NCT01308190|PROCEDURE|Transanal Endoscopic Microsurgery|6-8 weeks after Chemoradiotherapy
41004671|NCT01308190|PROCEDURE|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
41317784|NCT04012944|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System comprises seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)."
41317785|NCT03971500|DRUG|AntiPlatelet therapy|AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
41317786|NCT03971500|PROCEDURE|Percutaneous coronary intervention|PCI with DES implantation
41317787|NCT00091923|DEVICE|Eye patch|
41317788|NCT00091923|DEVICE|Spectacles|
41317789|NCT00247182|BEHAVIORAL|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
41317790|NCT00247182|BEHAVIORAL|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
41317791|NCT00247182|BEHAVIORAL|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
41317792|NCT05344027|DRUG|Mitotane|Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
41317793|NCT04195659|PROCEDURE|Mastectomy and chest masculinization|A surgical procedure in which the breasts are removed and the chest is given a masculine contour.
41317794|NCT01155596|BEHAVIORAL|negative pressure ventilator use|Body ventilators that assist ventilation by applying intermittent subatmospheric pressure around the thorax, abdomen, or airway and periodically expand the chest wall and inflate the lungs. They are relatively simple to operate and do not require tracheostomy. Chest cuirass is used in this study.
41317795|NCT02193828|BIOLOGICAL|Collagenase clostridium histolyticum|Single injection into nodule
41317796|NCT02193828|BIOLOGICAL|Placebo|Single injection into nodule
41317797|NCT01948895|DRUG|Desvenlafaxine|Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
41317798|NCT01374763|DRUG|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
41317799|NCT01374763|DRUG|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
41317800|NCT06099691|BEHAVIORAL|Qualitative Interviews|Participants will take part in one 90-minute interview (or two 45-minute interviews if preferred). The interview will have two sections. The first section will include discussion of what matters to participants. The second section will introduce PROMs which may be pertinent to measuring what matters. The participants will be helped to reflect on their relevance and usefulness to them.
41317801|NCT06036134|BEHAVIORAL|Baseline surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, gender, income, education level, relationship to the child), parental COVID-19 vaccine hesitancy, intentions to vaccinate child against COVID-19, and parents' attitudes, perceived norms, and perceived behavioral control about vaccinating their child against COVID-19,
41317802|NCT06036134|BEHAVIORAL|Digital Storytelling Intervention|In Aim 1, the investigators are creating intervention materials for Study Aim 2. These intervention materials include ten digital stories (each 2-3 minutes long) with a diverse sample of Hispanic parents and legal guardians who transformed from being COVID-19 vaccine-hesitant to vaccine-accepting. Each story uses individuals' own brief first-person visual narratives/stories that use digital images, audio recordings, music, and text to document personal experiences.
41317803|NCT06036134|BEHAVIORAL|Information Control Intervention|The control group participants will receive a CDC COVID-19 vaccine information sheet appropriate for their child's age.
41474717|NCT06098287|DEVICE|Residential mechanical ventilation system (Exhaust)|Exhaust-only ventilation system
41004672|NCT04552938|OTHER|pre-LVA|Venous serum samples were collected from patients before LVA.
41004673|NCT04552938|OTHER|post-LVA|Venous serum samples were collected from patients one-month after LVA.
41474718|NCT06098287|DEVICE|Residential mechanical ventilation system (CFIS) and air filtration upgrades|Central-fan-integrated-supply ventilation system and air filtration upgrades (MERV 10)
41474719|NCT06098287|DEVICE|Residential mechanical ventilation system (ERV) and air filtration upgrades|Balanced energy recovery ventilation system and air filtration upgrades (MERV 10)
41474720|NCT04776954|DEVICE|Forced Air Warming System|"The forced air warming system has a heater unit that blows air through a conduit to an air blanket that inflates with forced air that circulates throughout the blanket, and exits through tiny perforations on the patient-side of that blanket. The heat primarily warms the subject through convective means. As the warmed air escapes through the perforations in the blanket, it creates an environment of continuously circulating warm air that is in contact with the skin."
41474721|NCT04776954|DEVICE|Resistive Blanket Warming System|This blanket is equivalent to an operating-room-safe electric blanket. Through a power cord, a separate power source powers a semiconductor layer within the resistive blanket to generate heat. The heat primarily warms the subject by conductive warming through direct skin contact, and, secondarily, by warming the air around the participant in areas where there is no direct skin contact.
41474722|NCT00911599|DIAGNOSTIC_TEST|Blood metal ion levels|Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.
41474723|NCT00378651|PROCEDURE|Neck Auscultation|
41474724|NCT03170388|DRUG|IDP-126 Gel|Gel
41474725|NCT03170388|DRUG|IDP-126 Component A|Component A
41474726|NCT03170388|DRUG|IDP-126 Component B|Component B
41474727|NCT03170388|DRUG|IDP-126 Component C|Component C
41474728|NCT03170388|DRUG|IDP-126 Vehicle Gel|Vehicle Gel
41474729|NCT06616194|DRUG|Rimegepant|Rimegepant 75 mg orally disintegrating tablets
41004674|NCT04466475|BIOLOGICAL|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
41004675|NCT04466475|DRUG|Melphalan|Given via infusion
41004676|NCT04466475|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
41004677|NCT03544775|PROCEDURE|Isolated General Anesthesia|No nerve block identified through physician billing codes
41004678|NCT03544775|PROCEDURE|Peripheral Nerve Block|Nerve block identified through physician billing codes
41317804|NCT01286948|DRUG|Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
41317805|NCT01423773|DEVICE|Lotrafilcon A test contact lens|Silicone hydrogel single vision, soft contact lens with alternate parameters
41317806|NCT01423773|DEVICE|Lotrafilcon A control contact lens|Silicone hydrogel single vision, soft contact lens
41317807|NCT01423773|DEVICE|Ultra-High Resolution Optical Coherence Tomographer (OCT)|Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear
41341784|NCT00251277|DRUG|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
41474730|NCT06616194|DRUG|Placebo|Matching placebo oral disintegrating tablets
41474731|NCT04414475|DRUG|Selinexor|Participants will receive Selinexor oral tablets.
41474732|NCT04414475|DRUG|Dexamethasone|Participants will receive Dexamethasone oral tablets.
41474733|NCT04414475|DRUG|Bortezomib|Participants will receive Bortezomib SC injection.
41474734|NCT04414475|DRUG|Pomalidomide|Participants will receive Pomalidomide oral tablets.
41474735|NCT02994628|OTHER|Water|Water only without carbohydrate
41474736|NCT02994628|OTHER|Mini banana|Ingest mini banana containing higher phenolics and carbohydrate concentration
41474737|NCT02994628|OTHER|Cavendish banana|Ingest Cavendish banana (common banana)
41474738|NCT02994628|OTHER|6% sugar beverage|Ingest 6% sugar beverage containing same glucose and fructose profile as banana
41474739|NCT06616857|BEHAVIORAL|NUDGE|Individuals in this condition will receive intervention content to promote physical activity.
41474740|NCT06616857|OTHER|Education|Individuals will receive educational materials about how to increase physical activity
41474741|NCT00850681|DRUG|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
41004679|NCT03284216|PROCEDURE|Steady-state hyperglycemia|"Experimental diabetic like steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion."
41004680|NCT03284216|PROCEDURE|Fluctuating hyperglycemia|"Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections."
41004681|NCT03284216|BEHAVIORAL|Exercise|Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
41004682|NCT03637400|DRUG|TMP-SMX|TMP-SMX will be administered over a period of 7 days.
41004683|NCT03637400|DRUG|DOXY|DOXY will be administered over a period of 7 days.
41004684|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 1
41474742|NCT05800899|BEHAVIORAL|Brief Motivational Interviewing|Standard non-adapted brief motivational interviewing based on motivational interviewing.
41474743|NCT05800899|BEHAVIORAL|Culturally adaptation brief motivational interviewing|culturally adapted brief motivational interviewing based on motivational interviewing.
41474744|NCT06183450|DIAGNOSTIC_TEST|auditory level|"* Evaluation of auditory thresholds through audiometric tests.~* Evaluation of speech comprehension in noise through a vocal audiometry test in noise (FraMatrix).~* Evaluation of spatial auditory behavior and spatial precision using a spatial discrimination test (Minimum Audible Angle) and a static sound localization test in virtual reality."
41474745|NCT06183450|DIAGNOSTIC_TEST|cognitive level|"* Evaluation of attention and short-term memory functions with verbal and non-verbal tasks: Digit Span Test and Reading Span Test.~* Evaluation of inhibition capacities using the Stroop Test.~* Evaluation of executive functions, visual attention, reasoning, and mental arithmetic using the Raven's Matrix test."
41474746|NCT06183450|DIAGNOSTIC_TEST|quality of life level|- Evaluation of quality of live level via Speech, Spatial and Qualities of Hearing Scale (SSQ-12) and EuroQol-5D questionnaires.
40800734|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3A)|"The primary goal is to relate preoperative 64Cu-DOTA-ECL1i AAA uptake with CCR2+ cell activity in AAA tissue collected at the time of open repair. We will image AAA patients pre-operatively and collect tissue at the time of open repair in an attempt to demonstrate ex-vivo tissue corroboration of our imaging findings (n=20, 10 women and 10 men).~Participants with AAA will undergo routine clinical evaluation including ultrasound, CT scan and scheduling of open surgical repair. We will record age and tobacco use. If a renal function blood test has not been performed within the past 90 days, we will draw \~2 teaspoons of blood for a creatinine test. A contrast dye will be used for the CT portion of the PET-CT scan. Those having open surgery, their PET/CT imaging will be within 7-14 of the surgery and if available, collection of discarded aortic tissue at the time of surgery."
41317808|NCT02204826|DRUG|Korean Red Ginseng (KRG)|"The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks."
41317809|NCT02204826|PROCEDURE|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
41317810|NCT00460447|DRUG|Gemtuzumab Ozogamicin|
41474747|NCT00143299|DRUG|varenicline (CP-526,555)|
41474748|NCT05364437|DIETARY_SUPPLEMENT|Dietary Fibres Mix|The Fibre Mix, which comprises of a mix of dietary fibres (inulin, pectin and oat beta-glucan) will need to be taken by participants twice daily for 2 weeks with their usual food.
41474749|NCT05364437|DIETARY_SUPPLEMENT|Placebo|The placebo, which comprises of cellulose will need to be taken by participants twice daily for 2 weeks with their usual food.
41474750|NCT01711749|DRUG|Crestor®|Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
41474751|NCT01711749|DRUG|rosuvastatin calcium tablets|Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
41474752|NCT06397222|DRUG|Sin-Bev-SIRT|Sintilimab 200mg I.V. q3w and bevacizumab 7.5mg/kg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab and bevacizumab will last up to 24 months. Patients will be allowed to have sintilimab or bevacizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
41474753|NCT05487365|DEVICE|Comunicare Solutions Smartphone Application|The Comunicare patient support solution is specifically designed for digital support of HF. It consists of an application for patients and a dashboard for the caregivers. The application is a class 1 certified medical device. It includes different modules for patient education, medication adherence, symptoms tracking, electronic patient-reported outcome (ePRO), appointments, and video consultation. Caregiver dashboard application: this web-based application enables caregivers to administrate the care flow and review all patient-reported data and the alarm generated by the system. Security and Privacy: the application complies with strict security and privacy-related regulations. All data storages are encrypted on the patients' smartphone and a server located in an ISO-certified data center located in Belgium, and all information exchanges are highly secured. A GDPR-compliant privacy notice defines how patient personal data is processed and how data protection principles are applied.
41474754|NCT05487365|OTHER|Completing a quality of life (QOL)-questionnaire|Patients refusing to use Comunicare app will also be asked to complete a quality of life (QOL)-questionnaire at 0, 6 and 12 months which will be answered online.
41474755|NCT05468463|BEHAVIORAL|Living Donor Navigator Program|The investigators have developed a 4-session educational program that simultaneously addresses potential donor concerns with the evaluation/donation process and provides advocacy training to transplant candidates and their advocates.
41474756|NCT02279784|DEVICE|Freeway PTA|angioplasty with Freeway drug-eluting balloon
41474757|NCT02279784|DEVICE|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
41474758|NCT04254640|DRUG|Cladribine Injection|Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
41474759|NCT04254640|DRUG|Aclarubicin|aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
41474760|NCT04254640|DRUG|G-CSF|G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
41474761|NCT04254640|DRUG|cytarabine|cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
40800735|NCT04586452|DIAGNOSTIC_TEST|Non-AAA Group|We will determine the retention of 64Cu-DOTA-ECL1i in abdominal aorta of non-AAA volunteers (n=10, 5 women and 5 men). This group of participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard care. Both men and women, above the age of 40, with or without active tobacco use will be considered for participation.
41474762|NCT00613834|DRUG|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
41004685|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 2
41004686|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 3
41004687|NCT01529424|DRUG|Placebo|Dose 1
41317811|NCT04782804|DRUG|Capecitabine|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
41317812|NCT04782804|DRUG|PD-1 Antibody（Tislelizumab）|PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
41317813|NCT04119817|DIETARY_SUPPLEMENT|Mucosave® capsules|400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
41474763|NCT00613834|DRUG|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
41474764|NCT05893446|DIETARY_SUPPLEMENT|Nutrition care by RDN, medical nutrition therapy -stepped wedge cluster-randomized trial design. Everyone gets the intervention so no arms.|RDNs in the community will provide MNT and meals for three months post discharge from the hospital
41474765|NCT00078507|BEHAVIORAL|Sensory Re-training|
41474766|NCT00078507|BEHAVIORAL|Sensory Retraining|Facial Exercises
41474767|NCT00078507|BEHAVIORAL|Opening Exercises|
41157086|NCT05353296|BEHAVIORAL|Digital cognitive behavioral therapy for insomnia (CBT-I) program|A self-guided digital program of CBT-I (Somryst) that has been culturally adapted for Spanish-language speakers. Somryst is an interactive and tailored mobile-based program modeled on the primary tenets of face-to-face CBT-I. Patients will be asked to complete six cores (main intervention content) during the 9-week intervention period. The cores provide key content across six domains including behavioral (sleep restriction, stimulus control), cognitive (cognitive restricting), educational (sleep hygiene), overview, and consolidation/relapse prevention.
41317814|NCT04119817|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo capsules for a period of 8 weeks, once a day.
41317815|NCT02601443|DEVICE|Cervical Pessary|
41317816|NCT02026206|DEVICE|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
41317817|NCT02026206|DEVICE|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
41317818|NCT01016548|BIOLOGICAL|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
41317819|NCT01661920|OTHER|Intervention group|Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
41317820|NCT01661920|OTHER|Control group|Those antibiotic duration treatments which are not modified by their doctors.
41317821|NCT02103452|PROCEDURE|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin \&amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
41317822|NCT01884168|BIOLOGICAL|Dc-CIK immunotherapy|The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
41474768|NCT00549952|OTHER|no intervention study|
41474769|NCT00931996|DRUG|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
41474770|NCT01739634|DRUG|CASAD|CASAD is provided in 500mg capsules.
41474771|NCT04223778|DRUG|DOR/ISL|A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
41474772|NCT04223778|DRUG|ART|Baseline background ART regimen will be administered as per approved label. ART medication will not be provided by the Sponsor; participants will provide their own ART medications. Allowed drug classes include nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transferase inhibitors (InSTIs), fusion inhibitors, chemokine receptor 5 (CCR5) antagonists, post-attachment inhibitor, and pharmacokinetic (PK) boosters.
40800736|NCT04586452|OTHER|Ex Vivo Human AAA Specimens (Aim 2A)|The primary objective of this sub-aim is to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens from the Washington University Vascular Surgery Biobank (VS-BB). We will first perform a histopathological evaluation of human AAA specimens (n=75, including samples from this study) and categorize them based on clinical status (e.g, diameter) and degree of inflammation. We will consider healthy, nonatherosclerotic aorta (n=25) as negative controls, and non-aneurysmal aortas (n=25) from patients that have undergone surgery for aortoiliac occlusive disease as positive controls.
41004688|NCT01529424|DRUG|Placebo|Dose 2
41004689|NCT01529424|DRUG|Placebo|Dose 3
41474773|NCT06160414|DRUG|Metformin|Participants will receive Metformin orally, after fasting.
41317823|NCT02503176|DRUG|KCT-0809 ophthalmic solution|
41317824|NCT05257135|BIOLOGICAL|Biological collection|- Blood samples collected at different times: at inclusion and during treatment ( every 6 month)
41317825|NCT03256734|OTHER|Policy intervention|Incentive payment for physicians
41317826|NCT03398122|PROCEDURE|TACE|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
41474774|NCT06160414|DRUG|Rosuvastatin|Participants will receive Rosuvastatin orally, after fasting.
41474775|NCT06160414|DRUG|ALXN2080|Participants will receive ALXN2080 orally, after fasting.
41004690|NCT05934292|DRUG|Enlicitide Decanoate|Single oral dose
41317827|NCT03398122|DRUG|Apatinib|a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
41317828|NCT03270553|DRUG|plazomicin|single intravenous dose
41317829|NCT03270553|DRUG|metformin|single oral dose
41317830|NCT02621879|PROCEDURE|Bilateral Gluteal Advancement Flap|Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
41341785|NCT05369793|DRUG|Alpha lipoic acid|Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
41317831|NCT06121921|OTHER|Perioperative multi-component intervention|"Physical Component~Self-directed daily non-ambulatory exercise programme, comprising:~* Rubber ball squeezes (3 sets of 12 reps, per hand)~* Bicep curls (3 sets of 12 reps)~* Leg extensions (3 sets of 12 reps)~* Chair rises (3 sets of 12 reps)~* Arm stretches (3 sets of 3 reps) Additional encouragement to mobilise~Cognitive Component:~Delirium prevention strategies including orientation, hydration, bowel/bladder function, infection control, analgesia, polypharmacy and cognitive stimulation~Nutritional Component:~* Formal dietician review if MUST score ≥ 2~* IV ferritin if LVEF \<45% and serum ferritin \<100ng/mL or ferritin 100-299ng/mL with TSAT \<20%"
41317832|NCT03937193|DIAGNOSTIC_TEST|computerized tomography|abdomen contrast computerized tomography performed for both emergency and elective purposes in HK public hospitals.
41317833|NCT04469374|OTHER|Jumping exercise|Participants will be required to perform 10 maximal vertical jumps, with a 10-s rest interval between each jump, using an arm swing in countermovement style on three days per week. The jumps will be performed without shoes on a hard surface. The jumps will be preceded by a warm-up lasting approximately 3 min and consisting of mobilisation exercises for the legs and lower back. Jumping will be progressed over time and in accordance with individual needs.
41317834|NCT04469374|OTHER|Balance exercise (sham control)|Participants will be required to perform balance exercises. Participants will be required to balance on one leg for up to 60 seconds (2 x 60 s is equivalent in duration to the 10 jumps). This exercise will be progressed.
41474776|NCT01094028|DRUG|Oxytocin|20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
41474777|NCT04516408|BIOLOGICAL|Recombinant zoster vaccine|Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old. RZV contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system.
41474778|NCT04516408|BIOLOGICAL|Placebo|Sterilized water
41474779|NCT02707926|DRUG|Anti-HIV Agents|Therapy to treat HIV infection
41474780|NCT01906086|OTHER|nutritional intervention|
41474781|NCT01906086|OTHER|life style intervention|
41474782|NCT04684693|DEVICE|Laser|Laser puncture and exercise
41474783|NCT04684693|PROCEDURE|Control|Exercise
41474784|NCT06240689|DRUG|Sintilimab|Sintilimab is administered intravenously on the first day of each cycle. 21 days per cycle.
41474785|NCT06240689|DRUG|Placebo|Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.
41474786|NCT00852917|DRUG|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
41474787|NCT00852917|DRUG|Placebo|One Placebo tablet daily.
41474788|NCT06194006|OTHER|Follow-up|Follow-up grafted patients as long as their condition allows
41474789|NCT00913198|DRUG|IV CP-4126|1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
41317835|NCT00000450|DRUG|Naltrexone Tablet|
41317836|NCT00000450|DRUG|Matched Placebo Tablet|
41317837|NCT02387619|DRUG|Rosuvastatin|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
41317838|NCT02387619|DRUG|Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days
41317839|NCT02387619|DRUG|Rosuvastatin and Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
41317840|NCT00828685|PROCEDURE|CRPP|Closed reduction, percutaneous pinning
41317841|NCT00828685|PROCEDURE|ORIF|Open reduction, internal fixation
41317842|NCT01240148|DRUG|AZD3161|Single dose, intradermal injection
41317843|NCT01240148|DRUG|Lidocaine|Single dose, intradermal injection
41474790|NCT01473576|DIETARY_SUPPLEMENT|Nitrate|0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
41317844|NCT01240148|DRUG|AZD3161 Placebo|
41317845|NCT01789853|BEHAVIORAL|Intensive Walking|8 weeks high intensity walking training over multiple stepping tasks
41317846|NCT01789853|BEHAVIORAL|Conventional Physical Therapy|Regular physical therapy for 8 weeks
41317847|NCT01396239|DRUG|AVI-4658 (Eteplirsen)|Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen
41317848|NCT01396239|OTHER|Placebo|sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.
41474791|NCT01473576|DIETARY_SUPPLEMENT|Sodium chloride|0.15 mmol sodium chloride dissolved in 250 mL water.
41474792|NCT05131477|DRUG|KY1005|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
41474793|NCT05131477|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
41474794|NCT02589158|DRUG|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
41474795|NCT02589158|DRUG|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
41474796|NCT00186823|DEVICE|Miltenyi Biotec CliniMACS|A stem cell selection device.
41317849|NCT05911815|RADIATION|hysterosalpingography|hysterosalpingogram (HSG) is an X-ray visualization of the lumen of the uterus and fallopian tubes, which can detect abnormalities including blockage, polyps, and salinities
41317850|NCT05366270|DEVICE|WBH|Hyperthermia exposure using Heckel Hyperthermia Device
41317851|NCT05366270|DEVICE|Sham|Sham (mild heating) using Heckel Hyperthermia Device
41317852|NCT05260892|DEVICE|Narrow GM implants|Rehabilitation of superior lateral incisors or inferior central and lateral incisors with narrow implants supporting single unit or partial prostheses
41317853|NCT04436809|PROCEDURE|Sentinel Node Biopsy|"Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection)."
41317854|NCT04436809|PROCEDURE|Axillary Dissection|Axillary dissection is the surgical removal of all Berg level I and II lymph nodes present in the axilla. The operation is carried out, at our Institute, during the surgery to treat the cancer in the breast (either breast-conserving surgery - quadrantectomy, or mastectomy).
41474797|NCT00186823|PROCEDURE|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
41317855|NCT06050967|COMBINATION_PRODUCT|Enzyme replacement therapy for Gaucher disease in combination with altus care application|In coordination with the patient's treating physician and the home treating nurse, an individualized treatment plan was prepared for each patient within a pre-defined range of minimal and maximal once in two weeks enzyme replacement therapy dosages and timing frames for its administration. Per protocol, the patient's monthly dose was not changed, but each dose and the timing of administration was changed randomly using the app.
41474798|NCT00186823|DRUG|TBI, systemic chemotherapy and antibodies as follows:|Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
40800737|NCT04586452|OTHER|Relationship between radiotracer and CCR2 (Aim 2B)|The objective of this sub-aim is to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair. We will correlate the level of MMP expression and activity, as well as cytokine profiles, of each specimen, with the associated histopathological features. The relationship between 64Cu-DOTA-ECL1i binding and CCR2 expression in tissues with different degrees of disease severity will be evaluated using Pearson or Spearman correlation coefficients. This will allow us to speculate as to how tracer uptake will perform in vivo and what that uptake represents in regard to disease severity.
41004691|NCT05703893|DIAGNOSTIC_TEST|Supine resting (REST) and active standing (STAND)|Analysis of baroreflex sensitivity
41317856|NCT02674672|DEVICE|VenaTech® (VenaTech Retrievable Filter)|
41317857|NCT02190747|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
41317858|NCT02190747|DRUG|Placebo|
41317859|NCT00723411|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
41317860|NCT00723411|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
41317861|NCT00723411|DRUG|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270
41317862|NCT01764256|BIOLOGICAL|P2-VP8 subunit rotavirus vaccine|P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.
41317863|NCT01764256|OTHER|placebo|Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.
41317864|NCT05766839|DRUG|Patiromer|Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split
41317865|NCT00824928|PROCEDURE|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
41317866|NCT04682353|DRUG|TV-46046|SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)
41474799|NCT02744599|DEVICE|Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany|Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
41474800|NCT00002360|DRUG|Didanosine|
41474801|NCT01807117|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
41004692|NCT00337103|DRUG|Eribulin Mesylate|1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days
41004693|NCT00337103|DRUG|Capecitabine|Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
41474802|NCT01807117|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
41474803|NCT01807117|PROCEDURE|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
41474804|NCT01807117|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
41474805|NCT00167128|DEVICE|hearing aid, Phonak EduLink-FM System|
41317867|NCT04682353|DRUG|Depo-subQ Provera|SC injection of 104 mg/0.65 mL
40800738|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3B-Reproducibility)|We will demonstrate consistent 64Cu-DOTAECL1i uptake by performing repeated imaging studies in a separate group of non-surgical AAA patients (n=20, 10 women and 10 men). Completion of this sub-aim will provide support for the use of 64Cu-DOTA-ECL1i PET for evaluating AAA disease in a reliable fashion. These participants will have another PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results of Cu-64-DOTA-ECL1i. The physician will assess the participant's willingness and eligibility to have a second PET/CT scan.
40800739|NCT04601532|DEVICE|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Catasyn™ Advanced Technology Hydrogel is a wound hydrogel that provides a moist wound environment. A moist wound environment is supportive to wound healing. SynePure™ Wound Cleanser is a non-cytotoxic wound cleanser for the removal of foreign material from epidermal and dermal wounds, burns, cuts, abrasions and minor irritations of the skin.
41317868|NCT05585892|OTHER|Elaboration and individual mailed feedback|see above
41317869|NCT02303171|DRUG|Enoxaparin|Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
41317870|NCT02303171|DRUG|Warfarin|Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
41474806|NCT03023657|OTHER|Detection of arousal|Detecting facial microexpression before visible facial expressions in patient with disorder of consciousness after severe brain injury
41474807|NCT03187496|DRUG|Midazolam|Each subject will receive midazolam on Days 1 and 12.
41157087|NCT05353296|BEHAVIORAL|Minimally Enhanced Usual Care (mEUC)|A minimally enhanced usual care, which will include usual care by patients' Primary Care Provider and a sleep hygiene brochure.
41157088|NCT05353296|DEVICE|Somryst (culturally adapted)|FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) trains your brain for better sleep.
41157089|NCT04018547|DEVICE|Patient wears a wrist sensor oximeter device for one to two nights.|Patients will be asked to complete a study questionnaires of STOPBANG, SCI-8 (Sleep Condition Indicator-8 questionnaire for insomnia), Epworth questionnaires and medical history. The clinician will record blood pressure, pulse rate and regularity, body mass index and neck circumference. Subjects will be required to wear the wrist sensor pulse oximeter for 1-2 nights. The Oxitone 1000M device measures pulse rate, blood oxygen saturation and movement. The oxygen desaturation events from the wrist sensor device will be statistically compared with the diagnosis assessed using the conventional PPG oximetry, Peripheral Arterial Tonometry and clinical assessment. (clinicians will be masked when analysing the data from the wrist sensor pulse device).
41157090|NCT06344364|DIAGNOSTIC_TEST|Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)|Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph-FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite score that aggregates quantitative histological features of fibrosis severity measured by high resolution quantitative image analysis.
41474808|NCT03187496|DRUG|Caffeine|Each subject will receive caffeine on Days 1 and 12.
41474809|NCT03187496|DRUG|Rosuvastatin|Each subject will receive rosuvastatin on Days 2 and 13.
41474810|NCT03187496|DRUG|EDP-305|Each subject will receive EDP-305 on Days 5 through 15.
41474811|NCT05291052|DRUG|Tislelizumab|Tisleizumab 200 mg intravenously (IV) every 3 weeks (Q3W) ,D1
41474812|NCT05291052|DRUG|Lenvatinib|Lenvatinib 8 mg (for patient weight \< 60 kg) or 12 mg (for patient weight ≥ 60 kg), orally, QD, D1-21, Q3W
41474813|NCT05291052|DRUG|Oxaliplatin|"Oxaliplatin 130 mg/m2, IV， D1，Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
41474814|NCT05291052|DRUG|Capecitabine|"Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
41317871|NCT02977013|DIAGNOSTIC_TEST|Anti-Xa assay|Correlation between anti-Xa assay and the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
41317872|NCT01009983|BIOLOGICAL|panitumumab|Given IV
41474815|NCT01247792|BEHAVIORAL|SOPs for decision-making and communication|Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
41474816|NCT04689347|DRUG|Bevacizumab|Bevacizumab 5 mg/kg intravenous infusion every 2 weeks
41474817|NCT04689347|DRUG|Irinotecan|irinotecan 165 mg/sqm intravenous infusion every 2 weeks
41474818|NCT04689347|DRUG|Leucovorin|leucovorin 200 mg/sqm intravenous infusion every 2 weeks
41474819|NCT04689347|DRUG|5Fluorouracil|48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks
41474820|NCT04689347|DRUG|Temozolomide|Oral temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days. (75 mg/sqm; 100 mg/sqm; 125 mg/sqm or 150 mg/sqm)
41474821|NCT00344851|DRUG|metformin, exenatide or combined (metformin & exenatide )|
41474822|NCT02878408|GENETIC|Blood sampling|supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
41474823|NCT02365948|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous injection"
41474824|NCT02365948|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringes~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"
41474825|NCT01917435|DEVICE|video-stylet|
41474826|NCT01917435|DEVICE|fiberoptic bronchoscope|
41004694|NCT01262014|DRUG|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
41474827|NCT06534541|BEHAVIORAL|Attentional bias to food cues|Measurement of the amount of attention given to food cues
41474828|NCT05367037|DEVICE|PhysioVP|The Physiological ventricular pacing is achieved by delivering a stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, with a permanent lead. PhysioVP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct the PR interval and avoiding pacing-induced dyssynchrony. A specialized delivery sheath for His-Purkinje system pacing with appropriate or standard leads will be used. The atrial leads will be implanted in the right atrial appendage and will connect the leads to the standard dual-chamber PM. By continuously recording a 12-lead ECG, we determine whether cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, will be achieved.
41152255|NCT04260100|BEHAVIORAL|Diabetes Care Self-Management Mobile Health Application|In day 1, the participant will receive a Foot Care Kit consist of a mirror, a tube of lotion, a small towel, and a nail clipper. The participant will enrol in 3-hour workshop for general management of diabetes mellitus, diabetic foot care and dietary management. The participant will be invited to install Diabetes Care Self-Management Mobile Health Application. The mobile application is meant for sources of referral for diabetic foot care and dietary care, and for record purpose (diary) of any foot care activities carried out that participant needs to enter in the application during his/her home. The participant will be trained for the use of Diabetes Care Mobile Health Application. In addition, the participant will be invited to join a WhatsApp group for the medium of communication. The program will be lasting for 5 weeks.
41152256|NCT04322864|OTHER|Therapeutic exercises|Patients will perform strengthening exercises focusing on scapulothoracic muscles and shoulder lateral rotators.
41157091|NCT03198351|DRUG|Teriflunomide (HMR1726)|"Pharmaceutical form: tablet~Route of administration: oral"
41474829|NCT05367037|DEVICE|DDD-VPA|In dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance, also called managed ventricular pacing, the right ventricular (RV) lead is implanted in the myocardial right ventricular (septum or apex). In this pacing mode, the ventricular pacing is minimized by using algorithms for right ventricular pacing avoidance. Therefore, the RV leads will be implanted in the right ventricular myocardial sites (septum or apex) and standard bipolar active or passive fixation leads. In addition, the atrial leads will be implanted in the right atrial appendage and connect leads to the standard dual-chamber PM.
41474830|NCT04067388|OTHER|Rapid Evaporative Ionisation Mass Spectrometry (REIMS)|Use of iKnife instrument during standard operative practice
40800740|NCT04601532|DRUG|Silver Sulfadiazine|Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.
40800741|NCT05363501|DRUG|IM Naloxone Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
41004695|NCT03320681|DEVICE|Electrical Stimulation|Percutaneous electrical nerve stimulation
41317873|NCT01009983|DRUG|paclitaxel|Given IV
41317874|NCT01009983|DRUG|carboplatin|Given IV
41317875|NCT01009983|PROCEDURE|laboratory biomarker analysis|Correlative study
41317876|NCT01009983|PROCEDURE|immunohistochemistry staining method|Correlative study
41317877|NCT06364631|DRUG|Nivolumab|Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.
41341786|NCT05369793|DRUG|Roflumilast|Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
41004696|NCT03320681|OTHER|Dry Needling Stimulation|Percutaneous nerve stimulation
41474831|NCT06472544|BEHAVIORAL|Culturally Grounded Intervention|Education to increase awareness of Blackfeet culture and connectedness to Blackfeet community
41317878|NCT06364631|DRUG|Ipilimumab|"The second infusion will always be ipilimumab and will start at least 30 minutes after completion of the nivolumab infusion. Ipilimumab is to be administered as an approximately 30-minute IV infusion.~When administered together, nivolumab and ipilimumab will be administered on Day 1 of each 21-day cycle."
41474832|NCT03729154|BEHAVIORAL|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
41474833|NCT01574664|DEVICE|RFID Tag (Health Beacon)|The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
41474834|NCT02390648|DRUG|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
41317879|NCT06364631|DRUG|Pembrolizumab|Pembrolizumab is to be administered as an approximately 30-minute IV infusion.
41474835|NCT02390648|DRUG|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
40800742|NCT05363501|DRUG|Naloxone Nasal Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
41474836|NCT05349747|BIOLOGICAL|Biologic drugs|Assess the results of treatment with biologic drugs
41317880|NCT06364631|DRUG|Cabozantinib|Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.
41317881|NCT06364631|DRUG|Axitinib|Axitinib is a medication that is taken orally every day, 2 times a day continuously, at the starting dose of 5mg x2/day.
41474837|NCT06389513|BIOLOGICAL|MCV4|4 doses of vaccine on Day 0, Day30, Day 60 and Month 12
41474838|NCT03112148|DRUG|10 mg dose MR formulations,10 mg dose of tofacitinib IR solution|"For the the relative bioavailability (BA) assessment , the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast, MR-moderate, MR-slow). Each formulation contains 0.025 mg of tofacitinib/mg of microsphere. Reference: 10 mg dose of tofacitinib IR solution (1 mg of tofacitinib/mL).~For the the food effect assessment, the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) c-oadministered with high-fat FDA breakfast. Reference: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) administered under fasted state."
41474839|NCT01546922|DRUG|Hydrocortisone|Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
41152257|NCT06350084|BEHAVIORAL|Mother's Touch|Heel blood will be taken while the infant was Mother's Touch. Mother's touch will be applied to the infants before, during and after the procedure.
41474840|NCT00111566|DRUG|eptifibatide|
41474841|NCT00877357|BIOLOGICAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
40800743|NCT05363501|DRUG|Naloxone Nasal Swab|4 mg naloxone nasal swab administered in nostril
41317882|NCT06364631|DRUG|Lenvatinib|Lenvatinib is a medication that is taken orally every day, once a day at the initial dose of 20mg/day.
41317883|NCT04704895|DIETARY_SUPPLEMENT|Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
41317884|NCT04704895|DIETARY_SUPPLEMENT|Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
41317885|NCT01974986|OTHER|Water with flavoring and non-nutritive sweetener.|A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).
41317886|NCT01974986|OTHER|High-Na low-CHO beverage|A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).
41317887|NCT01974986|OTHER|Low-Na high-CHO beverage|A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
41317888|NCT03102320|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles
41317889|NCT03102320|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle
41317890|NCT03102320|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
41317891|NCT05048706|DEVICE|Laser lithotripsy (SP TLF)|Laser lithotripsy of urinary calculi using the Super Pulse Thulium fiber laser (SP TLF)
41474842|NCT03122587|DEVICE|Transcranial Alternating Current Stimulation at 10 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
41004697|NCT04601688|DRUG|Bevacizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
41004698|NCT04601688|DRUG|Bevacizumab Ophthalmic|Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
41317892|NCT05048706|DEVICE|Laser lithotripsy (Ho:YAG)|Laser lithotripsy of urinary calculi using the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser.
41004699|NCT00265824|DRUG|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
41004700|NCT00265824|DRUG|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
40800744|NCT05363501|DRUG|Naloxone Nasal Swab|8 mg naloxone nasal swab administered in nostril
41004701|NCT02923518|OTHER|Questionnaire|Observational study without any intervention described under intervention type
41152258|NCT06350084|BEHAVIORAL|Nurse's Therapeutic Touch|Heel blood will be taken while the infant was Nurse's Therapeutic Touch.Therapeutic Touch will be applied to the infants before, during and after the procedure.
41317893|NCT02770313|BEHAVIORAL|Intermittent Fasting|Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
41317894|NCT03812588|DRUG|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.
41317895|NCT03812588|DRUG|Placebo|A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
41317896|NCT03695393|BEHAVIORAL|ACT Therapy|The ACT intervention will consist of three 2-hour group sessions of culturally adapted ACT (intervention) to reduce stigma and related manifestations.Participants are recruited from a civil society organization and all other study procedures take place at a rehabilitation center. The ACT sessions will be scheduled to take place at the rehabilitation center following randomization.The First St. Petersburg Pavlov State Medical University is an alternative location where sessions can be conducted. Sessions will be planned to occur in weekly succession, with a goal of 3 sessions within the first month of study participation.
41474843|NCT03122587|DEVICE|Transcranial Alternating Current Stimulation at 40 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
41474844|NCT03122587|DEVICE|Active sham transcranial alternating current stimulation|Active sham (placebo)
40800745|NCT05363501|DRUG|Naloxone Nasal Swab|12 mg naloxone nasal swab administered in nostril
41004702|NCT04542070|DRUG|Cabotegravir Tablets|CAB tablets were available as film coated tablets for oral administration.
41004703|NCT04542070|DRUG|Cabotegravir Injectable Suspension (CAB LA)|CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.
41004704|NCT04542070|DRUG|Rilpivirine Tablets|RPV was administered as tablets for oral administration.
41004705|NCT04542070|DRUG|Rilpivirine Injectable Suspension (RPV LA)|RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.
41004706|NCT04542070|DRUG|BIKTARVY Tablets (BIK)|BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
41004707|NCT00817167|DEVICE|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
41004708|NCT00817167|DEVICE|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
41004709|NCT03688321|DIETARY_SUPPLEMENT|Probiotic capsule GR-1 and RC-14|Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation
41004710|NCT03688321|DIETARY_SUPPLEMENT|Placebo capsule|Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
41004711|NCT00962130|DEVICE|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
41004712|NCT02649881|PROCEDURE|The heart subject will undergo OCT|
41152259|NCT05538156|PROCEDURE|Control group|Vitrectomy and gas tamponade without internal limiting membrane peeling
41152260|NCT05538156|PROCEDURE|Intervention group|Vitrectomy, internal limiting membrane peeling and gas tamponade
41152261|NCT04823078|OTHER|Activity base therapy|"activity based therapy~Weight bearing activities of daily living like vertical lifting, bilateral body weight shifting, lifting and shifting, forward reaching and sideways reaching."
41317897|NCT00163072|DRUG|transdermal Megace|oral vs transdermal levels
41341787|NCT05297799|DEVICE|Ameda Pearl breast pump|The Ameda Pearl breast pump is a powered, multi-user breast pump with stimulation and expression modes and independently user-selectable speed and suction control in each mode.
41341788|NCT03074318|DRUG|Avelumab|Given IV
41341789|NCT03074318|DRUG|Trabectedin|Given IV
41004713|NCT01726010|DEVICE|22-G Procore Needle|
41474845|NCT01049347|DRUG|amitriptyline|150 mg oral, daily, single evening dose, 35 days
41004714|NCT04101266|OTHER|Interscalene block|30 minutes before anaesthesia induction interscalene nerve block will be applied with ultrasound guidance with %0,25 bupivacain 20 cc .The sham block consisted of after patients were placed in the lateral decubitus position skin preparation, ultrasound scanning of the suprascapular region, and a dry-needling, all performed to preserve patient blinding in the ISB group patients.
41152262|NCT04823078|OTHER|Strength training|Strengthening exercises of upper limb involved muscles (elbow extensors, shoulder adductors, abductors, wrist extensors, shoulder protractors and retractors
40800746|NCT05363501|DRUG|Naloxone Nasal Swab|12.5 mg naloxone nasal swab administered in nostril
40800747|NCT03275246|DEVICE|X-PSI Knee System|Patients are operated with X-PSI Knee System guides
40800748|NCT02258971|DRUG|BEA 2180 BR oral|Oral solution
40800749|NCT02258971|DRUG|BEA 2180 BR infusion|Solution for infusion to be reconstituted with isotonic saline
41317898|NCT02160886|BEHAVIORAL|child-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks.~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
40800750|NCT03200197|OTHER|Menthol chewing gum|The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.
40800751|NCT03200197|OTHER|Usual care (fasting)|The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
40800752|NCT01039324|OTHER|Reports|Primary care event reports and patient letters
40800753|NCT01039324|OTHER|Reports and Notices|Primary care event reports, patient letters and care manager notices
40800754|NCT01039324|OTHER|Usual care|This is the study's control group
41004715|NCT04101266|OTHER|suprascapular and infraclavicular nerve block|30 minutes before anaesthesia induction suprascapular with %0,25 bupivacain 10 cc .and infraclavicular nerve block with %0,25 bupivacain 10 cc will be applied with ultrasound guidance
41004716|NCT00799968|DRUG|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
41004717|NCT00799968|DRUG|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
41004718|NCT03632291|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
41341790|NCT01619527|DRUG|darunavir|Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
40800755|NCT01266252|DRUG|Dexmedetomidine|"Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
40800756|NCT04717024|DEVICE|Observational Study - no intervention|Observational Study - no intervention
40800757|NCT04931914|OTHER|Clinical pharmacy sharing in the patient care regimen|antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.
40800758|NCT02943070|DEVICE|Rezum System|"The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
40800759|NCT01014936|DRUG|MSC2156119J|
40800760|NCT05187897|BEHAVIORAL|CHV-NEO|CHV-NEO is a two-way SMS platform that supports communication between mothers and community health volunteers between home visits. The platform engages mothers with SMS communication and brings timely information and support - asking critical questions at crucial times in order to assess the needs and health of newborns and assist in care seeking decisions. The CHV-NEO SMS intervention is integrated into the current digital community health toolkit (dCHT) to support CHV workflow.
41004719|NCT01327352|DRUG|Oshadi D|oral administration
41004720|NCT03266068|GENETIC|DNA Analysis of Blood Sample|DNA analysis of the genes possibly involved in IBS.
41004721|NCT03266068|PROCEDURE|Flexible sigmoidoscopy with colonic biopsies|Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.
41004722|NCT03266068|PROCEDURE|Small bowel and colonic gastrointestinal permeability|A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.
41004723|NCT03266068|DIAGNOSTIC_TEST|Stool sample analysis|Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.
41004724|NCT04278534|OTHER|Educational Intervention|Complete radiation therapist-led education module using virtual reality
41004725|NCT04278534|OTHER|Educational Intervention|Receive the usual verbal and written education materials
41004726|NCT04278534|OTHER|Educational Intervention|Complete radiation therapist-led face-to-face education module
41341791|NCT01619527|DRUG|cobicistat|Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
41004727|NCT04278534|OTHER|Survey Administration|Ancillary studies
41152263|NCT01482871|DRUG|ALG-1001|1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
41152264|NCT01482871|DRUG|ALG-1001|2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
41152265|NCT01482871|DRUG|ALG-1001|5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
41317899|NCT02160886|BEHAVIORAL|parent-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks. .~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
41474846|NCT01049347|DRUG|paroxetine|40 mg oral, single dose, morning, 35 days
41474847|NCT06443359|RADIATION|hypofractionated radiation|All patients will receive a dose of 42.56 Gy in 16 daily fractions to the whole breast or chest wall and regional lymph nodes. A boost dose of 10 or 12.5 Gy in 4 or 5 daily fractions of 2.5 Gy, respectively, will be administered to either the lumpectomy cavity or mastectomy scar, as appropriate.
41474848|NCT04413734|DRUG|Combination therapy|Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin
41474849|NCT04413734|DRUG|Mono-chemotherapy|Gemcitabine plus Cisplatin by intravenous infusion
41474850|NCT04317313|OTHER|FDG PET radiomic feature evaluation|"A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features.~In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature."
40800761|NCT04763252|OTHER|Spectrum Therapeutics cannabis products|"For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products."
41004728|NCT04561401|DEVICE|Repeated Transcranial Magnetic Stimulation (rTMS)|rTMS will be applied at 10 Hz. Each train will consist of 40 supra threshold (120% resting motor threshold) pulses over 4 seconds with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3,000 pulses), and occur at the same time of day on every weekday for a period of three weeks (15 days total). During TMS, only passive activities will be allowed (i.e., watching movies or TV, listening to music). Three weeks of treatment was selected based on existing rTMS evidence in youth with treatment resistant major depressive disorder.
41004729|NCT04561401|OTHER|Intensive Pain Rehabilitation Program (IPRP)|The paediatric Intensive Pain Rehabilitation Program (IPRP) in Canada was established to target youth with severe chronic pain and consequent functional disability who do not respond to standard outpatient pain therapies. The IPRP at the Alberta Children's Hospital (ACH) involves three- to six-weeks of day-treatment rehabilitation, provided by an interdisciplinary team (e.g. Psychology, Physiotherapy, Family Therapy). This rehabilitative program teaches self-management strategies with the goal of helping youth and their families resume normal daily functioning.
41004730|NCT03671291|BEHAVIORAL|self-administrated questionnaire|Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
41474851|NCT01680874|DIETARY_SUPPLEMENT|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
41474852|NCT01680874|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
41474853|NCT02450877|DRUG|Azacitidine|
41474854|NCT02450877|OTHER|Control Arm|
40800762|NCT03222362|OTHER|Surgery|
41004731|NCT04283643|OTHER|Transcranial Focused Ultrasound|Non-invasive brain stimulation technique
41004732|NCT04283643|OTHER|Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
41004733|NCT01093404|PROCEDURE|Thrombus aspiration|Aspiration of thrombus material before angioplasty
41004734|NCT04765488|PROCEDURE|WashIn /WashOut|"According Wash In / WashOut procedure in study group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
41004735|NCT03661814|DEVICE|Prevena|The NPWT device is a wound dressing with a vacuum system that can be placed over abdominal wounds, placed in the immediate postoperative period over abdominal wounds after clean/contaminated colorectal surgical procedures.
41341792|NCT02262338|DRUG|AGT-182|Recombinant HIRMAb-IDS
41474855|NCT00813826|DRUG|SLC022|SLC022 150 mg capsule, 900mg daily dose
41474856|NCT00813826|DRUG|Placebo|Placebo capsule, TID
41474857|NCT00319046|DRUG|Miglustat|Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.)
40800763|NCT00331656|DEVICE|Non-invasive positive pressure mask ventilators|
40800764|NCT00331656|DEVICE|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
40800765|NCT05827328|OTHER|Observation|Observe the 30-day mortality and 30-day morbidity.
40800766|NCT00335283|DRUG|Lansoprazole Tablet|40 mg bid x 16 weeks
40800767|NCT00335283|PROCEDURE|PH and impedence testing|24 hour ph monitoring
40800768|NCT00335283|PROCEDURE|manometry|done prior to pH probe to measure length of esophagus
40800769|NCT00335283|DRUG|lansoprazole|40mg bid
40800770|NCT00335283|DRUG|placebo|one tablet bid
40800771|NCT04025762|DEVICE|Hybrid closed-loop system (CamAPS FX)|Hybrid closed-loop system
40800772|NCT04025762|DEVICE|Sensor augmented pump therapy|Sensor augmented pump therapy
40800773|NCT03989349|DRUG|Placebo|Placebo
40800774|NCT03989349|DRUG|Nemolizumab|Nemolizumab
41341793|NCT04511936|DEVICE|i-Lumen AMD|Microcurrent stimulator
41341794|NCT04511936|DEVICE|i-Lumen AMD Sham|Sham microcurrent stimulator
41341795|NCT01831804|DRUG|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
41341796|NCT01831804|DRUG|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
40800775|NCT02808897|DEVICE|Standard drainage|One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (Fr) shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
40800776|NCT02808897|DEVICE|Active Tube Clearance drainage|One (1) PleuraFlow chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 Fr shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
40800777|NCT05382741|DRUG|Durvalumab Injection for intravenous use 500 mg vial solution for infusion|MEDI4736
40800778|NCT05382741|DRUG|Regorafenib 30 mg capsules|BAY73-4506
40800779|NCT06117033|OTHER|video assisted mobilization training|Preoperative video-assisted mobilization training was given to patients undergoing coronary artery bypass graft surgery
40800780|NCT03941964|DRUG|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
40800781|NCT03941964|DRUG|Azacitidine|The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
40800782|NCT03941964|DRUG|Decitabine|The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
40800783|NCT01570517|DEVICE|IASD System|Implantation of the DC Devices Inc. IASD System
40800784|NCT04635254|OTHER|Halophites-based cream 24 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
41474858|NCT05605912|OTHER|Control|Participants perform five one-hour conventional training sessions at the Sint Maartenskliniek in which they perform functional exercises. After the conventional training program, the control group will receive a recommendation for physical activity at home for six weeks.
41474859|NCT05605912|DEVICE|Myosuit|Participants perform five one-hour Myosuit training sessions at the Sint Maartenskliniek in which they perform functional exercises and learn to don, doff and use the device for standing, walking, climbing the stairs and sit-to-stand transitions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home and a recommendation for physical activity at home for six weeks.
40800785|NCT04635254|OTHER|Halophites-based cream 48 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
40800786|NCT04635254|OTHER|Vehicle cream 24 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
40800787|NCT04635254|OTHER|Vehicle cream 48 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
40800788|NCT04635254|OTHER|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
40800789|NCT04635254|OTHER|Cowhage|The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
40800790|NCT02579148|BIOLOGICAL|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.'
40800791|NCT02579148|BIOLOGICAL|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'
40800792|NCT03529617|OTHER|Sample collection|Plasma, urine, BAL and ascitic fluid sample collection.
40800793|NCT01963182|DRUG|Irinotecan|
40800794|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
40800795|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
40800796|NCT02038777|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
40800797|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
40800798|NCT02038777|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
40800799|NCT02038777|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
40800800|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
40800801|NCT02038777|DRUG|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
41317900|NCT02791971|BEHAVIORAL|SpeakOut|"SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:~* Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~* Printed materials for recipients to keep and/or share with friends.~* Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~* Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic."
41317901|NCT02791971|BEHAVIORAL|Alcohol Control Intervention|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
41004736|NCT06474494|PROCEDURE|Application of one layer|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying one layer of Scotchbond Universal Plus adhesive
41004737|NCT06474494|PROCEDURE|Application of double layer|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying double layer of Scotchbond Universal Plus adhesive
41317902|NCT01937052|OTHER|Sample collection|Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
41317903|NCT01937052|BEHAVIORAL|Patient-reported outcomes|Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
41317904|NCT05665244|PROCEDURE|Laryngeal cryotherapy|Laryngeal cryotherapy is the therapeutic freezing of tissue in the throat to numb the overactive sensory nerves in the throat. This technique is believed to reduce cough symptoms in this study.
41474860|NCT05628558|DRUG|Desmopressin|"The interventions with desmopressin recorded in this study were all realized following the internationally recommended standard care of patients with mild/moderate hemophilia A. They were all retrospectively collected. These interventions comprised:~* An intravenous administration of desmopressin infused during 30 minutes at a dosage of 0,3-0,4 µg/Kg~* Measurements of Factor and von Willebrand factors levels just before the desmopressin infusion and after at 30 minutes, 1 hour, 2 hours, 4 hours and for some patients 6 hours and 24 hours.~The F8 gene variants were also diagnosed in the standard care."
41474861|NCT02915926|BEHAVIORAL|occupational performance coaching|
41474862|NCT02915926|BEHAVIORAL|standard OT|
41474863|NCT06203912|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41474864|NCT06203912|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
41474865|NCT06203912|DRUG|Cyclophosphamide|Given IV
40800802|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
41004738|NCT06474494|PROCEDURE|Etch-and-rinse application mode|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as etch-and-rinse application mode
41004739|NCT06474494|PROCEDURE|Selective enamel etching application mode|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as selective enamel etching mode
41004740|NCT05428475|DIAGNOSTIC_TEST|[18F]FDG-PET Scan|185 MBq of \[18F\]FDG will be administered IV 30 minutes prior to PET scan. Images will be acquired for 30 minutes. Resulting images will be evaluated for patterns of FDG-uptake to support the diagnosis of the participant symptoms of cognitive impairment.
41004741|NCT01448018|DRUG|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
41004742|NCT01448018|PROCEDURE|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
41004743|NCT02093637|OTHER|Placebo acupuncture|Placebo Comparator
40800803|NCT02038777|DRUG|LDAC|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
41004744|NCT02093637|OTHER|Battlefield Acupuncture|Experimental
41317905|NCT05665244|DEVICE|Cryoprobe|Cryoprobe is FDA approved for use for the destruction of unwanted tissue along the respiratory tract
41317906|NCT02763293|OTHER|Manual Therapy|Non-manipulative treatment osteopathic techniques combined direct and indirect soft appropriate in patients with Crohn's disease
41474866|NCT06203912|DRUG|Dexamethasone|Given PO
41474867|NCT06203912|PROCEDURE|Echocardiography|Undergo echocardiography
41474868|NCT06203912|BIOLOGICAL|Isatuximab|Given IV
41474869|NCT06203912|OTHER|Questionnaire Administration|Ancillary study
41474870|NCT06203912|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given IV
40800804|NCT04736290|OTHER|NLR|Calculation of NLR
40800805|NCT04736290|OTHER|PLR|Calculation of PLR
40800806|NCT00758069|DRUG|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
40800807|NCT00758069|DRUG|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
40800808|NCT00758069|DRUG|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
40800809|NCT00807586|DRUG|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
41004745|NCT00003491|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41152266|NCT01482871|DRUG|ALG-1001|7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
41317907|NCT00245414|DRUG|Pegasys®|180μg for s.c./week for 48 weeks
41317908|NCT00245414|DRUG|Pegasys®|180μg for s.c./week for 24 weeks
41474871|NCT03669068|PROCEDURE|Gastrointestinal endoscopy|"Two separated groups will be included in the registry:~1. Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~2. Patients undergoing elective gastrointestinal endoscopy."
41474872|NCT04281732|DEVICE|Virtual Reality Headset based tests|Visual task tests based on Oculus Rift
40800810|NCT00807586|DRUG|Placebo|Normal saline (1.6 cc)
40800811|NCT05059301|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
40800812|NCT02429193|DRUG|Abiraterone + prednisone|Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
40800813|NCT02429193|DRUG|Enzalutamide|Enzalutamide (160 mg/day p.o.)
40800814|NCT05069597|DRUG|CREON|Capsule; Oral
40800815|NCT04116177|DEVICE|Deep brain stimulation|Stimulation using VerciseTM system
40800816|NCT00740454|OTHER|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
40800817|NCT02628600|DRUG|LAI 590 mg|LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes
40800818|NCT02628600|DRUG|Multi-drug regimen|Multidrug antimycobacterial regimen from study INS-212
40800819|NCT05714514|DRUG|Imlifidase administered in the ConfIdeS study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.
40800820|NCT05714514|OTHER|Best available treatment administered in the ConfIdeS study|Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
41317909|NCT00250991|DRUG|activase|
41317910|NCT00250991|DRUG|integrilin|
41474873|NCT02598895|DRUG|Carboplatin|Given IV
41474874|NCT02598895|DRUG|Docetaxel|Given IV
41474875|NCT02598895|OTHER|Laboratory Biomarker Analysis|Correlative studies
41474876|NCT02605213|DRUG|Vancomycin|Vancomycin for treatment of primary sclerosing cholangitis
41474877|NCT02605213|DRUG|Placebo|Placebo for control Group of primary sclerosing vhlangitis
41474878|NCT02177006|BEHAVIORAL|Sun Protection Program|"The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys"
41474879|NCT04814784|RADIATION|Neoadjuvent radiotherapy either short or long course chemoradiation in treatment of locally advanced cancer rectum|Study the effect of neoadjuvent radiotherapy in treatment of locally advanced cancer rectum e higher possiblity of preservation of anal sphincter and decreased rate of locoregional recurrence compared to surgery alone
41474880|NCT05567939|OTHER|Natural course of disease|Sample and questionnaire collection
41474881|NCT03955939|DRUG|LY3295668 Erbumine|Administered orally.
41474882|NCT03955939|DRUG|Endocrine therapy|Administered according to label instructions.
40800821|NCT02858440|BIOLOGICAL|Infanrix-IPV/Hib|Subjects receive Infanrix-IPV/Hib three-dose primary vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
40800822|NCT00720356|DRUG|bevacizumab|10mg/kg administered intravenously every 2 weeks
40800823|NCT00720356|DRUG|erlotinib hydrochloride|150 mg/daily orally
40800824|NCT00996879|DRUG|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
41317911|NCT00213252|DRUG|Montelukast plus prednisolone|Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
41474883|NCT03955939|DRUG|Midazolam|Administered orally.
41317912|NCT00213252|DRUG|Prednisolone|Six daily doses of oral prednisolone
41317913|NCT04795128|BIOLOGICAL|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
41317914|NCT02310906|DRUG|Placebo|SRP-4053 placebo-matching solution for IV infusion.
41317915|NCT02310906|DRUG|SRP-4053|SRP-4053 (golodirsen) solution for IV infusion.
41317916|NCT03146221|OTHER|To look for serum microRNA profiles associated with restenosis|To look for serum microRNA profiles associated with restenosis
41317917|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
41317918|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
41317919|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
41317920|NCT00518921|DRUG|Placebo|Placebo, double dummy
41317921|NCT03539913|BIOLOGICAL|Probiotic : Saccharomyces boulardii|Treatment for 5 days
41317922|NCT03539913|BIOLOGICAL|Probiotic : Bacillus clausii|Treatment for 5 days
41317923|NCT02530671|DEVICE|Toothbrushing with manual toothbrush|
41317924|NCT02530671|DEVICE|Toothbrushing with power toothbrush|
41317925|NCT00964158|BIOLOGICAL|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections and a booster IM injection
41317926|NCT00364325|OTHER|Acute Decompensated Heart Failure|Standard of Care
41004746|NCT02302196|PROCEDURE|Autologous Fat Grafting of the Breast|In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
41004747|NCT02302196|OTHER|Control Arm|Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
41004748|NCT04248569|DRUG|DNAJB1-PRKACA peptide vaccine|"1. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and Day 1 of cycle 2, 3, 4 and 5 (priming phase). Boost vaccinations: every 3 cycles beginning C6D1. For Cohort A-(Initial) only: Patients with FLC cancer with no prior checkpoint inhibitor therapy treatment.~2. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and on Day 1 of cycle 2, 3 and 4 (priming phase). Boost vaccinations: every 3 cycles beginning C5D1.~   * Cohort A-(Expansion): Patients with FLC cancer with no prior checkpoint inhibitor treatment.~  * Cohort B: Patients with FLC cancer with prior checkpoint inhibitor treatment.~  * Cohort C: Patients with non-FLC cancer (solid tumors) with prior checkpoint inhibitor treatment eligible.~3. Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5mg Poly-ICLC"
41004749|NCT04248569|DRUG|Nivolumab|"1. Cohort A (Initial): Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 2-5 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 6.~2. Cohort A (Expansion), B and C: Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5.~3. Drug: 3mg/kg and 480mg IV"
41004750|NCT04248569|DRUG|Ipilimumab|"1. Cohort A (Initial): Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 2, 3, 4 and 5 of the study, every 3 weeks of the priming phase.~2. Cohort A (Expansion), B and C: Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 1, 2, 3 and 4 of the study, every 3 weeks of the priming phase.~3. Drug: 1mg/kg IV"
41004751|NCT02716233|DRUG|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
41004752|NCT02716233|DRUG|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
40800825|NCT00996879|DRUG|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
41004753|NCT03717038|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
41004754|NCT03717038|DRUG|TAS-102|TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.
41004755|NCT02160366|OTHER|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
41004756|NCT04891939|OTHER|Health education lessons (Smart-Kid's program)|The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So \& Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors
41004757|NCT04891939|OTHER|School Health and Education Program (SHEP)|The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
41004758|NCT04117126|BEHAVIORAL|Prompted voiding|"Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control."
41317927|NCT01806636|DEVICE|PneumRx Coil System|
41317928|NCT06293664|OTHER|α-MSH infusion|Pharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia www.auspep.com.au), a good manufacturing practice (GMP) accredited manufacturer of peptides, approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
41317929|NCT06293664|OTHER|Placebo solutions|Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.
41317930|NCT04790266|DIAGNOSTIC_TEST|Cardiac MRI|cCardiac MRI, ecocardiography and cardiotoxicity blood tests will be repeated as previously scheduled
41474884|NCT03703024|DIETARY_SUPPLEMENT|Raspberry Leaf Extract|Eligible subjects will be scheduled for an initial visit. The study will involve 3 visits over a 12 to 13-week period. One capsule to be taken every morning over a 12-13 week period.
41474885|NCT03703024|DIETARY_SUPPLEMENT|Placebo|Delivered in a capsule
40800826|NCT02435459|PROCEDURE|No lining|No lining material placed under amalgam dental restorations
40800827|NCT02435459|PROCEDURE|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
40800828|NCT02435459|PROCEDURE|RMGI cement|placement of lining material under amalgam dental restorations
40800829|NCT02435459|PROCEDURE|Resin Bonding Agent|placement of lining material under amalgam dental restorations
40800830|NCT04918381|DEVICE|CellFX System|Nano-Pulse Stimulation (NPS)
40800831|NCT00958360|OTHER|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
41004759|NCT04734496|OTHER|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
41004760|NCT05315999|DRUG|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
41004761|NCT05315999|DRUG|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
41004762|NCT05818371|DIAGNOSTIC_TEST|Sonographic determination of the optic nerve sheath diameter|Ultrasound-based determination of the optic nerve sheath diameter
41004763|NCT02457936|BEHAVIORAL|Mindfulness Based Cognitive Therapy|8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
41004764|NCT06415643|OTHER|Islet organoids transplantation|autologous transplantation of ex vivo expanded islet organoids.
41004765|NCT05753059|DRUG|Placebo|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21
41317931|NCT01689402|DEVICE|MRI Scan with the specified sequences below:|"Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.~Susceptibility weighted imaging (SWI)~Chemical Shift Imaging (CSI) multivoxel spectroscopi~Post contrast 3D box reconstruction"
41004766|NCT05753059|DRUG|Amiloride|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
41004767|NCT05753059|DRUG|Bendroflumethiazide|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
41004768|NCT03810066|DRUG|Osimertinib|All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).
41004769|NCT04408846|DEVICE|Lumbar fusion|Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
41317932|NCT05297656|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization with graston tecnique and Home exercises programe
41317933|NCT05297656|OTHER|Sham Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization to be applied superficially so it is not like a real graston tecnique and Home exercises programe
41317934|NCT05297656|OTHER|Home exercises programe|Only Home exercises programe
41317935|NCT04959253|COMBINATION_PRODUCT|Psilocybin assisted therapy|A package of psychological therapy and a single dosing session of psilocybin.
41317936|NCT04959253|COMBINATION_PRODUCT|Placebo assisted therapy|A package of psychological therapy and a single dosing session of placebo.
41004770|NCT00844792|DIETARY_SUPPLEMENT|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
41004771|NCT00844792|DRUG|Placebo|Twice a day with meals.
41004772|NCT03898765|DIAGNOSTIC_TEST|Dry blood spot screening|Dry blood spot measurement of biomarker for screening biliary atresia
40800832|NCT00958360|OTHER|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
40800833|NCT06374680|PROCEDURE|laminectomy at C3 level|laminectomy at C3 level
41004773|NCT00218543|DRUG|Atomoxetine|At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
41317937|NCT04432506|BIOLOGICAL|Anakinra|Given SC
41317938|NCT04432506|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
41004774|NCT06391879|GENETIC|Single cell sequencing, whole genome and metabolomic sequencing|The blood specimen of subjects in this cohort would be collected to conduct single cell sequencing, whole genome and metabolomic sequencing.
41004775|NCT03003975|DEVICE|PVI by single cryoballoon application guided by Achieve Mapping Catheter|Pulmonary vein isolation by single cryoballoon application guided by recorded electrogram signals from an internal Mapping Catheter and by temperature drop if mapping of signals is not possible (temperature cutoff \< or = -40 degrees C)
41004776|NCT03003975|DEVICE|PVI by 2 routine cryoballoon applications|Pulmonary vein isolation by 2 cryoballoon applications guided by degree of occlusion and by temperature drop according to discretion of physician
41004777|NCT01163994|DRUG|ceftriaxone|intravenously, 2 g, qd, 15 days
41004778|NCT01163994|DRUG|doxycycline|orally, 100 mg, bid, 15 days
41004779|NCT01163994|OTHER|erythema migrans patients treated with doxycycline|orally, 100 mg, bid, 15 days
41004780|NCT01317238|DRUG|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
41317939|NCT04432506|DRUG|Cyclophosphamide|Given IV
41317940|NCT04432506|DRUG|Fludarabine|Given IV
41317941|NCT00259740|DRUG|DENOSUMAB|120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
41317942|NCT05237180|OTHER|spatial localisation training|8 spatial localization training sessions MBAA and SSQ tests before and after training sessions.
41317943|NCT03844503|DIETARY_SUPPLEMENT|Cereal Bar no fiber|Cereal Bar no fiber
41317944|NCT03844503|DIETARY_SUPPLEMENT|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
41317945|NCT03844503|DIETARY_SUPPLEMENT|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
40800834|NCT04202068|DRUG|Ceftriaxone sodium and Sulbactam Sodium for injection|Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
40800835|NCT03931850|PROCEDURE|Pudendal nerve block|Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
40800836|NCT02008942|DRUG|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
41004781|NCT01800617|DRUG|Liothyronine, Sodium|
41004782|NCT01489969|DRUG|Neu-P11|1 tablet daily 1-2 before bed time for 28 days of double blind treatment
41004783|NCT04054687|DRUG|Tranexamic Acid|Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.
41004784|NCT04054687|OTHER|Placebo|This group will receive pledget soaked in saline. Protocol will continue as with TXA group.
41004785|NCT04939285|PROCEDURE|PEEP|The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
41004786|NCT04087291|OTHER|Chiropractic Care|"Chiropractic interventions:~1. Patient education.~2. Passive interventions, such as spinal manipulation and myofascial therapies which include thrust type (high velocity-low amplitude) spinal manipulation for the low back, non-thrust manipulation (joint mobilization), and use of manually held instruments, such as an Activator. Myofascial therapies are also commonly used, such as myofascial release and trigger point therapy.~3. Transitional interventions, such as therapeutic exercise.~4. Recommendations for active interventions, such as general exercise and mind-body therapies.~5. Self-management advice, which refers to advice given to build the capacity of a person to self-monitor, control, and/or reduce the impact of a condition over time."
41004787|NCT05254795|OTHER|Molecular tumor board assisted care|Participants in this group will obtain recommendations for care from the molecular tumor board.
41317946|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121 without MF59®
41317947|NCT05664334|BIOLOGICAL|IVX-241|75 mcg of IVX-241 without MF59®
41317948|NCT05664334|BIOLOGICAL|Placebo|Diluent
41317949|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121, without MF59®
41317950|NCT05664334|BIOLOGICAL|IVX-241|150 mcg IVX-241, without MF59®
41317951|NCT05664334|BIOLOGICAL|IVX-241|225 mcg of IVX-241, without MF59®
41317952|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121, with MF59®
41317953|NCT05664334|BIOLOGICAL|IVX-241|75 mcg of IVX-241, with MF59®
41317954|NCT05664334|BIOLOGICAL|IVX-241|150 mcg IVX-241, with MF59®
41317955|NCT05664334|OTHER|MF59®|MF59® as an adjuvant
41317956|NCT04377490|OTHER|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in Amiens Hospital until the day of patient discharge
41317957|NCT04377490|BIOLOGICAL|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in Amiens Hospital until the day of patient discharge
40800837|NCT02008942|DRUG|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
40800838|NCT03203824|DIETARY_SUPPLEMENT|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
40800839|NCT03203824|OTHER|non dark chocolate|No dark chocolate will be given to this group during the procedures.
40800840|NCT03008668|OTHER|acupuncture|a stimulation of the body or auricular points
41317958|NCT01661868|DRUG|Olaparib|Tablet formulation will be used.
40800841|NCT01846962|DRUG|Budesonide|The administered dose of topical steroid was 400mcg or 800mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
40800842|NCT01846962|DRUG|Fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
41157092|NCT05306340|DRUG|Giredestrant|Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
41317959|NCT06258135|DIETARY_SUPPLEMENT|Galacto-oligosaccharide|Single 7g dose daily for 28 days
41317960|NCT06258135|DIETARY_SUPPLEMENT|Maltodextrin|Single 7g dose daily for 28 days
41474886|NCT05554289|DEVICE|Depression Auxiliary Intervention Treatment Software|Depression Auxiliary Intervention Treatment Software
41317961|NCT00050986|DRUG|Temozolomide|Starting Dose Level: 100 mg/m\^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
41317962|NCT00050986|DRUG|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
41317963|NCT04622969|BEHAVIORAL|Healthy Child Development Program|The Healthy Child Development Program is a family-based intervention focused on strengthening positive behaviors in children, managing misbehavior, and addressing healthy lifestyle choices.
41317964|NCT05174130|DEVICE|RESPIRA device.com® Advanced|Ventilation of patients with continuous monitoring of the patient's clinical parameters and the parameters that the investigational medical device shows.
41317965|NCT00457470|DRUG|AG-014699|
41317966|NCT03604237|DIAGNOSTIC_TEST|Targeted group|Forceps biopsy is taken after surface evaluation of the large colorectal tumors.
41317967|NCT06157047|PROCEDURE|Crestal Bone Expansion obtained with the Magnetic Mallet®|A magnetodynamic instrument (Magnetic Mallet®, Metaergonomica, Turbigo, Italy) has been used to perform a horizontal bone expansion in edentulous sites that need to be rehabilitated with a dental implant.
41317968|NCT03661489|DRUG|Remimazolam|For induction and maintenance of general anesthesia
41317969|NCT03661489|DRUG|Propofol|For induction and maintenance of general anesthesia
41317970|NCT01956266|BEHAVIORAL|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson \& Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
41317971|NCT00661349|DRUG|Lopinavir/ritonavir|2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
41317972|NCT00661349|DRUG|Nevirapine|2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
40800843|NCT01846962|BEHAVIORAL|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
40800844|NCT01846962|DRUG|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1mg/day or 2mg/day (\<150 cm or \>150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
40800845|NCT06318247|PROCEDURE|site preservation|Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
40800846|NCT03002324|BEHAVIORAL|Baseline Survey|The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
41317973|NCT05164679|BEHAVIORAL|multimodal training (MMT)|Supervised multimodal exercise training (MMT) performed 1-2 hours weekly for 19 weeks
41317974|NCT02834234|GENETIC|comparative genomic analysis|DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation
40800847|NCT03002324|BEHAVIORAL|Current CDC Message|Participants randomized to the current CDC message arm will read a message taken almost directly from the CDC Vaccine Information Sheet (VIS) on HPV. This message was minimally altered for length and clarity.
41317975|NCT02189590|DEVICE|i-gel|Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
40800848|NCT03002324|BEHAVIORAL|Cervical Cancer Message|Participants randomized to the cervical cancer messaging arm will receive a message developed by the study team to appeal tenants of the Health Belief Model (self-efficacy, perceived benefit) and on the purity tenant of the moral foundations theory.
40800849|NCT03002324|BEHAVIORAL|Control Message|Participants randomized to the non-vaccine related control arm will read a bird-feeding passage.
40800850|NCT03002324|BEHAVIORAL|Post-Intervention Survey|The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
40800851|NCT00791050|DEVICE|Allon Thermowrap. MTRE Advanced Technologies Ltd.|"Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery."
41474887|NCT03537157|DRUG|Rifaximin delayed release tablets|Active intervention
41474888|NCT03537157|OTHER|Placebo|Comparator placebo
41474889|NCT00990847|DRUG|Procaterol, Salbultamol|
41317976|NCT02189590|DEVICE|air-Q|Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
41317977|NCT04716153|OTHER|Multifactorial sensory rehabilitation workshops|A multifactorial sensory rehabilitation Workshops : a multifactorial program in order to optimize the recovery of flavors, focused on smell and taste which integrates several non-drug interventions, which are part of the current recommendations: hydration of the mucous membranes with daily (3 times a day) liposomal sprays (nose and mouth), presentation of visual dishes.
41317978|NCT04716153|OTHER|Usual care|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified."
41317979|NCT04716153|OTHER|Tests and Questionnaire|fulfillment of Taste Strips Test, Sniffin'sticks test and QGO, FACT-G, HADS, l'EVA des ingesta and GPAQ questionnaires to assess the quality of life of patients
41317980|NCT00139139|BIOLOGICAL|Hepatitis A vaccine|
41317981|NCT06018610|OTHER|Rehabilitation|In addition to conventional rehabilitation, relaxation exercises and classical massage of the sole of the foot will be applied to the study group.
41317982|NCT06018610|OTHER|Control|Conventional rehabilitation will be applied to the control group.
41317983|NCT00608452|OTHER|Symptom Assessment Scale|"* Memorial Symptom Assessment Scale~* History and neurologic examination"
41317984|NCT06388330|OTHER|low FODMAP diet|strict low FODMAP diet followed by reintroduction of different FODMAPs and glucose (control)
41317985|NCT05557734|PROCEDURE|caudal block|injection of local anesthestic through the scral hiatus into the sacral canal to reach caudal epidural space
41317986|NCT05557734|PROCEDURE|perianal block|local anesthestic infiltration in the perianal area to block terminal branches of the nerves supplying the anal canal
41317987|NCT03117166|DRUG|lidocaine|A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
40800852|NCT05764252|DEVICE|BioEP|All patient's EEG will have the BioEP score conducted on it
40800853|NCT05616546|BIOLOGICAL|Influenza Vaccine|The vaccine used in this study will be a licensed seasonal inactivated influenza vaccine for intramuscular injection that is approved by the FDA. Enrolled subjects will receive licensed seasonal inactivated influenza vaccine (administered as a part of the study).
40800854|NCT04130776|DIAGNOSTIC_TEST|Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged|The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, digital rectal exam (nodules, no nodules), and prior negative biopsy (yes, no) to give physicians a personal score for each patient. The 4Kscore Test predicts the risk percent score from \<1% to \>95% of a man having aggressive cancer in a prospective biopsy.
41317988|NCT03117166|DRUG|Placebo|A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
41317989|NCT00638924|OTHER|Shuttle walk test|the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
40800855|NCT00589706|DRUG|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
40800856|NCT02277574|BIOLOGICAL|AMP-110|2, 5, or 10 mg/kg
40800857|NCT02277574|OTHER|Placebo|Placebo
40800858|NCT06429709|DEVICE|Advanced Ultrasound Otoscope|The Advanced Ultrasound Otoscope is a tool for visualization of the human tympanic membrane and detection of middle ear effusion type
40800859|NCT00993863|DRUG|Placebo|single dose
40800860|NCT00993863|DRUG|ADL5859 30 mg|single dose
40800861|NCT00993863|DRUG|ADL5859 100 mg|single dose
41004788|NCT06363487|DRUG|Semaglutide, 0.5 mg/mL|Injected subcutaneously (pre-filled pen) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. It is not possible to blind the researcher administering the medication/placebo because semaglutide comes in specific pre-filled pens. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
41317990|NCT04693689|OTHER|RNA vaccine|We elicit subjects' willingness to receive RNA COVID-19 vaccine
40800862|NCT00993863|DRUG|ADL5859 200 mg|single dose
40800863|NCT00993863|DRUG|ibuprofen 400 mg|single dose
40800864|NCT00154700|DRUG|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
41317991|NCT04693689|OTHER|20% adoption rate|We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
41004789|NCT06363487|OTHER|Placebo, 0.9% NaCl 1.5mL|Injected subcutaneously (subcutaneous injection syringe) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
41317992|NCT04693689|OTHER|40% adoption rate|We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
41317993|NCT04693689|OTHER|60% adoption rate|We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
40800865|NCT03256669|PROCEDURE|umbilical incision|exploration through umbilical incision
40800866|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
41317994|NCT04693689|OTHER|80% adoption rate|We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
41317995|NCT04693689|OTHER|Conventional vaccine|We elicit subjects' willingness to receive conventional COVID-19 vaccine
41317996|NCT04693689|OTHER|0% adoption rate|We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
41317997|NCT03230162|DRUG|Sildenafil|sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery
41317998|NCT03230162|DRUG|low molecular weight heparin|a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
41317999|NCT01318772|DEVICE|Radiography and Fluoroscopy Imaging System|"KALARE (DREX-KL80) is a new high resolution digital system designed for digital spot imaging, with the primary goal to address R/F and DSA clinical applications and produce images in a digital format.~The system includes a new digital camera and a new image processor."
40800867|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
41318000|NCT00253318|DRUG|Docetaxel|40 mg/m\^2 IV over 1 hour on Day 1.
41318001|NCT00253318|DRUG|RAD001|30 mg orally on Days 1 and 8.
41318002|NCT00253318|DRUG|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
41318003|NCT05764278|OTHER|exercise|exercise group: first bed exercise after 0\~24hr onset ; sit at bed after 24\~48hr onset control group: first bed exercise after 24\~48hr onset ; sit at bed after 48\~72hr onset
41318004|NCT03648307|DIAGNOSTIC_TEST|Blood sample|Blood sample for Hb A1C and lipid profile, blood pressure and BMI
40800868|NCT03685318|DEVICE|Use of conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo
40800869|NCT03685318|DEVICE|Use of shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo
40800870|NCT01911650|OTHER|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
40800871|NCT01911650|OTHER|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
40800872|NCT01911650|OTHER|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
40800873|NCT00955643|OTHER|oxygen|
40800874|NCT00955643|OTHER|other|
40800875|NCT05153603|DRUG|Olaparib mono-maintenance therapy|Olaparib mono-maintenance therapy in patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III-IV) ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer is defined as drug exposure. At least one dose of olaparib tablets monotherapy as maintenance therapy will be required.
40800876|NCT02797301|OTHER|synthetic test|The children performed the synthetic test with no time restriction.
40800877|NCT02797301|OTHER|computerised test|The children performed the computerised test with no time restriction.
40800878|NCT04405999|DRUG|Bromhexine Hydrochloride|Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
40800879|NCT04207892|PROCEDURE|Conservative (non-surgical) treatment|Cast Sling Splint Collar
40800880|NCT04207892|PROCEDURE|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) K-Wire External fixation
40800881|NCT05639309|DEVICE|near-infrared spectroscopy based cerebral/somatic oximeter system (INVOS™ system manufactured by Medtronics)|regional oxygen saturation measurement
41318005|NCT01747785|OTHER|Cardiac rehabilitation|Aerobic cardiac exercise training will be provided over the 12 week study duration.
41318006|NCT01747785|OTHER|Myocardial deformation imaging|A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.
41318007|NCT01747785|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
41318008|NCT01927419|DRUG|Nivolumab|
41318009|NCT01927419|DRUG|Ipilimumab|
41318010|NCT01927419|DRUG|Placebo|Matching nivolumab
41318011|NCT05273840|DIETARY_SUPPLEMENT|Ivital Control|Patients in the intervention group will take 2 sachets of nutritional supplements(Ivital Control) once a day in lieu of one meal, besides receiving lifestyle interventions.
41318012|NCT05273840|BEHAVIORAL|lifestyle intervention|Patients will receive lifestyle interventions.
41318013|NCT02726113|DRUG|cholecalciferol|softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
41318014|NCT02726113|OTHER|placebo|softgel containing no active ingredient daily for approximately two months prior to surgery (prostatectomy).
41318015|NCT02581865|DRUG|NBI-98854|
41318016|NCT02581865|DRUG|Placebo|
40800882|NCT03617601|DIAGNOSTIC_TEST|MET|Testing of the metabolic equivalent of task before aortic procedure
40800883|NCT04142138|OTHER|DASH|DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
41318017|NCT06141655|DRUG|Influenza vaccine|Participants will be individually randomized 1:1 to receive either QIV-HD or QIV-SD, one dose, the day of the inclusion in the trial
41318018|NCT02510170|OTHER|no intervention|
41318019|NCT05861284|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation method that can induce long-term changes in connections between neuronal networks.
40800884|NCT00862368|BEHAVIORAL|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
41318020|NCT01506050|DRUG|Desloratadine|Desloratadine ODT 5 mg
41318021|NCT06082869|DRUG|Protegera™ toothpaste (NaF)|Plaque Reduction
41318022|NCT06082869|DRUG|Crest™ Cavity Protection toothpaste (NaF)|Plaque Reduction
41318023|NCT02753036|DRUG|Chemotherapy|standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines
41318024|NCT00828334|DEVICE|Transcatheter PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
41318025|NCT02119884|DRUG|Terlipressin|Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
41318026|NCT02119884|DRUG|Octreotide|Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
41318027|NCT03779893|COMBINATION_PRODUCT|BioCoat® by Premier®.|Bioactive pits and fissure sealant
41318028|NCT03779893|COMBINATION_PRODUCT|3M™ Clinpro™ Sealant.|conventional pits and fissure sealant
41318029|NCT03363334|DRUG|Fostamatinib disodium 100 mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)
41004790|NCT05824806|BIOLOGICAL|PRP Protocol A|Platelet rich plasma protocol A
41004791|NCT05824806|BIOLOGICAL|PRP Protocol B|Platelet rich plasma protocol B
41004792|NCT05824806|DEVICE|Hyaluronic acid|Hyaluronic acid
41318030|NCT03363334|DRUG|Fostamatinib disodium 150 mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)
41318031|NCT02357797|DRUG|Vortioxetine|
41318032|NCT02357797|OTHER|Placebo|
41318033|NCT03007121|DRUG|Morphine intrathecal|Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS
41318034|NCT03007121|DRUG|Bupivacaine + Sufentanil epidural|Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
41318035|NCT03007121|DRUG|Morphine intravenous|Patiernt-controlled i.v. analgesia with morphine
41318036|NCT05519618|PROCEDURE|Epidural veins pressure and flow measurement|"The purpose of this study is to measure to pressure and flow of epidural venous plexus.~The procedure will be performed alongside during pre-operative embolization at the angiography suite.~It will be performed under general anesthesia. A the start of the procedure, a venous access will be established at the inguinal region. Co-axial catheters will be navigated to epidural venous plexus under the guidance of fluoroscopy. After the placement of catheter, the pressure and flow of epidural venous plexus will be measured at three time points: 1. Right after catheter reach the targeted location 2. Right before embolization. 3. After embolization. The participant will be instructed to control their breathe during measurement.~After measurement, the catheter will be removed alongside with embolization devices, and achieved hemostasis as routine."
41318037|NCT01486784|DRUG|Birinapant|IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion
41004793|NCT04752501|OTHER|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
40800885|NCT00862368|BEHAVIORAL|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
40800886|NCT00862368|BEHAVIORAL|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
41004794|NCT04752501|OTHER|Biomedical Education (Control)|This arm will provide education of basic knee anatomy, lower extremity mechanics, and simple exercises and will not address maladaptive psychological behaviors
41004795|NCT05976919|DIAGNOSTIC_TEST|Pulmonary function testing|Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.
41318038|NCT00905723|DRUG|estradiol|1 mg daily for 6 months
41318039|NCT00905723|DRUG|isoflavone|150 mg isoflavone daily for 6 months
41318040|NCT00905723|DRUG|Placebo|sugar pill daily for six months
41318041|NCT00698061|BIOLOGICAL|HBV-MPL vaccine 208129|3-dose primary vaccination and booster vaccination by intramuscular injection
41318042|NCT00698061|BIOLOGICAL|Engerix™-B|3-dose primary vaccination and booster vaccination by intramuscular injection
41004796|NCT00518908|DRUG|Sevoflurane|3.2 Vol % for postconditioning
41004797|NCT04712604|BEHAVIORAL|My Sleep Our Sleep (MSOS) Program|MSOS Program is a weekly one-hour Zoom session that focuses on psychoeducation on sleep health for both patients and their sleep partners.
40800889|NCT03028129|DRUG|Isoniazid 900 milligrams|Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.
41004798|NCT04316624|DRUG|C-CAR066|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
41004799|NCT02378766|BEHAVIORAL|Website A|"Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change."
41318043|NCT03782636|DRUG|Aldesleukin|"PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion"
41318044|NCT03782636|OTHER|Placebo|sterile diluent used for the aldesleukin preparation and 5% glucose
41318045|NCT04045717|RADIATION|Hypo-FLAME 2.0 study|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
41318046|NCT00795353|DRUG|Amevive exposure|Commercial alefacept prescribed by Physician
41318047|NCT01006863|DRUG|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
40800890|NCT03028129|DRUG|Placebo|Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
40800891|NCT04091932|DRUG|Pembrolizumab|Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
41004800|NCT02378766|OTHER|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
41004801|NCT00861211|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
41004802|NCT00861211|DRUG|Placebo|Placebo comparator
41004803|NCT03735862|BIOLOGICAL|Hepatic derived surgical matrix|Hiatal hernia repair with MIROMESH
41474890|NCT02924376|DRUG|Pemigatinib|Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
40800892|NCT05909033|PROCEDURE|Kasai procedure|All KPs were performed by a medical team. This technique involved creation of a 35-40 cm Roux loop to facilitate biliary drainage. After dissection of the hepatic vasculature at the hilum and excision of the hilar plate, hepaticojejunostomy was performed as an anastomosis extending from the bifurcation of the right hepatic artery into anterior and posterior branches to the Rex confluence of the left portal vein with the obliterated umbilical vein.
40800893|NCT02526810|DRUG|insulin lispro|continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level
40800894|NCT02526810|DRUG|Insulin Glargine|long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
40800895|NCT01130909|DRUG|AZD6765|75 mg
40800896|NCT01130909|DRUG|AZD6765|150 mg
40800897|NCT01130909|DRUG|Ketamine|0.5 mg/kg
40800898|NCT01130909|DRUG|Placebo|125 mL sterile NaCl 0.9%
40800899|NCT01672879|BIOLOGICAL|Placebo|Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
40800900|NCT01672879|BIOLOGICAL|SIM|Intravenous infusion over 30 minutes every 2 weeks
40800901|NCT05221996|BEHAVIORAL|Resistance training|Resistance circuit training
40800902|NCT04102709|DEVICE|Health Tag|Health Monitoring Device
40800903|NCT03086616|DRUG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
40800904|NCT01111734|DIETARY_SUPPLEMENT|N-Acetylcysteine|All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.
40800905|NCT01111734|DRUG|fMRI|All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
40800906|NCT06035406|DRUG|Retagliptin Phosphate Tablet|Retagliptin Phosphate Tablet;100mg
41318048|NCT01006863|DRUG|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
41318049|NCT01006863|DRUG|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine \[group 5 (n=30)\] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
41318050|NCT00304317|DRUG|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
40800907|NCT01320852|OTHER|PET Scan|All patients will have a PET scan as part of their pre-transplant assessment
40800908|NCT03027518|OTHER|WILD 5 Wellness|Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
40800909|NCT01047007|DRUG|adavosertib 20 mg|Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
40800910|NCT01047007|DRUG|5-FU 1000 mg/m^2/day|5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
40800911|NCT01047007|DRUG|CDDP|CDDP 60 mg/m\^2 to 100 mg/m\^2 administered as an IV infusion on Day 1.
40800912|NCT01047007|DRUG|adavosertib 65 mg|Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
40800913|NCT00809835|DRUG|Galantamine|Daily 8 mg galantamine capsule
40800914|NCT00809835|BEHAVIORAL|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
40800915|NCT06502639|OTHER|theraplay program|"A play therapy method called thermaplay aids in children's development of stronger bonds and relationships with others. It emphasizes the parts of communication that are nonverbal. When it comes to giving cerebral palsy children with hand therapy that is both effective and motivating, fun approaches have been shown to be both successful and appealing."
40800916|NCT06502639|OTHER|conventional physical therapy|conventional physical therapy program for like stretching and strengthening exercises, sponge ball exercises to the hand, and hand weight bearing exercises
40800917|NCT03897465|DEVICE|Lomatuell Pro|Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
40800918|NCT03897465|DEVICE|UrgoTul|Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
40800919|NCT05559905|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
40800920|NCT05559905|DRUG|Placebo|Placebo capsule matched to molnupiravir taken twice daily by mouth.
40800921|NCT05559905|BIOLOGICAL|RSV A Memphis 37b|RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of \~4 Log10 plaque forming units (PFUs).
40800922|NCT05444907|OTHER|No Intervention / Exposure|No intervention / exposure since this is an observational study
41004804|NCT05155228|BEHAVIORAL|Attachment Regulation and Competency|Trauma informed psychotherapy intervention for children with a history of exposure to trauma and their caregivers.
41004805|NCT05155228|BEHAVIORAL|Treatment as usual|Supportive psychotherapy
40800923|NCT06300749|OTHER|Chiropractic Cervical Manipulation|"In the chiropractic cervical manipulation group, the patient was placed in the supine position. The therapist moved to the patient's head, identified the C5-C6 segment by palpation, and manually performed spinal manipulation from the right side using the cervical rotary break/index push technique since the dominant side of the patients was the right extremity. In the cervical rotary break/index thrust technique, the lateral aspect of the practitioner's index finger was placed in contact with the posterior aspect of the participant's C5 facet joint, and a rotational thrust was performed between the C5-C6 vertebrae."
40800924|NCT06300749|OTHER|Sham Technique Practice|The sham technique can be defined as a technique that does not have any therapeutic effect and is preferred to determine whether the efficacy of another technique is superior. The patient was placed in the supine position. The therapist moved to the patient's head, and the C5-C6 segment localized in the lower cervical region was detected by palpation. The C5-C6 segment was positioned to perform chiropractic cervical manipulation and waited for 30 seconds without any pushing force.
40800925|NCT00284414|PROCEDURE|Ultrasonography or MRI|
40800926|NCT05253937|DRUG|Epinephrin|The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
40800927|NCT01101282|DEVICE|Positive expiratory pressure (PEP) mask therapy|PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
40800928|NCT03125031|DEVICE|Rainbow adhesive adult/pediatric sensor|
40800929|NCT03125031|DEVICE|Rainbow adhesive adult/neonatal sensor|
40800930|NCT02583633|DRUG|Transdermal nitroglycerin|
40800931|NCT02583633|DRUG|nifedipine|
40800932|NCT05606848|OTHER|Nutrition Emulsion (TPF-T)|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake control product with recommended energy.~* 1-8 days after surgery: Patients gradually increase control product intake to reach the recommended energy."
40800933|NCT05606848|OTHER|Foods for special medical purposes [FSMP] for patients with tumors|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake FSMP with recommended energy.~* 1-8 days after surgery: Patients gradually increase FSMP intake to reach the recommended energy."
40800934|NCT01078194|DEVICE|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
40800935|NCT01132950|BEHAVIORAL|Motivational Interviewing|Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.
40800936|NCT01132950|OTHER|Didactic Educational Counseling|Participant will watch an educational video while in jail and a second educational video at 3 months post release.
40800937|NCT06301776|DRUG|Ticagrelor|To compare the safety and efficacy of different DAPT duration combined with ticagrelor monotherapy.
40800938|NCT00000333|DRUG|Benztropine|
40800939|NCT03019523|DIETARY_SUPPLEMENT|Caffeine Blend|Taken orally in capsule form
40800940|NCT03019523|OTHER|Sugar Pill|Taken orally in capsule form
40800941|NCT04237181|DEVICE|Filmarray PCR multiplex-PCT assay|Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
40800942|NCT04685980|PROCEDURE|spinal anaesthesia with local anaesthetic and intrathecal morphine|Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine
40800943|NCT01812213|DRUG|[18F]NAV4694|
40800944|NCT02763813|DEVICE|Herbst (propulsion type oral appliance)|Oral appliance
40800945|NCT02763813|DEVICE|Retention type appliance (ORM)|
40800946|NCT01195376|DRUG|BEZ235|
40800947|NCT05301621|OTHER|Akcelerometry follow up|The patients and control group will be followed up with single accelerometer.
40800948|NCT06294262|BIOLOGICAL|TETRALITE|Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant
41004806|NCT04596540|DRUG|SEL-212 low-dose|"SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR"
41004807|NCT04596540|DRUG|SEL-212 high-dose|"SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.15 mg/kg) Other Names: SEL-110, ImmTOR"
41004808|NCT04596540|OTHER|Placebo|Normal saline
41157093|NCT05306340|DRUG|Exemestane|If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
41474891|NCT05373381|DIETARY_SUPPLEMENT|Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt|Following a screening period, subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles. Patients will receive dietary advice from a Registered Dietitian (RD) to allow for the design of personalized meal plans maintaining carbohydrates up to 33% of total caloric intake, and be asked to maintain a daily dietary log. To assist patients in understanding, monitoring and controlling their dietary choices to maintain a low carbohydrate diet, they will be trained and receive assistance on the use of an online tool for tracking nutrition \[Healthtrac\].
41474892|NCT04862884|DRUG|HRS4800 tablets|"1. Drug: HRS4800 tablets Low-dose group, single oral administration~2. Drug: HRS4800 tablets Low-medium dose group, single oral administration~3. Drug: HRS4800 tablets medium -dose group, single oral administration~4. Drug: HRS4800 tablets Medium and high dose group, single oral administration~5. Drug: HRS4800 tablets High-dose group, single oral administration"
41318051|NCT00304317|OTHER|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
41318052|NCT06098937|DEVICE|Kalifilcon Toric Lens|Kalifilcon A Daily Disposable Toric for Ametropia
41004809|NCT04874337|OTHER|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.|The subjects for the training program were prepared by the researchers by scanning the relevant literature. In particular, the ICN Framework of Disaster Nursing Competencies developed by the International Nurses Association (ICN) and the World Health Organization (WHO), the second is the universal standards that should be fundamental in nursing and midwifery education (Global Standards for the Initial Education of Professional Nurses and Midwives). The training program was conducted both theoretically and practically. The theoretical section is based on Jenning's disaster nursing management model. Investigator is a First and Emergency Aid instructor. In addition, support was received from an experienced psychologist and AFAD trainers who provided support to the victims of the Izmir earthquake during the training process. In this context, an 8-module training program was created.
41318053|NCT06098937|DEVICE|Total1 for Astigmatism|Total1 for Astigmatism
41318054|NCT06098937|DEVICE|Precision1 for Astigmatism|Precision1 for Astigmatism
41474893|NCT04862884|DRUG|placebo|"1. Drug: placebo Low-dose group, single oral administration~2. Drug: placebo Low-medium dose group, single oral administration~3. Drug: placebo medium -dose group, single oral administration~4. Drug: placebo Medium and high dose group, single oral administration~5. Drug: placebo High-dose group, single oral administration"
40800949|NCT04129983|COMBINATION_PRODUCT|Drugs and Stimulation|60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
40800950|NCT05050968|OTHER|Physical activity|Between V1 and V2 (i.e. 12 weeks), the APAG (Adapted Physical Activity Group) will participate at a physical training program, 3 sessions of 1h30 per week consisting of endurance activities (60-75% of VO2 peak) and muscle strengthening while the CG will not perform any controlled physical training program. Then, between V2 and V3, no APA (Adapted Physical Activity) program will be offered to both groups.
41318055|NCT06098937|DEVICE|MyDay Toric|MyDay Toric
41318056|NCT05240638|DEVICE|TD Drainage|Image-guided percutaneous cannulation of the TD and drainage with an endovascular catheter (microcatheter)
41318057|NCT03885089|DRUG|Infliximab [infliximab biosimilar 3]|\<Psoriasis\> The usual dose is 5 mg as Infliximab (Genetical Recombination) \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
41318058|NCT03832439|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamnosus GG 10 billion cells and microcrystalline cellulose
41474894|NCT03827018|COMBINATION_PRODUCT|mavrilimumab|1 mL of 150 mg in a pre-filled syringe
41474895|NCT03827018|COMBINATION_PRODUCT|placebo|1 mL of placebo in a pre-filled syringe
40800951|NCT03813784|DRUG|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
41318059|NCT03832439|DIETARY_SUPPLEMENT|microcrystalline cellulose|Placebo
41318060|NCT06278558|OTHER|Interviews with a psychologist/psychiatrist|All patients with a high score (≥11) on the HADS anxiety and/or depressive symptoms scale and who are not already receiving known psychological treatment or treatment mentioned in the file will be contacted by telephone by the investigator or a qualified person designated by him/her in order to conduct a telephone interview with the patient and refer him/her to a psychologist or psychiatrist if necessary. The number and percentage of consultations with a psychologist or psychiatrist following this telephone interview will be calculated in order to highlight the benefits of such a practice (HADS assessment + telephone interview with +/- referral) for earlier and easier referral. Depending on the number of patients contacted, consideration may be given to testing the effect of this approach on post-traumatic development.
41318061|NCT05310994|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
41474896|NCT03827018|DRUG|prednisone|Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
41474897|NCT01745354|DRUG|SD-101|SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
41474898|NCT01745354|RADIATION|Local Radiation|
40800952|NCT03813784|DRUG|Capecitabine|1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
40800953|NCT03813784|DRUG|Oxaliplatin|130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
40800954|NCT03813784|DRUG|Apatinib|250 mg administered as continuous oral once daily (QD) of each 3-week cycle.
41004812|NCT02362165|DRUG|Cyclophosphamide|500mg/d,once-weekly,per oral.
41004813|NCT02362165|DRUG|Bortezomib|1.3mg/㎡,once-weekly,subcutaneous injection
41318062|NCT05310994|DIETARY_SUPPLEMENT|Wasabi Leaf Extract Drink|consume 1 bottle per day
41318063|NCT01129180|DRUG|azacitidine|Given SC
40800955|NCT01872585|BEHAVIORAL|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
41318064|NCT01129180|DRUG|bortezomib|Given IV
41318065|NCT01129180|PROCEDURE|Correlative studies|Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
41318066|NCT06377345|DEVICE|AeviceMD device|The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management
41318067|NCT06377345|BEHAVIORAL|Standard care|All participants will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.
41318068|NCT06509711|OTHER|PLYOMETRICS jump training with HIIT (4 weeks,3 sessions per week)|First set of drills 6 x 40-cm hurdle jumps +5-s sprint\* at 130% of aerobic maximum speed. Second set of drills 6 x 30-cm hurdle jumps with extended legs + 5-s sprint at 130% of aerobic maximum speed. Third set of drills 6 x horizontal jumps + 5-s sprint at 130% of aerobic maximum speed. Fourth set of drills 3 right-leg and 3left-leg hops +5-s sprint at 130% of aerobic maximum speed. Each drills set was performed 2 times in a row. Afterwards, 10 seconds of rest were allowed. Thereafter, this sequence of effort-rest was repeated 8 times. After then, a 3-5 min recovery period was allowed before commencing the next drills set;
41474899|NCT01077817|DRUG|Alendronate|
41474900|NCT01077817|DRUG|Etidronate|
41318069|NCT06509711|OTHER|PLYOMETRICS JUMP TRAINING WITHOUT HIIT (4weeks, 3sessions Per week)|Plate pogo (4 reps, 3 sets) Broad jump( 4reps,3 sets)
41004814|NCT02362165|DRUG|Dexamethasone|40mg/d,once-weekly,per oral
41004815|NCT02362165|DRUG|Doxorubicin|9mg/㎡,d1-4
41318070|NCT03894774|BEHAVIORAL|Intensive in-patient psychotherapy treatment|Intensive non-pharmaceutical in-patient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic setting where patients live during the whole treatment (approximately a 1:1-Ratio caregiver per patient is given) of 6 to 8 month treatment duration.
41318071|NCT03894774|OTHER|Treatment as usual|Combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy
41318072|NCT05329779|DRUG|brexanolone|Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.
41004816|NCT04294004|COMBINATION_PRODUCT|TGplPTH1-34 in fibrin|TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage
41004817|NCT04294004|OTHER|Autologous Bone Graft|Local autograft collected from decompression which may be supplemented with iliac crest bone graft (ICBG) if local autograft is insufficient.
41152267|NCT03932032|BEHAVIORAL|Attention Bias Modification Treatment|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.
41318073|NCT05329779|DRUG|placebo|The placebo is a 0.45% sodium chloride infusion.
41474901|NCT01077817|DRUG|Ibandronate|
41318074|NCT00502320|DRUG|Ramelteon|one 8 mg tablet at bed for up to 4 months
41474902|NCT01077817|DRUG|Risedronate|
41474903|NCT01077817|DRUG|Raloxifene|
41474904|NCT04086771|BEHAVIORAL|Navigation|Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card
41318075|NCT00502320|DRUG|Placebo|one tablet at bedtime for up to 4 months
41474905|NCT04086771|OTHER|Information only|American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
41474906|NCT02610920|PROCEDURE|Iron-tracer guided axillary ultrasound and biopsy|After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
41474907|NCT02610920|DRUG|Iron tracer|All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
41474908|NCT00094094|DRUG|axitinib|Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
40800956|NCT04251832|DRUG|Sodium Thiosulfate|Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
40800957|NCT01142869|DRUG|Cetuximab|The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
40800958|NCT02725450|BEHAVIORAL|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
40800959|NCT02725450|BEHAVIORAL|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
40800960|NCT02183493|DRUG|BI 1356|
40800961|NCT00100256|DRUG|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
40800962|NCT01667133|DRUG|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
41318076|NCT05078099|DEVICE|CureSight|Binocular eye-tracking-based passive home treatment system delivering personalized amblyopia therapy
40800963|NCT01667133|DRUG|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
40800964|NCT01292980|DEVICE|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
40800965|NCT05245682|DRUG|Tolinapant|Given PO
40800966|NCT05245682|RADIATION|Radiation Therapy|Undergo radiation therapy
40800967|NCT05788666|PROCEDURE|GeriKit Mobile Application|Digital health app used for comprehensive geriatric assessment (CGA). The app includes a series of brief, well-validated instruments: the MiniCog, 30-Second Chair Stand, Activities of Daily Living, Instrumental Activities of Daily Living, Patient Health Questionnaire (PHQ-9), Mini Nutrition Assessment, 2-Item Fall Screen, and Polypharmacy screen.
40800968|NCT01557543|OTHER|Cell Therapy|Intramyocardial Injection of BMSCs
41004818|NCT06269172|BEHAVIORAL|intereviews|"An individual's experience of their breathlessness is influenced by multiple factors including their medical condition, psychology, sociological and situational circumstances which will include ethnicity. There is currently a lack of evidence exploring the impact of ethnicity in the experience and presentation of breathlessness.~The non-medical management of breathlessness in respiratory diseases includes pulmonary rehabilitation (PR). PR is a highly evidenced exercise-based intervention to help manage breathlessness, improving health-related quality of life and improving survival. Recent audits in England and Wales showed 89% of patients attending PR were recorded as having a White British ethnicity which is in contrast to national ethnicity demographics. This may be because the cultural acceptability of PR components are not fully considered."
41004819|NCT02302833|DRUG|Cabozantinib S-malate|Given PO
41004820|NCT02302833|OTHER|Laboratory Biomarker Analysis|Correlative studies
41004821|NCT02302833|OTHER|Questionnaire Administration|Ancillary studies
41004822|NCT01606046|DEVICE|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
41318077|NCT04888234|DRUG|Ru-Yi-Jin-Huang Powder|Ru-Yi-Jin-Huang Powder is the most common TCM topical drug for skin diseases. It is often used to treat skin ulcers, sprain of joint with swelling, and other inflammatory diseases.
41474909|NCT00500279|DRUG|Celecoxib|
41474910|NCT00537199|OTHER|Visual Examination|Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
41474911|NCT00537199|DRUG|OraTest|Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
40800969|NCT03533816|DRUG|EAGD T-cell infusion (Phase I)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
40800970|NCT03533816|DRUG|EAGD T-cell infusion (Expansion)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
40800971|NCT01890590|DEVICE|CyberKnife|Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
40800972|NCT05449132|DRUG|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
40800973|NCT05449132|DRUG|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
40800974|NCT06436014|OTHER|Providing VR experience|Participants undergoing VR intervention will experience a VR program of their choice based on personal preferences. Among these programs are videos offering natural visual experiences. For instance, participants can opt for videos featuring seaside views, forest tours, or lake landscapes.
41004823|NCT01606046|DRUG|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
41318078|NCT00061126|DRUG|ABX-EGF|
41318079|NCT00441441|DRUG|fluticasone propionate|fluticasone propionate 100mcg HFA
41318080|NCT00441441|DRUG|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
41318081|NCT04205578|DRUG|dl-3-n-butylphthalide (NBP)|25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
41318082|NCT04205578|DRUG|Normal Saline 0.9% Infusion Solution|100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
41318083|NCT04583111|DRUG|Domperidone|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
41318084|NCT04583111|DRUG|sulpiride|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
41474912|NCT05678855|BEHAVIORAL|A randomızed Controlled Study with pre-test and post-test|The intervention in this study is to apply multimedia-based instruction in distance education to the experimental group. control group students received distance education through traditional teaching. Experimental group students received distance education through interactive teaching prepared with multimedia tools. Experimental group, interactions were made using applications such as Icebreaker, Puzzle, QR code, Mentimeter, and Padlet. In addition, animation, infographics, animated slides (Multimedia tools) were used for the experimental group.In the control group, plain narration was given. Tests were administered to both groups before and after the intervention.
41318085|NCT00883220|BEHAVIORAL|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
41318086|NCT00289562|DRUG|forodesine hydrochloride (BCX-1777)|
41474913|NCT04204031|BEHAVIORAL|Presentation of the adherence record|Adherence record will be presented to participants with an actual time of use less than prescribed. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.
40800975|NCT05425498|OTHER|Physical activity program|12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model.
41318087|NCT03210779|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days
41318088|NCT03210779|DIETARY_SUPPLEMENT|Placebo|Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
41318089|NCT02990455|DRUG|Reduced nicotine cigarettes|Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
41318090|NCT03908710|OTHER|Treatment of hypertension using blood pressure self-measurement at home|The primary aim of the present study is to investigate whether home blood pressure recording via Bluetooth and continuous communication between doctor and patient will give improved blood pressure values when comparing the initial values with the blood pressure values recorded after 3 months. Secondary examinations include treatment of hypotension and adverse events, the patient's experience, the user's potential problems with the blood pressure cuff, app downloading, problems with history issues or problems with technical
41474914|NCT05550220|DIAGNOSTIC_TEST|Cuff Leak Test|Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.
41474915|NCT00392457|DRUG|ketoconazole|loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days
41474916|NCT00392457|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
40800976|NCT02561481|DRUG|Sulforaphane|See under active arm description
40800977|NCT02561481|DRUG|Placebo|See under placebo arm description
40800978|NCT01652053|DEVICE|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
40800979|NCT02031991|BIOLOGICAL|PF-06439535|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
40800980|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
41318091|NCT00426114|DRUG|Administration of an IV glucose-injection|
41318092|NCT05590767|PROCEDURE|Patients scheduled to undergo shoulder rotators repair surgery|Patients scheduled to undergo shoulder rotators repair surgery, and received combined general anesthesia and interscalene block
41318093|NCT03878524|DRUG|Abemaciclib|Given PO
41318094|NCT03878524|DRUG|Abiraterone|Given PO
41318095|NCT03878524|DRUG|Afatinib|Given PO
41318096|NCT03878524|BIOLOGICAL|Bevacizumab|Given IV
41318097|NCT03878524|DRUG|Bicalutamide|Given PO
41318098|NCT03878524|PROCEDURE|Biospecimen Collection|Undergo collection of biospecimens (including tissue, blood, or previously collected archival specimens)
41318099|NCT03878524|DRUG|Bortezomib|Given IV
41318100|NCT03878524|DRUG|Cabazitaxel|Given IV
41318101|NCT03878524|DRUG|Cabozantinib|Given PO
40800981|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
41318102|NCT03878524|DRUG|Capecitabine|Given PO
40800982|NCT00432328|DRUG|Avotermin|
41474917|NCT03451240|BEHAVIORAL|Corporate Athlete® Resilience|"The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~1. Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~2. Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work."
41474918|NCT05064774|OTHER|myofascial release technique|myofascial release group took myofascial release (MFR) therapy sessions twice a week for 4 weeks between 4 and 7 weeks. MFR was applied to upper trapezius, SCM, pectoralis major-minor and sternocostal fascia. muscle was replaced elongated position and pressure was applied for 60-120 second.
41004824|NCT04405609|DEVICE|ArmAssist|"The usability study protocol include 3 ArmAssist systems (2 designed for the left hand and one for the right hand) that could not be used in parallel because the aim of the study was to bring the systems to the home environment during part of the evaluation.~The usability study is carried out in two phases:~1. First phase: 5 weeks.~2. Second phase: 3 weeks. Each phase included a week of training at the Hospital or IMIBIC facilities with a physiotherapist, and then 2 weeks at the patient's home, being the first one with the physiotherapist supervision and the second one by their own with the possibility of physiotherapist remote support."
41004825|NCT03582488|DRUG|18F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
41318103|NCT03878524|DRUG|Carboplatin|Given IV
41474919|NCT05064774|OTHER|physiotherapy|patients used sling up to 4 weeks. They did first 4 weeks passive/ assistive range of motion exercise. In 6-8 weeks they did active exercises. 8-12 weeks they did progressive resistive exercises.
41474920|NCT05187611|DEVICE|Conduction system pacing|Lead placed in the His-Purkinje system in order to achieve QRS shortening.
40800983|NCT01648244|OTHER|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
41474921|NCT05187611|DEVICE|Biventricular pacing|Lead is placed in a tributary of the coronary sinus.
41474922|NCT05476614|OTHER|Yoga (Robot-instructed)|Yoga that is instructed by a social robot
41474923|NCT05476614|OTHER|Yoga (Human-instructed)|Yoga that is instructed by a human
41474924|NCT06612229|PROCEDURE|Conservative surgical treatment of liver echinococcosis, verification of occult biliary fistulas and their elimination by weaving and using medical cyanoacrylate glue|In conservative surgical operations for liver echinococcosis, the biliary fistula is identified, onto which a U-shaped suture is applied, after which medical cyanoacrylate glue is applied between the suture stitches to the fibrous capsule in the fistula area and the suture threads are tied.
41318104|NCT03878524|DRUG|Celecoxib|Given PO
41318105|NCT03878524|DRUG|Cobimetinib|Given PO
41318106|NCT03878524|DRUG|Copanlisib|Given IV
41318107|NCT03878524|DRUG|Dabrafenib|Given PO
41318108|NCT03878524|DRUG|Dacomitinib|Given PO
41004826|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
41004827|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
41004828|NCT01891851|DRUG|TMC435350 200 mg|Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
41004829|NCT01891851|DRUG|Ritonavir 100 mg|Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
41004830|NCT00427635|DRUG|Esomeprazole|
41004831|NCT00446433|DRUG|CC-5013|
41004832|NCT03904706|OTHER|Audits only|Formalized audit teams with monthly meetings at each facility.
41318109|NCT03878524|DRUG|Darolutamide|Given PO
41318110|NCT03878524|DRUG|Dasatinib|Given PO
41318111|NCT03878524|DRUG|Doxorubicin|Given IV
41318112|NCT03878524|BIOLOGICAL|Durvalumab|Given IV
41318113|NCT03878524|DRUG|Enasidenib|Given PO
41318114|NCT03878524|DRUG|Entrectinib|Given PO
41318115|NCT03878524|DRUG|Enzalutamide|Given PO
41318116|NCT03878524|DRUG|Erlotinib|Given PO
41318117|NCT03878524|DRUG|Everolimus|Given PO
41318118|NCT03878524|DRUG|Fluorouracil|Given IV
41318119|NCT03878524|DRUG|Idelalisib|Given PO
41318120|NCT03878524|DRUG|Imatinib|Given PO
41318121|NCT03878524|BIOLOGICAL|Ipilimumab|Given IV
41318122|NCT03878524|DRUG|Lenvatinib|Given PO
41318123|NCT03878524|DRUG|Leucovorin|Given IV
41318124|NCT03878524|DRUG|Lorlatinib|Given PO
41318125|NCT03878524|DRUG|Losartan|Given PO
41318126|NCT03878524|DRUG|Nab-paclitaxel|Given IV
41318127|NCT03878524|DRUG|Neratinib|Given PO
41474925|NCT01271179|PROCEDURE|sequential perfusion with ipv Ross solution and UW solution|Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
41474926|NCT01271179|PROCEDURE|sole perfusion with UW solution|Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
41318128|NCT03878524|BIOLOGICAL|Nivolumab|Given IV
41474927|NCT05618574|DIETARY_SUPPLEMENT|210 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)|The investigators propose to study the benefits nitrite therapeutics, using nitrate-rich beetroot juice to increase serum nitrite. The investigators hypothesize that increased nitrite will improve functional metrics and reduce fatigability in Veterans with long COVID as a result of enhanced skeletal muscle mitochondrial respiration. Participant will receive 210 ml per day of Beet-It nitrate beverage for 16 mmol of nitrate/day for 14 days vs the placebo.
41474928|NCT04191824|DIAGNOSTIC_TEST|APOL1 status|Participants will be randomized to immediate versus delayed return of results for positive or negative APOL1 status.
41474929|NCT04121117|OTHER|Chronic obstructive pulmonary disease screening|"To verify the tobacco withdrawal, the patients will make a cooximetry.~For the detection of a possible obstructive pattern a measurement of the ventilatory capacity will be make using the COPD-6 device and for the confirmation of COPD diagnosis and the assesment of the airflow obstruction severity a spirometry will be make.~The patients will also complete the COPD-PS questionnaire."
41474930|NCT00706355|DRUG|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
41474931|NCT01726114|DEVICE|Non-invasive Optical Glucose Monitor™|Test device
41474932|NCT01726114|DEVICE|YSI blood glucose analyzer|Reference device
41474933|NCT06061406|DEVICE|smart visit app|"Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician."
41474934|NCT01466322|DRUG|GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state|Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
41474935|NCT01640873|DRUG|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
41474936|NCT01640873|DRUG|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
41474937|NCT05016622|BIOLOGICAL|BNT162b2 vaccine|Administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.
41474938|NCT02864004|DRUG|Apomorphine|Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour
41474939|NCT02864004|OTHER|Best Medical Treatment|Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
41474940|NCT01139749|DRUG|oral isotretinoin|capsules of 20 mg a day, every other day, for six months
41004833|NCT03904706|OTHER|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
41318129|NCT03878524|DRUG|Olaparib|Given PO
41318130|NCT03878524|DRUG|Oxaliplatin|Given IV
41152268|NCT03932032|BEHAVIORAL|Neutral Control Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
41152269|NCT05480202|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
41318131|NCT03878524|DRUG|Palbociclib|Given PO
41318132|NCT03878524|DRUG|Panobinostat|Given PO
41474941|NCT01139749|DRUG|salicylic acid and ciclopirox olamine|Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
41474942|NCT00374582|DEVICE|Bodystat Quadscan 4000|device determining body composition and nutritional status
41474943|NCT00374582|DEVICE|bodystat quadscan 400|device determining body composition and nutritional status
41318133|NCT03878524|BIOLOGICAL|Pembrolizumab|Given IV
41318134|NCT03878524|BIOLOGICAL|Pertuzumab|Given IV
41318135|NCT03878524|DRUG|Ponatinib|Given PO
41318136|NCT03878524|OTHER|Quality-of-Life Assessment|Ancillary studies
41318137|NCT03878524|DRUG|Regorafenib|Given PO
41318138|NCT03878524|DRUG|Ruxolitinib|Given PO
41318139|NCT03878524|DRUG|Sirolimus|Given PO
41318140|NCT03878524|DRUG|Sorafenib|Given PO
41318141|NCT03878524|DRUG|Sunitinib|Given PO
41318142|NCT03878524|DRUG|Trametinib|Given PO
41318143|NCT03878524|BIOLOGICAL|Trastuzumab Emtansine|Given IV
41318144|NCT03878524|DRUG|Tretinoin|Given PO
41318145|NCT03878524|DRUG|Vemurafenib|Given PO
41318146|NCT03878524|DRUG|Venetoclax|Given PO
41318147|NCT03878524|DRUG|Vismodegib|Given PO
41318148|NCT03878524|DRUG|Vorinostat|Given PO
41474944|NCT01323452|DRUG|Entecavir|once daily
41318149|NCT05450458|DRUG|KNEE JOINT INFILTRATION WITH HYALURONIC ACID WITH SORBITOL SYNOLIS VA|KNEE INFILTRATION WITH HYALURONIC ACID WITH SORBITOL IN SPORTSMEN
41318150|NCT02387372|DRUG|Ceftolozane/Tazobactam - Multiple Doses|"4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~* Participants with CLCR \> 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
41318151|NCT02387372|DRUG|Ceftolozane/Tazobactam - Single Dose|Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
41318152|NCT02312583|BEHAVIORAL|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
41474945|NCT00349726|DRUG|Inositol lower volume|60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
41474946|NCT00349726|DRUG|Inositol higher volume|120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
40800984|NCT05618210|OTHER|regional anesthesia|"in the ESPB group, the linear ultrasound probe was placed in the erector spina muscles were visualized on the side where VATS was planned. block needle can be seen on ultrasound, the skin and erector spina muscles are passed in the cranio-caudal direction. ESPB will be administered with 20 ml of 0.5% bupivacaine by visualizing the local anesthetic spread linearly.~In the rhomboid intercostal block group, the ipsilateral arm is positioned towards the chest, allowing the scapula to move laterally and the area called auscultation triangle to be opened, and after the skin disinfection of the surgical side; By using a linear ultrasound probe, the rhomboid major and intercostal muscles will be defined in the auscultation triangle region, and T5-6 level with an in-plane approach with 20 ml of 0.5% bupivacaine and local anesthetic injection."
40800985|NCT06125197|BIOLOGICAL|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
40800986|NCT06125197|BIOLOGICAL|KEYTRUDA®|pembrolizumab, a monoclonal antibody binding PD-1
40800987|NCT00269113|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
40800988|NCT00269113|DRUG|Standard chemotherapy|As prescribed
41474947|NCT00349726|DRUG|Placebo lower volume|60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.
41474948|NCT00349726|DRUG|Placebo higher volume|120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
40800989|NCT05914077|DRUG|Secretin|Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.
40800990|NCT05914077|PROCEDURE|Endoscopic aspiration|Endoscopic aspiration of duodenopancreatic juice after secretin stimulation
41004834|NCT04073225|DEVICE|MindPod Dolphin|"The immersive video game being tested in this study is called Bandit the Dolphin, developed by neurologist Dr. John Krakauer, and engineers in the Brain, Learning, Animation, and Movement Lab at Johns Hopkins. Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke. The game has further been modified to a Microsoft Kinect-based system and piloted for play in non-laboratory settings among community-dwelling adults. The game offers a unique combination of skilled arm movements plus varying levels of cognitive challenge. In this way, the individual's arms are challenged the same way the legs would be when walking in a complex, outdoor environment. Importantly, the participant plays while standing, thus engaging the whole body in this novel multi-sensorial experience."
41152270|NCT05480202|OTHER|Designed chest physical therapy program|Percussion, vibration and postural drainage
41318153|NCT02312583|BEHAVIORAL|iFightDepression online programme|"iFightDepression online programme. During 7 weeks as a complement to the usual treatment.~Participants will complete the modules of a structured online programme for depression"
41318154|NCT06113497|DRUG|Cocktail injection|Morphine 5 mg, ropivacaine 150 mg, tramadol 40 mg, epinephrine 1 mg, ketorolac 60 mg, and ketamine 1 g will be mixed with normal saline to prepare a total volume of 60 ml
41318155|NCT01843400|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients treated with Regorafenib under practical manner for colorectal cancer.
41318156|NCT02849314|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
41318157|NCT02849314|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
41318158|NCT06248905|OTHER|Rehabilitation program based on the strengthening of gluteal muscles|Physiotherapy program (8 weeks)
41474949|NCT03508869|DRUG|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
41474950|NCT03508869|DRUG|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
41474951|NCT03508869|DRUG|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
41474952|NCT03221452|BEHAVIORAL|Memory, Attention, and Problem Solving Skills for Diabetes|Classes will include: (1) information on diabetes self-management including glucose self-monitoring and medication management; (2) assessment of cognitive problems; (3) resources and barriers to self-management; and (4) lifestyle changes to maximize cognitive health. Participants will also practice those skills with online computer games.
41474953|NCT03392740|DRUG|Lisinopril|Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.
41474954|NCT03392740|DRUG|Placebo Oral Tablet|Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
40800991|NCT05914077|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).
41318159|NCT06248905|OTHER|Extracorporeal shock wave therapy|Focused shock wave therapy (3 weeks)
41318160|NCT03178812|PROCEDURE|EUS with fine-needle aspiration of pancreatic cyst|EUS with fine-needle aspiration
41318161|NCT03178812|DIAGNOSTIC_TEST|Laboratory Blood test|Laboratory Blood Test
41318162|NCT04462757|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use
41004835|NCT04073225|DEVICE|Hand Bike|The control intervention in this study is a hand bike, a single-component upper-arm aerobic exercise device. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
41004836|NCT01755416|DRUG|Closed loop with sensor and Insulin|Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
41004837|NCT01755416|DRUG|Closed loop with sensor, Insulin and Liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
40800992|NCT04486638|BIOLOGICAL|Dengue Tetravalent Vaccine, Live|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Subcutaneous
41004838|NCT03765736|OTHER|Genetic Testing|Undergo genetic testing
41318163|NCT01333696|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
41318164|NCT05611840|PROCEDURE|Robotic surgery|one-stage robotic common bile duct exploration and cholecystectomy
41318165|NCT05611840|PROCEDURE|Endo-laparoscopic surgery|Two-stage therapeutic ERCP plus interval laparoscopic cholecystectomy
41318166|NCT02474524|BEHAVIORAL|Health intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
41318167|NCT02474524|BEHAVIORAL|Social intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
41318168|NCT00278772|DRUG|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
41318169|NCT00278772|OTHER|Placebo|oral dose, placebo
41318170|NCT02626845|DRUG|Rituximab|Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
41318171|NCT02626845|OTHER|Placebo|Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
41474955|NCT02190448|DIETARY_SUPPLEMENT|study herbal tea|3-5 cups, 8oz tea daily for 4 weeks
41474956|NCT02190448|DIETARY_SUPPLEMENT|herbal placebo tea|3-5 cups, 8oz each daily for 4 weeks
41004839|NCT02677090|DRUG|Placebo (including Maltodextrin)|
41004840|NCT02677090|DRUG|Dose 1 - Promitor®|
41004841|NCT02677090|DRUG|Dose 2 - Promitor®|
41004842|NCT02677090|DRUG|Dose 3 - Promitor®|
41318172|NCT05533255|OTHER|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Composite resin at room temperature is used.
41318173|NCT05533255|OTHER|Preheated composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative) is preheated to a temperature of 57 degrees Celsius using a composite warmer for 10 minutes is used.
41318174|NCT00020566|BIOLOGICAL|dactinomycin|Given IV
41004843|NCT03483935|OTHER|Microwave treatment|Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.
41004844|NCT05595629|BEHAVIORAL|App-based remote blood pressure monitoring|Fully synched bluetooth-enabled remote blood pressure monitoring using a smartphone application. The digital health company, Twistle, has modified an existing postpartum hypertension pathway in their app according to our hospital's management algorithm.
41004845|NCT05595629|BEHAVIORAL|text-message based remote blood pressure monitoring|Participants will receive automatic blood pressure cuffs and instructions as to how to upload their measurements to the Electronic Medical Record.
41318175|NCT00020566|DRUG|busulfan|Given orally and IV
41318176|NCT00020566|DRUG|doxorubicin hydrochloride|Given IV
41318177|NCT00020566|DRUG|etoposide|Given IV
41318178|NCT00020566|DRUG|ifosfamide|Given IV
41318179|NCT00020566|DRUG|melphalan|Given orally and IV
41318180|NCT00020566|DRUG|vincristine sulfate|Given IV
41004846|NCT04261270|DRUG|ASC09F+Oseltamivir|ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
41318181|NCT00020566|PROCEDURE|autologous hematopoietic stem cell transplantation|Given IV
41318182|NCT00020566|PROCEDURE|conventional surgery|Given to patients deemed to require it
41318183|NCT00020566|RADIATION|radiation therapy|Given to patients deemed to require it
41004847|NCT04261270|DRUG|Ritonavir+Oseltamivir|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
41004848|NCT04261270|DRUG|Oseltamivir|75mg ,once a day
41474957|NCT06338735|OTHER|Ultra-High Frequency Ultrasound scan of minor salivary glands|Patients will undergo ultra-high frequency ultrasonography (70 MHz) of minor salivary glands, and the scans will be assessed using the OMERACT scoring system. Score 0 will be assigned in the presence of normal glandular tissue, Score 1 will correspond to mild glandular alteration, fine echogenicity or diffuse hypo-echogenicity, Score 2 will be assigned to moderate glandular alteration and focal hypoechoic areas with partial conservation of normal parenchyma, while in Score 3 diffuse presence of hypoechoic areas in the absence of normal glandular parenchyma with glandular fibrosis will be observed.
41004849|NCT05705063|OTHER|LCHF Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 6 weeks
41004850|NCT04495114|OTHER|40g carbohydrate load (Apple juice)|A 40g carbohydrate drink will be administered to subjects with non-insulin dependent type 2 diabetes 3 hours prior to their operation. This is standard practice in subjects without diabetes.
41004851|NCT03707769|DEVICE|TIPS microspheres|TIPS microspheres manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) prepared as a paste with GranuGel.
41004852|NCT06306456|DRUG|GH21|Oral, 15mg BIW/6mg QD
41318184|NCT03266666|BEHAVIORAL|WellnessRX Lifestyle Change Classes|Lifestyle change classes on nutrition, physical activity, and stress management.
41318185|NCT03266666|OTHER|Thrive Market Grocery Credits (4x$25 each)|Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
41474958|NCT03939988|RADIATION|Photobiomodulation|Immediately after the installation of the separators, the subjects will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
41474959|NCT03939988|RADIATION|Placebo photobiomodulation|In the placebo group, the same procedures will be made, but the laser will be turned off.
41474960|NCT04114942|BEHAVIORAL|Never Coach|20 weeks of didactic training and 10 weeks of internship, but no coaching.
41004853|NCT06306456|DRUG|Tagrisso|Oral, 80mg QD
41004854|NCT02002494|OTHER|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
41474961|NCT04114942|BEHAVIORAL|Internship Only Coach|20 weeks of didactic training with no coaching and 10 weeks of internship with coaching.
41474962|NCT04114942|BEHAVIORAL|Constant Coach|20 weeks of didactic training and 10 weeks of internship, with coaching throughout.
41474963|NCT05870488|DEVICE|Use of iFuse TORQ|Use of iFuse TORQ for the treatment of SI Joint dysfunction
41004855|NCT01404468|DEVICE|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
41318186|NCT03248947|DRUG|buprenorphine/naloxone|To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
41318187|NCT03248947|OTHER|Pharmacist-administered buprenorphine/naloxone maintenance care|Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
41318188|NCT05024877|DRUG|Hetrombopag|Hetrombopag would be given started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
41318189|NCT05024877|DRUG|Stanozolol Tablets|Stanozolol would be given 2mg tid.
41318190|NCT02172079|OTHER|Real mobilization-with-movement (MWM)|
41474964|NCT04723147|DRUG|Carbidopa Levodopa|Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
41474965|NCT04723147|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
41474966|NCT06233110|DRUG|Fostamatinib|Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.
41004856|NCT01404468|OTHER|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
41004857|NCT01404468|DEVICE|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
41004858|NCT01589822|BIOLOGICAL|EVICEL Fibrin Sealant|Intraoperative
41004859|NCT05766306|DIETARY_SUPPLEMENT|Probiotic Blend|Participants will be taking 1 sachet a day, 3 billion CFU.
41004860|NCT05766306|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day.
41004861|NCT04892576|OTHER|Physical Therapy|"The control group recieved the standard physical rehabilitation program conducted for 45 minutes, twice a week for eight consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.~The SSC group received the same program in addition to the SSC exercises for 30 minutes, two times per week for eight successive weeks"
41004862|NCT00581776|DRUG|Bortezomib|Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
41004863|NCT00581776|DRUG|Rituximab|Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
41004864|NCT00581776|DRUG|Cyclophosphamide|Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
41004865|NCT00581776|DRUG|Doxorubicin|Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
41004866|NCT00581776|DRUG|Vincristine|1 mg administered by IV on day 3 of each cycle.
41004867|NCT00581776|DRUG|Dexamethasone|40 mg orally on days 1-4 of each cycle.
41004868|NCT03200782|DRUG|Empagliflozin|Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
41004869|NCT03200782|DRUG|Anakinra|IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
41004870|NCT03200782|OTHER|oral placebo (winthrop tablet)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
41004871|NCT03200782|OTHER|subcutaneous placebo (0.67 ml of 0.9% sodium chloride)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
41004872|NCT01941446|DRUG|Eravacyline, Moxifloxacin, and placebo|
41004873|NCT01632891|DRUG|Lopinavir/ritonavir|Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
41004874|NCT01632891|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
41004875|NCT01632891|DRUG|Efavirenz|Participants received one 600 mg tablet of efavirenz orally once daily.
41004876|NCT01632891|DRUG|Nevirapine|If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
41004877|NCT01632891|DRUG|Trimethoprim/sulfamethoxazole|Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
41004878|NCT05379296|BEHAVIORAL|Diabetes Prevention Program Plus (DPP+)|The DPP+ includes the CDC-approved DPP lifestyle program expanded to include a CDC-approved module on hypertension prevention and treatment
41004879|NCT05379296|BEHAVIORAL|Diabetes Prevention Program (DPP)|CDC-approved DPP lifestyle program
41004880|NCT03575884|BEHAVIORAL|Screen Time Reduction Curriculum|"Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year."
41004881|NCT02431208|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
41004882|NCT02431208|DRUG|Daratumumab|Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
41004883|NCT02431208|DRUG|Lenalidomide|Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.
41004884|NCT02431208|DRUG|Pomalidomide|Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
41004885|NCT02431208|DRUG|Dexamethasone|Participants will receive either 20mg or 40mg of dexamethasone PO every 7 days from Day 1 of each cycle.
41004886|NCT01064895|DEVICE|Benephit catheter for Targeted Renal Therapy|Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
41004887|NCT05664724|BEHAVIORAL|Receives interdisciplinary sessions|"Along with usual care, participants receive six interdisciplinary sessions at 2 months and 1 month pre-operatively and 2 weeks, 6 weeks, 3 months, and 6 months post-operatively attended by an orthopedic surgeon, a physiotherapist, a patient navigator, and the patient. The pre-operative interdisciplinary sessions will outline expectations, explore patients' questions and concerns, set expectations for the next interdisciplinary session, and ensure goal congruence between all members of the team.~Along with usual care during the post-operative period, participants will receive interdisciplinary sessions that address safety and medical issues, revisit patient expectations, reinforce care team expectations, focus on a personalized rehabilitation plan, and ensure goal congruence between the various team members."
41152271|NCT05965518|BEHAVIORAL|High-Intensity Interval Training|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
41152272|NCT05965518|BEHAVIORAL|Continuous Moderate Exercise|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
41152273|NCT06073665|DRUG|Levothyroxine Sodium|Levothyroxine dose will depend on dose at baseline and randomization group
40800993|NCT01056406|BEHAVIORAL|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
41152274|NCT03833206|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
40800994|NCT03753360|BEHAVIORAL|Internet-Based Mindfulness Program - Stress Free Now for Healers|Stress Free Now for Healers is an online stress management program developed at Cleveland. It's delivered in 4 components:1Weekly introductions to the concepts and meditation theme are delivered via Web page views or a 5to10-min audio clip2Weekly guided meditations 5-20 min ea.available as embedded/downloadable mp3 on the website or via the Stress Free Now for Healers phone app,which participants are invited to practice at least 4 times each week and to record those practices3Daily articles provide the scientific underpinnings and merits of each week's theme or discuss various cognitive and behavioral strategies,activities,and concepts supporting or related to mindfulness4Daily tips suggesting how to manage stress or incorporate mindfulness in daily activities,including motivational quotes.Participants will have access to a smartphone app with recordings of the 11 guided meditations.Ea. participant will be assigned an e-coach that will communicate with the participant at least weekly.
40800995|NCT03753360|BEHAVIORAL|Active Control Group - Relaxing Music|The control group will be given a flash drive and a link to a website where they can download several digital recordings of relaxing music and will be instructed to quietly listen to one or more of the recordings for at least 5 minutes every day for 6 weeks.
40800996|NCT04169503|DRUG|Immune Checkpoint Modulator|identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
40800997|NCT05382884|OTHER|Postpartumcare.ca (Web-Enabled Intervention)|Postpartumcare.ca is a web-enabled intervention accessible via computer, tablet or smartphone devices. The content and design of postpartumcare.ca were created based on the needs, opinions, and desires of birthing parents in British Columbia affected by postpartum depression and/or anxiety, which were solicited previously in phases 1 \& 2 of the SUPPORT study.
40800998|NCT05818540|DEVICE|Eclipse novel CPAP mask|Participants will wear the mask for 6 hours a night for 60 days.
40800999|NCT05818540|DEVICE|ResMed P-10 mask|Participants will wear the mask for 6 hours a night for 60 days.
40801000|NCT03884387|OTHER|Patient Decision Aid|The Patient Decision aid used in this project is a tool designed to facilitate shared decision making in patients with lumbar herniated disk. It is intended to complement counseling with health professionals and help patients become involved in decision making by making explicit the decision that needs to be made, providing information about the advantages and disadvantages of having or not having surgery, knowledge of treatment outcomes, and by clarifying personal values.
40801001|NCT04884880|DRUG|Luo-Fu-Shan Plaster|Luo-Fu-Shan Plaster 10g，once daily，4 weeks
40801002|NCT04884880|DRUG|The placebo 10g|Placebo 10g，once daily，4 weeks
40801003|NCT02580032|OTHER|No treatment given|No treatment given.
40801004|NCT00392834|BIOLOGICAL|filgrastim|given subcutaneously
40801005|NCT00392834|BIOLOGICAL|pegfilgrastim|given subcutaneously
41318191|NCT02172079|OTHER|Sham mobilization-with-movement (MWM)|
41318192|NCT04679259|DIAGNOSTIC_TEST|Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood|Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.
41474967|NCT06233110|DRUG|Ruxolitinib|Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.
40801006|NCT00392834|BIOLOGICAL|rituximab|given IV
40801007|NCT00392834|DRUG|cyclophosphamide|given IV
40801008|NCT00392834|DRUG|cytarabine|given intrathecally
40801009|NCT00392834|DRUG|doxorubicin hydrochloride|given IV
40801010|NCT00392834|DRUG|etoposide|given IV
41318193|NCT04679259|DIAGNOSTIC_TEST|Neurocognitive test|Neurocognitive test is performed before surgery and at 7 day after surgery
41318194|NCT04679259|DIAGNOSTIC_TEST|Assessment of delirium|Postoperative delirium is assessed daily during 7 days after surgery.
40801011|NCT00392834|DRUG|ifosfamide|given IV
40801012|NCT00392834|DRUG|leucovorin calcium|given IV
40801013|NCT00392834|DRUG|liposomal cytarabine|given intrathecally
40801014|NCT00392834|DRUG|methotrexate|given intrathecally
40801015|NCT00392834|DRUG|therapeutic hydrocortisone|given intrathecally
40801016|NCT00392834|DRUG|vincristine sulfate|given IV
40801017|NCT00149799|DRUG|Escitalopram|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
40801018|NCT00149799|DRUG|Placebo|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
40801019|NCT04779450|OTHER|Kinesiotherapy protocol|The kinesiotherapy protocol is an exercise-based treatment designed to gain upper limb range of motion and muscle strengthening.
40801020|NCT04779450|OTHER|Usual orientations|Usual orientations for post-breast cancer women, such as skin care, return to activities, upper limb functionality, self-care, lymphedema, and physical activity practice.
40801021|NCT00515528|BIOLOGICAL|4-peptide melanoma vaccine|Experimental cancer vaccine given as a shot under the skin once every two weeks
40801022|NCT00515528|DRUG|Ontak|A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
41152275|NCT02690025|DRUG|ZP1848|
41318197|NCT05669300|PROCEDURE|Yilmaz Suturation|uterine closure with Yilmaz Technique and single layer continue locked suturation
41152276|NCT01124916|PROCEDURE|Robotic assisted laparoscopic abdominal sacrocolpopexy|Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
41318198|NCT06251219|DIAGNOSTIC_TEST|PCR|PCR test for EV71, CA16, CA10, or CA6
41318199|NCT00211718|DRUG|intra-articular botulinum toxin type a|
41318200|NCT05015166|BEHAVIORAL|Experimental: Internet delivered self-help program with therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises which a therapist gives feedback on.
41318201|NCT05015166|BEHAVIORAL|Internet delivered self-help program without therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises.
41318202|NCT06372886|PROCEDURE|portal/superior vein resection|portal/superior vein resection
41318203|NCT05154513|OTHER|Cohort 1|No intervention provided in this study
41318204|NCT03162055|DRUG|Glycopyrronium/Formoterol Fumarate|Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
40801023|NCT02400606|OTHER|Constructing VP cases|The participants were presented with a short case overview. The control group solved the cases, whereas the intervention group also received the final diagnosis and had to complete the history, physical findings, and lab results. After a week, participants completed a transfer test involving two standardized patients presenting a respiratory case and a cardiology case, respectively. Performances were video-recorded and subsequently assessed by two blinded raters using the Reporter-Interpreter- Manager-Educator (RIME) framework. Knowledge gains were assessed using a pre- and post-test of a 95-item Multiple-Response-Questionnaire (MRQ).
40801024|NCT02400606|OTHER|Solving VP cases|See above
40801025|NCT00408707|PROCEDURE|local infiltration analgesia|
41318205|NCT03162055|DRUG|umeclidinium/vilanterol|Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
41474968|NCT03557359|DRUG|Nivolumab|Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
40801026|NCT05147532|PROCEDURE|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6
41318206|NCT03255993|DRUG|SPH3127 50mg|SPH3127 50mg
41318207|NCT03255993|DRUG|SPH3127 100mg|SPH3127 100mg
41318208|NCT03255993|DRUG|Placebo matching to SPH3127 50mg|Placebo matching to SPH3127 50mg
41318209|NCT03255993|DRUG|Placebo matching to SPH3127 100mg|Placebo matching to SPH3127 100mg
41474969|NCT01145924|PROCEDURE|EBUS TBNF|Transbronchial needle forceps will be use with the EBUS TBNA scope
40801027|NCT05746013|DIETARY_SUPPLEMENT|Lipid Emulsion|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.
40801028|NCT05178836|DRUG|F520+F007|"Drug: F007~F007 is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).~Drug: F520~F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)."
40801029|NCT01309997|DRUG|imatinib mesylate|Given PO
40801030|NCT01309997|BIOLOGICAL|rituximab|Given IV
40801031|NCT04476446|DRUG|Esketamine|Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
40801032|NCT05820139|PROCEDURE|Control Group|Patients will be randomized to a 200mL (control group)
40801033|NCT05820139|PROCEDURE|Test Group|Patients will be randomized to a cut-off of 150mL (test group)
40801034|NCT00935493|DRUG|Guanfacine|Guanfacine 0.1 mg po qhs
40801035|NCT00935493|DRUG|Guanfacine|Guanfacine 0.5 mg po qhs
40801036|NCT00935493|DRUG|Placebo|Placebo po qhs
40801037|NCT01204905|DRUG|Raltegravir and Maraviroc in combination|"Raltegravir 400 mg tablet twice a day, \~12 hours (10 to 14 hours) apart~Maraviroc 300 mg tablet twice a day, \~12 hours (10 to 14 hours) apart"
40801038|NCT01419496|GENETIC|protein expression analysis|
40801039|NCT01419496|OTHER|flow cytometry|
40801040|NCT01419496|OTHER|laboratory biomarker analysis|
40801041|NCT00615693|DRUG|AEB071|
40801042|NCT04505319|DEVICE|DEFINISSE CORE FILLER|"DEFINISSE CORE FILLER volume will be injected between 4.0 of 5.0 ml on the whole face (at the discretion of the treating physician to achieve an optimal aesthetic result).~A touch-up will be possible at the first follow-up visit (after one month) with a amount of product between 4.0 and 5.0 ml on the whole face"
41152277|NCT01124916|PROCEDURE|Standard laparoscopic abdominal sacrocolpopexy|Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
41318210|NCT03077113|DIAGNOSTIC_TEST|4-D CT Scan|The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
41318211|NCT03077113|DIAGNOSTIC_TEST|SPECT-CT Scan|It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
41318212|NCT02995330|PROCEDURE|Bone marrow transplantation|Infused with non-T-cell depleted bone marrow from a related female donor on Day 0
41318213|NCT02995330|DRUG|Cytoxan|Cytoxan 50mg/kg IV on Days +3 and +4
41474970|NCT03969199|BEHAVIORAL|Intervention|Dietary intervention in coordination with MANNA, who will deliver low sodium meals to patients for 90 days
41318214|NCT02995330|DRUG|testosterone cypionate|testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
41318215|NCT00003450|BIOLOGICAL|Ad5CMV-p53 gene|
41004888|NCT03395366|OTHER|Multifaceted Educational / Cognitive Behavioral Intervention|The intervention includes 8 to 12 one-on-one sessions over a 12-week period, run by a licensed social worker (LSW) with experience delivering therapy. Curriculum will introduce education relevant for self-management and consists of prepared slides, handouts \& worksheets. The education was designed based on slides developed and published online by the national kidney foundation and the national kidney disease education program. The curriculum was designed to be understandable by all potential subjects, including those with low literacy levels. Sessions will incorporate behavior-based activities designed to deliver education about and improve upon medication adherence, diet, exercise, and coping. These activities, based around CB strategies such as cognitive restructuring and behavior shaping, will include review of self-management logs, goal setting, creation of treatment plan, problem-solving techniques, reinforcing techniques, and coping with ESRD.
41004889|NCT02280980|OTHER|Oculomotor and Gaze Stability Exercises|Daily oculomotor and gaze stability exercises, twice a day, for three weeks
41004890|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
41004891|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
41004892|NCT02075320|DEVICE|Stationary Digital Chest Tomosynthesis|"The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.~Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction."
41004893|NCT05927753|DEVICE|Deseyne Daily Disposable Contact Lens (Test Device)|Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.
41004894|NCT03093675|DEVICE|TELELAP ALF-X Robotic Surgical System|The surgical procedures will be performed using the innovative TELELAP ALF-X robotic system, equipped with multiple independent arms. Initial entry will be through a classic open in which the arm with the video camera will be inserted. The device has four independent arms (one for the video camera and three for surgical instruments). Patients will be in the lithotomy position, supported by Allen stirrups and under general anesthesia. The uterus will be manipulated with a multi-use uterine manipulator. After having induced a pneumoperitoneum, high-definition 3D-technology optics will be inserted. Three laparoscopic instruments will be used to complete the procedure. Standard techniques will be used.
41004895|NCT04055857|OTHER||There is no Intervention.
41004896|NCT05716828|OTHER|Balint group activities|A Balint group is a working form that focuses on the professional doctor-patient relationship. Participants in the Balint group completed Balint training for a period of at least three months, which included two lectures and 10 small group discussion sessions held once a month for one hour at a time (on Thursdays from 12 to 1 PM). Balint group is a closed group including one to two group leaders and six to twelve participants, with sessions lasting 60 to 90 minutes.
41004897|NCT03621878|OTHER|Neural mobilization exercises -Tensioner technique|Exercise aiming to lengthen the neural structure using more than one joint.
41004898|NCT03621878|OTHER|Neural mobilization exercises -Slider technique|Exercise aiming to slide/glide the neural structure using more than one joint.
41004899|NCT03621878|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device aiming to decrease patient's symptoms.
41318216|NCT05277688|DRUG|adjuvant concurrent chemoradiotherapy|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
41318217|NCT05277688|RADIATION|radiotherapy|Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
41318218|NCT02946541|DRUG|evogliptin 5mg|evogliptin 5mg, QD
41474971|NCT03352895|DIETARY_SUPPLEMENT|resveratrol|Grape seed extract 100mg Microcrystalline Cellulose 90mg Magnesium Stearate 2mg Gelatin 100mg
41474972|NCT03352895|DIETARY_SUPPLEMENT|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
41004900|NCT00684424|OTHER|Non-Interventional Study|Observational Only
41004901|NCT02781636|DEVICE|Device: StimGuard Protect System|Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
41004902|NCT03672435|DRUG|Topical Solution|proparacaine 0.5% eye drop
41318219|NCT02946541|DRUG|Placebo|Placebo, QD
41318220|NCT00599261|PROCEDURE|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
41474973|NCT01333202|OTHER|Fresh lime|fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
41474974|NCT00384488|BEHAVIORAL|Interactive Voice Response System (IVR)|
41318221|NCT05389059|PROCEDURE|CAF+CM|Periodontal surgery including CAF+CM application
41318222|NCT05389059|PROCEDURE|I-PRF|Periodontal surgery including CAF+CM application with i-PRF
41318223|NCT00126581|DRUG|Carboplatin|Given IV
41318224|NCT00126581|DRUG|Erlotinib|Given PO
41318225|NCT00126581|DRUG|Erlotinib Hydrochloride|Given PO
41318226|NCT00126581|DRUG|Paclitaxel|Given IV
41004903|NCT03528746|OTHER|Isotonic Exercise|Participants will complete dynamic leg extension in a leg extension machine with a range of motion from approximately 90 degrees flexion to full extension. Each repetition will be completed with a 3s concentric contraction, 0s isometric and 4s eccentric contraction.This will be repeated for 8 repetitions and for 5 sets with 2 minutes rest between each set, as per Rio and colleagues. The load used during the isotonic exercise will be equivalent to participants 8 repetition maximum, which will be determined by an experienced tester in a standardised manner according to NSCA guidelines.
41004904|NCT03528746|OTHER|Isometric exercise|Participants will complete isometric quadriceps exercise, where they must hold a load statically for 45s with their knee in 60° flexion. This will be repeated for 5 sets with 2 minutes rest between each set. A load of 70% of the maximal voluntary isometric contraction (MVIC) will be used. MVIC will be assessed in an isokinetic dynamometer as per Rio and colleagues. Participants will be seated in a stable position in the dynamometer with the knee at 60° of knee flexion. First they will be familiarised with the procedure. Standardised instructions will be issued for participants to perform a maximal effort knee extension against the dynamometer for 3seconds. After a short break, the test will be repeated three times and the MVIC will be peak torque recorded during these three efforts.
41004905|NCT04990934|BEHAVIORAL|Semistructured Interview|Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.
41004906|NCT00960518|DRUG|adefovir|adefovir at 10 mg daily for 48 weeks
41004907|NCT00960518|PROCEDURE|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
41004908|NCT00779012|BIOLOGICAL|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
41004909|NCT00243516|DEVICE|PREtest Consult|
41004910|NCT03904771|BEHAVIORAL|Nutrition counselling + peer support|Behavioral nutrition counselling and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by a nutrition therapist.
41004911|NCT03904771|BEHAVIORAL|Social activation + peer support|Social activation and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by group leader.
41004912|NCT02805335|DEVICE|KTFIX PLUS|
41004913|NCT05564663|BEHAVIORAL|PTSD Coach App + Brief Support|PTSD Coach App + Brief Support will include downloading the PTSD Coach App for personal use and four, brief (\<20 minutes), weekly, individual support sessions. The sessions will focus on the instruction and encouragement of App use and activities (i.e., assessments, self-management strategies, and psychoeducational readings).
41004914|NCT05564663|BEHAVIORAL|Enhanced Usual Care (EUC)|EUC will consist of one brief session (with brochure) of PTSD and AUD psychoeducation and referral information for mental health clinics that provide PTSD services, with encouragement to schedule an appointment at one of the listed clinics to discuss PTSD-related symptoms.
41004915|NCT06019793|DEVICE|DBS for Chronic Pain|Participants ill receive deep brain stimulation to relieve their chronic pain symptoms.
41004916|NCT00079924|DRUG|teriparatide|
41004917|NCT00079924|DRUG|aldrenodate|
41004918|NCT00079924|DRUG|raloxifene|
41004919|NCT02206516|DEVICE|Transcranial Direct Current Stimulation|
41318227|NCT03986008|DRUG|Benaglutide|The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
41004920|NCT05658744|BEHAVIORAL|Video group|Insulin administration video was sent to the mobile phones of the patients assigned to the video group
41004921|NCT02660918|DRUG|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
41004922|NCT02660918|OTHER|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
41004923|NCT03060746|OTHER|Newly Diagnosed|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
41004924|NCT02562313|DRUG|BioChaperone insulin lispro|BioChaperone insulin lispro bolus infusion followed by test meal intake
41004925|NCT02562313|DRUG|Humalog®|Humalog® bolus infusion followed by test meal intake
41004926|NCT05374811|OTHER|Neuropathic Pain|Neuropathic pain degrees of the patients will be evaluated with the Douleur Neuropathic-4 (DN4) questionnaire.
41004927|NCT05431062|DRUG|Bupivacain|%0.25
41004928|NCT03522181|OTHER|saline|saline
41004929|NCT03522181|OTHER|Insulin|
41004930|NCT03692546|DRUG|Liposomal bupivacaine (LB)|Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
41004931|NCT04569045|DEVICE|HA+Lidocaine|20 mg
41318228|NCT03986008|DRUG|Liraglutide|The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
41318229|NCT00979238|GENETIC|Gene Transfer|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
41318230|NCT00979238|DRUG|scAAV2/8-LP1-hFIXco|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
41004932|NCT04569045|DEVICE|HA|20 mg
41004933|NCT06522308|DIAGNOSTIC_TEST|Hepatobiliary ultrasound|The presence of cholelithiasis in patients with umbilical hernia is detected by hepatobiliary ultrasound
41318231|NCT01594333|DRUG|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
41318232|NCT01594333|DRUG|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
41318233|NCT00232440|DEVICE|BodyFIX|
41318234|NCT01726413|DRUG|GRC 17356|
41318235|NCT01726413|DRUG|Matching Placebo|
41318236|NCT03329417|OTHER|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
41318237|NCT04586244|DRUG|retifanlimab|retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,
41004934|NCT06522308|DIAGNOSTIC_TEST|Umbilical region superficial tissue ultrasound|The presence of umbilical hernia in patients with cholelithiasis is detected by ultrasound of the superficial tissue of the umbilical region.
41004935|NCT00240370|DRUG|Muraglitazar|
41004936|NCT05940935|PROCEDURE|Arterial Blood Gas Base Deficit|The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.
41004937|NCT04059848|COMBINATION_PRODUCT|tDCS(Intelect Mobile Stimulation and Combination, DJO, France)|
41004938|NCT04059848|COMBINATION_PRODUCT|NMES(Enraf Nonius, Endomed-182, Netherlands)|
41004939|NCT02803112|PROCEDURE|Emergent craniotomy for traumatic brain injury|Emergent craniotomy for traumatic brain injury (either for removal of an epidural hematoma, subdural hematoma, intraparenchymal hematoma or decompressive craniectomy).
41004940|NCT03346122|DRUG|JNJ-64991524 Dose Level 1|Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
41004941|NCT03346122|DRUG|JNJ-64991524 Dose Level 2|Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
41004942|NCT03346122|DRUG|JNJ-64991524 Dose Level 3|Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
41318238|NCT04586244|DRUG|epacadostat|epacadostat will be administered daily twice daily orally up to and including day of surgery.
41474975|NCT06206603|DIAGNOSTIC_TEST|Intestinal biopsies|Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.
41474976|NCT06206603|DIAGNOSTIC_TEST|Blood sample|A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.
41474977|NCT05536726|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W ( 6 cycles) +80 mg Q4W during maintenance period
41474978|NCT05536726|DRUG|608 Q4W|608 160 mg Q4W ( 3 cycles) +160 mg Q8W during maintenance period
41004943|NCT03346122|DRUG|JNJ-64991524 Dose Level 4|Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
41004944|NCT03346122|DRUG|JNJ-64991524 Dose Level 5|Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
41004945|NCT03346122|DRUG|JNJ-64991524 Dose Level 6|Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
41004946|NCT03346122|DRUG|Placebo|Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
41004947|NCT03346122|DRUG|JNJ-64991524 Dose Level 7|Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
41004948|NCT03346122|DRUG|JNJ-64991524 Dose Level 8|Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
41004949|NCT03346122|DRUG|JNJ-64991524 Dose Level 9|Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
41004950|NCT01665365|PROCEDURE|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
41004951|NCT05676892|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured"
41004952|NCT02774681|PROCEDURE|Cognitive Assessment|Ancillary studies
41318239|NCT04586244|DRUG|INCAGN02385|INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
41474979|NCT05536726|DRUG|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
41318240|NCT04586244|DRUG|INCAGN02390|INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
41318241|NCT03170557|OTHER|Traditional chinese acupuncture|Traditional chinese acupuncture (somatopuncture points, auriculotherapy points, craniopuncture and wrist-ankle acupuncture). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
41318242|NCT03170557|OTHER|Aspecific needle skin stimulation|Superficial needling of needles in skin areas outside the pain affected dermatome(s). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
41318243|NCT04882709|DEVICE|Receiver-in-canal hearing aid 1 default|A receiver-in-canal hearing aid developed by the Study Sponsor used with the default settings as specified in the Study Sponsor's fitting software.
41004953|NCT02774681|DRUG|Palbociclib|Given PO
41004954|NCT02774681|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
41004955|NCT02774681|BIOLOGICAL|Trastuzumab|Given IV
41004956|NCT03033472|DRUG|600 mg Clindamycin orally|600 mg Clindamycin orally 30 minutes before treatment
41004957|NCT03033472|DRUG|Oral Placebo|Oral Placebo 30 minutes before treatment
41318244|NCT04882709|DEVICE|Receiver-in-canal hearing aid 2|A receiver-in-canal hearing aid developed by another hearing aid manufacturer used with the default settings as specified in the manufacturer's fitting software.
41318245|NCT04882709|DEVICE|Receiver-in-canal hearing aid 1 strategy 1|A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
41004958|NCT06135662|PROCEDURE|CAF + CTG|Surgical techniques for mandibular gingival recession: coronally advanced flap + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
41318246|NCT04882709|DEVICE|Receiver-in-canal hearing aid 1 strategy 2|A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
40801043|NCT06554535|DRUG|Serplulimab，Platinum-based Chemotherapy，Aspirin|Participants will receive an induction therapy consisting of Serplulimab (4.5 mg/kg IV on Day 1), Carboplatin (AUC 5 IV on Day 1) or Cisplatin (75 mg/m² IV on Day 1), Etoposide (100 mg/m² IV on Days 1-3), and Bayer Aspirin (100 mg PO daily). This induction phase will be administered every 3 weeks for 4 cycles. Following the induction phase, participants will transition to a maintenance therapy phase where they will continue to receive Serplulimab (4.5 mg/kg IV on Day 1, every 3 weeks) and Bayer Aspirin (100 mg PO daily) until disease progression or intolerable toxicity.
41318247|NCT04780945|DIAGNOSTIC_TEST|Functional RAD51 assay|ex vivo functional assay (RAD51 assay also known as Repair Capacity (RECAP) assay ) to test homologous recombination deficiencie (HRD) in viable tumor tissue
41318248|NCT04780945|DRUG|Olaparib Oral Product|300 mg bid
40801044|NCT01003756|OTHER|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
40801045|NCT02517255|DEVICE|Cardiac Magnetic Resonance Imaging|7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
40801046|NCT04886102|OTHER|An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital|Research protocol involving the human person (Category 3 - Non-interventional research_ not related to a health product) Serology, molecular biology, phylogenetic and phylodynamic analyzes of hepatitis B and D
41318249|NCT01539785|PROCEDURE|Secondary citoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
41318250|NCT01539785|PROCEDURE|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
40801047|NCT00641238|DEVICE|Radiofrequency ablation|Radiofrequency ablation
40801048|NCT02859727|DRUG|CDZ173|140 mg/day
40801049|NCT05466136|BEHAVIORAL|Mental fatigue condition|In mental fatigue condition, the mental fatigue manipulation will use a modified Stroop task with complete incongruent trials, which is wildly used to induce a mentally fatigued state in previous studies. The Stroop task included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), the color of the word will paint inconsistent with the semantic meaning of the word (e.g., red word printed in green). The task consisted of five 6-minute blocks and 1080 incongruent trials for each block. The total duration will be 30-min.
40801050|NCT05466136|BEHAVIORAL|Control condition|Similar to mental fatigue conditions, the modified Stroop task with complete congruent trials will be used, The Stroop task also included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), but the color of the word will paint consistent with the semantic meaning of the word (e.g., red word printed in red) in order to set up the match condition of relative less cognitive demanding for participants. Same with the mental fatigue condition, the task consisted of five 6-minute blocks and 1080 congruent trials for each block. The total duration will be 30-min.
40801051|NCT00641355|PROCEDURE|No intervention|No intervention
40801052|NCT05032677|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L2-3 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
40801053|NCT05032677|PROCEDURE|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|25G Dural Puncture Epidural Block at L2-3 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
41318251|NCT04209257|DEVICE|Functional Electrical Stimulation.|Functional electrical stimulation - electrical stimulation applied to a muscle during an activity (i.e. ankle dorsiflexors during swing phase of gait). It assists / elicits muscle activation in order to achieve a task.
41004959|NCT06135662|PROCEDURE|Tunnel Technique + CTG|Surgical techniques for mandibular gingival recession: tunnel technique + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
40801054|NCT04655807|DRUG|JNJ-64304500|JNJ-64304500 will be administered as SC injection.
40801055|NCT04655807|DRUG|Placebo|Matching placebo will be administered as SC injection.
40801056|NCT04655807|DRUG|Adalimumab|Adalimumab will be administered as SOC biological therapy.
40801057|NCT04655807|DRUG|Ustekinumab|Ustekinumab will be administered as SOC biological therapy.
40801058|NCT02011230|OTHER|Hoist Group|Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
40801059|NCT03107052|DRUG|Fremanezumab|Fremanezumab
40801060|NCT03504293|PROCEDURE|Combinatory EUS and ERCP|EUS performed as a supplementary procedure in addition to ERCP
40801061|NCT02101996|OTHER|high-fat diet|Subjects consume a high-fat diet for three weeks before the in-hospital stay.
40801062|NCT04726930|PROCEDURE|Intercostal nerve blocks|Intercostal nerve block is a regional anesthetic procedure for peri-operative pain management. It inhibits the action of the ipsilateral sensory and motor branches, and produces analgesic effects at the targeted thoracic level.
41004960|NCT02825069|OTHER|Early introduction of solid foods|Early introduction of solid foods
41004961|NCT01148004|DRUG|Fenofibrate|
41004962|NCT01148004|DRUG|Ritonavir|
41004963|NCT01148004|DRUG|Lopinavir/Ritonavir|
41004964|NCT06481956|DRUG|Ribociclib Oral Tablet|Patients with advanced breast cancer with at least one evaluable lesion and histologically proven invasive breast cancer were eligible for inclusion. Histopathologically positive for HER2 (IHC 3+, or IHC 2+ with fluorescence in situ hybridization (FISH) positive, either primary or metastatic. Patients with advanced breast cancer must have previously received first-line therapy or initial rescue therapy and have been treated with trastuzumab against HER2.
41004965|NCT05932186|PROCEDURE|Interscalene brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position. Interscalene block will be done as follows. US probe will be placed slightly lower to the level of the cricoid cartilage, followed by scanning of the neck to search for C5 and C6 nerve roots enclosed between the anterior and middle scalene muscles. The needle will be introduced in-plane from lateral to medial through the middle scalene muscle until the tip enters the brachial plexus sheath between the C5 and C6 roots, where LA will be injected.~Patients will be transported to the operation room where general anaesthesia will be induced with tracheal intubation Fentanyl (0.5 μg/kg) will be given to maintain the heart rate and mean blood pressure 20% lower than preinduction values. Intravenous 1 gram paracetamol and 8 mg dexamethasone will be given to all patients as part of multimodal analgesia"
41004966|NCT05932186|PROCEDURE|Upper trunk brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position like the the ISB group~Upper trunk will be visualized distal to the convergence of the C5 and C6 nerve roots but proximal to the departure of the suprascapular nerve (This nerve is a small hypoechoic circle that depart the lateral aspect of the upper trunk and courses posterolateral under the omohyoid muscle). The needle will be introduced in-plane from lateral to medial under the deep cervical fascia and through a very small portion of the middle scalene muscle, until the needle tip lies adjacent to the upper trunk, LA will be distributed below and above the upper trunk. Scanning for the upper trunk can be started from the supraclavicular fossa and moving proximal or opposite to cricoid cartilage and moving distal.~The following steps will be done as in the ISB group"
41318252|NCT05136378|DRUG|Low Dose Selenious Yeast Tablets|Low dose of Selenious Yeast Tablets
41004967|NCT01445392|BIOLOGICAL|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \&amp; 5 of a 21 day cycle for 2 cycles
41004968|NCT01445392|DRUG|Pemetrexed|500 mg/m\^2 on day 1 of each 21 day cycle until disease progression
41004969|NCT01445392|DRUG|Cisplatin|75 mg/m\^2 on day 1 of each 21 day cycle until disease progression
41318253|NCT05136378|DRUG|High Dose Selenious Yeast Tablets|High Dose Selenious Yeast Tablets
40801063|NCT04726930|PROCEDURE|Paravertebral block|Paravertebral block is the technique of injecting local anesthetic alongside the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramen. This produces unilateral, segmental, somatic, and sympathetic nerve blockade, which is effective for anesthesia and in treating acute and chronic pain of unilateral origin from the chest and abdomen
40801064|NCT06162273|DEVICE|IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company|Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
40801065|NCT06474468|DRUG|SHR-A2102；Adebrelimab；Cisplatin|"Drug: SHR-A2102 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Cisplatin Administration by intravenous infusion for a cycle of 3 weeks."
40801066|NCT00804895|DRUG|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
40801067|NCT00804895|DRUG|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
40801068|NCT00804895|DRUG|Verapamil|standard prophylactic treatment
41004970|NCT01445392|BIOLOGICAL|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
41004971|NCT00218374|DRUG|Gabapentin|Gabapentin initiated up to a daily dose of 2400mg PO x 5 weeks
41004972|NCT00004918|BIOLOGICAL|PR1 leukemia peptide vaccine|Given SC
41004973|NCT00004918|DRUG|Montanide ISA 51 VG|Given SC
41004974|NCT00004918|BIOLOGICAL|sargramostim|Given SC
41004975|NCT00004918|OTHER|laboratory biomarker analysis|Correlative studies
41004976|NCT02506335|DRUG|Cholate testing|The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
41004977|NCT06063486|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41004978|NCT06063486|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41004979|NCT06063486|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41004980|NCT06063486|DIETARY_SUPPLEMENT|Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement|Given PO
41004981|NCT06063486|DIETARY_SUPPLEMENT|Piperine Extract (Standardized)|Given PO
41004982|NCT06063486|DRUG|Placebo Administration|Given PO
41004983|NCT06063486|OTHER|Questionnaire Administration|Ancillary studies
41004984|NCT04484272|BEHAVIORAL|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]).|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. \[three video banks of RDE + Support\]).
41004985|NCT04484272|BEHAVIORAL|Self-monitoring of pain, stress, and opioid use + alerts/reminders.|Self-monitoring of pain, stress, and opioid use + alerts/reminders.
41004986|NCT01120210|DRUG|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
41004987|NCT01120210|DRUG|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
41004988|NCT01120210|DRUG|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
41004989|NCT01120210|DRUG|Placebo|1-hour infusion of matching placebo on Day 1
40801069|NCT04920071|DEVICE|Visual acuity and contrast sensitivity measurement|Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
40801070|NCT01918605|DEVICE|Diluted spacer|
40801071|NCT01918605|DEVICE|Non-diluted spacer|
40801072|NCT03628066|DRUG|Letrozole|Letrozole 2.5 mg by mouth daily for 24 weeks
40801073|NCT03628066|DRUG|Palbociclib|Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
40801074|NCT03628066|DRUG|Goserelin|Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
40801075|NCT03628066|DIAGNOSTIC_TEST|Oncotype DX Breast Recurrence Score|Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
40801076|NCT02835612|OTHER|Early stimulation|Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
40801077|NCT02835612|OTHER|Conventional care|skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
40801078|NCT02413476|PROCEDURE|Robotic-assisted Gastrectomy(RAG)|Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
40801079|NCT02413476|PROCEDURE|Laparoscopic-assisted Gastrectomy(LAG)|Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
41004990|NCT01120210|DRUG|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
41004991|NCT03765294|DRUG|ACT-541468|Film-coated tablet for oral use
41004992|NCT03765294|DRUG|Placebo|Film-coated tablet for oral use
41004993|NCT05668065|BIOLOGICAL|CoronaVac/CoronaVac|Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.
41004994|NCT05668065|BIOLOGICAL|CoronaVac/BNT162b2|"First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2"
41004995|NCT04605757|OTHER|Clinical, functional and radiological lung involvement evolution|Observational / Clinical, functional and radiological long term evolution of SARS-COV-2 lung involvement
41004996|NCT01619670|DEVICE|Apligraf|non adhesive layer
41004997|NCT02773043|DEVICE|CZT SPECT camera|
41004998|NCT02097355|OTHER|TriVox for clinical care|Use TriVox disease modules to manage patients
41004999|NCT05060393|BEHAVIORAL|Mindfulness-based cognitive therapy|Mobile application, mindfulness-based therapy
41005000|NCT05039346|OTHER|Phone interviews|Phone interviews will be used to determine the patient's quality of life, symptoms and performance status
41005001|NCT00138983|DRUG|Alendronate versus alfacalcidol (1-alpha OH vitamin D)|
41318254|NCT03604068|DEVICE|RecoveryRx|A pulsed shortwave therapy medical device
40801080|NCT05076773|PROCEDURE|Ultrasound guided block|Giving one regional block
40801081|NCT05076773|DRUG|IV morphine|given when VAS\>3
40801082|NCT06180499|DRUG|T-reg depleted DLI|Treg depleted Donor Lymphocytes Infusion
40801083|NCT05366088|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"MBCT is an 8-week therapy integrating formal mindfulness meditation (e.g. breath and body awareness) and informal mindfulness (e.g. eating, walking). Participants are taught to attend non-judgmentally to present moment experiences. MBCT includes cognitive therapy techniques to target the ruminative thought processes and identification with negative emotions seen in depression. MBCT teaches participants how to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns that perpetuate depressive symptoms and increase vulnerability to relapse."
41005002|NCT04568122|DEVICE|Saliva test kit|Kit including tube with closed reagents using loop-mediated isothermal amplification (LAMP) assay to detect SARS-CoV-2 virus.
41318255|NCT03604068|DEVICE|Sham RecoveryRx|A sham pulsed shortwave therapy medical device
41318256|NCT04870827|DRUG|13N Amonia|Administered during PET/CT scans
41318257|NCT01825980|DRUG|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
41318258|NCT01825980|DRUG|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
41318259|NCT01825980|DRUG|Placebo|Placebo
41318260|NCT04176445|DEVICE|Orthostatic board posture|Patients will be verticalized at at 45º, 60º and 80º using an orthostatic board. The total posture protocol will last 30 minutes
40801084|NCT05366088|BEHAVIORAL|Health Enhancement Program|HEP teaches health-enhancing techniques and was designed by University of Wisconsin and NIH as a manualized active control group program for mindfulness-based intervention trials (53,54). We have tailored HEP to be structurally equivalent to MBCT. HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin. Participants will learn about health promotion, healthy diet, music, and gentle exercise, but not about breathing techniques or meditation.
40801085|NCT02422693|OTHER|Aquatic Exercises|Exercises performed in the water.
40801086|NCT02422693|OTHER|Deep-water running|It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
41005003|NCT01893424|DRUG|Sativex buccal spray|buccal spray
41005004|NCT01893424|DRUG|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
41005005|NCT00004028|DRUG|carmustine|
41005006|NCT00004028|PROCEDURE|conventional surgery|
41005007|NCT03696043|OTHER|Axium Steatlh Image Guidance|The Axiem Stealth imaging guidance system uses a probe (AxiEM Registration Probe) and a side mount emitter (AxiEM Side Mount Emitter) to register the patient's head in relation to the probe. A trajectory (entry point and target) is then planned. This registration process takes an estimated 5-15 minutes to perform. A separate stylet (StealthStation EM Stylet) is designed specifically for the catheter and slides down the center of the catheter. A burr-hole is created at the predefined precise location and the catheter is passed to the target under electromagnetic guidance.
41005008|NCT03696043|OTHER|EVD placement|A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
41005009|NCT03817619|DRUG|Zepatier whole tablet|Single-dose ELB/GZR as a whole tablet in a fasted state.
41005010|NCT03817619|DRUG|Zepatier crushed tablet|Single-dose crushed ELB/GZR in a fasted state.
41005011|NCT04206293|DEVICE|Juvederm® VOLITE|1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).
41005012|NCT02534792|OTHER|Revalvulation|
41005013|NCT00131235|DRUG|Sulfadoxine-pyrimethamine treatment twice during pregnancy|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points."
41318261|NCT04176445|OTHER|Bedside sitting posture|Patients will be placed at the bedside, with support for the back and upper limbs. They will be kept at 90º of hip and knee flexion and feet supported. The total posture protocol will last 30 minutes.
41318262|NCT04687605|PROCEDURE|Temporary hypercapnia|Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH
41318263|NCT02437552|DEVICE|ergometer cycle exercise|
41318264|NCT02437552|OTHER|routine physiotherapy|routine physiotherapy
41318265|NCT06118567|DRUG|Nitrous oxide|Nitrous oxide gas.
41318266|NCT06118567|DRUG|Room Air|Room Air
41318267|NCT00945802|DRUG|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops two times a day
41318268|NCT00945802|DRUG|ciprofloxacin 0.3%, dexamethasone 0.1%|Instill four drops two times a day
41318269|NCT01240512|DRUG|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
41318270|NCT00380276|DRUG|MPC-7869|800 mg BID Oral dosing
41318271|NCT03457103|DEVICE|Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)|Tailored intervention emphasizing slow, quiet, regular nasal breathing pattern.
41318272|NCT03457103|DEVICE|Pulmonary Rehabilitation (PR)|Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
41318273|NCT00003810|DRUG|docetaxel|
41318274|NCT00003810|DRUG|gemcitabine hydrochloride|
41318275|NCT00333619|BEHAVIORAL|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
40801087|NCT05729113|BEHAVIORAL|Distraction technique|Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
40801088|NCT00543270|DEVICE|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
41318276|NCT00333619|BEHAVIORAL|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
41474980|NCT01931228|PROCEDURE|MI-E plus manually assisted coughing|MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
41474981|NCT01931228|PROCEDURE|manually assisted coughing|Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
41474982|NCT05945355|DEVICE|Pro2 - Low Dose - 40% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 40% of their MIP (maximum inspiratory pressure).
40801089|NCT00543270|PROCEDURE|Open Surgery|Open surgical abdominal aortic aneurysm repair
41474983|NCT05945355|DEVICE|Pro2 - High Dose - 75% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP (maximum inspiratory pressure).
40801090|NCT02224443|DRUG|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
40801091|NCT02224443|DRUG|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
40801092|NCT02224443|DRUG|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
40801093|NCT02224443|DRUG|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
40801094|NCT02224443|DRUG|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%
40801095|NCT01017224|OTHER|18F-FAZA|PET scan
40801096|NCT00969605|PROCEDURE|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
40801097|NCT05723536|PROCEDURE|Partial Left Atrial Isolation|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
40801098|NCT05723536|PROCEDURE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
41318277|NCT04090905|OTHER|Standard clinical monitoring|Standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
41318278|NCT04090905|DIAGNOSTIC_TEST|Holter monitoring|Cardiac rhythm monitoring before, during, and until hospital discharge (preferably ≥72 hours after abdominal surgery)
41318279|NCT01962519|DIETARY_SUPPLEMENT|Early oral feeding|Oral fluids starting on POD 1, followed by a soft diet (thin purée six times a day) on day 2, and regular solid diet thereafter
41318280|NCT01990755|BEHAVIORAL|CBT (Cognitive Behavioral Therapy)|It is a worldwide known form of psychotherapy for eating disorders
41318281|NCT01990755|OTHER|IBPP (individual psychology brief psychotherapy)|It is a worldwide known form of psychotherapy for eating disorders
41318282|NCT01990755|DRUG|CBT + OLANZAPINE|It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
41318283|NCT01990755|DIETARY_SUPPLEMENT|nutritional rehabilitation|all patients were followed-up monthly with nutritionist and dietitian visits
41318284|NCT01990755|DRUG|delorazepam|all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
41318285|NCT00013481|PROCEDURE|Stroke Rehabilitation|
41474984|NCT05945355|DEVICE|Pro2 - SHAM - 15% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that participants achieve a pressure target that is 15% of their MIP (maximum inspiratory pressure).
41318286|NCT02072382|DRUG|Metformin|metformin 850mg twice a day for eight weeks
41474985|NCT06104631|OTHER|BK003|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 3 g/day. The product is a powder for oral administration 1x/day.
41318287|NCT02072382|DRUG|Placebo|
41474986|NCT06104631|OTHER|Placebo|The placebo product has the same composition in excipient, same form and same posology as BK003.
41474987|NCT00183586|BEHAVIORAL|Family therapy (FT)|FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.
41474988|NCT00183586|BEHAVIORAL|Individual therapy (IT)|IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
41474989|NCT02754284|BIOLOGICAL|Autologous fat transplantation|Autologous abdominal fat will be injected into vocal cord beneath mucous under surgery microscope.
41474990|NCT02754284|BIOLOGICAL|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with adipose derived stem cells that are isolated from abdominal adipose tissue will be injected into vocal cord beneath mucous under surgery microscope.
41474991|NCT00616174|PROCEDURE|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
41474992|NCT01019707|DRUG|Atomoxetine, then Placebo|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
41474993|NCT01019707|DRUG|Placebo, then Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
41474994|NCT06172257|DRUG|Dexamethasone ophthalmic suspension (OCS-01)|"The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
41474995|NCT06172257|DRUG|Vehicle|"The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
41474996|NCT04667936|OTHER|Treatment group|None, solely treatment documentation
41474997|NCT03992313|OTHER|Community-based HCV rapid test|HCV rapid tests will be done in the village
41474998|NCT03992313|OTHER|Facility-based HCV rapid test|HCV rapid tests will be done in the health center
41474999|NCT03992313|OTHER|Plasmatic HCV viral load|HCV viral load will be done in provincial hospital on plasma using GenXpert
41475000|NCT03992313|OTHER|DBS HCV viral load|HCV viral load will be done in Phnom Penh by DBS using Omunis kit
41475001|NCT00256711|DRUG|Gefitinib|
41475002|NCT00256711|DRUG|Vinorelbine|
41475003|NCT03307057|BEHAVIORAL|Social Communication Growth Charts (SCGC)|The Social Communication Growth Charts (SCGC) is a web-based tool that parents can access to teach them the social communication milestones that are developing from 6 to 24 months of age. The SCGC has an explore function with hundreds of video clips illustrating 80 social communication milestones and a support video that has narration explaining how the parent in the video is supporting the child's development. The SCGC also has a charting function that parents can use by answering questions about their child's social communication milestones and then view charts in 5 developmental domains. Parents in the SCGC condition are also invited to a bi-weekly online Guided Tour to join other parents in a group meeting, like a book club, as they go through the SCGC.
41475004|NCT03307057|BEHAVIORAL|Parent-Implemented (P-I) Condition|"The Parent-Implemented (P-I) condition is based on the Early Social Interaction (ESI) model, which is an evidence-based parent-implemented intervention involving active and productive engagement for 5 hours per day, 5 days per week for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places.~Weekly home sessions with a family navigator include:~1. developing the visit agenda~2. intervention implementation including: guided/caregiver practice, feedback and problem solving~3. planning for parent implementation between sessions~Families can also access the Autism Navigator How-To Guide for Families (a self-guided, web-based course), the Online Guided Tour for the How-To Guide (an online group to engage families), and have the opportunity to interact with other families who suspect their child has autism through audio or video conferencing or typed chat."
41318288|NCT03018912|OTHER|Sleep VS|"During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~1. How many days a week are you satisfied with your sleep?~2. How many days a week is sleepiness a problem?"
41318289|NCT00004992|BEHAVIORAL|Intensive lifestyle|
41318290|NCT00004992|DRUG|Metformin|
41318291|NCT00004992|DRUG|Placebo|
41318292|NCT01887392|OTHER|Knowledge Translation Education Sessions|Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
41318293|NCT01654523|DEVICE|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
41475005|NCT03307057|BEHAVIORAL|Clinician-Implemented (C-I) Condition|The Clinician-Implemented (C-I) condition is based on the core principles of empirically-supported naturalistic developmental behavioral interventions (NDBI) for infants and toddlers with or at-risk for ASD, including Early Start Denver Model (ESDM), Project ImPACT (Improving Parents As Communication Teachers), Pivotal Response Treatment (PRT), and Early Social Interaction (ESI). The goal of C-I NDBI is to use naturalistic, developmental, and behavioral strategies with infants at-risk for ASD to improve social-communication, which includes eye contact, gesture use, intentional vocalizations, and language. Parents are not actively involved in C-I NDBI intervention sessions, though they may observe and the clinician will be given information about current social-communication targets.
41475006|NCT04499378|DIAGNOSTIC_TEST|Lung CT|Computed tomography of the thorax
41475007|NCT02858648|BEHAVIORAL|Behavior intervention with smart phone based self-monitoring|Use two smartphone applications for self-monitoring of diet, physical activity, weight, and blood glucose (connected via a blue-tooth enabled glucometer), plus 11 group session and 1 individual session focused on behavioral strategies
41475008|NCT02858648|BEHAVIORAL|Behavior intervention with paper diary based self-monitoring|Use paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer for self-monitoring of diet, physical activity, weight, and blood glucose, plus 11 group session and 1 individual session focused on behavioral strategies
41475009|NCT02162355|DRUG|GLPG0634 50 mg|2 tablets of 25 mg GLPG0634 once daily for 10 days
41475010|NCT02162355|DRUG|GLPG0634 100 mg|1 tablet of 100 mg GLPG0634 once daily for 10 days
41475011|NCT02162355|DRUG|GLPG0634 200 mg|2 tablets of 100 mg GLPG0634 once daily for 10 days
41475012|NCT02162355|DRUG|Placebo|1 or 2 matching placebo tablets once daily for 10 days
41475013|NCT04673708|DIAGNOSTIC_TEST|H - Test|Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.
41475014|NCT03617627|BEHAVIORAL|Self-management intervention|Self-management intervention will include presentation and discussion of various topics regarding chronic pain mechanisms and pain self-monitoring. The intervention will also incorporate a task-oriented approach focused on relevant activities in order to acquire coping skills.
41475015|NCT00783887|OTHER|Blood sample|Blood sample of 5 ml
41475016|NCT05487755|DRUG|Tadalafil 20Mg Oral Tablet|Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia
41475017|NCT05487755|DRUG|Pentoxifylline 400 MG Oral Tablet|Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
41475018|NCT06490120|OTHER|sampling method|feasibility outcomes will be compared between the 3 groups
41475019|NCT03984045|DRUG|Lidocaine topical|Intranasal 2% lidocaine delivered directly to SPG
41475020|NCT03984045|DRUG|Prochlorperazine Injection|intravenous prochlorperazine at 0.15mg/kg max 10 mg
41475021|NCT00038831|DRUG|Mylotarg|Starting dose 2 mg/m\^2 over 2-hour intravenous infusion on day -12.
41475022|NCT00038831|DRUG|Fludarabine|30 mg/m\^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.
41475023|NCT00038831|DRUG|Melphalan|140 mg/m\^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.
41475024|NCT00038831|DRUG|Anti-thymocyte globulin|Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.
41475025|NCT00038831|PROCEDURE|Stem cell transplant|Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.
41475026|NCT03974165|OTHER|Cereal-legume product 1|The intervention examines the effect of cereal based product fortified with legumes-1 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
41475027|NCT03974165|OTHER|Cereal-legume product 2|The intervention examines the effect of cereal based product fortified with legumes-2 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
41318294|NCT00040014|DRUG|exemestane|
41318295|NCT04498572|OTHER|dry needling|dry needling for Gluteus Medius muscle in combination with exercises
41318296|NCT04498572|OTHER|sham dry needling|sham dry needling for Gluteus Medius muscle in combination with exercises
41318297|NCT02559206|DRUG|Linaclotide|Oral, once daily
41318298|NCT02559206|DRUG|Matching Placebo|Oral, once daily
41318299|NCT03543358|DRUG|rovalpituzumab tesirine|Optional retreatment with rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing) for 2 dose cycles
41475028|NCT03974165|OTHER|Cereal product|The intervention examines the effect of cereal product in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
41475029|NCT03974165|OTHER|Reference food|The intervention examines the effect of reference food in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
41475030|NCT05895734|DEVICE|NDS-Powerball®,|Rehabilitation using the Powerball system
41475031|NCT05895734|OTHER|Conventional treatment|Rehabilitation by conventional treatment
41005014|NCT00131235|DRUG|Sulfadoxine-pyrimethamine at 4-week intervals|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
41318300|NCT03543358|DRUG|rovalpituzumab tesirine|Rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing). Subjects will receive rovalpituzumab tesirine on Day 1 of each 6-week cycle, omitting every third cycle until disease progression or study drug discontinuation.
41318301|NCT04191291|BEHAVIORAL|Lunch period length|We are randomly allocating a 10 minute or 20 period of seated lunch time.
41475032|NCT01142531|RADIATION|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm"
41475033|NCT03104621|DRUG|Benzalkonium chloride (BAK)|Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.
41475034|NCT03104621|DRUG|0.0015% tafluprost|Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
41475035|NCT03109119|DRUG|Sevoflurane|The patients in the group S will be exposed to routine concentrations of sevoflurane during anaesthesia.
41475036|NCT03109119|DRUG|Propofol|These patients will be induced with propofol 1.5 mg / kg and maintained with propofol infusion.
41475037|NCT00440609|DRUG|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
41005015|NCT00131235|DRUG|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
41475038|NCT03475628|DRUG|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
41475039|NCT00666887|DRUG|Minocycline|100 mg twice daily to be taken for up to 2 years
41475040|NCT00666887|DRUG|Placebo|placebo twice daily for 2 years
41475041|NCT03115528|BEHAVIORAL|Estimation of Prognosis Questionnaire|Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
41475042|NCT00362817|DRUG|carboplatin|IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
41475043|NCT00362817|DRUG|temozolomide|150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
41475044|NCT02593487|DRUG|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
40801099|NCT04842851|DEVICE|cardiac resynchronization therapy|Cardiac resynchronization therapy in patients with systemic right ventricle
41005016|NCT03618264|DRUG|Miscible liquid of dexamethasone and ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
41318302|NCT05293574|DRUG|norethisterone acetate|Norethindrone, a progesterone agonist
41318303|NCT01221688|PROCEDURE|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
41318304|NCT01221688|PROCEDURE|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
41318305|NCT05529290|DRUG|Dexketoprofen Trometamol + Thiocolchicoside|Dexketoprofen Trometamol + Thiocolchicoside (25mg + 4mg) is a NSAID. It was given to the patients twice a day.
41318306|NCT05529290|DRUG|Dexketoprofen Trometamol + Paracetamol|Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
41318307|NCT05529290|DRUG|Dexketoprofen Trometamol (25mg)|Dexketoprofen Trometamol (25mg) is a NSAID. It was given to the patients twice a day.
41318308|NCT05529290|DRUG|Paracetamol|Paracetamol (500 mg) is a mild analgesic and antipyretic. It was given to the patients to take only if needed as max. dose 2000mg.
40801100|NCT05116397|OTHER|Inspired gas|Inspired gas content
41318309|NCT04123418|BIOLOGICAL|WVT078|WVT078 will be administered IV (intravenously) in a dose escalation schedule
41475045|NCT02593487|DRUG|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
41475046|NCT02731014|OTHER|Dry Needling|Dry Needling targeting the posterior musculature of the cervical and thoracic spine.
41475047|NCT02731014|OTHER|Sham Dry Needling|Sham Dry Needling performed with Park sham acupuncture needles (Acuprime, UK) will be used to perform sham dry-needling. The device consists of 2 plastic tubes that slide into one another and cause a pricking sensation when pushed against the skin.
41475048|NCT02731014|OTHER|Manual Therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.
41475049|NCT02731014|OTHER|Exercise|Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.
40801101|NCT06421519|OTHER|BiPAP setting|"Infants in this arm of the study will each rotate through three different BiPAP settings. The following BiPAP settings will be used:~13cmH2O / 5cmH2O, 10cmH2O / 5cmH2O, 7cmH2O / 5cmH2O"
40801102|NCT01413243|DRUG|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
40801103|NCT04311268|DEVICE|F2D armband|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
40801104|NCT04072952|DRUG|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
40801105|NCT04072952|DRUG|ARV-471 in combination with palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
40801106|NCT01892150|OTHER|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
40801107|NCT06155006|DIAGNOSTIC_TEST|rapid diagnostic test HCV Ab Plus Rapid test|The sample will be taken by trained personnel by capillary puncture of the thumb region of the fingers of the right hand, after asepsis and antisepsis, the rapid diagnostic test HCV Ab Plus Rapid test with INVIMA registration 2018RD-0002353-R1 will be used with operational characteristics that allow its performance at the point of care obtaining a result in 15 to 20 minutes. This rapid test for antibodies against HCV may be replaced by another test with similar operational characteristics (sensitivity and specificity).
40801108|NCT01201824|PROCEDURE|intracavitary ultrasound|intracavitary ultrasound done during surgical intervention
40801109|NCT06534047|DEVICE|Brainsway H4 deep Repetitive Transcranial Magnetic Stimulation (rTMS) coil|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member."
40801110|NCT06534047|DRUG|Nicotine replacement|"Each participant will receive individualized NRT treatment through the advice of their study physician for 6 weeks. The study physician, in discussion with the participant, will decide the type, dosage, and combination of NRT to provide to the participant.~NRT provided can include:~* Patch (7mg, 14mg, and 21mg)~* Gum (2mg)~* Lozenge (2mg)~* Inhaler (10mg; 4mg of nicotine delivered)"
40801111|NCT00407368|PROCEDURE|Blood Sample|
41005017|NCT03618264|DRUG|Ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
41318310|NCT04123418|DRUG|WHG626|WHG626 will be administered orally in a dose escalation schedule
41475050|NCT04579276|PROCEDURE|Thoracic paravertebral block|Intrathoracic method undergone through video assisted surgery (VATS
40801112|NCT03951766|BEHAVIORAL|Smiling Instead of Smoking (SiS) App Version 2|The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
41005018|NCT06087965|DRUG|Fingolimod|0.5mg/day oral fingolimod over a course of 3 consecutive days
41005019|NCT03822728|DIAGNOSTIC_TEST|3D-DESS MRI (3 dimensional double echo steady state MRI)|3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
41318311|NCT06017648|DEVICE|Non Invasive Ultrasound (FUBA5200)|the Focused Ultrasound Fat Reduction device (FUBA5200) is manufactured by Shanghai Carnation Medical Technology Co., Ltd
41318312|NCT06017648|DEVICE|Non Invasive Ultrasound (Contour I V3)|the Focused Ultrasound Fat Reduction device (Contour I V3) is manufactured by Syneron Medical Ltd.
41318313|NCT00039468|DRUG|irinotecan hydrochloride|350 or 700 mg/m2 IV every 3 weeks
41318314|NCT00039468|DRUG|thalidomide|400mg/day oral
41318315|NCT00390247|DRUG|thalidomide|
41318316|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Plasma
41318317|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Serum
41318318|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Urine
41475051|NCT04579276|PROCEDURE|thoracic epidural analgesia|locoregional analgesia under ultrasound control
41475052|NCT00896194|BEHAVIORAL|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
41318319|NCT05579912|PROCEDURE|Esophageal and gastric resections requiring an anastomosis|Distal gastrectomies, total gastrectomies, bariatric gastric bypasses, subtotal esophagectomies, proximal gastrectomies, palliative bypasses, and total esophagectomies.
41318320|NCT03921138|OTHER|Histopathologic tube anomalies|Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)
41318321|NCT00870285|RADIATION|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
41152278|NCT01400217|DRUG|extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
41005020|NCT01265446|DRUG|Lidocaine 8mg + CPC 2mg|one single dose
41475053|NCT00896194|BEHAVIORAL|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
41475054|NCT01463150|DRUG|Clopidogrel|Clopidogrel 150mg per day for 15 days
41475055|NCT01463150|DRUG|Prasugrel|Prasugrel 5mg per day for 15 days
41475056|NCT01567826|DRUG|standard of care lipid therapy|"Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor \[any dose\] and Crestor \[less than 40mg\]"
41475057|NCT01567826|DRUG|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
41475058|NCT06142188|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
41005021|NCT01265446|DRUG|Lidocaine 1mg + CPC 2mg|one single dose
41005022|NCT01156285|OTHER|Filling in a patient questionnaire|Filling in a patient questionnaire
41005023|NCT02282696|OTHER|Questionnaire, focus group participation|participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
41005024|NCT05333549|DRUG|Istradefylline medication|2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
41005025|NCT03854916|OTHER|Caminemos Juntas App|A tailored mobile app that encourages Latinas and Hispanic women to walk together using location-based services.
41475059|NCT01577693|DRUG|dutasteride|novel dutasteride
41005026|NCT03854916|OTHER|World Walking App|A mobile app that encourages users to walk.
41318322|NCT04243616|DRUG|Cemiplimab|350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)
41318323|NCT04243616|DRUG|Paclitaxel|80 mg/m\^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)
41318324|NCT04243616|DRUG|Carboplatin (not mandatory)|Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)
41475060|NCT01577693|DRUG|dutasteride|dutasteride soft gel capsule
41475061|NCT06097845|DIAGNOSTIC_TEST|Transcranial Ultrasound|Patients who underwent reconstructive sonolucent cranioplasty will receive standard of care postoperative imaging (i.e. CT, MRI) in addition to ultrasound imaging. Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices (GE Venue Go, Fujifilm Sonosite X-Porte, GE Volusion E10 and Clarius HD3 etc.) currently used in routine clinical practice.
41475062|NCT04233086|OTHER|No intervention, observational only|No intervention, observational only
41475063|NCT01431443|OTHER|Flavanol-rich chocolate|The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
41475064|NCT01431443|OTHER|Placebo Chocolate|Placebo intervention
41475065|NCT02740920|DRUG|Pembrolizumab|
41475066|NCT02740920|PROCEDURE|CT Scan|
41005027|NCT03789201|DEVICE|TMS EEG|attempt to use TMS EEG to measure connectivity between cortical areas
41005028|NCT03789201|DEVICE|TMS fMRI|compare measurements to established functional connectivity measures; e.g., EEG coherence and fMRI
41005029|NCT02292628|DRUG|Infusion of mesenchymal stem cells from adipose tissue|
41005030|NCT02292628|OTHER|Infusion of placebo|
41005031|NCT01153581|DRUG|Ganirelix acetate|Ganirelix acetate: .25 ml/day by subcutaneous injection
41318325|NCT04243616|DRUG|Doxorubicin|60 g/m\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
41318326|NCT04243616|DRUG|Cyclophosphamide|600 g/m\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
41318327|NCT04077736|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
41005032|NCT01153581|DRUG|17β-Oestradiol|17 beta estradiol: 0.2 mg/day (patches)
41005033|NCT01153581|DRUG|Progesterone|progesterone, 200 mg day-1 oral
41005034|NCT05221853|DIAGNOSTIC_TEST|cardiovascular magnetic resonance|CMR scan at 3 Tesla
41318328|NCT04573205|DRUG|FSME-IMMUN Vaccine|0.5 ml intramuscular injection scheduled in the two different arms
41318329|NCT01390961|DRUG|alacaftadine and naphazoline HCl & pheniramine maleate|once a day
41475067|NCT05820386|PROCEDURE|Skin-to-skin Contact (SSC)|For the Skin-to-skin Contact (SSC) transfer, the bare-chested father will seat in a wheelchair. Newborns who will wear only a diaper and a cotton cap or noninvasive ventilation headgear will be placed in the kangaroo position against the father's chest to ensure direct contact with the father's skin. Preterm infants with gestational age less than 33 weeks will be wrapped with their father using plastic bags plus warmed cotton towels. More gestationally mature infants will be wrapped with only warmed cotton wraps. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
41475068|NCT05820386|PROCEDURE|Incubator|In the incubator group, infants will be transferred after resuscitation in an incubator with air temperature set to 36°C. The newborn will be laid on his/her back in a polyethylene bag with a cap. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
41475069|NCT04663438|DRUG|Chemotherapy Drugs, Cancer|Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
41318330|NCT05304000|BEHAVIORAL|Mindfulness Meditation|Participants are informed they should sit down in a chair or, if they preferred, to lie down, and then to set a timer for 5 minutes. Then they are told to close their eyes and to start breathing while focusing their mental attention on their forehead region between their two eyes. They are told that if their focus drifted from that location to re-recenter their attention by focusing back first on their breath and then on the forehead region between their eyes. They are told that as thoughts arise, to recognize that as normal, refocus their attention back to their forehead region and to continue the practice until time has elapsed.
41318331|NCT05304000|BEHAVIORAL|Cyclic Sighing Breathing|Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 minutes. Then they are told to inhale slowly, and that once their lungs are expanded, to inhale again once more to maximally fill their lungs -- even if the second inhale was shorter in duration and smaller in volume than the first, and then to slowly and fully exhale all their breath. They are told to repeat this pattern of breathing for 5 minutes. They are also informed that ideally, both inhales would be performed via their nose and the exhale would be performed via their mouth, but that if they preferred, they are welcome to do the breathing entirely through their nose. They are also informed that it is normal for the second inhale to be briefer than the first.
41318332|NCT05304000|BEHAVIORAL|Box Breathing|"Participants are informed they should sit down in a chair or lie down, and to get a timer. Then they are told to take the CO2 tolerance test as follows: Take 4 breaths through the nose. Then take a maximally deep breath and once your lungs are full, exhale as slowly as possible through your nose or mouth. Time how long it takes to empty your lungs; this will be your C02 discard duration. Use your discard duration to determine how long your inhales, exhales, and breath holds should be (CO2 discard time) by using this table: \<20 sec = 3 - 4 sec, 25 - 45 sec = 5 - 6 sec, 50 - 75+ sec = 8 -10 sec. They are then told to inhale, hold, exhale, hold (for the duration determined by the C02 discard table) and to repeat this pattern for the entire 5 minutes. If at any point they had to strain to reach these times, they should simply reduce the duration of inhales, exhales, and breath holds. We ask participants to perform all breathing through their nose, if possible."
41318333|NCT05304000|BEHAVIORAL|Cyclic Hyperventilation with Retention|"Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 min. Then they are told to inhale deeply (ideally through their nose but if that is not possible, to inhale through their mouth) and then exhale by passively letting the air fall out from the mouth. We inform them that for sake of this protocol, that pattern of a deep inhale through the nose and passively letting the air fall out from the mouth = 1 breath.~Then they are instructed to perform 30 breaths (in and out) in this manner, and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds."
41318334|NCT04877314|OTHER|Intermittent fasting|30 overweight male volunteers who will have 3 weeks intermittent fasting which has 16 hours fasting and 8 hours eating in a day period.
41318335|NCT00506571|DRUG|S-1, irinotecan, oxaliplatin|
41475070|NCT04450914|BEHAVIORAL|CV Prevention Choice Tool|The CV Prevention Choice SDM tool is a shared decision making intervention. It is embedded in the electronic health record and uses EHR data to estimate and display cardiovascular risk for individual patients and then foster conversations between clinicians and patients about available options for preventive care based on individual risk and preferences.
41475071|NCT04450914|BEHAVIORAL|Implementation Facilitation Strategies|During the active implementation stage, health systems will deploy tailored implementation facilitation and other tailored implementation strategies aimed at increasing adoption and use of shared decision making using CV Prevention Choice.
41475072|NCT03594409|DIAGNOSTIC_TEST|Biochemistry of gall stones|Analysis of gallstones is done to determine the biochemical types of gallstone like cholesterol stone, pigmented stones or mix stones
41475073|NCT06218745|OTHER|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
41475074|NCT03704857|OTHER|Foraminal Enlargement / Irrigating solutions / Filling materials|"Instrumentation with foraminal enlargement and various irrigation solutions and filling materials will be performed according to the allocated group.~The foraminal enlargement provides better results in the bacterial removal of the apical portion of the root canal. This instrumentation will be done with the Reciproc 40 or 50 system in the apical foramen, determined by the apical locator.~To contribute to disinfection of the root canal, sodium hypochlorite and chlorhexidine are the most widely used irrigators. Sodium hypochlorite has a broad antimicrobial spectrum and an effective ability to dissolve organic matter and necrotic tissue; while chlorhexidine shows substantivity and antimicrobial residual activity when used as an irrigating substance.~Besides that, MTA Fillapex or AH Plus will be used and the recommended filling technique will be lateral condensation."
41475075|NCT03704857|OTHER|Photobiomodulation|aPDT will be performed with 0.01% methylene blue solution and it will be inserted into the root canal for 5 minutes. The excess will be removed and irradiation will be performed inside the root canal with the red laser of Índio Gálio Alumínio Fósforo (660nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) for 90 seconds. Laser therapy with Gallium-Aluminum-Arsenic infrared laser (808nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) will be performed on the gingiva from the vestibular face and on the palatal / lingual face, both located in the periapical region for 40 seconds.
41005035|NCT02752191|DRUG|ferumoxytol|ferumoxytol as an MRI contrast agent infused over several minutes
41475076|NCT03704857|OTHER|Passive ultrasonic irrigation|PUI will be performed with Newtron P5 ultrasound (Satelec / Acteon Group, Bordeaux, France), at intensity 9 and with a 25mm (# 0.25, taper 0.00). The protocol of use will be 3 sequences of 20 seconds of ultrasonic activation with 2 ml of sodium hypochlorite 2.5% in each root canal.
41005036|NCT02752191|DRUG|gadofosveset|gadofosveset as an MRI contrast agent injected over several seconds
41005037|NCT02967367|DEVICE|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
41005038|NCT02967367|DEVICE|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
40801113|NCT06252311|BEHAVIORAL|Mindfulness-Based Breastfeeding Programme|Mindfulness-Based Breastfeeding Programme will consist of structure and anatomy of the breast and milk production, breast milk content, benefits of breast milk, breast care, frequency and duration of breastfeeding, correct and comfortable position for breastfeeding, effects of stress on lactation hormones and milk production, World Health Organization guidelines on duration and continuity of breastfeeding, time to start complementary feeding general information on recommendations, General information about breastfeeding with awareness, mentioning its purpose and programme flow, and it includes formal and informal practices such as breathing awareness exercises, noticing the autopilot, lying/sitting meditation, body scanning exercises and mindful breastfeeding practice.
41475077|NCT03704857|OTHER|OHIP-14|Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
41475078|NCT03704857|OTHER|Assessment of pain and edema|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
41475079|NCT03704857|OTHER|Assessment of periapical lesion|The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months.
41475080|NCT03704857|OTHER|Longevity of rehabilitations|The teeth will be rehabilitated with resin and glass fiber post. The longevity of rehabilitations will be performed clinically and radiographically for 24 months.
40801114|NCT04059081|DRUG|Obinutuzumab|"Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles."
41005039|NCT02967367|DEVICE|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
41005040|NCT04818359|BEHAVIORAL|MoviS Training|Patients will undergo a supervised exercise program consisting of 3 months of aerobic exercise training (2 d/week of directly supervised exercise and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min).
41005041|NCT02153944|DRUG|Propranolol|Propranolol 40 mg was given orally during study visit
41005042|NCT02153944|DRUG|Methylphenidate|Methylphenidate 20mg was given orally during study visit
41005043|NCT02153944|DRUG|Placebo|Placebo was given orally during study visit
41005044|NCT05899504|DEVICE|Over-The-Scope-Clip (OTSC) Stent Fix|A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. We will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure
41152279|NCT01400217|DRUG|standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
41318336|NCT04328233|BEHAVIORAL|Time-Restricted Eating|Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (mCC app). The participants will select a 10-h eating window that best suits their lifestyle. All food/beverages except water must be consumed within the time-interval. No further dietary restrictions will be applied. The participants will be provided with behavioral nutritional counseling by a dietician.
41318337|NCT00676793|DRUG|Polyphenon E|Four 200mg capsules daily taken with a meal, for the duration of the study.
41318338|NCT03848611|DRUG|CM082 plus JS001|CM082：150mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
41318339|NCT03754803|OTHER|HIV Symptom Distress Module Questionnaire|The Symptom Distress Module is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.
40801115|NCT05023785|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
40801116|NCT01607762|DRUG|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
41005045|NCT02718638|OTHER|physical exercises|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
41005046|NCT04080765|BEHAVIORAL|HIV-ASSIST|HIV-ASSIST is an online interactive patient-based tool that allows for individualized HIV treatment recommendations through the synthesis of patient-specific factors with existing guidelines and evidence.
40801117|NCT01607762|DRUG|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
41005047|NCT04080765|BEHAVIORAL|DHHS guidelines|This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.
41005048|NCT05709171|DRUG|18F-FDG|PET/CT scan approximately 60 min after injection of 18F-FDG
40801118|NCT01607762|DRUG|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
40801119|NCT01607762|DRUG|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
41005049|NCT05709171|DRUG|64Cu-Dotatate|PET/CT scan approximately 60 min after injection of 64Cu-Dotatate
41005050|NCT03904459|OTHER|no intervention|
41005051|NCT00472134|DRUG|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
41005052|NCT00472134|DEVICE|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
41005053|NCT00494572|DRUG|Montelukast|10 mg rapid dissolving granule in sterile water orally once
40801120|NCT01607762|DRUG|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
40801121|NCT02297711|PROCEDURE|Total ExtraPeritoneal|This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
40801122|NCT02297711|PROCEDURE|Open minimal suture repair|This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
40801123|NCT03337867|DEVICE|Magstim Super Rapid2 System|Intermittent theta-burst-stimulation (iTBS) protocol
40801124|NCT03337867|DEVICE|Magstim Super Rapid2 System|Sham stimulation
40801125|NCT06514274|DRUG|Berberine|Berberine 500 mg, twice daily for 14 days
41005054|NCT00494572|OTHER|sterile water|sterile water
41005055|NCT04266457|OTHER|No Intervention|No Intervention
41005056|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
41005057|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
41005058|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
41005059|NCT01489046|DRUG|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
41005060|NCT01489046|DRUG|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
41005061|NCT01489046|DRUG|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
41005062|NCT01489046|DRUG|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
41005063|NCT03779412|BEHAVIORAL|The Happiness Trap|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
41005064|NCT03779412|BEHAVIORAL|A Mindfulness-Based Stress Reduction Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
41005065|NCT00004448|DRUG|omega-3 fatty acids|
41005066|NCT00004448|DRUG|prednisone|
41005067|NCT02394080|DEVICE|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
40801126|NCT06514274|DRUG|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
40801127|NCT06514274|DRUG|Amoxicillin|Amoxicillin 1000mg, twice daily for 14 days.
40801128|NCT06514274|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
41475081|NCT03704857|OTHER|Cryotherapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
41318340|NCT03754803|OTHER|HIV treatment satisfaction questionnaire|The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility.
40801129|NCT06514274|DRUG|Clarithromycin|Clarithromy 500mg, twice daily for 14 days.
40801130|NCT06514274|DRUG|Esomeprazole|Esomeprazole 10mg, twice daily for 14 days.
40801131|NCT05268692|DRUG|GS|drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (\< 1.25 m2, 60 mg/d; ≥ 1.25 to \< 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.
40801132|NCT05268692|DRUG|GnP|"drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.~nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle."
41475082|NCT03704857|OTHER|Ozone therapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
41318341|NCT02299765|DRUG|Gefitinib|patients in arm A will be given gefitinib as target therapy
41475083|NCT03527004|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Italy.
41475084|NCT03527004|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in IQOS users residing in Italy.
40801133|NCT04053972|DRUG|Lenvatinib|oral lenvatinib after hepatectomy
40801134|NCT00442494|DRUG|intravenous hydrocortisone|
41318342|NCT02299765|DRUG|gemcitabine|patients in arm A will be given gemcitabine chemotherapy
41318343|NCT02299765|DRUG|carboplatin|patients in arm A will be given carboplatin chemotherapy
41318344|NCT05879627|DRUG|BAT8007 for injection|Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
41318345|NCT06140069|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
41318346|NCT00762372|DRUG|desflurane|volatile liquid for inhalation
41318347|NCT00762372|DRUG|desflurane/nitrous oxide|volatile liquid for inhalation with gas for inhalation
41318348|NCT00762372|DRUG|sevoflurane/nitrous oxide|volatile liquid for inhalation and gas for inhalation
41318349|NCT02892838|DEVICE|mobile bearing knee system for total knee arthroplasty|
40801135|NCT03087877|DEVICE|Acetaminophen Challenge (G6 CGM)|Evaluation of acetaminophen effect on CGM glucose sensing
40801136|NCT04963855|DRUG|GT300|SIngle oral dose
40801137|NCT04963855|DRUG|Microcrystalline cellulose|placebo
40801138|NCT04177615|PROCEDURE|Thromboectomy|Thromboectomy in Basilar Artery Occlusion patients
41318350|NCT02892838|DEVICE|fixed bearing total knee prosthesis|
41318351|NCT03179007|BIOLOGICAL|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
41475085|NCT01988168|PROCEDURE|Suture closure|A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.
41475086|NCT01988168|PROCEDURE|Staples closure|Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
41475087|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 30ug, Intramuscular administration
40801139|NCT01546233|BEHAVIORAL|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
40801140|NCT01546233|BEHAVIORAL|standard education|standard education before and after chemotherapy
40801141|NCT05653245|DRUG|RGD Peptide|adhesion molecules
41005068|NCT02411331|DRUG|Ethanol 40% + Enoxaparine 400UI/ml|
41005069|NCT02411331|DRUG|Vancomycine 5 mg/ml + Héparine 2500UI/ml|
41318352|NCT04006080|BIOLOGICAL|Vedolizumab|Intravenously administered selective leukocyte adhesion molecule inhibitor
41318353|NCT05045469|DRUG|dian dao san|dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks
41318354|NCT02168933|DEVICE|308 nm excimer laser|Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
41318355|NCT02168933|DEVICE|Sham laser|Sham laser treatment to the control side biweekly for a total of 8 weeks.
41475088|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 100ug, Intramuscular administration
41475089|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 300ug, Intramuscular administration
41475090|NCT03699241|BIOLOGICAL|Placebo|Tris-NaCl Diluent
41475091|NCT06293911|OTHER|Biorepair Plus Parodontgel Intensive|The Biorepair Plus Parodontgel Intensive gel will be used after home oral hygiene once a day.
41318356|NCT05027919|DRUG|Morphine|30mg subcutaneous injections of morphine 4 times daily on days 1 through 5.
41318357|NCT05027919|DRUG|Naloxone + lofexidine pretreatment|0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)
41475092|NCT06293911|OTHER|Placebo gel|The placebo gel (without hyaluronic acid, Lactobacillus Ferment, Aloe Barbadensis Leaf Juice Powder and lactoferrin) will be used after home oral hygiene once a day.
41475093|NCT00839059|DRUG|lenalidomide|"Dose escalation:~Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.~Duration of the first cycle: 56days, each following cycle will last 28 days"
41318358|NCT05027919|DRUG|Naloxone + placebo pretreatment|0.4mg naloxone injection during the Naloxone challenge
41318359|NCT05027919|DRUG|Lofexidine|Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.
41318360|NCT02351843|DEVICE|MECTA Spectrum 5000Q|
41318361|NCT02379754|DRUG|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
41475094|NCT05849688|OTHER|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied.
41475095|NCT05849688|OTHER|Bicycle Ergometry Training|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied + bicycle ergometry training
41475096|NCT02631876|DRUG|Mirvetuximab soravtansine|Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
41475097|NCT02631876|DRUG|Paclitaxel|Paclitaxel will be administered per dose and schedule specified in the arm.
41475098|NCT02631876|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
41475099|NCT02631876|DRUG|Topotecan|Topotecan will be administered per dose and schedule specified in the arm.
41475100|NCT06473506|DIAGNOSTIC_TEST|Saliva collection|Self-collected saliva sample with molecular testing performed. Results are compared to rapid antigen testing, bacterial throat culture and bacterial throat molecular testing
41318362|NCT01165099|PROCEDURE|acupuncture|The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
40801142|NCT02764359|DRUG|IV vancomycin|IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
40801143|NCT00140049|DRUG|Xalacom|
40801144|NCT00140049|DRUG|Cosopt|
40801145|NCT03313999|DEVICE|Lymphedema Indentometer|The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
40801146|NCT05842941|DRUG|DNL343|DNL343 is administered orally once daily per day for 24 weeks.
40801147|NCT05842941|DRUG|Matching Placebo|Matching placebo is administered orally once daily per day for 24 weeks.
40801148|NCT02467192|DEVICE|Low dose CT|Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
40801149|NCT02151916|OTHER|Dental care, AG, MI & fluoride varnish|Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
41318363|NCT05291416|DIAGNOSTIC_TEST|densitometry/ handgrip dynamometer|all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer
41318364|NCT04265170|DEVICE|BlastX with negative pressure therapy|Blast-X in combination with NPWT on,bacterial bio-burden in pressure ulcers assessed by Fluorescence imaging and quantitative biopsy.
41318365|NCT00145249|DRUG|Amphotericin B|Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
41318366|NCT00145249|DRUG|Fluconazole|Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
41318367|NCT05861804|PROCEDURE|Rhomboid Intercostal Nerve Block|Before the induction of general anesthesia, under aseptic conditions, rhomboid intercostal nerve block will be performed with a single dose of 20 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
41318368|NCT04729062|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
41318369|NCT01333852|DRUG|metformin up to 2500mg/d|metformin up to 2500mg/d
41318370|NCT01333852|DRUG|paclitaxel 175mg/m² q21d|paclitaxel 175mg/m² q21d
41318371|NCT01333852|DRUG|placebo|placebo
41318372|NCT06348810|BEHAVIORAL|Dual-task training|The dual-task training is a combination of cognitive tasks and motor tasks which is done simultaneously or at the same time.
40801150|NCT02151916|OTHER|Delayed intervention|Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
41318373|NCT06348810|BEHAVIORAL|Cognitive training|Participants only receive cognitive tasks
40801151|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
40801152|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
40801153|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
40801154|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
41005070|NCT03427385|DRUG|Ropivacaine 0.5%|The volume of local anesthetic Ropivacaine 0.5% will be determined by the response (success or failure of block, 30 minutes after local anesthetic injection) of the previous patient in that group. Block success is defined as an absence of ice sensation in the knee within 30 min of ropivacaine administration accompanied by tolerance to tetanic electrical stimulation (TES) at 60 mA(milliamp) for 5 seconds.
41005071|NCT01664143|DRUG|Placebo|Multiple doses of placebo
41005072|NCT01664143|DRUG|RO5508887|Multiple doses of RO5508887
41318374|NCT06348810|BEHAVIORAL|Motor training|Participants only receive motor tasks
41318375|NCT06348810|OTHER|Usual care|assist participants with activities of daily living, medication management, and social activities (such as singing, watching television).
41318376|NCT04546464|BEHAVIORAL|Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
41318377|NCT05487313|PROCEDURE|Erector spinae plane block|fascial plane injection guided by fluoroscopic device after ultrasound guidance
41318378|NCT02693795|OTHER|Baduanjin exercise|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
41318379|NCT02693795|OTHER|aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
41318380|NCT03017846|DRUG|Cantharidin|Application of topical cantharidin
41318381|NCT04408118|DRUG|Atezolizumab|"Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15.~The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes."
40801155|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
40801156|NCT00396786|DRUG|Enoxaparin|Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
41318382|NCT04408118|DRUG|Paclitaxel|Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.
40801157|NCT04031898|OTHER|Non Interventional|This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line
40801158|NCT01976546|DEVICE|Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps|Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
40801159|NCT05541822|DRUG|ABN401|"Tablets~Route of Administration: Oral"
40801160|NCT04004338|DRUG|Kyprolis|Patients receiving kyprolis (carfilzomib)
40801161|NCT01009905|DRUG|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
40801162|NCT05292495|DRUG|HR17031 injection|HR17031 injection; administered subcutaneously.
40801163|NCT01555970|DRUG|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
41005073|NCT02103829|BEHAVIORAL|Brief Intervention #1|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
41005074|NCT02103829|BEHAVIORAL|Brief Intervention #2|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
41005075|NCT02103829|BEHAVIORAL|Brief Intervention #3|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.
41005076|NCT01389297|BEHAVIORAL|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
41005077|NCT01389297|BEHAVIORAL|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
41005078|NCT05523531|OTHER|Self-administered questionnaires|"* Neuropathic Eye Pain Questionnaire~* 5-item Dry Eye Evaluation Questionnaire (DEQ-5)~* Visual Impact Assessment Questionnaire~* Concise Ophthalmic Pain Questionnaire~* Questionnaire to evaluate the effectiveness and tolerance of treatments~* Chronic pain questionnaire"
41152280|NCT02852486|DRUG|Pioglitazone 30 Mg Oral Tablet|30 mg/day, orally, for 3 months, before imatinib discontinuation
41152281|NCT02852486|OTHER|imatinib discontinuation|imatinib discontinuation after 3 months of pioglitazone
41152282|NCT00437086|DRUG|PS-341|1.6 mg/m2 by IV; 4 out of 5 weeks
41318383|NCT04408118|DRUG|Bevacizumab|Will be administered intravenously over 30-90 minutes on Days 1 and 15.
40801164|NCT01555970|DRUG|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
41005079|NCT05523531|PROCEDURE|Bilateral ophthalmologic examination|"* Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~* Lipiview® test~* Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~* In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy"
41005080|NCT00025285|DRUG|carboplatin|
41005081|NCT00025285|DRUG|irinotecan hydrochloride|
41005082|NCT00025285|DRUG|thalidomide|
41005083|NCT04183556|DRUG|Naproxen|use of naproxen twice a day orally in mens time
41005084|NCT04183556|DIETARY_SUPPLEMENT|Turmeric|Use of turmeric orally (1 gram powder formula) in mens time
41005085|NCT02386111|DRUG|Combination of varlilumab and sunitinib|"During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg."
41005086|NCT04033003|BEHAVIORAL|Group ANC|Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
41005087|NCT01234129|DRUG|zoledronic acid|zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
41005088|NCT05548608|OTHER|Reposition error (RE), pain at target positions of RE and flexibility of the TLF were assesed with iphone tiltmeter app, VAS and goniometric platform, respectively.|Target positions of reposition error were: 30º forward bending and 15º backward bending in sitting and standing.
41318384|NCT02101840|DRUG|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
40801165|NCT06049654|DEVICE|NVT ALLEGRA TAVI System TF|Transcatheter aortic valve implantation of a NVT ALLEGRA TAVI System TF in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
41475101|NCT06318832|OTHER|ICBT|ICBT: Participants will receive the 10-week tailored ICBT Wellbeing program consists of 1) education about how taking on the role of care-partner can impact emotional and cognitive wellbeing through introduction to the CBT model; 2) structured problem solving; 3) cognitive therapy and thought challenging to manage one's wellbeing and impact of caregiving; 4) building communication and intimacy; 5) physical symptoms of depression (i.e., hypo-arousal), anxiety/anger (i.e., hyper-arousal); practicing behavioural activation and controlled relaxation; 6) overdoing-underdoing cycle of activity levels and issues around the fear avoidance of social, physical, and cognitive activities; practicing activity pacing and gradually tackling avoidance; 7) occurrence of setbacks in thought, physical, behavioural, and cognitive symptoms; signs of setbacks and creating setback plans.
41475102|NCT06490887|OTHER|Use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing surgery or from pregnant women giving birth. Peripheral blood will be also collected from patients to conduct virological screening and isolate peripheral blood mononuclear cells.
41005089|NCT01046916|DRUG|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
41005090|NCT02340234|DRUG|Lebrikizumab|Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
41005091|NCT02340234|DRUG|Placebo|Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
41005092|NCT02340234|DRUG|TCS Cream|TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
41005093|NCT04046185|DRUG|PD-1 inhibitor combined progesterone|Toripalimab combine with progesterone
41005094|NCT04046185|DRUG|progesterone|progesterone
41318385|NCT02101840|DRUG|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
41318386|NCT02101840|DRUG|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
41318387|NCT00497016|DRUG|atorvastatin 80 mg|
41318388|NCT03450915|BIOLOGICAL|M-001|A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.
41318389|NCT03450915|BIOLOGICAL|Saline|0.9% sodium chloride (NaCl)
40801166|NCT06049654|DEVICE|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM|Transcatheter aortic valve implantation of an EDWARDS SAPIEN 3 SYSTEM in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
41475103|NCT04539626|DRUG|Estrogen Therapy|EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)
40801167|NCT05910879|BEHAVIORAL|Self-Affirmation Implementation Intentions (SAII) Intervention|"In an brief exercise, participants are asked to provide a personal story and positive experience during the challenging and sometimes stressful COVID19 pandemic, ...a time when you felt successful and proud of yourself. ...You can also tell us about a time that you did something to help someone in need. The self-affirmation is designed to offset effects of threats to self. In the next section participants are asked to formulate an if-then plan with one preferred self-affirmation-inducing cognition: If I feel sad, threatened, or discriminated against, then I will... a)...think about things I value about myself, b)...remember things that I have succeeded in, c) ...think about what I stand for, or d)...think about things that are important to me. After selecting response, participants read the full If-Then plan out loud and are provided with a paper copy of their exercise to take home."
40801168|NCT05910879|BEHAVIORAL|Promotores de Salud (Health Education)|The Promotores de Salud intervention includes: (1) a culturally tailored health education to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores (community health advocates) are on-site at Mexican Consulate events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
41318390|NCT04084626|DRUG|PD1 antibody|2mg/kg ivgtt on day 1(age\<18 years); 200mg ivgtt on day 1(age \>=18 years).
41318391|NCT04084626|DRUG|lenalidomide|5mg orally once a day（age\<18years) ,day 1-14; 10mg orally once a day(age\>=18years), day 1-14.
41318392|NCT03954444|DRUG|Oxymetazoline Hydrochloride|Test Comparator
41318393|NCT03954444|DRUG|Rhofade Cream, 1%|Reference Comparator
41318394|NCT03954444|DRUG|Placebo|Placebo Comparator
41475104|NCT04577573|DEVICE|Cognition glove|The investigators have developed and tested a functional prototype of an instrumented glove to alert the user about secure grasp of objects. Onboard force and flex sensors provide inputs to a machine learning algorithm (artificial neural network, ANN) to estimate secure grasp based on previously collected training data. The glove enhances agency by alerting the user to secure grasp through sensory feedback modules (visual - LED, audio - beeper, tactile - vibrator).
40801169|NCT04368299|OTHER|Telemedicine|Videoconferencing for follow-up
41318395|NCT01810549|DRUG|Anakinra|Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
41318396|NCT01810549|DRUG|Placebo|Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
41318397|NCT00565058|BIOLOGICAL|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
41475105|NCT04577573|DEVICE|Sensory brace|"A a size- and position-adjustable arm brace with weight-support capability and housing for vibration motors and EMG sensors. Position adjustment allows for physical therapists to find and recommend arm postures that are clinically relevant to~each person. The participant can then isometrically push/resist against the brace to strengthen target muscles while performing VR reach-to-touch. The person will receive visual feedback from the virtual environment to train movement performance and vibrotactile feedback at tendons to subconsciously adjust their muscle activation patterns"
41475106|NCT03968497|OTHER|Postoperative pain assessment with female investigator|Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
41475107|NCT03968497|OTHER|Postoperative pain assessment with male investigator|Postoperative pain evaluation by a male investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
41475108|NCT03998436|DRUG|Esmolol Hydrochloride|Galnobax-14% gel application along with Standard of Care
41318398|NCT05576480|RADIATION|Short-course radiotherapy|5×5Gy in Week 1
41318399|NCT05576480|DRUG|Penpulimab|Apply once in the first week, then every 3 weeks from the third week for four cycles
41318400|NCT05576480|DRUG|CAPEOX|Apply every 3 weeks from week 3 for 4 cycles
41318401|NCT05576480|PROCEDURE|TME surgery|Patient will receive radical rectal cancer surgery
40801170|NCT04368299|OTHER|Standard care|Standard in-person outpatient follow-up
40801171|NCT00042016|DRUG|decitabine (5-aza-2'deoxycytidine)|
41005095|NCT00473720|DRUG|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
41318402|NCT05899712|OTHER|Removable Partial Denture Construction|Construction of class I Removable partial denture by digital workflow
41318403|NCT03085355|PROCEDURE|Exercises and PNE|Exercise for stretching and strength for neck muscles and pain neuroscience education
41318404|NCT03085355|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment associated exercise for stretching and strength for neck muscles and pain neuroscience education
41318405|NCT03550131|BEHAVIORAL|Innovations in Dementia Empowerment and Action (IDEA)|The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.
41318406|NCT03550131|BEHAVIORAL|Reducing Disabilities in Alzheimer's Disease (RDAD)|The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
41318407|NCT00433446|BIOLOGICAL|CNTO 328|
41318408|NCT02466568|DRUG|Nivolumab|Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
40801172|NCT02565875|BEHAVIORAL|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
41005096|NCT00473720|DRUG|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
41005097|NCT05776758|DRUG|cisplatin based neoadjuvant chemotherapy|cisplatin based neoadjuvant chemotherapy
40801173|NCT02565875|BEHAVIORAL|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
40801174|NCT02565875|OTHER|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
41005098|NCT05776758|PROCEDURE|Radical cystectomy alone|RC alone
41005099|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET|At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
41005100|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC|At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
41318409|NCT02466568|BIOLOGICAL|GM.CD40L Vaccine|GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
41005101|NCT02958839|PROCEDURE|Catheter ablation|Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
41318410|NCT05398393|DRUG|oral Tenofovir Amibufenamide 25mg each day|patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day
41318411|NCT05398393|DRUG|lipid lowering drugs (e.g. Atorvastatin and amlodipine.)|lipid lowering drugs, , patients in group B1 continue take lipid lowering drugs
41318412|NCT01757405|BIOLOGICAL|Recombinant Factor VIIa BI (rFVIIa BI)|Administered approximately every 3 hours as an intravenous bolus injection on-demand
41318413|NCT01757405|BIOLOGICAL|Recombinant Factor VIIa BI (rFVIIa BI)|Administered as a single intravenous bolus injection on-demand
41475109|NCT03998436|OTHER|Only Standard of Care|Only Standard of Care treatment
41475110|NCT03998436|OTHER|Vehicle Gel|Vehicle gel application along with Standard of Care
40801175|NCT05276336|PROCEDURE|Radiofrequency turbinate reduction|Before the radiofrequency turbinate reduction procedure, local anaesthesia will be given by applying a cotton tamponade soaked in lidocaine adrenaline 1:5000 titration and added with xylocaine gel for 10 minutes in both nostrils. Then, a mixture of 1 mL of lidocaine 2% and 2 mL of sodium chloride 0,9% will be infiltrated to both nostrils using 3 mL and 1 mL needles until the inferior turbinates are pale. The radiofrequency probe (made by Sutter, both in monopolar and bipolar modes) will be inserted to the distal inferior turbinate until the black line from the probe is inside the inferior turbinate (approximately 10-12 mm). The procedure will be done for 10 seconds and the insertion of the probe can be done in 2-3 sites. After this, subjects from this group will be treated with pharmacology treatment using intranasal steroid and AH-1 according to ARIA WHO guideline 2008, similar to the pharmacology treatment received by the control group.
40801176|NCT05276336|DRUG|Pharmacology treatment|Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
40801177|NCT00479570|DRUG|PF-00446687|Single 200mg dose
40801178|NCT00479570|DRUG|Placebo|
41475111|NCT04344626|DEVICE|Intra-operative brain tonometry|Once the brain is exposed during surgery, a sterilized digital tonometer will be used to obtain brain tissue stiffness measurements at various locations of the cortex established based on results of pre-operative work-up. Precise stereotactic coordinates for each measurement will be recorded in a neuronavigation software to facilitate comparisons with results of other tests.
40801179|NCT02148536|PROCEDURE|Transjugular intrahepatic portosystemic shunt|
40801180|NCT00481455|DRUG|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
40801181|NCT00481455|DRUG|Temozolomide|Fixed dose
40801182|NCT05724862|DEVICE|Needle-less jet anaesthesia|Infiltration anesthesia without needle depending on injection pressure
40801183|NCT05724862|DEVICE|Conventional Injection Anesthesia|Regular Infiltration local anesthesia
41005102|NCT05630027|OTHER|Piroctone Olamine (PO), 2,4 Diaminopyrimidine oxide (2.4 DA) and Vichy mineralizing water|observational, prospective study
41005103|NCT06317493|OTHER|Stimuli|"Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras."
41152283|NCT02630927|DRUG|AG-519|AG519 will be tested.
41475112|NCT00017459|DRUG|cisplatin|
41475113|NCT00017459|DRUG|tirapazamine|
41475114|NCT00017459|DRUG|vinorelbine tartrate|
41475115|NCT00110188|DRUG|ridaforolimus|
41475116|NCT00003130|DRUG|paclitaxel|
41475117|NCT05194449|OTHER|Comfort Talk® App|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
41318414|NCT04584658|DIAGNOSTIC_TEST|Fibreoptic Endoscopic Evaluation of Swallowing (FEES)|This is the use of endoscopy during feeding trials. The patient is fed different consistencies of food and drink while an endoscope is in place (usually passed through the nasal passage and down into the throat). The endoscope provides a bird's eye view to the transit of food through the upper aero-digestive tract. This provides information from the point of food bolus formation in the mouth to the movement of the base of the tongue; the movement of pharyngeal muscles; the deflection of the epiglottis to protect the airway including the closure of the vocal cords and the passage of food into the oesophagus. Any abnormality in these steps are noted during FEES. Liquids, thickened fluids, semi-solids and solids are some of the food textures that are tested.
41475118|NCT05194449|OTHER|Placebo App|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
41475119|NCT02985619|DRUG|Bevacizumab Injection [Avastin] (IVB-I)|0,05ml intravitreal injection
41475120|NCT02985619|DRUG|Triamcinolone Acetonide 10mg/mL (IVT-II)|0,03ml intravitreal injection
41475121|NCT02985619|DRUG|Bevacizumab Injection [Avastin] (IVB-III)|0,05ml intravitreal injection
40801184|NCT01762774|DRUG|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
40801185|NCT01762774|DRUG|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
40801186|NCT01150786|DIETARY_SUPPLEMENT|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
40801187|NCT01150786|OTHER|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
40801188|NCT02920528|DRUG|Ketamine|sub-dissociative ketamine
40801189|NCT02920528|DRUG|Placebo|Normal Saline
40801190|NCT02963363|OTHER|Home-based Adapted Physical Activity|"Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks"
40801191|NCT04102800|DRUG|Benralizumab|subcutaneous injection
40801192|NCT03760198|DRUG|Meditoxin|50U of MEDITOXIN is injected intradermally to each axilla
40801193|NCT03760198|OTHER|Placebo|normal saline is injected intradermally to each axilla
40801194|NCT03419312|DEVICE|Proclaim™ Elite 5: Burst - Washout - Sham|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
40801195|NCT03419312|DEVICE|Proclaim™ Elite 5: Sham - Washout - Burst|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
41318415|NCT04584658|DIAGNOSTIC_TEST|Videofluoroscopy|A radio opaque dye is used to label the test food and drink items offered to the patient. Following this, x-ray technology is used to create a video of the outline of the patient and the structures responsible for chewing and swallowing as they injest the test materials. The study is carried out in real time in the radiology department in conjunction with a radiographer and an SLT.
41318416|NCT04584658|OTHER|Dysphagia Handicap Index (DHI)|This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
41475122|NCT00338130|DRUG|AZD6244|Oral liquid or Capsule
41475123|NCT00338130|DRUG|Temozolomide|oral
40801196|NCT03915158|PROCEDURE|bariatric surgery|sleeve gastrectomy
40801197|NCT00497419|PROCEDURE|fast track|
40801198|NCT03461549|DEVICE|Pressure and Temperature Sensor|This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.
40801199|NCT02406924|PROCEDURE|Biopsy|A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine
40801200|NCT02406924|RADIATION|Computerized Tomography|An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery
40801201|NCT02406924|OTHER|Standardized periapical radiographs|A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
40801202|NCT02406924|OTHER|Intraoral scanning|Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
40801203|NCT00943098|DRUG|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
40801204|NCT00943098|DRUG|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
40801205|NCT02672059|OTHER|Observation|No intervention
40801206|NCT05993988|OTHER|Exercise|Muscle relaxing Technique
41475124|NCT04030494|DIAGNOSTIC_TEST|BP measurement|sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation
41475125|NCT04030494|DIAGNOSTIC_TEST|AF detection|single lead ECG with Withings WPM04 and 12 lead ECG
41475126|NCT04030494|DIAGNOSTIC_TEST|VHD detection|phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography
41475127|NCT04963387|OTHER|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
41005104|NCT06270550|OTHER|Dynamic Movement Intervention|Dynamic movement intervention is a physical therapy approach for infants suffering abnormal developmental motor evolution caused by a known or unknown non-degenerative syndrome affecting the central nervous system
41005105|NCT03022617|DRUG|Apremilast|
41005106|NCT02699294|OTHER|Manual pressure release|Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
41005107|NCT02699294|OTHER|Contract-relax PNF stretch|Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
41005108|NCT02699294|OTHER|Z-stretch|Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
41152284|NCT02630927|DRUG|Placebo|Placebo will be tested.
41152285|NCT04291716|DEVICE|Motor Seizure Detection Algorithm (mSDA)|A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.
41152286|NCT00711776|DRUG|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
41152287|NCT00711776|DRUG|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
41152288|NCT05938959|DRUG|Sham block|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0,9% normal saline
41152289|NCT05938959|DRUG|ESPB|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0.2% Ropivacaine (max 2.5mg/kg)
41152290|NCT03703492|DRUG|(18F)FES|"18F-FES is an investigational new drug which will be used for this study. For complete information, please refer to the Investigator's Brochure: \[18F\]Fluoroestradiol: An investigational positron emission tomography (PET) radiopharmaceutical for injection, intended for use as an in vivo diagnostic for imaging estrogen receptors in tumors"
41152291|NCT03703492|DRUG|Gadobenate dimeglumine|Gadolinium-based intravenous contrast agent used for the MRI portion of this study
41152292|NCT06224335|DIAGNOSTIC_TEST|intra-abdominal pressure with Femfit® device during (jumps on the ground, jumps on a trampoline, weightlifting, slow running, fast running|Change in intravaginal and intra-abdominal pressure assessed by Femfit® , leakage of urine in grams assessed by inovative pad test during 5 sports activities.
41152293|NCT06077695|OTHER|therapeutic education|The themes covered concern head trauma in the chronic phase.
41152294|NCT06077695|OTHER|tDCS|The constant electric current will be delivered at an intensity of 2 mA for 20 minutes.The anode will be placed opposite the dorsolateral prefrontal area on the right. The cathode (or reference electrode) will be positioned opposite the supraorbital area on the left. This methodology is based on the general directions and results from scientific studies which aimed to improve the efficiency of neural networks engaged in attentional processes and working memory.
41318417|NCT04584658|OTHER|Voice Symptom Scale (VoiSS)|This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28.
41318418|NCT02435641|OTHER|Questionnaires|All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
41318419|NCT01011452|DRUG|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
41318420|NCT01011452|DRUG|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
41318421|NCT04124692|DEVICE|Sculptra Aesthetic new dilution|Treatment of cheek wrinkles
41318422|NCT03297437|OTHER|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
41318423|NCT00000113|OTHER|Progressive Addition Lenses|Varilux comfort with +2.00 addition
41318424|NCT00000113|OTHER|single vision lenses|
41318425|NCT01981278|DRUG|Tapentadol ER 250-mg TRF tablet|Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.
41318426|NCT01981278|DRUG|Tapentadol ER 250-mg PR2 tablet|Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
41318427|NCT01349686|PROCEDURE|Diet|Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).
41318428|NCT01349686|PROCEDURE|Fasting|No intake of fluids during labour.
40801207|NCT05964348|PROCEDURE|CT-Scan|semi-automated analyse by anatomical landmarks with a dedicated fully automated software
41318429|NCT02119234|DRUG|Beclometasone/formoterol/glycopyrrolate|
40801208|NCT05978349|DRUG|adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
40801209|NCT03528122|PROCEDURE|Recurrent opened macular hole|pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
40801210|NCT03689049|PROCEDURE|SPIDER|The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.
41318430|NCT02119234|DRUG|Placebo|
41318431|NCT04113148|OTHER|Physiological measurements from heel|Measurements of blood flow, tissue oxygen saturation, temperature, pressure
40801211|NCT03689049|PROCEDURE|Usual Care|Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
41318432|NCT00854178|DRUG|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
41475128|NCT04963387|OTHER|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
41475129|NCT04517929|OTHER|Group Psychotherapy|9 week group psychotherapy, given by a psychologist trained in group psychotherapy.
41475130|NCT01197157|DRUG|Placebo|Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
41475131|NCT01197157|DRUG|Nitazoxanide|• Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
41475132|NCT00330460|DRUG|Alendronate|ALN; 70 mg; oral; once weekly
41475133|NCT00330460|DRUG|Denosumab|60 mg; SC; every 6 months
41475134|NCT02336516|DRUG|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
40801212|NCT01894048|DRUG|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
40801213|NCT00797264|DRUG|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
40801214|NCT00797264|DRUG|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
41318433|NCT04149639|DIETARY_SUPPLEMENT|NeuroQ|Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
41318434|NCT02766790|DIETARY_SUPPLEMENT|TA-65MD|TA-65, a purified small molecule extracted from Astragalus root
41318435|NCT02766790|OTHER|Placebo|Placebo, an inactive formulation
41318436|NCT02813759|OTHER|Sucralose|Subjects drank 200 mL of water with 14 mg sucralose, followed by a standard breakfast.
41318437|NCT02813759|OTHER|Placebo|Subjects drank 200 mL of water alone (placebo), followed by a standard breakfast.
40801215|NCT00797264|DRUG|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
40801216|NCT04333979|OTHER|Drainage|Using drain after operation
40801217|NCT05450224|BEHAVIORAL|VVC-delivered Massed Imaginal Exposure|Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
40801218|NCT05720052|DRUG|MS-553|MS-553 oral tablet BID x 28-days
40801219|NCT01903122|DRUG|Cevimeline|
41318438|NCT00634114|DRUG|Esomeprazole|10mg once daily oral administration
41318439|NCT00634114|DRUG|Esomeprazole|20mg once daily oral administration
41318440|NCT00634114|DRUG|Omeprazole|10mg once daily oral administration
41318441|NCT02836860|OTHER|Tactile stimuli|Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
41318442|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
41475135|NCT02336516|DRUG|Placebo (glucose solution 10%)|
41475136|NCT04818437|OTHER|BALANCE TRAINING|Trunk, head, and upper limbs rotation from kneeling. 2- Upper limbs flexion and extension with simultaneous head movement from kneeling. 3-Pelvic bridging followed by raising one lower limb and extending knee. 4-Lifting opposite upper and lower limbs from Quadruped position. 6-Heel and toe raises, alternate rising of he right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed
41475137|NCT04818437|OTHER|CORE STABILITY EXERCISES|"1. Abdominal bracing while lying in supine position.~2. Abdominal bracing with heel slide while lying in supine position.~3. Abdominal bracing with Leg lifts while lying in supine position.~4. Abdominal bracing with bridging while lying in supine position.~5. Abdominal bracing while Standing.-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying"
41475138|NCT05440630|DIETARY_SUPPLEMENT|Probiotics|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria) for 16 weeks.
40801220|NCT00849355|DRUG|RCOMP-14 + rituximab|"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."
40801221|NCT00778076|DEVICE|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
40801222|NCT00778076|DEVICE|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
40801223|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
40801224|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
40801225|NCT04317443|PROCEDURE|Super-mini percutaneous nephrolithotomy (SMP)|SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.
40801226|NCT04317443|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
40801227|NCT03529838|OTHER|Combined exercise|The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
40801228|NCT00876096|OTHER|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
41152295|NCT06077695|OTHER|cognitive remediation|"Personalized sessions combining 2 approaches:•Retraining deficit components of working memory.exercise the strengthening of metacognition and the learning of reorganization-facilitation strategies. At the end of each exercise, the participant will be asked to analyze their performance and will benefit from feedback from the rehabilitator as well as a discussion on the use of the strategies. Finally, all of the proposed tasks will be made up of several levels of complexity; moving to a more complex stage will require more than 90% success in the exercise.•More ecological exercises will also be carried out in order to get as close as possible to the difficulties encountered by the patient on a daily basis. The examiner will guide the rehabilitation and propose tasks imitating his daily life."
41005109|NCT00653354|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
40801229|NCT05114707|DRUG|camrelizumab|Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.
40801230|NCT04960748|BEHAVIORAL|WOMEN FIGHTING TO STOP CERVICAL CANCER|The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.
41318443|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
40801231|NCT03755219|PROCEDURE|TEP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
41005110|NCT00653354|DRUG|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
41005111|NCT00653354|DRUG|placebo|placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
41005112|NCT03410979|DRUG|GLPG2737 single dose|GLPG2737 oral suspension, single ascending doses
41152296|NCT02612363|DRUG|Dexmedetomidine for sedation|"Dexmedetomidine or control drug for sedation~* Analgesia~* Propofol at lowest dosage.~* Dose range: 0.1- 0.7 u/kg/hour~* Target RASS score of -2 to +1~* Supplemental other sedatives at lowest effective dose"
41005113|NCT03410979|DRUG|Placebo single dose|Placebo, oral suspension.
41005114|NCT03410979|DRUG|GLPG2737 multiple dose|GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
41005115|NCT03410979|DRUG|GLPG2737 multiple dose|Placebo, oral suspension, daily for 14 days
41318444|NCT03799926|DRUG|placebo|Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
41318445|NCT03799926|DRUG|placebo|Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
41318446|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
41475139|NCT05440630|DIETARY_SUPPLEMENT|Postbiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain postbiotic (Heat treated bacteria) for 16 weeks.
40801232|NCT03755219|PROCEDURE|TAPP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
40801233|NCT04254653|BEHAVIORAL|American Indian and Alaska Native What Can I Eat?|Participants will engage in 5 \~90 minute diabetes nutrition education classes. They will learn about healthy eating for type 2 diabetes management. Classes include didactic lesson, hands on learning activity, sharing session, mindful nutrition practice, and physical activity
41005116|NCT03413332|OTHER|E-Talkcare|Women in the intervention group will receive the E-Talkcare web address, a user name, and a temporary password. The participant will be able to read or listen (through audio narration) to instructions on how to complete the intervention in order, though she can freely navigate between web modules. Each module will have an ever-present indicator (showing users' progress) and a link to for users to continue navigating through modules.We will ask participants to complete the full intervention within 3 months after intervention delivery and then complete a 3-month post-randomization interview (T1). The website will remain open for six months after intervention delivery to allow participants to use QPL if they wish. A 6-month post-randomization interview (T2) will then be administered.
41005117|NCT03413332|OTHER|Usual Care|Survivors randomized to the usual care group will receive care from their doctors as usual, allowing us to compare the intervention against real-world practice to inform next steps. Since we do not know if the intervention will be efficacious, we decided not to provide a delayed intervention to control participants.
41005118|NCT05520671|OTHER|Gamified online quizzing platform|"TESLA-G is a novel gamified quizzing platform designed based on Bloom's taxonomy of learning domains. Questions will be created in blocks, where each block will test a specific topic within a specialty (endocrine surgery has been selected for this study). Each block has 5 questions, and each question corresponds to each level of Bloom's taxonomy and each level in game.~For this study, we aim to create 56 blocks of 5 questions, totalling 280 questions. All questions will be created by two board-certified general surgeons and one endocrinologist, and validated by the research team.~The aim of the game is for players to get as many points as they can before the timer runs out. Gamification elements include levels, countdown timer, lives, a point multiplier system, leaderboard rankings and a personalised dashboard.~Participants in the intervention group will be provided with a link to access TESLA-G, sent from an automated Telegram bot; this access will be provided for 14 days."
41152297|NCT01007617|DEVICE|LLLT :low level laser therapy|"The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.~Main evaluation criteria: mucositis maximal intensity (WHO scale).~Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition."
41152298|NCT02920645|OTHER|AVM-related ICH|
41152299|NCT05261100|OTHER|Core stability exercises|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercises will be performed along with core stability exercises.."
41152300|NCT05261100|OTHER|Conventional Physical Therapy|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercise perform."
41318447|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
41318448|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
41318449|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
41318450|NCT02396342|GENETIC|AAV5-hFIX|AAV5hFIX gene therapy
41318451|NCT02589795|BIOLOGICAL|DNA-C CN54ENV|DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
41318452|NCT02589795|BIOLOGICAL|CN54gp140|Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
41318453|NCT02589795|DEVICE|Trigrid Delivery System - Intramuscular|Electroporation
41318454|NCT02589795|DEVICE|Trigrid Delivery System - Intradermal|Electroporation
41318455|NCT03665428|DRUG|PAMB treatment (modified quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
41318456|NCT03665428|DRUG|PBMT treatment (bismuth-containing quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
41318457|NCT00755846|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
41318458|NCT00755846|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
41318459|NCT00755846|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
41475140|NCT05440630|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for 16 weeks.
40801234|NCT00437957|DRUG|Temozolomide|75 Mg/m2/day for all Cohorts
41475141|NCT01045707|DRUG|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
40801235|NCT00437957|DRUG|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
41318460|NCT00755846|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
41318461|NCT00755846|DRUG|Alogliptin|Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
41475142|NCT01045707|DRUG|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
41475143|NCT03433131|DRUG|Pitolisant|Tablets
41475144|NCT01716676|OTHER|Telemedicine CPAP monitoring (webpage and televisit)|
41475145|NCT01716676|OTHER|Standard CPAP monitoring|
41475146|NCT02555293|DRUG|XIFAXAN® (Rifaximin)|
41475147|NCT00878696|PROCEDURE|TMS transcranial magnetic stimulation|"200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz."
41475148|NCT00261131|DRUG|Botulinum Toxin A|
40801236|NCT00437957|PROCEDURE|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
40801237|NCT06264466|DEVICE|POEM with Speedboat Ultraslim|POEM procedures, with or without fundoplication, will be conducted by expert endoscopists who have undergone prior training in the utilization of the ultraslim Speedboat. Incisions, whether anterior or posterior, submucosal tunneling, and myotomy will be performed using the Bipolar Radiofrequency Ablation (RFA) integrated into the device's tip. Additionally, for vessel coagulation, the microwave energy integrated into the device's tip will be employed. Successful myotomy will be confirmed by passage of the endoscope through the esophagogastric junction (EGJ) without restriction.
40801238|NCT05023291|DIAGNOSTIC_TEST|Positron Emissie Tomografie - Computer Tomografie|In this study, the high-resolution PET-CT system will be used to evaluate the cutting edges after tumor resection. The goal is to evaluate the distance of the tumor cells from the cutting edges of the surgical piece. The patient receives an intravenous injection of radiolabeled sugar (18F-FDG). 18F-FDG is the standard PET tracer for diagnostic PET-CT research. This standard dose will always be calculated according to the formula: 3.7 x body weight + 37 Mbq.
40801239|NCT01877850|PROCEDURE|weaning protocol|"Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator."
40801240|NCT00428935|BIOLOGICAL|rAAV2.5-CMV-minidystrophin (d3990)|Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
40801241|NCT04173286|PROCEDURE|antibiotherapy|\< 7 days
40801242|NCT04183504|BEHAVIORAL|Brief parenting intervention|Coaching session on positive parenting practices and promoting child development
40801243|NCT04944238|DEVICE|Ankoris|Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.
40801244|NCT01118403|DRUG|Sultamicillin|Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
40801245|NCT02977429|OTHER|standardized fluid therapy|The patients with ScvO2 \<70% will receive the standardized fluid therapy for 6 hours.
40801246|NCT02977429|OTHER|conventional fluid therapy|The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
40801247|NCT03693677|DRUG|Irinotecan Liposomal Injection|Nal-IRI at 80 mg/m2 IV over 90 minutes
40801248|NCT03693677|DRUG|5-FU/LV|5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
40801249|NCT03693677|DRUG|Nab-Paclitaxel|Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.
40801250|NCT03693677|DRUG|Gemcitabine|1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.
40801251|NCT05005273|DRUG|Nivolumab|Specified dose on specified days
40801252|NCT05005273|DRUG|Ipilimumab|Specified dose on specified days
40801253|NCT05005273|DRUG|BMS-986207|Specified dose on specified days
40801254|NCT05005273|OTHER|Placebo|Specified dose on specified days
40801255|NCT00699946|DRUG|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
40801256|NCT00699946|DRUG|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
40801257|NCT04644146|GENETIC|GENETIC|It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
40801258|NCT02531360|DRUG|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
40801259|NCT01389453|PROCEDURE|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
40801260|NCT04603313|OTHER|tele-advice system|The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
40801261|NCT04169984|OTHER|Myofunctional Therapy|Isometric, isokinetic and isotonic exercises for the upper airway muscles.
40801262|NCT04169984|OTHER|Placebo|Exercises that do not alter the function or morphology of the upper airway.
40801263|NCT06291012|DRUG|Quick response: Amoxicillin for 3 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Immediate stop of antibiotherapy (after 9 complete doses)~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
40801264|NCT06291012|DRUG|Delayed response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 5 days"
41152301|NCT02841176|OTHER|Thermography|Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
40801265|NCT06291012|DRUG|Quick response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Continuation of antibiotherapy for up to 5 days~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
40801266|NCT06291012|DRUG|Delayed response: Amoxicillin for 7 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 7 days"
40801267|NCT01023685|BIOLOGICAL|CAD106|
40801268|NCT05503979|DRUG|Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]|1 tab every 24 hrs for 12 weeks
40801269|NCT00565162|DRUG|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
40801270|NCT02443337|DRUG|LY3023414|Administered orally
40801271|NCT02443337|DRUG|Necitumumab|Administered IV
41152302|NCT02841176|BIOLOGICAL|Golimumab|Participants will start monthly Golimumab after their baseline visit
41152303|NCT02952235|OTHER|SPF50+|Sun protection
41152304|NCT02952235|OTHER|SPF100+|Sun protection
41318462|NCT00755846|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
41318463|NCT03206242|OTHER|Physiotherapy|Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
41318464|NCT03943953|BEHAVIORAL|Information and Therapy Guides|"We have developed seven self-guided information and therapy guides (ITGs), for people with facial palsy and/or their friends or relatives. We have written these guides by drawing on interventions with a strong evidence-base in other populations, such as cognitive behavioural therapy, social skills training and acceptance and commitment therapy:~1. Facial palsy: Coping with the early stages.~2. Facial palsy: Coping with comments, questions and staring.~3. Facial palsy: Communicating with confidence.~4. Facial palsy: Managing anxiety.~5. Facial palsy: Managing your mood.~6. Facial palsy: Building your self-esteem.~7. Facial palsy: Advice for friends, family and partners."
41318465|NCT02488096|DEVICE|TRUS-Guided Biopsy|The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
41475149|NCT00958867|BEHAVIORAL|Exercise program (AT)|Six-month, twice-weekly aerobic training (AT) program
41475150|NCT00958867|BEHAVIORAL|Exercise training (RT)|Six-month, twice-weekly resistance training (RT) program
41475151|NCT00958867|BEHAVIORAL|Exercise training (S & R; control)|Six-month, twice-weekly stretch \& relax (S \& R; control) program
40801272|NCT03748706|DRUG|PTI-125, 100 mg tablets|PTI-125, 100 mg tablets taken twice a day for 28 days
40801273|NCT04182477|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Neuro-cognitive test evaluating general mental status and performance
40801274|NCT00976287|PROCEDURE|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
41152305|NCT01538901|OTHER|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
41152306|NCT01538901|DRUG|imiquimod 5% cream|250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
41152307|NCT03894280|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals|2 inhalations in one study period
41475152|NCT00697970|BIOLOGICAL|HBsAg formulated with different concentrations of MPL and Aluminium Salts|Intramuscular injection, 3 doses
40801275|NCT00976287|PROCEDURE|Conserved Therapy|Conserved Therapy
41152308|NCT03894280|DRUG|SERETIDE DISKUS® 250/50 inhalation powder/GSK|2 inhalations in one study period
41152309|NCT03894280|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
41152310|NCT03533803|DRUG|Indomethacin 100Mg Suppository|Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
41475153|NCT00697970|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
40801276|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
40801277|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
40801278|NCT05521191|DRUG|RGLS8429|Solution for subcutaneous injection
40801279|NCT05521191|DRUG|Placebo|Solution for subcutaneous injection
41318466|NCT02488096|DEVICE|MRI + TRUS-Guided Biopsy|"A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.~The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy \~ 1 week after the MRI."
41475154|NCT02359201|DRUG|V0018|Oromucosal - Single dose
41475155|NCT02359201|DRUG|Placebo|Oromucosal - Single dose
41475156|NCT05676255|BEHAVIORAL|Cognitively-Based Compassion Training for Survivors|"CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
41475157|NCT05676255|BEHAVIORAL|Cognitively-Based Compassion Training for Dyads|"CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
41152311|NCT03533803|PROCEDURE|IVF/ICSI|patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.
41152312|NCT06585228|DIAGNOSTIC_TEST|Cardiac Computed Tomography|Cardiac CT acquired during the acute stroke imaging protocol
41152313|NCT06585228|DIAGNOSTIC_TEST|Transesophageal echocardiography|Ultrasound through the oesophagus to assess cardiac structures.
41152314|NCT06585228|DIAGNOSTIC_TEST|Repeated Cardiac Computed Tomography|A second cardiac CT performed after the TEE.
41152315|NCT05409066|DRUG|Epcoritamab|Subcutaneous Injection
41152316|NCT05409066|DRUG|Rituximab|Intravenous Infusion
41152317|NCT05409066|DRUG|Lenalidomide|Oral Capsules
40801287|NCT01213459|PROCEDURE|Cervical samples|Human papillomavirus detection and typing in cervical samples.
40801288|NCT01213459|OTHER|Data collection|Questionnaire completion
40801289|NCT04795115|OTHER|Auditory rhythmical cueing|Auditory rhythmical cueing intervention targeting balance and gait for 30 minutes x5 per week for 3 weeks.
40801290|NCT03302689|DRUG|Levobupivacaine Solution|TAP-block with Levobupivacaine 0,3% - 25 ml from each side
40801291|NCT03302689|DRUG|Ropivacaine Solution|TAP-block with Ropivacaine 0,3% - 25 ml from each side
40801292|NCT00025571|DRUG|HPPH|
40801293|NCT02701244|RADIATION|Permanent Breast Seed Implant (PBSI)|Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
40801294|NCT05691790|BEHAVIORAL|MMA and patient activation intervention scheme|"Design of booklet for older people's preventive care: We propose that the booklet will include 8 main topics based on what experts and current academic literature believe are important for encouraging older people's preventive care utilization. To add the social norms-related cues for the later three topics of the booklet, one qualitative study on older adults who are active in preventive care is needed. Therefore, we will interview \~20 older adults aged 70 years or above who are active in taking preventive care. We will conduct one-to-one in-depth interview to explore how participants overcome difficulties during decision making for vaccination and their positive feelings after making achievements. We will also explore and identify older adults who have a positive future perspective.~Patient activation sections: . Four undergraduate medical students will be trained as the coaches to deliver the patient activation sections over six weeks. Each section will be around 20 min."
41005119|NCT05520671|OTHER|Conventional quizzing platform|"The conventional quizzing platform will be a modified version of TESLA-G with all gamification elements removed. The same set of questions as the gamified version will be used. Upon entering the quiz, a question stem and five choices will be shown. When an option is selected, the right answer along with its explanation will be indicated. The next question will then be sent, and this process repeats until the participant leaves the platform or has answered every question.~Questions will be queued in blocks, with each block corresponding to a particular topic in endocrine surgery. Unlike the gamified version, questions within each block will be randomised, regardless of their level on the Bloom's taxonomy. Participants will also not be informed of the level of Bloom's taxonomy for individual questions. The access link to the platform will be sent to participants from an automated Telegram bot, and this access will last for 14 days."
41005120|NCT03301324|DEVICE|Intubation Assist Dashboard|The ZOLL X Series Intubation Assist Dashboard feature guides the operator through a three-step auscultation process to verify the proper placement of an endotracheal tube.
41005121|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected.
41005122|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected
41005123|NCT05572983|DRUG|Chidamide combined with CHOP|A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po
41005124|NCT05572983|DRUG|Chidamide|Chidamide: 20mg，qw（d1,d4）,po
41152318|NCT05097183|PROCEDURE|Accurate Commissural Alignment (ACA)|Software based, computed tomography analysis that allows planification of accurate commissural alignment of TAVR by inserting the delivery system in a patient-specific degree of rotation.
41318467|NCT02719236|PROCEDURE|direct anterior approach|"The procedure begins by positioning the patient supine on a normal table . Both feet are draped separately to assist with dislocating and proximal femural shaft exposure.The surgical incision begins 2-4 cm lateral to the anterior superior iliac spine of the pelvis . It is then carried distally and laterally for about 8-12 cm. After protecting the lateral femoral cutaneous nerve, the fascia overlying the tensor fascia latae (TFL) is incised, and a plane is then developed between the TFL and sartorius. After coagulating the ascending branch of the lateral femoral circumflex artery, a capsulectomy is performed. Placement of the final acetabular component is facilitated by the use of an offset inserter handle.~Femoral preparation begins by placing the operative limb in a position of extension, adduction and external rotation to improve the accessibility of the proximal femur.~Once the final implants are in situ, the hip is reduced and assessed."
41475158|NCT05676255|BEHAVIORAL|Health Education|"HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves.~HE will be administered to both breast cancer survivors and supportive partners together.~Module I (Week 1): Cancer Advocacy.~Module II (Week 2): Health Through the Lifespan.~Module III (Week 3): Nutrition.~Module III (Week 4): Nutrition.~Module IV (Week 5): Physical Activity.~Module V (Week 6): Sleep.~Module VI (Week 7): Stress.~Module VII (Week 8): Mental Health and Social Support."
41475159|NCT01247779|PROCEDURE|gynecologic surgery - standard coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
41475160|NCT01247779|PROCEDURE|gynecologic surgery - robot assisted coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
41475161|NCT03302572|OTHER|Brief information group|Patients will be given oral brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
40801295|NCT05691790|BEHAVIORAL|Control Group|"Participants in the control group will receive a pamphlet about recommendation for influenza, pneumococcal, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. As a control for the patient activation interviews, the control group will also be informed that they will join our telephone-based elderly care project by the end of the baseline assessment but instead of receiving the patient activation interviews, this group will receive six control telephone care visits over six weeks. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health."
41152319|NCT06048471|OTHER|HiTop|High tone transcutaneous electrical stimulation
41152320|NCT00023465|PROCEDURE|FDG-PET|
41152321|NCT00023465|PROCEDURE|spirometry|
41152322|NCT00023465|PROCEDURE|bronchoscopy with BAL|
41152323|NCT03138356|DRUG|2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet|Used in Treatment B and Treatment E.
41005125|NCT01456442|DEVICE|anorectal manometry|High-resolution anorectal manometry is done under standard clinical conditions with a 10 cm catheter inserted into the rectum loaded with pressure transducers at a distance of 6 mm in the sphincter area and an attached latex balloon at the catheter tip. It will measure the length of the anal sphincter, the static pressure and the clamping pressure during at least 3 over 40 seconds sustained maneuvers according to a standardized protocol. Mean and maximum pressure increase over the resting pressure during the first 30 seconds of the squeeze and the maximum possible squeeze time will be documented. Moreover, the initial anorectal perception threshold, the perception of urge to defecate and maximum tolerable volume balloon will be documented.
41005126|NCT01456442|DEVICE|barostat|For the barostat study a balloon will be attached to the catheter. Instead of a barostat machine a 60ml syringe and a sphygmomanometer will be connected to the catheter and the catheter will be positioned in the rectum. The balloon is then dilated gradually to assess perception, urge and discomfort threshold in relation to rectal volume.
41005127|NCT03289507|DIETARY_SUPPLEMENT|Treatment1|Longvida Capsule formulation A
41005128|NCT03289507|DIETARY_SUPPLEMENT|Treatment2|Longvida Capsule formulation B
41005129|NCT03289507|DIETARY_SUPPLEMENT|Treatment3|Curcuma longa extract of Rhizomes
41005130|NCT05268250|BEHAVIORAL|R2D2 mHealth intervention|R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
41005131|NCT00112203|DRUG|Itopride|
41005132|NCT02399085|DRUG|Tafasitamab|12 mg/kg
41005133|NCT02399085|DRUG|Lenalidomide|25 mg
41005134|NCT02047799|DIETARY_SUPPLEMENT|Calcitriol|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)
41005135|NCT02047799|DIETARY_SUPPLEMENT|Control|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
41005136|NCT01161758|OTHER|Passive cervical mobilisation|Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
41152324|NCT03138356|DRUG|2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet|Used in Treatment A and Treatment D.
41152325|NCT03138356|DRUG|5 mg dapagliflozin / 850 mg metformin XR FDC|Used in Treatment H.
41318468|NCT02719236|PROCEDURE|direct lateral approach|"The procedure begins by positioning the patient in the supine decubitus position.~A longitudinal incision is made extending 3-5 cm proximal and about 5-8 cm distal to the tip of the greater trochanter . The fascia is split at the interval between the TFL and gluteus. The tendon and muscle fibres of the gluteus medius are then visualized and split . The gluteus minimus and joint capsule are split. The surgeon then dislocates the femoral head, and performs a femoral neck osteotomy.~The acetabulum is prepared .Soft tissue landmarks and reamer positioning relative to the floor are used to verify acetabular version and inclination.~When preparing the proximal femur, the hip is adducted and externally rotated, with the knee flexed. The femural stem is then press-fitted. Once the final implants are in situ and the hip is reduced, the stability of the construct is assessed."
41318469|NCT02665364|BIOLOGICAL|IFNα-Kinoid|
41318470|NCT02665364|OTHER|Placebo|
41318471|NCT02665364|OTHER|ISA 51 VG|
41318472|NCT01148316|DRUG|fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
41318473|NCT01148316|BEHAVIORAL|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
41475162|NCT00191464|DRUG|premeal insulin lispro mixtures|
41475163|NCT00191464|DRUG|insulin glargine|
41475164|NCT00191464|DRUG|metformin|
41475165|NCT00668720|DEVICE|transcranial magnetic stimulation (Magstim rapid2)|Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.
41475166|NCT00668720|DEVICE|sham stimulation|The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
41475167|NCT02029781|PROCEDURE|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
41005137|NCT01161758|OTHER|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique. The light manual contact consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
41005138|NCT04940845|DRUG|HS-20090-2|Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
41005139|NCT04940845|DRUG|Prolia|Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
41005140|NCT04230148|DRUG|Egaten (Triclabendazole) 250 mg tablets|Egaten 250 mg scored tablets for oral use.
41005141|NCT04608266|DRUG|Camostat Mesylate|Camostat mesylate, oral administration 600mg/day (2 x 100mg tablets every 8 hours) for 14 days
41005142|NCT04608266|DRUG|Placebo|Placebo tablets, oral administration 2 tablets every 8 hours for 14 days
41005143|NCT06125821|OTHER|questionnaire|questionnaire
41005144|NCT01479907|DIETARY_SUPPLEMENT|Synbiotics|12 gr in 250 cc of water once daily X 15 days
41005145|NCT01479907|DIETARY_SUPPLEMENT|Placebo|12 gr in 250 cc of water once daily X 15 days
41152326|NCT03138356|DRUG|5 mg dapagliflozin / 1000 mg metformin XR FDC|Used in Treatment G.
41152327|NCT03138356|DRUG|2.5 mg ONGLYZA® (saxagliptin) tablet|Used in treatments C and F.
41152328|NCT03138356|DRUG|5 mg Forxiga® (dapagliflozin) tablet|Used in treatments C, F and I.
41152329|NCT03138356|DRUG|500 mg Glucophage XR®|Used in treatments C, F and I.
41152330|NCT02331771|DRUG|Donepezil|Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
41318474|NCT05625854|BEHAVIORAL|Blow a fan to the face combine aromatherapy|Blow a fan with aromatherapy to the face
41318475|NCT05625854|BEHAVIORAL|Blow a fan to the face|Blow a fan to the face
41318476|NCT05625854|BEHAVIORAL|Blow a fan to the feet|Blow a fan to the feet
41318477|NCT01827930|DRUG|Imatinib Mesylate 600 MG Oral Tablet|Imatinib Mesylate for CP CML
41318478|NCT01827930|DRUG|Imatinib Mesylate 400 MG Oral Tablet|Imatinib Mesylate for CP CML
41318479|NCT01827930|DRUG|Imatinib Mesylate|Imatinib Mesylate for CP CML
41005146|NCT00183716|BEHAVIORAL|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
41005147|NCT00183716|BEHAVIORAL|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
41005148|NCT02835274|DEVICE|BSC Deep Brain Stimulation System with Directional Lead|
41005149|NCT03023566|DRUG|Dotarem|Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
41005150|NCT03973242|DEVICE|Dual focus with narrow band imaging|dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
41005151|NCT01185873|DRUG|danoprevir|Repeated oral doses
41005152|NCT01185873|DRUG|ritonavir|Repeated oral doses
41005153|NCT02457533|BEHAVIORAL|Lifestyle behavioral. Health plan, telephone support|'Lifestyle behavioral. Health plan, telephone support'
41005154|NCT04578847|DRUG|Imatinib|Initial dose - 400 mg daily. If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
41005155|NCT04578847|DRUG|Nilotinib|Initial dose - 300 or 400 mg twice daily. If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.
41005156|NCT04578847|DRUG|Dasatinib|Initial dose 100 or 140 mg daily. If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.
41005157|NCT04578847|DRUG|Bosutinib|Initial dose 500 mg daily. If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.
41005158|NCT00855088|DRUG|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
41005159|NCT00855088|DRUG|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
41005160|NCT00855088|DRUG|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
41005161|NCT06084195|BIOLOGICAL|Blood sample and tissue sample|"During the surgery :~* Tissus sample : primary tumor and metastasis~* blood sample : 3 EDTA tubes~* ex vivo MRI data"
41005162|NCT06212102|DRUG|Progestin primed ovarian stimulation|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
41005163|NCT06212102|DRUG|GnRH antagonist|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
41005164|NCT00448422|DRUG|prulifloxacin|Tablet
40801296|NCT03776812|DRUG|Relacorilant, 100mg QD|Relacorilant is supplied as capsules for oral dosing
40801297|NCT03776812|DRUG|Nab-paclitaxel, 80mg/m^2|Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
41005165|NCT00220025|DEVICE|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
41005166|NCT00647621|DRUG|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
41005167|NCT00647621|DRUG|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
41005168|NCT03331068|BEHAVIORAL|online questionnaire of MAX-PC|Scale measuring of the anxiety specific of prostate cancer, French version.
41005169|NCT03450707|DRUG|Thiamine 500 mg IV|Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.
41005170|NCT03450707|OTHER|Placebo|100mL of intravenous normal saline will be given every 12hours for 5 doses in the placebo arm
41005171|NCT02243150|DRUG|G1T28-1 (CDK 4/6 Inhibitor)|
41005172|NCT02243150|DRUG|Placebo|
41005173|NCT00351234|DRUG|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
41005174|NCT02151708|DRUG|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
41005175|NCT02151708|DRUG|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
41005176|NCT01715506|BEHAVIORAL|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
41005177|NCT06292715|PROCEDURE|microwave ablation of the spleen|Ultrasound-guided percutaneous puncture for splenic ablation treatment
41005178|NCT06292715|OTHER|Splenic artery balloon implantation|Splenic artery balloon implantation
41005179|NCT03734120|OTHER|cryopreservation|Samples were frozen with a programmable freezing unit. Each semen sample was divided into two aliquots. One aliquot was plunged into liquid nitrogen and the other was stored in dry-phase nitrogen for 3 or 6 month. Thawing was performed at room temperature
41005180|NCT00632554|DRUG|prednisolone 0.5 mg/kg/day for three months|period of treatment
41005181|NCT00632554|DRUG|prednisolone 0.5 mg/kg/day for six months|period of therapy
41005182|NCT01867034|OTHER|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
41005183|NCT01867034|OTHER|Bare Metal Stent|
41005184|NCT02285231|DIETARY_SUPPLEMENT|Arginyl-fructose|
41005185|NCT02285231|DIETARY_SUPPLEMENT|Placebo|
41318480|NCT04785391|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
40801298|NCT03776812|DRUG|Nab-paclitaxel, 100mg/m^2|Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
40801299|NCT03776812|DRUG|Relacorilant, 150mg QD|Relacorilant is supplied as capsules for oral dosing
41152331|NCT02331771|DRUG|Placebo|Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
41152332|NCT00471549|DRUG|Statin (simvastatin)|
41152333|NCT03623100|BEHAVIORAL|Speech Production Treatment.|Speech production treatment will be delivered in two phases: Imitation and Spontaneous Production. Treatment will be provided two times weekly in 1-hour sessions, for up to 19 sessions. Every child's intervention program will target a single phoneme that was excluded from his or her phonemic inventory. Each treatment phoneme will be targeted through the production of five words that will be initially introduced to the child using a storybook reading format. Imitation treatment will continue until a child maintains 75% accurate production of the treated phoneme over two consecutive sessions (i.e. performance-based criterion) or until seven consecutive sessions are completed (i.e. time-based criterion). Spontaneous Production will continue until the child maintains either a performance-based criterion of 90% accurate production of the treated phoneme over 3 consecutive sessions, or a time-based criterion of 12 consecutive sessions.
41318481|NCT01945424|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|No Intervention as part of this protocol
41318482|NCT05711199|DRUG|Glyceroltrinitrat|transdermal patch
41318483|NCT04566822|BEHAVIORAL|High Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
41318484|NCT04566822|BEHAVIORAL|Medium Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
41318485|NCT04566822|BEHAVIORAL|Low Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
41318486|NCT04566822|BEHAVIORAL|Sleep Education Control|Participants in the sleep education control will not have access to a coach. Weekly sleep education will be accessible to the participant on a weekly basis. The sleep education content will be the same that is provided to the intervention participants.
41318487|NCT05528770|DEVICE|FCL+BPS|The automated insulin delivery system includes the Bolus Priming System, a software automatically analyzing past continuous glucose monitoring values to trigger priming insulin bolus delivery isn the suspected presence of meal like glycemic disturbances
41318488|NCT05528770|DEVICE|FCL|The automated insulin delivery system does not include the Bolus Priming System, and therefore does not automatically command priming boluses.
40801300|NCT02810288|BEHAVIORAL|Voluntarily response all items in the questionnaire.|"The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician."
40801301|NCT02531139|OTHER|MAP maintained at 80 mmHg|Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
40801302|NCT02531139|OTHER|MAP maintained at 60 mmHg|Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
40801303|NCT01017042|DRUG|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
40801304|NCT04177589|OTHER|Incidence of Delirium in Inpatient Elderly Patients|Study design: prospective cohort study.
40801305|NCT04963816|PROCEDURE|ultrasound guided quadratus lumborum block|Ultrasound guided quadratus lumborum block will be done to all groups using curved array transducer 5_2 MHz with the patient in supine position and the block will be done by anterior approach
40801306|NCT04963816|DRUG|Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given intravenously in group A
40801307|NCT04963816|DRUG|Bupivacaine Injection|Bupivacaine will be given to all groups locally with QLB
40801308|NCT04963816|DRUG|Dexamethasone Phosphate 4 MG/ML Injectable Solution locally|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given locally in Group B
40801309|NCT01682317|BEHAVIORAL|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, \< 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
40801310|NCT00690690|BEHAVIORAL|Video (group-delivered video-based intervention)|group-delivered video-based intervention
40801311|NCT00690690|BEHAVIORAL|HCT|Offer of HIV counseling and testing
40801312|NCT03281031|PROCEDURE|Additional MRI Examination|MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
40801313|NCT02473094|DRUG|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
40801314|NCT02473094|DRUG|Metformin|Metformin up to 2500mg/d
40801315|NCT02473094|RADIATION|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
40801316|NCT02473094|DRUG|Placebo|Placebo up to 2500mg/d
40801317|NCT01482806|BEHAVIORAL|CCBT+ISG/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
40801318|NCT01482806|BEHAVIORAL|CCBT/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
40801319|NCT00135538|DEVICE|Noninvasive positive pressure ventilation|
41005186|NCT05276804|DRUG|Sugammadex|The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
41005187|NCT04871334|DRUG|TWP-101|IV infusion Q2W for 4 weeks (28-day cycles)
41005188|NCT05510297|DEVICE|FitSitt Prototype|FitSitt merges features of a posture chair, exercise machine, and tracking means. It provides seated stepping, postural support, and semi-recline capabilities. A digital interface and app will allow users to set goals and track performance.
41005189|NCT01221974|DEVICE|Essure Micro Insert|
41005190|NCT02603809|DRUG|Aprocitentan 5 mg|One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
41005191|NCT02603809|DRUG|Aprocitentan 10 mg|Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.
41005192|NCT02603809|DRUG|Aprocitentan 25 mg|One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
41005193|NCT02603809|DRUG|Aprocitentan 50 mg|One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
41005194|NCT02603809|DRUG|Lisinopril 20 mg|One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan
41005195|NCT02603809|DRUG|Placebo|One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
41005196|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
41005197|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
41005198|NCT03962803|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
40801320|NCT02081508|BEHAVIORAL|Interference onset|Temporal duration of interference onset.
41005199|NCT01930058|DRUG|MK-8876|MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
41005200|NCT02993575|DRUG|Flucloxacillin|Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
41005201|NCT02934230|BEHAVIORAL|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
41005202|NCT03731533|BEHAVIORAL|WellStart|"1. Five weekly automated text messages linked to an online article on health and wellness.~2. Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~3. Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~4. Three group (up to 20 participants) health coach online visits (60 minutes).~5. Two online group visits with a dietitian in groups of 10-12 participants.~6. Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes)."
41005203|NCT05209685|OTHER|Resistance exercise on the lower extremities|Resistance exercise mainly on the lower extremities will be executed by carrying weight according to each participant's tolerance while performing certain movements, such as side step-up, sit-to-stand, and tip-toe-standing.
41005204|NCT05209685|OTHER|Resistance exercise on the lower extremities with blood flow restriction|Blood flow restriction on the thigh of the dominant leg will be used in combination with resistance exercise.
41005205|NCT05408481|DIAGNOSTIC_TEST|Serum cortisol level|Biochemical test
41005206|NCT01296516|BEHAVIORAL|Non-intervention group|A pedometer and written material on a healthy lifestyle.
41005207|NCT01296516|BEHAVIORAL|Face to face|Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.
41005208|NCT01296516|BEHAVIORAL|Telehelath Group|Participants will speak to Trestletree personnel once a week via phone.
41005209|NCT05594342|DRUG|Ivabradine 7.5Mg Tab|Patients will receive ivabradine 7.5 mg twice daily via oral route after dobutamine infusion by 30 minutes.
41005210|NCT05594342|DRUG|DOBUTamine Injectable Solution|Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute
41005211|NCT05466578|DRUG|abrocitinib|
41005212|NCT01176552|DRUG|GM-CSF, IFN alpha and IL-2|Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
41005213|NCT02357576|DRUG|Intralipid 20% I.V. Fat Emulsion|
41005214|NCT02722928|OTHER|Controlled Ventilation with 100% oxygen|Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
41318489|NCT03026335|BEHAVIORAL|Positive Action|Based upon a Cognitive Behavioral Therapy model, intervened schools were engaged in providing curriculum, school infrastructure elements, and parent/community involvement activities around a single model aimed to provide positive support for behaviors. Six areas were identified: self-concept, body/mind, responsible self-management, treating others they way you want to be treated, telling yourself the truth, and continual improvement of self.
41318490|NCT03026335|BEHAVIORAL|Control|Business as usual with students in non-itervened schools
41318491|NCT05779332|OTHER|survey application|Children's OHRQoL was measured by the Child Perceptions Questionnaire (CPQ8-10). Oral examination of children were conducted for presence and severity of MIH, dental caries experience and oral hygiene status.
41475168|NCT04783194|DRUG|Dexamethasone+ Bupivacaine|Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
41005215|NCT04348513|DRUG|T3 solution for injection|For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.
41005216|NCT04348513|DRUG|Placebo|Same as with T3 solution for injection.
41005217|NCT04814069|DRUG|Tislelizumab|Tislelizumab 200mg q3w
41318492|NCT02810652|OTHER|Usual Care|Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
41318493|NCT02810652|OTHER|Perioperative Geriatrics Intervention|Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
41005218|NCT01155895|DRUG|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
41005219|NCT00502697|BEHAVIORAL|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
41005220|NCT00502697|OTHER|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
41005221|NCT01826500|OTHER|blood test|blood test
41005222|NCT04633096|BEHAVIORAL|tailored feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
41005223|NCT04633096|BEHAVIORAL|standardized feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
41318494|NCT05690334|DRUG|Crystalloid - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
41318495|NCT05690334|DRUG|Crystalloid - 5 ml/kg|5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
40801321|NCT00873821|DRUG|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
40801322|NCT00873821|DRUG|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
40801323|NCT06340724|DRUG|Vonoprazan|20 mg tablet twice daily
41005224|NCT04429009|DEVICE|ZEPHYRx Respiratory Therapy (RT) System|A breath controlled video game system for respiratory therapy
41005225|NCT04429009|DEVICE|Standard Incentive Spirometer|A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
41318496|NCT05690334|DRUG|Crystalloid - 10 ml/kg|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
41318497|NCT01763463|DRUG|New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications|Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
40801324|NCT06340724|DRUG|Amoxicillin|1 g tablet three times daily
40801325|NCT06340724|DRUG|Banxiaxiexin decotion|100 ml liquid-medicine twice daily
40801326|NCT00003420|PROCEDURE|computed tomography|
41005226|NCT02262351|OTHER|30 Second Pulse Check|To detect atrial fibrillation
41005227|NCT02262351|DEVICE|Watch BP Home A|Blood pressure device that detects atrial fibrillation
41005228|NCT02262351|DEVICE|HeartCheck Hand-held ECG device|To detect atrial fibrillation
41005229|NCT01889017|OTHER|patient questionnaire (tablet pc based)|
41005230|NCT02928328|DRUG|GABA oral solution|Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
41005231|NCT02928328|DRUG|Intramuscular GABA|The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline
41005232|NCT02928328|DRUG|Pain modulation|The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
41005233|NCT02203591|DRUG|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
40801327|NCT03935867|BEHAVIORAL|C-PROFET|An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
41005234|NCT02203591|DRUG|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
41005235|NCT02203591|DRUG|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
41005236|NCT02203591|DRUG|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
41005237|NCT01934634|DRUG|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
41005238|NCT01934634|DRUG|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
41005239|NCT01934634|DRUG|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
41005240|NCT03945812|DRUG|Granulocyte Colony Stimulating Factor|Filgrastim, Amgen, California, USA 300 mg/1.0 mL
41005241|NCT03945812|OTHER|Platelet Rich Plasma Arm|Platelet Rich Plasma Arm
41005242|NCT03945812|OTHER|Saline|Saline 9%
41005243|NCT05589064|BEHAVIORAL|Experimental: Dietetic counseling|Patients will receive dietary counselling to increase caloric and nutrient intake, stabilize glycemia, and optimize hydration.
41005244|NCT05589064|DIETARY_SUPPLEMENT|Active Comparator: Omega-3, vitamin D3 and creatine monohydrate|Patients will be prescribed dietary supplements which will be taken daily for 8 weeks, as per the supplement protocol.
41152334|NCT03623100|BEHAVIORAL|Speech Production + Speech Perception Treatment.|This speech treatment condition will be administered in the same way as the Speech Production treatment. The difference in conditions will be that speech treatment in this condition will last for 50 minutes rather than 60 minutes. The remaining 10 minutes of each session will involve the speech perception training. These speech perception tasks will involve previously recorded word-level productions focusing on the same phoneme that is addressed in speech production treatment in word-initial position. A variety of words produced correctly and incorrectly by adults and children will be presented in pairs and the children will have to determine if the words contain the same word-initial phoneme or two different phonemes.
41005245|NCT05589064|BEHAVIORAL|Other : Physiotherapy treatment|Patients will receive weekly physiotherapy treatment.
40801328|NCT03098433|DRUG|Liothyronine|Single dose
40801329|NCT03098433|DRUG|Levothyroxine|Active comparator
40801330|NCT03098433|DRUG|Placebos|Placebo
40801331|NCT04701853|OTHER|Specific abdominal muscle training|Specific abdominal muscle training
40801332|NCT04701853|OTHER|Usual care|Care according to each center.
40801333|NCT00970723|BEHAVIORAL|high blood pressure treatment|over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
40801334|NCT00970723|BEHAVIORAL|sleep apnea treatment|over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
40801335|NCT00970723|BEHAVIORAL|diabetic macular edema treatment|over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
40801336|NCT01529593|DRUG|Temsirolimus|"Starting dose: 25 mg by vein weekly.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled."
41005246|NCT01282593|OTHER|Impact of CD9 expression level on motility assays|"1) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.~Adhesion results will be validated on patient samples of B-ALL."
41005247|NCT01282593|OTHER|Post-transcriptional regulation of CD9|"2) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.~Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples."
41005248|NCT03407872|DRUG|Esketamine DPI|Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
41005249|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high."
41005250|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high."
41005251|NCT03407872|DRUG|Placebo DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations."
41005252|NCT02922452|DRUG|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
41005253|NCT02922452|DRUG|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
41005254|NCT02554110|DEVICE|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
41005255|NCT02554110|DEVICE|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
41005256|NCT05828017|DEVICE|Hearing Aid - Standard Curve|Our current hearing aids which will be programmed to our standard frequency response curve.
41005257|NCT05828017|DEVICE|Hearing Aid - Variation #1|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
41005258|NCT01234545|DRUG|activated recombinant human factor VII|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
41005259|NCT05168007|DRUG|WID-RGC20(Cariprazine) 3mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
41152335|NCT03455153|OTHER|Physical activity monitoring|COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
41318498|NCT01763463|DRUG|New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))|Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
41318499|NCT03712345|DRUG|IFX-1 low dose|Single IV infusions of IFX-1
41318500|NCT03712345|DRUG|IFX-1 high dose|Single IV infusions of IFX-1
41318501|NCT03712345|DRUG|Placebo|Placebo
41318502|NCT05439460|DRUG|Phenylephrine|5 subjects will get Phenylephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
41318503|NCT05439460|DRUG|Epinephrine|5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
41318504|NCT05439460|DRUG|Arginine Vasopressin|5 subjects will get Arginine Vasopressin during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
41318505|NCT05154266|BEHAVIORAL|Taking it Further|This programme is offered to individuals who have already completed a Mindfulness-Based Cognitive Therapy (MBCT) or Mindfulness-Based Stress Reduction Programme (MBSR). In this programme, participants explore weekly themes (i.e. 'Responding not reacting' and 'Taking care of ourselves, taking care of others'). These themes reinforce the learning from the eight-week MBCT/MBSR courses whilst also providing new learning opportunities. The programme makes some of the dimensions that are implicit in MBCT/MBSR more explicit; for example, the cultivation of attitudes of mindfulness (such as equanimity, joy, and kindness). These attitudes of mindfulness require a foundational mindfulness practice and thus this is an additive learning theme from traditional MBCT/MBSR programmes.
40801337|NCT01529593|DRUG|Metformin|"Starting dose: 500 mg titrated over first 3 weeks.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled"
41475169|NCT04783194|DRUG|Bupivacaine|Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
41475170|NCT05724368|DIAGNOSTIC_TEST|Fecal Calprotectin ELISA kit|"* Routine stool examination will be done in addition to certain concentration, staining and culture techniques.~* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions."
40801338|NCT03636672|PROCEDURE|perturbation training|perturbation training during stationary bicycle riding
40801339|NCT05007197|BEHAVIORAL|The Effect of Diabetes Education Based on Learning Modality|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people; Visual learners; education booklet, brochure, slides (enriched with pictures and videos), lecture, insulin injector-pen, glucose meters, introduction and demonstration of blood glucose tracking book Auditory learners; education booklet, slides, videos, lecture, question-answer, group work, peer group discussion, experience sharing Tactile learners; education booklet, slides, demonstration, insulin injector-pen, glucose meter doing the application of tools and equipment such as on the model, on himself, on his friend, filling in the blood glucose tracking book.~Group-specific diabetes trainings were completed in 2 training sessions. Each training session lasted an average of 1.5 hours The learning modality of the control group were determined and standard group training was provided with the education booklet."
41005260|NCT05168007|DRUG|WID-RGC20(Cariprazine) 6mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
41005261|NCT05168007|DRUG|Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day|The placebo comparator is administered during the double-blind treatment period(6 weeks).
41005262|NCT05856305|DRUG|Chlorophyllin, Sodium Copper Complex|Additional Chlorophyllin tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
41005263|NCT05856305|DRUG|Placebo|Additional Placebo tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
41005264|NCT00722917|DRUG|TAK-379|TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
41005265|NCT00722917|DRUG|TAK-379|TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
41005266|NCT00722917|DRUG|TAK-379|TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
41005267|NCT00722917|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
41152336|NCT06585501|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
41005268|NCT00722917|DRUG|Placebo|TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
41005269|NCT00572507|DEVICE|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
41005270|NCT04400721|DRUG|Erector spinae plane block with ropivacaine 3.75mg/ml|Single shot erector spinae block
41005271|NCT05213858|DIAGNOSTIC_TEST|CAPS questionnaire|PTSD diagnosis and severity will be done using the CAPS-5 questionnaire.
41005272|NCT05213858|DIAGNOSTIC_TEST|Beck Depression Inventory|depression symptoms will be measured by the BDI-II. The BDI-II consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression.
40801340|NCT05757518|OTHER|Cryosauna|The intervention was Cryosauna - cryostimulation at -110°C for 1.5 minutes, for four consecutive days.
41005273|NCT05213858|DIAGNOSTIC_TEST|The Fibromyalgia Impact Questionnaire|The FIQ was developed from information gathered from patient reports, functional status instruments and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue and well-being over the past week.
41005274|NCT05213858|DIAGNOSTIC_TEST|The Pittsburgh Sleep Quality Index|"sleep patterns will be measured using the PSQI. This index assesses the quality and patterns of sleep in adults. It differentiates poor from good sleep quality by measuring seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, the use of sleeping medications and daytime dysfunction over the last month. Items are rated using a 0 to 3 scale. The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality."
41005275|NCT05213858|DIAGNOSTIC_TEST|Depression, Anxiety and Stress Scale-21 items|The DASS-21 is a three-scale self-report questionnaire designed to measure the emotional state of depression, anxiety and stress. Each scale contains 7 items, divided into subscales with similar content. Scores range between 0 and 21 in each subcategory.
41005276|NCT05213858|DIAGNOSTIC_TEST|Traumatic Events Questionnaire|"The TEQ examines experiences of traumatic events (e.g. sexual abuse, accidents and crime) that are considered potential triggers of PTSD symptoms. To assess trauma intensity, respondents provide information for each event that was experienced, as well as their age at the time of the event. The items are measured on a 9-point Likert scale from not at all to severely/extremely. The TEQ has previously been used in Israel."
40801341|NCT04558541|OTHER|Sensitivity to phonological rules|Assess whether children with developmental language disorder (DLD) are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon; children with speech sound disorder (SSD) are not predicted to be sensitive to the same phonological patterns.
40801342|NCT04558541|OTHER|Sensitivity to semantic category cues.|Assess whether all children, including those with DLD, show improved learning of OR rules when a semantic category cue is used.
41005277|NCT05213858|DIAGNOSTIC_TEST|Clinician Administered Dissociative States Scale|The CADSS is a 28-item structured clinical interview to assess state dissociation.
41005278|NCT05213858|DIAGNOSTIC_TEST|A diary will be used for seven consecutive nights|"A diary will be used for seven consecutive nights for the evaluation of:~* Mean sleep latency~* The number and duration of awakenings.~* Subjective total sleep time~* Subjective wake after sleep onset~* Sleep efficiency"
41005279|NCT05213858|DIAGNOSTIC_TEST|MRI|Brain imaging will include DTI and resting state for structural and functional MRI scanning. Images will be acquired on MAGNETOM Vida 3T Scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at the Department of Radiology at Shamir Medical Center.
41005280|NCT05213858|DIAGNOSTIC_TEST|Functional brain imaging|Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain. This technology measures brain activity by detecting changes associated with blood oxygenation, using blood-oxygen-level-dependent imaging (BOLD) contrast.
41005281|NCT05213858|DIAGNOSTIC_TEST|EEG analysis|EEG will be obtained using a point-of care device that consists of an EEG-Sense Headset, EEG-Sense Single-Use brush sensors, a pneumatic sensor positioning mechanism, EEG sampling electronics and software. The EEG-Sense Headset is an EEG electrode positioning system that quickly places electrodes in a uniform and consistent manner, to transfer electrophysiological EEG signals from an individual to a suitable EEG data collection device. The device is nonsterile, non-invasive and non-radiation emitting, and was developed for use in healthcare facilities and hospitals. Typical set-up and procedure time is several minutes. The device does not contain biologics, drugs, coatings or any claim of sterility. The EEG-Sense Single-Use brush sensors are made from well-established medical-grade materials; the Headset is made from Nylon 101. Electronic components and harnesses are embedded between two layers of nylon and are attached to each electrode port.
41318506|NCT05263128|OTHER|Investigation of the validity of the Hand-20 Questionnaire in individuals with carpal tunnel syndrome|To investigate the validity and reliability of the Hand-20 questionnaire used in individuals with upper extremity disease by comparing it with the Boston carpal tunnel syndrome questionnaire in individuals with carpal tunnel syndrome in Turkey
41318507|NCT04846166|DIAGNOSTIC_TEST|Periodontally healthy group|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium
41318508|NCT04846166|DIAGNOSTIC_TEST|Periodontitis|: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth
41475171|NCT05275972|DRUG|Ripasudil|Topical Ripasudil 0.4%
40801343|NCT04317339|DRUG|Zhigancao Tang granule|"Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
41005282|NCT05213858|DIAGNOSTIC_TEST|Autonomic nervous system monitors|"Data will be collected using Empatica's E4 wristband. Each of the study participants will wear the wristband for 7 days.~Data collected from the band will include:~ACC - Data from 3-axis accelerometer sensor in the range \[-2g, 2g\]. (sampled at 32 Hz) BVP - Data from photoplethysmography (PPG). (sampled at 64 Hz) EDA - Data from the electrodermal activity sensor in μS. (sampled at 4 Hz) IBI - Inter-beat intervals. (intermittent output with 1/64 second resolution) TEMP - Data from temperature sensors, expressed in degrees on the Celsius (°C) scale. (sampled at 4 Hz)"
40801344|NCT04317339|DRUG|Zhigancao Tang placebo granule|"Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
41005283|NCT01172548|DRUG|imatinib mesylate|
41005284|NCT03159884|DRUG|Conbercept|
41318509|NCT01086046|DRUG|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days."
41318510|NCT05874687|DRUG|hypotension + treat|Heart Rate and Mean Arterial Pressure (MAP) will be recorded throughout the procedure (every 2 minutes for the first 15 minutes). Ephedrine (in 6 mg increments) will be used as well as the isotonic balanced crystalloid solution to treat hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg (250 mL bolus). The Ephedrine dose will be recorded. Bradycardia, which is defined as a heart rate less than 50 beats per minute, will be treated with intravenous Atropine (0.5 mg).
41318511|NCT05101460|DEVICE|XVIVO Perfusion System (XPS™) with STEEN Solution™|XVIVO Perfusion System (XPS™) with STEEN Solution™
41318512|NCT02494388|PROCEDURE|Endoscopic ultrasound guided needle based confocal endomicroscopy|Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
41318513|NCT01600768|DRUG|Beta-Lactams|infusion time: 30 mins or 1 hr
41318514|NCT01600768|DRUG|Beta-Lactams|infusion time 4 hrs
41318515|NCT01469806|DEVICE|Zimmer Gender Solutions PFJ Knee Prosthesis|Partial knee arthroplasty of the patello-femoral joint
41318516|NCT04334915|DRUG|Cenicriviroc Mesylate (CVC)|Administered orally
41318517|NCT04334915|DRUG|Placebo|Administered orally
41318518|NCT02558556|DEVICE|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
41318519|NCT02558556|OTHER|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
41318520|NCT05688501|OTHER|descriptiv group|no intervention
40801345|NCT05441423|RADIATION|CBCT|CBCT Scans. conventional \& ultra low dose
40801346|NCT05612893|OTHER|pathogen|"The patients were divided into groups according to the pathogen(bacteria or virus).~The influenza upper respiratory tract infection cohort will be grouped mainly according to age."
40801347|NCT01861691|PROCEDURE|Open surgery|Conventional technique
40801348|NCT01861691|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
40801349|NCT03673280|PROCEDURE|Quadratus Lumborum Block|Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
41005285|NCT01289925|DIETARY_SUPPLEMENT|Selenium|200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.
41005286|NCT01289925|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
41318521|NCT02157506|DRUG|CXL-1427|
41005287|NCT00596011|DRUG|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
41005288|NCT00596011|DRUG|Placebo|Matching placebo BID
41005289|NCT04694196|DEVICE|Dentulous subjects|Determine the occlusal plane using CN in anterior border of ramus
41318522|NCT02157506|DRUG|Placebo|
41475172|NCT05275972|DRUG|Placebo|Topical Placebo
40801350|NCT04165408|DEVICE|Contino|The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
41475173|NCT03995017|DRUG|Rucaparib|Rucaparib tablet
41318523|NCT02172092|DRUG|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
41318524|NCT01760941|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
41475174|NCT03995017|DRUG|Ramucirumab|Ramucirumab intravenous solution
40801351|NCT03459469|DRUG|Tegavivint|This is an Investigational drug
41475175|NCT03995017|DRUG|Nivolumab|Nivolumab intravenous solution
41475176|NCT05429697|DRUG|SMT-NK inj.+Pembrolizumab|"SMT-NK inj. will be administered as an intravenous (IV) infusion on Day 1,Day 7 of each 21-day cycle.~Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle."
41475177|NCT05429697|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
40801352|NCT04888026|DEVICE|Quantitative sensory testing|"The following QSTs are conducted:~The pressure pain threshold on the tibialis anterior~The Cold-pressor test~Repeat of the pressure pain threshold to assess conditioned pain modulation"
40801353|NCT02833584|DRUG|Paracetamol|Paracetamol 500 mg x 1 tablets according to patient's body weight
40801354|NCT02833584|DRUG|Placebo|Placebo 500 mg x 1 tablets according to patient's body weight
40801355|NCT04579406|PROCEDURE|non-cardiac surgery|All the patients are undergoing non-cardiac surgery.
40801356|NCT03685474|BEHAVIORAL|Facing Your Fears - School Based|Participants receiving FYF-SB will receive cognitive-behavioral treatment (CBT), which is an evidence-based practice (EBP) for treating anxiety in typical youth, within their school setting.
40801357|NCT03685474|BEHAVIORAL|Usual Care|Participants receiving usual care will experience no different therapies, strategies, or recommendations other than what would typically be administered within the school setting in the absence of the proposed study.
40801358|NCT05790044|DRUG|Bupivacaine|intra-oral infra-orbital nerve block with bupivacaine alone
40801359|NCT05790044|DRUG|Clonidine|intra-oral infra-orbital nerve block with bupivacaine and clonidine
41157094|NCT05306340|DRUG|Fulvestrant|If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
41318525|NCT01760941|OTHER|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
41318526|NCT01760941|OTHER|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
41318527|NCT04721041|PROCEDURE|Washed Microbiota Transplantation (WMT)|Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5u, three times.
41475178|NCT05606952|DEVICE|Color Doppler|color Doppler with pulsed wave Doppler to accurately detect the position of epidural catheter
41475179|NCT06076369|PROCEDURE|The tubular adenoma group|Biopsy or removal of polyps for pathological examination. Collect baseline data such as gender, age, BMI, etc. If the pathology confirms a pure tubular adenoma, the observed object will be included in the group for final comparative analysis.
41475180|NCT00006387|BIOLOGICAL|QS21|
40801360|NCT03823586|DIAGNOSTIC_TEST|Questionnaire AQUA©, pediatric version|A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
40801361|NCT05073484|DRUG|BAT6021|Ⅳ infusions
41318528|NCT00141700|DRUG|Rituximab|
41318529|NCT00642018|DRUG|docetaxel|Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
40801362|NCT05073484|DRUG|BAT1308|Ⅳ infusions
40801363|NCT04660552|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 8 weeks.
41318530|NCT00642018|DRUG|LY2181308 sodium|LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
41318531|NCT00642018|DRUG|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
41318532|NCT00516425|BIOLOGICAL|pegfilgrastim|
41318533|NCT00516425|DRUG|cyclophosphamide|
41475181|NCT00006387|BIOLOGICAL|ras peptide cancer vaccine|
41475182|NCT00934596|PROCEDURE|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV \& Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
41475183|NCT00934596|DRUG|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
41318534|NCT00516425|DRUG|doxorubicin hydrochloride|
41005290|NCT06232382|OTHER|Hypnosis audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Hypnosis audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session (5 minutes).~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires (5 minutes).~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
41318535|NCT00516425|DRUG|epirubicin hydrochloride|
41318536|NCT00516425|GENETIC|proteomic profiling|
41475184|NCT01065116|DRUG|AL Blister-packs with Instruction leaflets|AL Blister packs with instruction leaflets will be dispensed
41475185|NCT01065116|DRUG|AL unit dose age specific pre-packs|Age specific colour coded Unit dose pre-packs will be used
41475186|NCT04565990|DRUG|Selexipag|Selexipag tablets will be administered orally at all dose strengths (200, 400, 600, 800, 1000, 1200, 1400 and 1600 microgram) twice daily.
41475187|NCT03652831|OTHER|Soft Tissue Mobilization with Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minute.~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
41475188|NCT03652831|OTHER|Soft Tissue Mobilization without Neural Mobilization|"* Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minutes Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
41475189|NCT02419235|OTHER|20% ethanol|Unmedicated 20% ethanol.
41475190|NCT02419235|OTHER|Homoeopathic complex|20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
41475191|NCT02638519|OTHER|Traditional Proton fMRI|Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
41475192|NCT02638519|OTHER|Hyperpolarized Xenon-129 fMRI|HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
41318537|NCT00516425|OTHER|diagnostic laboratory biomarker analysis|
41318538|NCT00516425|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
40801364|NCT00579553|DRUG|Intramuscular Progesterone|Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
40801365|NCT00579553|DRUG|Vaginal Progesterone|Vaginal Progesterone: 100 mg vaginal suppository daily
41318539|NCT00516425|OTHER|pharmacological study|
41318540|NCT00516425|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
41318541|NCT00516425|PROCEDURE|adjuvant therapy|
41318542|NCT00946530|DEVICE|Bright light|Participants uses bright light
41318543|NCT00946530|DEVICE|Control|Participants uses dim light
41318544|NCT03946826|DRUG|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
41318545|NCT03946826|DRUG|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
41318546|NCT03946826|RADIATION|Pulsed dye laser (PDL)|Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis,is effective in the treatment of psoriasis
41318547|NCT05124340|BIOLOGICAL|BCG vial vaccine|Intradermal injection
41318548|NCT05124340|BIOLOGICAL|BCG ampoule vaccine|Intradermal injection
41475193|NCT02638519|DRUG|Hyperpolarized Xenon-129|Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
41475194|NCT02638519|DEVICE|1H-129Xe Dual-Tuned Quadrature Head Coil|A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
41475195|NCT03977259|OTHER|Individually targeted fortification|"Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the base milk has protein 1 g/dL and calories 67/dL."
41475196|NCT00000486|PROCEDURE|coronary artery bypass|
40801366|NCT05738798|DIETARY_SUPPLEMENT|oral immunotherapy|oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.
41475197|NCT04203160|DRUG|CPI 613|Given intravenously
41475198|NCT04203160|DRUG|Gemcitabine|Given intravenously
41475199|NCT04203160|DRUG|Cisplatin|Given intravenously
41318549|NCT05824871|DRUG|Sudapyridine|Two weeks of loading dose followed by twenty-two weeks of maintenance dose Drug: Background regimen (BR) for RR-TB Background regimen (BR) for RR-TB selected according to WHO and local guidelines for up to 72 weeks.
41318550|NCT05824871|DRUG|Bedaquiline|"Two weeks of loading dose followed by twenty-two weeks of maintenance dose~Drug: Background regimen (BR) for RR-TB Background regimen (BR) for RR-TB selected according to WHO and local guidelines for up to 72 weeks."
41475200|NCT03765996|OTHER|Decongestive Physiotherapy|This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.
41475201|NCT03765996|OTHER|Decongestive Physiotherapy plus taping|This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
41475202|NCT03460158|DRUG|Restylane-L®|Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
41475203|NCT03460158|DRUG|Restylane-L® Lyft|Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
41475204|NCT03460158|DRUG|Restylane Silk®|Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
41475205|NCT03165955|DRUG|Oraxol|HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
40801367|NCT01434628|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
40801368|NCT02181946|DRUG|Fluconazole|
40801369|NCT02181946|DRUG|Nevirapine|
40801370|NCT01551654|DEVICE|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
40801371|NCT06179810|OTHER|Baduanjin exercise|Baduanjin exercise
40801372|NCT00861692|DRUG|argatroban|
40801373|NCT01732029|OTHER|Normobaric hypoxia chamber|
40801374|NCT00786968|DRUG|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
41318551|NCT03367065|RADIATION|Dynamic contrast enhanced computerised tomography|
41318552|NCT00219232|DRUG|Rivastigmine Transdermal Patch|
41318553|NCT04413721|PROCEDURE|RBC transfustion|When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
41318554|NCT04727606|DRUG|Ure-Na|"* Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day)~* Treatment will continue for approximately 1 month."
41318555|NCT05640856|PROCEDURE|intubation|Endotracheal tube placement
41318556|NCT05510778|DIETARY_SUPPLEMENT|Charcocaps|250 mg capsules containing Activated charcoal, Gelatin, Titanium Dioxide, and Carmine
41318557|NCT05510778|OTHER|Placebo|capsules containing \~250 mg cellulose
41318558|NCT01690169|DRUG|NNC0113-0987|A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
41475206|NCT06616090|BEHAVIORAL|Nurse Implemented Infant-Mother Attachment Security Program|The intervention will draw on video-feedback of mother-infant interactions during the well-child visit. Nurses will videotape the dyad during routine visit in the Family Health Center and show short clips to mothers during the session in order to provide mother positive feedback on their sensitive caregiving. Additionaly, intervention mothers will be exposed to the reminders (e.g., pictures, posters, short film screenings) reflecting maternal sensitivity and secure attachment in the waiting rooms of the intervention Family Health Centers.
41475207|NCT03330314|BIOLOGICAL|HM12460A|HM12460A is a long-acting insulin
41475208|NCT05336435|DIAGNOSTIC_TEST|Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin|The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
41318559|NCT01690169|DRUG|placebo|A single dose of oral placebo administered.
41318560|NCT03215082|OTHER|Vestibular-Visual Intervention|vestibular-visual exercises
41475209|NCT00804206|DRUG|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
41475210|NCT00804206|DRUG|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
41475211|NCT04652544|DRUG|Cholecalciferol (Vitamin D3)|Vi-De 3® Monthly Dose from Dr. Wild \& Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.
41005291|NCT06232382|OTHER|Mindfulness meditation audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Mindfulness Meditation audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
41475212|NCT04652544|OTHER|Placebo|A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.
41005292|NCT06232382|OTHER|Natural text audio (control audio)|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Control audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
41005293|NCT02108821|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
41475213|NCT06117943|OTHER|data collection|Pregnant women who smoke personally or are passively exposed to cigarette smoke
41475214|NCT05944458|DRUG|N acetyl cysteine|Fluimucil 600 mg iv to be taken twice daily as infusion
41005294|NCT03306342|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
41318561|NCT03215082|BEHAVIORAL|standard care|standard care
41475215|NCT03512002|DEVICE|HIRREM|Technology
41475216|NCT03512002|OTHER|Continued Current Care|Continue their current clinical care.
41475217|NCT05421793|OTHER|Fermented product of carrot derived rhamnogalacturonan I|Stimulation of human colonic biopsies with the fermented product of carrot derived rhamnogalacturonan I
41475218|NCT03736759|BEHAVIORAL|Exercise|10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
41318562|NCT04325945|DEVICE|Low level laser therapy|808nm low level laser therapy on acupuncture points
40801375|NCT06379503|OTHER|HEART YOGA|Heart yoga; It includes regular, balanced, safe light physical exercises, breathing exercises that provide breathing control, and meditation practices that include relaxation techniques.
41318563|NCT04178135|DRUG|rLH|rLH supplement from day 1 of stimulation
41318564|NCT04178135|DRUG|rLH|rLH supplement from day 6 of stimulation
41318565|NCT05220761|DIAGNOSTIC_TEST|Cornell Assessment of Pediatric Delirium|Cornell Assessment of Pediatric Delirium is a diagnostic test for PICU delirium State Behavioral Scale and Richmond Agitation and Sedation Scale are diagnostic tests for sedation and agitation in children
40801376|NCT06379503|OTHER|routine nursing care|Basic nursing care after heart surgery
40801377|NCT02282072|DEVICE|Deep brain stimulation：PINS Stimulation System|
41318566|NCT00718666|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose, as intramuscular injection
41475219|NCT05343221|DEVICE|High Fidelity Simulator|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the High Fidelity CPR Simulator. This simulator is adult human sized and specialized for CPR practice. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
41475220|NCT05343221|DEVICE|Haptic|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the 3D technology Haptic Device Simulator. This tool has a computer screen and a swing haptic pen. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
41475221|NCT05760352|DEVICE|Eccentric bike|Received eccentric cycling exercise
41318567|NCT03140995|BEHAVIORAL|Walking Programme|The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
41318568|NCT02523820|DRUG|fluticasone propionate|Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
41005295|NCT02624284|DEVICE|transcranial direct current stimulation (tDCS)|"Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS."
41152337|NCT05823051|OTHER|VASIDS-TP and Counseling Practice|VASIDS-TP will be implemented online as an individual training to the intervention group through the Microsoft Teams program, to be completed in 5 days-5 sessions in the time frames determined by the participants. The consultancy practice will start with a pre-test and participants will be assured that they can call the researcher 24/7, and the consultancy practice will be continued by phone call or messaging.
41318569|NCT02523820|DRUG|Placebo|NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
41475222|NCT05760352|DEVICE|Helmet ventilation|Using helmet ventilation during eccentric cycling exercise
40801378|NCT05289648|DRUG|Niraparib oral capsule|Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days
40801379|NCT03049358|OTHER|Physiologic Testing|Undergo UPSIT smell test
40801380|NCT03049358|OTHER|Quality-of-Life Assessment|Ancillary studies
40801381|NCT03049358|PROCEDURE|Sham Intervention|Undergo sham training
40801382|NCT03049358|PROCEDURE|Therapeutic Procedure|Undergo olfactory training
40801383|NCT03049358|OTHER|rose essential oil|patient smells rose oil in vial
40801384|NCT03049358|OTHER|lemon essential oil|patient smells lemon oil in vial
41152338|NCT00002371|DRUG|Indinavir sulfate|
41152339|NCT00002371|DRUG|Lamivudine|
41152340|NCT00002371|DRUG|Stavudine|
41152341|NCT00002371|DRUG|Zidovudine|
41318570|NCT03271788|OTHER|Mindfulness, MBSR|Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
41318571|NCT00213161|DRUG|iron supplement, iron drops|
41318572|NCT05684653|DRUG|Orelabrutinib Tablets|50 mg, single oral dose
41318573|NCT00801853|DRUG|Aerovant|Aerovant 1mg bid (dry powder)
41318574|NCT00801853|DRUG|Aerovant|Aerovant 3mg bid (dry powder)
41318575|NCT00801853|DRUG|Aerovant|Aerovant 10mg bid (dry powder)
41318576|NCT00801853|OTHER|placebo|placebo control (dry powder)
41318577|NCT03719482|DRUG|[18F]MNI-1054|Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-1054 injection and PET scan.
41318578|NCT03160664|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
41475223|NCT03163849|DRUG|Sofosbuvir , daclatasvir|Tablets
41475224|NCT03163849|DRUG|Placebos|oral tablets
40801385|NCT03049358|OTHER|clove essential oil|patient smells clove oil in vial
40801386|NCT03049358|OTHER|eucalyptus essential oil|patient smells eucalyptus oil in vial
41152342|NCT04385849|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
41152343|NCT04385849|OTHER|Saline|Sterile saline solution
41318579|NCT03160664|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
41318580|NCT03160664|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
41318581|NCT03687138|OTHER|24h urin sample|The samples will analyzed by proteomic techniques
41318582|NCT00781599|DRUG|Chantix|Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
41318583|NCT00781599|BEHAVIORAL|Adherence Counseling|Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.
41005296|NCT05855564|BEHAVIORAL|mindfulness matters|Classroom program will be provided to primary one students in eight primary schools and they will receive an 8 session mindfulness matters program, developed by Eline Snel, delivered by their teachers. Each session lasts for 30 minutes. The program includes mindfulness exercises, psychoeducation, discussion and sharing activities. For students with special needs, same programs will be delivered by teachers or social workers in small groups and each groups has 4 to 7 students. Program content is consistent with the classroom program.
41005297|NCT06382987|DRUG|Deucravacitinib|According to the product label
41005298|NCT06382987|DRUG|Apremilast|According to the product label
41152344|NCT01628822|BEHAVIORAL|Active relaxation|The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
41152345|NCT01628822|BEHAVIORAL|Placebo|Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
41152346|NCT05549479|BEHAVIORAL|Peer Matching|Participants will be matched with a peer based on evidence informed criteria. Partners will independently communicate and support each other around exercise for the duration of the study.
41475225|NCT05789758|OTHER|No Intervention|Administered as specified in the treatment arm.
41152347|NCT05549479|BEHAVIORAL|Qualified Exercise Professional Support Sessions|Dyads will participate in weekly virtual sessions with a QEP for 10 weeks. Each session will last up to 1 hour. The QEP (i.e., registered kinesiologist) will provide a tailored exercise program, focusing on aerobic activity for both individuals in the dyad based on personal circumstances, cancer-related characteristics, side effects, current fitness level (consistent with home-based exercise strategies), and personal preferences.
41475226|NCT04108247|DRUG|Abiraterone+SHR3162|Participants will receive Abiraterone combined with SHR3162 orally
40801387|NCT03049358|OTHER|canola oil placebo|patient smells canola oil in vial
41318584|NCT00781599|BEHAVIORAL|Standard Counseling|Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
40801388|NCT06140368|BEHAVIORAL|virtual reality|During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.
40801389|NCT04153981|DRUG|Insulin Glargine|Administered SC
40801390|NCT04666142|OTHER|Comparison of the personal characteristics of the experimental and control groups|General characteristics of the individuals in the experimental and control groups were compared.
40801391|NCT04666142|OTHER|Light applied experimental group, control group treated with standard intensive care lighting|"According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control"
40801392|NCT02077829|BEHAVIORAL|Illness Management and Recovery|Evidence-based practice given individually or in groups, weekly for 10-12 months.
41318585|NCT03280342|DRUG|IR-TPM (Topamax)|XR-TPM (Trokendi XR)
41318586|NCT03280342|DRUG|XR-TPM (Trokendi XR)|XR-TPM (Trokendi XR)
41318587|NCT03059719|BIOLOGICAL|Exenatide injection(Byetta)|
41475227|NCT00137657|DRUG|Cotrimoxazole (trimethoprim sulfamethoxazole)|
41475228|NCT01058551|DEVICE|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
41005299|NCT02351869|DRUG|Nitrous Oxide|
41005300|NCT02351869|DRUG|Midazolam|
41005301|NCT01211275|BIOLOGICAL|axitinib|axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
41005302|NCT01211275|DRUG|chemotherapy|cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
41005303|NCT02389595|OTHER|HIV positive subjects|This group will provide a blood sample.
41005304|NCT02389595|OTHER|Non-infected control subjects|This group will be de-identified blood samples from a commercial source.
41005305|NCT03310424|OTHER|No active intervention.|No active intervention is undertaken. Collection of samples for bio-informatic analysis only
41005306|NCT04702087|DIETARY_SUPPLEMENT|OLEP|omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
41005307|NCT04702087|COMBINATION_PRODUCT|Placebo|Isocaloric formula
41318588|NCT03059719|BIOLOGICAL|PB-119 injection|
41318589|NCT05913479|DEVICE|Mucogyne Gel|At inclusion visit (V0), the Investigator will ask the subject to apply MUCOGYNE® Gel as described in the Instructions For Use, i.e., internally, one application 2 to 3 times a week until symptoms improve during 5 weeks (D35 +/- 3)
41318590|NCT03623282|DRUG|Synatura® 15 mL|All subjects will receive Synatura® 15 mL every day three times for 3 months.
41318591|NCT04238676|DRUG|PP353|active administered by intradiscal injection
41318592|NCT04238676|OTHER|Placebo|Sham injection
41318593|NCT02680587|RADIATION|SBRT|SBRT (1-5 fractions) will be administered.
41318594|NCT04406051|PROCEDURE|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 5 mL/kg of colloid infusion prior to the initiation of spinal anesthesia
41318595|NCT04406051|PROCEDURE|norepinephrine infusion and crystalloid co-loading (NOR-CRYST)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 10 mL/kg of crystalloid infusion simultaneously with the initiation of spinal anesthesia
41318596|NCT01409993|DRUG|Sildenafil|Sildenafil 25 mg by mouth three times a day for three months
41318597|NCT01409993|DRUG|Placebo|Matching placebo three times a day for three months
41475229|NCT06111079|DRUG|aspirin discontinuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
41475230|NCT06111079|DRUG|aspirin continuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
41475231|NCT02635581|DEVICE|Delta TT acetabular cup|
41318598|NCT01409993|DIAGNOSTIC_TEST|Hyperglycemic clamp|Subjects with prediabetes will have a baseline hyperglycemic clamp (Aim 1) and then receive sildenafil or placebo for 3 months. Another hyperglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
41475232|NCT05687682|BIOLOGICAL|AM-928|AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.
40801393|NCT03375489|OTHER|Telehealth|"Teleconference meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness"
40801394|NCT03375489|OTHER|In-person PC|"In person meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness"
41475233|NCT04664816|DRUG|n-3PUFAs Treatment|Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.
41475234|NCT04664816|DRUG|Placebo Treatment|Placebo orally, twice a day for at least 12 months.
41475235|NCT01699919|DRUG|Intravenous lignocaine|Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
41475236|NCT06402344|OTHER|Hormonal implant|History of at least 1 hormonal implant with gestrinone in the last 6 months, applied by the participant's private doctor.
41475237|NCT06402344|OTHER|Control group|Young women who never used any hormonal implant.
41475238|NCT05766020|BEHAVIORAL|Listen training|Auditory skills with the inclusion of cognitive control.
41475239|NCT01321021|DRUG|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan 40mg, Diphenhydramine 40mg
41475240|NCT00401284|DRUG|EVT 201|
41475241|NCT00766155|DRUG|capecitabine|Given orally
41475242|NCT00766155|DRUG|oxaliplatin|Given IV
40801395|NCT04973202|OTHER|Stay for alcohol detoxification|Stay for alcohol detoxification : routine care.
41005308|NCT01277939|BEHAVIORAL|Therapeutic Education System (TES)|Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
41318599|NCT01409993|DIAGNOSTIC_TEST|Euglycemic clamp|Subjects with prediabetes will have a baseline euglycemic clamp (Aim 2) and then receive sildenafil or placebo for 3 months. Another euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
41475243|NCT04854564|BEHAVIORAL|Prehabilitation intervention|The investigators will identify participants' perceived important information to develop a prehabilitation intervention in this study. Prehabilitation intervention consisting of physical activities, nutrition, and stress management.
41475244|NCT04854564|BEHAVIORAL|Caregiver intervention|The investigators will provide caregivers with variety of educational resources for patients experiencing ESLD.
41475245|NCT06227026|BIOLOGICAL|Anti-CD19 CAR-T cells|Anti-CD19 CAR-T cells are autologous T cells, engineered to express an extracellular single chain variable fragment (scFv) derived from a murine anti-human CD19 hybridoma clone FMC63 linked in frame to hinge region derived from human CD8, transmembrane domain derived from Tumor Necrosis Factor Receptor Super Family 19 (TNFRSF19) the transactivation costimulatory domain 4-1BB, and CD3 zeta signaling domain (Miltenyi Biotec Inc). Anti-CD19 CAR-T cells will be cryopreserved in infusible cryomedia for a later infusion. Anti-CD19 CAR-T cells will be administered in 1 to 3 bags. Bag aliquoting, cell content and cryomedia composition will be done according to specifications in the CMC.
41005309|NCT01277939|BEHAVIORAL|Standard Care|Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
41005310|NCT02426281|DRUG|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
41005311|NCT02426281|DRUG|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
41475246|NCT06013917|DEVICE|Cardiac Monitoring|FDA cleared ECG monitoring device that will be used to obtain ECG recordings and capture cardiac arrhythmias/events from participants
41475247|NCT01998243|DEVICE|Intragastric Balloon (IGB), group A|the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
41475248|NCT01998243|OTHER|diet, control group B|the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
41005312|NCT03307148|DRUG|ATRA|Administered orally on D1-15 of each 28 day cycle.
41005313|NCT03307148|DRUG|Gemcitabine|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
41005314|NCT03307148|DRUG|Nab-paclitaxel|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
41475249|NCT03001999|BEHAVIORAL|PP-MI health behavior intervention|"The positive psychology exercises include 3 modules:~Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the 14 study sessions."
41475250|NCT02667821|OTHER|Head positions and spinal manipulation|Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue.
41475251|NCT03944681|DRUG|Droperidol Injectable Solution|An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
41005315|NCT03195959|OTHER|Hypoxia and Hyperoxia|10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.
41318600|NCT00680953|DRUG|Denosumab|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
41005316|NCT03710278|DEVICE|LPat Device|Performing Lumbar Puncture utilizing LPat device
41005317|NCT05090020|PROCEDURE|Treatment|Surgery and PAIR
41318601|NCT00680953|DRUG|Placebo|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
41475252|NCT06412926|DRUG|BAY 44-4400|Film-coated tablet, oral use
41475253|NCT06412926|DRUG|BAY 44-4400|Film-coated tablet, oral use
40801396|NCT00521209|BEHAVIORAL|Self-Care Stimulating Disease Prevention Program (SCSDPP)|"The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling"
40801397|NCT00521209|OTHER|Stand procedures, no intervention|
40801398|NCT01373008|DRUG|Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)|Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
40801399|NCT03512808|DRUG|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
40801400|NCT03512808|DRUG|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
40801401|NCT04625101|DRUG|NBI-827104|Triple T-type calcium channel blocker.
40801402|NCT04625101|DRUG|Placebo|Non-active dosage form.
40801403|NCT04776161|BEHAVIORAL|Cue-Reward Intervention|"Patients in the first intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Patients will also receive text messages reminding them of the habit they decided to link to their medication-taking.~Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf."
41318602|NCT00680953|DRUG|Alendronate sodium hydrate|Oral tablet once a week for 24 months
41318603|NCT02094053|DRUG|E2020-Donepezil hydrochloride|3 mg of E2020 (oral) once daily, for 24 weeks
41318604|NCT02094053|DRUG|E2020-Donepezil hydrochloride|5 mg of E2020 (oral) once daily, for 24 weeks
41318605|NCT02094053|DRUG|Placebo|placebo (oral) once daily, for 24 weeks
41318606|NCT02626741|DIETARY_SUPPLEMENT|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
41318607|NCT02626741|BEHAVIORAL|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
41318608|NCT05582161|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
41318609|NCT02183623|DRUG|Simvastatin|
41318610|NCT02183623|DRUG|10 mg BI 1356 BS|
41318611|NCT05991557|PROCEDURE|peroneus longus autograft|Peroneus longus tendon graft will be harvested with a longitudinal skin incision at 2 to 3 cm (2 finger-breadths) above and 1 cm (1 finger-breadth) behind the lateral malleolus, followed by superficial fascia incision in line with skin incision followed by incision of the tendon sheath proximal to the retinaculum. The peroneus longus and peroneus brevis tendons will be then identified. The tendon division location marked at 2 to 3 cm above the level of the lateral malleolus.The peroneus longus tendon will be exposed on its posterolateral surface through the incision after carefully incising the fascia
41318612|NCT05698043|DRUG|CKD-386(5)|Test
41318613|NCT05698043|DRUG|D013, D326, D337|Reference
41318614|NCT05460650|BEHAVIORAL|App Promoting Healthy Behaviours|Women on the study will receive two months access to the app.
41318615|NCT02429258|DRUG|Farxiga|Farxiga 10mg/day
41318616|NCT02429258|DRUG|Placebo|Placebo
41475254|NCT03975413|OTHER|Fecal Microbiota Transplantation (FMT)|Longitudinal FMT study: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
41005318|NCT03407326|DIETARY_SUPPLEMENT|Alternative RUTF|The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
41005319|NCT03407326|DIETARY_SUPPLEMENT|Standard RUTF|Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
41005320|NCT05068973|DEVICE|NOVATECH® LUCIOLA™ EB - (Fiducial Marker)|Bronchoscopic implantation in the lung of the NOVATECH® LUCIOLA™ EB fiducial marker
41318617|NCT02429258|DRUG|Metformin|Metformin background therapy \>/= 1500mg/day
41318618|NCT02429258|DRUG|Insulin|Insulin \>/= 30 units
41318619|NCT03230747|DEVICE|Edwards SAPIEN M3 System|SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock
41318620|NCT00131820|BIOLOGICAL|Typhoid Vi vaccine|
41318621|NCT00131820|BIOLOGICAL|Hepatitis A (control)|
41318622|NCT02284685|BEHAVIORAL|Promoting Eating Disorder Treatment among College Students|Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
41475255|NCT02043613|OTHER|Contextually enhanced physical surroundings of exercise|"Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.~The differences with the physical surroundings of exercise is the primary intervention for this study."
41475256|NCT02043613|OTHER|Neuromuscular exercise|The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
41475257|NCT01189500|DRUG|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
40801404|NCT04776161|BEHAVIORAL|Cue-Reward Intervention with possible intensification|"Patients in the second intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf.~After 6 weeks, patients who demonstrate an adherence under 80% to study medications (as measured by the electronic pill bottle) will begin receiving text messages reminding them of their selected cue."
41005321|NCT01481116|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
41005322|NCT01481116|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
41005323|NCT01481116|DRUG|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
41005324|NCT03827486|OTHER|Standard of care (exercise)|Exercise program according to the standard of care
41005325|NCT03827486|OTHER|Domicilary exercise program|Domicilary exercise program according to protocol (evidence based medicine)
41005326|NCT04361526|DEVICE|Cytokine Adsorption|Cytokine adsorption will be performed through a venous hemodialysis catheter, preferably jugular or femoral. The filtration system will be established with a cytokine adsorption cartridge in an hemoperfusion system using a blood flow rate of 150 - 200 ml/min. Adsorbent therapy will last 72 hours, changing cartridges every 24 hours. Prior to start, heparinization will be stablished by a 1mg/Kg iv Na heparin bolus plus iv perfusion. Activated Partial Thromboplastin Time (aPTT) control will be performed every 6 hours, with a goal range between 60 and 80 seconds.
41005327|NCT06406062|DEVICE|ANDOANGEL|"Polyps were identified by endoscopists assisted by an AI system: rectangular box marks; Monitoring of ileocecal position: whether blindness was reached was displayed in the lower left corner of the interface.~Mirror entry and exit time monitoring: the operation time is displayed in the upper left corner of the interface.~Colonoscopy withdrawal speed monitoring: the relative withdrawal speed was displayed on the left side of the interface."
41005328|NCT03984695|BEHAVIORAL|SHE-WOMEN|SHE-WOMEN is a text-Web intervention designed to increase jail-involved women's health literacy, reduce risk, and increase screening for prevention of cervical cancer, breast cancer, unintended pregnancy, and sexually transmitted infections.
41005329|NCT03746821|DIETARY_SUPPLEMENT|Biotin|Biotin supplements (2) to be taken daily
41005330|NCT05176652|RADIATION|ultrasound|ultrasonographic assessment of optic nerve sheath diameter
41005331|NCT02751983|BEHAVIORAL|ACT for Life|A novel protocol detailing the application of Acceptance and Commitment Therapy (ACT) to recovery from suicidal crises. Consists of three modules designed to be delivered in three to four 60-minute individual talk therapy sessions. Nearly all of the metaphors and experiential exercises are adaptations of core ACT techniques included in various empirically-supported applications of ACT to other health conditions. Additionally, the adjunctive intervention is designed to augment safety planning (a hierarchical list of strategies to recognize and cope with a suicidal crisis).
41005332|NCT02751983|OTHER|Treatment as usual|All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
41005333|NCT06174324|DEVICE|PreserFlo Microshunt|The PreserFlo MicroShunt was invented to create a minimally invasive glaucoma drainage device, that comes close to the eye pressure reduction and safety profile of the current gold standard, the trabeculectomy. Reference: Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, Palmberg P, Parrish RK 2nd, Weber BA, Kwon Y, Parel JM. The development of a micro-shunt made from poly(styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017 Jan;105(1):211-221. doi: 10.1002/jbm.b.33525. Epub 2015 Sep 18. PMID: 26380916; PMCID: PMC5215625.
41005334|NCT06486571|OTHER|Electromyography recording with HD-sEMG|Measurement of muscle electrical signal with HD-sEMG sensors, training of a pattern recognition classifier for hand gesture recognition, verification and comparison with state of the art.
41005335|NCT06486571|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application of TENS by means of non-invasive superifical electrodes on the stump skin of the participants to restore multimodal somatotopical sensations of mechanoception, nociception and thermoception.
41005336|NCT00003268|DRUG|amifostine trihydrate|
40801405|NCT04036201|DRUG|Bupivacaine|peribulbar block
41005337|NCT00003268|DRUG|cytarabine|
41005338|NCT00003268|DRUG|idarubicin|
41005339|NCT04126928|DIAGNOSTIC_TEST|Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.|
41005340|NCT03726177|DRUG|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
41005341|NCT03726177|DRUG|aspirin 81 mg|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
41005342|NCT03726177|DRUG|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
41005343|NCT04700748|RADIATION|Brain metastases radiation|Brain metastases radiation according to clinical practice.
41005344|NCT04604457|OTHER|Palliative care contacts primary care|Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
41152348|NCT01286376|DIETARY_SUPPLEMENT|Symbiotic Lactofos|Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day
40801406|NCT06014853|DRUG|SOL-804-F|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
41005345|NCT02857010|BIOLOGICAL|Allogenic mesenchymal stem cells|Cell therapy
41005346|NCT02857010|OTHER|Placebo|Serum without stem cells
41005347|NCT03935035|BEHAVIORAL|internet-delivered Cognitive Therapy for PTSD (iCT)|Participants will receive 10 hours of Cognitive Therapy for PTSD over 12 weeks, with a baseline assessment at the beginning and follow up interview at the end of treatment. The treatment consists of online modules (9 core modules, 11 optional modules and parent/carer modules) and a weekly phone call with a qualified and trained therapist.
41005348|NCT04765358|OTHER|Virtual Clinic|CGM, Clinical Care Support and Behavioral Health Support
41005349|NCT02802280|OTHER|Cardiovascular risk in HCV patients|"Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
41005350|NCT04174729|DEVICE|handgrip strength|First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
41005351|NCT04174729|DEVICE|Door handle device|To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
41005352|NCT04174729|DEVICE|Tap device|To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
41005353|NCT04174729|DEVICE|Door pull handle|To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
41005354|NCT04174729|DEVICE|Linear Switch device|To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
41005355|NCT04174729|DEVICE|Door Key device|To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
41005356|NCT05035017|DEVICE|Test Lens|Daily disposable with modified lens design for 2 days
41005357|NCT05035017|DEVICE|Control Lens|Daily disposable lens for 2 days
40801407|NCT06014853|DRUG|Zytiga|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
40801408|NCT02356523|DIAGNOSTIC_TEST|Confusion Assessment Method|Administration of Confusion Assessment Method at patent over 65 years at admission and every day until discharge
41005358|NCT01037946|BEHAVIORAL|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
41005359|NCT03001921|OTHER|No intervention|Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
41475258|NCT01189500|DRUG|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
41475259|NCT04873180|DIAGNOSTIC_TEST|sectioning and staining of renal neoplasms after nephrectomy operation|nephrectomy operations will be done to patients diagnosed as having renel tumors
40801409|NCT04856605|PROCEDURE|surgery|regular surgery
41005360|NCT01262313|BEHAVIORAL|Lifestyle Counseling|"Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes."
41475260|NCT05370261|DIETARY_SUPPLEMENT|Berberine LipoMicel|Berberine LipoMicel® soft-gels. Total dose of 500 mg of berberine
41005361|NCT05409235|DRUG|OTT166|Participants will receive OTT166 ophthalmic solution
41005362|NCT05409235|DRUG|Vehicle control|Participants will receive vehicle control
41005363|NCT01465646|DRUG|levothyroxine|
41005364|NCT01465646|DRUG|levothyroxine|
41005365|NCT02567461|DRUG|Edoxaban 60 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
41005366|NCT02567461|DRUG|Edoxaban 30 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
41475261|NCT05370261|DIETARY_SUPPLEMENT|Regular Berberine hard-gels|Total dose of 500 mg of berberine
40801410|NCT05561283|DIAGNOSTIC_TEST|Self-questionnaires|Self-questionnaires on satisfaction, burn-out, depression, anxiety, relational skills and sleep quality
40801411|NCT06262191|DEVICE|Differential and adjustable stiffness AFO (DAS-AFO)|Walking with a differential and adjustable stiffness AFO (DAS-AFO)
40801412|NCT02052115|BEHAVIORAL|12 month exercise and weight loss intervention|
40801413|NCT03932318|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
40801414|NCT03932318|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
41475262|NCT02330952|DRUG|Prednisone|40mg/day per os for 5 days
41005367|NCT02567461|DRUG|Clopidogrel 75 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
41152349|NCT01286376|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
41475263|NCT02330952|DRUG|Placebo|40mg/day per os for 5 days
41475264|NCT02450526|BIOLOGICAL|Botulinum toxin type A|
41475265|NCT02450526|BIOLOGICAL|Botulinum toxin type A|
40801415|NCT03932318|DRUG|Azacitidine|75 mg/m2 will be administered on days 1-7 of a 28-day cycle.
40801416|NCT00192920|BEHAVIORAL|Transfusion practice|
41005368|NCT02567461|DRUG|Aspirin 81 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
41005369|NCT04518891|BEHAVIORAL|Cognitive Functional Therapy (CFT)|Cognitive functional therapy (CFT) is an intervention that deals with potentially modifiable multidimensional aspects of pain (e.g. provocative cognitive, movement and lifestyle behaviours). Treatment with CFT will be individualised, the physiotherapist will listen to the complete patient pain history and the intervention will be focused on individual needs. A detailed examination will be crucial in identifying the modifiable multidimensional mediators of pain and disability (provocative cognitive, pain, movement and lifestyle behaviors) of each participant.
41005370|NCT04518891|DEVICE|Sham intervention|Due to the impossibility of applying placebo exercise, the control intervention in this study will be based on successful reports of placebo intervention in patients with chronic low back pain in the literature (Placebo photobiomodulation + neutral talking control)
41318623|NCT06031298|BIOLOGICAL|Dentin Graft|Dentin graft is a grafting technique of autogenous origin that uses the teeth extracted from the patient for the graft material preparation.
41318624|NCT01896908|OTHER|Sodium restriction|"Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY __ / __ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.~The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis."
41318625|NCT05429229|DRUG|VisuXL®|It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol succinate), one drop is applied in each eye every 4 hours for a month.
41318626|NCT05429229|DRUG|Lagricel PF®|It consists of a preservative-free eye drop composed of sodium hyaluronate 0.4%, one drop is applied in each eye every 4 hours for a month.
41318627|NCT05429229|DRUG|Humylub PF®|It consists of eye drops without preservatives composed of 0.1% sodium hyaluronate and 0.18% chondroitin sulfate, one drop is applied to each eye every 4 hours for a month.
41318628|NCT04000087|OTHER|AI-enabled ECG-based Screening Tool|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
41318629|NCT03711006|OTHER|Fecal Microbiota Transplantation Capsules|25 daily multi-donor FMT Capsules for 50 days
41318630|NCT04260919|PROCEDURE|Chest physiotherapy|
41318631|NCT01586806|DRUG|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
41318632|NCT01586806|DRUG|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
40801417|NCT01597765|DRUG|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
41318633|NCT01586806|DRUG|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
41475266|NCT02450526|DRUG|Placebo|50 Units
41475267|NCT02450526|DRUG|Placebo|20 Units
40801418|NCT01597765|DRUG|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
40801419|NCT00824252|BEHAVIORAL|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
40801420|NCT03414203|OTHER|tDCS|Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
41318634|NCT03827590|DRUG|Test|three times a day for five days
41318635|NCT03827590|DRUG|Active Comparator Control 1|three times a day for five days
41318636|NCT03827590|DRUG|Active Comparator Control 2|three times a day for five days
41318637|NCT03827590|DRUG|Placebo|three times a day for five days
41318638|NCT05366530|OTHER|Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
41318639|NCT01666691|DRUG|Beloranib|Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
41318640|NCT01666691|DRUG|Placebo|Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
41318641|NCT05350566|DIETARY_SUPPLEMENT|Olive leaf extract|A capsule containing 250 mg of an olive leaf extract preparation will be swallowed with a glass of water before exercise.
41318642|NCT05350566|DIETARY_SUPPLEMENT|Placebo|A capsule containing 336 mg of cellulose microcrystalline will be swallowed with a glass of water before exercise.
41318643|NCT03051841|DRUG|CKD-581|Intravenously on Days 1, 8 of each 21-day treatment cycle.
41318644|NCT03897868|DRUG|HCP1803|HCP1803
41318645|NCT03897868|DRUG|Amlodipine|Amlodipine
41475268|NCT02794935|OTHER|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
41475269|NCT02794935|OTHER|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
41475270|NCT04555278|DEVICE|Active rTMS|"A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). The intensity of rTMS will be set at 95 % of the first dorsal interosseous (FDI) resting motor threshold (RMT).~Active rTMS will consist of 40 trains of 5 seconds each at 10 Hz (25-s intertrain interval) applied over M1 (on FDI cortical representation), for a total of 2000 stimulations lasting 20 minutes."
41475271|NCT04555278|DEVICE|Sham rTMS|A sham coil will be use (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS (30 min).
41475272|NCT04555278|OTHER|Motor Control Exercises|The rehabilitation program will consist of a 30-minute session of motor control exercises following the rTMS (Active or Sham) intervention. This approach aims to improve spine health through the optimization of spine loading. The first session will be preceded by an individualized evaluation of the participant's abilities and deficiencies to tailor the training program to each participant.
41475273|NCT05114382|PROCEDURE|EP Procedure|Intracardiac signals will be passively recorded using CathVision Cube® System in parallel with the commercial (CE marked) EP recording system during a scheduled electrophysiology procedure
41475274|NCT00773682|OTHER|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
41475275|NCT03232255|OTHER|Mouthrinse (IQP-OLP-101)|Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.
41475276|NCT04858659|DRUG|PK101|1 tablet at each time, 2 times a day
41005371|NCT00846118|DRUG|Pitavastatin|1-4mg/day
41318646|NCT03897868|DRUG|Losartan|Losartan
41318647|NCT03897868|DRUG|Placebo|Placebo
41475277|NCT04858659|DRUG|PK101-002|1 tablet at each time, 2 times a day
41475278|NCT04858659|DRUG|PK101 placebo|1 tablet at each time, 2 times a day
41475279|NCT04858659|DRUG|PK101-002 placebo|1 tablet at each time, 2 times a day
41475280|NCT01060475|DRUG|LIM-0705 and tacrolimus|Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
41475281|NCT01060475|DRUG|LIM-0705 and tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
41475282|NCT01060475|DRUG|Placebo LIM-0705 and tacrolimus|Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
41475283|NCT01060475|DRUG|Drug LIM-0705 and placebo tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
41475284|NCT01582984|OTHER|video or education session in addition to standard consent|Video added to standard consent + handout Video + education session added to standard consent + handout
41475285|NCT04009889|DIETARY_SUPPLEMENT|capsule containing a probiotic blend of 5 different Lactobacilli|n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
41475286|NCT04009889|OTHER|capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.|n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
41475287|NCT04491357|DRUG|Calcium Gluconate|Intravenous calcium gluconate within 4 hours of skin closure after total thyroidectomy
41475288|NCT04491357|DRUG|Normal saline|Normal saline within 4 hours of skin closure after total thyroidectomy
41005372|NCT04389411|DRUG|Montelukast 10mg|10mg oral Montelukast will be taken daily for 60 days
41005373|NCT04269967|OTHER|Receiving routine rehabilitation care via tele-rehabilitation system|Drain care education, self-massage techniques and exercise (PT and OT)
41005374|NCT00113737|DRUG|fluoxetine|
41005375|NCT00113737|BEHAVIORAL|cognitive behavioral therapy|
41005376|NCT00580424|DRUG|Norethindrone|Norethindrone 0.35 mg orally daily
41005377|NCT03934866|RADIATION|Low Dose CT scan|Low Dose chest CT scan conferring an equivalent radiation dose of less than 2 mSv to the average size patient. The study aims to keep most scans under 1 mSv (ultra-low dose), and all scans under 2 mSv.
41005378|NCT04780425|BEHAVIORAL|DESMOND|as previously described
41318648|NCT02129335|OTHER|stress|stress level and survival
41318649|NCT00228150|DRUG|SR57667B|
41318650|NCT01363713|DRUG|DE-114 ophthalmic solution|
41318651|NCT00542724|DRUG|VIAject™|Dosage as individually required
41318652|NCT00542724|DRUG|Regular Human Insulin|Dosage as individually required
41318653|NCT02363270|PROCEDURE|Ketamine|IV Push or or IV Drip
41318654|NCT04482699|BIOLOGICAL|RAPA-501-Allo off-the-shelf Therapy of COVID-19|Allogeneic off-the-shelf RAPA-501 cells
41318655|NCT04482699|OTHER|Placebo|RAPA-501-Allo cell placebo
41005379|NCT04780425|OTHER|usual care|usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits
41005380|NCT02409862|DRUG|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
41005381|NCT02409862|DRUG|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
41318656|NCT05955079|OTHER|Whole blood|3 samples (before, after surgery and before chemotherapy)
40801421|NCT04238091|DRUG|Fecal material transfer therapy|"Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not."
41005382|NCT02353559|BEHAVIORAL|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
41005383|NCT05902208|DRUG|Antiviral treatment with conventional non-surgical treatment|Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
41005384|NCT05902208|DRUG|Placebo with conventional non-surgical treatment|Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
41005385|NCT04124172|DEVICE|Real rTMS (Magstim)|See arm description
41005386|NCT04124172|DEVICE|Sham rTMS|See arm description
41005387|NCT02874365|PROCEDURE|Endoscopic biopsies|intestinal biopsies
41005388|NCT03493334|OTHER|Visual feedback|Visual feedback of the neck will be given to participants using two mirrors while performing neck movements.
41005389|NCT03493334|OTHER|No visual feedback|Participants will be asked to perform active movements of their neck with the mirrors covered.
41005390|NCT00586469|BIOLOGICAL|Fluviral|One dose, Intramuscular injection
41005391|NCT05942456|DIAGNOSTIC_TEST|ELISA: enzyme-linked immunosorbent assay|enzyme-linked immunosorbent assay
41005392|NCT00906191|DRUG|SAM-531|
41318657|NCT05912712|OTHER|Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment|10 mL PRP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PRP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PRP leakage. The outflow was observed, and the amount of outflow was recorded.
41005393|NCT01043965|DRUG|Metformin|Metformin 850mg
41005394|NCT05950568|PROCEDURE|Quadratus lumborum block typen II|A 22 gauge needle was positioned between the quadratus lumborum muscle posterior border and the erector spinae muscle in the thoracolumbar fascia's middle layer
41005395|NCT05950568|PROCEDURE|Quadratus lumborum block III|A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
41005396|NCT05950568|PROCEDURE|Transversus abdominis plane block|A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
41005397|NCT04019691|DEVICE|Mix-and-Match|Phacoemulsification and implantation of Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
41005398|NCT04019691|DEVICE|EDOF|Phacoemulsification and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
41152350|NCT02626689|OTHER|Quality of Life (QOL) questionnaires|Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,
41005399|NCT04019691|DEVICE|Trifocal|Phacoemulsification and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
41005400|NCT04281277|DEVICE|increase of mean arterial pressure at 80-85 mmHg.|increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).
41005401|NCT04281277|DEVICE|increase of mean arterial pressure at 65-70 mmHg.|increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).
41005402|NCT04061694|PROCEDURE|Immediate loading, fully guided surgery and 3D printed restoration|Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
41005403|NCT04061694|PROCEDURE|Immediate loading|Only subjected to immediate loading. Conventional procedure.
41005404|NCT04284657|DRUG|Pravastatin|Pravastatin 40 mg QD
41152351|NCT02626689|OTHER|Healthcare Resource Utilization|Monitoring and reviewing HealthCare Resource Utilization information.
41152352|NCT04242342|RADIATION|Adaptative MR-Guided Stereotactic Body Radiotherapy|"If lesion near organs at risk:~* Prescription of 50 Gy in 5 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy and daily adaptive treatment~If lesion far of organs at risk:~* Prescription of 60 Gy in 6 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy without daily adaptive treatment"
41152353|NCT01702155|DRUG|DFP-10917|
41005405|NCT04284657|DRUG|sodium citrate|sodium citrate up to 30 ml TID
41005406|NCT02417454|DIETARY_SUPPLEMENT|ProbioStick|"One sachet daily, without or without meals (3 x 10\^9 CFU per sachet)~(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)"
41005407|NCT02417454|OTHER|Placebo|One sachet daily, without or without meals (0 CFU per sachet)
41005408|NCT04871243|OTHER|Qualitative Interview|Individual semi-structured interviews
41005409|NCT01826162|OTHER|acetate or placebo infusion|
41005410|NCT06147011|OTHER|3D printed educational model|Slide-based presention plus 3D printed thyroid fine needle aspiration model
41005411|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.5 Gy fx|Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
41005412|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.0 Gy fx|Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
41005413|NCT00057746|RADIATION|Prophylactic cranial irradiation, 1.5 Gy fx|Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
41005414|NCT00531843|DRUG|fondaparinux sodium|fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.
41005415|NCT00531843|DEVICE|sequential compression devices|Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.
41005416|NCT01202825|DRUG|TMC647055|One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
41005417|NCT01202825|DRUG|Placebo|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
41005418|NCT01202825|DRUG|TMC647055|Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
41005419|NCT01202825|DRUG|TMC647055|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
41005420|NCT01202825|DRUG|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
41005421|NCT01202825|DRUG|TMC435|Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
41005422|NCT01202825|DRUG|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
41005423|NCT01202825|DRUG|TMC647055|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
41005424|NCT01202825|DRUG|Placebo|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
41005425|NCT01202825|DRUG|TMC647055|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
41005426|NCT05448482|PROCEDURE|Transobturator tape|Mid urethral sling for treatment of female stress urinary incontinence
41005427|NCT01746758|BEHAVIORAL|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
41152354|NCT06577103|OTHER|Pericapsular nerve group block (PENG) with supra-inguinal fascia iliaca block (SIFIC)|Patients will receive pericapsular nerve group (PENG) block with supra-inguinal fascia iliaca (SIFIC) block.
41152355|NCT06577103|OTHER|Pericapsular nerve group block (PENG) with lateral femoral cutaneous nerve block (LFCN)|Patients will receive pericapsular nerve group (PENG) block with lateral femoral cutaneous nerve (LFCN) block.
41005428|NCT00041431|DRUG|Hormone Replacement Therapy|
41005429|NCT02510794|DRUG|Ranibizumab|Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
41005430|NCT05291364|DRUG|Group 1|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
41005431|NCT05291364|DRUG|Group 2|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
41152356|NCT03949699|OTHER|Resistance training|Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down, for a duration of eight weeks. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise: Weeks 1-4 will be 50-60% of the baseline calculated 1 repetition maximum (RM) values; Weeks 5-8 will use resistive loads equivalent to 50-60% of Week 4 1RM calculations
41152357|NCT02101554|DRUG|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
41152358|NCT02101554|DRUG|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
41152359|NCT06355037|DRUG|Quercetin|quercetin 1000mg d1-d3, qw
41152360|NCT06355037|DRUG|Dasatinib|Dasatinib 50mg d1-d3, qw
41152361|NCT06355037|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
40801422|NCT04238091|PROCEDURE|4mm Punch Biopsy of Scalp|For the skin biopsy, the doctor will select an appropriate area on the scalp (or skin) as the biopsy site. The area will then be numbed (anesthetized). The study doctor or his/hers designee will then use a cylindrical instrument with a sharp edge (similar to a small cookie-cutter) to remove a 4mm cylinder of skin (smaller than the size of a pencil eraser). After the skin is removed, the biopsy site will be closed with absorbable stitches when appropriate. Approximately 2 to 4 stitches may be placed at the wound site to improve healing. Multiple skin punch biopsies may be taken throughout the entire length of the study
40801423|NCT04238091|DIAGNOSTIC_TEST|Blood draw|Blood will be collected by a standard venipuncture procedure. 60-80cc of blood will be drawn from a patient per blood draw occurrence. Blood samples will be transferred to the research facility. Samples will be used to either stained with cell surface antibodies for fluorescence acquisition cell sorting (FACS) analysis (FACS experiments will allow for assessment of the subset and activation status of immune cells involved in AA or other cutaneous disorder pathology) or to extract DNA for the purposes of exome or genomic sequencing or genotyping of disease associated genes
40801424|NCT04238091|PROCEDURE|Skin Microbiome sampling|Skin microbiome will be collected using skin swabs at the time of recruitment according to established protocols outlined by the Human Microbiome Project. Sterile (germ-free) techniques will be used for collection of all specimens, with careful avoidance of contamination of collection area by gloved hands. The sites that will be sampled are (in sequence): Lesional AA skin, non-lesional scalp skin, retro-auricular crease, ante-cubital fossa, and anterior nares. Skin surface specimens will be collected with a Catch-All Sample Collection Swab swab that looks similar to a q-tip and is, moistened with sterile solution. Skin will be swabbed approximately 50 times along the scalp, behind your ear and on your arm, and twisted 2 times around the front of the nose.
40801425|NCT04238091|PROCEDURE|Hair Microbiome Sampling|Hair follicle microbiome (bacteria that live in the hair follicle) will be collected as follows: several hairs will be plucked from the scalp at a time using tweezers, once plucked the bulbs of the hairs will be cut using sterile surgical scissors and processed. Approximately 10-15 hairs will be plucked for processing. The number of hairs plucked may be increased depending on the number of hairs containing bulbs. Up to 50 hairs may be plucked, as long as the subject is able to tolerate it. Only several hairs will be plucked at a time in order to minimize pain and discomfort of the procedure.
40801426|NCT04238091|DRUG|Pre-FMT Antibiotic Cocktail|For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
41005432|NCT06408103|OTHER|Multi-component, transdisciplinary and multifocal intervention for the cognition|"Multi-component intervention (12 weeks, twice/week, with professional support at home)~Physical activity for the patient: dual training, strength, balance, with intensity increase monthly, plus moderate walking of 30 minutes/day, 5 days per week.~Nutritional advice for the patient: Month 1- reduction of added sugars and processed carbohydrates. Month 2- increase consumption of healthy fats and reduction of saturated fats; Month 3- increase in consumption of fruits and vegetables, and a monthly group practical workshop.~Cognitive training for the patient: activities focused on orientation, attention and concentration, working memory, mathematical reasoning, language, visual construction, executive functions, and reminiscence therapy.~Accompaniment for the family member: Activities aimed at care and self-care, understanding cognitive deterioration and its progression, support for patient adherence to the intervention, and activities in groups once a week."
41152362|NCT04458376|BEHAVIORAL|Internet-based self-help program|The program is divided into six short weekly lessons providing information about chronic dizziness and vestibular rehabilitation, and demonstrating the exercises by video. The program is freely available in the Norwegian electronic handbook for physicians (NEL). The participants in the study will receive the internet address after inclusion in the study.
41318658|NCT05912712|OTHER|Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment|10 mL PPP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PPP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PPP leakage. The outflow was observed, and the amount of outflow was recorded.
41475289|NCT01132664|DRUG|BKM120|Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
41318659|NCT05912712|DRUG|Mesalazine Suppository Treatment|For patients receiving mesalazine suppositories, the intervention was inserted through the anus with a disposable sanitary finger to the point of slight loss of resistance. To facilitate intervention, moisturize with water or cream. If the drug drains within 10 minutes, it should be re-inserted. The swelling at the local injection site on each group's intervention day was recorded.
41318660|NCT05912712|BIOLOGICAL|Infliximab Treatment|Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).
40801427|NCT04238091|DRUG|Bowel Prep|The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
41005433|NCT01653522|DRUG|Triptan|
41005434|NCT01653522|DRUG|Doxycycline|
41152363|NCT00432445|RADIATION|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
41005435|NCT05728164|BEHAVIORAL|Cinematic Simulation|Comprehensive videos from specific films will be selected as films fitting the needs of participants and the established objectives. The films comprehensively develops several characters enriching the values of positive emotions, resilience and empathy. The intervention film videos will be delivered on 5 sessions for each group (2 sessions per week).
41005436|NCT03650907|BEHAVIORAL|Group exercise program|"Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions.~Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks."
41005437|NCT03650907|BEHAVIORAL|Self exercise program|Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.
41005438|NCT04482569|DRUG|XNW4107|Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
41005439|NCT02595853|OTHER|Non interventional study|All upper gastro-intestinal bleeding need endoscopic hemostasis. Endoscopic hemostasis conventional methods are injection of saline with epinephrine, placement of hemoclips and thermic or plasma coagulation. Hemospray™ will be sprayed onto bleeding lesions seen in endoscopy after failure of conventional methods or in salvage therapy at the discretion of endoscopists. Retrospective analysis of prospectively cellected data.
41318661|NCT06341179|BEHAVIORAL|Sleep extension|Children and their parents will receive a behavioral intervention consisting of two in-person sessions and four virtual sessions. The two in-person sessions will take place at the beginning of the study (during weeks 1 and 2) and will focus on effective behavioral strategies to enhance sleep time, including goal setting (e.g., bedtimes and wake-up times), self-monitoring (via actigraphy), problem-solving and preplanning, stimulus control (i.e., sleep hygiene recommendations), and positive reinforcement. The four virtual sessions will take place at frequent intervals during the 12-week intervention (at weeks 4, 6, 8, and 10) and will act as reminders/refreshers to reinforce strategies to enhance changes in sleep time. Parents will receive advice in relation to altering only their children's sleeping routine (bedtime), and they will be instructed not to directly modify their children's food consumption or physical and sedentary activities during daytime.
41318662|NCT04179435|BEHAVIORAL|Behavioral testing on cognitive computerized tasks|Testing on cognitive computerized tasks
41318663|NCT04179435|OTHER|brain MRI|Brain MRI scans
41318664|NCT04179435|OTHER|TMS|Measure of the cortical inhibitory capacity using TMS measures
41318665|NCT04402853|DIAGNOSTIC_TEST|Tears swab|rtPCR on tears swabs samples
41318666|NCT01232751|DIETARY_SUPPLEMENT|Isoflavone supplement|The participants will consume 2 times 2 supplements per day, which will lead to a daily dose of 114 mg. (HPLC analysis confirmed an aglycone isoflavone content of 28.41 mg per supplement)
41318667|NCT03052439|OTHER|FODMAP|After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
41318668|NCT03047850|DIAGNOSTIC_TEST|Comparison of Delta Down and Delta Pulse Pressure|Comparison of Delta Down and Delta Pulse Pressure Before and After Sternotomy.
41318669|NCT03766724|DRUG|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD
41318670|NCT03766724|DRUG|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin|Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD
41318671|NCT03766724|DRUG|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD
41475290|NCT01132664|DRUG|Trastuzumab|Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
41475291|NCT01132664|DRUG|Capecitabine|1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
41475292|NCT04283916|DRUG|Botulinum Toxins|Botulinum toxin injection to abdominal wall
41475293|NCT05811702|OTHER|A randomized acute controlled trial of twenty-eight healthy overweight or obese women|A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD or LFD for 12 weeks. Our primary outcome of this study to investigated the effective diets HFKD and LFD on reduction of body weight, the percentage of body fat
41005440|NCT04223882|BEHAVIORAL|Management of Stress|"Psychoeducation:~Coronary artery disease, Percutaneous Coronary Intervention, traditional risk factors and emotional stress.~Stress: physiology, triggers, triad (thinking, emotion, action).~Skills training:~Identify warning signs - signs and symptoms; Monitoring of irrational automatic thoughts generating alternative interpretations of situations or unrealistic thinking patterns (Dysfunctional Thinking Records Sheet).~Self-control for stress management:~Assertiveness training, problem solving. Thought-stopping technique, designed for dysfunctional thoughts, such as, I won't do it, It won't work.~Stress Relief / Control Techniques:~Diaphragmatic Breathing: Expansion of the abdomen rather than the chest when breathing.~Progressive Muscle Relaxation: Maximize tension and alternately relax the muscles (legs, abdomen, chest, arms and face)."
41318672|NCT03766724|DRUG|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin|Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD
41318673|NCT02147496|OTHER|Dietary Intervention|
41475294|NCT00977548|DRUG|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
41475295|NCT06412042|DIETARY_SUPPLEMENT|Probiotic BLa80|Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
41475296|NCT06412042|OTHER|Placebo Maltodextrin|Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
41475297|NCT00483548|DRUG|Ziprasidone|Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
41475298|NCT00483548|DRUG|Placebo|Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
41475299|NCT02477241|PROCEDURE|Uroflowmetry|A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. Uroflowmetry is the measurement of urine speed and volume.
41475300|NCT02477241|DEVICE|fMRI|Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.
41475301|NCT00686582|BIOLOGICAL|IMVAMUNE|1x 10E8_TCID50
41475302|NCT00686582|BIOLOGICAL|IMVAMUNE|1x 10E8_TCID50
41475303|NCT00686582|PROCEDURE|Blood Draw Only|
41475304|NCT06317584|OTHER|Experimental: Empowerment Application for CAM Health Education|Using empowerment software application for complementary and alternative therapy education, explaining the risk factors that need to be considered, and teaching the use of assistive tool of the empowerment software application
41475305|NCT06317584|OTHER|Written Paper for CAM Health Education|Using written paper for complementary and alternative therapy education and explaining the risk factors that need to be considered
41475306|NCT05850884|DIAGNOSTIC_TEST|stool examination|Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis
41475307|NCT03347513|DRUG|triple attack therapy|eradication of H-pylori using triple attack therapy.
41475308|NCT03347513|DRUG|Ferrous(II)-glycine-sulphate complex 567.7 mg capsules|Iron therapy will be given to both groups twice daily for one month.
41475309|NCT00396331|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
41475310|NCT04885192|OTHER|Stepped-Care Model|"Step 0: Screening via Manage My Pain (MMP) App. Patients using MMP will be prompted to complete questionnaires on pain catastrophizing, depressive symptoms, anxiety, suicide risk and opioid risk. Those scoring above clinical risk cut-offs will be referred to Step 1.~Step 1: Acceptance and Commitment Therapy (ACT) Workshop. Patients will be offered a virtual ACT workshop focusing on practical coping skills for dealing with pain, emotional dysregulation, and disability, while maximizing functioning and quality of life with chronic pain. Thirty days later, patients will be prompted to complete all questionnaires through MMP again; those who score above clinical risk cut-offs will be referred to Step 2.~Step 2: Dialectic Behavior Therapy (DBT) group. A 6-week DBT-based skills group will cover topics such as self-compassion, radical acceptance, distress tolerance, and mindfulness, among others. Thirty days later, patients will be prompted to complete questionnaires through MMP."
41475311|NCT06242743|OTHER|Scalpel blade needles|Patients were assigned to IANB injection by double scalpel blade bevel needles.
41475312|NCT06242743|OTHER|standard blade needles|Patients were assigned to IANB injection by standard blade bevel needles.
40801428|NCT00939289|DEVICE|Continuous Glucose Monitoring|Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
40801429|NCT02262026|DRUG|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
41152364|NCT00432445|PROCEDURE|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
41152365|NCT04260282|DIAGNOSTIC_TEST|Polymerase Chain Reaction (PCR) for viruses and bacteria in nasal swab|PCR for viruses and bacteria in nasal swab
41152366|NCT04260282|DIAGNOSTIC_TEST|Induced sputum microbiome|Microbiome in induced sputum
41152367|NCT01816165|DRUG|Acipimox|Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
40801430|NCT02262026|DRUG|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
40801431|NCT02262026|DRUG|Placebo|Placebo
40801432|NCT02044952|DRUG|Mesalazine, Tripterygium glycosides|tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
41005441|NCT04223882|OTHER|Usual care|outpatient medical appointments
41152368|NCT01816165|DRUG|Placebo|Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
41152369|NCT05122078|DEVICE|ANI|Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
41152370|NCT05122078|OTHER|Control|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. Investigators will not monitor ANI in this group.
41152371|NCT03445845|DRUG|Secukinumab|Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
41318674|NCT06226688|PROCEDURE|Biofeedback device and other group control group|Intervention 1 :-Using the biofeedback device with dumble to strength affected arm post mastectomy
41318675|NCT06226688|PROCEDURE|Control group|Shoulder mobilization Shoulder ladder ex Shoulder wheel ex Ipc
41318676|NCT04357990|DEVICE|Viruxal Oral and Nasal Spray|Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf. The Device contains Omega3 Viruxide. The main components in Omega3 Viruxide are Neem oil and St. John's Wort oil. The Device is administered from a pressurized canister into the oral and nasal cavity, where it creates a physical barrier for temporary protection of the mucosal tissue.
41318677|NCT04357990|OTHER|Placebo|The placebo will be a similar spray containing saline only.
41318678|NCT04480931|BEHAVIORAL|mHealth Intervention Group|Access to the mobile health application with exercise plans and education
41318679|NCT04480931|BEHAVIORAL|Educational Brochure|An evidence-based educational brochure with general information about the benefits of physical activity during pregnancy
41475313|NCT06420414|OTHER|Virtual Reality|"Participants engaged in a 15-minute HIIT session using the Facebook Oculus Quest 2 VR headset with the FitXR fitness game. The advanced level workout (High Speed) was chosen, where participants performed functional movements like squats, lunges, and trunk rotations while punching virtual targets. The VR environment provided a 10-second rest period between intervals and featured a virtual trainer's guidance."
41475314|NCT06420414|OTHER|Traditional HIIT|"Participants followed a non-VR 15-minute HIIT programme designed to replicate the exercises and patterns seen in the FitXR game. The traditional exercises included squats, lunges, and punches, matching the VR programme's intensity and interval structure. Participants watched a pre-recorded video on a laptop, which guided them through the workout. The 10-second rest periods were also maintained for consistency."
41475315|NCT04385524|BIOLOGICAL|Adjuvanted Hepatitis B Vaccine|Adjuvanted Hepatitis B vaccine will be provided to healthcare workers previously vaccinated with the standard 3-dose series of Hepatitis B vaccine but who have failed to respond to two complete 3-dose series
41475316|NCT05804435|DEVICE|iNod™ System|The iNod™ Ultrasound Imaging System enables visualization of endobronchial lesions, peripheral lung nodules, or lung masses (referred to as lesions) using R-EBUS and performance of lung biopsy under direct R-EBUS visualization.
41475317|NCT05719831|DRUG|vonoprazan fumarate + high dose amoxicillin（H-10d）|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 10d
41475318|NCT05719831|DRUG|vonoprazan fumarate + low dose amoxicillin（L-10d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin1000mg/ time, 2 times/day, oral, for 10d
41475319|NCT05719831|DRUG|vonoprazan fumarate + amoxicillin（H-14d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 14d
41475320|NCT06126861|DRUG|[14C]LP-168|single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state
41475321|NCT05181826|DIAGNOSTIC_TEST|Multi-analyte Blood Test|Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer
41475322|NCT01850719|PROCEDURE|Arthroscopic Partial Meniscectomy|Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
41475323|NCT01850719|OTHER|Physical Therapy|"Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.~In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study."
41475324|NCT00987831|OTHER|Group B SLE one blood donation|Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
41475325|NCT00987831|OTHER|Blood drawing only Group C|Blood drawing and Brief medical history to ensure status of healthy control
41157095|NCT05306340|DRUG|Tamoxifen|If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
41318680|NCT05247619|DRUG|Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin|Tisleliumab 200mg, Bevacizumab 7.5mg/kg, Paclitaxel 175mg/m2, and Cisplatin 50mg/m2 (or Carboplatin AUC5) IV on day 1 of every 21-day cycle.
41318681|NCT02545842|DRUG|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41318682|NCT01353937|DRUG|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
41318683|NCT01969669|DRUG|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
41318684|NCT01969669|DRUG|Ketoconazole|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
41475326|NCT00987831|DRUG|Group A SLE prospective study|Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
41475327|NCT05602402|OTHER|CAEP-01|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
41475328|NCT05602402|OTHER|Placebo|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
41475329|NCT01397617|DEVICE|NobelActive Internal implant|Dental implant
41475330|NCT01397617|DEVICE|NobelActive External implant|Dental implant
41475331|NCT01397617|DEVICE|NobelReplace Tapered Groovy implant|Dental implant
41475332|NCT04660305|DRUG|AT278|Concentrated rapid acting insulin aspart
41157096|NCT05306340|DRUG|Everolimus|Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
41475333|NCT04660305|DRUG|NovoRapid|Rapid acting insulin aspart
41475334|NCT00003894|DRUG|thalidomide|
41475335|NCT02662088|PROCEDURE|laparoscopic-lavage|
41005442|NCT03643562|DRUG|Adrabetadex|Administered via lumbar puncture (LP) and IT infusion
41005443|NCT04296396|DRUG|0 to 20 tablets of oxycodone 5mg|Individualized opioid prescription protocol (IOPP) that includes shared decision making
41005444|NCT04296396|DRUG|Fixed opioid prescription|20 tablets of oxycodone 5mg
41475336|NCT04272203|DRUG|ABBV-184|Intravenous (IV) infusion
41318685|NCT04744636|DRUG|Other|"Healthy volunteers will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and Case Report Form (CFR) on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP) :~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR."
41475337|NCT02946216|GENETIC|ctDNA analysis|
41475338|NCT00736918|BEHAVIORAL|Case management|Case management, Usual clinical practice and Providing paper based information for suicide prevention
41475339|NCT00736918|OTHER|Enhanced usual care|Usual clinical practice and Providing paper based information for suicide prevention
41475340|NCT04508920|OTHER|Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)|Interventions were recorded in two groups of patients, who were randomly selected, in two different periods of time. The basal group was intervened from 15 May to 15 June 2019, a pandemic-free period. The outbreak group from 15 May to 15 June 2020, corresponding to increased activity of contagiousness and mortality associated with COVID-19, in general population in Mexico14 Basal measurement was performed in a face to face method. In Outbreak period, under social isolation conditions, patients were evaluated by telephone. The assessments were performed out by medical staff with specialized training, with evaluations to which patients were accustomed by regular cohort assessments. The questions were ordered and systematized in a patient evaluation, care, and follow-up guide (appendix). A causality association question of emotional distress perception was added. We recorded mortality and rehospitalization
41005445|NCT05927233|DRUG|Methylprednisolone|30 ml Methylprednisolone (30mg/kg) with a maximum dose of 500 mg
41005446|NCT05927233|DRUG|Saline|30 ml Normal saline
41475341|NCT00483587|DRUG|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
41475342|NCT01813071|BIOLOGICAL|WRSS1|
41475343|NCT01221090|BEHAVIORAL|PDA|Technological assistance
41005447|NCT04125316|OTHER|Observation, no intervention|Observational study, no intervnetion
41005448|NCT05687240|BEHAVIORAL|Qigong/Tai Chi|Participants will engage in 8 weeks of gentle movement/mindfulness videos provided in a daily text prompt, asking that this be practices most days of the week. A choice of practice video links will be provided, ranging from 10-30 minutes in length, and later confirmation texts will be employed to document if practiced, and what length was chosen.
41005449|NCT05687240|BEHAVIORAL|Heart rate variability biofeedback|"Randomized participants will be coached to practice a breathing technique that focuses attention on the sensations in the heart area, slowing and deepening the breath, and activating through memory or imagery a positive emotion. This practice is used along with a feedback device that provides information on achievement of the heart rate variability target, coherence that represents a neurocardiac state associated with vagal tone, or balance."
41005450|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
41005451|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
41005452|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
41005453|NCT01469065|DRUG|PF-0499132|Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
41005454|NCT01469065|DRUG|Placebo|Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
41475344|NCT01221090|BEHAVIORAL|CDSMP|6-week classes
41475345|NCT01221090|BEHAVIORAL|PDA/CDSMP|Combined technology and education
41475346|NCT00456495|DRUG|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
41475347|NCT02926781|DEVICE|Dask Advanced Sinus kit|a kit of specially designed drills for closed sinus lift
41475348|NCT02956616|DRUG|ketorolac|Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
41475349|NCT02956616|OTHER|Chewing Gum|Xylitol chewing gum will be provided to patients immediately after the procedure and will be provided 3 times per day for a duration of 30 minutes at each time, based on a metanalysis and systematic review. Patient's will be encouraged on its use for return of bowel function.
41475350|NCT02956616|PROCEDURE|Enhanced Recovery Protocol|enhanced recovery protocol (detailed previously) will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing and standing ketorolac for 24 hours postoperatively.
41475351|NCT01520636|PROCEDURE|standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
41475352|NCT01520636|PROCEDURE|experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
41475353|NCT02201979|PROCEDURE|Vertical breast lift with implants|
41475354|NCT06324955|BEHAVIORAL|Standard/common language during induction|The anesthesiologist taking care of the patient will use scripted common/standard language during the induction.
41475355|NCT06324955|BEHAVIORAL|Positive language during induction|The anesthesiologist taking care of the patient will use scripted positive language during the induction.
41475356|NCT00271739|DEVICE|Telemedicine Unit (HTU)|This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.
41475357|NCT00271739|OTHER|usual care|usual diabetes care, as provided by primary care providers
41475358|NCT01352728|DRUG|Axitinib|5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
41005455|NCT03419091|DEVICE|single-use flexible digital ureteroscope|Device being tested.
41005456|NCT03419091|DEVICE|Reusable Ureteroscope|Comparative device.
41005457|NCT04413929|DRUG|Ergoferon|Oral administration
41318686|NCT04744636|DRUG|Other|"Type 2 diabetic patients will be selected within 3 weeks before inclusion (Day 0).~The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and CFR on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP):~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR."
41318687|NCT05452876|OTHER|ABCp|Intervention is a care pathway that helps primary care physicians categorize back pain patients with each category having preferred interventions.
41475359|NCT04530279|PROCEDURE|Clinical assessment|Clinical assessment of burn depth and the percentage of total body surface area (TBSA) burnt with any method
41475360|NCT02666391|BIOLOGICAL|umbilical cord mesenchymal stem cells|
41475361|NCT00799916|DRUG|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
41475362|NCT00799916|DRUG|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
41475363|NCT05264961|BEHAVIORAL|voice therapy|sessions of voice therapy
41475364|NCT01546649|DRUG|TAP-144-SR(6M)|
41475365|NCT01546649|DRUG|TAP-144-SR(3M)|
41475366|NCT00733369|DEVICE|PFC Sigma RP-F|An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
41475367|NCT00733369|DEVICE|PFC Sigma RP|An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
41005458|NCT02309385|DRUG|8% Dexamethasone Sodium Phosphate - Visulex|
41475368|NCT05445531|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Functional and morphologic imaging of the lungs
41475369|NCT05445531|DIAGNOSTIC_TEST|Nailfold capillaroscopy|Imaging of nailfold microvasculature
41475370|NCT05445531|DIAGNOSTIC_TEST|Spiroergometry|Cardiopulmonary exercise testing
41475371|NCT05445531|DIAGNOSTIC_TEST|Realtime deformability cytometry|High-throughput measurement of cell deformability and physical properties
41475372|NCT05767736|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
41475373|NCT05767736|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
41005459|NCT02309385|DRUG|15% Dexamethasone Sodium Phosphate - Visulex|
41005460|NCT02309385|DRUG|Prednisolone Acetate (1%) Eye Drops|
41005461|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12% and CITROX|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
41005462|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12%|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
41005463|NCT02437565|OTHER|Stainless steel crown|Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
41005464|NCT02437565|OTHER|Occlusal Template|Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
41005465|NCT02373358|BEHAVIORAL|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety \& boundaries, strength \& power, assertiveness, intuition, trust, \& community) using mindfulness, breath work, and physical yoga poses.
41005466|NCT03567863|DEVICE|20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®|The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
41005467|NCT03567863|DEVICE|22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®|The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
41318688|NCT05452876|OTHER|Usual Care|Standard of care treatment
41318689|NCT01236313|PROCEDURE|TEE report|Information will be collected during cardiac surgery.
41318690|NCT00258388|DRUG|custirsen sodium|"640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)~Subsequent cycles:~weekly on days 1, 8, 15 (3 week cycles)"
41318691|NCT00258388|DRUG|docetaxel|75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
41318692|NCT00258388|DRUG|prednisone|5mg PO BID
41475374|NCT05767736|DRUG|Disease-Modifying Therapies (DMTs)|Administered as specified in the treatment arm.
41475375|NCT01051180|PROCEDURE|HALO|Ligation of haemorrhoidal arteries
41475376|NCT06226948|DEVICE|CGM|Participants will wear CGM monitors for 10 days.
41475377|NCT06226948|DIAGNOSTIC_TEST|Visualization|Enriched visualization of SCORE2 CVD risk.
41475378|NCT01908894|DRUG|BIOD-123|
41475379|NCT01908894|DRUG|BIOD-125|
41475380|NCT01908894|DRUG|Humalog|
41475381|NCT00334256|DRUG|Tenofovir (TDF)|
41475382|NCT00334256|DRUG|Emtricitabine (FTC)|
41475383|NCT04979884|DRUG|cyclosporine|Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
41005468|NCT03653793|OTHER|Natural Health Product: LivRelief Varicose Veins Cream|This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
41318693|NCT00980980|DRUG|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
41318694|NCT03067129|DRUG|Glecaprevir/Pibrentasvir Adult Formulation|Co-formulated film-coated tablet (100 mg/40 mg)
41318695|NCT03067129|DRUG|Glecaprevir + Pibrentasvir Pediatric Formulation|Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
41005469|NCT01167062|DRUG|Tamsulosin Hydrochloride OCAS 0.4 mg|One tablet OD for a maximum of 28 days
41005470|NCT01167062|OTHER|Placebo|One tablet OD for a maximum of 28 days
41005471|NCT05291299|BEHAVIORAL|Anti-inflammatory diet|Patients randomized to the intervention group will work with a registered dietitian to create an individualized diet program to help reduce inflammation and Rheumatoid arthritis related symptoms.
41318696|NCT02287701|PROCEDURE|PET/MRI|Simultaneous PET/MRI (3T system)
41318697|NCT01582971|OTHER|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
41318698|NCT05467462|DRUG|I.V carbetocin administration|Group I: carbetocin was intravenously administered immediately after birth of the baby.
41005472|NCT05291299|OTHER|Control/Standard of Care|Patients randomized to the control group will be following standard of care where their doctor will instruct them to follow a Mediterranean diet and provides them with an instructional sheet.
41005473|NCT00571129|PROCEDURE|DCR with no tubes or mitomycin|"The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR"
41157097|NCT05306340|DRUG|LHRH Agonist|Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
41318699|NCT05467462|DRUG|I.V Oxytocin administration|Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.
41005474|NCT01990677|DRUG|25mg Eplerenone|Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
41005475|NCT01990677|DRUG|Placebo|Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
41005476|NCT03454438|PROCEDURE|Referral strategies|Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
41005477|NCT05149417|OTHER|SMS reminding|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
41005478|NCT05149417|OTHER|telemonitoring|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
41157098|NCT05306340|DRUG|Dexamethasone Mouth Rinse|A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
41318700|NCT05467462|DRUG|I.V carbetocin and tranexamic acid administration|Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.
41318701|NCT05467462|DRUG|I.V Oxytocin and tranexamic acid administration|Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
41318702|NCT02072512|DRUG|Fulvestrant|Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
40801433|NCT01006655|DRUG|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
41005479|NCT05796128|PROCEDURE|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|In this group, infants will receive NIPPV during LISA procedure.
41005480|NCT05796128|PROCEDURE|Nasal continuous positive airway pressure (NCPAP)|In this group, infants will receive NCPAP during LISA procedure.
40801434|NCT01006655|DRUG|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
41318703|NCT02072512|DRUG|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
41318704|NCT02072512|DRUG|Anastrozole|Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
41318705|NCT02072512|DRUG|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
41318706|NCT04968340|PROCEDURE|conventional cs|opening the lower uterine segment with introduction of the surgeon hand below the fetal head during its extraction
41318707|NCT04968340|PROCEDURE|external pop out teqnique|support of lower uterine segment without introduction of the surgeon hand below the fetal head during its extraction
41318708|NCT04948463|DRUG|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies, until ANC recovery at 100mg/kg (max 4g) 6 hourly.
41318709|NCT04948463|DRUG|Cefepime Injection|Given if patient has non life-threatening hypersensitivity (preferred option), until ANC recovery at 50mg/kg (max 2g) 8 hourly.
41318710|NCT04948463|DRUG|Ceftazidime Injection|If non life-threatening hypersensitivity (second option), given until ANC recovery at 50mg/kg (max 2g) 8 hourly
41318711|NCT04948463|DRUG|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin, given until ANC recovery at 15mg/kg (max 500mg) 6 hourly
41318712|NCT04948463|DRUG|Amikacin Injection|Given until ANC recovery at 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s.
41152372|NCT03445845|DRUG|TNF blocker|"TNF blocker (originator or biosimilar) :~* infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~* etanercept: 50mg per week in subcutaneous injection,~* adalimumab: 40mg every other week in subcutaneous injection,~* certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~* golimumab: 50mg every month in subcutaneous injection, in case of overweight (\>100kg) an inadequate response, 100mg every month is allow."
41152373|NCT03445845|BIOLOGICAL|blood specimen|Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
41152374|NCT04915157|DEVICE|Spinal Cord Stimulator|All patients will receive an implanted spinal cord stimulator.
41152375|NCT00793299|BEHAVIORAL|Video Illness Narrative|video
41152376|NCT06344494|DEVICE|Arch EchoTM Intracardiac Ultrasound catheter and ultrasound system|Novel ICE catheter and combined ultrasound system
41152377|NCT06344494|DEVICE|SOUNDSTAR 3D Diagnostic Ultrasound catheter and ACUSON P500 system|Commercially available devices
41318713|NCT04948463|DRUG|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin, given until ANC recovery at 10 mg/kg (max 400 mg) 12 hourly
41318714|NCT04948463|DRUG|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies at 100mg/kg (max 4g) 6 hourly, stopping 48 hours post-fever resolution.
41318715|NCT04948463|DRUG|Cefepime Injection|If non life-threatening hypersensitivity (preferred option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
41318716|NCT04948463|DRUG|Ceftazidime Injection|If non life-threatening hypersensitivity (second option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
41318717|NCT04948463|DRUG|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin at 15mg/kg (max 500mg) 6 hourly, stopping 48 hours post-fever resolution
41318718|NCT04948463|DRUG|Amikacin Injection|At 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s, stopping 48 hours post-fever resolution
41318719|NCT04948463|DRUG|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin at 10 mg/kg (max 400 mg) 12 hourly, stopping 48 hours post-fever resolution
41318720|NCT03870685|PROCEDURE|TAP Block|Transversus Plane block
40801435|NCT00086983|DRUG|becatecarin|Given IV
40801436|NCT00086983|DRUG|oxaliplatin|Given IV
40801437|NCT00086983|OTHER|pharmacological study|Correlative studies
40801438|NCT05090163|OTHER|PREP Plus|Group based exercise in addition to PREP exercises
40801439|NCT05090163|OTHER|PREP|Group based exercise
40801440|NCT00002848|PROCEDURE|psychosocial assessment and care|
40801441|NCT00002848|PROCEDURE|quality-of-life assessment|
40801442|NCT03898271|OTHER|Virtual World|Participants will complete a synchronous PTSD training in an immersive virtual world environment.
40801443|NCT03153891|OTHER|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
41318721|NCT03870685|PROCEDURE|Surgical Site Infiltration|Surgical Site Infiltration
41318722|NCT03870685|DRUG|Exparel|liposomal bupivacaine
41475384|NCT01972347|DRUG|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
41318723|NCT05426629|DEVICE|Venus Glow|"The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline.~Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation.~The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore."
41318724|NCT01525940|DEVICE|PillCam Colon Capsule Endoscopy (Given® Diagnostic System)|2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
41318725|NCT04857749|OTHER|Standard care|As a pre-test to the patients in the group just before starting treatment; Informed Consent Form, Patient Identification Form, CTCAE v5.0 toxicity criteria, Quality of Life Scale will be applied. At the end of the seven weeks, the post-test (measurement tools included in the pre-test) will be applied.
41318726|NCT04857749|OTHER|Navigation Nursing|With the role of navigator, the nurse contributes to increase the quality of care and to positively affect the physical, psychological and social well-being of the patient. Navigator nurses address patient barriers to care that are complex and often not easily resolved. As a result of the navigation nurses participating in care in the field of oncology; Providing assistance to the side effects of cancer and its treatment, including symptom preventive measures, supporting communication between individuals participating in treatment, preventing delays in treatment, explaining the language of medical treatment, providing psychosocial support, defining and recommending resources.
40801444|NCT03153891|OTHER|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
40801445|NCT00711594|DRUG|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
40801446|NCT00711594|DRUG|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
40801447|NCT00711594|DRUG|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
40801448|NCT00711594|DRUG|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
40801449|NCT06554704|BEHAVIORAL|Isometric hand grip test|The five-minute heart rate variability and respiration rate will be measured for each condition including resting in supine, sitting and standing position, as well as the isometric hand grip test in supine, sitting and standing position.
40801450|NCT02704624|DIETARY_SUPPLEMENT|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
40801451|NCT02704624|OTHER|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
41005481|NCT04499079|OTHER|Learning Health System|This is a system-level intervention designed to improve collaboration among personnel from the juvenile and behavioral healthcare systems.
40801452|NCT02295696|BEHAVIORAL|EMMA|Consultations using dialogue tools
40801453|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
40801454|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
40801455|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
40801456|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
40801457|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
41005482|NCT02283502|DEVICE|MRgHIFU system|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
41005483|NCT00065533|DRUG|pemetrexed|
40801458|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
40801459|NCT03604172|BEHAVIORAL|Cognitive behavioral therapy|The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
40801460|NCT03604172|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
41152378|NCT03234842|RADIATION|Proton Beam Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
41005484|NCT01753453|DRUG|Plerixafor|240mcg/kg, solution, subcutaneous injection
41005485|NCT01753453|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
41005486|NCT00990483|DEVICE|3D mammograpgy system|In addition to the standard care diagnostic imaging, all participants underwent two experimental acquisitions, in two projections (Cranio-Caudal and Mediolateral Oblique) on the breast of concern: one acquisition in Mode A (narrow angle acquisition) and one acquisition in Mode B (wide angle acquisition). The experimental imaging is compared to the standard of care imaging
41005487|NCT04865796|OTHER|Lactoferrin products|Patiens will use a toothpaste and 2 tablets per day (between foods) for home oral care.
41152379|NCT03234842|RADIATION|Photon Radiation Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
41152380|NCT03234842|DRUG|Chemotherapy|Concurrent weekly chemotherapy at standard doses
41152381|NCT02198716|PROCEDURE|Percutaneous Coronary Intervention using drug eluting stents|Percutaneous Coronary Intervention using drug eluting stents
41152382|NCT02198716|PROCEDURE|Percutaneous Coronary Intervention using bare metal stents|Percutaneous Coronary Intervention using bare metal stents
41005488|NCT04865796|OTHER|Probiotics products|Patiens will use a toothpaste and a chewing-gum (for 10 minutes a day) for home oral care.
41005489|NCT04865796|OTHER|Standard home oral care|Patiens will use a normal toothpaste for home oral care.
41005490|NCT04731844|DRUG|Curcumin plus Piperine|Curcumin with piperine is a well-tolerated over-the-counter supplement.
41005491|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
41005492|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
41005493|NCT01267903|BIOLOGICAL|vaccine against EV71 of 160U/0.5ml|inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
41005494|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
41005495|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
41005496|NCT03038464|DIAGNOSTIC_TEST|Synovial biopsy|Biopsy of jint prior reimplantation of new joint prosthesis
41005497|NCT05556122|OTHER|intercostal nerve block|General anesthesia and intercostal nerve block were performed. The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
41005498|NCT05556122|OTHER|lateral intercostal nerve block|lateral intercostal nerve block
41005499|NCT05556122|DRUG|ropivacaine + compound betamethasone|The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
41005500|NCT04201561|DRUG|sodium selenite pentahydrate|High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.
41005501|NCT04201561|DRUG|Normal saline|Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.
41318727|NCT02327221|DRUG|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
41005502|NCT04201561|DRUG|Chemotherapy|Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
41005503|NCT03491150|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
41318728|NCT02327221|DRUG|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
41318729|NCT01174953|DRUG|finasteride|"Finasteride 5 mg once daily~Soy 4 capsules twice daily (160 mg total)"
41318730|NCT04356417|OTHER|- Synthetic anti-malarial drugs|Prevalent users will be those with at least one dispensing of AMD or ARBs/ACEi's from 01/01/2019 to 01/01/2020. Exposed users will be those among prevalent users who still received AMD or ARBs/ACEi's on 31/12/2019. The inclusion period will be from 01/01/2019 to 01/01/2020. The study end date will be 30/06/2020. For each treatment AMD or ARB/ACRi's, the persistence of treatment will be defined as the length of time from initiation to discontinuation. Initiation will be the date of the first reimbursement of AMD or ARB/ACRi's during the inclusion period. We will define the discontinuation of treatment as a period of more than 90 days without fulfilment of a prescription for the same treatment after the period covered by the previous prescription i.e 30 days. Exposure to a combination of drugs will be defined as a period shorter than 30 days between the prescription of two different systemic drugs and the fulfilment of another prescription for both drugs in the following 90 days.
41318731|NCT01842841|DRUG|velaglucerase alfa|15-60 U/kg, EOW
41005504|NCT05314686|OTHER|Five exercise sessions of forty-five minutes within the pulmonary rehabilitation centre and ten days of using a physical activity tracker.|"1. Five exercise sessions of forty-five minutes within the centre on a cycle ergometer using a pulse oximetry device connected to the telerehabilitation system through Bluetooth. Data recorded in the internal memory of the pulse oximeter will be compared with those transmitted through the telerehabilitation system.~2. Ten days of use of a physical activity tracker connected to the telerehabilitation system. Self-reported daily step count by the participants (using a standardized data sheet) will be compared with the daily step count transmitted through the telerehabilitation system."
41005505|NCT05314686|OTHER|Telerehabilitation|"An eight-week program including:~* Endurance training on a cycle ergometer (performed independently with remote monitoring or through video conference, according to the participant's preference), three times per week. Training prescription is progressively adjusted using an automated algorithm (aimed to first increase the training duration and then workload intensity).~* Peripheral muscle strengthening using the app (the patient will be requested to reproduce different exercises after watching a video) or through video conference, three times per week (thirty minutes).~* Daily walking with automated coaching.~* Self management education (one to nine sessions according to each individual needs, scheduled through videoconference).~* A self evaluation of symptoms through daily or weekly questionnaires. Different types of alert will be triggered at the center according to remote monitoring: non-adherence, clinical issue during endurance exercise sessions and change in symptoms."
41005506|NCT01410734|DRUG|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
41005507|NCT00595582|DIETARY_SUPPLEMENT|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
41005508|NCT06493630|BEHAVIORAL|Hypnobreastfeeding Education|Hypnobreastfeeding Education: Monitoring breastfeeding myths, breastfeeding expectations and breastfeeding self-efficacy with hypnobreastfeeding education
41005509|NCT00213148|DRUG|Anastrozole 1 mg|Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
41005510|NCT00213148|DRUG|Anastrozole 5 mg|Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
41005511|NCT00213148|DRUG|Anastrozole 10 mg|Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
41152383|NCT00871455|DRUG|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
41318732|NCT02103036|PROCEDURE|Core Stability Exercises (CSE)|The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
41318733|NCT02103036|PROCEDURE|Traditional Back School|The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
41318734|NCT02103036|DEVICE|TENS|"Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes."
41318735|NCT02103036|DEVICE|Infra-red|Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
41318736|NCT01241396|OTHER|Any MMY treatment|Any line of treatment for MMY
41318737|NCT05446025|DIAGNOSTIC_TEST|Blood sample|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be measured
41318738|NCT05279664|OTHER|Remote ischemic conditioning (RIC) + Standard of Care for NEC|RIC will consist of 4 cycles of limb ischemia (5 min) followed by reperfusion (5 min), repeated on two consecutive days. An appropriately sized blood pressure cuff (covering 2/3 of the distance between the shoulder and the elbow) will be applied by a trained research fellow or nurse to an arm (or leg if the arm is not available because of medical reasons such as central line insertion). The systolic blood pressure will be measured before the first RIC cycle using a different cuff of same size connected to a monitor. During ischemia time, the cuff will be inflated to a pressure of 15 mmHg above the child's systolic pressure. Neonates in this arm will continue to receive standard of care for NEC.
41318739|NCT05279664|OTHER|Standard of Care for NEC|Neonates in this arm (i.e. the control arm) will receive standard of care for NEC.
41318740|NCT00523341|BIOLOGICAL|Denosumab|Administered by subcutaneous injection once every 6 months.
41318741|NCT02701192|OTHER|Coccygectomy|Patient receiving coccygectomy surgery.
41318742|NCT02943018|OTHER|anovaginal distance variation|Kappa calculation
41318743|NCT04296006|DRUG|Sustained Release d-amphetamine|Twice daily administration of active or placebo d-amphetamine
41005512|NCT00213148|DRUG|Clomiphene Citrate 50 mg|Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
41005513|NCT00213148|DRUG|Clomiphene Citrate 100 mg|Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
41005514|NCT04476030|DRUG|SAGE-217|Oral capsules
41318744|NCT04296006|BEHAVIORAL|Money|Three money values offered as alternatives to cocaine
41475385|NCT01972347|DRUG|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
41005515|NCT04476030|DRUG|Matching Placebo|Oral capsules
41005516|NCT04476030|DRUG|Sertraline|Oral tablets
41005517|NCT04476030|DRUG|Escitalopram|Oral tablets
41005518|NCT04476030|DRUG|Citalopram|Oral tablets
41005519|NCT04476030|DRUG|Duloxetine|Oral capsules
41005520|NCT04476030|DRUG|Desvenlafaxine|Oral tablets
41152384|NCT05717647|OTHER|Observational study: neuromonitoring|collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
41152385|NCT06540248|DEVICE|Ialuadapter|minimally invasive syringe device for bladder catherization
41152386|NCT01607099|PROCEDURE|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
41152387|NCT04088500|BIOLOGICAL|Nivolumab|Specific dose on specific days
41152388|NCT04088500|BIOLOGICAL|Ipilimumab|Specific dose on specific days
41152389|NCT00139308|DEVICE|high frequency stimulation|
41152390|NCT05773209|DEVICE|RLRL device|Crossover device (RLRL of 5% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
41152391|NCT04304898|OTHER|Home spirometry|"* Patients will perform daily home spirometry for three months with a Bluetooth-enabled validated, CE-marked home spirometer (Spiro bank Smart, MIR, Italy). Subsequently, patients will perform weekly home spirometry for two years in total. During this period, patients will be asked to perform three measurements each week on the same day.~* Hospital-based spirometry will be performed according to international guidelines.~* Patients will complete patient-reported outcomes (PROMs) online in the secured application every six months."
41152392|NCT01202383|BEHAVIORAL|Household-based water treatment with NADCC tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
41152393|NCT01202383|BEHAVIORAL|Household-based water treatment with placebo tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
41152394|NCT03553056|OTHER|NZ Step Away app|Access to 10 modules of the app (namely: drinkers profile, goal setting, rewards, cravings, strategies, support, reminders, high risk times, moods, activities)
41152395|NCT03553056|OTHER|Modified NZ Step Away app|Access to 2 modules of the app (namely: drinkers profile and goals setting)
41152396|NCT05766124|DRUG|Tissue Plasminogen Activator|Intrapleural administration of tissue plasminogen activator
41152397|NCT06225427|PROCEDURE|Biopsy|Undergo tissue biopsy
41152398|NCT06225427|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41152399|NCT06225427|PROCEDURE|Computed Tomography|Undergo CT scan
41152400|NCT06225427|PROCEDURE|Echocardiography|Undergo echocardiography
41152401|NCT06225427|DRUG|Gilteritinib|Given PO
41152402|NCT06225427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41152403|NCT06225427|OTHER|Questionnaire Administration|Ancillary studies
41152404|NCT03030599|DRUG|JZP-258|JZP-258 oral solution 0.5 g/mL, which is equivalent to 0.413 g/mL of oxybate
41152405|NCT03030599|OTHER|Placebo|Matching placebo solution (aqueous solution containing sodium citrate, malic acid, and sucralose; all ingredients were compendial \[United States Pharmacopeia/ National Formulary\])
41152406|NCT06352034|BEHAVIORAL|Empathy Training|"The intervention contains five themes: 1) An overview of empathy and emotions. 2) Cognitive empathy and clarification technique. 3) Emotional empathy and reflection of feelings technique. 4) Awaring and dealing with the inner feelings while empathizing. 5) Empathy timing and emotional pendulum technique."
41152407|NCT00070707|DRUG|Mometasone|Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.
41152408|NCT00070707|DRUG|Placebo|Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
41152409|NCT00070707|DRUG|Albuterol/Salbutamol|Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.
41152410|NCT03520088|PROCEDURE|Inferior mesenteric Vein dissection|Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision
41152411|NCT03520088|PROCEDURE|Inferior mesenteric Artery dissection|Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision
41152412|NCT01182285|DRUG|Valproic Acid|"Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening"
41152413|NCT01182285|DRUG|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
41152414|NCT05923554|OTHER|Changes in Probing Depth to non-surgical periodontal therapy|Changes in Probing Depth following non surgical periodontal treatment performed with hand and ultrasonic tips
41152415|NCT03078699|RADIATION|stereotactic body radiation therapy|A total radiation dose of 35-50 Gy was delivered to the 50% isodose line covering at least 95% of the PTV (3.5-5Gy/fraction), and a total radiation dose of 49-70 Gy was delivered to the 70% isodose line covering at least 95% of GTV (4.9-7 Gy/fraction).
41152416|NCT05763121|DRUG|Dexpramipexole Dihydrochloride|oral administration of dexpramipexole tablet
41152417|NCT05763121|DRUG|Placebo|oral administration of placebo tablet
41152418|NCT04096261|DIAGNOSTIC_TEST|Diagnostic Test|Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.
41152419|NCT01544153|BEHAVIORAL|WEB|Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
41152420|NCT01544153|BEHAVIORAL|Social Network|"Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org."
41152421|NCT01544153|BEHAVIORAL|Nicotine Replacement Therapy (NRT)|A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
41005521|NCT04765007|OTHER|mindfulness-based stress reduction|"Eight sessions of two hours and a half, one day per week during eight weeks. In addition, patients will perform a day of intensive silent practice of 6-8 hours of duration.~The content of each session balances three activities: the presentation of a topic, moments of dialogue and group exploration (using appreciative inquiry) and a Mindfulness practice.~The sessions will take place in online format, through the google meet application"
41005522|NCT04765007|OTHER|Minimal intervention|A guided meditation program of eight weeks of duration will be provided to the patients and they will be informed about the procedure and the beneficial effects of the therapy.
41318745|NCT06198075|OTHER|Control Group|Subjects will receive 6 weeks of general physical therapy,3 times/week for 30 min each session. The exercise program will include lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor and stair walking. Final assessment will be done after 6 weeks
41318746|NCT06198075|DEVICE|Experimental Group|Subjects will watch a video on a screen from 1 meter in front of their chairs while sitting comfortably with their arms resting but they were not allowed to physically follow the video or move. The model of the video motion observation exercises will perform by the therapist and the training video consist of 4 stages that varied by difficulty and the video of each step was watched for the entire week. The participants watched a video of a task presented by the therapist and after completing the assignment they will perform the steps if step will too difficult to perform retraining will be conducted.
41318747|NCT01653158|DRUG|CP-751,871|"CP-751,871 was given intravenously \[IV\] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year)."
41318748|NCT01653158|DRUG|Docetaxel|Docetaxel up to 75 mg/m\^2 was administered intravenously \[IV\] on Day 1 of each 3-week dosing cycle.
41318749|NCT02632500|OTHER|Quality of chest compressions|
41318750|NCT06051981|DRUG|5% sodium fluoride|a flavored xylitol-sweetened, 5% sodium fluoride in a resin carrier delivered in a 1.2 ml syringe or in a 0.4 ml unit, Ultradent, USA) will be applied on all teeth according to the manufacturer's instructions.
41318751|NCT06051981|DRUG|Intensive 5% sodium fluoride|Intensive FV will be applied three times a week for a week (every two days).
41318752|NCT06051981|DRUG|Casein Phosphopeptide-Amorphous Calcium Phosphate|for 12 weeks. A thin layer from Tooth Mousse™ will be applied to the teeth after daily brushing with traditional toothpaste and left intact for 180 seconds before rinsing with distilled water
41318753|NCT06051981|DRUG|Resin infiltration|resin infiltration will be applied as specified by the manufacturer.
41318754|NCT01431729|OTHER|honey, hope,mucositis|Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
41318755|NCT01864824|DRUG|methyl donor|The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
41318756|NCT01864824|DRUG|Placebo|Placebo
41318757|NCT04973410|DIAGNOSTIC_TEST|Coronary Physiology|Invasive coronary physiology measurements during diagnostic CAG with thermodilution method with the CoroFlow® (Coroventis, Uppsala, Sweden)
41318758|NCT04973410|DIAGNOSTIC_TEST|15O-H2O-PET scan|Myocardial blood flow (MBF) measured with oxygen-15 (O-15) labelled water used as a tracer molecule with positron emission tomography (PET)
41318759|NCT06490198|DRUG|OBI-833/OBI-821|"OBI-833 is a glycoconjugate that consists of Globo H, a unique tumor-associated carbohydrate antigen (TACA), covalently linked to cross-reacting material 197 (CRM197), an inactive and nontoxic form of diphtheria toxin (DT) acting as the carrier protein.~OBI-821 is a saponin-based adjuvant derived from the bark of the Quillaja saponaria Molina tree. It is a purified saponin adjuvant structurally similar to adjuvant QS-21. The OBI-833/OBI-821 combination represents a carbohydrate-conjugate vaccine combined with an immune adjuvant, intended to serve as an active cancer immunotherapy."
41318760|NCT03054987|PROCEDURE|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
41005523|NCT00013117|BEHAVIORAL|Telephone specialist consultation|
41005524|NCT02505633|DEVICE|Stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.~1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL."
41005525|NCT02505633|DRUG|lidocaine mixed with epinephrine|2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
41152422|NCT01505699|GENETIC|RNA analysis|
41152423|NCT01505699|GENETIC|cytogenetic analysis|
41152424|NCT01505699|GENETIC|microarray analysis|
41152425|NCT01505699|OTHER|laboratory biomarker analysis|
41152426|NCT05120284|DRUG|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
41152427|NCT05120284|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
41152428|NCT03237598|OTHER||
41157099|NCT00230971|DRUG|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
41005526|NCT05585216|DRUG|platelet-rich plasma|intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
41318761|NCT03054987|PROCEDURE|ERCP|During the ERCP, a small catheter and guidewire is inserted into the bile duct and the stent can be deployed into the duct.
41157100|NCT00230971|DRUG|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
41005527|NCT01467076|DRUG|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
41005528|NCT01467076|DRUG|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
41005529|NCT01457495|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix-hexa™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
41005530|NCT01457495|BIOLOGICAL|DTPa-IPV/Hib (Infanrix-IPV/Hib™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
41005531|NCT01457495|BIOLOGICAL|HBV (Engerix™-B)|3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8
41005532|NCT00111228|DEVICE|Guardian RT|
41005533|NCT00111228|DEVICE|SMBG only|SMBG only
41005534|NCT05071092|BEHAVIORAL|Dietary counselling|Participants assigned to the intervention group will receive coaching from a dietitian to improve adherence to the Dutch dietary guidelines. Several behavioral change techniques will be used.
41005535|NCT02170610|DRUG|BIBR 1048 MS|
41318762|NCT01530282|OTHER|Invasive method|Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
41318763|NCT01530282|OTHER|Non invasive method|Non_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
41157101|NCT05582447|OTHER|ektacytometry of red blood cells|Evaluate red blood cell membrane mechanical characteristics by osmotic gradient ektacytometry
41005536|NCT02170610|DRUG|Pantoprazole|
41005537|NCT02034526|DEVICE|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
41005538|NCT02034526|DEVICE|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
40801464|NCT02370368|DEVICE|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
41005539|NCT03615950|DIAGNOSTIC_TEST|Bone Mineral Density (DEXA) scan|Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
41005540|NCT03615950|DIAGNOSTIC_TEST|Vitamin D Measurement|Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
41005541|NCT03615950|DIAGNOSTIC_TEST|Height measurement|Height will be measured at baseline and 12 months.
41005542|NCT03615950|OTHER|Assessment of medication compliance|Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
41005543|NCT01565291|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
41005544|NCT05832645|OTHER|Meditation with guided tea consumption|Mindful consumption of tea along with an approximately 10-min guide
41318764|NCT02182141|DRUG|BIBF 1120 ES|
41005545|NCT05832645|OTHER|Breathing meditation|10-min breathing meditation
41318765|NCT04641819|DRUG|Yangzheng Compound Mixture|"At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance.~Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions."
41318766|NCT04641819|OTHER|Conventional Treatment|Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.
41318767|NCT01973452|DRUG|Dexmedetomidine|
41318768|NCT01973452|DRUG|Placebo|
41318769|NCT04238884|DRUG|Voriconazole preemptive genotyping strategy|The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.
41475386|NCT04762940|DEVICE|Robotic|"The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user."
41475387|NCT04762940|DEVICE|Vibration|Vibration duration of approximately 20 minutes with a high vibration frequency will be conducted prior to robotic treatment. The intensity and timing of this treatment has been based on previous protocols, as previously justified in this project. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible (high frequency vibration of 300 Hz).
41475388|NCT00336115|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)|
41475389|NCT03323723|DEVICE|SUI Device|Pessary SUI device
41475390|NCT04625322|OTHER|HCV care provided by hospitalist during acute psychiatric admission|HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
41475391|NCT05367414|OTHER|aromatherapy massage (diluted tea tree oil)|massage with diluted tea tree oil was applied
41475392|NCT05367414|OTHER|aromatherapy massage (sweet almond oil)|massage with sweet almond oil was applied
41475393|NCT02429934|BIOLOGICAL|abatacept also known as Orencia also known as CTLA4-Ig|125mg injected subcutaneously weekly for 16 weeks
41475394|NCT02429934|DRUG|Placebo|
41475395|NCT05246033|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
41318770|NCT04238884|DRUG|Voriconazole clinical practice|The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
41475396|NCT05246033|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
41475397|NCT04977037|DEVICE|Active tDCS|Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
41475398|NCT04977037|DEVICE|Sham tDCS|Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
41475399|NCT03964519|OTHER|Acute changes|In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.
41475400|NCT03964519|OTHER|Chronic changes|In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.
41475401|NCT03964519|OTHER|Familiarization|Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM
41475402|NCT04686513|OTHER|Observation|observational study
41005546|NCT06399146|DEVICE|Picterus App|Take a photo off the patient's skin (sternum).
41318771|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted low dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
41318772|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
41318773|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
41318774|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted medium dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
41475403|NCT03844789|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Eligible participants will be use the t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM technology for 16 weeks during the main study. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase. This arm to be uset:slim X2 with Control-IQ Technology \& Dexcom G6 CGM
41475404|NCT03844789|DEVICE|Control Group|Eligible participants will be use the study Dexcom G6 CGM for 16 weeks during the main study. All participants will be provided the option of using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
41475405|NCT03920683|OTHER|Data collection|Retrospective : data from medical record Prospective : vital statuts from follow-up phone call
41475406|NCT00282750|DEVICE|Bar coded sponge and scanner|
41475407|NCT04669548|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
41005547|NCT04723433|OTHER|Oxygen gas -Conservative|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90% and 94%.
41005548|NCT04723433|OTHER|Oxygen gas -Liberal|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) higher than 96%.
40801465|NCT02370368|OTHER|Agility Ladder Drills|Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
40801466|NCT01692496|DRUG|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
41318775|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
41318776|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
41318777|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted high dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
41318778|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
41318779|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
41318780|NCT03814590|DRUG|Placebo (Saline solution)|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
41318781|NCT05167461|OTHER|Collection of imaging by ultrasonography|The investigators will collect burn image data to be processed through the software combined with the deep machine learning to find automated diagnostic burn assessment with accuracy of \>95% compared to human assessment
41318782|NCT01025258|BEHAVIORAL|Frequent Scheduled CF clinic visits|Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
41318783|NCT01025258|BEHAVIORAL|frequent telephone calls to patients pre and post visits to the clinic|Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
41318784|NCT03386331|BEHAVIORAL|diet and exercise|Diet and lifestyle intervention
41318785|NCT02816372|OTHER|Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)|Tidal volume reduction to 4 ml/kg predicted body weight from inclusion to weaning PEEP trial
41318786|NCT02952703|BEHAVIORAL|brief pre-delivery smoking cessation counseling|
41318787|NCT02952703|BEHAVIORAL|additional pre-delivery smoking cessation counseling|
41318788|NCT02952703|BEHAVIORAL|post- delivery smoking cessation counseling|
41318789|NCT02952703|BEHAVIORAL|incentives|
41318790|NCT00514436|BEHAVIORAL|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
41318791|NCT04972487|DRUG|Tofersen|Administered as intrathecal bolus injection
41318792|NCT02303873|DRUG|Alendronate|Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp \& Dohme．LTD.).
41318793|NCT03294668|BEHAVIORAL|KONTAKT Australia|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
41318794|NCT03294668|OTHER|Super Chef|The Super Chef is a cooking group designed for this study for adolescents on the Autism Spectrum, aimed at teaching basic cooking skills in a social environment. The Super Chef participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
41318795|NCT01475864|PROCEDURE|ERCP with metal stent|ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
41318796|NCT01678716|BEHAVIORAL|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
41318797|NCT01678716|DIETARY_SUPPLEMENT|Micronutrient powders|"In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others."
41318798|NCT01678716|BEHAVIORAL|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
41318799|NCT03989752|DEVICE|Wearable Robotic Exoskeleton for Ambulation|16-week walking program (34 sessions) with an overground walking robotic exoskeleton guided by a certified physical therapist
41318800|NCT03345433|BEHAVIORAL|interactive group drumming sessions|interactive group drumming sessions
41318801|NCT03987334|OTHER|Virtual Reality Treatment|Experimental Group (VRT) subjects will undergo Virtual Reality Motor Control exercises based on augmented feedback of their performance.
41318802|NCT03987334|OTHER|Control Group|Control Group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
41318803|NCT01995279|DEVICE|French ear acupuncture|Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.
40801467|NCT01764269|OTHER|text message surveillance for fever|
41318804|NCT01995279|OTHER|Sham Ultrasound|Ultrasound turned off.
41318805|NCT00061919|DRUG|Carboplatin, etoposide & thalidomide|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
41318806|NCT00061919|DRUG|Carboplatin, etoposide & placebo|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
41318807|NCT04113447|OTHER|observational|observational
40801468|NCT01740921|DRUG|Liraglutide|Administered once daily
41318808|NCT02500602|DRUG|doxazosin|active medication
41318809|NCT02500602|DRUG|placebo|placebo pill
41475408|NCT05886270|OTHER|Housing Assessment/Safety Modifications|A GHHI Assessor will complete three home visits to assess home injury hazards and provide a scope of work that includes home modifications that directly address each of the identified home injury hazards. The Assessor will also provide do-it-yourself education materials and injury prevention supplies to assist them in completing the modifications.
41475409|NCT01722682|BIOLOGICAL|Human pancreatic islet transplantation|
41475410|NCT05807139|OTHER|Placebo|Placebo
41475411|NCT05807139|DRUG|Spironolactone|"Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information."
41475412|NCT04735731|DIAGNOSTIC_TEST|Echography|Echography of diaphragma and other respiratory muscles
41475413|NCT02266394|DRUG|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
40801469|NCT01740921|OTHER|diet|reduction of caloric intake to promote weight loss
40801470|NCT01740921|DRUG|Aspirin|300mg of Aspirin per day
41005549|NCT05695222|OTHER|This is not an interventional study|This is not an interventional study
41005550|NCT01387321|DRUG|BYL719|
41318810|NCT01182337|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
41475414|NCT02266394|PROCEDURE|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
41475415|NCT05402787|OTHER|Virtual visit|A virtual visit will be made to mothers whose babies are hospitalized in the neonatal intensive care unit
41475416|NCT00399737|DRUG|repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor|
41475417|NCT05783661|OTHER|Conventional antibiotic strategies|Treatment according to the local guidelines of the Hospital Clinic de Barcelona.
41475418|NCT05783661|OTHER|Regimens guided by epidemiological surveillance|Treatment according to the local guidelines of the Hospital Clinic de Barcelona guided by colonization/epidemiological surveillance.
41475419|NCT05818982|DRUG|Afatinib|Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.
40801471|NCT04661423|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch.
40801472|NCT01032603|PROCEDURE|Bilateral lateral rectus recession (BLRc)|Bilateral lateral rectus recession surgery
41005551|NCT03019276|DRUG|TQ-B3101|Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
41005552|NCT05317975|BEHAVIORAL|Add-on telerehabilitation and home-based rehabilitation|"1. 12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.~2. Add-on telerehabilitation for instruction and supervision of exercise training"
41005553|NCT05317975|BEHAVIORAL|Home-based rehabilitation alone|12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.
41005554|NCT04163744|DEVICE|Double balloon catheter|Induction of labour with double balloon catheter
41005555|NCT00423891|DRUG|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
41318811|NCT01182337|DRUG|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
41475420|NCT05818982|DRUG|Irinotecan|Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
41475421|NCT05011045|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41475422|NCT05011045|OTHER|Neurocognitive Assessment|Undergo neurocognitive function assessment
41475423|NCT05011045|OTHER|Quality-of-Life Assessment|Complete questionnaires
41475424|NCT05011045|OTHER|Questionnaire Administration|Complete questionnaires
41475425|NCT01885416|OTHER|consumption of test meal based on dairy products|
41475426|NCT01885416|OTHER|consumption of high fat test meal without dairy products|
41005556|NCT03167762|DEVICE|Fluorescence and thermal imaging|Two cameras used to take images of the skin. One, to measure the fluorescence from the photosensitiser, and the second to measure the surface temperature of the skin
41318812|NCT05575284|PROCEDURE|Robot-assisted urological surgery|Patient with programmed robot-assisted urological surgery
41475427|NCT01885416|OTHER|consumption of high fat test meal with dairy products|
41475428|NCT02021318|DRUG|Roxadustat|Oral tablet.
41318813|NCT01894464|BEHAVIORAL|Teacher led intervention|
41318814|NCT05815680|DRUG|metformin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
41475429|NCT02021318|DRUG|Darbepoetin alfa|Subcutaneous or intravenous injection.
41475430|NCT00836719|DRUG|Polyphenon E|Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
41475431|NCT01684878|DRUG|Gemcitabine (Chemotherapy)|Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
41475432|NCT01684878|DRUG|Paclitaxel (Chemotherapy)|Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
40801473|NCT01032603|PROCEDURE|Unilateral lateral rectus recession with medial rectus resection (R&R)|A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
40801474|NCT06093958|DIAGNOSTIC_TEST|Manual loading of the chest wall|The chest wall will be loaded by either compression of the abdominal wall, compression of the lumbar spine, or compression of the sternum.
41318815|NCT05815680|DRUG|digoxin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
41318816|NCT05815680|DRUG|IBI362|Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.
41318817|NCT05815680|DRUG|warfarin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
41318818|NCT05815680|DRUG|atorvastatin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
41318819|NCT01640990|DRUG|Saline|30mins run-in period
41318820|NCT01640990|DRUG|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
41318821|NCT01640990|DRUG|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
41318822|NCT03235817|OTHER|Spontaneous ventilation|The patient will breathe spontaneously (on their own) while under general anesthesia throughout the duration of the surgery.
41318823|NCT03235817|DEVICE|Pressure support ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
41318824|NCT03235817|DEVICE|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
41475433|NCT01684878|DRUG|Pertuzumab|Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
41475434|NCT01684878|DRUG|Placebo|Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
41005557|NCT02781103|OTHER|Guided imagery plus active tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
41157102|NCT01073215|BEHAVIORAL|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
41318825|NCT05895279|OTHER|Media Intervention|Watch MiCaP Research Digest video
41318826|NCT05895279|OTHER|Media Intervention|Watch alternate video
41318827|NCT05895279|OTHER|Survey Administration|Complete survey
41318828|NCT00522574|DRUG|XL019|gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
41318829|NCT01623141|PROCEDURE|Pressure Pain measurement|The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
41475435|NCT01684878|DRUG|Topotecan (Chemotherapy)|Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
40801475|NCT05749666|DRUG|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 24 weeks
40801476|NCT05749666|DRUG|Prednisolone|Prednisolone taken daily according to preset tapering protocol
40801477|NCT05749666|OTHER|Placebo of tofacitinib 5mg|Placebo of tofacitinib 5mg BID taken orally for 24 weeks
40801478|NCT05749666|OTHER|Placebo of prednisolone|Placebo of prednisolone taken daily according to preset tapering protocol for 24 weeks
41318830|NCT05927818|DIAGNOSTIC_TEST|Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer|Described in previous sections
41318831|NCT01899859|DRUG|GR-MD-02|GR-MD-02; galactoarabino-rhamnogalaturonate
41318832|NCT01899859|DRUG|Placebo|GR-MD-02 Placebo
41318833|NCT00318903|DRUG|Irinotecan (drug)|50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.
41318834|NCT00318903|DRUG|Taxotere (drug)|Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.
41318835|NCT00318903|PROCEDURE|Radiotherapy (procedure)|Radiotherapy will be given in 28 fractions over 5-6 weeks at 1.8 Gy per fraction for a total of 50.4 Gy. This will begin concurrently with chemotherapy on Day 29 of treatment.
41318836|NCT00318903|PROCEDURE|Esophagectomy (procedure)|After approximately 14 weeks of treatment, the patient will be evaluated for surgery. Only those who have achieved a good response will be eligible.
41318837|NCT04093817|DEVICE|cardio pulmonary bypass machine|cardio pulmonary bypass machine is a machine that work to compensate for the function of the heart and the lungs in the operation
41475436|NCT06232239|DRUG|Empagliflozin-Test product|Empagliflozin 10 mg tablets Test product Manufactured by: Thai Meiji Pharmaceuticals Co., Ltd., Thailand
41475437|NCT06232239|DRUG|Empagliflozin-Reference product|Empagliflozin 10 mg tablets Reference product Manufactured by: Boehringer Ingelheim Pharma Gmbh \& Co. Kg, Germany
41475438|NCT05669807|DRUG|Camrelizumab|200mg d1, the first day, every 14 days as a cycle
41475439|NCT05669807|DRUG|Albumin-Bound Paclitaxel|100 mg/m2, the 1st, 8th and 15th days, every 28 days as a cycle
40801479|NCT01091038|OTHER|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
40801480|NCT01091038|OTHER|Routine Care|Routine Care
40801481|NCT01377909|DRUG|statin|daily statin orally for 48 weeks
40801482|NCT04285554|DEVICE|iRF System Hepatic Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).
40801483|NCT05922943|BEHAVIORAL|Harmony & Health program|Harmony \& Health program may help improve psychosocial wellbeing in participants and if improvements in physical activity and wellbeing can last after the program ends. Yoga combines gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
40801484|NCT04594135|DRUG|anti-CD5 CAR T cells|anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
40801485|NCT01700959|DRUG|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
40801486|NCT01700959|DRUG|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
40801487|NCT04749043|DEVICE|Oculus Quest 2 Virtual Reality Device|30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects
40801488|NCT04749043|DRUG|Nitrous oxide|30 min exposure for labor analgesia
40801489|NCT02902302|DRUG|Ibuprofen 400 mg/10 mL oral suspension|
40801490|NCT02902302|DRUG|MOMENT 400 mg coated tablet|
40801491|NCT01188551|DRUG|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
40801492|NCT01188551|DRUG|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
40801493|NCT01188551|DRUG|Midazolam|Sedative given pre-op.
40801494|NCT06497283|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
40801495|NCT02761681|BEHAVIORAL|ACT-CL Web-based guided self-help|
41318838|NCT04306055|OTHER|Questionnaire with precaution information|Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.
40801496|NCT02761681|BEHAVIORAL|Control Web-based guided self-help|
40801497|NCT04659408|DIETARY_SUPPLEMENT|Multistrain probiotic preparation|One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.
40801498|NCT04659408|DIETARY_SUPPLEMENT|Oat Bran|5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.
40801499|NCT00111449|DRUG|Etanercept|
40801500|NCT03013387|RADIATION|90Y-DOTA-3-tyr-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.
40801501|NCT03013387|PROCEDURE|Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
41318839|NCT04306055|OTHER|Experimental: Questionnaire without precaution information|Ever blood donors in this group would receive a questionnaire which dose not include the information above.
41318840|NCT02058485|DRUG|Midazolam|Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
40801502|NCT03013387|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
40801503|NCT05511376|DEVICE|AURICULAR VAGUS NERVE STIMULATION|For 4 weeks With the Vagustim device, in Biphasic, Frequency 10 Hz, Modulation mode, the pulse width of 300 μs, where the participants feel comfortable, the current intensity is kept constant for 30 minutes / 3 days/week. It will be applied as bilateral VSS from the tragus and turbinate parts of the ear.
40801504|NCT05511376|BEHAVIORAL|DIET|For 4 weeks, Protein intake to 30% of total daily calories or 1-1.2 g/kg Personal nutrition program created for ideal body weight (by BMI values for age)
40801505|NCT05511376|BEHAVIORAL|EXERCISE|Exercise: Moderate Resistance Exercise Protocol (60 min 3 days a week )+ 30 min/day as aerobic exercise ( 5 days a week)
40801506|NCT02690688|DEVICE|determination of dynamic preload variables|
40801507|NCT05725226|DEVICE|Double J Stent 6Fr x 26cms|Surgery will be performed by expert Urologist.
40801508|NCT05725226|DEVICE|Double J Stent 4Fr x26cms|Surgery will be performed by expert Urologist.
40801509|NCT01574287|DRUG|FACBC|Drug is give intravenously over 2 minutes at time of scan
41318841|NCT02058485|DRUG|Dexmedetomidine|Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
41475440|NCT05669807|DRUG|Irinotecan|180 mg/m2, the first day, every 14 days as a cycle
41475441|NCT01594047|DRUG|ketamine infusion|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
41318842|NCT00488592|BIOLOGICAL|WT1:126-134|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
41318843|NCT00488592|BIOLOGICAL|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
41475442|NCT01594047|DRUG|Methadone PCA|Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
40801510|NCT05197933|PROCEDURE|Laparoscopic resection|Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted
40801511|NCT00001766|DRUG|Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir|
40801512|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
40801513|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
40801514|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
40801515|NCT04493541|DRUG|BMS-986256|Specified Dose on Specified Days
40801516|NCT04493541|OTHER|BMS-986256 Placebo|Specified Dose on Specified Days
40801517|NCT02468531|OTHER|oxygen|50% oxygen inhalation
40801518|NCT02468531|DRUG|Xenon|50% Xenon inhalation
40801519|NCT06123715|DRUG|Vitamin C|Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day1 to day 56.
40801520|NCT06123715|DRUG|Placebo|Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
40801521|NCT01849692|DRUG|ESBA1008 solution|Intravitreal injection or infusion
40801522|NCT01849692|DRUG|Ranibizumab|Intravitreal injection
40801523|NCT03940638|OTHER|Data collection|Data collection
40801524|NCT00325260|BIOLOGICAL|Influvac; subunit influenza vaccine|
40801525|NCT05262777|DEVICE|GP0112|Injectable gel
40801526|NCT05262777|DEVICE|Restylane Lyft Lidocaine|Injectable gel
41475443|NCT03398148|DRUG|risankizumab IV|risankizumab intravenous (IV) infusion
41475444|NCT03398148|DRUG|placebo for risankizumab|placebo for risankizumab
41475445|NCT03398148|DRUG|risankizumab SC|risankizumab subcutaneous (SC) injection
41475446|NCT02617082|RADIATION|partial breast irradiation|The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
41475447|NCT03734887|BEHAVIORAL|Social Network Feedback|Social networks are cost-free and highly influential social relationships and interactions that influence behavior and conversely are influenced by a patient's behavior. In addition to receiving a private text message regarding their medication adherence rate, participant's feedback will also be shared to a loved-one or friend that the participant is willing to share medical information with.
41475448|NCT03734887|BEHAVIORAL|Private Feedback|Participant will receive medication adherence feedback from a pharmacist at the start of the study.
40801527|NCT02102685|PROCEDURE|VAC Therapy|within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
40801528|NCT02102685|PROCEDURE|TRADITIONAL THERAPY|after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
40801529|NCT01193634|DEVICE|VR 9250 / DR 9550 / CRT 9750|Active implantable defibrillators range
40801530|NCT04848519|DRUG|Pembrolizumab|Given IV as first line for locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy; or second line for locally advanced or metastatic urothelial carcinoma after progression on platinum-based chemotherapy
40801531|NCT04848519|DRUG|Propranolol Hydrochloride|Given PO for patients on the ICI plus propranolol arm
40801532|NCT04848519|DRUG|Nivolumab|Given IV as adjuvant treatment of urothelial carcinoma in high risk of disease recurrence after undergoing radical resection
40801533|NCT04848519|DRUG|Avelumab|Given IV as maintenance treatment in locally advanced or metastatic urothelial carcinoma following no progression on first-line platinum-containing chemotherapy
40801534|NCT00069134|DIETARY_SUPPLEMENT|sulfur amino acids|Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
40801535|NCT02321917|DEVICE|MECC system with rheoparin coating|MECC system for extracorporeal circulation equipped with rheoparin coating.
40801536|NCT06221761|DRUG|not using antibiotic|no antibiotic application
40801537|NCT06221761|DRUG|using antibiotic|antibiotic application
40801538|NCT03572231|DRUG|mirabegron|oral
40801539|NCT03572231|DEVICE|solifenacin|oral
40801540|NCT03572231|DRUG|darifenacin|oral
40801541|NCT03572231|DRUG|imidafenacin|oral
40801542|NCT03572231|DRUG|tolterodine|oral
40801543|NCT03572231|DRUG|oxybutynin|oral
41475449|NCT02693431|OTHER|Non interventional Study|"Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.~The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.~At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires."
41475450|NCT05754424|DRUG|AT278|Concentrated rapid acting insulin aspart
41475451|NCT05754424|DRUG|NovoRapid|Rapid-acting insulin aspart
41475452|NCT05754424|DRUG|Humulin R 500 UNT/ML Injectable Solution|Regular human insulin
41475453|NCT02096484|BEHAVIORAL|Group Metacognitive Therapy|
41318844|NCT00488592|DRUG|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
41475454|NCT02096484|BEHAVIORAL|Mindfulness Meditation Therapy|
41005558|NCT02781103|OTHER|Guided imagery plus Sham tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
41005559|NCT02597010|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
41005560|NCT02597010|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
40801544|NCT03572231|DRUG|trospium|oral
41005561|NCT00820924|DRUG|LAPATINIB|LAPATINIB 1500MG ORAL DOSE DAILY
41005562|NCT01813565|DRUG|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
41005563|NCT01067404|BIOLOGICAL|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
41005564|NCT04403321|DRUG|Tacrolimus|Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.
40801545|NCT03572231|DRUG|fesoterodine|oral
40801546|NCT03572231|DEVICE|propiverine|oral
40801547|NCT03870373|DEVICE|Pulse Oximeter|Aulisa's non-invasive pulse oximeter sensor is applied to a foot of the neonate; an adhesive patch secures the sensor to the neonate.
40801548|NCT04093193|PROCEDURE|Debridement|Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
40801549|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
41005565|NCT04403321|DRUG|Placebo (for Tacrolimus)|placebo will be given at 1mg bid.
40801550|NCT00255918|DRUG|Placebo|Placebo dosed to match active medication
40801551|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
40801552|NCT02305589|DRUG|Sugammadex|Muscle relax reversing agent
41005566|NCT02720575|OTHER|Consumption of capsule/bread with vitamin D|
41005567|NCT04074317|DRUG|PRAM9|SC injection
41005568|NCT04074317|DRUG|Regular Insulin + Pramlintide|Separate SC injections
41005569|NCT04074317|DRUG|Regular Insulin|SC injection
41157103|NCT01073215|BEHAVIORAL|Family-Based Lifestyle Modification Program|"The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management."
41318845|NCT00488592|BIOLOGICAL|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
41318846|NCT03998020|OTHER|scale of severity|assessment of the severity of the sleep disorders by scale
41005570|NCT01416168|OTHER|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
41005571|NCT04978792|BEHAVIORAL|Online self-compassion intervention|An online self-guided intervention that uses widely available exercises and information.
41005572|NCT04978792|BEHAVIORAL|Active Control|Participants will complete written exercises and breathing exercises that are not associated with self-compassion
41005573|NCT00330291|DRUG|Xyrem|
41005574|NCT05241886|OTHER|anthoropometric measurement, SARC- F questionnare|SARC-F, CC, MUAC
41318847|NCT03998020|GENETIC|blood sample|Genetical study, serum and sample
41318848|NCT06003257|OTHER|stainless steel crown|stainless steel full coverage crown for deciduous teeth
41318849|NCT06003257|OTHER|zirconia crown|zirconia full coverage crown for deciduous teeth
41318850|NCT06003257|OTHER|fiberglass crown|fiberglass full coverage crown for deciduous teeth
41318851|NCT02126943|DRUG|Opsumit (macitentan)|10 mg tablets
41318852|NCT00470652|DEVICE|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was \>4/10. After a 10-day test period, the post-intervention data collection started.
41318853|NCT00274157|BEHAVIORAL|Behavior|
41318854|NCT00274157|BEHAVIORAL|diet control, smoking cessation, exercize|
41318855|NCT01194804|DRUG|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
41318856|NCT04315480|DRUG|Tocilizumab|single intravenous administration 8mg/Kg
41318857|NCT05344625|DRUG|Ketamine 100 MG/ML|Ketamine Assisted Psychotherapy
41318858|NCT01396993|PROCEDURE|Breast Surgery|breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
41318859|NCT01396993|PROCEDURE|Breast Surgery|Breast conserving therapy without defect correction
41005575|NCT02788110|OTHER|Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
41005576|NCT02788110|OTHER|Nasal intermittent positive pressure ventilation (NIPPV)|"Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae."
41005577|NCT04973761|OTHER|Zirconium crowns|Prefabricated pirmary anteroir teeth zirconium crowns
41005578|NCT04973761|OTHER|Strip composite crowns|Strip composite crowns
41005579|NCT06021236|BEHAVIORAL|mindfulness-based intervention|Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing
41005580|NCT06021236|OTHER|CIED procedure routine care|CIED procedure home care guidance
41005581|NCT00771433|BIOLOGICAL|filgrastim|Given subcutaneously
41318860|NCT00272636|PROCEDURE|Radiofrequency catheter ablation|
41318861|NCT00272636|DRUG|Amiodarone and cardioversion|
41318862|NCT04677621|OTHER|Nurse Telehealth|Subjects will receive nurse telehealth Mobile Decision Support System (MAP) DBS care
41318863|NCT04677621|OTHER|STANDARD DBS|Subjects will receive standard in-person clinic-based DBS care administered without the use of Mobile Decision Support System (MAP) DBS
41318864|NCT00084929|PROCEDURE|CT Colonography|CT colonography performed for comparison with colonoscopy results performed during the same screening assessment.
41318865|NCT04287101|OTHER|Post-operative PT and OT|Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education
40801553|NCT02120781|BIOLOGICAL|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
40801554|NCT02120781|DRUG|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
41318866|NCT02188719|BIOLOGICAL|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is \<50/mm\^3 or when the maximal dose of 4.5/mg/kg has been given.
41318867|NCT02188719|BIOLOGICAL|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
41318868|NCT02188719|DRUG|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
41318869|NCT02188719|DRUG|Tacrolimus|"Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF"
41318870|NCT02188719|DRUG|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
41318871|NCT02188719|DRUG|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
41318872|NCT02188719|DRUG|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
41318873|NCT02188719|DRUG|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
41318874|NCT02188719|DRUG|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
41318875|NCT02188719|PROCEDURE|Leukapheresis|"Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.~Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level \>/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level \</=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis."
41318876|NCT02188719|PROCEDURE|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
41318877|NCT02188719|PROCEDURE|Liver biopsies|Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
41318878|NCT02188719|PROCEDURE|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
41318879|NCT00701155|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
41318880|NCT00679718|DRUG|diquafosol tetrasodium (INS365) ophthalmic solution|
41318881|NCT03132168|BEHAVIORAL|Assessments|These cognitive assessments will be utilized during the study to evaluate cognitive levels comparing prior to surgery and post-operatively in order to determine if the subject is delirious. BIS monitoring will be utilized for all subjects.
41318882|NCT03132168|PROCEDURE|Blood Draw|Subjects will have blood draws at surgical preadmission visit, Day 1, Day 2, and Day 3 post surgery only; one tube containing approximately one teaspoon (5 mL) of blood will be drawn at each visit.
41318883|NCT03132168|OTHER|Standardized Anesthetic Care|Standardized anesthetic care will be provided as described by the protocol for each subject consented for this trial.
41318884|NCT03864718|PROCEDURE|photodynamic therapy|Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
41318885|NCT00966303|OTHER|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
40801555|NCT04120844|BEHAVIORAL|Motivational interviewing (MI)-based patient empowerment program (PEP)|Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.
40801556|NCT04120844|BEHAVIORAL|Traditional lecture style health education|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
40801557|NCT04979026|DEVICE|active ankle pumping with a regular watch alarm|In addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge.
40801558|NCT04979026|DEVICE|intermittent pneumatic compression|In this group, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
40801559|NCT04631198|OTHER|Thoracoabdominal rebalancing|the patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
40801560|NCT03671421|PROCEDURE|ACL reconstruction - graft choice|Use of 3 different ipsilateral autograft options
40801561|NCT05291546|DRUG|REGN9035|Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
40801562|NCT05291546|DRUG|REGN5381|Part B: Selected doses administered by IV infusion on day 1.
40801563|NCT05291546|OTHER|Placebo|Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.
40801564|NCT05117684|PROCEDURE|Novel|Balloon- Occlusion thrombolysis was done in adjunct to thrombus maceration, balloon sweeping and thrombosuction.
40801565|NCT05117684|PROCEDURE|Conventional|Continuous catheter directed thrombolysis (Continuous urokinase infusion) was done along with thrombus maceration, balloon sweeping and thrombosuction.
41005582|NCT06306443|DRUG|extended-release buprenorphine (XR-B)|buprenorphine
41005583|NCT05797506|DRUG|Sulforaphane (Avmacol Extra Strength)|4 Tablets of Sulforaphane (Avmacol Extra Strength) per day in patients with Chronic Kidney Disease, stages 3-4.
41005584|NCT05797506|DIETARY_SUPPLEMENT|Placebo|These tablets will be matched placebos and will be provided by Avmacol.
40801566|NCT06478316|PROCEDURE|Intracervical block|local injection of lidocain to the cervix
40801567|NCT00162591|DRUG|remifentanyl|
40801568|NCT06176781|DRUG|Edaravone Dexborneol Sequential Therapy|Sequential treatment started with intravenous injection of edaravone dextrocamphorol 37.5 mg, twice a day for 5-10 days. Then, Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days (the total course of the two drugs was 14 days, a total of 28 times).
40801569|NCT06176781|DRUG|Placebo|Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
40801570|NCT06433479|DRUG|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation
40801571|NCT03357029|DEVICE|GammaCore Device|GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.
40801572|NCT03357029|DEVICE|Sham Device|Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
40801573|NCT05150340|DRUG|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
40801574|NCT00699387|DRUG|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
40801575|NCT03614741|DRUG|Tinzaparin continuous infusion|4500 IU continuous infusion of Tinzaparin
40801576|NCT03614741|DRUG|Tinzaparin bolus|4500 IU bolus of Tinzaparin
40801577|NCT04483193|DIAGNOSTIC_TEST|Duplex ultrasound|Point-of-Care compression ultrasound test combined with colour doppler imaging in the range from the groin to the popliteal region of both lower extremities.
41005585|NCT05508529|DIETARY_SUPPLEMENT|Chaga Mushroom|Effect of chaga on immune/mood support
41005586|NCT05508529|DIETARY_SUPPLEMENT|Algae Extract|Effect of algae extract on immune/mood support
41005587|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil|Effect of black cumin seed oil on immune/mood support
41318886|NCT03696706|RADIATION|LED photobiomodulation|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
41005588|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil + Astaxanthin|Effect of Black Cumin Seed Oil + Astaxanthin blend on immune/mood support
41318887|NCT03696706|RADIATION|Placebo LED photobiomodulation|In this group, the same procedures as the LED group will be made, but the device will be turned off.
41318888|NCT04841720|DRUG|HSK16149|HSK16149 capsules for single use: D1-D4 oral HSK16149 capsules 80 mg BID, D5 only oral HSK16149 capsules 80 mg in the morning on an empty stomach; wash-out period is about 4 days (D5-D8);
41005589|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil + Omega 3|Effect of Black Cumin Seed Oil + Omega3 blend on immune/mood support
41318889|NCT04841720|DRUG|Metformin Hydrochloride tablet|Metformin hydrochloride tablets for single use: D9-D11 oral metformin hydrochloride tablets 500 mg BID, D12 only take 500 mg metformin hydrochloride tablets in the morning on an empty stomach; wash-out period is about 4 days (D12-D15);
41318890|NCT04841720|DRUG|HSK16149+Metformin（phase 3）|Combined use of HSK16149 capsules and metformin hydrochloride tablets: D16-D19 oral metformin hydrochloride tablets 500 mg BID, D16-D19 oral HSK16149 80 mg BID; D20 oral metformin hydrochloride tablets 500 mg and HSK16149 capsules 80 mg in the morning on an empty stomach.
41318891|NCT04840706|DEVICE|HFNC Airvo|HFNC device (Airvo) long-term use in in stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute exacerbation of COPD
41318892|NCT04840706|OTHER|Standard care|No HFNC treatment
41318893|NCT05041322|DRUG|Buspirone|Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
41318894|NCT05041322|DRUG|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
40801578|NCT04835220|OTHER|Telehealth Calls|The telehealth nurse will record data in a case report form within the VA REDCap electronic data capture system that is stored within the VA firewall.
41005590|NCT05508529|DIETARY_SUPPLEMENT|Placebo|Placebo control
40801579|NCT00212875|DRUG|epoetin alfa|
41005591|NCT01077960|BIOLOGICAL|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
41005592|NCT00786695|DRUG|esomeprazole|esomeprazole (40 mg o d) for 14 days
41005593|NCT00786695|DRUG|Placebo|Identical looking Placebo, same regimen, for 14 days
41005594|NCT02515266|OTHER|nutrition: protein intake|additional protein fortification of human milk
41005595|NCT02118428|DEVICE|Mirasol-treated Whole Blood|Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
41318895|NCT00225290|DRUG|Thalidomide(Thado)|
41318896|NCT02262884|DEVICE|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
41318897|NCT02262884|DEVICE|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
41318898|NCT02786940|DEVICE|Cardiophone|Remote live monitoring for 15 days for detection or exclusion of arrhythmias
41318899|NCT04899713|OTHER|Survival survey|To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.
41005596|NCT02118428|BIOLOGICAL|Untreated Whole Blood|Transfusion with untreated fresh Whole Blood
41005597|NCT00937638|DIETARY_SUPPLEMENT|BOLD Diet|Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
41005598|NCT00937638|DIETARY_SUPPLEMENT|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
41005599|NCT00937638|DIETARY_SUPPLEMENT|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
41318900|NCT01532713|PROCEDURE|oxygen administration|nasal O2 5L/min via nasal cannula
41318901|NCT02140619|BEHAVIORAL|multiple health education interventions|
41318902|NCT06191965|DRUG|MitoQ|"MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~1. Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~2. CAS number: 444890-41-9 (phosphonium cation)~3. Molecular weight: 678.81~4. MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS986annex2.pdf?ua=1).~5. MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ."
41318903|NCT06191965|DRUG|Placebo|Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
41318904|NCT03119246|OTHER|CAPIT-HD beta|New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
40801580|NCT04923633|DEVICE|Quantifiable Soft Tissue Manipulation (QSTM)|Quantifiable soft tissue manipulation (QSTM) is a force sensing device system that can be used by a clinician to apply a massaging force while the system monitors objective metrics, i.e., the amount, rate, and angle of force applied.
40801581|NCT05586906|DEVICE|Multiple Breath Washout (MBW) tests|LCI measurements (EXHALYZER® D with Nitrogen Washout System, ECO Medics AG) will be performed every month during follow-up beginning 3 months after lung transplantation.
41318905|NCT03377244|BEHAVIORAL|HBHS|Faith based diabetes curriculum that teaches participants to connect faith and health plus church-level policy changes that encourages participants to engage in healthy behaviors.
41318906|NCT03377244|BEHAVIORAL|HBHS Policy|Church-level policy changes that encourages participants to engage in healthy behaviors.
41318907|NCT03377244|BEHAVIORAL|WORD DPP|Faith based diabetes curriculum that teaches participants to connect faith and health.
41318908|NCT00070980|PROCEDURE|Massage therapy|
41318909|NCT00830570|OTHER|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
40801582|NCT00249808|DRUG|Efalizumab - anti-CD11a recombinant human monoclonal antibody|Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment \[FT\]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
40801583|NCT03711370|OTHER|Clear Bottle|These mothers received usual care from their pediatric providers and each mother was given 12 conventional, clear bottles of various sizes (4-12 ounces) that were compatible with a variety of different nipples manufactured by leading bottle companies. Mothers were also given handouts about proper formula preparation and paced bottle-feeding, which included messages about feeding in response to infant cues.
40801584|NCT03711370|OTHER|Opaque Bottle|These mothers received everything provided to the clear group, but instead received 12 opaque bottles of various sizes (4-12 ounces). These bottles were stainless steel and compatible with a variety of different nipples manufactured by a leading bottle company. Mothers in the intervention group also received an additional handout that contained safety tips for their opaque bottles (e.g., never microwave your bottle).
41157104|NCT04403178|DIAGNOSTIC_TEST|Radiographic examination with a Migration of > 40 %|Radiographic examination
40801585|NCT02723552|BEHAVIORAL|Aerobic Exercise|40 minute aerobic exercise sessions 3x/week.
40801586|NCT02688699|PROCEDURE|EndoClot|"All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.~Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs."
40801587|NCT02120768|PROCEDURE|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
40801588|NCT01703052|DRUG|CHF 6001 SD or placebo|Dry Powder Inhaler
40801589|NCT01703052|DRUG|CHF 6001 MD or placebo|Dry Powder Inhaler
40801590|NCT04245449|BEHAVIORAL|TEAACH|"TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required \~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities."
40801591|NCT05849272|DRUG|toludesvenlafaxine hydrochloride sustained-release tablets|orally once a day
40801592|NCT01364480|DEVICE|Implantation of NeuroPort Arrays in the motor cortex|Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
40801593|NCT01267864|DRUG|Metoclopramide|10mg IVSS
40801594|NCT01267864|DRUG|Ketorolac|30g IVSS
40801595|NCT01267864|DRUG|Valproate|1gm IVSS
40801596|NCT03540706|DIAGNOSTIC_TEST|Care with C-reactive protein assay in micro method|Care with C-reactive protein assay in micro method
40801597|NCT00086528|DRUG|XL647|Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
41157105|NCT05844436|DRUG|Pritelivir|Participants receive a loading dose of 400 mg (4 x 100 mg tablet) pritelivir on first day followed by continuous dose of 100 mg per day.
41157106|NCT01624012|DEVICE|NIV NAVA|Non invasive ventilation with neurally adjusted ventilatory assist
41157107|NCT01624012|DEVICE|Nasal continuous positive airway pressure|Noninvasive respiratory support with continuous positive airway pressure
41157108|NCT03334799|DEVICE|sacroiliac belt|standing and walking with the belt on and with the belt off
41157109|NCT06553768|DRUG|Maralixibat|Maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), the study drug (maralixibat) will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of maralixibat. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (at least 16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
41005600|NCT01092247|OTHER|Nutritional support with Standard diet|Nutritional support with Standard diet
41318910|NCT02957149|OTHER|Autologous Platelet-Rich Plasma|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
41005601|NCT01092247|OTHER|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
41005602|NCT05901727|OTHER|No intervention|Observational data collection only.
41005603|NCT04977843|PROCEDURE|EARLY BRONCHOALVEOLAR LAVAGE|E-BAL done with instillation of 100cc normal saline and sucked out
41005604|NCT04708327|DRUG|STAT-205|naltrexone hydrochloride capsules 4.5 mg each
41005605|NCT00354172|BIOLOGICAL|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If \< 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
41005606|NCT00354172|BIOLOGICAL|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
41005607|NCT00354172|BIOLOGICAL|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
41005608|NCT00354172|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
41005609|NCT00354172|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of \>200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
41005610|NCT00354172|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
41005611|NCT00354172|DRUG|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
41005612|NCT00354172|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (\<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9 /L)."
41005613|NCT00354172|PROCEDURE|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
41318911|NCT02957149|DEVICE|Angel Concentrated Platelet Rich Plasma System|
41318912|NCT01745991|DEVICE|CoSeal spray|
41318913|NCT00505232|DRUG|Y-90 Ibritumomab tiuxetan|"Study Design~The present study will be split into two cohorts:~1. Patients younger than 60 years who will receive 8 chemotherapy cycles~2. Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) \[0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets \< 100,000/µl\] will be administered 8 to 12 weeks after last chemotherapy."
41318914|NCT00238225|DIETARY_SUPPLEMENT|calcitriol|
41318915|NCT00238225|DRUG|dexamethasone|
41005614|NCT00354172|RADIATION|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13)."
41318916|NCT00238225|DRUG|ketoconazole|
41318917|NCT02990819|DEVICE|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
41318918|NCT01996891|OTHER|Anti-Inflammatory Diet|The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
41318919|NCT00335998|DRUG|triapine|Given IV
41005615|NCT01345279|DRUG|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
41005616|NCT01345279|DRUG|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
41005617|NCT01345279|DRUG|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
41005618|NCT00381420|DEVICE|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
41475455|NCT00207194|BEHAVIORAL|Automated Telephone Program|The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.
41005619|NCT00381420|DEVICE|bare-metal stent|un-coated Bx VELOCITY Stent
41318920|NCT00335998|OTHER|laboratory biomarker analysis|Correlative studies
41318921|NCT00335998|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
41318922|NCT00335998|RADIATION|brachytherapy|Undergo intracavitary or interstitial brachytherapy
41318923|NCT00335998|DRUG|cisplatin|Given IV
41318924|NCT00335998|OTHER|pharmacological study|Correlative studies
41318925|NCT06390254|OTHER|Resilience-Enhancing Nursing Suppor|The resilience-building nursing intervention in this study is a multifaceted approach aimed at enhancing the psychological well-being and coping abilities of community-dwelling older adults. Unlike standard care, which typically focuses on symptom management, this intervention emphasizes proactive strategies to promote resilience and improve overall quality of life.
41318926|NCT03891394|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein 4 serum level in predicting persistent proteniuria
41005620|NCT00984581|DRUG|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
41005621|NCT00984581|DRUG|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
41005622|NCT00984581|DRUG|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
41005623|NCT06293846|BEHAVIORAL|What I Learned at Home|What I Learned at Home is a self-efficacy intervention intended to build home repair and management skills while improving performance self-efficacy.
41005624|NCT03641352|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
41005625|NCT03641352|DRUG|Placebo|Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
41318927|NCT01557764|DRUG|lapatinib ditosylate|Given PO
41318928|NCT01557764|BIOLOGICAL|trastuzumab|Given IV
41005626|NCT04528758|DRUG|Rhodamine 6G|Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
41005627|NCT01043796|OTHER|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
41005628|NCT01043796|OTHER|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
41005629|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid
41005630|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid
41005631|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid
41005632|NCT01561768|BIOLOGICAL|Novavax Trivalent vaccine|Trivalent Dose; intramuscular injection, deltoid
41005633|NCT01561768|BIOLOGICAL|cTIV|Preconfigured dose; intramuscular injection, deltoid
41005634|NCT00968591|DRUG|Everolimus|
41318929|NCT02746523|OTHER|Sensory Organization Test|Balance and proprioception test
41318930|NCT02746523|GENETIC|Biomarkers|Blood, urine, and saliva biomarkers
41318931|NCT02746523|OTHER|Conners' Adult ADHD Rating Scale (CAARS)|Adult ADHD rating scale
41318932|NCT02746523|OTHER|Depression Scale|Becks Depression Inventory and Patient Health Questionnaire 9 (PHQ-9)
41318933|NCT02746523|OTHER|Cognitive Assessment|Montreal Cognitive Assessment (MoCA)
41318934|NCT03441893|DIAGNOSTIC_TEST|parasitological diagnostics (coproscopy)|Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
41318935|NCT03441893|DRUG|Nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
41318936|NCT03441893|DRUG|Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
41318937|NCT03441893|DRUG|Mesalazine 250Mg|Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
41318938|NCT03441893|DRUG|Placebo tabletes|Tab. Placebo (shugar pills) will be given to the participants
41318939|NCT01746940|DRUG|Cocaine HCl 4% Topical Solution|Cocaine HCl 4% Topical Solution
41318940|NCT01746940|DRUG|Cocaine HCl 10% Topical Solution|Cocaine HCl 10% Topical Solution
41318941|NCT01746940|DRUG|Placebo Topical Solution|Placebo Topical Solution
41318942|NCT05551598|DRUG|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 12 weeks (Q12W)
41475456|NCT00207194|BEHAVIORAL|Health Behavior Education|Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
41005635|NCT04272398|OTHER|dynamic elastomeric fabric orthoses|Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
41005636|NCT03388190|DRUG|Nivolumab|"FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.~Nivolumab: 240 mg flat dose; IV administration every 2 weeks."
41005637|NCT03388190|DRUG|FLOX|FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.
41005638|NCT01471548|DRUG|TKI258|
41005639|NCT00742976|DRUG|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
41005640|NCT00742976|DRUG|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
41005641|NCT03379116|OTHER|enteral nutrition and parenteral nutrition|In the treatment of the burned patients injured,data on nutritional support and patient's outcomes were collected and analyzed.
41005642|NCT05236309|DRUG|Jing-Guan-Fang(JGF) : Chinese herbal decoction|Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
41005643|NCT00403273|DRUG|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
41005644|NCT00403273|DRUG|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
41005645|NCT00595569|BEHAVIORAL|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
41005646|NCT00203749|BEHAVIORAL|Community-Based HIV VCT|"COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.~EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.~POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission."
41005647|NCT00203749|BEHAVIORAL|Standard clinic-based VCT|Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
41005648|NCT05217797|BEHAVIORAL|Wearing glasses (any type)|Participants are asked to wear glasses in public spaces.
41475457|NCT03329976|OTHER|measurement of visual acuity|complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
40801598|NCT03758131|BEHAVIORAL|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
40801599|NCT03758131|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
41005649|NCT06197451|OTHER|Turkish Version of M. D. Anderson Dysphagia Inventory|Turkish Validation and Cultural Adaptation of M. D. Anderson Dysphagia Inventory in Neurologic Patients
41475458|NCT04951414|DIAGNOSTIC_TEST|ICF core set|KOA rehabilitation regimen based on the complete core combination of ICF was accepted
40801600|NCT03758131|OTHER|Waitlist Control|Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention. Then those in the Waitlist Control condition will receive the full PMI protocol.
40801601|NCT01472354|BEHAVIORAL|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
41005650|NCT00889343|DRUG|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
41005651|NCT00889343|DRUG|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
41475459|NCT03563846|DRUG|RP-G28|RP-G28 is a purified galacto-oligosaccharide (GOS) product
41475460|NCT04619199|DIAGNOSTIC_TEST|Blood sample|Blood sample performed at the inclusion and during the follow-up.
41475461|NCT06163872|BEHAVIORAL|survey study|survey study
41475462|NCT05002686|DRUG|Sintilimab|200 mg Q3W on Day 1 by IV infusion
41475463|NCT05002686|DRUG|Albumin-Paclitaxel|200 mg/m\^2 Q3W on Day 1 by IV infusion
41475464|NCT05002686|DRUG|Capecitabine|1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
41475465|NCT05002686|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
41005652|NCT00889343|DRUG|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
41005653|NCT00889343|DRUG|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
41318943|NCT03448861|DEVICE|Polso Wearebale watch|The objective of the Polso™ feasibility study is to demonstrate the suitability of Polso™ as a data acquisition and processing platform by comparison with the conventional British version of EWS (UK-NEWS) on aggregate and on each individual parameter score. Although in a full NEWS system, the frequency of testing is determined by the score itself, this aspect will not be evaluated, in the event that a divergence of scores would complicate clinical evaluation and correspondence of readings. In addition, good clinical practice calls for patient care to be fully motivated by the NEWS currently in use, as opposed to the experimental Polso™. Therefore, this compromise will be made, which will still permits system evaluation.
41318944|NCT02709083|DRUG|Dasatinib|Given orally
41318945|NCT02709083|DRUG|Imatinib Mesylate|Given orally
41318946|NCT02709083|DRUG|Nilotinib|Given orally
41318947|NCT00698035|DRUG|Testosterone Cream|1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
41318948|NCT00698035|DRUG|Estring|2mg ring inserted vaginally once every 12 weeks
41318949|NCT01608490|DEVICE|RePneu Lung Volume Reduction Coil System|The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
41475466|NCT05002686|RADIATION|Radiation|Radiotherapy for gastric lesions and high-risk areas of retroperitoneal lymph node before sugery, 45Gy\*25.
40801602|NCT00901238|PROCEDURE|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
40801603|NCT01116466|DEVICE|ActiGait|ActiGait - implantable drop foot stimulator
40801604|NCT04817475|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
40801605|NCT04470050|DRUG|Dexmedetomidine|Sublingual Film of Dexmedetomidine
40801606|NCT04470050|DRUG|Placebo|Sublingual Placebo film
40801607|NCT03637361|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
40801608|NCT03637361|DRUG|Placebo|
40801609|NCT05858476|OTHER|21-Day Detox and Green Drink supplement|"Detox plan description:~7AM Water 16oz. 8AM Green Drink 16oz. 9AM Ultra Shake 16oz. 9-12PM Water 24 - 48oz. 12PM Green Drink 16oz. 12:30 - 2PM Water 24 - 48oz. 2PM Green Drink 16oz. 3PM Ultra Shake 16oz. 3:30- 6PM Water 24 - 48oz. 6PM Green Drink 16oz. 7PM Detox Soup 16oz. 7:30 - 10PM Water 24 - 48oz. This 21-day period will be followed by 7 days of consuming the Green Drink Supplement."
40801610|NCT01147250|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
40801611|NCT01147250|DRUG|Placebo|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
40801612|NCT05484973|DEVICE|AMMA Portalbe Scalp Cooling System|AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
40801613|NCT05524857|DRUG|Fedratinib Oral Capsule 300 mg|300 mg by mouth, once daily
40801614|NCT05524857|DRUG|Decitabine 20 mg/m2|20 mg/m2 for injection, for intravenous use
40801615|NCT05524857|DRUG|Fedratinib Oral Capsule 400 mg|400 mg by mouth, once daily
40801616|NCT01503684|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
40801617|NCT05815433|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
40801618|NCT03280199|OTHER|simulation types|Different types of simulation interfaces and image acquisitions
40801619|NCT03146559|DEVICE|EMG and TENS|Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
40801620|NCT03146559|DEVICE|TENS only|Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
40801621|NCT01934712|DRUG|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
40801622|NCT01934712|DRUG|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
40801623|NCT04227795|DEVICE|Artificial intelligence-Assisted real time colonoscopy|The colonoscopy was performed under artificial intelligence assistance
41005654|NCT00889343|DRUG|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
41005655|NCT04341896|OTHER|Caregivers|Individuals who cared for themselves and their transplant recipient before and after kidney donation
41318950|NCT05166746|DRUG|Clindamycin|Oral clindamycin 300mg/2xdaily in 7 days. LACTIN-V applicators 1x at night in 7 days, then 2xper week at night for 7 weeks.
41318951|NCT05166746|OTHER|Placebo|"The Clindamycin placebo appear identical to active clindamycin by filling capsules with Mannitolium.~The LACTIN-V placebo product has no intrinsic effect and is used to study the effect of the therapeutically active product. It is supplied as a pre-filled vaginal applicator packaged under nitrogen gas with one desiccant packet (0.25 g) in a sealed foil pouch. Each applicator contains 200 mg of LACTIN-V placebo powder containing the inactive ingredients of the LACTIN-V drug product, but not Lactobacillus crispatus CTV-05 (CTV-05), the active ingedient. The excipients used in the manufacture of LACTIN-V placebo are identical to those in the LACTIN-V drug product. Each placebo applicator contains the following constituents: maltodextrin, trehalose, xylitol, colloidal silicon dioxide, and sodium ascorbate"
41318952|NCT02561299|DEVICE|Peripheral Orbital Atherectomy System|Orbital Atherectomy
41318953|NCT02561299|DEVICE|014 Drug Coated Balloon|Drug Coated Balloon
41318954|NCT04065373|DEVICE|ivWatch Model 400 with SmartTouch and fiber optic sensor|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored tissue at common IV sites over a 24 hour period.
41318955|NCT00413335|DRUG|Rosiglitazone|2mg to begin then 4mg, twice daily for 4 months
40801624|NCT05011136|OTHER|No intervention. This is a qualitative study|US nephrologists who care for dialysis patients will be asked to complete an internet based survey evaluating the time and effort required for home dialysis patient care.
40801625|NCT01604577|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
40801626|NCT03916536|PROCEDURE|Holmium Laser|Holmium laser enucleation of large sized prostate
40801627|NCT03916536|PROCEDURE|Thulium Laser|Thulium laser enucleation of large sized prostate
40801628|NCT03916536|PROCEDURE|Bipolar diathermy|Bipolar enucleation of large sized prostate
40801629|NCT05750056|DRUG|lidocaine|Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
40801630|NCT05750056|DRUG|0.9% saline|Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
40801631|NCT05750056|DRUG|Propofol|An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
41005656|NCT04341896|OTHER|Non-caregivers|Individuals who donated a kidney as a living donor but did not serve as the primary caregiver for their recipient
41005657|NCT01007695|DRUG|Valproic Acid|Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
41005658|NCT04190186|DEVICE|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
41005659|NCT03212963|DRUG|Halobetasol Topical Lotion|Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
41005660|NCT06492811|DRUG|GAT@F nanoenzyme hydrogel complex|The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
41318956|NCT00413335|DRUG|Placebo|Subject receives placebo.
41318957|NCT05123612|BEHAVIORAL|Fiber|Additional 20 grams of fiber/day.
41318958|NCT05123612|BEHAVIORAL|Fermented Foods|6 servings of fermented foods/day
41318959|NCT00160576|DRUG|Levetiracetam|
41475467|NCT05002686|PROCEDURE|Radical gastric cancer surgery|Radical gastric cancer surgery with D2 lymph node dissection
40801632|NCT05750056|DRUG|Sufentanil|Sufentail 0.1 ug/kg was administered for sedation induction.
40801633|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
40801634|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine|0.5 mL, IM
40801635|NCT06454279|OTHER|Dual Task Training|"Exercise which combines cognitive task with motor task e.g Backward counting during sit ups.~Calculation questions during stationary cycle for 10 mins. Sequentially perform movements on commands like normal standing (bipedal support with feet separated at shoulder width, Feet together (bipedal support with feet side by side), Semitandem stance, Tandem stance, one leg support on the dominant leg, one leg support on the nondominant leg by first laterally moving the trunk with shoulder abducted at least above 60 degree"
40801636|NCT06454279|OTHER|Task Specific Training|"Wide based gait training.~Auditory forward digit span:~Remember as many as possible of the number/letter forward sequence, you were told~Auditory backward digit span:~Remember as many as possible of the number/letter back sequence, you were told~Visual forward digit span:~Remember as many as possible of the number forward sequence shown to you by means of cardboard~Visual backward digit span:~Remember as many as possible"
41318960|NCT05948410|BEHAVIORAL|The State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) is a psychological inventory consisting of 40 self-report items on a 4-point Likert scale. The STAI measures two types of anxiety - state anxiety and trait anxiety. Higher scores are positively correlated with higher levels of anxiety.
41475468|NCT05460559|PROCEDURE|Group A (p-PCNL) procedure|In lithotomy position, ureteric catheter will be inserted allowing injection of contrast to obtain a pyelogram. Shifting the patients in prone position will be done. Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
41005661|NCT00950534|DRUG|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
41005662|NCT00950534|DRUG|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
41475469|NCT05460559|PROCEDURE|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
41475470|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 4 mg ephedrine in 10 ml saline was usd Intravenously
41318961|NCT05948410|BEHAVIORAL|Perceived Stress Scale|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes a number of direct queries about current levels of experienced stress. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all scale items. A short 4 item scale can be made from questions 2, 4, 5 and 10 of the PSS 10 item scale
41475471|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 8 mg ephedrine in 10 ml saline was usd Intravenously
41475472|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 12 mg ephedrine in 10 ml saline was usd Intravenously
41475473|NCT06014528|DRUG|IN10018|100mg QD orally (PO)
41475474|NCT06014528|DRUG|Placebo of IN10018|100mg QD orally (PO)
41318962|NCT05948410|BEHAVIORAL|Visual Analog Scale|The visual analogue scale (VAS) is a psychometric response scale that can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end points.
41005663|NCT02307552|DEVICE|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
41005664|NCT01720459|DIETARY_SUPPLEMENT|Micronized trans-resveratrol|
41318963|NCT05606679|GENETIC|Analysis combinations of maternal KIR and HLA-C genotypes|Analysis of combinations of maternal KIR and HLA-C genotypes of the egg donor and fetus (based on the genotypes of the donor and male partner), as well as different HLA-F SNP genotypes of the recipients
41475475|NCT06014528|DRUG|Pegylated Liposomal Doxorubicin|40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
41475476|NCT02907099|DRUG|CXCR4 Antagonist BL-8040|Given SC
41475477|NCT02907099|BIOLOGICAL|Pembrolizumab|Given IV
41475478|NCT02907099|OTHER|Pharmacological Study|Correlative studies
41475479|NCT00949195|OTHER|Measure pulmonary artery pressure change during exercise|Semi-supine echocardiography test
41475480|NCT00949195|OTHER|Pulmonary pressure response during exercise|Semi-supine echocardiography test
41475481|NCT01633294|DRUG|Ampicillin + gentamicin|ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
41318964|NCT05393921|DRUG|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
41475482|NCT04744155|BEHAVIORAL|Multi-Level Intervention|Behavioral intervention that assesses uptake of contraception and seeks follow-up care.
41475483|NCT04744155|BEHAVIORAL|Enhanced Standard of Care|Behavioral intervention that assesses uptake of contraception from follow-up care.
41475484|NCT02484313|OTHER|dietary treatments|commercially available food products
41475485|NCT02241135|BIOLOGICAL|CV7201 mRNA|CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
41475486|NCT04449536|DRUG|Mesna|Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg
41475487|NCT05998551|DRUG|Dexmedetomidine|intrathecal injection of dexmedetomidine added to hyperbaric bupivacaine
41475488|NCT05998551|DRUG|Fentanyl|intrathecal injection of fentanyl added to hyperbaric bupivacaine
41475489|NCT05998551|DRUG|Bupivacaine Hcl 0.5% Inj|intrathecal injection of hyperbaric bupivacaine only
41475490|NCT02328950|DRUG|Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide|Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
41005665|NCT01720459|DIETARY_SUPPLEMENT|Placebo|
41005666|NCT02412969|PROCEDURE|Lumbar Epidural|control group will receive lumbar puncture epidural
41005667|NCT02412969|PROCEDURE|Dural Puncture Epidural|intervention group will receive a dural puncture epidural
41005668|NCT05023590|PROCEDURE|ablation of left atrium during mitral valve open chest intervention|open chest mitral valve surgery (reconstruction or replacement) with additional ablation of left atrium by cryo or radio frequency method
40801637|NCT01498744|DRUG|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
41318965|NCT01254513|DRUG|Docetaxel every 3 weeks + Prednisone|"* Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks~* Prednisone 10 mg/day continuously"
41005669|NCT03660410|OTHER|Anamnesis|A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication
41005670|NCT03660410|OTHER|Oral clinical examination|Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
41005671|NCT01567488|DRUG|Everolimus|Everolimus 10mg/day
41005672|NCT01567488|DRUG|octreotide LAR|30 mg each 28 days
41005673|NCT06143475|DEVICE|FPS group|"Vibration frequency ranged from 0 to 100 Hz. There were 3 modes of FPS application during rehabilitation course. 1) anti-spasticity mode (FV): the stimulators were placed in the middle of the muscles of the affected limb (i.e. unilaterally); 2) bilateral mode of proprioceptive facilitation; and 3) the unilateral mode of the proprioceptive facilitation.~The 2 first sessions were realized with bilateral FPS stimulations plus the anti-spasticity FV mode to reduce the level of hypertonia. Then for 6 consecutive sessions unilateral FPS stimulations of the affected sides imitating the drawing of a straight lines (horizontal, vertical, diagonal), preparing for writing (drawing a circle, triangle, square, spiral) were realized. At last, the 4 remaining FPS sessions were realized unilaterally imitating and promoting the realization of everyday life activities."
41318966|NCT01254513|DRUG|Docetaxel weekly+ Prednisone|"* Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)~* Prednisone 10 mg/day continuously"
41005674|NCT06143475|OTHER|Conventional therapy group|Patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
41318967|NCT05837052|PROCEDURE|serplulimab plus chemotherapy as conversion treatment|Patients with unresectable NSCLC will receive serplulimab plus chemotherapy as conversion treatment, and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions.
41318968|NCT01697267|BIOLOGICAL|Rituximab|Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.
41318969|NCT01697267|DRUG|Azathioprine|"Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.~The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.~If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%."
41005675|NCT02142530|DRUG|Carfilzomib|
41005676|NCT02142530|DRUG|Belinostat|
41005677|NCT06043323|DRUG|Axicabtagene Ciloleucel|Given by IV (vein)
40801638|NCT02688829|DEVICE|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
40801639|NCT00171457|DRUG|Tegaserod|
41005678|NCT06043323|DRUG|Cyclophosphamide|Given by IV (vein)
41005679|NCT06043323|DRUG|Fludarabine phosphate|Given by IV (vein)
41005680|NCT06043323|DRUG|Prednisone|Given by IV (vein)
41005681|NCT06043323|DRUG|Diphenhydramine|Given by IV (vein)
41005682|NCT06043323|DRUG|Acetaminophen|Given by IV (vein)
41005683|NCT01574352|BEHAVIORAL|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
41005684|NCT01574352|BEHAVIORAL|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
41005685|NCT04085822|DEVICE|SMA-001|Intra-dermal injection of SMA-001 and control device.
41005686|NCT00175903|DRUG|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
41005687|NCT00175903|DRUG|Carbamazepine Controlled Release (CBZ-CR)|Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
41005688|NCT00175903|DRUG|Valproate Extended Release|Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
41005689|NCT00358462|DRUG|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
41005690|NCT00358462|DRUG|Doxycycline|one 100mg capsule administered twice daily for seven days
41005691|NCT00720941|DRUG|Pazopanib|800 mg administered once daily orally continuous dosing
41005692|NCT00720941|DRUG|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
41005693|NCT02678039|DEVICE|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
41318970|NCT05078606|DEVICE|IJV Ultrasonography|"Patient will be in supine position, The linear probe with frequency of 7- 12 M hz; depth of 3 cm. maximum IJV diameter (IJV-D) and area (IJV-A) will be recorded. M-mode will be used to obtain the distance between the 2 walls of the vein during inspiration and expiration.~Then, the patient will be positioned 10° Trendelenburg and similar ultrasonographic measurements will be again performed"
41318971|NCT05078606|DEVICE|Carotid Intima Media Thickness|"US Probe is slided superiorly (toward the head) or inferiorly (toward the feet) until the bifurcation of the common carotid artery (CCA) appears on the left side of the screen. This is the ideal location for imaging and CIMT measurements.~IMT is assessed in longitudinal view from the arterial far wall, along a 10mm length. CIMT will appear as two parallel lines (leading edges of two anatomical boundaries) from it: lumen- intima and media- adventitia interfaces perpendicular to ultrasound beams."
41318972|NCT05078606|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed in the sitting position at level of L3-4 or L4- 5 interspaces with a 25-gauge spinal needle. Local infiltration of skin and subcutaneous tissue with 2% lignocaine will be applied. After confirming cerebrospinal fluid flow, 10 mg of 0.5% hyperbaric bupivacaine plus 25 mcg fentanyl will be injected. The degree of sensory block (cold test by alcohol gauze) will be assessed in the study with a goal of T8 dermatomal level block.
41475491|NCT06363253|OTHER|No specific intervention|"Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group).~Follow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention~Control subjects will have no interventions performed as well."
41318973|NCT03983928|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
41318974|NCT03983928|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
41475492|NCT03331614|DEVICE|Flowaid FA-100 SCCD|The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.
41475493|NCT03959995|OTHER|High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT)|Ambulatory, consistently supervised group exercise training (3 training sessions of 40-45 min/week each). 10-12-week blocks of non-linearly periodized high intensity resistance and high impact aerobic dance exercises (HIT-setting) intermitted by 4-6-week periods of endurance-type exercise with high volume and lower intensity. Indi-vidualized training schedules for the RT-section.
41475494|NCT03959995|OTHER|Wellness|control group: 3x 10 week blocks, 1 training session/week à 45 min; stretching, light functional gymnastics, yoga with less strengthening techniques over 13 months.
41475495|NCT03623620|BEHAVIORAL|Digital Delivery of Mindfulness-Based Cognitive Therapy|12-week program that emphasizes mindfulness and cognitive behavioral skills
41475496|NCT01999426|OTHER|Airway clearance intervention|Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
41475497|NCT06347432|OTHER|Power wheelchair skills training using the IndieTrainer system|The IndieTrainer system will be used to provide the power wheelchair (PWC) skills training sessions. The IndieTrainer is comprised of a mobility device and an array of video-based gamified training modules designed to facilitate PWC training. The IndieTrainer mobility device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. Principles outlined in the Assessment of Learning Powered mobility use (ALP) Facilitating Strategies for each ALP Assessment phase will guide the intervention sessions.
41475498|NCT02130167|DRUG|Atropine|Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
40801640|NCT04760860|DRUG|Terazosin Hydrochloride|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
40801641|NCT04760860|OTHER|Placebo|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.
41005694|NCT02678039|PROCEDURE|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
41005695|NCT05703191|DEVICE|Nitric Oxide Generator and Delivery System|Initial at 20ppm is recommended by guidelines. The concentration is adjusted based on actual condition of subjects.
41005696|NCT04431362|BEHAVIORAL|Self-selected music|Participants will be given iPods and headphones to listen to their music
41005697|NCT01954485|PROCEDURE|Dental implant placement with a final prosthetic abutment|
41005698|NCT05263661|PROCEDURE|LIFT|Ligation of fistula tract between external and internal sphincter
41005699|NCT05263661|PROCEDURE|FLAP|Creation of a partial wall rectal flap to close internal opening of fistula tract
41318975|NCT04851002|PROCEDURE|Application of concentrated growth factor with dental implants|Concentrated growth factor(CGF) liquid applied to the implant cavity also CGF membrane covered socket and implant
41005700|NCT05549193|OTHER|Exercises Training|"Pelvic Floor Muscle Training: For slow contractions, it was asked to contract in 5 seconds gradually, wait at a maximum of 5 seconds and gradually relax in 5 seconds. For fast contractions, it was asked to contract at a maximum of 2 seconds and then to relax. 10 fast + 10 slow contractions were accepted as 1 set exercise. (10 sets x Every Day x 6 weeks)~Transversus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically. 15 repetitions were carried out, each consisting of contraction for 10 s and relaxation for 20 s. 2 sets of 15 repetitions were done.~Internal Obliquus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically and then try to touch the furthest point of their legs with their fingertips for 15 repetitions consisting of contraction for 10 s followed by relaxation for 20 s. The sequence was then repeated on the other leg."
41005701|NCT06413810|OTHER|Calmarell|Food ingredient
41005702|NCT06413810|OTHER|Placebo|Blinded placebo
41005703|NCT03307668|DEVICE|CaReSR-1S|CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.
41005704|NCT03307668|DEVICE|Microfracture|Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
41005705|NCT02807181|DRUG|Cisplatin-gemcitabine|Systemic chemotherapy
41318976|NCT04851002|PROCEDURE|Application of advanced platelet rich fibrin with dental implants|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity also A-PRF membrane covered socket and implant
41318977|NCT04851002|PROCEDURE|Control side of concentrated growth factor study group|Traditional implant methods applied
41005706|NCT02807181|DEVICE|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
41005707|NCT01539382|PROCEDURE|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow \>2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
41005708|NCT00262548|DRUG|Rosuvastatin; improvement of lipid profile|
41005709|NCT01749891|DRUG|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
41005710|NCT03903666|OTHER|Nocturnal gaz exchanges measurement|Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
41005711|NCT04568252|DEVICE|Wristband with millimeter wave emission.|Wristband treatment with millimeter wave emission twice a day for 3 months.
41005712|NCT04568252|DEVICE|Placebo of wristband with millimeter wave emission.|Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
41005713|NCT06406127|DRUG|Alpha Lipoic Acid 600 MG Oral Capsule|Single 600 mg daily dose
41005714|NCT03784612|BEHAVIORAL|App-technology for healthy eating habits|Access to smartphone-app, including a 12 week healthy eating program. A new theme on healthy dietary habits is presented each week.
41005715|NCT02397863|DRUG|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
41005716|NCT02224365|DIETARY_SUPPLEMENT|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
41005717|NCT02224365|DIETARY_SUPPLEMENT|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
41005718|NCT00011804|DRUG|Topiramate|
41005719|NCT04317248|DRUG|Cyclophosphamide|Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
41005720|NCT04317248|BIOLOGICAL|Multiple Signals loaded Dendritic Cells Vaccine|one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;
41318978|NCT04851002|PROCEDURE|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied
41318979|NCT05052541|DRUG|THC/CBD|Oral solution containing 5mg THC and 50 mg CBD per 1 ml
41475499|NCT05842304|DEVICE|active cTBS|Each patient will receive three 600-pulse cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
40801642|NCT03966209|DRUG|JS001(PD-1 inhibitor)|240mg I.V. Q3W
41318980|NCT05052541|DRUG|THC|Oral solution containing 5mg THC per 1 ml
41475500|NCT05842304|DEVICE|sham cTBS|Each patient will receive three 600-pulse sham cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
41475501|NCT01448356|PROCEDURE|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~1. 25°C and 45% humidity;~2. 25°C and 65% humidity;~3. 30°C and 45% humidity;~4. 30°C and 65% humidity~After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition."
41475502|NCT00206102|DRUG|quetiapine fumarate|flexible dose oral
41475503|NCT00206102|DRUG|risperidone|flexible dose oral
41318981|NCT05052541|DRUG|Placebo|Oral solution containing no active drug
41475504|NCT06617559|PROCEDURE|Anterior Cruciate Ligament Reconstruction with Quadriceps Autograft|The investigators will perform all-inside anterior cruciate ligament reconstruction using only the tendon portion of the quadriceps tendon (without bone fragments) in this group.
41475505|NCT06617559|PROCEDURE|Anterior Cruciate Ligament Reconstruction with Hamstring Autograft|The investigators will perform all-inside anterior cruciate ligament reconstruction using the hamstring tendon as a graft in this group.
41475506|NCT02985879|DRUG|Placebo|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
41475507|NCT02985879|DRUG|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr. For participants in Cohort 2, ABBV-8E12 doses may have been decreased after the evaluation by the Data Monitoring Committee of available safety, tolerability and pharmacokinetic data.
40801643|NCT02562300|DRUG|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
41318982|NCT03019744|DEVICE|MeCFES-assisted task-oriented upper limb rehabilitation|
40801644|NCT02562300|DRUG|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
41005721|NCT01797328|PROCEDURE|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
41005722|NCT01797328|PROCEDURE|warm arm|To the best of ability avoid feeling cold during 6 weeks
41005723|NCT00834912|DRUG|Tramadol hydrochloride|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
41005724|NCT00834912|DRUG|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
41475508|NCT05972018|DRUG|Liposomal bupivacaine|Rectus Sheath Block: Total 60mL: (20mL 1.3% Liposomal bupivacaine + 30mL 0.25% bupivacaine + 10mL NS).(30mL per side)
41475509|NCT05972018|DRUG|Ropivacaine|Total 60mLof 0.2% ropivacaine: (60mL of 0.2% ropivacaine (3 vials)
41475510|NCT05972018|DRUG|Bupivacain|Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS. 30mL per side)
41475511|NCT02449473|BIOLOGICAL|Tralokinumab|Subcutaneous Injection
41475512|NCT02449473|OTHER|Placebo|Subcutaneous Injection
41005725|NCT00834912|DRUG|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
41475513|NCT01514994|DEVICE|AngioScore's Valvuloplasty Scoring Balloon|All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
41475514|NCT03614533|BIOLOGICAL|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
41005726|NCT01034410|DRUG|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
41005727|NCT01034410|DRUG|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
41318983|NCT03019744|OTHER|Usual Care task-oriented upper limb rehabilitation|
41318984|NCT06398106|DRUG|Proactive TDM-based dosing of secukinumab|"Maintenance/normal dose is 300 mg/4 weeks.~First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 300 mg/3 weeks Second dose escalation step: 300 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
41318985|NCT06398106|DRUG|Proactive TDM-based dosing of ixekizumab|"Maintenance/normal dose is 80 mg/4 weeks.~First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 80 mg/3 weeks Second dose escalation step: 80 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
41318986|NCT06398106|DRUG|Proactive TDM-based dosing of guselkumab|"Maintenance/normal dose is 100 mg/8 weeks.~First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 100 mg/6 weeks Second dose escalation step: 100 mg/4 weeks Further dose escalation step: shortening with 1 additional week"
41475515|NCT03614533|BIOLOGICAL|Inactivated Poliovirus Vaccine (IPV)|Single 0.5-ml intramuscular injection
41475516|NCT01913795|OTHER|integrated pest management|integrated pest management and environmental strategy
41475517|NCT01913795|OTHER|air purifier|air purifiers
41475518|NCT01913795|OTHER|Sham air purifier|sham air purifiers
41475519|NCT05306951|DIAGNOSTIC_TEST|Computed tomography|Head computed tomography
41475520|NCT04253015|OTHER|Data-collection|Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.
40801645|NCT04583436|DEVICE|Endovascular recanalization|Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
40801646|NCT04583436|OTHER|Open surgery|Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
40801647|NCT00237666|DRUG|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
40801648|NCT01146184|DEVICE|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
41152429|NCT01825018|BEHAVIORAL|Social Network Leader Endorsement|Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
41152430|NCT01825018|BEHAVIORAL|HIV Counseling|At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
41152431|NCT01233193|BEHAVIORAL|Health education, Home blood pressure monitoring|Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
41152432|NCT06249594|PROCEDURE|targeted sensory reinervation|targeted sensory reinnervation (TSR) in hand amputation by using and reactivation of existing nerves to treat and prevent phantom pain
41152433|NCT03881267|OTHER|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
41152434|NCT03881267|OTHER|Additional Outer Dressing Application|Application of Moisture retentive dressing, and a multi-layer compression dressing
41152435|NCT03881267|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
41152436|NCT01358643|OTHER|Three home-based diet and exercise programs|"All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI \> 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program."
41152437|NCT05716971|PROCEDURE|Densiron-68 (heavy silicone oil) tamponade for retinal detachment|pars plana vitrectomy using Densiron-68 at thee end of surgery
41318987|NCT06345755|DRUG|VX-407|Solution or Suspension for oral administration.
41318988|NCT06345755|DRUG|Placebo|Solution or Suspension for oral administration.
41318989|NCT06345755|DRUG|Midazolam|Syrup for oral administration.
41318990|NCT04406935|DEVICE|treatment with the study device (NuEra)|"Multi-arm, prospective, multi-center, baseline-controlled study:~Arm 1: NuEra treatment using 475 KHz Arm 2: NuEra treatment using 1 MHz Arm 3: NuEra treatment using 2 MHz"
41318991|NCT00280241|DRUG|Fludarabine|Fludarabine is usually administered by IV infusion over 30 minutes or longer.
41318992|NCT00280241|DRUG|Cyclophosphamide|The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
41318993|NCT00280241|DRUG|Rituximab|First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
41318994|NCT00246948|PROCEDURE|Active conservative treatment of sciatica|
41318995|NCT04697433|DEVICE|Myotonometry|The examiner should exert a slight pressure on the determined point to the necessary depth, which will be indicated by changing the color from red to green light on the device. The device has an automatically controlled preload (0.18 Newton (N)) that will be applied to the contact area by an automatic mechanical pulse, with a duration of 15 milliseconds (ms) and a constant force of 0.4 N , these oscillations will be registered by an accelerometer next to the measurement mechanism inside the device. For each evaluation, a series of 10 consecutive pulses (multiscan mode) will be used with an interval of one second between each pulse. In each shot, the tone, stiffness, elasticity, relaxation time and creep will be calculated.
41318996|NCT00215436|DRUG|Formoterol Fumarate|
41318997|NCT05478330|DRUG|Flutamide 1% gel|Group A: Flutamide-treated patients: Consisted of 25 patients with acne vulgaris treated with 1% Flutamide topical gel on the face two times per day for a duration of 8 weeks.
41318998|NCT05478330|DRUG|topical gel without flutamide|Group B: Consisted of 25 patients with acne vulgaris treated with topical gel with the same component as the other group, except for flutamide, on the face twice per day for a duration of 8 weeks.
41318999|NCT05766865|PROCEDURE|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
41319000|NCT05766865|PROCEDURE|Conservative treatment|Standard treatment for intracerebral hemorrhage
41319001|NCT04358198|DIAGNOSTIC_TEST|Artificial intelligence|The AI algorithm based on the convolutional neural network (CNN) will be used for analysis the pictures of gastric intestinal metaplasia and normal mucosa. Then AI will be used as a diagnostic tool for GIM during routine endoscopy by using pathology as a gold standard.
41319002|NCT03001336|OTHER|no intervention|This is a cross-sectional study
41319003|NCT00004095|DRUG|gemcitabine hydrochloride|
41319004|NCT00004095|DRUG|irinotecan hydrochloride|
41319005|NCT05053997|BEHAVIORAL|NAVIGATE|Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
41319006|NCT02215408|BEHAVIORAL|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
41319007|NCT03176173|RADIATION|Image-guided Radiation Therapy|"Ablative treatment as 50 Gy in 5 or 10 fractions.~Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions."
41319008|NCT03176173|DRUG|Immunotherapy (physician's choice for standard of care immunotherapy)|Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.
41319009|NCT01839201|OTHER|control|No psychological intervention
41319010|NCT01839201|OTHER|suggestion|In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
41319011|NCT01839201|OTHER|dreamfilm|In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
41319012|NCT01933750|DEVICE|PresVIEW Device Implantation|
41319013|NCT01295580|DEVICE|ARTZ|Hyaluronic acid (five 2.5 mL injections)
41319014|NCT01295580|DEVICE|DUROLANE|Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)
41319015|NCT04504435|DRUG|GSK3494245|Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
41319016|NCT04504435|DRUG|Placebo|Matching placebo capsules will be provided
41319017|NCT02880397|DRUG|Garcinia mangostana|The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
41319018|NCT02880397|DRUG|Placebo gel|The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
41319019|NCT02858687|OTHER|Nasopharyngeal swab|
41475521|NCT06496074|DIAGNOSTIC_TEST|Head-up Tilt Test|Two protocols for the head-up tilt test (HUTT) are used in our center and in the collaborating centers: (1) passive or prolonged inclination protocol \[40 minutes\], (2) mixed protocol: passive phase \[first 20 minutes\] plus nitrate-provoked phase \[last 20 minutes\], with the use of 1.25 mg sublingual isosorbide dinitrate. All patients are submitted to 10 minutes of rest in the supine position at zero degree before the tilt phase of the HUTT. During this period, HR and systolic (SBP) and diastolic (DBP) measurements are obtained every 2 minutes. After this phase, the table is tilted at an angle of 70° with measurement of SBP / DBP and HR every minute. Patients older than 60 years are routinely investigated for carotid sinus hypersensitivity by carotid sinus massage during the passive phase of the HUTT. The exam is considered positive according to the criteria defined in guidelines.
41475522|NCT03178721|DIAGNOSTIC_TEST|blood sample|study B regulatory in blood and its correlation with atherosclerosis
41475523|NCT02975037|DRUG|Sildenafil|sildenafil 25 mg PO
41475524|NCT02975037|DRUG|Clarithromycin|clarithromycin 250 mg PO
40801649|NCT04190407|BEHAVIORAL|Intravenous access|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
41319020|NCT03428997|DEVICE|Lotion|Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.
41319021|NCT03428997|OTHER|Negative Control|Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
41319022|NCT04093258|DEVICE|Dailies Total 1® Multifocal Contact Lenses|TEST
41319023|NCT04093258|DEVICE|Air Optix® Multifocal Contact Lenses Plus HydraGlyde®|CONTROL
41319024|NCT06472388|DRUG|Everolimus 5 MG|oral everolimus 5 mg/daily
41319025|NCT05444010|BEHAVIORAL|mandala painting|nurse painted mandala for relaksing
41475525|NCT02975037|DRUG|Itraconazole|itraconazole 100 mg PO
41319026|NCT02092441|OTHER|Alcohol prep pad group|Subjects inhale scent of alcohol pad
41319027|NCT02092441|OTHER|Normal Saline prep pad|Subjects inhale scent of placebo (normal saline) pads
41319028|NCT06313177|PROCEDURE|syndesmosis fixation with screws|syndesmosis fixation with Syndesmotic screw in neutral position versus maximum ankle dorsiflexion in ankle fracture
41319029|NCT05982223|PROCEDURE|Acupuncture|The frequency of acupuncture will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
41319030|NCT05982223|PROCEDURE|Mind-body therapy|The frequency of mind-body therapy (hypnosis, guided imagery) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
41319031|NCT05982223|PROCEDURE|Touch therapy|The frequency of touch therapy (shiatsu, reflexology) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
40801650|NCT06395896|OTHER|Breast Cancer Prevention Journey Program Group|"The researcher will invite individuals to the study at Necip Fazıl Family Center and conduct a pre-test application. The day and time for the Fight Against Breast Cancer training, which is structured based on the Health Belief Model prepared by the researchers, will be determined and announced to the participants. The training will be held in a single session of 45-60 minutes. Slide presentation and a breast model showing the symptoms of breast cancer will be used as training materials. At the end of the training, it will be announced that free shuttle service will be provided for mammography screening and individuals will be invited to screening. On the specified day and time, participants will be taken to the Cancer Early Diagnosis, Screening and Education Center (KETEM) in Mamak and mammography screening will be performed. After the screening, a post-test will be performed."
40801651|NCT06395896|OTHER|Routine Cancer Screening Program Group|Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health. Health Ministry of Türkiye offers free mammography screening for breast cancer to women over the age of 40. In this context, women are called to the centers by phone and mammography screening is performed free of charge.
40801652|NCT01055938|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
41319032|NCT05982223|PROCEDURE|Movement therapy|The frequency of movement therapy (Tai-Chi, Qi-Qong) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
40801653|NCT01312805|OTHER|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
40801654|NCT01312805|OTHER|CHICA Control|This is CHICA without the asthma module, and was used as a control
40801655|NCT05294497|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
40801656|NCT05294497|OTHER|Product B|Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine
40801657|NCT05294497|OTHER|Product C|Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine
40801658|NCT05294497|OTHER|Product D|Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine
40801659|NCT05294497|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
40801660|NCT05294497|OTHER|Product E|Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
40801661|NCT00080080|DRUG|talabostat (PT-100) tablets|
40801662|NCT00080080|DRUG|Docetaxel|
40801663|NCT02574078|DRUG|Nivolumab|
40801664|NCT02574078|DRUG|Bevacizumab|
41152438|NCT04178096|OTHER|Quality Improvement Intervention|The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
41319033|NCT05982223|DIETARY_SUPPLEMENT|Herbal supplements|The choice of herbal supplement will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
41319034|NCT05982223|BEHAVIORAL|Emotional treatment|The frequency of emotional treatments (counseling, spiritual guidance) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
41319035|NCT03102359|DRUG|Dexmedetomidine|Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery
41319036|NCT03102359|DEVICE|Cooling Helmet|Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
40801665|NCT02574078|DRUG|Pemetrexed|
40801666|NCT02574078|OTHER|Best Supportive Care|Palliative radiation, palliative surgery and/or other best supportive care treatments
40801667|NCT02574078|DRUG|nab-Paclitaxel|
40801668|NCT02574078|DRUG|Paclitaxel|
40801669|NCT02574078|DRUG|Docetaxel|
40801670|NCT02574078|DRUG|Gemcitabine|
40801671|NCT02574078|DRUG|Erlotinib|
40801672|NCT02574078|DRUG|Crizotinib|
40801673|NCT02574078|DRUG|Carboplatin|
41319037|NCT01178736|PROCEDURE|Breast Cancer Screening and Diagnosis|Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.
40801674|NCT01790646|OTHER|intubation|intubation using Glidescope videolaryngoscope
40801675|NCT04787783|OTHER|Web based preoperative assessment|Preoperative assessment conducted through a web based application
41475526|NCT02607020|OTHER|Physical exercises in an self-management setting|"Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:~1. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session."
41475527|NCT02607020|OTHER|Relaxation|The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
41475528|NCT01104090|DEVICE|C-MAC direct laryngoscopy|Patients will be intubated using C-MAC with direct laryngoscopy.
41475529|NCT01104090|DEVICE|C-MAC Indirect laryngoscopy|Patients will be intubated using C-MAC with indirect laryngoscopy.
41475530|NCT04387071|BIOLOGICAL|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Given IT
41475531|NCT04387071|DRUG|VLP-encapsulated TLR9 Agonist CMP-001|Given SC and IT
41475532|NCT01758822|OTHER|No endotracheal suction|Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
41475533|NCT01233843|DRUG|carboplatin|70 mg per m2 and per day for four days. day 1; day 22; day 43
41475534|NCT01233843|DRUG|5 fluorouracil|600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43
41475535|NCT01233843|RADIATION|radiation therapy|total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
41475536|NCT06363630|DRUG|Itraconazole|Specified dose on specified days.
41475537|NCT06363630|DRUG|Rifampin|Specified dose on specified days
41319038|NCT01178736|PROCEDURE|Cervical Cancer Screening and Diagnosis|Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.
41319039|NCT01178736|PROCEDURE|Ovarian Cancer Screening and Diagnosis|Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
41475538|NCT06363630|DRUG|Golcadomide|Specified dose on specified days
41475539|NCT02505152|PROCEDURE|Percutaneous transhepatic intrahepatic portosystemic shunt|Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
41475540|NCT04682509|DRUG|Glecaprevir/pibrentasvir|Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
41475541|NCT01906359|OTHER|Native palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
41475542|NCT01906359|OTHER|Chemically interesterified palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
41475543|NCT01906359|OTHER|High oleic sunflower oil|Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
41475544|NCT03087786|DRUG|Nicotine Bitartrate Lozenge 4mg|Test Product
41475545|NCT03087786|DRUG|Nicotine Polacrilex 4Mg Lozenge|Active Comparator
41319040|NCT01178736|PROCEDURE|Endometrial Cancer Screening and Diagnosis|Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
41475546|NCT01419587|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
41475547|NCT00168116|PROCEDURE|radiation treatment and surgery|
41475548|NCT00168116|PROCEDURE|radiation alone|
41475549|NCT00004810|DRUG|-aminosalicylic acid|
41475550|NCT02303886|DRUG|Methylene blue|In NaCL0.9% 100 ml
41475551|NCT02303886|DRUG|Methylene blue|in NaCl 0.9% 100 ml
41475552|NCT04752488|OTHER|Telerehabilitation (TR)|The home exercise program will be educated to the patient on the first day. Exercises for isometric and isotonic strengthening, stretching, and stabilization of the neck muscles will be given. Exercises will be presented to the patients in audio-video format and detailed instructions with explanations. The exercise protocol will also be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
41475553|NCT04752488|OTHER|Conventional Rehabilitation (CR)|The home exercise program will be educated to the patient on the first day. Isometric and isotonic strengthening, stretching and stabilization exercises for the neck muscles will be given. Exercise information form including explanation and picture of the exercises will be given to the patients. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
41475554|NCT04691440|DRUG|Hyperbaric oxygen|The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
41319041|NCT02853032|DEVICE|Active repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
41319042|NCT02853032|DEVICE|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
41319043|NCT02853032|DEVICE|Sham repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
41319044|NCT00411736|DRUG|Study medication, azithromycin or placebo|Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
41319045|NCT00411736|DRUG|Azithromycin or placebo tablets|Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
41319046|NCT02941289|PROCEDURE|visual search performance of everyday objects in realistic scenes|
41319047|NCT01780909|DRUG|Paromomycin Sulfate Fasted State|
41319048|NCT01780909|DRUG|Paromomycin Sulfate Fed State|
41319049|NCT01780909|DRUG|Paromomycin Sulfate w/ domperidone|
41319050|NCT01780909|DRUG|Paromomycin Sulfate w/ loperamide HCl|
41319051|NCT03722914|DRUG|Benzonatate 200 mg|200 mg/pellet, 1pellet/time, 3times/day
41319052|NCT03722914|DRUG|blank control 0mg|0 mg/pellet, 1pellet/time, 3times/day
41319053|NCT03123055|DRUG|B-701|B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
41319054|NCT03123055|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
41319055|NCT00126399|DRUG|doxycycline|
41319056|NCT02333591|DRUG|GlucagonLikePeptide-1 (7-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
41475555|NCT05032326|DRUG|Follow-up study of the treated cohort|follow-up study of the patients in the treated cohort: that have been included in the otbb3 study
41475556|NCT05032326|OTHER|Follow-up study of the untreated cohort|follow-up study of the patients in the untreated cohort: that have NOT been included in the otbb3 study
41475557|NCT00856505|DRUG|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
41319057|NCT02333591|DRUG|GlucagonLikePeptide-1 (9-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
41319058|NCT02333591|DRUG|Saline|Infused intravenously for 2,5 hours.
41319059|NCT03786198|BEHAVIORAL|Activity program|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks
41319060|NCT03786198|BEHAVIORAL|Control|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
41319061|NCT02682030|DEVICE|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
41319062|NCT02682030|DEVICE|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
41475558|NCT05419349|PROCEDURE|esophagogastric junction cancer surgery|esophagogastric junction cancer surgery
41475559|NCT01270490|DRUG|Interferon-gamma, Recombinant|Interferon 50 mcg/m2 to be administered three times per week during two weeks
41475560|NCT05206422|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in ADHF patients
41475561|NCT02839421|DRUG|Scaling and Root Planing combined with moxifloxacin|Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
41475562|NCT00885677|DEVICE|Medtronic CareLink® Network|"Continuous monitoring via a disease remote management system.~Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur."
41319063|NCT03968614|OTHER|Electric dry needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
41319064|NCT03968614|OTHER|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
41319065|NCT01589055|DRUG|Intravenous Nicotine|Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
41319066|NCT01315847|DRUG|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
41319067|NCT01315847|DRUG|[11C]MK-4232|Single intravenous doses of \~300 MBq \[11C\]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
41319068|NCT02758223|BIOLOGICAL|TCM allogeneic humane central memory T cells, cryopreserved|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65\*10\^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
41319069|NCT00184782|PROCEDURE|FDG-PET|
41475563|NCT01555827|OTHER|Ophthalmological examination & Questionnaire|"The following examinations will be performed, after pupil dilation:~* Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)~* Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)~* Wide-field colour and autofluorescence imaging (Optomap)~* Measure of intra-ocular pressure (pneumotonometer)~The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:~* Age, gender~* educational level~* smoking~* cardiovascular diseases, current medications~* scores at neuropsychological tests"
41475564|NCT01705431|BEHAVIORAL|On Track|The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
41475565|NCT04079049|PROCEDURE|Surgical intervention|Surgical intervention by liver resection, ablation or stereotactic body radiotherapy as complement to oncological treatment
41005728|NCT02045771|BEHAVIORAL|Behavioral Activation|"Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010)."
41475566|NCT04079049|DRUG|Control|Oncological treatment in control group
41475567|NCT04211519|DIAGNOSTIC_TEST|sampling|sampling from endodontically infected primary and permanent teeth by using paper point method
41475568|NCT06286059|DRUG|Phentolamine|In addition to the conventional management, patients will receive phentolamine (Rogitamine; Egypharma) infusion at a rate of 0.5 μgm/kg/min for the first 15 minutes after a bolus dose of 5 mg. If significant hemodynamic change occurred, the infusion then will be discontinued and the patient will be excluded. Otherwise, the dose will be uptitrated gradually 0.5-2 ugm/kg/min and the infusion will be continue for 12 hours.
41475569|NCT04436926|BEHAVIORAL|opioid approach bias modification|The investigators will use a training version of the Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different opioid and 20 different non-medication alternative pain managing activities. Training effect is achieved by presenting opioid pictures in push format only and non-opioid pictures in pull format only. Two hundred training trials are presented per session.
41475570|NCT04436926|BEHAVIORAL|sham training|Sham training is identical to opioid approach bias training, except pictures are presented randomly in both formats.
40801676|NCT01157338|PROCEDURE|diagnostic cardiac catheterization|coronary intervention: angiography
40801677|NCT01157338|PROCEDURE|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
40801678|NCT02653586|OTHER|"program In Favor of Resilience Self"|A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
41475571|NCT01001260|DRUG|No ASA|Alternative antiplatelet therapy instead of aspirin
40801679|NCT03066700|DEVICE|Hemostatic powder|HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
40801680|NCT04222894|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
40801681|NCT04222894|OTHER|Control Diet|Participants will be asked to continue their usual diets for the 12-week study period.
40801682|NCT03292874|DIAGNOSTIC_TEST|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
40801683|NCT06231875|DEVICE|Press|Fabrication of clear aligners using press machine (Mini-star)
40801684|NCT00553436|DEVICE|Tissue Apposition System (TAS) Device|Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
41475572|NCT01001260|DRUG|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
41475573|NCT01001260|DRUG|325 mg ASA|high dose of aspirin prior to PTCA
41475574|NCT02744755|BIOLOGICAL|Adalimumab - GP2017|Adalimumab - GP2017
41475575|NCT02744755|BIOLOGICAL|Adalimumab - US licensed Humira|Adalimumab - US licensed Humira
40801685|NCT00282633|DEVICE|Dermabond|
41319070|NCT04350736|DRUG|TD-0903|Study drug to be administered by inhalation
41319071|NCT04350736|DRUG|Placebo|Placebo to be administered by inhalation
41319072|NCT05729425|DEVICE|Ultrasound Microvessel Imaging|Undergo microvessel ultrasound imaging
41319073|NCT02878629|DEVICE|Mandibular Advancement Devices|
41319074|NCT04527276|OTHER|Oral care with 0,12% Chlorhexidine|0, 12 % CHX, and standard oral care with 0,9% NaCl were compared to assess VAP rates. Both solutions were applied to critically ill children who were intubated.
41475576|NCT00006182|PROCEDURE|Blood Transfusion|
41475577|NCT00277160|DRUG|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
41475578|NCT02463799|DRUG|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
41475579|NCT02463799|BIOLOGICAL|Sipuleucel-T|3 infusions of sipuleucel-T alone
41475580|NCT01010750|DRUG|Lisdexamfetamine Dimesylate (LDX)|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
41319075|NCT05314361|BEHAVIORAL|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD (written by the NPA).
41319076|NCT05997186|PROCEDURE|Surgical reconstruction|Surgical reconstruction with a free reinnervated profunda artery perforator flap
41475581|NCT01010750|DRUG|Immediate Release Mixed Amphetamine Salts (MAS-IR)|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
41475582|NCT01010750|DRUG|LDX Placebo + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
41005729|NCT02045771|BEHAVIORAL|Support Group|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
41005730|NCT04382911|DRUG|18F-fluoroestradiol|Patients will receive the FES tracer during a PET/MRI scan
41005731|NCT03758911|OTHER|Semi-structured Interview|
41319077|NCT02086721|DRUG|L19-IL2|"Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle."
41319078|NCT03094832|DRUG|Miransertib|Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.
41319079|NCT03930641|DRUG|RTH258|6 mg in prefilled syringe
41319080|NCT03737422|DIETARY_SUPPLEMENT|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
41319081|NCT03737422|OTHER|control|no supplementation
41319082|NCT02462733|BEHAVIORAL|Tools of the Mind (TOM)|TOM is play-based but features explicit, scripted, teacher-directed activities aimed specifically at helping to improve children's self-control skills. Early evidence supports the program efficacy and suggests benefits for children's development more generally (including language, reading and mathematics).
41319083|NCT02462733|BEHAVIORAL|Playing to Learn (PTL)|PTl is a play based preschool program now in wide use in YMCA childcare settings across Canada (and some in the United States). The activities in PTL are child initiated and are not prescribed. Teachers are trained to observe children at play and to capitalize on learning opportunities as they arise.
41319084|NCT04532918|DRUG|Verinurad|The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.
41319085|NCT04532918|DRUG|Allopurinol|The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.
41319086|NCT04532918|DRUG|Cyclosporine|The subjects will receive single oral dose of soft capsule cyclosporine 600 mg on Day 1 of treatment period 2 under fasted condition.
41475583|NCT05915286|DRUG|Furosemide|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
41475584|NCT05915286|DRUG|Chlorthalidone|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
41475585|NCT02568709|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
41475586|NCT02568709|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
41475587|NCT01745952|DEVICE|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
41475588|NCT01745952|DEVICE|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
41475589|NCT01745952|DEVICE|sham rTMS coil (figure-of-eight)|commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
41475590|NCT02562417|DRUG|Normal saline|
41005732|NCT02023151|DRUG|Omalizumab|
41005733|NCT00947492|BIOLOGICAL|Venous blood sample|Venous blood sample twice a year during 3 years
41475591|NCT02562417|DRUG|IV dexamethasone|
41005734|NCT05419102|PROCEDURE|peri-implantitis surgery with enamel matrix derivative|surgical procedures around dental implants with peri-implantits to remove infectious material and apply enamel matrix derivative to the implant.
41319087|NCT04532918|DRUG|Rifampicin|The subjects will receive single oral dose of film coated tablets rifampicin 600 mg on Day 1 of treatment period 3 under fasted condition.
41319088|NCT05085431|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
41319089|NCT00280319|BEHAVIORAL|interpersonal psychotherapy for groups|psychotherapy
41319090|NCT00280319|BEHAVIORAL|creative play therapy|consisted of play activities
41319091|NCT04994652|DEVICE|Videolaryngoscopy|Indirect laryngoscopy using the C-MAC videolaryngoscope
41319092|NCT04994652|DEVICE|Direct laryngoscopy|Direct laryngoscopy with a standard laryngoscope
40801686|NCT05661864|BEHAVIORAL|Multi-Tiered Systems of Support for Teacher Training|In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
40801687|NCT02620878|DEVICE|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
40801688|NCT02620878|OTHER|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
41005735|NCT05819034|OTHER|Scoliosis-Specific Exercise Program|"Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour."
41319093|NCT04868747|DRUG|Lidocaine|The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
41319094|NCT04868747|DRUG|normal saline|The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
41319095|NCT05708937|BEHAVIORAL|Mindfulness based phone app|"Creating mindfulness-based suggestions for infertile women:~Mindfulness-based content was created by taking the opinions of experts in the fields of women's health nursing, psychology and linguistics. It consists of 6 different parts. The content of meditation that the patient will apply according to the treatment stage is different. Infertility mindfulness departments; Breath Awareness, Body \& Uterus Awareness, Needle Therapy and Ovarian Awareness, Pre-Egg Collection (OPU) Diaphragm Breathing, Pre-embryo Transfer Uterine Awareness, Embryo and Uterine Awareness (Post transfer).~Audio recordings of mindfulness-themed meditation content:~After the meditation contents are planned; the sound recording was taken with a professional recorder (Sony ICD-PX470). The audio recordings taken were professionally edited by the expert. Mp3 recordings were created by adding background music to sound recordings in computer environment. Audio recordings of mindfulness-themed meditation content"
41319096|NCT04556656|DRUG|Pridopidine|Pridopidine hard gelatin capsule
41319097|NCT04556656|DRUG|Placebo|Pridopidine-matching placebo hard gelatin capsule
41319098|NCT01731613|DIETARY_SUPPLEMENT|human milk fortifier|Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
41319099|NCT03350178|DRUG|fecal microbiota transfer|transfer of fecal microbiota from healthy donor to the patients
40801689|NCT01054560|DEVICE|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
40801690|NCT01054560|DEVICE|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
40801691|NCT02370316|BEHAVIORAL|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
41319100|NCT02143193|BEHAVIORAL|Skin-to-Skin Contact|
41319101|NCT02898519|OTHER|cohort|Blood sampling
41319102|NCT04520828|OTHER|postural repositioning|The 10-min transdisciplinary intervention aimed (1) to facilitate and activate axial extension during standing and then during sitting; (2) to actively mobilize the trunk, cervical spine, and pelvic and shoulder girdles during standing and then during sitting; and (3) to adjust the seated position, as needed, with supports to ensure its maintenance throughout the experiment. Cushion, balls, boxes, or rolls were used to stabilize the final seated position.
41319103|NCT01812486|RADIATION|dose de escalation|
41319104|NCT01812486|RADIATION|standard dose|
41319105|NCT01650818|OTHER|Aerobic exercise training|Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
41475592|NCT05750147|OTHER|Blood Sample Collection|Blood for DNA and biomarker analysis
40801692|NCT02370316|BEHAVIORAL|Clinical Structured Treatment|structured case management and symptom-targeted medication
40801693|NCT04904419|DIAGNOSTIC_TEST|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
41319106|NCT01650818|OTHER|Standard physical therapy (Stretching/Range-of-motion)|Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
41319107|NCT01692223|BEHAVIORAL|qualitative interviews|A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety \& Depression Scale (HADS), revised Impact of Events Scale (IES-R), \& a questionnaire about their health behaviors, to establish baseline distress levels \& health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider \& discuss resultant therapeutic \& management recommendations for the participants \& their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
41319108|NCT05496322|DEVICE|Continuous Non Invasive Blood Pressure Monitoring|Continuous non-invasive arterial pressure monitoring
41319109|NCT05496322|DEVICE|Intermittent Non Invasive Blood Pressure Monitoring|Intermittent non-invasive arterial pressure monitoring
41319110|NCT01207817|OTHER|Pupillometry|Pupillometry readings will be taken at low, intermediate and high ambient light
41319111|NCT02410096|OTHER|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
40801694|NCT02156206|BEHAVIORAL|123 women emergency phone line in Medellin, Colombia|"123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.~When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday."
40801695|NCT06349265|DRUG|Carpal Tunnel Hydrodissection with %5 dextrose in water injection|Under the inplane ulnar approach, 3ml injectate was injected to hydrodissect the median nerve from the flexor retinaculum, and the residual 2ml injectate was then injected to hydrodissect the inferior median nerve away from the flexor tendons.
40801696|NCT03090516|DRUG|Ginkgo biloba dispersible tablets|Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
40801697|NCT03090516|DRUG|Donepezil|Arm A：Aricept 5mg/day
41319112|NCT02410096|OTHER|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
41319113|NCT02410096|DIETARY_SUPPLEMENT|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
40801698|NCT03090516|DRUG|Ginkgo biloba dispersible tablets and Donepezil|Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
40801699|NCT04820114|OTHER|Proprioceptive wrist exercises|Exercises for recognition of writs position and thumb force sense.
41319114|NCT02410096|DIETARY_SUPPLEMENT|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
40801700|NCT04820114|OTHER|Wrist exercises|Passive and active exercises for improve range of motion in flexion, extension, ulnar and radial deviation
40801701|NCT02047422|DRUG|Furosemide|furosemide (doubling previous furosemide dose)
40801702|NCT02047422|DRUG|metolazone|metolazone (add 2.5mg qod)
41005736|NCT05819034|OTHER|Soft orthoses with external strapping.|Adolescents in the experimental group will receive a scoliosis-specific exercises program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping. The wearing schedule of the soft orthosis with the external strapping for every participant in this group will be 12 hours daily for 12 successive weeks.
41005737|NCT03148548|GENETIC|thrombophilia screening|genetic Evaluation of Factor-V-Leiden, Factor-II_G20210A Mutation;
41005738|NCT04083417|DRUG|Phenoxymethylpenicillin|tablet PcV 1000 mg x 3 for 10 days
41005739|NCT04083417|OTHER|No antibiotic treatment|No prescription of antibiotics
41005740|NCT03086174|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
40801703|NCT02047422|DRUG|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
40801704|NCT02047422|DRUG|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
40801705|NCT04031248|DEVICE|Whole body vibration|In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices \[Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)\]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.
40801706|NCT04031248|OTHER|EXERCISE group|The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
41005741|NCT02659332|DEVICE|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
41005742|NCT04570293|DRUG|5% lidocaine medicated plaster|The 5% lidocaine medicated plaster is measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w) For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
41005743|NCT04570293|DRUG|vehicle plaster|Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
41005744|NCT05441735|COMBINATION_PRODUCT|APP|APP as an instructional tool for visiting health education
41319115|NCT05415046|PROCEDURE|Sacral ESPB|Erector spinae plane block performed with 0,25% bupivacaine (1 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
41475593|NCT01409590|BEHAVIORAL|Exercise program|Homogenous exercise program in local fitness centers
40801707|NCT02748421|PROCEDURE|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
40801708|NCT02748421|PROCEDURE|Conventional Microscope|macular membrane dissection without OCT RESCAN
41005745|NCT03626116|PROCEDURE|silicone metacarpophalangeal arthroplasty (SMPA)|Replacement of the metacarpophalangeal (MCP) joint using a silicone arthroplasty
41005746|NCT03528434|DIETARY_SUPPLEMENT|Zinc|10mg dispersible zinc sulfate tablet
41005747|NCT03528434|OTHER|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
41005748|NCT06008964|OTHER|Ylang Ylang oil with inhalation|Ylang Ylang OIL WILL BE INHALED
41005749|NCT06008964|OTHER|Lavender oil with inhalation|LAVENDER OIL WILL BE INHALED
41005750|NCT04918680|DEVICE|EcoFit® Total Hip System with implacross® E Polyethylene|The EcoFit® Total Hip System is a primary hip replacement system indicated for patients who are candidates for a primary cementless hip replacement. implacross® E Polyethylene is one of the components in the EcoFit® system.
41005751|NCT03316833|DEVICE|Resolute Onyx|Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score \<33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family
41475594|NCT01409590|BEHAVIORAL|Diet|Weigh loss diet program prescribed by a professional nutritionist
41475595|NCT05150418|DRUG|Oxygen gas|Oxygen 15 l/min
41475596|NCT05150418|DRUG|Air|Room air 15 l/min
41475597|NCT05356182|OTHER|Diet|Control diet consisting of 20% protein, intervention diet consisting of 10% protein
41475598|NCT01010126|BIOLOGICAL|Bevacizumab|Given IV
41475599|NCT01010126|DRUG|Temsirolimus|Given IV
41475600|NCT04888949|BIOLOGICAL|Mesenchymal stem cell|1\*10\^8 cells are administered once a week, total four times intravenously.
41475601|NCT04888949|BIOLOGICAL|Placebo|Commercially available saline.
41319116|NCT05657951|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|The Insight-100 (ArcScan Inc., Golden, CO, USA) employs the high-frequency B-scan in the assessment of anterior segment parameters. Anormal saline coupling medium is formed with a disposable eyepiece between the 50 MHz transducer and the eye. The instrument moves the transducer in an arc so that the beam axis maintains approximate normality to the surface of the eye. The frequencies of cornea, anterior chamber, and lens are 60 MHz, 50 MHz and 50 MHz, respectively. The maximum arc scanning range is 70 degrees, and there is a linear scanning range of 29mm. The axial and lateral resolutions are 35 μm and 65 μm, respectively. It can measure structures behind the iris, including lens zonule.
41319117|NCT03110198|DRUG|Mesalazine|Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
41475602|NCT05732181|DRUG|The skin lidocaine patch.|The skin patch is applied before RFA while admission and is changed every day till discharge. Pain severity is evaluated by visual analogue scale using a 10-point scale recorded before RFA and after the procedure.
41475603|NCT05732181|DRUG|Placebo|patch without drugs
41475604|NCT04183179|BEHAVIORAL|Happy Family, Healthy Kids Program|"The 14-week healthy eating program activities including four components:~1. A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~2. Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~3. 14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~4. Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
41475605|NCT03184532|DIAGNOSTIC_TEST|ultrasound|ultrasound examination of pyloric antrum
41475606|NCT05563818|OTHER|WinterLight Mobile Phone Speech Analysis|N/A- observational study
41475607|NCT06260826|DEVICE|Auto CPAP via nasal mask (JPAP machine)|Auto Continuous Positive Airway Pressure via nasal mask using the JPAP system (Metran, Saitama, Japan) which can provide CPAP with a range of 2-10 cmH2O, the initial CPAP 2 cmH2O, then reach 7.5 cmH2O after a ramping time. CPAP values may vary with each breath until the obstruction is resolved
41319118|NCT03110198|DRUG|hydrocortisone sodium succinate|hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
41475608|NCT06260826|DEVICE|Constant CPAP via facial mask (O2-Max Trio system)|Patients connected to the O2-Max Trio CPAP system (Pulmodyne, Indianapolis, USA) with a facial mask that was adjusted to maintain a CPAP at 7.5 cm H2O and FiO2 30% continuously for the following 1 hour
41475609|NCT00466726|BIOLOGICAL|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
41319119|NCT03110198|DRUG|Mesalazine with hydrocortisone sodium succinate|Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
41475610|NCT00466726|BIOLOGICAL|sargramostim|
41475611|NCT00006245|DRUG|alvocidib|
41475612|NCT00006245|DRUG|paclitaxel|
41475613|NCT00961454|DEVICE|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
41475614|NCT02303314|DRUG|Trigonella Foenum-graecum Seed Extract|
41475615|NCT02303314|DRUG|Drug: Placebo|
41005752|NCT04936958|OTHER|patients having had an osteomyelitis since 2017|description of osteomyelitis and their management
41319120|NCT00192439|BEHAVIORAL|High Risk Respiratory Disease|
41475616|NCT01845402|BIOLOGICAL|blood and urine samples|A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
41475617|NCT06077734|OTHER|In vitro analyse|In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies
41475618|NCT05289934|BEHAVIORAL|Music Stimuli|Nine-minute-long Mozart K.448 (1st movement) and instrumental age-appropriate songs will be played via single-use earbuds with 10 minutes wash-out in between music stimuli.
41475619|NCT02623452|DRUG|Insulin Lispro|Administered subcutaneously (SC)
41319121|NCT02568124|DRUG|Tranexamic Acid|
41319122|NCT02568124|DRUG|Placebo|
41475620|NCT03589131|PROCEDURE|Total Operative time|Investigators compare the preparation time of the procedure in the operating room and the actual operative time
41475621|NCT03589131|PROCEDURE|Margin assessment|In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.
41475622|NCT03589131|PROCEDURE|Conversion rate to open surgery|In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery
41475623|NCT03589131|PROCEDURE|Baseline demographics|These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups
41475624|NCT03589131|PROCEDURE|Preoperative data|"These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared"
41475625|NCT03589131|PROCEDURE|Postoperative data|These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission \& 30-days mortality. All were analyzed and compared
41005753|NCT06290856|DIAGNOSTIC_TEST|Multiplex PCR-test for circulating tumor DNA|All recruited patients will be tested for
41319123|NCT01180114|BEHAVIORAL|Suubi-Maka ('Hope for Families')|Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.
41319124|NCT01180114|OTHER|Usual Care|Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
41319125|NCT05656898|DEVICE|Piezocision+GaALAs diode laser|After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .
41319126|NCT05656898|DEVICE|Piezocision|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
41319127|NCT05656898|DEVICE|Orthodontic fixed appliance|Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.
41319128|NCT05368129|PROCEDURE|Balloon dilation|Balloon dilation was performed after DES implantation.
41319129|NCT01705548|RADIATION|Hypofractionated Radiosurgery|Radiation Therapy will consist of partial brain irradiation delivered to the metastatic brain tumor or resection cavity, delivered in 5 treatments with 2-3 treatments delivered per week.
41319130|NCT01895491|BIOLOGICAL|VM206DNA|
41319131|NCT01895491|BIOLOGICAL|VM206Ad|
40801709|NCT02471534|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
41005754|NCT03949075|DRUG|Enalapril|Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.
41005755|NCT03949075|DRUG|Placebo|Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
41005756|NCT01698229|OTHER|Group 1|Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
41005757|NCT01836484|DIAGNOSTIC_TEST|Diffusion-weighted MRI|
41319132|NCT04625894|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|To irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate. Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy). Sequence of irradiation for multiple metastases will be at the discretion of the investigators based on their experience.
41319133|NCT04625894|DRUG|Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle|Administration of Carrelizumab will be started within one week upon SABR completion, and will be continued for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
41319134|NCT04474119|DRUG|KN046|In combine therapy stage, KN046 is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
41319135|NCT04474119|DRUG|KN046 placebo|"In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks.~In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks."
41319136|NCT00000255|DRUG|Nitrous oxide|
41319137|NCT04480242|DRUG|Inhaled Corticosteroids (ICs)|Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
40801710|NCT02506855|DRUG|Ropivacaine|
41005758|NCT01836484|DIAGNOSTIC_TEST|Fluorodeoxyglucose-18-PET/CT|
40801711|NCT02506855|OTHER|Placebo|
40801712|NCT02506855|PROCEDURE|Transversus Abdominis Plane Block|
40801713|NCT03818607|DRUG|ABP 959|intravenous infusion
40801714|NCT03818607|DRUG|Eculizumab|intravenous infusion
40801715|NCT01009944|DRUG|Lisinopril, Atenolol|once a day for 14 weeks
40801716|NCT04667598|DRUG|Modified Wenxin Decoction|Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
41005759|NCT01836484|DIAGNOSTIC_TEST|Fluoro-ethyl-coline-PET/CT|
41005760|NCT03800498|OTHER|DASH Education|DASH health education about general knowledge of DASH diet Plan and lifestyle modification
41005761|NCT01542515|PROCEDURE|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|"The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors."
41005762|NCT02204254|DEVICE|Radiofrequence|Associated to arm radiofrequence
41319138|NCT04480242|DRUG|Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)|Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
41319139|NCT04480242|DRUG|Other treatments|Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
41319140|NCT04480242|DRUG|Inhaler device|Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers.
41319141|NCT04480242|BEHAVIORAL|Regularly monitoring of the Inhalation technique through mobile app|App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2).
41005763|NCT02204254|DRUG|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
41319142|NCT00391417|DRUG|estradiol gel|
41005764|NCT04514575|BIOLOGICAL|Plasma transfusion|Transfusion of allogeneic fresh frozen plasma or cryoprecipitate
41005765|NCT03706235|OTHER|Blood draw (venipuncture)|Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
41319143|NCT02264899|OTHER|in Memento-VASCOD|"* Pulse wave velocity assessment~* Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences~* Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement~* Neuropsychological testing and behaviorial and mood scales~* Urinary albumin excretion measurement"
41319144|NCT03977350|DEVICE|EEG monitoring|EEG monitoring under general anesthesia
41319145|NCT02469792|PROCEDURE|Liposuction|
41319146|NCT02469792|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
41005766|NCT00177424|DRUG|sertraline|Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
41005767|NCT00177424|DRUG|Placebo|matching placebo tablets
41005768|NCT03365284|DEVICE|Smart Kneebrace with a smart phone app|Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.
41005769|NCT03365284|OTHER|regular rehabilitation procedure|regular rehabilitation procedure, especially muscle strengthening exercises
41005770|NCT04474652|OTHER|Single Blood Draw from each participant|Health Professionals will seek informed consent and take a single blood collection from the participant. This will take place during the patient's visit to the breast one stop clinic as part of their routine urgent breast referral pathway.
41005771|NCT01579396|DEVICE|septeX|12 h septeX CVVH treatment after cardiac surgery
41005772|NCT01579396|OTHER|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
41005773|NCT06319326|OTHER|Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.|This is an observation study involving measurement of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding. No intervention is given to study participants.
41005774|NCT00864162|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
41005775|NCT00864162|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
41005776|NCT06108817|OTHER|Information material|The intervention consists of the distribution of a poster for the waiting room and flyers to be given to patients aiming to inform both patients and GPs with respect to the correct indications for treatment of dyspepsia. After signing up, practices assigned to the intervention group received a package containing 60 flyers and one waiting room poster to use during consultations. The flyer and poster provide a short description of the correct indications for treatment of dyspepsia. Additionally, both the flyers and posters contained a QR-code linking to a decision aid explaining the correct indications and causes of dyspepsia.
41319147|NCT02469792|PROCEDURE|Arthroscopic surgery|
41319148|NCT02469792|OTHER|Intraarticular administration of autologous ADRC|
41319149|NCT05810844|DIAGNOSTIC_TEST|Motor Relearning Program (MRP)|MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke
41005777|NCT06108817|OTHER|No Intervention|These practices do not receive information material
41005778|NCT03584672|OTHER|Static Balance Test|Balance control is assessed by the Static Balance Test.
41005779|NCT03584672|OTHER|Berg Balance Scale|Functional balance is assessed by the Berg Balance Scale.
41005780|NCT03584672|OTHER|Timed Up an Go Test|Functional mobility is assessed by the Timed Up and Go test.
41005781|NCT03584672|OTHER|Four Square Step Test|Dynamic balance is assessed by the Four Square Step Test.
41319150|NCT05810844|DIAGNOSTIC_TEST|Neuro Development Treatment (NDT)|Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients
41319151|NCT03811886|DRUG|Natalizumab|"Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study."
41319152|NCT04536649|RADIATION|Radiotherapy|Multimodal brain imaging-guided radiotherapy using different beams
41319153|NCT05265143|OTHER|bolus/intermittant feeding|sequential randomization
41319154|NCT00546286|DRUG|dorzolamide hydrochloride (+) timolol maleate|"Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks."
41319155|NCT00546286|DRUG|Comparator: dorzolamide HCl/timolol maleate + prostaglandin|"Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks."
41319156|NCT03621423|PROCEDURE|ultrasound guided injection|"Patient will be positioned lying on side with the hemiplegic side up. The shoulder will be placed in a flexion and external rotation/abduction position, as possible by the patient, to give the ultrasound probe access to the posterior axillary fold.~As previously described in the literature, a line of best fit was calculated by bisection of hypothetical line connecting the inferior spine and the acromial tip, an 18-gauge, 10-cm needle will be inserted under direct ultrasound guidance and by a nerve stimulation . After placing the needle tip in the target point's 100 units of botulinum toxin will be injected."
41319157|NCT00830960|DRUG|Prasugrel|Oral, daily, 90 days
41319158|NCT00830960|DRUG|Clopidogrel|Oral, daily, 90 days
41319159|NCT03750071|BIOLOGICAL|VXM01|Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid
41319160|NCT03750071|BIOLOGICAL|Avelumab|Monoclonal anti-PD-L1 Antibody
41319161|NCT02229630|RADIATION|Pregnant women with intra-uterine growth restricted Foetuses|Diffusion-weighted cerebral MRI before 32 weeks of gestation
41319162|NCT01084109|OTHER|Lyophilized meat|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
41319163|NCT01084109|OTHER|Cereal|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
41319164|NCT04656418|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
41319165|NCT04656418|DRUG|Placebo|Buffer without active ingredient
41319166|NCT00606814|DRUG|IPI-504, docetaxel|"1. IPI-504 administered IV at a dose of 300mg/m2~2. Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
41319167|NCT03714035|OTHER|no intervention|no intervention
41475626|NCT02976259|DRUG|Dolutegravir|All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
41319168|NCT00781248|DEVICE|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
41319169|NCT04408066|DIAGNOSTIC_TEST|Sample Collection/Performance Evaluation (A)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Nasal/Throat/Nasal Throat Combo/ Nasopharyngeal (as per sites SOC) Swab~* Whole Venous Blood"
41319170|NCT04408066|DIAGNOSTIC_TEST|Sample Collection/Performance Evaluation (B)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Whole Venous Blood~* Fingerstick Capillary Sample"
41319171|NCT05270642|PROCEDURE|Microwave Thermal guided by Plan for Microwave Thermal Field system|When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.
41319172|NCT03183830|DIETARY_SUPPLEMENT|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
41319173|NCT03183830|DIETARY_SUPPLEMENT|Nitrate-deplete Beetroot Juice|"See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day."
41319174|NCT03361072|DIETARY_SUPPLEMENT|Oral immunotherapy|Milk, peanut or egg oral immunotherapy
41475627|NCT00037531|DRUG|Sirolimus (RAPAMUNE)|
41475628|NCT01609621|DEVICE|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
41475629|NCT05560555|DRUG|Tafamidis|61 milligrams (mg) as received in studies B3461028 and B3461045
41319175|NCT05978687|DRUG|OPHTESIC LIDOCAINE HYDROCHLORIDE 20MG/G|"In group A, all patients will receive topical 2% lidocaine gel (ophtesic lidocaine hydrochloride 20 mg/G) prior to surgery.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
41319176|NCT05978687|DRUG|Xylocaine with Epinephrine|"In group B, all patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle. When asked for, patients will receive additional topical 1% lidocaine eye drops.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
41319177|NCT06371339|DEVICE|"Additional acquisitions with the investigational gamma-camera  MoTI ."|"The gamma-camera MoTI will be used for the study to carry out 3 or 4 additional acquisitions (depending on the therapeutic indication) compared with those provided for in standard practice with a conventional gamma camera (Syngula).~Patients will receive their treatment as usual in two stages:~* 1/ Pre-therapy phase:~  1. Administration of a tracer dose of 131I (Day 0).~ 2. Assessment of 131I uptake/fixation rate at Day 0, Day 1, Day 5.~ 3. Determination of the therapeutic dose of 131I to be administered to the patient after collegial discussion.~* 2/ Therapy phase:~  1. Administration of the therapeutic dose (Day 0).~ 2. Thyroid scintigraphy and measurement of the 131I uptake rate within 4 hours of treatment.~For the study, measurements of 131I uptake/fixation rates will be carried out using both the standard gamma camera Syngula and the gamma camera MoTI."
41319178|NCT04276129|PROCEDURE|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
41319179|NCT04276129|OTHER|post-surgical CHX mouth-rinses indication|CHX mouth-rinses (0.12%) will be indicated 2 times/day after the surgical procedure
41319180|NCT05544227|DRUG|SV-102|SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
41319181|NCT04466501|DEVICE|ACR LAB|"The ACR \| LAB is a prescription-only, nurse- or clinician-conducted in vitro diagnostic (IVD) device. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm."
41319182|NCT02823041|BEHAVIORAL|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
41319183|NCT02823041|BEHAVIORAL|Aerobic Exercise|Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
41319184|NCT02823041|BEHAVIORAL|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
41319185|NCT02823041|BEHAVIORAL|Individual Placement and Support|An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
41319186|NCT03726333|DRUG|lorlatinib|continued daily administration of 100 mg lorlatinib
41319187|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
41319188|NCT03726333|DRUG|lorlatinib|continued daily administration of 100 mg QD lorlatinib
41319189|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
41319190|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
41319191|NCT05605483|OTHER|Salad bar|Schools where the school district has installed salad bars
41319192|NCT05605483|OTHER|Waitlisted control|Schools where the school district has not yet installed salad bars
41319193|NCT05605483|OTHER|Salad bar post-COVID|Schools where the school distract has re-opened salad bars will have methods repeated in a subset of schools post-COVID-19
41319194|NCT02263495|DRUG|Paclitaxel|175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
41319195|NCT02263495|DRUG|Eribulin|1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
41319196|NCT02263495|DRUG|Gemcitabine|PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
41319197|NCT03489681|DEVICE|acupuncture|"Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62)."
41319198|NCT03000387|DRUG|Nicotine Patch|Active nicotine patch of 21 mg, 14 mg and 7 mg
41319199|NCT03000387|DRUG|Placebos|Matching placebo patches of 21 mg, 14 mg and 7 mg
41005782|NCT03584672|OTHER|Functional Reach Test|Limits of stability is assessed by the Functional Reach Test.
41005783|NCT03584672|OTHER|One-leg Stance Test|Postural steadiness is assessed by the One-leg Stance Test.
41005784|NCT01767922|DIETARY_SUPPLEMENT|Extramel 10 mg - 140 UI SOD|"Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.~Each volunteer was seen for the 3 visits:~* visit V1, so-called inclusion visit (D0),~* visit V2 at 28 days, tolerance of +/- 3 days, (D28) and~* visit V3 at 84 days, tolerance of +/- 3 days, (D84)."
41005785|NCT01767922|DIETARY_SUPPLEMENT|Placebo - Excipient only|
41005786|NCT05956769|DRUG|Tranexamic Acid|Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
41005787|NCT05956769|DIAGNOSTIC_TEST|thromboelastography|thromboelastography (TEG6)
41005788|NCT05956769|DRUG|Placebo|Normal saline injection
41005789|NCT05914727|DIAGNOSTIC_TEST|eNose|Collection of breath profile with eNose
41005790|NCT05914727|DIAGNOSTIC_TEST|Volatile exhaled breath sample|Collection of exhaled breath in Tedlar bag
41005791|NCT05914727|DIAGNOSTIC_TEST|Condensate sample|Collection of exhaled breath condensate with EcoScreen
41005792|NCT04630093|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|A DNA sample by saliva (via mouthwash swish and expectorate collection) or buccal cell (via buccal brush) will be obtained for pharmacogenetic testing and questionnaires will be administered at baseline and then again at 3 months and 6 months after receiving PGx results.
41005793|NCT03642691|BIOLOGICAL|Ryplazim|Plasminogen IV replacement therapy
41005794|NCT02295748|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
41005795|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
41005796|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
41005797|NCT02210429|PROCEDURE|Elbow Fracture Fixation|
41005798|NCT05550012|OTHER|low-dose CT|those patients undergo low-dose liver CT in portal vein and delayed phase.
41005799|NCT03797638|DEVICE|Finger Force Manipuladum (FFM)|Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.
41005800|NCT04689256|DEVICE|MR-010|MR-010 includes a patient application and sensors with commercially available headphones and smartphones. Sensors are placed on the subject's shoes and measure gait metrics. The algorithm uses data from the sensors to inform changes made to the audio cues. These cues, which are embedded in time-shifted music, are delivered back to the users who aim to walk to the beat.
41319200|NCT03258697|DRUG|Levobupivacaine Hydrochloride|Different way of LevoBupivacaine injection
41319201|NCT01324687|OTHER|Telemedicine care|Availability of telemedicine
41319202|NCT01220986|PROCEDURE|Liver biopsy|0, 30, 60, 90 min post inflow-division
41475630|NCT02674386|DRUG|Investigational Medical Product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
41475631|NCT04703842|BIOLOGICAL|SRD-001|AAV1/SERCA2a
41475632|NCT04703842|DRUG|Placebo|SRD-001 matching placebo
41475633|NCT06193447|OTHER|None intervention|None intervention
41005801|NCT02529384|OTHER|Breast magnetic resonance scanning|Just a muti-b value series in breast MRI
41005802|NCT00614016|DRUG|Sodium ST20|single administration of oral dosage form
41005803|NCT04019158|DEVICE|Virtual reality headset|All participants will walk in the three conditions described earlier in this form
41005804|NCT02211469|DRUG|BMS-986104|
41005805|NCT02211469|DRUG|Placebo|
41005806|NCT02473068|DEVICE|CPAP|
41005807|NCT04168177|PROCEDURE|PCA|Patient controlled analgesia
41005808|NCT04168177|PROCEDURE|ESP|erector spinae plane block
41005809|NCT01394926|DRUG|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
41005810|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 10 days
41005811|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 15 days
41005812|NCT00910715|DRUG|placebo|control subjects without a history of Lyme borreliosis
41005813|NCT00691236|DRUG|Zoledronic acid|4mg IV 3 weekly for 6 doses
41005814|NCT00691236|DRUG|Standard chemotherapy|Adriamycin + Cisplatinum and Ifosfamide
41005815|NCT00029731|DRUG|Arginine hydrochloride|
41005816|NCT04409782|OTHER|Electronic portal education|Participants will receive education via an electronic portal covering the key messages pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
41005817|NCT04409782|OTHER|Online educational video|Participants will receive online education via a video and written web content. Key messages will include information pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
41005818|NCT03469921|DRUG|administered therapeutic regimens|administered therapeutic regimens
41005819|NCT02496780|DRUG|novolog insulin|3x daily rapid-acting insulin
41005820|NCT02496780|DRUG|levemir insulin|basal insulin once a day
41005821|NCT02496780|DRUG|placebo|once or 3x daily
41005822|NCT03080558|DRUG|Indocyanine green|Use of Indocyanine Green during Rectal shaving by laparoscopy.
41319203|NCT03300258|DEVICE|Robotic therapy|"The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour."
41475634|NCT02521077|DRUG|Ascorbic Acid|500 g ascorbic acid dissolved in 500 ml sterile water.
41475635|NCT02521077|OTHER|Normal Saline|Saline 0.9%
41475636|NCT01302847|DRUG|DTG film-coated tablets|DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
41475637|NCT01302847|DRUG|DTG granules for suspension|DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
41475638|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~0.8 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
41005823|NCT01772641|OTHER|Scheduled Gradual Reduction + Varenicline|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
41005824|NCT01772641|OTHER|Scheduled Gradual Reduction + Placebo Drug|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
41005825|NCT01772641|OTHER|Basic Advice + Varenicline|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
41005826|NCT01772641|OTHER|Basic Advice + Placebo Drug|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
41005827|NCT02760134|PROCEDURE|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
41005828|NCT06413199|OTHER|Hyper Training|Experimental group will perform 2 training session per week for 2 months, 1 set of 10 unloaded repetitions in arms as a warm-up, 4 sets with a goal of 8-12 Reps with 90 seconds rest between sets. 1.5 second concentric and 1.5 second eccentric contraction of bench press, The elbows had to be fully locked out to be counted as a repetition.
41005829|NCT06413199|OTHER|1 Repetition maximum training group|2 training session per week for 8 weeks, 1 set of 10 unloaded repetitions in arms as a warm-up, 1 Repetition maximum training group consisted of 5 attempts to lift as much weight as possible one time for that training visit with 90 seconds of rest between attempts, the load was progressively increased each attempt to try to reach or exceed their previous 1 repetition maximum.
41005830|NCT01945385|BEHAVIORAL|Video intervention|Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
41475639|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
41475640|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets."
41475641|NCT02331693|BIOLOGICAL|anti-EGFR CAR T|
41475642|NCT04364737|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma (1-2 units; \~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate
41475643|NCT04364737|OTHER|Saline solution|Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
41475644|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules|As previously published
41475645|NCT01205841|PROCEDURE|Buffalo Rule|As previously published
41475646|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia|As previously published
41475647|NCT01205841|PROCEDURE|Thompson Test|As previously published
41475648|NCT01205841|PROCEDURE|Palpation of the fibula|Palpation of the fibula over its entire length.
41475649|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + palpation of the cuboid bone|As previously published
41475650|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + palpation over the deltoid ligament|As previously published
41475651|NCT01205841|PROCEDURE|Malleolar Zone Algorithm|As previously published
41475652|NCT01205841|PROCEDURE|Low Risk Exam|As previously published
41475653|NCT01205841|PROCEDURE|Bernese Ankle Rules|As previously published
41475654|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + swelling of the distal fibula|As previously published
41475655|NCT00556491|DRUG|minocycline|given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
41475656|NCT00556491|DRUG|placebo|placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
41475657|NCT00963651|DEVICE|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
41475658|NCT04329416|OTHER|Predicted depth of insertion|A left-sided double-lumen tube was introduced beyond the vocal cords when the train-of-four stimulation of the ulnar nerve revealed 1 or 2 twitches, the stylet was removed, the double-lumen tube was rotated 90° counterclockwise and then advanced blindly to the predicted depth of insertion.
41475659|NCT04329416|OTHER|Optimized depth of insertion|The optimal position of the double-lumen tube, defined as the inflated endobronchial cuff is placed in the left main bronchus just below the carina without herniation, which was confirmed using a flexible bronchoscope in both supine and lateral decubitus positions.
41005831|NCT02042924|RADIATION|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
41005832|NCT02042924|DEVICE|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
41319204|NCT03300258|DEVICE|Aerobic therapy|The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
41319205|NCT01236742|DEVICE|ortho-k lenses|nightly wear of orthokeratology lenses to correct vision
41319206|NCT01236742|DEVICE|single-vision glasses|daily wear of spectacle glasses to correct vision
41005833|NCT04661345|OTHER|Proteomic analysis of synovial fluids|Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
41005834|NCT04661345|OTHER|Proteomic analysis of the isolated coagulase-negative Staphylococci|Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
41005835|NCT05994729|DIAGNOSTIC_TEST|Invasive Physiological Assessment of Coronary Circulation|After 2 months long rule-in phase required to exclude the unsuitable patients, study population will undergo RDN as indicated to treat resistant or difficult to control hypertension; 12 months after RDN, they will undergo invasive physiological study, comprehensive of Coronary Flow Reserve, Index of Microvascular Resistance, Mean Transit Time. These data will be then compared to the baseline ones obtained during the screening phase.
41005836|NCT00660062|DRUG|escitalopram|10 mg daily
41005837|NCT00660062|DRUG|escitalopram|20 mg daily dosage
41005838|NCT00660062|DRUG|escitalopram|30 mg daily dosage
41319207|NCT04785079|PROCEDURE|Graston Instrument assisted Soft tissue Mobilization|Instrument assisted soft tissue mobilization using the Graston tool and technique for 3 minutes on each of the three locations
41319208|NCT00903253|DRUG|LNK-754|
41319209|NCT06324279|DEVICE|Transvaginal ultrasound|Transvaginal ultrasound will be used to see the presence of cervical sliding sign
41475660|NCT04329416|OTHER|Adjustment of depth of insertion|If the endobronchial cuff was placed too deeply or too proximal, subsequently, the double-lumen tube was withdrawn or advanced, respectively, using the flexible bronchoscope until the optimum position of the double-lumen tube was achieved.
41475661|NCT03313648|PROCEDURE|Laparoscopic Hepatectomy|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
41475662|NCT03313648|PROCEDURE|Radiofrequency Ablation|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
41475663|NCT03678935|OTHER|Low FODMAP diet|The intervention group follows the low FODMAP diet for 4 weeks.
41475664|NCT02716350|DIETARY_SUPPLEMENT|B-GOS|comparison versus placebo
41475665|NCT02716350|DIETARY_SUPPLEMENT|Maltodextrin|placebo
41475666|NCT02611011|DEVICE|Congo Red Test (GV-005)|The GV-005 is a simple test has been developed to detect unfolded or misfolded proteins in urine.
41475667|NCT04008524|BIOLOGICAL|CAR-T cells|Chimeric Antigen Receptor-T cells
41475668|NCT01310673|DRUG|Allopurinol|"Allopurinol 300mg po QD for 30 days.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
41475669|NCT01310673|DRUG|Placebo|"Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
41475670|NCT06212050|DEVICE|Transcatheter Aortic Valve Implantation|TAVI in patients with severe BAV stenosis using ACURATE neo2
41475671|NCT04736108|DRUG|Abiraterone acetate|1000 mg orally daily for 24 weeks before radical prostatectomy
41475672|NCT04736108|DRUG|Prednisolone|5 mg oral low dose prednisone, once daily
41475673|NCT04736108|DRUG|Goserelin|10.8 mg goserelin hypodermic once per 12 weeks
41475674|NCT02862249|BIOLOGICAL|Faecal microbiota transplantation|The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
41475675|NCT02862249|BIOLOGICAL|Placebo|An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
41475676|NCT04490226|DIETARY_SUPPLEMENT|Beta-Hydroxybutyrate as Ca-Mg-salt, active|24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
41475677|NCT04490226|DIETARY_SUPPLEMENT|ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active|24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
41475678|NCT04490226|DIETARY_SUPPLEMENT|fasting, active|36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
41319210|NCT06324279|DRUG|Misoprostol 200mcg Tab|Induction of labor by misoprostol
41319211|NCT05510206|DEVICE|Leveling and alignment|"Polishing, Bonding of appliance, placement of the first arch wire for Super elastic NiTi group then the second wire after two months taking study model each month during the study For Smartarch Group placing experimental arch wire for 4 months , taking impression each month.~For both groups peri-apical X-Ray to lower anterior teeth is taken prior to treatment and 4 months later, also visual pain analogue scale is taken for 7 days after placing archwires"
41319212|NCT05089344|DRUG|Growth Hormone|growth hormone
41319213|NCT05089344|DRUG|Clomiphene citrate daily and recombinant FSH (Gonal-F®)|Clomiphene citrate daily and recombinant FSH (Gonal-F®)
41319214|NCT06138028|DRUG|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles.
41319215|NCT01892449|OTHER|prolonged inspiratory to expiratory (I:E) ratio (1:1)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the prolonged I:E ratio (1:1), mechanical ventilation is maintained with during I:E ratio 1:1 during steep trendelenburg with pneumoperitoneum.
41319216|NCT01892449|OTHER|conventional I:E ratio (1:2)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the conventional I:E ratio (1:2) group (n=40), mechanical ventilation is maintained with during I:E ratio 1:2 during steep trendelenburg with pneumoperitoneum.
41319217|NCT02793895|DEVICE|Medtronic SEEQ™ mobile cardiac telemetry system|The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
41319218|NCT02793895|OTHER|Usual Care|For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia. Inc) cardiac rhythm monitoring device.
41319219|NCT02793895|DEVICE|CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device|The CardioSTAT device is a wearable adhesive cardiac rhythm monitoring system which is low-profile, water-resistant, and is adhered onto the skin surface with 2 electrodes. This wearable adhesive device is designed for one-time use only. Each CardioSTAT device will provide 14 days of cardiac rhythm monitoring. For subjects randomized to the intervention group who will be monitored by the CardioSTAT device, they will receive 28 days of continuous cardiac rhythm monitoring.
41319220|NCT04196205|BIOLOGICAL|Anti-CD19 CAR-T|1 - 2×10\^6 Anti-CD19 CAR-T cells/kg body weigh
41319221|NCT03623334|RADIATION|Image-Guided Radiation Therapy|Radiotherapy to a potent tumorcidal dose
41475679|NCT04490226|DIETARY_SUPPLEMENT|fasting, inactive|"36 hours of fasting, in a metabolic chamber at physical activity level of 1.3, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.3.~The same intervention is reproduced one week later."
41475680|NCT05273931|OTHER|Lifestyle intervention|Documents explaining the strategies to achieve and maintain recommended behaviours as part of a healthier lifestyle
41475681|NCT00122447|DRUG|Aspirin|325 mg PO QD
41475682|NCT00122447|DRUG|Alpha lipoic acid|600 mg PO BID
41475683|NCT00122447|DRUG|Olmesartan|40 mg PO QD
41475684|NCT00122447|DRUG|Placebo|"Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD"
41005839|NCT00660062|DRUG|nortriptyline|100 mg daily dosage
41319222|NCT00475540|DEVICE|synthetic monofilament polypropylene mesh|Vaginal prolapse repair with mesh
41319223|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
41319224|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
41475685|NCT03898713|DIAGNOSTIC_TEST|Intelligence quotient|intelligence quotient (IQ) is a total score derived from several standardized tests designed to assess human intelligence
41475686|NCT02746627|BEHAVIORAL|Positive Affect|Positive psychology intervention to improve motivation for diabetes management.
41475687|NCT02746627|BEHAVIORAL|Education|Educational materials on diabetes management
41475688|NCT01570348|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
41319225|NCT01392378|DRUG|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
41319226|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
41319227|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
41319228|NCT01392378|DRUG|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
41319229|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
41319230|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
41005840|NCT02009033|DRUG|Lactated Ringer|When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
41319231|NCT01392378|DRUG|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
41319232|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
41005841|NCT02009033|DRUG|Hydroxyethylstarch|
41319233|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
41319234|NCT01392378|DRUG|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
41319235|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
41005842|NCT01864291|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
41005843|NCT03357458|BEHAVIORAL|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
41005844|NCT05441059|DRUG|Mepolizumab 100 MG|Treatment with mepolizumab for severe asthma
41319236|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
41319237|NCT04350905|OTHER|Mosquito Feeding|Mosquito feedings will be conducted with Aedes aegypti colonies raised at the CNM (National Malaria Center) Malaria and Vector Research Laboratory (MVRL), an established state of the art insectaries for mosquitoes was built in 2014 to ACL2 (arthropodcontainment level 2)-level specifications.
41319238|NCT05539469|DEVICE|Ortodontika app|parents will download and use Ortodontika smartphone application for all the duration of the study. It will be an aid during orthopedic treatment. During the activations, a notification will be set to remind the daily activation of RME. After the end of the activation protocol, parents will receive a notification every 2 weeks to instruct their children to proper oral hygiene maneuvers. Parents will have to show their children the videos for oral hygiene maintenance every 2 weeks until the end of the study.
41319239|NCT05539469|OTHER|Verbal instructions|verbal instructions will be given chairside to patients and parents regarding RME activation and its cleaning, together with instructions for daily oral hygiene manoeuvres.
41319240|NCT05731843|DRUG|Cohort 1 BEM + Ruzasvir|Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions
41319241|NCT05731843|DRUG|Cohort 2 Ruzasvir + BEM|Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions
41319242|NCT02603354|DRUG|peroxide gel tooth bleaching 6%|gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
41319243|NCT03810417|DRUG|Digoxin Antibodies Fab Fragments|Digoxin antibodies
41319244|NCT03810417|OTHER|Placebo|Saline
41319245|NCT04711876|BIOLOGICAL|Cytokine level in blood and CSF|Measure of cytokine level
41319246|NCT02483702|OTHER|Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
41319247|NCT02483702|OTHER|Non-Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
41319248|NCT02825433|OTHER|No intervention, only ventilation monitoring|
41319249|NCT06019923|OTHER|No intervention|No intervention
41319250|NCT06482580|OTHER|PNF exercise|Ankle and foot exercises practiced for 6 weeks.
41475689|NCT01570348|DRUG|Cyclophosphamide|Given IV
41475690|NCT01570348|DRUG|Fludarabine Phosphate|Given IV
41319251|NCT06482580|OTHER|Clam exercise|Hip exercise practiced for 6 weeks.
41319252|NCT06482580|OTHER|Short-foot exercise|Foot exercise practiced together for 6 weeks.
41319253|NCT03532581|OTHER|Indocyanine Green Solution|Given Subcutaneous injection
41319254|NCT03532581|PROCEDURE|Lymphangiography|Undergo lymphangiography
41319255|NCT04335604|DRUG|JPI-547|The dose levels will be escalated following a 3+3 dose escalation scheme.
41475691|NCT01570348|OTHER|Laboratory Biomarker Analysis|Correlative studies
41005845|NCT05307289|OTHER|Biposy|Biopsy at inclusion visit and at disease progression if applicable
41475692|NCT01570348|DRUG|Mycophenolate Mofetil|Given PO
41475693|NCT01570348|DRUG|Mycophenolic Acid|Given PO
41475694|NCT01570348|OTHER|Quality-of-Life Assessment|Ancillary studies
41475695|NCT01570348|DRUG|Tacrolimus|Given IV or PO
41319256|NCT03046043|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
41319257|NCT03046043|PROCEDURE|Low-Voltage & CFAE guided ablation|In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
41319258|NCT02921763|DRUG|Dydrogesterone|
41319259|NCT05009030|DRUG|COVID-19 vaccine|Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities
41319260|NCT00965783|OTHER|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
41319261|NCT00965783|OTHER|Extension|Bedtime is extended by 2 hours per night for 4 nights
41475696|NCT01570348|RADIATION|Total-Body Irradiation|Undergo TBI
41319262|NCT02590523|DRUG|Vancomycin|Intracameral vancomycin injection during cataract surgery
41475697|NCT00611884|DRUG|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
41475698|NCT00611884|DRUG|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
41475699|NCT00611884|DRUG|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
41475700|NCT00611884|DRUG|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
41475701|NCT00611884|DRUG|metformin|Tablets, 1500-2000 mg/day
41475702|NCT05364996|DIAGNOSTIC_TEST|bronchial endoscopy with bronchoalveolar lavage (LBA)|Bronchial endoscopy under laryngeal mask and general anesthesia. BAL of saline at room temperature of 3 milliliters per kilogram limited to 20 milliliters x 3 according to recommendations
41475703|NCT05364996|DIAGNOSTIC_TEST|Blood sampling|collection of 5 milliliters of blood for total white cells count, C-Reactive Protein, specific immunoglobulin E assays, serum sRAGE assay
41475704|NCT00332124|DRUG|Choline|900 mg every day until birth of infant
41475705|NCT00332124|DIETARY_SUPPLEMENT|Placebo|Corn oil every day in place of choline
41475706|NCT06471920|BEHAVIORAL|Educational Control|Patients randomized to the educational control group will receive registered access to a study website with access to evidence-based education for patients with chronic LBP. Each participant will have unique login credentials to allow for tracking of individual patient use. The website will include important education on the etiology of chronic LBP and evidence-based suggestions for self-management of symptoms. Education will focus on the importance of maintaining healthy levels of physical activity and avoiding bedrest.
41475707|NCT06471920|BEHAVIORAL|Telerehabilitation|Based on prior SBTS risk stratification, participants in the risk-informed telerehabilitation group will receive subsequent care using an evidence-based treatment protocol designed for video visits to be informed by a participant's baseline risk score with elements ranging from standard physical therapy telehealth visits (low-to-medium risk) to PIPT telehealth visits (high-risk).
41319263|NCT02590523|DRUG|Moxifloxacin|Intracameral moxifloxacin injection during cataract surgery
41319264|NCT02590523|DRUG|Placebo|Intracameral placebo injection with BSS during cataract surgery
41319265|NCT05776914|BIOLOGICAL|Donor Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of freeze-thawed donor stool
41319266|NCT05776914|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of stool collected from the same individual
41319267|NCT05299242|DRUG|Adalimumab Injection|40mg in 0.8ml preparation in vials from Fresenius Kabi Ltd
41319268|NCT05299242|DRUG|Placebo|Saline \[0.9% NaCl\]
41005846|NCT02915744|DRUG|NKTR-102|
41005847|NCT02915744|DRUG|Eribulin|
41005848|NCT02915744|DRUG|Ixabepilone|
41319269|NCT01383967|DRUG|LY2979165|Administered orally
41005849|NCT02915744|DRUG|Vinorelbine|
41319270|NCT01383967|DRUG|placebo|Administered orally
41475708|NCT05430841|DIAGNOSTIC_TEST|18F-FDG, 18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
41005850|NCT02915744|DRUG|Gemcitabine|
41005851|NCT02915744|DRUG|Paclitaxel|
41005852|NCT02915744|DRUG|Docetaxel|
41005853|NCT02915744|DRUG|Nab-paclitaxel|
41005854|NCT04419688|DRUG|STT-5058|Monoclonal Antibody STT-5058
41005855|NCT04419688|DRUG|Placebo|Matching placebo to STT-5058
41319271|NCT03689062|PROCEDURE|induction of labor|oxytocin intravenous drip
41319272|NCT03689062|PROCEDURE|follow up|hospitalization and antibiotics
41319273|NCT00794014|PROCEDURE|Conservative strategy|"* Main vessel stenting was performed.~* Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow \<3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) \>75% in LM subgroup.~* Side branch stenting was performed if TIMI flow \<3 in the Side branch after ballooning in non-LM subgroup, and DS \>50% or dissection in the Side branch after ballooning in LM subgroup."
41475709|NCT02315066|DRUG|PF-04518600|Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
41475710|NCT02315066|DRUG|PF-04518600|Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
41475711|NCT02315066|DRUG|PF-04518600 plus PF-05082566|Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
41319274|NCT00794014|PROCEDURE|Aggressive strategy|"* Main vessel was performed.~* Side branch ballooning and kissing ballooning were done if DS \>75% in the side branch after main vessel stenting in non-LM subgroup, and DS \>50% in LM subgroup.~* Side branch stenting was performed if DS \>50% in the side branch after ballooning in non-LM subgroup, and DS \>30% or dissection in the side branch after ballooning in LM subgroup."
41319275|NCT03922035|OTHER|Best Practice|Receive standard peri-/post-transplant supportive care
41319276|NCT03922035|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
41319277|NCT03297216|DRUG|17P|Synthetic progestin
41319278|NCT03297216|OTHER|Placebo|Non-active placebo comparator
41319279|NCT04910074|DEVICE|Low-level laser therapy|The proposed LLLT protocol will use the Biolase Epic X, an InGaAsP diode laser (940nm) using the pain relief handpiece, a device which has received FDA approval (GUDID 00647529002537) for the treatment of pain, muscle relaxation and healing via increased local circulation. The LLLT will be administered to the experimental group at 30 j/cm2. The laser will be applied extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
41319280|NCT04910074|DEVICE|Dummy LLLT|The Biolase Epic X with pain relief handpiece will be applied with no power extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
41319281|NCT00643487|PROCEDURE|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
41319282|NCT00078988|BIOLOGICAL|filgrastim|Given IV
41319283|NCT00078988|DRUG|carboplatin|Given IV
41319284|NCT00078988|DRUG|etoposide|Given IV
41319285|NCT00078988|DRUG|isotretinoin|Given IV
41475712|NCT02315066|DRUG|PF-04518600 plus PF-05082566|Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
41475713|NCT05738655|DIETARY_SUPPLEMENT|Pumpkin seed extract (Low dose)|Pumpkin seed extract standardized with specific peptides (300 mg/day)
41475714|NCT05738655|DIETARY_SUPPLEMENT|Pumpkin seed extract (High dose)|Pumpkin seed extract standardized with specific peptides (600 mg/day)
41005856|NCT05328492|DEVICE|iVAPS-AE|Patients randomised to this intervention will commence home NIV in iVAPS-AE mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
41005857|NCT05328492|DEVICE|ST-mode|Patients randomised to this intervention will commence home NIV in ST-mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
41005858|NCT04921358|DRUG|Tislelizumab|administered intravenously
41319286|NCT00078988|DRUG|thiotepa|Given IV
41475715|NCT05738655|DIETARY_SUPPLEMENT|Placebo|Placeo (300 mg/day)
41319287|NCT00078988|PROCEDURE|autologous bone marrow transplantation|Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)
41319288|NCT00078988|PROCEDURE|peripheral blood stem cell transplantation|Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
41319289|NCT02443571|RADIATION|Fluciclovine (18F)|Not applicable. This is an observational study.
41319290|NCT02534194|OTHER|Image acquisition|Images of baby's face (including ear) and feet
41319291|NCT06103448|DEVICE|Ankle-brachial index - system 100|Measurement of ankle brachial index on all four limbs, drawing three blood drops for point of care (POC) cholesterol meter and one drop of blood for POC glucometer
41005859|NCT04921358|DRUG|Docetaxel|administered intravenously
41005860|NCT04921358|DRUG|Sitravatinib|administered orally
41319292|NCT03252314|DEVICE|Second-generation hydrogel coils|Hydrogel coils 90% by length
41475716|NCT02632734|DEVICE|CoreBone Cone device|coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.
41475717|NCT02632734|DEVICE|CoreBone 500 device|coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
41005861|NCT02404311|BIOLOGICAL|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and \< 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
41005862|NCT02404311|BIOLOGICAL|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
41475718|NCT05836415|PROCEDURE|Tricuspid valve annuloplasty with 3D ring|A 3D ring is implanted to treat functional tricuspid valve regurgitation
41475719|NCT00908219|DRUG|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
41475720|NCT01779206|DRUG|Epirubicin|
41475721|NCT01779206|DRUG|Cyclophosphamide|
41475722|NCT01779206|DRUG|Docetaxel|
41475723|NCT01779206|DRUG|Paclitaxel|
41005863|NCT02404311|BIOLOGICAL|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
41005864|NCT02404311|BIOLOGICAL|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
41319293|NCT05128682|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra.
41319294|NCT00505895|DRUG|Melphalan|Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.
41475724|NCT06324058|PROCEDURE|Transurethral cryoablation|Using an intracavitary cryoablation balloon, cryoablation is performed on the wound surface after tumor resection. The wound surface is frozen for 2 rounds, with each round lasting 3 minutes, to fully cover the wound surface.
41475725|NCT06324058|PROCEDURE|Transurethral resection of bladder tumor|Resection of bladder tumor using resectoscopy, which is a standard procedure to treat non-muscle invasive bladder cancer
41319295|NCT00505895|DRUG|Fludarabine|30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
41319296|NCT00505895|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion on Day 0.
41319297|NCT00505895|DRUG|Rituximab|375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.
41319298|NCT03886831|DRUG|PRT543|PRT543 will be administered orally
41475726|NCT06324058|DRUG|Bcg Intravesical|Bacillus Calmette-Guerin instillation of bladder after surgery according to the NCCN bladder cancer guidelines. At least 6 weeks induction instillation is required for high-risk NMIBC patients. At least 1 year maintenance instillation is recommended.
41475727|NCT00108082|DRUG|carvedilol MR|Study drug
41475728|NCT00108082|DRUG|atenolol|Comparator
41475729|NCT00108082|DRUG|lisinopril|Comparator
41475730|NCT03740620|PROCEDURE|Bevel facing the cephalad direction of the patient|The bevel of the nasotracheal tube facing cephalad direction of the patient
41005865|NCT03922568|OTHER|Density Gradient Centrifugation|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
41475731|NCT03740620|PROCEDURE|Bevel facing leftward of the patient|The bevel of the nasotracheal tube facing the left side of the patient
41005866|NCT03922568|DEVICE|Physiological ICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
41005867|NCT03922568|DEVICE|Magnetic Activated Cell Sorting|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
41319299|NCT00425568|DRUG|AndroGel (Transdermal Testosterone Gel)|
41319300|NCT06197048|BEHAVIORAL|Nutritional counseling|"The intervention group will recieve 30 x 2 minutes with nutritonal counseling seperatet by a 15 minutes break. The participants will receive individually tailored guidance based on the information recieved at baseline measurments.~The couseling will be based on the Norwegian goverments dietary advices and the recommendation from the Directorate of Health for the prevention of cardiovascular diseases."
41319301|NCT00692510|DRUG|AZD3480|Capsule, oral, dose once daily, 7 days
41319302|NCT00692510|DRUG|Placebo|Capsule, oral, dose once daily, 7 days
41319303|NCT00692510|DRUG|Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)|"Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix"
41319304|NCT03085147|DRUG|Olaparib|For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
41475732|NCT02439632|DRUG|prulifloxacin|
41475733|NCT02439632|DRUG|Levofloxacin|Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
41475734|NCT02439632|DRUG|Prulifloxacin Placebo|Placebo of prulifloxacin film-coated tablet without active components.
41475735|NCT02439632|DRUG|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet without active components.
41475736|NCT03418792|OTHER|Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography|Head \& neck radiation with parotid sparing. Parotid sparing will be facilitated by avoidance of salivary ductal structures and stem cells, as identified by the pre-treatment MRI sialogram, in the radiation treatment plan.
41475737|NCT03744221|DIETARY_SUPPLEMENT|Corn protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
41475738|NCT03744221|DIETARY_SUPPLEMENT|Bovine plasma protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
41475739|NCT03744221|DIETARY_SUPPLEMENT|Whey protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
41475740|NCT00426010|DRUG|caffeine/placebo|caffeine or placebo, either overt or covert
41319305|NCT02935699|DRUG|Test Drug (JDP-205)|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
41319306|NCT02935699|DRUG|Active Control (Diphenhydramine)|Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
41319307|NCT04180501|COMBINATION_PRODUCT|SRS sequential sintilimab|The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
41319308|NCT06168500|PROCEDURE|Test group|3.0mm diameter implant
41319309|NCT06168500|PROCEDURE|Control group|4.0 diameter implant + guided bone regeneration
41319310|NCT04916535|OTHER|diagnostic flow|exams to estimate the risk of adverse events in patients with MAD
41319311|NCT00772694|DRUG|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
41319312|NCT03489993|DIAGNOSTIC_TEST|Ang II and Ang-(1-7)|Measured in plasma and urine using radioimmunoassays.
41319313|NCT03489993|DIAGNOSTIC_TEST|FGF23 and klotho|Measured using ELISA's.
41319314|NCT05091892|OTHER|Hydrotherapy programm|Treatment
41475741|NCT06167954|DEVICE|EXPLORER|8 sessions of use of the device in the home and the community of the participants
41475742|NCT01293552|BIOLOGICAL|ANT-1207|single dose application
41475743|NCT01293552|BIOLOGICAL|Vehicle|
41475744|NCT04948957|DRUG|Esmolol|
41475745|NCT04948957|DRUG|Nitroglycerin|
41475746|NCT03177382|RADIATION|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
41005868|NCT03108248|DRUG|ethiodized oil; doxorubicin;Gelfoam;|Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
41319315|NCT03805581|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
41319316|NCT01204333|DRUG|Endovascular thrombolysis|Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
41319317|NCT01204333|DRUG|Heparin|The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
41319318|NCT03839017|DEVICE|SIMMAXMARCHERYAN2|Digital cognitive aid during the management of simulated war wounded.
41319319|NCT03900754|DRUG|Oxytocin|Intranasal administration of oxytocin
41319320|NCT03900754|DRUG|Placebo|Placebo
41319321|NCT02677220|DEVICE|CI532 cochlear implant|
41319322|NCT03452891|OTHER|Methylcellulose|Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
41319323|NCT03452891|DRUG|Simvastatin-Methylcellulose|Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
41319324|NCT03255265|OTHER|no interventions|no interventions
41319325|NCT03992209|OTHER|Standard care|Usual operating room practice
41319326|NCT03992209|OTHER|Protocolized care|Hand washing per protocol
41319327|NCT06089668|OTHER|Observational Study|None, this is a non-interventional trial
41319328|NCT05001061|DRUG|Misoprostol Pill|sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
41319329|NCT01495338|DRUG|AC-170 0.17%|1 drop in one eye at one timepoint
41319330|NCT01495338|DRUG|AC-170 0.24% (Formulation 1)|1 drop in one eye at one timepoint
41319331|NCT01495338|DRUG|AC-170 0.24% (Formulation 2)|1 drop in one eye at one timepoint
41319332|NCT01495338|DRUG|Olopatadine hydrochloride 0.2%/Tears Naturale II|1 drop in one eye at one timepoint
41319333|NCT03477071|PROCEDURE|Angioplasty for Transplant Renal Artery Stenosis (TRAS)|The angioplasty is an endovascular treatment for artery stenosis, which could be associated with stenting or not.
41319334|NCT04494555|DEVICE|Static socket|For the static socket configuration, both the microprocessor control and user control are disabled, and the panels are positioned in their flush configuration to create the user's as-prescribed socket shape.
41319335|NCT04494555|DEVICE|User adjusted socket|Sockets are configured for user control by disabling automated control and enabling push buttons on the side of the socket to adjust socket size. Each button push effects a socket size change of approximately 0.3% volume. An upper button effects a socket size increase, and a lower button a socket size decrease. The buttons are countersunk so reduce risk of accidental pushes, and they do not function unless the user is stationary. An additional button push will not be executed until motor motion from the prior push has been completed. If a button is continuously held then the motor will continue moving until the button is released. Limits are set on cable length to ensure that sockets sizes threatening to the user's residual limb (too tight) are avoided. The push buttons effect inner-loop control that operates completely within the mechanism, achieving high-resolution adjustment of cable length with minimal error.
41319336|NCT04494555|DEVICE|Microprocessor-adjusting sockets|"A strategy for automatically controlling the size of the socket during walking to compensate for unknown changes in limb volume will be used. The controller is essentially a regulator that continuously measures socket fit, and adjusts the socket to maintain a prescribed reference set point. Because the fit is automatically sustained, the prosthesis user is unaware of its operation."
41475747|NCT03177382|RADIATION|concurrent chemoradiotherapy|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
41475748|NCT03177382|PROCEDURE|TME|The TME operation will be given after the end of the neoadjuvant treatment.
41475749|NCT03177382|DRUG|Adjuvant chemotherapy|Patients will receive another 6 cycles of CAPOX after TME.
41319337|NCT04518982|DRUG|Sintilimab and lenalidomide|Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14.
41319338|NCT04518982|DRUG|Sintilimab placebo and lenalidomide placebo|Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14.
41475750|NCT03323060|DEVICE|Transanal endoscopic surgical procedure|Resection of tumors or lesions
41319339|NCT04922697|OTHER|Educational Intervention|Watch educational videos and use wearable air pollution sensor
40801717|NCT01127672|BIOLOGICAL|platelet rich plasma|"30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).~Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
41319340|NCT04922697|OTHER|Questionnaire Administration|Complete questionnaires
41319341|NCT01031485|DIETARY_SUPPLEMENT|Milk peptides and plant sterols|
41319342|NCT01031485|OTHER|Placebo|
41319343|NCT04441736|DEVICE|High flow nasal cannula|Device gives high flow oxygen comparable to non invasive ventilation and conventional oxygen therapy
41319344|NCT05070728|DRUG|Sham Injector|Sham injection
41475751|NCT03743259|DRUG|LuminoMark inj. 0.1mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
41475752|NCT03743259|DRUG|LuminoMark inj. 0.2mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
41475753|NCT03743259|DRUG|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3\~1mL once in this study.
41475754|NCT06326502|DRUG|ETN101|Oral administration
41475755|NCT06483087|BEHAVIORAL|Animated Education Program|Eight minutes animated vedio; presented individually to children in their rooms. The vedio explains specific aspectsof the cardiac cathetrization procedure.
41475756|NCT00738361|DRUG|nab-paclitaxel|150 mg/m2 weekly for 3 of 4 weeks every 28 days.
41475757|NCT01615263|DEVICE|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
41475758|NCT01615263|DEVICE|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
41475759|NCT06472791|DIETARY_SUPPLEMENT|Centella Asiatica|Centella Asiatica is a perennial, herbaceous plant that is sold as a dietary supplement in the United States under the name Gotu Kola. It has been used for centuries in Ayurvedic and Chinese medicine. Evidence suggests it may help with resilience to aging and cognitive decline. The product for this study will be produced by Arjuna Natural.
41475760|NCT06472791|DIETARY_SUPPLEMENT|Placebo Comparator|The comparator will contain microcystalline cellulose in matched capsules. The comparator product for this study will be produced by Arjuna Natural.
41475761|NCT04916496|BEHAVIORAL|Acceptance and Commitment Therapy-based lifestyle counselling programme|"The ACT-LCP Group will receive an ACT-based lifestyle counselling programme, which composes of 5-weekly group sessions (2 hours per each, 15 hours in total). Acceptance, mindfulness, values clarification skills/exercises will be used to help patients to increase self-perspective taking and willingness to experience distressing sensations, discomfort and urges while engaging in healthy lifestyle behaviours.~One month after the programme, the participant will receive one 'booster' session (2 hours), followed by 2-weekly telephone follow-up calls (20-30 minutes per call) to evaluate the effort of behavioural change."
41319345|NCT05070728|DRUG|FAI Insert|FAI insert
41319346|NCT02698618|PROCEDURE|Diagnostic|"Pre-PCI and treatment:~1. At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~2. At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured."
41319347|NCT02698618|DRUG|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence \[Body Mass Index (BMI) ≥30 kg/m2\] with the implementation of a dedicated randomization list.
41475762|NCT04916496|BEHAVIORAL|Healthy lifestyle talk|"The Control Group will receive one 2-hour, healthy lifestyle education talk (at least 10 patients in the talk) based on the HEARTS technical package as recommended by the WHO as routine care. This package includes a collection of evidence-based protocols which standardizes a clinical approach to promote a healthy lifestyle among adults. The Control Group will receive routine psychiatric outpatient/rehabilitation services as provided by the clinic in NDH/community centre.~One month after the talk, three weekly follow-up telephone calls (20-30 minutes) will be arranged for each patient in the Control Group to evaluate the effort of behavioural change."
41475763|NCT04727684|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
41475764|NCT04727684|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
41475765|NCT04727684|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
41319348|NCT02698618|PROCEDURE|PCI|"1. Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~2. PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~3. Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR)."
41319349|NCT03794752|DEVICE|Head-Mounted Visual Enhancement Device|Evergaze has designed a head mounted electronic visual enhancement device that is compact and similar to glasses. It is powered by a battery pack connected to the device. The electronic display will be affixed over only one of the participant's eye. The vision through the unobstructed eye will aid with the participant's balance and spatial orientation. The prototype display and camera will be connected to a battery pack/control box that will allow the user to quickly select one of 3 modes. Each mode will represent a combination of parameters (brightness of the display, focus lock, color/black \& white, contrast, magnification) designed to optimize the image for different activities (e.g. reading, walking, computer use).
41319350|NCT03179280|DRUG|insulin|All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
41319351|NCT05514509|DRUG|APRETUDE|Available as intramuscular injection.
41319352|NCT05514509|DRUG|Cabotegravir tablet|Available as marketed orally administered tablets.
41319353|NCT00155454|PROCEDURE|Intravitreal long acting gas (10% C3F8)|At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
41319354|NCT05311293|DIAGNOSTIC_TEST|Endoscopy|Observe the extent of colonic lesions and obtain intestinal mucosal samples
41319355|NCT01488942|OTHER|monetary reinforcer|The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
41319356|NCT05250193|DEVICE|DK ScoreTM Coronary Scoring Balloon|After pre-dilation balloon is used (if any), DK Score is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
41319357|NCT05250193|DEVICE|Non-Slip Element Coronary Dilatation Catheter|After pre-dilation balloon is used (if any), NSE is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
41319358|NCT00565656|DRUG|BEVACIZUMAB|Administration of Bevacizumab
41319359|NCT05474911|DEVICE|Negative pressure therapy|The wound will be cleaned (irrigation with Physiological Serum), the cavity and the perilesional area will be dried with gauze. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing. The cavity will be filled with a sponge. When the depth of the wound is less than 1.5 cm, it will not be necessary to fill the defect. The appropriate dressing will be applied to the size of the incision, reinforcing the edges, and it will be connected to the TPN device, ensuring correct functionality.
41319360|NCT05474911|OTHER|Conventional wound care|The wound will be cleaned with physiological serum irrigation, the cavity will be dried with gauzes and filled with a dressing made of cellulose and silver. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing.
41319361|NCT00928356|PROCEDURE|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
41319362|NCT00928356|PROCEDURE|Off Pump CABG|Standard of Care Off Pump CABG
41319363|NCT04075526|DRUG|Povidone iodine|To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.
41319364|NCT04075526|DRUG|Vancomycin powder|2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia
41319365|NCT04075526|OTHER|Conventional|No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort
41319366|NCT03372629|DRUG|ID-085|Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg
41319367|NCT03372629|DRUG|Placebo oral capsule|Placebo capsules matching ID-085 capsules
41319368|NCT05657509|OTHER|Functional training|Functional training Length: 12 weeks; Training duration: 60 minutes; Intensity: 60 to 95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-2 minute rest between sets.
41319369|NCT05657509|OTHER|No intervention|The Control group continues regular traditional training exercises for 12 weeks with a training duration of 60 minutes and three days per week.
41319370|NCT00170742|DRUG|Octreotide, 30 mg i.m. LAR formulation|
41319371|NCT05176158|DRUG|Dexketoprofen 25 MG|Pill at morning
41319372|NCT05176158|DRUG|Dexketoprofen 25 MG|Pill at night
40801718|NCT01127672|DRUG|corticosteroid injection|"Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
41005869|NCT03108248|DEVICE|stent; idoine-125|In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.
41319373|NCT04875949|PROCEDURE|Immunoabsorption/plasmapheresis procedure|
41319374|NCT00685529|DRUG|Racemic formoterol|12 µg of racemic formoterol fumarate BID
41319375|NCT00685529|DRUG|Arformoterol tartrate inhalation solution|15 µg of nebulized arformoterol tartrate inhalation solution BID
41319376|NCT00685529|DRUG|Racemic formoterol|24 µg of racemic formoterol fumarate BID
41319377|NCT01462448|PROCEDURE|Blood Draw|Single blood draw of 30 ml
41319378|NCT03435263|OTHER|home management|pregnant women presented with PROM will be randomized into 2 groups group a will be discharged home after initial assessment and group B will be admitted to hospital as usual
41475766|NCT04727684|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
41475767|NCT03451006|DRUG|Metformin|Oral metformin (up to 2gm) will be given in divided doses
41475768|NCT03451006|DRUG|Placebo|Oral Placebo will be given in divided doses
41475769|NCT04158817|DRUG|68Ga-Labeled PSMA|All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.
41005870|NCT05595915|DIETARY_SUPPLEMENT|COMP-4|COMP-4 is a novel compound that consists of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.
41319379|NCT02556424|DRUG|Dexamethasone|Intravitreal implant at D0
41475770|NCT04158817|DRUG|Non-labeled PSMA|Patient will be injected with microdose (\<100 ug) of THP-PSMA
41319380|NCT02556424|DRUG|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
41475771|NCT01578668|DRUG|erlotinib|150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
41475772|NCT01578668|DRUG|pemetrexed|500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
41475773|NCT01578668|DRUG|cisplatin|cisplatin 20mg/m² iv on the 1st-3rd day (if PS\<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
41475774|NCT01578668|DRUG|erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
41475775|NCT06469762|OTHER|Dry Cupping|Dry cupping treatment session, using 4 regular plastic cups on the lumbar spine for 10 minutes.
41005871|NCT04683991|PROCEDURE|Subepithelial connective tissue graft|A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
41319381|NCT04248400|OTHER|Tai Chi training|A 24 weeks Tai Chi training with three 1-hour section per week
41319382|NCT04248400|OTHER|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
41319383|NCT03749798|PROCEDURE|Cataract surgery|Intraoperative wavefront measurements will be carried out during cataract surgery
41319384|NCT05755997|DRUG|Cerebrolysin|40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year
41319385|NCT05755997|DRUG|0.9 % NaCl|100 ml 0.9% NaCl per day for 4 days every month for 1 year
41319386|NCT04906993|DRUG|camrelizumab； famitinib malate|Camrelizumab intravenously ; Famitinib Orally
41319387|NCT04906993|DRUG|platinum-based chemotherapy|Physician's choice chemotherapy
41319388|NCT01403467|DEVICE|Continuous positive airway pressure|CPAP 8 cmH2O
41319389|NCT00483158|DRUG|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
41319390|NCT04031053|OTHER|Pharmacokinetic study|The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose
41475776|NCT06469762|OTHER|Placebo Dry Cupping|Dry cupping treatment session, using 4 plastic cups with two 2 mm holes drilled in either side of them, on the lumbar spine for 10 minutes.
41475777|NCT00873119|DRUG|belinostat, carboplatin, paclitaxel|
41475778|NCT00873119|DRUG|carboplatin, paclitaxel|
41475779|NCT00854802|DRUG|Debio 025|Debio 025 supplied in soft gel capsules
41475780|NCT00854802|DRUG|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
41475781|NCT00854802|DRUG|Ribavirin|Ribavirin supplied in tablets
41475782|NCT00854802|DRUG|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
41475783|NCT03330236|DEVICE|"Anesthetic depth management"|The propofol and remifentanil infusion rates will be adjusted to maintain the spectral edge frequency (SEF) value at 10-15 and the patient state index (PSI) value at 25-50 based on the SedLine EEG Brain Function Monitoring.
41319391|NCT06070740|DRUG|Durvalumab and Chemotherapy(oxaliplatin and capecitabine)|"Combination therapy includes:~Durvalumab: intravenous infusion with a fixed dose of 1500 mg on day 1, repeated every 3 weeks ± 3 days; Chemotherapy: Oxaliplatin 130mg/m2 intravenous infusion on day 1, capecitabine 1000mg/m2, orally, twice a day, from day 1 to day 14; repeated every 3 weeks ± 3 days;~After 6 cycles of combination therapy, maintain with durvalumab 1500 mg every 4 weeks ± 3 days for 2 years. Terminate the trial if confirmed disease progression, initiation of other anti-tumor therapy, unacceptable toxicity, withdrawal of informed consent or other reasons considered by the investigators."
41319392|NCT03031548|DEVICE|Point-of-care ultrasound exam|No intervention
41319393|NCT03031548|RADIATION|Reposition ETT|ETT will be repositioned based on CXR by fluoroscopy
41319394|NCT01392053|OTHER|Lumbosacral Massage|Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
41319395|NCT02887859|BIOLOGICAL|Human Acellular Vessel (HAV)|Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
41319396|NCT01310816|DRUG|IPI-926|Oral
41319397|NCT01310816|DRUG|Placebo Arm|oral placebo
41319398|NCT05511519|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
41319399|NCT05511519|DRUG|Placebo Oral Tablet|Placebo tablet manufactured to match ATI-450 in appearance
41319400|NCT04032626|DRUG|Lenalidomide 10 mg|Lenalid
41319401|NCT04032626|DRUG|Placebo|Placebo
41319402|NCT05338281|DEVICE|Negative Pressure Wound Therapy|The negative pressure wound therapy will be placed in addition to usual care of the abdominal donor site, such as closure with resorbable sutures, drain placements.
41319403|NCT05757089|DIETARY_SUPPLEMENT|ALCOFILTRUM|ALCOFILTRUM helps alleviate alcohol hangover symptoms after a single intake for 30 minutes before alcohol consumption.
41319404|NCT00817401|DEVICE|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
41319405|NCT04713579|OTHER|No intervention - observational study|There is no intervention in this study as it is purely observational.
41319406|NCT01967524|DRUG|botulinum toxin A + ropivacaïne|"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of botulinum toxin A associated with ropivacaïne~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
41319407|NCT01967524|DRUG|Ropivacaïne|"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain Questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
41005872|NCT01907633|DRUG|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
40801720|NCT02020434|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
41005873|NCT02489175|DEVICE|Stomaplasty KoringTM|In these patients, the stomaplasty Koring will be implanted at the time of the primary definitive stoma creation. The implantation of the Koring will be performed by experienced surgeons (expertise based, best team approach) who have already implanted the Koring (e.g. participated in the observational study) and/or have reviewed the video documentation. To ensure standardization for all participating centres an operative manual with standardized video sequences is available.
41319408|NCT03039933|BEHAVIORAL|Fear of Hypoglycemia|Participants will receive exposure and response prevention and/or hypoglycemia awareness training.
41319409|NCT03039933|OTHER|Treatment As Usual|Treatment As Usual
41319410|NCT04602676|DIAGNOSTIC_TEST|Rehydration calculator application with DEP algorithm|4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.
41319411|NCT04602676|DIAGNOSTIC_TEST|Rehydration calculator application|4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.
40801721|NCT01039545|DRUG|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
40801722|NCT01039545|DRUG|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
40801723|NCT03316118|DRUG|bupivacaine|Group 1 will receive genicular nerve block using bupivacaine
40801724|NCT03316118|DRUG|saline|Group 2 will receive genicular nerve block using normal saline
40801725|NCT03764319|OTHER|Ultra-protective ventilator settings|4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 \< Plateau pressure \< 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume \> 4 mL/kg Predicted body weight (PBW)); \< 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)
40801726|NCT03764319|OTHER|Standard ventilator settings|12-25 Breaths per minute; 8-12 cmH2O PEEP; max. 35 cmH2O Plateau pressure
40801727|NCT02029755|PROCEDURE|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
40801728|NCT02029755|PROCEDURE|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
40801729|NCT02029755|PROCEDURE|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
41319412|NCT06441110|DRUG|Tislelizumab in Combination with Bacillus Calmette-Guérin|Postoperative immediate instillation of epirubicin (50mg) is administered. Postoperatively, 200mg of tislelizumab injection is given intravenously every 3 weeks, with each 21-day period constituting one cycle. The medication is administered on day 1 of each cycle, continuing for one year. Eligible patients for the single-arm group (N = 76) begin BCG instillation after 2 weeks, with a dosage of 120mg per instillation, totaling 19 instillations: this starts with a 6-week induction phase of weekly BCG instillations, followed by BCG instillations every 2 weeks for three consecutive times; thereafter, maintenance instillation therapy commences, involving monthly BCG instillations for a total of ten times.
41319413|NCT00736866|DRUG|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
41319414|NCT00736866|DRUG|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
41319415|NCT03134313|DEVICE|Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor|
41319416|NCT02692170|BIOLOGICAL|CVI-HBV-001|Investigational Product
41319417|NCT02692170|BIOLOGICAL|Conventional Hepatitis B vaccine (20 μg)|Investigational Product
41319418|NCT00890071|OTHER|Fluid administration|500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
40801730|NCT03984890|DRUG|Vitamin D3|Vitamin D3 drops 800IU/d for 3 months
41319419|NCT05781763|BEHAVIORAL|High intensity interval training (HIIT)|"2 HIIT sessions/week in self-selected activity and type of interval-session with in total 15 minutes interval time (85-90% of MHR) with active rest (50-70% of MHR) between intervals for 12 weeks~1 self-selected session at moderate or high-intensity/week for 12 weeks Standardized physical and digital coaching by a physiotherapist"
41319420|NCT05781763|OTHER|Control group|Continuing with exercise as usual during 12 months
41319421|NCT05082298|BEHAVIORAL|Dental FearLess app|Dental FearLess, is a self-administered psychoeducational intervention that will be accessed by participants via their personal smart device (In other words, this is an online application in which investigators present information about dental procedures. The user selects the procedure on which they would like information and then views a brief video on the selected procedure. It uses evidence-based tools to help participants manage their thoughts, feelings, and behavior related to dental fear to reduce fear during encounters with dental professionals.
41319422|NCT05082298|BEHAVIORAL|In-Chair Treatment Protocol|This session is a 1-hour-in-person Cognitive Behavioral Therapy (CBT) dental fear session by study staff at the dental office. Participants will practice managing their thoughts, behaviors, and/or feelings when exposed to stimuli that they report still fearing. After each practice situation, the mental health provider and participant discuss the disconfirmatory evidence generated by the situation.
41319423|NCT00697658|DRUG|Paliperidone ER|6 mg tablet once daily, variable treatment length.
41319424|NCT00261248|BIOLOGICAL|Immunization with inactivated bacteria|
41319425|NCT06213129|DEVICE|Na and ultrafiltration profiling|Sodium and ultrafiltration profiling are method of dialysis in which dialysate sodium concentration and ultrafiltration rate are altered during the course of the dialysis session
40801731|NCT03984890|DRUG|Traditional treatment of CGD and TB|Anti-tuberculosis drugs, interferon-gamma
40801732|NCT05587179|OTHER|recovery position|A side-lying recovery position is a first aid intervention that can be performed by laypeople when victims are unresponsive but breathing normally and, hence, do not require cardiopulmonary resuscitation.
40801733|NCT02231892|DEVICE|TMS|HAC coil (real rTMS or sham rTMS)
40801734|NCT06084182|OTHER|Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment|6-minute walk test and 5-time sit-to-stand test (STS-5) were used for functional capacity assessment. For cognitive reserve assessment, the Cognitive Reserve Index questionnaire was used. Reaction time, cognitive function and visiospatial perception were evaluated with the mobile application. In addition, the Fatigue Severity Scale; Beck Depression Questionnaire and Nottingham Health Profile were used.
40801735|NCT06270082|DRUG|IK-595|Oral tablet administered in 28-day or 30-day cycles until treatment discontinuation criteria are met.
40801736|NCT02016391|DRUG|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
40801737|NCT01596140|DRUG|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
40801738|NCT01596140|DRUG|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
40801739|NCT01596140|DRUG|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
41319426|NCT04000555|DRUG|Oral Vancomycin|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
41319427|NCT04000555|OTHER|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
41319428|NCT04249505|DEVICE|"2WIN Photoscreener"|"non-cycloplegia refraction by Adaptica 2WIN"
41319429|NCT04249505|DEVICE|"Plusoptix A12"|"non-cycloplegic refraction by Plusoptix A12 photoscreener"
41319430|NCT04249505|DEVICE|"Retinomax"|"non-cycloplegic refraction by Retinomax K+ auto refractor"
41319431|NCT00594204|DRUG|varenicline tartrate (CP-526, 555-18)|1 mg twice a day for 12 weeks, starting with a 1-week titration period.
41319432|NCT00594204|DRUG|Placebo|matching placebo 1 tablet twice a day for 12 weeks
41319433|NCT03018457|DEVICE|ISQ|Measured by Osstell.
41319434|NCT05991674|DIAGNOSTIC_TEST|patch test for diagnosing allergic contact dermatitis|European Baseline Series (EBS) System of allergens
41319435|NCT03428685|DRUG|Dydrogesterone Oral Tablet|Oral dysdrogesteone 10mg tds will be prescribed from 12 - 36+6 weeks.
41319436|NCT03428685|DRUG|Placebo Oral Tablet|Placebos will be prescribed from 12 - 36+6 weeks.
41319437|NCT01124201|OTHER|Stabilization , strengthening and stretching|Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
41475784|NCT05450484|DRUG|Fluorescence endoscopy using durvalumab-680LT|"Tracer administration: The PD-L1-targeted fluorescent tracer durvalumab-680LT will be administered intravenously 2-4 days prior to the endoscopy at the UMCG. Afterwards, patients will be monitored for half an hour by measurements of vital parameters for potential side-effects, such as infusion-related reactions.~Endoscopy procedure: Patients will undergo two endoscopies, before and after neoadjuvant therapy. First, routine high-definition white-light (HD-WL) inspection is used. Quantification of fluorescence using multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy will be performed both in vivo and ex vivo. Subsequently, fluorescence molecular endoscopy (FME) and endoscopic ultrasound (EUS) will be performed. EUS enables single fiber reflectance/single fiber fluorescence (SFR/SFF) spectroscopy measurements via fine needle aspiration (FNA) to gain insight in the drug distribution throughout the tumor. Additionally, biopsies will be obtained."
41475785|NCT01810094|DEVICE|Fracture Fixation|Thoracolumbar Fracture Fixation
41475786|NCT03141879|OTHER|HUR equipment resistance training intervention|Resistance training intervention
41475787|NCT01042535|BIOLOGICAL|adenovirus-p53 transduced dendritic cell (DC) vaccine|Given intradermally (ID)
41475788|NCT01042535|DRUG|1-methyl-d-tryptophan|Given orally (PO)
41475789|NCT01042535|OTHER|Laboratory biomarker analysis|Correlative studies
41475790|NCT05026476|DIETARY_SUPPLEMENT|Resource Thicken up Junior|Each infant and child will be switch over to receive for a period of 7 days (new thickener)
41319438|NCT04430946|DIAGNOSTIC_TEST|Standardized test meal|A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes
41319439|NCT01330563|DRUG|CKD-501, Ketoconazole|Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
41475791|NCT05132725|BEHAVIORAL|diet therapy|Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.
41475792|NCT03311152|DIAGNOSTIC_TEST|"Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)"|The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.
41319440|NCT01965418|DRUG|Fufang Biejia Ruangan Tablet|
41319441|NCT01965418|DRUG|Placebo|
41319442|NCT05119959|OTHER|ECD intervention for CHEUs|The bi-weekly community health worker-delivered ECD 1 hour intervention using the modules from the SUPERCDZ curriculum which is a Zambian adaptation of UNICEF's Nurturing Care Framework
41319443|NCT05119959|OTHER|Usual care for CHEUs|No ECD interventions will be provided by community health workers. Children will be followed at clinics for growth and monitoring, vaccinations on a MoH approved schedule.
41319444|NCT01547468|PROCEDURE|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
41319445|NCT01547468|PROCEDURE|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
41319446|NCT05611099|DEVICE|Dreem 3 System vs WatchPAT One|Dreem 3 System and WatchPAT One will be worn simultaneously during 3 nights by each study participant, in order to compare the TST automatically outputted by both devices.
41319447|NCT05611099|OTHER|Usability Questionnaire|After having undergone the 3 nights of measurement, an end of Study Questionnaire will be performed on a separate day to obtain Usability feedback from participants who have undergone simultaneous recordings with the Dreem 3 + WatchPAT devices.
41319448|NCT01794247|DRUG|Magnesium sulfate|
41319449|NCT01794247|DRUG|Fentanyl|
41319450|NCT01794247|DRUG|Lidocaine|
41319451|NCT01951690|DRUG|defactinib (VS-6063)|
41319452|NCT01062568|DRUG|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
41475793|NCT02339610|DEVICE|ATTUNE Primary, Cemented Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four implant configurations of the ATTUNE knee ( CR FB, CR RP, PS FB, PS RP).
41475794|NCT00302549|DRUG|FK506|FK506,0.1mg/kg/d
41475795|NCT01026259|OTHER|Warming of surgical incision|A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
41319453|NCT01062568|DRUG|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
41319454|NCT00889993|DIETARY_SUPPLEMENT|Mixed Fiber Supplement|Breakfast Muffin containing 0g, 4g, 8g, and 12g of mixed fiber (total fiber amount as listed).
41319455|NCT03263936|DRUG|Decitabine|Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over __ hour on days 1 through 5
41319456|NCT03263936|DRUG|Vorinostat|Age \<18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.
41319457|NCT03263936|DRUG|Filgrastim (G-CSF)|Given on days 5 until evidence of ANC recovery (\>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)
41319458|NCT03263936|DRUG|Fludarabine|30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)
41319459|NCT03263936|DRUG|Cytarabine|2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
41319460|NCT00514202|DRUG|Placebo|matched placebo
41319461|NCT00514202|DRUG|Dextroamphetamine SR|60 mg/day
41319462|NCT05318105|DEVICE|Aquadex Smartflow® System|ultrafiltration
41319463|NCT05318105|DRUG|IV Loop Diuretics|diuretics
41319464|NCT00101621|DRUG|M40403|
41319465|NCT02874183|BEHAVIORAL|Pharmacist intervention|Pharmacist counseling and follow-up phone calls
41319466|NCT00209833|DRUG|Cytarabine|
41319467|NCT00209833|DRUG|Idarubicin|
41475796|NCT01026259|OTHER|Warming dressing without actual warming|The same type of surgical incision dressing is used but no warming treatments are administered.
41475797|NCT02990806|DRUG|NI-071|IV infusion.
41475798|NCT02990806|DRUG|Remicade|IV infusion.
41475799|NCT01232491|DRUG|Insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
41475800|NCT01232491|DIETARY_SUPPLEMENT|Dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
41475801|NCT03227224|DRUG|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
41475802|NCT03227224|DRUG|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
41475803|NCT03470584|OTHER|Diet Exposure|Vegetarian diet vs nonvegetarian diet
41475804|NCT05440019|DEVICE|IMAGE CAPTURE SESSION|"The M3T FERTIGO® is an instrument to be used by a certified gynecologist and in particular by an IVF expert physician in order to observe and monitor the state of the endometrium lining of patients. The M3T device serves as a mini hysteroscope capable of magnification, capturing images and optional image processing thereof. The M3T enables to acquire in-vivo, magnified images of the endometrium surface, to identify key morphological parameters, calculate their attributes and statistics thereof and compare those for different acquisition images and to some standard tissue state tracks. One may then attempt to predict the Embryo transfer optimal timing, based on this analysis."
41475805|NCT06129344|OTHER|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage Group:Performed by physiotherapists trained by Dr. Vodder School and licensed in Lymphatic Consolidation Detoxification Therapy (CDT). The patient's treatment posture is to lie down. First, start with the neck lymphatic drainage technique. After performing bilateral axillary lymph node activation and lymphatic valve contraction, the bilateral breast lymph fluid is drained to the bilateral lymph nodes. The time is about 20 minutes. Assist in removing milk from both breasts for 15 minutes each. Once a day for three consecutive days of treatment.
41475806|NCT06129344|OTHER|Ultrasound therapy group|Ultrasound therapy group: performed by a physical therapist. This study uses an ultrasonic therapy device (model: UTO US-750 Therapeutic Ultrasound), frequency: 1MHz, intensity set to 1.0 Watt/cm2, pulsed mode, duty cycle 100%, treatment time 2 5 minutes on each side, and then assist in removing the breast milk from both breasts for 15 minutes on each side. Once a day for three consecutive days of treatment.
41475807|NCT05384886|DIAGNOSTIC_TEST|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
41319468|NCT00209833|DRUG|Etoposide|
41319469|NCT00209833|DRUG|Fludarabine|
41319470|NCT00209833|DRUG|G-CSF|
41319471|NCT00209833|DRUG|Daunorubicine|
41475808|NCT06365099|DEVICE|Single-pulse TMS|Single-pulse TMS will be applied to the lesioned hemisphere while participants rest quietly with their eyes open
41319472|NCT00151749|DRUG|Colesevelam hydrochloride|
41319473|NCT00003893|DRUG|CMF regimen|
41319474|NCT00003893|DRUG|cyclophosphamide|
41319475|NCT00003893|DRUG|doxorubicin hydrochloride|
41319476|NCT00003893|DRUG|epirubicin hydrochloride|
41319477|NCT00003893|DRUG|fluorouracil|
41319478|NCT00003893|DRUG|methotrexate|
41319479|NCT00003893|DRUG|mitomycin C|
41319480|NCT00003893|DRUG|mitoxantrone hydrochloride|
41319481|NCT00003893|PROCEDURE|adjuvant therapy|
41319482|NCT00003893|RADIATION|radiation therapy|
41319483|NCT03558191|DRUG|SHR-1210|A humanized monoclonal immunoglobulin PD-1 antibody
41319484|NCT06076200|DRUG|Piperacillin Sodium and Tazobactam Sodium for Injection|Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.
41319485|NCT00674518|BEHAVIORAL|One on one counseling|Motivational Interviewing
41319486|NCT00674518|BEHAVIORAL|Group/team - based health education|peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.
41319487|NCT00674518|BEHAVIORAL|PACE physician counseling|PACE format for physician exercise and nutrition counseling annually.
41319488|NCT04274660|BEHAVIORAL|DWELL (Diabetes and WELLbeing) Programme|12-week psychoeducational programme
41319489|NCT04740736|PROCEDURE|Saline Infusion|Patient with hypovolemia on day 1 will be randomized to a saline or sham infusion prior to the Day 2 exercise test.
41319490|NCT06368778|OTHER|Verbal Advice|The participant will receive verbal instructions following the standard physical therapy.
40801740|NCT03879616|BEHAVIORAL|An Enhanced Reminder|"This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure."
40801741|NCT03287882|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
40801742|NCT03287882|BEHAVIORAL|Life skills based education|The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
40801743|NCT03338478|DIAGNOSTIC_TEST|Wii Balance Board|Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
40801744|NCT05657899|PROCEDURE|Cerclage fixation|The intervention is by surgical open reduction and internal fixation of the fracture using two 1.0mm cerclage.
40801745|NCT05657899|PROCEDURE|Tension band wiring|The intervention is by surgical open reduction and internal fixation of the fracture using a 1.0mm cerclage and two 1.6 mm k-wires as described in AO-guidelines.
41475809|NCT05931120|DEVICE|Dry needling|"dry needling using 50mm or 60mm sized needles based on individual muscle bulk. Targeted dry needling will be performed on the muscles presenting with tight hamstrings. hurdler Hamstring stretch, extended triangular pose 10 repetitions, 3 sets per session and 2 sessions per week for 4weeks.~total 8 sessions , each consisting of 40mins"
41475810|NCT05931120|DEVICE|IASTM|"Instrument assisted soft tissue mobilization tools targeting tight hamstrings. hurdler Hamstring stretch, extended triangular pose 10 repetitions, 3 sets per session and 2 sessions per week for 4weeks.~total 8 sessions , each consisting of 40mins"
41475811|NCT04297995|DRUG|HLX10|Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.
40801746|NCT01019122|RADIATION|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
40801747|NCT05542095|DRUG|Simvastatin|Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
40801748|NCT00002134|DRUG|Ganciclovir|
40801749|NCT05788796|BEHAVIORAL|Band-aid application|"Before starting the study, cotton and band-aids will be provided to the women in the application group by the researchers.~• Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid."
40801750|NCT04230265|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion over 3 days
40801751|NCT04230265|DRUG|Fludarabine (Non-IMP)|Intravenous infusion over 3 days
40801752|NCT04230265|DRUG|TM123 (IMP)|Intravenous Infusion for 20 days
40801753|NCT04230265|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
40801754|NCT05444504|DEVICE|Cup|an insertable vaginal cup ('cup')
40801755|NCT05444504|DEVICE|Cup+|the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
41005874|NCT03750734|DIAGNOSTIC_TEST|Bronchoscopy|Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.
41005875|NCT03750734|DIAGNOSTIC_TEST|Blood test|Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.
41005876|NCT02271308|BEHAVIORAL|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
41005877|NCT01552772|DRUG|Aripiprazole IM Depot|400 mg intramuscular injection of aripiprazole
41005878|NCT04065724|OTHER|Physical training as resistance and aerobic training.|
41005879|NCT03693768|BEHAVIORAL|Health coaching|Health coaching
41005880|NCT01178892|DIETARY_SUPPLEMENT|Placebo|Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
41319491|NCT06368778|OTHER|Bathroom Scale|The participant is given a sense of what a 20 kg load feels like using a scale.
41319492|NCT06368778|DEVICE|Loadsol Biofeedback|Average peak force (N) with be measured during partial weightbearing physical therapy routine for 2-minutes using the Loadsol device.
41319493|NCT05634889|RADIATION|De-escalation|No regional radiotherapy. Radiotherapy towards the remaining breast after breast conserving surgery, but no radiotherapy at all after mastectomy.
40801756|NCT00868088|PROCEDURE|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit."
40801757|NCT02370823|PROCEDURE|Regenexx SD|stem cell treatment
41319494|NCT04284280|DIETARY_SUPPLEMENT|Routine vs Selective use of Human Milk Donor Fortifier|Infants will be randomized to two groups. Both groups will be fed Premature Human Milk (either Maternal own milk or Premature donor human milk). However, one group will get fortified with Donor Human Milk Fortifier once full feed is reached while the second group will get fortified using the same fortifier only when weight gain is suboptimal.
41319495|NCT03171311|PROCEDURE|Angiographic guided PCI|Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
41319496|NCT03171311|PROCEDURE|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
41319497|NCT06352242|OTHER|Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients|"For each patient, a blood sample will be taken at D0 before the CAR-T cells are injected then at D3, D7, D10, D30 after the injection. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis by effector immune cells (T lymphocytes, NK cells, CAR-T cells) and to define the phenotypic signature of trogocytosis."
41319498|NCT06352242|OTHER|Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers|For each healthy volunteer, a single blood sample will be taken at enrollment. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis of normal lymphocytes and NK cells.
41319499|NCT01226706|DRUG|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
40801758|NCT01562314|DRUG|GWP42003|1 to 5 50 mg capsules taken BID
40801759|NCT01562314|DRUG|Placebo|1 to 5 matching capsules taken BID
41319500|NCT01226706|DRUG|Placebos|Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
40801760|NCT04741321|OTHER|VascuQol-6 questionnaire Spanish version|VascuQol-6 questionnaire was translated by two professional translators into Spanish.
40801761|NCT00248911|BEHAVIORAL|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
40801762|NCT03774043|OTHER|Acute Intermittent Hypoxia|Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
40801763|NCT03774043|OTHER|Sham Acute Intermittent Hypoxia|Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.
40801764|NCT04115878|DRUG|Atomoxetine and oxybutynin (ato-oxy)|Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin
40801765|NCT03144336|BEHAVIORAL|Information provision|All study participants will receive weekly messages with HIV prevention information.
41319501|NCT02368080|DEVICE|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
41319502|NCT03902782|PROCEDURE|ESP block|"ESP with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham intercostal block with 20 ml Normal Saline"
41319503|NCT03902782|PROCEDURE|Intercostal block|"Intercostal block with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham ESP with 20 ml Normal Saline"
41319504|NCT03902782|PROCEDURE|Sham ESP block|As described earlier
41319505|NCT03902782|PROCEDURE|Sham Intercostal block|As described earlier
41319506|NCT03902782|DRUG|Bupivacaine-epinephrine|As described earlier
41319507|NCT03902782|DRUG|Dexamethasone injection|As described earlier
41319508|NCT03902782|DRUG|Normal saline|As described earlier
41319509|NCT05010993|DIAGNOSTIC_TEST|Nine Hole Peg Test|Each person will be tested by the Nine Hole Peg Test (3 attempts per subtest)
41319510|NCT05010993|DIAGNOSTIC_TEST|Purdue Pegboard Test|Each person will be tested by the Purdue Pegboard Test (3 attempts per subtest)
41319511|NCT05010993|DIAGNOSTIC_TEST|Box and Block Test|Each person will be tested by the Box and Block Test (3 attempts per subtest)
40801766|NCT03144336|BEHAVIORAL|Weekly quizzes|Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
40801767|NCT03144336|BEHAVIORAL|Rewards for testing HIV-negative|Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
41005881|NCT01178892|DIETARY_SUPPLEMENT|Omega-3|The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
40801768|NCT01536561|BIOLOGICAL|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
40801769|NCT02966288|DRUG|Toradol|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
40801770|NCT02966288|DRUG|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
40801771|NCT02033629|DRUG|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
40801772|NCT02033629|DRUG|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
40801773|NCT02033629|DRUG|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
40801774|NCT01202188|DRUG|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
40801775|NCT01202188|DRUG|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
40801776|NCT01202188|DRUG|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
40801777|NCT01202188|DRUG|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
40801778|NCT01202188|DRUG|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
40801779|NCT00392158|DEVICE|Closed-loop anesthesia system|
40801780|NCT05941208|PROCEDURE|continuous fascia iliaca compartment block|ultrasound Patients were in supine position and the puncture site was selected at 1 cm below the junction point at 1/3 of the connection of anterior superior spine and pubic tubercle. An ultrasound apparatus (Sonosite) high-frequency probe was placed in parallel to the inguinal fold to distinguish the femoral fascia and fascia iliaca, the needle was inserted with out-of-plane technique at an angle of 45° and the tip of the needle was pointed to the head. Once needle-tip placement under the fascia iliaca by hydrolocation was confirmed, the probe was rotated 90° into a longitudinal parasagittal orientation to visualize the needle tip in-plane and to track cephalad spread of the injectate under fascia iliaca, identification of the fascia iliaca plane through the linear probe and introducing epidural catheter 18 G , continuous infusion of bupivacaine 0.25% by a set rate of 7 ml per hour for 24 hours,
40801781|NCT03292549|PROCEDURE|Robotic partial surgery|Robotic partial surgery
40801782|NCT05883995|OTHER|Phage therapy requests|Quantification of phage therapy requests received at the Hospices Civils de Lyon from 2015 to 2028
40801783|NCT01821066|DRUG|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
40801784|NCT01821066|DRUG|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
40801785|NCT01821066|DRUG|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
40801786|NCT01821066|DRUG|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
40801787|NCT04087941|BIOLOGICAL|VM-202|VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
40801788|NCT04589234|DRUG|Salmonella-IL2|Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
40801789|NCT04589234|DRUG|FOLFIRINOX Alone (Historical Controls)|We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
40801790|NCT04589234|DRUG|Gemcitabine/Abraxane Alone (Historical Controls)|We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
40801791|NCT03280849|OTHER|Implant of bilaminar chitosan scaffold|The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
40801792|NCT04554693|DRUG|Metronidazole Oral|250 mg oral three times a day for 14 days
40801793|NCT04554693|DRUG|Placebo|Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
40801794|NCT01761799|BEHAVIORAL|P3 Vaccine Promotion Package.|"P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients."
40801795|NCT00061854|DRUG|soblidotin|
41475812|NCT04297995|DRUG|HLX07|Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.
41475813|NCT04297995|DRUG|HLX07 placebo|HLX07 placebo 1000 mg every three weeks
40801796|NCT02988947|OTHER|PNE+HyP|This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
40801797|NCT04154293|DRUG|Isotretinoin|Topical Isotretinoin ointment
40801798|NCT04154293|OTHER|Vehicle|Topical Vehicle Ointment
40801799|NCT04930120|OTHER|Inter ICU long distance patient transfer|Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.
41005882|NCT01178892|BEHAVIORAL|Yoga|Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
41005883|NCT01178892|BEHAVIORAL|Exercise|The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
41005884|NCT01178892|BEHAVIORAL|Usual Activity|"Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership."
41005885|NCT06145490|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 250 mg, oral intake
41005886|NCT06145490|DRUG|Placebo|Placebo capsule, oral intake
41005887|NCT05309603|OTHER|Loaded Walking High|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried high on the back
41005888|NCT05309603|OTHER|Loaded Walking Mid|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried on the mid-back
41005889|NCT05309603|OTHER|Walking|Walking three miles on a treadmill at a self-selected speed
41005890|NCT06357637|DIAGNOSTIC_TEST|Measure of abdominal circumference|Measure of abdominal circumference preoperatively in both sitting and lying position
41005891|NCT04282356|DRUG|Intraperitoneal chemotherapy during surgery|During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection). They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8) with at least 3 courses performed (up to 4-6 allowed).
41005892|NCT04029467|DRUG|Dexmedetomidine|addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
41005893|NCT04571112|DEVICE|NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)|This will either be turned on or off depending on the arm which the patient is randomized to. After 8-weeks, the subject will switch arms for another 8-weeks.
41005894|NCT06141629|DEVICE|accu chek Aviva Expert|This bolus calculator estimates the dose of insulin to be administrated on the basis of the following parameters: current blood glucose, grams of carbohydrate, carbohydrate to insulin ratio, insulin sensitivity, target blood glucose and quantity of insulin previously administered.
41005895|NCT06141629|DEVICE|Accu Chek Aviva Nano|This meter is a normal glucometer without bolus calculator.
41005896|NCT04721990|DEVICE|Automatic Sound Management 3.0|The investigational front-end features include those within Automatic Sound Management 3.0 (i.e., Ambient Noise and Transient-Noise Reduction, and Adaptive Intelligence). Automatic Sound Management 3.0 will be accessed in the MAESTRO system software. The investigational front-end features within Automatic Sound Management 3.0 will be programmed in the SONNET2EAS processor.
41005897|NCT04637581|BEHAVIORAL|Wraparound|Wraparound is a 12-month family-driven intensive care coordination model.
41005898|NCT01634204|OTHER|KiloCoach|"Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted."
41005899|NCT01634204|OTHER|Control|"Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months."
41005900|NCT00143702|DRUG|d4T|See Detailed Description.
41005901|NCT00143702|DRUG|Abacavir|See Detailed Description.
41005902|NCT00143702|DRUG|Riboflavin and Thiamine (Supplementation)|See Detailed Description.
41005903|NCT05960591|DEVICE|ADEPTH|ADEPTH sensor will be used for bore depth measurements during plate osteosynthesis procedures.
41005904|NCT02318693|DRUG|Sitagliptin|Sitagliptin 50 mg orally once a day before breakfast for 14 days
41005905|NCT02318693|DRUG|Glibenclamide|Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
41005906|NCT02435251|DEVICE|dual energy X-ray absorptiometry|
41005907|NCT05001243|DRUG|Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac|PBOHB to improve uncorrected near vision in healthy presbyopic patients
41319512|NCT02755610|OTHER|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
41005908|NCT05001243|DRUG|Pilocarpine Hydrochloride|Apply in the fellow eye
41005909|NCT05001243|DRUG|Brimonidine Tartrate|Apply in the fellow eye
41005910|NCT04181918|BEHAVIORAL|AOT|During action observation, participants observe different daily actions (e.g. reading a newspaper; drinking an espresso) divided into up to four motor segments.
41319513|NCT01556802|DRUG|Minocicline|Minocicline 100mg oral twice a day for 5 days
40801800|NCT03376139|DRUG|Zonisamide|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
41319514|NCT01556802|DRUG|Placebo|Pills with vegetable fibers one pill oral twice a day for five days
41319515|NCT03441568|DEVICE|Modified Diprobase formulation (BAY987534)|The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.
41319516|NCT04874467|PROCEDURE|Supportive periodontal therapy|"A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit."
41319517|NCT00421603|DRUG|Adderall-XR and Topiramate|Adderall-XR 60mg/day and Topiramate 300mg/day
41319518|NCT00421603|DRUG|Placebo|Placebo
41319519|NCT03101059|PROCEDURE|Non invasive ventilation - Continuous Positive Airway Pressure|To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
41319520|NCT00002017|DRUG|Interleukin-2, Polyethylene Glycolated|
41319521|NCT00384826|DRUG|erlotinib|Erlotinib 150 mg/day (until progression)
40801801|NCT03376139|DRUG|Placebo Comparator|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
40801802|NCT03573206|DEVICE|Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)|The device will be used to close all femoral venous access sites at the end of the case.
40801803|NCT03989375|DEVICE|transcutaneous vagus nerve electric stimulator|The stimulator that can be attached to ears of the patient.We suppose that this device can reduce the incidence of perioperative neurocognitive disorders(PND)
40801804|NCT03717753|OTHER|Pathway|The study team emphasizes that all components of the pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the pathway will receive these standard of care components. Both groups will receive identical postoperative follow-up.
40801805|NCT00394043|PROCEDURE|Osteopathic Manipulative Treatment|A protocol of specific Osteopathic manipulative techniques was used.
40801806|NCT00394043|PROCEDURE|Placebo Sub-Therapeutic Ultrasound|Sub-therapeutic ultrasound was applied in a standardized method.
40801807|NCT05641584|OTHER|retrospective data review study|Patient information will be scanned retrospectively from the computer environment and patient cards. No intervention will be made to the patients.
41005911|NCT04181918|BEHAVIORAL|MI|During motor imagery, participants imagine themselves performing the same daily actions as in AOT in the absence of motor output
41319522|NCT00384826|DRUG|paclitaxel + carboplatine|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
41319523|NCT03281447|OTHER|Nurse navigation|
40801808|NCT04749888|BEHAVIORAL|Targeted nurse-led home visiting|The KECHI encompasses 25-29 home visits, group activities, and community service linkage by social workers from the prenatal period until the child reaches the age of 2 years; as such, it is a complex intervention involving various domains to address a wide range of outcomes. Pregnant women with two or more risk factors who are deemed to have difficulties in raising children are eligible for the targeted multiple nurse home visits. Each home visit is implemented based on families' needs, and individualized interventions are provided to improve parenting and the home environment in order to promote the child's health and development and maternal health. The program includes educational materials for parents, such as a booklet covering issues on prenatal care, child development, postnatal child care, parent-child attachment, play, communication, safety, and goal-setting.
40801809|NCT05709561|PROCEDURE|Acupresur|acupressure application was applied 2 times a week for a total of 12 weeks and 24 times.
41319524|NCT03281447|OTHER|Current care coordination|
40801810|NCT05709561|PROCEDURE|Mindfulness|Mindfulness practice was applied with the students once a week for 8 weeks, accompanied by a researcher. Then, students were asked to apply for 3 cycles.
40801811|NCT05709561|PROCEDURE|Plasebo|No intervention was applied to the control group.
40801812|NCT05033184|BEHAVIORAL|Brief Action Planning Exercise|The Brief Action Planning exercise is a previously developed goal-setting exercise which has been designed to incorporate aspects of motivational interviewing such as compassion, acceptance, evocation, and partnership. It is a tool that allows participants to identify an aspect of their life they would like to improve upon and guides them through the process of making a specific, measurable, achievable, realistic, and timely (SMART) goal. It also assesses their confidence in achieving this goal so as to assist with making alternative plans if confidence is low.
40801813|NCT05033184|BEHAVIORAL|Goal Setting Exercise|The Goal Setting exercise allows participants to identify an aspect of their life they would like to improve upon without incorporating aspects of motivational interviewing components or providing any guidance on how to set this goal.
40801814|NCT03028415|DEVICE|AMPLEX|A bone graft substitute
40801815|NCT03028415|PROCEDURE|Autogenous Bone Graft (ABG)|Control material administered by surgical implant
41005912|NCT04254614|DEVICE|Personalised mobile application for IBD patients|"Patients will use a mobile application for ±6months (exact period depends on interval of biologic treatment) with the following functionalities:~* Personal interactive timeline to prepare for biologic treatment with reminders for blood tests, a questionnaire to exclude contra-indications for biologic treatment (e.g. current infection) and a message from the gastroenterology nurse when blood tests results and the questionnaire have been checked. Only in case of abnormal results or answers patients will be contacted by telephone by their gastroenterology nurse, which is currently standard care.~* Information about the patients' diagnosis and biologic treatment.~* General information on e.g. IBD treatment, vaccinations, frequently used medical terms, preparing for outpatient visits, what to do in case of disease symptoms.~Patients will fill in a questionnaire to measure study outcomes at baseline and at the end of the study period."
40801816|NCT01731158|DRUG|Avastin in combination with Roferon-A|
40801817|NCT01731158|DRUG|Afinitor|
40801818|NCT01731158|DRUG|TKI: Sutent, Nexavar or Votrient|TKI
40801819|NCT00596674|BEHAVIORAL|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
40801820|NCT00596674|OTHER|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
40801821|NCT03574376|DRUG|Bupivacaine Liposome Injection|Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
40801822|NCT03574376|DRUG|Bupivacaine|The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
41005913|NCT04084353|OTHER|Intrapartum fetal monitoring training and quality improvement project|Intrapartum fetal monitoring training
41005914|NCT05357872|DEVICE|deep anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
41319525|NCT03839914|DRUG|Vancomycin powder|For the intervention group, the use of 1g vancomycin powder to be placed in the deep wound and subcutaneous layer prior to closure.
41319526|NCT01862432|OTHER|Immediate skin-to-skin|The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
41319527|NCT00740922|DRUG|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
41319528|NCT01796262|DIETARY_SUPPLEMENT|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
41005915|NCT05357872|DEVICE|light anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
41005916|NCT04240899|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2-3 times/week for 6-weeks. The yoga sessions will be delivered one-on-one and will include 5-7 minutes of breathing exercises 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
41005917|NCT00259857|DRUG|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
41005918|NCT01357993|DRUG|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
41319529|NCT01796262|DIETARY_SUPPLEMENT|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
41319530|NCT01010711|DIETARY_SUPPLEMENT|Migra 3|powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
41319531|NCT03215524|BIOLOGICAL|DCdP|Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
41319532|NCT03215524|BIOLOGICAL|DCd+P|Daratumumab, Cyclophosphamide, Dexamethasone, + Pomalidomide added only at first confirmed biochemical progression
41319533|NCT00370240|DRUG|Chlorhydrate de Ropivacaine|The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
41005919|NCT04555135|DEVICE|EndoVigilant Software|While using this device, colonoscopy will continue to be performed in the standard manner as is done without the use of this device. The video signal from the colonoscope will be fed into a computer running the EndoVigilant software in addition to the standard video output to the procedure monitor. The gastroenterologist performing the procedure will therefore be able to observe a standard colonoscopy video on the primary monitor and the augmented video on the second monitor. The gastroenterologist may rely on the second monitor (with augmented video generated from EndoVigilant software) for polyp detection, but the standard procedure monitor with the original feed will always be operational and available for maneuvers such as fast insertion, polypectomy etc.
41005920|NCT03553628|OTHER|Chlorhexidine, Propolis and Clove Oil mouthwash|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash
41319534|NCT00370240|OTHER|placebo|The PCB group received saline solution in equal volume.
41319535|NCT00440895|DRUG|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
41319536|NCT02075749|DRUG|Triamcinolone Acetonide|
41319537|NCT02075749|DRUG|licorice mucoadhesive films|30 patients received licorice mucoadhesive films
41319538|NCT00742807|DRUG|Low dose of alfentanil hydrochloride|Administration of low dose alfentanil hydrochloride before paracervical block
41319539|NCT00742807|DRUG|Normal dose of alfentanil hydrochloride|Normal dose of alfentanil hydrochloride is administered after paracervical block
41319540|NCT02604862|OTHER|FIB ONE|FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.
41319541|NCT02604862|OTHER|AZD1236|AZD1236 will be delivered at microdose concentrations and is thus considered to be unable to exert any pharmacologic effect outside the area of administration and unlikely to cause an adverse reaction.
41319542|NCT00403819|DRUG|Polyethylene glycol 3350 Na bicarbonate NaCl KCl (Movicol)|
41319543|NCT02488616|OTHER|5-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days."
41475814|NCT04297995|DRUG|Cisplatin/Carboplatin|Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.
40801823|NCT06425913|OTHER|Kinesio Taping (KT)|KT was applied to the symptomatic shoulder at the end of the baseline assessment by a certificated physiotherapist with over ten years of experience in Kinesio taping. After three days, participants were re-evaluated. KT application has been made according to the protocol for rotator cuff impingement or tendonitis including inhibition and correction techniques.
40801824|NCT06425913|OTHER|Cold Therapy (CT)|The initial application was administered by the physiotherapist. In a sitting position, a pack was wrapped in a thin towel and placed on the affected shoulder joint, including the painful locations. During the application, the participant was closely observed for discomfort or adverse reactions (redness, burning, numbness, itching, ...). The cold application was continued for 20 minutes.After the first application, participants were instructed to apply ice for 20 minutes five times a day for three days at home or work.
40801825|NCT06425913|OTHER|standardized home exercise program|All participants performed standardized home exercise program, including shoulder isometric and stretching exercises were . A physiotherapist taught the exercise program until the participants were able to exercise accurately on their own. All participants were instructed to perform the exercises three times a day for three days.
40801826|NCT03668470|DRUG|Dulaglutide|Dulaglutide 1.5mg : One injection per week during 24 weeks
40801827|NCT03668470|DRUG|Placebo|Placebo: one injection per week during 24 weeks
40801828|NCT00964002|DRUG|efavirenz|
40801829|NCT03888924|DRUG|Bacille Calmette-Guerin vaccine|"One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride."
40801830|NCT03888924|DRUG|Placebo|isotonic solution of sodium chloride (2mL vials).
41319544|NCT02488616|OTHER|5-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.~Participants will have been previously shown how to use the study insulin pump."
41319545|NCT02488616|DEVICE|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
40801831|NCT04778891|OTHER|Comprehensive Medication Management services|Comprehensive Medication Management services (CMM services) is an evidence-based and patient-centred service which involves an assessment of patient's medications to determine that each medication is appropriate, effective for the medical condition being treated, safe for the patient in the presence of other medications and co-morbidities, and that the patient is able and willing to take the medications as intended. As all patient care providers need a structured, rational thought process for sound clinical decision retrieval, the Pharmacotherapy Workup was developed and adopted as a systematic problem-solving process. This process represents the cognitive work taking place in the mind of the practitioner, and is used to identify, resolve, and prevent drug therapy problems (DTP), establish therapy goals, select interventions and evaluate outcomes.
40801832|NCT01755962|OTHER|Glycemic Load|
40801833|NCT01755962|OTHER|Resistance Training|
40801834|NCT04975412|DIAGNOSTIC_TEST|Whole blood zinc level|whole blood zinc levels determined through ashing acid digestion-inductively coupled plasma (ICP) using Shimadzu ICPS-7510, an inductively coupled plasma emission spectrometer.
40801835|NCT00148486|DRUG|NS 2330|
40801836|NCT03966963|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|Trauma-Focused Therapy
40801837|NCT00911196|OTHER|Retrospective analysis of already archived samples|Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
40801838|NCT04315727|GENETIC|WGS Diagnostic Blood take for genetic diagnostic.|Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).
41005921|NCT03553628|OTHER|Chlorhexidine mouthwash|Chlorhexidine HCL 0.12% mouthwash
41005922|NCT03420703|OTHER|erector spinae plane block|ultrasound guided erector spinae plane block will be administered to this group.
41005923|NCT03420703|DEVICE|Intravenous morphine patient controlled analgesia device|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
41005924|NCT00700791|DIETARY_SUPPLEMENT|Natural Vitamin E Tocotrienol supplement (TCT)|Oral Vitamin E Tocotrienol Supplement (TCT)
41319546|NCT02488616|DEVICE|Continuous glucose monitoring system|Enlite sensor®, Medtronic
41005925|NCT00700791|DEVICE|Natural Vitamin E Tocotrienol Cream (TCT)|Natural Vitamin E Tocotrienol(TCT)Topical Cream
41005926|NCT00700791|OTHER|Placebo|Oral Placebo
41319547|NCT02488616|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
40801839|NCT04315727|GENETIC|Hair collection|Hair including root will be collected from the scalp (\~15-20) and transferred to cultivation medium for the organoid cultivation
40801840|NCT03286543|DEVICE|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
40801841|NCT01001767|DRUG|Lovaza|Lovaza one gram twice a day for 24 weeks
40801842|NCT01001767|DRUG|Placebo|Placebo
41005927|NCT00700791|OTHER|Placebo Cream|Topical Placebo Cream
41005928|NCT05907135|DIETARY_SUPPLEMENT|Beet|Beet-based powder with other ingredients
41005929|NCT05907135|DIETARY_SUPPLEMENT|Placebo|Placebo powder.
41005930|NCT00577122|DRUG|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
41319548|NCT00859989|BEHAVIORAL|behavioral dietary intervention|
41319549|NCT00859989|BEHAVIORAL|exercise intervention|
41319550|NCT00859989|BEHAVIORAL|telephone-based intervention|
41319551|NCT00859989|OTHER|counseling intervention|
41319552|NCT00859989|OTHER|educational intervention|
41319553|NCT00859989|OTHER|immunoenzyme technique|
41319554|NCT00859989|OTHER|laboratory biomarker analysis|
41319555|NCT00859989|OTHER|questionnaire administration|
41475815|NCT04297995|DRUG|5-FU|5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.
41475816|NCT05045313|DRUG|Warfarin sodium tablets|Drug: Warfarin sodium, tablet, oral
41475817|NCT05045313|DRUG|Digoxin tablet|Drug: Digoxin, tablet, oral
40801843|NCT01964495|DRUG|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
40801844|NCT01964495|DRUG|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
41475818|NCT05045313|DRUG|Probenecid tablets|Drug: Probenecid, tablet, oral
41475819|NCT05045313|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
40801845|NCT01964495|DRUG|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
41005931|NCT00577122|DRUG|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
41319556|NCT00859989|OTHER|study of socioeconomic and demographic variables|
41475820|NCT05129254|DEVICE|Fractionated Thulium laser|For this study, the investigators will use non-ablative fractional Thulium laser (1927 nm), provided by LaseMD, (Lutronic, Inc, USA). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by LaseMD. More than one affected area of the scalp may be treated per session. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment preparation will consist of cleaning the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide.
40801846|NCT02498054|BEHAVIORAL|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
40801847|NCT04120246|DRUG|Alpha-tocopheryloxyacetic Acid|Given PO
41319557|NCT00859989|PROCEDURE|evaluation of cancer risk factors|
40801848|NCT04120246|BIOLOGICAL|Trastuzumab|Given IV
40801849|NCT00000428|DRUG|Amitriptyline|Amitriptyline 25 mg po
40801850|NCT00000428|DRUG|Amitriptyline plus Fluoxitine|Amitriptyline 25 mg po plus Fluoxitine 20 mg po
40801851|NCT04022525|DRUG|Leflunomide 20Mg Tab|blood samples of rheumatoid patients will be collected for SNPs detection and drug assay
40801852|NCT02929160|PROCEDURE|Percutaneous nephrostomy|Percutaneous nephrostomy tube insertion under radiological guidance
40801853|NCT02929160|PROCEDURE|Retrograde ureteric JJ stent|Retrograde ureteric JJ stent insertion using cystoscopy
40801854|NCT03640507|DRUG|Chlorhexidine-alcohol|Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.
41005932|NCT03880721|PROCEDURE|Microwave abaltion|Use microwave ablation to treat hepatocellular carcinoma
41005933|NCT04125108|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
41005934|NCT00193401|DRUG|Topotecan|
41005935|NCT04945434|DEVICE|S53P4 bioactive glass (BonAlive)|Surgical implantation of S53P4 in a bone defect created during debridement for chronic osteomyelitis.
41005936|NCT04321304|DEVICE|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
41319558|NCT00859989|PROCEDURE|support group therapy|
41319559|NCT04111107|DRUG|Investigational Agent|Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.
41319560|NCT04111107|OTHER|Supportive Care Regimens|Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.
41319561|NCT04111107|DIAGNOSTIC_TEST|Next Gen Sequencing Report|1) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.
41475821|NCT05129254|PROCEDURE|Autologous Platelet Rich Plasma Injection|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be injected with a syringe and needle subcutaneously into the participant's scalp.
41475822|NCT05129254|PROCEDURE|Autologous Platelet Rich Plasma Topical Application|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be applied topically with a syringe to one or more affected areas on the participant's scalp that were previously treated with thulium laser.
41475823|NCT00726102|OTHER|Meat|2 0z of locally available meat per day
41475824|NCT00726102|OTHER|Cereal|Daily provision of cereal to infants from 6-18 mos
41475825|NCT00726102|OTHER|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
41319562|NCT05805670|OTHER|Yoga and Mindfulness|"Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to and 1 post-operative visit (24 hours after surgery)~The 5 sessions will be carried out 1 session/week from inclusion to the day before surgery"
40801855|NCT03640507|DRUG|Povidine-iodine|Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.
41319563|NCT04765436|BIOLOGICAL|PTX-COVID19-B|Sterile solution for injection
41319564|NCT04765436|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
40801856|NCT03640507|DRUG|Sterile saline|Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
41319565|NCT04436029|BIOLOGICAL|Descartes 11|Car T-cells
41319566|NCT00400712|BEHAVIORAL|physical rehabilitation|two weeks intensive physical rehabilitation
41319567|NCT00546039|DRUG|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
40801857|NCT04798352|OTHER|6-minute walk test|6-minute walk test
40801858|NCT04798352|OTHER|WIQ functional questionnaire|WIQ functional questionnaire
40801859|NCT04798352|OTHER|quality of life questionnaires (EQ5D5L and SF-36)|quality of life questionnaires (EQ5D5L and SF-36)
40801860|NCT02516982|OTHER|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
41005937|NCT04321304|DEVICE|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
41005938|NCT04321304|DEVICE|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
41005939|NCT03561974|DEVICE|Humidification|Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
41319568|NCT00546039|DRUG|Placebo|Capsule
41319569|NCT05966844|BEHAVIORAL|Mindfluness and Virtual Reality|They will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
41319570|NCT03655574|BEHAVIORAL|Motivational + Family Check-up (MET+FCU)|In the MET session, motivational strategies of individualized normative feedback, examining decisional balance, and providing information/advice will be used to support goals for behavior change and to examine barriers to changes. There are four specific phases of the FCU session: (1) Self-assessment: Parents are asked if they learned anything about their family from participating in the assessment. (2) Support and clarification: The interviewer supports the parent's self-assessment efforts, assesses their level of understanding, and clarifies issues within the family. (3) Feedback: A summary form of the assessment is reviewed. (4) Action Plan: Throughout the session, the counselor works with the parent to develop a brief, written Action Plan about communication and monitoring.
41319571|NCT03655574|OTHER|Psychoeducation|Psychoeducation about substances is provided to teens and parents.
41319572|NCT05121909|OTHER|Colgate (R) Cavity Protection Toothpaste|Participants will use Colgate (R) Cavity Protection Toothpaste for brushing teeth twice daily.
40801861|NCT02516982|OTHER|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
40801862|NCT02516982|OTHER|Momentary questions|These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
40801863|NCT02516982|OTHER|Contextual questions|Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
40801864|NCT00741897|DRUG|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
40801865|NCT04345900|DRUG|Plinabulin|a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
40801866|NCT04345900|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
41005940|NCT01176292|DEVICE|Rotating Platform High-Flex Cruciate Substituting TKA|
41005941|NCT01176292|DEVICE|Rotating Platform Cruciate Substituting TKA|
41005942|NCT00726219|OTHER|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
41005943|NCT00004412|DRUG|Arginine Butyrate|To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
41005944|NCT00004412|OTHER|Standard local care dressing|To heal leg ulcers.
41005945|NCT00256490|PROCEDURE|PET/CT 20 days after the first cycle of chemotherapy|
41005946|NCT01973101|DRUG|Cisplatin|50 mg/m2 - Day 1
41005947|NCT01973101|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on day 1 and day 8.
41319573|NCT05121909|DEVICE|Colgate (R) Cello Toothbrush|Participants will use Colgate (R) Cello Toothbrush for brushing teeth twice daily.
41005948|NCT01973101|DRUG|cisplatin|Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
41319574|NCT05121909|OTHER|Prototype 1 Mouthwash|Participants will use 20 mL of Prototype 1 Mouthwash for 30 seconds after brushing twice daily.
40801867|NCT04193111|DIAGNOSTIC_TEST|TMD pain screener|The danish TMD pain screener is given to all participants
40801868|NCT02660593|DIETARY_SUPPLEMENT|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
40801869|NCT00960791|DEVICE|AZD1656|Oral single dose
40801870|NCT06132724|OTHER|Signal acquisition|"Synchronized signals from cardiac, respiratory and movements non invasive measurements.~One acquisition is 20 minutes long, and each subject participate to two sessions, separated by 1 to 15 days."
40801871|NCT01268592|PROCEDURE|oocyte vitrification|freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
40801872|NCT03168165|OTHER|Pain neuroscience education training|PNE training will consist of 6 weeks online training followed by one day training session.
41319575|NCT05121909|OTHER|Prototype 2 Mouthwash|Participants will use 20 mL of Prototype 2 Mouthwash for 30 seconds after brushing twice daily.
41319576|NCT05121909|OTHER|Prototype 3 Mouthwash|Participants will use 20 mL of Prototype 3 Mouthwash for 30 seconds after brushing twice daily.
40801873|NCT06439927|DEVICE|Polycaprolactone nasal mesh|a 3-dimensional fabricated Polycaprolactone nasal mesh
40801874|NCT00053677|DRUG|Naltrexone|For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.
40801875|NCT00053677|DRUG|Placebo|For subjects who were randomly assigned to placebo.
40801876|NCT01884324|OTHER|Early Delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
40801877|NCT03478254|BIOLOGICAL|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year."
40801878|NCT03478254|BIOLOGICAL|Pneumococcal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~* One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~* One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~* One PPSV 23 dose in the last 5 years.~* One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
40801879|NCT03478254|BIOLOGICAL|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
40801880|NCT00500357|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
40801881|NCT04209634|DRUG|Pozelimab|Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.
40801882|NCT06531187|OTHER|Evidence-Based Practice (EBP) Teaching|"The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).~The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP)."
41005949|NCT01973101|RADIATION|Radiotherapy|45 Gy
41005950|NCT01973101|RADIATION|Brachytherapy|80 Gy
40801883|NCT05394597|OTHER|Repellent lotion|lotion of the repellent active ingredient IR3535
41005951|NCT03359733|DRUG|TAK-659|TAK-659 tablet.
41005952|NCT03385252|OTHER|Eggs|Eggs provided as complementary food for the infant
41005953|NCT03385252|BEHAVIORAL|Visits|Twice weekly household visits by study staff
41005954|NCT00436748|DRUG|Darbepoetin Alfa|Administered by subcutaneous or intravenous injection
41005955|NCT00436748|DRUG|Placebo|Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
40801884|NCT05394597|OTHER|Repellent Wipe|wipe of the repellent active ingredient IR3535
40801885|NCT05988528|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis.
40801886|NCT05988528|DRUG|Nifuroxazide|Nifuroxazide is an oral antibiotic that has been approved as an effective antidiarrheal agent with no side effects in several gastrointestinal infections
40801887|NCT06280768|DRUG|SHR-2004 injection|dose 1 or dose 2 or dose 3 or dose 4 or dose 5 or dose 6
40801888|NCT01339819|DRUG|Dabigatran|Patients assigned to this group will receive Dabigatran
40801889|NCT01339819|DRUG|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
40801890|NCT05330936|COMBINATION_PRODUCT|Potent topical steroid|Cyanocobalamin in Avocado Oil Cream
40801891|NCT01958580|DRUG|Gemcitabine Hydrochloride|Given IV
40801892|NCT01958580|DRUG|Docetaxel|Given IV
41005956|NCT04415606|DEVICE|QuikClot Control+|Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
41005957|NCT01110629|DRUG|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
41005958|NCT01110629|DRUG|Placebo|daily dose: 3 tablets TID for 8 weeks.
41005959|NCT03440671|BIOLOGICAL|Hutox Inj|Hutox Inj(Clostridium botulinum type A)
41319577|NCT05121909|OTHER|Listerine (R) Cool Mint (R) Antiseptic Mouthwash|Participants will use 20 mL of Listerine (R) Cool Mint (R) Antiseptic Mouthwash for 30 seconds after brushing twice daily.
41319578|NCT05121909|OTHER|5% Hydroalcohol Mouthwash|Participants will use 20 mL of 5% Hydroalcohol Mouthwash for 30 seconds after brushing twice daily.
41319579|NCT02475850|OTHER|Evidence-based tailored fall prevention|
41319580|NCT02475850|OTHER|Usual care|
41319581|NCT04250402|PROCEDURE|Resection|Radical resection.
41319582|NCT02717065|OTHER|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
41319583|NCT02717065|OTHER|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
41005960|NCT03440671|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
41005961|NCT01639027|DRUG|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
41005962|NCT01639027|DRUG|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
41005963|NCT04619056|DRUG|CEB-01 membrane loaded with SN-38|CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.
41005964|NCT04561076|DRUG|HLX70|Single-dose, intravenous infusion
41005965|NCT04561076|OTHER|Placebo|Single-dose, intravenous infusion
41005966|NCT03607916|DRUG|Hyperbaric prilocaine 2%|Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
41005967|NCT03607916|DRUG|Hyperbaric prilocaine 2%|The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
41005968|NCT03607916|DRUG|Morphine|100µg morphine
41005969|NCT00186004|DEVICE|Continuous Glucose Monitor|Subjects are fitted with a CGM system and perform self blood glucose measures three or more times per day for 3 days.
41005970|NCT04453917|BIOLOGICAL|Collection of blood and urine|Collection of blood (47 mL) and urine (5 mL) at PML diagnosis and 1, 3 and 6 months after, for analysis of immune checkpoint molecules expression, detection of antiviral immune responses and virological analyses.
41005971|NCT04453917|BIOLOGICAL|Spinal tap|Spinal tap for monitoring of JC viral load at PML diagnosis and 1, 3 and 6 months after, and collection of CSF (2 mL) for virological analyses.
41005972|NCT04453917|DIAGNOSTIC_TEST|Brain MRI|Brain MRI at at PML diagnosis and 3 and 6 months after
41319584|NCT00986310|DRUG|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
41005973|NCT04453917|BIOLOGICAL|Neurological evaluation|Neurological evaluation at PML diagnosis and 1, 3 and 6 months after
41005974|NCT02371499|DIETARY_SUPPLEMENT|Lactobacillus casei DG|the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
41005975|NCT02371499|DIETARY_SUPPLEMENT|Placebo|the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
41005976|NCT01657110|OTHER|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
41005977|NCT03837795|DEVICE|Neurofeedback treatment|A treatment that developed to train adults with sensory modulation disorder by applying EEG (Curry 7 EEG system, Neuroscan-Compumedics). This treatment will aim to normalize the Alpha power (amplitude).
41005978|NCT00279565|DRUG|buprenorphine|
41005979|NCT00279565|DRUG|methadone|
41005980|NCT00279565|DRUG|pegylated interferon alfa-2b plus ribavirin|
41005981|NCT04976192|COMBINATION_PRODUCT|TEV-45779|TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
41005982|NCT04976192|COMBINATION_PRODUCT|XOLAIR® Injection|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
41319585|NCT00986310|DRUG|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
41005983|NCT05130411|DIETARY_SUPPLEMENT|DLM - Test product|The group will receive 60 gummies each (to take two gummies per day) across a four-week period. Each participant shall take two gummies per day
40801893|NCT01958580|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
40801894|NCT01958580|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41005984|NCT06074107|DRUG|BEBT-908 for injection|The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.
41005985|NCT00191828|DRUG|olanzapine|
41005986|NCT01705288|PROCEDURE|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
41005987|NCT01705288|DRUG|intravenous narcotics|given for pain management after surgery per physician orders
41005988|NCT01705288|DRUG|standard anesthesia|inhalant or intravenous during surgery
41005989|NCT01705288|DRUG|regional anesthesia|given by spinal or epidural infusion
41005990|NCT01705288|DRUG|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
41005991|NCT05914116|DRUG|DB-1311|Administered I.V.
41005992|NCT01257594|DRUG|erlotinib|"For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room."
41005993|NCT01257594|PROCEDURE|Cytoreductive Surgery|Standard procedure
41005994|NCT01577758|DRUG|MLN0264|MLN0264 30-minute infusion on Day 1 of each treatment cycle
41005995|NCT01785602|DRUG|QAW039|Capsules
41005996|NCT01785602|DRUG|Placebo|Capsules
41319586|NCT04907318|DEVICE|Cataract surgery|
40801895|NCT01958580|RADIATION|External Beam Radiation Therapy|Undergo EBRT
40801896|NCT01958580|OTHER|Laboratory Biomarker Analysis|Correlative studies
41005997|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1|Each dose of bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 cell culture infectious dose 50% (CCID50)/dose and 10\^5.8 CCID50/dose, respectively.
41005998|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 10\^6 CCID50/dose and 10\^5.8 CCID50/dose, respectively.
40801897|NCT02131090|DEVICE|Tegaderm TM|This is a generic adhesive dressing which is commonly used to secure epidural catheters.
40801898|NCT02131090|DEVICE|Lock-it Plus|This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
40801899|NCT02131090|DEVICE|Epifix|This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
40801900|NCT02435667|OTHER|Resistance Exercise Training|"1. Aerobic Exercise~   a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.~2. Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.~   a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises~3. Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises"
40801901|NCT02435667|RADIATION|DEXA bone scan|A DEXA scan that provides bone density measures.
40801902|NCT02435667|OTHER|Cardiopulmonary Max Exercise Test|Pedaling on a cycle ergometer to volitional fatigue.
40801903|NCT02435667|OTHER|Quality of Life Questionnaire|A 10 minute questionnaire that measures quality of life.
40801904|NCT02435667|OTHER|Submaximal Exercise Test|Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
40801905|NCT02435667|OTHER|Blood Draw|A blood draw amounting to 1 teaspoon of blood drawn.
40801906|NCT00789152|DRUG|desloratadine|desloratadine 5 mg daily x 8 days
40801907|NCT00789152|DRUG|levocetirizine|levocetirizine 5 mg daily x 8 days
40801908|NCT00505973|DRUG|SCA-136|
40801909|NCT00998452|BEHAVIORAL|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
40801910|NCT03107858|DRUG|Norepinephrine|Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
40801911|NCT03107858|DRUG|Dopamine|Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
40801912|NCT01722526|DRUG|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
40801913|NCT04320056|OTHER|Standard administration of oxygen flow|"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode"
40801914|NCT04320056|DEVICE|Automated oxygen administration - FreeO2|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
40801915|NCT02177331|DRUG|Lacidipine|
41319587|NCT00220766|DRUG|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
40801916|NCT00543933|DRUG|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
40801917|NCT01325051|DRUG|Raltegravir|400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
40801918|NCT01186887|DRUG|Celecoxib|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
40801919|NCT01186887|DRUG|Placebo|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
41005999|NCT02434770|BIOLOGICAL|BioFarma Bivalent Oral Poliomyelitis Vaccine|Each dose of the WHO prequalified Bio Farma bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 and 10\^5.8 infective units per dose, respectively.
41006000|NCT02183441|DRUG|BI 1356|
41006001|NCT02183441|DRUG|Ritonavir|
41319588|NCT00220766|DRUG|Dextrose, 5% in Water|
41319589|NCT06072859|OTHER|Humidified Forest Oils|60mls Limonene in 200mls water humidified with a diffuser.
41319590|NCT06072859|OTHER|Virtual Reality using Surface Pro and headphones|Surface Pro has a looped visual that can be manipulated by the participant to simulate walking on a forest path or through a forest visual. This is paired with headphones to experience ambient forest sounds.
41006002|NCT06363916|DEVICE|Insulin Management System in Manual mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm not activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
41319591|NCT01033487|DRUG|placebo|oral inhaled formulation, single dose
41319592|NCT01033487|DRUG|active comparator|oral inhaled formulation, single dose
40801920|NCT04098185|DEVICE|CT|Non-contrast Multidetector Computed Tomography will be done for all patients using 16 or 64 MDCT scanner. Standard scanning parameters of chest CT are used with slice thickness 5 mm, 120kv and automated mAs.The evaluation of pleural effusion attenuation will be done using the average measure of 3 slices with greatest amount of fluid. A region of interest (ROI) is placed for measurement of Hounsfield unit values, where pleural fluid is observed to be most intense and the density values of the pleural fluid and of the aorta are quantitatively measured in the same section with taking care not to involve adjacent ribs, lung parenchyma or areas of pleural thickening.
40801921|NCT02425956|DEVICE|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
40801922|NCT04303104|OTHER|GeneXpert Edge|Screening intervention: novel diagnostic for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at point-of-contact in a mobile van
41006003|NCT06363916|DEVICE|Insulin Management System in Automatic mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
41319593|NCT01033487|DRUG|Low Dose PF-03635659|oral inhaled formulation, single dose, low dose
41006004|NCT06172335|DIETARY_SUPPLEMENT|Cetoleic acid|Very long monounsaturated fatty acid (C22:1n-11)
41006005|NCT06172335|DIETARY_SUPPLEMENT|Control oil|Mix of oils with low cetoleic acid content
41006006|NCT02040662|PROCEDURE|Continuous Thoracic Epidural Block|Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
41319594|NCT01033487|DRUG|Mid Dose PF-03635659|oral inhaled formulation, single dose, mid dose
41319595|NCT01033487|DRUG|High Dose PF-03635659|oral inhaled formulation, single dose, high dose
41319596|NCT05421221|DEVICE|Sniffin' sticks Duftquartett|"4-odor training set over 12 weeks with Sniffin' sticks Duftquartett"
41319597|NCT00139620|DRUG|Tarceva, erlotinib, OSI-774|
41319598|NCT05092880|DEVICE|radioembolization|holmium-166 microspheres
41319599|NCT05092880|DRUG|Standard of care first-line systemic therapy|Capecitabine plus anti-VEGF antibody
41319600|NCT03160105|DRUG|Switch to DTG + FTC|Switch from standard cART to DTG + FTC dual maintenance therapy.
41319601|NCT03160105|OTHER|Patient-centered monitoring|Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
41319602|NCT06394401|DIETARY_SUPPLEMENT|BAL:GLU|80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
41319603|NCT06394401|DIETARY_SUPPLEMENT|BAL:GLU+FRU|53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
41319604|NCT06394401|DIETARY_SUPPLEMENT|DEF:GLU|80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
41319605|NCT06394401|DIETARY_SUPPLEMENT|DEF:GLU+FRU|53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
41319606|NCT00699842|DRUG|Lenalidomide|"Dose Level Lenalidomide Schedule~1. 15mg/day for d1-21 out of 28 days~2. 20mg/day for d1-21 out of 28 days~3. 25mg/day for d1-21 out of 28 days"
41319607|NCT05700955|DRUG|Pembrolizumab and Temozolomide|Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.
41319608|NCT03519672|OTHER|No intervention|This is a non-interventional study.
40801923|NCT04303104|OTHER|GeneXpert Ultra|Screening intervention: novel diagnostic test for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
41319609|NCT03172858|DEVICE|Intracervical balloon catheter|cervical ripening balloon
41319610|NCT03172858|DRUG|Oxytocin|medication used to induce contractions
41319611|NCT01187784|BEHAVIORAL|Coping Cat cognitive-behavioral therapy for anxious youth|Manualized, empirically supported CBT treatment for anxious youth
41319612|NCT00003466|DRUG|temozolomide|
41319613|NCT03006471|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
41319614|NCT03006471|DRUG|Placebo - Cap|one per day before breakfast during 12 weeks.
41319615|NCT01266434|DRUG|Simvastatin|10 mg once daily for 8 weeks
41319616|NCT01266434|DRUG|B1-6-12|1 tablet once daily for 8 weeks
41319617|NCT04973215|OTHER|no intervention|this is not an intervention study
41319618|NCT04282057|DEVICE|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45 degrees. The application was in capacitive mode, with a 7cm electrode, always in movement. The duration of the application was established in 15 minutes, maintaining the local temperature between 40 to 42 celsius degrees at the epidermis.
41319619|NCT04282057|DEVICE|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen's formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (5 minutes); body (30 minutes); and cooling (from 5 to 10 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
41475826|NCT05449093|OTHER|Periodontal clinical measurements and gingival crevicular fluid sampling|"Periodontal clinical meaurements including the probing depth, clinical attachment loss, the dichotomous recording (present/absent) of bleeding on probing, gingival index, and the plaque index at six sites (distobuccal, buccal, mesiobuccal, distopalatinal/lingual, palatinal/lingual, mesiopalatinal/lingual) on all teeth, except third molars, were performed using manuel periodontal probe.~Standardized absorbent paper strips were used for gingival crevicular fluid sampling. A sterile paper strip was gently inserted into the gingival sulcus/periodontal pocket until mild resistance was felt and were kept in place for 30 seconds. The absorbed fluid volume was measured by a precalibrated electronic device."
41319620|NCT04282057|DEVICE|Shock wave therapy|The shock wave device corresponds to the BTL-6000 X-Wave TM with a 20mm transmitter multifocal. The parameters used correspond to the pressure set between 2.8 and 3.5 bar, frequency 15 hertz and 3000 pulses per 10x15 cm area. It was used as a means contact gel for ultrasound, reference 033-051. In this procedure the participants found themselves in the supine position, with a pillow under the head and with the bending knees.
41006007|NCT02040662|PROCEDURE|Continuous Thoracic Paravertebral Block|Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
41006008|NCT02040662|PROCEDURE|Patient-Controlled Analgesia with Morphine|"Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:~* patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)~* paracetamol 1000 mg iv every 8 hrs~* ketoprofen 100 mg iv every 12 hrs"
41319621|NCT00216177|DRUG|Infliximab|Remicade
41475827|NCT00962884|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
41475828|NCT00962884|DEVICE|Sham Inspiratory Threshold Device|Breathing through device similar to active device but with the one-way threshold valve removed.
41475829|NCT00890552|DRUG|Lenalidomide|"Lenalidomide is a a derivative of thalidomide.~Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle."
41006009|NCT01547416|DRUG|epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose|"Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
41006010|NCT01547416|DRUG|no epidural drug administered|"Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
41475830|NCT00890552|DRUG|Melphalan|"Melphalan is a phenylalanine derivative of mechlorethamine.~Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle"
41319622|NCT00216177|DRUG|Adalimumab|Humira
41319623|NCT00255099|DRUG|TMC125|2 x 100 mg tablets b.i.d. / 96 weeks
41319624|NCT00255099|DRUG|Placebo|2 tablets b.i.d. / 96 weeks
41319625|NCT00223691|DRUG|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
41319626|NCT00223691|DRUG|Acarbose|25-100 mg, PO. Single dose.
41319627|NCT00223691|DRUG|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
41319628|NCT00223691|DRUG|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
41319629|NCT00223691|DRUG|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
41319630|NCT00223691|DRUG|placebo|PO.Single dose.
41319631|NCT00223691|DRUG|Modafinil|50-400 mg PO. Single dose
41319632|NCT00223691|DRUG|Octreotide|5-50 µg, S.C. Single dose.
41319633|NCT00223691|OTHER|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
41319634|NCT00223691|DRUG|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
41475831|NCT00890552|DRUG|Dexamethasone|"Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.~Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle"
41319635|NCT00223691|DRUG|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
41319636|NCT00223691|DRUG|Tranylcypromine|5 - 40 mg PO. Single dose
41319637|NCT00223691|DRUG|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
41475832|NCT00922324|DRUG|STP206 or vehicle control|STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
41475833|NCT03015064|OTHER|Myocardial Infarction|Observational study of myocardial Infarction patients
41475834|NCT04274023|DRUG|TSR-042|TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
41475835|NCT04451187|DRUG|Seltorexant Dose 1|Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.
41475836|NCT04451187|DRUG|Seltorexant Dose 2|Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.
41475837|NCT04451187|DRUG|Placebo|Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.
41475838|NCT04451187|DRUG|Zopiclone|Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.
40801924|NCT04563403|BEHAVIORAL|Projection-based augmented reality therapy (P-ARET)|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
40801925|NCT01858441|DRUG|Abiraterone Acetate|
40801926|NCT04966312|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
40801927|NCT04966312|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
40801928|NCT00688467|DRUG|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
40801929|NCT00688467|DRUG|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
40801930|NCT03076060|BEHAVIORAL|Ketogenic diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD."
40801931|NCT03076060|BEHAVIORAL|Sham Diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD."
40801932|NCT04982341|PROCEDURE|prone position|patients are returned from prone to supine position while receiving oxygenation through HFNC
40801933|NCT05441605|OTHER|Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections|Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.
40801934|NCT01032408|BIOLOGICAL|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
40801935|NCT01032408|BIOLOGICAL|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
40801936|NCT03780621|DIETARY_SUPPLEMENT|Andrographis and Withania|Combination of Andrographis paniculata and Withania somnifera
40801937|NCT03780621|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule
40801938|NCT00631280|BEHAVIORAL|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
40801939|NCT00631280|BEHAVIORAL|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
41319638|NCT00223691|DRUG|Celecoxib|50-200 mg PO. Single dose
41319639|NCT00223691|DRUG|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
41319640|NCT00223691|DRUG|Methylphenidate|5 or 10 mg PO. Single dose.
41319641|NCT00223691|DRUG|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
40801940|NCT05609305|OTHER|Discharge|observational study, not intervention
40801941|NCT04488354|COMBINATION_PRODUCT|CLBR001 and SWI019|No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy
40801942|NCT00050557|BEHAVIORAL|Multifamily Psychoeducation Group (MFPG)|MFPG will include 8 weekly 90-minute group therapy sessions.
41006011|NCT00670800|DRUG|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
41319642|NCT00223691|DRUG|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
41319643|NCT00223691|DRUG|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
41319644|NCT00223691|DIETARY_SUPPLEMENT|Bovril|6-10 g, PO. Single dose.
41319645|NCT00223691|DRUG|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
41319646|NCT00223691|DRUG|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
41319647|NCT00223691|DRUG|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
41319648|NCT00223691|DEVICE|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
41319649|NCT00223691|DEVICE|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
41319650|NCT02029495|DRUG|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection
41319651|NCT02029495|DRUG|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection
41319652|NCT02029495|DRUG|Placebo|Placebo administered via subcutaneous injection until week 24.
41475839|NCT02322788|DRUG|Terbutaline sulphate|Bricanyl Turbuhaler M2
41475840|NCT02322788|DRUG|Terbutaline sulphate|Bricanyl Turbuhaler M3
41475841|NCT02322788|DRUG|Placebo for terbutaline sulphate|Placebo Turbuhaler M2
41475842|NCT02322788|DRUG|Placebo for terbutaline sulphate|Placebo Turbuhaler M3
41319653|NCT04485234|DIAGNOSTIC_TEST|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Coronary Flow Reserve, Microvascular resistance|Calculation of the resting mean distal coronary to aortic pressure ratio (resting Pd/Pa), fractional flow reserve (Pd/Pa at hyperemia), Coronary flow reserve (peak flow/resting flow), microvascular resistance (Pd/flow).
40801943|NCT00050557|BEHAVIORAL|Treatment as usual (TAU)|Participants will receive standard care for mood disorders.
40801944|NCT05483699|OTHER|Squeezing a ball|The children in the squeezing soft ball group were given the ball before the procedure. They were told to squeeze and loosen the ball with the hand that was not used for the procedure while intravenous cannula was being inserted.
40801945|NCT05483699|OTHER|Blowing bubbles|The children in the blowing bubble group were shown the bubble blower before intravenous cannulation and they were told how bubbles were formed and how they would blow. During intravenous cannulation, the child blew the blower
41475843|NCT03498599|BEHAVIORAL|Novelty facilitated extinction|In the novelty-facilitated extinction design, the aversive outcome (i.e., mild unpleasant electrical pulse) is omitted and replaced by a low volume auditory tone.
40801946|NCT05483699|OTHER|Kaleidoscope|Children in the Kaleidoscope group were given the kaleidoscope before intravenous cannulation and they were shown how to use it. The children were told to look at the kaleidoscope during the procedure until the procedure ended
40801947|NCT00000805|DRUG|Ganciclovir|
40801948|NCT00858728|BEHAVIORAL|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
40801949|NCT00858728|BEHAVIORAL|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
41319654|NCT03364335|DRUG|Leu Sil 1.0mg|Leu 1100 mg + 1mg Sil BID
41319655|NCT03364335|DRUG|Leu Sil 4.0mg|Leu 1100 mg + 4mg Sil BID
41319656|NCT03364335|DRUG|Leu Met Sil 1.0mg|Leu 1100 mg + Met 500mg + 1mg Sil BID
41475844|NCT03498599|BEHAVIORAL|Standard Extinction|During standard fear extinction the expected aversive outcome is omitted.
41475845|NCT06253338|RADIATION|genomic alterations|Alteration of the genome under radiotherapy
41475846|NCT02978352|OTHER|learning|
40801950|NCT03160248|DRUG|Apremilast|This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
40801951|NCT03160248|DRUG|Placebo Oral Tablet|This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
41006012|NCT05061160|OTHER|Interval Aerobic Exercise training Group|"Interval Aerobic exercise will be on upper limb Bicycle with a pause of 3 mins interval Interval Aerobic Exercises: Frequency= 3 times per week Intensity= 50% of heart rate reserve for 2 mins 80% of heart rate reserve for 1 min Type= interval aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
41319657|NCT03364335|DRUG|Leu Met Sil 4.0mg|Leu 1100 mg + Met 500mg + 4mg Sil BID
41319658|NCT03364335|DRUG|Placebo|Placebo
41475847|NCT04077047|BEHAVIORAL|iEngage|The intervention is a network-based, social support intervention to improve Adolescents living with HIV (ALWH) retention in HIV care and antiretroviral therapy (ART) adherence
41475848|NCT03746548|DEVICE|Adhear|Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks
41475849|NCT03746548|DEVICE|Contact Mini (CM)|Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks
41475850|NCT03443791|DIAGNOSTIC_TEST|Women Enrolled|Diagnostic Testing will be performed. Results of individual test results will determine the degree of intervention offered.
41475851|NCT03443791|DIAGNOSTIC_TEST|Newborns of Female Study Participants|Newborns will be tested after birth as soon as possible for CMV positivity.
40801952|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
40801953|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
41319659|NCT02737735|DRUG|standard chemotherapy medicine combined with Chinese herbs|
41319660|NCT02737735|DRUG|standard chemotherapy medicine|
41319661|NCT05268705|OTHER|7-day diet|The participants must follow a 7-day high-carbohydrate-low-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
41319662|NCT05268705|OTHER|7-day diet|The participants must follow a low-carbohydrate-high-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
41475852|NCT05922631|PROCEDURE|Airway pressure release ventilation|ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
41475853|NCT05922631|PROCEDURE|low tidal volume|The ARDSnet method was used for LTV mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was \<30cmH2O
41319663|NCT05268705|OTHER|7-day diet|The participants must follow a low-carbohydrate-low-fat-high-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
41319664|NCT00862121|DRUG|Pentasa|6 g/day orally, 2 g in the morning and 4 g in the evening
41319665|NCT00862121|DRUG|Placebo|6 g/day orally, 2 g in the morning and 4 g in the evening
41319666|NCT02821793|OTHER|Consultation, evaluation questionnaire|Consultation, evaluation questionnaire
41319667|NCT02821793|OTHER|Geriatric consultation, evaluation questionnaire|Geriatric consultation, evaluation questionnaire
40801954|NCT05132400|BEHAVIORAL|Psychological-informed Physical Therapy (PiPT) Training|An approach designed to incorporate the concepts of cognitive behavioral therapy (CBT) for pain management into routine clinical PT practice in order to modify maladaptive responses associated with chronicity. The goal of PiPT is to promote a fast and optimal recovery by removing psychological obstacles, obviating the need for referral to a psychologist and facilitating triage to other health professionals in a timely manner when needed. PiPT training includes education about the neuropsychology of pain, patient communication skills, and identification of psychosocial risk factors for chronicity and treatment approaches that include reassurance, relaxation, and psycho-behavioral reactivation.
41319668|NCT03860883|PROCEDURE|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
41319669|NCT03860883|PROCEDURE|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
41475854|NCT06061705|PROCEDURE|Tumor Biopsy|"Following the start of immunotherapy, an ENT surgeon will perform a cervico-facial tumor biopsy between D30 and D180. This will only be carried out if the tumour tissue is externalized and therefore accessible, and if the biopsy can be performed under local anaesthetic without any constraints for the patient (pain, risk of bleeding).~It consists of a superficial sampling of the externalized tumour lesion under local anaesthetic (xylocaine spray 5%, or xylocaine injectable 1%).~Biopsy of cervico-facial lesions under local anaesthetic is a commonly performed procedure. The main risk of this procedure is bleeding, which is very rare.~The biopsy will not be performed if the surgeon considers that the risk of bleeding is too great. Given the externalized nature of the lesion, biopsy does not entail any risk of tumour dissemination (possible for deep biopsies).~* Four 10-mL blood samples from two heparinized tubes~* Four 5-mL unstimulated saliva samples: non-invasive examination."
41475855|NCT04813016|DRUG|Tramal 1|Early intraperitoneal injection of tramal and bupivacaine
41319670|NCT00000417|PROCEDURE|Counseling intervention|
41319671|NCT00000417|DEVICE|Informational film|
41475856|NCT04813016|DRUG|Tramal 2|Late intraperitoneal injection of tramal and bupivacaine
41475857|NCT04813016|DRUG|Dexmedetomidine 1|Early intraperitoneal injection of dexmedetomidine and bupivacaine
41475858|NCT04813016|DRUG|dexmedetomidine 2|Late intraperitoneal injection of dexmedetomedine and bupivacaine
41475859|NCT03660241|DRUG|PF-04965842|PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).
41475860|NCT05828355|OTHER|Knee Care@Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
41475861|NCT06389916|DEVICE|Euclid orthokeratology MAX (current design)|The current lens design
40801955|NCT06417385|DEVICE|taVNS soterix device|Soterix is a custom modified, FDA-cleared electrical stimulator that meets the criteria of the FDA for investigational use. Neoleads will be placed in order to deliver electrical stimulation using microcurrent (\<2.5mA) with breastfeeding, on with sucking and swallowing and off with rest for 5 feeds per week for 2 weeks.
40801956|NCT00577707|DRUG|erlotinib|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
40801957|NCT00577707|DRUG|Pemetrexed|pemetrexed 500 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
41319672|NCT01480557|PROCEDURE|liquefaction|Cataract extraction surgery type
41319673|NCT01480557|PROCEDURE|Torsional ip|A type cataract surgery using torsional ip technology
41319674|NCT00148850|DRUG|Pioglitazone|
41319675|NCT00156299|DRUG|choline magnesium trisalicylate|1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
41319676|NCT00156299|DRUG|Dexamethasone|10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
41319677|NCT06195501|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing (FEES) ; Transesophageal Ecocardiography (TEE)|"Flexible Endoscopic Evaluation of Swallowing (FEES):~FEES is performed for analysis of swallowing ability according to the same methodology as in the initial trial: one day before a TEE and max. 4 hours after TEE. Before the FEES anticongestive nose drops are applied and the nostrils are anaesthetized by applying a lidocaine gel via cotton sticks. During the FEES examination the participants sit upright and are asked to swallow various consistencies: FEES is aborted in case of aspiration of any of the consistencies during the examination.~Transesophageal Ecocardiography (TEE):~For the TEE anesthesia is applied via intravenous injection of propofol or a combined anesthesia, through intravenous application of propofol and local anesthesia, using lidocaine spray. All patients undergoing a TEE are sober before and at least two to four hours after TEE."
40801958|NCT00577707|DRUG|Cisplatin|cisplatin 75 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
40801959|NCT00577707|PROCEDURE|Resection|
41319678|NCT05221788|PROCEDURE|Goal-directed hemodynamic therapy|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If SV increased \>10%, 200 ml of electrolyte solution was continued until SV increased \<10%. After fluid shock, if SV increases \<10% but mean arterial pressure (MAP) \<65 mmHg and/or cardiac index (CI) \<2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output \<0.5 ml /kg/h and/or heart rate more than 20% above baseline), plasma was administered until urine output and/or HR returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
41475862|NCT06389916|DEVICE|Euclid orthokeratology MAX Phoenix (new design)|The new lens design
41475863|NCT00596206|DRUG|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
41475864|NCT03441295|PROCEDURE|Dynamic Intraligamentary Stabilization|DIS, Ligamys
41475865|NCT03441295|PROCEDURE|Internal Brace Ligament Augmentation|IBLA
40801960|NCT02596568|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
41319679|NCT01413542|DRUG|Sitagliptin (DPP4 inhibitor)|Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
41319680|NCT01413542|DRUG|Substance P,|Substance P intra-brachial artery (2,4,8 pmol/min)
41319681|NCT01413542|DRUG|bradykinin|bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
41319682|NCT01413542|DRUG|enalaprilat (ACE inhibitor)|intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
41319683|NCT01413542|DRUG|Glucagon-like peptide 1|intra-brachial artery (0.45-3.60 pmol/min)
41319684|NCT01413542|DRUG|brain natriuretic peptide|Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
41319685|NCT04011748|COMBINATION_PRODUCT|Stem Cell Educator therapy|AA subjects will be recruited and followed by the treatment with SCE therapy.
41319686|NCT05072717|PROCEDURE|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion in meniscal tear tissue.
41319687|NCT02240745|OTHER|Stress-echocardiography|Stress-echocardiography (incl dobutamin and atropin)
41319688|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 1)|Single dose of AZD3152 300 mg IM on Visit 2 Day 1
41319689|NCT05932641|BIOLOGICAL|Placebo (Cohort 1)|Single dose of Placebo IM on Visit 2 Day 1
41319690|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 2)|Single dose of AZD3152 600 mg IM on Visit 2 Day 1
41319691|NCT05932641|BIOLOGICAL|Placebo (Cohort 2)|Single dose of Placebo IM on Visit 2 Day 1
41319692|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 3)|Single dose of AZD3152 1200 mg IV on Visit 2 Day 1
41475866|NCT03441295|PROCEDURE|ACL Reconstruction|Conventional
40801961|NCT02596568|OTHER|Sham|tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
40801962|NCT01139203|DRUG|lamivudine adefovir entecavir HBIG|lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
41319693|NCT05932641|BIOLOGICAL|Placebo (Cohort 3)|Single dose of Placebo IM on Visit 2 Day 1
41319694|NCT02477293|DRUG|Hyeonggaeyeongyo-tang|
41319695|NCT04782986|DIAGNOSTIC_TEST|Pan-intestinal capsule endoscopy|Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn's Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation
41319696|NCT02635152|BEHAVIORAL|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
41475867|NCT05279508|BEHAVIORAL|Make My Day - stroke prevention program|A stroke prevention program within primary healthcare
41475868|NCT01316419|DRUG|Telmisartan|Telmisartan 40mg or 80mg
41319697|NCT02635152|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
41319698|NCT00629525|DRUG|RAD001|RAD001 at a dose of 10 mg PO daily
41319699|NCT04325282|DEVICE|Active rTMS|1Hz rTMS delivered for 15-20 minutes
41319700|NCT04325282|DEVICE|Sham rTMS|sham rTMS delivered for 15-20 minutes
41475869|NCT01316419|DRUG|amlodipine|amlodipine 5mg or 10mg
41319701|NCT01536002|DRUG|Propofol|Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
41319702|NCT06102642|BIOLOGICAL|Combining free gingival graft with frenotomy procedure|The aim of the study is to evaluate the usage of free gingival graft combined with frenotomy in order to measure the gain in the width of keratinized gingiva, relapse, mucosal healing and postoperative pain.
41475870|NCT06222541|BEHAVIORAL|"Nudges in Web-Based Supermarket"|"While shopping in the web-based supermarket, participants assigned to the nudge arm will see retail nudges to discourage sugary drink purchases and promote healthier substitutes."
41319703|NCT05298644|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
41319704|NCT05298644|DRUG|Active Comparator|Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.
41319705|NCT03734952|RADIATION|Neoadjuvant Radiotherapy Program:|Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
41475871|NCT02787317|DRUG|bivalirudin|Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
41475872|NCT02787317|DRUG|Heparin|Heparin is used in patients undergoing percutaneous coronary intervention.
41475873|NCT02220595|PROCEDURE|Carotid endarterectomy vs. carotid stenting|
41475874|NCT00539708|PROCEDURE|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
41319706|NCT03734952|DRUG|Neoadjuvant chemotherapy Program|Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
41475875|NCT01844531|DRUG|empagliflozin|single tablet empagliflozin
41475876|NCT01844531|DRUG|metformin (Glucophage®)|single tablet metformin
41319707|NCT03734952|PROCEDURE|Esophagectomy program:|Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy
41319708|NCT03734952|RADIATION|Postoperative radiotherapy program|A total dose of 18 Gy in10 fractions is delivered 5 days per week on workdays with IMRT.
41475877|NCT01844531|DRUG|metformin (Glucophage®)|single tablet metformin
41475878|NCT01844531|DRUG|empagliflozin|single tablet empagliflozin
41475879|NCT01844531|DRUG|empagliflozin and metformin|FDC tablet empagliflozin and metformin
41319709|NCT00960128|DRUG|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
41475880|NCT01844531|DRUG|empagliflozin and metformin|FDC tablet empagliflozin and metformin
41319710|NCT00960128|DRUG|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
41319711|NCT04368455|BEHAVIORAL|Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)|An intervention that includes a self-directed app based curriculum and virtual reality simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians.
41319712|NCT04368455|BEHAVIORAL|HPV Same Way Same Day App|An intervention that includes a self-directed app based curriculum
41319713|NCT01811901|OTHER|Reduction of DTN|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
41319714|NCT05741086|DRUG|Evolocumab|evolocumab (140 mg every 2 weeks)
41319715|NCT05741086|DRUG|Atorvastatin|Atorvastatin 20-40mg
41319716|NCT01106625|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
41319717|NCT01106625|DRUG|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
41319718|NCT01106625|DRUG|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
41319719|NCT01106625|DRUG|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
41319720|NCT03506022|OTHER|standard polysomnography|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters : electroencephalogram, electro-oculogram, electromyogram \[chin\], continuous nasal airflow body position, thoracic and abdominal strain gauges, haemoglobin oxygen saturation (SaO2) with an oximeter (Medatec) attached to finger. Blood pressure was measured in the evening during the physical examines, and then the CGMS recording startedpressure was measured in the evening during the physical examines, and then the CGMS recording started
41319721|NCT01252641|BIOLOGICAL|SB-728-T|Each infusion will be 5-30 billion modified CD4+ T-cells
41319722|NCT01700985|DRUG|122-0551|Applied twice daily for two weeks
41319723|NCT01700985|DRUG|Vehicle|Applied twice daily for two weeks
41475881|NCT00144833|DRUG|fosamprenavir/ritonavir (700mg/100mg BID)|
41475882|NCT00144833|DRUG|fosamprenavir/ritonavir (1400mg/100mg BID)|
41475883|NCT00144833|DRUG|fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)|
41475884|NCT03365999|DRUG|Oral Tranexamic Acid|Patients undergoing total knee replacement who will receive three doses of tranexamic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
41475885|NCT03365999|DRUG|Oral Aminocaproic Acid|Patients undergoing total knee replacement who will receive three doses of aminocaproic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
41475886|NCT05857462|PROCEDURE|Post-admission FICB|Post-admission supra-inguinal FICB in hip fracture patient with 0.33% bupivacaine 30 ml
41475887|NCT02127073|DRUG|Intranasal Oxytocin|Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
41475888|NCT00821002|DRUG|Latanoprost|Comparison of punctal plug placement between upper and lower puncta
41475889|NCT01056640|DEVICE|Intel Health Guide|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.
41475890|NCT01056640|OTHER|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required.
41475891|NCT03928535|DEVICE|High-FlowNasal Cannula|High-flowoxygenwas applied immediately after extubation through specific nasal cannula. Flow was initially set at 10 L/min and titrated upwards in 5-L/min steps until patients experienced discomfort.Temperature was initially set to 37°C, unless reported too hot by patients, and FIO2 was regularly adjusted to the target peripheral capillary oxygen saturation (SPO2) of greater than 92%. After 24 hours, high-flow was stopped and, if necessary, patients received conventional oxygen therapy.
41475892|NCT03928535|DEVICE|Noninvasive Ventilation|Full face mask NIV was continuously delivered immediately after extubation for a scheduled period of 24 hours after extubation. Afterward, NIV was withdrawn and oxygen was administered by Venturi mask.Both PEEP and inspiratory pressure supportwere adjusted to target a respiratory rate of 25/min and adequate gas exchange (arterial oxygen saturation \[SaO2\] 92%, with pH of 7.35). The FIO2 was adjusted to maintain SPO2 at less than 92%. Sedatives to increase tolerance to NIV were not allowed.
41475893|NCT02285205|DRUG|Oral administration of Lobeglitazone|Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
41475894|NCT00848042|DEVICE|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
41475895|NCT01510652|PROCEDURE|BiP Group|Implantation of standard Left Ventricular (LV) lead
41475896|NCT01510652|DEVICE|Quad Group|Implantation of quadripolar Left ventricular (LV) lead Quartet
41475897|NCT01118819|BIOLOGICAL|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
41319724|NCT02833220|DEVICE|Single-Pulse Transcranial Magnetic Stimulation|Single-pulse Transcranial Magnetic Stimulation activates neurons within the cortex of the brain by way of electromagnetic induction. This causes a small, focused electric field to become present in the brain, which activates the neurons.
41475898|NCT03302494|DEVICE|Coherex WaveCrest® Left Atrial Appendage Occlusion System|Percutaneous left atrial appendage closure
41157110|NCT06553768|OTHER|Placebo|Placebo matched to maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), study drug will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of study drug. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
41475899|NCT03302494|DEVICE|Watchman® LAA Closure Device|Percutaeous left atrial appendage closure
41475900|NCT02681484|BEHAVIORAL|Anthroposophic speech therapy|"Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking."
41475901|NCT02953678|DRUG|Ruxolitinib|
41475902|NCT02953678|DRUG|Prednisone or methylprednisolone|Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
41006013|NCT05061160|OTHER|Continuous Aerobic Exercise training Group|"Continuous Aerobic exercise will be on upper limb Bicycle Continuous Aerobic Exercise: Frequency= 3 times per week Intensity= 50% of heart rate reserve Type= continuous aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
41319725|NCT03948308|BIOLOGICAL|blood sample|blood sample before, during and after infection treatment
41319726|NCT02618343|DRUG|IPA|IPA Aromatherapy for the experimental arm
41319727|NCT02618343|DRUG|Ondansetron|Zofran will be administered to the Control arm. This is the drug historically administered by prehospital personnel.
41319728|NCT01754207|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
41319729|NCT01754207|DEVICE|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
41319730|NCT00251875|DEVICE|online health information journal|
41475903|NCT03201679|PROCEDURE|Repair of hip fracture|Patients undergoing hip fracture surgery
41475904|NCT02079168|DRUG|RXI-109|
41475905|NCT02079168|DRUG|Placebo|
41475906|NCT01886482|OTHER|nutrition intervention|high protein diet
41475907|NCT00604903|DEVICE|Implant of Pressure sensor.|Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
41475908|NCT02477852|DRUG|Isoniazid|preoperative treatment of spinal tuberculosis with Isoniazid
41319731|NCT06194981|DRUG|Oxaliplatin and capecitabine/ S-1 and capecitabine|Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
41319732|NCT02749877|BEHAVIORAL|Working Memory Training|(Training Details already described above)
41475909|NCT02477852|DRUG|Rifampicin|preoperative treatment of spinal tuberculosis with Rifampicin
41319733|NCT02749877|BEHAVIORAL|Physical Training|(Training Details already described above)
41319734|NCT03522883|DIETARY_SUPPLEMENT|carbohydrate intake prior to exercise|Participants will be submitted to carbohydrate supplementation prior to exercise
41319735|NCT01151540|DRUG|Rufinamide|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
41319736|NCT06033846|DRUG|Minocycline|treatment with minocycline combined with first/second-line drugs for autoimmune encephalitis
41475910|NCT02477852|DRUG|Ethambutol|preoperative treatment of spinal tuberculosis with Ethambutol
41475911|NCT02477852|DRUG|Pyrazinamide|preoperative treatment of spinal tuberculosis with Pyrazinamide
41475912|NCT00824369|DRUG|No drug will be administered|No drug will be administered.
41475913|NCT06097559|DIAGNOSTIC_TEST|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration) in a HRT cycle, according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET."
41475914|NCT06097559|DIAGNOSTIC_TEST|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration), according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET. In case of a non-receptive endometrium result, a second EB sample must be collected when indicated by the ERA report. Fluid sample collection will not be repeated in these cases."
41475915|NCT04658316|BEHAVIORAL|Iowa Oral Performance Instrument|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure
41475916|NCT04747704|BEHAVIORAL|Three Principles Counseling|A 10-week insight-based program offered in prisons in a group setting for 2 hours each week. Approximately 15 - 20 adults or youth in custody participate at a time, led by two trained teachers. The curriculum is designed to teach an understanding of the mind and human experience for the purpose of reducing risk factors, uncovering resiliency and to promote emotional and psychological well-being for adults and youth in the criminal justice system. This is taught through a compilation of sessions that speak to the potential, ability and resilience inherent in every individual. Sessions include a mix of lessons, experiential learning, and group conversations.
40801963|NCT02679937|BEHAVIORAL|Fit4Duty|Small (\<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
41475917|NCT02046668|DRUG|spironolactone|spironolactone 25mg daily for 12 weeks
41475918|NCT06322459|BEHAVIORAL|Sport Education Curriculum|The six characteristics of The Sport Education Model include season, affiliation, formal competition, culminating event, Record-keeping, and Festivity. The intensity of the training is increasing in the first 30 minutes, and the intensity is gradually decreasing in the next 10 minutes.
40801964|NCT02679937|OTHER|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
40801965|NCT02965794|OTHER|Care pathways for colorectal cancer|development of a care pathway for this patient group
41006014|NCT02471521|OTHER|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
41006015|NCT02471521|DRUG|Rocuronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
41152439|NCT05697822|OTHER|Mobile Phone and Cloud-based Electronic Contact and Recording System|A mobile phone application has been developed which is intended to be used by pregnant women and their healthcare workers. A pregnant woman can get registered in this app and enter information and data related to their health and current pregnancy. Their health worker at their health post can access this information on their mobile phone too. The pregnant woman can also input her daily symptom on this app. She can also input and/or access information on examination and tests that have been carried out. If a concerning symptom or event has been entered by a user in the app, the health worker will be notified through this app. The health worker can also track the pregnant women under their care through this application. A cloud-based database of pregnant women will have the details of all the pregnant women in a given ward or rural municipality. Health coordinators in the municipality will be able to access the database for their municipality and track the pregnant women, if needed.
41475919|NCT06322459|BEHAVIORAL|Normal teaching|The intervention content, frequency, and intensity were the same as those in the experimental group, but the type of intervention was different. The most significant difference between the two teaching methods lies in delivering basic content. The Sport Education Model includes Teacher-directed learning (10 minutes) and Team practice (10 minutes); Normal Teaching includes Teacher-directed learning (10 minutes) and Individual practice (10 minutes).
41475920|NCT06503107|DRUG|Nanobody-based biepitope BCMA-targeting CAR-T cells|Each patient will receive nanobody-based biepitope BCMA-targeting CAR-T cell by intravenous infusion on day 0.
41475921|NCT04301622|DEVICE|Primary Knee implants|Primary knee arthroplasty
40801966|NCT01032434|DRUG|sertraline|sertraline: 50-200mg/day
40801967|NCT03940846|DIAGNOSTIC_TEST|Virtual biopsy|Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
40801968|NCT01532076|PROCEDURE|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
40801969|NCT01532076|PROCEDURE|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
41006016|NCT03389646|DEVICE|CERAMENT G V|"During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM\|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM\|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM\|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU)."
41006017|NCT02808845|OTHER|microalbuminuria|
41006018|NCT01436279|DRUG|Mifepristone|200 mg po 20-24 hours prior to the procedure
41006019|NCT01436279|DEVICE|osmotic dilators|osmotic dilators placed in the cervix 20-24 hours prior to the procedure
41006020|NCT03331692|OTHER|monitoring of the proper level of general anesthesia|The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.
41006021|NCT01802775|DRUG|edoxaban|
41006022|NCT01802775|DRUG|Clopidogrel|75mg tablet
41152440|NCT04430673|OTHER|Home-School based VR system trial|Commercially available VR games operated Raspberry pi micro computer and Oculus Quest VR headsets provided for 2 weeks at dose and intensity selected by participants.
41152441|NCT04636463|PROCEDURE|Intraoperative Music|Hand Surgery performed with the participant awake, using local anesthesia. Headphones will be worn by the participant and surgery will be performed while the participant is listening to music
41152442|NCT00848640|DRUG|Sorafenib|400 mg twice daily
40801970|NCT02919891|OTHER|Questionnaire|Questionnaires
41006023|NCT01802775|DRUG|Aspirin|
41006024|NCT04047082|DIAGNOSTIC_TEST|Quantitative aortogram (videodensitometry)|Patients that performed TAVR will have their aortogram analysed in the cath-lab by videodensitometry (quantitative aortogram)
41006025|NCT02974647|DRUG|Ruxolitinib|
41006026|NCT01762943|DRUG|Leuprolide Acetate|All subjects will receive one IM injection (3.75 mg) each month for four months.
41006027|NCT01762943|DRUG|Micronized estradiol|All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
41006028|NCT01762943|DRUG|Progesterone|All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
41006029|NCT00895180|BIOLOGICAL|olaratumab|Given IV
41006030|NCT00895180|BIOLOGICAL|ramucirumab|Given IV
41006031|NCT02696356|BIOLOGICAL|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
41006032|NCT03199378|OTHER|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
41006033|NCT01434823|OTHER|Nocturnal coverage|"The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.~For the Intensivist Sleep and Work sub-study:~Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage."
41006034|NCT01916304|DRUG|Levothyroxine sodium new formulation|Levothyroxine tablets
41006035|NCT01420081|DRUG|PF-05212384|154mg IV weekly
41006036|NCT01420081|DRUG|PF-05212384|154mg IV weekly
41006037|NCT01420081|DRUG|PF-05212384|154mg IV weekly
41006038|NCT05649605|DRUG|Testosterone treatment|Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
41006039|NCT05649605|OTHER|Placebo treatment|Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
41006040|NCT04288622|OTHER|Weekly standardised, personalised feedback|The ESM-F group will receive standardised ESM-derived feedback immediately followed the weekly ESM data collection procedure, totalling 6 times in the entire intervention period. The feedback will be provided by the researcher in the format of written report and verbal explanation. The feedback on participants' momentary affective state in specific daily life contexts and the association with depressive symptoms will be given. The changes in positive affect level and the number of depressive complaints over the course of the ESM intervention will be shown.
41006041|NCT05886166|OTHER|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
41006042|NCT05232604|OTHER|Aerobic exercise|30-45 minutes of aerobic exercise in a cycle ergometer will be applied in three different intensities (low, moderate and high) along 12 weeks of treatment.
41006043|NCT05232604|OTHER|Neck motor control exercise|An specific neck motor control exercise targeted to the neck flexor and extensor muscles supervised by a physical therapist will be applied during 12 weeks of treatment.
41475922|NCT01956448|DEVICE|Drug eluting stent|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
40801971|NCT04839458|DEVICE|Dental Prescale II|"The participant will bite Dental Prescale II for about 3 seconds, using a force for  chewing beef . And the Dental Prescale II will be taken out from the mouth. Then the trial is end."
40801972|NCT04542499|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
41319737|NCT06046716|BEHAVIORAL|Mindful compassion based on behavioural change taxonomy experimental group|Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.
41475923|NCT04394338|OTHER|self-gripping mesh placement with plastic sheath in laparoscopic inguinal hernia|to apply these to the mesh graft placement process. In the first step, plastic sheaths self-gripping mesh placement with plastic sheathwere prepared configuration with the standard 9cmx15cm self-gripping mesh. Then the meshes were folded and unfolded over or under the plastic sheaths.
41475924|NCT01051713|BEHAVIORAL|Technology Supported|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
41475925|NCT01051713|BEHAVIORAL|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
40801973|NCT04542499|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
41152443|NCT02086071|PROCEDURE|re biopsy|re biopsy depending on the location of the pathology
41152444|NCT04795076|DIETARY_SUPPLEMENT|Infant formula|Regular infant formula will be concentrated to give a calorie density of about 90 kcal/100 mL.
41475926|NCT06366945|DRUG|Carboplatin|Carboplatin AUC 5 on weeks 1, 3, and 6
41475927|NCT06366945|DRUG|Tislelizumab|Tislelizumab 200 mg on weeks 3, 6, and 9;if adjuvant immunotherapy is omitted, Tislelizumab will be administered on weeks 1, 3, 6, 9, 12, 15 after surgery
41475928|NCT06366945|DRUG|Polymeric Micellar Paclitaxel|Polymeric Micellar Paclitaxel 300mg/mg/m2 on weeks 1, 3 and 6
41475929|NCT06366945|PROCEDURE|Surgical Resection of Primary +/- Neck Dissection|Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
41475930|NCT06366945|RADIATION|Post-operative radiation therapy|Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic assesment following induction systemic therapy and surgery is ypT(pCR 或 MPR) and ypN(pCR) or ypT（ pCR 或 MPR）and ypN（ MPR）without the presence of Serious Adverse Event, adjuvant radiation will not be administered. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
41475931|NCT00003330|BIOLOGICAL|recombinant interleukin-12|
40801974|NCT03702959|DRUG|Betamethasone|Corticosteroids
40801975|NCT02806336|BEHAVIORAL|Multi Modal Balance Training|Group balance class, obstacle course, strengthening exercises
40801976|NCT02806336|BEHAVIORAL|Weight Loss|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
40801977|NCT04852549|OTHER|Oculomotor exercise|"1. While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~2. While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~3. With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~4. The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions."
40801978|NCT05146154|DRUG|Imipenem/Cilastatin/Relebactam 1.25g|Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
40801979|NCT02333825|PROCEDURE|Medial patellofemoral ligament reconstruction surgery|Medial patellofemoral ligament reconstruction surgery using hamstring autograft
40801980|NCT02333825|OTHER|Physical therapy and rehabilitation|A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
41157113|NCT02711553|DRUG|Ramucirumab|Administered IV
41157114|NCT02711553|DRUG|Merestinib|Administered orally
41157115|NCT02711553|DRUG|Cisplatin|Administered IV
41157116|NCT02711553|DRUG|Gemcitabine|Administered IV
41157117|NCT02711553|DRUG|Placebo Oral|Administered orally
40801981|NCT06147128|PROCEDURE|Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model|Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system
40801982|NCT06277856|BEHAVIORAL|Peer interaction/control|This study was planned as a randomised controlled study with a two-group pretest and posttest design.
40801983|NCT06029868|DIETARY_SUPPLEMENT|Black seed oil capsule|700 mg black seed soft gel capsule once a day from Gorgan Essential Oil Pharmaceutical Company,
40801984|NCT06029868|DIETARY_SUPPLEMENT|Placebo Black seed oil capsule|Placebo Black seed oil capsule
40801985|NCT02085044|DIETARY_SUPPLEMENT|Ready-to-Used Supplement Food administration|
40801986|NCT03158740|BEHAVIORAL|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
40801987|NCT03158740|BEHAVIORAL|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
40801988|NCT01625416|BEHAVIORAL|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
41319738|NCT02483403|OTHER|Hyperpolarized Helium-3|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, Helium-3 gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
41319739|NCT02483403|DEVICE|MRI|
41319740|NCT03400215|DIAGNOSTIC_TEST|Diagnostic Breast Cancer Scan|clinically indicated diagnostic breast MRI scans
41319741|NCT03400215|DIAGNOSTIC_TEST|Research Scan for Gradient-echo Spectroscopic Imaging (GSI)|15-min research MRI scan
41319742|NCT02576015|PROCEDURE|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
41319743|NCT02576015|PROCEDURE|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
41319744|NCT02576015|DRUG|lidocaine|
41319745|NCT02576015|DEVICE|ultrasound|
41319746|NCT02576015|DEVICE|insulated needle (Contiplex B Braun, Melsungen, Germany)|
41319747|NCT02576015|DRUG|ropivacaine|
41319748|NCT02576015|DRUG|saline|
40801989|NCT00680979|BEHAVIORAL|Interpersonal Psychotherapy|
40801990|NCT00680979|BEHAVIORAL|Health Education|
40801991|NCT02209558|BEHAVIORAL|Visual Sternal Precautions|"Visual depiction of SPs in addition to standard of care written precautions"
40801992|NCT01058915|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
40801993|NCT01058915|DRUG|Rosuvastatin 40mg|Rosuvastatin 40mg/day
40801994|NCT02789436|DRUG|L. reuteri Prodentis® lozenges|Twice daily, for 28 days
40801995|NCT02789436|OTHER|Placebo lozenges|Twice daily, for 28 days
40801996|NCT01878578|DRUG|Eslicarbazepine acetate|Tablets containing ESL 600 mg
40801997|NCT01878578|DRUG|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
41319749|NCT00123149|DRUG|Epoetin alfa|
41319750|NCT04044209|DRUG|AG-120|The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
41319751|NCT04044209|DRUG|Nivolumab|On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle.
41475932|NCT01546142|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
41475933|NCT01546142|DRUG|Placebo|Phosphate buffered saline placebo for injection
40801998|NCT01878578|DRUG|Placebo|Tablets containing matching placebo
41319752|NCT05508399|OTHER|DNA panel and RNA Sequencing|"Interventions include collecting samples, DNA panel test and full transcriptome sequencing.~Before collecting samples, obtaining written informed consent from patient in advance.~1. Blood cell samples;~2. Paraffin sample of residual tumor tissue of biopsy;~3. Paraffin sample of residual tumor tissue and paracancer tissue after gastrectomy."
40801999|NCT05556083|DRUG|Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
41475934|NCT00955721|DRUG|Gemcitabine|Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
41475935|NCT00955721|DRUG|Oxaliplatin|Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
41475936|NCT00955721|DRUG|Sorafenib|Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
40802000|NCT05556083|DRUG|Placebo oral tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
41006044|NCT02484495|OTHER|Program evaluation (impact assessment)|"The program activities include: processed complementary food rations which will be distributed to all children 6-23 months of age, in a grain bank based on bartering of raw materials; enhanced Infant and Young Child Nutrition (IYCN) counselling will be given to the mothers of children 6-23 month of age, using improved Behavior messages based Change Intervention (BCI) on formative research.~Monthly 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day."
41475937|NCT04435002|OTHER|Acupressure|Acupressure technics applied to (Liv- 4 , Ht-7 Bilateral, Liv-3 Bilateral, Anmian Bilateral, Yin-Tang unilateral ve Sp-6 Bilateral)
40802001|NCT04743219|PROCEDURE|Selective removal to soft dentin, Biodentine|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the Biodentine group, Biodentine (Septodont) will be placed on the base of the cavity with a thickness of 2 mm.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
41006045|NCT01173302|BIOLOGICAL|Rabies vaccine, manufactured by ChengDa|1 dose before the antibody is tested
41006046|NCT05117463|OTHER|Optic Flow Stimulation|The optic flow will be displayed at different speeds. The subject will need to look at the center of the optic flow.
41319753|NCT01911013|PROCEDURE|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
40802002|NCT04743219|PROCEDURE|Selective removal to soft dentin, No Base|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the No base group, no bioactive material will be placed as a liner, the 3M Scothcbonf Universal Plus adhesive will be placed directly over the remaining dentin surface.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
41475938|NCT02607423|DRUG|Cisplatin|Given IV
41475939|NCT02607423|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
41475940|NCT02607423|DRUG|Docetaxel|Given IV
41475941|NCT02607423|RADIATION|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
40802003|NCT06351774|BEHAVIORAL|Physical therapy|Physical therapy for the treatment of chronic low back pain, as directed by a licensed Physical Therapist. The Healthy Minds Innovations (HMI) program is an app-based learning platform developed through the University of Wisconsin-Madison Center for Healthy Minds. The HMI app includes foundational meditation practices and short podcast-style lessons based on the science of wellbeing to cultivate mindfulness, positive relationships, and insight into the nature of the self.
41006047|NCT05117463|OTHER|Auditory Reaction Time|Two different pitches of tones will be played. The participants will need to press a button on the right or left hand based on the pitch of the tone.
41006048|NCT02586012|DRUG|rFVIII|Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].
41006049|NCT03215134|OTHER|Self-criticism intervention|Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre \& Rimes, submitted) and is now being evaluated in a primary mental-health service.
41006050|NCT06310434|OTHER|questionnaire|COOL Scale and DAS
41157118|NCT02711553|DRUG|Placebo IV|Administered IV
41475942|NCT02607423|DRUG|Gemcitabine Hydrochloride|Given IV
41475943|NCT02607423|DRUG|Pemetrexed Disodium|Given IV
41475944|NCT02607423|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT
41475945|NCT03717493|BEHAVIORAL|Affect Regulation Training|Following the guidelines for the 6-week intensive ART format, we scheduled one 180-minutes session per week (each consisting of two modules à 90min) for a period of six subsequent weeks. Training groups included four to eight participants. The implementation of ART followed standardized treatment protocols (Berking \& Whitley, 2014). ART was delivered by doctoral candidates (DCs) in clinical psychology who had completed or were in advanced stages of their clinical training. All therapists had been intensely trained and received weekly supervision from experienced ART trainers. To control adherence a random sample of 5% of all sessions was be videotaped and will be rated with regard to adherence.
41475946|NCT01911806|DEVICE|Back care pillow|back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees
41475947|NCT01911806|PROCEDURE|standard physical therapy treatment|standard physical therapy treatment are ultrasound therapy and hot pack
41475948|NCT02593227|BIOLOGICAL|Low dose FRα vaccine|165ug per peptide ID injection
41475949|NCT02593227|DRUG|Cyclophosphamide|IV infusion over 1 hour
41475950|NCT02593227|BIOLOGICAL|High dose FRα vaccine|500ug per peptide ID injection
41319754|NCT01911013|DEVICE|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
40802004|NCT05469425|BEHAVIORAL|Preoperative home-based exercise training|"Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week 2)~Weekly telephone supervision: A physical therapist will carry out weekly telephone calls with all participants to monitor adverse events and recommend strategies to overcome barriers that arise during the exercise program."
40802005|NCT02350335|DRUG|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
40802006|NCT04188834|DEVICE|Customized version of DAVID device|A customized version of the DAVID device will be used to expose participants to sensory flicker. The device consists of opaque glasses containing LEDs to present flickering light, as well as earbuds or headphones to present flickering sound.
41006051|NCT06310434|OTHER|Discussion group|Through discussion groups with students in secondary schools and university separately, a compassionate plan will be designed
41319755|NCT01911013|DEVICE|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
40802007|NCT04188834|DEVICE|Blackrock CereStim|The Blackrock CereStim is a fully programmable neurostimulator. The current pulses generated by the Blackrock CereStim are intended to stimulate neurons in proximity to a set of electrodes.
41006052|NCT06310434|OTHER|Reflective diary|Students can modify the interventions adapting them to their requirements to get the compassion needed for those in need.
41006053|NCT05567731|DRUG|ultrashort GnRHa|"the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm"
41319756|NCT01681576|DRUG|Valsartan|Valsartan 320mg tablet once daily
41157119|NCT01680302|BEHAVIORAL|High intensity exercise|
41319757|NCT01681576|DRUG|LCZ696|LCZ696 400mg tablet once daily
41319758|NCT03418051|OTHER|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade II anterior to posterior ankle joint mobilizations with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
41319759|NCT03418051|OTHER|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
41319760|NCT04344262|DRUG|Atracurium Besylate regular dose|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
41319761|NCT04344262|DRUG|Atracurium Besylate minial dose|atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal
41319762|NCT04180995|DRUG|TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)|TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
41319763|NCT00461578|DRUG|Chlorproguanil-dapsone + artesunate|
41319764|NCT02028585|DIETARY_SUPPLEMENT|Low-fat milk group|
41319765|NCT04082468|DIAGNOSTIC_TEST|Blood sample collection for coagulation profile|Factor VIII Activity Level, Factor VIII Antigen Level, Interleukin 6, vWF Antigen Level, Thrombin Activity, Protein C Activity, Protein C Antigen Level, CRP, PT/PTT/INR ,T \& B lymphocyte panel at above time points
41319766|NCT04632537|DRUG|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine will be diluted in preservative-free saline and given intradermally (0.1mL) in the deltoid area.
41319767|NCT04632537|DRUG|Preservative-free saline|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
41319768|NCT05227482|RADIATION|Personalized dosimetry approach|The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach
41319769|NCT05227482|RADIATION|Standard dosimetry approach|The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach
41319770|NCT05019755|DRUG|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
41319771|NCT05019755|DRUG|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
41319772|NCT01208701|DRUG|Atorvastatin|Zarator, 80 mg pr day for 5 days
41319773|NCT01208701|DRUG|Unikalk|1 tablet Unikalk pr day for 5 days
41319774|NCT06391957|DIETARY_SUPPLEMENT|Spirulina supplement|Participants consume a 3g spirulina supplement 3 times daily for 5 consecutive days.
40802008|NCT04106258|DRUG|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
40802009|NCT03326063|DRUG|Ifetroban|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
40802010|NCT03326063|DRUG|Placebo|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
41157120|NCT01680302|BEHAVIORAL|Moderate intensity exercise|
41006054|NCT05567731|DRUG|short GnRHa|"Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of \>18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture."
41152445|NCT04624074|BEHAVIORAL|Teen Marijuana Check Up|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
41319775|NCT06391957|PROCEDURE|Eccentric exercise|On the morning of Day 3 (where Day 1 is when participants start taking supplements), participants perform a single bout of eccentric exercise. The exercise protocol is performed on a single leg and involves 300 (10 sets of 30 repetitions separated by 120 seconds) voluntary maximal, isokinetic, eccentric contractions of the knee extensor. Exercise is performed using a Biodex System 3 isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA), and contractions are performed at 60◦/s over an 80◦ range of motion.
41319776|NCT06391957|DIETARY_SUPPLEMENT|Placebo supplement|Participants consume a macronutrient matched placebo supplement 3 times daily for 5 consecutive days.
41319777|NCT01191905|DRUG|high dose CRRT|clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
41319778|NCT01191905|DRUG|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
41319779|NCT04184115|DRUG|DPI-386 Nasal Gel|1.5 mg reservoir of scopolamine to be delivered over a 72-hour period
41475951|NCT02471937|BIOLOGICAL|Bacteriological analyses on clinical samples performed with Eswabs|"Clinical samples analysed :~mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR"
41319780|NCT04184115|DRUG|Placebos|Placebo Nasal Gel and placebo patch
41475952|NCT05657106|BEHAVIORAL|Harm reduction kiosk|The intervention involves enhancing an existing staffed harm reduction program (syringe service program) located in a local health department with a Kentucky Outreach Service Kiosk (KyOSK).
40802011|NCT02582814|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
40802012|NCT02582814|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
40802013|NCT02844244|BEHAVIORAL|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
41475953|NCT01956019|DEVICE|MRI scanning|
41475954|NCT00928226|RADIATION|Fractionated Stereotactic Radiosurgery (SRS)|Standard of care
41319781|NCT01898364|DRUG|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
41006055|NCT05567731|DRUG|long GnRHa|In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low estradiol (E2) \< 50 and Luteinizing Hormone \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
41006056|NCT02365636|DRUG|TV-45070|TV-45070 is an ointment applied topically twice daily to area of pain.
41006057|NCT02365636|DRUG|Placebo|The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
41006058|NCT05371964|DRUG|Imetelstat|Imetelstat sodium will be administered as intravenous (IV) every 28 days.
41006059|NCT05371964|DRUG|Ruxolitinib|Ruxolitinib will be administered, orally (PO), twice daily (BID) as the standard of care per local prescribing guidelines.
41319782|NCT01113554|OTHER|questionnaire administration|
41319783|NCT01113554|BEHAVIORAL|exercise intervention|
41319784|NCT01113554|PROCEDURE|quality-of-life assessment|
41319785|NCT01113554|OTHER|survey administration|
41319786|NCT01113554|PROCEDURE|management of therapy complications|
41319787|NCT01113554|PROCEDURE|psychosocial assessment and care|
41319788|NCT00218920|BEHAVIORAL|Strength training|a strength training regime of 4 series with 5 repetitions each, at approximately 90% of 1 repetition maximum (RM), in a leg press apparatus to develop maximal strength mainly from neural adaptation with minimal weight gain due to muscular hypertrophy.
41319789|NCT00218920|BEHAVIORAL|continuous moderate-intensity aerobic training|The moderate-intensity group walked continuously for 47 min at 60-70% of maximum heart rate (HRmax) to ensure that the training protocols were isocaloric.
41475955|NCT00928226|PROCEDURE|Surgical resection|Standard of care
41475956|NCT03245034|BEHAVIORAL|Auricular Acupuncture Therapy|"Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG)."
41006060|NCT00234559|DEVICE|VAC® Therapy System|
41006061|NCT02085564|PROCEDURE|Peritoneal washing cytology|The methode is describes in the detailed study description
41006062|NCT00279708|DRUG|Atorvastatin|Placebo vs. Atorvastatin
41006063|NCT00279708|OTHER|Placebo Oral Tablet|Placebo: Sham Therapy in an oral tablet formulation
41006064|NCT00004436|DRUG|leuprolide|
41006065|NCT00004436|DRUG|prednisone|
41006066|NCT00514410|DRUG|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
41006067|NCT00514410|DRUG|Placebo|Matching placebo taken once a day for three months
41157121|NCT01680302|BEHAVIORAL|Control|Advised to follow current guidelines for physical activity, but exercise on their own.
41157122|NCT06647017|DEVICE|Volta tAN System|Transcutaneous auricular neurostimulation (tAN)
41319790|NCT00218920|BEHAVIORAL|high-intensity interval aerobic training|High-intensity training consisted of a 10 min warm-up period at 50-60% of HRmax \[maximal HR (heart rate)\], followed by 4×4-min intervals at 85-95% of HRmax with 3 min active breaks in between the intervals, consisting of walking or jogging at 50-60% of HRmax. The exercise session was terminated by a 5 min cool-down period.
41319791|NCT04776811|DEVICE|Continuous glucose monitoring system|Medtronic Guardian Connect with Guardian Sensor 3
41319792|NCT06516042|DRUG|Dihydroartemisinin-piperaquine|Participants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and artemether-lumefantrine (AL) if female. They will take the first dose of the treatment under direct observed therapy, and will receive the rest of the tablets to take on their own for days two and three.
41319793|NCT01230749|DRUG|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
41319794|NCT01230749|DRUG|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
41319795|NCT01230749|DRUG|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
41319796|NCT02483104|DRUG|veliparib|Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
41319797|NCT02483104|DRUG|carboplatin|Carboplatin will be administered on Day 1 of each cycle, intravenously.
41319798|NCT02483104|DRUG|paclitaxel|Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
41319799|NCT02338492|DEVICE|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
41319800|NCT01164865|DEVICE|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
41475957|NCT03027921|OTHER|elastography|
41475958|NCT04792879|DIAGNOSTIC_TEST|Peripheral veins Doppler ultrasound|Patients undergoing a right heart catheterization for PH diagnosis or annual follow-up in the cardiological unit of the university hospital of Poitiers will be included. A venous Doppler ultrasound will be performed by a vascular physician, with experience in vascular ultrasound imaging, within 4 hours before the right heart catheterization. Morphological parameters of vena cava, and velocimetric parameters of femoral, jugular and supra-hepatic veins will be assessed in order to study their correlation with right auricular pressure value.
41475959|NCT03708159|DEVICE|active tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to active. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
40802014|NCT04491435|DIAGNOSTIC_TEST|Summated Xerostomia Inventory|structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)
40802015|NCT04491435|DIAGNOSTIC_TEST|Sialometry|unstimulated whole saliva (UWS) flow measurement
40802016|NCT01706731|BEHAVIORAL|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
40802017|NCT01706731|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
40802018|NCT00584532|DRUG|Placebo|10 Placebo Capsules taken orally every day.
40802019|NCT00584532|DRUG|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
40802020|NCT06012084|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF.
40802021|NCT04217811|OTHER|No intervention|No intervention
40802022|NCT00610857|DRUG|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
40802023|NCT02472587|OTHER|Questionnaire|
40802024|NCT03944265|OTHER|Counseling|Participate in treatment decision counseling session
40802025|NCT03944265|OTHER|Questionnaire Administration|Ancillary studies
40802026|NCT03944265|OTHER|Medical Chart Review|Ancillary studies
41319801|NCT01164865|DEVICE|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
40802027|NCT03163134|DEVICE|Lumbar Drain|
40802028|NCT05068505|BEHAVIORAL|Community health worker delivered multicomponent intervention|"The multi-component intervention will be centered on monthly household visits by trained CHWs for a period of seven months in a rural setting in Nakaseke, Uganda, consisting of the following; (1) blood pressure and sugar monitoring; (2) BMI monitoring; (3) cardiovascular disease risk assessment; (4) Using checklists to guide monitoring and referral to clinics; (5) healthy lifestyle counselling and education. During home visits, CHWs will remind patients of follow-up visits. We will measure blood pressure at baseline and 3-monthly for the entire cohort. We will conduct individual-level mixed effects analyses of study data, adjusting for time and clustering by patient and community.~We will conduct an interim analysis at 3 months to assess differences between groups. If a statistically significant difference is detected the intervention will be applied across the remaining clusters"
40802029|NCT02519478|BEHAVIORAL|Helmetless Tackling Training (HuTT)|see previous sections
40802030|NCT06281652|OTHER|Go classes|Classes of board games (Go), performed in groups of 6-10 subjects, once a week
40802031|NCT06281652|OTHER|Chess classes|Classes of board games (Chess), performed in groups of 6-10 subjects, once a week
40802032|NCT01435473|PROCEDURE|Cardiac Surgery|
40802033|NCT00104416|DRUG|lamotrigine (LAMICTAL) extended-release|Primary experimental dosage form
40802034|NCT00104416|DRUG|Placebo|Placebo control
41157123|NCT06647017|DEVICE|SHAM Volta tAN System|Participants randomized to the sham group will have an earpiece applied, but stimulation will not be turned on.
40802035|NCT00752739|DIETARY_SUPPLEMENT|selenium|Given orally
40802036|NCT00752739|OTHER|placebo|Given orally
40802037|NCT04610619|OTHER|Immunological challenge|In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
40802038|NCT03824873|PROCEDURE|Internal iliac artery ligation|Internal iliac artery ligation and cesarean hysterectomy
40802039|NCT03824873|PROCEDURE|cesarean hysterectomy|cesarean hysterectomy
40802040|NCT01449396|OTHER|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
40802041|NCT01449396|PROCEDURE|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
40802042|NCT01449396|PROCEDURE|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
41157124|NCT06191315|DRUG|Dupilumab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
41157125|NCT06191315|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
41319802|NCT01164865|DEVICE|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
41319803|NCT04799184|DRUG|Levobupivacaine 0.25% with epinephrine 5 ug/ml|"The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form."
40802043|NCT06282445|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 1200mg, administered every 3 Weeks (Q3W).
40802044|NCT06282445|DRUG|Oxaliplatin|130 mg/m2, ivgtt, d1, Q3W
40802045|NCT06282445|DRUG|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W
40802046|NCT06282445|DRUG|Bevacizumab|7.5mg/kg，ivgtt, d1, Q3W
40802047|NCT06299865|OTHER|Ungrouped|Ungrouped
40802048|NCT06090305|BEHAVIORAL|levidex|Participants will receive access to the digital health application levidex in addition to treatment as usual (TAU).
40802049|NCT06090305|BEHAVIORAL|Control|Participants will receive access to an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to treatment as usual (TAU).
40802050|NCT06090305|OTHER|treatment as usual (TAU)|treatment as usual (TAU)
40802051|NCT06315673|BEHAVIORAL|Digital Speech and Handwriting Assessment|"Subjects may complete all or some of these tests, depending on functional ability.~* Handwriting battery~* Pattern tracing battery~* Speech Assessment Battery"
40802052|NCT06496425|BEHAVIORAL|Music|Those randomized to the exercise and music group will receive pre-recorded music playlists along with the exercise. During the strength training (ST), participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), we will adjust the tempo of playlists to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
40802053|NCT01918891|BEHAVIORAL|Nurse Practitioner Only|
40802054|NCT01918891|BEHAVIORAL|Nurse Practitioner + Health Coach|
40802055|NCT03449940|PROCEDURE|Immediate repair|
40802056|NCT03449940|PROCEDURE|Delayed repair|
40802057|NCT03449940|DRUG|Lidocaine|10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
40802058|NCT03449940|DRUG|Ceftriaxone|Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
40802059|NCT03449940|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
40802060|NCT06156657|OTHER|subcostal TAP block|Comparison between subcostal TAP block and opioids for postoperative pain after laparscopic sleeve gastrectomy
40802061|NCT06454136|DEVICE|OTX-207|Experimental Pscyhoeducation and Intervention App
40802062|NCT06454136|DEVICE|Comparator App + Treatment as Usual (TAU)|Digitized content and information included in standard of care (i.e., TAU)
40802063|NCT02110355|DRUG|AMG 232|Given as an oral tablet in escalating doses
40802064|NCT02110355|DRUG|Trametinib|Trametinib is an anti-cancer agent
40802065|NCT02110355|DRUG|Dabrafenib|Dabrafenib is an anti-cancer agent
40802066|NCT01434901|DRUG|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
40802067|NCT01434901|DRUG|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
40802068|NCT01434901|DRUG|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
40802069|NCT01434901|DRUG|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
40802070|NCT02657694|DRUG|Sofosbuvir+Ledipasvir|DAA medication treatment
41475960|NCT03708159|OTHER|sham tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to sham. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
40802071|NCT02657694|DRUG|Sofosbuvir+Daclatasvir|DAA medication treatment
40802072|NCT02657694|DRUG|Sofosbuvir+Velpatasvir|DAA medication treatment
40802073|NCT06089863|OTHER|PAMPERO program|"This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow :~* 5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object~* 5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority~* 1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick~* 2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture~* 2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation"
40802074|NCT05036655|PROCEDURE|Perioperative glycemic management pathway|The PGMP is a shared-care pathway. It starts at the decision to undergo surgery, and includes preoperative planning, intraoperative management, the postoperative inpatient stay, and post-admission coordination of care to manage patients undergoing surgery based on a logic model for postoperative hyperglycemia. The PGMP identifies patients at high-risk of postoperative hyperglycemia at the time of surgical triaging using hemoglobin A1c (HbA1c) screening, based on Diabetes Canada recommendations. HbA1c screening estimates an individual's three-month average blood glucose, and is used to screen, diagnose, and titrate medications for diabetes. The PGMP then guides team members to monitor blood glucose postoperatively using POCT, and to manage hyperglycemia in high-risk patients using standardized care plans.
40802075|NCT04638413|BEHAVIORAL|Walking (W)|Participants engage in 30 min of walking daily, for three weeks.
40802076|NCT04638413|BEHAVIORAL|Walking + PolyRules! (W+PolyRules!)|Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
40802077|NCT01773005|DRUG|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
41475961|NCT00285584|DRUG|Bupropion|Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
41475962|NCT00285584|DRUG|Placebo|Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
41475963|NCT05010733|DEVICE|Total hip arthroplasty using the Exeter V40 cemented femoral stem|Consists of applying a cement layer of at least 2 millimeters surrounding an undersized prosthetic stem, so that this layer of cement fits between the femoral medullary canal and the prosthetic's femoral stem.
40802078|NCT01773005|DRUG|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
41157126|NCT04015128|DEVICE|Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
41319804|NCT04799184|DRUG|Levobupivacaine 0.25% without epinephrine 5 ug/ml|"The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form."
41319805|NCT02649530|DRUG|WNT974|
41319806|NCT04503928|DRUG|Euphorbia kansui Pill|1 g (10 pills) of Euphorbia kansui Pill taken by mouth, once a day for 7 consecutive days.
41475964|NCT05010733|DEVICE|Total hip arthroplasty using the Müller Straight Stem|Consists of applying a thin layer of cement, so that the prosthetic's femoral stem fills as much as possible the femoral medullary canal.
40802079|NCT05376059|BEHAVIORAL|How Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.
40802080|NCT05376059|BEHAVIORAL|How and Why Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.
40802081|NCT05376059|BEHAVIORAL|Incentive|Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).
41157127|NCT04077775|DIAGNOSTIC_TEST|assesment|assesment
41157128|NCT04390451|BEHAVIORAL|Whole Health STEPS|A peer-delivered package of Whole Health services.
41157129|NCT01091844|PROCEDURE|Voiding Trial|After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
41157130|NCT04041024|OTHER|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
41157131|NCT04041024|OTHER|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
41157132|NCT06042270|DIETARY_SUPPLEMENT|Betaine|3 grams per day for \~4 weeks
41157133|NCT06042270|DIETARY_SUPPLEMENT|Placebo|3 grams per day for \~4 weeks
41157134|NCT01046071|PROCEDURE|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
41157135|NCT01046071|PROCEDURE|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
41157136|NCT02968121|DRUG|Brexpiprazole, OPDC-34712|
41157137|NCT02127814|DIETARY_SUPPLEMENT|Lactobacillus reuteri|One chewable tablet of 1E8 CFU L. reuteri, once per day
41157138|NCT06577649|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|cTBS (50 Hz, 600 pulses, 80% resting motor threshold) for 40s was applied continuously as active rTMS at the face representation area of primary somatosensory cortex (S1)
41157139|NCT06577649|DEVICE|Sham repetitive transcranial magnetic stimulation (sham rTMS)|A sham rTMS was applied using the same stimulation parameters as with cTBS, but using a placebo coil, which produced similar sound as the real coil.
41157140|NCT05955365|DRUG|P2Y12 inhibitor|The choice of P2Y12 inhibitor is left at investigator's discretion.
41157141|NCT05955365|DRUG|Aspirin|Aspirin is administered for up to 1 month after PCI at investigator's discretion
41157142|NCT05955365|DRUG|DOAC|The choice of DOAC is left at investigator's discretion.
41157143|NCT04672655|BEHAVIORAL|ONBOARD|Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM \& social situations; Session 4: Building trust with your CGM
41157144|NCT04520971|DEVICE|780G|780G closed-loop insulin delivery system (Medtronic)
41157145|NCT04520971|DEVICE|standard of care|continue with standard of care treatment (pump without closed-loop or MDI)
41157146|NCT05532618|PROCEDURE|Adductor canal block|Before anterior cruciate ligament surgery an adductor canal block will be placed using ultrasound.
41157147|NCT05532618|DRUG|Levobupivacaine|Levobupivacaine
41157148|NCT05532618|DRUG|Placebo|10 ml of sodium chloride 0.9%
40802082|NCT01135888|DEVICE|Skin cooling devices|Cooling vest and cooling bandana
40802083|NCT02330354|BEHAVIORAL|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
41319807|NCT03852914|DEVICE|Sodium hyaluronate 2%|Each patient will receive a single injection of SH 2% and will be followed for 6 months. At 6 months follow up visit patients could be offered a second injection whenever and when they comply with the criteria established for re-treatment and will be followed for additional 6 months.
41319808|NCT01635010|PROCEDURE|continuous positive airway pressure (CPAP)|CPAP pressure is individually prescript according to polysomnography for CPAP titration
41475965|NCT02855619|PROCEDURE|Martin|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
41475966|NCT02855619|PROCEDURE|Cader|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
40802084|NCT00460460|DRUG|AZD4877|
40802085|NCT01978054|OTHER|Dissemination of public health knowledge|State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
41006068|NCT02553746|DEVICE|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
41319809|NCT06005298|BEHAVIORAL|Screening, Brief Intervention, Referral to Treatment (SBIRT)|"SBIRT has been defined by SAMHSA as a comprehensive, integrated, public health approach to the delivery of early intervention for individuals with risky alcohol and drug use and the timely referral to more intensive substance abuse treatment for those who have substance abuse disorders. There is consensus that a comprehensive SBIRT model includes screening, brief intervention/brief treatment, and referral to treatment. In addition there are following characteristics:~* It is brief (e.g., typically about 5-10 minutes for brief interventions; about 5 to 12 sessions for brief treatments)~* The screening is universal.~* One or more specific behaviors related to risky alcohol and drug use are targeted.~* The services occur in a public health non-substance abuse treatment setting.~* It is comprehensive (comprised of screening, brief intervention/treatment, and referral to treatment).~* Strong research or experiential evidence supports the model's effectiveness."
41006069|NCT02553746|PROCEDURE|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
41319810|NCT03528889|PROCEDURE|Femoral Extension and Derotation Osteotomy (ExtFDO)|Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
41319811|NCT00503178|PROCEDURE|Biological imaging guided antalgic radiotherapy|Biological imaging guided antalgic radiotherapy is followed.
41319812|NCT06518200|BEHAVIORAL|Individualised health recommentations|Individualised recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application based on patients reported status.
41319813|NCT06518200|BEHAVIORAL|General health recommendations|Recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application.
41319814|NCT06518200|BEHAVIORAL|Individualised physical exercise program|Follow-up of an individualised exercise program adjusted by daily monitoring of the level of physical, physiological and psychological condition.
41319815|NCT02795546|DRUG|Alendronate sodium|400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.
41319816|NCT02795546|BIOLOGICAL|beta-tricalcium phosphate bone substitute|beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
41319817|NCT00729326|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
41319818|NCT00729326|DRUG|sitagliptin|oral administration (100mg), once a day in the morning
41319819|NCT00729326|DRUG|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
41319820|NCT00729326|DRUG|placebo|oral administration (100mg), once a day in the morning
41319821|NCT02853955|DEVICE|Percutaneous edge-to-edge repair of the mitral valve|MitraClip in patients with recurrent MI after surgical mitral valve repair.
41319822|NCT05096013|OTHER|individual nutritional therapy|Intervention arm: Usual care + individualized nutritional therapy. Patients at risk for malnutrition and sarcopenia will receive a counselling by the nutritional therapist twice a week. The therapists will assess the patient's energy and protein demand in order to develope appropriate individual measures (e.g additional meals or supplements) to increase patients' energy and protein intake. Individual nutritional therapy is already usual care in patients with high risk for malnutrition, but not for patients with only light to moderate risk of malnutrition and risk of sarcopenia.
41319823|NCT04561921|DRUG|Magnesium sulfate|patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
41475967|NCT02855619|PROCEDURE|EDRIC|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
41319824|NCT04561921|DRUG|Mepivacaine-Levonordefrin Hydrochloride|patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
41319825|NCT05717959|BEHAVIORAL|Oropharyngeal Exercises|Oropharyngeal Exercises
41475968|NCT03336242|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
41006070|NCT00003739|BIOLOGICAL|filgrastim|
41319826|NCT01552187|DRUG|Colchicine|Colchicine 0.5 mg BID or colchicine 0.5mg (\<70kg) 48 to 72 hours before surgery till 1 months after surgery
41475969|NCT00035321|DRUG|Olanzapine|
41319827|NCT01552187|DRUG|Placebo|Placebo 48 to 72 hours before surgery till 1 months after surgery
41475970|NCT00035321|DRUG|Fluoxetine|
41006071|NCT04086264|DRUG|Azacitidine|Commercially available formulation given subcutaneously (SC) or intravenous (IV)
41319828|NCT03541655|DRUG|Bupivacaine HCl|0.25% Bupivacaine HCl
41475971|NCT04746079|BEHAVIORAL|Positive Imagery Therapy|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy.
41319829|NCT03541655|DRUG|F14 (celecoxib)|Celecoxib in novel drug delivery system (BEPO™)
41319830|NCT00790179|PROCEDURE|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|"0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA."
41475972|NCT02270749|DRUG|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
41319831|NCT01628094|DRUG|RO5024048|
41319832|NCT01628094|DRUG|RO5190591|
41319833|NCT01628094|DRUG|RO5466731|
41319834|NCT01628094|DRUG|ribavirin [Copegus]|
41319835|NCT01628094|DRUG|ritonavir|
41319836|NCT06139887|BEHAVIORAL|BESST|The BESST intervention is a suicide prevention program designed to meet the unique needs of Veterans receiving care from community mental health treatment settings. BESST can be delivered by a trained mental health staff member, such as a mental health nurse, social worker, psychologist, or psychiatrist. The intervention consists of two synergistic components that work to support the patient after a mental health-related discharge in community settings: 1) Brief educational session, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study interventionist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed.
41319837|NCT06139887|OTHER|Standard Mental Health Care|Patients randomized to the control arm will receive standard mental health care alone. Standard mental health care simply refers to the regular care provided to patients around the time of discharge from community care settings.
41319838|NCT00892957|BIOLOGICAL|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
41319839|NCT00892957|OTHER|Surgical gauze pads|Manual compression with surgical gauze pads
41319840|NCT02308176|BEHAVIORAL|APP + health advice|health advice and reinforcement to it
41319841|NCT02308176|BEHAVIORAL|health advice|health advice
41475973|NCT02270749|DRUG|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
41319842|NCT05374018|DIAGNOSTIC_TEST|urinary kit for pneumococcus antigen assay|urine test for detection of pneumococcus antigen
41006072|NCT04086264|DRUG|IMGN632|Study formulation given intravenously (IV)
41006073|NCT04086264|DRUG|Venetoclax|Commercially available formulation administered orally
41319843|NCT01492699|DRUG|PRX-03140|50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
41319844|NCT02925663|BEHAVIORAL|EFI-E|This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
41319845|NCT00853489|DEVICE|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
40802086|NCT05315674|DIAGNOSTIC_TEST|Frequent assessment of biomarker panel|During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.
41006074|NCT04625738|BIOLOGICAL|Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10\^6 MSC/kg day 3: 0.5. 10\^6 MSC/kg day 5: 0.5 . 10\^6 MSC/kg"
41006075|NCT04625738|BIOLOGICAL|Placebo|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
41319846|NCT00853489|PROCEDURE|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
41475974|NCT03739138|BIOLOGICAL|MK-4621|"MK-4621 is delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as follows:~For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle according to randomization.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data."
41475975|NCT03739138|BIOLOGICAL|Pembrolizumab|200 mg administered intravenously (IV) on Day 1 of each 21-day cycle beginning with Cycle 1 (Arm 2) or Cycle 2 (Arm 3).
40802087|NCT02749006|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
40802088|NCT02749006|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
41319847|NCT04793854|OTHER|Measure of the Life habits (MHAVIE)|"Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).~Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,...)."
41319848|NCT01522625|DRUG|tenofovir disoproxil fumarate 300mg per day|tenofovir disoproxil fumarate 300mg per day for 3 years
40802089|NCT03982784|PROCEDURE|single-injection TQLB(transmuscular quadratus lumborum block)|Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
41319849|NCT01522625|DRUG|Placebo|Placebo, identical to TDF in appearance, once daily for 3years
41319850|NCT02567214|DRUG|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
41319851|NCT02567214|DRUG|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
41319852|NCT03658993|DRUG|Rifaximin 550 MG|Oral Rifaximin 550 mg TID for 4 weeks.
41319853|NCT05316337|DEVICE|Electrocardiogram recording|ECG recording with investigational device
41319854|NCT05316337|DEVICE|Electrocardiogram recording|ECG recording with reference device
41319855|NCT06194175|PROCEDURE|Bariatric surgery|"Participants whose application for bariatric surgery was accepted, regardless of the type of surgical intervention (e.g., sleeve gastrectomy, Roux-en-Y Gastric Bypass).~This longitudinal study includes five measurement times: before surgery and then, 6 months, one year, one and a half years and two years after surgery. At each measurement time, participants are asked to respond to a set of online questionnaires. Responses are anonymous."
41319856|NCT03747744|OTHER|CD1c (BDCA-1)+ myDC|Intratumoral injection in subcutaneous, cutaneous, soft tissue metastases
41319857|NCT05017714|DRUG|Recombinant cytokine gene derived protein injection|"Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care."
41341797|NCT02306941|BEHAVIORAL|Internet-delivered CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
40802090|NCT03982784|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
41006076|NCT03294603|DRUG|CC-220|1mg \[14C\]-CC-220 will be administered as a single dose
41475976|NCT00872924|DRUG|sumatriptan 100mg|
41475977|NCT02732691|DEVICE|JenaValve Pericardial TAVR System|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.
41475978|NCT03256422|DRUG|Treatment discontinuation|"• Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir"
41475979|NCT04254835|DRUG|Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein|Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
41006077|NCT03294603|RADIATION|[14C]|Single dose of \[14C\]-CC-220 will contain approximately 1.4 μCi of radioactivity
41006078|NCT01325610|DIETARY_SUPPLEMENT|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
40802091|NCT02019615|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
40802092|NCT01255176|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
41475980|NCT04254835|DRUG|Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein|Conventional Fluoride varnish
40802093|NCT02290496|BEHAVIORAL|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
40802094|NCT02290496|BEHAVIORAL|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
40802095|NCT04015817|OTHER|paramedical and non-pharmacological services|Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
40802096|NCT06537765|DRUG|Medical treatment|All women with endometriosis in all groups (A, B, \& C) will receive their medical treatment as prescribed by the gynecologist.
40802097|NCT06537765|DEVICE|Therapeutic ultrasound (US)|Women will be asked to assume supine lying position, and the lower abdomen will be cleaned thoroughly with alcohol and dried well thereafter. Ultrasound gel will be distributed over the lower abdomen .The device will be adjusted to Frequency of 1MHz, Mode: continuous wave, Intensity: 1.5W/cm, duration of treatment: 15 minutes for the treatment site, then the skin will be cleaned again to remove ultrasound gel.
40802098|NCT06537765|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS electrodes will be placed on specific acupuncture points for women in supine position. These points include VB29, ST36, CV6, CV4, LV3, KD3, SP6, and SP9. The treatment aims to improve blood circulation, remove adhesions, regulate menstrual activity and hormones, and prevent new adhesions and menstrual reflux in endometriosis patients.
40802099|NCT03203941|BIOLOGICAL|Autologous Cord Blood Stem Cells|This is an individual patient expanded access protocol.
40802100|NCT00869492|DRUG|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
41475981|NCT00991510|DRUG|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
41475982|NCT00991510|DRUG|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
41475983|NCT01941108|BEHAVIORAL|Peer Navigation Arm|Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
40802101|NCT00869492|DRUG|nadifloxacine|Nadifloxacine 1% cream twice dailly
40802102|NCT03454997|OTHER|training including in-person and online|training, motivational interviewing practice
40802103|NCT03454997|OTHER|organizational strategy meetings|meetings with leadership to optimize implementation of evidence-based practices
40802104|NCT03454997|OTHER|performance coaching|to enhance ability to deliver the weight management intervention
40802105|NCT06045858|DRUG|Anticoagulation Agents|anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
40802106|NCT03179852|BEHAVIORAL|nutrition education|nutrition education
40802107|NCT01764477|DRUG|PRI-724|"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"
40802108|NCT03970876|BIOLOGICAL|ATGC-100|Clostridium Botulinum Type A
40802109|NCT03970876|BIOLOGICAL|Botox®|Clostridium Botulinum Type A
40802110|NCT00952328|DIETARY_SUPPLEMENT|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
40802111|NCT04808726|BEHAVIORAL|Teach Back Method|Effect of Breastfeeding Training on Breastfeeding Success Using The Teach Back Method: Randomized Controlled Study
41006079|NCT02192944|DRUG|Chloroquine|Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
41006080|NCT02192944|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
41341798|NCT01285414|DRUG|Verubulin|Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide \& Radiation Therapy
41341799|NCT01285414|DRUG|Temozolomide & Radiation Therapy|Temozolomide \& Radiation Therapy
41341800|NCT01148576|DRUG|entecavir|entecavir 0.5 mg qd for 12 months
41341801|NCT01148576|DRUG|entecavir|entecavir 0.5 mg qd for 12 months
40802112|NCT01057693|DRUG|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
41319858|NCT05081596|BEHAVIORAL|PATH-Pain|"The goals of PATH-Pain are to: 1) Teach problem solving skills to reduce negative emotions, by using emotion regulation and problem- solving strategies to overcome these difficulties. 2) Use compensatory strategies and environmental adaptation tools (notes, checklists, calendars, etc.) to avoid limitations resulting from memory problems, help improve emotion regulation, and create an easier environment to live in. If found helpful and participant agrees, a tablet application called WellPATH will be used to help the subject with emotion regulation techniques. The tablet will be given at the beginning of treatment and will be returned at the end of treatment. 3) Invite caregiver participation, when appropriate.~Subjects in the PATH-PAIN group will receive 8 weekly sessions (first 8 weeks) with a study therapist and 6 monthly phone sessions (3 individual and 3 group) for 9-36 weeks. Each session will last approximately 50 minutes."
41319859|NCT04164329|DRUG|General anesthetic|General anesthesia (propofol, fentanyl, sevorane, remifentanyl, rocuronium)
41475984|NCT01461941|DRUG|E6005|0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
41475985|NCT01461941|DRUG|E6005 ointment (vehicle)|0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
41475986|NCT02915237|DIETARY_SUPPLEMENT|Concord grape juice|Daily dietary supplementation with a commercially available Concord grape juice.
40802113|NCT01057693|DRUG|Placebo|Placebo is supplied as capsules and given 3 times daily.
41475987|NCT02915237|DIETARY_SUPPLEMENT|Placebo Beverage|Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
41475988|NCT03585907|DIETARY_SUPPLEMENT|MAD|A high fat, low carbohydrate diet
41475989|NCT03585907|DIETARY_SUPPLEMENT|MIND|A combination of the Mediterranean and DASH diets
41475990|NCT03341000|DEVICE|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system within the first 3-5 days of the current study.
41475991|NCT01675284|BIOLOGICAL|AT-301|Inactivated H5N1 Influenza Virion Vaccine
41475992|NCT05345782|DRUG|MARCAINE AND BETAMETHAZONE 1|Laparoscopic Hypo gastric Neural Plexus Block
40802114|NCT03985943|DRUG|Placebo|Placebo
41319860|NCT06027242|DIETARY_SUPPLEMENT|oral glutamine|10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
41319861|NCT06027242|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
41319862|NCT05713578|DRUG|apantamide+docetaxel+ADT|Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.
41319863|NCT05713578|DRUG|apantamide+ADT treatment|apantamide+ADT treatment
41341802|NCT01148576|DRUG|essentiale + entecavir|entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
41341803|NCT01148576|DRUG|Vitamin E + entecavir|entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
41475993|NCT05345782|DRUG|MARCAINE AND BETAMETHAZONE 2|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block
41475994|NCT05927181|PROCEDURE|TAOM|In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.
41475995|NCT03116061|OTHER|Questionnaire|This questionnaire was to explore potential decompensation risk factors within themes and subthemes of multimorbidity
41475996|NCT00734110|DEVICE|P.F.C. Sigma Total Knee System|An orthopaedic implant for total knee replacement
41475997|NCT04932941|DRUG|MP1032|Hard gelatin capsules for oral administration.
41475998|NCT04932941|DRUG|Placebo|Placebo capsules matched to MP1032 for oral administration.
40802115|NCT03985943|DRUG|Nemolizumab|Nemolizumab
40802116|NCT05081167|DRUG|REL-1017|REL-1017 tablet
40802117|NCT05081167|DRUG|Placebo|Placebo tablet
40802118|NCT04715854|DEVICE|Mask|addition of the mask above the nasal cannulas
40802119|NCT00269087|DRUG|fluticasone propionate/salmeterol combination DISKUS|
40802120|NCT03040518|BEHAVIORAL|Narrative SMS|Narrative SMS have been defined as interactive life stories based around a range of characters (varying in age and socio-demographics) which can simulate the processes that make group-based interventions successful: humour, banter, peer support, facts about diet and PA and evidence based BCTs. The narrative form draws on real world learning from the film, television and games industry. When theorised, the narrative enables engagement with characters who convey the message of the intervention, and facilitate the viewer's empathy. Through creating an empathic bond with the character, users pay more attention to and become engaged and immersed within the story. This appears to lead to optimal learning and conceptualisation of the target information.
40802121|NCT03040518|BEHAVIORAL|Endowment Incentive|All participants will be 'endowed' with an incentive at the start of the trial. It will be placed into a hypothetical personal account which is theirs for a year (no withdrawals). Participants will be able to secure money for verified weight loss at 3, 6, and 12 months.
40802122|NCT01761006|DEVICE|NIOX MINO®|
41475999|NCT00427674|DRUG|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
40802123|NCT01701362|DRUG|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
40802124|NCT01701362|DRUG|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
40802125|NCT00367562|DRUG|ENALAPRIL VALSARTAN METHYLPREDNISONE|
40802126|NCT05667883|DRUG|glucocorticoid + cytoxan|The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
40802127|NCT03601039|DEVICE|Absnow Absorbable ASD Closure System|the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
40802128|NCT04250558|PROCEDURE|Lower Extremity Amputation|patients 18 years of age or older who will have a planned lower leg (either below knee, through knee, or above knee) amputation surgery are scheduled to undergo a lower extremity amputation (either below knee, through knee or above knee), performed by a participating surgeon or delegate. Provision of informed consent.
40802129|NCT02919202|PROCEDURE|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.|Topical application to exposed dentine on one occasion.
40802130|NCT02919202|PROCEDURE|Self-etching Dentine Bonding Agent|Topical application to exposed dentine on one occasion followed by light-curing procedure.
40802131|NCT03637257|DEVICE|modified Guedel airway|Monitoring of breathing
40802132|NCT05466084|PROCEDURE|tissue Glue for mesh fixation|one arm of the study had their mesh fixed with tissue glue applied at multiple sites
40802133|NCT05466084|PROCEDURE|Metallic Tackers for mesh fixation|in the other arm mesh was fixed with tackers applied avoiding the triangle of pain and the triangle of doom using a three point fixation technique; Cooper's ligament, medial cranial edge of the mesh and just lateral to the inferior epigastric vessels.
40802134|NCT01741233|GENETIC|VitDgen|
40802135|NCT02515799|DRUG|Tacholiquine|Inhaled Tacholiquine ®1% - 5ml
41319864|NCT04695548|OTHER|Concentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
41319865|NCT04695548|OTHER|Isometric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
41319866|NCT04695548|OTHER|Eccentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of asking the participant to lower their shoulder, against the resistance of the elastic band, in a slow and controlled manner for 5 seconds.
41476000|NCT01613664|DRUG|tisseel|The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
41476001|NCT01613664|OTHER|no tisseel|the surgeon does not applied tissucol during the surgery
40802136|NCT02515799|OTHER|Placebo|Inhaled Placebo
41341804|NCT03999385|BEHAVIORAL|Mindful Self-Compassion (MSC)|The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.
41476002|NCT02451150|DRUG|Azilsartan|Azilsartan tablets
41476003|NCT00548379|DRUG|vitamin D|vitamin D 100,000 units once in 3 months
41476004|NCT00548379|DRUG|placebo|olive oil 1ml
41476005|NCT01481870|DRUG|Sorafenib-sunitinib|sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
40802137|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|200 mg dose daily for 12 weeks.
40802138|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|400 mg dose daily for 12 weeks.
40802139|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|600 mg dose daily for 12 weeks.
40802140|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|800 mg dose daily for 12 weeks.
40802141|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
40802142|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
40802143|NCT05426967|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS
40802144|NCT05426967|DEVICE|Sham rTMS|Sham comparator to active rTMS
40802145|NCT01191736|BEHAVIORAL|No training, assessed within 60 mins|Subjects receive no training in resuscitation
40802146|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
40802147|NCT01191736|BEHAVIORAL|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
40802148|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
40802149|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
40802150|NCT01191736|BEHAVIORAL|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
40802151|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
40802152|NCT01734785|DRUG|Linagliptin|tablet
40802153|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
40802154|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
40802155|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
40802156|NCT01734785|DRUG|Empagliflozin placebo + Linagliptin placebo|Matching Empagliflozin + Linagliptin low dose
40802157|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
40802158|NCT06279117|BEHAVIORAL|therapeutic touch|Individuals who undergo therapeutic touch will receive therapeutic touch for 20 minutes 30 minutes before the exam.
40802159|NCT06040385|DEVICE|Implant supported hybrid prosthesis|For each patient, implant supported mandibular hybrid prosthesis will be fabricated digitally. Frameworks will be tried in patient's mouth, scanned intraorally by intraoral scanner (IOS).
41319867|NCT04695548|OTHER|Analytic passive stretching|The patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
41319868|NCT03516409|DIETARY_SUPPLEMENT|Biokult|"Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia).~Each sachet contains:~* Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life~* DHA + EPA: \>1mg per sachet~* Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each"
41319869|NCT03516409|DIETARY_SUPPLEMENT|Placebo|"IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19.~Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets."
41319870|NCT04985318|DRUG|Cablivi®|Intervention with Cablivi® take place outside of the study
40802160|NCT05713981|PROCEDURE|Meibomian gland (MG) expression|The procedure is performed with a sterile cotton tip applicator once in the upper and lower eyelids of the subject's choosing.
41319871|NCT01545609|OTHER|Text messaging|Text messages to cell phone with education messages about the specific birth control they are using
41319872|NCT00555906|DRUG|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
41319873|NCT00555906|DRUG|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
40802161|NCT02172573|DRUG|Pramipexole|
40802162|NCT02172573|DRUG|Bromocriptine|
40802163|NCT02172573|DRUG|Placebo pramipexole|
40802164|NCT02172573|DRUG|Placebo bromocriptine|
40802165|NCT04597645|OTHER|Therapeutic elastic band resistance training|A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
41006081|NCT05402943|BEHAVIORAL|Nursing Care Program for Endometriosis|Nursing Care Program for Endometriosis, developed in line with Health Promotion Model
41006082|NCT05402943|BEHAVIORAL|EHP-5 Endometriosis Health Promotion Model.|EHP-5 Endometriosis Health Promotion Model. A questionnaire used to measure the quality of life of women with endometriosis
41476006|NCT01481870|DRUG|Sunitinib-sorafenib|sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
40802166|NCT01059487|OTHER|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
40802167|NCT06352151|OTHER|Routine Physiotherapy Group|Children with Down syndrome who receive routine physical therapy treatment in special education centers will undergo evaluation after eight weeks of treatment, followed by a control evaluation after 12 weeks.
40802168|NCT06352151|OTHER|Orofacial Treatment Group|"The orofacial treatment group receives therapeutic orofacial treatment in addition to routine physiotherapy treatment. Each week, one or two target exercises will be taught to the child with Down syndrome, and the exercises will gradually increase throughout the process. Parental involvement will be encouraged during the treatment to ensure active participation in therapy.~The goals of the therapy are as follows:~First Goal: Nasal hygiene and Sleep hygiene education~Second Goal: Nasal Breathing Exercise Training~Third Goal: Creating Awareness of Tongue Resting Position~Fourth Goal: Creating Lip Position Awareness - Lip Exercises~Goal Five: Chewing Muscle Exercises~Sixth Goal: Strengthening the Soft Palate~Seventh Goal: Reshaping Correct Swallowing"
40802169|NCT06352151|OTHER|Therapeutic Yoga Group|The therapeutic yoga group receives therapeutic yoga treatment and routine physiotherapy treatment. Children with Down syndrome will be given yoga exercises suitable for their age.
40802170|NCT03638050|OTHER|Functional Capacity Assessment|Individuals will be assessed on the third day after acute myocardial infarction. The six-minute walk test will be performed according to the norms of the American Thoracic Society.
40802171|NCT02557776|GENETIC|Germline genetic testing of BRCA1 and BRCA2|
40802172|NCT00002389|DRUG|Abacavir sulfate|
40802173|NCT00002389|DRUG|Lamivudine|
40802174|NCT00002389|DRUG|Zidovudine|
41006083|NCT05402943|BEHAVIORAL|Healthy Life Style Behaviours Scale II.|A questionnaire used to measure the Healthy Life Style Behaviours.
40802175|NCT04073511|DRUG|Eungyosan|This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
40802176|NCT04073511|DRUG|Samsoeum|This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
40802177|NCT04073511|DRUG|Placebo|It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
40802178|NCT02499913|BEHAVIORAL|breath alcohol monitoring|Daily breath alcohol monitoring
40802179|NCT02499913|BEHAVIORAL|contingency management|Participants can earn chance to win prizes for negative breath alcohol samples.
40802180|NCT05047302|DEVICE|BlueLeaf Procedure|The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.
40802181|NCT03141125|OTHER|Physalis angulata ethanol extract|Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
40802182|NCT03141125|OTHER|Placebo|No active component at the same dosage of 3x250 mg/day given orally for 3 months
41319874|NCT00555906|DRUG|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
41319875|NCT05866393|BEHAVIORAL|Clean Hands Accessible and Manageable for Patients|Use of a patient-smart hand sanitation dispenser that provides reminders that are non-beeping reminders.
41319876|NCT05469477|BEHAVIORAL|Persuasive education|The research team will use psychology and communications research to present information about seat belts and distracted driving in a way that builds intrinsic motivation to change. Because positively framed messages are more effective at promoting seat belt wearing, the team's messaging will employ this framing. Education will address common reasons that survey participants give for not consistently buckling up or for phone use while driving.
40802183|NCT01297608|DRUG|caoted suppository|coated suppository with active drug
40802184|NCT01297608|DRUG|coated suppository|coated suppository with placebo
40802185|NCT03853850|BEHAVIORAL|Mobile phone text messages|From their babies' day of birth until 6 months of age, participating mothers will receive supportive and educational text messages to promote breastfeeding. Messages will be on benefits of breastfeeding, newborn hunger cues, proper latch technique, healthy infant feeding practice, and maternal self care. Messages will be sent regularly, initially several messages every day during the babies' first few weeks of life, then few messages every week. A total of 158 (\*\*\*) messages will be sent. Messages will be sent in English or in Spanish depending on participant language preference.
40802186|NCT02069821|DRUG|combination administration|combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
41319877|NCT05469477|BEHAVIORAL|WOOP (aka, mental contrasting with implementation intentions., Wish, Outcome, Obstacle, Plan)|Participants will receive an intervention on improving driving behavior with a specific goal in mind and how to reach that goal. Participants will do this by thinking through 4 parts: a wish, an outcome, an obstacle and a plan. This has been shown to build motivation, and help achieve the desired change.
41319878|NCT05469477|BEHAVIORAL|Customized Habit Tips|Participants will receive weekly text-message tips, informed by findings from survey responses, plus reminders to address stated obstacles.
41319879|NCT05469477|BEHAVIORAL|Raffle Financial Incentive|Each week, participants who adhere to seat belt use or abstain from phone use while driving get a chance at prize money. One winner will be randomly chosen for each target behavior and earn prize money; the rest will not receive compensation.
41319880|NCT05469477|BEHAVIORAL|Shared Pot Financial Incentive|This will be identical to the raffle incentive, except that each week participants who adhere to seat belt use or abstain from phone use while driving will be guaranteed an equal share of prize money.
41319881|NCT05469477|BEHAVIORAL|Weekly SMS Support text|Participants will receive a support SMS to troubleshoot, etc. if the Way to Drive app is not collecting trip data.
40802187|NCT01833728|DRUG|nefopam-propacetamol combination|"Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours."
41476007|NCT04463290|OTHER|No intervention, Patients selection based on clinical symptoms and radiological imaging|No intervention
41476008|NCT01131299|OTHER|Placebo|2 tablets PO 3 times a day for 12-14 weeks
41319882|NCT05469477|BEHAVIORAL|Weekly SMS Encouragement|Those who have a perfect streak going midway through each week will receive an additional encouraging message cheering them on.
41476009|NCT01131299|DRUG|Alpha cyclodextrin|2g PO 3 times a day for 12-14 weeks
41476010|NCT02404519|DIETARY_SUPPLEMENT|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
41476011|NCT02404519|DIETARY_SUPPLEMENT|Placebo|1 tablet without MK-7 taken orally every day during 1 year
40802188|NCT01833728|DRUG|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
40802189|NCT02450435|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
41006084|NCT05402943|BEHAVIORAL|The Satisfaction Questionnaire for Nursing Care Program for women with Endometriosis.|A questionnaire used to measure the satisfaction levels of women with endometriosis who applied the Nursing Care Program for women with endometriosis.
41319883|NCT00668200|DRUG|Reclast (ZOL446, zoledronic acid)|"5 mg i.v. annually (real-life, physician prescribed)"
41319884|NCT00668200|DIETARY_SUPPLEMENT|Calcium|1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
41319885|NCT00668200|DIETARY_SUPPLEMENT|Vitamin D|800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
41319886|NCT06440850|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41319887|NCT06440850|DRUG|Cobimetinib|Given PO
41319888|NCT06440850|PROCEDURE|Computed Tomography|Undergo CT scan
41319889|NCT06440850|PROCEDURE|Diagnostic Imaging|Undergo I-123 diagnostic scan
41319890|NCT06440850|PROCEDURE|I-131 Uptake Test|Undergo I-131 whole body scan
41476012|NCT03301818|DEVICE|Vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after during a 3 month interval.
41319891|NCT06440850|RADIATION|Iodine I-131|Given PO
41319892|NCT06440850|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41319893|NCT06440850|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41319894|NCT06440850|BIOLOGICAL|Recombinant Thyrotropin Alfa|Given IM
41319895|NCT06440850|PROCEDURE|Ultrasound Imaging|Undergo neck ultrasound
41319896|NCT06440850|DRUG|Vemurafenib|Given PO
41319897|NCT01480479|DRUG|Rindopepimut (CDX-110) with GM-CSF|"Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF."
41319898|NCT01480479|DRUG|Temozolomide|150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
41319899|NCT01480479|DRUG|KLH|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
41319900|NCT03484351|OTHER|Fall Monty Activity Programme (FallMAP)|The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing \& falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.
41319901|NCT02661841|OTHER|LI-Guided Therapy|Preemptive treatment according to LI monitoring
41319902|NCT02661841|OTHER|Heart Failure Guidelines|Treatment according to clinical signs
41319903|NCT00817206|DRUG|LCP-Tacro|LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
41319904|NCT00817206|DRUG|Prograf|Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
41341805|NCT04546867|DIAGNOSTIC_TEST|Sonographic based visualization of a pancreatic stent|As described above. All patients start with an ultasound-based approach to visualize pancreatic stents position. Depending on the findings, x-ray will be performed if no stent is visualized in the pancreatic duct or an esophagogastroduodenoscopy will be performed to remove the pancreatic stent and confirm sonographic findings if the pancreatic stent is displayed in situ.
41341806|NCT00643097|BIOLOGICAL|PEP-3 vaccine|Given intradermally
41476013|NCT05154552|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training, which involves both the stretching and contracting of the muscle group being targeted. PNF stretching is one of the most effective forms of stretching for improving flexibility and increasing range of motion.
41319905|NCT03263156|BEHAVIORAL|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
41152446|NCT02746497|PROCEDURE|Acupuncture|"Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally."
41152447|NCT03934944|DEVICE|Phone application|Weekly foot alerts and educational video
41319906|NCT03863067|PROCEDURE|Epiduroscopy|Using epiduroscopy to treat the ligamentum flavum hypertrophy with Resaflex ,an instrument with Quantum Molecular Resonance for tissue coablation.
40802190|NCT02450435|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
40802191|NCT03333928|DRUG|HTD1801|HTD1801 tablets, 250 mg
40802192|NCT03333928|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
40802193|NCT00911976|DEVICE|Xience V coronary stent|The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
40802194|NCT01379248|DEVICE|manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|manual thrombus aspiration catheter to be used during percutaneous coronary intervention
41319907|NCT03721393|DEVICE|Wearable heart monitor|Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.
41319908|NCT03059992|DRUG|Ibrexafungerp|Experimental Study Drug
41319909|NCT03569865|DEVICE|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
41319910|NCT05994586|DIETARY_SUPPLEMENT|AP029 mix|Polyphenol-rich plant extracts Twice a day
41319911|NCT05994586|OTHER|Placebo|Twice a day
41319912|NCT00796042|OTHER|Usual care|Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.
41319913|NCT00796042|OTHER|Pressure management and Mobility program|Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
41341807|NCT00643097|BIOLOGICAL|sargramostim|Given intradermally
41341808|NCT00643097|DRUG|Temozolomide|Standard of care chemotherapy
40802195|NCT06227676|DIETARY_SUPPLEMENT|Cramp Bites by Aunt Flo's Kitchen|Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.
40802196|NCT05007899|DRUG|Ferrous sulfate|Alternate day dosing of ferrous sulfate
40802197|NCT05033587|DRUG|Anlotinib|Anlotinib a multi-target receptor tyrosine kinase inhibitor.
40802198|NCT05033587|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
41152448|NCT03934944|OTHER|Usual care|Usual routine of diabetic foot education
40802199|NCT05033587|RADIATION|Radiotherapy|The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.
40802200|NCT03734926|DRUG|ZSP1241|ZSP1241 tablets for oral administration.
40802201|NCT04843111|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
41006085|NCT05168475|BIOLOGICAL|Rituximab|Hospital stock of rituximab used as intervention; biosimilars are allowed
41006086|NCT05168475|BIOLOGICAL|Infliximab|Hospital stock of infliximab is used in the trial; biosimilars are allowed
41006087|NCT05168475|BIOLOGICAL|Tocilizumab|Hospital-supplied stock.
41319914|NCT04314479|BEHAVIORAL|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
41006088|NCT00261716|BEHAVIORAL|IPS|Individual Placement and Support Evidence based supported employment
41152449|NCT01189136|DEVICE|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period.
41319915|NCT04414696|BEHAVIORAL|Exercise intervention|eHealth exercise intervention for postpartum women at increased risk of depression
41319916|NCT01120379|DEVICE|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
41319917|NCT00067314|DRUG|Edotecarin|
41319918|NCT03632252|DEVICE|Powered ankle prosthesis|This device is a custom designed ankle prosthesis. Motors control force on the device through cables but are not worn by the person.
41319919|NCT03655717|DRUG|Dronabinol|Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.
41319920|NCT03655717|DRUG|Ethanol|Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).
41319921|NCT03655717|DRUG|Placebo dronabinol|Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)
40802202|NCT01543282|DEVICE|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
41006089|NCT00261716|BEHAVIORAL|IE|Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search
41006090|NCT00261716|BEHAVIORAL|VOMI|Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
41006091|NCT01406821|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
41006092|NCT01406821|PROCEDURE|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
41319922|NCT03655717|DRUG|Placebo ethanol|Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
40802203|NCT06440954|DRUG|Intrathecal pemetrexed|Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
40802204|NCT02200757|DRUG|Aldoxorubicin|230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
41006093|NCT02266056|DRUG|Deep neuromuscular block using rocuronium and reversal with suggamadex|Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
41006094|NCT02266056|DRUG|Moderate neuromuscular block using rocuronium and reversal with suggamadex|Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
41476014|NCT05154552|OTHER|Routine physical therapy|"Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises"
41006095|NCT01617603|OTHER|Cocoa Polyphenols|20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
41006096|NCT01984138|DRUG|ESTRING|ESTRING (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.
41319923|NCT05704439|DRUG|Neurologist Initiated Treatment|Neurologist Initiated Treatment for Hypertension or Hyperlipidemia
41476015|NCT00484419|DRUG|Colesevelam HCl|coleveselam tablets 625 mg; 6 tablets/day
41476016|NCT00484419|DRUG|rosiglitazone maleate|rosiglitazone tablets 4mg
41006097|NCT01984138|DRUG|Replens|Replens should be applied vaginally, with a supplied applicator, three times each week.
41319924|NCT05704439|OTHER|Placebo|Usual care
41319925|NCT00436319|PROCEDURE|Duration of GnRH agonist downregulation|"This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2\<80 pg/ml and progesterone \<1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history."
41006098|NCT00085943|DRUG|LEXIVA (GW433908)|
41006099|NCT00085943|DRUG|Ritonavir|
41006100|NCT00085943|DRUG|KALETRA|
41006101|NCT00085943|DRUG|EPIVIR|
41006102|NCT00085943|DRUG|Ziagen|
41006103|NCT00085943|DRUG|Abacavir/Lamivudine|
41006104|NCT00085943|DRUG|Fosamprenavir|
41152450|NCT01189136|OTHER|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
41152451|NCT03775187|BIOLOGICAL|Burosumab|
41152452|NCT05685251|OTHER|Health Coaching|Participants will receive a health coach telehealth/video visit or phone call every 2 weeks for 4 months, for a total of 8 calls. After these initial 8 calls, at approximately 6 months postpartum, the health coach will schedule maintenance calls 1 per month until approximately 12 months postpartum, for a total of 6 additional calls.
41319926|NCT05415345|BIOLOGICAL|Cecolin|Bivalent HPV Vaccine
41319927|NCT05415345|BIOLOGICAL|Hecolin|Hepatitis E vaccine
41319928|NCT02005224|OTHER|LCHF diet and a bout of exercise|Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
41319929|NCT01833325|RADIATION|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
41319930|NCT04273126|BEHAVIORAL|Adapted Family Resilience Intervention|The program consists of approximately 8-10 modules lasting approximately one hour. Sessions focus on psychoeducation and key resilience skills.
41319931|NCT02463136|BEHAVIORAL|questionnaires|Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
41476017|NCT00484419|DRUG|sitagliptin phosphate|sitagliptin phosphate tablets 100mg/day
41476018|NCT02396173|OTHER|Risk Score for non-return to work|"The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice)."
41476019|NCT06274866|OTHER|exercise program|Study group were followed up with a personalized home-based exercise program for 6 weeks. IThe exercise program of the individuals in the study group was checked at two-week intervals and adjustments were made in the exercise program
41476020|NCT06274866|OTHER|control group|Individuals in the control group were followed up with an exercise training brochure.
40802205|NCT02200757|DRUG|Topotecan|1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
40802206|NCT01996488|DRUG|Olanzapine Orally Disintegrating Tablets 5mg|
40802207|NCT00889603|DRUG|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
40802208|NCT00854724|DRUG|Puerarin, Placebo|400 mg, three times a day for 7 days
40802209|NCT06273735|DIAGNOSTIC_TEST|Pre- and postoperative determination of troponin as part of the study and 24-month FU survey|An intervention is carried out as part of the normal clinical procedure regardless of the study measurement parameters.
40802210|NCT05236179|OTHER|Integrative therapies|Integrative therapy methods used at the Filderklinik, such as music therapy, therapeutic painting, therapeutic sculptural forming, speech therapy, eurythmy therapy, rhythmical massage, external applications, coloured light therapy
40802211|NCT03818906|PROCEDURE|Molar extraction - Control Group|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.
41319932|NCT02463136|DEVICE|Functional magnetic resonance imaging w neurofeedback|"The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).~Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014)."
41476021|NCT05407506|DIAGNOSTIC_TEST|THYROID AI|thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules
40802212|NCT03818906|PROCEDURE|aPDT + Molar Extraction - Test Group 1|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT.
40802213|NCT03818906|PROCEDURE|Infrared + Molar Extraction - Test Group 2|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive local application of infrared in vestibular external portion
40802214|NCT03818906|PROCEDURE|aPDT + Infrared + Molar Extraction - Test Group 3|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT and after that will receive local application of infrared in vestibular external portion.
40802215|NCT02270528|BEHAVIORAL|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (\~5 minutes)
40802216|NCT02270528|BEHAVIORAL|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
41319933|NCT04574921|OTHER|Light Therapy System (LTS): Active setting|Exposure for 1 hour á day for consecutive days.
41319934|NCT04574921|OTHER|Light Therapy System (LTS): Sham setting|Exposure for 1 hour á day for consecutive days.
41319935|NCT00042484|PROCEDURE|Community-level intervention & policy change|
41319936|NCT03639012|DIETARY_SUPPLEMENT|Carbohydrate drink|Children randomised to this group will receive a preoperative carbohydrate drink 90-120mins prior to surgery
41319937|NCT03140423|DRUG|Arm 1. Routine Care (Mupirocin/CHG)|The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
40802217|NCT01606176|DRUG|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
40802218|NCT01606176|DRUG|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
40802219|NCT06504459|DRUG|Azacitidine|Given IV or SC
41006105|NCT03106727|BEHAVIORAL|Household model|The proposed intervention is a 'Household Model' where, instead of being assigned to HIV or TB patients, CHWs will rather be assigned to households and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program.
41152453|NCT05685251|OTHER|Home Blood Pressure Monitoring|Participants will be provided an A\&D UA-651 (BT) home blood pressure monitor with an appropriate cuff size, they will be asked to take their blood pressure at least three days a week, 2 measurements each time
41319938|NCT03140423|DRUG|Arm 2. Iodophor/CHG Decolonization|The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
41152454|NCT00001623|PROCEDURE|Allogeneic Bone Marrow Transplant|
41152455|NCT05849220|DRUG|Dapagliflozin|Dapagliflozin
41152456|NCT05849220|OTHER|Standard of Care|Standard of Care
41319939|NCT00000993|DRUG|Zidovudine|
41319940|NCT03520725|OTHER|No Intervention|This gruop did not have an intervention
41319941|NCT03520725|DIETARY_SUPPLEMENT|Pineapple snack bar|30 g daily of pineapple snack bar
41319942|NCT03520725|DIETARY_SUPPLEMENT|Mango snack bar|30 g daily of mango snack bar
41319943|NCT00084942|DRUG|capecitabine|
41476022|NCT02556892|DRUG|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
41476023|NCT03891329|DEVICE|Acticor/Rivacor ICDs/CRT-Ds|pre-defined device programming, measurements and follow-up schedule
41476024|NCT03891329|DEVICE|Plexa S DX|Implantation, measurements and follow-up schedule
41152457|NCT05513222|PROCEDURE|flipped autograft|Thick lingual flap was de-epithelized and partially dissected to increase its length then flipped and sutured to the buccal flap to obtain primary closure
41152458|NCT01942538|DEVICE|rTMS|one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold
41152459|NCT01942538|DEVICE|sham rTMS|same session as defined with the real rTMS, but with a coil not delivering magnetic field.
41152460|NCT04627259|OTHER|Thumb Disability Examination|Turkish Version of Thumb Disability Examination. The Turkish Version of Thumb Disability Examination consists of 20 questions related with thumb pain and functionality.
41152461|NCT04701073|DEVICE|LombaStab belt|"Instruction given to the patient will be to wear the LombaStab belt from 4 to 8 hours per days, over the whole duration of the study (12 weeks). The investigator will explain to the patient how to adjust it.~The LombaStab belt will be equiped with thermosensor to evaluate the belt wearing time at the end of the study."
41319944|NCT00084942|DRUG|gemcitabine hydrochloride|
41319945|NCT01835613|OTHER|Biomarkers Measures|At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.
41319946|NCT05360355|PROCEDURE|total face reconstruction surgery and intraoperative indocyanine green angiography|Patients with total facial scarring following burn injury were treated with monoblock pre-expanded prefabricated flaps for total face restoration. The opening of nostrils, oral and palpebral orifices, together with organ fabrication, were conducted under the guidance of intraoperative ICGA for hemodynamic evaluation.
41319947|NCT02246023|DEVICE|Flexible bronchoscopy in moderate sedation|Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
41319948|NCT02246023|DEVICE|Oxygen saturation|Continuous measurement of oxygen saturation;
41476025|NCT04109859|DRUG|Saline|When using saline, if found mean arterial pressure \<65mmHg, Cardic Output\>4L/min, Sequential Vascular Response\<800 (dyne×sec)/cm, starting dose of norepinephrine 0.04ug/min/kg
41476026|NCT04109859|DRUG|Methylene Blue|Patients in the methylene blue group were given methylene blue before anesthesia and continued intraoperative pumping
41319949|NCT02246023|DEVICE|Blood pressure|Measurement of non-invasive blood pressure every 3 minutes
41319950|NCT02246023|DEVICE|Propofol dosage|Report of dose adjustments und cumulative propofol dosage;
41319951|NCT02246023|DEVICE|Recovery time after bronchoscopy|Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
41319952|NCT03111550|DEVICE|Investigational Intraocular Lens Device #1: TECNIS Model ZHR00|Intraocular lens replaces the natural lens removed during cataract surgery.
41319953|NCT03111550|DEVICE|Investigational Intraocular Lens Device #2: TECNIS Model ZQR00|Intraocular lens replaces the natural lens removed during cataract surgery.
41319954|NCT03111550|DEVICE|TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00|Intraocular lens replaces the natural lens removed during cataract surgery.
41319955|NCT06499727|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
41319956|NCT06499727|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
41319957|NCT05143762|DRUG|paracetamol|patients will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day)
41319958|NCT05143762|DRUG|Dexamethasone|patients will receive dexamethasone 0.5mg/kg IV.
41319959|NCT05143762|DRUG|normal Saline|patients will receive placebo 10 ml normal saline IV.
41319960|NCT03201887|BEHAVIORAL|Sub-optimal effort|Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits
41319961|NCT03201887|BEHAVIORAL|optimal effort|Participants will be asked to perform tasks to the best of their abilities.
40802220|NCT06504459|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41319962|NCT04615702|DIAGNOSTIC_TEST|serum lipase or amylase|"Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) is helpful in diagnosis~Acute pancreatitis is diagnosed when two of three criteria are present including:~1. Clinically (abdominal pain consistent with acute pancreatitis),~2. Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits)~3. Imaging criteria of acute pancreatitis"
41319963|NCT04615702|DEVICE|ultrasound|helpful in diagnosis of acute pancreatitis and its etiology (Gallstones)
41319964|NCT04615702|DEVICE|CT|helpful in diagnosis of acute pancreatitis and its etiology . assist in detection of type and severity of acute pancreatitis
41319965|NCT04615702|DIAGNOSTIC_TEST|Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.|help in diagnosis of the etiology of acute pancreatitis elevated Bilirubin, ALT, AST and alkaline phosphatase suggest biliary pancreatitis
41319966|NCT04615702|DEVICE|EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)|helpful in idiopathic acute pancreatitis diagnosis
41319967|NCT04615702|DRUG|Ringer lactate|"The initial infusion rate for mild cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~* A mean arterial pressure of 65mmHg or more,~* Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters."
41476027|NCT03446352|OTHER|Psychomotor exercise program|"Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (40 min), cool-down (10 min), and finishing ritual (5 min).~At the initial stage, the activation of different muscle groups will be performed, providing an elevation of the neurophysiological parameters. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation- physical performance (cardiovascular, strength, balance, flexibility, agility and movement accuracy)- alternating with exercises mainly focused on cognitive stimulation- executive functions (planning ability, information processing speed, attention and dual-task performance).~At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants share their sensations experienced."
40802221|NCT06504459|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
40802222|NCT06504459|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
40802223|NCT06504459|DRUG|Cladribine|Given IV
41006106|NCT00650039|DRUG|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
41006107|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
41006108|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
41006109|NCT05369910|BEHAVIORAL|Light exposure (Flash)|Light exposure (Flash) is administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source (Dawe stroboscope type 1214B, 5 Hz).
41006110|NCT05369910|BEHAVIORAL|Light deprivation (Dark)|Light deprivation (Dark) is administered for one hour on 7 consecutive days. During the Dark intervention, participants are seated in a room in complete darkness.
41006111|NCT02733978|DEVICE|the ozone generator device (Human Pro medic, German)|noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)
41006112|NCT00072865|DRUG|Pemetrexed|
41319968|NCT04615702|COMBINATION_PRODUCT|NSAID / paracetamol +/- opiates+/- epidural analgesia|"Pain control (Modified World Health organization (WHO) analgesia ladder) Step1: NSAID / paracetamol Paracetamol 1gm IV infusion /8h + Diclofenac sodium 75mg /12h.~Step 2: Opiates +/- NSAID/ paracetamol Pethidine 25 mg IV/4h~Step 3: Interventional treatment (epidural analgesia) +/- opiates +/- NSAID/ paracetamol In case of severe pain not responding to the above analgesia"
41319969|NCT04615702|COMBINATION_PRODUCT|Quinolones + Metronidazole /Carbapenems ± Metronidazole|"* Mild attack: no antibiotic prophylaxis administered.~* Severe attack:~* Timing: Antibiotic prophylaxis administered to cases presented early within 72 hrs of disease onset.~* Duration: Not more than 2 weeks~* Antibiotics given:~  * Quinolones + Metronidazole ( the 1st choice in ward) Ciprofloxacin 400mg IV /12 h + metronidazole 500mg IV/8h~ * Carbapenems ± Metronidazole (the 1st choice in ICU patients and in case of sensitivity to quinolones) Imipenem .5gm IV/6h + metronidazole 500mg IV/8h~    b. Therapeutic (in cases with pancreatic or extrapancreatic infections)~ * In case of pancreatic infection, Carbapenems ± metronidazole were given."
41319970|NCT04615702|DIETARY_SUPPLEMENT|Fresubin 2Kcal fiber drink|"Severe cases Timing: Within at least 48 hrs of admission provided that there are no intestinal complications.~Route: Nasogastric tube Nutrients: Polymeric feeding formula~* Nutrient: Fresubin 2Kcal fiber drink 200ml (2Kcal/ml)~* Total caloric requirements ꞊ body weight (kg) X 30Kcal/day Pattern : Continuous infusion~* The nutrition started with small amount and increased gradually over 16hrs~* Infusion rate ꞊ Total caloric requirements / 16hrs"
41319971|NCT04615702|DEVICE|nasogastric tube|in case of ileus or vomiting
41476028|NCT03446352|OTHER|Combined exercise program|"The EG2 intervention combines the psychomotor exercise program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.~The WBV will integrate 3 sessions / week of 6 minutes each, with programed increased exercise time, series, and frequencies throughout the intervention."
41476029|NCT06615882|DEVICE|stent-angioplasty & nimodipine infusion (During the stent (Solitaire-X) -angioplasty, IA nimodipine was also infused)|"I. Procedure \& Intervention~1. Assess the presence and degree of cerebral vasospasm of the target vessel through cerebral angiography before the procedure.~2. Solitaire-X stent types are selected~3. During the stent-angioplasty, IA nimodipine was also infused.~4. Retrieve Solitaire-X after maintaining deployment for 3 minutes.~5. Additional procedures are determined through immediate post-procedure and 15-minute delayed cerebral angiography."
41476030|NCT03113526|PROCEDURE|remove drain|remove drain when output is less than 30ml or less than 100ml per 24-hour
41476031|NCT01413282|RADIATION|Cardiac CT|Calcium scan and CT coronary angiography
41006113|NCT00072865|DRUG|Carboplatin|
41006114|NCT00805116|DIETARY_SUPPLEMENT|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
41006115|NCT00805116|DIETARY_SUPPLEMENT|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
41006116|NCT02994537|OTHER|Different biochemical results or pathogenesis.|Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
41476032|NCT03795584|PROCEDURE|sterile repositionable hemostasis clipping device close the large duodenal papilla incision|After the bile duct stent was placed, the investigators can use sterile repositionable hemostasis clipping device to close large duodenal papilla incision at 11 o'clock on the duodenal papilla.
41476033|NCT05848401|DEVICE|Biosound Therapy System|Biosound Therapy consists of biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content.
41476034|NCT06546007|DIAGNOSTIC_TEST|CTC-DNA|ctDNA for the analysis of lung cancer mutations in patients with operable tumors.
41476035|NCT03186599|BEHAVIORAL|low adherence intervention group|Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
40802224|NCT06504459|DRUG|Cytarabine|Given SC
40802225|NCT06504459|PROCEDURE|Echocardiography|Undergo ECHO
41152462|NCT04392154|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
41152463|NCT06366724|DRUG|Pyridostigmine|"Pyridostigmine timeline:~Weeks 0-2: 20mg TID (1.67 mL TID)~Weeks 2-4: 40mg TID (3.33 mL TID)~Weeks 5-13: 60mg TID (5mL TID)"
41152464|NCT06366724|DRUG|Low-Dose Naltrexone|"LDN timeline:~Weeks 0-2: 1.5mg QD (1.5mL QD)~Weeks 2-4: 3.0mg QD (3.0mL QD)~Weeks 5-13: 4.5mg QD (4.5mL QD)"
41319972|NCT04615702|PROCEDURE|retroperitoneal necrosectomy|"* General anesthesia , Supine position with 30 degree tilt towards the right side~* A left subcostal 5 cm incision is performed one finger below the left costal margin over the midaxillary line and the muscles were divided sequentially~* Then, aspiration is done from the possible collection.~* After confirmation that it was the site of the collection, the fibrotic thick wall was opened by a scissor, as the collection is opened, pus drained spontaneously.~* At first, a wide suction was introduced in the cavity and the friable loose necrotic tissue was aspirated. Then, a circuit of flushing saline was created in the residual cavity by injection of saline through the previously placed PCD followed by aspiration of the saline and detached loose necrotic tissue fragments by the wide suction tube~* After completion of the procedure, large bore surgical drain was placed into the collection. The fascia was closed over the drains. The skin closed by interrupted sutures"
41152465|NCT06366724|OTHER|Placebo|"Placebo timeline:~Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)~Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)~Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)"
41152466|NCT01289899|DRUG|BR-A-657|120, 360mg or placebo 7days
41319973|NCT04615702|PROCEDURE|open necrosectomy|"Open necrosectomy was done after failure of the minimally invasive techniques. The procedure was done under general anesthesia under the coverage of Tienam (.5gm/6h IV) following the results of culture and sensitivity of the percutaneous drain effluent Surgical exploration of the peritoneal cavity was done through midline exploratory incision, there were 2 large pus collections extending from the Rt. and Lt. Lumber regions deep down into the pelvis, the intervening septa were divided and the pus was aspirated by a wide suction drain.~The lesser sac was opened and necrosectomy was done The previously placed PCD repositioned in the site of necrosectomy as a port for continuous irrigation while a wide tube drain was placed in the lesser sac for drainage. Another 2 tube drains were placed in the pelvis."
41319974|NCT04615702|PROCEDURE|Endoscopic transmural cystogastrostomy|"for pancreatic pseudocyst Antibiotic prophylaxis with Ciprofloxacin 400mg IV /12 hour was administered before the procedure and continued for 5 days after the procedure At first the cyst morphology was evaluated by EUS and color Doppler ultrasound is used to identify nearby vessels The puncture was performed using a 19-gauge needle, which was introduced into the pseudocyst via a therapeutic linear array echoendoscope. Then, a 0.035-inch guidewire was introduced through the needle and coiled within the pseudocyst under fluoroscopic guidance.~The needle was removed and a 10F cystotome was advanced over the guidewire and the tract was dilated by the cystotome, after dilatation, a 10F double-pigtail stent was placed and a sample of the aspirate is sent for chemical and microbiological analysis"
41476036|NCT01328912|OTHER|Remote ischemic preconditioning stimulus|The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.
41476037|NCT01328912|OTHER|control|These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
41476038|NCT00419549|DRUG|Glyceryl - trinitrate|Transdermal Patch once only
40802226|NCT06504459|PROCEDURE|Lumbar Puncture|Undergo LP
41476039|NCT00419549|DRUG|Valdecoxib|Single parenteral administration
41476040|NCT06196593|DEVICE|AcrySof™ IQ Vivity™ Toric intraocular lens|Uneventful phacoemulsification and implantation of IOL
41476041|NCT03201354|PROCEDURE|Filtration surgery with Ex-PRESS|Filtration surgery with Ex-PRESS
41476042|NCT03201354|PROCEDURE|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy
41476043|NCT03201354|PROCEDURE|Cataract extraction|Cataract surgery and IOL implantation
41476044|NCT00757614|GENETIC|DNA analysis|
41476045|NCT00757614|GENETIC|polymorphism analysis|
41476046|NCT00757614|OTHER|laboratory biomarker analysis|
41476047|NCT00757614|OTHER|questionnaire administration|
41476048|NCT01714050|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
41476049|NCT01714050|DEVICE|Light Therapy (LT)|SunRay (SunBox Company, Gaithersburg, MD)
40802227|NCT06504459|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40802228|NCT06504459|OTHER|Questionnaire Administration|Ancillary studies
40802229|NCT06504459|DRUG|Venetoclax|Given PO
40802230|NCT01020409|PROCEDURE|cardiac surgery with CPB use|cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
40802231|NCT00506402|DRUG|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
40802232|NCT00511628|DRUG|Risperidone|As prescribed
40802233|NCT00203918|BEHAVIORAL|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
41152467|NCT06049199|OTHER|Speech Enhancer|Speech Enhancer is an adaptive feature which increases the amplitude of speech signal when speech is detected. Speech Enhancer will be switched on and off for the Intervention
41476050|NCT01508819|OTHER|recommendations to admit to ICU all the patients included|recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
41476051|NCT00049699|DRUG|laromustine|
41476052|NCT03910660|DRUG|BXCL701 plus Pembrolizumab|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle."
41006117|NCT05433220|OTHER|Best Practice Advisory using Electronic Health Record|Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
41476053|NCT03910660|DRUG|BXCL701 monotherapy|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day."
41319975|NCT04615702|PROCEDURE|open cystogastrostomy|"for pancreatic pseudocyst general anesthesia, 1 gm of cefotax was given IV at the induction of anaesthesia, supine position over the operating table A transverse supraumbilical incision was performed. A 5 cm horizontal anterior gastrotomy was performed (Image 23a). Hemostasis of the submucosal vessels was performed before the incision of the gastric mucosa.~First, the cyst was punctured followed by an incision of 5 cm at the posterior gastric wall. Aspiration of the cyst content was done for chemical and microbiological analysis The wall of the pseudocyst is hemmed to the gastric wall with continuous sutures made of a vicryl 2/0 alongside the entire circumference of the orifice Nasogastric tube was placed in the stomach. The procedure was completed by suturing the anterior gastrotomy with a vicryl 2/0 continous sutures in 2 layers A tube drain was inserted at the pelvis with closure of the abdominal wound in a standard way."
41319976|NCT04615702|PROCEDURE|percutaneous catheter drainage (PCD) for infected necrosis|"PCD~* The percutaneous drainage catheter placed through peritoneal approach under US guidance, the drain size was 12 F.~* After placement of the percutaneous catheter, aspirate was sent for microbiological assessment~* The PCD was flushed with 50 ml saline, three times daily to keep the drain open and improve lavage of the collection"
41319977|NCT04615702|PROCEDURE|Endoscopic ultrasound (EUS) guided aspiration for infected necrosis|endoscopic approach it was done to one patient in the form of EUS guided aspiration of pus in a case with infected necrosis followed by percutaneous US guided aspiration of the residual
41476054|NCT04865913|OTHER|Observational|A brief 15 min phone call 1 week, 30 and 90 days post discharge.
41476055|NCT05560789|BEHAVIORAL|Physical activity (cycling on a stationary bicycle ergometer or walking on a treadmill)|At time 0, exercise will be initiated and intensity will be increased at 2 minute intervals to achieve low intensity for 30 minutes (as defined by heart rate target 50-55% of maximum heart rate determined as 220-age). Next, intensity will be increased at 2 minute intervals until the heart rate target for moderate intensity exercise is achieved (55-65% of max heart rate), or the total duration of exercise of up to 60 minutes is achieved.
41476056|NCT04482855|DEVICE|Low-level laser|Low-level laser therapy
41476057|NCT06357949|DEVICE|High-intensity laser|"All patients will receive a rehabilitation program consisting of stretching, strengthening, balance, and walking exercises targeting the lower extremities for 45 minutes, 5 days a week, for 6 weeks. Walking training will initially begin on level ground and gradually progress to different levels and surfaces.~High-intensity laser will be applied continuously in biostimulation mode 3 days a week, once a day, for a total of 9 sessions over 3 weeks"
41476058|NCT06357949|DEVICE|Sham laser|The same procedure will be followed, but sham laser will be applied at 0 j/cm2 for 10 minutes.
41476059|NCT01741779|OTHER|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
41476060|NCT01741779|OTHER|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
41476061|NCT01741779|OTHER|Whole body vibration training & diet|Combination of whole body vibration training and hypocaloric diet
41476062|NCT00387920|DRUG|sunitinib malate|Given orally
41476063|NCT00387920|OTHER|pharmacological study|Correlative studies
41476064|NCT00387920|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
41476065|NCT00387920|OTHER|laboratory biomarker analysis|Correlative studies
41476066|NCT04639297|DEVICE|NeuroVision® IONM|Using NeuroVision® prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
41319978|NCT01766479|RADIATION|CT colonography|
40802234|NCT00203918|BEHAVIORAL|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
40802235|NCT01523743|DEVICE|SpeediCath Compact|The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
40802236|NCT01523743|DEVICE|Standard care|The coated intermittent catheter normally used by subject
40802237|NCT05908994|OTHER|Examination|Exmainations including imaging, neurophysiological, kinetic and kinematic measurmetns. Behavioral assessments
40802238|NCT04267887|DRUG|Abiraterone Acetate|Given PO
40802239|NCT04267887|DRUG|Antiandrogen Therapy|Given ADT per standard of care
40802240|NCT04267887|DRUG|Apalutamide|Given PO
41319979|NCT02974387|DRUG|Fluorometholone(FML)|
40802241|NCT04267887|DRUG|Prednisone|Given PO
40802242|NCT04267887|PROCEDURE|Computed Tomography|Undergo CT scan
40802243|NCT04267887|PROCEDURE|Bone Scan|Undergo bone scan
40802244|NCT04267887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40802245|NCT04267887|OTHER|Questionnaire Administration|Ancillary studies
40802246|NCT02775591|DRUG|DA-9701|DA-9701 30mg Tablet
40802247|NCT02775591|DRUG|DA-9701 placebo|Placebo pill manufactured to mask DA-9701 30mg Tablet
40802248|NCT00711230|BIOLOGICAL|DermaVir|
40802249|NCT00711230|BIOLOGICAL|Placebo|glucose/dextrose
41476067|NCT04639297|DEVICE|Hospital Based IONM|Using hospital based IONM prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
41476068|NCT04834739|OTHER|6 minute walk test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. 30 m long corridor is used for this test .
40802250|NCT00586716|DRUG|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
40802251|NCT05969639|BEHAVIORAL|HEYA|The HEYA program is a 12-week app-delivered psychoeducational program that comprises of nutrition education, skills training on self-regulation, and weekly feedback.
40802252|NCT04985500|PROCEDURE|ESP block|peripheral nerve block
41006118|NCT01313429|DRUG|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
41006119|NCT01313429|BIOLOGICAL|Allogenic tumor Cell Vaccine (K562)|4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
41476069|NCT04834739|OTHER|1 minute Sit to Stand Test|The 1-minute STS test is performed with a chair of standard height of 46 cm without arm rests. The patient should be ensured to be seated upright on the chair positioned against a wall. The patient sat with the knees and hips flexed to 90°, feet placed flat on the floor hip-width apart, and the hands placed on the hips.The number of repetitions is measured.
40802253|NCT04985500|PROCEDURE|PIF block|peripheral nerve block
41006120|NCT01313429|DRUG|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
40802254|NCT04985500|PROCEDURE|Ultrasound|Ultrasound guidance
41006121|NCT02643251|DRUG|Clonidine Hydrochloride Topical Gel, 0.1%|Clonidine Gel is supplied as an aqueous gel formulation for topical use.
41006122|NCT02643251|DRUG|Clonidine Hydrochloride Gel Comparator|Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
40802255|NCT04985500|DRUG|Bupivacain|10-20 mL of 0.25% bupivacaine
40802256|NCT05056558|DRUG|Baricitinib|Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
41319980|NCT02974387|DRUG|Loteprednol (Lotemax)|
41319981|NCT01054976|DRUG|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
41319982|NCT00976248|DRUG|RAD001|Taken orally once a day
41476070|NCT04834739|OTHER|Fatigue Severity Scale|The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders
40802257|NCT05056558|DRUG|Placebo|Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
40802258|NCT00856596|DRUG|Sertaconazole nitrate cream 2%|Once a day topical cream
40802259|NCT00211796|DRUG|Divalproex Sodium ER|
40802260|NCT03645096|DRUG|Pregnenolone 500 mg|Pregnenolone 500 mg capsule.
40802261|NCT03645096|DRUG|Pregnenolone 800 mg|Pregnenolone 800 mg capsule.
40802262|NCT03645096|DRUG|Placebo|Placebo capsule manufactured to mimic pregnenolone capsule.
40802263|NCT03097523|DEVICE|Custom Thigh Cuff|The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
40802264|NCT05132179|DRUG|Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution|Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.
40802265|NCT02613494|DRUG|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
40802266|NCT02613494|DRUG|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
40802267|NCT02613494|OTHER|Placebo|Placebo twice daily, increasing to placebo three times daily
40802268|NCT03171584|DRUG|Terbinafine|oral antifungal drugs
40802269|NCT00100074|DRUG|Lobeline|
40802270|NCT06253455|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
40802271|NCT01173107|DRUG|colchicine|colchicine 1T tid
40802272|NCT03066323|OTHER|Rice with tea extract|Rice with tea extract
40802273|NCT03066323|OTHER|Rice without tea extract|Rice without tea extract
40802274|NCT00764543|DEVICE|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
40802275|NCT03697005|OTHER|BioHPP PEEK single posterior crowns|BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
41319983|NCT05568056|BEHAVIORAL|Visualizing and Verbalizing for Language comprehension and Thinking|The V/V intervention program is a language remediation program designed by Dr. Nanci Bell, and developed by the Lindamood-Bell Learning Processes (LBLP) (Bell, 1991b). It has been widely used among children with reading disorders, but not with children with ASD. This intervention is based on the use of nonverbal sensory input, in the form of imaged gestalts, in order to develop oral and written language comprehension, establish vocabulary, and develop higher order thinking skills (Bell, 1991a,b).
41319984|NCT04223024|DRUG|CCRT+Nimotuzumab|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
41319985|NCT04223024|DRUG|CCRT alone|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
41319986|NCT01310218|OTHER|extended postoperative dressing|2 weeks of bulky dressing
40802276|NCT03697005|OTHER|zirconia-based single posterior crowns|ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
40802277|NCT06456008|OTHER|Standard of care|Standard of care
41319987|NCT01310218|OTHER|short postoperative dressing|2 days bulky dressing followed by bandaid
41319988|NCT05735509|DEVICE|Rubber dam|Intraoral impressions can be taken with rubber dam in place. The care provider will take two impressions, one with the rubber dam in place and one without. The investigator will randomly chose one of the two impressions for crown manufacturing, and the crown will be delivered by the care provider blindly
41319989|NCT02603185|DRUG|Hemay007|
41319990|NCT02603185|DRUG|placebo|
41319991|NCT03587870|OTHER|Enteral nutrition with Fresubin Intensive|Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
41319992|NCT02293356|DRUG|Nimotuzumab Injection|patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
41319993|NCT02521688|PROCEDURE|incisional biopsy from placenta and GCF sample|A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
41319994|NCT06410079|PROCEDURE|total hip replacement|Replacement of the hip joint with a total prosthesis, a femoral stem, an acetabular cup, a joint head, in metal, ceramic, dual mobility or polyethylene
41319995|NCT03453021|DRUG|Mepolizumab|
41476071|NCT04834739|OTHER|Medical Research Council (MRC) dyspnea scale|"The MRC dyspnea scale is a questionnaire that consists of five statements about perceived breathlessness: grade 1, I only get breathless with strenuous exercise; grade 2, I get short of breath when hurrying on the level or up a slight hill; grade 3, I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level; grade 4, I stop for breath after walking 100 yards or after a few minutes on the level; grade 5,  I am too breathless to leave the house."
41476072|NCT04834739|OTHER|SF-12|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
41476073|NCT04834739|OTHER|Beck Depression Inventory|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
40802278|NCT02088879|BEHAVIORAL|chest compression with kneeling position|
40802279|NCT02088879|BEHAVIORAL|chest compression with standing position|
40802280|NCT04619238|DIAGNOSTIC_TEST|King's Health Questionnaire|patients fulfilled questionnaire
40802281|NCT04619238|DIAGNOSTIC_TEST|the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form|patients fulfilled ICIQ-SF questionnaire
40802282|NCT03005561|BEHAVIORAL|Play Back Sessions|"100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool."
40802283|NCT01927523|BEHAVIORAL|BAM|BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.
40802284|NCT01927523|OTHER|Match|An intensive math tutoring program.
40802285|NCT00042952|DRUG|imatinib mesylate|Given orally
40802286|NCT00042952|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
41319996|NCT02802878|DEVICE|Hybrid Training using Electrodes and Joint Motion Sensors|"Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
41319997|NCT02802878|DEVICE|Isokinetic Training with Isokinetic Dynamometer|Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
41319998|NCT04922034|DRUG|Amoxicillin|Outcome of patients with negative oral challenge to amoxicillin
41319999|NCT05739812|DEVICE|telesurgery by domestic surgical robot|telesurgery of urological diseases by domestic surgical robot
41320000|NCT05097248|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
41320001|NCT05097248|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 on D1 every 3 weeks; 6 cycles are planned to be completed or discontinued due to intolerable toxicity or progression.
41320002|NCT05097248|DRUG|Losartan|Losartan will be orally administered at 50 mg for three days and increased to 100 mg if tolerated until the whole course of chemotherapy; if not tolerated, it will be maintained at 50 mg until the whole course of chemotherapy
41320003|NCT05467930|OTHER|Survey|Survey completion by the participant to collect information about health and social experience
41320004|NCT05467930|OTHER|Medical History Review|Review of the participant's medical history at New York Presbyterian/Columbia University Irving Medical Center
41320005|NCT05467930|OTHER|Sample Collection|Collection of nasal and blood samples
41320006|NCT02388841|RADIATION|Pulmonary embolism|the thrombus were assessed with Computed tomographic pulmonary angiography
41320007|NCT01152736|DRUG|Nicotine|2 mg Single-dose
41320008|NCT03128385|OTHER|Intensive CIT Model Program|"Day Camp Model:~1. The treatment was delivered in group-based design, 6 hours a day for 6 days (36 hours in total)~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand"
41320009|NCT03128385|OTHER|Distributed CIT Model Program|"Home-Based Model:~1. The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand"
41320010|NCT03314558|OTHER|pulmonary rehabilitation|a pulmonary rehabilitation program of 30 sessions, (3X1h/ week), will be followed by the COPD patients
41320011|NCT04339270|DRUG|Azithropycin according to symptoms|"Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed."
41320012|NCT04339270|DRUG|Azithromycin according to rheology or symptoms|"Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70).~The rheology of mucus will be quantified every 3 months.~* If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed."
41006123|NCT03570866|DIAGNOSTIC_TEST|Positron emission tomography and computed tomography|Preoperative staging of early stage intermediate and high-risk endometrial cancer with positron emission tomography and computed tomography.
41320013|NCT06164145|OTHER|Usual care|The training program used in this study is the stroke rehabilitation program focusing on health education for stroke and a routine exercise program based on the National Strategic Plan for Stroke Rehabilitation in Myanmar.
41320014|NCT04331990|OTHER|Standard Physcial Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle strengthening and stretching, and neuromuscular control exercises. Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
41476074|NCT04834739|OTHER|Beck Anxiety Inventory|Beck Anxiety Scale is a 21-item, internationally valid, self-report rating inventory that measures the anxiety level.
41476075|NCT04834739|OTHER|5 times sit to stand test|The 5XSST scoring is based on the amount of time (to the nearest decimal in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. The equipment need in performing 5XSST test includes: Stopwatch and standard height chair with straight back (43-45 cm, 17-18 inches high). Then the instruction is given by asking the test taker to sit on the chair by resting their back. Also, the test taker is instructed to fold their arms across their chest. Then the test taker should be instructed to do sit-to-stand five times, as quickly as possible, at the count of go and without their back or leg resting on the chair between the interval of repetition.
40802287|NCT00042952|OTHER|laboratory biomarker analysis|Correlative studies
40802288|NCT04164433|DEVICE|Oral HIV Self-Test (OraQuick)|The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
40802289|NCT05809050|DIAGNOSTIC_TEST|BM aspirate|Bone Marrow aspiration \& Examination
40802290|NCT05192616|DEVICE|Covered stent implantation|Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions
40802291|NCT05733234|DEVICE|Laser ,Fotona, Light Walker AT, Ljubljana, Slovenia|Laser is used adjunctively in the surgical treatment of peri-implantitis for decontamination of the implant surface
40802292|NCT05733234|DRUG|Mechanical Treatment|Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
40802293|NCT03631771|DRUG|Iohexol|Iohexol administered intravascularly
40802294|NCT03631771|DRUG|Iodixanol|Iodixanol administered intravascularly
40802295|NCT03631771|DRUG|Iopromide|Iopromide administered intravascularly
40802296|NCT03631771|DRUG|Ioversol|Ioversol administered intravascularly
40802297|NCT01334216|OTHER|CHICA Smoking Cessation Module|The CHICA module helped to screen parents for smoking and assist them in quitting.
40802298|NCT01334216|OTHER|CHICA Placebo|This was CHICA without the study module.
41320015|NCT04331990|OTHER|Intermittent Mechanical Traction|In addition to the standard treatment, patients in this group will receive intermittent knee joint decompression for 20 minutes. Patients will be lying supine with the knee semiflexed to 30° and supported by a wedge under the knee. A customized leg cuff will be placed around the lower leg and two ropes will be extending horizontally from the cuff to the vertical traction weight using a pulley system to transfer the traction force to the tibiofemoral articulation. The magnitude of the traction force will be between 10-15% of the patient's body weight. The traction force will be applied for 10 application cycles; each cycle comprised of 2 minutes traction followed by 30 seconds relief. This will sum up to 20 minutes of actual joint traction duration. The traction force application and relief time will be controlled manually by the treating therapist. Knee joint traction procedures will be applied at the end of the physical therapy session.
41320016|NCT04331990|OTHER|Continuous Mechanical Traction|Patients assigned to this group will receive the same treatment protocol as those in the Intermittent Mechanical Traction group. However, the knee traction force will be applied continuously for 20 minutes without intermittent force relief periods.
41320017|NCT04493957|BEHAVIORAL|ACCOMPAGNE Education Program|"The following workshops will be organised :~* Presentation workshop~* Cognitive skills workshop~* Perception and Environment workshop~* Responsibilities workshop~* Representation workshop -~* Caregivers workshop,~* Solutions workshop"
41320018|NCT04493957|BEHAVIORAL|Usuals recommandations|Recommendations consist of a description of the cognitive and sensorimotor risk factors specific to the patient for driving and advice for the adaptation of driving or the recommendation of the stopping of driving. It is usually served by oral or written to the patient, with mention in the patient's file of the recommendation and issued in the presence of his close companion.
41320019|NCT03364673|OTHER|Fitness Tracker|Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes
41320020|NCT03364673|OTHER|Social Incentive (Way to Health)|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
41320021|NCT04613505|BEHAVIORAL|Semi-structured interview|Participants will be asked a set of questions as applicable to each phase. Researchers will be able to ask additional questions as they arise within each interview.
41320022|NCT04613505|BEHAVIORAL|Same day consent questionnaire|A questionnaire (yet to be developed) will be administered to participants.
41320023|NCT04907591|DEVICE|mHealth App and wearable device|an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band worn on wrist for 12 months.
41320024|NCT05931055|DIAGNOSTIC_TEST|Fragmentomics|The fragmentation patterns of cfDNA fragments in plasma and the uneven coverage of the genome can indirectly reflect the state of gene expression regulation in vivo. Its characteristics mainly include copy number variation (CNV), Nucleosome footprint, fragment length and motif. Fragomics relies on WGS (Whole Genome Sequencing), and the target covers the whole Genomics level. Thus, the cfDNA Fragmentomics testing can help differentiation and early diagnosis.
41320025|NCT03334396|DRUG|Baricitinib|Administered orally.
41320026|NCT03334396|DRUG|Placebo|Administered orally.
41320027|NCT01768468|DRUG|LAYLA tablet|1 tablet twice a day
41320028|NCT01768468|DRUG|JOINS tablet|1 tablet at each time, 3 times a day
40802299|NCT03910790|DEVICE|19 gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 19 gauge core needle for liver biopsy.
41006124|NCT03570866|PROCEDURE|Surgical treatment|Surgical treatment of early stage intermediate and high-risk endometrial cancer by usual practice: peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic and para-aortic lymphadenectomy.
41320029|NCT01403701|BEHAVIORAL|Physical therapy|pelvic floor physical therapy
40802300|NCT02048644|DRUG|fostair|beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
40802301|NCT02048644|DRUG|placebo|placebo matched inhaler 2puffs to be taken twice a day for 28 days
40802302|NCT01341535|RADIATION|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
41320030|NCT00906867|OTHER|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
40802303|NCT01341535|RADIATION|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
41006125|NCT01485861|DRUG|Abiraterone|Orally once daily
41006126|NCT01485861|DRUG|Apitolisib|Orally once daily
41006127|NCT01485861|DRUG|Ipatasertib|Orally once daily
41320031|NCT00906867|PROCEDURE|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
41320032|NCT06182813|OTHER|Beta auditory beats (Group A)|Beta auditory beats for 25 min and then perform alternate wall toss test.
41320033|NCT06182813|OTHER|white noise (Group B)|Involves participants receiving White noise for 25 min and then perform alternate wall toss test.
41320034|NCT01527019|DRUG|Norfloxacin|Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
41320035|NCT01527019|DRUG|Cephalosporins|Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
41320036|NCT01527019|DRUG|Cephalosporins|Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
41320037|NCT02385877|DRUG|[18F]4F-MHPG|IV injection of \[18F\]4F-MHPG
40802304|NCT02691910|DRUG|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
41320038|NCT02385877|DRUG|[18F]3F-PHPG|IV injection of \[18F\]3F-PHPG
41006128|NCT01485861|DRUG|Placebo|Orally once daily
41006129|NCT01485861|DRUG|Prednisone|Orally bid
41006130|NCT01485861|DRUG|Prednisolone|Orally bid
41006131|NCT02863978|OTHER|Multimodal signal acquisitions|"Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.~Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras."
41006132|NCT01458327|DRUG|Midomafetamine|125 mg MDMA followed by 62.5 mg MDMA 1.5 to 2.5 hours later
41006133|NCT01458327|BEHAVIORAL|Therapy|Non-directive therapy
41006134|NCT00678691|DRUG|armodafinil|50-250mg/d
41006135|NCT00678691|DRUG|placebo|matching placebo
41006136|NCT02107703|DRUG|Abemaciclib|Administered Orally
41006137|NCT02107703|DRUG|Fulvestrant|Administered IM
41006138|NCT02107703|DRUG|Placebo|Administered Orally
41006139|NCT00803127|DEVICE|vs-sense|detection swab
41320039|NCT04578106|BIOLOGICAL|Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination|After 13 weeks of neoadjuvant treatment, a breast MRI will be performed. If a complete response is observed on breast MRI, patients will undergo a stereotactic-guided VAB of the marker area to obtain 12 cylinders of breast parenchyma, which is equivalent to 2 grams of tissue. If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB, patients will be eligible to omit loco-regional surgery.
41476076|NCT04834739|OTHER|6 point Likert Scale|"Job performance was assessed by asking How do you evaluate your job performance? on 6-point Likert scale.A 6 point likert scale forces choice and gives better data.The 6 point Likert scale offers options for ''Excellent, very good, good, fair, poor and very poor''. 6 point scale anges from 1(very poor) to 5 (excellent)."
40802305|NCT02691910|DRUG|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
40802306|NCT04975984|DIAGNOSTIC_TEST|qualitative hCG levels and ultrasound criteria|detect upper limit of qualitative hCG levels associated with successful expectant management of ectopic pregnancy
40802307|NCT02667041|DEVICE|NeuroQore rTMS Device|
40802308|NCT04823286|OTHER|Virtual reality health platform during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis. The game will also aim at providing nutritional advice, and improving psychological wellbeing and cognitive function.
41320040|NCT03467295|PROCEDURE|Surgery|For patient in surgically treated group, surgical removal of intracerebral CMs by craniotomy is performed according to the principles as follows: less transgression of normal brain tissue; identification and protection of eloquent brain tissue; sparing associated developmental venous anomaly; hemosiderin rim resection for non-eloquent and superficial CMs and sparing yellowish tissue for eloquent and deep ones; Extended resections (mesial resection, standard temporal lobe resection) are recommend for epileptogenic CMs based on intra-operative EEG.
41476077|NCT06437106|BEHAVIORAL|A blanket impregnated with the mother's odor|Intervention group 1 consists of premature babies who receive a blanket impregnated with the mother's odor.
41476078|NCT06437106|BEHAVIORAL|blanket without mother's smell|Intervention group two consists of preterm infants who receive blanket without mother's odor.
41320041|NCT03467295|PROCEDURE|Observation|Observation is performed in conservatively treated patients with best medicine and supportive treatment, such as antiepileptic drugs, analgesic drugs and neurotrophic drugs. For patients with underlying diseases such as hypertension, hyperlipidemia or diabetes mellitus, after consulting with the relevant experts, the patients can be treated accordingly.
41320042|NCT00002391|DRUG|Abacavir sulfate|
41476079|NCT06437106|BEHAVIORAL|control group|The control group includes premature babies who are not subjected to any intervention and receive the usual care.
41476080|NCT00068081|DRUG|Capsaicin Dermal Patch|
41476081|NCT03686150|DIETARY_SUPPLEMENT|Vitamin D3 oral regimen|Vitamin D3 oral regimens supplementation
41476082|NCT02457884|OTHER|Temporal Group|Visual Processing Training
41476083|NCT02457884|OTHER|Spatial Group|Spatial visual span training
41476084|NCT02457884|OTHER|Combined Group|Visual processing speed and spatial visual span training
40802309|NCT05456997|PROCEDURE|Muscle biopsy|Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
40802310|NCT02639169|OTHER|Music Therapy|apply live music through the techniques of music therapy
41320043|NCT00002391|DRUG|Lamivudine|
41320044|NCT00002391|DRUG|Zidovudine|
41320045|NCT01529385|DEVICE|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
41320046|NCT01529385|DEVICE|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
41320047|NCT06342323|RADIATION|SBRT|the fiducial marker was implanted with 3D template assistance under CT guidance
41476085|NCT02457884|OTHER|Control Group|Leisure reading activities
40802311|NCT01220401|BEHAVIORAL|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
41476086|NCT00932282|DRUG|Peanut Oral Immunotherapy|Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
40802312|NCT04413916|DIAGNOSTIC_TEST|miRNA expression|Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.
40802313|NCT05422495|BEHAVIORAL|training with Cycléo device (COTTOS ®),|8 weeks of training
40802314|NCT05422495|OTHER|non intervention|non intervention
41006140|NCT04774159|DRUG|Colchicine 0.5 MG Oral Tablet|"Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label."
41006141|NCT04774159|DRUG|Colchicine-Placebo|Colchicine-Placebo tablet
41006142|NCT06316466|OTHER|Lp(a)|The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
41006143|NCT05699070|DRUG|DWC202211 100mg|"DWC202211 for 5 days~Aspirin 100mg"
41476087|NCT00932282|DRUG|Omalizumab|Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
41476088|NCT05289986|DRUG|DELSTRIGO 100Mg-300Mg-300Mg Tablet|"Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~- TDF/3TC/DOR)"
41476089|NCT04092920|DEVICE|laser and SLA|"ligible patients will be randomized to 2 groups control group will receive SLA surface treated implant to replace badly broken tooth immediately after extraction and a study group will receive laser surface treated implant to replace badly broken tooth immediately after extraction.~atraumatic extraction will be performed and socket will be examined for presence of bone dehesince or fenestration if no, implant will be placed immediately and a implant primary stability will be measured using an ISQ unit and recorded as base Line reading .~gingival former will be attached to the implant and removed at 2 ,4,8,12 week intervals to record ISQ readings."
41006144|NCT05699070|DRUG|DWC202212 5mg|"DWC202212 for 3 days~Rabeprazole 5mg"
40802315|NCT01766804|DIETARY_SUPPLEMENT|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
40802316|NCT01766804|DIETARY_SUPPLEMENT|placebo|
40802317|NCT06282237|OTHER|survey|Quality of life survey and motor performace survey
40802318|NCT05003180|PROCEDURE|Surgical stabilization|The surgical stabilization can be either open or minimally invasive. The recommended procedure is posterior fixation with pedicle screws and rods. Both short and long segment fixation are allowed in the study. It is up to the treating surgeon to decide on fusion or decompression. If feasible, pedicle screws are inserted in the fractured vertebra.
40802319|NCT00332384|DRUG|brimonidine/timolol fixed combination|
41476090|NCT05530070|OTHER|Dietary intervention|Patients will participate in a structured, group-based dietary counseling. Consultations will be organized online (Zoom meeting) lasting approximately 60 min/occasion. The intervention will include 6 sessions for 1 year (monthly for 5 months and finally at month 9). The aim of the counseling is to maintain a GFD and to develop a healthy lifestyle, in line with the Mediterranean diet.
40802320|NCT06553118|PROCEDURE|Total knee arthroplasty|Patients already admitted for total knee arthroplasty for knee osteoarthritis will have the procedure as planned
40802321|NCT04479059|OTHER|follicular fluid flushing|Follicular fluid obtained during OPU will be used for endometrial cavity flushing.
40802322|NCT05714449|DEVICE|eye patch|standard amblyopia treatment
40802323|NCT05714449|DEVICE|After-image and MIT trainer|Common clinical training for foveation
40802324|NCT01674049|DIETARY_SUPPLEMENT|Immediate Nutrition|Nutritional supplement consumed either immediately following a 40min resistance exercise bout
40802325|NCT01674049|DIETARY_SUPPLEMENT|Nutrition 3 hours Post-Bout|Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
40802326|NCT01674049|OTHER|Resistance Exercise|A single 40 minute circuit-style bout of resistance exercise
41320048|NCT06339333|BEHAVIORAL|ACT Now GAIN Later|ACT Now GAIN Later is a Psychologist Guided Self Help Parenting Programme. This has been developed by HSE Senior psychologist,. Dr. Michelle Howard to help parents manage challenging behaviors in their children. Parents of children who are referred to HSE Psychology Services with behavioural difficulties are invited to participate in this 7 week programme.
41320049|NCT06339333|OTHER|Control Group|Waitlist Group
41320050|NCT03728504|DRUG|ASN002|Daily dose of ASN002 for 32 weeks
41320051|NCT03728504|DRUG|Placebo Oral Tablet|Daily dose of Placebo Oral Tablet for 16 weeks
41320052|NCT00067613|OTHER|Benchmarking Management Practices|"The Benchmarking intervention included:~1. Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.~2. Training in Continuous Quality Improvement (CQI) Techniques~3. Review of best existing evidence~4. Site visits to the Centers with the Lowest Rates of BPD~5. Selection of Practices to change: Each site team selected practices for modification at their own center"
41320053|NCT00067613|OTHER|Standard Management Practices|Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
41320054|NCT03765983|DRUG|Trastuzumab|"Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system"
41320055|NCT03765983|DRUG|GDC-0084|GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
41320056|NCT00574496|DRUG|cyclophosphamide|
41320057|NCT00574496|DRUG|cyclosporine|
41320058|NCT00574496|DRUG|fludarabine phosphate|
40802327|NCT02924441|OTHER|Lidocaine|Applied to breast skin
40802328|NCT02924441|OTHER|Calming Music|Played during mammography
40802329|NCT02924441|OTHER|No Music|No music played during mammography
40802330|NCT00861172|PROCEDURE|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
41320059|NCT00574496|DRUG|gemcitabine hydrochloride|
41320060|NCT00574496|DRUG|ifosfamide|
41320061|NCT00574496|DRUG|mechlorethamine hydrochloride|
41320062|NCT00574496|DRUG|melphalan|
41320063|NCT00574496|DRUG|methotrexate|
41320064|NCT00574496|DRUG|mycophenolate mofetil|
41320065|NCT00574496|DRUG|prednisone|
41320066|NCT00574496|DRUG|procarbazine hydrochloride|
41320067|NCT00574496|DRUG|vincristine sulfate|
41320068|NCT00574496|DRUG|vinorelbine tartrate|
41320069|NCT00574496|PROCEDURE|allogeneic bone marrow transplantation|
41320070|NCT00574496|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41320071|NCT00574496|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
41320072|NCT00574496|PROCEDURE|peripheral blood stem cell transplantation|
41320073|NCT00574496|PROCEDURE|umbilical cord blood transplantation|
41320074|NCT00574496|RADIATION|total-body irradiation|
41476091|NCT05530070|OTHER|Standard of care|Patients will receive standard of care and baseline dietary education.
41476092|NCT05530070|DIAGNOSTIC_TEST|Cardiovascular risk-related parameters|Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.
40802331|NCT06233162|DRUG|Febuxostat-Test product|Febuxostat 80 mg tablets Manufactured by: Zydus Lifesciences Limited, India
40802332|NCT06233162|DRUG|Febuxostat-Reference product|Febuxostat 80 mg tablets Manufactured by: Patheon France, France
40802333|NCT00990431|PROCEDURE|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
41006145|NCT05699070|DRUG|DWC202211 100mg + DWC202212 5mg|"DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg"
41006146|NCT04670991|RADIATION|EXATRAC imaging|Exatrac imaging performed before the standard CBCT imaging prior to each chemotherapy session
41006147|NCT06225089|DRUG|pericapsuler nerve block|-Ultrasound Guided pericapsuler nerve block: will be externally rotated and abducted to 45 degrees. The shoulder area will be sterilized with povidone-iodine. High-frequency linear ultrasound perpendicularly between the coracoid and the humeral head probe. The deltoid muscle, subscapular muscle and tendon, and humeral head will be identified on the ultrasound screen. With the in-plane technique, a 22 gauge, 50 millimeter (mm) simplex A peripheral nerve block needle will be used. After passing the deltoid muscle, the needle will contact the tendon of the subscapularis muscle. The needle will be slightly withdrawn and directed between the deltoid muscle and the tendon of the subscapularis muscle and a local injection consisting of will be applied.
41006148|NCT03878134|DEVICE|PHOTON COUNTING CT Scanner|Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.
41006149|NCT01800903|DEVICE|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
41006150|NCT01800903|DEVICE|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
41006151|NCT01800903|DEVICE|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
41006152|NCT00024089|DRUG|gefitinib|
41006153|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
41006154|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
41006155|NCT02310542|DEVICE|MARS albumin dialysis system|
41006156|NCT02310542|DEVICE|SPAD albumin dialysis system|
41006157|NCT01495481|DRUG|Dexmedetomidine|Dexmedetomidine 2 mcg/kg, Intravenous push
41006158|NCT01495481|DRUG|Adenosine|Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
41476093|NCT01526460|DRUG|Atorvastatin|80 mg
41320075|NCT05138874|BEHAVIORAL|Trending Feedback|Clinicians randomized to Trending Feedback will receive monthly feedback on the provider dashboard page.
41006159|NCT00556842|DEVICE|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
41006160|NCT00556842|DEVICE|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
41006161|NCT03055000|BIOLOGICAL|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
41320076|NCT05138874|BEHAVIORAL|Benchmark Peer Comparison Feedback|Clinicians randomized to Benchmark Peer Comparison Feedback will receive monthly feedback on the provider dashboard page.
41320077|NCT05138874|BEHAVIORAL|Private Commitment|Clinicians assigned to the Private Commitment will be prompted in the provider dashboard to make a personal commitment to evidence-based use of antibiotics that will not be shared with their patients.
41476094|NCT01526460|DRUG|Rosuvastatin|40 mg
41476095|NCT01526460|DRUG|Placebo|no statin loading dose
40802334|NCT00990431|PROCEDURE|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
41006162|NCT03055000|BIOLOGICAL|AGS-v + adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
41006163|NCT03055000|OTHER|Placebo|WFI (0.5mL) on Day 0 and Day 21
41006164|NCT05854875|PROCEDURE|Laparoscopic Roux en Y gastric bypass|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb.
41320078|NCT05138874|BEHAVIORAL|Public Commitment|Clinicians assigned to Public Commitment will be prompted in the provider dashboard to make a commitment to evidence-based use of antibiotics that will be shared with their patients.
40802335|NCT01262638|DRUG|ETC-1002|ETC-1002 daily for 12 weeks
40802336|NCT01262638|DRUG|Placebo|Placebo daily for 12 weeks
40802337|NCT04597216|DEVICE|sample of blood and saliva|sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
40802338|NCT01241188|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
40802339|NCT01241188|BIOLOGICAL|2 TU Tuberculin PPD RT 23 SSI|The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
40802340|NCT00520702|PROCEDURE|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
41476096|NCT04421092|PROCEDURE|Superior laryngeal nerve block|Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.
41476097|NCT04421092|PROCEDURE|Injection of placebo (saline)|Superior laryngeal nerve block using 1mL of saline as the injection.
41476098|NCT04421092|PROCEDURE|Injection of steroid-lidocaine mixture|Superior laryngeal nerve block using 1mg 1:1 triamcinolone 40mg: 1% lidocaine with 1:200000 epinephrine as the injection.
41476099|NCT01332786|DRUG|Tigecycline|"Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~* Level 1: 50 mg daily x 10 doses; 1 week rest~* Level 2: 100 mg daily x 10 doses; 1 week rest~* Level 3: 150 mg daily x 10 doses; 1 week rest~* Level 4: 200 mg daily x 10 doses 1 week rest~* Level 5: 250 mg daily x 10 doses; 1 week rest~* Level 6: 300 mg daily x 10 doses; 1 week rest~* Level 7: 350 mg daily x 10 doses; 1 week rest"
41476100|NCT03512184|BEHAVIORAL|YMCA class|The Gastroenterologists of Weill Cornell Medical College that are associated with this trial want to implement the YMCA's DPP in the NAFLD population as a structured lifestyle modification/educational intervention. The hypothesis is that the NAFLD patients who complete the YMCA's DPP will also have weight loss and improvement in hepatic steatosis. Importantly, positive results in this New York City-based pilot study would provide a strong rationale for determining whether such a program could be useful to treat NAFLD at established YMCA DPP sites across the country.
40802341|NCT00520702|PROCEDURE|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
40802342|NCT00956137|PROCEDURE|Ultrasound guidance|ultrasound imaging
40802343|NCT00956137|PROCEDURE|Manual palpation|Manual Palpation of vertebra
40802344|NCT03813758|DIAGNOSTIC_TEST|wrinkle test|soaking in 40 deg water for 40 min. every 10 min the hand will be photo
40802345|NCT04507048|OTHER|Active educational intervention|an active educational intervention will be provided in the experimental arm, consisting in the administration of a booklet (passive intervention) + an oral standardized explanation of the booklet given by a trained dermatologist for each center.
40802346|NCT04507048|OTHER|Passive educational intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
40802347|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knotless suture-bridge technique|"A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff."
40802348|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knot-tying suture-bridge technique|After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
40802349|NCT06554977|OTHER|Laboratory|CBC Kidney function (Urea, creatine) Platelets to albumin ratio Albumin /creatine ratio CRP Urine analysis Abdominal us Kidney function , CBC , Albumin will be done at the time of admission i
41006165|NCT05854875|PROCEDURE|Laparoscopic Roux en Y gastric bypass with fundus resection|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb. Fundus resection is further applied in this arm.
41006166|NCT05446350|PROCEDURE|transcranial alternating current stimulation (tACS)|transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception
41006167|NCT05446350|PROCEDURE|electroencephalography (EEG)|analyse rhythmic electroencephalography responses that outlast the stimulation
41006168|NCT05446350|PROCEDURE|brain imaging (fMRI)|Using brain imaging (fMRI) to predict optimal stimulation protocols for individual participants
41006169|NCT05446350|PROCEDURE|electroencephalography (EEG) with neurofeedback|Using neurofeedback to teach participants to enhance their own neural entrainment
41006170|NCT06031259|DRUG|Idursulfase-IT|Idursulfase-IT intrathecally via IDDD.
41006171|NCT06031259|DRUG|Elaprase|Elaprase IV infusion.
41006172|NCT00749775|DRUG|Selara|Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
41006173|NCT03541746|BIOLOGICAL|Platelet Rich Plasma|After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.
41006174|NCT03541746|DEVICE|Intrauterine Foley's Catheter|After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
41476101|NCT02808208|BIOLOGICAL|Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)|A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period.
41476102|NCT02808208|DRUG|Placebo|5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.
40802350|NCT04234009|OTHER|Healthy Lifestyle|"The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle."
40802351|NCT00192764|DRUG|high-dose cyclophosphamide|
40802352|NCT02781129|OTHER|electrical stimulation|Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
40802353|NCT05633836|PROCEDURE|Fluorescence guided surgery|During exploratory laparoscopy or at the end of macroscopically complete cytoreduction surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
41006175|NCT04655911|BIOLOGICAL|ABO-101|Gene therapy rAAV9.CMV.hNAGLU
41320079|NCT02451202|PROCEDURE|Deep Neuromuscular Blockade|"* During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).~* At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2."
41320080|NCT02451202|PROCEDURE|Moderate Neuromuscular Blockade|- During maintenance phase, if recovery at the presence of \<10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
41320081|NCT02451202|DRUG|Sugammadex|
41320082|NCT02451202|DRUG|Rocuronium|
41320083|NCT04246112|OTHER|Handwriting intervention|children will practice handwriting 5 days p/week, 15-20 minutes p/day for 12 weeks using the movalyzer software program.
41320084|NCT00002392|DRUG|Thalidomide|
41320085|NCT05424887|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
41320086|NCT05424887|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
41320087|NCT00694629|DRUG|rifampin|tablet, 10 mg/kg, daily, 8 weeks
41320088|NCT00694629|DRUG|rifapentine|tablet, 10 mg/kg, daily, 8 weeks
41320089|NCT00694629|DRUG|rifapentine|tablet, 15 mg/kg, daily, 8 weeks
41320090|NCT00694629|DRUG|rifapentine|20 mg/kg, daily, 8 weeks
41320091|NCT00004799|BIOLOGICAL|whole-cell pertussis vaccine|
41320092|NCT00004799|BIOLOGICAL|diphtheria-tetanus vaccine|
41320093|NCT03409029|DIAGNOSTIC_TEST|MRI Scan|Additional imaging using MRI scan
41320094|NCT04091334|DEVICE|Focused ultrasound of the lungs (FLUS) and focused cardiac ultrasound (FoCUS)|"FLUS: Scanning 8 zones of the front and lateral of the thorax. Record number of B-lines, consolidations, pneumothorax, pleural effusions.~FoCUS: Scan the heart in different views and record the ejection fraction, size of the right side of the heart, pericardial effusion, tricuspid annular plane systolic excursion (TAPSE), inferior vena cava (IVC) diameter, and IVC collapsibility Index (IVC-CI)."
41320095|NCT04091334|OTHER|Standard care|Standard care and evaluation and monitoring
41476103|NCT02808208|BIOLOGICAL|Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)|Two topical applications of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period at stage one and two of fistula surgery
41476104|NCT05122221|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
41006176|NCT06009952|OTHER|Cryolipolysis and cavitation devices with vegan diet|"Cryolipolysis: In all cases of group A, (OPTIMIZED CRYOLIPOLYSIS 360 DEVICE, model: AF2000-02, made in china) uses a vacuum-based huge applicator (Cool Max) and vacuum medium applicators (either CoolCore or Cool- Curveþ) for the abdomen (30 minutes session twice monthly for three successive3 months).~•Cavitation: in all cases of group B, (CAVITATION DEVICE, Item No.:AU61, Made in china) of 45 KHz frequency (30 min twice weekly for three successive3 months)."
41006177|NCT05828277|DRUG|repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
41320096|NCT02943265|OTHER|Care Coordination Strategies|Co-located Care coordinator will use EMR-driven registry to facilitate patient transitions between primary care and oncology care and enhance teamwork through coaching and technical assistance.
41320097|NCT04199793|DEVICE|Lavare On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
41320098|NCT04199793|DEVICE|Lavare Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
41320099|NCT04623502|OTHER|13C-Glucose|Patients in the 13C-glucose arm will receive an infusion of a 13C-glucose solution. In most cases, the glucose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
41320100|NCT04623502|OTHER|13C-Acetate|Patients in the 13C-acetate arm will receive an infusion of a 13C-acetate solution. In most cases, the acetate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
41320101|NCT04623502|OTHER|13C-Lactate|Patients in the 13C-lactate arm will receive an infusion of a 13C-lactate solution. In most cases, the lactate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
40802354|NCT04154423|OTHER|Glow! Group Prenatal Care|Glow! is an enhanced group prenatal care model that offers co-located social services provided by established community programs with independent funding streams targeting low-income families. The Glow! group prenatal care model pairs a trained facilitator with a licensed prenatal care practitioner from a practice site to provide billable prenatal care to the practice's own patients. Over the course of 8-10 sessions, 10-12 women (within a 6- week gestational age range) receive prenatal medical care, risk assessments, and social support, and gain knowledge and skills related to pregnancy, birth, and parenting.
40802355|NCT04154423|OTHER|Individual Prenatal Care with CPSP|Comprehensive Perinatal Services Program (CPSP) is a state-funded program for Medi-Cal eligible families to receive enhanced care and service coordination. Participants assigned to CPSP individual care may participate in the CPSP assessments with a Comprehensive Perinatal Health Worker at their prenatal care site, where individual prenatal care will be provided
40802356|NCT00321243|BEHAVIORAL|Visual clues|
40802357|NCT01301053|OTHER|Current UVA intensive care insulin protocol|Current UVA intensive care insulin protocol used for insulin management for 12 hours
40802358|NCT01301053|OTHER|"Current UVA intensive care insulin protocol with brakes"|"Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose \<70 mg/dl)and severe hypoglycemia (blood glucose\<50 mg/dl)."
40802359|NCT02455336|DRUG|Fenofibrate|Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
40802360|NCT02455336|OTHER|No intervention|A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
40802361|NCT02396108|DRUG|Paclitaxel + Carboplatin + ASLAN001|"Phase I~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~* PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~* PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks"
40802362|NCT01808638|DRUG|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
40802363|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 1|"Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
40802364|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 2|"Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
40802365|NCT02841579|DRUG|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
40802366|NCT01712997|DRUG|Iloprost|
41320102|NCT04623502|OTHER|13C-Glutamine|Patients in the 13C-glutamine arm will receive an infusion of a 13C-glutamine solution. In most cases, the glutamine infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
40802367|NCT01712997|DRUG|Bosentan|
41006178|NCT02187328|OTHER|Grapefruit juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
40802369|NCT05711875|OTHER|Virtual Reality (VR) glasses|During the Non Stress Test (NST), the pregnant women in the experimental group watched a video of nature scenery with Virtual Reality (VR) glasses for 10 minutes
40802370|NCT01447342|DEVICE|Cryo-Touch II|Percutaneous treatment with the device
40802371|NCT01905943|DRUG|Bendamustine|Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
40802372|NCT01905943|DRUG|Chlorambucil|Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
40802373|NCT01905943|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
40802374|NCT01905943|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.
40802375|NCT01905943|DRUG|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
40802376|NCT00496977|PROCEDURE|annual CT screening|
40802377|NCT04002583|DIAGNOSTIC_TEST|Computer assisted ambulatory electroencephalogram|A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
41006179|NCT02187328|OTHER|Apple juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
41006180|NCT04420702|DEVICE|MRI with DBSI analysis|-The procedure will take approximately 1 hour of the participant's time
41006181|NCT00569686|DRUG|lovaza|lovaza 4 gm po daily
40802378|NCT06072144|OTHER|Validity and reliability study|Test-retest method will be used to assess reliability. For this purpose, participants will be re-evaluated one week later with the Smart Speed device. For validity assessment, concurrent validity and agreement between measurements will be evaluated. Concurrent validity will be assessed by correlation analysis and agreement between measurements will be assessed by Bland Altman.
40802379|NCT01140867|DRUG|zonisamide|zonisamide 100 mg tablet
40802380|NCT05672641|OTHER|Inertial training|Inertial training group performed their training three times a week (Monday, Wednesday, and Friday) between between 7:00 a.m. and 8:30 a.m. for 6 weeks. Participants performed inertial training using Cyklotren (Inerion, Poland). Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
41006182|NCT00569686|DRUG|placebo|placebo
41006183|NCT04437394|DIAGNOSTIC_TEST|flexible endoscopic evaluation of swallowing|The patients were assessment with flexible endoscopic swallowing evaluation was performed with colored pudding.
41320103|NCT04623502|OTHER|13C-Fructose|Patients in the 13C-fructose arm will receive an infusion of a 13C-fructose solution. In most cases, the fructose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
41320104|NCT01091909|PROCEDURE|Dental extractions|All dental extractions were performed at an outpatient clinic at the USP Dental School. In addition, all extractions were performed under local anesthesia by the same experienced dentist, in accordance with the standards established by Peterson et al (2008).
41320105|NCT01978158|DRUG|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects
41320106|NCT00981318|DRUG|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
41320107|NCT04523064|DRUG|Empagliflozin 25 MG|Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.
41320108|NCT03591094|DRUG|PTI-428|Active
41320109|NCT03591094|DRUG|Placebo|Placebo
41320110|NCT05399849|BEHAVIORAL|Mindfulness Exercises and Meditations|Mindfulness exercises will be completed independently using the LoveYourBrain Foundation Meditation Library, a free, online resource containing traumatic brain injury-focused mindfulness-focused exercises and meditations. Mindfulness-based exercises and meditations to be completed will be chosen by study personnel based on tools utilized in mindfulness-based stress reduction programs that are provided on the LoveYourBrain Meditation Library. Specific mindfulness-based exercises and meditations will include body scan, acceptance, awareness, and breathing.
41320111|NCT02490917|DEVICE|ACT™ device|Implantation of the Adjustable Continence Therapy device ACT®
41476105|NCT05122221|DRUG|Interleukin-2|Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.
41476106|NCT05122221|BIOLOGICAL|CRTE7A2-01 TCR-T Cell|On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.
41476107|NCT01138826|DRUG|Amlodipine - reference|10 mg tablet, single dose, with water
41006184|NCT04437394|DIAGNOSTIC_TEST|The analysis of voice|Voice recordings were taken from the patients to evaluate the voice disturbance and acoustic evaluation was taken with PRAAT program.
41006185|NCT04063033|DRUG|IV iron - Sodium Ferric Gluconate Complex|IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
41006186|NCT05047991|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
41006187|NCT05047991|DRUG|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
41006188|NCT05047991|DRUG|Leucovorin|Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
41006189|NCT05047991|DRUG|Oxaliplatin|Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
41006190|NCT05047991|DRUG|Nab paclitaxel|Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
41006191|NCT05047991|DRUG|Gemcitabine|Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
41006192|NCT00001839|DRUG|Antithymocyte globulin|
41006193|NCT00001839|DRUG|Cyclosporine|
41006194|NCT04912921|DIETARY_SUPPLEMENT|palmitoylethanolamide|4 tablets taken daily (2 in the am and 2 in the pm)
41006195|NCT04912921|DIETARY_SUPPLEMENT|Placebo|4 tablets taken daily (2 in am and 2 in pm)
41006196|NCT04912921|DIETARY_SUPPLEMENT|Curcumin|500 mg HydroCurc® twice a day
41006197|NCT04912921|DIETARY_SUPPLEMENT|Control (microcrystalline cellulose)|2 tablets taken daily
41320112|NCT02490917|DEVICE|AMS 800 ™ device|Implantation of the artificial urinary sphincter AMS 800 ™
41320113|NCT01763866|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
41320114|NCT01763866|DRUG|Ezetimibe|Administered orally once a day
41320115|NCT01763866|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
41320116|NCT01763866|DRUG|Placebo to Ezetimibe|Administered orally once a day
41320117|NCT01763866|DRUG|Atorvastatin|Administered orally once a day
41320118|NCT01763866|DRUG|Rosuvastatin|Administered orally once a day
41320119|NCT01763866|DRUG|Simvastatin|Administered orally once a day
41320120|NCT06386172|OTHER|Clinical decision support trigger|Investigation of CDS-triggers effect on primary care physicians detection and management of chronic kidney disease
41476108|NCT01138826|DRUG|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, with water
41476109|NCT01138826|DRUG|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, without water
41476110|NCT04415008|DRUG|HAD induction with intermediate dose cytarabine|daunorubicin,cytarabine,homoharringtonine
41320121|NCT03419221|PROCEDURE|PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions|"Open-label randomized controlled superiority trial in patients with SAB without infective endocarditis at the time of inclusion comparing whole-body PET/CT in arm A and routine care with performance of imaging studies according to anamnesis and clinical symptoms in arm B. To demonstrate that PET/CT is associated with a 20% higher frequency of detection of DFI during SAB, the inclusion of 145 patients in each arm is required.~Randomization will be stratified on centre and SAB setting of acquisition (healthcare vs community)."
41320122|NCT03419221|OTHER|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
41320123|NCT05904184|DRUG|Epoxy resin-based sealers (ERS)|All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Epoxy resin-based sealers.
41320124|NCT05904184|DRUG|Calcium silicate-based sealers (CSS)|All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Calcium silicate-based sealers.
41320125|NCT04291872|OTHER|Glass -Ionomer Cement with /without Led Light Cure|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
41320126|NCT04457128|BEHAVIORAL|Just-in-Time Adaptive Intervention|Randomized factorial design
41320127|NCT01840228|DRUG|Micronized progesterone suppository|
41320128|NCT01753388|DEVICE|Liberty Stent|
41320129|NCT05677191|DEVICE|Proximal Femoral Nail|open reduction
41320130|NCT05677191|COMBINATION_PRODUCT|Dual Mobility Arthroplasty|Hip Arthroplasty Surgery
41320131|NCT03076866|OTHER|observational follow-up:clinical, radiological et biological|
41320132|NCT02374034|OTHER|Corrective exercise|Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
41320133|NCT01673191|DRUG|Dexamethasone intravitreal implant|
41320134|NCT01673191|DRUG|Steroid plus NSAID eye drop combination therapy|
41320135|NCT04639401|OTHER|motor entrainment to auditory cues and music during walking on quality of movement|The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
41320136|NCT01214941|DRUG|Placebo|The subjects will be given orally placebo twice a day for 5 days prior to the study.
41320137|NCT01214941|DRUG|Ticlopidine|The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
41320138|NCT01214941|DRUG|Ticlopidine and itraconazole|The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
41320139|NCT03402152|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
41320140|NCT03402152|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
41320141|NCT03402152|DRUG|Placebo|Placebo oral capsule
41320142|NCT02317341|DRUG|Ketamine|Single intravenous dose
41320143|NCT02317341|DRUG|Placebo (saline)|Given intravenously over 40 minutes
41320144|NCT02317341|DRUG|Ketamine|Single intravenous dose given over 40 minutes
41320145|NCT02317341|DRUG|Midazolam|Given intravenously over 40 minutes
41320146|NCT02317341|DRUG|Midazolam(placebo)|Given intravenously over 40 minutes
41320147|NCT01274455|GENETIC|Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes|Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
41320148|NCT02178293|DRUG|Benzidamine hydrochloride|
41320149|NCT02178293|DRUG|Ketoprofen lysine salt|
41320150|NCT00186654|PROCEDURE|Acupuncture|
41320151|NCT00186654|PROCEDURE|Perinatal massage|
41320152|NCT04826458|DEVICE|TreC-Onco|"At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission."
41320153|NCT04826458|OTHER|Paper diary|Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
41320154|NCT01213069|OTHER|Questionnaires|The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
41476111|NCT00969124|DEVICE|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
41476112|NCT04252482|DEVICE|CPAP|CPAP useg 3month
41476113|NCT00767520|DRUG|Exemestane + Dasatinib|Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
41476114|NCT00767520|DRUG|Exemestane + Placebo|Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
41476115|NCT06142149|PROCEDURE|ultrasonographic evaluation|Screen the front of neck using ultrasound
41476116|NCT00003020|BIOLOGICAL|LMB-7 immunotoxin|
41476117|NCT02331238|BEHAVIORAL|"Coaching Boys into Men program"|"Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
41476118|NCT01946984|PROCEDURE|ERCP|endoscopy, retrograde cholangio-pancreaticography.
41476119|NCT01946984|DRUG|Diclofenac hydroxyethylpyrrolidine|
41476120|NCT01946984|DRUG|Normal Saline|
41476121|NCT00389779|DRUG|Darusentan|Darusentan capsules administered orally once daily
41476122|NCT00389779|DRUG|Guanfacine|Guanfacine capsules administered orally once daily
41476123|NCT00389779|DRUG|Darusentan Placebo|Placebo to match darusentan administered orally once daily
41476124|NCT05715814|DRUG|Empagliflozin 25 MG|PO once daily
41476125|NCT05424614|OTHER|Functional outcome follow-up of patients|Patients were followed up by telephone after discharge, every 4 weeks, until the end of the 3-month follow-up. Their functional status was determined based on the MRS score (modified Rankin Scale). Those with less than 3 points were defined as having a good prognosis, and those with more than 3 points were defined as having a poor prognosis
41476126|NCT05414084|DIETARY_SUPPLEMENT|Oral (poly)phenol challenge test (OPCT)|Nutritional challenge with standardized (poly)phenol-rich tablets
41476127|NCT00560027|OTHER|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
41476128|NCT06446310|DRUG|QLG2198|Participants receive QLG2198 three times a week (0,5 micrograms/kg dry body weight). QLG21988 is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
41476129|NCT06446310|DRUG|Placebo|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis
41006198|NCT04174313|DIAGNOSTIC_TEST|CT scan|"Mechanical variables and PaO2/FiO2 were registered daily for 14 days or until initiating assisted ventilation. These data were obtained in passive mechanical conditions.~Ventilator-induced lung injury vortex was defined as a progressive increase in driving pressure (ΔP) as Vt remained constant or even decreased.~Refractory hypoxemia was defined as PaO2/FiO2 \<100 despite the optimization of mechanical ventilation and prone positioning."
41006199|NCT05691426|DIAGNOSTIC_TEST|Assessment of pulse wave amplitude (PWA)|Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)
41320155|NCT03603834|DRUG|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours~2. Leucovorin, 400 mg/m2, IV over 2 hours~3. Irinotecan, 150 mg/m2, IV over 90 minutes~4. 5 FU, 400 mg/m2, IV bolus~5. 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
41320156|NCT02397603|DRUG|dexmedetomidine bupivacaine|perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block
41320157|NCT02397603|DRUG|Bupivacaine saline|perineural bupivacaine saline mixture in the thoracic paravertebral catheter
41476130|NCT02851719|OTHER|PFMT with biofeedback + Home PFMT|24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
41320158|NCT01737658|OTHER|Exercise Program|Exercise Program for Obese Adolescents
41476131|NCT02851719|OTHER|PFMT without biofeedback + Home PFMT|24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
41476132|NCT06429514|DIETARY_SUPPLEMENT|Ganoderma lucidum spore powder|One bag at a time, 2 times a day, 2g / bag
41476133|NCT06429514|OTHER|placebo|One bag at a time, 2 times a day, 2g / bag
41476134|NCT04588688|DRUG|Mifepristone|Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.
41476135|NCT03715322|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
41476136|NCT03715322|OTHER|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
41476137|NCT03715322|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
41476138|NCT00920088|DRUG|darunavir/ritonavir|DRV/RTV 600/100mg
41476139|NCT00920088|DRUG|lopinavir/ritonavir|LPV/RTV 400/100mg
41476140|NCT00920088|DRUG|Midazolam|Midazolam 3mg
41320159|NCT00961922|OTHER|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
41320160|NCT00961922|OTHER|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
41476141|NCT00920088|DRUG|Dextromethorphan|Dextromethorphan 30mg
41476142|NCT00920088|DRUG|Flurbiprofen|Flurbiprofen 50mg
41476143|NCT00920088|DRUG|GSK2248761|NNRTI under investigation
41476144|NCT03104348|DIAGNOSTIC_TEST|COPD screening|Self-questionnaire with 5 questions Fagerström's test Spirometry
41476145|NCT02324673|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
41476146|NCT06453460|DRUG|Letermovir|Subjects will receive 14 weeks of letermovir prophylaxis at standard recommended dose follow by CMV-TCIP-directed extended prophylaxis.
41476147|NCT06453460|DEVICE|CMV T Cell Immunity Panel (CMV-TCIP)|Viracor CMV-TCIP assay to measure how a person's immune system responds to CMV. Viracor CMV-TCIP will be measured monthly, starting at week 14, until positive, then at week 30 and 52.
41476148|NCT06453460|DIAGNOSTIC_TEST|CMV DNA PCR|Plasma level of CMV DNA PCR will be measured at enrollment and at least weekly through week 30, then at least every 2 weeks through week 52 of transplant if no GVHD or CMV reactivation.
41476149|NCT03574311|DRUG|Ferric carboxymaltose|A single dose of drug or placebo is administered preoperatively to participants
41476150|NCT03574311|OTHER|Physiological saline|Single infusion 100 ml physiological saline infusion preoperatively
41476151|NCT02524184|DRUG|sildenafil|sildenafil 100 mg per day for 7 days.
41320161|NCT03036449|BEHAVIORAL|Education program for NICU caregivers.|"Intervention includes a main initial educational program, maintenance education programs and tools supply~- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation.....~* Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~* Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists..."
41476152|NCT02524184|DRUG|placebo|an identical placebo per day for 7 days
41476153|NCT04953078|BIOLOGICAL|Baiya SARS-CoV-2 Vax 1|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
41476154|NCT04171024|DEVICE|Sham electrical stimulation|A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes
41476155|NCT04171024|DEVICE|Transcutaneous diaphragm electrical stimulation|A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
41476156|NCT04713514|DRUG|OSE2101|subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
41476157|NCT04713514|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
41320162|NCT00243113|DRUG|docetaxel|
41476158|NCT04216615|BEHAVIORAL|preoperative anxiety|patients who are anxious
41476159|NCT04079491|OTHER|questionnaire survey|A web-based questionnaire will be send by the trade union for dental hygienists
41476160|NCT00270933|DEVICE|Registry|
41476161|NCT00000334|DRUG|Buprenorphine|
41476162|NCT05467046|DEVICE|Smartwatch system|The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.
41476163|NCT01430819|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|0.5 mL, Intramuscular
41476164|NCT01430819|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation|0.5 mL, Intramuscular
41476165|NCT06205706|DRUG|BI-1910|BI-1910 administered as a flat-dose IV infusion once every 3 weeks
41476166|NCT06205706|DRUG|Pembrolizumab|Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion
41476167|NCT02291692|PROCEDURE|paravertebral blockade|ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
41476168|NCT00266240|DRUG|GK Activator (2)|Escalating doses po bid
41476169|NCT00266240|DRUG|Placebo|po bid
41320163|NCT00243113|RADIATION|radiation therapy|
41320164|NCT01530516|DEVICE|Brackets plus Forsus springs|Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
41320165|NCT01530516|DEVICE|Xbow plus full brackets|Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
41476170|NCT01407224|BEHAVIORAL|Improve Early Breastfeeding|One arm got only training, another arm training and supervision and third arm without any intervention as control.
41476171|NCT03432065|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
41476172|NCT06615739|DEVICE|Regenerex Tissue Attachment Augments|Patient will have been previously implanted with Regenerex Tissue Attachment Augments in combination with the Comprehensive Segmental Revision System
41476173|NCT06078813|RADIATION|Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)|Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume_1 (PTV_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV_2 will remain the same through all dose levels. All doses are prescribed to the target volume.
41476174|NCT06290219|COMBINATION_PRODUCT|platelet-rich plasma combined with hyaluronic acid|The project investigator injects plasma mixed with hyaluronic acid into the nasal septum and the medial side of the middle turbinate of the patient's nasal cavity under a nasal endoscope.
41476175|NCT06290219|DRUG|Zinc Gluconate 10 MG Oral Tablet|one tablet three times a day for a period of 12 weeks
41476176|NCT06290219|DEVICE|4 bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove oil|Sniffing each odorant for 10 seconds, twice a day for 12 weeks
41320166|NCT05497895|BIOLOGICAL|5% thymoquinone (TQ) gel|Mode of Administration In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performing the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application.
40802381|NCT05672641|OTHER|Body building training|Body building group performed body building training three times a week (Monday, Wednesday, and Friday) between 7:00 a.m. and 8:30 a.m. for 6 weeks using free weights. Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
41320167|NCT05497895|BIOLOGICAL|SRP and placebo|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
41320168|NCT05497895|PROCEDURE|Only SRP-one stage prophylaxis|The Group III patients will be subjected to one-stage oral prophylaxis.
41476177|NCT02010294|GENETIC|DNA samples, GAS strains|DNA samples,GAS strains
41476178|NCT06442059|OTHER|Kinesiophobia Level Due to Dyspnea|Kinesiophobia Level Due to Dyspnea
41476179|NCT05396664|BEHAVIORAL|ATWA|The Adolescent Transition in West Africa (ATWA) program is an in-school (Niger, Mali, Burkina Faso) and out-of-school (Niger and Mali) educational intervention implemented by local staff members at Save the Children, local community members, and teachers. ATWA provides internationally-recognized life skills education (LSE) to adolescents ages 10-19 years, and seeks to improve adolescents' knowledge and behaviors regarding sexual and reproductive health and rights. Outcome indicators to assess knowledge, behavior and attitudes of adolescents will vary by adolescent demographics as well as by country context, as based on the final set of curriculum deemed appropriate by the respective Ministries of Education (MOE).
41476180|NCT03823235|OTHER|Human embryo culture|humidifed or dry incubator
41476181|NCT02709486|DRUG|Tanezumab|2.5 mg
41476182|NCT02709486|DRUG|Tanezumab|5 mg
41476183|NCT02709486|DRUG|Placebo|Placebo
41476184|NCT04070339|OTHER|transfontanelle ultrasound|cerebral blood flow investigation using transfontanelle ultrasound
41476185|NCT05357859|DIETARY_SUPPLEMENT|solubilized vitamin D3|solubilized vitamin D3
41476186|NCT05357859|DIETARY_SUPPLEMENT|medium chain triglyceride|MCT with same amount
41476187|NCT02264093|DRUG|Propranolol|
41476188|NCT02264093|DRUG|Talsaclidine|
41476189|NCT06200428|OTHER|sleep support pillow|A sleep support pillow will be used in this study.
41476190|NCT02941510|DRUG|Budesonide|Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
41476191|NCT02941510|OTHER|Placebo|Subject(s) will participate in all study activities but will receive placebo.
41476192|NCT02580084|PROCEDURE|Hybrid Intervention|"The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims."
41476193|NCT02580084|PROCEDURE|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
40802382|NCT03530995|DRUG|Belumosudil|Development candidate
41006200|NCT05691426|DIAGNOSTIC_TEST|Salivary Nitric Oxide|assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,
41006201|NCT05523973|OTHER|Lingual Endurance Exercise|Participants will participate in 3 training sessions per day for 8 weeks. Group 1 will complete 3 sessions of lingual endurance exercise. For example, if the participant completed 100 repetitions during the baseline measurement, they would complete 75 repetitions during their exercise session.
41476194|NCT04507035|DRUG|Anlotinib hydrochloride capsules|Using anlotinib of 2 cycles as the first-line therapy.
41006202|NCT05523973|OTHER|Lingual Endurance + Transference Exercise|"Group 2 will complete lingual endurance exercise for 2 sessions, and for the 3rd training session participants will complete 30 swallows where they are instructed to press their tongue hard on the bulb and swallow their saliva. The TongueometerTM will provide biofeedback on performance and will be instructed to generate more pressure during this effortful swallow than during a natural, saliva swallow."
41006203|NCT00972803|DRUG|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
41006204|NCT00972803|DRUG|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
40802383|NCT03530995|DRUG|Itraconazole|Perpetrator drug
40802384|NCT03530995|DRUG|Rabeprazole|Perpetrator drug
40802385|NCT03530995|DRUG|Rifampicin|Perpetrator drug
41006205|NCT00972803|DRUG|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
41006206|NCT03837262|COMBINATION_PRODUCT|Flash Glucose Monitoring and structured education|A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
41006210|NCT03826758|OTHER|E-DYNAMIC Clinical Decision Support|Clinical decision support system
41006211|NCT00280254|PROCEDURE|Hemodynamically Oriented Echocardiography-based Strategy|
41006212|NCT05817929|OTHER|blood sample|5 ml blood sample will be withdrawn at the surgery start and at the surgery end
41006213|NCT04001153|OTHER|Dental impressions|"Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state."
41006214|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI|
41006215|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI|
41006216|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
40802386|NCT03530995|DRUG|Omeprazole|Perpetrator drug
40802387|NCT05026840|PROCEDURE|GDM screening criteria|difference in risk factors and clinical outcomes between groups
40802388|NCT00289289|DEVICE|Intervention Pacing Features|Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
40802389|NCT00073411|DRUG|duloxetine|
40802390|NCT00073411|DRUG|escitalopram|
40802391|NCT00073411|DRUG|placebo|
40802392|NCT06053138|DIETARY_SUPPLEMENT|Ketone monoester|Supraphysiological levels of ketosis acutely, part 1, and intermittently and longer lasting, part 2, as obtained by ingestion of a ketone monoester dietary supplement
41006217|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
41006218|NCT02359292|DRUG|Placebo pMDI|
41006219|NCT05598229|OTHER|Tik Tok|Encourage and do not restrict watching Tik Tok
41006220|NCT04838366|DIETARY_SUPPLEMENT|Carbohydrate loading|study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). Surgical patients will be asked to drink a beverage containing 100 grams carbohydrate the night before surgery. On the day of surgery, patients will drink a beverage containing 50 grams carbohydrate 2 hours before surgery under the supervision of research team member. We will provide glucose-D (Dabur Nepal Private Limited, Bara, Nepal, (Regd No.: 3506/045/046, DFTQC No.: 01-33-55-03-218).
41006221|NCT01437228|DRUG|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
41006222|NCT01437228|DRUG|placebo|NO İNTERVENTİON
41006223|NCT04702373|OTHER|passive range of motion exercise therapy|Systematic flexion-extension with gentle compression at the end of the movement is performed 10 times at the wrist, elbow, shoulder, ankle, knee, and hip joints. Ten repetitions of adduction-abduction are performed at the shoulder and hip joints.
41006224|NCT03417661|DRUG|HEXI-PREP By Clinell Wipes|Sterile single sachet wipe containing 3ml solution.
41006225|NCT03417661|DRUG|Chloraprep|Sterile applicator containing 3ml solution.
41006226|NCT03417661|DRUG|Placebos|Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
41006227|NCT05934435|OTHER|Empowered Relief|psycho-educational pain skills training
41006228|NCT02727348|PROCEDURE|Sciatic with or without femoral block|Sciatic with or without femoral block performed either with ultrasound and/or nerve stimulator on the patient with 3mg/kg of ropivacaine
41006229|NCT02727348|PROCEDURE|Spinal anaesthesia|Spinal anaesthesia with up to 3mls of 0.5% bupivacaine
41006230|NCT00002183|DRUG|Abacavir sulfate|
41006231|NCT00002183|DRUG|Amprenavir|
41006232|NCT00002183|DRUG|Lamivudine|
41006233|NCT00002183|DRUG|Zidovudine|
41006234|NCT04931901|DEVICE|EMG TOF device|Use of Stimpod NMX450X as an electromyographic neuromuscular monitor
41320169|NCT01509872|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy
41320170|NCT01509872|BEHAVIORAL|Child Friendly Space|9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
41476195|NCT00369382|DRUG|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
41476196|NCT00369382|DRUG|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
40802393|NCT06053138|DIETARY_SUPPLEMENT|Placebo|The placebo vehicle is matched to the ketosis intervention in the experimental arm with regards to taste, volume, viscosity, appearence, and packaging
40802394|NCT00033423|BIOLOGICAL|rituximab|
40802395|NCT00033423|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
41320171|NCT06449417|BEHAVIORAL|Experimental Aurora Training|Patients will be asked to record their physical activity in the logbook every week, at the end of the intervention, each patient will have to dedicate a letter to another patient who will receive the same Aurora Kit.
40802396|NCT05492227|DIAGNOSTIC_TEST|Left-overs|Totally nasal swab leftovers were stored from the biobank of Hospital Puerta del Hierro. The coded specimens were kept at -80°C and analyzed using the SARS-CoV-2 NAD Kit. Previously these specimens were analyzed using the gold-standard RT-PCR.
40802397|NCT02371460|DIETARY_SUPPLEMENT|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
40802398|NCT02371460|COMBINATION_PRODUCT|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
41006235|NCT04770376|OTHER|Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.|Collection of blood samples during blood draws performed before each cycle of chemotherapy as per clinical practice.
41006236|NCT02176733|DRUG|cyclosporine|
41006237|NCT03545607|BIOLOGICAL|MultiStem|single intravenous infusion 18-36 hours after stroke
41006238|NCT03545607|BIOLOGICAL|Placebo|single intravenous infusion 18-36 hours after stroke
41320172|NCT03591055|OTHER|CGA, medication review, exercise and cognitive stimulation|Comprehensive geriatric assessment. Patient-centered interventions according to the different target areas identified in the geriatric assessment. Medication review. Groupal Exercise plan and memory workshops.
41320173|NCT02659605|PROCEDURE|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
41320174|NCT02659605|PROCEDURE|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
41320175|NCT03184857|PROCEDURE|open maxillary sinus lifting|biopsy of the region 6 months later
41006239|NCT05286190|DRUG|Bupivacaine 0.25% Injectable Solution|Bupivacaine 0.25% Injectable Solution
41320176|NCT04268095|OTHER|Dressing protocol|Patients are assigned with different postoperative dressing protocols.
41320177|NCT04747522|DRUG|SARS-CoV-2 vaccine|SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
41320178|NCT03344848|DEVICE|Orion Visual Cortical Prosthesis System|The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.
41320179|NCT00700895|DRUG|Warfarin Sodium|All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
41320180|NCT00044486|DRUG|Posaconazole oral suspension|
41320181|NCT06327620|COMBINATION_PRODUCT|Daivobet ointment, topical steroids|"Daivobet Ointment: This intervention involves the topical application of Daivobet ointment, which is a combination of calcipotriol and betamethasone. The application is to be done three times daily for four weeks.~Topical Steroid: This intervention entails the topical application of a steroid ointment three times daily for four weeks. The specific steroid and its details are not disclosed in the provided information."
41476197|NCT03479931|PROCEDURE|Without placement of a catheter|Elective cesarean section without preoperative placement of a urinary catheter.
41476198|NCT03479931|PROCEDURE|With placement of a catheter|Elective cesarean section with preoperative placement of a urinary catheter.
41476199|NCT02135965|DRUG|2mg of Albuterol|2mg of Albuterol on metabolic rate
41476200|NCT02135965|DRUG|4mg of Albuterol|4mg of Albuterol on metabolic rate
41476201|NCT02135965|DRUG|100mg of Caffeine|100mg of caffeine on metabolic rate
41476202|NCT02135965|DRUG|200mg of Caffeine|200mg of Caffeine on metabolic rate
41476203|NCT02135965|DRUG|Albuterol 2mg & Caffeine 100mg|Albuterol 2mg and 100mg of Caffeine
41476204|NCT02135965|DRUG|Albuterol 2mg and Caffeine 200mg|Albuterol 2mg and Caffeine 200mg on metabolic rate
41476205|NCT02135965|DRUG|Albuterol 4mg and Caffeine 100mg|Albuterol 4mg and Caffeine 100mg on metabolic rate
41476206|NCT02135965|DRUG|Albuterol 4mg and Caffeine 200mg|Albuterol 4mg and Caffeine 200mg on metabolic rate
41476207|NCT04704349|RADIATION|Scintigraphy|The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.
41476208|NCT04355949|DIAGNOSTIC_TEST|Serum vitamin D, vitamin B12, folic acid|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
40802399|NCT06485713|DRUG|trifluridine/tipiracil combined with fufuquitinib|trifluridine/tipiracil combined with fufuquitinib
41006240|NCT02332551|DEVICE|NanoKnife|Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
41006241|NCT04253717|OTHER|Motor control exercise program|Structure physical training aimed at strengthening muscles of the lumbo-pelvic-hip core complex in order to improve stabilization and alignment of the spine and pelvis.
41320182|NCT03173612|DRUG|Dasatinib|Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
41320183|NCT00289185|BIOLOGICAL|RTS,S/AS02D|3-dose intramuscular injection in the thigh
41320184|NCT00289185|BIOLOGICAL|Engerix-B®|3-dose intramuscular injection in the thigh.
41320185|NCT00289185|BIOLOGICAL|TETRActHib™|3-dose intramuscular injection in the thigh.
41320186|NCT00987623|DEVICE|nelfilcon A contact lens|Commercially marketed, hydrogel, single-vision contact lens for daily wear, daily disposable use.
41006242|NCT04131101|BEHAVIORAL|Community Organizing|The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
41006243|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
41006244|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
41006245|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
41006246|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
40802400|NCT06485713|DRUG|fufuquitinib|fufuquitinib
41006247|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
41320187|NCT00987623|DEVICE|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens for daily wear, daily disposable use.
40802401|NCT06485713|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil
40802402|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
40802403|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
40802404|NCT05430503|DIAGNOSTIC_TEST|Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise|DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking
41006248|NCT00949624|DRUG|Docetaxel|Intravenous 100 mg/m2 every three weeks
41006249|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
41006250|NCT00949624|DRUG|AG-013736|Oral tablet 5 mg BID continuous
41006251|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
41006252|NCT04061603|DEVICE|Adagio AF Cryoablation System (iCLAS™)|Endovascular ablation of the left and right atrium
41006253|NCT06050408|DEVICE|1hz repetitive transcranial magnetic stimulation|1hz rTMS applied over P3 EEG 10-20 location. Total of 1200 pulses administered. Figure of eight coil used to stimulate, held tangential to the scalp.
41006254|NCT04355884|DIAGNOSTIC_TEST|Standard 12-lead ECG, NT-proBNP, echocardiography|Cardiac assessment
41006255|NCT01341886|DRUG|Metformin|in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
41006256|NCT06379490|DRUG|Ropivacaine 0.2% Injectable Solution|30 ml of Ropivacaine 0.2% = 60 mg ropivacaine
41006257|NCT06379490|DRUG|Lidocaine epinephrine|30 ml of Lidocaine 1% with 5 μg/ml epinephrine = 300 mg lidocaine + 150 μg epinephrine
41006258|NCT06379490|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL of Ropivacaine 0.5% = 150 mg Ropivacaine
41006259|NCT04088682|BEHAVIORAL|Quality improvement strategies and tools|Quality improvement strategies and tools
41006260|NCT05218759|DRUG|Anlotinib|anlotinib administration at a dose of 10 mg daily
41006261|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using custom 3D printed templates|A patient dental model is acquired by digital scan then digital waxing-up is performed using the Exocad software to 3D print clear templates for direct composite resin restoration.
41006262|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using conventional strip crowns|Direct composite resin restoration using celluloid crown forms
41006263|NCT01474642|DRUG|Capecitabine/Cisplatin(XP)|Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
41320188|NCT05321940|BIOLOGICAL|STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells|Autologous human ultraviolet (UV)-irradiated (dead) leukemia cells loaded with STAVs administered via intravenous injection. Each treatment will administer 5 ml via syringe.
41476209|NCT01612039|DRUG|ASP3291|Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
41476210|NCT01612039|DRUG|Placebo|Matching placebo tablets
41476211|NCT05877391|BEHAVIORAL|SGM Communication Intervention|Evaluate the feasibility and acceptability of the SGM communication intervention by hospice staff. I will pilot test the training with hospice staff to refine the content and delivery of the training. Outcomes in the pilot clinical trial will include feasibility, acceptability, and staff satisfaction with training.
40802405|NCT01447498|OTHER|Screening for risk factors for ulcer bleeding|"Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~1. screening and risk assessment~2. control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: \< 60: 0; 60-69: 1; 70-79: 2; \>=80: 3 ___ Dyspepsia: 1 ___ Uncomplicated ulcer: 2 ___ Complicated ulcer 3 ___ NSAID 2 ___ Steroids 2 ___ SSRI 2 ___ Anticoagulant Tx 2 ___"
40802406|NCT02469987|DRUG|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
41006264|NCT01474642|DRUG|Capecitabine/Paditaxel(XG)|Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
41320189|NCT05321940|BIOLOGICAL|Dendritic Cell Vaccine|15-20 Million mature dendritic cells per dose administered via intravenous injection.
41320190|NCT05514106|DRUG|meta-iodobenzylguanidine (MIBG) (123I)|1 administration of 123I-MIBG for a single SPECT scan
41320191|NCT05514106|DIAGNOSTIC_TEST|123I-MIBG scintigraphy|SPECT scan involving 123I-MIBG as the ligand
41476212|NCT06616948|BEHAVIORAL|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
41476213|NCT06616948|BEHAVIORAL|coaching calls|individuals will receive a phone call every 14 days to discuss ongoing exercise maintenance efforts.
40802407|NCT02469987|DRUG|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
40802408|NCT02469987|DRUG|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
41006265|NCT03787316|DEVICE|Study group|4 weeks of custom-made insoles in the home and outside the home environment , follow the home exercise program during this process.It is planned to perform gait parameters and pain assessment before and after the treatment.
41006266|NCT01217918|DRUG|1 mg|1 mg or placebo a material sparing tablet per day for 10 days
41006267|NCT01217918|DRUG|5 mg|5 mg or placebo as material sparing tablet per day for 10 days
41006268|NCT01217918|DRUG|10 mg|10 mg or placebo as a material sparing tablet per day for 10 days
41152468|NCT02165696|OTHER|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
41320192|NCT04545788|DRUG|Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.|AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
41320193|NCT00367198|DIETARY_SUPPLEMENT|Pro-Stat|two separate oral ingestions of nutrition supplement (either 30 ml per serving or at 60 ml per serving) during the hemodialysis session
41320194|NCT00231855|DRUG|Topotecan and Taxotere|
41320195|NCT02745236|OTHER|Nurse Practitioner Led-Care|Diagnosis and treatment plan decisions will be determined by Nurse Practitioner Led-Care.
41320196|NCT02745236|OTHER|Cardiologist Led-Care|Diagnosis and treatment plan decisions will be determined as per usual care by the Cardiologist
41320197|NCT06390917|DEVICE|PVA recognition function|Ventilator with the function of identify and judge PVAs
41320198|NCT01176370|DEVICE|C-Pulse™ (Implantable Counterpulsation Therapy)|C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device.
41476214|NCT06616948|BEHAVIORAL|No coaching calls|Following completion of the 6-month cycling sessions, no maintenance calls will be placed.
41476215|NCT05896969|DRUG|SNK-396 - SAD cohort|A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.
41476216|NCT05896969|DRUG|SNK-396 - MAD Cohort|Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.
41476217|NCT01582919|OTHER|Neuroimaging|
41476218|NCT02155374|DRUG|Sliding scale insulin|
41476219|NCT02155374|DRUG|Intermediate acting insulin|
41476220|NCT02155374|BEHAVIORAL|Dietary advice|Dietary advice to avoid food products with high glycemic index / high glucose load
41476221|NCT02155374|DRUG|Glucose lowering medication|Regular glucose lowering medication as prescribed by the patient's own physician before study entry
41476222|NCT02155374|DRUG|Chemotherapy|Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
41476223|NCT04039919|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
41476224|NCT04039919|DRUG|Placebo (PSL)|Placebo will be provided matching Padsevonil to maintain the blinding.
41476225|NCT03070691|DRUG|LDE225B|Cream, 2x daily
41476226|NCT03070691|DRUG|Vehicle|cream, 2x daily
41476227|NCT04756778|PROCEDURE|Aortic surgery +/- aortic valve replacement|Replacement of aneurysmal proximal thoracic aorta +/- replacement of diseased bicuspid aortic valve
41476228|NCT00374075|DRUG|Valproic Acid|
40802409|NCT05781945|DIETARY_SUPPLEMENT|probiotics|supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2
40802410|NCT05781945|OTHER|standard therapy|standard therapy for sars-cov-2
40802411|NCT05386862|BEHAVIORAL|Reduce THC Use|Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity
40802412|NCT02876458|OTHER|Immediate coronary angiogram|An immediate coronary angiogram will be performed
41006269|NCT01271543|DEVICE|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
41320199|NCT06375980|OTHER|Intraoperative Mechanical Ventilation Strategies|The intervention involves the management of mechanical ventilation during major abdominal surgery. This includes the adjustment of ventilation parameters such as tidal volume, respiratory rate, peak pressure, positive end-expiratory pressure (PEEP), and inspiratory flow rate. The aim is to optimize ventilation strategies to reduce the risk of postoperative pulmonary complications
41320200|NCT06391944|DRUG|JMT101 Injection|JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 or 21 days
41320201|NCT06391944|DRUG|Osimertinib tablet|Osimertinib 80 or 160mg po everyday
41320202|NCT01430572|DRUG|Pazopanib|Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
41320203|NCT01430572|DRUG|Everolimus|"Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase."
41320204|NCT03550287|DIETARY_SUPPLEMENT|Experimental product|10 g/day
41320205|NCT03550287|DIETARY_SUPPLEMENT|Placebo product|10 g/day
41320206|NCT04843826|PROCEDURE|papilla reconstruction|subepithelial connective tissue graft for interdental papillary reconstruction around delayed
41320207|NCT02662413|OTHER|Validation of Asthma Control Questionnaire|This is an observational study so there is no planned intervention.
41320208|NCT00709917|DRUG|repaglinide|Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
41476229|NCT03544359|DEVICE|Transcranial electrical stimulation (tES)|"In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS."
41476230|NCT03708965|DRUG|JR-141|IV infusion (lyophilized powder)
41476231|NCT06239688|BEHAVIORAL|essentiALZ|essentiALZ is a web-based training that contains three hours of self-paced content separated into five modules, plus a final review. Modules include: 1) Alzheimer's disease and dementia; 2) person-centered care; 3) assessment and care planning; 4) activities of daily living; and 5) behaviors and communication. Staff will be encouraged to take the training over the course of four weeks.
41476232|NCT06239688|BEHAVIORAL|Project ECHO|ECHO is a virtual tele-mentoring model grounded in case-based learning. It includes six weekly one-hour sessions of didactic and discussive learning. The first five sessions will reflect the content of the five essentiALZ modules, and the final session will address maintenance. ECHO sessions are group sessions that will be conducted via Zoom.
41476233|NCT00453817|DRUG|ferucarbotran (iron-based MRI contrast agent)|islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
41320209|NCT04426838|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference|The CBTi protocol will include stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring which will be done over 4 weeks with one session weekly delivered via videoconference.
41476234|NCT00453817|PROCEDURE|Islet transplantation|intraportal percutaneous islet transplantation
40802413|NCT02876458|OTHER|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
40802414|NCT02363972|DEVICE|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
41476235|NCT00453817|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
41476236|NCT03235479|DRUG|Rimegepant|75 mg tablet QD
41476237|NCT03235479|DRUG|Placebo|Placebo tablet to match rimegepant dose QD
41476238|NCT00791141|DRUG|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
41476239|NCT01471899|DRUG|Ketorolac Tromethamine|10 drops each 8 hours for 4 days.
41476240|NCT01471899|DRUG|Naproxen|2 tablets every 8 hours for 4 days
41476241|NCT04711720|DEVICE|"VTS surgical navigation system"|"TheVTS surgical navigation system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track the surgical instruments during the operation, and update the position of the surgical instruments on the patient's image in real time, so that the doctor can clearly understand the position of the surgical instruments relative to the patient's anatomical structure, and make the operation procedure more accurate and safer."
41476242|NCT01267006|DRUG|GSK1325756|GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
41320210|NCT02322411|DEVICE|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
41320211|NCT02322411|BEHAVIORAL|Compensatory approaches|
41476243|NCT01267006|DRUG|Placebo tablet|Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
41476244|NCT03896984|DRUG|Radium-223 (Xofigo, BAY88-8223)|Ra-223 was approved by the FDA in May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
40802415|NCT04012502|OTHER|Toxicities reduced treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
41006270|NCT01138280|DEVICE|CWP 103H (Gambro, Sweden): a heat disinfection device|Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
41006271|NCT04979585|DRUG|Camrelizumab|200mg ,IV,d1,Q3W.
41320212|NCT02102984|DEVICE|covered biliary stents|endoscopic placement of covered biliary stents
41006272|NCT04979585|DRUG|Anlotinib|8mg,oral, d1-14,Q3W.
41006273|NCT04979585|DRUG|nab-Paclitaxel|260mg/m2,IV,d1,Q3W.
41152469|NCT02165696|OTHER|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
41152470|NCT05852171|DRUG|Baricitinib|Baricitinib administered orally
41320213|NCT02102984|DEVICE|uncovered biliary stents|endoscopic placement of uncovered biliary stents
41320214|NCT03108209|OTHER|Photoderm Max lait SPF50+|Subjects apply Photoderm Max lait SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
41320215|NCT03108209|OTHER|Photoderm Max Stick SPF50+|Subjects apply Photoderm Max Stick SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
41320216|NCT04779944|OTHER|other|questionnaire
41320217|NCT06330285|OTHER|e-learning|"CPET (Cardiopulmonary exercise test) e-learning application The content, planning and design of 4 lessons are as follows:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples"
41476245|NCT03896984|DRUG|Abiraterone|Abiraterone is a CYP17 inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2011, and for patients with metastatic high-risk castration-sensitive prostate cancer in 2018.
41476246|NCT03896984|DRUG|Enzalutamide|Enzalutamide is an androgen receptor inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2012, with warning and precautions added in 2017 regarding the risk of seizure and encephalopathy.
41476247|NCT01709994|DRUG|Aspirin|100 mg/day of aspirin
41476248|NCT01095419|OTHER|Massage Therapy|After discharge from the intensive care unit to the ward during the postoperative period, patients which were randomized for 3 nights to receive intervention (Massage Therapy)which were consisted of massage of the neck, shoulders, and back. The massage was initiated with light manual compression and progressed to deep compression. The compression was performed with the inner region of the fingers, hand-shaped clamp, and friction (digital compression with the thumb) on trigger points, cervical traction, and mobilization in all planes (front, back, and sides)
41476249|NCT01095419|OTHER|Control|no intervention
41476250|NCT04617392|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing a part of the stomach, limiting the amount of food the patient can eat.
41476251|NCT04617392|OTHER|Strength endurance training|Patients included in the active cohort arm with physical activity will undergo three months of strength endurance training under the supervision of a professional physiotherapist
41476252|NCT04363749|OTHER|hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint|the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure
41476253|NCT06616012|DEVICE|Neosense umbilical catheter|The Neosense umbilical catheter is used instead of a standard umbilical catheter
41476254|NCT02918682|OTHER|Exercise - FIRST PHASE|the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;
41476255|NCT02918682|OTHER|Exercise - SECOND PHASE|the participants do not need to perform the second phase or can advance to the third phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8-1 m/s and ability to walk 60 meters; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO and FFEC stance for more than 5 seconds and the Tandem EO stance for 10-20 seconds; 4. Having sitting stability limits with eyes closed; 5. Being able to bend the trunk forward, standing parallel to a wall, between 20-32 cm ad being stable. For muscle strength: being able to perform hip flexion with 60% of 1 RM for 8 repetitions; hip extension with 60% of 1RM for 8 repetitions; hip abduction without load but between 8-12 repetitions; knee extension with 60% of 1RM for 8 repetitions; knee flexion with 60% of 1RM for 8 repetitions;
41006274|NCT03193606|OTHER|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
41006275|NCT01914484|DRUG|Nilotinib|Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
41320218|NCT06330285|OTHER|face to face learning|"CPET (Cardiopulmonary exercise test) face to face education. The content, planning and design of 4 lessons are as follows:~Contents:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples"
41476256|NCT02918682|OTHER|Exercise - FOURTH PHASE|at the end of the exercise protocol, the participants who have reached the fourth phase must be able to achieve: 1. Gait speed of 0.8-1 m/s and able to walk 90 meters; 2. Stand up and sit down five times from the chair properly within less than 15 seconds; 3. TUG performance less than 14 seconds; 4. Maintenance of 30 seconds in FFEO and FFEC stance, maintenance of 30 seconds in Tandem EO and Tandem EC stance, maintenance of the single-leg stance for more than 21 seconds; 5. Normal sitting stability limits with eyes closed; 6. Bending the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For muscle strength: able to perform hip flexion with 70% of 1 RM for 6-10 repetitions; hip extension with 70% of 1RM for 6-10 repetitions; hip abduction with 40-60% of 1RM for 8-12 repetitions; knee extension with 70% of 1RM for 6-10 repetitions; knee flexion with 70% of 1RM for 6-10 repetitions.
41006276|NCT01914484|DRUG|Ruxolitinib|"In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).~No intra-patient dose-escalation will occur. JAK inhibitor"
41006277|NCT02269891|DIETARY_SUPPLEMENT|Nu Femme|Combination product of Labisia pumila and Eurycoma longifolia extracts
41006278|NCT02269891|OTHER|Placebo|
41006279|NCT05190042|DEVICE|Cotinuous suture|Cotinuous suture using surgery thread
41006280|NCT05190042|DEVICE|Clips|Hemostatic clips
41006281|NCT00702130|DRUG|Pravastatin|pravastatin 40mg per os once daily
41006282|NCT06249308|OTHER|Blood collection|Blood sample will be collected
41006283|NCT04118010|DRUG|Vitamin D3|High-dose vitamin D3 50,000 IU /week for 12 weeks
41006284|NCT04118010|DRUG|Placebo vitamin D3|Matching to Vitamin D3 placebo capsules for 12 weeks
41006285|NCT04118010|DRUG|Inulin|Chicory-derived prebiotic inulin 12 g/day for 12 weeks
41006286|NCT04118010|DRUG|Placebo Inulin|Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
41006287|NCT04264286|DRUG|Prophylactic esmolol|Patients will receive prophylactic esmolol after the end of the surgery
41006288|NCT04264286|DRUG|Placebo|Patients will prophylactic placebo after the end of the surgery
41006289|NCT04352140|DEVICE|Tetragraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
41006290|NCT04352140|DEVICE|ToFscan|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured
41006291|NCT02423941|PROCEDURE|Retrogade reperfusion|Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
41006292|NCT02423941|PROCEDURE|Antegrade reperfusion|Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
41006293|NCT02577237|BEHAVIORAL|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
41320219|NCT02567617|DIETARY_SUPPLEMENT|Polyphenols|Capsules with five substances (polyphenols) at a concentration of 3000mg per day
40802416|NCT04012502|OTHER|conventional treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
40802417|NCT05483712|DEVICE|Brass Mesh Bolus|During a standard-of-care 15 fraction radiotherapy treatment, a brass mesh bolus will be used for a single fraction. Small in-vivo dosimeters will be used for three treatment fractions to measure and compare skin doses for quantification purposes.
41320220|NCT02567617|DIETARY_SUPPLEMENT|Placebo controlled|Starch capsules
41320221|NCT00002386|DRUG|Indinavir sulfate|
41320222|NCT00002386|DRUG|Lamivudine|
41320223|NCT00002386|DRUG|Stavudine|
41320224|NCT00002386|DRUG|Zidovudine|
41320225|NCT00002386|DRUG|Zalcitabine|
41320226|NCT00002386|DRUG|Didanosine|
41320227|NCT04605536|OTHER|animation videos|watch animation videos about capsule endoscopy
41320228|NCT04605536|OTHER|explanation about endoscopy endoscopy|Give general explanations about endoscopy endoscopy
41006294|NCT02577237|BEHAVIORAL|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
41006295|NCT02577237|OTHER|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
41320229|NCT04345302|BEHAVIORAL|Brief motivational treatment|"The treatment will be delivered by general psychologists with at least three years of experience in primary care. They will receive training and then will demonstrate proficiency in a simulated client session.~During recruitment, therapy sessions will be recorded, and ten percent of them will be reviewed using a proficiency scale. Then, a feedback report will be issued and discussed with each therapist."
41320230|NCT04345302|BEHAVIORAL|Enhanced Usual Care|During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.
41476257|NCT02918682|OTHER|Exercise - THIRD PHASE|participants do not need to perform the third phase or can advance to the fourth phase if they have obtained: 1 Gait speed of 0.8-1 m/s and walk 90 meters; 2 perform the stand up and sit down five times from the chair properly within less than 15 seconds; 3 Performing the TUG test within less than 14 seconds; 4 Maintaining the FFEO and FFEC stance for 30 seconds, maintaining the Tandem EO and Tandem EC stance for 30 seconds and maintaining the single-leg stance for more than 20 seconds; 5 Having sitting stability limits with eyes closed; 6 In the upright position, to bend the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For the muscle strength test, perform hip flexion with 60 % of 1 RM for 8-12 repetitions; hip extension with 60 % of 1RM for 8-12 repetitions; hip abduction without load or 5% of 1RM for hip abductor and between 8-12 repetitions; knee extension with 60 % of 1RM for 8-12 repetitions; knee flexion with 60 % of 1RM for 8-12 repetitions;
41476258|NCT01397708|BIOLOGICAL|INXN-2001|"* approximately 1.0 x 1012 viral particles (vp) per injection~* one intratumoral injection of INXN-2001 per study cycle~* maximum of 6 study cycles"
41006296|NCT02577237|OTHER|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
41006297|NCT02639481|BEHAVIORAL|Standard physiotherapy|Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
41320231|NCT05739760|BEHAVIORAL|Poem book about relational health|Poem book will consist of illustrations, poetry, and tips for parents on how to resolve their child's upset, their own upset, and to develop a stronger relationship. The study physician may read the book to the families at the visit. Then, families are instructed to read the book at least once, for as many times as the parent opts to.
41320232|NCT05739760|BEHAVIORAL|Poem book about physical health and safety|Poem book will consist of illustrations, poetry, and tips for parents on how to keep their child physically healthy and safe, and to avoid accidental injuries. The study physician may read the book to the families at the visit. Then families are instructed to read the book at least once, for as many times as the parent opts to.
41320233|NCT00823524|BIOLOGICAL|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
41320234|NCT00164736|DRUG|Maternal zidovudine/lamivudine/lopinavir-ritonavir|Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
41320235|NCT00164736|DRUG|Infant nevirapine|"Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding."
41320236|NCT00164736|DIETARY_SUPPLEMENT|Maternal protein and calorie supplement|High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
41320237|NCT00406991|DRUG|aspirin|
40802418|NCT04992013|DRUG|Niraparib|Capsule taken by mouth
40802419|NCT00759876|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with milk. Dosing based on participant body weight
40802420|NCT01157572|DRUG|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
41320238|NCT00406991|DRUG|clopidogrel|
41320239|NCT03213977|DRUG|R-DA-EPOCH|R-DA-EPOCH-21 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
40802421|NCT01157572|DRUG|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
40802422|NCT00562822|PROCEDURE|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
40802423|NCT00562822|OTHER|Physical and medical therapy|Treatment with physical and medical therapy alone
40802424|NCT03935672|PROCEDURE|PET-CT scans|"Patients will have three scans during the trial.~* The 1st scan (prePET) is a baseline diagnostic scan. The patient is in a thermoplastic shell and PET CT will be used by to define a bGTV_P. bGTV_P will then be used as an adjunct to help us delineate the GTV_P.~* The 2nd scan (iPET) takes place following 2 weeks (10 fractions) of chemo-radiotherapy. The patient is in a thermoplastic shell and the PET CT will be used to delineate the remaining avid disease (bGTV_iP).~* The 3rd scan takes place 3 months following the last dose of radiotherapy. It will be used to ascertain whether any avid disease remains and may inform the need for further treatment."
40802425|NCT03935672|PROCEDURE|Outlining the biological GTVs (bGTV_P and bGTV_iP)|The biological GTVs (bGTV_P and bGTV_iP) will be automatically delineated by ATLAAS and verified manually by a nuclear medicine physician and a clinical oncologist. It will consist of the high FDG uptake volume based on visual assessment whilst using suitable windowing levels. Any differences in contouring will be settled either by the two doctors reaching a consensus or by a third doctor if differences between the first two cannot be resolved.
40802426|NCT03935672|PROCEDURE|Blood samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
40802427|NCT03935672|PROCEDURE|Salivary samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
40802428|NCT03877614|OTHER|ASCVD risk score|ASCVD score\< 10% will be in the control or low-risk group
41006298|NCT02639481|DEVICE|Erigo®Pro group without FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
41006299|NCT02639481|DEVICE|Erigo®Pro group with FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
41006300|NCT05105243|DRUG|CVN766|highly selective orexin-1 receptor (Ox1R) antagonist
41006301|NCT03594162|DRUG|iC9-CAR19 cells|One of two dose levels will be given: 1 x 10\^5 or 5 x 10\^5
41006302|NCT03594162|DRUG|AP1903|Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
41006303|NCT03594162|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
41320240|NCT03213977|DRUG|R-CEOP90|R-CEOP90 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
40802429|NCT03831178|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
40802430|NCT03831178|DRUG|Placebo oral capsule|Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
40802431|NCT03802630|DRUG|Brolucizumab 6 mg|Solution for injection (intravitreal use)
40802432|NCT03802630|DRUG|Aflibercept 2 mg|Solution for injection (Intravitreal use)
40802433|NCT03802630|OTHER|Sham injection|"Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator."
41320241|NCT01844622|OTHER|Domperidone|Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
41006304|NCT03594162|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
41476259|NCT01397708|DRUG|INXN-1001|"* 4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~* 7 oral daily doses of INXN-1001 per study cycle~* maximum of 6 study cycles~* 1 Expansion cohort at a single dose level at or below MTD (160mg/day)"
41476260|NCT06616350|DEVICE|esTOCma: an app to fight stigma associated with OCD|The intervention consists of playing a serious game, called esTOCma, on a mobile phone. In the game, players must use their knowledge to battle the stigma monster of OCD, complete 10 missions, and release 10 individuals who have been afflicted by the esTOCma monster, a creature that feeds on false beliefs and misinformation in society.
41006305|NCT02041130|DEVICE|Renal Denervation|
41006306|NCT02059148|DRUG|LY2835219|Administered orally.
41006307|NCT06431828|OTHER|APP|The patients will download an app through which they will be able to report adverse events related to their cardiovascular health.
41006308|NCT06276257|PROCEDURE|Paravertebral block|An ultrasound-guided technique will be used to inject a volume of 40 mL of ropivacaine 0.2%, up to a maximum of 1.5 mg/kg, into the paravertebral space between the T3 and T4 vertebrae.
41006309|NCT06276257|PROCEDURE|Usual analgesia|The patient will receive analgesia as per the anesthesiologist's preferences.
41476261|NCT00006143|DRUG|Somatropin|
41476262|NCT01674439|PROCEDURE|Supplementation of ADRC|Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
41476263|NCT01674439|PROCEDURE|Without supplementation of ADRC|Standard fat graft preparation
40802435|NCT05757440|OTHER|Icon resin application|Application of the low-viscosity resin infiltration (Icon) to the white spot enamel lesions
40802436|NCT04069949|DRUG|sorafenib; toripalimab|Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
40802437|NCT02850224|BEHAVIORAL|Motivational interviewing to elicit PCO in pediatrics|A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
40802438|NCT03678337|OTHER|observational cohort with plasma samples|plasma samples
40802439|NCT04896619|OTHER|Kori tofu bread|34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.
41320242|NCT05796804|PROCEDURE|ERECTOR SPINAE PLANE BLOCK|ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%
41320243|NCT05796804|PROCEDURE|Peng block + lateral femoral cutaneous nerve block|ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%
41320244|NCT05796804|PROCEDURE|spinal anesthesia|bupivacaine 0.5% 2.2 ml
41320245|NCT03371342|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
41320246|NCT03371342|DRUG|Botox|Botox(Botulinum toxin type A)
41320247|NCT04143763|OTHER|Ecological Momentary Intervention (EMI)|Using the messaging function of mobile devices, EMI offers a framework to deliver health information to the target population, corresponding to each individual's demands in terms of type (e.g., photo, text and/or voice message), timing, duration, and frequency of the messages, which are different to the features from other interventions
41320248|NCT01923233|BIOLOGICAL|AlloStim|allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.
41320249|NCT01995136|DRUG|Travoprost Ophthalmic Solution 0.004%|benzalkonium chloride (BAC) free
41320250|NCT02748941|DEVICE|HITS quantification, Ultrasound examinations, High Resolution MRI|"Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque~Description of different modalities:~HITS quantification~Ultrasound examinations:~* Ulceration \>2 mm~* Plaque thickness~* GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop~* CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging)~High Resolution MRI:~* Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated~* Quantification of shear stresses (Pa) on the surface of the plaque~mi-RNA identification and quantification"
41320251|NCT02158091|DRUG|IPI-145|oral PI3K delta/gamma inhibitor
41320252|NCT02158091|DRUG|Fludarabine|intravenous chemotherapy
40802440|NCT04896619|OTHER|Whey protein bread|Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread
41320253|NCT02158091|DRUG|Cyclophosphamide|intravenous chemotherapy
41320254|NCT02158091|DRUG|Rituximab|intravenous immunotherapy
41320255|NCT04201977|OTHER|Foam Roller Recovery|Myofascial self-release will be developed through the foam roller (FR), where participants will use a custom-made foam roller constructed from a hollow polyvinyl chloride tube that will have an outside diameter of 10cm and a thickness of 0.5cm and will be surrounded by neoprene foam with a thickness of 1cm. Each volunteer will be shown the technique for the 5 muscle groups involved and the technique used for each muscle group. FR will consist of 45s of rolling for each muscle in the left lower extremity, 15s of rest, 45s in the lower right extremity. They will be instructed to begin with the practice on the most distal portion of the muscle. They will be instructed to place as much tolerable body mass on the FR at all times and to roll their body mass back and forth along the roller as smoothly as possible at a rate of 50 beats per minute (ie , 1 rolling motion for 1 to 2s). The total technique time is estimated at 10 to 15min (PEARCEY et al., 2015).
41320256|NCT04201977|OTHER|Active recovery|Active recovery for 20 minutes (MIKA et al., 2016) will consist of pedaling on a stationary bike at a speed of 50 to 60 rpm. The load (49 ± 9 W) will be adjusted individually so that the heart rate is close to 100 bpm (about 50% of the theoretical maximum heart rate). This effort intensity is similar to that used in the literature (CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010)
41320257|NCT04201977|OTHER|Immersion in cold water|Immersion in cold water will consist of the individual sitting in a plastic pool with water at the water level of the umbilical scar. Water temperature is between 11 and 15ºC, for a period between 10 and 15 minutes immediately after the exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009). Water temperature will be controlled by adding or removing ice. This method has been applied by studies conducted by our research group (MISSAU; SIGNORI, 2017).
41320258|NCT04201977|OTHER|Passive recovery|Volunteers will be seated for 20 min after the resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
41476264|NCT02234206|DRUG|Chandrakanthi Choornam (CKC)|"12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs \& cosmetic act 1940"
41476265|NCT05125731|BEHAVIORAL|Parental absence|Parent does not accompany the child during dental treatment
41476266|NCT05125731|BEHAVIORAL|Parental visual support|The parent does not accompany the child during the dental treatment but watches behind the glass and is seen by the child.
41476267|NCT05125731|BEHAVIORAL|Parental presence|Parent accompanies the child during dental treatment
41476268|NCT04702724|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
41476269|NCT05988931|BEHAVIORAL|Web Program + App|Youth receive a brief interactive web program made available online to prevent alcohol misuse. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
41006310|NCT02181556|DRUG|FOLFIRI Protocol|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
41006311|NCT02181556|DRUG|Aflibercept Injection|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
41320259|NCT05536193|DRUG|Topical Metformin Emulgel and salicylic acid|"Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid"
41476270|NCT05988931|BEHAVIORAL|Web Program + App + Text Messages|Youth receive a brief interactive web program made available online to prevent alcohol misuse. This is followed by 8 weeks of supportive text messages. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
41006312|NCT03161561|OTHER|capacity of primary phagocytes|measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
41006313|NCT01350427|DIETARY_SUPPLEMENT|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
41320260|NCT05536193|DIAGNOSTIC_TEST|Insulin- Like growth factor (ILGF-1)|3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
41320261|NCT03446651|DRUG|Lysine Chloride|Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
41006314|NCT01350427|DIETARY_SUPPLEMENT|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
41006315|NCT01350427|DIETARY_SUPPLEMENT|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
41320262|NCT03446651|OTHER|Placebo|Patients will receive 7 days of therapy using placebo. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
41320263|NCT00067470|DRUG|Placebo|
41320264|NCT00067470|DRUG|N-acetylgalactosamine 4-sulfatase|
41320265|NCT01404442|DRUG|placebo(distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
41320266|NCT01404442|DRUG|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally
41320267|NCT01404442|DRUG|Midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
41320268|NCT05271422|DEVICE|Real Pulse Electrical Stimulation (NuEyne 01)|Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
41476271|NCT03282734|OTHER|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks
40802441|NCT05407012|OTHER|Application of the barrier enhancing preparation.|Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
41320269|NCT05271422|DEVICE|Sham Pulse Electrical Stimulation|Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
41320270|NCT00055536|DRUG|natalizumab|
41320271|NCT03754062|DRUG|Placebo - Cap|Administration of Placebo by pill.
41476272|NCT03282734|OTHER|Conventional home rehabilitation exercise|Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
41476273|NCT05865977|DEVICE|diaphragmatic tissue Doppler imaging，dTDI|dTDI was performed at the end of the SBT to assess excursion, velocity, and acceleration.
40802442|NCT05454462|DRUG|IMP Application KM-001|KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
40802443|NCT05454462|DIAGNOSTIC_TEST|Chemistry|patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
40802444|NCT05454462|DIAGNOSTIC_TEST|Hematology|patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
41006316|NCT02047110|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
41320272|NCT03754062|DRUG|L-dopa|Administration of L-dopa by pill.
41320273|NCT03754062|DRUG|Haloperidol|Administration of Haloperidol by pill.
41320274|NCT01110772|DEVICE|2-octyl cyanoacrylate [InteguSEAL®]|At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
41320275|NCT01110772|DEVICE|Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]|At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
41320276|NCT06035588|OTHER|Daily whitening|Daily application of a 16% carbamide peroxide bleaching gel in volunteers without sensitivity.
41320277|NCT06035588|OTHER|Alternate whitening|Volunteers will apply the whitening gel at 16% carbamide peroxide, alternating a rest day with an application day. Patients should not be sensitive before starting the study.
41341809|NCT05110404|OTHER|The high-volume HIIT|patients will undergo a warm up at 65%-70% of HRpeak for 5 minutes, and then they will walk on a treadmill for 4 intervals of 4 min each at an intensity corresponding to 85%-90% of HRpeak with 3 min active recovery interval interval in between at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted between intervals to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.
41476274|NCT05829759|BEHAVIORAL|Tele-B6|Participants will be part of the Tele-B6 intervention that includes six group sessions delivered over the course of six weeks. Survey assessments for the intervention group (first phase) will be conducted at enrollment (baseline), 2 months (immediate post-intervention survey), 4 months (interim-survey, post-intervention), and 6 months (endline).
41476275|NCT05829759|BEHAVIORAL|Delayed intervention (waitlist control)|Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (preintervention), 6 months (immediate post-intervention), and 8 months (post-intervention).
41476276|NCT05052242|DIAGNOSTIC_TEST|primary angle closure disease|2 swept source OCT biometers, IOL Master700 and Anterion
40802445|NCT05454462|DIAGNOSTIC_TEST|Urinalysis|Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
40802446|NCT05454462|DIAGNOSTIC_TEST|Serelogy|Patients will provide a blood sample for serelogy test at day -14 (screening visit)
40802447|NCT05454462|DIAGNOSTIC_TEST|12-Lead ECG|patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
40802448|NCT05454462|DIAGNOSTIC_TEST|Pregnancy test|Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
40802449|NCT05454462|DIAGNOSTIC_TEST|Blood PK sampling|PK test will be performed on day 1, 7, 28, 35 and on ET visit
40802450|NCT05454462|PROCEDURE|Physical Examination|patients will undergo a physical examination on all the clinical visits
40802451|NCT05454462|PROCEDURE|Vital signa|patient's vital signs will be measured on all the clinical visits
40802452|NCT05454462|DIAGNOSTIC_TEST|Investigator's Global Assessment|patient's disease evaluations will be evaluated on all the clinical visits
40802453|NCT05454462|DIAGNOSTIC_TEST|Itch Assessment via PP-NRSj|patient's disease evaluations will be evaluated on all the clinical visits
40802454|NCT05454462|OTHER|E-diary data|The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
40802455|NCT04099355|DRUG|Dronabinol 5mg Cap|1 QAM and 2 QHS PO 14 days
40802456|NCT04099355|DRUG|Non-active comparator|1 QAM and 2 QHS PO 14 days
40802457|NCT01697423|DRUG|platelet-rich plasma|
41006317|NCT02047110|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
40802458|NCT01697423|DRUG|durolane|
41006318|NCT00463060|DRUG|sunitinib malate (Sutent)|Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
41152471|NCT06275906|OTHER|Mediterranean diet and moderate intensity physical exercise (outdoor walking).|Mediterranean Diet, based on the different percentage of carbohydrates and lipids, associated with a program of moderate intensity aerobic physical exercise (outdoor walking), in patients with obesity and NAFLD.
40802459|NCT02051751|DRUG|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
40802460|NCT02051751|DRUG|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
40802461|NCT06263608|DEVICE|(Cardio)Respiratory polygraphy (NOX T3s)|This home-based device enables the detection of obstructive sleep apnea by calculating the apnea hypopnea index (AHI).
40802462|NCT06263608|DIAGNOSTIC_TEST|Polysomnography|Polysomnography allows both sleep and respiration monitoring during an overnight stay in a dedicated sleep clinic.
40802463|NCT06263608|DEVICE|Devices to deliver Continuous Positive Airway Pressure (CPAP), Bilevel Positive Airway Pressure (BiPAP) or Adaptive support ventilation (ASV)|Devices can be used to deliver CPAP, BiPAP, or ASV treatment to open up the airways, making breathing during sleep possible.
40802464|NCT06263608|DEVICE|Fitbit smartwatch|The smartwatch enables the semi-continuous monitoring of the heart rhythm via the installed FibriCheck algorithm.
40802465|NCT05806554|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device
40802466|NCT02780583|DRUG|kineret|anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone
40802467|NCT02780583|DRUG|placebo|placebo injection administered every 6 hours along with intravenous methylprednisolone
40802468|NCT06421064|PROCEDURE|Perforation repair|All patients were operated with slight difference but all had perforation repaired.
40802469|NCT06053151|BEHAVIORAL|exercise counselling|. The experimental group will receive the cloud platform integration model for exercise consultation intervention for two phases continue 24 weeks to promote exercise behavior during pregnancy. The goal of the first phase was to start regular exercise, and the goal of the second phase was to continue regular exercise.
41006319|NCT00463060|PROCEDURE|radiotherapy|Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
41006320|NCT03962335|BEHAVIORAL|Vegetarian diet|7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months
41152472|NCT02746237|DRUG|KAR5585 Capsules|Single and multiple ascending doses of KAR5585 (100 mg initial dose)
41152473|NCT02746237|DRUG|Placebo Capsules|Single and multiple ascending doses of placebo (100 mg initial dose)
41341810|NCT05110404|OTHER|The low-volume HIIT|Each session will start with a 5-minute warm up at 65-70% of peak HR. Then they will walk on a treadmill for 4 intervals of 2 min each at an intensity corresponding to 85%-90% of HRpeak with three intervals of active recovery in between for 2 min at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted.
41152474|NCT04730570|BEHAVIORAL|Essential Coaching for Every Mother|Essential Coaching for Every Mother consists of 53 standardized text messages that provide evidence-based information that women should be aware of related to caring for their newborn and maternal mental health. Messages are personalized with the name of the child. Messages sent from birth to six-weeks postpartum, with two messages sent per day in the first two weeks and a daily message for weeks 3-6. The following topics covered in Essential Coaching for Every Mother include anxiety, depression, maternal self-care, postnatal follow-up, breastfeeding or formula feeding, infant concerns, cord care, well-baby care, normal development, crying, and safe sleep. Women who receive the messages will be able to self-select breastfeeding or formula feeding messages.
41320278|NCT04387318|DEVICE|Multimodal training|"IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks.~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
41320279|NCT04387318|DEVICE|IMT + Pulmonary Rehabilitation|"IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
41320280|NCT04387318|DEVICE|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
41320281|NCT04387318|DEVICE|Pulmonary Rehabilitation|Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
41320282|NCT04825119|DRUG|Nusinersen|Patients with SMA who will be treated with nusinersen will be included.
41320283|NCT03519516|DRUG|PRO-174|"Pharmaceutical form: ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle"
41320284|NCT03519516|DRUG|Sophixín Ofteno®|"* Active substance: Ciprofloxacin 0.3%~* Pharmaceutical form: Ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle"
41320285|NCT03664232|DRUG|JNJ-42165279|Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.
41320286|NCT03664232|DRUG|Placebo|Participants will receive a matching placebo orally twice daily for 12 weeks.
41320287|NCT04839354|DRUG|Arginine Hydrochloride|One-time L-arginine loading dose (200 mg/kg IV) + standard dose (100 mg/kg IV TID)
41320288|NCT04839354|OTHER|Normal saline|Placebo (normal saline) loading dose (2ml/kg IV) + 1ml/kg IV TID
41320289|NCT04450056|OTHER|No intervention|No intervention
41476277|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 1|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30)
41476278|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 2|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30-200,201)
41476279|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 3|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30)
41320290|NCT01175213|BIOLOGICAL|SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37."
41476280|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 4|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30-200,201)
41476281|NCT01072786|BIOLOGICAL|Placebo|One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
41006321|NCT03962335|BEHAVIORAL|Mediterranean diet with butyrate|7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months
41006322|NCT03962335|BEHAVIORAL|Mediterranean diet|7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months
41006323|NCT02423265|DRUG|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
41006324|NCT02423265|DRUG|Placebo|Matching placebo: up-titration after 1 week
41006325|NCT02852265|DRUG|Etonogestrel contraceptive implant|Place nexplanon
41006326|NCT04325529|DEVICE|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
41006327|NCT01725568|DEVICE|BioMonitor|Implantable cardiac monitor
41006328|NCT00302003|RADIATION|radiation therapy|Undergo radiation therapy
41006329|NCT00302003|DRUG|doxorubicin hydrochloride|Given IV
41320291|NCT01175213|BIOLOGICAL|SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose."
41320292|NCT01175213|BIOLOGICAL|IV treatment with IGSC, 10%|During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
41320293|NCT03870256|DRUG|misoprostol|Patient receive 600mic gm sublingual misoprostol
41320294|NCT03870256|DRUG|Carbetocin|Patient receive 100 mic gm carbetocin IV
41320295|NCT03870256|DRUG|TA|The patient receives 1gm oral tranexamic acid
41320296|NCT02862223|DIETARY_SUPPLEMENT|Neoprinol|
40802470|NCT06321445|OTHER|providing ASA score|ASA scoring, or the American Society of Anesthesiologists (ASA) Physical Status Classification System, is a framework used by anesthesiologists to assess the preoperative physical fitness of a patient before surgery. It categorizes patients into six classes based on their overall health status, ranging from ASA I (a healthy patient) to ASA VI (a declared brain-dead patient whose organs are being removed for donor purposes). The ASA score helps in predicting perioperative risks and assists healthcare professionals in making informed decisions about anesthesia management and the need for special precautions during and after surgery.
41006330|NCT00302003|DRUG|vincristine sulfate|Given IV
41006331|NCT00302003|DRUG|prednisone|Given orally
41006332|NCT00302003|DRUG|cyclophosphamide|Given IV
41006333|NCT00302003|DRUG|ifosfamide|Given IV
41320297|NCT03624218|BEHAVIORAL|Prolonged Exposure Therapy|Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
41320298|NCT02325687|PROCEDURE|Lumbar Puncture (Standard-of-Care)|All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).
41320299|NCT02275767|DEVICE|50% cortical/50% cancellous FDBA|Ridge preservation after tooth extraction using 50% cortical/50% cancellous FDBA
41320300|NCT02275767|DEVICE|100% cortical FDBA|Ridge preservation after tooth extraction using 100% cortical FDBA
41006334|NCT00302003|DRUG|vinorelbine tartrate|Given IV
41006335|NCT00302003|DRUG|dexamethasone|Given IV
41006336|NCT00302003|DRUG|etoposide phosphate|Given IV
41006337|NCT00302003|DRUG|cisplatin|Given IV
41006338|NCT00302003|DRUG|cytarabine|Given IV
41006339|NCT00302003|BIOLOGICAL|filgrastim|Given IV or subcutaneously
41006340|NCT00989729|DRUG|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
41320301|NCT02275767|DEVICE|100% cancellous FDBA|Ridge preservation after tooth extraction using 100% cancellous FDBA
41006341|NCT00989729|DRUG|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
41006342|NCT00006219|DRUG|clarithromycin|
41006343|NCT00006219|DRUG|prasterone|
41006344|NCT04976491|DIETARY_SUPPLEMENT|CD-C-Food|CD patients combined with the characteristics of Chinese diet, remove the refined food, and combined with food intolerance detection method to check the corresponding food
41006345|NCT04976491|DIETARY_SUPPLEMENT|EEN|EEN goup received EEN continuously for 6 moths
41006346|NCT04145570|DRUG|Erlotinib HCl 150 mg|"Concentrations of erlotinib were measured from the samples collected over a 72 hour interval after receiving either Erotinib generic or Tarceva original. Later, after 14 days, a crossover was took place with the same measures.~dosing in each period."
41006347|NCT04145570|DRUG|Tarceva®|Tarceva® 150 mg
41006348|NCT02197390|BEHAVIORAL|Family wellness workshops|Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.
41006349|NCT02197390|BEHAVIORAL|Obesity chronic care model|
41320302|NCT03071003|DRUG|SENS-401|Oral Administration
41006350|NCT02197390|BEHAVIORAL|Physical activity, healthy eating, water drinking, healthy sleep promotion|
41006351|NCT02197390|BEHAVIORAL|Environment, policy, systems changes in clinic setting only|
41006352|NCT02197390|BEHAVIORAL|No intervention|No intervention.
41006353|NCT02197390|BEHAVIORAL|Environment, policy, and systems changes in schools, early child care education & recreation|
41320303|NCT03071003|DRUG|Placebo|Oral Administration
41320304|NCT05151679|DRUG|Chelated Iron|"Treatment will be started 24rh after initial visit women will be randomized used random sequence computer generated list in such a way that every patient had equal chance to be among any of the two groups either to group 1 , where they will receive I.V ferrous sucrose in the E.U in Women's Health Hospital Assuit University as an i.v infusion in 250 ml 0.9% sodium chloride slowly over 30 minutes.~The total required dose of iron will be divided into three doses, which will be given every 3 days, and the maximum daily dose is 200mg ( 2 ampoules )."
41320305|NCT05151679|DRUG|Iron sucrose|to group 2 where they will receive chelated oral iron, they will be given iron chelated amino acid containing 15 mg of elemental iron once daily for 6 weeks. the women will be advised to take 1 tab of iron chelated amino acid containing 15mg of elemental iron once daily with meals for 6 weeks from the day of recruitment.
41320306|NCT01136668|PROCEDURE|Transversus Abdominis Plane Block|A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
41320307|NCT01136668|PROCEDURE|Standard|Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
41320308|NCT00756886|DRUG|Atorvastatin|40 mg QD 7 day continue after procedure for 14 days
41320309|NCT00756886|DRUG|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
41320310|NCT06460142|DIAGNOSTIC_TEST|Aortic/ cardiac magnetic resonance imaging|MRI scans will be performed to detect systemic vascular involvement in GCA patients, aiming to provide detailed images of affected tissues.
41320311|NCT06460142|DIAGNOSTIC_TEST|Vascular ultrasound|Vascular ultrasound will be employed to examine the temporal and axillary arteries in GCA patients, searching for signs indicative of active inflammation.
41320312|NCT06460142|DIAGNOSTIC_TEST|Transorbital Ultrasound|Transorbital ultrasound will be employed to assess the ophthalmic artery and its branches in GCA patients to detect intracranial inflammatory processes that could lead to severe neuro-ophthalmological complications.
41320313|NCT06460142|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|Contrast-Enhanced Ultrasound (CEUS) is utilized to evaluate aortic involvement in GCA patients as an alternative, bed-side, realtime, radiation-free diagnostic tool.
41320314|NCT06460142|DIAGNOSTIC_TEST|Optical coherence tomography angiography|OCTA will be used to assess vascular changes in the retina of GCA patients, providing detailed imaging that can help detect early signs of ocular involvement and identify risk factors of anterior ischemic optic neuropathy.
41006354|NCT06156254|BEHAVIORAL|Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB)|Patients randomized to the CHW intervention will receive up to 3 psychoeducational sessions in English or Spanish targeting the specific reason(s) why a patient is not up to date with their COVID-19 vaccine. CHWs will use motivational interviewing techniques to promote vaccination behaviors.
41006355|NCT04222179|DEVICE|ultrathın esophagogastroduodenoscope|Place the naso-enteric tube together with the ultrathin esophagogastroduodenoscope from the same nasal cavity
41006356|NCT01069289|DRUG|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
41006357|NCT01069289|DRUG|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
41006358|NCT01060267|DRUG|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
41006359|NCT01060267|DRUG|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
41006360|NCT03309683|DEVICE|Olympus Quick Clip Pro - Single Use Repositionable Clips|A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
41006361|NCT01991119|DRUG|Propafenone|
41006362|NCT01991119|DRUG|Dronedarone|
41006363|NCT05487963|DRUG|Tofacitinib Citrate|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
41006364|NCT05487963|OTHER|placebo ointment|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
41320315|NCT06460142|DIAGNOSTIC_TEST|Fluorescein angiography|Fluorescein angiography will be performed to evaluate blood circulation and highlight any blockages in the blood vessels of the retina in patients with GCA to detect vascular abnormalities that may lead to severe vision complications.
41320316|NCT06460142|DIAGNOSTIC_TEST|Fundus autofluorescence|This imaging technique will be used to observe the health of the retina and detect any changes in GCA patients that could suggest disease activity, particularly useful for assessing the integrity of the retinal pigment epithelium.
41341811|NCT02997774|OTHER|Cooler dialysis|Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
40802471|NCT05270941|PROCEDURE|COMPARISON OF PLATELET-RICH FIBRIN PREPARED WITH TITANIUM AND SUBEPITHELIAL CONNECTIVE TISSUE GRAFT|In the study, 118 maxillary bilateral multiple Miller Class I gingival recessions in 20 patients were treated. The gingival recessions were randomly treated with either T-PRF (58 teeth) or SCTG (60 teeth) using the modified coronally positioned flap technique. Gingival index, plaque index, probing pocket depth, gingival thickness, recession height, recession width, keratinized gingival width, and open root surface area were measured and recorded at baseline and at the 6th month. Postoperative pain levels were evaluated using the VAS (Visual Analogue Scale), and healing status was evaluated using the wound healing index. The pre- and post-treatment results of both treatment groups and the differences between the groups were evaluated and compared.
40802472|NCT05562206|DEVICE|CGMIS (Continuous Glucose Monitoring Infusion Set)|An integrated combination CGM/insulin infusion system
40802473|NCT05655533|DIAGNOSTIC_TEST|Magnetic resonance Imaging scanners of sacroiliac joints.|"Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not"
41152475|NCT06448845|PROCEDURE|Arm intravenous regional anesthesia|After placement of the upper arm and forearm tourniquets and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the arm tourniquet cuff is inflated to a pressure of 250 mmHg. The double arm cuff pneumatic pressure tourniquet is placed immediately above the elbow crease and on the top of a circumferentially placed cotton cast padding before inflation. Subsequently, tourniquet failure is ruled out by observing the absence of distal circulation and 40 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand. The tourniquet remained inflated for 60 minutes from injection of lidocaine to reduce the risk of local anesthetic systemic toxicity (LAST)
41320317|NCT06460142|DIAGNOSTIC_TEST|Color Fundus Photography|Color fundus photography will be used to document the appearance of the optic disc and retinal vasculature in GCA patients, aiding in the long-term monitoring of ocular changes and the effects of therapeutic interventions.
41320318|NCT06460142|DIAGNOSTIC_TEST|Cell-based ex-vivo assay with high-content analysis|This assay predicts individual patient responses to different DMARDs by analyzing patient-derived PBMCs for specific immune responses to therapeutic agents.
41320319|NCT06460142|DIAGNOSTIC_TEST|3'mRNA sequencing|3'mRNA sequencing analyzes gene expression profiles related to the immune response in PMR/GCA patients, aiding in understanding the genetic underpinnings of inflammation and vascular remodeling.
41320320|NCT06460142|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Used to measure cytokine levels in the serum and plasma of PMR/GCA patients, ELISA aids in profiling inflammatory markers that are indicative of disease activity and response to treatment.
41320321|NCT06460142|DIAGNOSTIC_TEST|Flow cytometry|Employed to analyze immune cell phenotypes in patients with PMR and/or GCA, this test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and guiding therapy.
41320322|NCT06460142|DIAGNOSTIC_TEST|Laboratory assessment:|Serum Chemistry (nt-proBNP, troponin T, CRP, ESR, blood count)
41320323|NCT06460142|DIAGNOSTIC_TEST|Immunohistochemistry of Temporal Artery Biopsies|Immunohistochemistry staining of TAB to assess local expression of endothelial adhesion molecules in acute inflammation.
41320324|NCT06460142|DIAGNOSTIC_TEST|Functional assessment questionnaires|The following questionnaires will be applied: FACIT-Fatigue, SF-36, BAS, Birmingham Vasculitis Activity Score, Montreal Cognitive Assessment, Mini-Mental Status Examination. These questionnaires collectively provide a comprehensive evaluation of the functional status, quality of life, and mental health of patients with GCA and PMR.
41320325|NCT04404010|OTHER|Immersive Virtual Reality|Participants randomized to the iVR simulator utilizes a head-mounted display producing 3D visuals with haptic controllers for an immersive operating room experience. The module produced consists of the key steps in performing a reverse shoulder arthroplasty using virtual versions of the equipment used in the real procedure. Prior to initiation, participants will be provided with a safety and training demonstration on the use of the VR module by study personnel. Participants will be provided as much time as they require to watch the video, including repetition if desired, which they will be timed for completion.
41320326|NCT04404010|OTHER|Surgical Technical Instructional Video|Participants will be provided as much time as they require to watch the instructional video, including repetition if desired, which they will be timed for completion.
41320327|NCT02051725|OTHER|Active life-style intervention|
41320328|NCT03115112|DRUG|Bexagliflozin|tablets containing 20 mg bexagliflozin
41320329|NCT03115112|DRUG|Sitagliptin|tablets containing 100 mg sitagliptin
41320330|NCT03115112|DRUG|Placebo for sitagliptin|inactive tablets to match the appearance of sitagliptin tablets
41320331|NCT03115112|DRUG|Placebo for bexagliflozin|inactive tablets to match the appearance of bexagliflozin tablets
40802474|NCT02544035|OTHER|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;
41152476|NCT06448845|PROCEDURE|Forearm IVRA block|After placement of the forearm double tourniquet and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the forearm tourniquet cuff is inflated to a pressure of 250 mmHg. The forearm tourniquet will be placed 5 cm distal to the medial epicondyle of the humerus and on the top of a circumferentially placed cotton cast. Subsequently, tourniquet failure is ruled out by observing the distal circulation and 25 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand.
41152477|NCT01100372|DRUG|gemcitabine hydrochloride|
41152478|NCT01100372|DRUG|liposome-encapsulated doxorubicin citrate|
41152479|NCT01100372|PROCEDURE|quality-of-life assessment|
41152480|NCT03101098|PROCEDURE|Retroperitoneal liagation of uterine artery|the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH
41006365|NCT02109328|DRUG|Alisertib|"SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle."
41320332|NCT00249977|DRUG|Capecitabine in Combination with Cisplatin and Irinotecan|"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2."
41006366|NCT02109328|DRUG|Paclitaxel|Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
41006367|NCT02109328|DRUG|Placebo|Placebo oral tablets
41006368|NCT01638338|BEHAVIORAL|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
41006369|NCT01638338|BEHAVIORAL|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
41006370|NCT01782313|DRUG|tivozanib|Given PO
41006371|NCT01782313|OTHER|laboratory biomarker analysis|Correlative studies
41006372|NCT01349283|BIOLOGICAL|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
41006373|NCT01349283|BIOLOGICAL|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
41006374|NCT05802693|DRUG|Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection|Infusion of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T(EGFRvIII CAR-T) with Omaya capsule
41006375|NCT01392950|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
41006376|NCT01392950|DEVICE|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
41320333|NCT03521193|DEVICE|patent foramen ovale closure|Pts undergoing PFO closure will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure; they will be compared to healthy subjects on aspirin treatment
41320334|NCT01587573|OTHER|saliva collection prior to clinically driven oral biopsy|cell free saliva to be used to measure mRNA and proteins by PCR and ELISA
41320335|NCT03404635|DRUG|Apixaban|Apixaban as standard of care for VTE
41320336|NCT03404635|DRUG|Rivaroxaban|Rivaroxaban as standard of care for VTE
41320337|NCT02411526|DRUG|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
41320338|NCT02411526|DRUG|Risperdal Consta|Risperdal Consta administered as a IM injection
41320339|NCT02411526|DRUG|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
41320340|NCT00211250|DRUG|Valproic Acid and Depakote ER|
41320341|NCT06006884|PROCEDURE|Bronchoscopies and Bronchoalveolar Lavages (BALs)|Bronchoscopies use a thin, lighted tube, which enters through the mouth or nose and moves down the throat to the airways to look at the lungs. BALs are done during bronchoscopies to collect samples from the lungs for testing. During this procedure, a saline solution is put through the tube to wash the airways and collect a fluid sample.
41320342|NCT06006884|DIAGNOSTIC_TEST|Chest Tomography (CT)|X-ray to create images of the bones and internal organs of the body
40802475|NCT02544035|OTHER|Play Partner|Each child will first play alone then play with parent.
40802476|NCT01581229|PROCEDURE|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
41006377|NCT01587495|DRUG|Ertapenem|Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
41006378|NCT01693328|DRUG|PecFent® (fentanyl) nasal spray|
41006379|NCT03296228|RADIATION|Flexibility Radiographs (supine, supine side-bend, FB)|Supine, supine side-bend, fulcrum bend
41006380|NCT03296228|RADIATION|Flexibility Radiographs (awake traction)|awake traction
41006381|NCT03296228|RADIATION|Flexibility Radiographs (STUGA)|supine traction under GA
41320343|NCT06006884|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Measures the electrical activity of the heart by using sticky pads that are placed on your chest and limbs.
41476282|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 5|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
40802477|NCT01581229|PROCEDURE|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
41006382|NCT01087424|DRUG|R mini CHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
41006383|NCT01988870|RADIATION|Intra-operative Radiation Therapy (IORT)|IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
41006384|NCT05673577|DRUG|Camrelizumab+cetuximab+chemotherapy|"Camrelizumab: 200mg vgtt q3w, 3 weeks as a cycle; Cetuximab first dose 400mg/m2, vgtt, following by 250 mg/m2 after first dose, qw, 3 weeks as a cycle; albumin paclitaxel: 125mg/m2, vgtt, d1, 8, q3w，for up to 6 cycles; cisplatin: 75mg/m2, vgtt，d1，q3w, for up to 6 cycles;~Then, in maintenance therapy, Camrelizumab: 200mg vgtt q2w; Cetuximab 500mg/m2, vgtt q2w until intolerable toxicity or disease progression"
41006385|NCT04587622|DRUG|Icenticaftor|Single oral dose of 300 mg of icenticaftor (QBW251)
41152481|NCT03101098|PROCEDURE|Classical ligation of uterine artery|the site of ligation of uterine artery is the area alongside the cervix
41476283|NCT03357887|OTHER|Analysis of cerebrospinal fluid and serum|Analysis of biomarkers in patient biological samples
41006386|NCT04102475|OTHER|Eatline|"After discharge from a first hospitalization:~Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.~* Added to treatment as usual (TAU): outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
41006387|NCT04102475|OTHER|Control|"After discharge from the first hospitalization:~* No specific phone calls~* TAU: outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
41006388|NCT01689896|DRUG|Testosterone Gel|
41006389|NCT01689896|DRUG|Placebo Gel|
41006390|NCT05399524|OTHER|Standard of Care|Neuronavigation and intraoperative 5-ALA
41006391|NCT05399524|OTHER|Additional pre- and intra-operative imaging|Additional DTI scan during routine pre-operative tumour MRI scan, additional use of intraoperative ultrasound in addition to normal to standard of care (Neuronavigation and intraoperative 5-ALA)
41006392|NCT03148743|BIOLOGICAL|Fecal microbiota|fecal microbiota transplantation
41006393|NCT03825289|DRUG|Hydroxychloroquine|Given PO
41320344|NCT06006884|DIAGNOSTIC_TEST|Pulmonary function tests (PFTs)|Testing to measure how well lungs are working
41320345|NCT06006884|DIAGNOSTIC_TEST|6 minute walk test (6MWT)|Walking test to see how well the lungs function with exercise over 6 minutes
41320346|NCT04745286|DRUG|S-ketamine|Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Agent preparation method of S-ketamine group (Group S): Draw the dosage of S-ketamine 0.25mg ·kg -1 and dilute it with normal saline to 5ml in opaque 5-ml syringes.
41320347|NCT04745286|DRUG|normal saline group|"Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Normal saline group (Group N): 5ml of normal saline, labeled as study agents."
40802478|NCT00612378|DEVICE|GFX System|The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
40802479|NCT05667610|OTHER|Immune-supportive diet|The intervention includes a immune-supportive diet over a period of 4 months
41320348|NCT06215456|DEVICE|Virtual reality therapy|VR therapy will be applied using a head mounted display, the PICO G2 4K headset (Barcelona, Spain). For VRD de application'SyncVR Relax \& Distract' (SyncVR Medical, Utrecht, The Netherlands) will be used. This application contains a wide range of relaxation games, relaxing 360 videos, and relaxation exercises each with a duration of 5-20 minutes. Patients can choose videos, games, or exercises according to their own preferences. For VRH sessions, the application HypnoVR (Strasbourg, France) will be used. This app contains several hypnotic narratives integrating sequences of controlled breathing, cardiac coherence, and hypnotic suggestions. Each VRH sessions can be personalized through selecting different environments and musical compositions.The first VRH session will be set to last 20 minutes and the second VRH session will be set to the continuous setting.
41320349|NCT01724983|DRUG|ketamine|
41320350|NCT01724983|DRUG|fentanyl|
41320351|NCT03141268|DIAGNOSTIC_TEST|Lactulose breath test|Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
41320352|NCT00857753|DRUG|Fentanyl patch 25 ug/nr Sandoz|
40802480|NCT00019968|DRUG|melphalan|
40802481|NCT00019968|DRUG|tumor necrosis factor|
40802482|NCT04497103|OTHER|control|The traditional therapy included immersing the hand in paraffin for 10 min; soft massaging with a moisturizing gel for 5 min; passive mobilization of the wrist, MP, PIP, and DIP joints; active/passive ROM and stretching exercises; strengthening exercises (done in static mode initially and progressed in the second month to dynamic strengthening using elastic bands); desensitizing sensory stimulation of hypertrophic scars, occupational therapy.
40802483|NCT04497103|OTHER|Xbox kinect|The traditional plus Xbox Kinect games were related to five target activities determined according to the person-centered analysis results were chosen for each patient.
41006394|NCT03825289|DRUG|Trametinib|Given PO
41320353|NCT00857753|DRUG|Duragesic|
41320354|NCT01226212|DIETARY_SUPPLEMENT|Synbiotic (Synergy 1/B. longum)|Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum
41320355|NCT01226212|DIETARY_SUPPLEMENT|Placebo|maltodextrose
41320356|NCT04584853|DRUG|Abemaciclib|Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
41320357|NCT04584853|DRUG|Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)|Standard of care endocrine therapy for a minimum of 5 years from randomisation
40802484|NCT04497103|OTHER|task oriented training|The traditional plus the target activities involved training with the materials (clothes, spoons, pencils, buttons, rope, etc) needed for the activity as well as Velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
41006395|NCT01140477|DEVICE|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
41006396|NCT01140477|DEVICE|Accommodating Lens|Accommodating lens implanted after cataract extraction
41006397|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 30 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 30 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
41006398|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 15 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 15 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
41006399|NCT00594828|DEVICE|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
41341812|NCT02997774|OTHER|Standard Dialysis|Having dialysis at a standard temperature (36.5 degrees Celsius)
41341813|NCT02897154|DIAGNOSTIC_TEST|In-vitro|
41006400|NCT00594828|DEVICE|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
41006401|NCT02348528|DRUG|Lenalidomide|
41320358|NCT03686696|DRUG|Beta blocker|Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
41320359|NCT03686696|DRUG|ACEI|Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
41320360|NCT03686696|DRUG|ARB|Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
41320361|NCT00327548|BEHAVIORAL|guided imagery|
41320362|NCT03179696|BEHAVIORAL|Mobile-assisted CBT|mCBTn combines the CBT components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group therapy and mobile smartphone interventions from our prior clinical trials research.
41320363|NCT06269900|DRUG|Dexamethasone|Dexamethasone phosphate injection is given as a slow injection or infusion (intravenous drip) into the veins.
41320364|NCT06269900|DRUG|Placebo|Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.
41320365|NCT06079866|DEVICE|Mask A (Oran Park Mask) then Mask B (Evora Mask)|Mask A (Oran Park Mask) for 7 days followed by Mask B (Evora Mask) for 7 days
41320366|NCT06079866|DEVICE|Mask B (Evora Mask) then Mask A (Oran Park Mask)|Mask B (Evora Mask) for 7 days followed by Mask A (Oran Park Mask) for 7 days.
41320367|NCT05646654|PROCEDURE|Erector spinae plane block|Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected
41320368|NCT05646654|PROCEDURE|Interscalene brachial plexus block|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
41320369|NCT05058898|OTHER|blood samples|5 mL
41476284|NCT01993602|PROCEDURE|Breathing exercises|"The intervention groups (CPAP, VIS, FIS and DB) used the specific device (or not) according to the group allocation.~The intervention was performed 3 times per day, from 1 to 5 postoperative day. Patients performed 5 sets of 10 repetitions of the specific breathing exercise, with 30 seconds rest between each set.~The sessions were held in the morning, early afternoon and early evening, always supervised by a physiotherapist.~Before starting each session, the patient reported the sensation of pain, and if he quantify pain intensity more than 3 in the visual numeric scale (0 to 10) was asked the doctor to administer analgesics aiming that him to perform properly the breathing exercise."
41006402|NCT02348528|DRUG|Dexamethasone|
41320370|NCT05058898|OTHER|Scabs and pus samples|if available
41320371|NCT03701646|DEVICE|Measurement by Clearsight device|Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
41320372|NCT01606735|DRUG|IBI-10090|dexamethasone
41320373|NCT00218426|DRUG|naltrexone implant|naltrexone implant is 1000 mg naltrexone
41320374|NCT00218426|DRUG|oral naltrexone|oral naltrexone 50 mg/day
41006403|NCT04186442|DRUG|Botulinum toxin type A injection|Experimental
41006404|NCT04186442|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
41320375|NCT00218426|DRUG|oral placebo naltrexone|oral placebo naltrexone resembles active medication
41320376|NCT00218426|DRUG|placebo implant|placebo implant resembles active medication
41320377|NCT04165941|BIOLOGICAL|DRI cell therapy|Drug Resistant Immunotherapy with gamma delta modified T cells to be resistance to temozolomide will be infused into the surgical cavity following the completion of standard concurrent radiation and chemotherapy with temozolomide.
41320378|NCT02030613|GENETIC|Blood test|
41476285|NCT01937819|DEVICE|SMART arm|The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
41006405|NCT04634149|DRUG|BMS-986036|Specified dose on specified days
41006406|NCT01565330|DRUG|florbetapir F 18|single dose IV injection
41320379|NCT01313208|DRUG|etanercept|Administered by subcutaneous injection once weekly.
41320380|NCT01313208|DRUG|Placebo|Placebo subcutaneous injection
41320381|NCT01313208|DRUG|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
41320382|NCT06512948|PROCEDURE|High tibial osteotomy|Surgical treatment for patients with osteoarthritis and indications for high tibial osteotomy
41320383|NCT02218372|DRUG|Fidaxomicin oral suspension|Participants from birth to \< 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days.
41320384|NCT02218372|DRUG|Fidaxomicin tablets|Participants aged ≥ 6 years to \< 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
41320385|NCT02218372|DRUG|Vancomycin oral liquid|Participants from birth to \< 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days.
41476286|NCT06389006|DRUG|Disitamab Vedotin for Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed
41476287|NCT06389006|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks,every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
41320386|NCT02218372|DRUG|Vancomycin capsules|Participants aged ≥ 6 years to \< 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
41006407|NCT01008111|DRUG|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
41006408|NCT01008111|DRUG|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
41320387|NCT01160653|DEVICE|FES-IM|implantable Functional Electrical Stimulation
41476288|NCT06389006|DRUG|Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed.
41476289|NCT06389006|DRUG|Cyclophosphamide|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed
41320388|NCT01160653|OTHER|Cognitive training|training of impaired cognitive processes
41476290|NCT01812135|BIOLOGICAL|400 U EV71 vaccine with adjuvant|400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
41476291|NCT06401967|BEHAVIORAL|Pivot Clear|A mobile app and program for alcohol reduction.
41320389|NCT03965793|DEVICE|Automated management of hypotension|Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
41320390|NCT01374217|DRUG|Tadalafil|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
41320391|NCT01374217|DRUG|Lenalidomide|Lenalidomide will be administered as it was prior to study entry.
41320392|NCT01374217|DRUG|Dexamethasone|Dexamethasone will be administered as it was prior to study entry.
41476292|NCT06401967|DEVICE|BACtrack breathalyzer|Personal breathalyzer device that measures blood alcohol content.
41476293|NCT00782028|OTHER|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
41476294|NCT00782028|OTHER|Standard Care|
41320393|NCT01374217|DRUG|Clarithromycin|Clarithromycin will be administered as it was prior to study entry.
41476295|NCT02758860|PROCEDURE|Colonoscopy|Patients will be submitted to diagnostic colonoscopy
41476296|NCT05665959|OTHER|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing.
41476297|NCT04744324|BEHAVIORAL|Self-supporting Care|Individualized self-supporting care with four principals (i.e., drinking water, exercise, excretion, and nutrition)
41476298|NCT04744324|BEHAVIORAL|Home health education|Individualized home health education
41476299|NCT01095042|BEHAVIORAL|emotion|Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.
41006409|NCT05731401|OTHER|Explanations of the cause of pain|"When analyzing the responses to the question Why do you think you have or have had this pain? two themes emerged from the data: 'explanations associated with damage', and 'explanations not associated with damage'.~The themes were sub-classified into sub-themes, according to the type of explanation"
41006410|NCT01256775|DRUG|NCX-4016|NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
41320394|NCT02097433|DRUG|Dacomitinib|A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
41320395|NCT05319080|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp on the left side of the head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
41320396|NCT00618449|DRUG|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 \& Day 30 for a total of 2 doses.
41320397|NCT00618449|DRUG|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
41320398|NCT03596658|DRUG|SHR9549|If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
41320399|NCT05314881|GENETIC|TNFS4, NCF gene|study the gene polymorphisms from the blood sample of the included SLE patients
41476300|NCT05427279|DIETARY_SUPPLEMENT|Placebo|The participant will consume a supplemental dose of a placebo (20g maltodextrin with 50mg vitamin C)
41006411|NCT01256775|DRUG|NCX4016 placebo|NCX4016 placebo b.i.d. for 6 months
41006412|NCT03641378|OTHER|Palliative Care Intervention|team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
41006413|NCT03641378|OTHER|Standard Transplant Care|Standard care per hospital guidelines
41006414|NCT03580096|OTHER|Core stability|Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.
41320400|NCT06460597|OTHER|Papworth Technique|The Papworth breathing technique is used by respiratory physiotherapists to control and correct breathing. Instead of using the chest, Papworth technique encourages to take more relaxed breathing by using the abdomen. Breathing in slowly through the nose and breathing out through pursed lips as if blowing out a candle. Repeat this cycle for 3-5 times
41320401|NCT06460597|OTHER|Pranayama|Pranayama is an ancient breath technique that originates from yogic practices in India. Sitting comfortably, slowly inhale through the nose and count to five. Direct the breath across the back of the throat as you inhale so the air makes a slight hissing sound keeping the lips sealed, breathe out through the nose and try to match the length of your inhale. The breath should make a noise like waves crashing as you exhale. Continue to inhale and exhale using the same process for 5 to 8 minutes. Aim to do this exercise for 10 to 15 minutes as become more practiced.
41320402|NCT03699449|DRUG|olaparib+cediranib combination therapy|Cediranib (30mg p.o. qd) + Olaparib (200mg p.o. bid) until disease progression
41320403|NCT03699449|DRUG|durvalumab + olaparib combination therapy|Durvalumab (1500mg i.v. every 4 weeks starting on week 5 day1 for up to 12 months) + Olaparib (300mg p.o. bid) until disease progression
41320404|NCT03699449|DRUG|durvalumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 6 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
41320405|NCT03699449|DRUG|durvalumab + tremelimumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (75mg i.v. every 4 weeks for up to 4 doses) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin (PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
41320406|NCT03699449|DRUG|durvalumab + tremelimumab + paclitaxel treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (300mg i.v. once) + non-platinum-based standard of care chemotherapy (weekly paclitaxel up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 60mg/m2 (day 1,8,15 every 4 weeks)"
41476301|NCT05427279|DIETARY_SUPPLEMENT|Hydrolized Collagen|The participant will consume a supplemental dose of Hydrolized collagen (20g with 50mg vitamin C)
40802485|NCT05688202|PROCEDURE|Simultaneous combination of fractional CO2 laser and subcision|"Fractional CO2 laser is performed immediately following subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
41006415|NCT03580096|OTHER|Standard intervention|Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.
41006416|NCT03108846|DRUG|Escitalopram|5-15 mg/day (target: 15mg/day if tolerated)
41006417|NCT03108846|DRUG|Placebo|Masked placebo
41006418|NCT00482495|BIOLOGICAL|bevacizumab|
41006419|NCT00482495|GENETIC|gene expression analysis|
41006420|NCT00482495|GENETIC|protein expression analysis|
41006421|NCT00482495|OTHER|laboratory biomarker analysis|
41320407|NCT03699449|DRUG|durvalumab +chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
41320408|NCT00243100|DRUG|vorinostat|Given orally
41320409|NCT00243100|DRUG|gemcitabine hydrochloride|Given IV
41320410|NCT00274872|DRUG|fluorouracil|
41320411|NCT00274872|DRUG|leucovorin calcium|
41320412|NCT00274872|DRUG|oxaliplatin|
41320413|NCT03978624|DRUG|Pembrolizumab|200 mg IV on day 1 and day 22
41320414|NCT03978624|DRUG|Entinostat|5 mg given orally on day 1, day 8 and day 15
41006422|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
41476302|NCT05427279|DIETARY_SUPPLEMENT|PrimaColl|The participant will consume a supplemental dose of PrimaColl, a vegan collagen supplementation (20g with 50mg vitamin C)
41476303|NCT05427279|DIETARY_SUPPLEMENT|Whey protein|The participant will consume a supplemental dose of whey protein (20g whey isolate with 50mg vitamin C)
41476304|NCT04797442|DRUG|WST01 strain product|orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5\*10\^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)
41006423|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
41006424|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
41006425|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose|Injection in the muscle
41006428|NCT03657472|DRUG|CJ-30061|Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
41320415|NCT05334680|DEVICE|ANNE Sensor|The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
41320416|NCT01756066|BEHAVIORAL|Different levels of cost sharing|
41320417|NCT00257023|DRUG|paliperidone|
41476305|NCT04797442|DRUG|placebo powder|orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)
41476306|NCT03696355|DRUG|GDC-0084|Given PO
41320418|NCT04567446|OTHER|Stool|collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
41476307|NCT03696355|RADIATION|radiation therapy|Both photon and proton therapy modalities will be allowed.
41476308|NCT00027794|PROCEDURE|conventional surgery|
41476309|NCT03585959|DEVICE|superDimension™ Navigation System Version 7.2|superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy
41320419|NCT04567446|OTHER|Blood sample|20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
41320420|NCT06148012|OTHER|dental implant|"Digital panoramic radiographs taken during the patients' treatment periods (T0, T1) were used in the study. Measurements of marginal bone levels on radiographs were performed using the Image J software. The distance between the most coronal part of the implant neck and the most apical part of the defect caused by marginal bone loss was measured.~Fractal analysis (FA) was conducted on panoramic radiographs (OPG) with a size of 2952x1435 pixels and a depth of 32 bits. FA on these radiographs at T0 and T1 times was performed using the box counting method determined by White and Rudolp with the ImageJ program(23)."
41320421|NCT06382337|OTHER|Group A : ice cream cone technique|collagen membrane and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
41320422|NCT06382337|OTHER|Group B : the vestibular socket therapy|cortical lamina fixed by bone tacks and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
41320423|NCT00124241|DRUG|telbivudine|
41476310|NCT03494543|PROCEDURE|Endoscopic Papillectomy|Endoscopic resection of ampullary of Vater neoplasms
41476311|NCT04233879|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
41476312|NCT04233879|DRUG|BIC/FTC/TAF|BIC/FTC/TAF 50/200/25 mg FDC tablet taken once daily by mouth.
41476313|NCT04233879|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
41476314|NCT04233879|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL taken by mouth.
41476315|NCT00359788|DRUG|tiotropium|
41006429|NCT03657472|DRUG|Exforge® 5/160mg & Lipitor® 20mg|Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
41320424|NCT00124241|DRUG|lamivudine|
41320425|NCT00418379|DRUG|300 IR (4M)|300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
41006430|NCT00370526|PROCEDURE|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
41006431|NCT06179082|COMBINATION_PRODUCT|Botox then threads|patients in which Botox injection then threads insertion were used
41006432|NCT06179082|PROCEDURE|threads only|patients in which threads insertion only was used
41476316|NCT00359788|DRUG|Combivent (Ipratropium/Albuterol)|
41476317|NCT02504814|DEVICE|Nasal Highflow (NHF)|changes in breathing physiology in NHF
41476318|NCT00293202|DRUG|Etanercept|Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week
41476319|NCT00293202|DRUG|Placebo|Hemodialysis patients will receive Saline by subcutaneous injection twice a week
41476320|NCT00110344|DRUG|Nexavar (Sorafenib, BAY43-9006)|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
41476321|NCT00110344|DRUG|Placebo|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
41476322|NCT00737737|DRUG|MS Contin|
41476323|NCT00737737|DRUG|Placebo|
41476324|NCT01727349|OTHER|HbA1c measurement|
41476325|NCT01727349|OTHER|Oral Glucoce Tolerance Test|Oral Glucoce Tolerance Test
41476326|NCT00990587|DRUG|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
41476327|NCT05457517|DRUG|YL-13027，Sintilimab|"YL-13027 combined with Sintilimab will be used as a cycle for 21 days. YLl-13027 is administered orally twice a day. Starting dose of YL-13027 is 240mg/d，with escalation to 360mg/d in phase Ib, and RP2D was administered orally twice a day in phase II.~Sindilizumab is administered intravenously 200mg every three weeks"
41476328|NCT02226731|DEVICE|Early Belfort-Dildy Balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.
41320426|NCT00418379|DRUG|300 IR (2M)|300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
41476329|NCT02226731|DEVICE|Late Belfort-Dildy balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
41476330|NCT05703035|PROCEDURE|standby while firing staple|VOLUNTEER PATIENTS WHO ACCEPT THE SURGERY WILL HAVE TISSUE CLOSURE AND CUTTING WITH STAPLER IN AVERAGE 30 MINUTES DURING THE SURGERY AND THE PATIENT WILL BE FOLLOWED FOR 30 DAYS.
41476331|NCT00588328|DEVICE|PET/CT scan|PET/CT scans
41476332|NCT05888324|OTHER|Questionnaires|Questionnaires by phone at 1 and 6 months after inclusion
41476333|NCT01815112|OTHER|Magnetic resonance imaging|CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
41476334|NCT01815112|OTHER|Positron emission tomography|Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
41006433|NCT00480636|DRUG|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
41006434|NCT03377946|BIOLOGICAL|probiotics|the probiotics group was taking probiotics 4 packets a day
41006435|NCT03377946|BIOLOGICAL|placebo|the placebo group was taking placebo 4 packets a day
41006436|NCT02100891|PROCEDURE|Allogeneic HCT|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
41006437|NCT02100891|DRUG|Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
41006438|NCT00020670|BIOLOGICAL|CD 40|
41006439|NCT05731934|DRUG|HX301|At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
41006440|NCT05133882|DRUG|Clifutinib Besylate|The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
41320427|NCT00418379|DRUG|Placebo|Placebo tablet
41476335|NCT04172519|OTHER|Pre- and post prostatectomy supervised PMFT|intervention before and after surgery, supervised exercises
41006441|NCT00542152|DRUG|CYCLOSPORINE VS INFLIXIMAB|"* Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.~* Infliximab 5mg/kg at weeks 0, 2 and 6"
41476336|NCT04172519|OTHER|Unsupervised PMFT|intervention after surgery, unsupervised exercises
41476337|NCT04172519|OTHER|Supervised PMFT|intervention after surgery and supervised exercise
41476338|NCT04159519|DRUG|Symbicort®|Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation and Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
41476339|NCT04159519|DRUG|Fasenra®|Participants received Benralizumab 30 mg/mL, 1 mL fill volume via Subcutaneous every 4 weeks for first 3 doses.
41476340|NCT04159519|DRUG|Ventolin®|Participants received Salbutamol sulfate 100 μg per inhalation as needed.
41476341|NCT02282202|DEVICE|Oscillating Positive Expiratory Pressure (Aerobika ®)|"The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.~There is only one intervention for this study. Subjects are on treatment for three weeks and off for the alternate three weeks."
41476342|NCT04837027|BEHAVIORAL|Aerobic training|Aerobic training on stationary bike 5x a week for 30 minutes a day
41006442|NCT01332734|DRUG|Magnesium Sulfate|2 gram in 1 hour
41006443|NCT03829735|OTHER|Human biological samples|Collection of capillary blood for HbsAg testing. Collection of 12 mL of blood for HbsAg positive women and 1 mL for HbsAg positive children.
41006444|NCT03613896|PROCEDURE|conventional dentures|conventional dentures
41006445|NCT03613896|PROCEDURE|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional heat processing
41006446|NCT03117881|BEHAVIORAL|DirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
41006447|NCT03117881|BEHAVIORAL|TeleCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.
41320428|NCT02856685|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
41320429|NCT04348656|BIOLOGICAL|Convalescent plasma|Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.
41320430|NCT00249639|BEHAVIORAL|Contingency management|Rewards valued $1-$100
41320431|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
41320432|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
41476343|NCT04837027|BEHAVIORAL|Balance training|Training 5x a week for 30 minutes. Standard of care
41320433|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
41006448|NCT03117881|BEHAVIORAL|rDirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks by a therapist via videoconferencing technology. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
41006449|NCT05315271|DRUG|Bupivacaine-ketamine injection|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.
17067408|NCT05845606|BEHAVIORAL|Benzodiazepine Taper|The BZ-TP is a 14-week intervention that assists participants in reducing their benzodiazepine prescription through a gradual taper at approximately 10%-20% reduction per week for a total of 12 weeks. Dose reduction will be recommended but not required. This intervention is identical in both arms.
17067409|NCT05845606|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The telehealth delivered CBT is an 11-week intervention that includes psychoeducation, interoceptive exposure, somatic skills, and cognitive restructuring.
41320434|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
41320435|NCT05365386|DEVICE|Tixel C|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology.
41320436|NCT05289076|DRUG|Chemotherapy drug|Different combinations of chemotherapies will be tested in combination with monoclonal antibodies in zebrafish embryos against inplanted patients livermetastatic tissues.
41476344|NCT03902652|PROCEDURE|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
41476345|NCT03902652|PROCEDURE|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
41476346|NCT05208658|OTHER|Experimental: Classical Vision Therapy Treatment|Do classical vision therapy treatment for improve vergence
41476347|NCT05208658|OTHER|Control: Eye Movement Therapy Treatment|Do eye movement therapy treatment in order not to improve vergence
41476348|NCT01612416|DEVICE|RS-3000 OCT measurements|Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
41476349|NCT01587131|BIOLOGICAL|FVH1 - a DNA-based influenza vaccine|0.9 mg FVH1 vaccine
41006450|NCT05315271|DRUG|Bupivacaine injection with intravenous ketamine infusion|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
17067410|NCT05845606|BEHAVIORAL|Health Education|The Health Education (HE) intervention will include 11 weeks of an interactive health education program to match for therapy time. The HE is a published multimedia program addressing various health, wellness and lifestyle topics such as nutrition, dental care, immunizations, health screening, smoking, and time management.
41006451|NCT00117143|DRUG|Romiplostim|Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
41006452|NCT06128525|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41476350|NCT00103402|DRUG|Alfuzosin|
41476351|NCT00103402|DRUG|Placebo|
41006453|NCT06128525|DEVICE|Microwave Ablation|Undergo transperineal MRI/US fusion guided transperineal targeted microwave ablation
41006454|NCT06128525|DEVICE|Multiparametric Magnetic Resonance Imaging|Undergo planning mpMRI of prostate
41006455|NCT06128525|OTHER|Questionnaire Administration|Ancillary studies
41006456|NCT06128525|PROCEDURE|Radical Prostatectomy|Undergo RP
41476352|NCT05424484|DEVICE|Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).
41006457|NCT04347265|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
41320437|NCT04438252|DIAGNOSTIC_TEST|ICDAS II|Index for caries detection
41320438|NCT04438252|DEVICE|CariScan Pro|Device for early caries detection
41320439|NCT04438252|RADIATION|Digital Radiograpgy|Device for digital x-ray imaging
41320440|NCT02293096|DRUG|metoprolol succinate|
41320441|NCT02293096|GENETIC|Genotyping|CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
41320442|NCT02293096|PROCEDURE|CYP2D6 Phenotyping|Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
41476353|NCT02582372|DRUG|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
41320443|NCT04485117|DEVICE|Bispectral Index Monitor|Bispectral Index (BIS) sensor electrodes are applied over the patient's forehead after cleaning the forehead thoroughly with an alcohol swab.
41476354|NCT02582372|DRUG|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
41320444|NCT04485117|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
41476355|NCT03232099|DIETARY_SUPPLEMENT|Red Wine consumption|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
41476356|NCT03232099|OTHER|Period without alcohol consumption|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
41476357|NCT01702779|OTHER|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
41476358|NCT01702779|OTHER|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
41476359|NCT01655524|DRUG|ASSUAGE Protocol|75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
41476360|NCT02046525|BIOLOGICAL|Autologous fecal microbiota therapy|
41476361|NCT02046525|OTHER|Placebo|Saline enema
41476362|NCT00358293|DRUG|Tizanidine (sublingual or oral)|
41476363|NCT04635332|BEHAVIORAL|Food literacy and physical activity promotion interactive group sessions + Developed health promotion intervention materials (booklet)|"Information, skills training, goal setting and feedback interactive group sessions to improve food literacy aimed at increasing consumption of fruits and vegetables~Information, skills training, goal setting and feedback interactive group sessions to increase engagement in moderate physical activity~Information and skills training to increase ability to evaluate nutrition information~In general, focus will be on increasing knowledge, skills and self-efficacy to develop a lifelong healthy and gastronomic relationship with food and physical activity."
41476364|NCT04635332|BEHAVIORAL|Developed health promotion intervention materials (booklet).|In the control arm, participants will only be given the developed intervention materials (designed in form of the usual awareness programs). No group sessions will be conducted
41476365|NCT03432234|OTHER|Biomarkers|This is an observational study, there is no intervention
41476366|NCT00792519|BEHAVIORAL|HIV support group|group support
41476367|NCT00792519|BEHAVIORAL|CBT|group cognitive behavioral treatment
41476368|NCT00141661|DRUG|PF-04494700 - Low Dose Arm|30 mg loading dose for 6 days, followed by 10 mg daily
41476369|NCT00141661|DRUG|PF-04494700 - High Dose Arm|60 mg loading dose for 6 days, followed by 20 mg daily
41476370|NCT00141661|DRUG|Placebo Comparator|Matching placebo.
41476371|NCT02994355|OTHER|Systems Analysis and Improvement Approach|"1. Understanding the cascade from FP clinic enrollment to HIV testing~2. Use process mapping to identify modifiable bottlenecks~3. Define and implement workflow adaptations to eliminate modifiable bottlenecks~4. Monitor change in performance~5. Repeat the analysis and improvement cycle (steps 1-4)"
41476372|NCT03406884|BIOLOGICAL|c-kit+ cells|The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
41476373|NCT05073120|OTHER|Piqray Prescriber's/HCP guide for hyperglycemia|oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA will be provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
41006458|NCT00110812|DRUG|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
41476374|NCT04854252|DRUG|Fentanyl|TIVA opioid-containing anesthesia: fentanyl in a bolus dose of l3 mcg/kg (corrected weight) TIVA opioid-free anesthesia: dexmedetomidine 1-1.5 mcg/kg (corrected weight) for 40 minutes
41006459|NCT05439356|DRUG|Colchicine|Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
41006460|NCT05439356|DRUG|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
41006461|NCT04992559|DRUG|Consolidation Toripalimab|Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
41320445|NCT04485117|DRUG|Sevoflurane|Anesthesia is induced inhalationally by face mask with 8% sevoflurane in 100% oxygen, then decreased to 2-3% in 40% oxygen thoroughout the operation for maintenance of anesthesia.
41476375|NCT00690482|DRUG|AZD1981|Oral tablet, twice daily
41476376|NCT00690482|DRUG|Placebo|Placebo Oral tablet, twice daily
41476377|NCT06180408|OTHER|manual therapy and exercise for the big toe|Maitland mobilization (Grade 3,4), Mulligan mobilization with movement techniques, muscle energy techniques, manual therapy for plantar fascia, strengthening exercises and self-stretching exercises was performed
41320446|NCT04485117|DRUG|Propofol|Anesthesia is induced by propofol (2mg/kg), then maintained using an infusion of fixed concentration (10-15 mg/kg/h) as titrated by the anesthesiologist .
41320447|NCT03516734|DIETARY_SUPPLEMENT|Iron fortified lentils|Lentils will be iron-fortified using NaFeEDTA iron fortificants
40802486|NCT05688202|PROCEDURE|Sequential combination of fractional CO2 laser and subcision|"Fractional CO2 laser conducted two weeks after subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
41320448|NCT03516734|OTHER|Non Iron-fortified lentils|Non-fortified lentils will be provided
41320449|NCT03516734|OTHER|Usual Intake|No lentils will be provided.
41320450|NCT00664209|DRUG|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
41320451|NCT00664209|DRUG|placebo|placebo therapy
41320452|NCT01471860|DEVICE|BAROSTIM NEO System|
41320453|NCT01471860|DRUG|Medical Management|
41476378|NCT06180408|OTHER|lumbar stabilization exercise|core training and myofascial release therapy
40802487|NCT05688202|DEVICE|Fractional CO2 laser|Fractional CO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) on both sides of the face sequentially with a two-week interval between sessions for each face's side by a single physician, with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes. At the first pass, only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density in the static operating mode. At the second pass, the whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density in the static operating mode with less than 10% overlap.
41006462|NCT01239368|PROCEDURE|Adoptive Immunotherapy|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
41320454|NCT00737685|DRUG|cyclophosphamide, fludarabine , thymoglobulin|cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 \& -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 \& -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 \& -1)
41320455|NCT00598169|BIOLOGICAL|rituximab|375mg/m2 on Day 1
41320456|NCT00598169|DRUG|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
41320457|NCT00598169|DRUG|carboplatin|"Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x \[creatinine clearance + 25\]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2."
41320458|NCT00598169|DRUG|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
41320459|NCT00598169|DRUG|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
41320460|NCT00598169|DRUG|ifosfamide|"Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2."
41320461|NCT00598169|GENETIC|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
41320462|NCT00598169|GENETIC|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
41320463|NCT00779324|DRUG|Amantadine Hydrochloride|100 mg every morning and noon
41320464|NCT00779324|DRUG|Placebo|one placebo tablet every morning and 12 Noon
41341814|NCT03228849|PROCEDURE|Suture anchor technique|Suture anchors were used to attach bony fragment. On week 6, patients were then started on physical therapy for 2 weeks.
41341815|NCT03228849|PROCEDURE|Conservative Treatment|The injured finger was immobilized in an aluminium splint for 6 weeks. Patients were then started on physical therapy for 2 weeks.
41320465|NCT05945901|DRUG|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
41476379|NCT00621920|DRUG|FM-601|Dose-escalation, split dosage, liquid
41006463|NCT01239368|BIOLOGICAL|Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)|Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
41006464|NCT01239368|BIOLOGICAL|Th1/Tc1 Rapa Cell Therapy|Th1/Tc1Rapa: 5 x 10e(6) cells/kg
41006465|NCT01613339|OTHER|Balance training using Body awareness therapy|Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Example of exercises are weight-balancing in standing and relaxation exercises.
41006466|NCT04990986|OTHER|Complex intervention|Will be co-developed during the study.
41006467|NCT00907283|DRUG|Deferiprone|15 mg/Kg/twice for 1 year
41006468|NCT03624621|BEHAVIORAL|Functional Remediation|Functional remediation includes directed group sessions tapping into the main cognitive domains affected in depression (executive functioning, attention and memory) as well as their implication in daily living.
41476380|NCT05440331|OTHER|Training with AnesList©|Training with AnesList© as tool
41006469|NCT03624621|DEVICE|Computerized Cognitive Training (CCT)|12 add-on sessions (20-minute long) after each group session to train cognitive domains.
41006470|NCT03624621|BEHAVIORAL|Psychoeducation|12 sessions of psychoeducation on depression, providing information about the disease, causes, consequences and other useful data for the management of depression.
41006471|NCT03624621|DEVICE|Online games|Participants play non-directed online games during 20 minutes after each psychoeducation grup session to make the two active intervention more similar.
41006472|NCT04915404|DRUG|Berubicin Hydrochloride|Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
41006473|NCT02487589|OTHER|Telephone support, telemonitoring and tele-exercise|"The care model will provide 24/24 h assistance for six months and include:~Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .~Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.~Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist."
41006474|NCT01918475|DRUG|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
41006475|NCT01918475|DRUG|Placebo|1ml of NaCl 0.9% is administered intravenously
41006476|NCT03730948|BIOLOGICAL|DC vaccine|DC vaccine for colorectal cancer
41006477|NCT05208216|DEVICE|Geko device|A small battery powered device that provides neuromuscular stimulation to the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
41006478|NCT05208216|DEVICE|Flowtron DVT|A pneumatically powered pair of calf boots device that intermittently compress the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
41006479|NCT04620148|DRUG|TAK-242|TAK-242 concentrate solution 80 mg/mL for dilution and infusion
41006480|NCT04620148|DRUG|Placebo|Matching placebo concentrate solution
41006481|NCT03945877|OTHER|No interventions|No interventions
41006482|NCT06408116|RADIATION|photon|radiation with 4-5 cm safte margin
41006483|NCT06408116|PROCEDURE|surgical therapy|surgery based on PET-CT/MRI staging
41006484|NCT06408116|DRUG|Chemotherapy|neoadjuvant chemotherapy
41006485|NCT04564625|OTHER|Vitamin D Assessment|index admission vitamin D assessment
41006486|NCT04564625|OTHER|Fracture|rate of nonunion (i.e., failure of a fractured bone to heal)
41476381|NCT02584088|OTHER|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
41476382|NCT01071447|OTHER|Nurse-led clinic vs rheumatologist-led clinic|The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
41320466|NCT05945901|DRUG|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
41320467|NCT03265743|OTHER|Self-report Written Questionnaire|Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
41320468|NCT04229472|DIAGNOSTIC_TEST|High density electrophysiological mapping|Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.
41320469|NCT04229472|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Late gadolinium enhance cardiac magnetic resonance imaging (in AcQMap group only)
40802488|NCT05688202|PROCEDURE|Subcision|Subcision is operated in all participants using an 1812G Nokor needle (BD Nokor™ Admix Needles, Becton, Dickinson and Company, New Jersey, United States). The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine. After obtaining appropriate anesthesia, a Nokor needle is inserted into the skin close to the depressed scars and progressed until it lays precisely under the scar. The insertion depth is at the dermal-hypodermal junction. Initially, the subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue. Once the fibrous mass has been sufficiently fractured, the needle is slid in a direction parallel to the skin's surface in order to detach the scar from its tethers. For densely fibrous scars, several needle insertion sites are used to undermine the defect from various angles.
40802489|NCT05688202|DRUG|Lidocaine/Prilocaine 2.5%-2.5% Topical Application Cream|Preoperative, lidocaine 2.5% and prilocaine 2.5% cream (EMLA 5%, eutectic mixture of local anesthetic; AstraZeneca LP, Wilmington, DE, USA) is applied under occlusion for 60 minutes prior to the removal of local anesthetics
40802490|NCT05688202|DRUG|Paracetamol|A 500 mg paracetamol-based oral analgesic (Efferalgan, Upsa SAS, France) is administered right before the procedure.
40802491|NCT05688202|DRUG|Lidocaine 2% Injectable Solution|The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine.
40802492|NCT05889793|DRUG|Emetine Hydrochloride|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
40802493|NCT05889793|DRUG|Placebo|Participant takes a placebo for 10 consecutive days.
40802494|NCT03144128|DIETARY_SUPPLEMENT|Vitamin D|5,000IU vitamin D given daily for 12 weeks
40802495|NCT03144128|DIETARY_SUPPLEMENT|Placebo|Placebo capsules given daily for 12 weeks
40802496|NCT01863069|DRUG|Interferon beta 1a|
41320470|NCT03534726|DEVICE|7 T CMR|7 tesla MRI device
41320471|NCT05275621|DEVICE|Virtual Reality|"A Virtual Reality game is provided through a headset. Subjects play in a virtual environment. Positioning of the headset occurs before starting the procedure and is maintained throughout the procedure. The headset used will be Oculus Rift 2 by Facebook Tech. ltd.. The software is designed specifically for the purpose by Softcare Studios. The game played is called Drums."
41320472|NCT05275621|PROCEDURE|PICC positioning|A PICC is inserted under ultrasound guidance through a modified Seldinger technique in a deep vein of the upper arm. The skin is infiltrated with 0.5-1ml 2% lidocaine before dilation of the skin. Tip guidance and positioning is achieved through intracavitary ECG.
41320473|NCT05175209|DIAGNOSTIC_TEST|EMG|Electromyelography
40802497|NCT01863069|DRUG|(IM) AVONEX®|
40802498|NCT00599534|DRUG|Montelukast|4 mg oral tablets
40802499|NCT00599534|DRUG|Placebo|5mg tablets
40802500|NCT00796731|DRUG|SAR3419|administered by intravenous infusion
40802501|NCT03063723|DRUG|Ledipasvir-Sofosbuvir|8 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
41320474|NCT03563456|BEHAVIORAL|structured combined exercise|A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.
40802502|NCT03063723|DRUG|Daclatasvir-Sofosbuvir|7 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
40802503|NCT06316856|DRUG|Autologous CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
40802504|NCT06316856|DRUG|Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
40802505|NCT06316856|DRUG|Newly matched donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
40802506|NCT05606211|OTHER|No intervention|Observational, no intervention
40802507|NCT06532929|DEVICE|Orthopaedic surgeries (ankle)|ankle lateral ligament reconstruction in ligamentoplasty procedures
40802508|NCT06532929|DEVICE|Orthopaedic surgeries (shoulder)|rotator cuff repair
41320475|NCT03563456|BEHAVIORAL|cardiorespiratory exercise|Once per week continuous cardiorespiratory training of moderate intensity
40802509|NCT06532929|DEVICE|Orthopaedic surgeries (knee)|knee cruciate ligaments reconstruction in ligamentoplasty procedures
40802510|NCT06532929|DEVICE|Orthopaedic surgeries|rotator cuff repair or closure of capsule after arthroplasty surgery
40802511|NCT06532929|DEVICE|Orthopaedic surgeries (foot)|stabilization of metatarsal and phalangeal osteotomies during treatment of hallux
41320476|NCT00693680|DIETARY_SUPPLEMENT|Zincas Forte|25 mgZn/day + imipramine (100-200mg/day)
41476383|NCT00295139|BEHAVIORAL|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)|Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
40802512|NCT02574884|PROCEDURE|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
41320477|NCT00693680|DIETARY_SUPPLEMENT|Placebo|placebo + imipramine (100-200mg/day)
40802513|NCT03760887|OTHER|Home exercise program only|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program only
40802514|NCT03760887|OTHER|Home exercise program and home program of sensory discrimination|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program and two 5 minutes sessions of sensory training at home each day.
40802515|NCT00319202|DRUG|Candesartan|32 mg/d for 6 months
40802516|NCT00319202|DRUG|Placebo|Placebo administration for 6 months
40802517|NCT02543073|BIOLOGICAL|MSCs|MSCs will be given at a median dose of 1×10\^6 cells/kg once weekly for 4 weeks as one cycle treatment.
40802518|NCT02543073|DRUG|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
40802519|NCT02543073|DRUG|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
41006487|NCT02044536|OTHER|No intervention|retrospective data review
41006488|NCT04999631|DRUG|Squaric Acid Dibutyl Ester|Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.
41006489|NCT04999631|DRUG|Ethanol Solution|Control
41006490|NCT01144156|DRUG|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
41006491|NCT06366971|OTHER|The Patient Education|The patient education will be given through a brochure and the content of the education included an exercise training consisting of simple exercises for lumbar stabilization (supine bridge, cat-camel, and lumbar stretching) and the participants will be asked to perform these exercises in 3 sets of 10 repetitions 3 days a week for 6-weeks.
41320478|NCT01499901|PROCEDURE|bilateral cochlear Implantation in sequential|bilateral cochlear Implantation in sequential
41320479|NCT01499901|PROCEDURE|bilateral cochlear Implantation in simultaneous|bilateral cochlear Implantation in simultaneous
41320480|NCT00661102|DRUG|Corticosteroids|As prescribed
41476384|NCT00295139|BEHAVIORAL|Supportive Treatment in Addiction Recovery (STAR)|Manualized substance abuse treatment as usual
41476385|NCT00295139|BEHAVIORAL|Critical Time Intervention (CTI)|Case management component
41476386|NCT01430975|DRUG|CardioGen-82|CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously
41320481|NCT00661102|DRUG|Placebo|As prescribed
40802520|NCT05330494|OTHER|transcutaneous electrical acupoint stimulation(TEAS)|transcutaneous electrical acupoint stimulation (TEAS), the modern therapies derived from traditional acupuncture, which could activate nerve endings or fibers and generate action potentials.s. TEAS uses self-adhesive electrodes placed on the surface of acupoints, instead of needles for electrical stimulation.The resulting stimulation signals, which are transmitted to the spinal cord and brain, stimulate the central nervous system to generate specific chemical mediators to induce relevant physiological effects.
40802521|NCT02152475|DRUG|mouthwash with curcumin|Mouthwash with 20 ml of curcumin solution for 5 minutes
40802522|NCT02152475|DEVICE|blue LED illumination|Oral cavity was illuminated with blue light for 5 minutes
40802523|NCT03226249|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
40802524|NCT03226249|DRUG|Dacarbazine|Given IV
40802525|NCT03226249|DRUG|Doxorubicin Hydrochloride|Given IV
41006492|NCT06366971|OTHER|The Pelvic Proprioceptive Neuromuscular Facilitation Techniques Training|The content of the pelvic proprioceptive neuromuscular facilitation techniques training will include the application of the anterior depression pattern with the rhythmic initiation technique and the application of the posterior elevation pattern with the contract-relax stretch technique. All PNF techniques will be performed in 3 sets of 10 to 12 repetitions. The pelvic proprioceptive neuromuscular facilitation techniques training will be delivered face to face 3 days a week for 6 weeks by an experienced and trained physiotherapist.
40802526|NCT03226249|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
41320482|NCT00661102|DRUG|capecitabine [Xeloda]|As prescribed
41320483|NCT00661102|DRUG|dexpantenol [Bepantol]|As prescribed
41320484|NCT04791267|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
41006493|NCT03129672|PROCEDURE|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
41006494|NCT02321982|OTHER|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
41320485|NCT05557669|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is a procedure of removal of the gallbladder and a gold standard in treatment of gallstone disease.
41320486|NCT02445599|DRUG|Diclofenac|Orally 100 mg Diclofenac, administered 1 hour before surgery
41476387|NCT01430975|DRUG|CardioGen-82|Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.
41476388|NCT02335515|DEVICE|Soctec|Gastroretentive Drug Delivery System
41476389|NCT05322902|DRUG|remimazolam group|Remimazolam 6 mg/kg/hr is administered as an intravenous infusion until the patient loses consciousness. Anesthesia is maintained at 1 mg/kg/hr of remimazolam. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
41476390|NCT05322902|DRUG|propofol group|Propofol intravenous infusion is initiated by the application of a target concentration infusion (TCI) pump to cause the patient to lose consciousness. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
41476391|NCT06273020|DRUG|Cerebrolysin|Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days
41006495|NCT05637645|PROCEDURE|Midline Approach|In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
41320487|NCT02445599|DRUG|Midazolam|5 mg Dormicum intramuscularly, administered 1 hour before surgery
41320488|NCT02445599|DRUG|Atropine|0.5 mg Atropine intramuscularly, administered 1 hour before surgery
41320489|NCT02445599|DRUG|bucain + fentanyl|Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
41320490|NCT02445599|DRUG|Nalbuphine|1st choice for rescue analgetic 10-20 mg intravenously
41320491|NCT02445599|DRUG|Diclofenac|2nd choice for rescue analgetic 250ml intravenously
41320492|NCT02445599|DRUG|Metamizole-sodium|Additional rescue analgetic 2g intravenously
40802527|NCT03226249|OTHER|Laboratory Biomarker Analysis|Correlative studies
40802528|NCT03226249|BIOLOGICAL|Pembrolizumab|Given IV
41006496|NCT05637645|PROCEDURE|Paramedian Approach|The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
41006497|NCT05637645|PROCEDURE|Taylors approach|his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
41320493|NCT02445599|DRUG|Tramadol|Additional rescue analgetic 100mg intravenously
41320494|NCT01853436|DEVICE|Strattice™ Reconstructive Tissue Matrix|Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
41320495|NCT00004418|DRUG|glyceryl trierucate/glyceryl trioleate|Administration of glyceryl trierucate/glyceryl trioleate
41320496|NCT00868166|DRUG|Olesoxime|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
41320497|NCT00868166|DRUG|Placebo Comparator|2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
41320498|NCT00868166|DRUG|Riluzole|Riluzole given as add-on therapy 50mg bid
41320499|NCT02000453|DRUG|GSK2586184 400mg|White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
41320500|NCT03148626|OTHER|MINDI mindfulness curriculum|A seven-session mindfulness curriculum implemented over six-months during pediatric internship.
41320501|NCT03148626|OTHER|Control|Usual Education
41476392|NCT06273020|PROCEDURE|Brain-MRI with contrast after 10-14 days of cerebrolysin|Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging. DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue.The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.
41476393|NCT04293549|DRUG|Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops|"rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment"
40802529|NCT03226249|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
40802530|NCT03226249|DRUG|Vinblastine Sulfate|Given IV
41320502|NCT05093998|DRUG|AV5080|oral hard gelatin capsules
41320503|NCT05093998|OTHER|Placebo|Hard gelatin capsules with a white body
41320504|NCT01405118|DRUG|Metformin/CP-690,550|Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
41320505|NCT02307656|DRUG|Atazanavir|
41320506|NCT02307656|DRUG|Cobicistat|
41320507|NCT02307656|DRUG|Active Pharmaceutical Ingredient|
41320508|NCT01431144|PROCEDURE|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
41476394|NCT04523324|BIOLOGICAL|Flublok™ Quadrivalent by Sanofi, Inc.|0.5 mL intramuscular dose of Flublok
41476395|NCT04523324|BIOLOGICAL|VaxigripTetra™ by Sanofi, Inc.|0.5 mL intramuscular dose of Vaxigrip
41476396|NCT01164306|BEHAVIORAL|LifeSkills Training|"LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.~Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions."
40802531|NCT03208660|DRUG|Fycompa|Oral suspension
41476397|NCT01164306|BEHAVIORAL|Healthy Lifestyle Behavior Choices|"The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.~Parents will also be given health related information by mail to parallel the information students receive in school health classes."
41476398|NCT01164306|BEHAVIORAL|NRT and Motivational Interviewing (MI)|For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
41476399|NCT02612454|DRUG|Dupilumab|Weight-tiered dosing administered subcutaneous (SC)
41476400|NCT00287313|DRUG|Vitamin K|
41476401|NCT05150756|DRUG|Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]|At induction of anesthesia, patients will receive a loading dose of 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% till the end of surgery
41476402|NCT05150756|DRUG|morphine sulphate (10mg/ ml ampoule)|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
40802532|NCT04772352|DRUG|febuxostat treatment|According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
40802533|NCT04772352|BEHAVIORAL|lifestyle intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
40802534|NCT03727022|DRUG|Placebo|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
40802535|NCT03727022|DRUG|SM04690|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
41320509|NCT01431144|PROCEDURE|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
41320510|NCT06467123|OTHER|Tissue Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
41320511|NCT06467123|OTHER|Biopsychosocial Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
41320512|NCT02461394|DEVICE|Blood glucose monitoring systems for self-testing|
41320513|NCT03536598|DRUG|Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg|
41320514|NCT03536598|DRUG|Amlodipine 10 mg + Valsartan 160 mg|
41320515|NCT03536598|DRUG|Valsartan 160 mg + Rosuvastatin 20 mg|
41320516|NCT04603391|DRUG|dl-Methylphenidate plus Cannabidiol|Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution
41320517|NCT04603391|DRUG|dl-Methylphenidate plus Cannabidiol Placebo solution|Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution
41320518|NCT01398267|DRUG|aleglitazar|150 mcg orally daily, 4 weeks (Day 15 to Day 43)
41476403|NCT02382549|DRUG|BRAF inhibitor|BRAF inhibitor
41476404|NCT02382549|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
41476405|NCT02382549|DRUG|MEK inhibitor|MEK Inhibitor
41476406|NCT02790541|DEVICE|Hyperbaric Oxygen Therapy|60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
41476407|NCT03875014|DEVICE|surgery with implant for hip fracture|hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed
41476408|NCT03452124|DEVICE|I quit ordinary smoking (IQOS)|I quit ordinary smoking (IQOS) assisted cessation program
40802536|NCT02181491|OTHER|[11C]-P943|
40802537|NCT01014572|BEHAVIORAL|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
40802538|NCT01014572|DRUG|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
40802539|NCT01014572|BEHAVIORAL|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
40802540|NCT06489184|DRUG|Zanubrutinib|patients with treatment naive or R/R CLL who treatment with Zanubrutinib
41320519|NCT01398267|DRUG|lisinopril|20 mg orally daily, 6 weeks (Day 1 to Day 43)
41320520|NCT01398267|DRUG|placebo|aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
40802541|NCT03993444|BEHAVIORAL|communication and problem solving|a program for supervisors and employees including skills training, validating communication, problem solving
41320521|NCT05787652|BEHAVIORAL|ARTEMIS mobile app|Access to a self-regulation based mobile application.
41476409|NCT03452124|OTHER|Conventional cigarette|Conventional cigarette smoking continuation
41320522|NCT01500928|DEVICE|SOLO insulin pump|Use of the SOLO insulin pump for treatment of type 1 diabetes.
41476410|NCT01492972|RADIATION|Radiation|"Consists of:~1. Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~2. High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~3. Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)"
41476411|NCT01492972|DRUG|Androgen Suppression Therapy|Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
41476412|NCT01563926|DRUG|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
41476413|NCT04438590|DIETARY_SUPPLEMENT|Kelulut Honey|The Substance being tested to be used as an alternative
41476414|NCT04438590|DIETARY_SUPPLEMENT|Carborie|The commercially available substance
41476415|NCT03442881|PROCEDURE|Excision of adnexal mass through laprotomy|Through laparotomy incision, the adnexal mass will be excised
41476416|NCT02365259|DEVICE|Phototherapy|Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
41476417|NCT00253981|DEVICE|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
41476418|NCT03121014|DRUG|Fludarabine|40 mg/m\^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
41476419|NCT03121014|DRUG|Busulfan|targeting a 4800μM/min/ day from day -5 through day -2
41476420|NCT03121014|DRUG|ATG|0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
40802542|NCT03993444|BEHAVIORAL|psychoeducation|lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
40802543|NCT00982046|DEVICE|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
40802544|NCT00982046|DEVICE|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
40802545|NCT00982046|DEVICE|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
40802546|NCT00982046|DEVICE|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
40802547|NCT00982046|DEVICE|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
40802548|NCT00982046|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
40802549|NCT02894957|DRUG|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
40802550|NCT03211611|BEHAVIORAL|Questionnaire given to the two groups|"Questionnaire given to the two groups :~Patients with BRCA ½ mutation GP"
40802551|NCT04834193|PROCEDURE|Endoscopic ultrasound-guided fine-needle biopsy|Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)
40802552|NCT04492748|COMBINATION_PRODUCT|Collagen and platelet rich plasma (PRP)|Ultrasound guided injections
40802553|NCT04492748|COMBINATION_PRODUCT|Collagen|Ultrasound guided injections
41006498|NCT03234738|DRUG|TP-271|multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
41006499|NCT03234738|DRUG|Placebo|Placebo is sterile 0.45% saline randomized 3:1 to receive
41006500|NCT02191189|DRUG|Nevirapine suspension, into Enterion™ capsule|
41006501|NCT02191189|DRUG|Nevirapine suspension|
41320523|NCT02849249|BIOLOGICAL|allergovac polimerized (100/100)|Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.
41320524|NCT06210958|OTHER|Intertransverse process block|The patients will be randomized into 2 groups which will receive the different techniques of the intertransverse process block
41476421|NCT03121014|RADIATION|Total Marrow Irradiation|dose of 3Gy on days -3, -2 and -1
41476422|NCT03121014|PROCEDURE|Stem Cell Product Infusion|Day 0 according to BMT unit policy
41476423|NCT03121014|DRUG|Tacrolimus|The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
41476424|NCT03121014|DRUG|Methotrexate|5mg/m\^2 on Day 1, 5 mg/m\^2 on Days 3, 6 and 11
40802554|NCT04492748|COMBINATION_PRODUCT|Platelet rich plasma (PRP)|Ultrasound guided injections
41006502|NCT03015051|DRUG|Oxygen|
41006503|NCT03397290|DEVICE|Ultrasound (US) Imaging|Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
41006504|NCT01748786|BEHAVIORAL|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
41320525|NCT00720421|DRUG|AZD7325|AZD7325 10 mg oral 2 capsules
41320526|NCT00720421|DRUG|AZD7325|AZD7325 1 mg oral 2 capsules
41320527|NCT00720421|DRUG|AZD7325|AZD7325 Placebo oral 2 capsules
41320528|NCT00720421|DRUG|Lorazepam|Lorazepam 1 mg oral 2 tablets
41476425|NCT06467565|DRUG|Liposomal irinotecan|NALIRIFOX（Oxaliplatin 60 mg/m2 IV over 2 hours ; Liposomal Irinotecan 50 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion） on days 1 of a 14-day cycle.
41476426|NCT06151782|DIETARY_SUPPLEMENT|Wheat gluten 1000 mg|Nothing to add here
41476427|NCT06151782|DIETARY_SUPPLEMENT|Barley gluten 1000 mg|Nothing to add here
41476428|NCT06151782|DIETARY_SUPPLEMENT|Barley gluten 50 mg|Nothing to add here
41476429|NCT06151782|DIETARY_SUPPLEMENT|Barley hydrolyzed gluten 50 mg|Nothing to add here
40802555|NCT00703274|BEHAVIORAL|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
40802556|NCT03828097|DIETARY_SUPPLEMENT|Experimental supplement|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
40802557|NCT03828097|DIETARY_SUPPLEMENT|Placebo|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
40802558|NCT04377321|DRUG|Colchicine Tablets|colchicine tabletes for 6 months
40802559|NCT05755932|DRUG|HFO MDI|"* Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA"
41006505|NCT01748786|OTHER|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
41006506|NCT05054530|DRUG|GMA106 Injection|GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.
41006507|NCT05054530|DRUG|GMA106 Matching Placebo|Matching Placebo for GMA106
41476430|NCT05442242|PROCEDURE|Unicompartmental knee arthroplasty|Medial Unicompartmental knee arthroplasty
41476431|NCT05442242|PROCEDURE|High tibial osteotomy|Medial open wedge high tibial osteotomy
41476432|NCT03798379|OTHER|Exercise|Strengthening, balance and aerobic exercises were explained to the patients examined before chemotherapy sessions and demonstrated by applying on the patient.
41476433|NCT04194684|DRUG|nab-paclitaxel|nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
41476434|NCT03478228|OTHER|Multi-Sensory Training|
41476435|NCT04762459|DRUG|Almonertinib|Almonertinib 110mg PO once daily
41476436|NCT04762459|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) Pemetrexed
40802560|NCT05755932|DRUG|HFA MDI|"* Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA."
40802561|NCT02147210|OTHER|biological analysis|
40802562|NCT02144688|DRUG|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
40802563|NCT02819843|DRUG|TALIMOGENE LAHERPAREPVEC (TVEC)|
40802564|NCT02819843|RADIATION|Hypofractionated Radiotherapy|
40802565|NCT06166459|PROCEDURE|Drug-coated balloon combined with provisional drug-eluting stent implantation|(1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).
40802566|NCT02244840|DEVICE|Electronic bidet|commercial electronic bidet
40802567|NCT02244840|DEVICE|Sitz bath|Conventional sitz bath
40802568|NCT05850819|DRUG|Colloidal silver gelatin sponge|Augment the extraction socket with Gelatamp
41006508|NCT00447928|DRUG|OrthoDerm transdermal nitroglycerin patch|
41006509|NCT06210529|DEVICE|a high-intensity focused ultrasound tumor treatment system (Super Knife)|All participants will be randomly divided into groups A and B. Participants in group A will receive a high-intensity focused ultrasound tumor treatment (Super Knife) once, and participants in group B will receive treatment twice (4 weeks, one cycle).. Breast cancer surgery was performed at 3 months ± 1 week after the Super Knife treatment.
41476437|NCT04762459|DRUG|Cisplatin|75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
41476438|NCT01491035|DRUG|Vortioxetine|5 mg tablets for 14 days; orally; once daily
41476439|NCT01491035|DRUG|Vortioxetine|10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily
41476440|NCT01491035|DRUG|Vortioxetine|15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily
41476441|NCT01491035|DRUG|Vortioxetine|20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
41476442|NCT02760706|DEVICE|Computed Tomography scan|
41476443|NCT01882179|DRUG|Mineralocorticoid receptor antagonist potassium-canrenoate|
41476444|NCT01882179|DRUG|placebo|
40802569|NCT05850819|DRUG|Sterile gauze pack|Extraction socket allowed to heal without augmentation with any material
41006510|NCT00753207|DRUG|epirubicin hydrochloride|
41006511|NCT00753207|DRUG|lapatinib ditosylate|
41006512|NCT00753207|OTHER|biomarker analysis|
41006513|NCT00753207|OTHER|immunohistochemistry staining method|
41006514|NCT00753207|OTHER|liquid chromatography|
41006515|NCT00753207|OTHER|mass spectrometry|
41006516|NCT05779566|DIAGNOSTIC_TEST|bone densitometry|bone densitometry every 6 month
41006517|NCT06265402|PROCEDURE|Tab block versus retrolaminar block in abdominal plastic surgery|i inject 20ml bupivacine either 4mg dead in each side
41006518|NCT05908279|OTHER|Walking test|Walk with and without a metronome
41006519|NCT05908279|OTHER|Disease assessement|Disease stage assessed by a doctor
41006520|NCT02215590|DEVICE|Re-Step|"Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week."
41006521|NCT04126512|OTHER|PDA ligation|PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
41006522|NCT05566340|PROCEDURE|mitral valve repair|Repair of mitral valve concomitant to aortic valve replacement.
41320529|NCT00720421|DRUG|Lorazepam|Lorazepam Placebo oral 2 tablets
41320530|NCT01870219|DRUG|Sevoflurane|sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
41320531|NCT01870219|DRUG|Ketamine|ketamine was given to 1mg/kg ıv bolus
41320532|NCT03837353|DRUG|DKN-01|DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.
41320533|NCT03837353|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.
41320534|NCT00000240|DRUG|Buprenorphine|
41320535|NCT03803592|BEHAVIORAL|Dyadic MCS program|"In the first 4 weeks, the dyads will attend the center-based FTF sessions. Each session will last for 1.5 hours. In the first 60 minutes, MCS activities (e.g. reality orientation, calculation and drawing) will be led by an occupational therapist. Skills in delivering the MCS activities will also be taught to equip CG with skills in leading the home-based sessions later. CG will leave in the last 30 minutes to attend a psychoeducation group on caregiving (led by social workers) and the PWD will continue the session.~From week 5 onwards, The home based session (Week 5-15) will be delivered by the CG 3 times weekly at home (30 - 45min/ session).The sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions held on the 8th and 12th week over the period."
41320536|NCT03040765|DRUG|Denosumab 60 MG/ML Prefilled Syringe|Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major
41320537|NCT03040765|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
41320538|NCT03181074|OTHER|Non-Interventional|Non-Interventional
41320539|NCT03905395|BEHAVIORAL|Meditation and mindfulness|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
41320540|NCT04402346|PROCEDURE|Radiofrequency-assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a radio frequency device
41320541|NCT04402346|PROCEDURE|Stapler assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a stapler device with/without seamguard
41320542|NCT06161155|COMBINATION_PRODUCT|Protein digestibility|"Two protein sources differing in digestiblity will be used in the dietary intervention to create a difference in protein flow into the large intestine, resulting in different levels of protein fermentation.~Participants will swallow an ingestible that senses biomarkers related to protein fermentation."
41320543|NCT05977153|PROCEDURE|PEEP (positive end-expiratory pressure) - maximum|"Breathing assistance from the breathing assist machine using a method in which doctors try to find the pressures that expands the lungs the best. This is based on measurements of one's respiratory pressures and volumes. This is done by adjusting the pressure settings. This allows one's lungs to expand with the least amount of change in pressure during breathing.~PEEP (positive end-expiratory pressure) will be set at the maximum static respiratory system compliance (Crs) during a descending PEEP titration curve."
41320544|NCT05977153|PROCEDURE|PEEP (positive end-expiratory pressure) - standard|"Breathing assistance from the breathing assist machine using the pressure settings typical for your disease.~Standard ARDSNet low-stretch PEEP (positive end-expiratory pressure) protocol: PEEP will be set following a routinely used PEEP table according to patients' blood oxygenation status."
41320545|NCT06362460|DRUG|[14C] RAY1216|400 mg suspension containing 100μCi of \[14C\]RAY1216
40802570|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
41006523|NCT04776967|PROCEDURE|Hyperbaric Compression Profile|A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.
41006524|NCT00774098|DRUG|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
41006525|NCT00774098|DRUG|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
41320546|NCT02625675|OTHER|Ultrasound scan|
40802571|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
41320547|NCT04782180|DRUG|Descovy 200Mg 25Mg Tablet|daily Descovy tab by mouth
41320548|NCT04782180|BEHAVIORAL|PrEP|PrEP will be provided in a community setting by community-based harm reduction program.
40802572|NCT03605927|DRUG|BMS-986004|BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended dose level in the phase 1 expansion cohort.
41006526|NCT00774098|DIETARY_SUPPLEMENT|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
41320549|NCT02405585|DRUG|mFOLFIRINOX|mFOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
41006527|NCT00774098|DRUG|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
41320550|NCT02405585|BIOLOGICAL|Algenpantucel-L Immunotherapy|HAPa1 and HAPa2 immunotherapy components Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection for up to 28 doses total.
41320551|NCT02405585|RADIATION|SBRT|Subjects that have at least stable disease at evaluation (day 93-100) are eligible to receive SBRT radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
40802573|NCT03605927|DRUG|Sirolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
40802574|NCT03605927|DRUG|Tacrolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
41006528|NCT05349162|DEVICE|Implantable cardioverter defibrillator use|Implantation of an implantable cardioverter defibrillator (epicardial or transvenous)
41006529|NCT00189748|DRUG|Tacrolimus|
41320552|NCT02405585|DRUG|Gemcitabine|"Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.~Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles after surgical resection."
41320553|NCT01641757|PROCEDURE|non-surgical periodontal therapy|dental scaling and root planing of full mouth will be done
41320554|NCT03173586|OTHER|Sugar sweetened beverage (SSB)|This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
41320555|NCT04447703|OTHER|Interview|Attend Interview
41320556|NCT04447703|OTHER|Internet Based Intervention|Use web-based genetic education tool online
41320557|NCT04447703|OTHER|Survey Administration|Ancillary Studies
40802575|NCT06552793|BIOLOGICAL|autogenous partially demineralized dentin graft|tooth cleaning : form decay, tartar, soft tissue debris, fillings, cement then cut into fragments (5×5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). A disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.The decontamination of the granules will take place through UVA rays and ultrasounds, with temperature variations always lower than 43 ◦C to avoid damage to proteins. After 25 min, particle graft biomaterials will be obtained. The particles size will range from 815 µm with peaks up to 1110 µm.
40802576|NCT06552793|BIOLOGICAL|Xenograft|Cortico-cancallous Bovine powder
40802577|NCT02942836|DEVICE|non-intrusive respiration monitor|Equivalence of CareTaker's respiration rate detection capability to that of predicate device
41006530|NCT01302821|BIOLOGICAL|Adenovirus-p53 transduced dendritic cell vaccine|The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
41006531|NCT01302821|DRUG|1-methyl-D-tryptophan|Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
41006532|NCT01302821|RADIATION|Carbon C 11 alpha-methyltryptophan|The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
41006533|NCT01045304|DRUG|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
41006534|NCT01045304|DRUG|Gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
41006535|NCT01045304|DRUG|Carboplatin|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
41006536|NCT05242510|PROCEDURE|Patching|The subject will occlude the non-dominant eye for 24 hours.
41006537|NCT05242510|PROCEDURE|Prism Adaptation|The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.
41320558|NCT04447703|OTHER|Genetic Counseling|Receive in-person, telehealth, or over-the-phone genetic counseling
41320559|NCT04447703|GENETIC|Genetic Testing|Undergo genetic testing
40802584|NCT00952861|DRUG|Doxycycline|200 mg QD in 5 days
40802585|NCT00952861|DRUG|Placebo (matching)|Placebo QD i 5 days
40802586|NCT04416152|PROCEDURE|Pelvic reconstruction surgery|Pelvic reconstruction surgeries, such as anterior/posterior colporrhaphy, sacrospinous ligament fixation, transvaginal mesh repair and sacrocolpopexy.
40802587|NCT05514535|DRUG|Semaglutide|Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.
40802588|NCT05514535|DRUG|Insuline glargine U100 (reduced)|Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
40802589|NCT05514535|DRUG|Insuline glargine U100 (titrated)|Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
40802590|NCT05503095|GENETIC|Genetic analysis for PCSK9 polymorphisms|Determination of PCSK9 gene polymorphism and serum PCSK9 concentration
40802591|NCT04263116|PROCEDURE|Balloon Assisted Maturation|Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein
40802592|NCT02467127|DIETARY_SUPPLEMENT|vitamin D supplementation|In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
41320560|NCT04447703|OTHER|Survey Administration|Ancillary Studies
41320561|NCT04447703|OTHER|Genetic Counseling|Receive in-person, telehealth, or over-the-phone genetic counseling
40802595|NCT01904396|DRUG|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
40802596|NCT00559104|DRUG|carmustine|Unique to the Carmustine in Conditioning arm
40802597|NCT00559104|DRUG|cyclophosphamide|Used in Both Arms
41006538|NCT05862857|BEHAVIORAL|HIV-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free HIV testing at the local clinic
41006539|NCT05862857|BEHAVIORAL|Multi-disease-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free health screenings that may include hypertension, diabetes, HIV, malaria (if febrile), and TB (if symptomatic), and pregnancy at the local clinic
41006540|NCT01670162|DRUG|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
41006541|NCT05933681|DEVICE|Neural recordings and stimulation|Neural activities from the dorsolateral prefrontal cortex and implanted DBS generator will be recorded, during resting and working memory tasks, and with the DBS target turned on and off.
41006542|NCT05076266|OTHER|Questionnaire|Complete the survey questions
41006543|NCT02984410|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection
41006544|NCT02984410|PROCEDURE|Trans Oral Surgery (TOS)|TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection
41006545|NCT00839293|DRUG|ABT-335|Once, see arm description for more information
41006546|NCT02133729|OTHER|Blood sampling and OGTT|
40802598|NCT00559104|DRUG|etoposide|Used in Both Arms
40802599|NCT00559104|PROCEDURE|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
40802600|NCT00559104|PROCEDURE|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
40802601|NCT00559104|RADIATION|total-body irradiation|Unique to the Radiation in Conditioning Arm
40802602|NCT00559104|DRUG|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
40802603|NCT05233488|DEVICE|Pulsed Ultrasound Therapy|Ultrasound therapy is applied in the pulsed mode.
40802604|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Scoliosis specific corrective exercises and physical activity counseling
41006547|NCT01276314|DRUG|anti- TNF-a|25mg BIW, SC
41006548|NCT01276314|DRUG|Prednisolone|1-1.5 mg / kg / day
41006549|NCT01187082|BEHAVIORAL|bladdertraining in groups|Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
41006550|NCT01187082|BEHAVIORAL|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
41006551|NCT01531946|PROCEDURE|MRI Scan|"Patients will have to spend additional 10min in the scanner.~Additional scan modalities used:~1. Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.~2. Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.~An overall 20min scan period."
40802605|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises|Only scoliosis specific corrective exercises
40802606|NCT02061072|OTHER|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
40802607|NCT02638467|DRUG|Bosutinib|Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
40802608|NCT02638467|PROCEDURE|Bone Marrow Transplant|"Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.~The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.~The goal is to transplant \> 3 x 106 CD34+ cells/kg BW recipient from bone marrow or \> 3 x 108 nucleated cells/kg BW recipient from bone marrow"
41006552|NCT05256017|DRUG|Acoziborole|Acoziborole tablets
41006553|NCT05256017|DRUG|Placebo|matching placebo of acoziborole tablets
41006554|NCT05137873|OTHER|Dunn-2 infant Sensory Profile (PS2-N)|The Dunn-2 infant Sensory Profile evaluates the child's sensory integration process
41006555|NCT00846924|DEVICE|a 30-day ambulatory cardiac event monitor|Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
41006556|NCT00846924|DEVICE|24-hour Holter|Repeat standard 24-hour Holter Monitor
40802609|NCT02638467|DRUG|Bone Marrow cells|
41006557|NCT02550457|OTHER|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
41320562|NCT04447703|OTHER|Internet-Based Intervention|Use web-based genetic education tool online
41320563|NCT04447703|GENETIC|Genetic Testing|Undergo genetic testing
40802610|NCT06388746|OTHER|BRIX3000®|A gel that when applied to the tooth completely removes carious tissues in a chemo mechanical way without rotary instruments. It contains an enzyme that has bactericidal, bacteriostatic and anti-inflammatory properties and proteolytic properties that help soften and break down decayed tissue without destroying the underlying healthy collagen fibers.
40802611|NCT06388746|OTHER|Riva Star Aqua, SDI Limited, Australia|A solution that contains 44,800 ppm F and 253,870 ppm Ag. It acts as a fluoride storage for the acid challenges, while inhibites demineralization of hydroxyapatite crystals and preserves collagen from degradation in demineralized tissues.
40802612|NCT03043690|DIETARY_SUPPLEMENT|Ammonium succinate|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
41320564|NCT04447703|OTHER|Survey Administration|Ancillary Studies
41476445|NCT06208826|DRUG|Toripalimab|Toripamab, IV, 240mg, every 3 weeks for 15 cycles
40802613|NCT03043690|OTHER|Placebo|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
40802614|NCT03122808|DIAGNOSTIC_TEST|Uterine Activity Analysis|Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.
40802615|NCT03122808|DIAGNOSTIC_TEST|Partogram Analysis|Analysis of slope of partogram
40802616|NCT05636046|PROCEDURE|transseptal catheterization|puncture of interatrial septum at the level of fossa ovalis, using transseptal needle.
41006558|NCT02550457|OTHER|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
41320565|NCT06091189|BEHAVIORAL|Relevant Trier Social Stressor Test (TSST)|The Relevant TSST condition is a behavioral intervention that catalyzes an internalized stress response in the presence of a relevant social identity.
41320566|NCT06091189|DRUG|Ethanol|The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol. None of the control (placebo) drinks will contain ethanol.
41320567|NCT06091189|BEHAVIORAL|Placebo Trier Social Stressor Test (TSST)|The Placebo TSST is an established behavioral intervention that does not prompt significant stress responses.
41320568|NCT06091189|BEHAVIORAL|Placebo Beverage|Placebo drinks will not contain ethanol; Drinks given to participants in the placebo beverage condition will contain a mixer that does not contain ethanol.
40802617|NCT02258568|BEHAVIORAL|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
40802618|NCT03333096|DEVICE|Ocusweep test battery|"Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)"
41006559|NCT02550457|OTHER|Rigid Tape|Application of Micropore tape in the erector spine muscles.
41006560|NCT03527212|DRUG|SJP-0035 0.001%|Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
41320569|NCT06091189|BEHAVIORAL|Irrelevant Trier Social Stressor Test (TSST)|The Irrelevant TSST condition is a behavioral intervention that functions as an alternative comparative condition, given no internalized stress response is expected in the presence of an irrelevant social identity.
41320570|NCT05972044|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
41320571|NCT05972044|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
41320572|NCT05972044|DRUG|Placebo|Placebo tablets, taken once daily
41476446|NCT06208826|RADIATION|Radiation Therapy|Radiation Therapy
41476447|NCT06208826|DRUG|Cisplatin|Chemotherapy agent
41476448|NCT01372124|DRUG|NOX-E36|All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
41476449|NCT02257619|DRUG|Itacitinib|Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.
41476450|NCT02257619|DRUG|docetaxel|Administered as an intravenous infusion in the clinic at 75 mg/m\^2 Q3W for Part 1 of the study.
41476451|NCT02251119|DRUG|Tipranavir|
41476452|NCT02251119|DRUG|Ritonavir|
40802619|NCT03333096|DIAGNOSTIC_TEST|Neuropsychological test battery|Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
40802620|NCT06531213|OTHER|experimental|"Experimental Group: Baseline rehabilitation, Visual Perception Interventions. Home base activities, Baseline Rehabilitation (Strengthing exercise, achieving missing milestones).~Visual Perception Interventions~• Puzzle:Give step-by-step • printable activities • Sudoku. SET, Search Word, Spot it, what is missing, Tic Tac Toe, I Spy"
40802621|NCT06531213|OTHER|controlled|Controlled: Baseline rehabilitation. Home-based activities, Baseline Rehabilitation (strengthening exercise, achieving missing milestones).3. Activities Play Dough ( Manipulation) Draw on sketch Cup stacking.
40802622|NCT03335072|DRUG|Azithromycin|Mass Drug Administration
40802623|NCT06297096|DRUG|Tocilizumab|Tocilizumab 162 mg s.c./week
40802624|NCT06297096|DRUG|Nintedanib|Nintedanib - established doses of nintedanib for adults in the treatment of ILD, also SSc-ILD: 2 x 150 mg daily, in the event of e.g. increased liver enzyme levels, poorer treatment tolerance (e.g. diarrhea), the dose can be reduced to 2 x 100 mg
40802625|NCT06297096|DRUG|Standard therapy|mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
40802626|NCT04097028|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
40802627|NCT04097028|DRUG|Oxaliplatin|Given IV
40802628|NCT04296188|PROCEDURE|serratus anterior plane block|ultrasound guided serratus anterior plane block will be done with % 0.25 bupivacaine.
40802629|NCT04296188|PROCEDURE|erector spina plane block|ultrasound guided erector spina plane block will be done with % 0.25 bupivacaine.
40802630|NCT01996696|DRUG|Metformin|Metformin 500 mg PO TID x 30-36 months
40802631|NCT01996696|DRUG|Placebo|Identical placebo TID x 30-36 months
40802632|NCT01127464|DRUG|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
40802633|NCT01127464|DRUG|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
40802634|NCT01127464|DRUG|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
40802635|NCT00118638|DRUG|Darbepoetin alfa - 2.25 mcg/kg|Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
40802636|NCT00118638|DRUG|Darbepoetin alfa - 500mcg|Darbepoetin alfa 500mcg Q3W dosing / placebo QW
41320573|NCT04460417|BEHAVIORAL|Enhanced Care|The session began with the therapist reviewing the participants' personal feedback sheet within the context of clear messaging that there is no safe level of smoking and of how smoking affects the participant individually and the Black community collectively. The participant was encouraged to quit smoking, else to reduce smoking if abstinence was not desired, and to use NRT within the next week to help foster behavior change and alleviate withdrawal symptoms. This portion of the counseling was presented within a culturally-targeted framework such that myths regarding NRT common among persons with low health literacy were discussed and debunked and historical mistrust of the medical community and concerns about exploitation were also addressed. Each participant in EC was offered a starter kit of NRT with a one week supply of patches or lozenges.
40802637|NCT02889497|BIOLOGICAL|the first batch vaccine|
41320574|NCT04460417|BEHAVIORAL|TAU|"Participants met with a research assistant for 3-5 minutes and received the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information. They did not receive counseling or specialized care and were advised to refer to the resources should they be interested in quitting smoking."
41320575|NCT02861755|BEHAVIORAL|Positive Affect Skills Training|Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
41320576|NCT02861755|BEHAVIORAL|5-week Emotion Reporting|
41320577|NCT03126331|DRUG|Nivolumab|"Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more."
41320578|NCT03126331|DRUG|Ipilimumab|Ipilimumab is dosed at 1mg/kg over 30 minutes every 3 weeks
41320579|NCT03707964|OTHER|Crisis Resource Management Skill Training|Focused crisis resource management training which targets at the cognitive skills needed to monitor and challenge a superior's decision.
41476453|NCT02251119|DRUG|Loperamide|
40802638|NCT02889497|BIOLOGICAL|the second batch vaccine|
40802639|NCT02889497|BIOLOGICAL|the third batch vaccine|
40802640|NCT06334159|PROCEDURE|Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being fixed with non-resorbable pins (Test Group).
40802641|NCT06334159|PROCEDURE|Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being left unfixed (Control Group).
40802642|NCT02364804|DRUG|Aprepitant|The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.
40802643|NCT00936637|OTHER|Extensively hydrolyzed infant formula|
40802644|NCT03566771|BEHAVIORAL|Usual care|The child and parent(s) at regular visits to the pediatric clinic for childhood obesity treatment
40802645|NCT03566771|BEHAVIORAL|CLOSS|Usual care plus using mobile applications to register weight and physical activity as well as for communication with the clinic. A web-based support system enables health care professionals to follow the patient's daily objectively measured weight and physical activity online.
41006561|NCT03527212|DRUG|Placebo|Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
41006562|NCT01461304|DRUG|triheptanoin|subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours; subjects who experience cardiomyopathy may receive doses up to 4 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.
41320580|NCT03707964|OTHER|Standard ACLS Training|Standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
41320581|NCT06295432|DRUG|DZD9008+AZD4205|Daily dose of DZD9008+AZD4205 until intolerant, disease progression or patient decision. Starting dose of DZD9008 is 200mg once daily and starting dose of AZD4205 is 75mg once daily orally used. If tolerated, subsequent cohorts will evaluate increasing doses of the combination therapy.
40802646|NCT00001033|DRUG|Ethambutol hydrochloride|
40802647|NCT00001033|DRUG|Isoniazid|
40802648|NCT00001033|DRUG|Pyrazinamide|
40802649|NCT00001033|DRUG|Pyridoxine hydrochloride|
40802650|NCT00001033|DRUG|Levofloxacin|
40802651|NCT00001033|DRUG|Rifampin|
40802652|NCT02471118|DRUG|Adalimumab 40 mg|Adalimumab will be self-administered via subcutaneous (SC) injection
40802653|NCT02471118|DRUG|Placebo|Placebo will be self-administered via subcutaneous (SC) injection
40802654|NCT04200794|BEHAVIORAL|musical instrumental training|Learning to play a string instrument in a group setting (school class)
40802655|NCT04200794|BEHAVIORAL|sensitization to music|sensitization to music via listening, theory, moderate practice on small percussive instruments and choir singing in a group setting (school class)
40802656|NCT04511143|OTHER|muscle strength and ultrasound imaging measurement|hamstring muscle strenght measured by hand held dynamometer. The long head of Biceps Femoris, Semitendinosus, Semimembronosus were evaluated by B-mode ultrasound imaging.
40802657|NCT04887168|BEHAVIORAL|Survive & Thrive|Psychoeducational Intervention: Survive \& Thrive (Ferguson, 2008; Mahoney et al, 2018). A total of 10 manualised sessions of approximately 1.5 hour duration are offered. Individual sessions run using an educational format and in an informal setting, with a strong emphasis on avoiding individual disclosures. Groups will be delivered utilising a multi-disciplinary work force consisting of mental health staff in a ratio of 2 per group. Groups will consist of a maximum of 8-10 participants
40802658|NCT01935323|OTHER|High Intensity Interval Training|
41006563|NCT03376243|OTHER|LIPIKAR BAUME AP+ emollient|Structured education on prevention guidelines
41320582|NCT04557163|DRUG|TS-142|TS-142 will be given as 1 mg per capsule administered orally with water.
41320583|NCT04557163|DRUG|Itraconazole|Itraconazole will given as 50 mg per capsule administered orally with water.
41320584|NCT01546844|OTHER|Participation in Care4Life|Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
40802659|NCT01935323|OTHER|Moderate Intensity Training|
40802660|NCT01899508|PROCEDURE|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
40802661|NCT01899508|DEVICE|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
40802662|NCT06007508|DRUG|Insulin Glargine|Long-acting insulin
40802663|NCT06138353|DRUG|Shuxuening injection or placebo|Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
40802664|NCT00637624|DRUG|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
40802665|NCT00637624|DRUG|Placebo|Placebo once every 3 weeks intravenous saline fluid
40802666|NCT02180685|OTHER|Anchor fixation|
40802667|NCT06246838|DIAGNOSTIC_TEST|Ga-68 V/Q PET/CT|Head-to-head comparison of Ga-68 V/Q PET/CT vs Tc-99m V/Q SPECT/CT
40802668|NCT00613327|DRUG|Oxybutynin chloride OROS|Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
40802669|NCT03483779|DRUG|Ginkgo biloba pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
40802670|NCT03483779|DRUG|placebo pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
40802671|NCT01835288|DRUG|arsenic trioxide|Given IV
40802672|NCT01835288|OTHER|laboratory biomarker analysis|Correlative studies
40802673|NCT00386750|DRUG|Artemether-lumefantrine|
41006564|NCT01232296|DRUG|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
41006565|NCT01232296|DRUG|sorafenib|400 mg p.o. b.i.d.
41006566|NCT02412631|DRUG|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
41006567|NCT02412631|DRUG|Varenicline|Chantix is an FDA approved medication for smoking cessation
40802674|NCT06389344|DRUG|Esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
40802675|NCT06389344|DRUG|normal saline|Same amount of normal saline will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
40802676|NCT01221753|DRUG|docetaxel|
40802677|NCT01221753|DRUG|cisplatin|Given intravenously on day 1 of each cycle
40802678|NCT01221753|DRUG|5-FU|
40802679|NCT01221753|RADIATION|IMRT|
40802680|NCT01221753|DRUG|cetuximab|
41320585|NCT01571648|DRUG|Oral azacitidine|Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
41476454|NCT05012202|DEVICE|Hemi device|A sample of vaginal blood will be collected following delivery and analyzed by the device to provide a hematocrit level, which will be masked to the clinical team.
40802681|NCT01221753|DRUG|carboplatin|
41006568|NCT02412631|DRUG|Placebo|Placebo for lorcaserin
41006569|NCT05749081|DRUG|Lacidophilin tablets in combination with vonorazan dual therapy|2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
41476455|NCT01611207|DEVICE|Negative Pressure Wound Therapy|KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
41476456|NCT01611207|OTHER|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
41476457|NCT03822221|OTHER|MVIC and NMES with hip at 85º and knee at 20º|With hip joint at 85º (seated) and knee at 20º (SK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
41476458|NCT03822221|OTHER|MVIC and NMES with hip at 85º and knee at 60º|With hip joint at 85º (seated) and knee at 60º (SK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
41476459|NCT03822221|OTHER|MVIC and NMES with hip at 0º and knee at 20º|With hip joint at 0º (lying) and knee at 20º (LK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
41476460|NCT03822221|OTHER|MVIC and NMES with hip at 0º and knee at 60º|With hip joint at 0º (lying down) and knee at 60º (LK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
40802682|NCT00969306|DRUG|Chloroquine, A-CQ 100|"Administration:~* Orally~* Timing: Once daily~* Tablets of 100 mg~* During or after meals~* In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~* Patients should always note date and time of intake on the chloroquine monitoring form."
40802683|NCT00120081|BIOLOGICAL|Na-ASP-2/Alhydrogel Hookworm Vaccine|The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
40802684|NCT00120081|BIOLOGICAL|Saline placebo|Inactive saline placebo control
40802685|NCT04952662|GENETIC|Genetic variants|COL1A1 rs1800012, COL1A2 rs412777, COL5A1 rs12722, ACTN3 rs1815739, ACE rs1799752, ESR1 rs2234693, MMP3 rs679620, VDR rs2228570 and GDF5 rs143383
40802686|NCT00084708|DIETARY_SUPPLEMENT|calcitriol|
40802687|NCT00084708|DRUG|dexamethasone|
40802688|NCT00084708|DRUG|gefitinib|
40802689|NCT05809544|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
40802690|NCT05809544|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
40802691|NCT01802580|BEHAVIORAL|Internet Survey|
41006570|NCT05749081|DRUG|Placebo in combination with vonorazan dual therapy|2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
41320586|NCT01025011|DEVICE|Fundus photography, cubital blood draw|blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
41320587|NCT00877604|DRUG|tauroursodeoxycholic acid (TUDCA)|Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
41320588|NCT00877604|DRUG|Placebo|identical placebo by oral route at the same dosing schedule
41320589|NCT00453232|BIOLOGICAL|bleomycin sulfate|
40802692|NCT01802580|DRUG|fluocinonide 0.05% ointment|
40802693|NCT03138460|OTHER|standard medications crossed over to cannabis|
40802694|NCT06180629|BEHAVIORAL|Music conset|The music modes to be used (Rast and Hüseyni), classical music, nature music, and listening time of 20-30 minutes were determined by taking expert opinion from a faculty member from the Conservatory department and by reviewing the literature. The researcher asked the patients to choose the music genres. After each patient decided on the music they wanted to listen to, the researcher recorded the selected music genres on their smartphones. The music playback application was played to the patients in the experimental group for 20-25 minutes in each session for 4 sessions, i.e. 4 times in total, once a week for a month, until the end of one course. During each session, the patients listened to the music genre they had chosen each week.
40802695|NCT06180629|OTHER|normal treatment routine|normal treatment routine
40802696|NCT04622501|PROCEDURE|posterior spinal decompression and posterior spinal instrumented fusion|posterior spinal decompression and posterior spinal instrumented fusion performed on a patient with Spinal Epidural Lipomatosis
41320590|NCT00453232|BIOLOGICAL|pegfilgrastim|
41320591|NCT00453232|DRUG|cisplatin|
41320592|NCT00453232|DRUG|etoposide|
41320593|NCT00505102|DRUG|Everolimus|cyclosporine dose reduced of 50% after introduction of everolimus
41476461|NCT02948257|DEVICE|Cardiva Medical VASCADE VCS|At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.
41476462|NCT03914235|COMBINATION_PRODUCT|Tumescent Anesthesia|A tumescent solution is prepared with 2% lidocaine (10ml), 1:1000 epinephrine (0.4ml) and 7.5% sodium bicarbonate (4ml) dissolved in 0.9% saline solution (40ml) and applied from 3 to 20ml (depending on the pathology to be repaired) at the incision site.
41006571|NCT05225896|GENETIC|Description of clinical characteristic and genetic tumors|"This is a non-interventional study involving clinical data and biological samples (DNA). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
41320594|NCT03260972|DRUG|Chloroprocaine Hcl 2% Inj|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
41476463|NCT03914235|DRUG|Lidocaine|Apply 3 to 20 ml at the incision site, depending on the pathology to be repaired(carpal tunnel syndrome, trigger finger or Quervain syndrome).
41476464|NCT03914235|DEVICE|Pneumatic tourniquet|Level of the forearm at 250 mmHg, after exsanguination with Esmarch bandage.
41476465|NCT03914235|PROCEDURE|Open release of the tendon|Standard surgical procedure for carpal tunnel syndrome, trigger finger and Quervain syndrome.
41476466|NCT00393536|BEHAVIORAL|Educational outreach visiting|
41320595|NCT03260972|DRUG|Normal saline|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
41320596|NCT02652507|DRUG|Dexmedetomidine|2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
41476467|NCT01048502|DRUG|Fenofibrate (Tricor) tablets|One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
41476468|NCT01048502|DRUG|Placebo|Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
41476469|NCT01048502|DRUG|Lovaza|900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
41476470|NCT00382629|DRUG|BHT-3009 0.5 mg|
40802697|NCT05088915|BEHAVIORAL|Primary Care Intervention for PTSD (PCIP)|"This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb."
41320597|NCT02652507|DRUG|Ketamine|Bolus dose 2 mg/kg after first set of research images are obtained
41320598|NCT02133742|DRUG|Axitinib|Axitinib at starting dose of 5 mg and 3 mg BID.
41476471|NCT00382629|DRUG|BHT-3009 1.5 mg|
41476472|NCT00382629|DRUG|Placebo|
40802698|NCT05088915|BEHAVIORAL|Treatment As Usual|Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
41320599|NCT02133742|DRUG|MK-3475|MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
41320600|NCT03162458|DRUG|Anaferon for children (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
41320601|NCT03162458|DRUG|Placebo (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
41320602|NCT01244347|DRUG|folic acid|
41476473|NCT04510129|DIAGNOSTIC_TEST|OncoPrism™ assay|OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
41476474|NCT06525272|DRUG|Recombinant Human Chymotrypsin(OsrhCT)|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.
40802699|NCT00551434|DIETARY_SUPPLEMENT|Creatine|Creatine 21 g daily
40802700|NCT00551434|DIETARY_SUPPLEMENT|L-arginine and creatine|L-arginine
40802701|NCT00551434|DIETARY_SUPPLEMENT|l-arginine|l-arginine 9 g daily
40802702|NCT00551434|DIETARY_SUPPLEMENT|placebo, double|placebo
40802703|NCT02237001|DEVICE|Suture-based meniscal repair|Suture-based meniscal repair
40802704|NCT00219193|DRUG|aliskiren|
40802705|NCT00119769|DRUG|Placebo|Placebo, 0.7 mg/day injected subcutaneously
41006572|NCT01829932|DIETARY_SUPPLEMENT|Factor Altered Diet|
41320603|NCT01244347|DRUG|folic acid|
41320604|NCT05915494|OTHER|intermittent pneumatic compression, physiotherapy, and walking|intermittent pneumatic compression group (n = 20 inhalation injury children). in this children group, intermittent pneumatic compression will be used to resist diaphragm muscle during 10-set-training session which will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). In other inhalation group, n =20, traditional physical therapy program will be handled only). Also, free walking for 30 minutes daily will be performed by children.
41320605|NCT05915494|OTHER|physiotherapy and walking|in this children group, n = 20, for 12 weeks, traditional physical therapy program (chest physical therapy, flexibility exercises, range of motion exercises) will be handled. Also, free walking for 30 minutes daily will be performed by children.
40802706|NCT00119769|DRUG|Genotropin (human recombinant Growth hormone)|Genotropin, 0.7 mg/day injected subcutaneously
40802707|NCT05431595|DRUG|Haloperidol|Given by Vein (IV)
40802708|NCT05431595|DRUG|Chlorpromazine|Given by Vein (IV)
40802709|NCT05431595|DRUG|Valproate|Given by Vein (IV)
40802710|NCT05431595|DRUG|Placebo|Given by Vein (IV)
41320606|NCT04724733|BEHAVIORAL|Smoke Sense|Smoke Sense is a smartphone application (app). Smoke Sense participants will be asked to establish a profile which includes demographics, baseline health information and current beliefs about smoke and air pollution. In the Symptoms \& Smoke Observations tab, participants are asked to report their weekly observations of smoke, health symptoms, and exposure reduction behaviors. In the Fire \& Smoke Near Me tab, participants review the most recent AQ data measured at an AQ monitoring sites. Participants are asked to complete the AQ 101 module which test knowledge of AQ facts and provides correct answers. Badges are awarded for accomplishments within the app to promote certain desired behaviors: completing a user profile, launching the app weekly to check local AQ, reporting smoke and symptom observations, expanding AQ knowledge with AQ lessons, and exploring the map. Finally, participants can engage with other users by viewing cumulative statistics of symptoms and smoke observations.
41320607|NCT04724733|BEHAVIORAL|Smoke Sense Plus|Participants randomized to the Smoke Sense Plus intervention will be asked to do everything that the Smoke Sense intervention group does on a weekly basis, as well as: 1) Receive weekly push notifications that remind them to, for example, review their asthma action plan, refill any expired medications, take their daily controller medication, identify a clean air space in their home and community, 2) Monitor their lung function weekly via mobile spirometry, and 3) Subscribe to a social network to share strategies to minimize exposure.
41320608|NCT04393350|DRUG|Lenvatinib|Given PO
41320609|NCT04393350|DRUG|Lenvatinib Mesylate|Given PO
41320610|NCT04393350|BIOLOGICAL|Pembrolizumab|Given IV
41320611|NCT04393350|OTHER|Quality-of-Life Assessment|Ancillary studies
41320612|NCT04393350|OTHER|Questionnaire Administration|Ancillary studies
41320613|NCT03919968|BEHAVIORAL|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
41320614|NCT03919968|BEHAVIORAL|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
41320615|NCT05875376|BEHAVIORAL|Couple group therapy|"1. Introduction of I statements~2. Focus of each conversation~3. Emotion acknowledgement~4. Self-assurance and positive feedback~5. teamwork and cooperation~6. Reflection"
41320616|NCT03172481|DRUG|PRC-063 oral capsules|Daily dose
41320617|NCT03172481|DRUG|Placebo oral capsules|Daily dose
41320618|NCT05641038|OTHER|Peloid treatment|The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. Peloid was applied in a layer of approximately 1.5-2 cm thick, then the foot was wrapped in a nylon bag and covered with a towel. After 20 minutes of application, the peloid layer was removed and disposed of in medical waste. The treatment area was cleaned with soft cloths moistened with hot water and the session was ended. In addition to peloid therapy, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for the patients to do simultaneously.
41476475|NCT06525272|DRUG|Placebo for Recombinant Human Chymotrypsin(OsrhCT)|Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.
41476476|NCT02492841|DRUG|Mineral trioxide aggregate|Mineral trioxide aggregate
40802711|NCT04787549|DEVICE|Virtual reality exergames|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.
40802712|NCT05665335|DEVICE|Renuvion APR System|"The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites."
40802713|NCT04845919|DRUG|5-Aminolevulinic Acid|"SDT treatment with 5-ALA using the ExAblate Model 4000 Type-2 Neuro-System."
40802714|NCT02378233|DIETARY_SUPPLEMENT|iodine|The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
40802715|NCT02378233|DIETARY_SUPPLEMENT|Placebo|Patients are given a non-iodine containing multivitamin tablet
40802716|NCT06467071|BEHAVIORAL|SH+ combined with a session for PMLD|The intervention integrates WHO's Self Help Plus (SH+) and a session for Post-Migration Living Difficulties (PMLD) for Syrian women. SH+ is a guided self-help program with five weekly sessions led by facilitators, aimed at managing stress and psychological distress without requiring a diagnosis. This scalable intervention is based on solid research, proven effective in reducing stress and preventing mental health disorders (Tol et al., 2020; Turrini et al., 2019). The PMLD session, based on WHO's Problem Management Plus (PM+), involves focus groups to identify post-migration challenges. Participants share experiences, learn coping strategies, discover local resources, and strengthen social support networks. This integrated approach aims to enhance mental health, address post-migration difficulties, and improve stress reduction skills, supporting adaptation to a new country.
40802717|NCT04734483|DIAGNOSTIC_TEST|spirometry|spirometry
40802718|NCT04734483|RADIATION|MRI and CT|MRI and CT
40802719|NCT04734483|OTHER|Laryngoscopy|laryngoscopy
40802720|NCT04734483|OTHER|electromyography|electromyography
40802721|NCT03754127|DEVICE|tDCS|Transcranial direct current stimulation
40802722|NCT03754127|DEVICE|sham tDCS|Sham transcranial direct current stimulation
40802723|NCT00292201|DRUG|Atorvastatin|The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
40802724|NCT03136224|DEVICE|Thermocautery|
40802725|NCT03136224|DEVICE|Plastic Clamping|
40802726|NCT03136224|DEVICE|Surgical Circumcision|
40802727|NCT00371215|BIOLOGICAL|rThrombin|1000 U/mL applied topically
40802728|NCT05483231|BEHAVIORAL|Family integrated care intervention group|If the very low birth weight infants' vital signs are stable at 32 weeks of corrected gestational age, parents who have been fully trained will provide all non-medical care measures and developmental care for the VLBWIs in the NICU for not less than 6 hours per day for at least 3 weeks, and other medical practice and care measures will be the same as the routine group.
40802729|NCT05483231|BEHAVIORAL|Routine nursing care group|Routine practice and in-hospital education will be given to the very low birth weight infants and parents. All care measures will be led by the nursing staff, without the participation of parents.
40802730|NCT02822183|OTHER|Online Survey|
40802731|NCT02279368|BEHAVIORAL|Family Counselling and safeguarding|
40802732|NCT00081549|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
40802733|NCT01887613|DRUG|Regnite|oral
40802734|NCT05647837|DIAGNOSTIC_TEST|lumper puncture|lumper puncture
40802735|NCT04463563|OTHER|Physiological|Changes to carbon dioxide, oxygen flow, cardiac output, blood pressure, haemoglobin, surgical surveillance, depth of anaesthesia, patient position.
40802736|NCT06446375|OTHER|exercise|FIFA 11+ KIDS Training Protocol consists of seven different exercises: three for unilateral, dynamic stability of the lower limbs (hopping, jumping and landing); three for whole body and trunk strength/stability; and one exercise on falling technique.
40802737|NCT06446375|OTHER|Regular daily activity|Regular physical activity
40802738|NCT00351767|DRUG|placebo|Topically applied
40802739|NCT00351767|DRUG|telbermin|Topically applied
40802740|NCT06203457|BIOLOGICAL|Efgartigimod|Patients receiving efgartigimod infusions
40802741|NCT00124163|PROCEDURE|Imaging procedure of CT colonography|
40802742|NCT02752633|DRUG|Allopurinol|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
40802743|NCT02752633|DRUG|Febuxostat|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
40802744|NCT06238336|DRUG|CAR-T cell therapy|The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
40802745|NCT05887713|DEVICE|Experimental: Alpha-Stim 100|Subjects in CES intervention group will run CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to CES treatment, gather CES usage data for the week and to answer any questions.
40802746|NCT05887713|DEVICE|Sham Comparator|Subjects in CES sham group will run sham CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to sham CES treatment, gather sham CES usage data for the week and to answer any questions.
40802747|NCT02697981|BEHAVIORAL|nutrition counseling|nutrition counseling and guidance.
40802748|NCT04211792|DEVICE|Icare Tonometer|Icare tonometers are a new class of rebound tonometers for IOP measurements. The Icare series of tonometers are hand-held tonometers, which are easy to operate and generally do not require topical anaesthesia for IOP measurements.
40802749|NCT05066750|BEHAVIORAL|Mindful breathing|Participants watch a 10 minute mindful breathing video
40802750|NCT05066750|BEHAVIORAL|Control video|Participants watch a 10 minute control video
40802751|NCT02745678|DRUG|Thermosensitive gel rectal formulation|
40802752|NCT03316573|DRUG|Pembrolizumab|The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
40802753|NCT03920462|DEVICE|Programme of intelligent electric bike for health|It is a programme of 6 excursions with an intelligent electric bike for health and connected vests during 1 month (two excursions per week according the weather)
40802754|NCT02566187|DRUG|Fimasartan/Atorvastatin Combination Tablet|
40802755|NCT02566187|DRUG|Fimasartan|
40802756|NCT02566187|DRUG|Atorvastatin|
40802757|NCT04930861|DRUG|Covidir injections|administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
40802758|NCT04930861|DIAGNOSTIC_TEST|One Step Test|rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.
40802759|NCT04930861|DIAGNOSTIC_TEST|IgM and IgG dosage|blood collection for dosage of Anti SARS-CoV-2 antibodies.
40802760|NCT04930861|DIAGNOSTIC_TEST|RT-PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
40802761|NCT04930861|DIAGNOSTIC_TEST|Screening blood test|complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.
40802762|NCT04930861|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram with report.
40802763|NCT04930861|DIAGNOSTIC_TEST|Medical evaluation|evaluation by the principal investigator or assistant physician with a complete physical examination.
41320619|NCT05641038|OTHER|Paraffin treatment|The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. After the foot was dipped and removed 10 times, it was wrapped in a nylon bag and left for 20 minutes. Then the paraffin was peeled off the feet and disposed of in medical waste. Likewise, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for them to do simultaneously.
40802764|NCT04930861|DIAGNOSTIC_TEST|NEWS-2 score|assessment of the participant by the NEWS-2 score.
40802765|NCT04930861|DIAGNOSTIC_TEST|WHO score|assessment of the participant by the score of the World Health Organization.
40802766|NCT04923737|DRUG|Dexmedetomidine|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
40802767|NCT04923737|DRUG|0.9% sodium chloride|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
40802768|NCT01634880|DRUG|Postoperative Radiotherapy and Panitumumab|"The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.~Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses)."
40802769|NCT02821065|DEVICE|Remote Patient Monitoring|
40802770|NCT04379687|OTHER|Virtual reality|Use of virtual reality glasses for balance work
40802771|NCT04379687|OTHER|Control group|Balance treatment with according to Bayouk physiotherapy
40802772|NCT00175916|DRUG|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
40802773|NCT02606123|DRUG|EPI-506|"Patients will receive EPI-506 as an oral softgel capsule.~Part 1:~Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.~Part 2:~The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria."
40802774|NCT00588237|DRUG|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
41320620|NCT05685888|OTHER|Medication history|The study was retrospective and did not involve the application of interventions
40802775|NCT01071252|DRUG|AIN457|
41320621|NCT00171106|DRUG|valsartan|
41320622|NCT00316342|DEVICE|Back supports|
41320623|NCT05690269|DEVICE|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patients fingers a few minutes before arterial blood gases. SpO2 will be recorded during that time and up to 10 minutes.
41320624|NCT03286712|DRUG|Renogen|Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
41320625|NCT04975542|OTHER|Osteopathic Manipulative Medicine|Manipulative therapies based on Osteopathic principles.
40802776|NCT01071252|DRUG|Placebo|
40802777|NCT04547634|OTHER|Therapeutic Exercise and Education|The intervention will consist of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualized based on the evaluations of muscular strength and endurance. Sessions lasted 1 hour, carried out twice a week, for 12 weeks. This intervention will be complemented by nutritional education.
40802778|NCT05025397|DRUG|Danavorexton|Danavorexton intravenous infusion.
40802779|NCT05025397|DRUG|Danavorexton Placebo|Danavorexton placebo-matching intravenous infusion.
40802780|NCT05025397|DRUG|Propofol|Propofol intravenous bolus.
40802781|NCT05025397|DRUG|Sevoflurane|Sevoflurane inhalation.
40802782|NCT05025397|DRUG|Propofol|Propofol intravenous infusion.
40802783|NCT05474703|OTHER|SF-36 Scores|"From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied."
40802784|NCT04033081|DEVICE|CivaSheet|Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence
40802785|NCT02713984|BIOLOGICAL|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
40802786|NCT03245554|DRUG|Propranolol|0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
41320626|NCT04975542|OTHER|Sham|Light touch techniques to mimic to osteopathic treatment.
41320627|NCT00380211|BIOLOGICAL|Influenza vaccine (A/H3N2, A/H1N1, and B strains)|
41320628|NCT00380211|BIOLOGICAL|Fluarix|
41320629|NCT05140395|DIAGNOSTIC_TEST|ABTEST card|Pre transfusional control with the referent ABTEST card and the in study ABDTEST Card
41320630|NCT04070170|DEVICE|Low-level Laser Therapy|Low-level laser therapy is applied on premolars that will be extracted for treatment plan reasons
40802787|NCT00344318|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
40802788|NCT00344318|BIOLOGICAL|Prevenar|3 Intramuscular injections
40802789|NCT00344318|BIOLOGICAL|Tritanrix-HepB|3 Intramuscular injections
40802790|NCT00344318|BIOLOGICAL|Hiberix|Reconstituted with Tritanrix before injection
40802791|NCT00344318|BIOLOGICAL|Polio Sabin.|3 oral doses.
40802792|NCT00344318|BIOLOGICAL|Poliorix.|3 intramuscular injections
40802793|NCT04949516|DRUG|Aspirin|Aspirin is discontinued the day after drug-eluting stent implantation
40802794|NCT04949516|DRUG|Colchicine|Colchicine is started the day after drug-eluting stent implantation
40802795|NCT02907216|BIOLOGICAL|Squarekids|Three doses administered subcutaneously in the upper arm or thigh
40802796|NCT02907216|BIOLOGICAL|Rotarix|Two doses administered orally
40802797|NCT02032758|DRUG|Propranolol|Single oral dose of 10 mg propranolol
40802798|NCT02032758|DEVICE|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
40802799|NCT02032758|PROCEDURE|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
40802800|NCT02032758|DEVICE|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
40802801|NCT00879034|DRUG|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
40802802|NCT00879034|DRUG|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
40802803|NCT00879034|DRUG|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
40802804|NCT00429676|DRUG|Haloperidol|
40802805|NCT01095991|DRUG|AZD1656|Oral tablet bd,
40802806|NCT01095991|DRUG|Sitagliptin|Oral tablet od
40802807|NCT00356772|DRUG|Azithromycin|
40802808|NCT01897727|DRUG|Spironolactone|
40802809|NCT01897727|DRUG|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
40802810|NCT05560243|BEHAVIORAL|Tobacco cessation|Tobacco cessation program consisting of cognitive-therapy sessions and pharmacological management
40802811|NCT06306196|BIOLOGICAL|Hecolin® Recombinant Hepatitis E Vaccine|30㎍/dose, 0.5mL administered intramuscularly
40802812|NCT06306196|BIOLOGICAL|Isotonic Sodium Chloride injection|0.5mL administered intramuscularly
40802813|NCT03490292|COMBINATION_PRODUCT|Avelumab combined with Chemoradiation|Co-administration of avelumab with chemoradiation in pre-operative period.
40802814|NCT03490292|DRUG|Carboplatin|Weekly Carboplatin (AUC2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
40802815|NCT03490292|DRUG|Paclitaxel|Weekly paclitaxel \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
40802816|NCT03490292|RADIATION|Radiation|Radiation therapy \[23 fractions, M-F, estimated completion day 35\]
40802817|NCT05368389|DEVICE|Healthdot attachment|"The wearable health monitoring device Healthdot 5 will be attached to the patient's skin at left lower rib and data like heart rate, respiratory rate, posture and activity will be collected for 10 days.~A questionnaire will be sent to patients to fill out at the 10th day after the device attachment."
40802818|NCT01691105|OTHER|AD + Integrated Tobacco Order Set|"Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center"
40802819|NCT05287958|DIAGNOSTIC_TEST|EIT|EIT comprises a chest belt that is connected to a computer via a universal serial bus (USB) or an Ethernet cable. The chest belt captures EIT data, which is transmitted via the USB or Ethernet cable to the computer. Tomography-like impedance images of the lungs are computed and displayed on the computer. The impedance images will be used to evaluate lung recruitment and other pulmonary function parameters that are currently measured using standard-of-care PFT devices.
40802820|NCT00342628|BIOLOGICAL|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
40802821|NCT00342628|BIOLOGICAL|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
40802822|NCT00342628|BIOLOGICAL|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
40802823|NCT03668496|DRUG|SHR-1210|Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
40802824|NCT03668496|DRUG|The placebo|in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
40802825|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277510A|One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
40802826|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277509A|One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
40802827|NCT02177734|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
40802828|NCT04528017|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
40802829|NCT04528017|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
41476477|NCT02492841|DRUG|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
40802830|NCT06481436|BEHAVIORAL|Use of ChatGPT|Patients will be provided with the opportunity to ask ChatGPT questions about their primary presenting problem at a time point during their initial Urogynecology consultation visit.
40802831|NCT04058392|BIOLOGICAL|Camu Camu Capsules|Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study
41476478|NCT02492841|DRUG|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
40802832|NCT02249091|DRUG|Selinexor|Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m\^2 or 6 doses of 60 mg per induction cycle).
40802833|NCT02249091|DRUG|Idarubicin|Infusion, iv, 10 mg/m\^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
40802834|NCT02249091|DRUG|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m\^2, iv,
40802835|NCT01921556|BEHAVIORAL|active comparator, QualiCCare education|"Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
40802836|NCT04519216|BEHAVIORAL|Telesimulation|Telesimulation educational intervention
40802837|NCT01496326|DRUG|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
41476479|NCT00978913|BIOLOGICAL|DC vaccine|DC vaccination, one vaccine biweekly
41476480|NCT05397548|DIAGNOSTIC_TEST|Measurement of levels of circulating exosomal lncRNA-GC1|Each participant was enrolled to assess the levels of circulating exosomal lncRNA-GC1
41476481|NCT01320020|DRUG|catumaxomab|Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
40802838|NCT01496326|DRUG|placebo|2 grams of placebo cream for 14 days
40802839|NCT04662190|DEVICE|3D printing model/guide.|Orbital decompression surgery will be previously planned and simulated using 3D-printed individualized models. In the operating room, surgery will be assisted with 3D-printed individualized guides.
40802840|NCT04662190|PROCEDURE|Standard surgery|Orbital decompression surgery will be previously planned and simulated using the actual standard methods.
41152482|NCT00701506|DEVICE|Patterned Electrical Neuromuscular Stimulation|"* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* PENS for 20 minutes:~  * Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~ * Minimal twitch for 5 minutes.~ * Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~* Electrodes placed on quadriceps and hamstrings"
41152483|NCT00701506|DEVICE|Placebo PENS|"* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* Placebo PENS for 20 minutes:~* Electrodes placed on quadriceps and hamstrings."
40802841|NCT02150551|BIOLOGICAL|Allogeneic bone marrow-derived mesenchymal stromal cells|This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; \<18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :\> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : \>34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
40802842|NCT01059045|PROCEDURE|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
40802843|NCT01059045|OTHER|Control|No intervention
40802844|NCT02364245|DEVICE|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
40802845|NCT02364245|OTHER|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
41152484|NCT03532568|OTHER|skin biopsy|4mm punch skin biopsy
41152485|NCT03532568|RADIATION|narrowband ultraviolet B|narrowband ultraviolet B for CKD-aP patients
41152486|NCT06222671|DRUG|608|608 subcutaneous (SC) injection.
41476482|NCT03545191|DRUG|Daridorexant 25 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
41152487|NCT06222671|DRUG|608|608 subcutaneous (SC) injection.
41152488|NCT06222671|DRUG|Placebo|Placebo subcutaneous (SC) injection.
41152489|NCT04441983|DIAGNOSTIC_TEST|7 Tesla MRI of the foot|7 Tesla MRI
41152490|NCT04944589|PROCEDURE|ROOT CANAL TREATMENT|Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.
41152491|NCT03600922|PROCEDURE|the patella was resurfaced.|Patellar resurfacing was undertaken using a cemented, inset domed component in TKA.
41476483|NCT03545191|DRUG|Daridorexant 50 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
41476484|NCT03545191|OTHER|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
41476485|NCT02547402|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
41476486|NCT02547402|DRUG|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
41476487|NCT02547402|DRUG|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
41476488|NCT04150822|OTHER|Registry and Saliva sample|Non-interventional registry with saliva sample collected for DNA analysis
40802846|NCT02364245|OTHER|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
41476489|NCT06364332|BEHAVIORAL|Social Media campaign|Participants receive content three times a week; in total 24 pieces of content in 8 weeks. The content can consist of one or more photos or images with a caption (explanation in text).
41476490|NCT00000813|BIOLOGICAL|ALVAC-HIV gp160MN (vCP125)|
41476491|NCT00000813|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
41476492|NCT00000813|BIOLOGICAL|rgp120/HIV-1 SF-2|
41476493|NCT01868282|PROCEDURE|Hamstrings block|patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.
41476494|NCT01868282|PROCEDURE|Obturator block|Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1
41476495|NCT01868282|PROCEDURE|Control group|The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
41476496|NCT01194973|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
41476497|NCT05064748|DRUG|Benvitimod|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
41476498|NCT00720226|DRUG|Losartan|Losartan 100 mg daily
41476499|NCT00720226|DRUG|Placebo|Placebo pill daily
41476500|NCT05497141|DEVICE|Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.
41476501|NCT05568979|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
41476502|NCT05568979|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
41476503|NCT05647707|DIETARY_SUPPLEMENT|L-Carnitine|The 36 patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose of 50 mg/kg IV every 8 h.
41476504|NCT00699478|DRUG|mecobalamin|Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
41476505|NCT05931406|BEHAVIORAL|Control|A normal working day from of 12h
41152492|NCT01436604|OTHER|Cardiac MRI|"The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~* Sequences locating anatomical~* T2 black blood (such as ESF)~* rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~* T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage."
41476506|NCT05931406|BEHAVIORAL|Sit-and-stand desk|a working day during which the participants have to get up at least 5 min/hour
41476507|NCT05931406|BEHAVIORAL|Cycloergometer|a working day during which they can use a cycloergometer installed under the desk
41152493|NCT02766764|DRUG|DHEA|Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.
41476508|NCT05044728|DRUG|Anti-PD-1 antibody combined with Paclitaxel and carboplatin.|"Anti-PD-1 antibody, 240 mg, IV infusion for 30min (not less than 20min and not more than 60min), d1, every 3 weeks for total 2 cycles. Stratified regimen: group A, 24 hours after the end of chemotherapy; Group B will be given immunotherapy on the first day of each cycle.~Paclitaxel, 135 mg/m2, IV, d1, q3w, for total 2 cycles. Carboplatin, AUC=5 (according to Calvert formula), IV, d1, every 3 weeks for a total of 2 cycles. Stratified regimen: group A, chemotherapy will be given on day 1 of each cycle; Group B will be given chemotherapy drugs 24 hours after the end of immunotherapy."
41476509|NCT05044728|PROCEDURE|Surgical treatment stage|After the completion of neoadjuvant immunochemotherapy, patients will be tested again for the functional subsets of peripheral CD8 positive T cells. Alternative treatments will be sought for inoperable patients. For patients who are operable will receive minimally invasive or open surgery was performed 1 month after completion of neoadjuvant chemotherapy immunotherapy, and the functional subsets of peripheral CD8 positive T cells were detected again after surgery.
41476510|NCT02224573|DRUG|GWP42003-P|
41476511|NCT03418168|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
41476512|NCT03656549|DRUG|Pemetrexed|3+3 dose escalation study of pemetrexed in patients with impaired renal function
41006573|NCT04054037|OTHER|No intervention|This is an observation study, no intervention will be indicated during diagnosis and treatment.
41006574|NCT01502644|DRUG|Oxycodone|Daily dosage up to 120 mg
41006575|NCT01502644|DRUG|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
41006576|NCT01502644|DRUG|Placebo|Placebo-matching oxycodone, placebo-matching morphine
41006577|NCT04900077|DEVICE|Carriere® Motion™ Appliance|class II malocclusion corrector
40802847|NCT01922362|DEVICE|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
40802848|NCT01922362|DEVICE|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
40802849|NCT01335256|DRUG|BAY1000394|BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
41476513|NCT04747314|DRUG|Antidepressant|"The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes.~The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change."
40802850|NCT05242068|DEVICE|Veinlite|Use of vein imaging device for visualization of veins during peripheral IV placement
41476514|NCT04747314|OTHER|Enhanced Fear Avoidance Rehabilitation|The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
41476515|NCT02024373|DRUG|Atorvastatin|20 mg (every evening orally) for 8 weeks
41476516|NCT02024373|DRUG|placebo|20 mg (every evening orally) for 8 weeks
41476517|NCT05990842|DRUG|Antibiotic|the individual will receive 1 dose of antibiotic during anesthetic induction
41476518|NCT05990842|OTHER|placebo|the individual will receive 10 ml of saline during anesthetic induction
41476519|NCT02128555|PROCEDURE|Total Ankle Replacement|The joints are resurfaced with metal implants and a mobile plastic liner is placed between them as the gliding surface.
41476520|NCT02128555|PROCEDURE|Arthrodesis|The remaining damaged cartilage is removed from the ends of the bone and the two bones are then held together in compression using screws, or plates until they join to become one (bone fusion), so that there is no longer any movement at that joint.
41476521|NCT02083926|DRUG|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
40802851|NCT05242068|OTHER|Standard care|Patients received standard intravenous catheterization.
40802852|NCT05335304|OTHER|intervention group 1|Kinesio taping The intervention of this experimental study is therapeutic taping (kinesio tape) on the respiratory muscles of the participants.
40802853|NCT05335304|OTHER|intervention group 2|Rigid taping The intervention of this experimental study is therapeutic taping (rigid tape) on the respiratory muscles of the participants.
41320631|NCT04070170|PROCEDURE|Orthodontic force|Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement
41476522|NCT02083926|OTHER|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
40802854|NCT05335304|OTHER|intervention group 3|Thoracic Mobilization The intervention of this experimental study is active-passive Thoracic mobilization techniques on the on the upper, middle or lower parts of the chest of the participants
40802855|NCT05335304|OTHER|intervention group 4|Core Stabilization The intervention of this experimental study is Core Stabilization exercises to the trunk muscles of the participants.
40802856|NCT05335304|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
40802857|NCT00830375|DRUG|Memantine|10-30mg, by mouth, daily
40802858|NCT05031338|DEVICE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the SX-One MicroKnife with ultrasound guidance.
41152494|NCT02766764|DRUG|Growth hormone|Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.
41152495|NCT02766764|DRUG|Placebo 1|Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI
41320632|NCT03537352|PROCEDURE|Any appropriate surgical treatment|Any appropriate surgical treatment for the management of patient's current disorder
41320633|NCT03537352|DRUG|Any appropriate drug or non-drug treatment excluding surgery|Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
41476523|NCT00591435|OTHER|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
41476524|NCT02075606|DRUG|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
41476525|NCT04754802|DRUG|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
41476526|NCT04754802|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
41476527|NCT04344132|PROCEDURE|Scalp Block|standard practice of controll the pain after surgery. Block of the nerve emergences.
41476528|NCT01464554|BEHAVIORAL|Usual care|alcohol and drug education
41476529|NCT01464554|BEHAVIORAL|Project Free Talk|motivational interviewing alcohol and drug program
41476530|NCT01363141|OTHER|Regular AGE Diet|Regular AGE Diet
41476531|NCT01363141|OTHER|Low AGE Diet|One year reduction in dietary AGE intake.
41476532|NCT00615524|DRUG|exemestane and pazopanib|
41476533|NCT03914118|DRUG|Preoperative modafinil + postoperative placebo|200 mg modafinil pre-operatively and placebo immediately post-operatively.
41476534|NCT03914118|DRUG|Preoperative modafinil + postoperative modafinil|200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.
41476535|NCT03914118|DRUG|Preoperative placebo + postoperative placebo|Placebo pre-operatively and placebo immediately post-operatively.
41476536|NCT05410028|OTHER|No intervention in clinical treatment|No intervention in clinical treatment
40802859|NCT05031338|PROCEDURE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the traditional mini-open technique without ultrasound guidance.
40802860|NCT01159678|BEHAVIORAL|online psychoeducation|"The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:~1. Important of sexuality to quality of life. \& Definitions of sexual desire and arousal.~2. Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.~3. Sexual beliefs.~4. Mindfulness.~5. Genital anatomy and physiology.~6. Body Image.~7. Relationship satisfaction and communication.~8. Body-oriented mindfulness exercises (focusing and self-observation).~9. Using Thought records.~10. Mindfulness and the thought stream.~11. Sexual aids to boost arousal.~12. Moving on.~In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond."
40802861|NCT00090779|DRUG|Emtricitabine/ tenofovir disoproxil fumarate|once daily
41320634|NCT06051136|BEHAVIORAL|Pulmonary rehabilitation|"The RP intervention consists in 8 sessions supervised by the physiotherapist weekly or biweekly and 2 therapeutic education group meetings on the importance of exercise and CRF management, over the 3 months of intervention. The RP comprise exercise program performed autonomously at home. Both the outpatient and the autonomously home-based exercise sessions comprise aerobic, resistance and respiratory exercise.~The exercise program is individualized and can be delivered in telerehabilitation."
41320635|NCT02766322|OTHER|Oral Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
41476537|NCT02613078|BEHAVIORAL|Gut-Directed Hypnotherapy|Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
40802862|NCT00090779|DRUG|Lopinavir/Ritonavir|twice daily
41320636|NCT02766322|OTHER|Oral Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
41320637|NCT02766322|OTHER|Intravenous Alcohol Challenge Test (Clamp)|Subjects will be evaluated with an alcohol clamp (i.e. alcohol will be infused intravenously until reaching 60mg/dl and this blood alcohol concentration will be kept constant for two hours). We will record subjective responses to alcohol throughout different times of the clamp.
41320638|NCT02766322|OTHER|Intravenous Alcohol Self-administration Test|"Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit."
41320639|NCT06395324|OTHER|High arabinose diet|Participants will consume a high arabinose diet for 18 consecutive days.
41320640|NCT01317615|DRUG|RAD001|Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
41320641|NCT01317615|DRUG|Paclitaxel|Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
41320642|NCT01317615|DRUG|Carboplatin|Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
41320643|NCT01205958|PROCEDURE|acupuncture|Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks
41320644|NCT01722812|DRUG|Cromoglicate|Twice daily topical treatment for 14 days
41320645|NCT01722812|DRUG|Placebo|Twice daily topical treatment for 14 days
41320646|NCT05254613|DRUG|ALXN1830|ALXN1830 will be administered as SC infusion(s).
41320647|NCT05254613|DRUG|Placebo|Placebo will be administered as SC infusion(s).
41320648|NCT00425477|BIOLOGICAL|sargramostim|
41320649|NCT00425477|DRUG|bexarotene|
41320650|NCT00425477|GENETIC|cytogenetic analysis|
40802863|NCT03698578|OTHER|combat fight|Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
40802864|NCT04431843|DIETARY_SUPPLEMENT|Spirulina maxima extract|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 1.5 g/day) for 12 week
40802865|NCT04431843|DIETARY_SUPPLEMENT|Placebo|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 0 g/day) for 12 week
40802866|NCT00003923|DRUG|porfimer sodium|
40802867|NCT00133263|BEHAVIORAL|Primary Bereavement Care|a standardized bereavement intervention in Primary Care
40802868|NCT00133263|BEHAVIORAL|the current bereavement care in primary care|the non-standardized bereavement care that usually provided family physicians in primary care
41320651|NCT00425477|GENETIC|fluorescence in situ hybridization|
41320652|NCT00425477|OTHER|flow cytometry|
41320653|NCT00425477|OTHER|laboratory biomarker analysis|
41320654|NCT00425477|PROCEDURE|biopsy|
41320655|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
41320656|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
41006578|NCT05905588|DIETARY_SUPPLEMENT|Hydrogen-rich water|Patients drink 600mL hydrogen-rich water per day by applying hydrogen-rich water cup (Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks. The dissolved hydrogen concentration is 5 ppm.
41476538|NCT02613078|DIETARY_SUPPLEMENT|Nutritional Supplement|SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10\^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
41476539|NCT02613078|BEHAVIORAL|Self-Monitoring|Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
41476540|NCT05391711|BEHAVIORAL|Culturally Smart Relationships|"Mentors assigned to the intervention will receive the following trainings and support:~1. Online Justice, Equity, Diversity, and Inclusion (JEDI) trainings (self-paced)~2. Culturally Smart Relationships Training (live, virtual)~3. JEDI enhanced monthly supervision from case managers~4. Monthly emails with activity suggestions for mentors and youth"
41476541|NCT03282006|DRUG|pivmecillinam|Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
41476542|NCT03903159|BEHAVIORAL|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
41476543|NCT05466279|DRUG|remazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.
41476544|NCT05466279|DRUG|Propofol|Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus
41476545|NCT05466279|DRUG|Midazolam|Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam
41476546|NCT05333224|OTHER|Telerehabilitation|Family-centered, goal-oriented early physiotherapy approaches will be applied.
41476547|NCT05333224|OTHER|Control|Family-centered, goal-oriented early physiotherapy approaches will be applied.
41476548|NCT01557582|DEVICE|Ventripoint Medical System|"The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images."
41476549|NCT00128934|DRUG|levonorgestrel/ethinyl estradiol|
41476550|NCT01364324|DRUG|standard first line anti-TB drugs|We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
41006579|NCT05905588|DIETARY_SUPPLEMENT|placebo|Patients drink 600mL tap water per day by applying analogue cup for 12 weeks. This cup has the same appearance as the hydrogen-rich water cup, and the hydrogen-rich water and placebo water were indistinguishable. The dissolved hydrogen concentration is 0 ppm in placebo water.
41006580|NCT00748956|DRUG|Low dose NPY|50nmol, administered intranasally
41006581|NCT00748956|DRUG|High dose NPY|100nmol administered intranasally
41006582|NCT00748956|DRUG|Placebo|placebo comparator (0nmol)) administered intranasally
41152496|NCT02766764|DRUG|Placebo 2|Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
41320657|NCT01327872|DRUG|E5501 40mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
41476551|NCT04920903|DRUG|COR588|Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
41152497|NCT00795977|BIOLOGICAL|dendritic cells, OK-432|Single Group Assignment
41320658|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
41320659|NCT04511780|OTHER|questionnaire filling|assessment of post-traumatic stress, anxiety and burn out
41320660|NCT01738737|DEVICE|Active Laser|18 points of application of active laser in the knee (frontal faces, lateral and medial)
40802869|NCT03102827|DRUG|Oxygen|Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
40802870|NCT03102827|OTHER|Placebo|Ambient air without high-flow therapy administered during first night
40802871|NCT02752919|DRUG|Galunisertib|Administered orally
40802872|NCT05295121|DRUG|XC221 100 mg tablets|XC221, 3 discrete doses separated by 7-day wash-out periods
40802873|NCT05484934|PROCEDURE|Regenerative post mastectomy surgery|Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)
40802874|NCT01198210|DRUG|saline|local peritonsillar infiltration of 2 ml saline,
40802875|NCT01198210|DRUG|Ketamine|local peritonsillar infiltration of ketamine (0.5 mg/kg)
40802876|NCT01198210|DRUG|Dexamethasone|local peritonsillar infiltration dexamethasone (0.2 mg/kg))
40802877|NCT01198210|DRUG|ketamine-dexamethasone|local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
40802878|NCT05871424|DRUG|buprenorphine patch group|5 mcg/h buprenorphine patch will be applied preoperatively
40802879|NCT05871424|DRUG|placebo group|simple dressing tape only will be applied
40802880|NCT00617058|DRUG|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
40802881|NCT00617058|BEHAVIORAL|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
40802882|NCT05816343|DRUG|Orlistat|Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
40802883|NCT05816343|DRUG|Placebo|Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
40802884|NCT05511727|DEVICE|single versus double Foley's catheter in pre-induction cervical ripening|The single balloon catheter (i.e. Foley catheter \[FC\]) and Cook cervical ripening balloon have been the most commonly used mechanical method
40802885|NCT00002050|DRUG|Thymopentin|
40802886|NCT01266109|BEHAVIORAL|Contingency Management-Family Engagement (CM-FAM)|Evidence-based outpatient intervention for adolescent substance use
41320661|NCT01738737|OTHER|Stretching exercises|7 stretching exercises for lower limbs lasting 30 seconds with 4 repetitions
41320662|NCT01738737|DEVICE|placebo laser therapy|18 points of application of placebo laser in the knee (frontal faces, lateral and medial)
40802887|NCT01266109|OTHER|Usual Services (US)|Typical community-based substance abuse treatment services
40802888|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
40802889|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
40802890|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
40802891|NCT05773807|OTHER|Bispectral index|In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.
40802892|NCT05773807|OTHER|Observer's assessment alert Sedation|In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.
40802893|NCT05773807|PROCEDURE|Gastroscopy|Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
40802894|NCT05773807|DRUG|Propofol|Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
41320663|NCT03513250|DRUG|hyoscine-n-butylbromide|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
40802895|NCT05533294|DRUG|ARO-RAGE Injection|ARO-RAGE injection for sc administration
40802896|NCT05533294|DRUG|Placebo|normal saline (0.9% NaCl) by sc injection
40802897|NCT00526656|DRUG|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
40802898|NCT04154644|DEVICE|CryoPop|The new CryoPop device will be tested on women with abnormal cytology. Benchmark testing occurred in the previous study and CryoPop was found to be non-inferior to standard cryotherapy device (MedGyn) in woman with normal cytology.
40802899|NCT03248531|DRUG|Bimekizumab|Bimekizumab in different dosages (dose 1 and 2).
40802900|NCT03248531|DRUG|Adalimumab|Adalimumab in different dosages (dose 1, 2 and 3).
40802901|NCT03248531|OTHER|Placebo|Placebo will be provided matching Bimekizumab.
40802902|NCT03178825|DEVICE|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
40802903|NCT00046293|DRUG|Reopro|
40802904|NCT00046293|DRUG|Retrovase|
40802905|NCT04163861|DIAGNOSTIC_TEST|2d speckle tracking echocardiography|2d speckle tracking echocardiography
40802906|NCT04163861|DIAGNOSTIC_TEST|serum BNP level|serum BNP level of HFpEF study subjects
40802907|NCT01586598|BEHAVIORAL|sensory retraining protocol|"1. within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day~2. one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day~3. three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day"
40802908|NCT03071315|OTHER|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
40802909|NCT03071315|OTHER|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
40802910|NCT01794208|DRUG|Follitropin Epsilon|
40802911|NCT01794208|DRUG|Follitropin Alfa|
40802912|NCT01489709|DRUG|Vesicare|oral
40802913|NCT04075513|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
41476552|NCT04920903|DRUG|Placebo|Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
40802914|NCT04075513|DRUG|Insulin degludec, 100U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
40802915|NCT04075513|DRUG|Background therapy: Rapid acting insulin analogs|Route of administration: SC injection
40802916|NCT04251234|OTHER|Light intensity, ~30 lux|\~30 lux compared to very dim light baseline condition \<1 lux
40802917|NCT04251234|OTHER|Baseline light intensity, <1 lux|Very dim light condition
40802918|NCT02295631|DEVICE|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
40802919|NCT02295631|DEVICE|ETView VivaSight SL|ETI with ETView VivaSight SL
40802920|NCT02502292|BEHAVIORAL|Fotonovela|"Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet."
41476553|NCT01207440|DRUG|Ponatinib|Ponatinib tablets.
40802921|NCT02922816|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
40802922|NCT02922816|PROCEDURE|Bowel preparation|Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
40802923|NCT02922816|PROCEDURE|Stool or perirectal swab sampling|Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
40802924|NCT02922816|OTHER|Fasting|In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
40802925|NCT02808052|DRUG|Minocin (minocycline) for Injection|200mg IV Minocin given over 1 hour
40802926|NCT05733949|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40802927|NCT05733949|PROCEDURE|Computed Tomography|Undergo CT
40802928|NCT05733949|RADIATION|Stereotactic Body Radiation Therapy|Undergo ST-SBRT
40802929|NCT01504516|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
40802930|NCT01504516|DRUG|Aricept|Aricept 10 mg Tablets
40802931|NCT03851328|OTHER|BPMH structured interview|creating a standardized medication list by interviewing patient and/ or relatives according to Best Possible Medication History (BPMH) after patient transfer to medical ward
40802932|NCT02482298|DRUG|Ticagrelor|Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
40802933|NCT02482298|DRUG|Placebo|10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
41320664|NCT03513250|DRUG|control group|an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.
41320665|NCT03975374|DRUG|Tobramycin/dexamethasone opthalmic solution|To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
41476554|NCT06460441|DIAGNOSTIC_TEST|SUNRISE© device|"The device under study is the Sunrise© sensor, a single-use Class IIa medical device with CE marking and ISO 13485 certification.~The system combines a mandibular movement sensor with an artificial intelligence program to collect and interpret data. It consists of a three-gram device that is placed on the chin using an adhesive. The sensor is linked to a (free) mobile app, enabling data to be sent to the Sunrise© company's secured platform at the end of the night, and results to be transmitted to the prescribing physician."
41476555|NCT05649449|BEHAVIORAL|Self-Directed Care|Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.
40802934|NCT02340858|DEVICE|NanoKnife LEDC System|Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
41476556|NCT05649449|BEHAVIORAL|Services as usual|Participants receive usual outpatient psychiatric care delivered at community programs from which the person can choose from an array of services negotiated with the state mental health authority.
41476557|NCT01551147|DRUG|ONO-6950|200 mg QD for 8 days
41476558|NCT01551147|DRUG|Placebo|Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
41476559|NCT01551147|DRUG|Montelukast|10 mg Montelukast QD for 8 days
41476560|NCT03508687|DRUG|300mg Gemcabene|300mg Gemcabene
41476561|NCT03508687|DRUG|600mg Gemcabene|600mg Gemcabene
41476562|NCT03632317|DRUG|Panobinostat|30 mg/m\^2
41476563|NCT03632317|DRUG|Everolimus|3.0 mg/m\^2
41476564|NCT00449319|PROCEDURE|Identification of appropriate therapies according to risks factors|
41476565|NCT00449319|DRUG|Daunorubicine|
41476566|NCT00449319|PROCEDURE|Transplant|
41476567|NCT04375995|DIAGNOSTIC_TEST|Impulse oscillometry|Impulse oscillometry test will be applied to all groups.
40802935|NCT00009880|BIOLOGICAL|filgrastim|
41476568|NCT04375995|DIAGNOSTIC_TEST|Spirometric pulmonary function test|Spirometric pulmonary function test will be applied to all groups.
41476569|NCT04375995|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide (FENO) test|FeNO test will be applied to asthma group.
41476570|NCT04375995|DIAGNOSTIC_TEST|Thorax Computed Tomography|Thorax Computed Tomography will be taken to the asthma group.
41476571|NCT04375995|DIAGNOSTIC_TEST|Blood eosinophil level|The blood eosinophil level will be evaluated to determine the phenotype in the asthma group.
41476572|NCT04375995|OTHER|Asthma control test|Asthma control test questions will be applied to the asthma group.
41476573|NCT04375995|OTHER|Asthma quality of life scale|Asthma quality of life scale (AQLQ) will be applied to the asthma group.
41476574|NCT04375995|DIAGNOSTIC_TEST|Chest X Ray|Chest X Ray will be applied to the healthy control group.
41476575|NCT05055648|RADIATION|Photon Radiotherapy|nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
41320666|NCT03975374|DRUG|Tobradex Opthalmic Solution|Tobradex Opthalmic Solution
41320667|NCT00941889|DRUG|Saline|0.5 ml
41476576|NCT05055648|RADIATION|Proton Radiotherapy|nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
41476577|NCT02866240|DEVICE|Cathodal Transcranial Direct Current Stimulation (tDCS).|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
41476578|NCT00462891|OTHER|IT System|
41476579|NCT05695495|DRUG|N,N-Dimethyltryptamine (5mg)|Intravenous bolus application over 45 seconds
41476580|NCT05695495|DRUG|N,N-Dimethyltryptamine (10mg)|Intravenous bolus application over 45 seconds
41476581|NCT05695495|DRUG|N,N-Dimethyltryptamine (15mg)|Intravenous bolus application over 45 seconds
41476582|NCT05695495|DRUG|N,N-Dimethyltryptamine (20mg)|Intravenous bolus application over 45 seconds
41476583|NCT05695495|DRUG|N,N-Dimethyltryptamine (25mg)|Intravenous bolus application over 45 seconds
40802936|NCT00009880|DRUG|cisplatin|
40802937|NCT00009880|DRUG|fluorouracil|
40802938|NCT00009880|DRUG|paclitaxel|
40802939|NCT00009880|RADIATION|radiation therapy|
40802940|NCT03394651|DRUG|Oral medications to treat lower urinary tract symptoms|Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
41320668|NCT00941889|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.
41476584|NCT05695495|DRUG|Placebo (saline)|Intravenous bolus application over 45 seconds
41476585|NCT06489834|OTHER|Group Drumming|Weekly group drumming for 8 weeks
41476586|NCT05282979|DEVICE|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
41476587|NCT04919759|BEHAVIORAL|R-Basic|Participants in the R-Basic arm received access to a static website that contained educational materials on healthier eating and physical activity and the study questionnaires. The R-Basic intervention was implemented in the University of Sharjah.
40802941|NCT03394651|PROCEDURE|Minimal invasive transurethral prostate procedures|Patients in this group will receive surgical treatment.
40802942|NCT04176874|PROCEDURE|Robotic-assisted diastasis of the rectus abdominis muscles repair|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
40802943|NCT05288361|DIAGNOSTIC_TEST|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|"Patients presenting with symptomatic ischemic heart disease (including chronic stable angina or unstable angina) without evidence of myocardial infarction who require elective or urgent cardiac catheterization, and who meet all eligibility criteria will be enrolled.~Participants will undergo routine coronary angiography as well as comprehensive physiologic assessment with intracoronary acetylcholine provocation for diagnosis of vasospastic angina (VSA), coronary thermodilution to evaluate for coronary microvascular dysfunction (CMD), and intracoronary imaging with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) to evaluate for the presence of atheroma, plaque burden, and myocardial bridging."
40802944|NCT02241733|BEHAVIORAL|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
40802945|NCT02241733|BEHAVIORAL|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
40802946|NCT03851887|COMBINATION_PRODUCT|TAI combine SBRT|TAI combine SBRT
40802947|NCT03176862|DIAGNOSTIC_TEST|cardiac magnetic resonance scan|An MRI scan of the heart
40802948|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test with stress echocardiogram|An exercise bicycle test with echocardiogram done during the exercise.
40802949|NCT03176862|DIAGNOSTIC_TEST|24-hour ECG holter monitor|3 stickers attached to a small monitor are worn for 24 hours.
40802950|NCT03176862|DIAGNOSTIC_TEST|12-lead ECG|Can be done immediately by the bedside.
40802951|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|An exercise bicycle test. No stress echocardiogram.
40802952|NCT03176862|BIOLOGICAL|Blood test|20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
40802953|NCT01926899|DRUG|Bortezomib administration|
40802954|NCT05525130|DIETARY_SUPPLEMENT|Food supplement|FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
40802955|NCT05525130|DIETARY_SUPPLEMENT|Placebo|Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
40802956|NCT05754944|DIAGNOSTIC_TEST|ABI/TBI|ABI/TBI to be performed after surgery while patient is still admitted at the hospital.
40802957|NCT05754944|OTHER|Questionnaires|PAD symptoms questionnaire to be administered at baseline before surgery. mLEFS (included in PAD symptoms questionnaire) and WIQ to be administered at baseline before surgery. mLEFS and WIQ will be administered 1 month, 3 months, 6 months after surgery and every 6 months after that for a goal of at least 1 year.
40802958|NCT06192472|PROCEDURE|Chemical sclerotherapy|Sclerosant will be retained within the vein
40802959|NCT06192472|DRUG|1% Sodium Tetradecyl Sulphate|1% Sodium Tetradecyl Sulphate
40802960|NCT06192472|DRUG|3% Sodium Tetradecyl Sulphate|3% Sodium Tetradecyl Sulphate
41476588|NCT04919759|BEHAVIORAL|R-Enhanced|The R-Enhanced intervention was guided by the Social Cognitive Theory and employed a variety of behavior modification strategies, including self-monitoring, goal setting, self-efficacy, and social support to facilitate changes in diet and physical activity. In addition, participants in the R-Enhanced intervention had online access to a nutritionist. The R-Enhanced intervention was implemented in the United Arab Emirates University.
40802961|NCT06192472|DRUG|0.5% Polidocanol|0.5% Polidocanol
40802962|NCT06192472|DRUG|3% Polidcanol|3% Polidcanol
40802963|NCT03090659|BIOLOGICAL|LCAR-B38M CAR-T cell injection|
40802964|NCT06343818|OTHER|The Compassion Project: Intervention to Reduce Empathy-Based Stress in Staff|Six month package of training and resources delivered to ward staff, including bite-sized audio, video and written materials. Face to face training will be provided weekly by a clinical psychologist. A staff group of 'compassion champions' will be responsible for embedding the intervention.
41476589|NCT04818749|DRUG|Saline|Saline (placebo) will be administered intravenously before block performance and after the induction of general anaesthesia.
40802965|NCT01301287|DRUG|Chlorella|
40802966|NCT00420082|DRUG|Bilastine|Encapsulated Bilastine 20 mg tablets Q.D.
40802967|NCT00420082|DRUG|Fexofenadine|Encapsulated Fexofenadine 120 mg tablets Q.D.
40802968|NCT00420082|DRUG|Cetirizine|Encapsulated Cetirizine 10 mg tablets Q.D.
40802969|NCT00420082|DRUG|Placebo|Encapsulated Placebo tablets Q.D.
40802970|NCT04475523|DRUG|CI-8993|CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
40802971|NCT00864175|DRUG|INCB007839|100 mg BID
40802972|NCT00864175|DRUG|INCB007839|200 mg BID
40802973|NCT00864175|DRUG|INCB007839|300 mg BID
40802974|NCT00864175|DRUG|INCB007839|300 mg BID
40802975|NCT00864175|DRUG|trastuzumab|trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.
40802976|NCT00864175|DRUG|Docetaxel|
40802977|NCT01521923|BIOLOGICAL|Certolizumab Pegol + Methotrexate (MTX)|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week."
40802978|NCT01521923|BIOLOGICAL|Placebo + Methotrexate (MTX)|"1 syringe of Placebo every 2 Weeks and MTX.~The MTX treatment is to remain between 15-25 mg/week."
40802979|NCT03200431|OTHER|New adhesive strip|This is a newly developed strip.
40802980|NCT05656183|DIAGNOSTIC_TEST|TruGenome Cardiovascular Disease test|The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.
40802981|NCT05264987|OTHER|intensive care follow-up|The need for the mechanical ventilator, the length of stay in the intensive care unit, and outcomes of mothers were recorded. Deceased patients were evaluated in detail.
40802982|NCT03115827|DRUG|Droxidopa|Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
40802983|NCT03115827|DRUG|Carbidopa|Carbidopa 200mg twice a day
40802984|NCT00320554|BEHAVIORAL|Durometer analysis|
40802985|NCT05234918|DEVICE|Pediatric Rotary File Systems|"* Kedo S plus (p1 molar file ) (A1 anterior file)~* Kidzo-file system 25/4 30/4 30/6"
40802986|NCT04964505|DRUG|Azacitidine|Given IV or SC
41006583|NCT04917094|DEVICE|Compression stocking|"A below-the-knee compression stock will be worn daily for 2 weeks from waking up to before sleep.~Bioelectrical impedance will be performed before and 2 weeks after wearing the stocking to assess the total body water content.~Measuring the calf and neck circumference will be done before and after wearing the compression stocking. After 2 weeks, the patient will return back to the clinic for calf and neck circumference measurement.~Sleep test will be done the night before and 2 weeks after wearing the compression stocking. Oxygen Desaturation Index(ODI) will be assessed through a level 4 home sleep apnea testing device.~Patients recruited will have mild excessive to severe excessive daytime sleepiness and/or STOP-Bang score of 3 or more, with underlying conditions such as type II diabetes and hypertensive patients using the Epworth sleepiness scale. Epworth sleepiness scale will be assessed again 2 weeks after to assess for increase sleep efficiency."
41006584|NCT03343769|OTHER|BERG scale|Complete the BERG balance scale
41006585|NCT03343769|OTHER|Functional tests|timed up and go, Mini motor test, retropulsion test
41006586|NCT03343769|OTHER|Measurement of balance on a force platform|4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)
41320669|NCT04441879|BEHAVIORAL|Be a Mom Coping with Depression|Be a Mom Coping with Depression is a blended cognitive-behavioral intervention for the treatment of postpartum depression. It consists of 13 weeks of face-to-face and online sessions, each session targeting a specific thematic content, and providing participants with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content.
41320670|NCT04441879|BEHAVIORAL|Be a Mom|Be a Mom is an online intervention consisting of 6 modules, each one targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Women will receive biweekly phone calls from a psychologist between completion of each module to provide support.
41476590|NCT04818749|DRUG|Dexamethasone 12 mg|Dexamethasone 12 mg will be administered intravenously before block performance and saline (placebo) will be administered intravenously after the induction of general anaesthesia.
41476591|NCT04818749|DRUG|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Dexamethasone 12 mg will be administered intravenously before block performance and dexmedetomidine 1 mcg/kg will be administered intravenously after the induction of general anaesthesia.
41320671|NCT03368625|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery before surgical resection of brain mets.
41476592|NCT03676751|DRUG|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
41476593|NCT03676751|DRUG|Placebo|Oral suspension of placebo for azithromycin
41476594|NCT05985382|OTHER|Lower Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
41476595|NCT05985382|OTHER|Upper Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
41476596|NCT00027079|DRUG|ondansetron (Zofran)|
40802987|NCT04964505|DRUG|Uproleselan|Given IV
40802988|NCT04964505|DRUG|Venetoclax|Given PO
40802989|NCT02003794|DRUG|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
40802990|NCT00116038|DEVICE|Femoral implant (Versys Fiber Metal Taper®)|
40802991|NCT05577000|BIOLOGICAL|Manufactured Anti-BCMA CAR-T cells|Given IV
40802992|NCT05577000|DRUG|Fludarabine|Given IV
41006587|NCT03343769|OTHER|Measurement of maximal moment of the plantar flexor and dorsiflexor muscles|5-second repetitions
41006588|NCT03343769|OTHER|Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements|3 10-second repetitions
41320672|NCT05596903|OTHER|EMDR 2.0 group protocol|EMDR 2.0 group protocol
41320673|NCT05596903|OTHER|Mhgap stress module|Mhgap stress module
41320674|NCT01900678|DEVICE|VytronUS Ablation System|Pulmonary vein isolation.
41476597|NCT00027079|DRUG|naltrexone (ReVia)|
41476598|NCT00027079|BEHAVIORAL|Cognitive Behavioral Therapy|
40802993|NCT05577000|DRUG|Cyclophosphamide|Given IV
40802994|NCT00904670|DRUG|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
40802995|NCT00904670|DRUG|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
40802996|NCT00904670|DRUG|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
40802997|NCT03177512|BEHAVIORAL|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
40802998|NCT04050410|DRUG|Moxonidine|active drug given as 1 dose
40802999|NCT04050410|DRUG|Placebo|placebo pill given as 1 dose
40803000|NCT05040165|DEVICE|Iceform liner and sleeve|Subjects will be asked to use the investigational device as their primary prosthesis for up to 6 months. TPE material durability evaluated through monthly online questionnaires.
40803001|NCT00014989|DRUG|magnesium sulfate|
40803002|NCT02701959|DIETARY_SUPPLEMENT|High Nitrate Lettuce|The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~530 mg nitrate derived).
40803003|NCT02701959|DIETARY_SUPPLEMENT|Low Nitrate Lettuce|The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~3 mg nitrate derived).
40803004|NCT03650413|DRUG|UTTR1147A|UTTR1147A will be administered based on disease status, as described in the protocol.
40803005|NCT00164008|DRUG|zoledronic acid vs pamidronate|
40803006|NCT03863561|BEHAVIORAL|Diabetes self-management education (DSME) program|Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
40803007|NCT05388383|DEVICE|Ti-robot|Tianji ROBOT--Orthopedic surgery robot led by Beijing Jishuitan Hospital
41476599|NCT04281394|DEVICE|Robot assisted gait training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks.
40803008|NCT04290247|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging for fracture diagnosis before conventional X-ray
40803009|NCT06245486|DIETARY_SUPPLEMENT|Crispact®|Contains 20 Bld CFU/Stick of probiotic Lactobacillus crispatus M247
40803010|NCT06245486|DIETARY_SUPPLEMENT|Placebo|Placebo
40803011|NCT00392587|DRUG|GW856553|
40803012|NCT03026231|BIOLOGICAL|PRIM-DJ2727|Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules
40803013|NCT03026231|DRUG|Placebo (for PRIM-DJ2727)|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
40803014|NCT02303756|DEVICE|Pillcam® COLON Capsule|colonoscopy
40803015|NCT05421130|DEVICE|Selective Cerebral Perfusion Catheter|This product is intended to be placed in the branches of the aortic arch for the cerebral perfusion during surgery of aorta.
40803016|NCT03976024|OTHER|DHBN-FN arm|DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
40803017|NCT03976024|OTHER|Control arm (Erysipelas)|The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
40803018|NCT06407128|BIOLOGICAL|Collection of biological samples|Collection of biological samples (blood sample + valve tissue sample + saliva, periodontal and feces sample)
40803019|NCT05415254|DRUG|Calcitriol|Calcitriol supplementation orally
41320675|NCT05958758|DRUG|Psilocybin-assisted therapy within a community of practice model (group administered)|The community of practice is 10 weeks long, meeting virtually for 2 hours each week, in a structured process, run through the Roots to Thrive treatment program. The psilocybin-assited therapy sessions occur midway through the 10-week program.
41320676|NCT03905629|OTHER|None (retrospective observational study)|"This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay \>15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~* Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~* Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~* Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors"
41320677|NCT00347035|DRUG|brimonidine|
41320678|NCT06018935|OTHER|No intervention|No intervention
41320679|NCT00126789|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
41476600|NCT04281394|OTHER|conventional gait training|even level gait training and range of motion exercises
41476601|NCT00563017|DRUG|Long-acting Risperidone microspheres injection|
41476602|NCT01974908|PROCEDURE|Fibrillatory Factor calculation (FF)|During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
41476603|NCT01387425|DRUG|varenicline|varenicline at a dose of 1 mg twice a day for 12 week
41476604|NCT01387425|DRUG|placebo tablet is made of lactose|placebo at a dose of 1 mg twice for 12 week
40803020|NCT06352697|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
40803021|NCT06352697|DIETARY_SUPPLEMENT|Placebo|Placebo
40803022|NCT01942824|BEHAVIORAL|Text Messages|
40803023|NCT03938766|DIAGNOSTIC_TEST|PSMA PET/CT|Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
40803024|NCT02266147|DRUG|SD-101|
40803025|NCT02266147|RADIATION|Radiation therapy|
40803026|NCT00328887|GENETIC|CD40 Gene Transfer|gene transfer, intratumoral administration
40803027|NCT01887561|DRUG|dasatinib|
40803028|NCT03085459|BEHAVIORAL|work Time|nurse got qualification certificate and the working time
40803029|NCT05498935|OTHER|CPB time|Cardiopulmonary bypass time
40803030|NCT05940857|DEVICE|OCS Liver|The TransMedics® Organ Care System (OCS) Liver is an FDA approved portable extracorporeal liver perfusion and monitoring system.
40803031|NCT01230996|DRUG|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
40803032|NCT01230996|RADIATION|Intensity-modulated radiation therapy|Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
40803033|NCT01230996|PROCEDURE|Intracavitary brachytherapy|Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
41476605|NCT04593212|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Evaluation of microcirculatory dysfunction by assessment of retinal and choroidal microvasculature with optical coherence tomography angiography (OCTA)
40803034|NCT05046990|DIAGNOSTIC_TEST|Regular Arrangement of Collecting Venules|This is a prospective, multicentre, international study without a control group.
40803035|NCT00305903|DRUG|Rivastigmine, memantine|
40803036|NCT03654924|DEVICE|Laryngeal Mask|General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
40803037|NCT00956722|DRUG|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
40803038|NCT04423679|DEVICE|Evalyn Brush|a standard brush-based cervicovaginal self-collection device
41320680|NCT01769469|DRUG|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
41320681|NCT01368666|DEVICE|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
41320682|NCT04889963|BIOLOGICAL|adypose mesenchymal conditioned medium and ligament derived conditioned medium|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
41320683|NCT01042951|BIOLOGICAL|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
41320684|NCT01042951|OTHER|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
41320685|NCT06498752|DRUG|PD-1 monoclonal antibody consolidation therapy|PD-1 monoclonal antibody-based consolidation therapy for 1 year after completion of radiotherapy (or combination chemotherapy up to 4 cycles if less than 4 cycles of chemotherapy). Specific dosing: PD-1 monoclonal antibody, 200mg every 3 weeks.
41320686|NCT04961099|DRUG|HY01|low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7
41320687|NCT01919905|DIETARY_SUPPLEMENT|Vitamin D|High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
41476606|NCT03393416|BIOLOGICAL|MASCT-I|The final products of MASCT-I(Multiple-antigen specific cell therapy) technology are dendritic cells (DC) and effector T cells.Treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
41476607|NCT03393416|DRUG|PD1 antibody|"Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study."
41476608|NCT01615887|DRUG|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
41476609|NCT01615887|DRUG|placebo|sugar pill
41476610|NCT04289454|OTHER|Flavor additive|Various flavor additives will be tested (vs. no added flavor) to determine which show promise for making KE drinks taste less unpleasant
41152498|NCT01717755|OTHER|Intra-arterial treatment|IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
41320688|NCT05955209|DRUG|Disitamab Vedotin（RC48-ADC）|Participants will receive RC48-ADC intravenous injection (2.0 mg/kg, Q2W) until disease progression or death.
41320689|NCT02975700|DRUG|PLX3397|1000 mg/day (400 mg in the morning and 600 mg in the evening)
41320690|NCT00914043|GENETIC|gene expression analysis|
41476611|NCT04214717|COMBINATION_PRODUCT|DC-CIK combined with Chemotherapy|Patients will receive 4 cycles of DC-CIK treatments combined with Chemotherapy within 8 months.
41320691|NCT00914043|GENETIC|microarray analysis|
41320692|NCT00914043|GENETIC|polymerase chain reaction|
41320693|NCT00914043|GENETIC|polymorphism analysis|
41320694|NCT00914043|GENETIC|reverse transcriptase-polymerase chain reaction|
41320695|NCT00914043|OTHER|biologic sample preservation procedure|
41320696|NCT00914043|OTHER|enzyme-linked immunosorbent assay|
41320697|NCT00914043|OTHER|laboratory biomarker analysis|
41320698|NCT00914043|PROCEDURE|fatigue assessment and management|
41320699|NCT02451033|DRUG|standard medical therapy|diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed
41320700|NCT02451033|DRUG|G-CSF|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year
41320701|NCT02451033|DRUG|Growth Hormone|Growth Hormone in low dose of 1unit sc daily for 1 year
40803039|NCT02142335|DRUG|Rituxan|The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 \& 3 (days 1 \& 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
40803040|NCT00899821|BIOLOGICAL|aldesleukin|
40803041|NCT00899821|BIOLOGICAL|recombinant interleukin-12|
40803042|NCT00899821|BIOLOGICAL|sargramostim|
40803043|NCT00899821|OTHER|immunologic technique|
40803044|NCT00899821|PROCEDURE|biopsy|
40803045|NCT01299337|DRUG|T3|Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
40803046|NCT01221623|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
40803047|NCT01221623|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
40803048|NCT04452058|OTHER|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
41006589|NCT01554566|DIETARY_SUPPLEMENT|honey|The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
41320702|NCT06079957|PROCEDURE|Ergonomic training|"1. Individuals will be given a copy of ergonomic guidelines to follow which includes:~* Organize workstation according to the primary , secondary and tertiary zones.~* Place frequently used items within the reach of an arm.~* Don't move head while reading documents instead raise or lower the eyes to read.~* Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~* Keep reference material upright at desk.~* Avoid slouched postural habits, sit upright.~* Adjust chair height in such a way that it shouldn't compress the thigh.~* Arm rest should be at elbow flexion of 90 degrees.~* Phone must be cradled between neck and shoulder to avoid forward head posture."
41320703|NCT06079957|PROCEDURE|Neck Exercises|"Neck Exercises Strengthening exercises of Deep cervical flexors,rhomboids,lower Trapezius, Middle Trapezius, serratus anterior.~Neck Stretching of Suboccipitals,Sternocleidomastoid ,Scalenes,Upper trapezius, Levator scapulae,Pectoralis major and minor."
41320704|NCT02214485|BEHAVIORAL|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
41320705|NCT02214485|BEHAVIORAL|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
41320706|NCT02503774|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arms' description.
41320707|NCT02503774|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arms' description.
41320708|NCT02652312|DRUG|Dexmedetomidine|A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
41320709|NCT02652312|DRUG|Placebo|A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
41320710|NCT02652312|PROCEDURE|Ondansetron|0.15 mg/kg intravenous (IV) will be given as a pre-medication
41320711|NCT02652312|PROCEDURE|fentanyl|1.5 μg/kg intraoperative
41320712|NCT02652312|PROCEDURE|propofol|10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
41320713|NCT02652312|PROCEDURE|Atracurium|0.5 mg/kg IV for endotracheal intubation
40803049|NCT06515574|BEHAVIORAL|developmental care|Individualized Developmental Care that includes the light, noise, sleep, etc.
40803050|NCT03709069|DIETARY_SUPPLEMENT|Albumin supplementation|Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
40803051|NCT00066599|DRUG|voriconazole|
40803052|NCT06365437|BIOLOGICAL|TCD601|Investigational Product
40803053|NCT06365437|DRUG|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
40803054|NCT06365437|DRUG|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
40803055|NCT06365437|DRUG|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
40803056|NCT06365437|DRUG|ATG|Standard of Care induction therapy in solid organ transplantation
40803057|NCT04930835|PROCEDURE|Implant supported dentures|Placement of dental implants with different loading protocols for supporting full arch dentures.
40803058|NCT01485731|DRUG|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
40803059|NCT01485731|DRUG|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
40803060|NCT01485731|RADIATION|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
41006590|NCT01433263|DRUG|BYM338 active drug|
41006591|NCT01433263|DRUG|Placebo|
41006592|NCT01848990|DRUG|Commercial Hylenex® recombinant (hyaluronidase human injection)|
40803061|NCT01485731|RADIATION|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
40803062|NCT01485731|PROCEDURE|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
40803063|NCT01485731|PROCEDURE|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
40803064|NCT01485731|PROCEDURE|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
40803065|NCT01485731|PROCEDURE|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
40803066|NCT01485731|PROCEDURE|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
40803067|NCT01485731|PROCEDURE|Proctoscopy|Optional. Pre-Treatment
40803068|NCT01485731|PROCEDURE|Cytoscopy|Optional. Pre-Treatment
41320714|NCT02652312|PROCEDURE|diclofenac sodium|1 mg/kg for postoperative analgesia
41320715|NCT02652312|PROCEDURE|desflurane|1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
41320716|NCT05759845|DRUG|Topiramate 25Mg Tab|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks
41320717|NCT05759845|DRUG|Amitriptyline 25 Mg Oral Tablet|Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
41320718|NCT05759845|DRUG|topiramate 25mg plus amitriptyline 25mg|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
41320719|NCT00592670|DRUG|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
41476612|NCT04214717|DRUG|Chemotherapy|Patients will only receive Chemotherapy.
40803069|NCT01485731|PROCEDURE|Renal Ultrasound|Optional. Pre-Treatment
40803070|NCT01485731|PROCEDURE|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
40803071|NCT01485731|PROCEDURE|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
40803072|NCT00115271|DRUG|Nutritional supplements|
40803073|NCT00568763|BIOLOGICAL|sargramostim|
40803074|NCT00568763|OTHER|immunoenzyme technique|
40803075|NCT00568763|OTHER|immunohistochemistry staining method|
40803076|NCT00568763|OTHER|immunologic technique|
40803077|NCT00568763|OTHER|laboratory biomarker analysis|
40803078|NCT00568763|PROCEDURE|biopsy|
40803079|NCT00568763|PROCEDURE|cryosurgery|
40803080|NCT00568763|PROCEDURE|radiofrequency ablation|
40803081|NCT04938310|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
40803082|NCT04938310|DEVICE|support garment|A custom made support garment
40803083|NCT05719857|PROCEDURE|Hepatic vein pressure gradient measurement|HVPG will be performed after light conscious sedation and with noninvasive vital sign monitoring. The right jugular vein will be catheterized with ultrasound assistance and after local anesthesia. Then a venous introducer will be placed and a balloon-tipped catheter will be advanced under fluoroscopic control into the right hepatic vein. Free hepatic pressure will be obtained with the balloon deflated, keeping the catheter tip in the right hepatic vein. Then, wedged venous pressure will be measured by inflating the balloon with 2 ml of air. At this moment, complete occlusion of the catheterized hepatic vein can be confirmed by injecting iodinated contrast and observing its retention. The presence of veno-venous communications can be detected during the test. To calculate the gradient, we perform the simple difference between the two measurements. Measurements will be performed in triplicate and the average used as the final value.
40803084|NCT05719857|PROCEDURE|Ultrasound-guided percutaneous liver biopsy|Percutaneous liver biopsy will be performed with the aid of US to choose the best site for the procedure, minimizing the incidence of complications. With the patient in dorsal decubitus, venous analgesia with fentanyl 25-50 mcg will be performed. After marking the appropriate site, skin asepsis and antisepsis will be performed with Chlorhexidine® and topical anesthesia with 1% lidocaine. Then, the liver will be punctured using a 14G semi-automatic tru-cut single-use liver biopsy needle. The recovered material will be stored in a 50 ml flask with 10% formaldehyde. Patients will remain at rest supervised for 4 hours, with hourly measurement of blood pressure (BP), heart rate (HR) and assessment of symptoms (abdominal pain, nausea, etc.). In the absence of any complications, patients will be discharged from the hospital.
40803085|NCT05719857|DIAGNOSTIC_TEST|Multiparametric Abdominal Magnetic Resonance with Elastography|The evaluation of the abdomen by MRI, with special interest to the liver and spleen, will be performed in a Siemens 3.0T Magnetom Prisma MR system. In addition to the routine protocol without contrast administration, MR elastography will be performed to assess liver stiffness and spleen stiffness. Data processing will be carried out at a Syngovia workstation.
41006593|NCT01848990|DRUG|Precommercial Hylenex recombinant (hyaluronidase human injection)|
41320720|NCT00592670|DRUG|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
41320721|NCT00790101|DRUG|Risedronate|
41320722|NCT00790101|DRUG|Raloxifene|
41320723|NCT00790101|OTHER|Placebo|
41320724|NCT05246007|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
41476613|NCT02276898|DRUG|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
41476614|NCT02276898|DRUG|Isotonic Saline 0.9% (Placebo)|
40803086|NCT05665101|PROCEDURE|Coil embolization of aneurysm sac|Patients are treated with standard EVAR with additional coiling of the aneurysm sac. The distinct type of coils used is not predefined.
40803087|NCT00453037|BEHAVIORAL|structured educational program|structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
40803088|NCT00453037|BEHAVIORAL|participation in the educational program after 6 months|Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
40803089|NCT05712369|OTHER|Blood sampling|"Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~* 50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~* 8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction."
40803090|NCT06040424|COMBINATION_PRODUCT|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
40803091|NCT06040424|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
40803092|NCT00635349|DRUG|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
40803093|NCT00635349|DRUG|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
40803094|NCT00635349|DRUG|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
40803095|NCT04644588|DIAGNOSTIC_TEST|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
40803096|NCT05611645|RADIATION|Hypofractionated Stereotactic Radiotherapy|Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.
40803097|NCT05611645|DRUG|Bevacizumab|Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
40803098|NCT00785590|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
40803099|NCT03919084|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
41006594|NCT01848990|DRUG|Insulin lispro|
41006595|NCT01848990|DRUG|Insulin aspart|
41006596|NCT01848990|DRUG|Insulin glulisine|
41006597|NCT00095758|DRUG|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
41006598|NCT00095758|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
41006599|NCT02489227|DRUG|CHS-1420|
41476615|NCT05811026|DEVICE|Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)|"* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W2): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W8): Four weeks after the third treatment, a follow-up assessment will be performed"
41006600|NCT02489227|DRUG|Adalimumab|
41006601|NCT00006412|DRUG|Pravastatin sodium|
41006602|NCT00006412|DRUG|Fenofibrate|
41006603|NCT05479578|DRUG|Cyclophosphamide|Given PO
41006604|NCT05479578|DRUG|Dexamethasone|Given PO
41006605|NCT02092090|BEHAVIORAL|Dietary sodium reduction|Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
41006606|NCT03339375|DEVICE|esophageal Doppler|Goal directed fluid therapy using dynamic parameters from esophageal Doppler
41006607|NCT03112161|OTHER|Eucaloric Feeding Period|
41006608|NCT03112161|OTHER|Overfeeding Feeding Period|
41006609|NCT03112161|OTHER|Underfeeding Feeding Period|
41006610|NCT05869227|DRUG|Capecitabine/Placebo combined with toripalimab|Combined
41006611|NCT01632371|DEVICE|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
41006612|NCT01632371|DEVICE|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
41006613|NCT01962558|DEVICE|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
41006614|NCT01962558|DEVICE|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
41006615|NCT05067933|DRUG|VXA-CoV2-1.1-S|COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine
41006616|NCT05067933|OTHER|Placebo Tablets|Placebo tablets matching the active vaccine tablets
41476616|NCT05811026|DEVICE|Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)|"* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed"
41476617|NCT01304420|DEVICE|Ultrasonography|Scanning 5 joints bilaterally with an ultrasound scanner
41476618|NCT01884584|DRUG|Indocyanine green (ICG)|Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
41006617|NCT04110301|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycles (One dose every two cycles).
41006618|NCT04110301|DRUG|Lenalidomide|Dose on days 2-22 every 28 days x 12 cycles: the starting dose is 10-mg ; Adjusted dose according to the tumor response or toxicity reaction
41476619|NCT02380079|DRUG|SCD-101|Administered as gelatin capsules
41476620|NCT00005119|PROCEDURE|Measures of calcium and bone turnover|
41006619|NCT06075485|OTHER|Ketocal|ketogene diet
41006620|NCT03427866|DRUG|Ruxolitinib|Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.
41006621|NCT05582330|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of Telephone Based ABILOCO-Stroke
41006622|NCT05322187|DRUG|PD-1 inhibitor|Sequential PD-1/PD-L1 Inhibitor and LENvatinib treatment after chemotherapy resistance
41006623|NCT02420106|PROCEDURE|Osteopathic Manipulative Medicine|Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
41006624|NCT00649116|DRUG|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
41320725|NCT05246007|DRUG|Normal Saline|Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
41320726|NCT06095752|OTHER|blood viscosity , albumin / fibrinogen ratio and red cell distribution|In multiple myeloma patients ,we get blood viscosity , albumin / fibrinogen ratio and red cell distribution directly after confirmed diagnosis to determine the prognosis of the disease in association with these tests results
41006625|NCT00649116|DRUG|Lopressor® Tablets 100 mg|100mg, single dose fed
41320727|NCT02690207|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
41320728|NCT02262234|OTHER|Education Program Type 1|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
41320729|NCT02262234|OTHER|Education Program Type 2|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
41006626|NCT01533246|DRUG|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
41006627|NCT01533246|OTHER|laboratory biomarker analysis|Correlative studies
41006628|NCT05094297|BEHAVIORAL|Investigate the effects of an exercise intervention on U.S. Veterans.|Enrolled subjects will be asked to complete 94 total visits (4 study testing visits and 90 exercise visits). They will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months.
41006629|NCT02806479|OTHER|Observational: Arrhythmogenic Substrate|
41006630|NCT02690675|DIETARY_SUPPLEMENT|Iron fortified formula milk|One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
41006631|NCT00748644|DRUG|Rituximab|"rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
41320730|NCT03276013|DRUG|Pembrolizumab|pembrolizumab in combination with doxorubicin
41320731|NCT01492296|PROCEDURE|endoscopy after short fasting|patients were evaluated with endoscopy after fasting for two hours
40803100|NCT03919084|OTHER|Pharmacy Care Program services|Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
41320732|NCT01492296|PROCEDURE|conventional fasting|patients were evaluated after fasting for 8 hours
41476621|NCT01183117|DEVICE|SM-01|SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
40803101|NCT03919084|OTHER|Patient Navigation Services|In traditional patient navigation programs, a lay person from the community guides individuals through the healthcare system to receive appropriate services. For the present study, the research team will train pharmacy liaisons (pharmacy technicians or pharmacy interns with at least a high school degree and four years of pharmacy experience) to provide patient navigation services, in addition to providing medication adherence support and assistance resolving barriers to accessing medication. In an effort to avoid duplication of services the patient navigation intervention will be delivered via a pharmacy liaison trained in patient navigation, thereby decreasing multiple intervention providers and increasing the potential for sustainability should the intervention prove effective.
40803102|NCT03919084|OTHER|Motivational Interviewing|Motivational interviewing is a counseling method that encourages patient-centered discussions. Motivational interviewing will be delivered by the intervention arm pharmacy liaison-patient navigators to identify the patient's unmet needs and encourage the patient to adopt behavior change that will promote engagement with resources and services to mitigate or alleviate HRSN.
40803103|NCT03919084|OTHER|Linkage to Community Partner Organization|The pharmacy liaison-patient navigator will partner with a community organization, Action for Boston Community Development (ABCD). ABCD will help connect patients receiving THRIVE+ to community resources including childcare, food, heating, and housing. The pharmacy liaison-patient navigator will interface directly with ABCD to coordinate receipt of resources for their patients.
40803104|NCT00062855|PROCEDURE|Skin Biopsy|
41006632|NCT00748644|DRUG|Azathioprine|"azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
41006633|NCT02672371|DEVICE|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
41006634|NCT02672371|DEVICE|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
41320733|NCT03242005|DEVICE|MiniMed® Pro-set®|Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.
41320734|NCT03242005|DEVICE|MiniMed® Quick-set®|Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
41320735|NCT01613547|DRUG|Amoxicillin|80 mg/kg/day for 7 days
41320736|NCT01613547|DRUG|Placebo|7 days
41320737|NCT05259930|OTHER|Amino MP9|Name used by Nualtra for their product of BCAA
41320738|NCT04257084|DIAGNOSTIC_TEST|chromoendoscopy with target biopsy; NBI with target biopsy|"Chromoendoscopy with target biopsy: 0.03% indigo carmine solution based chromoendoscopy (using high-definition colonoscopy) will be fulfilled and target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia.~NBI with target biopsy: After inserting a high definition colonoscopy up to cecum, endoscopists observe the colon in combination of white light and NBI (white light first and then NBI). Target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia."
41320739|NCT00059618|DRUG|PS-341 (Bortezomib)|Starting dose 0.8 mg/m\^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.
41320740|NCT00059618|DRUG|Carboplatin|AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.
41320741|NCT03058822|DRUG|BMS-931699|BMS-931699 single subcutaneous dose on Day 1
41320742|NCT03090464|OTHER|Use of digital disease management tool|The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
41320743|NCT03737045|OTHER|Decision Aid|Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
41320744|NCT05380349|DRUG|combinations of up to 3 FDA approved drugs from a panel of compounds|personalized drug combinations
41320745|NCT02800473|DEVICE|Strorz (commercial)|
41476622|NCT01183117|DEVICE|PTA|balloon angioplasty
41320746|NCT02800473|DEVICE|CyPaM2 (experimental)|
41476623|NCT04610060|BEHAVIORAL|Power walking|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~It is a form of exercise where active upper body movement is performed along with usual walking. It is a fast walking exercise done at a speed of 6 to 8 km/h. During power walking the back is kept straight with the centre of gravity moving from heal, sole, and to hallux. There is active swing back and forth movement of elbow joint with 90 degrees of flexion while walking.~Weekly protocol for power walking~* Week 1 60-65 % of the target heart rate (THR) 5,000 to 7,499 steps/day~* Week 2 65-70 % of the target heart rate (THR) 7,500 to 9,999 steps/day~* Week 3 70-75 % of the target heart rate (THR) \>=10,000 steps/day~* Week 4 75-80 % of the target heart rate (THR) \>12,500 steps per day"
41476624|NCT04610060|BEHAVIORAL|Standardised outpatient cardiac rehabilitation|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines the intervention group received the following four weeks of intense training program
41476625|NCT05529472|DEVICE|Peripheral Orbital Atherectomy System (OAS)|Treatment with Orbital Atherectomy System (OAS) followed by Percutaneous Old Balloon Angioplasty (POBA), pre-dilation and Drug Coated Balloon (DCB) - Medtronic IN.PACT™ Admiral™
41476626|NCT01706016|PROCEDURE|Thermic destruction of tissue by Laser using the Novilase device|
41476627|NCT01345318|BIOLOGICAL|PF-04236921|Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.
40803105|NCT00062855|GENETIC|Gene Modified Neuroblastoma Cells|"The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.~A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).~At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received."
41006635|NCT01515969|DRUG|Erlotinib hydrochloride|Given PO
41006636|NCT01515969|DRUG|Dovitinib lactate|Given PO
41006637|NCT00557791|DRUG|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
41006638|NCT00557791|DRUG|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
41320747|NCT02540096|OTHER|Mental practice|"The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups)."
41320748|NCT02540096|OTHER|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
41320749|NCT01244191|DRUG|Tivantinib|Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day
41320750|NCT01244191|DRUG|Placebo|Tivantinib Placebo tablets given twice a day
41320751|NCT01244191|DRUG|Erlotinib|Erlotinib 150 mg oral tablets, given once a day
41320752|NCT03224481|OTHER|Electronic reminder|The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
41320753|NCT00096590|OTHER|coagulation study|
41320754|NCT00096590|OTHER|immunoenzyme technique|
41476628|NCT01345318|BIOLOGICAL|PF-04236921|Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
41476629|NCT01626963|PROCEDURE|Single-port access surgery|Surgery carried out through a single incision laparoscopic approach
41476630|NCT01626963|PROCEDURE|Conventional Laparoscopic Access|Surgery through standard multiport laparoscopic approach
41320755|NCT00096590|OTHER|laboratory biomarker analysis|
40803106|NCT02143856|DRUG|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
41006639|NCT06355869|OTHER|repeated 3D gait-analysis|An observational 3D gait-analysis was performed with a period of 1-14 days is foreseen between the two measurements.
41006640|NCT00378313|DRUG|gemcitabine, epirubicin, paclitaxel|
41006641|NCT00832351|PROCEDURE|Mobilisation|Mobilisation
41006642|NCT03357406|PROCEDURE|ultrasound implant site preparation|piezoelectric bone surgery will be used to create implant bone ostectomy
41006643|NCT03357406|PROCEDURE|conventional implant site preparation|twist drills will be used to create implant bone ostectomy
41006644|NCT03212703|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|8-week mindfulness skills training sessions based on Mindfulness-Based Cognitive Therapy (MBCT) program by Zindel Segal, Mark Williams and John Teasdale
41006645|NCT03212703|OTHER|Waitlist control (WLC)|Observation surveys at baseline, mid-point and end-point of an 8-week period
41006646|NCT00556855|OTHER|E-DO|topical lotion, once daily (evening), total duration: 4 weeks
41006647|NCT00556855|OTHER|Placebo|topical lotion, once daily (evening), total duration: 4 weeks
41006648|NCT06126549|BEHAVIORAL|Building Better Caregivers|Peer-led, group intervention for caregivers focused on problem-solving
40803107|NCT03420495|BEHAVIORAL|Decision-Making Tasks|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).
40803108|NCT01509976|OTHER|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
40803109|NCT03593486|DEVICE|Low-level Pulsed EMF|Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
40803110|NCT03593486|DEVICE|Sham Stimulation|The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
41476631|NCT00933881|OTHER|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
41476632|NCT03413384|DRUG|Ceftriaxone|1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
41320756|NCT00096590|OTHER|physiologic testing|
41320757|NCT00096590|PROCEDURE|study of high risk factors|
40803111|NCT04144322|DEVICE|Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition|Placement of a short implant
40803112|NCT04144322|DEVICE|Zimmer T3 with DCD Ex Hex Parallel Walled implants|Placement of a long implant with sinus lift and bone graft
41320758|NCT02138396|DRUG|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
41320759|NCT02138396|DRUG|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
41476633|NCT03413384|OTHER|Placebo|Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
41476634|NCT00379223|PROCEDURE|vitrectomy with radial optic neurotomy|
40803113|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
40803114|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
40803115|NCT02283905|DRUG|amphotericin-B|continuously infused
41320760|NCT02138396|DRUG|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
41476635|NCT04787770|OTHER|non-intervention|non-intervention
41476636|NCT05520606|PROCEDURE|pancreatoduodenectomy|Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region
41006649|NCT06126549|BEHAVIORAL|Problem Solving Training|Clinician-led, one-to-one intervention for caregivers focused on problem-solving
41320761|NCT06531226|OTHER|Fill in personality questionnaires|For patients who need to undergo colonoscopy, we invite them to fill out a personality survey questionnaire after obtaining their informed consent. The questionnaire contains 60 survey questions, which cover the five dimensions of the Big Five personality traits. Each question has five options, corresponding to the five states of very disagree to very agree. The questionnaire was developed based on the Chinese population and has four norms applicable to different age groups to ensure the reliability of the questionnaire.
41320762|NCT00173693|BEHAVIORAL|exercise for strength, balance, health education|
40803116|NCT02283905|DRUG|voriconazole|intravenously or orally administered
41320763|NCT01889654|OTHER|Venous blood sampling|
41320764|NCT03143556|DEVICE|Magnetic stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure will be assigned to magnetic stent or routine stent using computer generated randomization method in the operating room. Those who receive magnetic stent would get their stent removal by magnetic device retrieval and not by routine cystoscopy.
41476637|NCT03135652|RADIATION|adjuvant SBRT|adjuvant SBRT of liver lesions
41476638|NCT03135652|DRUG|Chemotherapy|mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
41476639|NCT00834899|DRUG|Eptifibatide|Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
41476640|NCT00834899|DRUG|Placebo|Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
41476641|NCT02571803|BEHAVIORAL|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
40803117|NCT03370380|DRUG|Aflibercept|Patients are treated according to authorization of Aflibercept
40803118|NCT06134115|DIETARY_SUPPLEMENT|Lipocet® (food supplement)|1 sachet, 10 ml corresponding to 1500 mg of Cetylated fatty acids
40803119|NCT06134115|DIETARY_SUPPLEMENT|Lipocet Placebo|Lipocet Placebo matching to Lipocet
41006650|NCT06126549|BEHAVIORAL|Usual Care|Usual discharge training and support offered to family caregivers of ABI patients
41006651|NCT00874068|OTHER|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
41006652|NCT00874068|OTHER|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
41476642|NCT02571803|OTHER|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
40803120|NCT00372619|DRUG|clofarabine|Given IV for 5 days
40803121|NCT00372619|DRUG|cytarabine|Given IV
40803122|NCT00372619|DRUG|methotrexate|Given intrathecally or IT age based dosage
40803123|NCT00372619|OTHER|laboratory biomarker analysis|
41320765|NCT05239559|DEVICE|Bubble CPAP oxygen delivery device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the nasopharynx of the baby. An underwater tube (expiratory arm) that acts as a blow off valve is interposed between the oxygen source and the baby. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the baby. The constant bubbling of gas through the blow off mechanism delivers the bubbling CPAP effect. Oxygen may be delivered by nasal prongs inserted into the nostril of child.~The system has three components:~1. Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~2. A nasal interface connecting the child's airway with the circuit:~3. An expiratory arm with the distal end submerged in water to generate end-expiratory pressure.~The source of oxygen will be either an oxygen concentrator or cylinder, central distribution through pipelines."
40803124|NCT01109121|DRUG|Combination 400|Tranilast 300 mg QD; Allopurinol 400 mg QD
40803125|NCT01109121|DRUG|Allopurinol|Allopurinol 400 mg, QD
41320766|NCT03165942|OTHER|Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
40803126|NCT01109121|DRUG|Combination 600|Tranilast, 300 mg QD; Allopurinol 600 mg QD
40803127|NCT03325348|DRUG|Nifedipine 10 mg|Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
41320767|NCT03165942|OTHER|Non-Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
41320768|NCT03165942|DRUG|Ethanol|
40803128|NCT03325348|DRUG|Labetalol|IV labetalol 20 mg \& mint tablet will be given to patients every 15 min until one hour
40803129|NCT00297960|DRUG|ziprasidone or olanzapine|
40803130|NCT00297960|PROCEDURE|hyperinsulinaemic euglycaemic clamp|
40803131|NCT00297960|PROCEDURE|microdialysis (skeletal muscle)|
40803132|NCT04739319|OTHER|N/A Observational study|N/A Observational study
40803133|NCT05777785|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
41320769|NCT03019224|PROCEDURE|Selection and preparation of the volunteers|Patients who sought the postgraduate dental clinic for whitening were invited to participate in the study. They were informed by the researcher (dentist) about all the aspects of the study and who might participate or discontinue the participation at any moment during the treatment. In addition, it was clarified that their participation was voluntary and refusal to participate would not result in any penalty or loss of benefits.
41476643|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
40803134|NCT04963036|OTHER|Entropy and NOL-Guided Goal Directed Anesthesia|Entropy-guided Anesthesia (Propofol infusion in order to maintain Entropy between 45 and 55) and NOL-guided Analgesia (Remifentanil infusion in order to maintain NOL-Index between 10 and 25).
40803135|NCT04963036|OTHER|Standard of Care Group (Entropy and blinded NOL)|"Entropy-guided Anesthesia (Propofol infusion in order to obtain Entropy between 45 and 55) and Remifentanil infusion at the discretion of the anesthetist in charge, based on current practice: patient vitals (Heart Rate, Blood Pressure, Respiratory Rate...), movements, spontaneous breathing, experience....~In this group, nociception monitor screen will be concealed and the NOL index will not be available for guidance of remifentanil dosing)."
40803136|NCT06329466|OTHER|intervention (EFT) group|It is the group to which EFT is applied.
40803137|NCT05431387|DRUG|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
40803138|NCT05431387|DRUG|Placebo|film-coated oral tablets containing matched placebo
40803139|NCT05431387|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
40803140|NCT06249152|DRUG|QLS-111, 0.015%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
40803141|NCT06249152|DRUG|QLS-111, 0.030%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
40803142|NCT06249152|DRUG|QLS-111, 0.075%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
40803143|NCT06249152|DRUG|QLS-111 vehicle ophthalmic solution|Vehicle drops applied QPM for 14 days the BID for 14 days.
40803144|NCT03309254|OTHER|High Glycemic Index|High Glycemic Index Food
40803145|NCT03309254|OTHER|Low Glycemic Index|Low Glycemic Index Food
40803146|NCT01555073|DRUG|pregabalin/celecoxib|pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
40803147|NCT01555073|DRUG|pregabalin/placebo|pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
40803148|NCT01555073|DRUG|celecoxib/placebo|celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
40803149|NCT01555073|DRUG|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
40803150|NCT05502926|DIAGNOSTIC_TEST|lung ultrasound score|peroperative and postoperative 12 point trans-thoracic lung ultrasound
40803151|NCT05223179|BIOLOGICAL|CODA-VAX H1N1|Intramuscular Live Attenuated Influenza H1N1 Vaccine
40803152|NCT05223179|BIOLOGICAL|Flucelvax Quad|Licensed Seasonal Injectable Influenza Vaccine
40803153|NCT05223179|OTHER|Saline|Saline
40803154|NCT00203866|DRUG|G250 peptide|
40803155|NCT00203866|DRUG|IL-2|
40803156|NCT00361231|DRUG|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
40803157|NCT00361231|DRUG|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
41476644|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
40803158|NCT00361231|DRUG|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
40803159|NCT06331546|DIETARY_SUPPLEMENT|Low-oxalate diet|4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
40803160|NCT06331546|DIETARY_SUPPLEMENT|High-oxalate diet|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium content (600-1000 mg/day)
40803161|NCT06331546|OTHER|soluble oxalate gut absorption test|Oral ingestion of 13C2-oxalate and sucralose.
40803162|NCT04381416|DEVICE|SEAD treatment|up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic
40803163|NCT03990623|RADIATION|Computed Tomography Perfusion Imaging|Undergo perfusion CT
40803164|NCT03990623|PROCEDURE|Liver Biopsy|Undergo liver biopsy
40803165|NCT03709277|BEHAVIORAL|Pharmacist-Driven Intervention|The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
40803166|NCT04081402|BIOLOGICAL|HU-014|Hutox Inj(Clostridium botulinum type A)
40803167|NCT04081402|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
40803168|NCT05627232|DRUG|Tazemetostat|Given PO
41006653|NCT03521453|OTHER|PEPPER robot|Presence of a Robot (PEPPER Robot), designed and programmed to give informations, using a screen and vocal. All the patients in the second period will have access to,the robot, while waiting for the visit.
41476645|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
41006654|NCT06287060|OTHER|strawberry extract.|strawberry has a whitening effect due to its content of ellagic and maleic acids. the presence of acidic components namely ascorbic acid may increase the surface energy by removing the surface debris, thereby allowing the citric and maleic acids to penetrate into tooth surface to remove the surface stains.
41006655|NCT05875038|OTHER|video system|The video surveillance system will analyze the position of subjects in real time using algorithms based on artificial intelligence. The system works continuously without video capture and sends an alert with a photo if a person is lying down after a fall. The alert is confirmed after an operator has checked the photo capture on a dedicated platform.
41006656|NCT05875038|OTHER|Tele-alarm|Tele-alarm
41006657|NCT03618797|DRUG|HL-PIF cap.160/2mg + Placebo|Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
41476646|NCT00725621|BIOLOGICAL|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
41476647|NCT02373995|BIOLOGICAL|LAB4|Additional treatment with the specific LAB4 probiotic preparation
40803169|NCT05627232|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
40803170|NCT05627232|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
40803171|NCT05627232|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40803172|NCT05627232|DRUG|Palbociclib|Given PO
40803173|NCT04410848|OTHER|To determine the diagnostic of Choledocholithiasis with symbolic regression model|To determine the diagnostic of Choledocholithiasis with symbolic regression model
40803174|NCT04333888|BEHAVIORAL|Neurofeedback|fMRI neurofeedback training of amygdala downregulation
41006658|NCT03618797|DRUG|Livalo tab. 2mg + Placebo|Pitavastatin ca 2mg
41006659|NCT01015846|OTHER|Exercise|Redcord (sling exercise) and traditional exercise
41476648|NCT02199015|DEVICE|Lateral spinal cord surgical implant of electrodes|"The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.~A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG)."
41476649|NCT00466804|PROCEDURE|Heart transplant|People in this study will have a heart transplant and be monitored for signs of rejection
41476650|NCT01167517|OTHER|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge
41476651|NCT05732272|DRUG|Bupropion|150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
41476652|NCT03829358|DRUG|Lactobacillus plantarum IS-10506|Fermented milk containing probiotic Lactobacillus plantarum IS-10506 to be consumed once daily for three weeks.
41476653|NCT03829358|DRUG|Placebo|Fermented milk containing placebo to be consumed once daily for three weeks.
40803175|NCT06493786|OTHER|Collection of body odor samples|"Skin odor is collected using polymer sticks, placed in contact with the skin for approximately 1 hour.~In this study, odor collection will be carried out on the thigh, forearm, armpit, neck and, if applicable, on the cancerous lesion."
40803176|NCT02765815|DRUG|Liposomal bupivacaine, 266mg|
40803177|NCT02765815|DRUG|Bupivacaine 0.5 % with Epinephrine|
41006660|NCT01015846|OTHER|Core stability exercise|Traditional core stability exercise
40803178|NCT02765815|DRUG|Ketorolac 30mg|
40803179|NCT02765815|DRUG|Morphine 10mg|
41006661|NCT03395431|OTHER|Fingerprick autologuos blood (FAB)|Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
40803180|NCT02765815|DRUG|Bupivacaine 0.25% with Epinephrine|
40803181|NCT02463708|BEHAVIORAL|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
40803182|NCT05880849|DRUG|Choline|Eight 275mg capsules taken orally twice daily (4 capsules with breakfast \& 4 capsules with dinner) x 180 days
40803183|NCT04641728|DRUG|Pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
40803184|NCT04641728|DRUG|Olaparib|olaparib 300 mg twice daily (BID)
40803185|NCT06125184|DRUG|Vasopressor test|Mean arterial pressure will be increased from 65 mmHg to 85 mmHg to improve organ perfusion pressure.
40803186|NCT03777254|BIOLOGICAL|RC28-E|RC28-E intravitreous injection 50ul
40803187|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
40803188|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
41320770|NCT03019224|PROCEDURE|Evaluation of the tooth color|"The evaluation of the tooth color was performed by using a spectrophotometer (Easyshade, Vident, Brea, CA, USA). The color was analysed with the tooth hydrated before of the start the first whitening session and one week after.~The spectrophotometer was always used in the same position by a silicon guide, which was prepared with dental arch molds by adding high viscosity vinyl polysiloxane material (Express XT, 3M ESPE, Sumaré, SP, Brazil). After polymerization, an opening was made in the mold corresponding to the buccal surface of the upper central incisors, allowing the color of the tooth to be evaluated with the tip of the spectrophotometer at the height of the middle third."
40803189|NCT06096090|DRUG|Interleukin-2|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
40803190|NCT06096090|DRUG|Placebo|Placebo administration
40803191|NCT00559455|DRUG|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
41320771|NCT03019224|PROCEDURE|Relative isolation|The clinical procedures were performed under relative isolation using lip retractor (Arcflex, FGM, Joinville, SC, Brazil) and dental cotton rollers to apply a gingival protection barrier (Top Dam, FGM, Joinville, SC, Brazil) extending from right first molar to left first molar in both arches.
41320772|NCT03019224|PROCEDURE|Gingival protection barrier|The gingival protection barrier was placed over the margins and gingival papilla corresponding to the areas receiving the whitening gel with approximately 3 mm in height and photopolymerized for 20 seconds in each group of three tooth. Photo-activation was performed with high power LEDs (light intensity = 600mw / cm²) (RadiiCal, São Paulo, SP, Brazil).
40803192|NCT00559455|DRUG|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
40803193|NCT00559455|DRUG|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
40803194|NCT04905524|DIETARY_SUPPLEMENT|VIOME Precision Nutrition Program|Diet and supplements recommendations
40803195|NCT04453358|DEVICE|InCourage-Connect|This intervention will provide patients with clearly stated treatment goals and provide them with interactive feedback based on usage date to help support airway clearance therapy adherence.
41320773|NCT03019224|PROCEDURE|Application of desensitizing gel|The desensitizing gel containing 5% potassium nitrate associated with 2% sodium fluoride (Desensibilize KF 2%, FGM, Joinville, SC, Brazil) was applied with a microbrush (Brush KG, KG Sorensen, Cotia, SP) on the buccal surface from right first molar to left first molar in both arches and remaining for 10 minutes. Then, the desensitizer was then removed with water jet and disposable plastic suction cannula.
41320774|NCT03019224|DRUG|Hydrogen peroxide|The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen peroxide for 1 drop of thickener, with this mixture being sufficient for application to at least three tooth. The gel remained in contact with the buccal surface of the tooth for 15 minutes and was removed with disposable plastic suction cannula and water wash. This procedure was performed three times per clinical session. The volunteers underwent three whitening clinical sessions with one week interval between them.
40803196|NCT04453358|DEVICE|InCourage|This intervention will provide standard of care airway clearance therapy with no interactive feedback on treatment goals and usage.
40803197|NCT04129268|OTHER|Cycle ergometry exercise at 60% VO2max|Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
40803198|NCT04482972|PROCEDURE|DCB|Angioplasty with DCB is an angioplasty technique which allows drug delivery to the coronary artery without stent implantation.
40803199|NCT04482972|PROCEDURE|DES|Angioplasty with DES is an angioplasty technique which permits drug delivery to the coronary artery and permanent implantation of a stent.
40803200|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
40803201|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
40803202|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
40803203|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
40803204|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
40803205|NCT00479505|DRUG|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
40803206|NCT00479505|DRUG|Placebo|Placebo
40803207|NCT02096952|DRUG|Methylphenidate extended-release liquid formulation|
41006662|NCT03743948|GENETIC|Non invasive prenatal diagnosis|15 pregnant women and their spouses Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
41006663|NCT05254938|BEHAVIORAL|The Halland Obesity Municipal Effort for children|A comprehensive, intensive lifestyle intervention for the children with the greatest need of intensive treatment.
41006664|NCT05717595|DIETARY_SUPPLEMENT|fructose|oral ingestion of fructose vs dextrose
41476654|NCT01084382|DIETARY_SUPPLEMENT|Arthrospira platensis|"Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks."
41006665|NCT05023694|OTHER|Video recordings|"In the first phase it will proceed to completion of the registration system by collecting data revivals and video recordings.~In a second phase, the video is displayed and analysis of the resuscitation performance will take place. We will identify and make a registration of incidents. At this point the observational descriptive analysis will take place.~Third phase: to develop preventive measures necessary to limit the number of incidents or to contain or minimize adverse effects resulting thereof: restructure and adapt the protocol."
41006666|NCT05023694|OTHER|Video recordings after corrective measures in adverse events|"Fourth phase: Training department staff on improvements to optimize performance times protocol using simulation.~Fifth stage: final implementation of corrective measures of adverse events during the performance resuscitation.~Sixth stage: successive evaluations of impact of corrective measures. With this evaluation, it will be held another descriptive case series. With the secondary formulate hypothesis after analysis of the errors, the protocol is optimized and measured if errors are minimized: analytical observational prospective cohort study."
41006667|NCT00348205|DEVICE|Technolas 217z Zyoptix Laser|Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
41006668|NCT06078046|BEHAVIORAL|Mind-body interventions|Parallel randomized controlled trial
41320775|NCT03019224|PROCEDURE|Used a dentifrice|Among the clinical whitening sessions, each volunteer used an unidentified dentifrice corresponding to their experimental group, which was previously defined by means of a draw made by a dentist who did not participate in the study. Thus, the researcher (dentist) who provided the dentifrice and the volunteer were not aware of which experimental group belonged (i.e. double blind).
41320776|NCT02615795|DEVICE|Tele Monitoring, using Tunstall monitoring device|Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
41320777|NCT04010890|BEHAVIORAL|Culturally adapted CBT|Culturally adapted CBT for South Asian Canadians
41320778|NCT03726619|BEHAVIORAL|e-CHEC-uP|One time online-based education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
41320779|NCT03726619|BEHAVIORAL|CHEC-uP|One time face-to-face education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
41320780|NCT05890313|DIAGNOSTIC_TEST|Mini Mental State Examination|MMSE is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is of three to four years of schooling. It is validated in the general Portuguese population and can discriminate normal cognition from dementia.
41320781|NCT05890313|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|MoCA is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is, at least, of four years of schooling. It is validated in general Portuguese population and can discriminate MCI from dementia.
41320782|NCT05890313|DEVICE|Brain on Track (version BOT.0.0.0 03.03.2023)|Brain on Track is a class I web-based software medical device, accessible on most platforms, including desktops and laptops. It is designed to allow periodic self-administered cognitive tests to be performed, enabling a cognitive assessment and continuous monitoring of the cognitive state of the patient remotely. It is based on the classic tests of neuropsychological assessment and allows assessing the main areas of cognition through a test lasting approximately 22 minutes. The stimuli that integrate each subtest are randomized between sessions, which reduces the effect of learning and allows the accomplishment of serial assessments.The test is available in three versions, adapted to different levels of schooling: 1-4 years, 5-9 years and 10+ years. The performance in each test is compared with normative population data and performance over time. For each test performed, Brain on Track presents a cumulative risk score for the presence of cognitive impairment.
41320783|NCT02440295|PROCEDURE|Lower Extremity Amputation|
41476655|NCT01417819|OTHER|Mobile short message service|Mobile short message service reminder for appointments of parents of cataract children
41476656|NCT01084018|BEHAVIORAL|soulageTAVIE|VITaPaCS consists in a 30 minute-computer-tailored preoperative session, which is animated by a virtual nurse who guides the participant through a learning process about analgesic medication intake, pain communication, and cognitive restructuring. The information and the strategies provided are specifically tailored to the participants' profile, determined by a screening questionnaire, but also by their responses in real-time during the computer session. Two postoperative clinical reinforcements of ten minutes are also provided by the treating nurse based on the flags identified through the preoperative session.
40803208|NCT06517069|OTHER|TEAS|Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction
40803209|NCT06517069|DRUG|Oxycodone|Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
40803210|NCT00351793|DEVICE|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
40803211|NCT02680938|DRUG|oxytocin|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
40803212|NCT02680938|DRUG|saline|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
40803213|NCT04728360|DRUG|BAT2206|45 mg/0.5 mL
40803214|NCT04728360|DRUG|Stelara (EU-sourced)|45 mg/0.5 mL
40803215|NCT05695040|BEHAVIORAL|"dietary workshop proteins"|"The workshop will have 2 objectives:~* Information of the importance of protein after bariatric surgery and the different sources of protein in the diet.~* Manipulation of a tool in the form of a real size and shape stomach (before and after surgery) that patients will be able to fill and manipulate in order to visualize the quantities needed to achieve the sensation of satiety."
40803216|NCT03730233|PROCEDURE|Hiatal hernia repair by tension-free mesh closure|
40803217|NCT03730233|PROCEDURE|Hiatal hernia repair by simple suturing|
40803218|NCT05523830|OTHER|No Intervention|No intervention
40803219|NCT03184493|DRUG|Celebrex plus Metformin|This group patients will receive metformin and celebrex.
40803220|NCT03184493|DRUG|Celebrex|This group patients will receive celebrex.
40803221|NCT03184493|DRUG|Metformin|This group patients will receive metformin.
41006669|NCT05723367|PROCEDURE|lumbar ESPB group where ESPB is performed at L4 with local anesthetics 20ml|ultrasound guided fascial plane injection
40803222|NCT03852381|DEVICE|Spinal Cord Stimulation|Paresthesia-based SCS(PB-SCS), with stimulating frequencies between 30 to 80 Hz that confer a tingling sensation. Three different paresthesia-free SCS (PF-SCS) modes that use frequencies in the range of 400-10,000 Hz include Burst, High Frequency stimulation at 1.2 kHz and High Density stimulation at 400 Hz.
40803223|NCT06110936|DEVICE|Transcutaneous Spinal Direct Current Stimulation|Transcutaneous spinal direct current stimulation (ts-DCS), a neuromodulation technique, is one of the non-invasive brain stimulation techniques. ts-DCS occurs when a continuous and low-intensity electric current passes through electrodes with moist sponges placed on the spinal cord.
40803224|NCT04627090|OTHER|Data collection|Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
40803225|NCT01329276|DRUG|Symbicort® forte Turbohaler®|320 µg budesonide / 9 µg formoterol fumarate dihydrate
40803226|NCT02193737|PROCEDURE|Early oral fluid recovery.|
40803227|NCT02193737|PROCEDURE|Delayed oral fluid recovery.|
40803228|NCT03889340|DEVICE|IQool|Subjects will undergo hypothermia therapy with the IQool system
41320784|NCT02440295|DEVICE|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
41320785|NCT02440295|DRUG|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
41320786|NCT03302208|DRUG|Pregabalin|Pregabalin capsule 150 mg oral
40803229|NCT02798224|BEHAVIORAL|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
40803230|NCT02798224|BEHAVIORAL|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
41320787|NCT03302208|DRUG|Placebo|Placebo
41320788|NCT02633839|DRUG|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
41320789|NCT02633839|DRUG|Carbidopa|Administered orally according to the carbidopa dosing schedule.
41320790|NCT04929756|BEHAVIORAL|Visual Feedback|Gaze-contingent visual feedback
40803231|NCT01834950|OTHER|Blood test|
40803232|NCT04643587|BIOLOGICAL|CSL787|Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer
40803233|NCT04643587|DRUG|Placebo|Normal saline (0.9% NaCl)
41320791|NCT02535832|DRUG|Pioglitazone|Pioglitazone CT Scan DXA scan Needle muscle biopsy
40803234|NCT06552832|OTHER|CAVEAT|Brief manualized parent-child psychotherapy
40803235|NCT04818307|OTHER|Macquarie Injury Management group|Group A was treated by MIMG (soft tissue mobilization) with base line treatment (Hot pack for 10 mint, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with extended knee, therapist places both hands on the knee and gently apply soft tissue release. This procedure was applied for 2 to 3 minutes.
41006670|NCT01950546|DRUG|nanosilver fluoride|The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
41006671|NCT04209361|OTHER|Questionnaire|Data will be obtained through a printed questionnaire for assessment of knowledge, attitude and practice of dentists at military hospitals regarding child abuse and neglect. The collected data will be saved and tabulated on a computer and finally will be statistically analyzed.
41006672|NCT03242499|DRUG|Lovastatin|Lovastatin 80mg or placebo use for 48 weeks.
41006673|NCT03242499|DRUG|Placebo|placebo for 48 weeks
41006674|NCT00071812|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
41006675|NCT00071812|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
41320792|NCT02535832|DRUG|Placebo|Placebo CT Scan DXA scan Needle muscle biopsy
41320793|NCT02913742|PROCEDURE|monitoring by depth electrode|During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
41320794|NCT05847491|DIAGNOSTIC_TEST|IGRA/Tuberculin skin test|"All patients will receive:~* Clinical evaluation;~* Chest x-ray.~* IGRA (or tuberculin skin test if immunocompromised)~* Therapeutic proposal if eligible"
41320795|NCT05723315|DRUG|recombinant human B-type natriuretic peptide|The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide
41320796|NCT00225147|DRUG|Recombinant Human C1 Inhibitor|IV
41320797|NCT00225147|DRUG|placebo|saline solution
41320798|NCT01609179|DRUG|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
41320799|NCT04768699|DRUG|TQG203|TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
41320800|NCT04768699|DRUG|TQG203/NovoSeven®|In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
41320801|NCT04768699|DRUG|TQG203|TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
41006676|NCT00071812|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
41006677|NCT00071812|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
41006678|NCT05887622|DIETARY_SUPPLEMENT|Potassium chloride supplement|Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.
41006679|NCT05887622|DIETARY_SUPPLEMENT|Placebo|Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
40803236|NCT04818307|OTHER|Mulligan Mobilization with Movement|Group B was treated by Mulligan Mobilization with movement with base line treatment (Hot Pack for 10 mints, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with 30 degree knee flexion, therapist places right hand below the knee and left hand above the knee. Apply the lateral glide on the joint. This procedure was applied for 3 times.
41006680|NCT04380207|DRUG|QPX7728|antibiotic
41476657|NCT02466802|DRUG|Regorafenib|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
41476658|NCT02466802|DRUG|Sildenafil Citrate|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
41476659|NCT02784782|DEVICE|Orthesis|
41476660|NCT02784782|BEHAVIORAL|No orthesis|
41476661|NCT03179449|DIAGNOSTIC_TEST|Diagnostic (ferumoxytol-enhanced MRI)|Undergo ferumoxytol-enhanced MRI
41476662|NCT03179449|PROCEDURE|Surgery|Undergo surgical resection
41476663|NCT03179449|DRUG|Ferumoxytol|Given IV
41476664|NCT03179449|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
41476665|NCT04831086|DRUG|Steroid Drug|Steroids doses will be optimized in the intervention group according the risk based on predictive models
41476666|NCT04831086|DRUG|Tocolytic Agents|Tocolysis duration will be optimized in the intervention group according the risk based on predictive models
41476667|NCT02428582|DEVICE|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
41476668|NCT02428582|DEVICE|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
41476669|NCT00165230|DRUG|Thalidomide|
41476670|NCT00165230|DRUG|Temodar|
41476671|NCT04821388|DEVICE|Rontis DCB|"The Rontis DCB is intended for use as a percutaneous transluminal angioplasty (PTA) catheter to dilate stenotic or obstructive vascular lesions in the lower extremities for the purpose of improving limb perfusion and decreasing the incidence of restenosis.~In this study, it is intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries"
41476672|NCT06064734|DEVICE|LF-rTMS|H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval ≥2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses).
41476673|NCT00722631|DRUG|Pioglitazone|Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
41006681|NCT04380207|DRUG|Placebo|Placebo comparator
41320802|NCT04014270|DEVICE|Self-modulated functional electrical stimulation (SM-FES)|"The patient actively self-administers the electrical stimulation on the impaired limb by controlling the electrical stimulation device with the non-impaired hand. A device called the Intento PRO will be used to deliver the experimental treatment.~Duration: 90 min per day, 5 days per week, for 2 weeks."
41320803|NCT04014270|OTHER|Standard Care|"The patient performs intensive, goal-oriented, repetitive functional exercises.~Duration: 90 min per day, 5 days per week, for 2 weeks."
41476674|NCT00722631|DRUG|Glimepiride|Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
41476675|NCT05787002|DRUG|AZD0780|AZD0780 will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
41006682|NCT04380207|DRUG|QPX2014|antibiotic
41320804|NCT02438215|DRUG|IRX4204|IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
41320805|NCT02853981|DEVICE|Harmonic scalpel|a method for liver parenchymal transection
41320806|NCT02853981|DEVICE|Kelly clamp crush technique|a method for liver parenchymal transection
41320807|NCT01230736|DRUG|Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)|One drop in study eye(s) once daily for 8 weeks
41006683|NCT03650010|PROCEDURE|Total ankle replacement|total ankle prosthesis through a lateral or an anterior approach
41476676|NCT05787002|DRUG|Rosuvastatin|Rosuvastatin will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
41476677|NCT04877587|DRUG|Ascorbate|"A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~* 2 60 g/m2 IV Days (1,2,8,9,15,16)~* 1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~  * 1 30 g/m2 IV Days (1,2,8,9,15,16)"
41476678|NCT04877587|DRUG|Gemcitabine|Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
41476679|NCT01264159|DEVICE|Lung impedence-guided therapy|
41476680|NCT01264159|OTHER|Usual treatment of patients with developing acute heart failure|
41476681|NCT02037165|DRUG|Placebo to BI 1026706|Placebo tablet
41476682|NCT02037165|DRUG|Pregabalin|Pregabalin hard capsule
41006684|NCT01248026|OTHER|Buttermilk|"Consumption of the 2 experimental periods~1. buttermilk (45 g/d)~2. placebo (45 g/d,)"
41320808|NCT00110578|PROCEDURE|Adoptive transfer of HIV-specific CD8+ T cells|
41320809|NCT00110578|DRUG|Aldesleukin|
41320810|NCT00003476|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
41320811|NCT06322706|DRUG|ABSK021|ABSK021 oral
41320812|NCT06322706|DRUG|Omeprazole|Omeprazole oral
41320813|NCT02131012|DRUG|Intravitreal Celecoxib|1-4 mg intravitreal celecoxib
41320814|NCT05248555|DIAGNOSTIC_TEST|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
41476683|NCT02037165|DRUG|BI 1026706|BI 1026706 oral solution
41476684|NCT02037165|DRUG|Celecoxib|Celecoxib hard capsule
41476685|NCT01378741|DRUG|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
40803237|NCT03404063|DRUG|Cardiac Drug|"Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group."
40803238|NCT03404063|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
40803239|NCT03539744|DRUG|Pomalidomide|capsule, oral
40803240|NCT03539744|DRUG|Dexamethasone|oral, locally available form
41006685|NCT05029141|DRUG|CAHAG regimen|"Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
41006686|NCT05029141|DRUG|Placebo regimen|"Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
40803241|NCT03539744|DRUG|Venetoclax|tablet; oral
40803242|NCT03302884|OTHER|biological sampling|Tumor and blood samples
41320815|NCT04253834|DEVICE|Incentive spirometer|The incentive spirometer is a device that measures how deeply a person can inhale (breathe in). It helps with taking slow, deep breaths to expand and fill the lungs with air, which helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator to help users control their breathing.
41320816|NCT04253834|DEVICE|GO2 Mouthpiece|The GO2 Mouthpiece is a simple, comfortable, and straightforward silicone rubber-made, bidirectional oxygenation mouthpiece that effectively delivers PEEP with every breath.
41320817|NCT02531464|OTHER|Supportive care|Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
41006687|NCT03683381|BEHAVIORAL|Sleep Health|Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
41006688|NCT03683381|OTHER|Patient education|Participants in the Patient education group will receive weekly information on insomnia symptoms
40803243|NCT02371785|DEVICE|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
40803244|NCT03575663|DIAGNOSTIC_TEST|Indirect bronchial challenge|Mannitol dry powder inhalation
40803245|NCT03575663|OTHER|Sham bronchial challenge|Mock dry powder inhalation
40803246|NCT01390298|OTHER|Observational|Observational study only
40803247|NCT00069875|DRUG|Gemcitabine|
40803248|NCT00069875|DRUG|LY293111|
40803249|NCT00069875|DRUG|cisplatin|
40803250|NCT00310336|DRUG|S-adenosyl-L-methionine|
40803251|NCT00310336|DRUG|betaine|
41006689|NCT02866838|DRUG|Tranexamic acid|intravenous
41006690|NCT02866838|DRUG|Saline 0.9%|intravenous
41320818|NCT04762407|DRUG|HGP1910|Take it once per period.
41320819|NCT04762407|DRUG|HGP1909|Take it once per period.
41320820|NCT04762407|DRUG|HCP1903|Take it once per period.
40803252|NCT00310336|DRUG|pegylated interferon alpha2b|
40803253|NCT00310336|DRUG|ribavirin|
40803254|NCT00723151|BEHAVIORAL|Milieu Communication Teaching|Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
40803255|NCT05313269|OTHER|ISAFE technique for adductor canal catheter insertion|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
40803256|NCT05313269|OTHER|Conventional technique for adductor canal catheter insertion|Adductor canal block catheter tip located lateral to the femoral artery.
40803257|NCT00475085|DRUG|aprepitant|Given orally or IV
40803258|NCT00475085|DRUG|dexamethasone|Given orally or IV
41320821|NCT01970930|PROCEDURE|Blood specimen|4 green top tube 40 cc of blood draw
41320822|NCT00422708|PROCEDURE|Local anesthesia|
41320823|NCT00800865|OTHER|Biomarker sample collection before and after dosing with cytotoxic agent(s)|Participants will have blood and urine samples collected at Visit 1. After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at baseline, and at 24 and 48 hours post dosing with cytotoxic agent(s).
41320824|NCT00800865|OTHER|Biomarker sample collection before and after dosing with cytotoxic agent(s)|A second group of participants will have blood and urine samples collected at Visit 1 (there is no baseline). After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at at 24, 32 and 48 hours post dosing with cytotoxic agent(s).
41320825|NCT04209894|DIAGNOSTIC_TEST|Ultrasound|Evaluation consisted of the detection of grey scale (GS) enthesitis and Power Doppler signal in enthesis areas of participants. The Madrid Sonography Enthesitis Index (MASEI) scoring system was used to quantify the extent of sonographic entheseal abnormalities
41320826|NCT03264794|DRUG|Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial|Gefitinib Tab （CTTQ），First medication,250mg；
41320827|NCT03264794|DRUG|Gefitinib tablets (Yi Ruisha），First medication|Gefitinib tablets (Yi Ruisha），First medication,250mg；
41320828|NCT03264794|DRUG|Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.|From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
41320829|NCT05566821|BEHAVIORAL|STRENGTH Outreach Intervention|The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
41320830|NCT04633057|DRUG|TJ101|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.
41320831|NCT04633057|DRUG|NordiFlex|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
41476686|NCT01378741|DRUG|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
40803259|NCT00475085|DRUG|granisetron hydrochloride|Given orally or IV
40803260|NCT00475085|DRUG|palonosetron hydrochloride|Given orally or IV
40803261|NCT00475085|DRUG|prochlorperazine|Given orally or IV
41006691|NCT03159728|BEHAVIORAL|Educative intervention:|"* In the induction of the new group members are present, including caregivers who start the program and those who coordinated.~* In Module I: to strengthen the knowledge of the situation and the people involved in care.~* In Module II: to strengthen the value in the caregiver through decision making, skill and social support to back it up.~* In Module III: or end, after analyzing that uneasy caregiver, patience is reviewed through the meaning of family care and self."
40803262|NCT00475085|DRUG|placebo|Given orally
40803263|NCT03703232|DEVICE|Investigational prosthetic foot|Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
40803264|NCT04060888|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
40803265|NCT04060888|DRUG|Ustekinumab 90 milligram (mg)|Participants will receive 90 mg ustekinumab via SC route.
40803266|NCT04060888|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
40803267|NCT04620772|DRUG|Cyclophosphamide injection|Cyclophosphamide vs placebo
41006692|NCT03460522|DRUG|Inotuzumab ozogamicin|Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.
41006693|NCT02227524|OTHER|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
41320832|NCT00625898|DRUG|Docetaxel|"75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B"
41320833|NCT00625898|DRUG|Trastuzumab|"First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B"
41320834|NCT00625898|DRUG|Carboplatin|6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
41006694|NCT02227524|DEVICE|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
41006695|NCT02227524|DEVICE|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
41006696|NCT02227524|DEVICE|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
41006697|NCT02573610|DRUG|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
40803268|NCT05558358|DEVICE|Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation|6 months of active stimulation -- \> 6 months of sham stimulation
40803269|NCT05558358|DEVICE|Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation|6 months of sham stimulation -- \> 6 months of active stimulation
40803270|NCT02289196|DRUG|Vx-006: 0,5mg|
40803271|NCT02289196|DRUG|Vx-006: 1mg|
40803272|NCT02289196|DRUG|Vx-006: 5mg|
40803273|NCT02289196|DRUG|Vx-006: 10mg|
40803274|NCT03018197|OTHER|Medication Education|Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
40803275|NCT02675751|DEVICE|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
41006698|NCT02573610|DRUG|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
41006699|NCT01860261|BEHAVIORAL|Aerobic and Strength Training Intervention|The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
40803276|NCT03143153|BIOLOGICAL|Nivolumab|Specified dose on specified days
41006700|NCT03778970|OTHER|Pain Neuroscience Education|Pain neuroscience education (2 sessions during 40 minutes) administered by an interactive workshop
41006701|NCT03778970|OTHER|Self-Management Education|A self-management education (2 sessions during 40 minutes) administered by an interactive workshop
41006702|NCT03778970|OTHER|Movement Control Exercises|Eight sessions of movement control exercises (30 minutes each) + advice to perform the exercises at home twice a week.
41006703|NCT05047965|PROCEDURE|Dixon MRI|Undergo Dixon MRI
41006704|NCT05047965|PROCEDURE|Magnetic Resonance Imaging|Undergo standard MRI
40803277|NCT03143153|BIOLOGICAL|Ipilimumab|Specified dose on specified days
40803278|NCT03143153|DRUG|Cisplatin|Specified dose on specified days
40803279|NCT03143153|DRUG|Fluorouracil|Specified dose on specified days
40803280|NCT04653922|DEVICE|LinkCor Bioengineered Corneal Implant|Intrastromal implantation of a bioengineered corneal equivalent device
40803281|NCT02216968|BEHAVIORAL|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
40803282|NCT00434980|BEHAVIORAL|Family-Directed Cognitive Adaptation Program|
40803283|NCT02250794|DRUG|metformin and sitagliptin|metformin 750 mg PO twice daily
41006705|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
41006706|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
41006707|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
41006708|NCT06380478|DEVICE|aspicio Monofocal IOL|A bi-aspheric monofocal IOL is implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
41006709|NCT00017758|DRUG|Pravastatin sodium|
41006710|NCT00017758|DRUG|Simvastatin|
41006711|NCT00017758|DRUG|Atorvastatin calcium|
41476687|NCT05618535|DEVICE|Transcranial Doppler.|"Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler."
40803284|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin glargine given once daily
40803285|NCT02250794|DRUG|metformin and sitagliptin|sitagliptin 100 mg PO once daily
40803286|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
41006712|NCT00017758|DRUG|Nelfinavir mesylate|
41006713|NCT00017758|DRUG|Efavirenz|
40803287|NCT06553300|PROCEDURE|Autotransplantation with PRF|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth with the application of PRF
40803288|NCT06553300|PROCEDURE|Autotransplatation Only|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth.
40803289|NCT00050206|DRUG|Olanzapine|
40803290|NCT00050206|DRUG|Placebo|
40803291|NCT05618340|DEVICE|Pulsed electric field ablation device;Cardiac Pulsed Electric Field Ablation Catheter|"Routinely placing a coronary sinus electrode catheter, puncturing the interatrial septum, placing one sheath into the left atrium, confirming that the catheter is well in place, and setting the treatment time of the pulse ablation system in advance.~Pulmonary vein-by-pulmonary vein ablation using a circular pulse catheter, waiting for the end of the pulse ablation phase and immediate effect confirmation."
41320835|NCT00625898|DRUG|Bevacizumab|"15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B"
40803292|NCT01454128|BEHAVIORAL|exercise|36 session supervised exercise intervention
40803293|NCT03070639|BEHAVIORAL|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
40803294|NCT03070639|BEHAVIORAL|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
40803295|NCT01332591|PROCEDURE|Percutaneous coronary intervention|"PCI of significant stenoses of non-infarct coronary arteries"
40803296|NCT02482428|DRUG|Investigational Treatment|Applied twice daily for up to 12 weeks
40803297|NCT02482428|DRUG|Aldara|Applied 3 times a week for 16 weeks
40803298|NCT02374281|DRUG|Glucose sucking|
41320836|NCT00625898|DRUG|5-Fluorouracil|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
41320837|NCT00625898|DRUG|Epirubicin|90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
41320838|NCT00625898|DRUG|Cyclophosphamide|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
41320839|NCT01372371|BIOLOGICAL|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
41320840|NCT01372371|BIOLOGICAL|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
41320841|NCT01372371|BIOLOGICAL|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
41476688|NCT06312423|DRUG|Oligonucleotides, Phosphorothioate|Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days
40803299|NCT02374281|DRUG|Water sucking|
40803300|NCT02374281|OTHER|No sucking|
40803301|NCT04142424|DRUG|AZD2693|Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
40803302|NCT04142424|DRUG|Placebo|Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
40803303|NCT03724058|DEVICE|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty
40803304|NCT03724058|DEVICE|Trident® Hemispherical Acetabular Shell|Hip arthroplasty
40803305|NCT02771574|DRUG|Lyo avexitide|Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
41476689|NCT04681625|BEHAVIORAL|Pelvic floor muscle training (PFMT) with suppressive urgency technique|"Pelvic floor muscle training with suppressive urgency technique:~1. Education about proper urination training in the period without pathological urgency.~2. Education about conscious urgency suppression through PFMT - suppressive urgency technique.~3. Education on the principle and effect of PFMT.~4. Exercises of varying intensity of pelvic floor muscles in different positions.~5. Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day."
40803306|NCT02771574|DRUG|Liq avexitide|Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
40803307|NCT00140907|DRUG|losartan potassium|25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
40803308|NCT00140907|DRUG|Comparator: Placebo|25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
40803309|NCT06427096|BEHAVIORAL|Multifaceted intervention|"The multifaceted interventions is comprised of the following components:~1. To establish a BP management team led by healthy family instructor. The team members also include family leaders and village doctors.~2. To conduct multifaceted intervention, which includes low-sodium diet, weight management, physical exercise, BP monitoring and antihypertensive treatment."
40803310|NCT00289172|BIOLOGICAL|Live attenuated human rotavirus vaccine|
40803311|NCT04774588|OTHER|VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.|1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
40803312|NCT01575639|DRUG|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
41006714|NCT04450251|OTHER|Data Collection|Collect observational fetal electrocardiogram (ECG) readings with a novel wearable device.
41320842|NCT03247413|DRUG|Dexamethasone 4 mg/ml|dexamethasone 4 milligram given post-ablation at each lesion site
41320843|NCT03247413|DRUG|Normal saline|Placebo, normal saline administered post-ablation at each lesion site
41320844|NCT00262977|BEHAVIORAL|Electronic prompt plus patient-directed intervention|
41320845|NCT00262977|BEHAVIORAL|Electronic prompt to clinician to prescribe aspirin|
41320846|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
40803313|NCT03839225|OTHER|Community intervention|"Community intervention will be built depending on contextual factors and will contain the following elements:~* Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~* The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~* Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions."
40803314|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
40803315|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
40803316|NCT02812264|BEHAVIORAL|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
40803317|NCT02812264|BEHAVIORAL|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
40803318|NCT02812264|BEHAVIORAL|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
40803319|NCT02812264|BEHAVIORAL|scale|Connected scale that will transfer weight information to app
40803320|NCT06151639|PROCEDURE|general anesthesia|General anesthesia was performed by muscle relaxant(rocuronium 0,6 mg/kg), opioids(phentanyl 1-2 mcg/kg) and propofol 2mg/kg. Inhation anesthetics and remiphentanyl infusion were used for maintance general anesthesia.
40803321|NCT06151639|PROCEDURE|peripheral nerve blocks|With the help of ultrasonography, at the 2nd rib level, between the fasciae of the pectoralis major and minor muscles at the mid-clavicle level (PECS I block, interpectoral fascial plane block) and at the 4th rib level, at the mid-axillary level, between the fasciae of the pectoralis minor and serratus muscles (PECS II block, pectoroseratal fascial plane block) local anesthesia was applied. In patients who underwent PECS block, a high-frequency linear ultrasonography (Esaote, My LabFive-Genova, Italy) probe and a 50 mm tip insulated needle (echoplex+, Vygon Ecouen-France) were used. 0.200% bupivacaine 15 ml was applied for the PECS I block, and 0.200% bupivacaine 20 ml was applied for the PECS II block, and fascial separation was observed. Sensory control was performed in the breast and axilla area and the patients were taken into surgery.
40803322|NCT05523609|DRUG|Letrozole 2.5mg|20 patients will receive Letrozole only for 12 weeks
40803323|NCT05523609|DRUG|Letrozole + vitamin D3 and calcium|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.
40803324|NCT03292640|DRUG|DFD-03 (0.1% tazarotene) Lotion|DFD-03 Lotion (0.1% tazarotene) - twice daily application
40803325|NCT03292640|DRUG|DFD-03 (0% tazarotene) Lotion (Placebo)|DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application
40803326|NCT02677207|DRUG|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
40803327|NCT02677207|DRUG|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
41320847|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.
41320848|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 45 μg|120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.
41320849|NCT01336166|BIOLOGICAL|Placebo control|120 adults were assigned to receive 1 dose of placebo.
41320850|NCT02107430|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
41320851|NCT02107430|RADIATION|Standard radiotherapy|radiotherapy
41320852|NCT02800486|DRUG|Intra-arterial Cetuximab|
40803328|NCT01816191|DRUG|Diltiazem Hydrochloride Cream and Oral Diltiazem|
41320853|NCT02800486|DRUG|Intra-arterial Mannitol|
41320854|NCT02800486|RADIATION|Hypofractionated re-irradiation|
41320855|NCT04705441|BEHAVIORAL|SMART 2|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions (up to 10 participants per group), which will be collaboratively delivered over Zoom by a Nurse Educator and a Peer Educator with epilepsy. Telephone call-in and supplemental printed materials will be available for those who do not have internet access. The initial group session portion of SMART will be completed over 10-12 weeks. Educational components address the challenges imposed by epilepsy and comorbidity, as well as problem-identification and goal-setting, while Peer Educators and the group format address adherence, social support/social isolation, and self-efficacy. Following group sessions, participants will have 3 brief (no more than 15 minutes) monthly web-based or telephone maintenance sessions conducted by the Nurse Educator. Telephone sessions will address on-going issues of epilepsy self-management, including treatment adherence.
41320856|NCT02992158|BEHAVIORAL|behavioral activation|
41320857|NCT02992158|BEHAVIORAL|treatment-as-usual|psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
41476690|NCT03980210|PROCEDURE|Hyperbaric oxygen therapy|"1. FiO2 0.21 - 1 ATA~2. FiO2 1 - 1 ATA~3. FiO2 1 - 2.5 ATA~4. FiO2 0.21 - 2.5 ATA~5. FiO2 0.21 - 1 ATA"
40803329|NCT01781806|DRUG|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to \<50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl \<30 mL/min, Truvada will be discontinued.
41006715|NCT04749290|OTHER|Study Formula|Study infant formula for term infants containing OPO and CPP
41006716|NCT00391352|DRUG|IFN-β-1a (Rebif®)|44 mcg Three times a week, subcutaneous injection
41476691|NCT03153826|OTHER|Comparison of clinical and biological characteristics of patients|Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
41476692|NCT03532230|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|No specific OMT techniques will be required for the present study. However, data on the number of OMT sessions patients receive will be collected.
41320858|NCT06240299|PROCEDURE|Neurofeedback|A noninvasive method based on the voluntary modulation of brain activity, with feedback provided through a graphical user interface shown on a computer screen
41320859|NCT04072172|DEVICE|Mole Freckle Pen|Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
41320860|NCT01106742|DIETARY_SUPPLEMENT|AndoSan|AndoSan, 20mlx3, 12 days
41320861|NCT05457348|PROCEDURE|Planned incisions during phacoemulsification|Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
41476693|NCT01792414|DEVICE|Sham TES|Neuroconn Eldith device
41476694|NCT01792414|DEVICE|Active TES|Neuroconn Eldith device
41476695|NCT03239236|PROCEDURE|Rapid sequence induction t-RSI|Preoxygenation via face mask, no ventilation with no PEEP until intubation
41476696|NCT03239236|PROCEDURE|Rapid sequence induction m-RSI-PEEP|Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
41476697|NCT03239236|PROCEDURE|Rapid sequence induction m-RSI-vent|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
41320862|NCT02505542|BIOLOGICAL|Certolizumab Pegol|"* Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"
41320863|NCT02505542|OTHER|Placebo|"* Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"
41320864|NCT02935686|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV at a dose of 5\*10\^10 viral particles (vp), administered intramuscularly.
41320865|NCT02935686|BIOLOGICAL|Clade C gp140 plus adjuvant|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.
41320866|NCT02935686|BIOLOGICAL|Clade C gp140/Mosaic gp140 plus adjuvant|Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.
41320867|NCT02935686|OTHER|Placebo|Placebo Containing 0.9 percent normal saline, administered intramuscularly.
41320868|NCT02935686|BIOLOGICAL|gp140 HIV Bivalent Vaccine|gp140 HIV Bivalent Vaccine is adjuvanted protein co-formulation with a dosage strength of 80 mcg Clade C protein, 75 mcg Mosaic protein and 425 mcg aluminum (as aluminum phosphate adjuvant).
41320869|NCT00356057|DEVICE|Protos DR/CLS and Stratos LV CRT pacemakers|Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
41320870|NCT05603507|OTHER|inspiratory muscle training|training done with a pressure threshold-loading device
41476698|NCT03239236|PROCEDURE|m-RSI-vent-cric|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
41320871|NCT05603507|OTHER|pulmonary rehabilitation|Circuit training of aerobic and resistive exercise
41320872|NCT03038659|DEVICE|Penile Duplex|Measuring intima media thickness
41320873|NCT04508725|DIAGNOSTIC_TEST|Doppler Ultrasound|Power doppler measurements will be made
41320874|NCT04508725|DEVICE|SIEMENS S3000 and Verasonics Vantage 256|Vantage 256 used for power doppler ultrasound, manufactured by Verasonics
41320875|NCT04508725|DRUG|Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor plus immune checkpoint inhibitor|Participants will receive less than 4 weeks of TKI treatment during the first 12 weeks. Plus immune checkpoint inhibitor (arm 1) or non-immune checkpoint inhibitor (arm 2)
41320876|NCT02071264|BEHAVIORAL|HIV/STI intervention|The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
41320877|NCT02702518|DRUG|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
41320878|NCT02702518|DRUG|Vehicle|Drug vehicle 4 times a day for 8 weeks
41476699|NCT03239236|PROCEDURE|Cricoid Pressure|Cricoid Pressure will be applied during RSI until laryngoscopy
41476700|NCT03239236|DRUG|Anesthetics|Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
41476701|NCT03239236|DIAGNOSTIC_TEST|Aspiration of gastric air via nasogastric tube|A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
41476702|NCT03239236|DIAGNOSTIC_TEST|Impression of gastric inflation at laparoscopy.|The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.
41320879|NCT04130828|DRUG|Ferrous Fumarate|Ferrous fumarate 200 mg PO PC
41320880|NCT01824173|OTHER|Increase in the levels of plasma amino acids|Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
41320881|NCT01824173|OTHER|Aerobic exercise|Moderate intensity for 45 minutes
41320882|NCT05572827|BEHAVIORAL|Breathing exercises|Breathing exercises for COVID-19 patients after intensive care increase their quality of life.
41320883|NCT01398072|DRUG|Moxifloxacin|An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
41476703|NCT03239236|DIAGNOSTIC_TEST|Arterial blood gas|Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.
41320884|NCT01398072|DRUG|Azithromycin|An oral dose of 250 mg once daily three times a week (every other day).
41320885|NCT01398072|DRUG|Doxycycline|An oral dose of 100 mg once daily.
41476704|NCT01797926|DRUG|Reference Treatment: 5 mg amlodipine + 50 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
40803330|NCT02644213|OTHER|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):~* simulated road march using a virtual reality environment without additional load~* simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~* without physical or cognitive load (without march, waiting between performance evaluations) as control."
40803331|NCT04027283|DIETARY_SUPPLEMENT|Erythritol|50g erythritol dissolved in 300mL tap water
40803332|NCT04027283|DIETARY_SUPPLEMENT|Erythritol + lactisole|50g erythritol + lactisole (450ppm) dissolved in 300mL tap water
40803333|NCT04027283|DIETARY_SUPPLEMENT|D-allulose|25g D-allulose dissolved in 300mL tap water
40803334|NCT04027283|DIETARY_SUPPLEMENT|D-allulose + lactisole|25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water
40803335|NCT04027283|DIETARY_SUPPLEMENT|Tap water|300mL tap water
40803336|NCT04027283|DIETARY_SUPPLEMENT|Tap water + lactisole|300mL tap water + lactisole (450ppm)
40803337|NCT05563311|OTHER|Exercise on High-intensity interval training|3 times a week, for 8 weeks
40803338|NCT05046873|DRUG|Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
40803339|NCT05046873|DRUG|semaglutide 1.34 mg/mL (placebo)|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
40803340|NCT05046873|DRUG|Semaglutide 1.34 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
40803341|NCT05046873|DRUG|NNC0480-0389 A 10 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
40803342|NCT01804933|DRUG|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
40803343|NCT05171400|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
40803344|NCT05171400|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
40803345|NCT05171400|DEVICE|Palatal Wound treated with Insulin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with insulin and 4.0 silk sutures.
40803346|NCT02483091|BEHAVIORAL|Multifaceted KT intervention|"The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.~After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.~The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months."
40803347|NCT05302869|OTHER|None intervention|None intervention
41006717|NCT02607488|DRUG|Placebo|"Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
41006718|NCT02607488|DRUG|Lidocaine 1%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
41006719|NCT02607488|DRUG|Lidocaine 1.5%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
41006720|NCT02607488|DRUG|Lidocaine 2%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
41320886|NCT01398072|DRUG|Placebo|Oral dose of one table once daily.
40803348|NCT02619591|OTHER|Ultrasound Imaging|views of a hemithorax was obtained using the Zonare Ultrasound machine.
40803349|NCT01038479|DIETARY_SUPPLEMENT|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
40803350|NCT01038479|BEHAVIORAL|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
40803351|NCT03780530|PROCEDURE|subcuticular suturing|Those undergoing Subcuticular suturing of perineal skin using 910 polyglactin vicryl No 2/0 (EGYCRYL®).
40803352|NCT03780530|PROCEDURE|Surgical glue|Those undergoing perineal skin closure using adhesive glue n-butyl-2-cyanoacrylate (Histoacryl®).
40803353|NCT03780530|PROCEDURE|adhesive steri-strip tape|Those undergoing closure of perineal skin via Adhesive surgical water-resistant tape application. (3M® Transpore™ Surgical Tapes).
41320887|NCT01690689|DEVICE|Implant surgery|surgery
40803354|NCT02993822|DRUG|Orvepitant Maleate|Tablet, once daily, oral
41006721|NCT04595487|PROCEDURE|Left ventricular septal pacing|"In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion."
41006722|NCT04595487|PROCEDURE|Right ventricular pacing|In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
41006723|NCT05539235|DRUG|different degrees of adjustment of the injection interval|"Treatment was an intravitreal injection of 0.5 mg conbercept using modified T\&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks."
41006724|NCT03101709|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
41320888|NCT03615911|BIOLOGICAL|vaccine candidate MVA-MERS-S|vaccination with MVA-MERS-S in two escalating dose regimes
41320889|NCT05109130|PROCEDURE|Surgical approach|Different surgical methods for rectal cancer resection
41320890|NCT02405806|DIETARY_SUPPLEMENT|low carbohydrate food|low carbohydrate food
41320891|NCT02405806|DIETARY_SUPPLEMENT|standard food|standard food
41320892|NCT00312299|DEVICE|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
41476705|NCT01797926|DRUG|Reference Treatment:5 mg amlodipine + 100 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
40803355|NCT02993822|DRUG|Placebo|Tablet, once daily, oral
40803356|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
40803357|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
40803358|NCT01153711|DRUG|Ketoconazole|400 mg tablet
40803359|NCT01153711|DRUG|Ketoconazole|400 mg tablet
40803360|NCT05915195|OTHER|Postural and Kinesthetic Awarness|Firstly, patient performed therapeutic activities/exercise to achieve balance in sitting position using chair with arm rest and with planted feet then progressed to sitting on chair without arm rest with proper feet placement. Once the patient achieved balance in sitting on chair then shifted to sitting on the stool and later standing in parallel bar that leads to balance training in independent standing.
40803361|NCT05915195|OTHER|Routine Physical Therapy|Range of motion exercises (Active assisted), stretching exercises, strengthening and positioning.
40803362|NCT05931471|OTHER|Yogurt Intervention|Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.
40803363|NCT05207644|DRUG|30 mg letrozole followed by 800 mcg misoprostol|30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
40803364|NCT04701606|DRUG|Artecom® (pyronaridine-artesunate)|"\* Participant body weight (Artecom® dose)~* ≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~* ≥ 45kg and \< 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)"
40803365|NCT04701606|DRUG|Placebo|"\* Participant body weight (Placebo dose)~* ≥ 65kg (Placebo 4 tablets)~* ≥ 45kg and \< 65kg (Placebo 3 tablets)"
40803366|NCT04155619|BEHAVIORAL|No change in meal timing|Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
40803367|NCT04155619|BEHAVIORAL|No change in light exposure|Participants will not change their light exposure habits.
40803368|NCT04155619|BEHAVIORAL|Early Time-Restricted Feeding|Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.
40803369|NCT04155619|BEHAVIORAL|Timed Light Therapy|Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
40803370|NCT00812396|DRUG|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
40803371|NCT00812396|DRUG|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
40803372|NCT00812396|DRUG|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
41320893|NCT00312299|DEVICE|Round edge PMMA IOL|Round edge PMMA IOL
41320894|NCT00312299|DEVICE|Acrysof IOL|Acrysof IOL
41476706|NCT01797926|DRUG|FDC 5/50 amlodipine/ losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
41476707|NCT01797926|DRUG|FDC 5/100 amlodipine /losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
40803373|NCT00969644|DRUG|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
40803374|NCT00969644|DRUG|Pegvisomant|s.c. injections once daily (10-15 mg/day)
40803375|NCT02739763|BIOLOGICAL|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
40803376|NCT01016717|DRUG|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
40803377|NCT01016717|DRUG|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
40803378|NCT03987139|OTHER|Hypertension|"Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes."
40803379|NCT03987139|OTHER|Hyper- and hypoxia|The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
40803380|NCT03987139|OTHER|Hyper- and hypocapnia|The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
40803381|NCT02973295|DRUG|Silymarin|Capsules contains 100 mg of silymarin
40803382|NCT02973295|OTHER|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
40803383|NCT03719092|DIETARY_SUPPLEMENT|Vitamin A Compound|Given PO or enterally
40803384|NCT01388049|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
40803385|NCT00191945|DRUG|Atomoxetine Hydrochloride|
40803386|NCT00191945|DRUG|placebo|
40803387|NCT00810277|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
40803388|NCT05860257|BEHAVIORAL|PeerLearning.net|PeerLearning.net provides an easy-to-use, scalable, and widely accessible means to support teachers in effectively designing and delivering high-fidelity Cooperative Learning (CL) lessons and, in turn, it has the potential to amplify the positive effects of CL found in previous research. Using PeerLearning.net, teachers design their lesson by selecting from among a set of typical CL lesson templates (e.g., jigsaw, peer tutoring, group projects) which they can customize and populate with their own curriculum and materials. These design templates represent the optimal, high-fidelity design that is required in order for CL to be successful. During lesson delivery, PeerLearning.net manages membership in learning groups, distributes instructional materials, directs student activities according to a pre-specified timetable, supports teacher observations of student behavior, and delivers post-lesson group activities and reviews.
41320895|NCT00312299|DEVICE|square Edge PMMA IOL|Square edge PMMA intra ocular lens
41320896|NCT00312299|DEVICE|Square Edge PMMA IOL|Square Edge PMMA IOL lens
41320897|NCT04172753|RADIATION|Radiotherapy on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
40803389|NCT04224714|COMBINATION_PRODUCT|FFR|FFR measurement: Pressure guid wire(radianalyzer Xpress 12711) is produced in Switzerland. After the pressure of the aorta and the pressure guide wire is balanced, Send the pressure guide wire to the distal part of the lesion(more than 20 mm away from the lesion) . Adenosine is injected into the vein,then,record the FFR index 3 times and take the average value as the final measurement index.
40803390|NCT03101488|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
40803391|NCT03656848|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
41320898|NCT04172753|DIAGNOSTIC_TEST|Imaging on the MR Linac|Only imaging performed on the MR Linac
41320899|NCT01216449|DRUG|Intravenous Citalopram|Single dose of 20mg parenteral citalopram diluted in 250mL of 0.9% sodium chloride solution, infused over 30 minutes
41320900|NCT01216449|DRUG|Normal Saline|Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
41320901|NCT00295217|DEVICE|ExAblate 2000|
41320902|NCT05684601|DEVICE|Third molar surgery|It was extracted one impacted mandibular third molar per patient with piezoelectric or rotating drills device
40803392|NCT03656848|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
40803393|NCT02250079|DEVICE|polyethylene plastic bag|Inborn neonates with both a gestational age \>29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
41320903|NCT02843581|DEVICE|Cryosurgery|Argon-helium cryosurgical system
41320904|NCT02843581|BIOLOGICAL|NK immunotherapy|Nutral killer cell immunotherapy for more than 6 times
41320905|NCT02118857|OTHER|Omnivore, vegetarian and vegan subjects.|Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
41006725|NCT03101709|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).
41320906|NCT06041295|BEHAVIORAL|on-the-job training of lung expansion therapy|on-the-job training of lung expansion therapy
41320907|NCT01911299|DIETARY_SUPPLEMENT|Choline|5.25 ml of liquid glycerophosphocholine (approximately 1240 mg GPC), equivalent to 625 mg of choline
41320908|NCT01911299|DIETARY_SUPPLEMENT|placebo supplementation consisting of vegetable glycerin (50% by volume) and deionized water|
41476708|NCT01673698|DEVICE|ReShape Duo balloon|
41476709|NCT01673698|OTHER|Diet counseling|
40803394|NCT02250079|DEVICE|Conventional treatment|Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
40803395|NCT00540657|DRUG|CCX282-B|250mg capsule, twice daily, 13 weeks
40803396|NCT00540657|DRUG|Placebo|Placebo capsule, twice daily, 13 weeks
40803397|NCT01143363|BEHAVIORAL|resting - control|
40803398|NCT01143363|BEHAVIORAL|Moderate intensity exercise|
41006726|NCT03101709|BIOLOGICAL|CART-19|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
41320909|NCT06289842|DEVICE|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
41320910|NCT04958421|DEVICE|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
41320911|NCT05269550|RADIATION|High Intermediate Risk Patients|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Six months of androgen deprivation therapy will commence with the start of radiotherapy (concurrent plus adjuvant)
41320912|NCT05269550|RADIATION|High Risk or Very High-Risk Patients|Patients will receive 35Gy/5 fractions to the whole prostate (25Gy to whole Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Pelvic lymph nodes will receive 25Gy/5 fractions synchronous with prostate treatment with a simultaneous boost to imaging involved nodes to a maximum of 35Gy/5 fractions. Eighteen months of androgen deprivation therapy will commence with the start of radiotherapy (concurrent plus adjuvant)
41320913|NCT03273517|PROCEDURE|Elective surgery|Elective surgery in children aged 0-15 years ASA I and II
41320914|NCT00960713|DRUG|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
41320915|NCT04493294|RADIATION|Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis|Low dose whole lung radiotherapy may decrease the cytokines storm related to the viral infection and may improve survival by decreasing the need for artificial ventilation
41320916|NCT00379262|DRUG|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
41320917|NCT00379262|DRUG|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
41320918|NCT00379262|DRUG|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
41320919|NCT00822484|BIOLOGICAL|ILV-095|
41320920|NCT00822484|OTHER|Placebo|
41320921|NCT04439370|DIAGNOSTIC_TEST|Microneurography to measure muscle sympathetic nerve activity (MSNA)|Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves
41320922|NCT04439370|DIAGNOSTIC_TEST|Baroreflex sensitivity testing|Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.
41320923|NCT04439370|DIAGNOSTIC_TEST|Sympathoexcitatory Maneuvers|Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed
41320924|NCT04439370|DIAGNOSTIC_TEST|Blood tests|Serum FSH, estrogen, progesterone, and testosterone will be measured
41320925|NCT03825263|DEVICE|Intermittent Pressure Compression|The intervention group use the IPC device for 6 months. Clinic assessment were completed at the beginning and at 3 and 6 months. Participants in the intervention group were invited to use the IPC device twice a day every day during this period.
41320926|NCT04914117|DRUG|RC118 for injection|RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
41320927|NCT03685487|PROCEDURE|decolonization|current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all
41320928|NCT03685487|OTHER|compliance questionnaire|We asked if the patient has done the whole decolonization procedure
41320929|NCT00043212|DRUG|Dendritic cell immunotherapy|
40803399|NCT01143363|BEHAVIORAL|High intensity intermittent training|
40803400|NCT01143363|BEHAVIORAL|Short sprint|
40803401|NCT03832322|PROCEDURE|Water exchange colonoscopy|During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.
41320930|NCT05239377|OTHER|IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator|Digital decision support
41320931|NCT03371732|BEHAVIORAL|Motivational Intervention group|Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
41476710|NCT01673698|OTHER|Exercise counseling|
40803402|NCT03832322|PROCEDURE|CO2 insufflation colonoscopy|During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
41320932|NCT03371732|BEHAVIORAL|Educational advises group|Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
41320933|NCT01555905|DEVICE|Threshold PEP or IMT device Phillips-Respironics|The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
41320934|NCT04212052|RADIATION|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). The dose of 30Gy with a fraction dose of 5Gy was delivered to PTV-GTV as the hypo-RT course. Patients were eligible to receive the hypo-boost when there was no disease progression and no persistent ≥G2 treatment-related toxicities. For patients with persistent ≥G2 toxicities, a re-evaluation was planned every 2 weeks to determine whether they were qualified to receive the hypoboost. All eligible patients underwent a repeat 4DCT simulation scan to reformulate the adaptive radiation therapy plan. The adaptive plan of the hypo-boost was delivered to the residual tumor (PTV-GTV-residual) at a dose of 30Gy in 6 fractions (5 Gy per fraction).
41320935|NCT04212052|DRUG|concurrent chemotherapy|Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy. Intended chemotherapy included 4 cycles throughout the course of treatment.
41320936|NCT04212052|DRUG|consolidation immunotherapy|Patients without disease progression or persistent grade2+ toxicities after thoracic radiotherapy were recommended to receive consolidation immunotherapy
41320937|NCT03475576|OTHER|Keuzewijzer|"The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian. The most important value of this intervention is the approachability and the structured, but adjusted manner of support, focused on the individual context of care with their specific needs.~The 'Keuzewijzer' is an online tool whereby, in conversation with the informal care group and older civilian, the following aspects will be discussed in the context of the care for the older civilian: 1) analyzing the problem, 2) detection of possibilities or alternatives, 3) clarifying of motives and feelings and 4) weighting between values."
41320938|NCT05708768|OTHER|Receiving physician manned rapid response car services|All patients receiving services from the physician manned rapid response car will be included
41320939|NCT04580212|BEHAVIORAL|Poultry hygiene intervention|The intervention will consist of a series of participatory training exercises designed to accomplish three main goals: (1) increase awareness of health risks and lost livelihood benefits of current poultry management practices, (2) build practical skills for poultry management, and (3) build supportive community norms by facilitating savings group discussions on poultry management. The intervention will be delivered through three activities: (1) triggering exercise designed to raise awareness of both the health risks of the current practices and the economic potential of a more active poultry management approach, and ultimately to motivate participants for behavior change, (2) poultry management training activity based on local needs and norms, and (3) periodic follow-on coaching to reinforce messages from the initial training and emphasize action planning, monitoring of plan execution, and troubleshooting.
41320940|NCT01074658|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
41320941|NCT05362331|OTHER|Web Application|Internet based application
41320942|NCT05486936|RADIATION|hypofractionated radiation|Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists.
41320943|NCT03700970|DRUG|Liposomal bupivacaine|20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
41320944|NCT03700970|DRUG|Regular bupivacaine|20mL of 0.25% bupivacaine injected on each side.
41320945|NCT01199055|DRUG|CS-7017|Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks)
41320946|NCT01199055|DRUG|Carboplatin|Drug: Carboplatin IV, AUC of 6 mg/mL\*min, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
41320947|NCT01199055|DRUG|Paclitaxel|Drug: Paclitaxel IV, 200mg/m\^2, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
41320948|NCT01064076|DEVICE|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
41320949|NCT00795964|OTHER|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
41320950|NCT00795964|OTHER|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
41320951|NCT02923752|DEVICE|MRI|Contrast-enhanced MRI
41320952|NCT02022072|DEVICE|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
41320953|NCT02830035|PROCEDURE|Real-time Ultrasound-guided|Real-time ultrasound guided paramedian spinal anesthesia
41320954|NCT02830035|PROCEDURE|Anatomical Landmark Technique|Conventional anatomical landmark technique for paramedian spinal anesthesia
41320955|NCT03780036|DEVICE|Megaprosthetic Implants the Next Generation (MING)|Use of either porous of porous+hydroxyapathite collars.
41320956|NCT01713855|BIOLOGICAL|Inactivated Trivalent Influenza vaccine|
41320957|NCT01877824|OTHER|Fast-track training|
41320958|NCT02234934|BIOLOGICAL|Lentiviral G1XCGD Gene Therapy|"The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10\^6 cells per kg of body weight transduced ex vivo with 1 x 10\^8 IG/mL of lentiviral vector to achieve \> 0.3 integrated copies per cell."
41320959|NCT01601470|DRUG|LCZ696|LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
41320960|NCT01601470|DRUG|Sildenafil|Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
41320961|NCT03974113|DRUG|Fitusiran|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous
41320962|NCT00476177|BIOLOGICAL|Infusion of donor dendritic cells|Given in the outpatient setting
41320963|NCT00476177|BIOLOGICAL|Infusion of donor lymphocytes|Given in outpatient setting
41320964|NCT03803202|BIOLOGICAL|ASP3772|Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly
41320965|NCT03803202|BIOLOGICAL|PCV13|Participants received a single dose of PCV13 intramuscularly.
41320966|NCT03803202|BIOLOGICAL|PPSV23|Participants received a single dose of PPSV23 intramuscularly.
41320967|NCT04387929|DIAGNOSTIC_TEST|Detection of anti-COVID-19 antibody level|Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.
41320968|NCT02842112|OTHER|PBSC mobilization and leukapheresis|"Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques."
41320969|NCT02950012|DIETARY_SUPPLEMENT|OPTI-BIOME™ Bacillus subtilis MB40|
41320970|NCT02950012|OTHER|Placebo|
41320971|NCT05113719|OTHER|Exercise|Both groups will perform bridge exercise
41320972|NCT00604435|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
41320973|NCT00604435|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
41320974|NCT00680160|DRUG|AN2690|AN2690 7.5% Solution, once daily for 28 days
41320975|NCT04162535|DRUG|Lidocaine 1% Injectable Solution|"Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~* Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~* Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~* Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop"
41320976|NCT04162535|BIOLOGICAL|Blood extraction|The patients will donate after consent 10 ml of blood prior and after surgery for further study
41320977|NCT04162535|DRUG|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
41320978|NCT04162535|DRUG|Propofol|Patients will receive a general anesthesia with Propofol as anesthetic agent
41320979|NCT00388323|OTHER|blood and biopsies|blood and biopsies
41320980|NCT05367219|DEVICE|Air sterilizer|The invesitigators will try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the Air sterilizer group.
41320981|NCT01925859|DRUG|EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
41320982|NCT04849819|DRUG|Corticosteroids, immunosuppressors, biological agents|We do not prescribe new medications to patients but only observe their adverse effects on the eye.
41320983|NCT00676208|BEHAVIORAL|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
41320984|NCT06042530|DIAGNOSTIC_TEST|Neuropsychological investigation|Comprehensive neuropsychological test battery covering logical reasoning, different attention functions, executive functions, visuospatial functions, different memory functions, psychomotor speed, motor functions, and smell identification
41320985|NCT06042530|DIAGNOSTIC_TEST|Optometric investigation|Extended vision examination including symptom assessment, visual acuity, visual field (confrontation), eye movements, eye teaming and clinical assessment of hypersensitivity to visual stimuli.
41476711|NCT01583257|BEHAVIORAL|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
41476712|NCT04441099|DRUG|NBE-002|NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
41476713|NCT01090999|OTHER|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
41476714|NCT05403710|DRUG|Botulinum toxin|Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
41476715|NCT00053235|GENETIC|Comparative Genomic Hybridization|Correlative studies
41476716|NCT00053235|OTHER|Laboratory Biomarker Analysis|Correlative studies
41476717|NCT00053235|GENETIC|Polymerase Chain Reaction|Correlative studies
41006727|NCT06060574|DEVICE|Platelet rich fibrin device|"Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes."
41006728|NCT04614766|DRUG|Lutathera|intravenous administration
41006729|NCT04614766|DRUG|Azedra|intravenous administration
41320986|NCT06042530|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI sequence protocol includes resting state fMRI before and after the participants do an established 20 min long reaction time measurement paradigm (E-prime). During the paradigm a pseudo-continious arterial spin labeling sequence (pCASL) is acquired for continuous measurement of brain perfusion. Following the functional sequences the imaging protocol also includes a high resolution 3D T1weighted sequence Magnetization Prepared Rapid Gradient Echo (MPRAGE) for brain structure, a high resolution 3D T2-weighted sequence Fluid-Attenuated Inversion Recovery (FLAIR) for pathology and a 3D susceptibility weighted image (SWI) for microvascular abnormalities.
41320987|NCT06042530|DIAGNOSTIC_TEST|Immunological biomarkers|Venous blood samples (10-20 ml) are taken from the elbow crease. They are drawn in the morning, and the participants are asked to fast for 12 hours prior to sampling. They are also asked to avoid physical activity prior to blood sampling. The samples are drawn into citrated tubes.
41320988|NCT03860350|DIETARY_SUPPLEMENT|Aged Garlic Extract|
41320989|NCT03860350|DIETARY_SUPPLEMENT|Placebo|
41320990|NCT04711499|BEHAVIORAL|Fatigue|The intervention will be assessing the participant in a fatigued state compared to a non fatigued state
41320991|NCT03374553|DEVICE|MINI DO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
41320992|NCT03374553|DEVICE|MINI SO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
41320993|NCT02576457|BIOLOGICAL|BMS-936559|
41320994|NCT02576457|OTHER|Placebo|
41320995|NCT00703469|DRUG|MDX1106-02|Single dose
41320996|NCT00703469|DRUG|Placebo|Placebo single dose
41320997|NCT03453918|DIETARY_SUPPLEMENT|polyphenols|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
41476718|NCT02650401|DRUG|Entrectinib|TRKA/B/C, ROS1, and ALK inhibitor
41476719|NCT04206722|DEVICE|Shock Wave Therapy|Shock Wave therapy - hip osteoarthritis program
41476720|NCT04206722|DEVICE|Ultrasound|Ultrasound 0.7W/cm2
41476721|NCT04812639|OTHER|Buccal infiltration technique|a technique for injecting local anesthetic solution in the buccal mucobuccal fold between the roots of the targeted tooth
41476722|NCT04812639|OTHER|Inferior alveolar nerve block technique|a technique for injecting local anesthetic solution to anesthetize the inferior alveolar nerve
41476723|NCT02849236|DRUG|Ropivacaine (PECS bloc)|"Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles"
41476724|NCT02849236|DRUG|Placebo|20 mL saline 0.9%
41476725|NCT04569513|BIOLOGICAL|Thyroid and parathyroid disease|To analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.
40803403|NCT04424823|PROCEDURE|LED photobiomodulation|Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
40803404|NCT03778749|DIAGNOSTIC_TEST|TOF measurements|The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
40803405|NCT04806061|DRUG|Sodium bicarbonate|sodium bicarbonate 8.4% to achieve urinary pH \>7.5
40803406|NCT04806061|DRUG|standard care|standard care
40803407|NCT02706418|PROCEDURE|Clinical Massage Therapy|
40803408|NCT02142400|DRUG|DS-1093|DS-1093 in capsules with 2.5mg or 25mg per capsule
40803409|NCT02142400|DRUG|placebo|matching placebo capsules to DS-1093 capsules
40803410|NCT00665054|DRUG|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
40803411|NCT00665054|DRUG|Placebo|Matching placebo tablets orally prior to sexual activity
40803412|NCT02546258|DEVICE|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
40803413|NCT05727007|DIAGNOSTIC_TEST|MRI in colon cancer|The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast
40803414|NCT05727007|DIAGNOSTIC_TEST|CT in colon cancer|The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
40803415|NCT04041544|DRUG|SN1011|SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
40803416|NCT04041544|DRUG|SN1011 placebo|The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
40803417|NCT01114087|DRUG|Imatinib treatment|Imatinib is a tyrosin-kinase inhibitor
40803418|NCT01681069|DIETARY_SUPPLEMENT|IQP-VV-102|
40803419|NCT01681069|OTHER|Placebo|
40803420|NCT00079261|DRUG|CHOP regimen|
40803421|NCT00079261|DRUG|cyclophosphamide|
40803422|NCT00079261|DRUG|doxorubicin hydrochloride|
41320998|NCT03453918|OTHER|Placebo|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
40803423|NCT00079261|DRUG|gemcitabine hydrochloride|
41006730|NCT03613207|OTHER|Dermal pharmacokinetic measurement|"* Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~* Each test site receives 2 dOFM probes~* Dosing:~  * 2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~ * 2 test sites: untreated test site~* ISF sampling: 24 hours post-dose~* Blood sampling: 7 samples post-dose"
40803424|NCT00079261|DRUG|prednisone|
41006731|NCT03613207|DRUG|Lidocaine and prilocaine cream|lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
41006732|NCT03613207|DRUG|Oraqix® gel|Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
41006733|NCT03613207|DEVICE|dOFM-System|Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours
40803425|NCT00079261|DRUG|vincristine sulfate|
40803426|NCT04409561|DEVICE|Blood collection|9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits
40803427|NCT04309877|DRUG|Theophylline ER|Capsules of theophylline ER
40803428|NCT04309877|OTHER|PO placebo|Capsules of methylcellulose
40803429|NCT04309877|BIOLOGICAL|Lipopolysaccharide (LPS)|Purified bacterial wall component as an inflammatory challenge
40803430|NCT04309877|OTHER|IV placebo|Normal (0.9%) saline
40803431|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
40803432|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
40803433|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 3|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
40803434|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 4|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
41476726|NCT01768819|BEHAVIORAL|Physical Activity|The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
40803435|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 5|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
40803436|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
40803437|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
40803438|NCT02220153|BIOLOGICAL|Intravenous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: intravenous infusion"
41006734|NCT03613207|PROCEDURE|Blood sampling|8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
41320999|NCT06197022|DEVICE|Mozec™ SEB Sirolimus Eluting Rx PTCA Balloon Dilatation Catheter|Combination of scoring-balloon angioplasty (SBA) plus sirolimus-eluting balloon angioplasty (SEBA) for diffuse (lesion length ≥20 mm), small vessel (diameter 1.5 mm -2.75 mm) coronary disease.
41321000|NCT02411383|DEVICE|NeuRx Diaphragm Pacing System|NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
41321001|NCT01899586|OTHER|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
41006735|NCT01285804|OTHER|Cuffed ETT|Kimberly Clark
41006736|NCT01285804|OTHER|Uncuffed ETT|Kimberly Clark
41321002|NCT01899586|OTHER|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at \>50% of heart rate reserve (HRR) for 45 minutes, three days per week.
41321003|NCT05108610|OTHER|Shi-style manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
41321004|NCT05108610|OTHER|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
41321005|NCT01154881|DRUG|insulin degludec|Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
41321006|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|JS001sc Q3W combination with gemcitabine and cisplatin.
41321007|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|JS001sc long period combination with gemcitabine and cisplatin.
41476727|NCT01398202|DIETARY_SUPPLEMENT|vitamin D3|20 micrograms per day for 10 weeks
41476728|NCT01398202|DIETARY_SUPPLEMENT|25-hydroxyvitamin D3|7 microgram/day for 10 weeks
41476729|NCT01398202|DIETARY_SUPPLEMENT|25-hydroxyvitamin D (20 microgram/day)|20 microgramday for 10 weeks
41476730|NCT01398202|DIETARY_SUPPLEMENT|Placebo|0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
41476731|NCT05420779|DRUG|TSL-1502 capsules(low dose)|350 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
41476732|NCT05420779|DRUG|TSL-1502 capsules(high dose)|500 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
40803439|NCT02220153|BIOLOGICAL|Subcutaneous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: subcutaneous infusion"
40803440|NCT05243121|DIAGNOSTIC_TEST|MRI|undergoing enhanced MRI
40803441|NCT04615234|DEVICE|Pharmacogenomics test (PGx)|"The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) use as directed (labelled as Green), 2) use with caution (labelled as Yellow), 3) use with extreme caution (labelled as Red)"
40803442|NCT00141648|DRUG|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
40803443|NCT00141648|RADIATION|Radiotherapy|Total 45 Gy in 25 fractions
41006737|NCT02866877|OTHER|Pharmacokinetic modeling|Timed blood draws and urine collections to model drug clearance
41006738|NCT03302702|OTHER|Exercise program|Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
41321008|NCT05751486|BIOLOGICAL|Toripalimab /JS001|JS001 IV (if applicable) .
41321009|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|Additional cohort (if applicable)
41321010|NCT06199622|OTHER|music|20 minutes of classical Turkish musicor classical western music
41321011|NCT01011036|DRUG|clobazam|test substance
41321012|NCT01011036|DRUG|clonazepam|positive control
41321013|NCT01011036|DRUG|tolterodine|active placebo
41321014|NCT00543621|OTHER|daily enteral nutritional product and/or behavioral changes|
41321015|NCT00576251|DRUG|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
41006739|NCT04709965|DIAGNOSTIC_TEST|Face2Gene|This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.
41006740|NCT06091553|DRUG|Duloxetine alone|30 mg once daily for 1 week, then 60 mg once daily
41321016|NCT00576251|DRUG|TOBRADEX|TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
41321017|NCT03943979|OTHER|Cognitive Training|Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
41321018|NCT03943979|DEVICE|transcranial Direct-Current Stimulation (tDCS)|tDCS: 4 consecutive days, 20 min session, delivered through multichannel tDCS (Starstim, Neuroelectrics), with an excitatory target over the r-dlPFC, and an inhibitory target on the contralateral lobe (l-dlPFC). The positioning of the multichannel tCS (electrode location and currents) was solved using the Stimweaver (Ruffini 2013). The resulting tCS montage employed 8 gelled Ag/AgCl electrodes of π cm2 size (Pistim, Neuroelectrics) placed at AF3(-1093uA), AF4 (1178uA), F3 (-1161uA), F4 (1104uA), F7 (-414uA), F8 (530uA), FC5 (1189uA), FC6 (-1332uA).
41321019|NCT04150562|DRUG|rhIL-15|Recombinant human Interleukin-15 (rhIL-15) will be administered by continuous intravenous infusion (CIV) at a starting dose of 2 mcg/kg/day for the first dose level followed by a second dose level of 4mcg/kg/day on days 1-5 of the 28-day cycle of each of four cycles.
41321020|NCT04150562|BIOLOGICAL|Avelumab|avelumab (800mg by intravenous (IV) will be administered on days 8 and 22 of the 28- day cycle for four cycles
41321021|NCT02019524|BIOLOGICAL|E39 peptide vaccine|500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
41321022|NCT02019524|BIOLOGICAL|E39 vaccine then J65 vaccine|The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
41321023|NCT02019524|BIOLOGICAL|J65 vaccine then E39 vaccine|The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
41321024|NCT04342520|OTHER|Dyads Patient / caregiver|adult patient / caregiver couples, patient are 55 years of age or older and have Alzheimer's disease or a related disease
41321025|NCT02611700|DRUG|Nimotuzumab|400mg,day1,weekly,until disease progression or toxicity
41321026|NCT02611700|DRUG|Paclitaxel|175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
41321027|NCT02611700|DRUG|Cisplatin|60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
41321028|NCT02611700|DRUG|Placebo|400mg,day1,weekly,until disease progression or toxicity
41321029|NCT03283618|BEHAVIORAL|Video Conferencing Group|
41321030|NCT04781569|OTHER|data collection|Health-related personal data such as year of birth, sex, Body Mass Index (BMI), infection classification, concomitant infections, comorbidities according to medical chart, standard diagnostic markers (CRP, blood differential plots, creatinine, ...), medication, treatment start, treatment end and discharge from hospital will be collected.
41321031|NCT04781569|DIAGNOSTIC_TEST|blood draw|2 blood drawing events (in total 22.5 ml) will be performed in the patient. 1 blood drawing events will be performed in the healthy proband.
41321032|NCT04781569|DIAGNOSTIC_TEST|nose swabs|2 nose swabs will be taken in the patient. 1 nose swab will be performed in the healthy proband.
41321033|NCT04781569|DIAGNOSTIC_TEST|Intraoperative tissue samples|Intraoperative tissue samples from the site of infection during surgery will be taken in the patient.
41321034|NCT05239364|PROCEDURE|Catheter ablation|Catheter-based ablation of arrhythmias using radiofrequency.
41006741|NCT06091553|DRUG|Duloxetine augmented with gabapentin|30 mg once daily for 1 week, then 60 mg once daily 300 mg at bedtime
40803444|NCT04704687|OTHER|Transcranial Direct Current Stimulation|Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.
41006742|NCT06091553|DRUG|Duloxetine augmented with amitriptyline (as combined therapy)|10 to 25 mg once daily at bedtime 30 mg once daily for 1 week, then 60 mg once daily
41006743|NCT05863741|DEVICE|Implantation of GMK Sphere with conventional instrumentation|Implantation of GMK Sphere with conventional instrumentation (control group)
41006744|NCT05863741|DEVICE|Implantation of GMK Sphere using the NextAR guidance system|Implantation of GMK Sphere using the NextAR guidance system (NextAR group)
41321035|NCT05651516|DRUG|18F-PI-2620 PET/CT|PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
41321036|NCT04874532|OTHER|Community Paramedic Program|Patients will be seen for a 1-hr in person evaluation and follow-up will be determined on an individual basis based on patient need. During each visit, CPs will perform health status and social determinants of health assessments, physical exam, medication review/counseling, and goal setting/review.
41321037|NCT04874532|OTHER|Education Material|Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
41321038|NCT00943982|DRUG|Interferon Gamma 1-b|
41321039|NCT00254735|DRUG|quetiapine fumarate|
41321040|NCT00254735|DRUG|SSRI/Clomipramine|
41321041|NCT00181935|DRUG|risperidone (Risperdal)|
41321042|NCT00181935|DRUG|olanzapine (Zyprexa)|
41321043|NCT04657653|PROCEDURE|core decompression|:The procedure was performed under general anesthesia with the aid of image intensifier. All patients were positioned in supine position on a fracture table. The core decompression was performed using the direct lateral approach with 2 cm skin incision. A fluoroscope guided large single drill with 8 mm diameter over a guide wire was used to remove the necrotic tissues from the femur head through the lateral cortex distal to trochanteric tubercle. After the removal of the core necrotic bone, the track was filled with 5 ml synthetic bone paste substitute (tricalcium phosphate) and an intraoperative fluoroscope was used to confirm the adequacy of the decompression and grafting.
41321044|NCT05821153|DRUG|Aldesleukin|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
41321045|NCT04696237|OTHER|Questionnaire|a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed
41321046|NCT01352065|DRUG|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
41321047|NCT01352065|DRUG|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
41321048|NCT01352065|DRUG|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
41476733|NCT05420779|DRUG|Investigator's choice of chemotherapy|Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip (15 \~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 \~ 5 min)
41476734|NCT00279955|DEVICE|Cardiac Resynchronization Therapy Device|Patients with an ICD indication, a CRT indication and symptomatic heart failure who are implanted with a Cardiac Resynchronization Therapy Device.
41476735|NCT02430805|OTHER|dna extraction and genotyping|blood and urine sample
41321049|NCT06204302|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using Komodo Research Database (KRD)
41321050|NCT06204302|DRUG|Enzalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
41321051|NCT06204302|DRUG|Apalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
41321052|NCT03445754|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
41321053|NCT03445754|DEVICE|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
41321054|NCT01159509|BEHAVIORAL|sodium taste tests|The cohort group will had sodium taste tests and an interview regarding diat habits.
41321055|NCT00979017|DRUG|Avastin|Avastin, by intravenous infusion, 10 mg/kg every 14 days
41476736|NCT00207948|DRUG|Dose adjustment of Kaletra|Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
40803445|NCT01832493|DEVICE|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
41321056|NCT00979017|DRUG|Temozolomide|Oral temozolomide at 200 mg/m2 daily for 5 days
41321057|NCT00979017|DRUG|Irinotecan|Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
41321058|NCT00264446|DRUG|ADH300004|
41321059|NCT00771173|DRUG|phenazopyridine HCl|Phenazopyrdine HCl 200 mg q8h x 24
41321060|NCT00771173|OTHER|Placebo|Placebo tablet administered q8 hours for 24 hours postop.
41321061|NCT04671615|DRUG|palbociclib|As provided in real world practice
41321062|NCT02293902|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
41321063|NCT02293902|OTHER|Placebo (for sarilumab)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
41321064|NCT02293902|DRUG|Methotrexate|Dispensed according to local practice.
41321065|NCT02293902|DRUG|Folic acid|Dispensed according to local practice.
41321066|NCT01718626|DRUG|S1+Docetaxel|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
41321067|NCT01718626|DRUG|S1+Docetaxel followed by S1|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
41321068|NCT05708924|DRUG|FT538|FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.
40803446|NCT04329728|DRUG|AVM0703|Intravenous infusion over \~1 hours
41321069|NCT05708924|BIOLOGICAL|Enoblituzumab|Enoblituzumab 15 mg/kg IV begin on Day -6 and continuing once every 3 weeks beginning on Day 22 until disease progression or unacceptable toxicity - refer to Section 7.2.1 for timing of the enoblituzumab dose on Day 22 if steroid pre-meds are needed due to an infusion reaction with the 1st enoblituzumab dose as there is a 14 day ban on corticosteroid use after the last dose of FT538
41321070|NCT05049447|DRUG|Pascoflair|1 x 2 tablets (single-dose)
41321071|NCT05049447|OTHER|Placebo|1 x 2 tablets (single-dose)
41321072|NCT00587769|DRUG|Bupropion SR & Varenicline|"Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.~Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment."
41321073|NCT02447120|DEVICE|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
41321074|NCT03689881|DEVICE|Tomosynthesis of SI joints|"All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis.~Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction."
41321075|NCT00765128|DRUG|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
41321076|NCT00765128|DRUG|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
41321077|NCT05055570|OTHER|No intervention|No intervention
41321078|NCT00371111|DRUG|Intravitreal injection of Triamcinolone|4 mg of Triamcinolone
41321079|NCT00371111|DRUG|Intravitreal injection of Avastin|Injection of 1.25 mg of Avastin and
41321080|NCT03707158|BEHAVIORAL|Therapist-led Face-to-Face Cognitive-Behavioral Therapy|Participants receiving face-to-face cognitive-behavioral therapy will participate in therapist-led, office-based or telehealth CBT treatment for up to 16 weeks. Sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
41321081|NCT03707158|BEHAVIORAL|Digital Cognitive-Behavioral Therapy|Participants receiving digital cognitive-behavioral therapy will complete an online, largely self-administered CBT program for up to 16 weeks with 8 modules and adjunctive therapist phone support. Treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
41321082|NCT02492685|DEVICE|Quantitative analysis by using the new developed software program VueBox|After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.
41321083|NCT02518100|DEVICE|Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
41321084|NCT02518100|DEVICE|Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
41321085|NCT06528015|DRUG|probiotics combined with enteric-coated budesonide capsule|"In the 9-month treatment period, the following treatments will be received: probiotics combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics (each bag added active probiotic Lactobacillus casei Zhang ≥100 billion CFU) +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules."
41321086|NCT06528015|DRUG|probiotics placebo combined with enteric-coated budesonide capsules|"In the 9-month treatment period, the following treatments will be received: probiotics placebo combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics placebo +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules."
41321087|NCT03549858|OTHER|Quality of life measure (survey)|The QoL tool is a questionnaire
41321088|NCT02714504|DRUG|Voriconazole or posaconazole|Azole with activity against molds
41321089|NCT06175442|DEVICE|Intraoperative intestinal decompression|Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction
41321090|NCT01847612|PROCEDURE|indocyanine green fluorescent cholangiography|
41321091|NCT01847612|DRUG|methylene blue|
41321092|NCT03882398|OTHER|Balance|"Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)"
41321093|NCT03882398|OTHER|Endurance|"Progressive-cycle program (15-25 minutes)~Warming up Pedalling with 0 resistance (2 minutes)~Main Part\* Week 1-2 : 3x2 minutes Week 3-4 : 4x2 minutes Week 5-6 : 5x2 minutes Week 7-8 : 6x2 minutes~Return to resting stage Pedalling with 0 resistance (1 minute)~(\*Pedalling with resistance set at 3-4. Rest: 2 minutes between sets or 120 beats/minute. One more set added every two weeks and workout intensity maintained at 70% of heart rate reserve-HRR)"
41321094|NCT00373100|DRUG|Zinc acetate|
41321095|NCT00373100|DRUG|Placebo|Placebo
41321096|NCT01178346|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
40803447|NCT03996681|DRUG|methylcantharidimide tablets|"Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor."
40803448|NCT03934580|OTHER|hallucinated meal|a breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated by participants under hypnosis
40803449|NCT03934580|OTHER|Real meal|A real breakfast (white bread plus ham and cheese with 250 ml still water) is consumed by participants
41321097|NCT01178346|BIOLOGICAL|Placebo|Placebo vaccine given 6 times over 6 months
41321098|NCT05978856|OTHER|Accuracy of computer software in predicting soft tissue profile changes|"Separate analyses will be performed on the initial and final cephalograms.~* All of the cephalometric analyses will be done via computer software,the linear and angular measurements will be done via the software.~* Through the use of software, the initial cephalogram and the initial photograph will be linked.~* Then, the final values of some angles will be tracted from the post-treatment cephalogram.~* These values will be inserted in the treatment simulationsection of the software.~* A post-treatment projected image of the patient will be simulated by the software.~* Then the actual post-treatment photograph will be placed on the simulated image in transparent form.~* From the pupil , real horizontal and vertical reference lines will be drawn.~* Then certain measurements will be taken from referance lines to fixed points on the soft tissue to determine the discrepancies between the real and simulated images."
41321099|NCT00438789|DRUG|eculizumab|600mg IV every week and 900mg IV every 2 weeks
41321100|NCT00282568|DRUG|Tacrolimus Modified Release (MR)|Oral
41321101|NCT00282568|DRUG|tacrolimus|Oral
41321102|NCT04475822|BEHAVIORAL|Intermittent fasting|Intermittent fasting group:During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
41321103|NCT04475822|BEHAVIORAL|Low carb diet|Low carb diet:The daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
41321104|NCT04475822|BEHAVIORAL|Low carbon diet and intermittent fasting group|Low carbon diet and intermittent fasting group:Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
41321105|NCT05865873|BEHAVIORAL|Health education|Health education will be delivered for six months, two times per month; one session will take one hour, and an overall 12 sessions will be conducted. One health education session consists of key messages on normal pregnancy and childbirths, ODS during pregnancy, delivery, and the postpartum period, the practice of BPCR, and the benefits of MHSU. The other actions executed by WDT facilitators will be the motivating mother and their families to utilize MHS. One hour will be allocated for each session, from this 20 minutes will be allowed for the pre-recorded an audio-based lecturer and the remaining 40 minutes will be allowed for raising questions and responses (discussion). After the session, some of the women will be selected to carry out role play which is basic to demonstrate the important messages and share experiences.
41321106|NCT05085028|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
41321107|NCT04185441|DRUG|Tanzânia association|Tanzânia association capsule
41321108|NCT04185441|DRUG|Omnic Ocas|Tamsulosin 0,4 mg
41321109|NCT04185441|OTHER|Omnic Ocas placebo|Tamsulosin placebo
41321110|NCT04185441|OTHER|Tanzânia association placebo|EMS association placebo
41321111|NCT05940597|DEVICE|Pulse field ablation|ablation of paroxysmal atrial fibrillation by Pulse field ablation
41321112|NCT05940597|DEVICE|Cryoballoon pulmonary vein isolation|ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation
41321113|NCT01615796|DRUG|Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined|Subjects receive a single dose of GSK2140944
41321114|NCT01615796|DRUG|Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined|Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
40803450|NCT02274935|OTHER|Exercise|Balance and gait exercise twice a week for an hour
40803451|NCT02263196|OTHER|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
41321115|NCT04388098|OTHER|Diagnosis of caries experience and periodontal health|
41321116|NCT05275452|OTHER|No intervention|No intervention
41321117|NCT00120653|DRUG|Metoclopramide|
41321118|NCT02578823|DEVICE|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
40803452|NCT02263196|OTHER|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
40803453|NCT05097560|DEVICE|high flow nasal cannula|HFNC provides humidified, heated, oxygen-enriched air at constant concentration with a flow up to 60L/min through a nasal cannula. It washouts the anatomical dead space and decreases the work of breathing.
40803454|NCT05097560|DEVICE|Venturi mask|VM is commonly used by COPD patients during exercise training.
40803455|NCT01149005|DRUG|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
40803456|NCT01149005|DRUG|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
40803457|NCT00958347|DEVICE|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
41321119|NCT02578823|DEVICE|Arcticgel™|
40803458|NCT02360670|OTHER|control imaging|
40803459|NCT02360670|OTHER|additional multimodal imaging|
40803460|NCT01709617|DIETARY_SUPPLEMENT|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
40803461|NCT03803358|OTHER|exercise training with non-invasive ventilation|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
40803462|NCT03803358|OTHER|standard exercise training without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
40803463|NCT05965869|OTHER|diabetes program|CHWs will contact participants weekly via phone or text, send bimonthly diabetes education videos, and provide optional monthly seminars.
40803464|NCT01951989|DRUG|Imiglucérase (drug) pharmacokinetics|
40803465|NCT03462927|DRUG|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
40803466|NCT03462927|DRUG|CAL/BDP combination|Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
40803467|NCT03377816|BEHAVIORAL|Art Therapy|In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
40803468|NCT03377816|BEHAVIORAL|Sham Art Therapy|In a group setting participants will engage in Mandala coloring
40803469|NCT03800524|DRUG|Tauroursodeoxycholic Acid|"* Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
41321120|NCT02578823|PROCEDURE|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
41321121|NCT04037917|DEVICE|CorNeat EverPatch|Covering Ophthalmic Implants
41321122|NCT05956587|DRUG|BL-B01D1|Administration by intravenous infusion
40803470|NCT03800524|DRUG|Placebo|"* Placebo 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
40803471|NCT02048137|DEVICE|Transcranial direct current stimulation|
40803472|NCT01147887|DRUG|Drug combination/ 26489112|On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
40803473|NCT01604525|BEHAVIORAL|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
41321123|NCT05956587|DRUG|SI-B003|Administration by intravenous infusion
40803474|NCT01604525|BEHAVIORAL|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
41321124|NCT05202223|BEHAVIORAL|Harmony at HOME (H@H)|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
41321125|NCT01818986|DRUG|Sipuleucel-T|
41321126|NCT01818986|RADIATION|Stereotactic Ablative Body Radiation|
41321127|NCT02336139|DRUG|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
40803475|NCT01604525|OTHER|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
40803476|NCT03254706|OTHER|Peak etch-and-rinse (P1)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.
40803477|NCT03254706|OTHER|Peak applied for double time(P2X)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.
40803478|NCT03254706|OTHER|Single Link etch-and-rinse (SL1)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.
41321128|NCT05871970|BIOLOGICAL|TARA-002|All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.
41476737|NCT01627925|DEVICE|nasal mask and continuous positive airway pressure|nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
40803479|NCT03254706|OTHER|Single Link double time (SL2X)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
40803480|NCT02408718|BEHAVIORAL|Assistive Device Training|Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
41476738|NCT03039348|OTHER|semi-structured interview using a questionnaire|semi-structured interview using a questionnaire
40803481|NCT02642393|DRUG|Inosine|capsules containing 500 mg of inosine
40803482|NCT02642393|DRUG|Placebo|capsules containing \~500 mg of lactose and appearing indistinguishable from inosine capsules
40803483|NCT06433778|OTHER|No Intervention|This is a non-interventional study.
40803484|NCT00956007|BIOLOGICAL|cetuximab|intravenously
40803485|NCT00956007|RADIATION|intensity-modulated radiation therapy|daily fractions
41476739|NCT05223829|DRUG|Brexanolone|Brexanolone will be administered as a continuous IV infusion over 20 hours under medical observation
40803486|NCT04469387|PROCEDURE|Limited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis|In terms of limited decompression at the adjacent segment, partial laminotomy, flavectomy, and bilateral medial facetectomies up to the pedicle will be performed. Complete laminectomy and destroy of posterior ligament complex will be avoided.
41476740|NCT00479388|DRUG|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
41476741|NCT00479388|DRUG|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
41476742|NCT00479388|DRUG|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
41476743|NCT03629600|DRUG|Lactated Ringer|High-volume Lactated Ringer Solution
41476744|NCT03629600|DRUG|Rectal Form Indometacin|Post-ERCP rectal administration of 100 MG Indomethacin
41476745|NCT03515902|DEVICE|mouthguard|mouthguard
40803487|NCT04469387|PROCEDURE|Responsible segments fused|In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).
40803488|NCT01599312|DEVICE|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
40803489|NCT02242136|BEHAVIORAL|FORNET|
40803490|NCT03322046|BEHAVIORAL|Lifestyle Program|4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
40803491|NCT04941183|DRUG|NTR-441|NTR-441
40803492|NCT04941183|DRUG|Placebo|Placebo
40803493|NCT00624468|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
40803494|NCT00624468|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
40803495|NCT05171309|DRUG|Apatinib|250 mg once daily (QD) oral dosing.
40803496|NCT05171309|DRUG|Camrelizumab|200 mg intravenously every 2 weeks.
40803497|NCT05171309|DRUG|NK cell|Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days
40803498|NCT03450694|DEVICE|ultrasound|ultrasound is a non-invasive and not expensive method, availiable at almost all institutions.
41476746|NCT03515902|DEVICE|mouthguard with desensitizing toothpaste|mouthguard with desensitizing toothpaste containing 8% arginine with calcium carbonate
41476747|NCT03341546|OTHER|A single measurement of the patient's abdominal depth|A single measurement of the patient's anterior-posterior abdominal depth
41476748|NCT01876849|DRUG|exenatide|subcutaneous injection, 5mcg or 10 mcg, twice daily
41476749|NCT04654234|DEVICE|Total body PET/CT (uExplorer)|A total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER) with a 192-cm scan range was applied for cancer diagnosis, organ function assessment and treatment outcome prediction. The total-body PET scanner can acquire scans with lower administered activity or short acquisition time, total-body dynamic acquisition at a longer delayed time point, and high detectability of exiguous changes of the whole body, and tumor as well.
41476750|NCT05246787|BEHAVIORAL|breastfeeding|nonphamacological methods
41476751|NCT05246787|COMBINATION_PRODUCT|Breastfeeding and Shotblocker|combined Breastfeeding and Shotblocker device
41321129|NCT06202209|PROCEDURE|Circumferential Pulmonary Vein Isolation|Circumferential pulmonary vein isolation (CPVI) is a type of cardiac ablation procedure. Cardiac ablation procedures involve creating small scars in the heart using thermal or cold energy to block irregular electrical signals and restore normal heart rhythm. CPVI specifically creates small scars in the area where the four pulmonary veins connect to the left atrium of the heart. The pulmonary veins carry oxygen-rich blood from the lungs to the heart.
40803499|NCT00586040|PROCEDURE|tissue bonding|application of rose bengal and treatment with green light
40803500|NCT00586040|PROCEDURE|sutures|interrupted superficial sutures
40803501|NCT01168830|DEVICE|AMS-3.0|
40803502|NCT06516081|DIETARY_SUPPLEMENT|Micronutrient powder (Sprinkles®)|
41321130|NCT03125876|DRUG|CT053PTSA|receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
40803503|NCT00769171|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
40803504|NCT00769171|DRUG|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
40803505|NCT00002297|DRUG|Inosine pranobex|
40803506|NCT05788419|DIAGNOSTIC_TEST|sonography|imaging method, functional test of hip joint
40803507|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
40803508|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
40803509|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
40803510|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
40803511|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months|
40803512|NCT02507661|DRUG|no-preservation of alveolar ridge - 2 months|
40803513|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months|
40803514|NCT02507661|DRUG|no-preservation of alveolar ridge - 4 months|
41321131|NCT04534036|DIETARY_SUPPLEMENT|PDS-08|PDS-08 is a novel synbiotic comprised of nine probiotic bacterial strains and FOS-inulin as a prebiotic.
41321132|NCT04534036|OTHER|Placebo|Placebo sachets will contain potato or tapioca maltodextrin.
41321133|NCT04159077|DRUG|Tamsulosin Hydrochloride|"Tamsulosin HCL is an alpha blocker. It relaxes the muscles in the prostate and bladder neck, making easier to urinate. The dosage used will be 0.4 mg (administered once daily)~Other names: Flomax"
41321134|NCT04159077|DRUG|Placebos|Half of the patients will be assigned to receive placebo tablets in the same manner as the active intervention. These tablets will have no effect.
41321135|NCT00003026|DRUG|bicalutamide|
41321136|NCT00003026|DRUG|flutamide|
41321137|NCT00003026|DRUG|triptorelin|
41321138|NCT00003026|RADIATION|radiation therapy|
41476752|NCT05246787|DEVICE|shotblocker|it is a small plastic tool
41476753|NCT00433316|DRUG|ropivacaine|1% ropivacaine
41476754|NCT00433316|DEVICE|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
41476755|NCT02801435|DRUG|0.5% Icotinib hydrochloride cream|Topical administration for twice daily
41476756|NCT02801435|DRUG|1.0% Icotinib hydrochloride cream|Topical administration for twice daily
41476757|NCT02801435|DRUG|2.0% Icotinib hydrochloride cream|Topical administration for twice daily
40803515|NCT02507661|PROCEDURE|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months|
41321139|NCT00556192|DRUG|rituximab|"1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period."
41321140|NCT03675438|OTHER|Sub-epitheilal TCA Inlay|A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
41321141|NCT05399030|DRUG|ICP-332|ICP-332 will be administered as tablet
41321142|NCT05399030|OTHER|Placebo|Matching placebo will be administered as tablet
41476758|NCT02801435|DRUG|4.0% Icotinib hydrochloride cream|Topical administration for twice daily
41476759|NCT02801435|DRUG|Placebo|Topical administration for twice daily
41476760|NCT01155778|BIOLOGICAL|Recombinant human heparan N-sulfatase (rhHNS)|
40803516|NCT02507661|DRUG|no-preservation of alveolar ridge - 9 months|
40803517|NCT03350035|DRUG|IV Ganaxolone active|IV
40803518|NCT03350035|DRUG|IV Placebo, non-active|IV
40803519|NCT03718884|DRUG|Drug Cocktail|Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
40803520|NCT03718884|DRUG|Mirikizumab|Administered SC
41321143|NCT01354613|DRUG|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
41321144|NCT01354613|DRUG|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
41321145|NCT00354497|OTHER|physiologic testing|
41321146|NCT00354497|OTHER|study of socioeconomic and demographic variables|
41476761|NCT05767203|OTHER|Biological samplings|Blood and/or skin samples
41476762|NCT02689245|DRUG|Tenofovir|
41476763|NCT02689245|DRUG|Fecal Microbiota Transplantation (FMT)|
41476764|NCT04462016|OTHER|Calamansi|250 ml of a commercially sourced calamansi drink
41476765|NCT04462016|OTHER|Glucose|75 g of glucose dissolved in 250 ml of drinking water
41476766|NCT05967871|BIOLOGICAL|Fecal Microbiota Transplant|Participants will receive approximately 50 grams of human stool/150mL (approximately 107 microbes/mL of suspension) in saline, prepared as per standard collection, preparation, and screening protocols for FMT infusion developed by our institutional stool bank in accordance with recognized standards. Fecal microbiota transplant infused via existing enteral feeding tube or upper elective endoscopy (with infusion into the duodenum) x1.
41476767|NCT03908528|DIETARY_SUPPLEMENT|Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks..
40803521|NCT03714217|BEHAVIORAL|Telenutrition Counseling|A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
40803522|NCT05016817|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41321147|NCT00354497|PROCEDURE|evaluation of cancer risk factors|
41321148|NCT00354497|PROCEDURE|mutation carrier screening|
41321149|NCT00354497|PROCEDURE|study of high risk factors|
41321150|NCT00004696|DRUG|morphine|
41321151|NCT02199613|DRUG|Treatment simplification|Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
41321152|NCT04024059|BEHAVIORAL|Contingency Management for adherence|Incentives contingent on buprenorphine adherence
41321153|NCT04024059|BEHAVIORAL|Contingency Management for abstinence|Incentives contingent on opiate abstinence
41476768|NCT03908528|OTHER|Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|Placebo with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.
41476769|NCT03328728|DEVICE|Cellular Matrix / A-CP HA Kit|Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
41476770|NCT03328728|DEVICE|Synvisc-One|Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
40803523|NCT01026090|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
40803524|NCT01026090|DRUG|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
40803525|NCT03076216|DEVICE|OncoSil™|The implantation of OncoSil™ under EUS
40803526|NCT04400916|DRUG|Tranexamic acid|A single drop administered topically
40803527|NCT04400916|OTHER|Balanced Salt Solution|A single drop administered topically
40803528|NCT00425698|DRUG|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
40803529|NCT00425698|DRUG|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
40803530|NCT06404021|OTHER|interventional cardiology procedures with proctoring system|Interventional procedures are performed by utilizing a monitoring platform that provides real-time support without engineer in the electrophysiology laboratory
40803531|NCT06404021|OTHER|interventional cardiology procedures with engineer in the electrophysiology laboratory|Biomedical engineers supervise the performance of interventional cardiology procedures in the electrophysiology laboratory.
40803532|NCT05648617|DIETARY_SUPPLEMENT|SUSTINEX Hydrolyzed Whey Protein|Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein. The participants will be asked to add it to = to reach the goal of consuming 30g daily. SUSTINEX Whey Protein Plus is an authorized protein supplement which is manufactured and made in Malaysia by Nova Laboratories Sdn. Bhd. (179832-D). It consists of whey protein isolate and whey protein hydrolyze to achieve sufficient protein requirement.
40803533|NCT05339841|OTHER|Mobile health application|The mHealth app delivers a personalized support program of digital health. Specifically, using ad hoc designed algorithms which uses the data self-reported by the subject and/or collected by the recruiter at baseline, the App delivers periodic messages with advice, motivational reminders and support to improve lifestyle habits and risk factor control.
40803534|NCT03878381|COMBINATION_PRODUCT|Skin Care Cream|The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.
40803535|NCT03878381|DRUG|Placebo|The placebo will be a formula with no active ingredients
41321154|NCT06414538|OTHER|Digital Mind Map Technique|"Students determined as a result of randomization will be given a pre-test before entering the Family Planning course planned according to the academic calendar. The determined topics will be explained to the students using the digital mind map technique. A post-test will be administered to the students 1 week after the end of the subject and a satisfaction survey of the digital mind map technique will be administered. Permanence test will be applied 35 days after the last test application."
41321155|NCT06414538|OTHER|Classic Method Group|After the students in the control group are determined, a pre-test will be conducted before the subject is given training. The same knowledge test will be repeated as a final test after students have received classical course training and completed the subject. Students will be given a retention exam 35 days after the last exam. After the retention test application, the mind map method will be explained to the students in the control group and the determined topics of the course will be explained with the prepared digital mind map technique. In this way, all students participating in the study will also have access to the additional educational materials used.
41321156|NCT04092998|PROCEDURE|Thermocautery circumcision|Histopathological changes from thermocautery circumcision
41321157|NCT04260061|DEVICE|training systems|Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).
41321158|NCT00493974|DRUG|Zileuton|Zyflo tablets, 600 mg, 4 times a day
41321159|NCT00493974|DRUG|Placebo|Placebo 4 x daily
41321160|NCT04965376|PROCEDURE|Glenohumeral joint steroid injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
41476771|NCT05893316|DIAGNOSTIC_TEST|urine sample collection|The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.
41476772|NCT02489591|DEVICE|Oral appliance|Patients will bring their prescribed oral appliance.
40803536|NCT05024916|DIETARY_SUPPLEMENT|Intervention|26 g packets of freeze-dried blueberries (equivalent to 1 cup of fresh blueberries) will be given to participants to be consumed daily. Participants will be asked to consume 1 packet per day for 3 months.
40803537|NCT05024916|DIETARY_SUPPLEMENT|Control|26 g packets of isocaloric carbohydrate-matched powder will be given to participants to be consumed daily. Participants will be asked to consume 1 packet/day for 3 months.
40803538|NCT04347512|DRUG|Hydroxychloroquine and azithromycin treatment arm.|"Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
41476773|NCT02489591|DEVICE|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
40803539|NCT04347512|DRUG|Hydroxychloroquine|"Patient allocated in this arm receive hydroxychloroquine for 5 days. For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~Every patient receives as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
40803540|NCT04347512|DRUG|Control arm|In this arm, no experimental treatment is prescribed. Patients receive IV antibiotics and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
40803541|NCT03620136|DRUG|locoregional analgesia by a block on the adductor channel|"The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test.~Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision."
41321161|NCT04965376|PROCEDURE|Suprascapular nerve block steroid injection|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
41321162|NCT00265967|DRUG|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
41321163|NCT05396313|DEVICE|CRT/ICD|The patients received implantation of CRT/ICD.
41476774|NCT04321798|BEHAVIORAL|Physical Activity|Four group sessions and one individual session delivered over a period of 12 weeks in a primary care setting. Each session includes patient education and support for behaviour change as well as a supervised practical exercise component. The intervention is based upon a combination of self-determination theory and COM-B framework (capability, opportunity, motivation and behaviour) and employs motivational interviewing techniques.
41476775|NCT04667247|DRUG|FoTv|8 capsules three times a day for 14 consecutive days.
41476776|NCT05794724|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
41476777|NCT00363155|DRUG|KRN7000|
41476778|NCT05681312|DRUG|systemic proteolytic enzyme (Tibrolin)|Tibrolin is a fixed dose combination of(Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg)
41476779|NCT05681312|DRUG|Amoxicillin 500mg+metronidazole 500mg+ doliprane 100mg|Amoxicillin is given with metronidazole 500mg 1\*3' Doliprane 1000mg is given 1\*1
41476780|NCT01010022|DRUG|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
41476781|NCT01010022|DRUG|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
41476782|NCT04119999|DEVICE|Mandibular Advancement Device|Mandibular advancement device (MAD) has been a novel method in the management of snoring and OSA. For mild to moderate sleep apnea, MADs have been a boon. A guideline published by American Academy of Sleep Medicine stated that MAD was indicated as first-line therapy for mild OSA and a second-line therapy for moderate to severe OSA
41476783|NCT04119999|DEVICE|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people with OSA
41476784|NCT05814991|DRUG|Nitroglycerin solution|Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage.
41476785|NCT05814991|DEVICE|monitoring of cerebral oxygen saturation|NIRS-based monitoring of rSO2 has unique advantages: directly or indirectly detecting physiological changes and metabolic processes, it is easy to realize, and involves simple procedures.
41476786|NCT00653991|BEHAVIORAL|SOLVE-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
41476787|NCT03054831|DRUG|liquid oxycodone|"The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).~In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU)."
41476788|NCT01066949|BEHAVIORAL|Behavioral self mangement|Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.
41321164|NCT04258046|DRUG|Trametinib tablet|Drug is supplied in 0.5 mg and 2 mg tablets
41476789|NCT01066949|BEHAVIORAL|Support and discussion|Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
41476790|NCT01435226|DRUG|GS-5885|"Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD"
41476791|NCT01435226|DRUG|GS-9451|"Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD"
41476792|NCT01435226|DRUG|tegobuvir|tegobuvir 30 mg BID
41476793|NCT01435226|DRUG|placebo to match tegobuvir|tegobuvir placebo BID
41476794|NCT01435226|DRUG|placebo to match RBV|Ribovirin placebo BID
40803542|NCT03620136|DRUG|locoregional analgesia by periarticular local infiltrations|"A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group.~During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure."
40803543|NCT03465644|DRUG|Tailored antithrombotic strategy|Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months
40803544|NCT03465644|DRUG|Conventional antithrombotic strategy|Clopidogrel + aspirin for 12months
40803545|NCT00353808|DRUG|[S,S]-Reboxetine|
40803546|NCT01170052|DRUG|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
40803547|NCT01170052|DRUG|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
40803548|NCT01170052|DRUG|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
40803549|NCT03303170|DEVICE|Sebacia Microparticles|Topical microparticle suspension
40803550|NCT03303170|DEVICE|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
40803551|NCT05049564|PROCEDURE|keyhole microneurosurgery|microsurgical clipping via keyhole approach
40803552|NCT05049564|PROCEDURE|conventional microneurosurgery|microsurgical clipping via conventional craniotomy
40803553|NCT05049564|PROCEDURE|endovascular coiling|endovascular coiling via femoral approach
41006745|NCT05053672|DEVICE|ReOxy|"ReOxy therapy is a protocol which employs passive (the patient is at rest), short (up to 10 min) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia (up to 5 min). The gas mixtures are supplied to a patient via facial mask on continued measuring of oxygenation status of the patients, lasting about 45 min in total per treatment session.~The hypoxic load will be individually adjusted, based on the results of a preliminary hypoxic test. The patient inhales air with low oxygen content (10-14%) at atmospheric pressure in a continuous mode through a mask withing 10-min.~During the ReOxy - treatment session, the software automatically adjusts the gas mixture switching, based on changes in physiological parameters (blood oxygen saturation and heart rate) in response to hypoxic and hyperoxic impact (biofeedback control)."
41006746|NCT05053672|DEVICE|Sham ReOxy|Placebo treatment with 'sham' ambient air breathing to simulate ReOxy-therapy sessions. Placebo-mode breathing set visually similar to standard breathing set but have a mask with open intake valve. The masks are chosen in a way to provide maximum degree of similarity to reduce the risk of unblinding on the patient-side.
41321165|NCT04706169|DEVICE|Surface Electromyography|SEMG was used to measure the amplitude and onset of five shoulder muscle electrical signal, performing glenohumeral abduction. In this movement, the middle deltoid muscle was selected because it is a main motor. The infraspinatus muscle represented the rotator cuff muscle group. The middle deltoid muscle was selected as the representative of shoulder abduction because it is a main motor in this movement. The trapezius muscle and the serratus anterior muscle were chosen as representative established of the ascending scapular rotator muscles.
41321166|NCT00368498|DRUG|teicoplanin|
41476795|NCT01435226|DRUG|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
41476796|NCT00085306|BIOLOGICAL|recombinant interferon beta|recombinant interferon beta
41476797|NCT03262727|DRUG|BMS-986165|Oral administration of specified dose on specified days
41476798|NCT03262727|DRUG|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
41476799|NCT02667002|PROCEDURE|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
41476800|NCT02667002|PROCEDURE|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
41476801|NCT02667002|OTHER|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
41476802|NCT01008384|DIETARY_SUPPLEMENT|Vitamin D3|50,000 units taken orally once a week for 8 weeks
41476803|NCT04445220|BIOLOGICAL|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
41476804|NCT05694182|OTHER|Other: Oral superfruits supplement|The supplement contain superfruits that are beneficial for human health
40803554|NCT04452305|PROCEDURE|Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting|Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.
40803555|NCT02264379|RADIATION|normal fractionated irradiation|25\*2 Gy (once a day, 5 days a week)
41006747|NCT01438541|DEVICE|Window|Dressing
41321167|NCT03151252|DIAGNOSTIC_TEST|Cytobrush|During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.
41321168|NCT00467714|PROCEDURE|rhinoplasty|COLUMELLA STRUT PLACEMENT
41476805|NCT00168090|DRUG|Blood coagulation Factor VIII and vWF, human|
41006748|NCT02310191|PROCEDURE|Carotid stenting|Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
41476806|NCT05562908|PROCEDURE|Pedicled|Surgical procedure: A prior marking was made on both sides of the LIMA and its veins with bi-polar technique. Hereafter the LIMA and its veins were dissected free with scissor and forceps. Clips were added to all side branches. When the full length of LIMA was obtained, the LIMA and its veins were divided distally by adding clips on the peripheral part of the vessels and proximately dividing by scissor. A vessel-clamp was placed distally and the pedicled LIMA placed in the jugular cavity with a cloth containing papaverine.
40803556|NCT02264379|RADIATION|hypo fractionated irradiation|3\*10 Gy (once a day, 2-3 days a week)
41006749|NCT02517905|DRUG|Bupivacaine liposome|Local administration
41006750|NCT02517905|DRUG|Placebo|Local administration
41006751|NCT03154710|DEVICE|MOOVCARE|web-mediated follow up
41006752|NCT05832346|BEHAVIORAL|Laughter yoga programme|"Intervention for intervention group:~This is a 4-week laughter yoga programme (8 sessions) to help adolescents with intellectual and physical disabilities bring more happiness, laughter and joy to promote their mental health status. As laughter yoga therapy can reduce people's levels of stress, anxiety, depression, loneliness, strengthen the immune system and keep the mind positive. Each laughter yoga session will last for 15 minutes and in total there will be 8 sessions for four weeks (two sessions per week). Each laughter yoga session consists of hand clapping warming-up exercise, followed by deep breathing exercise, childlike playfulness exercise, and then laughter exercise. The intervention group also receives routine care provided by special school."
41006753|NCT06048484|RADIATION|Stereotactic body radiotherapy (SBRT)|SBRT 40 gray (Gy) over 5 fractions
41006754|NCT06048484|DRUG|Zimberelimab|240 mg intravenously (IV)
41006755|NCT06048484|DRUG|Quemliclustat|100 mg IV
41006756|NCT06048484|DRUG|Etrumadenant|150 mg orally
41006757|NCT06048484|DRUG|Modified FOLFIRINOX|"* Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)"
41006758|NCT03343691|DIAGNOSTIC_TEST|Screening Population|Blood samples taken from screening population
41006759|NCT03343691|DIAGNOSTIC_TEST|Breast Cancer Population|Blood samples taken from Breast Cancer population
41006760|NCT04920851|DEVICE|cytokine hemadsorption|to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
41006761|NCT03279588|DIAGNOSTIC_TEST|Bedside Ultrasound|Patients presenting to the Emergency Department with abdominal pain suspected of acute diverticulitis are evaluated with standard care by an Emergency Physician (tutor); at the time the tutor requests an imaging test performed by Radiologist (CT scan or US scan), he notifies another physicians skilled in bedside abdominal US (ultrasonographer), who evaluates the patient and performs the US scan. Ultrasonographer after completation of US and knowing blood samples results fills in a standardized form reporting the diagnostic hypotesis, the need for additional work-up (if deemed necessary), and the disposition of the patient. The standardized form completed by the ultrasonographer will be compared with the actual management of the patient.
41006762|NCT01533610|PROCEDURE|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
41006763|NCT05845788|PROCEDURE|Peripheral nerve block|Ultrasound guided peripheral nerve block
41006764|NCT03268967|BEHAVIORAL|Structured admission procedure|A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
41006765|NCT02487394|PROCEDURE|Exhaled Breath Condensate (EBC)|Collection of EBC condensate
41321169|NCT01283997|OTHER|Placebo|One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
41321170|NCT01283997|DRUG|Minocycline|200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
41006766|NCT00128180|DRUG|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
41006767|NCT00128180|DRUG|Placebo|Placebo
41006768|NCT00200954|DIETARY_SUPPLEMENT|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
41006769|NCT00200954|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
41006770|NCT03521492|DIAGNOSTIC_TEST|serum vitamin D , calcium , parathyroid hormone and albumin level|measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
41006771|NCT02240888|BIOLOGICAL|0,5 mg Prevenar i.m.|
41006772|NCT02240888|BIOLOGICAL|0,5 mg seasonal influenza vaccine i.m.|
41006773|NCT00239057|DRUG|Enteric-Coated Mycophenolate Sodium|
41006774|NCT02456831|OTHER|Experimental Infant Formula 1|method A phytate reduction and 5% protein hydrolysis
41006775|NCT02456831|OTHER|Experimental Infant Formula 2|method A phytate reduction and 10% protein hydrolysis
41006776|NCT02456831|OTHER|Experimental Infant Formula 3|method B phytate reduction and 5% protein hydrolysis
41006777|NCT02456831|OTHER|Active Comparator: Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
41006778|NCT00393939|DRUG|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
40803557|NCT01278238|DRUG|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
40803558|NCT01278238|DEVICE|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
40803559|NCT01278238|OTHER|Placebo|Neither phenylephrine nor lower limb bandaging
40803560|NCT00000487|DRUG|antihypertensive agents|
40803561|NCT00000487|BEHAVIORAL|smoking cessation|
40803562|NCT00000487|BEHAVIORAL|diet, fat-restricted|
40803563|NCT00000487|DRUG|diuretics|
40803564|NCT04579536|OTHER|Light curable resin modified glass ionomer varnish|Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
40803565|NCT04579536|OTHER|Vanish White Varnish|5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
40803566|NCT04994028|OTHER|Conventional treatment|Behavioral and life style modification and dyspnea prevention education i.e. Sitting: Sit upright with back against chair, feet wide apart, leaning forward with arms on bedside table or on knees. Standing: Lean back against wall with feet slightly apart with head and shoulder relaxed. In Bed: Elevate head of the bed, support and elevate arms with pillow. Stairs: Lean forward with on banister when climbing stairs.
40803567|NCT04994028|OTHER|conventional treatment with volume Spirometry and deep breathing|Group B or interventional group was received conventional treatment along with volume Spirometry and deep breathing exercise, total 5 breaths with 3sec inhalational breath hold for each breath at one session per day for volume Spirometry and for deep breathing exercise 10 times with breath hold 2sec at every session for 5 minutes 3 times per week for total duration of two weeks.
40803568|NCT05953597|BEHAVIORAL|Nutrition Education|The intervention will consist of 12 monthly nutrition education sessions catered to people with spinal cord injuries. The curriculum is based on the 2020-2025 Dietary Guidelines for Americans such as consuming recommended amounts of fruits/vegetables, whole grains, etc. The sessions will be approximately 30-60 minutes and will be available in-person.
40803569|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
40803570|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
41006779|NCT00393939|DRUG|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
41006780|NCT04869735|OTHER|Data collection: DTPolio vaccine delivery|"with information about booster vaccination group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS without information about booster vaccination group: no intervention"
41006781|NCT02555995|DEVICE|OCT scan (as yet unnamed)|OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
41006782|NCT04044417|PROCEDURE|currettage|open flap debridement
41006783|NCT04044417|DRUG|curcumin simvastatin paste|Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
41006784|NCT04044417|DRUG|EDTA root conditioning|EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
41006785|NCT04958733|PROCEDURE|Autologous bone grafting|Autologous bone grafting is the excess bone obtained from graft preparation and the coring reamer
41006786|NCT04958733|PROCEDURE|Absence of autologous bone grafting|Donor sites will be left unfilled
40803571|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
40803572|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
40803573|NCT01541904|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
40803574|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
40803575|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
40803576|NCT05786937|OTHER|Commercial ringer´s lactate solution|Placebo
40803577|NCT02402205|BEHAVIORAL|TF-CBT|Web TF-CBT implementation or Web + Live TF-CBT implementation
40803578|NCT01404403|DEVICE|Rapid System|
40803579|NCT02810769|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
40803580|NCT02810769|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
40803581|NCT02810769|DIETARY_SUPPLEMENT|Powdered berry drink|Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
40803582|NCT05662280|DEVICE|Active Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
40803583|NCT05662280|DEVICE|Sham Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
40803584|NCT00332085|DRUG|Chromium Picolinate|
40803585|NCT02507466|BEHAVIORAL|exercise|Variable conditions of stepping practice
40803586|NCT02222688|DRUG|cirmtuzumab|
40803587|NCT04027595|PROCEDURE|Neodymium-doped Yttrium Aluminum Garnet (Nd: YAG) Laser Capsulotomy|A Nd: YAG laser will be used to open the cloudy posterior capsule of the lens to improve central visual acuity.
40803588|NCT02274480|DEVICE|cardiac MRI with DWI|
40803589|NCT05103553|OTHER|Outpatient Clinic|Follow-up in outpatient clinic
41006787|NCT01427205|DRUG|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
41006788|NCT01427205|DRUG|OSI-906|150 mg by mouth twice a day.
41006789|NCT01427205|OTHER|Placebo|Placebo taken by mouth twice daily.
41006790|NCT06000878|OTHER|first aid e-book|interactive first aid e-book interventions
41006791|NCT00287768|DRUG|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
41006792|NCT00287768|DRUG|S-1|S-1 po days 1-28 every 6 weeks
41006793|NCT05044234|DRUG|Cedirogant|Capsule, Oral
41006794|NCT05044234|DRUG|Placebo|Capsule, Oral
41006795|NCT06482047|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
41006796|NCT06482047|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
41321171|NCT00233818|DEVICE|Sirolimus-coated Bx VELOCITY Stent|
40803590|NCT03560960|DRUG|Pramlintide challenge test|Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.
41321172|NCT04861558|DRUG|5Fluorouracil|Injection of 250-850 mg/m2.
41321173|NCT04861558|DRUG|Irinotecan|Injection of 360 mg/m2
41321174|NCT04861558|DRUG|Oxaliplatin|Injection of 460 mg/m2
41321175|NCT01078987|PROCEDURE|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
41476807|NCT05562908|PROCEDURE|Surgical skeletonised|Surgical procedure: The fascia of the LIMA was opened with a scissor. Hereafter the LIMA was dissected free with scissor and forceps, clips on all LIMA side-branches and divided by scissor. When the full length of LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
41476808|NCT05562908|PROCEDURE|Thunderbeat skeletonised|Surgical procedure: With Thunderbeat the fascia of LIMA was opened. The LIMA was dissected free with Thunderbeat including all side-branches. When the full length of the LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
41476809|NCT01961752|DRUG|Saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
41476810|NCT01961752|DRUG|Bupivacaine + saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
41476811|NCT01961752|DRUG|Bupivacaine + triamcinolone acetonide|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
41006797|NCT06482047|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
41006798|NCT00004031|BIOLOGICAL|rituximab|375 mg/m2 IV every 21 days
41006799|NCT00004031|DRUG|CHOP regimen|
41006800|NCT00004031|DRUG|carmustine|
41006801|NCT00004031|DRUG|cyclophosphamide|
41006802|NCT00004031|DRUG|doxorubicin hydrochloride|
41321176|NCT03718702|OTHER|ePain|Electronic pain management programme (ePain)
41321177|NCT05172037|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
41321178|NCT05172037|BIOLOGICAL|Placebo|Saline
41006803|NCT00004031|DRUG|etoposide|
41321179|NCT04465123|DRUG|Spironolactone or hydrochlorothiazide|"Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours."
41006804|NCT00004031|DRUG|prednisone|
41006805|NCT00004031|DRUG|vincristine sulfate|
41006806|NCT00004031|PROCEDURE|bone marrow ablation with stem cell support|
41006807|NCT00004031|PROCEDURE|peripheral blood stem cell transplantation|
41006808|NCT00004031|RADIATION|radiation therapy|
41006809|NCT04990895|OTHER|Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires|A web-based portal that prompts participants to enter tumour-specific ePROs at regular intervals in between clinic visits
41006810|NCT04165096|BIOLOGICAL|Pembrolizumab|IV infusion
41006811|NCT04165096|BIOLOGICAL|Boserolimab|IV infusion
41006812|NCT04165096|BIOLOGICAL|MK-4830|IV infusion
41006813|NCT04165096|DRUG|diphenhydramine|PO
41006814|NCT04165096|DRUG|acetaminophen|PO
41006815|NCT04165096|BIOLOGICAL|MK-0482|IV infusion
41321180|NCT04465123|DRUG|Placebo|"Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours."
41321181|NCT01925638|DRUG|BAY86-9766|
41321182|NCT01925638|DRUG|Ketoconazole|
41321183|NCT04218799|DRUG|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
41321184|NCT02116816|DIETARY_SUPPLEMENT|Polyphenol|Polyphenol
41321185|NCT02483689|DRUG|Pre Incisional Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
41321186|NCT02483689|OTHER|Pre-Incisional Saline|Patient will be given a max of 30 cc injected through a 22g needle to area of incision.
41321187|NCT02483689|DRUG|Post-Closure Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
41321188|NCT02483689|OTHER|Post-Closure Saline|Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
41476812|NCT00731224|DRUG|Rivastigmine transdermal patch|
40803591|NCT06128889|BEHAVIORAL|Supporting Transition and Resilience to Clinical Nursing Education (STRONG) Program|The STRONG program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher. Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics. Overall, the program will be delivered over in one week lasting six hours.
41321189|NCT04564430|DRUG|Catapresan|The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
41321190|NCT04564430|OTHER|Saline|controlgroup receiving saline
41321191|NCT03449121|BEHAVIORAL|Slow breathing techniques|8 sessions of instruction in slow breathing exercises over 12 weeks of study
41321192|NCT04090437|PROCEDURE|Catheter ablation procedure|Catheter ablation procedure using Acutus mapping system
41321193|NCT05631548|DEVICE|iTBS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. Approximately 25% of the nasion-inion distance, or Talairah coordinates X 0 Y+60 Z+60 will be measured.The first session will begin with the acquisition of the resting motor threshold (rMT; lowest stimulus intensity that elicits a visible twitch on 50% of the trials) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last about 3 minutes. Each participant will receive 2 sessions with a 15-20 minute interval between sessions.
41321194|NCT05631548|DEVICE|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 2 sessions with a 15-20 min interval between sessions.
41321195|NCT05786014|BEHAVIORAL|High Intensity Interval Exercise|Patients in the Cycling Intervention arm will undergo two training sessions at the exercise physiology core lab to ensure participants understand the intervention exercise protocol and can safely perform it at home. The Participants will perform high intensity interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will then perform this exercise training at their own homes using recumbent exercise bikes provided by the investigators for that purpose. Study investigators will check in up to weekly with participants and remotely track exercise data and compliance via activity tracker.
41321196|NCT05786014|BEHAVIORAL|Moderate Intensity Walking|Patients will undergo two familiarization training sessions in the exercise physiology core lab to ensure participants understands the walking intervention and can properly gauge intensity. Participants will be asked to walk briskly or jog so they achieve a moderate intensity (70-75% of the maximal heart rate achieved during the VO2peak test). The goal for participants in this condition will be to accumulate at least 150-minutes per week at this heart rate by brisk walking or jogging. Participants will also receive a gift card to be used to purchase a pair of walking shoes to facilitate their engagement.
41321197|NCT00229164|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS)|
41321198|NCT01606293|BEHAVIORAL|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
41321199|NCT05482282|BIOLOGICAL|Recombinant Hepatitis B new Bulk vaccine|"1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma)~1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region."
41321200|NCT05482282|BIOLOGICAL|DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine|3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
41321201|NCT05482282|BIOLOGICAL|Recombinant Hepatitis B vaccine (Registered BioFarma)|1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)
41476813|NCT04156412|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
41476814|NCT05173870|DEVICE|Wearable device|The wearable devices has a biosensor able to daily collect,in a remote way, many biometric measurements such as: blood pressure, blood oxygenation, heart and respiratory rate
41476815|NCT02621801|BEHAVIORAL|Stress Management and Resiliency Training for Residents (SMART-R)|The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
41476816|NCT01764295|DRUG|DWJ1276|
41476817|NCT01764295|DRUG|Olmesartan|
40803592|NCT01621256|DRUG|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
40803593|NCT01621256|DRUG|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
41321202|NCT05482282|BIOLOGICAL|Pentabio|3 doses of Pentabio
41321203|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, modular cemented tibia|modular cemented tibia
41321204|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.|non-modular cemented tibia.
41476818|NCT01764295|DRUG|Rosuvastatin|
41476819|NCT01764295|DRUG|Placebo|
41476820|NCT02938520|DRUG|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
41006816|NCT02880566|PROCEDURE|Scalp block|Full scalp block
41321205|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia|non-modular uncemented tibia
41321206|NCT05057143|DEVICE|Implants|3D printed implants
41321207|NCT05057143|DEVICE|Plates|Titanium plates
41321208|NCT01270100|BEHAVIORAL|Recovery management|
41006817|NCT00411619|DRUG|Everolimus|Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
41152499|NCT04818047|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Videofeedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
41152500|NCT01090232|OTHER|blood samples|
41321209|NCT05987293|DEVICE|Tracheal tube-tongue pressure is measured using a computerized occlusal analysis system based on T-Scan® technique, suitable for multi-point real-time monitoring of intraoral pressure.|A flexible film sensor with a thickness of 0.11mm is placed between the tongue and the tracheal tube to measure the distribution, join force and dynamic changes of pressure at different site of the tongue. Five channels of pressure values will be recorded separately: (Ch1) the tip of the tongue, (Ch2) the middle of the tongue, (Ch3) the base of the tongue, (Ch4) the right side at the base of the tongue, (Ch5) the left side at the base of the tongue. The pressure values at the following points during the operation will be recorded: (t1) after intubation, (t2) highest pressure during patient positioning, (t3) after position fixed, (t4) at the end of surgery, (t5) before extubation.
41321210|NCT01362686|DRUG|Donepezil|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
41152501|NCT01090232|OTHER|blood samples|
41321211|NCT01362686|DRUG|Galantamine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
41321212|NCT01362686|DRUG|Rivastigmine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
41321213|NCT05696262|BEHAVIORAL|6-walking program|Perform 6 minutes of walking exercise 3 times a day, 3 days a week, in a comfortable manner
41321214|NCT00507598|OTHER|No intervention|Correlative study collecting serum and tissue samples
41321215|NCT03798249|OTHER|Gluten|Tereos
41321216|NCT03798249|OTHER|Placebo|Nestlé Health Science
41321217|NCT05137886|DRUG|PD-1 inhibitor|decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.
41321218|NCT03641547|DRUG|M6620|M6620 is an unlicensed small molecule ATR inhibitor which can be used in combination with DNA damaging agents. In pre-clinical models it has substantial activity when given with DNA damaging drugs or ionising radiation. The clinical agent (M6620) is currently studied in a phase I trial in Oxford and other centres in combination with gemcitabine, cisplatin, gemcitabine/cisplatin and cisplatin/etoposide.
41321219|NCT03641547|DRUG|Cisplatin|Cisplatin is a platinum based chemotherapy drug licensed to treat a number of different types of cancer. Cisplatin use is not considered standard practice in Stage A2 \& B, therefore Cisplatin is considered an investigational medicinal product for the purpose of this trial.
41476821|NCT02938520|DRUG|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose."
40803594|NCT02621541|DEVICE|PET/CT|
40803595|NCT04400019|DRUG|Hydroxychloroquine Only Product in Oral Dose Form|The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
40803596|NCT05398159|DEVICE|Trim II|"Eligible subjects will receive 3 bi-weekly treatments (once in 2 weeks) with Trim II hands-free applicator belt according to the study protocol.~Trim II hands-free applicator composed of 4 units applied to the abdominal area, using a single-use belt.~Each treatment duration will be 45-60 minutes. Study duration for each subject is approximately 6 months (including screening, 3 treatments and 2 follow-up visits at 1 and 3 months post last treatment)."
41006818|NCT06072235|BEHAVIORAL|Verbal communication|Verbal communication; by talking and listening
41006819|NCT00003380|DRUG|etoposide|
41152502|NCT06540846|OTHER|No intervention|No intervention since this is an observational study
40803597|NCT06554054|DRUG|GZR18|Oral administered the GZR18 tablet
40803598|NCT01997593|DRUG|intraperitoneal infiltration of ropivacaine|intraperitoneal infiltration of ropivacaine by a special equipment
41152503|NCT04826744|OTHER|Standard dermatology consultation|"with clinical examination, score filling such as SCORAD and DLQI~* Standard Allergy consultation, with clinical examination, research of atopic or allergic personal and familial history~* Allergy skin testing: patch tests with the Standard European Battery and with some products bring by the patient if necessary, skin prick tests with aero allergens. Two reading of the patch tests will be performed, at H48 and H72.~* ophthalmologic consultation with slit lamp examination and OSDI (self questionnaire)"
41476822|NCT02938520|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
40803599|NCT03865498|BEHAVIORAL|Twitter for Hispanic caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support
40803600|NCT03865498|BEHAVIORAL|Twitter for African American caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
40803601|NCT04768205|DEVICE|Kinesio tape|The Kinesio tex tape is a medical tape that had been certified and patented.
40803602|NCT02836470|DRUG|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
40803603|NCT02836470|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
40803604|NCT03962907|DRUG|Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun|5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
40803605|NCT03962907|DRUG|BACTROBAN® Nasal ong|Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
40803606|NCT04802512|PROCEDURE|validity and reability study|validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)
40803607|NCT03139994|OTHER|Diagnostic|OBSERVATIONAL, DIAGNOSTIC PROCEDURES. Young adults with no signs or symptoms of TMD will be assessed. The chewing function, condylar path angles and lateral guidance angles will be recorded. Maximum comfortable and unassisted jaw opening, hemispheric dominance and hemimandibular retrognathia will be considered as secondary pre-specified outcomes. Three-Four years later, both TMJs of each participant presenting signs and/or symptoms will be evaluated according to DC/TMD. Same recordings as baseline will be carried out.
40803608|NCT00143494|PROCEDURE|measurement of abdominal pressure|measurement of abdominal pressure with different volume and saline temperature
40803609|NCT04367155|DRUG|Tranexamic acid injection|hemostatics use
40803610|NCT03702569|DIAGNOSTIC_TEST|Left ventricular global longitudinal strain measure|Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
40803611|NCT00254150|PROCEDURE|Increase oxygen extraction rate|
40803612|NCT02791932|BEHAVIORAL|Exercise|See description above.
40803613|NCT03029182|OTHER|Walking+simulated-altitude|Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
40803614|NCT03029182|BEHAVIORAL|Walking (control)|Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
40803615|NCT03922594|DIAGNOSTIC_TEST|Differential diagnosis for infectious causes of microcephaly|Zika virus, cytomegalovirus, rubella, toxoplasmosis
40803616|NCT01774669|DEVICE|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
40803617|NCT01774669|OTHER|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
40803618|NCT04624919|OTHER|Hot/Dry|Work is completed in a hot/dry environment.
40803619|NCT04624919|OTHER|Warm/Humid|Work is completed in a warm/humid environment
40803620|NCT03939962|DRUG|SHR1210 combined with FOLFOX|"1. SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~2. FOLFOX: Oxaliplatin 85mg/m2 ivgtt 2h d1; 5-fluorouracil 400mg/m2 iv d1; leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2400mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication."
40803621|NCT06169787|PROCEDURE|sentinel lymph node biopsy|sentinel lymph node biopsy
41006820|NCT00003380|DRUG|pegylated liposomal doxorubicin hydrochloride|
40803622|NCT06169787|PROCEDURE|comprehensive pelvic lymphadenectomy|comprehensive pelvic lymphadenectomy
40803623|NCT03323476|OTHER|Discontinuation (or not initiation) of Immunosuppressive Therapy|Discontinuation (or not initiation) of Immunosuppressive Therapy
40803624|NCT03323476|DRUG|Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®|Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
40803625|NCT04199975|DEVICE|Orthoses|Power-Driven or Mechanical Orthoses
40803626|NCT05397041|DRUG|BMB-101|Participants will receive one of several different oral doses of BMB-101 once or twice daily
40803627|NCT05397041|DRUG|Placebo|Matched Placebo
40803628|NCT05700058|OTHER|Dietary protein supplement|3 different doses of super-whey protein supplements will be given in a randomised crossover fashion to participants
40803629|NCT02957747|BEHAVIORAL|SHE|SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
40803630|NCT04883749|BIOLOGICAL|Acalabrutinib|Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)
40803631|NCT02248649|BEHAVIORAL|Structured physical activity|Walking instruction and encouragement
40803632|NCT02248649|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
40803633|NCT00073736|DRUG|MB07133 300mg/m2/day|7-day continuous infusion in 28-day cycles
40803634|NCT00073736|DRUG|MB07133 600 mg/m2/day|7-day continuous infusion in 28-day cycles
40803635|NCT00073736|DRUG|MB07133 1200 mg/m2/day|7-day continuous infusion in 28-day cycles
40803636|NCT00073736|DRUG|MB07133 1800 mg/m2/day|7-day continuous infusion in 28-day cycles
40803637|NCT00073736|DRUG|MB07133 2400 mg/m2/day|7-day continuous infusion in 28-day cycles
40803638|NCT01885884|BEHAVIORAL|Embedded Supportive Care|
40803639|NCT00039780|DRUG|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
40803640|NCT00039780|DRUG|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
40803641|NCT03580278|BIOLOGICAL|ABY-035/AFO2|Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
40803642|NCT03960567|DEVICE|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
40803643|NCT00700882|DRUG|dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
40803644|NCT06036355|DRUG|Oral NMN combined with DC cell vaccine|The whole intervention cycle was treated with NMN (Vital NAD) 600mg/day for at least 50 days. During this period, the first DC cell injection was given on the 10th day, and then another DC cell injection was given at 2 weeks, 4 weeks and 6 weeks after the first injection.
40803645|NCT03186443|DRUG|Pregabalin|Pregabalin was taken 300mg,q 12h for 6 month.
40803646|NCT03186443|DRUG|Gabapentin|Gabapentin was taken 0.4, tid for 6 month.
40803647|NCT04301934|DEVICE|Mona Lisa Touch|Fractional CO2 LASER
40803648|NCT04301934|DRUG|Conjugated estrogen|Current standard treatment for recurrent UTIs in postmenopausal women
40803649|NCT04301934|DRUG|Estradiol|Current standard treatment for recurrent UTIs in postmenopausal women
40803650|NCT04091581|DRUG|Systane Complete|Systane Complete will be instilled and rate of evaporation assessed before and after.
40803651|NCT00489320|DEVICE|Cypher Stent|
40803652|NCT03641781|OTHER|isometric strength training and isokinetic strength training|"Isokinetic strength program included strength training at 5 different velocities from slow to fast. Participants were trained on speed of 30°/sec, 90°/sec, 150°/sec, 210°/sec and 270°/sec. Flexion and extension movements were completed with 5 repetitions at each speed.~Participants of isometric strength training group performed isometric contractions at 30°, 45° and 60° of knee flexion with five repetitions at each angle for both hamstring and quadriceps."
40803653|NCT01951586|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
40803654|NCT01951586|DRUG|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
40803655|NCT01951586|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
40803656|NCT01951586|DRUG|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
40803657|NCT01951586|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
41006821|NCT03113591|PROCEDURE|Minimum invasive total hip arthroplasty|Minimum invasive total hip arthroplasty using the osteo introducer system
41006822|NCT03113591|PROCEDURE|Common total hip arthroplasty|Common total hip arthroplasty using common instruments
41006823|NCT00431171|DRUG|Lithium carbonate|
41006824|NCT03306888|OTHER|Physical Activity Coaching|Physical activity coaching over 4 months
41321220|NCT03641547|DRUG|Capecitabine|Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 \& B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
41321221|NCT03641547|RADIATION|Radiotherapy|Stage A1 uses palliative radiotherapy. Stage B uses definitive radiotherapy.
41321222|NCT03454412|PROCEDURE|Intensive Neurophysiological Rehabilitation|Intensive Neurophysiological Rehabilitation System (INRS) is a combination of different treatment modalities that complement and reinforce each other. It includes spinal manipulative therapy, physical therapy, occupational therapy, joints mobilization techniques, special massage therapy, mechanotherapy, computer games therapy and other treatments with daily duration up to 4 hours.
41321223|NCT00627835|DRUG|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
41006825|NCT04520945|BIOLOGICAL|Chondrogen|Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid
41006826|NCT04520945|BIOLOGICAL|Placebo|Consist of saline and hyaluronic acid
41321224|NCT00627835|DRUG|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
41006827|NCT03438526|DRUG|Melatonin (Circadin ®)|4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
41321225|NCT00627835|DRUG|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
41321226|NCT00627835|DRUG|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
41321227|NCT00627835|DRUG|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
41321228|NCT05317013|DRUG|CBD|CBD
41321229|NCT05317013|OTHER|Placebo|Placebo
41321230|NCT01611350|OTHER|RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay|We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
41321231|NCT01611350|OTHER|RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel|Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
41321232|NCT01611350|OTHER|RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves|We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
41006828|NCT03438526|DRUG|Placebo|Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
41006829|NCT01296958|DRUG|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
41152504|NCT05760885|BEHAVIORAL|Balance training with sensory augmentation|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.
41152505|NCT05760885|BEHAVIORAL|Balance training|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.
41006830|NCT01296958|BEHAVIORAL|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
41006831|NCT04863976|OTHER|Dynamic stretching|Dynamic movements of the joints controlled by the quadriceps muscle (hip and knee)
41152506|NCT05043298|DRUG|IBI 360 Injection|IBI 360 dose level of escalation IV Q3W Day 1
41152507|NCT05043298|DRUG|IBI 360 Injection Sintilimab|IBI 360 dose level of escalation IV Q3W Day 1 Sintilimab 200mg IV Q3W Day 1
41152508|NCT05939050|DEVICE|Powered toothbrush|Oral-B Powered toothbrush
41321233|NCT02261883|DRUG|IV Remodulin|Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
41321234|NCT02261883|DRUG|Placebo|Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).
41321235|NCT05750420|OTHER|There was no intervention, the study was a cross-sectional observational study|Questionnaires for measuring self-care, anxiety, depression, emotinal distress and quality of live were administered to patients with chronic cardiovascular disease
41321236|NCT02491697|BIOLOGICAL|DC-CIK Immunotherapy|DC-CIK cells are used to treat advanced breast cancer with capecitabine.
41321237|NCT02491697|DRUG|Capecitabine Monotherapy|All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
41321238|NCT01188096|DRUG|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
41321239|NCT03111017|OTHER|Exercise Training|HFpEF patients randomized to either 16 weeks of exercise training or attention control group.
41321240|NCT02769351|DEVICE|periph. minimal invasive ultrafiltration|ultrafiltration via a peripheral single-needle
41321241|NCT02882737|DRUG|Glucagon before exercise|
41006832|NCT04863976|OTHER|Passive stretching|passive stretching of the quadriceps muscle
41006833|NCT04863976|OTHER|Self-stretching|Self-stretching of the quadriceps muscle
41006834|NCT05660928|OTHER|Multidimensional intervention|Multidimensional intervention, with mutidisciplinary approach.
41321242|NCT02882737|DRUG|Glucagon after exercise|
41321243|NCT02882737|DRUG|Glucagon after resting|
41321244|NCT03497442|DRUG|Brimonidine Tartrate|Topical brimonidine tartrate will be applied to one half of each participant's face. A randomization process will be used to determine which side of the face each participant will apply treatment to. The untreated side of the face will receive a placebo vehicle. Patient and clinician will be blinded to treatment side.
41006835|NCT03277846|DEVICE|Nexalin Based Trans-Cranial Electrical Stimulation|The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
41006836|NCT02569671|DEVICE|Straumann Bone Level Tapered Implant - Immediate Placement|Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
41006837|NCT02569671|DEVICE|Straumann Bone Level Tapered Implant - Delayed Placement|Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
41006838|NCT02872922|OTHER|Low intensity therapeutic ultrasound|The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
41152509|NCT04953793|BEHAVIORAL|TAY SUCCESS|TAY SUCCESS stands for transition age youth supported, comprehensive cognitive enhancement and social skills. The cognitive-behavioral intervention teaches a number of strategies for executive functioning, social cognitive functioning and social communication.
41152510|NCT04953793|OTHER|Usual Care|Usual care involved the typical vocational supportive education program delivered in the educational setting
41321245|NCT03497442|DRUG|Placebo Vehicle Gel|Vehicle Gel
41321246|NCT03180827|PROCEDURE|ovarian tissue biopsy|ovarian tissue biopsy during general anesthesia
41321247|NCT04585451|DIAGNOSTIC_TEST|ALGOS System|A Quantitative Electroencephalography (QEEG) based pain biomarker assessment that scales with patient reported Numeric Rating Scale (NRS)
41321248|NCT06061042|BEHAVIORAL|Early time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM
41321249|NCT06061042|BEHAVIORAL|Late time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM
41321250|NCT04273542|OTHER|liquid biopsy|Blood sample collection during follow-up of the three cohorts of patients
41321251|NCT04437173|DEVICE|Virtual Reality Headset Distraction|Patient wears a virtual reality headset during interventional pain procedure
41321252|NCT05923450|PROCEDURE|Colorectal Resection|Radical resection of colorectal cancer
41321253|NCT05397483|BEHAVIORAL|Legal Education plus Trauma-informed Therapy (LETiT)|Group-1: Experimental (n=75 participants) will receive the LETiT which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
41321254|NCT05397483|BEHAVIORAL|Intervention As Usual (IAU)|Group-2: Controlled (n=75 participants) will receive the IAU which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
41321255|NCT05181904|OTHER|Gastric ultrasound|Assessment of gastric content with gastric ultrasound monitoring: gastric ultrasounds will be performed in eligible children, when enteral feeding is stopped for planned extubation, and repeated 6 hours after, at extubation and every hour between feeding interruption and extubation. The stomach will be classified as empty or full according to PERLAS criteria. In total, 8 gastric ultrasounds will be performed over a period of 12 hours.
41321256|NCT00236522|DRUG|levofloxacin|
41321257|NCT05289206|OTHER|Vaccine - ChAdOx1-S/nCoV-19 [recombinant]|ChAdOx1-S/nCoV-19 \[recombinant\] - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
41321258|NCT06047899|DIETARY_SUPPLEMENT|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
41321259|NCT06047899|OTHER|Placebo|mannitol formulated for oral administration (capsules)
41321260|NCT04154696|PROCEDURE|Liver transplantation of a graft after assessment by normothermic perfusion|Liver transplantation of a graft after assessment by normothermic perfusion
41321261|NCT03299738|BIOLOGICAL|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
41321262|NCT03789890|DRUG|BAY1902607|BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.
41321263|NCT03789890|DRUG|Itraconazole|Itraconazole is administered at a dose of 200 mg once a day (oral solution of 10 mg mL-1) on Day 1 to Day 14 of study period 2.
41321264|NCT03623425|DRUG|68Ga-PSMA-11 PET|a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
41321265|NCT03623425|DRUG|18F-FCH PET|a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
41321266|NCT01560221|BEHAVIORAL|Therapeutic Workplace|Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
41321267|NCT01560221|DRUG|Methadone|Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
41321268|NCT01560221|DRUG|Buprenorphine|Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
41006839|NCT03766100|BEHAVIORAL|Cognitive behavioural therapy (CBT-i)|CBT-i aims to alter behaviours that sustain or add to insomnia and correct cognitions that drive these behaviours. The behavioural components of CBT-i are stimulus control (SC) and Sleep Restriction Therapy (SRT). SC works through the extinction of a conditioned arousal that emerges when bed and bedroom have become associated with wakefulness. With SRT time in bed is reduced to build up sleep pressure. When wakefulness is decreased, time in bed is gradually increased until optimal sleep is attained. With the cognitive component, insomnia is treated by identifying and changing unhelpful or inaccurate thinking regarding sleep and distressing emotional responses to insomnia. The last component of CBT-i aims to reduce hyperarousal with relaxation techniques, scheduled worry time, creating a time to unwind, and employing cognitive therapy strategies.
41006840|NCT03887091|OTHER|Postwire|Postwire© is a web-based, video platform
41321269|NCT02104999|DEVICE|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
41321270|NCT03662633|DIAGNOSTIC_TEST|Breast cancer group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
41476823|NCT02938520|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
41006841|NCT01304485|DRUG|Sodium Acetate C11|PET Imaging with Sodium Acetate C11
41152511|NCT04389944|OTHER|convalescent plasma application to SARS-CoV-2 infected patients|In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up.
41152512|NCT02176018|DRUG|Dextromethorphan and quinidine|
41152513|NCT02176018|DRUG|Placebo|
41152514|NCT00306735|DRUG|Palonosetron|
41476824|NCT02938520|DRUG|ABC/DTG/3TC STR - Tablet|"It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate."
41476825|NCT02938520|DRUG|DTG Tablet|"It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate."
41476826|NCT03690882|OTHER|systematic review of medical imaging|
41476827|NCT03068650|BIOLOGICAL|rindopepimut|Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
41476828|NCT05189314|PROCEDURE|Thyroidectomy|Surgical Resection of thyroid nodules
41476829|NCT05189314|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation of thyroid nodules
41476830|NCT03235869|DRUG|Durvalumab|Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
41476831|NCT03235869|RADIATION|Radiation Therapy|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)
41476832|NCT01188265|DRUG|Valproate|
41476833|NCT01188265|DRUG|Dextromethorphan 60 mg per day|VPA plus dextromethorphan 60 mg per day
41476834|NCT01188265|DRUG|Placebo|VPA plus placebo
40803658|NCT03716778|OTHER|Eccentric rehabilitation sessions|"ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode."
40803659|NCT01891396|DEVICE|Hyaluronic Acid and TH (Cingal®)|Injection into knee
40803660|NCT01891396|DEVICE|Hyaluronic Acid (Monovisc®)|Injection into knee
40803661|NCT01891396|DEVICE|Saline|Saline placebo packaged to look identical to comparator syringes. Injection into knee.
41006842|NCT05681429|DRUG|Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib|To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
41006843|NCT00020111|DRUG|arsenic trioxide|
41006844|NCT05065125|DEVICE|digital single-operator cholangioscopy|"1. Duodenoscope passes through esophagus and stomach to the papilla of Vater~2. SpyScope DS Catheter passes through the duodenoscope and into common bile duct~3. After direct visualization of anastomosis site stricture, guidewire is passed through SpyScope DS Catheter above the stricture site."
41006845|NCT06324474|DRUG|Hyaluronic acid|Gengigel syringe containing 1ml of 0.8% HA
41152515|NCT03433378|DRUG|Tretinoin cream, 0.05%|Tretinoin cream, 0.05%
41152516|NCT03433378|DRUG|RETIN-A® (tretinoin) cream, 0.05%|RETIN-A® (tretinoin) cream, 0.05%
41152517|NCT03433378|DRUG|Vehicle of the test product|Vehicle of the test product
41476835|NCT01188265|DRUG|Dextromethorphan 30 mg|VPA \& Dextromethorphan 30 mg per day
40803662|NCT05749991|DEVICE|Dryshield|"DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)"
40803663|NCT05749991|DEVICE|Cotton roll isolation|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
41006846|NCT06324474|BEHAVIORAL|scaling and root planning|scaling and root planning using ultrasonic scaler
41006847|NCT05498948|DIETARY_SUPPLEMENT|Probiotic mixture|orally take .
41006848|NCT01621399|DRUG|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
41006849|NCT01621399|DRUG|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
41152518|NCT05519579|DRUG|Methotrexate|Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
41152519|NCT05519579|DRUG|Blinatumomab|Blinatumomab 28ug/day continuous infusion for 4 weeks
41476836|NCT04786977|OTHER|No Intervention, Observational Study|No Intervention
41476837|NCT05235659|BEHAVIORAL|Basic modules|Caregivers will only have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child.
41476838|NCT05235659|BEHAVIORAL|"Basic modules and experimental condition My coach"|Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Professional support of the caregiver will be provided. Caregivers will receive one phone call (50 minutes) to support processing of information from module 1 and 2. Finally, they will receive text messages or emails with the core message of the modules.
40803664|NCT00596557|DRUG|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
41006850|NCT04269603|DEVICE|Take blood (TA-8V (Stago®)|Healthy volunteers will have 3 blood samples at M0, M3 and M6.
41006851|NCT06323642|DIETARY_SUPPLEMENT|probiotic containing Lactobacillus rhamnosus GG.|probiotic containing Lactobacillus rhamnosus GG will be given daily for 3 days
41006852|NCT06323642|OTHER|placebo|milk as placebo
41006853|NCT02072291|DRUG|Nifedipine|PO Nifedipine 5mg single dose
41006854|NCT01985737|OTHER|Sample collection|
41006855|NCT04310761|PROCEDURE|one single blastocyst transfer, both fresh and warmed|Ultrasound guided transvaginal embryo transfer.
41006856|NCT03078946|DRUG|Dexmedetomidine Hydrochloride|30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
41006857|NCT03078946|DRUG|Morphine and Midazolam|30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
41006858|NCT05424471|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN intervention lesson is taught to participants previously randomized into the FSN intervention group during the PECO 1 study. Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the 1 - 45 minute lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
41006859|NCT05424471|OTHER|Control Group - Vehicle Safety|The control (vehicle safety) lesson is taught to participants previously randomized into the control group during the PECO 1 study. Control group participants receive 1 - 30 minute lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
41152520|NCT02282917|DRUG|AR-42|AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
41152521|NCT01993342|OTHER|arthrocentesis|The made a diagnostic arthrocentesis to all patient we included
41321271|NCT03662633|DIAGNOSTIC_TEST|Benign breast tumor group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
41321272|NCT02226978|DRUG|Tipranavir|
41321273|NCT02226978|DRUG|Ritonavir|
41321274|NCT02226978|DRUG|Valaciclovir|
41321275|NCT01788982|DRUG|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
41321276|NCT01788982|DRUG|Placebo|
41321277|NCT00609453|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
41321278|NCT03083509|OTHER|Resistance exercise weight training session|A resistance exercise session was performed. Following a warm-up that consisted of five-minutes cycling at a self-selected intensity, as well as three progressive lifts at 50, 75, and 90% 6 rep max (RM), participants performed four sets of six repetitions at 100% of 6RM (as determined by the maximal weight lifted during the maximal strength assessment) of the following lifts; back squat, front squat, good mornings, and Bulgarian split-squat. Two minutes rest was afforded between sets and exercises.
41321279|NCT03083509|OTHER|High-Intensity stochastic cycling session|A high-intensity stochastic cycling session was performed. The cycling protocol was performed using a magnetically-braked cycle ergometer (Velotron, RacerMate). Following a 10 minute standardised warm-up including 3 × 3s sprints, participants completed a simulated road-race, consisting of sprints of varied length, differing work to rest ratios and short time-trials.
41321280|NCT03083509|OTHER|Simulated Team sport protocol|A simulated team sport protocol was performed. Participants performed a standardised warm-up consisting of performing three laps of the circuit jogging, and three laps at 50, 75, and 90% of perceived maximal speed. Participants were then afforded five minutes to perform self-selected stretching prior to commencing the session. Participants performed two sets of 45 minutes of the simulated team sport protocol, separated by 15 minutes rest. Each 45 minute period consisted of a one minute circuit repeated 45 times that replicates typical movement patterns observed during team sports and includes walking, jogging, jumping, sprinting, agility, and decelerations. Each circuit was initiated on the minute, therefore enabling participants to rest following the completion of each circuit. Pilot testing showed participants completes each circuit in approximately 48-55 seconds (sec) therefore enabling 5-12sec rest after each circuit.
41476839|NCT05235659|BEHAVIORAL|"Basic modules and experimental module Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
41476840|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Who am I and where do I belong? and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 5. Finally, they will receive text messages or emails with the core message of the modules."
41006860|NCT03906669|DRUG|Letrozole|PO daily for 14 days
41152522|NCT01993342|OTHER|ultrasonography of the knee|We explored the affected knee with an ultrasound explanation in order to describe inflammatory changes based on standard examination.
41321281|NCT00049218|BIOLOGICAL|Autologous dendritic cell-adenovirus p53 vaccine|
41321282|NCT00049218|DRUG|Carboplatin|
40803665|NCT01225133|OTHER|Complex Ayurvedic Treatment|In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
40803666|NCT01225133|OTHER|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
40803667|NCT01650649|DRUG|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
40803668|NCT01650649|DRUG|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
40803669|NCT00706108|BEHAVIORAL|Observational study|Observational (descriptive) study of technical and non-technical performance
41321283|NCT00049218|DRUG|Etoposide|
41321284|NCT00852306|PROCEDURE|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
41476841|NCT05235659|BEHAVIORAL|"Basic modules and experimental module You are safe here"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
41476842|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 4. Finally, they will receive text messages or emails with the core message of the modules."
41476843|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
40803670|NCT00177294|DRUG|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
41321285|NCT03822871|DRUG|CTT1403|Escalating doses of 0.75 GBq - 9.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
40803671|NCT00177294|BEHAVIORAL|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
40803672|NCT00177294|BEHAVIORAL|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
40803673|NCT00196027|DEVICE|PFX Closure System|
40803674|NCT00582543|OTHER|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
40803675|NCT04624867|DRUG|HP-1050 Patch|Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
40803676|NCT05245110|BEHAVIORAL|tele-exercise training|a 12-week tele-exercise training program
41321286|NCT03822871|DRUG|CTT1057|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
40803677|NCT03660865|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary eye will receive Light adjustable lens with Light delivery Device treatments
40803678|NCT03660865|DEVICE|Control IOL|Fellow eye will receive control IOL
40803679|NCT02448992|RADIATION|hippocampal-sparing WBRT|
40803680|NCT00434447|DRUG|Zoledronic acid|
41321287|NCT03822871|DRUG|68Ga-PSMA-11|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
41476844|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 4, and 5. Finally, they will receive text messages or emails with the core message of the modules."
41476845|NCT05235659|BEHAVIORAL|"Basic modules and experimental module Watch out!"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior."
41476846|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 3. Finally, they will receive text messages or emails with the core message of the modules."
41476847|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
41152523|NCT05428839|DIAGNOSTIC_TEST|Pharyngeal width measurement|A simple, non-invasive measurement of the pharyngeal width inside each subjects mouth
41321288|NCT02816125|DIETARY_SUPPLEMENT|omega-3 fatty acid|SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
41321289|NCT00839423|DRUG|Placebo|capsules, daily, orally
41321290|NCT00839423|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
41321291|NCT00839423|DRUG|Venlafaxine XL|capsules, daily, orally
41321292|NCT05192954|DEVICE|LigaSureTM vessel sealing device|Device will be used to clamp, cauterize, seal, and transect tissue during vaginal hysterectomy.
41321293|NCT04627012|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
41321294|NCT04627012|DRUG|Opdivo|3mg/mg intravenously every 3 weeks
41321295|NCT04627012|DRUG|Camrelizumab|200mg intravenously every 3 weeks
41321296|NCT04627012|DRUG|Keytruda|200mg intravenously every 3 weeks
40803681|NCT04571424|DRUG|BIIB133 (Dapirolizumab pegol)|Administered as specified in the treatment arm
41321297|NCT04627012|DRUG|Toripalimab|240mg intravenously every 3 weeks
41321298|NCT04627012|DRUG|Sintilimab|200mg intravenously every 3 weeks
41321299|NCT04627012|DRUG|Tislelizumab|200mg intravenously every 3 weeks
41321300|NCT04488848|OTHER|bolus glucose|bolus Glucose
40803682|NCT04571424|DRUG|Placebo|Administered as specified in the treatment arm
40803683|NCT02685566|DEVICE|FFDM Plus DBT|FujiFilm Aspire Cristalle System
40803684|NCT02685566|DEVICE|FFDM|FujiFilm Aspire Cristalle System
40803685|NCT03770208|DRUG|Intervention: Lidocaine|IV Lidocaine bolus plus infusion. Weight based.
40803686|NCT03770208|DRUG|Control: Standard Care + Placebo|Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
41152524|NCT05984147|DRUG|AUR108|3 Days dosing, and 4 days no dose in a week
41321301|NCT04488848|OTHER|continuous clucose|continuous clucose
41321302|NCT02667548|PROCEDURE|PCI|percutaneous coronary intervention
41321303|NCT04496947|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~* Elicitation of the Relaxation Response (RR) through mind-body techniques;~* Discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and~* Coping strategies and adaptive perspective-taking to promote positive well-being."
41321304|NCT00178464|DRUG|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
41321305|NCT01148563|DEVICE|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
41321306|NCT06118164|BEHAVIORAL|pursing- lip breathing combined with aerobic walking exercise|pursing- lip breathing combined with aerobic walking exercise
41321307|NCT06118164|BEHAVIORAL|pursing- lip breathing|pursing- lip breathing
41321308|NCT06118164|BEHAVIORAL|aerobic walking exercise|aerobic walking exercise
41006861|NCT03906669|DRUG|Letrozole and Prometrium|PO daily for 14 days
41006862|NCT03906669|DRUG|Tamoxifen and Prometrium|PO daily for 14 days
40803687|NCT05420181|OTHER|Short 10hr fast|Participants will fast from 11pm the night before the study day
40803688|NCT05420181|OTHER|Long 16h fast|Participants will fast from 5pm the night before the study day
40803689|NCT04632238|BEHAVIORAL|Metrics-driven quality improvement (MDQI)|The intervention broadly consists of training and coaching to clinic staff and leadership on 1) clinical quality measure monitoring; 2) clinical practice process change management; and 3) use of tools for shared decision making and patient treatment progress monitoring.
40803690|NCT06196658|DRUG|anti-EX02 CAR T cells|"Conditioning chemotherapy:~• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion~Investigational Product:~• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator~• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg"
40803691|NCT03073317|DIAGNOSTIC_TEST|FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)|Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
40803692|NCT04715828|OTHER|Cryopreserved semen|sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).
40803693|NCT04715828|OTHER|Acute and low irradiation|sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy
40803694|NCT04715828|OTHER|Long and low irradiation|sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.
40803695|NCT04715828|OTHER|Long and medium irradiation|sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
41152525|NCT02842125|DRUG|Ad-P53|Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
41152526|NCT02842125|DRUG|Xeloda|Oral metronomic chemotherapeutic agent
41152527|NCT02842125|DRUG|Keytruda|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
41321309|NCT02245451|DRUG|Tipranavir|
41321310|NCT02245451|DRUG|Ritonavir|
41321311|NCT02245451|DRUG|Methadone|
41321312|NCT01671956|BIOLOGICAL|Bertilimumab|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
40803696|NCT01003236|DRUG|placebo|140 mg placebo tablets, 3 times per day for 3 months
40803697|NCT01003236|DRUG|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
40803698|NCT06440122|DIAGNOSTIC_TEST|FDG-PET Scan|Positive for activated brown adipose tissue (SUVmax \>1.5) FDG-PET scan
40803699|NCT02452216|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
40803700|NCT02452216|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
41006863|NCT05493995|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
41006864|NCT05493995|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
41006865|NCT05493995|DRUG|Nab paclitaxel|125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.
41006866|NCT05493995|DRUG|Gemcitabine|1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.
41006867|NCT06452836|OTHER|Green color exposure|Patients will wear green colored glasses before and during the surgery.
41006868|NCT06452836|OTHER|Red color exposure|Patients will wear red colored glasses before and during the surgery.
41006869|NCT06452836|OTHER|Blue color exposure|Patients will wear blue colored glasses before and during the surgery.
41152528|NCT02842125|DRUG|Opdivo|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
41152529|NCT04639076|BEHAVIORAL|Behavioral Weight Loss Program|The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and progressive weekly increases of physical activity (PA). Supporting behavioral lessons based on materials used in the Diabetes Prevention Program (DPP) will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial. Participants will receive digital tools including a study smart phone app that incorporates diet self-monitoring, tracking of behavioral goals, behavioral lessons and resources, and integration of data from a study-provided Wi-Fi enabled scale and physical activity tracker.
41321313|NCT01671956|BIOLOGICAL|Placebo|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
41321314|NCT05378022|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
41006870|NCT06452836|OTHER|control|Patients will wear translucent glasses before and during the surgery.
41006871|NCT04690127|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
41006872|NCT02397356|DRUG|Ketamine first AB|Nebulised ketamine 1mg/kg
41006873|NCT02397356|DRUG|Placebo first BA|Nebulised saline 1-2ml
41006874|NCT06121271|DRUG|Lu-177 DOTATATE (Lutathera®)|Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
41321315|NCT05378022|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
41321316|NCT04577183|DEVICE|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
41321317|NCT00102557|DRUG|Hydroxychloroquine|
41321318|NCT02993458|OTHER|DASH diet|DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat
41321319|NCT02993458|OTHER|Low Na diet|Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
41476848|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 5. Finally, they will receive text messages or emails with the core message of the modules."
41476849|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and You are safe here"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
41321320|NCT02993458|OTHER|High Na diet|Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.
41321321|NCT02993458|OTHER|Usual Diet|The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
41321322|NCT00074802|DRUG|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
41321323|NCT00074802|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
41321324|NCT03723005|DEVICE|Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
41321325|NCT03723005|DEVICE|Standard-of-Care|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
40803701|NCT02452216|PROCEDURE|Magnetic Resonance Imaging|All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
41006875|NCT00178945|DRUG|Botulinum Toxin Type A|
41006876|NCT04698161|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
41006877|NCT04698161|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
41006878|NCT04698161|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
41006879|NCT05862064|DRUG|epirubicin,cyclophosphamide,paclitaxel,Carrelizumab|Conventional chemotherapy in combination with carrelizumab
41006880|NCT05862064|DRUG|epirubicin,cyclophosphamide,paclitaxel|Conventional chemotherapy
41006881|NCT01932216|PROCEDURE|Cholecystectomy|Gallbladder removal
41321326|NCT01292044|OTHER|Elastography|A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
41321327|NCT04799353|DRUG|Budigalimab|Subcutaneous (SC)
41321328|NCT04799353|DRUG|Placebo|Subcutaneous (SC)
41321329|NCT04799353|DRUG|Budigalimab|Intravenous (IV)
41321330|NCT04799353|DRUG|Placebo|Intravenous (IV)
41476850|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 4. Finally, they will receive text messages or emails with the core message of the modules."
40803702|NCT01518686|DEVICE|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|"We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)"
40803703|NCT02649959|DRUG|CM-AT|Single unit does powder of active substance (CM-AT) administered 3 times per day
41476851|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
41006882|NCT05625477|BIOLOGICAL|TNM002 (low dose)|Single dose of TNM002 administered by intramuscular injection
41006883|NCT05625477|BIOLOGICAL|TNM002 (medium dose)|Single dose of TNM002 administered by intramuscular injection
41006884|NCT05625477|BIOLOGICAL|TNM002 (high dose)|Single dose of TNM002 administered by intramuscular injection
41321331|NCT02765178|OTHER|Children's Motivation Scale|A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.
41321332|NCT02765178|OTHER|Yale Global Tic Severity Scale (YGTSS)|Clinician administered questionnaire given to Tourette patients. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
41321333|NCT02765178|OTHER|Studies Depression Scale for Children (CES-DC)|"Clinician administered questionnaire given to Tourette patients. Consisting of 20 items, respondents are asked to indicate how strongly they have felt a certain way during the past week using a Likert-type scale that ranges from not at all to a lot. Only two items on the questionnaire relate specifically to sleep or fatigue. CES-DC is a validated score for assessing depression in children and adolescents"
41321334|NCT02765178|OTHER|Gilles de la Tourette Syndrome Quality Of Life scale|Clinician administered questionnaire given to Tourette patients. Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL) is a recently validated score for the assessment of quality of life in patients with Tourette syndrome. Consisting of a 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive).
41321335|NCT02765178|OTHER|Demographic Data|Data will be collected including: age, age at disease onset, gender, current medication regimen and presence of co-morbidities (like a diagnosis of ADHD, OCD, depression or insomnia).
41321336|NCT03716453|PROCEDURE|Standard protocol|Give narcotic according to vital signs
41321337|NCT03716453|PROCEDURE|ANI protocol|"ANI score 50-70 indicates optimal narcotic effect. ANI score \> 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score \< 50 indicates inadequate narcotic and narcotic should be given."
41321338|NCT03356392|OTHER|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
41321339|NCT02236741|DRUG|Mirapexin® (Sifrol®)|
41321340|NCT05520749|DRUG|Luspatercept|Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS
41321341|NCT05649644|PROCEDURE|Selective Trunk Block (SeTB)|Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. After local anesthetic (LA) infiltration (1-2 ml lidocaine 1%), the nerve block needle will be inserted and placed within the interscalene groove. Then, a 7 ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. After that, the tip will be redirected lateral to the middle trunk. A further 8 ml of the LA mixture will be injected after which the nerve block needle will be completely withdrawn. The transducer will then be manipulated to a sub-omohyoid position. After LA infiltration, the nerve block needle is inserted in-plane until the needle tip is positioned close to and lateral to (9-12 o'clock position) the inferior trunk. A 10 ml of the LA mixture is injected in small aliquots and the needle will be removed after the injection.
41006885|NCT05625477|BIOLOGICAL|HTIG|Single dose of HTIG administered by intramuscular injection
41006886|NCT05625477|BIOLOGICAL|Placebo|Single dose of placebo administered by intramuscular injection
41006887|NCT04176003|OTHER|Qualitative interview|Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies
41006888|NCT04176003|OTHER|Member checking|Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.
40803706|NCT04593186|PROCEDURE|Trans-oral magnifying endoscopy with NBI|"Endoscopic procedures would be performed by endoscopists with expertise on performing magnifying NBI endoscopy. Topical local anaesthetic will be applied to the oropharynx and nasopharynx. In addition, intravenous sedation by use of Midazolam and Fentanyl would be given. Endoscopes with magnification and NBI function would be used (GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached to the tip of the endoscope for better focal length adjustment.~Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall will be systematically examined with white light and NBI. Target suspicious areas would be examined by use of magnification with the power up to 80X. Biopsy would be taken if suspicious lesion is identified during the procedure."
40803707|NCT06419556|PROCEDURE|Cervical Plexus Block|"The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. the probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt."
41321342|NCT05649644|PROCEDURE|Supraclavicular Brachial Plexus Block (SC BPB)|Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. Patient will receive a subcutaneous infiltration with 1-2 ml of 0.9% normal saline (NS) at the superior and middle trunk level after which the needle will be completely withdrawn. Then, a local anesthetic (LA) infiltration (1-2 ml lidocaine 1%) will then be performed at the supraclavicular fossa and the nerve block will be inserted in-plane to place the needle tip at the corner pocket. After that, 15-ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. Once completed, the needle tip is gently withdrawn and redirected into the cluster formed by the divisions of brachial plexus. Then, the remaining 10-ml of the same LA mixture will be injected in small aliquots and the needle will be removed after the injection.
41321343|NCT01313364|DEVICE|"25G x 1 Needle Autoinjector"|All subjects will self-administer 4 IM injections using single-use autoinjectors.
41321344|NCT04611178|DEVICE|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
41321345|NCT02052934|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.
41321346|NCT02052934|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5b cohort receive 3 doses of 25 mcg.
40803708|NCT01374321|DRUG|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
41321347|NCT05138237|PROCEDURE|endoscopy or surgery|"we choose the proper intervention surgery or endoscopy for management of the indeterminate common bile duct stricture according to its nature benign or malignant"
41321348|NCT02878512|PROCEDURE|PCNL under General Anesthesia|Patients undergoing percutaneous Nephrolithotomy received General anesthesia.
41321349|NCT02878512|PROCEDURE|Segmental Epidural Anesthesia|Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
41321350|NCT04923919|DRUG|Anti-CLL1 CART cells|In this study, patients with acute myeloid leukemia were treated with autologous anti-CLL1 CAR T cells by a single, intravenous infusion.Blood and bone marrow were collected before and 12 months after infusion to detect the number and activity of CAR T cells, and to evaluate the efficacy of CAR T cells.
41321351|NCT01184846|BIOLOGICAL|10% liquid formulation of human immunoglobulin|
41321352|NCT01804036|DRUG|Zolpidem|Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
41321353|NCT01804036|BEHAVIORAL|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
41321354|NCT05911464|DRUG|HS-10386|Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
41321355|NCT05867199|BEHAVIORAL|Motor Imagery and Action Observation Training|The training consists of watching videos of actions performed with the hand. At the end of the video the subject is subsequently asked to imagine performing the action just seen
41321356|NCT05436886|DRUG|Neurogabin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
41321357|NCT05436886|DRUG|Parketin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
40803709|NCT01374321|DRUG|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
40803710|NCT04097275|OTHER|Skin biopsy|The biopsy will be performed by means of punch biopsy (diameter 2.5 mm) under local anesthesia on a forearm. The skin biopsy will be transferred to sterile cell culture Dulbecco's Modified Eagle Medium (DMEM) 1% Penicillin 1% Streptomycin 1% Gentamycin medium 10% FBS.
41321358|NCT00518232|DRUG|OROS-methylphenidate|
41321359|NCT02060318|DRUG|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
41321360|NCT03933514|OTHER|Plaque control|Children were instructed about the hygiene procedures
41321361|NCT00106821|DRUG|Tiotropium Bromide Inhalation Powder|
40803711|NCT04097275|OTHER|Withdraw of blood|"Blood will be collected in:~* 1 x Ethylene Diamine Tetraacetic Acid (EDTA) tube (7.5 ml) - for further leucocytes extraction that are a potential backup for new iPS cell lines generation~* 1 x Citrate Phosphate Dextrose Adenine (CPDA) tube (8.5 ml) - for EBV-transformed lymphoblastoid cell lines generation~* 1 x Dried Blood Spot DBS-filtercard, called CentoCard® - for quality control confirmatory genetic testing"
40803712|NCT05894135|DRUG|BG2109 100mg|One tablet of BG2109 100mg , oral , once daily
40803713|NCT05894135|DRUG|BG2109 200mg|One tablet of BG2109 200mg, oral , once daily.
40803714|NCT05894135|DRUG|ABT(E2 1 mg / NETA 0.5 mg)|One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily
40803715|NCT05894135|DRUG|BG2109 100mg Placebo|One tablet of BG2109 100mg Placebo, oral , once daily.
40803716|NCT05894135|DRUG|BG2109 200mg Placebo|One tablet of BG2109 200mg Placebo, oral , once daily.
40803717|NCT05894135|DRUG|ABT Placebo|One tablet of ABT Placebo, oral, once-daily
40803718|NCT04325295|PROCEDURE|Laparoscopic ovarian drilling|LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached \> 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
40803719|NCT04325295|DRUG|Recombinant FSH (rFSH)|A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
40803720|NCT06346509|DRUG|PORT-77|Healthy adult participants will receive a single oral dose of PORT 77.
40803721|NCT06346509|DRUG|Placebo|Healthy adult participants will receive matching placebo on Day 1.
40803722|NCT03593122|DEVICE|WO2085 Moisturising Cream|"Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day)."
40803723|NCT00814021|DRUG|sunitinib malate|
40803724|NCT03363191|DRUG|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol will be supplied as inhalation powder in ELLIPTA DPI. It will contain 2 strips with 30 blisters per strip. First strip will contain fluticasone furoate 100 mcg dry white powder blended with lactose. Second strip will contain vilanterol 25 mcg dry white powder blended with lactose and magnesium stearate.
40803725|NCT03363191|DRUG|Fluticasone Furoate|Fluticasone furoate will be supplied as inhalation powder in ELLIPTA DPI. It will contain a single strip with 30 blisters, containing fluticasone furoate 100 mcg dry white powder blended with lactose.
40803726|NCT03363191|DRUG|Salbutamol/Albuterol|Salbutamol/albuterol will be provided to subjects to use as rescue medication on an as-needed basis.
40803727|NCT03118856|DIAGNOSTIC_TEST|Prediction of Histology|The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
40803728|NCT04599803|DEVICE|Verily Sleep Apnea (VSA) Program/App|The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.
41006889|NCT02021591|BEHAVIORAL|Mobile Diabetes Detective (MoDD)|MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
41006890|NCT06387329|DRUG|Nitrofurantoin 100 MG|No additional information
41321362|NCT05507970|DRUG|MMV367|Single dose dispersed in sterile water.
41321363|NCT05507970|DRUG|Placebo|Single dose dispersed in sterile water.
41321364|NCT02860754|OTHER|Six-minute walk test to perform before surgery|During the outpatient preoperative assessment, eligible patients will perform the six-minute walk test.
41321365|NCT05007717|BEHAVIORAL|Data-informed Stepped Care (DiSC)|"The DiSC intervention is comprised of a data-driven system to assign adolescents to care based on their health needs and the different levels of care for each assignment group.~The trajectory of services moves from a relative position of ALHIV autonomy to more intensive service provision. Intervention steps start with 1) multi-month refills or community treatment delivery (differentiated care); 2) a standard of care level for those with medical needs such as pregnancy or opportunistic infections or patient choice; 3) patient reminders/tracking and counseling and referral services for mental health needs; 4) case management of unsuppressed individuals, including enhanced counseling and case conference problem-solving"
41321366|NCT04830228|DEVICE|Ballon expandable stent and PTA|Endovascular treatment for the peripheral artery disease of the Iliac artery
41321367|NCT00600028|DRUG|Thalidomide|Thalidomide 50 - 100 mg by mouth daily
41321368|NCT00600028|DRUG|Placebo|Placebo 50-100 mg by mouth per day
41476852|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation. They will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Further access will be provided to module 4 You are safe here on improving children´s relationship-related safety and facilitating solid relationships. Access to module 5 Who am I and where do I belong? will support caregivers in helping their child develop an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support will be provided. They will receive four phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, 4, and 5. Text messages or emails with the core message of the modules will be provided."
41321369|NCT00485589|DRUG|Methotrexate|Oral repeating dose
41476853|NCT04659551|DRUG|Epirubicin|Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles
41476854|NCT04659551|DRUG|Cyclophosphamide|Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
41476855|NCT04659551|DRUG|Triptorelin|Triptorelin 3.75 mg i.m. every 4 weeks until surgery
41006891|NCT05614245|BIOLOGICAL|VBI-2901e|Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants
41006892|NCT04411342|DIAGNOSTIC_TEST|Albumin creatinine ratio|normal range of albumin in urine in patients with type 2 diabetes
41006893|NCT05588024|DEVICE|Head Up CPR based bundle of care|All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
41006894|NCT05961774|DEVICE|Transcranial magnetic stimulation|The stimulation point is the lumbar multifidus hotspot. The parameters will be set at frequency 10 Hz, 50 number of pulses, 40 train of stimulation (5 seconds stimulation and 25 seconds inter-stimulation interval). The position of coil will be placed tangentially at 45 degrees on the LM hotspot. The stimulation will be 20 minutes.
41006895|NCT05961774|DEVICE|Neuromuscular electrical stimulation|The neuromuscular electrical stimulation will be set as interferential current 6000 Hz, amplitude 20-50 Hz with scanning mode, duration 20 minutes, intensity to elicit the LM contraction.
41321370|NCT00485589|DRUG|Ocrelizumab|Intravenous repeating dose
41476856|NCT04659551|DRUG|Exemestane|Exemestane 25 mg oral continuous daily dose until surgery
41476857|NCT04659551|DRUG|Nivolumab|Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
41476858|NCT00003621|DRUG|carmustine|
41476859|NCT00003621|DRUG|cisplatin|
41476860|NCT00003621|DRUG|etoposide|
41476861|NCT00003621|RADIATION|radiation therapy|
41476862|NCT04897113|PROCEDURE|plasma exchange with albumin|plasma exchange with albumin, two per week, 110% of the circulating plasma volume
40803729|NCT03957915|DRUG|INA03 administration|INA03 will be administered IV on Day 1, Day 14 of 28-day cycles. The administration of INA03 will begin at 0.02 mg/kg. Study Part I is a titration study to determine the dose for the first INA03 infusion. Patients will be enrolled in sequential cohorts of 2 patients to receive ascending starting doses of INA03, starting from the lowest starting dose (0.02 mg/kg), and followed by subsequent administrations of INA03 (D14 and beyond) at a fixed dose of 0.1 mg/kg. The starting dose will be increased every cohort of 2 patients until evidence of absence of marrow residual erythroblasts by D14 myelogram. This dose is referred to as the MEID and will be selected as the D1 dose for the study Part 2. Patient accumulation in Part I of the study will continue until no evidence of non-hematological DLT within 28 days post dosing
41321371|NCT00485589|DRUG|Placebo|Intravenous repeating dose
41321372|NCT03569306|DEVICE|ENB|ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
41476863|NCT04897113|PROCEDURE|plasma exchange without albumin|plasma exchange without albumin, two per week, 110% of the circulating plasma volume
41476864|NCT00120276|DEVICE|Less invasive mitral valve repair|
41476865|NCT02710513|DIETARY_SUPPLEMENT|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
41476866|NCT05161819|DEVICE|Repetitive transcranial magnetic stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses
40803730|NCT04168203|DRUG|Apixaban 2.5 MG|apixaban 2.5 mg orally twice daily for a duration of 12 months
41321373|NCT03569306|DEVICE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
41321374|NCT02289274|DRUG|NVP-1203|NVP-1203(eperisone SR + aceclofenac)
41321375|NCT02289274|DRUG|Eperisone SR tab. + and Airtal tab.|Eperisone SR and aceclofenac
41321376|NCT03350867|OTHER|Personalized Insole Group|Personalized Insole Group
41321377|NCT03350867|OTHER|Placebo Group|Placebo Group
41321378|NCT00036543|DRUG|Atrasentan|
41006896|NCT06099262|BEHAVIORAL|GenPMTO|GenPMTO is a parenting programme which involves trained practitioners using active teaching approaches (such as group problem-solving, role-play, and video modelling) to support caregivers in using positive parenting strategies at home. The programme is designed to improve parenting practices, as well as a range of outcomes for young people, including improving academic performance, reducing school exclusions, and reducing offending and criminal behaviour. The version of the programme investigated in this project is delivered to groups of parents.
41006897|NCT01069055|OTHER|Sterile Saline|Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
41006898|NCT01069055|DRUG|Intravenous lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
41321379|NCT06256029|PROCEDURE|Recruitment maneuver|The recruitment maneuver will be performed by increasing the current peak pressure (Ppeak) by 5 cm H2O, changing the inspiratory/expiratory ratio from 1:2 to 1:1, with PEEP values of 5 and 7 cm H2O. The respiratory rate during the recruitment maneuver will be 10 breaths per minute, and the recruitment maneuver will last 30 seconds (5 breaths). The recruitment maneuver will be performed 3 times: the first time immediately after the formation of the pneumoperitoneum and the positioning of the patient in the reverse Trendelenburg position with a PEEP of 5 cm H2O, the second time with a PEEP of 7 cm H2O, during the duration of the operation. The third recruitment maneuver will be performed with a PEEP of 7 cm H2O at the end of the operative procedure, and immediately before the patient wakes up. After each increase, PEEP will be maintained at higher pressure values with a peak value of 7 cm H2O.
40803731|NCT04168203|DRUG|Placebo oral tablet|placebo oral tables twice daily for a duration of 12 months
41006899|NCT01069055|DRUG|Intravenous paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
41321380|NCT03831308|DIAGNOSTIC_TEST|clinical and physical assessment|information will be collected on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
41321381|NCT03121066|DEVICE|Active Transcranial Magnetic Stimulation|The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)
41321382|NCT03121066|DEVICE|Sham Transcranial Magnetic Stimulation|The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
40803732|NCT05126511|DEVICE|Application of CES via ear clips|Use of 100µA CES for one hour per day over PR program
41321383|NCT00977015|DRUG|Treatment A|Inhaled, 750/150, single dose
41321384|NCT00977015|DRUG|Treatment B|Inhaled, 750/150, single dose
41321385|NCT02207556|DRUG|Doxycycline|"Doxycycline will be continued until one of the following criteria is met:~* Patient has completed 1 year of doxycycline therapy~* Patient develops any grade 3-4 toxicity related to doxycycline use."
40803733|NCT05126511|DEVICE|Sham: No application of CES via ear clips|Use of Sham CES for one hour per day over PR programm
41321386|NCT02067416|DRUG|Anthracycline based chemotherapy|standard of care neoadjuvant treatment with anthracycline based chemotherapy
41321387|NCT02067416|DRUG|taxane-based chemotherapy|neoadjuvant taxane based chemotherapy given as standard of care
40803734|NCT05509647|DRUG|Unfractionated heparin|Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
40803735|NCT06132191|DRUG|Cemiplimab|
41006900|NCT00808288|DRUG|PF-00610355|oral, inhaled, dry powder, 600ug, OD
41006901|NCT00808288|DRUG|PF - 00610355|oral, inhaled, dry powder, 300ug, OD
41006902|NCT00808288|DRUG|PF- 00610355|oral, inhaled, dry powder, 100ug, OD
41006903|NCT00808288|DRUG|Placebo|oral, inhaled, dry powder, placebo, OD
41006904|NCT00808288|DRUG|Salmeterol|salmeterol, 50ug, BID
41006905|NCT03208738|BEHAVIORAL|VetChange|VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.
40803736|NCT03935789|BEHAVIORAL|BLAST|12-week self-guided intervention using a web-based platform
40803737|NCT02659033|DRUG|ceftriaxone|ceftriaxone (1 gram per day)
41006906|NCT03208738|BEHAVIORAL|web-based drinking assessment and feedback tool (AFT)|Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
41006907|NCT00630968|DRUG|Levetiracetam (Keppra)|
41006908|NCT01989013|OTHER|biweekly intervention|10 step craniosacral therapy protocol through manual therapy at feet , thoracic diaphragm, neck and cranium
41006909|NCT04594096|BEHAVIORAL|Telehealth visits|Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle
41006910|NCT04594096|BEHAVIORAL|Standard of Care|Receiving care as usual from the UC Davis Comprehensive Cancer Center
41006911|NCT02498093|BEHAVIORAL|Maximal strength training|
41006912|NCT02498093|BEHAVIORAL|conventional rehabilitation|
40803738|NCT02659033|DRUG|Cefotaxime|cefotaxime (1 gram every 8 hours)
41006913|NCT00983281|DRUG|Hextend|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
41321388|NCT06259864|OTHER|EXOPULSE Mollii Suit method|EXOPULSE Mollii Suit method, one of the newest rehabilitation technology products, is a non-invasive neuromodulation approach with a garment that covers the whole body and electrodes placed inside. Designed to improve motor function by reducing spasticity and pain, the method is based on the principle of reciprocal inhibition, which occurs by stimulating the antagonist of a spastic muscle at low frequencies and intensities.
41476867|NCT05161819|DEVICE|Sham stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses (with sham coil)
41476868|NCT06297655|DRUG|Recombinant human activated coagulation factor VIII for injection|Recombinant human coagulation factor VIII for injection is a recombinant DNA product with functional characteristics comparable to endogenous factor VIII.
41006914|NCT01411878|BEHAVIORAL|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
41006915|NCT01411878|BEHAVIORAL|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, \& Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
41006916|NCT02236390|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms
41006917|NCT02236390|BEHAVIORAL|Cognitive Processing Therapy - Cognitive|12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
41006918|NCT01536496|BIOLOGICAL|Blood product transfusion based on conventional coagulation tests.|Transfusion of blood products.
41006919|NCT01536496|BIOLOGICAL|Blood product transfusion based on rapid thrombelastography (r-TEG) results.|Transfusion of blood products.
41006920|NCT02530294|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
41006921|NCT02530294|OTHER|Vehicle|Vehicle (placebo) topical wipes
41006922|NCT03384251|BEHAVIORAL|comprehensive sex education|A comprehensive sex education program to be delivered in approximately six (6) sessions comprising of an introductory lesson on susceptibility and severity of teenage pregnancy, personal and community values, female reproductive system, contraception and decision-making skills.
41006923|NCT04952220|DEVICE|ultrasound|Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee
41006924|NCT01603875|BIOLOGICAL|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
41006925|NCT04630405|DEVICE|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
41006926|NCT04630405|DEVICE|Aerogen Solo|Aerogen Ltd., Galway, Ireland
41006927|NCT06290401|BEHAVIORAL|SCThrive|SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
41006928|NCT06290401|OTHER|SCHealthED|Standard of care plus 7 SCD educational text messages to ensure education is uniform across sites
41006929|NCT01870622|PROCEDURE|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
41476869|NCT05727449|PROCEDURE|General Anesthesia|General Anesthesia was intruduced for Cesarean Delivery
41476870|NCT05727449|PROCEDURE|Spinal Anesthesia|Spinal Anesthesia was intraduced for Cesarean Delivery
41476871|NCT00002702|BIOLOGICAL|aldesleukin|
41006930|NCT01870622|PROCEDURE|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
41006931|NCT02543931|DRUG|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
41476872|NCT00002702|PROCEDURE|adjuvant therapy|
41476873|NCT00002702|PROCEDURE|conventional surgery|
41476874|NCT00002702|PROCEDURE|neoadjuvant therapy|
41476875|NCT00002702|RADIATION|radiation therapy|
41476876|NCT01226251|DEVICE|In vitro chair side test|Colour evaluation of a strip
41476877|NCT05114759|DRUG|SHR-A2009|"In dose Escalation:~SHR-A2009 will be administered intravenously. Six dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy."
41006932|NCT02543931|DRUG|placebo|Placebo capsules containing inert ingredients
41321389|NCT01434264|PROCEDURE|Energy healing|"Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair."
41006933|NCT04719416|BEHAVIORAL|Guided Meditation|Approximately 10 minute recording of guided meditation focuses on muscle relaxation.
41006934|NCT04027218|DEVICE|Dry heat|The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.
41006935|NCT04027218|DEVICE|High pressure|It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
41321390|NCT02205398|DRUG|INC280|
40803739|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
40803740|NCT01059864|DRUG|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
40803741|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
40803742|NCT01059864|DRUG|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
41006936|NCT04027218|DEVICE|Combination of dry heat and high pressure|"The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse."
40803743|NCT03569449|BEHAVIORAL|Usual care|Family partners will keep records and communicate with families using standard information technology, including telephones, electronic medical records, and standard desktop software.
40803744|NCT03569449|BEHAVIORAL|Clinic-based visits|Family partners will be restricted to working at the primary care clinic - communication will be restricted to telephone, text, and clinic visits
40803745|NCT03569449|BEHAVIORAL|Standard pediatric surveillance|Monitoring is determined by standard pediatric practice. Behavioral screening is usually done annually.
40803746|NCT03569449|BEHAVIORAL|Structured, schedule-based visits|Family Partners will utilize a predetermined schedule of contacts with families
41006937|NCT03424538|OTHER|Neurorehabilitation|5-week-long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
41006938|NCT03424538|OTHER|Physiotherapy|5-week-long intervention, physiotherapy, stretching, walking preparation, strengthening
41321391|NCT02205398|DRUG|cetuximab|
41321392|NCT00595257|DEVICE|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
41321393|NCT03372668|OTHER|massage therapy combined with components of mirror therapy|"Individualized 20-minute, Swedish massage to address participant's unique phantom limb pain experience as if occurring on the corresponding, non-amputated limb. A specially designed apparatus is positioned such that a fixed, real-time image in place of the amputated limb is viewed by the participant during the massage session. The apparatus has a mirror, masking material to hide therapist and participant's lower body, electronic video display, electronic video camera, and equipment to electronically communicate the video signal to the video display. The mirror and video camera positioned to see a reflection of the existing limb being massage feds the image to a live video display situated in front of the participant to the correct orientation naturally represent the missing limb."
40803747|NCT03569449|BEHAVIORAL|Enhanced pediatric surveillance|"In Massachusetts, behavioral screening is mandated at every pediatric visit, which for children in the target population (ages 3-12 years) is annually. With enhanced monitoring, Family Partners will screen children using validated instruments quarterly and communicate results to the child's care team"
41321394|NCT02162121|PROCEDURE|Continuous lumbar plexus: stimulating catheter|"Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia."
41321395|NCT02162121|PROCEDURE|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
41321396|NCT02162121|PROCEDURE|Local anesthetic infusion|Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
41321397|NCT02162121|PROCEDURE|Intravenous analgesia|Ketorolac 30mg 3 times a day
41321398|NCT02162121|PROCEDURE|Opioids rescue analgesia|Buprenorphine 0,2mg twice a day if VAS\>4
41476878|NCT04467359|OTHER|ERAS|Optimize physical conditions; Fasting solid diet 6h before surgery, fasting clear fluid 2 h before surgery; If there is no chief complaint of dizziness, nausea or other discomfort after the operation, warm water (no more than 100ml) can be immediately drunk. Pain management; Encourage patients to engage in early activities under the premise of effective pain control; If no dural puncture and other complications occur, the patient has no chief complaints of headache, dizziness, nausea and other discomfort, and there is no need to lie supine, the comfortable position such as semi-supine lateral supine position can be taken immediately (avoid 90-degree upright position for patients with hip joint); Prevention of thrombosis; Prevention and treatment of nausea and vomiting; Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the operation.
41476879|NCT04467359|OTHER|Perioperative routine rehabilitation nursing|Fasting and water deprivation at 12 o 'clock on the first day before surgery; Fasting water 6-8 hours after surgery; Lie flat on your pillow for 6 hours; Get out of bed activity 1 day after operation
41476880|NCT01885702|BIOLOGICAL|DC vaccination|DC vaccination
41476881|NCT03244124|OTHER|Self-Etching Application Strategy|In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
41476882|NCT03244124|OTHER|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
41476883|NCT03244124|OTHER|Etch&Rinse Dry Application Strategy|In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
40803748|NCT03569449|BEHAVIORAL|Technology enhanced care coordination|Behavioral: technology enhanced care coordination FPs will also have access to Act.MD, a cloud-based care coordination and communication tool that offers the potential to improve communication with families, schools, and the primary care site through administration of online questions, videoconferencing, and common portals that can be used by parents and multiple providers (e.g., FP, pediatrician, teacher).
41321399|NCT02162121|DRUG|Mepivacaine 1%|
41321400|NCT02162121|DRUG|Levobupivacaine 0,5%|
41476884|NCT03244124|OTHER|Etch&Rinse Wet Application Strategy|In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
41476885|NCT02104817|DRUG|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
41006939|NCT01936259|DEVICE|Mini Stem|The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments.
41321401|NCT02162121|DRUG|Ropivacaine 0,2%|
41321402|NCT02162121|DRUG|Ketorolac 30mg|
40803749|NCT03569449|BEHAVIORAL|:Individually-tailored visits|Family Partners will be able to meet with families on an as-needed basis, with no predetermined schedule of contacts
40803750|NCT03569449|BEHAVIORAL|Clinic-based visits and community visits|In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
40803751|NCT03841513|PROCEDURE|Laparoscopic Burch Colposuspension|The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
40803752|NCT03926923|OTHER|no intervention|There will be no intervention. The blood sample is taken while a routine blood sampling.
40803753|NCT05625516|DEVICE|Bilateral external torque device|"The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent."
40803754|NCT05912894|PROCEDURE|Videolaparoscopic cholecystectomy|Evaluation of Rouvière's Sulcus Anatomical Variation.
40803755|NCT05306834|PROCEDURE|Retinal Imaging|Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
40803756|NCT05306834|GENETIC|Blood sample|Analyses of molecular biomarkers including
40803757|NCT05306834|PROCEDURE|Evaluation of cardiovascular risks|Measurement of blood pressure and arterial stiffness
40803758|NCT05306834|PROCEDURE|Brain imaging (MRI)|3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
40803759|NCT05306834|OTHER|Cognitive Tests|Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
40803760|NCT05306834|OTHER|Geriatric Depression Scale (GDS)|15 items
40803761|NCT05306834|OTHER|Instrumental Activities of Daily Living (IADL)|Instrumental Activities of Daily Living (IADL)
40803762|NCT05306834|DIAGNOSTIC_TEST|Unipodal standing test|Unipodal standing test
40803763|NCT05306834|OTHER|Walking speed measurement|over 5 meters
40803764|NCT00542490|RADIATION|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
40803765|NCT00533728|DRUG|Soluble beta-glucan (SBG)|
40803766|NCT00906178|BEHAVIORAL|CyberSenga|Internet-based HIV prevention program
40803767|NCT04651686|OTHER|Preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
40803768|NCT02686632|BEHAVIORAL|Palatal brushing|Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
41476886|NCT02104817|DRUG|corn oil control|corn oil control arm
41476887|NCT01002794|PROCEDURE|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital and Martina Hansens Hospital.
41476888|NCT01002794|OTHER|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training. Carried out at Nimi Ullevaal Oslo or Gnist trending- og fysioterapi, Baerum
41476889|NCT05215093|OTHER|Direct access physiotherapy for acute low back pain|Interventions include physiotherapeutic treatment, without prescription of the general practitioner, for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
40803769|NCT01582516|BIOLOGICAL|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
40803770|NCT02144402|OTHER|infant formula with DHASCO|
40803771|NCT02144402|OTHER|infant formula with DHASCO-B|
40803772|NCT01719458|DRUG|(S,S)-[11C]MRB|PET radioligand
40803773|NCT01748188|PROCEDURE|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
40803774|NCT01748188|PROCEDURE|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
40803775|NCT01748188|PROCEDURE|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
40803776|NCT01748188|PROCEDURE|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
40803777|NCT01748188|PROCEDURE|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
40803778|NCT02309645|BIOLOGICAL|EVICEL® Fibrin Sealant|Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.
40803779|NCT02309645|OTHER|Sutures Only|Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
40803780|NCT04998916|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses of continuous theta burst stimulation with the active sham coil (double blinded using the integrated active sham system).
41321403|NCT02162121|DRUG|Buprenorphine 0,2mg|
41321404|NCT02162121|DEVICE|Stimulong, Pajunk, Germany.|
41006940|NCT01936259|DEVICE|Nano|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
41006941|NCT05912504|OTHER|Phoen survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
41006942|NCT04065789|DRUG|Carfilzomib|Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.
41006943|NCT04065789|DRUG|Daratumumab|Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.
41006944|NCT04065789|DRUG|Lenalidomide|Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.
41006945|NCT04065789|DRUG|Dexamethasone|Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
41152530|NCT04639076|BEHAVIORAL|Personalized Behavioral Weight Loss Program|The PBWL group will receive a calorie goal based on measured resting energy expenditure and baseline PA. In Weeks 1-4, participants will be randomly assigned to test patterns that manipulate diet composition (low-fat or low-carbohydrate), meal frequency (3 or 5-6 meals/day), and PA goals (weekly minutes or daily minutes goals). Following this period, the optimal combination will be identified by the participant and interventionist, based on weight loss, blood glucose, hunger and ability to adhere to the prescription. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment. Participants will receive the same digital tools as the BWL group with resources specific to following the prescription they are following during any given program week.
41476890|NCT05215093|OTHER|Usual care for acute low back pain|Interventions include standard of care by the general practitioner for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
41152531|NCT01320514|DRUG|Fibrin Sealant (Artiss)|
41476891|NCT00530543|PROCEDURE|Robot-assisted gait training|
41152532|NCT01608919|OTHER|blood tests|thromboelastogram platelet mapping
41321405|NCT02162121|PROCEDURE|Continuous lumbar plexus: non-stimulating catheter|
41321406|NCT01549223|DRUG|Oxytocin Infusion|500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
41321407|NCT01549223|DRUG|Oxytocin Bolus|3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
40803781|NCT04998916|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the integrated active sham system). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
40803782|NCT02767869|DRUG|Banaba|Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
40803783|NCT02767869|DRUG|placebo|Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
40803784|NCT00197418|DRUG|rabeprazole, amoxicillin, clarithromycin, metronidazole|
40803785|NCT03624478|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
40803786|NCT00272155|BEHAVIORAL|Educational intervention|Educational outreach visits to the CME-groups, work-shops, audit and feedback
40803787|NCT00272155|BEHAVIORAL|Educational intervention program|The 433 recruited GPs had a total of 1336 717 office consultations of which 171 679 (12.8%) were RTIs encounters for 118 621 different patients. The GPs participated in peer continuing medical education (CME) groups in southern Norway. A multifaceted intervention was tailored, where key components were educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers conducted the educational outreach visits. During these visits, evidence-based recommendations of antibiotic prescriptions for RTIs were presented and software handed out for installation in participants PCs, enabling collection of prescription data. These data was linked to corresponding data from the Norwegian Prescription Database (NorPD). Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic intervention.
40803788|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
40803789|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
40803790|NCT00705445|OTHER|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
41006946|NCT00934544|DRUG|Ruxolitinib|5 mg tablets packaged as 60-count in high-density polyethylene bottles
41006947|NCT00934544|DRUG|Best Available Therapy (BAT)|Prescribing and usage per respective package inserts
41006948|NCT02692833|OTHER|No intervention|No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
41006949|NCT02803710|OTHER|Microbiological study|
41321408|NCT04700436|DRUG|Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)|"IP~* Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~* Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)"
40803791|NCT01887730|BEHAVIORAL|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
40803792|NCT01887730|BEHAVIORAL|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
40803793|NCT01887730|BEHAVIORAL|Control|
40803794|NCT04149470|DRUG|Omeprazole 20mg BID|High dose PPI therapy (Omeprazole 20mg twice daily)
40803795|NCT00345566|PROCEDURE|Nutrition composition|
40803796|NCT00395824|PROCEDURE|anticoagulation procedure|
40803797|NCT04517695|DEVICE|BVA-100|The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin.
40803798|NCT04517695|DEVICE|Transpulmonary Thermodilution (TPTD)|TPTD consists of placing a thermistor-equipped catheter in a central artery (usually the femoral or axillary artery) and injecting cold saline solution into a central vein through a central venous catheter.
40803799|NCT04517695|DEVICE|Sublingual Microcirculation|With incident dark field imaging, the CytoCam device can record digital image sequences using a handheld camera. In the current study the camera will be used to non-invasively record images of the sublingual microcirculation.
41321409|NCT04198233|DRUG|Diazepam|Diazepam 10 mg compounded suppository
41321410|NCT04198233|DRUG|Placebos|Placebo suppository
41321411|NCT04588831|DEVICE|Mouthguard|Protective device for orofacial complex for patients playing contact sports
41321412|NCT03196193|PROCEDURE|Open Reduction and Internal Fixation|Fractured bone fragments are reduced and stabilized by intramedullary nail.
41321413|NCT03196193|DEVICE|ZNN CM Asia|Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
41321414|NCT03196193|DEVICE|Anterior Support Screw|Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
41321415|NCT05429554|DRUG|Vildagliptin|observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
41321416|NCT04557254|DEVICE|graft|evaluate the early and long-term clinical results, up to 5 years (through follow-up outpatient visits), of a silver and triclosan knitted collagen coated polyester vascular graft (InterGard Synergy), in patients submitted to aortic surgical repair, and compare them with concurrent results of standard Dacron grafts.
40803800|NCT00070109|DRUG|trabectedin|Given IV
40803801|NCT00070109|OTHER|pharmacological study|Correlative studies
41321417|NCT00216541|DRUG|epoetin alfa|
40803802|NCT02468687|DRUG|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
40803803|NCT03992716|DRUG|SmofKabiven® extra Nitrogen|SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
40803804|NCT03992716|DRUG|Olimel N9E|Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
40803805|NCT04626687|DEVICE|test DCB|use paclitaxel coated coronary balloon catheters to treat SVD
40803806|NCT04626687|DEVICE|RESTORE DCB|use paclitaxel coated coronary balloon catheters(RESTORE DCB) with NMPA approval indication for treating SVD
40803807|NCT05070455|BIOLOGICAL|Asceniv™|Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
40803808|NCT04874883|DIETARY_SUPPLEMENT|Simbyotic|6 grams of the symbiotic will be administered twice a day
40803809|NCT04874883|DEVICE|Control Group|6 grams of the maltodextrin will be administered twice a day
40803810|NCT02540187|OTHER|blood specimen|
40803811|NCT05113121|DIAGNOSTIC_TEST|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)
40803812|NCT01027494|DRUG|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
40803813|NCT05891080|DRUG|Toripalimab|Specified dose on specified days.
40803814|NCT05891080|DRUG|JS004|Specified dose on specified days.
41321418|NCT00818571|DRUG|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
40803815|NCT05891080|DRUG|Pemetrexed|Specified dose on specified days.
41321419|NCT00818571|DRUG|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
41321420|NCT00818571|DRUG|Vildagliptin|Matching healthy volunteers receiving 25 mg vildagliptin once daily.
40803816|NCT05891080|DRUG|Nab-paclitaxel|Specified dose on specified days.
40803817|NCT05891080|DRUG|Carboplatin|Specified dose on specified days.
40803818|NCT05891080|PROCEDURE|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
40803819|NCT06552936|OTHER|Diode Laser 980 nm.|A Diode laser is commonly used in simple surgical procedures on soft tissue, such as skin or mucosa. Its tip can work when non-activated, causing inductive effects, and when activated, it causes the ablation of soft tissue.
40803820|NCT02565758|DRUG|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
40803821|NCT00003352|DRUG|cyclophosphamide|600 mg/m2, IV, every 3 weeks
40803822|NCT00003352|DRUG|Taxotere|60 mg/m2, IV, every 3 weeks
41321421|NCT00818571|DRUG|Vildagliptin|Matching healthy volunteers receiving 50 mg vildagliptin once daily
41321422|NCT00657124|DIETARY_SUPPLEMENT|Aminolevan EN|The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
41321423|NCT00657124|DIETARY_SUPPLEMENT|Placebo|placebo
41321424|NCT03224585|DRUG|Anakinra|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days"
41321425|NCT03224585|DRUG|Placebo|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days"
41321426|NCT01071096|DRUG|OnabotulinumtoxinA|"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
41321427|NCT01071096|DRUG|Saline|"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
41006950|NCT06394388|BEHAVIORAL|Cuidando juntos|"Caregiver TLC program will be culturally tailored by including a focus on addressing cultural values to promote social connectedness and translated into Spanish (Cuidando Juntos).~Cuidando Juntos consists of 8 modules: stress management; behavioral activation; building resilience; building self-care skills; managing difficult emotions; reducing isolation; and two on understanding and responding to difficult behaviors of the PLWD."
41321428|NCT04865185|DIAGNOSTIC_TEST|Xylocaine spray 100mg/ml|Topical application
40803823|NCT00003352|DRUG|Adriamycin|60 mg/m2, IV, every 3 weeks
40803824|NCT03999099|DRUG|Suvorexant 20 mg|Suvorexant at a high dose (20 mg)
40803825|NCT03999099|DRUG|Suvorexant 10 mg|Suvorexant at a low dose (10 mg)
40803826|NCT03999099|DRUG|Placebo oral tablet|Placebo
40803827|NCT02381717|OTHER|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
40803828|NCT02381717|DRUG|bupivacaine|
40803829|NCT02381717|DRUG|morphine|
40803830|NCT04317521|DEVICE|Use of EKO Core and EKO Duo electronic stethoscopes|Listen to heart murmurs
41321429|NCT04865185|DIAGNOSTIC_TEST|Ethanol|Topical application
41321430|NCT00307424|DEVICE|AutoCPAP|
40803831|NCT03853382|BEHAVIORAL|Cognitive analytic informed brief therapy|"The brief CAT-informed therapy will take place over two sessions. Session one will last around 90 minutes. In session one, we will discuss with the participant their experience of self-harm and begin to support them to make sense of patterns in their self-harming behaviour. This will be done by thinking about the events that come before or follow self-harm, as well as thoughts and emotions associated with self-harm; it will also be done by thinking about ways that the participant relates to him/herself and other people. By the end of the first session, the researcher and the participant will have collaboratively developed a written diagram which shows patterns in the participant's self-harm.~Session two will involve revisiting the mapping of patterns. The researcher and participant will the collaboratively develop 'exits' or ways to break patterns and cycles of thinking, feeling and behaviour. Both sessions will have structured endings."
40803832|NCT04742439|DEVICE|Sham transcranial direct current stimulation|Participants will receive 30 seconds of ramp up and down stimulation at the start and end of the 20 minute stimulation period.
41321431|NCT00307424|DEVICE|FixCPAP|
41321432|NCT03771599|OTHER|Intervention Group|"Traditional massage of thirty minutes duration ( five minutes of massage was provided to all four limbs, front and back of trunk area) prior to routine physical therapy.~Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks."
40803833|NCT04742439|DEVICE|Individualized transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at the individualized dose (maximum of 4mA).
40803834|NCT04742439|DEVICE|2mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 2mA dose.
40803835|NCT04742439|DEVICE|4mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 4mA dose.
40803836|NCT05092828|DRUG|Intrathecal Morphine Injection|In addition to standard post-operative pain management, Intratechal morphine will be given to patients in this group.
41321433|NCT03771599|OTHER|Control group|Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
41321434|NCT02452177|DRUG|Vitamin D|
40803837|NCT05092828|DRUG|Pain Relieving|Patient in this group will receive standard postoperative pain medications other than inthrathecal injection of morphine
40803838|NCT03334981|PROCEDURE|Concentrations in Meconium of Buprenorphine and Methadone|buprenorphine or methadone concentration measurement
40803839|NCT04193449|DIAGNOSTIC_TEST|colonoscopy|colonoscopy procedure
40803840|NCT06370624|DIAGNOSTIC_TEST|MRI-scan|IRM-scan at rest under neonatologist monitoring.
40803841|NCT06400290|PROCEDURE|Percutaneous coronary intervention (PCI)|Coronary artery stenting for stable angina
40803842|NCT06400290|DIAGNOSTIC_TEST|Symptom assessment during experimentally induced ischaemia|Transient experimental balloon occlusion across coronary stenosis to determine the symptoms conferred by ischaemia at this stenosis.
40803843|NCT04309851|DIAGNOSTIC_TEST|deep learning|the deep learning method is a field of study involving artificial neural networks and similar machine learning algorithms with many hidden layers.
41006951|NCT05933434|BIOLOGICAL|Allogenic adipose derived mesenchymal stem cells (AD-MSC)|Laboratory isolated, cultivated and cryopreserved allogenic adipose derived mesenchymal stem cells (AD-MSC) from health donors undergoing cometic plastic surgery will be thawed on the injection day and formulated in 10 mL saline. The AD-MSCs will then be intraarticular injected using ultrasonic guidance.
41006952|NCT05933434|OTHER|Saline|10 mL saline will be intraarticular injected using ultrasonic guidance.
41006953|NCT03128697|BEHAVIORAL|Satiating diet|
41006954|NCT03128697|BEHAVIORAL|Control diet|
41321435|NCT00195767|DRUG|divalproex sodium|
41321436|NCT03489135|DEVICE|ReVene Thrombectomy Catheter|Endovascular treatment of an acute iliofemoral DVT
41321437|NCT03737292|DRUG|Exparel|The intercostal blocks will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions. On average, 5-6 intercostal spaces will be injected with 4-5 ml of local anesthetic at each level.
41321438|NCT03737292|DRUG|Bupivacaine|The intercostal injections of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml total will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions.
41321439|NCT05208723|BEHAVIORAL|Stress and emotion management|The handbook materials and lay helper scripts are based on principles of Acceptance and Commitment Therapy (ACT), and aims to enhance psychological flexibility. Psychological flexibility reflects how a person adapts to fluctuating situational demands, reconfigures mental resources, shifts perspective, and balances competing needs. ACT teaches alternative methods to accommodate difficult thoughts and feelings, primarily through mindfulness techniques. At the same time, ACT also focuses on guiding participants to live in ways consistent with their personal values.
40803844|NCT04265157|PROCEDURE|Surgical technique surgical occlusion|Occlusion of hepatoduodenal ligament by clamp or occlusive bands
41321440|NCT00664755|DRUG|varenicline|"Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study."
41321441|NCT00664755|DEVICE|transdermal nicotine patch|"Weeks 0-3: 21mg patch~Transdermal nicotine patch is used for a duration of 3 weeks in this study."
41476892|NCT02914249|OTHER|Orange juice (500 mL/d)|Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
41476893|NCT01774279|OTHER|Tissue, blood and clinical data collection|
41476894|NCT06133218|OTHER|Mepitel Film|A safetac-based barrier film with a clinically insignificant bolus effect to protect the skin during radiotherapy.
41476895|NCT02919826|BEHAVIORAL|Adapted Dialectical Behaviour Therapy|12 weekly sessions of DBT group therapy
41476896|NCT03497832|OTHER|magnetic resonance spectroscopy (MRI)|Each healthy subject will get 3 MRI examinations at 7:30, 13:30 and 18:00. Each MRI scan lasts an average of 20 minutes.
41476897|NCT05247931|DIAGNOSTIC_TEST|TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine|Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2
41476898|NCT02782091|BEHAVIORAL|Multiple Errands Test (MET)|1 hour assessment in an unknown district with 2 independent raters.
40803845|NCT00752934|DRUG|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
40803846|NCT00752934|DRUG|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
40803847|NCT06170463|DRUG|Metformin Hydrochloride|Met Group Received metformin hydrochloride 500 mg tab 3 times Daily
40803848|NCT06170463|DRUG|MI/DCI combination in 40:1 ratio|MI-group received MI/DCI combination in 40:1 ratio twice daily
40803849|NCT06170463|DRUG|Combination of Metformin hydrochloride and MI/DCI|MM Group Received both Met and MI Groups Treatment
40803850|NCT02987361|DEVICE|DC-STIMULATOR PLUS|2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
40803851|NCT04473274|DRUG|Pioglitazone|Receive pioglitazone 15mg - 30mg daily
40803852|NCT03420755|BEHAVIORAL|Mothers and Babies 1-on-1|MB 1-on-1 is a 12-session intervention divided into five modules. An introductory 2-session module establishes key concepts related to stress, monitoring of one's mood, and ways in which one's mood influences one's internal thoughts and external environment; three 3-session modules correspond with key cognitive-behavioral elements: pleasant activities, thoughts, and social support/contact with others; a 1-session summary reviews content and identifies areas for future use of MB skills. Throughout MB, mood management skills are integrated using psycho-educational activities that encourage participants to understand connections between their mood and their activities, thoughts, and contacts with others.
40803853|NCT03420755|BEHAVIORAL|Mothers and Babies Plus Text|MB 1-on-1 along with text enhancements, both in English and Spanish. These texts focus on: a) skill reinforcement (e.g., Some thoughts just come to us, but we can make a conscious effort to think of positive thoughts.); b) homework reminders (e.g., What pleasant activity will you try today?), and c) self-monitoring (e.g., On a scale of 1-9, how would you rate your mood?). These texts will be linked with the 12 MB sessions. Specifically, after completing each in-person session, 3 texts will be sent by a home visitor to her client; one text will focus on skill reinforcement, one will be a homework reminder, and one will focus on self-monitoring.
40803854|NCT01882556|DRUG|onabotulinumtoxinA|
40803855|NCT01882556|DRUG|Placebo|
40803856|NCT06137430|DRUG|Sodium-glucose cotransporter 2 inhibitor|Sodium glucose cotransporter 2 inhibitiors
41476899|NCT05185258|DRUG|Enstilar|Topical foam
41476900|NCT05185258|DRUG|Placebo-vehicle|Topical foam
41476901|NCT00281476|DRUG|Simvastatine|
41476902|NCT02770105|OTHER|Theanine|Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
41476903|NCT02770105|OTHER|Caffeine|Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
41476904|NCT02770105|OTHER|Theanine-Caffeine Combination|Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
41476905|NCT02770105|OTHER|Placebo|Oral administration of 200ml of distilled water
41476906|NCT03935022|OTHER|Rice|"Each group will randomly receive, during three different experimental days, one of the following treatments by different allocation sequences:~1. 80g of black rice Venere (Group A)~2. 80g of black rice Artemide (Group B)~3. 80g of brown rice (Group C) The three treatments will be separated by a 7 day wash-out period. After an overnight fast, volunteers will consume the rice serving within 10-15 min, immediately after the first basal blood collection at 8:00 a.m. (baseline). Other blood withdrawals will be carried out a 0.5, 1.0, 2.0 and 3.0 h after rice administration."
41476907|NCT00747292|PROCEDURE|epidural|Patients in this limb receive epidural analgesia
41476908|NCT00747292|PROCEDURE|PCA|Patients in this limb receive a PCA for their pain control
41476909|NCT00747292|PROCEDURE|Spinal|Patients in limb will receive spinal analgesia
41476910|NCT03431064|OTHER|Lung Recruitment Maneuver|Lung Recruitment Maneuver by Anesthesiologist
41476911|NCT03431064|OTHER|Fluid Administration|Administration of IV Fluid by Anesthesiologist
41006955|NCT05650372|OTHER|High intensity resistive exercise|Participants of this group will be applied manual lymphatic drainage and compression bandaging every day of the week, and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition, 2 days of the week. Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises.Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull-down, bicep curl, triceps extension, lateral raise, and wrist curl.
41006956|NCT05650372|OTHER|Low intensity resistive exercise|"participants in this group will be applied manual lymphatic drainage and compression bandaging every day of the week and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition 2 days of the week.~Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises. Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull- down, bicep curl, triceps extension, lateral raise, and wrist curl."
40803857|NCT06164652|DEVICE|walking with Ceriter Stride One|Subjects walk on the GAITRite with the CSO insole in their shoes.
40803858|NCT04252313|OTHER|Music|Studies have been conducted to assess the effects of sound and noise on neonatal stress. Recently, music is being used in neonatal units to improve physiological and behavioral outcomes (Harling et al, 2009). Of the few studies done on the effectiveness of music during circumcision is a randomized double-blinded controlled trial conducted by Joyce et al (2001): it found that some physiologic outcomes were significantly lower among the music group in comparison to the EMLA group. They concluded that there is preliminary evidence to support the efficacy of EMLA and music in pain management of newborn circumcision; however, more rigorous studies are warranted for conclusive results.
41321442|NCT05157386|OTHER|Braining|Core components of Braining: Personnel-led training sessions, motivating contact with psychiatric staff, measurement and evaluation before and after the training period; usually 12 weeks. PE is added on to treatment as usual (TAU). The training sessions are moderate to intense aerobic group training, 30-45 minutes. Each training session is preceded by a short (5-10 minutes) individual meeting with staff including assessment of daily form, motivational work, and the opportunity to ask questions. The target frequency for participation is preferably at least three training sessions/week during a 12 week period. The training period for each patient begins with an informative and motivating group or individual lecture or and an individual introductory meeting with staff including psychiatric and somatic examination, self-assessment scales for symptoms and quality of life, and blood samples. The training period ends with a meeting with staff with follow-up on the parameters.
41321443|NCT04818528|OTHER|Constraint Induced Movement Therapy and Routine Physical Therapy|"Intensive, graded practice of the paretic upper limb to enhance task-specific use of the affected limb. Constraint or forced use therapy, with the non-paretic upper limb contained in a mitt to promote the use of the impaired limb during 90% of the total hours awake. Adherence enhancing behavioral methods designed to transfer the gains obtained in the clinical setting or the laboratory to patients' real-world environment (ie, a transfer package).~As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization."
41321444|NCT04818528|OTHER|Routine Physical Therapy|As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization.
41321445|NCT04134741|OTHER|Kinetic Control|"The Kinetic Control training included a functional examination of motor disorders and individual training. The KC training included active exercises, active exercises with torso muscle resistance and exercises involving lower limbs.~The duration of one training was 20-30 minutes."
41321446|NCT03106948|DRUG|Placebo|Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
41476912|NCT05351814|OTHER|Exercise|While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
41476913|NCT00314431|PROCEDURE|Care coordination by telephone contacts with a nurse|
41476914|NCT06103279|DRUG|Empagliflozin 10 MG|1 tablet once daily of (EMPAGLIMAX® 10 mg) continuously starting from 1 week before starting doxorubicin till the end of last Dox-based chemotherapy dose according to the given chemotherapy protocol
41006957|NCT02974985|DEVICE|injection of Restylane Lyft and Restylane L|Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups
40803859|NCT05895877|DRUG|Goofice®|Once daily before breakfast.
40803860|NCT05895877|DRUG|Goofice® Placebo|Once daily before breakfast.
40803861|NCT05001152|DRUG|Ozanimod|Taste assessment
40803862|NCT05939245|PROCEDURE|Furosemide Injection|Continuous infusion of furosemide is administered starting at 2 mg/hour and can be titrated until the target urine output of 1-2 cc/kg/hour is achieved for 48 hours. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
40803863|NCT05939245|PROCEDURE|Placebo Injection|Continuous infusion of placebo fluid is administered at a rate of 2 mL/hour. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
40803864|NCT01760538|BEHAVIORAL|Exercise training|exercise training
40803865|NCT01760538|BEHAVIORAL|usual care|received usual medical care after heart transplantation
40803866|NCT02712983|DRUG|TIP|TIP dose regimen
40803867|NCT02712983|DRUG|TIP and placebo|TIP and inhaled placebo dose regimen
40803868|NCT02712983|DRUG|Placebo|Inhaled placebo dose regimen
40803869|NCT02904850|BIOLOGICAL|group of patients|Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
40803870|NCT05175430|DRUG|Paroxetine|Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
40803871|NCT05175430|DRUG|Lysergic Acid Diethylamide|LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
41321447|NCT03106948|DRUG|Ascorbic Acid|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
41476915|NCT02541084|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
40803872|NCT05175430|DRUG|Placebo|Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
40803873|NCT04909008|OTHER|Exercise Training|10 weeks of supervised exercise training, 3 sessions per week at the cardiac rehab clinic at Mayo Clinic Florida.
40803874|NCT00207623|BEHAVIORAL|Arthritis Basics for Change Education program|
40803875|NCT01762384|PROCEDURE|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
40803876|NCT01762384|PROCEDURE|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
40803877|NCT01762384|DEVICE|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
40803878|NCT05088746|PROCEDURE|Non-surgical periodontal therapy|NSPT will be performed following the principles of minimally invasive non-surgical therapy (MINST) described by Nibali et al. (Nibali et al., 2015, Nibali et al., 2019)
40803879|NCT03026114|OTHER|No intervention is planned in our study.|No intervention is planned in our study.
40803880|NCT04050787|PROCEDURE|D2 Lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
41006958|NCT03640676|DEVICE|FlowOx|FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
41006959|NCT00963690|DEVICE|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
41006960|NCT00963690|PROCEDURE|Standard compression|Use standard compression to achieve hemostasis
41006961|NCT00526058|DEVICE|Secura then Futura|Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
41476916|NCT00697216|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
40803881|NCT04050787|PROCEDURE|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
40803882|NCT04078958|DIETARY_SUPPLEMENT|Salmon fishmeal|Salmon fishmeal with high protein content
40803883|NCT04078958|DIETARY_SUPPLEMENT|Whey|Whey with high protein content
40803884|NCT02584452|DRUG|Mepivacaine|20cc of 2% mepivacaine \<20 minutes prior to in room time.
41476917|NCT00697216|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
40803885|NCT02584452|PROCEDURE|adductor canal continuous nerve catheter|Placement of ultrasound guided adductor canal continuous nerve catheter
41006962|NCT00526058|DEVICE|Futura then Secura|Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
41006963|NCT03672903|DEVICE|Weight Vest|A vest with added weights up to a maximum of 15 kg.
41006964|NCT03018392|DEVICE|Stryker Tritanium Spinal System|open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
41321448|NCT03106948|DRUG|Cuprimine Oral Product|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
41321449|NCT03771456|PROCEDURE|Colorectal resections|Colorectal resections
41321450|NCT00935337|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
41321451|NCT00935337|BEHAVIORAL|Sleep Hygiene|treatment as usual
41476918|NCT00284804|DRUG|MDX-060|anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
40803886|NCT02584452|DRUG|Normal Saline as bolus followed by bupivacaine|normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h
40803887|NCT02584452|PROCEDURE|adductor canal nerve block|ultrasound guided adductor canal nerve block
40803888|NCT02584452|DRUG|ropivacaine and dexamethasone|10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve
40803889|NCT02584452|DRUG|Propofol|Anesthesia induction will include a propofol bolus.
40803890|NCT02584452|DRUG|Fentanyl|Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
40803891|NCT00145210|DRUG|Nebivolol and Atenolol|
40803892|NCT02110680|DEVICE|Sports TENS 2|transcutaneous electric stimulation
40803893|NCT00570011|DRUG|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
40803894|NCT00570011|DRUG|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
40803895|NCT00784888|OTHER|Aromatase inhibitors|non-interventional study
40803896|NCT06051019|OTHER|Aerobic training|Aerobic training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Sessions will be performed with the assistance or supervision of a physical therapist and will consist of the following steps: 1) warm up with a stationary bike (no load, 10 min, 60 cycles/min); 2) upper and lower limb stretching (10 min); 3) 10 min rest in a sitting position; 4) first exercise bout: stationary bike, 15 min, 60 cycles/min (the load will be modulated so that the participant's heart rate is between 60 and 70% of the estimated maximum heart rate, and the patient perceives moderate fatigue on the Borg Rating of Perceived Exertion; 5) upper and lower limb stretching (10 min); 6) 10 min rest in a sitting position; 7) second exercise bout (same parameters as the first exercise bout); 8) upper and lower limb stretching (10 min).
40803897|NCT06051019|OTHER|Balance training|Balance training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Treatments will be performed with a physical therapist and will consist of the following exercises: 1) standing with feet together, 2) standing with closed eyes, 3) standing on unstable surfaces, 4) standing while performing upper limbs movements; 5) standing while performing head rotations; 6) walking on a treadmill at alternating speeds; 7) leg press and chest press exercises for training trunk balance during ballistic movements of the upper and lower limbs. These constituents of balance training can be combined in the same task according to the participant's ability.
40803898|NCT03629223|DRUG|Tepotinib TF2|Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
40803899|NCT03629223|DRUG|Tepotinib TF3|Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
41006965|NCT00075166|PROCEDURE|Stereotactic surgery (SRS)|
41006966|NCT00075166|PROCEDURE|Craniotomy|
40803900|NCT01231334|DRUG|Dapsone plus Adapalene|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
40803901|NCT01231334|DRUG|Clindamycin/benzoyl peroxide plus Adapalene|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
40803902|NCT01120470|DRUG|OGX-427|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
40803903|NCT01120470|DRUG|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427"
40803904|NCT06470451|DRUG|Hypericin|HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
41006967|NCT01064791|DRUG|sotrastaurin (Dose 1) + tacrolimus + standard of care medications|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
41006968|NCT01064791|DRUG|sotrastaurin (Dose 2) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
41006969|NCT01064791|DRUG|sotrastaurin (Dose 3) + tacrolimus + standard of care medications|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
41006970|NCT01064791|DRUG|mycophenolic acid + tacrolimus + standard of care medications|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
41476919|NCT04076488|OTHER|Dividat Fit|tablet based, remote assisted home-training
41476920|NCT03570450|DRUG|Adipose derived Stem Cell|4 doses
41476921|NCT03570450|OTHER|placebo|placebo
41476922|NCT03378414|PROCEDURE|Intravenous infusion|Intravenous infusion of mesenchymal stem cells: 2 \* 10\^7 cells (30ml)
41476923|NCT03378414|PROCEDURE|Intrathecal injection|Intrathecal injection of mesenchymal stem cells: 2 \* 10\^7 cells (1ml)
41476924|NCT03378414|BIOLOGICAL|umbilical cord mesenchymal stem cell|Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure
41321452|NCT06145464|BEHAVIORAL|Adhesion to the use of collective shadow|Quantitative evaluation of the use of shadow provided by one or two collective fabric devices, with 6 per 3 metres of size, containing 100% UV blocking filters, that will be installed in the sand on Foz do Lizandro beach, according to the recommendations provided in all groups of the study.
41321453|NCT06145464|BEHAVIORAL|Adhesion to the use of sun protector|Quantitative evaluation of the use of sun protector according to the recommendations provided in all groups of the study.
41476925|NCT04703621|DRUG|Daratumumab Injection|subcutaneious daratumumab administration
40803905|NCT06470451|DRUG|Placebo|Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
40803906|NCT00397761|DRUG|capecitabine|
40803907|NCT00397761|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
40803908|NCT00397761|PROCEDURE|neoadjuvant therapy|
40803909|NCT00933608|DRUG|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
40803910|NCT00933608|DRUG|Placebo|participants will be asked to take 2 tablets per day to match active drug
40803911|NCT01140100|DRUG|propofol|
40803912|NCT01140100|DRUG|thiopental,propofol|
40803913|NCT02111915|BEHAVIORAL|THPP-P|Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
40803914|NCT02111915|OTHER|EUC|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
40803915|NCT03641716|BEHAVIORAL|Mealtime PREP Intervention|Each session will include didactic elements and skills training along with skills practice and feedback. Parents will learn to build structured mealtime routines, manage child mealtime behavior, and incorporate exploration and play into routines.
40803916|NCT05965583|DRUG|BI 1815368|BI 1815368
40803917|NCT05965583|DRUG|Itraconazole|Itraconazole
40803918|NCT02943317|DRUG|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
41321454|NCT06145464|BEHAVIORAL|Adhesion to the use of the information disposed in the infographic|Quantitative evaluation of the use of the information disposed in the infographic and provided in all groups of the study.
41321455|NCT06145464|BEHAVIORAL|Adhesion to the health literacy sessions in the interventional groups|Provision of health literacy sessions about skin cancer prevention by two different types of providers in the two interventional groups, 15 days before the use of sun protective interventions implemented at the beach
41321456|NCT04191603|DEVICE|MONOPOLAR HOOC|COLPOTOMY WITH MONOPOLAR HOOC
41476926|NCT00290251|DRUG|ulipristal acetate 20 mg|ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
41476927|NCT00290251|DRUG|ulipristal acetate 10 mg|10 mg given daily for three menstrual cycles or 90 - 102 days
40803919|NCT02943317|DRUG|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
40803920|NCT06320106|OTHER|Virtual Reality baseline assessment|"They undergo a baseline assessment (including cognitive level and pen and paper tests for visuo-spatial abilities). Then they perform a spatial navigation assessment with an immersive virtual reality application delivered by the Oculus Quest viewer. The spatial navigation application consists of a 5-way star-maze adapted from (Biffi et al 2020 Front. Psychol.) where the participants have to find a treasure hidden at the end of one way. The application measures both the learning of spatial information and the strategy used (egocentric or allocentric).~After the session, the participants fill questionnaires related to cyber-sickness and usability of the application."
40803921|NCT00412958|DRUG|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
40803922|NCT00412958|DRUG|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
40803923|NCT00412958|DRUG|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
40803924|NCT00412958|DRUG|Placebo|Intravitreal injection of placebo
40803925|NCT06301516|BEHAVIORAL|Virtual Reality|VR: The goal of the VR intervention is to provide youth an immersive, engaging, and therapeutic environment to reduce CD and CU traits
40803926|NCT06301516|OTHER|Comparative Control|Complete a one-time PowerPoint presentation that provides an overview of emotion expressions and instructions on how to recognize emotions in others.
40803927|NCT02382874|BIOLOGICAL|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
41321457|NCT04191603|DEVICE|PLASMAKINETIC BIPOLAR SPATULA|COLPOTOMY WITH BIPOLAR SPATULA
41321458|NCT06303492|PROCEDURE|GUS|Aspiration risk assessment by GUS
41321459|NCT06197542|OTHER|Active Release Technique|active TrP was identified, and sustained and constant pressure was applied .for stretching of the SCM muscle, the patient performed contralateral lateral flexion and ipsilateral rotation of the head to achieve stretching, for trapezius the therapist performed lateral flexion of the neck.
41321460|NCT06197542|OTHER|Instrument Assisted Soft Tissue Mobilization|The therapist applied IASTM strokes for 20 seconds parallel to muscle fibers, followed by strokes for 20 seconds perpendicular to muscle fibers with the tool held at a 45° to the skin. .
41321461|NCT03385174|OTHER|Carbon monoxide|Carbon monoxide inhalation
41321462|NCT04990375|DEVICE|tDCS|5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)
41476928|NCT00290251|DRUG|placebo|placebo given once daily for 3 menstrual cycles or 90 - 102 days
41006971|NCT04216082|DRUG|Anlotinib|Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
41006972|NCT05039970|OTHER|WellQuest™|WellQuest™ is a mobile device-based serious health game.
41006973|NCT04675320|BIOLOGICAL|blood samples|Blood sampling during PARP inhibitor therapy
41006974|NCT02884089|DRUG|Abemaciclib|Administered orally
41006975|NCT02884089|DRUG|Metformin|Administered orally
41006976|NCT02884089|DRUG|Iohexol|Administered intravenously (IV)
41006977|NCT02884089|DRUG|Placebo|Administered orally
41006978|NCT05580731|DIAGNOSTIC_TEST|Diagnostic test: 5 different Rapid diagnostic test and Reference tests|Diagnostic test: 5 different Rapid diagnostic test and Reference tests
41006979|NCT01588002|DRUG|danoprevir|multiple oral doses
40803928|NCT03082911|OTHER|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention."
41006980|NCT01588002|DRUG|efavirenz|multiple oral doses
41006981|NCT01588002|DRUG|ritonavir|multiple oral doses
41006982|NCT05168540|OTHER|no intervention|Children will be included on the occasion of an admission to pediatric unit, the emergency room, the intensive care unit or a consultation in a specialized unit for children at risk of abuse. Their primary care pathway will be analyzed.
41006983|NCT00742313|BIOLOGICAL|FloSeal Matrix|10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
41006984|NCT04143412|DRUG|Tritace (Ramipril 10 mg)|Stratified randomized clinical trial
41006985|NCT06571188|OTHER|THORACIC EPIDURAL BLOCK|In group TEB, The epidural catheter will be inserted preoperatively at the T5-T7 vertebral level; the exact level will be at the discretion of the attending anaesthesiologist. A loading dose of bupivacaine 0.25% (max 10 ml) will be administered, followed by an intraoperative infusion of bupivacaine 0.125 % with fentanyl 1 μg/ml.\].
41321463|NCT04641390|OTHER|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
41321464|NCT04641390|OTHER|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome not resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
41321465|NCT02915107|DEVICE|BioFreedom|PCI with BioFreedom
41321466|NCT02915107|DEVICE|Orsiro|PCI with BioFreedom
41321467|NCT03179579|PROCEDURE|HIPEC with neoadjuvant chemotherapy|HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles
41321468|NCT03179579|PROCEDURE|Systemic chemotherapy|NACT 3 cycles +CRS +ACT 4-6 cycles
41321469|NCT03293186|COMBINATION_PRODUCT|MEDICLORE|use MEDICLORE at the end of surgery as antiadhesive product
41321470|NCT05841264|BEHAVIORAL|good feeding, cleaning|taking healthy food which contain minerals, vitamins essential for normal growth
41321471|NCT00369967|DRUG|NuvaRing|Initiation of NuvaRing for contraception
41321472|NCT00517283|DRUG|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
41321473|NCT00517283|DRUG|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
41321474|NCT00517283|DRUG|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
41321475|NCT00293423|BIOLOGICAL|HSPPC-96|25 mcg
41006986|NCT06571188|OTHER|ERECTOER SPINE BLOCK|The ESP block will be performed as described by Forero et al
41321476|NCT00293423|PROCEDURE|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
41321477|NCT01026389|DRUG|Dotarem|DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
41006987|NCT02756793|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
41006988|NCT02756793|OTHER|Standard of Care Treatment|"May include:~* Continue with current systemic agent(s)~* Observation~* Switch to next-line treatment~Palliative radiotherapy is allowed in this arm."
41006989|NCT00733343|DEVICE|Europe: AutoSet CS (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
41006990|NCT05630807|DRUG|Bepirovirsen|Bepirovirsen will be administered.
41006991|NCT05630807|OTHER|Placebo|Matching placebo will be administered.
41006992|NCT06123884|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
41006993|NCT06123884|DRUG|Cisplatin|the usage and dosage should be determined by the investigator
41321478|NCT01026389|DRUG|Gadovist|Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
41321479|NCT00988260|DRUG|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
41321480|NCT00988260|DRUG|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
41476929|NCT03015714|OTHER|MIRT|MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
41006994|NCT06123884|DRUG|Bevacizumab Injection|Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
41006995|NCT06123884|DRUG|carboplatin|the usage and dosage should be determined by the investigator
41006996|NCT06123884|DRUG|Paclitaxel for Injection|the usage and dosage should be determined by the investigator
41006997|NCT01027793|DRUG|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
41006998|NCT01027793|DEVICE|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
41006999|NCT02403908|DEVICE|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery \<2 mm proximal from both ostia of right and left pulmonary arteries.
41321481|NCT00988260|DRUG|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
41321482|NCT03627494|DRUG|GSK3439171A|Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
41321483|NCT03627494|DRUG|Placebo|Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
41321484|NCT04311801|DIAGNOSTIC_TEST|Optical Coherence Tomography|Every patient underwent OCT examination before and after surgery.
41321485|NCT02530957|DEVICE|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
41321486|NCT02530957|DEVICE|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
41321487|NCT04142515|OTHER|no intervention|no intervention
41321488|NCT04422106|DIAGNOSTIC_TEST|Predictors of intestinal anastomosis leakage, application of new predictors and new scores|Early detection of disruption and leakage of intestinal anastomotic sites whether small or large intestine by using biochemical markers as predictors and indicators of leakage with application of scoring scale to assess presence or absence of leakage.
41321489|NCT05929885|DRUG|Low Dose OXIRI (LD-OXIRI)|"The LD-OXIRI regimen will be administered in the following sequence:~* metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis;~* intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 minutes on days 1 and 8 of a 21 day-cycle; followed by~* intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle. The dose of irinotecan will be based on the particular patient's UGT1A1\*6 and UGT1A1\*28 genotype status."
41321490|NCT06147713|DEVICE|Vibrotactile foot device (Smart shoe)|A foot device deliver vibrotactile stimulation triggered by a foot pressure sensor.
41476930|NCT03015714|OTHER|MIRT-AT|Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
41476931|NCT03971487|BEHAVIORAL|Psychosis and cognitive assessments|Administration of MINI, PANSS and Quality of Living scales
41007000|NCT02514252|DRUG|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
41007001|NCT02514252|BEHAVIORAL|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
41476932|NCT03971487|BEHAVIORAL|Physical and neuro-cognitive evaluations|Physical, neurological and cognitive evaluations.
41476933|NCT03971487|DIAGNOSTIC_TEST|Safety labs and electrocardiogram|Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
41476934|NCT03971487|BIOLOGICAL|Ocrelizumab infusion|Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
41476935|NCT03405376|DRUG|Intravitreal aflibercept injection|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
41476936|NCT06427902|OTHER|Periodontal clinical measurements, Saliva sampling|Clinical periodontal indices; Probing depth, Clinical attachment level, bleeding on probing, gingival index, and plaque
41476937|NCT03226119|DIAGNOSTIC_TEST|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
41321491|NCT00624728|RADIATION|18F Fluorothymidine PET CT|"18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (\>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (\> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction."
41007002|NCT02514252|BEHAVIORAL|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
41007003|NCT02514252|BEHAVIORAL|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
41007004|NCT01010282|DRUG|Glycerin and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
41007005|NCT01010282|DRUG|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
41007006|NCT01010282|DRUG|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
41007007|NCT01403090|DEVICE|Angel Catheter|The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
41476938|NCT01838382|DEVICE|classic LMA insertion|Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
41476939|NCT04831320|DRUG|nab-paclitaxel|Supplied by Celgene Corporation
41476940|NCT04831320|DRUG|Nivolumab|Supplied by Bristol-Myers Squibb
41007008|NCT01698463|OTHER|Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes|"The intervention was delivered in two visits and two follow-up phone calls.~* Physician identifies that the patient is at risk of falls or fractures~* Visit one: individualized exercise prescription by a physiotherapist.~* Visit two: motivational interviewing (behavioural counselling) by kinesiologist~* Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions."
41007009|NCT01057043|DEVICE|Pulsatile cupping|8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
41007010|NCT06267235|OTHER|Dietary protein restriction|The consumption of different diets restricted in protein replaced by either carbohydrate or fat and an habitual diet.
41007011|NCT00139126|BEHAVIORAL|Fire safety education|Education on smoke alarm maintenance based on behavioral theories
41321492|NCT00838006|DEVICE|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
41321493|NCT00838006|DEVICE|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
41476941|NCT01754818|DRUG|Bendavia 10mg|
41476942|NCT01754818|DRUG|Bendavia 50mg|
41476943|NCT01754818|DRUG|Bendavia 100mg|
41007012|NCT02204891|DIETARY_SUPPLEMENT|Probiotics in SIBO|Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days
41476944|NCT01754818|DRUG|Placebo|
41007013|NCT02204891|DIETARY_SUPPLEMENT|Probiotics|One capsule twice daily for 30 days
41007014|NCT03921411|BIOLOGICAL|Nemolizumab|Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
41321494|NCT00838006|DEVICE|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
41321495|NCT05715944|DRUG|AZD 1222|Vaccine
41476945|NCT04969042|DEVICE|Pins Medical G122 RS|G122RS model implanted spinal cord stimulation device, which could give closed-loop functional stimulation in the epidural space
41152533|NCT00730496|PROCEDURE|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
41476946|NCT04773717|DRUG|Ascorbic acid|200mg/kg/24h in four equal parts
41476947|NCT04773717|DRUG|Placebo|The same regimen as ascorbic acid.
41476948|NCT04478461|DRUG|PD-1 monoclonal antibody|"The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W"
41476949|NCT01583218|DRUG|Betrixaban|"Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days"
41476950|NCT01583218|DRUG|Enoxaparin|"Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days"
41007015|NCT03761251|BEHAVIORAL|Pet Fish|"Participants will be provided a fish tank with supplies to care for the fish and access to a fish (Betta splendens) from a local pet store. All participants will receive specific instructions for coupling the fish care and diabetes care:~1. feed fish one pellet in the morning after waking; check and record BG reading at that time~2. feed fish one pellet in the evening before dinner; check and record BG reading at that time~3. feed fish one pellet at night before bedtime; check and record BG reading at that time~4. every week clean the tank alternating with test the water quality in partnership with caregiver; review blood glucose readings with caregiver with each weekly fish care activity and problem solve any issues related to the blood glucose pattern.~Each child will also receive two books intended to supplement and enrich their pet fish experience."
41007016|NCT03744377|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
41007017|NCT00066196|BIOLOGICAL|MEDI--522|IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
41007018|NCT00066196|BIOLOGICAL|Integrin + Dacarbazine|supplied in other formulations
41007019|NCT01598116|PROCEDURE|Urine collection and ultrasonography|Bagged urine collection and ultrasound at each visit
41007020|NCT01598116|PROCEDURE|Urine collection|Bagged urine collection
41007021|NCT03578510|DEVICE|Hemocontrol hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.
41007022|NCT03578510|DEVICE|Standard hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.
41007023|NCT00197379|DRUG|roxithromycin|
41007024|NCT03553316|DRUG|PK101-002|-(Single) PK101-002
41007025|NCT03553316|COMBINATION_PRODUCT|PK101|-(Combination) PK101-001, PK101-002
41007026|NCT03066765|DEVICE|Linguaflex Tongue Retractor|Tongue implant
41007027|NCT06193434|DRUG|IBI356 for MAD|Receive IBI356 in a multiple dose.
41476951|NCT01371994|DRUG|solifenacin succinate|oral
41476952|NCT01371994|DRUG|Placebo|oral
41476953|NCT04154826|DRUG|Recombinant human interleukin-7|weekly intra-muscular (IM) administration
41476954|NCT05826132|OTHER|Adjusted Content Intervention|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman
41007028|NCT06193434|DRUG|Dupilumab for MAD|Active comparator
41007029|NCT06193434|DRUG|IBI356 for SAD|Receive IBI356 in a single dose.
41007030|NCT06193434|DRUG|Placebo for SAD|Receive placebo in a single dose.
41007031|NCT06193434|DRUG|Placebo for MAD|Receive placebo in a multiple dose.
41007032|NCT01790464|DRUG|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
41007033|NCT01790464|DRUG|placebo|
41007034|NCT05970120|DEVICE|NUVISION NAV Ultrasound Catheter|Participants will be scheduled to have a clinically-indicated ablation procedure using NUVISION NAV ultrasound catheter for management of atrial procedure.
41007035|NCT05154448|DEVICE|Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
41007036|NCT05154448|OTHER|Sham procedure|Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy
41007037|NCT05066620|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
41007038|NCT01408186|DRUG|Rabeprazole|Rabeprazole 20 mg daily
41007039|NCT01408186|DRUG|Famotidine|Famotidine 40mg daily
41007040|NCT05907304|DRUG|Naporafenib|Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor
41152534|NCT00249847|DRUG|Paroxetine controlled-release|2-12.5 mg tablets, orally, every day for 4 weeks
41007041|NCT05907304|DRUG|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
41007042|NCT03228810|OTHER|Blood draw|(2) 10 mL tubes will be collected
41007043|NCT03228810|PROCEDURE|Tissue biopsy|Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
41007044|NCT04671459|COMBINATION_PRODUCT|TTFields and SRS|SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.
41007045|NCT06192225|BEHAVIORAL|pre-trained guided slow paced breathing (~6 breaths per minute)|Slow PACE breathing
41007046|NCT01637350|PROCEDURE|digestive tract reconstruction|Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
41007047|NCT05519228|DEVICE|ToggleLoc 2.9 mm Soft Tissue System|The ToggleLoc 2.9 mm Soft Tissue System consist of non-resorbable device intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation
41007048|NCT05558228|DEVICE|FloPatch FP120|FloPatch FP120 is an FDA 510(k) cleared device indicated for the non-invasive assessment of blood flow in the carotid artery by medical professionals, such as physicians and nurses. FloPatch uses ultrasound and the Doppler effect to assess blood flow.
41007049|NCT05983575|DEVICE|LIPUS-Brain|Transcranial low-power pulsed-wave ultrasound device
41007050|NCT05983575|DEVICE|Placebo|Placebo
41007051|NCT06095843|PROCEDURE|placement of dental implants|placement of dental implants in mandibular reconstruction.
41007052|NCT02637843|DEVICE|Slender Sheath|Comparing outcomes for two different sheaths used during radial CAG/PCI
41007053|NCT04528810|OTHER|not applicable (Observational Study)|This is an observational study and does not include interventions.
41476955|NCT05826132|OTHER|Non-Adjusted Intervention Video|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics
41476956|NCT00057486|DRUG|IL-12|
41321496|NCT05625971|OTHER|MRD Assessment|MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).
41007054|NCT01227512|DRUG|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
41007055|NCT01227512|OTHER|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
41007056|NCT04394728|DRUG|Trabectedin|1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.
41007057|NCT06281028|DEVICE|SOLACEA-H/HYDROLINK-NVU|Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU.
41007058|NCT06281028|DEVICE|HYDROLINK-NVU/SOLACEA-H|Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H.
41007059|NCT04358497|DEVICE|Medtronic® Concerto® detachable coil system|coil embolization of the reflux pathways
41007060|NCT04358497|PROCEDURE|sclerosis|Pelvic varices sclerosis with polidocanol foam
41007061|NCT04358497|DRUG|Diosmin / Hesperidin|Best chronic medial treatment
41007062|NCT04358497|DRUG|Ibuprofen 400 mg|NSAID treatment
41007063|NCT06296303|OTHER|Pulsed electromagnetic therapy|Pulsed etromagnetic therapy (1000 gauss) on sciatic nerve in gluteal fold. ( 30 min )
41007064|NCT06296303|OTHER|Ultrasound phonophoresis|Phonophoresis using dexamethasone and topical diclofenac sodium gel on sciatic nerve in subgluteal fold and mid thigh
41007065|NCT06296303|OTHER|Conventional physical therapy|"Conventional physical therapy consisting of~1. IF current on lumbar spine. (15 min )~2. Hotpack on lumbar spine . (15 min )~3. Neurodynamic mobilization .~4. Mobilization and manipulation for lumbar spine.~5. Exercises"
41007066|NCT04488029|OTHER|PCT|PCT is designed to deliver similar therapy as is conventionally provided in-clinic by a Speech Language Pathologist (SLP), which the patient can access from any location using the application installed on a supported tablet. The device functions by allowing clinicians to create a personalized therapy program for each patient from 75 categories of clinical therapies, which patients may access from their tablet device remotely. The PCT software is comprised primarily of authentication and an algorithm that suggests advancement of the therapy program based on observed patient deficits and progress.
41007067|NCT04488029|OTHER|Workbooks|Subjects in this group will be provided with a standard regime of paper workbooks (e.g. Workbook for Aphasia: Exercises for Expressive and Receptive Language Functioning; Brubaker, 2006) that are typically used by clinicians to practice therapy tasks with individuals. Notably, the control procedure employed here is similar to that employed on a large-scale study examining technology as a treatment option and involved usual care control group by Palmer and colleagues (2015).
41007068|NCT01384084|PROCEDURE|POP repair plus mini-sling|"For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.~A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh."
41007069|NCT01384084|PROCEDURE|POP repair|For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
41007070|NCT01974193|DRUG|Floseal|application of floseal on intervention arm
40803929|NCT03082911|OTHER|Invitation letter|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
41007071|NCT01586468|DRUG|WF10|0.5 mg/kg B.W.
41007072|NCT01586468|DRUG|NaCl Solution|NaCl Solution
41007073|NCT02985294|OTHER|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
41007074|NCT00737516|BIOLOGICAL|HPC, Cord Blood|Search for HLA compatible cord blood units using the NMDP registry
40803930|NCT04324541|DIAGNOSTIC_TEST|PET scan of the brain with Flortaucipir|PET scan of the brain with non FDA approved Radio tracer.
40803931|NCT04861818|BEHAVIORAL|Moderate-intensity aerobic exercise|Eligible participants will come into the lab on day 1 and 3 at the same time of day (either morning at 7-10am or afternoon at 3-5pm). They will be then randomly assigned for a rest or an exercise session prior to the memory test. For the rest condition, they will be required to sit and relax while watching Planet Earth for 30 minutes on a cycle ergometer. During the exercise session, they will complete a moderate-intensity cardiovascular exercise for 20 minutes following a 5-min warm-up and followed by a 5-min cool-down on a cycle ergometer. They will start the memory test immediately after the rest/exercise session.
40803932|NCT00203736|DRUG|Sulfadoxine-pyrimethamine|
40803933|NCT00203736|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
40803934|NCT05045430|DEVICE|Silver II Non-Woven Dressing|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
40803935|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.11 mL x subject height
40803936|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.22 mL x subject height
40803937|NCT03691337|DRUG|Sodium chloride|Fascia iliaca block with volume 0.11 mL x subject height
40803938|NCT03652363|DRUG|glial cell line-derived neurotrophic factor|Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
40803939|NCT00178919|DRUG|L-NMMA|IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.
40803940|NCT00178919|DRUG|Trimethaphan|IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
40803941|NCT03608241|DRUG|PF-06651600|200 mg by mouth (PO) Once daily (QD) for 11 days
40803942|NCT03608241|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
40803943|NCT02026674|DEVICE|FloRite|Disposable home use urine flow meter.
40803944|NCT02173639|DRUG|BI 1356/metformin|fixed dose combination tablet
40803945|NCT02173639|DRUG|BI 1356|
40803946|NCT02173639|DRUG|Metformin|
40803947|NCT01912443|DRUG|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
40803948|NCT05501210|DEVICE|WBV|Whole body vibration (WBV) therapy
40803949|NCT05501210|DEVICE|PEMF|Pulsed electromagnetic fields (PEMF)
40803950|NCT05638412|BEHAVIORAL|JASPER|JASPER is a therapist and caregiver-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes caregivers as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
41007075|NCT02178033|DRUG|Split dose low-volume PEG solution|"All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure."
41007076|NCT06130722|DRUG|FL115|FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
41321497|NCT05699317|OTHER|Thermal stimuli|"Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).~Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.~Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied."
41321498|NCT04526119|DRUG|Acotiamide hydrochloride hydrate|A white film-coated tablet containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase Administered orally, one tablet a time and three times a day before meals for 28 days in the open-label phase
41321499|NCT04526119|DRUG|Placebo|A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase
41321500|NCT00451750|DRUG|Cortisol|20 mg for 3 times
41321501|NCT04991883|OTHER|case series review of clinical and histological data|We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.
41321502|NCT03605199|DRUG|Denosumab|Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.
41476957|NCT06085573|DRUG|Dexmedetomidine Hydrochloride|"\<Sedation of non-invasive procedures and tests without intubation in pediatrics\> For children aged 2 years or older, the usual dosage of dexmedetomidine is 12 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~For children aged 1 month to \< 2 years old, the usual dosage of dexmedetomidine is 9 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~The infusion rate should be reduced according to patient's condition."
41321503|NCT03046342|DIAGNOSTIC_TEST|Molecular method (PCR)|"Stool samples are being processed through molecular method (PCR) for children with GE.~Epidemiology of acute Gastroenteritis in the pediatric population in Qatar"
41321504|NCT05043246|BIOLOGICAL|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
41321505|NCT01338883|DRUG|Cenicriviroc 100 mg|100 mg CVC plus Truvada
41321506|NCT01338883|DRUG|Cenicriviroc 200 mg + Truvada|200 mg CVC plus Truvada
41321507|NCT01338883|DRUG|Sustiva + Truvada|Sustiva plus Truvada
41321508|NCT06071637|PROCEDURE|Double low-power laser therapy simultaneous applicated|Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck
41476958|NCT05198388|DIAGNOSTIC_TEST|βeta endorphins, interleukin 6 and interleukin 38|"* - Collection of peripheral blood samples in gel tube.~* - Creparation of samples in centrifuge to obtain serum.~* - Measurement of interleukin 6 and interleukin 38 and βeta endorphins using ELISA method."
41007077|NCT06448741|OTHER|Replantation of amputated penis|Replantation of the amputated penis done macroscopically, but testicular replantation was not done because of lack of microsurgical access
41007078|NCT02567513|BEHAVIORAL|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
41007079|NCT02567513|BEHAVIORAL|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
41007080|NCT01179971|DIETARY_SUPPLEMENT|Fish oil, gamma-linolenic acid|3 g/d DHA + EPA
41007081|NCT03325166|DRUG|Ferumoxytol|Given IV
41007082|NCT03325166|OTHER|Laboratory Biomarker Analysis|Correlative studies
41007083|NCT03325166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41007084|NCT03325166|BIOLOGICAL|Pembrolizumab|Given IV
41321509|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
41321510|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
41321511|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
41321512|NCT01112423|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
41321513|NCT01464242|DRUG|Meglumine antimonate|Glucantime® 20mg/kg/day IM daily for 20 days
41321514|NCT01464242|DRUG|Placebo|Placebo 400mg orally 3 times a day for 20 days
41321515|NCT01464242|DRUG|Pentoxifylline|Pentoxifylline 400mg orally 3 times a day for 20 days
41321516|NCT03511820|DRUG|Lipo-AB® (amphotericin B) liposome|"1. Name: Lipo-AB® (amphotericin B) liposome for injection~2. Dosage form: Lyophilized powder 50 mg/vial~3. Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day~4. Dosing schedule:~All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision."
41321517|NCT05092295|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
41321518|NCT05092295|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
41321519|NCT00142012|BEHAVIORAL|Nutrition Intervention|
41321520|NCT03427541|PROCEDURE|Surgeries|Surgeries
41321521|NCT06356948|DRUG|Tranexamic Acid (TXA)|Study drug administration
41321522|NCT02700295|DEVICE|Orthokeratology lens|
41007085|NCT03304899|DRUG|RiaSTAP Injectable Product|"RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~(\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))"
41007086|NCT02580370|BIOLOGICAL|Botulinum toxin type A|Topical botulinum toxin type A
41007087|NCT02580370|BIOLOGICAL|Placebo comparator|Topical placebo comparator
41321523|NCT03907787|DIETARY_SUPPLEMENT|Zingiber officinale and Acmella oleracea|Subjects were supplied for four weeks with two tablets/day and there was the evaluation of pain intensity, by a 30-days Visual Analogue Scale (VAS) and b) the assessment of knee function by Western Ontario and McMaster Universities Arthritis Index and by Tegner Lysholm Knee Scoring collected at baseline, at 15 and 30 days after treatment, Health-related quality of life, by the ShortForm36, inflammation by C-reactive protein and Erythrocyte Sedimentation Rate, body composition by dual-energy X-ray absorptiometry measured at baseline and 30 days after treatment.
41321524|NCT04101578|DRUG|Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
40803951|NCT05638412|BEHAVIORAL|Psychoeducational Curriculum|The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The material provided will be similar to what a pediatrician or developmental specialist may review as a part of routine care.
40803952|NCT06290531|DEVICE|Buzzy device (cold and vibration)|The device produces cold and vibration to act on the gate control theory and provide painless injection by nerve distraction
40803953|NCT06290531|DEVICE|Buzzy device (vibration only)|The device produces vibration to act on the gate control theory and provide painless injection by nerve distraction
40803954|NCT06290531|OTHER|precooling|Ice cubes used for applying coolness at the injection area
40803955|NCT06290531|OTHER|Flavored Benzocaine topical anesthetic gel 20%|Topical anesthetic gel
40803956|NCT00804752|DRUG|Adding vitamin D|Adding 1000IU/Vitamin D daily
40803957|NCT00804752|DRUG|Vitamin D|Addition of 1000IU/day Vitamin D
40803958|NCT06277947|PROCEDURE|China Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC)|The C-HIPEC would be performed at bedside in the general ward within 24 hours after surgery. The HIPEC treatment instruments are BR-TRG-II system, which can control the temperature stably to 43℃±0.1℃.
40803959|NCT05020834|OTHER|Functional Electrical Stimulation|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
40803960|NCT05020834|OTHER|TheraTogs Orthotic Undergarment|TheraTogs Arm The participating children worn TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
40803961|NCT05398029|DRUG|VERVE-101|Intravenous (IV) infusion.
41152535|NCT00249847|DRUG|Conjugated equine estrogen|0.625 mg tablet, orally, every day for 4 weeks
41007088|NCT03918343|OTHER|Blood sample|blood samples (4 times; 14ml per visit)
41007089|NCT00350766|PROCEDURE|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
41007090|NCT02136875|DRUG|Double dose of Salmeterol + Fluticasone Propionate|
41007091|NCT02136875|BEHAVIORAL|Self-management education on the use of a self-administered prescription for exacerbation.|Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
41007092|NCT02136875|DRUG|Self-administered prescription|"An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days"
41007093|NCT06097884|OTHER|Main study intervention-Salt substitute|replacing regular salt with salt substitute in school meals
41152536|NCT03696147|DEVICE|Magnetic resonance imaging|Diffusion weighted sequence of MRI
41152537|NCT04967274|PROCEDURE|Startling acoustic stimulus|StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus.
41321525|NCT03943888|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration
41321526|NCT03943888|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration
41321527|NCT03943888|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration
40803965|NCT02954887|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
41007094|NCT06097884|OTHER|Main study control-Usual salt|Use usual salt in school meals
41007095|NCT06097884|OTHER|Ancillary study intervention-Meal trays|Replacing bowls with trays in school cafeteria
41007096|NCT06097884|OTHER|Ancillary study control-Bowls|Use bowls in school cafeteria
41007097|NCT00330551|DRUG|Oral Risperidone|Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.
41321528|NCT03943888|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
41476959|NCT05462730|DRUG|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
41007098|NCT00330551|DRUG|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
40803966|NCT02476032|DEVICE|Prof applied oxalate|Crest Sensi-Stop strips (Procter \& Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
40803967|NCT02476032|DEVICE|Self applied oxalate|Subjects will apply the strips (Procter \& Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
40803968|NCT02476032|DEVICE|Prof applied placebo|Crest Sensi-Stop strips (Procter \& Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
40803969|NCT03365687|DIETARY_SUPPLEMENT|Vitamin D|2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months
40803970|NCT03365687|DIETARY_SUPPLEMENT|Placebo|2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
41007099|NCT04640948|DEVICE|High flow nasal therapy|Controlled oxygen administration using at least 20 L/min of flow rate and titrated up as tolerated. Titration of supplemental oxygen to an arterial saturation between 88 - 92%.
41007100|NCT04640948|DEVICE|Low flow oxygen|Controlled oxygen administration using (venturi mask or nasal cannulae) titrated to an arterial saturation between 88 - 92% as the initial oxygen administration method with a flow rate of \<20 L/min.
41321529|NCT04344379|DRUG|hydroxychloroquine|200 mg BID per day
41321530|NCT04344379|DRUG|azithromycin|250 mg per day
41321531|NCT04344379|DRUG|hydroxychloroquine placebo|200 mg BID per day
41321532|NCT04861948|DRUG|IBI188|intravenous
41476960|NCT05462730|DRUG|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
40803971|NCT01455922|DRUG|ITCA 650|ITCA 650 is exenatide in DUROS
40803972|NCT01455922|DRUG|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
40803973|NCT05412927|DEVICE|PMA P150009 AngelMed Guardian® System|"The AngelMed Guardian® System is an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The Guardian® System is indicated for use in patients who have had prior ACS events and who remain at high risk for recurrent ACS events. The Guardian® System is indicated as an adjunct to patient recognized symptoms. The Guardian® System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events.~A Guardian® System alert is a more accurate predictor of ACS events when compared to patient recognized symptoms alone and demonstrates a reduced rate over time of patient presentations without ACS events (false positives) when compared to patient recognized symptoms alone. In the absence of symptoms, the Guardian® System may identify asymptomatic ACS events and prompt the patient to seek medical attention."
40803974|NCT01296893|BEHAVIORAL|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
41476961|NCT00732524|DRUG|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
41476962|NCT00732524|DRUG|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
40803975|NCT06475989|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40803976|NCT06475989|DRUG|Cabozantinib|Given PO
40803977|NCT06475989|PROCEDURE|Computed Tomography|Undergo CT scan
40803978|NCT06475989|DRUG|Dabrafenib|Given PO
41321533|NCT04861948|DRUG|GM-CSF|subcutaneous injection
41321534|NCT04861948|DRUG|Cisplatin/Carboplatin|intravenous
41321535|NCT04861948|DRUG|Bevacizumab|intravenous
41321536|NCT04861948|DRUG|Sintilimab|intravenous
41321537|NCT04861948|DRUG|Pemetrexed|intravenous
41321538|NCT01758211|PROCEDURE|fMRI Navigation AVM resection|intraoperative fMRI navigation guided resection in AVM patients
41321539|NCT01758211|PROCEDURE|conventional resection|conventional resection in AVM patients
41321540|NCT06216587|DIETARY_SUPPLEMENT|BLa80|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BLa80.
41321541|NCT05823168|DRUG|Antiepileptic Drug|we osberve the efficacy of antiepileptic drungs on preventing seizures and their impact on rehabilitation outcome
41321542|NCT05118542|DRUG|Propylthiouracil|PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
41321543|NCT05118542|DRUG|Methimazole|methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
41321544|NCT02402712|DRUG|Docetaxel|Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
41321545|NCT02402712|DRUG|pertuzumab [Perjeta]|Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
40803979|NCT06475989|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40803980|NCT06475989|OTHER|Questionnaire Administration|Ancillary study
41007101|NCT00699972|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
41007102|NCT00699972|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
41007103|NCT00699972|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
41152538|NCT01268488|DEVICE|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
41321546|NCT02402712|DRUG|trastuzumab [Herceptin]|Subcutaneous administration of 600 mg/5 mL every 3 weeks
41321547|NCT00012896|BEHAVIORAL|Telephone Care + Educational (AV Materials)|
41321548|NCT05425719|DRUG|MB-102|18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
41321549|NCT05425719|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants had a transdermal sensor placed on their upper chest, and the MediBeacon Transdermal GFR Measurement System was initiated to collect background fluorescence. After collection of background fluorescence, participants received a single dose of MB-102.
41321550|NCT01900756|BEHAVIORAL|THRIVES|Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
41321551|NCT03838445|DEVICE|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovals and straddles the interatrial septum.
41321552|NCT00897052|GENETIC|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
41321553|NCT00897052|OTHER|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
41321554|NCT00609011|DRUG|MPC-6827 + Temozolomide|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
41321555|NCT04868370|OTHER|Assessment of the upper limb (VPIT + PPIT)|Assessment of the upper limb sensorimotor function (VPIT and PPIT)
41321556|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: intermittent theta burst to dorsolateral prefrontal cortex|TMS will be delivered over the dorsolateral prefrontal cortex (dlPFC) using an intermittent bursting pattern
40803981|NCT06475989|DRUG|Trametinib|Given PO
41321557|NCT05931913|BEHAVIORAL|Exposure with Response Prevention|ERP will be delivered daily, immediately following TMS
40803982|NCT01635270|RADIATION|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
40803983|NCT01635270|RADIATION|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
40803984|NCT03953508|OTHER|Cigarette flavor type|Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
40803985|NCT04254692|DRUG|Liposomal bupivacaine|Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.
40803986|NCT04254692|OTHER|Standard of care|Participants in the standard of care group will receive intraoperative injection of bupivacaine only to the abdominal wall
41007104|NCT04734340|PROCEDURE|EIT-guided PEEP setting|Ventilator parameter setting by EIT
41007105|NCT04734340|PROCEDURE|ARDS-net PEEP setting|Ventilator parameter setting according to ARDS-net table
41007106|NCT00640510|DRUG|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
41007107|NCT00640510|DRUG|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
41007108|NCT05012605|OTHER|Observation|Observe physical function and sleep disorder symptoms following stroke
41152539|NCT00924209|DRUG|Gemcitabine|1250 mg/m\^2 dose for two doses on days 1 and 8
41152540|NCT00924209|DRUG|Cisplatin|80 mg/m\^2 on day 1
41152541|NCT00924209|DRUG|Bevacizumab|7.5 mg/m\^2 on day 1 every 21 days for first two cycles only
41152542|NCT00924209|PROCEDURE|Surgery|thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
41321558|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: Sham|Sham stimulation will use the Magstim sham air-cooled coil, which produces auditory signals and appears identical to an active coil but contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (\<3%) magnetic field is delivered to the cortex
41321559|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area|TMS will be delivered over the pre supplementary motor area (preSMA) using a continuous bursting pattern
41321560|NCT01752439|DEVICE|Anodal transcranial direct current stimulation|
41476963|NCT01849016|DRUG|N-Acetylcysteine|
40803987|NCT00617084|DEVICE|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
40803988|NCT00617084|DEVICE|Abbott Xience V|Abbott Xience V
41476964|NCT01849016|DRUG|Placebo|
41007109|NCT03318848|OTHER|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
41007110|NCT00298831|DRUG|Sugammadex|At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
41007111|NCT00298831|DRUG|Rocuronium|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
41007112|NCT00446719|DRUG|Rellidep|2000 mg P.O. daily for 8 weeks
41007113|NCT01894828|DIETARY_SUPPLEMENT|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
41007114|NCT05411796|DEVICE|Tampax menstrual cup|regular flow size
41007115|NCT05411796|DEVICE|Other menstrual cup|size 1
41152543|NCT00924209|DRUG|Etoposide|100 mg/m\^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
41476965|NCT03711214|PROCEDURE|Periodontal scaling|Periodontal scaling and root planing
41321561|NCT01752439|DEVICE|Sham transcranial direct current stimulation|
41321562|NCT05891691|BEHAVIORAL|Music Activities, Yoga, Massage|The program begins with music and dance movements using percussion instruments (rhythm stick, stone triangle, drum, cymbal, tambourine, maracas, etc.) and body percussion. In this phase, the children will follow the instructions of the researcher. The goal is to warm up the bodies and musically experience the beginning of the program After the warm-up, yoga postures are combined with breathing techniques that focus on developing awareness of body sensations and feelings.The daily program ends with massage. During the massage application, the children sit in a circle. The massage is performed by the children observing the movements of the researcher on their arms and legs and applying them on their own arms and legs.Yoga postures, breathing techniques, and massage practices are accompanied by stories to ensure children's active participation, encourage their development, and facilitate their acquisition of new approaches.
41476966|NCT03940482|BEHAVIORAL|Time Restricted Eating As Treatment (TREAT) for Diabetes.|Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
41476967|NCT05616078|OTHER|laser treatment|a maximum of 4 sessions, with an interval of 3 to 4 weeks
40803989|NCT06235359|DEVICE|intercostal tube|"A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand."
40803990|NCT02579421|DRUG|Progesterone|generic progesterone
40803991|NCT02579421|DRUG|placebo|placebo
41476968|NCT05616078|OTHER|cryotherapy|a maximum of 4 sessions, with an interval of 3 to 4 weeks
41476969|NCT03475134|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
41007116|NCT04925297|OTHER|No intervention|No intervention will be given
41007117|NCT03477500|DRUG|Cyclophosphamide and ATG|Hematopoetic stem cell transplantation
40803992|NCT01465867|DIETARY_SUPPLEMENT|Selenium|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
40803993|NCT01465867|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
41007118|NCT03477500|DRUG|Alemtuzumab|Alemtuzumab (Lemtrada)
41007119|NCT03477500|DRUG|Cladribine Pill|Cladribine (Mavenclad)
41007120|NCT03477500|DRUG|Ocrelizumab|Ocrelizumab (Ocrevus)
41007121|NCT00224211|BEHAVIORAL|Music|
41007122|NCT00689481|DRUG|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
41007123|NCT00689481|DRUG|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
41007124|NCT00004923|DRUG|docetaxel|
41007125|NCT00004923|DRUG|irinotecan hydrochloride|
41007126|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
41007127|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
41007128|NCT02268981|DEVICE|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
41152544|NCT00653419|DRUG|buspirone HCl|Tablets, 30 mg, single-dose
41152545|NCT00653419|DRUG|Buspar|Tablets, 30 mg, single-dose
41152546|NCT06011928|OTHER|MOPEX Exercise|"Exercises to be done in order:~1. Pelvic tilt in supine position~2. Bridge building~3. Pelvic stretching~4. Ball spin~5. Cat-camel exercise~Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds"
41476970|NCT03475134|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
40803994|NCT01465867|OTHER|Selenium + L-Thyroxine (LT4)|"83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
40803995|NCT01465867|OTHER|Sugar Pill Placebo + L-Thyroxine (LT4)|"Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
40803996|NCT02620423|BIOLOGICAL|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
40803997|NCT02620423|DRUG|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
40803998|NCT02620423|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
40803999|NCT02620423|DRUG|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
40804000|NCT02620423|DRUG|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
40804001|NCT02620423|DRUG|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
40804002|NCT02620423|DRUG|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
40804003|NCT01803100|OTHER|No intervention|There is no intervention in this trial
40804004|NCT05435131|DIAGNOSTIC_TEST|GCF obtaining|GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant
40804005|NCT05435131|DIAGNOSTIC_TEST|Saliva Obtaining|Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant
40804006|NCT05435131|DIAGNOSTIC_TEST|Serum obtaining|Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum
40804007|NCT06071663|PROCEDURE|Single and two visits pulpectomy|Comparison of clinical and radiographic outcome of Single and two visits pulpectomy
40804008|NCT00681395|DRUG|ABT-143|once daily for 6 days
40804009|NCT00681395|DRUG|ABT-335|once daily for six days
40804010|NCT00681395|DRUG|Rosuvastatin|Once daily for 6 days
40804011|NCT04891575|BEHAVIORAL|Active Control Intervention educational sessions|The participant will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
40804012|NCT04891575|BEHAVIORAL|Family Dyad Intervention|The participant and a co-participating family member will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
40804013|NCT05026658|DEVICE|Visibly Digital Acuity Product|"The order of testing (two VDAP home environments and ETDRS) will be randomly assigned for each subject as one of four sequences:~1. V1, E, V2~2. E, V1, V2~3. V2, E, V1~4. E, V2, V1~Where E denotes the ETDRS assessment, V1 denotes the VDAP assessment in home environment 1, and V2 denotes the VDAP assessment in home environment 2.~The randomization will be blocked in groups of 4 subjects to ensure balance for the VA testing sequences."
41321563|NCT01497535|DRUG|insulin detemir|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
41321564|NCT01497535|DRUG|insulin glargine|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
41321565|NCT01464788|DRUG|Low Dose Argatroban|100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
41321566|NCT01464788|DRUG|High Dose Argatroban|100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
41321567|NCT01464788|DRUG|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
41321568|NCT01549743|DRUG|Celecoxib|Celecoxib 200mg will be administered orally twice a day for 3 days
41321569|NCT01549743|DRUG|Rebamipide|Rebamipide 100mg will be administered orally three times a day for 3 days
41321570|NCT01549743|DRUG|Celecoxib plus Rebamipide|"Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide"
41321571|NCT06435182|DRUG|OT202 conc 0.5%|Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily
41321572|NCT06435182|DRUG|OT202 conc 0.1%|Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily
41321573|NCT06435182|DRUG|Placebo|Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily
40804014|NCT05734911|DRUG|Niraparib|We did not set a fixed starting dose and strict medication standard,compared with a randomized controlled trial.In our study,enrolled patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death in reality. We were interested in the dose adjustment and duration of niraparib in real world.
40804015|NCT04908384|BEHAVIORAL|Improving Asthma Care Together (IMPACT)|IMPACT is a novel health application and wearable device
40804016|NCT05085093|BIOLOGICAL|HPV vaccine|Patients choose to be vaccinated or not to be vaccinated with HPV vaccine according to their own wishes
40804017|NCT05869058|DIAGNOSTIC_TEST|a deep convolutional neural network|a deep convolutional neural network developed for detection and assessing the perfusion of parathyroid gland during endoscopic thyroidectomy
41321574|NCT01787799|DEVICE|SYNERGY|Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.
41321575|NCT01479374|DRUG|AL-4943A ophthalmic solution|
41321576|NCT01479374|DRUG|AL-4943A vehicle|Inactive ingredients used as placebo
40804018|NCT03855787|PROCEDURE|Ureteroscopy|Ureteroscopy for 1.5cm or less renal stones.
41007129|NCT05980780|BEHAVIORAL|video game group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a video game. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The game will be played at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
40804019|NCT02371577|DRUG|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
40804020|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with mechanical debridement|Non-surgical treatment of peri-implantitis with mechanical debridement .
41007130|NCT05980780|BEHAVIORAL|Education booklet group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a training booklet. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The booklet will be read at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
41007131|NCT05844696|DEVICE|Soterix MXN-5 HD-tES Model 5005A. Medtronic Percept DBS platform.|"〔Part 1〕Using Soterix MXN-5 HD-tES Model 5005A. Three treatment groups: sham control, continuous tDCS, slow-oscillatory tDCS.~〔Part 2〕Using Medtronic Percept DBS platform. Single group:Neuromodulation."
41321577|NCT01479374|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
41321578|NCT02211183|PROCEDURE|Best Repair of torn Rotator Cuff|
41321579|NCT02211183|DEVICE|InSpace™ system|
41321580|NCT02881879|BIOLOGICAL|Allergovac depot DPT/DF (50:50)|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
41321581|NCT00728312|DRUG|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
40804021|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with air polishing|Non-surgical treatment of peri-implantitis with air polishing
40804022|NCT04645316|DRUG|Sevoflurane|In the sevoflurane group (n = 25), after the induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, the Sevoflurane concentration will be adjusted between 1-2%, the BIS value will be 40-60, and it will be inhaled with an air / O2 mixture to be FiO2: 0.4.
40804023|NCT04645316|DRUG|Desflurane|In the desflurane group (n = 25), after induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, Desflurane concentration will be adjusted between 6-8%, BIS value will be 40-60 and it will be inhaled with a mixture of air / O2 mixture to be FiO2: 0.4.
41321582|NCT00728312|DRUG|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
41321583|NCT00967109|OTHER|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
40804024|NCT04645316|DRUG|Propofol|In the propofol-remifentanyl group (n = 25), rocuronium 0.6 mg / kg will be administered for intubation after 2 mg / kg propofol and 1 µg / kg remifentanil. Maintenance of anesthesia will be adjusted to be between 10 mg / kg / h for the first 10 minutes, 8 mg / kg / h for the following 10 minutes, and then by 6 mg / kg / h propofol infusion, with the BIS value between 40-60. Patients in this group will be inhaled with a mixture of air / O2 to be FiO2: 0.4. Inhalation anesthetics will not be used in this group.
41321584|NCT00967109|OTHER|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
41476971|NCT03475134|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
41321585|NCT05896046|DRUG|SHR2554+ SHR1701|SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.
40804025|NCT03365258|DIETARY_SUPPLEMENT|Trophic feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.
40804026|NCT03365258|DIETARY_SUPPLEMENT|volume-based feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
40804027|NCT05257499|BEHAVIORAL|On line debriefing|Online Debriefing in the Simulation Sessions of the Helping Babies Breathe Course
40804028|NCT02397915|DRUG|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
40804029|NCT02397915|DRUG|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
40804030|NCT01748708|DEVICE|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
40804031|NCT01748708|DEVICE|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
40804032|NCT04150146|DRUG|Rebamipide SR 150mg after high-fat meal|Test Drug
40804033|NCT04150146|DRUG|Rebamipide SR 150mg under fasting condition|Reference Drug
40804034|NCT02458131|BEHAVIORAL|TEEN HEED|Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
41321586|NCT05896046|DRUG|SHR-1701|Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.
41476972|NCT03475134|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
40804035|NCT00954629|DRUG|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
40804036|NCT00954629|DRUG|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
40804037|NCT00386217|BEHAVIORAL|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
41321587|NCT03164785|DRUG|Jinshuibao Capsule|1.98g t.i.d. p.o. for 6 months
40804038|NCT04646304|OTHER|Objective Feedback (Motion Capture)|Participants assigned to the objective feedback group will be given a report after completing Set 1 and Set 2. This report will outline their performance for each significant factor (identified in Phase 1) relative to a target interval, derived from the staff surgeon group average (± one standard deviation). Participants assigned to the objective feedback group will then be able to repeat the tasks knowing which variables to improve.
41321588|NCT00997321|DRUG|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
41321589|NCT00997321|DRUG|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
40804039|NCT05479097|DRUG|Anti-Hypertensive|Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
40804040|NCT02431780|DEVICE|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
40804041|NCT02903225|BEHAVIORAL|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
41007132|NCT05664035|BIOLOGICAL|Diagnosis of SPAD using immunization with PPV23|Diagnosis of SPAD using immunization with PPV23
41007133|NCT03228134|DRUG|Ke Chuan Liu Wei Granule|Traditional Chinese Medicine
41321590|NCT05278676|DRUG|Dotinurad|Dotinurad oral tablet.
41321591|NCT03225937|DRUG|Trastuzumab, Lapatinib|Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
41476973|NCT03475134|DRUG|Nivolumab|Nivolumab will be administered for maximum 24 months as follows: first year: 240 mg every 2 weeks; second year: 480 mg every 4 weeks.
41476974|NCT06527794|BEHAVIORAL|RHYTHM (Remote Hypertension Tracking Help Management)|Home blood pressure telemonitoring with remote medication management by a centralized multidisciplinary team led by a pharmacist; and social support, lifestyle education and connection to community resources to address social needs, provided by a community health worker who is embedded with the centralized team and is tightly connected to community resources and partners
41007134|NCT03228134|DRUG|Yang He Ping Chuan Granule|Traditional Chinese Medicine
41007135|NCT03228134|OTHER|Ke Chuan Liu Wei Granule placebo|Placebo
41321592|NCT03225937|DRUG|Pertuzumab, trastuzumab-emtansine|"Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.~Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first."
41321593|NCT04395963|DEVICE|Tobii Pro Glasses 50 Hz wearable wireless eye tracker|This system can measure eye movements using cameras integrated into the eyeglasses which record the corneal reflection of infrared lighting to track pupil position, mapping the subject's focus of attention on video recordings of the subject's field of vision (gaze).
41321594|NCT03310736|DIAGNOSTIC_TEST|Intrinsic Hepcidin IDx™ Test|ILS scientists developed the bioanalytical method for quantitation of human serum hepcidin using a Beckman FX automated liquid handling platform. The method uses a competitive ELISA format that has a proprietary sensitive and specific monoclonal antibody to hepcidin that captures native hepcidin in a sample. During the reaction a competition between a synthetic, bioactive, biotinylated hepcidin tracer and native hepcidin occurs. Bound biotinylated tracer is detected with a streptavidin-HRP conjugate and TMB substrate. Quantitation is based on an eight-point standard curve using validated, synthetic hepcidin calibrators. The standard curve and the hepcidin concentrations of patients samples are calculated using 4-parameter logistic curve fitting (Prism; Graphpad, Inc., La Jolla, CA). Serum hepcidin concentrations are expressed in ng/ml serum.
41321595|NCT03600714|DRUG|Peg-interferon lambda|Peg-interferon Lambda is a covalent conjugate of human recombinant non- pegylated interferon (IFN) lambda and a 20-kDa linear pegylated (PEG) chain.
41321596|NCT03600714|DRUG|Lonafarnib|Oral prenylation inhibitor
41476975|NCT06527794|BEHAVIORAL|Enhanced usual care (UC)|All participating sites will receive training on appropriate blood pressure measurement and education on guideline-based hypertension therapy. Additionally, participants in usual care will receive a standardized packet with evidence-based hypertension education material and a blood pressure monitor to complete blood pressure measurements at home.
41476976|NCT04470531|DRUG|oral co-trimoxazole|oral co-trimoxazole + standard therapy
41007136|NCT03228134|OTHER|Yang He Ping Chuan Granule placebo|Placebo
41007137|NCT06417086|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
41007138|NCT06417086|OTHER|Sham Acupuncture|The Streitberger placebo needle will be used to simulate an acupuncture procedure without penetrating the skin. The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
41007139|NCT06417086|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks.
41007140|NCT02361528|DRUG|Sargramostim: Leukine (Genzyme USA)|Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
41007141|NCT02361528|DRUG|Placebo|placebo subcutaneously, for 5 days
41007142|NCT05836610|DRUG|Hydrocortisone|intravenous bolus hydrocortisone therapy during hypothermia treatment
41007143|NCT04701775|DIETARY_SUPPLEMENT|Only Lactobacillus rhamnosus GG strains|1x106 colony forming unit (CFU) Lactobacillus rhamnosus GG probiotic capsule
41321597|NCT03600714|DRUG|Ritonavir|Booster of lonafarnib action
41476977|NCT01787617|BEHAVIORAL|Aerobic Plus Resistance Training Group|Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
41476978|NCT01787617|BEHAVIORAL|Control Group|Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
41007144|NCT04701775|COMBINATION_PRODUCT|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis strains|combination of Lactobacillus acidophilus 1x109 CFU and Bifidobacterium animalis subsp.lactis 1x109 CFU probiotic capsule
41007145|NCT04701775|OTHER|Placebo|Placebo probiotic capsule
41007146|NCT01919424|DRUG|Methacholine Chloride|"Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma"
41007147|NCT01919424|DEVICE|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
41007148|NCT01919424|DEVICE|The English-Wright nebulizer|"Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada"
41007149|NCT00002495|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15
41007150|NCT00002495|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15
41007151|NCT00002495|RADIATION|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
41476979|NCT04514055|PROCEDURE|De-epithelialized connective tissue graft wall|A de-epithelialized free gingival connective tissue graft will be used to treat Cairo's recession type 2 and type 3 associated with inta-bony defects
41007152|NCT00515827|DRUG|Raltegravir (MK-0518)|400 mg tablet taken orally twice daily
41007153|NCT00515827|DRUG|Placebo|400 mg placebo tablet taken orally twice daily
40804042|NCT02145052|OTHER|Continuous suture|A continuous suture is considered standard of care.
40804043|NCT02145052|OTHER|Interrupted suture|Interrupted sutures are considered standard of care.
40804044|NCT00738569|DRUG|Raltegravir|Raltegravir 400 mg PO BID for 12 months
40804045|NCT00070928|DRUG|valerian|
40804046|NCT03117868|OTHER|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
40804047|NCT04294901|BEHAVIORAL|Direct to patient medication brochure|An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
41007154|NCT03497559|OTHER|Music|Classical music
41007155|NCT02043015|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
41007156|NCT02043015|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
41007157|NCT02043015|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
41007158|NCT02043015|DRUG|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
41007159|NCT02043015|OTHER|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
41007160|NCT02043015|BEHAVIORAL|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
41007161|NCT02043015|BEHAVIORAL|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
41007162|NCT03742141|DEVICE|Intraoperative Video Laryngoscopy|The IOVL is a disposable, otherwise standard fiberoptic laryngoscope that is inserted alongside the endotracheal tube following intubation for surgical procedures.
41007163|NCT03742141|DRUG|Glycopyrrolate|0.004mg/kg as per routine prior to intubation
41007164|NCT02529410|PROCEDURE|Cardiac Resynchronisation Therapy|
41007165|NCT06448767|DIETARY_SUPPLEMENT|Multispecies probiotics|Multispecies probiotics consisting of Bacillus subtilis W201, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus rhamnosus W140, Lactococcus lactis W19, Propionibacterium freudenreichii W200 at a dose of 5x10\^9 Colony Forming Units (CFU), once daily, orally.
41007166|NCT06448767|OTHER|Placebo|Placebo identical in taste, smell and color to the multispecies probiotics.
41476980|NCT03959215|BEHAVIORAL|Back in the Game|"A six-month programme of cognitive-behavioural therapy delivered by smartphone application. The intervention commences in the first week after ACL reconstruction. The smartphone app is delivered in parallel with usual rehabilitation care.~Usual rehabilitation care: all participants will be referred to physiotherapy following ACL reconstruction. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the treatment aims is at the clinical discretion of the treating physiotherapist."
40804048|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
40804049|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
41007167|NCT02806726|DEVICE|iDesign 1.3-PRESBY treatment|Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
41007168|NCT02806726|DEVICE|iDesign 1.3 treatment|Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
41007169|NCT06459557|PROCEDURE|cast|children with displaced distal radius fractures would be managed by a cast in the emergency room
41007170|NCT06459557|PROCEDURE|surgical reduction|anatomical reduction of pediatric displaced distal radius fractures under general anesthesia in the operating room
41321598|NCT05767710|BEHAVIORAL|AI telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
40804050|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
40804051|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
40804052|NCT01062724|OTHER|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
40804053|NCT01679600|DEVICE|Feedback-controlled robotics-assisted treadmill exercise|Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
40804054|NCT01679600|DEVICE|Robotics-assisted treadmill exercise|Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
40804055|NCT00253773|DRUG|acetominophen, sulfer amino acids; cysteine and methionine|
40804056|NCT00698438|DEVICE|Ex-PRESS implantation|"I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture."
40804057|NCT00698438|PROCEDURE|Trabeculectomy|standard trabeculectomy
40804058|NCT03273647|RADIATION|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
40804059|NCT06476275|BIOLOGICAL|Influenza A/Texas/71/2017 (H3N2)|Virus will be administered intranasally
40804060|NCT06476275|BIOLOGICAL|Sham placebo|Placebo will be administered intranasally
40804061|NCT03133819|DEVICE|Q-Sense_QST (TSA II)|QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
41007171|NCT00157599|PROCEDURE|various diagnostic measures for DVT (e.g., CUS)|
41007172|NCT02064452|OTHER|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
41007173|NCT02064452|BEHAVIORAL|Placebo Comparator|Enhanced Usual Community Care-Waitlist
41007174|NCT05168995|DRUG|BDP/FF NEXThaler® 100/6 micrograms|"BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)"
41007175|NCT01670929|DRUG|Progesterone|
41007176|NCT01670929|OTHER|Placebo|
41007177|NCT03191903|COMBINATION_PRODUCT|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
41007178|NCT03191903|DEVICE|Monovisc|Hyaluronic acid
41007179|NCT03191903|DRUG|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
41007180|NCT01079871|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
41476981|NCT03959215|OTHER|Usual rehabilitation care|Following ACL reconstruction, as per routine clinical practice, all participants will be referred to physiotherapy. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the required treatment aims is at the clinical discretion of the treating physiotherapist.
41321599|NCT05767710|BEHAVIORAL|general telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
41476982|NCT05876728|GENETIC|Genotyping|Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.
41476983|NCT04458493|BEHAVIORAL|satiety|satiety ratings, appetite and desire to eat (10-point visual analogue scale) will be measured at 30, 60 and 120 minutes after each meal replacement drink
41476984|NCT04458493|DIETARY_SUPPLEMENT|Dietary Supplement: Generation UCAN supplementation|meal replacement, Generation UCAN supplement, 400ml, 20% solution
41476985|NCT06456879|OTHER|extra-coronal restoration type|primary molar crown type
41476986|NCT01690975|DRUG|Placebo|Placebo - single dose at start of each treatment period
41007181|NCT05464121|BEHAVIORAL|• Blended treatment for AjD combining a self-applied Internet-based program (TAO) with face-to-face sessions via videoconference.|"The self-applied Internet-based program called TAO is accessible online from the platform https://psicologiaytecnologia.labpsitec.es. It is organised into 7 sequential modules of approximately 60 minutes. The patient will do a treatment module every 10-12 days, plus an individual session via videoconference with a therapist (approximately 20-30 minutes long). During these sessions, the therapist will explain the main contents of each module, resolve doubts and motivate the patient to continue with the therapy. It takes about 12 weeks to complete the intervention.~TAO is the optimised version of the original intervention protocol for AjD developed by Botella et al. by Botella et al. (2008) and includes the following therapeutic components: psychoeducation, emotion regulation techniques, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention."
41007182|NCT06444477|OTHER|ITP and cancer|ITP and cancer
41007183|NCT02610868|DRUG|MYOBLOC|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
41007184|NCT03792685|OTHER|Normo-carbohydrate meal intake|Subjects are going to receive the normo-carbohydrate meal.
41007185|NCT03792685|OTHER|High-carbohydrate meal intake|Subjects are going to receive the high-carbohydrate meal.
41007186|NCT03792685|OTHER|High-fat meal intake|Subjects are going to receive the high-fat meal.
41476987|NCT01690975|DRUG|Benzonatate - 400 mg|Benzonatate - 400 mg single dose
41476988|NCT01690975|DRUG|Benzonatate - 600 mg|Benzonatate - 600 mg single dose
41476989|NCT00795808|DRUG|Metformin|500mg tds for 6 months
41476990|NCT00795808|DRUG|Placebo|One tablet tds for 6 months
41476991|NCT00795808|DRUG|Metformin + Clomiphene|500mg tds + Ovulatory dose for 6 months
41476992|NCT00795808|DRUG|Metformin|500mg tds for 6 months
41476993|NCT00795808|DRUG|Clomiphene|Ovulatory dose for 6 months
41476994|NCT04800341|OTHER|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
41476995|NCT05846464|DEVICE|Meta Quest 2|The Meta/Oculus Quest (along with the SignWave software) delivers an immersive audio/visual-based game environment where the users hand is created and displayed in the virtual environment and matches target gestures to the beat of the music.
41476996|NCT06250036|DRUG|Single agent zimberelimab|Single agent zimberelimab (PD-1 inhibitor) Q3W
41476997|NCT06250036|DRUG|Combination zimberelimab + domvanalimab|Combination zimberelimab + domvanalimab (TIGIT inhibitor) Q3W
41476998|NCT04745208|BEHAVIORAL|Simulation based education|high fidelity simulation with moulage
41476999|NCT02965872|OTHER|No intervention|
41477000|NCT03695705|DRUG|Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day|Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
41477001|NCT06084741|OTHER|Omitting of usage of intraabdominal drains after repair of peptic ulcer perforations|omitting the intraabdominal drains
40804062|NCT05878678|DEVICE|Fixed positions of arm down and arm up|In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.
41321600|NCT05767710|BEHAVIORAL|traditional rehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
40804063|NCT00113204|DRUG|IPI-504|
40804064|NCT04098419|BEHAVIORAL|Science for Life|The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.
40804065|NCT04963244|OTHER||
40804066|NCT01703091|DRUG|Ramucirumab|Administered IV
40804067|NCT01703091|DRUG|Placebo|Administered IV
40804068|NCT01703091|DRUG|Docetaxel|Administered IV
40804069|NCT04608383|OTHER|Additional and minimal collection of products of the human body carried out during a sample for standard of care|"* Swab of the peritoneal fluid for traces of COVID19. The collection of peritoneal fluid is a standard care practice.~* Swab from the laparoscopy filter"
40804070|NCT01613586|DRUG|ASP3652|Oral
40804071|NCT01613586|DRUG|Placebo|Oral
40804072|NCT00999635|DEVICE|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
40804073|NCT00204594|DRUG|rM28|
40804074|NCT00204594|DRUG|autologous PBMCs|
40804075|NCT04923906|DRUG|Aumolertinib|"Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4\~6 cycles, followed by Aumolertinib daily with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity."
40804076|NCT04923906|DRUG|Placebo Aumolertinib|Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
40804077|NCT02860208|PROCEDURE|3 years follow-up|Examination 3 years after surgical treatment of peri-implantitis
40804078|NCT06547697|OTHER|Dialysate sodium concentration|
41007187|NCT03792685|OTHER|High-protein meal intake|Subjects are going to receive the high-protein meal.
41007188|NCT04309435|BEHAVIORAL|Self-esteem intervention|See relevant study arm for description
41007189|NCT04309435|BEHAVIORAL|Self-stigma intervention|See relevant study arm for description
41007190|NCT04309435|BEHAVIORAL|Jumping to conclusions intervention|See relevant study arm for description
41007191|NCT04309435|BEHAVIORAL|Control procedure (assessment only)|See relevant study arms for description
41007192|NCT00418691|DRUG|IR Methylphenidate|10 mg by mouth (PO) twice daily x 4 Weeks
41007193|NCT00418691|DRUG|Modafinil|200 mg PO Once Daily x 4 Weeks
41007194|NCT00418691|DRUG|SR Methylphenidate|18 mg PO Once Daily x 4 Weeks
41007195|NCT02188381|OTHER|Stool Sample and Blood Sample|All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
41321601|NCT05767710|BEHAVIORAL|AI telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
41321602|NCT05767710|BEHAVIORAL|general telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
41477002|NCT06084741|OTHER|Using intraabdominal drains|The investigators will put intraabdominal drains
41477003|NCT05696080|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
40804079|NCT05407649|RADIATION|Radiotherapy Combined with GM-CSF|Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).
40804080|NCT01469143|DRUG|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
40804081|NCT01469143|DRUG|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
40804082|NCT02058316|DEVICE|Lateral Flow Device Test|Testing of leftover BAL samples from clinical routine by the lateral flow device test
40804083|NCT06393270|DIAGNOSTIC_TEST|Modified US Public Health Service (USPHS) criteria|Dental caries classification system
40804084|NCT00576628|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Recommended starting dose 1.2 micrograms/kg sc monthly
40804085|NCT04075006|DRUG|Ketamine|standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
40804086|NCT05322291|BEHAVIORAL|Mobil Application|The mobile application developed will be installed on the phones of hemodialysis patients
40804087|NCT01766297|RADIATION|Proton Radiotherapy|
40804088|NCT01814397|DRUG|Anastrozole|1 mg orally daily
40804089|NCT01814397|DRUG|exemestane|25 mg orally daily
40804090|NCT01814397|DRUG|letrozole|2.5 mg orally daily
40804091|NCT04772625|DEVICE|Patellofemoral arthroplasty|Insertion of an artificial joint between the front of the femur and the back of the patella. The femoral component consists of a metal implant, and the patellar component is a polyethylene implant. The two components replace the original articular cartilage of the patellofemoral joint.
40804092|NCT04829786|DRUG|palovarotene low-dose|oral capsules
40804093|NCT04829786|DRUG|palovarotene high-dose|oral capsules
40804094|NCT00425997|DRUG|Valsartan/HCTZ|
40804095|NCT00425997|DRUG|amlodipine|
40804096|NCT00425997|DRUG|HCTZ|
40804097|NCT03814382|DEVICE|Acupuncture needle|Acupuncture needle
40804098|NCT03213743|DRUG|Dexmedetomidine Injection|Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
40804099|NCT01814046|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
40804100|NCT01814046|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
40804101|NCT01814046|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
40804102|NCT01814046|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
40804103|NCT05051670|PROCEDURE|da vinc SP gastrectomy|radical subtotal gastrectomy performed by da vinci SP
40804104|NCT05346744|OTHER|Chairside CAD/CAM ceramic materials for dental restoration|"6 crowns made from 6 chairside ceramic materials were milled by CEREC MCXL-EF mode for mandibular first molar of each participant.~The six materials are as follows:~ZIR: InCoris TZI (Dentsply Sirona, York, PA)， CD: Celtra Duo (Dentsply Sirona, York, PA), EMA: e.max CAD (ivoclar, Vivadent AG), LC: LiCi (UPCERA, China), ENA: Vita Enamic (Vita Zahnfabrik, Bad Sackingen, Germany) RC: RunCi (UPCERA, China)"
40804105|NCT03861104|OTHER|medical educational video|information based on visual and auditory communication
40804106|NCT06014606|DRUG|placebo|oral formulation
40804107|NCT06014606|DRUG|haloperidol 2mg|oral formulation
40804108|NCT06014606|DRUG|propranolol 40mg|oral formulation
40804109|NCT05223569|DEVICE|Home OCT monitoring model|A home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester
40804110|NCT05223569|DEVICE|Hospital-based monitoring with a staff-administrated OCT|Participants come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators
40804111|NCT02038972|GENETIC|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
40804112|NCT03385915|PROCEDURE|Aortic valve replacement|Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis
40804113|NCT03756155|PROCEDURE|isometric intervention|The research participants will perform isometric repetitions against the hand held dynamometer
40804114|NCT02696057|OTHER|manual technics|soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
40804115|NCT02696057|OTHER|Exercise|spinal stabilization exercise applied three sessions per week, totally six week.
40804116|NCT01849575|BEHAVIORAL|Intervention|"Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2-4 weeks a follow-up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period."
40804117|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking.
40804118|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking. Additional one-one-one exercise and nutrition support is provided too.
41477004|NCT05696080|DRUG|Placebo for PCV15 + PPSV23|Saline in each 0.5 mL sterile solution
41477005|NCT05696080|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
41477006|NCT05696080|BIOLOGICAL|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
41477007|NCT01929395|DEVICE|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
41477008|NCT05376618|OTHER|no intervention|no intervention
41477009|NCT04553913|DEVICE|cooling device|device placed on patient in recovery on non surgical side to determine resolution of spinal anesthetics.
41477010|NCT01981499|DRUG|PF-05180999|Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
41477011|NCT01981499|DRUG|Placebo|Placebo tablets
41477012|NCT01981499|DRUG|120 mg MR PF-05180999|Single 120 mg dose administered as modified release formulation
41477013|NCT01981499|DRUG|360 mg MR PF-05180999|Single 360 mg dose administered as modified release formulation
41477014|NCT01981499|DRUG|10 mg cetirizine|Single 10 mg dose of cetirizine
40804119|NCT05687773|DEVICE|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
41007196|NCT04593901|BEHAVIORAL|Video and App Review|"Scenario Review: The scripts and/or videos will be iteratively reviewed by individual and small groups of home healthcare personnel using Zoom, Microsoft Teams, or similar. The participants will review scripts and/or recordings of the scripts and discuss how well each situation has been represented, how to improve it, and whether it is applicable in their agency.~App Review: Following review of the scenarios, participants will review the smartphone app currently under development, including the control buttons, their placements, and other features of the screen interface. The first 9-12 participants (approximately) will be asked to provide feedback on the app's layout, control locations, and overall appearance. Once suggested changes have been made, the app will then be reviewed by the remaining participants for final review and usability assessment."
41477015|NCT01981499|DRUG|Placebo|Placebo tablets
41477016|NCT04611984|PROCEDURE|Piezocision|Piezocisions were performed on the mesial and distal sides of the right maxillary canines. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
41477017|NCT04611984|PROCEDURE|Control|The mesial and distal sides of the left maxillary canines served as controls and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
41477018|NCT01671982|OTHER|Tenofovir Dose Adjustment|In subjects with a confirmed CLcr 30 to \<50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
41477019|NCT00869986|DRUG|dirucotide|500mg, intravenous, every 6 months for 15 months
41477020|NCT00869986|DRUG|placebo|intravenous, once every six months for 15 months
41477021|NCT00378950|BEHAVIORAL|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
41477022|NCT00378950|BEHAVIORAL|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
41477023|NCT01795742|DEVICE|Human-Powered Nebulizer|
41477024|NCT03986450|OTHER|Enhanced recovery after surge(ERAS) protocol|"The components of ERAS multidisciplinary pathway concerning preoperative, operative, and postoperative period are as follows:~1. Preoperative care:~   Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis~2. Perioperative care:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia~Postoperative care:~Application of midthoracic, epidural anesthesia/analgesia Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization"
41477025|NCT06388837|OTHER|Injectable Platelet Rich Fibrin|Patients underwent mandibular symphysis Onlay bone graft mixed with injectable platelet rich fibrin (I-PRF) placement.
41477026|NCT06388837|OTHER|Xenograft|Patients underwent mandibular symphysis Onlay bone graft mixed with Xenograft (InterOss® Anorganic Cancellous Granules).
41477027|NCT04978636|OTHER|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The continuous low-tidal volume ventilation with using FiO2 of 0.21 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 0.21 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
41477028|NCT04978636|OTHER|Continuous low tidal volume ventilation with using FiO2 of 1.0|The continuous low-tidal volume ventilation with using FiO2 of 1.0 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 1.0 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
41477029|NCT04978636|OTHER|Apnea During CPB|There will be no ventilation used. But, during the sub-study part of the Apnea CPB extra blood samples will be drawn before and after CPB.
41477030|NCT01404117|DRUG|Laquinimod 0.6|Laquinimod 0.6 capsule
41007197|NCT01777997|DRUG|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
41321603|NCT05767710|BEHAVIORAL|traditional rehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
41321604|NCT05767710|BEHAVIORAL|AI telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
41477031|NCT01404117|DRUG|Laquinimod 1.2|Placebo
41477032|NCT01404117|OTHER|Glatiramer Acetate or interferon-beta+ Placebo|GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
41477033|NCT05408182|PROCEDURE|Robotic colorectal resection with ERAS (or eRCS) perioperative care|All patients will undergo robotic colorectal resections using the Da Vinci xi system. All common colorectal procedures will be included: right/left colectomy, sigmoid colectomy, anterior resection with PME/TME/TaTME. Patient will undergo an enhanced recovery pathway perioperatively ensuring prompt recovery and early discharge. Most ERAS guidelines will be followed including preoperative nutrition, behavioral training, avoidance of drains, NG tubes, catheters, opioids, patient based volume repletion, wound local anesthetic infiltration, early mobilization, early postoperative feeding, spirometry and physiotherapy.
41477034|NCT02032355|PROCEDURE|spinal anesthesia|
41477035|NCT05310799|OTHER|Shared Decision Making (SDM)|The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis and clinic visit. Discussion will be guided by a discussion guide and the PERSON-JIA Report, which is generated in real time on the physician's smart phone.
41477036|NCT03347760|DRUG|DOTATOC-68Ga PET initial|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
41007198|NCT05537233|DRUG|Semaglutide|Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
41007199|NCT05537233|DRUG|Placebo|Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
41007200|NCT01099085|DRUG|Simvastatin|simvastatin 40 mg qd daily
41007201|NCT01099085|DRUG|Placebo|Placebo
41007202|NCT03930459|PROCEDURE|Static cold storage (SCS)|The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
41007203|NCT03930459|DEVICE|Normothermic machine perfusion (NMP)|During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
41007204|NCT00758511|PROCEDURE|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
41007205|NCT00758511|PROCEDURE|facilitated tucking|facilitated tucking before, during and after heel stick
41007206|NCT00758511|PROCEDURE|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
40804120|NCT05687773|DEVICE|Leap Motion Controller in Head-Mounted Display|For the immersive group, the same equipment mentioned above Leap Motion Controller will be projected on the Head-Mounted Display model Oculus Quest 2 (Meta Platforms Inc.). The device has binocular displays with Fresnel lenses with a resolution of 1832 by 1920 pixels per eye. It is equipped with a Qualcomm Snapdragon XR2 processor with the refresh rate of 72hz - 120hz and 6GB of RAM. The equipment has a 90º field of view and approximately 500 grams of total weight. The treatment protocol and patient positioning will be the same as previously mentioned, except for the type of projection used. At the 2-minute rest interval between games, the HMD will be removed from the user to change the game in question, returning at the end of this period.
40804121|NCT04679506|DRUG|Cladribine|CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL
40804122|NCT01191645|DRUG|naloxone|Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min
40804123|NCT01191645|DRUG|remifentanil|Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
40804124|NCT01191645|DRUG|Sodium Chloride|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
40804125|NCT01191645|DRUG|metoclopramide|Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
40804126|NCT01071499|DRUG|Morphine|One dose of morphine (0.1 mg/kg)
40804127|NCT01071499|DRUG|Morphine|One dose of morphine (0.2 mg/kg)
40804128|NCT01071499|DRUG|Morphine|One dose of morphine (0.3 mg/kg)
40804129|NCT04707118|DRUG|cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
40804130|NCT04707118|DRUG|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
40804131|NCT01709110|DRUG|Teriparatide|Administered SC
40804132|NCT01709110|DRUG|Risedronate|Administered orally
41007207|NCT04541875|OTHER|MAR-Scale|The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
41321605|NCT05767710|BEHAVIORAL|general telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
41321606|NCT05767710|BEHAVIORAL|traditional rehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
41477037|NCT03347760|DRUG|DOTATOC-68Ga PET at 6 months|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
40804133|NCT01709110|DRUG|Placebo|"Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC."
40804134|NCT01709110|DRUG|Calcium|Administered orally
40804135|NCT01709110|DRUG|Vitamin D|Administered orally
40804136|NCT04818216|DRUG|Placebo|Placebo capsule containing inert ingredient
40804137|NCT04818216|DRUG|Nicotinamide riboside|250 mg Nicotinamide riboside capsules
40804138|NCT01326091|OTHER|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
40804139|NCT00164840|DRUG|Esomeprazole|
40804140|NCT00152711|DEVICE|nCPAP|
40804141|NCT03718806|DRUG|Zoliflodacin|oral suspension; oral administration
40804142|NCT03718806|OTHER|high calorie, high fat breakfast|fasted/fed conditions
40804143|NCT06182098|OTHER|1/2 maintenance fluids|Patients will receive 1/2 maintenance normal saline (with a maximum of 50 mL/hr), over one hour.
41007208|NCT04136769|PROCEDURE|Visceral Debranching|Visceral debranching is defined as a vascular reconstruction with the aim of ensuring a sufficient arterial blood flow to the mesentery and liver after the subsequently planned tumor resection, which usually comprises ligation of the gastroduodenal artery or other relevant collateral vessels. All open vascular procedures can be employed for visceral debranching. Examples are aorto-visceral or iliaco-visceral bypasses using autologous vein or an allogeneic graft, or re-insertion of the superior mesenteric artery or celiac trunk into the aorta.
40804144|NCT06182098|DRUG|Ketorolac|0.5mg/kg, with a maximum of 30mg
40804145|NCT06182098|DRUG|Diphenhydramine|0.5mg/kg, with a maximum of 25mg
40804146|NCT06182098|DRUG|Prochlorperazine|0.15mg/kg, with a maximum of 10mg
40804147|NCT06182098|OTHER|bolus|20mL/kg normal saline bolus, with a maximum of 1L, given over one hour
41477038|NCT03347760|BIOLOGICAL|blood sample|blood tests will be carried out during the control visit to ensure that biological parameters are normalized
40804148|NCT04982315|PROCEDURE|Standard Acupuncture|The standard acupuncture intervention is based on classical Chinese acupuncture therapy. Participants randomized to standard acupuncture will receive up to 15 acupuncture treatments over 3 months with the total number being determined by the patient and acupuncturist together. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
40804149|NCT04982315|PROCEDURE|Enhanced Acupuncture|The enhanced acupuncture intervention includes the 3 months of standard acupuncture plus an additional 3 months of maintenance acupuncture. Participants randomized to enhanced acupuncture will receive up to 21 acupuncture treatments over 6 months. The maintenance acupuncture treatment sessions are expected to consist of the same intervention used in the first 3 months of care described in the standard acupuncture arm, plus up to 6 treatments during the maintenance phase. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
40804150|NCT02342691|DRUG|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
40804151|NCT02342691|DRUG|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
40804152|NCT04239066|PROCEDURE|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
40804153|NCT04239066|PROCEDURE|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
40804154|NCT03506412|DRUG|Entresto™ 49Mg-51 mg tablet|Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
40804155|NCT01538355|OTHER|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
40804156|NCT01538355|OTHER|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
40804157|NCT01538355|OTHER|Control diet|Patients stay on their regular diet.
40804158|NCT01468948|DRUG|Octanoic Acid|
40804159|NCT03914430|OTHER|Food|The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)
40804160|NCT04714827|BIOLOGICAL|KQ-2003 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .
40804161|NCT04904406|DRUG|Dolutegravir / Lamivudine Oral Tablet|Discontinuing abacavir by switching from three-drug regimen with dolutegravir/abacavir/lamivudine to two-drug regimen with dolutegravir/lamivudine
40804162|NCT02388477|DRUG|Doxycycline|antibiotic used to treat infection
40804163|NCT02388477|DRUG|sugar pill|placebo with no pharmacologic effect
41007209|NCT00420680|DRUG|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
40804164|NCT04166591|BEHAVIORAL|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
41007210|NCT00420680|DRUG|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
41321607|NCT05862558|DEVICE|Shockwave Balloon|Intravascular lithotripsy (IVL) performed with the Shockwave balloon (Shockwave Medical Inc) enables treatment of calcified stenosis of the peripheral arteries by using sonic pressure waves to selectively disrupt superficial and deep calcium without impacting healthy tissue
41321608|NCT01019772|BIOLOGICAL|LBVH0101 (Hib vaccine)|
40804165|NCT04166591|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
40804166|NCT03652766|BEHAVIORAL|Daily Weight Tracking|Daily weight tracking + weekly email or text message feedback
40804167|NCT02341768|DEVICE|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
40804168|NCT01672281|OTHER|vibrox- vs. resistance training|Comparison between two exercise interventions
40804169|NCT05199636|OTHER|Dragon fruit product|Frozen dragon fruit based beverage
41007211|NCT00420680|DRUG|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
41007212|NCT04586803|DRUG|SHR4640|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
41007213|NCT04438928|DIETARY_SUPPLEMENT|Elevit Pregnancy 2nd & 3rd Trimester|Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)
41007214|NCT04438928|OTHER|Non-Supplement|Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
41007215|NCT04192929|DEVICE|Narrow band imaging|Blue light is used during withdrawal phase instead of the regular white light to highlight surface changes
41007216|NCT04192929|OTHER|Chromoendoscopy|Indigo carmine will be sprayed during withdrawal phase of colonoscopy
41007217|NCT04192929|OTHER|High definition white light endoscopy|High definition equipment will be used to perform colonoscopy
41321609|NCT01019772|BIOLOGICAL|Hiberix™ Vaccine|
41477039|NCT00254020|DRUG|Citalopram|Patients who are found to have major depression will be referred to a psychologist
41477040|NCT05663372|DRUG|Efez 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
41477041|NCT05663372|DRUG|INSPRA® 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
41477042|NCT00227331|DRUG|Oral amoxicillin|
41477043|NCT05369078|DRUG|THR-1442 20mg Single dose|THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
41477044|NCT05369078|DRUG|THR-1442 20mg Multiple dose group|THR-1442 20mg is administrated QD for 7days, then follow till day 14.
41477045|NCT03329079|BEHAVIORAL|Mobile Technology Plus|The intervention group MT+ will receive the premium-version mobile phone app with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
41477046|NCT03329079|BEHAVIORAL|Mobile Technology|The comparison group MT will receive the basic-version mobile phone app only to self monitor eating, activity, and weight.
40804170|NCT06474000|BEHAVIORAL|Oxytocin induction group|"Participants in the oxytocin induction group filled out the Information Form at the time of application to the delivery room. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
40804171|NCT06474000|BEHAVIORAL|Control group|"Participants in the control group filled in the Information Form when they applied to the birth centre. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
40804172|NCT06012747|OTHER|Questionnaire|The patients receive a questionnaire every 6 hours during the first 24 hours after their cesarean section, and again after 2, 7, and 30 days.
40804173|NCT01321944|OTHER|Direct to Smoker Outreach Program|"Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs."
40804174|NCT03451513|BEHAVIORAL|Pride Body Project|"PBP is a 2-session eating disorder prevention program. Each session is 2 hours, and separated by a week. Groups have 4 to 7 participants and are led by a peer and a clinician. This program allows a forum for young men to critique the appearance ideal. These exercises should induce cognitive dissonance, which subsequently lead to a reduction of internalization of the ideal. In session 1, participants: (1) define the ideal body type in the gay community, (2) discuss its origin and perpetration, (3) brainstorm its costs, (4) participate in a verbal challenge where they counter the ideal, and (5) are asked to complete three assignments. In session 2, participants: (1) review homework, (2) engage in role-plays to counter pursuit of the ideal, (3) discuss ways to challenge body talk statements, (4) list ways to resist the pressure to pursue this ideal (body activism), (5) discuss barriers to body activism and how to overcome those barriers, and (6) select an exit activity."
40804175|NCT03451513|BEHAVIORAL|Media Advocacy|We will use a media advocacy (MA) intervention as an active, time- and attention-matched control. MA is a 2 session, group-based program with co-leaders (1 peer and 1 clinician). The MA content centers on acknowledging and discussing the role the media has on shaping body image ideals. In session 1, there is a discussion on describing the ideal body in the gay community and how the media impacts this ideal. Following this, participants will watch a video on how the media influences body image among gay men, and the consequences of internalizing these messages. In session 2, participants will watch a second video. Next, the group discusses other forms of media (e.g., pornography, social media) and how it impacts body image.
41007218|NCT00544076|DRUG|sildenafil citrate|Given orally
41007219|NCT00544076|DRUG|alprostadil|Given intraurethrally
41007220|NCT00544076|PROCEDURE|robotic-assisted laparoscopic surgery|Undergo prostatectomy
41007221|NCT00544076|PROCEDURE|quality-of-life assessment|Ancillary studies
41007222|NCT00544076|OTHER|questionnaire administration|Ancillary studies
41007223|NCT00496301|DRUG|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
41477047|NCT00006091|DRUG|arsenic trioxide|
41477048|NCT04349631|BIOLOGICAL|HB-adMSCs|Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.
41477049|NCT01197768|BEHAVIORAL|Nutrition Intervention|Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
41477050|NCT04732988|DRUG|HSG4112|Once-daily oral administration
41477051|NCT04732988|DRUG|Placebo|Once-daily oral administration
41477052|NCT05205018|BEHAVIORAL|Motivational interviewing performed remotely through videocalls|Remote motivational interviewing will be performed seven time over 12 months, through videocalls. The first four interventions will be performed within two months and the following three will be performed at five, eight and eleven months from enrollment.
41477053|NCT05962502|DRUG|Cetuximab and irinotecan|chemotherapy plus targeted therapy
41477054|NCT00964288|DRUG|GSK1014802 low dose|oral tablet
41477055|NCT00964288|DRUG|Lidocaine|positive control
41477056|NCT00964288|DRUG|GSK1014802 high dose|oral tablet
41007224|NCT04865939|PROCEDURE|sterile water irrigation|Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
41007225|NCT04865939|DRUG|Gemcitabine|Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
41477057|NCT00964288|DRUG|Placebo|To match GSK drug and positive control
41477058|NCT05253924|DIAGNOSTIC_TEST|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1, Piezo1, Piezo2, TRPV1 andTRPM8) will be investigated. Saliva sample will be collected for PT and FT. Genomic DNA will be extracted from aliquots of 0. 4 ml of each saliva sample with the Oragene OG575 (DNA Genotek) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
40804176|NCT03962088|DIAGNOSTIC_TEST|miRNA|"15 ml of whole blood samples are collected in Vacutainer tubes with spray-coated K2EDTA and stored at room temperature. To minimize the hemolysis and nucleic acids degradation, plasma separation undergoes within 2 h.~Within 1 h, tubes are subjected to a first centrifugation step at 2200 x g and room temperature for 15 min. Plasma supernatants are transferred to 15 mL tubes, carefully avoiding contact with the lymphocytic ring, and tubes are centrifuged a second time at 3000 x g and RT for 10 min to remove cellular debris.~Plasma samples are then collected into 1.5 mL cryovials and all the aliquots are stored at -80 °C."
40804177|NCT06158867|DEVICE|FMD WK|micro-needle patches containing active anti-wrinkle ingredients
40804178|NCT05961241|OTHER|runnin training program|gradual training program
40804179|NCT03577340|OTHER|implant of cardiac device as per guidelines|Observation of performance to validate matrix
40804180|NCT03346421|BEHAVIORAL|diet and physical activity|
40804181|NCT01166893|DEVICE|Modulated Imaging and Laser Speckle Imaging|wound healing
40804182|NCT06155149|OTHER|Mobile application|"Mobile application: The content of the mobile application that can be used continuously after the presentation in the education of families will consist of three parts.~In the first section: There will be short information notes and visuals on burn diagnosis and types.~Second part: Frequently seen burns as a result of home accidents will be introduced and the precautions to be taken will be included through visuals.~Third Section: First aid applications specific to each type of burn (scalding, fire-flame, hot contact, electrical, chemical) will be presented with visuals and information notes."
40804183|NCT06155149|OTHER|Family Information Training|Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.
40804184|NCT02952313|DEVICE|Nasal Implant|
40804185|NCT04839068|DEVICE|covid 19 on pregnancy outcomes|covid 19 on pregnancy outcomes and sex ratio at birth
40804186|NCT00425022|PROCEDURE|thoracoscopy|
40804187|NCT03617536|DRUG|CR845 0.25 mg Oral Tablet|CR845 0.25 mg medication taken orally 1 time/day
40804188|NCT03617536|DRUG|CR845 0.5 mg Oral Tablet|CR845 0.5 mg medication taken orally 1 time/day
40804189|NCT03617536|DRUG|CR845 1 mg Oral Tablet|CR845 1 mg medication taken orally 1 time/day
40804190|NCT03617536|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
40804191|NCT05400603|COMBINATION_PRODUCT|Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate|"The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10\^7 and then 3 x 10\^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10\^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels."
40804192|NCT01777464|BIOLOGICAL|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
40804193|NCT01777464|BIOLOGICAL|sham|sham solution
40804194|NCT06346431|COMBINATION_PRODUCT|DSPT - Digital Support for Problem-solving Therapy|Mobile app breaking major treatment and social needs into subtasks, providing information, prompts and in-app payment to complete those tasks.
40804195|NCT01152593|DRUG|Mupirocin|Intranasal cream given to patient after confirmation of colonization
41007226|NCT04121325|DEVICE|Enterra|To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
41321610|NCT06264349|OTHER|Lifestyle Educational Intervention|The Lifestyle Educational Intervention (LEI) consists of promoting a healthy lifestyle during pregnancy and breastfeeding. In particular, the contents concern: i). macro- and micronutrient requirements during pregnancy/breastfeeding; ii). definition of the concept of the food pyramid and healthy plate also considering aspects of food sustainability; iii). definition of the principles of food safety during pregnancy; iv). importance of maternal and infant sleep quality; v). importance of maternal physical activity during pregnancy and lactation; vi). psychological aspects regarding the mother-child dyad.
40804196|NCT02024425|DIETARY_SUPPLEMENT|Functional bioactive supplement|1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
41007227|NCT02911675|DEVICE|EVD/IVC and the IPM/Camino|This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
41007228|NCT03085329|DEVICE|Seattle-PAP|Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
41007229|NCT03085329|DEVICE|Conventional bubble nasal CPAP|Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher \& Paykel bubbler device, which is the standard of care at Nationwide Children's.
41321611|NCT01261546|DRUG|Dexamethasone|"* Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~* Ranitidine 5 mg/kg IV, q.d. for 2 days~* Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
41321612|NCT01261546|DRUG|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
41321613|NCT05379894|PROCEDURE|Percutaneous nephrolithotripsy|Extraction of kidney stones through skin using nephroscope
40804197|NCT02024425|DIETARY_SUPPLEMENT|Control supplement|
40804198|NCT00252031|BEHAVIORAL|Dialectical Behavioral Therapy|
40804199|NCT01150058|GENETIC|western blotting|
40804200|NCT01150058|OTHER|flow cytometry|
40804201|NCT01150058|OTHER|laboratory biomarker analysis|
41321614|NCT05948852|PROCEDURE|metabolic surgery (SADIS and OAGB)|TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
41321615|NCT05716594|COMBINATION_PRODUCT|Plant enteral-extended anti-reflux stents|Plant enteral-extended anti-reflux stents in EUS-guided drainage of pancreatic pseudocysts
41321616|NCT05716594|COMBINATION_PRODUCT|Plant traditional stents|Plant traditional stents in EUS-guided drainage of pancreatic pseudocysts
41321617|NCT06192953|OTHER|Functional Proprioceptive Stimulation|Orthoses with a system of 12 stimulators producing mechanical oscillations are attached to the joints of the upper limbs (wrist, elbow and shoulder) or lower limb joints (ankle, knee, hip). These stimulators, which are all synchronized, deliver mechanical oscillations (FPS) that give the illusion of complex movements, while the patient is bedridden, neither moving nor producing effort.
41007230|NCT05702216|OTHER|Rehabilitation|Hybrid approach in cardiac telerehabilitation. Patients underwent 20 cardiac rehabilitation sessions: alternatively, patients underwent 10 classical cardiac rehabilitation sessions in the clinic and 10 cardiac telerehabilitation sessions at home.
41007231|NCT01812928|DRUG|Diclofenac|
41321618|NCT03421002|DRUG|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.
41477059|NCT05253924|DIAGNOSTIC_TEST|EEG acquisition|Both PT and FT infants will have their EEG signal recorded during mother-baby interaction according to a modified version of the Still Face paradigm; the EEG signal will be recorded by means of the medical system eego mylab (AntNeuro), using special headphones equipped with 32 electrodes and suitable to acquire the EEG signal since early childhood. After spectral analysis of the EEG signal, the difference in signal strength in the alpha band recorded by two homologous electrodes (or electrode clusters) (i.e. right alpha - left alpha) will be calculated to obtain the FAA index. Because the alpha frequency band is associated with cortical inhibitory activity, a lower asymmetry reflects less left hemisphere activation than right hemisphere activation. The analysis of EEG data will be performed in MatLab environment using the eeglab software and algorithms developed ad hoc.
41477060|NCT01373060|DRUG|ASP1941|oral
41477061|NCT01373060|DRUG|Placebo|oral
40804202|NCT04535817|DRUG|Omalizumab Injection [Xolair]|300mg via 2 subcutaneous injections every 4 weeks
41007232|NCT03211169|PROCEDURE|Biopsies of bile duct stricture with pediatric biopsy forceps|Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps
41007233|NCT03211169|PROCEDURE|Biopsies of bile duct stricture with cholangioscopy-directed biopsies|Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
40804203|NCT00954564|OTHER|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
40804204|NCT00954564|OTHER|medical chart review|Observational only
41007234|NCT02156427|DEVICE|VITICELL|graft of autologus cells (kaeratonicytes and melanocytes) obtained after trypsinization of thin skin biopsy resuspended into hyaluronic acid
41321619|NCT01193140|DRUG|veliparib|Dose orally twice daily for 7 days, consecutively, every cycle
41321620|NCT01193140|DRUG|Temozolomide|Dose orally once daily for 5 days, consecutively, every cycle
41321621|NCT00095368|DRUG|Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)|
41321622|NCT00776555|DRUG|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
41321623|NCT00776555|DRUG|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
41321624|NCT02941341|DRUG|r-hFSH|As per standard practice
41321625|NCT01543139|DRUG|Valproate+Cytidine-+Creatine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
41321626|NCT01543139|DRUG|Valproate+Cytidine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day
41477062|NCT03629613|DIETARY_SUPPLEMENT|Oral antioxidant cocktail|"Oral antioxidant cocktail intake will occur after baseline measurements:~Dose 1 (immediately after baseline testing): 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2 (30 minutes after Dose 1): 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
40804205|NCT00954564|OTHER|questionnaire administration|Observational only
40804206|NCT00954564|PROCEDURE|assessment of therapy complications|Observational only
41007235|NCT02156427|DEVICE|PLACEBO|hyaluronic acid alone
41007236|NCT02231242|BIOLOGICAL|Autologous Stem Cell Transplantation|"Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.~Intrathecal Autologous Bone Marrow TNC"
41321627|NCT01543139|DRUG|Valproate|Valproate: Week0-8: 300mg/day
41321628|NCT04126031|DRUG|Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3|Single intravenous infusion of ceftazidime-avibactam over 2 hours
41321629|NCT04126031|DRUG|Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3|Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
41321630|NCT03076125|BEHAVIORAL|SCORRE|3 components based on the Health Belief Model
41321631|NCT03076125|BEHAVIORAL|Attention-Control Activity|sexual health education
41321632|NCT04141592|PROCEDURE|Bariatric Surgery|Already clinically indicated surgical procedures
41321633|NCT02683018|DRUG|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
41477063|NCT03629613|OTHER|Baseline|No oral antioxidant cocktail intake or placebo intake will occur prior to baseline measurements
41321634|NCT02683018|DRUG|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
41477064|NCT05054894|OTHER|Therapeutic Plasma Exchange (TPE)|"Following all necessary screening and consenting protocol, patients will be scheduled for the plasmapheresis procedure.~Plasmapheresis~On the days of the scheduled procedure, patients will undergo up to 1.5 hours of plasmapheresis treatment. Patients will be awake and situated in a relaxed position in a reclined chair. The plasmapheresis device to be used is the Fresenius Kabi 'Amicus', which is currently FDA approved for a variety of clinical conditions. In one treatment, roughly 60-70% of a patient's plasma can safely be replaced; by using six consecutive treatments, more of the patient's plasma (approaching 100%) will be replaced in an exponential fashion."
41321635|NCT00769236|OTHER|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
41321636|NCT00769236|OTHER|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
41321637|NCT00769236|OTHER|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
41321638|NCT04082702|BEHAVIORAL|Faith-enhanced diabetes prevention program|The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (\~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.
41321639|NCT04082702|BEHAVIORAL|Standard diabetes prevention program|The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
41321640|NCT02905903|DRUG|Tricholoacetic Acid (TCA)|We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
41477065|NCT01370486|DRUG|melatonin|melatonin cp 2 mg 1x/d for 1 month
41477066|NCT01370486|DRUG|placebo|placebo cp 1x/d for 1 month
41477067|NCT02969772|OTHER|Assessment of upper limb variables|International Standards for Neurological and Functional Classification of Spinal Cord Injuries of American Spinal Injury Association (ASIA); Functional Independence Measure (FIM); The following kinematic variables of arm were studied: shoulder, elbow and wrist angles; percentage of time to peak velocity; movement time; peak velocity and movement smoothness (number of velocity peaks and index of curvature); Capabilities of Upper Extremity instrument (CUE); Spinal cord independence measure (SCIM II); electromyography (Clavicular portion of pectoralis major, long head of biceps brachii, anterior and posterior deltoid, triceps and wrist extensors).
41477068|NCT02969772|OTHER|Training protocol|The strengthening sessions consisted of 20 minutes of electrical stimulation on triceps, extensor carpi radialis longus, extensor digitorum communis, lumbricalis, flexor digitorum superficialis and opponens pollicis muscles. The functional training sessions was performed through movements the reach and palmar grasp with NMES of the several cylindrical and conical objects of different weights (30 minutes sessions).
41477069|NCT00094458|BIOLOGICAL|infliximab infusion; AZA placebo caps|Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
41477070|NCT00094458|OTHER|infliximab (IFX) infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
41477071|NCT00094458|DRUG|infliximab (IFX) placebo infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
40804210|NCT05331300|DRUG|LASN01|Escalating single and multiple doses of LASN01
40804211|NCT05331300|DRUG|LASN01|LASN01 will be administered intravenously
41007237|NCT01263574|DRUG|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
40804212|NCT05331300|DRUG|Placebo|Escalating doses of matching placebo
40804213|NCT05331300|DRUG|Placebo|Placebo will be administered intravenously
41007238|NCT01469325|OTHER|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
41007239|NCT01469325|OTHER|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
41321641|NCT05306548|PROCEDURE|Surgical carpal tunnel release|Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve
41477072|NCT04694612|DRUG|Favipiravir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
41477073|NCT04694612|DRUG|Placebo|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
40804214|NCT05118165|DIETARY_SUPPLEMENT|Dietary supplement with protein|Will be included protein supplements in the preoperative diet.
40804215|NCT01933698|DRUG|amoxicillin|Comparison of pharmacokinetics of both formulations
40804216|NCT06429046|OTHER|LIDOCAINE GEL|To LG group patients, 20 ml lidocaine gel will be applied intrarectally (double application: 5cc to the perianal region, covering the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed in the rectum.
41321642|NCT05306548|DRUG|Injection, Triamcinolone Hexacetonide, Per 5 Mg|Ultrasound-guided injection of 20 mg of triamcinolone hexacetonide (or -acetonide) into the carpal tunnel space close to the median nerve
41321643|NCT03287245|DRUG|Idasanutlin|All participants will receive 150 milligrams (mg) idasanutlin orally, once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years). Intra-participant dose-escalation to 200 mg daily for 5 days may be permitted after Cycle 3 for those who demonstrate no hematocrit (Hct) control and/or for those with inadequately controlled leukocytosis and/or thrombocytosis in which the investigator judges that better control is important.
40804217|NCT06429046|OTHER|COLD LIDOCAINE GEL|In CLG group patients, 20 ml of cold lidocaine gel kept in the refrigerator at +4 0C will be applied intrarectally (double application: 5cc to the perianal region, including the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed into the rectum.
40804218|NCT02795624|PROCEDURE|Spirometry|Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.
40804219|NCT02795624|PROCEDURE|Pulse Wave Analysis|It is a non-invasive assessment of the pulse character
40804220|NCT02795624|PROCEDURE|Peripheral arterial tonometry|It is a non-invasive method to measure endothelial dysfunction.
41321644|NCT04529434|OTHER|Star Homes|110 identical novel-designed houses, known as Star Homes, include the critical structural components e.g. building orientated to provide optimal shading throughout the day, light-weight \& durable roof, facade and openings screened from insects to reduce insect entry while assuring airflow, an outdoor fly-proof latrine, and solar power providing electric light at night etc.
41321645|NCT04529434|OTHER|Traditional African houses|A traditional mud house: with wattle and daub walls, a thatched roof, and no electricity or piped water supply.
40804221|NCT04022629|PROCEDURE|Arthroscopic Washout Only|To wash out the shoulder joint with a sterile solution through an arthroscope (keyhole surgery) under a general anaesthetic.
40804222|NCT04022629|PROCEDURE|Arthroscopic Bankart Repair|To repair the torn glenoid labrum in the shoulder, using key-hole (arthroscopic) surgery techniques under general anaesthetic. The Bankart technique is well described and will be performed using suture anchors.
40804223|NCT03490591|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of warm-up exercise and 40 minute of robot-assisted hand exercise intervention. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task, robot-assisted task, and game task.
41007240|NCT06198907|DRUG|Golidocitinib|Daily dosing of golidocitinib
41007241|NCT06198907|DRUG|Sintilimab|Sintilimab, 200mg, intravenous, every 3 weeks.
41007242|NCT06198907|DRUG|platinum doublet chemotherapy|Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles
41321646|NCT05615766|DEVICE|Experimental: Device Intervention|The robotic rehabilitation programme using the MARK from Myomo (myomo.com) for the intervention group will last for 12 weeks with up to four sessions of rehabilitation per week, i.e. total of 48 sessions. Spinal cord injured inpatients in the study will have this intervention on their dominant arm in addition to the traditional rehabilitation programme assigned and standard care.
41321647|NCT03769324|DIAGNOSTIC_TEST|Osmolarity Test|Osmolarity Test
41321648|NCT03043729|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2, as 2h infusion on Day 1 (Arm A + Arm B)
41321649|NCT03043729|DRUG|5-FU|5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusion q2w (Arm A + Arm B)
41321650|NCT03043729|DRUG|Leucovorin|Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
41321651|NCT03043729|BIOLOGICAL|Aflibercept|Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (Arm B, Cycles 1 to 5)
41321652|NCT00546793|BIOLOGICAL|veltuzumab|veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
41321653|NCT00111930|DRUG|DHEA|
41321654|NCT02623296|DRUG|GLPG1205|Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13
41321655|NCT02623296|DRUG|Placebo|Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
41321656|NCT02623296|DRUG|Cocktail of CYP450 substrates|Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
41321657|NCT00643344|BEHAVIORAL|Craving and Lifestyle Management through Mindfulness(CALMM+)|MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
41477074|NCT04694612|DRUG|Remdesivir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
41477075|NCT01481740|DRUG|Phenylephrine bolus|10 ml of 100mcg/ml phenylephrine and placebo infusion
41477076|NCT01481740|DRUG|phenylephrine infusion|60ml infusion of 100mcg/ml phenylephrine and placebo bolus
41321658|NCT03601208|DIAGNOSTIC_TEST|Mitra|When the patients have their bloods done through venepuncture, an additional 5-10mls will be taken (one EDTA bottle for tacrolimus and one serum bottle for creatinine; and two Mitra VAMs). Patients will also have a fingerprick test and 20 microlitres of blood taken using Mitra volumetric absorptive microsampling (VAMs)
41321659|NCT05126745|DEVICE|color flow Doppler ultrasonography|Doppler ultrasonography
41321660|NCT03809221|DRUG|Triptorelin acetate|Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
41321661|NCT04701047|DEVICE|vaginal pessary|insertion and follow up of a vaginal pessary
41321662|NCT04701047|PROCEDURE|Vaginal prolapse surgery|surgery and follow up after vaginal prolapse surgery
41477077|NCT02283450|DRUG|Qiliqiangxin Capsule|
41477078|NCT05122767|DRUG|Dolutegravir|"Groups 1a/1b: Participants will take the FDA-approved weight-based DTG once daily + either TDF/FTC, TDF/3TC, ABC/3TC or AZT/3TC x 4 weeks. During HP treatment and for two weeks afterward, DTG dose will be increased to twice daily.~Participants will continue with the NRTI regimen they have previously tolerated, except where their age and weight allow them to transition from either AZT or ABC to TDF, as per South African National ART Guidelines. HLA-B\*5701 screening will therefore not be performed, as children will be currently taking and tolerating an ABC-containing regimen at enrolment. If any clinically suspected hypersensitivity reaction to ABC is suspected by history, ABC will not be continued.~Groups 2a/2b: Participants will take weight-based DTG dosing twice or once daily, depending on the results of the modelled data for the Group 1a (for Group 2a) and/or Group 1b (for Group 2b) participants in the interim analysis."
41321663|NCT04880850|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
41477079|NCT05122767|DRUG|3HP|3HP Dosing is by Age and Weight Children 2-15 years of age: 10-15kg (P 300mg, H 300mg); 16-23kg (P 450mg, H 500mg); 24-30kg (P 600mg, H 600mg); 31-34kg (P 750mg, H 700mg). Children 15-17 years, \>=30kg (P 900mg, H 900mg)
41477080|NCT02959008|DEVICE|measure TOI and BP|Both groups measure TOI and BP.
41477081|NCT06048289|OTHER|Blood samples, tumor biopsy specimens will be collected|Blood samples, tumor biopsy specimens at baseline will be collected
41007243|NCT04545177|DEVICE|NICO Myriad and Tissue Preservation System (TPS)|Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
41477082|NCT03114696|DIETARY_SUPPLEMENT|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
41007244|NCT03262948|DRUG|nab-paclitaxel|albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
41007245|NCT03262948|DRUG|Paclitaxel|paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
41321664|NCT04880850|DRUG|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 26 weeks
40804224|NCT05764005|BEHAVIORAL|web-based tool (MAP- Management of Active surveillance in Prostate Cancer)|A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}
41321665|NCT04880850|DRUG|Insulin aspart|Participants will receive subcutaneous (s.c.) injections of insulin aspart 2-4 times daily for 26 weeks
41321666|NCT02819505|DIETARY_SUPPLEMENT|beta-alanine|
41321667|NCT02819505|DIETARY_SUPPLEMENT|Placebo|
41321668|NCT03602261|DRUG|Calcifediol Oral Capsule|Capsule, weekly
41321669|NCT03602261|DRUG|Placebo oral capsule|Capsule, weekly
41321670|NCT06335823|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit turned on and half will have the TENS unit turned on to a 80 hz preset frequency with 100 mA as the pulse width.
41321671|NCT06335823|DEVICE|Placebo Transcutaneous electrical nerve stimulation (TENS)|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit will not be turned on.
41321672|NCT05244499|OTHER|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
41321673|NCT05244499|OTHER|Conventional training|7-modules online training over six months. Independent reading only.
41321674|NCT05599854|PROCEDURE|vitrectomy and silicone oil injection|Parsplana vitrectomy and silicone oil injection
41321675|NCT06106243|PROCEDURE|The conventional heat pressing temporary flexible maxillary removable partial denture|An intraoral scan will be made for each patient's maxillary and mandibular jaws in addition to digital bite registration using (Medit i700; Medit corp.) the resultant data will be exported in the form of a Standard Tessellation Language (STL) file. The denture base and the teeth will be designed using computer-aided design software (Partial Cad, Dental CAD software). Each patient will receive two RDPs, fabricated with two different manufacturing techniques. Based on randomization, the patients will start by receiving either partial denture that is fabricated by conventional heat pressing technique of 3D printed castable resin (Cast V1resin) followed by partial denture that is fabricated by 3D printing of printable resin (Flexo denture base, resin) and teeth (permanent crown,resin) or the other way around. In 3D-printed RDP, the artificial teeth will be attached to the fabricated denture bases using printable denture base resin material
41321676|NCT06106243|PROCEDURE|3D-printed and digitally designed temporary flexible maxillary removable partial denture|3D-printed and digitally designed temporary flexible maxillary removable partial denture
41321677|NCT02697630|DRUG|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
41321678|NCT02697630|DRUG|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
41321679|NCT05331456|DEVICE|Unilateral alveolar cleft repair|Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty
41321680|NCT03743233|DEVICE|Hand file|A crown-down technique will be performed until reaching the provisory WL. The root canals will be initially deobstructed with size #3 and #2 Gates-Glidden burs (Dentsply-Maillefer) at the coronal and middle root thirds. Then, hand stainless steel K-files (Dentsply-Maillefer) with decreasing sizes will be used (#40, #35, #30, #25). The WL will be determined by an electronic apex locator (Novapex; Forum Technologies, Rishon Le-Zion, Israel). A radiograph will be taken to confirm the WL, which should be 1 mm short of the root apex. Apical patency will be reached and maintained with a size #15 K-file (Dentsply-Maillefer). The root canals will be reinstrumented and a size #50 K-file will be standardized as the master apical instrument. A step-back procedure in 1-mm increments followed until merging with the crown-down rotary enlargement (size #70) will be achieved.
41321681|NCT03743233|DEVICE|Reciprocating|Reciproc R25 file will be used for gutta-percha removal, until reaching the WL. The instrument will be introduced into the canal applying slight movements of 3-mm amplitude. Apical patency will be maintained with a size #15 K-file. The root canals will be reinstrumented using the Reciproc R50 file. For both groups, after the root canal filling removal and reinstrumentation protocol, a new radiograph will be taken, without any intracanal instrument, for posterior analysis of the percentage of remaining filling material in the root canal. If the radiograph demonstrates the persistence of filling material, the technique will be repeated with the last instrument used in the chemomechanical preparation (hand or reciprocating file), also using H-files with circumferential movements against the dentinal walls in order to remove these residual material, followed by abundant irrigation with NaOCl.
41321682|NCT04078334|OTHER|MATCH|In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.
41321683|NCT04078334|OTHER|PATH|In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can be completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions.
41321684|NCT04078334|OTHER|PATH 2.0|"In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.~In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions."
41321685|NCT05723458|COMBINATION_PRODUCT|Cream|A cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa
41321686|NCT05723458|DRUG|Placebo|Placebo cream containing vaseline
41321687|NCT04374812|OTHER|Exposure to registered nurses|Change in outcomes associated with a one hour per patient day increase in exposure to registered nurses
41321688|NCT04374812|OTHER|Exposure to nursing assistants|Change in outcomes associated with a one hour per patient day increase in exposure to nursing assistants
41321689|NCT00398957|DRUG|OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).|
41007246|NCT03262948|DRUG|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
41007247|NCT02897596|DRUG|Grazoprevir 100 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
41321690|NCT03914495|DIETARY_SUPPLEMENT|Inulin|Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
41321691|NCT03914495|DIETARY_SUPPLEMENT|Placebo|Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
41321692|NCT00004207|DRUG|liposomal daunorubicin citrate|
41321693|NCT05516693|OTHER|Myofacial muscle training protocol.|Muscle training for orofacial motricity stimulation
41321694|NCT04468334|DEVICE|LARIAT + PVI|LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
41321695|NCT02325817|DEVICE|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
41477083|NCT03114696|DIETARY_SUPPLEMENT|Placebo|1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)
41477084|NCT00502801|DRUG|doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
41477085|NCT02940678|OTHER|No intervention|
41477086|NCT03922074|PROCEDURE|Sedation directed by an endoscopist|"The nurse begins with fentanyl infusion in bolus: 75 μg (1.5 ml) and initial propofol dose (10mg/ml) in bolus of 0.5 - 2.5 mg/Kg followed by a maintenance dose of 20 - 60ml/h through Target-controlled infusion (TCI) pump. In this way, we get a target level sedation between 1 - 3, according to Observer's Assessment of Alertness/Sedation Scale (OAAS).~The role of the nurse, directed by an endoscopist, it is exclusively the administration of intravenous drugs and the patient monitorship throughout the procedure."
41477087|NCT03922074|PROCEDURE|Sedation directed by an anesthesiologist|The choice of the drugs and the target level sedation are directed by an anesthesiologist
41477088|NCT00003293|DRUG|leflunomide|
41477089|NCT00003293|DRUG|procarbazine hydrochloride|
41477090|NCT05198882|PROCEDURE|Laser technology for intracerebral thermocoagulation|One intervention : LITT (Laser Interstitial Thermal Treatment), technology that uses laser energy to thermally destroy (photo-thermal treatment) a brain injury under continuous MRI control (Validated by FDA - CE marking). The operator console + surgical laser generator + software that manages the power delivered by the laser is connected to an MRI - Provided by MEDTRONIC - FDA approved and CE certified.
40804225|NCT05764005|BEHAVIORAL|MUSIC website|Standard of care educational materials {add more detail}
40804226|NCT02159898|DEVICE|EndoMAXX Endoluminal Valve Technology (EVT)|
41321696|NCT02325817|DEVICE|Uncoated ballloon|Treat the side branch of bifurcation lesion with uncoated balloon
41321697|NCT05663840|BEHAVIORAL|Progressive resistance exercise|Patients with predominant symptoms of cervical dystonia will receive exercise training. Patients will receive progressive resistance exercise focused cervical and shoulder training (PERFECT) plus standard-of-care (SOC) therapy. Resistance training will consist of mainly muscle-strengthening exercises for the neck, shoulder and arms and a few upper trunk muscles. Resistance training will be guided by physical therapists at twice a week schedule for 6 months. These participants will also receive SOC therapy.
41321698|NCT05663840|BEHAVIORAL|Standard of care|Subjects will receive SOC therapy only
41007248|NCT02897596|DRUG|Elbasvir 50 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
41321699|NCT05181540|BIOLOGICAL|AB-205|Allogeneic genetically engineered human umbilical vein endothelial cells
41321700|NCT05181540|OTHER|Placebo|Placebo
41321701|NCT02180217|DRUG|osilodrostat|Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
41321702|NCT02180217|DRUG|LCI699 matching placebo|Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
41321703|NCT01473329|OTHER|Structured Diabetes Education|The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
41321704|NCT02858973|DRUG|Q203|
41321705|NCT02858973|DRUG|Placebo|
41477091|NCT04668976|DEVICE|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
40804227|NCT02159898|DEVICE|EndoMAXX|
41477092|NCT04668976|DRUG|Floxuridine (FUDR)|Please see Detailed Description.
41477093|NCT04668976|DRUG|Gemcitabine|Please see Detailed Description.
41477094|NCT04668976|DRUG|Oxaliplatin|Please see Detailed Description.
41477095|NCT04668976|DRUG|Irinotecan (CPT-11)|Please see Detailed Description.
41477096|NCT04668976|DRUG|Fluorouracil|Please see Detailed Description.
41477097|NCT04668976|DRUG|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
41477098|NCT00609284|DRUG|cetuximab|D-7, D1, D8, D15, D22, D29, D43, D50
40804228|NCT01108731|DRUG|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
41007249|NCT02897596|DRUG|Grazoprevir 100 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
41007250|NCT02897596|DRUG|Elbasvir 50 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
41477099|NCT00609284|DRUG|Carboplatin, 5FU concomitant|Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
41477100|NCT00609284|RADIATION|Radiotherapy|70 Gy in 7 weeks
41152547|NCT06011928|OTHER|Relaxation Exercise|Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened.
40804229|NCT01108731|DRUG|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
41321706|NCT03805555|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation by radiofrequency ablation
41321707|NCT03805555|PROCEDURE|Cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation
41321708|NCT02993055|DRUG|Ulimorelin|
41477101|NCT02356211|OTHER|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
41477102|NCT04452279|DEVICE|iStent or iStent inject implantation with concomitant cataract surgery|Standard phacoemulsification cataract surgery followed by ab interno implantation of either iStent or iStent inject trabecular micro-bypass stent(s). Preoperatively and at specified visits through 3 months postoperative, patients will complete evaluations of their ocular surface disease (specifically OSDI score, hyperemia, corneal/conjunctival staining, and tear break-up time).
40804230|NCT04653090|DIAGNOSTIC_TEST|Xray|Hip AP Xray
40804231|NCT04420832|PROCEDURE|Surgical treatment|Se above
40804232|NCT04420832|OTHER|Non-surgical treatment|See above
40804233|NCT02841007|DEVICE|geko neuromuscular electrostimulation device|
40804234|NCT00395486|DRUG|Rosuvastatin|10mg
40804235|NCT00395486|DRUG|Atorvastatin|10mg
40804236|NCT02945358|PROCEDURE|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
40804237|NCT02021383|BEHAVIORAL|Bi-weekly in person meetings with a Registered Dietician|"Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.~Participants in the Contest only and Control group were not eligible to receive these meetings."
40804238|NCT02021383|BEHAVIORAL|Financial incentives for weight loss maintenance|Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
40804239|NCT02626429|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
40804240|NCT05148650|DIAGNOSTIC_TEST|Standard laboratory coagulation tests and rotational thromboelastometry measurements|"Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM."
40804241|NCT02403063|DRUG|Sugammadex|Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
41321709|NCT02993055|OTHER|Placebo|
41321710|NCT01603030|DRUG|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
41321711|NCT01603030|DRUG|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
41321712|NCT06197737|OTHER|Moderate Intensity Interval Training|Participants in this group will perform moderate intensity interval training in which they will perform stair climbing 3 times a week and for every 1 interval I will ask them to take rest for 3 minutes.
41321713|NCT06197737|OTHER|Sprint Interval Training|sprint interval training in which they will do stair climbing 3 times a week with a fast pace.
41321714|NCT06197737|OTHER|pharmacological treatment|They will be on pharmacological treatment as prescribed by their pulmonologist.
41321715|NCT03661450|DIAGNOSTIC_TEST|Clinical Decision-Support System|Patient Data is evaluated by a Clinical Decision-Support System searching for age-adapted pediatric SIRS-criteria, aiming for a high sensitivity and specificity
40804242|NCT02403063|DRUG|Neostigmine|Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
40804243|NCT02403063|DRUG|Neostigmine-sugammadex|Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
41007251|NCT05062668|PROCEDURE|cataract operation and istent|a cataract operation and the placement of one or two iStent inject or inject W at the same time
41007252|NCT05062668|PROCEDURE|cataract operation only|Patients have a classic postoperative treatment after cataract.
41007253|NCT02753894|DRUG|ASP1585|Oral
41007254|NCT04259190|BEHAVIORAL|interoceptive exposure|Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
41321716|NCT02022033|DRUG|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
40804244|NCT04089670|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention|"The intervention includes 8 modules (i.e, Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Away Moves and Letting Go of Control, helps establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. Noticing Hooks and Stepping Back focus on defusion, self as context, and mindfulness. While, mindfulness is overtly addressed in the module Stepping Back it is weaved through each module. Your Values and How You Want to Act focus on helping participants identify their values. Goal Setting and Making Commitments focus on committed action. Each module ends with a practice assignment which participants are asked to engage in over the next week."
40804245|NCT01822899|DRUG|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
40804246|NCT01822899|DRUG|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
41321717|NCT00426556|DRUG|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
41321718|NCT00426556|DRUG|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel \& Trastuzumab
41321719|NCT00426556|DRUG|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
41321720|NCT04374279|DRUG|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily for 7 days
41321721|NCT03691753|DEVICE|Fitaya Vena Cava Filter System|After the implantation of Fitaya Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
41321722|NCT03691753|DEVICE|Aegisy Vena Cava Filter|After the implantation of Aegisy Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
41321723|NCT01928992|DEVICE|3D|subjects that underwent 3D mammography
41321724|NCT01928992|DEVICE|2D|those subjects that underwent 2D mammography
41321725|NCT04699214|DRUG|Endostar (recombinant human endostatin injection)|The experimental group is Endostar combined with AI
41321726|NCT04699214|DRUG|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
41321727|NCT02789605|DRUG|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
41321728|NCT02789605|DRUG|Placebo|Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
41321729|NCT05750134|OTHER|OBPLUS Clinical Database : data analysis|The data processed relates to patients cared for in the Hepato-gastroenterology and nutrition department of the Antoine Béclère Hospital at the Assistance Publique - Hôpitaux de Paris (AP-HP. All of the clinical and paraclinical data are collected during the visits and entered into the OBPLUS database (database registered in the AP-HP register). These data will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
41321730|NCT05750134|OTHER|"Biological collection Liver, bile ducts and pancreas: sample analysis"|"The samples (plasma, serum, saliva, stool) collected during the samples taken as part of the patient's care were the subject of a biological collection Liver, bile ducts and pancreas. These samples will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication."
41321731|NCT05563714|BEHAVIORAL|Clinician Notification with Nurse Facilitation (CNNF)|An anticoagulation clinic nurse sends a templated message to the patient's target clinician that identifies the patient as high risk for upper GI bleeding, summarizes guidelines on appropriate antiplatelet medication use and PPI gastroprotection, and recommends that the clinician consider either discontinuing the patient's antiplatelet medication(s) or initiating a PPI for gastroprotection. The nurse will also offer to pend the order for a PPI if the clinician wants to initiate a PPI and will provide education to the patient on any medication changes recommended by the clinician.
41321732|NCT05563714|BEHAVIORAL|Wait list control|The anticoagulation clinic will not send the clinician notification letter or other project-specific materials to the clinician or patient, and the patient will be included on a list of patients who will receive the intervention at the conclusion of the trial.
41321733|NCT04665414|DIAGNOSTIC_TEST|MRI|preoperative MRI
41321734|NCT04665414|DIAGNOSTIC_TEST|transvaginal ultrasound|preoperative transvaginal ultrasound
41321735|NCT04665414|DIAGNOSTIC_TEST|transvaginal ultrasound elastography|preoperative transvaginal ultrasound elastography
41321736|NCT05880407|PROCEDURE|SERI osteotomy|Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire
41321737|NCT05880407|PROCEDURE|percutaneous osteotomy according to Chevron|Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.
41321738|NCT01648829|DRUG|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
41321739|NCT01648829|DRUG|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
41321740|NCT06014294|BEHAVIORAL|HIIT|Participants will receive a 16-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 34 to 40 minutes with progression of training. Each HIIT section will include ten combined exercises with self-weight. For Weeks 1-2, the HIIT section will include 10 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 9 intervals of 60 seconds of active recovery.
41477103|NCT05211999|BEHAVIORAL|Precede-Proceed Model Based Simulation Experience|The program was created on the basis of the PRECEDE-PROCEED Model.The program consists of eight phases. It will be carried out with theoretical training and simulation experience in the experimental group. In the control group, theoretical training will be given. Results will be followed.
41477104|NCT05211999|BEHAVIORAL|Control Group|No intervention in control group just theoretical education was done for them.
41477105|NCT03894241|BEHAVIORAL|physical activity|"Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)"
40804247|NCT01822899|DRUG|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
40804248|NCT01822899|DRUG|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
40804249|NCT05183516|BIOLOGICAL|tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
40804250|NCT03229772|DEVICE|Discovery NM/CT 670 CZT Imaging Scan|At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
40804251|NCT04322435|OTHER|Continuous blood glucose measurement|Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
40804252|NCT04322435|OTHER|Measurement of capillary blood glucose|"Measurement of capillary blood glucose :~* In the morning on an empty stomach, every first week of each month for 12 months.~* In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips."
40804253|NCT05365997|OTHER|Default Nudge|For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
40804254|NCT01576939|RADIATION|Intensity Modulated Radiation Therapy|"We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to \< 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s)."
41007255|NCT03436368|PROCEDURE|Continuous spinal anesthesia|Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
41007256|NCT03436368|PROCEDURE|General anesthesia|Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
41007257|NCT04212468|OTHER|no intervention|no intervention
41007258|NCT02976896|DRUG|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
41321741|NCT06014294|BEHAVIORAL|Baduanjin|As a typical MICT, Baduanjin Qigong will be performed. The instructor will provide group teaching with individual instructions on specific movements. The same training principles of individuality and progression used in the HIIT group will also be applied to Baduanjin Qigong group.
41321742|NCT06014294|BEHAVIORAL|Workshop|Participants in the non-exercise control group will receive a series of workshops related to daily recreation.
41321743|NCT00810095|DEVICE|MindFrame System|Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
41477106|NCT05580952|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
41477107|NCT02771041|PROCEDURE|medical consultation 8 days before surgery|"This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
41321744|NCT05833971|DRUG|cadonilimab+chemotherapy|cadonilimab plus cisplatin and Nab-PTX, Q3W
41477108|NCT04916483|OTHER|group cognitive stimulation therapy|The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
41477109|NCT04916483|OTHER|usual care|The control group maintains the unit routine treatment.
41477110|NCT02340494|BEHAVIORAL|Online Enhanced Education Tool|The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
41321745|NCT00338065|BEHAVIORAL|Postural change|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
41321746|NCT00338065|BEHAVIORAL|Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
41321747|NCT00397176|DRUG|desvenlafaxine succinate sustained release (DVS SR)|
41321748|NCT00001911|DRUG|Interleukin-12|
41477111|NCT04331964|PROCEDURE|partial pulpotomy|Removal of a small portion of coronal pulp tissue after exposure, followed by application of a biomaterial directly onto the remaining pulp tissue prior to placement of a permanent restoration.
41477112|NCT05488717|OTHER|art-based mandala application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
41321749|NCT02248857|OTHER|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
41477113|NCT05275959|OTHER|A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China|"Myopia and obesity in children and adolescents have become serious public health problems that endanger public health, especially in China. Unhealthy lifestyle behaviors are environmental drivers of both myopia and obesity. This protocol describes a study to evaluate the effectiveness of 22510SS, that is 2 h of daytime outdoor activities ('2'); Limit screen time to no more than 2 h per day ('2'); Consume at least 5 servings of fruits and vegetables daily ('5'); Attain 1 h of physical activity daily ('1'); Consume 0 sugar-sweetened beverages ('0'); Reasonable sleep duration ('S'); Regular supervision ('S'). A school-based, multifaceted intervention strategy for myopia and obesity prevention, and to assess and explore the implementation of 22510SS with regards to acceptability, feasibility, adoption, usage and maintenance."
41477114|NCT06463717|DRUG|Transplant, Autologous|High-dose melphalan followed by autologous stem cell transplantation
41477115|NCT06463717|DRUG|Chemotherapy drug|Regimen such as Bortezomib plus Lenalidomide plus Dexamethasone
41477116|NCT03123783|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody
41477117|NCT03123783|DRUG|Nivolumab|Nivolumab is an immune checkpoint (PD-1) blocking antibody
41477118|NCT00466973|DEVICE|Dry bipolar radiofrequency (RF) clamp|Specified device used for ablation during standard surgical procedure
41477119|NCT00466973|DEVICE|Unipolar microwave antenna|Specified device used for ablation during standard surgical procedure
41477120|NCT00466973|DEVICE|Unipolar cryothermic probe|Specified device used for ablation during standard surgical procedure
41477121|NCT00466973|DEVICE|Irrigated unipolar RF antenna|Specified device used for ablation during standard surgical procedure
41477122|NCT00466973|DEVICE|Irrigated bipolar RF clamp|Specified device used for ablation during standard surgical procedure
41477123|NCT00466973|DEVICE|Hi-intensity focused ultrasound wand|Specified device used for ablation during standard surgical procedure
41477124|NCT01452594|DRUG|Diphenylcyclopropenone|Topical administration
41477125|NCT01452594|DRUG|Placebo|Placebo
41477126|NCT01920542|DRUG|Dexmedetomidine|administration of dexmedetomidine on dexemedetomidine group
41477127|NCT01920542|DRUG|no dexmedetomidine|no administration of dexmedetomidine on control group
41477128|NCT03418987|OTHER|Medical File data analysis|Analysis of the 2D/3D spine images (performed with the sterEOS software and the MATLAB software)
41477129|NCT02433119|DRUG|OROSARTAN® 5/160mg|
41477130|NCT02433119|DRUG|CODIOVAN® 160/12.5mg|
41477131|NCT01795248|DRUG|Liraglutide|1.8 mg liraglutide
41477132|NCT01795248|DRUG|Placebo|Liraglutide without the GLP-1 analogue
41477133|NCT02332980|DRUG|Ibrutinib|Given PO
41477134|NCT02332980|DRUG|Idelalisib|Given PO
41007259|NCT02948842|DRUG|Clostridium Histolyticum Collagenase|0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.
41007260|NCT02948842|OTHER|Saline|0.08ml of injectable normal saline
41321750|NCT02248857|OTHER|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
41321751|NCT01047748|DRUG|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
41321752|NCT01047748|DRUG|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
41321753|NCT01714297|DRUG|dalteparin 5000 IU s.c.|All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
41321754|NCT02456376|PROCEDURE|Sensory Integration Testing|Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
41321755|NCT02456376|PROCEDURE|SR stimulation & Sensory integration testing|Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
41007261|NCT00519649|BIOLOGICAL|Engerix™-B Kinder|Intramuscular injection, 1 dose
41007262|NCT01873989|DRUG|Testosterone replacement|
41007263|NCT01873989|OTHER|Waitlist control|
40804255|NCT04990505|DIAGNOSTIC_TEST|lung ventilation/perfusion scintigraphy|"Chest CT-scan will be performed with blocked inspiration.~Lung ventilation/perfusion scintigraphy imaging will be performed within 24hrs after CT pulmonary angiography, 410MBq of Technegas will be inhaled by patients and ventilation tomography performed thereafter. Then, 185MBq 99mTc-macroaggegates will be injected intravenously followed by the perfusion tomography.~A combined CT acquisition will be performed.~The day following lung ventilation/perfusion scintigraphy, 740MBq of Tc99m labeled albumin will be intravenously administered.~Cardiac gated-blood-pool scintigraphy will be then performed in best septal left anterior oblique and left profile according to specific parameters.~45-60 min after injection, a non-gated tomographic acquisition over the lungs will be done, with the same parameters than for PS SPECT, resulting in a late albumin acquisition."
40804256|NCT03353363|DRUG|Bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of bupivacaine 0.5% plain will be infiltrated into the wound by the obstetrician team in a standardized fashion.
40804257|NCT03353363|DRUG|Liposomal bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of one liposomal bupivacaine will be infiltrated into the wound by the obstetrician team in a standardized fashion.
41007264|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
41007265|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|
41321756|NCT02209649|DRUG|Lacidipine and Telmisartan fixed dose combination (FDC) tablet|
41321757|NCT02209649|DRUG|Lacidipine|
41477135|NCT02332980|OTHER|Laboratory Biomarker Analysis|Correlative studies
41477136|NCT02332980|BIOLOGICAL|Pembrolizumab|Given IV
41477137|NCT03322020|RADIATION|Cyberknife boost 18 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx
41477138|NCT03322020|RADIATION|Cyberknife boost 21 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx
41477139|NCT05547334|BEHAVIORAL|Inference Based Approach (IBA)|The Inference Based Approach (IBA) (as described by Visser et al., 2015 and adapted for use in adolescents by L. Webers)is a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly and carried out as specified in a Dutch session-by-session IBA protocol, containing standardized forms for exercises and homework assignments. Each session has a standard format, starting with agenda setting and evaluating homework assignments, followed by determining and executing a new exercise and determining new homework. The IBA model is based on the assumption that adolescents with OCD and poor inside misjudge the actual state of affairs. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the childs attention from observable reality.
41477140|NCT04429529|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)
41477141|NCT04429529|OTHER|0.9% Saline|Placebo
41007266|NCT01205165|DRUG|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
41321758|NCT02209649|DRUG|Telmisartan|
41477142|NCT04894084|DEVICE|CP321|The primary objective is to evaluate the system performance of the test product. This is done by asking subjects to answer questions throughout the study
41477143|NCT05424718|BEHAVIORAL|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk young men that have sex with men (YMSM).
41007267|NCT01633944|DRUG|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
41007268|NCT01633944|DRUG|Placebo|Matching Placebo Buccal Film twice daily
41007269|NCT00774995|BIOLOGICAL|EngerixTM-B|Intramuscular injection, one dose.
41321759|NCT02726529|BEHAVIORAL|Brighter Bites|
41321760|NCT02726529|BEHAVIORAL|CATCH|The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
41321761|NCT03308565|BIOLOGICAL|Autologous, Adipose derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
41321762|NCT04658420|DRUG|Ketamine Hydrochloride|Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes
41321763|NCT04658420|OTHER|Music|"A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:~https://open.spotify.com/playlist/37i9dQZF1DWVbGPBkXJYHF"
41477144|NCT03988517|OTHER|timing of receiving the drug|each group took levothyroxine in different timing
41477145|NCT01937247|PROCEDURE|Patients will be inducted in the induction room|The patients will be inducted in the induction room
41477146|NCT01937247|PROCEDURE|Redesigned process|The registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room
41477147|NCT01937247|DRUG|patient will be reversed with sugammadex 4mg/kg IV|The patient will be reversed with sugammadex 4mg/kg IV, and then extubated before being moved out of the OR
41477148|NCT01937247|PROCEDURE|STANDARD PROCESS|standard process
41321764|NCT00927264|BEHAVIORAL|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits \& 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
41321765|NCT00927264|BEHAVIORAL|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
41321766|NCT00144755|DRUG|Darbepoetin alfa|prophylactic administration of darbepoetin alfa in experimental arm
41321767|NCT02614287|DRUG|Galcanezumab|Administered SC
41321768|NCT01046383|DIETARY_SUPPLEMENT|IMN1207|20 grams of IMN1207 per day for 40 weeks.
40804258|NCT03353363|DRUG|Placebos|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
40804259|NCT05494463|DEVICE|Miller blade|After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
40804260|NCT04712643|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.
41007270|NCT04184076|BEHAVIORAL|Time-restricted feeding (TRF) with dietary counseling|"1. Subjects will be instructed to administer time-restricted feeding.~2. Subjects have to compete a 3-d food record, including 2 regular day and 1 holiday. At baseline, a dietitian will provide 15 min of instruction to each participant on how to complete the food records. Subjects will be asked to measure the volume of foods consumed with household measures. The timing of food intake will be also recorded. Food records will be collected each week during the experiment and will be reviewed by the dietitian for accuracy and completeness. A database for food content will be used to calculate the total daily intake of energy, fat, protein, carbohydrate, cholesterol, and fiber. All subjects will be asked to maintain their level of physical activity throughout the entire trial.~3. Blood withdraw will be performed prior to the first consumption of food and analyze some biochemistry data."
41007271|NCT05390203|DIAGNOSTIC_TEST|Penile duplex study, Hormonal Assay (Total Testosterone, Prolactin and E2)|we will do penile duplex and hormonal profile preoperatively and 6 months postoperatively.
41007272|NCT05112393|OTHER|Development of new estimating Glomerular Filtration Rate (eGFR) equation|"Development Cohort:~A new estimating Glomerular Filtration Rate(eGFR) equation will be developed by using a nonlinear regression model utilizing a generalized least squares algorithm."
41007273|NCT05112393|OTHER|Validation of new estimating Glomerular Filtration Rate (eGFR) equation|"Validation Cohort:~Internal validation will be performed by comparing bias, precision and accuracy of the new equations and the other established equations to the measured GFR."
41007274|NCT04856033|BEHAVIORAL|TM|Transcendental Meditation instruction, 12-sessions over 3-4 months with monthly follow-up
41152548|NCT06011928|OTHER|Combine Exercise|"Exercises to be done in order:~Pelvic tilt in supine position Bridge building Pelvic stretching Ball spin Cat-camel exercise Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds.~Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened."
41321769|NCT01046383|DIETARY_SUPPLEMENT|Casein|20 grams of Casein per day for 40 weeks
41321770|NCT04324138|DRUG|Jianpi Qinghua granules|3 times a day and 1 hour after a meal, for 4 weeks
41321771|NCT04324138|DRUG|Jianpi Qinghua placebo granules|3 times a day and 1 hour after a meal, for 4 weeks
41321772|NCT06171672|OTHER|Semi-structured interview|Pediatric intensive care nurses in Hong Kong will be invited to join an individual in-depth semi structured interview.
41007275|NCT04856033|BEHAVIORAL|PCT|Present Centered Therapy, 12-sessions over 3-4 months with monthly follow-up
41007276|NCT03946163|DIETARY_SUPPLEMENT|cinnamon capsules|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
41007277|NCT03946163|DRUG|Placebo oral capsule|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
41321773|NCT02823678|PROCEDURE|Pancreatectomy|Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.
41321774|NCT04416126|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.
41321775|NCT04416126|OTHER|Placebo|The placebo for this study is 0.9% sterile saline.
41321776|NCT05521100|PROCEDURE|Vascular closure device|Suture of lower extremity veins using the Proglide Vascular Closure Device
41321777|NCT05521100|PROCEDURE|figure eight stitch|Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures
41321778|NCT02919683|DRUG|Nivolumab|
41321779|NCT02919683|DRUG|Ipilimumab|
41321780|NCT02919683|PROCEDURE|Standard of Care Surgery|
40804261|NCT04712643|DRUG|Becavizumab|Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.
40804262|NCT04712643|DEVICE|Transarterial chemoembolization (TACE)|TACE will be performed by clinical demand.
41321781|NCT03674203|BIOLOGICAL|Platelet-Rich Plasma|1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
41321782|NCT01248494|DRUG|BEZ235|"* Dose level 1: 400mg PO BID~* Dose level -1: 400mg PO in AM and 200mg PO in PM~* Dose level -2: 200mg PO BID"
41321783|NCT01248494|DRUG|BKM 120|"* Dose Level 1: BKM120, 100 mg PO daily~* Dose level -1: BKM120, 80 mg PO daily~* Dose Level -2: BKM120, 60 mg PO daily"
41321784|NCT01248494|DRUG|Letrozole|All levels: 2.5mg/day PO
41321785|NCT01248494|DRUG|BKM120|"* Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~* Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~* Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly"
41321786|NCT01943318|PROCEDURE|Liver biopsy|Histologic evaluation
41321787|NCT01943318|DEVICE|Hepatic venous pressure gradient (HVPG) measurement|Hepatic venous pressure gradient (HVPG) measurement
41321788|NCT00326222|BEHAVIORAL|Lifestyle counseling|Self-management group education
41321789|NCT02278081|DRUG|lansoprazole|the lansoprazole will be taken orally.
41321790|NCT02278081|DRUG|placebo|the lansoprazole placebo will be taken orally.
41321791|NCT00653913|DRUG|SCH 58235|SCH 58235 10 mg (once daily)
41321792|NCT00653913|DRUG|pitavastatin|Pitavastatin 2 mg (once daily)
41152549|NCT02499835|BIOLOGICAL|Pembrolizumab|Given IV
41152550|NCT02499835|BIOLOGICAL|pTVG-HP Plasmid DNA Vaccine|Given ID
41321793|NCT05034458|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet|Patients will receive, in addition to their normal treatment, polymeric formula + diet
41321794|NCT02252575|DEVICE|Electromagnetic field|Exposure to the electromagnetic fields of electric motors
41321795|NCT05701488|DRUG|Durvalumab|Intravenous infusion
41321796|NCT05701488|DRUG|Tremelimumab|Intravenous infusion
41321797|NCT05701488|DEVICE|SIRT|SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.
41321798|NCT05821907|BEHAVIORAL|data collection group|The scale development process generally consists of three stages as item production, theoretical analysis and psychometric analysis. The researcher provides theoretical support to the item pool during item production. In the theoretical analysis stage, the content validity of the new scale is evaluated and the first item pool is ensured to reflect the desired structure. In the final stage of the psychometric analysis, the researcher evaluates whether the new scale establishes validity and reliability.
41321799|NCT00730626|DIETARY_SUPPLEMENT|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
41321800|NCT00730626|DIETARY_SUPPLEMENT|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
41321801|NCT00730626|DIETARY_SUPPLEMENT|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
41321802|NCT04998357|OTHER|Endovascular autologous mitochondrial transplantation|During standard-of-care endovascular reperfusion procedure, subjects will have autologous mitochondria infused via microcatheter into ischemic brain.
41321803|NCT01894477|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
41321804|NCT01894477|DRUG|Fludarabine Phosphate|Intravenously administered Fludarabine Phosphate
41321805|NCT01894477|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
41321806|NCT01894477|RADIATION|Total-Body Irradiation|Undergo TBI
41321807|NCT01894477|DRUG|Treosulfan|Intravenously administered Treosulfan
41321808|NCT01894477|OTHER|Laboratory Biomarker Analysis|Correlative Studies
41477149|NCT00617370|DRUG|epirubicin, cyclophosphamide, Paclitaxel,|EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
41321809|NCT04563819|GENETIC|Genom-wide association study (GWAS) and biological pathway analyses|
41321810|NCT01066884|DRUG|erlotinib [Tarceva]|150mg po daily
41321811|NCT01333306|PROCEDURE|Transcranial direct current stimulation (tDCS)|
41321812|NCT00967733|DIETARY_SUPPLEMENT|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
41321813|NCT00967733|DIETARY_SUPPLEMENT|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
41321814|NCT00967733|DIETARY_SUPPLEMENT|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
41321815|NCT00967733|DIETARY_SUPPLEMENT|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
40804263|NCT03389724|DRUG|Capoten®|ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
41321816|NCT04675606|BEHAVIORAL|Regular diet|Patients in the regular diet arm (which is the experimental arm) will not have any diet limitations and will be recommended to consume a healthy balanced diet for American adults as recommended by the United States Department of Agriculture (USDA) and US Food and Drug Administration (FDA).
41321817|NCT04675606|BEHAVIORAL|Low fiber diet|Patients in the low fiber diet arm (which is the control arm) will be recommended to consume foods that are low in fiber content per United Ostomy Associations of America Recommendations
41477150|NCT03738527|DRUG|Tranexamic Acid 100mg/mL, 20mL topical|"Drug: Tranexamic Acid~20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure"
41477151|NCT03738527|DRUG|Normal Saline Flush, 0.9%, 20mL topical|"Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure"
41477152|NCT05859321|OTHER|Virtual reality Exercises|Virtual reality exercises along with transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
41477153|NCT05859321|OTHER|Routine Physiotherapy|transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
41477154|NCT01770431|DRUG|Huaier Granule|Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
41477155|NCT05041114|DEVICE|Motor Neuroprosthesis|Type of implantable brain computer interface
41321818|NCT00250406|DEVICE|Ureteral Stent|triclosan-eluting ureteral stent
41477156|NCT04247984|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered on day 1 of a 2-week cycle.
40804264|NCT02403934|DEVICE|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
41321819|NCT00250406|DEVICE|Ureteral Stent|Percuflex Plus Stent as the control
41321820|NCT05381558|DRUG|Triamcinolone Injection|local injection in sinus tarsi
41321821|NCT06410924|DRUG|DD01|Dual GLP-1 and glucagon receptor agonist
41477157|NCT04247984|DRUG|Capecitabine|2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.
40804265|NCT03489772|DRUG|ITI-214|Oral
40804266|NCT03489772|DRUG|Placebo|Oral
40804267|NCT00648388|DRUG|Cilostazol Tablets 100 mg|100mg, single dose fasting
41007278|NCT00953329|DRUG|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
41321822|NCT06410924|DRUG|Placebo|Placebo matching DD01
41321823|NCT03620812|DIETARY_SUPPLEMENT|rapeseed or soy protein or no protein|25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
41321824|NCT04761172|PROCEDURE|Intraoperative near-infrared fluorescence imaging using indocyaninegreen|ICG administration before/during surgery and using near-infrared fluorescence imaging for intra-operative detection and identification of GISTs
41321825|NCT03181477|DEVICE|Radiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
41321826|NCT01879319|BIOLOGICAL|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
41477158|NCT04247984|DRUG|Irinotecan|180 mg/m2 intravenously administered on day 1 of a 2-week cycle.
41477159|NCT04247984|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 and 2400 mg/m2 continuous infusion over 44 hours of a 2-week cycle.
41477160|NCT04247984|DRUG|CF|300 mg/m2 intravenously administered on day 1 of a 2-week cycle.
41477161|NCT04247984|DRUG|Irinotecan|150 mg/m2 intravenously administered on day 1 of a 2-week cycle.
41477162|NCT04303702|DRUG|Continue Oxytocin|The administration and titration of oxytocin for labor augmentation is per a hospital based protocol. To summarize, oxytocin is initiated intravenously at 2 milliunits/minute and increased by 2 milliunits/minute every 20 minutes until an adequate contraction pattern is attained or a maximum of 40 millunits/minute has been achieved. This protocol for titration and administration will be applied in this study to the oxytocin group. The intravenous pumps on Labor and Delivery have automated functions for intravenous administration of oxytocin that is milliunit-based and the same routine pumps will be used in this study. The study bag will be administered per current oxytocin protocol. Since patients will already be on oxytocin at time of randomization, their current bag of oxytocin will be continued by the primary provider at a rate of their discretion.
40804268|NCT00648388|DRUG|Pletal® Tablets 100 mg|100 single dose fasting
40804269|NCT05645237|RADIATION|radiotherapy|Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
40804270|NCT04693702|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
40804271|NCT00232284|DRUG|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
40804272|NCT00232284|BEHAVIORAL|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
41007279|NCT02033733|DRUG|Cisatracurium infusion|"This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group)."
41007280|NCT02033733|DRUG|Cisatracurium prn bolus|Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
41007281|NCT04689087|COMBINATION_PRODUCT|TTFields|For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
41152551|NCT02857309|DEVICE|OPTIMIZER|The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
41152552|NCT02857309|DRUG|Optimal medical therapy|OMT using standard heart failure (HF) drugs
41321827|NCT01879319|BIOLOGICAL|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
41321828|NCT05451472|DIAGNOSTIC_TEST|thyroid function tests|Thyroid function tests:thyroid stimulating hormone (TSH), total thyroxine (T4), free thyroxine (FT4), total triiodothyronine (T3), and free triiodothyronine (FT3)
41321829|NCT05451472|DIAGNOSTIC_TEST|complete blood count|complete blood count
41007282|NCT03429491|DIETARY_SUPPLEMENT|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
41007283|NCT03429491|DIETARY_SUPPLEMENT|Leucine-enriched protein|Leucine-enriched whey protein
41007284|NCT03429491|DIETARY_SUPPLEMENT|LC n-3 PUFA|LC n-3 PUFA
41007285|NCT02908529|DRUG|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
41152553|NCT06154733|PROCEDURE|Photobiomodulation usinf low level laser therapy|Diode laser will be used (SIROLaser Blue®, Sirona, Germany) at a wavelength of 660 nm and a power of 100 mW for 10 sec, corresponding to an energy dose of 1 J. Irradiation will be performed at the hypomineralized area: two irradiations scanning the surface in the mesiodistal direction and two in the occlusogingival direction (perpendicular to the tooth surface) precisely over the lesion, in a uniform scanning motion with relative isolation. Treatment will be performed in 3 sessions with a 72-hour interval between sessions.
41152554|NCT06154733|PROCEDURE|Resin-based sealant|Cotton rolls and a four-handed technique will be applied for isolation. Scotchbond Universal will be rubbed in the cleaned surface for 20 seconds and air dried for 5 seconds. Afterwards, Fissured Novo Plus will be applied with a syringe. Before light-curing, the presence of air bubbles will be checked and teased out. Light curing for 40 seconds will be done. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
41152555|NCT06154733|PROCEDURE|Glass ionomer sealant|"Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.~For the duration of the study, children will be instructed to undergo regular tooth brushing and flossing. Any other needed treatment will be done for the child."
41152556|NCT06632457|DRUG|Survodutide|Subcutaneous injection
41152557|NCT06632457|DRUG|Placebo matching survodutide|Subcutaneous injection
41152558|NCT00425906|DRUG|nicotine|
41152559|NCT00425906|OTHER|Placebo|
41152560|NCT00425906|PROCEDURE|Quality of life|
41152561|NCT01643018|PROCEDURE|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
41152562|NCT01643018|PROCEDURE|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
41152563|NCT03490747|BEHAVIORAL|Physical activity referral scheme|An 18-week physical activity referral scheme co-developed by a local multidisciplinary stakeholder group. Behaviour change support underpinned by Self-Determination Theory (Ryan \& Deci, 2000) will be provided by an exercise referral practitioner at weeks 1,4,8,12 and 18 to facilitate increased physical activity levels. Patients will be supported to develop a tailored programme of physical activity that may involve use of the fitness centre facilities (e.g. swimming, group classes, gymnasium use), participation in community-based initiatives, and changes to habitual physical activity. Focus on promoting patient autonomy and tailoring activities to patient's preferences and needs. Subsidised access to fitness centre facilities for first 12 weeks.
41321830|NCT05451472|DIAGNOSTIC_TEST|serum creatinine|serum creatinine
41321831|NCT05451472|DIAGNOSTIC_TEST|blood urea|blood urea
41321832|NCT05451472|DIAGNOSTIC_TEST|serum electrolyte|serum electrolyte
41321833|NCT05451472|DIAGNOSTIC_TEST|serum calcium|serum calcium
40804273|NCT05446038|BEHAVIORAL|Multi-Family Guided Self-Help FBT|Previous research has shown that Family-Based Treatment (FBT) is an effective treatment for Anorexia. We hope to learn whether an adaptation of Family-Based Treatment (FBT), called online Multi-Family Guided Self-Help FBT, is feasible and acceptable for families of young people with Anorexia. The 'Self-Help' aspect of the treatment consists of a series of educational videos for parents about how to help their child with Anorexia, which parents watch on an online platform. The 'Multifamily' and 'Guided' aspects of the treatment consists of weekly meetings by Zoom for a group of parents of young people with Anorexia, with a facilitator present to guide a group discussion around whether parents feel they understood the content of the videos and whether the content is helpful.
41321834|NCT05451472|DIAGNOSTIC_TEST|serum phosphorus|serum phosphorus
41321835|NCT05451472|DIAGNOSTIC_TEST|parathyroid hormone level|parathyroid hormone level
41321836|NCT05451472|DIAGNOSTIC_TEST|liver function test|ALT_AST_Total biliruin_total protein _serum albumin
41321837|NCT05451472|DIAGNOSTIC_TEST|arterial blood gases|PH_PCO2_PO2_HCO3_base deficit
41321838|NCT05451472|DIAGNOSTIC_TEST|complete urine analysis|complete urine analysis
41321839|NCT06481657|OTHER|train with oxygen and without oxygen enrichment (placebo).|The experimental group will train with oxygen goggles in the aerobic part of the training The control group will train with oxygen goggles without oxygen enrichment (placebo).
41321840|NCT04295200|OTHER|Dry needling with electrical stimulation|Paravertebral dry needling to L3, 4, 5 multifidi. Electrical stimulation will be applied through the needles for up to 10 minutes total or to the participant's tolerance.
40804274|NCT02332993|DIETARY_SUPPLEMENT|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
41007286|NCT02908529|DRUG|Placebo, 2 tablets|Placebo 2 tablets 2 hours before sleep
41007287|NCT03676361|DRUG|Desmopressin|Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
40804277|NCT00705497|PROCEDURE|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
40804278|NCT04970823|DEVICE|The somatosensory interactive game for preschool children|The somatosensory interactive game, an independent nursing intervention, promotes pain relief for preschool children.
40804279|NCT04970823|DEVICE|A VR (virtual reality) game for school-age children|A VR (virtual reality) game environment promotes pain relief for school-age children.
41152564|NCT03490747|BEHAVIORAL|Usual care exercise referral scheme|A comparative usual care exercise referral scheme that includes fitness centre based activities (e.g. swimming, group classes, gymnasium use). Patients meet an exercise referral practitioner at their induction (week 1) and week 12 (post scheme). Patients are typically prescribed a gym-based, 12-week programme. Subsidised access to fitness centre facilities for 12 weeks.
41321841|NCT00460681|DRUG|Thymopentin|subcutaneously or intramuscular inject at the dosage of 10 mg every second day (twice a week) for consecutive 3 months.
41321842|NCT02219633|DRUG|LEO 39652 cream|Applied for 21 days
41477163|NCT04303702|OTHER|Discontinue Oxytocin|Patients will have their oxytocin discontinued in the second stage of labor. The patient will receive routine maintenance IV fluids per the discretion of the provider.
41477164|NCT00002869|BIOLOGICAL|recombinant interferon alfa|
41477165|NCT00002869|DRUG|cytarabine|
40804280|NCT01947621|OTHER||
40804281|NCT02027311|DRUG|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
40804282|NCT02027311|DRUG|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
40804283|NCT02027311|DRUG|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders \> 80 years old were administered 25mg iv bolus.
40804284|NCT01903772|OTHER|Inspiratory Muscle Training|
41007288|NCT05814120|BEHAVIORAL|BLS training program|BLS training program was in accordance with the 2020 AHA cardiopulmonary resuscitation (CPR) guidelines. The BLS training program adopts 4D teaching techniques, namely description (Describe), demonstration (Demo), implementation (Do), feedback (Debriefing).
41007289|NCT02358889|BIOLOGICAL|hI-con1|Intravitreal injection of hI-con1 0.3 mg
41007290|NCT02358889|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
41321843|NCT01792245|DEVICE|Phototherapy|
41321844|NCT06138886|DEVICE|Pulsed electromagnetic therapy group|The appliance will be connected to electrical mains supplying 230V± 10%. The solenoids are adjusted to be over the upper abdominal area. The options of the appliance are adjusted with very low frequency (15 HZ), very low intensity (20 G) for 20 minutes, and 3 sessions / week for successive 3 months.
41321845|NCT02098460|DRUG|Atorvastatin, Probucol, Cilostazol|
41321846|NCT00804375|DRUG|2PX|cutaneous solution to be applied twice daily for 84 days
41321847|NCT00804375|DRUG|Placebo|cutaneous solution to be applied twice daily for 84 days
41321848|NCT04105413|DIAGNOSTIC_TEST|Blood culturs|CBC, Blood culture and CRP
41321849|NCT00889681|DEVICE|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
41321850|NCT00843843|DEVICE|Bright light box|Bright light of about 5000 lux, administered while sitting at a desk.
41321851|NCT03865459|OTHER|Video group|Patients in the video group started to watch the relaxing video about 5-10 minutes before cystoscopy, and continued to watch video during the whole procedure.
41477166|NCT00002869|DRUG|hydroxyurea|
41477167|NCT03927924|PROCEDURE|High-intensity focused ultrasound|Energy employed to exert its effect through thermal and mechanical destruction of cancer tissue
41321852|NCT03231215|DRUG|Dexamethasone|dexamethasone + plain Bupivacaine injected epidurally.
41007291|NCT02358889|OTHER|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
41007292|NCT05313165|DEVICE|LimFlow Stent Graft System|Creation of an arteriovenous fistula in the desired limb location
41007293|NCT06158802|OTHER|Questionnaire|"Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.~The questionnaire is completed by the patient."
41007294|NCT06004674|DRUG|Lovenox 40mg|Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.
41477168|NCT05511220|BEHAVIORAL|PRIMeR|Virtual PRIMeR intervention consists of coaching parents to use strategies derived from Social Routines (to boost positive affect) and Reciprocal Imitation Training (to boost toy play)
41477169|NCT05511220|BEHAVIORAL|PRT|Virtual PRT intervention consists of coaching parents to use key PRT strategies to enhance children's communication skills
41007295|NCT01558882|DEVICE|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
41007296|NCT04805307|DRUG|CMG901|CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
41007297|NCT00002816|DRUG|cytarabine|Given IV
41321853|NCT04198103|DEVICE|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting using EchoLaser system. The treatment consists of the trasmission of laser energy into the tissue through the percutaneous insertion of optical fiber under local anesthesia. Within each needle, an optic fiber of 300 µm will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 3W. At the end of the first ablation there is a pull-back of about 1 cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used for a total duration of about 30minutes. At the end of the treatment corticosteroid is given for anti-edema and anti-inflammatory effects and Antibiotic therapy and gastroprotective therapy is given. After an adequate amount of time for observation, the patient is dismissed.
41477170|NCT02673879|OTHER|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
41477171|NCT02673879|OTHER|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated
40804285|NCT01175876|DEVICE|remote limb ischemic preconditioning|Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
40804286|NCT01175876|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid stenosis.
40804287|NCT04222699|DRUG|Mupirocin calcium ointment, 2%|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
40804288|NCT04222699|DRUG|Topical Chlorhexidine, 4%|"Chlorhexidine is an antiseptic that fights bacteria.~Topical chlorhexidine is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury."
40804289|NCT00602225|DRUG|clofarabine|Given IV
40804290|NCT00602225|DRUG|cytarabine|Given IV
40804291|NCT00602225|BIOLOGICAL|filgrastim|Given subcutaneously
40804292|NCT06173544|BEHAVIORAL|Standard of Care (SOC)|Participants randomized to this arm will received enhanced standard of care.
40804293|NCT06173544|BEHAVIORAL|Adapted Friendship Bench (AFB)|Participants randomized to this arm will receive the Adapted Friendship Bench protocol delivered by a trained counselor.
40804294|NCT06173544|BEHAVIORAL|Enhanced Friendship Bench (EFB)|Participants randomized to this arm will receive the Enhanced Friendship Bench protocol delivered by a trained counselor and a peer supporter.
41007298|NCT00002816|DRUG|dexamethasone|Given IV
41007299|NCT00002816|DRUG|etoposide|Given IV
41007300|NCT00002816|DRUG|idarubicin|Given IV
41007301|NCT00002816|DRUG|ifosfamide|Given IV
40804295|NCT02855021|OTHER|Explorations|"Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.~Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.~These tests do not require discontinuation of Parkinson's disease treatment."
40804296|NCT02293252|DEVICE|Remote patient monitoring (Motiva)|interactive bi-directional home telemonitoring system that provides remote monitoring
40804297|NCT00800527|DRUG|Gabapentin|Gabapentin 800 mg one a day up to 30 day
40804298|NCT00800527|DRUG|Diclofenac|Diclofenac 75 mg one a day up to 30 day
41007302|NCT00002816|DRUG|leucovorin calcium|
41007303|NCT00002816|DRUG|mesna|Given IV
41007304|NCT00002816|DRUG|pegaspargase|Given IV
41007305|NCT00002816|DRUG|therapeutic hydrocortisone|
41321854|NCT02229110|OTHER|Signal|Automatic signal in the electronic medical record
40804299|NCT05415267|BIOLOGICAL|diphtheria and tetanus toxoids (adsorbed) vaccine|The diphtheria/tetanus toxoids vaccine will be given to participants enrolled into Group 1 as a comparator vaccine to the mRNA COVID-19 booster vaccine with the aim of determining whether the results related to COVID-19 vaccine timing also apply to more traditional protein-based vaccines.
41007306|NCT00002816|DRUG|thioguanine|
41007307|NCT00002816|DRUG|vincristine sulfate|Given IV
41007308|NCT00002816|RADIATION|low-LET cobalt-60 gamma ray therapy|
41007309|NCT00002816|RADIATION|low-LET electron therapy|
41007310|NCT00002816|RADIATION|low-LET photon therapy|
41007311|NCT00002816|DRUG|Methotrexate|Given IV
41007312|NCT01337297|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
41007313|NCT00001249|DRUG|Yttrium-90 radiolabeled anti-Tac antibody|
41152565|NCT01745380|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
41321855|NCT03120637|DRUG|Methylene Blue|
41321856|NCT02807064|DRUG|Bifidobacteria|0.5 ml per os all days for 2 months
41321857|NCT02807064|DRUG|placebo|0,5 ml per os all days for 2 months
41321858|NCT02600741|OTHER|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
41321859|NCT02600741|OTHER|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
41321860|NCT02600741|DRUG|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
41321861|NCT02600741|DRUG|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41007314|NCT04322396|DRUG|Azithromycin|Azithromycin
41007315|NCT04322396|DRUG|Hydroxychloroquine|Hydroxychloroquine
41007316|NCT04322396|DRUG|Placebo oral tablet|Placebo Azithromycin
41007317|NCT04322396|DRUG|Placebo oral tablet|Placebo Hydroxychloroquine
41007318|NCT02628275|BEHAVIORAL|Moderate to vigorous physical activity|55-90% maximum heart rate for 150min/week (current recommendations)
41007319|NCT02628275|BEHAVIORAL|Light physical activity|40-55% maximum heart rate for 150min/week
41007320|NCT00259558|DRUG|retarded release phosphatidylcholine|
41007321|NCT02096458|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
41007322|NCT02224872|PROCEDURE|Bone marrow transplant|Day 0
41007323|NCT02224872|DRUG|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
41152566|NCT01745380|DRUG|Placebo|The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
41007324|NCT02224872|DRUG|Fludarabine|30 mg/M2 IV on days -6 to -2
41007325|NCT02224872|DRUG|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
41007326|NCT02224872|RADIATION|TBI|200 cGy on day -1
41007327|NCT02224872|DRUG|Mesna|40 mg/kg IV on days 3, 4
41007328|NCT02224872|DRUG|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
41007329|NCT02224872|DRUG|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
41007330|NCT03287856|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
41007331|NCT00714246|DRUG|Bortezomib|Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
41007332|NCT00714246|DRUG|Carboplatin|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
41007333|NCT00714246|DRUG|Docetaxel|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
41007334|NCT06352944|DIAGNOSTIC_TEST|procalcitonin|level of procalcitonin in bronchoalveolar lavage
41007335|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System|Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD
41007336|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems|Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
41007337|NCT01493271|DRUG|Placebo|Placebo to RO5093151
41007338|NCT01493271|DRUG|RO5093151|oral doses twice daily for up to 28 days
41152567|NCT05905445|DRUG|ozone gel|the activity of omega-3 in the ozone gel may be advantageous as a host-modulating agent in the supplemental treatment of periodontitis
41321862|NCT02600741|DRUG|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321863|NCT02600741|DRUG|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321864|NCT02600741|DRUG|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321865|NCT02600741|DRUG|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321866|NCT02600741|DRUG|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321867|NCT02600741|DRUG|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321868|NCT02600741|DRUG|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41477172|NCT05385848|PROCEDURE|Autologous Platelet-rich Plasma (PRP) Injection|PRP contains a high concentration of platelets which contains multiple vaso-active peptides and cytokines such as Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) and Sphingosine-1-phosphate. Many of these cytokines have been implicated in important roles in ovarian function, follicular genesis and oocyte maturation. Intraovarian autologous PRP infusion was recently introduced in the context of addressing ovarian insufficiency, with several studies showing an increase in ovarian function and promising ART outcomes. Possible mechanisms include anti-inflammatory and mitogenic potentials in this growth factor rich fraction contributing towards tissues regeneration. Through being involved in the cell regeneration cycle, autologous PRP potentially gives women with premature ovarian insufficiency (POI) or diminished ovarian insufficiency (DOR) hope in achieving a healthy genetically related offspring.
41477173|NCT01663727|DRUG|Bevacizumab [Avastin]|Intravenous repeating dose
41321869|NCT02600741|DRUG|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321870|NCT02600741|DRUG|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321871|NCT02600741|DRUG|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41007339|NCT04116554|DRUG|0.25% bupivacaine.|20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
41152568|NCT05486819|DRUG|Propofol Injection|adding lignocaine or sodium bicarbonate to propofol to reduce pain during injection
41477174|NCT01663727|DRUG|Paclitaxel|Intravenous repeating dose
41152569|NCT01772381|DRUG|Dexamethasone|Long acting corticosteroid
41321872|NCT02600741|DRUG|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321873|NCT02600741|DRUG|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321874|NCT02600741|DRUG|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321875|NCT02600741|DRUG|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
40804300|NCT05415267|BIOLOGICAL|COVID-19 vaccine|All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm
40804301|NCT04892524|OTHER|Virtual multidisciplinary review|The virtual multidisciplinary review involves participants being reviewed by a multi-disciplinary team of specialist doctors, nurses and radiologists in a virtual environment. The team will analyse radiologic scans and make a recommendations for any follow-up scans, procedures or appointments that may be required
40804302|NCT01668446|DRUG|Sildenafil|sildenafil tablets(50 mg) daily
41007340|NCT04116554|DEVICE|0.9%saline|20 ml of 0.9%saline will be injected on each side
41007341|NCT02229877|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
41007342|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
41321876|NCT02600741|DRUG|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321877|NCT02600741|DRUG|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321878|NCT02600741|DRUG|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41321879|NCT02600741|DRUG|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
40804303|NCT01668446|DRUG|estradiol valerat|
40804304|NCT01536028|DRUG|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
40804305|NCT01536028|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
40804306|NCT01536028|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
41007343|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
41321880|NCT02600741|DRUG|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
41152570|NCT03640793|DEVICE|Implantation|Implantation of 6 PPIS implants
41152571|NCT01179659|DRUG|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
41321881|NCT02350933|PROCEDURE|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
41321882|NCT03799328|OTHER|multi-OIT|low dose OIT to multiple foods
41321883|NCT05096546|OTHER|No intervention|No intervention will be applied for the observational study.
41321884|NCT05402098|PROCEDURE|Endodontic treatment using traditional access|Endodontic treatment will be carried out following complete removal of pulp chamber roof and achieving straight line access
41321885|NCT05402098|PROCEDURE|Endodontic treatment using conservative access|Endodontic treatment will be carried out following partial removal of pulp chamber roof, extended only to the extent which helps to locate all the orifices with no efforts will be made to achieve straight line access
41321886|NCT02602717|OTHER|lymph nodes cyto-punction|
41477175|NCT01663727|DRUG|Placebo|Intravenous repeating dose
41007344|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
41007345|NCT03446703|BEHAVIORAL|SCIT|SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.
41007346|NCT03446703|BEHAVIORAL|TAR|TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
41007347|NCT02661828|OTHER|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
41007348|NCT02661828|OTHER|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
41007349|NCT06278675|DEVICE|Acupuncture needles|"1. Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.~2. Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days."
41007350|NCT05979792|DRUG|CAR-T Therapy|CAR-T cell infusion
41007351|NCT01180712|DIETARY_SUPPLEMENT|Mirtoselect|"Male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days."
41007352|NCT00222469|DRUG|bevacizumab|10mg/kg IV on Day 1 Q 2 weeks
41007353|NCT00222469|DRUG|gemcitabine|1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
41007354|NCT00222469|DRUG|oxaliplatin|100mg/m2 on Day 2 and Q 2 weeks.
41007355|NCT03428516|DEVICE|Fixed CPAP|CPAP is a device that applies continous fixed positive pressure to the airways in order to keep them opened during sleep
41007356|NCT03428516|DEVICE|Auto-adjusting CPAP|Auto-adjusting CPAP is a device that applies auto-adjusting continous positive pressure to the airways in order to keep them opened during sleep
41321887|NCT04771988|RADIATION|yttrium-90 radioembolization|selective/superselective treatment using resin microspheres labeled with Yttrium-90
41321888|NCT05177822|DRUG|Anakinra|Anakinra 100 mg/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment;
41321889|NCT05177822|OTHER|Placebo|0.9% NaCl/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment.
41477176|NCT01996059|PROCEDURE|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
41477177|NCT01996059|PROCEDURE|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
40804307|NCT01536028|DRUG|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
41007357|NCT02281721|DEVICE|Surpass Flow Diverter(s)|Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
41007358|NCT06243497|PROCEDURE|Ultrasound CycloPlasty|All procedures were performed using the EyeOP1 device . The coupling cone was placed and adjusted on the centre of the patient's eye by visualising an equal white scleral ring surrounding the cornea. The coupling cone was kept in place via vacuum suction activated using a foot pedal and was then filled with a balanced salt solution to allow ultrasound transmission. The transducers were automatically activated at a frequency of 21 MHz and an acoustic power of 2.45 W, with an 8-s duration for each sector and a 20-s pause between each treatment to allow complete evacuation of heat.
41007359|NCT04782778|DRUG|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
41007360|NCT02548988|OTHER|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
41007361|NCT05850871|DRUG|CAZ/AVI plus Aztreonam|Samples of the patients will be examined such as the routine blood test, blood culture et al.
41007362|NCT05850871|OTHER|Conventional treatment|Conventional treatment
41007363|NCT03627728|DRUG|Regorafenib|regorafenib/placebo
41007364|NCT03627728|OTHER|placebo|regorafenib/placebo
41007365|NCT03237234|OTHER|Motor Skill Training|Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
41321890|NCT04147871|DRUG|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.
41321891|NCT04147871|DRUG|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
41007366|NCT03237234|DEVICE|Transcranial direct current stimulation (tDCS)|The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
41007367|NCT01776983|DEVICE|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
41007368|NCT05267067|OTHER|respiratory exercises|Manual respiratory exercises versus respiratory exercises with pressure meter
41007369|NCT01969071|DRUG|Levosimendan|The effects of levosimendan on renal function
41007370|NCT01969071|DRUG|Dobutamine|Standard Inotropic agent
41007371|NCT05521204|DRUG|Olverembatinib|Given PO
40804308|NCT04801459|PROCEDURE|Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction|In this study, intervention methods include two kind directions of gastrointestinal anastomosis in Roux-en-Y reconstruction after distal curative gastrectomy for gastric cancer. One is the isoperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was consistent. The other is the antiperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
40804309|NCT01360749|DRUG|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
40804310|NCT01360749|DRUG|Placebo|Placebo dose: 2 g for 10 cm2.
40804311|NCT03316716|PROCEDURE|active warming|Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
40804312|NCT05447520|DRUG|Montelukast|Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
41007372|NCT05193474|BEHAVIORAL|integrated palliative care|shared decision making with patient, and timely integrated palliative care according to patient's preference
41007373|NCT06114264|BEHAVIORAL|Multimodal + Resistance Programs|"Exercise: will focus on working the all body by performing functional tasks. Behaviour change: An 'idle alert' of the wrist-worn activity prompter will be set to vibrate after 45 min without movement. Participants will be encouraged to take a 1-2 min activity break.~Education: The basic contents will explain to the patient the main mechanism of chronic pain (pain as a protective system, consequences, etc).~The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group and a Mindfulness practice.~Resistance functional exercises will replicate functional movements, such as standing from a bed, carrying bags, picking up groceries from the ground, etc."
41007374|NCT06114264|OTHER|Control group|No experimental intervention. The group will receive the same multimodal intervention as the experimental group when the experimental period is over.
41007375|NCT02316717|BIOLOGICAL|IMM-124E|IMM-124E
41007376|NCT02316717|OTHER|Placebo|Matched placebo
41007377|NCT04613180|DRUG|Montelukast Sodium|Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
41007378|NCT04613180|DRUG|Placebo|placebo containing no active substance
41007379|NCT04107571|PROCEDURE|A type of operation for coranary heart disease patients.|A type of operation for coranary heart disease patients.
41007380|NCT03940378|DRUG|Levamisole Hydrochloride|Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
41007381|NCT03940378|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
41007382|NCT02467725|OTHER|Dynamic culture platform|Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
41007383|NCT05988957|OTHER|Semi-structured interviews using an IRB-approved interview guide|A single, semi-structured interview will be conducted using an IRB-approved interview guide. The interviews will be approximately 30 minutes total.
41007384|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
41477178|NCT00346892|BIOLOGICAL|Rotavirus (vaccine)|
40804313|NCT05447520|DRUG|Placebo|Oral tablet once daily
40804314|NCT05447520|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
41321892|NCT05331430|OTHER|Dry needling on cervical trigger point|One experimental group will receive dry needling treatment on the upper trapezius fibres using the Hong technique and the other experimental group will receive passive muscle stretching treatment on the upper trapezius fibres.
41321893|NCT03383978|BIOLOGICAL|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
41321894|NCT03383978|DRUG|Ezabenlimab|Intravenous infusion of Ezabenlimab 240mg q 3 weeks
41321895|NCT00684112|DRUG|Gabapentin|Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
40804315|NCT04321473|PROCEDURE|PCI on left main|PCI on left main coronary stenosis
40804316|NCT02963168|DRUG|Oradoxel|oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
41321896|NCT00684112|DRUG|Placebo|Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
41321897|NCT05992168|DEVICE|Stent-Retriever|all the participants in this group will be performed with Stent-Retriever
41321898|NCT03428841|PROCEDURE|Audiometry|
41477179|NCT04455178|DRUG|Spironolactone|spironolactone 20mg once daily, up-titrated to 40mg once daily at 4-week or 8-week visit
41321899|NCT04986020|DIAGNOSTIC_TEST|MRI|Identification of novel biomarkers from MRI
41477180|NCT04455178|DRUG|Indapamide|indapamide 1.5mg once daily, up-titrated to 3mg once daily at 4-week or 8-week visit
41477181|NCT05430945|BIOLOGICAL|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
41477182|NCT04597489|PROCEDURE|Fractional flow reserve|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
41477183|NCT04597489|PROCEDURE|Angiography-only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
41477184|NCT03042468|DRUG|177Lu-PSMA-617|177Lu-PSMA-617 \[50mCi (1.85GBq) - 300mCi (11.1GBq)\] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
41477185|NCT03042468|DRUG|68Ga-PSMA-HBED-CC|68Ga-PSMA-HBED-CC \[5 ±2mCi or 185 ±74MBq\] intravenous during screening and at 12 weeks with standard imaging
40804317|NCT01244230|DRUG|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
40804318|NCT05945069|DEVICE|TriLift device|Dynamic Muscle Stimulation combined with tripolar Radiofrequency, administered on the skin of the inferior orbital rim and below the lower eyelids
40804319|NCT01716039|DRUG|MTX 12.5|"once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
40804320|NCT01716039|DRUG|MTX 25|"once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
40804321|NCT01716039|DRUG|Adalimumab|Subjects will receive 18 weekly doses of adalimumab
41007385|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
41007386|NCT00365248|DRUG|Fibrinogen human (TachoSil)|Resection of the liver with or without segmental liver transplantation
41007387|NCT02797262|DEVICE|Proteus digital health feedback (PDHF) system|Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
41007388|NCT01794104|DRUG|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
41477186|NCT05473819|DRUG|Buffered Local Anesthesia|"Buffered local anesthesia will be administered after being previously prepared just before the injection time.~Buffering Local Anesthetic Solutions Using 8.4% Sodium Bicarbonate in a 19:1 Ratio: Using the REMOVE AND REPLACE hand buffering method~-Under sterile conditions, 0.09 mL of local anesthetic solution will be removed from the cartridge using a 0.5 mL syringe with a 28- gauge, 0.5-inch needle (Kendall Monoject Insulin Syringe \[Tyco Healthcare, tyco.com\] lot number 027501). Using a separate unused syringe, 0.09 mL of the commercially available 8.4% sodium bicarbonate will be removed from the 50 mL vial and immediately injected into the local anesthetic cartridge. The cartridge will be inverted 5 times to mix the solution, and no precipitation will be present."
41477187|NCT05473819|DRUG|Conventional Unbuffered Local Anesthesia|The control group will receive the unbuffered conventional anaesthetic solution
41477188|NCT03014193|DEVICE|Semiquantitative Multi-Level Pregnancy Test|
40804322|NCT02483793|DRUG|Tamsulosin|
41477189|NCT05256472|DRUG|AK104|anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
41477190|NCT05256472|DRUG|axitinib|an oral, small molecule, TKI selective for VEGFRs 1, 2 and 3; 5mg bid orally
40804323|NCT02483793|DRUG|Oxybutynin|
40804324|NCT04555863|DEVICE|haMSter smartphone app|the app tracks patient reported outcomes
40804325|NCT02364427|DEVICE|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
40804326|NCT06495645|DEVICE|AI-assisted upper gastrointestinal endoscopy|AI-assisted upper gastrointestinal endoscopy
41321900|NCT03312868|RADIATION|SBRT|Stereotactic Body Radiotherapy
41321901|NCT04242238|DRUG|DCC-3014|DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014.
41321902|NCT04242238|DRUG|Avelumab|Start Day 1 on first cycle with further infusions of avelumab every 14 days
41321903|NCT01575899|DRUG|Levofloxacin-Amox/clav.|Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.
41321904|NCT01575899|DRUG|Clarithromycin-Amoxicillin|Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
41007389|NCT01446562|BIOLOGICAL|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
41007390|NCT04985253|OTHER|prediction of overall survival using Web based PREDICTV2.0 portal|"Predict is an online prognostication and treatment benefit tool developed in the UK, using cancer registration and survival data recorded by the Eastern Cancer Registration and Information Centre (ECRIC) for 5694 women diagnosed in East Anglia from 1999-2003.~The model was validated in a second cohort of 5468 women from the West Midlands Cancer Intelligence Unit and is available online (www.predict.nhs.uk) providing 5-and 10-year survival estimates and treatment benefit predictions. Wong et al, tested the predictive accuracy of PREDICT V1.0 in the southeast Asian population. There were 67% Chinese patients while 13% were Indians. They showed concordance in observed and predicted OS in most subgroups except for women whore less than 40 years of age."
41007391|NCT04428866|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed during visit 1 in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
41007392|NCT04428866|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days to assess activity, concurrent with CGM sensor wear.
41007393|NCT04428866|DIAGNOSTIC_TEST|Mixed meal tolerance test|After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
41007394|NCT04428866|DIAGNOSTIC_TEST|Glucagon Sensitivity Testing|After baseline blood sampling, glucagon will be administered by injection, and blood samples will be collected for analysis of glucose and hormone responses. This will allow us to assess whether sensitivity to glucagon is altered in PBH.
41007395|NCT04428866|DIAGNOSTIC_TEST|Hypoglycemic Hyperinsulinemic Clamp|This test will assess hormonal responses to hypoglycemia. Participants will arrive after an overnight fast. After baseline blood sampling, an infusion of insulin and glucose will be started, and infusions will be adjusted to allow glucose levels to drop very gradually. Blood samples will be collected for measurement of hormonal responses to lowering of glucose. This test will allow us to determine whether secretion of hormones which counteract hypoglycemia (counterregulatory hormones) is reduced in patients with PBH as compared with other groups.
41007396|NCT04428866|DIAGNOSTIC_TEST|analysis of fecal microbiome|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
41007397|NCT04933591|DRUG|Diosmin / Hesperidin|Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
41007398|NCT00787410|DRUG|ZD1839|250mg tablet, once daily, orally administered
41007399|NCT01556672|DRUG|Adalimumab|Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.
41007400|NCT01556672|DEVICE|Capsule endoscopy|All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
41007401|NCT06104189|DIAGNOSTIC_TEST|MRI|MRI based classification of breast cancer histological factors and subtypes
41007402|NCT02986204|PROCEDURE|removal of ENG implant|"the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~* questions about your medical/contraception history~* Review medical record~* physical examination~* urine sample for pregnancy test~Visit 2a - Radiology~* Have an ultrasound of your arm~* The radiologist will mark your arm at the location of the implant.~Visit 2b~* ultrasound of your arm to locate the implant. This is done by feeling the area.~* Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~* Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~* Provide a urine sample for pregnancy test~* Have the implant removal site examined"
41007403|NCT02986204|PROCEDURE|continuation of ING implant|"the researcher(s) will ask you to:~* To answer questions about your medical and contraception history~* Review your medical record~* Have a physical examination by the researcher~* Provide a urine sample for pregnancy test~* Have an ultrasound of your arm"
41007404|NCT01086592|OTHER|No intervention|Daily life activities
41007405|NCT01086592|OTHER|Strong progressive strengthening exercises of lower limbs|Lower limb weight
41007406|NCT01086592|OTHER|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
41007407|NCT01086592|OTHER|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
41321905|NCT03927638|BEHAVIORAL|sit/stand|Subjects will be asked to both sit and stand during a single trial.
41321906|NCT03173482|OTHER|questionnaire|asking about details of indication of cesarean section
41321907|NCT06044519|BIOLOGICAL|different types of dressings|different types of dressings were compared ti see the effectiveness for for STSG donor site wound
41321908|NCT00234728|DEVICE|Occlusive dressing|
41321909|NCT00250185|DRUG|Sodium Nitrate|
41321910|NCT00250185|DRUG|Acetylcholine|
41321911|NCT03058172|OTHER|Odor presentation (for participants' perception)|Several different odors will be diffused by an olfactometer under the participants' nostrils, though a controlled airflow, and synchronously with the participants' respiration. fMRI designs require repeated stimulus presentation. Odors will also be presented (in flasks or in odor pens) outside the scanner.
41321912|NCT03058172|OTHER|Image presentation (for participants' perception)|Several different pictures will be displayed in front of the participants' face, though a through a mirror system in the scanner, or on a computer screen outside the scanner.
41321913|NCT00917085|BEHAVIORAL|Skin-to-Skin contact|Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
41321914|NCT05374148|BEHAVIORAL|health education|health education to prevent respiratory diseases among workers
41477191|NCT04884061|OTHER|NBI images and/or videos|A library of NBI images and/or videos will be established from previously recorded bronchoscopies in 30 patients (10 with a SARS-CoV2 infection, 10 with a lower respiratory tract infection not related to SARS-CoV2, and 10 in patients with pulmonary nodule). NBI images and/or videos of the bronchial tree will then be analysed by three experimented interventional pulmonologists blinded to the patient ID. Each investigator will describe the vasculature pattern according to a prespecified grid: Normal mucosal vascularity / increased capillary density / presence of capillary loops / presence of dotted vessels / complex vascular networks of tortuous vessels or abrupt ending vessels / dilated longitudinal vessels. In case of discordance between the investigators, images will be reviewed to obtain a consensus.
41152572|NCT04288778|DRUG|Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)|Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.
41152573|NCT00068718|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
40804327|NCT01628354|DRUG|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of \>5 letters or increase in retinal thickness of \>100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
40804328|NCT03958864|DRUG|CC-90001|CC-90001
40804329|NCT03969745|BEHAVIORAL|Time restricted feeding|Restrict energy intake window to between 8am and 4pm
40804330|NCT03969745|BEHAVIORAL|Caloric restriction|Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
40804331|NCT05712096|DRUG|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
40804332|NCT04103944|PROCEDURE|Core Decompression|10 patients will be randomized chosen in this group
40804333|NCT04103944|PROCEDURE|Osteonecrotic Repair Device|10 patients will be randomized chosen in this group
40804334|NCT05178316|DRUG|JZP150|Oral administration of JZP150 once daily in the morning
40804335|NCT05178316|DRUG|Placebo|Oral administration of placebo once daily in the morning
40804336|NCT05424978|OTHER|Standardized green channel treatment methods for stroke|The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.
40804337|NCT04387006|OTHER|OMT|OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field
41007408|NCT00931307|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel, spherical, soft contact lens
41152574|NCT04810104|DRUG|AZD0328|Active study drug
41321915|NCT00974051|DRUG|Terbutaline|Oral (2.5mg) one time administration at 9:00pm
41007409|NCT01329510|DEVICE|One-night polysomnographic recordings|One-night polysomnographic recordings before and during methylphenidate treatment.
41152575|NCT04810104|DRUG|Placebo|Non-active study drug
41152576|NCT02710578|DRUG|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
41152577|NCT02710578|DRUG|Placebo|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
41321916|NCT00974051|OTHER|20% basal insulin reduction|Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
41321917|NCT00974051|OTHER|Control|No treatment is given for the study. This arm is for comparison with the two intervention arms.
41321918|NCT00001906|BIOLOGICAL|Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants|
41321919|NCT04591041|DEVICE|HoloSIM Software via Hololens 2|Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
41477192|NCT06060548|OTHER|Monitoring of patients presenting with PVCs|Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs to assess for the incidence of all cardiac arrhythmias. They will also be evaluated for clinical, biomarker and radiological evidence of myocarditis to understand association with incident arrhythmias.
41321920|NCT04591041|OTHER|Training by Mannequin Based Simulation|Medical students will train a via traditional mannequin based medical crisis scenario
41321921|NCT04624035|PROCEDURE|Implantable Collamer Lens (ICL) in treatment of myopia in adults.|ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.
41321922|NCT04624035|PROCEDURE|Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.|IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.
41321923|NCT04632407|DIETARY_SUPPLEMENT|"Flax milk"|See above
41321924|NCT04632407|DIETARY_SUPPLEMENT|"Oat fibre milk"|See above
41321925|NCT01829217|DRUG|Sunitinib|
41321926|NCT01064219|DRUG|human chorionic gonadotrophin|intrauterine injection of 100 IU hCG followed by endometrial biopsy .
41321927|NCT04684914|BIOLOGICAL|HepTcell|Intramuscular injection
41321928|NCT04684914|DRUG|Placebo|Intramuscular injection
41321929|NCT03763903|OTHER|3D training|Skills (FLS tasks) training using 3D visualization
41477193|NCT02773199|OTHER|Preoperative Fasting for 8 hours|Patients will be exposed to preoperative fasting
41007410|NCT05604560|DRUG|Tislelizumab|Patients will receive Tislelizumab (200 mg intravenous) on Day 1 of Cycles 1-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
41007411|NCT05604560|DRUG|SX-682|Patients will receive SX-682 (200 mg twice daily by mouth) on Days 1-14 of Cycles 1-2 and Days 1-21 of Cycles 3-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
41321930|NCT03763903|OTHER|2D training|Skills (FLS tasks) training using 2D visualization
41477194|NCT02773199|OTHER|Preoperative Fasting for more than 12 hours|Patients will be exposed to preoperative fasting
41477195|NCT02773199|DRUG|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia with heavy bupivacaine 0.5% is provided.
41477196|NCT03840252|DIAGNOSTIC_TEST|3D gait analysis|Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics
41477197|NCT03840252|DIAGNOSTIC_TEST|rsfMRI|MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).
41321931|NCT05003063|DRUG|Donepzil|Test
41321932|NCT05003063|DRUG|Placebo oral tablet|Test
41477198|NCT03840252|DIAGNOSTIC_TEST|Montreal Cognitive assesment (MoCA)|Standard clinical questionnaire
41477199|NCT01008137|BIOLOGICAL|H1N1 influenza A Vaccine (PANFLU.1)|H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
41321933|NCT03200093|DRUG|Oral Vancomycin|Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.
41321934|NCT03200093|DRUG|Placebo|Ora-Sweet 5mL taken by mouth once daily.
41321935|NCT02296437|OTHER|Transcranial direct current stimulation combined with cognitive training|
41321936|NCT06097767|DRUG|Caffeine citrate|It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
41321937|NCT06097767|DRUG|Amikacin|it includes preterm infants with respiratory distress syndrome who received amikacin in regular intervention therapy in control group
41321938|NCT05663736|DRUG|Gemigliptin|DPP-4 inhibitor
41321939|NCT05663736|DRUG|Glimepiride|Glimepiride
41321940|NCT00200018|DEVICE|Enterra Therapy System (H9900014)|
41321941|NCT01205451|DRUG|Botulinum toxin type A|Botulinum toxin type A
41321942|NCT01102218|DRUG|Erythropoietin|Standard of Care
41321943|NCT01102218|DRUG|Erythropoietin|Standard of Care
41321944|NCT01102218|DRUG|Pentoxifylline|400 mg qd po for 6 months
41321945|NCT03260907|PROCEDURE|Electroacupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used. An electric acupuncture device (CellMac STN-110, Stratek Co, Republic of Korea) will be connected to the CV3-CV4, KI3-SP6 acupoints and deliver stimulation with a 2-Hz frequency, asymmetric bimodal pulse, continuous wave mode, maximum intensity below the threshold (7.6\~13.9mA).
41321946|NCT03260907|PROCEDURE|Acupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used.
41321947|NCT02827279|OTHER|emotional induction|The eye-tracking mesure the reaction at emotional induction using of sound stimuli in a group of children with or without ASD, in a context of
40804338|NCT04387006|OTHER|MP|MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
40804339|NCT02368093|DRUG|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
40804340|NCT04246775|DEVICE|Peristeen|rectal irrigation
40804341|NCT01645735|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
40804342|NCT01645735|DRUG|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
40804343|NCT03092999|DRUG|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
40804344|NCT01388179|DEVICE|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
40804345|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose L|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
40804346|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose A|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
40804347|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose B|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
40804348|NCT06134648|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
40804349|NCT02079116|OTHER|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 60 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
40804350|NCT02079116|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
40804351|NCT00757952|OTHER|Fourier transform ion cyclotron resonance mass spectrometry|
40804352|NCT00757952|OTHER|chromatography|
41007412|NCT03989193|DEVICE|Computer guided alveolar ridge splitting technique|"The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm."
41321948|NCT00039741|DRUG|NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)|Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor
41477200|NCT01008137|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine (ANFLU)|Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
40804353|NCT00757952|OTHER|diagnostic laboratory biomarker analysis|
40804354|NCT00757952|OTHER|questionnaire administration|
40804355|NCT04833686|BEHAVIORAL|Mozart|Music composed by Mozart, a musical piece 24 minutes long.
41007413|NCT03200613|DRUG|Apixaban|2.5 mg orally twice daily
41007414|NCT03200613|DRUG|Low molecular weight heparin|Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
41007415|NCT03843684|DEVICE|3D-printed foot orthoses|3D printed foot orthoses with arch support
41007416|NCT03843684|DEVICE|5 degrees lateral wedge insoles|Insoles with a lateral inclination set at 5 degrees
41321949|NCT00039741|DRUG|NNRTIs (EFV, NVP)|"Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)~Prescribed per participant's doctor"
40804356|NCT04833686|BEHAVIORAL|Instrumental music|Instrumental music , a musical piece 24 minutes long
40804357|NCT04833686|BEHAVIORAL|Silence|Silence, a piece 24 minutes long.
40804358|NCT05864430|OTHER|Face-to-face Training Group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
40804359|NCT05864430|OTHER|DataMatrix supported Face-to-face training group|Students will follow the lesson with the QR code given simultaneously with the training given during the education process. The training will be held in such a way that the students will be given the opportunity to ask questions and will end with 10 minutes of time to be given to the questions of the students.
40804360|NCT05864430|OTHER|Online training group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
40804361|NCT02776605|DRUG|Prednisone|Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)
40804362|NCT02776605|DRUG|Vincristine|Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.
40804363|NCT02776605|DRUG|Daunorubicin|Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.
40804364|NCT02776605|DRUG|Prednisone|Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.
40804365|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg, PO from day 1 to consolidation
41007417|NCT05802537|OTHER|Home-based exergame program|The home-based exergame program was conducted at the participants' homes for 50 min, three times a week, for eight weeks. Online education on fall prevention and musculoskeletal health management was provided once a week for 50 minutes, one day a week, for 8 weeks.
41007418|NCT00019435|BIOLOGICAL|LMB-9 immunotoxin|
41007419|NCT04503564|DEVICE|coil-reinforced soft polymer indwelling cannula|This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).
41007420|NCT00052845|DRUG|docetaxel|70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle
41007421|NCT00052845|DRUG|estramustine phosphate sodium|280 mg PO tid Days 1-5 of ea cycle
41007422|NCT00052845|DRUG|exisulind|Two 125 mg capsules PO bid Days 1-21 of ea cycle
41007423|NCT06023784|PROCEDURE|left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
41007424|NCT06023784|PROCEDURE|right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
41007425|NCT00000735|DRUG|Ampligen|
41007426|NCT02669290|OTHER|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
41007427|NCT02669290|OTHER|Non-guided|LV lead placement will be conventional posterolateral placement
41007428|NCT00004881|BIOLOGICAL|MVA-MUC1-IL2 vaccine|
41007429|NCT04089267|DRUG|TPO|
41007430|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.1 μg vaginal dose of AZU-101 weekly for 4 doses
41007431|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.5 μg vaginal dose of AZU-101 weekly for 4 doses
41007432|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|1 μg vaginal dose of AZU-101 weekly for 4 doses
41007433|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.1 μg vaginal dose of AZU-101 twice-weekly for 8 doses
41007434|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.5 μg vaginal dose of AZU-101 twice-weekly for 8 doses
41007435|NCT06237257|BIOLOGICAL|SHR-1316|SHR-1316（Adebrelimab Injection）
41007436|NCT06237257|DRUG|Cisplatin Injection/Carboplatin Injection|Cisplatin Injection/Carboplatin Injection
41007437|NCT06237257|RADIATION|External Beam Radiotherapy (EBRT)/Brachytherapy|External Beam Radiotherapy (EBRT)/Brachytherapy
41007438|NCT05002946|DRUG|SP-104|single oral dose
41007439|NCT05002946|DRUG|Naltrexone Hydrochloride 50Mg Oral Tablet|single oral dose
41007440|NCT05897177|BEHAVIORAL|Subjective Scale of Stigma and Discrimination (SISD).|"Subjective Scale of Stigma and Discrimination (SISD) A sixdimension self-administered scale will be used that included statements with which the participants agreed or disagreed. The scale consists of 23 Likert-type items and responses range from 1 (completely in disagreement) to 5 (completely in agreement), grouped together to represent the six indicators making up this part of the scale"
41007441|NCT04488705|DRUG|ETD002 - single dose|Single ascending doses of ETD002
41007442|NCT04488705|DRUG|Placebo - single dose|Single doses of placebo
41007443|NCT04488705|DRUG|ETD002 - 7 day repeat dose|Twice daily doses of ETD002 for 7 days
41007444|NCT04488705|DRUG|Placebo - 7 day repeat dose|Twice daily doses of Placebo for 7 days
41007445|NCT04488705|DRUG|ETD002 - 14 day repeat dose|Twice daily doses of ETD002 for 14 days
41007446|NCT04488705|DRUG|Placebo - 14 day repeat dose|Twice daily doses of Placebo for 14 days
41007447|NCT04488705|DRUG|Salbutamol|Twice daily doses of salbutamol for 3 days (Days 5, 6 \& 7)
41007448|NCT02316197|DRUG|MSC2490484A (M3814)|Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
41007449|NCT02720926|DRUG|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
41007450|NCT02720926|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
41007451|NCT02720926|DRUG|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
41007452|NCT04507958|DIAGNOSTIC_TEST|auscultation by using conventional stethoscope without PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
41007453|NCT04507958|DIAGNOSTIC_TEST|auscultation by using electronic stethoscope in full PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
41007454|NCT02267629|DRUG|Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13)
41007455|NCT02919787|DRUG|5-FU|Neoadjuvant treatment
41007456|NCT02919787|DRUG|Oxaliplatine|Neoadjuvant treatment
41007457|NCT02919787|DRUG|Irinotecan|Neoadjuvant treatment
41007458|NCT02919787|PROCEDURE|Pancreatic surgery|All patients
41007459|NCT02919787|DRUG|5-FU|Adjuvant treatment
41007460|NCT02919787|DRUG|Oxaliplatine|Adjuvant treatment
41007461|NCT02919787|DRUG|Irinotecan|Adjuvant treatment
41007462|NCT02966171|DRUG|HMPL-453|oral administration
41007463|NCT03413878|OTHER|Breathing in the simulated avalanche snow|Breathing in the simulated wet or dry avalanche snow with a small or large air pocket
41007464|NCT01935765|OTHER|Polysomnography|Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
41007465|NCT01935765|OTHER|Evaluation of the autonomous nervous system|blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
41007466|NCT01935765|OTHER|Clinical examination of the sleep|Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
41321950|NCT00039741|DRUG|PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)|"Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)~Prescribed per participant's doctor"
41321951|NCT03082989|DEVICE|fractional flow reserve performed|assessing fractional flow reserve to drive revascularization
41321952|NCT03082989|OTHER|fractional flow reserve not performed|description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
41321953|NCT01653002|OTHER|No intervention|
41321954|NCT02521623|DEVICE|SurgiMend® Acellular Dermal Matrix|See arm description.
41321955|NCT02521623|DEVICE|Strattice™ Acellular Dermal Matrix|See arm description.
41321956|NCT06159348|DIAGNOSTIC_TEST|Anemia Diagnostic Assistant (ADA)|The Anemia Diagnostic Assistant is non-invasive and simultaneously detects two markers of anemia, blood hemoglobin and the End-Tidal carbon monoxide levels. The device comprises an optical sensor module and ETCO breath sampling module.
41321957|NCT06159348|DIAGNOSTIC_TEST|Serum hemoglobin|Venous blood will be drawn on the same day as the ADA was applied and sent to the hospital lab for hemoglobin analysis.
41321958|NCT00806689|PROCEDURE|Cardiac rhythm monitor implantation|post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
41321959|NCT00806689|DEVICE|Reveal® XT 9525|During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
41321960|NCT04403854|DIAGNOSTIC_TEST|MRI|If possible with spectroscopy
41321961|NCT04403854|PROCEDURE|Spinal Tap|together with CSF pressure estimate
41321962|NCT02439944|DRUG|Nicotine patch|
41321963|NCT02439944|DRUG|Nicotine mouthspray|
41321964|NCT04715412|OTHER|patient counseling and adherence support|"Technical interventions include; identification of possible reasons for non-adherence, adherence support by developing simplified schedules for taking medications that were customized to individualized patient's lifestyle. Reminders for dose as well as tools/strategies the RTR may use to follow the dosing schedules if needed as pillbox were provided as needed~Clinical pharmacists' guided patient training was individualized, repetitive, covered 6 months, and included more aspects and provided practical hints and strategies for medication management.~Initial clinical pharmacist face-to-face session will be up to 60-minute then 30-minute follow-up sessions will be conducted monthly for 6 months during the scheduled post-transplant clinic visits as coordinated with the transplant physician to allow for single office visits for transplant related issues and comorbidities."
41321965|NCT02469532|DEVICE|Balloon Angioplasty|Device: Balloon Angioplasty Selection is driven by preference of the operator
41321966|NCT02469532|DEVICE|Atherectomy System|Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
41321967|NCT00357149|DRUG|Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|
41321968|NCT00357149|DRUG|Concomitant cisplatin, 5-FU and radiotherapy|
41321969|NCT00436293|DRUG|Docetaxel|75 mg/m²
41321970|NCT00436293|DRUG|Cisplatin|75 mg/m²
41321971|NCT01578785|DRUG|Glatiramer Acetate|Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
40804366|NCT02776605|DRUG|Mercaptopurine|Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
41321972|NCT01578785|DRUG|Placebo|Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
41321973|NCT05530278|DRUG|Galicaftor|Oral
41321974|NCT05530278|DRUG|ABBV-576|Oral
41321975|NCT05530278|DRUG|Navocaftor|Oral
41321976|NCT05530278|DRUG|Midazolam|Oral
41321977|NCT02731807|DIETARY_SUPPLEMENT|Dose A: TA-65 24mg, powder|
41321978|NCT02731807|DIETARY_SUPPLEMENT|Dose B: TA-65, 8mg, powder|
41321979|NCT02731807|DIETARY_SUPPLEMENT|Dose C: TA-65 3.2mg, capsule|
41321980|NCT02731807|DIETARY_SUPPLEMENT|Dose D: TA-65 8mg, capsule|
41321981|NCT02731807|DIETARY_SUPPLEMENT|Dose E: TA-65 32mg, capsule|
40804367|NCT02776605|DRUG|Methotrexate|MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
40804368|NCT02776605|DRUG|VP-16|VP-16: 100 mg/m2/12 h, IV, days 14 and 42
40804369|NCT02776605|DRUG|ARA-C:|ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
40804370|NCT02776605|DRUG|TIT|TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.
40804371|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.
40804372|NCT02776605|PROCEDURE|Autologous transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation
40804373|NCT02776605|PROCEDURE|Allo transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation
40804374|NCT00496678|BEHAVIORAL|Navigation|Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system
40804375|NCT00496678|BEHAVIORAL|Standard of Care|Cancer patients receive standard of care for their cancer treatment
40804376|NCT02340208|DRUG|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
40804377|NCT03299244|DRUG|Etelcalcetide|Administered intravenously three times per week.
40804378|NCT03299244|DRUG|Cinacalcet|Cinacalcet administered orally once a day.
40804379|NCT04513054|GENETIC|Blood collection for genetic analysis|Blood collection for genetic analysis
40804380|NCT01963793|DRUG|Aprepitant|Aprepitant gel (10 mg/g)
40804381|NCT01963793|DRUG|Placebo|gel without active component
40804382|NCT02951403|PROCEDURE|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
40804383|NCT02951403|OTHER|Conservative treatment|Physiotherapy protocol is introduced to patients.
40804384|NCT03228459|DIAGNOSTIC_TEST|Dried blood spot test|Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
40804385|NCT03228459|DIAGNOSTIC_TEST|Urine test|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
40804386|NCT03228459|DIAGNOSTIC_TEST|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
40804387|NCT03228459|DIAGNOSTIC_TEST|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
40804388|NCT03228459|DIAGNOSTIC_TEST|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
40804389|NCT03228459|DIAGNOSTIC_TEST|Determination of advanced glycation-end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
40804390|NCT03228459|DIAGNOSTIC_TEST|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
40804391|NCT03228459|OTHER|Biological sample collection|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
40804392|NCT03228459|OTHER|Result and recommendation report|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
40804393|NCT03228459|DIAGNOSTIC_TEST|Pulse wave velocity|Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
40804394|NCT02504398|OTHER|Fast injection speed by immunizer|
40804395|NCT02504398|OTHER|Slow injection speed by immunizer|
40804396|NCT00578851|DEVICE|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
40804397|NCT02115724|DIETARY_SUPPLEMENT|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
40804398|NCT02115724|OTHER|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
40804399|NCT02115724|OTHER|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
40804400|NCT02115724|DRUG|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
40804401|NCT03789123|DRUG|Estradiol valerate/dienogest|The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
40804402|NCT02705105|BIOLOGICAL|Mogamulizumab + Nivolumab|i.v. administration
40804403|NCT00276939|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|
41321982|NCT03315728|OTHER|Quality Improvement Strategy|Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
41321983|NCT06086756|BEHAVIORAL|Exposure intervention plus positive mood induction|Positive mood induction followed by a brief VR exposure session for public speaking anxiety.
41321984|NCT06086756|BEHAVIORAL|Exposure intervention plus negative mood induction|Negative mood induction followed by a brief VR exposure session for public speaking anxiety.
41321985|NCT03285763|DRUG|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
41321986|NCT01240408|DRUG|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
41321987|NCT01240408|DRUG|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
41321988|NCT00598715|DEVICE|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
41321989|NCT00598715|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
41152578|NCT02325258|OTHER|Telephone call|Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
41321990|NCT00845494|BEHAVIORAL|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
41321991|NCT00715312|OTHER|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake
41321992|NCT00715312|OTHER|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
41321993|NCT00154167|DRUG|NV-101 (phentolamine mesylate solution)|
41321994|NCT04619888|DIAGNOSTIC_TEST|HeartLogic|In case of HeartLogic index ≥16, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment. The management will be standardized across centers according to the Manage-HF protocol.
40804404|NCT02818764|PROCEDURE|Blood Draw|5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
40804405|NCT02818764|PROCEDURE|Cerebral Spinal Fluid collection|Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
41321995|NCT00511953|DRUG|Gabapentin Extended Release tablets|1800mg
40804406|NCT02818764|DEVICE|Electroencephalogram|Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
40804407|NCT02818764|DEVICE|Cerebral blood flow and oxygen extraction fraction|NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
40804408|NCT05092997|DIAGNOSTIC_TEST|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
41321996|NCT00511953|DRUG|Gabapentin|1800mg
41007467|NCT01935765|OTHER|Clinical examination of diabetology|history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
41007468|NCT01935765|OTHER|Biological dosages|Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
41321997|NCT03846219|DRUG|IMU-838 (30 mg/day)|"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily."
41321998|NCT03846219|DRUG|IMU-838 (45 mg/day)|"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily."
41321999|NCT03846219|DRUG|Placebo|"* Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~* Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose."
41322000|NCT03846219|DRUG|IMU-838 (10 mg/day)|"* Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~* Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable."
41322001|NCT05884359|DIAGNOSTIC_TEST|3D Electroanatomical Mapping (NavX)|To utilize 3D mapping as a tool to explore electro-anatomical and electrocardiographic characteristics of the Left Bundle Branch Area. Patients will undergo placement of standard Left Bundle Area pacing leads for routine indications, during the implantation procedure electro-anatomical map of the target area and neighboring tissues will be created. Map characteristics will be analyzed and used intra-operatively to assist with lead placement along with standard pacing metrics and standard X-ray criteria. We plan on prospectively reviewing the data found from 3D mapping the left bundle branch implantation cases.
41322002|NCT03941691|DEVICE|Fully Absorbable VSD Occlusion System|Under echocardiography guided treatment of VSD with a novel fully degradable clolsure system
41322003|NCT03941691|DEVICE|VSD Occluder|Under echocardiography guided treatment of VSD with commercially available occluder.
41477201|NCT00896324|BEHAVIORAL|Cognitive Rehabilitation|The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
41477202|NCT00896324|BEHAVIORAL|Active Neurofeedback Training|Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.
41477203|NCT00896324|BEHAVIORAL|Neurofeedback Training (placebo / Sham)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
41477204|NCT00210613|DRUG|Dapoxetine|
41007469|NCT01935765|OTHER|Electrocardiogram (ECG)|Electrocardiogram (ECG)
41477205|NCT05043259|BIOLOGICAL|inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
41477206|NCT05043259|BIOLOGICAL|Low dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
41007470|NCT01935765|OTHER|Carotid echography|Carotid echography
41007471|NCT01935765|OTHER|Blood pressure|Blood pressure
41007472|NCT00240422|DRUG|Telmisartan|
41007473|NCT00240422|DRUG|Ramipril|
41007474|NCT01206985|OTHER|Von Frey electronic|Change in pain threshold testing mechanical stimulation (von Frey electronic)
41007475|NCT02254538|DRUG|BILR 355 BS|
41007476|NCT02254538|DRUG|PEG 400|
41322004|NCT04694105|DRUG|Dexmedetomidine injection|perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
41322005|NCT04694105|DRUG|Dexamethasone|perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)
41322006|NCT04694105|DRUG|saline|perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline
41322007|NCT00966810|PROCEDURE|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect \> 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
41322008|NCT03922633|DRUG|E3112|Intravenous infusion.
41322009|NCT03922633|OTHER|Placebo|Intravenous infusion.
41322010|NCT02797639|OTHER|Co-PID|"The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students."
41322011|NCT02797639|OTHER|IS|IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
41322012|NCT04226963|DRUG|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
41322013|NCT04799951|OTHER|a survey questionnaire to find knowledge, attitude and practices in treatment of breast cancer.|an electronic webbased survey to assess knowledge, attitudes and practices amongst surgeons with regards to breast conservation surgery and mastectomy
41322014|NCT05165992|DRUG|Nebulized Fentanyl|Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
41322015|NCT06224972|DEVICE|Vlab|The study is observational, there is no intervention.
41322016|NCT01156207|DRUG|Aliskiren|300mg Aliskiren qd for 6 month
41322017|NCT03226132|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Brief Behavioral Therapy for Insomnia
41322018|NCT03226132|BEHAVIORAL|Repeated Contact|Repeated Contact
41322019|NCT06070116|DRUG|Ivermectin w/ Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)
41322020|NCT06070116|DRUG|Ivermectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
41322021|NCT06070116|DRUG|Moxidectin + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)
41322022|NCT06070116|DRUG|Moxidectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
41322023|NCT03798184|PROCEDURE|Non-carious cervical lesion restoration|Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass
41322024|NCT05517330|BIOLOGICAL|Tislelizumab|200mg IV Q3W
41322025|NCT05517330|DRUG|Afatinib|30mg PO QD
41477207|NCT05043259|BIOLOGICAL|High dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.2 ml / dose, contains 2×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
41477208|NCT04815382|OTHER|Dynamic Upper Limb Orthosis|"The dynamic upper limb orthosis extends from subdeltoid level to 10 mm distal to the metacarpal-phalangeal joints. The orthosis will be tailored to include 20 degrees of wrist extension and to abduct the thumb. They made from nylon and lycra.~The orthosis will be used throughout the day, being removed when the patient lies down.~The orthosis will be used during 3 months"
41477209|NCT05987735|BEHAVIORAL|BLAME-LESS|The BLAME-LESS program was designed to educate about common defense responses that may occur during and after (sexual) violence. The main goal of the program is to reduce the feelings of shame and/or guilt related to these responses. The program was created in collaboration with licensed developmental and clinical psychologists with extensive psycho-trauma expertise, young adults who are experienced experts, visual artists, and web designers. The program is offered via a website and consists of three modules.
41477210|NCT06211413|OTHER|no intervention|no intervention
41322026|NCT00205699|DRUG|risperidone|randomized to begin 12 week trial of risperidone
41322027|NCT00205699|DRUG|olanzapine|randomized to begin 12 week trial of olanzapine
41322028|NCT00205699|DRUG|aripiprazole|randomized to 12 week trial of aripiprazole
41322029|NCT03585673|DRUG|Docetaxel-PM|Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression
41322030|NCT03585673|DRUG|Oxaliplatin|Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression
41322031|NCT01811381|DRUG|Curcumin|Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
41322032|NCT01811381|BEHAVIORAL|aerobic yoga|Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
41322033|NCT01811381|BEHAVIORAL|non aerobic yoga|"Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.~Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home."
41322034|NCT01811381|DIETARY_SUPPLEMENT|Placebo|Subjects will take 4 capsules x BID of placebo
41007477|NCT01971827|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
41322035|NCT04066530|DRUG|AD-203|AD-203 administered two times daily for two weeks
41322036|NCT04066530|DRUG|Mucosta tab.|Mucosta tab. administered three times daily for two weeks
41322037|NCT02521740|OTHER|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
41477211|NCT02384694|OTHER|Zumba dance|Twelve weeks, 3 times weekly 1 hour training
41477212|NCT05449782|DIETARY_SUPPLEMENT|Cocoa flavanol|Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)
41322038|NCT00176124|PROCEDURE|leukocyte depletion of whole blood|
41322039|NCT00176124|OTHER|Leukocyte filtration/Depletion|leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
41322040|NCT03555188|DRUG|Ondansetron|Ondansetron is a highly selective receptor antagonist (5-HT3RA)
41322041|NCT00818285|DEVICE|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
41477213|NCT05449782|OTHER|Placebo|Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)
41477214|NCT03663790|OTHER|Foot Progression|The intervention will be a gait retraining biofeedback focused on foot angle during gait trials
41477215|NCT03663790|OTHER|Trunk Lean|The intervention will be a gait retraining biofeedback focused on trunk lean angle during gait trials
41477216|NCT05236842|DRUG|Sulthiame|oral
40804409|NCT05092997|OTHER|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
41322042|NCT01589510|DRUG|bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
41322043|NCT04169854|DRUG|Lidocaine 5% patch|The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
41322044|NCT04169854|DRUG|Placebo patch|The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
41322045|NCT05599698|OTHER|Chemotherapy|Standard chemotherapy protocols for adjuvant \& neoadjuvant treatment for different types of solid malignancies
40804410|NCT00231686|BEHAVIORAL|Supervised aerobic training|
40804411|NCT00231686|BEHAVIORAL|Supervised strength training|
40804412|NCT00231686|BEHAVIORAL|Unsupervised training|
41007478|NCT01589432|DRUG|ABT-639|two 50 mg oral capsules
41007479|NCT01589432|DRUG|Placebo|2 placebo capsules
41007480|NCT01589432|DRUG|Lidocaine|3mg/kg infusion over 30 minutes
41322046|NCT05511675|DEVICE|cold application|ISO-BALL
41322047|NCT04151095|OTHER|BFR Exercise Training|Participants will complete exercise training on a recumbent bike placed on a 45 degree incline (BFR).
41322048|NCT04151095|OTHER|CTL Exercise Training|Participants will complete exercise training on a recumbent bike placed on flat ground (CTL).
41322049|NCT04683107|OTHER|Eccentric protocol|Participants in this arm will perform progressive eccentric exercise protocol
41322050|NCT04683107|OTHER|Isometric protocol|Participants in this arm will perform progressive isometric exercise protocol
41322051|NCT04297826|BEHAVIORAL|Harvest for Health|Please see previous description
41322052|NCT01541527|BIOLOGICAL|blood test|One blood test entering in the usual follow-up of the patient
41322053|NCT03509987|DEVICE|HemaCue|comparing hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.
41322054|NCT00957255|DEVICE|OrthoADAPT|soft tissue augmentation device
41322055|NCT00957255|PROCEDURE|Standard of care|Standard of care rotator cuff repair
41477217|NCT01562626|DRUG|APS001F|APS001F infusion on Days 1,2,3 of each 28 day cycle.
41477218|NCT01562626|DRUG|Flucytosine (5-FC)|oral doses on Days 11-15 and 18-22, each 28 day cycle
41477219|NCT01562626|DRUG|10% maltose|10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
41477220|NCT05859399|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
41477221|NCT05692284|OTHER|routine care group|Firstly, informed consent was obtained from the patients in the control group, a pre-test was applied with the existing data collection methods, and routine nursing care continued. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
41477222|NCT05692284|OTHER|Care in accordance with Orem's theory group|Firstly, informed consent was obtained from the Intervention group, for which the pre-test was applied, and then care was given during their stay in the hospital in accordance with Orem's theory. This care was performed when the patient came to each chemotherapy cycle. After discharge, patient follow-up and care continued with the mobile application designed with Orem's theory, which will ensure the continuity of this care given in the clinic. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
41477223|NCT05870371|BEHAVIORAL|Feldenkrais Awareness Through Movement technique|10 group sessions, 50 minutes each, over a period of five weeks, which will include the application of the Feldenkrais Awareness Through Movement technique
41322056|NCT02453438|OTHER|Patient Reported Outcomes|Patient reported outcomes will be collected using a variety of questionnaires that assess mood symptoms.
41322057|NCT02437487|DRUG|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
41322058|NCT02437487|DRUG|Placebo|Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
41322059|NCT01116687|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
41322060|NCT01116687|OTHER|laboratory biomarker analysis|Correlative studies
41322061|NCT01891422|OTHER|Non-interventional.|
41322062|NCT02565615|OTHER|No intervention|Because this is a non-interventional study, there is no intervention here.
41322063|NCT03437317|BEHAVIORAL|Perceptual Retraining|"Participants viewed faces varying in their expression of anger and were asked to identify if the face was angry or neutral via button press. Participants were provided with feedback if their categorization of the face as neutral or angry was correct. Each participant was assigned 4 levels of angry faces based on their decision point of anger detection in faces. Faces were selected based on the closest existing anger morph to the category boundary; for example, a decision point of 40% anger was closest to the 38% anger face, and so the faces used would have been 17%, 31%, 45%, and 59% anger. For this example, responses of neutral to the 31% angry face would be marked as correct, whereas a similar response to the 45% angry face would be incorrect, as it was above their decision point."
41322064|NCT03437317|BEHAVIORAL|Gender Discrimination|Participants viewed faces varying in their expression of anger and were asked to identify if the face was male or female via button press.
41322065|NCT03967275|OTHER|bone marrow harvest|During bone marrow harvest, an additional 10 mL sample will be collected for the study.
41322066|NCT00844285|DRUG|Cimzia|The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
41322067|NCT01949298|PROCEDURE|dental implant placement|
41007481|NCT01236196|BEHAVIORAL|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
41007482|NCT01236196|BEHAVIORAL|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
41007483|NCT01233375|DRUG|CO-1.01|"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
41007484|NCT04777890|OTHER|suboccipital inhibition|The therapist will seat at the patient's head height and place his second, third, fourth and fifth fingertips'over the patient's suboccipital area during a 10-minute period.
41322068|NCT04591795|DRUG|Sahastara remedy extract|The concentration of SHT extract is 100 mg per capsule
41322069|NCT04591795|DRUG|Diclofenac|Diclofenac sodium, 25 mg enteric-coated tablets
41322070|NCT02573376|BEHAVIORAL|Directly Observed Therapy|
41322071|NCT02573376|BEHAVIORAL|Wirelessly Observed Therapy|
41322072|NCT05225051|OTHER|skin biopsy|skin biopsy
41322073|NCT03687086|OTHER|Program A|Cognitive behavioral therapy type A plus medications prepared in packaging type A.
41007485|NCT04777890|OTHER|INYBI|The therapist will place the INYBI at the suboccipital area, specifically placing the fingers of the instrument at the lower border of the occipital. If needed, a rolled towel will be placed behind the INYBI, in order to maintain the physiological lordosis, checking out that the patient doesn't make a cervical extension. Then the therapist will press the vibration button and turn it off after 10 minutes. All patients will receive the treatment with the INYBI's hardest head with a 50 HZ frequency.
41322074|NCT03687086|OTHER|Program B|Cognitive behavioral therapy type B plus medications in packaging type B.
41322075|NCT06138327|DRUG|BMN 255|Oral Capsule
41322076|NCT06138327|DRUG|Placebo|Oral Capsule
41322077|NCT01762306|DRUG|Diclofenac Potassium|
41322078|NCT01762306|DRUG|Folic Acid|
41322079|NCT03138018|DIAGNOSTIC_TEST|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuropsychological tests
41322080|NCT03138018|DIAGNOSTIC_TEST|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuroimaging biomarkers of neurodegeneration
41322081|NCT02645383|DEVICE|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
41322082|NCT02645383|DEVICE|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
41322083|NCT05137730|DRUG|rhPTH(1-84)|Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
41322084|NCT02235402|DRUG|Lacidipine|
40804413|NCT00758368|DRUG|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
40804414|NCT01301066|DRUG|Pitavastatin|Pitavastatin 4 mg QD
41477224|NCT05870371|BEHAVIORAL|Acupuncture|10 sessions, two per week, of 25 minutes acupuncture each, which will include the insertion of a sterile disposable needle into standardized local, regional, and systematic or general acupuncture points that modify pain behavior in area of Cervical Spine.
41477225|NCT05870371|BEHAVIORAL|Stretching|10 sessions, two per week, of 15 minutes stretching each, which will include lateral flexion and counterrotation of the head performed for the upper part of the trapezius and the anterior scalene, lateral flexion and corresponding rotation for the levator scapulae, and flexion for the extensors of the Cervical Spine. The following muscles will be applied: upper trapezius, levator scapulae, scalenes, extensors of the Cervical Spine (splenoid, spinous, semispinalis, longus cephalic and cervical, iliocostalis cervical, multifidus and subscapularis), and sternocleidomastoid.
40804415|NCT01301066|DRUG|Pravastatin|Pravastatin 40 mg QD
41322085|NCT02235402|DRUG|Bendrofluazide|
41322086|NCT02235402|DRUG|Placebo|
41477226|NCT02150759|DRUG|Dexmedetomidine|dexmedetomidine infusion during spinal anesthesia
41477227|NCT02150759|DRUG|Fentanyl|add dexmedetomidine during position change
40804416|NCT04094259|BEHAVIORAL|Questionnaire.|patients will respond to a specific questionnaire regarding the use of alternative medicine
40804417|NCT00276055|DRUG|Gemcitabine, Docetaxel and Bevacizumab|During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
41322087|NCT04574388|OTHER|open label placebo|open label placebo pill
41322088|NCT05295745|BEHAVIORAL|Cognitive remediation therapy and multidisciplinary intervention|"The Randomized Controlled Trial will comprise of multidisciplinary intervention and remediation cognitive therapy which will be conducted with obese diagnosed adults of 19-60 years old. The enrolled patients will be randomized in a two-arm control trial with repeated measures and follow-up of three months. The experimental group participants will receive the intervention, while the control group remains on a waiting list.~Nutritional and physical activity plus cognitive remediation therapy sessions to improve the thoughts style, problem-solving, planning and organization, the emotions and body image are included"
41477228|NCT02150759|DRUG|Ketamine|add dexmedetomidine during position change
41477229|NCT01322971|DRUG|Metronidazole|Metronidazole 500mg orally twice daily for seven days
41477230|NCT01322971|DRUG|Placebo|Placebo will be administered orally twice daily for seven days
40804418|NCT00106119|DRUG|Liothyronine and Levothyroxine|Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
40804419|NCT04932434|DRUG|Psilocybin therapy|"* Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring"
40804420|NCT03148379|DEVICE|Customized patient instruments|Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.
41152579|NCT03823261|BEHAVIORAL|Cognitive Behavioral Therapy|HIV(+) Koreans with depressive symptoms or poor adherence are our target population. This study is a hospital based implementation research. Most PLWH in South Korea regularly visit ID clinics in tertiary hospitals. The ID clinic of study site can reach the target population. In the clinic, the levels of adherence are routinely measured, and depressive symptoms will be asked with key questions We plan to enroll 50 subjects for CBT-AD intervention. In addition, 2 nurses who providing CBT service, and 6 health care workers will be enrolled for survey for providers and healthcare workers.
41322089|NCT03795818|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|IPT-A is a psychosocial intervention for adolescents that focuses on improving interpersonal relationships that seem to be associated with the psychiatric symptoms.
41322090|NCT05069285|OTHER|self-help book|information and advice given in the self-help book
41477231|NCT05527691|BEHAVIORAL|SupportGroove|"An app-delivered program consisting of positive psychology-based activities, such as expressing gratitude, finding meaning, savoring, and fostering connections. Participants complete daily quests suggested through the app, some of which are completed on their own, and some with their partner."
41477232|NCT04104555|OTHER|Birthday card|Birthday card sent to participants in the post
41477233|NCT04104555|DEVICE|Prefabricated orthoses|Prefabricated insole
41477234|NCT04104555|OTHER|Signposting to multimedia|Signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.
41477235|NCT04104555|OTHER|Usual supportive care - exercises and footwear advice (the comparator)|Active comparator
41477236|NCT00003598|DRUG|tretinoin|
41477237|NCT03978091|DRUG|AZACTAM|A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum
41477238|NCT03978091|DRUG|Ceftazidime-Avibactam|An antibacterial combination product containing ceftazidime and avibactam
41477239|NCT00454519|PROCEDURE|cytoreductive surgery|the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.
41477240|NCT00454519|PROCEDURE|intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin|Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
41477241|NCT02545647|DEVICE|BRYGB|65 patients undergo a banded RYGB
41477242|NCT04206228|DRUG|Intravenous iron isomaltoside|"The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min)."
41477243|NCT04206228|DRUG|Placebo|The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
41477244|NCT00338052|DRUG|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
41477245|NCT04142242|BIOLOGICAL|Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection; Route of administration: Intramuscular
41477246|NCT04142242|OTHER|Blood sample|Blood sample for assessment of antibody persistence.
41152580|NCT03356145|DRUG|12 mL paracervical block|Injection of 12 mL of lidocaine
41152581|NCT03356145|DRUG|20 mL paracervical block|Injection of 20 mL of lidocaine
41152582|NCT03637621|OTHER|ORIF|open reduction internal fixation of the distal humerus
41152583|NCT03520790|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
41322091|NCT05069285|OTHER|sleep hygiene advice|information and advice given on the sheet of paper with sleep hygiene
41322092|NCT00889395|BEHAVIORAL|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
41477247|NCT03921151|DRUG|Mirtazapine 15 MG Oral Tablet|The intervention will be a 15mg of mirtazapine oral tablet given to participants prior to their treatment scan and assessments. In order to ensure that biases or social desirability do not contaminate baseline assessments, all participants will also be given a tablet consisting of dextrose in gelatin prior to their baseline scan and assessment.
41477248|NCT04553224|OTHER|Clinical evaluations|SCORAD and target SCORAD
41477249|NCT04553224|OTHER|Non-invasive instrumental measurements|TEWL, cutaneous hydration, skin lipidic analysis, colorimetry, hydration index
41477250|NCT04553224|OTHER|Subject's evaluations|PO-SCORAD, target PO-SCORAD and subject's questionnaire
41477251|NCT01007474|DEVICE|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
41477252|NCT01007474|DEVICE|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
41477253|NCT01007474|DEVICE|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
41477254|NCT01007474|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
41477255|NCT01007474|DEVICE|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
40804421|NCT03148379|DEVICE|Traditional Metal Instruments|Traditional metal instrument will be used to make bone cuts and size the components in this control group.
40804422|NCT02853396|OTHER|Cognitive Behaviour Therapy|
41322093|NCT05217953|DEVICE|LovedBy App|The LovedBy solution aims to leverage modern technologies such as smartphones, continuous glucose monitors (CGM), and other smart wearables to assist young sufferers managing their condition. The LovedBy platform offers a mobile application which connects to the user's smart wearables and CGM to monitor data streams that have been linked to long term risk. The mobile application is then able to deliver personally relevant educational content to the user through numerous channels including private social media message
41477256|NCT03399617|DIETARY_SUPPLEMENT|Micronutrient Powders|Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.
41477257|NCT03399617|BEHAVIORAL|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.
40804423|NCT02853396|OTHER|Psychoeducation|
41477258|NCT03399617|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study does not include sugar.
41477259|NCT03554603|BEHAVIORAL|Modified Report|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important.
40804424|NCT05170958|DRUG|LBL-024 for Injection|LBL-024 was given every three weeks for treatment
41007486|NCT04777890|OTHER|INYBI + upper cervical manipulation|The participant will also be treated with the INYBI during a 10-minute period. After that, the therapist will carry out the upper cervical manipulation technique. Keeping the patient's head on an upper cervical flexion position, the therapist will turn his/her head to the maximum possible rotation, always maintaining its longitudinal axis. Once this is done, a high velocity and short articular amplitude manipulation in rotation will be carried out
40804425|NCT00146926|DRUG|kétamine 20mg|
40804426|NCT00146926|DRUG|ephedrine 3mg|
40804427|NCT00146926|DRUG|lidocaine 40mg|
40804428|NCT00632827|DRUG|Gemcitabine|Chemotherapy medication used to treat a number of types of cancer
40804429|NCT00632827|DRUG|Navelbine|Navelbine is an chemotherapy medication used to treat a number of types of cancer
41477260|NCT01983319|DEVICE|active anodal transcranial Direct Current Stimulation (tDCS)|Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
41477261|NCT01983319|DEVICE|sham transcranial Direct Current Stimulation|sham transcranial Direct Current Stimulation 30 min with CIMT
41477262|NCT01983319|BEHAVIORAL|Constraint Induced Movement Therapy (CIMT)|2 weeks of CIMT
41477263|NCT05410054|OTHER|no intervention|observational research
41477264|NCT03081039|DRUG|Carboplatin|Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
41477265|NCT03081039|DRUG|Cisplatin|Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
40804430|NCT00632827|DRUG|Doxorubicin Hydrochloride Liposome Injection|Doxorubicin Hydrochloride Liposome Injection is an anti-cancer chemotherapy drug
40804431|NCT00632827|DRUG|Granulocyte-colony stimulating factor (G-CSF)|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
40804432|NCT00632827|DRUG|Pegfilgrastim|Colony-stimulating factor 3 (CSF 3) and, is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. May be used instead of G-CSF
40804433|NCT00632827|DRUG|Cyclophosphamide|Cancer medication that interferes with the growth and spread of cancer cells in the body
40804434|NCT00632827|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat cancer. Vincristine works by stopping the cancer cells from separating into 2 new cells to stops the growth of the cancer
40804435|NCT00632827|DRUG|Leucovorin|Leucovorin is used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer.
40804436|NCT00632827|DRUG|Methotrexate|Methotrexate is a chemotherapy medication used to treat cancer
41007487|NCT06262360|PROCEDURE|General anesthesia with mask ventilation|Randomization to General anesthesia with mask ventilation
41477266|NCT03081039|DRUG|Gemcitabine|"Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight."
41477267|NCT00257920|DRUG|Zemplar® injection|6 mcg QOD
41477268|NCT00257920|DRUG|Hectorol® injection|3.6 mcg QOD
41477269|NCT00685490|PROCEDURE|Vitrectomy w/o ILM peeling for macular edema with BRVO|Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
41477270|NCT04801108|PROCEDURE|Robotic or VATS lobar fissure completion|The lobar fissure adjacent to the target lobe will be completed using a surgical stapler through robotic or video-assisted thoracic surgery.
41477271|NCT04801108|DEVICE|Endobronchial valves placement|Endobronchial valves will be placed in the target lobe after the fissure completion.
41477272|NCT03913182|DRUG|apatinib|500mg po Qd
41477273|NCT05604079|DEVICE|Electrolarynx|The device transmits electronic sound source vibrations through soft tissue, either the neck at the level of the glottis, or less commonly the check. Speech is created through movements of articulators including the lips, tongue and jaw.
41477274|NCT05481359|DEVICE|Ablamap Software|Subjects will receive cardiac ablation guided by the Ablamap software. The software will identify atrial fibrillation sources to help guide ablation therapy in patients with persistent atrial fibrillation.
41477275|NCT06048094|DRUG|18F fluciclovine|Participants will receive 5-mCi dose (± 20%) of 18F-fluciclovine intravenously as a bolus injection immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
41477276|NCT00414349|DRUG|Topical analgesic|max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
40804437|NCT00632827|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride is a chemotherapy medication used to treat cancer
40804438|NCT00632827|DRUG|Cytarabine|Medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma
40804439|NCT00632827|DRUG|Etoposide|Etoposide is a is a chemotherapy medication used to treat cancer
40804440|NCT00632827|DRUG|Carmustine|Carmustine is a chemotherapy medication used to treat cancer
40804441|NCT00632827|DRUG|Denileukin diftitox|Denileukin diftitox is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells
40804442|NCT00129090|DRUG|R-CHOEP 14 with 12x Rituximab|after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
40804443|NCT03294044|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
40804444|NCT03294044|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
40804445|NCT00003321|PROCEDURE|psychosocial assessment and care|
40804446|NCT00003321|PROCEDURE|quality-of-life assessment|
40804447|NCT04789629|DEVICE|low level laser therapy|3 session per week laser with exercises
40804448|NCT05720949|DRUG|Genicular Nerve Block with bupivacaine and preservative free dexamethasone|"A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee.~The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius.~Bupivacaine - Drug class: Sodium channel blocker~Dexamethasone - Drug class: Glucocorticoid"
40804449|NCT03865433|OTHER|Aerobic Exercise|Sub-symptom threshold aerobic exercise at a dose of 30 minutes per day, five days per week.
41477277|NCT00414349|DRUG|oral intake|300 to 600 mg per day taken orally
41477278|NCT00414349|DRUG|Topical analgesic|3 plasters for PHN patients per day 4 plasters for DPN patients per day
41477279|NCT02605252|DRUG|Peginterferon alfa-2b|peginterferon alfa-2b 80 micrograms/week for 48 weeks
40804450|NCT03865433|OTHER|Placebo/Stretching|A detailed, progressive stretching program to be performed for approximately 20-30 minutes per day, five days per week
40804451|NCT05582018|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
40804452|NCT01234454|DRUG|Risperidone|6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
40804453|NCT01234454|DRUG|Olanzapine|20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
40804454|NCT04674111|DEVICE|Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)|The Vortex System is intended to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
40804455|NCT00815568|DRUG|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7\~D-2) Busulfan (3.2mg/kg, iv, D-6\~D-3) Total body irradiation (200cGy/day, D-2,-1)
40804456|NCT01116999|PROCEDURE|light guided tracheal intubation|Tracheal intubation light guided technique.
40804457|NCT01736423|DRUG|YM060|oral
40804458|NCT02548481|OTHER|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
40804459|NCT02315248|RADIATION|Quantitative computed tomography scan for bone density analysis|A low radiation dose quantitative computed tomography (QCT) of the spine (L1 and L2) and the hips will be performed to measure bone density in the spine and hips.
40804460|NCT01391169|OTHER|seromuscular flap enforcement|seromuscular flap enforcement
41007488|NCT06262360|PROCEDURE|General anesthesia and spontaneous laryngeal mask ventilation|Randomization to General anesthesia and spontaneous laryngeal mask ventilation
41007489|NCT06262360|PROCEDURE|General anesthesia with spontaneous laryngeal mask ventilation with pressure support|Randomization to General anesthesia with spontaneous laryngeal mask ventilation with pressure support
41322094|NCT05387252|DIETARY_SUPPLEMENT|Mulberry juice|Mulberry is a common macrophanerophyte that can be found in fields or farms. Mulberry fruits contain a large amount of anthocyanins and a relatively small amount of pro-anthocyanins. The plant is easy to grow and the fruit price is low compared with other types of plants producing anthocyanins, and thus a reliable source for anthocyanin supplements. Current laboratory evidence has shown that specific anthocyanins can reduce inflammation status, and potentially thrombosis. One of the enzymes inhibited by specific anthocyanins is cyclooxygenase which catalyzes the synthesis of prostanoids, including thromboxane and prostaglandins. Moreover, a critical study has shown that cyanidin 3-O-glucoside, the main anthocyanin in mulberry fruit, is an allosteric regulator of interleukin-17A.
41322095|NCT01088438|BEHAVIORAL|Contextualization workshop|A four-hour course on contextualization.
41322096|NCT00645918|DRUG|clopidogrel|oral, 75 mg daily for 6 months starting on day of randomization
41322097|NCT00645918|DRUG|placebo|oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
41007490|NCT01778166|DRUG|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
41152584|NCT03520790|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
41322098|NCT00645918|DRUG|clopidogrel|oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
41322099|NCT00980421|DIETARY_SUPPLEMENT|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
41322100|NCT02219087|DRUG|Liposomal bupivacaine|
41322101|NCT02219087|DRUG|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
41322102|NCT00861679|PROCEDURE|Transplantation with Stem Cells from Umbilical Cord|"According to results from published experiences in children following suggestions are given:~1. Number of Cells:~   * Number of nucleated cells infused exceed 2,5x10\*7/kg recipient BW or~  * Number of nucleated cells collected exceed 3x10\*7/kg BW~  * Number of CD34+ cells infused exceed 2x10\*5/kg Recipient BW~2. GVHD-prophylaxis:~   • MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)~   • UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.~3. HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.~4. If many choices available ABO- major incompatibility should be avoided."
41007491|NCT01778166|DRUG|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
41007492|NCT00148603|DRUG|montelukast|
41152585|NCT03520790|DRUG|Paricalcitol|Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.
41152586|NCT03520790|OTHER|Placebo|Placebo
41322103|NCT01188525|DRUG|10 parents drugs adminstration|A single and concomittant administration of 10 parent drugs will be performed: Acetaminophene, cafeine, dextrometorphan, digoxin, memantine,midazolam, omeprazole, repaglinide, rosuvastatine, tolbutamide.
41322104|NCT01167582|BIOLOGICAL|Red blood cell transfusion|Liberal versus restrictive transfusion
41322105|NCT00000341|DRUG|Buprenorphine|
41007493|NCT02007928|OTHER|Rispéridone, aripiprazole, olanzapine|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
41007494|NCT05789836|OTHER|Nursing care|Involving the mother in nursing care
41152587|NCT03538834|DIETARY_SUPPLEMENT|Cod meal from residual material|Cod meal from residual material, 8 g protein daily for 8 weeks
41152588|NCT03538834|DIETARY_SUPPLEMENT|Control|Placebo
41152589|NCT03120949|DRUG|Olokizumab 64 mg SC q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
41152590|NCT03120949|DRUG|Olokizumab 64 mg SC q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
41477280|NCT03973099|DIETARY_SUPPLEMENT|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner. Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
41322106|NCT04327518|DEVICE|TECNIS® Toric II|Toric Intraocular Lens
41322107|NCT05783453|OTHER|Cosmetic study|"LIPIKAR BAUME LIGHT AP+M~* Formula: 2039055 06~* Aspect: Emulsion~* Batch nº: RAUO0063~* Expiry date: 10/2022~* Application area: Face and Body~* Application mode: Apply to face and body twice a day.~* Quantity of product to be applied: About 1 flask (400g) per month"
41322108|NCT05553626|DEVICE|Left bundle branch pacing|Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region
41322109|NCT05553626|DEVICE|Bi-ventricular pacing|Bi-ventricular pacing by a CRT/CRTD device
41322110|NCT02038569|DRUG|LEO 80185 gel|
41322111|NCT03716518|DRUG|Tonifying Spleen and Kidney Sequential Regimen|TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.
41322112|NCT03716518|DRUG|Placebo of 'Tonifying Spleen and Kidney Sequential Regimen|Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
41322113|NCT02712177|BIOLOGICAL|4CMenb|
41322114|NCT02712177|BIOLOGICAL|diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB|
41322115|NCT02712177|BIOLOGICAL|conjugated pneumococcal vaccine|
41322116|NCT02712177|BIOLOGICAL|MMRV|
41322117|NCT05643157|DEVICE|Adaptive Optics - Optical Coherence Tomography (AO-OCT) retinal imaging|AO-OCT used in this study is an investigational OCT imaging system. . In this instrument, ocular aberration sensing and correction is achieved with a Shack-Hartmann wavefront sensor (SHWS) and deformable mirror, respectively. A pupil camera and fixation target are used to position the participant's head and eye for scanning a particular retinal region within 15 degrees of the fovea. Data collected generally includes AO-OCT volume videos and SHWS measurements of ocular aberrations.
41322118|NCT01053117|OTHER|Protocolized approach to convert dialysis catheter to fistula|This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
41007495|NCT02634138|DEVICE|Revitive IX|A foot plate Neuromuscular Electrical Stimulation Device
41322119|NCT04740099|OTHER|SOONER Video & Kit|A brief animated video including basic instructions for opioid overdose response accompanied by a Naloxone kit with an info graphic.
41322120|NCT04740099|OTHER|Standard of Care|A handout including a map and list of locations offering this service.
41322121|NCT02381548|DRUG|Adavosertib|Given PO
41322122|NCT02381548|DRUG|Belinostat|Given IV
41322123|NCT02381548|OTHER|Laboratory Biomarker Analysis|Correlative studies
41322124|NCT02381548|OTHER|Pharmacological Study|Correlative studies
41477281|NCT01680783|DEVICE|Non invasive ventilation using a helmet hyperbaric device|"Patients randomized to the intervention group will receive noninvasive ventilation delivered via a latex-free helmet connected to the ventilator by conventional tubing.~If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay."
41007496|NCT05706363|PROCEDURE|Quadriceps graft|Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor
41007497|NCT04206111|PROCEDURE|Preoxygenation|preoxygenation with high flow nasal cannula at 40l/min for 5min
41007498|NCT04696705|BIOLOGICAL|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
41322125|NCT01668030|DRUG|Enzymatic agent|Enzymatic agent
41322126|NCT01668030|DRUG|Bacitracin|
41322127|NCT05843110|OTHER|Decision-making process|Retrospective evaluation using scales, questionnaires and a semi-structured interview
41007499|NCT01223144|BEHAVIORAL|Iowa Gambling Task and Ekman facial recognition test|"Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger)."
41007500|NCT05835453|OTHER|Whitening|Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray. Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each tray, completing a total of 4 weeks of whitening procedure.
41007501|NCT02128295|DEVICE|Electric breast pump - A|
41007502|NCT02128295|DEVICE|Electric breast pump - B|
41007503|NCT03012100|DRUG|Cyclophosphamide|Given PO
41007504|NCT03012100|OTHER|Laboratory Biomarker Analysis|Correlative studies
41007505|NCT03012100|BIOLOGICAL|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
41007506|NCT03012100|OTHER|Placebo Administration|Given ID
41007507|NCT03012100|BIOLOGICAL|Sargramostim|Given ID
41007508|NCT00157378|DRUG|Risperidone, Haloperidol|
41007509|NCT02847793|BEHAVIORAL|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
41322128|NCT00599027|DRUG|Mometasone furoate nasal spray (MFNS)|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
41322129|NCT00599027|DRUG|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
41322130|NCT05157711|DRUG|Anusol|Daily at night and in the morning and after each bowel movement for two weeks
41007510|NCT02847793|BEHAVIORAL|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
41007511|NCT01964911|DRUG|Ropivacaïne|"The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN \<3/10 : non opioids, EN 3-5/10 : weak opioids, EN\>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days)."
41007512|NCT00130962|DRUG|ALGRX 4975|
41007513|NCT02900820|OTHER|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
41007514|NCT02900820|OTHER|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
41007515|NCT00333684|DEVICE|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
41007516|NCT02800148|DRUG|Azelaic acid foam|
41322131|NCT05157711|DRUG|Relief [Name]|Daily at night and in the morning and after each bowel movement for two weeks
41322132|NCT05157711|DRUG|Placebo|Daily at night and in the morning and after each bowel movement for two weeks
41322133|NCT05239468|DRUG|Bezafibrate 100 mg|One tablet of bezafibrate 100 mg IR once daily
41322134|NCT05239468|DRUG|Bezafibrate 200 mg|Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR
41007517|NCT02800148|DRUG|Azelaic acid foam|
41007518|NCT02800148|DRUG|Azelaic acid foam - Placebo|
41007519|NCT01437553|DEVICE|iMAP|IVUS and iMAP analysis for acute coronary syndromes
41007520|NCT02177266|DRUG|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
41007521|NCT02177266|DRUG|Placebo|The placebo will match the study drug.
41007522|NCT01740583|DEVICE|percutaneous annuloplasty|plication of the mitral valve annulus
41007523|NCT01910064|DRUG|GK530G|
41007524|NCT05052424|DIAGNOSTIC_TEST|Analysis of cytokines and immun cell related markers|blood samples
41007525|NCT06479109|BEHAVIORAL|Motivational materials for pregnant women attending antenatal care visits to improve supplement adherence|During the antenatal care visit, pregnant women will receive the information sheet used by the provider and a dangler/poster to hang in a visible location in the participant's house. This will serve as a reminder for her and her family to take the daily pill.
41322135|NCT05239468|DRUG|Obeticholic Acid 5 mg|One tablet of obeticholic acid 5 mg tablet once daily.
41322136|NCT05239468|DRUG|Obeticholic Acid placebo|One tablet of obeticholic acid placebo tablet once daily
41322137|NCT05239468|DRUG|Bezafibrate Placebo|One tablet of bezafibrate placebo tablet once daily
41322138|NCT06373276|OTHER|multiplanar balance training exercise with education|7 minute daily balance training exercises
41322139|NCT06373276|BEHAVIORAL|education only|5 educational broshures
41322140|NCT03676153|OTHER|Nurse-provided guidance|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
41322141|NCT03676153|OTHER|Integrative medicine treatment program|Integrative medicine treatment program
41007526|NCT06479109|OTHER|Providers|"Providers in intervention sites use an information sheet that serves as a job aid to counsel women about the benefits of the supplements. The sheet also includes adherence tips, such as involving family to increase adherence. The information sheet is provided to the woman to take home.~Antenatal care providers will use an information sheet describing the supplement's benefits and adherence tips to help pregnant women take IFAS or MMS."
41007527|NCT01800292|DRUG|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
41007528|NCT01918527|DRUG|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
41322142|NCT03444870|DRUG|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
41322143|NCT03444870|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
41007529|NCT01918527|DRUG|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
41007530|NCT01502722|BEHAVIORAL|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
41007531|NCT02961907|PROCEDURE|PEPCI|"Both parents will receive:~* consultation with a psychiatrist then psychologist follow-up if required, addiction specialist physician consultation then liaison nurse follow-up if required~* endocrinologist consultation then dietitian follow-up if required~* actiphysician consultation and follow-up if required This program will be added to the usual routine course Both parents will receive a 3 months personalized follow-up if required from the multi disciplinary consultation and before the first ART attempt."
41007532|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
41007533|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
41007534|NCT03989297|RADIATION|Radiation|Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
41007535|NCT01914666|DRUG|Duloxetine|Administered orally
41007536|NCT06110676|BIOLOGICAL|LZM012|Recombinant anti-human IL-17A/F humanized monoclonal antibody injection
41007537|NCT06110676|BIOLOGICAL|Secukinumab|Cosentyx
41007538|NCT02438566|DRUG|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
41007539|NCT02438566|DRUG|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
41007540|NCT05425420|DRUG|methadone hydrochloride 0.1mg/kg|Single dose of methadone hydrochloride administered via intravenous (IV)
41007541|NCT05329597|GENETIC|Genotyping|Genotyping is performed using the subjects' blood cells
41007542|NCT03755141|DRUG|Herzuma|Herzuma + Treatment of Physician's Choice
41007543|NCT06395311|OTHER|COPD psychological well-being assessment|Patients will complete the following questionnaires: Hospital Anxiety and Depression Scale (HADS), COPD Assessment Test (CAT), State Shame and Guilt Scale (SSGS), Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE), Brief Fear of Negative Evaluation Scale (BFNE), Self-Compassion Scale Short Form (SCS-SF). Dyspnea will be evaluated with the mMRC scale, and functional capacity will be assessed with the six-minute walking test (6MWT).
41322144|NCT03404518|DRUG|Norco|Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control
41322145|NCT03404518|DRUG|Ibuprofen|Ibuprofen as first line therapy every 6 hours as needed for pain control
41007544|NCT04015661|DRUG|Nab-paclitaxel|induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
41322146|NCT00237445|DRUG|telithromycin|
41007545|NCT03850873|DRUG|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
41007546|NCT05120167|DIAGNOSTIC_TEST|Endocervical liquid-base cytology|Endocervical sample collected by brushing and preserved in a liquid-base.
41007547|NCT05120167|DIAGNOSTIC_TEST|Endocervical cell block|"Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology."
41322147|NCT00237445|DRUG|azithromycin|
41322148|NCT04900038|DRUG|GSK3640254|GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
41322149|NCT04900038|DRUG|Dolutegravir|DTG was available as 50 mg tablets administered orally.
41322150|NCT04900038|DRUG|Lamivudine capsules|3TC was available as 300 mg capsules administered orally as a blinded treatment.
41322151|NCT04900038|DRUG|Lamivudine tablets|3TC was available as 300 mg tablets administered orally as an unblinded treatment.
41322152|NCT02181010|BEHAVIORAL|Intervention|Intervention components will occur at the policy level (working within Baltimore City policy makers to sustain intervention components, and develop virtual simulations of the Baltimore food environment); food wholesaler level (working with wholesalers to stock healthier food items and provide pricing incentives to storeowners on healthier foods); small food retail outlet level (working with corner store and carry-out owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with Baltimore college students to deliver nutrition intervention sessions to younger youth in recreation centers in intervention neighborhoods); household level (providing a text messaging and social media program that provides parents and caregivers tips for healthier eating in their respective neighborhoods).
41322153|NCT06335420|DIETARY_SUPPLEMENT|Carrot juice from Yellowstone carrots cultivars|Consumption of 100 ml of carrot juice daily for 1 year
41322154|NCT06335420|DIETARY_SUPPLEMENT|Placebo juice|Consumption of 100 ml of placebo juice daily for 1 year
41322155|NCT02466412|OTHER|CHTP 1.1 M|Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)
41322156|NCT02466412|OTHER|mCC|Single use of subject's own menthol conventional cigarette (mCC)
41007548|NCT05120167|DIAGNOSTIC_TEST|Endocervical curettage|Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
41007549|NCT02140034|PROCEDURE|Extensive Peritoneal Lavage|
41007550|NCT05639270|DEVICE|use of an auricular electrode|Use of the auricular electrode throughout the duration of the study (30minutes/day) combined with assessment of pain, tolerance, vagal tone.
41007551|NCT00228891|PROCEDURE|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
41007552|NCT00228891|PROCEDURE|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
41007553|NCT05626036|DEVICE|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
41007554|NCT05626036|DEVICE|Synthes Fibulink|High-tensile strength suture syndesmosis repair
41007555|NCT03236844|DRUG|Gantenerumab|Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
41007556|NCT02353481|OTHER|Heart Failure Management|
41322157|NCT02222389|BEHAVIORAL|CM for Alcohol|"Escalating reinforcement for alcohol abstinence.~Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
41322158|NCT02222389|BEHAVIORAL|CM for drugs|"Escalating reinforcement for drug abstinence.~Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
41322159|NCT02222389|BEHAVIORAL|CM for both substances|"Escalating reinforcement for drug and alcohol abstinence.~Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
41322160|NCT02222389|BEHAVIORAL|Non-Contingent group|Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
41322161|NCT02557412|DEVICE|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
41477282|NCT01680783|OTHER|Noninvasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
41477283|NCT06468306|PROCEDURE|non-invasive ventilation teraphy, NIV|Routine management regimes of NIV
41322162|NCT02557412|BEHAVIORAL|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% \[saturated fats \<7% monounsaturated fats up to 20% and polyunsaturated fats \<10% \] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
41007557|NCT05408663|DRUG|EXT608|EXT608 is an investigational drug administered via subcutaneous injection
41322163|NCT02557412|OTHER|Conventional treatment|Hygiene and diet recommendations on sleep
41007558|NCT05408663|OTHER|Placebo|matching placebo administered via subcutaneous injection
41322164|NCT03579992|BEHAVIORAL|60-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 60 minutes per session
41322165|NCT03579992|BEHAVIORAL|90-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 90 minutes per session
41322166|NCT03579992|BEHAVIORAL|90-min movement MyCI training|EMG-controlled in-lab training without restraint for 90 minutes per session
41322167|NCT02203669|OTHER|Home therapy|Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.
41322168|NCT02203669|OTHER|Structured In-Office Therapy|Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
41322169|NCT06315244|PROCEDURE|US Guided Perineural Injection and Neuroprolotherapy|Participants will receive an ultrasound-guided injection of a solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve.
41477284|NCT03092882|BEHAVIORAL|Diabetes Self-Management Program|The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
41477285|NCT01905709|BIOLOGICAL|Human fecal matter|
41477286|NCT04323735|DRUG|Culturelle 10 Billion CFU Capsule|"LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day (Low dose) or twice daily for a total of four doses (High dose) according to randomization group."
41477287|NCT05739968|OTHER|Usual care + oncology case manager (OCM) care|Usual care + oncology case manager (OCM) care
41007559|NCT01135810|BEHAVIORAL|Hypnosis|
41007560|NCT01135810|BEHAVIORAL|Meditation|
41007561|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|"* Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.~* Health education sessions and relaxation sessions: one per week.~* Smoking and diet checking: as recommended by doctor."
41007562|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
41322170|NCT05782582|DIAGNOSTIC_TEST|Package investigation|Investigations performed on a single visit, according to arm description
41322171|NCT05782582|DEVICE|Sound registration with Cadscore® and added risk calculation|Recording of cardiac diastolic sounds enabling the calculation of a risk score.
41322172|NCT05782582|DIAGNOSTIC_TEST|Standard investigation|Sequential investigations according to arm description
41322173|NCT02940717|OTHER|Vita suprinity|New glass ceramic material
41322174|NCT02940717|OTHER|Emax CAD|standard etchable glass ceramic used for laminate venneers
41007563|NCT01356433|DRUG|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
41007564|NCT01356433|DRUG|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
41322175|NCT05581706|COMBINATION_PRODUCT|Place the freshly prepared calcium hydroxide in to the root canals|Calcium hydroxide (Merck, Darmstadt, Germany): prepared by mixing with sterile distilled water and then placed in the coronal 1/3 of the root canals.
41477288|NCT05739968|OTHER|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
41477289|NCT05613751|BEHAVIORAL|Nudge|Three text messages that are sent four weeks apart reminding to obtain the vaccines
41477290|NCT06397820|DEVICE|Percutaneous coronary intervention (PCI)|Revascularization by percutaneous coronary intervention for vessels with decreased PET-derived flow indexes
41477291|NCT04307472|BEHAVIORAL|Clinician Nudge|Active choice intervention in the electronic health record and peer comparison messaging on performance
41477292|NCT04307472|BEHAVIORAL|Patient Nudge|Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician
40804461|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
40804462|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
41007565|NCT01228630|DRUG|Cloratadd-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
41007566|NCT01228630|DRUG|Allegra-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
41007567|NCT04047017|DRUG|Apatinib|250mg, po, qd
41007568|NCT04047017|DRUG|Camrelizumab|200mg, q2w
41322176|NCT05581706|COMBINATION_PRODUCT|Place the freshly prepared double antibiotic paste in to the root canals|Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in airtight containers. The same amount of each drug powder (1:1) was mixed and the mixed samples were combined with sterile distilled water to form an ointment. DAP was introduced in roots canals using a lentulo to fill the entire root canal space.
41322177|NCT05581706|DIAGNOSTIC_TEST|Taking standart periapical radiography with film holder|"Post-operative periapical radiographs were obtained with Digora Optime SPP system (Soredex Corp., Tuusula, Finland) using intraoral film holders to keep the plates parallel to the long axis of the teeth. A size #2 SPP was used for all exposures. SPPs were exposed with a Gendex Oralix DC dental x-ray unit (Gendex Dental Systems, Milan, Italy) operating at 60 kVp, 7 mA, 0.25 sec. and the plates were scanned immediately after exposure. The clinical and radiographical follow up was performed on 12th months.~Image-J program (version 1.47, National Institutes of Health, Bethesda, MD) with TurboReg plug-in (Biomedical Imaging Group, Swiss Federal Institute of Technology, Lausanne, Switzerland) was used to determine the increase in root length, root width, and radiographic root area at 12th month follow up."
41322178|NCT05581706|OTHER|Sample collection for immunofluorometric assay|Periapical exudate samples were collected at the beginning of the RET and at 14th day. MMP-8 levels were measured by immunofluorometric assay (IFMA). Briefly, two monoclonal MMP-8-specific antibodies, 8708 and 8706 (Oy Medix Biochemica Ab, Espoo, Finland) were used as catching antibody and tracer antibody, respectively. Samples were diluted in enzyme buffer (50 mM Tris-HCl, pH 7.5; 0.2 mM NaCl, 1 mM CaCl2). Twenty microlitres of samples and 80 μl of assay buffer (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 0.5% BSA, 0.05% sodium azide and 20 mg/l diethylenetriaminepentaacetic acid with 2 μg/ml normal mouse serum) were pipetted into the wells. The tracer antibody was labelled using europium chelate. After adding the enhancement solution, fluorescence was measured using a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland).
41322179|NCT03111355|DIETARY_SUPPLEMENT|Brazil nut|one nut a day for 2 months, no intervention for 2 months
41322180|NCT01951248|DEVICE|CPAP - continuous airway pressure|3 months of treatment with CPAP treatment
41322181|NCT06314529|OTHER|Assessments|Safety and efficacy assessments
41322182|NCT06184737|BEHAVIORAL|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
40804463|NCT00006144|DRUG|Lopinavir/Ritonavir|
40804464|NCT00006144|DRUG|Emtricitabine|
40804465|NCT00006144|DRUG|Stavudine|
40804466|NCT03172078|PROCEDURE|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
41007569|NCT01795924|DRUG|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
41007570|NCT04884152|PROCEDURE|Home Exercise Group|Educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
41007571|NCT04884152|PROCEDURE|Telerehabilitation Group|Telerehabilitation program combined with educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
40804467|NCT04003207|DRUG|Recombinant human Growth hormone|Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.
41322183|NCT06184737|BEHAVIORAL|Patient Education (PE)|The PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
40804468|NCT04393597|DRUG|DWJ1458 (fasted)|Subjects take single dose of DWJ1458 on a fated condition
40804469|NCT04393597|DRUG|DWJ1458 (fed)|Subjects take single dose of DWJ1458 after high-fat diet
41322184|NCT05838209|DRUG|test|Ozone oil used as an adjunctive of scaling and root planing and control,
41322185|NCT05838209|DRUG|Control|saline solution 0.09% used as an adjunctive as scaling and root planing
41322186|NCT03864809|BEHAVIORAL|sleep disturbance|we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group
41322187|NCT00795509|DRUG|Tolterodine tartrate|"Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
41322188|NCT02325947|DEVICE|hand exoskeleton, brain-computer interface (BCI),|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
41322189|NCT02325947|DEVICE|hand exoskeleton, sham BCI|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
41322190|NCT04861519|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
41322191|NCT05273658|DRUG|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
41322192|NCT05273658|DRUG|Alcohol|Participants will ingest alcohol to achieve the target breath alcohol level
41322193|NCT00479024|DRUG|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
41322194|NCT04569695|DRUG|JNJ-70033093|JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.
41007572|NCT05463003|DIETARY_SUPPLEMENT|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity
41007573|NCT03839589|BEHAVIORAL|Mindfulness Based Stress Reduction Adapated (MBSR-A)|Mindfulness-based stress reduction (MBSR) is a group-based intervention developed in 1979 by Dr. Jon Kabat-Zinn to provide mindfulness training in order to decrease stress and improve overall well-being. MBSR has been shown to be effective for a series of patient outcomes including depression, anxiety disorders, sleep disorders, and chronic pain management. MBSR is a structured intervention delivered through an 8-week course of up to 30 participants who meet for 2.5 hours per week.
41007574|NCT00677495|DIETARY_SUPPLEMENT|Gluten-free diet|Gluten-free diet
41007575|NCT01538693|DRUG|escitalopram oxalate|10 mg 4.5 hours prior to testing
41007576|NCT01538693|DRUG|Cyproheptadine|8mg 4.5 hours prior to testing
41007577|NCT01538693|DRUG|sugar pill|4.5 hour prior to testing
41322195|NCT00318565|DEVICE|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
40804470|NCT05087368|BIOLOGICAL|ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
41322196|NCT01536106|OTHER|Autologous Bone marrow mononuclear cells|Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
40804471|NCT05087368|BIOLOGICAL|CoronaVac (Sinovac Biotech)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
40804472|NCT05087368|BIOLOGICAL|Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
40804473|NCT02091362|DRUG|LY2409021|Administered orally
40804474|NCT02091362|DRUG|Placebo|Administered orally
40804475|NCT02091362|DRUG|Metformin|Administered as background therapy.
40804476|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
40804477|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
40804478|NCT00913887|DRUG|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
40804479|NCT00883168|DRUG|Placebo|Placebo
40804480|NCT00883168|DRUG|azelastineHcl|azelastine hydrochloride 548 mg
40804481|NCT00883168|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
40804482|NCT00883168|DRUG|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
41322197|NCT01536106|OTHER|Placebo control|Intracoronary infusion of autologous peripheral blood.
41322198|NCT00111579|BIOLOGICAL|CAIV-T|A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
41322199|NCT00111579|OTHER|TIV|A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
40804483|NCT00603096|DEVICE|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
41007578|NCT01538693|OTHER|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
41007579|NCT05850156|PROCEDURE|basal blood collection|blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
41322200|NCT04511819|DRUG|Losmapimod oral tablet|Losmapimod will be administered with food when possible.
41322201|NCT04511819|DRUG|Placebo oral tablet|Placebo will be administered with food when possible.
41322202|NCT05262582|PROCEDURE|Sigle port RATS|The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
41322203|NCT05262582|PROCEDURE|Two ports RATS|The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.
41322204|NCT05630430|PROCEDURE|The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures|Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
41322205|NCT02611063|DRUG|fostamatinib|100mg qd, 150mg qd, or 100mg bid
41322206|NCT04367441|DRUG|608|recombinant humanized anti-IL17A monoclonal antibody injection
41322207|NCT04367441|DRUG|Placebo|auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80
41322208|NCT00363051|DRUG|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
41322209|NCT00363051|DRUG|Octreotide Depot|
41322210|NCT01106482|OTHER|Serology blood draw|Blood draw only, no vaccine
40804484|NCT06264986|DIETARY_SUPPLEMENT|Ashwagandha|The intervention will be 600mg of KSM-66, a branded supplement derived from the root extract of the herb ashwagandha, with a consistent rate of 5% withanolides for 28 days. It is the most clinically studied extract of the herb and is the only type of ashwagandha to receive third party testing certification (Informed Sport, Informed Ingredient, Banned Substances Control Group, Clean Label Project). The laboratory where the product is made, Ixoreal Biomed, has received Current Good Laboratory Practices (cGLP), quality controlled and tested against heavy metals and pesticides.
41007580|NCT05850156|PROCEDURE|blood collection M6|6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
41007581|NCT05850156|PROCEDURE|blood collection M12|12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
41322211|NCT03831802|DEVICE|Embrace with Alert and Mate apps|Patients will wear the device on their wrist as often as possible during the day and night. The Embrace Watch contains sensors and memory recordings of electrodermal activity, temperature and physical activity from the wearer. This group will receive notifications on the mobile phone when seizure takes place. Quality of life questionnaires will be filled by the patients at the first follow-up and final assessments.
41477293|NCT05177159|OTHER|The regional cerebral oxygen saturation (rSO2)|Measurement of rSO2 with non-invasive near-infrared light spectrum monitor. The average, left and right frontal regions absolute rSO2 values will be collected every 30 seconds during the whole surgery until postoperative 2 hours, and the mean values will be calculated. Absolute rSO2 value and AUT (area under the threshold) send beneath the absolute threshold limits of 40%, 50% and 20%, 30% under the baseline. AUT will be calculated based on this formula: AUT (present)=AUT (past)+(rSO2 threshold-rSO2 value)×sample rate
41477294|NCT05177159|OTHER|The glial fibrillary acidic protein (GFAP)|Venous blood sample will be collected and tested for plasma GFAP. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
40804485|NCT06264986|OTHER|Placebo|600mg chickpea flour in a hydroxypropyl methylcellulose capsule, once a day for 28 days
41477295|NCT05177159|OTHER|The brain-derived-neurotrophic factor (BDNF)|Venous blood sample will be collected and tested for plasma BDNF. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
40804486|NCT05976646|DRUG|Placebo|Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.
40804487|NCT05976646|DRUG|Auvelity|Orally-administered combination of 45 mg dextromethorphan with 105 mg Bupropion (trade name Auvelity). Auvelity will initially be administered orally once daily for three days. After 3 days on once daily AUVELITY, the participants will begin taking AUVELITY twice daily for 4 additional days as recommended in the FDA-approved prescribing information.
40804488|NCT03926741|DRUG|GSNO|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
40804489|NCT01626586|BEHAVIORAL|Group Therapy|Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
40804490|NCT01534585|DRUG|Icotinib|"Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.~Phase II:According to the maximum tolerated dose, 50 patients will been recruited."
40804491|NCT01534585|RADIATION|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
40804492|NCT01534585|DRUG|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
41007582|NCT02306356|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
41322212|NCT03831802|DEVICE|Embrace with Mate app only|Patients will wear the device on their wrist as often as possible during the day and night. This group will just use the Mate app that summarizes Embrace Watch data for the owner and captures contextual information around events.This group will not receive any alert notification on the mobile phone when a seizure takes place.
41322213|NCT03700736|BEHAVIORAL|Healthy Moms|The 6-month intervention will include dietary and exercise counseling and tips to help participants meet their healthy lifestyle goals. Participants will receive personalized calorie and physical activity goals to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Counselors will encourage and support participants to make a plan for incorporating regular physical activity into their lives in a way (i.e., duration per session, frequency per week) that works for that individual woman. We will encourage participants to track their diet and exercise daily. We will encourage participants to use My Fitness Pal to track their diet and activity.
41322214|NCT02781350|OTHER|HFHC meal|900 Cal high fat high carbohydrate fast food meal (HFHC). meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).
41477296|NCT00699530|OTHER|Cabergoline|Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
41477297|NCT03413137|PROCEDURE|Transperineal mpMRI-US Fusion prostate biopsy|mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).
41477298|NCT03413137|PROCEDURE|Transrectal mpMRI-US Fusion prostate biopsy|using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.
41322215|NCT02781350|DIETARY_SUPPLEMENT|HFHC MEAL plus Fiber|900 Cal high fat high carbohydrate fast food meal containing egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).with FiberOne Original cereal 14 grams (half cup) each before and after the HFHC meal
41007583|NCT05593796|BEHAVIORAL|cognitive behavioral therapy|12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .
41007584|NCT00373243|DRUG|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
41152591|NCT03120949|DRUG|Concomitant treatment|"Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent"
41322216|NCT03153020|OTHER|Patients with stroke or transient ischemic attack|Determination of factors associated to the conformity to secondary prevention treatment 1, 2 and 3 years post a stroke or transient ischemic attack.
41322217|NCT00895648|DRUG|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
41322218|NCT00895648|DRUG|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
41322219|NCT04702048|DRUG|Aflibercept Injection|Patients randomized to Arm A will receive 2 mg IVT aflibercept injections every 4 weeks (Q4W) to Week 20, followed by 2-mg aflibercept injections Q8W to Week 52.
41322220|NCT04702048|DRUG|Sham injection|Patients randomized to Arm B will receive sham intravitreal injections every 4 weeks (Q4W) to Week 20, followed by sham intravitreal injections Q8W to Week 52. Sham means eye will be numbed and a syringe with no needle will be touched to the eye.
41322221|NCT02080286|BEHAVIORAL|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
41322222|NCT02080286|DEVICE|Anodal tDCS|"Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
41322223|NCT02080286|DEVICE|Sham tDCS|"Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
41322224|NCT04007913|BEHAVIORAL|teleCBIT|Eight sessions of individual behavior therapy
41322225|NCT00168064|DRUG|mechlorethamine-MCH (nitrogen mustard)|All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
41322226|NCT02745301|OTHER|Collection of urine and bladder tumor specimens|Voided urine (pre- and post surgical) and intraoperative bladder tumor specimens to be processed for the presence of specific biomarkers.
41322227|NCT01005056|DRUG|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
41322228|NCT00003828|DRUG|vinorelbine|
41322229|NCT04016896|BEHAVIORAL|WIdowed Elders' LIfestyle after Loss (WELL)|Digital monitoring; motivational health coaching; personalized feedback
41322230|NCT04016896|OTHER|Enhanced Usual Care|psychoeducation plus study assessments controlling for time and attention
41322231|NCT01928082|DRUG|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
41322232|NCT06139861|BEHAVIORAL|TranS-C|Transdiagnostic Sleep and Circadian Intervention (TranS-C) is an evidence based cognitive-behavioral sleep therapy.
41322233|NCT06139861|BEHAVIORAL|Psychoeducation|The overarching principle is to provide information about how sleep, stress, diet, health, exercise, accidents and mood are inter-related and have reciprocal effects.
41322234|NCT00442676|DRUG|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
41322235|NCT00442676|DRUG|Placebo|Gelatin capsules of lactose
41322236|NCT05597917|DRUG|Trabectedin|Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
41322237|NCT05597917|BIOLOGICAL|tTF-NGR|Patients will receive standard trabectedin according to arm 1 plus the safe dose according to safety run-in part of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) per day for 4 or lower number of consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following days, q d 22 x until disease progression or contraindications against further application.
41322238|NCT03982238|DRUG|Insulin|Continuous subcutaneous insulin infusion therapy for 1 month
41322239|NCT03982238|DRUG|Metformin|Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
41322240|NCT03982238|DRUG|Dapagliflozin|Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
41477299|NCT06298552|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
41477300|NCT06298552|OTHER|Placebo IV|Intravenous infusion of placebo
41477301|NCT05815082|PROCEDURE|Colorectal cancer resection combined with liver metastasis resection.|The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
41477302|NCT05815082|DRUG|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
41477303|NCT03898102|DRUG|Regorafenib|regorafenib plus zinc gluconate
41477304|NCT03898102|DIETARY_SUPPLEMENT|Zinc gluconate supplement|Zinc gluconate supplement
41477305|NCT04784884|DEVICE|HSI|diagnostic hyperspectral imaging
41477306|NCT03513042|RADIATION|Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy|"Standard of care:~* IMPT (conventional fractionation \[35x1,55/2Gy, 5 fractions/week\] or accelerated fractionation \[35x1,55/2Gy, 6 fractions/week\])~* with or without concurrent cisplatin (100 mg/m2 \[d1, d22 and d43\] or 40 mg/m2 weekly) or cetuximab (weekly 400 mg/m2 in 2h followed by 250 mg/m2 in 1h)"
41477307|NCT02777918|BEHAVIORAL|Recipe provision|6 recipes will be provided every 2 weeks by post for 12 weeks
41477308|NCT00233987|DRUG|carmustine|150 mg/m\^2 IV over 2 hours 4, 5, and 6 days before transplant.
41477309|NCT00233987|DRUG|cyclophosphamide|100 mg/kg IV 2 days before transplant.
41477310|NCT00233987|DRUG|etoposide|60 mg/kg IV over 4 hours 4 days before transplant.
40804493|NCT01534585|OTHER|Quality of life|The EORTC QLQ-C30 and H\&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
40804494|NCT01534585|GENETIC|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
40804495|NCT05103579|DEVICE|MindMics|Patients rhythms was recorded using MindMics device
40804496|NCT04870463|PROCEDURE|Maxillary and mandibular Cone Beam Computed Tomography record|A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)
40804497|NCT05252494|OTHER|animal assisted therapy|In the intervention group, the child will be given to the mother's lap just before the invasive procedure. During the process, the aquarium with the fish will be placed on a shelf at a distance of about 50-60 cm, at an angle that the child can see. The camera on which the blood collection will be recorded will be placed on a tripod and placed on another shelf in such a way that the child can be seen completely. A video recording will be started 1 minute before the procedure, a pulse oximeter device will be attached to the child immediately after the child is seated on his mother's lap, physiological parameters, pain scores and stress will be determined. During the procedure, children's physiological measurements pain score and stress will be re-evaluated after the needle is inserted into the site. After the procedure, children's physiological measurements pain score and stress will be re-evaluated 1 minute after the needle is removed from the injection site
40804498|NCT01404559|DEVICE|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
40804499|NCT01404559|DEVICE|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
40804500|NCT01404559|DEVICE|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
40804501|NCT03046927|DRUG|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
41477311|NCT00233987|DRUG|melphalan|150 mg/m\^2 IV 1 day before transplant.
41477312|NCT00233987|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|2.0 x 10\^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.
41477313|NCT00233987|RADIATION|radiation therapy|150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
41477314|NCT00002351|DRUG|Indinavir sulfate|
41477315|NCT05709652|DIAGNOSTIC_TEST|Aortic CTA, .23s|Aortic CTA performed with short (0.23 sec) gantry rotation time.
41477316|NCT05709652|DIAGNOSTIC_TEST|Aortic CTA, .28s|Aortic CTA performed with standard (.28 sec) gantry rotation time.
41477317|NCT01862419|OTHER|Alert|
41477318|NCT04681651|DRUG|Normobaric Hyperoxia|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
41322241|NCT04163107|DRUG|Hydroxychloroquine|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
41322242|NCT04163107|DRUG|Carfilzomib Injection|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
41322243|NCT04163107|DRUG|Dexamethasone|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
41477319|NCT04681651|DRUG|Sham Normobaric Hyperoxia|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%；
41477320|NCT04681651|PROCEDURE|Endovascular Thrombectomy|EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.
41477321|NCT05975177|DEVICE|Sterify Gel|A mucoadhesive polymeric hydrogel in a prefilled syringe for nonsurgical treatment of periodontal and peri-implant pockets, composed of polyvinyl polymers, hydroxytyrosol, nisin, and magnesium ascorbyl phosphate
41477322|NCT05975177|PROCEDURE|Scaling and root planing|The non-surgical procedure involved SRP under local anesthesia with EMS scalers and Gracey curettes.
41477323|NCT04567576|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"Within a non-experimental setting, the routine disease-modifying antirheumatic drugs (DMARDs) prescription will be evaluated as the exposure."
41322244|NCT04042675|DIAGNOSTIC_TEST|observational study|There will be two groups in this study. One of the groups will consist of 30 parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage. The other group will consist of 30 healthy individuals between the ages of 40-75 and without any neurological disorders. Participants' respiratory muscle strength, exercise capasity, fatigue and physical activity levels will be assessed. All asessements will done for only one time.
41477324|NCT04013074|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt
41477325|NCT04013074|OTHER|Standard Medical Treatment|Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
41477326|NCT01272921|DRUG|Bupivacaine|Varying doses to determine the duration of analgesia
41477327|NCT01272921|DRUG|Ropivacaine|Varying doses to determine the duration of analgesia
41477328|NCT05196360|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
41477329|NCT05442203|DEVICE|Zio Patch Monitor|Patch monitor will be applied and worn for a 2-week period at baseline, month 6, and month 12 after assignment to the AF arm.
41477330|NCT05442203|DEVICE|Echocardiogram|Ultrasound study of the heart will be completed upon patient consent after assignment to the SHD arm.
41477331|NCT04822376|DRUG|ansuvimab|Human monoclonal antibody to Zaire strain GP (EBOV GP)
41477332|NCT04822376|BIOLOGICAL|Ervebo|Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
41477333|NCT01351350|DRUG|MLN0128|MLN0128 capsules
41477334|NCT01351350|DRUG|paclitaxel|paclitaxel intravenous infusion
41322245|NCT01057914|DIETARY_SUPPLEMENT|Nutritional supplementation with a liquid formula|The patient consumes 400 kcal from a liquid supplementation formula
41322246|NCT01057914|OTHER|Dietary advice|The patient receives dietary advice for one hour during the hospital stay.
41322247|NCT01057914|OTHER|Combination of supplement and dietary advice|The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
41322248|NCT04372043|OTHER|Questionnaire|"Sleep Hygiene Index and demographic questions."
41322249|NCT03117530|DRUG|Minocycline|Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
41322250|NCT01958125|DEVICE|gammaCore|Vagal stimulation
41322251|NCT00735670|DRUG|Venlafaxine HCl|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
41322252|NCT00735670|OTHER|Placebo|Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
41322253|NCT02362542|DEVICE|tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
40804502|NCT03046927|OTHER|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
41477335|NCT01351350|DRUG|trastuzumab|trastuzumab intravenous infusion
40804503|NCT00046761|DRUG|ONO-2506|
40804504|NCT01811485|DRUG|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
41477336|NCT06355284|OTHER|Functional MRI|While in the MRI scanner, participants will complete several classic experimental tasks designed to capture brain activity related to core cognitive features of overcontrol that impact social functioning. Tasks include the Stop Signal Task (error monitoring), Delay Discounting Task (valuation, impulsivity), and Reversal Learning (cognitive flexibility).
41007585|NCT04543552|DEVICE|Bladder scan|Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
40804505|NCT01811485|DRUG|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
40804506|NCT01811485|DRUG|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
41322254|NCT05631262|DRUG|SKB264|Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy
41477337|NCT01012557|BIOLOGICAL|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
41477338|NCT01012557|BIOLOGICAL|Focetria|3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
41322255|NCT05631262|DRUG|Docetaxel|Part II Control group will receive docetaxel monotherapy.
41322256|NCT00643604|DRUG|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
41322257|NCT00707343|RADIATION|FLT-PET Imaging|radiopharmaceutical 3'-deoxy-3'-\[F-18\]fluorothymidine, \[F-18\]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
41322258|NCT06459622|DIAGNOSTIC_TEST|Serum IL_25 and eosinophils in nasal polyp tisuee|Serum IL-25 and eosinophils in nasal polyps tisuer obtained and measured to identify the sensitivity of nasal polyps to corticosteroids
41322259|NCT06253013|DEVICE|Hyfe Smartwatch|Passive recording of audio with detection of explosive sounds. When explosive sounds are detected, a 0.5-1 seconds audio clip is recorded, and run through an algorithm to determine whether or not it is a cough.
41322260|NCT06253013|DEVICE|FitBit Versa 2|Commercial watch with the capability to monitor vital signs including oxygen saturation, respiratory rate and heart rate. Patients will be able to view their data in the FitBit app.
41322261|NCT06253013|DEVICE|Home Spirometer|Patients will be able to perform spirometry testing at home. They will be able to view their data, and it will be uploaded to a dashboard for clinicians.
41322262|NCT06253013|BEHAVIORAL|Audio recording|Patients will be asked to record several sentences which will be analyzed to detect speech patterns that may indicate changes in respiratory conditions.
41322263|NCT01921634|OTHER|Modified Pathologic Analysis|
41477339|NCT01012557|BIOLOGICAL|Focetria|15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
41477340|NCT01012557|BIOLOGICAL|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1
41477341|NCT05661734|DRUG|VX-548|Tablets for oral administration.
40804507|NCT05555641|DRUG|Nafamostat Mesylate|ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
41477342|NCT02475382|DRUG|Nivolumab|Specified dose on specified days
41477343|NCT00755768|BEHAVIORAL|additional review by dietician|
41477344|NCT04424849|DIAGNOSTIC_TEST|CT-Scan|Chest CT scan on admission to the intensive care unit
41477345|NCT02736630|OTHER|body temperature|intermittant tympanic temperature measurement during surgery
41152592|NCT02674555|DRUG|radio-labeled naquotinib|Oral administration
41322264|NCT06098209|DRUG|Dexmedetomidine|Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.
41322265|NCT06098209|DRUG|Propofol|Patient will receive propofol 0.3-4 mg/kg/h.
41322266|NCT03987919|DRUG|Tirzepatide|Administered SC
41322267|NCT03987919|DRUG|Semaglutide|Administered SC
41322268|NCT02658201|DEVICE|MRI|Ultrafast MRI to assess constipation
41322269|NCT01756872|PROCEDURE|Measurements of ovarian reserve|Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
41322270|NCT00001449|DRUG|gemcitabine|
41322271|NCT00001449|DRUG|fluorodeoxyuridine|
41322272|NCT00001449|DRUG|leucovorin|
41322273|NCT00353184|DRUG|Montelukast 5-mg orally added to standard therapy|
41322274|NCT00185354|DRUG|BAY86-5016, SH P00331F|Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
41322275|NCT00185354|DRUG|SH P00331N|Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
41322276|NCT06112002|OTHER|Educational Intervention|Attend an educational session
41322277|NCT06112002|BEHAVIORAL|Health Education|Receive educational materials
41322278|NCT06112002|OTHER|Survey Administration|Ancillary studies
41477346|NCT03421704|DEVICE|DreamStation BiPAP autoSV|Philips Respironics DreamStation BiPAP autoSV (PR DS-autoSV) is designed to deliver pressure support for patient ventilatory assistance
41477347|NCT03201211|BIOLOGICAL|Blood sampling|A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.
41152593|NCT02674555|DRUG|naquotinib|Oral administration
41322279|NCT00080886|BIOLOGICAL|rituximab|
41322280|NCT00080886|DRUG|carmustine|
41322281|NCT00080886|DRUG|cytarabine|
41322282|NCT00080886|DRUG|etoposide|
41322283|NCT00080886|DRUG|melphalan|
41322284|NCT00080886|PROCEDURE|autologous bone marrow transplantation|
41322285|NCT00080886|PROCEDURE|peripheral blood stem cell transplantation|
41322286|NCT05426369|BIOLOGICAL|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein for injection (Strength: 1 mg/ml, 0.5ml/vial)
41322287|NCT00284349|DEVICE|Use of a rehabilitation brace instead of a plaster|
41477348|NCT03201211|BIOLOGICAL|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
41477349|NCT03201211|BIOLOGICAL|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
41477350|NCT03201211|DRUG|Placebo|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
41477351|NCT03407118|DRUG|LY900014|Administered SC.
41477352|NCT03407118|DRUG|Insulin Lispro|Administered SC.
41477353|NCT03267420|DIAGNOSTIC_TEST|BpTRU First, Unattended Omron Second|"Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted."
41477354|NCT03267420|DIAGNOSTIC_TEST|Unattended Omron First, BpTRU Second|"Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings."
41477355|NCT03267420|DIAGNOSTIC_TEST|Partially Attended Omron First, Unattended Omron Second|"Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted."
41477356|NCT03554252|OTHER|Frequencies|Results are presented as natural frequencies (e.g. the drug was effective for 1 out of 10 people) while side effects are presented as percentages (e.g. 40% participants experienced severe side effects)
41007586|NCT03773757|BEHAVIORAL|IN-PEACE Dementia Care Coordination|Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
41007587|NCT04441567|OTHER|Right-size clinic visits|The curve created in Phase 1 will be used to guide the number of clinic visits based on PROMs reported by the participants in Phase 2.
41007588|NCT05316662|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
41007589|NCT06277934|DRUG|RGT001-075|Administered orally
41007590|NCT06277934|DRUG|Placebo|Administered orally
41152594|NCT03599934|OTHER|Lifestyle integrated functional exercise program|Lifestyle-integrated exercise training targeting to improve strength and balance. Strategy to embed the exercise in the daily activity would also be taught so that the life exercise can be performed at any time of the day. The exercise would be taught in 6 home visits over 6-months.
41152595|NCT03599934|OTHER|Home safety assessment|Home safety assessment and modification that targets to reduce environmental risk factors of falls.
41477357|NCT03554252|OTHER|Percentages|Results are presented as percentages (e.g. the drug was effective for 10% of people) while side effects are presented as natural frequencies (e.g. 4 out of 10 participants experienced severe side effects)
41477358|NCT00958802|OTHER|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
41477359|NCT00958802|OTHER|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
41477360|NCT03649178|OTHER|salt|Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks
41477361|NCT04780334|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
41007591|NCT04024475|OTHER|Observation|
41007592|NCT06073925|DRUG|VIT D|50000 IU per week of VIT D
41007593|NCT01959646|DIETARY_SUPPLEMENT|Aged Garlic Extract Supplementation Group|Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
41007594|NCT01959646|OTHER|Standard for Groups|To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
41007595|NCT01959646|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to consume three (3) placebo capsules with food twice a day.
41322288|NCT05998655|OTHER|tele nursing|"In the research, tele-nursing applications based on technological competence theory will be applied to the experimental group. In the content of the application, training, consultancy and follow-up will be made on breast cancer, the problems experienced in the treatment process of breast cancer, the most frequently experienced chemotherapy symptoms and management strategies. Technology knowledge will be based on the concepts of collaborative design and participant interaction. A five-week group training will be implemented once a week. The training will be applied to all the participants in the experimental group and will be held over Google Meet. Educational program; pre-prepared powerpoint presentations, oral narration, discussion and group training will be made using e-booklets."
41322289|NCT05231993|PROCEDURE|Conization|A cone biopsy to remove abnormal tissue.
41322290|NCT05231993|PROCEDURE|Colposcopy|"1. Colposcopy with biopsy within 3 months,endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~2. Colposcopy after 12 months if the first colposcopy and biopsies are normal~3. Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
41322291|NCT01989754|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily for 156 weeks
41322292|NCT01989754|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
41322293|NCT01989754|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
41322294|NCT00003091|BIOLOGICAL|aldesleukin|
41322295|NCT00003091|BIOLOGICAL|recombinant interferon alfa|
41322296|NCT04873076|DEVICE|Audiovisual distraction using 2d video glasses from HappyMed GmbH|Patients receive optical and acustical relaxing material during the procedure by using 2d video glasses from HappyMed GmbH
41322297|NCT02069236|OTHER|G6PD Test|All subjects are tested by multiple G6PD tests
41322298|NCT04043403|DEVICE|Open Loop DBS|Standard DBS therapy at a constant frequency and voltage
41322299|NCT04043403|DEVICE|Adaptive (Closed Loop) DBS|DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state
41322300|NCT04043403|DEVICE|Intermittent Open Loop DBS|Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.
41322301|NCT02098694|OTHER|Physiotherapy follow-up|"Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise."
41322302|NCT00861861|DRUG|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
41322303|NCT00861861|DRUG|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
41322304|NCT02001363|DRUG|liraglutide (Novo Nordisk, Bagsværd, Denmark)|once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
41322305|NCT02001363|DRUG|liraglutide placebo (Novo Nordisk)|once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
41477362|NCT04780334|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
40804508|NCT05555641|DRUG|Unfractionated Heparin|ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
40804509|NCT05215470|DRUG|Nivolumab|Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
40804510|NCT05215470|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
40804511|NCT06112288|OTHER|Compressive Myofascial Release|Compressive myofascial release is manual therapy technics.
41322306|NCT01830816|DRUG|Ixazomib|Ixazomib capsules
41322307|NCT03444194|PROCEDURE|liver biopsy|Liver biopsy of neoplastic tissue and normal liver tissue.
41322308|NCT00434499|DRUG|EGCG|EGCG 400 mg by mouth twice/daily for 4 weeks duration.
41322309|NCT01359046|DEVICE|silver SPC|subject randomized to receive silver alloy impregnated catheter
41322310|NCT01359046|DEVICE|standard SPC|subject randomized to receive standard catheter
41322311|NCT00796133|DRUG|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P\<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
41322312|NCT05224154|BEHAVIORAL|Abstinent Contingent (AC) Re-Connect|Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO\<=6ppm).
41322313|NCT05224154|BEHAVIORAL|Submission Contingent (SC) Re-Connect|Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
41322314|NCT06145152|PROCEDURE|Adaptive exercise training|The training recommendation for the day will be adjusted based on the readiness level. The adjustments can be both up or down (increased or decreased training)
41322315|NCT06145152|PROCEDURE|Static exercise training|The training recommendation for the day will not be adjusted based on the readiness level.
41322316|NCT01757756|DRUG|Pf-05175157|200-mg administered twice daily for 14 days
41322317|NCT01757756|DRUG|placebo|placebo administered twice daily for 14 days
40804512|NCT06112288|OTHER|Ankle mobilisation|ankle mobilization is manual therapy technics.
40804513|NCT01469936|DIETARY_SUPPLEMENT|PERMEAPROTECT|"Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~* First Week of intervention : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
40804514|NCT01469936|DIETARY_SUPPLEMENT|PLACEBO|"Duration : 5 weeks +/- 1 week.~Dosage:~* First Week : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
40804515|NCT01267110|OTHER|MI2 intervention arm|For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
40804516|NCT01267110|OTHER|Control|Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
40804517|NCT00043355|DRUG|interferon gamma-1b|500 mcg, oral, three times weekly
40804518|NCT03239951|DEVICE|iTind|temporary implant
40804519|NCT00453609|DRUG|long-lasting injectable naltrexone|
40804520|NCT00161837|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
40804521|NCT00161837|BIOLOGICAL|Egg-derived Influenza Vaccine|
41007596|NCT05287191|DRUG|Magnesium sulfate and then Digoxin|We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast Atrial Fibrillation persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance \<60 ml/min measured by the Modification of diet in renal disease formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
41322318|NCT01757756|DRUG|midazolam|midazolam 3-mg admistered as single doses on Day 0 and Day 11.
41322319|NCT02555657|BIOLOGICAL|pembrolizumab|
41322320|NCT02555657|DRUG|capecitabine|
41322321|NCT02555657|DRUG|eribulin|
41322322|NCT02555657|DRUG|gemcitabine|
41322323|NCT02555657|DRUG|vinorelbine|
41322324|NCT04000919|DRUG|5HTP|5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
41322325|NCT04000919|DRUG|L-DOPA|L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)
41322326|NCT04000919|DRUG|Placebo oral tablet|Placebo
41322327|NCT04000919|DRUG|Carbidopa|Carbidopa (50mg)
41322328|NCT04552431|DRUG|Ciprofloxacin|Ciprofloxacin, 500 mg twice daily
41322329|NCT04552431|DRUG|Tamsulosin Hydrochloride|Tamsulosin Hydrochloride, 0.4 mg once daily
41322330|NCT04552431|DRUG|Tamsulosin Hydrochloride Placebo|Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily
41322331|NCT04552431|DRUG|Ciprofloxacin placebo|Ciprofloxacin placebo (Placebo-CF) one tablet twice daily
41322332|NCT04624828|PROCEDURE|Radiotherapy|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
40804522|NCT04568486|OTHER|Diabetes Empowerment Education Program|The Diabetes Empowerment Education Program (DEEP) is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
40804523|NCT02353819|RADIATION|Stereotactic Ablative Radiotherapy|SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
40804524|NCT05243524|OTHER|Maveropepimut-S|SC injection on days 7, 28, then q8w
41322333|NCT04624828|DRUG|androgen deprivation therapy (ADT)|"ADT as for clinical practice:~* for oligorecurrent patients, ADT will be started at time of polimetastatic progression after SBRT;~* for oligoprogressive patients, ADT will be continued during SBRT and untill polimetastatic progression"
41322334|NCT04624828|BIOLOGICAL|immune evaluation|We will use the flow cytometer FACSymphony, to analyse multiple immune populations from a limited sample of blood. We will monitor the dynamics of most innate (monocytic and granulocytic cells, Natural killer cells) and adaptive (T cells, B cells) immune subsets in the peripheral blood of PC patients before and after RT. We will deeply characterize CD4+ and CD8+ T cell subpopulations circulating in the patients enrolled in the study. In this attempt our panel will include markers of T cell differentiation and activation, including CD25, CD39, PD-1, CTL4, KLRG1, TIM3. We will analyse neutrophils subpopulations and investigate the functional profile of granulocytes in enrolled patients. Markers such as CD66b, CD24, CD16, MHC-II, LOX1, CD36 and CD62L will be included in our analysis. In conclusion our experimental strategy will result in a comprehensive profiling of the immune landscape in PC patients at single cell level.
41477363|NCT02463305|DRUG|Creatine monohydrate|21 grams creatine monohydrate total per day
41477364|NCT02463305|OTHER|Placebo|7 grams of dextrose dissolved in 500mL water, taken three times daily
41477365|NCT02207335|DRUG|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
41477366|NCT02207335|DRUG|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
41477367|NCT01832402|DRUG|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
41477368|NCT01832402|DRUG|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
41477369|NCT01832402|OTHER|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
40804525|NCT05243524|DRUG|Cyclophosphamide 50mg|PO BID, one week on, one week off
40804526|NCT03300024|DEVICE|Expanded polytetrafluoroethylene Graft|Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
40804527|NCT03300024|DEVICE|Bovine Carotid Artery Graft|Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
40804528|NCT03195790|BEHAVIORAL|Family-based pediatric obesity treatment|Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
40804529|NCT01067118|DRUG|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
41007597|NCT05287191|DRUG|Amiodarone|We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
41007598|NCT06343077|DRUG|Poly-ICLC intramuscular (IM) injection|1.5 mg IM (week 1), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.
41477370|NCT01832402|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
40804530|NCT01067118|DRUG|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
40804531|NCT00472316|BEHAVIORAL|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
41007599|NCT06343077|DRUG|Poly-ICLC, Intertumoral (IT) injection|1 mg IT once (week 2)
41007600|NCT04127760|RADIATION|radiotherapy|Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
41007601|NCT03086785|DRUG|Apatinib|apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w
41007602|NCT02850536|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells
41007603|NCT02051972|DEVICE|Implanted with a Nanostim leadless pacemaker system|
41007604|NCT02090452|DEVICE|Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden|
41007605|NCT00514267|DRUG|YM 155|IV
41007606|NCT00514267|DRUG|Docetaxel|IV
41007607|NCT00514267|DRUG|Prednisone|Oral
41477371|NCT01832402|BEHAVIORAL|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
41477372|NCT06368557|BEHAVIORAL|CoolMinds: Internet-based cognitive behavioral therapy (iCBT)|The intervention consists of 14 weeks of iCBT, where the main treatment components are psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The program comprises eleven sessions for adolescents and ten sessions for parents to be completed simultaneously. The participants will have the opportunity to get therapist feedback during the treatment period, the therapist may spend a maximum of 15 minutes giving feedback per week per participant.
41007608|NCT01690039|DRUG|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
41007609|NCT01500148|DEVICE|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
41007610|NCT01298297|DRUG|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
41477373|NCT01010789|DRUG|Armodafinil|flexible dose 150-250mg/day
41477374|NCT01010789|DRUG|Armodafinil|150-250mg/day; flexible dose
41477375|NCT01010789|DRUG|Matching placebo|Placebo comparator
41477376|NCT04430582|OTHER|Cognitive Assessment (not diagnostic)|Cognitive testing will assess working memory and attention, verbal memory and delayed memory, executive function, and psychomotor speed.
41477377|NCT04430582|DIAGNOSTIC_TEST|ECG|ECG will take place during screening visit.
41477378|NCT00183885|DRUG|mitomycin-c, cisplatin|Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
41477379|NCT05839327|DIAGNOSTIC_TEST|Montreal cognitive assessment scale (MOCA)|Tests to evaluate cognitive disorders (MOCA), anxiety and depression (HADS) Pos-traumatic stress disorder (PCL-C) and quality of life (SF-36)
41477380|NCT01872052|DEVICE|Acutus Medical System Mapping|Mapping with the Acutus Medical System followed by intracardiac ablation of typical atrial flutter
41007611|NCT01298297|DRUG|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
41477381|NCT01513031|OTHER|Education and telephone follow-up|Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
41477382|NCT04477551|PROCEDURE|Diode laser (device) with scaling and root planing|Combined use of diode laser device and scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
41477383|NCT04477551|PROCEDURE|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
41477384|NCT02230618|DRUG|insulin degludec/insulin aspart|Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
41477385|NCT00359632|DRUG|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
41477386|NCT00359632|DRUG|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
41322335|NCT05353751|BEHAVIORAL|Kind Minds Program|"The KMP intervention uses an online mindfulness phone based program. During the 9-week program, Community Health Worker (CHW) Kindness Coaches will meet weekly for 30 minutes via Zoom with either a) the caregiver and adolescent (in separate meetings), or b) the adolescent only to review and complete a new session using the online mindfulness program. Participants will be prompted to complete mindfulness activities between sessions by notifications, conducive to their school and work schedules. Weekly content and meditations/activities focus on mindfulness skills of present moment awareness, nonjudgment, compassion, and gratitude."
41007612|NCT05567640|BEHAVIORAL|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
41477387|NCT04998578|DEVICE|Comparison of aesthetic techniques|Comparison of aesthetic techniques for rejuvenation and glazing of the genital region
41007613|NCT05567640|BEHAVIORAL|Space for depression|Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
41322336|NCT04839536|DRUG|Sevoflurane inhalant product|Sevoflurane will be delivered in an incremental dose to throughout procedure to achieve clinical sedation endpoint OAAS 3.
41007614|NCT05567640|BEHAVIORAL|Space for resilience|This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
41007615|NCT01830140|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
41007616|NCT01830140|DRUG|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
41007617|NCT06184334|DRUG|Solfenacin|pills taken once day
41007618|NCT06184334|DRUG|Mirabegron|pills taken once day
41477388|NCT04031612|DRUG|Neoadjuvant therapy|Neoadjuvant therapy
41477389|NCT06147726|OTHER|Upper extremity position matching exercises in virtual reality|In addition to conventional treatment approaches for 20 minutes 2 days a week for 8 weeks, joint positioning exercises (4 different game sequences of 4 minutes, 1 minute rest between each sequence, total 20 minutes) designed specifically for the individual's existing range of motion will be applied to the VR group.
41477390|NCT06147726|OTHER|Conventional physiotherapy|proprioceptive neuromuscular facilitation techniques, parkinson-specific upper extremity and balance and gait exercises
41477391|NCT02113176|DRUG|Minocycline|
41477392|NCT00817947|DEVICE|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
41477393|NCT05485220|OTHER|Aerobic exercise|Aerobic exercise group: Peak workload will be determined by performing an exercise test on the patients. Training will be given at 60-70% of the peak workload for 45 minutes with an arm ergometer 3 days a week for 8 weeks.
41477394|NCT05485220|OTHER|High-intensity interval training|High-intensity interval training Group: Peak workload will be determined by performing an exercise test on the patients and arm ergometer HIIT will be done with a total of 45 minutes, 90-95% of the peak workload for 30 seconds, 60 seconds in between, active recovery at 40-50% workload, 3 days a week for 8 weeks.
41477395|NCT02658916|DRUG|BIIB092|Same dose as corresponding CN002003 study panel.
41477396|NCT02215148|DRUG|Tolvaptan|
41477397|NCT03384706|BEHAVIORAL|Cognitive Processing Therapy (CPT)|"CPT looks at the impact the traumatic event has had on your life and helps you to examine and change unhelpful thoughts and feelings related to the event, yourself, others and the world.~CPT will be conducted in 5-15, 60 minute sessions held once or twice a week."
41477398|NCT03384706|BEHAVIORAL|Accelerated Resolution Therapy (ART)|"ART, like CPT also involves processing thoughts and feelings related to the event, but does this in a different way relying more on visualization or imagination rather than talking.~ART will be conducted in 5-15, 60 minute sessions held once or twice a week."
41477399|NCT06415695|BEHAVIORAL|Education sessions|Ten 40-minute education sessions appropriate to Saudi people will be developed and will cover essential topics for enhancing diet, lifestyle, and health. Each session comprises four modules, including activities and homework reviewed by a dietitian. Based on the EMPOWER weight loss program developed by the Nakamura lab for the US population, adjustments will be made to align with Saudi preferences, including food choices and cooking methods. Participants will access these materials online.
41477400|NCT03631082|OTHER|Slump stretching|Slump stretching will be provided to this group along with standardized exercises.
41477401|NCT03631082|OTHER|Lumbar mobilization|Lumbar mobilizations will be provided to this group along with standardized exercises.
41477402|NCT01534078|DRUG|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
41477403|NCT01534078|DRUG|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
41477404|NCT02309853|OTHER|Visual and tactile scanning training|"20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.~1. Visual or tactile scanning in the personal space~2. Visual or tactile scanning and trunk rotation in the peripersonal space~3. Visual scanning and trunk rotation in the extrapersonal space"
41477405|NCT02309853|OTHER|Uni-modal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
41477406|NCT06193824|DEVICE|Experimental: downhill treadmill walking at -10% and -20% gradient|The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-10% or -20% incline)
41477407|NCT00775788|PROCEDURE|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
41477408|NCT01216657|DRUG|Sunitinib|50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
41477409|NCT05601076|PROCEDURE|fixed with the triple-buffer system|The steps were as follows: i) elastic cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) was used at the proximal 15 cm from the incision, with 5 × 2.5 cm pieces glued to the skin and fixed with the drainage tube using surgical knots; ii) the distal end of the ligation was fixed using the same method, while the ligation position was higher than the first; iii) the ligature point was fixed next to the elastic soft cotton tape (5 × 5 cm), using the high-platform method to fix the drainage tube, with the drainage tube curved; and iv) the drainage tube between the two fixed points was inserted with a specific radian.
41007619|NCT06184334|DRUG|Tadalafil 5mg|pills taken once day
41322337|NCT04083001|DEVICE|OTR4132MD|"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."
41322338|NCT02877355|DRUG|semaglutide|All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
41322339|NCT04828785|OTHER|MTM|weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
41322340|NCT04828785|OTHER|Food Subsidy|$40/month food subsidy
41322341|NCT02370940|OTHER|High phytate intake|
41007620|NCT03012854|PROCEDURE|short-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
41322342|NCT02370940|OTHER|Low phytate intake|
40804532|NCT02074670|OTHER|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
40804533|NCT02748044|DEVICE|CC-Cruiser|An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
40804534|NCT05772689|OTHER|Usual Care|Caregivers assigned to the usual care group will be enrolled in the course at the 3-month mark after consenting. All caregivers will then participate in quantitative interviews at post- 6months of their baseline
40804535|NCT05772689|OTHER|Caring While Black|Caregivers assigned to this group will receive a schedule for their completion of the course over the next 2 months and supplemental course materials through the mail. The Canvas platform will enable the course to monitor everyone's movement in the cohort through the asynchronous part of the course. Nudges and reminders will be sent twice a week via text or email with the participant's consent.
40804536|NCT01016119|DRUG|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
40804537|NCT01016119|DRUG|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
40804538|NCT02547038|DRUG|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
40804539|NCT02547038|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
41007621|NCT03012854|PROCEDURE|long-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
41007622|NCT03012854|PROCEDURE|full-thickness myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
41007623|NCT03012854|PROCEDURE|circular myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
41322343|NCT01225978|DEVICE|GeneInsight Clinic (GIC)|"GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.~The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing."
41322344|NCT00450047|DEVICE|Speed-feedback therapy system with a bicycle ergometer|
41322345|NCT00450047|DEVICE|Ergometer at conventional settings|
41322346|NCT00836277|DRUG|Panitumumab|9mg/kg IV Day 1 Cycle = 21 days
41322347|NCT00836277|DRUG|Irinotecan|125mg/m2 IV Day 1 and Day 8
41322348|NCT02716194|BIOLOGICAL|BAX 826|
41322349|NCT02716194|BIOLOGICAL|Octocog alfa|
41322350|NCT04241146|DEVICE|Enteric Tube|A post pyloric feeding tube used in patients requiring enteral nutrition
41322351|NCT04241146|DEVICE|CORTRAK enteral access system|Electromagnetic guidance system for enteric feeding tube placement
41322352|NCT00672360|DIETARY_SUPPLEMENT|Folic acid|Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.
41322353|NCT00672360|DIETARY_SUPPLEMENT|Placebo|Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
41322354|NCT06156514|DRUG|Gemcitabine|Weekly application of gemcitanibe at 300 mg/m2 intravenously in a 30-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
41322355|NCT06156514|DRUG|Cisplatin|Weekly application of Cisplatin at 40 mg/m2 intravenously in a 60-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
41322356|NCT03833817|BEHAVIORAL|Talking about Cancer (TAC)|The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.
41477410|NCT05601076|PROCEDURE|fixed using the conventional lifting platform method|In terms of the control group, two lines of flexible cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) measuring 10 × 2.5 cm were used, and the drainage tube was fixed parallel to the long axis and glued to the middle-position 360° winding tube once the drainage tube was 0.5 cm higher than the surrounding skin. Next, the drainage tube was fixed at both ends to the patient's skin using adhesive tape. Then, the tube and the adhesive plaster were overlapped vertically and horizontally, the tube was inserted, the adhesive plaster was added, and then the chest tube was fixed on the adhesive plaster by knotting the interspersed cotton rope, which was equal to indirectly fixing the tube on the patient's skin
41477411|NCT04161183|DEVICE|Extracoporeal shock wave therapy|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 6 weeks
41477412|NCT04161183|DEVICE|Placebo|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second but no energy once a week for 6 weeks
41477413|NCT00337428|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)|GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
41477414|NCT00337428|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)|GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
41477415|NCT00337428|BIOLOGICAL|Comparator: REPEVAX™ (Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
41477416|NCT00337428|BIOLOGICAL|Comparator: REPEVAX™ (Non-Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
41477417|NCT01056094|DRUG|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
41477418|NCT03119493|BEHAVIORAL|Periodized aerobic interval training|The periodized training program consist in 3 phases: light (I) (training range varying between 20 to 39% of heart rate reserve and active recuperation of 19% of heart rate reserve); moderate (II) (training range varying between 40 to 59% of heart rate reserve and active recuperation of 30% of heart rate reserve) and high (III) (training range varying between 70 to 90 % of heart rate reserve and active recuperation of 50% of heart rate reserve).
41477419|NCT00152191|DRUG|UFT (uracil, tegafur)|uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years
41477420|NCT00152191|DRUG|cyclophosphamide, methotrexate, and fluorouracil|cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
41477421|NCT03420768|DRUG|BMS-986263|Administered by intravenous (IV) infusion
41477422|NCT03420768|OTHER|Placebo|Administered by intravenous (IV) infusion
41477423|NCT01976013|DEVICE|Coaguchek|The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
41322357|NCT01287481|BEHAVIORAL|Stress and Emotions|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
41322358|NCT01287481|BEHAVIORAL|Thoughts and Behaviors|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
41322359|NCT01287481|BEHAVIORAL|Brain and Body|Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
41477424|NCT03858218|OTHER|questionnaires set|questionnaires set: The Chinese version of the Pittsburgh Sleep Quality Index (PSQI)+The Chinese version of the Center for Epidemiologic Studies Depression Scale for Children (CES-DC)+ The Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0)
40804540|NCT05978440|PROCEDURE|onlay preparation|CAD-CAM onlay restorations will be fabricated using rubber dam scanning techniques and evaluated clinically up to 12 months
41322360|NCT02241928|BIOLOGICAL|Stem Cell|Intrathecal Autologous bone marrow mononuclear cell transplantation
41322361|NCT05535309|DRUG|cefoperazone sulbactam sodium|Cefoperazone sodium and Sulbactam Sodium for injection (1; 1) are white or almost white powder drugs, and the components are cefoperazone sodium and sulbactam sodium
41322362|NCT02884830|DEVICE|continuous positive airway pressure|positive airway pressure given by a medical device through a nasal mask
41322363|NCT04457570|OTHER|mortality|To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection
41322364|NCT03213483|PROCEDURE|Coronally advanced flap and subepithelial connective tissue graft|The connective tissue graft is obtained by a single line incision from the palate.
41322365|NCT03213483|PROCEDURE|Coronally advanced flap and deepithelialized free gingival graft|The connective tissue graft is obtained by deepithelialization of a free gingival graft.
41322366|NCT00370877|DRUG|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
41322367|NCT00370877|PROCEDURE|Standard Care|Patients will recieve standard care for post partum hemorrhage according to current recommendations.
41322368|NCT02395653|DRUG|fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
41322369|NCT04791033|PROCEDURE|Hysterectomy|Elective procedure with hysterectomy due to benign gynecological condition
41322370|NCT03033251|DEVICE|Non Invasive Ventilation|Patients will receive non invasive ventilation as a standard of care.
41322371|NCT03033251|DEVICE|High Flow Oxygen Cannula 50|Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
41322372|NCT03033251|DEVICE|High Flow Oxygen Cannula 30|Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
41322373|NCT06314165|OTHER|music medicine practice|Music medicine will be applied
41322374|NCT03554070|PROCEDURE|Thulium Fiber Laser Enucleation of the Prostate|Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.
41477425|NCT00845325|BEHAVIORAL|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
41477426|NCT00845325|BEHAVIORAL|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
41477427|NCT00654654|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm biopsies~2. Two injection treatments of facial wrinkles and creases~3. Conduct of study assessments"
41477428|NCT05342649|PROCEDURE|P-CTG|soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
41477429|NCT05342649|PROCEDURE|CTG|soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
41477430|NCT03033719|PROCEDURE|Laparotomy|Open surgery
41477431|NCT03033719|PROCEDURE|Laparoscopy|Minimally invasive surgery
41477432|NCT05871086|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 soft gelatin capsules daily for 3 months
41477433|NCT05871086|OTHER|Placebo|Placebo Capsules
41007624|NCT02358746|OTHER|combined endo/epicardial approach|
41477434|NCT05871086|DRUG|Standard Regimen|"Patients may be receiving any of these commonly used JIA treatments including:~* Ibuprofen - 30 to 40 mg/kg/day in 3 to 4 divided doses~* Diclofenac - 2 to 3 mg/kg/day in divided doses 2 to 3 times daily~* Methotrexate - Initial: 10 to 15 mg/m2 once weekly; adjust gradually up to 20 to 30 mg/m2 once weekly~* Leflunomide - Weight based, 10-20 mg once daily~* Sulfasalazine - 30 to 50 mg/kg/day in 2 divided doses~* Etanercept - 0.8 mg/kg/dose once weekly~* Adalimumab - Weight based, 10-40 mg every other week"
41007625|NCT02358746|OTHER|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
41322375|NCT03554070|DEVICE|"Thulium Fiber Laser Urolase"|"Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.~Max. power of 120 W and energy of 8 J. Wavelength - 1,94 µm, incision depth - 0,2 mm."
41322376|NCT06512025|BEHAVIORAL|WWWT psychoeducative intervention|"What Were We Thinking (WWWT) is a highly structured, interactive, gender-informed, couples-based, psycho-educational program for parents and a first newborn to promote confident parental caretaking, optimize functioning in the intimate partner relationship and improve infant care manageability.~The adaptation of the WWWT programme (Catalan and Spanish version) comprises 2 sessions, each lasting 2 hours, that will be designed for groups of 5-7 families - within the first 6 weeks postpartum -, each consisting of mother, partner (or other caregiver) and their infant(s)."
41322377|NCT05161637|DRUG|TLC590|TLC590 490mg or 588mg
41322378|NCT05161637|DRUG|Bupivacain|Bupivacaine 75mg
41322379|NCT05161637|DRUG|Ropivacaine|Ropivacaine 150mg
41322380|NCT05161637|DRUG|Normal saline|Normal saline 20mL or 24mL
41322381|NCT02746848|BIOLOGICAL|Amniotic Membrane Extract Eye Drop|Amniotic Membrane Extract use as eye drop for patients with corneal injury.
41322382|NCT02595840|DRUG|Afatinib|
41322383|NCT02595840|DRUG|Pemetrexed|
41322384|NCT04428359|DRUG|Measles-Mumps-Rubella Vaccine|Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.
41322385|NCT04428359|DRUG|Vit D|Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier
41322386|NCT02764983|BEHAVIORAL|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2
41322387|NCT02764983|BEHAVIORAL|Fitness-to-Drive Screening Measure|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
41007626|NCT03228680|DRUG|Follitropin delta|Single daily subcutaneous administration through pre-filled injection pen
41322388|NCT02764983|OTHER|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Strength. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
41322389|NCT02764983|BEHAVIORAL|Propensity for Angry Driving Scale|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
41322390|NCT02764983|BEHAVIORAL|Community Integration Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
41007627|NCT03228680|DRUG|Follitropin beta|Single daily subcutaneous injection in the abdomen
41007628|NCT06161792|DRUG|0.8 mg RCN3028|Oral
41007629|NCT06161792|DRUG|Placebo|Oral
41007630|NCT03091803|DEVICE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo GOCART DCE MRI
41007631|NCT03091803|DRUG|Gadobenate Dimeglumine|Given IV
41007632|NCT03091803|DRUG|Gadoterate Meglumine|Given IV
41477435|NCT06440278|BEHAVIORAL|Behavioral Activation for Health and Depression (BA-HD)|BA-HD includes 8 - 10 sessions delivered over 10-12 weeks. Sessions use behavioral activation techniques to connect patient core values with goal-setting targeting activities that improve mood, alongside personalized adjustments to cardiovascular health behaviors (i.e., tobacco cessation, medication adherence, physical activity, diet, and sleep). Educational materials and commercially available tools like activity trackers, pillboxes, and portion control aids will accompany the goal-setting process to facilitate behavior change.
41477436|NCT06440278|OTHER|Enhanced Usual Care|Patients will receive depression and heart disease education, as well as a list of local mental health resources.
41477437|NCT02554734|DRUG|levodopa, carbidopa, ODM-104|
41477438|NCT02554734|DRUG|levodopa, carbidopa, entacapone|
41477439|NCT03351387|COMBINATION_PRODUCT|SPY Intra-operative Angiography|The SPY Intra-operative Angiography Fluorescent Imaging System consists of an imaging head equipped with a charged coupled device (CCD) camera, a laser light source and a distance sensor. The imaging head is attached to an articulating arm on a mobile cart containing the central processing unit, keyboard, monitor, and mouse. SPY is used in tandem with indocyanine green (ICG), a water-soluble tricarbocyanine dye. Once the camera is in place, 5 cc of diluted ICG is pushed through an IV line and is flushed immediately; simultaneously the room lights must be dimmed. Perfusion images will be recorded then the SPY system will be removed from the operating room.
41477440|NCT04054284|DIETARY_SUPPLEMENT|Antidiabetic Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
41477441|NCT04054284|DIETARY_SUPPLEMENT|Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
41477442|NCT00995085|DRUG|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
41477443|NCT05877079|DRUG|Menthol|Patients will wear hand and foot wraps with 8% w/w menthol lotion (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
41477444|NCT05877079|DRUG|Placebo|Patients will wear hand and foot wraps with lotion without menthol (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
40804541|NCT00503412|DRUG|AZD2171|oral 14C
40804542|NCT06106581|BIOLOGICAL|VLA1553 full dose|Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate
40804543|NCT06106581|BIOLOGICAL|VLA1553 half dose|Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate
40804544|NCT06106581|BIOLOGICAL|Control|Nimenrix
40804545|NCT00193791|OTHER|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
40804546|NCT03532698|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
41007633|NCT03091803|DEVICE|Magnetic Resonance Imaging|Undergo QSM and T1WI imaging
41007634|NCT05466019|DRUG|Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)|FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ, Q2W Toripalimab 3mg/kg, intravenously administered on the first day of each cycle, Q2W.
41007635|NCT04966338|BIOLOGICAL|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) will be administered via intravenous (IV) infusion.
41007636|NCT04966338|BIOLOGICAL|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) will be administered via intravenous (IV) infusion.
41007637|NCT04103528|OTHER|morning surgery|31 patients will be operated on between 8:00 and 12:00 in the morning.
41007638|NCT04103528|OTHER|afternoon surgery|31 patients will be operated on between 14:00 and 18:00 in the afternoon.
41322391|NCT02764983|BEHAVIORAL|Satisfaction with Life Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
41322392|NCT02764983|PROCEDURE|Driving simulator evaluation|The driving simulator evaluation uses a driving simulator with simulated drives engineered to address Veteran driving concerns such as reactions to other drivers and road conditions (e.g., debris). The simulator is used at baseline and post-tests 1 and 2. The intervention sessions (X3) also occur using simulator.
41322393|NCT02764983|OTHER|Focus Group Discussion Interview Guide|Focus group discussion will occur once using the interview guide
41322394|NCT03159806|DEVICE|Microdialysis sampling|Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
41322395|NCT06377722|DRUG|Cabozantinib|This study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney.
41322396|NCT01060683|BIOLOGICAL|Hemoglobin determination + NaCl 0.9% bolus|
41322397|NCT01060683|BIOLOGICAL|hemoglobin determination + Venofundin bolus|
41477445|NCT03349359|DRUG|HIV antiretroviral therapy|HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs
41477446|NCT04825717|OTHER|Nutrition and fluid plans prepared using calorimetry-based measurements.|Nutrition and fluid plans prepared using calorimetry-based measurements.
41477447|NCT01368926|DRUG|RO4917523|single oral doses
41477448|NCT01368926|DRUG|RO4917523|multiple oral doses
41477449|NCT01368926|DRUG|placebo|oral doses
41477450|NCT05319613|OTHER|Virtual clinical visits with home lab kits and mailed HIV PrEP|Rural participants who enter PrEP care with University of Colorado HIV Prevention Program will receive PrEP services via telemedicine with home lab kits and mailed HIV PrEP
41477451|NCT01976728|DRUG|Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump|
41477452|NCT01976728|DRUG|Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump|
41477453|NCT01976728|DRUG|Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump|
41477454|NCT01976728|DRUG|Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)|
41477455|NCT00190879|DRUG|Atomoxetine hydrochloride|
41477456|NCT00190879|DRUG|placebo|
41477457|NCT02766426|BEHAVIORAL|Lifestyle change program|"Women attended a multidisciplinary counseling (by both the dietitian and the gynecologist). They were given nutritional advice about lifestyle and physical activity, in agreement with the Italian Guidelines for a healthy diet during pregnancy. The diet given comprised 1500 kcal/day and consisted of 3 main meals and 3 snacks (breakfast, snack, lunch, snack, dinner, and evening snack) that corresponds to the baseline metabolism of a pregnant woman. In view of the physical activity program, the dietitian added an amount of 200 kcal/day for obese or 300 kcal/day for overweight women.~The exercise intervention was focused on increasing walking and developing a more active lifestyle. The recommendation for physical activity was to perform 30 min of moderate intensity activity at least 3 days a week."
41477458|NCT04910516|BEHAVIORAL|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage fo
41477459|NCT06394726|BEHAVIORAL|Exercise İntervention|Aerobic and Core Stabilization Exercise Intervention
41477460|NCT05674799|BEHAVIORAL|NDPP-NextGen|"NDPP-NextGen will incorporate content on preconception/prenatal health into standard NDPP. Participants will be encouraged to make sustainable improvements in diet and activity, but without pre-set goals to better accommodate diverse, low-income populations. Upon pregnancy, recommendations will adjust to support appropriate GWG, breastfeeding, and postpartum weight loss. We will provide education on diet and activity during pregnancy/postpartum, including sufficient energy intake and exercise safety to support the growing fetus. NDPP-NextGen will include 3 strategies to better engage young women. (1) Pre-sessions to increase knowledge of diabetes risks, self-efficacy, and readiness to change using motivational interviewing techniques. (2) Delivering classes remotely (via phone- and video-conference) to facilitate participation regardless of inclement weather, dependent care, illness, transportation, etc. (3) Offering classes specially for young women to increase personal relevance."
41477461|NCT00572117|DRUG|Topiramate|Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
41477462|NCT03803033|OTHER|Clinical pharmacy-based home medication management review service|A baseline interview by the clinical pharmacist was conducted with patients at their homes to assess their use of treatment and to collect all relevant information needed to identify TRPs. Upon TRP identification at baseline, the clinical pharmacist generated a written report of findings and recommendations, which was delivered directly to the patient's physician in a sealed envelope. Patients were asked to refer back to their physicians if they required confirmation of any changes in treatment. Physicians maintained the blinding of patients with regard to whether changes were based on recommendations by the pharmacist. In both the intervention and the control groups, the clinical pharmacist performed a follow-up interview with patients 3 months after the initial interview, during a regular follow-up visit to their physician at the hospital. Assessments in the follow-up interview, regardless of the study group, involved changes in treatment and number of TRPs.
41322398|NCT00673894|DRUG|Sitagliptin|Glutamine 30g +sitagliptin 100mg
41322399|NCT00673894|DRUG|Placebo|Glutamine 30g +placebo (matching sitagliptin 100 mg)
40804547|NCT03532698|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
40804548|NCT00428571|PROCEDURE|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
40804549|NCT00428571|PROCEDURE|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
40804550|NCT00428571|PROCEDURE|Intensive Medical Management|lifestyle, diet, medication optimization
40804551|NCT04287309|OTHER|CAR-T cells|CD19 targeted CAR-T treatment
40804552|NCT02565264|OTHER|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
40804553|NCT06382870|OTHER|education|Providing simulation-based training to nurses on child neglect and abuse in the hospital environment
40804554|NCT00072046|BIOLOGICAL|bevacizumab|10mg/kg IV infusion on Days 1 \& 15 of each cycle
41007639|NCT05057416|BEHAVIORAL|Exercise Adherence|Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.
41007640|NCT03842176|PROCEDURE|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
41007641|NCT03842176|PROCEDURE|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
41007642|NCT00385970|DRUG|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
41007643|NCT00385970|DRUG|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
41007644|NCT00385970|DRUG|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
41007645|NCT03732066|BEHAVIORAL|Usual Text Messages|Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
41007646|NCT03732066|BEHAVIORAL|Personalized Reminders|"1. The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of \>180 mmHg or \<90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on.~2. Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days."
41007647|NCT03732066|BEHAVIORAL|Interactive Responses|"1. Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians.~2. The researchers will communicate with the patients every month."
41007648|NCT01430585|DRUG|PF-04691502|PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
41007649|NCT01430585|DRUG|PF-04691502 in combination with Letrozole|PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
41007650|NCT01430585|DRUG|Letrozole|Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
41007651|NCT03857802|BEHAVIORAL|Sleep hygiene intervention|"An individual education will be carried out following a bidirectional feedback method. It is intended to develop skills to make conscious and autonomous decisions. The explanation will consist:~1. Information and reading with discussion of the educational sheet: The 9 tips for a healthy sleep will be read, point by point. The nurse will be open to discuss those that generate doubt.~2. Confrontation: even if the patient does not ask any questions about it, it will be necessary to ask if he has understood the advice.~3. Participated information: Questions will be asked to the patient such as: Did you already know any of these tips?.~A telephone call per month will be made as an educational reinforcement to the intervention."
41007652|NCT01150214|PROCEDURE|DE-MRI|Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
41322400|NCT05662202|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT):~Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
41322401|NCT05662202|COMBINATION_PRODUCT|Vehicle and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT):~Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
41322402|NCT03480958|DEVICE|Intravenous morphine patient controlled device|24 hour morphine consumption will be recorded
41322403|NCT03480958|OTHER|Erector Spinae Plane Block|erector spinae plane block will be administered before the surgery
41322404|NCT03480958|OTHER|Thoracic Paravertebral Block|thoracic paravertebral block will be administered before the surgery
40804555|NCT00072046|BIOLOGICAL|recombinant interferon alfa|9 million units subQ injection 3 x/week for 4 weeks
40804556|NCT05105581|BEHAVIORAL|Quality of life scale|"1. To assess the quality of life of patient~2. To assess the degree of OCD"
40804557|NCT06112080|DEVICE|RESP™ Biosensor|The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.
41477463|NCT05813938|DEVICE|LabTest Checker|A set of blood laboratory tests is ordered. Test results are recorded in the LabTest Checker. LabTest Checker's diagnostic engine automatically generates a personalized questionnaire that is filled out by the patient. After obtaining all necessary information, including the patient's chronic diseases, medications taken, and symptoms, the tool presents an interpretation of test results.
41477464|NCT04637126|OTHER|Cardiac output measurement by transpulmonary thermodilution and transthoracic echocardiography|Cardiac output is measured for all patients with transpulmonary thermodilution TPTD and transthoracic echocardiography TTE according to the recommendations
41477465|NCT02152202|OTHER|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
41007653|NCT06231368|BIOLOGICAL|CNCT19 CAR-T cell therapy|CNCT19 was a second-generation CAR T-cell with scFv derived from clone HI19α and 4-1BB/CD3-ζ costimulatory domain.
41007654|NCT04230096|DEVICE|low level laser therapy|apply low level laser therapy on buccal surface of maxillary jaw on anterior segment for three minutes at every three weeks in fixed orthodontic patients in their regular follow up visits
41007655|NCT03702478|OTHER|Questionnaire|No intervention only observational
41007656|NCT03950284|DEVICE|immediate loading with all on four technique in FFF|All cases will undergo surgery under local regional anesthesia. Injection of local anaesthesia (Articaine 4% and 1:100000 epinephrine) for regional infiltration. Sequential drilling then insertion of the dental implant fixtures and abutments on which the prefabricated temporary prosthesis will be fixed.
41007657|NCT05501106|OTHER|Integrated Improvement strategies|"Integrated improvement strategies include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases.~1. A checklist (named as Risk Assessment and Preparedness for Postpartum Hemorrhage (Traffic Light in Delivery Room)) will be used in each virginal delivery to help obstetric staff and teams identify risk factors after admission, before and during labor, and improve the adherence to all known best practices.~2. The Postpartum Hemorrhage Rescue Format will be asked to be used in each postpartum hemorrhage rescue to record the rescue process.~3. Each case of postpartum hemorrhage exceeding 1000 ml will be reviewed. We will convene a QI Panel and a Task Force to assist the hospitals in postpartum hemorrhage case review and quality improvement strategy development."
41007658|NCT01209897|BEHAVIORAL|Smoking cessation booklet|
41007659|NCT02930850|DEVICE|Rad-67 Pulse oximeter|Noninvasive pulse oximeter that measures hemoglobin
41007660|NCT03428776|BEHAVIORAL|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
41007661|NCT03428776|BEHAVIORAL|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
41007662|NCT03428776|OTHER|Record keeping|Electronic immunization records on cloud-based software platform and use of biometric identification
41007663|NCT06294821|DRUG|4-Aminopyridine|Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
41152596|NCT01856647|PROCEDURE|Adipose tissue biopsy (fat biopsy)|An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (\~3 ml) will be obtained from the lower abdomen following local anesthesia.
41322405|NCT04489927|DEVICE|Tcore|Temperature Measurement of standard care versus the Tcore measurement
41322406|NCT05314712|BEHAVIORAL|Sleep intervention|Participants will receive a 9-week sleep intervention through text and Facebook that include traditional Blackfoot cultural components combined with scientifically validated strategies for sleep.
41322407|NCT03446989|BEHAVIORAL|Case management|completing assessment, detecting the presence of RA complications, consultation about taking medications and exercise, education for patients and their family, assist in formulating a management, and providing a basis for continuing care for each patient. Additionally, the management plan was rationally modified in accordance with the individualized therapeutic alliance of the patient, his/her family, the physician or other members of the medical team.
41322408|NCT06333392|PROCEDURE|Total underwater colonoscopy|one grooup will be randomized to receive a total underwater colonoscopy
41007664|NCT06294821|OTHER|Placebo|Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
41322409|NCT06333392|PROCEDURE|Conventional colonoscopy|one group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal
41322410|NCT04653142|DRUG|BI 765063|BI 765063
41477466|NCT02152202|OTHER|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
41322411|NCT04653142|DRUG|BI 754091|BI 754091
41007665|NCT01622946|DRUG|Tranexamic Acid|3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
41007666|NCT01622946|DRUG|placebo|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
41007667|NCT04708717|BEHAVIORAL|Stimulation Rate|Psychophysical training listening to stimulation rate as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
41322412|NCT01077388|BEHAVIORAL|Dietician electronic support|Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
41322413|NCT04940507|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy Acquisition|Partial ablation of tumor using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel) and blood and CSF draws for liquid biopsy
41322414|NCT04940507|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound Thalamotomy|Ablation of VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel) and blood draws.
40804558|NCT01745744|OTHER|Mesenchymal stem cells from adipose tissue|- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
40804559|NCT05700786|BEHAVIORAL|Mindful compassion for perfectionism|The intervention is a 8-week group psychotherapy in a hybrid format: 8 weekly online sessions lasting 2 hours plus an in presence half-day of silence lasting 4 hours.
40804560|NCT05984654|PROCEDURE|Platelet rich plasma therapy|"Approximately 30 ml of the patient's blood sample will be drawn from a peripheral vein in ACD (acid citrate dextrose) tubes. A double spin method will be used for the preparation of PRP.~Note this is not a device or a medicine as this is autologous plasma."
40804561|NCT04762992|DRUG|subcutaneous Enoxaparin|Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
40804562|NCT04762992|OTHER|standard of care|Obsteric standard of care.
40804563|NCT04240041|DIAGNOSTIC_TEST|Transcerebellar diamater|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, trans-cerebellar diameter is identified by obtaining an oblique view through posterior fossa that included visualization of midline thalamus, cerebellar hemispheres and cisterna magna.
40804564|NCT04240041|DIAGNOSTIC_TEST|Placental thickness|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, placental thickness will be measured at the level of the umbilical cord insertion excluding the myometrium and sub-placental veins
41322415|NCT02741219|DRUG|Normal saline|Control Group receives normal saline bolus after delivery
40804565|NCT02890953|DRUG|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
40804566|NCT02890953|DRUG|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
41007668|NCT04708717|BEHAVIORAL|Electrode Location|Psychophysical training listening to electrode location as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
41322416|NCT02741219|DRUG|Dexmedetomidine|Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery
41322417|NCT02741219|DRUG|Sufentanil|sufentanil PCA after surgery
41322418|NCT02741219|DRUG|Sufentanil and dexmedetomidine|sufentanil combined with dexmedetomidine PCA after surgery
41322419|NCT06123910|DIETARY_SUPPLEMENT|Colostrum bovine|Colostrum bovine supplements, 25 kcal per portion, containing 0.25 g fats, 2.0 g CHO and 3 g protein. Lactose reduced.
41322420|NCT06123910|OTHER|Placebo|Dairy comercial product. 25 kcal per portion, 1.3 g fats, 1.95 CHO and 1.3 protein. Lactose based.
41322421|NCT05360823|OTHER|Birth ball|Exercises for childbirth
41322422|NCT05360823|OTHER|Squatting|Exercises for childbirth
41322423|NCT03937258|DRUG|PF-04965842|Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions
41477467|NCT03409991|BEHAVIORAL|Opening Doors|This project is designed as a three-stage mixed methods study to test the efficacy of a career guidance intervention for individuals with psychiatric disabilities. We are using both a randomized clinical trial design coupled with a small qualitative sub-study.
40804567|NCT02293967|DRUG|MT-1303|
40804568|NCT01252160|DRUG|QUTENZA|Cutaneous patch
40804569|NCT01827436|BEHAVIORAL|Conventional physical therapy|
40804570|NCT01827436|BEHAVIORAL|Asymmetrical gait training|
40804571|NCT03299205|BEHAVIORAL|Exercise|The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
40804572|NCT05731817|OTHER|Observational study|N/A - observational study.
41007669|NCT03568422|DRUG|CFI-402257|Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16
41322424|NCT03937258|DRUG|Probenecid|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
41322425|NCT04290481|OTHER|oxygen saturation and perfusion index screening|Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.
41322426|NCT04775472|PROCEDURE|Early left atrial septostomy within 12 hours after VA-ECMO implantation|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation. Left atrial septostomy will be done using percutaneous technique.
41477468|NCT01868763|DEVICE|telemedical devices (weighing machine and step counter)|
41477469|NCT01868763|BEHAVIORAL|care calls once per week for 12 weeks|
41007670|NCT03568422|DRUG|Paclitaxel|80 mg/m2 IV days 1, 8 \& 15 every 28 days
41322427|NCT04775472|PROCEDURE|Selective left atrial septostomy|Left atrial septostomy will be done in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
41477470|NCT03679273|DIETARY_SUPPLEMENT|Abound|Study Group will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
41477471|NCT02610270|DIETARY_SUPPLEMENT|2 Gums|760 mg DHA
41477472|NCT02610270|DIETARY_SUPPLEMENT|3 Gums|1140 mg DHA
41477473|NCT05001464|DEVICE|reflectance pulse oximeter|Wearing reflectance pulse oximeter at the same time on the night of PSG examination
41477474|NCT03447340|BEHAVIORAL|Canteen and Behavior intervention|"canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes"
41477475|NCT03447340|OTHER|Canteen Only|canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
41477476|NCT02918747|DRUG|pegaspargase|"P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four."
41477477|NCT02918747|DRUG|Gemcitabine|800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
41477478|NCT02918747|DRUG|Oxaliplatin|85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
41477479|NCT02918747|DRUG|Dexamethasone|15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
41477480|NCT02918747|DRUG|Cyclophosphamide|750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
41477481|NCT02918747|DRUG|Doxorubicin|50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
41477482|NCT02918747|DRUG|Vincristine|1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
41477483|NCT02918747|DRUG|Prednisone|60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
41477484|NCT02918747|RADIATION|IMRT|After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
41477485|NCT04062682|BEHAVIORAL|Healthy Diet|Receive counseling to meet guidelines for healthy dietary patterns
41322428|NCT00002247|DRUG|Ganciclovir|
41322429|NCT06406881|OTHER|physical therapy|"Ocular muscle exercise which is consist of three exercise like palm exercise, blinking exercise, pencil pushup exercise.~3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. each exercise consist of 3 sets of 5 repetition 5 days a week.~Total of three sessions ."
41322430|NCT06406881|OTHER|myofascial release therapy|"Experimental group given MFR along with neck isometric and ocular muscle exercise.~myofascial release technique on sternocleidomastoid muscle and upper trapezius muscles. Patients will be treated 3 seconds to 2 minutes, three days in a week.~Ocular muscle exercise will perform 3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. This exercise will performed 3 sets of 5 repetition 5 days a week.~Total of three sessions ."
41322431|NCT04319419|DIETARY_SUPPLEMENT|Supplement with micronutrients|Obese children were divided in 2 groups. A group received the supplement plus nutrition education and other group was a control, only received nutrition education.
41322432|NCT04319419|OTHER|Nutrition education|Group received nutrition education program during 6 months
41477486|NCT02166034|BEHAVIORAL|garden intervention|The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
41477487|NCT02587312|OTHER|Very low nicotine content cigarettes|
40804573|NCT04919031|DEVICE|Inspiratory muscle trainer|POWER breathe IMT is a drug-free, hand-held breathing training device. The medical term for this type of breathing training is Inspiratory Muscle Training, or IMT. POWER breathe IMT exercises the main muscles you use to breathe in, primarily your diaphragm and intercostal
41477488|NCT02587312|OTHER|Standard nicotine content cigarettes|
41477489|NCT05571267|DRUG|Zimura|Zimura 2 mg, administered by intravitreal injection
41477490|NCT05571267|DRUG|Avastin|Avastin 1.25 mg, administered by intravitreal injection
41477491|NCT05571267|DRUG|Lucentis|Lucentis 0.5 mg, administered by intravitreal injection
40804574|NCT04919031|OTHER|diaphragmatic release|diaphragmatic release is a manual technique use for restoring the ability of the diaphragm to go through a full range of motion
40804575|NCT03032211|DEVICE|Alfapump|Implant Alfapump® System
41477492|NCT05571267|DRUG|Eylea|Eylea 2 mg, administered by intravitreal injection
41477493|NCT02954159|DRUG|Tacrolimus|Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
41477494|NCT02954159|DRUG|Vedolizumab|Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
41477495|NCT02954159|OTHER|Placebo|Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
41477496|NCT01376310|DRUG|GSK1120212|up to 2 mg/day
40804576|NCT04654221|DIAGNOSTIC_TEST|mGFR by iohexol clearance|Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
40804577|NCT00551148|DRUG|PD 0200390|oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
40804578|NCT00551148|DRUG|PD 0200390|oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
41322433|NCT05797363|OTHER|Continuous midwife support|The individuals included in the experimental group will be provided with consultancy services on many issues from the pre-pregnancy period to the postpartum period.
41477497|NCT01376310|DRUG|Docetaxel + GSK1120212|dose as defined in the dose escalation protocol.
41477498|NCT01376310|DRUG|Erlotinib + GSK1120212|dose as defined in the dose escalation protocol.
41477499|NCT01376310|DRUG|Pemetrexed + GSK1120212|dose as defined in the dose escalation protocol
41477500|NCT01376310|DRUG|Carboplatin + GSK1120212|dose as defined in the dose escalation protocol
41477501|NCT01376310|DRUG|Nab-paclitaxel + GSK1120212|dose as defined in the dose escalation protocol
41477502|NCT01376310|DRUG|Gemcitabine + GSK1120212|dose as defined in the dose escalation protocol
41477503|NCT01376310|DRUG|Everolimus + GSK1120212|dose as defined in the dose escalation protocol
40804579|NCT00551148|DRUG|PD 0200390|oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
40804580|NCT00551148|DRUG|PD 0200390|oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
40804581|NCT00551148|OTHER|Placebo|oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
40804582|NCT00313144|DRUG|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
40804583|NCT01939977|DRUG|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
40804584|NCT01939977|DRUG|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
40804585|NCT04678037|BEHAVIORAL|PROs assessment using sickle cell disease mobile app (SCD-app)|A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
41007671|NCT01018420|DRUG|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
41007672|NCT01018420|DRUG|Moxifloxacin|400 mg capsule at the 6 hour point
41477504|NCT03249740|DRUG|GB-102|Intravitreal injection of GB-102
41477505|NCT03249740|DRUG|Aflibercept|Intravitreal injection of Aflibercept.
41477506|NCT04222114|DRUG|Catumaxomab|The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.
41477507|NCT04222114|DRUG|The treatment of investigator choice|the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
41007673|NCT04223076|DRUG|Chlorhexidine 0.2%, Corsodyl|Comparison of Corsodyl and Curasept
41007674|NCT04223076|DRUG|Chlorhexidine 0.2%, Curasept|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
41322434|NCT02000713|OTHER|MRI|Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
41322435|NCT02000713|OTHER|Clinical Exam|Brief neurological exam will be performed.
41322436|NCT03008733|OTHER|Ultrasound UHF peripheral nerves|Ultrasound UHF peripheral nerves
41322437|NCT03008733|OTHER|Electro myography surface nerves|Electro myography surface nerves
41477508|NCT03965728|DRUG|BAY1830839|Tablet, oral.
41477509|NCT03965728|DRUG|Placebo|Tablet, oral.
41477510|NCT03965728|DRUG|Midazolam|For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2
41477511|NCT03965728|DRUG|Methotrexate|Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
41477512|NCT03907514|BEHAVIORAL|"FALE Application"|"FALE is a digital tool, in the form of an application for smartphones, which aims to demonstrate empathy and facilitate communication between the adolescent patient and the dentist. The application contains 14 questions regarding dental anxiety, feelings and patient coping preferences regarding dental care."
41477513|NCT00345059|DRUG|docetaxel|
41477514|NCT00345059|DRUG|vinorelbine|
41477515|NCT00345059|DRUG|gemcitabine|
41477516|NCT00345059|DRUG|capecitabine|
41477517|NCT04290286|OTHER|i2TransHealth|i2TransHealth: online intervention for TGD people
41477518|NCT04357613|DRUG|Experimental drug|Imatinib 800mg/d during 14days
41477519|NCT00734201|DRUG|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
41477520|NCT03176355|PROCEDURE|Canaliculo- Dacryocystorhinostomy|Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa
41477521|NCT00236249|DRUG|Lidocaine|
41322438|NCT04973891|DRUG|Canagliflozin combined with metformin|"Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.~Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS."
41477522|NCT04783116|DIETARY_SUPPLEMENT|Plant stanols (3g/day)|Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
41477523|NCT04783116|DIETARY_SUPPLEMENT|Placebo|Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
41477524|NCT01679197|DRUG|Metreleptin|
41477525|NCT04450849|PROCEDURE|guided tissue regeneration with using an absorbable collagen membrane associated with inorganic bovine bone associated.|Dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) associated with inorganic bovine bone associated with collagen matrix (Bio-Oss® Collagen).
41477526|NCT04450849|PROCEDURE|guided tissue regeneration with using an absorbable collagen membrane associated or not with inorganic bovine bone associated with collagen matrix.|dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) alone.
41477527|NCT02707133|OTHER|No intervention|
41477528|NCT01700478|DRUG|Misoprostol + vasopressin|400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
41477529|NCT01700478|DRUG|Vasopressin|Vasopressin was used in all patients during surgery.
41477530|NCT06012721|DRUG|ORIC-114|Food effect healthy subjects
41477531|NCT03452072|DRUG|0.25% Timolol gel with paraffin gauze dressings|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing
41477532|NCT03452072|OTHER|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
41477533|NCT04977830|DEVICE|Xenon-129|Patients will undergo a hyperpolarized MRI with administered Xenon gas
41322439|NCT04973891|DRUG|metformin|Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
41477534|NCT04715997|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
41477535|NCT04715997|DRUG|Placebo|Normal saline
41477536|NCT00365287|DRUG|anti-thymocyte globulin|
41477537|NCT00365287|DRUG|cyclophosphamide|
41477538|NCT00365287|DRUG|cyclosporine|
41477539|NCT00365287|DRUG|fludarabine phosphate|
41477540|NCT00365287|DRUG|mycophenolate mofetil|
41477541|NCT00365287|PROCEDURE|radiation therapy|
41477542|NCT00365287|PROCEDURE|umbilical cord blood transplantation|
41477543|NCT05393713|BIOLOGICAL|Anti-PD-L1 Monoclonal Antibody IMC-001|Given intra-lymphatically via DoseConnect device
41322440|NCT03411057|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|An interactive form of meditation that includes gentle yoga.
41322441|NCT03411057|OTHER|Control|Standard of care including an educational video.
41477544|NCT05393713|PROCEDURE|Punch Biopsy|Undergo punch biopsy
41477545|NCT00467831|DRUG|Losartan|Losartan potassium tablet, 25 mg by mouth every night at bedtime.
41477546|NCT00467831|DRUG|Zileuton|Zileuton tablet, 1200 mg by mouth twice daily.
41477547|NCT00467831|DRUG|N-Acetylcysteine|N-acetylcysteine solution, 600 mg by mouth three times daily.
41477548|NCT00467831|DRUG|Pravastatin|Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
41477549|NCT00467831|DRUG|Erythromycin|Erythromycin tablet, 333 mg by mouth three times daily.
41477550|NCT02769884|DEVICE|MMPPC algorithm artificial pancreas|An artificial pancreas system using the MMPPC algorithm, Roche insulin pump, and Dexcom CGM
41477551|NCT00393120|DRUG|INCB009471|100mg SR (sustained release) orally once daily
41477552|NCT00393120|DRUG|INCB009471|300mg SR (sustained release) orally once daily
41477553|NCT00393120|DRUG|Placebo comparator|Orally once daily
41477554|NCT04446988|DEVICE|Sacroiliac joint injection|Injection of sacroiliac joint with local anesthetic and steroid
41477555|NCT05258851|DRUG|Ceftazidime-avibactam|Experimental
41477556|NCT05258851|DRUG|Colistin|Control
41477557|NCT01569776|OTHER|Amino Acid formula|Amino Acid baby formula
41477558|NCT01569776|OTHER|Commercially available Amino Acid Formula|Hypoallergenic Baby formula
41477559|NCT04558333|OTHER|blood and exhaled breath specimens|identification of possible biomarkers
41477560|NCT05439811|PROCEDURE|Swan-Ganz Catheter|Swan-Ganz Catheter
41007675|NCT04458714|PROCEDURE|Aortoiliac angioplasty|In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.
41007676|NCT04237961|PROCEDURE|Botox and brow lift|Botox injection
41322442|NCT02790554|DEVICE|Moyo strap-on|Continous monitoring
41322443|NCT02790554|DEVICE|Hand-held Doppler|Intermittent monitoring
41007677|NCT04237961|PROCEDURE|Injection|Fat injection and botox
40804586|NCT04812769|DEVICE|eCARE-ID|The intervention, eCARE-ID, consists of: 1) telehealth video clinical consultation services for nursing homes residents; 2) electronic consultation services for healthcare personnel; 3) telehealth video antibiotic stewardship services for healthcare personnel
40804587|NCT04812769|OTHER|Standard of Care|Standard of care will be delivered to the control home.
40804588|NCT01581021|DEVICE|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
40804589|NCT01581021|DEVICE|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
41007678|NCT04237961|PROCEDURE|Suture|Suspension suture
41007679|NCT04659070|DRUG|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
41007680|NCT04659070|DRUG|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
41007681|NCT04659070|DRUG|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
41007682|NCT01571661|DRUG|GSK189075A|20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
41322444|NCT01237561|OTHER|provider support tools plus spirometer|Patient Activation Tool, Provider Web-based decision support tool, academic detailing
41322445|NCT02181985|DRUG|Full dose TNK-tPA|
41322446|NCT02181985|DRUG|Half dose TNK-tPA|
41322447|NCT02181985|DRUG|Heparin|
41322448|NCT02181985|DRUG|Enoxaparin|
41322449|NCT02181985|DRUG|Abciximab|
41322450|NCT01815580|DRUG|Atripla or Stribild|Antiretroviral therapy
40804590|NCT06406582|DEVICE|Zirconia laminate veneer|Zirconia veneers are milled with computer-aided manufacturing technology from multilayered zirconia discs with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with a hydrofluoric acid-nitric acid mixture. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
41007683|NCT01571661|OTHER|Placebo|Placebo
41007684|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
41007685|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
41007686|NCT00184015|DRUG|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
41007687|NCT00184015|DRUG|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
41007688|NCT00816101|OTHER|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
41007689|NCT00816101|OTHER|Mepilex® Border Lite|Self-adherent foam dressing
41007690|NCT00816101|DEVICE|Adhesive Bandage|Adhesive bandage
41007691|NCT00202904|DRUG|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
41007692|NCT00202904|DRUG|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
41007693|NCT03123159|DIAGNOSTIC_TEST|DxN HBV Assay|Molecular diagnostic test to detect Hepatitis B
41007694|NCT00675857|DRUG|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
41007695|NCT00675857|OTHER|placebo|Dosage: 4 capsules BID for 26 weeks
41007696|NCT05005858|PROCEDURE|Alveolar ridge splitting|Patients with Kennedy Class I. and II. mandibles with insufficient bone width were included in this study. Ridge splitting was carried out with the use of a piezoelectric surgery device by preparing osteotomies and after mobilization of the buccal cortical by placing an autologous bone block harvested from the retromolar region as a spacer between the buccal and lingual cortical plates. Block-grafts were stabilized by osteosynthesis screws. Implant placement was carried out after a 3-month healing period.
41007697|NCT05005858|DEVICE|Creating osteotomies with piezoelectric device|Osteotomies were carried out with piezoelectric surgery device (NSK Variosurg3 Ultrasonic Bone Surgery System, NSK Europe GmbH, Eschborn, Germany)
41007698|NCT02748577|OTHER|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
41322451|NCT03345940|DRUG|Fingolimod|Fingolimod is a currently approved oral DMT for the treatment of relapsing remitting MS. It modulates sphingosine-1 phosphate receptors.
41322452|NCT03345940|DRUG|Dimethyl Fumarate|Dimethyl Fumarate is a currently approved oral DMT for the treatment of relapsing remitting MS. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects.
41322453|NCT05006339|DEVICE|Dental Monitoring|Patients in this arm are not required to attend in-office retention appointments except if they have any problems with their retainers and when data collection is necessary. Instead they are required to submit scans of their teeth through the DM mobile application at the designated intervals.
41322454|NCT05006339|OTHER|Clinic Review|Patients in this arm are required to attend in clinic appointments for their retention review
41322455|NCT04392336|OTHER|Trust/Respect feedback|This feedback includes information on the level of trust/respect that a consumer has for their clinician in addition to symptom feedback.
41322456|NCT00776399|DEVICE|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
41322457|NCT02879916|DRUG|Levobupivacaine|Inject 3ml of levobupavacaine into the stellate ganglion area
41007699|NCT02748577|OTHER|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
41007700|NCT03771833|DEVICE|MARIA scan|The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.
41007701|NCT01983657|DRUG|rhGM-CSF|GM-CSF will be given subcutaneously according to the rule in different groups.
41007702|NCT01983657|PROCEDURE|Whole Lung Lavage(WLL)|using double lumen endotracheal tube (DLT) to selectively lavage one lung
41007703|NCT02157766|BEHAVIORAL|Intensive Meditation Practice|Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).
41007704|NCT02157766|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week class designed to enhance well-being through training in mindfulness.
41007705|NCT02157766|BEHAVIORAL|Health Enhancement Program|8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
41007706|NCT00915798|BEHAVIORAL|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
41007707|NCT00915798|BEHAVIORAL|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
41007708|NCT04748510|PROCEDURE|Functionally Aligned Total Knee Arthroplasty|Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.
41007709|NCT04748510|PROCEDURE|Mechanically Aligned Total Knee Arthroplasty|Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
41007710|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
41152597|NCT03491774|BEHAVIORAL|Montessori Intervention|The Montessori method is a system of teaching developed by Maria Montessori based on principles to promote learning and independence in children. In the context of dementia care, this method has been tried in research settings in older people and was found to be effective in improving certain behavioral outcomes such as eating behaviors, agitation, and mood. The intervention is based on designing and offering activities that take into consideration the interests, needs, past experiences and preferences of participants. Importantly, participants demonstrating positive engagement with the intervention, suggesting that this may be a promising form of support to investigate and develop further for the care of people with dementia.
41152598|NCT04528875|DEVICE|Ultrasound imaging|Imaging of low back with ultrasound
41152599|NCT01679613|DRUG|Nintedanib|low or medium dose depending on pilot part
41322458|NCT02879916|DRUG|NaCl 0.9%|Inject 3ml of NaCl 0.9% into the stellate ganglion area
41322459|NCT03051828|PROCEDURE|fencing|No intervention: practice fencing
41007711|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
41007712|NCT03571516|DRUG|Teduglutide|SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
41007713|NCT03571516|OTHER|Standard Medical Therapy|Standard medical therapy will be administered for 24 weeks.
41007714|NCT03571516|DEVICE|Syringe|Teduglutide will be administered using syringe (510k number: K980987).
41322460|NCT05751057|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|All NSTEMI patients will undergo to CMR before invasive coronary intervention.
41322461|NCT05541484|DRUG|SGLT2 inhibitor|See above.
41322462|NCT05541484|DEVICE|Biosense Breath Ketone Analyzer|The hand-held device tests ketones in exhaled breath
41322463|NCT00993395|BEHAVIORAL|peer mentor-based disease management|peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
41322464|NCT01789346|DEVICE|532nm KTP|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
41152600|NCT01679613|DRUG|Nintedanib|low dose oral administration
41007715|NCT03571516|DEVICE|Needle|Teduglutide will be administered using needle (510k number: K021475).
41007716|NCT04015219|DEVICE|Self retained cryopreserved amniotic membrane|PROKERA SLIM
41007717|NCT04015219|OTHER|lifitegrast ophthalmic solution|Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
41007718|NCT03533075|BEHAVIORAL|Teachable Moment Brief Intervention|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt
41152601|NCT01679613|DRUG|Ketoconazole|oral administration
41152602|NCT01679613|DRUG|Nintedanib|low dose oral administration
41152603|NCT01679613|DRUG|Nintedanib|low or medium dose depending on pilot part
41152604|NCT01679613|DRUG|Ketoconazole|oral administration
41152605|NCT00688051|OTHER|My Life with CF game|Play the game My Life with CF
41152606|NCT02883140|OTHER|Three-dimensional sialography CBCT and MRI sialography|"1. MRI sialography: Achieved on a 3 Tesla MRI (INGENA 3T Philips Medical Systems). Patient supine positioned. Sialo-MR sequences (3D T2 DRIVE, TSE, SENSE and SPIR) and conventional sequences (T2 turbo spin echo).~2. 3D CBCT sialography: Achieved same day as the MRI sialography, after acute episode subsided. 0.5ml of high concentration, water-soluble, iodinated contrast product (HEXABRIX 320®, 320g /L, Guerbet, France) is injected in the symptomatic salivary gland and maintained in the gland. Image acquisition performed on a wide-field CBCT device (NewTom VGi, QR, Verona, Italy). Front and profile scout views achieved. mA and exposure time modulated according to scout views. Reconstruction in Maximal Intensity Projection, 3-dimensional and MultiPlanar Reconstructions sections"
41152607|NCT05128227|BEHAVIORAL|Pharm-SAVES|A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.
41152608|NCT05128227|BEHAVIORAL|Interactive video cases|Two video interactive cases (approximately 10-minutes combined total) ask participants to complete open and close-ended questions about patients who exhibit suicidal behavior at the pharmacy. Participants will receive continuing education credits (0.1 CEUs) for completing the course.
41152609|NCT05223283|OTHER||
41152610|NCT04564027|DRUG|Ceralasertib|Tablets will be administered orally
41152611|NCT05644236|OTHER|mouthwash|After obtaining baseline information and randomizing the participants into two groups, dental scaling was performed, followed by clinical treatment. The participants were instructed to gargle twice daily for 7 days. All the participants were instructed not to eat or drink anything for at least 4 hours before the experiment. Oral hygiene, such as gargling and tooth brushing, was prohibited for 8 hrs before the visit.
41152612|NCT01007851|DRUG|triptorelin acetate|single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
41152613|NCT01007851|DRUG|NaCl %0.9|0.1 ml sterile saline sc injection 3 days after embryo transfer
41152614|NCT01248078|DRUG|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
41152615|NCT01248078|DRUG|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
41152616|NCT01248078|DRUG|saline solution|100cc administered before skin incision
41152617|NCT00494286|BEHAVIORAL|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
41322465|NCT01789346|DEVICE|595nm PDL|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
41322466|NCT05820620|PROCEDURE|TAP block|The transversus abdominis plane (TAP) block was introduced as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle.
41322467|NCT05820620|PROCEDURE|QLB block|"Quadratus lumborum block is a block of the posterior abdominal wall, interfascial plane block, which is performed exclusively under ultrasound guidance. It was described as a variant of the TAP block."
41007719|NCT03863210|OTHER|"60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk"|"All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits."
41477561|NCT05606588|BEHAVIORAL|Playful sensorimotor training|"For the max. duration of the first in-hospital phase (3weeks), all children will receive supervised training. When children go home they will be supplied with a manual, specific exercises and the necessary training devices. Regular supervision will allow to ensure that the training is performed at maximum benefit. Each session will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises chosen from a standardized pool of exercises according to the child's age, with increasing difficulty in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue."
41477562|NCT00180076|DRUG|Budesonide|
41007720|NCT04683185|DRUG|E6742|E6742 tablets.
41477563|NCT06159309|OTHER|Hyperbaric oxygen therapy|HBOT per local protocol, i.e. 40 sessions 2.4 ATA, at the discretion of the hyperbaric physician
41322468|NCT05820620|OTHER|Control Group|Control Group + Patient Control Analgesia (PCA)
41322469|NCT03176836|DIAGNOSTIC_TEST|Whole body STIR MRI|Standard technique that detects abnormalities related to excess of water in tissues (edema).
41322470|NCT03176836|DIAGNOSTIC_TEST|DW-MRI|MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.
41322471|NCT03176836|DIAGNOSTIC_TEST|PET-MRI|MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
41477564|NCT02497794|OTHER|chew gum|The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
41322472|NCT01481090|PROCEDURE|Acupuncture, Electro-Acupuncture|Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
41322473|NCT06436625|OTHER|outpatient pulmonary rehabilitation|Patients undergo six weeks of an outpatient rehabilitation program in one of the rehabilitation centers (Therme Wien Med, Klinik Pirawarth in Wien).
41007721|NCT04683185|DRUG|Placebo|E6742-matched placebo tablets.
41322474|NCT05942729|OTHER|Determine the etiology of hypokinetic and hypertrophic heart disease on transthoracic echocardiography data alone|The origin of the pathology will have been previously diagnosed for each patient thanks to complementary examinations performed as part of routine care (e.g. cardiac CT, cardiac MRI, coronary angiography, thorough biology, nuclear medicine). This information will be used (i) to guide the learning of the AI method developed during the project from a sub-population (80% of the collected database will be used to train the algorithms); (ii) to serve as an evaluation criterion from a test sub-population (remaining 20% of the collected database)
41322475|NCT04584320|OTHER|Stool sample|Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
41322476|NCT03744182|DRUG|HM15211|A sterile solution of HM15211 contained in pre-filled syringes
41322477|NCT03744182|DRUG|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
41477565|NCT01965184|BEHAVIORAL|Cognitive-Behavioral Therapy for Anger and Aggression|
40804591|NCT06406582|DEVICE|Lithium Disilicate laminate veneer|Lithium Disilicate veneers are milled with computer-aided manufacturing technology from lithium disilicate blocks with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with hydrofluoric acid. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
41007722|NCT05476562|OTHER|Tyrosine Kinase Inhibitors (TKIs)|The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.
41477566|NCT01965184|BEHAVIORAL|Supportive Psychotherapy (SPT)|
41477567|NCT06177002|DIAGNOSTIC_TEST|Collection of biological data|Biological sample will be collected from the COVID19 patients and from healthy donors
41477568|NCT01421199|PROCEDURE|Myringotomy|tube placement for children with multiple ear infections
41477569|NCT03492658|DRUG|Abatacept|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
41477570|NCT03492658|DRUG|Methotrexate|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
41007723|NCT06103942|DIAGNOSTIC_TEST|CO2 angiography|A supplemental CO2 angiography will be performed before and after the stent graft placement.
41007724|NCT01163604|DRUG|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
41007725|NCT01163604|DRUG|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
41007726|NCT06263335|OTHER|Mindfulness Based Stress Reduction Intervention|During an eight-week intervention period, clients were to engage in mindfulness practices lasting between 45 minutes to an hour each session. The intervention would incorporate various components of the Mindfulness-Based Stress Reduction (MBSR) program, including mindfulness of the present moment, body scans, mindful eating, walking meditation, yoga exercises, and discussions on applying mindfulness to everyday experiences and stress management. Sessions would typically range from 30 to 90 minutes per week, with an additional full-day retreat session towards the end of the program. In addition to mindfulness practice, participants were to receive teachings on stress management and its application to interpersonal and daily life situations.
41007727|NCT01988571|DRUG|Atorvastatin|40 mg tablet taken by mouth each morning for 24 months.
41007728|NCT01988571|DRUG|Placebo|One placebo tablet taken each morning orally for 24 months.
41322478|NCT01270230|BEHAVIORAL|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
41322479|NCT01270230|BEHAVIORAL|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
41322480|NCT05437393|DEVICE|Deep brain stimulation|Deep brain stimulation of the centromedian nucleus (bilateral)
41322481|NCT03084289|BIOLOGICAL|ChAd63-METRAP|The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.
41322482|NCT03084289|BIOLOGICAL|MVA ME-TRAP|The candidate vaccine applicable to the clinical trial is the Modified Vaccinia virus Ankara expressing Multiple epitopes and thrombospondin related adhesion protein.
41322483|NCT05883007|RADIATION|Accelerator-based BNCT with borofalan(10B)|Patients will be treated with BNCT regulated as 12, 15, or 18 Gy-Eq of the mucosal maximum dose.
41322484|NCT04133805|DIETARY_SUPPLEMENT|viscous fiber|ex. barley b-glucan, oat b-glucan, konjac glucomannan, psyllium, guar gum, and pectin
41322485|NCT02173392|DRUG|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
41322486|NCT01802554|BEHAVIORAL|Pleasant Events Program (PEP)|Behavioral Activation Therapy
41477571|NCT01795079|DEVICE|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
41477572|NCT00362830|DRUG|vinflunine + ixabepilone|solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
40804592|NCT03423446|DRUG|Telotristat Ethyl|Telotristat ethyl (TE) 250 mg (1 x 250-mg tablet), single dose
40804593|NCT01279291|BIOLOGICAL|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
40804594|NCT01279291|DRUG|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
41007729|NCT02708680|DRUG|Entinostat|An orally available histone deacetylases inhibitor (HDAC).
41007730|NCT02708680|DRUG|Atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
41007731|NCT02708680|DRUG|Placebo|A pill containing no active drug ingredient
41007732|NCT03060434|DRUG|Pentoxifylline Oral Tablet|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
41007733|NCT03060434|DRUG|Ibuprofen|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
41322487|NCT01802554|BEHAVIORAL|Information Support (IS)|Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
41322488|NCT05296837|DRUG|Doxycycline 40 MG ( 20mg twice daily)|Submicrobial dose doxycycline (40mg) to be administered as 20mg twice daily
41322489|NCT05296837|DRUG|Doxycycline 200 MG ( 100 mg twice daily)|200 mg dose doxycycline to be administered as 100mg twice daily
41322490|NCT05296837|DRUG|Placebo|Placebo to be administered in tablet form twice daily
41322491|NCT05806021|DRUG|Triamcinolone Acetonide|Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline
41322492|NCT05096494|DRUG|SP-103|SP-103 topical system is worn daily for 12 hours per day for 28 days
41322493|NCT05096494|DRUG|Placebo|Placebo topical system is worn daily for 12 hours per day, for 28 days
41322494|NCT02003729|DEVICE|Portable Sleep Monitor|ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
41477573|NCT00058214|DRUG|perifosine|Given orally
41007734|NCT02404363|DRUG|Clopidogrel|"Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --\> clopidogrel 150 mg/d x 7days then 75mg/d"
41322495|NCT05670405|OTHER|The Trauma PORTAL|"Participants will have 9 weeks to complete the 8 modules which each take on average 45 minutes to complete. Each module consists of psychoeducational handouts, videos, interactive exercises, and discussion topics that has been adapted from the R\&R curriculum. The participants will also receive a pdf of the handouts from the modules, which can be used to take notes or refer back to in the future.~There will be an optional 60-minute weekly virtual group session for participants to engage with other participants in their group and for group facilitator providers to discuss the materials covered and answer any questions. Participants will join a Zoom video group visit to access the group. Each weekly group will be facilitated by 2 clinicians specializing in trauma-focused therapy within the WCH TTP who have extensive experience with in-person and virtual synchronous R\&R."
41322496|NCT01793519|DRUG|Etanercept|Subcutaneous
41322497|NCT01793519|DRUG|Infliximab|Infusion
41322498|NCT01793519|DRUG|Adalimumab|Subcutaneous
41322499|NCT01793519|DRUG|Placebo|Matching Placebo
40804595|NCT01279291|DRUG|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
41322500|NCT05101395|OTHER|Giemsa stain|Giemsa special stain was employed for detection of H. Pylori microorganisms.
41322501|NCT05388019|OTHER|Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires)|Subject will receive care from a multidisciplinary team (physical therapy, occupational therapy, palliative care, social work) in addition to their standard of care VAD clinic visits. Subject will also perform a CPET, six-minute-walk-test, MoCA, and be administered quality of life questionnaires.
41322502|NCT05388019|BEHAVIORAL|Caregiver Self-Assessment|Primary caregivers of both interventional VAD patient cohorts will be administered a Caregiver Self-Assessment to assess burnout.
41322503|NCT06141941|DEVICE|CGM|Continuous glucose monitoring
41322504|NCT04087603|BEHAVIORAL|Weekend Morning Bright Light & Early Bedtime|
41322505|NCT03129204|BEHAVIORAL|SAF-T|The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
41322506|NCT05064332|DRUG|PF-06650833|400 mg by mouth (PO) Once daily (QD) for 11 days
41477574|NCT00058214|OTHER|laboratory biomarker analysis|Correlative studies
40804596|NCT01279291|DRUG|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
40804597|NCT05140304|DEVICE|OCT angiography|OCT angiography of foveal avascular zone in diabetic retinopathy
40804598|NCT01166789|DRUG|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
41322507|NCT05064332|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
40804599|NCT01166789|DRUG|Placebo|2 capsules daily, taken in morning and evening
40804600|NCT00863044|PROCEDURE|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
40804601|NCT00863044|PROCEDURE|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
40804602|NCT05780801|DRUG|Allogeneic Microbiota in Glycerol (10%) (AMG)|Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.
41007735|NCT02404363|DRUG|Placebo|"Placebo tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --\> placebo 150 mg/d x 7days then 75mg/d"
41322508|NCT03490435|DIAGNOSTIC_TEST|Tests for diagnosis of intestinal parasitic diseases|"Feces testing:~1. fresh fecal samples will be used to preparing direct (saline and iodine wet) mounts using supplementary techniques (flotation, sedimentation), as well as temporary mounts (hematoxylin and trichrome staining). Other technique of fresh fecal samples examination will be ParaSys™~2. A non-preserved stool samples will be stored below -20°C. Defrosted fecal specimen will be subjected to enzyme-linked immunosorbent assays (ELISA) - Giardia antigen test (coproantigens)"
41477575|NCT04828798|DEVICE|Deep brain stimulation of the VIM Thalamic nuclei|Deep brain stimulation of the thalamus, in a directional and nondirectional manner
41477576|NCT02471079|RADIATION|Radiotherapy|
41477577|NCT02171390|DRUG|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
41477578|NCT02171390|DRUG|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
41007736|NCT01956110|DRUG|Follitropin Delta (FE 999049)|
41007737|NCT01956110|DRUG|Follitropin Alfa (GONAL-F)|
40804603|NCT04917952|DEVICE|Blood Flow Restriction (BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, 80% at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the intervention group will receive an exercise protocol with blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Blood flow restriction will be applied at 80% by using pressure cuffs. The cuffs will be applied to the proximal thigh. Cuff pressure needed for a 100% vascular occlusion will be determined for each individual at a seated and relaxed position."
41007738|NCT05098639|BEHAVIORAL|BASICS|In the BASICS condition, individuals receive information about alcohol use on campus and discuss safe drinking practices. They also receive personalized normative feedback based on their alcohol use and their use of protective behavioral strategies.
41007739|NCT05098639|BEHAVIORAL|Deviance Regulation Theory (DRT)|The Deviance Regulation Intervention comprises tailored intervention messages based on perceived norms. Participants complete an initial session that focuses on perceived norms of protective behavioral strategy (PBS) use and heavy drinking among peers. The therapist engages participants in a tailored discussion based on their perceived norms. If individuals believe PBS use is uncommon, the therapist discusses the positive social image that PBS use portrays. If the participant believes PBS is common, the therapist engages the participant in discussion of the negative aspects of non-PBS use. A similar strategy is taken for common and uncommon heavy alcohol use. Finally, the participant carries a mobile device which provide real-time adaptive positive or negative messages (consistent with the initial session) based on the perceived drinking and PBS norms of their current drinking environment.
40804604|NCT04917952|DEVICE|Sham Blood Flow Restriction (sham BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, Sham BFR, 10mm Hg at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the control group will receive an exercise protocol with sham blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Sham technique for blood flow restriction will be applied by using pressure cuffs inflated at 10mm Hg. The cuffs will be applied to the proximal thigh. Cuff pressure will be applied for each individual at a seated and relaxed position."
41007740|NCT02089061|DRUG|BMS-919373|
41322509|NCT04072185|OTHER|Physical activity|TThe intervention group will participate in a group physical activity program for 4 months. It will consist of 60 minutes of walking sessions 2 days a week. The sessions will be directed by two referents of each primary care center. Also once a month, coinciding with the walk, you will visit some sociocultural municipal equipment to promote a community connection.
41322510|NCT05443451|DEVICE|3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH|The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge.
41007741|NCT02089061|DRUG|Rosuvastatin|
41007742|NCT02089061|DRUG|Atorvastatin|
41007743|NCT02892981|OTHER|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
41007744|NCT05952648|PROCEDURE|Lower tract respiratory samples|Within 1 hour from HAP or VAP suspicion, quantitative tracheal aspirate or bronchoalveolar lavage will be performed to confirm the diagnosis. Clinicians will be encouraged to perform BAL whenever possible
41007745|NCT05952648|DIAGNOSTIC_TEST|Multiplex PCR assay (Film-array Pneumonia Panel Plus)|The lower tract respiratory samples will be analyzed with Multiplex PCR assay (Film-array Pneumonia Plus).
41152618|NCT00494286|BEHAVIORAL|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
41322511|NCT06307015|RADIATION|De-escalation|Surgical resection of primary oropharyngeal tumour followed by de-escalated radiation therapy (30Gy) with concurrent platinum-based chemotherapy to oropharynx + neck, followed by surgical neck dissection
41322512|NCT06307015|RADIATION|Standard of care|Radiation therapy (70Gy) with concurrent platinum-based chemotherapy to oropharynx + neck
41007746|NCT05952648|DIAGNOSTIC_TEST|Lower respiratory tract standard culture|The lower tract respiratory samples will be analyzed using convention microbiological methods (including conventional Gram stain and semiquantitative culture on both selective/differential and screening agar media)
41322513|NCT04742049|OTHER|Telerehabilitation-based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. Online exercise training protocol will be apply for patients. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks with a physiotherapist. Exercise protocol will start with the warm-up exercises and finish with cooling exercises.
41322514|NCT04742049|OTHER|Follow-up based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. An exercise document including the same exercise protocol in study group will be sent the patients. Patients will be called by the physiotherapist once a week for follow-up. .
40804605|NCT04573439|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary supplement: Protein intake|"Oral consumption of hourly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates and fats from a protein-free formula mixture.~The last 4 meals will contain labelled 13C phenylalanine."
40804606|NCT01271907|DRUG|fludarabine|Fludarabine 25 mg/m\^2 x 5 days
40804607|NCT01271907|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
40804608|NCT01271907|DRUG|Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Up to 1x10e10 CTL-05 cells
40804609|NCT01271907|DRUG|Aldesleukin|Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
40804610|NCT05200611|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Participants with positive fecal immunochemical test results were further examined by colonoscopy.
40804611|NCT00222235|DRUG|d-cycloserine|
40804612|NCT00222235|DRUG|glycine|
40804613|NCT00222235|DRUG|placebo|
40804614|NCT00601692|DRUG|cisplatin|Given IV
40804615|NCT00601692|DRUG|docetaxel|Given IV
40804616|NCT00601692|DRUG|irinotecan hydrochloride|Given IV
40804617|NCT00601692|RADIATION|radiation therapy|Given 5 days a week for 3 weeks
40804618|NCT06400589|DRUG|tanfanercept|TNF inhibitor
40804619|NCT06400589|DRUG|Vehicle|Same composition as tanfanercept but without the active ingredient
41322515|NCT01712217|DRUG|AT13387|HSP90 inhibitor
41322516|NCT01712217|DRUG|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
40804620|NCT01450696|DRUG|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
40804621|NCT01450696|DRUG|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
40804622|NCT01450696|DRUG|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
40804623|NCT03465137|BEHAVIORAL|Coordinated Anxiety Learning and Management (CALM)|Exposure-focused cognitive behavioral therapy
40804624|NCT06009991|DRUG|Remimazolam besylate|"Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need)."
40804625|NCT06009991|DRUG|Propofol|"Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance"
40804626|NCT02182024|DRUG|Dabigatran etexilate high dose|
40804627|NCT02182024|DRUG|Dabigatran etexilate low dose|
40804628|NCT03089333|DRUG|Dapagliflozin 10mg|Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
40804629|NCT03089333|DRUG|Glibenclamide 5Mg Tablet|Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
40804630|NCT01210963|DEVICE|SENSIMED Triggerfish|Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
40804631|NCT05047939|DRUG|remimazolam-based TIVA|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.
40804632|NCT05047939|DRUG|propofol-based TIVA|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).
40804633|NCT02615938|DRUG|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
40804634|NCT02615938|OTHER|Placebo|Apply Placebo not to modify lysosomal pH
40804635|NCT00304616|DRUG|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
40804636|NCT01158820|DRUG|Dexmedetomidine load|Dexmedetomidine 1 µg/kg prior to bronchoscopy
40804637|NCT01158820|DRUG|Ketamine load|Ketamine 30 mg bolus prior to bronchoscopy
40804638|NCT01158820|DRUG|Midazolam load|2 mg bolus prior to bronchoscopy
40804639|NCT01158820|DRUG|Fentanyl load|50 µg bolus prior to bronchoscopy
41007747|NCT05952648|DIAGNOSTIC_TEST|Blood sample standard culture|When HAP or VAP are suspected, blood samples from peripheral vein will be collected and analyzed with conventional microbiological methods
41007748|NCT04028011|DIAGNOSTIC_TEST|Novel Wearable device|patient will wear novel wearable device overnight along with normal standard of care
41007749|NCT05936255|BEHAVIORAL|Give to Others Module|Negative interpersonal beliefs are targeted via cognitive-behavioral strategies, including evaluation of cognitive distortions, and activity planning and tracking.
41007750|NCT05961891|PROCEDURE|The Use of Composite Bone and Nail Bed Graft Combined With Cutaneous Flaps for Reconstruction of Finger Tip Amputations|"1. The amputated finger tip is cleaned and a composite graft including the nail bed and bone of distal phalanx is taken from the amputated part.~2. The bone of the amputated part is fixed to the remaining stump of the distal phalanx with an axial 21gauge needle or by a K-wire (0.8 mm).~3. The nail bed graft is sutured with 6-0 vicryl to the remaining nail bed.~4. A local or regional cutaneous flap is used to cover the volar aspect and tip of the distal phalanx bone e.g. V-Y advancement flap, thenar flap or cross finger flap .The flap should protrude beyond the tip, providing extra skin which is recontoured to a rounded tip.~5. The nail plate is inserted in the nail fold to prevent the formation of synechiae between the nail fold and the injured nail bed.~6. The finger is immobilized for two weeks in a below elbow dorsal slab.~7. Patients are followed up for 3 months. Postoperative complications and their management will be recorded."
41007751|NCT02451566|DEVICE|Ovation Prime Abdominal Stent Graft System|
41007752|NCT05565911|OTHER|no intervention|this is an observational study, there is no intervention.
41007753|NCT02170246|DRUG|Telmisartan|
41007754|NCT01126164|BEHAVIORAL|Parent Handbook and Peer Basics|Parent and Peer delivered interventions
41007755|NCT05782595|OTHER|Aquatic therapy|"• Each session was divided into three phases:~1. Aquatic environment adaptation phase~2. stretching phase~3. a phase of static and dynamic exercises for balance"
41007756|NCT03524703|OTHER|chewing gum|Chewing gum four times per day for 5 days, 15 minutes each time.
41007757|NCT06037746|OTHER|Graston|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 10 minutes in the longitudinal, vertical and oblique directions.
41007758|NCT06037746|OTHER|Percussive massage|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 5 minutes in all directions without being bound to a single direction.
41007759|NCT00876317|DRUG|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
41007760|NCT00876317|DRUG|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
41007761|NCT02100007|DRUG|ME-344|"Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator."
41007762|NCT02100007|DRUG|Topotecan|Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
41322517|NCT02119026|DRUG|Capecitabine|"800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance"
41322518|NCT02119026|DRUG|Capecitabine|1000mg/m2 bid d1-14,
40804640|NCT01158820|DRUG|Dexmedetomidine maintenance|0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
40804641|NCT01158820|DRUG|Ketamine maintenance|8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
41322519|NCT02119026|DRUG|Bevacizumab|7,5 mg/kg given on d1 q3w
41322520|NCT02119026|DRUG|Oxaliplatin|130mg/m2 iv. d 1 q3w
41322521|NCT02119026|DRUG|Irinotecan|200mg/m2 iv. d 1 q3w .
40804642|NCT01158820|DRUG|Midazolam demand|0.5 mg demand bolus at discretion of pulmonologist
40804643|NCT01158820|DRUG|Fentanyl demand|12.5 µg demand bolus at discretion of pulmonologist
40804644|NCT01158820|DRUG|Benadryl demand|25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
40804645|NCT05558137|DRUG|Mivacurium|0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
41322522|NCT04198896|OTHER|incidece of cancers|With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified
41322523|NCT01061320|DRUG|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
40804646|NCT01618435|BIOLOGICAL|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
40804647|NCT01869036|DRUG|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
40804648|NCT01869036|DRUG|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
41322524|NCT01061320|DRUG|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
41322525|NCT02797691|OTHER|CaCBT|Culturally Adapted Cognitive Behaviour Therapy
41322526|NCT02797691|OTHER|Medication/ Psychotherapy|Medication/ Psychotherapy used as usual
41322527|NCT04600921|DRUG|Ertugliflozin 5 mg|The subject will receive Ertugliflozin 5mg orally once daily for 52 weeks.
41322528|NCT04600921|DRUG|Placebo 5mg|The subject will receive Placebo 5mg orally daily for 52 weeks.
41477579|NCT00493246|DRUG|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
41477580|NCT00493246|DRUG|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
40804649|NCT06169943|OTHER|mHealth social support program|This is a 3-month program comprises mobile app, group discussion, individual telephone contact, and reminders.
40804650|NCT06169943|OTHER|Control|The same mobile app as the intervention group but with limited function.
41007763|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
41322529|NCT00749164|PROCEDURE|MSC transplantation|1-2X10\^6 MSC per kg
41322530|NCT01661166|DRUG|Fesoterodine|4 mg
41007764|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
41007765|NCT00785486|DRUG|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
41007766|NCT00785486|DRUG|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
41322531|NCT01661166|DRUG|Placebo oral tablet|Placebo
41322532|NCT00370890|DRUG|Adjuvant chemotherapy (gemcitabine and cisplatin)|Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles
41322533|NCT01730287|DRUG|Control|The teeth in this group restored only by filling material,without liner application.
41322534|NCT01730287|DRUG|Calcium Hydroxide|Calcium Hydroxide paste applied.
41322535|NCT01730287|DRUG|Mineral Trioxide Aggregate(MTA)|MTA applied .
41322536|NCT01730287|DRUG|CEM cement|CEM cement applied .
41007767|NCT00785486|DRUG|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
41152619|NCT02351609|BEHAVIORAL|Intervention|"Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.~Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation."
41322537|NCT04268472|DRUG|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
41322538|NCT04268472|DRUG|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
41322539|NCT04268472|DRUG|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
41322540|NCT04268472|DRUG|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
41322541|NCT02849626|DRUG|Perampanel|E2007
41322542|NCT05622344|BEHAVIORAL|Traditional Therapy|Exercises that teaches subjects to move their heads while viewing still or moving targets.
41322543|NCT05622344|DEVICE|SWAN|The SWAN device uses video-oculography to monitor head motion while guiding participants to move their head in yaw, pitch, roll planes for 15 minutes. Feedback is provided regarding frequency and plane of head rotation
41477581|NCT05304026|DEVICE|Technique 1|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F pigtail catheter placed at the level of renal arteries to identify the lowest renal artery.
41477582|NCT05304026|DEVICE|Technique 2|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F introducer placed at the end of the proximal sealing zone to identify the lowest renal artery.
41152620|NCT02351609|OTHER|Enhanced Traditional Care control|List of smoking cessation resources and educational brochure.
41152621|NCT02302625|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
41322544|NCT05387577|DRUG|Estradiol Tablets|Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks
41322545|NCT05387577|DRUG|Transdermal patch|Estradiol patch therapy for 8 weeks
41322546|NCT05387577|DRUG|Estradiol Tablets|Oral estradiol 1 mg BID for 8 weeks
41322547|NCT04856956|OTHER|Diagnostic decision support software|Comparing use of decision support group (intervention group) to use only of common literature (control group) among pediatric trainees diagnosing patients with possible rheumatologic disorder
41322548|NCT01014949|OTHER|Coronary microcirculation assessment|"Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014 coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine \[140 ug/kg/min\] to induce steady state maximal hyperemia."
41322549|NCT01962285|DRUG|propofol targel controlled infusion|slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
41477583|NCT05304026|DEVICE|Technique 3|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F pigtail catheter through the pigtail catheter placed at the level of renal arteries.
41477584|NCT05304026|DEVICE|Technique 4|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F introducer placed at the level of the contralateral iliac limb.
41477585|NCT05915793|OTHER|Diaphragm strengthening and accessory muscles stretchings|Diaphragm strengthening and accessory muscles stretchings
41477586|NCT05915793|OTHER|Diaphragm strengthening|Diaphragm strengthening
41322550|NCT05186766|DEVICE|Video-Assisted Operating Room Introduce Program|Video demonstration about operation room
41322551|NCT03833622|OTHER|Shared Decision Aid Assessment|Provide feedback on a shared decision making tool to aid in discussion on goals of care in the emergency department
41322552|NCT03713957|DRUG|GRF6021|GRF6021 for IV infusion
41322553|NCT03713957|OTHER|Placebo|Placebo for IV infusion
41322554|NCT04235439|DRUG|Gan & Lee Insulin Lispro Injection|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
41322555|NCT04925518|DEVICE|Closed Loop Mechanical Ventilation|Closed loop ventilation mode (Intellivent-ASV+®). Intellivent-ASV+® was initiated by activating the controllers for minute volume, PEEP (range 5 to 18 cmH2O) and fraction of inspired oxygen (FiO2) (range 21 to 100 %). The target shift ranges for CO2-management were set between -2.5 and +2.5 kPa, and for O2-management between -2 and +2 %.
41322556|NCT04925518|DEVICE|Conventional Mechanical Ventilation|Mechanical ventilation with a conventional mode, usually either biphasic positive airway pressure ventilation (DuoPAP®) or adaptive support ventilation (ASV®)
41322557|NCT04597892|DIAGNOSTIC_TEST|serum creatinine assay|point-of-care and standard laboratory assay of serum creatinine
41007768|NCT05667285|DEVICE|BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System|"The investigator will use visual inspection or QCA to assess the diameter of the artery and the length of the lesion during the operation to select the stent. For each lesion, the investigator will determine the number of stents to be used based on the actual situation. The length of the stent should cover from the proximal end of the normal reference vessel to the distal end of the normal reference vessel to ensure full coverage of the lesion.~For each lesion, the investigator will determine the number of stents to be used based on the actual situation. A second stent or more stents can be used when the first stent does not completely cover the lesion. In this case, the second stent or even more stents must be this investigational stent, unless it is clinically contraindicated. Please refer to the IFU operating procedure of the stent.~If the stents are placed overlappingly, the overlapping part should be at least 2 mm."
41007769|NCT00648219|DRUG|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fed
41007770|NCT00648219|DRUG|Benicar® Tablets 40 mg|40mg, single dose fed
41007771|NCT05715567|OTHER|Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)|Following the intervention of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)
41007772|NCT04596150|DRUG|CX-2009|Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)
41007773|NCT04596150|DRUG|CX-072|Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)
41007774|NCT00726570|DEVICE|Sequential compression device therapy|"Pneumatic stockings will be applied to patients.~Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery."
41007775|NCT00726570|DRUG|Dalteparin|"* 2500 UI qd if ≤ 50 kg body weight~* 5000 UI qd if \> 50 kg"
41007776|NCT00726570|PROCEDURE|TEG|"A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~* Patient admission (before SCD start)~* 40-60 min after admission~* Morning after surgery"
41007777|NCT02932891|DRUG|DSXS topical|topical treatment
41007778|NCT03593408|DRUG|Dexmedetomidine|Administered for sedation management per hospital protocol
41007779|NCT03593408|DRUG|Fentanyl|Administered for sedation management per hospital protocol
41007780|NCT03593408|DRUG|Midazolam|Administered for sedation management per hospital protocol
41007781|NCT03593408|DRUG|Morphine|Administered for sedation management per hospital protocol
41007782|NCT02002234|PROCEDURE|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
41007783|NCT02002234|PROCEDURE|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
41007784|NCT05703061|BEHAVIORAL|10-hour Time in Bed|Participants will be asked to increase their time in bed to 10-hours per night for 7 consecutive days.
41007785|NCT01539226|COMBINATION_PRODUCT|Placebo Vaginal Ring|Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
41007786|NCT01539226|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Dapivirine Vaginal Ring containing 25 mg of dapivirine
41007787|NCT01504724|DRUG|bevacizumab|intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
41007788|NCT00368940|BEHAVIORAL|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
41007789|NCT00368940|BEHAVIORAL|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
41322558|NCT05782166|BEHAVIORAL|Betel Quid Educational Booklet|"Eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~Participants will be given an educational booklet containing general information regarding betel quid and areca nut, risk associated with betel quid chewing behaviour, cessation strategies that are modeled after tobacco cessation and some relevant researcher's contact details.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
41007790|NCT02393963|DRUG|Tranexamic Acid|0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
41007791|NCT02393963|OTHER|Placebo|0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
41007792|NCT03866759|BEHAVIORAL|Determine the Incidence and Point Prevalence|Determine the Incidence and Point Prevalence of human immunodeficiency virus (HIV) Infection and the Most Common Sexually Transmitted Infections in Individuals With Sexual Risk Behavior.
41007793|NCT05072353|DEVICE|SEFFICARE|"The SEFFI is a 5-step technique:~1. Preparation: the lower/lateral abdomen is chosen as the donor site.~2. Anesthesia: the donor site is injected with a local anesthetic.~3. Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL.~4. Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom).~5. Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained.~The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound."
41007794|NCT02729649|DEVICE|ArmAssist robotic training|
41007795|NCT02729649|OTHER|Conventional therapy|
41007796|NCT02729649|OTHER|Extended conventional therapy|
41007797|NCT01441193|BIOLOGICAL|HIV-1 Tat/delta-V2 Env combined vaccine|
41007798|NCT01441193|BIOLOGICAL|HIV-1 delta-V2 Env vaccine|
41152622|NCT03523858|DRUG|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
41152623|NCT03115879|OTHER|Hip mobilization|High velocity low amplitude hip mobilization of the experimental group
41152624|NCT03115879|OTHER|Hip manipulation simulation|Hip manipulation simulation
41007799|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 7.5 microg|
41007800|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 30 microg|
41007801|NCT04237077|OTHER|telephone coaching program|telephone coaching program : 7 phone calls by nurse
41007802|NCT04237077|OTHER|no telephone coaching program|no telephone coaching program : 7 phone calls by nurse
41007803|NCT03636750|DRUG|HB002.1T|HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
41007804|NCT01825369|DRUG|IV L-carnitine|See arm description
41007805|NCT01004367|OTHER|Experimental|Environmental- and individual based components carried out in the school.
41007806|NCT03712475|DRUG|Pregabalin|pharmacokinetic study under fasting conditions
41007807|NCT03132948|BEHAVIORAL|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
41007808|NCT00079833|DRUG|Esomeprazole magnesium (Nexium)|
41007809|NCT04338711|DRUG|tofacitinib modified release (MR)|"Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution"
41007810|NCT04204018|OTHER|Experimental Arm|"* First, these providers will receive educational materials (e.g. a slide deck) meant to mimic what physicians will receive in the real-world market as they learn about the Progenity technology.~* Second, within each of their four cases, intervention-arm physicians only will receive simulated test results from the Progenity PE test at the clinically-appropriate point in each case."
41007811|NCT00003724|PROCEDURE|surgical procedure|
41007812|NCT05118841|DRUG|ZX-4081|Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
41007813|NCT04567121|BEHAVIORAL|Intensive intervention group|Establish a team of chronic disease prevention managers (5 people), with each educator responsible for the intervention of 200 people. For sub-health population and chronic disease patients, there would be conducted health education interview twice, 4 calls, online communication 50 times once a year, controlling risk factors and making treatment plan.
41007814|NCT04567121|BEHAVIORAL|standard intervention group|Conduct general health education without active management
41007815|NCT02148328|BIOLOGICAL|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
41007816|NCT02148328|BIOLOGICAL|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
41007817|NCT02148328|BIOLOGICAL|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
41007818|NCT02148328|BIOLOGICAL|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
41007819|NCT03460587|DEVICE|Telerehabilitation|The Telerehabilitation system will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
41322559|NCT05782166|BEHAVIORAL|Betel Quid Cessation Intervention Module|"All eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~An interactive, educational talk will be given regarding the content of the educational booklet.~Participants will undergo a 5-intervention sessions cessation program (M-BENIT) and will be given topical worksheets on every session to monitor their triggers, lifestyle changes, social support system and others.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
41322560|NCT00453843|DEVICE|rehabilitation robotics|sequence of intervention
41322561|NCT00453843|PROCEDURE|Movement therapy|sequence of intervention
41007820|NCT03445416|BEHAVIORAL|POL arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
41007821|NCT03445416|BEHAVIORAL|Comparison arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
41007822|NCT05355844|DRUG|Benzoyl peroxide|Benzoyl peroxide application in the incision area before surgery
40804651|NCT05119374|DEVICE|SenseGuard Investigational Device|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~* RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~* ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~* SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
40804652|NCT02681419|PROCEDURE|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
41007823|NCT04020302|BEHAVIORAL|Self-monitoring shopping intervention|Intervention will occur once per week for a duration of 8 weeks. The intervention format will alternate between individual and group sessions, so that the first week of intervention will be provided in a group format, the second week will be provided in an individual format, and so forth. Sessions will be 90 minutes in duration. Data will be collected during individual sessions, which will occur every other week. During individual sessions, each participant will meet at the facility for the first 15 minutes, will travel to a local grocery store for 45 minutes, and then reconvene at the facility for the final 30 minutes. Group sessions will follow the same structure; however, all ten participants will be present. Each of the 8 sessions will consist of the following: awareness training; facilitation of strategy generation; facilitation of error detection; reinforcement of self-monitoring techniques; and opportunity for participants to practice self-monitoring techniques.
41007824|NCT00659867|DEVICE|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|chromoscopy-guided endomicroscopy with targeted biopsies
41152625|NCT05414071|DEVICE|NMS Assist|The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
41152626|NCT00207935|BEHAVIORAL|Swallow instruction|
40804653|NCT02681419|PROCEDURE|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
40804654|NCT06364150|BIOLOGICAL|Autologous Peripheral Blood Stem Cell injection|For peripheral blood stem cell mobilization, G-CSF and EPO will be injected for a total of 4 days, followed by collection of mobPBSC via apheresis. In ex-vivo setting, mobPBSC will be primed with Ang1 for 1 hour. A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery.
40804655|NCT01943058|DRUG|megestrol acetate|Given PO
41007825|NCT00659867|DEVICE|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|Standard endoscopy with random and targeted biopsies
41007826|NCT01486017|DRUG|ASP015K|oral
41007827|NCT05657028|DRUG|Dexmedetomidine|-In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
41007828|NCT05657028|DRUG|Lidocaine IV|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
41007829|NCT02379585|DRUG|Doxorubicin|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
41007830|NCT02379585|DRUG|cyclophosphamide|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
41007831|NCT02379585|DRUG|paclitaxel|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
41007832|NCT02379585|DRUG|docetaxel|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
41007833|NCT02379585|DRUG|Trastuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
40804656|NCT01943058|DEVICE|levonorgestrel-releasing intrauterine system|Given IUD
40804657|NCT01943058|OTHER|laboratory biomarker analysis|Correlative studies
40804658|NCT01943058|OTHER|questionnaire administration|Ancillary studies
40804659|NCT04691245|DEVICE|3D US|3D US guided access to femoral artery
41007834|NCT02379585|DRUG|Pertuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
41007835|NCT01752205|DRUG|Paclitaxel|45mg/m2/w,total 6 weeks
41007836|NCT01752205|DRUG|Erlotinib|150mg/d,days 1-42,total 6 weeks
41007837|NCT01752205|RADIATION|Radiation therapy|
41007838|NCT02088658|BEHAVIORAL|Technology Intensified|The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
41007839|NCT01143090|DRUG|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
41007840|NCT04582552|DRUG|PARP inhibitors|Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
40804660|NCT04691245|DEVICE|2D US|2D US guided access to femoral artery
41007841|NCT02812667|DRUG|Nivolumab + Plinabulin|
41007842|NCT06116331|OTHER|Data collection|Participants will answer questionnaires and submit stool samples.
41152627|NCT05166785|OTHER|DPP Tailored for Older Adults and delivered via Telehealth|Diabetes Prevention Program (DPP) Tailored for Older Adults and delivered via Telehealth (DPP-TOAT) will be composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions
41152628|NCT05166785|OTHER|In-Person Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP) is composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions over 12 months in person approved by the Centers for Disease Control and Prevention (CDC)
40804661|NCT01508377|BEHAVIORAL|Exposure for PTSD with cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
40804662|NCT01508377|BEHAVIORAL|Exposure for PTSD without cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
40804663|NCT03536780|DRUG|Avelumab and Gemcitabine|"* Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~* Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle"
41007843|NCT01792999|DEVICE|Contrast-enhanced KBCT|Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
41007844|NCT02482350|BEHAVIORAL|Reading Training|"Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text."
41007845|NCT02299531|OTHER|Varying meal energy density and portion size|
41007846|NCT06333938|DEVICE|Bridge|Percutaneous Nerve Field Stimulation using a disposable battery operated and device, approved by the FDA for the treatment of clinical symptoms related to opioid withdrawal.
41152629|NCT02411422|DEVICE|Conventional endotracheal tube|Conventional endotracheal tube
41152630|NCT02411422|DEVICE|Reinforced endotracheal tube|Reinforced endotracheal tube
41152631|NCT02750371|OTHER|Evaluation of autobiographical memory|Patients will answer several questionnaires one and two years after irradiation treatment end.
40804664|NCT01697475|BEHAVIORAL|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
40804665|NCT06290466|DRUG|Low dose group|300 mg,single dose.
40804666|NCT06290466|DRUG|High dose group|400 mg, single dose.
41477587|NCT03536182|RADIATION|Carbon Ion Radiation Therapy (CIRT)|Patient will receive CIRT daily, 4 days a week for a total of 12 fractions/treatments plus concurrent chemotherapy (gemcitabine) weekly for 3 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic. Within 6 weeks of completing radiotherapy, patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
41322562|NCT04819802|OTHER|Measurement of sublingual microcirculation|Sublingual microcirculation will be evaluated using a MicroScan (Microvision Medical, Amsterdam, the Netherlands) incident dark field imaging device. Perfusion measurements will be taken once a day during the first three days after inclusion (i.e. three measurement times). At each measurement time, five sequences of 20 secs will be recorded at five different sites. The video clips will be secondarily analyzed by a trained, blind investigator.
41322563|NCT04819802|OTHER|Plasma sampling|Additional volume during blood draw to assess plasma levels of the following endothelial markers: syndecan-1, angiopoietin-2, vascular endothelial growth factor-A (VEGF-A), thrombomodulin.
41322564|NCT03341611|BEHAVIORAL|Neuro-imaging during behavioral decision-making task|All participants will make simple decisions while in a scanner.
41322565|NCT06364956|DRUG|Tislelizumab combined with two predefined dose groups of palbociclib|Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.
41322566|NCT06364956|DRUG|RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.|After the exploration of Tislelizumab, 200mg q3W combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
41322567|NCT04154943|DRUG|Cemiplimab|Intravenous (IV) infusion every 3 weeks (Q3W)
41322568|NCT01204697|DRUG|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
41322569|NCT01204697|DRUG|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
41322570|NCT01204697|DRUG|erlotinib [Tarceva]|150 mg/day orally as monotherapy
41322571|NCT00716638|BEHAVIORAL|Trauma-focused Cognitive Behavior Therapy|This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.
41322572|NCT00716638|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|This intervention comprises 10 sessions of EMDR according to the standard protocol.
41322573|NCT03169049|DEVICE|High-Frequency Stimulation|high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
40804667|NCT06353633|DIETARY_SUPPLEMENT|formula|The calories needed by the person are calculated and half of the calories are provided by formulas and the other half based on the elimination diet
40804668|NCT06353633|BEHAVIORAL|exclusion diet|In this group, only the elimination diet is considered as an intervention
41007847|NCT06333938|DEVICE|BFA|BFA is an auricular acupuncture technique (developed within the VA/ DoD health systems) delivered by providers using 1mm acupuncture needles.
41007848|NCT03111420|DRUG|P2Y12 inhibitor|Administration of P2Y12 inhibitor antiplatelet therapy
41322574|NCT03169049|DEVICE|sham Stimulation|Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
41322575|NCT01916616|BEHAVIORAL|Four therapy sessions with a psychologist utilizing cognitive-behavioral therapy techniques|At the four therapy sessions, subjects will work with the psychologist to identify the triggers of their VCD episodes, learn to self-monitor symptoms and reactions, and be taught breathing retraining/relaxation techniques. The goal is to decrease patterns of subjects' thinking or behaviors that exacerbate distress from VCD symptoms.
41322576|NCT06366295|DEVICE|subgingival mechanotherapy with perioscopy|Subgingival mechanotherapy using a machine scaler, curettes and a perioscope
41322577|NCT06366295|DEVICE|classical subgingival mechanotherapy|Subgingival mechanotherapy using a machine scaler and curettes
41322578|NCT02920606|PROCEDURE|Pulpotomy|
41322579|NCT02920606|PROCEDURE|Endodontic treatment|
41322580|NCT03647436|OTHER|Comprehensive Geriatric Assessment. Both groups.|Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
41322581|NCT04871542|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
40804669|NCT05913050|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
40804670|NCT05913050|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
41007849|NCT03111420|DEVICE|Platelet function test|Blood is drawn for testing of platelet aggregation activity
41007850|NCT00820612|DRUG|Indomethacin|100 mg PR once at the time of ERCP
41322582|NCT04871542|OTHER|Questionnaire Administration|Complete questionnaires
41322583|NCT02013128|DRUG|Ublituximab|Ublituximab (IV infusion)
41322584|NCT02013128|DRUG|Ibrutinib|Ibrutinib oral daily dose
40804671|NCT02709460|PROCEDURE|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
40804672|NCT02709460|PROCEDURE|Cervical occlusion|Cervical occlusion of the uterine artery
40804673|NCT05273372|OTHER|Placebo|Placebo treatment with the food white rice flour. 1,000 mg BID
40804674|NCT05273372|OTHER|Medical Food - Anhydrous Enol-Oxaloacetate|Active treatment with oxaloacetate. 1,000 mg BID
40804675|NCT01795976|GENETIC|NY-ESO-1 T cells|
40804676|NCT01795976|DRUG|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
41007851|NCT00820612|OTHER|Placebo suppositories|2 placebo suppositories at the time of ERCP
41322585|NCT04477109|DEVICE|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt
40804677|NCT01795976|DRUG|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
40804678|NCT01795976|BIOLOGICAL|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
41007852|NCT04724239|DRUG|Sintilimab|200mg IV on Day 1 Q3W
41007853|NCT04724239|DRUG|Chidamide|30mg PO BIW each 3-week cycle
41007854|NCT04724239|DRUG|IBI305|7.5mg/kg IV on Day 1 Q3W
41007855|NCT05053984|PROCEDURE|Percutaneous Echoguided Neuromodulation|Once the nerve is located, a needle is introduced in the vicinity of the nerve and is stimulated using an electrical current with a frequency of 10 Hz, with a pulse width of 250 µs and a tolerable intensity causing a visible muscle contraction for 1.5 minutes.
40804679|NCT00211354|DRUG|Anecortave Acetate|ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
41322586|NCT04477109|OTHER|sham laser application in addition to diet recommendations|sham laser application in addition to diet recommendations
41322587|NCT05365009|DIAGNOSTIC_TEST|Multidisciplinary aproach|regular tests
41322588|NCT02960555|BIOLOGICAL|Isatuximab|Given IV
41322589|NCT02960555|OTHER|Laboratory Biomarker Analysis|Correlative studies
41322590|NCT05870319|DRUG|SKB264|intravenous (IV) infusion (Q2W)
40804680|NCT06324942|OTHER|Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg|Surgeon-administered Transversus Abdominis Plane Block
40804681|NCT06328270|OTHER|Ozone - oxygen Therapy|Ozone gas is a structurally unstable molecule that contains three oxygen atoms.
40804682|NCT06328270|OTHER|Corticosteroid|1 ml betamethasone
40804683|NCT05143528|DRUG|Nilotinib BE 84mg|84 mg capsule
40804684|NCT05143528|DRUG|Nilotinib BE 112 mg|112 mg capsule
40804685|NCT05143528|DRUG|Placebo|placebo capsule
40804686|NCT01661751|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
40804687|NCT01661751|BIOLOGICAL|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
41007856|NCT00847496|DEVICE|AWBAT|One-time application of dressing over partial-thickness burns
41007857|NCT00847496|DEVICE|Biobrane|One-time application over partial-thickness burns
41007858|NCT06103513|DRUG|Somatropin|The treatment of children with subcutaneous recombinant human growth hormone (rhGH) is the current gold standard of care for children with diagnosed GHD. This study will serve only to investigate the optimal dose of treatment in the first year of treatment with rhGH.
41007859|NCT03360916|DRUG|Lipitor 20Mg Tablet|One tablet by mouth every day for 12 weeks.
41007860|NCT03360916|DRUG|Lipitor 80Mg Tablet|One tablet by mouth every day for 12 weeks.
41007861|NCT03360916|DRUG|Placebo|One matching placebo tablet by mouth every day for 12 weeks.
41322591|NCT05870319|DRUG|Pemetrexed|500 mg/m2 intravenous (IV) infusion (Q3W)
41322592|NCT05870319|DRUG|Carboplatin|AUC 5 intravenous (IV) infusion (Q3W) 4cycles
41322593|NCT05870319|DRUG|Cisplatin|75 mg/m2 intravenous (IV) infusion (Q3W) 4cycles
41322594|NCT02487888|OTHER|Unblinded to Genetic Testing Results|The physicians of this group of patients will be unblinded to the results of the genetic testing.
41322595|NCT02487888|OTHER|Blinded to Genetic Testing Results|The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
40804688|NCT06244407|DRUG|Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets|Vildagliptin and Metformin Hydrochloride 50/1000 mg Film-coated Tablets
40804689|NCT06409936|DRUG|Asciminib|both arms will include asciminib treatment
40804690|NCT06409936|DRUG|Nilotinib|in the arm B the nilotinib will be added on in all patients
40804691|NCT02143453|OTHER|Endurance training|30 to 60-minute continuous exercise at 80% of the peak heart rate
40804692|NCT02143453|OTHER|High intensity interval training|3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
40804693|NCT02243319|DRUG|HGP1201|
40804694|NCT02243319|DRUG|HGP0904|
40804695|NCT02243319|DRUG|HGP0904 and HGP1201 co-administraion|
40804696|NCT00841776|DRUG|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
40804697|NCT00841776|DRUG|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
40804698|NCT02661386|DEVICE|Motility Procedure|The use of esophageal manometry device during general anesthesia
40804699|NCT00566982|DRUG|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
40804700|NCT00566982|DRUG|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
40804701|NCT01519687|DRUG|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
40804702|NCT06079190|DRUG|GSK4527226|GSK4527226 will be administered.
41152632|NCT03683212|PROCEDURE|Early intensive care bundle|"The care bundle comprises a list of items to follow and tick on a handover checklist within 4 hours of ED management:~1. Treatment of the congestion: (international guidelines and recommendations)~2. Treatment of precipitating factors~3. NIV (non-invasive ventilation) if respiratory distress with hypercapnia and pH \< 7.35 in absence of contra indication.~4. Preventive LMWH (low molecular weight heparin) if no pre-existing anticoagulation therapy."
41322596|NCT03801356|DRUG|Selective Nerve Root Block|Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
40804703|NCT06079190|OTHER|Placebo|Placebo will be administered.
40804704|NCT04499781|BEHAVIORAL|ACCESS II mHealth Intervention|Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.
40804705|NCT04499781|BEHAVIORAL|ACCESS II control condition|Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
41322597|NCT02268448|DRUG|Clonidine|
41322598|NCT02268448|DRUG|Naltrexone|
40804706|NCT04827342|OTHER|data collection in the Ada DDSS prototype|Entry of patients' data (medical history, symptoms and findings) in the Ada DDSS prototype. The tool then automatically creates a list of possible diagnostic suggestions based on the information, which are compared with the diagnoses of the attending physician.
40804707|NCT02066831|BEHAVIORAL|Telemedical coaching|
40804708|NCT02066831|OTHER|Telemedicine|
41007862|NCT03360916|BEHAVIORAL|Exercise Program|Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
41007863|NCT05411510|PROCEDURE|Densah bur|Surgical treatment
41152633|NCT03073122|DIAGNOSTIC_TEST|Brain MRI, neurocognitive and psychological testing|MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
41152634|NCT05964166|DEVICE|TetraGraph NMT Monitor|TetraGraph is a unique, EMG=based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
41152635|NCT05729152|OTHER|Sample blood|Partecipants will undergo a baseline assessment by history, objective examination, laboratory tests, ECG, 6-minute walking test and echocardiogram
41322599|NCT03685552|OTHER|Prog: Purify-2|"Nutritional Supplements to be administered:~* Protein Shakes: one protein shake twice a day~* Probiotics (Bacillus Coagulans) once a day~* Biome NO+ ( blend of amino acids, specifically l-arginine and l-citrulline, combined with red beet root, grape polyphenol extract, vitamins and minerals) twice a day~* In.Form Purify ( blend of psyllium hull, inulin, L-glutamine, fruit, fruit extracts and zinc) twice a day"
41322600|NCT04006535|GENETIC|genetic analysis|Saliva sample collection for genetic analysis
41007864|NCT06098950|OTHER|Artificial Intelligence model predictions without explanation|During 6 clinical vignettes, participants will see AI model predictions without a corresponding AI explanation. The AI model will provide a score for each diagnosis (heart failure, pneumonia, COPD) on a scale of 0-100 estimating how likely the patient's presentation was due to each of these diagnoses. In 3 of the clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions, with the model specifically biased against one of the three diagnoses.
41007865|NCT06098950|OTHER|Artificial intelligence model predictions with explanation|During 6 clinical vignettes, participants will see AI model predictions with explanation. The AI model will provide a score for each diagnosis on a scale of 0-100. In 3 clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions with the model specifically biased against one of the three diagnoses. If the AI model provides a score above 50 an AI model explanation will be shown as gradient-weighted class activation mapping (Grad-CAM) heatmaps overlaid on the chest X-ray that highlighted which regions of the image most affecting the AI model's prediction.
41152636|NCT00731276|DRUG|irinotecan hydrochloride|
41007866|NCT06098950|OTHER|AI model biased against heart failure|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against heart failure, always predicting that heart failure is present with high likelihood in survey vignette patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses (pneumonia, COPD).
41007867|NCT06098950|OTHER|AI model biased against pneumonia|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against pneumonia, always predicting that pneumonia is present with high likelihood in survey vignette patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses (heart failure, COPD).
41007868|NCT06098950|OTHER|AI model biased against COPD|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against COPD, always predicting that COPD is present with high likelihood in survey vignette patients where a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses (heart failure, pneumonia).
41007869|NCT01813981|DIETARY_SUPPLEMENT|Low roast coffee|Instant coffee
41007870|NCT01813981|DIETARY_SUPPLEMENT|High roast coffee|Instant coffee
40804711|NCT05070845|BIOLOGICAL|PF-06835375|CXCR5 inhibitor
41007871|NCT01813981|DIETARY_SUPPLEMENT|Control (Caffeine dissolved in water)|Caffeine dissolved in water
41007872|NCT03284866|OTHER|Laboratory Biomarker Analysis|Correlative studies
41007873|NCT03284866|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
41007874|NCT03284866|OTHER|Saline|Given IM
41007875|NCT00323128|PROCEDURE|Calculation of inuline clearance|Calculation of inuline clearance.
41152637|NCT00731276|OTHER|pharmacogenomic studies|
41152638|NCT00731276|OTHER|pharmacological study|
41007876|NCT00323128|PROCEDURE|Measuring serum creatinine|Measuring serum creatinine.
41007877|NCT06354153|OTHER|Polarity Management Training Program|60 first-line nurse managers received a training program involving theoretical and practical sessions
41322601|NCT04694625|OTHER|Structured Rehabilitation Program|Early Function Phase (Protective phase) week 1 Progressive Function Phase (Recovery Phase) 2nd and 3rd week Advance Function Phase (Activity Phase) 4th week
41322602|NCT04694625|OTHER|Conventional Physical Therapy|• Rapid post-operative mobilization • Range of motion exercises started • Passive extension by placing pillow under foot • Flexion-by dangling the leg over the side of bed • Muscle strengthening exercises • Weight bearing is allowed on 1st post-operative
40804714|NCT06472726|BEHAVIORAL|IONA Mind app|The IONA Mind app is a smartphone app that delivers mental health support.
41007878|NCT05148312|DRUG|Budesonide Inhalant Product|Single-dose of budesonide solution administered by nebulization.
41152639|NCT00003057|DRUG|loperamide hydrochloride|
41322603|NCT03097614|DEVICE|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
41322604|NCT02543502|PROCEDURE|periodontal treatment|treatment of periodontal cleaning
40804715|NCT06548087|DEVICE|Gigstride Ambulatory Device|"For patients who are scheduled to be seen by the investigator in clinic with one of the above diagnoses, and recommended to use some type of ambulatory aid, the investigator will offer the Gigstride ambulatory device as an alternative and inquire about the patient's interest in participating in the study. After choosing to be a part of the study, the participant will use Gigstride device to perform the following tasks:~* Walk a different distances to assess speed and fatigue~* Perform functional mobility tasks (sit-to-stand, stand-to sit, stand-pivots, etc.)~The participant will then be asked to fill out a questionnaire, Gigstride Clinical Trial Questionnaire that will be used for qualitative data, such as ease of use and comfortability with using the device.~The overall amount of time for the evaluation and questionnaire will take approximately 30 minutes to 1 hour."
41152640|NCT00003057|DRUG|octreotide acetate|
41152641|NCT05582421|DRUG|Diclofenac Sodium|intracanal medication
41152642|NCT01808144|DRUG|lesinurad|Tablets, 400 mg once daily (QD)
40804719|NCT02489318|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
40804720|NCT02489318|DRUG|Placebo|Participants will receive Placebo orally once daily in each 28 day treatment cycles.
40804721|NCT02489318|DRUG|Androgen Deprivation Therapy (ADT)|All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
40804722|NCT01352962|DRUG|Gemcitabine|1,000mg/m2 IVPB over 30 min x 1
40804723|NCT01352962|DRUG|Carboplatin|AUC 5\*\* IVPB over 30 min x 1
40804724|NCT01352962|DRUG|Lenalidomide|Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
40804725|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose1|A topical drop of BRM424 ophthalmic solution.
40804726|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose2|A topical drop of BRM424 ophthalmic solution.
41152643|NCT01808144|DRUG|lesinurad|Tablets, 200 mg QD
40804728|NCT05646784|DRUG|Cerebiome|Evaluate the effect of oral intake of a probiotic agent on plasma inflammatory markers, gut bacterial profile and depressive state in a subgroup of target patients versus a subgroup treated with placebo
40804729|NCT05646784|DRUG|Placebo|Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment for 12 weeks
40804730|NCT06263023|OTHER|Sub-Normothermic Machine Preservation and Assessment|Human kidneys from HTP deceased donors will be transported to the Sponsor's central preservation and assessment facility and placed onto a machine perfusion system in a sterile operating room for a brief period of Sub-Normothermic Machine Perfusion (SNMP). Basic parameters including internal renal resistance, oxygen, and electrolyte levels will be recorded using standard point-of-care hospital analyzers. Accepted kidneys will be transported to a participating transplant center using a portable oxygenated LifePort Hypothermic Machine Preservation (HMP) device.
41152644|NCT01808144|DRUG|febuxostat|Tabletsm 80 mg QD
40804732|NCT04749628|DRUG|cannabidiol|Epidiolex (cannabidiol) oral solution
40804733|NCT04749628|OTHER|Ora-sweet SF|Ora-sweet SF placebo
40804734|NCT05704257|DEVICE|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the gastroschisis.
40804735|NCT05875727|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|One dose of 20vPnC will be administered intramuscularly.
40804736|NCT04837703|DRUG|Eltrombopag|Eltrombopag should be taken at least two hours before or four hours after any products such as antacids, dairy products, or mineral supplements containing polyvalent cation (e.g. aluminum, calcium, iron, magnesium, selenium and zinc). Eltrombopag may be taken with food containing little (\< 50 mg) or preferably no calcium.
40804737|NCT03611816|BIOLOGICAL|Blood taken|Collection of clinical data
40804738|NCT03611816|GENETIC|Blood taken|Collection of DNA
40804739|NCT03611816|GENETIC|Blood taken|Collection of plasma
40804740|NCT05241834|DRUG|LOXO-260|Oral
41007879|NCT03192150|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
41007880|NCT03192150|OTHER|Vehicle|Vehicle twice daily for 16 days
41007881|NCT05425901|OTHER|biopsy|endoscopy biopsies (6)
41007882|NCT03752281|OTHER|Investigation of health and activity|During a six months multidisciplinary investigation of health status, activity and working ability for individuals receiving long-term social assistance, the health and activity status as well as function will be described using established questionnaires and the International Classification of Functioning
41007883|NCT03165981|BIOLOGICAL|PCV13|ACIP Recommended vaccine
41152645|NCT03190317|OTHER|HIV-infected Veterans who use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
41322605|NCT06016257|OTHER|Use of VirtuaCare™ for home program|Use of VirtuaCare™ system for the Home Program.
40804741|NCT05237505|DEVICE|bi-level positive pressure non invasive ventilation|Participants randomized to the bi-level arm will be provided with an auto bi-level device that automatically delivers the required pressure. The settings in the auto bi-level will be minimum EPAP of 4 cmH2O, maximum IPAP of 24 cmH2O, and a range of pressure support between 6-10 cmH2O. For those participants who have been randomized to the bi-level group but have not successfully acclimated to the device with the automatic bi-level settings, we will conduct an in-lab titration of the bi-level therapy during the optional Overnight visit 2.
40804742|NCT05237505|DRUG|Oxygen gas|The dose of nocturnal oxygen in all participants in the oxygen therapy arm will be 2 liters/minute. Patients with daytime hypoxemia, measured as sustained desaturations below 89% during wake time and/or arterial blood PO2 ≤ 55 mmHg, will be excluded from this study (as specified in the exclusion criteria) for ethical reasons since withholding oxygen in hypoxemic patients would be at odds with standard of care.
41152646|NCT03190317|OTHER|HIV-infected Veterans who do not use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
41152647|NCT03190317|OTHER|Providers and staff of HIV-infected veteran|The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
41152648|NCT00006436|BIOLOGICAL|Rituximab|2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
41152649|NCT00006436|BIOLOGICAL|Filgrastim|Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle
40804747|NCT05421663|BIOLOGICAL|JNJ-90014496|JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)19 and CD20.
40804748|NCT06348251|BEHAVIORAL|FoodSteps|Participants will get access to the FoodSteps digital intervention with coaching for 16 weeks and receive a weekly stipend benefit to aid with implementing health behavior changes
40804749|NCT03934372|DRUG|Ponatinib|Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
40804750|NCT05765344|DRUG|Bulevirtide|Administered via subcutaneous injections.
41152650|NCT00006436|DRUG|EPOCH|combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
40804752|NCT05904236|DRUG|Treatment with ICVB-1042 administered intravenously|Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels
41152651|NCT02085590|BIOLOGICAL|BCG vaccine|
41152652|NCT02085590|BIOLOGICAL|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
41152653|NCT00537758|BEHAVIORAL|Cognitive Behavior Therapy|
41322606|NCT05533333|BEHAVIORAL|Falls prevention exercises|A dual-task activity involves the simultaneous performance of two activities involving physical and cognitive tasks.
40804756|NCT03932773|DEVICE|Active rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be used to deliver 1 hertz (Hz) stimulation to right dorsolateral prefrontal cortex (rDLPFC) at 110% of a participant's rTMS motor threshold. The device passes electric current through a coil generating an alternating magnetic field. When positioned over the skull, the changing magnetic field causes electromagnetic inducted current flow in brain regions subjacent to the coil. Magnetic pulses (1.5-2.0 Tesla) lasting 100-300 microseconds at 1 Hz will be used.~Motor threshold will be defined by the TMS intensity to right motor region required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
40804757|NCT03932773|DEVICE|Sham rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be paired with sham coil. The sham coil will induce electrical current flow in the tissue above the skull but will not induce current flow in brain tissue. The sham coil will be placed over the right prefrontal scalp region to target current flow in rDLPFC. Magnetic pulses lasting for 100-300 microseconds at 1 Hz will be used.~For consistency across the rTMS conditions, motor threshold in the sham condition also will be determined by positioning the active rTMS coil over the right motor region and identifying the stimulation intensity required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
41007884|NCT03165981|BIOLOGICAL|DTaP|ACIP Recommended vaccine
41007885|NCT03165981|BIOLOGICAL|IIV|ACIP Recommended vaccine
41152654|NCT00537758|BEHAVIORAL|CBT and BWL|
41152655|NCT00537758|BEHAVIORAL|Behavioral Weight Loss Treatment|
41152656|NCT00665106|DRUG|"NOVA63035 Corticosteroid"|Single injection in the study eye
41152657|NCT01536795|DRUG|WR279,396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
41152658|NCT01536795|DRUG|WR 279,396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
41322607|NCT05166655|BEHAVIORAL|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
41322608|NCT05079867|DEVICE|Cochlear implantation|Electrode surgically implanted in patient's cochlea to improve hearing
41322609|NCT03317574|DRUG|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
40804758|NCT03932773|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidenced based, trauma-focused treatment for Posttraumatic Stress Disorder (PTSD). CPT is a recommended form of treatment in the Veterans Administration - Department of Defense Clinical Practice Guideline for PTSD. The CPT manual delineates the agenda for each of 12 sessions (60 minutes per session): 1) Introduction to CPT and Patient Education regarding PTSD, 2) Meaning of the Trauma, 3) Identification of Thoughts and Feelings related to the Trauma, 4) Remembering the Trauma, 5) Identification of Stuck points, 6) Challenging Questions about the Trauma, 7) Dysfunctional/Maladaptive Thinking patterns related to the Trauma, 8) Safety Issues, 9) Trust Issues, 10) Power and Control Issues, 11) Self-Esteem Issues, and 12) Intimacy Issues.
40804759|NCT04912869|DRUG|Crovalimab|Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).
40804760|NCT04912869|DRUG|Placebo|Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab
40804761|NCT06208163|PROCEDURE|Chiropractic|Chiropractic spinal adjustments
40804762|NCT03844672|BEHAVIORAL|Low Power|Participants will receive a low power e-cigarette to use for 3 weeks
40804763|NCT03844672|BEHAVIORAL|High Power|Participants will receive a high power e-cigarette to use for 3 weeks
40804764|NCT03844672|BEHAVIORAL|Low Concentration|Participants will receive a low concentration e-liquid to use for 3 weeks
40804765|NCT03844672|BEHAVIORAL|High Concentration|Participants will receive a high concentration e-liquid to use for 3 weeks
41152659|NCT02366455|PROCEDURE|Measurement of the length of the right main stem bronchus|Measurement of the length of the right main stem bronchus on CT-Scan
41152660|NCT02366455|PROCEDURE|Measurement of the right upper lobe bronchus antero-posterior angulation|Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
41152661|NCT04605471|DRUG|Iopromide(Ultravist, BAY86-4877)|The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.
41152662|NCT01565239|DEVICE|Fiix prothrombin time|The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
41152663|NCT00972036|DEVICE|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
41152664|NCT06040138|DIAGNOSTIC_TEST|End expiratory occlusion maneuver|An end expiratory occlusion maneuver will be performed during pressure support ventilation in patients with prolonged weaning.
40804772|NCT06425887|DIAGNOSTIC_TEST|Smart watch|not interventional
41152665|NCT01608958|DRUG|Oxytocin|10 IU oxytocin in 500 ml infusion
40804774|NCT04552041|DRUG|Prospekta|Oral administration.
40804775|NCT04552041|DRUG|Placebo|Oral administration.
41152666|NCT01608958|DRUG|Oxytocin|10 IU oxytocin IM injection
41152667|NCT06228417|OTHER|Adaptive digital intervention|Participants received reminder for medication intake on daily basis. Also, short message regarding hypertension, medication and lifestyle changes
41007886|NCT04737538|OTHER|Experimental Dentrifrice|Toothpaste containing sodium bicarbonate, sodium hyaluronate and sodium fluoride
41007887|NCT04737538|OTHER|Positive control dentifrice|Dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride
41007888|NCT04737538|OTHER|Negative control dentifrice|Dentifrice containing 1100ppm fluoride as sodium fluoride (Crest Cavity Protection)
41007889|NCT03420482|DRUG|Fecal Microbiota Transplant (FMT) oral capsules|Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.
41007890|NCT03420482|DRUG|Placebo oral capsule|Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
41007891|NCT02248129|DRUG|Telmisartan and hydrochlorothiazide|
41007892|NCT02539875|BEHAVIORAL|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
41007893|NCT02065674|DRUG|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
41007894|NCT05901285|DRUG|VAX014|Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
41007895|NCT00218192|BEHAVIORAL|Behavior Therapy|
41007896|NCT02165111|DRUG|Onabotulinumtoxin A|
41152668|NCT02978846|OTHER|Clinical Observation|Undergo side effects evaluation using cards
41152669|NCT00527514|DRUG|Amlodipine|Tablets
41152670|NCT00527514|DRUG|Olmesartan medoxomil plus amlodipine|Tablets
41152671|NCT06647160|DEVICE|Blue star MAX-5 spectacle lens|The children in the experimental group will wear Blue star MAX-5 spectacle lens and receive follow-up examinations every half year.
41152672|NCT06647160|DEVICE|Single-vision spectacle lens|The children in the single-vision lenses group will wear single-vision spectacle lens and receive follow-up examinations every half year.
41152673|NCT04560322|DRUG|Venetoclax|Tablet, taken by mouth
41152674|NCT04560322|DRUG|Obinutuzumab|Intravenous infusion
41152675|NCT04560322|DRUG|Acalabrutinib|Capsule, taken by mouth
41152676|NCT02465775|DEVICE|UltraShape treatment|Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
41152677|NCT05159778|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
40804778|NCT06463431|BEHAVIORAL|Cognitive Processing Therapy|We propose a conceptual model for the relationship between PTSD, substance use, \& sexual risk behaviour wherein using substances to avoid posttraumatic cognitions \& affect leads to risky sexual behaviour through impaired safer sex negotiation. These mechanisms are consistent with the theory underlying CPT. Behaviourally, substance use (and potentially risky sexual behaviour) is negatively reinforced through avoiding unwanted negative affect. Cognitively, PTSD-based predictions may generate unrealistic risk appraisals that contribute to sexual risk. CPT addresses these specified pathways by a) identifying how trauma leads to maladaptive beliefs about the self, others, \& the future, b) cognitive interventions to address these beliefs, \& c) an overall trauma-focused orientation that addresses cognitive, affective \& behavioural avoidance, using cognitive restructuring to lead to more realistic/adaptive beliefs, less cognitive/affective avoidance, \& more goal-directed approach behaviours.
40804779|NCT06203392|OTHER|Very low carbohydrate ketogenic diet|Very low carbohydrate ketogenic diet provided for six weeks
40804780|NCT06203392|OTHER|Mediterranean diet|Mediterranean diet provided for six weeks
40804781|NCT04245306|OTHER|computerized test for pragmatic inferences|Computerized tests
41152678|NCT05159778|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
41152679|NCT02843542|DEVICE|PET-MR|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
41152680|NCT02843542|DEVICE|PET-CT|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
41322610|NCT03317574|DRUG|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
41152681|NCT02038114|BEHAVIORAL|Instructed to read patient education pamphlets|The intervention in this study is the administration of patient education pamphlets and instructions to read them. Half of all patients who participate in this study will be required to read pamphlets on symptoms that are relevant to them (i.e. symptoms that they are experiencing). Subsequent to reading pamphlets, patients will complete study questionnaires to assess their impact.
41152682|NCT05700279|PROCEDURE|Stellate Ganglion Block|Stellate Ganglion Block (SGB) procedure involves an injection of a local anesthetic (0.5% ropivacaine) around the stellate ganglion (a bundle of nerves located at the base of the neck) to block the transmission of pain signals. The SGB injection is administered by an anesthesiologist.
41322611|NCT04718324|OTHER|e-PROMS|Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity. This is a one-time intervention
41322612|NCT04718324|OTHER|p-PROMS|Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
41477588|NCT03536182|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Patient will receive IMRT daily, 5 days a week for a total of 28 fractions/treatments plus concurrent chemotherapy (gemcitabine or capecitabine) weekly for 5 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic,within 6 weeks of completing radiotherapy,patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
40804795|NCT03563742|DRUG|Rilpivirine 25 mg|Participants will receive rilpivirine 25 mg tablet orally once daily.
40804796|NCT03563742|DRUG|Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)|Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
40804797|NCT06233942|DRUG|BG-C9074|administered by intravenous infusion
40804798|NCT06233942|DRUG|Tislelizumab|administered by intravenous infusion
40804799|NCT06477003|DEVICE|Multispectral Optoacoustic Tomography|The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.
40804800|NCT06477003|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
40804803|NCT04262466|DRUG|Brenetafusp|Brenetafusp IV infusions
40804804|NCT04262466|DRUG|Brenetafusp and pembrolizumab|Brenetafusp and pembrolizumab IV infusions
40804805|NCT04262466|DRUG|Brenetafusp and chemotherapy|Brenetafusp and chemotherapy IV infusions
40804806|NCT04262466|DRUG|Brenetafusp and monoclonal antibodies and chemotherapy|Brenetafusp and a monoclonal antibody therapy and chemotherapy
40804807|NCT04262466|DRUG|Brenetafusp and tebentafusp|Brenetafusp and tebentafusp IV infusions
40804808|NCT04262466|DRUG|Brenetafusp and bevacizumab|Brenetafusp and bevacizumab IV infusions
40804809|NCT04262466|DRUG|Brenetafusp and kinase inhibitors|Brenetafusp and oral kinase inhibitors
40804810|NCT05410925|DRUG|Recombinant staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
41007897|NCT02165111|DRUG|sterile saline solution|
41007898|NCT04908254|DEVICE|Crossover Device (PCD or Dayspring - alternate to first group)|Cross over arms after a month of use and a month of washout period
40804811|NCT05410925|DRUG|Placebo|Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
41152683|NCT05700279|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a form of trauma-based talk therapy that will be conducted by clinical therapists. CPT can help people identify and challenge unhelpful trauma-related beliefs about themselves, others, and the world.
41152684|NCT05377827|BIOLOGICAL|WU-CART-007|Provided by Miltenyi Biotec
41007899|NCT00864773|PROCEDURE|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
41322613|NCT06108349|DRUG|Cannabidiol|Cannabidiol (CBD) is a non-psychoactive minor cannabinoid component of Cannabis sativa that is emerging as a treatment to mitigate pain, numbness, and tingling associated with peripheral neuropathy. CBD acts through multiple receptors to modulate central and peripheral neuropathic signaling pathways to alleviate pain.
41322614|NCT02017821|BEHAVIORAL|high intensity aerobic training|
41322615|NCT05534035|BIOLOGICAL|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
41152685|NCT04218708|OTHER|Nicotine patch and gum|Nicotine patch and gum will be given to subjects in the Nicotine replacement therapy cohort every visit after providing exhaled CO/Saliva cotinine test.
41152686|NCT04218708|BEHAVIORAL|Minnesota Nicotine Withdrawal Scale (MNWS)|The MNWS assesses symptoms associated with nicotine withdrawal (i.e., craving, irritability, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depression, and insomnia).
41322616|NCT05534035|BIOLOGICAL|Vaxzevria®|The AstraZeneca COVID-19 Vaccine is a colorless to slightly brown solution, clear to slightly opaque with a pH of 6.6. One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 1010 viral particles (vp) (corresponding to not less than 2.5 × 108 ifu).
41007900|NCT00412165|BEHAVIORAL|Cell Phone|The cell phone arm receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
41007901|NCT00412165|BEHAVIORAL|Weekly access to interactive web site|This group receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
41007902|NCT00412165|BEHAVIORAL|Group|The Group arm receives monthly face to face group sessions plus access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
41007903|NCT05028374|DRUG|"A single booster dose of the Moderna mRNA COVID-19 vaccine"|All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
41007904|NCT04629833|BIOLOGICAL|MC0518|MC0518 will be intravenously infused immediately after thawing.
41007905|NCT04629833|BIOLOGICAL|BAT|BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.
41007906|NCT05004259|DRUG|Daratumumab / Hyaluronidase Injection|Subcutaneous injection of daratumumab and hyaluronidase
41322617|NCT01214317|PROCEDURE|plasmapheresis|3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
41322618|NCT04686318|DIAGNOSTIC_TEST|Biomarkers for acute pyelonephritis|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of CRP, PCT and suPAR. Laboratory staff will be blinded to participant diagnosis and outcome. CRP and PCT results will be available to the treating physician, but the suPAR result will not be available.~* Diagnostic test of CRP. CRP will be measured using an immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi Cobas© systems.~* Diagnostic test of PCT: Plasma PCT will be quantified by an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas© within two hours from collection according to standard procedure.~* Diagnostic test of suPAR: Plasma suPAR will be quantified by using the commercial available suPARnostic© Tubilatex assay reagents (ViroGates, Denmark) on Cobas© as previously validated (35). Separated plasma is kept refrigerated and analysed for suPAR within 48 hours after collection."
41322619|NCT02983058|RADIATION|PET/SPECT Scan|PET scan will be performed on a mCT scanner
41322620|NCT02983058|DEVICE|MRI Scan|Structural MRI will be obtained to permit co-registration of PET images
41007907|NCT04152447|DEVICE|VR device|Patients use a VR device
41007908|NCT04262336|DRUG|DB-020|Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water
41007909|NCT04262336|DRUG|Placebo|Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
41152687|NCT04218708|BEHAVIORAL|ASSIST (the Alcohol, Smoking and Substance Involvement Screening)|The ASSIST is the Alcohol, Smoking and Substance Involvement Screening Test. It is a brief screening questionnaire to find out about people's use of psychoactive substances (alcohol, smoking and substance involvement).
41152688|NCT04218708|BEHAVIORAL|Counseling|At each study visit, participants will receive counseling protocol that will be based on effective counseling manuals. The PI will train the research assistant who will assist the PI in tailoring the manual to the target group: counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects known to contribute to smoking among PLWHA (e.g., tips on dealing with depression and feeling stigmatized particularly in relation to HIV).
41152689|NCT04218708|OTHER|NIDA Standardized Research E-cigarettes (SREC)|"NIDA SREC has a case with a liquid tank. The e-liquid is supplied in sealed disposable cartridges that deliver \>300 puffs / cartridge. The SREC uses a battery recharged via a micro USB port. A single charge is designed to outlast the capacity of an e-liquid cartridge. The e-liquid is tobacco flavored and contains nicotine."
41152690|NCT04782596|PROCEDURE|Posterium nasal septum resection|Posterium nasal septum resection is required to ensure approach during transnasal endoscopic pituitary surgery in patients with pituitary adenoma.
41152691|NCT00588042|DEVICE|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
41322621|NCT06437145|OTHER|Type of Exercise|The high-intensity interval training session consists of 5-min warm-up and 5-min cool-down periods. The main part has 7 cycles. Each cycle consists of 1.5 min of 80-90% of HRpeak and 3 min of 65-70% of HRpeak. The moderate-intensity continuous training session consists of 5 min warm-up and 3-min cool down period. The main part consists of 32 min of 75% of HRpeak.
40804816|NCT05968495|DEVICE|Renuvion APR Handpiece|The Renuvion® APR (Apyx Plasma/RF) handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with a compatible generator for the delivery of radiofrequency energy and helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for cutting, coagulation or ablation of soft tissue during open surgical procedures. The compatible generators operate at an adjustable power of up to 40 W (expressed as 0 - 100% where 100% is 40 W) and provide an adjustable helium gas flow of 1 - 5 L/Min. APR Handpiece has a non-extendable electrode to generate helium plasma.
40804817|NCT06091943|DRUG|Tislelizumab IV|Planned doses will be administered intravenously.
40804818|NCT06091943|DRUG|Tislelizumab SC|Planned doses will be administered via subcutaneous injection.
40804819|NCT06091943|DRUG|Histology-Based Chemotherapy Doublet|"Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
41322622|NCT06026007|OTHER|advices|each pregnant woman was advices how to elevate her legs and daily positions to elevate edema
41477589|NCT05342207|PROCEDURE|Endoscopic plantar fascia release in cases of chronic resistant plantar fasciopathy|A medial portal will be developed 1cm away from the plantar skin along a vertical line passing through the posterior border of the medial malleolus with the foot in neutral position. A 5 mm cannula will be then introduced through the lateral portal over the trocar. Irrigation fluid will be then connected. A 30-degree 4.0 mm endoscope will be inserted inside the cannula. A 4.5 motorized incisor blade will be then used to debride the subcutaneous tissue until full visualization of the shiny fibers of the plantar fascia will be possible. A needle was inserted vertically through the heel skin to act as a land mark for the middle of the plantar fascia. A scalpel blade will then introduced through the medial portal to divide the full thickness of the medial half of the plantar fascia into two leaflets under direct visualization . The posterior leaflet will be then totally debrided using a motorized incisor blade . The tunnel will then be irrigated and stitches will be done.
41477590|NCT06023849|DEVICE|IUD insertion|Trans Caesarean Intra Uterine Contraceptive Device Insertion and Conventional Postpartum 6 Weeks Insertion
41322623|NCT06026007|OTHER|Traditional physical therapy|each pregnant woman was advised about daily routine in addition to circulatory exercise
41322624|NCT06026007|OTHER|Acupressure|each pregnant woman was advised about daily routine in addition to acupressure therapy
41477591|NCT06271902|OTHER|Singapore Youth Shoulder Overuse Injury Prevention Program|A 10-minute, 4-exercises program that targets shoulder eccentric external rotation strength, shoulder internal rotation range of morion, and thoracic rotation range of motion. The topic for the 45-minute educational workshop will be on overuse injuries among youth athletes.
41477592|NCT06271902|OTHER|Lower body stretching program|A 10-minute, 5-stretches sham exercise program that does not target the upper extremity and are only held for 10 seconds.
41477593|NCT06449872|DEVICE|Obstetrics and Gynecology clinical applications for ultrasound diagnostic systems|Up to 5 healthcare professionals trained and experienced in Obstetrics and Gynaecology ultrasound qualitatively assessed the diagnostic image quality of the Kosmos Diagnostic Ultrasound System against the benchmark Mindray M9 Ultrasound System.
41322625|NCT02492087|DRUG|Topical tranexamic acid|Topical tranexamic acid 2g diluted with normal saline 0.9% to a volume of 120mls solution (Concentration 16.7mg/ml)
41477594|NCT03146637|BIOLOGICAL|Activated CIK|Activated CIK armed with bispecific antibody were infused for 3 days，after 2 days，bispecific antibody was infused separately for 3 days
41477595|NCT03146637|BIOLOGICAL|CIK|Traditional CIK were infused for 3 days
41477596|NCT06453239|DIAGNOSTIC_TEST|Pro-Neurotensin level as a Serum Biomarker|Pro-Neurotensin mediates the development of fatty liver disease. Neurotensin (NT) is a 13-amino acid peptide secreted by the neuroendocrine cells of the small intestine in response to fat ingestion, which facilitates fatty acid absorption through the gut in relation to food lipid content.
40804820|NCT05028348|DRUG|Selinexor|Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.
40804821|NCT05028348|DRUG|Elotuzumab|Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.
40804822|NCT05028348|DRUG|Pomalidomide|Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.
40804823|NCT05028348|DRUG|Dexamethasone Oral|Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for \>75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.
41152692|NCT00588042|DEVICE|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
41322626|NCT02492087|DRUG|Normal saline 0.9%|Sterile Normal saline 0.9% 120mls solution
40804826|NCT06445062|DRUG|RMC-6236|Oral tablet
41322627|NCT02937532|BEHAVIORAL|GHE + TOBT training|All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
40804827|NCT06445062|DRUG|mFOLFOX6 regimen|IV infusion
40804828|NCT06445062|DRUG|bevacizumab|IV infusion
40804829|NCT06445062|DRUG|mFOLFIRINOX regimen|IV infusion
40804830|NCT06445062|DRUG|cetuximab|IV infusion
40804831|NCT06445062|DRUG|gemcitabine|IV infusion
41322628|NCT02937532|BEHAVIORAL|CBT + TOBT training|All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
41322629|NCT03036423|BEHAVIORAL|Online video education|
40804832|NCT06445062|DRUG|nab-paclitaxel|IV infusion
41007910|NCT03219060|BEHAVIORAL|Motivational interviewing for smoking cessation in nurses|Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.
41477597|NCT05790148|DEVICE|3Shape|original (Straumann), non-original (Medentika) and generic scan-bodies (3Shape) were utilized for direct digitalization using intraoral scanner with image stitching algorithm. Full contour temporary restorations were fabricated from each digital record, and were evaluated in terms of clinical and analytical.
41007911|NCT03219060|BEHAVIORAL|Brief advice|Brief advice based on 5As
41322630|NCT03036423|BEHAVIORAL|Computerized mental exercises|
41322631|NCT00532428|DRUG|Raloxifene|60 mg QD
41007912|NCT00940303|DRUG|5-FU|3200mg/m2 continuous iv infusions, day 1 every 2 weeks
41007913|NCT00940303|DRUG|bevacizumab [Avastin]|5mg/kg iv infusion, day 1 every 2 weeks
41007914|NCT00940303|DRUG|irinotecan|165mg/m2 iv infusion, day 1 every 2 weeks
41007915|NCT00940303|DRUG|leucovorin|200mg/m2 iv infusion, day 1 every 2 weeks
41007916|NCT00940303|DRUG|oxaliplatin|85mg/m2 iv infusion, day 1 every 2 weeks
41007917|NCT04581499|COMBINATION_PRODUCT|DynamiCare Motivation Support Program|DynamiCare is an evidence-based, multi-service platform that combines software, smartphone and pocket-sized alcohol and drug testing hardware, and recovery services, designed to remotely deliver evidence-based methodologies to facilitate people's motivation and accountability to overcome alcohol, nicotine and other drug use disorders, whether in formal treatment or not.
41322632|NCT00532428|DRUG|Raloxifene|120 mg QD
41477598|NCT00894842|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
41477599|NCT00894842|DRUG|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
41477600|NCT00225537|DRUG|4-Methylumbelliferone (Heparvit®)|
41477601|NCT06445218|OTHER|Data collection|Collection of various data from patients' medical file, such as demographic data, diagnostic results, discharge, treatment....
41152693|NCT04919330|BEHAVIORAL|Family Acceptance and Commitment Therapy-based Eczema Management Programme|"The parent-child dyads will receive four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP). In each session, a group of 6-8 parent-child dyads will receive 90 minutes of ACT, followed by 30 minutes of education related to eczema management. Throughout the sessions, ACT strategies will help the dyads achieve the following therapeutic processes: To weaken the rumination cycle and fused thoughts related to eczema with body-image concern, shame and self-criticism for extending kindness and understanding to oneself; to build self-perspective-taking when seeing one's experience as part of the larger human experience; to strengthen their stands for their values related to self-kindness with acceptance of one's experience; and to take steps to act on values while practising kindness and compassion. Same as the waitlist control, the dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation."
41322633|NCT00532428|DRUG|Placebo|Placebo
41007918|NCT04581499|OTHER|Untreated or Routine Care Control Group|No specific intervention, i.e., research participation plus any community-based treatment the individual seeks to obtain.
41007919|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Full|Participants in the active treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT) prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
41007920|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Partial|Participants in the sham condition arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT) prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session receiving less than a fully pressurized 100% oxygen dose.
41007921|NCT02645994|DEVICE|Target Controlled Infusion|Used to control intravenous propofol delivery with target plasma concentratioins changed manually
41007922|NCT02645994|DEVICE|Closed Loop Anesthesia Delivery System|Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
41007923|NCT04380857|DRUG|Dexamethasone ophthalmic insert 0.4 mg|intracanalicular dexamethasone insert
41322634|NCT02273037|DEVICE|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
41322635|NCT02273037|PROCEDURE|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
41322636|NCT06063239|OTHER|Test Group|Subjects will receive orally administred probiotics based on L. plantarum and L. rhamnosus for 90 days
41322637|NCT06063239|OTHER|Positive Control|Subjects will receive orally administred probiotics based on placebo 90 days
41322638|NCT06063239|OTHER|Negative Control|Subjects will receive esclusively instruction to perform oral hygiene procedures properly.
41322639|NCT01371448|DRUG|Paroxetine|
41477602|NCT00097045|DRUG|omega interferon|
41477603|NCT00097045|DRUG|Ribavirin|
41477604|NCT04305379|PROCEDURE|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction including a Medial Umbilical Ligament Sling plus Intussusception
41477605|NCT04305379|PROCEDURE|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction with Intussusception Only
41477606|NCT05048641|OTHER|Whatsapp reminder|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
41152694|NCT04919330|BEHAVIORAL|Wait-list Control Group|The parent-child dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation. To ensure equity of access to potentially effective treatment (i.e., family ACT-based eczema management programme), the dyads in the wait-list control group will receive the same programme after the completion of all assessments of the intervention arm.
41007924|NCT04380857|DRUG|Topical Prednisolone Acetate Ophthalmic Drops|"Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue"
41007925|NCT05041088|DIETARY_SUPPLEMENT|ProdromeNeuro Plasmalogen|The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
40804836|NCT06580938|BIOLOGICAL|PF-07921585|IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously
40804837|NCT06580938|BIOLOGICAL|Sasanlimab|Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously
40804838|NCT04244981|DRUG|Prothrombin Complex Concentrate, Human|A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
40804839|NCT04244981|DRUG|Fresh Frozen Plasma|When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
40804840|NCT05327946|DRUG|BI 770371|BI 770371
40804841|NCT05327946|DRUG|ezabenlimab|ezabenlimab
41152695|NCT05311956|DEVICE|Active tDCS|The study intervention will be participants self-applying 40 tDCS active stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
40804844|NCT06366464|DRUG|Pitolisant tablet|Pitolisant tablet
40804845|NCT06366464|OTHER|Placebo tablet|Placebo tablet
40804846|NCT03245242|OTHER|Enhanced Recovery after Surgery|Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
40804847|NCT03245242|OTHER|Historical usual surgical care|"Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol."
41007926|NCT05310266|PROCEDURE|Transversus abdominis plane block|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
41007927|NCT05310266|PROCEDURE|Quadratus Lumborum Block|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
41007928|NCT05583188|DEVICE|Aliya Pulsed Electric Fields (PEF) ablation|Patients will undergo PEF ablation
41007929|NCT05583188|DRUG|Nivolumab plus Platinum Doublet Chemotherapy|If EGFR/ALK mutation negative, patients will receive standard of care dosing of three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) post-PEF ablation followed by resection.
40804852|NCT06460493|DRUG|Ensifentrine 3mg|All subjects will receive ensifentrine.
40804853|NCT00098072|PROCEDURE|Heart Catheterization|Heart Catheterization and collection of samples
40804854|NCT04119804|DIAGNOSTIC_TEST|cellular neural networks-genetic algorithm|Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
40804855|NCT03955783|DRUG|Venetoclax|Given by mouth
40804856|NCT03955783|DRUG|Selinexor|Given by mouth
40804857|NCT04551898|DRUG|BGB-DXP593|Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
40804858|NCT04551898|DRUG|Placebo|Placebo to match BGB-DXP593 administered as specified in the treatment arm
40804859|NCT05947851|DRUG|Nemtabrutinib|5 and 20 mg tablets
40804860|NCT05947851|DRUG|Venetoclax|10, 50, and 100 mg tablets
40804861|NCT05947851|BIOLOGICAL|Rituximab|100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion
40804862|NCT01393483|OTHER|serum and tissue mesothelin|"Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs."
40804863|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
41007930|NCT05583188|DRUG|Standard of care neoadjuvant therapy|Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
41007931|NCT05583188|OTHER|Surgical Resection|Patients not eligible for systemic therapy will receive definitive surgery without neoadjuvant therapy as per institutional standard of care post-PEF ablation.
41322640|NCT05766228|OTHER|Web-Based Intercultural Midwifery Training|The training program is a program where students can log in via the internet using the password given to them by a smartphone or computer. The web base is compatible with mobile phones and is suitable for use at any time of the day. The trainings were prepared and explained by the researchers on the web page in the form of a video presentation with the theory-based didactic classroom technique using a Power Point presentation. The training program covered six weeks and consisted of two sessions of 30 minutes each week. In the first five weeks, general information on the development of intercultural midwifery and the main components of cultural competence models are explained. In the last week, training was completed with case presentations in the form of two sessions.
41477607|NCT05510024|PROCEDURE|Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous immunotherapy|The regulation and monitoring of the entire soft-coagulation process are conducted via the radiofrequency generator under endoscopic guidance. Lateral out-fracture of the inferior turbinate is performed if necessary. One month after surgery, allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
41477608|NCT05510024|PROCEDURE|SCIT|Allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
41477609|NCT00717184|DRUG|Interleukin, NK cells|
41477610|NCT02740179|DRUG|Eplerenone|Eplerenone 50mg by mouth twice daily
41477611|NCT02740179|DRUG|Placebo|Placebo by mouth twice daily
41477612|NCT02740179|BEHAVIORAL|Lifestyle Modification|Counseling regarding diet and healthy activity
41477613|NCT04760392|BEHAVIORAL|Goal-directed mobilization|"* A short educational intervention with handout of a leaflet on GDM.~* Definition of personal mobility goal level.~* Communication of the mobility goal level to involved stakeholders.~* Regular reassessment of the mobility goal level and booster sessions by physiotherapists."
41477614|NCT05876533|DEVICE|Cordio HearO|"Cordio HearO is a software medical device that remotely monitors Congestive Heart Failure (CHF) patients by detecting changes in the patients' recorded voice relative to a baseline. The system is comprised of a mobile application (or app) that is deployed on a mobile platform, and a web-based portal that enables caregivers to manage their patients"
41477615|NCT01771315|BEHAVIORAL|Telephone follow-up|The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
40804864|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
41152696|NCT05311956|DEVICE|Sham tDCS|In this arm of the study participants will self-apply 40 sham tDCS stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
41152697|NCT05432258|DEVICE|Bulk-fill composite resin|Restoration of the mandibular first molars with bulk-fill composite resin as the manufacturer advises after the cavity preparation
41152698|NCT05432258|DEVICE|Nano-fill composite resin|Restoration of the mandibular first molars with nano-fill composite resin as the manufacturer advises after the cavity preparation
41152699|NCT01001637|DIETARY_SUPPLEMENT|Curcumin Formulation|2000mg or 3000mg daily BID
41007932|NCT00789282|OTHER|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
41152700|NCT01001637|DIETARY_SUPPLEMENT|Placebo|Placebo
40804871|NCT05572606|BEHAVIORAL|Hypnotherapy|Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
40804875|NCT06145035|BIOLOGICAL|umbilical cord-derived mesenchymal stromal cells (UC-MSCs)|The study product will consist of 100 million UC-MSCs suspended in a final volume of 60 ml given at a rate of 3.3 million cells/min. The product will be infused into vein via intravenous line placed in the arm.
40804877|NCT06491823|BEHAVIORAL|Adaptation|Auditory adaptation in speech
40804878|NCT06491823|BEHAVIORAL|Adaptation baseline|Auditory baseline in speech
40804879|NCT06491823|DEVICE|Motor evoked potentials|motor evoked potentials will be obtained in each recording block
40804880|NCT06491823|DEVICE|Auditory evoked potentials|auditory evoked potentials will be obtained in each recording block
40804881|NCT06491823|DEVICE|Somatosensory evoked potentials|Somatosensry evoked potentials will be obtained in each recording block
41477616|NCT05356806|OTHER|Supportive periodontal and periimplant care|"Periodontal and peri-implant maintenance therapy will be carried out at baseline, 3 and 6-month visit. This session will include the removal of biofilm and calculus on teeth and implants (except those that have just been restored) with an ultrasonic device using a plastic tip ( for implants. and a conventional metal tip ( for teeth. At the end, polishing will be done with a rubber cup~Subsequently, patients will be explained that they must continue with their usual oral hygiene technique on their teeth, using the same type of brush (which can be electric or manual), interproximal devices, toothpaste or mouthwash used to date. Finally, they will receive specific instructions for the supragingival biofilm control in the area of the new restoration and will be given interdental brushes that suit to the space"
40804882|NCT05425732|BIOLOGICAL|V116|0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
41322641|NCT01462916|DIETARY_SUPPLEMENT|honey|A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control \[I/C\] and control to intervention \[C/I\] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
41322642|NCT01324934|DRUG|ATG-Fresenius S|"Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.~(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids)."
41477617|NCT06415214|DRUG|Placebo|Placebo
41477618|NCT06415214|DRUG|HRS-7535|HRS-7535
41477619|NCT00622115|DRUG|Enoxaparin|
40804883|NCT05425732|BIOLOGICAL|PCV20|0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
40804884|NCT05281653|BEHAVIORAL|Neuromuscular exercise Training|Progressive neuromuscular exercise training
40804885|NCT05281653|BEHAVIORAL|Routine training sessions|Routine training sessions
41152701|NCT00265096|BIOLOGICAL|golimumab|50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
41152702|NCT00265096|BIOLOGICAL|Placebo; golimumab|SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
41152703|NCT00265096|BIOLOGICAL|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
40804889|NCT03193970|BEHAVIORAL|Post-Operative Recovery Registry|Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
40804890|NCT06002555|DRUG|Apraglutide|Peptide analogue of GLP-2
40804891|NCT06302452|BEHAVIORAL|Adopting Comprehensive Training for FireArm Safety in Trauma Centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
41477620|NCT04835649|OTHER|Exercise|Both groups will receive exercise-based training
40804892|NCT06480968|DRUG|CTH120|"FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD.~FIH-CTH120-FI: One dosage of CTH120 will be assessed in 12 healthy male and female subjects in two conditions (Fed and Fasting). Subjects will be randomly assigned to 2 sequences: 6 subjects in a sequence fed then fasting condition, 6 subjects in the reverse sequence (fasting, then fed condition)."
41007933|NCT00789282|OTHER|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
41007934|NCT00789282|OTHER|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
41007935|NCT04662307|DEVICE|Intelligent cardiopulmonary rehabilitation system (ICRS)|Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%\~80% HRR determined in the pretest of cardiopulmonary exercise test.
41152704|NCT05893017|OTHER|Virtual Reality Exercises|Virtual Reality Exercises will be apply for muscle strengthening
41152705|NCT05893017|OTHER|Virtual Reality Exercises and Kinesiotaping|Virtual Reality Exercises will be apply for muscle strengthening, Kinesiotaping will be applied at Quadriceps muscle and Hamstring muscle
41322643|NCT00834886|DIETARY_SUPPLEMENT|Melatonin|Capsules, 3 mg, once every night
41322644|NCT00834886|OTHER|Bright light|Bright light therapy 10.000 lux by Miljølys AS
41322645|NCT00834886|OTHER|Placebo red light|Red light 400 lux as placebo light
41322646|NCT00834886|OTHER|Placebo capsule|Capsules containing 3 mng rice flour, once every night
41322647|NCT00793182|DRUG|Ioversol 320 mgI/mL|125 mL of Ioversol administered in the vein
41322648|NCT00793182|DRUG|Iodixanol 320 mgI/mL|125 mL of Iodixanol administered in the vein
40804893|NCT06480968|OTHER|Placebo|"FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD."
41152706|NCT05893017|OTHER|Virtual Reality Exercises and Valgus Orthoses|Virtual Reality Exercises will be apply for muscle strengthening, Orthoses is for correction at knee alignment
41152707|NCT06107205|DRUG|TTYP01|1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)
40804896|NCT04939090|DRUG|Olanzapine|Given PO
40804897|NCT04939090|DRUG|Megestrol Acetate|Given PO
40804898|NCT04939090|OTHER|Questionnaire Administration|Ancillary studies
41007936|NCT00584038|BEHAVIORAL|educational instruction and phone follow-up|Educational instruction and phone follow-up.
41007937|NCT00584038|BEHAVIORAL|educational instruction in clinic|Educational instruction in clinic.
41322649|NCT05454930|OTHER|Filtered Air|The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
41322650|NCT02789449|OTHER|assessment of DLNO and DLCO|
41322651|NCT00565214|DIETARY_SUPPLEMENT|Group 1|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
41322652|NCT00565214|DIETARY_SUPPLEMENT|Group 2|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
41322653|NCT04009213|DEVICE|LiquiBand FIX8®|An n-butyl-2-cyanoacrylate adhesive monomer and D\&C Violet #2 dye
41322654|NCT04009213|DEVICE|AbsorbaTack™|An absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D\&C Violet No. 2.
41322655|NCT01577199|DRUG|Low-dose Clomiphene|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5
41322656|NCT01577199|DRUG|High dose gonadotropins|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
41322657|NCT03427450|DIAGNOSTIC_TEST|Blood draw|Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.
41322658|NCT01768234|OTHER|Supplemental water|1-2L of supplemental water provided between pre-test and post-test
41322659|NCT03101046|DRUG|Cabazitaxel|Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m² every 3 weeks up to 10 cycles.
41322660|NCT03101046|DRUG|Docetaxel|standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
41322661|NCT01853098|BEHAVIORAL|Positive Affect Training (PAT)|During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
41322662|NCT06436729|PROCEDURE|Splinting|The joining of two or more teeth into a rigid unit by means of a fixed or removable restorations/devices
41322663|NCT06436729|PROCEDURE|MINST alone|Minimally invasive non surgical therapy alone
41322664|NCT04990661|BEHAVIORAL|intradialytic massage|intradialytic massage for lower extremity ( the massage included both feet and legs up to and including the knee) applied to the intervention group in three sessions a week and a total of six sessions for two weeks
41152708|NCT06107205|DRUG|Radicava|1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
41152709|NCT06107205|DRUG|Radicava ORS|1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
41322665|NCT00631540|DEVICE|Formula Balloon-Expandable Stent|renal artery stenting
41322666|NCT00061503|DRUG|Travoprost|
41322667|NCT04046341|BEHAVIORAL|Sleep Well!|The intervention comprehensively addresses poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers. Interventionists will use strategies to engage with and empower families, such as motivational interviewing and collaborative problem-solving. Session content will be reinforced via phone calls from interventionists. Families will receive intervention session appointment reminders and information about intervention content (e.g., reminders to follow a bedtime routine) via text message.
40804899|NCT06049095|DRUG|LTG-001|Oral doses
40804900|NCT06049095|DRUG|Placebo|Oral doses
41007938|NCT01546116|DRUG|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
41322668|NCT01273493|DRUG|Trabectedin|Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.
41007939|NCT02214277|DEVICE|Cerebral Protection System-The SENTINEL System with TAVR|Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
41007940|NCT02214277|DEVICE|TAVR|
41007941|NCT00183872|DRUG|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
41007942|NCT06136221|BEHAVIORAL|LiverWatch Intervention|The LiverWatch Intervention will include standard cirrhosis care and include additional components utilizing the W2H system. Details on this intervention are included in the study arm description.
41007943|NCT01400841|DEVICE|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
41007944|NCT00420550|BEHAVIORAL|Relaxation Response using Guided Imagery|
41007945|NCT05620290|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
41007946|NCT05620290|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
41007947|NCT03253549|DEVICE|SMArTVIEW|Remote automated, continuous monitoring in hospital after cardiac or vascular surgery, followed by 30-day at home monitoring, daily nurse video visits and a self-management training program.
41007948|NCT03560323|DRUG|Beta-hydroxy-butyrate|"Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (26 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end"
41322669|NCT01273493|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg/m\^2, 30 minutes prior to trabectedin.
41322670|NCT03583320|DIAGNOSTIC_TEST|Cardiac CT angiogram|To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
41322671|NCT02306239|DRUG|Terlipressin|
41007949|NCT00706966|DRUG|dutasteride|6 months of dutasteride 3.5 mg daily
41007950|NCT04302467|PROCEDURE|fluid therapy during operation|ERAS protocol of lobectomy will implemented to all the participants during perioperation,two groups of participants will be given different intraoperative fluid therapy strategy.
41007951|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °
41007952|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
41007953|NCT02832674|DEVICE|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
41007954|NCT03162601|PROCEDURE|Neurovascular percutaneous intervention|Patient will receive one extra CACT scan while they are receiving percutaneous neurovascular intervention.
41007955|NCT05037565|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum|Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
41007956|NCT01336478|PROCEDURE|Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Infusion of donor derived ex-vivo selected NK cells to patients after transplant
41007957|NCT01336478|PROCEDURE|Haematology / Blood chemistry sampling|Haematology / Blood chemistry sampling, collection of blood for ancillary lab research
41007958|NCT05103124|DEVICE|Hydral|The investigational product GUM Hydral will be administered for a 30-days treatment period
41007959|NCT05103124|OTHER|Placebo|The placebo product will be administered for a 30-days treatment period
41322672|NCT02306239|DRUG|Norepinephrine|
41322673|NCT04879654|PROCEDURE|endoscopic surgery|endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
41322674|NCT01736631|BEHAVIORAL|Cognitive behavioural therapy (CBT)|The CBT intervention will follow the model of social phobia by Clark \& Wells (Clark \& Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
41322675|NCT05941858|OTHER|Best Practice|Receive standard cessation treatments
41322676|NCT05941858|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
41322677|NCT05941858|OTHER|Internet-Based Intervention|Receive access to WaQi program
41322678|NCT05941858|DRUG|Nicotine Replacement|Receive referral for NRT
41322679|NCT05941858|OTHER|Survey Administration|Ancillary studies
41322680|NCT05941858|OTHER|Tai Chi|Practice Tai Chi
41322681|NCT00213980|DRUG|Zoledronate|4 mg IV over 15 minutes administered once every 12 weeks times 4
41322682|NCT05552118|PROCEDURE|Cochlear™ Remote care|"Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review.~Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit."
41152710|NCT06633133|PROCEDURE|Virtual ileostomy|A pre-stage ileostomy, anchored under the abdominal wall by a vascular sling or rubber tape through the mesenteric window, is delivered to the outside of the abdomen, where the VI is pulled through the abdominal wall.
41322683|NCT05552118|PROCEDURE|Standard of care|Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro
40804903|NCT05580562|DRUG|Dordaviprone (ONC201)|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.
40804904|NCT05580562|DRUG|Dordaviprone (ONC201) + Placebo|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments
40804905|NCT05580562|OTHER|Placebo|Participants will receive placebo (same number of capsules as the ONC201 dose) on dosing days
40804906|NCT04970901|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion
40804907|NCT04970901|DRUG|Polatuzumab Vedotin|IV infusion
40804908|NCT04970901|DRUG|Glofitamab|IV infusion
40804909|NCT04970901|DRUG|Mosunetuzumab|Subcutaneous (SC) injection
40804910|NCT04970901|DRUG|Obinutuzumab|IV infusion
41152711|NCT05070637|PROCEDURE|No-touch laparoscopic radical nephrectomy|We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.
41152712|NCT05070637|PROCEDURE|Conventional laparoscopic radical nephrectomy|Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.
41152713|NCT05070637|PROCEDURE|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.
41152714|NCT03283449|DRUG|18F-AV-1451|
41152715|NCT03283449|DEVICE|PET|PET scanner for brain imaging
41152716|NCT05199701|DEVICE|Mammography|Hologic pre-market Mammography
41152717|NCT00995618|DRUG|Tranilast|Tranilast tablets, 300 mg, QD
41152718|NCT00995618|DRUG|Febuxostat|Febuxostat Tablets, 40 mg, QD
41152719|NCT00995618|DRUG|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
41152720|NCT02578628|OTHER|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
41152721|NCT01295619|DEVICE|I-020805|A thin layer of I-020805 applied up to two times on the sutured dura mater
41152722|NCT04148716|PROCEDURE|additional biopsies|additional biopsies during a fibroscopy planned in the care
41152723|NCT01436045|DRUG|Insulin glulisine|Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
41152724|NCT01436045|DRUG|Saline|Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
41152725|NCT04241380|DRUG|Anticoagulant Solutions|Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
41322684|NCT05552118|DEVICE|Cochlear Implant CI600 Series, CI500 Series or Freedom Series and Sound processor Nucleus 7 or Kanso 2 (or latest compatible Sound Processor)|CI600 Series (CI612, CI622, CI632), CI500 Series (CI512, CI522, CI532), Freedom Series (CI24RE(CA), CI24RE(ST), CI422). Nucleus 7 (CP1000) or Kanso 2 (CP1050)
41152726|NCT04241380|OTHER|No anticoagulant solutions|They will receive non-coagulant or coagulant treatment according to clinical conditions.
41152727|NCT04241380|DRUG|Anticoagulant management|"Continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) for a few days.~Aspirin 5 mg/kg will be given every eight hours subsequently for 3 months."
41152728|NCT00628706|DRUG|Delta9-tetrahydrocannabinol (THC)|inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
41152729|NCT02600988|DRUG|1000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
41152730|NCT02600988|DRUG|5000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
41152731|NCT04891809|DRUG|Isatuximab-Irfc 20 MG/ML [Sarclisa]|Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
41152732|NCT04891809|DRUG|Lenalidomide|"Induction: 25mg\*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~\*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) \< 50 mL/min) starting dose is 10 mg"
41152733|NCT04891809|DRUG|Dexamethasone Oral|"Induction:~Patients aged \<75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly"
41152734|NCT05753358|OTHER|Total Worker Health for Wildland Firefighters|The program is structured as 30-minute modules that can be done individually, with a partner, as a group or in a classroom setting. The six core modules are supplemented with eight elective modules. The program can be accessed on a smartphone, tablet or computer, and if needed can be downloaded as a pdf.
41152735|NCT00665392|DRUG|cisplatin|75 mg/m², day 1. 3 cycles
41152736|NCT00665392|DRUG|docetaxel|75 mg/m² Day 1. 3 cycles
41322685|NCT02219841|PROCEDURE|radiofrequency catheter ablation|
41322686|NCT04227184|DRUG|Trospium|Drug to treat overactive bladder
41322687|NCT04227184|DRUG|Placebo oral tablet|Placebo tablet containing no active drug
41322688|NCT01369212|DRUG|Tenofovir|300 mg daily for 192 weeks (4 years)
41322689|NCT01369212|DRUG|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
41322690|NCT00321269|BEHAVIORAL|Single Illness Management|8 week nursing intervention addressing Congestive Heart Failure
41322691|NCT00321269|BEHAVIORAL|Comorbid Illness Management|8 week nursing intervention to address Congestive Heart Failure and emotional coping
40804926|NCT02506153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40804927|NCT02506153|PROCEDURE|Computed Tomography|Undergo CT scan
40804928|NCT02506153|BIOLOGICAL|Ipilimumab|Given IV
40804929|NCT02506153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40804930|NCT02506153|BIOLOGICAL|Pembrolizumab|Given IV
40804931|NCT02506153|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40804932|NCT02506153|OTHER|Quality-of-Life Assessment|Ancillary studies
40804933|NCT02506153|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV and SC
41152737|NCT00665392|DRUG|fluorouracil|750 mg/m² day 1 to day 5. 3 cycles
41152738|NCT00665392|DRUG|Cetuximab|400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
41152739|NCT01678755|DRUG|ABT-126|ABT-126 Low Dose
40804937|NCT06465069|DRUG|LY4052031|Intravenous
40804938|NCT06555016|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
40804939|NCT06555016|BEHAVIORAL|Walking|Overground walking.
41152740|NCT01678755|DRUG|ABT-126|ABT-126 High Dose
40804941|NCT06573814|DIETARY_SUPPLEMENT|Bio Gelee Royale Forte|Two capsules of Bio Gelee Royale Forte will be taken in the morning on empty stomach once per day for 98 days.
40804942|NCT06573814|OTHER|Placebo|Two capsules of placebo will be taken in the morning on empty stomach once per day for 98 days.
40804943|NCT00861705|BIOLOGICAL|Bevacizumab|Given IV
40804944|NCT00861705|DRUG|Carboplatin|Given IV
40804945|NCT00861705|DRUG|Cyclophosphamide|Given IV
40804946|NCT00861705|DRUG|Doxorubicin Hydrochloride|Given IV
40804947|NCT00861705|OTHER|Laboratory Biomarker Analysis|Correlative studies
40804948|NCT00861705|DRUG|Paclitaxel|Given IV
40804949|NCT06458062|DEVICE|Pocket Colposcope|Each patient will receive treatment in order to prevent cervical cancer
41152741|NCT01678755|DRUG|Placebo|Placebo
41152742|NCT03944499|DRUG|FS-1502|"Dose-Escalation Phase (Phase 1a)： FS-1502 dose-escalation will be proceeded on standard 3+3 design with starting dose of 0.1 mg/kg, IV, once per 28 days, 28 days as a cycle in the V1.2 and V2.0 regimens; IV, once per 21 days, 21 days as a cycle in the V3.0 regimens..~Dose level 1: 0.1 mg/kg; Dose level 2: 0.2 mg/kg; Dose level 3: 0.4 mg/kg; Dose level 4: 0.6 mg/kg; Dose level 5: 0.8 mg/kg; Dose level 6: 1.0 mg/kg; Dose level 7: 1.3 mg/kg. If 1.3mg/kg is still tolerated safely and in line with linear kinetic characteristics, and combined with the results of PK, PD, safety and effectiveness, a comprehensive assessment is made to determine whether to continue the dose escalating. The subsequent dose increase ratio is 33% (the dose increase ratio can be adjusted according to the previous data results) until MTD or RP2D.~Dose-expansion Phase (Phase 1b) : RP2D determined in phase 1a, IV."
40804952|NCT05707871|DRUG|SPECTRUM cigarettes|SPECTRUM cigarettes have varying amount of nicotine content
40804953|NCT05707871|OTHER|usual brand of Cigarettes|Usual Brand of Cigarettes
41322692|NCT00168324|DRUG|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
41322693|NCT00168324|DRUG|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
40804956|NCT00001160|DRUG|68-Gallium Dotatate|For evaluation risk/benefit evaluation
41322694|NCT00168324|OTHER|Sham Injection|Sham injection on Day 0.
41322695|NCT01779713|GENETIC|Case-control transcriptomic study|No intervention
41322696|NCT04609995|BEHAVIORAL|Incentives|No financial incentive
41322697|NCT01899677|OTHER|distilled water|0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
41322698|NCT01899677|DRUG|symbiotic|Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
40804957|NCT05740982|BIOLOGICAL|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.
41007960|NCT06104267|BEHAVIORAL|7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients|"The programme is based on the 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group."
41007961|NCT05833503|BEHAVIORAL|Integrative Couple Treatment for Addiction (ICT-A)|Couple-based intervention called Integrative Couple Treatment for Addiction (ICT-A).
41007962|NCT05833503|BEHAVIORAL|Treatment individual as usually offered|Individual-based treatment as usually offer by the specialized centres in addiction.
41007963|NCT02016963|BIOLOGICAL|Raxibacumab|Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
41322699|NCT04369755|OTHER|MRI|A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)
41322700|NCT01399749|OTHER|Implantation of autologous cells|Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
41007964|NCT00225706|DRUG|Caldolor|
41322701|NCT05406557|PROCEDURE|Partial pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of pulp chamber.
41322702|NCT05406557|PROCEDURE|Miniature pulpotomy|In case of miniature pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of only affected pulp horn
41322703|NCT01797991|DRUG|Dexamethasone per os|
41322704|NCT01797991|DRUG|Matching placebo for dexamethasone IV|
41322705|NCT01797991|DRUG|Dexamethasone IV|
41322706|NCT01797991|DRUG|Matching placebo for dexamethasone per os|
41322707|NCT03819478|BEHAVIORAL|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
41322708|NCT03819478|BEHAVIORAL|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
41322709|NCT03819478|DIETARY_SUPPLEMENT|NutraBio™ CarboMax Supplement|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (NutraBio™ CarboMax, \~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
41322710|NCT03819478|DIETARY_SUPPLEMENT|6-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 6-month higher protein / lower CHO diet group (6-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
40804959|NCT03473730|PROCEDURE|Biopsy|Undergo biopsy
40804960|NCT03473730|BIOLOGICAL|Daratumumab|Given IV
41007965|NCT01820611|DEVICE|Arcos Revision Stem System|Revision Hip System
40804961|NCT03473730|OTHER|Laboratory Biomarker Analysis|Correlative studies
40804962|NCT03473730|PROCEDURE|Metastasectomy|Undergo metastasectomy
40804963|NCT03473730|PROCEDURE|Nephrectomy|Undergo nephrectomy
40804964|NCT05753501|DRUG|ABBV-101|Oral:Tablet
41152743|NCT00830284|PROCEDURE|Recruitment maneuver|"Three types of maneuvers will be performed.~1. 6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.~2. 6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.~3. PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher."
40804966|NCT05306665|BEHAVIORAL|ACT intervention|One day in person workshop + telephone booster
40804967|NCT04929041|PROCEDURE|Biopsy|Undergo tissue biopsy
40804968|NCT04929041|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40804969|NCT04929041|PROCEDURE|Computed Tomography|Undergo CT
40804970|NCT04929041|PROCEDURE|Echocardiography|Undergo ECHO
40804971|NCT04929041|BIOLOGICAL|Ipilimumab|Given IV
40804972|NCT04929041|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40804973|NCT04929041|BIOLOGICAL|Nivolumab|Given IV
40804974|NCT04929041|PROCEDURE|Positron Emission Tomography|Undergo PET
40804975|NCT04929041|OTHER|Quality-of-Life Assessment|Ancillary studies
40804976|NCT04929041|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41152744|NCT03296176|BIOLOGICAL|blood sample|blood sample for metabolome analyse
40804978|NCT06445647|OTHER|core Stability exercise|core stability exercise training
40804979|NCT06445647|OTHER|Breathing exercises|Deep breathing and diaphragmatic breathing exercises
41007966|NCT03360292|OTHER|Higher target range|Intervention is using a higher oxygen saturation target range than in routine practice
41007967|NCT03517267|DIAGNOSTIC_TEST|ultrasound and FNA|The nodule to undergo FNA will be chosen according to TIRADS ACR criteria and the ATA risk criteria ( if there is a disagreement between the methods whether to perform FNA the FNA will be performed ) If both methods do not recommend FNA , but the referring doctor has requested the procedure or the patient is unable to stay on follow up , the FNA will be performed .
40804980|NCT05096273|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations
40804981|NCT05532722|DRUG|ABC008|Given subcutaneous injection
41152745|NCT03697837|BEHAVIORAL|Parent Management Training|The online digital parent training (DPT) program consists of 8 self-guided courses that take approximately 10 minutes to complete and include text and animated parent-child simulations. The courses are designed to closely parallel the content of existing evidence-based parent management training approaches that exist in numerous parenting books.
41152746|NCT02413502|BIOLOGICAL|BCG|BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10\^8 CFUs.
41322711|NCT03819478|DIETARY_SUPPLEMENT|18-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 18-month higher protein / lower CHO diet (18-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention and the 12-month follow-up.
41322712|NCT05854251|DRUG|Anakinra|Subjects receive an s.c. injection of 100 mg Anakinra on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
41322713|NCT05854251|DRUG|Placebo|0.67 ml of s.c. injection of saline will be taken on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
41152747|NCT00487799|DRUG|Ularitide|
41152748|NCT00960284|DRUG|capecitabine|Given orally
41152749|NCT00960284|DRUG|cisplatin|Given IV
41152750|NCT00960284|DRUG|epirubicin hydrochloride|Given IV
40804987|NCT05357339|OTHER|20% Albumin|100ml boluses 20% Albumin
40804988|NCT05357339|OTHER|Crystalloid|100ml bolus of crystalloid
41152751|NCT00960284|DRUG|fluorouracil|Given IV
41152752|NCT00960284|DRUG|gemcitabine hydrochloride|Given IV
41152753|NCT00647699|DRUG|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
41152754|NCT00647699|DEVICE|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
41152755|NCT03899259|DRUG|Baricitinib|Administered orally
41322714|NCT05930990|BEHAVIORAL|Mamas in Harmony|Mothers attend 8x 1 hour weekly classes with their infant. Classes take place in a community venue. Mothers sit with their infant on the floor in circle formation on cushioned mats. Group singing facilitated for 40 minutes by the intervention facilitator, a professional musician/choir leader. A mix of songs are introduced that are easy to learn without the need for lyric sheets. Mothers will be encouraged to sing along. Mothers will be encouraged to interact with their infant through various sensory stimuli involving touch, sound and visual. The end of each singing session involves a short period of quiet time, soothing sounds are provided by the intervention facilitator using voice and instruments. 20 minutes of facilitated social support will follow and mothers will be provided with refreshments. Mothers will be encouraged to interact with other mothers to promote social connection.
41322715|NCT02646267|DRUG|standard intensity warfarin|target international normalised ratio(INR) was 2.1-3.0
41152756|NCT03899259|DRUG|Placebo|Administered orally
41152757|NCT04063267|OTHER|E cigarettes|Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to reduce nicotine withdrawal symptoms
41007968|NCT00705575|DRUG|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
41322716|NCT02646267|DRUG|low intensity warfarin|target international normalised ratio(INR) was 1.7-2.2
41322717|NCT02646267|DRUG|dabigatran etexilate|110mg, twice a day, oral
41322718|NCT00881361|DRUG|systemic chemotherapy|
41322719|NCT00881361|PROCEDURE|axillary lymph node dissection|
41322720|NCT00881361|PROCEDURE|neoadjuvant therapy|
41322721|NCT00881361|PROCEDURE|sentinel lymph node biopsy|
41322722|NCT00881361|PROCEDURE|therapeutic conventional surgery|
41322723|NCT00881361|PROCEDURE|ultrasound imaging|
41322724|NCT02156232|PROCEDURE|TIPS|TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
41322725|NCT02156232|PROCEDURE|SPSS embolization|Embolization of SPSS will be conducted via the same jugular vein before TIPS implantation. The major procedures included (a) angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of SPSS with coils of varying diameters or Amplatzer Vascular Plug, which resulted in the SPSS disappearing at postembolization angiography.
41322726|NCT00311558|BIOLOGICAL|recombinant interferon alfa-2b|SSG x 5 week
41322727|NCT00311558|DRUG|sodium stibogluconate|SSG \& IFN
41322728|NCT00311558|DRUG|SSG & interferon|1 arm study with SSG \& interferon
41152758|NCT04063267|OTHER|Nicotine Replacement Therapy|Nicotine patches and gum to last them the first week based on their baseline recorded smoking. Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings.
41152759|NCT02829411|BEHAVIORAL|Workforce Readiness Program|job readiness workshops, organized into ten daily sessions over two weeks.
40804997|NCT06389136|DRUG|Upadacitinib Dose A|Oral tablet
41007969|NCT00705575|DRUG|Aliskiren (300 mg)|During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
41007970|NCT04733157|DRUG|Tranexamic acid injection|Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section
41007971|NCT04733157|OTHER|Normal saline placebo|10ml of normal saline will be administered intravenously at onset of skin incision at caesarean section to the placebo group
41007972|NCT05402527|DIETARY_SUPPLEMENT|Fish nutrients|Intake of fish protein, omega-3 fatty acids, and vitamin D
41322729|NCT06202001|DRUG|Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab|This study followed a classic 3+3 design, in which patients received escalating doses of TAS-102 (20, 25, 30, or 35 mg/m2/dose, administered twice daily for days 1-5) and irinotecan (135, 150, 165, or 180 mg/m2 on day 1) with a fixed dose of bevacizumab (5 mg/kg on day 1), repeated every 14 days.
41322730|NCT00736788|DRUG|AZD1704|single dose oral suspension, 4 different dose levels
41322731|NCT00736788|DRUG|Placebo|single dose oral suspension
41477621|NCT05104099|DRUG|Metvixia Topical Cream|"Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp.~The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area.~If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones."
41477622|NCT02231424|DRUG|Drug: Berodual®|
40804998|NCT06389136|DRUG|Dupilumab Dose A|Subcutaneous (SC) injection
40804999|NCT06389136|DRUG|Upadacitinib Dose B|Oral tablet
41152760|NCT02829411|BEHAVIORAL|Relationship education|"25-hours of Within My Reach curriculum and relationship skills education sessions"
41007973|NCT05402527|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
41477623|NCT02696031|DRUG|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
41477624|NCT02696031|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
41007974|NCT05402527|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
41007975|NCT06005025|OTHER|Reminder message|"Experimental group will be counselled for 6 months after the training and a reminder message will be sent via SMS on Monday every week as Check your modifiable risk factors for breast cancer and their feedback will be received."
41007976|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.
41007977|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
41007978|NCT05894850|OTHER|Manually remind the patients|Medical staff remind patients manually .
41007979|NCT03275558|DRUG|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
41322732|NCT04735549|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
41322733|NCT04735549|DRUG|Topical hormone estriol|Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
41007980|NCT03275558|DRUG|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
41007981|NCT03275558|DRUG|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
41007982|NCT05240846|PROCEDURE|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
41007983|NCT05240846|PROCEDURE|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on ultrasound assistance paramedian spinal. Spinal anesthesia with a paramedian approach was performed based on the optimum puncture point, suggested puncture angles, and puncture depth. The suggested puncture angles included the cephalad angle measured by the built-in angle program of the ultrasound and the medial angle measured by a 180° protractor (Deli). The puncture depth, the distance from the skin to the posterior complex, was measured utilizing the ultrasound clipper tool.
41007984|NCT03663595|OTHER|Model 1|Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.
41007985|NCT03663595|OTHER|Model 2|Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
41007986|NCT04783168|OTHER|Best Practice|Receive usual care
41322734|NCT04735549|DIAGNOSTIC_TEST|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis, Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study).
41322735|NCT04735549|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
41477625|NCT04250831|DIETARY_SUPPLEMENT|agglomerated glucomannan, oligofructose and chromium mixture|Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.
41477626|NCT02326974|DRUG|T-DM1|Neoadjuvant treatment is for a total of 18 weeks.
41477627|NCT02326974|DRUG|Pertuzumab|Neoadjuvant treatment is for a total of 18 weeks.
41477628|NCT02326974|PROCEDURE|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
41322736|NCT04735549|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), cytology, microbiological analysis with Gram staining (to evaluate procedure efficiency).
41322737|NCT04735549|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
41322738|NCT04735549|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
41322739|NCT04735549|OTHER|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
41322740|NCT04735549|OTHER|Vulvovaginal Symptoms Questionnaire|Vulvovaginal Symptoms Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
41152761|NCT00801151|DRUG|Zolinza (vorinostat), vinorelbine|"Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.~Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).~Patients may receive a maximum of 6 cycles of study medication."
41152762|NCT06094842|DRUG|Bendamustine|Given IV
41152763|NCT06094842|PROCEDURE|Biopsy|Undergo tissue biopsy
41007987|NCT04783168|OTHER|Health Promotion and Education|Install and use Fitbit app
41007988|NCT04783168|OTHER|Medical Device Usage and Evaluation|Use Fitbit to monitor step count
41322741|NCT04735549|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
41322742|NCT04735549|DIAGNOSTIC_TEST|Elastography (ultrasound investigation)|Ultrasound investigation for assessing elasticity / stiffness of tissues of vulva region with Mindray device (head L14-6WU) (to evaluate procedure efficiency).
41152764|NCT06094842|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41152765|NCT06094842|PROCEDURE|Bone Scan|Undergo bone scan
40805007|NCT06571383|DRUG|Semaglutide|Participants will receive semaglutide s.c(under the skin) once weekly.
41152766|NCT06094842|PROCEDURE|Bridge Therapy|Undergo bridging therapy
41007989|NCT04783168|OTHER|Quality-of-Life Assessment|Ancillary studies
41007990|NCT04783168|OTHER|Questionnaire Administration|Ancillary studies
41007991|NCT05855863|DRUG|Ginkgo Ketone Ester Tablets|Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
41007992|NCT05855863|DRUG|placebo|placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
41007993|NCT02431858|DEVICE|E-Catheter (Pajunk)|
41007994|NCT02431858|DEVICE|Sonolong Catheter (Pajunk)|
41007995|NCT03633435|PROCEDURE|assisted home hemodialysis patients|Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
41007996|NCT05224947|OTHER|Infant Formula|Two infant formulas differing in composition
41007997|NCT01427296|DRUG|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
41152767|NCT06094842|PROCEDURE|Computed Tomography|Undergo CT
41152768|NCT06094842|DRUG|Cyclophosphamide|Given IV
41152769|NCT06094842|PROCEDURE|Echocardiography|Undergo ECHO
41152770|NCT06094842|DRUG|Fludarabine|Given IV
41152771|NCT06094842|PROCEDURE|Leukapheresis|Undergo leukapheresis
41152772|NCT06094842|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41152773|NCT06094842|BIOLOGICAL|T-cell Receptor-engineered T-cells|Given autologous L1CAM-specific CAR+EGFRt+ T cells IV
41152774|NCT06094842|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
41322743|NCT04735549|DIAGNOSTIC_TEST|Perineometry|Pressure force of vaginal walls measurement with EmbaGYN device (to evaluate procedure efficiency).
41322744|NCT04735549|OTHER|Visual Analogue Scale (VAS)|Visual Analogue Scale will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
41322745|NCT04626193|DRUG|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid
41322746|NCT04626193|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
41322747|NCT05518669|DEVICE|Electromagnetic Navigation Bronchoscopy (superDimension™ Navigation System) and Mobile Cone-Beam CT (Cios Spin)|Subjects with biopsy of peripheral pulmonary nodule using electromagnetic navigation bronchoscopy and mobile cone-beam CT.
41322748|NCT02290964|PROCEDURE|ANH|After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
41322749|NCT00338468|DRUG|epoetin alfa|
40805009|NCT03980743|BEHAVIORAL|iOTA text messaging intervention|Over 6 months, participants in the iOTA arm will have monthly in-person visits with a health coach who will work with the participant to set goals for the upcoming month related to healthy eating and activity. The participant will receive daily text message health tips related to their goals, and will be prompted once a week to respond with a text indicating their weight and how they are doing with their goals. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
40805010|NCT03980743|BEHAVIORAL|Health Education text messaging intervention|Over 6 months, participants in the Health Ed arm will also have monthly in-person visits with a health coach who will provide education on energy balance and problem-solving. Specific goals will not be set, but the health coach will assist participants in problem-solving any challenges. Participants will receive a weekly automated motivational text message health tip from the study related to what they learned in their health coaching sessions. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
40805011|NCT06055959|DRUG|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants.
40805012|NCT05222412|DRUG|Iptacopan|Patients receive Iptacopan
41152775|NCT02720783|DRUG|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
41152776|NCT02720783|DRUG|Placebo plus Econazole nitrate 150 mg vaginal pessary|
40805015|NCT06115499|DRUG|Nab paclitaxel|Given IV
40805016|NCT06115499|DRUG|Gemcitabine|Given IV
40805017|NCT06115499|DRUG|Cisplatin|Given IV
40805018|NCT06115499|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40805019|NCT06115499|PROCEDURE|Computed Tomography|Undergo CT
40805020|NCT06115499|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41152777|NCT02720783|DRUG|Placebo plus Benzydamine HCl 6 mg vaginal pessary|
41152778|NCT02720783|DRUG|Placebo vaginal pessary|
41152779|NCT01504919|BEHAVIORAL|Health Education|Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).
40805024|NCT06284460|DRUG|ASTX029|Given by PO
40805025|NCT06284460|DRUG|ASTX727|Given by PO
40805026|NCT05767398|DRUG|Zanubrutinib|Administered as a tablet or capsule
40805027|NCT04516538|BEHAVIORAL|Mini Mental State Examination|test for evaluating a person's cognitive functions and memory capacity
40805028|NCT04516538|DIAGNOSTIC_TEST|6 Minutes Walk Test|a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
40805029|NCT04516538|DIAGNOSTIC_TEST|Timed up and go|A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.
40805030|NCT04516538|DIAGNOSTIC_TEST|Isokinetic Body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isokinetic BW-QIF test blocks consist in 100 contractions at 120° deg.s-1 and 60° of range of motion (0.5-s contraction /0.5-s rest)."
40805031|NCT04516538|DIAGNOSTIC_TEST|Cycloergometer body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The BW-QIF test blocks on the cycloergometer consist in 100 s of cycling at 60 Revolution Per Minute (RPM)."
40805032|NCT04516538|DIAGNOSTIC_TEST|Isometric BW-QIF Test (Body weight-based quadriceps intermittent fatigue test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isometric BW-QIF test blocks consist in 10 contractions (5-s contraction / 5-s rest)."
41007998|NCT01427296|DRUG|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
40805033|NCT06230224|DRUG|Odronextamab|Administered by intravenous (IV) infusion
41007999|NCT05188352|OTHER|Chest physiotherapy|The program included diaphragmatic breathing exercises, thoracic expansion exercises, incentive spirometer exercises, and coughing techniques.
41152780|NCT01504919|BEHAVIORAL|Questionnaires|Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.
41152781|NCT01504919|BEHAVIORAL|Telephone Counseling Sessions|9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.
41152782|NCT01504919|DRUG|Nicotine Patches|6-week supply of nicotine patches given to participants ready to quit smoking.
41152783|NCT05067972|DRUG|PF-07260437|B7-H4 x CD3 bi-specific mAb
40805034|NCT06230224|DRUG|Ifosfamide|Administered by IV infusion, as part of the ICE ± R salvage therapy
40805035|NCT06230224|DRUG|Carboplatin|Administered by IV infusion, as part of the ICE ± R salvage therapy
40805036|NCT06230224|DRUG|Etoposide|Administered by IV infusion, as part of the ICE ± R salvage therapy
40805037|NCT06230224|DRUG|Rituximab|Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.
40805038|NCT06230224|DRUG|Dexamethasone|Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.
40805039|NCT06230224|DRUG|Cisplatin|Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.
40805040|NCT06230224|DRUG|Cytarabine|Administered by IV infusion, as part of the DHAP ± R salvage therapy.
40805041|NCT06230224|DRUG|Gemcitabine|Administered by IV infusion, as part of the GDP ± R salvage therapy.
41152784|NCT05067972|DIAGNOSTIC_TEST|B7-H4 IHC|B7-H4 expression
40805043|NCT06262048|DRUG|Tamsulosin Hydrochloride|2 days pre-op, day of surgery, 2 days post-op
40805044|NCT06262048|OTHER|Placebo|2 days pre-op, day of surgery, 2 days post-op
40805045|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy|CPT as described in the treatment manual
40805046|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy (CPT) + Memory Support|CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
40805047|NCT06141486|DRUG|Frexalimab|SAR441344 Solution for IV infusion
40805048|NCT06141486|DRUG|Placebo|Solution for IV infusion
40805049|NCT06141486|DRUG|MRI contrast-enhancing agents|IV, as per respective label
41152785|NCT03987672|DIETARY_SUPPLEMENT|Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula|Kate Farm Peptide 1.5 nutritional Formula
41152786|NCT05510102|DEVICE|WHOOP strap 4.0 (full data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will have full remote monitoring data access throughout the entirety of the study (6 months).
41152787|NCT05510102|DEVICE|WHOOP strap 4.0 (partial data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will be blinded to remote monitoring data for the first 3 months of the study followed by an unblinding and full access to remote monitoring data at the 3 month mark (continued for the remainder of the study).
41152788|NCT06340334|BIOLOGICAL|Tegoprazan-amoxicillin dual therapy|A total of 600 Hp-positive patients who had not received Hp eradication therapy before or had had Hp eradication in the early stage but had not undergone eradication therapy in the past six months were randomly divided into two groups: group A subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, tid; Group B subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid. The duration of treatment is 14 days. The eradication rate, adverse reactions, and compliance of the two groups were compared.
41152789|NCT01642030|DRUG|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
41152790|NCT01642030|DRUG|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
40805056|NCT06535854|DEVICE|Prevail DCB|The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.
40805057|NCT06535854|DEVICE|Agent DCB|The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).
40805058|NCT04188405|DRUG|Decitabine|Given IV
40805059|NCT04188405|DRUG|Ponatinib|Given PO
40805060|NCT04188405|DRUG|Venetoclax|Given PO
41008000|NCT05188352|OTHER|Aerobic exercise training|"A treadmill was used for aerobic exercise. Training intensity was used at 60-75% of maximal VO2.~Each session had a five-minute warm-up and cool-down period. Blood pressure and ECG were recorded during training sessions before exercise, at the third minute of each workload, after exercise, and during each minute of the recovery period."
41008001|NCT01735292|DEVICE|Automatic Respiration Transfer System- Timer|
40805061|NCT06340321|DIAGNOSTIC_TEST|Metabolic flexibility in the fasted state|Measured at baseline during the InSight study (2008-2009). Calculated as the respiratory exchange ratio in the fasting state adjusted for the circulating concentrations of free fatty acids
40805062|NCT06340321|OTHER|Metabolic flexibility in euglycemic-hyperinsulinemic clamp|Measured at baseline during the InSight study (2008-2009). Calculated as the change in respiratory exchange ratio adjusted for glucose disposal rate
40805063|NCT06340321|OTHER|Metabolic flexibility in the metabolic chamber|Measured at baseline during the InSight study (2008-2009). Calculated as the difference between awake respiratory exchange ratio (from 8 a.m. to 11 p.m.) and sleeping respiratory exchange ratio during a 23-hour stay in the metabolic chamber
41152791|NCT01642030|DRUG|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
41152792|NCT04872465|DEVICE|TBS|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
41152793|NCT04872465|DEVICE|sham|Participants will receive sham (placebo) TBS treatment the same as experimental group
41152794|NCT00690950|DRUG|Dutasteride|0.5mg capsule, taken once daily for 12 months
40805069|NCT05813275|DRUG|AD109|Oral administration at bedtime
40805070|NCT05813275|DRUG|Placebo|Oral administration at bedtime
40805074|NCT05804162|DRUG|Cagrilintide|Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.
40805075|NCT05804162|DRUG|Cagrilintide Placebo|Participants will receive cagrilintide placebo subcutaneously once weekly.
40805076|NCT05804162|DRUG|Moxifloxacin|Partcipants will receive a single dose of moxifloxacin orally.
40805077|NCT05804162|DRUG|Moxifloxacin Placebo|Partcipants will receive a single dose of moxifloxacin orally.
41152795|NCT02395588|OTHER|Guideline based care|Patient education using guideline based teaching guides
40805079|NCT06235099|DRUG|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for the detection of PSMA expression.
41008002|NCT02354638|BEHAVIORAL|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
41008003|NCT02354638|DRUG|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
41008004|NCT01570023|BEHAVIORAL|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
41008005|NCT02087462|OTHER|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks."
41008006|NCT02087462|OTHER|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
41008007|NCT02087462|DRUG|Voltaren|"Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
41008008|NCT02087462|DRUG|Vitamin B1|"Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
41008009|NCT04341038|DRUG|Tacrolimus|the necessary dose to obtain blood levels of 8-10 ng / ml
41008010|NCT04341038|DRUG|Methylprednisolone|120mg of methylprednisolone daily for 3 consecutive days
41477629|NCT03856593|BEHAVIORAL|Standard letter|The standard letter will be signed by the Chief Medical Examiner-Coroner and County Health Officer of Los Angeles County to notify prescribers of the death in their practice. The letter includes the decedent's name, date of birth and date of death, and outlines the annual number and types of prescription drug deaths seen by the medical examiner, discusses the value of and way to access the State's prescription drug monitoring program and includes five Centers for Disease Control and Prevention (CDC) guideline-recommended safe prescribing strategies: 1) Avoid co-prescribing of opioids with benzodiazepines, 2) prescribe minimal dose necessary for acute pain, 3) consider slow tapers with pauses to below 50 morphine milligram equivalents (MME) per day, 4) avoid prescriptions lasting greater than 3-months for pain, and 5) prescribe naloxone in conjunction with opioids for patients taking \> 50 MME per day. The letter also states that CURES review is required by law as of October 2, 2018.
41152796|NCT03013725|OTHER|No intervention|No intervention
41152797|NCT06169878|DEVICE|Adjustable lower limb abduction apparatus|"To ensure abduction in the lower extremities after total hip replacement surgery, a specially adjustable apparatus developed according to the height and weight of each individual was used.~This developed product was used by patients while they were lying down and walking."
41008011|NCT00215774|DRUG|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
40805082|NCT04868682|BEHAVIORAL|Behavioral Education Intervention I|Manual-based education program provided in individual sessions.
40805083|NCT04868682|BEHAVIORAL|Behavioral Education Intervention II|Manual-based education program provided in individual sessions.
41008012|NCT03291912|PROCEDURE|Chuna Manual Therapy|"* Unique manual therapy in traditional Korean medicine~* Mandatory techniques for neck part and selective techniques for other part (if necessary)~* Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)"
41152798|NCT05987839|PROCEDURE|robotic system|Total knee arthroplasty assisted by knee navigation and positioning system
41152799|NCT01212952|DRUG|pomalidomide|Given orally
41152800|NCT01212952|DRUG|bortezomib|Given IV
41152801|NCT01212952|DRUG|dexamethasone|Given orally
41152802|NCT01212952|OTHER|laboratory biomarker analysis|Optional correlative studies
41152803|NCT01212952|OTHER|gene expression analysis|Optional correlative studies
41152804|NCT01265914|BIOLOGICAL|FP-01.1|Ascending doses of FP-01.1 will be administered
41152805|NCT01265914|BIOLOGICAL|placebo|
41152806|NCT04747717|PROCEDURE|chemotherapy/surgery|NEO chemotherapy/interval debulking surgery/AD chemotherapy
41152807|NCT02135419|DRUG|imiquimod|Applied topically
41152808|NCT02135419|DRUG|fluorouracil|Applied topically
41152809|NCT02135419|DEVICE|infrared photocoagulation therapy|Undergo infrared coagulation
41322750|NCT05743751|DEVICE|Normothermic machine perfusion|XVIVO (perfusion company, Gothenburg, Sweden), functions to be included in perfusion equipment, cardiopulmonary bypass machine and neonatal cardiopulmonary bypass machine, including polyethylene pipeline, heating equipment (perfusion temperature 37 ℃), venous pool (venous pressure is 0 mmHg, adjust the height of perfusion pool), centrifugal pump (arterial pressure is set at initial 75 mmHg, maintain 65 mmHg). The perfusion solution contains 215ml of dextran/albumin solution and 400ml of hematocrit, 2ml of 10% calcium gluconate, 1300u/L heparin and 400mg of cefazolin sodium. The oxygen/carbon dioxide ratio is (95%/5%, 2L/min) for continuous perfusion, and pO2 is maintained at 650mmHg during perfusion. During perfusion, continue to use verapamil, amino acid, glucose and insulin. Lactic acid Ringer solution (10ml/h) was used to supplement the lost circulation volume due to urine production during perfusion.
41008013|NCT03291912|PROCEDURE|Usual care|"1. Physical therapy based on traditional Korean medicine theory~   * Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~  * Heat stimulation: either Hot pack or Infrared lamp~2. Patient education~   * Physical and pathological explanation of cervicogenic dizziness~  * Cause and risk factors of cervicogenic dizziness~  * Functions of muscles related to cervicogenic dizziness~  * Home exercising to self-manage cervicogenic dizziness"
41322751|NCT05743751|DEVICE|Hypothermic machine perfusion|LifePort Kidney Transporter is designed to integrate with the clinical environment by using readily available supplies, requiring minimal user intervention, and by being easy to use. LifePort Kidney Transporter is a portable, isolated kidney perfusion and transport system, designed to support a donated kidney and to maintain the organ in a near-normal physiologic state under hypothermic aseptic conditions. An insulated plastic housing encloses the kidney and perfusate within a LifePort Kidney Transporter Disposable Perfusion Circuit. LifePort Kidney Transporter components include an Ice Container, Pump Deck, Control Panel, Outer Display, Bubble Detectors, External Connections Panel, sensors, and four lithium-ion batteries. Two handles make the unit easy to lift and carry
41322752|NCT02201355|RADIATION|Intensity Modulated Radiotherapy|Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
41322753|NCT00862654|DRUG|clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo \& ketoconazole shampoo
41322754|NCT00862654|DRUG|clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo \& ketoconazole shampoo
41322755|NCT00862654|DRUG|clobetasol propionate shampoo (2/week)|Monotherapy with clobetasol propionate shampoo
41322756|NCT00862654|DRUG|ketoconazole shampoo (2/week)|Monotherpay ketoconazole shampoo (2/week)
41322757|NCT06299813|DRUG|Bentelan|The experimental treatment group will be administered betamethasone 0.1 mg per kg.
41008014|NCT00088296|PROCEDURE|Blood Draw|
41322758|NCT06299813|DRUG|Placebo|The placebo used in the study will consist of 100 ml of purified water (PPI BBU).
41322759|NCT01461408|BEHAVIORAL|Health Education Session|"The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect-their hairdressers-will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.~The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during down times in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26."
41477630|NCT03856593|BEHAVIORAL|Comparator letter|"The comparator letter includes all the details in the standard letter plus additional text involving an if/when/then statement along with an injunction to providers to share safety information with patients so that they identify as a safe prescriber. Specifically, the additional text reads as follows: When your next patient presents with pain, keep the above 5 recommendations close at hand to assist with their safe care. Also, be comfortable voicing your concern about prescribing safety with them so that they are also aware of the dangers scheduled drugs may carry. If/when/then is a form of pre-suasion that provides simple rules that tie goals to specific actions and has been used successfully to encourage behavior in many areas including medication adherence and drug abuse rehabilitation."
41477631|NCT03418857|DRUG|Yogurt smoothie with BB-12|During the one month intervention period, the participants will consume one yogurt smoothie with BB-12 daily.
41477632|NCT03418857|DRUG|Yogurt smoothie|During the one month control period, the participants will consume one yogurt smoothie daily.
41477633|NCT02988869|DRUG|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
41008015|NCT03755024|DEVICE|ultrasound|"The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~* Biparietal diameter~* Head circumference~* Abdominal circumference~* Femur length~* Humerus length"
41008016|NCT04949269|DRUG|Deucravacitinib|Specified dose on specified days
41008017|NCT04949269|DRUG|Famotidine|Specified dose on specified days
41152810|NCT02135419|DEVICE|thermal ablation therapy|Undergo hyfrecation/electrocautery therapy
41152811|NCT02135419|DEVICE|laser therapy|Undergo laser therapy
41477634|NCT02988869|DRUG|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
41477635|NCT02988869|DRUG|Formoterol|Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
40805084|NCT06416150|BEHAVIORAL|Stage 1 SOC|Participants will receive high Standard Care, consisting of a telephone call approximately one month before the appointment to confirm the appointment date for the baseline colposcopy appointment, followed by a notification letter including scheduled appointment date and clinic contact information should the clinic be unable to reach the patient by telephone.
40805085|NCT06416150|BEHAVIORAL|Stage 1 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
40805086|NCT06416150|BEHAVIORAL|Stage 2 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
40805087|NCT06416150|BEHAVIORAL|Stage 2 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as health coaching (HC) after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
40805088|NCT06416150|BEHAVIORAL|Stage 3 SOC|Participants will receive a telephone call before their 12-month follow-up appointments to remind participants about their upcoming appointment and schedule/reschedule if needed.
41008018|NCT03848546|BEHAVIORAL|PDA|"Subjects receive personal dietary fiber advice to increase their fiber intake. This advice will be provided using an online web-portal, where subjects can choose high-fiber alternatives that closely match their own intake. The aim is to swap product for low in fiber for a high fiber alternative (such as white bread, whole wheat bread)."
41008019|NCT03848546|OTHER|Control (no intervention)|No intervention
41008020|NCT02953990|BEHAVIORAL|MOMS Program|
40805089|NCT06416150|BEHAVIORAL|Stage 3 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
40805090|NCT06416150|BEHAVIORAL|Stage 3 HERS+HC|Participants will receive text message barriers counseling as well as HC after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
40805091|NCT06416150|BEHAVIORAL|Stage 4 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
40805092|NCT06416150|BEHAVIORAL|Stage 4 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as HC. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
41152812|NCT02135419|OTHER|clinical observation|Undergo active monitoring (High Resolution Anoscopy \[HRA\]) with biopsies
41152813|NCT02135419|OTHER|laboratory biomarker analysis|Correlative studies
41152814|NCT02521025|OTHER|Intermittent feeding pattern|Intermittent feeding
41152815|NCT02521025|OTHER|Continuous feeding pattern|Continuous feeding
41152816|NCT01532830|DEVICE|n-VNS|
41152817|NCT00079599|DRUG|L-carnitine|A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
40805099|NCT04270149|BIOLOGICAL|ESR1 peptide vaccine|ESR1 peptides plus Montanide and GM-CSF
41152818|NCT00079599|OTHER|Placebo|A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
40805101|NCT02756962|DRUG|Cytarabine|
40805102|NCT02756962|PROCEDURE|Allogeneic stem cell transplant|
40805103|NCT02756962|PROCEDURE|Bone marrow aspiration|"* Baseline~* Approximately 30 days after cytotoxic induction therapy~* End of treatment"
40805104|NCT02756962|PROCEDURE|Punch skin biopsy|"* The first will be obtained with the initial blood and bone marrow collections, whenever possible.~* The second will be obtained at the time of re-biopsy to confirm remission."
40805105|NCT02756962|DEVICE|ClinSeq|Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab
41152819|NCT04911322|DEVICE|ultrasonography|"A full obstetric ultrasound scan will be performed to assess signs of placental invasion, to document fetal biometry, estimated fetal weight, amniotic fluid index, assess fetal lung maturity parameters as pulmonary artery Doppler waveforms, amniotic fluid free floating particles, bowel echogenicity, fetal epiphyseal ossific centers, liver/lung echogenicity and kidney length.~Pulmonary artery Doppler: Fetal echocardiography will be done. Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time ratio will be measured in the main pulmonary artery."
41152820|NCT06445023|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
41152821|NCT06445023|BIOLOGICAL|Matching placebo|Matching placebo Subcutaneous Administration
41152822|NCT02210949|DRUG|Erythropoietin subcutaneously and Iron intravenously|Administration of Erythropoietin subcutaneously and administration of iron intravenously
40805110|NCT05669989|DRUG|Isatuximab intravenous (IV)|Route of administration: IV infusion; Pharmaceutical form: Vial
41322760|NCT01510834|BEHAVIORAL|Multibehavioral, Computerized Tailored Intervention STR2IVE|All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
41322761|NCT04065191|OTHER|High-intensity interval training|Heart rate based high-intensity interval training
41322762|NCT00063583|DRUG|Pirfenidone|Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
41322763|NCT00143975|DRUG|Cytarabine|3 g/m2 bid. i.v day 1-3
41322764|NCT00143975|DRUG|Mitoxantrone|12 mg/m2 i.v. day 2 and 3
41322765|NCT00143975|DRUG|Gemtuzumab Ozogamicin|3mg/m² i.v. day 1
41322766|NCT00143975|DRUG|All-trans-Retinoid Acid|45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28
40805111|NCT05669989|DRUG|Cemiplimab (SAR439684)|Route of administration: IV infusion; Pharmaceutical form: Vial
40805112|NCT05669989|DRUG|Dexamethasone|Route of administration: Oral or IV infusion; Pharmaceutical form: Tablets/single use vial
40805113|NCT05669989|DRUG|Lenalidomide|Route of administration: Oral; Pharmaceutical form: Capsules
40805114|NCT05669989|DRUG|Pomalidomide|Route of administration: Oral; Pharmaceutical form: Hard capsules
40805115|NCT05669989|DRUG|Isatuximab subcutaneous (SC)|Route of administration: SC injection with the investigational isatuximab injector device; Pharmaceutical form: Vial
40805116|NCT05669989|DRUG|Carfilzomib|Route of administration: IV infusion; Pharmaceutical form: Vial
41152823|NCT04074304|OTHER|I-HoME|A multi-component technology-based care intervention.
41322767|NCT02017613|DRUG|RP6530|Escalating doses starting at 25 mg BID
40805119|NCT04874038|DRUG|Lidocaine 20mg/ml|Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).
40805120|NCT04874038|DRUG|Placebo|Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
40805121|NCT04812028|DRUG|Magnesium sulfate|Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
41322768|NCT01601808|DRUG|Placebo|Orally once a day, continuously throughout the study
41322769|NCT01601808|DRUG|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
41477636|NCT02988869|DRUG|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
41477637|NCT03716934|DEVICE|Arctic Front Advance® balloon catheter|Cryoablation of bidirectional block of all pulmonary veins
41477638|NCT03716934|DRUG|Antiarrhythmic drug|The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.
41477639|NCT03716934|DEVICE|Confirm RX heart monitor® (Abbott)|Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function
41477640|NCT05633914|DRUG|Tucidinostat|20mg, po., biw, q3w
41008021|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day."
41008022|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful."
41008023|NCT06476223|DRUG|Artificial saliva containing cumin and ginger extract|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
41008024|NCT06476223|DRUG|Placebo|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
41008025|NCT02129075|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
41008026|NCT02129075|DRUG|Poly ICLC|Given SC
41008027|NCT02129075|BIOLOGICAL|Recombinant Flt3 Ligand|Given SC
41008028|NCT01687166|DEVICE|Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|
41008029|NCT01687166|DEVICE|FDA Approved Open-Irrigated Ablation Catheter|
41008030|NCT03182348|PROCEDURE|Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
41477641|NCT05633914|DRUG|nab-paclitaxel|125mg/m2, d1, iv.drip, q7d
41008031|NCT04631939|DEVICE|Metacognitive training game|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The intervention consists of 4 different puzzles. Unbeknownst to the player, the first pieces of evidence of each puzzle are often misleading, i.e. indicate the wrong solution, such that hasty decisions are punished. Players receive immediate feedback and are shown the correct response after submitting their solution, as well as explicit cues that educate them on the value of making adequately informed decisions. The order of the puzzles is fixed for each player, but different per session."
41477642|NCT04412057|DRUG|CERC-002|Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.
41008032|NCT04631939|DEVICE|Control games|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The control intervention consists of 4 different puzzle games requiring exclusively dexterity and accuracy (i.e., not including any metacognitive elements). The order of the puzzles is fixed for each player, but different per session."
41477643|NCT04412057|DRUG|Placebo|Administered once subcutaneously
41477644|NCT05305560|DRUG|Ivermectin Tablets|Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
41477645|NCT05305560|DRUG|Matching placebo tablets|Daily placebo tablets intake for 28 days
41008033|NCT03144180|DEVICE|Q-cup|This technology is a different way of collecting umbilical cord blood.
41008034|NCT00355446|DRUG|Bimatoprost 0.03%|
41152824|NCT04748445|DIAGNOSTIC_TEST|SARS-CoV-2/Influenza/RSV RT-PCR|nasal swab
41152825|NCT01551121|OTHER|It will then allow them to intervene at the right time and the right place|The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
40805123|NCT05999630|DRUG|Artificial Tears Methylcellulose|Participants will self-administer the artificial tears according to the schedule.
41477646|NCT00789113|DRUG|Extended Release Lamotrigine|
41477647|NCT01715896|BIOLOGICAL|Golimumab 50 mg|Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
41008035|NCT03522376|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% and 50% of maximal inspiratory pressure. The orders of the two loaded test conditions will be conducted in random order with at least 24 hours separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
41008036|NCT02091791|PROCEDURE|Traction sessions|
41008037|NCT04960228|BEHAVIORAL|Altruism Video|The video provides three vignettes about a diverse set of people who may be more vulnerable to serious health consequences from COVID-19. In each of the stories, high vaccine uptake of those around these vulnerable individuals serves to protect them. This communicates that getting the COVID-19 vaccine can be done for prosocial reasons and to foster a sense of community, as it provides protection not only to oneself, but also to others.
41008038|NCT04960228|BEHAVIORAL|COVID-19 Informational Text|The topics included in the text are how COVID-19 spreads, hygiene, physical distancing, and travel restrictions. Participants will complete three comprehension questions, one after each of the following sections: hygiene, physical distancing, and travel restrictions.
41008039|NCT01668316|BEHAVIORAL|Weight loss|"1. Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~2. Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~3. Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~4. Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work."
41008040|NCT01947504|BEHAVIORAL|education and support intervention|
41477648|NCT01715896|BIOLOGICAL|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
41477649|NCT03794791|BEHAVIORAL|education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
41008041|NCT00656253|DRUG|Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)|12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
41008042|NCT00656253|DRUG|Placebo|12 months period of placebo plus 1 month period without placebo
41008043|NCT03992807|OTHER|A patient decision aid|Potential participants receive a printed decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
41008044|NCT03992807|OTHER|A usual education booklet|Potential participants receive a usual booklet about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
41008045|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D|Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol
40805126|NCT02422641|DRUG|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
40805127|NCT05405114|DRUG|NDec - oral decitabine-tetrahydrouridine|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
40805128|NCT05405114|DRUG|HU - Hydroxyurea|Participants will get capsules daily (oral administration) according to local labelling
40805129|NCT05405114|DRUG|Placebo|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
40805130|NCT06152042|DRUG|BMF-219|BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
40805131|NCT06327373|DRUG|Oxygen|Supplemental oxygen by oxygen concentrator
40805132|NCT06327373|DRUG|Room air|Room air without oxygen concentrator
40805133|NCT04643457|DRUG|UCB9741|- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
40805134|NCT04643457|DRUG|Intravenous Placebo|- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
40805135|NCT04643457|DRUG|Subcutaneous Placebo|Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
41152826|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
41152827|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
41152828|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectivel
41322770|NCT04786132|OTHER|Cognitive-motor training|"A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise."
41152829|NCT01396733|DRUG|alpha-lipoic acids|alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
41152830|NCT01039116|BEHAVIORAL|High Intensity|High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
41152831|NCT01039116|BEHAVIORAL|Low Intensity|Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
41152832|NCT00608387|BEHAVIORAL|Chronic disease management Web-based software|Participants will have access to remotely based medical providers through the use of the Web-based software.
40805143|NCT06529003|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) unit|All participants in this study will receive the standard of care, which includes oral ibuprofen and a paracervical block at the time of laminaria insertion. Those in the treatment group will receive an adjunctive TENS unit with specific instructions for use in the interval between laminaria insertion and dilation and evacuation the next day. TENS is a non-invasive, inexpensive, over-the-counter, nonpharmacologic option to relieve pain. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
40805144|NCT06529003|DEVICE|Placebo|Participants in the placebo group will be given a TENS unit without a battery with similar to the intervention group but will be advised that they may or may not feel a sensation from the electrodes. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
41152833|NCT00082576|DRUG|Azithromycin/Chloroquine|
40805146|NCT06465810|DRUG|Treatment of transthyretin (ATTR) amyloidosis in observational study setting|Data will be collected on patients with ATTR amyloidosis in a real-world setting
41152834|NCT00082576|DRUG|Mefloquine|
40805148|NCT03427814|DRUG|Pamiparib|60 mg orally twice daily
40805149|NCT03427814|DRUG|Placebo|60 mg orally twice daily
41008046|NCT04070833|DRUG|Fish oil|Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
41008047|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
41008048|NCT04070833|DRUG|Fish oil placebo|Fish oil placebo
41008049|NCT01469286|DEVICE|TEA|Electroacupuncture at ST36
41477650|NCT03794791|BEHAVIORAL|no education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
40805150|NCT05740527|DEVICE|Noninvasive electrical stimulation of genital nerves|A closed-loop system (in-bladder sensor, radio, algorithm, and stimulator) is being tested for the feasibility of inhibiting neurogenic bladder overactivity in an ambulatory setting.
41008050|NCT01469286|DEVICE|Sham-TEA|Electroacupuncture at sham-points
41008051|NCT06081166|DRUG|Obicetrapib|obicetrapib 10 mg daily
41008052|NCT06081166|DRUG|Atorvastatin Calcium|Atorvastatin 80 mg
41477651|NCT06454942|DIETARY_SUPPLEMENT|Nutrient-fortified egg|Consumption of nutrient-fortified eggs with habitual diet
40805151|NCT06120283|DRUG|BGB-43395|Planned doses administered orally.
41477652|NCT06454942|DIETARY_SUPPLEMENT|Regular egg with habitual diet|Consumption of regular egg with habitual diet
41008053|NCT06081166|DRUG|Rosuvastatin Calcium|Rosuvastatin 40 mg
41477653|NCT00000476|DRUG|digitalis|
40805152|NCT06120283|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
40805153|NCT06120283|DRUG|Letrozole|Standard dose administered orally as a tablet.
40805154|NCT04433741|DRUG|Oxytocin|Oxytocin administered intravenously
40805155|NCT04433741|DRUG|Placebo|Placebo administered intravenously
40805156|NCT02417662|RADIATION|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
41008054|NCT04491162|OTHER|Body weight support treadmill training + conventional therapy|"Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.~Patients in intervention arm were additionally trained with a 40% body weight support and a comfortable walking speed on treadmill for twenty minutes. The training, which was conducted three times a week, for period of two weeks."
40805157|NCT02417662|OTHER|Non-investigational SACT|There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
40805158|NCT03145064|DRUG|Zanubrutinib|Administered at a dose of 160 mg BID orally.
40805159|NCT05861999|DRUG|risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
40805160|NCT05464940|OTHER|Intravenous caffeine|"Group assigned to receive caffeine will receive intravenous(IV) caffeine and sodium benzoate infusion starting at 250-500 mg.~This method will use an automated algorithm that adjusts the flow of the infusion depending on the individual's sex and weight and then in a serial fashion in response to blood caffeine measurements. Serial blood caffeine measurements at pre-determined intervals according to the algorithm will be until a steady state is obtained."
40805161|NCT05464940|OTHER|Masked Placebo|"The patients assigned to the masked placebo will receive 5% dextrose in 0.45% saline using the same infusion protocol for a random length of time that was within 1 standard deviation(SD) of the mean time to achieve a steady state using the caffeine protocol (17+4 min).~To maintain blinding, caffeine blood concentration measurements that will be randomly generated within 2 SDs of the predicted values calculated by the algorithm will be used and verbally communicated for placebo infusions."
40805162|NCT03846427|DRUG|Zanubrutinib|Zanubrutinib at a dose of 160 mg orally twice a day (BID)
41322771|NCT04786132|OTHER|Motor training|A training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups.
41322772|NCT01992848|OTHER|Venous blood sampling|40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).
41322773|NCT01992848|OTHER|4-day food diary|
41322774|NCT01992848|OTHER|1 week UV dosimeter|To be worn on outerwear for one week week prior to attendance for pQCT
40805168|NCT03978598|DRUG|Etonogestrel|Immediate v. Standard insertion.
40805169|NCT03978598|DEVICE|Nexplanon|Implant.
41322775|NCT01992848|RADIATION|Peripheral Quantitative Computed Tomography of the radius|To be performed within one month of attendance for CT coronary angiography
41322776|NCT05568498|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic delivered in powdered form.
40805170|NCT04216563|DRUG|Asciminib|Given PO
40805171|NCT05509192|DRUG|MTPI|Patients from both study groups will receive premedication in the usual fashion, typically 0-2 mg of IV midazolam at the discretion of the care team. Patients in both study groups will receive 1 mg/kg of lidocaine intravenously, followed by an opioid such as fentanyl (1-2 mcg/kg), prior to administration of induction drugs. Patients assigned to MTPI will then be given rocuronium (0.6mg/kg), followed by propofol intravenously as a single bolus within 10 seconds. A typical propofol bolus for induction ranges from 1-2mg/kg, depending on the patient's age, medical history, and co-morbidities. Propofol dosing will be at the discretion of the care team. Patients will count down from one hundred. Once apnea occurs, as indicated by a lack of respiratory effort, the eyes will be taped, and intubation with C-MAC (Karl Storz 8403ZX, Tuttlingen, Germany) is initiated.
40805172|NCT05509192|DRUG|Classic Induction|Patients assigned to CI will be induced as per routine care using lidocaine 1 mg/kg, an opioid such a fentanyl (1-2 mcg/kg), propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg, and the intubation will be performed with a C-MAC. Patients will also count down from one hundred. The medications used for induction of anesthesia in both arms of the study are those used for routine anesthesia care. In both study arms, dosing of medications for induction of anesthesia is standardized (lidocaine 1 mg/kg, fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg). The only difference between the two arms will be the timing of the medication administration, and the order in which medications are administered. The documentation of induction and intubation will be the same as that of the MTPI group. Vital signs and other parameters will continuously be recorded in the intraoperative record. Emergence and extubation are not protocolized.
41322777|NCT05568498|DIETARY_SUPPLEMENT|Placebo|Oral placebo delivered in powdered form.
41322778|NCT01684891|DRUG|RG1662|multiple doses of RG1662
41008055|NCT04491162|OTHER|Conventional therapy|Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.
41322779|NCT03843736|BEHAVIORAL|Lifestyle intervention|"1. Balance the diet;~2. Limit high-calorie and high-fat food intake, reduce eating out, and establish regular eating habits;~3. Monitor body weight, avoid sedentary, get more sun and regular activities;~4. Mental health regulation."
41008056|NCT02054364|BEHAVIORAL|FBT and CRT|
41322780|NCT03843736|DRUG|Probiotic Agent|Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
41322781|NCT03843736|DRUG|Oral contraceptive|The patient needs to take drospirenone ethinyl estradiol tablets (trade name: Yousi Yue) 1 tablet daily for 3 months.
41477654|NCT03542084|OTHER|Unsolicited endocrine e-consult|The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
41152835|NCT01330719|PROCEDURE|Diseased periodontal treatment|"Treatment includes scaling and root planing with systemic antibiotics, Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days. At certain intervals after the scaling and root planing, your gums will be reevaluated. You will receive further surgical gum therapy only if your gums haven't shown improvement after first treatment on the reevaluation appointments. If surgery is needed, a bone substituting material may be necessary to fill the spaces where bone has been destroyed by the disease. Extraction of teeth might also be part of gum treatment if the disease is very severe. Re-treatment with antibiotics also may be necessary depending on the response after treatment. You are usually re-examined and receive additional cleanings every 3 to 6 months to ensure the disease does not come back."
40805176|NCT04651764|DEVICE|ColubrisMX Endoluminal Surgical (ELS) System|Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
40805177|NCT05735015|DRUG|encaleret|Oral administration, twice a day
40805178|NCT05580770|DRUG|Mirdametinib|Mirdametinib administered orally
40805179|NCT05580770|DRUG|BGB-3245|BGB-3245 administered orally
40805180|NCT03826901|DRUG|delgocitinib|Cream for topical application
41152836|NCT01330719|PROCEDURE|Conventional periodontal treatment|Scaling and gum measurement will be taken to compare to the treated group.- If it is determined that you do not have this disease, a conventional cleaning is done, usually every 6 months. This is all part of normal clinical care.
41152837|NCT04076956|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw
40805183|NCT06426693|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
40805184|NCT06426693|DEVICE|Control feedback|Participants provided with control (sham, yoked to another participant) feedback (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
41152838|NCT01095237|DEVICE|ProEndoTecc Vascular Graft|Implantation of the device as an interponate / bypass of the superficial femoral artery
41322782|NCT03280069|DEVICE|THERMIeyes® 20 RF System|The masked evaluating physician will be blinded as to which eye is treated. The evaluation on all visits will be performed on both eyes by the masked physician who will not know which eye has been treated with the THERMIeyes® 20 RF System. The treating technician will be aware of the treated eye so as to ensure all treatments are performed to the same eye.
41322783|NCT04871685|DIAGNOSTIC_TEST|lung ultrasound|the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19
41322784|NCT05438810|DRUG|FCN-437c,Fulvestrant,Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles ； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
41152839|NCT00006747|DRUG|carmustine|IV
41152840|NCT00006747|DRUG|melphalan|IV
41152841|NCT00006747|DRUG|etoposide|IV
41152842|NCT00006747|DRUG|cytarabine|IV
41008057|NCT02054364|BEHAVIORAL|FBT and art therapy|
41008058|NCT04026906|DEVICE|Cyanoacrylate glue|One drop of cyanoacrylate glue will be applied to the intravenous (IV) insertion site and another drop under the hub of the IV catheter
41152843|NCT00006747|DRUG|tacrolimus|IV
41152844|NCT00006747|DRUG|methotrexate|IV
41152845|NCT00006747|DRUG|sargramostim|IV
41008059|NCT04026906|OTHER|Transparent polyurethane dressing|The IV will be secured in the usual manner with tape and a transparent dressing.
41008060|NCT05244031|PROCEDURE|superficial erector spina plane block|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
41008061|NCT05244031|PROCEDURE|Standard (opioid-based) analgesia|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
41152846|NCT00006747|PROCEDURE|transplant|
41152847|NCT04879875|DEVICE|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed after end of surgery.
41152848|NCT04879875|DEVICE|IscAlert 72h|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed 72 hours after end of surgery
41322785|NCT05438810|DRUG|Placebo,Fulvestrant,Goserelin acetate|Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
41477655|NCT04811014|DRUG|Buprenorphine, Naloxone Drug Combination|8mg of buprenorphine/2mg of naloxone to initiate MOUD treatment and bridge, if necessary, until referral to MOUD clinic can be made for ongoing treatment
41322786|NCT06257329|OTHER|register|Multicentre prospective observational register
41322787|NCT03956329|OTHER|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
41322788|NCT03956329|OTHER|Individualised Digital Intervention|Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
41477656|NCT04811014|BEHAVIORAL|Individual Counseling|One-on-one counseling with a licensed chemical dependency counselor
41477657|NCT04811014|BEHAVIORAL|Peer Recovery Support Services|24/7 support from our team of certified peer recovery support specialists to assist with emotional support and case management
41008062|NCT04361461|DRUG|Hydroxychloroquine Sulfate|400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.
41477658|NCT04811014|BEHAVIORAL|Support Group|Referrals to youth-focused support groups and eventual creation of in-house youth-focused support groups
41008063|NCT04361461|DRUG|Hydroxychloroquine Sulfate + Azythromycin|400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.
41322789|NCT01682070|BIOLOGICAL|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
41322790|NCT01682070|BIOLOGICAL|Placebo|
41322791|NCT02450734|PROCEDURE|Ultrasound-guided intermediate cervical plexus block|
41322792|NCT02739256|PROCEDURE|Retrograde voiding trial|A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
41477659|NCT04811014|BEHAVIORAL|Referral to Medication Management|Study staff will refer patients to long-term MOUD providers in the community
41477660|NCT04811014|BEHAVIORAL|Assertive Outreach|The investigators will conduct weekly outreach to youths who experienced an opioid overdose and attempt to initiate treatment. Outreach is completed by a paramedic and peer coach.
41477661|NCT06525922|BEHAVIORAL|Center M|Center M consists of weekly, 1-hour, telehealth, mindfulness-based Cognitive Behavioral Therapy (CBT) group sessions for four consecutive weeks. Participants joined group sessions on their personal computer, tablet, or phone. Each visit involved the introduction of a core mental well-being theme, learning skills to develop non-judgmental self-awareness and/or cognitive reappraisal skills, skills practice, and discussion of home practice materials. Home practice materials included written mindful awareness instructions, audio-guided meditations, self-compassion exercises, and practices in recognizing the interrelationships between thoughts, feelings, and behaviors.
41477662|NCT00946049|DEVICE|Vicryl Plus|
41477663|NCT00946049|DEVICE|Vicryl|
41477664|NCT02540447|PROCEDURE|Purge|In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
41477665|NCT05712642|DRUG|Intravitreal Bevacizumab|Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
40805193|NCT05503264|DRUG|Satralizumab|"In Part 1, study drug will be administered after all other study related procedures have been performed at a site visit at Weeks 0, 2, 4, and Q4W thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.~In Part 2, participants will be asked to choose from one of the following options:~Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments"
40805194|NCT05503264|OTHER|Placebo|Satralizumab placebo PFS is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an NSD and extended finger flange) filled with 0.5 mL of solution, corresponding to 60 mg satralizumab, may be used in Part 2 once it becomes available at the study site.
40805195|NCT05143593|DIAGNOSTIC_TEST|results of SSBD are used to guide antibiotics adjustment|secretions from low resipratory will be obtained on day1,day 3 and day7 after enrollment and detected by SSBD at bedside at once. Antibiotics will be adjusted on the results by experienced doctors.
41322793|NCT02016729|DRUG|AMG 232|Given an an oral tablet in escalating doses.
41322794|NCT02016729|DRUG|Trametinib|Trametinib is an oral tablet given in a fixed dose.
40805198|NCT06111053|OTHER|ENDS|Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
40805199|NCT06111053|OTHER|CI|Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
40805200|NCT06111053|OTHER|No ENDS|Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.
40805201|NCT06111053|OTHER|NI|Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
40805202|NCT05902169|DEVICE|SonoCloud-9 (SC9)|Implantation of SC9 device and repeat activation at constant acoustic pressure
40805203|NCT05902169|DRUG|Carboplatin|"Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula:~Dose (mg) = target AUC (mg/mL x minute) x \[glomerular filtration rate (GFR) mL/minute + 25\]."
40805204|NCT05902169|DRUG|Lomustine|Dosed and administered per labelling.
40805205|NCT05902169|DRUG|Temozolomide|Dosed and administered per labelling.
41008064|NCT06218043|BEHAVIORAL|Restrict subjects' intake of iodine-containing foods|Replace subjects' iodized salt with non-iodized salt.
40805206|NCT05131321|PROCEDURE|Primary ankle arthrodesis (fusion)|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
40805207|NCT05131321|PROCEDURE|ORIF (open reduction and internal fixation)|ORIF: ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
40805208|NCT05131321|PROCEDURE|Intramedullary Fibular Nailing (IMFN)|Intramedullary Fibular Nailing: Participants allocated to the IMFN group will receive a locked fibular nail using a previously described technique.
40805209|NCT05962151|DRUG|Nalbuphine ER|Oral tablets
40805210|NCT05962151|DRUG|Placebo|Oral tablets
41008065|NCT05473923|DRUG|Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.|Patients will be treated with FDA-approved chemotherapeutic or targeted drugs which were recommended by the molecular tumor board (MTB), based on their expertise, patients willingness as well as evidences from PTCs-drug screening and bioinformatic prediction for drug response.
41008066|NCT00934999|PROCEDURE|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
40805211|NCT04902040|BIOLOGICAL|Atezolizumab|Given IV
40805212|NCT04902040|DRUG|Avelumab|Given IV
40805213|NCT04902040|BIOLOGICAL|Durvalumab|Given IV
40805214|NCT04902040|BIOLOGICAL|Nivolumab|Given IV
40805215|NCT04902040|BIOLOGICAL|Pembrolizumab|Given IV
40805216|NCT04902040|DRUG|Plinabulin|Given IV
40805217|NCT04902040|RADIATION|Radiation Therapy|Undergo radiation therapy
41008067|NCT00934999|PROCEDURE|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
41008068|NCT02563158|PROCEDURE|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
41322795|NCT00041353|OTHER|cytology specimen collection procedure|
41322796|NCT00041353|PROCEDURE|comparison of screening methods|
41322797|NCT00041353|PROCEDURE|study of high risk factors|
41322798|NCT05666882|OTHER|Non-interventional|Non-interventional
41322799|NCT05249985|DEVICE|NMES|Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.
41477666|NCT04755257|DEVICE|Isokinetic test|Using IsoMed 2000 device (D. \& R. Ferstl GmbH, Hemau, Germany) we conducted the isokinetic test of concentric (CON) and eccentric (ECC) shoulder internal (IR) and external (ER) strength at the angular velocity of 60˚/s in both Method I (scapular position) and Method II (25⁰ Abd and 20⁰ ER). There were seven days between the testing sessions, and both tests were conducted at the same time of day. The same examiner with experience in performing isokinetic testing with IsoMed 2000 tested all subjects in both testing sessions.
41152849|NCT01567176|BIOLOGICAL|Blood sample|It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
41152850|NCT06050226|DRUG|MY008211A tablets|The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.
41477667|NCT05364008|DRUG|Green Tea Extract|Green tea extract 1650 mg/day (45% EGCG) along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
41477668|NCT05364008|OTHER|Placebo|Placebo 1650 mg/day along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
41322800|NCT05249985|DIETARY_SUPPLEMENT|Protein|Participants will consume a daily protein supplement
41008069|NCT01282424|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
41008070|NCT05824845|PROCEDURE|Hip/Knee Replacement|Hip/Knee Replacement
41008071|NCT06051058|BEHAVIORAL|Care Transitions App|Patients in the intervention arm will be randomized to receive the Care Transitions App and utilize it to support their care transition care plan for multiple chronic conditions.
41322801|NCT00671580|DRUG|PZ-601|750 mg
41322802|NCT00671580|DRUG|PZ-601|1000 mg
41322803|NCT00671580|DRUG|Standard of Care|as directed
41322804|NCT02855320|OTHER|Nurse-led self-management education intervention|A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
41322805|NCT05947305|PROCEDURE|Surgical Blade|Using a 15c blade to de-epithelialize the soft tissue extra-orally
41322806|NCT05947305|PROCEDURE|Mucotome|Using Megagen Mucotome to de-epithelialize the soft tissue intra-orally
40805221|NCT06130475|OTHER|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
40805222|NCT06130475|OTHER|Water|Participants will be administered water during one of the study visits
40805223|NCT04502316|DEVICE|Barostim™ System|Implantation of the Barostim™ System
40805224|NCT06463743|DRUG|metformin|metformin
40805225|NCT06463743|DRUG|Placebo|Placebo
40805226|NCT03722420|DRUG|Radotinib|Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).
40805227|NCT03722420|DRUG|Imatinib|Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
40805228|NCT06238479|DRUG|LY4101174|Intravenous
40805229|NCT06129422|DRUG|NMK89|Route of administration: intravenous infusion
41008072|NCT04160299|BEHAVIORAL|Dance-based exergaming|Dance sessions
41008073|NCT05545670|DRUG|Placebo|not containing drugs
41008074|NCT05545670|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
41008075|NCT04106791|DEVICE|closed-loop system for vasopressor administration|The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
41008076|NCT02384603|OTHER|Global postural reeducation|
41008077|NCT02384603|OTHER|Segmental muscle stretching exercises|
41008078|NCT02384603|OTHER|Cognitive behavioral therapy|
41008079|NCT02545907|DRUG|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
41008080|NCT02545907|DRUG|Thalidomide|50mg capsule.
41008081|NCT02545907|DRUG|Dexamethasone|2mg tablet.
41322807|NCT05947305|PROCEDURE|Diamond Bur|Using a surgical diamond bur to de-epithelialize the soft tissue intra-orally
41322808|NCT05947305|PROCEDURE|Er:YAG Laser|Using an Er:YAG Laser to de-epithelialize the soft tissue intra-orally
41322809|NCT06123000|PROCEDURE|Modified Widman Flap (MWF)|At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.
41322810|NCT06123000|PROCEDURE|Fiber Retention Osseous Resective Surgery (FibReORS)|At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed.
41322811|NCT05233982|DRUG|Olaparib Oral Product|Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients
41008082|NCT04563312|PROCEDURE|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
41008083|NCT03424421|PROCEDURE|subscapular sling|semitendinosus subscapular sling procedure
41008084|NCT05018572|BEHAVIORAL|I AM|"I am has a biopsychosocial perspective with a focus on pain management in migraines. The cognitive behavioural interventions being tested are Mindfulness, Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy and Physiotherapist-led cardiotherapy. The treatment program consists of ten modules of texts, animated films with a fictional person to identify with, recorded audio exercises adapted for patients with migraines and filmed physiotherapeutic exercises with physiotherapists.The interventions in I am are personalised in that the first three modules and module 10 are for those who are being helped by a shorter treatment. The other modules, four to ten, are a more in-depth treatment for those who have frequent or chronic migraines. The participants are in contact with processors via message function as well as via phone at startup, at the middle of treatment and termination. The duration of treatment is 4-10 weeks."
41008085|NCT06074575|BEHAVIORAL|Emotion induction|The participants will receive different emotion inductions through short video clips.
41008086|NCT03724825|DIAGNOSTIC_TEST|lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))|blood samples will be collected after 10 hours fasting
41322812|NCT01213095|DRUG|rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
41322813|NCT04564326|PROCEDURE|Pericapsular nerve Group block|Under ultrasound guidance a needle is inserted between the iliopectineal eminence and the iliopsoas muscle and tendon to block articular branches supplying the capsule of hip joint.
41322814|NCT04564326|PROCEDURE|Facia Iliaca block|Under ultrasound guidance a needle is inserted between the fascia iliaca and Psoas muscle to block the femoral, obturator and lateral cutaneous nerves.
41322815|NCT04564326|DRUG|Fentanyl|Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
41322816|NCT04261452|DIAGNOSTIC_TEST|isokinetic dynamometer|"Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. Positioning of the subjects (sitting with hips flexed to 75°) was standardized based on the length of the thigh and leg to minimize individual differences. Correction for the effect of gravity on neuromuscular performance was accomplished by incorporating limb mass into the calculation of torque production. Previous warm-up was repeated five time with an angular velocity of 400°/s. All patients randomly performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.~Measurements of torque, work (J), power (W) maximum (peak), and fatigue index were obtained in both tests. In addition, data were analysed at percent of prediction (percent pred) by reference values previously described for the Brazilian population, corrected by muscle mass and peak values."
41477669|NCT01978210|DEVICE|Wireless Moisture Pager (WMP)|The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
41477670|NCT02485002|DEVICE|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
41008087|NCT03724825|DIAGNOSTIC_TEST|Total testosterone|blood samples will be collected after 10 hours fasting
41008088|NCT03724825|DIAGNOSTIC_TEST|Adropin|blood samples will be collected after 10 hours fasting
41008089|NCT03724825|DIAGNOSTIC_TEST|Adiponectin|blood samples will be collected after 10 hours fasting
41008090|NCT04774510|OTHER|Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography|Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
41477671|NCT02485002|DEVICE|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
41477672|NCT03923699|DEVICE|Anesthesia Control Tower monitoring|Real time data will be monitored through the AlertWatch® system as well as the patient's EHR.
41477673|NCT06305520|DEVICE|Investigational medical device (SkinPlus-HYAL Implant Lidocaine)|\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
41477674|NCT06305520|DEVICE|Active Comparator: Active Comparator Medical Device (RESTYLANE Lidocaine)|\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
41008091|NCT02066857|DEVICE|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
41008092|NCT02066857|DEVICE|"Generic off the shelf removable splint"|"Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture."
41008093|NCT00003002|BIOLOGICAL|HER-2/neu peptide vaccine|
41008094|NCT00003002|BIOLOGICAL|sargramostim|
40805230|NCT06370923|BEHAVIORAL|Peer Distribution|In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.
40805231|NCT06370923|BEHAVIORAL|Community Health Worker Distribution|Distribution of HIV self tests by community health workers
41322817|NCT04261452|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|"All exercise tests were performed on an electronically braked cycle ergometer. Standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system.~The incremental exercise test started with 2-min unloaded cycling and increments of 3-10 Watts per min until exhaustion. The anaerobic threshold was estimated by the ventilatory equivalents and V-slope methods and it was determined in agreement by a cardiologist and pulmonologist. Heart rate was determined using the 12-lead electrocardiogram. Throughout the experiment, the pulse hemoglobin saturation (SpO2) was assessed with a pulse oximeter and the 'shortness of breath' was asked at exercise cessation using the 0-10 Borg category ratio scale. All measurements were expressed as percentage predicted for the Brazilian population."
41322818|NCT04261452|DIAGNOSTIC_TEST|Functional Capacity Tests|"The six-minute walk test (6MWT) was in accordance with the American Thoracic Society (ATS). The four-minute step test (4MST) consisted of going up and down a 20-cm high, 40-cm wide and 40-cm long step for 4 minutes.~The investigators measured the heart rate and pulse hemoglobin saturation at rest before each test and every minute of both tests. The investigators assessed dyspnoea and leg fatigue at rest and with the modified Borg scale immediately after finishing the test."
41322819|NCT04261452|DIAGNOSTIC_TEST|Lung Function Test|"Spirometry, gas transfer, and static lung volumes were measured in all patients, and airflow was measured using a Pitot-tube based on the American Thoracic Society/European Respiratory Society guidelines. Measurement of maximal inspiratory and expiratory pressures was performed from the residual volume and total lung capacity. Resting blood gases were obtained by samples from the radial artery."
41322820|NCT04261452|DIAGNOSTIC_TEST|Doppler Echocardiography|The same medical doctor performed all echocardiograms and all patients underwent comprehensive echocardiography.
41322821|NCT04261452|DIAGNOSTIC_TEST|Anthropometry and Body Composition|"Body composition was assessed using a body composition analyzer. Percent body fat was estimated from the resistance and reactance values.~Resistance values and the subject's height (meters), weight (kg), sex, and age (years) were entered into a computer program to estimate percentage of fat, fat mass (FM), and muscle mass (MM)."
41322822|NCT03529123|DRUG|INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
41322823|NCT03529123|DRUG|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
41322824|NCT03529123|DRUG|Metformin|"Pharmaceutical form: Tablet~Route of administration: Oral"
41322825|NCT03529123|DRUG|Insulin Glulisine (HMR1964)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
41322826|NCT04469803|BEHAVIORAL|Intra-Shift Napping|The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.
41322827|NCT02610205|OTHER|caring touch|The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
41322828|NCT00293150|DRUG|Eplerenone|
41322829|NCT06416397|DIAGNOSTIC_TEST|Proteomic profile|"Proteomic analysis of bile samples will be performed every 5 bile samples. Bile samples will be taken during endoscopy with retrograde papillary catheterization or radiological procedures in selected patients. In clinical practice, bile samples are taken for bacteriological purposes. An average of 10 mL is taken.~Five mL are required for bacteriological analysis. The remaining millilitres, which are usually discarded, will be kept for storage and to form the bile bank at the Biological Resources Centre before to be analyzed in proteomics."
41322830|NCT00383227|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
41322831|NCT04934306|OTHER|Nasometry|Repetition of several stimuli (syllables, sentences ) in the microphones of the Nasometer
41322832|NCT06391658|OTHER|Functional Training|Functional training was performed for eigth weeks. The group participated on the supervised training once a week and twice a week at home. The training was arranged in a circuit method, consisting of three to four blocks with two to three exercises each, with an execution time of two minutes and recovery of thirty seconds between exercises and one minute between each block. The exercises emphasized integrated, functional and multi-joint movements for mobility, flexibility, strength, power and muscular endurance with overload, as well as agility, speed and balance exercises.
40918480|NCT03892278|BEHAVIORAL|Water-based aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and \<85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and \<85% of HRat for 1 minute.
40805232|NCT06222346|BEHAVIORAL|CommonGround|"Through collaboration with people living with LTCs, clinicians, academics, and web design experts, we have co-designed an online peer support and psychoeducation platform to help people with physical health conditions connect, support others, share experiences, and receive evidence-based information and advice on self-management. The web-based platform offers users access to peer support forums with embedded psychoeducation content.~The following components are key features of the platform:~* A discussion forum~* A private My Garden page that stores posts from other users and psychoeducation content that the user has decided to 'save'.~* A resources page giving access to evidence-based psychoeducation material on the mind-body link~* A 'Crisis and Further Support' page, where users can find further organisations and sources of support, particularly for crisis situations. The peer support platform does not offer one-to-one or crisis support."
40805233|NCT06222346|BEHAVIORAL|NHS Mental Health|"Participants in the control arm will be directed towards the Mental Health webpage(s), an online resources page provided by the NHS. These resources are not specifically targeted at people living with LTCs. They include information sheets and mental health support on topics such as advice for life situations and events. Additionally, it hosts a self-help section that includes guides, tools, and activities to support mental health, but does not include any interactive or peer support elements."
40805234|NCT05219149|BEHAVIORAL|Qualitative Interviews|Conduct qualitative interviews with patients and families who are considering treatment options for new or recurrent CNS tumors to identify specific barriers to full participation in treatment and clinical trial enrollment (e.g., transportation, childcare, ancillary expenses). Qualitative interviews will be structured to comprehensively address potential barriers but also open-ended to give patients and families freedom to discuss a wide range of challenges.
40805235|NCT03690401|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.
40805236|NCT03690401|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
41322833|NCT02321618|BEHAVIORAL|BP measurement & pharmacy|Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
40805237|NCT04115514|DRUG|Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.|"Study Drug Administration:~* Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~* Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~* Method: Instilled via a catheter through the ETT directly into the airway."
40805238|NCT04115514|OTHER|Non-intervention|Standard of Care (SOC)
40805239|NCT04322318|PROCEDURE|Biopsy|Undergo a biopsy
40805240|NCT04322318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40805241|NCT04322318|PROCEDURE|Bone Scan|Undergo a bone scan
40805242|NCT04322318|DRUG|Carboplatin|Given IV
40805243|NCT04322318|PROCEDURE|Computed Tomography|Undergo a CT scan
41008095|NCT05081323|BEHAVIORAL|Self-applied treatment for phobias|The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
41008096|NCT01866709|DRUG|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
40805244|NCT04322318|DRUG|Cyclophosphamide|Given IV
40805245|NCT04322318|DRUG|Doxorubicin|Given IV
40805246|NCT04322318|DRUG|Etoposide|Given IV
40805247|NCT04322318|DRUG|Ifosfamide|Given IV
40805248|NCT04322318|DRUG|Irinotecan|Given IV
40805249|NCT04322318|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40805250|NCT04322318|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
41322834|NCT02321618|BEHAVIORAL|BP educational materials|Exposure to hypertension educational materials
40805251|NCT04322318|RADIATION|Radiation Therapy|Undergo RT
41008097|NCT01866709|DRUG|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
41008098|NCT01934153|DRUG|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
41008099|NCT02037711|DRUG|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
41152851|NCT06299696|DRUG|VNZ/TEZ/D-IVA|FDC granules for oral administration
41322835|NCT00110123|DRUG|fotemustine|
41322836|NCT00110123|DRUG|isolated perfusion|
41322837|NCT00113178|DEVICE|Catheter-based cardiac cryoablation|
41477675|NCT04818996|BEHAVIORAL|Mediterranean Diet|"While calculating the energy of the Mediterranean diet applied to the individuals participating in the study, Mifflin-St. Jeor equation is used. The macronutrient composition of the Mediterranean diet was calculated as 36-40% fat, 40-45% carbohydrate and 15-20% protein. This diet is enriched with natural foods (fruits, vegetables, legumes, whole grain foods, fish, olive oil and oilseeds such as walnuts and almonds).~In addition, anthropometric measurements and body composition analysis of the participants were performed both at the beginning and at the end of the study, and some biochemical parameters (IL-6, TNF-α, CRP, MDA, TAS, TOS and routine blood parameters) were evaluated."
41477676|NCT05785689|DRUG|Dexmedetomidine|To reduce postoperative agitation
41477677|NCT05785689|DRUG|Placebo|Placebo bolus saline
41477678|NCT03353298|DRUG|Allopurinol 300 mg|Allopurinol oral tablets 300 mg given to participants once daily for 9 months
41477679|NCT03353298|DRUG|Placebo Oral Tablet|placebo oral tablets given to participants once daily for 9 months
41477680|NCT04337684|DRUG|Long Term Follow-Up|"Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up."
40805252|NCT04322318|PROCEDURE|Surgical Procedure|Undergo surgery
40805253|NCT04322318|DRUG|Topotecan|Given IV
40805254|NCT04322318|PROCEDURE|Transabdominal Ultrasound|Undergo abdominal ultrasound
40805255|NCT04322318|DRUG|Vincristine|Given IV
40805256|NCT04322318|PROCEDURE|X-Ray Imaging|Undergo a chest x-ray
40805257|NCT06071793|OTHER|Family involvement|Family delivery of mobility activities
41152852|NCT06114511|DRUG|BL-M07D1|Administration by intravenous infusion
41152853|NCT05126199|OTHER|Time restricted eating|"Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks.~Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
40805260|NCT04234204|DRUG|Fezolinetant|Oral
40805261|NCT04234204|DRUG|Placebo|Oral
40805262|NCT06385262|DRUG|Alirocumab|300 mg subcutaneously every 4 weeks prior to surgery
40805263|NCT06385262|DRUG|Cemiplimab|350mg IV every 3 weeks prior to surgery
41477681|NCT06304935|OTHER|Use of injectable platelet rich fibrin after tonsillectomy by injection of IPRF in one tonsillar bed and use of other side as control|Compare both sides of tonsillar beds in post operative healing, pain and hemostasis
41008100|NCT02037711|DRUG|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
41477682|NCT00004876|DRUG|carboplatin|
41477683|NCT00004876|DRUG|thalidomide|
41477684|NCT01926275|DEVICE|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
41477685|NCT01926275|DEVICE|NPPV|noninvasive positive pressure ventilation
40805264|NCT06385262|DRUG|Chemotherapy|Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery
40805265|NCT05327660|COMBINATION_PRODUCT|Quitline Treatment as Usual (TAU)|Quitline TAU is services provided by the state quitline and includes phone coaching, nicotine replacement, supplemental materials (e.g., text messaging, online content).
40805266|NCT05327660|COMBINATION_PRODUCT|Remote Carbon Monoxide (CO) Monitoring|Remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor.
40805267|NCT05327660|COMBINATION_PRODUCT|Incentivized Remote CO Monitoring|Incentivized remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor and delivers small monetary incentives for each use of the CO monitor.
41008101|NCT06246253|PROCEDURE|Virtual implant placement following safe angle concept|Virtual implant placement following safe angle concept in anterior maxillary teeth.
41477686|NCT01926275|DEVICE|IMT|inspiratory muscle training
41477687|NCT01713231|DIETARY_SUPPLEMENT|standard-dose vitamin D (400IU per day)|
41477688|NCT01713231|DIETARY_SUPPLEMENT|high-dose vitamin D (2000 IU per day)|
40805268|NCT05977816|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
40805269|NCT05977816|OTHER|Standard wound dressing|Application of a standard wound dressing to the wound post laparotomy
40805270|NCT06631469|BEHAVIORAL|Personalised behavioural sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support (based on previous personalised nutrition trials and usual care in dietetic practice), plus the addition of receiving personalised behavioural support and strategies.
40805271|NCT06631469|BEHAVIORAL|Personalised sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support and strategies (based on previous personalised nutrition trials and usual care in dietetic practice).
40805272|NCT05936840|DEVICE|Mira Monitor tracking|Using the Mira monitor to track the menstrual cycle
41477689|NCT02778503|OTHER|High Cost|Surfaces allocated to this group will be treated with a high-cost glass ionomer cement restoration (Fuji IX, GC America, USA), according to the manufacturer's instructions.
41008102|NCT06246253|PROCEDURE|actual implant placement following safe angle concept|actual implant placement following safe angle concept in anterior maxillary teeth
41008103|NCT02791815|DRUG|Midazolam|Single oral dose of 7.5 mg midazolam (tablet)
41008104|NCT02791815|DRUG|Selexipag|Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
41152854|NCT05126199|OTHER|Normal ad libitum diet|"Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed.~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
41152855|NCT00205205|BEHAVIORAL|peer mentoring|
41152856|NCT03698721|PROCEDURE|Transurethral Resection of Prostate|Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.
41322838|NCT02541448|DEVICE|SurgiQuest AIRSEAL® Insufflation System (AIS)|"The SurgiQuest AirSeal Optical Trocar \& Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization."
41322839|NCT01817647|PROCEDURE|Colorectal surgery|
40805282|NCT04053855|BIOLOGICAL|Urinary sample|Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
41322840|NCT00234819|DRUG|Bazedoxifene/Conjugated Estrogen|
41322841|NCT05904353|PROCEDURE|Ambulant nurse-assisted administration of zoledronic acid|Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.
41322842|NCT05904353|PROCEDURE|Usual care|General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
40805286|NCT04603807|DRUG|Entrectinib|Entrectinib will be self-administered orally at a dose of 600 mg (three 200 mg capsules per day) once daily with or without food.
40805287|NCT04603807|DRUG|Crizotinib|Crizotinib will be self-administered orally at a dose of 250 mg twice daily with or without food.
41322843|NCT06183632|BIOLOGICAL|blood sampling|3 x 7mL EDTA blood tubes
40805289|NCT05254990|DRUG|Reparixin|Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.
41008105|NCT01532765|PROCEDURE|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
41008106|NCT01532765|PROCEDURE|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
41008107|NCT01532765|PROCEDURE|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
41008108|NCT05029752|DEVICE|Vendys II Device|Using the device
41008109|NCT01585480|BEHAVIORAL|Weight Gain Prevention Intervention|"1. Behavioral Approaches~   1. Distribution of pedometers~  2. Traffic light labeling in worksite cafeteria and vending machines~2. Informational \& Persuasive Messages~   1. Stair use prompts~  2. Posters, pamphlets, table toppers~  3. Website~3. Social Approaches~   a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~4. Environmental Changes~   1. Traffic light labeling~  2. 1/2 portions at 1/2 price~  3. Walking routes~  4. Introduction of healthier foods~  5. Rearrangement of foods in the cafeteria~  6. Adjusting serving spoon size"
41008110|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
41322844|NCT06103955|BEHAVIORAL|Digital Breathing Biofeedback system|The biofeedback system provides information to the patient and physio about the muscle coordination of breathing.
41322845|NCT01666145|DEVICE|Advanced Image Guidance|Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
41322846|NCT02912728|BEHAVIORAL|CGM + Family Behavioral Intervention|use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
40805290|NCT05254990|OTHER|Placebo|"Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.~Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion."
40805291|NCT04723355|DEVICE|An innovative 3-lead wireless water resistant Holter device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
40805292|NCT04723355|DEVICE|A conventional device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
40805293|NCT04185337|PROCEDURE|Fine-Needle Aspiration|Undergo ultrasound-guided FNA
40805294|NCT04185337|PROCEDURE|Lymph Node Biopsy|Undergo ultrasound-guided lymph node biopsy
40805295|NCT04185337|PROCEDURE|Photoacoustic Imaging|Undergo ultrasound-guided PAI
40805296|NCT04185337|PROCEDURE|Ultrasound|Undergo ultrasound
40805297|NCT04185337|DEVICE|Multispectral optoacoustic tomography (MSOT) acuity instrument|Use multispectral optoacoustic tomography (MSOT) acuity instrument
41008111|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
41322847|NCT02912728|DEVICE|Standard CGM|use of CGM alone to assess CGM adherence
41322848|NCT05974046|DRUG|[14C]IDV184001AN|\[14C\]-IDV184001AN 200 mg/\~100 µCi/ 15 g oral suspension
41008112|NCT00782210|DRUG|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
41008113|NCT01109316|DRUG|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
41008114|NCT01109316|DRUG|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
41008115|NCT01109316|DRUG|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
41008116|NCT05264324|PROCEDURE|Maximal Exercise Capacity|Maximal Exercise Capacity in incremental ramp exercise tests.
41008117|NCT02378844|DEVICE|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
41008118|NCT02378844|DEVICE|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
41008119|NCT06163066|OTHER|Newborn Basic Care Training|These talented fathers will be given both face-to-face practical training and the industrial web-based training type of information technologies will be used. In this way, the positive developments provided by the two trainings will be abandoned and the understandability and usefulness of the training from the people's perspective will be increased. A website suitable for mobile phones will be designed by transferring digital materials. With this website, fathers will be able to access information about basic care via phone whenever and wherever they want. Thus, in a short time, without human resources and time, all the fathers in need throughout the country will reach the capacity to obtain appropriate information.
41008120|NCT03541694|BIOLOGICAL|Stamaril®|Routine vaccination with Stamaril yellow fever vaccine
41008121|NCT06390228|PROCEDURE|Major hepatectomy|the extent of liver resection
41008122|NCT02251665|OTHER|No intervention|a single-center prospective observational study
41008123|NCT05679791|DEVICE|Dynamometer|to assses hand grip
41008124|NCT05909735|PROCEDURE|transplantation of a Descemet's Membrane corneal onlay, partial LSCD|The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity and improvement in limbal stem cell deficiency, and monitored for adverse events.
41008125|NCT05909735|PROCEDURE|transplantation of a Descemet's Membrane corneal onlay, total/near-total LSCD|The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane (DM) corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity, limbal stem cell deficiency, and persistent epithelial defects/recurrent erosions, and monitored for adverse events.
41008126|NCT01020019|DRUG|Dronabinol|Dronabinol: 20 mg/TID
41008127|NCT01020019|DRUG|Placebo|Placebo control
41322849|NCT03944798|OTHER|Frequency: Every 3 Months|every 3 months
41322850|NCT03944798|OTHER|Frequency: Every 6 Months|every 6 months
41008128|NCT01020019|DRUG|Lofexidine|Lofex: .6 mg/ TID
41008129|NCT02674178|PROCEDURE|Invitro fertilization|"All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days~Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm \[18\]~Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval"
41008130|NCT06146387|DIETARY_SUPPLEMENT|Investigational Formula|Participants in this arm will receive stage 1 and stage 2 investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
41008131|NCT06146387|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
41008132|NCT06146387|DIETARY_SUPPLEMENT|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
41008133|NCT05754528|DRUG|Standard of care administration of Endocrine therapy|Standard daily dosing of endocrine therapy. Defined as taking endocrine therapy every day from the start.
41008134|NCT05754528|DRUG|Dose-frequency escalation administration of Endocrine therapy|Endocrine therapy dose-frequency escalation. Defined as taking endocrine therapy every other day for 1 month and then daily.
41322851|NCT03944798|OTHER|Imaging Modality: Chest Radiograph (CXR)|Chest radiograph (CXR)
41322852|NCT03944798|OTHER|Imaging Modality: Chest CT|Chest computed tomography (CT)
41322853|NCT02801422|OTHER|fMRI|
41322854|NCT01760759|BEHAVIORAL|cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
41322855|NCT01760759|BEHAVIORAL|contingency management for adherence|Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
41477690|NCT02778503|OTHER|Low Cost|Surfaces allocated to this group will be treated with a low-cost glass ionomer cement restoration (Maxxion R, FGM, BRA), according to the manufacturer's instructions.
41477691|NCT00825552|DRUG|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
41152857|NCT01973296|BEHAVIORAL|ED to home care transition|The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.
41152858|NCT01973296|OTHER|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
41008135|NCT01970202|DRUG|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
41008136|NCT01970202|DRUG|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
41008137|NCT01970202|OTHER|Control|no treatment
41322856|NCT05576610|PROCEDURE|Standard preventive advice+ enzymatic mouth sprays ( Oral7 mouth spray)|"The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the Mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
41322857|NCT05576610|PROCEDURE|Standard Preventive Advice + placebo mouth spray ( normal saline mouth spray )|"The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
41322858|NCT03553550|OTHER|biospecimen collection|Peripheral blood collection Archival tissue collection
41322859|NCT03852693|OTHER|Histopathological review|Histopathological review
41322860|NCT03296852|DIAGNOSTIC_TEST|SONAS Ultrasound Device|To assess a baseline value, ultrasound will be transmitted following an automated protocol to increase subsequently the output voltage from 5 volts to 50 volts. At each voltage step the received signals will be acquired and stored. Once the maximum output voltage of 50 Volts has been reached an additional 10 ultrasound pulses will be transmitted and the received data acquired. The total duration of this first data acquisition is 20 seconds. Following the IV bolus injection of Lumason™, ultrasound will be transmitted and received signals acquired following the same protocol as before.
41322861|NCT03296852|DRUG|Lumason|An IV line will be placed in a cubital or forearm vein. A bolus of 1.0ml of the ultrasound contrast agent (so called 'Microbubbles') Lumason™, internationally known as SonoVue (Bracco Pharmaceuticals, Italy), will be injected into the IV line, followed by a 5.0ml IV bolus injection of saline. Lumason™ has been FDA approved for cardiac applications to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. In the context of the present study Lumason™ would be used off-label.
41322862|NCT00959530|PROCEDURE|lingualized occlusion|occlusal surface arranged by lingualized occlusion
41322863|NCT00959530|PROCEDURE|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
41322864|NCT06236230|DRUG|levodopa/carbidopa/entacapone|"On Day 1, subjects will be treated with levodopa/carbidopa/entacapone. Based on previous regimen. The dosage of levodopa/carbidopa/entacapone will be equal to the previous total daily dose of LD, and the frequency of administration of levodopa/carbidopa/entacapone is three or four times a day.~Levodopa/carbidopa/entacapone could be titrated in next 2 weeks according to the investigator's judgment, based on individual clinical response and tolerability.~After 2-week titration, the dose of levodopa/carbidopa/entacapone will remain as constant as possible to the end of study."
41477692|NCT05212883|BEHAVIORAL|Behavioral questionaires|Behavioral surveys and questionnaires
41008138|NCT01973322|OTHER|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
41008139|NCT01973322|OTHER|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
41008140|NCT01973322|OTHER|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
41008141|NCT01973322|BIOLOGICAL|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
41152859|NCT04172571|BIOLOGICAL|AK105|Anti-PD-1 antibody; IV infusion, 200 mg Q3W
41152860|NCT04172571|DRUG|Anlotinib Hydrochloride|multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off
41152861|NCT00002099|DRUG|Lentinan|
41152862|NCT00002099|DRUG|Didanosine|
41152863|NCT00067925|BEHAVIORAL|Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program|
41152864|NCT00002540|OTHER|Laboratory Biomarker Analysis|Correlative studies
41152865|NCT00002540|PROCEDURE|Medical Examination|Undergo DRE
41152866|NCT00002540|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
41152867|NCT04010981|OTHER|study group|The treatment protocol will consist of Nintendo wii fit virtual reality exercises (yoga,aerobic exercises,muscle strengthening exercises)
41322865|NCT03411772|PROCEDURE|TAP block|Injection of 20 mL of 0.25% bupivacaine in the transversus abdominis plane under ultrasound guidance after performing bariatric surgery
40805302|NCT04934839|DIAGNOSTIC_TEST|Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.|"Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts."
41008142|NCT02596529|DEVICE|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
40805303|NCT03720626|DRUG|crizanlizumab|IV formulation with 30 min infusion, 5mg/kg dosage
40805304|NCT04776616|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
40805305|NCT04776616|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
41152868|NCT04010981|OTHER|control group|The treatment protocol will consist of home based video exercises ;yoga,aerobic exercises,muscle strengthening exercises
41152869|NCT02507297|DEVICE|Positive Airway Pressure (PAP)|Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
41152870|NCT02475499|DRUG|DPP-4 inhibitors|Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
41477693|NCT04127955|OTHER|Theory of Planned Behavior based Physical Activity Intervention|"Health education: The first component of intervention consisted of one session 30 minutes educational lesson relation to physical activity.~Group walking: The format of the 15-minute group walking session included 5 minutes of warm-up, 5 minute moderate intensity walking, 5 minute cool-down.~Counseling (individually tailored): The nurse received training about motivational interview technique for use in their physical activity counseling with participants. Using pedometers and step diary to set goals and monitor progress.~Pedometer: pedometer will be used objective physical activity assessment. Measurement of physical activity levels, wearing a pedometer (Omron HJ321E) on a belt over one hip, all day for 7 days, removing for bathing and sleeping. A diary is also provided to record step count. The pedometer will be used for baseline and outcome measurement of step-counts for the trial."
41477694|NCT00831623|RADIATION|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
41477695|NCT00831623|RADIATION|Proton|As above
41152871|NCT02475499|DRUG|GLP-1 analogs|Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
41152872|NCT02475499|DRUG|Sulfonylureas|Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
41152873|NCT02475499|DRUG|Biguanides|Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
41152874|NCT02475499|DRUG|Thiazolidinediones|Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
41152875|NCT02475499|DRUG|Alpha-glucosidase inhibitors|Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
41008143|NCT02596529|OTHER|NO Fixation|NO Fixation of the posterior malleolus.
41008144|NCT05796544|BEHAVIORAL|Remote self-care education|The intervention group will receive a total of four remote educational sessions over 2 months.
41008145|NCT05796544|BEHAVIORAL|In-person self-care education|The active comparator group will receive a total of four in-person educational sessions over 2 months.
41152876|NCT02475499|DRUG|Meglitinides|Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
41152877|NCT02963922|DRUG|Liraglutide 3.0 mg|Injected subcutaneously (s.c., under the skin) once daily
41152878|NCT02963922|DRUG|Placebo|Injected subcutaneously (s.c., under the skin) once daily
41152879|NCT04659083|DEVICE|Neurally adjusted ventilatory assist ventilation mode|This technique uses the electrical activity of the diaphragm (Edi) to control respiratory support and the NAVA level as an amplification factor that converts the Edi signal into a proportional pressure.
41152880|NCT03126188|DRUG|Sertraline|Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
41152881|NCT03126188|DRUG|Dosulepin|Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
41322866|NCT03411772|PROCEDURE|Bariatric surgery|Bariatric surgery will be conducted
41477696|NCT02384252|OTHER|functional tissu atrial analysis|
41477697|NCT05628779|DEVICE|TriClip TTVr system (Abbott Vascular)|Edge-to-edge leaflet approximation for the tricuspid valve
41477698|NCT05628779|DEVICE|PASCAL TTVr system (Edwards Lifesciences)|Edge-to-edge leaflet approximation for the tricuspid valve
41322867|NCT03293628|PROCEDURE|Vaginal Packing|This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
41322868|NCT04917497|DRUG|Levosimendan|Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.
41477699|NCT05088031|DEVICE|shock waves therapy|"Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)"
41477700|NCT01185028|DRUG|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
41152882|NCT03126188|DRUG|Venlafaxine|Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
41152883|NCT05183997|DIAGNOSTIC_TEST|complete blood count|laboratory test
41152884|NCT05183997|DIAGNOSTIC_TEST|prothrombin time|laboratory test
41152885|NCT05183997|DIAGNOSTIC_TEST|prothrombin concentration|laboratory test
40805318|NCT05607303|OTHER|Clinical estrogen therapy|No research interventions will be used as a part of the study since the research is observational. Estrogen treatment will be prescribed and followed by participant's clinical physician.
40805319|NCT06174805|DEVICE|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm
40805320|NCT04668833|PROCEDURE|Autologous lymphocyte infusion (ALI)|On the day after completing the last dose of radiation therapy, the patient will have an appointment scheduled in the Apheresis Unit for the infusion of unmunipulated cryopreserved cells. Patients will be pre medicated with acetaminophen (325-650 mg PO) and diphenhydramine (12.5-25 mg PO or IV) prior to infusion. Cells will be infused without a leukoreduction filter at a rate determined by cell volume.
40805321|NCT04037254|BIOLOGICAL|Gonadotrophin Releasing Hormone|Receive standard of care GnRH agonist androgen suppression therapy
40805322|NCT04037254|RADIATION|Intensity-Modulated Radiation Therapy|Undergo standard of care IMRT
40805323|NCT04037254|DRUG|Niraparib|Given PO
41322869|NCT02204033|DRUG|99mTc - labelled hMAb BIWA 4|
41152886|NCT05183997|DRUG|Verapamil|drug will be add to prolong the effect of regional block
41152887|NCT04457583|DEVICE|Inspiratory muscle training with powerbreathe|Participants will be submitted to a linear pressure resistance (Powerbreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 exercises for 12 weeks.
40805326|NCT04745637|DRUG|Ruxolitinib|Patients receive Ruxolitinib
41322870|NCT02204033|DRUG|186 Re - labelled hMAb BIWA 4|
41322871|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - low dose|
41322872|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - medium dose|
41322873|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - high dose|
41477701|NCT01299805|DRUG|Vortioxetine|Encapsulated tablet
41477702|NCT01299805|DRUG|Placebo|Vortioxetine placebo-matching capsules.
41477703|NCT01932099|DEVICE|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
40805327|NCT04435600|DRUG|Risankizumab|Subcutaneous Injection
40805328|NCT04435600|DRUG|Ustekinumab|Subcutaneous Injection
40805329|NCT02724579|DRUG|Cisplatin|Given IV
40805330|NCT02724579|DRUG|Cyclophosphamide|Given IV
40805331|NCT02724579|OTHER|Laboratory Biomarker Analysis|Correlative studies
40805332|NCT02724579|DRUG|Lomustine|Given PO
40805333|NCT02724579|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40805334|NCT02724579|RADIATION|Radiation Therapy|Undergo craniospinal radiation therapy
40805335|NCT02724579|DRUG|Vincristine|Given IV or via minibag
40805336|NCT02724579|DRUG|Vincristine Sulfate|Given IV or via minibag
41152888|NCT05416970|BEHAVIORAL|SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES|To assess the impact of the SARS-CoV-2 spread related lifestyle changes on body composition analysis and metabolic syndrome components worsening as well as hepatocellular carcinoma occurrence.
41152889|NCT00374673|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
41152890|NCT04728659|DRUG|Desogestrel 0.075 MG|It will be given orally for 3 to 5 days during FSH administration for ovarian stimulation
41322874|NCT04365894|OTHER|Transformative learning theory|According to the transformative learning theory, learning methods in education should include four activities as investigate, collaborative, higher-order thinking and interactive learning activities
41322875|NCT01611766|PROCEDURE|Secondary Cytoreductive Surgery|Complete Cytoreduction
41322876|NCT01611766|DRUG|Salvage Chemotherapy|6 cycles of postoperative chemotherapy
41477704|NCT01178164|GENETIC|Blood sampling for biological and genetic analysis|"* Clinical examination~* Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females."
41008146|NCT05470439|BEHAVIORAL|My Interprofessional Care team for Adherence and Research Engagement (MI-CARE)|MI-CARE is an innovative, tailored coordinated care intervention by pharmacist-community health worker (CHW) team derived from a previous research and a clinical pilot implementation. MI-CARE will identify and address individual, clinical, social-cultural and structural barriers to medication adherence and hypertension management. MI-CARE consists of an initial individualized needs assessment (Baseline). During Months 1-2, pharmacist-CHW team will deliver a tailored intervention including an individualized medication chart, preferred adherence aids, hypertension therapy optimization, tailored education based on medication beliefs, tools to combat social stressors, and referrals for structural barriers such as food insecurity, transportation and drug costs. Tailored family/care partner participation and telehealth visits will be provided when needed during this time. A booster visit to assess patient progress and reinforce intervention components will occur at Month 2.
41008147|NCT01552538|DEVICE|Cyberonics VNS System|Stimulation with an active implantable electrical vagal nerve stimulation device
41008148|NCT01242657|BEHAVIORAL|Physical Activity Module|"Participants were provided pedometers in order to track specific Step Goals, which were defined for male or female participants. In addition, each participant recorded other forms of physical activity in a Challenge Log."
41008149|NCT01242657|BEHAVIORAL|Not On Tobacco (N-O-T) Program|Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
41008150|NCT01917071|OTHER|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
41008151|NCT02383667|DEVICE|Electrocardiogram holter|
41008152|NCT00503386|DRUG|Palonosetron|
41008153|NCT00503386|DRUG|Granisetron|
41008154|NCT02747069|DEVICE|NICU electronic stethoscope|Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU
41008155|NCT02747069|DEVICE|Newborns <32 weeks and ECG|The three leads from the ECG device will be pre placed onto a plastic bag prior to delivery. The pre term infant (\<32 weeks) placed into the bag at the time of delivery and heart rate will be assessed for up to 30 minutes
41008156|NCT02953899|BEHAVIORAL|Contingency Management|In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
41008157|NCT02953899|BEHAVIORAL|Cognitive Behavioural Therapy|This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
41008158|NCT05893979|DEVICE|Spectacle Lenses|Standard Spectacle Lenses
41008159|NCT04707534|DRUG|Dexamethasone|Dexamethasone
41008160|NCT06382857|DIETARY_SUPPLEMENT|MDF|MDF will be provided to children on a weekly basis for children with SAM and bi-weekly basis for children with MAM at the health center until programmatic recovery but not thereafter.
41008161|NCT06382857|DIETARY_SUPPLEMENT|RUTF|RUTF will be provided to all children on a weekly basis at the health center until programmatic recovery but not thereafter
41322877|NCT06332027|DIAGNOSTIC_TEST|Hystro-Salpingo-Foam-Sonography (HYFOSY)|antibiotic prophylaxis oral azithromycin 500 mg per day 3 days the patient lie in dorsal lithotomy cervix visualized by Cusco speculum, cleaned with betadine 7% 6-Fr pediatric Foley's balloon catheter will be introduced into the cervical canal inflated with 2 ml of saline to prevent backflow of contrast through the cervix TV-US probe will be introduced,The foam will be created by mixing 3-4ml of 2% rialocaine gel (lidocaine hydrochloride 2%, Riadh Pharma,Saudi Arabia) with 16-17 ml of saline shaking the mixture between two syringes until a whitish suspension 20ml of lidocaine foam infused into uterine cavity observing the flow in each fallopian tube using greyscale and power Doppler (PD) 2D ultrasound Foam flow over the whole length of the tube fimbrial outflow, or peritoneal spillage of contrast provided evidence of tubal patency Patients observed for15-30 min for any complication or increase in pain Comparison between results and that of laparoscopy in operative list
40805337|NCT06449209|DRUG|BNT327 Dose Level 1 (DL1)|Intravenous (IV) infusion
41008162|NCT06382857|DIETARY_SUPPLEMENT|RUSF|RUSF will be provided on a biweekly basis at the health center until programmatic recovery but not thereafter
41322878|NCT03120364|BIOLOGICAL|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
40805338|NCT06449209|DRUG|BNT327 Dose Level 2 (DL2)|IV infusion
40805339|NCT06449209|DRUG|Topoisomerase Inhibitor A|IV infusion
40805340|NCT06449209|DRUG|Alkylating agent|IV infusion
40805341|NCT06449209|DRUG|Taxane|IV infusion
41008163|NCT03254901|OTHER|Screening test by Oraquick test|The OraQuick assay uses an indirect immunoassay method to detect hepatitis C antibodies in oral fluid or blood
41008164|NCT03160963|OTHER|Power Testing|Chair stand, vertical jump, computerized squat
41008165|NCT05525819|DRUG|Control group|The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
41008166|NCT05525819|DRUG|Intrathecal group|The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
41008167|NCT05525819|DRUG|Intravenous group|The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
41152891|NCT04728659|DRUG|Orgalutran|It will be given subcutaneously for 3 to 5 days during FSH administration for ovarian stimulation
41322879|NCT03120364|BIOLOGICAL|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
40805342|NCT06449209|DRUG|Topoisomerase Inhibitor B|IV infusion or oral capsules
41322880|NCT05943067|BIOLOGICAL|CD45RA depleted donor lymphocyte infusion (DLI)|CD45RA depleted donor lymphocyte infusion (DLI) after TCRα/β depleted haploidentical HCT
41322881|NCT04535206|DIAGNOSTIC_TEST|Venous blood collecting and test and ultrasound screening|To collect the venous blood samples before the PICC catheterization, and perform ultrasound examination before and after the catheterization at the specified time point in follow-up.
41322882|NCT01503580|DRUG|tolterodine, solifenacin|The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
41152892|NCT02511847|DRUG|Afatinib|"1. Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not~2. Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course."
40805345|NCT06407453|OTHER|control|There will be no interference ergonomics training
40805346|NCT06407453|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
40805347|NCT06488092|OTHER|Cesarean Risk Calculator|The cesarean risk calculator will be incorporated into routine care at the site
40805348|NCT03053440|DRUG|BGB-3111|160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
40805349|NCT03053440|DRUG|Ibrutinib|420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
40805350|NCT06018311|BEHAVIORAL|Exercising together|The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.
40805351|NCT06637423|DRUG|Sacituzumab tirumotecan|Intravesical administration
40805352|NCT03794349|BIOLOGICAL|Dinutuximab|Given IV
40805353|NCT03794349|DRUG|Eflornithine Hydrochloride|Given PO or via NG or G tube
40805354|NCT03794349|DRUG|Irinotecan Hydrochloride|Given IV
40805355|NCT03794349|BIOLOGICAL|Sargramostim|Given SC or IV
40805356|NCT03794349|DRUG|Temozolomide|Given PO or via NG or G tube
40805357|NCT05053139|DRUG|NNC0365-3769 (Mim8)|Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.
40805358|NCT05685238|DRUG|Mim8|Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 will use the DV3407 pen injector.
41152893|NCT05786768|DRUG|single infusion of Rituximab|single infusion of Rituximab 375 mg/m2
41152894|NCT05786768|DRUG|single infusion of Obinutuzumab|single infusion of Obinutuzumab 300mg/1.73 m2
41152895|NCT02920216|DRUG|indocyanine green|intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
40805362|NCT06335537|DRUG|Potassium citrate|Urocit-K 30 mEQ orally taken in the morning and evening.
40805363|NCT06335537|DRUG|Sodium bicarbonate|Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in the morning and ½ Teaspoon (29.5 mEq) in the evening.
41152896|NCT06472960|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
40805365|NCT06309966|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
40805366|NCT06309966|DRUG|BHV-7000|BHV-7000 75 mg. Participants will take blinded investigational product (IP) once daily
40805367|NCT06309966|DRUG|Placebo|Matching placebo taken once daily
41152897|NCT06472960|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
40805369|NCT06564142|DRUG|Povetacicept|Subcutaneous injection administration.
40805370|NCT06564142|DRUG|Placebo (matched to Povetacicept)|Placebo matched to Povetacicept subcutaneous injection administration.
40805371|NCT06461897|DRUG|Upadacitinib|Oral Tablet or Oral Solution
40805372|NCT06461897|DRUG|Dupilumab|Subcutaneous Injection
40805373|NCT03407079|OTHER|Sucralose|Sucralose is an organochlorine and is approximately 600 times sweeter than sucrose. Participants will receive sucralose (approximately 4mg/kg/day) or placebo by mouth in a capsule for 28 days. This dose corresponds to the amount of sucralose contained in approximately 3 or 4 twelve ounce cans of commercially-available diet soda for a 70 kg adult.
40805374|NCT03407079|OTHER|Placebo|Placebo capsules will be taken orally for 28 days
41152898|NCT06472960|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
40805376|NCT06564779|OTHER|New memory assessment|The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.
41152899|NCT01953406|DRUG|5-fluorouracil|5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks
40805378|NCT06325046|PROCEDURE|Computed Tomography|Undergo CT
40805379|NCT06325046|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
40805380|NCT06325046|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo near margin-less ART
40805381|NCT06325046|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40805382|NCT06325046|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo standard SABR
40805383|NCT06325046|OTHER|Survey Administration|Ancillary studies
40805384|NCT05687032|DRUG|inotuzumab ozogamicin|Given IV
41152900|NCT01953406|DRUG|Mitomycin|Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
40805386|NCT06136559|DRUG|Nemtabrutinib|Administered orally
40805387|NCT06136559|DRUG|Ibrutinib|Administered orally
41152901|NCT02228083|DRUG|Lidocaine with epinephrine|Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
41152902|NCT00893477|BIOLOGICAL|rituximab|
41152903|NCT00893477|BIOLOGICAL|sargramostim|
41152904|NCT00893477|GENETIC|gene expression analysis|
41152905|NCT00893477|GENETIC|gene rearrangement analysis|
41152906|NCT00893477|GENETIC|polymerase chain reaction|
41152907|NCT00893477|GENETIC|polymorphism analysis|
41152908|NCT00893477|OTHER|laboratory biomarker analysis|
41152909|NCT06288750|DEVICE|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
41152910|NCT06288750|DEVICE|No indocyanine green|Conventional means of identification and assessment of PGs are mainly based on surgeon-dependent identification of their anatomical location and appearance (color, shape, etc.) by the naked eye.
41152911|NCT06474234|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
41008168|NCT01639040|DRUG|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
41008169|NCT01639040|DRUG|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
41008170|NCT01639040|OTHER|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
41322883|NCT02608229|DRUG|BVD-523|
41322884|NCT02608229|DRUG|Nab-paclitaxel|
41322885|NCT02608229|DRUG|Gemcitabine|
41322886|NCT02608229|PROCEDURE|Tumor biopsy|
41322887|NCT02675725|DEVICE|Measurement of sublingual microcirculation with Cytocam-IDF camera|"The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes."
41322888|NCT02247401|DRUG|2 DAA|ABT-450/r/ABT-267 tablets
41322889|NCT02247401|DRUG|RBV|Ribavirin tablets
41322890|NCT04969341|OTHER|Survey Administration|Complete survey
41322891|NCT04969341|OTHER|Electronic Health Record Review|Review of medical records
41322892|NCT01182389|PROCEDURE|Robotic VT Ablation|Robotic VT Ablation
41322893|NCT01182389|OTHER|Conventional Therapy|Review of ICD programming to ensure that detection and therapy will occur appropriately
41322894|NCT06483230|DEVICE|Intensive Visual Stimulation Device|The therapist installs the patient in front of the device. First, patient puts the healthy side on the table and the therapist records several movements. The software of the device flips the video in order to create a mirrored image of the movement (pretty close to the mirror therapy approach). When all the movements are recorded, patient installs the affected side on the table and the screen is placed over the hand. Likewise, patient has the impression the hand is moving again. Thanks to this action observation principle, therapist can encourage the patient in trying to move again and increase brain plasticity.
41322895|NCT01262612|DRUG|immediate cediranib|cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken
40805388|NCT06136559|DRUG|Acalabrutinib|Administered orally
41008171|NCT01536639|DRUG|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
41322896|NCT01262612|DRUG|Start cediranib after 28 days Best Supportive Care|patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
41322897|NCT01469572|DRUG|Pasireotide|Pasireotide is given as an injection.
41322898|NCT01469572|PROCEDURE|Sir-sphere Radioembolization|A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
41322899|NCT01469572|DRUG|Everolimus|Given orally every day for the duration of the study
41322900|NCT04846894|DIAGNOSTIC_TEST|Ga-68 PSMA-11 PET/CT imaging|Sequential PET/CT imaging using analog and digital PET/CT scanners after single intravenous injection of Ga-68 PSMA-11
41322901|NCT02027168|OTHER|CPA|Site specific, patient centered manual physical therapy regimen focused on restoring function to the entire body
41322902|NCT05693038|DIAGNOSTIC_TEST|Electromyography|Electromyography (EMG) monitoring will be performed, using the instrumentation available (Nemus 2, EB Neuro, Italy), to evaluate the occurrence of brachial plexus injury (BPI). EMG will be performed at the end of each pronation cycle. To rule out BPI at ICU admission, an EMG will be performed within two hours from the first pronation maneuver. Particularly, somatosensory evoked potential (SSEP) and sensory action potential (SAP) will be obtained from radial, ulnar, median and sural nerves. In case patients are awake, compound muscle action potential (CMAP) will be obtained as well.
40805389|NCT05629585|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion
40805390|NCT05629585|DRUG|Durvalumab|Experimental drug. Provided in 50mg vials. IV infusion
40805391|NCT05629585|DRUG|Capecitabine|Active Comparator. Tablet. Oral route of administration
40805392|NCT05629585|DRUG|Pembrolizumab|Active Comparator. Provided in 100mg vials. IV infusion
40805393|NCT06564311|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRIIb, resulting in down regulation of B cell activity
40805394|NCT06564311|DRUG|Placebo|Placebo
41008172|NCT02997033|OTHER|No intervention|No intervention
41008173|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube
41008174|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / LMA ETT™|After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube
41008175|NCT03109678|DEVICE|Crossover FASTRACH™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube
41008176|NCT03109678|DEVICE|Crossover FASTRACH™ / LMA ETT™|After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
41008177|NCT00006475|DRUG|imatinib mesylate|
41008178|NCT05371535|DEVICE|MatrixOssTM Bone Graft plus Bio-Gide membrane|To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
41008179|NCT03019627|DRUG|NGF|Eye Drop 20 μg/mL
41008180|NCT03019627|OTHER|Vehicle|Vehicle Eye Drop
41008181|NCT02607514|BEHAVIORAL|hyperthermic yoga|heated yoga, 90-minutes
41008182|NCT05009758|PROCEDURE|Blood sampling|Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
41008183|NCT05009758|PROCEDURE|Nasosorption|Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
41008184|NCT05009758|PROCEDURE|Oral sampling|For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
41322903|NCT05693038|DIAGNOSTIC_TEST|Muscle strength measurement|Muscle strength measure willl be assessed at ICU discharge using hand-held dynamometer.
41322904|NCT00884052|DRUG|Low dose levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
41322905|NCT00884052|DRUG|High dose levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
41477705|NCT03647631|PROCEDURE|sentinel lymph node biopsy|Authors discuss a possible usefulness of SNLB for staging and diagnosis in porocarcinoma.
41477706|NCT00002199|DRUG|Indinavir sulfate|
41477707|NCT00002199|DRUG|Lamivudine/Zidovudine|
41477708|NCT00002199|DRUG|Abacavir sulfate|
41152912|NCT06474234|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
41152913|NCT02559479|BEHAVIORAL|Weight loss interventional study with a low-calorie 18%-protein diet|
40805397|NCT06012240|DRUG|Upadacitinib|Oral Tablets
40805398|NCT06012240|DRUG|Placebo|Oral Tablets
41152914|NCT02559479|BEHAVIORAL|Weight loss interventional study with a low-calorie 35%-protein diet|
41152915|NCT00669149|DRUG|clopidogrel + aspirin|
40805401|NCT05568680|BIOLOGICAL|SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR|Autologous T cells Transduced with Mesothelin KIR-CAR
41152916|NCT00669149|DRUG|heparin + clopidogrel + aspirin|
41152917|NCT00669149|DRUG|enoxaparin + clopidogrel + aspirin|
41152918|NCT00669149|DRUG|bivalirudin + clopidogrel + aspirin|
41322906|NCT03894098|PROCEDURE|Nerve block|High ankle nerve block
41322907|NCT04007601|DEVICE|Active tDCS|Participants will receive active 1mA direct current stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
41322908|NCT04007601|DEVICE|Sham tDCS|Participants will receive sham (no direct current) stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
41322909|NCT03859492|DEVICE|Contrast Enhanced Digital Mammography|High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image
41322910|NCT05733364|DIETARY_SUPPLEMENT|Capsules with B vitamins & taurine|Administered orally in a span of 28 days between mealtimes
41477709|NCT05607251|OTHER|No intervention|There is no intervention as this is an observational study
41477710|NCT00894114|BIOLOGICAL|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
41477711|NCT00894114|BIOLOGICAL|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
41477712|NCT03083626|OTHER|Cold pressor test|"The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached."
41152919|NCT01399502|BEHAVIORAL|Mood Memo emails|Participants will receive 12 emails over 6 weeks.
41152920|NCT04285151|PROCEDURE|Nd:YAG laser Hyaloidotomy|Using the YAG laser for opening the posterior hyaloid in eyes with premacular hemorrhage, and evacuating the entrapped hemorrhage
41152921|NCT00627432|DRUG|gemcitabine hydrochloride|
41152922|NCT00627432|DRUG|oxaliplatin|
41152923|NCT01780584|DRUG|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
41152924|NCT01780584|DRUG|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
41152925|NCT01780584|DRUG|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
41152926|NCT05464992|OTHER|Additional CEST sequences during PET/MRI exam|CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare
41152927|NCT06476483|BEHAVIORAL|DIALOG+|A person-centred and solution-focused intervention linked to the DIALOG outcome measure (a measure of patient experience and quality of life).
41152928|NCT06476483|BEHAVIORAL|DIALOG|An outcome measure consisting of 11 questions, with 8 related to quality of life and 3 items on treatment satisfaction. Patients can rate their satisfaction on a 7-point scale for each of the 8 life domains and 3 treatment aspects, resulting in scores for both quality of life and treatment satisfaction. The DIALOG scale does not provide any guidance for patient and clinician interactions.
41152929|NCT00281983|BIOLOGICAL|alemtuzumab|
41477713|NCT03686020|DIAGNOSTIC_TEST|Enzyme Linked Immunosorbent assay (ELISA)|measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)
41477714|NCT00336128|BEHAVIORAL|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
41477715|NCT00336128|BEHAVIORAL|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
41477716|NCT00465049|OTHER|PRIMARY CLOSRE|SUTURE
41477717|NCT00465049|OTHER|SECONDARY CLOSURE|ALLOW TO HEAL SPONTANEOUSLY
41152930|NCT00281983|BIOLOGICAL|anti-thymocyte globulin|
41152931|NCT00281983|BIOLOGICAL|filgrastim|
41152932|NCT00281983|BIOLOGICAL|rituximab|
41152933|NCT00281983|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41152934|NCT00281983|DRUG|busulfan|
41152935|NCT00281983|DRUG|cyclophosphamide|
41152936|NCT00281983|DRUG|cyclosporine|
41152937|NCT00281983|DRUG|fludarabine phosphate|
41152938|NCT00281983|DRUG|methotrexate|
41152939|NCT00281983|DRUG|mycophenolate mofetil|
41152940|NCT00281983|PROCEDURE|peripheral blood stem cell transplantation|
41152941|NCT00281983|RADIATION|radiation therapy|
41152942|NCT06434545|BEHAVIORAL|Palliative Reasoning methodology|Twenty nursing teams will be trained in the Palliative Reasoning methodology during a four hour training, split into two sessions. Additionally, teams receive a coaching session ones a month and practice with a real life case every week or two weeks during a one hour team meeting. This will be compared with 20 other nursing teams that will continue to provide care as usual.
41152943|NCT00788632|BEHAVIORAL|Patient educational DVD and brochure|"Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster."
41152944|NCT00788632|BEHAVIORAL|Physician web modules|Web based osteoporosis continuing medical education (CME) materials
41152945|NCT00788632|BEHAVIORAL|System|Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
41152946|NCT03035149|OTHER|Weight Management Program|Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
41152947|NCT01196741|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
41008185|NCT05009758|PROCEDURE|Bronchoscopy|The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
40805425|NCT06257277|DRUG|GBCAs|GBCAs are given per routine clinical practice.
40805426|NCT05844111|DRUG|[14C]-BGB-11417|A single oral dose of liquid formulation
40805427|NCT04521231|DRUG|Blinatumomab|Blinatumomab will be administered as a subcutaneous (SC) injection.
41152948|NCT01196741|DRUG|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
41152949|NCT01196741|DRUG|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
40805430|NCT06024239|DRUG|ABBV-932|Capsule; oral
40805431|NCT06024239|DRUG|Placebo for ABBV-932|Capsule; oral
41152950|NCT03490942|DRUG|Glucagon|CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.
41152951|NCT03490942|DRUG|Placebo|The placebo solution is a non-active formulation containing excipients only.
41152952|NCT01540877|PROCEDURE|Application of capsaicin 0.6%|topical application of 0.6% capsaicin on the volar forearm
40805434|NCT05844943|DEVICE|ReHeal glove with Negative Pressure Wound Therapy (NPWT)|ReHeal glove hand dressing with Negative Pressure Wound Therapy (NPWT).
41152953|NCT01540877|PROCEDURE|Application of local anesthetics (EMLA plaster)|topical application of EMLA on the volar forearm
41152954|NCT01540877|PROCEDURE|Application of 1 capsaicin 0.6% and 2. EMLA|topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm
41477718|NCT00465049|OTHER|SPONTANEOUS HALING|SECONDARY HEALING AFTER I\&D
40805438|NCT06170619|DEVICE|Obsidio™ Conformable Embolic|Embolization with Obsidio™ Conformable Embolic.
41477719|NCT06502197|PROCEDURE|Silastic Stenting|Drill-out frontal sinus procedures, are a well-established surgical intervention in the management of CRS, involves extensive sinus surgery with the creation of a large, surgically exposed area of raw bone. This raw bone, left exposed postoperatively, poses a unique challenge in the context of mucosal healing. Silastic stents, inserted into the sinus cavities, offer a promising solution by providing structural support and facilitating mucosal re-mucolisation in this critical period of postoperative recovery.
41477720|NCT04131231|DRUG|microparticles packaging methotrexate (MPs-MTX)|50ml, intrapleural infusion, day5,6,7,8
41477721|NCT04131231|DRUG|recombinant human interleukin-2(rhIL-2)|50ml, intrapleural infusion, day5,8,11
41477722|NCT05580991|DRUG|CAN1012|CAN1012 IT injection (once every 4 weeks)
40805440|NCT05582395|DRUG|Mavacamten|Specified dose on specified days
40805441|NCT05582395|OTHER|Placebo|Specified dose on specified days
41477723|NCT02601274|DRUG|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
41152955|NCT01540877|PROCEDURE|Application of 1. EMLA and 2. capsaicin 0.6%|topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
41152956|NCT02095938|DRUG|amisulpride|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
41152957|NCT01282983|DIETARY_SUPPLEMENT|Fiber|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) with 4grams of fiber in each pack.
41322911|NCT05733364|OTHER|Microcrystalline cellulose placebo|Administered orally in a span of 28 days between mealtimes
41322912|NCT05549648|OTHER|Home oral excrise|The current study aimed to evaluate the efficacy and user experience of mobile phone APP, a mobile application with AI component in facial movement tracking, in improving oral functions of elderly people
40805446|NCT02311933|DRUG|Endoxifen Hydrochloride|Given PO
40805447|NCT02311933|OTHER|Laboratory Biomarker Analysis|Correlative studies
40805448|NCT02311933|OTHER|Pharmacological Study|Correlative studies
40805449|NCT02311933|DRUG|Tamoxifen Citrate|Given PO
40805450|NCT02890355|DRUG|Fluorouracil|Given IV
41008186|NCT05009758|PROCEDURE|Nasal biopsy|Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
40805451|NCT02890355|DRUG|Fluorouracil|Given IV bolus
40805452|NCT02890355|DRUG|Irinotecan Hydrochloride|Given IV
40805453|NCT02890355|OTHER|Laboratory Biomarker Analysis|Correlative studies
40805454|NCT02890355|DRUG|Leucovorin Calcium|Given IV
40805455|NCT02890355|DRUG|Veliparib|Given PO
41322913|NCT00765440|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|Given orally
40805457|NCT05411081|BIOLOGICAL|Atezolizumab|Given IV
40805458|NCT05411081|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40805459|NCT05411081|PROCEDURE|Bone Scan|Undergo bone scans
40805460|NCT05411081|DRUG|Cabozantinib S-malate|Given PO
40805461|NCT05411081|PROCEDURE|Computed Tomography|Undergo CT scans
40805462|NCT06355414|DRUG|Psilocybin|Drug administration under supportive conditions
40805463|NCT06355414|DRUG|Methylphenidate|Drug administration under supportive conditions
40805464|NCT03981640|OTHER|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
40805465|NCT03981640|OTHER|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
41008187|NCT05009758|PROCEDURE|Nasal sampling|Swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the anterior naris and middle meatus of each nostril
41008188|NCT05009758|PROCEDURE|Nasal mucosa mRNA sampling|Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.
41322914|NCT00765440|OTHER|placebo|Given orally
41322915|NCT00247260|DEVICE|32P BioSilicon|
41322916|NCT02524756|PROCEDURE|laparoscopic nerve-sparing radical hysterectomy-type III/C1|
41477724|NCT05483582|DEVICE|4-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
41477725|NCT05483582|DEVICE|2-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
41477726|NCT00976794|DRUG|lithium plus carbamazepine|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability"
41322917|NCT02524756|PROCEDURE|laparoscopic radical hysterectomy (type III/C2).|
41322918|NCT03495453|DEVICE|Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS|"Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is a small catheter with a diamond crown. The doctor inserts it at the groin and advances into the leg.The OAS works by spinning around inside the artery to sand down the buildup of material along the artery walls while leaving the healthy vessel behind."
41322919|NCT03495453|DEVICE|Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device|HawkOne Directional Atherectomy System (DAS) also is the small catheter with cutting device. Doctor slowly and smoothly advances it across the blockage in your artery and shaves the plaque from the vessel wall and collects it in the reservoir.
41322920|NCT04173871|DEVICE|Protac Myfit®|A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
41322921|NCT05680194|PROCEDURE|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
41322922|NCT05680194|DRUG|Bisphosphonate|Bisphosphonate
41322923|NCT00920036|DEVICE|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
41322924|NCT04540081|OTHER|Epic Healthy Planet Population Health Module|Electronic population health module which is tailored to increased adherence to USPSTF and CDC recommendations
41322925|NCT05227209|DRUG|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
41322926|NCT03771404|OTHER|blood sampling|Patients' peripheral blood will be obtained before the surgical excision of the primary tumor as well as 1-month post-op and every 3-6 months thereafter until disease progression and upon disease relapse for the evaluation of ctDNA and CTCs. Different sites of the primary tumor as well as the regional involved lymph nodes and, in selected patients, biopsies from metastatic sites will be genotyped by NGS as well.
41322927|NCT00218790|PROCEDURE|Cool Dialysate|Decreased temperature of the dialysis bath
41322928|NCT00443235|DRUG|Melphalan/Prednisone/Velcade|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
41322929|NCT00443235|DRUG|Thalidomide/Prednisone/Velcade|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity \< grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
41322930|NCT03833375|OTHER|Decision Aid|Shared-decision making tool
41008189|NCT05009758|DIAGNOSTIC_TEST|Pregnancy test|In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.
41008190|NCT05009758|OTHER|Medical history of patients, demographic data, concomitant medication, questionnaire|Patients will be asked for their medical history including demographic data and concomitant medication. Details will be noted in the source data file. Furthermore, patients will receive a questionnaire including tools to assess QOL impairment by CRS and asthma
41152958|NCT01282983|DIETARY_SUPPLEMENT|Placebo|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) without fiber.
41322931|NCT06048926|DRUG|Carrelizumab|200 mg/time, iv, Q3W
41322932|NCT06048926|DRUG|Paclitaxel injection|50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
41322933|NCT06048926|DRUG|Cisplatin|25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times
41322934|NCT06048926|RADIATION|Concurrent chemoradiotherapy|Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
41322935|NCT02766595|OTHER|hyperventilation while sitting up during routine EEG|Child will be asked to perform hyperventilation while lying down as well as while sitting up
41322936|NCT04008108|OTHER|Activity sensor|Activity sensor worn on the wrist during 7 days, 24h/24 to evaluate physical activity of patient (measured by the number of step per day) before and after Artificial Urinary Sphincter Implantation.
41477727|NCT00976794|DRUG|lithium plus valproate|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability."
41477728|NCT00857259|DRUG|Everolimus|5 mg oral tablet
41477729|NCT00857259|DRUG|Ranibizumab|0.5 mg administered by intravitreal injection
41477730|NCT06107478|OTHER|Self-report questionnaires (only for parents)|"Quantitative part (all investigating centers): When they come to the various timepoints (T0, T1, T2), participants will be asked to fill in self-questionnaires, either electronically or on paper. If they are unable to come to the center at T1 and/or T2, they will be offered the option of completing the self-questionnaires online. These can also be sent by e-mail or postal mail and received by the same means if necessary.~The tools:~* Quality of life: Pediatric Quality of Life Inventory~* Anxiety: Edmonton Symptom Assessment System; Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale~* Depression: Edmonton Symptom Assessment System; PROMIS depression scale~* Parent-child relationship: Ad hoc questionnaire~* Parent-caregiver relationship: Enabling Practices Scale Socio-demographic data on parents and children, data relating to supportive care will be collected at inclusion. Massage habits will be collected at T1 and T2."
41477731|NCT06107478|OTHER|Interview (only for parents)|"Qualitative part (exclusively at CLB):~Participants (parents) in the qualitative part of the study will be asked to complete a self-administered questionnaire on socio-demographic data when they come to the center at T0. Clinical data will also be collected at T0. At T1, an interview will be organized with a researcher dedicated to the study. Qualitative interviews will preferably take place face-to-face, although videoconferencing may be used in certain circumstances."
41477732|NCT06107478|OTHER|Clinical data collection (only concerning Children)|The children's medical data (patients) will be collected in a Case Report Form (CRF; e.g. type of cancer, date of diagnosis, anti-cancer treatments received, symptoms) at T0.
41008191|NCT05009758|DIAGNOSTIC_TEST|UPSIT smell test|University of Pennsylvania Smell Identification Test (UPSIT) smell test will be performed by the patients during the study. It consists of 40 questions in 4 different booklets. The patient needs to scratch a sniff strip with the microencapsulated odorant using a pencil and mark his choice on four-choice multiple-choice questions. The test is then scored by the study team out of the 40 items.
41008192|NCT05009758|PROCEDURE|Spirometry|Lung function will be measured by spirometry in the lung function unit of the Department of Pulmonology. Spirometry will be performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines by authorized and properly certified personal.
41008193|NCT05009758|PROCEDURE|FeNO|Airway inflammation will be evaluated using a standardized single-breath FeNO test in accordance with the lung function unit of the Department of Pulmonology. A single exhalation technique recommended by the manufacturer will be followed. The FeNO measurements will not be performed within 2 weeks of a respiratory infection. The FeNO test will be performed prior to spirometry. Subjects should not eat or drink 1 hour prior to having the FeNO test. Subjects should not use their rescue SABA medication (e.g., albuterol/salbutamol) within 6 hours of the measurement. Inhaled bronchodilators (including ICS/LABA) should be withheld for the effect duration specific to the bronchodilator. If not, the assessment should be postponed till after the required time has passed since the meal or drink or bronchodilator inhalation. The NIOX VERO® Airway Inflammation Monitor will be used to measured FeNO in the lung function unit of the Department of Pulmonology.
41008194|NCT05009758|PROCEDURE|Lung X-Ray|After the bronchoscopy, a lung x-ray will be performed and patients will stay overnight in the ward of the Department of Pulmonology.
41322937|NCT03392987|GENETIC|OTL-200|OTL-200 is an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence
41322938|NCT02750267|DEVICE|Diabetes Assistant (DiAs) with Closed-Loop|All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
41322939|NCT03729934|DIETARY_SUPPLEMENT|Ketone Ester|This arm receives 25 g ketone ester.
41477733|NCT04912115|DRUG|Ketamine|Ketamine is an FDA-approved N-methyl-D-aspartate (NMDA) receptor-modulating drug pharmacologically classified as an NMDA receptor antagonist (also noted to be a weak opioid receptor agonist).
41477734|NCT04912115|DRUG|Midazolam|Midazolam is a benzodiazepine used for anesthesia, procedural sedation, trouble sleeping, and severe agitation.
41008195|NCT05584007|DRUG|Flucloxacillin Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment
41008196|NCT05584007|DRUG|Placebo Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
41152959|NCT06471842|OTHER|MCH (Montreal Children's Hospital) feeding scale questionnaire and parental questionnaire|The patient's parents will answer the questionnaire and the investigator will complete the parental questionnaire while asking the questions.
41152960|NCT05271799|DRUG|Gepotidacin|Gepotidacin will be administered
41152961|NCT02074878|DRUG|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
41477735|NCT03499119|DRUG|AMG 334 Dose 1|"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2"
41477736|NCT03499119|DRUG|AMG 334 Dose 2|Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
41477737|NCT03499119|DRUG|AMG 334 Dose 3|Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
41477738|NCT05558449|DEVICE|Hypnosedation|"Hypnosedation session with a virtual reality headset during the regional anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
41477739|NCT05558449|DRUG|Midazolam injection|Midazolam intravenous injection 1 mg until RASS -3
41477740|NCT05558449|DEVICE|Virtual reality|"Only virtual reality without a hypnosedation session. The virtual reality headset will be used on these patients without external voice or hypnosis device. The virtual reality module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
41322940|NCT03729934|DIETARY_SUPPLEMENT|Ketone Salt|This arm receives 25 g ketone salt.
41477741|NCT02408328|DRUG|Caffeine citrate|Loading dose and continues use of caffeine until 44 weeks postmenstrual age
41477742|NCT02408328|DEVICE|Home monitor|Use of home monitor until 44 weeks postmenstrual age
41477743|NCT02408328|OTHER|Continued inpatient monitoring until apnea resolution|Continued inpatient monitoring until apnea resolution
41477744|NCT00759720|DRUG|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
41477745|NCT00759720|DRUG|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
41477746|NCT00759720|DRUG|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
40805466|NCT03981640|OTHER|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
40805467|NCT06027814|BEHAVIORAL|Patient Navigation and mHealth (PN+mHealth)|Intervention consists of patient navigation with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone.
41008197|NCT00280566|DRUG|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
41008198|NCT00280566|DRUG|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
41322941|NCT05100433|PROCEDURE|Ultrasonic irrigation|Ultrasonic irrigation will be used as a complementary step to chemomechanical procedures to test whether it can improve root canal disinfection.
41322942|NCT03874754|OTHER|Tailored Technology-Enhance Home-based exercise program (iHBE)|The tailored technology enhanced home-based exercise (iHBE) program is a 12-week program with 1 assessment home visit session, 5 home visits and 7 phone follow ups during exercise. The technologies, a wearable device, and a smartphone application, will be used as a tool to monitor physical performance (heart rate \[HR\], step count), provide immediate feedback, send daily reminding message through Mobile Ecological Momentary Assessment (mEMA). The coded raw data without personal identification information from the wearable device will be sent to the servers where the investigators can store it in the database alongside the mEMA data and create custom reports showing Heart Rate (HR) 30 minute before each Ecological Momentary Assessment (EMA) survey, showing HR and previous self-report responses before/ after each automatically triggered EMA.
41477747|NCT06420830|PROCEDURE|SAPIEN 3 Ultra RESILIA Valve|Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.
41322943|NCT01220505|PROCEDURE|Surgery|All subjects will have spinal surgery between the levels of T1 and Ilium using the Polaris Deformity Spinal System
41008199|NCT06153290|PROCEDURE|Chiropractic adjustment|A single-session of genuine/real high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
41322944|NCT00002783|DRUG|cisplatin|
41322945|NCT00002783|DRUG|floxuridine|
41322946|NCT00002783|DRUG|fluorouracil|
41322947|NCT00002783|DRUG|leucovorin calcium|
41477748|NCT05174117|COMBINATION_PRODUCT|single irradiation|46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
41477749|NCT05174117|COMBINATION_PRODUCT|Double irradiation|46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
41322948|NCT00002783|PROCEDURE|conventional surgery|
41477750|NCT05263284|DRUG|8-Chloroadenosine|Given IV
41477751|NCT05263284|DRUG|Venetoclax|Given PO
41477752|NCT05221424|OTHER|Patient Education|"The training program about hypertension prepared according to the Roy Adaptation Model was performed in a room in the cardiology outpatient clinic of a state hospital. The training content was shaped according to 4 (four) basic areas of the Roy Adaptation Model (physiological field, self-concept field, role function field and interdependence field). The training taught to each patient individually and interactively with the support of powerpoint presentation lasted for averagely 45-50 minutes. A Hypertension Training Booklet was prepared according to the Roy Adaptation Model in order to be used during the training and to strengthen the training."
41477753|NCT02714231|DRUG|diclofenac sodium (cataflam)|The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
41477754|NCT02714231|DRUG|hyoscine butyl bromide (buscopan)|The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
41477755|NCT04387734|DRUG|Ocrelizumab|Ocrevus will be administered following the FDA's regulations.
41477756|NCT04387734|DRUG|Platform|The applications of the platform DMTs will follow the FDA-approved regulations.
41477757|NCT00005586|DRUG|L-leucovorin|
41477758|NCT00005586|DRUG|fluorouracil|
41008200|NCT06153290|PROCEDURE|Sham adjustment|A single-session of simulated/sham high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
41322949|NCT06016140|OTHER|Medication plan|Involved participants will jointly agreed on continued medication treatment (treatment aim, planned monitring and evaluation and responsibility, and the physician will document the plan in the electronic health record
41008201|NCT03915288|OTHER|Group continuous training at moderate intensity|70 minutes for intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60-80% FCM), with fast walking or endless tread with the floor inclined to reach the desired intensity. Also on bicycle, rowing and elliptical; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
41008202|NCT03915288|OTHER|Group high Intensity Interval Training|70 minutes for intervention, where 10 minutes were for warm-up (Respiratory exercises, walking, stretching), 30 minutes consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group that we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%). ; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
41008203|NCT03915288|OTHER|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities.
41008204|NCT00191893|DRUG|teriparatide|
41008205|NCT05395819|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within \< 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
41008206|NCT05395819|PROCEDURE|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
41008207|NCT00133081|DRUG|All registered antiepileptic drugs|
41008208|NCT05697042|BEHAVIORAL|MY-Skills for Long COVID|8 week online intervention with therapeutic yoga and self-management education
41008209|NCT00763542|BEHAVIORAL|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
41008210|NCT00763542|BEHAVIORAL|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
41008211|NCT00219934|DRUG|Antiretroviral therapy|HAART therapy
41152962|NCT02074878|DRUG|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
41322950|NCT06257537|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
41322951|NCT06257537|DEVICE|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
41322952|NCT06257537|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
41322953|NCT06257537|OTHER|SAM Patch|Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.
41322954|NCT04886518|DRUG|Pitolisant Oral Tablet|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
41322955|NCT04886518|DRUG|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
41322956|NCT02585999|DEVICE|Xulane Contraceptive Patch|Extended use (12 weeks) of contraceptive patch
41152963|NCT02074878|DRUG|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
41152964|NCT05046301|PROCEDURE|Biospecimen Collection|Correlative studies
41152965|NCT05046301|OTHER|Contrast Agent|Given IV
41322957|NCT02585726|DEVICE|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
41322958|NCT04280406|DRUG|Azithromycin|azithromycin 500mg one hour before implant placement
41322959|NCT04280406|DRUG|Placebo oral tablet|identical placebo one hour before implant placement
41322960|NCT02441855|DEVICE|echocardiography|echocardiography: Left and right ventricular functions and aortic elastic properties.
41322961|NCT04840017|OTHER|rehabilitation exercise|Rehabilitation exercise of intrinsic foot muscles
41322962|NCT04034043|DEVICE|ceramic-on-ceramic total hip arthroplasty|ceramic-on-ceramic, cementless total hip arthroplasty for post-traumatic hip osteoarthritis.
41322963|NCT04370912|DIAGNOSTIC_TEST|Bed side Ultrasound|Handgrip strength will be measured using a digital grip strength dynamometer (Sammons Preston, Nottinghamshire, UK). This measurement is carried out three times using the subject's dominant hand, and then averaged
41322964|NCT03011450|DRUG|K-877|
41322965|NCT03011450|DRUG|Fenofibrate|
41322966|NCT03011450|DRUG|Placebo (for K-877)|
41322967|NCT04278508|DRUG|Progesterone|To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
41322968|NCT04048655|DRUG|Neostigmine, Combinations|All patients have neostigmine induced recovery of neuromuscular block.
41322969|NCT06451263|BEHAVIORAL|Nudge|Referral to gynecologic oncology is recommended when patients are diagnosed with a complex adnexal mass on imaging (i.e., O-RADS 4 or 5 on ultrasound or MRI, Codex 4 or 5 on CT). When patients are identified as having an adnexal mass, the order will be pended by the clinical research coordinator and sent to the ordering provider with a message to sign. The order will be pended within 48 hours of resulting imaging. The message will include content about national guidelines on referral to gynecologic oncology with opt-out framed language.
41322970|NCT04904965|DRUG|Propofol Group 1|Propofol 2.0 mg/kg/hr per 10 min
41322971|NCT04904965|DRUG|Propofol Group 2|Propofol 4.0 mg/kg/hr per 10 min
41322972|NCT04904965|DRUG|Propofol Group 3|Propofol 6.0 mg/kg/hr per 10 min
41322973|NCT04904965|DRUG|Propofol Group 4|Propofol 8.0 mg/kg/hr per 10 min
41477759|NCT00005586|PROCEDURE|adjuvant therapy|
41477760|NCT02015689|BEHAVIORAL|Benefits to Child|CDC VIS + message emphasizing benefits to child of MMR vaccine
41477761|NCT02015689|BEHAVIORAL|Benefits to Society|CDC VIS + message emphasizing benefits to society of MMR vaccine
41477762|NCT02015689|BEHAVIORAL|Benefits to Child and Society|CDC VIS + message emphasizing benefits both to child and to society of MMR vaccine
41477763|NCT02015689|BEHAVIORAL|CDC VIS|CDC Vaccine Information Statement (VIS)
41477764|NCT05790954|OTHER|Guided imagery|Three days before the cesarean section, the participants will be given a guided imagery audio recording and will be asked to listen to it before going to bed every evening until the day of the cesarean section. On the morning of the cesarean section, after the patient is prepared, the guided imagery audio recording will be played again.
41477765|NCT04732416|DRUG|HM15136|Low dose of HM15136/ High dose of HM15136, SC injection, weekly
41477766|NCT04621916|DRUG|FVIII|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
41322974|NCT05800977|BIOLOGICAL|Prizloncabtagene autoleucel|Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens
41322975|NCT05339386|DRUG|Hyperpolarized Xe129|Lung MRI using gaseous contrast agent hyperpolarized 129Xe.
41322976|NCT06195293|BIOLOGICAL|Neoantigen Polypeptide Vaccine|Deliver neoantigen polypeptide vaccine into patients for anti-ancer therapy.
41322977|NCT00780702|DRUG|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
41322978|NCT00780702|DRUG|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
41477767|NCT04621916|DRUG|Emicizumab|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
41322979|NCT05875129|DEVICE|VAVA prototype|Cognitive behavioral therapy for insomnia
41322980|NCT03625154|PROCEDURE|ankle open reduction internal fixation|Open Reduction and Internal Fixation with plates and screws
41322981|NCT03625154|OTHER|non operative management|closed reduction and splinting followed by progressive weight bearing
41477768|NCT06202924|BEHAVIORAL|Static balance assessment|Biodex stabilometer device will be used to evaluate the static balance of the participants.
41477769|NCT06202924|BEHAVIORAL|Dynamic balance assessment:|Individuals' dynamic balance performances were evaluated with the Y balance test. Y balance test is a test method with proven validity and reliability in athletes and healthy subjects. (Intra-class correlation 0.99-1, Inter-class correlation 0.85-0.91).
41477770|NCT06202924|BEHAVIORAL|Isokinetic strength evaluation:|Quadriceps muscle strength of the participants will be evaluated with an isokinetic dynamometer. Isokinetic dynamometers are considered the gold standard in muscle strength measurements. These devices have the ability to objectively report the amount of force produced by individuals at predetermined angular speed and joint range of motion.
41477771|NCT04807751|DRUG|Delgocitinib cream|Cream for topical application
41322982|NCT04613999|DRUG|Ralinepag|"Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~* Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~* Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~* Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose."
41477772|NCT04807751|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
41477773|NCT00095433|DRUG|rhuFab V2 (ranibizumab)|
41477774|NCT06418425|BEHAVIORAL|counselling on home-based exercise program and dietary protein intake|Participants in the intervention group will be on a home-based exercise program and go through counselling on dietary protein intake with the aim of achieving prevention of frailty status. Participants will be required to attend the 3 study visits throughout the study period. Research procedures include physical measurements (eg. Weight, height, waist and hip circumference, calf circumference, hand grip strength, blood pressure, short physical performance battery tests), administration of questionnaires on sociodemographics, physical activity, dietary habits, smoking, alcohol, health conditions, health-related quality of life, clinical frailty status and sarcopenia screening. At three months and twelve months, the intervention group participants will see the care coordinators who will check their compliance to the exercise programme and high protein diet, reinforce the interventions.
41477775|NCT04086641|DEVICE|Crossover foot|A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.
41477776|NCT04086641|DEVICE|Energy Storing Foot|A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
41477777|NCT03316378|DRUG|Ropivacaine injection|single dose, subcutaneous injection
41152966|NCT05046301|PROCEDURE|Contrast-Enhanced Mammography|Undergo contrast-enhanced mammography
41322983|NCT02882763|OTHER|Parents As Teachers (PAT)|A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
41322984|NCT05706649|BEHAVIORAL|Plant-based diet|21 day diet that excludes any form of meat and other animal products, including dairy products.
41322985|NCT03279341|DRUG|polyethylene glycol|osmotic laxative
41477778|NCT01300624|BEHAVIORAL|Verb Network Strengthening Treatment|Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
41477779|NCT01284855|DRUG|Antivenom|Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
41477780|NCT02823314|DEVICE|Cure Tape™ covering T 7 and T 8 dermatomes|The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.
41477781|NCT02823314|DEVICE|Cure Tape™ away from dermatomes T 7 and T 8|The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.
41477782|NCT01319786|OTHER|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
41477783|NCT01319786|OTHER|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
41322986|NCT03279341|DRUG|Bisacodyl|stimulant laxative
41477784|NCT00016276|DRUG|dexrazoxane hydrochloride|Given IV
41477785|NCT00016276|DRUG|doxorubicin hydrochloride|Given IV
41477786|NCT00016276|DRUG|cyclophosphamide|Given IV
41477787|NCT00016276|DRUG|paclitaxel|Given IV
41477788|NCT00016276|BIOLOGICAL|trastuzumab|Given IV
41477789|NCT00016276|PROCEDURE|therapeutic conventional surgery|Undergo breast conservation surgery, modified radical mastectomy, or mastectomy
41477790|NCT00016276|RADIATION|radiation therapy|Undergo radiation therapy
41152967|NCT05046301|OTHER|Questionnaire Administration|Ancillary studies
41152968|NCT02156089|OTHER|Highly unsaturated omega-3 fatty acids|Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).
41322987|NCT03279341|DRUG|Prucalopride|prokinetic
41322988|NCT04945824|DRUG|Dexamethasone Ophthalmic|Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.
41322989|NCT04945824|DEVICE|Dilator|Intracanalicular Dilator Device
41322990|NCT04953065|OTHER|COVID-19 vaccine hesitancy and acceptance survey|Participants will be provided with a COVID-19 vaccine hesitancy and acceptance survey developed by the study team.
41322991|NCT02494778|DRUG|Pridopidine|45 mg BID
41322992|NCT00745953|DRUG|Valsartan|Valsartan 320mg PO daily for 8 months
41322993|NCT00745953|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
41322994|NCT06100484|DIAGNOSTIC_TEST|Echocardiography|Two-dimensional RV strain imaging will be performed by using three consecutive cardiac cycles of 2D images in the apical four-chamber view to assess RV-GLS
41322995|NCT05432102|DIAGNOSTIC_TEST|Pulse oxymetry|Diagnostic intervention to diagnose OSA.
41322996|NCT05432102|DIAGNOSTIC_TEST|Respiratory polygraphy|Diagnostic intervention to diagnose OSA.
41477791|NCT00016276|DRUG|tamoxifen citrate|Given orally
41477792|NCT00016276|OTHER|laboratory biomarker analysis|Correlative studies
41477793|NCT00865631|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
41477794|NCT00865631|DRUG|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
41477795|NCT00865631|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
41477796|NCT05553782|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Percutaneous CT image-guided placement of the microdevice(s). At least one, and up to 3, devices will be placed in each tumor.~* Drugs will be released from the microdevice into local tumor tissues. The duration of drug release will be for a period of 3-5 days while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice harbors up to 20 drugs and/or drug combinations relevant to the treatment of salivary cancer. The drugs used will include some standard agents approved by the Food and Drug Administration (FDA) for treatment of different types of cancers, or drugs classes under investigational.~  * Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations: Lenvatinib, Axitinib, All trans retinoic acid (ATRA), Venetoclax, Pembrolizumab, Cisplatin, Carboplatin, Vinorelbine"
41477797|NCT04334655|OTHER|Physical Therapy|Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.
41477798|NCT03664050|DRUG|group A 2.5 mg letrozole oral tablets|2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.
41322997|NCT00823940|DRUG|GSK1362885|5 - 100mg of GSK1362885 or placebo
41477799|NCT03664050|PROCEDURE|laparoscopic ovarian drilling|Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
41477800|NCT01931527|DRUG|Rasburicase|one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
41477801|NCT02701413|DEVICE|ApexM (Stimulation) Device|Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
41477802|NCT02701413|DEVICE|Sham Device|A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
41322998|NCT00823940|DRUG|GSK1362885|100 - 600mg or placebo
41477803|NCT02447926|PROCEDURE|Leukapheresis|"Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.~On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.~During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.~Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours."
41477804|NCT06490237|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression, vestibular neurotomy, meningioma or schwannoma removal), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests in noise and in silence. During the operation, stimuli are delivered in silence and in noise, under the same conditions as during the preoperative auditory exploration."
41477805|NCT03380520|DRUG|Ferric Carboxymaltose|Ferric carboxymaltose will be administered according to product specification dosing
41477806|NCT03380520|DRUG|Placebo|IV nacl 0.9%
41477807|NCT04176588|DRUG|Etrasimod|Drug:Etrasimod Tablet other name:APD334
41477808|NCT04176588|DRUG|Placebo|Drug:placebo Tablet
41322999|NCT00823940|DRUG|Glucagon|0.5mg IV bolus
41323000|NCT00823940|DRUG|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
41323001|NCT05816967|PROCEDURE|Medication review and discharge counseling|Medication reconciliation of home therapy will be performed by the clinical pharmacist through a standardized form. Next, the clinical pharmacist will perform a medication review, based on but not limited to the RASP list (Van der Linden 2014). The goal is optimization of therapy. Before discharge the clinical pharmacist will perform a second medication review, together with the treating physician and a medication reconciliation in orde to provide the best possible discharge medication list. The medication list will be provided 3 times: once for the patient and/or his/her caregiver, once for the general practitioner and once for the primary care pharmacist. Finally the clinical pharmacist will have a counseling session with the patient and/or his/her caregiver.
41323002|NCT03496129|BEHAVIORAL|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
41477809|NCT04557176|DEVICE|CRP, point-of-care assay|CRP is a non-specific marker of inflammation whose levels rise in the setting of interleukin 6 (IL-6)-mediated inflammation, such as active TB. In clinical settings, CRP is used to identify patients with systemic inflammation from infection or non-infectious cases. In settings with high TB prevalence, the investigators hypothesize that CRP can be used to accurately screen individuals for active TB (i.e., distinguish individuals with high likelihood of having active TB from those individuals unlikely to have active TB).
41477810|NCT00971984|OTHER|Medical records summary|Summary of Medical files and laboratory results.
41477811|NCT01174355|DRUG|ND0801|Confidential
41477812|NCT03293173|COMBINATION_PRODUCT|R-CHOEP|rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
41477813|NCT03293173|COMBINATION_PRODUCT|DA-EPOCH-R|dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
41477814|NCT00753220|BIOLOGICAL|VDC2008|"Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10\^7, 7.5 x 10\^7 or 1.0 x 10\^8 cells"
41477815|NCT00753220|DRUG|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles \[1 cycle = 4 weeks\] starting Week 2 after cryoablation and going to Week 26)
41477816|NCT01731899|DRUG|agomelatine|Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
41152969|NCT02831751|BIOLOGICAL|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
41477817|NCT01343095|DEVICE|Foam Earplugs|Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
41008212|NCT05844878|BEHAVIORAL|Cognitive behavioral therapy (CBT) by using Distraction technique.|"Distraction: The distraction in this arm will be done by hearing of soft music; the name of music that will be used is relaxing piano music and water sounds 24/7 - ideal for stress relief. This music will be used in both the reception room and in the dental room treatment from the time-point that patient enters the reception room, and continues into the dental treatment room until the end of dental treatment when the patient exits the dental treatment room"
41008213|NCT05844878|BEHAVIORAL|Mindfulness technique by using of relaxation breathing with muscle relaxation|"The mindfulness technique consist of combination of 2 procedures:~1. Relaxation breathing: this will be done during the course of dental treatment by asking the patient to do the following Gently breathe in - hold - and let go. This procedure will be applied at the first moment when the patient sits on the dental chair before any dental treatment is done and the patient is asked to repeat this twice, each for a duration of 10 seconds. This procedure will be repeated twice; at zero time and after an interval of 16 minutes of dental treatment that extend for a 30-minute duration for each patient.~2. Muscle relaxation: this will be done by asking the patient during dental treatment to do the following Hands - gently clench - hold - and let go. This procedure will be applied after 8 minutes from starting dental treatment, and ask the patient to do it twice for about 10 seconds. This procedure will be repeated twice; at 8 minutes and at 24 minutes of dental treatment."
41477818|NCT01343095|DEVICE|Noise Canceling Headphones|Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
41008214|NCT00774033|DEVICE|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
41008215|NCT00774033|PROCEDURE|classic skin grafts|classic skin grafts used for the treatment of acute burn
41008216|NCT06090110|DEVICE|Vagal Nerve Stimulation|Transcutaneous Auricular Vagal Nerve Stimulation
41477819|NCT03330782|DRUG|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
41477820|NCT03330782|DRUG|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
41477821|NCT04882319|DRUG|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously
41477822|NCT04882319|DRUG|HP-5000 Placebo Patch|HP-5000, placebo and saline will be administered simultaneously
41477823|NCT04882319|DRUG|Saline Patch|HP-5000, placebo and saline will be administered simultaneously
41477824|NCT05760755|BEHAVIORAL|Stick Together|The intervention consists of 12 online modules, completed flexibly during and immediately after primary cancer treatment. The intervention contains interviews with other couples, psychoeducational information, and interactive exercises on themes such as dyadic coping and communication, being diagnosed at a young age, fertility and children, and life after treatment.
41477825|NCT02171767|DRUG|BIBW 2992 MA2 - single rising dose|
41477826|NCT04944082|DRUG|Ivermectin|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
41477827|NCT00532935|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period
41477828|NCT00532935|DRUG|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.
41477829|NCT02506608|PROCEDURE|Operation of sensorized hand prosthesis|"Four TIME-4H electrodes will be implanted in the median and ulnar of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the sensorized prostheses. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prostheses movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
41477830|NCT03832738|DRUG|JTE-451 Tablets|Active drug tablets containing JTE-451
41477831|NCT03832738|DRUG|Placebo Tablets|Placebo tablets matching in appearance to the active drug tablets
41477832|NCT02544542|DEVICE|Rectum cooling system|
41477833|NCT02544542|DEVICE|Hyper-hypothermia blanket|
41477834|NCT05670782|DRUG|KM-819|Participants will receive oral doses of KM-819 once-daily
41477835|NCT05670782|DRUG|Placebo|Participants will receive matching placebo once-daily
41323003|NCT03496129|BEHAVIORAL|Personalized feedback and text messages|"Experimental: Personalized feedback and text messages~Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions."
41323004|NCT03496129|BEHAVIORAL|Information Only|"Active Comparator: Information Only~Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message."
41323005|NCT04457193|DEVICE|TIF|Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.
41323006|NCT04080869|DRUG|retinyl palmitate|topical retinyl palmitate loaded ethosomes
41323007|NCT04080869|DRUG|Tretinoin|topical tretinoin
41152970|NCT02831751|BIOLOGICAL|60 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
41477836|NCT06468293|OTHER|Psychological support|Psychological support intervention
41477837|NCT01700426|DRUG|Vitamin E|A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
41152971|NCT02831751|BIOLOGICAL|FluLaval® Tetra (15 µg/strain)|Single dose of a licensed quadrivalent vaccine
41152972|NCT02831751|BIOLOGICAL|Fluzone® High-Dose (60 µg/strain)|Single dose of a licensed trivalent vaccine
41152973|NCT05733793|OTHER|NGS tests|"This study is an observational, the patients with have an available NGS report performed in context of clinical practice or collected in clinical trials.~Patients enrolled in the current study will be managed as for clinical practice and no additional genetic tests or other procedure will be required."
41008217|NCT06090110|DEVICE|Sham stimulation|Sham stimulation with a non-conduction electrode
41152974|NCT03171389|DRUG|Ponatinib 30 MG|Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.
41323008|NCT03520439|DRUG|Mifepristone|Oral mifepristone 10mg (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
41323009|NCT03520439|DRUG|Placebo|Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
41323010|NCT04262401|BEHAVIORAL|Standard health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
41477838|NCT01700426|OTHER|Placebo|The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
41477839|NCT01269281|DRUG|Sumatriptan|Sumatriptan Succinate Tablets 100 mg
41477840|NCT00604201|BIOLOGICAL|Umbilical Cord Blood|unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
41477841|NCT06327802|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the Beck, Zarit, HAD, FAS CARERQOL-7D questionnaires
41152975|NCT01023022|OTHER|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
41152976|NCT04438369|PROCEDURE|Erector Spinae Plane Block|Cathether based Erector Spinae Plane Block for postoperative pain management.
41152977|NCT02247141|BIOLOGICAL|Subgam® (Human Normal Immunoglobulin Solution)|
41152978|NCT01702688|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
41323011|NCT04262401|BEHAVIORAL|Habit-focused health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
41323012|NCT01836744|DEVICE|Survival rate dental implant (OsseoSpeed™)|
41323013|NCT00412906|DRUG|Escherichia Coli Endotoxin|
41323014|NCT00276770|OTHER|fluorine F 18 fluorothymidine|
41323015|NCT00276770|PROCEDURE|positron emission tomography|
41323016|NCT04470492|COMBINATION_PRODUCT|Doctormate®+Medical Management|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) twice daily and conventional medication for 3 months.
41323017|NCT04470492|DRUG|Medical Management|Patients will be treated with conventional medication for 3 months.
41323018|NCT06499285|BIOLOGICAL|KER-050|KER-050 administered subcutaneously every 4 weeks
41323019|NCT06499285|DRUG|Placebo|Placebo administered subcutaneously every 4 weeks
41323020|NCT02967094|DRUG|Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)|
41323021|NCT02967094|DRUG|Administration of water before upper endoscopy|
41323022|NCT04159012|DEVICE|Transcranial direct current stimulation|"A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline.~The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4)."
41323023|NCT00863980|DRUG|Micardis (Telmisartan)|40-80 mg/day oral administration
41323024|NCT00863980|DRUG|Blopress (Candesartan)|8-12 mg/day oral administration
41323025|NCT00599235|DRUG|sildenafil|50mg 3 times daily for 7 days
41477842|NCT06142370|OTHER|Descriptive|The patients will be asked by the recruiting physicians to perform a clinical examination looking for the LCV, which will take a total of five seconds. This is a self-test and not part of a regular clinical examination
41477843|NCT03155737|OTHER|Self-acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
41477844|NCT03155737|OTHER|Knee health education|A course regarding knee health will be offered to the subjects in this group.
41477845|NCT01731717|BEHAVIORAL|Active monitoring|General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
41323026|NCT00599235|DRUG|hydralazine|25mg 3 times daily for 7 days
41323027|NCT00599235|DRUG|placebo|3 times daily for 7 days
41008218|NCT05204381|DEVICE|Theta-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.
41323028|NCT00818207|OTHER|Full Smoking Cessation Treatment Coverage (100%)|This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
41323029|NCT00818207|OTHER|No Smoking Cessation Treatment Coverage (0%)|None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
41323030|NCT06105567|BEHAVIORAL|Training given according to the health promotion model by applying the Philips 66 technique|The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress
41477846|NCT01731717|BEHAVIORAL|Bibliotherapy|"Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision."
41323031|NCT00735085|DRUG|SLV334|1000mg SLV334 as a single dose
41477847|NCT01731717|BEHAVIORAL|Online self-help|"Patient works with online self-help program Deprexis under general physician's supervision."
41477848|NCT01731717|BEHAVIORAL|Outpatient psychotherapy|Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
41477849|NCT01731717|PROCEDURE|Psychiatric treatment|Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
41477850|NCT01731717|BEHAVIORAL|Combined psychotherapy and psychopharmacological treatment|Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
41477851|NCT01731717|OTHER|Control group: treatment as usual|treatment as usual
41008219|NCT05204381|DEVICE|Theta-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.
41323032|NCT00735085|DRUG|SLV334|1000mg SLV334 b.i.d. for one day
41323033|NCT00735085|DRUG|SLV334|2000mg SLV334 b.i.d. for one day
41323034|NCT00735085|DRUG|SLV334|2000mg SLV334 b.i.d. for three days
41323035|NCT00735085|DRUG|Placebo|SLV334 Placebo arm
41323036|NCT02382783|OTHER|FLARE Intervention Group|"Everything being completed in this group is also being completed in the Standard of Care (SOC) Group except for the following...~The participants randomized to this group will be asked to complete FLARE Questionnaires on a monthly basis and will call us each month with their results. The last question on the questionnaire asks if the patient feels he/she is having a flare. If the patient says yes to this question, then the study coordinator will arrange for an appointment to be scheduled with a rheumatology health care provider at Mayo Clinic Rochester. The goal will be to have this appointment take place within seven days of the FLARE Questionnaire results being reported."
41323037|NCT03472274|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks x 3 cycles
41323038|NCT03472274|DRUG|Tremelimumab|Tremelimumab 75 mg every 4 weeks x 3 cycles
41323039|NCT03472274|DRUG|Cisplatin-based neoadjuvant chemotherapy|"Regimen 1: 21-day treatment cycle x 3 cycles.~* Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~* Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~* Methotrexate 30mg/m2 intravenously on day 1~* Vinblastine 3mg/m2 intravenously on day 2~* Doxorubicin 30mg/m2 intravenously on day 2~* Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~* Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~* Paclitaxel 80 mg/m2 intravenously on day 1 and 8~* Cisplatin 70mg/m2 intravenously on day 1"
41477852|NCT05089695|DEVICE|Noninvasive respiratory support|Treatment of acute hypoxemic respiratory failure
41477853|NCT02722252|DEVICE|Embryoscope|
41008220|NCT05204381|DEVICE|Arrhythmic near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.
41008221|NCT05204381|DEVICE|Arrhythmic independent stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.
41008222|NCT05204381|DEVICE|Alpha-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.
41008223|NCT05204381|DEVICE|Alpha-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
41008224|NCT05142683|OTHER|Treatment As Usual|Various typical interventions for adolescents with depression.
41008225|NCT05142683|OTHER|CARIBOU-2|Integrated Care Pathway intervention for adolescents with depression.
41008226|NCT06010394|OTHER|conventional physiotherapy|ultrasound electrotherapy cold applications
41008227|NCT06010394|OTHER|exercises for the knee area|range of motion exercises strengthening exercises exercises to reduce edema
41008228|NCT06010394|OTHER|payment oriented massage|10 / 15-minute massage treatments to reduce payment
41008229|NCT06371222|DRUG|Ivabradine|5 mg for 3 months
41008230|NCT06371222|DRUG|Beta blocker|controlled group
41323040|NCT01686958|DEVICE|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
41323041|NCT04209530|DRUG|EN3835|Collagenase Clostridium Histolyticum (CCH)
41323042|NCT03628950|PROCEDURE|ICSSB group|At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .
41323043|NCT03628950|PROCEDURE|ISB group|The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
41323044|NCT00217516|DRUG|selenium|Given orally
41008231|NCT02940691|DRUG|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
41323045|NCT00217516|OTHER|placebo|Given orally
41323046|NCT00442767|DRUG|Insulin|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal.
41323047|NCT00442767|DRUG|Pramlintide + Insulin|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
41477854|NCT02722252|DEVICE|Embryo culture system without incorporated camera|
41008232|NCT00494494|DRUG|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
41008233|NCT00494494|DRUG|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
41008234|NCT00386256|DEVICE|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
41008235|NCT00386256|OTHER|Telephone counseling|
41008236|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg
41008237|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg
41008238|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
41008239|NCT02246504|DEVICE|HIFU treatment|
41008240|NCT00622635|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
41008241|NCT00622635|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
41008242|NCT00622635|DRUG|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
41008243|NCT01819805|DRUG|No intervention|This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
41152979|NCT01702688|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
41323048|NCT03752333|DRUG|Pembrolizumab|"Pembrolizumab has high affinity and potent receptor blocking activity for PD-1, based on preclinical in vitro data. Pembrolizumab has an acceptable preclinical and clinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies.~The PD-1 pathway represents a major immune control switch, which may be engaged by tumour cells to overcome active T-cell immune surveillance. Pembrolizumab is a potent and highly selective humanized mAb of the Immunoglobulin (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection."
41323049|NCT03384524|DRUG|Bromocriptine 2.5 MG|Administered daily
41323050|NCT03384524|DRUG|Metoprolol 25 MG|Administered daily
41323051|NCT03384524|DRUG|Tamsulosin 0.4 MG|Administered daily
40805474|NCT04557098|DRUG|Teclistamab|Teclistamab will be administered SC.
41323052|NCT03384524|OTHER|Placebo|Three pills, matching active drugs to be administered daily
41323053|NCT02238548|BIOLOGICAL|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
41323054|NCT02238548|OTHER|Raw milk|
41323055|NCT01201707|PROCEDURE|Angioplasty|In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.
41323056|NCT01201707|OTHER|Observation|Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
41323057|NCT02483078|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
40805475|NCT05944081|DEVICE|ArcadiusXP L® Interbody Fusion System|The ArcadiusXP L® Interbody Fusion System is a stand-alone device intended to be used with four bone screws if no supplement fixation is used to stabilize the lumbar spine through an anterior approach. Levels of anterior lumbar interbody fusion for the indications listed in the instructions for use are from L2-S1.
40805476|NCT05126810|OTHER|Questionnaire Administration|Complete questionnaire
41152980|NCT02133066|PROCEDURE|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
41008244|NCT04256616|OTHER|This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.|"urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC."
41008245|NCT03199703|DEVICE|Baylis transseptal system group|
41323058|NCT02483078|DRUG|Placebo|
41323059|NCT02483078|DRUG|Optimized Background Regimen|Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
41323060|NCT00201981|DRUG|Rebamipide|"1. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~2. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks"
41323061|NCT03229681|BEHAVIORAL|Baduanjin exercise|"Participants in this groups received routine rehabilitation training and Baduanjin exercise. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. Baduanjin exercise protocol according to the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Due to the low-activity tolerance of CHF patients, we performed with a refined version of Baduanjin. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
41152981|NCT02133066|DEVICE|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
41152982|NCT02133066|PROCEDURE|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
41152983|NCT03809871|BIOLOGICAL|Cardiometabolic biomarkers|This is for measures of cholesterol (HDL, LDL and total cholesterol), blood glucose and HbA1c, vitamin D, vitamin B12 and iron levels.
40805481|NCT03332017|DRUG|Zanubrutinib|Oral administration as a capsule
40805482|NCT03332017|DRUG|Obinutuzumab|Intravenous administration
41152984|NCT02790047|DEVICE|A non-re-breathing face mask with conical-PEP device|Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.
41323062|NCT03229681|BEHAVIORAL|Routine rehabilitation group|Participants in this qroup only received the routine rehabilitation training. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. They should also come to rehabilitation center for physical exercise,45 minutes per day，twice per week, lasts 12 weeks.
41323063|NCT04980313|DEVICE|Xenogenic collagen matrix|Use of xenogenic collagen matrix for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
41008246|NCT03199703|DEVICE|Standard conventional transseptal group|
41008247|NCT06311383|DRUG|First-line Ribociclib + endocrine therapy|Ribociclib + letrozole, or Ribociclib + anastrazole, or Ribociclib + exemestane, or Ribociclib + fulvestrant
41008248|NCT06311383|DRUG|First-line endocrine therapy|As of physicians choice
41323064|NCT04980313|DEVICE|Autogenous connective tissue graft|Use of connective tissue graft for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
41323065|NCT00411086|BIOLOGICAL|Rituximab|375 mg/m\^2 By Vein Weekly on Days 1, 8, 15, and 22.
41323066|NCT00411086|BIOLOGICAL|Sargramostim (GM-CSF)|250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
41477855|NCT00247299|DEVICE|IPL Quantum Product manufactured by Luminis Ltd.|
41477856|NCT06220513|PROCEDURE|erector spinae plane block (ESP)|patients will receive Ultrasound-guided erector spinae plane block (ESP) block for postoperative analgesia of adult patients undergoing laparoscopic appendectomy.
41477857|NCT06220513|PROCEDURE|transversus abdominis plane block(TAP)|patients will receive Ultrasound-guided transversus abdominis plane block(TAP) Block for postoperative analgesia of adult patients undergoing laparoscopic appendectomy.
41477858|NCT03916042|DRUG|Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks
41323067|NCT04842890|RADIATION|Pencil Beam Scanning Proton SBRT|The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
41323068|NCT01030380|DEVICE|Slendertone Face|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
41323069|NCT01187836|DRUG|TRV120027|Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
41477859|NCT03916042|DRUG|Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
41477860|NCT01398059|OTHER|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
41323070|NCT01187836|DRUG|Placebo|Placebo administered for 14 hours.
41323071|NCT03838562|OTHER|Vestibular rehabilitation with virtual reality|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group."
41477861|NCT01398059|OTHER|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
41477862|NCT01398059|OTHER|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
41477863|NCT06139224|DIETARY_SUPPLEMENT|10 day prebiotic consumption|20 HIV-infected ART-suppressed individuals will be provided a with commercially available prebiotic (FOS) for 10 days. Participants will be instructed to consume the prebiotic daily during the first three days and then twice daily for an additional seven days. Participants will be instructed to consume the powder in the morning on the first three days, then in the morning and afternoon for the following week. Each participant will have a baseline visit and a follow up visit after 10 days of the FOS intervention. Blood and stool will be collected at both visits.
41477864|NCT06309277|DRUG|GM-1020|N-methyl-D-aspartate (NMDA) receptor antagonist
41477865|NCT04919941|OTHER|A Guide to Conservative Care|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
40805486|NCT06131983|DRUG|ARO-DUX4 for Injection|single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
40805487|NCT06131983|DRUG|Placebo|calculated volume to match active treatment by IV infusion
41323072|NCT03838562|OTHER|Standard optokinetic stimulator or dynamic visual surround|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group."
41323073|NCT01630759|DEVICE|Telemonitoring|Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
41323074|NCT01630759|OTHER|Control|The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
41323075|NCT03118011|OTHER|No smoking|No smoking
41323076|NCT03118011|OTHER|Smoking|Ability to go out to smoke
41477866|NCT02619448|DRUG|Carboplatin|chemotherapy
41477867|NCT02619448|DRUG|Paclitaxel|chemotherapy
41477868|NCT02619448|RADIATION|70 Gy in 20 fractions over 4 weeks|accelerated hypofractionated RT
41477869|NCT05382520|DIAGNOSTIC_TEST|Questionares and practice|Questionares and practice
41152985|NCT02790047|OTHER|A home-base exercise program|"Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~1. Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~2. Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale \< 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~3. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes"
41323077|NCT05424549|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days
41008249|NCT06311383|DRUG|First-line chemtherapy|As of physicians choice
41323078|NCT05424549|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed six times over two consecutive days
41477870|NCT05536037|DRUG|Metformin|Given PO
41477871|NCT05536037|PROCEDURE|Biopsy|Undergo biopsy
41477872|NCT00571194|DRUG|pravastatin|"A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study"
41477873|NCT04523610|BEHAVIORAL|Telehealth phone calls|The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).
41477874|NCT04523610|OTHER|Volunteer of TIP-OA Program|Participant is a volunteer of the TIP-OA Program
40805490|NCT06581224|OTHER|Primary Hospital Provider Team|The PHP team aims to enhance continuity during hospital readmissions with a consistent cohort of seven hospital medicine physicians and two advanced practice providers (APPs). To improve care transitions, the team will have an integrated case manager who will continue following PHP patients during subsequent hospitalizations. Physicians will follow a standard seven-day service schedule, with the two APPs alternating five-to-seven-day periods. Daily huddles between physicians and APPs will further promote continuity. During the index admission, the PHP team will create a care plan in consultation with the patient to improve standardization of inpatient care and transition to outpatient settings. Communication will be a core tenet of the team, with scheduled monthly team meetings of physicians, APPs, case manager, dyad partner, and representatives from nursing and therapy services to revise individualized care plans for PHP patients and brainstorm solutions for complex challenges.
40805491|NCT02709226|RADIATION|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
41477875|NCT04523610|OTHER|Stakeholder of TIP-OA Program|Participant is a stakeholder of the TIP-OA Program
40805492|NCT04522336|DRUG|Docetaxel|Given IV
40805493|NCT04522336|DRUG|Fluorouracil|Given IV
40805494|NCT04522336|DRUG|Oxaliplatin|Given IV
40805495|NCT04522336|BIOLOGICAL|Pembrolizumab|Given IV
40805496|NCT04522336|RADIATION|Radiation Therapy|Receive radiation therapy
40805497|NCT05677490|DRUG|Fluorouracil|Given IV
40805498|NCT05677490|DRUG|Leucovorin Calcium|Given IV
40805499|NCT05677490|DRUG|Oxaliplatin|Given IV
41477876|NCT04115709|DEVICE|Beacon Caresystem device with advice|Beacon Caresystem device provides ventilator settings advice to Doctors
40805500|NCT05677490|DRUG|Irinotecan|Given IV
41477877|NCT04115709|DEVICE|Beacon Caresystem device without advice activated|Beacon Caresystem device does not give ventilator settings advice
41477878|NCT01368627|DEVICE|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
41477879|NCT00949455|DRUG|lapatinib ditosylate|Given orally
40805501|NCT05677490|BIOLOGICAL|Nivolumab|Given IV
40805502|NCT05677490|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40805503|NCT05677490|PROCEDURE|Computed Tomography|Undergo a CT Scan
41477880|NCT00949455|OTHER|Placebo|Given orally
41477881|NCT00865514|DRUG|Dichloroacetate|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
41477882|NCT00865514|GENETIC|Genotyping|Subjects will have 5 mls of blood drawn for genotyping
40805504|NCT05677490|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40805505|NCT05677490|OTHER|Questionnaire Administration|Ancillary studies
41477883|NCT00865514|OTHER|Leucine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
41477884|NCT00865514|OTHER|tyrosine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
41477885|NCT01473550|BEHAVIORAL|Access to TELUS Health Space and Smart Phone|Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
41477886|NCT00311350|DRUG|MOA-728|
41477887|NCT00021060|DRUG|paclitaxel|Given IV
41477888|NCT00021060|DRUG|carboplatin|Given IV
41477889|NCT00021060|BIOLOGICAL|bevacizumab|Given IV
41477890|NCT00021060|OTHER|laboratory biomarker analysis|Correlative studies
40805506|NCT06316934|DRUG|Lavandula angustifolia, Aura Cacia|Lavender essential oil will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
40805507|NCT06316934|OTHER|Placebo|Distilled water will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
40805508|NCT05816473|OTHER|LLM|Use of a Large Language Model (LLM) chatbot interface to Interact with the Machine Learning Algorithm and interpretability dashboard.
41152986|NCT02790047|OTHER|Health education|"Health education include~1. Knowledge of COPD disease~2. Smoking status and smoking cessation~3. Medication correctly~4. Self dyspnea management~5. Basic nutrition for COPD"
41008250|NCT01194206|RADIATION|stereotactic body radiation therapy|At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
41008251|NCT02168166|BEHAVIORAL|Executive Function Training|
41008252|NCT02168166|BEHAVIORAL|Placebo|Placebo version of executive function training
41008253|NCT05726578|OTHER|Lung recruitment|establishment of lung recruitment using high frequency ventilation and assessment with chest ultrasound and echocardiography
41008254|NCT01818804|DIETARY_SUPPLEMENT|n-3PUFA|
41008255|NCT01818804|DIETARY_SUPPLEMENT|olive oil|
41152987|NCT02790047|OTHER|ฺBreathing strategies for self secretion clearance|"Using a modified active cycle breathing technique (mACBT) include~1. Control breathing~2. Pursed lip breathing (PLB)~3. Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~4. Force expiratory technique (FET) with low to medium lung volume~5. Huffing or coughing"
41477891|NCT01014624|DRUG|Prasugrel|"Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
41477892|NCT01014624|DRUG|Clopidogrel|"Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
41008256|NCT05155969|DRUG|Esketamine|esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction
41008257|NCT05155969|DRUG|Normal saline|Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.
41008258|NCT05596526|BIOLOGICAL|recombinant zoster vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
41008259|NCT03149328|OTHER|Educational Support|In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
41008260|NCT02080767|DRUG|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
41008261|NCT00132340|DEVICE|Electrodes|
41008262|NCT05681871|DIETARY_SUPPLEMENT|Ferrous gluconate syrup or ferrous fumarate/folic acid tablets|Oral iron supplementation dosed based on body weight
41008263|NCT02953834|DRUG|kisspeptin 112-121|Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
41152988|NCT02790047|DRUG|The medication following the COPD GOLD guidelines (2015)|"Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~1. Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~2. Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~3. Xanthine derivative (sustained release theophylline)~4. Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~5. Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~6. Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~7. Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)"
41152989|NCT02819271|DRUG|CXL-1427 Ascending Dose|
40805513|NCT04727632|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT
40805514|NCT05558592|DIETARY_SUPPLEMENT|Dietary supplementation with fresh oranges|"the subjects enrolled in this group, will have to consume 400gr of oranges Navelina net of waste / day / per person for a month. The oranges will be provided, to each participant, by the IRCCS Saverio de Bellis."
41008264|NCT02953834|OTHER|Insulin Resistance Test|Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
41008265|NCT02953834|OTHER|Placebo|Receive IV fluids for up to 16 hours that do not contain any study drug
41008266|NCT03952793|OTHER|extended biopsy|Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
41008267|NCT04935307|DIAGNOSTIC_TEST|MRI and paraclinical tests|The patients and controls will be evaluated using MRI and furthermore a large test battery of questionnaires and paraclinical tests. Including the following test: MCS checklist, BDS-Checklist, Symptom Checklist-92 (SCL-92), Whiteley-8, SF-36, Major Depression Inventory (MDI), GAD-10 anxiety scale, and related questionnaire, behavioral olfactory test (TDI), habituation test, pain measurement thresholds tests, Heart Rate Variability and cognitive testing.
41323079|NCT04230798|OTHER|Injury prevention program|The intervention program consisted in 16 sessions, performed during eight weeks, twice per week. Intervention group performed 20 minutes sessions before their habitual volleyball training. The structure of the prevention program consisted in a warm up, a lower limb strength exercise; two core exercises; a lower limb plyometric exercise, and a lower limb stability exercise. While the injury prevention program was being performed, both groups continued with their volleyball training sessions.
41323080|NCT01943422|DRUG|High-dose Interferon alfa-2b|•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
41323081|NCT01943422|DRUG|Vemurafenib|"Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene."
40805515|NCT05558592|DIETARY_SUPPLEMENT|Balanced Diet without oranges|the subjects enrolled in this group, will have to consume 400 gr of fruit (with the exception of citrus fruits) net of waste / day / per person for a month.
40805516|NCT05784129|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
40805517|NCT05784129|DRUG|Placebo|Placebo will be administered subcutaneously.
40805518|NCT05199233|DEVICE|Muse S™ Headband system|Clinical grade, headband style, wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (smartphone or tablet).
41008268|NCT00437034|BIOLOGICAL|aflibercept|Given IV
41008269|NCT04414384|OTHER|Abdominal Binder|Abdominal Binder placement
41008270|NCT04414384|OTHER|Step Counter|step counter to track steps
41008271|NCT03591575|DRUG|Deferiprone oral solution|Liquid formulation of deferiprone, with a concentration of 80 mg/mL
41008272|NCT03591575|DRUG|Placebo|Liquid solution that matches deferiprone oral solution in appearance and taste
41017837|NCT04205279|OTHER|Experimental: Treadmill training|Participants will be given thirteen slips and thirteen trips in stance and walking, followed by two slips and two trips at a higher intensity (posttest). Subjects would be consented if they would like to undergo fMRI pre and post-training. Participants not willing to undergo imaging would not be excluded. Three day training consisting of blocks of five consecutive gait-slips at varying intensities will be provided. Individuals with stroke would undergo an additional session (total 4 training sessions over 4 weeks (1session/week) since these individuals get easily fatigued and also might need more training sessions with sufficient rest interval to induce reactive adaptation. Training at a specific level will persist until the subjects show a recovery step response in at least 3/5 trials in a single block. Once subjects successfully adapt to this level, the perturbation intensity will be increased until they show a recovery response in at least 3/5 trials.
41152990|NCT02819271|OTHER|Placebo|
41152991|NCT02819271|DRUG|CXL-1427 Descending Dose|
41152992|NCT05664009|DIETARY_SUPPLEMENT|Redsenol-1 Plus|Two capsules of Redsenol-1 Plus will be taken three times per day for 12 weeks (84 days).
41152993|NCT05664009|OTHER|Placebo|Two capsules of Placebo will be taken three times per day for 12 weeks (84 days).
41152994|NCT06477848|OTHER|Integrated Behavioral Health System with SUD Resources|This is a system-level intervention designed to improve collaboration among personnel from primary care clinics and SUD resources.
41323082|NCT03745300|DRUG|ATORVASTATIN|Scaling and Root Planing (SRP) followed by placement of atorvastatin gel
40805519|NCT05636969|BEHAVIORAL|Multimodal prehabilitation|The multimodal prehabilitation programme will consist of 1) twice weekly, supervised exercise training at the hospital gym for approximately 12-16 weeks; 2) nutritional consultation and diet optimization and supplementation if needed; 3) individual or group-based psychological support.
41008273|NCT04196556|BEHAVIORAL|Active Families|This intervention, based on the methodology of meaningful learning, will have two components: group education aimed at parents (caregivers) and and education directed to children in the reviews in consultation. Group education (caregivers) groups will consist of 6 sessions, which will be given every two weeks, as determined in the program's follow-up annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
41008274|NCT04196556|OTHER|Madrid's Primary Healthcare Standardized Service portfolio|"An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook."
41323083|NCT03745300|DRUG|SIMVASTATIN|Scaling and Root Planing (SRP) followed by placement of simvastatin gel
40805520|NCT04976881|BEHAVIORAL|Medication Reconciliation (MedRec) Tool|Patients will receive a print MedRec tool, generated via the EHR, which includes a list of medications prescribed according to the patient record. Patients are asked to review this list, to add/remove drugs to reflect actual use, to note how they are taking each medication, and to describe any concerns.
40805521|NCT04976881|BEHAVIORAL|Provider Alert and Decision Support|During the clinic visit, an automated, EHR alert will notify the provider that the patient is a woman of reproductive age with T2DM and should receive counseling on the importance of glycemic control, the use of contraception until glycemic control is achieved, and the benefits of folic acid.
41008275|NCT04783129|OTHER|Education program based on 10 monthly lectures|The education program consist of 10 lectures on the management of motor and non-motor alterations associate with PD will be offered by a nurse, physiotherapist, occupational therapist, speech therapist, neurologist, lawyer, nutritionist, and psychologist.
40805522|NCT04976881|BEHAVIORAL|PREPSheet|When patients leave an encounter, they will receive a patient-friendly educational material (a.k.a. the PREPSheet) that reviews potential risks of pregnancy in the context of T2DM and highlights the importance of: 1) achieving glycemic control through diabetes self-care, 2) using effective contraception until glycemic control is achieved and pregnancy is desired, 3) discussing medication use with a provider if planning or becoming pregnant, and 4) taking folic acid daily to reduce increased risk of neural tube defects.
41008276|NCT04783129|OTHER|No intervention|Participants will follow no education program (lecture) and will be instructed to follow their usual routine for the treatment of the disease
41008277|NCT03393221|BEHAVIORAL|ER|Emotion regulation content
41008278|NCT03393221|BEHAVIORAL|SBWC|
41008279|NCT05181007|DRUG|Mefanamic Acid|mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5
41008280|NCT05181007|DRUG|Valproate|valproate once daily on Day 4 to Day 8, Ciprofol on Day 1 and Day 8
41323084|NCT03745300|DRUG|PLACEBO|Scaling and Root Planing (SRP) followed by placement of placebo gel
41323085|NCT06269289|OTHER|web based education|Training presentations will be prepared in 5 modules by taking expert opinions in line with the literature. Training will be aimed at empowering patients to control asthma. It will include topics such as medication use, device use, exercise and disease management. Each week, an intervention group will be invited online to a module and the training will be given by the researcher.
41323086|NCT06269289|OTHER|Standard education brochure|The control group will not be given web-based training, but will be given the standard asthma education brochure of the Ministry of Health.
41323087|NCT01540968|BEHAVIORAL|Nutrition & physical exercise|Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
41323088|NCT03463096|OTHER|High G acceleration on a long-arm human centrifuge|Gx (chest-to-back) and Gz (head-to-toe)
41323089|NCT03241238|OTHER|Eating|Participants will have 10 minutes to eat all of the brownie and drink 6 oz of water. They will then have 20 minutes to eat as much or as little of a meal (consisting of a sandwich, grapes and chips).
41323090|NCT02090985|PROCEDURE|Lipomodelling of symptomatic peri-stomal skin contour abnormalities|
41323091|NCT02302885|OTHER|Blood collection|Blood Collection
40805523|NCT04976881|BEHAVIORAL|Text Messaging|Within \~5 days of their index clinic visit, intervention patients will begin to receive daily, unidirectional text messages to reinforce diabetes self-care behaviors.
40805524|NCT06326008|DRUG|Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy|Peripheral blood mononuclear cells for the production of CD19 CAR T cells and CD22 CAR T cells are collected from donors and haematopoietic stem cells are collected from donors.
40805525|NCT04401800|DRUG|Lenvatinib|Capsules administered orally once daily
40805526|NCT04401800|DRUG|Tislelizumab|200 mg intravenous (IV) infusion administered on Day 1 of each cycle
40805527|NCT01436656|DRUG|LGX818|
40805528|NCT06110156|BEHAVIORAL|Patient-tailored deprescribing assessment and intervention|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors (clinical, socioeconomic), identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results of the comprehensive medication review with the primary care clinician. Once the primary care clinician has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling (including Motivational Interviewing) and will follow-up with the patient at least once per month via video visit or phone to assess side effects, adverse effects, and provide support.
40805529|NCT05538910|OTHER|Placebo Nicotine Patch|Comparator
41008281|NCT04514991|DEVICE|Foundation|Collagen-based, bone filling augmentation material used to stimulate bone formation in extraction sockets or bone defects in the alveolar ridge.
41008282|NCT01660711|DRUG|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
41008283|NCT01660711|DRUG|Leucovorin|400 mg/m2 by IV infusion over 2 hours
41008284|NCT01660711|DRUG|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
41323092|NCT05755022|PROCEDURE|Maxillary Segment Repositioning|"* Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using 3D photogrammetry technique.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed."
41323093|NCT05755022|PROCEDURE|Maxillary Segment Repositioning|"* Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using the commercial scanners.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed."
41323094|NCT01606397|DRUG|Placebo|Administered orally (capsule)
41323095|NCT01606397|DRUG|LY2409021|Administered orally (capsule)
41008285|NCT01660711|DRUG|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
41323096|NCT04152148|BIOLOGICAL|500mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
41323097|NCT04152148|BIOLOGICAL|750mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
41323098|NCT04152148|BIOLOGICAL|900mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
41323099|NCT04152148|BIOLOGICAL|1000mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
41323100|NCT03911778|OTHER|Improvement of symptoms|Improvement of symptoms on the Patient Global Impression of Improvement Index (PGI-I) scale (score 1, 2, or 3) at 6 weeks postoperatively
41323101|NCT04103775|BEHAVIORAL|Cognitive Remediation|See Cognitive Remediation Arm description.
41323102|NCT04103775|BEHAVIORAL|Active Control|See Active Control Arm description.
41008286|NCT00945503|DRUG|GSK1018921|GSK1018921 is a GT1 recepor antagonist
41323103|NCT06524427|PROCEDURE|Robot-assisted lobectomy|Patients will receive robot-assisted lobectomy using Da Vinci surgical system
41323104|NCT06524427|PROCEDURE|Video-assisted lobectomy|Patients will receive video-assisted lobectomy
41323105|NCT03777202|PROCEDURE|High-flow nasal oxygen|High-flow nasal oxygen will be applied to the patients using Optiflow system through nasal openings during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
41323106|NCT03777202|PROCEDURE|Low-flow nasal oxygen|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
41323107|NCT03148158|DEVICE|Cystoscopy|Outpatient flexible cystoscopy and inpatient rigid cystoscopy
41323108|NCT05191355|BIOLOGICAL|blood test|Blood spot collection for sampling
41323109|NCT06041646|DRUG|Sublingual film containing Igalmi|Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
41323110|NCT06185894|PROCEDURE|Uterovesical tourniquet before uterine devascularization steps|Insertion of a Foley catheter tourniquet through broad ligament apertures \& tightening it immediately before hysterotomy in cases of conservative management of placenta accreta spectrum
41323111|NCT06185894|PROCEDURE|Conventional conservative surgery|Conventional conservative surgery
41323112|NCT01290445|DRUG|varenicline|This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.
41323113|NCT01290445|BEHAVIORAL|cigarette smoke from maternal smoking|This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
41323114|NCT01290445|OTHER|Non-Exposure|This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
40805530|NCT05538910|DRUG|Nicotine Patch|Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
41152995|NCT03606759|PROCEDURE|Weekly assessment|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours)"
41152996|NCT03606759|PROCEDURE|Weekly assessment ajusted|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours) Individually Adjusted Therapy scale (ATI)"
41152997|NCT03110692|BEHAVIORAL|Default initiation|A default prescription template will be introduced in the palliative setting in order to reduce unnecessary daily image guided radiation.
41477893|NCT04197128|DEVICE|Resorbable Collagen membrane with bone graft for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision. Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, bovine bone graft will be place with overlying resorbable collagen membrane. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted Vicryl 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)"
41008287|NCT05136729|BEHAVIORAL|Self-Natural Posture Exercise training|SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.
41008288|NCT00648531|DRUG|Balsalazide Disodium Capsules 750 mg|3x750mg, single dose fasting
41008289|NCT00648531|DRUG|Colazal® Capsules 750 mg|3x750mg, single dose fasting
41008290|NCT02821585|BEHAVIORAL|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
41008291|NCT01721590|DRUG|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
41008292|NCT01721590|DRUG|placebo|3 capsules/time，3times/day for 1 year
41008293|NCT00139568|DRUG|Tegaserod|
41008294|NCT01971138|OTHER|this is a survey|
41008295|NCT01585766|DRUG|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
41008296|NCT01585766|DRUG|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
41323115|NCT01476748|DEVICE|LaproStop|One of the subject's trocars will be randomized to be used with a LaproStop device.
41323116|NCT03401294|DRUG|FOLFOXIRI and Bevacizumab|Every 2 week for a total of 12 cycles
41008297|NCT01585766|DRUG|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
41323117|NCT03089970|DIAGNOSTIC_TEST|Exhaled breath condensate collection|Breath from humans is cooled, condensed, and collected
41323118|NCT02281981|DIETARY_SUPPLEMENT|Curcumin|333mg CurcuWin OAHTCUR002-2014
41323119|NCT02281981|DIETARY_SUPPLEMENT|Placebo|OAHTCUR005-2014
41323120|NCT04799067|OTHER|observational study|no study drug involved, observational study.
41323121|NCT02271009|DRUG|AllerT|Ultrafast immunotherapy
41323122|NCT02271009|DRUG|Placebo|placebo control
41323123|NCT05027256|DEVICE|Entia Liberty|Home Monitoring solution
41323124|NCT05197140|OTHER|food: cooked 85% lean ground beef|see arm description
41152998|NCT03942783|OTHER|WORKWELL|Individualised, tailored work advice and work/vocational rehabilitation, including self-management and job modifications.
41152999|NCT03942783|OTHER|Control|Published arthritis work booklets;written guidance on work problem identification; potential actions
40805536|NCT03870451|DEVICE|VascuTherm5 vascular compression device|VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
41153000|NCT02789098|OTHER|(15)-O water positron emission tomography and Biomarkers|Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.
41153001|NCT04927299|DRUG|Losartan/Chlorthalidone in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
41323125|NCT05197140|OTHER|food: Impossible Burger (R)|see arm description
41008298|NCT01585766|DRUG|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
41323126|NCT06252766|BEHAVIORAL|Experiment (Clown)|Children included in the intervention group will be accompanied by a clown at the door from the moment they enter the intervention room and The child will be made to sit on the blood collection chair by playing games with them. Meanwhile, the nurse will take blood from the child. lasts for about 2-3 minutes. During this process, the clown is constantly playing games and foam will continue to distract you by blowing up balloons. The child's pain and anxiety score during the procedure the researcher will be evaluated by both the parent and the child. After the procedure is finished, the children will be will be taken out of the room and taken to the waiting area in the next room. Afterwards, the children will be asked how much pain and anxiety they felt during the blood collection procedure. After being allowed to rest for 1-2 minutes a questionnaire form will be applied to the children.
41323127|NCT01929265|DRUG|Bendamustine|"INDUCTION PHASE~Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):~Rituximab: 375 mg/sqm iv, day 1\*~Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice~Repeat cycles every 28 days for a total of 4 cycles~\*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.~CONSOLIDATION PHASE~Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):~Rituximab: 375 mg/sqm iv day 1~Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice~Rituximab two monthly doses~Rituximab: 375 mg/sqm iv week 24 and 28"
41323128|NCT04213040|DIAGNOSTIC_TEST|Serum levels of Procalcitonin, C-reactive protein, lactate|"Serum PCT, CRP, and lactate values were collected postoperatively every day starting on postoperative 12 hours, postoperative days 1 through 5.~After the operation, all postoperative complications were recorded during the first seven days period.~The relations between diagnostic tests and postoperative complications are sought by the use of the statistical analysis methods."
41323129|NCT03979027|DIETARY_SUPPLEMENT|Breakfast: ready-to-eat-cereal and milk|
41153002|NCT04927299|DRUG|Losartan + hydrochlorothiazide in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
41153003|NCT00169962|DRUG|rhDNAse (pulmozyme)|
41323130|NCT01655238|OTHER|BMI|Screening guideline to assess body mass index.
41323131|NCT03694054|OTHER|Care coordination tool|Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.
40805550|NCT05074810|DRUG|avutometinib and sotorasib|The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion
40805551|NCT05074810|DRUG|avutometinib and sotorasib and defactinib|The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion
40805552|NCT05694871|DRUG|Palbociclib|Given PO
40805553|NCT05694871|BIOLOGICAL|Cemiplimab|Given IV
40805554|NCT05694871|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
40805555|NCT05694871|PROCEDURE|Computed Tomography|Undergo a CT Scan
40805556|NCT05694871|PROCEDURE|Biospecimen collection|Undergo blood sample collection
40805557|NCT05694871|OTHER|Questionnaire Administration|Ancillary Studies
40805558|NCT06163950|OTHER|Fatigability assessment|An isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
40805559|NCT05627674|BEHAVIORAL|Usual Care|Usual care incorporates guideline awareness and brief advice.
40805560|NCT05627674|BEHAVIORAL|RiskProfile-Clin|RiskProfile-Clin incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors.
40805561|NCT05627674|BEHAVIORAL|RiskProfile-Gen|RiskProfile-Gen incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors and genetic factors.
41153004|NCT00762853|DRUG|Fluoride|Brush half mouth once with assigned study treatment
40805563|NCT05710406|DRUG|Encorafenib|Given PO
40805564|NCT05710406|BIOLOGICAL|Cetuximab|Given IV
40805565|NCT05710406|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40805566|NCT05710406|PROCEDURE|Computed Tomography|Undergo CT
40805567|NCT05710406|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40805568|NCT05710406|OTHER|Patient Observation|Undergo observation per usual care
40805569|NCT05987605|DRUG|1A46 Drug Substance|Cycle 1 which will consist of an initial dose given on C1D1 and an intermediate dose given on C1D8, followed by a maintenance dose beginning on C1D15 and continuing while the patient is treated at that dose level
41153005|NCT00762853|DRUG|Fluoride and triclosan|Brush half mouth once with assigned study treatment
41153006|NCT04006652|DRUG|ApoGraft|ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
41153007|NCT05066230|DRUG|KSI-301|Intravitreal injection
41323132|NCT02034552|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks x 6 doses intravenous slow bolus
41008299|NCT01585766|DRUG|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
41008300|NCT01585766|DRUG|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
41323133|NCT02034552|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
41323134|NCT02034552|DRUG|Prednisone|Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
41323135|NCT02034552|DRUG|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
41323136|NCT03498547|PROCEDURE|caudal block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ulştrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
41323137|NCT03498547|PROCEDURE|saddle block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonographyguidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
41323138|NCT02030470|OTHER|Fotosan®630. LED lamp. Toluidinblue. Photoactivated disinfection|
41323139|NCT00992004|DIETARY_SUPPLEMENT|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
41323140|NCT01277913|DRUG|Vitamin D3|1000 IU once daily for 12 months
41323141|NCT01277913|DRUG|Vitamin D3|500 IU once daily for 12 months
41323142|NCT01937481|BEHAVIORAL|The Food Friends|The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
41323143|NCT05061797|DIETARY_SUPPLEMENT|Thermogenic Energy Drink - Active Study Product Formula|The Thermogenic Energy Drink is the Active Study Product (ASP). This energy drink formula combines, caffeine, guarana, Vitamins C, B3, B6, B12, Magnesium, Potassium, L-Citrulline, L-Arginine HCl, L-Glutamine, and Chlorogenic Acids from green coffee bean extract. Participants will consume an assigned amount of the beverage (355 ml), under observation. They will be monitored for the following 180 minutes with measurements of respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via Visual Analog Scale (VAS).
41323144|NCT05061797|DIETARY_SUPPLEMENT|Placebo|A carbonated soft drink with the same appearance, flavor and aroma as the active study product. Study participants will consume an assigned amount of the beverage (355 ml) under observation. They will then be monitored for the subsequent 180 minutes with measurements for respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via a Visual Analog Scale (VAS).
41323145|NCT03689387|OTHER|the Medical Program Information Systems (PMSI)|The selection of the files will be carried out using the Medical Program Information Systems (PMSI) and search convocations for post-stroke follow-up consultations conducted by the Secretariat of Neurological MPR Amiens University Hospital.
41323146|NCT01882244|BEHAVIORAL|Neural Pathfinder Training|Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
41323147|NCT01882244|BEHAVIORAL|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
41323148|NCT04110860|DRUG|voriconazole gel once daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
41323149|NCT04110860|DRUG|voriconazole gel twice daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
41323150|NCT04110860|DRUG|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
41323151|NCT02600000|RADIATION|Myocardial scintigraphy|Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
41323152|NCT02600000|DEVICE|Cardiopulmonary test|Assessment of maximal functional capacity
41323153|NCT02600000|DEVICE|AVD-Glittre Test|Evaluation of submaximal functional capacity after inspiratory muscle training.
41323154|NCT02600000|DEVICE|Diaphragm ultrasound|Evaluation of thickness and diaphragmatic mobility
41323155|NCT00560222|DIETARY_SUPPLEMENT|bovine lactoferrin|1gm of lactoferrin will be given each day
41323156|NCT00560222|DIETARY_SUPPLEMENT|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
41323157|NCT05710965|DEVICE|FRx-001|Wearable digital therapy
41323158|NCT05710965|DEVICE|FRx-003|Wearable digital therapy
41323159|NCT05710965|DEVICE|FRx-004|Wearable digital therapy
41323160|NCT02779881|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus LGG|
41323161|NCT05859048|DIAGNOSTIC_TEST|NT-proBNP|blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory
41323162|NCT05859048|DIAGNOSTIC_TEST|AI echocardiogram|Artificial intelligence driven transthoracic echocardiogram
41323163|NCT05859048|DIAGNOSTIC_TEST|electrocardiogram|tracing of electrical cardiac activity of the heart
41323164|NCT05859048|OTHER|Cardiovascular physical examination|basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg)
41323165|NCT06372197|DRUG|Psilocybin|Following Oregon Psilocybin Services (OPS) rules, participants will be placed in cohorts of five to six, which whom they will do two 90-minute preparation session, two psilocybin sessions, and two 90-minute integration sessions. All sessions will be guided by two licensed facilitators.
41323166|NCT03665012|OTHER|Pediatric Development Clinic (PDC)|All children enrolled in PDC will be at screened for any medical condition they may have and be referred for treatment as required. Nutrition and development support are also provided to clinic enrollees, based on clinic protocols which include regular monitoring and intervention.
41323167|NCT03593863|BEHAVIORAL|Physical Education (PE) programme|The intervention consists of a 10-month (one academic year, September-June) physical activity programme delivered by PE teachers during regular Year-8 PE lessons. The Intervention involves roughly 20 minutes of prescribed activities per week.
41323168|NCT05366257|OTHER|CAR-T|infusion of CAR-T therapy among patients with r/r DLBCL
41323169|NCT05366257|OTHER|Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
41323170|NCT04535154|OTHER|No interventions|No interventions
41323171|NCT01245764|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
41323172|NCT01245764|BIOLOGICAL|Placebo|
41323173|NCT00405652|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
41323174|NCT06283992|OTHER|Digital Navigation|1:1 educational support at the bedside about the functions of the patient portal and telehealth that can help with care transitions.
41323175|NCT01957787|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
41323176|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Vaginal Ring containing 25 mg dapivirine
41323177|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 100 mg|Vaginal Ring containing 100 mg dapivirine
41323178|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 200 mg|Vaginal Ring containing 200 mg dapivirine
41323179|NCT00792701|DRUG|cisplatin|Given IV
41323180|NCT00792701|DRUG|gemcitabine hydrochloride|Given IV
41323181|NCT05100069|DRUG|Brigatinib|Brigatinib Tablets
41323182|NCT04105569|PROCEDURE|Stent-Induced Biofilm Overgrowth|Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
41323183|NCT03437044|DRUG|Ticagrelor|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
41323184|NCT03437044|DRUG|Clopidogrel|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
41323185|NCT04545099|DRUG|Sugammadex|Administration of Sugammadex for muscle relaxation reversal
41323186|NCT04545099|DRUG|Neostigmine|Administration of Neostigmine for muscle relaxation reversal
41323187|NCT03078023|DEVICE|swallowed sponge device|Swallowed sponge: Subjects having a clinical upper endoscopy will be asked to swallow the sponge 2 hours prior to EGD
41008301|NCT00978731|DRUG|Dasatinib|"Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~* 5 days on, 2 days off~* 6 days on, 1 day off~* Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study"
41323188|NCT03986190|BEHAVIORAL|Healthy Juntos|"Parent-adolescent dyads will log in to a secured website for a total of eight weeks. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
41323189|NCT05893667|DIAGNOSTIC_TEST|Inflammatory markers|analysis of inflammatory scores
41323190|NCT06086132|COMBINATION_PRODUCT|Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy|Follow-up visits at baseline, 3-months, and 1-year
41323191|NCT05448599|DRUG|6MW3211 injection with Intravenous Infusion|phaseI: 6MW3211 will be administered in 30mg/kg and 45mg/kg intravenously once every 2 weeks; phaseII: 6MW3211 will be administered in 45mg/kg intravenously in both 2 cohorts.AZA will be administered in 75mg/m2 by subcoutaneous injection in cohort 1 as well as cohort 2 from Day1-Day7 every 28-day cycle. VEN will be administered orally with dose escalation to 400mg daily every cycle.
41323192|NCT01345370|DRUG|Temozolomide|According to sites procedures
41323193|NCT01345370|RADIATION|Radiation Therapy|According to sites procedures
41323194|NCT03783338|COMBINATION_PRODUCT|Aerobic exercises and Vitamin D supplementation|"Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks."
41323195|NCT00454272|DRUG|Teicoplanin|
41323196|NCT00454272|DRUG|Vancomycin|
41323197|NCT06312046|OTHER|HiBalance-MS|See arm description for intervention group.
41153008|NCT05066230|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
41008302|NCT01674686|DRUG|Sarpogrelate|Sarpogrelate 100mg twice a day
41008303|NCT01674686|DRUG|Atorvastatin|Atorvastatin 80mg daily
41153009|NCT02088723|BEHAVIORAL|Head of bed elevation|head of bed elevation elevation the head of the bed with 15 cm (head of bed elevation) and compare the apnea-hypopnea index with the standard polysomnography
41323198|NCT04262622|DEVICE|Group TEA: thoracic epidural analgesia group|in this group TEA will be performed by the insertion of transthoracic epidural catheter before induction of general anesthesia. Analgesia will be started on wound closure by injecting local anesthetic mixture into the epidural catheter
41323199|NCT04262622|DEVICE|Group RSB: rectus sheath block group|Two sets of epidural catheters which have multiple perforations at the end of the tubing will be surgically applied bilaterally into the rectus sheaths for each patient in this group on wound closure. By the end of surgery,injection of local anesthetic mixture will be started.
41323200|NCT05885022|DEVICE|Calibreye System|Implantation of a glaucoma device to reduce intraocular pressure
41323201|NCT01213693|DRUG|Salmeterol/Fluticasone combination|Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
41323202|NCT01213693|DRUG|Salmeterol|Salmeterol 50 mcg 1 inhalation bid
41323203|NCT02607332|DRUG|Paclitaxel|
41323204|NCT04655963|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
41323205|NCT05220241|BIOLOGICAL|Nasopharyngeal swab for RT-PCR SARS-CoV-2|2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
41323206|NCT04579796|OTHER|ultrasound exam|An abdominal ultrasound exam to assess the placenta implantation site.
41323207|NCT04579796|PROCEDURE|hysteroscopy diagnostic|Diagnostic hysteroscopy to asses the placenta implantation site.
41323208|NCT05020093|PROCEDURE|Injection molding|preheated bilk-fill composite, co-cured universal adhesive, David Clark cavity design
41153010|NCT03897049|BEHAVIORAL|Trans Women Connected|The intervention will address the unique needs of transgender women and the lack of evidence-based, transgender-specific HIV prevention. It is a mobile app delivered sexual health promotion program that engages transgender women through a strengths based approach to HIV prevention and sexual health that uses the power of social networks to identify and encourage protective factors that support the health of transgender women. This approach recognizes the social and structural barriers that transgender women face. In the context of these barriers, which include stigma and discrimination in a number of interconnected spheres, individually-focused behavioral interventions are insufficient. This intervention takes a more comprehensive approach that intentionally targets community strengths and challenges. The mobile app will include more than 30 interactive activities including resource maps, PrEP/PEP content, and communication forums.
40805578|NCT03962894|DRUG|Prednisolone|During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
40805579|NCT03611881|BEHAVIORAL|Counseling|4 or 8 weeks of behavioral counseling support to promote smoking cessation.
40805580|NCT03611881|DRUG|Nicotine patch|2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.
40805581|NCT03611881|BEHAVIORAL|Community Resource|Counselor-facilitated referral to a community-based program to address social needs.
40805582|NCT03869996|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
40805583|NCT03869996|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
41153011|NCT03897049|BEHAVIORAL|General Health App|The control group will download a mobile app that addresses COVID and provides COVID resources.
41153012|NCT00003116|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
41153013|NCT00003116|DRUG|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
41153014|NCT00003116|DRUG|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
41153015|NCT00003116|DRUG|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
41008304|NCT04037202|OTHER|Foot massage|Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
41008305|NCT02147808|DRUG|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
41008306|NCT02147808|DRUG|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup \[2mg/mL\]).
41008307|NCT03169491|DEVICE|Continuous positive airway pressure (CPAP)|CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
41323209|NCT05020093|PROCEDURE|Incremental packing|Incremental packing of conventional composite; pre-cured universal adhesive, non-beveled cavity design
41323210|NCT03495817|DRUG|ATI-50002|ATI-50002 Topical Solution
41323211|NCT03224910|OTHER|Cytologic techniques used for rapid on site interpretation|Diagnostic efficiency of touch imprints of needle core biopsies vs smears of fine needle aspirations during rapid on-site interpretation
41323212|NCT05996783|DEVICE|Colli-Pee Small Volumes|Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
40805592|NCT06373354|DEVICE|Digital Breast Tomosynthesis (DBT)|Undergo tomosynthesis imaging
40805593|NCT05898581|PROCEDURE|PENG Block|Participants will receive a PENG block with local anesthetics (which is a freezing medication, in this case, 0.5% ropivacaine) before receiving spinal anesthesia.
41008308|NCT02759120|DRUG|Antimicrobial therapy: Co-trimoxazole or Doxycycline|160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight \< 50 kilograms or 100mg twice daily if weight \> 50 kilograms for up to 36 months
41008309|NCT02759120|OTHER|No Intervention: Standard of Care|Standard of care
41008310|NCT02135224|DRUG|Fentanyl|
41008311|NCT02135224|DRUG|Normal saline|
41008312|NCT00772096|DRUG|n-3 fatty acids|
41008313|NCT06062875|DRUG|Adalimumab|Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
40805594|NCT05898581|PROCEDURE|Control Group|Participants will receive a sham PENG block performed with 20ml of normal saline solution before spinal anesthesia. After, patients will receive ILAI (performed by the operating surgeon) with a plain solution of ropivacaine 0.25% 60ml.
41008316|NCT03392636|PROCEDURE|Herniotomy|In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
41008317|NCT01804556|PROCEDURE|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 \~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
41008318|NCT05849402|DEVICE|Active Comparator: Active aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
41323213|NCT05996783|DEVICE|Evalyn Brush|Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
41323214|NCT01975077|DRUG|fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
41323215|NCT04219488|OTHER|Radial nerve mobilization|
41008319|NCT05849402|DEVICE|Sham Comparator: Sham aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
40805595|NCT05467891|DRUG|Ribociclib|400 mg orally once daily Days 1-21 (28 day Cycle)
41008320|NCT05035771|DEVICE|Pressure wire measurement in peripheral vascular disease|The aim of IMPACT PAD is to examine the safety and feasibility of intraprocedural flow, pressure and resistance rate changes to help predict the success of a peripheral endovascular intervention.
41008321|NCT01251484|DRUG|BIBF1120|Tablet 200 mg twice daily until progression
41008322|NCT00536367|OTHER|No intervention - observational study only|
41008323|NCT00578565|DRUG|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
41323216|NCT04219488|OTHER|Supervised home program|
41323217|NCT01705964|DRUG|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
41323218|NCT01705964|OTHER|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
41323219|NCT04688216|OTHER|risk factors of infection with multidrug-resistant organisms|"1. General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.~2. Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.~3. The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs"
41323220|NCT00568282|PROCEDURE|phlebotomy|Standard of care
41323221|NCT04328922|OTHER|Fecal microbial transplantation|Capsules of fecal matter solution (feces from healthy donor, glycerol and saline solution)/
41323222|NCT04328922|OTHER|Placebo capsuls|capsules of glycerol and saline (placebo).
41323223|NCT05960110|DRUG|Fluoride varnish|Fluoride varnish 26200 ppm
41323224|NCT05960110|DRUG|Fluoride toothpaste|Fluoride toothpaste 1450 ppm
41323225|NCT02562183|DRUG|kallikrein|Using kallikrein
41323226|NCT04043715|DEVICE|Transcutaneous spinal stimulation|Physical therapy to improve standing and walking
41323227|NCT04043715|DEVICE|Epidural spinal stimulation|Physical therapy to improve standing and walking
41477894|NCT04197128|DEVICE|Ribose cross linked collagen matrix for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision.~Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, ribose cross linked collagen matrix will be cut and adapted to the buccal wall and ridge around the buccal aspect of healing abutment. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)."
41477895|NCT02529202|DRUG|Dexmedetomidine|Dexmedetomidine infusion
41477896|NCT02919813|BEHAVIORAL|Mindfulness Based Group Cognitive BehaviorTherapy|Mindfulness Based Group Cognitive Behavior Therapy is a type of counseling that teaches women to have more control over their pain.
41477897|NCT02919813|BEHAVIORAL|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
41477898|NCT06210802|OTHER|Korean version of Defense and Veterans Pain Rating Scale|Defense and Veterans Pain Rating Scale translated into Korean
41477899|NCT03998579|OTHER|The CanMoRe programme|An exercise intervention in Primary Health Care
41477900|NCT03998579|OTHER|Home exercise|An active control group
41477901|NCT02834884|GENETIC|RP-1828 IMMUcan|WES, lcWGS and RNAseq, multiplex IF and IMC
41477902|NCT02834884|GENETIC|RP-1759 AYA/TYA|WES, RNAseq and EPIC array
41477903|NCT02834884|GENETIC|RP-1843 Arcagen|NGS panel
41477904|NCT02834884|GENETIC|RP-1920 BioRadon|NGS panel
41477905|NCT06406322|OTHER|PFMT|Pelvic floor muscle training will be given to patients with strengthening and endurance exercises for 8 weeks. PFMT will be applied at a patient-specific progression for 8 weeks.Exercises will be given in different positions (supine, sitting, etc.).
41477906|NCT06406322|OTHER|Aerobic Exercise|Aerobic exercise will be applied as a progressive program in the form of a walking program, at least 4 days a week for 8 weeks. There will be 5-minute warm-up and cool-down periods (walking at a light pace) before and after exercise.
41323228|NCT04240171|DRUG|Dapagliflozin 5Mg Tab|Dapagliflozin 5mg tablets daily
41477907|NCT05271136|OTHER|Anti-aging Serum|Serum composed of a patent-pending botanical extract, bioavailable peptides, antioxidants, post-biotics, and short and long-term moisturizers
41477908|NCT05271136|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after serum
41477909|NCT05271136|OTHER|Cleansing Lotion|Facial cleansing lotion to be used by study participants
41477910|NCT05271136|OTHER|Sunscreen|Sunscreen to be applied after application of serum in the morning. Participants were asked to reapply every 2 hours
41008324|NCT02645916|DRUG|Danggui-Sayuk-Ga-Osuyu-Saenggang-tang|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
41477911|NCT05271136|OTHER|Sunscreen|Sunscreen to be applied after application of facial moisturizer in the morning. Participants were asked to reapply every 2 hours
41477912|NCT05680870|DRUG|Omeprazole|Omeprazole 40 mg 3 times daily for 5 days ..to start 2 days before chemotherapy cycles
41008325|NCT02645916|DRUG|Placebo: corn starch|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
41323229|NCT04240171|DRUG|Glimepiride 4Mg Tab|Glimepiride Tablets daily
41477913|NCT06288022|OTHER|total tubeless mini-PCNL|When finish the mini-PCNL operation, patient not receive placement both ureteral drainage tube (DJ-stent) and nephrostomy tube.
41477914|NCT06288022|OTHER|tubeless mini-PCNL|When finish the mini-PCNL operation, patient receive placement ureteral drainage tube (DJ-stent) but not receive nephrostomy tube.
41477915|NCT00640263|DRUG|lopinavir/ritonavir (LPV/r)|Oral liquid formulation lopinavir/ritonavir(80 mg lopinavir + 20 mg ritonavir/mL); Dosing : 40/10mg twice daily if infant weight is between 2 to 4 kg and 80/20mg twice daily if infant weight is above 4kg The lopinavir/ritonavir will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
41477916|NCT00640263|DRUG|Lamivudine (3TC)|"Oral liquid solution lamivudine(10 mg/mL). Dosing : 7,5 mg twice daily if if infant weight is between 2 to 4 kg ; 25 mg twice daily if infant weight is between 4 to 8 kg ; 50 mg twice daily if infant weight is above 8kg.~The lamivudine will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight."
41323230|NCT02636920|OTHER|Therapeutic Education to the Patient (TEP)|"* Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.~* Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.~* Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.~* Assessing of the knowledges acquired by patients."
41323231|NCT01446679|DRUG|atrovastatin|oral
41477917|NCT00784524|BIOLOGICAL|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10\^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
41323232|NCT00532714|DRUG|Irinotecan plus capecitabine|"Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)."
41323233|NCT02999100|DRUG|IH Oxytocin|Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
41323234|NCT02999100|DRUG|IM Oxytocin|Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
41323235|NCT02999100|DRUG|IV Oxytocin|Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
41323236|NCT02999100|DEVICE|ROTAHALER|ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
41323237|NCT02409758|BEHAVIORAL|Voice therapy|Voice therapy applied during 6 weeks.
41323238|NCT04031404|DEVICE|Single-pulse TMS|Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).
40805596|NCT05467891|DRUG|Fulvestrant|500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+
41477918|NCT00784524|BIOLOGICAL|aldesleukin|Subcutaneous aldesleukin (10 x 10\^6 International Units) will be given on day 7 and day 8 after each LMI injection.
41477919|NCT05156424|OTHER|Exercise|An individualised, progressive and autoregulated exercise programme, supervised by a trained professional.
41477920|NCT02645344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
40805597|NCT05467891|DRUG|Anastrozole|1 mg orally once daily
40805598|NCT05467891|DRUG|Letrozole|2.5 mg orally once daily
40805599|NCT05467891|DRUG|Exemestane|25 mg orally once daily
41008326|NCT01941953|DRUG|Metformin and Fluorouracil|metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
41008327|NCT01610791|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
41008328|NCT01720095|DRUG|Niaspan|
41008329|NCT01978431|DRUG|cocaine hydrochloride|
41008330|NCT01978431|DRUG|methylphenidate|
41008331|NCT01987427|DRUG|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
41008332|NCT01987427|DRUG|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
41008333|NCT01987427|DRUG|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
41153016|NCT00003116|PROCEDURE|bone marrow ablation with stem cell support|
41323239|NCT02227849|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 52 weeks
41323240|NCT02227849|DRUG|GLP-1 analogue|
41323241|NCT04186715|DEVICE|Near-infrared spectroscopy|The Near-infrared spectroscopy probes will be placed in the frontal region.
41323242|NCT05423002|OTHER|Flickering light stimuli|The intervention will be exposed to flickering lights (≤200 lux). More specifically, the participants will be asked to be exposed to a specified flickering light (1Hz, 30 seconds On, and 30 seconds OFF) for 2 hours starting at their habitual bedtime (HBT).
41323243|NCT05423002|OTHER|Constant light stimuli|The intervention will be exposed to constant background lights (≤200 lux). The participants will be asked to be exposed to a specified constant light for 2 hours starting at their habitual bedtime (HBT).
41323244|NCT05423002|OTHER|Dim light|This light condition is the baseline (≤10 lux).
41323245|NCT02253017|OTHER|Children operated on for cataract|Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
41477921|NCT02645344|BEHAVIORAL|Sensory Cueing (SC)|
41477922|NCT02645344|BEHAVIORAL|Conventional Rehabilitation|
41323246|NCT01244958|BIOLOGICAL|Rituximab|1000 mg Rituximab infusion
41323247|NCT01244958|DRUG|Placebo|infusion of Sodium citrate, Polysorbate, Sodium chloride
41323248|NCT01644955|DRUG|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
41323249|NCT01644955|PROCEDURE|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
41477923|NCT01739725|DEVICE|Stent insertion|The patient will receive the helical stent
40805600|NCT03031626|BIOLOGICAL|Medical Air vs Oxygen|Medical Air/Oxygen will be given
41008334|NCT03567850|BEHAVIORAL|Problem solving Skills Training|"Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier."
41008335|NCT04251533|DRUG|alpelisib|300 mg orally, once per day (QD), tablets
41323250|NCT04197518|DIAGNOSTIC_TEST|neuro trax system and a neurology test.|"the neurology will check the patience before and after tonsillectomy or adenotonsillectomy usung the neurotrax system, these parameters will be measured in this system : Non verbal memory, Go no go test, stroop interference, Visual spatial processing, Staged information processing speed, catch game, problem solving."
41323251|NCT02493322|DRUG|Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg|1 tablet a day
41323252|NCT02493322|DRUG|Olmesartan medoxomil 20mg + Chlortalidone 25mg|1 tablet a day
41323253|NCT02493322|DRUG|Olmesartan 20mg + hydrochlorothiazide 12,5mg|1 tablet a day
41323254|NCT02976727|DRUG|Topical Vitamin D (Calcipotriol) application|Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
41323255|NCT02976727|DRUG|Placebo cream application|placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
41323256|NCT02976727|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
41323257|NCT02976727|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
41323258|NCT02976727|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
41323259|NCT02976727|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
41323260|NCT02976727|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
41323261|NCT01692002|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate capsule or tablet
41323262|NCT01692002|DIETARY_SUPPLEMENT|Sodium Chloride|Placebo capsule or tablet
41323263|NCT01692002|PROCEDURE|Oral glucose tolerance test|
41323264|NCT01692002|PROCEDURE|Intravenous glucose tolerance test.|
41008336|NCT04251533|DRUG|placebo|300 mg orally, once per day (QD), tablets
40805601|NCT03206970|DRUG|Zanubrutinib|Administered as specified in the treatment arm.
41008337|NCT04251533|DRUG|nab-paclitaxel|100 mg/m\^2 IV infusion, once per day (QD)
41008338|NCT04099862|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
41008339|NCT04099862|PROCEDURE|EUS-BD|Endoscopic UltraSound Biliary Drainage
41008340|NCT05678335|DRUG|Hydroxychloroquine|Oral hydroxychloroquine 200mg twice daily for 12weeks.
41008341|NCT05678335|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
41008342|NCT02633956|DRUG|Obeticholic Acid|Once a day (QD) by mouth (PO)
41008343|NCT02633956|DRUG|Atorvastatin|"Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated."
41323265|NCT00180271|DEVICE|Cardiac resynchronization therapy with defibrillation|Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation
41323266|NCT00180271|DEVICE|Implantable Cardioverter Defibrillator (ICD)|Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator
41323267|NCT02017899|BIOLOGICAL|S. sonnei 1790GAHB|
41323268|NCT02017899|BIOLOGICAL|Placebo|
41323269|NCT02447458|DRUG|MLN3126|MLN3126 tablets
41323270|NCT02447458|DRUG|MLN3126 Placebo|MLN3126 placebo-matching tablets
41323271|NCT06552923|OTHER|ECHO Tele-Education|A common curriculum was developed that covered best practices in multidisciplinary diabetes care for the primary care setting that was guided by the ADA Clinical Care. guidelines. FQHCs attended one-hour tele-ECHO sessions twice a month for 6-months.
41323272|NCT02570282|DRUG|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
41323273|NCT02570282|DRUG|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
41008344|NCT02633956|DRUG|Placebo|Once a day (QD) by mouth (PO)
41153017|NCT00003116|PROCEDURE|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
41323274|NCT03095053|PROCEDURE|comprehensive chromosome screening|"Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA)."
41323275|NCT01760187|DRUG|lomitapide|
41323276|NCT00160992|BIOLOGICAL|Melan-A analog peptide|
41323277|NCT00022152|DRUG|vinorelbine tartrate|
41008345|NCT05787951|DIAGNOSTIC_TEST|Bone marrow aspirite for diagnosis|Routine investigation of acute myeloid leukemia such as bone marrow aspirite for diagnosis ,cbc
41008346|NCT00250211|PROCEDURE|Functional MRI imaging and tomotherapy|
41008347|NCT00333229|DRUG|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
41008348|NCT00333229|DRUG|Placebo|Matching Placebo
41323278|NCT01463020|BEHAVIORAL|Smartphone delivered BA|A 8 week behavioural activation therapy delivered through smartphone
41323279|NCT01463020|OTHER|Smartphone delivered mindfulness|A 8 week mindfulness intervention delivered through smartphone
41323280|NCT03930420|BEHAVIORAL|Connect to Wellness|The research team will train LHD staff and offer them technical assistance to work with small worksites. LHD staff will be trained to deliver the Connect to Wellness program to worksites. Connect to Wellness is a program to disseminate EBIs to small worksites. Worksites receive guidance about EBIs and ongoing implementation assistance from a trained interventionist. In this study, LHD staff will be the interventionists. Worksites participating in Connect to Wellness complete three phases of activities, Assessment, Recommendations, and Implementation. LHD staff will receive Connect to Wellness intervention materials, multiple webinars delivered in real-time, access to a comprehensive intervention and training platform with features that allow them to connect with each other and with research staff, and group technical assistance calls to support their ability to recruit worksites in their communities and deliver Connect to Wellness to these worksites.
41323281|NCT04829266|BEHAVIORAL|mental simulation|Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.
41323282|NCT01258517|DEVICE|near infrared spectroscopy (INVOS 5100)|monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
41323283|NCT01097148|DRUG|Atracurium, TBW|Dose atracurium 0.5 mg/kg based on total body weight
41323284|NCT04223401|OTHER|Prehabilitation|"Patients will undergo 6 Minutes Walking Test (6-MWT), spiroergometry (VO2 max; AT), a grip strength test, a timed Up \& Go (TUG) test, 10 m sprint test and sit to stand test before and after prehabilitation. The trimodal intervention will involve:~1. Nutritional intervention~2. Psychological intervention~3. Exercise intervention"
41323285|NCT02671461|DRUG|BMS-986141|
41323286|NCT02671461|DRUG|Aspirin|
41323287|NCT02671461|OTHER|Placebo|
41323288|NCT03582735|OTHER|Nerve gliding exercise|A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
41008349|NCT02751151|OTHER|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
41323289|NCT02592395|DRUG|FOLFIRINOX|"The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous"
41323290|NCT02592395|DEVICE|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
41323291|NCT00259441|DRUG|Simvastatin|
41008350|NCT03957538|BEHAVIORAL|Virtual reality angiogram experience video|The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
41008351|NCT03073278|RADIATION|Stereotactic Body Radiotherapy|Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.
41153018|NCT04034056|DRUG|Obinutuzumab|Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).
41323292|NCT00709033|BIOLOGICAL|autologous or syngeneic PBTLs and EBV-CTLs|"Three dose levels are being evaluated namely:~GROUP 1~PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2~GROUP 2~PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2~GROUP 3~PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2"
41323293|NCT06511440|DEVICE|Vision-700|OCT machines used for diagnostic purposes
41323294|NCT00159159|DRUG|Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l|
41153019|NCT05455281|DEVICE|CHLOE|CHLOE is designed to automatically analyze events related to embryo development from Time Lapse Incubator (TLI) images and provide prediction on the likelihood of embryos developing to the blastocyst. This information can assist embryologists and IVF professionals in the selection of the most viable embryo for transfer or freezing, when there are multiple embryos deemed suitable.
41477924|NCT04259138|BIOLOGICAL|Treatment Algorithm A|Participants who are not on UC treatment at screening (or who have only used topical therapy) will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (azathioprine, 6-mercaptopurine, or methotrexate), with optional oral corticosteroid up to a maximum of 30 mg or prednisone or equivalent, will be initiated.
41477925|NCT04259138|BIOLOGICAL|Treatment Algorithm B|"Participants who are taking oral 5-ASA, immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), and/or oral corticosteroid at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
41477926|NCT04259138|BIOLOGICAL|Treatment Algorithm C|"Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
41477927|NCT02704234|OTHER|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
41477928|NCT02704234|OTHER|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
41477929|NCT03692091|PROCEDURE|Subacromial Injection|Injection in to subacromial space in the shoulder from anterior portal
41477930|NCT05893511|PROCEDURE|Endoscopic ultrasound-guided gallbladder drainage|Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). EUS-GBD would be performed by either the conventional or direct method. A 10mm stent system would be used if the largest gallstone is smaller than 10mm in size and a 16mm stent is used if the largest gallstone is larger than 10mm. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder is completely emptied by suction and irrigation until the effluent through the stent is clean. The need of inserting an additional double pigtail plastic stent through the LAMS would be decided by the endosonographer. A course of antibiotics will be continued for 7 days after the procedure .
41477931|NCT05893511|DRUG|Antibiotics first|Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
41477932|NCT02546843|DRUG|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
41477933|NCT02546843|DRUG|Cisatracurium|cisatracurium 0.15mg/kg intravenously
41477934|NCT02546843|DRUG|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
41477935|NCT02546843|DRUG|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
40805604|NCT06516874|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy for complex presentation (TF-CBT-CP)|This TF-CBT-CP is a short-term intervention to treat outpatients. This will be carried out via videoconference.
41153020|NCT04060641|GENETIC|Geneticure for RDN Genetic Panel|This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation
40805605|NCT06516874|OTHER|TAU|waiting list, access to pharmacological treatment, and/or non-specialized PTSD psychotherapy sessions.
41153021|NCT02623686|OTHER|Aroma Therapy Massage and Inhalation Patch|
41153022|NCT06539390|OTHER|Transforaminal Epidural Injections?|Pain, lumbar disc herniation,Transforaminal Epidural Injections?
41153023|NCT02897063|DRUG|Droxidopa|Single oral dose 300 mg
41153024|NCT02897063|DRUG|Midodrine|Single oral dose 10 mg
41323295|NCT00159159|DRUG|Ciclosporine 200 µg/l < T0 ciclosporinemia < 300 µg/l|
41323296|NCT04411212|DRUG|Granulocyte colony-stimulating factor and platelet-rich plasma group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
41323297|NCT04411212|OTHER|Control group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
41477936|NCT02546843|DRUG|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
41477937|NCT02546843|DRUG|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
41477938|NCT05443100|OTHER|Whole-body cryostimulation (WBC)|Multidisciplinary rehabilitation program consisting of 10 WBC sessions.
41153025|NCT02897063|DRUG|Placebo|sugar pill
41477939|NCT05443100|OTHER|Rehabilitation program|Multidisciplinary rehabilitation program consisting of diet and physical exercise.
41323298|NCT03949140|PROCEDURE|Laser hair removal|Those who consent to participate in the study will be treated with up to 8 sessions of laser hair removal utilizing a long-pulsed laser to the natal cleft at treatment intervals of 4-6 weeks.
41323299|NCT02787603|OTHER|Interruption of antibiotic treatment due to PCT measurement|In group A at day 5, if the patient shows no clinical signs of infection and PCT levels \< 0,25ng/mL OR PCT \> 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
41323300|NCT01344252|DRUG|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
41323301|NCT05035823|DEVICE|Motor Neuroprosthesis (MNP)|Type of implantable brain computer interface
41323302|NCT04776421|PROCEDURE|Diverting ileostomy|Diverting ileostomy
41323303|NCT02641314|DRUG|metronomic therapy|"* Propranolol 0.5 mg/kgxd p.o. day 1,~  1. mg/kgxd p.o. day 2,~ 2. mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~* Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~* Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~* Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~* Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"
41323304|NCT05267197|OTHER|3D Telemedicine|3D Telemedicine system
41323305|NCT05267197|OTHER|2D Telemedicine|2D Telemedicine system
41323306|NCT05610358|DEVICE|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory or cardiovascular diseases.
41323307|NCT02420223|DRUG|Propranolol|
41323308|NCT04387526|DRUG|(SOF and DCV)|
41008352|NCT04694807|BEHAVIORAL|Group-based Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 2.25 hours for the group format.~Group-based CBTgrief will follow the same content and exercises for each session as individually delivered CBTgrief."
41323309|NCT04387526|DRUG|(SOF, DCV, and RBV)|
41323310|NCT00525408|BIOLOGICAL|Mycobacterium w.|Immunomodulator
41323311|NCT00525408|DRUG|Docetaxel|Chemotherapeutic agent
41323312|NCT02353039|DRUG|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
41323313|NCT02353039|DRUG|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
41323314|NCT02353039|DRUG|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
41323315|NCT02353039|DRUG|Placebo|Administer placebo t.i.d for 2 weeks
41323316|NCT04075773|BEHAVIORAL|Expressive Writing|The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
41323317|NCT03335787|OTHER|Intervention|Kinesio Tape apply to peroneal muscles in supine position starting from the peroneal muscle origin with using muscle activation technique by a certified KT1 and KT2 practitioner. Then ligament technique which will go through around ankle starting from medial and lateral metatarsophalangeal joints in order to improve ankle stability. Taping will be applied one week later and two weeks later prior to first application.
41323318|NCT03335787|OTHER|Control|Any sham taping was not applied to the control group in order to prevent the sensory stimulant effect of taping. In order to achieve patients' blinding both groups participant will sign a same consent but control group will be called for taping a month later after study data collection completed.
41323319|NCT00920478|OTHER|Musculoskeletal Ultrasound|Gray scale and power doppler - to identify the presence of synovitis
41323320|NCT00920478|OTHER|28 Joint Disease Activity Score|Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
41323321|NCT02776956|DRUG|atorvastatin group|Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation
41323322|NCT02776956|DRUG|non-atorvastatin group|Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
41323323|NCT05628025|OTHER|Organ phantom of prostate|Participants will operate on a 3D printed model of the prostate.
41323324|NCT02252237|BIOLOGICAL|Pharmacokinetic|Blood sample of 2 ml at enrolment and then at following visits. Buccal cell collection swab
41323325|NCT03334474|OTHER||no intervention
41323326|NCT00556621|DRUG|cisplatin|
41323327|NCT00556621|DRUG|gemcitabine hydrochloride|
41323328|NCT00556621|PROCEDURE|biopsy|
41323329|NCT00556621|PROCEDURE|cystoscopy|
41323330|NCT00556621|PROCEDURE|therapeutic conventional surgery|
41323331|NCT00556621|RADIATION|radiation therapy|
41323332|NCT04496648|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
41323333|NCT04496648|PROCEDURE|Sham-percutaneous coronary intervention|Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.
41477940|NCT03758482|OTHER|Probe meal|The probe meal (total caloric content 750 Kcal) will be ingested at a standard rate in 10 min.
41477941|NCT04794387|BIOLOGICAL|Amended LLS COVID-19 Registry|Do people with blood cancer who did not develop antibodies after a complete COVID-19 vaccination, develop antoibodies after a COVID-19 booster?
41323334|NCT03693118|BEHAVIORAL|Reh1,Reh2|The initial group comprised 86 subjects including. The Nine Hole Peg Test (NHPT), administered to all of the patients, was used to evaluate the subjects' manual dexterity. The standardized scale enabled obtaining scores of high validity (right: r= 0.984, left: r = 0.993). Having been administered the NHPT test the initial 86-patient group was reduced to a cohort of 40 subjects qualified for the study, who were subsequently randomly divided into two groups - the study and the control - each consisting of 20 subjects. Three times a week the study group received the upper limb treatment by means of the cognitive function platform. They were expected to achieve 96 levels of visuo-motor coordination in 3 months or the treatment was to be terminated. Prior to the first session of the treatment the patients were provided with all relevant instructions and information about the test displayed on the monitor. They could also choose which hand they would start with.
41323335|NCT03679429|DEVICE|NBI Function|In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
41477942|NCT02489604|DRUG|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
41477943|NCT02489604|DRUG|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
41477944|NCT02870036|DRUG|Simmitecan|
41477945|NCT02870036|DRUG|5-fluorouracil and Leucovorin Calcium|
41477946|NCT02870036|DRUG|Thalidomide|
41477947|NCT00904748|DRUG|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose without water
41477948|NCT00904748|DRUG|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose with water
41153026|NCT02814279|PROCEDURE|CAF plus connective tissue graft|Periodontal surgery for root coverage by the trapezoidal flap associated with connective tissue graft.
41477949|NCT00904748|DRUG|Viagra®|sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
41477950|NCT01154959|DRUG|Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol|Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
41477951|NCT05957419|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
41477952|NCT02940730|DRUG|Dalbavancin via Intravenous Administration|Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
41477953|NCT02940730|DRUG|Dalbavancin via Intraperitoneal Administration|Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
41477954|NCT03544151|DEVICE|Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V)|Swan-Ganz CCOmbo V insertion
41477955|NCT01394848|DEVICE|Endothelial cell capture stent with 1 month clopidogrel|75mg PO clopidogrel per day for 1 months
41477956|NCT01394848|DEVICE|Everolimus eluting stent with 12 month clopidogrel|75mg PO clopidogrel per day for over 12 months
41477957|NCT01394848|DRUG|Atorvastatin 20mg loading|Atorvastatin 20mg loading before index percutaneous coronary intervention
41477958|NCT01394848|DRUG|Atorvastatin 80mg loading|Atorvastatin 80mg loading before index percutaneous coronary intervention
41477959|NCT01129934|DRUG|Morphine-Promethazine|administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline
41477960|NCT01129934|DRUG|morphine|Administration of intravenous morphine 0.1 mg/kg
41477961|NCT04625452|BEHAVIORAL|BBCC+5A's+GS|"It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.~All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information."
41477962|NCT05759117|PROCEDURE|thoracentesis|A type of pleural procedure that will yield pleural fluid for subsequent analysis
41477963|NCT00986453|DEVICE|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
41477964|NCT00986453|PROCEDURE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
41477965|NCT00164749|DRUG|Placebo and ginkgo extract|Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
41477966|NCT00164749|DRUG|Curcumin and ginkgo extract|1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
41477967|NCT00164749|DRUG|Curcumin and ginkgo extract|4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
40805606|NCT05761639|OTHER|conventional rehabilitation|The program will be attended in person in the clinic's cardiac rehabilitation program and consists of physical exercise supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation, for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up. , muscle strengthening of lower and upper limbs, continuous aerobic training and return to calm.
41323336|NCT02271867|PROCEDURE|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
41323337|NCT05101486|BIOLOGICAL|Ad26.RSV.PreF-based Vaccine|Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.
41323338|NCT06422429|DRUG|Traditional deep-fried Youtiao|45g 4 times a week for 4 months
41323339|NCT06422429|DRUG|PI Youtiao|45g 4 times a week for 4 months
41323340|NCT00538746|DEVICE|BIPAP|
41323341|NCT00538746|DEVICE|PSV|
41323342|NCT00538746|DEVICE|PSV + CPAP|
41323343|NCT01597011|PROCEDURE|Fibrin Sealant|Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
41323344|NCT01597011|PROCEDURE|Tissue-penetrating mesh-fixation|Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
41323345|NCT03615118|OTHER|IVR/SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale; An automated phone system for monitoring and improving self-care and health outcomes
41323346|NCT03615118|OTHER|SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale
41323347|NCT02591238|OTHER|non-smoker oral placebo|Participants oral placebo last 2 weeks.
41323348|NCT02591238|DRUG|non-smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
41477968|NCT02794155|DRUG|HDV Insulin Lispro|HDV Insulin Lispro: \~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)
41323349|NCT02591238|OTHER|smoker oral placebo|Participants oral placebo last 2 weeks.
41323350|NCT02591238|DRUG|smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
41323351|NCT04902534|DRUG|Naoqingzhiming Tablets (contains echinacoside 180mg)|Single dose escalation and multiple dose escalation
41323352|NCT04902534|DRUG|placebo of Naoqingzhiming Tablets (without echinacoside)|Single dose escalation and multiple dose escalation
41477969|NCT02794155|DRUG|Insulin LISPRO|Insulin Lispro: no bound insulin
41477970|NCT04825041|DIAGNOSTIC_TEST|Patency test|Successive flow test, bubble flow test and peristalsis test
41477971|NCT02776813|BIOLOGICAL|ACTR087|
41477972|NCT02776813|BIOLOGICAL|rituximab|
41477973|NCT04062149|OTHER|single leg stance treatment|SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.
41477974|NCT04062149|OTHER|Usual physiotherapy|Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
41477975|NCT01980342|DRUG|Efavirenz|Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
41323353|NCT05556551|OTHER|Full Ceramic restoration|Two different dental restoration inserted in patient mouth ( split mouth)
41323354|NCT05556551|OTHER|Hybrid resin Ceramic restoration|Hybrid resin Ceramic restoration
41323355|NCT04142216|DIETARY_SUPPLEMENT|Chewing Gum|The patients will chew one piece of regular chewing gum six times in a day and feeling of thirst for ten minutes for three months.
41323356|NCT01626989|DEVICE|BiPAP auto Advanced|Auto Servo Ventilation Device
41323357|NCT01626989|DEVICE|BiPAP auto SV4|Auto Servo Ventilation Device
41323358|NCT01365377|OTHER|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
41323359|NCT05352906|DIAGNOSTIC_TEST|Intraocular pressure|Measurements of intraocular pressure in millimeter mercury (mmHg).
41323360|NCT02928926|OTHER|intravenous thrombolysis|patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
41323361|NCT02488525|DRUG|Prophylactic treatment with Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
41323362|NCT04345497|OTHER|Diabetes-Specific Formula|Diabetes-Specific Formula and Standard of Care
41323363|NCT04345497|OTHER|Standard Of Care|Standard of Care
41323364|NCT04096326|DRUG|AGN-151586|AGN-151586 solution for injection.
41323365|NCT04096326|DRUG|Placebo|Placebo solution for injection.
41477976|NCT02285634|DRUG|Oxymetazoline 0.05%|sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
41477977|NCT02285634|DRUG|Phenylephrine 0.25%|sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
41323366|NCT00759746|BEHAVIORAL|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
41323367|NCT00759746|BEHAVIORAL|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
41323368|NCT00759746|BEHAVIORAL|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
41323369|NCT04003753|OTHER|VR App|Participants will be exposed in three different virtual height scenarios (rural mountain, urban town, cloudy weather). At the beginning of each exposure session participants will be standing on a virtual platform at ground level (level 0). From level 0 they will proceed to further levels according to a predefined exposure scheme based on SUDS ratings (scale 0=no fear to 10=extreme fear). Participants will have to stay at each level until their SUDS are 3 or below for two times consecutively (assessment via gaze selection). In each scenario there will be 15 different height levels available (corresponding to a range of heights between 1-75m). Each exposure session will be terminated by a time limit of 20 minutes (study phase 1) or 30 minutes (study phase 2) irrespective of achieved level.
41323370|NCT05589844|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo standard of care allogeneic hematopoietic stem cell transplant
41323371|NCT05589844|PROCEDURE|Biospecimen Collection|Correlative studies
41323372|NCT05589844|BIOLOGICAL|CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine|Given intradermally
41323373|NCT00871377|DRUG|Placebo|corn oil (n-6 fatty acids)
41323374|NCT00871377|DRUG|High Dose Fish Oil|n-3 fatty acids, 1060 mg EPA + DHA
41323375|NCT00871377|DRUG|Low Dose Fish Oil|n-3 fatty acids, 2160 mg EPA + DHA
41323376|NCT02516150|DRUG|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
41323377|NCT02516150|DRUG|Glucagon|injection of 50 micrograms of glucagon
41323378|NCT03411850|BIOLOGICAL|Orencia|FDA approved biologic
41323379|NCT03411850|OTHER|Placebo|
41323380|NCT00660777|BEHAVIORAL|Deep breathing, bilateral alternate chewing, nasal lavage|Deep breathing, bilateral alternate chewing, nasal lavage
41477978|NCT02285634|DRUG|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
41477979|NCT02285634|DRUG|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
41477980|NCT00518622|DRUG|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
41477981|NCT00518622|DRUG|Comparator: Placebo|MK7009 Placebo
41323381|NCT00660777|BEHAVIORAL|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
41323382|NCT04950140|PROCEDURE|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
41323383|NCT04950140|PROCEDURE|Laparoscopic Surgery for the Treatment of Parastomal Hernia|Laparoscopic Surgery for the Treatment of Parastomal Hernia in Cancer Patients
41477982|NCT06026852|DEVICE|Prediction of plasma concentration of piperacillin-tazobactam or meropenem|For included patients, a prediction will be made by developed machine learning models about the expected plasma concentration of piperacillin-tazobactam or meropenem by using routinely collected health care data.
41477983|NCT06026852|DIAGNOSTIC_TEST|Determination of plasma concentration of piperacillin-tazobactam or meropenem|For included patients, the total plasma concentration of piperacillin-tazobactam or meropenem will be determined. Were possible, this will be done using a blood sample that was collected during routine daily bloodwork which is performed in the morning. If no routine sample is available, a study specific sample will be drawn at approximately the same time as a routine sample would be drawn.
41477984|NCT06026852|OTHER|Daily short questionnaire|Physicians who care for patients included in the study will be asked to fill in a short daily questionnaire that evaluates the perceived necessity and added value of daily therapeutic drug monitoring.
41477985|NCT04088266|COMBINATION_PRODUCT|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA®
41323384|NCT04494464|OTHER|No intervention|
41323385|NCT05536154|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
41323386|NCT05536154|DRUG|Cytarabine|Day 1\~Day 2: 200mg/m\^2, q12h
41323387|NCT05536154|DRUG|PEG-rhG-CSF|Day 6: 6mg
41323388|NCT02882815|DEVICE|IrisFIT PFO Occluder|
41477986|NCT02165306|BEHAVIORAL|Motivational Interviewing (MI)|"A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure"
41477987|NCT02165306|BEHAVIORAL|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
41477988|NCT05336305|DIETARY_SUPPLEMENT|Polydextrose|Administration of 3g polydextrose per day, for 2 months
41477989|NCT04316130|DEVICE|Uincare Homeplus|Interactive digital healthcare system
41477990|NCT04316130|OTHER|Brochure|Brochure
41323389|NCT02001675|DEVICE|magnetic resonance imaging (MRI)|
41323390|NCT02001675|DEVICE|31-phosphorous magnetic resonance spectroscopy (MRS-P31)|
41323391|NCT04114500|DIAGNOSTIC_TEST|serum estradiol and progesterone|blood sample for measuring serum estradiol and progesterone level on the same day of FET
41323392|NCT01873443|DRUG|Rituximab, MTX, folic acid|Rituximab IV 1000mg MTX 10\~25mg/week Folic acid at least 5mg/week
41323393|NCT00469846|PROCEDURE|L-arginine supplementation in a medical food|
41323394|NCT00469846|PROCEDURE|Vitamin C and E supplementation in a medical food|
41323395|NCT02625987|PROCEDURE|Continuous intradermic stitch|Appendectomy wound closure with an intradermic Polyglactina 910 stitch
41323396|NCT02625987|PROCEDURE|Separated stitches|Appendectomy wound closure with a separated stitches.
41323397|NCT04490317|DIAGNOSTIC_TEST|Cardiac MRI|"1. Cardiac MRI be taken to CO poisoned patients~2. Cardiac CT be taken to CO poisoned patients~3. TTE be taken to CO poisoned patients~4. Brain MRI be taken to CO poisoned patients~5. Neurocognitive function tests be taken to CO poisoned patients~6. Laboratory tests be taken to CO poisoned patients"
41323398|NCT04490317|PROCEDURE|Hyperbaric oxygen therapy|"1. Hyperbaric oxygen therapy be used for CO poisoned patients~2. Therapeutic hypothermia be used for CO poisoned patients"
41323399|NCT01313520|DRUG|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
41477991|NCT01638650|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTIs)|in accordance with current clinical HIV treatment guidelines
41477992|NCT01638650|DRUG|ritonavir|100 mg bid orally, Days 1-14
41323400|NCT01313520|DRUG|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
41323401|NCT04777578|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
41323402|NCT05812469|BEHAVIORAL|Brain Awareness Intervention|effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders
41323403|NCT05812469|BEHAVIORAL|Being Healthy Education|This training included trainings on Healthy Nutrition, Sexually Transmitted Diseases, Importance of Physical Activity and Personal Hygiene prepared by the researcher in the form of presentations for the patients in the control group.
41323404|NCT05052528|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19 CAR T cells IV
41323405|NCT05052528|DRUG|Cyclophosphamide|Given IV
41323406|NCT05052528|DRUG|Fludarabine Phosphate|Given IV
41323407|NCT05052528|BIOLOGICAL|Rituximab|Given IV
41323408|NCT02590887|DIETARY_SUPPLEMENT|Drink manufactured from lupine peptides|Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (14, and 28 days) drinking the beverage.
41323409|NCT03351439|DRUG|Zopiclone|Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
41323410|NCT03351439|DRUG|Gabapentin|Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
41323411|NCT03351439|DRUG|Celebrex|Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
41323412|NCT03351439|DRUG|Percocet|Standard of Care
41323413|NCT03351439|DRUG|Naprosyn|Standard of Care
41323414|NCT05479305|DEVICE|The Valiant Captivia Stent Graft|Aortic arch/Descending aorta Repair
41323415|NCT04949724|OTHER|translation and adaptation study|translation and adaptation study
41323416|NCT05627570|DIETARY_SUPPLEMENT|Healthy, balanced Diet A|Healthy, balanced diet following Eatwell Guide recommendations
41323417|NCT05627570|DIETARY_SUPPLEMENT|Healthy, balanced Diet B|Healthy, balanced diet following Eatwell Guide recommendations
41323418|NCT05627570|BEHAVIORAL|Behavioural support intervention|Participants will work with a behavioural scientist to create a personal plan to eat a healthier diet and be more physically active. This support will last for 6 months, with ongoing monthly telephone/video calls with the research team.
41323419|NCT01812070|BEHAVIORAL|ACT|
41323420|NCT01812070|BEHAVIORAL|CBT|
41477993|NCT01638650|DRUG|saquinavir [Invirase]|500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
41477994|NCT03501537|PROCEDURE|Free gingival graft obtained from the palate and debridement of the peri-implant lesion|granulation tissue debridement and grafting of a free gingival strip obtained from the palate
41477995|NCT01725282|DRUG|quetiapine extended release (XR)|Extended release tablets
41477996|NCT01725282|DRUG|Placebo|matching tablets
41477997|NCT02401477|DRUG|Ilaprazole + Amoxicillin|Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
41477998|NCT04652284|DRUG|Rifabutin|150 mg
41477999|NCT04652284|DRUG|Amoxicillin|1000 mg
41478000|NCT04652284|DRUG|Esomeprazole|40 mg
41478001|NCT04652284|DRUG|Clarithromycin|500 mg
41478002|NCT04652284|DRUG|Tinidazole|500 mg
41478003|NCT00869024|BIOLOGICAL|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells|Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
41478004|NCT05838521|DRUG|Sacituzumab govitecan|This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
41478005|NCT03662906|OTHER|Electroacupuncture|"Bilateral BL32 and BL 33 will be inserted to a depth of 70-95 mm with an angle of 20-30° inward and downward into the second and third sacral foramen. Bilateral BL35 will be inserted to a depth of 60-70 mm with a slightly superolateral direction using needles (0.30 mm in diameter, 75 mm in length). Bilateral BL23 and SP6 will be inserted vertically to a depth of 25-30 mm using needles (0.30 mm in diameter, 40 mm in length). The electric stimulators (6805-D electroacupuncture apparatus, Guangzhou Jiayu Medical Company, China) will connect the bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 5-10 mA for BL 32 and BL 33 and an intensity of 1-5 mA for SP 6 will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
41478006|NCT03662906|OTHER|Sham electroacupuncture|"Sham BL 23, BL32 and BL33 which are 2 cm lateral to BL23, BL33 and BL35 will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. Sham SP 6 which is at the midpoint between the spleen meridian and the kidney meridian will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. The electric stimulators (SDZ-V electroacupuncture apparatus, Suzhou Medical Appliance Factory, China) will connect bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 0.1-0.3mA will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
41478007|NCT00283413|DEVICE|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
41478008|NCT00283413|DEVICE|Bare metal stent|Any commercially available bare metal stent for coronary indication
41478009|NCT01688726|OTHER|SYSTANE® BALANCE eyedrops|
41478010|NCT01688726|OTHER|Minims® Saline 0.9% eyedrops|
41008353|NCT04694807|BEHAVIORAL|Individually delivered Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 1 hour for the individually delivered format.~Individually delivered CBTgrief will follow the same content and exercises for each session as group-based CBTgrief."
41478011|NCT01616121|OTHER|Usual treatment of patients with developing acute heart failure|
41153027|NCT02814279|PROCEDURE|Tunnel plus connective tissue graft|Periodontal surgery for root coverage by the tunnel flap associated with connective tissue graft.
41478012|NCT01616121|DEVICE|Lung Impedance-Guided Therapy|Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
41478013|NCT00062751|DRUG|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily
40805607|NCT05761639|BEHAVIORAL|Education|1 time a week 30 minutes for each patient individually and in a group with topics: knowledge of the disease, use of medications, warning signs, anxiety management, relaxation techniques, exercises at home, sexual relations and adequate nutrition
41323421|NCT06364683|OTHER|Survey study|The data collection tools to be used in the study will be filled. It does not include any invasive or non-invasive intervention.
41478014|NCT00062751|DRUG|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks
41478015|NCT00062751|DRUG|Letrozole|Letrozole 2.5 mg daily
41478016|NCT01564459|DRUG|MK-6096|MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
41478017|NCT01564459|DRUG|Placebo|Matching compressed tablets, taken once daily at bedtime for 14 days.
41478018|NCT03767855|DRUG|CK-3773274 - Granules in Capsule|CK-3773274 formulated as granules in capsule
41478019|NCT03767855|DRUG|Placebo - Granules in Capsule|Placebo formulated as granules in capsule
41478020|NCT03767855|DRUG|CK-3773274 - Tablets|CK-3773274 formulated as tablets
41478021|NCT03581513|PROCEDURE|Deferred or Immediate Stent Implantation|IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.
41478022|NCT06061783|DRUG|Hypotonic Solution|"Intravenous administration of 5% glucose solution 1,200ml every 8 hours for a total of 3,600ml per day.~If hyperglycemia is present, it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily."
41478023|NCT06061783|DRUG|Water Purified|administration of bottled water through the nasogastric or orogastric tube at a dose of 150 ml/hour for a total of 3,600 ml per day.
41478024|NCT04757181|OTHER|The IBD-AID|Subjects will meet with study personnel for to fill out baseline questionnaires (approximately a 1-hour visit). Subjects will be instructed to make dietary changes based one the IBD-AID guidelines. Dietary instruction will be delivered via individual and group sessions led by trained study personnel. Participants will be expected to learn the skills of dietary change to the IBD-AID and will begin their 8 weeks compliance period followed by endpoint measures. Participants are encouraged to attend 3 cooking classes (1.5 hours duration) in our teaching kitchen.
41478025|NCT03003260|OTHER|CBD chewing gum|
41323422|NCT05200156|DIETARY_SUPPLEMENT|Phosphatidyl Choline|conventional management + phosphatidyl choline tablets
41323423|NCT02417896|DRUG|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
41478026|NCT03003260|OTHER|Placebo|
41478027|NCT06348056|DIETARY_SUPPLEMENT|30 mg Zn Amino Acid daily for 13 days|A 30 mg zinc amino acid supplement is taken p.o. in the fasted state for 13 days.
41478028|NCT06348056|DIETARY_SUPPLEMENT|30 mg Zn Gluconate daily for 13 days|A 30 mg zinc gluconate supplement is taken p.o. in the fasted state for 13 days.
41478029|NCT05081336|DRUG|Statin|Statin +/- ezetimib +/- Alirocumab
40805608|NCT05761639|OTHER|telerehabilitation|"The program will be assisted by virtual technology and consists of physical exercise at home (for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up, muscle strengthening of lower and upper limbs, continuous aerobic training and cool down ) supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation through the Google Meet platform"
40805609|NCT05761639|BEHAVIORAL|follow-up|Telephone calls will be made 3 times a week as a follow-up method to obtain information from each person about their heart rate and perception of effort in relation to the activities carried out where they are encouraged to exercise at home on days without intervention.
40805610|NCT05027958|DRUG|Tuberculin Purified Protein Derivative|PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU
40805611|NCT04210219|DRUG|JNJ-64264681|JNJ-64264681 capsule will be administered orally.
40805612|NCT05610163|DRUG|Capecitabine|Given PO
40805613|NCT05610163|DRUG|5-fluorouracil|Given IV
40805614|NCT05610163|DRUG|Leucovorin calcium|Given IV
40805615|NCT05610163|DRUG|Irinotecan|Given IV
40805616|NCT05610163|DRUG|Oxaliplatin|Given IV
40805617|NCT05610163|RADIATION|Long Course Chemoradiotherapy|Receive LCRT
40805618|NCT05610163|PROCEDURE|Computed Tomography|undergo CT
40805619|NCT05610163|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
41008354|NCT05489094|COMBINATION_PRODUCT|Nutrition Education and Growing Up Milk for 1 - 3 years old|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories. while Intervention product is formulated to deliver macro- and micronutrients as part of the dietary intake for children at 1-3 years old with Iron-C formula
41323424|NCT02401243|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: pre-filled disposable pen~Route of administration: subcutaneous"
40805620|NCT05610163|PROCEDURE|Sigmoidoscopy|undergo sigmoidoscopy
40805621|NCT05610163|PROCEDURE|biopsy|undergo biopsy
40805622|NCT04023370|DEVICE|Treatment of primary iliac artery stenosis and/or occlusive lesions|Stent implantation
41323425|NCT03522493|DEVICE|"Yaalom Katom"|Full face Gas mask
41323426|NCT04890106|DRUG|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
41478030|NCT04387682|DIETARY_SUPPLEMENT|β-glucan|β-glucan, a biological response regulator, derived from yeast has been known for more than 45 years, and has anti-infective and anti-tumor activities. β-glucan is a molecule with a β-1,3-linked D-glucose backbone and β-1,6-linked side chains. Thus far, at least 4 receptors for β-glucan have been discovered in humans, which are surface antigens associated with macrophages or myeloid precursor cells as complement receptor 3 (CR3; CD11b/CD18, Mac-1, αMβ2 integrin) (Vetvicka et al. 1996; Xia et al. 1999), lactosylceramide (Zimmerman et al. 1998), scavenger receptor (Rice et al. 2002) and dectin-1 (Brown et al. 2003; Taylor et al. 2007; Saijo et al. 2007).
41478031|NCT03102593|DRUG|ARGX-113|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
41478032|NCT03102593|OTHER|Placebo|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
41478033|NCT05624255|OTHER|Ophthalmologic consultation|Complete ophthalmologic examination including angio-OCT
41478034|NCT00026871|PROCEDURE|Radiotherapy|
41478035|NCT02606526|BIOLOGICAL|BCG at birth|See previous description
41478036|NCT02606526|BIOLOGICAL|Control arm: Delayed BCG|See previous description
41478037|NCT02055443|OTHER|12-lead holter monitor application|"-- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.~* The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.~* After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan."
41478038|NCT00000651|DRUG|Zidovudine|
41478039|NCT00000651|DRUG|Zalcitabine|
41478040|NCT04631887|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"The Doing What Matters in Times of Stress: An Illustrated Guide is a booklet that is developed by World Health Organization. It is a stress management booklet formed to provide people skills for coping with stress and adversity. The booklet has accompanying audio exercises."
41478041|NCT00604227|OTHER|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
41478042|NCT02172482|DRUG|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
41478043|NCT04531670|BEHAVIORAL|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
41153028|NCT02814279|DRUG|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
41323427|NCT04890106|DRUG|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the second arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
41323428|NCT03496727|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
41323429|NCT03496727|PROCEDURE|Patient controlled analgesia|Patient-controlled analgesia
41478044|NCT04531670|OTHER|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
41478045|NCT04952831|OTHER|diffusion MRI (dMRI)|All participants underwent dMRI scan at baseline
41008355|NCT05489094|BEHAVIORAL|Nutrition Education|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories.
41478046|NCT04269733|DEVICE|Right ventricular pacing|Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block
41478047|NCT06384742|BEHAVIORAL|Shift Worker Intervention for Sleep Health|SWISH, a multicomponent behavioral intervention based on cognitive behavioral therapy for insomnia that is individually administered via telehealth across seven approximately weekly sessions that range in length from 30-60 minutes
41008356|NCT01294995|DIETARY_SUPPLEMENT|Tea-flavor Liquor|30 mL of Tea-flavor Liquor(45% alcohol content)
41008357|NCT01294995|DIETARY_SUPPLEMENT|Guizhou Meijiao Liquor|30 mL of Guizhou Meijiao Liquor (45% alcohol content)
41008358|NCT05314946|PROCEDURE|No feeding tube placed|The experimental arm will forego placement of a feeding tube.
41008359|NCT05314946|PROCEDURE|Placement of a percutaneous feeding tube|The standard arm will have a feeding tube placed (G-tube or GJ-tube by IR; or surgically placed J-tube)
41008360|NCT02163928|OTHER|Food-based intervention; increased fruits and vegetables|4-6 cups of fruits and vegetables daily for 8-weeks
41008361|NCT06193538|DRUG|Recombinant NV-A01 adenovirus injection|Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
41323430|NCT05186909|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
41008362|NCT00384137|DRUG|Tacrolimus|Immunosuppression
41323431|NCT05186909|OTHER|Placebo|Placebo
41008363|NCT04587934|DEVICE|iRes Warmer with ResusView|Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age
41008364|NCT04587934|OTHER|iRes Warmer without ResusView|Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
41008365|NCT04955106|DIAGNOSTIC_TEST|SEM Scanner|They will perform 2 sets of 3 measures (1 on sacrum, 1 on the right heel and 1 on the left heel)for each patients
41153029|NCT02814279|DRUG|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
41153030|NCT03456830|DRUG|ALLN-177|ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
41153031|NCT03456830|DRUG|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
41153032|NCT00050167|DRUG|Paclitaxel|80 mg/m\^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
41153033|NCT00050167|DRUG|Docetaxel|75 mg/m\^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
41323432|NCT00563368|DRUG|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
41323433|NCT00563368|DRUG|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
41323434|NCT00563368|DRUG|topiramate|topiramate 46 mg, po once daily
41323435|NCT00563368|DRUG|topiramate|topiramate 92 mg, po once daily
41323436|NCT00563368|DRUG|phentermine|phentermine 7.5 mg, po once daily
41323437|NCT00563368|DRUG|phentermine|phentermine 15 mg, po once daily
41323438|NCT00563368|DRUG|VI-0521|placebo, po once daily
41323439|NCT00386490|DRUG|larazotide acetate|capsule for oral administration
41323440|NCT05078580|DRUG|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
41323441|NCT05078580|DRUG|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
41323442|NCT05078580|DRUG|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
41478048|NCT00750126|DRUG|Fludarabine, Busulfan, Thymoglobulin|"study :~* acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~* the effectiveness of the protocol on tumor response~* overall survival"
41478049|NCT04542850|DIETARY_SUPPLEMENT|5-ALA-Phosphate + SFC (5-ALA + SFC)|"Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days"
41478050|NCT00682214|DRUG|Cholecalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
41323443|NCT05078580|DRUG|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
41323444|NCT04578015|DRUG|Metronidazole|Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
41323445|NCT04578015|DRUG|Placebo|Participants in this arm will receive placebo
41323446|NCT00648141|DRUG|Celecoxib|200 mg oral capsule once daily for 12 weeks
41153034|NCT00050167|DRUG|Capecitabine|1500 mg/m\^2 by mouth Twice Daily x 2 Weeks
41153035|NCT04435522|DRUG|Maraviroc|Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
41153036|NCT02267746|DRUG|Tazarotene (Fabior™)|
41153037|NCT02267746|DRUG|Tazarotene (Actavis)|
41153038|NCT02267746|DRUG|Vehicle foam|
41153039|NCT03240458|DEVICE|Optical Coherence Tomography|an objective non-invasive method for high-resolution cross-sectional imaging of the retina
41323447|NCT00648141|DRUG|Celecoxib|200 mg oral capsule twice daily for 12 weeks
41323448|NCT00648141|DRUG|Diclofenac|75 mg oral capsule twice daily for 12 weeks
41323449|NCT02120157|DRUG|Cyclophosphamide|Chemotherapy administration
41323450|NCT02120157|RADIATION|TBI|Radiation Therapy
41323451|NCT02120157|DRUG|Busulfan|Chemotherapy Administered
41323452|NCT02120157|OTHER|Unmanipulated Bone Marrow|Bone Marrow Transplant
41323453|NCT02120157|DRUG|Tacrolimus|Immunosuppressive Drug Administered
41323454|NCT02120157|DRUG|Mycophenolate mofetil|Immunosuppressive Drug Administered
41323455|NCT04045574|PROCEDURE|The 1T1T concept versus conventional implant loading protocol|Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
41323456|NCT00091936|DRUG|Didanosine|
41323457|NCT00091936|DRUG|Efavirenz|
41323458|NCT00091936|DRUG|Lamivudine|
41323459|NCT00091936|DRUG|Standard TB treatment|
41323460|NCT01807260|PROCEDURE|Shock wave lithotripsy|All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
41323461|NCT02532426|PROCEDURE|Muscle biopsy|The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
41323462|NCT05573529|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
41323463|NCT05573529|DEVICE|intraocular lens implantation|intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
41323464|NCT02436044|PROCEDURE|HAIC using oxaliplatin plus fluorouracil/leucovorin|Hepatic arterial infusion chemotherapy using oxaliplatin plus fluorouracil/leucovorin
41323465|NCT02436044|DRUG|Oxaliplatin|Oxaliplatin, 130mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
41323466|NCT02436044|DRUG|Fluorouracil|Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
41323467|NCT02436044|DRUG|Leucovorin|Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
41323468|NCT00019227|DRUG|pentetic acid calcium|
41323469|NCT00019227|RADIATION|yttrium Y 90 daclizumab|
41323470|NCT02833519|BEHAVIORAL|group exercise|"1. Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.~   The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).~   The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.~2. The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.~3. A weekly supportive email."
41323471|NCT06205394|OTHER|Non-Interventional Study|Non-interventional study
41323472|NCT04115618|RADIATION|Simultaneous integrated boost intensity-modulated chemoradiotherapy|Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
41323473|NCT05460572|DIETARY_SUPPLEMENT|Peripheral Parental Nutrition|Peripheral parenteral nutrition (PPN) through an intravenous (iv) line
41323474|NCT03119818|DEVICE|Phosphorus (31P) magnetic resonance spectroscopy|Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.
41323475|NCT03119818|OTHER|Hemodialysis|Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
41153040|NCT03229525|BEHAVIORAL|Trauma Related Expressive Writing|Participants will write about the traumatic event over the course of six sessions.
41153041|NCT03229525|BEHAVIORAL|Neutral Expressive Writing|Participants will write about a neutral event over the course of six sessions.
41153042|NCT01961804|DRUG|Reversion|Administration of prothrombin complex concentrates: KANOKAD before CT Scan
41153043|NCT00464932|DRUG|Vasoactive Intestinal Peptide (VIP)|
41153044|NCT06074055|OTHER|FET Protocol|Participants are randomized to either another programmed FET Protocol vs. a modified natural FET protocol
41008366|NCT02694341|PROCEDURE|Abdominal traction stitch|Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.
41008367|NCT02694341|DEVICE|Bakri Balloon|uterine compression balloon
41478051|NCT00682214|DRUG|Lactose placebo|Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
41478052|NCT01283815|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).
41323476|NCT05079763|OTHER|Bacterial cellulose-monolaurin hydrogel|Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
41323477|NCT05079763|OTHER|Placebo cream|Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
41323478|NCT05355428|OTHER|offering of breast milk feed 3 hours prior to p lanned surgery start|parents will be asked to offer a breast milk feed (from breast or expressed in bottle) at a given time 3 hours prior to planned induction time
41323479|NCT03686865|DEVICE|dental implants|extraction sockets regenerated with xenograft
41478053|NCT01283815|PROCEDURE|Conservative management with percutaneous drainage|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
41478054|NCT03936049|DRUG|Liraglutide|Liraglutide dispensing claim is used as the exposure group
41478055|NCT03936049|DRUG|DPP-4 inhibitor|DPP-4 inhibitor dispensing claim is used as the reference group
41008368|NCT04618718|DEVICE|cerebral embolic protection during TAVR|The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.
41008369|NCT04314193|DRUG|Methotrexate|Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
41008370|NCT04314193|DRUG|Prednisolone|Oral prednisolone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
41008371|NCT06103006|OTHER|Telerehabilitation|The structured telerehabilitation program focused on 4 specific objectives: breathing, stretching, posture, and stability. The duration was between 20-30 minutes. Exercises involving the major muscle groups (upper, lower extremity, and trunk muscle groups) were applied by the physiotherapists. Strengthening and stretching sets and repetitions were started with 1 set of 8-15 reps (progress to \>1 set).
41008372|NCT04581603|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I is conducted weekly for eight sessions during which the subjects meet individual with the study clinician for 45 minutes on the first session and for 30 minutes for sessions 2-8. Session 1 serves as an orientation and the onset of Sleep Restriction Therapy. Sessions 2 \& 3 deliver the three main components that include, Sleep Restriction Therapy, Stimulus control, and Sleep Hygiene. All the sessions excluding the last two sessions are dedicated to the titration of total sleep time and to ensure patient adherence. The fifth session is used to deliver a specific form of cognitive therapy. The final session is used to engage the patient in a relapse-prevention didactic (i.e., to review how insomnia becomes chronic and strategies that abort an extended episode of insomnia). The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
41008373|NCT04581603|BEHAVIORAL|Sleep Hygiene Education|This non-active control arm of behavioral sleep intervention consists of psychoeducation on sleep hygiene, sleep-related disturbances, and the effects of stress on sleep that will be delivered weekly for 8 weeks, for a time duration that is identical to the CBT-I sessions. The effect of stress on sleep is a commonly used control condition in insomnia clinical trials. SHE is preferred to a monitor-only condition as it will control for contact with the therapist and elapsed time during sessions. The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
41323480|NCT02079558|DRUG|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
41323481|NCT02079558|DRUG|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
41323482|NCT01412060|DRUG|Placebo|Placebo was supplied in capsules.
41323483|NCT01412060|DRUG|Cariprazine|Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
41478056|NCT04026373|BEHAVIORAL|modified Prolonged Exposure|
41478057|NCT04026373|BEHAVIORAL|Treatment as usual|May include consult to health psychology and any follow-up deemed appropriate
41478058|NCT01580657|BEHAVIORAL|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
41323484|NCT00304915|BEHAVIORAL|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
41153045|NCT03253783|BEHAVIORAL|Pulse|
40805625|NCT06308341|OTHER|Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy|Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min
41323485|NCT02679807|BIOLOGICAL|Bifidobacterium animalis subsp. lactis Bl-04|
41323486|NCT02679807|OTHER|sucrose|
41323487|NCT01925651|RADIATION|No Bolus|no bolus use
41323488|NCT01925651|RADIATION|Alternate Bolus|0.5cm bolus use in alternate days
41323489|NCT01925651|RADIATION|Continuous Bolus|0.5 cm bolus use in continuous days
41323490|NCT02679196|DRUG|KA2237|PI3 Kinase p110β/δ inhibitor
41323491|NCT02881710|OTHER|contrast product used to assess biomarkers variations|
41323492|NCT00503360|DRUG|SAD448|
41323493|NCT05589480|OTHER|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
41478059|NCT01580657|BEHAVIORAL|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
41478060|NCT01580657|BEHAVIORAL|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
41323494|NCT01419015|DEVICE|SAPIEN XT NovaFlex delivery system|Transcatheter aortic valve implantation via transfemoral approach.
40805626|NCT06308341|OTHER|Virtual Reality + Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with cycling and walking for 10-15 minutes.~VR techniques for 10-15 minutes The first eight weeks focus on simple activities to enhance balance and motor function, such as tennis, boxing, bowling, kicking, soccer, table tilt, penguin slide, tilt city, single-leg extension, and torso twist. Exercise difficulty is adjusted based on performance, gradually progressing from easier to more challenging activities."
40805627|NCT06308341|OTHER|Motor Imagery +Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with Cycling and walking for 10-15 minutes MI techniques for 10-15 minutes The motor imagery program me will be performed in three steps; STEP I: The patients will watch the videos recorded by the examiner. STEP II: The patients will be asked to close their eyes, focus, and imagine how they are doing the task they had previously observed ten times.~Step III: The patient will be asked to attempt the activity with his affected limbs according to the verbal command of the examiner Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min."
41008374|NCT05483244|OTHER|discontinuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator (spontaneous breathing trial with heat moist exchanger).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
41153046|NCT03079284|OTHER|Holding during cooling|An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
41153047|NCT01039558|DRUG|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
41323496|NCT05747755|BEHAVIORAL|ADEPT Program|Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality and safety personnel in change management, pilot testing and refinement of Safety I and Safety II interventions to reduce systemic causes of diagnostic errors and to increase resilience, thus promoting diagnostic excellence.
41323497|NCT04599049|OTHER|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
41478061|NCT01580657|BEHAVIORAL|Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
41478062|NCT01580657|BEHAVIORAL|General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
41478063|NCT01580657|BEHAVIORAL|No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
41478064|NCT02826941|OTHER|hypothermia|Systemic hypothermia by Cincinnati Sub-Zero Blanketrol II®, servo-controlled to 33.0 degrees C rectal temperature, started within 6hours of hypoxic ischemic birth, and continued for 48hours
41478065|NCT02826941|OTHER|normothermia|Rectal temperatures in neonates receiving normothermia were maintained at 37.0+or -0.5 degrees C, using overhead warmer or Cincinnati Sub-Zero Blanketrol II®, servo-controlled to rectal temperature of 37.0 degrees C.
41478066|NCT03720574|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks
41478067|NCT03720574|DRUG|Matching Placebo BID|Matching Placebo tablet each morning and evening for a duration of 48 weeks
41478068|NCT01090375|OTHER|Exercise|
41478069|NCT01090375|OTHER|Non Exercise|
40805630|NCT04772079|DRUG|Deucravacitinib|Specified dose on specified days
40805631|NCT04772079|OTHER|Placebo matching deucravacitinib|Specified dose on specified days
41153048|NCT01039558|DRUG|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
41153049|NCT01039558|DRUG|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
41153050|NCT02135588|DRUG|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
41153051|NCT02579941|PROCEDURE|Blood sampling (pregnant)|"5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
40805636|NCT06524635|DRUG|Lutikizumab|Subcutaneous (SC) Injection
40805637|NCT02402244|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection
40805638|NCT02402244|OTHER|Medical Chart Review|Undergo medical data review
41153052|NCT02579941|PROCEDURE|Blood sampling (non pregnant)|"5.4 ml of venous blood will be taken.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
40805640|NCT04266301|DRUG|Sabatolimab|A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).
40805641|NCT04266301|DRUG|Azacitidine|A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
41008375|NCT05483244|OTHER|continuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support (spontaneous breathing trial trial under continuous positive airway pressure condition).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
41323498|NCT02713789|DRUG|hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)|
41323499|NCT02713789|DRUG|Placebo (PBS-20% sucrose)|
41323500|NCT00477555|DEVICE|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
41323501|NCT02680405|PROCEDURE|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
40805642|NCT04266301|DRUG|Placebo|A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
40805643|NCT06416878|DEVICE|Brief ES at the time of decompression for cauda equina syndrome|In patients operated for acute cauda equina syndrome with autonomic dysfunction epidural ES will be delivered utilising SCS trial electrode. It will be delivered for 10 minutes caudal to compression site and for 60 mins cranial to compression site while the wound is closed and patient recovered.
40805644|NCT06416878|DEVICE|Brief ES to facilitate mcturition/removal of catheter|In patients who do not fully recover function following decompression, brief ES will be applied before second micturition attempt.
41153053|NCT01647802|DEVICE|"Standing attempts with the Vertic'Easy Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
41323502|NCT02680405|PROCEDURE|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
41323503|NCT02680405|PROCEDURE|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
41323504|NCT02307539|PROCEDURE|Psychosocial Assessment and Care|Undergo PCPI
41323505|NCT02307539|OTHER|Palliative Therapy|Undergo PCPI
41323506|NCT02307539|OTHER|Quality-of-Life Assessment|Undergo QOL assessment
40805647|NCT06113471|DRUG|Povorcitinib|Oral, Tablet
40805648|NCT06113471|DRUG|Placebo|Oral, Tablet
41323507|NCT02307539|OTHER|Questionnaire Administration|Undergo questionnaire administration
41323508|NCT04101435|BIOLOGICAL|AdimFlu-S (QIS)|This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.
40805653|NCT04557956|PROCEDURE|Biopsy|Undergo tumor biopsy
40805654|NCT04557956|PROCEDURE|Computed Tomography|Undergo CT scan
40805655|NCT04557956|DRUG|Dabrafenib Mesylate|Given PO
40805656|NCT04557956|PROCEDURE|Echocardiogram Recording|Undergo ECHO
40805657|NCT04557956|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40805658|NCT04557956|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40805659|NCT04557956|DRUG|Tazemetostat Hydrobromide|Given PO
40805660|NCT04557956|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
40805661|NCT06113445|DRUG|Povorcitinib|Oral, Tablet
40805662|NCT06113445|DRUG|Placebo|Oral, Tablet
40805664|NCT05583227|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
40805665|NCT05583227|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
40805666|NCT05583227|OTHER|Placebo|Placebo subcutaneous injection
40805667|NCT05734105|DRUG|Ripretinib|50 mg tablets
40805668|NCT05734105|DRUG|Sunitinib|12.5 mg tablets
40805669|NCT05836324|DRUG|INCA33890|INCA33890 will be administered at protocol defined dose.
40805670|NCT03451292|DRUG|Albutein 20% Injectable Solution|Within 96 hours after discharge and following randomization, subjects will receive the first Albutein 20% infusion at the dose of 1.5 g/kg body weight (maximum 100 grams per subject). Thereafter, subjects will receive Albutein 20% infusions at the dose of 1.5 g/kg body weight (maximum 100 grams per subject) every 10 ± 2 days for the rest of the study (up to a maximum of 12 months). Subjects in this treatment group will also receive SMT.
40805671|NCT03451292|OTHER|Standard medical treatment|Subjects will receive SMT according to published guidelines for the management of decompensated cirrhosis.
41008376|NCT05588596|BEHAVIORAL|Trauma Resiliency Mindfulness-Informed Intervention|The total duration of the intervention was once a week for eight weeks. The aim of the intervention was to teach patients a range of trauma recovery mindfulness skills
41008377|NCT02171598|DRUG|Clopidogrel|
40805672|NCT02617563|DEVICE|Minimally invasive lumbar fusion|Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
40805673|NCT04551963|DRUG|Zanubrutinib|Capsules administered at a dose and frequency as specified in the treatment arm
40805674|NCT04551963|DRUG|Fluconazole|Capsules administered at a dose and frequency as specified in the treatment arm
40805675|NCT04551963|DRUG|Diltiazem|Capsules administered at a dose and frequency as specified in the treatment arm
40805676|NCT04551963|DRUG|Voriconazole|Capsules administered at a dose and frequency as specified in the treatment arm
40805677|NCT04551963|DRUG|Clarithromycin|Capsules administered at a dose and frequency as specified in the treatment arm
41008378|NCT02171598|DRUG|Dabigatran high dose|
41008379|NCT02171598|DRUG|Dabigatran low dose|
41008380|NCT05957133|PROCEDURE|Multicomponent exercise without action observation.|Different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
41008381|NCT05957133|PROCEDURE|Multicomponent exercise associated with action observation|Different exercise modalities are integrated: aerobic, mobility, strength, balance and coordination exercises carried out at all times by the physiotherapist and observed by the participants.
41008382|NCT04194775|DRUG|Nofazinlimab (CS1003)+Lenvatinib|Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily
40805678|NCT03379259|DRUG|BGB-A333|Anti-PD-L1 antibody
40805679|NCT03379259|DRUG|BGB-A317|Anti-PD-1 antibodies
40805680|NCT05055011|OTHER|Electronic Health Record Review|Review of medical records
40805681|NCT05055011|OTHER|Survey Administration|Complete survey
40805682|NCT06312410|OTHER|VIA Family 2.0|Multidisciplinary team based preventive intervention. For details, please see arm/group description.
40805683|NCT06417814|DRUG|Dato-DXd|Dato-DXd will be administered as IV infusion.
40805684|NCT06417814|DRUG|Osimertinib|Osimertinib will be administered orally.
40805685|NCT06417814|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion.
40805686|NCT06417814|DRUG|Carboplatin|Carboplatin will be administered as IV infusion.
40805687|NCT06417814|DRUG|Cisplatin|Cisplatin will be administered as IV infusion.
40805688|NCT03332173|DRUG|Zanubrutinib|Oral administration using 80 mg capsules
41153054|NCT01647802|DEVICE|"Standing attempts with the Turner Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
41153055|NCT01647802|DEVICE|"Standing attempts with the Tina device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
41153056|NCT02395224|OTHER|cancer treatment and follow-up according to current regional and national guidelines|
41008383|NCT04194775|DRUG|Nofazinlimab (CS1003) Placebo+Lenvatinib|Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily
41008384|NCT01368575|PROCEDURE|CABG|CABG
41008385|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
41323509|NCT01524237|DRUG|LY2979165|Capsules administered orally
41478070|NCT06188130|OTHER|active rTMS|Participants recevied 20 Hz high frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed dominant side abductor pollicis brevis (APB).The patient received robotic therapy for lower extremity just after each active TMS sessions.
40805695|NCT06191874|OTHER|Standard-of-care (SOC) surgery plan|Use of SOC clinical planning tools to prepare for DBS (deep brain stimulation) surgery
40805696|NCT06191874|OTHER|HoloDBS hypothetical surgery plan|Use of next generation visualization tools and surgical targeting models to hypothetically prepare for DBS (deep brain stimulation) surgery
40805697|NCT04299503|DRUG|Crisaborole Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
40805698|NCT04299503|DRUG|Placebo Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
41153057|NCT03977337|PROCEDURE|Major emergency abdominal surgery|Major emergency gastrointestinal surgery performed within 72 hours of an acute admission or an acute reoperation.
40805700|NCT05115110|DRUG|RO7204239|"RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen.~RO7204239 will be investigated at low- and high-dose in Part 1."
40805701|NCT05115110|DRUG|Placebo|Placebo will be administered Q4W by SC injection into the abdomen.
40805702|NCT05115110|DRUG|Risdiplam|Risdiplam will be administered orally once daily (QD) for the duration of the study.
41008386|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
41008387|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
41008388|NCT01368575|PROCEDURE|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
41008389|NCT05024565|BEHAVIORAL|prolonged intravenous infusion of β-lactams Antibiotics|(1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
41008390|NCT05765968|PROCEDURE|Double Stimulation Protocol|cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle
41008391|NCT05765968|PROCEDURE|Antagonist Stimulation Protocol|cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol
41008392|NCT01015248|DRUG|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
41153058|NCT03172897|DRUG|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.
41323510|NCT01524237|DRUG|LY2140023|Tablets administered orally
41323511|NCT01524237|OTHER|Placebo|Administered orally
41323512|NCT01524237|OTHER|Ketamine|Administered intravenously (IV)
41323513|NCT02340468|DEVICE|diffuse optical spectroscopy|diffuse optical spectroscopy
41323514|NCT02790333|PROCEDURE|traditional reloads|Blue cartridge with3.0mm height staple was used for pancreatic stump
41323515|NCT02790333|PROCEDURE|Tri-Staple reloads|Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump
41323516|NCT00169117|BEHAVIORAL|Songs/posters aimed at behaviour change|This was a behavioural intervention, using songs and posters composed/designed by community members which aimed at behaviour change to increase repair and maintenance of mosquito nets
40805703|NCT06430463|DIAGNOSTIC_TEST|pure tone audiometry levels|The patient will be examined by ENT physician on the morning of the operation, otoscopic examination will be performed, pure tone audiometry, speech audiometry and tympanometric examination will be performed and recorded.The same tests will be performed at the next day after the surgery but before the discharge and also when he/she applies for the first week check-up.
41153059|NCT03172897|DRUG|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
41153060|NCT01578278|DRUG|Bepotastine besilate formulation|Nasal Spray
40805706|NCT04907825|DRUG|Oral anticoagulant|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with ACC/AHA/HRS Guidelines
41323517|NCT04631068|PROCEDURE|Cataract surgery|Small incision cataract surgery with implantation of an intraocular lens
41323518|NCT05124977|DRUG|Antimicrobial Stewardship|Antimicrobial stewardship based on daily clinical assessment of clinical cure. Discontinuation of appropriate antibiotic therapy antibiotics if criteria of clinical cure of confirmed pneumonia are met. Intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
41323519|NCT05124977|DRUG|Standard management|Standard management: duration of appropriate antibiotic for confirmed pneumonia fixed for 7 days according to guidelines. In the control group, intensivists will perform clinical assessment daily, but the antibiotic will not be discontinued until 7 days whatever the clinical cure.
41323520|NCT05256082|DIAGNOSTIC_TEST|six-minutes-walking test|Patients conducting a six-minutes-walking test
41323521|NCT04437030|DEVICE|MSOT Acuity Echo device|The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.
41323522|NCT01279304|RADIATION|radiation - no radiation see intervention description|after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
40805707|NCT04791215|OTHER|Observational|All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
41008393|NCT02510911|DRUG|Caffeine (100 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
41323523|NCT01279304|RADIATION|radiation: see intervention description|after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
40805708|NCT03606967|PROCEDURE|Biopsy|Undergo tumor biopsy
40805709|NCT03606967|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
40805710|NCT03606967|DRUG|Carboplatin|Given IV
40805711|NCT03606967|PROCEDURE|Computed Tomography|Undergo CT scan
40805712|NCT03606967|BIOLOGICAL|Durvalumab|Given IV
40805713|NCT03606967|DRUG|Gemcitabine Hydrochloride|Given IV
40805714|NCT03606967|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41153061|NCT01578278|DRUG|Fluticasone propionate|Nasal Spray
41153062|NCT01578278|DRUG|Bepotastine besilate-fluticasone propionate|Nasal Spray
41153063|NCT01578278|DRUG|Placebo Comparator|Nasal Spray
41478071|NCT06188130|OTHER|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for lower extremity just after each sham TMS sessions.
41153064|NCT06069596|COMBINATION_PRODUCT|Natalis Obstetric Lubrican Gel|The obstetric lubricant gel was applied to the vaginal canal with a special applicator at the beginning of the active phase of the labor. The gel used in the study was highly viscose and isotonic with a slight acid pH of 6.0 - 6.7 and contained hydroxyethylcellulose, propylene glycol, glycerin. The gel box contained a sterile syringe (15 ml) and a flexible applicator.
40805715|NCT03606967|DRUG|Nab-paclitaxel|Given IV
41008394|NCT02510911|DRUG|Caffeine (200 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
41323524|NCT01279304|RADIATION|radiation: see intervention description|after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
41478072|NCT06188130|OTHER|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the Cz central (International 10/20 Electroencephalogram System) area, corresponding to the location of the dominant hemisphere lower extremity motor cortex and cathodal to the contralateral supraorbital region. The patient received robotic therapy for lower extremity just after each active tDCS sessions.
41153065|NCT00669292|BIOLOGICAL|URLC10-177, TTK-567, CpG-7909|peptide, peptide, TLR-9 agonist
41153066|NCT00109161|DRUG|Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)|
41478073|NCT06188130|OTHER|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for lower extremity just after each sham tDCS sessions
41478074|NCT04515537|DIETARY_SUPPLEMENT|Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),|Patient use 2 capsules 3 time a day by oral.
41478075|NCT04515537|PROCEDURE|Infiltrtion of SVf|After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF
41153067|NCT06454799|BEHAVIORAL|Akupressur|The application will be carried out on 3 body points. These; Pericardium 6, Yintang and Shen men points. Acupressure will be applied to each of these acupressure points for 1 minute.
41153068|NCT01154699|DEVICE|Bilevel PAP (4 weeks)|Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
41153069|NCT01154699|OTHER|Usual Care (4 weeks)|Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.
41153070|NCT01154699|OTHER|Washout Period (4 weeks)|Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
40805716|NCT03606967|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Given SC
40805717|NCT03606967|DRUG|Poly ICLC|Given SC
41323525|NCT02687750|DEVICE|MRI|Investigational device is a dual tuned (fluorine/proton) MRI surface coil designed and produced by Clinical MR solutions
41323526|NCT00220584|DRUG|donepezil|donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
40805718|NCT03606967|BIOLOGICAL|Sacituzumab Govitecan|Given IV
40805719|NCT03606967|BIOLOGICAL|Tremelimumab|Given IV
40805720|NCT05755620|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.
40805721|NCT05755620|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
40805722|NCT05755620|BIOLOGICAL|VRC-FLUNPF099-00-VP (H1ssF_3928)|The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 \[PEG lipid\]).
41153071|NCT03759132|PROCEDURE|Transcranial direct current stimulation|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
41323527|NCT03634904|DRUG|Drug bood sampling|"Total: 6 per patient~* after the first administration of ceftazidime (loading dose): sampling #1: at trough before 1st dialysis; sampling #2: after the end of the dialysis session;~* after the second administration of ceftazidime (maintenance dose): sampling #3: at trough before 2d dialysis session;~* after the third administration of ceftazidime (maintenance dose): sampling #4: at trough before 3d dialysis session;~* after the fourth third administration of ceftazidime (maintenance dose): sampling #5: at trough before 4th dialysis session; sampling #6: after the end of the dialysis session"
41323528|NCT02679443|DIETARY_SUPPLEMENT|Folate and B12|Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
41153072|NCT05888402|DRUG|Toripalimab|Two cycles of induction Toripalimab (240mg every 3 weeks) plus platinum-based doublet chemotherapy as induction chemoimmunotherapy.
41153073|NCT05888402|RADIATION|Concurrent chemoradiation therapy and consolidation immunotherapy|Thoracic radiation therapy (54-66Gy/25-33F/5-7week), concurrently with platinum-based doublet chemotherapy, followed by consolidation Toripalimab (240mg every 3 weeks) as consolidation immunotherapy for up to 12 months.
41153074|NCT00748358|DRUG|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
40805727|NCT02152982|OTHER|Laboratory Biomarker Analysis|Correlative studies
41008395|NCT02510911|DRUG|corn starch (250 mg approx.)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
41008396|NCT02510911|OTHER|Radiopaque marker|"On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%)."
41323529|NCT02195934|OTHER|Standard (blonde) orange juice|Consumption of 500ml standard (blonde) orange juice daily for 28 days
41323530|NCT02195934|OTHER|Blood orange juice|Consumption of 500ml blood orange juice daily for 28 days
41323531|NCT05895227|PROCEDURE|Oocyte retrieval|
41323532|NCT03341923|DEVICE|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily disposable wear
41323533|NCT03341923|DEVICE|Etafilcon A multifocal contact lenses|Hydrogel multifocal contact lenses for daily disposable wear
41323534|NCT05634096|DIAGNOSTIC_TEST|Oximetry|Children underwent oximetry simultaneously with video-polygraphy or video-polysomnography in routine clinical practice. The data are retrospectively collected from the patient's recording.
41153075|NCT05626452|BEHAVIORAL|PrEP Education|Education for participants regarding PrEP
41323535|NCT00855257|DRUG|Acid Nicotinique|
41323536|NCT00855257|DRUG|Placebo|
40805728|NCT02152982|OTHER|Placebo Administration|Given PO
40805729|NCT02152982|OTHER|Quality-of-Life Assessment|Ancillary studies
40805730|NCT02152982|DRUG|Temozolomide|Given PO
40805731|NCT02152982|DRUG|Veliparib|Given PO
41153076|NCT05626452|BEHAVIORAL|Provider training|Training for medical providers at CHCs about how to identify participants eligible for PrEP, how to perform behavioral risk assessment and discussion of PrEP, and how to prescribe PrEP and monitor PrEP
41153077|NCT05626452|OTHER|EMR Optimization|EMR modifications to enhance PrEP care continuum outcomes including HIV risk assessment, identification of participants eligible for PrEP, provision of PrEP education, clinical decision support tools for prescription of PrEP, and tracking of PrEP care continuum outcomes using an electronic population health management tool
41153078|NCT05626452|OTHER|PrEP Navigation|Use of CHC staff members to assist participants with obtaining PrEP and attending PrEP care appointments
41153079|NCT05626452|OTHER|Provider Audit and Feedback|Audit of provider rates of PrEP prescription and persistence among participants and regular provision of feedback to providers with their performance on these PrEP measures
40805739|NCT04452331|OTHER|Open Access Audio|Patient obtains secure access to an audio recording of the medical encounter post-visit that is accessible from any internet enabled device.
40805740|NCT04452331|OTHER|No Access, Patient and Provider Aware of Recording|Patient does not obtain access to audio recording but both patient and provider are aware visit is being recorded.
40805741|NCT04452331|OTHER|No Access, Provider Unaware of Recording|Patient does not obtain access to audio recording and provider is unaware visit is being recorded.
41153080|NCT00443755|DRUG|metformin|To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
41153081|NCT00443755|DRUG|pioglitazone|To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
41153082|NCT00443755|DRUG|Placebo|Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
40805745|NCT02975999|DRUG|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
41323537|NCT06048367|DRUG|CNSI-Fe(II) 30 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
41323538|NCT06048367|DRUG|CNSI-Fe(II) 60 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
40805746|NCT02975999|DRUG|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
40805747|NCT00748618|DIETARY_SUPPLEMENT|Standard vitamin D3 treatment|10,000 I.U./wk of vitamin D3 orally for 6 months
40805748|NCT00748618|DIETARY_SUPPLEMENT|High dose vitamin D3 treatment|50,000 I.U./wk of vitamin D3 orally for 6 months
41153083|NCT05696392|DRUG|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
41478076|NCT05686148|OTHER|Vibration|The device used for vibration application is produced to control pain and direct attention by providing 6000/min vibration. According to Melzack and Wall's Gate Control Theory, the application of local vibration reduces perceived pain by stimulating nerve fibers. Therefore, it should be ensured that the device is in full contact with the skin. The device can be used again by wiping with 70% alcohol. The device is placed 3 cm above the area to be injected. Vibration is applied to the area for 5 minutes before the procedure.
41478077|NCT03333499|DRUG|YanXinShi placebo pills|participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure
41153084|NCT02558322|OTHER|Primary medical care|All study participants receive primary care as usual in the respective region
41153085|NCT03012321|DRUG|Olaparib|
41153086|NCT03012321|DRUG|Abiraterone Acetate|
41153087|NCT03012321|DRUG|Prednisone|
41153088|NCT03453489|OTHER|Carbon C 11 Alpha-methyltryptophan|Undergo AMT-PET
41153089|NCT03453489|OTHER|Laboratory Biomarker Analysis|Correlative studies
41478078|NCT03333499|DRUG|YanXinShi pills|participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure
41478079|NCT03333499|DRUG|Trimetazidine pills|participants will take 20mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
40805761|NCT06453213|DRUG|Cenobamate|"The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the subject does not experience a seizure in the 100 mg/day Maintenance Phase, he/she can enter the Optional Extension Period (100 mg/day).~The 200 mg/day treatment period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. If the subject does not experience a seizure during the 200 mg/day Maintenance Phase, he/she can enter the 26 week Optional Extension Period (200 mg/day)."
40805762|NCT06385795|DRUG|NOE-115|NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.
40805763|NCT02097706|DRUG|NMDA receptor antagonist (active drug)|
40805764|NCT02097706|OTHER|Lactose packed capsule (inert/inactive arm)|
40805765|NCT05538065|OTHER|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
40805766|NCT05538065|OTHER|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
40805767|NCT05538065|OTHER|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
41153090|NCT03453489|PROCEDURE|Positron Emission Tomography|Undergo AMT-PET
40805769|NCT05128786|BIOLOGICAL|CCT301-38|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT301-38. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single or multiple dose of CCT301-38 via intravenous injection.
41153091|NCT03453489|DRUG|Telotristat Etiprate|Given PO
41153092|NCT05219409|DRUG|Sitagliptin|The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2)
41153093|NCT05219409|DEVICE|Professional CGM|The sensor records the patient's glucose readings every 15 minutes for up to 14 days.
41323539|NCT06048367|DRUG|CNSI-Fe(II) 90 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
41323540|NCT00717535|OTHER|cryopreservation|
41478080|NCT03333499|DRUG|YanXinShi and Trimetazidine pills|participants will take 1800 mg YXS and 20 mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
41153094|NCT06585514|DRUG|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
41153095|NCT01623180|DEVICE|Biofreedom™ Drug Coated Stent (DCS)|Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT
41153096|NCT01623180|DEVICE|Gazelle™ Bare Metal Coronary Stent (BMS)|Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
41153097|NCT02351388|DEVICE|Transcranial Direct Current Stimulation|
41153098|NCT02351388|OTHER|Sham Stimulation|
41478081|NCT00304707|DRUG|Bupropion|300 mg QD
40805778|NCT06395870|BIOLOGICAL|LUCAR-G39D cells product|Prior to infusion of the LUCAR-G39D, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
41153099|NCT04908488|DEVICE|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
41153100|NCT04908488|DEVICE|Etafilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
40805781|NCT05620836|DRUG|Povorcitinib|Oral, Tablet
40805782|NCT05620836|DRUG|Placebo|Oral, Tablet
40805783|NCT06252870|DRUG|Methotrexate|15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
40805784|NCT06252870|DRUG|Post-Transplant Cyclophosphamide|50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
40805785|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
40805786|NCT06252870|DRUG|Cycophosphamide|Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)
40805787|NCT06252870|DRUG|Anti-Thymoglobulin|Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
40805788|NCT06252870|RADIATION|total body irradiation|2 grays on Day-1 before graft (=Day0)
40805789|NCT06252870|OTHER|hematopoietic stem cells|High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
40805790|NCT06252870|OTHER|Graft nuclear cells|Graft nuclear cells CD3+ cells if needed after transplantation
40805791|NCT06252870|OTHER|Donor Lymphocytes Injection|DLI with CD3+ if relapse after transplantation or in prevention of relapse
40805792|NCT06252870|DRUG|Clofarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
41008397|NCT01701258|DRUG|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
41478082|NCT00304707|DRUG|placebo|placebo
41478083|NCT04263428|BEHAVIORAL|Irregular sleep|Experimental-induced sleep variability
41478084|NCT06231394|OTHER|multimodal pelvic floor rehabilitation|A multimodal pelvic floor rehabilitation program will be performed on all children for 10 weeks, two days a week and approximately 45 minutes. A multimodal pelvic floor rehabilitation will include education, bladder and bowel training, manual techniques, exercise training (diaphragmatic breathing exercise, pelvic floor muscle training, trunk stabilization exercises based on developmental kinesiology) and a home program. The home program will be given on other days of the week.
40805793|NCT06252870|DRUG|Thiotepa|Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)
40805794|NCT06252870|DRUG|Busulfan|Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)
41008398|NCT01701258|DRUG|Placebo|single-dose placebo capsule during the fMRI session only
41153101|NCT02459132|BEHAVIORAL|High-intensity aerobic interval exercise|See arm/group description
41323541|NCT00717535|OTHER|questionnaire administration|
41323542|NCT00717535|OTHER|study of socioeconomic and demographic variables|
41478085|NCT04428099|BEHAVIORAL|Lifestyle change promotion program|The intervention consists of 8 group sessions centered on healthy physical activity, healthy diet, social life, Good Sleep Hygiene, healthy sun exposure, nature contact, how to stop ruminating, review and maintenance tips.
41478086|NCT04428099|BEHAVIORAL|Mindfullness based cognitive program|The intervention consists of 8 group sessions with a mindfulness-based cognitive program
40805795|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
41153102|NCT00919061|DRUG|Gemcitabine|Gemcitabine: 800 mg/m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
41153103|NCT00919061|DRUG|Cisplatin|20 mg /m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
41153104|NCT00919061|DRUG|Sorafenib|400 mg PO once a day continuously.
40805799|NCT06238895|DRUG|Tardyferon|Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)
40805800|NCT05507567|DRUG|Neumifil|Liquid for intranasal spray administration
41323543|NCT04090047|DRUG|PF-06700841|PF-06700841 oral tablets in 5mg and 25mg provided for a 30mg dose
41323544|NCT04090047|DRUG|Itraconazole|200 mg oral solution administered as 20 milliliters(mL) (10 mg/mL)
40805801|NCT05507567|DRUG|Placebo|Liquid for intranasal spray administration
40805802|NCT06344104|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~* 1 mg per tablet for 1mg baxdrostat Arm~* 2 mg per tablet for 2mg baxdrostat Arm"
40805803|NCT06344104|DRUG|Placebo|Placebo tablet administered orally, once daily (QD).
40805804|NCT04643873|OTHER|physical activity counseiling +pilates exercise group|It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
40805805|NCT04643873|BEHAVIORAL|physical activity counseiling group|During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
40805806|NCT03842189|DRUG|M281|Participants will receive once weekly intravenous (IV) infusions of M281
40805807|NCT06019039|DRUG|Normal Saline Flush|Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.
40805808|NCT06019039|DEVICE|Doppler|"All color flow Doppler images will be performed with a Phillips CX50 ultrasound machine using a 5.0 MHz a low frequency curvilinear US probe. A two-dimensional transverse interspinous view was used to visualize the posterior complex (ligamentum flavum, epidural space and dura). After loss of resistance to normal saline, the color flow Doppler function will be turned on to examine flow through the epidural needle tip.~The ultrasound probe was positioned in the transverse axis slightly below the epidural needle but still in the interspinous space ."
41008399|NCT01073488|BEHAVIORAL|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
41008400|NCT00001996|DRUG|Atovaquone|
41008401|NCT00001996|DRUG|Pentamidine isethionate|
41008402|NCT02561507|BEHAVIORAL|Survey|
40805809|NCT06303375|OTHER|Kinesio taping|"Kinesiotaping using inhibition technique in tight muscles and facilitation technique in weak muscles for LCS. Treatment sessions 3 days per week for almost 04 weeks.~10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
40805810|NCT06303375|OTHER|Conventional physical therapy|"10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
40805811|NCT06200597|DRUG|LAD603|LAD603 SC injection.
40805812|NCT06200597|OTHER|Placebo|Matching placebo SC injection.
40805813|NCT05311176|BIOLOGICAL|IMU-131|IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.
40805814|NCT05311176|DRUG|Ramucirumab plus Paclitaxel|Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
41153105|NCT00911183|BIOLOGICAL|filgrastim|Given subcutaneously
41153106|NCT00911183|BIOLOGICAL|pegfilgrastim|Given subcutaneously
41153107|NCT00911183|BIOLOGICAL|rituximab|Given IV
41153108|NCT00911183|DRUG|cyclophosphamide|Given IV
41153109|NCT00911183|DRUG|liposome-encapsulated doxorubicin citrate|Given IV
41153110|NCT00911183|DRUG|prednisone|Given orally
41153111|NCT00911183|DRUG|vincristine sulfate|Given IV
41323545|NCT00160394|DRUG|Duac® Gel / Differin® Gel|
41323546|NCT02873364|DRUG|Vitamin D3 (High dose)|Daily 4000 unites vitamin D
41323547|NCT02873364|DRUG|Vitamin D3 (Low dose)|Daily 600 unites vitamin D
41323548|NCT01079286|DRUG|Nelfinavir and temsirolimus|Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
41323549|NCT05915936|PROCEDURE|LVMR|laoparoscopic ventral mesh rectopexy
41153112|NCT06093971|DRUG|remimazolam|Remimazolam is administered for anesthesia induction.
41323550|NCT05915936|PROCEDURE|PSR|perineal stapler resection
41323551|NCT03505749|BEHAVIORAL|Trauma Informed Mindfulness-Based Relapse Prevention|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
40805815|NCT05311176|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
41153113|NCT06093971|DRUG|Propofol|Propofol is administered for anesthesia induction.
41153114|NCT03048058|DRUG|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
41153115|NCT03048058|DRUG|brimonidine topical gel 0.33% & SOC|All subjects will receive standard-of-care brimonidine topical gel 0.33%
40805819|NCT06447779|BIOLOGICAL|Recombinant Zoster Vaccine (CHO Cell)|"0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105.~Intramuscular injection"
40805820|NCT06447779|BIOLOGICAL|NaCl solution Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection
41153116|NCT00002792|DRUG|busulfan|
40805822|NCT02905799|DRUG|oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
40805823|NCT02905799|DRUG|oral placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
40805824|NCT05172245|PROCEDURE|Biopsy|Undergo tumor biopsy
40805825|NCT05172245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40805826|NCT05172245|DRUG|Cisplatin|Given IV
41153117|NCT00002792|DRUG|cyclophosphamide|
41323552|NCT03505749|BEHAVIORAL|Treatment As Usual (TAU)|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
41323553|NCT05258708|BIOLOGICAL|mRNA-1273 COVID-19 vaccine|two doses of mRNA-1273 vaccine at 28-day intervals
41323554|NCT03101514|DRUG|Kanglaite|Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
41323555|NCT03101514|DRUG|chemotherapy|Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
41323556|NCT00066118|DEVICE|Dental amalgam restorations|
41478087|NCT04428099|BEHAVIORAL|Written Information|Written information about lifestyle change suggestions
41478088|NCT00802282|DRUG|psilocybin|dose manipulation as described in the protocol and to which volunteers are blinded
40805827|NCT05172245|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40805828|NCT05172245|DRUG|Ipatasertib|Given PO
40805829|NCT05172245|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40805830|NCT05172245|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40805831|NCT05172245|RADIATION|Radiation Therapy|Undergo radiation therapy
41153118|NCT00002792|DRUG|cyclosporine|
41153119|NCT00002792|DRUG|methotrexate|
41153120|NCT00002792|DRUG|tacrolimus|
41153121|NCT00002792|PROCEDURE|allogeneic bone marrow transplantation|
40805836|NCT02921230|DEVICE|Peripheral stenting|stent implantation during the index procedure
41153122|NCT00002792|PROCEDURE|peripheral blood stem cell transplantation|
41153123|NCT01129011|DRUG|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
41153124|NCT01129011|DRUG|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
41153125|NCT01636778|DRUG|SB-497115-GR|TPO receptor agonist to increase platelet count
41153126|NCT04828486|DRUG|Futibatinib|Given PO
41153127|NCT04828486|BIOLOGICAL|Pembrolizumab|Given IV
41153128|NCT04828486|OTHER|Quality-of-Life Assessment|Ancillary studies
41153129|NCT03502525|BEHAVIORAL|Break the Cycle Intervention|The intervention uses motivational interviewing to enhance persons who inject drugs' (PWID) motivation and skills to avoid helping non-PWID transition to injecting. The intervention entails discussions with participants in 8 areas: the participant's first time injecting; the participant's exposures to situations where helping with non-PWIDs' first injections is an option, and the extent to which they helped; their behaviors that might encourage non-PWID to inject for the first time; the risks associated with injection drug use; role-playing in which participants develop behaviors and scripts for avoiding or refusing requests to initiate non-PWID into injection; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using naloxone to reverse overdoses.
40805839|NCT06442566|DRUG|Buprenorphine Patch|Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated
40805840|NCT06442566|DRUG|Placebo|double-blinded randomization to placebo or transdermal buprenorphine
40805841|NCT06442566|DEVICE|Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to REAL intermittent theta burst (iTBS) rTMS
41478089|NCT00802282|BEHAVIORAL|Intensity of support for spiritual practice|Volunteers will be assigned to standard or high support, as described in the protocol
41478090|NCT00802282|BEHAVIORAL|Number of sessions|Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
40805842|NCT06442566|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to SHAM intermittent theta burst (iTBS) rTMS
40805843|NCT05764161|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
40805844|NCT05764161|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
40805845|NCT05235165|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood
41008403|NCT05036564|PROCEDURE|Lumbar puncture|"A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse."
41008404|NCT06185049|BEHAVIORAL|PROCARE+ 2.0 two booster sessions.|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include two booster sessions at 6 and 12 months into the intervention.
41008405|NCT06185049|BEHAVIORAL|PROCARE+ 2.0 one booster session.|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include abooster sessions at 6 months into the intervention.
41478091|NCT03574922|OTHER|Balance exercises|Balance Exercises
41478092|NCT03574922|OTHER|Core Stabilization exercises|Core Stabilization exercises
41478093|NCT02987803|OTHER|Data|The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
41478094|NCT00347529|BIOLOGICAL|pPML7789 with and without pPJV2012 administered by PMED|
41478095|NCT03936179|RADIATION|high dose radiation therapy with concurrent chemotherapy|standard dose of 50 Gy concurrent weekly with paclitaxel (45 mg/m2) and carboplatin (area under curve 1.5 ), immediately followed by hyperfractionated radiotherapy boost of 36 Gy in 30 fractions of 1.2 Gy to residual metabolic disease as defined by PET/CT
41478096|NCT04917718|DRUG|Conversion from IR Tacrolimus to XR Tacrolimus|All participants will be consented to the study on IR Tacrolimus. After their baseline visit, they will be converted to XR Tacrolimus
41478097|NCT03196674|OTHER|Biofeedback via motion capture|The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.
41478098|NCT00215449|DRUG|Formoterol Fumarate|
40805846|NCT05235165|PROCEDURE|Computed Tomography|Undergo CT
40805847|NCT05235165|OTHER|Questionnaire Administration|Ancillary studies
40805848|NCT05235165|PROCEDURE|Thoracoscopy|Undergo video-assisted thoracoscopic surgery or VATS
40805849|NCT05235165|PROCEDURE|Thoracotomy|Undergo open thoracic surgery
40805850|NCT03773237|DIETARY_SUPPLEMENT|SMOFLipid|SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
41153130|NCT05335811|DRUG|4-[18F]Fluoro-1-Naphthol|By vein (IV)
41153131|NCT02359552|DRUG|Rasagiline|
41153132|NCT02359552|DRUG|Placebo|
41478099|NCT02691741|DEVICE|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
41478100|NCT02691741|DEVICE|AT LISA® tri IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
41478101|NCT04825015|DEVICE|VEnaRt Cardiac Output|Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter
41478102|NCT03716076|DRUG|Carbetocin|50 mcg or 100 mcg bolus of carbetocin
41478103|NCT05901259|DEVICE|Exopulse Mollii Suit|The registry is designed to demonstrate the impact of Exopulse Mollii Suit on improvement of muscle relaxation, muscle activation, local blood circulation and/or chronic pain relief. The subjects included use the suit for 60 minutes every other day, unless other is specified by the Investigator, in their home environment for up to a maximum of 12 consecutive weeks. Qualitative and quantitative measures will be collected at baseline (T0), after 60 minutes stimulation (T1), after 4 weeks (T4) and at the end of the 12-week intervention period (T12).
41478104|NCT02100319|DRUG|Azilsartan|Azilsartan tablets
41478105|NCT02159781|PROCEDURE|periodontal treatment - scaling and root planning|
40805851|NCT03773237|DIETARY_SUPPLEMENT|Intralipid|Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
41153133|NCT06309771|BEHAVIORAL|Stress management, sleep improvement and fatigue reduction, sedentary behaviors reduction and physical activity promotion.|"The study seeks to quantify the impact of a complex intervention based on 3 modules :~1. Stress management~2. Sleep improvement and fatigue reduction,~3. Sedentary behaviors reduction and physical activity promotion.~Students from the interventional group will follow these 3 different health-related modules in a random order (6 predetermined order). Each module will be composed on 3 sessions. Each session includes individual interviews covering initial assessment and personalized goal setting."
41153134|NCT02430935|BEHAVIORAL|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
41008406|NCT06185049|BEHAVIORAL|PROCARE+ 2.0 without booster sessions|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors.
41008407|NCT02210585|OTHER|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)"
41008408|NCT01513252|BEHAVIORAL|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
41008409|NCT03844373|DIETARY_SUPPLEMENT|STOCKHOLM|STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
41008410|NCT01196728|DRUG|CM3.1-AC100|SAD study with single ascending subcutaneous doses
41008411|NCT02961426|DRUG|sofosbuvir + ravidasvir|combination of sofosbuvir + ravidasvir
41008412|NCT04950530|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
41008413|NCT02310672|DRUG|Macitentan|All patients take open-label macitentan 10mg o.d.
41008414|NCT05336903|BEHAVIORAL|APP-led model of care for chronic pain management|"The APP will provide an assessment using a biopsychosocial approach. The assessment will include:~* taking a comprehensive history~* screening for pathologies contributing to the participant's chronic pain~* a physical assessment~* screening for comorbid health conditions, using the appropriate screening tools, that require specific care (e.g., depression, addiction, post-traumatic stress)~* identifying psychosocial risk factors associated with pain and disability~* evaluating pain severity and interference~The APP will make recommendations to the participant and the chronic pain clinic health care team based on findings from the comprehensive assessment. These recommendations include, but are not limited to, the need for urgent or emergent referrals, medication management, referral and integration of other health care providers, the need for interventional procedures, or group-based treatment options."
41008415|NCT05738200|OTHER|Nordic Hamstring Exercise|A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
41008416|NCT00626262|DRUG|Esomeprazole|Oral and Intravenous
40805867|NCT03946774|DIETARY_SUPPLEMENT|Dietary protein shake|"It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate."
40805868|NCT03569878|BEHAVIORAL|Peer-Integrated Multidisciplinary Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
41008417|NCT00000436|BEHAVIORAL|Self-efficacy and muscle strength training|
41008418|NCT00000436|PROCEDURE|High-intensity strength training|
41008419|NCT03858075|DRUG|BLU-782|oral capsules
41008420|NCT03858075|DRUG|Placebo|oral capsules
41008421|NCT03858075|DRUG|BLU-782 taken with food|oral capsules
41323557|NCT03219567|DEVICE|Optical Coherence Tomography (OCT)|"Optical coherence tomography (OCT) is a non-contact, micrometer scale imaging technique, it provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D.~The study team will develop the hardware systems and software algorithms necessary to enable simultaneous OCT imaging of all the refractive surfaces of the eye."
41323558|NCT03219567|DEVICE|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in the body.
41323559|NCT03518632|BEHAVIORAL|Interval training|Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.
41323560|NCT03518632|OTHER|Standard Oncologic care|Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.
41323561|NCT03450525|OTHER|No intervention|No intervention
41323562|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Imatinib|
41323563|NCT01771458|PROCEDURE|Tumor biopsy|
41323564|NCT01771458|DRUG|Standard Chemotherapy|
41323565|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Everolimus|
41323566|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Vemurafenib|
41323567|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Sorafenib|
41323568|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Erlotinib|
41323569|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab|
41323570|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Dasatinib|
41323571|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)|
41323572|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Abiraterone|
41323573|NCT02287402|DRUG|AO-128|AO-128 tablet
41323574|NCT01819506|BEHAVIORAL|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
41323575|NCT01670656|DRUG|Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)|Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles
41478106|NCT05362006|DEVICE|Exopulse Mollii Suit|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate 40 groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
41478107|NCT05362006|DEVICE|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
41323576|NCT01670656|DRUG|Etonogestrel containing contraceptive vaginal ring (ENG-CVR)|Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles
41478108|NCT03144102|BEHAVIORAL|Virtual Reality-based therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.
41323577|NCT01670656|DRUG|Placebo|Placebo to match vaginal ring, intravaginally for two 28-day cycles
41323578|NCT01670656|DRUG|Ibuprofen|Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
41478109|NCT03144102|DEVICE|Anodal transcranial direct-current stimulation (tDCS)|Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.
41478110|NCT03144102|BEHAVIORAL|Occupational Therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.
40805869|NCT03569878|BEHAVIORAL|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with plan for mental health inpatient consultation will be the comparator condition.
41478111|NCT03144102|DEVICE|Sham transcranial direct-current stimulation (tDCS)|Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.
40805870|NCT04042909|BEHAVIORAL|Counter Attitudinal Advocacy|same as Counter Attitudinal Advocacy arm
41323579|NCT03430583|DRUG|MZ101|Drug
41323580|NCT00799929|OTHER|in vitro fertilization (IVF/ICSI)|
41323581|NCT00855387|OTHER|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
41323582|NCT04863937|DEVICE|Distal Thigh Compression Garment, Knee Sleeve|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
41323583|NCT02007954|DEVICE|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
41323584|NCT02960698|OTHER|IRM and comportemental tasks|
41323585|NCT01237028|DRUG|Calcitriol|Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
41323586|NCT03345732|DIAGNOSTIC_TEST|ICG and SPY system for wound complications|
40805871|NCT04042909|BEHAVIORAL|Personalized Normative Feedback|same as Personalized Normative Feedback arm
40805872|NCT04110756|BEHAVIORAL|ChangeGradients|In the proposed intervention, adolescents at the UCSF clinics who endorse alcohol use on the Health e-Check screen, a 5-minute confidential risk behavior module, will be randomly assigned to either the CHANGEGRADIENTS Intervention or Comparison (no intervention). The CHANGEGRADIENTS system will generate behavior change narrative episodes that are tailored to the adolescent (e.g. level of alcohol use) while also universally addressing a core set of topics related to health behavior change. Shortly following the clinic visit, through 4 weekly, 20 minute episodes, adolescent participants will interact with the CHANGEGRADIENTS health behavior change environment outside of clinic. Adolescents will complete a brief alcohol screening-past 7-day use-at the beginning of each episode. At the end of the final episode, the system will produce an individualized adolescent report that summarizes use of the CHANGEGRADIENTS modules as well as self-reported alcohol use since clinic visit baseline.
41008422|NCT05928702|PROCEDURE|temperature-elevating armbath|Hydrotherapeutic Approach
41008423|NCT02821884|DEVICE|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
41008424|NCT02821884|DEVICE|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
41008425|NCT02821884|DEVICE|Combination of sham tDCS and sham NMES|Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
41153135|NCT02430935|BEHAVIORAL|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
41153136|NCT01309555|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
41153137|NCT00398749|DRUG|Epoetin alfa|40,000 IU once weekly, variable treatment length
40805873|NCT05549258|DRUG|Inebilizumab|Inebilizumab administered intravenously (IV) over a total of 28 weeks.
40805874|NCT03223753|OTHER|Educational Intervention|Receive educational handouts about to physical activity
40805875|NCT03223753|OTHER|Internet-Based Intervention|Access limited version of device app/website
40805876|NCT03223753|OTHER|Internet-Based Intervention|Access full version of interactive reward-based device app/website
40805877|NCT03223753|OTHER|Laboratory Biomarker Analysis|Correlative studies
40805878|NCT03223753|DEVICE|Medical Device Usage and Evaluation|Wear physical activity tracking device
40805879|NCT03223753|OTHER|Quality-of-Life Assessment|Ancillary studies
40805880|NCT03223753|OTHER|Questionnaire Administration|Ancillary studies
41323587|NCT02581358|OTHER|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
41323588|NCT01121003|BEHAVIORAL|weight maintenance, low sugar diet|
41323589|NCT01121003|BEHAVIORAL|weight maintenance, high fructose diet|
41323590|NCT01121003|BEHAVIORAL|weight maintenance, high fructose diet+ exercise|
41323591|NCT04041908|OTHER|Experimental Product|2 sachets per day
41323592|NCT02329002|DEVICE|Magnetic resonance imaging|MR imaging protocol should include a thin-slice (3-4 mm) short TI inversion recovery (STIR) sequence or fat-saturated T2-weighted images in axial direction. Furthermore, a 3D-T1 weighted sequence with isotropic voxels will be obtained, with reconstruction in 3 directions. If suspicious lesions are detected, additional MR imaging has to be performed, including contrast-enhanced images.
41323593|NCT05565976|DRUG|Dapagliflozin 10mg Tab|10mg PO q24h for 12 months
41323594|NCT05565976|DRUG|Statins (Cardiovascular Agents)|Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h
41478112|NCT06257316|DRUG|EPHEDrine Hydrochloride 5 mg/ml|"In the present study, the expected rate of recovery of the internal carotid artery according to the dose of the inotropic agent was similar to that in a previous study in which the fraction maintaining mean arterial pressure within 80% of baseline by dose of inotropic agent was 0.9% for the ephedrine 0.1, 0.6, 0.8, 1. 0, 1.2, and 1.4 doses (mg/kg) were 9.9%, 21%, 41%, 47%, 65.5%, and 40%, respectively (Br J Anaesth. 2023 May;130(5):603-610), and it was assumed that the rate of internal carotid artery recovery by inotrope dose would be 90% of that result.~The study will randomize to dose in six cohorts and will include dose group and cohort variables in a logistic regression model to assess the trend between inotropic dose and rate of carotid revascularization after correcting for cohort effects on the outcome variable."
40805881|NCT04817839|BEHAVIORAL|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
40805882|NCT04817839|BEHAVIORAL|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
40805883|NCT06161116|BIOLOGICAL|MK-6194|SC Injection
40805884|NCT06161116|BIOLOGICAL|Placebo|SC Injection
40805885|NCT05656469|OTHER|Personalised medication advice based on pharmacogenetic testing|Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
40805886|NCT06510803|DRUG|The case intervention is the sevoflurane concentrations with the Drager Apollo workstation|The increases in the sevoflurane concentrations during induction of anesthesia with the Drager Apollo compared with the GE Ohmeda workstations
41323595|NCT05565976|DRUG|Platelet Antiaggregant|Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h
41323596|NCT05565976|DRUG|Antidiabetic|Previously established medical treatment for type 2 diabetes will be maintained.
41323597|NCT05393076|DRUG|Linerixibat|Linerixibat dose and administration as per study intervention.
41323598|NCT02943005|PROCEDURE|Rotator cuff repair|
41323599|NCT04970394|BEHAVIORAL|Cervical Screening Reminder|Verbal reminder and if seen face-to-face, a written appointment booking slip.
41323600|NCT01755312|DEVICE|Medication reminder|Medication reminder
41323601|NCT03351569|DRUG|Intravenous immunoglobulin|Intravenous drip.
41323602|NCT00353327|PROCEDURE|Plasma infusion|
41323603|NCT03216083|DRUG|Tranexamic Acid Injectable Solution|1g IV tranexamic acid mixed in normal saline (67mL)
41323604|NCT03216083|OTHER|Placebo|67mL IV normal saline
41323605|NCT05545904|BEHAVIORAL|Substance use brief intervention (BI)|The BI will be delivered in a single session (20-30 minutes) using motivational interviewing techniques and the FRAMES model i.e.(i) providing feedback on screening results (ii) ensuring responsibility on the part of the adolescents (iii) giving clear advice to stop/cut down (iv) giving menu of options (alternative healthy behaviors to engage in) (v) expressing empathy, and (vi) encouraging self-efficacy (15). The BI will be delivered for the highest scoring substance or the one the adolescent identifies as the most problematic.
41323606|NCT05545904|BEHAVIORAL|substance use education intervention|This intervention will entail review of material in the NACADA substance use education manual for adolescents, and will be followed by a question and answer session. The manual contains summarized and simple information on the harms and myths related to alcohol, tobacco, cannabis, prescription medication and khat use, substances. This education intervention will be delivered over a single 20-30 minute session by a counselor stationed at Rafiki clinic.
41323607|NCT03557515|BEHAVIORAL|Stress Management and CBT|"Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Cognitive Behavioral Therapy will focus on:~1. Intro to CBT-Tracking Automatic Thoughts~2. Identifying Distorted Thoughts~3. Challenging Distorted Thoughts~4. Core Beliefs/Relapse Prevention"
41323608|NCT03557515|BEHAVIORAL|Stress Management and Metta-Meditation|"Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Metta-Meditation will focus on:~1. Intro to Meditation vis Mindfulness of the Breath and Body-Noticing Critical Self Talk~2. Intro to Brief Loving-Kindness Meditation and Self-Care~3. Continuing with Additional Metta-Based Exercises to Cultivate Compassion for Oneself and Others and Mitigating Self-Criticism~4. Review/Plan for Future"
41323609|NCT04141553|DRUG|Diltiazem Injection|Randomization to one of to active comparator groups
41323610|NCT04248062|OTHER|Survey|Survey: 38 preselected patient and parent reported outcomes; rating scale: 9 point likert scale (1=not at all important - 9=very important)
41323611|NCT03360045|DRUG|Tranexamic Acid|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
41323612|NCT03360045|DRUG|Normal saline|5 cc normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
41323613|NCT03360045|DEVICE|Merocel|Merocel packing is applied.
41323614|NCT05514145|DEVICE|Nance/Transpalatal arch space maintainer|A combined design of both Nance and Transpalatal arch space maintainers as a space maintainer for the maxillary arch in mixed dentition
41323615|NCT05514145|DEVICE|Nance space maintainer|Conventional space maintainer for the maxillary arch used in mixed dentition
41323616|NCT05341570|DRUG|BPI-21668|Subjects will receive BPI-21668 until disease progression
41323617|NCT01770691|DEVICE|TIPI vaginal pessary|TIPI vaginal pessary G3 model, and TIPI SMD's
41323618|NCT01610076|OTHER|Code Status Video|"10 minute video about Code Status"
41323619|NCT02729948|OTHER|Survey Administration|Ancillary studies
41323620|NCT02729948|DEVICE|Tethered Capsule Endoscope|Undergo TCE
41323621|NCT05218057|PROCEDURE|Ureteroscopic lithotripsy|Ureteroscopic lithotripsy is one of the surgical procedure options for ureteric stone less than 1.5 cm. While many energy systems has been used for stone fragmentation during ureteroscopy, laser energy is the most commonly used approach for stone fragmentation.
41323622|NCT00165061|PROCEDURE|Esophagectomy|
41323623|NCT00165061|PROCEDURE|Chemoradiation|
41323624|NCT03059472|BEHAVIORAL|Group 1 (Intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
41323625|NCT03059472|BEHAVIORAL|Group 2 (Delayed intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
41323626|NCT04643223|OTHER|kinesio tape with tension|The application of kinesio tape follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following the application of kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
41323627|NCT04643223|OTHER|kinesio tape without tension|The application of kinesio tape without tension follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following application of the kinesio tape, no tension on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
41323628|NCT01669642|DRUG|Ketamine|participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
41153138|NCT06480864|DRUG|Adebrelimab Injection|Adebrelimab injection (1200mg) will be administered by intravenous infusion during the induction phase and maintenance phase on day 1 in a 3-week treatment cycle.
41323629|NCT00479557|BIOLOGICAL|ACC-001 + QS-21|Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
41323630|NCT00479557|BIOLOGICAL|ACC-001|Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
41323631|NCT00479557|BIOLOGICAL|QS-21|QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
41323632|NCT00479557|DRUG|Placebo: Phosphate buffered saline|Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
41323633|NCT01541267|DRUG|aliskiren, eplerenon, telmisartan|aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
41323634|NCT02021825|DRUG|Mitoxantrone|The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
41153139|NCT06480864|DRUG|Apatinib Mesylate Tablets|Apatinib mesylate tablets (250 mg) will be administered orally in a 3-week treatment cycle, once a day.
41153140|NCT06480864|DRUG|Carboplatin|Carboplatin (AUC 4-5mg/mL/min) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
41153141|NCT06480864|DRUG|Cisplatin|Cisplatin (75mg/m2) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
41323635|NCT01203787|DRUG|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
41323636|NCT01203787|DRUG|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
40805890|NCT04022226|DRUG|Ketamine|Induction agent that suppresses infra-slow waves
41323637|NCT03900806|BEHAVIORAL|online cognitive rehabilitation|The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.
41323638|NCT02146248|DRUG|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
40805891|NCT04022226|DRUG|Methohexital|Induction agent that does not suppress infra-slow waves
40805892|NCT04660812|DRUG|AB680|AB680 is a cluster of differentiated CD73 Inhibitor
40805893|NCT04660812|DRUG|Etrumadenant|Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist
41323639|NCT02146248|DRUG|DepoProvera|injectable hormonal contraceptive
41323640|NCT02491398|DRUG|Bendamustine + Rituximab|
40805894|NCT04660812|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclononal antibody
41153142|NCT06480864|DRUG|Etoposide|Etoposide(100mg/m2) intravenous infusion will be administered during the induction phase from day 1 to 3 in a 3-week treatment cycle.
41323641|NCT02616185|BIOLOGICAL|PF-06755992|PF-06755992 will be administered on Day 1 of Cycles 1 and 2.
41323642|NCT02616185|BIOLOGICAL|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
41323643|NCT02616185|DEVICE|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
41323644|NCT02616185|BIOLOGICAL|Tremelimumab|PF-06753388 will be administered every 28 days.
41323645|NCT02616185|BIOLOGICAL|PF-06801591|PF-06801591 will be administered every 28 days.
41323646|NCT02616185|BIOLOGICAL|PF-06753512|Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
41323647|NCT05296408|BEHAVIORAL|motor learning based therapy|Motor learning based therapy will include functional task/task component training and will be employed to practice hand-to-mouth, forward reach, grasp-release, and object manipulation. Training will include high repetition both in the clinic and during home exercise practice. Tasks will be decomposed into component parts and practiced in this manner with the goal of returning to full task performance as skill develops Training will be tailored to each individual subject's capability and progressed according to a motor control hierarchy to ensure adequate challenge. Training is always started at the appropriate level of challenge for an individual to ensure adequate challenge is delivered whether the individual is higher or lower functioning.
41478113|NCT04313049|DEVICE|JACO2|Performing tasks using joystick control
40805895|NCT04660812|DRUG|Bevacizumab|Bevacizumab is administered as part of standard chemotherapy regimen
40805896|NCT04660812|DRUG|m-FOLFOX-6 regimen|mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen
40805897|NCT04660812|DRUG|Regorafenib|Regorafenib is adminstered as part of standard chemotherapy regimen
40805898|NCT06273722|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner (Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
41478114|NCT04313049|DEVICE|VOCAL CONTROL|Performing tasks using vocal control
40805899|NCT05289492|DRUG|EOS884448|EOS884448 will be administered in arm A,B and C
40805900|NCT05289492|DRUG|Iberdomide|Iberdomide will be administered in arm B and C
41478115|NCT05223491|PROCEDURE|En Bloc resection|Tumour is resected and removed from the bladder in one piece, if possible.
40805901|NCT05289492|DRUG|Dexamethasone|Dexamethasone will be administered in arm C
40805902|NCT05241860|OTHER|Pharmacotherapy Discontinuation|Stop hormonal medications (Abiraterone, Enzalutamide, Apalutamide, Leuprolide, Goserelin, Degarelix, Relugolix)
40805903|NCT05241860|OTHER|Follow-Up|Undergo follow-up
40805904|NCT05241860|OTHER|Questionnaire Administration|Ancillary studies
40805905|NCT05241860|OTHER|Quality-of-Life Assessment|Ancillary studies
40805906|NCT06323161|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
40805907|NCT06323161|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
40805908|NCT06323161|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
41153143|NCT03401411|BEHAVIORAL|Survey|Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.
41153144|NCT03401411|BEHAVIORAL|Algorithm-based Triage Tool|Newly designed flowchart-based triage guide to prioritize each patient case scenario into one of the 5-point likert-scale categories, used in conjunction with SCCMP for ICU admission.
41153145|NCT03617016|DRUG|Domperidone|Participants will receive domperidone tablets orally.
41153146|NCT03617016|DRUG|Placebo|Participants will receive matching placebo to domperidone tablets orally.
41153147|NCT04502745|DEVICE|Minimally Invasive Cortical Access System (MICAS)|Temporary surgical tool that provides access to the sub-dural space through the cranium.
41478116|NCT05223491|PROCEDURE|Conventional TURB|Tumour is resected piecemeal.
41323648|NCT05296408|BEHAVIORAL|MyoPro|The MyoPro supports motor learning-based training by reinforcing coordinated movement practice, allowing for finely incrementalized training progression, and encouraging high repetition of movement. Importantly, the device assists the user to move the paretic limb in a manner they may otherwise be unable to do. This further motivates the user to continue attempts to move the paretic limb. When a user attempts to volitionally contract a weak muscle, sensors embedded within the MyoPro detect the EMG signal, which triggers activation of a motor within the device. The motor assists the user to complete the desired movement (e.g. opening of the hand).Subjects experience real-time biofeedback through their ability to sense and see movement of the target joint(s) and via their interface with the software on a computer that provides visual feedback of the EMG level of the contracting muscle
41323649|NCT05296408|BEHAVIORAL|Home Exercise Program|Every subject will be assigned an individualized HEP. Therapy staff will create written handouts for the user to follow. The HEP will include photographs of the study participant performing his/her exercises/functional tasks along with written instructions. Each individual will have their own personalized HEP that will be created during their study participation and will be dispensed only to them. The HEP will reinforce in-clinic therapy. The HEP will be progressed regularly, and individuals will log practice time. The HEP for M+ML will include practice with and without the MyoPro; the HEP for ML-alone will include practice without MyoPro. Each HEP session will require approximately 90 minutes to complete.
41323650|NCT05489120|OTHER|Consumption of FLAVIS|Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.
41323651|NCT04966195|RADIATION|stereotactic body raiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
41323652|NCT01905670|DEVICE|WiCS-LV system|Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
41323653|NCT00797485|BIOLOGICAL|bevacizumab|Given IV
41323654|NCT00797485|DRUG|capecitabine|Given orally
41323655|NCT00797485|DRUG|fluorouracil|Given IV
41323656|NCT00797485|DRUG|irinotecan hydrochloride|Given IV
41323657|NCT00797485|DRUG|leucovorin calcium|Given IV
41323658|NCT05067452|OTHER|Food support|Diabetes-tailored food support. Project Open Hand will provide intervention participants twelve weeks of supplemental food support. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian. All food support will be home delivered.
41323659|NCT05067452|OTHER|Case-management|"Project Open Hand client services staff will conduct three case management sessions with the participant. The first session will initiate food services and ensure orientation to the intervention and set up delivery; the second session will support the participant with any issues related to the intervention (logistical or nutrition-related, with referral to the POH registered dietitian as needed); the third session will provide transition from the intervention, connect the participant with local food resources, and ensure a warm hand-off to nutrition"
41323660|NCT04254796|BEHAVIORAL|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
41478117|NCT03078582|DRUG|Zilucoplan (RA101495)|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
41478118|NCT00227266|DRUG|Valproic Acid and Levocarnitine|VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
41478119|NCT00227266|DRUG|Placebo|
40805909|NCT05504187|DRUG|KP104|KP104 will be administered.
41153148|NCT05727553|RADIATION|Online adaptive radiotherapy|Postoperative radiotherapy will be indicated conform the standard medical care and guidelines. The radiation is delivered with online adaptive radiotherapy performed on the Ethos. This technique will be evaluated.
41153149|NCT04150250|DRUG|iOWH032|Anti-secretory synthetically manufactured small molecule designed to inhibit the cystic fibrosis transmembrane conductance regulator chloride channel.
41153150|NCT04150250|DRUG|Placebo|Oral tablets matching iOWH032 on taste, appearance, dissolution time with the same excipients but no active ingredients.
41153151|NCT04150250|OTHER|V. cholerae Challenge|Freshly-harvested, wild-type Vibrio (V.) cholerae El Tor Inaba strain N16961,10\^6 cfu suspended in 30 mL of sodium bicarbonate solution ingested orally.
41153152|NCT04150250|DRUG|Antibiotics|"Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)"
41153153|NCT02569944|PROCEDURE|Bladder stimulation|"Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients."
41323661|NCT00971425|BIOLOGICAL|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
41323662|NCT00971425|BIOLOGICAL|Fluarix™|1 dose intramuscular injection
41323663|NCT00971425|BIOLOGICAL|Placebo|1 dose intramuscular injection
41323664|NCT03968341|OTHER|Pharmacokinetic and pharmacodynamic study of antibiotics used in severe endophthalmitis from samples taken from treated patients|"A 5mL dry tube will be taken by puncture of the humeral vein like a conventional blood test. This tube is not usually collected unless specifically requested by the ophthalmologist. This sample will be sent quickly (within two hours) to the CHNO Medical Biology Laboratory for centrifugation, serum separation and storage at -80°C.~Samples stored at -80°C will be sent weekly to the Microbiology and Anti-infectives Laboratory at Hospital Paris Saint-Joseph, with the dosage request form duly completed with the usual information."
41153154|NCT02569944|PROCEDURE|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
41153155|NCT05704465|BEHAVIORAL|Reiki Therapy|Reiki therapy involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. In this technique, energy is guided by therapist's hands placed near patient's body to activate the ability of the body to heal and restore its balance. 1st session for explanation of aim and objectives of program. 2nd one focused on knowledge about negative emotional state. 3rd one discussed Reiki technique and its concept, mode of action, and process. The 4th through 7th sessions were practical. During these sessions, a Reiki practitioner moves his/her hands close to the patient's body in a set of positions. Each hand position focuses on a different part of the body. The hands are held in position for 3 to 10 min., depending on patient's needs. By the end of the session, the patient and therapist reflect on their experience and the emotions with the technique. The eighth session was a recapitulation of the program and ended with evaluation or post-testing.
41323665|NCT03728712|DIAGNOSTIC_TEST|SPECT/CT|"Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours.~Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation."
41323666|NCT00041691|DRUG|hMN14 (labetuzumab)|
41323667|NCT04721574|DEVICE|Philips EnergyUp Energy light HF3418/01|high brightness LED light box
41323668|NCT04721574|DEVICE|Philips EnergyUp Energy light HF3418/01 with filter|high brightness LED light box with filters that reduced lamp output to less than 50 lux
41323669|NCT04059406|DRUG|sapablursen|sapablursen administered subcutaneously
41323670|NCT06261112|OTHER|kaleidescope|used to kaleideskope
41323671|NCT01108562|DRUG|Lidocaine|Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
41323672|NCT01108562|OTHER|Normal Saline|Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
41323673|NCT04794946|BIOLOGICAL|Covishield|2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days). This schedule will be followed for the first 100 participants, following which vaccination schedule as per the prevailing Government protocols shall be followed as a part of Adaptive Clinical Trial.
41323674|NCT00288522|DRUG|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
41323675|NCT01995812|BEHAVIORAL|Hula and heart health education|
41323676|NCT05075967|OTHER|Health Equity|This community-level structural component will use a standardized, nationally replicable community coalition model (Black Treatment Advocates Networks \[BTAN\]) to implement an enhanced program model geared to 1) facilitate the effects of the other HPTN 096 interventions by minimizing barriers to HIV testing, PrEP use and viral suppression through sensitizing a local network of service providers (e.g., social, legal, economic sectors) to the needs of Black MSM and maintaining an online platform for exchanging information about the local network that can be used to link Black MSM to resources and services, and 2) amplify the effects of other HPTN 096 components by increasing Black MSM's receptivity to those activities through the integration and promotion of HPTN 096 into the activities of the community coalition model.
41323677|NCT05075967|BEHAVIORAL|Social Media Influencers|"In this community-level component, social media influencers (SMI) will be defined for the purposes of this study as users on social media who have established credibility, trust and access to a large audience of Black MSM, and who can persuade them by virtue of their authenticity and reach. SMI will provide tailored messaging for Black MSM in intervention communities on the topics of:~* HIV/sexually transmitted infections (STI) testing promotion~* PrEP (and general HIV prevention) awareness and promotion~* Definition and benefits of viral suppression.~Messages may include direction towards health care facilities (HCFs) involved in the intersectional stigma reduction component and information about the virtual peer support platform or BTAN+ events."
40805912|NCT06559306|DRUG|Seltorexant|Seltorexant will be administered orally.
40805913|NCT06559306|DRUG|Placebo|Matching Placebo tablets will be administered orally.
40805914|NCT06559306|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|SSRI/SNRI will be administered orally.
40805915|NCT06215820|DRUG|MR-107A-02|tablet
40805916|NCT06215820|DRUG|Tramadol|over-encapsulated tablet
41008426|NCT04061200|DRUG|Semaglutide, 1.34 mg/mL|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks. Participants will be randomized and up titrated to semaglutide 1.34 mg/ml or matching placebo once weekly during the following 26 weeks in a 1:1 ratio.
41008427|NCT04061200|OTHER|Placebo, 1,34 mg/mL|Participants will be randomised to either semaglutide or placebo as an add on treatment after 26 weeks of intervention with empagliflozin 25 mg.
41008428|NCT04061200|DRUG|Empagliflozin 25 MG|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks.
41008429|NCT00293384|DRUG|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
41323678|NCT05075967|BEHAVIORAL|Intersectional Stigma Reduction|This organizational-level component will take place in HCFs and is designed to improve cultural responsiveness in the provision of HIV prevention and health care services to Black MSM. It is expected to contribute to a reduction in HIV incidence by creating an affirming and autonomy-supportive healthcare environment that supports Black MSM engagement in HIV-related care and services and that promotes increased HIV/STI testing, PrEP uptake and viral suppression rates.
41323679|NCT05075967|BEHAVIORAL|Peer Support|"Peer support workers will be trained and compensated to provide emotional and practical support services. These peer support workers will have shared lived experiences with those whom they are supporting, be self-reflective of those experiences, and know when to share those experiences with others in an appropriate and supportive manner. Once trained, the peer-support workers will have demonstrated competencies in the following domains:~* HIV, PrEP, nPEP, other HIV prevention options and ART education~* Adherence to PrEP, ART and medical care~* HIV/STI testing~* New HIV diagnosis~* Addressing intersectional stigma (anti-Black racism, sexual stigmas, HIV-related stigma)~* Self-care~* Information about national and local resources and assistance programs, Black MSM-centered health services, and the cost and insurance coverage of medications and medical care~* Multicultural competency (as it relates to the HIV epidemic for Black MSM in the southern US)"
41323680|NCT05075967|OTHER|Standard-of-care|Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.
41323681|NCT06291506|OTHER|Radiofrequency ablation of heart atrial tissue.|Ablation with radiofrequency, advances techniques: contact force-guided, improved tissue temperature sensors, automark algorithms.
41323682|NCT04417114|DRUG|Rosuvastatin|Statin
41323683|NCT03674333|DIETARY_SUPPLEMENT|Folic Acid|Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.
41323684|NCT03674333|OTHER|Placebo|Placebo - a sugar pill
41478120|NCT05151575|BEHAVIORAL|supervised group-based walking and non-supervised individual-based walking interventions|Group exercise interventions tended to be systematic and supervised by professionals. The current intervention is proposing to conduct a randomized control trial that is not only examining the nature of walking on older adults' well-being but also involving the elements of group-based and professional supervision intervention, aiming at comparing with the individual-based intervention without professional supervision. Qualified professional fitness trainers (1 male and 1 female separately for male and female groups, respectively) will be involved in the group-based intervention programs in order to provide appropriate guidance and supervision to the participants. Whereas, the non-supervised individual-based intervention will be conducted by a research assistant (males and females) to ensure the attendance and general safety, but without providing professional advice or supervision.
40805917|NCT06215820|DRUG|Placebo|over-encapsulated tablet and/or tablet
41478121|NCT06188052|DRUG|Tranexamic acid|Comparing the 3 groups regarding intraoperative bleeding, hemoglobin level pre and postoperative and the need of blood transfusion
41008430|NCT00293384|DRUG|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
41008431|NCT00293384|DRUG|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
41008432|NCT00293384|DRUG|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
41008433|NCT01624727|DIETARY_SUPPLEMENT|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
41008434|NCT00951054|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
41008435|NCT00203203|DEVICE|Intramyocardial Injection of stem cells via NOGA Mapping|Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
41008436|NCT00203203|OTHER|Control, then Stem Cell Therapy|Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
40805920|NCT03514511|DRUG|LEO 138559|LEO 138559 is a compound in development at LEO Pharma A/S
40805921|NCT03514511|DRUG|LEO 138559 placebo|LEO 138559 placebo
40805922|NCT05536414|DRUG|Centanafadine|capsule
40805923|NCT05536414|DRUG|Escitalopram|capsule
41008437|NCT02694081|PROCEDURE|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
40805924|NCT05536414|DRUG|Placebo|capsule
40805925|NCT06305299|BIOLOGICAL|iC9-CAR.B7-H3 T cells|iC9-CAR.B7-H3 T cells will then be administered intraperitoneally
40805926|NCT06305299|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
41323685|NCT05301023|OTHER|Individualized antibiotic therapy|Individualized antibiotic therapy is based on the duration of illness after treatment initiation, as the antibiotic therapy can be stopped three days after the participant has become healthy. The participant is classified as healthy if he/she is afebrile (\<38.0 °C), has experienced significant clinical improvement, and have no flank pains or dysuria.
41008438|NCT02694081|PROCEDURE|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
41008439|NCT01516879|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
41008440|NCT01516879|BIOLOGICAL|Placebo|Administered by subcutaneous injection once a month
41008441|NCT01516879|DRUG|Atorvastatin|Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
41008442|NCT01516879|DRUG|Ezetimibe|Background lipid lowering therapy: ezetimibe 10 mg orally once a day
41008443|NCT01516879|OTHER|Diet Only|Diet only, no lipid lowering background drug given
41323686|NCT05301023|OTHER|Standard antibiotic therapy|Standard antibiotic therapy is 10 days of antibiotic therapy regardless of the duration of illness after treatment initiation.
41323687|NCT00898404|OTHER|laboratory biomarker analysis|Correlative studies
41323688|NCT01932931|DIETARY_SUPPLEMENT|cholecalciferol (50ug)|The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
41323689|NCT00040547|DRUG|Farnesyl Protein Transferase Inhibitor|
40805927|NCT06305299|DRUG|Fludarabine|fludarabine 30 mg/m2 IV will be given.
41153156|NCT05704465|BEHAVIORAL|Qi-gong Therapy|Qi-gong involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. It involves coordination of breathing and physical movement with mental energy to promote cognitive performance. Both 1st and 2nd sessions were similar to Reiki technique group. The 3rd one addressed the concept of Qi-gong therapy. The 4th through 7th sessions involved patients' doing simple movements and breathing techniques. The practitioner is at about a one-foot distance from the patient's body, to guide and manipulate movements. Breathing patterns are like yoga, with Qigong movements in a mindful link to inspiration and expiration, with incorporation of deep diaphragmatic breathing. The 8th session was similarly for program recapitulation and post-testing.
41153157|NCT01083537|DRUG|Cisplatin|"1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~1. Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~2. Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
41008444|NCT01178229|OTHER|Physiotherapy|"The physiotherapeutic intervention was based on the Awareness through Movement technique. Ten sessions were planed. Each session lasted three hours.~The children of the experimental group and their parents were guided by two physiotherapist and the sessions took place in a room rounded by mirrors.~Each session developed as follows: presentation to the parents of the somatic awareness technique for each day; movements, games, motor tales and exercises performed by the children; in each session, a guide book with cartoons was given to the children and their parents to reinforce the exercises at home to keep a long-term result.~All the children assisted together to all the sessions and the instructions and instruments given to the children and their parents were the same for all of them."
41008445|NCT00268138|DRUG|elmex gel|elmex gel once a week
41008446|NCT00165971|PROCEDURE|BIS monitoring|
41323690|NCT06119451|BEHAVIORAL|Traditional Music Therapy|Intervention using traditional music therapy as an alternative therapy for burnout syndrome
41323691|NCT05121038|DRUG|CEND-1|The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).
41008447|NCT03189394|BEHAVIORAL|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
41153158|NCT01083537|DRUG|Paclitaxel|"2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~1. Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~2. Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~3. Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
41153159|NCT05995275|BIOLOGICAL|mRNA-1769|Sterile liquid for injection
41323692|NCT05121038|DRUG|Panitumumab|"Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called RAS/BRAF wild type will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX."
41478122|NCT01484418|BEHAVIORAL|Exposure in vivo|5-10 sessions based on an individualized fear hierarchy
41478123|NCT01484418|BEHAVIORAL|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
41478124|NCT00728442|DEVICE|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
41008448|NCT03189394|BEHAVIORAL|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
41008449|NCT03189394|BEHAVIORAL|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
41008450|NCT01911507|DRUG|INC280|Given PO
41323693|NCT05121038|DRUG|Folfirinox|"FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home."
41323694|NCT03487406|DRUG|Ticagrelor|One 90 mg tablet, oral, twice daily for 6 months.
41323695|NCT03487406|DRUG|Aspirin|One 75 mg tablet, oral, once a day, for 6 months.
41323696|NCT03487406|DRUG|Placebo Aspirin|Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
41323697|NCT03487406|DRUG|Placebo Ticagrelor|Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
41323698|NCT00835003|PROCEDURE|Elective caesarean section|Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)
41323699|NCT00835003|PROCEDURE|Elective caesarean section|Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
41323700|NCT05871229|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
41323701|NCT05871229|OTHER|Standard treatment for peri-implantitis|Standard treatment for peri-implantitis as per international, national and clinic guidelines
41323702|NCT03292393|BEHAVIORAL|Financial reward|In contingency management, financial rewards are contingent upon an individual changing behavior. In our study, financial incentives are contingent upon group behavioral changes.. In the intervention phase participants will be randomly assigned to one of the three treatment arms and they will receive the financial incentive that corresponds to their treatment arm. Data will be collected for four months and all participants will continue receiving a compensation for participation
41323703|NCT03292393|BEHAVIORAL|Social norms|To build social norms the study adds a group component to a contingency management model. In contingency management, financial rewards are contingent upon an individual changing behavior. Social norms are expected to emerge as a result of the designed group contingency management, monthly-facilitated meetings at a local clinic, and daily basis interaction through social media. The intervention will build social norms that improve medication adherence of each member of a group. A three-arm randomize trial is designed to test this hypothesis. Hypertensive patients will be randomly assigned to a group contingency management (GCM) arm, an individual contingency management (ICG) arm, or a control arm.
41323704|NCT03292393|DEVICE|Home Blood Pressure Monitoring|Participants will be reminded that they will receive and learn how to use a Home Blood Pressure Monitor (HBPM) device that participant will keep for the duration of the study
41153160|NCT05995275|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
40805943|NCT06410352|DRUG|Semaglutide, Empagliflozin|subcutaneous Semaglutide (GLP-1RA) 1 mg once a 7 day with oral Empagliflozin (SGLT-2i) 25 mg once a day
40805944|NCT06410352|PROCEDURE|Minigastric bypass|Endovideososcopic techniques with the intraperitoneal using of synthetic/biological materials. MGB is performed to reduce the absorption surface of the gastrointestinal tract by shunting the greater part of the stomach, the duodenum and the initial section of the small intestine, which reduces the absorption of food and leads to a decrease in the production of gastrointestinal hormones.
40805945|NCT06410352|DIETARY_SUPPLEMENT|Analimentary detoxication|very-low-calorie-restriction diet ('Analimentary-detoxication') including \<100 kcal/day with fat-free vegetables (tomato/cucumber) and salt intake (5-6 g/day), optimum physical activity, and sexual self-restraint.
41008451|NCT01911507|DRUG|erlotinib hydrochloride|Given PO
41008452|NCT01831375|BEHAVIORAL|Speak Up|Intervention group_treatment group
41008453|NCT01831375|BEHAVIORAL|Get connected|Participants will learn to be connected with social resources in the community.
41008454|NCT00013130|BEHAVIORAL|Provision of health status information to patients provider|
41008455|NCT05884697|OTHER|K-Talk Intervention (Storytelling and K-Bot)|The K-Talk intervention group receives a combination of a storytelling intervention and an artificial intelligence chatbot (K-Bot) education.
41008456|NCT05884697|OTHER|Storytelling Intervention|The storytelling intervention features 12 authentic stories from young Korean immigrants and Americans. Each video is about 3 minutes long and includes stories from 1st, 1.5, and 2nd generation young Korean individuals, highlighting their perceptions of HPV and HPV vaccines, and their experiences with HPV vaccination.
40805946|NCT06410352|BEHAVIORAL|Ramadan fast's weight loss|"The participants adhered to fasting on RF season. They strictly adhered to two principles of nutrition during RF: 1) no blood, no smell of fat which means don't eat meat and don't eat fatty foods; 2) the 'Sehri time' (a meal eaten before dawn) included just 1.5-2.0 glass of water and fruits of 80-100 gr (apple, dates, and persimmon). Indeed, the patients followed a diet in which they ate one meal a day - participants have a meal during 'Iftar time' (a meal eaten after sunset)."
40805947|NCT04967287|DEVICE|MyopiaX|MyopiaX treatment twice a day
40805948|NCT04967287|DEVICE|Myopia control spectacles|To be used all as prescribed
40805949|NCT03964909|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
40805950|NCT03964909|PROCEDURE|Magnetic Resonance Imaging|Undergo CVR MRI
40805951|NCT03964909|PROCEDURE|Resting State Functional Connectivity Magnetic Resonance Imaging|Undergo rs-fMRI
40805952|NCT04607174|OTHER|Pathologic group|"Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb."
40805953|NCT06514261|DRUG|Azacitidine|Given IV or SC
41153161|NCT00574301|PROCEDURE|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
41323705|NCT03292393|DEVICE|Medication adherence assessment|Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
41323706|NCT00649441|DRUG|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
41323707|NCT00649441|DRUG|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
41323708|NCT00904995|DRUG|Voriconazole|Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
41323709|NCT00904995|DRUG|Voriconazole|6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.
41323710|NCT00719953|DIETARY_SUPPLEMENT|Cognitex|Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks
41323711|NCT05510609|DEVICE|BK 5000 Ultrasound Machine|Both 2D and 3D ultrasound is being used. 3D using optical tracking.
41323712|NCT03248050|BEHAVIORAL|Pharmacy encouraged to promote call centre use to clients|The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
41323713|NCT03745235|OTHER|stress reduction program based on mindfulness|a two and a half hour session per week for 8 weeks
41323714|NCT03745235|BIOLOGICAL|venipunctures|1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months
40805954|NCT06514261|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40805955|NCT06514261|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40805956|NCT06514261|PROCEDURE|Buccal Swab|Undergo buccal swab
40805957|NCT06514261|DRUG|Iadademstat|Given PO
40805958|NCT06514261|DRUG|Venetoclax|Given PO
40805959|NCT06225518|BEHAVIORAL|Individualized physical activity management system|Participants will be provided with personalized exercise recommendations determined by a decision system by public health nursing and physiotherapy and rehabilitation experts via the mobile application. Targets will be determined for participants based on their completion of physical activity recommendations every day and every week in the mobile application. The initial program will be individually created based on the initial data collected and each participant's lifestyle, physical activity level and barriers to physical activity. Then, depending on the participants' ability to achieve their goals, the duration and intensity of the suggestions given will be individualized to a level that the person can complete.
40805960|NCT04360005|DRUG|Asciminib|Patients receive Asciminib
41153162|NCT03967093|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.
40805962|NCT05432596|DRUG|ATI-1777 2.0% w/w|ATI-1777 topical solution 2.0% w/w
41323715|NCT03745235|OTHER|psychometric questionnaires|"* Cohen PSS' perceived stress scale~* Beck's anxiety and depression questionnaires~* Watson's affectivity questionnaire, positive affect and negative affect schedule~* optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~* IN-OUT DASQ dispositional affective style questionnaire"
40805963|NCT05432596|DRUG|ATI-1777 1.0% w/w|ATI-1777 topical solution 1.0% w/w
40805964|NCT05432596|DRUG|ATI-1777 0.5% w/w|ATI-1777 topical solution 0.5% w/w
40805965|NCT05432596|DRUG|Vehicle|Vehicle topical solution
40805966|NCT04305769|DRUG|Alanyl-glutamine|The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
40805967|NCT05735171|PROCEDURE|GTR surgery|Gross total resection of the enhancing tumor volume
40805968|NCT05735171|PROCEDURE|AI-guided surgery|Supramarginal resection including high-risk areas of recurrence
41153163|NCT03392779|DRUG|ZSP1601 25 mg|ZSP1601 tablet administered orally once daily under fasted condition
41008457|NCT05884697|OTHER|K-Bot Intervention|The K-Bot intervention is a conversational and button-based artificial intelligence Chatbot that is available in both English and Korean.
41323716|NCT04430283|DRUG|FDY-5301|FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
41323717|NCT04430283|OTHER|Placebo|Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.
41323718|NCT03103880|DEVICE|BreatheSmart|BreatheSmart is a comprehensive asthma monitoring system that combines a medical device and mobile application that are designed for use with Apple and Android mobile devices. The medical device connects to the mobile application using Bluetooth to facilitate the collection of controlled medication adherence, rescue medication usage, and asthma control.
41323719|NCT04285944|OTHER|Mavig X-ray Protective Drapes|Mavig X-ray Protective Drapes®
41323720|NCT01593579|BEHAVIORAL|Autonomic Function Tests|Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine \& standing heart rate \& blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
41323721|NCT01593579|OTHER|supine and standing catecholamines|patients will have blood drawn from supine and standing catecholamines.
41008458|NCT05884697|OTHER|Written Information|The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.
41008459|NCT06178874|DRUG|Insulin Glargine|hyperglycemic control
41008460|NCT06178874|DRUG|Insulin Degludec|hyperglycemic control
41008461|NCT06178874|DRUG|Insulin regular|hyperglycemic control
41008462|NCT03620318|DRUG|Crenolanib besylate|
41008463|NCT04399161|DRUG|Chlorhexidine mouthwash|A commercially available Chlorhexidine mouth rinse (Hexidine- 0.2 percentage Chlorhexidine gluconate) containing 0.2 percentage chlorhexidine gluconate per 10 ml will be used. 7.5 ml of the concentrate diluted with equal amounts of water to make 15ml will be used for rinsing.
41008464|NCT04399161|DRUG|Xylitol|Xylitol mouth rinse at 10 percentage concentration will be used. The mouth rinse will be prepared by dissolving 1.5 gm of xylitol powder in 15 ml of water.
41153164|NCT03392779|DRUG|Placebo 25mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
41153165|NCT03392779|DRUG|ZSP1601 50 mg|ZSP1601 tablet administered orally once daily under fasted condition
41153166|NCT03392779|DRUG|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
41153167|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily in the fasting state
41153168|NCT03392779|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
41323722|NCT01854593|DRUG|Bevacizumab|0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
41323723|NCT01854593|PROCEDURE|Vitrectomy|vitrectomy of 25 gauge system.
41323724|NCT01854593|DEVICE|Sham injection|Sham injection one day before vitrectomy
40805970|NCT05508984|DEVICE|Amma Cooling Caps|"Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen."
41153169|NCT03392779|DRUG|ZSP1601 175 mg|ZSP1601 tablets administerekd orally once daily under fasted condition
40805972|NCT04242095|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, and stool samples
40805973|NCT04242095|OTHER|Medical Chart Review|Review of medical records
41323725|NCT04055987|BEHAVIORAL|Visual biofeedback, auditory feedback and models|The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.
41323726|NCT04021459|PROCEDURE|blood samples|"3 samples: One before surgery on the arm vein (peripheral)~Two during the surgery, on two different venipuncture site :~* One on the arm vein (peripheral)~* One on ovarian vein (close to the tumor) All samples will be tested by the CellSearch method."
41323727|NCT02272283|DEVICE|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
41153170|NCT03392779|DRUG|Placebo 175 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
41153171|NCT03392779|DRUG|ZSP1601 275 mg|ZSP1601 tablets administered orally once daily in the fasting state
40805974|NCT04310436|BEHAVIORAL|Modifying saccades by looking down to naval.|Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.
41153172|NCT03392779|DRUG|Placebo 275 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
41323728|NCT01117012|DRUG|Ivacaftor|
41323729|NCT03219892|DEVICE|High-frequency rTMS|It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.
40805975|NCT04310436|BEHAVIORAL|Modifying saccades by looking in air.|Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
40805976|NCT04790344|DEVICE|Investigational LUX-Dx ICM Implant|All subject will receive an investigational version of the LUX-Dx ICM device.
41153173|NCT03392779|DRUG|ZSP1601 350 mg|ZSP1601 tablets administered orally once daily under fasted condition
41153174|NCT03392779|DRUG|Placebo 350mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
40805979|NCT05706155|BEHAVIORAL|Control Diet|Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 45 to 55% of energy from carbohydrates, prioritizing those with low glycemic index; 25 to 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
40805980|NCT05706155|BEHAVIORAL|Plant-based Diet|Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 45 to 55% of energy from carbohydrates, prioritizing those with a low glycemic index; 25 to 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
40805981|NCT06289426|OTHER|Yoga|The yoga program will consist of body awareness, meditation, poses, breathing practices, relaxation, and positive affirmations in Sanskrit and English.
41153175|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition
40805983|NCT06271265|DRUG|EXPAREL|A single dose of EXPAREL Injectable Product via LIA
41478125|NCT04916340|BEHAVIORAL|Muscular Strength Training Group|"Week 1 3 days/week Bench Press - 1 set at 80% of one repetition maximum~(1RM) Bent Over Row - 1 set at 80% 1RM Back Squat - 1 set at 80% 1RM Romanian Deadlift - 1 set at 80% 1RM~Week 2 3 days/week Bench Press - 2 sets at 80% 1RM Bent Over Row - 2 sets at 80% 1RM Back Squat - 2 sets at 80% 1RM Romanian Deadlift - 2 sets at 80% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 80% 1RM Bent Over Row - 3 sets at 80% 1RM Back Squat - 3 sets at 80% 1RM Romanian Deadlift - 3 sets at 80% 1RM"
41478126|NCT04916340|BEHAVIORAL|Muscular Fitness Training Group|"Week 1 3 days/week Bench Press - 1 set at 65% 1RM Bent Over Row - 1 set at 65% 1RM Back Squat - 1 set at 65% 1RM Romanian Deadlift - 1 set at 65% 1RM~Week 2 3 days/week Bench Press - 2 sets at 65% 1RM Bent Over Row - 2 sets at 65% 1RM Back Squat - 2 sets at 65% 1RM Romanian Deadlift - 2 sets at 65% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 65% 1RM Bent Over Row - 3 sets at 65% 1RM Back Squat - 3 sets at 65% 1RM Romanian Deadlift - 3 sets at 65% 1RM"
40805984|NCT06271265|DRUG|bupivacaine|A single dose of 0.25% bupivacaine via LIA
40805985|NCT06388564|DRUG|Axatilimab|Axatilimab will be administered at protocol defined dose.
40805986|NCT06388564|DRUG|Ruxolitinib|Ruxolitinib will be administered at protocol defined dose.
41008465|NCT04399161|DRUG|Probiotic|Probiotic mouth rinse will be prepared by using a commercially available probiotic product (Sporolac Plus powder- 1gm sachet containing not less than 1.5 billion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, Saccharomyces boulardii). Each sachet will be dissolved in 15 ml of water in a measuring cup and used as a mouth rinse.
41008466|NCT04002674|DRUG|Placebo oral capsule|"Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
41008467|NCT04002674|DRUG|Nilotinib Oral Capsule|Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
41008468|NCT05986552|BEHAVIORAL|Individual Schema Therapy (IST)|IST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in individual sessions by trained therapists.
41008469|NCT05986552|BEHAVIORAL|Individual-Group Schema Therapy (IGST)|IGST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in the combination of individual sessions and group therapy sessions by trained therapists.
41153176|NCT03392779|DRUG|Placebo 100mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
40805987|NCT06388564|DRUG|Corticosteroids|Corticosteroids will be administered at protocol defined dose.
41153177|NCT03392779|DRUG|ZSP1601 50 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
40805989|NCT05160012|BEHAVIORAL|Peer Comparison Message|"In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~1. If HTN control rate \<50th percentile, PCP is told they are below median~2. If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~3. If HTN control rate is between 90-100th percentile, PCP is told they are a high performer"
41153178|NCT03392779|DRUG|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
41478127|NCT03223948|DEVICE|'Optiflow'|High flow nasal oxygen delivery device 'Optiflow'
41153179|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
41153180|NCT03392779|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
41153181|NCT05056207|OTHER|Cohort I (patients receiving annual lymphedema screening|patientns who previously underwent preoperative perometer lymphedema screening
41153182|NCT05056207|OTHER|Cohort II (patients followed intensively for lymphedema)|patients who have recently undergone ALND
41153183|NCT03681171|OTHER|Therapeutic Dance|Participants attended therapeutic ballet sessions three times per week for six weeks.
41153184|NCT03441152|DEVICE|tDCS|Transcranial direct current stimulation
41153185|NCT01132222|DRUG|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
41153186|NCT00981578|DEVICE|ExAblate 2100|Conformal Bone System
41478128|NCT01479257|BEHAVIORAL|Questionnaires|36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
41153187|NCT00443599|DRUG|Insulin|Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
41323730|NCT03219892|DEVICE|Sham rTMS|The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
41478129|NCT01479257|DEVICE|Accelerometer|Small device worn on the hip for 7 consecutive days that measures physical activity.
41478130|NCT01479257|DEVICE|Smart Phone|Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
41478131|NCT03910764|OTHER|no intervention|Investigators review patients' medical records and collect personal data, underlying diseases, indwelling catheter duration, laboratory data, diagnosis, treatment and prognosis.
41478132|NCT01000610|DRUG|rituximab [MabThera/Rituxan]|1000 mg iv infusion on days 1 and 15
41153188|NCT00443599|OTHER|Usual Care|Participants receive standard Cardiac ICU care without tight blood glucose control.
41153189|NCT03087851|DRUG|Zoledronic Acid|Intravenous infusion of 5 mg zoledronic acid
41153190|NCT03806283|PROCEDURE|Omental Biopsy|The surgeon and clinical care team will conduct the c-section to deliver the baby and the placenta as clinically indicated. After delivery, during the closing procedures, the surgeon will indicate a time for a participating Ob/Gyn physician on the study team to collect the omental bio-specimen. Omentum is frequently excised or removed for clinical reasons during surgical procedures. Omentum has small blood vessels within it that have been used for evaluation of vascular functional changes in research. The investigators wish to isolate one to three vessels of 5 to 7 cm length. The surgeon will then close and the clinical care team will resume their standard of care activities.
41153191|NCT05534451|BEHAVIORAL|video laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
41323731|NCT02273557|DRUG|Asasantin ER (new formulation I - low)|
41323732|NCT02273557|DRUG|Asasantin ER (new formulation III - medium)|
41323733|NCT02273557|DRUG|Asasantin ER (new formulation II - high)|
41323734|NCT02273557|DRUG|Asasantin ER (present commercial formulation)|
41323735|NCT06304519|DEVICE|Dynamic ankle-foot orthosis|customized, carbon fiber, passive ankle-foot orthosis
41323736|NCT02014727|BIOLOGICAL|Group A1 : 50µg AMA1-DiCo + Alhydrogel|
41323737|NCT02014727|BIOLOGICAL|Group A2 : 50 µg AMA1-DiCo+ GLA-SE|
41323738|NCT02014727|BIOLOGICAL|Group B2 : Placebo|
41478133|NCT01000610|DRUG|methotrexate|10-25 mg weekly (oral or parenteral)
41478134|NCT01000610|DRUG|methylprednisolone|100 mg iv prior to each rituximab infusion
41478135|NCT02170350|PROCEDURE|Meditation therapy|Use brief mindful meditation practice
41478136|NCT02170350|OTHER|Quality-of-life assessment|Ancillary studies
41478137|NCT02170350|OTHER|Questionnaire administration|Ancillary studies
41478138|NCT00983918|DRUG|Desflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
41478139|NCT00983918|DRUG|Sevoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
41478140|NCT00983918|DRUG|Isoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
41153192|NCT05534451|BEHAVIORAL|video rigid laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video rigid laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
41153193|NCT05534451|BEHAVIORAL|video fiberoptic scope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be randomly divided into video fiberoptic scope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
41153194|NCT02330861|DEVICE|combowire and IVUS|
40805999|NCT03067181|OTHER|Best Practice|Undergo observation
41323739|NCT02871401|DRUG|Valganciclovir|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
40806000|NCT03067181|PROCEDURE|Biopsy|Undergo a tumor biopsy
40806001|NCT03067181|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40806002|NCT03067181|BIOLOGICAL|Bleomycin Sulfate|Given IV
40806003|NCT03067181|DRUG|Carboplatin|Given IV
41323740|NCT02871401|DRUG|Placebo|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
40806004|NCT03067181|DRUG|Cisplatin|Given IV
40806005|NCT03067181|PROCEDURE|Computed Tomography|Undergo a CT scan
40806006|NCT03067181|DRUG|Etoposide|Given IV
40806007|NCT03067181|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40806008|NCT03067181|OTHER|Pharmacogenomic Study|Correlative studies
40806009|NCT03067181|PROCEDURE|Pulmonary Function Test|Undergo a pulmonary function test
40806010|NCT03067181|OTHER|Quality-of-Life Assessment|Ancillary studies
40806011|NCT03067181|OTHER|Questionnaire Administration|Ancillary studies
40806012|NCT06412835|OTHER|cooperative learning|Students working in groups
41008470|NCT00799149|DRUG|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
41323741|NCT02938221|DEVICE|Telemedical video-oculography system|Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
40806014|NCT04379635|DRUG|Tislelizumab|administered via Intravenous (IV) injection
40806015|NCT04379635|DRUG|Cisplatin injection|administered via IV infusion
40806016|NCT04379635|DRUG|Paclitaxel injection|administered via IV infusion
40806017|NCT04379635|DRUG|Pemetrexed Disodium|administered via IV infusion
40806018|NCT04379635|DRUG|Placebos|Placebo to match tislelizumab IV infusion
40806019|NCT04379635|DRUG|Carboplatin|administered via IV infusion
41323742|NCT00691093|DRUG|fesoterodine|4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
41323743|NCT02776501|DRUG|Coppertone (BAY987521)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: Y49-103)
41008471|NCT02095184|DRUG|Anastrozole|1 mg daily
41323744|NCT01966263|PROCEDURE|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
41008472|NCT02095184|DRUG|Letrozole|2.5 mg daily
41008473|NCT02515539|DEVICE|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
41008474|NCT00019474|BIOLOGICAL|filgrastim|
41008475|NCT00019474|BIOLOGICAL|recombinant interferon alfa|
41323745|NCT01966263|PROCEDURE|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
40806020|NCT04549571|OTHER|Decision Aid iCanDecide - ESE website|Utilize the iCanDecide - ESE website
40806021|NCT04549571|OTHER|Decision Aid iCanDecide - S website|Utilize the iCanDecide - S website
40806022|NCT04549571|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40806023|NCT04549571|OTHER|Interview|Participate in interview
40806024|NCT04549571|OTHER|Training|Receive training
40806025|NCT04549571|OTHER|Media Intervention|Utilize the CDB
40806026|NCT04549571|OTHER|Best Practice|Utilize usual care
40806027|NCT04549571|OTHER|Survey Administration|Ancillary studies
40806028|NCT04549571|OTHER|Quality-of-Life Assessment|Ancillary studies
40806029|NCT05181618|DRUG|Emicizumab|The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
40806030|NCT05157971|DRUG|Cyclophosphamide|Given IV
41323746|NCT01966263|PROCEDURE|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
41323747|NCT01966263|PROCEDURE|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
41323748|NCT01790711|PROCEDURE|FMT through mid-gut|
40806031|NCT05157971|DRUG|Cytarabine|Given SC, IV or IT
40806032|NCT05157971|DRUG|Daunorubicin Hydrochloride|Given IV
40806033|NCT05157971|DRUG|Mercaptopurine|Given PO
41323749|NCT05560893|BEHAVIORAL|Relational Savoring Intervention|Relational savoring (RS) involves recalling a time when one supported or comforted another person and doing so brought deep positive emotion (joy, satisfaction, love, or peace); these moments of connection in service of another are common among the CSPs who work for our community agency, but may go unnoticed in the face of the urgent stressors the COVID-19 pandemic has brought about. Prolonging and enhancing attention to these moments has the potential to both help CSPs restore regulation in the face of stress and to motivate CSPs to continue engaging in meaningful work that serves their communities.
41323750|NCT01564667|BEHAVIORAL|Attention Bias Modification Training Protocol|Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
41323751|NCT05941169|PROCEDURE|Cytoreductive Nephrectomy|The experimental intervention consists of cytoreductive nephrectomy (CN) or any ablative local therapy within 6 months and 1 year after start of systemic treatment. All types of ablative local therapy are allowed as a substitute for CN
41323752|NCT02195817|DRUG|Selincro® 18 mg with continuous psychosocial support: Cohort A|
41323753|NCT02195817|OTHER|Initial psychosocial support: Cohort B|
41323754|NCT00345501|DRUG|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
41153195|NCT02877680|BEHAVIORAL|T1Doing Well|Strengths-based mobile health (mHealth) app for parents of adolescents with type 1 diabetes, which will prompt parents to recognize and reinforce their adolescents' diabetes-related strength behaviors
41323755|NCT00345501|DRUG|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
40806034|NCT05157971|DRUG|Methotrexate|Given IT
40806035|NCT05157971|DRUG|Pegaspargase|Given IM or IV
40806036|NCT05157971|DRUG|Prednisone|Given PO
40806037|NCT05157971|DRUG|Venetoclax|Given PO
40806038|NCT05157971|DRUG|Vincristine Sulfate|Given IV
41008476|NCT00019474|DRUG|fluorouracil|
41008477|NCT00019474|DRUG|hydroxyurea|
41323756|NCT06123390|OTHER|The Responses to Illness Severity Quantification (RISQ) System|The RISQ System involves: \[1\] the RISQ score: calculated routinely using the \[2\] documentation record and linked to \[3\] score-matched recommendations. Introduction into clinical care is supported by \[4\] the RISQ System implementation package. During the 2 month prior to implementation, front-line staff in the intervention arm will be trained on and will practice the use of the RISQ System .
41323757|NCT06336343|DRUG|Bimekizumab|Bimekizumab 320 mg via subcutaneous injections. Bimekizumab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to and neutralizes the biologic functions of both interleukin-17A (IL-17A) and IL-17F, which are known to increase inflammation.
41323758|NCT05855395|DRUG|Glucocorticoid|standard of care combined with glucocorticoid(dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)
41323759|NCT03212846|OTHER|Hippotherapy|Children will receive the hippotherapy treatment, based on horse walking in a regular way led by an experienced leader. Sessions will be performed for 45 minutes once weekly for 12 consecutive weeks in an indoor riding area.
41008478|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
41323760|NCT02128984|DIETARY_SUPPLEMENT|Symbiotic Formula with DHA and antioxidants|6 months intervention.
41323761|NCT02128984|DIETARY_SUPPLEMENT|Standard Formula|6 months intervention.
41323762|NCT01725256|DRUG|AIR001 (sodium nitrite inhalation solution)|Dose arms specify dose loaded into the I-neb AAD System nebulizer
41323763|NCT04470128|DRUG|Stage I: HSK21542 0.5 μg/kg|intravenous injection
40806039|NCT05476887|DRUG|KP104|KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.
41153196|NCT05852054|BEHAVIORAL|OB Provider Clinical Decision Support (CDS)|When an eligible patients' chart is opened by a provider, the provider will be alerted to counsel patients about future risk for T2D and hypertension and the need to establish a primary care medical home. The alert will include a 'referral' to primary care and a brief guide with 'key points for counseling'. For patients with prior GDM, this will also include an option to order guideline-recommended oral glucose tolerance test (OGTT) with a single click.
40806041|NCT04516070|OTHER|Questionnaire Administration|Ancillary studies
40806042|NCT04516070|RADIATION|Stereotactic Radiosurgery|Undergo SRS
40806043|NCT06407349|OTHER|Communication Board|communication board based on a functional communication picture of basic needs of categories ( food, clothes, object, and actions)
40806044|NCT06407349|OTHER|Traditional Therapy|Traditional Therapy
41323764|NCT04470128|DRUG|Stage I: HSK21542 1 μg/kg|intravenous injection
41323765|NCT04470128|DRUG|HSK21542 0.5 μg/kg|intravenous injection
41323766|NCT04470128|DRUG|HSK21542 1 μg/kg|intravenous injection
41323767|NCT04470128|DRUG|HSK21542 2 μg/kg|intravenous injection
40806049|NCT06200155|DRUG|Psilocybin|Given by PO
40806050|NCT06200155|OTHER|Niacin|Given by PO
41323768|NCT04470128|DRUG|Placebo|intravenous injection
41323769|NCT05678842|OTHER|Descriptive|Descriptive
41323770|NCT01962688|DEVICE|Handheld ultrasound|Handheld ultrasound determination of IVC diameter
41008479|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
40806054|NCT05359276|DRUG|Olipudase alfa|GZ402665
41008480|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
41008481|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
41008482|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
41008483|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
41008484|NCT00678561|DRUG|Placebo Vehicle|Topical treatment once daily for 28 days
41323771|NCT01962688|DEVICE|Sham ultrasound|sham ultrasound to facilitate blinding
41323772|NCT04705337|DRUG|Levosimendan|administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
41323773|NCT04705337|OTHER|Placebo|administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
41153197|NCT05852054|BEHAVIORAL|Patient Education (OB Visit)|A 1-page document will be printed or delivered electronically for eligible patients after every postpartum OB visit during the STEP-UP condition. The document will encourage patients to know the risk and will describe the importance of routine primary care and chronic disease evaluation and management. It will also provide tips for lowering risk through lifestyle changes. Patient materials will be delivered in English or Spanish based on the structured EHR variable for preferred language.
40806056|NCT04979793|DRUG|L-citrulline|3 gram sachet, L-citrulline
41323774|NCT01985373|DRUG|Intravenous immunoglobulin infusion|Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
41323775|NCT02758613|DRUG|Baricitinib|Administered orally.
41323776|NCT02758613|DRUG|Placebo|Administered orally.
41323777|NCT02378246|DIETARY_SUPPLEMENT|Iodine|
41323778|NCT02378246|DIETARY_SUPPLEMENT|Placebo|
40806057|NCT04979793|DRUG|Placebo|Milk powder placebo
41153198|NCT05852054|BEHAVIORAL|Text messaging|At 3 months postpartum, all eligible patients who have not scheduled a primary care visit will receive a motivational text to prompt scheduling; a second text will be sent for those who still have not made an appointment. Among those who schedule a visit, a reminder text will be sent before the visit. Texts will be in English or Spanish based on patients' preferred language field in the EHR and written at a \<5th grade reading level.
41153199|NCT05852054|BEHAVIORAL|Patient Outreach|Patients who have not scheduled a primary care visit by 4 months postpartum will receive outreach from a trained coordinator who will assist with scheduling and help patients troubleshoot common barriers, such as concerns about transportation or cost.
41153200|NCT05852054|BEHAVIORAL|Primary Care Provider Clinical Decision Support (CDS)|The CDS will notify the provider that the patient had a recent high-risk pregnancy and signal the need to counsel the individual about their future risk for T2D and/or hypertension and the need for ongoing care. A brief guide with 'key points for counseling' described in plain language will be provided. For patients with prior GDM, the CDS will also include an easy to access 'smartset' to order appropriate testing (A1c, FG, or OGTT) based on time since delivery and provider discussions with the patient.
41323779|NCT05910814|BEHAVIORAL|Sleep Deprivation (SD)|Participants in the sleep deprivation group will spend a night awake, under the supervision of an investigator, at Croix-Rousse Hospital. The investigator will provide a list of activities to maintain the participant awake.
41323780|NCT05910814|BEHAVIORAL|Normal Night (Night)|Participants in the normal night group will spend one night sleeping in their own home.
41153201|NCT05852054|BEHAVIORAL|Patient Education (Primary Care Visit)|A 1-page material will again be automatically printed or delivered electronically for eligible patients after their first primary care visit; it will replicate content from prior material provided after the OB visit.
41323781|NCT05910814|BEHAVIORAL|Physical Exercise (HIIE)|"Participants in the physical exercise group (i.e. IM+HIIE, PP+HIIE, SD+PP+HIIE) will start with a 2-minute warm-up on an ergometer cycle.~After the warm-up, they will perform 3 minutes of exercise at a workload customized to their maximal aerobic power (MAP) corresponding to 80 % their MAP and then rest actively for 2 minutes at 40 % of MAP. This cycle of 5 minutes will be repeated 3 times in row, resulting in a total of 17 minutes of physical exercise including the warm-up."
41153202|NCT02176317|BIOLOGICAL|Autologous Umbilical Cord Blood|All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10\^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
41153203|NCT05056701|OTHER|annual follow-up during 10 years|an annual follow-up is carried out systematically for a total of 10 years in order to detect the subsequent occurrence of CKD
41323782|NCT05910814|BEHAVIORAL|Rest control|Participants will watch a documentary during an equivalent time as the physical exercise (i.e. 17 minutes).
41323783|NCT05910814|BEHAVIORAL|Motor imagery|On the bimanual finger tapping task composed of 8 elements, the participant will be required to repeat the motor sequence mentally using MI (mental rehearsal of movement) during twelve blocks of 30 seconds. Participant will imagine performing the sequence as fast and accurately as possible without overt movement.
41323784|NCT05910814|BEHAVIORAL|Physical Practice (PP)|Participants will practice a bimanual sequential finger tapping task composed of 8 movements. Participant will be required to perform the sequence as fast and as accurately as possible during blocs of 30 s (i.e. twelve blocs during training).
41323785|NCT03717363|PROCEDURE|Training programme|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
41323786|NCT03717363|BEHAVIORAL|Educational talk|An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
41323787|NCT00825019|DRUG|amibegron (SR58611A)|oral administration of 2x 700 mg/day in 12h intervals
41323788|NCT00825019|DRUG|placebo|oral administration in 12h intervals
41323789|NCT00825019|DRUG|paroxetine|oral administration of 20 mg/day
41323790|NCT03790384|DRUG|Mitomycin|Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
41323791|NCT01286116|DEVICE|Parachute Implant|Mechanical ventricular partitioning
41323792|NCT02992834|BIOLOGICAL|IL-2 pre-treated CD19 cells|IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
41008485|NCT00678561|DRUG|Placebo Vehicle|Topical treatment twice daily for 28 days
41323793|NCT02992834|BIOLOGICAL|IL-7/IL-15 pre-treated CD19 cells|IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
41323794|NCT04231955|DIAGNOSTIC_TEST|numerical rating scale|patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10 and the result was recorded as pain intensity level.
41323795|NCT04231955|OTHER|visual analogue scale|"Patients were asked to marked their pain intensity level on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
41323796|NCT04231955|OTHER|color analogue scale|"Patients were asked to marked their pain intensity level on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
41323797|NCT04231955|OTHER|faces rating scale|"Patients were asked marked their pain on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
41323798|NCT04027101|DRUG|Baricitinib|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
41323799|NCT04027101|DRUG|Placebos|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
41323800|NCT05418569|DEVICE|Intervention arm - A new smartphone application for pediatric type 1 DM|An evidence-based locally tailored Chinese smartphone application for pediatric type 1 DM
41323801|NCT05418569|OTHER|Standard diabetic eduction|Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic
41323802|NCT03997929|DIAGNOSTIC_TEST|1.3 BETA D GLUCAN|dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)
41323803|NCT02181036|OTHER|family work shop|2-3 hours per session, one session per week, a total of 6 weeks of family work shop
41323804|NCT04752943|OTHER|Tips By Text Messages|Texts sent to caregivers meant to increase parent child interaction around literacy, sent to participants 3 x a week for 7 months
41323805|NCT00526461|DRUG|HPPH|IV
41323806|NCT03882255|DRUG|Ponesimod dose range (2 - 20 mg)|Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.
41323807|NCT03882255|DRUG|Placebo Propranolol|Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.
41323808|NCT03882255|DRUG|Propranolol 80 mg|Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.
41323809|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
41323810|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
40806065|NCT05314543|OTHER|Hypoxia|Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
40806066|NCT06462365|BIOLOGICAL|TRX103|TRX103 infusion via central line.
41153204|NCT01323309|BEHAVIORAL|Individual Meaning-Centered Psychotherapy (IMCP)|IMCP is based on the principles of Viktor Frankl's Logotherapy, and is designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose in their lives even as they approach the end of life. IMCP is structured as a 7-session (1-hour weekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. In addition we will be asking patients in the IMCP arm to complete an optional weekly session rating survey
41323811|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
41323812|NCT00685841|DRUG|Salmeterol MDI|Salmeterol MDI 42 mcg BID
41323813|NCT00685841|DRUG|Placebo|Placebo BID MDI
41323814|NCT06348953|OTHER|selective caries removal and conventional non-bioactive restorative system|conventional dental restorative adhesive and resin based composite
41323815|NCT06348953|OTHER|selective caries removal and bioactive restorative system|bioactive dental restorative resin based system
41323816|NCT02863705|DRUG|brimonidine tartrate/timolol malate Ophthalmic Solution|One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
41323817|NCT02863705|DRUG|bimatoprost ophthalmic solution 0.01%|Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
41323818|NCT01125878|DIETARY_SUPPLEMENT|Placebo|placebo
41323819|NCT01125878|DIETARY_SUPPLEMENT|Starch composite B|fiber mixture
40806072|NCT05778864|DRUG|LY3473329|Administered orally.
40806073|NCT05626322|DRUG|Maplirpacept|Intravenous infusion
40806074|NCT05626322|DRUG|Tafasitamab|Intravenous infusion
40806075|NCT05626322|DRUG|Lenalidomide|Oral (by mouth)
40806076|NCT06364696|DRUG|ASP4396|Intravenous (IV) infusion
41323820|NCT01125878|DIETARY_SUPPLEMENT|Starch composite C|fiber mixture
41323821|NCT01125878|DIETARY_SUPPLEMENT|Starch composite D|fiber mixture
41323822|NCT00502632|DRUG|Urokinase and Dornase alfa|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
41323823|NCT00502632|DRUG|Urokinase|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* 25ml normal saline, twice daily for 4 days"
41478141|NCT00983918|DRUG|Propofol|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
40806078|NCT06550895|DRUG|Cilta-cel|Cilta-cel infusion will be administered intravenously.
41323824|NCT01094951|BEHAVIORAL|ENGAGE|During Stage 2, investigators will train Neighborhood House caseworkers to 1. provide psychoeducation that addresses client-specific barriers to evaluation and care; 2. use shared decision-making strategies to engage seniors and arrive at a decision about where and from whom to receive an evaluation and possible care; and 3. provide connections to preferred community-based mental health services.
41323825|NCT03304327|BEHAVIORAL|Mindfulness and Yoga Training|"Centering and Breathing- Practice begins by turning attention to the breath to help participants make the transition from the busy, doing, outward focus of daily life into the mindful, balanced, internal focus central to yoga practice.~Practices:Breath awareness, the relaxed abdominal breath. Posture Practice-Warm up with the range-of-motion sequence to take the major joints of the body through their full range of motion.This is done lying down with the head on the floor; the head can be supported by a small, folded towel if desired.~Practices: Knee-to-chest sequence, Arms and Shoulders, Gentle Spinal Twist, Apanasana.~Standing Poses for Strength and Balance, to enhance function and confidence. Practices: Mountain Pose, Flying Crane Sequence, Tree Pose, Warrior 2 and Side Angle.~Relaxation- Practice concludes with guided relaxation to quiet the mind and calm the body.~Practices: Seated Mountain Pose, even breath, extended exhalation,Yoga Nidra."
41323826|NCT05344976|BIOLOGICAL|MSLN STAR-T cells|Patients with advanced MSLN-positive solid tumors will be recruited, and autologous-derived MSLN-STAR-T cells will be infused intravenously at escalating doses of 1×10\^7-1×10\^8 MSLN-STAR-T cells. The CAR-T ratio will be monitored at predetermined times (day 0, day 4, day 7, day 10, day 14, day 28).
41323827|NCT00630812|DRUG|inhaled mannitol|400 mg BD for 26 + 26 weeks
41008486|NCT03454555|BEHAVIORAL|Shared Decision Making|"The Shared Decision Making (SDM) intervention is a patient-provider communication intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision about chronic pain treatment. The intervention will have both clinician and patient educational components. The content of the clinician component will be based on the Agency for Healthcare Research and Quality's SHARE: Seek, Help, Assess, Reach, Evaluate Approach, which is a 5-step process for shared decision making that includes exploring and comparing the benefits, harms, and risks of each option through meaningful dialogue about what matters most to the patient. Participants randomized to Arm 1 will have their study visits and opioid use managed by an SDM-trained clinician at their practice."
41323828|NCT00630812|DRUG|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
41323829|NCT01887782|DEVICE|HFL rTMS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
41323830|NCT01887782|DEVICE|iTBS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
41323831|NCT04270487|OTHER|IBS Diet|Patients will be randomized to a diet or a mediation treatment
41323832|NCT04270487|DRUG|Otilonium Bromide|Patients will be randomized to a diet or a mediation treatment
41008487|NCT03454555|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain|The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) intervention is an empirically based behavioral pain management behavioral therapy intervention, including MI to enhance motivation for active participation in the CBT-CP, and the use of CBT-CP to enhance pain coping skills. One individual MI session will focus on patient engagement and enhancing a patient's own intrinsic motivation for CBT-CP participation. MI will also be woven into the group CBT-CP sessions. We will deliver 8 sessions of CBT-CP, as is standard in a group setting, in-person or virtually.
41008488|NCT05902390|DEVICE|hydrogel spacer|Randomly assigned to either the treatment group, who were injected with hydrogel spacer, or the control group, who were not injected with hydrogel spacer.
41478142|NCT00608192|BEHAVIORAL|Testing, Education, & Counseling (TEC)|Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
41478143|NCT00608192|BEHAVIORAL|Hepatitis Care Coordination (HCC)|HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
41478144|NCT04047537|OTHER|Medical Food Formulation 1|WBF-0011
41478145|NCT04047537|OTHER|Medical Food Formulation 2|WBF-0011 (0.2X concentration)
41008489|NCT05666401|PROCEDURE|follicle diameter and duration of procedure|to investigate if smaller follicles thrive embryos as the bigger follicles
41478146|NCT04047537|OTHER|Placebo|Placebo Capsules identical to those containing Formulation 1 and 2
41323833|NCT01362699|DRUG|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
41323834|NCT01362699|DRUG|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
41478147|NCT01901848|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
41478148|NCT01901848|DRUG|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
41323835|NCT06066957|DRUG|Letermovir 480 MG [Prevymis]|"Letermovir for CMV prophylaxis in thoracic organ transplant recipients.~Letermovir will be administered by oral administration, as per study protocol. The intended duration of therapy will be up to 365 days, depending on organ transplanted and donor and recipient CMV status. However, treatment may discontinued as discussed in Section 7.~Letermovir is dosed at 480mg daily for patients with CrCl \>10. Dose adjustment, as per package insert, is recommended in setting of co-administration of cyclosporine, with dose reduction of letermovir to 240mg daily. Missed doses of letermovir will not be made up."
41478149|NCT01901848|DRUG|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
41478150|NCT01901848|BEHAVIORAL|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
41478151|NCT01901848|BEHAVIORAL|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
41478152|NCT02691832|DEVICE|"Dräger double sensor"|"The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature."
41478153|NCT02610816|OTHER|1 Food Elimination Diet|Participants eliminate milk from the diet for 12 weeks
41478154|NCT02610816|OTHER|4 Food Elimination Diet|Participants eliminate milk, egg, wheat, soy from the diet for 12 weeks
41323836|NCT02691221|BEHAVIORAL|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
41323837|NCT04325906|DEVICE|high flow nasal cannula (HFNC)|HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher \&Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.
41478155|NCT02610816|OTHER|4 Food Elimination Diet (post 1FED failure)|Participants that fail to respond to 1FED in phase 1 eliminate milk, egg, wheat, soy from the diet for 12 weeks in Phase 2
40806079|NCT06550895|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
40806080|NCT06550895|DRUG|Daratumumab|Daratumumab will be administered subcutaneously as a part of DRd induction therapy.
40806081|NCT06550895|DRUG|Lenalidomide|Lenalidomide will be administered orally as a part of DRd induction therapy.
40806082|NCT06550895|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously as a part of DRd induction therapy.
41478156|NCT02610816|DRUG|Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)|Participants that fail to respond to 4FED in phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily for 12 weeks in Phase 2
41478157|NCT00155233|DRUG|Nalbuphine and morphine|
41478158|NCT04851275|BEHAVIORAL|Physicians trained in shared decision making|Physicians in this group were trained in shared decision making
40806083|NCT03520920|DRUG|Zanubrutinib|Administered zanubrutinib 160 mg orally (PO) BID continuously
40806084|NCT03520920|DRUG|Rituximab|Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.
40806085|NCT02096211|DEVICE|COC 36mm|Total Hip Replacement with COC 36mm Acetabular Cup System
41323838|NCT04325906|PROCEDURE|Prone positioning (PP)|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.
40806087|NCT05308407|OTHER|Focus Groups|No intervention involved in this phase of the study
41323839|NCT02282176|DRUG|Azithromycin|Azithromycin IV 10mg/kg daily for 10 days
41323840|NCT02282176|DRUG|Placebo|Azithromycin placebo (5% Dextrose) daily for 10 days
41323841|NCT03517449|DRUG|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
40806088|NCT05308407|OTHER|Pilot randomized controlled trial|The intervention is a virtually delivered, 12 weekly group-based active video game-centered lifestyle physical activity intervention (POWER UP) targeting affect to improve function and quality of life in insufficiently active AYAs with central nervous system tumors.
40806089|NCT05145127|DRUG|PF-06741086|"For participants aged ≥12 years 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.~For participants aged ≥6 to \<12 years is marstacimab 150 mg SC for initial loading dose followed by 75 mg SC QW. 150 mg sc qw is prescribed for participants who meet dose escalation criteria."
40806090|NCT04169529|DEVICE|Reveal LINQ|Insertion of Reveal LINQ device to characterize collected data from patients with COPD.
40806091|NCT04060108|DRUG|MDMA|80mg, 120mg, Placebo
41008490|NCT00424372|DRUG|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
41008491|NCT00628290|DRUG|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
41008492|NCT00628290|DRUG|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
41008493|NCT01857063|DRUG|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
41008494|NCT01857063|DRUG|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
41323842|NCT03517449|DRUG|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
41323843|NCT03517449|DRUG|Paclitaxel|80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
41323844|NCT03517449|DRUG|Doxorubicin|60 mg/m\^2 administered by IV on Day 1 of each 21-day cycle.
41478159|NCT04851275|BEHAVIORAL|Physicians were not trained in shared decision making|Physicians did not receive training in shared decision making
41478160|NCT00567437|OTHER|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
41478161|NCT01584531|DRUG|rigosertib|"Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis.~Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose.~The patient will fill a diary indicating the day and time of drug intake."
41323845|NCT03499080|BEHAVIORAL|Medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
41323846|NCT03499080|BEHAVIORAL|Treatment as usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
41323847|NCT03499080|BEHAVIORAL|Treatment as usual Åråsen|Unit colocated with the medication free unit. Similar treatment program. Short treatment duration (average 3 weeks).
41478162|NCT00650988|PROCEDURE|Cryospray Ablation|Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
41478163|NCT05470933|DRUG|WJ01075|"Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials."
40806092|NCT04878510|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
40806093|NCT04878510|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
40806094|NCT05034042|DRUG|Fezolinetant|oral
40806095|NCT05034042|DRUG|Placebo|oral
41323848|NCT06067282|OTHER|Microteaching|"This program selects five kinds of core teaching skills for training, and the training program is extracted in Microteaching ."
41323849|NCT03442348|DIETARY_SUPPLEMENT|Omega 3 fatty acid|Participants in the bottom median of dietary fibre intake (\<15 g per day) will be randomised into one of two arms. Participants in the second arm (N\>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
41323850|NCT03442348|DIETARY_SUPPLEMENT|Inulin fibre|The participants in the control arm (N\>32) will be asked to take 20 g of fibre (resistant starch + inulin) per day that are known favour production of SCFAs in the colon for a period of 6 weeks. The inulin powder will be provided in pre-weighed sachets containing 10g each which can be taken mixed in water or a suitable beverage of choice taken twice (morning and evening) per day.
40806099|NCT02870517|OTHER|Relaxing Music|Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have \<60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
40806100|NCT02870517|OTHER|No Music|The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
40806101|NCT05952973|BEHAVIORAL|SkillTalk|Online Educator Mircoskill Training and Parent Microskill Training
41323851|NCT01314976|DRUG|Metronidazole|"Metronidazole, oral suspension, 40mg/ml.~1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents."
41323852|NCT01314976|DRUG|Placebo|"Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis."
41008495|NCT05470816|DRUG|Tranexamic Acid 100Mg/ml Inj Vial 10ml|Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery
41323853|NCT00003077|DIETARY_SUPPLEMENT|omega-3 fatty acid|
40806102|NCT05653843|DEVICE|Endoscopic clip placement in the gastrointestinal tract.|The placement of a mechanical endoscopic clip in the gastrointestinal tract.
40806103|NCT03150693|DRUG|Allopurinol|Given PO
40806104|NCT03150693|DRUG|Cytarabine|Given IT, IV, SC
40806105|NCT03150693|DRUG|Daunorubicin Hydrochloride|Given IV
40806106|NCT03150693|DRUG|Vincristine Sulfate|Given IV
40806107|NCT03150693|DRUG|Dexamethasone|Given PO or IV
40806108|NCT03150693|DRUG|Pegylated L-Asparaginase|Given IV
40806109|NCT03150693|DRUG|Methotrexate|Given IT, IV, PO
40806110|NCT03150693|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
40806111|NCT03150693|DRUG|Cyclophosphamide|Given IV
40806112|NCT03150693|DRUG|Mercaptopurine|Given PO
40806113|NCT03150693|BIOLOGICAL|Rituximab|Given IV
41008496|NCT05470816|DRUG|Placebo|Normal saline
41008497|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
40806114|NCT03150693|DRUG|Doxorubicin|Given IV
40806115|NCT03150693|DRUG|Thioguanine|Given PO
40806116|NCT03150693|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
40806117|NCT03150693|OTHER|Laboratory Biomarker Analysis|Correlative studies
40806118|NCT05815095|OTHER|PREAUT grid|Patient with abnormal results in this evaluation would be referred to a specialized center early for advice and treatment if necessary
40806119|NCT01708941|BIOLOGICAL|Ipilimumab|Given IV
41008498|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
41008499|NCT00143611|DRUG|Placebo|Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
41008500|NCT03995576|OTHER|thoracic sympathetic ganglion block|thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body
41008501|NCT03071796|DIETARY_SUPPLEMENT|multivitamin supplement|supplement includes 97 natural extracts
41008502|NCT03071796|DIETARY_SUPPLEMENT|Placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
41008503|NCT03266575|BEHAVIORAL|Pulmonary Rehabilitation Exercise|Participants will undergo Pulmonary Rehabilitation exercise. Participants will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session
41008504|NCT03266575|BEHAVIORAL|Home Based Exercise|Participants will undergo Home based exercise program consisting of strength and conditioning. Participants will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Participants will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
41008505|NCT01486563|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
41008506|NCT01486563|DRUG|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
41008507|NCT01753635|DEVICE|supraglottic airway placement and use|
41008508|NCT05118594|BEHAVIORAL|Pre-treatment psychotherapy recommendations|After patients complete an intake evaluation and prior to starting therapy, the assigned therapist will receive automatized feedback that consists of recommendations regarding the most suitable interventions (i.e., cognitive, behavioral, interpersonal or patient-centered) for each individual patients, based on patients' baseline characteristics and a machine learning algorithm developed in a previous study. Besides the interventions recommended, therapist will receive within the system guideline and tutorial videos showing how to deliver adequately the specific interventions recommended.
41008509|NCT05664997|BEHAVIORAL|playing assessment|Investigators used Edinburgh Handedness Inventory, the Wong-Baker Faces Pain Rating Scale, the Disability of Arm, Shoulder and Hand - Sports/Musicians (DASH-SM), the Rapid Upper Limb Assessment, and the 11-item revised version of the Occupational Balance Questionnaire (OBQ11 - T). All have their Turkish validity studies. A correlation analysis was performed to examine the relationship between the variables.
41323854|NCT01271387|DRUG|tasimelteon|20 mg tasimelteon capsules, PO single dose
41323855|NCT04383314|BEHAVIORAL|10-week exercise program on HA accumulation|A 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (2010), will be individually prescribed to 25 T2DM patients.Exercise training will be performed on Days 1 and 2 of each week under the supervision of licensed physical therapists. Participants will have the choice of using a treadmill or a recumbent stepper. The physical therapists will monitor blood glucose level, blood pressure, heart rate, and RPE during each exercise session. Participants will be asked to exercise at home on Day 3 of each week, and will not be supervised by the study team.
41323856|NCT03384628|DEVICE|First pair Senofilcon A contact lens|Fit assessment of the first pair contact lenses.
41323857|NCT03384628|DEVICE|Second pair Senofilcon A contact lens|Fit assessment of the second pair of contact lenses.
41323858|NCT03384628|DEVICE|Third pair Senofilcon A contact lens|Fit assessment of the third pair of contact lenses.
41323859|NCT03889327|BEHAVIORAL|Neuropsychological Feedback & Psychoeducation (Cognition)|The customary practice of providing feedback on neuropsychological test performance can address patient misperceptions of cognitive impairment by distinguishing between perceived and objective neuropsychological test performance. Explaining how normative data is derived by comparison to same age peers, patients are able to better understand their current cognitive functioning. The proposed intervention will employ both psychoeducation and neuropsychological feedback for participants assigned to the treatment group, and psychoeducation for participants assigned to the control group. Both groups will watch 3 brief videos (exactly the same length in time) and answer two qualitative questions following each video.
41323860|NCT03889327|BEHAVIORAL|Psychoeducation (Health)|Information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The control intervention will include expert testimony from a nutritionist and expert dietician.
41323861|NCT04564066|BIOLOGICAL|efgartigimod IV|intravenous infusions of efgartigimod
41323862|NCT04564066|BIOLOGICAL|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
41008510|NCT03310957|DRUG|ladiratuzumab vedotin|Given into the vein (IV; intravenously)
41008511|NCT03310957|DRUG|Pembrolizumab|IV infusion every 3 weeks
41008512|NCT04922333|DRUG|Risedronate|150mg over-encapsulated risedronate
41008513|NCT04922333|DRUG|Placebo|Capsules containing placebo tablets
41008514|NCT05498636|COMBINATION_PRODUCT|Selinexor combined with Prednisone, Etoposide, and Lenalidomide|Selinexor combined with Prednisone, Etoposide, and Lenalidomide
41008515|NCT04465175|DRUG|Magnesium Sulfate|Second dose magnesium sulphate infusion over one hour
41323863|NCT00108953|DRUG|Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Multi kinase inhibitor plus Chemotherapy
41323864|NCT00108953|DRUG|Doxorubicin/Placebo|Chemotherapy plus Placebo
41323865|NCT01316029|PROCEDURE|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
41323866|NCT03038802|BIOLOGICAL|Therapeutic hepatitis B vaccine|HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant
41323867|NCT03038802|BIOLOGICAL|Commercial Hepatitis B vaccine|Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant
41008516|NCT04465175|DRUG|Placebo|Normal saline (2.5 ml/kg) infusion over one hour
41008517|NCT00253565|DRUG|capecitabine|
40806120|NCT01708941|OTHER|Laboratory Biomarker Analysis|Correlative studies
41008518|NCT00253565|DRUG|imatinib mesylate|
41008519|NCT04280783|BEHAVIORAL|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
41008520|NCT04280783|BEHAVIORAL|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
41008521|NCT02584751|DRUG|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
41008522|NCT02584751|DEVICE|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
41008523|NCT02584751|PROCEDURE|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
41323868|NCT00979680|RADIATION|High-Dose radiotherapy|Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
41323869|NCT00979680|RADIATION|Chemo-radiotherapy|Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
41323870|NCT01701219|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
41323871|NCT00163904|BEHAVIORAL|High mono-unsaturated fat/low carbohydrate diet|
41323872|NCT00163904|BEHAVIORAL|High carbohydrate/low fat diet|
41323873|NCT01146041|DRUG|Rivastigmine|Rivastigmine 1.5 mg Capsules
41323874|NCT01381718|DRUG|modafinil|Given PO
41323875|NCT01381718|OTHER|placebo|Given PO
41323876|NCT03308162|BEHAVIORAL|Cognitive behavioral experiential group therapy|The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
41323877|NCT03398746|PROCEDURE|LOOP Technique|Placement of subcutaneous loop drain
41323878|NCT03398746|PROCEDURE|Standard incision and drainage|Incise and drain with placement of packing
41323879|NCT02260648|DRUG|Evacetrapib|Administered orally
41008524|NCT02584751|PROCEDURE|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
41008525|NCT02584751|PROCEDURE|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
41008526|NCT02584751|PROCEDURE|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
41323880|NCT02260648|DRUG|Ezetimibe|Administered orally
41323881|NCT02260648|DRUG|Atorvastatin|Administered orally
41323882|NCT02260648|DRUG|Placebo|Administered orally
41323883|NCT02924818|OTHER|Clinical assessment|
41323884|NCT02924818|BEHAVIORAL|questionnaires|
41323885|NCT02924818|OTHER|pulmonary function test|
41323886|NCT02924818|BIOLOGICAL|blood test|
41323887|NCT02924818|BIOLOGICAL|microbiology|
41323888|NCT02924818|BIOLOGICAL|histology|
41323889|NCT02924818|OTHER|imaging|
41323890|NCT06364644|BEHAVIORAL|Community Champions|The UNLOAD-Heart Failure Program intervention includes problem solving training, community health worker support, and exercise support from health coaches at YMCAs.
41323891|NCT06364644|BEHAVIORAL|Homegrown Heroes|Monthly newsletters/videos on diabetes self-management, healthy lifestyle and heart failure prevention will be provided, as well as a membership to the local YMCA.
41323892|NCT03711877|DEVICE|Scalp cooling system|Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
41323893|NCT03711877|DEVICE|Cold cap|The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
41323894|NCT05494749|OTHER|zirconomer|teeth meeting the inclusion criteria are assigned to receive Zirconomer® restorations
41323895|NCT05494749|OTHER|HVGI-Equia Forte|teeth meeting the inclusion criteria are assigned to receive HVGI-Equia Forte® restorations.
41323896|NCT04934527|DRUG|Cytotect|"The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12."
41323897|NCT03139929|DIAGNOSTIC_TEST|MSFP|MSFPhold and MSFParm
41323898|NCT00243685|OTHER|Laboratory Assay|Chemotherapy
41323899|NCT00243685|OTHER|Mick Assay|Chemotherapy doctor determined from results
41323900|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia w. extra support|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
41323901|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.
41008527|NCT02584751|PROCEDURE|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
41008528|NCT04208412|DRUG|KVD900|KVD900 tablet 600 mg
41008529|NCT04208412|OTHER|Placebo|KVD900-matched Placebo Tablet
41323902|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia and depression|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.
41478164|NCT05974917|DEVICE|Serious Game (SG)|"SG which was conceived as a running game, in which an Avatar runs through the forest and overcomes obstacles through the player's performance of physical exercises.~Children will play while watching an imaginary Avatar, who shows the right movements to perform in order to collect rewards. SG will be projected with a 4K projector and controlled by the child's movements, which will be tracked in markerless mode using Azure's Kinect sensor. SG will include an adaptive tool to enable the experience based on the child's specific motor skills.~The dynamics of SG will be adapted by considering real motor and physiological data acquired during each SG session via a wristband. These data are necessary to keep the child in the aerobic zone (60-80% of maximum heart rate). The movements are:~1. Side bending: Moving an obstacle to open a passage.~2. High jump: Overcoming a low, frontal obstacle.~3. Side lunge: Avoiding a side obstacle.~4. Squat: Passing under a low, frontal obstacle."
41478165|NCT05415020|BEHAVIORAL|Lifestyle Behavior Protocol|Virtual training on building a skillset to improve lifestyle behavior that reduces migraine attacks
41323903|NCT01663844|BEHAVIORAL|Therapist Guided Internet-CBT for depression plus insomnia placebo|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
41478166|NCT05415020|BEHAVIORAL|Sham Behavior Protocol|Virtual training on the disease of migraine and how migraine can progress to chronic migraine.
41478167|NCT02357342|DRUG|Sirolimus|intravitreal injection
41478168|NCT02357342|DRUG|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
41478169|NCT03532633|PROCEDURE|cord blood|collection of cord blood
41478170|NCT03532633|PROCEDURE|blood sample infant|collection of remnant of clinically indicated blood sample
41478171|NCT03532633|PROCEDURE|blood sample mother|collection of remnant of clinically indicated blood sample. If not available blood sample is taken after mother agreed
41478172|NCT03532633|PROCEDURE|breast milk|collection of breast milk 1/week during neonatal care (maximum 8 weaks)
41478173|NCT03357081|DRUG|CEUS or Contrast enhanced Ultrasound|Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
41478174|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with interactivity and stigma content|Participants viewed an interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
41008530|NCT01470469|DRUG|SPD503 (extended-release Guanfacine hydrochloride)|Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
41008531|NCT01470469|DRUG|Placebo|Once-daily oral dosing in the evening for 12 weeks.
41008532|NCT00712088|BEHAVIORAL|Project ICARE|Group-level intervention (Project ICARE)
41323904|NCT04766151|DRUG|Transdermal glyceryl trinitrate 10mg patches|Transdermal patches applied to skin 30 minutes before cardiac catheterization
41323905|NCT04766151|DRUG|Placebo patches|Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
41008533|NCT00712088|BEHAVIORAL|HCT|Offer of HIV counseling and testing
41008534|NCT05580224|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
41323906|NCT01902862|DRUG|Bortezomib|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m\^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
41323907|NCT01902862|DRUG|Rituximab|Rituximab will be administered as intravenous infusion as 375 mg pert m\^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
41478175|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with stigma content only|Participants viewed a non-interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
41478176|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with interactivity only|Participants viewed an interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
41478177|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with no interactivity and no stigma content|Participants viewed a non-interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
40806121|NCT01708941|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV or SC
40806122|NCT06152575|DRUG|Elranatamab|Elranatamab will be administered subcutaneously
41323908|NCT00484549|PROCEDURE|Blood sample|Ischemic stroke hospitalized
40806123|NCT06152575|DRUG|Elotuzumab|Elotuzumab will be administered intravenously
41478178|NCT06076551|DIAGNOSTIC_TEST|Adenosine stress echocardiography|Transthoracic echocardiographic assessments will be performed using an ultrasound device (Vivid E95, General Electric Healthcare, Liestal, Switzerland). Color Doppler flow of the distal left anterior descending artery was examined from the modified apical four-chamber view of the anterior interventricular groove. Pulsed-wave Doppler registered blood ﬂow velocity patterns using a sample volume (2-3.0 mm) placed on the color signal. The ultrasound beam was aligned parallel to the vessel ﬂow. The velocity scale of color Doppler was set to 0.21 m/s. Coronary ﬂow Doppler images were acquired at baseline and at 1, 2, and 3 min after adenosine infusion in the same part of the artery. Anti-anginal medications, including calcium channel blockers, were discontinued before the study.
41008535|NCT01158625|OTHER|Change of time of administration|Change of time of administration
41008536|NCT03125369|PROCEDURE|Sleeve gastrectomy + duodeno-jejunal bypass|
41008537|NCT03125369|PROCEDURE|Roux-Y gastric bypass|
41008538|NCT03653754|DIAGNOSTIC_TEST|Measurement of growth and body composition|Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
41008539|NCT05230251|DRUG|177Lu-PNT2002|Men randomized to receive 177Lu-PSMA will receive 1 cycle of 177Lu-PSMA at a dose of 6.8MBq administered intravenously 2 weeks prior to the planned HDR administration in the Department of Nuclear Medicine as per local practice for the administration of therapeutic radiopharmaceuticals and consistent with good practices.
41008540|NCT05230251|RADIATION|High Dose Radiation|HDR brachytherapy will be administered as per local practice. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction.
41008541|NCT05713123|OTHER|A SPECT-CT whole body is added in VERITON-CT camera|A SPECT-CT whole body in VERITON-CT camera is added after the conventional procedure recorded in Anger camera
41008542|NCT06026891|DRUG|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
41008543|NCT02469610|OTHER|Intercostal block Bupivacaine based|Intercostal Bupivacaine block of 100ml over five intercostal spaces.
41008544|NCT00333606|BEHAVIORAL|Acupuncture|Body acupuncture of 1 specific point per trial session
41008545|NCT03194048|OTHER|Functional Chewing Training|"FuCT;~* Family training~* Providing optimal sitting posture for children to support oral sensorimotor functions~* Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~* Massage of the upper and lower gums through the front teeth to molar area~* Chewing training to stimulate lateral and rotational tongue movements~* Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day"
41008546|NCT03194048|OTHER|Classical Oral Motor Exercises|"Classical Oral Motor Exercises;~* Family training~* passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day"
41008547|NCT00153491|DRUG|artemether-lumefantrine|
41008548|NCT03273036|DRUG|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
41008549|NCT03273036|DRUG|Placebos|no injected agent
41008550|NCT05599035|DEVICE|repititive transcranial magnetic stimulation|a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
41008551|NCT06225466|DRUG|Rocuronium|After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.
41008552|NCT06225466|DRUG|Sugammadex|When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.
41008553|NCT06225466|OTHER|Anesthesia without neuromuscular blockade|Anesthesia without rocuronium or sugammadex
41008554|NCT04186962|OTHER|Behavioral: Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
41008555|NCT00004144|DRUG|bryostatin 1|
41008556|NCT00004144|DRUG|gemcitabine hydrochloride|
41008557|NCT01790412|BEHAVIORAL|Exercise group|Combined two land aerobic sessions and one aquatic activities session
41008558|NCT02970838|OTHER|Structured weight-loss program|"During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.~Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling."
41008559|NCT02999958|BIOLOGICAL|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
41008560|NCT04928326|DIAGNOSTIC_TEST|CorWatch|Non-invasive wearable monitor for the assessment of central venous pressure
41323909|NCT05504577|DRUG|Tranexamic acid injection|Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
41478179|NCT05134194|DRUG|Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine|Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
41008561|NCT00724451|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
41008562|NCT00724451|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
41008563|NCT00724451|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
41008564|NCT04856176|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|250 mcg
41008565|NCT04856176|DRUG|Pembrolizumab|200mg every 3 weeks
41323910|NCT05504577|DEVICE|apply the QCG|apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
41323911|NCT05504577|DEVICE|apply surgical gauze|apply the normal surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
41323912|NCT04282681|OTHER|Accelerometer Live-Streaming Tool|The only 'intervention' that will take place is the placement of the XLS tool(s) on the upper left chest and/or left wrist of the patient.
41323913|NCT04897438|PROCEDURE|Kidney allograft biopsy depending on donor-derived cell-free DNA levels|Kidney allograft biopsy is performed, when absolute levels of donor-derived cell-free DNA are above 50 copies/ml
41323914|NCT02658344|BIOLOGICAL|JOINTSTEM|Jointstem (Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml), 1 time injection
41323915|NCT02658344|DRUG|Saline solution|Saline solution (Sodium chloride 9mg/ml), 1 time injection
41323916|NCT05619679|OTHER|Kidney Transplantation|Kidney transplantation
41323917|NCT00984880|DRUG|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
41323918|NCT01128335|DRUG|MMF(1000mg bid) + tacrolimus + standard of care medications|MMF(1000mg bid) + tacrolimus + standard of care medications
41323919|NCT01128335|DRUG|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
41323920|NCT01128335|DRUG|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
41323921|NCT01128335|DRUG|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
41323922|NCT05133544|DEVICE|Endocuff with AI|Use of endocuff with computer assisted polyp detection
41323923|NCT05133544|DEVICE|AI alone|Use of computer assisted polyp detection
41323924|NCT01326117|DRUG|tadalafil|7 days of Cialis for Daily Use (5mg)
41323925|NCT05740579|PROCEDURE|laparoscopic cryopreservation of one ovary|Laparoscopic removal of one ovary as child. In adulthood cortical tissue is replaced in the abdomen in order to improve fertility and pregnancy rates in Turner syndrome women.
41323926|NCT02415764|BEHAVIORAL|Behavioral/Attitudinal OnTrack Role-Playing Game|"The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).~While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys."
41323927|NCT02297737|BEHAVIORAL|Tai Chi|
41323928|NCT02297737|OTHER|Health Education|
41323929|NCT05438459|BIOLOGICAL|Phase I part|Administration of GAIA-102 as a single agent or GAIA-102 and pembrolizumab in combination.
41323930|NCT05438459|BIOLOGICAL|Phase II part|Randomized into group of administration of GAIA-102 as a single agent or GAIA-102 or pembrolizumab in combination, group of standard treatment
41323931|NCT02576886|DEVICE|Gamma Camera|All images acquired with the General Electric Discovery 530c
41323932|NCT02576886|PROCEDURE|Prone Imaging|
41323933|NCT00098020|DRUG|Isotretinoin|
41323934|NCT04385147|OTHER|Endoscopic management according to standard of care|Endoscopic management according to standard of care by ERCP or EUS according to the indication in each case
41323935|NCT05939037|DRUG|Zanubrutinib Oral Product|Treatment will consist of Rituximab administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22 only (4 total infusions). The experimental part of the treatment will consist of Zanubrutinib, given once daily 320 mg (4 x 80 mg capsules). Although Zanubrutinib is taken continuously, therapy cycles are calculated per 28 days. Participants will be treated for a minimum of 6 cycles per protocol. Participants who still use Zanubrutinib at the end of study can continue indefinitely until registration and reimbursement in the Netherlands.
40806124|NCT06152575|DRUG|Pomalidomide|Pomalidomide will be administered orally
40806125|NCT06152575|DRUG|Dexamethasone|Dexamethasone will be administered orally
40806126|NCT06152575|DRUG|Bortezomib|Bortezomib will be administered subcutaneously or intravenously
40806127|NCT06152575|DRUG|Carfilzomib|Carfilzomib will be administered intravenously
41008566|NCT04856176|DRUG|pemetrexed|500mg/m2
41008567|NCT04856176|DRUG|Paclitaxel|200mg/m2
41008568|NCT04856176|DRUG|Carboplatin|AUC 5/6
41323936|NCT04224818|DRUG|Dual trigger|Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)
41323937|NCT04224818|DRUG|hCG (standard)|human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)
41323938|NCT04145869|PROCEDURE|Cholangiography|All patients will be subjected to intraoperative fluorescent and concommitant X-ray cholangiography
41323939|NCT03664284|PROCEDURE|subcutaneous disinfection|The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
41323940|NCT04562142|DEVICE|CAD-det|CAD-det test will be done on participants with suspected CAD clinically referred for ICA at a participating clinical investigation site.
41323941|NCT04810585|DRUG|Aflibercept + FOLFIRI|"Day 1. Aflibercept + FOLFIRI~* aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)~* Folinic acid: 400 mg/m2 IV infusion for over 2 hours~* Irinotecan: 150 mg/m2 IV infusion for over 1 hours~* 5-FU: 400 mg/m2 IV bolus injection for over 5 minute~* 5-FU: 2400 mg/m2 IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity"
41323942|NCT04843969|BEHAVIORAL|Stress induction|Exposure to a psychosocial stressor
41323943|NCT04843969|BEHAVIORAL|Control stress exposure|Exposure to a control task (no stress)
41323944|NCT04843969|BEHAVIORAL|Cue induction|Exposure to a smoking-related task
41323945|NCT04843969|BEHAVIORAL|Neutral cue exposure|Exposure to neutral cues
41008569|NCT01252459|RADIATION|Radiation Therapy|Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
41008570|NCT01252459|RADIATION|Radiation Therapy|Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
41323946|NCT02480179|DEVICE|H.E.G. (hematoencephalography) based neurofeedback|H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
41323947|NCT03712800|OTHER|Rhythmical massage|Rhythmical Massage according to Dr Ita Wegman, derived from Swedish Massage in the 1920s. Applied for various indications in the context of Anthroposophic Medicine, aiming at a recovery of self-regulation and self-healing forces.
41008571|NCT01647867|OTHER|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
41008572|NCT00972491|PROCEDURE|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
41008573|NCT02258152|DRUG|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
41478180|NCT05134194|DRUG|Capecitabine/eribulin/gemcitabine/vinorelbine|Capecitabine or eribulin or gemcitabine or vinorelbine
41478181|NCT04911465|DEVICE|Flashback CRI T1 Tablet|Collect continuous data on the compensatory reserve index, a measurement of a patient's central volume status.
41478182|NCT01219452|BIOLOGICAL|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
41478183|NCT06051084|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
41478184|NCT06051084|BEHAVIORAL|App-Delivered Coloring|An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
41323948|NCT03712800|BEHAVIORAL|HRV biofeedback|One of various biofeedback types, HRV biofeedback gives a visual feedback of the participant's heart rate variability as an indicator for general health, physical and cognitive performance, self-regulation and a decreased risk of illness.
41323949|NCT05485259|DIETARY_SUPPLEMENT|DL-alpha lipoic acid|Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.
41323950|NCT05485259|OTHER|placebo (rice starch)|Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months
41323951|NCT03347812|PROCEDURE|Endovascular Aortic Repair|Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.
41323952|NCT03347812|PROCEDURE|Total Arch Replacement|A kind of open surgery is performed for the replacement of total aortic arch.
41323953|NCT02383680|BIOLOGICAL|Yellow Fever Vaccination|The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.
41323954|NCT00570440|DRUG|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
41478185|NCT06181747|DEVICE|a serious mobile device-based game prototype (Save the Muse Home)|The cognitive impairment corresponding to the symptoms, which we are interested in, focuses on executive inhibition, motor inhibition, sustained attention, selective attention, working memory, and planning ability. The training content will be presented in different scenarios as effective training components. The story line of the warrior breakthrough runs through the whole game, each level is adapted according to the functional damage areas of different patients, and each level involves reward and punishment mechanisms to keep the interest of the players, the difficulty gradient of each level is kept moderate, and the game includes design elements such as space, time, object attributes, actions, rules, skills, and probabilities, etc., which ultimately completes Save the Muse Home, a serious game for the treatment of ADHD.
41478186|NCT00792727|DRUG|ketoprofen Patch|2 topical patches applied once daily for 28 days
41478187|NCT00792727|OTHER|Placebo Patch|2 topical placebo patches applied once daily for 28 days
41478188|NCT00143429|DRUG|Xalatan|
41478189|NCT06296524|OTHER|Footcore exercises and conventional therapy|30 minutes exercises protocol will be provided
41478190|NCT06296524|OTHER|conventional therapy|conventional therapy will be provided.
41478191|NCT02059720|PROCEDURE|HSCT|Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
41478192|NCT05672927|BIOLOGICAL|9-valent HPV vaccine, 2 doses alternate timing|Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.
41478193|NCT05672927|BIOLOGICAL|9-valent HPV vaccine, 3 doses standard timing|This will be the comparison group for the 2-dose group.
41323955|NCT04370964|OTHER|Lausanne Trilogy Play|"Trilogical game of Lausanne (Lausanne Trilogue Play in English abbreviated LTP), which allows an evaluation of the family alliance. This systematic observation provides a snapshot of the family structure and its adaptive abilities. It is based on the assumption that the ability to solve small tasks is representative of the ability to solve more important tasks.The LTP consists of modelling the different possibilities of interaction in a triad according to a four-part scenario: 1) one parent plays with the child, the other parent is simply present; 2) the parents switch roles; 3) both parents play together with the child; and 4) both parents have to talk together."
41323956|NCT04370964|OTHER|Lausanne Family Play|Lausanne Family Play (LFP) is a game situation adapted to families with more than one child. Thus, like the LTP, the LFP takes place in four phases:1) one parent plays with siblings while the other is in a third-observer position; 2) the parents reverse their roles;3) children play while parents are talking and 4) family members play together.
41323957|NCT05828732|OTHER|Using a mobile app that integrates with wearable devices|Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
41323958|NCT04426370|OTHER|Observational|Physical examination and questionnaires
41323959|NCT05698745|PROCEDURE|bioespecimen samples|Blood, serum, plasma, urine, stools, small/large bowel tissue.
41323960|NCT01303432|DIETARY_SUPPLEMENT|Yogurt supplemented with Mobilee|One yogurt (125mL) per day including 80mg of Mobilee
41323961|NCT01303432|DIETARY_SUPPLEMENT|Yogurt|One yogurt (125mL) per day
41478194|NCT00368095|BEHAVIORAL|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
41323962|NCT04509804|OTHER|non-interventional|non-interventional
41323963|NCT03317249|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram
40806128|NCT04644770|DRUG|JNJ-69086420|Participants will receive IV injection of JNJ-69086420.
41323964|NCT03317249|DIAGNOSTIC_TEST|heart rate monitor|24-hour heart rate monitor used to calculate mean heart rate and heart rate variability
41323965|NCT03317249|DIAGNOSTIC_TEST|Autonomic Nervous System (ANS) Activity|"Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):~Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements."
41323966|NCT03317249|DIAGNOSTIC_TEST|Haemodynamic variables|Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.
41323967|NCT03317249|OTHER|Echocardiogram|optional (for non-IST participants only)
40806129|NCT06341114|DRUG|BAT8008 injection|BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.
40806130|NCT06341114|DRUG|BAT1308 injection|One vial of 4 mL of concentrate contains 100 mg of BAT1308
41008574|NCT02258152|DRUG|Placebo|Placebo QD
41008575|NCT03579199|DEVICE|exploration of abdominal cavity and liver using a NIR/ICG camera|exploration of abdominal cavity and liver using a NIR/ICG camera
41008576|NCT04286282|BEHAVIORAL|Group Pyschotherapy|Group psychotherapy
41323968|NCT02331524|BEHAVIORAL|Activity Feedback and Encouragement|"The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!"
41478195|NCT01497626|DRUG|Lapatinib and bortezomib|"Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts."
41478196|NCT01560507|DRUG|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
40806131|NCT06065540|DRUG|Cagrilintide|Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of cagrilintide is reached.
40806132|NCT06065540|DRUG|Semaglutide|Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.
41008577|NCT04286282|OTHER|Depression Standard of Care|Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).
41008578|NCT04286282|OTHER|HIV Standard of Care|Standard clinical care for HIV
41008579|NCT05183685|PROCEDURE|telecare consultation|Participants will use zoom to communicate with the doctors in clinic.
41008580|NCT05183685|PROCEDURE|Usual face to face consultation|Participants will have face-to-face communication with the doctors in clinic.
41008581|NCT00754247|DRUG|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
41008582|NCT00754247|DRUG|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
41323969|NCT02331524|OTHER|Health Coaching/Home Exercise|The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
41323970|NCT06275243|DIAGNOSTIC_TEST|Kit Buccal swab collection & stabilization de Canvax®|Assessment of ApoE variant in saliva samples as a potential biomarker for Alzheimer's disease.
41323971|NCT06275243|OTHER|Cholesterol levels according to ApoE Genotype|Enhancing the quality of life of study participants by investigating cholesterol levels based on their ApoE genotype.
40806133|NCT06065540|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
40806134|NCT06065540|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
40806135|NCT06544616|DRUG|JNJ-64042056|JNJ-64042056 will be administered intramuscularly.
40806136|NCT06544616|DRUG|Placebo|Placebo will be administered intramuscularly.
41323972|NCT06275243|OTHER|Assessing cardiovascular risk factors in all participants|Through individual interviews, record cardiovascular factors and assess their correlation with Alzheimer's disease.
41323973|NCT06051851|DRUG|Penpulimab|"Penpulimab 200mg IV D1~1 cycle every 21 days"
41323974|NCT06051851|DRUG|Anlotinib|"Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days"
41323975|NCT06051851|DRUG|Nab paclitaxel|"Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days"
41323976|NCT06051851|DRUG|Gemcitabine|"Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days"
41323977|NCT05136651|BEHAVIORAL|OurRelationship|The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
41323978|NCT00089453|DRUG|Dexamethasone|Dexamthasone 40mg every day, days -5 to -1 only will be given.
41323979|NCT00089453|DRUG|Cyclophosphamide|A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
41478197|NCT01560507|DRUG|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
41478198|NCT01560507|DRUG|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
41323980|NCT00089453|DRUG|Melphalan|Melphalan will be given as a single dose of 140mg/m2 on day -1. Subject weighing more than 60kg will be dosed according to their calculated body weight.Melphalan will be diluted in normal saline(0.9%NaCl) to a concentration of 1.5mg/ml. A dose of 140mg/m2 will be administered intravenously over a period \<or= 20 minutes on day -1.
40806138|NCT01575548|PROCEDURE|Computed Tomography|Undergo CT
40806139|NCT01575548|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41323981|NCT00089453|DRUG|Fludarabine|dose of 1.0mg/m2 on days -8,-5,-2.
41323982|NCT00089453|DRUG|Bortezomide|A dose of 1.0mg/m2 will be given as a bolus dose on day-8, day-5 and day-2 as per standard practice
41323983|NCT00089453|PROCEDURE|Leukapheresis|On day 0 to collect donor cells for NK cell isolation
41478199|NCT00065013|BEHAVIORAL|strength training|
41478200|NCT05116488|DIAGNOSTIC_TEST|ECG(electrocardigraph)|Detection of electrocardiographic Brugada patterns using high precordial leads positioning as placing the precordial leads in the second intercostal space has been proposed to add sensitivity to the ECG diagnosis of Brugada syndrome.
41478201|NCT01047579|DRUG|Rivastigmine transdermal|
41478202|NCT02523937|OTHER|Soluble Fibrin|Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.
41478203|NCT02553902|DEVICE|Sleep position trainer|
41478204|NCT02553902|DEVICE|Mandibular advancement device|
41478205|NCT02553902|DEVICE|Continuous positive airway pressure|
40806140|NCT01575548|DRUG|Pazopanib Hydrochloride|Given PO
40806141|NCT01575548|OTHER|Placebo Administration|Given PO
40806142|NCT01575548|OTHER|Questionnaire Administration|Ancillary studies
40806143|NCT05027971|DEVICE|Flexiva Pulse High Power Single-Use Laser Fibers|Flexiva Pulse High Power Single-Use Laser Fibers are intended to be used as a device that transmits Ho:YAG laser energy from cleared laser consoles to urological anatomy.
41323984|NCT00089453|DRUG|Interleukin|2 at 3x10x6 IU on days +1 to 13.
41323985|NCT00089453|PROCEDURE|Infusion #1|Infusion of donor NK Cells #1 on day 0
41323986|NCT00089453|PROCEDURE|Leukapheresis #2|on day +2
41323987|NCT00089453|PROCEDURE|Infusion #2|on day +2
41323988|NCT00089453|PROCEDURE|Auto Graft|on day +14
41323989|NCT05797688|DEVICE|The Celution System|The Celution System will isolate regenerative cells, including stem cells, from fat harvested from the treatment patients.
41323990|NCT00943488|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
41323991|NCT02000518|RADIATION|external beam radiotherapy|
41323992|NCT00174785|DRUG|dronedarone (SR33589)|oral administration (tablets)
41323993|NCT00174785|DRUG|placebo|oral administration (tablets)
41478206|NCT02470091|BIOLOGICAL|Denosumab|Given SC
41478207|NCT02470091|OTHER|Laboratory Biomarker Analysis|Correlative studies
41478208|NCT02470091|OTHER|Pharmacological Study|Correlative studies
41323994|NCT06168370|RADIATION|CT guided strategy|"1. With signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI are switched from SAPT to apixaban. Patients fulfilling the dose reduction criteria according to the drug label, or with a Clinical Frailty Scale ≥4 will receive 2.5mg bid, patients not meeting these criteria will receive a standard dose of 5mg bid.~2. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI, without another indication for antiplatelet therapy stop their SAPT.~3. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI with another indication for antiplatelet therapy continue life-long SAPT."
41323995|NCT00506948|DRUG|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
41323996|NCT00506948|DRUG|Thymoglobulin|1.5 mg/kg by vein daily for 4 days
41323997|NCT00506948|DRUG|Sirolimus|6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.
41323998|NCT00506948|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
41323999|NCT02056717|DRUG|Dexamethasone|Administration of dexamethasone 10 mg IV 1 h before UAE
41324000|NCT02056717|DRUG|Normal saline|Administration of normal saline 2 mL IV 1 h before UAE
41324001|NCT01013168|PROCEDURE|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
41324002|NCT01512147|OTHER|Isoflurane, Propofol, Dexmedetomidine|"We will include following general anesthesia techniques:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.~After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.~After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.~Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr."
41324003|NCT04320277|DRUG|Baricitinib|Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.
41324004|NCT01238406|DEVICE|MD-logic Artificial Pancreas (MDLAP)|Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System
41324005|NCT01238406|DEVICE|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
41324006|NCT05936268|DRUG|Genakumab for injection|150 mg/1ml/bottle
41324007|NCT05936268|DRUG|Colchicine|0.5mg/table
41478209|NCT00788593|DRUG|Placebo|Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
41324008|NCT01697852|OTHER|Indoor residual spraying with bendiocarb|2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
41008583|NCT00754247|DRUG|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
41008584|NCT02128841|DRUG|Rivaroxaban|Direct Factor Xa Inhibitor
41008585|NCT03188965|DRUG|Elimusertib (BAY1895344)|Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
41478210|NCT00788593|DRUG|EUR-1008 (APT-1008) High Dose|EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
41324009|NCT01697852|OTHER|LLIN by universal coverage campaign|Long lasting Insecticide treated mosquito net
40806147|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level|Sodium Zirconium Cyclosilicate (SZC) Dose: Paediatric dose based on body weight equivalent to an adult 2.5 g
41324010|NCT03277768|DEVICE|Resonance Raman Spectroscopy (RRS)|Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 data collection times in infants with and without PDAs.
41324011|NCT04663139|DRUG|Xla1|Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)
41324012|NCT04663139|DRUG|Placebo|Matching placebo
41324013|NCT04338516|DEVICE|Ossix™ Bone|a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen
41324014|NCT04338516|DEVICE|Bio-Oss® Collagen|90% bovine derived xenograft granules and 10% porcine collagen
41324015|NCT00438893|DIETARY_SUPPLEMENT|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
41324016|NCT04961918|PROCEDURE|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
41324017|NCT05511818|DIETARY_SUPPLEMENT|Rest Study Product Usage|Participants will use their Radicle Rest study product as directed for a period of 4 weeks.
41324018|NCT05363709|DRUG|Balstilimab|Given by Vein (IV)
41324019|NCT02270684|DEVICE|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
41324020|NCT00030615|DRUG|decitabine|Given IV
41324021|NCT00030615|OTHER|pharmacological study|Correlative studies
41324022|NCT00030615|OTHER|laboratory biomarker analysis|Correlative studies
41324023|NCT06521866|DRUG|Toripalimab|240 mg IV on Day 1, every 3 weeks
41324024|NCT06521866|DRUG|Chemotherapy|"Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours"
41324025|NCT06521866|RADIATION|SABR|SABR: 25-60 Gy/5 Fx
41324026|NCT06521866|DRUG|Targeted therapy|Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly Bevacizumab: 5 mg/kg IV on Day 1
41324027|NCT05698121|DEVICE|CapriXpress|The app is a digital, tailored intervention aimed at activating patients during their waiting period between discharge from hospital and start of their cardiac rehabilitation by providing certainty and guidance. The goal of the intervention is to reach the end-goal: the start of the rehabilitation. Progression towards this end-goal is made automatically as time advances. The intervention provides guidance by providing the patient with a set of daily messages. These messages are pre-made by representatives of different disciplines within cardiac rehabilitation. The messages contain discipline-related information and suggestions as well as a perspective on peer experiences. Each day, the patient is free to choose which and the number of messages to engage with.
41324028|NCT00397709|DRUG|I ( isoniazid), II (isoniazid + rifampin )|
41324029|NCT00681538|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
41324030|NCT00681538|DRUG|Placebo|containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
41324031|NCT00194025|DRUG|Valproate|Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
41324032|NCT00992602|DRUG|methotrexate|Given IV
41324033|NCT00992602|DRUG|liposomal cytarabine|Given IT or via LP
41324034|NCT00992602|OTHER|quality-of-life assessment|Ancillary studies
41324035|NCT00992602|OTHER|laboratory biomarker analysis|Correlative studies
41324036|NCT01235169|DEVICE|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation|
41324037|NCT01839175|BIOLOGICAL|Hexavalent vaccine|0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
41324038|NCT01839175|BIOLOGICAL|NeisVac-C|0.5 mL intramuscular injection at 2 and 4 months of age
41324039|NCT01839175|BIOLOGICAL|Prevenar 13|0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
41324040|NCT01839175|BIOLOGICAL|RotaTeq|2 mL oral administration at 2, 3 and 4 months
41324041|NCT01839175|BIOLOGICAL|Nimenrix|0.5 mL intramuscular injection at 12 months
41324042|NCT01839175|BIOLOGICAL|M-M-RVAXPRO|0.5 mL intramuscular or subcutaneous injection at 13 months of age
41324043|NCT03909555|OTHER|Complications assessment|Records of cardiovascular diseases (CVD), carotid ultrasonography, electrocardiogram, echocardiography, fundus photography, urinary albumin excretion, Toronto Clinical Neuropathy Scale and Composite Autonomic Symptom Score.
40806148|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)|Sodium Zirconium Cyclosilicate (SZC)Paediatric dose based on body weight equivalent to an adult 5 g
40806149|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 10 g
41324044|NCT03831893|OTHER|Nopal food product 1|Dried Nopal incorporated in a food product
41324045|NCT03831893|OTHER|Nopal food product 2|Dried Nopal incorporated in a food product
41324046|NCT03831893|OTHER|control|Food Product without nopal
41324047|NCT06454851|BEHAVIORAL|Prosocial VR intervention|A four-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include four weekly sessions, each lasting between 15 to 20 minutes. Each session will depict a different daily life scenario-campus, lecture hall, canteen, and library, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
41324048|NCT06454851|OTHER|No intervention|The waitlist control group will not receive the intervention during the study.
41324049|NCT00325338|BIOLOGICAL|Ragweed MATAMPL|
41324050|NCT03393468|DRUG|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
41478211|NCT00788593|DRUG|EUR-1008 (APT-1008) Low Dose|EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
40806150|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 15 g
41324051|NCT04638868|DEVICE|Microsieve device|Both portal venous and peripheral blood will be processed through a label-free size-based silicon microsieve microfiltration device, which will isolate both epithelial-type and mesenchymal-type pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
41324052|NCT04638868|DEVICE|Cell surface marker-based platform|Both portal venous and peripheral blood will be processed through a cell surface marker-based platform, which contains antibodies for epithelial cell markers on pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
41324053|NCT00922350|OTHER|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
41324054|NCT00922350|OTHER|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
41478212|NCT04873531|DRUG|Neostigmine|"For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
41478213|NCT04873531|DRUG|Normal saline|"For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
41478214|NCT04142008|DEVICE|Walk with Me app|For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
40806151|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase|A 28-day period during which SZC is administered orally once daily (QD) to maintain normokalaemia. A dose titration regimen starting with QD administration of the dose of SZC the participants received TID in the CP will be studied in the MP and continued in the LTMP. The maximum dose that can be used is the calculated body weight equivalent to the 15 g adult dose
41153205|NCT01323309|BEHAVIORAL|standard Individual Supportive Psychotherapy (ISP)|The ISP intervention utilized as the comparison treatment condition in this study, is adapted from the Supportive Group Psychotherapy manualized intervention developed by David Payne (1997) and adapted by Drs. Kissane, Breitbart and colleagues into the ISP manualized intervention. This intervention is a 7-session individual supportive psychotherapy utilizing an approach to supportive psychotherapy based on models described by Rogers. The essential components of supportive psychotherapy are integrated into this manualized intervention, including: reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.
41153206|NCT01323309|BEHAVIORAL|enhanced usual care (EUC)|"We are therefore including what we refer to as an enhanced usual care arm to this randomized controlled trial to address the ethical issues raised by utilizing a usual care condition in a vulnerable advanced cancer population. Participants will receive feedback about their level of distress (based on the DT administered at screening) and given appropriate targeted referrals based on levels of distress and problem areas endorsed. Participants will be given a letter with a list of appropriate referrals."
41478215|NCT03595163|DRUG|Sevoflurane|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
40806158|NCT04952597|DRUG|Ociperlimab|Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle
40806159|NCT04952597|DRUG|Tislelizumab|Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle
40806160|NCT04952597|DRUG|Concurrent Chemoradiotherapy|"Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
40806161|NCT04904744|OTHER|Low tailored message|2 low tailored text or phone message reminders that child is overdue for well child check visit
40806162|NCT04904744|OTHER|No message|No reminders are sent
40806163|NCT04904744|OTHER|Low tailored message plus COVID-19 vaccine message|2 low tailored text or phone message reminders that child is overdue for well child check visit and that COVID-19 vaccine is available
40806164|NCT05142696|DRUG|[177Lu]Lu-DOTA-TATE|"Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed"
40806165|NCT05142696|DRUG|Atezolizumab|Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period
41324055|NCT00922350|OTHER|HELIOX+POSTURE|"Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th ."
41324056|NCT00922350|OTHER|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
41324057|NCT02586077|DRUG|Exparel|
41324058|NCT02846805|PROCEDURE|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.
41324059|NCT01265342|DRUG|Beclomethasone|Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days
41324060|NCT01265342|DRUG|Placebo|Placebo nebulised suspension twice a day for 10 days
41324061|NCT05070416|DEVICE|Lithium disilicate crowns|The study population is separated in two groups. The teeth will be etched in total etch mode with 37% phosphoric acid (Total Etch, Ivoclar Vivadent AG). After the application of Adhese Universal-adhesive (Ivoclar Vivadent AG), MultiCore Flow (Ivoclar Vivadent AG) will be applied. The crowns will be polished, then etched with IPS Ceramic Etching Gel (Ivoclar Vivadent AG) and conditioned with Monobond Plus (Ivoclar Vivadent AG). The crowns will be luted as described for group 1 or 2. A final intraoral polishing step will be done with OptraGloss (Ivoclar Vivadent AG). All required light-curing steps are conducted with Bluephase G4 (Ivoclar Vivadent AG).
41324062|NCT00424294|DRUG|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
41324063|NCT00424294|DRUG|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
41324064|NCT00424294|DRUG|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
41324065|NCT04373785|RADIATION|Intensity-modulated radiation therapy|Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
41324066|NCT04373785|DRUG|Temozolomide|"Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles."
41324067|NCT04373785|DRUG|NG101m|Oral NG101m capsule continuously twice daily.
41324068|NCT03697486|BEHAVIORAL|diet with different composition|"Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
41324069|NCT01216397|DRUG|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
41324070|NCT01216397|DRUG|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
41324071|NCT01184456|DIETARY_SUPPLEMENT|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
41324072|NCT01184456|DRUG|Placebo|1 capsule per day for 90 days.
41324073|NCT01371526|DRUG|depot tetracosactide|1mg, 3x weekly by sc injection
41324074|NCT06187948|OTHER|Video|All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
41324075|NCT02165345|DRUG|Tocilizumab|162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (\<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (\>=) 30 kg: every 2 weeks; sJIA participants \<30 kg: every 2 weeks; sJIA participants \>/= 30 kg: once weekly
41324076|NCT04015440|BEHAVIORAL|HBMT|Individual is presented with words with some letters missing and told to complete the word.
40806166|NCT05142696|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
41324077|NCT04015440|BEHAVIORAL|Other Training|Alternative to HBMT training
41324078|NCT05626244|BEHAVIORAL|Being a Parent|Being a Parent (BaP) is a group parenting intervention for parents of children (2-11 years old) with behavioral problems. It consists of 2-hour sessions facilitated by psychologists for between 8-12 parents. Based on attachment, family systems, and cognitive-behavioral theories, BaP successfully integrates knowledge acquisition, behavior change with adult learning and social support. Each course session is highly interactive involving an engaging blend of small and large group discussion, role play, demonstrations, information sharing and reflection. This enables parents to practice and use new skills to achieve specific goals (Day et al., 2020).
41478216|NCT03595163|DRUG|Propofol|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
41324079|NCT05491655|DEVICE|High Intensity His Bundle pacing|All patients will be implanted with an Implantable cardioverter defibrillator (ICD) and an ICD lead in the right ventricle (either RV apex or RV septum). In all patients a pacing lead will be positioned in the right atrium (typically the right atrial appendage). All patients will have a pacemaker lead positioned on the His bundle to obtain direct His-bundle capture.
41324080|NCT00255294|DRUG|Cellulose sulfate vaginal gel|
41324081|NCT06006910|BEHAVIORAL|Column-based nudge in the EHR|The nudge is a column in EPIC that flags patients coming to the clinic as a new visit with documented ER+ breast cancer. The nudge flag can pop up when hovered over to remind surgeons of the Choosing Wisely criteria and to consider omission of SLNB.
41153207|NCT06121401|DRUG|Olaparib|Olaparib is considered the study treatment. Olaparib tablets will be taken at the dose of 300 mg (2 x 150 mg tablet) twice daily adding to bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks
41324082|NCT06006910|BEHAVIORAL|No column-based nudge in the EHR|No intervention control period prior to nudge deployment.
41324083|NCT02077946|DRUG|liraglutide|No treatment given.
41324084|NCT02077946|DRUG|sitagliptin|No treatment given.
41324085|NCT02620709|BEHAVIORAL|Hula intervention|Hula and heart health education
41324086|NCT02917629|OTHER|Laboratory Biomarker Analysis|Correlative studies
41324087|NCT02917629|DRUG|Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|Given PO
41324088|NCT02917629|OTHER|Pharmacological Study|Correlative studies
41324089|NCT02917629|OTHER|Placebo|Given PO
41324090|NCT00171028|DRUG|valsartan|
41324091|NCT02711904|DRUG|Extubation U|"Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:~* 20 years old - 6.0 mcg/Kg/h~* 30 years old - 5.7 mcg/Kg/h~* 40 years old - 5.3 mcg/kg/h~* 50 years old - 5.0 mcg/kg/h~* 60 years old - 4.6 mcg/kg/h~* 70 years old - 4.3 mcg/kg/h~* 80 years old - 4.0 mcg kg/h."
40806167|NCT05142696|OTHER|Carboplatin|Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
41324092|NCT02711904|DRUG|Extubation T|"Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:~The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.~The remifentanil dose was adjusted according to the randomization:~* 20 years old - 9.0 mcg/Kg/h~* 30 years old - 8.5 mcg/Kg/h~* 40 years old - 8.0 mcg/kg/h~* 50 years old - 7.5 mcg/kg/h~* 60 years old - 7.0 mcg/kg/h~* 70 years old - 6.5 mcg/kg/h~* 80 years old - 6.0 mcg kg/h."
41324093|NCT00753688|DRUG|PAZOPANIB|800 mg once daily orally
41324094|NCT00753688|DRUG|Placebo|matching placebo 800 mg once daily orally
41324095|NCT05420415|OTHER|CSTME|Tumor microenvironment collagen signature
41324096|NCT04182789|DRUG|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
40806168|NCT05142696|OTHER|Etoposide|Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
41153208|NCT06121401|DRUG|Bevacizumab|Bevacizumab will be taken at a dose of 15 mg per kilogram of body weight every 3 weeks
41324097|NCT01142453|DRUG|Interferon beta 1a|A dosage of 44 µg interferon beta 1a subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase (depending on the respective preliminary therapy)
41324098|NCT01171287|PROCEDURE|Driving with an Aircast Walker|
41324099|NCT01171287|PROCEDURE|Driving with a walking cast|
41324100|NCT01171287|PROCEDURE|Driving with a running shoe|
41324101|NCT00393068|DRUG|Erlotinib|Erlotinib
41324102|NCT00393068|DRUG|Bevacizumab|Bevacizumab
41324103|NCT00393068|DRUG|Paclitaxel|Paclitaxel
41324104|NCT00393068|DRUG|Carboplatin|Carboplatin
41153209|NCT02709265|DRUG|amikacin/fosfomycin|single aerosolized dose
41153210|NCT02518659|DIETARY_SUPPLEMENT|Inulin|This is the Intervention
41324105|NCT00393068|DRUG|5-FU|5-FU
41324106|NCT00393068|PROCEDURE|Radiation therapy|Radiation therapy
41324107|NCT00393068|PROCEDURE|Surgery|Surgery
41324108|NCT04736329|DRUG|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.
41324109|NCT01472991|DRUG|TC-5619-238 5mg|TC-5619-238 5mg capsule taken once daily for 4 weeks
41478217|NCT03660215|OTHER|mediation|support throughout their care journey during the 90 days following an emergency visit. This support will be carried out by a specific staff trained in medico-social mediation
41324110|NCT01472991|DRUG|TC-5619-238 25mg|TC-5619-238 25mg capsules taken once daily for 4 weeks
41324111|NCT01472991|DRUG|Placebo|Placebo capsules will be taken once daily for 4 weeks
41324112|NCT00813618|DRUG|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
41324113|NCT00813618|DRUG|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
41324114|NCT00813618|DRUG|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
41324115|NCT04254432|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 4 weeks.
41324116|NCT06207695|BEHAVIORAL|Brief Group Intervention|This brief intervention consisted of four sessions. The contents of sessions were psychoeducation, emotion processing, practicing emotion regulation strategies, cognitive processing, reframing thoughts, practicing mindful exercises, strength social support networks, and problem management skills.
41324117|NCT05349942|DEVICE|Intraoral scanning and data acquisition|Intraoral scanner data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.
41324118|NCT01612377|DRUG|Prednisolone-Dipyridamole|Oral, QD
41324119|NCT01612377|DRUG|Prednisone|Oral QD Prednisone 5mg
41324120|NCT01612377|DRUG|prednisone|Oral, QD prednisone 7.5mg
41324121|NCT03205982|BEHAVIORAL|Wise app with medication adherence reminders|The Intervention group will receive the Wise app that delivers medication adherence reminders.
41324122|NCT03205982|BEHAVIORAL|Wise app with fitness reminders|The control group will receive the Wise app with fitness reminders
41324123|NCT05143567|OTHER|standard of care anticoagulation in absence of thrombotic complications|Subgroup IA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IB - patients receive LMWH (enoxaparin) for the prevention or treatment of VTE Subgroup IC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
41324124|NCT05143567|OTHER|standard of care anticoagulation in presence of thrombotic complications|Subgroup IIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) for the prevention or treatment of VTE Subgroup IIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
41324125|NCT05143567|OTHER|standard of care anticoagulation in combination with elastic compression|Subgroup IIIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE
41324126|NCT03532880|DRUG|Olaparib Pill 50 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
41324127|NCT03532880|DRUG|Olaparib Pill 100 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
41324128|NCT03532880|DRUG|Olaparib Pill 150 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
41324129|NCT03532880|DRUG|Olaparib Pill 200 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
41478218|NCT01355159|DRUG|Folic Acid 4 mg|Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
41478219|NCT01355159|DRUG|Placebo|Placebo x 4 tablets will be taken daily by oral administration.
41478220|NCT01762124|DEVICE|Native Outflow Tract TPV|Transcatheter placement of a pulmonary valve
41478221|NCT04540055|PROCEDURE|Paravertebral block|The subjects in this group received general anesthesia and USG-guided paravertebral block
41478222|NCT04540055|PROCEDURE|General Anesthesia|The subjects in this group underwent MRM under routine general anesthesia without peripheral nerve block supplementation.
41478223|NCT05283603|DIAGNOSTIC_TEST|ECG, Echocardiogram, Magnetic resonance|Clinical and instrumental follow-up
41478224|NCT05322629|BEHAVIORAL|PrEP adherence biofeedback|Services for women in the intervention arm includes bio-feedback adherence counseling based on urine lateral flow assays of tenofovir to measure adherence with rapid PrEP delivery .
41478225|NCT05322629|BEHAVIORAL|Standard of care counseling|Adherence counseling based on self report and following national guidelines
41478226|NCT05518448|DIETARY_SUPPLEMENT|Ketone - beta-hydroxybutyrate (β-OHB)|Ketone - beta-hydroxybutyrate (β-OHB)
41478227|NCT00350155|DRUG|Lumiracoxib|
41478228|NCT02293473|DEVICE|LiDCO Rapid|LiDCO Rapid haemodynamic monitor
41478229|NCT02293473|DEVICE|BIS-Bispectral Index Monitor|Depth of anaesthesia
41478230|NCT02293473|DEVICE|INVOS-Cerebral Oxygenation Monitor|regional brain tissue oxygenation
41478231|NCT02293473|OTHER|Standard of care|Using standard of care
40806169|NCT05303467|DEVICE|TheraSphere GBM|Single treatment of TheraSphere GBM device
40806170|NCT06032104|DIETARY_SUPPLEMENT|Dry beans|0.5 cup of Bush's Best Cannellini Beans, three times per day before meals blended into a smoothie. If interested and depending on tolerance, participants will also have the opportunity to gradually increase the bean smoothie to a maximum of 1 cup three times per day before meals during the last week of the two-week bean smoothie intervention. If patient cannot not tolerate 1.5 cup of canned cannellini bean, we will reduce per tolerance or offer the option of choosing a bean-based flour (100 gram/day, 23% fiber from Archer Daniels Midland)
41324130|NCT03532880|DRUG|Olaparib Pill 250 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
41324131|NCT03532880|DRUG|Olaparib Pill 300 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
41324132|NCT03532880|RADIATION|Radiotherapy|The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.
41324133|NCT04712799|DRUG|Otrivin|oxymetazoline nasal spray
41324134|NCT05605977|BEHAVIORAL|Traditional visual-motor training program|Traditional visual-motor program includes play and paper-and-pencil activities
41324135|NCT05605977|BEHAVIORAL|Computerized visual-motor training program|Computerized visual-motor training program includes tablet visual-motor games
41324136|NCT01473303|BIOLOGICAL|ganitumab|Given IV
41324137|NCT01473303|DRUG|fluorouracil|Given IV
41324138|NCT01473303|DRUG|irinotecan hydrochloride|Given IV
41324139|NCT01473303|DRUG|leucovorin calcium|Given IV
41324140|NCT01473303|DRUG|oxaliplatin|Given IV
41324141|NCT01473303|OTHER|placebo|Given IV
41324142|NCT01473303|OTHER|questionnaire administration|Completed on paper
41324143|NCT01445964|DRUG|Atenolol|Atenolol oral administration
41324144|NCT01445964|DRUG|Atenolol with apple juice 1200 mL|Atenolol oral administration with apple juice 1200 mL
41324145|NCT01445964|DRUG|Atenolol with apple juice 600 mL|Atenolol oral administration with apple juice 600 mL
41478232|NCT00156715|DRUG|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
41478233|NCT03359824|OTHER|Exercise|
41478234|NCT00754442|DRUG|Teriparatide|"Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls"
41478235|NCT03159286|BEHAVIORAL|Abstainer|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.
41478236|NCT03159286|BEHAVIORAL|Abstainer + User|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
41478237|NCT03159286|BEHAVIORAL|Control|Participants view social networking site profiles with no alcohol content.
41478238|NCT02884323|DEVICE|geko™ device|The geko™ (T-2 and R-2) devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg.
41478239|NCT04294342|BEHAVIORAL|Active Comparator: Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program. Each session consisting of warm-up, balance, strength, power and break fall exercises. There is clear a progression within the 10 week program in three main blocks. Block 1: learning the exercises and principle movements, Block 2 more resistance and advance falling techniques, Block 3 Power training and falling strategies from stand up positions.
41324146|NCT01519401|DRUG|3 mg drospirenone and 20 µg ethinyl-estradiol|
41478240|NCT00452608|DRUG|amido pill|one pill of amido/d by mouth for 10 days
41478241|NCT00452608|DRUG|atorvastatina|atorvastatina 80 mg/day by mouth for 10 days
41324147|NCT01519401|DRUG|3 mg drospirenone and 30 µg ethinyl-estradiol|
41324148|NCT01975246|DRUG|Telmisartan + amlodipine|FDC tablet
41324149|NCT01975246|DRUG|hydrochlorothiazide|tablet
41478242|NCT05516459|BIOLOGICAL|Pfizer BNT162b2 Vaccine|The Pfizer-BioNTech COVID-19 vaccine (INN: tozinameran), sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada
41324150|NCT01975246|DRUG|Telmisartan + amlodipine|FDC tablet
41324151|NCT01975246|DRUG|Placebo|placebo matching hydrochlorothiazide tablet
41324152|NCT04278482|DIETARY_SUPPLEMENT|Dietary supplement, DHA or Placebo|Consumption of 2 capsules per day of the dietary supplement, DHA or Placebo
41324153|NCT03178617|OTHER|Educational Intervention|Attend standard of care LIP
41324154|NCT03178617|OTHER|Educational Intervention|Attend HIP
41324155|NCT03178617|OTHER|Quality-of-Life Assessment|Ancillary studies
41324156|NCT03178617|OTHER|Questionnaire Administration|Ancillary studies
41324157|NCT05971953|OTHER|Muscle Energy Technique|"They would be receiving treatment as follow:~The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance( 75% of his and her available strength). After the relaxation, the muscle is lengthened more aggressively beyond the barrier and held for up to 15 seconds. Frequency: 10 reps for 4 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 20 mins"
41478243|NCT03184220|PROCEDURE|Physiotherapy treatment|"The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.~* Suboccipital induction~* Posterior elongation of the cervical fascia in Supine position~* Assisted cervical fascia~* Myofascial induction of sternocleidomastoid"
41478244|NCT03184220|PROCEDURE|Physiotherapy treatment|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
41008586|NCT06251713|OTHER|VeXUS score guided fluid management strategy|"During the first 3 postoperative days, the VeXUS score is estimated daily by ultrasound. If VeXUS score \>1, diuretic-induced fluid removal will be administred (target diuresis: 2-4mL/kg/h). The diuretic administration protocol is derived from the CARRESS HF study: bolus followed by a continuous administration of Furosemide with thiazide added based on preoperative diuretic administration status.~To prevent hypokalaemia and dysnatremia, a protocol for potassium supplementation and intravenous administration of chloride serum or hypotonic perfusion is planned.~Fluid removal will be suspended if severe metabolic disturbance (pH\>7.55 with HCO3-\>40mmol/L or serum K+ \<3 mmol/L or serum Na\>150 mmol/L) or haemodynamic instability (hypoperfusion) with fluid responsiveness occurs. Regardless of the VeXUS score, diuretics will be introduced in case of pulmonary oedema.~Haemodynamic status will be every 12 hours to detect side effects attributable to diuretic-induced fluid removal."
41008587|NCT06251713|OTHER|Usual care|Fluid management will be at the discretion of attending physician, who will be blinded to the patient's VeXUS score status.
41478245|NCT03103074|DRUG|Botulinum B Toxin|Intradermal injections
41478246|NCT03103074|OTHER|Placebo Saline|Intradermal injections
41478247|NCT00836147|DRUG|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
41478248|NCT00836147|DRUG|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
41478249|NCT04306640|OTHER|Sagittal Cervical Posture Corrective Orthotic Device|The subjects in the traction group will receive the deneroll extension traction. The subjects will be asked to lie supine on the ground with their legs straight, upper arms by their sides and forearms gently folded across their trunk. The therapist will place the apex of the denneroll either in the mid cervical region or the lower cervical region depending on the apex of cervical curvature deformity of each subject. Initially, participants begin with three minutes of sustained denneroll extension traction and progressed to the goal of 20 min per session with one to two additional minutes per session
41478250|NCT05695872|PROCEDURE|subtarsal approach|surgical approach
41478251|NCT05695872|PROCEDURE|conventional transconjunctival approach|surgical approach
41008588|NCT02064738|BEHAVIORAL|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
41008589|NCT06259084|DEVICE|Seedchrony|The seedchrony probe is coupled to the transfer catheter. When the transfer catheter is placed inside the uterus, the probe measures the biomarker concentraction in the fluid entering the catheter. The measurements last two minutes.
41008590|NCT06003725|BEHAVIORAL|Culturally Adapted Adolescent Substance Use Treatment|The Cannabis Youth Treatment Series (CYT) (MET/CBT12 model) aims to reduce alcohol and cannabis use.
41478252|NCT05695872|PROCEDURE|transconjunctival approach with Y- modification|surgical approach
41008591|NCT04856696|DIAGNOSTIC_TEST|PGT-A|trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform
41008592|NCT04856696|DIAGNOSTIC_TEST|non-invasive PGT-A|cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform
41008593|NCT01275183|DRUG|raltegravir and cisplatin|"Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours~Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19~Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles"
41008594|NCT06466954|OTHER|Evaluating spinopelvic alignment parameters|Evaluation of thoracic kyphosis, lumbar lordosis, pelvic tilt, and pelvic torsion
41478253|NCT00126126|OTHER|EBAR Program|Evidence Based Amputee Rehabilitation Program
41478254|NCT06469177|DEVICE|Pain Coach App|Pain Coach App is a mobile application that offers patients undergoing shoulder, hip and knee arthroplasty surgery preoperative educational tools and questionnaires to provide patient specific details to their surgeons for prescribing purposes as well as post operative pain assessment and medication reminders/tracking, problem troubleshooting and a resource library for further pain management tools and education.
41478255|NCT06273202|OTHER|Infant Massage|Infant massage will be performed three times a day (10 minutes per session) until they reach the 35th week of post-conceptional age (35+6) by the two departmental physical therapists (ADP and ADV).
41478256|NCT05660031|PROCEDURE|LHB Tenotomy|Will be performed arthroscopically by cutting the LHB at its origin with arthroscopic scissors
41478257|NCT05660031|PROCEDURE|LHB Tenodesis|"ill be performed arthroscopically with a tenodesis at the top of the articular margin using an onlay technique."
41478258|NCT05080647|BEHAVIORAL|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
41478259|NCT05732974|OTHER|Resected non small cell lung cancer|plasma sample, tissue sample and computed tomography scan images
41478260|NCT02054013|PROCEDURE|Prostatic artery embolization|
41324158|NCT05971953|OTHER|Conventional PT|"They would be receiving conventional treatment as follow:~including hot pack for 10 mins ischemic compression for 60 seconds .Frequency: 5 reps with 60 sec hold for 4 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
41324159|NCT05521971|OTHER|multifaceted pharmacist-led intervention|"* Educational sessions were provided to the physicians and nursing staff.~* Discontinuation regimens were developed. Prescribers were free to choose whether or not to actually use them. The regimens were derived from the regimen used by Petrovic et al. and encouraged a switch from any benzodiazepine to lorazepam 1 mg OD for one week followed by drug stop. Z-drugs were switched to zolpidem 5 mg OD for one week followed by drug stop. If deemed necessary, a pro re nata regimen of lorazepam 1 mg or zolpidem 5 mg for one additional week was prescribed respectively. The discontinuation regimens were incorporated into the hospital's electronic prescribing system. Furthermore, a clinical decision support system provided additional support.~* Patient education sessions were provided upon enrolment and at discharge. Specific patient leaflets were used to facilitate patient education.~* The patient's primary care physician and, if applicable, the nursing home were informed by phone."
41324160|NCT05521971|OTHER|Usual care group|all patients received comprehensive geriatric care without any systematic clinical pharmacist involvement regarding deprescribing of hypnotics. Treating physicians were not actively informed on the patient's participation in this particular study.
41324161|NCT04211844|DRUG|sofosbuvir plus daclatasvir|50 patients in the first group will receive 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks.
41324162|NCT04211844|DRUG|Sofosbuvir plus Ledipasvir|50 patients in the second group will receive 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks.
41324163|NCT06068296|DIAGNOSTIC_TEST|short term memory assessment|"Aphasia group: The Dutch verbal STM assessment tool will be administered over a time span of maximum two consecutive days depending on how fatigued the patient is during testing.~Healthy control group: the Dutch verbal STM assessment tool will be administered."
41324164|NCT06068296|DIAGNOSTIC_TEST|Oxford cognitive screen|Evaluation of the cognitive abilities of the patients with aphasia.
41324165|NCT06068296|DIAGNOSTIC_TEST|Token Test|Evaluation of the severity of the aphasia in patients with aphasia.
41324166|NCT06068296|DIAGNOSTIC_TEST|Montreal cognitive assessment|Evaluation of cognitive dysfunction in the group of healthy volunteers.
41324167|NCT04261049|DRUG|Triamcinolone Acetonide Extended-Release Injectable Suspension|A single ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) intra-articular knee injection.
41478261|NCT02054013|PROCEDURE|monopolar transurethral prostatectomy|
41478262|NCT03678779|BEHAVIORAL|Incentive|$5 grocery gift card
41478263|NCT03678779|BEHAVIORAL|Education|Video-based brief nutrition education
41478264|NCT03678779|BEHAVIORAL|Combined|Both Incentive and Education interventions received
41478265|NCT02355756|DRUG|Maxadilan|
41478266|NCT02355756|DRUG|Placebo|
41478267|NCT02531594|BEHAVIORAL|SBIRT|"The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials."
41478268|NCT02531594|BEHAVIORAL|HHC|"The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials."
41478269|NCT03095573|DEVICE|Lateral-viewing CapsoCam device|Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
41478270|NCT03095573|DEVICE|Axial-viewing capsule|Small bowel capsule endoscopy examination with the Axial-viewing capsule device
41478271|NCT04633655|OTHER|outcome measures for CIPN testing|questionnaires administration, physician based scales for CIPN data collection
41478272|NCT03095898|DEVICE|Electroacupuncture|Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.
41478273|NCT01418677|DRUG|E7389|Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
41478274|NCT01418677|DRUG|E7389|Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
40806171|NCT06032104|DIETARY_SUPPLEMENT|Usual diet|Usual diet without adding the bean smoothie
41478275|NCT01418677|DRUG|E7389|Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
41478276|NCT00280072|DEVICE|Renal Assist Device|
41324168|NCT04496557|DEVICE|PROCESS-INSTRUCTED SELF NEURO-MODULATION (PRISM)|"Neurofeedback sessions targeting down-regulation of deep limbic structures, specifically the amygdala, delievered via PRISM: a non-significant risk device (software) intended to be used in research studies testing the clinical efficacy of an innovative paradigm for EEG-based neurofeedback.~The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on non-consecutive days. Each session will last 30 minutes.~EFP-EEG-NF training: Each NF training session consists of 5 consecutive sequences of NF presentations. During a watch condition (60 seconds) participants are instructed to passively view the animation, and are told that that the scenario does not influence their brain activity. In the regulate phase (60 seconds) participants are instructed to lower the room's unrest level. A rest phase (15 seconds) follows each sequence, allowing participants to relax."
41324169|NCT04724304|DIAGNOSTIC_TEST|Real-Time Myocardial Echocardiography (RTMPE)|Uses sound waves (ultrasound) to produce an images of the heart. During RTMPE a microbubble contrast agent is administered through an intravenous line (IV) to make the images of your heart clearer.
41324170|NCT04724304|DIAGNOSTIC_TEST|Magnetic resonance image (MRI)|Imaging that focuses on the heart or blood vessels to assess size and function of the heart's chambers, thickness and movement of the walls of the heart, and blood flow in the blood vessels.
41324171|NCT03027843|DRUG|Growth Hormone|in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.
41324172|NCT00089479|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
41324173|NCT00089479|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
41324174|NCT00089479|DRUG|Taxotere|100mg/m2 iv on day 1 of each 3 week cycle
41324175|NCT01584258|PROCEDURE|Prostatectomy|Radical prostatectomy: performed open, laparoscopically or using a robotically assisted laparoscopic approach.
41324176|NCT01584258|RADIATION|Conventionally Fractionated Prostate Radiotherapy|"Conventional fractionation delivered to a dose of:~(PACE-B) 78 Gy in 39 fractions or 62 Gy in 20 fractions; (PACE-C) 60 Gy in 20 fractions"
41324177|NCT01584258|RADIATION|Prostate SBRT|Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
41324178|NCT01772836|DRUG|RPX7009|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
41324179|NCT01772836|DRUG|Biapenem|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
41324180|NCT01772836|DRUG|Normal saline|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
41324181|NCT04800471|DEVICE|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
41324182|NCT04800471|OTHER|Point of Care Glucose Group|Participants in this group will be monitored by POC glucose values.
41324183|NCT04359342|DIETARY_SUPPLEMENT|HIIT + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
41324184|NCT04359342|DIETARY_SUPPLEMENT|HIIT + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
41324185|NCT04359342|DIETARY_SUPPLEMENT|HIIT and resistance training + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
41324186|NCT04359342|DIETARY_SUPPLEMENT|HIIT and resistance training + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
41324187|NCT04655703|DEVICE|DJO X4 brace with Motion Intelligence Platform|The X4 Knee brace with the Motion Intelligence platform uses both a bio-measurement equipment with an interactive application thereby providing the patient with immediate feedback on their exercise regime. The X4 Knee brace is a postoperative brace worn by a patient to monitor compliance to prescribed protocol based on the movement and function of the knee joint. The device also connects wirelessly to a companion mobile application, Motion Intelligence, and streams both real-time and collected data for review and record collection. Prescribed exercises are uploaded into the patient application, with a number of the exercises actively tracked by the Mi360 sensor housed in the X4 brace. Compliance can be tracked by the physician in real-time between postoperative visits and any medical staff on a separate dashboard.
41324188|NCT05738772|DIAGNOSTIC_TEST|serum sample for ELIZA|Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).
41324189|NCT03509844|BEHAVIORAL|Psychotherapy|Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.
41478277|NCT01791153|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
41324190|NCT04026763|PROCEDURE|prostate biopsy|standard of care
41324191|NCT04026763|PROCEDURE|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy, Transperineal Ultrasound guided fusion prostate biopsy
41324192|NCT04026763|DEVICE|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
41478278|NCT01791153|DRUG|Prednisone|Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
41478279|NCT01791153|DRUG|Tocilizumab Placebo|Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
41008595|NCT06466954|OTHER|Measuring uterine dimensions|Measurement of corpus length, corpus width, cervix length, and cervix width
41324193|NCT04223063|BEHAVIORAL|Exercise program|As per the intervention arm
41324194|NCT02748122|OTHER|MMT 723|Subjects will have the insulin pump inserted. With the aid of a small needle, the catheter (tube) of the insulin pump will be inserted through the skin into fatty tissue and will be taped in place. The subject will be required to wear the pump for three (3) months.
41324195|NCT03255811|DRUG|apatinib|Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.
41478280|NCT01791153|DRUG|Prednisone Placebo|Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
41478281|NCT01791153|DRUG|Corticosteroids|Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
41478282|NCT01791153|DRUG|Methotrexate|Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
41478283|NCT06292494|DEVICE|Exablate 4000 Transcranial MRgfUS System|Focused ultrasound interrupt structure of epilepsy network to improve seizure.
41478284|NCT04265690|BEHAVIORAL|Cooking classes|Participants will receive 2 cooking classes (each 1-hour long) during their Centering group-care visit at the BMC teaching kitchen, taught by a Registered Dietitian. The recipes taught during the cooking classes will follow the Special Supplemental Nutrition Program for Women, Infants, and Children, the 2015-2020 Dietary Guidelines for Americans, and recommendations from The American College of Obstetricians and Gynecologists.
41478285|NCT04265690|BEHAVIORAL|Text messages|Participants will receive text messages, through a password secured phone, based on their content and frequency preferences.
41478286|NCT04432519|PROCEDURE|Immediate dental implant placement|Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
41478287|NCT01193738|PROCEDURE|osteopathic compression of Pterygopalatine node|osteopathic compression of Pterygopalatine node
41478288|NCT01007747|OTHER|Geranium oil|Daily topical application over neuropathic pain
41478289|NCT01823276|OTHER|Tyrosine-Containing Bar|
41478290|NCT01823276|OTHER|Placebo Bar|
41478291|NCT04936776|BEHAVIORAL|Text messaging|Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.
41324196|NCT05688319|BEHAVIORAL|Problem-Solving Training|Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks. The duration of each training session was 60-90 minutes.
41324197|NCT02617186|PROCEDURE|Video-assisted thoracoscopic surgery|patients randomized to this arm will receive video-assisted thoracic surgery (VATS)
41324198|NCT02617186|PROCEDURE|Robotic thoracic surgery|patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
41324199|NCT03865511|DRUG|TAGRISSO® 80mg (Osimertinib)|Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
41478292|NCT02329119|OTHER|electrophysiological recordings|
41478293|NCT03560921|DIAGNOSTIC_TEST|urinary NGAL|measurement urinary NGAL using the ARCHITECT technique
41478294|NCT02002000|DRUG|vitamin D (cholecalciferol)|Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor
41478295|NCT02002000|DRUG|Placebo, similar in appearance and taste to cholecalciferol|Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
41478296|NCT02948920|DRUG|Ephedrine|9 mg of ephedrine (3 ml)
41478297|NCT02948920|DRUG|NSS|3 ml of normal saline
41478298|NCT03827941|OTHER|1 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
41478299|NCT03827941|OTHER|20 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
41478300|NCT00536484|DRUG|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
41324200|NCT03865511|GENETIC|Tumor biopsies|"Tumor biopsies performed at baseline and clinical progression will be processed (fixed) on site, and sent to Nantes University Hospital for analysis.~The following analysis will be performed:~1. Analyses performed on a regular basis, in order to allow subsequent inclusion in other clinical trials :~   * C797S testing (digital PCR)~  * MET amplification (dPCR/FISH)~  * Histological examination of the tissue sample (to identify small cell transformation)~  * Expression of proteins by immunohistochemistry: PD-L1 (Ventana SP263 antibody); CD73 ; CD4; CD8.~2. At the end of inclusions, deep sequencing analysis to identify acquired mutations and copy number variations (amplifications)."
41478301|NCT00536484|DRUG|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
41478302|NCT00396461|DRUG|MCT/LCT (1:1)|Emulsion based on 20% MCT/LCT (50:50 ratio)
41008596|NCT02310659|OTHER|No intervention|No intervention
41008597|NCT03266562|DIAGNOSTIC_TEST|F-18 FES|Evaluate uptake of F-18 FES in breast tissue
41008598|NCT03266562|DIAGNOSTIC_TEST|F-18 FDG|Evaluate uptake of F-18 FDG in breast tissue
41324201|NCT03865511|GENETIC|ctDNA analysis|"ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial.~These samples will be sent at room temperature by courier to the central laboratory (Nantes University Hospital). There they will be centrifuged, and plasma will be frozen (-80°C).~Analyses :~* Detection of the EGFR activating mutation in plasma at baseline By dPCR (characterization of patients enrolled)~* Detection of the EGFR activating mutation at d7 and m1 by dPCR (early detection of response to osimertinib)~* Analysis of the plasma samples collected at clinical progression in order to identify acquired mechanisms of resistance by NGS (and comparison with analysis of the biopsies).~* Kinetics studies of the alterations"
41324202|NCT05825196|DIAGNOSTIC_TEST|tumor tissue and blood tests|In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.
41324203|NCT06303349|OTHER|Samples collection|"from D1 to D10, 1 SSTII (Serum separator tubes II) dry tube of 6 mL blood and 1 EDTA (Ethylenediamine tetraacetic acid) tube of 6 mL blood are collected.~1 SSTII dry tube of 6 mL cerebral spinal fluid will be collected distally in external ventricular drain, after eliminating the dead volume of the collection burette, for patients with it."
41324204|NCT01634945|DRUG|SP/amodiaquine|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
41324205|NCT01634945|DIETARY_SUPPLEMENT|FeFum fortified porridge|6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
41324206|NCT01634945|DRUG|SP/Amodiaquine + FeFum fortified porridge|"One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months."
41324207|NCT01634945|DIETARY_SUPPLEMENT|Ferric pyrophosphate fortified porridge|6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
41324208|NCT01634945|OTHER|Placebo|Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
41324209|NCT00339118|DRUG|doxorubicin, cytoxan|
41324210|NCT02378883|DEVICE|Apollo™ Onyx™ Delivery Micro Catheter|
41324211|NCT02480894|DRUG|BMS-663068|BMS-663068
41324212|NCT02480894|DRUG|Maraviroc|Maraviroc
41324213|NCT05630560|OTHER|Psychotherapy treatment|The psychotherapist will conduct psychotherapy as normally done by them in their practice. The treatment will thus be un-manualized and consist of a broad range of therapeutic orientations and treatment lengths.
41324214|NCT03446001|DRUG|TRx0237 16 mg/day|Oral TRx0237 4-mg tablets administered twice daily
41324215|NCT03446001|DRUG|Placebo|Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily
41324216|NCT03446001|DRUG|TRx0237 8 mg/day|Oral TRx0237 4-mg tablet administered twice daily
41324217|NCT03240718|PROCEDURE|Laser treatment|CORE fractional CO2 laser treatment
41324218|NCT02166229|DRUG|Divalproex sodium|
41324219|NCT02026518|DIETARY_SUPPLEMENT|Soy isoflavones|
41324220|NCT02026518|DIETARY_SUPPLEMENT|cholecalciferol|
41324221|NCT02026518|DIETARY_SUPPLEMENT|Placebo of soy isoflavones|
41324222|NCT02026518|DIETARY_SUPPLEMENT|placebo of cholecalciferol|
41324223|NCT05271110|PROCEDURE|Liver resection (ablation)|Treatment of liver metastases from pancreatic cancer by surgery or ablation
41324224|NCT00803543|DRUG|Valacyclovir|500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
41324225|NCT00803543|DRUG|Placebo|Dosage: Two tablets once a day for 24 weeks
41324226|NCT00000118|DEVICE|Sustained-Release Intraocular Drug Delivery System|
41324227|NCT05551091|DIETARY_SUPPLEMENT|glycomacropeptide (GMP)|For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).
41324228|NCT00122421|BEHAVIORAL|Pharmacist recommendations to primary care providers|recommendations based on chart review by pharmacist, given to pcp at time of visit
41324229|NCT00122421|OTHER|pharmacist recommendations|recommendations based on chart review by pharmacist, given to pcp at time of visit
41324230|NCT06107036|DRUG|BI 1015550|BI 1015550
41324231|NCT06107036|DRUG|Moxifloxacin|Moxifloxacin
41324232|NCT06107036|DRUG|Placebo|Placebo-matching BI 101550
41324233|NCT03581929|DIETARY_SUPPLEMENT|Memormax|Memormax is a food supplement indicated to support cognitive functions thanks to the Melissa officinalis; it also contains lyophilized Royal Jelly, Blueberry extract and Blueberry juice.
41324234|NCT03581929|OTHER|Placebo|Placebo comparator
41324235|NCT01003353|BEHAVIORAL|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
41324236|NCT04664140|OTHER|QFR-based virtual PCI|Procedural planning of PCI based on the pullback trace given by the QFR systems in order to obtain an optimized functional result after PCI
41324237|NCT04664140|OTHER|angiography-based PCI|PCi according to international guidelines, local protocols and practice
41324238|NCT00221429|DRUG|Lithium|lithium
41324239|NCT00221429|DRUG|sodium divalproex|Depakote
41324240|NCT00221429|OTHER|Placebo|Placebo
41324241|NCT05653804|PROCEDURE|tele-visit|The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
41324242|NCT03104985|DEVICE|LASMIK|the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).
40806177|NCT06054113|DRUG|Blinatumomab|Administered via CIVI
40806178|NCT03983382|DIAGNOSTIC_TEST|Left Ventricular Ejection Fraction|LVEF assessment at baseline, 6 months, and 12 months
41324243|NCT03104985|OTHER|Conventional therapy|"* An elastic compression of lower extremities,~* Pharmacotherapy,~* Topical treatment"
41478303|NCT00396461|DRUG|MCT/LCT/omega-3 (5:4:1)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
41324244|NCT02600494|DRUG|ITI-007 (Lumateperone)|
41324245|NCT02600494|DRUG|Placebo|
41324246|NCT01223326|DRUG|Acetylcysteine (NAC)|NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
41324247|NCT01223326|DRUG|Saline|Na Cl 0.9% infusion
41478304|NCT02960438|DRUG|E6011|subcutaneous administration
41478305|NCT02960438|DRUG|Placebo|subcutaneous administration
41478306|NCT03937128|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout the training.
41478307|NCT03937128|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
41478308|NCT01311752|PROCEDURE|surgical management of high grade lesions|"Clinical, pathological and biological, data at diagnosis and during follow-up will be collected.~Surgical sample will be collected to study human papillomavirus related genital pathology."
41478309|NCT01425723|BIOLOGICAL|rFIXFc|Administered as specified in the treatment arm.
41478310|NCT06110247|DEVICE|NIRS|After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.
41478311|NCT06110247|OTHER|Taking a blood sample|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded.
41478312|NCT06417333|DEVICE|xiaomi mi band 7 smart wristband|Patients with mild dementia have been distributed xiaomi mi band 7 smart wristbands for health data collection
40806183|NCT06637254|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma
40806184|NCT06637254|DRUG|Placebo|the placebo comparator of study
41324248|NCT03579225|DEVICE|MATRx plus test|The MATRx plus is a home-based test that allows the healthcare provider to determine if a patient with obstructive sleep apnea will benefit from oral appliance therapy. Prior to the test, a dentist fits the patient with dental trays and measures the patient's comfortable jaw range of motion. The trays are connected to a mandibular positioner. During sleep, the device collects airflow from a nasal cannula and blood oxygen saturation from a pulse oximeter. These signals are used by the device software to control the mandibular positioner and protrude the mandible. During the test, the device moves the lower jaw within the patient's range of motion to predict if the patient is likely to benefit from oral appliance therapy and, if so, the appropriate amount of protrusion. Additional study nights may be required if the data from either of the first two nights are insufficient or if a more precise determination of the amount of jaw protrusion that provided a therapeutic benefit can be made.
40806185|NCT06129591|DRUG|Lazarus Naturals THC-Free CBD Tincture (flavorless) + Silicone patch|"The study intervention is prospective in nature. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessment will be done over a period of 6 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale. Statistical analysis will assess whether CBD oil improves short-term and long-term scar appearances."
40806186|NCT06129591|DRUG|Silicone patch|A non-treatment group is included in this study to comply with the standard of care, as to treat post-operative wounds with silicone patches to improve final scar outcomes.
41324249|NCT06092632|OTHER|Pigmented rice|Cooked black rice
41324250|NCT06092632|OTHER|White Rice|Cooked white rice
40806189|NCT04684368|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood samples
40806190|NCT04684368|DRUG|Carboplatin|Given IV
40806191|NCT04684368|DRUG|Etoposide|Given IV
40806192|NCT04684368|BIOLOGICAL|Filgrastim|Given subcutaneously (SC) or IV
40806193|NCT04684368|DRUG|Ifosfamide|Given IV
41324251|NCT03303287|BEHAVIORAL|School health education|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
41324252|NCT01693718|DRUG|Hydroxyurea|Hydroxyurea at 1gm(PO)12hrs x 11days(2gm/day). The first daily dose of hydroxyurea on days 1-5 is given 2 hrs prior to the first fraction of daily radiotherapy.
41324253|NCT01693718|DRUG|5- Fluorouracil|"Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs.~Radiation therapy is administered twice daily at 150 cGY per fraction, every other week with chemotherapy."
41324254|NCT01693718|DRUG|Cisplatin|Cisplatin 100mg/m2 I.V. on the evening of the day 1, on cycles 1,3,and 5 only in 200cc NS IV over 2 h. Ensure adequate hydration to keep urine output \> 100 cc/ hour.
41478313|NCT02551393|BEHAVIORAL|Home Blood Presssure Monitoring, Education|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
41324255|NCT05564442|DRUG|20% benzocaine gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
41324256|NCT05564442|DEVICE|Transcutaneous electric nerve stimuli|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
41324257|NCT05564442|DRUG|Emla gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
41478314|NCT04528199|DRUG|[18F]FLOR (FC303) Injection|Single dose of 10 ±1 millicurie (mCi) of \[18F\]FLOR (FC303) injection followed by the PET/CT scan.
41478315|NCT02225665|GENETIC|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
41478316|NCT02225665|GENETIC|SB-728mR-T|- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
41478317|NCT02225665|DRUG|Cyclophosphamide|- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
41478318|NCT05261490|DRUG|maplirpacept (PF-07901801)|PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.
41478319|NCT05261490|DRUG|Pegylated Liposomal Doxorubicin (PLD)|RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
41478320|NCT04999033|OTHER|no intervention|This is a cross-sectional study, and no intervention will be included
41478321|NCT04051684|PROCEDURE|Transverse abdominal plane block|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
41478322|NCT04051684|DRUG|Ropivacaine|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
41478323|NCT06082297|DEVICE|Chattanooga Physio, DJO, neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) was applied with a device called Chattanooga Physio (DJO), testing 10 different combinations of parameter-settings. The parameter-settings that were varied and combined were frequency (1Hz and 36Hz) and plateau times (0.5s, 1.5s, 3s, 5s, 7s). The NMES was applied to the calf of the participants via transversally placed textile electrodes (3x3 cm) integrated in a sock starting with very low current amplitude followed by gradual small increases in current amplitude until induction of ankle plantar flexion, at which time-point the outcomes where measured.
41478324|NCT02980302|PROCEDURE|Cutaneous biopsy|Under local anesthesia
41478325|NCT01443559|GENETIC|Xenogenic cornea|lamellar acellular xenogenic corneas were sterilised by radiation
41478326|NCT01443559|GENETIC|homogenic cornea|homogenic corneas were sterilised by radiation
41478327|NCT06137157|DRUG|ATR12-351|Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis
41478328|NCT00619359|DRUG|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
41478329|NCT00619359|DRUG|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
41478330|NCT00619359|DRUG|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
41478331|NCT00619359|DRUG|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
41478332|NCT00619359|DRUG|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
41478333|NCT00389831|DRUG|Rotigotine Nasal Spray|Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
41478334|NCT00389831|OTHER|Placebo Nasal Spray|Daily single dose of placebo delivered as single puff of nasal spray solution
41478335|NCT00300326|PROCEDURE|Computer assist|same implant using a computer-assisted surgical technique.
41478336|NCT03653494|PROCEDURE|phrenic block|phrenic block by 1% ropivacaine 5ml
41478337|NCT03653494|PROCEDURE|no phrenic block|no phrenic block
41478338|NCT00573157|DRUG|Atacicept|Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
41478339|NCT00573157|DRUG|Mycophenolate mofetil|MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
40806194|NCT04684368|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41478340|NCT00573157|DRUG|Placebo|Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
41478341|NCT00573157|DRUG|Corticosteroids|High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
41478342|NCT02446834|BEHAVIORAL|intensive lifestyle intervention|3 months low GI diet and exercise
41478343|NCT02446834|DRUG|GLP-1 Receptor Agonists|Use GLP-1 Receptor Agonists 3 months to treat PCOS
41478344|NCT02446834|DRUG|Metformin|Use metformin 3 months to treat PCOS
41478345|NCT02446834|DRUG|Acarbose|Use acarbose 3 months to treat PCOS
41478346|NCT00882206|DRUG|cytarabine|"At baseline when peripheral blood draw and bone marrow aspirate performed.~\*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg."
41478347|NCT00882206|DRUG|decitabine|Days 1-4, 15 mg/m\^2 intravenously (IV) over 1 hour
41478348|NCT00882206|DRUG|doxorubicin hydrochloride|Day 5, 60 mg/m\^2 intravenously (IV) over 15 minutes
41478349|NCT00882206|DRUG|imatinib mesylate|340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age \<18 years and 400 mg orally every day for \>18 years on Days 5-33.
40806195|NCT04684368|DRUG|Mesna|Given IV or orally
40806196|NCT04684368|BIOLOGICAL|Pegfilgrastim|Given SC
41478350|NCT00882206|DRUG|methotrexate|\*\*Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
41478351|NCT00882206|DRUG|pegaspargase|2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
41478352|NCT00882206|DRUG|prednisone|40mg/m2/day divided BID (days 5 - 33)
41478353|NCT00882206|DRUG|vincristine sulfate|1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
41478354|NCT00882206|DRUG|vorinostat|Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
41478355|NCT01857648|OTHER|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
41478356|NCT00288717|DRUG|Candesartan|
41478357|NCT00288717|DRUG|Telmisartan|
41478358|NCT02459145|BEHAVIORAL|Graduated exercise protocol|Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
41478359|NCT03722355|RADIATION|Conventional RT|Radiation therapy
41478360|NCT03722355|RADIATION|Hyperfractionated RT|Radiation therapy
40806197|NCT04684368|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
41324258|NCT05564442|OTHER|Ice application|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
41324259|NCT00002577|RADIATION|radiation therapy|
41324260|NCT00925691|DEVICE|RV lead|The RV lead is implanted at the apex or at the interventricular septum
41324261|NCT01296698|DRUG|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
41324262|NCT01296698|DRUG|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
41478361|NCT03722355|DRUG|Carmustine|Chemotherapy
41478362|NCT04844021|BEHAVIORAL|Nudge|"EHR-based nudge"
41478363|NCT04844021|BEHAVIORAL|Nudge+|"EHR-based nudge plus facilitation"
41478364|NCT03327090|OTHER|Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).|Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
40806198|NCT04684368|OTHER|Questionnaire Administration|Ancillary studies
40806199|NCT04684368|RADIATION|Radiation Therapy|Undergo WVSCI radiation therapy
40806200|NCT04684368|RADIATION|Radiation Therapy|Undergo radiation therapy
41324263|NCT05065307|DIAGNOSTIC_TEST|Venipuncture|Diagnostic venipuncture
41324264|NCT04084249|DIAGNOSTIC_TEST|ctDNA-analysis|Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).
41324265|NCT04084249|OTHER|Intensified Follow-up Schedule|PET/CT-scans every 3. month
41324266|NCT02398084|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
41324267|NCT01682577|DRUG|Perindopril 4 mg tablets of PT Dexa Medica|Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
41324268|NCT01682577|DRUG|Perindopril 4 mg tablets of Servier|Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
41324269|NCT01769703|DRUG|Dabigatran 110/150 mg BID|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
41324270|NCT00352313|DRUG|ATN-161|Given IV
41478365|NCT02092883|DRUG|ACTH|PK PET scan before and after ACTH treatment
41478366|NCT05101993|DEVICE|AtriClip|Received AtriClip for exclusion of left atrial appendage during concomitant cardiac procedure
41478367|NCT04965857|DIAGNOSTIC_TEST|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
41478368|NCT05730504|OTHER|Mobile app-based self-guided interventions|self-guided, app-based mobile psychological interventions based on CBT, meditation, mindfulness, journaling, and audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation
41478369|NCT02246868|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
41478370|NCT02708888|OTHER|Trunk training|The experimental group receives 16 hours of additional trunk training (4 days/week, 4 weeks) focusing on trunk muscle strength, coordination and selective movements executed on stable and unstable surfaces.
41478371|NCT02708888|OTHER|Cognitive exercises|The control group will be receiving the same amount of repetitive cognitive exercises within arm's range to ensure no anticipatory postural adjustments of the trunk.
41478372|NCT00493454|DRUG|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
41478373|NCT00493454|DRUG|Rituximab|250 mg/m\^2 IV Over 6 to 8 Hours
41478374|NCT00493454|DRUG|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
40806201|NCT04684368|PROCEDURE|Second-Look Surgery|Undergo second-look surgery if needed
40806202|NCT04684368|DRUG|Thiotepa|Given IV
40806203|NCT05298423|BIOLOGICAL|pembrolizumab/vibostolimab|Administered as an intravenous (IV) infusion
40806204|NCT05298423|BIOLOGICAL|durvalumab|Administered as an IV infusion
40806205|NCT05298423|DRUG|cisplatin|Administered as an IV infusion
40806206|NCT05298423|DRUG|pemetrexed|Administered as an IV infusion
40806207|NCT05298423|DRUG|etoposide|Administered as an IV infusion
40806208|NCT05298423|DRUG|carboplatin|Administered as an IV infusion
40806209|NCT05298423|DRUG|paclitaxel|Administered as an IV infusion
40806210|NCT05298423|RADIATION|thoracic radiotherapy|Administered as an external beam radiation
41324271|NCT00352313|DRUG|carboplatin|Given IV
41324272|NCT02504177|DRUG|novel oral anticoagulant for 30 days|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
41324273|NCT02504177|DRUG|novel oral anticoagulant for 24 hour|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
41324274|NCT03206112|OTHER|PAS25|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
41324275|NCT03206112|OTHER|PAS10|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles. TBS is a special form of
40806211|NCT06637527|DRUG|OK-101 0.05%|0.05% Ophthalmic Solution
40806212|NCT06637527|DRUG|OK-101 0.1%|0.1% Ophthalmic Solution
40806213|NCT06637527|DRUG|Placebo|Placebo
41153211|NCT06283693|OTHER|mindfulness-based stress reduction|Müdahale grubundaki kadınlara depresyon, anksiyete ve stres düzeylerini azaltmak için farkındalık temelli bir stres azaltma programı uygulanacaktır. Program, haftada bir seans olmak üzere haftada iki kez toplam 4 hafta boyunca 8 seanstan oluşacaktır. Müdahale grubu haftada 2 seans alacaktır. Her seans 80 dakika sürecektir. Çalışmadaki seanslar, katılımcıların iş yoğunluğu, hayattaki sorumlulukları ve 4 hafta boyunca düzenli olarak katılamama ihtimalleri göz önünde bulundurularak zoom programı üzerinden gerçekleştirilecektir. 4 hafta/8 oturumluk MBSR programı tamamlandıktan sonra müdahale grubundaki kadınlara veri toplama formları tekrar uygulanacak ve son test ölçümleri yapılacaktır. Son test ölçümlerinden sonra müdahale grubundaki kadınların takip ölçümleri ölçümlerden 8 hafta sonra yapılacaktır.
41153212|NCT01074099|BIOLOGICAL|BMAC|Injection of BMAC into ischemic myocardium during CABG
41153213|NCT01074099|PROCEDURE|CABG only|Control subjects will undergo CABG surgery without BMAC injection
41478375|NCT05017259|DIETARY_SUPPLEMENT|calorie restriction diet|The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
41478376|NCT04556890|DEVICE|Active rTMS/Active iTBS DFPLC/Sham Pain M1|Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1
41478377|NCT04556890|DEVICE|Active rTMS/Active iTBS|Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1
41153214|NCT05887479|DRUG|Botulinum toxin type A|Toxin of Clostridium Botulinum
41324276|NCT03206112|OTHER|PAS25-cTBS150|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
41324277|NCT01593228|DRUG|Iniparib (SAR240550/BSI-201)|"Pharmaceutical form:Solution~Route of administration: Intravenous"
41324278|NCT01593228|DRUG|Carboplatin|"Pharmaceutical form:Solution~Route of administration: Intravenous"
41324279|NCT01593228|DRUG|Doxorubicin HCL liposome injection|"Pharmaceutical form:Solution~Route of administration: Intravenous"
41324280|NCT01593228|DRUG|Gemcitabine|"Pharmaceutical form:Solution~Route of administration: Intravenous"
41324281|NCT01593228|DRUG|Irinotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
41324282|NCT01593228|DRUG|Paclitaxel|"Pharmaceutical form:Solution~Route of administration: Intravenous"
41478378|NCT01576302|BEHAVIORAL|Diaphragmatic breathing|Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).
41153215|NCT05887479|DRUG|%0,9 NaCl|%0,9 NaCl
41153216|NCT03552471|OTHER|Laboratory Biomarker Analysis|Correlative studies
41153217|NCT03552471|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
40806221|NCT04929028|PROCEDURE|Anoscopy|Undergo anoscopy
40806222|NCT04929028|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40806223|NCT04929028|DRUG|Capecitabine|Given PO
40806224|NCT04929028|PROCEDURE|Colonoscopy|Undergo colonoscopy
40806225|NCT04929028|PROCEDURE|Computed Tomography|Undergo CT or FDG PET/CT
40806226|NCT04929028|PROCEDURE|Digital Rectal Examination|Undergo digital rectal exam
40806227|NCT04929028|PROCEDURE|Echocardiography|Undergo ECHO
40806228|NCT04929028|OTHER|Fludeoxyglucose F-18|Receive FDG
41324283|NCT01593228|DRUG|Topotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
41324284|NCT05596786|DRUG|Rituximab|One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)
41324285|NCT05596786|OTHER|Placebo|One course of IV placebo of rituximab consisting of a first infusion of 500 mL of saline (0.9% sodium chloride) infusion (day 1), and a second infusion of 500 mL of saline infusion two weeks later (day 15)
40806229|NCT04929028|DRUG|Fluorouracil|Given IV
40806230|NCT04929028|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40806231|NCT04929028|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
40806232|NCT04929028|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
40806233|NCT04929028|DRUG|Mitomycin|Given IV
40806234|NCT04929028|BIOLOGICAL|Nivolumab|Given IV
40806235|NCT04929028|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT or PET/MRI
40806236|NCT04929028|PROCEDURE|Proctoscopy|Undergo proctoscopy
40806237|NCT04929028|OTHER|Questionnaire Administration|Ancillary studies
40806238|NCT04929028|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
41153218|NCT03552471|OTHER|Pharmacokinetic Study|Correlative studies
41153219|NCT03552471|DRUG|Rucaparib Camsylate|Given PO
41153220|NCT00598156|DRUG|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
41153221|NCT00598156|DRUG|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
41153222|NCT01138098|BIOLOGICAL|Engerix™-B|Intramuscular, single dose
41153223|NCT03188549|OTHER|AniosGel 85 NPC|Hand hygiene formula
41153224|NCT03188549|OTHER|Softa-Man (Braun)|Hand hygiene formula
41153225|NCT03188549|OTHER|Septol|alcohol-based hand rub
41324286|NCT02465346|DEVICE|MSU-based stroke management|Prehospital stroke treatment with a mobile stroke unit
41324287|NCT02465346|DEVICE|Control stroke management|Conventional stroke management
41324288|NCT02170038|DRUG|Microgynon|Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
41153226|NCT03749616|DRUG|Ibuprofen|NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
41153227|NCT03749616|DRUG|Acetaminophen|Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
41153228|NCT04004520|BEHAVIORAL|Virtual Reality with Meditation|The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).
41324289|NCT02170038|DRUG|Noristerat(BAY86-6308)|Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
40806264|NCT06637488|PROCEDURE|cleft lip repair using fisher technique|Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. suturing the nasal conformer in the cleft side
41324290|NCT04393077|BEHAVIORAL|Emotional Freedom Technique|EFT application was started by showing the meridian points to the participants through the picture. It was advised that these points should be clicked with the index finger and middle finger without hurting, but with certain strokes, and it was ensured that they understood the regions by showing and applying them. Then, the following basic steps, which should be followed by the EFT session (four in total lasting 20 minutes), were carried out in succession with the researcher.
41324291|NCT00316654|BIOLOGICAL|Meningococcal C conjugate vaccine|
41324292|NCT05535101|DEVICE|Intermittent theta burst transcranial magnetic stimulation (iTBS)|The amphetamine users will undergo a one-month iTBS intervention. From Week 1 to Week 4, subjects will be treated five times a week.
41324293|NCT05535101|DEVICE|Sham stimulation|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
41324294|NCT03114566|OTHER|Leukapheresis|Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.
41324295|NCT00871091|PROCEDURE|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
41324296|NCT00871091|PROCEDURE|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
41478379|NCT01576302|BEHAVIORAL|Muscle relaxation|Progressive passive muscle relaxation
41478380|NCT03444441|PROCEDURE|Foot or ankle surgery|Surgery for foot or ankle
41324297|NCT00871091|PROCEDURE|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
41324298|NCT03543670|DIETARY_SUPPLEMENT|Oncoxin-Viusid|Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).
40806265|NCT06637488|PROCEDURE|cleft lip repair using fisher technique|Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. No nasal conformers used in this group
40806266|NCT06639854|OTHER|Hematopoietic Cell Transplant|"Participants choices may include to receive standard post-transplant virus prevention with letermovir or other standard drugs without being part of this study. Participants may choose to receive other investigational therapy, if available.~These alternative treatments have risks and benefits that may be the same or different than those in this research study."
41324299|NCT01784588|DEVICE|Solyx Single Incision Sling System|Solyx Single Incision Sling System
41324300|NCT01784588|DEVICE|Obtryx II Sling System|Standard outside-in transobturator sling
41324301|NCT04600687|OTHER|Placebo tablets|Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.
41324302|NCT01280266|DRUG|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
41324303|NCT03342937|DRUG|Oxaliplatin+Capecitabine+Pembrolizumab|"For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~1. Safety validation part: all Cycles are 21 days in length.~2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days."
41478381|NCT00591331|DRUG|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
41478382|NCT00591331|DRUG|placebo|
41478383|NCT00822393|DRUG|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
41478384|NCT00822393|DRUG|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
41478385|NCT00388895|DRUG|chemotherapy|
41478386|NCT00388895|DRUG|Glivec|
41478387|NCT05160714|RADIATION|Real-time ADC-guided response adaptive Boost in HNC|"40 Gy in 20 fractions over 5 weeks (Monday to Thursday) to the adjuvant neck, simultaneous integrated boost with 56 Gy in 20 fractions in 5 weeks to the low-risk macroscopic tumor.~Once weekly Dose-escalated SBRT adaptive boost to an ADC-based high risk subvolume with graduated dose levels of 5x5 Gy, 5x5.5 Gy, 5x6 Gy, 5x6.5 Gy"
41478388|NCT01947478|DEVICE|MDT-2113 Drug-Eluting Balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
41478389|NCT01947478|DEVICE|Standard angioplasty balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
41153229|NCT04004520|BEHAVIORAL|Audio Control|The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.
41324304|NCT05066035|DRUG|Neostigmine|"The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge."
41153230|NCT04004520|BEHAVIORAL|Virtual reality Control|The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
41153231|NCT00042302|PROCEDURE|Chemotherapy|
41153232|NCT00042302|DRUG|tariquidar + paclitaxel/carboplatin|
41153233|NCT00042302|DRUG|placebo + paclitaxel/carboplatin|
41153234|NCT04372186|DRUG|Placebo|Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.
40806275|NCT05945485|BIOLOGICAL|DCVC H1 HA mRNA vaccine|A modified nucleoside messenger RNA (mRNA) vaccine encoding the full length HA of influenza A/California/07/2009 (H1N1) encapsulated in lipid nanoparticle (LNP) composed of ionizable lipid, DSPC, cholesterol, and PEG lipid for delivery
40806276|NCT05945485|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|The vaccine contains recombinant hemagglutinin (HA) proteins from four influenza viruses, expressed using a baculovirus vector. These HA proteins are produced in a continuous insect cell line.
40806277|NCT05945485|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
41153235|NCT04372186|DRUG|Tocilizumab|Participants will receive one IV infusion of TCZ 8 mg/kg, with a maximum dose of 800 mg. Up to one additional dose may be given.
41153236|NCT03352661|OTHER|Collect retrospectively data|Collect retrospectively data
41153237|NCT05465278|DRUG|Alirocumab|18 months treatment with alirocumab
40806281|NCT06645457|OTHER|stress ball|Patients squeeze the stress ball
40806282|NCT06645457|OTHER|4-7-8 breathing technique|breathing in quietly through the nose for 4 seconds. holding the breath for a count of 7 seconds. exhaling forcefully through the mouth for 8 seconds.
41324305|NCT05066035|DRUG|Sugammadex|The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to \>0.9 in the recovery room before discharge to the ward.
41324306|NCT04291976|PROCEDURE|Back-to-back high-definition white light endoscopy|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached, with a second segmental inspection after the first examination in the same session.The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
41478390|NCT06063096|DIETARY_SUPPLEMENT|D-allulose|Fruit-flavoured drink with d-allulose at 2 dosages
41478391|NCT06063096|DIETARY_SUPPLEMENT|Placebo|Fruit-flavoured drink with high fructose corn syrup
40806283|NCT05457556|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40806284|NCT05457556|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40806285|NCT05457556|DRUG|Busulfan|Given intravenously (IV)
40806286|NCT05457556|DRUG|Cyclophosphamide|Given IV
40806287|NCT05457556|PROCEDURE|Echocardiography|Undergo ECHO
40806288|NCT05457556|DRUG|Fludarabine|Given IV
40806289|NCT05457556|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo haploHCT
40806290|NCT05457556|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
40806291|NCT05457556|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
40806292|NCT05457556|PROCEDURE|Matched Unrelated Donor Hematopoietic Cell Transplantation|Undergo MUD-HCT
41478392|NCT03919448|BIOLOGICAL|Bevacizumab|Single-dose infusion
41478393|NCT01825135|DEVICE|Neuromuscular electrical stimulation|
41478394|NCT01825135|DEVICE|sham stimulation|sham stimulation will be applied to the quadriceps
40806293|NCT05457556|DRUG|Melphalan|Given IV
40806294|NCT05457556|DRUG|Methotrexate|Given IV
40806295|NCT05457556|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40806296|NCT05457556|DRUG|Mycophenolate Mofetil|Given IV
40806297|NCT05457556|PROCEDURE|Myeloablative Conditioning|Receive myeloablative conditioning regimen
40806298|NCT05457556|OTHER|Quality-of-Life Assessment|Ancillary studies
40806299|NCT05457556|OTHER|Questionnaire Administration|Ancillary studies
40806300|NCT05457556|BIOLOGICAL|Rituximab|Given IV
40806301|NCT05457556|PROCEDURE|T-Cell Depletion Therapy|Undergo haploHCT with alpha beta T cell depletion
40806302|NCT05457556|DRUG|Tacrolimus|Given IV
40806303|NCT05457556|DRUG|Thiotepa|Given IV
40806304|NCT05457556|RADIATION|Total-Body Irradiation|Undergo TBI
41153238|NCT00006137|DRUG|enalapril|
41153239|NCT02826759|OTHER|diabetes|the exposure of interests are obesity, diabetes and insulin-resistance
41153240|NCT01095809|DRUG|bevacizumab|2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol
41153241|NCT01095809|DRUG|triamcinolone acetonide|2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
41324307|NCT04291976|PROCEDURE|single-pass high-definition white light endoscopy|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
41324308|NCT04291976|PROCEDURE|chromoendoscopy|After introduction of the endoscope into the colon a dye (methylene blue or indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two interventions.
41324309|NCT00377429|DRUG|catumaxomab|Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
41324310|NCT01883869|DRUG|ticagrelor|
41324311|NCT01883869|DRUG|placebo|placebo
41324312|NCT06229067|DRUG|Adebrelimab|Adebrelimab at a dose of 1200 mg via intravenous infusion every three weeks. Adebrelimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
41324313|NCT06229067|DRUG|Vinorelbine|Metronomic oral vinorelbine 20 mg every other day. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
41324314|NCT06229067|DRUG|Cyclophosphamide (tablet)|Metronomic oral cyclophosphamide 50 mg daily. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
41324315|NCT06229067|DRUG|Capecitabine|Metronomic oral capecitabine 500 mg three times daily. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
41324316|NCT02487277|DRUG|PEGPH20|
41324317|NCT02487277|DRUG|Gemcitabine|
41324318|NCT02487277|DRUG|Nab-paclitaxel|
41324319|NCT04220385|OTHER|Group A|Subjects will perform following exercises, Single Leg Extension, Arm and Leg Lift, Balance Bridge, Single-Leg Twist, Single Leg Reach, Sideways Leg Lift, Single Arm Stand, Torso Twists and Plank exercise with minimum one set and maximum two sets. 30 seconds will be rest time between each set. Subjects will be encouraged to increase the number of repetitions after every 2 weeks, except in Plank exercise in which holding position time will be initially 30 seconds in each set and will be encouraged to increase holding time after every 2 weeks.
41478395|NCT06301087|DEVICE|Web Application|web application for monitoring children's development and postnatal depression of mothers
41324320|NCT04220385|OTHER|Group B|Subjects will perform Side Bridge, Bird Dog and Beginner Curl-up exercise in the first three weeks and Side Bridge, Bird Dog and Intermediate Curl-up exercise in the last three weeks. Repetitions per set will be 5, 4, 3 in first two weeks, 7, 6, 5 in third and fourth weeks and 9, 8, 7 in last two weeks. 8-10 seconds will be holding time in each repetition. 30 seconds will be rest time between each set
41324321|NCT04783220|BEHAVIORAL|Comprehensive structured parent intervention|"1. Educational sessions and coaching on infants' behavior cues~2. Skills on motor stimulation~3. Written instructions for play and stimulation activities at discharge~4. Multidisciplinary follow-up~5. Developmental tracking and advice via a mobile app"
41324322|NCT02305875|OTHER|MCN scoring|Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
41324323|NCT03944083|OTHER|Treatment as usual for ADHD|Children are given treatment according to diagnostic conclusion and clinical recommendations.
41324324|NCT00151125|DRUG|recombinant interleukin-11|25 mcg/kg subcutaneously daily for seven days
41324325|NCT00151125|DRUG|recombinant interleukin-11|50 mcg/kg subcutaneously daily for 7 days
41324326|NCT00151125|DRUG|recombinant interleukin-11|10 mcg/kg subcutaneously daily for 7 days
41324327|NCT02700139|DEVICE|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
41324328|NCT01790009|DIETARY_SUPPLEMENT|Flavanol rich drink|
41324329|NCT01790009|DRUG|Acetaminophen|2x500 mg Acetaminophen
41324330|NCT04753138|DEVICE|TotalFill Bioceramic Sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
41478396|NCT00411957|DRUG|Atazanavir|ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
41324331|NCT04753138|DEVICE|AH+ Sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
41324332|NCT05008458|DIAGNOSTIC_TEST|von willebrand factor and copeptin|biomarkers increase in children with febrile seizures
41324333|NCT05894044|OTHER|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
41324334|NCT05894044|OTHER|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
41324335|NCT05894044|OTHER|Pulsed current 500 µs phase|Pulsed current, modulated in 50 Hz, 500 µs
41478397|NCT05528640|OTHER|Mental Health Literacy Program|Six educational sessions will be delivered on a private YouTube channel which consists of information about mental health literacy (knowledge about priority mental illnesses, attitude/ stigma related to mental illnesses, and help-seeking efficacy). There will be six-weeks unrestricted access period. Afterwards, the round-up session which consists of problem-based learning and group sharing will be delivered in person. Two vignettes based on the clinical scenarios will be given for discussion. Furthermore, participants are encouraged to share their opinion on mental health literacy, strategies for dealing with difficulties of caring for patients with mental illnesses in general hospitals, way to promote mental health literacy of healthcare professionals in general hospitals
41478398|NCT04126421|DEVICE|Prosthesis component (acetabular cup) E1 cup|Semented acetabuar cup With E1 cup
41478399|NCT04126421|DEVICE|Prosthesis component (acetabular cup) Marathon cup|Semented acetabuar cup With Marathon cup
41478400|NCT06108258|DRUG|IV iron administration|IV iron administration during pregnancy
41478401|NCT02983136|BEHAVIORAL|Dialogue and inter-professional learning|"The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:~* Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and~* The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice."
41324336|NCT05894044|OTHER|Pulsed current 200 µs phase|Pulsed current, modulated in 50 Hz, 200 µs
41478402|NCT04446039|DRUG|Escitalopram|Treatment for depression
41008599|NCT03460184|DIAGNOSTIC_TEST|G.A Group A:|"G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage."
41478403|NCT04446039|DRUG|Paroxetine|Treatment for depression
41478404|NCT04446039|DRUG|Fluoxetine|Treatment for depression
41478405|NCT04446039|DRUG|Mirtazapine|Treatment for depression
41008600|NCT01648309|OTHER|Neuropsychological testing|This is an observational study
41478406|NCT04446039|DRUG|Duloxetine|Treatment for depression
41008601|NCT04573036|DRUG|HRS4800 tablets|single oral administration
41478407|NCT04446039|DRUG|Sertraline|Treatment for depression
41478408|NCT04446039|DRUG|Venlafaxine|Treatment for depression
41153242|NCT05240482|PROCEDURE|ST36 acupuncture|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
41324337|NCT06220552|DRUG|Sintilimab|Sintilimab 200mg D1, Q3W
41008602|NCT04573036|DRUG|Placebo tablets|single oral administration
41008603|NCT05993728|BEHAVIORAL|Body Project|The Body Project prevention program is a body acceptance program to promote a healthy body image and prevent eating disorder onset.
41008604|NCT05993728|BEHAVIORAL|Psychoeducational control|Participants randomized to the educational control condition will receive videos addressing body image and eating disorders
41008605|NCT00064246|BIOLOGICAL|rituximab|Given IV
41324338|NCT06220552|RADIATION|Low-dose Radiotherapy|Radiotherapy 1Gy/1F, D1/D2/D8/D15, Q3W
41008606|NCT00064246|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
41478409|NCT04446039|DRUG|Tianeptine|Treatment for depression
41478410|NCT04446039|DRUG|Vortioxetine|Treatment for depression
41478411|NCT04446039|DRUG|Desvenlafaxine|Treatment for depression
41478412|NCT04446039|DRUG|Bupropion|Treatment for depression
41478413|NCT00107718|DRUG|SB-485232|
41478414|NCT00157859|DRUG|Chloroquine and sulphadoxine-pyrimethamine|
41008607|NCT00064246|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
41008608|NCT04453384|DRUG|XAV-19|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
41008609|NCT04453384|DRUG|Placebo|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
41008610|NCT02837432|DRUG|Hydrocortisone acetate|
41008611|NCT02837432|DRUG|Placebo|
41008612|NCT04607226|OTHER|Active transcutaneous vagus nerve stimulation|respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes
41324339|NCT00854256|PROCEDURE|Canaloplasty|Canaloplasty surgery
41324340|NCT00854256|PROCEDURE|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
41478415|NCT00970008|OTHER|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
41478416|NCT00970008|OTHER|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
41008613|NCT04607226|OTHER|Sham transcutaneous vagus nerve stimulation|stimulation of the auricle for 30 minutes
41008614|NCT05288205|DRUG|JAB-21822|KRAS G12C inhibitor
41008615|NCT05288205|DRUG|JAB-3312|SHP2 inhibitor
41008616|NCT00881075|DRUG|SeeMore(TM)|single dose intravenous injectable
41008617|NCT05491707|OTHER|Music|Patients will choose a genre of music from the following list; pop, gospel, classical, jazz, and soul, at the preoperative visit. This will be played on disposable ear phones at a self-selected volume for the duration of the surgical procedure.
41008618|NCT04835402|DRUG|Pembrolizumab|400mg every 6 weeks
41008619|NCT04835402|DEVICE|Irreversible electroporation|Percutaneous ablation of one liver metastasis
41324341|NCT05424991|BEHAVIORAL|comedy movie group|The patients watched the collage videos of Turkish cinema Yeşilçam comedy films created by the researchers for 25 minutes. The videos were created by making collages from videos on youtube.
41324342|NCT02773056|DEVICE|Ischial Ramus Containment (IRC)|Ischial Ramus Containment (IRC) is the standard of care socket
41324343|NCT02773056|DEVICE|Dynamic Socket Ischial Ramus Containment (IRC)|Dynamic Socket Ischial Ramus Containment (IRC) is a comparator study socket
41008620|NCT04035785|DRUG|Kangfu Anti-inflammatory Suppository|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
41008621|NCT03096522|DRUG|Phenytoin 2% spray|Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
41008622|NCT03096522|PROCEDURE|Anal fistulotomy|Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base
41008623|NCT04258839|DRUG|Brexpiprazole|Oral tablet; taken once daily
41008624|NCT04441294|BEHAVIORAL|ACE-Plus|
41008625|NCT01529359|DIETARY_SUPPLEMENT|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
41324344|NCT02773056|DEVICE|Sub-Ischial Interface (Sub-I)|Sub-Ischial Interface (Sub-I) is a comparator study socket
41324345|NCT04929613|BEHAVIORAL|Mindfulness-Based Resilience Training|2.5-day intensive MBRT training sessions.
41478417|NCT00970008|OTHER|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
41478418|NCT00970008|OTHER|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
41478419|NCT00128037|DRUG|mitomycin C, vindesine, cisplatin and radiotherapy|
41478420|NCT03804164|OTHER|Educational Intervention|Attend Emerging from the Haze psychoeducational sessions
41478421|NCT03804164|OTHER|Quality-of-Life Assessment|Ancillary studies
41008626|NCT01529359|DIETARY_SUPPLEMENT|Placebo|Placebo 2 gelules per days for 6 weeks
41008627|NCT04341480|DRUG|Chemotherapy|Routine chemotherapy for individual tumor type.
41008628|NCT00618215|BEHAVIORAL|peer group educational implementation strategy|"Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice"
41008629|NCT01670357|DRUG|DA-6034 3%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
41008630|NCT01670357|DRUG|DA-6034 5%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
41008631|NCT01670357|DRUG|DA-6034 Placebo|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
41008632|NCT00654628|DRUG|ezetimibe (+) simvastatin|Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
41008633|NCT01632800|DEVICE|High pulsed magnetic fields|Magnetic fields will escalate in strength
41008634|NCT04722640|DRUG|SKYRIZI|SKYRIZI
41008635|NCT05429450|DRUG|Methotrexate|Three periocular injections of methotrexate at week 0, week 3 and week 6.
41008636|NCT05429450|DRUG|Triamcinolone Acetonide|Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.
41008637|NCT03862976|DIAGNOSTIC_TEST|computerized cardiotocography|computerized cardiotocography (C-CTG)
41008638|NCT06030414|BIOLOGICAL|LMN-301|Intranasally administered powder.
41008639|NCT00354224|DRUG|capecitabine|
41008640|NCT00354224|DRUG|oxaliplatin|
41008641|NCT05232448|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy focuses on challenging and changing cognitive distortions and behaviors, improving emotional regulation and the development of personal coping strategies that target solving current problems.
41008642|NCT00947583|BIOLOGICAL|Osteocel Plus|biologic
41008643|NCT02907359|DRUG|Guadecitabine|
41153243|NCT01662661|DRUG|JNJ-47910382 (suspension)|Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
41324346|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
41324347|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
41324348|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
41324349|NCT04711759|DEVICE|High flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
41324350|NCT04711759|DEVICE|Standard oxygen therapy|Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.
41324351|NCT01293006|DRUG|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants \<65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
41478422|NCT03804164|OTHER|Survey Administration|Ancillary studies
41478423|NCT05113459|DRUG|Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy|disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
41478424|NCT00037102|DRUG|interferon beta 1a|
41478425|NCT00037102|DRUG|methotrexate|
41008644|NCT02907359|OTHER|Treatment Choice|"* BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~* LDAC: 20 mg/m\^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~* Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m\^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m\^2/day) or idarubicin (9-12 mg/m\^2/day) or mitoxantrone (8-12 mg/m\^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice."
41008645|NCT00397995|PROCEDURE|above- or under elbow cast|
41008646|NCT00054561|BIOLOGICAL|recombinant interferon alfa|
41008647|NCT00054561|DIETARY_SUPPLEMENT|vitamin E|
41008648|NCT00054561|DRUG|isotretinoin|
41008649|NCT00054561|PROCEDURE|adjuvant therapy|
41008650|NCT03515460|OTHER|sugar oral load|The individuals will receive a sugar oral load (high sugar meal)
41008651|NCT03515460|OTHER|fat oral load|The individuals will a receive fat oral load (high fat meal)
41008652|NCT03515460|OTHER|sugar and fat oral load|The individuals will a receive sugar and fat oral load (high sugar and high fat meal)
41008653|NCT01260987|DRUG|Conventional photodynamic therapy|Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
41008654|NCT01260987|DRUG|Fractional CO2 laser assisted PDT|Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
41008655|NCT04400097|PROCEDURE|suture|suture methods of autograft conjunctival transplantation
41008656|NCT03101475|DRUG|Durvalumab (MEDI4736)|Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
41008657|NCT03101475|DRUG|Tremelimumab|Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
41008658|NCT03101475|RADIATION|Sterotactic body radiation therapy (SBRT)|delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
41008659|NCT03101475|OTHER|Radiofrequency ablation (RFA)|performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
41008660|NCT05995002|OTHER|Anthocyanin-rich diet|A weekly food plan aims to increase the consumption of anthocyanin-rich sources such as berries, black grapes (or currants), cherries, strawberries, pomegranates, and red onions.
41008661|NCT00220818|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
41008662|NCT00220818|DRUG|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
41008663|NCT04793880|BEHAVIORAL|Medication Cost Information|This version of the HFrEF medication checklist includes patient-specific estimated monthly out-of-pocket cost for each medication. TailorMed, a company designed to provide financial counseling and planning for patients, will generate the patients' out-of-pocket cost based on insurance status. The costs for non-generic HFrEF medications will then be populated onto a checklist of recommended heart failure medications so that patients and their clinicians will have this information available during their clinical encounter.
41008664|NCT04793880|BEHAVIORAL|Heart Failure Medicines Checklist|The Heart Failure Medicines Checklist is an evidence-based medication checklist that describes guideline-recommended medications for HFrEF. This tool is used during the clinical encounter to facilitate a discussion about medications that may be most appropriate for the patient.
41008665|NCT04333680|DIAGNOSTIC_TEST|Focused Assessment of Sonography for Trauma Exam|Speed and image quality of ultrasound exams performed with either transducer specified in the arms.
41008666|NCT03265093|OTHER|Platelet Rich Fibrin Injection|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge. I- prf will be injected on one side and corticosteroid will be injected on the other side in patients with bilateral oral lichen planus. Once a week in the first month after treatment and one time at the end of the second month, the patient will be called to the control.
41008667|NCT03265093|DRUG|Corticosteroid|Corticosteroid injection
41478426|NCT01967693|PROCEDURE|Retrospective analysis of data|Retrospective data analysis
41478427|NCT00933283|DRUG|Telaprevir|Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
41008668|NCT05878613|DEVICE|treadmill training with KT group (TTKT group)|The area to be taped will be cleaned with an alcohol swab, and the I-shaped elastic KT was applied to the four trunk muscles from their insertion to their origin. Patients will then undergo treadmill walking with easy speed control for 20 minutes. The training will be immediately stopped if the subject complain of fatigue during treadmill training; training will be resumed after sufficient rest.
41008669|NCT05878613|DEVICE|treadmill training without KT group (TT group)|General treadmill training without taping will be carried out for the same time as the gait training of the experimental group, and the treadmill speed will also be a comfortable speed in the same manner as in the experimental group.
41008670|NCT02388984|DRUG|Compound danshen dripping pills|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
41008671|NCT02388984|DRUG|Placebo|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
41008672|NCT03996785|BEHAVIORAL|Walking in Urban setting|Walking for 60 minutes as described above
41008673|NCT03996785|BEHAVIORAL|Walking in nature setting|Walking for 60 minutes as described above
41008674|NCT05281250|OTHER|Supervised physical exercise|A supervised exercise is randomized. Although this intervention is not standard in our setting, it is a recommended practice, since it is known that rehabilitation strategies in hospitalized patients have different benefits.
41008675|NCT00179647|DRUG|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
41324352|NCT01293006|DRUG|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
41008676|NCT00179647|DRUG|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
41008677|NCT04400513|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart sounds using electronic stethoscopes
41008678|NCT00301405|DRUG|Thalidomide|Open label drug
41008679|NCT05226650|OTHER|Regular meal pattern|6 meals every day
41008680|NCT05226650|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
41008681|NCT00485446|PROCEDURE|blood analysis|
41008682|NCT04991480|DRUG|ART4215|Participants will receive ART4215 by mouth daily in 21-day cycles.
41008683|NCT04991480|DRUG|Talazoparib|Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
41324353|NCT04114513|DIETARY_SUPPLEMENT|Maltodextrin|NOVAPRODUKT, white powder 5 weeks intervention
41478428|NCT00933283|DRUG|Methadone|Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
41478429|NCT00867841|PROCEDURE|nasopharyngeal swab|PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
41478430|NCT02278458|DRUG|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
41478431|NCT02278458|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
41478432|NCT01095679|DRUG|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
41478433|NCT01095679|DRUG|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
41478434|NCT03848247|OTHER|Injection of Isotonic saline|Half the participants will be injected in a neck muscle with isotonic saline (Control group) and the other half will get NGF (Neck pain group).
41478435|NCT03848247|OTHER|Injection of NGF|Half the participants will be injected in a neck muscle with NGF (Neck pain group).
41478436|NCT04392284|BEHAVIORAL|Diet Counseling|"Delivery of nutrition counseling intervention to improve diet quality. Suggested energy intake will be prescribed with the intent to maintain energy balance and current body weight. A total of 16 nutrition counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of nutrition counseling through the end of the study, meeting with the dietitian every other week. Starting at week 9, those identified as non-responding participants will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
41008684|NCT04991480|DRUG|Niraparib|Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
41008685|NCT04989049|DRUG|Folic Acid 5 MG|folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
41008686|NCT04989049|OTHER|placebo|an inactive drug looking exactly like active drug will be given, patients will be asked to put it on ulcers 2 times per day
41008687|NCT06352905|OTHER|Whole body vibration (WBV)|WBV is a platform that vibrates while a person stands or sits and performs exercises. The WBV session will consist of 5 sets of 60 seconds set at 6 Hertz (frequency), 3 mm (amplitude) while performing mid-squats. There will be a 1 minute rest in between each set. These parameters were chosen as commonly used parameters in previous studies of WBV in people with PD.
41008688|NCT06352905|OTHER|Control|Mid-squats performed on level ground 5 repetitions of 60 seconds with 1 minute rest in between each set.
41008689|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
41008690|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
41324354|NCT04114513|DIETARY_SUPPLEMENT|Inulin|BENEO-Orafti, white powder 5 weeks intervention
41324355|NCT04114513|DIETARY_SUPPLEMENT|Pectin|BANG \& BONSOMER GROUP OY, white powder 5 weeks intervention
41324356|NCT04114513|DIETARY_SUPPLEMENT|Beta-glucan|Tate \& Lyle, white powder 5 weeks intervention
41324357|NCT04114513|DIETARY_SUPPLEMENT|Galactooligosaccharides|FrieslandCampina, white powder 5 weeks intervention
41324358|NCT02152358|DRUG|Aciclovir|Intravenous 15 mg/kg/d during 14 days
41324359|NCT02152358|DRUG|Ganciclovir|intravenous 10 mg/kg/d for 14 days
41324360|NCT02152358|DRUG|Placebo|
41324361|NCT04011124|DRUG|Fluzoparib|single dose on Day 1 and Day 12
41153244|NCT01662661|DRUG|JNJ-47910382 (tablet)|Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
40806318|NCT06644833|DEVICE|Transcranial magnetic stimulation|Transcranial Magnetic Stimulation (rTMS) sessions, targeting the dorsolateral prefrontal cortex, at a frequency of 10 Hz. Each session will last approximately 30 minutes, with 5 sessions per week for 4 to 6 weeks.
40806319|NCT06644833|DRUG|Antidepressant|Selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, SNRIs
41153245|NCT05615558|OTHER|Dietary Intervention|Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.
41324362|NCT04011124|DRUG|Rifampicin|QD on Day 5-14 for 10 days
41478437|NCT04392284|BEHAVIORAL|Exercise Counseling|"Delivery of exercise counseling intervention to increase engagement in physical activity. The exercise specialist will counsel participants to progressively increase their weekly physical activity. Weight loss is not a primary goal of these exercise counseling sessions. A total of 16 exercise counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of exercise counseling through the end of the study, meeting with the exercise specialist every other week. Starting at week 9, those identified as non-responders will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
41478438|NCT05852795|OTHER|Virtual Reality-mediated Mindfulness-Based Interventions|"The Experimental will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a multisensory experience merging visual and digital auditory stimuli. The audio recording also included some ambient natural sound effects, to make the practice more immersive."
41478439|NCT05852795|OTHER|Virtual Reality-mediated Mindfulness-Based Interventions without audio guided experience|"The Control will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a monosensorial experience with video guided stimulation of naturalistic scenarios."
41478440|NCT05354141|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
41478441|NCT05354141|OTHER|Intravenous normal saline|Placebo
41324363|NCT03453190|COMBINATION_PRODUCT|Apremilast and Clobetasol|Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.
41324364|NCT01798017|DRUG|Mifepristone and misoprostol|Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
41324365|NCT01595438|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
41153246|NCT04357587|DRUG|Pembrolizumab|200 mg intravenously (IV) on days 1, 22, and 43
41153247|NCT04357587|RADIATION|External beam radiation|Daily fractions of 200 cGy, 5 days a week for the first 5 weeks of the study, excluding weekends
41324366|NCT01595438|DRUG|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
41153248|NCT04357587|DRUG|Capecitabine|825 mg/m2 orally twice a day on days where radiation therapy is given
40806323|NCT04332536|OTHER|Exercise with and without Codeine|This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
40806324|NCT06643234|PROCEDURE|Ventral hernia repair|Comparative between both techniques
41153249|NCT03147742|DRUG|Ruxolitinib|Ruxolitinib starting dose level 10 mg orally, twice daily (BID).
41153250|NCT03093233|OTHER|no intervention|only descriptive data analysis
41153251|NCT00972114|PROCEDURE|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
41324367|NCT01595438|DRUG|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
40806332|NCT05769218|BEHAVIORAL|CHORUS+|The CHORUS+ intervention will include a baseline interview with a peer recovery coach to encourage uptake of HIV PrEP (pre-exposure prophylaxis) and medications for opioid use disorder (MOUD) through motivational interviewing (MI). Participants will also be offered HIV self-testing on the day of recruitment, HIV PrEP (if they are HIV negative) and MOUD. Participants will then receive peer coaching for 6 months to increase adherence to PrEP and or MOUD.
40806333|NCT05769218|OTHER|Standard of care|Normal protocols for care of participants who inject opioids will be followed.
41153252|NCT00972114|PROCEDURE|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
40806335|NCT04711109|DRUG|Denosumab|Given SC
40806336|NCT04711109|DRUG|Placebo|Given SC
40806337|NCT04711109|OTHER|Quality-of-Life Assessment|Ancillary studies
40806338|NCT06266364|DEVICE|Active VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive active Vagus nerve stimulation (VNS) in phase 1
40806339|NCT06266364|DEVICE|Sham VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive sham Vagus nerve stimulation (VNS) in phase 1
41153253|NCT00972114|PROCEDURE|CABG alone|Coronary artery bypass graft surgery alone
41153254|NCT03151551|DRUG|Ixekizumab|Administered SC
41153255|NCT03151551|DRUG|Adalimumab|Administered SC
41153256|NCT01126177|DRUG|Interferon beta 1a|SNG001, IFN-β1a solution for inhalation
41153257|NCT01126177|DRUG|Placebo|Placebo (excipients of the SNG001 solution only)
41153258|NCT06029920|OTHER|Overground Walking|Walk on a flat surface for a distance of 15 meters, with a duration of 20 minutes, increasing by 5 minutes each week until the target heart rate is achieved during the exercise, for 8 weeks.
41153259|NCT05264311|OTHER|Pilates exercise program|"The Pilates Exercise Program (PEP) (1 h x 2 sessions per week x 2 months) was delivered by one Pilates professional (with a mean of 6.5 years of experience in Pilates). The PEP carried out by Pilates instructor has been published in a previous study \[31\]. The exercises focused on core stability, posture, breathing, flexibility, strength, and muscle control, being the active awareness of the use of trunk muscles to stabilize the pelvic-lumbar region the main approach. The exercises performed were: the hundred, the rolled up, single leg circles with bent leg, spine stretch, rolling like a ball and single leg stretch. Each exercise was performed as follows: 4 repetitions of 30 seconds with 2 minutes of recovery between repetitions. In order to complete the 60 minutes session two exercises: the superman and the double leg bridge were added to the mentioned PEP."
41153260|NCT01418599|DRUG|Torrent's Alfuzosin Extended Release Tablet|
41153261|NCT02867332|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
41153262|NCT02867332|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
41153263|NCT02867332|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
41153264|NCT01634620|DEVICE|NIOX MINO® Instrument (09-1100)|"FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)"
40806352|NCT06058377|PROCEDURE|Biospecimen Collection|Undergo optional collection of tissue and/or blood
40806353|NCT06058377|DRUG|Cyclophosphamide|Given IV
40806354|NCT06058377|DRUG|Doxorubicin|Given IV
40806355|NCT06058377|BIOLOGICAL|Durvalumab|Given IV
40806356|NCT06058377|OTHER|Genetic Testing|Undergo MammaPrint testing
40806357|NCT06058377|PROCEDURE|Mammography|Undergo mammography
40806358|NCT06058377|DRUG|Paclitaxel|Given IV
40806359|NCT06058377|OTHER|Quality-of-Life Assessment|Ancillary studies
41153265|NCT00358722|DRUG|Fermagate|Film coated tablet 500mg
41008691|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
41153266|NCT04173273|DRUG|Etrasimod|Dose A taken by mouth, once daily.
40806362|NCT06577025|DRUG|Cilta-cel|Cilta-cel infusion will be administered intravenously.
40806363|NCT06577025|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
40806364|NCT06577025|DRUG|Daratumumab|Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D and Tec-D consolidation.
41324368|NCT01595438|DRUG|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
41153267|NCT04173273|DRUG|Etrasimod|Dose B taken by mouth, once daily.
40806365|NCT06577025|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
40806366|NCT06577025|DRUG|Bortezomib|Bortezomib will be administered subcutaneously as a part of induction.
40806367|NCT06577025|DRUG|Lenalidomide|Lenalidomide will be administered orally as a part of induction.
40806368|NCT06577025|DRUG|Dexamethasone|Dexamethasone will be administered orally as a part of induction.
40806369|NCT06577025|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously as a part of conditioning regimen.
40806370|NCT06577025|DRUG|Fludarabine|Fludarabine will be administered intravenously as a part of conditioning regimen.
40806371|NCT05297786|DRUG|Lanadelumab Injection [Takhzyro]|Lanadelumab 300 mg subcutaneous injection
40806372|NCT05297786|DRUG|Placebo|Placebo injection
40806373|NCT03651765|DRUG|Setmelanotide|Once daily subcutaneous injection
41153268|NCT04173273|DRUG|Placebo|Etrasimod matching placebo tablet taken by mouth, once daily.
41153269|NCT01038206|BEHAVIORAL|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
41324369|NCT00588887|DEVICE|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
41324370|NCT00588887|DEVICE|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
41008692|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
41324371|NCT02685397|DRUG|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
41324372|NCT02685397|DRUG|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
41324373|NCT02685397|DRUG|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
41324374|NCT02685397|DRUG|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
41324375|NCT02685397|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
41324376|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
41324377|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500 mg|Tablets for oral administration, once daily, once per treatment period
41324378|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
41324379|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
41324380|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
41324381|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
41324382|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
41324383|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
41324384|NCT01337167|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 4, and 6 months of age
41324385|NCT01337167|BIOLOGICAL|DAPTACEL™|DAPTACEL™ 0.5 mL intramuscular injection at 15 months of age
41324386|NCT01337167|BIOLOGICAL|PedvaxHIB™|PedvaxHIB™ 0.5 mL intramuscular injection at 15 months of age
41324387|NCT01337167|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
41324388|NCT01337167|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
41324389|NCT01337167|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age
41324390|NCT01337167|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
41324391|NCT01337167|BIOLOGICAL|ActHIB™|ActHIB™ 0.5 mL intramuscular injection at 15 months of age
41324392|NCT01629901|DEVICE|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator used for up to 20 minutes in a session.
41324393|NCT02331615|DEVICE|neuroConn_CE_DC-STIMULATOR|right frontal anodal stimulation
41324394|NCT02331615|DEVICE|neuroConn_CE_DC-STIMULATOR|left frontal anodal stimulation
41478442|NCT03432988|BEHAVIORAL|Nursing Solution-Focused|Two two-hour training modules were designed. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays. Solution-focused communication on IDWG. In the case of IDWG improvement, nurses were trained to congratulate the patient and then to explore in detail, from a stance of curiosity, how s/he had accomplished the weight reduction. Nurses were trained to invite patients to share specific behavioral details, to describe their own behavior from the perspective of significant family members and also to compliment patients on their accomplishments and to invite them to keep track of anything else they might find useful to control fluid intake over the next days.
41478443|NCT06465732|DRUG|Dupilumab|the active comparator arm receive dupilumab only
41478444|NCT06465732|DRUG|Tofacitinib|the experimental arm receive dupilumab plus tofacitinib.
41008693|NCT00791791|PROCEDURE|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
41324395|NCT02331615|DEVICE|SHAM|no meaningful stimulation will be given
41324396|NCT03199638|DRUG|Glutamine vs. Placebo|oral supplementation with either glutamine or placebo twice daily for 3 months
41324397|NCT03199638|BEHAVIORAL|Exercise|short bouts of exercise ('exercise snacks') 3 times daily for 3 months
41324398|NCT03967756|DEVICE|Automatic polyp detection system|When colonoscopists withdraw the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the automatic polyp detection system, which made it feasible to detect lesions in real time. When any potential polyp is detected by the system， there will be a tracing box on an adjacent monitor to locate the lesion with a simultaneous sound alarm.
41324399|NCT00790127|DRUG|HQK-1001|HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
41324400|NCT00790127|DRUG|Placebo|Matching placebo capsules administered once a day, orally, for 56 days
41324401|NCT00133835|PROCEDURE|Extracorporeal shock wave lithotripsy|
41324402|NCT00133835|PROCEDURE|Endoscopic drainage of the main pancreatic duct|
41324403|NCT02898142|OTHER|Postprandial test|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
41153270|NCT02831439|BEHAVIORAL|Basic public reporting|The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.
41153271|NCT02831439|BEHAVIORAL|Enhanced intervention|The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.
41153272|NCT02831439|BEHAVIORAL|Control group - observational|"Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3."
41324404|NCT03856658|DRUG|Floxuridine (FUDR)|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
41324405|NCT03856658|DEVICE|Hepatic Artery Infusion Pump|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. The primary tumor will be resected or ablated with irreversible electroporation at the time of HAI pump placement. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
41324406|NCT03856658|DRUG|Heparinized Saline|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
41478445|NCT05295654|OTHER|Kinect validation|Participants will perform several movements while both the vicon and kinect are measuring.
41324407|NCT02030665|BEHAVIORAL|Contingency Management|Reinforcement provided contingent upon demonstration of negative drug tests
41324408|NCT02030665|BEHAVIORAL|Individualized Assessment & Treatment|Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
41478446|NCT04799613|OTHER|walking speed|walking speed (normal speed vs. fast speed). fast speed was 25% faster than normal speed
40806397|NCT06574880|DRUG|Lu-PSMA-617|"Lu-PSMA will be administered at a fixed dose of 7.4GBq per cycle, on a dose escalation schedule:~* Level 0: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT.~* Level 1 (Starting Dose Level): Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2.~* Level 2: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2, followed 6 weeks later by cycle 3."
40806398|NCT06574880|RADIATION|5-fraction Stereotactic Body Radiation Therapy (SBRT)|Prostate and nodal SBRT will begin at the completion of cycle 1 (6 weeks after the first Lu-PSMA-617 infusion, ± 4 weeks).
41478447|NCT04799613|OTHER|visual loading|visual loading (walking through narrow pathway using VR)
41478448|NCT04799613|OTHER|dual task|dual task (serial subtraction using VR)
41478449|NCT04799613|OTHER|best side reduction|best side reduction (split belt mode, the speed of best side was reduced by 25% compared to the other side)
40806402|NCT05027802|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day.
40806403|NCT01708954|DRUG|Cabozantinib S-malate|Given PO
40806404|NCT01708954|DRUG|Erlotinib Hydrochloride|Given PO
40806405|NCT01708954|OTHER|Laboratory Biomarker Analysis|Correlative studies
40806406|NCT06556875|BEHAVIORAL|HIIT|high intensity interval training
40806407|NCT06556875|BEHAVIORAL|HIIT combined IET|high intensity interval training combined with isometric exercise training
40806408|NCT04616183|DRUG|Abemaciclib|Given PO
40806409|NCT04616183|BIOLOGICAL|Cetuximab|Given IV
40806410|NCT04616183|DRUG|ERK1/2 Inhibitor LY3214996|Given PO
40806416|NCT02998411|OTHER|Titration|
40806417|NCT05812807|BIOLOGICAL|Pembrolizumab|Given IV
40806418|NCT05812807|OTHER|Patient Observation|Undergo observation
40806419|NCT05812807|PROCEDURE|Biopsy|Undergo biopsy
40806420|NCT05812807|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40806421|NCT05812807|OTHER|Questionnaire Administration|Ancillary studies
40806422|NCT05812807|OTHER|Quality-of-Life Assessment|Ancillary studies
40806424|NCT06435299|DRUG|Cannabis oil|Patients in this arm will have to take Cannabis oil (50mg/mL) twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
41008694|NCT03906318|DRUG|Iticitinib|
40806425|NCT06435299|DRUG|Placebo|Patients in this arm will have to take Placebo oil twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
40806426|NCT01804686|DRUG|Ibrutinib|Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
40806427|NCT02500407|DRUG|BTCT4465A (Mosunetuzumab) IV|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.
40806428|NCT02500407|DRUG|Atezolizumab|Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
40806429|NCT02500407|DRUG|BTCT4465A (Mosunetuzumab) SC|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
40806430|NCT06187766|DIAGNOSTIC_TEST|Social Media Addiction|Social Media Addiction level will be determined by Bergen Social Media Addiction Scale
40806431|NCT06331156|COMBINATION_PRODUCT|HRV PCV-free|2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
40806432|NCT06331156|COMBINATION_PRODUCT|IPV|3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.
40806433|NCT06049017|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
40806434|NCT06049017|DRUG|Placebo|Placebo tablet will be administered orally.
40806435|NCT06236815|DRUG|Delta-9-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
40806436|NCT06236815|DRUG|Delta-8-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
41008695|NCT01037478|DRUG|Resminostat (4SC-201)|oral administration
41008696|NCT03320239|BEHAVIORAL|HIV risk assessment and tailored suggestions|The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link
41324409|NCT02030665|BEHAVIORAL|Cognitive-Behavioral Treatment|Standard psychoeducational approach to coping skills training
41008697|NCT03320239|BEHAVIORAL|HIV risk behavior assessment|It only contains HIV risk behavior assessment and routine education
41008698|NCT03320239|BEHAVIORAL|placebo control|It only contains HIV/AIDS knowledge assessment and routine education
41153273|NCT00702520|DRUG|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
41153274|NCT00702520|DRUG|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
41324410|NCT04780256|PROCEDURE|Endoscopic resection|"The endoscopic resection is the procedure that allows to remove cancerous or precancerous conditions of digestive tract. Endoscopic resection can be preformed by several techniques:~1. Endoscopic mucosal resection (EMR): it allows to remove mucosal lesions~2. Endoscopic submucosal dissection: it allows to remove mucosal lesions that involved submucosal layer and large lesions~3. Full-thickness resection: it allows to remove infiltrating lesions by the resection of a little piece of the entire gastrointestinal wall"
41324411|NCT00482300|PROCEDURE|Systematic pelvic lymphadenectomy|
41324412|NCT04605939|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
41324413|NCT04605939|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
41324414|NCT00936117|DRUG|Posaconazole|200 mg (liquid) by mouth 3 times per day.
41324415|NCT04689841|OTHER|Vojta Therapy|"Reflex locomotion is activated by the reflexogenic pathway. In context with reflex locomotion, the term reflex does not represent the mode of neuronal control, but rather refers to defined, automatic and always equal motor responses produced by external stimuli, applied therapeutically."
41324416|NCT04689841|OTHER|placebo|In the control group, a placebo intervention is administered, similar to an experimental intervention
41324417|NCT04280887|DEVICE|MyPad|Ultrasound bed wetting alarm
41324418|NCT01508494|DRUG|Galantamine|16 mg galantamine daily P/O
41324419|NCT01508494|DRUG|placebo|placebo
41324420|NCT03748485|BEHAVIORAL|wait and watch|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),without(wait and watch) adjuvant chemotherapy
41324421|NCT03748485|DRUG|adjuvant chemotherapy|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
41324422|NCT03628521|DRUG|Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin|Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
41324423|NCT05200052|DRUG|Colchicine 0.5 mg Oral Tablet|Colchicine loading dose 1 mg and maintenance dose 0.5 mg for 6 months in addition to standard anti ischemic treatment.
41324424|NCT01017822|BIOLOGICAL|conatumumab|
41324425|NCT01017822|DRUG|capecitabine|
41324426|NCT01017822|DRUG|gemcitabine hydrochloride|
41324427|NCT01017822|RADIATION|3-dimensional conformal radiation therapy|
41478450|NCT04576182|BEHAVIORAL|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
41478451|NCT04576182|BEHAVIORAL|Emotions-Focused treatment|Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
41478452|NCT04532398|OTHER|Gugging swallowing screen - ICU (GUSS-ICU) index test|"Gugging swallowing screen - ICU (GUSS-ICU) index test:~Screening for post-extubation dysphagia: GUSS-ICU performed by 2 speech therapists independently. The GUSS-ICU model contains the core features of the original GUSS tool with the added assessment items specific to the ICU Patient (RASS score (Richmond Agitation and Sedation Scale)).~Stage one of the screen focuses on the preliminary investigation of indirect swallowing. Stage two is comprised of varying steps that directly test swallowing. This would include the administration of semisolids, water and bread with four distinct signs that were being assessed for - deglutition, coughing, drooling and voice change. The GUSS test is evaluated using a points system (0-10) which determines the severity of dysphagia and recommends a diet form that largely minimizes the risk of aspiration. (e.g. 10 points: No dysphagia = normal food)."
41478453|NCT04532398|OTHER|Flexible Endoscopic Evaluation of Swallowing (FEES) reference test|"Flexible Endoscopic Evaluation of Swallowing (FEES) reference test:~Flexible Endoscopic Evaluation of Swallowing (FEES) is a technique to directly view the pharynx, larynx and esophagus during swallowing. The swallowing test is carried out first with saliva and then with different consistency (liquid, pulpy, solid) and different sized swallowing portions. This reference test is performed independently from the GUSS-ICU index test."
41478454|NCT01298778|DRUG|Duramorph 150|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
41478455|NCT01298778|DRUG|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
41478456|NCT01298778|DRUG|Duramorph 300|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
41478457|NCT04705870|DEVICE|cerebral MRI|"MRI of routine care in the context of MS includes at least the following sequences:~* 3D T1 TFE (2 minutes)~* T2 TSE (2 minutes)~* 3D FLAIR (3 minutes)~* SWI EPI 0.6 iso (7 minutes)~The sequences added by the search are:~* SWI non EPI QSM 6 echo (10 minutes)~* SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)~* SWI EPI to TR equivalent to SWI non EPI (6 minutes)"
41478458|NCT01953822|OTHER|Data collection|Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
41478459|NCT06310265|OTHER|Retrospective observational study|Our study includes child earthquake victims, regardless of gender, between the ages of 0-18, who applied to our clinic within six months after the February 6, 2023 earthquake and underwent surgery.
40806437|NCT06236815|DRUG|Placebo|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
41324428|NCT03780491|OTHER|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
41324429|NCT05983835|PROCEDURE|Patients receive subsegmentectomy|Patients receive lobectomy
41324430|NCT04046757|OTHER|Mechanical thrombectomy|Neuroradiological endovascular treatment
41324431|NCT01913860|BEHAVIORAL|Improving GP antibiotics prescribing behaviour|GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
41153275|NCT00702520|DRUG|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
41153276|NCT00702520|BIOLOGICAL|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
41324432|NCT03831815|DRUG|Cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist participating in the surgery. In group C, the patients in whom cisatracurium was given and the R group consisted of the patients in whom rocuronium was administered. It is emphasized that the choice of the neuromuscular blocker was made by the preference and experience of the anesthesiologist of the case and not by randomization or lottery of the patients.
41324433|NCT00810459|DEVICE|Trilogy Ventilator|Exposure to one hour on the Trilog ventilator
41324434|NCT00810459|DEVICE|Standard of Care|Exposure of one hour on the Participants prescribed ventilator
41324435|NCT03585699|DIAGNOSTIC_TEST|Fluoroscopy Guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
40806442|NCT05980416|DRUG|EO-3021|Anti-Claudin 18.2 antibody drug conjugate
40806443|NCT05468697|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg.
40806444|NCT05468697|DRUG|Palbociclib|75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
40806445|NCT05195437|OTHER|QoLiSSY and PedsQL 4.0 questionnaires|"Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy."
41008699|NCT06273553|BIOLOGICAL|RG002 injection|In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
41324436|NCT03585699|DIAGNOSTIC_TEST|CT guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
41324437|NCT05877703|OTHER|close kinetic chain exercises|CKC include mini squats, leg press, step-up and step-down, wall slides etc along with their respective modality as quadriceps drill and static cycle ergometer respectively on grade-3 knee OA patients
41324438|NCT05877703|OTHER|open kinetic chain exercises|The distal segment of the body components can move freely during OKC exercise.OKC exercises include quadriceps setting, knee extension in sitting and straight leg raise in lying position; it also includes quadriceps drills as part of OKC exercises
41324439|NCT01884961|OTHER|Boost of radiotherapy + high dose IL-2 treatment|Boost of radiotherapy + high dose IL-2 treatment
41324440|NCT00854555|OTHER|Locomotor training with robot|60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
41324441|NCT00854555|OTHER|Locomotor training with manual assistance|60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
41324442|NCT02919410|DEVICE|iodophor-impregnated adhesive drapes|
41324443|NCT02919410|OTHER|No adhesive drapes|
41324444|NCT00943085|BEHAVIORAL|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
41324445|NCT00943085|BEHAVIORAL|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
41324446|NCT03070561|BIOLOGICAL|sublingual film with peanut extract|
41324447|NCT06325176|OTHER|Cryotherapy|During the 1st visit of the patients, they will be assessed for pain and episiotomy wound. The cryotherapy group will include 12 postnatal women. This group will use a bag of ice pack applied to the perineal region. The ice pack will be sealed in plastic bag and wrapped with one layer of a thin cotton tissue so that the skin of the participant would not be in direct contact with ice, which could cause discomfort. During the intervention, the women will be asked to remove their underpants and hygienic pads and remain in the dorsal recumbent position during cryotherapy that lasted 20 minutes. This procedure will be done twice a day for seven consecutive days
41324448|NCT06325176|DEVICE|Infrared light therapy|Infrared group will include 12 postnatal women they will encourage to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for twenty minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researcher will demonstrate for each woman how to use infrared lamp, and it will be followed by re demonstrations and discussions. These procedures will carry out in the morning and evening for seven consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study
41478460|NCT03383419|DRUG|Epclusa|If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
41478461|NCT01252849|DEVICE|iStent|Implantation of One iStent through a small temporal clear corneal incision.
41008700|NCT05036993|BEHAVIORAL|Coaching|Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months
41324449|NCT00377585|BIOLOGICAL|Fluarix|
41324450|NCT00377585|BIOLOGICAL|adjuvanted influenza vaccine|
41324451|NCT00603733|DRUG|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
41324452|NCT00603733|DRUG|5-ASA (5-Aminosalicylate)|500 mg tablet
41324453|NCT00472017|DRUG|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
41478462|NCT01252849|DEVICE|iStent|Implantation of Two iStents through a small temporal clear corneal incision
41478463|NCT01252849|DEVICE|iStent|Implantation of Three iStents through a small temperal clear corneal incision
41478464|NCT03445299|BEHAVIORAL|Music|Listening to music for 30 minutes at bedtime
41478465|NCT03399318|DRUG|Acetaminophen|"30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm~Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments"
41478466|NCT03399318|DRUG|Ibuprofen|10 mg/kg Q6 hours for the Aggressive Antipyretic Arm
41478467|NCT03399318|DRUG|placebo for acetaminophen|"placebo for acetaminophen for children in the Usual Care arm~For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo"
40806447|NCT04729322|PROCEDURE|Biopsy|Undergo biopsy
40806448|NCT04729322|PROCEDURE|Fecal Microbiota Transplantation|Undergo colonoscopic FMT
40806449|NCT04729322|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
41008701|NCT05304858|PROCEDURE|Biopsy|Standard of care surgical procedures to collect prostate cancer tissue from men with metastatic prostate cancers. Non-experimental.
41008702|NCT04160260|DRUG|Omadacycline|Omadacycline: PO Tablets
41478468|NCT03399318|DRUG|placebo for ibuprofen|placebo for ibuprofen
40806450|NCT04729322|DRUG|Metronidazole|Given PO
40806451|NCT04729322|DRUG|Neomycin|Given PO
40806452|NCT04729322|BIOLOGICAL|Nivolumab|Given IV
40806453|NCT04729322|BIOLOGICAL|Pembrolizumab|Given IV
40806454|NCT04729322|OTHER|Questionnaire Administration|Ancillary studies
41324454|NCT01874249|OTHER|Electronic detailed information|Electronic detailed information about non alcoholic fatty liver disease.
41324455|NCT01874249|OTHER|NAFLD Score|diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
41324456|NCT01874249|OTHER|Transient elastography|Transient elastography values greater than 8 kPa
41324457|NCT01511432|DRUG|telaprevir formulation A|A single 1125-mg dose administered orally
41324458|NCT01511432|DRUG|telaprevir Formulation B|A single 1125-mg dose administered orally
41324459|NCT01511432|DRUG|telaprevir Formulation C|A single 1125-mg dose administered orally
41324460|NCT01511432|DRUG|telaprevir Formulation D|A single 1125-mg dose administered orally
41324461|NCT01450475|PROCEDURE|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
41324462|NCT05220137|BEHAVIORAL|Modified A-B-C: Working with Events, Thoughts, and Feelings|The Modified A-B-C session teaches the Veteran how to draw connections between events, thoughts, and feelings and incorporates preliminary cognitive restructuring to help challenge stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
41324463|NCT05220137|BEHAVIORAL|Challenging Questions|The Challenging Questions session teaches the Veteran to question and confront maladaptive self-statements and stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
41324464|NCT05220137|BEHAVIORAL|Patterns of Problematic Thinking|The Patterns of Problematic Thinking session teaches the Veteran to identify counterproductive thinking patterns. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
41478469|NCT02135120|DRUG|Combined spinal epidural anesthesia technique with intrathecal morphine|
41478470|NCT02135120|DRUG|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
41008703|NCT06146166|DIETARY_SUPPLEMENT|Oral herbal supplement|Oral supplement containing an oral blend taken once daily
41478471|NCT02135120|DRUG|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
40806455|NCT04729322|DRUG|Vancomycin|Given PO
41008704|NCT06146166|DIETARY_SUPPLEMENT|Oral placebo supplement|Oral placebo supplement taken once daily
41324465|NCT05220137|BEHAVIORAL|Challenging Beliefs|The Challenging Beliefs session teaches the Veteran to generate alternative thoughts based on the outcome of cognitive restructuring. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
41324466|NCT05220137|BEHAVIORAL|Veteran's choice of Module (Safety/Trust/Power and Control/Esteem/Intimacy)|The therapist will present the Module options to the Veteran and the Veteran will select one Module to work on. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
41324467|NCT00990249|DRUG|Busulfan|Test Dose 32 mg/m\^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
41324468|NCT00990249|DRUG|Clofarabine|40 mg/m\^2 by vein over 1 hour daily Day -6 through Day -3
41324469|NCT00990249|DRUG|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
41478472|NCT05060432|DRUG|EOS-448|Anti-TIGIT monoclonal antibody
41478473|NCT05060432|DRUG|pembrolizumab|Anti-PD-1 monoclonal antibody
41478474|NCT05060432|DRUG|inupadenant|A2A receptor antagonist
41478475|NCT05060432|DRUG|Dostarlimab|Anti-PD-1 monoclonal antibody
41153277|NCT00702520|BIOLOGICAL|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
41153278|NCT02251405|BEHAVIORAL|One bag, stainless container|
41324470|NCT00990249|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
40806459|NCT03960060|BIOLOGICAL|CCT301-59|Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
41008705|NCT00274599|DRUG|Telmisartan|
41008706|NCT00274599|DRUG|Ramipril|
41008707|NCT00084695|BIOLOGICAL|anti-thymocyte globulin|Given IV
41008708|NCT00084695|DRUG|busulfan|Given orally
41008709|NCT00084695|DRUG|cyclophosphamide|Given IV
41008710|NCT00084695|DRUG|fludarabine phosphate|Given IV
41008711|NCT00084695|DRUG|melphalan|Given IV
41008712|NCT00084695|DRUG|methylprednisolone|Given IV
41008713|NCT00084695|RADIATION|radiation therapy|Patients undergo radiation therapy two times daily on days -7 to -4.
41008714|NCT01585142|OTHER|Test formula|Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
41324471|NCT05765292|DIETARY_SUPPLEMENT|Probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa
41324472|NCT05765292|DIETARY_SUPPLEMENT|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
41478476|NCT05060432|DRUG|SOC chemotherapies|SOC chemotherapies in 1L mNSCLC
41478477|NCT05992428|DRUG|DA-8010 5mg|\[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
41478478|NCT05992428|DRUG|Paroxetine 20mg|\[Part 1\] DA-8010 5mg + Paroxetine 20mg
41478479|NCT05992428|DRUG|Mirabegron 50mg|\[Part 2\] DA-8010 5mg + Mirabegron 50mg
41478480|NCT04429334|DRUG|nangibotide|nangibotide 1.0 mg/kg/h
41478481|NCT04429334|DRUG|placebo|matching placebo
41324473|NCT04315493|DRUG|pyrotinib maleate fasted in P1, low-fat diet in P2|pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2
41324474|NCT04315493|DRUG|pyrotinib maleate low-fat diet in P1, fasted in P2|pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
40806464|NCT01880294|DRUG|No intervention|Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
41008715|NCT03175224|DRUG|APL-101 Oral Capsules|Subjects will receive APL-101 capsules BID for oral administration.
41008716|NCT04652128|DRUG|Zoledronic acid|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
41008717|NCT04652128|DRUG|Placebo|Subject will receive a single infusion of physiological saline 100mL intravenously.
41008718|NCT00003294|BIOLOGICAL|filgrastim|
41008719|NCT00003294|DRUG|amifostine trihydrate|
41008720|NCT00003294|DRUG|carboplatin|
41008721|NCT00003294|DRUG|paclitaxel|
41008722|NCT05473975|PROCEDURE|Placement of the EGG|Placement of the EGG before the beginning of the thrombectomy
41008723|NCT01430065|DRUG|ASP015K|oral
41008724|NCT01430065|DRUG|Tacrolimus|oral
41008725|NCT05054296|BEHAVIORAL|Educational Intervention|Receive general education exercise packet
41008726|NCT05054296|BEHAVIORAL|Exercise Intervention|Participate in supervised and self-directed exercise sessions
41324475|NCT04247815|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
41324476|NCT04247815|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
40806465|NCT05180799|BIOLOGICAL|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
40806466|NCT05180799|BIOLOGICAL|Nivolumab|Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1
40806467|NCT05180799|BIOLOGICAL|Pembrolizumab|Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor
41008727|NCT05054296|DEVICE|FitBit|Wear FitBit for activity tracking
41008728|NCT05054296|OTHER|Quality-of-Life Assessment|Ancillary studies
41008729|NCT05054296|OTHER|Questionnaire Administration|Ancillary studies
41008730|NCT02627859|DEVICE|Durolane SJ|1ml single intra-articular injection in ankle
41008731|NCT05867147|DRUG|Vanzacaftor|Tablets for oral administration.
41008732|NCT05867147|DRUG|Vanzacaftor Placebo|Placebo for oral administration.
41008733|NCT05867147|DRUG|Moxifloxacin|Tablets for oral administration.
41008734|NCT05867147|DRUG|Moxifloxacin Placebo|Tablets for oral administration.
41008735|NCT02041598|OTHER|CHW Intervention|5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
41008736|NCT02132000|DRUG|toremifene or tamoxifen|
41008737|NCT04917302|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
41008738|NCT04917302|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
41008739|NCT04013191|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
41324477|NCT04247815|DRUG|Methotrexate|7.5 mg to 25 mg weekly
40806468|NCT05180799|DRUG|Pemetrexed (Alimta)|pemetrexed with either cisplatin or carboplatin
40806469|NCT05541406|BEHAVIORAL|Proud & Empowered|Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
41008740|NCT01633697|BEHAVIORAL|Pranayama|Specific yoga-related breathing method.
41008741|NCT01633697|BEHAVIORAL|Education alone|No special attention to breathing
41008742|NCT00042094|BIOLOGICAL|Cell-Cultured Smallpox Vaccine compared to Dryvax®|
41008743|NCT00304785|DRUG|latanoprost 0.005%|
41008744|NCT00304785|DRUG|Fotil|
41008745|NCT00304785|DRUG|placebo|
41008746|NCT00403338|DEVICE|CYPHER® Bx Velocity™ stent (sirolimus-eluting)|
41008747|NCT05388890|DRUG|MLD|Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
41008748|NCT05388890|DRUG|WFC|Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.
41008749|NCT01684384|RADIATION|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
41008750|NCT05880433|DEVICE|NIRS(INVOS 5100; Covidien Somanetics, Troy, MI|NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
41008751|NCT04865835|DRUG|placebo|single dose of placebo
41008752|NCT04865835|DRUG|SEP-363856|single dose of SEP 363856 100 mg
41008753|NCT04865835|DRUG|metformin|metformin-HCl 850 mg
41324478|NCT00187889|DRUG|Eplerenone|Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
41324479|NCT00187889|DRUG|Placebo or sugar pill|Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
41324480|NCT04968964|DEVICE|DiviTum® TKa assay|-Determines serum enzymatic activity of TK1
41324481|NCT04968964|OTHER|Study Care Plans|-Study Care Plans will be completed prior to and post release of serum DiviTum® TKa value
41324482|NCT03594253|BEHAVIORAL|Regulation Focused Psychotherapy for Children|RFP-C is a manualized, psychodynamic psychotherapy that last 10 weeks. Children meet individually with a therapist for play therapy (twice a week for 16 sessions) and parents meet with the therapist for four full sessions (without the child).
41153279|NCT01596699|DRUG|Alemtuzumab|0.5 mg/kg (max 15 mg or max 6 mg), IV, Day -12 to Day -10 pre-HCT
41153280|NCT01596699|DRUG|Busulfan|0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT
40806472|NCT06051318|OTHER|Standardized breakfast A|Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.
40806473|NCT06051318|OTHER|Standardized breakfast B|Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
41153281|NCT01596699|DRUG|Fludarabine|40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
41324483|NCT00012883|BEHAVIORAL|Homewalking exercise program|
41324484|NCT00031499|DRUG|Azithromycin|Single 2 gram oral dose (4 tablets) at Day 1.
41324485|NCT00031499|DRUG|Benzathine Penicillin|Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
41324486|NCT00031499|DRUG|Doxycycline|Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
41324487|NCT01548417|DRUG|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
41324488|NCT01548417|DRUG|Sugar Pill|600 mg/day, oral pill, 7 days
41324489|NCT00363441|PROCEDURE|Intensity Modulated Radiotherapy|
41324490|NCT01947959|DRUG|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
41324491|NCT01947959|DRUG|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
41324492|NCT02330107|OTHER|MAT & LAT|"For MAT, the magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear."
41324493|NCT05677295|DRUG|duloxetine|Duloxetine 30 mg per day
41324494|NCT05677295|DRUG|Imipramine|Imipramine 25 mg per day
41324495|NCT01726283|DEVICE|Corneal Cross-Linking|Corneal cross-linking procedure conducted during vision correction surgery.
41324496|NCT01726283|DRUG|Riboflavin|Riboflavin will be instilled prior to corneal cross linking.
41324497|NCT01170702|DRUG|0.9% Normal Saline|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
41324498|NCT01170702|DRUG|0.2% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
41478482|NCT05723718|OTHER|Observational Survey|Evaluation of the nutritional status and body composition on tumor regression grade in gastric cancer patients scheduled for multimodal treatment. Nutritional status assessment will include: selected clinical variables evaluation (weight, BMI, nutritional status scales), bioelectrical impedance analysis and selected laboratory parameter assessment. After inclusion in the study, each patient will have four consecutive nutritional status assessments: (1) one day prior staging laparoscopy or during qualification to neoadjuvant chemotherapy, (2) one day before the gastrectomy, (3) one month after the gastrectomy, (4) after the last cycle of adjuvant chemotherapy.
41478483|NCT04958122|DRUG|Cefixime 400mg|Oral cefixime 400 mg, one capsule, twice a day for 10 days
41153282|NCT01596699|DRUG|Clofarabine|10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
41008754|NCT03860961|OTHER|Questionnaire Administration|Ancillary studies
41478484|NCT04958122|DRUG|benzathine penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
41008755|NCT03860961|OTHER|Survivorship Care Plan (SCP)|Given survivorship care plan
41008756|NCT03860961|OTHER|Treatment Plan|Given treatment plan
41153283|NCT04088136|BEHAVIORAL|Everyday Metacognitive Memory Intervention|Provides training in use of techniques and procedures to enhance proactive self-regulatory control over everyday memory demands, including strategies for learning information, planning for meeting everyday goals, and monitoring of efficacy of goal pursuit.
41153284|NCT04088136|BEHAVIORAL|Memory Strategy Control Intervention|Trains use of standard mnemonic techniques such as imagery and sentence generation for learning new associations and organizational and distinctiveness-based strategies for learning sets of items (e.g., word lists).
41008757|NCT01641367|DRUG|Darunavir|Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])
41153285|NCT02572999|PROCEDURE|Not applicable (observational design)|
41153286|NCT05618717|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation using irrigated ablation catheter
41153287|NCT00369239|DRUG|risperidone long acting injectable|
41478485|NCT00140413|DRUG|Nutropin AQ|Daily injection. Dosage dependent on weight.
41478486|NCT04787952|OTHER|cold expossure|subjects were exposed for the cold, to activate and diagnose potential brown tissue activity
41478487|NCT03564041|BEHAVIORAL|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
41478488|NCT03564041|BEHAVIORAL|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
41324499|NCT01170702|DRUG|0.5% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
41324500|NCT01170702|DRUG|0.75% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
41324501|NCT02720653|PROCEDURE|Endoscopic sinus surgery|
41324502|NCT03328624|DEVICE|Deep Vein Thrombosis (DVT) Cuff|Recovery Force's DVT II Cuff
41324503|NCT04562558|DRUG|Methotrexate|50mg intramuscularly on Days 1, 3, 5, 7 . Repeat every 14 days
41324504|NCT04562558|DRUG|Leucovorin|15mg intramuscularly on Days 2, 4, 6, 8. Repeat every 14 days
41324505|NCT04562558|DRUG|Dactinomycin|1.25mg/m2 (2mg max dose)intravenous every 14 days.
41153288|NCT03158519|BEHAVIORAL|iMETX intervention|"Pre-intervention the participants will wear the running watch for 3 weeks so that researchers can collect data about their daily routines regarding where and how much energy they expend.~During the intervention participants will wear the running watch for 12 weeks. Every 1-3 days the participants will be given an individualized recommendation for how to increase their activity via the iMETX application. Participants will be able to provide feedback to the researchers throughout intervention period regarding what works and does not in terms of the recommendations for increasing activity.~Post-intervention the participants will wear the running watch for 12 weeks so that researchers can collect data in order to determine whether physical activity changes made during the intervention are sustained."
40806479|NCT03811535|DRUG|Somapacitan|Somapacitan will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
40806480|NCT03811535|DRUG|Norditropin®|Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
41153289|NCT04369547|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation.
41324506|NCT06046547|OTHER|Pulmonary rehabilitation integrating education about palliative care|"PR will include exercise training twice a week, and education and psychosocial support once per week during 12 weeks.~The intervention will include an education session on palliative care, a Peer-to-peer session, a Get-apart session and online sessions.~The education session on palliative care will be facilitated by two specialist healthcare professionals. The main topics that will be discussed are: concept of palliative care, symptom control, disease impact, psychosocial support and planning for the future.~Participants will be the primary communicators in the Peer-to-peer session, and the dialogue will be based on their suggestions. Those who feel more reluctant to reveal private thoughts in front of their loved ones will have the opportunity to discuss their issues in a Get-apart environment.~Individual cases will be referred to a specialist palliative care team or to any other health/social care professional according to the unmet needs identified."
41324507|NCT06046547|OTHER|Pulmonary rehabilitation|"Participants will receive the same PR program as the experimental group besides the education session on palliative care, the Peer-to-peer session, the Get-apart session and the online sessions (i.e. traditional pulmonary rehabilitation)."
41324508|NCT01823770|DRUG|Rotigotine|Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
41478489|NCT00077584|DRUG|Bosentan 62.5 mg|Oral tablets containing 62.5 mg of bosentan
41478490|NCT00077584|DRUG|Bosentan 125 mg|Oral tablets containing 125 mg of bosentan
41478491|NCT00077584|DRUG|Placebo|Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
41478492|NCT00494624|DRUG|prednisolone|
41478493|NCT04273282|DRUG|Dexycu intracameral dexamethasone|To evaluate the safety and ocular efficacy of Dexycu.
41478494|NCT04273282|DRUG|Prednisolone Acetate|To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
41478495|NCT00363402|PROCEDURE|PET-CT|
41478496|NCT00614822|DRUG|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
41153290|NCT04369547|DRUG|Roflumilast|Roflumilast 250mcg
41153291|NCT04369547|DRUG|Placebo oral tablet|Placebo capsule matched to roflumilast capsule
41153292|NCT02433392|PROCEDURE|CM-BC2|CM-BC2 is a drug-eluting bead, a drug-device combination
41324509|NCT01823770|DRUG|Placebo patchs|Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
41324510|NCT05243277|OTHER|Oculomotor tests|"There will be four visits. Each visit is associated with a different exposure in terms of level of oculomotor conflict.~At each visit, several oculomotor tests will be performed, followed by a comfort questionnaire. The oculomotor tests are subjective tests during which the participant will be asked to fix his/her eyes on one or more targets that can move in space and to indicate the way he/she perceives this/these target(s). Depending on the test, lenses may be inserted between the participant and the target to modify his/her perception.~The comfort questionnaire consists to rate on a scale of 1 (not at all) to 5 (very much) the presence of visual symptoms, such as burning, watering or dryness.~The participant will then have to perform four different perceptual tasks. His/her level of accommodation (i.e. focus) will be monitored throughout the tasks.~Each exposure is followed again by eye tests and a comfort questionnaire."
41324511|NCT03587571|PROCEDURE|Surgical intervention|Open reduction and plate osteosynthesis.
41324512|NCT04254055|OTHER|exercises|Those subjects included in the experimental group will receive an intervention through a program with plyometric, proprioceptive and strength exercises. The subjects included in the control group will not receive any intervention.
41324513|NCT00184652|DRUG|somatropin|
41324514|NCT06271239|OTHER|Intervention group (ViviFrail)|The participant will be guided to follow a daily exercise routine at home, lasting 30-45 minutes, from Monday to Friday, over six months. A one-week break every six weeks for reassessment, totaling seven months of activities, will be provided. They will be informed that every six weeks, they may receive new exercises in their exercise passport or continue with the same, based on their physical reassessment. Each exercise passport will have a wheel illustrating the exercise circuit for easy reference. An 'Activity Diary' will be provided for tracking progress and frequency. During 'CIRCUIT' sessions, participants should complete the entire circuit, while 'WALKING' sessions should focus solely on walking for that day. They will be motivated to keep this diary updated. The ViviFrail exercise passports cater to various levels of physical frailty and fall risk and can be accessed at https://vivifrail.com/en/materials-2/.
41324515|NCT06271239|OTHER|Group Suggestions for a Healthy Life (CG)|The participants in the group Suggestions for a healthy life (CG) will receive guidance on maintaining a healthy and independent lifestyle for three months. They will also be provided with a booklet containing strength, balance, and flexibility activities, suggesting that participants perform these activities five times a week, for around 30 minutes per day. At the end of the initial three complete months of the intervention (14 weeks), participants in the control group will commence the ViviFrail exercise protocol and will continue until the end of the study. Throughout the entire study period, participants in the control group will receive the same monitoring as the intervention group.
41324516|NCT03299309|DRUG|PEP-CMV|Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21, with injection of the PEP-CMV vaccine as follows: PEP-CMV Component A mixed with Montanide ISA-51 intradermally administered half in the RIGHT groin and half in the LEFT groin.
41324517|NCT02334670|DRUG|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
41324518|NCT01922778|PROCEDURE|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D\&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter."
41153293|NCT05655624|OTHER|Pursed lip Breathing along Mat Pilates|Experimental Group: will be treated with Pursed lip Breathing along Mat Pilates Training.
41008758|NCT01641367|DRUG|Etravirine|Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
41324519|NCT02448316|PROCEDURE|endoscopic surgery|"Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,"
41324520|NCT02448316|DRUG|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
41324521|NCT02448316|DRUG|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
41153294|NCT05655624|OTHER|pursed lip breathing without Mat Pilates Training|Control Group will be treated pursed lip breathing without Mat Pilates Training
41153295|NCT06266065|DEVICE|Coronary Sinus Reducer|Implantation of Coronary Sinus Reducer
41153296|NCT05024578|DEVICE|DREEM2|Closed-loop EEG monitoring and auditory stimulation in which 100ms pulses of pink noise are delivered on the ascending phase of slow oscillations during N3 sleep.
41153297|NCT05024578|DEVICE|Placebo|EEG monitoring with the same headband as in the DREEM2 intervention, but without any sound stimulation.
41008759|NCT01641367|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
41008760|NCT01641367|DRUG|Raltegravir|Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
41324522|NCT02448316|BEHAVIORAL|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
41324523|NCT05984810|PROCEDURE|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
41324524|NCT00228930|DRUG|Tamoxifen (pharmacodynamic analysis)|Tamoxifen 20mg po daily
41324525|NCT01958879|DRUG|ringer with corticosteroid|200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
41324526|NCT01958879|DRUG|ringer without corticosteroid|200 mL Ringer solution
41324527|NCT06265168|OTHER|Simulation|Physicians will participate in a simulated scenario of an adult comatose patient. The intervention will be presented as a learning situation where the physician interacts with a high-fidelity mannequin. The mannequin simulating the patient will manifest a Glasgow Coma Score of 3 (improving over time to a GCS of 4) and a range of physiological and pathological symptoms. Physicians will have access to emergency equipment, including intubation equipment, a defibrillator, and medications. A trained nurse will be present to assist with the simulation. After 20 minutes the patient will regain consciousness in order to avoid a frustrating experience for the physicians. After simulation termination, a senior physician will join the resident and ask him to report the current scenario and will stop the simulation. The entire scenario will be video-recorded.
41324528|NCT05341635|DIAGNOSTIC_TEST|Swab sampling|Collection of three nose-pharyngeal and oral swabs
41324529|NCT01154179|OTHER|Hypocaloric feeding|This intervention group will be prescribed 60% of recommended (by Schofield) requirements.
41324530|NCT00633308|DEVICE|NxStage System One (NxStage Medical, Lawrence, MA)|Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.
41324531|NCT01800279|OTHER|Physiotherapy Protocol|"Kinesitherapy~* Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.~* Tongue in the palate for all applied exercises.~* Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).~Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.~Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid."
41324532|NCT01800279|OTHER|Deontology Therapy|"For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):~* Impression of the maxilla with chromatic alginate Phase plus (Zhermack ©, Rovigo, Italy).~* Emptying working models in plaster-stone type IV Elite Rock (Zhermack ©, Rovigo, Italy).~* Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate The Machine Dentaflux ©, Ripoll, Madrid."
41324533|NCT03104998|DRUG|Coenzyme Q10|200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
41324534|NCT02356640|PROCEDURE|EUS-guided celiac ganglion neurolysis|EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
41478497|NCT04359563|BEHAVIORAL|Mindfulness-Based Intervention|"The MBI consists of four 2h online group sessions spread over eight weeks. In between sessions, online support will be offered to assist participants in their practice. Each session consists of guided mindfulness exercises (e.g., focus on the breath, body scan, breathing space, mindful yoga, insight meditation, walk meditation), sharing of experiences of these exercises, reflections in small groups, psycho-education (e.g., stress, depression, self-care), and review of home practices. An overview of core elements is given in Van der Gucht et al. (2017b).~The MBI is supported by homework assignments and audio material. Groups will include 5 participants, yielding 6 groups in total. The MBI will be delivered by highly qualified certified trainers with more than 10 years of experience in mindfulness meditation and extensive experience working with adolescents. Trainers will attend inter- and supervision moments on a regular basis to check treatment fidelity and trainer adherence."
41478498|NCT05098457|DEVICE|GP0112|Injectable gel
41478499|NCT05098457|DEVICE|Restylane Lyft Lidocaine|Injectable gel
41153298|NCT06585410|DRUG|Cemiplimab|Administered per protocol
41153299|NCT06585410|PROCEDURE|Standard of care|Primary surgery
41153300|NCT00149071|DEVICE|rTMS|15 treatments of rTMS active with a duration of 30 minutes each
41153301|NCT00149071|DEVICE|TMS|Transcraniel Magnetic Stimulation active and sham
41008761|NCT01641367|DRUG|Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
41153302|NCT00149071|DEVICE|rTMS|active Transcranial Magnetic Stimulation
41153303|NCT00149071|DEVICE|rTMS|daily for three weeks
41153304|NCT02014298|RADIATION|non-ablative fractional laser|3 treatments with 4-6 weeks interval
41153305|NCT02014298|OTHER|control|observation, comparison to laser-treated area
41153306|NCT03029234|DRUG|Dexamethasone|20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles.
41153307|NCT03029234|DRUG|Carfilzomib|Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle.
41153308|NCT04223661|DRUG|Lenalidomide Pill|Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.
41324535|NCT02356640|PROCEDURE|Percutaneous celiac plexus neurolysis|Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson \&Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
41324536|NCT02356640|DEVICE|Olympus UM 2000|
41324537|NCT02356640|DEVICE|B-D Quincke Type Point|
41324538|NCT02356640|DRUG|Levobupivacaine|
41324539|NCT01852929|OTHER|Subject using usual positive airway pressure therapy while sleeping for one night|Participants use their usual positive airway pressure therapy while sleeping overnight
41324540|NCT00992732|DRUG|HQK-1004|1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
41324541|NCT00992732|DRUG|Valganciclovir (may substitute with ganciclovir)|900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
41324542|NCT05752786|BEHAVIORAL|"Eat Less Meat Challenge"|Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
41324543|NCT05200884|DRUG|Lidocaine 2%|The child will be injected with lidocaine 2% and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker FACES pain rating scale
41324544|NCT05200884|DRUG|Articaine 4%|The child will be injected with 4% Articaine and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and face scale
41324545|NCT03909932|OTHER|Observational study : no intervention|Observational study : only exporting data
41324546|NCT00196196|DEVICE|Codman VPV System|Valve Positioning Verification (VPV) System
41008762|NCT01641367|DRUG|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
41008763|NCT01641367|OTHER|SOC adherence versus SOC+CPI adherence|"* not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence."
41153309|NCT04223661|DRUG|Dexamethasone|Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
41153310|NCT04223661|DRUG|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
41008764|NCT03826420|BEHAVIORAL|SCF Supervision with Secure Confinement Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
41324547|NCT02908633|PROCEDURE|canaloplasty and phacoemulsification|
41324548|NCT03471481|OTHER|No Intervention. Study is Cross Sectional in nature|No Intervention. Study is cross sectional in nature
41324549|NCT05881460|DEVICE|Active vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
41324550|NCT05881460|DEVICE|Sham vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
41324551|NCT01852695|BEHAVIORAL|Family Integrated Care|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
41324552|NCT01932281|DIETARY_SUPPLEMENT|SierraSil|SierraSil is a natural, mineral supplement currently used to improve joint health and function.
41324553|NCT01932281|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic SierraSil 667 mg capsule
41324554|NCT01788072|DRUG|Intranasal Oxytocin|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
41324555|NCT01788072|DRUG|Placebo|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
41324556|NCT02431130|OTHER|low-fidelity instructor driven simulation training|
41324557|NCT03485222|DRUG|Empagliflozin|6 months
41324558|NCT03485222|DRUG|Placebos|placebo equivalent for 6 months
41324559|NCT02645279|OTHER|oral 30% glucose|30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.
41324560|NCT02645279|DRUG|IV midazolam|IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
41008765|NCT03826420|BEHAVIORAL|SCF Supervision with Work Release Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
41008766|NCT03826420|BEHAVIORAL|SCF Supervision with GPS Supervision Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
41324561|NCT05200455|DEVICE|Microelectrodes|Microelectrode implantation
41324562|NCT02233907|DRUG|Ventilat® - metered dose inhaler|
41324563|NCT03424577|DRUG|H3B-6527|Oral capsule
41324564|NCT01620450|DRUG|biphasic human insulin 30|Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
41324565|NCT00944788|OTHER|qi-gong|Physical activity similar to tai-chi
41478500|NCT05182619|PROCEDURE|ultrasound-guided stellate ganglion block|under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side
41478501|NCT00692315|DRUG|Methylcobalamin (methylB12)|75 ug/Kg methylB12 every 3 days by subcutaneous injection
41478502|NCT03204071|DRUG|placebo gel|Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
41478503|NCT03204071|DRUG|Aloevera|Oral prophylaxis followed by placement of aloevera gel
41008767|NCT05305599|DRUG|ZED1227|ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
41008768|NCT05305599|DRUG|Placebo|Placebo
41008769|NCT03447171|DEVICE|App Vision Screening|Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
41008770|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* on pre-operative d-1/d, post-operative d1 and d5(+/-2),~* one month post-operative,~* at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
41008771|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* before starting the therapy~* at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~* at the end of the study or at the date of disease progression."
41008772|NCT02696096|OTHER|FMRI|all participants will complete 2 FMRIs
41008773|NCT02696096|DRUG|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
41324566|NCT03562754|PROCEDURE|reduced systemic heparin anticoagulation|receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate
41324567|NCT03562754|PROCEDURE|Regional Citrate Anticoagulation|intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer
41324568|NCT02266732|DEVICE|Stimuplex HNS 12|
41324569|NCT04591210|DRUG|Angiotensin converting enzyme inhibitor|The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.
41324570|NCT04591210|DRUG|Angiotensin II Receptor Blockers|The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.
41478504|NCT03204071|DRUG|Metformin|Oral prophylaxis followed by placement of metformin gel
41478505|NCT05012176|BEHAVIORAL|Behavioral Intervention|Participate in EFT
41478506|NCT05012176|BEHAVIORAL|Behavioral Intervention|Participate in ERT
41478507|NCT05012176|OTHER|Quality-of-Life Assessment|Ancillary studies
41478508|NCT05012176|OTHER|Questionnaire Administration|Ancillary studies
41478509|NCT03399240|DEVICE|Vitasitiq device|Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.
41478510|NCT04778293|OTHER|Diacutaneous fibrolysis|An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized, in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
41478511|NCT02521181|DRUG|Lower Dose Sodium Bicarbonate|Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
41478512|NCT02521181|DRUG|Higher Dose Sodium Bicarbonate|Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
41008774|NCT00202618|DRUG|Valsartan|
41478513|NCT02521181|DRUG|Placebo|Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
41478514|NCT01063959|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
41008775|NCT00202618|DRUG|Amlodipine|
41008776|NCT01986829|DEVICE|Microwave ablation|"* Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~* Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
41478515|NCT01063959|PROCEDURE|Laparoscopic Gastric Bypass|Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
41324571|NCT03636568|OTHER|Fluid Restricted Group|"Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients \< 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients \>100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh \<=100 kg and 1200 cc/24 hours for patients who weigh \> 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:~1. Serum Na level must be \< 145 mEq/l~2. Patient should be taking fluids by mouth~3. Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated."
41324572|NCT01408667|DRUG|TRC150094|50 mg Tablets once a day
41324573|NCT01408667|OTHER|Placebo|Tablets once daily
41324574|NCT03858608|DIETARY_SUPPLEMENT|Counterweight Plus|Total diet replacement followed by food reintroduction and weight maintenance.
41324575|NCT03858608|OTHER|Usual asthma care|Usual asthma management
41324576|NCT06278129|DIAGNOSTIC_TEST|Vestibular myogenic potentials|observational study
41324577|NCT00290589|DRUG|Intramuscular methylprednisolone acetate|Intramuscular methylprednisolone acetate 160mg
41324578|NCT00290589|DRUG|Placebo|Normal saline intramuscular injection
41324579|NCT01641718|DRUG|Tissue glue|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
41324580|NCT01641718|DEVICE|Staples|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
41324581|NCT03185104|DRUG|Silver Diamine Fluoride|Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
41324582|NCT03185104|DRUG|Distilled Water|Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
41324583|NCT00336778|DRUG|3TC, TDF, NLV|3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
41324584|NCT01022346|DRUG|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
41478516|NCT04531787|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
41008777|NCT01986829|DEVICE|Cryoablation|"* Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~* Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
41324585|NCT01022346|DRUG|RO5217790|RO5217790 will be administered at a dose of 5\*10\^7 pfu subcutaneously on Days 1, 8, and 15.
41324586|NCT01345097|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty
41324587|NCT03143972|DRUG|Dexmedetomidine|Single drug administration
41478517|NCT00554320|PROCEDURE|tDCS|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most \[or predominant\] painful side \[or the side where the symptoms begin or the left as a default\]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
41478518|NCT00554320|PROCEDURE|tDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
41324588|NCT03143972|DRUG|Remifentanil|Single drug administration
41324589|NCT00351819|DRUG|AndroGel|5g gel, applied once daily to the upper arms, upper back or shoulders.
41324590|NCT00351819|OTHER|Placebo|5g gel, applied once daily to the upper arms, upper back or shoulders.
41324591|NCT05517356|PROCEDURE|Tailored management strategies|"Our basic surgical strategies for the central repair operations for ATAAD are as follows. As arterial lines for cardiopulmonary bypass, side branches of the axillary and femoral arteries were used. Circulatory arrest was established when the nasopharyngeal temperature reached 25°C. Anterograde selective cerebral perfusion was performed through the right axillary artery, and the brain was perfused at approximately 5 mL/kg/min. The extent of aortic replacement was determined according to the extent of dissection involvement.~For malperfused patients with symptom onset within 6 hours, the immediate central repair was performed followed by repeat CTA postoperatively, and endovascular reperfusion was applied if the malperfusion persisted. While for patients with symptom onset beyond 6 hours, delayed central repair were performed after the organ functions improved."
41324592|NCT01017887|DEVICE|Airseal access port for laparoscopic surgery|The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
41324593|NCT01017887|DEVICE|Standard Laparoscopy ports|Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
41324594|NCT03277703|BIOLOGICAL|Influenza vaccine|"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
41324595|NCT04771143|DRUG|AFQ056|oral administration
41324596|NCT04771143|DRUG|Placebo|matching placebo for oral administration
41324597|NCT02085057|PROCEDURE|Functional Magnetic Resonance Imaging|
41324598|NCT02839941|DRUG|Iguratimod|Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
41324599|NCT02839941|DRUG|Mycophenolate mofetil|All subjects will receive mycophenolate mofetil for consecutive 52 weeks
41478519|NCT01385982|OTHER|Actionable Test Result Management/Standardization|The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
41478520|NCT04149028|PROCEDURE|PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml|intraovarian injection of 2 mml of PRP by laparoscopic guide
41324600|NCT02839941|DRUG|Tacrolimus|All subjects will receive tacrolimus for consecutive 52 weeks
41324601|NCT02839941|DRUG|Glucocorticoids|All subjects will receive glucocorticoids for consecutive 52 weeks
41153311|NCT02713698|DRUG|Propofol|"The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL."
41478521|NCT04734119|OTHER|Pre operative evaluation and anesthesia administration by the same anesthesiologist|Pre operative evaluation and anesthesia administration by the same anesthesiologist (instead of two different anesthesiologists, as routinely performed in our medical center)
41153312|NCT03002233|DRUG|TRK-820|
41153313|NCT00734851|DRUG|Docetaxel|Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
41153314|NCT00734851|DRUG|Sunitinib|Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
41153315|NCT00734851|RADIATION|EBXRT|External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
41153316|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 2X 4 administrations 2 weeks apart
40806509|NCT05994924|BEHAVIORAL|Educational Handout|Educational handout describing responsive feeding practices.
40806510|NCT05994924|BEHAVIORAL|Video Series|Videos geared toward responsive feeding practices.
40806511|NCT05994924|BEHAVIORAL|Group Discussion Sessions|Group discussion following video viewing led by Imprints Cares, a community organization focused on early childhood education.
40806512|NCT04435691|DRUG|Azacitidine|Given SC or IV
41008778|NCT01986829|DEVICE|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
41008779|NCT01986829|OTHER|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
41008780|NCT01986829|OTHER|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
41008781|NCT02567396|OTHER|Laboratory Biomarker Analysis|Correlative studies
41008782|NCT02567396|OTHER|Pharmacological Study|Correlative studies
41008783|NCT02567396|DRUG|Talazoparib|Given PO
41008784|NCT04942080|BIOLOGICAL|CALR allele burden quantification|"* DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~* at diagnosis and follow-up (inclusion period: 3 years)~* max 1 sample/year~* secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis"
41008785|NCT04518124|DRUG|Propranolol|Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.
40806513|NCT04435691|BIOLOGICAL|Magrolimab|Given IV
40806514|NCT04435691|DRUG|Venetoclax|Given PO
41324602|NCT05289154|OTHER|self- applied acupressure plus Qigong course plus advice literature|daily self applied acupressure over 20min plus 2 times per week online live Qigong course of each 45min- both over 8 weeks.
40806516|NCT05040971|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
41324603|NCT05289154|BEHAVIORAL|advice literature with naturopathy|advice literature with naturopathic remedies will be handed out and application will be supported with dairies and phone calls
41324604|NCT04800120|OTHER|Hyperbaric Oxygen Therapy|Delivery of 100% oxygen within a hyperbaric oxygen therapy chamber
41478522|NCT01674647|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
41478523|NCT01674647|DRUG|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
40806517|NCT05040971|DRUG|Placebo|Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
40806518|NCT06561685|DRUG|LY4050784|Oral
40806519|NCT06086704|DRUG|18F-fluorofuranylnorprogesterone|18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.
40806520|NCT06086704|DEVICE|Positron Emissions Tomography / Magnetic Resonance Imaging|Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)
40806521|NCT06086704|DRUG|Anastrozole|hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days
40806522|NCT06086704|OTHER|Blood Sampling|Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions
40806523|NCT06086704|DRUG|FDA-approved gadolinium-based intravenous contrast agent|FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study
40806524|NCT05010200|BIOLOGICAL|PGV-001|personalized genomic peptide vaccine
40806525|NCT05010200|BIOLOGICAL|Poly-ICLC|immune modulator
41008786|NCT02479854|DRUG|Asmakast|1 chewable tablet contains 5 mg montelukast
41324605|NCT02765503|RADIATION|External beam radiotherapy|External beam radiotherapy using megavoltage radiotherapy with radical intent.
41324606|NCT05655858|OTHER|Management of allergic rhinitis|Collection of patient data in real-life
40806526|NCT05010200|BIOLOGICAL|CDX-301|soluble recombinant human protein to work on stem cell
40806527|NCT06636318|DIAGNOSTIC_TEST|Blood Sample Collection|"To characterize the phenotype and function of immune cells in surgery residents before and after a 24-hour shift, and before and after a month of being on call. Along with to investigate the relationship between sleep deprivation, physical activity, and different immune responses."
41478524|NCT05887349|OTHER|Neck Stabilization Exercise|"1. Control Group exercise program (Cervical Stabilization exercises group)~The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects."
40806528|NCT06636318|DEVICE|Actigraph (GT9X-BT) Monitor|Participants will be asked to wear their monitor every day for a week. The monitor will collect their step count, sleep and heart rate automatically. Participants will return their monitor at visit 5 (day 30) of the study.
40806529|NCT06634459|DEVICE|Reia System|Reia pessary
40806530|NCT06634459|DEVICE|Standard of Care Pessary|Gellhorn pessary or ring with/without support without knob pessary
41153317|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 4 administrations 2 weeks apart
41153318|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 4 administrations 4 weeks apart
40806533|NCT06635434|DEVICE|AR Pain assessment|Age-stratified (age 7-11 and age 12-17 years old) augmented reality app to evaluate for pain and opioid-related adverse events with equivalent English and Spanish text, audio, and narration
40806534|NCT01522976|DRUG|Azacitidine|Given SC or IV
40806535|NCT01522976|OTHER|Laboratory Biomarker Analysis|Correlative studies
40806536|NCT01522976|DRUG|Lenalidomide|Given PO
40806537|NCT01522976|DRUG|Vorinostat|Given PO
40806538|NCT06628869|DIETARY_SUPPLEMENT|Fructanase|Participants will consume one capsule containing 400 INU inulinase (325 mg, includes maltodextrin) with a mixture of oatmeal (40 grams) and inulin (25 grams). Participants will be directed to consume the capsule after two spoonfuls of oatmeal. The fructanase was obtained from Aspergillus tubingensis.
40806539|NCT06628869|DIETARY_SUPPLEMENT|Maltodextrin placebo|Participants will consume one capsule containing 300 mg maltodextrin with a mixture of oatmeal (40 grams) and inulin (25 grams). Participants will be directed to consume the capsule after two spoonfuls of oatmeal. The maltodextrin was obtained from tapioca.
41153319|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 8 administrations 2 weeks apart
41153320|NCT00729508|BIOLOGICAL|Cat-PAD|Placebo
41478525|NCT05887349|OTHER|Neck Stabilization Exercise + Rocabado Exercises|"2. Intervention group exercise program (the group to which Robacado exercises will be added in addition to cervical stabilization exercises) The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. In addition, individuals in this group will be given Robacado exercises.~Robacado exercises:~1. Resting position for the tongue: The tip of the tongue is placed on the upper palate, just behind the front teeth (resting position for the tongue).~2. When the body is in an upright position, scapular retraction and depression movements are performed without disturbing the position of the cervical region.~3. When the body is in an upright position, at C2-C7 levels, hands are clamped on the neck and cranio-cervical flexion is studied."
41478526|NCT05592353|OTHER|Brace|Brace following hip arthroscopy
41153321|NCT01919255|DRUG|Picolight + Coolprep|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]
41008787|NCT02479854|DRUG|Singulair|1 chewable tablet contains 5 mg montelukast
41008788|NCT02690285|DRUG|Dichloroacetate (DCA)|Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
41008789|NCT02690285|OTHER|GSTZ1 haplotyping|One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
41478527|NCT01819324|BEHAVIORAL|Targeting the Teachable Moment|TTMI material (every other week for 4 months)
41153322|NCT01919255|DRUG|Picolight + Clicolon|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]
41153323|NCT03045289|BEHAVIORAL|Plant-Based Diet|Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
41324607|NCT02993913|DRUG|Simmiparib|Simmiparib Tablets, oral administration
41324608|NCT04715048|DRUG|PrabotulinumtoxinA|Glabellar line correction
40806547|NCT06630234|DRUG|DCC-3009|Administered orally
40806548|NCT05947461|DRUG|100mg diclofenac|All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure
40806549|NCT05947461|DRUG|100mg indomethacin|All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
41008790|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds|2 times a day
40806550|NCT05302167|BEHAVIORAL|Molehill Mountain app|"The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain).~The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study."
40806551|NCT05302167|DEVICE|Molehill Mountain app|As above.
41008791|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair|2 times a day
41008792|NCT04574947|DRUG|Intravenous lidocaine|Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
41324609|NCT04715048|DRUG|Onabotulinum toxin A|Glabellar line correction
40806552|NCT06444048|BIOLOGICAL|EV68-228-N|EV68-228-N is a recombinant human monoclonal IgG1 antibody which is produced by genetically engineered plasmids in Nicotiana benthamiana. This intervention is directed against enterovirus EV-D68 capsid protein potentially providing treatments for EV-D68 infection and AMF.
40806553|NCT06444048|OTHER|Placebo for EV68-228-N|The placebo is a sterile buffer solution formulated to match the EV68-228-N Drug Product. The formulation is 20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80, with a target pH of 5.5. The placebo will be filled into glass vials at 10 mL per vial. The formulation buffer is a clear colorless liquid.
41153324|NCT00984399|DRUG|Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist|The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
41478528|NCT01819324|BEHAVIORAL|Standardized Lifestyle Management|SLM material (every other week for 4 months)
41478529|NCT06288191|DRUG|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
41153325|NCT03082196|DRUG|Test varnish|Topical application of test varnish to the teeth 4 times per year.
40806556|NCT05068791|DRUG|Psilocybin|0.36 mg/kg will be administered orally to participants
40806557|NCT05068791|DRUG|Dextromethorphan|2.6 mg/kg of active placebo will be administered orally to participants
40806558|NCT04109807|OTHER|Ozone|ozone exposure
41008793|NCT04574947|DRUG|Intravenous placebo|During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
41008794|NCT04574947|PROCEDURE|Intra-cuff lidocaine|The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.
41008795|NCT04574947|PROCEDURE|Intra-cuff placebo|The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
41008796|NCT01646697|OTHER|cytology specimen collection procedure|Undergo cytopathologic sample collection
41008797|NCT03940209|BEHAVIORAL|Basic needs navigation|Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
41478530|NCT02243293|DRUG|ABT-493|Tablet
40806559|NCT04109807|OTHER|FA|Filtered air exposure
41153326|NCT03082196|DRUG|Standard varnish|Topical application of test varnish to the teeth 4 times per year
41153327|NCT02718053|OTHER|L-stiff|spasticity measurement with Lokomat
41153328|NCT02718053|OTHER|Ashworth|spasticity measurement with Ashworth scale
41153329|NCT05568095|DRUG|Domvanalimab|Intravenous (IV) Aqueous Solution
41153330|NCT05568095|DRUG|Zimberelimab|IV Aqueous Solution
41478531|NCT02243293|DRUG|ABT-530|Tablet
41478532|NCT02243293|DRUG|ribavirin (RBV)|Tablet
41478533|NCT02243293|DRUG|ABT-493/ABT-530|Tablet; ABT-493 co-formulated ABT-530
41478534|NCT04440319|BEHAVIORAL|Intervention group|Intervention group is individual with T2DM who will receive DM Nutrition education for 3 months. There are 75 subjects in Intervention group at 2 districts and 4 Public Health Care (PHC).
41478535|NCT02370914|DEVICE|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
41478536|NCT02370914|BEHAVIORAL|SCAT|A Neurocognitive evaluation of the patients to assess for concussion.
41478537|NCT03063424|DIAGNOSTIC_TEST|Eucapnic voluntary hyperventilation|
41478538|NCT03063424|DIAGNOSTIC_TEST|Exercise challenge on a cycle ergometer|
41478539|NCT03609281|RADIATION|Ultrasound assessement of uterine scar|3D ultrasound assessment of scar characteristics
41153331|NCT05568095|DRUG|Capecitabine|Oral Tablets
41153332|NCT05568095|DRUG|Fluorouracil|IV Aqueous Solution
41153333|NCT05568095|DRUG|Leucovorin|IV Aqueous Solution
41153334|NCT05568095|DRUG|Oxaliplatin|IV Aqueous Solution
41153335|NCT05568095|DRUG|Nivolumab|IV Aqueous Solution
41153336|NCT00266162|DRUG|Bosentan administration|
41153337|NCT05324384|DRUG|Sirolimus|Use of different doses of the same drug
41153338|NCT05208593|BEHAVIORAL|Negative Event + Counterfactual Task|Participants will complete a counterfactual based intervention where they come up with three if only..then statements about how a past drinking behavior could have been altered to be better and to think about protective behavioral strategies that they could use in a future similar situation to make the outcome better.
41153339|NCT05208593|BEHAVIORAL|Personalized Normative Feedback|Participants will be asked to rate the frequency and quantity of students who use protective behavioral strategies while drinking. They will be given feedback on how close their estimate is from the national averages.
41153340|NCT05208593|BEHAVIORAL|Negative Event + Factual Thinking Task|Active Control condition where participants write about a negative event and list three facts about it
41478540|NCT05603052|BIOLOGICAL|EuCorVac-19|COVID-19 vaccine
41478541|NCT05603052|BIOLOGICAL|ChAdOx1 nCoV-19|COVID-19 vaccine
40806564|NCT06420349|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40806565|NCT06420349|PROCEDURE|Computed Tomography|Undergo CT
41478542|NCT00192855|DRUG|Entacapone|Entacapone 600mg BID
41478543|NCT02857829|DIETARY_SUPPLEMENT|CAF+|CAF+ will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (1 mg), and cobalamin (20 mg).
41478544|NCT02857829|DIETARY_SUPPLEMENT|Caffeine-alone|Caffeine (100 mg)
40806566|NCT06420349|BIOLOGICAL|Heat Shock Factor 1 Pathway Inhibitor NXP800|Given PO
40806567|NCT06420349|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40806568|NCT06420349|PROCEDURE|Positron Emission Tomography|Undergo PET
40806569|NCT06420349|PROCEDURE|Ultrasound-Guided Biopsy|Undergo ultrasound-guided liver biopsy
40806570|NCT04545424|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
40806571|NCT04545424|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
40806572|NCT04545424|DEVICE|Standard of care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
40806573|NCT06477965|PROCEDURE|Artery Embolization|Embolic Solution are intended for use in occluding blood vessels for therapeutic or operative purposes. The embolic solution is used during an outpatient procedure, the physician will insert a small catheter onto the artery supplying the lining of the target joint or target localized pain. Tiny particles are then injected through the catheter into these arteries, reducing blood flow to the target area. This reduces the amount of inflammation associated with osteoarthritis, tendonitis, tenosynovitis or an injury, a process that can help decrease symptoms or eliminate the associated localized pain to this area. With understanding that it does not treat the underlying cartilage destruction or underlying condition causing pain but would like to determine the efficacy and validity of this treatment.
41153341|NCT05208593|BEHAVIORAL|Negative Event Only|Participants are asked to write about a negative event related to alcohol and write about it
41153342|NCT02010021|DRUG|Letrozole|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
40806576|NCT05614609|DRUG|Lidocaine topical|Comparing lidocaine spray and muscle relaxing medication
40806577|NCT04712097|DRUG|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12
41008798|NCT04623164|DRUG|Cocktail from complex phytoadaptogens (CFA)|Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
41478545|NCT02857829|OTHER|Placebo|Rice flour
41478546|NCT04628104|RADIATION|cardiac magnetic resonance|"o CMR protocol:~* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.~* T2-weighted imaging to detect extent \& distribution of myocardial edema.~* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.~* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.~* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.~* Post-processing analysis will be done on a dedicated workstation"
41478547|NCT01528020|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
40806578|NCT04712097|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
40806579|NCT04712097|DRUG|Rituximab|Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
40806580|NCT04712097|DRUG|Tociluzumab|Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
41153343|NCT06121739|BEHAVIORAL|Child Mental Health Literacy Program|The workshop has a participant-oriented character, seeking to apply the more theoretical contents to the local school context. It has four units and a total of nine modules, each lasting 90 or 120 minutes, with reference material on an educational platform. The topics are : 1) the person behind the role of educator; 2) the school community and its influence on the healthy development of students; 3) the expected development and its alterations in the different evolutionary stages; 4) common and differential factors of child and adolescent mental health disorders; 5) Stigma in Mental Health; 6) screening, the first care, and use of devices for the prevention and treatment of mental health disorders in children and adolescents.
41324610|NCT03302897|BIOLOGICAL|LEP-F1 + GLA-SE|Investigational vaccine
40806584|NCT01013649|RADIATION|3-Dimensional Conformal Radiation Therapy|daily fractions
40806585|NCT01013649|DRUG|Capecitabine|tablet
40806586|NCT01013649|DRUG|Chemotherapy|single agent chemotherapy or combination chemotherapy using allowed agents
40806587|NCT01013649|DRUG|Erlotinib Hydrochloride|tablet
40806588|NCT01013649|DRUG|Fluorouracil|intravenously
40806589|NCT01013649|DRUG|Gemcitabine Hydrochloride|intravenously
40806590|NCT01013649|RADIATION|Intensity-Modulated Radiation Therapy|daily fractions
40806594|NCT03842228|PROCEDURE|Biopsy|Undergo tumor biopsy
41324611|NCT02707679|OTHER|Mulligan's Straight leg-raise with traction|Mulligan's Straight leg raise technique was performed on patients with patellofemoral pain syndrome. The extremity on which the practice would be performed in supine position was grasped from the ankle level and was, then, subjected to traction longitudinally. Afterwards, the knee was lifted up passively while in extension and was kept for waiting for a few seconds at the point where tension was felt and was, then, returned to its initial position. The practice was repeated 10 times, and 3 sets of practice at 1-minute-intervals were performed.
41324612|NCT02707679|OTHER|Mulligan's Mobilization with Movement|Mulligan's Mobilization with Movement technique was performed on patients with patellofemoral pain syndrome. Each patient was tested in every direction in the course of the active knee flexion-extension movement so as to find out the best pain-free tibial gliding direction (medial-lateral part of the tibia, anterior-posterior, internal-external rotation). At the time of the active movement of the knee, the tibial gliding direction where pain was felt at the least was selected as the treatment direction of mobilization technique along with movement. The practice was performed by doing 10 repetitions for 3 sets and by providing 1-minute-resting time between the sets.
41324613|NCT02707679|OTHER|Kinesiotaping|Kinesiotaping was applied on patient with patellofemoral pain syndrome. To maintain proprioceptive stimulation in the quadriceps (from origo towards insertio) and to alleviate the tension of hamstring muscle, a 'Y''-shaped kinesiotape was applied by using the muscle technique.
40806595|NCT03842228|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41324614|NCT02707679|OTHER|Exercise|All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.
40806596|NCT03842228|PROCEDURE|Computed Tomography|Undergo CT
41324615|NCT01268033|DRUG|Rituximab|two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
40806597|NCT03842228|DRUG|Copanlisib Hydrochloride|Given IV
41008799|NCT04623164|PROCEDURE|Standard non-surgical periodontal treatment (NSPT)|Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate
41324616|NCT01268033|DRUG|Placebo|two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
41324617|NCT00441103|DRUG|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
41324618|NCT00441103|DRUG|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
41153344|NCT04521933|OTHER|Survey|"Each participant completes a questionnaire. In the questionnaire, he performs a subjective qualitative evaluation of Point-of-Care ultrasound records of the heart.~Each participant will complete a questionnaire in which they perform a subjective qualitative evaluation of ultrasonographic recordings of the heart."
41478548|NCT01528020|BEHAVIORAL|Individual and Group Supportive Therapy|The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
41478549|NCT06177314|OTHER|correlate the molecular signatures of active lesions of contact dermatitis with allergological results|Data will be collected retrospectively and prospectively from patients' medical records, and will include: clinical information (history, treatments, lifestyle, exposures, lesion location and appearance), patch-test results, histological analysis results, molecular analysis results.
41008800|NCT02698358|DEVICE|Epic stent (Boston Scientific)|
41008801|NCT05581966|DIAGNOSTIC_TEST|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
41008802|NCT03556046|DIAGNOSTIC_TEST|89Zr-Girentuximab|Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
41153345|NCT03972137|BEHAVIORAL|Cognitive-Behavioral Smoking Cessation|Participants were provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
41153346|NCT03972137|BEHAVIORAL|Heart Rate Variability Biofeedback (HRVB)|All participants were provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
40806598|NCT03842228|BIOLOGICAL|Durvalumab|Given IV
40806599|NCT03842228|PROCEDURE|Echocardiography|Undergo ECHO
40806600|NCT03842228|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40806601|NCT03842228|DRUG|Olaparib|Given PO
40806602|NCT03842228|PROCEDURE|X-Ray Imaging|Undergo x-ray
40806603|NCT04296305|DRUG|Hydromorphone|Given IV after
40806604|NCT04296305|DRUG|Placebo Administration|Given IV after
40806605|NCT04296305|OTHER|Questionnaire Administration|Ancillary studies
40806606|NCT03110978|BIOLOGICAL|Nivolumab|Given IV
40806607|NCT03110978|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
41153347|NCT03972137|DRUG|Transdermal Nicotine patch|All participants were offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
41153348|NCT00550927|BIOLOGICAL|bevacizumab|
40806614|NCT04550832|DRUG|Delpazolid|Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.
40806615|NCT04550832|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.
40806616|NCT03924219|OTHER|CMV T cell Immunity Assay|Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
41153349|NCT00550927|DRUG|enzastaurin hydrochloride|
41153350|NCT00550927|OTHER|diagnostic laboratory biomarker analysis|
41153351|NCT00550927|OTHER|pharmacological study|
41153352|NCT02467049|DEVICE|ECG-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
41153353|NCT02467049|DEVICE|ULTRASOUND-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
40806622|NCT03504488|BIOLOGICAL|CAB-ROR2-ADC|Conditionally active biologic anti-ROR2 antibody drug conjugate
40806623|NCT03504488|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
40806624|NCT03547739|BEHAVIORAL|Home visits|If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
40806625|NCT03547739|BEHAVIORAL|HIV Self-testing|Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
41324619|NCT00441103|DRUG|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
40806626|NCT05723055|DRUG|Axatilimab|Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).
40806627|NCT05723055|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
41153354|NCT04169906|DRUG|Placebo|Participants will receive placebo once daily for 7 consective days
41008803|NCT00981500|PROCEDURE|gastric bypass|Roux-en-Y gastric bypass
41324620|NCT02293993|DRUG|SGI-110|
41324621|NCT02667379|OTHER|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
41324622|NCT01811355|DRUG|Mexiletine|Sodium channel blocker
41324623|NCT01811355|DRUG|Placebo|Placebo
41324624|NCT02892825|OTHER|Music|headphones with music
41324625|NCT02892825|OTHER|No Music|headphones without music
41153355|NCT04169906|DRUG|TS-142, 10 mg|Participants will receive 10 mg of TS-142 once daily for 7 consective days
41153356|NCT04169906|DRUG|TS-142, 20 mg|Participants will receive 20 mg of TS-142 once daily for 7 consective days
41324626|NCT00450164|PROCEDURE|esofagic varices ligation|
41153357|NCT04169906|DRUG|TS-142, 30 mg|Participants will receive 30 mg of TS-142 once daily for 7 consective days
41324627|NCT00450164|DRUG|Nadolol|
41324628|NCT00450164|DRUG|Isosorbide mononitrate|
41324629|NCT00450164|DRUG|Prazosin|
41324630|NCT06064903|BIOLOGICAL|CD7-CART01|A single IV infusion of CD7-CART01 on Day 0
41153358|NCT03937076|PROCEDURE|PECS II block|"Pectoral muscles Nerve block for postsurgical pain, PECS II, based on BUPIVACAINE:~Pectoral muscles nerve block is a procedure in which local anesthetic is injected into two sites.~1. between the major and minor pectoral muscles, in order to anesthetize the lateral and medial nerve. This injection is referred to as PECS I block.~2. between the minor pectoral muscle and the anterior serratus muscle, in order to anesthetize the intercostal nerves."
41153359|NCT03362684|DRUG|Cetuximab|Cetuximab every 2 weeks
41153360|NCT03362684|DRUG|FOLFOX|FOLFOX-4 every 2 weeks
41153361|NCT05301842|DRUG|Tremelimumab|Tremelimumab IV (intravenous)
41153362|NCT05301842|DRUG|Durvalumab|Durvalumab IV (intravenous)
41153363|NCT05301842|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
41153364|NCT05301842|DRUG|Lenvatinib|Lenvatinib (oral)
41153365|NCT00029276|PROCEDURE|Prefrontal transcranial magnetic brain stimulation|
41153366|NCT00005088|DRUG|cisplatin|
40806638|NCT04164199|DRUG|Tislelizumab|Administered intravenously.
40806639|NCT04164199|DRUG|Pamiparib|Administered orally.
40806640|NCT04164199|DRUG|Temozolomide|Administered orally.
40806641|NCT04164199|DRUG|Sitravatinib|Administered orally.
40806642|NCT04164199|DRUG|Ociperlimab|Administered intravenously.
40806643|NCT04164199|DRUG|BAT1706|Administered intravenously.
40806644|NCT04164199|DRUG|Fruquintinib|Administered orally.
40806645|NCT04164199|DRUG|BGB-15025|Administered orally.
40806646|NCT04164199|DRUG|Zanidatamab|Administered intravenously.
40806647|NCT04164199|DRUG|BGB-A445|Administered intravenously.
40806648|NCT04164199|DRUG|Surzebiclimab|Administered intravenously.
40806649|NCT04164199|DRUG|Lenvatinib|Administered orally.
40806650|NCT04164199|DRUG|LBL-007|Administered intravenously.
40806651|NCT05530863|BEHAVIORAL|Assisted Therapy|The participant will receive coaching calls and support
40806652|NCT05530863|BEHAVIORAL|Sleep Hygiene|Standard Sleep Hygiene instructions.
40806653|NCT06477393|OTHER|Regular rehababilitation|Subjects of the experimental and control groups will receive routine procedures applied in the resort sanatorium: physiotherapy (28-32), occupational therapy (12-18), dry hydromassage (7-8), psychotherapy or audiovisual relaxation (3-4), social worker's visit ( 1-2), physiotherapy (magnetotherapy, ultrasound therapy (8-9).
40806654|NCT06477393|OTHER|Heat procedures|"The bath is filled with 200 litres of warm tap water at 36-38°C. The participant lies in the prepared bath, ensuring the chest area remains uncovered. While in the bath, the participant performs gentle movements. The procedure lasts 12-15 minutes. Air is pumped into the water to increase the oxygen saturation in the bath environment.~A prepared gel pack will be placed in another bag and heated to 50-55°C. The heated pack will be delivered to the treatment area using pumps. For applications, the gel pack is used at 40-42°C. Temperature of the gel pack can range between 38-43°C."
40806655|NCT06477393|OTHER|Healing mud application|"Therapeutic mud applications: peat brought from the quarry is sifted, ground, and mixed with natural mineralisation of 20-22g/l with mineral water in a ratio of at least 4:1 until the consistency of thick sour cream. The prepared peat mud is heated to 50-55 degrees. The heated mud is fed to the place where the procedures are performed with the help of pumps. Mud mass at 40-42 degrees is used for applications. A mud temperature range of 38-43 degrees is possible.~Before the procedure, it is recommended not to eat, go to the toilet, or take a warm shower. A polyethene film is laid on a special heated couch, and a 2-4 cm thick layer of mud is poured into the area of the hands and feet, covered with a blanket. After the procedure, the subject takes a warm, lukewarm shower, wipes himself with a soft towel, and rests. Peloids are not reused."
40806656|NCT06477393|OTHER|Mineral water bath|The pearl bath is prepared by a physical method. The bath is filled with 200 l of warm 36-38 C mineral water, the subject lies in the prepared bath, leaving the heart area open, while lying in the bath he performs light movements. The duration of the procedure is 12-15 minutes. Air is blown into the water, which increases oxygen saturation in the bath environment. Before the procedure, it is recommended not to eat, go to the toilet, take a warm shower. After the procedure, the subject takes a warm, lukewarm shower, wipes himself with a soft towel and rests. Mineral waters are not reused.
41153367|NCT00005088|RADIATION|radiation therapy|
41153368|NCT03260270|DIAGNOSTIC_TEST|color doppler ultrasound|All patients are going to be examined by color Doppler ultrasound and the high risk patients are going to be examined by direct MDCT venography .
41153369|NCT01034683|DRUG|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
41153370|NCT04652050|DRUG|Tolsura|Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
40806661|NCT06353295|OTHER|P4P intervention|The final Peers for PrEP (P4P) intervention components were refined based on stakeholder engagement, key informant interviews, and focus group discussions. Trained peers will deliver the following intervention with remote clinician support and ongoing mentorship: pre-exposure prophylaxis (PrEP) access and refills in community/at hotspots; HIV testing, with option for HIV self-testing (HIVST); Rapid post-exposure prophylaxis (PEP) access for unplanned exposures; Family planning integration; Phone/text messaging hotline for peer support
40806662|NCT04436107|DRUG|Zanubrutinib|160 mg administered orally twice daily (BID)
40806663|NCT04436107|DRUG|Lenalidomide|Administered as specified in the treatment arm
41153371|NCT06647108|DIETARY_SUPPLEMENT|Food Supplement|The composition of the dietary supplement is the following (for 1 sachet): 450 mg glucomannan, 250 mg white mulberry dry extract (d.e.), 200 mg gymnema (d.e.), 200 mg olive (d.e.), 200 mg Cassia nomame (d.e.), 200 mg Nopal, 5 mg policosanols and 20 µg chromium
41153372|NCT06647108|OTHER|Placebo|Placebo
41153373|NCT00215709|DRUG|docetaxel|
40806664|NCT04577456|DEVICE|The Insides System|Novel pump designed to return effluent from the ostomy bag to the distal gut
40806665|NCT05591859|DEVICE|Restoration Anatomic Acetabular Shell|Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
41153374|NCT04746690|OTHER|Slider, tensioner neurodynamic mobilization techniques and stretching exercises of back, hamstrings and gastrocnemius|neurodynamic mobilization techniques of sciatic nerve and stretching exercises of back extensors, hamstrings and lower limbs for patients with chronic discogenic sciatica.
41153375|NCT06076746|BEHAVIORAL|NIC Psychotherapeutic Intervention(s) for İneffective Coping|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
40806668|NCT02196181|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40806669|NCT02196181|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40806670|NCT02196181|DRUG|Dabrafenib Mesylate|Given PO
40806671|NCT02196181|PROCEDURE|Echocardiography|Undergo ECHO
40806672|NCT02196181|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40806673|NCT02196181|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40806674|NCT02196181|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
41324631|NCT04004377|OTHER|Scale of quality life|"The PANQOL scale (Penn Acoustic Neuroma Quality-of-Life) is a specific questionnaire containing 26 items Interviewing 7 areas: hearing, balance, facial expression, anxiety, vitality, pain, and 'general health. The score is encrypted from 0 to 100, and the highest score is a reflection of the best possible quality of life. This score has been translated from French into English and validated according to the reverse translation rules by usual Oddon et al.~Three questions for this score were added, evaluating quality of life parameters that seem particularly interesting: the first regarding the difficulties in driving, the second questioning the recovery of a normal life, and the third assessing difficulties in working life."
40806675|NCT06030466|OTHER|With virtual standardized patients|The virtual standardized patient is a software system that presents on a computer screen like a video conference, allowing medical students to interact with it for medical consultation. The virtual character modeling adopts 3D model, the expression of the character is delicate, and the voice feedback is clear. After the students' questions are asked by voice recognition and key words are extracted, appropriate responses are given.
40806676|NCT06030466|OTHER|With physical standardized patients|The physical standardized patient is a real person who has received professional training courses in the department of medical education of National Taiwan University Hospital, and can help medical students practice consultations.
40806677|NCT03597581|DRUG|ompenaclid|RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.
40806678|NCT03597581|DRUG|FOLFIRI|FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
40806679|NCT03597581|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor.
41324632|NCT02546427|RADIATION|Helical TomoTherapy (HT)|
41324633|NCT02546427|RADIATION|CyberKnife SBRT|
41324634|NCT02546427|RADIATION|Permanent Prostate Implant (PPI)|
40806680|NCT03597581|DRUG|FOLFOX regimen|The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines
41153376|NCT06076746|BEHAVIORAL|psychotherapeutic intervention|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
41153377|NCT05690477|PROCEDURE|Corrective osteotomy of the distal radius|Corrective osteotomy of the distal radius with a palmar locking plate osteosynthesis without the use of a bone graft and without cortical contact.
40806683|NCT06122961|OTHER|No treatment given|No treatment given
40806684|NCT05024045|DRUG|LOXO-338|Oral
40806685|NCT05024045|DRUG|Pirtobrutinib|Oral
41153378|NCT00796640|DRUG|ER Paliperidone|
41153379|NCT05202301|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
40806688|NCT03594747|DRUG|Tislelizumab|Administered intravenously as described
40806689|NCT03594747|DRUG|Paclitaxel|Administered intravenously as described
40806690|NCT03594747|DRUG|Nab-paclitaxel|Administered intravenously as described
40806691|NCT03594747|DRUG|Carboplatin|Administered intravenously as described
41153380|NCT05202301|DRUG|Enzalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
40806693|NCT03549572|BEHAVIORAL|Coma Recovery Scale-Revised|Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
41324635|NCT02546427|RADIATION|HDR brachytherapy|
41324636|NCT00516984|PROCEDURE|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
41324637|NCT00516984|PROCEDURE|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
41008804|NCT00981500|PROCEDURE|gastric banding|laparoscopic adjustable gastric banding
41153381|NCT05202301|DRUG|Apalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
41153382|NCT04549948|PROCEDURE|0.017X0.025 Stainless steel|Leveling curve of Sppe using 0.017X0.025 SS archwire
40806699|NCT04628767|PROCEDURE|Biopsy|Undergo tissue biopsy
40806700|NCT04628767|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40806701|NCT04628767|DRUG|Cisplatin|Given IV
40806702|NCT04628767|PROCEDURE|Computed Tomography|Undergo CT
40806703|NCT04628767|DRUG|Doxorubicin Hydrochloride|Given Iv
40806704|NCT04628767|BIOLOGICAL|Durvalumab|Given IV
40806705|NCT04628767|DRUG|Gemcitabine Hydrochloride|Given IV
40806706|NCT04628767|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40806707|NCT04628767|DRUG|Methotrexate|Given IV
40806708|NCT04628767|BIOLOGICAL|Pegfilgrastim|Given via injection
41478550|NCT03353402|PROCEDURE|Fecal Microbiota Transplant (FMT)|Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
41478551|NCT02556307|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
40806709|NCT04628767|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41478552|NCT02556307|DRUG|Ribavirin|Ribavirin according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
41478553|NCT01921491|PROCEDURE|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
41478554|NCT01921491|DEVICE|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
41478555|NCT05312242|DIETARY_SUPPLEMENT|United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) MMS|Introduction of UNIMMAP MMS along with novel counseling strategies to increase acceptability and adherence to prenatal supplementation
41478556|NCT05312242|DIETARY_SUPPLEMENT|Iron Folic Acid Supplement|Standard of Care Intervention
41478557|NCT00780923|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
40806710|NCT04628767|DRUG|Vinblastine Sulfate|Given Iv
40806711|NCT05069558|DEVICE|Investigational PFO Closure Device|Occlutech Flex II PFO Closure Device
40806712|NCT05069558|DEVICE|Standard of Care PFO Closure Device|Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
40806713|NCT05689671|DRUG|Atezolizumab|1200 mg i.v. q3w
40806714|NCT05689671|DRUG|Nab paclitaxel|100 mg/m² i.v. qw
40806715|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
40806716|NCT05689671|DRUG|Pembrolizumab|200 mg i.v. q3w
40806717|NCT05689671|DRUG|Cisplatin|75 mg/m² i.v. q3w
40806718|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
40806719|NCT05689671|DRUG|Pemetrexed|500 mg/m² i.v. q3w
41153383|NCT04549948|PROCEDURE|0.019X0.025 Stainless steel|Leveling curve of Sppe using 0.019X0.025 Stainless steel archwire
41153384|NCT04549948|PROCEDURE|0.021X0.025 B-Titanium archwire|Leveling curve of Sppe using 0.019X0.025 B-Titanium archwire
40806722|NCT05936619|DEVICE|Mind Extender (MindEx)|NeuroPort Multi-Port Arrays allow for the local recording of cerebral cortex. The Mind Extender (MindEx) system is primarily composed of two NeuroPort Multi-Port Arrays. Each Multi-Port device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D), and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array. The four arrays of the two Multi-Port device will be implanted into prefrontal cortex, premotor cortex, primary motor cortex, and posterior parietal cortex.
40806723|NCT04295681|DRUG|MMH-MAP|Oral administration
40806724|NCT04295681|DRUG|Placebo|Oral administration
40806725|NCT06471361|DRUG|Zilucoplan|Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
40806726|NCT06544785|DRUG|Zanubrutinib Oral Product|"Zanubrutinib drug product is supplied as 80 mg strengths in capsules for oral administration.~In both arms A and B, zanubrutinib 320 mg will be taken qDay with or without food. Patients will take zanubrutinib with water at approximately the same time every day."
41008805|NCT00981500|PROCEDURE|sleeve gastrectomy|vertical sleeve gastrectomy
41008806|NCT05766891|BEHAVIORAL|Group 1|Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery
41324638|NCT00516984|PROCEDURE|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
41324639|NCT01122030|DRUG|Naldemedine|Tablets or solution for oral administration
41478558|NCT03390348|DEVICE|LENA Recorder|Use of the LENA recorder to document crying and fussing
41478559|NCT04153448|OTHER|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
40806727|NCT06544785|DRUG|Obinutuzumab|"Each dose of obinutuzumab is 1000 mg administered intravenously, per institutional standards, with the exception of the first infusion in Cycle 2 (arm A) or Cycle 13 (arm B). It is recommended that the initial 1000 mg dose be administered over Day 1 (100 mg) and Day 2 (900 mg). For subjects who tolerate the initial 100 mg dose well and required no dose interruption or modification of the infusion rate, the treating physician may opt to administer the remaining 900 mg on Day 1.~Arm A: patients will receive obinutuzumab on days 1 (100 mg), 2 (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 2 of zanubrutinib treatment, and on the day 1 of cycles 3-7 (1000 mg).~Arm B: patients will receive obinutuzumab on days 1 (100 mg), 2 ( (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 13 of zanubrutinib treatment, and on the day 1 of cycles 14-18 (1000 mg)."
41153385|NCT03575572|DRUG|Colchicine|Colchicine is an alkaloid approved in 1961 for the use in Familial Mediterranean Fever in adults and children 4 years of age or older. It has been widely used for decades in other indications, such as Gout, recurrent pericarditis, pericardial effusions and other inflammatory diseases. This drug is commercially available and is approved in children 4 years and older.
41153386|NCT04276142|BEHAVIORAL|ceprica (additional to treatment as usual)|ceprica is a dialogue-based online psychological intervention for patients with migraine. This intervention includes elements that address pain management, pain reduction etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
41324640|NCT01122030|DRUG|Placebo|Tablets or solution for oral administration
41324641|NCT00387270|DRUG|Dimebon|Dimebon 10 or 20 mg TID x 7 days
41324642|NCT04046445|DRUG|ATP128|5-6 SC injections
41478560|NCT06213467|DEVICE|diode laser 940nm|Exposure for the two implants was done at the same visit, with one implant being exposed using diode laser and the other implant using traditional method
41478561|NCT00043537|BEHAVIORAL|Social Effectiveness Therapy for Children (SET-C)|
41478562|NCT00043537|DRUG|Fluoxetine|
41478563|NCT00043537|DRUG|Pill Placebo|
41478564|NCT01059721|PROCEDURE|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
41478565|NCT00514969|DRUG|Imatinib (STI571)|
41324643|NCT04046445|DRUG|BI 754091|≥ 7 IV infusions
41478566|NCT04815694|RADIATION|RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT|The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis. Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously. A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated. If ERI will be inferior than 13.1 the patient will continue the original treatment. If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
41478567|NCT00836329|BEHAVIORAL|Intensive Glucose Management|Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
41478568|NCT00836329|BEHAVIORAL|Traditional Glucose Management:|Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
41478569|NCT05405231|BEHAVIORAL|Crisis Line Facilitation (CLF)|Crisis Line Facilitation (CLF) is a promising translational strategy designed to increase MVCL use among NG members during periods of elevated suicidal risk by addressing individual-level barriers.
41478570|NCT05405231|BEHAVIORAL|Passive Implementation|The PI condition includes an educational resource brochure describing the MVCL, including the phone number for the crisis line, as well as other mental health services available to National Guard members.
41324644|NCT04046445|DRUG|VSV-GP128|1 single IV injection
41478571|NCT02409602|OTHER|Doppler ultrasonographic examination|Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
41478572|NCT03321994|DEVICE|stereotaxic unit, navigation|CT-guided needle guidance using stereotaxic unit, navigation
41478573|NCT03321994|DEVICE|conventional biopsy technique|CT-guided needle guidance using conventional biopsy technique
41478574|NCT03606720|OTHER|low level laser therapy|low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
41324645|NCT04142385|OTHER|Cytology Specimen Collection Procedure|Undergo blood, urethral swab, penile skin cell, and anal swab collection
41324646|NCT04142385|OTHER|Laboratory Biomarker Analysis|Correlative studies
41324647|NCT04142385|PROCEDURE|Medical Examination|Undergo anal and penile clinical exam
41324648|NCT04142385|PROCEDURE|Physical Examination|Undergo targeted physical exam
41324649|NCT04142385|PROCEDURE|Proctoscopy with Biopsy|Undergo HRA
41324650|NCT04142385|OTHER|Questionnaire Administration|Ancillary studies
41153387|NCT04276142|BEHAVIORAL|active control intervention (additional to treatment as usual)|the active control intervention contains psychoeducational content regarding migraine
41153388|NCT06645704|DRUG|EP262|Single dose of \[14C\]-EP262 administered orally.
40806733|NCT04509700|DRUG|Parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
40806734|NCT04509700|DRUG|parsaclisib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
41478575|NCT03606720|OTHER|pelvic stabilization exercises|special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
40806735|NCT04509700|DRUG|parsaclisib + ruxolitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
40806736|NCT04509700|DRUG|parsaclisib + ibrutinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
40806737|NCT05251259|DRUG|Atuliflapon|Randomised participants will receive Atuliflapon
40806738|NCT05251259|DRUG|Placebo|Randomised participants will receive placebo
41153389|NCT06475092|OTHER|Tanita device|bioelectric impedance analysis
41153390|NCT05096741|DEVICE|OCS Liver|Transplanted with a OCS preserved liver
40806741|NCT06269185|DRUG|Infliximab|Infliximab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
40806742|NCT06269185|DRUG|Adalimumab|Adalimumab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
41153391|NCT06584864|DIAGNOSTIC_TEST|bedside ultrasound examination of the lumbar spinal canal|The ultrasound examination will be performed using a Lumify linear probe (frequency range 4-12 MHz). In the longitudinal projection, the doctor will assess the spinal cord endings by marking them with a sterile marker - a horizontal line on the patient's back. In the same projection, the doctor will designate a safe and optimal place (the greatest width of the dural sac) for performing a lumbar puncture by marking it with a sterile marker. Additionally, in the longitudinal projection, the researcher will measure the depth from the skin surface to the dura mater. Then, in the transverse projection, the doctor will confirm the absence of the spinal cord at the planned puncture site and the optimal amount of cerebrospinal fluid in the selected space. This information will be passed on to the operator, who will ultimately decide on the lumbar puncture site.
41153392|NCT06471413|OTHER|The Prevention Toolbox : BOAT®|The Prevention Toolbox targets all forms of violence, but in particular sexual and gender-based violence, through 1 out of 5 themes (Relationships and sexuality) and 10 out of 34 sub-themes. The other 4 themes (Psychosocial skills, Respect and difference, From the virtual to the real, and Understanding and respect for the law) cover all the risk and protection factors for all types of violence.
41153393|NCT03261934|OTHER|No intervention|No intervention
41153394|NCT03314116|OTHER|Guidance on auditory protection|by video or medic
40806747|NCT05858164|DRUG|BAY2862789|Oral administration, solution or tablets
40806748|NCT06368622|DEVICE|Surpass Evolve Flow Diverter System|Endovascular treatment with Surpass Evolve Flow Diverter System was performed in patients diagnosed with intracranial aneurysms
41478576|NCT03490474|OTHER|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
41478577|NCT03490474|OTHER|Pain Free Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
40806751|NCT05497115|BEHAVIORAL|Trauma Resilience and Recovery Program|The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).
40806752|NCT03474913|DEVICE|Upright MRI|Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
40806753|NCT03474913|DEVICE|Standard MRI|standard of care closed 3T MRI
40806754|NCT04481204|DRUG|Cisplatin|Given IV
40806755|NCT04481204|DRUG|Fluorouracil|Given IV
40806756|NCT04481204|DRUG|Gemcitabine|Given IV
40806757|NCT04481204|DRUG|Irinotecan|Given IV
40806758|NCT04481204|DRUG|Leucovorin|Given IV
40806759|NCT04481204|DRUG|Nab-paclitaxel|Given IV
40806760|NCT04481204|DRUG|Oxaliplatin|Given IV
40806761|NCT04481204|RADIATION|Radiation Therapy|Undergo RT
40806764|NCT05033886|DRUG|fezolinetant|oral
40806765|NCT05033886|DRUG|placebo|oral
40806766|NCT06352060|OTHER|No intervention or administration will be performed due to the observational nature of the study|Charts of patients enrolled in the study will be reviewed for an initial monitoring method and any changes in management.
40806767|NCT06462040|PROCEDURE|Fixation of osteochdral fragments with reabsorbable screws|Arthroscopic or mini-open fixation of free-intrarticular or unstable osteochondral fragments due to osteochondritis dissecans or osteochondral fractures with reabsorbable screws
41153395|NCT00615355|RADIATION|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
41324651|NCT03560635|BEHAVIORAL|Weight Loss Maintenance (Control vs. Reverse Diet)|Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
41008807|NCT05766891|BEHAVIORAL|Group 2|Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room
41478578|NCT03490474|OTHER|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
41153396|NCT00615355|DEVICE|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
41153397|NCT02683317|DIETARY_SUPPLEMENT|docosahexaenoic acid|Docosahexaenoic acid is a dietary supplement derived from algae.
40806773|NCT04670068|DRUG|CAR.B7-H3|Two dose levels will be evaluated: Dose Level 1 (7.5x10\^7 cells/infusion), dose Level 2 (2x10\^8 cells/infusion). If dose limiting toxicities (DLTs) are observed per protocol, Dose Level -1 (3.75x10\^6 cells/infusion) will be evaluated.
40806774|NCT04670068|DRUG|Fludarabine|30 mg/m\^2 IV for 3 consecutive days
40806775|NCT04670068|DRUG|Cyclophosphamide|300 mg/m\^2 IV for 3 consecutive days
40806776|NCT05074680|DIAGNOSTIC_TEST|Blood sampling|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
40806777|NCT06212999|DRUG|Povorcitinib|Oral; Tablet
41153398|NCT02683317|DIETARY_SUPPLEMENT|sunflower oil|Sunflower similar to the excipient used in experimental group
41153399|NCT01879488|DRUG|technetium-99m - Diethylenetriaminepentaacetic acid|
41153400|NCT01879488|DEVICE|Vibrating-mesh nebulizer|
40806781|NCT03710044|DRUG|Cyclosporine A|"Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks."
40806782|NCT04771299|DRUG|Cariprazine|Cariprazine is a novel atypical antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for treatment of schizophrenia, manic or mixed, and depressive episodes associated with bipolar I disorder.
40806783|NCT04771299|OTHER|Placebo|Placebo is an inactive substance that looks identical to the study medication that contains no therapeutic ingredient.
41153401|NCT01879488|OTHER|Gamma scintigraphy|
41153402|NCT01879488|OTHER|Preoperative spirometry|
41153403|NCT05912543|PROCEDURE|Titration of FiO2|The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
40806787|NCT06442423|DRUG|Psilocybin|Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg.This is an open-label clinical trial with a single treatment arm. This is an open-label clinical trial with no blinding.
40806788|NCT06107374|DRUG|[18F]F-AraG|Two PET scans
40806789|NCT04264520|BEHAVIORAL|PTSD Psychoeducation + Skills Intervention|A brief computer-assisted intervention (psychoeducation + skills) for pregnant women with elevated PTSD symptoms.
40806790|NCT06369753|BEHAVIORAL|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period
41478579|NCT04637633|DRUG|topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,|topical preservative free artificial tears Q.I. D.
41478580|NCT00888784|PROCEDURE|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
40806791|NCT06369753|BEHAVIORAL|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
41153404|NCT06561256|DRUG|Janus Kinase Inhibitor|Janus Kinase Inhibitor in combination with corticosteroids
41153405|NCT06416189|DEVICE|Fixed appliances|MBT Brackets 0.022 inch
41153406|NCT04011995|BEHAVIORAL|Intermittent caloric restriction|"The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
40806795|NCT02569476|DRUG|Zanubrutinib|
40806796|NCT02569476|DRUG|Obinutuzumab|
40806797|NCT04929223|DRUG|Inavolisib|Inavolisib will be administered orally as per schedule specified in the respective arms.
40806798|NCT04929223|DRUG|Bevacizumab|Bevacizumab IV will be administered as per schedule specified in the respective arm.
40806799|NCT04929223|DRUG|Cetuximab|Cetuximab IV will be administered as per schedule specified in the respective arm.
41008808|NCT05766891|BEHAVIORAL|Group 3|Participants will receive standard general anesthesia and medications during surgery to control your pain.
40806800|NCT04929223|DRUG|Atezolizumab|Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
40806801|NCT04929223|DRUG|Tiragolumab|Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
40806802|NCT04929223|DRUG|SY-5609|SY-5609 will be administered by mouth as per schedule specified in the respective arm.
40806803|NCT04929223|DRUG|Divarasib|Divarasib will be administered orally as per schedule specified in the respective arms.
40806804|NCT04929223|DRUG|FOLFOX|FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
40806805|NCT04929223|DRUG|FOLFIRI|FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
40806806|NCT06510374|DRUG|Nadofaragene Firadenovec|Vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification.
41153407|NCT04011995|BEHAVIORAL|Low carbohydrate diet|"During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
41153408|NCT04011995|BEHAVIORAL|Health education on reducing the cardiometabolic risk|Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
41153409|NCT05167318|OTHER|frequent standardized oral care|Standardized oral care will be provided every 3-4 hours
41153410|NCT00228813|DRUG|Granulocyte Colony Stimulating Factor|"FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.~Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.~Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.~Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.~Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection"
41008809|NCT03794284|DIAGNOSTIC_TEST|VereMTB|At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.
41008810|NCT05800054|DIETARY_SUPPLEMENT|Nutritional Support Team|Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral intake cannot meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
41008811|NCT05800054|DRUG|Docetaxel|60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy
41153411|NCT02815618|DEVICE|BabyLux Neuro-monitor|Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
40806812|NCT05063162|DRUG|Rozanolixizumab|"* Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive pre-specified doses of rozanolixizumab."
40806813|NCT05063162|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive placebo."
40806814|NCT05247905|DRUG|Lutetium Lu 177 Dotatate|Given IV
41008812|NCT05800054|DRUG|cisplatin|cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy
41153412|NCT04297423|DRUG|Plenvu|randomization 1:1
41153413|NCT02553616|BEHAVIORAL|Intervention to Promote Healthy Behaviors|Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
41324652|NCT01238913|PROCEDURE|Endoscopy|Endoscopic placement of an esophageal metal stent as per medical indication.
40806815|NCT05247905|DRUG|Capecitabine|Given PO
40806816|NCT05247905|DRUG|Temozolomide|Given PO
40806817|NCT05247905|OTHER|Quality-of-Life Assessment|Ancillary studies
40806818|NCT05247905|OTHER|Questionnaire Administration|Ancillary studies
41153414|NCT05652686|DRUG|PT217|A bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47).
41324653|NCT03703271|DRUG|Methotrexate|single-agent 5-day methotrexate, two weeks a cycle
41324654|NCT03703271|PROCEDURE|hysteroscopic repeat curettage|Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
40806824|NCT05609370|DRUG|LBL-007|Low dose intravenously (IV) once every 3 weeks.
40806825|NCT05609370|DRUG|LBL-007|Medium dose IV once every 3 weeks
40806826|NCT05609370|DRUG|LBL-007|High dose IV once every 2 or 3 weeks
40806827|NCT05609370|DRUG|Tislelizumab|Low dose IV once every 3 weeks
40806828|NCT05609370|DRUG|Tislelizumab|High dose IV once every 4 weeks
40806829|NCT05609370|DRUG|Bevacizumab biosimilar|7.5 mg/kg IV every 3 weeks
40806830|NCT05609370|DRUG|Bevacizumab biosimilar|5 mg/kg IV once every 2 weeks
40806831|NCT05609370|DRUG|Capecitabine|850 milligrams per square meter (mg/m\^2) twice daily orally for 2 weeks, followed by a one-week treatment break every 3 weeks
40806832|NCT05609370|DRUG|5-Fluorouracil|1600 to 2400 mg/m\^2 IV every 2 weeks
40806840|NCT06044337|DRUG|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
41153415|NCT05650580|DRUG|TR115|TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
41153416|NCT05672862|DEVICE|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
40806847|NCT05966090|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).
40806848|NCT05966090|BIOLOGICAL|HZ/su vaccine|Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.
41153417|NCT06102538|BEHAVIORAL|# The importance of service in the IDF # Physical activity # Healthy nutrition # Psychological support|# Education for the importance of service in the IDF # Education and training for physical activity adapted to abilities # Training for a healthy diet # Psychological support
40806850|NCT05970172|DRUG|Roxadustat|Oral
40806851|NCT01829568|DRUG|Ibrutinib|Given PO
40806852|NCT01829568|OTHER|Laboratory Biomarker Analysis|Correlative studies
40806853|NCT01829568|DRUG|Lenalidomide|Given PO
40806854|NCT01829568|OTHER|Pharmacological Study|Correlative studies
40806855|NCT01829568|BIOLOGICAL|Rituximab|Given IV
40806856|NCT05611255|PROCEDURE|Systematic Intermittent Catheterization|A strategy that consists of draining urine only once, in all patients, after surgery (in the operating room).
40806857|NCT05611255|PROCEDURE|Bladder Scan Guided Catheterization|A strategy of standardized and reproducible assessment of bladder volume before discharge from the post anesthesia care unit, and draining urine only in patients who require it.
40806858|NCT05783323|DRUG|Larotrectinib monotherapy|Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.
40806859|NCT05783323|RADIATION|131I therapy|Patients will receive 131I therapy after 6 months of larotrectinib.
40806860|NCT04058561|DEVICE|MAGEC® Spinal Bracing And Distraction System|The magnetically controlled growth rod (MCGR) system is a remotely distractible, magnetically controlled growing rod. The remote capabilities allow for less invasive and less time-consuming outpatient distraction visits, which solves many of the problems facing current growing rod technologies. The MCGR system allows for more frequent lengthenings, and the implanted growing rods can be lengthened more often, which allows MCGR to better approximate normal spine growth compared to Traditional Growing Rods.
41153418|NCT04118088|BIOLOGICAL|Darvadstrocel|Darvadstrocel suspension of human expanded adipose stem cells.
41153419|NCT05759000|DRUG|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT2) inhibitor is considered one of the four foundational therapies (ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors) for HFrEF (6). However, guidelines do not specify the sequence and the timing of which therapy to be commenced. In particular, dapagliflozin has been shown in randomized controlled trials to reduce the combined risk of cardiovascular death or HF hospitalization and improve quality of life in HF patients with both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), respectively, regardless of the presence or absence of diabetes in the DAPA-HF and DELIVER trials (
41153420|NCT04477954|COMBINATION_PRODUCT|Hyperbaric Oxygen|Hyperbaric oxygen therapy (HBOT): inhalation of pressurized oxygen through a hyperbaric chamber (Revitalair430)
41153421|NCT04601883|DRUG|Colchicine 0.5 MG|"The intervention tablets are commercially available Colchicine Tiofarma"
41153422|NCT04601883|DRUG|Placebo|Encapsulated placebo tablets. Placebo is identical to the active intervention.
41153423|NCT02653001|OTHER|Stool sample collection|Collection of complete stool sample
41008813|NCT05800054|RADIATION|Radiotherapy|image-guided intensity-modulated radiotherapy (IGRT) or intensity-modulated radiotherapy (IMRT); Irradiation targets include primary lesions, clinical targets, positive lymph nodes, and lymph node drainage areas. Dose splitting/prescription dose, 95% volume PGTV-T60-66Gy/30-35 times, PGTV-N 60-66Gy/30-35 times, PCTV-T 46-50Gy/23-25 times, PCTV-N46-50Gy/23-25 times.
41008814|NCT02691767|DRUG|pazopanib|
41153424|NCT01527500|DRUG|LFG316|LFG316 5 mg/50 μL solution for IVT injection,
41008815|NCT01173562|DRUG|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
41153425|NCT01527500|DRUG|Sham|Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
41153426|NCT01527500|DRUG|LFG316 Lower dose|LFG316 5 mg/50 μL solution for IVT Injection
41153427|NCT03369314|DRUG|octaplasLG®|Data will be collected in all patients who have received at least one infusion of octaplasLG®
41153428|NCT01678898|DRUG|PRX-102|
41153429|NCT06219902|DRUG|Elinzanetant (BAY3427080)|Oral administration of multiple doses of elinzanetant.
41153430|NCT06219902|DRUG|Placebo to elinzanetant|Oral administration
41153431|NCT06219902|DRUG|Zopiclone|Oral administration
41153432|NCT06219902|DRUG|Placebo to zopiclone|Oral administration
41153433|NCT03083600|DIETARY_SUPPLEMENT|Plant-based Protein Hydrolysate 1|Plant-based Protein Hydrolysate 2 for 12-weeks
41153434|NCT03083600|DIETARY_SUPPLEMENT|Plant-based Protein Hydrolysate 2|Plant-based Protein Hydrolysate 2 for 12-weeks
41153435|NCT03083600|DIETARY_SUPPLEMENT|Placebo|Cellulose Placebo for 12-weeks
41153436|NCT00513461|DRUG|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given PO
41153437|NCT00513461|OTHER|placebo|Given PO
41153438|NCT00513461|OTHER|laboratory biomarker analysis|Correlative studies
41153439|NCT00513461|OTHER|immunoenzyme technique|Correlative studies
41153440|NCT00513461|OTHER|high performance liquid chromatography|Correlative studies
41153441|NCT04596358|OTHER|Observational|Evaluation of adherence to the Mediterranean diet through the administration of the Med Diet Score questionnaire.
40806869|NCT04428788|DRUG|CC-94676|Specified dose on specified days
40806870|NCT04428788|DRUG|CC1083611|Specified dose on specified days
40806871|NCT04428788|DRUG|CC1083610|Specified dose on specified days
41153442|NCT04903912|DIAGNOSTIC_TEST|Vascular ultrasound or other imaging methods according to current guidelines|Peripheral vascular ultrasound / ankle/brachial index / CT angiography / MR angiography / angiography
41153443|NCT04903912|DIAGNOSTIC_TEST|Laboratory tests|Metabolic profile and platelet reactivity
41153444|NCT04903912|DRUG|Medical treatment according to current guidelines|Antithrombotic drugs, lipid-lowering drugs, antihypertensive drugs, and pharmacotherapy to increase walking capacity according to current guidelines
40806875|NCT06401694|OTHER|Home-delivered meals|Delivery of prepared meals compliant with Older Americans Act nutrition programs guidelines
40806876|NCT06401694|OTHER|Wellness check and socialization visit|At-home delivery with opportunity for driver observation and interaction
40806877|NCT06401694|BEHAVIORAL|Community Health Worker calls|Calls from a certified Community Health Worker (CHW) to assess needs, identify gaps in care and resources, and then support health and resource coordination
40806878|NCT06401694|OTHER|Supplemental grocery bag|Monthly delivery of a grocery bag containing a variety of nutritionally balanced foods and educational materials
40806879|NCT04741789|DRUG|Capmatinib|Tablet for oral use, dose Up to 400mg, twice daily
40806880|NCT04521686|DRUG|LY3410738|Oral LY3410738
40806881|NCT04521686|DRUG|Gemcitabine|Intravenous gemcitabine
40806882|NCT04521686|DRUG|Cisplatin|Intravenous cisplatin
40806883|NCT04521686|DRUG|Durvalumab|Intravenous durvalumab
40806884|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using liposomal bupivacaine and bupivacaine mixture|Liposomal bupivacaine and bupivacaine mixture were used for transverse thoracic muscle plane block (TTMPB) in experimental group.
40806885|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using bupivacaine hydrochloride|Bupivacaine hydrochloride was used for transverse thoracic muscle plane block (TTMPB) in active control group.
40806886|NCT04476901|BIOLOGICAL|allogeneic human mesenchymal stem cells (hMSCs)|allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).
41008816|NCT05770466|DRUG|P1101 (Ropeginterferon alfa-2b)|"1. Name: P1101 (Ropeginterferon alfa-2b)~2. Dosage form: pre-filled syringe~3. Strength: A single dose of 250 mcg/0.5 mL~4. Dosage and administration: 250 mcg per subcutaneous injection~5. Mechanism of action (if known): Interferon work by binding to specific membrane receptors on the cell surface which in turn induce a complex sequence of intracellular events. These events include the induction of particular enzymes, suppression of cell proliferation, inhibition of virus replication in virus infected cells and immunomodulating activities.~6. Pharmacological category: Antineoplastic and immunomodulating agents/ Immunostimulants/ Cytokines"
41008817|NCT05770466|PROCEDURE|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
41153445|NCT04903912|PROCEDURE|Endovascular od surgical peripheral revascularizations|Endovascular od surgical peripheral revascularizations according to current guidelines
40806887|NCT04476901|OTHER|Placebo|Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)
40806888|NCT04003051|OTHER|Internet-Based Intervention|Use Project Prepare website
40806889|NCT04003051|OTHER|Quality-of-Life Assessment|Ancillary studies
40806890|NCT04003051|OTHER|Questionnaire Administration|Ancillary studies
40806891|NCT06646965|PROCEDURE|individual dietetic counseling|only the pregnant patient receives dietetic counseling
40806892|NCT06646965|PROCEDURE|family-based dietetic conseling|the pregnant patient and her companion receive dietetic counseling
40806893|NCT04458532|OTHER|Aerobic Training|300 min/wk for 16 weeks
40806894|NCT04458532|OTHER|Aerobic Training|150 min/wk for 32 weeks
40806895|NCT04458532|OTHER|Aerobic Training|300 min/wk for 32 weeks
40806896|NCT04458532|OTHER|Aerobic Training|150 min/wk for 16 weeks
40806897|NCT05420961|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
40806898|NCT05420961|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension
40806899|NCT05420961|BIOLOGICAL|PPSV23|Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
40806900|NCT05838378|OTHER|Package image sorting with pictorial warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with pictorial warnings on each pack.
40806901|NCT05838378|OTHER|Package image sorting with Surgeon General text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with Surgeon General text-only warnings on each pack.
40806902|NCT05838378|OTHER|Package image sorting with FDA text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with FDA text-only warnings on each pack.
41153446|NCT03572998|DRUG|Indocyanine Green (ICG)|Injection of ICG as a fluorophore for Near Infrared fluorescence Imaging (NIRF)
41153447|NCT00464737|DRUG|Rotigotine|Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
40806904|NCT06244771|DRUG|FMC-376|Oral Capsule
41153448|NCT00464737|DRUG|Rotigotine|Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
41153449|NCT00464737|OTHER|Placebo|Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
41153450|NCT00297089|DRUG|ABT-751|200 mg ABT-751 daily for 14 days every 21 days
41153451|NCT00297089|DRUG|pemetrexed|Standard pemetrexed every 21 days
40806909|NCT06285643|DRUG|AAV2-GDNF Gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
40806910|NCT06285643|PROCEDURE|Control Surgery|Bilateral partial burr/twist holes without dural penetration
41153452|NCT00297089|DRUG|placebo|Placebo daily for 14 days every 21 days
41153453|NCT03063346|DIETARY_SUPPLEMENT|Protein hydrolysate high dose|
41153454|NCT03063346|DIETARY_SUPPLEMENT|Protein hydrolysate low dose|
40806914|NCT05170724|DRUG|Remibrutinib|Remibrutinib should be taken in accordance with the recommendations in the treatment plan.
41153455|NCT03063346|DIETARY_SUPPLEMENT|Placebo|
41153456|NCT03612258|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging scans will be completed to assess neural responses to painful, non-painful sensory, and emotion-eliciting stimuli.
41478581|NCT00888784|DRUG|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
40806917|NCT05027633|DRUG|Pembrolizumab|given by IV
40806918|NCT05027633|DRUG|Docetaxel|given by IV
40806919|NCT05027633|DRUG|Cisplatin|given by IV
40806920|NCT05027633|DRUG|Carboplatin|given by IV
41153457|NCT05499117|DEVICE|Light terapy|Carex Day-Light Classic, Light intensity is white Light, 10000UX, and color temperature is 4000K
41153458|NCT05499117|DEVICE|pseudo-light therapy|The pseudo-light stimulation group was red light with intensity less than 100lux
41153459|NCT04419532|DRUG|DS-1055a|"Administered as an intravenous infusion on Day 1 of every 21-day cycle following low dose administration(s) in priming dose period.~Infusion duration: 180 minutes for the first infusion, and if no infusion-related reaction, 120 minutes for subsequent infusions"
41153460|NCT03137654|OTHER|Affective Training|Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with emotionally salient stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
41153461|NCT03137654|OTHER|Neutral Training|Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with neutral stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
41008818|NCT01651572|DRUG|Cisatracurium|"Cisatracurium (Nimbex):~* initial dose: 0.2 mg/kg~* maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
40806926|NCT05882877|DRUG|Rocatinlimab|Subcutaneous (SC) injection
40806927|NCT05882877|OTHER|Placebo|SC injection
40806928|NCT06025695|COMBINATION_PRODUCT|GSK's liquid oral live attenuated HRV|2 doses of GSK's liquid oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
40806929|NCT06025695|COMBINATION_PRODUCT|PCV-free liquid formulation of GSK's oral live attenuated HRV|2 doses of PCV-free liquid formulation of GSK's oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
40806930|NCT06492174|DEVICE|AGENT DCB 40 mm|Drug coated PTCA balloon catheter 40 mm size
40806931|NCT06545955|DRUG|Nadofaragene Firadenovec|vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
40806932|NCT06545955|DRUG|Gemcitabine|Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel.
40806933|NCT06545955|DRUG|Docetaxel|Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine.
41008819|NCT01651572|DRUG|Rocuronium|"Rocuronium (Esmeron):~* initial dose: 0.6 mg/kg~* maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
40806934|NCT06545955|DRUG|Pembrolizumab|Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion.
40806935|NCT05334069|OTHER|Questionnaire Administration|Complete questionnaire
40806936|NCT05334069|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
40806937|NCT00359684|DRUG|Cysteamine|Cystine-depleting agent
40806939|NCT04850222|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
40806940|NCT04850222|DRUG|Calcium|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
40806941|NCT06285097|DRUG|PF-07820435|immune agonist
40806942|NCT06285097|BIOLOGICAL|Sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
41153462|NCT06585631|BEHAVIORAL|CC PrTNER|Participants randomized to CC PrTNER will be assigned a peer coach. They will conduct interviewer-administered behavioral surveys. The surveys provide an in-depth assessment of SU, HIV prevention and care, engagement, and adherence. Behavioral surveys are administered monthly. The coach will discuss with the participant the areas that are flagged by the psychiatrist; provide psychoeducation around areas identified, and work with the participant to identify their health goals and how changes in SU may help feed into self-defined goals. The coach will meet weekly with the consultant addiction psychiatrist who will make a provisional diagnosis and define a treatment plan with clear goals for treatment outcome. Recommendations will be communicated electronically to the HIV or PrEP provider to facilitate implementation. The coach utilizes MI skills to implement the individually tailored to facilitate the adoption and maintenance of health behaviors.
41153463|NCT04485793|DIETARY_SUPPLEMENT|Dietary supplement|"Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM).~Oral administration: 1 tablet/day at evening meal"
41153464|NCT04485793|OTHER|Placebo|Oral administration: 1 tablet/day at evening meal
41153465|NCT03978299|DIAGNOSTIC_TEST|Positive Prostate-Specific Antigen test result|Positive PSA test result as part of opportunistic screening or due to the presence of symptoms suggestive of disease.
41153466|NCT00472056|DRUG|Carmustine|300 mg/m\^2 IV for 1 Day
41153467|NCT00472056|DRUG|Etoposide|Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
41153468|NCT00472056|DRUG|Cytarabine|Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
41153469|NCT00472056|DRUG|Melphalan|140 mg/m\^2 IV x 1 Day
41153470|NCT00472056|DRUG|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion.
41153471|NCT02943109|OTHER|High Touch|"Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient."
41153472|NCT02943109|OTHER|Low Touch|"Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control)."
40806954|NCT05800015|DRUG|fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
40806955|NCT05800015|DRUG|cemiplimab|Administered IV Q3W
40806956|NCT05800015|DRUG|Pemetrexed|IV Infusion, Q3W
40806957|NCT05800015|DRUG|Paclitaxel|IV Infusion, Q3W
40806958|NCT05800015|DRUG|Carboplatin|IV Infusion, Q3W
40806959|NCT05800015|DRUG|Cisplatin|IV infusion, Q3W
40806960|NCT05800015|DRUG|Placebo|IV infusion, Q3W
41153473|NCT02943109|OTHER|High Tech|Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.
40806962|NCT03172754|DRUG|Nivolumab|PD-1 inhibitor
40806963|NCT03172754|DRUG|Axitinib|Tyrosine kinase inhibitor
40806964|NCT06423183|BEHAVIORAL|A Mindful Approach to Building a Resilient Healthcare Workforce (RENEW)|Synchronous, 4-month intervention that teaches skills in mindfulness, stress management, and resilience as an individual and as a team. Sessions occur monthly and include a 1 hour in-person introductory session followed by 3 50-minute virtual sessions.
41153474|NCT02943109|OTHER|Low Tech|Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.
41153475|NCT03660254|BEHAVIORAL|tai chi|tai chi exercise intervention，two times a week and each time cost one hour
41153476|NCT03999697|DRUG|Autologous chimeric antigen receptor T cell transfusing agent targeting CD22|The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
41153477|NCT04747496|DRUG|Edoxaban|This is a non-interventional, observational study.
41478582|NCT02609412|OTHER|Static compression of LMTRP|Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
41153478|NCT03162523|RADIATION|High-Dose Rate Brachytherapy|
40806970|NCT05935358|DRUG|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
40806971|NCT05673148|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SABR
40806972|NCT05673148|PROCEDURE|Resection|undergo surgical resection
41153479|NCT01554371|DRUG|Eribulin|"Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only"
40806973|NCT05673148|PROCEDURE|Microwave Ablation|undergo microwave ablation
40806974|NCT05673148|DRUG|Chemotherapy|Receive SOC chemotherapy
40806975|NCT05673148|PROCEDURE|Computed Tomography|Undergo CT scan
40806976|NCT05673148|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40806977|NCT05673148|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40806978|NCT00479128|DRUG|Bortezomib|Starting dose: 0.8 mg/m\^2 IV Over 3-5 Seconds
40806979|NCT00479128|DRUG|Gemcitabine|Starting dose: 225 mg/m\^2 IV Up to 90 Minutes
40806980|NCT00479128|DRUG|Doxorubicin|Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes
40806981|NCT05532735|BIOLOGICAL|ANXV|ANXV (Human recombinant Annexin A5 protein)
40806982|NCT04585750|DRUG|PC14586|First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.
40806983|NCT04585750|DRUG|pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
41153480|NCT01554371|DRUG|Cyclophosphamide|Given IV
40806985|NCT04790279|DRUG|Amlodipine|Initiation of amlodipine 2.5 mg
40806986|NCT04790279|DRUG|NIFEdipine ER|Initiation of nifedipine ER 30 mg
40806987|NCT06249555|DRUG|Vedolizumab (VDZ)|Participants will receive VDZ as part of routine care.
40806988|NCT06249555|DRUG|Ustekinumab (UST)|Participants will receive UST as part of routine care.
40806989|NCT06249555|DRUG|Risankizumab (RISA)|Participants will receive RISA as part of routine care.
41153481|NCT00082784|DRUG|Bortezomib|Given IV
41153482|NCT00082784|DRUG|Alvocidib Hydrochloride|Given IV
41153483|NCT00082784|OTHER|Pharmacological Study|Correlative studies
41153484|NCT04958629|OTHER|familial hypercholesterolemia|Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.
41153485|NCT05835037|DRUG|Zinc Gluconate 30 MG|Participants will take one tablet per day (30 mg Zinc gluconate) for 1 year
41153486|NCT05835037|DRUG|Placebo|Participants will take one placebo tablet per day for 1 year
41153487|NCT05308199|OTHER|thoracic manipulation|thoracic manipulation for unlocking of facet joints
41153488|NCT05308199|OTHER|muscle enegy technique|to release muscle spasm of cervical musces
41153489|NCT05800990|BEHAVIORAL|dietary intervention|Research participants will be assigned to two dietary conditions.
41153490|NCT04312971|DRUG|Placebo|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
41153491|NCT04312971|DRUG|Norepinephrine|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.
41153492|NCT04312971|OTHER|Increase infusion rate|Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments
41153493|NCT04312971|OTHER|Decrease infusion rate|Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements
41008820|NCT01899469|PROCEDURE|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
41008821|NCT01899469|PROCEDURE|Transcutaneous Electrical Neurological Stimulation|"Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)~20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home."
41008822|NCT01899469|PROCEDURE|Back School|25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
41008823|NCT00417443|DRUG|Clonidine|
41153494|NCT00060268|DRUG|HPPH|iv
41153495|NCT03441737|BEHAVIORAL|Exercise|20 minutes of aerobic exercise (walking on a treadmill) at 2/3 of participant's maximum heart rate (maximum heart rate calculated as 220-age).
41153496|NCT03441737|BEHAVIORAL|Non-Exercise|20 minutes of sitting in the laboratory with access to magazines and the internet.
41153497|NCT00561275|BIOLOGICAL|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
41153498|NCT05153499|BIOLOGICAL|CP101|CP101 is an investigational microbiome therapeutic designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent Clostridioides difficile infection (CDI).
41153499|NCT05153499|OTHER|Placebo|Placebo
41153500|NCT05116865|BIOLOGICAL|HH-120 Dose 1|Dose level 1 of HH-120
41153501|NCT05116865|BIOLOGICAL|HH-120 Dose 2|Dose level 2 of HH-120
41153502|NCT05116865|BIOLOGICAL|HH-120 Dose 3|Dose level 3 of HH-120
41153503|NCT05116865|DRUG|Placebo|Placebo to match
41153504|NCT00984347|DRUG|Oxytocin|"For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas \[6th delivery and up\] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol"
41153505|NCT00984347|PROCEDURE|breast pump nipple stimulation|breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
41153506|NCT01844362|PROCEDURE|uterine transplantation|Transplantation of the uterus from live donor and IVF treatment.
41153507|NCT01325519|OTHER|video decision aid|video
41153508|NCT06647095|DIETARY_SUPPLEMENT|D-Limonene Gelcaps|Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups
41153509|NCT06647095|DIETARY_SUPPLEMENT|Fish Oil Concentrate, 1000 Mg Oral Capsule|Capsules containing fish oil will be optionally given during the breath test to all participants of all groups
41153510|NCT02843698|DRUG|Dexmedetomidine|Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
41153511|NCT02843698|DRUG|Normal saline|Normal saline
41153512|NCT05544539|DRUG|Ozone-Based Agent|In the study group Ozone oil was placed inside the socket of the extracted tooth following suturing of the flap
41153513|NCT05544539|DRUG|Placebo|In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
41153514|NCT00518310|DRUG|Placebo|
41153515|NCT00518310|DRUG|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
41153516|NCT00749671|DEVICE|Bispectral index monitoring|The monitoring of the EEG signal is designed to determine if the sedation is adequate.
41153517|NCT00749671|OTHER|Ramsey Sedation Scale|The determination of the degree of sedation is accomplished using an established sedation scale.
41153518|NCT00553800|DRUG|bevacizumab|
41153519|NCT00553800|DRUG|Erlotinib|
41153520|NCT03729999|DEVICE|Portable, Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
41153521|NCT06086665|DRUG|Niraparib|Niraparib
41478583|NCT02609412|OTHER|Dynamic self-myofascial release of calf|Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
41153522|NCT03460444|DIETARY_SUPPLEMENT|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days. Dosing will begin at 5ml/dose for Days 1-2, 10ml for Days 3-4, and 15ml for the remainder of the intervention.
41153523|NCT02931994|OTHER|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
41153524|NCT04758156|DRUG|CleanViewAL|1L PEG + ascorbic acid bowel preparation for colonoscopy
41153525|NCT04758156|DRUG|SUPREP|Oral sulfate solution for colonoscopy bowel preparation
41153526|NCT05257434|BEHAVIORAL|inbody|Body fluid composition
41478584|NCT02609412|DEVICE|Placebo laser acupuncture of LMTRP|Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
41478585|NCT02898103|DEVICE|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 5 minutes in the recovery room
41478586|NCT02898103|DEVICE|Sham stimulation|Sham (placebo) stimulation for 5 minutes in the recovery room
41478587|NCT02898103|DEVICE|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 2-4 weeks at home
41153527|NCT06559098|DEVICE|Vibrotactile coordinated reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain
40807006|NCT06025942|BEHAVIORAL|Purrble intervention|"When the Purrble is picked up, it emits a frantic heartbeat that slows down if the person uses calm stroking movements. If the Purrble is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to young people in emotional moments when they would attempt to utilise emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in young peoples' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2.~* see JMIR Res Protoc 2021;10(11):e28914 (doi: 10.2196/28914)"
41153528|NCT04715711|OTHER|Forearm coolng|forearm immersion will be performed for active cooling assessment
41478588|NCT02504723|DRUG|carvedilol|Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure \>90 mm Hg.
41478589|NCT02504723|DRUG|cyanoacrylate|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
41478590|NCT03382249|COMBINATION_PRODUCT|Sonodynamic therapy (SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
41153529|NCT04715711|OTHER|Wet-towel cooling|Wet towels will be wrapped around the participant's arms for active cooling
41153530|NCT04715711|OTHER|mist-fan|a mist-fan will be placed in front of the participant for active cooling
41153531|NCT04715711|OTHER|passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
41153532|NCT05733013|OTHER|Surveillance Visit|Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
41153533|NCT02468037|PROCEDURE|Phlebotomy|Patients donate blood until tissue iron levels are in the lowest quartile of normal.
41153534|NCT01374971|DRUG|Certolizumab Pegol (CZP)|CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
41153535|NCT01374971|PROCEDURE|Arthroscopic synovial tissue biopsy|Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
41153536|NCT01738087|DRUG|NEXThaler 100/6 mcg DPI|
41153537|NCT01738087|DRUG|Flixotide Accuhaler 500 mcg|Active comparator
41153538|NCT01738087|DRUG|NEXThaler 200/6 mcg DPI|
41153539|NCT01738087|DRUG|NEXThaler placebo|Placebo comparator
41153540|NCT06027008|DEVICE|Mechanical Insufflation-Exsufflation|"MI-E will be applied twice a day in invasively ventilated patients. Since the severity of illness can change in the ICU, each day the attending nurse will check for clinical reasons to not apply MI-E with regard to safety. The following clinical criteria are predefined as a reason to refrain from MI-E at that day:~* severe ventilator instability (requiring \> 12 cm H2O PEEP and dependency of \> 60% FiO2);~* severe hemodynamic instability (a need for large and sustained increase in continuous administration of intravenous vasopressive medication that are adjusted on a frequent basis in each nursing shift);~* extra corporal membrane oxygenation (ECMO); and~* deeply sedated patient (RASS score ≤ -4)."
41478591|NCT03382249|COMBINATION_PRODUCT|pseudo-SDT|Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
41478592|NCT06490003|DRUG|Fluoro Uracil|Esophageal cancer chemotherapy（First line treatment)
41153541|NCT01860222|PROCEDURE|SR|
41153542|NCT01860222|PROCEDURE|PLAT|
41153543|NCT05959447|DRUG|Camlipixant + Gemfibrozil|Camlipixant will be administered alone as well as in co-administration with gemfibrozil
41153544|NCT05959447|DRUG|Dabigatran etexilate + camlipixant|Dabigatran etexilate will be administered alone as well as in co-administration with camlipixant
41153545|NCT01116830|DRUG|Placebo|Orally daily for 6 weeks
41153546|NCT01116830|DRUG|RO4917838|10 mg daily orally for 6 weeks
41153547|NCT01116830|DRUG|Standard Antipsychotic Therapy|Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
41153548|NCT00966056|DRUG|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
41153549|NCT00966056|DEVICE|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
40807019|NCT06482203|OTHER|Trunk Extensor Endurance training & Scapular mobilization|"Trunk Extensor Endurance Training Level 1:Prone shoulder extension or prone shoulder raises Level 2: Prone back extension Level 3: Prone Ys or Y raises Level 4:Super man pose Level 5:Super man or prone cobra~(The given position should be hold for 10 seconds and performs 25 repetitions with 3 sec rests in between the efforts)~Scapular Mobilization:~Intervention program includes, supero-inferior, medio-lateral along with circumduction movements).~3 sets of 10-15 repetitions of each of the supero-inferior ,medio-lateral, and circumduction movements Between each session, there was a10 or 30-second break. The length of rests was adjusted depending on the patient's endurance"
40807020|NCT05645406|DRUG|Estrogel 0.06 % Topical Gel|estradiol topical products
40807021|NCT05645406|DRUG|Compounded estradiol product|estradiol topical products
40807022|NCT06215118|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
40807023|NCT06215118|DRUG|Iberdomide|cereblon-modulating agent
40807024|NCT05130632|BEHAVIORAL|The community working group|"The intervention consists of educational working group (WG) sessions over a 12-week period. Eight core modules-the essential ingredients-and 4 periphery modules to help identify community-driven interventions to reduce plastic burning in household fires, consume less plastic, recycle, and repurpose plastic, will be held.~Participants will prioritize 1 task that can be attained in the next 9 months, with the guidance of community workers (promotoras), such as: -starting an organic compost pile free of plastic waste -training on community recycling, focusing on plastics recycling -making organic soaps, to use for personal grooming or washing clothes, eliminate plastic packaging -creating materials out of plastic, like bottle planters, crocheted plastic bags, purses."
41153550|NCT05719155|DRUG|CKD-379|1 tablet administration under fed condition
40807026|NCT05868265|DRUG|Enfortumab Vedotin|All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles.
40807027|NCT05868265|PROCEDURE|Radical surgery|Radical surgery, such as radical nephroureterectomy, nephrectomy or ureterectomy is to take place within 60 days from the last dose of treatment end of cycle 3 (i.e., cycle 3 day 22).
40807028|NCT01274338|BIOLOGICAL|Ipilimumab|Given IV
40807029|NCT01274338|OTHER|Quality-of-Life Assessment|Ancillary studies
40807030|NCT01274338|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV and SC
41153551|NCT05719155|DRUG|D759+D745+D150|3 tablet coadministration under fed condition
41153552|NCT02158793|PROCEDURE|Craniomaxillofacial allotransplantation|Transplantation of donor face
40807033|NCT04645680|OTHER|Dietary Intervention|Consume isocaloric whole foods diet higher in fiber
40807034|NCT04645680|OTHER|Dietary Intervention|Whole foods diet
40807035|NCT04645680|OTHER|Quality-of-Life Assessment|Ancillary studies
40807036|NCT04645680|OTHER|Questionnaire Administration|Ancillary studies
40807037|NCT05307705|DRUG|LOXO-783|Oral
41008824|NCT02006238|DEVICE|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
40807038|NCT05307705|DRUG|Fulvestrant|Intramuscular
41008825|NCT02006238|DEVICE|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
41008826|NCT00222287|BEHAVIORAL|Feldenkrais Movement class|
41008827|NCT03364049|DRUG|MK-7162|oral tablets
41008828|NCT03364049|BIOLOGICAL|Pembrolizumab|IV infusion
41008829|NCT00001720|DRUG|Alendronate|
41008830|NCT01545921|OTHER|Quality Of Life questionnaires completion|"Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D."
40807039|NCT05307705|DRUG|Imlunestrant|Oral
40807040|NCT05307705|DRUG|Abemaciclib|Oral
41153553|NCT03263104|DIETARY_SUPPLEMENT|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402
41153554|NCT03263104|DIETARY_SUPPLEMENT|Maltodextrin|
41153555|NCT04380038|DRUG|Dupilumab Injectable Product|Nasal inoculation, single dose 300 TCID50 in 1ml.
41153556|NCT05118009|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
41153557|NCT04374019|DRUG|Ivermectin|"Ivermectin:~Days 1-2: Weight \< 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight \> 75kg: 5 tabs (15 mg total daily dose)"
41153558|NCT04374019|DRUG|Camostat Mesilate|Days 1-14: 2 tab TID after a meal (600 mg total daily dose)
41153559|NCT04374019|DIETARY_SUPPLEMENT|Artemesia annua|Days 1-14: tea or coffee pod TID (1350 mg total daily dose)
41153560|NCT04374019|DRUG|Artesunate|Days 1-14:
41153561|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg|MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
41153562|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg|MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
40807041|NCT05307705|DRUG|Anastrozole, Exemestane, or Letrozole|Oral
40807042|NCT05307705|DRUG|Paclitaxel|Intravenous
41153563|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg|MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
41153564|NCT01502371|DRUG|Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg|MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks
41153565|NCT01502371|DRUG|Placebo Metered Dose Inhaler (MDI)|Placebo MDI, 2 puffs BID for 12 weeks
41153566|NCT01502371|DRUG|Placebo Dry Powder Inhaler (DPI)|Placebo DPI, 1 puff QD for 12 weeks
41153567|NCT06478056|PROCEDURE|pancreatectomy|patients operated on for pancreatic adenocarcinoma in the digestive surgery department of Rouen University Hospital
41153568|NCT06153901|PROCEDURE|endoloop mediated cardioplication (ECLC) procedure|The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
41153569|NCT02572778|PROCEDURE|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
41153570|NCT00640042|DRUG|morphine sulfate extended release capsules|30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
41153571|NCT00644735|DRUG|Esomeprazole|
41153572|NCT00644735|DRUG|Lansoprazole|
41153573|NCT00328276|DRUG|Sarcosine|
40807054|NCT05645393|DRUG|topical estrogen product|estrogen topical gel or cream
41153574|NCT03327688|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed by an emergency physician
41153575|NCT03322475|DEVICE|PiQo4 laser system|The PiQo4 laser system
41153576|NCT00473512|DRUG|Abiraterone acetate|Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
41153577|NCT00473512|DRUG|Abiraterone acetate MTD|Abiraterone acetate MTD orally for 12 cycles (28 day each).
41153578|NCT00473512|DRUG|Dexamethasone|Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
41153579|NCT02652299|BIOLOGICAL|Synovial biopsy|Synovial tissue for analysis and biobank.
41153580|NCT03468387|PROCEDURE|Primary realignment|Endoscopic realignment of rupture urethra over a urethral catheter
41153581|NCT03468387|PROCEDURE|Suprapubic cystostomy|Percutaneous cystostomy catheter will be inserted under sonographic guidance
41324655|NCT04744610|DIAGNOSTIC_TEST|Add 4-hour delayed radiographs|Normal patients only need to take delayed radiographs 24h after HSG operation. In this study, 4-hour delayed radiographs were added to the 24-hour delayed radiographs, so that the patients had to take one more delayed radiographs .
41478593|NCT05197829|DEVICE|Continuous Glucose Monitoring|Participants in the experimental arm will receive an unblinded flash continuous glucose monitor.
40807066|NCT01167712|BIOLOGICAL|Bevacizumab|Given IV
40807067|NCT01167712|DRUG|Carboplatin|Given IV
40807068|NCT01167712|PROCEDURE|Computed Tomography|Correlative studies
40807069|NCT01167712|DRUG|Paclitaxel|Given IV
40807070|NCT01167712|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40807074|NCT03995550|DRUG|LEO 142397|A compound in development by LEO Pharma A/S
40807075|NCT03995550|DRUG|Placebo|Placebo
40807076|NCT05139329|DIAGNOSTIC_TEST|Imaging|To better understand the prevalance of further imaging for evaluation of myocarditis, all patients with negative workup will be included and see what number of patients undergo further CMRI, FGD-PET, or speckle tracking echocardiography. Patients will then be categorized as those with myocarditis with positive diagnosis, negative diagnosis or unknown.
40807078|NCT06549595|DRUG|AZD0486|a fully human bispecific monoclonal IgG4 antibody
40807079|NCT06549595|DRUG|R-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
40807080|NCT06549595|DRUG|R-CVP|Rituximab, Cyclophosphamide, Vincristine and Prednisone
40807081|NCT06549595|DRUG|BR|Bendamustine, Rituximab
40807082|NCT05315115|OTHER|Sham intervention|The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust.
40807083|NCT05315115|OTHER|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
40807084|NCT05315115|OTHER|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Spinal Cord Injuries children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
40807085|NCT04566900|BEHAVIORAL|Neurofeedback|Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
40807086|NCT04566900|OTHER|Placebo|Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.
41153582|NCT02934815|OTHER|Supportive-expressive group therapy|The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
40807088|NCT06489678|DIAGNOSTIC_TEST|Robotic Assisted Bronchoscopy|Cone-beam computed tomography (CBCT) technology and robotic-assisted bronchoscopy (RAB) present promising methods to enhance biopsy accuracy and procedural safety through 3-dimensional reconstructions and increased bronchoscope tip flexibility. Additionally, the transfer of navigational data between CBCT and RAB may further improve diagnostic yield. Given their distinct approaches to enhancing diagnostic outcomes, two separate study arms are warranted for CBCT and RAB.
40807089|NCT02101905|OTHER|Laboratory Biomarker Analysis|Correlative studies
40807090|NCT02101905|DRUG|Lapatinib|Given PO
40807091|NCT02101905|DRUG|Lapatinib Ditosylate|Given PO
40807092|NCT02101905|OTHER|Pharmacological Study|Correlative studies
40807093|NCT02101905|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
41008831|NCT06158737|DRUG|JS010 injection|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
41008832|NCT06158737|DRUG|Placebo|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
41324656|NCT01646463|BEHAVIORAL|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
41153583|NCT01924806|DEVICE|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
41153584|NCT01924806|DEVICE|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
41153585|NCT03652792|DRUG|Azilsartan (Zhaoke)|Azilsartan 20mg tablets from Zhaoke
41324657|NCT01646463|BEHAVIORAL|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
41153586|NCT03652792|DRUG|Azilsartan (Takeda)|Azilva 20mg tablets from Takeda
41153587|NCT03813602|DRUG|Cannabis Sativa|750 mg cannabis cigarette with 12.5% THC
41153588|NCT06326281|PROCEDURE|unilateral external oblique intercostal plane block group|USG guided external oblique intercostal plane block will perform unilateral with Bupivacaine 25 patient included and patients were observed for pain for 24 hours
41153589|NCT06326281|PROCEDURE|unilateral oblique subcostal transversus abdomınıs plane block group|USG guided oblique subcostal transversus abdomınıs plane block block will perform unilateral with Bupivacaine. 25 patient included and patients were observed for pain for 24 hours
41153590|NCT06326281|PROCEDURE|Local anesthetic infiltration group|Bupivacaine infiltration will be performed to trocar insertion sites. 25 patient included and patients were observed for pain for 24 hours
41153591|NCT06326281|DRUG|Control group|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol patient controlled analgesia. Tramadol at a concentration of 5 mg/mL is included in our patient controlled analgesia protocol (total volume 100 mL.) patient controlled analgesias were set to no basal infusion and 10 mg bolus doses with a 20 min lock time 25 patient included and patients were observed for pain for 24 hours
41153592|NCT05045638|DRUG|Rosuvastatin|Oral dose
41153593|NCT05045638|DRUG|Sotorasib|Oral dose
41324658|NCT00248378|DRUG|Smoked Cannabis|
41324659|NCT05035095|DRUG|Oral semaglutide|Participants will receive a daily dose of oral semaglutide.
41324660|NCT05035095|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
41324661|NCT04950842|BIOLOGICAL|JB-101|induced T cell with suppressive function
41153594|NCT04560192|BEHAVIORAL|Mindfulness based Emotion regulation therapy (MBERT) - Treatment as usual (TAU)|"1. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation.~2. Waiting period with TAU."
41324662|NCT02638870|DRUG|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
41008833|NCT05548244|BEHAVIORAL|Behavioral Activation Therapy|Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
41008834|NCT05548244|BEHAVIORAL|Baseline assessment procedures|Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Abbreviated Scale of Intelligence - 2nd Edition to assess IQ.
41008835|NCT00813124|DRUG|Fludarabine|40 mg/m\^2 by vein over 60 minutes on Day -5 through Day -2.
41008836|NCT00813124|DRUG|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
41008837|NCT00813124|DRUG|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
41324663|NCT02243917|DRUG|CB-5083|
41478594|NCT05197829|OTHER|Care Coordination|All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.
41478595|NCT01674413|DRUG|Adalimumab|Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38
41478596|NCT01674413|DRUG|Adalimumab PRN|"160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with~* PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,~* Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is \< 167 mcg/gram of stool."
41478597|NCT01674413|DRUG|Placebo|1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
41478598|NCT00177463|DRUG|L-carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
41478599|NCT03827564|DEVICE|Intranasal Tear Neurostimulator (ITN) [TrueTear®]|The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.
41478600|NCT02715219|OTHER|Asthma Education Programme|The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
41478601|NCT05473000|BEHAVIORAL|Exercise|Submaximal and maximal exercise
41478602|NCT05473000|OTHER|Ozone|Delivery of ozone air pollution at 170ppb
41478603|NCT05473000|OTHER|Room air|Delivery of room air
41478604|NCT04714151|DRUG|K-877 ER 0.2 mg/day (once daily)|K-877 ER 0.2 mg tablet
41478605|NCT04714151|DRUG|K-877 ER 0.4 mg/day (once daily)|K-877 ER 0.4 mg tablet
41478606|NCT04714151|DRUG|K-877 IR 0.2 mg/day (twice daily)|K-877 IR 0.1 mg tablet
41478607|NCT02560974|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
41324664|NCT03374644|DEVICE|SentriTM ETCO2 adult nasal cannula|Sentri nasal cannula is the device which designed to sample exhaled ETCO2 in non-intubated patients during the administration of supplementary oxygen. By delivering oxygen through one prong and sampling exhaled gas from the other prong, the nasal cannula can provide end tidal values comparable to those achieved with intubated patients. It is fitted to the patients as same manner as conventional nasal cannula. Furthermore, it consists of curved prong to improve the anatomical fit.
41478608|NCT02560974|DRUG|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m\^2 on Day 1 of each 3-week cycle for 8 cycles.
41478609|NCT06226922|OTHER|No intervention|No intervention
41478610|NCT04199117|DRUG|Varenicline|Participants randomized to intensive treatment who choose to use this intervention will receive one 0.5 mg pill for the first 3 days, starting 7 days prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. This will not be used at the same time as combination nicotine replacement therapy.
41324665|NCT05386121|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane deep to erector spinae muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline and observing the ﬂuid lifting the erector spinae muscle off the transverse process (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the spinous process on a parasagittal plane, to visualize the erector spinae muscle and transverse process, directing the needle craniocaudally using the in-plane technique. The spread of the injectate will be observed to distribute within this plane.
41478611|NCT04199117|DRUG|Combination nicotine patch and nicotine mini-lozenge treatment|Participants randomized to intensive treatment who choose to use this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges for use starting on the target quit date and the following 12 weeks. Participants will be instructed to use 9-20 mini-lozenges per day (one every 1-2 hours) for the first 6 weeks, then reduce to a mini-lozenge every 2-4 hours for 3 weeks, and then a mini-lozenge every 4-8 hours for 3 weeks. Combination nicotine patch and nicotine mini-lozenge treatment will not be used at the same time as varenicline.
41478612|NCT04199117|BEHAVIORAL|Monetary incentives for initiating treatment|Participants randomized to this intervention will earn an incentive each time they complete a first counseling session in an available treatment, up to 2 rounds of counseling per year, and up to 4 rounds of counseling over 2 years of enrollment.
41324666|NCT05386121|PROCEDURE|Ultrasound-guided Quadratus Lumborum Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane between the quadratus lumborum and psoas major muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the L2 spinous process on an axial plane, to visualize the transverse process with psoas major muscle anterior, quadratus lumborum muscle lateral and erector spinae muscle posterior to it. The needle is inserted from the medial side of the probe and advanced laterally using the in-plane technique. The spread of the injectate will be observed to distribute within the target plane.
40807100|NCT05730556|DEVICE|Nerivio ®|Non-invasive wearable, remote electrical neuromodulation (REN) device controlled by a smartphone application worn on an armband on the upper arm.
41008838|NCT00813124|DRUG|Azacitidine|Start cycles of 32 mg/m\^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
41324667|NCT05386121|DEVICE|Ultrasound Machine|Sonosite S-Nerve (USA) with a linear multi-frequency 6-13 MHz (hockey stick) transducer
41324668|NCT05386121|DEVICE|Echogenic needle|A 22-gauge 80 mm needle the sonoplex needle manufactured by PAJUNK (USA)
41324669|NCT05386121|DRUG|Fentanyl|Given intravenously (1 µg/kg) as part of induction of general anesthesia (GA) added to propofol 2 mg/kg and atracurium 0.5 mg/kg Intraoperatively, intravenous fentanyl 0.5 µg/kg (with a maximum dose of 2 µg/kg) will be administered in response to any increase in hemodynamics by more than 20% of baseline values in response to skin incision or there after throughout surgery (after exclusion of other causes of hemodynamic changes)
41324670|NCT05386121|DRUG|Pethidine|Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.
41008839|NCT00813124|PROCEDURE|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
41324671|NCT05399550|DRUG|Balovaptan|Intravenous Solution
41324672|NCT05399550|DRUG|Placebo|Matching Intravenous Solution
41478613|NCT04199117|BEHAVIORAL|Automated tailored outreach|Participants randomized to this intervention will receive 5 tailored letters delivered every 4-6 months. Letter content will be tailored to participant demographics and use of study treatment, and personalized with references to their primary care teams and tobacco care manager. Letters offer encouragement to quit and information about how to access available treatments.
40807101|NCT05730556|DEVICE|Sham|Electrical stimulation to mimic study treatment intervention
41008840|NCT03140202|DEVICE|CPRmeter (feedback device) with feedback|Participants have a real time feedback and record.
41008841|NCT03140202|DEVICE|CPRmeter (feedback device) without feedback|Participants have a real time record without feedback.
41008842|NCT00907920|OTHER|laboratory biomarker analysis|Correlative studies
41008843|NCT06499701|DRUG|Ringer's Lactate|Ringer's Lactate is administered at a dose of 30ml/kg, with the first 20ml/kg given at a constant rate over the initial 30 minutes, followed by a 30-minute pause, and then an additional 10ml/kg over the next 15 minutes, completing the infusion within 75 minutes.
41008844|NCT03229564|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
41324673|NCT03748277|PROCEDURE|Decompression|Bilateral decompression
41324674|NCT03748277|PROCEDURE|PLIF|Traditional open surgery
41324675|NCT03748277|PROCEDURE|MIS TLIF|On the one side - Wiltse approach, on the other side - percutaneous
41324676|NCT03748277|PROCEDURE|Screw Fixation|Transpedicular Screw Fixation
41324677|NCT03943173|DRUG|Chemotherapy|Given standard chemotherapy
40807102|NCT04428281|DRUG|RO7248824|In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of 48 weeks.
40807103|NCT03459534|DRUG|Radotinib HCl|"1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature."
40807104|NCT03419897|DRUG|Tislelizumab|Administered intravenously
41157149|NCT06123819|DEVICE|elastography|. First, strain elastography (it is based upon the fact that hard tissue is more difficulty compressed than soft tissue. SE is a technique that measures the tissue deformation generated by compression, which may be applied with a probe on the body surface for static imaging) will be performed. The elastogram image of the detected lesion, will be evaluated Using color coding ranging from blue, through green and red. All lesions will be scored on elastogram in terms of their Stiffness compared to normal parenchyma. Second, shear wave elastography (is a method to generate shear waves and measure SWV ,based on the principle of fast propagation of shear wave speed in hard tissue and slow propagation in soft tissue , the hardness of tissue is indirectly reflected by measuring shear wave speed ) , will also be calculated individually.
41324678|NCT03943173|DRUG|Olaparib|Given PO
40807107|NCT04327362|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
41008845|NCT03229564|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
41008846|NCT02424240|OTHER|IGF-1/IGFBP-3 ratio|IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 \& IGFBP-3 combination
41324679|NCT03943173|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41324680|NCT05475574|OTHER|Discontinuation of contact precautions for ESBLE|Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
41324681|NCT03061045|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
41324682|NCT04319406|PROCEDURE|Prolotherapy|Test group will be administered 12.5% Dextrose mainly into superior joint space according to symptoms of patient at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
41324683|NCT04319406|PROCEDURE|Dry needling|Only dry needling will be performed at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
40807108|NCT04327362|BEHAVIORAL|Prolonged Exposure Therapy|All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
40807109|NCT06014229|DEVICE|cryoablation|Single session with an argon-based cryoablation device; an specific applicator will be used for the treatments; gas release 100% for cryoablation; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
40807110|NCT06057935|DRUG|Pemetrexed|Pemetrexed will be administered intravenously
40807111|NCT06057935|DRUG|Cisplatin|Cisplatin will be administered intravenously
41008847|NCT04162951|PROCEDURE|Ordinary approach paravertebral block|Ultrasound guided thoracic paravertebral block. At the appropriate dermatome, the needle (22-gauge, 8-10-cm, short bevelled spinal needle, or a Touhy needle if a catheter is to be placed) is inserted 2.5-3 cm lateral to the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process at a variable depth (2-4 cm) depending on the build of the individual. The needle is then walked above the transverse process and gradually advanced until a loss of resistance to air or saline, or a subtle 'click' is felt as the superior costotransverse ligament is penetrated, usually within 1-1.5 cm from the superior edge of the transverse process.
41324684|NCT00992186|DRUG|Carlumab|Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
41324685|NCT00351091|DRUG|RISEDRONATE|
41324686|NCT00003194|BIOLOGICAL|filgrastim|
41324687|NCT00003194|DRUG|carboplatin|
41324688|NCT00003194|DRUG|cyclophosphamide|
41324689|NCT00003194|DRUG|etoposide|
41324690|NCT00003194|DRUG|thiotepa|
41324691|NCT00003194|DRUG|topotecan hydrochloride|
41324692|NCT00003194|PROCEDURE|peripheral blood stem cell transplantation|
41324693|NCT01331720|DRUG|hMG-HP|
41324694|NCT01677624|DEVICE|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
41324695|NCT00187629|BEHAVIORAL|dietary phosphorus|varying amts dietary phosphorus
41478614|NCT04199117|BEHAVIORAL|Care management|Participants randomized to this intervention will receive 5 live, proactive phone calls lasting 10-15 minutes from as assigned Tobacco Care Manager who will provide manualized support and motivational encouragement, discuss available treatment options, and inform the participant how to initiate treatment when ready to quit.
41478615|NCT04199117|OTHER|Wisconsin Tobacco Quit Line referral|This is recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. The Wisconsin Tobacco Quit Line (WTQL) offers a single 20-minute counseling session to all Wisconsin residents ready to set a date to stop smoking in the next month, at no charge, and offers those who meet their medical eligibility criteria a 2-week supply of either nicotine patches, lozenges, or gums, at no charge. The WTQL assumes full clinical responsibility for participants' use of cessation medications dispensed by the WTQL.
40807112|NCT06057935|DRUG|Carboplatin|Possible substitution with carboplatin based on clinician discretion
40807113|NCT03640325|BEHAVIORAL|PRISM (Promoting Resilience in Stress Management)|Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
41153595|NCT04560192|OTHER|Treatment as usual (TAU) - Mindfulness based Emotion regulation therapy (MBERT)|"1. Waiting period with TAU.~2. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation."
41008848|NCT04162951|PROCEDURE|Retrolaminar paravertebral block|In the retrolaminar approach to TPVB or retrolaminar block (RB), local anesthetic (LA) is injected into the retrolaminar plane to achieve a truncal sensory block like that of traditional TPVB. It has been postulated that during RB, LA spreads from the injection plane to the thoracic paravertebral space (TPVS) through the superior costotransverse ligament (SCTL). Retrolaminar block will be performed under ultrasound guidance, as a single injection.
41324696|NCT00554138|DRUG|placebo|1 dd for 7-10 days
41324697|NCT00554138|DRUG|rosuvastatin|1 dd 20 mg for 7-10 days
41324698|NCT06418126|BIOLOGICAL|blood sampling before radiotherapy|A blood sample (20 ml) will be taken prior to radiotherapy
41324699|NCT06418126|BIOLOGICAL|blood sampling after the fourth radiotherapy session|A blood sample (20 ml) will be taken immediately after the 4th radiotherapy session.
41324700|NCT06418126|OTHER|collection of acute toxicity (radiodermatitis)|for the entire duration of radiotherapy
41324701|NCT06418126|OTHER|collection of late toxicity|every year for 5 years
41324702|NCT06418126|OTHER|collection of disease status|throughout the study
41324703|NCT06418126|RADIATION|Radiotherapy - Breast +/- lymph node areas|40.05 Gy in 15 fractions of 2.67 Gy, one fraction per week, 5 days per week Or 50 Gy in 25 fractions of 2 Gy, one fraction per week, 5 days per week
41324704|NCT06418126|RADIATION|Radiotherapy - Boost operating bed|10 Gy in 4 fractions of 2.5 Gy, one fraction per week, 5 days per week Or 16 Gy in 8 fractions of 2 Gy, one fraction per week, 5 days per week
41324705|NCT01504048|PROCEDURE|Colonoscopy with Indigo-Carmine Chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
41324706|NCT02962219|BEHAVIORAL|Pre-operative Exercise Programme (my-PEP)|A pre-operative personalised exercise programme (my-PEP) consisting of: 1) actions to promote exercise, using behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a home exercise programme (HEP) - which is also current standard care, 4) a 4 week hospital-supervised aerobic and muscle strengthening programme (Hos-PEP) .
41324707|NCT02962219|BEHAVIORAL|Home Exercise Programme (HEP)|Written advice on exercise at home
41324708|NCT04731623|DRUG|ION904|ION904 will be administered by SC injection.
41324709|NCT04731623|DRUG|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection.
41478616|NCT04199117|OTHER|Primary care provider referral|This is a form of recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. Participants who choose to use this intervention will be referred electronically to their primary care provider for counseling and/or medication if they express an interest in quitting in the next 30 days and agree to this referral.
41478617|NCT04199117|BEHAVIORAL|Untailored outreach|Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
41478618|NCT04199117|BEHAVIORAL|Multiple smoking cessation coaching calls|Participants randomized to intensive treatment access who choose to quit will receive three 15-20-minute quit coaching calls from a trained smoking cessation health counselor. Calls will be scheduled for one week pre-quit, one day after the target quit day, and one week after the target quit day.
41478619|NCT06198036|OTHER|Hold-Relax Technique|Participants in this group will be treated with hold-relax PNF Technique
41478620|NCT06198036|OTHER|Muscle Energy Technique|Participants in this group will be treated with Muscle Energy Technique via Reciprocal Inhibition Mechanism
41478621|NCT02480582|OTHER|Almonds|Whole raw almonds provided as a mid-morning snack - 0.9g\\kg
41478622|NCT02480582|OTHER|Cheese Savouries|Cheese savoury crackers provided as a mid-morning snack - 0.9g/kg
41008849|NCT01912248|OTHER|strength training|strength training, lower limb.
41008850|NCT03620851|OTHER|effect of age|effect of age on the efficiency of enhanced recovery program
40807120|NCT05368259|DEVICE|AGBS|The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
41008851|NCT06055088|OTHER|Hand and foot exercise|"The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week.~Patients in the massage ball group will be given a massage ball to be used in exercises. Patients in the stress ball group will be given a stress ball to be used in exercises."
41008852|NCT01117727|DEVICE|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
41008853|NCT02134457|BIOLOGICAL|ranibizumab|
41008854|NCT06503588|OTHER|Guidelines promoting surgical abstention|Guidelines promoting surgical abstention
41008855|NCT04687956|PROCEDURE|LYMPHA|Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
41008856|NCT04687956|PROCEDURE|control|In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.
41008857|NCT04073316|DRUG|Rivaroxaban 20 MG|Rivaroxaban intake, 20mg/day
41153596|NCT02341599|DRUG|MK-6183|MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.
40807124|NCT06097533|DRUG|Cannabisextrakt Avextra 10/10 Lösung|medical cannabinoids
41478623|NCT02276079|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 - 0.7 × age).
41478624|NCT02276079|BEHAVIORAL|Non-Aerobic Exercise|Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
41478625|NCT05288868|OTHER|Educational Intervention: online didactic lecture and educational simulation activity|"The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief."
41478626|NCT02428179|PROCEDURE|StOP? - Control group|Control group - Surgical procedure without Study Intervention
41478627|NCT02428179|PROCEDURE|StOP? - Intervention group|Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
41478628|NCT03971149|BEHAVIORAL|EMPOWER|EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
41478629|NCT03902899|OTHER|Educational intervention (oral presentation)|A brief oral presentation (30-45 minutes) which focused on making endoscopists aware of the significance and characteristics of serrated polyps.
41478630|NCT01947231|OTHER|Global Postural Re-education|Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.
41478631|NCT01947231|OTHER|Standard manual physical therapy|Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
41478632|NCT02369120|OTHER|Educational intervention|The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
41478633|NCT02369120|OTHER|Normal care by GP|Patients will follow GP advice including NSAID medication if needed
41478634|NCT05044884|OTHER|Otago Exercise training|"1. Warm-up exercises. Chair March, Arm swings ( 30 second), Head movement, neck movement, back extension, trunk movement, ankle movement (repeat 5 times).~   Back of thigh stretch, calf stretch, (hold for 8 seconds).~2. Strengthening exercises Front knee strengthening, back knee strengthening, side hip strengthening (2 or more sets of 10 reps) Calf raises, toe raises (repeat this exercises 10 to 20 times)~3. Balance improvement exercises Knee bends, heel-toe standing, heel toes walking, one leg stand ( start with 5 sec move up to 10 sec) Side walk, heel walking, sit to stand, backwards walking, heel toes walking backwards, walking and turning around, stair walking (10 steps).~4. Cool-down session Back of thigh stretch, calf stretches ( 10 to 20 sec hold, 1 to 3 reps)~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles."
41008858|NCT04073316|DRUG|Warfarin|Warfarin intake, with target INR range between 2 and 3
41008859|NCT03126097|DRUG|JNJ-64155806 150 mg|JNJ-64155806 150 mg (3\*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] and on Days 60 to 66 \[JNJ-64155806 + COCP Coadministration Phase\].
41008860|NCT03126097|DRUG|Ethinylestradiol/drospirenone 0.02 mg/3 mg|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
41008861|NCT03126097|DRUG|COCP Placebo|Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
41008862|NCT00305617|OTHER|antitumor drug screening assay|
41008863|NCT00338195|BEHAVIORAL|Individualized caffeine cessation instructions|Intervention is described in the protocol
41478635|NCT05044884|OTHER|Circuit training|"1. Functional strength exercises Heel raise, toe raise, walking on toes, step ups in all directions ( forward, backward and sideways) (2 sets and 8 reps)~2. Stance exercises Tandem, narrow, one leg stance, and stand on uneven surfaces with open eyes (each exercise 30 seconds) Tandem, narrow, one leg stance, and stand on uneven surfaces with eyes closed (each exercise 15seconds).~3. Transition exercises Sit to stand from chair with arms (10 reps) and then without arms support (5 reps).~   Sit on floor and stand up with assistance and then without assistance.~4. Gait training Walking tandem, sideway and backward with arm support. Walking tandem, sideway and backward without arm support Walking tandem, sideway and backward over obstacles~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles"
41478636|NCT03918941|DEVICE|Carey|mobile application
41478637|NCT03918941|OTHER|conventional information|leaflet, internet link and oral information
41478638|NCT06091748|DRUG|68Ga-DOTATOC|Detection of somatostatin positive lesions in GEP-NETs
41008864|NCT02493634|PROCEDURE|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
41008865|NCT02493634|DEVICE|MRWire|
41008866|NCT01177033|OTHER|Best endovascular treatment or Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
41324710|NCT05314478|DEVICE|Continuous laryngoscopy during exercise test using the HALOS headgear|"The participant will undergo the CLE test following standard clinical practice.~The order of events of the aspects of the investigation related to the headgear will be:~1. The headgear is prepared for use.~2. The headgear is fitted onto the participant's head.~3. The endoscope is inserted into the participant.~4. The endoscope is fitted onto the headgear.~5. The CLE test is carried out.~6. The endoscope is removed from the headgear.~7. The endoscope is removed from the participant.~8. The headgear is removed from the participant.~9. The headgear is cleaned and stored."
41324711|NCT02156804|DRUG|Nivolumab (BMS-936558)|
41324712|NCT05994313|DIETARY_SUPPLEMENT|Habitual potato consumption|Potatoes are to be consumed in the evening meal, every evening for 12-weeks.
41478639|NCT04788446|BEHAVIORAL|Mini-flipped Game-based Learning|The intervention was 8 weeks, forty minutes adjusted Mediterranean diet learning plan once a week, which includes the 20 minutes for the Mediterranean food table game, and the 20 minutes for the Mediterranean diet nutrition course. The topic of the course includes the relationship between Mediterranean diet and dementia, knowledge of Mediterranean diet, how to integrate local food ingredients into the Mediterranean diet, etc.
41478640|NCT04788446|BEHAVIORAL|Balanced diet|Given a balanced diet nutrition health education manual for the aged.
41478641|NCT01414751|BEHAVIORAL|Absolute risk reduction|Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction
41478642|NCT01414751|BEHAVIORAL|Prolongation of life|Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
41478643|NCT02672202|DRUG|Duloxetine|"* 60 mg/d - twice before surgery and once a day for post operative days 3-7~* 30 mg/d - once a day for post operative days 1-2"
41478644|NCT02672202|DRUG|Pregabalin|"* 75 mg/d - twice a day for post operative days 1-2~* 150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery"
41478645|NCT02672202|DRUG|Placebo|"* non-active - twice before surgery~* non-active - twice a day for post operative days 1-7"
41008867|NCT02915549|OTHER|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
41324713|NCT05994313|DIETARY_SUPPLEMENT|Habitual non-nutrient-dense staple consumption|White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.
41324714|NCT02663479|DIETARY_SUPPLEMENT|Cardiopressin|
41324715|NCT02663479|DIETARY_SUPPLEMENT|Placebo|
41324716|NCT01231607|DRUG|1mg Finasteride active|1mg finasteride active, by mouth once daily
41478646|NCT00751738|DRUG|azimilide dihydrochloride|oral, once daily until sponsor stopped the study
41324717|NCT01231607|DRUG|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
41324718|NCT01231607|DRUG|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
41478647|NCT03627234|BEHAVIORAL|Same Day Discharge|Patients will be randomized to same day discharge
41478648|NCT03627234|BEHAVIORAL|Overnight Stay|Patients will be randomized to stay overnight
41478649|NCT03221348|BIOLOGICAL|CHO-H01|Glyco-engineered anti-CD20 antibody
40807125|NCT05906472|OTHER|Feeds continued|Enteral feeds are continued up until time of surgery
40807126|NCT05906472|OTHER|Feeds held|Enteral feeds are stopped 6 or more hours before surgery
40807127|NCT06381076|DRUG|Liposomal curcumin|participants will consume the product ad libitum for the 24 treatments.
40807128|NCT06381076|DRUG|Food colorant|participants will consume the product ad libitum for the 24 treatments as a placebo.
40807129|NCT05270668|DRUG|Tulisokibart|Tulisokibart administered at timepoints as directed by the protocol
40807130|NCT05270668|DIAGNOSTIC_TEST|Companion diagnostic ( CDx)|CDx+ or CDx-
40807131|NCT05270668|DRUG|Placebo|Placebo
41324719|NCT01231607|DRUG|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
40807132|NCT03815058|BIOLOGICAL|Autogene cevumeran|Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
40807133|NCT03815058|DRUG|Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
40807135|NCT04406818|DRUG|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
40807136|NCT04785534|OTHER|Clinical Evaluation|Undergo clinical evaluation
40807137|NCT04785534|OTHER|Laboratory Biomarker Analysis|Correlative studies
40807138|NCT04785534|PROCEDURE|Liver Ultrasonographic Elastography|Undergo fibroscan
40807139|NCT04785534|OTHER|Survey Administration|Complete survey
40807140|NCT06325657|BIOLOGICAL|RSVpreF vaccine|RSVpreF vaccine
40807141|NCT06325657|BIOLOGICAL|Placebp|Placebo
40807142|NCT03721783|PROCEDURE|Cryoablation|Image guided cryoablation therapy of soft tissue lesions
41153597|NCT00352391|OTHER|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
41153598|NCT04620681|BIOLOGICAL|CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes|Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent
41324720|NCT01231607|DRUG|Finasteride placebo|finasteride placebo, by mouth once daily
41153599|NCT04620681|DRUG|Standard of Care Chemotherapy|Standard of care cytarabine-based chemotherapy
41153600|NCT03296488|DRUG|Nalbuphine Sebacate|intramuscular single dose of NALDEBAIN 24±12 hours before surgery.
41153601|NCT03296488|DRUG|Fentanyl Citrate|Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
40807147|NCT03493451|DRUG|Tislelizumab|Administered intravenously
40807148|NCT04206397|BEHAVIORAL|affective touch|Various types of touch such as brushing, pressure, and tapping, as well as heat pain
41153602|NCT02595593|DEVICE|Rib Fixation System|This intervention involves a surgical procedure to affix rib plates to broken ribs
40807150|NCT06247345|DRUG|ADEL-Y01 - healty participants|In our Part 1 clinical trial, we plan to enroll up to 40 healthy participants, aged 18 to 65, to test the safety and tolerability of ADEL-Y01. The study is divided into 5 cohorts, each with 8 participants, where 6 receive a single dose of ADEL-Y01. Screening is done 28 days prior, followed by randomization and dosing. Participants undergo initial assessments until Day 4 and additional safety and PK evaluations over 12 weeks. Starting at 2.5 mg/kg, the ADEL-Y01 dose may increase up to 100 mg/kg based on Safety Review Committee assessments, ensuring a detailed evaluation of the drug's safety.
40807151|NCT06247345|DRUG|Placebo - Healthy Participants|In Part 1 of our trial, we will enroll 2 placebo participants per cohort in up to 5 cohorts, undergoing the same protocol as those receiving ADEL-Y01 but with a placebo. They'll be part of the study from Day -1 to Day 4 for initial assessments and continue for 12 weeks for further safety and PK evaluations. This inclusion of placebo groups ensures a blinded study design for unbiased comparison of ADEL-Y01's safety and efficacy.
40807152|NCT06247345|DRUG|ADEL-Y01 - MCI/AD|"In Part 2 of our trial, we assess ADEL-Y01 in 33 participants aged 50 to 80 with MCI or mild AD, administering multiple IV doses every 2 weeks for 12 weeks. Each of the 3 cohorts will have 8 participants receiving ADEL-Y01, totaling 6 doses. After initial screening and consent, participants are randomized to start treatment on Day 1, with a follow-up in the clinical research unit for safety assessments. Additional safety and PK assessments occur bi-weekly up to 22 weeks, based on the start from the last dose on Day 71.~Doses are set at 7.5, 20, and 50 mg/kg, adjusted based on Part 1 results and SRC safety reviews after at least 3 doses over 6 weeks. This phase focuses on understanding ADEL-Y01's safety and efficacy in AD patients through a cautious dosing strategy."
41153603|NCT04406142|DEVICE|VISUAL|thin catheter insertion between vocal cords under direct specially adapted videolaryngoscopy
41153604|NCT01498445|DRUG|Dasatinib|Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
41153605|NCT01498445|DRUG|Decitabine|Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
41153606|NCT01498445|DRUG|Decitabine|Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
41153607|NCT04927559|OTHER|Survey Administration|Complete survey
41324721|NCT01231607|DRUG|Dutasteride placebo|dutasteride placebo, by mouth once daily
41324722|NCT04928495|DRUG|Vitamin C|Vitamin C 500 mg / day for ten days
41324723|NCT04928495|DRUG|N-acetylcysteine (NAC)|N-acetylcysteine 1800 mg / day for ten days.
41324724|NCT04928495|DRUG|NAC + Bromhexine (BMX)|NAC + Bromhexine (BMX) 32 mg / day for ten days.
41324725|NCT03380624|DRUG|Refresh Optive|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose
41324726|NCT03380624|DRUG|Refresh Optive MEGA-3|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose
41324727|NCT00529698|BIOLOGICAL|Biologically active recombinant Tat protein|
41478650|NCT02893995|DRUG|Slow Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
41478651|NCT02893995|DRUG|Rapid Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
41478652|NCT04984421|BEHAVIORAL|Healthy School Start|The Healthy School Start program is a universal 4-component family support program for children starting school (5-7 years of age) promoting healthy dietary habits and physical activity in the home environment to prevent childhood obesity and parents' risk of developing type 2 diabetes. It is targeting both children and parents.
41478653|NCT02616484|DRUG|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
41478654|NCT02616484|OTHER|Placebo|Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
41478655|NCT02616484|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
41478656|NCT03421756|DRUG|Alemtuzumab|Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
41478657|NCT03421756|RADIATION|Total Body Irradiation|300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.
41478658|NCT03421756|DRUG|Sirolimus|Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
41478659|NCT00549016|DEVICE|PTPE Encapsulation of Nitinol Stents|Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
40807153|NCT06247345|DRUG|Placebo - MCI/AD|"In Part 2 of our clinical trial focusing on patients with MCI or mild AD, alongside the active treatment groups, we plan to include placebo groups within the 3 cohorts. Out of the 33 participants aged 50 to 80, 3 in each cohort, totaling 9 participants, will receive a placebo instead of the active drug, ADEL-Y01, administered every 2 weeks for 12 weeks. These placebo participants undergo the same screening, consent, and randomization procedures as those receiving the active drug. They are administered the placebo following the same schedule as the active groups, ensuring a controlled and blinded study environment to accurately assess ADEL-Y01's effects without bias.~Placebo participants are crucial for comparing the active drug's impact on safety, tolerability, and effectiveness against a non-therapeutic intervention, maintaining the study's integrity and providing a benchmark for evaluating ADEL-Y01's true pharmacological effects on MCI or mild AD conditions."
41153608|NCT01441258|BEHAVIORAL|Dialectical Behavior Therapy Skills (DBT-S) Groups|The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).
41153609|NCT01441258|BEHAVIORAL|Wait List-Treatment as Usual|Participants will be seen by their standard treaters for 18 weeks as usual.
40807156|NCT06186908|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
40807157|NCT06438471|DRUG|EC5026 oral tablet|"There will be two ascending dose regimens of EC5026, which will be administered over two consecutive Treatment Periods. During each Treatment Period, EC5026 will be administered orally once daily for 7 consecutive days, with a loading dose on Day 1 and a maintenance dose on Days 2-7 of each treatment period. All study subjects will be enrolled in both Treatment Periods and will receive both dose regimens consecutively, for a total duration of 14 days.~Oral doses of EC5026 tested in each Treatment Period:~Treatment Period 1: 6 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 Treatment Period 2: 8 mg loading dose on Day 8 / 4 mg Maintenance dose on Days 9-14"
40807158|NCT06438471|DRUG|Placebo oral tablet|Participants will be administered a matching oral placebo for 14 consecutive days.
40807159|NCT05337982|OTHER|Downhill Eccentric Treadmill Training with Electrical Stimulation|Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.
41008868|NCT02915549|OTHER|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
41478660|NCT00211965|BIOLOGICAL|S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate|single IM dose of 200 mcg total conjugate
41478661|NCT00211965|BIOLOGICAL|placebo|single dose IM
41478662|NCT02655055|PROCEDURE|high frequency voluntary apheresis blood donation|
41478663|NCT04685551|BEHAVIORAL|Change in knowledge, motivation, skills, and resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to improve survivorship outcomes.
41478664|NCT05298787|DRUG|RLS-0071|RLS-0071 is administered as an IV infusion
41478665|NCT05298787|DRUG|Saline Placebo|Placebo is administered as an IV infusion
41478666|NCT06355479|DRUG|OsrHSA|Recombinant Human Serum Albumin from Oryza Sativa
41478667|NCT06355479|DRUG|Plasbumin®-20|Albumin (Human) 20%, USP
40807160|NCT06035172|BEHAVIORAL|guided imagery|The guided imagery technique, which is one of these methods, is used in the method of pain by establishing a connection between mind and body. In the technique, a peaceful scene is depicted in which positive energy is reflected in the person to ensure complete relaxation and relaxation.
40807161|NCT06035172|BEHAVIORAL|music recital|It is stated that the acemasiran tune (instrumental music) has a reducing effect on the duration of labor, as well as having labor pain and muscle relaxant properties.
40807162|NCT04530487|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
40807163|NCT04530487|DRUG|Cyclosporine|Given IV and PO
40807164|NCT04530487|DRUG|Etoposide|Given IV
40807165|NCT04530487|DRUG|Fludarabine Phosphate|Given IV
40807166|NCT04530487|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
40807167|NCT04530487|DRUG|Melphalan|Given IV
41324728|NCT03121118|OTHER|Scan Opportunity|Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
40807168|NCT04530487|DRUG|Mycophenolate Mofetil|Given IV or PO
40807169|NCT04530487|DRUG|Tacrolimus|Given IV and PO
40807170|NCT04530487|DRUG|Thiotepa|Given IV
40807171|NCT05647265|BIOLOGICAL|Nivolumab|Given IV
40807172|NCT05647265|BIOLOGICAL|Ipilimumab|Given IV
40807173|NCT05647265|PROCEDURE|Surgical Procedure|Undergo surgery
40807174|NCT05647265|PROCEDURE|Computed Tomography|undergo CT
41153610|NCT01441258|BEHAVIORAL|No intervention-treatment as usual|Participants will receive the intervention after 18 weeks in the treatment as usual group.
41153611|NCT02893371|DRUG|Lithium Carbonate|Exposure to all dosages and delivery forms.
41324729|NCT05931185|OTHER|low frequency transcutaneous electrical stimulation and Therapeutic Ultrasound|patients will receive low-frequency transcutaneous electrical stimulation for 15 minutes and therapeutic Ultrasound for 10 minutes as a treatment and patients will receive a total of 12 treatment sessions (3 sessions per week for 4 weeks and then follow-up will be done for the next 2 weeks) and the total duration of each session will be of 25 minutes.
41478668|NCT04667702|BEHAVIORAL|Interviews|We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.
41478669|NCT01782482|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
40807175|NCT05647265|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40807176|NCT05647265|PROCEDURE|Positron Emission Tomography|Undergo PET
41478670|NCT01782482|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color
40807177|NCT05005403|DRUG|ABBV-514|Intravenous (IV) Infusion
40807178|NCT05005403|DRUG|Budigalimab|IV Infusion
40807179|NCT03430843|DRUG|Tislelizumab|200 mg administered intravenously (IV)
40807180|NCT03430843|DRUG|Paclitaxel|135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
40807181|NCT03430843|DRUG|Docetaxel|75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
40807182|NCT03430843|DRUG|Irinotecan|125 mg/m\^2 administered IV
40807183|NCT06010303|DRUG|LBL-007|LBL-007 will be administered at a standard dose intravenously.
40807184|NCT06010303|DRUG|Tislelizumab|Tislelizumab will be administered at a standard dose intravenously.
40807185|NCT06010303|DRUG|Chemotherapy Doublet|"Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
40807186|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 5 mg subQ once weekly
40807187|NCT03415594|DRUG|FE203799 Placebo GLP-2 analogue|Placebo subQ once weekly
40807188|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 10 mg subQ once weekly
40807189|NCT06129474|OTHER|Proton Pump Inhibitor deprescribing tool|The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.
40807191|NCT06405438|OTHER|No intervention|No intervention.
40807192|NCT05733091|BEHAVIORAL|Standard of Care|Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation
41324730|NCT05931185|OTHER|Therapeutic Ultrasound|patients will receive a therapeutic ultrasound for 10 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
41008869|NCT06165068|DRUG|Aspirin 81Mg Ec Tab|Patients take aspirin 81 mg per day.
41008870|NCT06165068|DRUG|Clopidogrel|Patients take clopidogrel 75 mg per day.
40807193|NCT04541043|DRUG|Nefecon 16mg daily|All study patients received Nefecon 16 mg daily for 9 months.
40807194|NCT05898620|GENETIC|NGN-401|NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene.
41008871|NCT06165068|DRUG|N-acetylcysteine|Patients are given N-acetylcysteine 600 mg per day.
41324731|NCT05931185|OTHER|Low frequency transcutaneous electrical stimulation|participants will receive low-frequency transcutaneous electrical stimulation for 15 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
40807195|NCT05626114|BIOLOGICAL|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
40807196|NCT05995964|DRUG|PF-07275315|subcutaneous injection
40807197|NCT05995964|DRUG|PF-07264660|subcutaneous injection
40807198|NCT05995964|OTHER|Placebo|subcutaneous injection
40807199|NCT06046443|DRUG|LB54640|Oral daily administration
40807200|NCT06046443|DRUG|Placebo|Placebo matched to LB54640
40807201|NCT05658796|BEHAVIORAL|+RxWell|During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download the app. Once the participant has downloaded the app, they will be paired with a UPMC coach who will guide the person through the sessions using in-app texting to help give them the tools needed to actively cope with anxiety and/or depression. The UPMC coaches are supervised by a licensed UPMC mental health clinician. The participant will have access to the app and coach for six months after they have consented. The digital behavioral tool includes over 30 brief Cognitive Behavioral Therapy (CBT) and mindfulness-based techniques.
41008872|NCT04187365|OTHER|Duration of Indwelling Catheter|Foley catheter
41008873|NCT00384813|BEHAVIORAL|Project ASPIRE Home-Based Family Intervention|Home-based psychoeducational family intervention jointly conducted by psychology postdoctoral fellow and respiratory therapist over 4 months
41008874|NCT00384813|BEHAVIORAL|Project ASPIRE Enhanced Treatment As Usual|Psychoeducational family intervention addressing the written asthma action plan during a single home visit, conducted by a respiratory therapist
41008875|NCT05095740|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation used to regulate the contribution of the laryngeal motor cortex to voice production and laryngeal motor muscle activation.
41008876|NCT05095740|DEVICE|sham rTMS|Repetitive transcranial magnetic stimulation used to a cortical area not associated with change in outcomes at an intensity substantially lower than that of the established threshold.
41008877|NCT01583010|DEVICE|ANV(R)|"Device: Advanced Needle Visualization Technology ®~Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.~Arms: ANV ® Group"
41008878|NCT05582993|BIOLOGICAL|Recombinant von Willebrand Factor (rVWF)|rVWF administered by intravenous injection.
41008879|NCT05582993|BIOLOGICAL|ADVATE|ADVATE administered by intravenous injection.
41008880|NCT03640663|OTHER|Midwife led continuity model of care|Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
41008881|NCT01400867|DRUG|Ceftaroline fosamil|"Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects \< 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)"
41153612|NCT02893371|DRUG|Lamotrigine|Exposure to all dosages and delivery forms.
41153613|NCT02893371|DRUG|Valproic Acid|Exposure to all dosages and delivery forms.
41153614|NCT02893371|DRUG|Oxcarbazepine|Exposure to all dosages and delivery forms.
41153615|NCT02893371|DRUG|Carbamazepine|Exposure to all dosages and delivery forms.
41324732|NCT05370742|PROCEDURE|Latarjet surgery|Results of using a screw-only plate for fixation of the corocoid bone in recurrent shoulder dislocations
41324733|NCT02575677|OTHER|oxycodone|oxycodone 0,1/kg up to 10 mg sc.
41324734|NCT05518799|DRUG|Midazolam|Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.
41324735|NCT02655445|PROCEDURE|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
40807202|NCT05658796|BEHAVIORAL|-RxWell|Treatment as usual
40807203|NCT03601442|BIOLOGICAL|CTL019|CTL019
40807204|NCT04184050|DRUG|MK-4002|IV infusion
40807205|NCT05886036|PROCEDURE|Biopsy|Undergo tissue biopsy
40807206|NCT05886036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40807207|NCT05886036|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41324736|NCT02655445|PROCEDURE|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
41324737|NCT02655445|PROCEDURE|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
41324738|NCT01383642|OTHER|No intervention, observational study|
41324739|NCT06182930|OTHER|Within the scope of the research, caregivers will be given face-to-face training in 2 sessions, 15 days apart.|They will receive routine home health care follow-up.
41324740|NCT04370730|OTHER|clinical, neuroimaging and DNA assessments|Selected assessments, including evaluation of treatment response to specific antipsychotic drugs, will be performed at follow-up visits after 1, 3 and 5 years
41324741|NCT02711605|DEVICE|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
40807208|NCT05886036|PROCEDURE|Computed Tomography|Undergo PET/CT
40807209|NCT05886036|OTHER|Fludeoxyglucose F-18|Receive FDG
41008882|NCT01400867|DRUG|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|"Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed"
41324742|NCT04009746|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass
41324743|NCT00888069|DRUG|CTAP101 Capsules|Single dose oral administration
41324744|NCT00888069|DRUG|CTAP101 Injection|single IV injection
41478671|NCT03319095|DEVICE|Intravaginal Electrical Nerve Stimulation|The Intervention group will receive Intravaginal Electrical Nerve Stimulation using Quark® Dualpex equipment, once per week during 8 weeks. The selected current will be biphasic, and the stimulation parameters will be: 50 Hz frequency, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds, relaxation time (Toff) of 10 seconds, intensity of current defined according to the sensitivity (tolerance) of the patient, and total stimulation time of 20 minutes once a week delivered by an experienced Physiotherapist. In the last 10 minutes of each electrical nerve stimulation session women will be requested to perform voluntary PFM contractions along with the contractions induced by the electrical stimulation. Women will not be instructed to perform any aditional exercise or therapy at home.
41478672|NCT02815202|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-034)
41478673|NCT01218984|DRUG|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
41478674|NCT01218984|DRUG|Medisorb naltrexone 150 mg|Single administration via IM injection.
40807210|NCT05886036|BIOLOGICAL|Mosunetuzumab|Given SC
41008883|NCT01400867|DRUG|Cephalexin or Clindamycin or Linezolid|"Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO."
41008884|NCT00315276|DRUG|Modafinil|
41008885|NCT03356210|BEHAVIORAL|Neurofeedback|The intervention will consist of 20 sessions of symptom-based NF tailored to the individual patient. Training will be conducted using the Othmer method of NF from EEGinfo, comprising bipolar, infra-low frequency training, with the inclusion of synchrony and alfa-/theta training as needed.
41008886|NCT06340971|OTHER|Policy|"We will work with stakeholders' policy groups e.g. RCOG, RCM, RCP and policy makers e.g. Department for Health and Social Care, Transport Emissions at the Greater London Authority or Mayor of London's office to disseminate our findings and develop public health messages.~We aim to develop guidance on how pregnant women and their families can reduce their exposure to air pollution by highlighting for example travel routes with less pollution and wear face masks."
40807211|NCT05886036|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40807212|NCT05886036|BIOLOGICAL|Rituximab|Given IV
40807213|NCT05886036|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
41324745|NCT02824848|BEHAVIORAL|Passive Stretching|Passive stretching and associated strengthening activities to change head/neck and body alignment
41324746|NCT02824848|BEHAVIORAL|Perception-Action Approach|Environmental set-up and gentle manual guidance to promote spontaneous exploration of alternative head/neck and body alignment possibilities
41324747|NCT02794090|BEHAVIORAL|Usual care, individual visits|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
41324748|NCT02794090|BEHAVIORAL|Telephone coaching|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
41324749|NCT00378755|DRUG|velcade|
41478675|NCT01218984|DRUG|Medisorb naltrexone 300 mg|Single administration via IM injection.
41153616|NCT02893371|DRUG|Ziprasidone|Exposure to all dosages and delivery forms.
41153617|NCT02893371|DRUG|Risperidone|Exposure to all dosages and delivery forms.
41153618|NCT02893371|DRUG|Quetiapine|Exposure to all dosages and delivery forms.
41153619|NCT02893371|DRUG|Olanzapine|Exposure to all dosages and delivery forms.
41153620|NCT02893371|DRUG|Aripiprazole|Exposure to all dosages and delivery forms.
41153621|NCT02893371|DRUG|Fluoxetine / Olanzapine|Exposure to all dosages and delivery forms.
41153622|NCT02893371|DRUG|Haloperidol|Exposure to all dosages and delivery forms.
41153623|NCT02893371|DRUG|Perphenazine|Exposure to all dosages and delivery forms.
41324750|NCT05330611|DEVICE|Cryoneurolysis of Intercostal Nerves|"Patients will be offered a minimally invasive intervention procedure for pain control called cryoneurolysis using an ultrasound-guided device called the Iovera Smart Tip 190.~The direct application of cold to the intercostal nerves via Iovera device produces lesions in peripheral nervous tissue to block the pain caused by rib fractures.~This procedure is particularly beneficial for patients who are not candidates for surgical stabilization of their rib fractures.~Application of cryoneurolysis as an analgesic will reduce the amount of narcotics patients might need and instead provide them short- or long-term pain control with minimal risk.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
40807220|NCT05750459|DRUG|Artesunate|Artesunate is a succinic ester of artemether.
40807221|NCT03424993|OTHER|Dietary Sodium Restriction|A registered dietician will counsel participants to reduce daily habitual dietary salt intake below 2000mg over 4 weeks
40807222|NCT03424993|OTHER|Control|Participants will consume their routine habitual dietary sodium intake \> 3400mg per day with regular pre determined check in phone calls from a registered dietician.
41324751|NCT05330611|OTHER|Standard of Care|"Patients will be provided regular standard of care at the Stanford Hospital with short- or long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.~Standard of care for patients with rib fractures that are not eligible for surgical stabilization includes multi-modal pain therapy and pulmonary toilet.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
41324752|NCT00712751|BEHAVIORAL|questionnaires|"Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, usual care will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline."
40807223|NCT03849820|DEVICE|Robotic-assisted partial nephrectomy|Application of the da Vinci surgical robot to assist the partial nephrectomy
40807224|NCT03849820|OTHER|Open partial nephrectomy|Open surgery to conduct the partial nephrectomy
41153624|NCT02893371|DRUG|Clozapine|Exposure to all dosages and delivery forms.
41324753|NCT00712751|BEHAVIORAL|CSI-SH- Cancer Survivorship Intervention|This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
41324754|NCT04774614|PROCEDURE|anterior laminate veneers|VITA ENAMIC multiColor
41324755|NCT01560442|DRUG|Buprenorphine and Methadone Hydrochloride|To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
41324756|NCT00101153|DRUG|cytarabine|
41324757|NCT00101153|DRUG|daunorubicin hydrochloride|
41324758|NCT00101153|DRUG|tipifarnib|
41478676|NCT01218984|DRUG|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
41153625|NCT02893371|DRUG|Asenapine|Exposure to all dosages and delivery forms.
41478677|NCT01218984|DRUG|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
41153626|NCT02893371|DRUG|Lurasidone|Exposure to all dosages and delivery forms.
41153627|NCT02893371|DRUG|Paliperidone|Exposure to all dosages and delivery forms.
41153628|NCT02893371|DRUG|Mirtazapine|Exposure to all dosages and delivery forms.
40807230|NCT05917496|OTHER|LENA tool: Language ENvironment Analysis|"Recording of the language environment of the child at home, in daily environment, with the LENA.~The parameters recorded relate to four domains: adult words, conversation turns, child vocalizations and exposure to electronic media.~The LENA box is worn for 10-16 hours, with a minimum of 10 consecutive hours. the families make 2 separate recordings of 6 months at T1 and T2."
40807231|NCT05917496|BEHAVIORAL|Return of the analysis of the data of LENA|The analysis of the LENA data is carried out by the speech therapist using the LENA Pro Version Software v3.4, during the times T1 and T2. The return of the analysis of the data collected via the LENA will be made to the family of the patient after T1 and after T2 and personalized advice will then be given to parents with the aim of improving their child's language skills.
41153629|NCT02893371|DRUG|Bupropion|Exposure to all dosages and delivery forms.
41153630|NCT02893371|DRUG|Desvenlafaxine|Exposure to all dosages and delivery forms.
41153631|NCT02893371|DRUG|Duloxetine|Exposure to all dosages and delivery forms.
41008887|NCT02432794|PROCEDURE|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
41008888|NCT00567775|DRUG|human insulin|
41008889|NCT00567775|DRUG|inhaled human insulin|
41008890|NCT05754177|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria), administered orally by 1 capsule a day, for 84 days
41153632|NCT02893371|DRUG|Venlafaxine|Exposure to all dosages and delivery forms.
41153633|NCT02893371|DRUG|Citalopram|Exposure to all dosages and delivery forms.
41324759|NCT03668535|PROCEDURE|Bladder Filling|Group A have a triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
41324760|NCT03668535|PROCEDURE|Bladder deflation|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
41478678|NCT01709734|DRUG|galeterone|
41478679|NCT05897918|DRUG|Tranexamic Acid 500 MG|Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions
41478680|NCT04945772|BIOLOGICAL|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
41478681|NCT04945772|PROCEDURE|Sham Injection|Sham Injection
41478682|NCT06330519|DRUG|Dexamethasone sodium phosphate injection|Patients receive 0.8ml of dexamethazone by periodontal ligament injection 30 minutes before the inferior alveolar nerve block
41478683|NCT06330519|OTHER|1,1,1,2 tetrafluoroethane|EndoIce (1,1,1,2 tetrafluoroethane) applied on the buccal, lingual (3 s/surface), and occlusal surfaces (4 s) for a total of 10 s then standard IANB was administered
41478684|NCT06330519|OTHER|intraoral soft tissue cryotherapy|Small ice packs (wrapped in sterile gauze) placed intraorally in the mouth on the vestibular surface of the treated tooth for 5 minutes then standard IANB was administered
41478685|NCT05992948|DEVICE|Transanal stapling device|Transanal stapling device used in low anterior- or anterior rectum resection, sigma resection, left hemicolectomy and intestinal reconstruction operations
41008891|NCT05754177|OTHER|Placebo|Participants in this arm will receive an equivalent placebo for 84 days.
41008892|NCT00414661|DRUG|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
41153634|NCT02893371|DRUG|Escitalopram|Exposure to all dosages and delivery forms.
41478686|NCT03966859|DRUG|Atorvastatin 20mg|oral dose, once daily for 7 days
41478687|NCT03966859|OTHER|Lactose placebo|oral dose, once daily for 7 days
41478688|NCT01414049|PROCEDURE|On-pump CABG|Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
41478689|NCT01414049|PROCEDURE|Off-pump CABG|CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
41478690|NCT00027508|DRUG|trabectedin|
41478691|NCT02823730|OTHER|PCI with Synergy Stent|500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
41478692|NCT03100734|BIOLOGICAL|Benepali|As specified in the treatment arm
41478693|NCT03100734|BIOLOGICAL|Enbrel|As specified in the treatment arm
41478694|NCT05906199|DRUG|Renexin CR 200/160mg|Single oral administration of Renexin CR 200/160mg, QD
41478695|NCT05906199|DRUG|Aspirin 100mg|Single oral administration of Aspirin 100mg, QD
41478696|NCT03923231|DRUG|Atazanavir 300mg/ Ritonavir 100 mg once daily|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care
41478697|NCT03923231|DRUG|Atazanavir 250 mg / ritonavir 80 mg|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg
41478698|NCT00403182|DRUG|chemotherapy|
41478699|NCT00403182|DRUG|letrozole|
41153635|NCT02893371|DRUG|Fluoxetine|Exposure to all dosages and delivery forms.
41153636|NCT02893371|DRUG|Fluvoxamine|Exposure to all dosages and delivery forms.
41153637|NCT02893371|DRUG|Paroxetine|Exposure to all dosages and delivery forms.
41153638|NCT02893371|DRUG|Sertraline|Exposure to all dosages and delivery forms.
41153639|NCT02893371|DRUG|Vilazodone|Exposure to all dosages and delivery forms.
41153640|NCT02893371|DRUG|Doxepin|Exposure to all dosages and delivery forms.
41478700|NCT06236568|DEVICE|D-HOPE machine perfusion|use of the device
41478701|NCT06236568|PROCEDURE|Liver transplantation|Liver transplantation for HCC within Milan criteria
41478702|NCT04526392|OTHER|Questionnaire|Pubertal course questionnaire
41478703|NCT06417164|BEHAVIORAL|Functional Movement Training Group|The program control group will use traditional physical training methods, while the experimental group will use a training program based on FMS functional movement design. The experimental group will receive a 12-week FMS functional movement training intervention, with each session lasting 40 minutes. The experimental group will be divided into two phases, a corrective intervention phase and a capacity enhancement phase, and the main assessment criteria will include the seven movements of the FMS Functional Movement Test (squat, hurdle step, deep squat, shoulder mobility, active straight leg raise, trunk stabilizing push-ups, and trunk rotational stabilization), as well as the ability to control the body's dynamic and static postures during aerobic exercise.
41478704|NCT01004042|DRUG|Botulinum Toxin Type A|Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
41478705|NCT01785121|BEHAVIORAL|Structured access to a Wii game computer (Wii)|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
41478706|NCT01785121|BEHAVIORAL|Motivational support only|The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
41478707|NCT05904275|DRUG|caudal epidural injection|Preoperative Ultrasound guided caudal epidural injection in lumbosacral spine surgeries for postoperative analgesia.
41478708|NCT03780946|PROCEDURE|Magnetic anastomosis for pancreaticojejunostomy|Magnetic anastomosis for pancreaticojejunostomy
41153641|NCT04225078|DRUG|Loperamide|Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.
40807236|NCT05155345|DRUG|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
40807237|NCT05155345|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
40807238|NCT04858815|BEHAVIORAL|yogic breathing|participation in yogic breathing
40807239|NCT03358875|DRUG|Tislelizumab|Intravenous injection (Anti-PD-1 monoclonal antibody)
40807240|NCT03358875|DRUG|Docetaxel|Intravenous injection (Antineoplastic, cytotoxic, taxane)
41153642|NCT04225078|OTHER|Placebo|Matching loperamide placebo capsules will be administered orally.
41153643|NCT04225078|DRUG|Moxifloxacin|Moxifloxacin tablets will be administered orally.
41324761|NCT06382363|PROCEDURE|POC-cHbA1c testing|The point-of-care HbA1c instrument employed in this study will be the Cobas b 101 (Roche Diagnostics, Switzerland) diagnostic test system. A capillary blood sample will be obtained by dermal puncture of a fingertip using a disposable lancet and resorbed in the specially marked area of the Cobas b 101 test disc. The disc will be inserted in the autoanalyzer. Test results displayed in both % and mmol/l will be available within 10 minutes.
41324762|NCT00869388|BIOLOGICAL|rBBX-01|
41478709|NCT03780946|PROCEDURE|Traditional hand-sewn anastomosis|Traditional manual anastomosis for pancreaticojejunostomy
41478710|NCT02221037|DRUG|GSK2862277|"It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
41478711|NCT02221037|DRUG|Placebo|"It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
41153644|NCT04895202|OTHER|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
41153645|NCT00161954|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
40807245|NCT04629391|DEVICE|Total shoulder arthroplasty|A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
40807246|NCT04266730|BIOLOGICAL|PANDA-VAC|The primary therapeutic neoantigen vaccine product, Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine (PANDA-VAC), will be comprised of 6 peptides at a dose of 300 micrograms (µg) per peptide admixed with local adjuvant Stabilized polyriboinosinic/polyribocytidylic acid (Poly-ICLC).
40807247|NCT04266730|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV dose every three weeks. The subject may transition to 400 mg every six weeks if, after the first scan done after start of treatment, they have a partial response or better or after two scans with stable disease or better.
41153646|NCT05083871|OTHER|European Trauma Course|"Structured learning program specifically focused on Trauma management. The course provides frontal lessons, workshops for the technical skills and simulated scenarios.~Please see https://www.erc.edu/courses/european-trauma-course for additional details"
41153647|NCT00728832|DRUG|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
41153648|NCT01847599|OTHER|Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib|
41324763|NCT02705768|DRUG|Carbamazepine|Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
41324764|NCT02705768|DRUG|Oxcarbazepine|Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
41478712|NCT00534794|DRUG|Elestat|Elestat BID for 2 days
41478713|NCT00534794|DRUG|Pataday|Pataday QD for 2 days
41478714|NCT05302921|PROCEDURE|Cryoablation Therapy|"Cryoablation therapy is an established method of cancer treatment in adults and pediatrics with certain types of tumors and is standard of care for certain tumors in the setting of progression/relapse.~Percutaneous image-guided Cryoablation (cryosurgery, cryotherapy) is a technique that utilizes successive rapid freeze/thaw cycles to destroy tumor cells. This technique is performed by inserting specialized needles known as cryoprobes into target tumors under imaging guidance with Computed Tomography (CT) and Ultrasound (US), or Magnetic Resonance Imaging (MRI). After the cryoprobe needles are placed within the target tumor, rapid cooling of liquid gas inserted into these probes leads to temperatures reaching -20 to -40 degrees Celsius.~Cryoablation therapy of one disease site will be done starting Day 3 and prior to Day 15 of Cycle 1 only."
41478715|NCT05302921|DRUG|Nivolumab|"Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
41478716|NCT05302921|DRUG|Ipilimumab|"Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation \[CD\]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
41478717|NCT03074539|DRUG|Riociguat|Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.
41478718|NCT03074539|PROCEDURE|Pulmonary Endarteriectomy|Patients will receive Pulmonary Endarteriectomy if they are suitable for this procedure according to the recommendation of the local CTEPH board. Patients must also consent to this surgical procedure.
41478719|NCT03074539|PROCEDURE|Ballon Pulmonary Angioplasty|Patients will receive Ballon Pulmonary Angioplasty if they are suitable for this procedure according to the recommendation of the local CTEPH board (e.g. not suitable for PEA). Patients must also consent to this procedure.The BPA will be accomplished in several interventions.
41478720|NCT03596619|DEVICE|PBN|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation \[SD\] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
41478721|NCT01129453|BIOLOGICAL|CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine|CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10\^6, 10\^7, 10\^8, or 10\^9 CFU per mL. Route: oral.
41478722|NCT01129453|OTHER|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
41478723|NCT00643214|DEVICE|Tetrix|Twice daily topical application
40807248|NCT03501992|BEHAVIORAL|Current care|The current care arm consists of the contemporary efforts now in practice to support provider recommendation including a shared, standard immunization schedule, a shared rooming process, a shared well child visit schedule, a shared electronic prompt at point-of-care of vaccines due.
41478724|NCT00643214|DEVICE|Tetrix|Twice daily topical application
41478725|NCT04353024|DRUG|Dimethyltryptamine (DMT)|Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min
41478726|NCT04353024|DRUG|Saline|Intravenous saline bolus and/or saline maintenance perfusion over 90 min
40807249|NCT03501992|BEHAVIORAL|Reminder-recall|The communication will use expectant (announcement-style or presumptive) language noting the child's HPV vaccination status and stating that the child's provider strongly recommends the child receive the HPV vaccination now. The communication will also describe availability of topical anesthetics (less pain), indicate the availability and convenience of nurse visits for HPV vaccination (less fuss), and describe the immunological and logistical benefits of early vaccination (right now).
40807250|NCT03501992|BEHAVIORAL|Audit-and-feedback|The intervention includes two components. The first is a missed opportunities audit-and-feedback. The second is a provision of a strong recommendation provider-toolkit, along with a broad education of the practice staff-nurses, medical secretaries, receptionists, and clinical assistants-regarding the nature of the intervention, its goals, and its likely impact on the practice. The broad education will be conducted through supervisory communications only to practice staff in practices allocated to the intervention at the beginning of the step.
40807251|NCT03501992|BEHAVIORAL|Combined reminder-recall and audit-and-feedback|The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
40807252|NCT04282018|DRUG|BGB-10188|Administered as specified in the treatment arm
40807253|NCT04282018|DRUG|Zanubrutinib|Administered as specified in the treatment arm
40807254|NCT04282018|DRUG|Tislelizumab|Administered as specified in the treatment arm
40807255|NCT04511871|BIOLOGICAL|CCT303-406|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.
41153649|NCT01347099|BEHAVIORAL|Internet-based cognitive behavior therapy|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
41478727|NCT03071328|DRUG|Isovue-M 200|Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
41478728|NCT02079675|DRUG|SKI3246 Low Dose|SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
41478729|NCT02079675|DRUG|SKI3246 High Dose|SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
41478730|NCT02079675|DRUG|Placebo|SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
41478731|NCT02237742|DRUG|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
41478732|NCT01276717|DRUG|Drug: Carfilzomib|Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
41478733|NCT01276717|DRUG|Vorinostat|Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
41478734|NCT01852734|PROCEDURE|embolizations ,uterine fibroid|"26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)~26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop"
41478735|NCT01852734|PROCEDURE|embolizations|comparison between the two microspheres
41478736|NCT01345994|PROCEDURE|electro-acupuncture|acupuncture stimulation with electricity
41153650|NCT01347099|BEHAVIORAL|Support therapy on Internet|Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
41153651|NCT06584825|DEVICE|Enhanced Vitals Monitoring|"For participants in the intervention group, they will receive the enhanced continuous vital sign monitoring, on top of the standard of care monitoring as prescribed per the care team. The enhanced monitoring will be provided during the entire time period of hospitalization (up to 30 days after surgery), using the Philips monitor (i.e. heart rate and oxygen saturation continuously and blood pressure once an hour while awake). Participants and caregivers will be educated how to put on and off the devices by the study coordinator.~When participants return home, they will perform thrice-daily monitoring using the Cloud DX Inc. Home kit and daily questionnaires at home 7 days after discharge (or 30 days after surgery, whichever occurs first)."
41153652|NCT03291899|COMBINATION_PRODUCT|FOLFIRINOX|combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
40807257|NCT03367962|DRUG|[18F]F-Ara-G|the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
41153653|NCT03244202|OTHER|Decision Aid Plus Counselling|The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.
41153654|NCT03244202|OTHER|Genetic Counselling Only|Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
41153655|NCT06645990|DEVICE|Impella|LV unloading with Impella (ECMELLA) before or within 24 h of ECMO initiation
41153656|NCT06645990|DEVICE|IABP|LV unloading with IABP before or within 24 h of ECMO initiation
41153657|NCT04870814|DEVICE|Tactical tourniquet set up|The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.
41478737|NCT05369299|DEVICE|Implant Straumann® Pure Ceramic Two Piece Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
41478738|NCT05369299|DEVICE|two-piece titanium implant Neoss® ProActive Tapered Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
41478739|NCT00000239|DRUG|Buprenorphine|
41478740|NCT01311557|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
41478741|NCT01311557|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
41478742|NCT03286478|BEHAVIORAL|Mindfulness|Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
41478743|NCT03286478|BEHAVIORAL|Dissonance|Dissonance-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
41478744|NCT03286478|BEHAVIORAL|Dove Confident Me|Dove Confident Me body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
41478745|NCT04013113|DRUG|Haemoperfusion|"Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required."
41478746|NCT04013113|DRUG|Standard Medical Treatment|Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
41478747|NCT04013113|OTHER|Plasma Exchange|"Fresh frozen plasma will be used as replacement fluid.TPE treatment shall be given on first day and continued on an a dailybasis/alternate day till the desired clinical or biochemical response is achieved.~The procedures of TPE and hemoperfusion will be stopped if any major side effects occur (described below), the patient expires or the patient is transplanted within 30 days (whichever is earlier)."
41478748|NCT00746902|DEVICE|nCPAP|Active nCPAP
41478749|NCT00402220|DRUG|TMS|Active Transcranial Magnetic Stimulation
41478750|NCT00402220|DEVICE|Sham TMS|Sham Transcranial Magnetic Stimulation
41478751|NCT04913207|PROCEDURE|method of device size selection|device size selection based on 3D-CTA
41478752|NCT05777759|DEVICE|Restylane Lyft with Lidocaine|hyaluronic acid
41478753|NCT05777759|DEVICE|Juvederm Voluma XC|hyaluronic acid
40807259|NCT06349460|BEHAVIORAL|FoodSteps behavioral intervention|Behavioral intervention that targets binge eating and weight-related behaviors. Each week, users are recommended or assigned one of five targets, set a relevant goal, and track their progress. If a target is recommended, the user can choose to select that target or a different target.
41153658|NCT04870814|DIAGNOSTIC_TEST|Medical ultrasound|The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.
41478754|NCT03349827|PROCEDURE|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical gastrectomy and cytoreductive surgery
40807262|NCT05787587|DRUG|IDE-161|Oral Medication
41478755|NCT03349827|PROCEDURE|HIPEC|Normal saline 3000ml-4000ml, Docetaxel 50mg/m2, Lobaplatin 50mg/m2, 43°C, 60min.
41478756|NCT03349827|DRUG|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. S1: 60mg, twice daily, day 1 to day 14. S1:60mg twice daily for two weeks, and then suspend for one week
41478757|NCT03349827|DRUG|Apatinib|500mg, once daily, day 1 to day 21.
41478758|NCT04686227|DIAGNOSTIC_TEST|3D Ultrasound|Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology
41478759|NCT01198834|DRUG|MRX-7EAT|Application of up to two patches at the discretion of the investigator for up to 7 days.
41478760|NCT01198834|DRUG|Placebo|Application of up to two patches at the discretion of the investigator for up to 7 days.
41478761|NCT01198834|DRUG|Lidocaine|Application of up to two patches at the discretion of the investigator for up to 7 days.
41478762|NCT01198834|DRUG|Etodolac|Application of up to two patches at the discretion of the investigator for up to 7 days.
41478763|NCT01201759|DRUG|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
41478764|NCT01201759|DRUG|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
41478765|NCT06284447|OTHER|Non-Interventional Study|Non interventional study
41478766|NCT06175936|OTHER|Laugther Yoga|Laughter yoga will be applied to the intervention group in 6 sessions (45 minutes each session).
41478767|NCT02980250|DRUG|Low dose|0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
41478768|NCT02980250|DRUG|normal dose|0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
41478769|NCT02980250|DRUG|over dose|0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
41478770|NCT02980250|DRUG|Glucose|Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.
41478771|NCT00273234|PROCEDURE|Autologous Platelet Gel (APG)|
41478772|NCT05646628|BEHAVIORAL|Qualitative Interviews|Semi-structured Qualitative Interviews
41478773|NCT02676284|DEVICE|Durolane SJ|DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL .
41478774|NCT01699529|DEVICE|Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system|The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
41478775|NCT03166813|PROCEDURE|Remote Ischaemic Preconditioning|The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.
41478776|NCT03166813|OTHER|Control|Placement of blood pressure cuff without inflation for 30 minutes.
41478777|NCT01884688|DRUG|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
41478778|NCT04432675|DRUG|hydroxyethl starch|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
41478779|NCT04432675|DRUG|Lactated Ringer's solution|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
41478780|NCT02573935|DRUG|Clarithromycin|p.o. clarithromycin 500 mg twice daily for 63 days
40807263|NCT05787587|DRUG|Pembrolizumab|Intravenous Infusion
40807264|NCT05008848|BEHAVIORAL|Smoking Cessation Intervention|Participate in schedule gradual reduction program
40807265|NCT05008848|OTHER|Health Promotion and Education|Receive cessation support messages
41153659|NCT04870814|OTHER|Questionnaire|"The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter)."
41153660|NCT04864236|DEVICE|Novel isolation device to contain aerosol|"The novel isolation device is called SLACC (Suction-assisted Local Aerosol Containment Chamber). SLACC has the ability to isolate the atmosphere around the patient's upper airway (nose, mouth, throat) via negative pressure in a manner analogous to isolation rooms used to house patients with communicable diseases spread by aerosol (e.g. tuberculosis).~The SLACC uses an external suction source to maintain a negative pressure micro-atmosphere around a patient's head (the source of infectious aerosols). The components of SLACC include a clear polymer frame, a flexible drape, and integrated sealed arm sleeves to protect the hands and forearms of the health care provider. The structure is flexible during use, transparent, can be rapidly assembled, and easily collapsible for removal and transport. Once deployed with the patient's head inside the chamber, the drape is secured across the open side of the chamber with adhesive and covers the patient's torso."
41153661|NCT04263558|BEHAVIORAL|Emotion child|The MFS will include an idiographic measure of personal aims, symptom burden, displayed on a visual data dashboard to guide further intervention. The EMOTION intervention for children 9 to 12 years with symptoms of anxiety and/or depression will be used in a standard/long version (16 sessions) and a short (8 sessions) but optimized version, using a partial web-based solution with virtual reality (VR)-technology for behavioral experiments and exposure (in short and long version). Parental involvement: Parental participation in a 5-session parent group (high involvement) versus sharing information with parents via a brochure (low Parental involvement).
41478781|NCT02573935|DRUG|Placebo|Placebo tablet twice daily for 63 days
41478782|NCT02573935|DRUG|VCD induction therapy|Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
41478783|NCT01922752|DRUG|CEP-37440|"CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined."
41478784|NCT01145131|OTHER|Intact or minced beef meat|135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
41478785|NCT02470117|DRUG|Alginate-based reflux suppressant|
41478786|NCT02470117|DRUG|magnesium-aluminium antacid gel|
40807266|NCT05008848|OTHER|Informational Intervention|Receive NCI's Clearing the Air booklet
41478787|NCT03136874|OTHER|Interview and questionaires|"* Quantitative method : Two questionnaires will be used to define sociodemographic data, motivations and personality traits of donors.~* Qualitative method : Clinical interviewing allows data collection adapted to study the motivations of sperm/egg donors, their representations, the experience and the inscription of the donation in their personal stories."
41478788|NCT02677259|DRUG|17-beta estradiol|
41478789|NCT02677259|DRUG|Micronized progesterone|
41478790|NCT02112721|DIETARY_SUPPLEMENT|Vitamin D|
41478791|NCT02112721|DIETARY_SUPPLEMENT|Placebo|
41478792|NCT02759341|OTHER|Manual for the Assessment and Documentation of Psychopathology (AMDP 8)|
41478793|NCT02759341|OTHER|Million Clinical Multiaxial Inventory 3 (MCMI-III)|
41478794|NCT02759341|OTHER|State-Trait Anxiety Inventory form Y (STAI-Y)|
41478795|NCT02759341|OTHER|SF-36 Health-Related Quality of Life|
40807267|NCT05008848|OTHER|Questionnaire Administration|Ancillary studies
40807268|NCT06169319|BIOLOGICAL|EN3835|Biologic: Intrafascial injection
40807269|NCT06169319|OTHER|Placebo|Intrafascial injection
40807270|NCT03941873|DRUG|Sitravatinib|Administered orally as a capsule
40807271|NCT03941873|DRUG|Tislelizumab|Administered intravenously
40807272|NCT06434064|PROCEDURE|Biopsy|Undergo tumor biopsy
40807273|NCT06434064|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40807274|NCT06434064|PROCEDURE|Computed Tomography|Undergo CT scan
40807275|NCT06434064|PROCEDURE|Echocardiography|Undergo echocardiography
40807276|NCT06434064|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40807277|NCT06434064|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
40807278|NCT06434064|DRUG|Tamoxifen|Given PO
41008893|NCT03411525|BEHAVIORAL|Commitment Invitation for Clinicians (Clinician Intervention)|Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.
41324765|NCT03972826|OTHER|Provodine|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
41324766|NCT01207388|DRUG|Blinatumomab|Continuous intravenous infusion
41324767|NCT01153477|BEHAVIORAL|Telephone Monitoring and Counseling - Enhanced|Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
41324768|NCT00950976|OTHER|citrulline|TID for 5 days
41324769|NCT00950976|OTHER|Lemonade|TID for 5 days
41324770|NCT05836129|BEHAVIORAL|Transcendental Meditation (TM) practice|See previous description
41324771|NCT05836129|OTHER|Stress reduction class (online)|See previous description
41324772|NCT02759861|DRUG|harvoni|8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy
41324773|NCT06430710|DEVICE|Intrusion|2 different methods for incisor intrusion
41324774|NCT04635761|BEHAVIORAL|Educational Intervention|Complete AIR Program and receive the High-Risk Lung Cancer Tip Sheet
41324775|NCT04635761|BEHAVIORAL|Questionnaire Administration|Ancillary studies
41324776|NCT04003181|DRUG|Antibiotics|Ciprofloxacin or Rifaximin for 10 days.
41324777|NCT04003181|DRUG|Bile Acid Binder|Cholestyramine or Colesevelam lifelong.
41324778|NCT00305747|DRUG|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
41324779|NCT00618995|DRUG|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
41324780|NCT00618995|DRUG|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
41153662|NCT00840918|DRUG|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
41324781|NCT00618995|DRUG|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
41324782|NCT00618995|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
41324783|NCT05785130|OTHER|background noise|Using sound machine for 3 days at bedtime for 7 hours(11p.m.- 6a.m.) in a decibel of 40-50.
41478796|NCT02759341|OTHER|Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)|
41478797|NCT04840784|DRUG|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
41478798|NCT01976455|OTHER|20% fewer calories|
41478799|NCT01976455|OTHER|40% fewer calories|
41478800|NCT05507762|BIOLOGICAL|UC-MSCs|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection Duration: 5 injections per trial group for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively"
41153663|NCT00840918|OTHER|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
40807282|NCT03062280|DRUG|Hydrocortisone|Modified release hydrocortisone
41153664|NCT01072396|DRUG|Tiotropium|double blind randomized crossover
41153665|NCT01072396|DRUG|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
41153666|NCT00349713|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 in GSK Biologicals' AS02A
41153667|NCT00349713|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert Rabies vaccine
41153668|NCT00837096|DEVICE|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
41153669|NCT00837096|DEVICE|Moist wound therapy (MWT)|Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
41324784|NCT05002699|DIAGNOSTIC_TEST|Alzheimer's disease CSF biomarkers|Measurement of amyloid beta peptide 1-42, amyloid beta peptide 1-40, and total tau in cerebrospinal fluid.
41324785|NCT00118911|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
41324786|NCT00118911|OTHER|Relaxation techniques and education about ADHD|Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
41324787|NCT04511442|OTHER|Evaluation of food preferences during a standardized and validated buffet.|"The dietary preferences of people will be collected by a direct measurement of eating behavior in front of a dedicated and standardized ad-libitum buffet.~As part of this buffet, 3 dichotomous categories of food will be studied:~* high / low in fat (HF / LF)~* high / low in carbohydrates (HC / LC)~* high / low in protein (HP / LP). During the buffet, participants will be filmed to study their food choices and the microstructure of their meal. We will define food preferences as the relative consumption choices of the food categories studied. We will also collect the time spent at the buffet, the duration of ingestion, the total duration of the meal, the number of bites per minute, the total number of bites and the number of bites by type of food.~Weighing's will be carried out before and after consumption in order to determine the total energy intake and the macronutrient intake (proteins, lipids, carbohydrates) of the participants."
41324788|NCT02513771|DRUG|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
41324789|NCT02513771|DRUG|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
41324790|NCT00476996|DRUG|Leflunomide|Oral repeating dose
41324791|NCT00476996|DRUG|Methotrexate|Oral or parenteral repeating dose
41157150|NCT01346826|DRUG|Standard 2 hours-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7."
41324792|NCT00476996|DRUG|Ocrelizumab|Intravenous repeating dose (200mg)
41324793|NCT00476996|DRUG|Ocrelizumab|Intravenous repeating dose (500mg)
41324794|NCT00476996|DRUG|Placebo|Intravenous repeating dose
41324795|NCT01428999|DIETARY_SUPPLEMENT|probiotics|probiotics 1 pack (2g) bid for three weeks
41324796|NCT03779061|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
41324797|NCT03779061|DRUG|Propofol|Initial dose plus supplemental doses as necessary
41324798|NCT02535637|OTHER|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
41324799|NCT03802656|DEVICE|Anterior Vertebral Body Tethering|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
41324800|NCT04578119|PROCEDURE|Sliding Intubating Technique|Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
41324801|NCT02384395|DRUG|Dolutegravir 50 mg|Initial therapy for AHI
41324802|NCT02384395|DRUG|Lamivudine 300 mg|Initial therapy for AHI
41324803|NCT02384395|DRUG|Abacavir 600 mg|Initial therapy for AHI
41324804|NCT03721237|OTHER|EBC-assisted|"After definitive catheter positioning, esophageal balloon calibration will be performed in:~1. volume-controlled mode with tidal volume set to obtain 6-8 lm/kg of ideal body weight (reference),~2. pressure support ventilation (PSV) with support set to obtain a tidal volume ranging between 6-8 ml/kg of ideal body weight at equal PEEP of volume control mode (PSV baseline);~3. PSV + sigh ventilation (sigh setting: total inspiratory pressure equal to 35 cmH2O at a rate of 1/ minute; inspiratory time equal to 4 seconds)."
41324805|NCT02986919|DRUG|CPI-0610|"* Optional tumor biopsy will be obtained prior to Day 1 of CPI-0610 administration.~* CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break. The 14 days of CPI-0610 dosing and the 7-day break together constitute 1 cycle of treatment. The dose will not be adjusted for body weight or body surface area."
41324806|NCT03013829|BEHAVIORAL|KPD Educational Video|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch an embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
41324807|NCT05414370|DRUG|Liquid oxygen|Liquid medical oxygen will be administered for 6 hours using high-flow nasal cannula delivery system with an Fi02 of 100% and flow rate of 60 litres per minute.
41324808|NCT05414370|DRUG|medical air|Synthetic medical air will be administered for 6 hours using high-flow nasal cannula delivery system with a flow rate of 60 litres per minute.
41324809|NCT06419361|DRUG|[68Ga]Ga-Sa-DABI-4|Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
41324810|NCT06282419|OTHER|USE OF MOBILE ULTRASOUND|"First stage; Women and their partners who meet the research criteria are at the 32-35th week of pregnancy. was included in the study during the week. First, introductory information forms will be applied to the women and expectant fathers assigned to the experimental and control groups through face-to-face interview technique.~Then, fetal images and fetal heart sounds will be recorded from the pregnant women in experimental group 1 with a mobile phone compatible portable USG device. Fetal USG images and fetal heart sounds taken with the portable USG device of their babies will be sent to the prospective fathers in experimental group 1 by the researcher via WhatsApp application twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp twice a week for 4 weeks after birth."
41324811|NCT06282419|OTHER|ultrasound image taken from the internet|First stage; Fetal USG images and fetal heart sounds, not belonging to their babies, taken from the internet, will be sent to the fathers in experimental group 2 via WhatsApp application by the researcher twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp application twice a week for 4 weeks after birth.
41324812|NCT02850952|OTHER|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
41324813|NCT03698188|PROCEDURE|Injectable platelet-rich fibrin|A blood sample will be drawn from the patient, centrifuged at 700 rpm for 3 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
41324814|NCT03698188|PROCEDURE|Platelet-rich plasma|A blood sample will be drawn from the patient, centrifuged at 3000 rpm for 10 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
41324815|NCT01619163|DRUG|Placebo|
41324816|NCT01619163|DRUG|Prednisolone|low dose, 7.5 mg/day
41324817|NCT00695708|BEHAVIORAL|Brain Fitness Program|Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention
41324818|NCT00695708|BEHAVIORAL|Cogpack|Computer-aided cognitive program for cognitive abilities
41324819|NCT06528054|OTHER|Development of a model for predicting 90-day mortality and to compare various treatment strategies for anastomotic leakage|The prediction model and comparison of various treatment strategies will be studies when the data is available for analysis.
41324820|NCT02435550|GENETIC|Molecular diagnostic testing|Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
41153670|NCT03885622|DEVICE|ANTHEM™ CR Total Knee System|The ANTHEM CR Total Knee System is a CE marked device. It is a cruciate retaining (CR) total knee system. It is intended to be used in patients for primary total knee replacement surgery where the posterior cruciate ligament and collateral ligaments remain intact. It is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties.
41153671|NCT05985109|DRUG|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
41153672|NCT05985109|DRUG|regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
41153673|NCT06057532|DIETARY_SUPPLEMENT|UCAN SuperStarch|Intervention patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the intervention study drink and record information about how they feel before and after consumption.
41153674|NCT06057532|DIETARY_SUPPLEMENT|Gatorade|Active control patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the active control study drink and record information about how they feel before and after consumption.
41153675|NCT06313099|OTHER|Survey|Participants' musculoskeletal system disorders were assessed using the Cornell Musculoskeletal Disorders Questionnaire (CMDQ), fatigue levels were measured using the Fatigue Severity Scale (FSS), sleep quality was evaluated using the Visual Analog Scale (VAS), depression levels were assessed using the Beck Depression Inventory (BDI), and quality of life was measured with the Nottingham Health Profile (NHP). Google Forms was used to create the data collection tools, which were then sent to the participants' email addresses and collected online.
41324821|NCT01577784|DRUG|Pazopanib|800 mg / day of pazopanib in monotherapy.
41324822|NCT00799500|OTHER|Screening|Weekly vaginal pH
41324823|NCT03310580|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
41324824|NCT03310580|DRUG|AR-13324 Ophthalmic Solution 0.04%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
41324825|NCT03310580|DRUG|AR-13324 Ophthalmic Solution Placebo|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
41324826|NCT03919838|DIETARY_SUPPLEMENT|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive two probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
41324827|NCT03919838|DIETARY_SUPPLEMENT|Placebo - No probiotics|A half of the participants will be randomly allocated to the placebo group. They will receive two no probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
41324828|NCT02827994|OTHER|neurophysiology of pain education and exercises|"Pain neurophysiology education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. It was delivered in small groups (4 to 7 participants). A total of 4 sessions were delivered over 4 weeks (1 session per week). Each session took between 45 minutes and 1 hour.~Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular muscles delivered over 3 sessions (the first session covered pain neurophysiology education only). Each exercise was performed in 3 series of 10 repetitions. The number of exercises targeting the same group of muscles increased from one in the 2nd session to 2/3 in the 4th session."
41324829|NCT00891163|DRUG|Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)|30 minute applicable on antecubital fossa
41324830|NCT00891163|DRUG|Placebo Patch|placebo
41324831|NCT02449408|OTHER|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
41324832|NCT01113996|BEHAVIORAL|Protein supplementation and strength training|Protein supplementation and strength training
41324833|NCT01113996|DIETARY_SUPPLEMENT|Protein supplementation|Protein supplementation
41478801|NCT05507762|BIOLOGICAL|Saline solution|Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection Duration: 5 injections per person for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
41478802|NCT05842967|BIOLOGICAL|RSVpreF|120-µg
41478803|NCT05842967|OTHER|Placebo|Placebo
41478804|NCT04130659|COMBINATION_PRODUCT|MARIAL® + PPI (generic Omeprazole)|"MARIAL® administration: 1 stick twice daily after meals from day 1 to 28.~Omeprazole administration: 20 mg cps once daily from day 1 to day 28"
41478805|NCT04130659|DRUG|PPI alone (generic omeprazole)|Omeprazole administration: 20 mg cps once daily from day 1 to day 28
41478806|NCT04130659|DEVICE|MARIAL® alone|MARIAL® administration: 1 stick twice daily after meals from day 29 to month 6.
41478807|NCT01509482|OTHER|blood samples|blood samples to test for primary and secondary outcome measures
40807294|NCT04340141|DRUG|Oxaliplatin|Given IV
40807295|NCT04340141|DRUG|Irinotecan Hydrochloride|Given IV
40807296|NCT04340141|DRUG|Leucovorin Calcium|Given IV
40807297|NCT04340141|DRUG|Fluorouracil|Given IV
40807298|NCT04340141|PROCEDURE|Resection|Undergo surgical resection
40807299|NCT04340141|OTHER|Questionnaire Administration|Ancillary studies
40807303|NCT04472650|DRUG|Sitravatinib|Administered orally as a free base capsule
40807304|NCT04472650|DRUG|Sitravatinib|Administered orally as a malate salt capsule
40807305|NCT05139316|GENETIC|DTX401|nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)
40807306|NCT05139316|OTHER|Placebo|Normal Saline infusion
40807307|NCT05139316|DRUG|Oral corticosteroids|Participants who receive DTX401 solution will receive oral corticosteroids
40807308|NCT05139316|DRUG|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind
40807309|NCT05850663|OTHER|Ecologic Momentary Assessment (EMA)|"EMA enables measurement of phenomena in real-time, natural settings.~EMA data will be used to identify moments of high distress, assess cancer treatment side effects, and assess barriers to care.~The EMA methodology used in this study will ask about current emotional, physical, behavioral, and social states.~The EMAs will consist of time-based sampling (i.e. a daily dairy), which will be prompted and initiated by the phone."
41478808|NCT01509482|OTHER|Blood samples|IR Cholesterol HDL LDL Fasting Glucose Triglycerides
41324834|NCT04282668|DRUG|TAS1440|Form: Capsule or Tablet Route of Administration: Oral
41324835|NCT04282668|DRUG|TAS1440 + ATRA|Form: Capsule or Tablet Route of Administration: Oral
41324836|NCT00517335|PROCEDURE|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
41324837|NCT05806736|DEVICE|Transcutaneous auricular vagus nerve stimulation (real stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
41324838|NCT05806736|DEVICE|Transcutaneous auricular vagus nerve stimulation (sham stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the left earlobe. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
41324839|NCT01926847|DRUG|Riociguat (Adempas, BAY63-2521)|
41478809|NCT01546324|PROCEDURE|Blood draw|Maternal blood draw at approximately 8-17 weeks gestation.
41324840|NCT01926847|DRUG|Placebo|
40807316|NCT06029283|DIETARY_SUPPLEMENT|dietary nitrate|dietary nitrate in a chewing gum delivery vehicle
40807317|NCT06029283|OTHER|Placebo chewing gum|placebo chewing gum
40807318|NCT05039801|BIOLOGICAL|Bevacizumab|Given IV
40807319|NCT05039801|DRUG|Glutaminase-1 Inhibitor IACS-6274|Given by PO
41008894|NCT03411525|OTHER|Health Education Materials to Patients (Patient Intervention)|During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.
41008895|NCT05844514|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of four hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.
41324841|NCT02155361|DRUG|Topical Citrullus colocynthis fruit oil (1%)|
41324842|NCT02155361|DRUG|Topical vehicle oil|
41324843|NCT01915108|DRUG|Remifentanil|All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
41324844|NCT03427138|BEHAVIORAL|Jasper|Families in the joint attention intervention will receive 10 weeks of the JASPER (Joint Attention Symbolic Play Engagement Regulation) protocol. JASPER is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari at the Center for Autism Research and Treatment, at University of California, Los Angeles. Our research staff will be trained on the specific techniques of JASPER guided by Connie Kasari (consultant on project) and her colleagues The study's intervention involves 2 days/week of 60-minute sessions with a trained experimenter (which may take place in the lab or home, depending on the needs of the family). The primary goal for the intervention will be to increase the frequency and range/variety of joint attention and to advance the child to higher levels (e.g., from requesting to initiating joint attention acts).
41478810|NCT03816813|OTHER|blood and saliva sampling|blood and saliva sampling
41478811|NCT06260579|BEHAVIORAL|Exercise/physical activity|personalized exercise training and physical activity program
41478812|NCT02150772|PROCEDURE|Shear Wave Elastography (SWE)|
41478813|NCT03637335|COMBINATION_PRODUCT|irradiation + carboplatin|30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin
40807320|NCT05039801|DRUG|Paclitaxel|Given by IV (vein)
40807321|NCT05039801|DRUG|Capivasertib|Given by PO
40807322|NCT05236725|DEVICE|Remote Blood Pressure Cuff|specialized, Bluetooth enabled BP monitoring cuff
40807323|NCT05236725|DEVICE|Blood Pressure (BP) monitoring smart phone app, BabyScripts™|app that works with the monitoring cuff
40807324|NCT05236725|BEHAVIORAL|Instructions|Verbal and written instructions to conduct BP checks at home
40807325|NCT03983850|DRUG|Busulfan|Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.
40807326|NCT03983850|DRUG|Fludarabine|Fludarabine will be infused by IV over 60 minutes.
40807327|NCT03983850|DRUG|Cyclophosphamide|IV cyclophosphamide will be administered over 2 hours. Slower rates of infusion may be used to decrease side effects. A fluid intake of greater than 2 L/day is recommended during and for 1 to 2 days after cyclophosphamide administration.
40807328|NCT03983850|DRUG|Mycophenolate Mofetil|Any oral formulation should be taken on an empty stomach, 1 hour before or at least 2 hours after meals. Oral formulations should not be administered simultaneously with antacids. Avoid inhalation or direct contact with skin or mucous membranes of dry powder contained in capsules or suspension. IV solutions should be administered over at least two hours through either a peripheral or central vein and should not be administered by rapid or bolus injection.
40807329|NCT03983850|DRUG|Sirolimus|Oral tablets should be administered approximately 4 hours after cyclosporine administration. Sirolimus is administered orally, once daily, without food. Patients unable to tolerate tablets may take the oral solution formulation.
40807330|NCT06531109|DRUG|Ritlecitinib|As provided in the real world practice.
40807331|NCT06167291|RADIATION|Arm 1- Ipsilateral|Given by I-RT
41478814|NCT03637335|COMBINATION_PRODUCT|irradiation + placebo|30 Gy en 10 fractions de 3 Gy + 10 injections of placebo
41478815|NCT01476228|DEVICE|EEG recording|EEG recording
41478816|NCT04190563|BEHAVIORAL|Pain De-Catastrophizing|Experimenter-administered education and skill practice.
41478817|NCT04190563|BEHAVIORAL|Pain Education|Experimenter-administered education.
41478818|NCT04772391|OTHER|Exercise Sessions|Participant will complete up to 8 exercise sessions
41478819|NCT03675334|PROCEDURE|Root coverage with collagen matrix graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
41478820|NCT03675334|PROCEDURE|Root coverage with subepithelial connective tissue graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
41008896|NCT02035007|DEVICE|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
41008897|NCT03721198|COMBINATION_PRODUCT|Acidulated phosphorous flouride|Acidulated phosphorous flouride is used to prevent white spot lesions
41008898|NCT03721198|OTHER|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish is used to prevent white spot lesions
41008899|NCT04456816|DRUG|100 mg AP1189|100 mg AP1189 tablet
41008900|NCT04456816|DRUG|Placebo|Matching placebo tablet
41324845|NCT03427138|BEHAVIORAL|Parent Education|Families in the parent education intervention. Parent education will be provided in group sessions. During the sessions information is presented about ASD, how to deal with behavioral difficulties and available services, and parents are given an opportunity to share experiences. Parents will attend a weekly session for 10 weeks. 10 different topics will be discussed, which include: causes and symptoms of autism, diagnosis process, treatment options, enhancing communicative abilities in children with autism, emotion regulation, dealing with distress, correcting behavior difficulties, applying structure and routines.
41324846|NCT02297113|DEVICE|Macintosh blade|conventional endotracheal intubation
41324847|NCT02297113|DEVICE|C-MAC videolaryngoscope|
41324848|NCT04864678|OTHER|Referral to the Young People's Health Service immunisation nurse|Young people who have been referred to an immunisation nurse at the Young People's Health Service.
41324849|NCT03741725|OTHER|Pay-it-forward|Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
41324850|NCT03741725|OTHER|Pay-what-you-want|Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
41324851|NCT06078787|DRUG|Olaparib 150 MG|Olaparib should be dosed 2 x 150 mg tablets (300 BID)
41324852|NCT04540835|DRUG|Calcium phosphate desensitizer|Calcium phosphate containing desensitizing agent that creates hydroxyappatite
41324853|NCT05152290|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41324854|NCT00425711|DRUG|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
41324855|NCT06504251|DIAGNOSTIC_TEST|Delirium Diagnostic Tool-Provisional ( DDT-Pro )|The Delirium Diagnostic Tool-Provisional (DDT-Pro) is another tool created to assist in the diagnosis of delirium. It does not require specialist expertise. It can assess the main symptoms of acute confusion, including cognitive ability (Cognition), higher-level thinking skills (Higher level thinking), and the sleep-wake cycle (Sleep-wake cycle).
41478821|NCT03675334|OTHER|Basic periodontal treatment|profilaxis, coronary polishing and scaling and root planning
41008901|NCT00841126|DRUG|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
41008902|NCT00841126|DRUG|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
41008903|NCT00841126|DRUG|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
41008904|NCT00599937|DRUG|ATRA|early introduction of ATRA
41008905|NCT00599937|DRUG|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
41008906|NCT04688281|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
41008907|NCT04688281|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
41008908|NCT05311007|OTHER|Evaluation of the incidence and nature of adverse events|Evaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
41008909|NCT02962037|OTHER|Melatonin and light therapy|
41008910|NCT00482391|BIOLOGICAL|trastuzumab|
41008911|NCT00482391|DRUG|cyclophosphamide|
41008912|NCT00482391|DRUG|doxorubicin hydrochloride|
41478822|NCT03250975|DRUG|Budesonide and Azithromycin|Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
41478823|NCT03250975|OTHER|Placebo control of budesonide and azithromycin|placebos of the medications will be given for 14 days in patients randomized to the control group
41478824|NCT02617524|DEVICE|Valve Medical Dedicated Sheath version 00|The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
41478825|NCT04133649|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
41478826|NCT03657108|RADIATION|Civasheet 60 Gy|implantable proposed doses of Civasheet are 60 Gy
41478827|NCT03657108|RADIATION|Civasheet 75 Gy|implantable proposed doses of Civasheet are 75 Gy
41478828|NCT03657108|RADIATION|Adjuvant external beam radiation therapy|45 Gy in 25 fractions
41478829|NCT04352465|DRUG|Methotrexate|Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
41478830|NCT04352465|DRUG|Methotrexate|Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
41153676|NCT01592565|OTHER|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
41324856|NCT02213822|OTHER|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
41324857|NCT00439153|DEVICE|Tourniquet instrument capable of measuring LOP in combination with tourniquet cuffs|See Detailed Description.
41324858|NCT04631458|OTHER|standard of care.|Observational trial.
41324859|NCT04255277|DRUG|Combined oral contraceptives (COC)|A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
41153677|NCT02333071|DRUG|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
41008913|NCT00482391|DRUG|lapatinib ditosylate|
41324860|NCT04255277|DRUG|Moxifloxacin 400mg|A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
41324861|NCT04255277|DRUG|Cenerimod 0.5 mg|This will be administered orally as a film-coated tablet in the morning.
41324862|NCT04255277|DRUG|Cenerimod 4 mg|This will be administered orally as a film-coated tablet in the morning.
41324863|NCT04255277|OTHER|Charcoal, activated|Granules for oral suspension will be used and administered open-label.
41324864|NCT04255277|DRUG|Matching Placebo|Cenerimod matching placebo tablets will be administered once daily orally in the morning.
41324865|NCT02822846|OTHER|lung ultrasound|
41324866|NCT02409901|BEHAVIORAL|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
41324867|NCT04503941|DEVICE|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
41324868|NCT04503941|DEVICE|False Needle treatment|False Needle treatment treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
41324869|NCT04345406|DRUG|ACEIs|Captopril or enalapril
41324870|NCT04345406|DRUG|Conventional treatment|alexoquine
41324871|NCT04454580|DRUG|Venetoclax|treatment with azacitidine or decitabine in combination with venetoclax
41153678|NCT02333071|OTHER|Placebo|Placebo
41008914|NCT00482391|DRUG|paclitaxel|
41008915|NCT00482391|OTHER|laboratory biomarker analysis|
41008916|NCT02387021|PROCEDURE|Continuous femoral nerve block|
41008917|NCT02387021|PROCEDURE|Continuous adductor canal block|
41008918|NCT02387021|PROCEDURE|infragluteal Sciatic nerve block|
41008919|NCT02387021|DRUG|Ropivacaine 0.2%|
41008920|NCT02387021|DRUG|Saline|
41153679|NCT01316809|DRUG|AZD8055|Patients will start at 120 mg once daily
41153680|NCT02637362|PROCEDURE|Ankle block|Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
41157151|NCT01346826|DRUG|Accelerated 1 hour-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7."
41324872|NCT04695899|DEVICE|Dental Implant|"See Section Procedures."
41324873|NCT06299579|DRUG|GD-11 for injection test group|The first dose of GD-11 was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
41324874|NCT06299579|DRUG|Placebo control group|The first dose of placebo was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
41324875|NCT00617656|DRUG|Cisplatin, Docetaxel|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
41157152|NCT01346826|DRUG|Accelerated 30 minutes-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5."
40807336|NCT04876404|DIAGNOSTIC_TEST|PET/MR Imaging|The hybrid PET/MR scanner can provide information on brain activity during various motor and cognitive tasks.
40807337|NCT04771520|DRUG|Avapritinib|Given PO
41008921|NCT05703529|BEHAVIORAL|Positive Psychotherapy|A 6-week group-based positive psychotherapy was conducted in this group. The themes of each week include positive introduction, three good things and positive reactions, gratitude, positive memory, identifying personal strengths and utilizing strengths.
41324876|NCT00617656|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
41324877|NCT00617656|DRUG|Docetaxel, Cisplatin|Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
41324878|NCT00617656|DRUG|Docetaxel|Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
41324879|NCT05930899|OTHER|Genetics|TOmAS is a biobank and all patients will be genotyped
41324880|NCT02253641|BEHAVIORAL|Standard Weight Loss Intervention|14-session/6-month standard behavioral weight loss intervention
41324881|NCT02253641|BEHAVIORAL|Stress-Focused Weight Loss Intervention|14-session/6-month tailored behavioral weight loss intervention
41324882|NCT01436695|DEVICE|Epicall|The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
41324883|NCT01425229|DRUG|Bosentan|"* Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~* Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14"
40807338|NCT05963204|COMBINATION_PRODUCT|Sculptra and Alastin Restorative Skin Complex|Biostimulator and cosmetics
41324884|NCT02427750|BIOLOGICAL|Aggripal®|TIV
41324885|NCT05872295|DRUG|IKS014|IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
41324886|NCT02168296|DIETARY_SUPPLEMENT|Plant-based ingredient added to starchy meal|
41324887|NCT02168296|DIETARY_SUPPLEMENT|Plant-based ingredient added to liquid|
40807339|NCT05963204|COMBINATION_PRODUCT|Sculptra and CeraVe Daily Moisturizing Lotion|Biostimulator and cosmetics
40807340|NCT05609994|DRUG|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
40807341|NCT02153957|BEHAVIORAL|Physical Activity|12 weeks of enhanced physical activity with Zamzee monitor.
41324888|NCT02168296|DIETARY_SUPPLEMENT|No Plant-based ingredient|
40807343|NCT06022029|DRUG|ONM-501|Intratumoral injection
40807344|NCT06022029|DRUG|Cemiplimab|Intravenous administration of 350 mg
41008922|NCT05703529|OTHER|Usual Care|Usual Care means treating as usual, including a regular home visit.
41324889|NCT03609736|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|"* A bolus of less than or equal to 9 mCi (333 MBq) of 18F-DCFPyL will be injected IV by slow IV push.~* After administration of the 18F-DCFPyL the line will be flushed with saline (0.9% w/v).~* Subjects should be encouraged to drink up to 500 mL of water shortly after the administration of 18F-DCFPyL.~* At 60-minutes (± 10 minutes) after administration of 18F-DCFPyL, the PET/CT scan will be acquired with the subject in the supine position and the FOV including the mid-thighs to skull base."
41008923|NCT03750981|BEHAVIORAL|12 week pilot intervention study.|Participants will begin a 12-week high-intensity functional training program conducted at CrossFit® in the D, located in downtown Detroit, Northville Athletix in Northville and Five Lakes CrossFit® in Farmington Hills.
41324890|NCT02013089|DRUG|Erlotinib or Gefitinib|Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
41008924|NCT00700011|DRUG|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
41324891|NCT02013089|DRUG|Everolimus|Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
41324892|NCT02013089|DRUG|Imatinib|Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
41008925|NCT00700011|DRUG|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
41008926|NCT05339607|OTHER|Thermal ablation of resection margins by STSC and biliary orifice by cystotome.|Patients who are eligible will undergo thermal ablation of the resection margins.
41324893|NCT02013089|DRUG|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
41324894|NCT02013089|DRUG|Vandetanib|Vandetanib 300 mg orally once daily for patients with RET gene fusion.
41324895|NCT06325306|BEHAVIORAL|Traditional APA|12 sessions of 1,5 hour are organized (once per week). The first session is primarily focused on the PL assessment, followed by a comprehensive introduction to physical conditioning exercises. Each of the subsequent sessions (n=10), participants will receive an intervention focused on the development of their physical fitness (endurance, strength, flexibility, balance). Each session will commence with a 15 minute warm-up comprising of a blend of cardiovascular and joint mobilization exercises. The core part of each session will be dedicated to session-specific exercises targeting key physical competencies such as endurance, strength, flexibility, and balance, along with other motor skills. . The size of the group will never exceed a number of 15 participants. At the conclusion of each session, participants will be guided through a return-to-calm sequence that included stretching and relaxation exercises.
41478831|NCT04352465|DRUG|Methotrexate|Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
41008927|NCT01405638|BEHAVIORAL|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
41008928|NCT01405638|BEHAVIORAL|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
41008929|NCT05440682|PROCEDURE|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
41008930|NCT05114356|DEVICE|TIDAL Cervical Interbody Fusion implant|Cervical interbody fusion device
41008931|NCT01457872|BEHAVIORAL|Strength-based case management|Strength-based case management
41008932|NCT01457872|BEHAVIORAL|Control condition - referral only|Referral only
41008933|NCT02402452|DRUG|Voxilaprevir|100 mg tablet administered orally
41008934|NCT05009251|BEHAVIORAL|Reminder|Mailed letter, short message service (SMS) text, and/or patient portal message
41008935|NCT05009251|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
41008936|NCT05009251|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
41008937|NCT05009251|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
41008938|NCT04440293|OTHER|BBAT|The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.
41008939|NCT04440293|OTHER|CT|The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.
41008940|NCT05049161|DRUG|Temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
41008941|NCT05049161|DRUG|Temelimab 36mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
41008942|NCT05049161|DRUG|Temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
41008943|NCT03222375|DEVICE|SQUED™ series 28.1 home-use|"Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.~Some autowaves have the properties of quasi-particles!"
41008944|NCT04035720|OTHER|Quantitative risk|Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
41008945|NCT00405574|DRUG|ATN-224|ATN-224 high dose: 300mg ATN-224 low dose: 30mg
41008946|NCT06024876|BIOLOGICAL|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
41008947|NCT00322335|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
41008948|NCT00322335|BIOLOGICAL|Infanrix™ penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
41008949|NCT00322335|BIOLOGICAL|Infanrix™ hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
41008950|NCT00322335|BIOLOGICAL|Engerix-B|Intramuscular injection into the thigh as a birth dose
41153681|NCT02637362|PROCEDURE|Sham ankle block|In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
41153682|NCT02637362|PROCEDURE|Metatarsal block|A metatarsal block will be performed using a standardised technique
41008951|NCT00322335|BIOLOGICAL|NeisVac-C™|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
41008952|NCT00322335|BIOLOGICAL|Infanrix™ IPV/HIB|Intramuscular injection into the thigh as primary vaccination at 4 months of age
41008953|NCT00322335|BIOLOGICAL|Meningitec™|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
41008954|NCT04197635|DIAGNOSTIC_TEST|Maximal functional capacity by cardiopulmonary exercise testing|It will be done with cycle ergometer (CORTEX Metamax3B), starting with 10W of power and increasing 10W every minute. During the test, heart rate, rhythm and blood pressure will be monitored. Gas exchange data shall be evaluated every 10 seconds and the peak oxygen consumption (peak VO2) shall be considered the maximum value obtained during the last 20 seconds of exercise. The main parameters to be determined are: maximum functional capacity, peak VO2, slope of the VE/VCO2 ratio, and chronotropic incompetence variables. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
41157153|NCT06008288|DRUG|JAB-21822|800mg, orally QD with 21 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
41008955|NCT04197635|DIAGNOSTIC_TEST|Echocardiography|The following parameters will be evaluated: a)left ventricular volumes; b) left ventricular systolic function; and c)left atrial volume and E/e' ratio. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
41153683|NCT02637362|PROCEDURE|Sham metatarsal block|In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
41153684|NCT00991133|DRUG|Clofarabine incorporated into a 5-drug regimen|Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
41324896|NCT06325306|BEHAVIORAL|APA+PL|The general content and duration of this intervention is the same as in the traditional APA intervention, but with an extra particular and explicit emphasis on PL dimensions (6) during the sessions. While the dimension of physical competence is consistently incorporated into the sessions, the remaining 5 dimensions of PL are addressed twicely over the course of the semester with the setting of specific goals and intervention content. This could involve quizzes or games integrated into circuits or exercise workshops, role-play exercises simulating real-life situations, or social interactions between participants with a particular focus on PL-related topics. In addition to the sessions, a follow-up telephone call is scheduled between the educator and each participant during the 2 weeks following the initial PL assessment to share individual PL assessment results and assist participants in setting person-centered goals using a motivational interviewing technique.
41324897|NCT04689672|DIAGNOSTIC_TEST|Lung ultrasound|Bedside lung ultrasound
41324898|NCT03629691|OTHER|lung cavitation|apatinib treated patients developed lung cavitation
41324899|NCT00399594|PROCEDURE|A|LV lead placement in region of latest mechanical velocity (tissue doppler)
41324900|NCT00399594|PROCEDURE|B|LV lead placement in standard (lateral / posterolateral) position.
41324901|NCT04286464|OTHER|No intervention|No intervention
41324902|NCT04616495|PROCEDURE|Liver transplantation|Chemotherapy and liver transplantation
41324903|NCT00765713|DEVICE|Nasal continuous positive airway pressure|Nocturnal
41324904|NCT06152419|DEVICE|Questionnaire|Patients will be asked to complete questionnaires to evaluate the quality and the impact of the video and to assess the need for additional information.
41324905|NCT05507060|DEVICE|Vibrating MESH nebulizer (Aerogen Ultra)|Medication will be applied with Vibrating MESH nebulizer
41324906|NCT05507060|DEVICE|Jet nebulizers (Philips Respironics)|Medication will be applied with Jet nebulizers
41324907|NCT02016469|OTHER|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days
41324908|NCT02016469|OTHER|single fecal microbiota transplantation|single fecal microbiota transplantation once the first day
41153685|NCT03517371|OTHER|mHealth delivered exercise program|"Participants in the mobile health condition have up to 10 in-person visits with a physical therapist over 12 months. The exercise program, consisting of walking, strengthening and stretching exercises, is prescribed through an app and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week."
41324909|NCT02016469|DIETARY_SUPPLEMENT|pure give pectin 20g/d for five days|pure give pectin 20g/d for five days
41324910|NCT05480254|OTHER|clamped catheter|Q3 clamped catheter protocol is applied before urinary catheter removal
41324911|NCT04712266|DRUG|Glucagon|calculated IV insulin:Glucagon molar ratio
41324912|NCT04712266|DRUG|Insulin|calculated IV Insulin dose infused at a constant rate
41324913|NCT00531245|DRUG|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
41324914|NCT03858270|DRUG|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
41324915|NCT03858270|OTHER|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week Placebo will be administered at 10 mg tablet twice/day for 51 weeks.
41324916|NCT04995900|OTHER|Community education|Heart Matters coordinators will deliver heart health education to the community using HM materials and Partner resources.
41324917|NCT06397742|OTHER|Physical activity|"Patients received a set of exercises to execute at home. The home exercise program comprised 12 exercises conducted in sequence:~1. Symmetrical shoulder raises with retraction~2. Rolling upper extremities using a ball~3. Symmetrical shoulder raises~4. Band exercises strengthening the upper girdle and arm~5. Exercise of the shoulder joint flexors~6. Side arm raises in supine position~7. Lateral arm raises in supine position~8. Head raises with rotation in supine position~9. Side arm raises in prone position~10. Front arm raises in prone position~11. Rising and lowering the upper girdle in prone position~12. Neck muscles stretches"
41324918|NCT06397742|OTHER|Physical therapy - myofascial techniques|"Physical therapy program comprised five parts. I. Fascial manipulation targeted three most active center of coordination - center of fusion points within head, neck, shoulder, shoulder blade, or chest - during each session, time depending on the patients' adaptability.~II. Manual mobilization of the scar area with each training session including: active myofascial stretching; manual scar mobilization by stretching perpendicularly and in parallel with the scar; soft tissue mobilization by rolling and pulling the surface tissues; myofascial relaxation by breaking through restrictions.~III. Relaxation of muscle contractures using post-isometric muscle relaxation of the scalene muscle, sternocleidomastoid muscle, and neck muscles - until the sessions provided no muscle elongation.~IV. Neuromuscular stimulation with proprioceptive neuromuscular facilitation - included scapula movement patterns, dynamic reversal, stabilizing reversal, upper extremity movement patterns."
40807345|NCT04724694|BEHAVIORAL|Brief CBT for Chronic Pain|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
41008956|NCT04197635|BEHAVIORAL|Evaluation of health related quality of life|Assessment of the quality of life through the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Spanish version. It will be completed at baseline and at 30 and 90 days after treatment initiation. The score of the questionnaire is 0 to 105 points.
41153686|NCT03517371|OTHER|Exercise only|Participants in the control group have up to 10 in-person visits with the intervention physical therapist over 12-months. Participants are instructed by the physical therapist to engage in walking and perform progressive resistance and stretching exercises (tailored to their needs and provided in written format) 5 days per week.
41153687|NCT01102985|BEHAVIORAL|aerobic resistance exercise|three times per week aerobic resistance exercise for 12 months
41153688|NCT01102985|BEHAVIORAL|home based health promotion|education and support to adapt national guidelines for 30 minutes physical activity most days of the week
41153689|NCT06006754|OTHER|Observational study|No intervention: observational study
41153690|NCT02735278|OTHER|different test paradigms|
41153691|NCT04655222|DRUG|Interferon Beta Therapy|Administered as specified in the treatment arm.
41324919|NCT03190096|PROCEDURE|SVC isolation|After PVI ablation SVC will be performed. The CB will be retrieved to the right atrium and the achieve catheter will be advanced in the SVC. The CB will be inflated in the right atrium and advanced towards the ostium of the SVC to occlude the vessel
41324920|NCT01241656|BEHAVIORAL|DESI for home viewing|Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.
41324921|NCT01241656|BEHAVIORAL|DESI for viewing at Shared Medical Appointment|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
41324922|NCT01241656|BEHAVIORAL|Option of SMA and DESI or DESI only|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
41153692|NCT03206489|DEVICE|noninvasive high-frequency ventilation (nHFOV)|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in one of the preterm twins infants with respiratory distress syndrome
41153693|NCT03206489|DEVICE|nasal continuous positive airway pressure (nCPAP)|nasal continuous positive airway pressure (nCPAP) as a primary mode of ventilation in another of the preterm twins infants with respiratory distress syndrome
41153694|NCT05734976|DEVICE|electroacupuncture|This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
41153695|NCT00148499|DRUG|Ambroxol hydrochloride (Mucoangin?)|
41153696|NCT00148499|DRUG|benzocaine|
41157154|NCT04667442|DIAGNOSTIC_TEST|Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)|COVID-19 Rapid Antigen Diagnostic Test
41157155|NCT03788954|OTHER|Kinesiotaping|Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.
41157156|NCT00247702|DRUG|warfarin|
41478832|NCT04914624|BEHAVIORAL|ACBT training|Performed 5 days before surgery and one month after surgery, twice a day.
41478833|NCT04914624|DEVICE|acpella®PEP|Continuously instruct patients to perform positive expiratory pressure training 5 days before surgery and one month after surgery, twice a day.
41478834|NCT04914624|DEVICE|EDP-type II external diaphragm pacemaker|Use external diaphragm pacemaker to stimulate patients' diaphragms.
41008957|NCT04197635|DIAGNOSTIC_TEST|Submáximal functional capacity assesment by 6 minutes walk test|It will be performed in an area equipped for cardiopulmonary resuscitation. Subjects will be asked not to perform a vigorous physical exercise in the previous 2 hours. They will be allowed to have a light meal before the test. Before the test, the vital signs will be determined in a seated position after a rest of 10 minutes. Subjects will be instructed to walk at their own pace to cover as much distance as possible in 6 minutes. It will be performed by a trained nurse blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
41008958|NCT04197635|OTHER|Clinical evaluation|Evaluation of signs and symptoms of heart failure
41324923|NCT04399980|DRUG|Mavrilimumab|Treatment infusion
41324924|NCT04399980|DRUG|Placebos|Placebo infusion
41324925|NCT00085917|DRUG|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
41324926|NCT00085917|DRUG|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
41324927|NCT00110474|DRUG|Glucosamine sulfate|
41324928|NCT00110474|DRUG|Acetaminophen|
41478835|NCT01783002|RADIATION|11C-Methionine PET/CT scanning|PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
41478836|NCT01783002|RADIATION|18F-FDG PET/CT scanning|For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
41478837|NCT01783002|RADIATION|SPECT-CT scanning|For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
41478838|NCT01576094|DRUG|Milrinone|Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
41478839|NCT01576094|DRUG|Levosimendan|Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
41478840|NCT01415050|DEVICE|Whole body vibration|15 times WBV
41478841|NCT00608595|DRUG|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
41478842|NCT00608595|GENETIC|gene expression analysis|not noted
41008959|NCT00362804|DRUG|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
41008960|NCT05211622|DRUG|1. alpha acid lipoic - tables|600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days
41478843|NCT00608595|GENETIC|protein expression analysis|Not noted
41008961|NCT05211622|DRUG|2. ozonated oil - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks
41008962|NCT05211622|DRUG|3. chlorhexidine 0,2% - mouthwash|1 minute- three times/die after oral hygiene, possibly, from five days after the beginning of chemotherapy and for subsequent 2 weeks
41008963|NCT05211622|DRUG|4. sodium bicarbonate 5% solution - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 3 weeks
41324929|NCT05194787|DIAGNOSTIC_TEST|Cognitive test scores, clinical diagnosis and blood biomarkers|"Clinical diagnosis of Alzheimer's disease, mild cognitive impairment or normal ageing.~Cognitive test score on CANTAB Blood biomarker (p-tau 181) level"
41324930|NCT02219711|DRUG|MGCD516|MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
41324931|NCT00556335|PROCEDURE|manual aspiration|air aspiration
41324932|NCT00556335|PROCEDURE|conventional drainage|drainage, pneumocath
41478844|NCT00608595|OTHER|immunohistochemistry staining method|not noted
41478845|NCT00608595|OTHER|laboratory biomarker analysis|not noted
41478846|NCT00608595|OTHER|mass spectrometry|
41153697|NCT05234008|OTHER|High intensity training at home|"A HIT exercise intervention is performed. Four sessions are performed at REVAL Research Center to educate participants on the exercise protocol. Eight exercise sessions are performed at home with support of Physitrack (a mobile application for participants and a software platform for researchers).~In-center program (2 weeks, 4 sessions): Participants perform a concurrent exercise protocol of 1h-1.5h, as published by our research team previously, consisting of cardiorespiratory, general resistance, and core muscle training, all at high intensity.~Home sessions (4 weeks, 8 sessions): Researchers provide participants with a fitness bike, smartwatch, and training mat. Using Physitrack, researchers formulate a personalized HIT program to be performed at home for each participant by selecting from \>3500 exercises or insert a new exercise to add to the library. This HIT program resembles the program performed in the rehabilitation center as much as possible."
41153698|NCT03985826|OTHER|Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood|The cohort of ALL survivors has all been diagnosed and treated for ALL in childhood
41153699|NCT06464614|DRUG|Adebrelimab|Adebrelimab 1200mg，d1，q3w, until disease progression or unacceptable toxicity
41153700|NCT06464614|DRUG|Apatinib|Apatinib 250mg，d1-21，q3w, until disease progression or unacceptable toxicity
41153701|NCT06464614|DRUG|Investigator chosen chemotherapy (ICC)|"Nab-paclitaxel: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles;Intravenous infusion of 100 mg, D1, qw is used at the same time as radiotherapy.~Ilinotecan: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles; Capecitabine, 625 mg/m2 orally, d1-14, q3w; continued until disease progression, intolerable toxicity, or withdrawal due to other reasons; when synchronized with radiotherapy, 625mg/m2, bid, oral, d1-5, qw."
41153702|NCT06464614|RADIATION|Radiotherapy|Radiotherapy mode: IMRT for the primary lesion and SBRT for the metastasis; If the patient has symptoms of dysphagia, the radiation dose is 1.8 Gy×28 F or 2 Gy×25 F, d1-5 5 times a week; If oligometastatic lesions occur in the body: the radiation dose is 8 Gy×5F, d1-5; If oligometastatic lesions occur in the brain, the radiation dose is 7 Gy×5F, d1-5.
41153703|NCT00323895|DEVICE|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
41153704|NCT00323895|DEVICE|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
41153705|NCT00323895|DEVICE|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
41153706|NCT00711555|DRUG|aprepitant, ondansetron, dexamethasone|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting."
41157157|NCT00115986|BIOLOGICAL|Influenza A/H5N1 Vaccine|
41478847|NCT00608595|PROCEDURE|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
41478848|NCT00608595|PROCEDURE|neoadjuvant therapy|not noted
41478849|NCT00608595|PROCEDURE|therapeutic conventional surgery|not noted
41478850|NCT00635830|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
41008964|NCT02850874|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
41478851|NCT04217655|DIAGNOSTIC_TEST|Low-dose computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
41478852|NCT04217655|DIAGNOSTIC_TEST|Standard-dose computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
41478853|NCT06454396|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
41478854|NCT02217696|OTHER|Computerized reading training|
41478855|NCT01312181|BEHAVIORAL|HealthCall and Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
41478856|NCT01312181|BEHAVIORAL|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
41478857|NCT01312181|BEHAVIORAL|HIV/AIDS health education|The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
40807346|NCT04724694|OTHER|Treatment as usual|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
40807347|NCT03300141|OTHER|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
40807348|NCT03300141|OTHER|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
40807349|NCT03300141|OTHER|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
41008965|NCT02850874|PROCEDURE|Open pancreaticoduodenectomy|"Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications."
41008966|NCT02850874|DRUG|Gemcitabine|Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
41008967|NCT03097653|OTHER|Decision-aid|Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification.
41008968|NCT03097653|OTHER|Standard information|Web platform with a standard brochure. This standard brochure represents a combination of the best information available from the three participate centre' brochures.
41008969|NCT06085898|DRUG|Stryphnodendron Adstringens 3% - once daily post bath|Intimate Soap
41008970|NCT03819868|PROCEDURE|High cost|Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.
41008971|NCT03819868|PROCEDURE|Low Cost|Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
41478858|NCT03588052|PROCEDURE|VISTA using PRF|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
41478859|NCT03588052|PROCEDURE|VISTA using SCTG|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
41478860|NCT02948725|OTHER|Cross-education + standard rehabilitation|
41478861|NCT02003911|DRUG|Azithromycin|Azithromycin suspension (200mg/5mL)
40807350|NCT01527305|DRUG|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
41478862|NCT02003911|DRUG|Placebo|
41478863|NCT04948294|DEVICE|Channeled blade|In the present group, a tracheal tube was launched in the channel of the blade before tracheal intubation
41478864|NCT04948294|DEVICE|Non-channeled blade|In the present group, a tracheal tube was not launched in the videolaryngoscope blade before tracheal intubation
41478865|NCT06451718|DEVICE|Intracorneal implantation|Intracorneal implantation of the nitinol investigational device
41478866|NCT03074396|DEVICE|Use of DialysisNet for doctor|DialysisNet is mobile application for physicians for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record standard.
41478867|NCT03074396|DEVICE|Use of Avatar Beans for patient|Avatar Beans is mobile application for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record.
41478868|NCT02213952|DRUG|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
41478869|NCT02213952|OTHER|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
41153707|NCT05742256|DRUG|Oxycodone 1mg/kg|Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml
41478870|NCT02409394|DRUG|Hetrombopag Olamine|
41008972|NCT03662100|BIOLOGICAL|LY3074828|Administered SC
41008973|NCT03662100|DRUG|LY3074828|Administered SC
41008974|NCT03662100|DEVICE|Auto-injector (AI)|AI to administer LY3074828
41478871|NCT01754506|DIETARY_SUPPLEMENT|Fish Oil|EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
41478872|NCT01189526|DRUG|Ranibizumab|Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
41008975|NCT03662100|DEVICE|Prefilled syringe (PFS)|PFS to administer LY3074828
41008976|NCT05459064|DEVICE|Motiva Flora TE|This is a retrospective, observational study - collecting data on patients who have gone through the staged procedure with the Motiva Flora Tissue Expander / Long-term breast implant.
41008977|NCT05889052|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
41008978|NCT00613600|DIETARY_SUPPLEMENT|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
41478873|NCT01189526|PROCEDURE|macular laser photocoagulation|Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
41478874|NCT04133246|BEHAVIORAL|Focus group|Groups of 6 to 10 patients and spouses led by the psychologist about their parenthood lasting 2 hours
41008979|NCT00613600|DIETARY_SUPPLEMENT|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
41008980|NCT01191710|OTHER|In vitro fertilization|In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
41008981|NCT03766503|OTHER|Daily|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
41324933|NCT05016791|DEVICE|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~1. Routinely once per day from the day of randomisation till the 12-month visit after AF CA (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~2. If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~3. If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
41478875|NCT04133246|BEHAVIORAL|Individual interview|Interview led by the psychologist about the patient's parenthood
41478876|NCT02214368|OTHER|Early application of NIV|"Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."
41478877|NCT02214368|DEVICE|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
41478878|NCT02214368|DRUG|Propofol|"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention."
41478879|NCT02214368|OTHER|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate\>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2\> 0.5 or breathing at least 10 L/min oxygen.
41478880|NCT06205472|RADIATION|Adjuvant SIB radiotherapy|Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions,mainly depending on the dose constraints of OARs.
41478881|NCT00430950|DRUG|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
41478882|NCT00430950|DRUG|olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
41324934|NCT04420910|OTHER|Non-Motor Symptoms|NMSs of the participants were evaluated using the Non-Motor Symptoms Scale (NMSS). The scale consists of 30 yes-no questions and is administered face to face with the therapist.
41324935|NCT04420910|OTHER|Balance|To measure balance, the Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used. The participants were asked to position themselves in a comfortable position on the platform, and their foot position coordinates were recorded. The participants focused on a characteristic dot on the monitor screen. Their task was to balance the body in such a way that the dot was in the center of a circle displayed on the monitor at the point of intersection of the coordinate axes. The test consisted of three 20 s trials, each separated by 10 s breaks. Measurements were conducted while their eyes were open and close, and the results were analyzed by calculating the average value of the measurements.
41478883|NCT06102408|OTHER|second line investigations for uveitis etiological workup|Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
41478884|NCT04823819|DEVICE|Magnetic Stimulator DuoMag|Stimulation of the left dorsolateral prefrontal cortex
41478885|NCT04823819|DEVICE|neuroConn DC-STIMULATOR|One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
41478886|NCT00965055|DRUG|Ezetimibe|10 mg
41478887|NCT00965055|DRUG|Atorvastatin|"Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period"
41478888|NCT00578071|DRUG|Panitumumab|Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
41478889|NCT00578071|DRUG|Capecitabine|Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
41478890|NCT00578071|DRUG|Oxaliplatin|Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
41478891|NCT00578071|RADIATION|Radiation Therapy (RT)|Daily for 6 weeks
41478892|NCT00411398|DRUG|Namenda/Memantine|5mg tablets, 1-4 tabs by mouth per day
41478893|NCT04216420|DEVICE|MERM-observed self-administered therapy|The MERM device has an electronic module and a medication container that records adherence, stores medication, emits audible and visual on-board alarms to remind patients to take their medications on time and refill, and enables providers to download the data and monitor adherence. It is manufactured by Wisepill Technologies, South Africa.
41478894|NCT02575508|DRUG|Fluorouracil|Given IV
41478895|NCT02575508|DRUG|Irinotecan Hydrochloride|Given IV
41478896|NCT02575508|OTHER|Laboratory Biomarker Analysis|Correlative studies
41478897|NCT02575508|DRUG|Oxaliplatin|Given IV
41008982|NCT02500069|OTHER|placebo|infusion of tap water in all regions (duodenum, jejunum and ileum)
41478898|NCT02575508|DRUG|pan FGFR Kinase Inhibitor BGJ398|Given IV
41478899|NCT02575508|OTHER|Pharmacological Study|Correlative studies
41478900|NCT01191528|DEVICE|capnostream 20, Oridian Medical 1987 ltd, Needham MA|"Oxygen blood saturation measured by a s sensor that reflects infrared light on oxygenated and deoxygenated arterial blood via a noninvasive, clip on digit sensor connected to a combination capnometer and pulse oximeter monitor.~End-tidal Carbon dioxide (EtCO2) is measured with a noninvasive nasal cannula sampling line which calculates the EtCO2 from exhaled air. Measurements recorded at 5 second intervals."
41478901|NCT04715776|DIETARY_SUPPLEMENT|Brown seaweed|Uptake of 1650 mg brown seaweed product twice daily
41478902|NCT04715776|DIETARY_SUPPLEMENT|placebo|Uptake of 1650 mg placebo twice daily
41478903|NCT05491239|PROCEDURE|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
41478904|NCT05491239|PROCEDURE|Continuous regional paravertebral block|"The PVB catheter is placed under general anaesthesia at the beginning of the VATS procedure under direct thoracoscopic vision. The level of the PVB catheter placement is chosen at the intercostal space of the largest incision (mostly thoracic level 4 or 5). Under direct thoracoscopic vision, the surgeon inserts a Touhy needle. The tip of the needle is observed beneath the pleural surface thoracoscopically. Injection of about 2 mL ropivacaine 7.5mg/mL will create subpleural hydrodissection to reach the adequate paravertebral plane for placement of the catheter. The PVB catheter is subsequently placed under direct thoracoscopic vision and left next to the sympathetic chain in the paravertebral space. Next, a bolus of ropivacaine (total amount 20 mL including the given amount for hydrodissection) is given through the catheter.~Postoperatively, a ropivacaine 2 mg/mL pump for continuous infusion is given with an infusion rate of 8-14 ml/hour."
41478905|NCT05491239|PROCEDURE|Single shot intercostal nerve block|At the end of the surgery a single shot ICNB will be placed at 9 levels (thoracic level 2 to 10) with 2-3mL local anaesthetics per intercostal space under direct thoracoscopic vision. The injection site will be chosen just lateral from the sympathetic trunk. This group will have no analgesic catheters for continuous analgesia. No mobility restrictions are instructed in this group.
41008983|NCT02500069|OTHER|Casein (in duodenum)|infusion of protein in duodenum
41478906|NCT02677181|DRUG|ATG|rabbit ATG（Sanofi）
41478907|NCT02677181|DRUG|CsA|cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
41008984|NCT02500069|OTHER|Casein (in jejunum)|infusion of protein in jejunum
41008985|NCT02500069|OTHER|Casein (in ileum)|infusion of protein in ileum
41008986|NCT03997318|BIOLOGICAL|AMDC-USR|Autologous Muscle Derived Cells for Urinary Sphincter Repair
41008987|NCT03997318|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
41478908|NCT02677181|DRUG|mycophenolate mofetil|From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
41478909|NCT02677181|DRUG|Methotrexate|short-term methotrexate
41478910|NCT03710590|OTHER|ECIG Lab Session 15 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
41008988|NCT04921930|DRUG|Artesunate Oral Product|Dose escalation intake of artesunate
41478911|NCT03710590|OTHER|ECIG Lab Session 15 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.).
41478912|NCT03710590|OTHER|ECIG Lab Session 15 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
41478913|NCT03710590|OTHER|ECIG Lab Session 30 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
41478914|NCT03710590|OTHER|ECIG Lab Session 30 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
41478915|NCT03710590|OTHER|ECIG Lab Session 30 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
41008989|NCT01061749|BIOLOGICAL|Cixutumumab|Given IV
41008990|NCT01061749|OTHER|Laboratory Biomarker Analysis|Correlative studies
41008991|NCT01061749|OTHER|Pharmacological Study|Correlative studies
41008992|NCT01061749|DRUG|Selumetinib|Given PO
41008993|NCT06341127|DRUG|Fluoxetine|Oral fluoxetine daily, 2.5 to 5 mg.
41008994|NCT04657536|DEVICE|high frequency fulguration equipment|All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
41008995|NCT04657536|DRUG|promestriene vaginal soft capsules|Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
41157158|NCT01037829|OTHER|Non-intervention observational study|Non-intervention observational study
41008996|NCT05869929|DIETARY_SUPPLEMENT|Vegetables|4-5 servings of vegetables daily, per USDA guidelines.
41008997|NCT03363230|BEHAVIORAL|Mindfulness skills training|Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.
41008998|NCT03363230|BEHAVIORAL|Interpersonal Effectiveness skills training|Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
41153708|NCT05742256|DRUG|Oxycodone 1.5mg/kg|Test group 2 (OCB group): oxycodone 1.5mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
41153709|NCT05742256|DRUG|Sufentanil|Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
41008999|NCT02100072|DEVICE|Nd:YAG 1440 nm laser|
41009000|NCT00484302|BEHAVIORAL|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
41153710|NCT04291560|BEHAVIORAL|Stretching Exercise Intervention|Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.
41153711|NCT06401447|RADIATION|Radiotherapy|Simultaneously optimizing the target, dosage, and synchronized drugs for radiotherapy.
41153712|NCT04293055|BEHAVIORAL|Maintenance program|1-year weight loss maintenance program, consisting of monthly newsletters
41324936|NCT04420910|OTHER|Lower Limb Strength|A Biodex® System 4 Dynamometer device was used to evaluate muscle strength. The participants' dominant extremity was determined by asking them the foot with which they most often hit the ball.The dynamometer arm of the device was placed at the lateral condyle level of the knee, and the belt at the distal end of the dynamometer was attached to the lower leg on the malleolus. Knee flexion and extension movements were evaluated in sitting position between 90ᵒ flexion and 0ᵒ extension angles. The individual was asked to perform it with the maximum strength, while the therapist motivated the individual with verbal stimulation.
41478916|NCT05329818|DEVICE|high definition transcranial direct current stimulation|"Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down."
41478917|NCT05987917|DEVICE|BTL-785-2|Treatment with BTL-785 device (BTL-785-2 applicator) for non-invasive facial rejuvenation
41478918|NCT05987917|OTHER|No Treatment|The subject who will serve as control will not be treated with the study device.
41478919|NCT05503251|OTHER|Best Practice|Receive usual care
41009001|NCT00484302|BEHAVIORAL|Non-manualized standard treatment|Treatment by case-manager
41009002|NCT03833076|DEVICE|Medical device Procto|Medical device Procto presents itself as a translucent green gel with a typical smell.
41009003|NCT03833076|DEVICE|Matching placebo|IP placebo presents itself as a translucent green gel with a typical smell.
41153713|NCT04293055|BEHAVIORAL|Phone coaching|Some individuals will receive 4 consecutive weeks of phone coaching. The first coaching call will be approximately 30 minutes in duration and follow-up calls will be 10-15 minutes in duration. Coaches will help support participants in their weight loss maintenance efforts. Once coaching calls are completed, the participant will not have any other contact with their coach.
41153714|NCT00457171|DRUG|GI-270384|
41153715|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
41009004|NCT03434756|OTHER|Propioceptive training of the abdominal wall muscles|At the beginning, patients will be in a supine position, the lower edge of the StabilizerTM will be placed between the posterior superior iliac spines, aligned with the sacral base. Abdominal manoeuvre will be developed by the patients until they reach 40 mmHg and hold steadily for 10 seconds. Prior the examination, each subject practiced the abdominal manoeuvre three times with an ultrasound image feedback.
41324937|NCT04420910|OTHER|Functional mobility|The Timed Up and Go test (TUG) was used in the evaluation of functional mobility. . For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. Dual task performance was performed by adding cognitive and motor tasks into the TUG.
41478920|NCT05503251|BEHAVIORAL|Neuropsychological Assessment|Undergo neuropsychological evaluation
41478921|NCT05503251|OTHER|Quality-of-Life Assessment|Ancillary studies
41478922|NCT05503251|OTHER|Questionnaire Administration|Ancillary studies
41478923|NCT03500042|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
41478924|NCT02575612|PROCEDURE|vacuum-assisted biopsy|Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (\> 50 ultrasound guided minimal invasive biopsies per year, \> 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
41478925|NCT06067451|BEHAVIORAL|SMART GOALS Setting Tool/ Protocol|The participants randomized to the study group will receive the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT), which will be used in tandem. The participant will first receive the SGSG which will highlight 3 domains of SMART goals (exercise, diet, and behavior). Each domain will have 1 predetermined and unchanging primary goal which will serve as the standard for all participants to strive for.
41478926|NCT04555304|DRUG|KH903 + Paclitaxel|KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
41478927|NCT04555304|DRUG|Placebo + Paclitaxel|Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
41478928|NCT04754334|DRUG|ORMD-0801|Oral Insulin
41478929|NCT04754334|OTHER|Placebo|Fish Oil
41478930|NCT04608799|DRUG|Perampanel|Efficacy of epilepsy drugs
41478931|NCT06090682|DEVICE|Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)|We observed the changes in cognitive function of patients before and after different brain stimulation treatments, and further compared the effects of different brain stimulation treatments on cognitive function of PD patients and the related mechanisms according to whether DBS surgery was performed or TMS therapy was given only according to the surgical indications.
41478932|NCT00692224|DRUG|zinc gluconate|zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
41478933|NCT00692224|DRUG|placebo|placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
41478934|NCT02602834|OTHER|interval training|4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.
41478935|NCT02602834|OTHER|moderate exercise|30 minutes (moderate intensity) aerobic exercise on treadmill without rest.
41478936|NCT02377635|DIETARY_SUPPLEMENT|Anhydrous selenite|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
41009005|NCT00664716|BIOLOGICAL|Baminercept alfa 1|experimental - one dose level
41009006|NCT00664716|BIOLOGICAL|Placebo|Placebo comparator
41009007|NCT00664716|BIOLOGICAL|Baminercept alfa 2|experimental - second dose level
41009008|NCT00664716|BIOLOGICAL|Baminercept alfa 3|experimental - third dose level
41009009|NCT00664716|BIOLOGICAL|Baminercept alfa 4|experimental - fourth dose level
41009010|NCT00664716|BIOLOGICAL|Baminercept alfa 5|experimental - fifth dose level
41009011|NCT03621943|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped.
41009012|NCT03621943|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped as soon as possible and within 60 seconds of delivery.
41009013|NCT03893266|OTHER|Interviews|An interview will be realized with each patient in order to precise the issues they have to reconcile their diabetes and their work. Some questions will be posed to the patients and they respond as they wish.
41009014|NCT03191539|DRUG|Apremilast|30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
41009015|NCT04904523|DIAGNOSTIC_TEST|Diagnostic Test:Blood test|Drop of blood for RNA and metabolic analysis
41324938|NCT01596530|DRUG|Drug-AZD8931|Active drug for biological activity
41324939|NCT01596530|DRUG|Drug-Placebo|Placebo comparator for biological activity comparison
41324940|NCT03645889|OTHER|PLTG|A combination of 13 herbal granules
41324941|NCT03645889|OTHER|Placebo|90% starch filler and 10% PLTG
41324942|NCT04649762|BEHAVIORAL|activating consciousness technique (hypnosis)|activating consciousness technique (hypnosis)
41324943|NCT00805610|BIOLOGICAL|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
41324944|NCT00643357|DRUG|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
41324945|NCT00643357|DRUG|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
41009016|NCT05897879|BIOLOGICAL|Nasopharyngeal swab|"For hospitalized patients :~Nasopharyngeal swab (1 aspiration or 2 swabs (1 in each nostril))~For ambulatory patients :~Deep nasal swab: 2 swabs (1 in each nostril), or 1 swab only for children for whom taking 2 swabs is complicated."
41009017|NCT05897879|BIOLOGICAL|Blood samples|For hospitalized patients : 3 to 7.5 ml For ambulatory patients: Fingertip blood sampling
41324946|NCT04945213|DRUG|Biperiden|5mg of biperiden diluted in 100 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
41324947|NCT04945213|OTHER|Placebo|1ml sterile vehicle (sodium lactate, lactic acid, sodium hydroxide and water for injections) diluted in 100 ml 0.9% saline - every 6 hours for 10 consecutive days - IV
41324948|NCT00655161|BIOLOGICAL|GI-4000|subcutaneous injection, 40YU weekly for 3 weeks followed by monthly for 6 months them quarterly until recurrence
41324949|NCT03084718|DRUG|CHF 718 pMDI|Dose Response: Test one of three different doses of CHF 718 pMDI
41324950|NCT03084718|DRUG|Placebo pMDI|Placebo Control
41324951|NCT03084718|DRUG|Beclomethasone Dipropionate (BDP)|Active Control
41324952|NCT02473835|OTHER|Calorie restriction|Participants will reduce calorie intake by 50 % for a period of 3 consecutive days.
41324953|NCT02473835|OTHER|Activity monitoring|For 1 week, participants will be fitted with an activity monitor (Actiheart) to estimate energy expenditure (during the same week as the diet monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
41324954|NCT02473835|OTHER|Diet monitoring|For 1 week, participants will be asked to record all food and fluids consumed to estimate energy intake (during the same week as the activity monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
41324955|NCT01340391|DEVICE|Omnicast|dorsal splint 2-5 weeks
41324956|NCT00842361|DRUG|insulin degludec/insulin aspart|The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
41324957|NCT00842361|DRUG|biphasic insulin aspart 30|The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
41324958|NCT05754697|OTHER|Instrument assisted soft tissue mobilization in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
41478937|NCT02377635|DIETARY_SUPPLEMENT|Sodium chloride|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
41478938|NCT05116748|BIOLOGICAL|COVID19 mRNA vaccine|Administration of COVID19 mRNA vaccine
41324959|NCT05754697|OTHER|Positional release technique in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
41324960|NCT05754697|OTHER|Traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
41478939|NCT06063759|DEVICE|VitalDetect|measurement of microcirculating blood flow, SpO2 (mmHg or %), heart rate (beats/min)
41478940|NCT01334684|DRUG|Metformin|Metformin, pills, 850 mg three times a day for three months
41478941|NCT05335213|DIAGNOSTIC_TEST|16S rRNA gene sequencing|"DNA extraction and 16S rRNA gene sequencing DNA extraction, 16S rRNA gene amplification, and deep sequencing of the 16S rRNA amplicon performe.~The V4-V5 region of the 16S rRNA gene amplify with barcodes for multiplexing."
41478942|NCT02561234|DRUG|Co-ArgI-PEG|Administered IV
41478943|NCT01366443|PROCEDURE|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
41324961|NCT02029638|BIOLOGICAL|anti-thymocyte globulin|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
41324962|NCT02029638|DRUG|Fludarabine|Fludarabine at dose 30 mg/m\^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
41324963|NCT02029638|DRUG|Cyclophosphamide|"1. Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~2. High dose cyclophosphamide \[50mg/kg (Ideal Body Weight)\] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume."
41324964|NCT02029638|RADIATION|Total Body Irradiation|Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
41324965|NCT02029638|DRUG|acetaminophen|650 mg orally prior to antithymocyte globulin infusion.
41324966|NCT02029638|DRUG|diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
41324967|NCT02029638|DRUG|methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
41324968|NCT02029638|BIOLOGICAL|bone marrow transplant|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0.
41478944|NCT01366443|PROCEDURE|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
41478945|NCT01366443|PROCEDURE|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
41478946|NCT00419887|DRUG|Vildagliptin (LAF237)|
41324969|NCT02029638|DRUG|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
41324970|NCT02029638|DRUG|mycophenolate mofetil|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
41324971|NCT02029638|DRUG|prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
41324972|NCT02029638|DRUG|filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
41324973|NCT06295601|OTHER|Traditional rehabilitation|The program consists of a joint treatment in which lower extremity strengthening and balance exercises are carried out synchronously. The program will include a total of 5 minutes of warm-up, 5 minutes of cool-down and 30 minutes of exercises related to the program. The difficulty of the program will increase by changing the number of exercises and increasing the weight in strengthening exercises. Progress in balance and coordination exercises will vary by changing the ground, increasing the standing time, and keeping the eyes open and closed.
41324974|NCT06295601|OTHER|Action observation therapy and motor imagery|In the experimental group, in addition to traditional telerehabilitation, action observation and motor imagery of 4 exercises will be performed in each session. A video will be prepared for 4 exercises. Then, the participant will perform 2 minutes of action observation of each movement, followed by 1 minute of motor imagery. In addition to the traditional telerehabilitation program, a 12-minute combination of action observation and motor imagery will be performed in each session. Exercises will be changed every two weeks, gradually increasing the difficulty.
41324975|NCT04724512|DEVICE|suture|a type of suture used in entropion surgery
41324976|NCT02142257|PROCEDURE|Gastric Bypass|Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
41324977|NCT02142257|DEVICE|AspireAssist Aspiration Therapy|AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
41324978|NCT00270413|DRUG|SU11248|sutent 50 mg daily 4w on 2w off
41324979|NCT01332019|DRUG|peginterferon beta-1a|Administered as specified in the treatment arm
41324980|NCT02545491|BEHAVIORAL|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
41324981|NCT02545491|BEHAVIORAL|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
41324982|NCT06189170|DRUG|KP405|Experimental drug
41478947|NCT01878721|RADIATION|PET/CT|positron emission tomography/computed tomography
41009018|NCT03595371|DRUG|dapansutrile|500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
41009019|NCT00638703|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks
41009020|NCT00638703|DRUG|Placebo|placebo
41009021|NCT06108856|DEVICE|Hemodialysis machine|machine by which people undergo dialysis on it.
41009022|NCT01396863|PROCEDURE|HDF during the first examination|"The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.~During the second examination the patient will receive treatment with low flux hemodialysis.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
41009023|NCT01396863|PROCEDURE|HD during the first examination|"The patient will receive treatment with low flux hemodialysis during the first examination.~During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
41324983|NCT06189170|DRUG|Placebo|Placebo
41324984|NCT03101748|DRUG|Cyclophosphamide|Given IV
41324985|NCT03101748|DRUG|Doxorubicin|Given IV
41324986|NCT03101748|OTHER|Laboratory Biomarker Analysis|Correlative studies
41324987|NCT03101748|DRUG|Neratinib|Given PO
41009024|NCT00515307|PROCEDURE|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
41324988|NCT03101748|DRUG|Paclitaxel|Given IV
41324989|NCT03101748|BIOLOGICAL|Pertuzumab|Given IV
41324990|NCT03101748|BIOLOGICAL|Trastuzumab|Given IV
41324991|NCT02532387|OTHER|Telephone follow-up|Prospectively enrolled subjects will have a 7- and 30-day phone call.
41478948|NCT02854696|PROCEDURE|Islet graft|Patients will be transplanted with pancreatic islet cells
41478949|NCT02854696|DRUG|best medical care|Patients will continue their insulin treatment
41478950|NCT01014416|DRUG|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
41478951|NCT02872792|DEVICE|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
41324992|NCT00225888|BEHAVIORAL|Digital Photography of meals/snacks and group discussion|Digital Photography of meals/snacks and group discussion
41324993|NCT05336006|OTHER|High-intensity aerobic training with high protein diet|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
41009025|NCT04226079|DIAGNOSTIC_TEST|Collection of exhaled breath|Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups
41324994|NCT05336006|OTHER|Control group|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
41324995|NCT02665078|OTHER|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
41324996|NCT02982486|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
41324997|NCT02982486|DRUG|Nivolumab|Ninolumab 240 mg IV every 2 weeks
41324998|NCT04545398|OTHER|Food. Beef, Pasture-raised|Pasture-raised beef
41324999|NCT04545398|OTHER|Food. Beef, Grain-fed|Grain-fed beef
41325000|NCT04545398|OTHER|Food. Meat alternative|Meat alternative
41478952|NCT02872792|OTHER|Standard physiotherapy|Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
41478953|NCT03030716|DIETARY_SUPPLEMENT|95% condensed proanthocyanidins from grape seed extract|0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each
41478954|NCT04851431|BEHAVIORAL|one-to-one peer mentoring|Weekly meetings with a peer family caregiver
41009026|NCT03242681|PROCEDURE|Endoscopy Assisted Probing procedure|The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
41009027|NCT05555433|OTHER|NO INTERVENTION|no intervention
41009028|NCT00120432|DRUG|1% tropicamide and 10% phenylephrine|single dose vs three doses of 1%tropicamide and 10%phenylephrine
41009029|NCT02468843|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes~3. Biphasic pulse stimulation mode (immediate assessment)~4. Biphasic pulse stimulation mode (assessment at 1h)~5. Biphasic pulse stimulation mode (assessment at 2h)"
41009030|NCT02468843|OTHER|Unified Dystonia Rating Scale|Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
41009031|NCT02468843|OTHER|Burke-Fahn- Marsden scale|Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
41325001|NCT04545398|OTHER|Food, Lamb|Lamb
41325002|NCT04298190|BEHAVIORAL|Dialectical Behaviour Therapy for Adolescents (DBT-A)|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
41325003|NCT04298190|BEHAVIORAL|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive family and/or pharmacological treatment as needed.
41325004|NCT04965129|DRUG|Placebo|Drug: Placebo olive oil pill manufactured to mimic fish oil. Other Names: • Placebo
41325005|NCT04965129|DRUG|Fish oil|All subjects will be given fish oil with a dose of of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
41478955|NCT00116519|DRUG|PPAR alpha|
41478956|NCT00116519|DRUG|placebo|
41478957|NCT04178031|DEVICE|IUD insertion|"Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman."
41478958|NCT01106521|RADIATION|Permanent breast seeds implant|Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
41478959|NCT04711967|BIOLOGICAL|Fecal Microbiota Transplantation|fecal microbiota transplantation
41478960|NCT04711967|DRUG|drug|drug
41478961|NCT02490306|DEVICE|Strokefinder MD100 measurement|A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
41325006|NCT03944070|DRUG|Ranibizumab|Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.
41325007|NCT05765487|DRUG|Sildenafil|Sildenafil Cream, 3.6%
41325008|NCT05765487|DRUG|Vehicle|No Active or experimental ingredients
41325009|NCT05765487|DRUG|Placebo|Cream with only L-arginine
41325010|NCT00002908|DRUG|bryostatin 1|
41325011|NCT00002908|DRUG|vincristine sulfate|
41325012|NCT02376491|DEVICE|Transcranial magnetic stimulation|
41325013|NCT04394455|BEHAVIORAL|Brief cognitive behavioral therapy|9 structured psychotherapy sessions, weekly, 60-90 minutes duration. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
41325014|NCT04394455|BEHAVIORAL|Crisis intervention therapy|3 structured sessions of crisis intervention. One session each week for three weeks. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
41325015|NCT00222742|PROCEDURE|induced moderate hypothermia|Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
41325016|NCT01406652|PROCEDURE|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
41325017|NCT03712332|BEHAVIORAL|Distress Tolerance Group|The intervention is a distress tolerance skills-based group informed by mindfulness and acceptance principles and dialectical behavioural therapy (DBT).
41325018|NCT02640118|DRUG|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
41325019|NCT02640118|DRUG|Lixisenatide-Placebo|
41478962|NCT01426035|DRUG|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G|APLIED 4 TIMES/DAY AT LESION
41153716|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
41153717|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
41157159|NCT04274699|DIAGNOSTIC_TEST|Hemosonics Quantra coagulation monitor|There is no categorisation or allocation of any subject to any intervention vs non-intervention group. Blood sampling and the addition of a Quantra coagulation test is the only 'intervention', and the sampling protocol is identical for all subjects. Post-testing treatment of all subjects is as per established routine and Quantra results will not be used by clinical team.
41325020|NCT02640118|OTHER|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
41325021|NCT00779311|DRUG|sorafenib|Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
41325022|NCT00779311|DRUG|bevacizumab|Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
41325023|NCT00779311|DRUG|mFOLFOX6 regimen|The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
41325024|NCT03945734|BEHAVIORAL|Expressive Helping|Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.
41325025|NCT01530555|DRUG|Rabbit ATG, Thymoglobuline (Genzyme)|"1. Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months"
41325026|NCT00313027|RADIATION|PET scan|
41325027|NCT06468111|BEHAVIORAL|Animal Assisted Therapy|Blood and dental extraction will be performed according to the usual protocol of the health center in both groups; with the additional assistance of the therapy dog in experimental group.
41325028|NCT01520584|DIETARY_SUPPLEMENT|Vitamale|men will receive the vitamale dietary supplement compared to a sham pill
41325029|NCT04019769|DRUG|L-glutamine|product will be obtained by Endari and administered by NIH pharmacy. Patient will take supplement as prescribed
41325030|NCT02693236|BIOLOGICAL|adenovirus-transfected autologous DC vaccine plus CIK cells|
41325031|NCT01082367|DRUG|TOBI|TOBI (tobramycin inhaled solution)
41325032|NCT01082367|DRUG|Placebo|Placebo
41325033|NCT00460837|DRUG|bowel preparation: senna & gastrofin versus picolax (standard)|The intervention is a bowel cleansing procedure
41325034|NCT01769144|DEVICE|Acticoat Absorbent|wound dressing
41325035|NCT01769144|DEVICE|BCT|wound dressing
41325036|NCT00975429|DRUG|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
41478963|NCT05998616|BEHAVIORAL|Exercise Training Program|The intervention group will be encouraged to complete aerobic and resistance training exercises three times a week, and either at home, in the community (e.g., park, shopping mall), or any suitable environment of the participant's choice. Exercise equipment for monitoring walking and complete resistance training will be provided to the intervention group. The exercise training prescription involves 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and resistance training consisting of 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.
41325037|NCT00975429|DRUG|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
41009032|NCT06435247|BEHAVIORAL|With or without accompaniment in the recovery anaesthetic area|one grup will have family accompaniment in the recovery area and the other group will not in both groups the QoR15 scale will be used to measure the quality of anesthetic recovery
41009033|NCT02142452|BEHAVIORAL|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
41009034|NCT02142452|OTHER|Usual Prenatal Care|
41009035|NCT01020071|PROCEDURE|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
41009036|NCT00003585|BIOLOGICAL|aldesleukin|
41009037|NCT00003585|BIOLOGICAL|recombinant interferon alfa|
41009038|NCT00003585|DRUG|fluorouracil|
41009039|NCT00003585|DRUG|isotretinoin|
41009040|NCT00003585|PROCEDURE|surgical procedure|
41009041|NCT02440880|DRUG|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
41157160|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day on a 21-day cycle
41009042|NCT02440880|DRUG|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
41009043|NCT02440880|DRUG|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
41009044|NCT02440880|DRUG|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
41009045|NCT02440880|OTHER|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
41009046|NCT05676671|PROCEDURE|Applications of self-etching adhesives and dental restorations|
41009047|NCT01746784|DRUG|N6022|Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
41009048|NCT01746784|DRUG|Normal saline|Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
41009049|NCT02189187|BEHAVIORAL|Mindfulness|
41009050|NCT02189187|BEHAVIORAL|Psychoeducation|
41009051|NCT05510323|DRUG|Prednisolone|RAS blockade as much as tolerated or allowed
41009052|NCT05510323|DRUG|Prednisolone plus Cyclophosphamide|RAS blockade as much as tolerated or allowed
41009053|NCT02155595|OTHER|500 without BP treatment|lab tests, X-ray, bone scan or MRI, as needed
41009054|NCT02155595|OTHER|500 with BP treatment|lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
41009055|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active."
41009056|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive."
41009057|NCT00425399|PROCEDURE|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
41325038|NCT03934424|BEHAVIORAL|Weight stigma|Subject will read an article depicting discrimination against individuals with higher body weights for 5-10 minutes on one day
41325039|NCT03934424|BEHAVIORAL|Ethnic stigma|Subject will read a control article for weight stigma depicting discrimination against individuals from a minority ethnic group for 5-10 minutes on one day
41325040|NCT04869176|DIAGNOSTIC_TEST|Electrocardiogram|Recording of the electrical activity of the heart during sleep; sleep phases were evaluated. The bed was initially in horizontal position and tilted for 30° head-up after 20 minutes of continuous tracing.
41325041|NCT04869176|DIAGNOSTIC_TEST|Monitoring of vital functions|Measuring of heart rate, breathing frequency, arterial oxygen saturation and body temperature while recording ECG.
41009058|NCT06101264|DEVICE|Virtual Reality Intervention|Participants will be given a virtual reality (VR) intervention following corrective scoliosis surgery for adolescent idiopathic scoliosis. The VR intervention will utilize a commercial device manufactured by Oculus. The intervention will utilize a software that simulates a low-physical load environment for the user. Starting on postoperative day 1, the participant will receive a 20-minute VR intervention 30 minutes prior to each physical therapy session. There will be two physical therapy sessions daily. Outcome measures will be assessed before and after every VR intervention and after the physical therapy session. The VR interventions will continue for each postoperative day until the participant is discharged from the hospital.
41009059|NCT03354429|DRUG|Ticagrelor|Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
41325042|NCT04869176|DRUG|Caffeine Citrate 5 mg/kg|Caffeine in the form of suspension was given to the newborns.
41009060|NCT03354429|DRUG|Placebo|Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
41009061|NCT03065465|DEVICE|Over-the-scope hemoclipping device|A endoscopic entrapment of tissue for control of bleeding or other applications.
41009062|NCT03065465|OTHER|Standard endoscopic treatment|Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
41009063|NCT01686243|OTHER|epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
41157161|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed intermittently on a 21-day cycle
41157162|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
41157163|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
40807355|NCT06512675|OTHER|Resistance combined with cardiovascular training|Participants will undergo a 6-week exercise program designed under the supervision of a board certified sports medicine physician. The exercise program will consist of a 3 day per week schedule: Monday will be lower body resistance training, Wednesday will be aerobic exercise, and Friday will be upper body resistance training. Each session will be approximately up to 1 hour.
40807356|NCT06444854|PROCEDURE|early chest tube removal|Chest tube removal
40807357|NCT00542373|OTHER|Cytology Specimen Collection Procedure|Undergo oral tissue collection
40807358|NCT00542373|PROCEDURE|Diagnostic Microscopy|Mouth tissue examined microscopically for cytologic features
40807359|NCT00542373|PROCEDURE|Diagnostic Procedure|Undergo standard white light headlamp oral examination
40807360|NCT00542373|PROCEDURE|Fluorescence Imaging|Undergo widefield fluorescent and reflectance imaging
40807361|NCT00542373|PROCEDURE|Fluorescence Spectroscopy|Undergo point fluorescent spectroscopy
40807362|NCT05866679|DRUG|Hyperpolarized 13-C-pyruvate|Given by PO
41153718|NCT06143488|PROCEDURE|Endovascular therapy|"Drug: Best medical management All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.~Procedure: Endovascular therapy In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
41009064|NCT01686243|OTHER|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
41153719|NCT06143488|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
41009065|NCT02579616|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
41009066|NCT05268861|BEHAVIORAL|Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. Subjects will receive an elbow flexion error of 15 degrees to encourage elbow extension.
41009067|NCT05268861|BEHAVIORAL|No Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. In this case, subjects that do not receive EA feedback will act as sham comparators.
41009068|NCT03645629|DIAGNOSTIC_TEST|skin test with food at different storage times|Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
41009069|NCT01375218|OTHER|Pavlik Brace|Pavlik Brace
41009070|NCT01375218|OTHER|Plastizote Brace|Plastizote Brace
41009071|NCT00473915|DRUG|fluticasone furoate|corticosteroid nasal spray
41153720|NCT01219153|DRUG|Extended high dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
41153721|NCT01219153|DRUG|Short low dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
41153722|NCT03677102|OTHER|higher chloride crystalloid|Normal saline (chloride concentration 154 mmol/L)
41153723|NCT03677102|OTHER|lower chloride crystalloid|Ringer's Lactate (chloride concentration 110 mmol/L)
41153724|NCT02899676|OTHER|neuropsychological testing|
41153725|NCT02899676|OTHER|functional magnetic resonance imaging|
40807373|NCT04171219|BIOLOGICAL|Pembrolizumab|Given IV
40807374|NCT04171219|DRUG|Talabostat Mesylate|Given PO
41009072|NCT02730416|DRUG|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
41009073|NCT05017116|DRUG|RBD1016|subcutaneous injection
41009074|NCT05017116|DRUG|Placebo|subcutaneous injection
41009075|NCT05017116|DRUG|Entecavir|Take orally.
41153726|NCT02899676|OTHER|simple arithmetic operations|
41153727|NCT02878720|DEVICE|Transcutaneous vagal nerve stimulation|"The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy during the real or sham tVNS stimulation"
41153728|NCT05889221|OTHER|Drug and medical device|Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.
41153729|NCT06537141|PROCEDURE|selective embolization of thyroid arteries (SETA)|selective embolization of thyroid arteries
41153730|NCT00819676|OTHER|analysis of exhaled breath by biosensors|
41153731|NCT00819676|OTHER|measurement of exhaled nitric oxide|
41009076|NCT03181828|DRUG|Acetohydroxamic Acid Oral Tablet|A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
41009077|NCT03181828|OTHER|No treatment|No treatment
41009078|NCT05063396|PROCEDURE|opioid free anesthesia|Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.
41009079|NCT05063396|PROCEDURE|Opioid-sparing anesthesia|patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
41009080|NCT03380923|BEHAVIORAL|Moderate Intensity|Exercise prescription intensity is moderate
41009081|NCT03380923|BEHAVIORAL|High Intensity|Exercise prescription intensity is high
41009082|NCT00499603|DRUG|Paclitaxel|80 mg/m\^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
41478964|NCT05998616|BEHAVIORAL|Flexibility Program|The control group will be encouraged to complete stretching and range of motion exercises three times a week, and either at home, in the community (e.g., park, shopping mall), or any suitable environment of the participant's choice. Exercise equipment (yoga mat) for monitoring walking and complete flexibility training will be provided to the control group. The flexibility training prescription involves stretches from the Stretching for People with MS: An Illustrated Manual from the National MS Society.
41009083|NCT00499603|DRUG|5-Fluorouracil|500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
41009084|NCT00499603|DRUG|Epirubicin|100 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
41009085|NCT00499603|DRUG|Cyclophosphamide|500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
41009086|NCT00499603|DRUG|RAD001|30 mg by mouth weekly on Days 1, 8, \& 15 for 12 cycles.
41009087|NCT05075616|PROCEDURE|Percutaneous endoscopic gastrostomy|Percutaneous endoscopic gastrostomy (PEG) is a minimally-invasive endoscopic procedure that creates a passage from the patient's stomach to the abdominal wall via a feeding tube and provides a means of feeding if oral intake is not adequate.
41009088|NCT05882513|DRUG|Serplulimab and neoadjuvant therapy|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1."
41009089|NCT05882513|PROCEDURE|surgical resection of lung cancer|radical resection of lung cancer
41009090|NCT05882513|OTHER|Tumour will be Collected from participant. Fate of sample is Destruction after use|Tumour sample will be collected after surgery
41153732|NCT02218671|DRUG|WE 941 OD tablets|
40807383|NCT06246916|DRUG|fianlimab|Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab
41153733|NCT03973047|DRUG|Bremelanotide|Sterile aqueous solution for injection, provided as an autoinjector pen
41153734|NCT03973047|DRUG|Zofran|8 mg tablet (over-encapsulation in a capsule)
41153735|NCT03973047|DRUG|Placebo|capsule
41153736|NCT05229848|PROCEDURE|3D electroanatomical mapping alone guided CTI ablation|3D electroanatomical mapping in combination with fluoroscopy has been traditionally used in conventional CTI ablation for AFL.
40807384|NCT06246916|DRUG|cemiplimab|IV administration Q3W in combination with fianlimab
41325043|NCT05232669|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
41325044|NCT05232669|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
41325045|NCT05232669|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
40807385|NCT06246916|DRUG|relatlimab+nivolumab|IV administration every 4 weeks (Q4W)
40807386|NCT03947281|OTHER|Almond snack|The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
40807387|NCT03947281|OTHER|Cereal-based snack|The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
41153737|NCT05229848|PROCEDURE|ICE plus 3D electroanatomical mapping guided CTI ablation|ICE imaging catheter is typically introduced through an 11-F hemostatic sheath and positioned under fluoroscopic guidance in the right atrium. After catheter coupling to the imaging platform, imaging frequency is optimized by the operator using adjunctive gain, depth, and focal length controls to define anatomic structures and minimize noise. Imaging is performed at different levels in the right atrium, if needed. Imaging targets included the right atrium, coronary sinus orifice, fossa ovalis, interatrial septum (IAS), tricuspid valve, left atrium, left atrial appendage, orifice of all pulmonary veins, mitral valve, papillary muscles, aortic and pulmonary valve leaflets, right ventricle, RVOT, pericardial space, esophagus, aorta and adjoining left ventricular and right ventricular myocardium.
41009091|NCT05166213|OTHER|focus group discussions (FGD)|FGD to explore patients' attitudes/ concerns towards OLP implementation into clinical practice by means of assessment of qualitative information: 1) Patients' attitudes towards clinical usage of OLPs 2) Personal acceptance of OLP intervention 3) Perceived ideas, concerns regarding OLP implementation. Core questions: 1) Attitudes: After all that I told you about placebos, i.e. that there is a concept that patients are openly elucidated that they receive placebos: What does this elicit in you/What is your opinion on this? How do you like the idea? 2) Context of Acceptance: Under which conditions would you personally take placebos knowing that they are placebos? 3) Concerns: Why would you not take openly administered placebos? 4) Ideas for clinical implication: How could an open placebo intervention look like in the hospital? Where could it be possible to receive placebos and how could a placebo intervention in the best manner take place? What would be important from your point of view?
41009092|NCT01786629|DRUG|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
41153738|NCT02651961|PROCEDURE|Exchange of total hip or knee arthroplasty on same time|Removal of the index implants, extensive debridement, reimplantation of a new prosthesis
41478965|NCT01805726|DRUG|xylocain|Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum
41153739|NCT02651961|PROCEDURE|Exchange of total hip or knee arthroplasty in two time|Removal of the index implants in first time, extensive debridement, reimplantation of a new prosthesis in seconde time
41153740|NCT00213226|DRUG|dexamethasone|
41325046|NCT05232669|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
41325047|NCT03111342|DRUG|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
41325048|NCT03111342|PROCEDURE|Dry-needling|A placement of thin needle into the cervix without substance injection
41325049|NCT05109702|DRUG|0.25% Tanfanercept Ophthalmic Solution|Tanfanercept ophthalmic solution.
41325050|NCT05109702|DRUG|Placebo|Placebo vehicle solution.
40807396|NCT05445778|DRUG|Mirvetuximab soravtansine plus Bevacizumab|Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks
40807397|NCT05445778|DRUG|Bevacizumab|Participants will receive Bevacizumab 15mg/kg every 3 weeks
40807398|NCT04708418|PROCEDURE|Biopsy|Undergo biopsy
40807399|NCT04708418|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40807400|NCT04708418|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40807401|NCT04708418|BIOLOGICAL|Pembrolizumab|Given IV
40807402|NCT04708418|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40807403|NCT04708418|PROCEDURE|Surgical Procedure|Undergo surgery
41009093|NCT01786629|DRUG|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
41325051|NCT05351333|OTHER|placebo|Sugar pill, with an essential-oil smell and of blue color used for conditioning.
41325052|NCT02292498|DEVICE|FLIR ONE|
41325053|NCT02902029|DRUG|Vemurafenib|960 mg vemurafenib BID until progression or unacceptable toxicity develops
41325054|NCT02902029|DRUG|Cobimetinib|60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops
41325055|NCT02902029|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops
41325056|NCT01646398|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
41325057|NCT01646398|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
41325058|NCT03332472|OTHER|Telemedicine group|
41325059|NCT03332472|OTHER|Conventional group|
41325060|NCT00002544|DRUG|docetaxel|
41325061|NCT00002544|DRUG|mitoxantrone hydrochloride|
41325062|NCT01410799|DRUG|Growth Hormone Releasing Hormone (GHRH )|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
41325063|NCT05511025|DRUG|AZD6234|Participants will receive a single dose of AZD6234 as a solution via SC or IV injection
41325064|NCT05511025|DRUG|Placebo|Participants will receive matching volumes of the placebo as a solution via SC or IV injection
41478966|NCT01805726|DRUG|Alfentanil|(A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
41478967|NCT01805726|DRUG|Dexmedetomidine|(D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
41478968|NCT00733031|DRUG|AZD6918|liquid suspension, daily, oral dose
41478969|NCT00733031|DRUG|gemcitabine|intravenous, doses are on an intermittent schedule
40807404|NCT04708418|DRUG|VLP-encapsulated TLR9 Agonist CMP-001|Given SC or intratumorally
40807405|NCT06525636|DRUG|KK8123|Subcutaneous administration
40807406|NCT06369285|DRUG|Alisertib|Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
40807407|NCT06369285|DRUG|Endocrine therapy|"Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter"
40807408|NCT03267433|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
40807409|NCT03267433|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40807410|NCT03267433|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
40807411|NCT03267433|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
40807412|NCT03267433|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40807413|NCT03267433|PROCEDURE|Positron Emission Tomography|Undergo PET or PET/CT
40807414|NCT03267433|BIOLOGICAL|Rituximab|Given IV
40807415|NCT03267433|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
40807416|NCT06376162|DRUG|Ziftomenib|Oral capsule
40807417|NCT06376162|DRUG|Cytarabine|Intravenous (IV) infusion
40807418|NCT06376162|DRUG|Fludarabine|IV infusion
40807419|NCT06557356|DRUG|LY3532226|Administered SC
40807420|NCT06557356|DRUG|Placebo|Administered SC
40807421|NCT00937937|DRUG|Dinaciclib|Given IV
40807422|NCT05896163|DRUG|maplirpacept (PF-07901801)|Intravenous infusion
40807423|NCT05896163|DRUG|Glofitamab|Intravenous infusion
41325065|NCT05511025|COMBINATION_PRODUCT|Acetaminophen|Participants will receive a single dose of acetaminophen as part of a meal
40807424|NCT05896163|DRUG|Obinutuzumab|Intravenous infusion
40807425|NCT04161092|PROCEDURE|Liver transplantation Ltx|Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.
40807426|NCT04161092|OTHER|Best alternative care|All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.
41157164|NCT03435614|DRUG|Opioids|Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
41157165|NCT04448925|OTHER|inertial-load exercise (ILE)|Length of time between exercise bouts
40807429|NCT06456463|DRUG|Tagraxofusp|Tagraxofusp will be administered by intravenous infusion on days 4, 5, and 6 of each 28-day cycle.
40807430|NCT06456463|DRUG|Venetoclax|Venetoclax will be administered as an oral tablet (400 milligrams) daily of each 28-day cycle.
41325066|NCT01478893|BIOLOGICAL|SEL-068|Sub-cutaneous injection, multiple dose
40807431|NCT06456463|DRUG|Azacitidine|Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.
40807432|NCT04019288|DRUG|Batiraxcept|Given IV
40807433|NCT04019288|BIOLOGICAL|Durvalumab|Given IV
40807434|NCT02494973|DRUG|Oxaliplatin HAI|Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
40807435|NCT02494973|DRUG|Oxaliplatin IV|Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
40807436|NCT02494973|DRUG|mFOLFOX6|Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
40807437|NCT02494973|DRUG|LV5FU2|Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
40807438|NCT06632496|DEVICE|BD Prevue(TM) II|Ultrasound-guided peripheral intravenous catheter placement procedure using the BD Prevue(TM) II
41325067|NCT01478893|BIOLOGICAL|Saline|Sub-cutaneous injection, multiple dose
41325068|NCT04372342|DRUG|nalbuphine|Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.
41325069|NCT04372342|DRUG|remifentanil|remifentanil
41325070|NCT01626053|BEHAVIORAL|ASMART|Motivational Interviewing, Stages of Change, Psychological Testing, Bio-psychosocial assessment, responsive diabetes education, support, Cognitive-behavioral interventions
41325071|NCT01626053|OTHER|Control Group|no intervention
41325072|NCT02379390|DRUG|Cabazitaxel XRP6258|
41325073|NCT02379390|DRUG|Ezalutamide|
41325074|NCT02379390|DRUG|Abiraterone acetate|
41157166|NCT02784535|DRUG|Atomoxetine|norepinephrine transporter inhibitor
41157167|NCT02784535|DRUG|Placebo|placebo
41157168|NCT03087461|BEHAVIORAL|Exercise and self-management|The intervention will include aerobic exercise and self-management education using technology.
40807444|NCT06532500|BEHAVIORAL|CBT-MyOWL|12-sessions of CBT-MyOWL
40807445|NCT06532500|BEHAVIORAL|CBT-as-usual|12-sessions of CBT using Mind Over Mood or Anxiety Phobia
40807446|NCT06104488|DRUG|Avutometinib|Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle
40807447|NCT06141473|DRUG|Frexalimab|SAR441344 Solution for IV infusion
40807448|NCT06141473|DRUG|Teriflunomide|Aubagio oral tablet
40807449|NCT06141473|DRUG|Placebo infusion|Solution for IV infusion
40807450|NCT06141473|DRUG|Placebo tablet|Oral tablet
40807451|NCT06141473|DRUG|MRI contrast-enhancing agents|IV, as per respective label
40807452|NCT06141473|DRUG|Cholestyramine|oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
40807453|NCT06141473|DRUG|Activated charcoal|oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
40807454|NCT06405607|DRUG|Psilocybin|30 mg single dose
40807455|NCT06405607|DRUG|Ketamine|0.75 mg/kg weight-based single dose
41009094|NCT01835249|OTHER|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP \<120 mmHg.
41009095|NCT01835249|OTHER|Standard BP arm|Participants in the Standard BP arm have a goal of SBP \<140 mmHg.
41009096|NCT04467827|DIAGNOSTIC_TEST|examining group|Posture assessment in young healthy people depending on their level of physical activity
41009097|NCT02187302|DRUG|CRLX101|
41009098|NCT02187302|DRUG|Bevacizumab|
41009099|NCT02187302|DRUG|Standard of Care (Investigator Choice)|
41325075|NCT02379390|DRUG|Prednisone|
41325076|NCT02267278|DRUG|Ruxolitinib|Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.
41325077|NCT02267278|DRUG|Pracinostat|Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
41325078|NCT02267278|BEHAVIORAL|Questionnaire|Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
41325079|NCT02219997|DEVICE|Clear clip-on glasses|Clip-on glasses with no blue light filtering properties used as a placebo
41478970|NCT00733031|DRUG|pemetrexed|intravenous, dose administered every 21-days
41478971|NCT01631526|DIETARY_SUPPLEMENT|vitamin D|vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
41478972|NCT01816815|DRUG|BAY1002670|
41478973|NCT01816815|DRUG|Placebo|
41478974|NCT00488813|DRUG|Third generation cephalosporins|
41478975|NCT02560428|BEHAVIORAL|ESCALATES|The investigators collect and analyze qualitative data to identify the most effective combinations of intervention strategies for various practice types, contexts, and organizational characteristics, and to understand why and how those combinations are effective. The investigators also gather de-identified quantitative data that the R18s collected.
41478976|NCT02549794|PROCEDURE|CT angiography with high concentration contrast agent|Standard concentration of iodine contrast agent for CT
41478977|NCT02549794|PROCEDURE|CT angiography with low concentration contrast agent (320)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
41009100|NCT05601505|OTHER|circulating tumor DNA|This study will further testify the prognostic value of ctDNA in the treatment term of locally advanced rectal cancer, the higher the VAF value, the higher the risk of recurrence and metastasis.
41009101|NCT05617846|OTHER|Anti-osteoporosis therapy|Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.
41009102|NCT00451282|BEHAVIORAL|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
41478978|NCT02549794|PROCEDURE|CT angiography with low concentration contrast agent (270)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
41478979|NCT00606502|DRUG|Pralatrexate|"Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
41478980|NCT00606502|DRUG|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
41009103|NCT03992326|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
41325080|NCT02219997|DEVICE|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs
41325081|NCT02219997|DEVICE|ACRYSOF® IQ IOL|AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted
41325082|NCT02219997|DEVICE|Clear IOL|Clear IOL, previously implanted
41325083|NCT04205695|PROCEDURE|CEMP (closed-ended multiport catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
41009104|NCT03992326|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
41478981|NCT00606502|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment."
41009105|NCT03992326|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
41009106|NCT03992326|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
41009107|NCT03992326|OTHER|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
41009108|NCT04483440|BIOLOGICAL|4D-110|4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.
41153741|NCT02181400|DEVICE|Ellex Integre NIR laser|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
40807457|NCT05275608|DIETARY_SUPPLEMENT|VLCKD diet with replacing meals|Patients will receive an accurate teaching + brochure on VLCKD diet from an expert dietician and freely receive the correct amount of supplements provided from Labotaoire Therascience (4 or 5 meals). The supplements contain (in total) between 600 and 800 kcal, mainly fats, 1,2/1,5 g/body weight of proteins, very low amount of charbohydrates (\<30/40g/die), 10-20g fibers, + minerals and vitamins covering the needings of patients. After 6-8 weeks, 1 meal will be replaced with a natural dish rich in proteins.
41009109|NCT05857657|OTHER|: lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes for one session
41009110|NCT05857657|OTHER|propriocepticve neuromuscular facilitation|:Proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
41153742|NCT04374253|DRUG|Gantenerumab|Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
41153743|NCT04374253|DRUG|Gantenerumab|Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
41153744|NCT03534778|DIAGNOSTIC_TEST|Lymph Node Yield (LNY) and Lymph Node Ratio (LNR)|LNY and LNR will be examined after neck dissection
41153745|NCT03518047|DRUG|risankizumab|rizankizumab subcutaneous (SC) infusion
41153746|NCT03518047|DRUG|placebo for rizankizumab|placebo for rizankizumab subcutaneous (SC) infusion
41325084|NCT04205695|PROCEDURE|OESP (open-ended single port catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. hhe Non-Stimulating Needle and the Non-Stimulating open-ended catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
41325085|NCT04205695|PROCEDURE|Patient-controlled analgesia|A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
41325086|NCT04354155|DRUG|Enoxaparin Prefilled Syringe [Lovenox]|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
41325087|NCT02832596|DRUG|Norepinephrine|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
41157169|NCT00119795|BEHAVIORAL|Exercise|Increase Physical Activity to 150 min/wk
41325088|NCT02832596|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
41325089|NCT03049007|DIAGNOSTIC_TEST|Survey|Completion of surveys with diagnostic measurements (e.g., PGD, depression, anxiety, PTSD).
41325090|NCT01481909|DRUG|Rupatadin|20 mg, 28 days over 60 days
41325091|NCT02675179|DEVICE|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
41325092|NCT02675179|DEVICE|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
41325093|NCT00108797|DRUG|eptacog alfa (activated)|
41325094|NCT00108797|DRUG|Feiba VH|
41325095|NCT02562872|DRUG|DSM265|DSM265 400 mg single oral dose
41325096|NCT02562872|DRUG|Placebo|Placebo to match DSM265, single oral dose
40807458|NCT05275608|BEHAVIORAL|Hypocaloric mediterranean Diet|Patients will receive an accurate teaching + brochure on an hypocaloric Mediterranean style diet (LARN 2014) from an expert dietician. Patients will follow the istructions on grams and foods to eat. The calories will be around minus 400-500 kcal from energy requirement (measured by indirect calorimetry \* physical activity score).
40807459|NCT05207033|OTHER|Regulated ad condition|This intervention will determine if restriction of appealing features in e-cigarette ads deter young adults from trying the product.
41478982|NCT00606502|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment."
40807460|NCT05207033|OTHER|Unregulated ad condition|This intervention will determine if unrestricted appealing features in e-cigarette ads deter young adults from trying the product.
41153747|NCT02604147|DEVICE|Inspiratory pressure-threshold muscle training device.|The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.
41153748|NCT02604147|DEVICE|nspiratory pressure-threshold muscle training device.|The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
41325097|NCT02562872|BIOLOGICAL|Sporozoites|Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites
41157170|NCT00119795|BEHAVIORAL|Weight Loss|Lose 7-10% of body weight and increase physical activity to 150 min/wk
41157171|NCT00119795|BEHAVIORAL|Health Education Control|Lectures on information relevant to successful aging
41325098|NCT02562872|BIOLOGICAL|Infective mosquito bite|Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum
40807466|NCT03976843|DRUG|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
41325099|NCT04997824|PROCEDURE|Artificial Intelligence-based atrial fibrillation catheter ablation|"1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. AI-guided prediction for poor responder of AFCA in the outpatient clinic~3. Sharing information on the AI prediction with the patient and family member~4. AFCA after consent to the procedure~5. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~6. Monitoring esophageal temperature~7. Evaluation of Procedure and ablation time, and complication afer procedure~8. Post-procedure rhythm follow-up is carried out according to the study design above."
41478983|NCT00742599|DRUG|NPO-11|20 ml NPO-11
41478984|NCT00742599|DRUG|Placebo|20 ml NPO-11(Placebo)
41478985|NCT05614206|BEHAVIORAL|Behavioral intervention based on Applied Behavior Analysis principles|"Intervention sessions are conducted by licensed therapists with a training in applied behavior analysis or behavior analysts. One-to-one interventions for 3 h/week are carried out over a period of 5 months.~The intervention focused on two target symptoms, imitation and joint attention, as two of the pivotal skills in early development. Behavior analytic techniques are used, including discrete trial, shaping for positive reinforcement, systematic prompting and fading procedures, and reinforcement procedures, according to the published manual.~Imitation sessions start with imitation recognition and imitation of familiar actions (gestural and object imitation) and end with the imitation of novel actions. Joint attention evolvs from initiating requests (starting with gaze shift with the child looking away from an interesting object to the adult and back) to coordination of gaze shift, vocalization and gestures through reaching, and pointing and showing behaviors."
41478986|NCT03424850|RADIATION|HDR brachytherapy|"* Dose constraints for 21 Gy:~  * Bladder and rectum: V70 \< 1 cc~ * Urethra: V115 \< 1 cc~ * V135: 0%~* Dose constraints for 23 Gy:~  * Bladder and rectum: V65 \< 1 cc~ * Urethra: V105 \< 1 cc~ * V125: 0%~* Dose constraints for 25 Gy:~  * Prostate V100 \>90% (\>95% preferred)~ * Bladder and rectum: V70 \< 1 cc, Dmax \<115%~ * Urethra: V110 \< 1 cc, Dmax \<120%"
41325100|NCT04997824|PROCEDURE|Medical Therapy|"1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. Decision for AFCA based on clinical guidelines and the experience of the attending physician~3. AFCA after consent to the procedure~4. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~5. Monitoring esophageal temperature~6. Evaluation of Procedure and ablation time, and complication afer procedure"
41325101|NCT02637024|RADIATION|APBI: 30 Gy|30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
41325102|NCT02637024|RADIATION|APBI: 27.5 Gy|27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
41325103|NCT01767870|PROCEDURE|FIT-sigmoidoscopy|Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
41325104|NCT01767870|PROCEDURE|Colonoscopy|Advanced colorectal adenoma detection by colonoscopy
41325105|NCT01081717|DRUG|systemic non-biological treatments|as prescribed
41478987|NCT04013945|DIETARY_SUPPLEMENT|Superba Boost (Active)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Superba Boost.
41478988|NCT04013945|DIETARY_SUPPLEMENT|Vegetable oil (Placebo)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Placebo.
40807467|NCT06347016|DRUG|Plozasiran Injection|ARO-APOC3 Injection
40807468|NCT06347016|DRUG|Placebo|sterile normal saline (0.9% NaCl)
40807471|NCT05512065|DEVICE|Ultrasound|Ultrasound scan of the right and left uterine arteries and umbilical artery.
40807472|NCT06194604|DEVICE|Instrument-assisted soft tissue mobilization|Instrumented soft tissue mobilization is a type of manual therapy method.Istrumented soft tissue mobilization aims to reduce fascial limitations by increasing circulation. Increases in localized blood flow and soft tissue realignment promote muscle function, increased normal joint movement, and decreased pain.
40807473|NCT06194604|OTHER|Routine rehabilitation programe|Routine rehabilitation programe consisting of stretching and strengthening exercises will be applied.
41325106|NCT01081717|BIOLOGICAL|anti-TNF biologics|as prescribed
41325107|NCT01081717|BIOLOGICAL|golimumab|as prescribed
40807476|NCT06389721|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|Measure the electrical activity of your brain before you receive chemotherapy treatment and once monthly for a maximum of 6 measurements.
41009111|NCT05857657|OTHER|propriocepticve neuromuscular facilitation with lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes with proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
41009112|NCT03184792|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of cervical spinal cord over the skin
41478989|NCT00777127|DRUG|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
41478990|NCT00777127|DRUG|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
41478991|NCT06166784|DEVICE|Mectascrew B|reconstruction of ACL or PCL rupture
41009113|NCT03184792|OTHER|Physical therapy|Physical therapy to improve arm and hand functions
41009114|NCT01840670|DRUG|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
41009115|NCT05010174|DRUG|MDR product|Observation of patients previously receiving MDR product(s)
41009116|NCT04155996|DEVICE|data collection|Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
41325108|NCT01081717|BIOLOGICAL|non-anti-TNF biologics|as prescribed
41325109|NCT01081717|OTHER|general population|non-treated cohort
41325110|NCT02573233|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
41325111|NCT02573233|DRUG|Dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
41325112|NCT02573233|DRUG|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
41325113|NCT02573233|DRUG|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
41325114|NCT02573233|DRUG|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
41325115|NCT06187311|DRUG|Rivaroxaban 20 MG|Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
41325116|NCT06187311|DRUG|Rivaroxaban 15 MG|Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
41478992|NCT02553278|DEVICE|VelaShape device|Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
41478993|NCT02553278|DEVICE|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
40807477|NCT04877288|BIOLOGICAL|Belatacept|Specified dose on specified days
40807478|NCT04877288|DRUG|Tacrolimus|Specified dose on specified days
41009117|NCT05897216|DRUG|CKD-383|QD, PO
41009118|NCT05897216|DRUG|CKD-501, D745, D150, D029|QD, PO
41009119|NCT00004091|OTHER|Papanicolaou test|
41009120|NCT00004091|OTHER|cytology specimen collection procedure|
41009121|NCT00004091|OTHER|fluorescent antibody technique|
41009122|NCT00004091|PROCEDURE|colposcopic biopsy|
41009123|NCT00004091|PROCEDURE|study of high risk factors|
41009124|NCT00952341|DRUG|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
41009125|NCT00952341|DRUG|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
41009126|NCT00952341|DRUG|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
41009127|NCT00952341|DRUG|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
41009128|NCT00952341|DRUG|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
41009129|NCT05644327|BEHAVIORAL|Cardiovascular training (CT)|12 weeks of CT
41009130|NCT05644327|BEHAVIORAL|Resistance training (RT)|12 weeks of RT
41009131|NCT05644327|BEHAVIORAL|Multimodal training (MT)|12 weeks of MT
41009132|NCT04055116|DRUG|Buffered Lidocaine|Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
41478994|NCT04636593|DRUG|Almonertinib|All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20\<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.
41478995|NCT03824990|BEHAVIORAL|Quality improvement of management of neonatal jaundice|During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
41478996|NCT05019482|BEHAVIORAL|University-based intervention to promote PA and reduce ST|"This intervention was realized with all college student and involved:~1. Design-based innovative workshops during the first week;~2. 8-weeks program of Physical Activity constructed by users~3. Information session focusing on the promotion of active behaviors~4. Feedback provided to the users with an individualized report"
41478997|NCT05982821|OTHER|Artificial Intelligent|Artificial intelligence assisted radiologists to extract ultrasound features of thyroid nodules.
41478998|NCT04344457|DRUG|Hydroxychloroquine|200 mg PO BID 7 days
41478999|NCT04344457|DRUG|Indomethacin|50 mg PO TID 14 Days
41479000|NCT04344457|DRUG|Zithromax Oral Product|500 mg PO QD 3 Days
41479001|NCT03417791|OTHER|no intervention|no intervention
41479002|NCT06172413|DEVICE|transcranial alternating current stimulation (tACS)|"Three conductive electrodes will be applied to the scalp: one 4.45 × 9.53 cm electrode placed over the forehead (Fpz, Fp1, and Fp2 in the 10/20 international placement system) and two 3.18 × 3.81 cm electrodes over the mastoid areas.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~Each subject will receive 40 sessions of tACS intervention during 4 consecutive weeks at a fixed day time twice per day (once in morning and afternoon, respectively) from Monday through Friday. Each session lasts 40 min."
41479003|NCT06172413|DEVICE|Sham tACS|Sham tACS
41479004|NCT00002352|DRUG|Lobucavir|
41479005|NCT00842530|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
41479006|NCT00842530|BIOLOGICAL|Inactivated rabies virus vaccine|0.5 mL, Subcutaneous
41479007|NCT00842530|BIOLOGICAL|Placebo|Sodium chloride 0.9%
41479008|NCT05636566|DRUG|Sevoflurane|inhalational anaesthesia for maintenance
41325117|NCT03595384|BEHAVIORAL|Soccer-based adaptation to the DPP|"Participants will complete online education modules during an initial 12 week conditioning phase where they will participate in soccer drills and other fitness routines (two 1-hour sessions per week). At the 12 week mark participants will transition onto a soccer league team for the following 12 weeks where they will continue to complete online modules and meet with the soccer coach monthly.~During the soccer sessions and games participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. In addition, they will also be asked to wear a Garmin fitness tracker for the duration of the study to measure steps and moderate and vigorous activity.~The online education will be a version of the Diabetes Prevention Program and can be completed on a phone or computer with internet access."
41325118|NCT06261242|DEVICE|Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)|The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
41325119|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation.|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days"
41479009|NCT05636566|DRUG|Propofol infusion for maintance|propofol infusion after induction for maintenance of anaesthesia
41479010|NCT05636566|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia
41479011|NCT01904422|PROCEDURE|conventional periodontal treatment|
41479012|NCT02221908|DEVICE|Mespere Venus 1000 CVP System|
41479013|NCT00688428|DRUG|Esomeprazole 40mg/ASA 325mg|combination capsule, administered as a single oral dose
41479014|NCT00688428|DRUG|Esomeprazole|40mg capsule, administered as a single dose
41479015|NCT00688428|DRUG|ASA|325mg tablet, administered as a single oral dose
41479016|NCT05560724|DEVICE|Transcranial direct current stimulation (tDCS)|Anodal stimulation or sham
41479017|NCT02978924|DEVICE|tsDCS|20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
41479018|NCT02039752|OTHER|Treatment|
41479019|NCT00769626|OTHER|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
41009133|NCT06504030|DRUG|modified-DEP|"For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed."
41009134|NCT01652456|OTHER|Addiction support|one consultation with an addiction specialist
41325120|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
41325121|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased."
41479020|NCT00769626|OTHER|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
41479021|NCT04030520|BEHAVIORAL|POPPi behavioral intervention|behavioral intervention with offer of HIV self test
41479022|NCT04030520|BEHAVIORAL|POPPi behavioral intervention|behavioral intervention
41479023|NCT02133001|DRUG|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
41479024|NCT02133001|DRUG|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
41479025|NCT02947724|DRUG|SURGICEL®|Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
41479026|NCT01045421|DRUG|MLN8237 (Alisertib)|"Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period."
41009135|NCT04628962|PROCEDURE|Collection and Raman analysis of saliva for the database|Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model
41479027|NCT01231750|DRUG|Capsaicin|0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
41479028|NCT01231750|OTHER|Placebo cream|cream, 4cm spread over 8cm x 15cm area of skin
40807479|NCT04877288|DRUG|Cyclosporine A|Specified dose on specified days
40807480|NCT04877288|DRUG|Mycophenolate Mofetil|Specified dose on specified days
40807481|NCT04877288|DRUG|Enteric Coated Mycophenolate Sodium|Specified dose on specified days
40807482|NCT04877288|DRUG|Corticosteroids|Specified dose on Specified days
41153749|NCT02660047|DRUG|Liraglutide|"Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
41479029|NCT04300413|OTHER|High-Intensity Rehabilitation plus Mobility (HeRo)|Progressive, high-intensity strengthening and functional intervention coupled with structured mobility based in principals of behavioral economics.
41479030|NCT01091103|DRUG|Enzalutamide|
41479031|NCT02963402|DRUG|Tocilizumab|
41479032|NCT02963402|DRUG|Adalimumab|
41479033|NCT02377921|DRUG|aceneuramic acid extended-release (Ace-ER)|tablets for oral use
41153750|NCT02660047|DRUG|Liraglutide - Placebo|"Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
41479034|NCT02377921|DRUG|Placebo|tablets for oral use
41009136|NCT02953821|DRUG|Acthar Gel|1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)
41479035|NCT02459041|OTHER|Elastography, contrast enhancement|"Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors."
41479036|NCT00846859|DRUG|varenicline (Champix/Chantix)|14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
41479037|NCT00846859|DRUG|placebo for varenicline|14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
41479038|NCT03737318|BEHAVIORAL|Biofeedback-ultrasound|In ultrasound biofeedback, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
41479039|NCT03737318|BEHAVIORAL|Biofeedback--visual-acoustic|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
41479040|NCT03737318|BEHAVIORAL|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
41479041|NCT02486913|OTHER|Enhanced Health Check|National Health Service Health Check enhanced by risk report
41479042|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Placebo|Colored water
41479043|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Caffein|Sugar free energy drink at 5mg/kg caffeine
41479044|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Decaf|Sugar free decaf energy drink (vitamins only)
41009137|NCT02953821|DRUG|Placebo Gel|1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
41009138|NCT03765307|DEVICE|SyMap Bronchial Ablation System|The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
41009139|NCT03765307|DEVICE|Boston Scientific Alair System|The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
41009140|NCT03393611|DRUG|CPX-351|Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17
41325122|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection combined with Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
41479045|NCT02167542|DEVICE|Noninvasive Positive Pressure Ventilation|Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2\>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
41009141|NCT03393611|DRUG|Fludarabine|Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)
41009142|NCT03393611|DRUG|Melphalan|Melphalan 140 mg/m2 (Day -2)
41009143|NCT03393611|DRUG|Rabbit Anti-Human T-Lymphocyte Globulin|Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)
41479046|NCT02167542|DEVICE|CPAP valve (Boussignac)|"Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.~Oxygen flow will be titrated by the investigator to ensure SpO2\>92%."
41479047|NCT00121160|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM) group intervention|Participants will meet in closed, structured groups of 4 to 6 women for ten weekly, 2-hour group sessions. The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Group members and group leaders are used as role models for effective coping and the use of social support. The groups also encourage emotional expression and provide an opportunity to practice techniques learned in the group and experience social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Each week participants also experience a different relaxation technique. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
41479048|NCT00838942|BEHAVIORAL|Questionaries|MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
41479049|NCT01972035|DRUG|Valacyclovir|Experimental Arm
41479050|NCT01972035|DRUG|Valganciclovir|Standard of care
41479051|NCT03687879|OTHER|Questionnaires|Reporting of medical gestures or acts, speech, embarrassing or hurtful attitudes during pregnancy follow-up or during hospitalization outside childbirth, or during childbirth or immediate after birth among women giving birth in one of the 26 maternity hospitals in the period of observation period.
41153751|NCT05756348|DEVICE|Marathon® XL No Sting Cyanoacrylate Skin Protectant and 3M™ Cavilon™ Advanced Skin Protectant|All participants will receive both device interventions listed above.
40807488|NCT06320678|OTHER|Nursing Students Education|Effect of Concept Mapped Blended Learning Self-Directed Learning
40807489|NCT03142841|OTHER|RESCUE Problem Solving Intervention|This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
40807490|NCT05601726|DRUG|ABD-3001|Each patient will receive a single and fixed 4 hours-intravenous infusion dose of ABD-3001. The first dose of the first cohort will receive an estimated infusion dose of 18 mg/m² at Day 1. Subsequent cohorts will be given the following doses: 54 mg/m², 135 mg/m², 270 mg/m², 405 mg/m², 540 mg/m².
40807491|NCT05601726|DRUG|ABD-3001|"Based on PK data gathered during the SAD, a dose regimen optimization will be done using population Pharmacokinetic modelling in order to set the optimal frequency of infusion per week to achieve sustained exposition throughout treatment period. Based on this analysis, the Sponsor will, in accordance with the Safety review Committee, define the occurrence of infusion to 1, 2 or 3 times per week, during 4 weeks (28 days ± 3 days).~Number of infusions given per week and dose increase between each dose will be set so that, whatever the initial dose used in the MAD part, total dose increase will never get above the MTD determined in the SAD part or a dose defined by the SRC, if no MTD is determined during the SAD part."
41325123|NCT03372603|DRUG|GSK2798745|GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient \[API\]) to be taken with a glass of water (approximately 240 mL).
41009144|NCT03393611|BIOLOGICAL|Haplo-Cord Stem Cell Transplantation|Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.
41009145|NCT05716711|OTHER|LAVENDER OIL|IT WILL BE APPLIED TO 60 PATIENTS, 20 IN EACH GROUP, WITH A COLOSTOMY
41009146|NCT00154453|PROCEDURE|obtain surgical specimen for analysis|
41325124|NCT03372603|DRUG|Placebo|Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
41325125|NCT04266106|DRUG|SuperBio probiotic|One capsule po BID for 28 days
41325126|NCT04266106|DRUG|Placebo|One capsule po BID for 28 days
41325127|NCT00860418|BEHAVIORAL|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
41157172|NCT05129371|OTHER|Breathing exercise|Following the protocol prepared, the breathing exercise group is given breathing exercises for about 20 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application. Reminders (by text message or voice call) are used for the remaining 4 days of the week, allowing the patient to do it on their own.
41325128|NCT00860418|BEHAVIORAL|Standard asthma education|Standard asthma education during 2 home visits.
41325129|NCT03838367|DRUG|350 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
41325130|NCT03838367|DRUG|525 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
41325131|NCT03838367|DRUG|700 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
41325132|NCT03838367|DRUG|AUC 5 Carboplatin|Carboplatin is an anticancer drug chemotherapy drug.
41325133|NCT03838367|DRUG|Maximum Tolerated Dose (MTD) of leronlimab|The decision on the MTD will be made following the results obtained from Phase I studies
41325134|NCT03864536|BEHAVIORAL|Cognitive Prescriptions|Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
41325135|NCT03159819|GENETIC|CAR-CLD18 T Cells|Dose escalation will be applied in this study.
41325136|NCT05453006|DEVICE|COPAN 552c.80 FLOQSwab|The study will implement HPV self-sampling as an option for cervical cancer screening alongside usual care for Somali women, and evaluate changes pre and post implementation, compared to Fairview intervention clinics.
41325137|NCT04449276|BIOLOGICAL|CVnCoV Vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
41325138|NCT04449276|DRUG|Placebo|Participants will receive an intramuscular injection by needle in the deltoid area.
41325139|NCT00292747|DRUG|Drotaverine|
41325140|NCT00292747|DRUG|Drotaverine Placebo|
41325141|NCT00292747|DRUG|Ibuprofen|
41325142|NCT00292747|DRUG|Ibuprofen Placebo|
41325143|NCT04722484|DRUG|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
41479052|NCT05557448|DRUG|TYNADOTE|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
41479053|NCT05557448|DRUG|Placebo Oral Tablet|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
41479054|NCT03088618|PROCEDURE|Nasal septoplasty|Type of surgery
41325144|NCT06283173|DEVICE|ColActive Plus Collagen Matrix Dressing|"Induction phase: Test article applied with Hill Top chamber every 48+ hours over 3 weeks. Rest phase: 10-day rest period with no application.~Challenge phase: Test article applied for 48 hours and evaluated through 48 hours post removal.~The positive control is evaluated at Induction 1 only. The negative control is applied following the same schedule as the test article."
40807496|NCT05056805|OTHER|Aerobic Exercise|Receive aerobic exercise encouragement
40807497|NCT05056805|OTHER|Dietary Intervention|Consume high protein snack/meal/shake
40807498|NCT05056805|OTHER|Nutritional Intervention|Receive nutritional consultation and guidelines
40807499|NCT05056805|OTHER|Quality-of-Life Assessment|Ancillary studies
40807500|NCT05056805|OTHER|Questionnaire Administration|Ancillary studies
40807501|NCT05056805|OTHER|Resistance Training|Complete strengthening exercise
40807502|NCT04622670|OTHER|Media Intervention|Receive DVD
40807503|NCT04622670|OTHER|Quality-of-Life Assessment|Ancillary studies
40807504|NCT04622670|OTHER|Questionnaire Administration|Ancillary studies
41325145|NCT00050479|DRUG|Celecoxib (Celebrex)|
41325146|NCT06141811|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
41325147|NCT06141811|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
40807505|NCT04622670|OTHER|Survey Administration|Ancillary studies
40807506|NCT04622670|PROCEDURE|Yoga|Attend yoga class
41479055|NCT02572349|DRUG|IW-1701|
41009147|NCT00049062|DRUG|anastrozole|
41479056|NCT02572349|DRUG|Matching Placebo|
41479057|NCT05612282|DIAGNOSTIC_TEST|body composition analysis|A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer
41479058|NCT05612282|OTHER|anthropometric measurements|An assessment of the status of nutrition based on anthropometric measurements was carried out.
41325148|NCT01824693|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
41325149|NCT01824693|DRUG|Busulfan|Given IV
41325150|NCT01824693|DRUG|Cyclophosphamide|Given IV
41325151|NCT01824693|DRUG|Fludarabine Phosphate|Given IV
41325152|NCT01824693|OTHER|Laboratory Biomarker Analysis|Correlative studies
41009148|NCT00049062|DRUG|gefitinib|
41325153|NCT01824693|DRUG|Melphalan|Given IV
41325154|NCT01824693|DRUG|Mycophenolate Mofetil|Given IV or PO
41325155|NCT01824693|OTHER|Pharmacological Study|Correlative studies
41325156|NCT01824693|DRUG|Tacrolimus|Given IV or PO
41325157|NCT03182842|DEVICE|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
41325158|NCT03182842|DEVICE|SMBG - Blinded Sensor|Insulin dosing based on SMBG
41009149|NCT04546854|BEHAVIORAL|Appeals|Written text motivating participants to take up the seasonal influenza vaccination
41153752|NCT03715413|OTHER|pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.|Patients were lying prone. Firstly, T2, 3, 4 disc level was detected then the target 2nd, 3rd and 4th thoracic nerve roots were identified. After marking the entry points, adequate sterilization of the skin was achieved using bovidone iodine then the skin was anasthesied by 2 ml lidocaine 2% at each entry point. The Baileys radio frequency (RF) 22G, 10 cm, sharp needles with 10 mm active tip was introduced to face the 2nd, 3rd and 4th thoracic nerve roots.The PRF course was carried out at 42°C for 120 s twice at each level followed by injection of 1 ml lidocaine 2% and 1 ml dexamethasone 4 mg at each level.
41153753|NCT03715413|DRUG|Tamoxifen|received Tamoxifen 10 mg daily
41325159|NCT05889351|DRUG|Vehicle gel, 4 + 4 applications or 4 + 2 applications|Control arm/placebo
41325160|NCT05889351|DRUG|LTX-109 3% gel, 4 + 4 applications|Cohort 1 active treatment
41325161|NCT05889351|DRUG|LTX-109 3% gel, 4 + 2 applications|Cohort 2 active treatment
41325162|NCT02027415|DIETARY_SUPPLEMENT|Beet juice|2 cups of beet juice will be given before the car ride
41325163|NCT02027415|DIETARY_SUPPLEMENT|Orange juice|2 cups of orange juice will be given before the car ride
41325164|NCT02637440|PROCEDURE|FFR guided PCI|Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8
41325165|NCT02637440|PROCEDURE|Angio guided PCI|Patients receive PCI without FFR measurement
41325166|NCT01729650|BEHAVIORAL|Physical and diet educational group|educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
41325167|NCT02675738|OTHER|good clinical practice|
41325168|NCT02604615|DRUG|Capecitabine(Aibin)|capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
41325169|NCT02604615|DRUG|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
41325170|NCT02604615|RADIATION|Radiotherapy|concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
41325171|NCT04565600|DRUG|Etoricoxib|Etoricoxib 60 Mg Oral Tablet
41325172|NCT05487131|BEHAVIORAL|electrical stimulation|different types of weak electrical stimulation will be used
41325173|NCT05161312|BEHAVIORAL|iACT-BC: Oncovox|A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years
41325174|NCT00089271|DRUG|alvespimycin hydrochloride|Given IV
41325175|NCT00089271|OTHER|laboratory biomarker analysis|Correlative studies
41325176|NCT04598711|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
41325177|NCT04598711|BEHAVIORAL|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
41325178|NCT04598711|BEHAVIORAL|Muscle Power training|All participants undergo power training of the quadriceps muscles using unilateral and bilateral leg presses (Total Gym GTS, San Diego, CA), 3 times/week for 4 consecutive weeks (12 sessions). Power training will follow standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Power training is provided at visits 3-14.
41479059|NCT05612282|OTHER|Interview questionnaire|An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.
41325179|NCT04598711|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-14.
41325180|NCT04598711|BEHAVIORAL|Treadmill Training|All participants will undergo short burst interval treadmill training using self-selected and fast walking speeds.
41325181|NCT00997178|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
41325182|NCT00997178|OTHER|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
41153754|NCT05376735|BEHAVIORAL|Purrble intervention|"The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing.~The Purrble is introduced to the student as an anxious creature that may need kind attention from humans. When picked up, the Purrble emits a frantic heartbeat that slows down if the child uses calm stroking movements. If it's soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to students in emotional moments when they would attempt to practice emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in students' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2."
41157173|NCT05129371|OTHER|Placebo Breathing Group|The placebo group is asked to breathe normally through the nose with eyes closed, sitting in the same position as the intervention group for 10-15 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application.
41325183|NCT04464785|DEVICE|CentriMag Circulatory Support System|The CentriMag Circulatory Suppose System is indicated for providing support for up to 30 days for one or both ventricles of the heart to treat post-cardiotomy patients who fail-to-wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.
41325184|NCT01837017|BEHAVIORAL|Home-based Exercise|This is a control group with no intervention
41325185|NCT05076045|DEVICE|Personal sound amplification products|Participants will be tested with bilateral personal sound amplification products.
41325186|NCT06524596|DRUG|tartaric acid butorphanol|The group received 0.02 mg/kg tartaric acid butorphanol intravenously over 5 minutes, 30 minutes before anaesthesia induction
41325187|NCT06524596|DRUG|normal saline|The group received 0.02 mg/kg normal saline intravenously over 5 minutes, 30 minutes before anaesthesia induction
41325188|NCT06524596|DRUG|propofol and remifentanil|Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
41325189|NCT01029015|PROCEDURE|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
41325190|NCT01029015|PROCEDURE|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
41325191|NCT00553553|DRUG|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
41325192|NCT00553553|DRUG|Morphine hydrochloride, remifentanil hydrochloride|"Pre-induction intrathecal morphine HCl (\< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure"
41325193|NCT00650598|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
41325194|NCT00650598|DRUG|diclofenac|diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
41325195|NCT02360553|BEHAVIORAL|ObeseGO!|The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.
41325196|NCT02360553|BEHAVIORAL|Pamphlets material|The control group will be given pamphlets material on diet and physical activity.
41325197|NCT05606978|BEHAVIORAL|FASTb|FAST blended
41479060|NCT05612282|DIAGNOSTIC_TEST|biochemical parameters|The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.
41479061|NCT05612282|DIAGNOSTIC_TEST|cardiopulmonary fitness test|Cardiopulmonary fitness was assessed using the Modified Bruce protocol
41325198|NCT05606978|BEHAVIORAL|FASTr|FAST regular
41325199|NCT03027141|BEHAVIORAL|Face recognition task|Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
40807516|NCT06287463|DRUG|DCC-3084|Administered orally
40807517|NCT04484909|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
40807518|NCT04484909|RADIATION|Radiation Therapy|Undergo radiation therapy
40807519|NCT06275776|DEVICE|Ethicon Monocryl Smooth Suture|Monocryl Smooth Suture 3-0 antibacterial with PS-2 needle. Monofilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
40807520|NCT06275776|DEVICE|Ethicon Vicryl Rapide Braided Suture|Vicryl Rapide Braided Suture 3-0 with FS-2 needle. Multifilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
40807521|NCT06275776|DEVICE|Flexifuze Indermil Topical Skin Adhesive|Flexifuze Indermil Topical Skin Adhesive. The skin glue is applied after the application of the suture to further seal the wound from the external environment. Currently used in standard care.
40807522|NCT06275776|DEVICE|Dermabond Prineo Skin Closure System|Dermabond Prineo Skin Closure System. Novel skin closure system consisting of a self-adhesive transparent mesh, over which skin glue is applied as well. This system approximates the wound edges, shields the wound from the external environment, enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
40807523|NCT06275776|DEVICE|Stryker Zip Skin Closure System|Stryker Zip Skin Closure System. Novel skin closure system consisting of two self-adhesive strips placed parallel to either side of the wound. Zip tie/Cable tie-like structures running perpendicular to the adhesive strips can be tightened to approximate the wound edges and thusly close the wound. This system enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
41325200|NCT03978104|DIETARY_SUPPLEMENT|Okara biscuits|Consumption of okara-enriched biscuits together with habitual diet.
41325201|NCT03978104|DIETARY_SUPPLEMENT|Bio-okara biscuits|Consumption of bio-okara-enriched biscuits together with habitual diet. Bio-okara is a form of fermented okara.
41325202|NCT03978104|DIETARY_SUPPLEMENT|Control biscuits|Consumption of control biscuits together with habitual diet.
41325203|NCT01294982|DRUG|AOBO-001|AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
41325204|NCT01294982|DRUG|AOBO-001|AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily
41325205|NCT01294982|DRUG|Placebo|Placebo Oral Capsules twice daily
41479062|NCT05612282|OTHER|nutritional interview|A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.
41157174|NCT05669287|DIAGNOSTIC_TEST|CT Perfusion|CT Perfusion
41157175|NCT05542914|BEHAVIORAL|electronic screening and brief intervention.|e-SBIs is an evidence based approach to engage non-treatment-seeking individuals who use substances to reduce use or enter treatment. It consists of completing screening instruments related to substance use and sexual risk behavior and receiving a tablet-based, Motivational Interviewing intervention to help individuals build motivation to reduce their use and plans to achieve their substance use and HIV risk reduction goals.
41325206|NCT02751021|OTHER|pacemaker diagnostic algorithm|evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
41325207|NCT02751021|OTHER|Attended cardiorespiratory sleep study|sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
41325208|NCT00001777|DRUG|Sertraline|
41325209|NCT04825288|BIOLOGICAL|XB2001 or Placebo|XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.
41325210|NCT01707368|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
41325211|NCT02800720|BEHAVIORAL|Meditation Awareness Training|8 Week Meditation Intervention
41325212|NCT02800720|BEHAVIORAL|Cognitive Behavioral Therapy for Groups|8 week intervention based on Cognitive Behavioral Theory
41153755|NCT05376735|BEHAVIORAL|Single Session Intervention|"The SSI has been co-produced with university students and clinical experts, combining the theories of ER with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~* Initial guided reflection exercise (helping understand one's experience with Purrble in the 1st week).~* Short interactive psychoeducation, introducing the concept of window of tolerance, the Process Model of Emotions (Gross2015), and specific ways in which Purrble can help students down-regulate emotions within the context of the process model.~* Action plan to identify: moments when Purrble could be useful, what ER strategies they would like to use in those moments, what obstacles they may encounter, and how to overcome them.~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
40807528|NCT03884660|DEVICE|remede System|Patients undergoing a remede System implant attempt. Study devices will be used per approved indications for use for each geography.
40807529|NCT05467839|DEVICE|derma pen|Derma pen is automatic and rechargeable device (vibrating frequency:6500-10000 r/m, vibration speed level 5, model: Ultima A6, company: Dr. Pen and country: Korea). With every case the needle should be replaced. Needle length is adjustable from 0.25mm to 2mm according to the treated areas. The pen is convenient in treating narrow areas such as the nose, around the eye and the mouth. The vibration speed of the pen can be controlled in 5 levels
40807530|NCT06130254|DRUG|Adagrasib|Given by PO BID
40807531|NCT06130254|DRUG|Olaparib|Given by PO BID
41009150|NCT01222494|BEHAVIORAL|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
41479063|NCT06264791|OTHER|Stress|To manipulate stress, we follow the personalized imagery script procedure developed by Sinha and colleagues. Participants randomly assigned to the stress condition will be interviewed about one week prior to the lab session. They will share a detailed description of a stressful event from their life (last 12 months) with the interviewer. Based on this interview, the experimenter will write a script (\~500 words), that will then be audiotaped. Participants will listen to this personalized audiotape during the experiment, and will be asked to imagine this event as vividly as possible. Participants randomly assigned to the no stress condition will listen to a generic audiotape that describes a non-stressful event (\~500 words). They will not be interviewed. During the lab session, participants will first complete a 3-min color counting task. The participant will then listen to the audiotape (personalized stressful audiotape in stress condition, generic non-stressful audiotape in no stress c
40807533|NCT06635148|DRUG|JNJ-81201887|No study intervention will be administered as part of this LTE study.
41009151|NCT01222494|BEHAVIORAL|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
41009152|NCT05683600|BIOLOGICAL|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
41009153|NCT05683600|BIOLOGICAL|Placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
41009154|NCT01691027|BEHAVIORAL|Visuo-motor training|Participants will undergo training on three developed software modules on Samsung Galaxy Note Pro tablets to see their effect on low vision rehabilitation
41009155|NCT02355132|OTHER|Insurance Intervention|Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
41009156|NCT06068569|BIOLOGICAL|GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)|Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed. 1st injection - component I, 2nd injection - component II.
41009157|NCT06196567|DEVICE|PEMF|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions
41009158|NCT06196567|OTHER|exercise|do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery
40807534|NCT06635148|OTHER|Sham Procedure|No study intervention will be administered as part of this LTE study.
40807535|NCT04974047|DRUG|Tislelizumab|Administered intravenously as specified in the treatment arm.
41153756|NCT03322579|DEVICE|Balloon dilatation Eustachian tuboplasty|Eustachian tuboplasty by balloon dilation involves the recanalization of the cartilaginous portion of the ET via the nasopharynx with a balloon catheter. This catheter is inflated to multiple atmospheres of pressure for a short amount of time and then removed.
41325213|NCT05911412|BEHAVIORAL|Mindfulness-based cognitive therapy using neuroscience (NMBCT)|Mindfulness-based cognitive therapy using neuroscience (NMBCT) is a standardized 8-week course taught by trained instructors. The NMBCT is a group therapy that takes place once a week for about 90 minutes per session. The program consists of mental education for each session, 2-3 mindfulness meditation practice, mindfulness practice in daily life, and about 30 minutes of daily home mindfulness meditation task. While participating in the program, the subjects will receive psychoeducation and various mindfulness meditation techniques (eating meditation, breathing meditation, sedentary meditation, viewing meditation, and listening meditation, etc.).
41153757|NCT02154893|DEVICE|Ultrasound plus Laser and therapeutic exercise|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.
40807542|NCT05646862|DRUG|Inavolisib|Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle.
40807543|NCT05646862|DRUG|Fulvestrant|Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.
40807544|NCT05646862|DRUG|Alpelisib|Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
40807545|NCT06629220|OTHER|Tools|In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of men with suicidal thoughts/behavior.
40807546|NCT05053321|DRUG|Valbenazine|All participants will be treated with Valbenazine for 7 weeks.
40807547|NCT04809766|BIOLOGICAL|Autologous Mesothelin-specific TCR-T Cells|Receive FH-TCR Tᴍsʟɴ IV
40807548|NCT04809766|DRUG|Cyclophosphamide|Given IV
40807549|NCT04809766|DRUG|Fludarabine|Given IV
40807550|NCT04809766|DRUG|Bendamustine|Given IV
41325214|NCT01445106|DRUG|Nelfinavir|
40807552|NCT03735667|DEVICE|ACURATE neo2™ Transfemoral TAVR System|ACURATE neo2™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
40807553|NCT03735667|DEVICE|Medtronic CoreValve TAVR System|Medtronic CoreValve Evolut R or Evolut PRO Transcatheter Aortic Valve Replacement (TAVR) System (or any future Corevalve iterations): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
40807554|NCT03735667|DEVICE|Edwards SAPIEN 3 TAVR System|Edwards SAPIEN 3 TAVR system (or any future SAPIEN iterations): balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
41009159|NCT02591628|BEHAVIORAL|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
41009160|NCT03970434|OTHER|Venous blood collection|Venous blood collection
41009161|NCT03970434|OTHER|Peripheral blood collection|Peripheral blood collection
41009162|NCT02831270|PROCEDURE|Acute normovolemic hemodilution (ANH)|
41009163|NCT02831270|DRUG|hydroxyethyl starch (HES 130/0.6)|
41009164|NCT00002010|DRUG|Fluconazole|
41009165|NCT05117944|OTHER|"drama-supported patient role experience"|The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
41325215|NCT01445106|DRUG|Nelfinavir Mesylate|
41325216|NCT04673604|DIAGNOSTIC_TEST|Assessment of ocular surface staining (Oxford score 0-15 scale)|Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).
41325217|NCT04673604|DRUG|mean diurnal intraocular pressure-lowering|At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
41325218|NCT03856528|OTHER|collection of patient data|Patient data will be obtained using digital patients records systems. The following data will be assessed: Demographics and baseline patient characteristics (e.g., gender, age, hospital admission and discharge dates), diagnoses, comorbidities (history of meningitis and/or encephalitis, epileptic disorders, remote stroke, remote intracranial bleeding, remote autoimmune disease, neurodegenerative disorders), laboratory features (blood cultures, lumbar puncture), features of neuroimaging (e.g., time admission-to-CT), therapeutic features (incl. time admission-to-treatment), Patients' outcome measures (Glasgow Outcome Score)
41325219|NCT01095068|BEHAVIORAL|Physical exercise|
41009166|NCT03795922|DRUG|MT10109L|MT10109L will be injected into the GL.
41009167|NCT03795922|DRUG|Placebo|Placebo will be injected into the GL.
41009168|NCT02719158|DRUG|6 mg ciprofloxacin|Single administration of OTO-201
41009169|NCT02719158|DRUG|12 mg ciprofloxacin|Single administration of OTO-201
41009170|NCT02719158|OTHER|Sham|
40807555|NCT03735667|DEVICE|ACURATE Prime™ Transfemoral TAVR System XL|ACURATE Prime™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
41153758|NCT02154893|DEVICE|Ultrasound plus Laser|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
41325220|NCT04876989|PROCEDURE|US-SGB|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.
41153759|NCT02154893|DEVICE|Utrasound plus Laser Placebo|The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
41153760|NCT02612116|DRUG|Pulverized ticagrelor sublingually|Pulverized ticagrelor (180 mg) administered sublingually
41153761|NCT02612116|DRUG|Pulverized ticagrelor orally|Pulverized ticagrelor (180 mg) administered orally
41153762|NCT02612116|DRUG|Integral ticagrelor|Integral ticagrelor (180 mg) administered orally
40807561|NCT06484179|BEHAVIORAL|Targeted Self-Help|In addition to usual care participants will receive a self-help booklet specific for their cancer type. There are five booklets available, written at a 5-6th grade reading level and targeted by cancer type, that explain the connection between smoking and each cancer type, describe the benefits of quitting smoking after cancer, and address some of the barriers cancer patients face to quit smoking when fighting cancer. Each booklet also includes four testimonials inspired from conversations with patients.
40807562|NCT06484179|BEHAVIORAL|Usual Care|Participants will receive the standard care typically offered for smoking cessation.
40807563|NCT06402955|RADIATION|11C-UCB-J|Radiotracer for imaging.
40807564|NCT06212063|BEHAVIORAL|Cadet Health|Integrated physical and mental optimization training program used as tool for young individuals readying themselves to join the military
40807565|NCT05592626|DRUG|STAR0602|solution, intravenous infusion
41153763|NCT04421118|OTHER|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient based on three-dimensional modeling and fluid dynamics simulation
41153764|NCT06077929|OTHER|No intervention done|No interventions done
41009171|NCT05380661|PROCEDURE|Self-catheterization|Participants will perform self-catheterization, following the same routine for intermittent catheterization at home
41009172|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant blinded to time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting blood pressure and heart rate will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be draped and they will be not aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
41325221|NCT04876989|PROCEDURE|US-TPVB|Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.
41153765|NCT00422786|DRUG|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
40807571|NCT06492707|BIOLOGICAL|Decoy-resistant interleukin-18|Given SC
41325222|NCT04228562|OTHER|non-modifiable factor|the presence of an uncontrollable / unremovable risk factor for a disease
40807572|NCT06492707|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40807573|NCT06492707|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41009173|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant aware of time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting BP and HR will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be visible to participant and they will be fully aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
41009174|NCT00150020|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
41009175|NCT03410225|BEHAVIORAL|CAMI-TPP|The TPP group will receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; the sessions will be guided by personalized feedback aimed at increasing condom use, supporting female partners in contraceptive use, and obtaining reproductive health services and STI testing. MI counseling sessions will be conducted by phone or video call.
41325223|NCT04228562|OTHER|induction of anticipated regret|higher level of elaboration on potential regret
40807574|NCT06034743|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths:~* 1 mg per tablet for 1 mg baxdrostat Arm;~* 2 mg per tablet for 2 mg baxdrostat Arm."
41325224|NCT00120289|DRUG|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
41325225|NCT00120289|DRUG|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
41325226|NCT04668794|PROCEDURE|Osteosynthesis|Reduction and fixation of the carpometacarpal fracture dislocation of the hand with osteosynthesis (Kirschners wires, plate and screws)
41325227|NCT01918787|DEVICE|repetitive TMS|rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
41325228|NCT03201848|DRUG|Placebo|Placebo given to subject will be adjusted by body weight (\<10kg, Placebo given to subject will be adjusted by body weight(\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
41325229|NCT03201848|DRUG|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
40807575|NCT06034743|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
40807576|NCT06546202|OTHER|No Drug|This is an non-interventional, observational study. No drug was administered during this study.
41325230|NCT06419647|BEHAVIORAL|Intervention|Daily mood tracking tasks
41153766|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, 10 Hz condition|10 Hz (2,000 pulses) at left DLPFC
41153767|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, Sham condition|sham
41153768|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, iTBS condition|50 Hz, iTBS (600 pulses) at left DLPFC
41325231|NCT00960258|DRUG|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
41325232|NCT03082053|DRUG|varlitinib|IMP
40807577|NCT05799521|DRUG|Optate|Alkaline Buffer
41325233|NCT03082053|DRUG|capecitabine|Companion Medication
41325234|NCT02602171|OTHER|Oldenburger sentence test, localization test|
41153769|NCT01771081|DRUG|Ranibizumab (or other DME treatment)|Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
41325235|NCT05929638|BEHAVIORAL|lavender oil|The patients participating in the study were provided with the steps of applying lavender oil by inhalation, the points to be considered during the application, and the application was done in the same way by all patients.
40807578|NCT05799521|DRUG|Placebo|Normal Saline
40807579|NCT06435416|OTHER|No intervention|No intervention
41153770|NCT05055999|DRUG|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day
41153771|NCT02321371|DRUG|Lactulose + Rifaximin|Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
41153772|NCT02321371|DRUG|Lactulose|Continuation of Lactulose therapy for further 48 hours.
40807580|NCT03505788|DRUG|Acetazolamide|In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide
40807581|NCT03505788|DRUG|Placebo|In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
40807582|NCT03275506|DRUG|Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab|Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
40807583|NCT03275506|DRUG|Chemotherapy - Bevacizumab|Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
40807584|NCT05785286|OTHER|BPH 3-item questionnaire|BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).
40807585|NCT04999384|DRUG|AN4005-dose level 0|50mg BID
40807586|NCT04999384|DRUG|AN4005-dose level 1|100mg BID
41325236|NCT05962918|OTHER|Perinal massage|"Perineal massage was administered to all pregnant women in the experimental group during both the labor and resting phases between contractions. The participants received an average of 5-10 minutes of perineal massage two, four and four to six times at the latent (0-3-cm cervical dilation), active (4-7-cm cervical dilation) and transition (8-10-cm cervical dilation) phases of labor, respectively. These women continued to receive perineal massage at every push throughout the second stage of labor. The researcher midwife gently widened the perineal muscles by making stretching movements with her fingers. Perineal massage was applied using all three of the from one edge to the other, U shape and pressure massage techniques. The researcher gently applied a rhythmic U pressure with both fingers, moving them on the vagina downwards about 3 to 9 o'clock. Each pressure movement was maintained laterally for 1-2 minutes towards the rectum."
41325237|NCT00003157|DRUG|cisplatin|
41325238|NCT00003157|DRUG|gemcitabine hydrochloride|
41325239|NCT00003157|RADIATION|radiation therapy|
41325240|NCT05855681|OTHER|therapeutic exercises|strengthening exercise and stretching exercise
41325241|NCT04911699|BEHAVIORAL|breast adenocarcinoma receiving chemotherapy|for chemotherapy
41325242|NCT04911699|BEHAVIORAL|Control-for|hormonal drug treatment
41325243|NCT03807115|OTHER|Implementation of stroke mobility guidelines|Delivery of weekly online educational capsules on 4 evidence-based stroke recommendations (motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task-oriented training including fitness and mobility exercises, and aerobic training) plus feedback on participant's awareness, agreement, satisfaction with, and perceived value of the content, perceived implementation success and facilitators and barriers encountered.
41325244|NCT02319213|OTHER|Intraocular pressure measurement with 9 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
41325245|NCT02319213|OTHER|Intraocular pressure measurement with 12 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
41479064|NCT06264791|OTHER|Alcohol|Intoxication: Participants randomly assigned to the alcohol condition will be administered 100-proof Vodka mixed with orange juice (1:3 ratio) to induce a BAC of .06% (based on Widmark's formula). They will be breathalyzed every 5 minutes until they reach peak BAC, at which point they will continue with the experiment. Participants randomly assigned to the no alcohol condition will be administered water mixed with orange juice (1:3 ratio). Each participant in the no alcohol condition will be yoked to a participant in the alcohol condition and will complete the same number of breath tests. Once participants in the alcohol condition reach peak BAC and participants in the no alcohol condition performed the same number of breath tests as the participant they are yoked to, participants will continue to the stress induction.
40807587|NCT04999384|DRUG|AN4005-dose level 2|200mg BID
40807588|NCT04999384|DRUG|AN4005-dose level 3|400mg BID
40807589|NCT04999384|DRUG|AN4005-dose level 4|600mg BID
40807590|NCT04999384|DRUG|AN4005-food effect|Dose to be determined upon the MTD determination
40807591|NCT03192280|DRUG|Leukotriene B4|Leukotriene B4 (LTB4)
41479065|NCT04920916|BIOLOGICAL|Dupilumab|Participants will receive a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous injections) on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
41479066|NCT04920916|DRUG|Placebo|Normal Saline.
40807592|NCT03192280|DEVICE|FLIR One|Thermal imaging attachment to iPhone
40807593|NCT03192280|DEVICE|SCIO|Handheld near-IR molecular spectroscopy device
40807594|NCT03192280|DEVICE|MS Band 2|"Wearable watch-like device with multiple sensors"
40807595|NCT03192280|DEVICE|AGE reader|Portable bench top device for in-clinic near UV assessment
40807596|NCT03192280|DEVICE|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
40807597|NCT03192280|DEVICE|iPhone 7|Smart phone
41153773|NCT01842399|DIETARY_SUPPLEMENT|Resveratrol|Nutriceutical
41153774|NCT01842399|DRUG|Placebo|2x/day orally
40807600|NCT03931382|BEHAVIORAL|Virtual Reality Simulator|The VR intervention is underpinned by experiential learning and social cognitive theory, such that user will observe successful performance and simulation to encourage imitation and reinforce success in the assessment. All participants will be undergoing a simulation assessment with the head coil.
41153775|NCT02665806|DRUG|Ciclesonide|intranasal ciclesonide spray 200 µg once daily
41153776|NCT02665806|DRUG|Fluticasone|fluticasone propionate aqueous nasal spray 200 µg twice a day
41153777|NCT00460577|DRUG|Formoterol fumerate|12 micrograms stat (twice if necessary). Inhaled via aerolizer
41153778|NCT00460577|DRUG|fenoterol/ipratropium bromide|0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
41153779|NCT00895297|DRUG|Dasatinib (Sprycel)|100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.
41479067|NCT03897478|DIAGNOSTIC_TEST|ISCDX blood test|"The ISCDX test is based on gene expression changes that occur as a result of the ischemic stroke. When the stroke occurs, the immune system in the body reacts and causes changes in gene expression in several types of cells, including white blood cells, related to activation of innate and adaptive immune systems.~The ISCDX test distinguishes between cardioembolic and large artery atherosclerotic origin of stroke using a gene signature. The pattern or signature of up or down regulation for all genes for a patient determines whether the patient's pattern of gene expression is more like the pattern seen in other cardioembolic patients or more like the pattern seen in patients with large artery atherosclerotic cause of stroke."
41479068|NCT03845413|BEHAVIORAL|Control|Schedule an appointment to attend tobacco cessation at Basic Health Unit
40807601|NCT03931382|BEHAVIORAL|Mock MRI Simulator|The mock MRI is provided by the Child Life Specialist, according to the current care plan which consists of exposing children to the MRI simulator, medical devices, and procedures. The mock MRI is located within the medical imaging facility. All participants will be undergoing a simulation assessment with the head coil.
40807602|NCT03931382|BEHAVIORAL|Standard Preparation Manual|The standard MRI preparation manual provides access to a series of printed photos and text showing the MRI experience step-by-step to help prepare for MRI. All participants will be undergoing a simulation assessment with the head coil.
41009176|NCT03410225|BEHAVIORAL|CAMI-Fitness|The Fitness group will also receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; these sessions will be guided by personalized feedback aimed at healthy diet, physical activity and tobacco avoidance. MI counseling sessions will be conducted by phone or video call.
41009177|NCT05958212|BEHAVIORAL|Gait training program|"Gait training program at PolyU is a supervised rehabilitation program performed on the dual-belt treadmill. It consists of forward walking at increased speed over the affected leg and retro walking (backward walking) at individual's own pace (5 minutes/set for three sets, with rest periods in each session). This program also consists of a standardized set of warm-up and cool-down exercises at each training session.~Participants will also receive conventional physiotherapy treatment in the outpatient physiotherapy clinic."
41009178|NCT05958212|BEHAVIORAL|Conventional training only|Conventional physiotherapy treatment in the outpatient physiotherapy clinic.
41153780|NCT03861429|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
41153781|NCT00403299|PROCEDURE|MDCT of the coronary arteries.|
41153782|NCT04834388|DRUG|Anakinra|Anakinra treatment is started within 8 hours of symptom onset
41153783|NCT00391521|DRUG|AS703569|Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
41153784|NCT00391521|DRUG|AS703569|Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
41153785|NCT00391521|DRUG|AS703569|Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
41325246|NCT02319213|OTHER|Intraocular pressure measurement with 15 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
41479069|NCT03845413|BEHAVIORAL|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
41479070|NCT03744078|DEVICE|Foley balloon catheter|18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
41479071|NCT01552967|DRUG|Capecitabine|"Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.~Efficacy will be evaluated every three cycles."
41479072|NCT00248170|DRUG|Letrozole|2.5 mg tablets
41479073|NCT00248170|DRUG|Anastrozole|1 mg tablets
41479074|NCT00573170|DRUG|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)
41009179|NCT04173130|DEVICE|Anuscope with needles|Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
41009180|NCT05883605|DEVICE|Measuring blood pressure|Measuring blood pressure using electronic device and using a mercury sphygmomanometer
41153786|NCT01513447|DRUG|Intracutaneous injections|Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
41153787|NCT05213559|OTHER|wheat biscuit enriched with plant proteins|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a biscuit enriched with plant proteins
41479075|NCT00573170|DRUG|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]
41153788|NCT05213559|OTHER|common wheat biscuit|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a common wheat biscuit
41153789|NCT01898442|DRUG|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
41153790|NCT01898442|DRUG|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
41153791|NCT01898442|DRUG|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
41153792|NCT02515526|DRUG|caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Reference period
41153793|NCT02515526|DRUG|ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Test period
41153794|NCT02658032|BEHAVIORAL|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
41153795|NCT02658032|BEHAVIORAL|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
41153796|NCT02658032|OTHER|standard care|
41009181|NCT02260427|DEVICE|Insertion of the i-gel|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
41009182|NCT02260427|DEVICE|Insertion of the air-Q sp|
41009183|NCT03337724|DRUG|Ipatasertib|Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
41153797|NCT03219476|DRUG|Anastrozole|1 mg once daily.
41325247|NCT03607474|OTHER|Questionnaires of life quality for patients|"* the WhoQoL~* a specific scale of Cushing's syndrome~* The Beck II scale~* HAD scale~* Rosenberg questionnaire~* Stunkard, Sorensen and Schlusinger (1983) figurines~* Brief Cope scale"
41325248|NCT03607474|OTHER|Questionnaires of life quality for caregivers|"* the WhoQoL~* The Beck II scale~* HAD scale"
41325249|NCT02850497|DEVICE|optical coherence tomography at 6 months|6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
41325250|NCT02884518|DEVICE|PET|Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
41325251|NCT02884518|BEHAVIORAL|clinical scale|Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
41479076|NCT00573170|DRUG|placebo|placebo
41153798|NCT03219476|DRUG|Letrozole|2.5mg once daily.
41153799|NCT03219476|DRUG|Exemestane|25 mg once daily.
41153800|NCT03219476|DRUG|Tamoxifen|20 mg once daily.
41479077|NCT00556101|PROCEDURE|Whole body magnetic resonance angiography|
40807603|NCT06414733|BIOLOGICAL|Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 720 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 720, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
40807604|NCT05366179|DRUG|CAR.B7-H3T cells infusion|"The Chimeric Antigen Receptors (CAR).B7-H3T cells will be administered via intraventricular infusion up to 3 weekly infusions. A suspension of T cells infusion is given, over 5-10 minutes, via a Rickham catheter and will be followed by a normal-saline flush.~Dose escalation will be performed considering the dose limiting toxicities (DLTs) listed in the protocol. Six doses will be explored. The starting dose will be 2 × 10\^6 transduced cells/infusion (Dose Level (DL) 1) and will enroll at least 3 subjects. If there are no dose DLTs within 4 weeks of the third cellular product administration in the first 3 subjects, then the next cohort will evaluate 5 × 10\^6 transduced cells/infusion (DL2)."
40807605|NCT05706623|DRUG|Apraglutide|Single dose of apraglutide 5mg.
41153801|NCT04250181|OTHER|RF ablation of atrial fibrillation|Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation
40807607|NCT03575065|DRUG|BGB-290|Administered orally
40807608|NCT06473779|COMBINATION_PRODUCT|Tezepelumab|IMP. Subcutaneous injection. Unit dose strengths 210 mg.
40807609|NCT06473779|COMBINATION_PRODUCT|Budesonide/formoterol|AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation
40807610|NCT06473779|COMBINATION_PRODUCT|Albuterol/budesonide (AIRSUPRA®)|AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.
40807611|NCT06473779|COMBINATION_PRODUCT|Mannitol|NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules
40807612|NCT06473779|COMBINATION_PRODUCT|Salbutamol|AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation
40807613|NCT05699551|BEHAVIORAL|Exercise regimen|Exercise will take place Monday, Wednesday, and Friday from 12:00-1:00 pm for 6 weeks. Aerobic exercise will consist of walking, beginning with a 10-minute duration, with gradual progression to 20 minutes. Muscle strength, endurance and range-of-motion exercise will then be performed. Muscle strength and endurance training will begin using no weight and performing one set of 6 repetitions. Progression using added resistance in the form of dumbbell weights (1-6 lbs.) and increased sets and repetitions will be applied as Subjects become increasingly fit. For static range of motion exercise, positions will be held for 10-15 seconds in the beginning and increased over time. Exercise will be kept at a moderate level of intensity. Each session will then end with relaxation training.
40807614|NCT05623475|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
40807615|NCT05623475|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
40807616|NCT05623475|BEHAVIORAL|E-learning|Delirium care video
40807617|NCT03473743|DRUG|Erdafitinib|Participants will receive erdafitinib orally.
40807618|NCT03473743|DRUG|Cetrelimab|Participants will receive cetrelimab by intravenous infusion.
40807619|NCT03473743|DRUG|Cisplatin|Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.
40807620|NCT03473743|DRUG|Carboplatin|Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.
40807621|NCT01081262|BIOLOGICAL|Bevacizumab|Given IV
40807622|NCT01081262|DRUG|Capecitabine|Given PO
40807623|NCT01081262|DRUG|Carboplatin|Given IV
40807624|NCT01081262|OTHER|Laboratory Biomarker Analysis|Correlative studies
40807625|NCT01081262|DRUG|Oxaliplatin|Given IV
40807626|NCT01081262|DRUG|Paclitaxel|Given IV
40807627|NCT01081262|OTHER|Quality-of-Life Assessment|Ancillary studies
40807628|NCT04451226|DRUG|Fezolinetant|Oral
41153802|NCT01552642|BEHAVIORAL|face-to-face meetings and access to a website|The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
41009184|NCT03337724|DRUG|Paclitaxel|Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
40807630|NCT06397937|BEHAVIORAL|SHIFT team intervention|The SHIFT team, comprising a community health worker (CHW), community social worker (CHW), and community nurse (CN) will visit the participant starting within 72 hours of hospital discharge and provide social service referrals related to food insecurity, housing, immigration, and employment, and assist with medical appointment preparation (CHW), deliver individualized counseling focused on coping skills, reducing caregiver strain, and the psychological distress associated with experiences of racism and SDOH (CSW), and address health literacy and review of treatment goals and medications (CN).
40807631|NCT03994211|DRUG|pamiparib 60 mg|Single dose of 60 mg pamiparib orally on Days 1 and 10
40807632|NCT03994211|DRUG|pamiparib 20 mg|Single dose of 20 mg pamiparib orally on days 1 and 7
40807633|NCT03994211|DRUG|itraconazole|200 mg itraconazole once a day al Day 3 to day 8
40807634|NCT03994211|DRUG|rifampin|600 mg rifampin once a day from days 3 to 11
40807635|NCT03994211|DRUG|pamiparib|60 mg pamiparib orally twice a day in 28-day cycles
40807636|NCT03736226|DEVICE|SYNERGYTM Stent System|no intervention design in the study
41153803|NCT05789199|DRUG|Cefiderocol|Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.
41153804|NCT03711799|BEHAVIORAL|Access to services via peer coaching|This intervention will allow for half of the participants, randomly selected, to get help navigating the system of acquiring services for their child. These participants will be assisted by a coach who are also parents of a child with autism and have already been through the process.
41153805|NCT01669720|DRUG|Aflibercept|Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
41153806|NCT00662415|DEVICE|mirror-box treatment|15 minutes daily for 4 weeks
41153807|NCT00662415|BEHAVIORAL|observation|observation
41153808|NCT05613504|OTHER|Acupuncture treatment|"Acupoint selection: 4 general points + syndrome differentiation acupoints (select or replace 2-4 acupoints according to symptom 1, select 1-2 acupoints according to symptom 2 and symptom 3), and adjust acupoints according to symptoms every week.~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
41153809|NCT05613504|OTHER|Sham acupuncture treatment|"Acupoint selection: According to the selected acupoints of the electroacupuncture group, 5-7 positions were selected at the non-meridian and non-acupoint points(points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
40807647|NCT06238817|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
40807648|NCT06238817|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
40807651|NCT05058196|RADIATION|Whole breast radiotherapy|Whole breast radiotherapy after surgery
40807652|NCT05058196|RADIATION|Intra Operative Radiotherapy|Intra Operative Radiotherapy
40807653|NCT04521946|DRUG|Etoposide|Given IV
40807654|NCT04521946|DRUG|Fludarabine Phosphate|Given IV
40807655|NCT04521946|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
40807656|NCT04521946|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
40807657|NCT04521946|DRUG|Melphalan|Given IV
40807658|NCT04521946|DRUG|Mycophenolate Mofetil|Given PO or IV
40807659|NCT04521946|DRUG|Tacrolimus|Given IV
40807660|NCT04521946|DRUG|Thiotepa|Given IV
40807663|NCT03905148|DRUG|Lifirafenib|RAF Dimer Inhibitor
40807664|NCT03905148|DRUG|mirdametinib|MEK Inhibitor
40807665|NCT05254951|DIAGNOSTIC_TEST|Tidal Volume Challenge|Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
40807666|NCT04747054|DRUG|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
40807667|NCT04747054|RADIATION|Loco-regional radiotherapy|"Depending on the choice of radiotherapy timing:~* Before 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time between one week after the first administration of pembrolizumab and the first day of the 3rd cycle.~* After 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time after 3rd cycle (C3D1) and up to a maximum of 4 weeks after the 6th cycle of pembrolizumab.~Dose/fraction of radiotherapy: 54 Gy/18 fractions (recommended schedule) or 70Gy/33-35 fractions or other curative dose/fraction schedules with shorter duration and biologically equivalent dose of at least 60Gy at the discretion of local investigators, in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary. Other cycles of pembrolizumab will be administered during and after radiotherapy."
40807668|NCT04747054|DRUG|Chemotherapy|"If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles"
41325252|NCT06420596|OTHER|Conventional Physiotherapy|Conventional physiotherapy is one prescription of 9 in person physiotherapy sessions (according to FMH Switzerland guidelines). The frequency of the physiotherapy sessions are at the discretion of the treating clinician, but the recommendation is 1 to 2 sessions per week.
40807669|NCT05051722|DIAGNOSTIC_TEST|Tampon Collection|A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
40807670|NCT05051722|DIAGNOSTIC_TEST|Blood Collection|A blood sample will be collected from each participant prior to undergoing any exams or procedures.
41153810|NCT02646644|OTHER|Metastasized intestinal NET|This is an observational study
41153811|NCT00730210|DRUG|a: PTH (1-84)|preotact 100 microgram subcutaneous a day in 6 months
41325253|NCT06420596|DEVICE|Akina Cloud|Akina Cloud is a digital health application that supports therapeutic exercises in people with musculoskeletal disorders. It is the first app-supported physiotherapy solution available in Switzerland.
41325254|NCT00329134|DRUG|Administration of quinine sulphate taste-masked pellets|
41325255|NCT04024072|DRUG|Brinzolamide 1% ophthalmic suspension|Test product
41153812|NCT00730210|DRUG|b:placebo|100 microgram placebo subcutaneous a day for 6 months
41153813|NCT01313299|BIOLOGICAL|Botulinum toxin type A|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
41153814|NCT01313299|BIOLOGICAL|Botulinum toxin type A|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
40807676|NCT04203316|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40807677|NCT04203316|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41325256|NCT04024072|DRUG|Azopt 1% Ophthalmic Suspension|Reference product
41325257|NCT02204514|PROCEDURE|Surgery for external snapping hip|
41325258|NCT05772442|DIAGNOSTIC_TEST|Extra blood samples (5-10 mL) drawn|Extra blood samples will be sent for metabolomics analysis.
40807678|NCT04203316|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40807679|NCT04203316|DRUG|Enasidenib|Given PO
41153815|NCT01313299|DRUG|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
41325259|NCT01610908|OTHER|The Schroth exercises treatment|"The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.~Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months."
41325260|NCT01610908|OTHER|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
41325261|NCT04929418|OTHER|10 km continuous running|Trial participants will perform a 10 km continuous running exercise
41325262|NCT04929418|OTHER|1.5 km continuous swimming|Trial participants will perform a 1.5 km continuous swimming exercise.
40807680|NCT04203316|DRUG|Enasidenib Mesylate|Given PO
40807681|NCT01928589|OTHER|PBI with sequential chemotherapy|270 cGy x15
40807682|NCT01928589|OTHER|PBI with concurrent chemotherapy|270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
40807683|NCT05228275|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40807684|NCT05228275|OTHER|Survey Administration|Complete survey
41157176|NCT05542914|BEHAVIORAL|Men's Health Project (MHP)|This intervention will be offered to participants with moderate or greater severity substance use. This is a 4-session Motivational interviewing based intervention that has shown efficacy in prior studies. We are providing this as a possible referral program for study participants (either arm) who are interested in receiving substance abuse intervention.
41157177|NCT05087329|BEHAVIORAL|Virtual Mindfulness Meditation|Four week virtual mindfulness meditation course composed of four weekly group Zoom webinars during which participants will listen to a 15-20 minute pre-recorded meditation, facilitated by a study provider
40807687|NCT03851406|DEVICE|5% Hypertonic Saline|Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.
40807688|NCT03851406|OTHER|No treatment|No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
40807689|NCT04293224|OTHER|DGA Mediterranean diet pattern, energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations.
40807690|NCT04293224|OTHER|DGA Mediterranean diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations
40807691|NCT04293224|OTHER|TAD diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the be based on evidence collected from What We Eat in America (WWEIA) data. Based on this data the participants will be provided a diet that reflects American dietary trends.
40807692|NCT03407469|BEHAVIORAL|Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
40807693|NCT02668770|DRUG|MGN1703|"Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
40807694|NCT02668770|DRUG|Ipilimumab|Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
40807695|NCT04367311|DRUG|Atezolizumab|Atezolizumab 1200 mg
40807696|NCT04367311|DRUG|Docetaxel|Docetaxel 60-75 mg/m\^2
40807697|NCT04367311|DRUG|Cisplatin|60-75 mg/m\^2
40807698|NCT04367311|DRUG|Pemetrexed|Pemetrexed 500mg/m\^2
41157178|NCT03904875|OTHER|collection of data about each acute exacerbation of COPD|COPD is chronic obstructive pulmonary disease. Data collected are need of hospitalisation, final diagnosis, home address, work address and air quality data.
41157179|NCT00439361|DRUG|Bortezomib|1.0 mg/m\^2 by Vein Over 5 Seconds on Days 1 and 4
41325263|NCT05821348|DIAGNOSTIC_TEST|salivary markers|a description of the salivary biochemical profile of GER infants vs. GERD, so that we can develop non-invasive diagnostic strategies and detect personalized therapeutic treatments.
41009185|NCT03337724|DRUG|Placebo|Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
41009186|NCT05483491|BIOLOGICAL|KK-LC-1 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
41009187|NCT05483491|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV every 8 hours will be preferentially administered as an inpatient within 24 hours after KK-LC-1 TCR-T cell infusion for up to 6 doses; however up to 24 hours may elapse between doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
41009188|NCT02459392|OTHER|Epiduroscopy|"Epiduroscopy has two main uses in the pain clinic:~Releasing epidural adhesions for the relief of chronic sciatica. Adhesions can form around the lower lumbar nerve roots after decompressive surgery for disc disease or after a bad bout of inflammatory sciatica in the absence of surgery. Epidural adhesions can usually be identified on an enhanced magnetic resonance scan using intravenous gadolinium. They also cause uneven spread of X-ray contrast when performing an epidurogram.~Injecting mixtures of local anesthetic and depot steroid around inflamed nerve roots when epidural injections / nerve root blocks have been unsuccessful. The presence of adhesions can prevent epidurally injected drugs from reaching the inflamed nerve roots."
41325264|NCT01342952|DRUG|Ambrisentan|open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
40807702|NCT06400576|OTHER|Headphone and Smartphone Intervention|Asessment of participants' static balance and pressure distrubiton, posturographic balance and dynamic balance whilst using headphones and messaging.
40807703|NCT06079281|DRUG|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
40807704|NCT06079281|DRUG|Placebo|Placebo will be administered via SC injection.
41153816|NCT02504034|PROCEDURE|Transhepatic portosystemic shunt|Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
41153817|NCT02504034|DEVICE|6-French sheath|
40807707|NCT06168058|DIAGNOSTIC_TEST|Transcatheter Venography|Venographic assessment of ovarian veins and internal iliac veins
40807708|NCT06168058|PROCEDURE|Bilateral ovarian vein embolization|Intervention will include sclerosis of pelvic varices and coil embolization of the bilateral ovarian veins.
40807709|NCT01272037|DRUG|Anastrozole|Given PO
40807710|NCT01272037|DRUG|Exemestane|Given PO
40807711|NCT01272037|OTHER|Laboratory Biomarker Analysis|Correlative studies
40807712|NCT01272037|DRUG|Letrozole|Given PO
40807713|NCT01272037|OTHER|Quality-of-Life Assessment|Ancillary studies (closed as of 12/1/12)
40807714|NCT01272037|DRUG|Systemic Chemotherapy|Given IV
40807715|NCT01272037|DRUG|Tamoxifen Citrate|Given PO
40807716|NCT06232980|PROCEDURE|urological surgical intervention|Anesthesia induction will be performed with propofol, and ventilation will be maintained with a laryngeal mask for urological surgical procedures.
40807717|NCT04145115|BIOLOGICAL|Ipilimumab|Given IV
40807718|NCT04145115|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40807719|NCT04145115|BIOLOGICAL|Nivolumab|Given IV
41009189|NCT02459392|DRUG|Hyaluronic Acid|Drug administration
41153818|NCT02504034|DEVICE|22-gauge chiba needle|
41153819|NCT02504034|DEVICE|260-cm-long stiff shaft wire|
41153820|NCT02504034|DEVICE|Balloon catheter|
41153821|NCT02504034|DEVICE|Bare metal stent|
41153822|NCT02504034|DEVICE|Covered stent|
41153823|NCT06113822|DEVICE|ultrasonography|We used ultrasonography to measure the patients' masseter muscle thickness. Measurements were performed simultaneously for both the right and left sides using a high frequency linear scanning probe (13-6 MHz) of an ultrasound device (Fujifilm Sonosite Edge II). In order to prevent possible artifacts and oblique imaging, the probe was kept perpendicular to the skin surface, and the distance between the location of the hyperechoic linear appearance of the mandibular and temporal bone in the transverse section and the muscular fascia were measured.
41153824|NCT06247878|DEVICE|Skiin underwear chest band|Participants will be asked to wear a skiin underwear chest band during a polysomnography test.
41153825|NCT01762345|DEVICE|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter \& Gamble
41009190|NCT02459392|DRUG|DepoMedrol|Drug administration
41009191|NCT00796965|DRUG|AZD7268|Solution/Capsule, Oral, once daily
41153826|NCT02419664|DRUG|Gallium-68 DOTATOC PET|The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
41153827|NCT03334747|DRUG|KAE609|Exploration of different doses of KAE609 to establish safety profile.
41153828|NCT03334747|DRUG|Coartem|Control Arm
41153829|NCT05655715|RADIATION|Stereotactic body radiotherapy|8 Gray x 3
41153830|NCT05655715|DRUG|Ipilimumab Injection [Yervoy]|1 mg/kg IV Q3W for four doses,
41153831|NCT05655715|DRUG|Nivolumab Injection [Opdivo]|Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W
41153832|NCT05655715|PROCEDURE|Biopsies|From soft tissue metastases.
41153833|NCT02544841|BEHAVIORAL|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.
41153834|NCT02544841|BEHAVIORAL|Female Sexual Health|Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
40807762|NCT04189783|DRUG|Liposomal Bupivacaine|Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity
40807763|NCT04189783|DRUG|Quadratus Lumborum Block|"Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery"
40807764|NCT04189783|OTHER|Questionnaire Administration|Ancillary studies
40807765|NCT04004221|DRUG|Tislelizumab|200mg intravenously (IV) every 3 weeks (Q3W)
40807766|NCT03639623|DRUG|Saroglitazar|Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
41009192|NCT00796965|DRUG|Placebo|
41009193|NCT05443997|BEHAVIORAL|MIYCN capacity building|"* MIYCN knowledge, skills, and motivation of FLWs~* Supportive supervision~* Decentralized programmatic decision-making using data~* PRI member involvement~* Availability of THR~* IYCF knowledge and practices"
41009194|NCT04497987|DRUG|Bamlanivimab|Administered IV.
41009195|NCT04497987|DRUG|Placebo|Administered IV.
41009196|NCT04497987|DRUG|Etesevimab|Administered IV.
41153835|NCT02379377|BIOLOGICAL|Fluorine F 18 L-glutamate Derivative 18F-FSPG|Undergo 18F-FSPG PET scan
40807770|NCT01766739|BIOLOGICAL|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
41153836|NCT02379377|BIOLOGICAL|Carbon C 11 Acetate|Undergo 11C-acetate PET scan
41153837|NCT02379377|PROCEDURE|Positron Emission Tomography|Undergo 18F-FSPG, 11C-acetate, or 18F-FDG PET
41153838|NCT02379377|OTHER|Laboratory Biomarker Analysis|Correlative studies
41153839|NCT02379377|BIOLOGICAL|Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose|Undergo 18F-FDG PET scan
41153840|NCT02580981|OTHER|Acute Lymphobastic Leukemia (ALL) Treatment Options|Depending on the genomic testing results, patients with targetable genomic lesions will be enrolled onto available national clinical trials that are sponsored by the NCI National Clinical Trials Network (NCTN) (COG and other adult NCI Cooperative Groups). If no suitable NCTN trial exists, appropriate therapeutic regimens (including currently accepted standards-of-care), alterations in therapy, or treatment with targeted agents to specific genomic lesions will be considered.
40807776|NCT04583215|DEVICE|Paired Associative Stimulation (PAS)|On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
40807777|NCT06365216|DRUG|NX210c|3 times a week, for 4 weeks
40807778|NCT06365216|DRUG|Placebo|3 times a week, for 4 weeks
41153841|NCT00301015|DEVICE|Rapid diagnostic test for malaria|We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
41153842|NCT00317135|BIOLOGICAL|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
40807781|NCT02713386|DRUG|Carboplatin|Given IV
40807782|NCT02713386|DRUG|Paclitaxel|Given IV
40807783|NCT02713386|DRUG|Ruxolitinib Phosphate|Given PO
40807784|NCT02713386|PROCEDURE|Therapeutic Conventional Surgery|Undergo TRS
41325265|NCT01185704|DRUG|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period \[S0\]) until r-hCG day (at least 2 follicles \>=17 mm)
41157180|NCT00439361|DRUG|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
41157181|NCT00439361|DRUG|Etoposide|100 mg/m\^2 By Vein Over 2 Hours On Days 1-3
41009197|NCT02462577|DRUG|local instillation of morphine to surgical wound|comparison between different drug doses effects on pain
40807787|NCT04609592|DRUG|Lutathera|4 administrations of 7.4 gigabecquerel (GBq) (200 mCi) 177Lu Dotatate +/ 10% at the date and time of infusion, accumulative dose of 29.6 GBq (800 mCi). T
40807788|NCT04609592|DRUG|Gallium 68 Dotatate|Standard of care, 2 Megabecquerel (MBq)/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi)
40807789|NCT04609592|PROCEDURE|Computed Tomography (CT)|Medical Imaging
40807790|NCT04609592|PROCEDURE|Magnetic Resonance Imaging (MRI)|Medical Imaging
41009198|NCT02784301|DEVICE|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
41157182|NCT00439361|DRUG|Ifosfamide|5 Gm/m\^2 By Vein Continuous Infusion Over 24 Hours On Day 1
40807791|NCT04609592|PROCEDURE|PET/CT|Medical Imaging
40807792|NCT05317143|OTHER|Evaluation of prostate cancer margins|Evaluation of prostate cancer margins
40807793|NCT04523623|DRUG|Oxycodone|oxycodone 0.2mg/kg, max 10mg to be administered, randomized between that and Ibuprofen
40807794|NCT04523623|DRUG|Ibuprofen|ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
40807795|NCT05434754|OTHER|eHealth Tool|text messaging algorithm
41325266|NCT01185704|DRUG|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period \[S6\]) until r-hCG day (at least 2 follicles \>=19 mm)
41479078|NCT05213260|OTHER|Flipped Teaching method|Before the clinical skill laboratory session, the students will receive the learning materials that they have to read and assimilate before the in-class part which will include interactive, discussion-oriented, and practice-oriented activities.
41479079|NCT05443906|BEHAVIORAL|Home exercise|Exercise to address limitations impacting walking
40807796|NCT06284590|DRUG|L19IL2|Arm 1: The amount of L19IL2 that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13 MioIU/1 mL of L19IL2.
40807797|NCT06284590|DRUG|L19TNF|Arm 2: The amount of L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 400 μg/1 mL of L19TNF.
40807798|NCT06284590|DRUG|L19IL2/L19TNF|Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are recorded after the first L19IL2/L19TNF dose administration, the L19TNF dose is reduced to 200 μg for the following administrations.
40807799|NCT06284590|DRUG|KEYTRUDA®|KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.
41153843|NCT00317135|BIOLOGICAL|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
41153844|NCT03934437|BEHAVIORAL|mLTCR|mHealth-enhanced Linkage to Care and Retention
41153845|NCT03934437|BEHAVIORAL|LTCR|Linkage and Retention Services (Standard-of-Care)
40807803|NCT04969094|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months
40807804|NCT04969094|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
40807805|NCT06026540|BEHAVIORAL|Pilates Exercise|"After the first measurements were made and the groups were determined; Students in the experimental group will be given pilates exercises 2 days a week for 6 months. Pilates mat, pilates circle, tiny pilates ball and pilates band will be used during the pilates exercise. The duration of the Pilates exercise is 30 minutes in total, and the peer-guided application via Zoom includes the following order:~Stretching 5 minutes, superman 1 minute, quodratus stretch 2 minutes, marble 1 minute, half plank kick 4 minutes, side kick 4 minutes, pelvic curl 2 minutes, cat pose 1 minute, spine stretch 2 minutes, one leg circle 3 minutes, side leg lift 3 minutes, single leg kick 2 minutes."
40807806|NCT05103384|OTHER|Virtual Reality Environment|Participants complete various tasks in a virtual home and grocery store environment.
40807807|NCT05436535|BIOLOGICAL|Dupilumab|Adult dupilumab-naïve topical steroid non-responder (EASI \>7) participants beginning treatment with dupilumab will initially receive a loading dose of two 300 mg subcutaneous injections. The two injections will be administered at different sites in the abdomen, thighs, or upper arms. Pediatric dupilumab-naïve topical steroid non-responder participants beginning treatment with dupilumab will receive a loading dose, according to their weight. Dupilumab-naïve topical steroid non-responsive participants will continue use of dupilumab on a schedule determined by their age and weight until their penultimate scheduled visit (Day 140-196).
40807808|NCT05436535|DRUG|Vanicream- Dupilumab-naïve|Dupilumab-naïve AD participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at their penultimate visit (Day 140-196) through the End of Study Assessment.
41153846|NCT00647985|DRUG|Fexofenadine Tablets 180 mg|180mg, single dose fed
41153847|NCT00647985|DRUG|Allegra® Tablets 180 mg|180mg, single dose fed
41153848|NCT03341754|BIOLOGICAL|D/ChAd63-CA|Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA
41153849|NCT03341754|BIOLOGICAL|D/ChAd63-CAT|Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT
41153850|NCT03341754|OTHER|Infectivity Control (IC) Group|Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
41479080|NCT04816747|BIOLOGICAL|Autologous PRP|Participants enrolled in this study will be managed with intradiscal and/or intra-articular injections of autologous PRP according to features of underlying pathology. Participants featuring FJS will be prior to PRP diagnostically and therapeutically injected with local anesthetic in order to verify FJS as the etiology of experienced pain. Injected PRP solution volume is designed to be 0.5-1 ml and 0.5 ml in cases of intradiscal and intra-articular injection, respectively. All participants are planned to receive a single dose of PRP, whilst a maximum of two compromised discs and four facet joints will be treated in each patient.
41479081|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
41479082|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
41479083|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
41479084|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
41479085|NCT00952276|BIOLOGICAL|Normal saline solution|0.5 mL, Intramuscular on Day 0
40807809|NCT05436535|DRUG|Triamcinolone Acetonide|"On Day 7, all dupilumab-naïve AD participants will begin applying triamcinolone 0.1% ointment (provided by the study) twice daily to the specified target area. Additionally, dupilumab-naïve AD participants will apply triamcinolone 0.1% ointment twice daily to active lesions on non-sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply triamcinolone 0.1% ointment (provided by the study) once or twice daily, per clinician discretion, to the specified target area. Additionally, participants will apply triamcinolone 0.1% ointment once or twice daily, per clinician discretion, to active lesions on non-sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply triamcinolone 0.1% ointment as needed to active lesions on non-sensitive, non-target skin."
40807810|NCT05436535|DRUG|Hydrocortisone|"On Day 7, all dupilumab-naïve AD participants will apply hydrocortisone 2.5% ointment twice daily to active lesions on sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply hydrocortisone 2.5% ointment once or twice daily, per clinician discretion, to active lesions on sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply hydrocortisone 2.5% ointment as needed to active lesions on sensitive, non-target skin."
41009199|NCT02784301|BEHAVIORAL|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
41009200|NCT02784301|BEHAVIORAL|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
41479086|NCT00731549|DRUG|Aripiprazole IM Depot|300mg or 400mg
41479087|NCT01727687|BEHAVIORAL|behavioral training for crossing road|behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
41479088|NCT04904016|DEVICE|FlowOx™|The FlowOx™ system generates a negative oscillating pressure which cause rapid fluctuations in blood flow in the leg and foot.
41479089|NCT05443269|DIETARY_SUPPLEMENT|Jump Start Nutritional Program|Nutri-meal Active meal replacement shake and Metabolism pill at breakfast, lunch, and dinner, morning and evening Health Pak (multivitamin), 1 probiotic stick, and 300 calories fruits and vegetables daily
41479090|NCT01333072|DRUG|Aripiprazole|The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
41479091|NCT01333072|DRUG|Risperidone|Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
41479092|NCT03487848|DRUG|Daclatasvir|Specified dose on specified days for specified duration
41479093|NCT03487848|DRUG|Sofosbuvir|Specified dose on specified days for specified duration
41479094|NCT04638439|DRUG|P1101 + Nivolumab + Entecavir|"P1101 (Ropeginterferon alfa-2b) 450 µg subcutaneously (SC) Q2W for 6 doses (12 weeks) \*, followed by 0.3 mg/kg Nivolumab for 6 doses (12 weeks) \*\*, with a follow up of 24 weeks. All patients will also receive Entecavir 0.5 mg QD from Day 1 to Follow-up 24.~\*: HBsAg will be checked at treatment week 12 (or 16, if applicable).~\*\*: Only patients with \> 0.5 log10 decline in HBsAg at treatment week 12 or 16 will be sequentially treated with Anti-PD1."
41479095|NCT01005329|BIOLOGICAL|Bevacizumab|Given IV
41479096|NCT01005329|DRUG|Carboplatin|Given IV
41479097|NCT01005329|DRUG|Cisplatin|Given IV
41479098|NCT01005329|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41479099|NCT01005329|DRUG|Paclitaxel|Given IV
41479100|NCT06403345|BEHAVIORAL|Green Activity Program|See arm description.
41009201|NCT05192577|OTHER|Electrical stimulation|At the beginning of the session, an electrode will be attached to the participant's ankle. Electrical stimulation will be applied to estimate the electrical perception threshold. This threshold will be used as condition stimuli when different thermal thresholds are assessed.
41009202|NCT05815446|DEVICE|CT|NON CONTASR COMPUTED TOMOGRAPHY
41009203|NCT06058897|OTHER|MRI|MRI examinations will be conducted on the 3T MRI technical platform. During the MRI examination, images reflecting the integrity of the LC (quantification of neuromelanin as well as its functional connections with the different brain regions (resting functional MRI) will be acquired. High-resolution T1 and T2 weighted images of the the entire brain will also be acquired for the volumetry of cerebral areas.
41153851|NCT03742232|DRUG|PEG3350|"PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
41479101|NCT06071819|DIAGNOSTIC_TEST|Structured Clinical Interview for DSM-5|A structured interview will be administered to confirm the diagnosis reported in clinical charts
41479102|NCT01705860|BIOLOGICAL|Santyl|
41479103|NCT00821366|BEHAVIORAL|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
41479104|NCT00821366|DIETARY_SUPPLEMENT|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
41479105|NCT00821366|DRUG|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
41479106|NCT05461118|PROCEDURE|Experimental:Treatment group|Osteotomy surgical planning to be done using intraoperative mixed reality augmentation of a commercially available navigation platform.
41479107|NCT00107042|BIOLOGICAL|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
41479108|NCT00107042|BIOLOGICAL|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
41479109|NCT01084434|DIETARY_SUPPLEMENT|probiotic|Bifidobacterium lactis HN019 10\^9 CFU/day 1 sachet once a day for 7 weeks
41479110|NCT01084434|DIETARY_SUPPLEMENT|prebiotic|Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
41479111|NCT01084434|DIETARY_SUPPLEMENT|Synbiotic|(Bifidobacterium lactis 10\^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
41479112|NCT01084434|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
41479113|NCT00938145|PROCEDURE|Specimen Ultra-High field MRI|Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.
41479114|NCT00938145|DRUG|chemotherapy|The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
41479115|NCT00938145|PROCEDURE|Cystectomy and Lymphadenectomy|The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.
41479116|NCT03665948|OTHER|Dietary Intervention - Ketogenic Diet (KD)|The experimental procedure for each randomly assigned participant included a 4-week of KD diet.
41479117|NCT03665948|OTHER|Dietary Intervention - Low-Glycemic Index Diet (CHO-LGI)|The experimental procedure for each randomly assigned participant included a 4-week of CHO-LGI diet.
41479118|NCT02879110|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.
41479119|NCT02879110|OTHER|Placebo|Placebo tablet is composed of starch.
41325267|NCT01185704|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
41325268|NCT01185704|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period \[S1\]) until r-hCG day
41153852|NCT03742232|DRUG|Macrogol 4000|"SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
41153853|NCT02029027|DEVICE|GYNEFFIK(R)|Vaginal electro-stimulation medical device
41479120|NCT05680779|OTHER|ultrasound-guided percutaneous neuromodulation|It´s an intervention of physiotherapy
41479121|NCT05680779|OTHER|dry needling|It´s an intervention of physiotherapy
41479122|NCT04781114|DRUG|JS002|JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
41479123|NCT04781114|DRUG|Placebo|JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
41479124|NCT06245759|OTHER|This was a retrospective study and no patient intervention was performed|This was a retrospective study and no patient intervention was performed
41479125|NCT01124695|DRUG|tamoxifen|PO
41479126|NCT01946074|DRUG|paclitaxel|Paclitaxel will be administered by intravenous infusion.
41479127|NCT01946074|DRUG|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
41479128|NCT01946074|DRUG|ABT-165|ABT-165 will be administered by intravenous infusion at escalating dose levels.
41479129|NCT01946074|DRUG|ABBV-181|ABBV-181 will be administered by intravenous infusion.
41479130|NCT02038231|BEHAVIORAL|Parenting Mindfully Program|see Arm Description.
41479131|NCT02038231|OTHER|Parent Education Program|See Arm Description.
41479132|NCT04782128|BIOLOGICAL|RC28-E injection|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
41479133|NCT04430127|OTHER|No supplementary intervention is performed|No supplementary intervention will be applied
40807811|NCT05436535|DRUG|Vanicream- Active|Non-AD control participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
40807812|NCT05436535|DRUG|Vanicream- Experienced Dupilumab|Long-term dupilumab participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
40807813|NCT06311682|DRUG|Tralokinumab + TCS|The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
41479134|NCT05162651|BEHAVIORAL|Contingency-management|In addition to structured assessments at baseline, four, eight and twelve months, subjects randomized to the contingency-management group will receive a contingent bonus if the participants show successful abstinence at the end of weeks 4, 8 and 12.
41479135|NCT05162651|OTHER|Enhanced usual care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.
40807814|NCT06311682|DRUG|Placebo + TCS|The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
40807815|NCT01302834|BIOLOGICAL|cetuximab|400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks
40807816|NCT01302834|DRUG|cisplatin|100 mg/m2 IV on days 1 and 22 of IMRT
40807817|NCT01302834|RADIATION|IMRT|35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
40807818|NCT03650894|DRUG|Nivolumab|Nivolumab 240 mg IV every 2 weeks
40807819|NCT03650894|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV every 6 weeks.
41009204|NCT06058897|OTHER|eye-tracking|Eye tracking examinations will be conducted using an EyeBrain medical device (class IIa) developed by Suricog. This eye tracker will be installed in a box, in an experimental room. The eye tracker is combined with a computer to present visual cognitive tasks. Pupillary dilation/constriction measurements will be acquired at rest (when fixing a cross presented on the screen) and during the performance of different cognitive tasks (exploration and processing of scenes visuals, reading texts, making saccades or anti-saccades when presenting visual targets). These pupillary measurements will then be linked to the memorization of the stimuli presented, this recognition being tested at the end of the exam.
41153854|NCT02029027|OTHER|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
41153855|NCT06244693|OTHER|No intervention|No intervention
41325269|NCT01841528|OTHER|fresh embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
41479136|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy|The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
41479137|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Cooking for Diabetes|The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
40807820|NCT03650894|DRUG|Bicalutamide|Oral bicalutamide 150mg (3 x 50mg tablets) daily
40807821|NCT06033833|DRUG|Amlitelimab|Injection Solution: by subcutaneous injection (SCI)
40807822|NCT06033833|DRUG|Placebo|Injection Solution: by subcutaneous injection (SCI)
40807823|NCT05348993|DRUG|G03-52-01|G03-52-01 administered intramuscularly
40807824|NCT05348993|DRUG|Placebo|placebo
40807825|NCT05782244|DRUG|Sildenafil Citrate low dose|Sildenafil citrate 20 mg, oral, TID
40807826|NCT05782244|DRUG|Placebo|Placebo, oral, TID
40807827|NCT05782244|DRUG|Sildenafil medium dose|Sildenafil 40 mg, oral, TID
40807828|NCT05782244|DRUG|Sildenafil high dose|Sildenafil 80 mg, oral, TID
41153856|NCT05971758|DRUG|Fimepinostat|The study will allow us to determine the efficacy and safety of these doses in the treatment of Cushing Disease (CD) and guide dose selection for subsequent, larger studies.
40807830|NCT06405165|OTHER|student success|The effect of the flipped education-Jigsaw learning model on the knowledge level of urinary catheter care in nursing students.
41153857|NCT04696926|OTHER|Edwards Intuity TM Valve implantation|aortic valve replacement with an Edwards Intuity TM bioprosthesis
41153858|NCT01905293|OTHER|Feeding Study|
41153859|NCT04837235|DRUG|Hemay005|oral
41153860|NCT05888558|DEVICE|Body fluid diagnosis|miRNAs derived from exosomes in the serum
41153861|NCT01951261|PROCEDURE|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
40807831|NCT06426875|DIAGNOSTIC_TEST|Isometric Exercises|Isometric External Rotation (Perform isometric external rotation exercises with a resistance band to strengthen the rotator cuff.) Hold each contraction for 10-15 seconds. Isometric Internal Rotation (Hold each contraction for 10-15 seconds) Isometric Abduction (Supraspinatus). ( each contraction for 10 -15 sec) 10 repetition 3 sets Isometric Adduction (Subscapularis) Overhead Isometric Holds (Hold each contraction for 15-20 seconds) Isometric Shoulder External Rotation Against Resistance: (Hold each contraction for 15-20 seconds) Isometric Shoulder Press (Hold each contraction for 15-20 seconds) 15 to 20 repetitions 4 sets Total duration of 30 to 35 minute session three sessions per week total four weeks of intervention, reading will be taken on baseline and after 2nd week and 4th week
40807832|NCT05373784|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual into the gastrointestinal tract of another individual. This is currently an accepted method of treatment for recurrent colitis secondary to Clostridium difficile infection refractory to antibiotics/medical management. FMT can be delivered via capsule endoscopy or via colonoscopy. In this study, it will be administered via colonoscopy.
41325270|NCT01841528|OTHER|frozen-thawed embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
41009205|NCT06058897|OTHER|cognitive exams|Cognitive measures will be acquired during an evaluation session through interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare (Covirtua Cognition software). Some exercises will test cognitive systems a priori dependent on NA release (episodic memory, working memory, selective attention, selective inhibition, planning) and other a priori independent of NA (semantic memory: categorization, naming).
41325271|NCT02302144|BEHAVIORAL|Balance & Strengthening Exercises|Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
41325272|NCT05435144|DIETARY_SUPPLEMENT|Elderberry|European black elderberry extract
41325273|NCT05435144|OTHER|Placebo|Inactive placebo
41479138|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub|The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
41009206|NCT01782781|DRUG|ropivacaine, ketorelac and epinephrine|Active group
41153862|NCT04351100|DRUG|Diacerein|Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.
41479139|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub|The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
40807833|NCT04639466|DRUG|Placebo Administration|Given IM in the non-dominant upper arm
41325274|NCT05543642|BIOLOGICAL|Hepatitis A vaccine|Vaccination series administered to prevent hepA infection.
41479140|NCT05681754|PROCEDURE|Experimental: RCT using hydraulic calcium silicate sealer and L-PRF + GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR +/- LPRF
41479141|NCT05681754|PROCEDURE|Experimental: RCT using conventional sealer and L-PRF + GTR|Endodontic treatment with conventional sealer followed by periodontal treatment with PRF + GTR
41479142|NCT05681754|PROCEDURE|Experimental: RCT using hydraulic calcium silicate sealer and GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR only
41479143|NCT05681754|PROCEDURE|Active Comparator: RCT using conventional sealer and GTR (bone substitute + collagen membrane)|Endodontic treatment with conventional sealer followed by periodontal treatment with GTR only
40807834|NCT04639466|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM in the non-dominant upper arm
41479144|NCT06331520|DRUG|Netupitant / Palonosetron Oral Capsule [Akynzeo]|Akynzeo is the fixed-combination antiemetic comprising netupitant (neurokinin-1 receptor antagonist \[NK1 RA\]) and palonosetron (5-hydroxytryptamine-3 receptor antagonist \[5-HT3 RA\]).
41479145|NCT06331520|DRUG|Olanzapine|Olanzapine is an effective antipsychotic drug used in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders. It belongs to the 2nd generation antipsychotics, its mechanism of action ranks among multireceptor antagonists (MARTA); it affects the dopamine, serotonin, adrenaline, histamine, and muscarinic systems.
41479146|NCT06331520|DRUG|Dexamethasone Oral|synthetic glucocorticoids
41479147|NCT04310488|OTHER|The Centre of excellence self-administered (CESAM) questionnaire items|Complete a self-administered questionnaire within two days of their museum visit.
40807835|NCT05267054|DRUG|Ociperlimab|administered intravenously
40807836|NCT05267054|DRUG|Tislelizumab|administered intravenously
41325275|NCT05543642|BIOLOGICAL|Diphtheria, pertussis, and tetanus booster vaccine|Vaccination booster administered to prevent diphtheria, pertussis, and tetanus
41325276|NCT02155348|PROCEDURE|Bilateral cataract surgery with implantation of multifocal IOLs|Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D
40807837|NCT05267054|DRUG|Rituximab|administered intravenously
40807838|NCT05347095|DRUG|Guselkumab|Guselkumab will be administered subcutaneously/IV infusion.
40807839|NCT05347095|DRUG|Placebo|Matching placebo will be administered subcutaneously/IV infusion.
41153863|NCT06477887|BIOLOGICAL|Allogeneic Dentin Matrix|"Steps of Allogenic Dentin Processing:~Wash with distilled water for 30-120 minutes. Ultrasonic Cleaning Cycles: 1st with distilled water for 5-10 minutes, 2nd with 5-7% hydrogen peroxide for 10-30 minutes, then the 3rd with distilled water for 5-10 minutes at 60-80.~Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours. Demineralization with 0.5N HCL for 10-60 min. Dehydration with Neutral Ethyl Alcohol for 30 minutes, then Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours.~Wash with normal saline and freeze dry, then sterilise using ethylene oxide gas.~The extracted socket will be filled with allogenic dentin"
41325277|NCT02155348|PROCEDURE|Bilateral cataract surgery with monovision|Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D
41325278|NCT02155348|DEVICE|Lentis LS-313|
41325279|NCT03812523|DRUG|Duloxetine 60 mg qd|60 mg tablet Taken by mouth, Once Daily for 180 Days
41325280|NCT03812523|DRUG|Lorcaserin|10 mg tablet Taken by mouth Twice Daily for 180 Days
41325281|NCT00109772|DRUG|lenalidomide|Two 5 mg capsules taken one time per day
41325282|NCT00109772|DRUG|Placebo|Two placebo capsules taken one time per day
41325283|NCT03736629|DRUG|Azithromycin|8 weeks of Azithromycin (250 mg) once daily by mouth
41325284|NCT03736629|DRUG|Placebo|Placebo
41325285|NCT02079051|BEHAVIORAL|Moderate intensity weight loss|A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.
41325286|NCT02079051|BEHAVIORAL|High intensity medical weight loss|Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
41325287|NCT02767856|DEVICE|IO-therapy Glasses|
41325288|NCT04991064|OTHER|Complete denture base modified by Titanium dioxide nanoparticles.|Titanium dioxide nanoparticles will be mixed with resin powder of the denture base before mixing the powder and liquid of the heat cure denture base material.
41325289|NCT01360762|DRUG|Pentamidine|Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
41325290|NCT05793216|BEHAVIORAL|VestibulOTherapy|"For this study, the following activity-orientated interventions will occur within the natural learning environments so that generous opportunities exist for neural plasticity and growth.~Each student will be engaged in 20-30 minutes/day of intermittent classroom activities, plus 20-30- minutes of daily stability work embedded into classroom routines including stabilizing self on a Hokki stool or t-stool or standing on a balance board during sedentary work, such as circle time or read-a-loud."
41325291|NCT02930369|PROCEDURE|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
41325292|NCT05408117|DEVICE|5-0 Polypropylene epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
41325293|NCT05408117|DEVICE|5-0 Fast gut epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
41325294|NCT06528730|DIAGNOSTIC_TEST|DCM|Confirm degenerative cervical myelopathy by Orthopaedic surgeon and MRI
41325295|NCT00226395|DRUG|Oxymorphone immediate release|
41153864|NCT06477887|BIOLOGICAL|Autogenous Partially Demineralized Dentine Matrix|"The extracted tooth will be cleaned with a diamond bur under abundant irrigation with physiological water. All filling materials (gutta-percha, composite, luting cements, etc.) will be removed with the outmost care and under magnification.~Subsequently, the tooth will be cut into fragments (5 × 5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). According to the manufacturer, a disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.~After 25 minutes, particle graft biomaterials will be obtained. The particle size will range from 815 µm with peaks up to 1110 µm.~The socket will be filled with the graft."
40807841|NCT05476497|BIOLOGICAL|VLP Peanut|solution for subcutaneous administration
40807842|NCT05476497|BIOLOGICAL|Placebo|solution for subcutaneous administration
40807843|NCT05476497|BIOLOGICAL|VLP Peanut|solution for Skin-prick testing
40807844|NCT04493970|OTHER|High School Students Survey|To assess retention, effectiveness and factors impacting comprehension of cardiopulmonary resuscitation (CPR) training among high school students.
40807845|NCT06534411|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
40807846|NCT06534411|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
40807847|NCT06534411|DRUG|Tirzepatide|Participants will receive once-weekly tirzepatide subcutaneously.
41325296|NCT00131664|DRUG|Avandamet|Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
41153865|NCT05238116|DRUG|PC945|Sterile aqueous liquid for Nebulization
40807855|NCT06492616|DRUG|Elacestrant|Administered as oral tablets
41325297|NCT00131664|DRUG|Avandia and Amaryl|Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
41325298|NCT00131664|DRUG|Metformin|Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
41325299|NCT02834091|PROCEDURE|Hypnoanalgesia|
41325300|NCT01338935|DRUG|CW 002|"For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage \*.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~\*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1)."
41325301|NCT01338935|DRUG|CW 002|"Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study."
41325302|NCT01338935|DRUG|CW 002|"In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus."
41325303|NCT01351402|PROCEDURE|Massage or Rest|Participants either received 15 minutes of moderate pressure Swedish massage on the upper back, or rested quietly sitting in a chair for 15 minutes.
41325304|NCT02455778|DIETARY_SUPPLEMENT|Cinnamon|
41325305|NCT02455778|DIETARY_SUPPLEMENT|Placebo|
41325306|NCT01002053|PROCEDURE|Nerve conduction study and Ultrasound of the PTN|Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
41325307|NCT05506904|DEVICE|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. The clinical outcome case report form will be completed at the time of hospital discharge.
41325308|NCT00166517|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
41325309|NCT00166517|BIOLOGICAL|Comparator: Placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
41325310|NCT02031432|DRUG|Cebranopadol|Film-coated tablet; strengths: 200, 400, or 600 µg
41325311|NCT06372054|OTHER|Biological sample collection|Collection of biological samples (blood, urine, saliva) and clinical data
41325312|NCT02466165|BEHAVIORAL|Physical exercise|
40807856|NCT06492616|DRUG|Anastrozole|Administered as oral tablets
40807857|NCT06492616|DRUG|Letrozole|Administered as oral tablets
40807858|NCT06492616|DRUG|Exemestane|Administered as oral tablets
40807859|NCT06492616|DRUG|Tamoxifen|Administered as oral tablets
41153866|NCT05238116|DRUG|Placebo|Sterile aqueous liquid for Nebulization
41153867|NCT01482819|DEVICE|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
41009207|NCT01782781|DRUG|Placebo|Placebo group
41009208|NCT00610532|DRUG|phenytoin|intravenous phenytoin (15 mg/kg) single dose
41153868|NCT01482819|DEVICE|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
41153869|NCT01482819|DEVICE|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
41153870|NCT01482819|DEVICE|polymacon|contact lenses worn bilaterally for 8-12 hours
41009209|NCT00610532|DRUG|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
41009210|NCT00222937|BEHAVIORAL|Lessac-Madsen Resonant Voice Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
41009211|NCT00222937|BEHAVIORAL|Casper-Based Confidential Flow Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
41153871|NCT01482819|OTHER|spectacles|habitual spectacles owned by subject, non-specific manufacturer
41009212|NCT02312726|PROCEDURE|Postplacental IUD insertion|Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
41009213|NCT04729387|DRUG|Alpelisib|Alpelisib will be administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle
41009214|NCT04729387|DRUG|Olaparib|Olaparib will be administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
41009215|NCT04729387|DRUG|Paclitaxel|Paclitaxel will be administered at 80 mg/m2 as an intravenous infusion weekly during a 28-day treatment cycle, starting on Cycle 1 Day 1, and on Day 8, Day 15 and Day 22 of every cycle thereafter
41009216|NCT04729387|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered at 40-50 mg/m2 (physician discretion) as an intravenous infusion once every 28-days in a 28 day treatment cycle, starting on Cycle 1 Day 1
41153872|NCT00033462|DRUG|erlotinib hydrochloride|Given orally
41009217|NCT03697954|DEVICE|full stage implantation of sacral neuromodulation|full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence
41009218|NCT03076138|DEVICE|Gene-activated matrix (OCP + plasmid DNA with VEGF gene)|Bone grafting procedure with investigated medical device
41009219|NCT00770120|DRUG|everolimus|
41009220|NCT02149433|DRUG|Prednisone|The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
41325313|NCT06259357|OTHER|Protocolized protective mechanical ventilation in prone position|Prone Position: Study subjects randomized to the intervention group will be placed and maintained in prone position for at least 16 hours/day until the time of organ procurement or decline (typically 24-48 hours after donation consent) or the time that the lungs are declined for transplant.
41325314|NCT02593968|DRUG|Recombinant Human Interferon a-2b Gel|
41325315|NCT02593968|DRUG|Placebo|
41325316|NCT04522791|BEHAVIORAL|RFB|The RFB protocol entails a combination of 8 weekly, in-lab training sessions using HRV biofeedback software (Physiocom, Seattle, WA) and daily paced breathing homework using a mobile-based HRV biofeedback app (Inner Balance, HeartMath, LLC, CA).
41325317|NCT04522791|BEHAVIORAL|VSOP|The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.
41009221|NCT02149433|DRUG|Placebo|
41009222|NCT03612622|OTHER|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
41009223|NCT00627679|DRUG|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
41153873|NCT00033462|OTHER|laboratory biomarker analysis|Correlative studies
41153874|NCT00884793|DRUG|raltegravir|The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).
41153875|NCT00884793|DRUG|Study NNRTI|Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
41009224|NCT00627679|DRUG|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
41009225|NCT00627679|DRUG|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
41009226|NCT00627679|DRUG|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
41009227|NCT04548882|DEVICE|Calypso Knee System|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
40807864|NCT05807854|PROCEDURE|Arthroscopy|The surgeon reattaches the torn tendon to the bone with anchors and sutures.
40807865|NCT05807854|DEVICE|Reverse Shoulder Arthroplasty|It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
40807866|NCT02315599|DRUG|anti-CD19 CAR|
41009228|NCT03077165|DRUG|S42909 100 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
41009229|NCT03077165|DRUG|S42909 200 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
41009230|NCT03077165|DRUG|S42909 400 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
41009231|NCT03077165|DRUG|S42909 800 mg|200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
41009232|NCT03077165|DRUG|S42909 1200 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
41009233|NCT03077165|DRUG|Placebo Oral Tablet|Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
41009234|NCT04820816|OTHER|pelvic tilt effect on balance, sensory integration and risk of fall|BIODEX balance system, Limits of stability test, Risk of Fall test, m-CTSIB test
41009235|NCT00383838|BEHAVIORAL|brief, voluntary substance use intervention|
41153876|NCT00884793|DRUG|Study PI|Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
41153877|NCT05560945|DRUG|0.32% Sodium Fluoride Dentifrice Toothpaste|Toothpaste
41325318|NCT04522791|BEHAVIORAL|IR|Guided imagery relaxation, equal in dose and frequency to RF practice, will be used to control for relaxation effects that may occur via RFB (which could provide an alternative explanation for outcomes). IR activities will be facilitated using the Insight Timer mobile-based app, which emphasizes the use of visualization and imagery strategies to help the body relax.
41325319|NCT04256304|BEHAVIORAL|PHEinAction-Personalized Patient Engagement Plan|The intervention includes two face-to-face sessions, a telephone consultation, and written home-based exercises. The first session aims to promote an awareness of patients with diabetes management, define an action plan to encourage engagement, introduce the patient to follow their strategy for the next four weeks, and encourage them to adopt the instruments with home-based exercises to reach their specified health goals. Two weeks after the first interview session, the researcher will provide telephone consultation to check the patient for their progress and support them to maintain motivation. The second session will include collecting patient's experiences and discussing the home-based exercises, re-determining the patient health engagement phase through the PHE-s®, discussing the personalized care goals by providing feedback aiming to support improvements, and setting a new engagement goal with the current status and encouraging the patient to maintain the health engagement plan.
41325320|NCT04671342|DEVICE|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing.
41325321|NCT00682240|PROCEDURE|laser treatment with PASCAL®|panretinal laser treatment - single-session
41325322|NCT00682240|PROCEDURE|laser treatment with PASCAL®|panretinal laser treatment - multi-session
41325323|NCT00682240|PROCEDURE|laser treatment with PASCAL®|grid / focal laser treatment
41325324|NCT00682240|PROCEDURE|laser treatment with conventional laser system|panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
41009236|NCT00820001|BEHAVIORAL|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
41153878|NCT05560945|DRUG|1.5% Arginine Dentifrice|Toothpaste
41325325|NCT01757977|DEVICE|double lumen endotracheal tube placement and use|
41325326|NCT00546429|DEVICE|Intramedullary nailing|Trochanteric nailing for proximal femoral fractures.
41325327|NCT01016691|DRUG|High Dose Drug Device|device inserted for 4 days
41325328|NCT01016691|DRUG|Low Dose Drug Device|device inserted for 4 days
41325329|NCT01016691|DRUG|Placebo Device|device inserted for 4 days
41325330|NCT01016691|DRUG|bimatoprost 0.03%|one drop in each eye on one day only
41325331|NCT01608399|BEHAVIORAL|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
41325332|NCT00352950|DRUG|AMG 954/Panitumumab|
41325333|NCT05613842|DRUG|Copper-64 labelled SAR-Bombesin|radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
41325334|NCT01745601|DRUG|escitalopram 10 mg|Reference product
41325335|NCT01745601|DRUG|escitalopram 10 mg|Test product
41325336|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
41325337|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - active control session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
41153879|NCT05560945|DRUG|8.0% Arginine Dentifrice|Toothpaste
41153880|NCT00936195|DRUG|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
41153881|NCT00936195|DRUG|Zidovudine-Lamivudine-Lopinavir/Ritonavir|"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"
41153882|NCT00702338|DRUG|corifollitropin alfa|SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
41009237|NCT00820001|BEHAVIORAL|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
41009238|NCT00820001|OTHER|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
41009239|NCT00820001|OTHER|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
40807867|NCT05906485|BEHAVIORAL|fNIRS Neurofeedback-VR Training|In the fNIRS Neurofeedback-VR Training, we have designed a classroom scenario modeled and children are expected to learn how to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
41325338|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - sham control session.|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
41325339|NCT02836483|DRUG|LCB01-0371 800mg, QD|Oral administration
41325340|NCT02836483|DRUG|LCB01-0371 400mg, BID|Oral administration
41325341|NCT02836483|DRUG|LCB01-0371 800mg, BID|Oral administration
41325342|NCT02836483|DRUG|Tubes 3~5Tablet, QD|Oral administration
41325343|NCT02836483|DRUG|Zyvox 600mg, BID|Oral administration
41325344|NCT02836483|DRUG|LCB01-0371 1200mg, QD|Oral administration
41325345|NCT05736562|DIETARY_SUPPLEMENT|Ritual Epre Multimineral-Vitamin Supplement|The Ritual Epre supplement is a commercially available multivitamin-mineral supplement designed for pregnant and lactating women.
41325346|NCT05736562|DIETARY_SUPPLEMENT|Placebo Control|This is a customarily designed blank placebo provided by Ritual.
41325347|NCT05205278|OTHER|exercise training|The core stability training programme was performed 3 days per week over an 8-week period, and each training session lasted approximately 50 minutes.We created a special programme for our study based on the literature; the core stability training programme was divided into 3 phases: easy(1-2 weeks), moderate(3-5 weeks) and difficult(6-8 weeks In the easy phase(phase1), the athlete was intended to gain sensorimotor control that would ensure the smoothness of the neutral spine during slow movements. The participants learned the hallowing technique and how to use this technique while doing core exercises. In the moderate phase(phase2), muscular neural adaptation and neuromuscular facilitation were targeted with the transition to high threshold strength training.In the last, difficult, phase(phase3), subconscious control of movement was taught using combined movement patterns with the aim of transitioning to functional positions and activities.
41325348|NCT04823767|OTHER|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
40807868|NCT05906485|BEHAVIORAL|Computerized Cognitive Training|In the Computerized Cognitive Training, children will complete a range of tasks covering attention control and working memory using a conventional training programme, namely Cogmed.
41009240|NCT05595291|OTHER|investigation of the factors affecting walking characteristics|In order to investigate the factors affecting walking characteristics, 2-minute walking test, 10-point VAS (overall prosthesis satisfaction level, socket comfort and satisfaction level, knee joint satisfaction level, prosthetic foot satisfaction level, pain level in amputated extremity) and locomotor capacity index will be applied.
41009241|NCT01166594|DRUG|Bevacizumab|Intrableb injection
41325349|NCT04715256|BEHAVIORAL|Cognitive assessment of obsessive-compulsive and impulsive behaviours|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
41325350|NCT04715256|GENETIC|Genomic analysis|A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
41325351|NCT04715256|DIAGNOSTIC_TEST|Glucoregulation assessment|Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
41325352|NCT02292992|DEVICE|Nasal Pillow CPAP|Nasal Pillow CPAP in extubated patients
41325353|NCT04564716|BIOLOGICAL|Gam-COVID-Vac|vaccine for intramuscular injection
41325354|NCT04564716|OTHER|Placebo|placebo comparator
41325355|NCT03404271|DIETARY_SUPPLEMENT|Beta-hydroxy beta-methylbutyrate|3 grams per day of the calcium salt form of beta-hydroxy beta-methylbutyrate (HMB).
41325356|NCT03404271|OTHER|Resistance Training|Performing supervised resistance training three times per week.
41325357|NCT03404271|DIETARY_SUPPLEMENT|Protein Supplementation|Consuming a protein supplement daily.
41325358|NCT03404271|BEHAVIORAL|Time-Restricted Feeding|Consuming all calories within a specified 8-hour period of time each day.
41325359|NCT00018629|OTHER||
41325360|NCT06130410|BIOLOGICAL|COMIRNATY intramuscular injection|Booster injection in the muscle, 1 dose
41325361|NCT01539811|PROCEDURE|Surgical incision and drainage of diabetic foot infection|Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
41325362|NCT01539811|DRUG|Short course antibiotics|Short course (\<2 weeks) of antibiotics will be prescribed
41009242|NCT01166594|DRUG|Control|intrableb BSS injection
41009243|NCT05069012|DRUG|Morphine Sulfate|Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief
41009244|NCT05957367|DRUG|DCC-3116|Oral Tablet Formulation
41325363|NCT01539811|DRUG|Long course antibiotics|Long course (\>2 weeks) of antibiotics will be prescribed
41009245|NCT05957367|DRUG|Ripretinib|Oral Tablet Formulation
41009246|NCT01147419|DEVICE|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
40807869|NCT05537064|BEHAVIORAL|Non-visit Based Intervention|At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.
40807870|NCT05537064|BEHAVIORAL|Visit-Based Intervention|"The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated."
40807871|NCT05691478|PROCEDURE|Bone Scan|Undergo bone scintography
41325364|NCT04938362|OTHER|FDG-PET|\[18F\]Deoxyglucose-positron emission tomography at 0-10 years after brain abscess
41325365|NCT04938362|OTHER|EEG|Electroencephalography (EEG) at 0-10 years after brain abscess
40807872|NCT05691478|DRUG|Cabozantinib S-malate|Given PO
41009247|NCT01147419|DEVICE|femoral-popliteal bypass with artificial blood vessel|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
41009248|NCT00485875|DRUG|Atomoxetine Hydrochloride|
40807873|NCT05691478|DRUG|Cisplatin|Given IV
40807874|NCT05691478|PROCEDURE|Computed Tomography|Undergo CT
41009249|NCT06359405|BEHAVIORAL|drug safety simulation|"The intervention's purpose is to develop a simulation program to increase nursing students' crisis management skills regarding medication safety. This simulation program will provide students with the opportunity to develop skills in recognizing, evaluating, and effectively intervening in medication errors in real-world scenarios.~The simulation program will include interactive case scenarios, virtual patients, and simulation sessions led by an instructor providing feedback to students. Also, medicine Learning materials covering preventing, recognizing, and correcting errors will also be provided."
41009250|NCT01826175|DRUG|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
41009251|NCT01826175|DRUG|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
41325366|NCT00949910|DRUG|Erlotinib|Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
41325367|NCT01158729|DRUG|Antithrombin (Recombinant)|Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
40807875|NCT05691478|DRUG|Doxorubicin Hydrochloride|Given IV
40807876|NCT05691478|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40807877|NCT05691478|DRUG|Methotrexate|Given IV
41325368|NCT01158729|OTHER|Placebo|Single dose of placebo (0.9% NaCl) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: Placebo dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
41325369|NCT04391855|DRUG|Tramadol with ropivacaine|A solution of tramadol 2mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
41009252|NCT01826175|DEVICE|Optical Coherence Tomography|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
41157183|NCT00439361|DRUG|Mesna|5 mg/m\^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m\^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
41325370|NCT04391855|DRUG|Dexmedetomidine with ropivacaine|A solution of dexmedetomidine 1μg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
41325371|NCT04391855|DRUG|Magnesium with ropivacaine|A solution of magnesium 10 mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
40807878|NCT05691478|PROCEDURE|Surgical Procedure|Undergo surgery
40807879|NCT05691478|PROCEDURE|X-Ray Imaging|Undergo X-ray
40807880|NCT05803161|DRUG|Congrong Runtong oral liquid|"Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola"
40807881|NCT05803161|DRUG|Placental Congrong Runtong oral liquid|Placental Congrong Runtong oral liquid
41153883|NCT00702338|BIOLOGICAL|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
41153884|NCT00702338|BIOLOGICAL|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
41153885|NCT00702338|BIOLOGICAL|hCG Bolus injection|Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
41153886|NCT05813249|DRUG|Rybelsus Oral Product|Oral Semaglutide
41153887|NCT05813249|DRUG|Ozempic Injectable Product|Subcutaneous Semaglutide
41153888|NCT05813249|DRUG|Tocopherol and/or Actos|Vitamin E and/or Pioglitazone
41153889|NCT06181968|DIAGNOSTIC_TEST|Cardiothoracic ultrasound protocol|Combined echocardiography and lung ultrasound for guiding therapy
41009253|NCT05461248|PROCEDURE|stoma drainage reinfusion|1 month after radical rectal surgery, the stoma drainage fluid was reinfused once a week for 2 months. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
41009254|NCT05461248|PROCEDURE|Standard of Care - No Return of Stoma Drain|No Return of Stoma Drain
41009255|NCT03330535|BEHAVIORAL|Reminders once a week|Participants in this group will receive active oral hygiene reminders through text messaging once a week.
41009256|NCT03330535|BEHAVIORAL|Verbal oral hygiene instructions|Participants in this group will receive verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
41009257|NCT03330535|BEHAVIORAL|Reminders three times a week|Participants in this group will receive active oral hygiene reminders through text messaging three times a week.
41009258|NCT03330535|BEHAVIORAL|Daily reminders|Participants in this group will receive active oral hygiene reminders through text messaging on a daily basis.
41153890|NCT06315647|PROCEDURE|DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation|comparison between different technique in difficult CBD cannulation
41153891|NCT05453292|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|Patients will be first assessed by DFI-EUS and CE-EUS. Then. EUS guided RFA will be performed using the 19G electrode ablation needle connected to the Starmed radiofrequency generator (Taewong Medical, Seoul, South Korea). After EUS identification of the GIST, a place without interposing vessels will be found by the endosonographer. Puncture of the tumor will be performed directly with the ablation probe inserted through the working channel of the echoendoscope. Time - seconds will depend by the tumor dimension, localization, distance from vital structures (e.g., aorta) and EUS appearance (e.g., hyperechoic). Power will be set at no more than 30W. If the tumor is in contact with vital structures a 10mm safe margin will be kept from these to avoid thermal injury. Multiple applications can be performed in the same or separate session depending on the residual tumor tissue evaluated with DFI-EUSor CE-EUS immediately after procedure.
41153892|NCT01437384|DRUG|E5501|20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
41153893|NCT00685347|DRUG|Levalbuterol HFA MDI|"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
41153894|NCT00685347|DRUG|Racemic Albuterol|"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
41153895|NCT00147745|DRUG|Colesevelam|Colesevelam 3.8g for 12 weeks
41153896|NCT00147745|DRUG|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
41325372|NCT04391855|DRUG|Ropivacaine plus normal saline|A solution of ropivacaine hydrochloride (10mg/ml) 100mg with 5ml of isotonic saline 0.9% mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
41153897|NCT00147745|DRUG|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
41325373|NCT00488995|DRUG|CP-675,206|
41325374|NCT02348424|DRUG|Solithromycin|Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.
41153898|NCT02415335|DRUG|dexamethasone phosphate|Intravenously administration minimum of 30 minutes preoperatively.
41153899|NCT02415335|DRUG|Isotonic NaCl|Intravenously administration minimum of 30 minutes preoperatively
41153900|NCT04337502|DIAGNOSTIC_TEST|Machine learning model|Machine learning, such as logistic regression, random forest, and deep learning
41325375|NCT01907841|OTHER|Ischemic Preconditioning|
41325376|NCT02030444|PROCEDURE|PET-MRI and EBUS-TBNA|
41325377|NCT06446180|DIETARY_SUPPLEMENT|SsK12@Lip@GSH|SsK12@Lip@GSH powder contained no less than 5×10\^8 CFU viable cells of SsK12@Lip@GSH as the active ingredient.
41325378|NCT05610917|COMBINATION_PRODUCT|CBRM (community-based rehabilitation management)|The case group patients will undergo drug treatment (Selective Serotonin Reuptake Inhibitors), health education, cognitive-motor dual task training, cognitive-training.
41009259|NCT04002765|DIAGNOSTIC_TEST|pulmonary function tests|"1. Lung function tests (standard of care)~   1. Dynamic and static volumes (FVC, FEV1, TPC, RV)~  2. Lung diffusion capacity for CO (DLCO)~2. Chest Xrays~3. High resolution CT scanner (HRCT)"
41009260|NCT02516124|PROCEDURE|Autologous HSCT|1st AHSCT
41325379|NCT05610917|COMBINATION_PRODUCT|TAR(treatment as routine)|Patients in control group will be treated rountinely which includes drug treatment (SSRIs) and traditional health education.
41325380|NCT03485092|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg tablets for oral self administration once a day
41325381|NCT03485092|DRUG|Placebo Oral Tablet|placebo tablets for oral self administration once a day
41325382|NCT05505097|DRUG|Hydroxymethylquinoxalindioxyde|"Dioxidin (Hydroxymethylquinoxalindioxyde), solution for topical and external use, 0.25 mg/ml, applied as:~A - single rinsing of the oropharynx with 15.0 ml of the drug solution for at least 30 seconds B - single irrigation of the oropharynx by spraying the preparation 4 times with a spray nozzle C - irrigation of the skin on the back by spraying the preparation 4 times from a distance of 10 cm on 1% of the body surface using a spray nozzle and exposing the solution for 30 minutes or D - Dioxidin (Hydroxymethylquinoxalindioxyde), solution for infusion and external application, 5 mg/ml, single intravenous 5 mg/ml in 1 ml"
41153901|NCT04577586|OTHER|oral contrast|negative oral contrast utilization in PET/CT studies
40807890|NCT05460533|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.
40807891|NCT04657835|DEVICE|cardiac Magnetic Resonance Imaging (MRI)|Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.
40807892|NCT04657835|BIOLOGICAL|Blood sample|Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.
40807893|NCT04657835|PROCEDURE|Cardiac muscle biopsy|Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.
40807894|NCT04657835|DEVICE|Holter-electrocardiogram (ECG)|Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.
40807895|NCT04657835|OTHER|medical examination|medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
40807896|NCT02777203|DEVICE|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag. This study is a pilot study with one arm (all patients will use the new EcoSac400 ECO-T bag.
40807897|NCT05898672|DRUG|Rosuvastatin|Single oral dose of rosuvastatin tablets
40807898|NCT05898672|DRUG|Nirmatrelvir/ritonavir|Twice daily oral doses of nirmatrelvir/ritonavir tablets
41153902|NCT01372735|RADIATION|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
41153903|NCT01372735|RADIATION|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
41325383|NCT03823599|BEHAVIORAL|Mobile chat-based instant messages|Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline
41325384|NCT03823599|BEHAVIORAL|Alcohol brief intervention|The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
41325385|NCT02196987|OTHER|Urination during urethral catheterisation|Requesting the patient to urinate while inserting urethral catheter
41153904|NCT04812925|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
40807902|NCT06121609|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy
40807903|NCT05610826|PROCEDURE|cytoreductive surgery|Cytoreductive surgery is an operation to remove as much tumor tissue as possible.
40807904|NCT05610826|DRUG|Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)|"PRRT is a form of targeted treatment (think of a lock and key) done by the use of a small molecule (Lutathera). Lutathera acts as a key to lock onto certain areas your tumor cells called receptors when injected into a vein and travels through blood."
41009261|NCT02436512|DRUG|Inhaled Nitric Oxide|"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~* (Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~* (Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"
41009262|NCT05552040|BEHAVIORAL|START NOW Group|START NOW psychotherapy is a CBT, DBT and skills-based intervention
41009263|NCT04382612|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
41009264|NCT02188368|DRUG|POM|
41009265|NCT02188368|DRUG|Steroids|
41009266|NCT02188368|DRUG|PLD|
41009267|NCT02188368|DRUG|CFZ|
41009268|NCT02188368|DRUG|BTZ|
41009269|NCT02188368|DRUG|CLA|
41009270|NCT02188368|DRUG|CY|
41009271|NCT03969355|OTHER|Mortality|Patients who died during PICU stay
41153905|NCT02599987|DEVICE|POWERbreathe® Classic Light|Inspiratory Muscle Training
41153906|NCT04335383|BIOLOGICAL|Isolation of anti-Pseudomonas antibodies from type B lymphocytes|Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.
41325386|NCT02196987|OTHER|Urethral catheterisation, without further guidance|Lying, inserting urethral catheter, without further guidance from health care professional
41325387|NCT03994393|DRUG|Tremelimumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
41009272|NCT02244333|DRUG|ALNA®|
41325388|NCT03994393|DRUG|Durvalumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
41325389|NCT00334152|DRUG|casopitant|
41325390|NCT03805971|DEVICE|Study of the pleural cavity with a confocal laser endomicroscope.|Probe based confocal laser endomicroscope can be introduced through the working chanel of the thoracoscope. this allows the study of the pleural cavity with this new tool.
41325391|NCT04239547|PROCEDURE|Alveolar Recruitment maneuver (ARM) +PEEP|Following anesthesia induction and intubation, alveolar recruitment maneuver followed by 5 mmHg PEEP
41009273|NCT00006184|DRUG|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
41009274|NCT00006184|DRUG|Bortezomib|Induction chemotherapy: 1.3 mg/m\^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
41009275|NCT00006184|DRUG|Cyclophosphamide|Induction chemotherapy: 600 mg/m\^2 day 4 Transplant: 1200 mg/m\^2 intravenous x 4 days (days -6, -5, -4, -3)
41009276|NCT00006184|DRUG|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
41009277|NCT00006184|DRUG|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3
41009278|NCT00006184|DRUG|Etoposide|Induction chemotherapy: 50 mg/m\^2 day continuous intravenous days 1-3
41009279|NCT00006184|DRUG|Fludarabine phosphate|Induction chemotherapy: 25 mg/m\^2 day intravenous days 1-3 Transplant: 30 mg/m\^2 day x 4 days (days -6, -5, -4, -3 )
41009280|NCT00006184|DRUG|Prednisone|60 mg/m\^2 day 1-4
41009281|NCT00006184|DRUG|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m\^2 day continuous intravenous days 1-3
41009282|NCT00006184|DRUG|Methotrexate|Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11
41009283|NCT00006184|BIOLOGICAL|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m\^2 subcutaneously every day, days 1-4
41009284|NCT00006184|BIOLOGICAL|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) \> 1000/ul x 2 days
41009285|NCT01495962|DRUG|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
41009286|NCT01495962|DRUG|Placebo|Placebo (Normal Saline)
41009287|NCT02928341|OTHER|Improved water supply|
41009288|NCT05082194|PROCEDURE|balance with open and closed eyes|"The UNTERBERGER TEST. The subjects performed the test once with their eyes open and then with their eyes closed. The participant's task was to assume a standing position with legs apart at hip-width and then walk in place (50 steps).~Static and dynamic balance testing on the Biodex SD balance platform. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. Before starting the tests, surface electrodes were glued to the patient's body (according to the SENIAM procedure). Five surface electrodes were used, consisting of three channels. They were placed on the abdomen of the right sternocleidomastoid muscle, two more were placed on the left longus colli muscle, and one reference electrode on the right shoulder process of the scapula. After each completed test, an ongoing test report was generated."
41009289|NCT00169637|DRUG|rhGH|
41009290|NCT05553925|OTHER|Online Weight Management Program with Coaching and Patient Navigator Support|"Patients will enroll in a 12-month digital health program available in online and mobile versions with live, personalized coaching and patient navigator support.~Patient Interface~* Digital scale and Fitbit~* Brief lessons that focus on helping patients improve their nutrition, exercise, sleep, and stress~* Weight, diet, and physical activity tracking~* Regular, personalized feedback and support from a health coach~* Spanish Version~Patient navigators are non-licensed staff. Their responsibilities will include enrolling patients in the program, monitoring their progress, and updating providers periodically. They also will be able to connect patients with additional resources and services, such as the Center for Weight Management and Wellness, if appropriate."
41325392|NCT04239547|PROCEDURE|PEEP|Following anesthesia induction and intubation, only 5 mmHg PEEP
41325393|NCT05705895|PROCEDURE|CENTRAL VENOUS CATHETER CARE PROTOCOL|"Catheter care is provided in line with the CVC care protocol developed by the researcher:~* For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used.~* The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry.~* Vein valve/needleless connector will be used.~* Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention.~* Needle-free connectors will be replaced every 96 hours at the latest.~* If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators.~* Pulsatile give stop give stop technique will be used in the washing process."
41009291|NCT02694224|DRUG|vismodegib|Smo inhibitor
41009292|NCT02694224|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
41009293|NCT02694224|DRUG|Epirubicin|dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
41009294|NCT02694224|DRUG|Cyclophosphamide|dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
41009295|NCT00321035|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
41009296|NCT01064921|DRUG|vorinostat|The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
41009297|NCT01064921|DRUG|cisplatin|Given IV
40807905|NCT05610826|PROCEDURE|Peptide receptor radionuclide therapy (PRRT)|PRRT is a molecular targeted therapy used to treat neuroendocrine tumors (NET). Molecular targeted therapies use drugs or other substances to identify and attack cancer cells while reducing harm to healthy tissue. PRRT delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects.
41009298|NCT01064921|RADIATION|radiation therapy|Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
41009299|NCT01064921|PROCEDURE|Correlative Studies|Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
41153907|NCT03741283|OTHER|Optimisation of nutrition and medication|"1. Inter-professional optimisation of medication prescribing:~   Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.~2. Nutritional intervention:~If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:~* Dysphagia: occupational therapy intervention.~* Oral cavity problems: odontological intervention.~* Depression: geriatric intervention.~* Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention."
41153908|NCT01138137|DRUG|Paclitaxel|"Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle~Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle~6 treatment cycles"
41325394|NCT05322057|DRUG|Darvadstrocel|Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract
41325395|NCT00628758|DRUG|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
41325396|NCT00628758|DRUG|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
41325397|NCT04011800|PROCEDURE|Catheter ablation|Pulmonary vein isolation, or additional left or right-sided atrial lesions.
41325398|NCT04011800|COMBINATION_PRODUCT|Risk Factor Modification|dietary restriction, physical exercise, reduced alcohol intake with antiarrhythmic drugs
41325399|NCT01771211|DEVICE|tDCS|anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
41325400|NCT04777019|OTHER|Not applicable as standard of care Colonoscopy|Not applicable since not an intervention
41153909|NCT01138137|DRUG|N-acetylcysteine|"A group of 5 subjects will be evaluated at each dose level.~On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.~6 treatment cycles~Dose escalation schema:~Level 1: 150mg/kg~Level 2: 300mg/kg~Level 3: 600mg/kg~Level 4: 800mg/kg~Level 5: 1000mg/kg~Level 6: 1200mg/kg"
41325401|NCT02077985|BEHAVIORAL|Sensory Adapted Dental Environment|See study arm description.
41325402|NCT02316626|DRUG|Subcutaneous progesterone|25 mg daily for 14 days
41325403|NCT02316626|DRUG|Vaginal progesterone|90 mg daily for 14 days
41325404|NCT05022745|OTHER|Multimodal, multidisciplinary approach|The patient management is adapted pre-operatively, per-operatively and post-operatively
41009300|NCT02385812|PROCEDURE|Low-dose computed tomography Annual scan x3|Annual scan x3
41325405|NCT05690971|BEHAVIORAL|App|"HORIZONS is self-administered with several features to promote engagement and health behavior change including gamification strategies, videos of chronic GVHD survivors, and optional content.~HORIZONS includes five interactive modules to be completed during an eight week period. HORIZONS also includes a sixth optional helpful resources section with a review of the domains and skills covered in the first five modules"
41325406|NCT05690971|BEHAVIORAL|Usual Care|Patients in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.
41325407|NCT02027922|OTHER|Fluor Protector S|Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
41009301|NCT02385812|PROCEDURE|Low-dose computed tomography Baseline scan only|Baseline scan only
41325408|NCT05791162|OTHER|Blood collection|Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)
41325409|NCT05791162|OTHER|Urine sample|Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)
41009302|NCT03031288|DEVICE|A|standard bottle
41009303|NCT03031288|DEVICE|B|vented base bottle
41009304|NCT05927610|DIAGNOSTIC_TEST|Lumber Puncture|During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy).
41009305|NCT00238277|DRUG|temozolomide|
41009306|NCT00238277|PROCEDURE|adjuvant therapy|
41009307|NCT00238277|PROCEDURE|chemotherapy|
41009308|NCT00238277|PROCEDURE|radiation therapy|
41009309|NCT02644967|DRUG|IMO-2125|Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
41009310|NCT02644967|DRUG|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
41009311|NCT02193594|RADIATION|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
41153910|NCT01138137|DRUG|Cisplatin|"Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion~6 treatment cycles"
41153911|NCT06465615|DEVICE|Self-education with dichoptic reading on tablet|"Intervention 25 min/day, 5 days a week for 6 weeks at home (125-minute weekly load), under the supervision of a parent, on a dichoptic reading application on a loaned digital tablet, wearing anaglyph glasses provided and the patient's optical correction (if applicable).~During the first half of treatment (first 3 weeks), dichoptic separation takes place at the word level, and during the second half of treatment (last 3 weeks), it takes place at the individual letter level to promote precise eye alignment. This shift from dichoptic separation at word level to letter level increases the difficulty of the task. The text is freely chosen by the child and parent from a bank of age-appropriate books."
40807913|NCT03967977|DRUG|Tislelizumab|200 mg administered Intravenously (IV) as specified in the treatment arm
40807914|NCT03967977|DRUG|Placebo|Tislelizumab placebo to match
41325410|NCT01015729|DRUG|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
41325411|NCT01015729|DRUG|Esomeprazole|oral, single dose
41325412|NCT01015729|DRUG|ASA|Tablet, oral, single dose
41325413|NCT02604810|BIOLOGICAL|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
41479148|NCT04917081|BEHAVIORAL|Mindful Self-Compassion|Mindful Self-Compassion has been developed by Neff and Germer as a specific kind of Mindfulness-Based Interventions to promote self-compassion. It combines the skills of mindfulness and self-compassion, providing a powerful tool for emotional resilience and enhancing the capacity for emotional wellbeing. In this study, a shortened version of the MSC program is used which is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
41009312|NCT02193594|PROCEDURE|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
41479149|NCT04917081|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a deep relaxation technique that helps relieve muscle tension and is based on the premise that mental calmness is a natural result of physical relaxation. In this study, Progressive Muscle Relaxation is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
41325414|NCT02604810|BIOLOGICAL|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
41325415|NCT03368326|DIAGNOSTIC_TEST|Critical-Care Pain Observation Tool (CPOT)|The CPOT includes 4 behaviors: (1) facial expression, (2) body movements, (3) compliance with the ventilator, and (4) muscle tension. Each behavior is rated from 0 to 2 for a possible total score ranging from 0 to 8.
41325416|NCT03556748|OTHER|whole-body electromyostimulation|WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
41325417|NCT01654042|OTHER|Prolonged interval between PT testing|Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
41325418|NCT02881983|OTHER|the presentation of pictures (static stimuli) or videos (dynamic stimuli)|
41479150|NCT00407758|DRUG|enzastaurin hydrochloride|
40807915|NCT03967977|DRUG|Cisplatin|70 mg/m2 administered IV as specified in the treatment arm
40807916|NCT03967977|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 administered IV as specified in the treatment arm
41325419|NCT06447571|OTHER|Trunk Rehabilitation|Activating and strengthening the trunk muscles.
41325420|NCT06447571|OTHER|Core Stability|Standard core stability fucus on lower trunk.
41325421|NCT02828007|DEVICE|NIV Group|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
41325422|NCT03650764|DRUG|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
41325423|NCT03650764|DRUG|Pembrolizumab|Pembrolizumab is commercially available
41479151|NCT03458247|DRUG|Abiraterone acetate standard dose|1000 mg/day
40807917|NCT03967977|DRUG|Carboplatin|Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
40807918|NCT06524414|BIOLOGICAL|PG4|Multivalent pneumococcal conjugate vaccine
40807919|NCT06524414|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine
41479152|NCT03458247|DRUG|Abiraterone acetate escalated dose|2000 mg/day
41479153|NCT04399642|PROCEDURE|Arthroplasty|All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision
41479154|NCT04684524|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
40807920|NCT05852938|DRUG|BION-1301|BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.
40807921|NCT05852938|DRUG|Placebo|Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
40807922|NCT06379893|DRUG|Voltaren Gel 1% (diclofenac sodium) (US only)|Participants in the US will use Volatren Gel containing 1% diclofenac sodium.
40807923|NCT06379893|DRUG|Voltaren Gel 1.16% (diclofenac diethylammonium) (EU only)|Participants in the EU will use Volatren Gel containing 1.16% diclofenac diethylammonium.
40807924|NCT06379893|DRUG|Voltaren Gel 2.32% (diclofenac diethylammonium) (EU only)|Participants in the EU will use Volatren Gel containing 2.32% diclofenac diethylammonium.
40807925|NCT01989585|PROCEDURE|Biopsy|Undergo biopsy
40807926|NCT01989585|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41325424|NCT03650764|OTHER|EORTC QLQ-30|-Screening, start of cycle 2, start of cycle 5
41479155|NCT04684524|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
41479156|NCT02854059|BIOLOGICAL|IdeS (0.25 mg/kg)|Single i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of efficacy and safety in the first 3 patients the dose may be increased in the following 3 patients to 0.5 mg/kg.
41479157|NCT02854059|BIOLOGICAL|IdeS (0.50 mg/kg)|Single i.v. infusion of IdeS (0.50 mg/kg).
41479158|NCT05127694|OTHER|Vestibular Rehabilitation|Vestibular Rehabilitation which is consist of repetitive exercises and canalit repositioning maneuvers
41479159|NCT02728011|OTHER|Scientific Brain Training (SBT)|Cognitive training
41479160|NCT02728011|OTHER|Tetris|
41479161|NCT06161142|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(2-4 weeks after the 1st measurement)
41325425|NCT03650764|OTHER|FACT H&N|-Screening, start of cycle 2, start of cycle 5
41325426|NCT03650764|PROCEDURE|Peripheral blood|-Baseline
41479162|NCT06161142|DIAGNOSTIC_TEST|Extended laboratory diagnostics|Laboratory testing investigating features that support the diagnosis of hypophosphatasia or exclude it by indicating secondary hypophosphatasemia for other reasons (including parameters such as serum calcium, inorganic serum phosphate, vitamin B6, vitamin B12, folic acid, bone-specific alkaline phosphatase, vitamin D3, and more).
40807927|NCT01989585|PROCEDURE|Computed Tomography|Undergo CT
40807928|NCT01989585|DRUG|Dabrafenib|Given PO
40807929|NCT01989585|PROCEDURE|Echocardiography|Undergo echocardiography
40807930|NCT01989585|OTHER|Laboratory Biomarker Analysis|Correlative studies
41009313|NCT02193594|DRUG|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA\>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
41325427|NCT05825599|DEVICE|Hydroxypropyl methylcellulose eye drops|Hydroxypropyl methylcellulose (HPMC)-based eyedrops
41325428|NCT04753047|OTHER|No intervention|No intervention
41325429|NCT01022385|DIETARY_SUPPLEMENT|24-hour low-residual diet|
41479163|NCT06161142|DIAGNOSTIC_TEST|Symptom and clinical findings checklist for hypophosphatasia|Checklist including numerous symptoms and clinical findings regarding the musculoskeletal system and non-musculoskeletal body parts
41479164|NCT06161142|DIAGNOSTIC_TEST|SF-36|Quality of life questionnaire
40807931|NCT01989585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40807932|NCT01989585|PROCEDURE|Multigated Acquisition Scan|Undergo multigated acquisition scan
40807933|NCT01989585|BIOLOGICAL|Navitoclax|Given PO
40807934|NCT01989585|OTHER|Pharmacological Study|Correlative studies
40807935|NCT01989585|DRUG|Trametinib|Given PO
41153912|NCT06465615|PROCEDURE|Conventional orthoptic rehabilitation|Conventional orthoptic rehabilitation consisting of 12 x 25-minute sessions twice a week over 6 weeks, carried out with an orthoptist from Montpellier University Hospital, combined with reinforcement exercises to be carried out at home for 15 minutes a day under parental supervision, 5 days a week (125-minute weekly load). This is the standard orthoptic treatment offered in France to patients with symptomatic convergence insufficiency, according to orthoptic procedures (10-15 sessions of the order of 20-25 minutes and 10-15 minutes of daily reinforcement exercises at home).
41153913|NCT01690286|DRUG|JNJ-38518168 3 mg|One oral daily dose of JNJ-38518168 3 mg for 25 days.
41153914|NCT01690286|DRUG|JNJ-38518168 30 mg|One oral daily dose of JNJ-38518168 30 mg for 25 days.
41153915|NCT01690286|DRUG|JNJ-38518168 10 mg|One oral daily dose of JNJ-38518168 10 mg for 25 days.
41153916|NCT01690286|DRUG|Ketoconazole 200 mg|Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
41153917|NCT05812547|DEVICE|Lumen|subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.
41325430|NCT03323996|OTHER|Semi-Structured interviews|individual semi-structured interviews
41325431|NCT02584413|DEVICE|Magnetic resonance imaging|-Standard of care
41325432|NCT02584413|DRUG|Gadolinium contrast|-Standard of care
41479165|NCT06161142|DIAGNOSTIC_TEST|Short physical performance battery (SPPB) score|The short physical performance battery is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older or disease-affected people. The scores range from 0 (worst performance) to 12 (best performance). The SPPB has been shown to have predictive validity showing a gradient of risk for mortality, nursing home admission, and disability.
41479166|NCT06161142|DIAGNOSTIC_TEST|Physical examination|A full rheumatological examination will be performed.
41479167|NCT06161142|DIAGNOSTIC_TEST|Recording of vital signs|(including body temperature, blood pressure, heart rate)
41479168|NCT06161142|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|A body composition measurement by BIA (Bioelectrical Impedance Analysis \[proportional mass of muscle, water and fat in kg\]) will be performed.
41479169|NCT06161142|DIAGNOSTIC_TEST|Genetic testing of the alkaline phosphatase gene|Investigation of mutations regarding the alkaline phosphatase gene
41479170|NCT00750048|DRUG|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
41479171|NCT01659164|BEHAVIORAL|Group treatment for adults with ADHD|14 weeks of group treatment for adults with ADHD
41479172|NCT00402025|BIOLOGICAL|Talimogene Laherparepvec|Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
41479173|NCT03360175|OTHER|No intervention - observational study|No intervention - observational study
41479174|NCT01264549|DEVICE|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
40807945|NCT05022849|DRUG|JNJ-75229414|JNJ-75229414 infusion will be administered intravenously.
40807946|NCT05022849|DRUG|Bridging Therapy|Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.
41479175|NCT06233578|DEVICE|RADPAD|The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
41325433|NCT06293677|DRUG|Dosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem|"Meropenem dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR 120-149 : 40 mg/kg q6 h eGFR 150-199 : 30 mg/kg q4h eGFR 200-299 : 40 mg/kg q4h eGFR \&amp;gt;/= 300 : 40 mg/kg q4h~Piperacillin-tazobatam dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR 120-149 : 150 mg/kg q6 h eGFR 150-199 : 120 mg/kg q4h eGFR 200-299 : 150 mg/kg q4h eGFR \&amp;gt;/= 300 : 180 mg/kg q4h~The maximum doses for the antibiotic prescription before the first drug monitoring will be 2gr of MER every 4 hours and 4gr of PIP every 4 hours.~The duration of infusion will be set to 2 h."
41325434|NCT06293677|DRUG|Standard dosages of piperacillin-tazobactam or meropenem|"Meropenem dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR\> 50 : 40mg/kg q8h eGFR 25-49 : 40mg/kg q12h eGFR 15-24 : 20mg/kg q12h~Piperacillin-tazobactam :~eGFR \>50 : 100mg/kg q6h eGFR 20-49 : 50mg/kg q6h eGFR 15-29 : 50 mg/kg q8h"
40807947|NCT05053152|DRUG|Placebo Administration|Given PO
40807948|NCT05053152|OTHER|Quality-of-Life Assessment|Ancillary studies
40807949|NCT05053152|DRUG|Relugolix|Given PO
40807950|NCT05053152|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
40807951|NCT04223765|DRUG|CAR.k.28|Three dose levels will be evaluated: Dose level 1 (5x10\^5 cells/kg), Dose level 2 (1x10\^6), and dose level 3 (2x10\^6 cells/kg).
40807952|NCT04223765|DRUG|Fludarabine|30 mg/m\^2/day IV for 3 consecutive days
40807953|NCT04223765|DRUG|Cyclophosphamide|500 mg/m\^2/day IV for 3 consecutive days
40807954|NCT04223765|DRUG|Bendamustine|70 mg/m\^2/day administered over 3 consecutive days.
40807955|NCT04799171|OTHER|Isometric Contraction Exercise - Young Adults (Age group 18-39)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
40807956|NCT04799171|OTHER|Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
40807957|NCT04799171|OTHER|Isometric Contraction Exercise - Old Adults (Age group >60)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
41325435|NCT01233700|BEHAVIORAL|Motivational Interviewing|Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.
41325436|NCT01233700|BEHAVIORAL|Healthy Lifestyles Education|Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
40807958|NCT03305588|DEVICE|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
40807959|NCT06126575|DRUG|Elacestrant dihydrochloride|A single oral dose of 200 mg elacestrant (2 x 100 mg tablets).
41153918|NCT05812547|OTHER|Glucose monitoring mobile app|The control group will use a designated glucose monitoring mobile app to record their glucose levels
41153919|NCT05110651|DRUG|Hydroxychloroquine|Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels \> 2000ng/ml
41153920|NCT04559516|BEHAVIORAL|Exercise Intervention|"The Ethica mobile app will provide a daily alert accompanied by a short educational statement about PAH, disease self-management tips, dietary and nutritional advice, goal setting, and a motivational statement to encourage patients.~Participation with each session will be assessed by a mobile app-embedded survey administered at the end of the day. Patients will be presented with weekly alerts to complete validated patient-reported quality of life questionnaires using the EmPHasis-10 and the Living with Pulmonary Hypertension Questionnaire, as well as the PRAISE self-efficacy score for pulmonary rehabilitation. The app will also ask patients to report their WHO/NYHA functional class every week. Using in-app buttons, participants can log adverse events associated with each exercise session."
41153921|NCT04559516|BEHAVIORAL|Standard Care|Participants will be provided usual care administered at the PH clinic at the University of Calgary and no supervised exercise session will be performed.
41325437|NCT03024840|DRUG|Sevoflurane|Sevoflurane: 1%\~2%
41325438|NCT03024840|DRUG|Propofol|Propofol: 9-15 mg/kg/h
41479176|NCT05319834|DRUG|Aspirin tablet|group1: oral aspirin at a dose of 100mg once daily at the same time with progesterone
41153922|NCT03274206|BIOLOGICAL|BLS-ILB-E710c|BLS-ILB-E710c 250mg/capsule
41153923|NCT03274206|DRUG|Placebo|BLS-ILB-E710c-placebo
41479177|NCT05319834|DRUG|Placebo|group 2: oral placebo once daily at the same time with progesterone
41153924|NCT00183222|DRUG|naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days|
41153925|NCT06301529|DRUG|Invokana Pill|100 mg and 150 mg doses, taken every day and every-other day, respectively.
41325439|NCT04571918|PROCEDURE|Biodegradable spacer|Implantation of a biodegradable balloon used as a subacromial spacer.
40807967|NCT06308198|DRUG|AGN-151586|Intramuscular Injections
41479178|NCT05557903|BIOLOGICAL|Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection|Single dosing: DLT observation for 7 days after administration; Multiple dosing: 3times/weeks,12 times, 28 days of DLT observation
40807968|NCT06308198|DRUG|Placebo|Intramuscular Injections
40807969|NCT06419959|DEVICE|NightWare|Nightware intervention app (enabled) will attempt to detect when an individual is having a nightmare based on a Nightware proprietary algorithm and attempt to disrupt the nightmare without awakening. In the sham comparator group the NightWare app will be disabled and not deliver an intervention.
41153926|NCT05989243|DEVICE|Conventional prosthetic socket|Participants will use their own conventional rigid socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for \~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
41153927|NCT05989243|DEVICE|Adjustable Quatro socket|Participants will use an adjustable Quatro socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for \~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
41325440|NCT04571918|PROCEDURE|Debridement and biceps tenotomy|Surgery with arthroscopic debridement and biceps tenotomy
41325441|NCT04193670|OTHER|Clinical examination|This is a classic dermatological clinical examination during a classic consultation
41325442|NCT04193670|PROCEDURE|Biopsies|"2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group.~The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory.~The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq.~The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample."
41479179|NCT03815968|OTHER|low sodium diet|included in the diet mostly low sodium food. avoid tinned or smoked, food. avoid adding salt to the food.
41479180|NCT01739296|OTHER|Neutral insole with subtalar strapping (sham)|Neutral insole with subtalar strapping (sham)
40807978|NCT04629547|DRUG|Suvorexant 20 mg|Suvorexant 20mg will be taken nightly for 24 months.
40807979|NCT04629547|DRUG|Placebo|Placebo will be taken nightly for 24 months.
40807980|NCT06548165|DEVICE|Wearable|Participants will wear an electrode on the chest for the measurement of the heart rate variability, a sensor for temperature measurement, and a sensor for continuous blood glucose measurement. Food intake will be recorded via pictures. One mixed meal tolerance test will be performed as a reference for further analyses. Females have the option to use a device for intravaginal temperature measurement.
40807981|NCT05844098|DEVICE|K-wire|K-wire No. 2.0 insertion was done additionally from arthroscopic assisted CC-stabilization by inserting K-wire from acromion process to distal clavicle.
40807982|NCT03793166|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40807983|NCT03793166|DRUG|Cabozantinib|Given PO
40807984|NCT03793166|PROCEDURE|Computed Tomography|Undergo CT scan
40807985|NCT03793166|BIOLOGICAL|Ipilimumab|Given IV
40807986|NCT03793166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40807987|NCT03793166|BIOLOGICAL|Nivolumab|Given IV
40807988|NCT03793166|OTHER|Quality-of-Life Assessment|Ancillary studies
40807989|NCT03793166|OTHER|Questionnaire Administration|Ancillary studies
40807990|NCT02543983|DEVICE|Magnetic Resonance Imaging scanner, 3T|Non-significant risk device used for brain imaging.
40807991|NCT02543983|DEVICE|NeurOptics PLRTM-3000 Pupillometer|The NeurOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
40807992|NCT02543983|DEVICE|Experimental Anxiety Devices|Acoustic startle and shock devices are used to evaluate anxious responses to stimuli. Both are considered non-significant risk under this study.
40807993|NCT02543983|DEVICE|Magnetic Resonance Imaging scanner, 7T|Non-significant risk device used for brain imaging.
40807994|NCT02543983|DRUG|Ketamine Hydrochloride|A non-competitive N-methyl-D-aspartate receptor antagonist. This drug is exempt from FDA IND review under the study.
40807995|NCT00588770|BIOLOGICAL|Bevacizumab|Given IV
40807996|NCT00588770|DRUG|Carboplatin|Given IV
40807997|NCT00588770|DRUG|Cisplatin|Given IV
40807998|NCT00588770|DRUG|Docetaxel|Given IV
40807999|NCT00588770|DRUG|Fluorouracil|Given IV
40808000|NCT00588770|OTHER|Laboratory Biomarker Analysis|Correlative studies
40808001|NCT04918290|DEVICE|Tegaderm Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
40808002|NCT04918290|DEVICE|Transpore Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
40808003|NCT05067283|DRUG|MK-1084|Oral dose
40808004|NCT05067283|BIOLOGICAL|Pembrolizumab|Intravenous infusion of 200 mg
40808005|NCT05067283|DRUG|carboplatin|Per label
40808006|NCT05067283|DRUG|pemetrexed|Per label
40808007|NCT05067283|BIOLOGICAL|cetuximab|Per label
40808008|NCT05067283|DRUG|oxaliplatin|Per label
40808009|NCT05067283|DRUG|leucovorin|Per label
40808010|NCT05067283|DRUG|5-fluorouracil|Per label
40808011|NCT00324805|BIOLOGICAL|Bevacizumab|Given IV
40808012|NCT00324805|DRUG|Cisplatin|Given IV
40808013|NCT00324805|DRUG|Docetaxel|Given IV
40808014|NCT00324805|DRUG|Gemcitabine Hydrochloride|Given IV
40808015|NCT00324805|OTHER|Laboratory Biomarker Analysis|Correlative studies
40808016|NCT00324805|DRUG|Pemetrexed Disodium|Given IV
40808017|NCT00324805|OTHER|Questionnaire Administration|Ancillary studies
40808018|NCT00324805|DRUG|Vinorelbine Tartrate|Given IV
41009314|NCT04643106|PROCEDURE|Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)
41009315|NCT04643106|PROCEDURE|suturing with barbed sutures during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding
41479181|NCT01739296|OTHER|Lateral wedge insole with subtalar strapping|Lateral wedge insole with subtalar strapping
41479182|NCT02988479|OTHER|Out of pocket payments in patients|
41153928|NCT01523028|OTHER|Soluble Coffee|"Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~* 200 mL coffee or~* 200 mL coffee + 2 bread rolls + honey~* 200 mL coffee + 1 bread roll + peanut butter"
41153929|NCT02990299|BEHAVIORAL|mHealth for Diabetes Adherence Support|Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
40808021|NCT05614739|DRUG|LOXO-435|Oral
40808022|NCT05614739|DRUG|Pembrolizumab|IV
40808023|NCT04216290|PROCEDURE|Biopsy of Bladder|Undergo bladder biopsy
40808024|NCT04216290|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample collection
40808025|NCT04216290|DRUG|Cisplatin|Given IV
40808026|NCT04216290|PROCEDURE|Computed Tomography|Undergo CT
40808027|NCT04216290|PROCEDURE|Cystoscopy|Undergo cystoscopy
40808028|NCT04216290|BIOLOGICAL|Durvalumab|Given IV
40808029|NCT04216290|DRUG|Fluorouracil|Given IV
40808030|NCT04216290|DRUG|Gemcitabine Hydrochloride|Given IV
40808031|NCT04216290|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41153930|NCT02409732|DRUG|aminolevulinic acid hydrochloride|
41153931|NCT02409732|PROCEDURE|Photodynamic therapy with blue light|
41479183|NCT04163978|DRUG|Nitric Oxide|in situ 240mL nitric oxide releasing sinus irrigation solution
41479184|NCT04163978|DRUG|Budesonide|Saline based sinus irrigation 1mg Budesinide solution
41479185|NCT03307564|DEVICE|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments.
41479186|NCT02689999|DRUG|Dexrabeprazole 10 mg Enteric-Coated Tablets|
41479187|NCT04440449|BEHAVIORAL|Lifestyle App|A mobile app used to assist with lifestyle changes
41479188|NCT04440449|BEHAVIORAL|Look AHEAD behavior lifestyle intervention|A modified Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
41479189|NCT04440449|BEHAVIORAL|Abbreviated Look AHEAD behavior lifestyle intervention|An abbreviated Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
41479190|NCT04417582|PROCEDURE|bariatric surgey|patients undergone bariatric surgery or prescribed antiobesity drugs
40808032|NCT04216290|DRUG|Mitomycin|Given IV
40808033|NCT04216290|OTHER|Patient Observation|Undergo observation
41153932|NCT03559452|PROCEDURE|Eccentric exercise|300 eccentric contractions of the knee extensors
41153933|NCT01563445|DRUG|activated recombinant human factor VII|Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
41479191|NCT01787279|DRUG|Peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
41479192|NCT01557842|DRUG|Drug Treatment|Class I and III antiarrhythmic drug treatment.
41479193|NCT01557842|DEVICE|Catheter Ablation|Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
40808034|NCT04216290|RADIATION|Radiation Therapy|Undergo radiation therapy
40808035|NCT00569127|BIOLOGICAL|Bevacizumab|Given IV
40808036|NCT00569127|OTHER|Laboratory Biomarker Analysis|Correlative studies
40808037|NCT00569127|DRUG|Octreotide Acetate|Given IM
40808038|NCT00569127|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given SC
41153934|NCT01563445|DRUG|placebo|Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
41153935|NCT01693159|DEVICE|ECA|In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).
41479194|NCT01720420|DEVICE|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
41479195|NCT02560441|OTHER|chemotherapy followed by radiotherapy|
41479196|NCT02560441|OTHER|radiotherapy followed by chemotherapy|
41479197|NCT02560441|DRUG|IPGDP regimen chemotherapy|
41479198|NCT03643679|OTHER|Kwit smartphone app|The Kwit smartphone app combines several popular features of tobacco cessation apps, including game-like features (e.g., unlocking achievement milestones for completing cessation-related tasks), useful statistics (e.g., money saved), and an ability to share progress with friends. Users can actively engage with the app to track cravings or view progress, such as life expectancy gained. A passive component notifies users when milestones have been achieved, e.g., when blood no longer contains nicotine. Motivational messages can be actively requested at any time; they can also appear unsolicited, as when the user logs cravings.
40808047|NCT04887584|OTHER|Control diet|The control Typical American Diet (TAD) diet pattern will mimic the level of intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium in the general U.S. population. This diet will feature no servings of pulses per day.
40808048|NCT04887584|OTHER|Low Pulse diet|The Low Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 0.2 cups of pulses per day at 2,000 kilocalories (kcals).
41009316|NCT03271736|BEHAVIORAL|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
41325443|NCT04193670|OTHER|Blood test|A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
41325444|NCT00453180|DRUG|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
41325445|NCT00453180|DRUG|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
41325446|NCT02169804|DRUG|Androxal 25 mg|
41325447|NCT00870974|DRUG|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]F-PEB
41479199|NCT03362996|DIETARY_SUPPLEMENT|Freshly-Pressed Extra Virgin Olive Oil|Dietary Supplement: Freshly-pressed extra virgin olive oil Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
41479200|NCT03362996|COMBINATION_PRODUCT|extra virgin olive oil|Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
41479201|NCT03362996|OTHER|mediterranean diet|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
41479202|NCT03064087|DEVICE|Colli-Pee|First, two first-void urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium) at home, the day before a visit to the colposcopy centre at a gynecology clinic.
41479203|NCT03064087|DEVICE|Multi-Collect Swab|At the colposcopy clinic, one vaginal self-sample will be collected with the Multi-Collect Swab (Abbott GmbH \& Co. KG, Wiesbaden, Germany).
41479204|NCT03064087|DEVICE|Evalyn Brush|Another vaginal self-sample will be collected also at the colposcopy centre either with the Evalyn Brush (Rovers Medical Devices B.V., Oss, Netherlands)
40808049|NCT04887584|OTHER|High Pulse diet|The High Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 1.5 cups of pulses per day at 2,000 kilocalories (kcals).
41153936|NCT01693159|OTHER|Standard topical treatment of the institution, e.g. Lotio|Standard treatment of the institution to treat painful cetuximab-induced rhagades
41153937|NCT01012999|DRUG|sufentanil|Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
41479205|NCT03064087|DEVICE|Qvintip|or with Qvintip (Aprovix AB, Uppsala, Sweden).
41153938|NCT01828476|DRUG|Abiraterone|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
41153939|NCT01828476|DRUG|ABT-263|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
41153940|NCT01828476|DRUG|Hydroxychloroquine|ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
41325448|NCT01382199|DRUG|Lactoferrin|
41479206|NCT03064087|DIAGNOSTIC_TEST|Abbott RealTime High Risk HPV|The hrHPV assay used, will be the Abbott PCR (Abbott GmbH \& Co. KG, Wiesbaden, Germany), which detects separately DNA of HPV16 and HPV18, as well as the pool of twelve other hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The accuracy of this PCR assay for the detection of CIN2+ will be determined on all samples: on the first urine sample and on the vaginal and cervical samples. Furthermore, it is possible that in the future other assays will be validated.
41479207|NCT00480623|DRUG|Satraplatin plus radiation therapy|
41325449|NCT03696940|DRUG|L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg|Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.
41325450|NCT03696940|DRUG|Atorvastatin 10mg|Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
41325451|NCT06375252|OTHER|Central Jugular Vein Catheter Lumen Holder Apparatus|Participants will experience the central jugular vein catheter lumen holder apparatus, perform walking, sitting, supine, right and left side lying activities and fill out the evaluation forms prepared by the researcher. They will then experience the same activities without the apparatus.
41479208|NCT02623049|OTHER|New oral anticoagulant pharmacodynamic analysis (blood level assesment)|
41479209|NCT01253395|BEHAVIORAL|Strength training|Daily supervised strength training.
41479210|NCT01253395|BEHAVIORAL|Aerobic exercise|Daily supervised aerobic exercise.
41479211|NCT05179694|DIAGNOSTIC_TEST|Prostate biopsy|Prostate biopsy via either the Transrectal route (comparator) or Transperineal route (experimental), each under local anaesthetic.
41479212|NCT02035020|DRUG|gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
41479213|NCT01923584|DRUG|EPI-743 400mg|
41325452|NCT05603754|DRUG|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 mL vehicle
41325453|NCT05603754|DRUG|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
41009317|NCT03271736|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
41009318|NCT05177198|PROCEDURE|M-MIST + Clindamycin augmented PRF|modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
41479214|NCT01923584|DRUG|EPI-743 200mg|
41479215|NCT02197026|DRUG|Hylan G-F 20|
41479216|NCT02197026|DRUG|Standard treatment|Standard drug treatment at the discretion of the investigator
41479217|NCT02197026|PROCEDURE|Physiotherapy|
41479218|NCT02197026|PROCEDURE|Hydrotherapy|
41009319|NCT05177198|PROCEDURE|M-MIST + PRF|modified minimally invasive surgical technique with platelet-rich fibrin alone.
41479219|NCT04698772|DRUG|Ketamine|Blinded study group will receive ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)
41479220|NCT04698772|DRUG|Morphine|Blinded study group will receive morphine 4 mg IV push over 3-5 minutes for pain control
41479221|NCT06121284|DRUG|D-Cycloserine|Participants will orally ingest a capsule containing a weight-based dose (25mg/17.5kg) of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.
41325454|NCT01670175|DRUG|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
41157184|NCT05156216|OTHER|Patient education|Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.
41479222|NCT06121284|DEVICE|intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).
41479223|NCT06121284|DRUG|Placebo oral tablet|Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
41479224|NCT01978652|BIOLOGICAL|Peginterferon Beta-1a|As specified in the treatment arm
41479225|NCT06490770|DIAGNOSTIC_TEST|Gait analysis, Magnetic Resonance Imaging|Gait analysis and Magnetic Resonance Imaging to investigate the functionality and the pathological condition of the knee, respectively
41479226|NCT03978312|OTHER|Nominal consensus group|NLit-UK linguistic and cultural adaptation (NLit-UK) 2 x nominal consensus groups evidence review and topic expert engagement
41479227|NCT03978312|OTHER|Observational cohort (validity and reliability testing)|Nutrition Literacy Measurement Tool validation (NLit-UK). Target sample 366 on treatment cancer patients confirmatory binary analysis for validity and reliability.
41479228|NCT01200940|OTHER|Sucralose|sucralose will be given at doses of 68 mg (equivalent to one 12 oz soda) 170 mg (equivalent to two and one-half 12 oz sodas, and 250 mg (equal to 100% of the FDA s acceptable daily intake for a 50kg individual).
41479229|NCT01200940|OTHER|Aspartame|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
41479230|NCT01200940|OTHER|Acesulfame-Potassium|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
41479231|NCT01200940|OTHER|Control|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
41479232|NCT03233451|BEHAVIORAL|Psycho-behavioral intervention|The psycho-behavioral intervention included 12-week weekly guided psychological intervention (8 modules of behavioral intervention) and 24-week monthly maintenance psychological support.
41479233|NCT01675024|DRUG|Rotigotine, Period 1|"Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
41479234|NCT01675024|DRUG|Rotigotine, Period 2|"Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
41479235|NCT06264479|PROCEDURE|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
41479236|NCT04633642|PROCEDURE|Ultrasound group|Every week during a six-week treatment period
41479237|NCT04633642|PROCEDURE|Surgical group|Every week during a six-week treatment period
41479238|NCT01733147|DRUG|Omega-3 polyunsaturated fatty acids|3 capsules a day of Omega 3 polyunsaturated fatty acids taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
41479239|NCT01733147|DRUG|Placebo|3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
41479240|NCT00701974|BIOLOGICAL|collagenase (IRUXOL)|patients will be treated with collagenase one time per day.
41479241|NCT00701974|BIOLOGICAL|collagenase (Kollagenase)|patients will be treated with collagenase one time per day.
41479242|NCT04049916|DRUG|Pyronaridine Tetraphosphate/Artesunate|Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
41479243|NCT04049916|DRUG|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
41479244|NCT04049916|DRUG|Primaquine Diphosphate|Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
41479245|NCT01387763|DRUG|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
41479246|NCT01387763|DRUG|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
41479247|NCT01387763|DRUG|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
41479248|NCT01387763|DRUG|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
41479249|NCT01387763|DRUG|Hydrea|Capsule Hydrea 500-2000 mg orally QD or BID
41479250|NCT02021253|DIETARY_SUPPLEMENT|Probiotic|Lactibiane TOLERANCE vs Placebo
41479251|NCT02021253|DIETARY_SUPPLEMENT|Placebo|
41479252|NCT02059330|DRUG|Palbociclib 75mg|In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
41479253|NCT02059330|DRUG|Palbociclib 125mg|In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
41479254|NCT02059330|DRUG|Palbociclib 100mg|In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
41325455|NCT03555240|OTHER|Biobank creation and Pharmacogenetic analysis|Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
41325456|NCT00934011|OTHER|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
41325457|NCT00934011|OTHER|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
41325458|NCT05982639|PROCEDURE|two lung ventilation|The intervention do not involve a drug or device. It will be compared two different approaches to ventilate the lungs during the procedure . In this arm both lungs will be ventilated inserting a disposable trocar into the pleural cavity, and insufflating CO2 into the thoracic cavity via an insufflator. The insufflation pressure and the flow rate will be set as 8 mmHg and 10 l.min-1, of the cavity with CO2. The insufflator will be adjusted for cavity pressure in 8mmHg and flow of 10L/min.
41479255|NCT02059330|DRUG|Palbociclib|In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
41479256|NCT02059330|DRUG|Palbociclib 125mg|In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
41479257|NCT05849012|OTHER|Low Sulfur Diet|"Subjects will be placed on a low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
41479258|NCT05849012|OTHER|Usual Diet|"Subjects will continue on their usual diet for 8 weeks. At the end of 8 weeks, if participants are interested, they will be offered treatment with low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
41479259|NCT01199120|DIETARY_SUPPLEMENT|Omega 3|measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
41479260|NCT01917968|DEVICE|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
41479261|NCT01917968|PROCEDURE|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
41479262|NCT04628936|DRUG|KZR-616|Subcutaneous 30 mg for 1 week, then 45 mg weekly
41479263|NCT04882982|BEHAVIORAL|Caria app|App to improve symptoms of menopause
41479264|NCT04882982|BEHAVIORAL|Menopause Education|Educational materials about symptoms of menopause
41479265|NCT06317948|OTHER|treatment plan comparison|In order to assess inter-Institute variability of DVH prediction of the various models, for the different situations and the different OARs, DVH and dose statistics (min, mean, median, max and SD of the dose received by each OAR) predicted on the patients owning to the different centers by the different models will be compared
41153941|NCT03456206|OTHER|Intake of red and processed meat and fibres|The intention is to analyse exposure groups in tertiles: 1) Upper tertile (33.3% of the total sample) based on the ratio: meat/fibre intake is associated with higher risk of CID. 2) Low intake of fibre (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of red and processed meat (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with higher risk of CID, and their synergy (interaction between the factors meat and fibres) gives the highest risk outcome.
41153942|NCT03456206|OTHER|Lifestyle factors independently or combined|Lifestyles factors are defined as: red and processed meat, vegetables, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/fat, protein/fat from red and processed meat, glycemic index.
41479266|NCT05920564|OTHER|Upper fibers of trapezius stretching|The Upper fibers of trapezius stretching intervention involves specific stretching exercises designed to target the upper fibers of the trapezius muscle. The stretching exercises will be performed under the guidance of a licensed physical therapist and will involve extending the neck while gently pulling the head downward to stretch the upper fibers of the trapezius muscle. The intervention is designed to improve neck range of motion, reduce pain intensity, and reduce disability in patients with cervical spondylosis. The duration and frequency of the stretching exercises will be standardized across participants, and adherence will be monitored throughout the study period.
41153943|NCT00307671|DRUG|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
41153944|NCT00307671|DRUG|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
41325459|NCT05982639|PROCEDURE|one lung ventilation|In this arm only one lung (the contralateral lung) will be ventilated using a Carlens type orotracheal tube
41325460|NCT01608282|BEHAVIORAL|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
41325461|NCT06035549|BEHAVIORAL|Culturally Tailored Digital Resilience-Building|The Culturally Tailored Digital Resilience-Building intervention consists of 6 modules, including an introduction of advance care planning and resilience skills that specifically address cultural beliefs and barriers.
41153945|NCT00307671|DRUG|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
41153946|NCT04523571|BIOLOGICAL|BNT162b1|Intramuscular injection
41153947|NCT04523571|OTHER|Placebo|Intramuscular injection
41009320|NCT03762603|DEVICE|Robotic exoskeleton device|It is a non invasive and non significant risk medical device which wraps around operated knee to support motion.
41009321|NCT05941026|OTHER|Structured education|"The educational content of the research was created by the researcher in line with the literature and expert opinions and covers the following topics.~Educational subjects~1. Culture and Concepts Related to Culture~2. Culture/Cultural Characteristics and Cultural Elements in Terms of Social Structure~3. Cultural Factors Affecting Health and Disease~4. Concepts and Practices Related to the Field of Study~The training is an online training and continued via video conference, and a session invitation was sent to the participants before each session. In addition, after the training, brochures containing the training topics of each week were prepared and delivered to the participants. The trainings were conducted by the researcher in a total of four sessions (each session 20 minutes) once a week during the training process. During the training, the questions of the participants were answered."
41325462|NCT03364634|DIAGNOSTIC_TEST|Intracranial pressure monitoring|Weekly ICP monitoring sessions beginning at discharge from the neuro-intensive care unit and carried out until 1 month after cranioplasty.
41325463|NCT05611515|PROCEDURE|TORS|"* Arm 1: Intensity-Modulated Radiation Therapy (IMRT)~* Arm 2: Trans-oral Laser Microsurgery (TLM)~* Arm 3: Trans-oral Robotic Surgery (TORS)"
41009322|NCT03865290|DRUG|Ondansetron 8mg|Oral Ondansetron 8 mg
41325464|NCT03768141|PROCEDURE|Liver surgery|"All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)"
41325465|NCT02890043|PROCEDURE|robot-assisted spine surgery|robot-assisted spine surgery using Tirobot system
41325466|NCT02890043|PROCEDURE|free-hand surgery|traditional free-hand surgery
41325467|NCT02890043|DEVICE|TiRobot system|a robot-assisted spine surgery system
41325468|NCT03617029|DEVICE|Microcoil|Needle localization with microcoil
41479267|NCT05920564|OTHER|Standard care|The Control Group in this study will receive standard care, including heat treatment and strengthening exercises, but will not receive the specific Upper fibers of trapezius stretching intervention that is being tested in the Treatment Group.
41479268|NCT04554706|BEHAVIORAL|Mobile-phone delivered Treatment for Excessive Rumination|This is a one-month three-arm clinical control trial to reduce the rumination and interpersonal impairment link.
41479269|NCT05021913|DEVICE|DKL crosslinked sodium hyaluronate 23|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 23 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
41479270|NCT05021913|DEVICE|Juvéderm Volift™ with lidocaine (Allergan, Inc)|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Volift™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
41479271|NCT05883033|DEVICE|VAC|Vacuum Assisted Closure device
41009323|NCT03865290|DRUG|Placebo|Oral matched placebo
41009324|NCT02420496|DRUG|Enteral fish oil|
41325469|NCT03617029|DRUG|Lipiodol|Needle localization with contrast injection
41325470|NCT02651792|DRUG|ketamine- propofol|1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
41009325|NCT02420496|DRUG|Ursodeoxycholic Acid|
41009326|NCT02420496|DRUG|Placebo|
41009327|NCT00218062|DRUG|D-Amphetamine 30mg|
41009328|NCT00218062|DRUG|D-Amphetamine 60mg|
41009329|NCT00218062|DRUG|Modafinil 200mg|
41009330|NCT00218062|DRUG|Modafinil 400mg|
41009331|NCT00218062|BEHAVIORAL|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
41009332|NCT00218062|DRUG|Placebo|
41325471|NCT02651792|DRUG|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
41325472|NCT00141856|BEHAVIORAL|Telephone care|
41325473|NCT03728140|PROCEDURE|Self-spent Culture Medium|Replace embryo transfer solution with Self-spent culture medium in IVF-ET.
41325474|NCT04424199|BEHAVIORAL|Rightward Attentional Shift (R-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward attentional shift.
41325475|NCT04424199|BEHAVIORAL|Leftward Attentional Shift (L-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a leftward attentional shift.
41325476|NCT04203563|BEHAVIORAL|Strong People Strength Training|A community-based progressive strength training program
41325477|NCT02678312|DRUG|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
41325478|NCT02678312|DRUG|Enalapril|Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
41325479|NCT02678312|DRUG|Placebo of LCZ696|
41009333|NCT06019858|OTHER|Vitamin Energy Shot|"Vitamin Energy® shot is a naturally-caffeinated functional energy shot that contains:~Vitamin B3 Vitamin B6 Vitamin B12 Natural Caffeine (green tea extract) L-Carnitine Tartrate Potassium Sorbate Taurine Sucralose"
41009334|NCT04631497|DIAGNOSTIC_TEST|test|"1. Beck's Test~2. Test STAI~3. Test PSS~4. the scale of the fascination with death~5. COPE"
41009335|NCT01650181|DRUG|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
41009336|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
41009337|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
41009338|NCT01650181|DRUG|Metformin|Patients with fatty liver treated with diet, exercise and metformin
41009339|NCT06027749|DEVICE|Epitel's™ Remote EEG Monitoring System's (REMI™)|Ambulatory electroencephalography (EEG) monitoring
41009340|NCT00324779|BIOLOGICAL|rituximab|
41009341|NCT04943016|DRUG|CD19 Chimeric Antigen Receptor (CAR) T Cells|This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies. The overall goal of this study is to validate the safety profile of administration CD19 CAR T cells and describe the toxicities in children and adults with relapsed/ refractory B cell malignancies. Each patient implements leukapheresis 2 weeks after enrollment and infuse CD19 CAR-T cell around 2 weeks after leukapheresis, and administrated chemotherapy lymphodepletion regimen 1 week before infusion. Furthermore, the treated subject would be following up around 2 years.
41009342|NCT01622205|OTHER|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
41009343|NCT01622205|OTHER|Ordinary rehabilitation|Ordinary rehabilitation
41009344|NCT05372016|BIOLOGICAL|Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9vHPV vaccine ,0.5mL, three doses, 0,2,6 months
40808061|NCT05751993|BEHAVIORAL|ADAPT|The intervention is testing the feasibility of a reinforcement learning model to pull in participants' behavioral data (calories, activity, and weight) and use this data along with participants' past behavioral goal achievements to deliver the type of message that should be most effective for a given participant at a given time. At each decision point (morning, midday, and evening on a daily basis), the system evaluates which behaviors a participant is eligible to receive a message about (eating, activity, self-weighing), which intervention options a participant is eligible to receive, and then chooses what type of behavioral message a participant should receive. Over time, the model uses participant data and response to interventions to better tailor message choice.
41009345|NCT05372016|BIOLOGICAL|Active Comparator: GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
41009346|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
41009347|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
41153948|NCT05898802|DIETARY_SUPPLEMENT|Kimchi|Two different kimchi, one traditional kimchi and one fermented with a lactic acid bacteria having anti-obesity effect, hereafter starter kimchi, are flash freeze dried, powdered and encapsulated.
41325480|NCT02678312|DRUG|Placebo of Enalapril|
41325481|NCT02678312|DRUG|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
41325482|NCT02404896|DRUG|Metreleptin|Metreleptin open-label treatment
41325483|NCT03655587|DEVICE|Solid ankle foot orthotic|
41325484|NCT03655587|DEVICE|Resting night splint|
40808062|NCT06029127|DRUG|BGB-A445|Administered intravenously at protocol defined dose
40808063|NCT06029127|DRUG|Docetaxel|75 milligrams per square meter (mg/m\^2) administered intravenously
40808064|NCT06029127|DRUG|Ramucirumab|10 mg/kg administered intravenously
40808065|NCT06029127|DRUG|BGB-15025|Administered orally at protocol defined dose
41325485|NCT01927393|OTHER|palliative care|Receive PCPI
41325486|NCT01927393|BEHAVIORAL|educational intervention|Receive education sessions
41325487|NCT01927393|PROCEDURE|quality-of-life assessment|Ancillary studies
41325488|NCT01927393|OTHER|questionnaire administration|Ancillary studies
41325489|NCT01927393|BEHAVIORAL|telephone-based intervention|Receive telephone contacts
41153949|NCT05898802|DIETARY_SUPPLEMENT|Placebo|Lactose with kimchi flavor
41325490|NCT04035629|COMBINATION_PRODUCT|MagniXene, hyperpolarized 129Xe MRI|"All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung. Hyperpolarized 129Xe gas is prepared in a process termed spin-exchange optical pumping.~Xenon is highly lipophilic and therefore soluble in blood and tissue, making it an excellent tool for imaging the gas in both the air spaces (gas-phase imaging) and dissolved in the lung parenchyma (dissolved-phase imaging). This solubility in combination with xenon's chemical shift properties, results in the possibility of quantifying pulmonary gas exchange and gas transport within the parenchyma.~Additionally, previous images and lung function tests will be reviewed to compare findings and evaluate if there is a correlation between the obtained results."
41153950|NCT02001649|GENETIC|SNP Genotyping|Individuals were genotyped at a total 96 SNP from 15 candidate gene
41153951|NCT02001649|GENETIC|SNP genotyping|
40808069|NCT06166342|DIETARY_SUPPLEMENT|Placebo sachet|Consume 1 sachet daily
40808070|NCT06166342|DIETARY_SUPPLEMENT|TCI153 probiotic sachet|Consume 1 sachet daily
40808071|NCT05998070|OTHER|Training group|Hip strengthening exercises will be performed 3 times a week for 6 weeks in the training group. 3 exercises consisting of 2 sets and 10 repetitions will be performed every week. A rest interval will be given between sets.
41009348|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
41009349|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
41009350|NCT00535886|DIETARY_SUPPLEMENT|Man-made Trans FA|EA as 6% of total energy
41325491|NCT00983359|RADIATION|Radiation Therapy|Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
41325492|NCT01590394|DEVICE|Large plastic biliary stent|Stent placement for bile duct obstruction.
41325493|NCT04943172|DEVICE|Hancock-Jaffe bioprosthetic venous valve (VenoValve®)|Surgical implantation of the VenoValve device
41325494|NCT03167164|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
41325495|NCT03167164|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
41325496|NCT03167164|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
41325497|NCT03167164|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
41325498|NCT03167164|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
41325499|NCT03167164|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
41325500|NCT03167164|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
40808072|NCT05584410|OTHER|Patient information|Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
40808073|NCT05584410|OTHER|Smart phone application based exercises|Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.
40808074|NCT05584410|OTHER|Web based exercises|Generic osteoarthritis exercise, including about 20 different exercises, provided by real-time videos and written description
41009351|NCT00535886|DIETARY_SUPPLEMENT|Natural Trans FA|VA as 6% of total energy
41009352|NCT00535886|DIETARY_SUPPLEMENT|Oleic Acid|OA as 6% of total energy
41009353|NCT00080223|DRUG|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
41009354|NCT04535284|BEHAVIORAL|Coaching|"Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching."
41009355|NCT03366350|PROCEDURE|Allogeneic hematological stem cell transplantation|Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.
41325501|NCT03167164|DRUG|nab-Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
41325502|NCT03167164|DRUG|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
41325503|NCT03167164|RADIATION|Stereotactic Body Radiation Therapy|radiation
41325504|NCT03167164|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
41325505|NCT03167164|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
41325506|NCT03167164|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
41325507|NCT03167164|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
41325508|NCT03167164|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
41325509|NCT01213498|DRUG|Atorvastatin|Zarator, 80 mg pr. day for 5 days
41325510|NCT01213498|DRUG|Unikalk|1 tablet Unikalk pr day for 5. days
41325511|NCT03049995|PROCEDURE|Left ventricular contractile reserve SE|Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.
40808075|NCT05584410|OTHER|Group based information|Osteoarthritis specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).
40808076|NCT05584410|OTHER|Supervised rehabilitation|The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
40808077|NCT05584410|OTHER|Self-monitoring|Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment
41325512|NCT03049995|PROCEDURE|B-lines SE|SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.
41009356|NCT03538340|PROCEDURE|Thoracic Epidural|The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
41009357|NCT03538340|PROCEDURE|Intercostal Cryoanalgesia|The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
41009358|NCT01369875|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
41009359|NCT01369875|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
41325513|NCT03049995|PROCEDURE|Left ventricular outflow tract gradient SE|SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).
41325514|NCT03049995|PROCEDURE|Diastolic function SE|SE will be performed with special focus on E/e', pulmonary artery systolic pressure, B-lines and left ventricular end-diastolic volume (3,4).
41325515|NCT03049995|PROCEDURE|Mitral regurgitation SE|SE will be performed with special focus on mitral regurgitation and aortic valve gradients assessment (3,4).
41325516|NCT03049995|PROCEDURE|Pulmonary hemodynamics SE|SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.
41325517|NCT03049995|PROCEDURE|Coronary flow reserve SE|SE will be performed with special focus on regional wall motion + coronary artery flow velocity reserve.
41325518|NCT04521335|DRUG|Disulfiram|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
40808078|NCT05584410|BEHAVIORAL|Motivational notifications|Automatic and daily reminders and / or motivational notifications
40808079|NCT05584410|OTHER|Home based rehabilitation|Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
40808080|NCT04587830|DRUG|ADI-PEG 20|Investigational Medicine
40808081|NCT04587830|DRUG|Temozolomide|Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.
40808082|NCT04587830|DRUG|Placebo|Investigational Medicine
40808083|NCT04360239|DIETARY_SUPPLEMENT|Fish Oil|Fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
40808084|NCT06450886|DRUG|Ulviprubart (ABC008)|All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
41009360|NCT01369875|BIOLOGICAL|Aldesleukin|720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
41325519|NCT04521335|DRUG|Copper Gluconate|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
41325520|NCT04645862|DIAGNOSTIC_TEST|CT scans|4D CTA imaging
41325521|NCT02823600|DEVICE|RetinaVue 100 camera|Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
41325522|NCT05421429|BIOLOGICAL|KN057 doseⅠ|KN057 subcutaneous (SC) injection
41325523|NCT05421429|BIOLOGICAL|KN057 dose Ⅱ|KN057 SC injection
41009361|NCT01369875|BIOLOGICAL|Tumor Infiltrating Lymphocytes|Intravenous (IV) over 30 minutes on day 0
41009362|NCT01410149|OTHER|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
41009363|NCT01410149|OTHER|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
41009364|NCT01410149|OTHER|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
41009365|NCT03246867|OTHER|Isolytic stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Afterwards active-assistive stretching is done. Evaluations will be done before and just after stretching exercise.
41325524|NCT05421429|BIOLOGICAL|KN057 dose Ⅲ|KN057 SC injection
41325525|NCT03443609|DIAGNOSTIC_TEST|68Ga-HBED-CC-PSMA PET / CT|Patient will receive a specific PET / CT with PSMA
40808085|NCT00804154|DRUG|Intrathecal Resiniferatoxin|phase I, single-site, non-randomized, open-label, dose-escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy
40808086|NCT04636840|DEVICE|Space From Body and Eating Concerns- Teen|Mobile application with coaching component
41153952|NCT00626158|DRUG|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
41153953|NCT00626158|DRUG|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
40808089|NCT04659174|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium chloride 20 mg BID on days 3-7. The dosage is increased to xanomeline 125 mg/trospium chloride 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium chloride 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium chloride 30 mg will have the option to return to xanomeline 100 mg/ trospium chloride 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
41153954|NCT06458309|PROCEDURE|spine surgery|"AO Classification6 It classifies thoracolumbar fractures into 3 major groups, based on the mechanism of injury.and each of them subdivided to 3 subgroups.~A. Compression B. Distraction C. multi-directional with translation Thoracolumbar AO spine injury score"
40808091|NCT02858310|BIOLOGICAL|E7 TCR cells|T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
40808092|NCT02858310|DRUG|Aldesleukin|Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.
40808093|NCT02858310|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
40808094|NCT02858310|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
41153955|NCT04089332|OTHER|Oral Glucose Tolerance Test (OGTT)|Eligible subjects will undergo MRI scanning before and after oral glucose tolerance test.
40808096|NCT03822455|DRUG|OligoG DPI|OligoG Dry Powder for Inhalation
41009366|NCT03246867|OTHER|Static stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Evaluations will be done before and just after stretching exercise.
41325526|NCT01691053|DRUG|Spironolactone|50mg once daily
41325527|NCT01691053|DRUG|Placebo|Placebo
41325528|NCT04449783|OTHER|pre-operative screening|reported symptoms plus nose and throat swabbing 48 hrs prior to surgery
41325529|NCT04449783|OTHER|telephone consult|telephone consult 14 days (+/- 2 days) to assess for any COVID-19 symptoms
41325530|NCT04101448|OTHER|prevalence|percentage of bronchectasis in COPD and its effect as prognostic measure
40808097|NCT05561595|BEHAVIORAL|Healing HEARTS|Session topics will include: psychoeducation; myths and stereotypes; cognitive distortions and restructuring; coping strategies; interpersonal effectiveness; self-efficacy; mindfulness and self-compassion; acceptance and positive self-image; disclosure and finding support; stigma in health care; and empowerment and advocacy.
40808098|NCT05561595|BEHAVIORAL|Peer Support|Peer support groups will cover general topics such as symptom management, stress, and social support. Stigma will not be a formal topic of discussion, and group leaders will be trained to avoid initiating conversations about stigma; however, to capture realistic discussions in peer support groups, participants will not be prohibited from discussing the topic should they bring it up.
40808099|NCT03061721|DRUG|Saroglitazar magnesium 1 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
40808100|NCT03061721|DRUG|Saroglitazar magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
40808101|NCT03061721|DRUG|Saroglitazar magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
40808102|NCT03061721|DRUG|Placebos|Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
40808103|NCT05686551|DRUG|Tominersen 60 mg|60 mg tominersen administered intrathecally every 16 weeks
40808104|NCT05686551|DRUG|Placebo|Matching placebo administered intrathecally every 16 weeks
40808105|NCT05686551|DRUG|Tominersen 100 mg|100 mg tominersen administered intrathecally every 16 weeks
41009367|NCT03246867|OTHER|Control group|Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.
41009368|NCT03707288|OTHER|Spine Exercise Program|Spine exercises should be done 20 minutes/ 3 days per week Desk stretches should be done when exposed to prolonged sitting for greater than 60 mins
41153956|NCT04089332|DEVICE|3 Tesla MRI|A 3 Tesla MRI will be used to assess brain structure, quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits.
41153957|NCT04089332|DEVICE|Intravenous Catheter|A blood sampling IV catheter will be used to draw blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin.
41325531|NCT01245205|DRUG|Akt inhibitor MK2206|Given PO
41325532|NCT01245205|DRUG|lapatinib ditosylate|Given PO
41325533|NCT01245205|OTHER|pharmacological study|Correlative studies
41325534|NCT01245205|OTHER|laboratory biomarker analysis|Correlative studies
41325535|NCT03441347|BEHAVIORAL|Specific rehabilitation program|17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.
41325536|NCT03441347|OTHER|Usual Care|Participants will receive their usual care for 17 weeks, which may vary for each individual
41325537|NCT04791787|OTHER|Standard weight maintaining diet|Diet containing diet approximately 25-35% protein, 45-55% carbohydrate, 20- 30% fat
41479272|NCT00682617|BEHAVIORAL|Structured exercise program|Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
41479273|NCT00682617|BEHAVIORAL|Waitlist, delayed intervention|Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
41325538|NCT04791787|OTHER|Weight maintaining isocaloric ketogenic diet|Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat
41325539|NCT04791787|DIETARY_SUPPLEMENT|Beta-hydroxy butyrate|A supplement of ketone ester of beta-hydroxy butyrate
41325540|NCT05719051|DRUG|Albumin infusion|Albumin infusion was administrated according to the standard clinical practice
41325541|NCT02320630|DRUG|Entanercept|Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
41325542|NCT02320630|DRUG|HCQ|Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
41325543|NCT02320630|DRUG|MTX|MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
41325544|NCT03685045|PROCEDURE|Campaign days|Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
41325545|NCT02389686|DEVICE|INTRABEAM (Carl Zeiss, Oberkochen, Germany)|Boost with 16 Gy during NSM for nipple-areola complex (NAC)
41325546|NCT04663984|BEHAVIORAL|publication rates|publication rates of theses produced in the Department of Anesthesiology and reanimation
41325547|NCT04492878|DRUG|IKERVIS®1mg/mL|One drop of study medication once daily in each eye at bedtime during 90 days.
41479274|NCT01311401|OTHER|NONE intervention|NONE intervention
41153958|NCT04089332|OTHER|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
41009369|NCT03279276|PROCEDURE|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
41479275|NCT04310306|DEVICE|Thrombectomy using EmboTrap II|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, using a stent retriever, contact aspiration EmboTrap II. The number of thrombectomy attempts is at the operator's discretion. Combination of balloon guide catheter or intermediate catheter is recommended.
41479276|NCT01974128|PROCEDURE|ASC isolation and implantation|This trial will study ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy
41479277|NCT06458153|BEHAVIORAL|Neural responses to speech functional localizer|Measuring speech-related brain activity using fMRI during a speech listening task.
41479278|NCT06458153|BEHAVIORAL|Neural responses to silent articulation|Measuring speech-related brain activity using fMRI during a silent articulation task.
41009370|NCT02904811|OTHER|Testing for Ct infection immediately|Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.
41009371|NCT02904811|OTHER|Testing for Ct infection at the end of the study|Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
41325548|NCT03492645|BEHAVIORAL|Telephone-and technology-facilitated treatment protocol|"1. 8 video or telephone counseling sessions targeting PTSD symptoms related to smoking lapse. The first of these sessions will last approximately 45-60 minutes, and the remaining 7 sessions will last 20-30 minutes.~2. Use of the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed by our co-investigators at the National Center for PTSD to complement the IC protocol with evidence-based tools to support smoking cessation, such as motivational messaging and coping tools for managing PTSD symptoms associated with smoking lapse.~3. Use of the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor, compatible with iOS and Android smartphones, that provides CO readings to the user at any time in order to self-monitor progress in quitting. The Covita iCO mobile app is used with the iCO Smoerlyzer to display CO readings."
41325549|NCT03492645|BEHAVIORAL|Office-based treatment protocol|Weekly face-to-face sessions using the unmodified treatment manual developed by McFall and Saxon, a protocol combining office-based therapy plus evidence-based pharmacotherapies for smoking cessation that doubled quit rates in veteran smokers with PTSD.
41325550|NCT04879784|OTHER|No intervention|No intervention
41325551|NCT02148211|OTHER|Data collection|Initial and follow-up data was collected using questionnaires.
41009372|NCT03376997|DRUG|Perampanel|IV infusion
41009373|NCT03376997|DRUG|Perampanel|Oral tablet
41009374|NCT04505020|OTHER|3D Print + Conventional imaging|This group will have a 3D reconstruction of their hip printed using a 3D printer so that the PI can use it in their pre and intra-operative planning along with traditional imaging.
41009375|NCT04505020|OTHER|Conventional imaging|This group will have CT, MRI and X-Ray imaging completed so that the PI can use it in their pre and intra-operative planning.
41009376|NCT03661515|DRUG|Selinexor|"According to escalation level:~* Level -1: Selinexor 40 mg/day, once weekly~* Level 1: Selinexor 60 mg/day, once weekly~* Level 2: Selinexor 80 mg/day, once weekly~* Level 3: Selinexor 100 mg/day, once weekly"
41009377|NCT03661515|DRUG|fludarabine|fludarabine 30 mg/m2/day intravenously on days 1 to 4
41009378|NCT03661515|DRUG|idarubicin|idarubicin 10 mg/m2/day intravenously on days 1 to 3
41009379|NCT03661515|DRUG|cytarabine|cytarabine 2 g/m2/day intravenously on days 1 to 4
40808107|NCT04346173|PROCEDURE|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
40808108|NCT02616562|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) once-weekly.
40808109|NCT02616562|DRUG|Norditropin® FlexPro® pen|Administered subcutaneously (s.c., under the skin) once daily.
40808110|NCT06192758|DEVICE|TheraSphere PCa|Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).
40808111|NCT05522582|DRUG|Methotrexate tablets|Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
40808112|NCT05522582|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
40808113|NCT05522582|RADIATION|Radiotherapy|6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
40808114|NCT05285215|PROCEDURE|Integrated psychological program (IPP)|"Patients will listen to the music for 30 minutes before delivery, and resume music listening once they are comfortable after delivery. Upon discharge, they will be asked to have music listening at least 30 minutes per day until 8 weeks postnatal survey.~Mindfulness training via mobile application is administered before delivery. After delivery, they are asked to perform mindfulness training for 10 minutes daily, until last follow-up at 8 weeks post-delivery.~Mobile electronic survey will be used to assess patients' EPDS scores fortnightly, until the last follow-up at week 8 post-delivery. If the EPDS scoring is found to be equal to or more than 10, video counselling and/or face-to-face consultation will be arranged.~Video counselling sessions will be offered if patients are found to have EPDS score of 10-12. For women found to have EPDS≥13, a face-to-face initial psychiatry consultation will be conducted."
41157185|NCT04029792|COMBINATION_PRODUCT|Combination of plant extracts (BSL_EP028)|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
41325552|NCT03157440|DIAGNOSTIC_TEST|Ring oxymetry|a new type oxymetry wear on index finger like a ring
41325553|NCT02584777|BIOLOGICAL|Pacritinib|QD (Once a day)
40808118|NCT06101342|DRUG|Lenacapavir Injection|Administered subcutaneously
41009380|NCT03661515|DRUG|G-CSF|G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5
40808119|NCT06101342|DRUG|Lenacapavir Tablet|Administered orally
40808120|NCT06101342|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
41009381|NCT00000102|DRUG|Nifedipine|
41009382|NCT03069027|PROCEDURE|External nasal nerve block|Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
40808121|NCT04585269|BEHAVIORAL|Bright IDEAS-YA|Bright IDEAS-YA is a manualized problem-solving skills training intervention conducted by a trainer who teaches the participant the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach.
41009383|NCT03069027|DRUG|saline adrenaline|
41009384|NCT03069027|DRUG|Xylocaine, adrenaline|
41009385|NCT01365780|PROCEDURE|Hyperbaric Oxygen Therapy|The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
41009386|NCT03461627|DRUG|Salmeterol Xinafoate and Fluticasone Propinate Powder|50ug/250ug 1 puff twice a day for 4 weeks
41009387|NCT03461627|DRUG|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
41009388|NCT05891938|OTHER|H2 gas inhalation|H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
41009389|NCT01122511|DRUG|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
41009390|NCT01122511|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab into study eye
41009391|NCT01122511|OTHER|sham|Sham needle-less injection administered in the study eye
40808122|NCT05623787|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
40808123|NCT00862433|DRUG|Alpha tocopherol|intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
40808124|NCT00862433|OTHER|Vitamin E|Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
40808125|NCT00862433|OTHER|Vitamin C|Oral vitamin C, one gram daily.
41009392|NCT01356511|DRUG|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
41009393|NCT01356511|DRUG|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
41009394|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
41009395|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
41009396|NCT02112097|DRUG|Gadolinium|For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
40808126|NCT03896750|DRUG|PA-824|PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
40808127|NCT04699838|DRUG|Cisplatin|Cisplatin
40808128|NCT04699838|DRUG|Carboplatin|Carboplatin
40808129|NCT04699838|DRUG|Etoposide|Etoposide
40808130|NCT04699838|DRUG|Durvalumab|Durvalumab
41009397|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
41009398|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
41153959|NCT06003478|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
41153960|NCT05422040|OTHER|Dry needling|Invasive treatment will be performed on the most symptomatic lumbar iliocostalis muscle.
41153961|NCT05422040|OTHER|Tecartherapy treatment|Treatment will be carried out with deep thermotherapy in the lumbar region.
41153962|NCT01920399|DRUG|CAZ-AVI|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
41157186|NCT04029792|COMBINATION_PRODUCT|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
41325554|NCT03330041|DEVICE|Fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material
41325555|NCT02517853|DEVICE|Posterior tibial nerve stimulation|
41325556|NCT02517853|DEVICE|Sham posterior tibial nerve stimulation|
41325557|NCT04137562|BIOLOGICAL|ADSTEM Inj.|Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL
41325558|NCT04137562|OTHER|Placebo|330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.
41325559|NCT00544011|BIOLOGICAL|bevacizumab|
41325560|NCT00544011|DRUG|capecitabine|
41325561|NCT00544011|DRUG|fluorouracil|
41325562|NCT00544011|DRUG|irinotecan hydrochloride|
41325563|NCT00544011|OTHER|diagnostic laboratory biomarker analysis|
41325564|NCT01546285|DEVICE|Blood Pressure Readings on B40 Patient Monitor|Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
41325565|NCT05903937|DRUG|Autologous Tumor Infiltrating Lymphocytes|Administered via hepatic arterial infusion (HAI)
40808131|NCT04699838|DRUG|Ceralasertib|Ceralasertib
41325566|NCT05903937|DRUG|Melphalan|Administered via isolated hepatic perfusion
41325567|NCT05903937|DRUG|Interleukin-2|low-dose, administered s.c.
41325568|NCT02966353|DRUG|ruxolitinib|Ruxolitinib was supplied in 5 mg tablets to be taken orally approximately 12 hours apart (morning and night)
41325569|NCT01566591|DEVICE|Deep TMS Treatment|24 TMS treatments over 6 weeks .
40808135|NCT04726241|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or bone marrow samples
41325570|NCT01566591|DEVICE|Sham Treatment|24 TMS treatments over 6 weeks
41325571|NCT00032838|DRUG|Yohimbine|
41325572|NCT00270998|BEHAVIORAL|Behavioral Therapy|Pelvic muscle training and exercises
41325573|NCT00270998|DEVICE|Intravaginal Pessary|Intravaginal pessary
40808136|NCT05813925|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
40808137|NCT05813925|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
41325574|NCT00270998|DEVICE|Pessary combined with behavioral therapy|Intravaginal pessary and behavioral therapy
41325575|NCT02835677|BEHAVIORAL|Behavioral|Education and skills building, including problem solving, cognitive restructuring, and stress management
41325576|NCT01617655|DRUG|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
41325577|NCT01617655|DRUG|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
41325578|NCT01617655|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
41325579|NCT05246670|DRUG|Palmidrol|Given PEA PO
41325580|NCT05246670|DRUG|Placebo Administration|Given PO
41325581|NCT05246670|OTHER|Quality-of-Life Assessment|Ancillary studies
41325582|NCT03683056|BEHAVIORAL|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
41325583|NCT05439018|OTHER|Integrated Neuromuscular inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique ) traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
41325584|NCT05439018|OTHER|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
41325585|NCT03050216|BIOLOGICAL|ALT-803|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4~ALT-803 Stimulated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.~ALT-803 to Facilitate NK Cell Survival and Expansion:~ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total"
41325586|NCT05602285|DEVICE|Dislodgement device|Breakaway device that prevents IV dislodgement
41325587|NCT00003856|DRUG|temoporfin|
40808138|NCT05813925|DRUG|Placebo Semaglutide|Participants will receive placebo matched to semaglutide
40808139|NCT04238481|DRUG|Pudexacianinium chloride|Intravenous
40808140|NCT06540911|OTHER|Personalized physical back training program|The study intervention is a 4-week personalized physical back training program. The study intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are selected through a clinical reasoning process, i.e., they are tailored and problem-oriented, based on the results of a clinical assessment.
40808141|NCT06540911|OTHER|Non-personalized physical back training program|The control intervention is a 4-week non-personalized physical back training program. The control intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are not selected through a clinical reasoning process, i.e., they are neither tailored nor problem-oriented nor based on the results of a clinical assessment.
41325588|NCT05496894|DRUG|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 3 months (Q3M)
41325589|NCT01954888|PROCEDURE|Blind technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).
41325590|NCT01954888|PROCEDURE|Ultrasound-guided technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
41325591|NCT00672295|DRUG|Dasatinib, Paclitaxel, and Carboplatin|"Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m\^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn."
41325592|NCT00566449|DRUG|Placebo|one dose daily for 4 weeks
41325593|NCT00566449|DRUG|JNJ-31001074|10 mg daily for 4 weeks
41325594|NCT00566449|DRUG|JNJ-31001074|30 mg daily for 4 weeks
41325595|NCT05976477|OTHER|educational intervention|"1. four short videos (about one-minute/one-minute and half duration) concerning the topic of reducing dietary salt intake to control the blood pressure in elderly hypertensive patients: the mini-videos will be designed with a common thread starting from providing general information regarding diet to enhance awareness of the amount of salt that is usually introduced with the diet, up to give suggestions on which products to choose/avoid during grocery shopping and how to behave during the preparation and consumption of food at home to reduce salt intake;~2. Four images informing participants about the risk of excessive salt intake and health benefits of a low-sodium diet and tips on how to reduce daily salt intake;~3. Four recipes for tasty easy-to-prepare meals, avoiding added salt."
41325596|NCT00520637|DRUG|EZN-2208|
41325597|NCT04965506|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
41325598|NCT04965506|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
41325599|NCT04965506|OTHER|Dulaglutide|Dulaglutide administered subcutaneously (SC) once a week.
41479279|NCT06458153|BEHAVIORAL|Neural responses to self vs. externally generated speech|Measuring speech-related brain activity using fMRI during self-generated vs. externally-generated speech.
40808142|NCT06208150|DRUG|Talquetamab|Talquetamab will be administered as a SC injection.
40808143|NCT06208150|DRUG|Pomalidomide|Pomalidomide will be administered orally.
41325600|NCT02668744|BEHAVIORAL|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
41325601|NCT00599170|DRUG|Rituximab|375 mg/m2 IV
41479280|NCT06458153|BEHAVIORAL|Event-related potentials for speech|Measuring electroencephalography (EEG) based evoked potentials for self vs. externally generated speech
41479281|NCT06458153|BEHAVIORAL|Neural responses to induced speech errors|Measuring speech-related brain activity using fMRI during conditions that induce auditory speech errors.
41479282|NCT06458153|BEHAVIORAL|Neural responses to sensory-motor adaptation|Measuring brain activity using fMRI during a learning task with sustained altered auditory feedback.
41479283|NCT06458153|BEHAVIORAL|Speech production behaviors|Behavioral measurements of speech during reading passages and words
41479284|NCT06458153|BEHAVIORAL|Auditory acuity testing|Measurements of auditory acuity during listening tasks.
41479285|NCT06458153|BEHAVIORAL|Neural responses to learning a non-speech auditory motor behavior|Mapping of brain areas using fMRI during learning of non-speech sound-evoking movements.
41479286|NCT03313882|OTHER|no intervention is involved|
41479287|NCT02019082|DEVICE|Electrical Stimulation (BTL-5000 series, United Kingdom)|Direct current ES
40808144|NCT06208150|DRUG|Teclistamab|Teclistamab will be administered as a SC injection.
40808145|NCT06208150|DRUG|Elotuzumab|Elotuzumab will be administered intravenously.
40808146|NCT06208150|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
40808147|NCT06208150|DRUG|Bortezomib|Bortezomib will be administered as a SC injection.
40808148|NCT06122662|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
41479288|NCT02019082|DEVICE|placebo|the intervention procedure was the same as that the ES group, but the current intensity was zero
41479289|NCT02201290|DRUG|Eltrombopag Tablets|Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).
41479290|NCT02201290|DRUG|Eltrombopag PfOS|Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
40808149|NCT06122662|OTHER|Placebo|Matching Placebo Comparator
41153963|NCT01920399|DRUG|0.9% Normal Saline|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
41009399|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
41325602|NCT03945032|OTHER|TICOP|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
41325603|NCT01115075|OTHER|Dietary fat/intake of carbohydrate|Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.
41479291|NCT06108219|DRUG|Miricorilant (Cohort A)|Miricorilant 100 mg for oral dosing
41479292|NCT06108219|DRUG|Placebo (Cohort A)|Matching placebo for oral dosing for 48 Weeks
41479293|NCT06108219|DRUG|Miricorilant (Cohort B)|Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing
41479294|NCT06108219|DRUG|Placebo (Cohort B)|Matching placebo for oral dosing for 24 Weeks
41479295|NCT05677126|DRUG|Tralement|Tralement with Manganese
41479296|NCT05677126|DRUG|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese
41479297|NCT03600233|DRUG|CVM-1118|"Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met."
41153964|NCT05647109|OTHER|No intervention|No intervention
41153965|NCT01190449|BIOLOGICAL|ofatumumab|Given IV
41153966|NCT06244745|DRUG|Administration of letrozole|Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.
41153967|NCT03814278|BEHAVIORAL|complete bed rest|Patients in this group received standard care for PPROM according to the institution protocol, including antepartum confinement to bed.
41153968|NCT03814278|BEHAVIORAL|activity restriction|Patients in this group received standard care for PPROM according to the institution protocol but to had bathroom privileges and walks to the ward canteen four times per day.
41153969|NCT05294328|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
41153970|NCT05294328|DRUG|Aceclidine ophthalmic solution|LNZ100- aceclidine ophthalmic solution
41479298|NCT03651726|DRUG|THX-110 (dronabinol plus PEA)|2.5 mg dronabinol capsules and 400 mg PEA tablets
41479299|NCT03651726|DRUG|Placebo|Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
41479300|NCT00812422|DRUG|Dexibuprofen|one dose of Dexibuprofen 2.5 or 5 mg/kg
41479301|NCT00812422|DRUG|Dexibuprofen|one dose of Dexibuprofen 3.5 or 7 mg/kg
41479302|NCT00812422|DRUG|Ibuprofen|one dose of Ibuprofen 5 or 10 mg/kg
41479303|NCT00489281|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
41009400|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
41009401|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
41325604|NCT01115075|BEHAVIORAL|Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.|Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
41325605|NCT02376595|DRUG|Rocuronium Bromide|Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
41009402|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
41009403|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 12|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
41009404|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 24|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
41009405|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 36|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
41009406|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 12|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
41009407|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 24|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
41153971|NCT05294328|DRUG|Vehicle Proprietary Ophthalmic Solution|Proprietary Vehicle Ophthalmic Solution
41325606|NCT06036641|DEVICE|NIRS monitoring|All participants will undergo NIRS monitoring of muscle and cerebral tissue oxygenation intraoperatively.
41479304|NCT00489281|DRUG|Fludarabine|Fludarabine 30 mg/m\^2/day IV on Days -6, -5, -4, -3, and -2.
40808156|NCT05907954|DRUG|Darovasertib|Oral, potent, selective inhibitor of Protein Kinase C
41325607|NCT06036641|DEVICE|Laser Doppler flowmetry|Cutaneous blood flow will be assessed intraoperatively via Laser Doppler flowmetry in all participants
41325608|NCT06036641|OTHER|Inflammatory and Oxidative stress biomarkers|Blood samples will be taken to measure biomarkers of inflammation and oxidative stress at specific time points
41479305|NCT00489281|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.
41479306|NCT00489281|DRUG|Sirolimus|The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.
41479307|NCT00489281|PROCEDURE|Allogeneic bone marrow transplant|An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
41479308|NCT00489281|RADIATION|Total body irradiation - 200|200 centigray (cGy) in one fraction on Day -1.
41479309|NCT00489281|DRUG|Levetiracetam|Given at 500 mg PO twice daily from Day -6 to Day +365.
41479310|NCT00489281|BIOLOGICAL|Anti-thymocyte globulin|Test dose of 0.5 mg/kg IV given on Day -9, then 2 mg/kg/day IV on Day -8 and -7.
40808157|NCT06321302|DRUG|BI 764524|BI 764524
40808158|NCT06321302|DRUG|Sham comparator to BI 764524|Sham comparator to BI 764524
40808159|NCT06321302|DRUG|Aflibercept (Eylea®) - US only|Aflibercept (Eylea®) - US only
40808160|NCT05029128|BEHAVIORAL|Endurance exercise intervention|All participants engage in treadmill walking 4 days/week, 60 minutes/day, at 70-80% of HRmax for 4 weeks.
40808161|NCT06285318|OTHER|Teclistamab|No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into Case Report Form (CRF).
41325609|NCT05666661|OTHER|Sound and light therapy (BBT and FL group)|During intervention, the participants close their eyes and wear an eye mask and stereo earphones. They then listen to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phone. The intervention music was first embedded in the participant's mobile phone and the BBT music application was purchased from the mobile phone app (Brainwave Studio software, Dalcoms Inc). When listening to music, 10 Hz light stimulation was added to the BBT and FL group (using a mobile phone). Table 1 shows the intervention status. The rhythmical photic stimulation program was a commercially available mobile phone app (Strobe Therapy software released by FuwhatSoft).
41325610|NCT05666661|OTHER|Sound therapy group (BBT)|Participants in the sound therapy group (BBT) listened to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phones. Except for rhythmical photic stimulation, the other steps were the same as the BBT and FL group.
41325611|NCT05666661|OTHER|Relaxing music group|Participants listened to 30 minutes of relaxing music (the same as that of the experimental groups) through their mobile phone. Except for rhythmical photic stimulation and 10 Hz BBT, the other steps were the same as the experimental groups.
41479311|NCT00489281|RADIATION|Total body irradiation - 400|400 centigray (cGy) in one fraction on Day -1.
41479312|NCT01371084|BEHAVIORAL|Pedal@Work Worksite Wellness|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
41479313|NCT01371084|BEHAVIORAL|Pedal@Work|Worksite wellness program.
41479314|NCT02056470|DEVICE|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
41479315|NCT02056470|DEVICE|Total Knee Replacement|total Knee replacement implant
41479316|NCT02056470|DEVICE|Freedom Total Knee System|Total Knee replacement implant
41479317|NCT02984774|PROCEDURE|Cystectomy|Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis
41479318|NCT02984774|PROCEDURE|Endometrial sampling|Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
41479319|NCT02984774|PROCEDURE|Peripheric blood sampling|4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
41479320|NCT02984774|PROCEDURE|Ovarian tissue sampling|2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
41479321|NCT03363477|DRUG|Enoxaparin|
40808162|NCT06285318|OTHER|Talquetamab|No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.
41153972|NCT05230134|PROCEDURE|Cervical sympathetic block|All participants will get the cervical sympathetic block and catheter under ultrasound guidance.
40808163|NCT06435364|OTHER|Vagus nerve stimilation|This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents through the external ear. Somatosensory innervation is provided by the auricular branch.
41479322|NCT03363477|DRUG|Clexane|
41009408|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 36|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
41153973|NCT02115945|OTHER|DN4 test|The DN4 test was used to evaluate neuropathic pain.
41153974|NCT02115945|OTHER|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
41479323|NCT01790113|DEVICE|Univers™|Control
41479324|NCT01790113|DEVICE|Eclipse™ Total Shoulder Replacement|Investigational
41479325|NCT05555394|OTHER|Basic Body Awareness Therapy|The intervention will be twice a week during 12 weeks. It lasts 90 min of movements of daily life, massage and self-reflections.
41479326|NCT05555394|OTHER|Stretching Exercise|It consists in stretching movements of whole body
41479327|NCT03811626|PROCEDURE|cognitive-behavioral rehabilitation|Combination of clinical examination and neuropsychological and psychological tests
41479328|NCT02697773|OTHER|Placebo|Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
41153975|NCT02115945|OTHER|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
41479329|NCT02697773|BIOLOGICAL|Tanezumab 2.5 mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
41153976|NCT02115945|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
41153977|NCT02115945|PROCEDURE|femoral block|
41153978|NCT02115945|PROCEDURE|epidural block|
41153979|NCT06285383|OTHER|Music listening|Participants will listen to the music pieces Pachabel Canon in D major (30 minutes), free from external sounds (max 70 dB through headphones).
41153980|NCT06285383|OTHER|classic physical therapy|classic physical therapy
41153981|NCT02679079|DRUG|NBI-98854|
41153982|NCT02679079|DRUG|Placebo|
41325612|NCT05400187|BEHAVIORAL|Body composition assessment and smart-phone based counselling|"As for the body composition assessment, body fat and muscle thickness, body fat percentage and distribution will be measured and a brief face-to-face counseling soon after the measurement will be implemented to the participants. Body assessment were measured by the InBody 270 (Biospace, Seoul, Korea) device, which provides a convenient way of accurate body fat measurement comparable with those obtained using air displacement plethysmography (ADP) (about 90% precision).~As for the Whatsapp-based counselling and communication session, qualitative dietary counselling will be offered every two weeks through the Whatsapp. One session contains 15 minutes, including the topics like making a balanced diet (55 % glucose, 30 % lipids and 15 % proteins), diversifying food intake, dietary advices and recommendations in healthy eating behaviors (e.g., eat slowly, eat at a regular time, avoid to skip a meal, drink at least 1.5 L of water each day)."
41325613|NCT05454397|OTHER|Observational study, no intervention|Observational study, no intervention
41325614|NCT04352595|DRUG|Hemay808|Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
40808164|NCT06435364|OTHER|Manual therapy|Manual therapy is mostly defined by the tissue targeted by the practitioner; it can be joint biased, muscle and connective tissue biased and/or neurovascular system biased techniques.
41153983|NCT04513535|OTHER|Thoracic Manipulation|A supine thoracic manipulation will be utilized. Participants will be lying supine on the plinth with their arms crossed over their chest, making sure the forearms are not crossed. An experienced clinician will place their hand on the inferior segment (T4); the superior segment (T3) will be placed in the midrange of thoracic flexion and extension. The clinician will apply a high velocity, end range, anterior to posterior thrust by using their body weight to deliver the thrust through the participants crossed elbows, thus creating a bilateral gapping of the facet joints. If a cavitation is achieved after the first thrust, the thoracic manipulation intervention is complete. If not, one more attempt will be made to achieve a cavitation. Regardless of if there was a cavitation or not, after the second attempt the intervention is complete.
41157187|NCT00836914|DRUG|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
41157188|NCT00836914|DRUG|Placebo|Placebo capsules administered orally BID for 7 days
41157189|NCT05999513|DRUG|casdatifan|Administered as specified in the treatment arm
41325615|NCT00807300|RADIATION|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
41479330|NCT02697773|BIOLOGICAL|Tanezumab 2.5mg/5mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
41479331|NCT04623021|DRUG|Nafamostat Mesilate|Administered intravenously as a continuous infusion
41479332|NCT00892788|BEHAVIORAL|contingency management|Prize-based contingency management for weight loss
41479333|NCT00892788|BEHAVIORAL|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
41479334|NCT04320979|RADIATION|internal mammary nodal irradiation|chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
41157190|NCT06407947|DRUG|Chimeric antigen receptor modified T cells Infusion|chimeric antigen receptor T cells
41325616|NCT00807300|PROCEDURE|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
41325617|NCT00193349|DRUG|Imatinib|
41479335|NCT04320979|RADIATION|no internal mammary nodal irradiation|chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
41479336|NCT06000917|DRUG|pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel|"Pyrotinib tablets: 320mg qd, oral administration after breakfast, 21 days for 1 cycle, continuous administration of 6 cycles.~Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles.~Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given.~Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration"
41325618|NCT00193349|DRUG|Irinotecan|
41325619|NCT00193349|DRUG|Carboplatin|
40808173|NCT06274515|PROCEDURE|Tumor Tissue and Blood Draw|Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.
41009409|NCT02112097|DRUG|Adverse Reactions of Enbrel subcutaneously|Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
41479337|NCT05717582|DRUG|apalutamide|Patients receive apalutamide 240mg,qd,po.
41479338|NCT05717582|DRUG|androgen deprivation therapy|Patients receive systemic ADT.
41479339|NCT05717582|PROCEDURE|cytoreductive radical prostatectomy with/without pelvic lymph node dissection|Patients receive cytoreductive radical prostatectomy with/without pelvic lymph node dissection.
41479340|NCT05717582|RADIATION|metastasis-directed therapy with radiation|Patients receive metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases.
41325620|NCT02366741|RADIATION|Whole brain radiotherapy with reduced dose to the hippocampi|VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
41009410|NCT02112097|DRUG|Adverse Reactions of Enbrel subdermally at Week 36|Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
41009411|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
41009412|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
41009413|NCT02112097|DRUG|Gadolinium|For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
41009414|NCT00690638|DRUG|PHX1149T|200 mg
41009415|NCT00690638|DRUG|PHX1149T|400 mg
41325621|NCT05979233|PROCEDURE|staged managment|staged management
41325622|NCT05979233|PROCEDURE|one session ERCP then LC|one session ERCP then LC
41325623|NCT05979233|PROCEDURE|one session LC then ERCP|one session LC then ERCP
41009416|NCT00690638|DRUG|Placebo|Placebo
41009417|NCT06276725|BEHAVIORAL|Writing Wrongs|A repeated exposure writing practice targeting symptoms resulting from microaggressions experienced by minoritized students at predominantly White institutions.
41325624|NCT05475600|BEHAVIORAL|Classical APA group:|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
41325625|NCT05475600|BEHAVIORAL|APA with Exergaming device|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
41325626|NCT05475600|BEHAVIORAL|APA associated with biofeedback relaxation|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à Exergaming device 3 - Cool down: 20min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
41479341|NCT03504995|DEVICE|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
41479342|NCT04712149|DEVICE|Weekly digital follow up|weekly digital follow-up by sending a questionnaire to patients and sending alerts based on the questionnaire to the care team
41325627|NCT01957852|OTHER|FloSeal|
41325628|NCT02366390|BEHAVIORAL|Psychoeducative intervention|Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
41479343|NCT00555802|OTHER|exercise|exercise
41479344|NCT02349620|BIOLOGICAL|PRF|implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
41479345|NCT02999594|DRUG|Tramadol Hydrochloride|50mg intramuscularly
41479346|NCT02999594|DRUG|Distilled Water|2ml intramuscularly
41479347|NCT05513716|OTHER|Retrospective tissue sample analysis|Archival formalin-fixed, paraffin-embedded (FFPE) tumour tissue from colorectal cancer peritoneal metastasis and paired primary tumours, where available - taken as standard care
40808177|NCT03462719|DRUG|Ibrutinib|Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
41009418|NCT01412775|BEHAVIORAL|short-term group intervention program|"The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration."
41009419|NCT00036920|DRUG|canfosfamide hydrochloride|
41479348|NCT00588640|DRUG|d-Methadone|8 subjects to receive 40 mg d-Methadone twice a day
41009420|NCT00964808|DRUG|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
41009421|NCT00964808|DRUG|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg \* 2 pr. day until time to discharge from the Hospital or latest at day 12.
41009422|NCT00691210|DRUG|Vorinostat|"Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells."
41009423|NCT00691210|DRUG|Niacinamide|"Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer."
41009424|NCT00691210|DRUG|Etoposide|"Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor."
41009426|NCT01606085|BEHAVIORAL|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
41009427|NCT01606085|BEHAVIORAL|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
41009428|NCT03643003|BEHAVIORAL|Music therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
41009429|NCT03643003|BEHAVIORAL|Non-Music Verbal Interaction (Placebo)|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
41325629|NCT06315855|BEHAVIORAL|Telehealth Intervention (THI)|The THI is a 6-month intervention. On a monthly basis, the survivor will be queried via telehealth (zoom or smart phone) oral and health related symptoms by nurse practitioner or navigator. Based on the initial imaging and the monthly assessments, the patients will be provided with tools and instructions for oral health maintenance which may consist of mucositis management and/or diet and lifestyle counseling. All participants will be provided a Resource directory that is to be used to identify a dentist that is best suited for him/her. Post intervention, follow-up assessments will be conducted at 6-, 9- and 12-months post randomization.
41325630|NCT05551338|OTHER|Serious games|The training protocol will entail using a tablet-based program that includes 6 serious games. Patients will be asked to use the program twice a week for 3 months. The serious games that will be used in this study were developed to challenge short-term memory and selective attention in six different games. Each of the six games comprise 20 different stages of varying difficulty, where stage 1 is the easiest and stage 20 is the most difficult.
41325631|NCT00406211|BIOLOGICAL|MMRV|
41325632|NCT00406211|BIOLOGICAL|MMR (Priorix®)|
41325633|NCT00406211|BIOLOGICAL|Varicella (Varilrix®)|
41325634|NCT02816437|BIOLOGICAL|OpenBiome Fecal Microbiota Transplantation retention enema|Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
41325635|NCT03329599|DRUG|Polycap|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
40808178|NCT03462719|DRUG|Venetoclax|Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
41157191|NCT06431295|DEVICE|FaceScan|"Digital visual acuity device built for iOS (iPhone) that conducts an assessment of visual acuity using a combination of integrated light detection and ranging (LiDAR) and voice processing."
41157192|NCT06236139|BIOLOGICAL|Anti-STEAP1 CAR T-cells|Given IV
40808179|NCT03462719|DRUG|Chlorambucil|Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
40808180|NCT03462719|DRUG|Obinutuzumab|Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
41157193|NCT06236139|PROCEDURE|Biopsy|Undergo tumor biopsy
41325636|NCT02288611|DIETARY_SUPPLEMENT|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.
41325637|NCT02288611|DIETARY_SUPPLEMENT|Maltodextrin/Dextrose|Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
41479349|NCT00588640|DRUG|D-methadone|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
41325638|NCT02220946|DEVICE|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
41325639|NCT04923698|OTHER|yoga training|All women in group B were treated by the same antidepressant drugs as in group A and yoga program, 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
41325640|NCT01576406|DRUG|crizotinib|crizotinib 250 mg twice a day
41325641|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
41479350|NCT00588640|DRUG|placebo|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
41325642|NCT01576406|DRUG|crizotinib|crizotinib 250 mg twice a day
41325643|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
41325644|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
41325645|NCT03130712|DRUG|GPC3-CART cells|Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
41009430|NCT05500859|OTHER|Data collection at Baseline, 3 months after baseline (BL), 1-year follow-up, Telephone follow-up and questionnaire 3 years and 5 years after BL|Data collection (Patient characteristics including medical history, current medication, cardiovascular risk factors, routine laboratory analysis (including lipids, Hb1c, NT-proBNP), clinical status, electrocardiogram, echocardiography data from latest echo, cardio pulmonary exercise testing (CPET), questions on general health behavior (diet, weekly exercise load), Quality of Life and questions on socio-economic parameters)
41325646|NCT00375960|DRUG|V3381|
41325647|NCT00375960|DRUG|Placebo|
41325648|NCT02742857|BIOLOGICAL|BQ-A Peptide Extract|BQ-A Peptide Extract
41325649|NCT02742857|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cells
41325650|NCT02742857|DEVICE|Transcranial Laser Therapy|Transcranial Laser Therapy
41479351|NCT03870113|BIOLOGICAL|Vaccinated group|Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
41325651|NCT02742857|DEVICE|Median Nerve Stimulator|Median Nerve Stimulator
41325652|NCT04899960|DRUG|Clinical Pharmacist Intervention|Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.
41325653|NCT04861311|BEHAVIORAL|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention|The intervention is based on the principles of Acceptance and Commitment Therapy (ACT). Therefore, the intervention is an ACT-based smartphone app delivered for 6 weeks in which participants will be applying the mindfulness and acceptance exercises embedded in the app. The mindfulness and acceptance exercises are audio-guided mindfulness meditations and video lessons about ACT.
41325654|NCT04378699|OTHER|SMR (12-15 Hz)|SMR training sessions (12-15 Hz) C4 unipolar placement, central region
41009431|NCT02111252|DRUG|TAK-850|TAK-850 injection
41325655|NCT04378699|OTHER|alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
41325656|NCT05161182|OTHER|High fat, low carbohydrate diet|Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
41325657|NCT05161182|OTHER|Low fat, high carbohydrate diet|Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
41325658|NCT05269641|OTHER|Food: whole almonds|60g of whole almonds will be consumed daily.
41325659|NCT05269641|OTHER|Food: non-nut snack|A non-nut snack will be consumed daily.
41325660|NCT03222440|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
41325661|NCT05650515|OTHER|Co-creation|The development of a technology-based exercise intervention based on ideas of older adults and experts in the field of geriatric rehabilitation/research/medicine
41325662|NCT01559064|DEVICE|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
41325663|NCT04958109|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Administration of a 75 gm oral glucose tolerance test
41479352|NCT06414460|DRUG|ISM3412|ISM3412 will be administered orally once daily.
41479353|NCT02772094|BIOLOGICAL|Single arm, open-label|"Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ."
41479354|NCT00006108|BIOLOGICAL|trastuzumab|
41325664|NCT04958109|DRUG|Kisspeptin|Intravenous administration of kisspeptin 112-121 x 16 hours
41325665|NCT04958109|DRUG|Placebo|Intravenous administration of Placebo 16 hours
41325666|NCT05146583|PROCEDURE|Autologous bone marrow aspirate injected intradiscal after microdiscectomy|Harvested from SI-joint, 2-5ml BMA is injected in the discectomy defect.
41325667|NCT05146583|PROCEDURE|Discectomy only|Transflaval discectomy with or without the use of a microtube (according to surgeons' preference).
41325668|NCT03461432|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a psychological therapy that has been developed with a general immediate focus on improving impaired cognitive domains but ultimately aimed at improving social and functional outcomes.
41479355|NCT00006108|DRUG|capecitabine|
41479356|NCT00006108|DRUG|paclitaxel|
41479357|NCT02427295|DRUG|Sandostatin (Octreotide Acetate)|"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~* Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -\> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~* Frequency: every 4 weeks.~* Route of administration: IM injection."
41479358|NCT04529447|OTHER|Survey|The patient satisfaction survey consisted of 8 items, including 7 Likert scale questions and 1 multiple choice question.
41479359|NCT03480438|DRUG|Blinatumomab|Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.
41325669|NCT00614653|DRUG|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
41325670|NCT00614653|DRUG|Erlotinib|100 mg by mouth Once Daily on days with radiation.
41325671|NCT00614653|DRUG|Capecitabine|400 mg/m\^2 PO Twice Daily on days with radiation.
41325672|NCT00614653|RADIATION|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
41479360|NCT03346252|DRUG|Botulinum Toxin type A|"All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.~In addition, they will undergo 3 cycles of treatment, each 12 weeks apart."
41479361|NCT05472402|BEHAVIORAL|LADIES online intervention (R33 phase)|Participants will participate weekly online group sessions over 6 months. Participants will also receive access to written intervention materials, access to an online walking program, and access to weekly podcasts that are aligned with the intervention sessions and that support physical activity lessons with biblical scriptures.
41009432|NCT02601040|BIOLOGICAL|Attenuated Hepatitis A Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-16 years \\6.50 lgCCID50/ml in adults aged 17 up to 65 years old
41009433|NCT02601040|BIOLOGICAL|Inactivated Hepatitis A Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months \\320EU/Vial in children aged 3-16 years \\640EU/Vial in adults aged 17 up to 65 years old\\boost at month 6\\two-dose
41325673|NCT02087293|BEHAVIORAL|Intervention arm - automated call and phone-based pharmacist counseling|patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
41325674|NCT03594864|PROCEDURE|Liver transplantation with hyper-reduced grafts|Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
41009434|NCT02601040|BIOLOGICAL|Group A Meningococcal Polysaccharide vaccine|30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
41009435|NCT05525182|DRUG|ES16001 40 mg|Composition: Elaeocarpus extract 40mg tablet
41325675|NCT01345851|RADIATION|hypofractionated radiation therapy|Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks
41009436|NCT05525182|DRUG|ES16001 80 mg|Elaeocarpus extract 80 mg tablet
41009437|NCT05525182|DRUG|ES16001 160 mg|Elaeocarpus extract 160 mg tablet
41009438|NCT05525182|DRUG|Placebo|Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
41157194|NCT06236139|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41157195|NCT06236139|PROCEDURE|Bone Scan|Undergo NM bone scan
41325676|NCT01345851|OTHER|laboratory biomarker analysis|Correlative studies
41325677|NCT01345851|RADIATION|image-guided radiation therapy|Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.
41325678|NCT01345851|DRUG|carboplatin|The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.
41325679|NCT01345851|DRUG|paclitaxel|The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.
41325680|NCT01345851|RADIATION|stereotactic body radiation therapy|Undergo hypofractionated RT
41325681|NCT05396794|BEHAVIORAL|Standard weight loss education|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider.
41325682|NCT05396794|BEHAVIORAL|Standard weight loss education + Educational Video|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider followed by a 15-minute educational video detailing the benefits of weight loss.
41325683|NCT04569799|DRUG|Lumason|2.4 mL per lesion
41325684|NCT00344955|DRUG|HMG-CoA reductase inhibition (atorvastatin)|
41325685|NCT04685499|DRUG|OBP-301|Telomerase-specific Type 5 Adenovirus. OBP-301 OBP 301 will be injected intratumorally into tumor lesions.
41325686|NCT04685499|DRUG|Pembrolizumab|Standard dose pembrolizumab 200 mg IV every 3 weeks for up to one year
41325687|NCT03775590|PROCEDURE|Water|To evaluate using water in the treatment of atopic dermatitis
41325688|NCT03775590|PROCEDURE|Bleach|To evaluate using water + dilute bleach in the treatment of atopic dermatitis
41325689|NCT03775590|PROCEDURE|Acetic acid|To evaluate using water + vinegar in the treatment of atopic dermatitis
41325690|NCT02017886|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks
41479362|NCT05472402|BEHAVIORAL|LADIES online control (R33 phase)|Participants will receive online access to a written self-guided curriculum that is self-paced and teaches participants how to increase physical activity. Participants will be encouraged to complete the self-guided curriculum within 6 months.
41479363|NCT01509521|DRUG|Ephedrine|An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
41479364|NCT01509521|DRUG|Phenylephrine|An infusion of maximum 4 mg/hour for maximum 60 minutes.
41325691|NCT02017886|DIETARY_SUPPLEMENT|Placebo|Placebo tablet twice daily for three weeks
40808181|NCT03462719|DRUG|Ibrutinib (as Subsequent Therapy)|Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
41479365|NCT03128736|DRUG|Esomeprazole group|Esomeprazole 40mg qd
41479366|NCT03128736|DRUG|Dexlansoprazole group|Dexlansoprazole 60mg qd
41479367|NCT04691310|DEVICE|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
41479368|NCT05099484|DRUG|The MedMilk study|This observational, pragmatic PK study will enroll lactating women who are taking medications that were prescribed by their treating medical provider or as an over-the-counter medication.
41479369|NCT02170948|DRUG|Dexmedetomidine|An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
41479370|NCT02516384|BIOLOGICAL|Fecal Microbiota Transplantation|We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (\>18 year old) patients with active ulcerative colitis (UC).
41479371|NCT05123313|BEHAVIORAL|Deprescribing intervention|"The intervention is comprised of a minimum of three consultations with a general practitioner (GP), where adjustment of the patient's medication is made according to the patient's preference, goals and needs~Consultation 1: Patient and GP discuss how the patient feels about their medical treatment, and the GP provides the patient with written material for the patient to prepare prior to the next consultation.~Consultation 2: A clinical pharmacist have beforehand examined the patient's medication list and provided suggestions to the GP on which drugs can be deprescribed. The patient and GP discuss the patient's preferences and initiate deprescribing initiatives aligned with the patient's priorities.~Consultation 3: Patient and GP follow up on the changes initiated and initiate new deprescribing initiatives if such can be identified. If needed, subsequent consultations (Consultation X) are planned until the patient and GP consider the patient's medical treatment optimal."
41479372|NCT02882672|OTHER|Experimental|Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging
41157196|NCT06236139|PROCEDURE|Computed Tomography|Undergo CT scan
41009439|NCT05597007|BEHAVIORAL|VPICS Clinic|Participants will complete a mix of mandatory synchronous and asynchronous sessions with their Health Group to address PICS. Participants will spend 15 minutes daily on physiotherapy, and 15 minutes on cognitive therapy. There are also 2h time slots everyday for participants to join for an optional check-in with their health coach, who can support them in their individual activities. Participants will spend 15 minutes weekly responding to journal prompts about nutrition and general challenges.
41009440|NCT00797667|DRUG|Telcagepant 140 mg|
41479373|NCT02882672|OTHER|Control|They did not do ant exercise training during 8 weeks.
41479374|NCT02694549|DEVICE|CaveoVasc|
41479375|NCT06115304|OTHER|Large liquid meal, spinal catheter and venous line|"Large liquid meal (e.g. Nutricia® Energy 500 ml (750 kcal) admixed paracetamol 1000 mg (for estimation of gastric emptying).~Spinal catheter for 4 hours, with samples taken at one hour interval.~2 venous lines, one for saline and one for venous sampling every half hour"
41479376|NCT00398931|DRUG|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
41157197|NCT06236139|DRUG|Cyclophosphamide|Given IV
41157198|NCT06236139|PROCEDURE|Echocardiography|Undergo ECHO
40808185|NCT03006848|DRUG|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
41009441|NCT00797667|DRUG|Telcagepant 280 mg|
41009442|NCT00797667|DRUG|140 mg telcagepant placebo|
41325692|NCT04129086|DRUG|Ketamine plus usual care|Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
41325693|NCT04129086|DRUG|Usual Care|Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
41479377|NCT00398931|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
41479378|NCT03654664|BIOLOGICAL|Inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 250 U (Name of viral strain: TZ84)
40808186|NCT03006848|OTHER|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
40808187|NCT05845710|DEVICE|Neuroguard IEP Direct System|carotid artery stenting, direct access with blood flow redirection
41009443|NCT00797667|DRUG|280 mg telcagepant placebo|
41009444|NCT05239403|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
41009445|NCT05239403|OTHER|Questionnaire Administration|Complete questionnaires
41157199|NCT06236139|DRUG|Enzalutamide|Given PO
41157200|NCT06236139|DRUG|Fludarabine|Given IV
41325694|NCT04953117|DEVICE|DCB of Lepu Medical(dimeter≥2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter≥2.00 mm)
41479379|NCT03654664|BIOLOGICAL|Havrix Inj|720 ELISA/0.5 mL Junior (Inactivated hepatitis A virus antigen 160 U (Name of viral strain: HM175 Inj)
41479380|NCT02857556|BIOLOGICAL|Blood sample|
41479381|NCT02857556|OTHER|Retinal photography:|
41479382|NCT02857556|OTHER|dialyse|
41479383|NCT03410043|DRUG|Osimertinib|Given PO
41479384|NCT03410043|RADIATION|Radiation Therapy|Undergo radiation therapy
41479385|NCT03410043|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40808188|NCT05881278|DEVICE|Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)|Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
41153984|NCT04513535|OTHER|Cervical Manipulation|Participants will be lying supine on the plinth on the table. A high velocity low amplitude manipulation will be performed to the cervical spine by an experienced clinician.The clinician will place the right proximal phalanx of the index finger over the posterolateral aspect of the articular pillar at the right C4/C5 segment to maximally influence the C5 myotomal distribution. The clinician's left hand will be cradling the participants head. The participant will be brought into midrange flexion-extension, ipsilateral side bend, and contralateral rotation of C4/5. Once a firm end feel is felt the manipulation will be administered into left rotation in an arc toward the left eye. If a cavitation is achieved after the first thrust, the intervention is complete. If not, one more attempt will be made to achieve a cavitation;after the second attempt the intervention is complete.
41325695|NCT04953117|DEVICE|Restore DEB|subjects receiving Restore DEB
41153985|NCT04513535|OTHER|glenohumeral posterior glide mobilization|Participants will be instructed to lay supine on the plinth and a plastic orthopedic wedge will be placed under their scapula for stabilization on the side that is receiving the mobilization. The experienced clinician will stand on the same side being mobilized and held the participant's arm proximal to the medial and lateral humeral epicondyles. The clinician will hold the participant's arm in the scapular plane, approximately 55 degrees of abduction and slight ER with a grade one long axis distraction applied and sustained throughout the entire mobilization. A grade three oscillatory mobilization will be applied for three sets of 30 seconds with a 30 second rest in between.
41157201|NCT06236139|PROCEDURE|Leukapheresis|Undergo leukapheresis
41325696|NCT04953117|DEVICE|DCB of Lepu Medical(dimeter<2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter\<2.00 mm)
40808193|NCT05255991|DRUG|Placebo|Placebo administered QID
40808194|NCT05255991|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
40808195|NCT05255991|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
40808196|NCT04062214|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
40808197|NCT05815810|OTHER|Attuned: A mobile application|Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.
41325697|NCT01001364|DRUG|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
40808198|NCT05815810|OTHER|In-Person Voice Modification Therapy|Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
41325698|NCT01001364|DRUG|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
41325699|NCT03895112|DRUG|AVID200|dose cohorts of 21-day cycles
41325700|NCT05637801|DEVICE|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
41325701|NCT05637801|DEVICE|Sensory Stimulation System (GS120) - Sham|Sensory Stimulation System (GS120) - Sham settings
41325702|NCT00453856|DRUG|Sulfadoxine Pyrimethamine|
41325703|NCT02137837|DRUG|Fulvestrant|
41325704|NCT02137837|DRUG|Anastrozole|
41325705|NCT02137837|DRUG|Everolimus|
41479386|NCT00093002|DRUG|Fulvestrant|250 mg \& 500 mg intramuscular injection
41479387|NCT01725919|BEHAVIORAL|CI therapy|constraint induced movement therapy
41479388|NCT04226235|BEHAVIORAL|Yoga session|a 1-hour yoga session was completed by all participants following a DVD.
41479389|NCT00658931|DRUG|Drug treatment with Cymbalta|Drug treatment with Cymbalta
41325706|NCT02137837|DRUG|Placebo - Anastrozole|
41325707|NCT02137837|DRUG|Placebo - Everolimus|
41479390|NCT01829087|DRUG|Botox|
41479391|NCT01829087|DRUG|placebo|
41479392|NCT04624152|BEHAVIORAL|Soccer heading|A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.
41479393|NCT00764231|BEHAVIORAL|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
41153986|NCT04513535|OTHER|Sleeper stretch|Participants will be positioned in a side lying position with the arm to be stretched on the table. The arm to be tested will then be positioned at a 90-90 shoulder abduction and elbow flexion position. A support will be positioned behind the patient to ensure there is no compensatory trunk movement during the stretch, and an examiner verified the arm is in a 90-90 position. A sleeper stretch will be subsequently completed, in which the participant will internally rotate the arm to stretch the posterior shoulder musculature. Three, thirty second stretches will be completed
41153987|NCT04783987|OTHER|Walking asessments|Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.
41153988|NCT01435499|BIOLOGICAL|melanoma GVAX|Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.
41153989|NCT01435499|DRUG|Cyclophosphamide|200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
41325708|NCT02644148|PROCEDURE|Conventional Roux-en-Y Gastrojejunostomy|Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
41325709|NCT02644148|PROCEDURE|Uncut Roux-en-Y Gastrojejunostomy|Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
41479394|NCT00764231|BEHAVIORAL|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
41153990|NCT04272099|OTHER|Administration of standardized questionnaires|Administration of questionnaires assessing subjective socioeconomic status (SES), health literacy, perceived health, health related quality of life, self-esteem and diabetes self-efficacy
41153991|NCT04272099|DEVICE|Physical activity tracker|PG1 will be asked to wear a physical activity tracker for one week to monitor activity patterns including walking distance, calorie expenditure, sedentary time and sleep.
41153992|NCT04272099|OTHER|Dietary log|PG1 (or PG2 as proxies when appropriate) will report to a study coordinator via phone a full dietary log of PG1 once per week on rotating days of the week for three weeks.
41157202|NCT06236139|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41325710|NCT00431821|BEHAVIORAL|Exercise|Home-based exercise prescriptions with weekly motivational telephone calls.
41479395|NCT00569790|DRUG|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15."
40808209|NCT04452357|RADIATION|PLDR|"PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows:~Dose level 1: 56 Gy; Dose level 2: 66 Gy Drug: Gemcitabine"
40808210|NCT02974582|BEHAVIORAL|Exposure to smoking advertising with coupon|Direct mail marketing of smoking advertising with discount coupon
40808211|NCT02974582|BEHAVIORAL|Exposure to smoking advertising without coupons|Direct mail marketing of smoking advertising without discount coupon
40808212|NCT02974582|BEHAVIORAL|Exposure to non health related images|Control group
40808213|NCT05144893|BEHAVIORAL|Virtual Mindfullness-Based Intervention|Virtual administration of the social support components of an adapted 4-week Mindfulness Based Cognitive Therapy for Postpartum Depression (MBCT-PD) intervention. Each session includes a review of assigned online mindfulness practice and barriers to practice, other homework if also assigned, psychoeducation, and mindfulness practices relevant to the session's theme.
40808214|NCT05907096|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
41479396|NCT04332016|OTHER|biological samples collection|collection of whole blood samples, urine and stool samples, upper respiratory samples, post-mortem biopsies
40808215|NCT05907096|OTHER|Placebo|Intravenous administration of placebo
40808216|NCT03783442|DRUG|Cisplatin|Administered IV
40808217|NCT03783442|DRUG|Oxaliplatin|Administered IV
40808218|NCT03783442|DRUG|Fluorouracil (5-FU)|Administered IV
40808219|NCT03783442|DRUG|Capecitabine|Administered orally
40808220|NCT03783442|DRUG|Paclitaxel|Administered IV
40808221|NCT03783442|DRUG|Tislelizumab|Administered IV
40808222|NCT03783442|DRUG|Placebo|Placebo to match Tislelizumab
40808223|NCT05290402|OTHER|JEEVA (new digital health navigator app)|An app can be used on a mobile phone or tablet.
40808224|NCT03866408|BEHAVIORAL|Immediate weight loss|Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
40808225|NCT03866408|DRUG|Pioglitazone|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
40808226|NCT03866408|BEHAVIORAL|Deferred weight loss|Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
40808227|NCT03866408|DRUG|Placebo|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
40808229|NCT04699032|DRUG|Apraglutide|Single dose of apraglutide 5 mg.
40808230|NCT06532032|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
40808231|NCT06532032|DRUG|Docetaxel|Docetaxel will be administered as IV infusion.
40808232|NCT06206291|DRUG|Placebo|Matching placebo twice daily for first 4 weeks
40808233|NCT06206291|DRUG|Cannabidiol (CBD) 200mg|First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.
40808234|NCT06206291|DRUG|Cannabidiol (CBD) 400mg|Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.
40808235|NCT06047080|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab
40808236|NCT06047080|DRUG|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin in combination with R-CHP
40808237|NCT06047080|DRUG|Rituximab|Participants will receive IV rituximab
41325711|NCT00431821|OTHER|Stroke education|Stroke education program with matched attention phone calls
41325712|NCT00930709|DRUG|Botulinum toxin type A (Botox®, Allergan)|Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
41325713|NCT00930709|BEHAVIORAL|Active strength training and stretching|Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
41325714|NCT01565434|OTHER|CR1 impact|
41325715|NCT01637818|PROCEDURE|Lichtenstein's operation|
41479397|NCT04933786|BEHAVIORAL|Digital Health Nudging|Short daily text messages with information and motivation concerning physical activity.
41479398|NCT01369017|DRUG|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
41479399|NCT01369017|DRUG|Placebo|Injection of NS
41479400|NCT04012372|OTHER|ROSA Water|Ad libitum hydration with ROSA oligomineral water
40808238|NCT06047080|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide as part of CHP chemotherapy
40808239|NCT06047080|DRUG|Doxorubicin|Participants will receive IV doxorubicin
40808240|NCT06047080|DRUG|Prednisone|Participants will receive oral prednisone as part of CHP chemotherapy
41153993|NCT01003379|DRUG|TC-5619|TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
41153994|NCT01003379|DRUG|Placebo|Placebo will be provided with exactly the same shape, size and appearance.
40808243|NCT01932372|DRUG|Tofacitinib (Xeljanz)|5 mg Tablet BID
40808244|NCT01932372|DRUG|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
41153995|NCT03134976|DRUG|Levothyroxine|Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
41325716|NCT01637818|PROCEDURE|Mesh Plug Repair|
41325717|NCT01637818|DRUG|Opiate|Postoperative pain therapy
41479401|NCT04012372|OTHER|Control water|Ad libitum hydration with other waters
41479402|NCT04627480|DEVICE|Fisher Wallace Neurostimulation Device|a Cranial Electrotherapy Stimulator Device (CES).
41479403|NCT00141986|DIETARY_SUPPLEMENT|vitamin D3|2000 IU per day
41157203|NCT06236139|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41479404|NCT00141986|DIETARY_SUPPLEMENT|vitamin D3|400 IU per os once daily
41479405|NCT02214719|BEHAVIORAL|EASI-IDM use|EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
41479406|NCT00038987|BIOLOGICAL|Wetvax (APSV)|
41479407|NCT05839535|BEHAVIORAL|BDJ|BDJ is a mind-body intervention
41479408|NCT05839535|DEVICE|tDCS|tDCS is a brain stimulation method.
40808247|NCT01143558|DEVICE|Lyme Disease Xenodiagnosis|Clean laboratory-bred ticks are the FDA registered IDE. These ticks are placed on patients to search for evidence of Borrelia burgdorferi.
41325718|NCT01637818|DRUG|Paracetamol|Postoperative pain therapy
41325719|NCT01637818|DRUG|non-steroidal anti-inflammatory drug|Postoperative pain therapy
40808250|NCT06250322|DEVICE|Intervention|No study treatments will be administered during this study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
41325720|NCT04303793|DEVICE|Percutaneous PDA closure|transcatheter patent ductus arteriosus closure
41009446|NCT06402058|DEVICE|DMSB01|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
41325721|NCT03963804|DEVICE|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
41325722|NCT00592917|DIETARY_SUPPLEMENT|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
41325723|NCT05491447|DRUG|BMX-010|Ointment
41325724|NCT05491447|DRUG|Placebo|Ointment
41325725|NCT02650297|OTHER|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
41479409|NCT05839535|DEVICE|sham tDCS|sham tDCS
41479410|NCT05839535|OTHER|exercise|exercise including stretching and other activities.
41479411|NCT00358748|DRUG|Hydrocortisone|See detailed description above.
41479412|NCT00937651|DRUG|Placebo|Placebo
41479413|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 20 mg|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
41479414|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 60 mg|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
41479415|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 180 mg|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
41479416|NCT02358967|DIETARY_SUPPLEMENT|TRF (Tocotrienol-rich-fraction)|2 x 150 mg capsules
41479417|NCT02358967|DIETARY_SUPPLEMENT|Placebo|2 x 150 mg capsules
41325726|NCT02650297|DEVICE|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
41479418|NCT04859842|OTHER|Pulse Electromagnetic Field|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with PEMF in prone position. Each session will be 45 minute long with a 15 minute PEMF therapy and a 30 minute conventional therapy program.
41479419|NCT04859842|OTHER|Interferential Current|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with Interferential current in prone position. Four interferential electrode will be placed on low back region. Each session will be 45 minute long with a 15 minute interferential current and a 30 minute conventional therapy program.
41009447|NCT06402058|DEVICE|Rejuran®|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
41009448|NCT00004903|BIOLOGICAL|filgrastim|
41009449|NCT00004903|BIOLOGICAL|recombinant interferon alfa|
41009450|NCT00004903|DRUG|cisplatin|
41325727|NCT04507776|DRUG|Etanercept|Patients with spondyloarthrosis as provided in real world practice
41325728|NCT05108688|DRUG|Mirtazapine|Mirtazapine 30 mg tablet once daily for 3 successive days
41325729|NCT05108688|DRUG|Sumatriptan|Sumatriptan 50 mg tablet once daily for 3 successive days
41325730|NCT05108688|OTHER|Placebo|Placebo tablets once daily for 3 successive days.
41325731|NCT01572818|PROCEDURE|phlebotomy|7 ml/kg without exceeding 500 mL
41325732|NCT01572818|BEHAVIORAL|dietary and lifestyle counseling|dietary and lifestyle counseling
41325733|NCT02659475|DRUG|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
41325734|NCT03670069|DRUG|Itacitinib|Given PO
41325735|NCT03670069|OTHER|Laboratory Biomarker Analysis|Correlative studies
41325736|NCT05536245|OTHER|Questionnaire|To prevalence of psychological, physical and sexual violence suffered or committed in a population of patients suffering from one or more addictions
41325737|NCT04846348|COMBINATION_PRODUCT|Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.|Combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base (Vanicream).components: Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor
41325738|NCT05594433|DRUG|Lenograstim|Injection sub cutaneous of Lenograstim during 4 days, once per day
41325739|NCT05779345|PROCEDURE|surgery|short implant placement
41479420|NCT04859842|OTHER|Sham|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with conventional therapy and sham electrotherapy. Sham application will be performed on prone position with four electrodes and electrodes will stay for 15 minutes on this region.
41479421|NCT05209828|DEVICE|pfmmedical implantable vascular access ports|Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.
41479422|NCT00061217|DEVICE|Unrectified prosthetic socket|
41153996|NCT03427879|DRUG|Low flavonoid beverage|A low flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), placebo blueberry powder (2.4%), alkalized cocoa powder (1.6%), and whey protein isolate (0.6%). The beverage will contain approximately 5mg flavonoids per serving.
41325740|NCT00361894|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
41325741|NCT00361894|DRUG|Enoxaparin|Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
41325742|NCT05760638|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
41153997|NCT03427879|DRUG|High flavonoid beverage|A high flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), blueberry powder (2.4%), cocoa powder (1.6%), green tea extract (0.1%) and whey protein isolate (0.6%). The beverage will contain approximately 620 mg flavonoids per serving.
41009451|NCT00004903|DRUG|cyclophosphamide|
41009452|NCT00004903|DRUG|cytarabine|
41009453|NCT00004903|DRUG|etoposide|
41009454|NCT00004903|DRUG|melphalan|
41009455|NCT00004903|PROCEDURE|peripheral blood stem cell transplantation|
41153998|NCT05400525|DIETARY_SUPPLEMENT|YMETA|1 sachet containg a total of 3g i.e. 2.5g Galacto-oligosaccharides, 0.5g Bifidobacterium polysaccharides (daily)
41153999|NCT05400525|OTHER|Placebo control|3g Maltodextrin (i.e. DE 10) daily
41154000|NCT06584981|PROCEDURE|pectoral nerve block (PECS II), parasternal and serratus plane blocks|These block applications are performed under sterile conditions under the guidance of ultrasonography
41154001|NCT06584981|OTHER|analgesic|Analgesia needs of patients who do not receive blockade are met with intravenous drugs.
41325743|NCT00219518|PROCEDURE|defecography|insertion of catheter to record pressure. Insertion of barium to outline rectum and fluoroscopy to define change in rectal contour and expulsion of barium during the study.
41325744|NCT06014385|DRUG|Scopolamine|TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg
41325745|NCT06014385|RADIATION|[11C]EMO ([11C]LSN3172176)|A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of \[11C\]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.
41479423|NCT00061217|DEVICE|Rectified prosthetic socket|
41325746|NCT00654953|DRUG|sertraline|Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
41325747|NCT00654953|DRUG|Placebo|Placebo (cellulose or lactose) administered twice per day for 12 weeks.
41325748|NCT00654953|DRUG|gabapentin|Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
41325749|NCT03853512|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
41325750|NCT03853512|OTHER|Semisolid vaseline|Product is applied to the other side of the inguinal region.
41325751|NCT00978679|DEVICE|Orthokeratology lenses|Nightly use of orthokeratology lenses to correct the refractive errors
41325752|NCT00978679|DEVICE|Spectacles|Daily use of single vision lenses to correct refractive errors
41325753|NCT03368040|DEVICE|Tcore|Monitoring system to measure body temperature based on heat-flux technology
41325754|NCT03879876|DRUG|Human T Lymphoid Progenitor (HTLP) injection|Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)
41325755|NCT06517862|DRUG|Zinc sulfate|Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.
41325756|NCT06517862|DRUG|Ursodeoxycholic acid|Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.
41325757|NCT00030095|DRUG|2-methoxyestradiol|
41325758|NCT02580240|DRUG|Hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
41325759|NCT02580240|DRUG|saline|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
41325760|NCT00054158|DRUG|dexamethasone|
41009456|NCT03067779|OTHER|mHealth Tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy."
41009457|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
41009458|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
41154002|NCT00485914|BEHAVIORAL|On-site work evaluation|Researchers will measure the effects of worksite assessment through an on-site work evaluation by an occupational therapist on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through one-to-one contact and an individualized work plan. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
41325761|NCT00054158|DRUG|doxorubicin hydrochloride|
41325762|NCT00054158|DRUG|thalidomide|
41325763|NCT00054158|DRUG|vincristine sulfate|
41325764|NCT03235375|DRUG|MEDI0382|MEDI0382 administered subcutaneously
41325765|NCT00880763|DRUG|Vaniprevir|Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
41479424|NCT04808882|DRUG|Tinzaparin, Low dose prophylactic anticoagulation|"Participants randomized to the LD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: LD-PA : 3500 IU/24h. Depending on the type of tinzaparin pre-filled syringe available in the participating center, the dose of 4000 IU/24h will be allowed in place of 3500 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
41325766|NCT00880763|DRUG|Pegylated Interferon (peg-IFN)|Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
41325767|NCT00880763|DRUG|Ribavirin|Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
41325768|NCT00880763|DRUG|Comparator: Placebo|Placebo to vaniprevir oral capsule twice daily for 28 days
41325769|NCT06528808|OTHER|Simple reality simulator application|Women in the intervention group will be given an application aimed at breast cancer awareness with a simple valid simulator.
41157204|NCT06236139|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41325770|NCT06408246|DRUG|Guanfacine|Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.
41325771|NCT06408246|DRUG|Sertraline|Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.
41325772|NCT05321966|OTHER|Visual video education|The intervention group watched three episodes of a training video a week for 12 weeks. Each session started 90 minutes after the HD treatment
41479425|NCT04808882|DRUG|Tinzaparin, High dose prophylactic anticoagulation|"Participants randomized to the HD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: HD-PA : 7000 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: HD-PA: 4000 IU/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
41325773|NCT06174883|DIETARY_SUPPLEMENT|Folic acid fortified iodized salt|addition of folic acid to iodized salt to be consumed daily and assess rise in serum folate levels.
41325774|NCT05419414|DEVICE|Shear wave elastography|Both groups were examined with shear wave elastography.
41325775|NCT02535078|DRUG|Tebentafusp (IMCgp100)|soluble gp100-specific T cell receptor with anti-CD3 scFV
40808253|NCT05145322|DEVICE|Composite with 90 degree cavosurface angle|Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the preparation will be restored with a bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
40808254|NCT05145322|DEVICE|Composite with wide bevel|Lesion-specific cavity design with wide bevel throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the cavity will be restored in with a pre-warmed (using Bioclear Heatsync Kit) bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
41154003|NCT00485914|BEHAVIORAL|Educational material|Researchers will measure the effects of worksite assessment through educational materials on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through educational materials to develop strategies to compensate. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
41154004|NCT04796948|DRUG|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|irinotecan liposome in combination with oxaliplatin and 5-FU/LV
41154005|NCT00765921|DRUG|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
41325776|NCT05568927|OTHER|SEARCH algorithm|The SEARCH algorithm is a structured, stepwise approach to follow up testing after acute PE that will enable timely diagnosis of post PE sequelae. The test results at each step inform the performance of the subsequent steps. The order of the tests in the algorithm uses the acronym SEARCH: Symptom screen, exercise function, arterial perfusion, resting heart function, confirmatory imaging, and hemodynamics.
41009459|NCT05122949|DEVICE|3D Printed Ankle-Foot Orthosis|3D Printed (Fused Deposition Modelling) Ankle-Foot Orthosis with Polyamide Nylon-12 material
41325777|NCT03053726|PROCEDURE|Variable Frequency Stimulation|vary the frequency of the stimulation parameter
41325778|NCT00879437|DRUG|Valproic acid|"Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.~Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml"
41325779|NCT00879437|DRUG|Bevacizumab|All patients will receive bevacizumab (10 mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
41009460|NCT05122949|DEVICE|Thermoformed Ankle-Foot Orthosis|Thermoformed Ankle-Foot Orthosis with homopolymer polypropylene
41009461|NCT00004357|DRUG|Methylprednisolone|IV
41009462|NCT00004357|DRUG|Prednisolone|Oral
41325780|NCT00879437|RADIATION|Radiation therapy|Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. The total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
41325781|NCT01360229|PROCEDURE|Acupuncture|Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
41325782|NCT01360229|OTHER|Acupuncture to treat fatigue in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
41325783|NCT05922098|OTHER|Texture Modified Foods Manual for chewing dysfunctions in older adult|Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
41325784|NCT05993000|OTHER|432 Hertz frequency music|432 Hertz frequency music was played to patients through headphones during hotpack and TENS applications.
41325785|NCT05993000|OTHER|TENS|The TENS treatment was conducted using a double-channel TENS device equipped with four electrodes. The electrodes were placed around the painful area to ensure targeted stimulation. Each session lasted for 30 minutes, during which the TENS device operated at a high frequency range of 60-120 Hz. To achieve the desired analgesic effect, a short transition time of 20-120 microseconds was employed.
41325786|NCT05993000|OTHER|Mobilization|Electrophysiological agents were administered to the affected shoulder joint area before initiating mobilization. The Cyriax mobilization techniques targeted the scapula, clavicular, and GH joints, considering their biomechanical interaction and the specific dysfunction of each patient.
41325787|NCT05993000|OTHER|Exercises|The combined utilization of exercises targeting the glenohumeral (GH) joint, scapulothoracic (ST) region, and stretching has demonstrated significant effectiveness in ameliorating range of motion and alleviating pain during the treatment of Frozen Shoulder (FS). These exercises were closely supervised and administered by the physiotherapist in each session. Furthermore, a home exercise program was provided to the patients, consisting of exercises for posture, thera band, and finger ladder. They were instructed to perform 10-15 repetitions of these exercises twice a day independently.
41325788|NCT05993000|OTHER|Hotpack|Each group of patients received a 20-minute hot pack application to the scapula and shoulder circumference.
41325789|NCT03375138|DRUG|belatacept|Specified dose on specified days
41325790|NCT05831345|DRUG|Methadone Hydrochloride|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
41009463|NCT05351203|PROCEDURE|caudal block|". Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound,. Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
41009464|NCT05351203|PROCEDURE|Erector spinae block|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
41009465|NCT04318002|BIOLOGICAL|RH5.1/Matrix-M|3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)
41009466|NCT04545515|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
41009467|NCT04545515|DRUG|IVA|Tablet for oral administration.
41009468|NCT04284696|DIETARY_SUPPLEMENT|Pregnan-C-Gum(R) chewing gum|"Using a chewing gum with 150mg vitamin C (per piece/gum) for 14 days ad libitum"
41009469|NCT04284696|DIETARY_SUPPLEMENT|Placebo chewing gum|"Using a chewing gum without vitamin C (per piece/gum) for 14 days ad libitum"
41154006|NCT04542109|BEHAVIORAL|READyR A|Two active sessions to conduct an individually-tailored dementia-related needs assessment, incorporating the participant's care values and objective data from remote in-home monitoring.
41325791|NCT05831345|DRUG|Sufentanil Citrate|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
41325792|NCT00321022|BEHAVIORAL|Accelerated Diagnostic Protocol Emergency Department Observational Unit|
41009470|NCT02816216|BEHAVIORAL|CampAir|An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
41154007|NCT04542109|BEHAVIORAL|READyR B|Active comparator. Two sessions to deliver general information about dementia-related care needs.
41325793|NCT03223493|OTHER|No treatment given|Completion of a questionnaire
41325794|NCT01788150|DEVICE|Coronary Stenting|
41325795|NCT06527859|DRUG|Levothyroxin|The disease group were divided into two groups ,25ugLT4 (HA group, n=17) and 50ugLT4 (HB group, n=17) respectively.
40808263|NCT03393936|BIOLOGICAL|CCT301-38|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
41325796|NCT01235728|DRUG|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
40808264|NCT03393936|BIOLOGICAL|CCT301-59|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
40808265|NCT06005428|DRUG|CRD-4730|Oral CRD-4730 in capsule form
40808266|NCT06005428|DRUG|Placebo|Placebo to match CRD-4730 in capsule form
41325797|NCT01235728|DRUG|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
41009471|NCT00263523|DRUG|[11C] (-)-RWAY|
41009472|NCT01108575|OTHER|IMST|inspiratory muscle strength training
41009473|NCT01108575|OTHER|Sham IMST|sham inspiratory muscle strength training
40808267|NCT04637776|OTHER|Hospitalization|Hospitalization for any reason
41009474|NCT04566328|DRUG|Bortezomib|Given SC
41009475|NCT04566328|BIOLOGICAL|Daratumumab and Hyaluronidase-fihj|Given SC
41009476|NCT04566328|DRUG|Dexamethasone|Given PO
41325798|NCT01235728|DRUG|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm\^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
41325799|NCT02712281|BEHAVIORAL|Autism MEAL Plan|"The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.~The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson."
41009477|NCT04566328|DRUG|Lenalidomide|Given PO
41009478|NCT04566328|OTHER|Quality-of-Life Assessment|Ancillary studies
41009479|NCT05949476|OTHER|ozone therapy|"Ozone in the gaseous state produced by a machine at concentrations for medical use (sssssssssss9) injected after anesthesia in the surgery site and in the post-extraction alveolus after suture.~* Topical ozone in the form of a gel (indicate the brand) to be applied to the post-surgical site 2 times a day for 7 days."
41009480|NCT00854503|DRUG|Simvastatin|20 mg/day in one oral administration
41009481|NCT00854503|DRUG|Rosuvastatin|20 mg/day in one oral administration.
41009482|NCT01743261|OTHER|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
41009483|NCT01743261|OTHER|usual care|"specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.~the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty"
41009484|NCT06388551|DRUG|LY03017|single dose, administered orally
41009485|NCT06388551|DRUG|LY03017-Placebo|single dose, administered orally
41009486|NCT01384058|DRUG|ezetimibe|ezetimibe 10 mg per day for six weeks
40808268|NCT06446596|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software a digital physiotherapy and telerehabilitation. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
40808269|NCT06446596|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
40808270|NCT05686317|DEVICE|Edwards APTURE transcatheter shunt system|Treatment with APTURE shunt
40808271|NCT05686317|DIAGNOSTIC_TEST|Sham procedure|CS angiography
41009487|NCT01384058|DRUG|simvastatin|Simvastatin 20 mg per day for six weeks
41009488|NCT01384058|DRUG|Ezetimibe 10/Simvastatin 20|Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
41009489|NCT06054048|OTHER|Telemedicine|"Web Real-Time Communication (WebRTC), which enables a peer-to-peer connectivity. Communication platform for all TCs was the software CompuGroup Medical Electronic Visit (CGM ELVI), which provides end-to-end encrypted video conferencing between physicians and their patients."
41009490|NCT02212730|DRUG|Pembrolizumab Pre-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles
41009491|NCT02212730|PROCEDURE|Surgical Resection|Standard of care surgical resection of RCC tumor
41009492|NCT02212730|DRUG|Pembrolizumab Post-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
41154008|NCT00464217|DRUG|ARA-C|
41325800|NCT02712281|BEHAVIORAL|Parent Education|"The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.~Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial."
40808272|NCT05359003|BEHAVIORAL|12-week physical activity program|Program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps). Includes weekly meetings with a trained health coach.
41154009|NCT00464217|DRUG|Idarubicin|
41009493|NCT00909636|DRUG|ABT-333|See arm description for more information
41009494|NCT00909636|DRUG|Placebo|See arm description for more information
41009495|NCT04709575|DRUG|REGN5713|Administered subcutaneously
41009496|NCT04709575|DRUG|REGN5714|Administered subcutaneously
40808274|NCT04069468|DEVICE|TheraSphere|Participants will receive treatment with TheraSphere in accordance with Instructions for Use
40808275|NCT06641323|OTHER|Ozonized gel|Administration of Ozonized Gel GeliO3
40808276|NCT06641323|DEVICE|Ozonized water|Admininstration of Gaseous ozone (Healozone X4)
41009497|NCT04709575|DRUG|REGN5715|Administered subcutaneously
41009498|NCT04709575|DRUG|Placebo|Placebo that replaces REGN5713-5714-5715
41009499|NCT01942941|DEVICE|geko™ electrical stimulation|applied to stimulate peroneal nerve and cause active muscle twitch
41009500|NCT00977067|DRUG|GDC-0152|Intravenous escalating dose
41009501|NCT03074903|DEVICE|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
41009502|NCT04444128|DIAGNOSTIC_TEST|Cardiac Imaging|Subjects undergo CMR study with contrast agent (gadobutrol 0.1 mmol/kg; mapping, volumes, function, strain and LGE); transthoracic echocardiography and blood testing.
41009503|NCT04582422|OTHER|"Touch Therapy"|During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation
41154010|NCT00464217|DRUG|Leucomax|
41154011|NCT00004662|DRUG|dehydroepiandrosterone|
41154012|NCT05374408|BEHAVIORAL|BBN for Trauma Informed Care|"Brief explanation of BBN will be provided. Patient will be directed to areas of the app that are congruent with treatment focus identified during their standard of care appointment.~Patient will complete by going online or being contacted by a member of the research team member. The research assistant will contact all the patients in 2-3 days to help the patient navigate the BBN and complete the baseline survey if needed.~The patient will continue to meet with their BHP as determined by the standard of care interactions. BHP will highlight features contained in BBN for patient to use in between appointments.~Follow-up phone calls will be scheduled for 2 week and 6 weeks after the initial visit. During these phone- calls the participant will be contacted by a member of the research team to complete follow-up surveys."
41154013|NCT03024593|BEHAVIORAL|Health- and illness-related internet use|
41325801|NCT05252923|DRUG|Sulodexide|Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
41325802|NCT01641991|BIOLOGICAL|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
41325803|NCT01641991|BIOLOGICAL|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
41325804|NCT03746067|DRUG|TS-134|5 mg, 10 mg, or 20 mg oral solution
41325805|NCT03746067|DRUG|Placebo|Matched Placebo oral solution
41479426|NCT04808882|DRUG|Tinzaparin,Therapeutic anticoagulation|"Participants randomized to the TA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: TA : 175 IU/kg/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: TA: 100 IU/kg/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
41325806|NCT01629979|PROCEDURE|Grafting with epidermal cells|"A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
41325807|NCT01629979|RADIATION|UVB treatment|the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
41325808|NCT06580730|PROCEDURE|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
41325809|NCT06580730|OTHER|Standard medical treatment|Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician.
41325810|NCT05953571|PROCEDURE|Dismembered Pyeloplasty|dismembered Anderson-Hynes repair was performed using 5/0 absorbable suture.
41325811|NCT00956215|DRUG|Aprepitant|80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery
41325812|NCT00956215|DRUG|Aprepitant placebo|80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
41325813|NCT02861053|OTHER|regular and moderate physical activity|regular and moderate physical activity will be done 3 times per week more than usual
41325814|NCT02861053|OTHER|No regular and moderate physical activity more than usual|regular and moderate physical activity will be done as usual
41325815|NCT05431569|DRUG|6MW3211|6MW3211 injection ,30mg/kg,iv drip，Q2W
41325816|NCT04796428|DRUG|Canagliflozin|Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.
40808277|NCT06643858|OTHER|No intervention|This study does not involve any interventions.
41325817|NCT04796428|DRUG|Dapagliflozin|"Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used."
41325818|NCT04796428|DRUG|Empagliflozin|"If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used."
41325819|NCT05608330|OTHER|PETRUSHKA tool|In the experimental arm, the PETRUSHKA tool will automatically select the antidepressants that have the best profile in terms of efficacy and acceptability for each individual participant (based on their baseline demographic and clinical characteristics) and then ask the participant to provide their preferences about common (and non-serious) adverse events. Based on patient's preferences and their individual characteristics, the PETRUSHKA tool will then identify the three best antidepressants for the participant. The clinician and the participant will be presented with an overall recommendation (in the format of a pictogram) showing how strongly each antidepressant is recommended for that individual patient. Via a shared decision-making process, the participant and the clinician will then agree on which antidepressant to choose from the shortlist.
41325820|NCT05608330|OTHER|Usual Care|Any antidepressant prescribed by clinician based upon their clinical judgement.
41154014|NCT01112371|DRUG|Contractubex|"Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.~Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in."
41154015|NCT04026074|DRUG|Fentanyl|Weight adapted drug application
41154016|NCT04026074|DRUG|Remifentanil|Weight adapted drug application
41479427|NCT02816502|BEHAVIORAL|Stress Management Skill Building Program A|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
41479428|NCT02816502|BEHAVIORAL|Stress Management Skill Building Program B|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
41479429|NCT01088919|DRUG|ASP1941|oral tablet
41009504|NCT05697900|DIETARY_SUPPLEMENT|Creatine Monohydrate|The CrM group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The CrM supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
41009505|NCT05697900|DIETARY_SUPPLEMENT|Placebo|A placebo group intakes five grams of maltodextrin daily throughout the study. The placebo supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
41009506|NCT05697900|DIETARY_SUPPLEMENT|Creatine Hydrochloride|The Cr-HCl group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The Cr-HCl supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
41009507|NCT04879745|OTHER|MyVoice:Rheum|Participants will be given access to MyVoice:Rheum, a web-based decision aid (DA).
41479430|NCT01088919|DRUG|pioglitazone hydrochloride|oral tablet
41479431|NCT00033813|DRUG|Oxatomide (tinset)|
41479432|NCT03041168|DEVICE|Carotid Stenotic Scan|Each subject will have been scheduled for a carotid ultrasound, or other imaging test of the neck (carotids) as ordered by his/her physician for clinical or screening purposes. These studies will be read by a Jefferson radiologist and a report generated for standard clinical purposes. These reports and the images will be collected and de-identified to be used as comparator measurements to the CSS results. The CSS device is shaped like a stethoscope with 3 small gel pads. It is positioned with a gel pad on either side of the neck and one on the front of the chest. The scan takes about 1-2 minutes to provide an image on the screen of the device cart. The scan device pads just lie on the skin and do not use any invasive techniques to provide the image.
41479433|NCT02269644|DRUG|Dalbavancin|dalbavancin 1500 mg IV over 30 minutes on Day 1
41479434|NCT02269644|DRUG|Linezolid|linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
41479435|NCT02269644|DRUG|Linezolid Placebo|Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
41479436|NCT02269644|DRUG|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
41479437|NCT00644384|DRUG|acitretin|
41009508|NCT04879745|OTHER|Pamphlet|Participants in this arm will be given a copy of an existing patient pamphlet
41009509|NCT04423042|BIOLOGICAL|Tocilizumab|Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors and has been shown to inhibit interleukin 6-mediated signalling.
41009510|NCT02489747|DIETARY_SUPPLEMENT|WBE|wheat bran extract (3 g/day)
41479438|NCT00644384|GENETIC|gene expression analysis|
41479439|NCT00644384|GENETIC|northern blotting|
41479440|NCT00644384|GENETIC|polymerase chain reaction|
41479441|NCT00644384|GENETIC|protein expression analysis|
41479442|NCT00644384|OTHER|laboratory biomarker analysis|
41479443|NCT00517959|RADIATION|Stereotactic Conformal radiotherapy|SCRT
41479444|NCT00517959|RADIATION|Conventional radiotherapy|
41479445|NCT02834806|DEVICE|BioNIR Ridaforolimus Eluting Coronary Stent System|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
41479446|NCT00609388|DRUG|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
41479447|NCT00609388|OTHER|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
41479448|NCT00204022|DRUG|Mycophenolate mofetil|Mycophenolate mofetil
41479449|NCT00204022|DRUG|Azathioprine|Azathioprine
41009511|NCT02489747|DIETARY_SUPPLEMENT|Placebo|Placebo
41479450|NCT02904668|OTHER|self-managmeent program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (...), which were complemented by a problem-based session.
41479451|NCT03018808|OTHER|Minimal questionnaire|The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
41009512|NCT01957475|DEVICE|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
41009513|NCT01957475|DEVICE|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
41009514|NCT00392613|PROCEDURE|Strict versus lenient rate control|
41009515|NCT03899610|DRUG|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"1. Neoadjuvant treatment:~   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~2. Interval debulking surgery~3. Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
41009516|NCT02148003|PROCEDURE|RFA at 90 degrees Celsius|Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius
41154017|NCT04026074|DRUG|Clonidine|Weight adapted drug application
41479452|NCT03018808|OTHER|Medical interview|Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
41479453|NCT03018808|OTHER|CAT|The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
41479454|NCT03018808|PROCEDURE|Blood test|Blood samples will be collected at indicated time points
41479455|NCT03018808|OTHER|anthropometric measures|Anthropologic measures will be performed.
41479456|NCT03018808|OTHER|Oximetry|Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
41325821|NCT03939611|OTHER|Foot Reflexology|Reflexology is one of the complementary health approaches; it is based on systematic pressure and stimulation with fingers to energy points in feet and hands and is a topic nowadays studied. Reflexology argues that the reflex maps in the hands and feet with all of the parts of the body are in contact. The pressure applied to each point stimulates the circulation of blood and energy like a sensor, gives a sense of relaxation, provides homeostasis. With a touch that is a different way of communication with children, is supported to create physical awareness via reflexology techniques, and is provided healthy nutrition of the stimulated tissue.
41154018|NCT04026074|DRUG|EMLA Cream|Salve application on the body part where the regional anaesthesia will be administered
40808281|NCT06110364|DEVICE|Low-Level Tragus Stimulation|Low-Level Tragus Stimulation via TENS unit will be monitored with a Holter.
40808282|NCT06110364|BEHAVIORAL|Heart Rate Variability- Biofeedback|Heart Rate Variability- Biofeedback will be monitored with a Holter.
41325822|NCT03939611|OTHER|Placebo Foot Reflexology|Placebo reflexology was performed by touch without pressure to the same rotation and to the same points as foot reflexology application. It was performed only to compare foot reflexology with a placebo effect.
40808283|NCT06110364|OTHER|Conventional Medical Therapy|Conventional Medical Therapy by Beta Blockers will be added to subjects usual care by their doctor if they are not already taking this medication.
40808284|NCT03383913|BEHAVIORAL|Heart Rate Variability Biofeedback|Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
40808285|NCT06520657|OTHER|Community Health Worker|Participants are screened for social determinants of health and work with a community health worker for three months to connect them with community and government services to address their family's needs.
40808286|NCT06520657|BEHAVIORAL|Child weight management intervention|This is a 12-week family-based behavioral group intervention to address childhood overweight and obesity.
41325823|NCT05099237|DEVICE|OURA Ring|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
40808287|NCT06520657|OTHER|Standard of Care referral to resources|One-time referral to resources based on need that families can access independently either by providing electronic referral to or providing written contact information for a community resource.
40808288|NCT06181435|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
40808289|NCT06181435|DRUG|Placebo|"Pharmaceutical form:~Injection solution Route of administration: SC injection"
41009517|NCT02148003|PROCEDURE|RFA at 80 degrees Celsius|Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius
41009518|NCT02148003|DEVICE|C-arm guided 20-gauge radiofrequency needle|Needles will be adjusted to optimize sensory and motor stimulation.
41009519|NCT03815422|PROCEDURE|Regional anesthesia|Short lasting sciatic nerve block and long lasting plantar block with distal deep peroneal block
41009520|NCT00003082|BIOLOGICAL|monoclonal antibody A27.15|
41009521|NCT00003082|BIOLOGICAL|monoclonal antibody E2.3|
41325824|NCT05099237|DEVICE|WithingsScan Watch|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
41325825|NCT05099237|DRUG|Isansys Patient Status Engine|Participants in cohort 3 will also be asked to wear Isansys monitoring devices whilst they are in hospital. They will begin to wear the monitors prior to CAR T-cell therapy and continue for 28 days post infusion. Participants will be asked to wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.
40808290|NCT06090864|DRUG|Chemotherapy|Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the ATLCAR.CD30.CCR4 cell infusion.
40808291|NCT06090864|BIOLOGICAL|Cell infusion|ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.
40808292|NCT05109429|BEHAVIORAL|Neutral Cue-induced Craving|For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
41009522|NCT04295889|DIAGNOSTIC_TEST|Approach A (PeeSpot urine collection device).|The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.
41009523|NCT04295889|DIAGNOSTIC_TEST|"Approach B (ACR | EU Test kit)."|"The participant will receive the ACR \| EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app."
41009524|NCT00355238|DRUG|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
41009525|NCT01150838|DRUG|propofol|Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
41154019|NCT04026074|DRUG|Placebo iv|i.v. administration of 0,9% NaCl
41154020|NCT04026074|DRUG|Placebo salve|Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
41479457|NCT06051383|OTHER|Self management|"patients will be assessed at base line using tool I,II Patients will receive self-management intervention in the form of sessions. Four to six patients in each session. Each session will last approximately 20 minutes~Session 1 :~* Introduction to the concept of self-management.~* Education/reassurance~* Managing fluid intake.~* Caffeine abstinence~* Alcohol advice~Session 2 :~* Adjusting medications~* Constipation advice.~* Strategies for dribbling. pelvic floor exercise.~* Double-voiding.~* Bladder re-training.~Session 3:~• Booster session All sessions are supported with a self-management booklet given in session. All patients will be reassessed after three months"
41479458|NCT00750646|DEVICE|MEMS cap|The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
41479459|NCT04588441|DRUG|Adenosine|Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days). Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer.
41479460|NCT04209010|PROCEDURE|one-stage technique|breast reconstruction in one stage using silicone implant and acellular dermal matrix.
41325826|NCT05099237|OTHER|Quality of Life Surveys|On a weekly basis participants will be asked to complete satisfaction surveys for the devices they are wearing (ring and watch) and report on their quality of life through standardised questionnaires. These surveys will be delivered electronically to participants via their smartphone or tablet device. There will be an option for participants to report adhoc symptoms via an app on their smartphone or tablet device.
41479461|NCT00134173|DRUG|torcetrapib/atorvastatin|
41479462|NCT00134173|DRUG|atorvastatin|
41479463|NCT00841906|DEVICE|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
41009526|NCT01574872|DEVICE|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
41325827|NCT05099237|DIAGNOSTIC_TEST|Blood Samples|"COHORT 3 ONLY~Participants in Cohort 3 only will be asked to provide a series of blood samples to measure inflammatory molecules during the study. These will be requested at various intervals during face-to-face visits and whilst the patient is in hospital:~* Baseline blood sample during study enrolment~* Post-lymphodepletion and prior to CAR T-cell infusion (this may be on day -1 or day 0 as needed)~* Post CAR T-cell infusion:~  * Day 1~ * Day 3~ * Day 6~ * Day 9~ * Day 14 (if the participant remains in hospital)~A sample of blood will be taken at baseline and a further sample post lymphodepletion and prior to CAR T-cell infusion. Post CAR T-cell infusion, samples will be taken at two timepoints (morning and afternoon) on each of the sampling days."
41325828|NCT05099237|OTHER|Daily Weights|"COHORT 3 ONLY~During their inpatient stay, up to a maximum of 28 days, participants in Cohort 3 will be supported to weigh themselves daily using a Withings Body Scale."
41479464|NCT00841906|DEVICE|Alice PDx with written and verbal instructions|Participants will be provided instruction by a trained sleep professional on the set up of the Alice PDx device. They will then be asked to follow the instructions for the Alice PDx device, if necessary, and undergo a sleep study in their home. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
41479465|NCT03250949|PROCEDURE|implant site over drilling protocol|"Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.~osteotomy site of the implant is wider by 0.2mm than the implant diameter"
41479466|NCT04624347|BEHAVIORAL|Access to video and movement curves|intervention of caregivers with access to videos and motion curves of the premature infant
41009527|NCT01574872|DEVICE|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
41009528|NCT06406205|DRUG|Voclosporin（QL1074）|QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.
41009529|NCT06406205|DRUG|Placebo|Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
41009530|NCT00956410|BIOLOGICAL|CAD106|
41479467|NCT03380533|DRUG|Buprenorphine|Buprenorphine 10mg transdermal patch used during the first five postoperative days after arthroscopic rotator cuff repair
41479468|NCT03380533|DRUG|Placebo Patch|Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
41479469|NCT03380533|DRUG|Multimodal Oral Scheme|Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
41479470|NCT03380533|DRUG|Tramadol|Tramadol 50mg tablet that the patient consumes every 8 hours during the first five days
40808293|NCT05109429|BEHAVIORAL|Visual Opioid Cue-induced Craving|For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).
41154021|NCT06585423|DIAGNOSTIC_TEST|Sterile commercially available bandage contact lens|Medical grade acrylic tip covered by a sterile commercially available bandage contact lens
41154022|NCT06585423|DIAGNOSTIC_TEST|Medical grade silicone of a thickness <100 µm|Medical grade acrylic tip coated with medical grade silicone of a thickness \<100 µm
41325829|NCT03129412|RADIATION|radical radiotherapy|radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.
41325830|NCT06445894|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossesous (FDI) muscle of the left motor cortex will be targeted using neuronavigation software.
41325831|NCT06445894|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
41325832|NCT03162393|PROCEDURE|nerve transfer|
41325833|NCT05351710|BEHAVIORAL|Exposure-Based Treatment for Perfectionism|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
41325834|NCT05351710|BEHAVIORAL|Stress Management|Videos focused on education about healthy habits and relaxation. Each session is approximately twenty minutes.
41325835|NCT03420443|DIETARY_SUPPLEMENT|Oat bran|45 g oat bran.
41325836|NCT03420443|DIETARY_SUPPLEMENT|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bra + probiotic bacteria.
41325837|NCT03420443|DIETARY_SUPPLEMENT|No oral supplementation|No oral supplementation.
41325838|NCT06303622|PROCEDURE|MRI-USG fusion approach|MRI-USG fusion approach prostate biopsy
41325839|NCT06303622|PROCEDURE|Cognitive-guided approach|Cognitive-guided approach prostate biopsy
41325840|NCT02151682|DRUG|Tapentadol prolonged release|
41325841|NCT02151682|DRUG|Morphine prolonged release|
41325842|NCT06040307|PROCEDURE|SPI (Surgical Pleth Index)|Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by SPI during general anesthesia in the experimental arm.
41325843|NCT03046160|OTHER|Manual therapy (Mobilization with movement)|grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
41325844|NCT03046160|OTHER|neck and scapular exercises.|A program of 12 neck and scapular exercises.
41325845|NCT03046160|OTHER|corrective tape|elastic tape used to correct the anterior tilt of the scapula
41325846|NCT00500838|DEVICE|Transthoracic Impedance|Impedance measures will be automatically collected via the device
41325847|NCT04269655|DEVICE|Cloud-Based Continuous Glucose Monitoring|The CGM data will be transmitted via bluetooth to a smartphone. The smartphone will automatically transmit values to a secure cloud-based platform, which then populates to the: (1) web-based, CGM data management tool for evaluation purposes (both groups), and (2) Digital Dashboard for monitoring and intervention (intervention only).
40808294|NCT05109429|BEHAVIORAL|Visual and Tactile Opioid Cue-induced Craving|For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.
41154023|NCT06585423|DIAGNOSTIC_TEST|Medical grade silicone of a thickness >100 µm|Medical grade acrylic tip coated with medical grade silicone of a thickness \>100 µm
41325848|NCT02483455|DRUG|2014-ALC-919-US|A topical solution to be applied twice daily for the treatment of Common Warts
41325849|NCT02483455|DRUG|Vehicle-Control Topical Solution|A topical solution to be applied twice daily for the treatment of Common Warts
41325850|NCT00646568|DRUG|s.c. human chorionic gonadotropin (Pregnyl)|S.C. Pregnyl 10000 IU once
41325851|NCT05567393|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
41325852|NCT05567393|DRUG|TAK-951|TAK-951 SC injection
41325853|NCT03479216|DRUG|Precedex|10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.
41009531|NCT05056168|OTHER|Dermatology-Specific Treatment Satisfaction Instrument|Study subjects will also be administered a dermatology-specific treatment satisfaction questionnaire, as well as other questionnaires including the generic validated Treatment Satisfaction Questionnaire for Medication (TSQM-9) and the validated Dermatology Life Quality Index (DLQI). Study participants will also self-report their disease severity using PGA. Depending on patients' preferred method of interacting with the study team, the investigators will collect their responses to these questionnaires either in-person, over the phone, or electronically via secure research platforms.
41154024|NCT05476978|DIAGNOSTIC_TEST|EUS-AI model|The test subset (approximately 20% of total patients) is reserved for the final evaluation of the EUS-AI model. Clinical parameters and EUS pictures of each patient in the test subset will be inputed into the trained EUS-AI model, and the most possible diagnosis will be given by the model.
41154025|NCT04968314|BEHAVIORAL|Chicago Parent Program|Chicago Parent Program (ChiPP) is a 12-session group-based parenting skills program
41325854|NCT03479216|DRUG|Magnesium Sulfate|10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
41479471|NCT03380533|DRUG|Placebo Tablet|Placebo tablet that the patient consumes every 8 hours during the first five days
41154026|NCT03512587|PROCEDURE|Personalized quantum sonotherapy|Quantum sonotherapy is an alternative non-pharmacological treatment that effects a molecular reorganization that occurs after the sound stimulus. The audible words and their waves have the ability to generate vibrations and stimulate the psycho-neuro-endocrine chain, independent of the semantic meaning of the words. It is an alternative therapy that uses non-musical sound waves.
41154027|NCT03512587|PROCEDURE|Placebo|Headphones will be place in patients without playing quantum sonotherapy
40808302|NCT05046067|PROCEDURE|Computed Tomography|Undergo CT
40808303|NCT05046067|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery per standard of care
41154028|NCT00130728|DRUG|bevacizumab|intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
40808305|NCT05923827|DEVICE|Omnipod 5 System|The Omnipod 5 system is a tubeless patch pump that receives glucose values and trend data from the glucose sensor every 5 minutes, automatically calculates insulin dose, and sends delivery commands to the Pod for the delivery of insulin.
40808306|NCT05783128|OTHER|Airway management techniques (exposure)|The exposure reffers to the different methods of airway management during general or regional anesthesia.
40808307|NCT03661307|DRUG|Decitabine|Given IV
40808308|NCT03661307|DRUG|Quizartinib|Given PO
40808309|NCT03661307|DRUG|Venetoclax|Given PO
40808310|NCT05926349|DRUG|Andexanet alfa|Andexanet is a recombinant version of human FXa
40808311|NCT05926349|DRUG|Usual Care|As per the label of the chosen usual care product(s) and/or usual care standards.
41154029|NCT00130728|DRUG|erlotinib HCl|oral erlotinib HCl 150 mg/day orally
41154030|NCT00130728|DRUG|placebo|intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
40808314|NCT04382586|DRUG|Zanubrutinib|320 mg (4 x 80 mg) capsules administered orally once daily
40808315|NCT04382586|DRUG|Supportive Care|Supportive care treatment was selected and administered as deemed appropriate by the study investigator
40808316|NCT04382586|DRUG|Placebo|Placebo to match zanubrutinib
41009532|NCT03676530|DEVICE|Pro-Tec Shin Splint Compression Wrap|EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
41009533|NCT02449356|DEVICE|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
41009534|NCT02594722|DEVICE|FES-cycling|Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
41154031|NCT02599376|DEVICE|LiDCOrapid|Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
41154032|NCT04712786|OTHER|pars plana vitrectomy|23 gauge pars plana vitrectomy was performed for retinal detachment, vitreous hemorrhage or epiretinal membrane
41009535|NCT02594722|DEVICE|Classic cycloergometer|Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
41479472|NCT04073628|DEVICE|Lighting Intervention|Lighting Intervention consisting of a cool or warm light source.
41479473|NCT02009748|DIETARY_SUPPLEMENT|Vitamin D supplementation|oral administration of colecalciferol 2.800 IU once daily
41479474|NCT02009748|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo (vehicle) once daily
41154033|NCT02567786|PROCEDURE|Surgery with CPB|
41009536|NCT05889858|OTHER|Data collection|Data collection
41009537|NCT05233878|OTHER|Characterization of a population with cervical paragangliomas|Characterization of a population with sporadic or genetically predisposed cervical paragangliomas in order to evaluate : the initial presentation of the PGL, patients management and patients outcome
41154034|NCT02567786|OTHER|Fresh Frozen Plasma|
41154035|NCT02567786|OTHER|Plasmalyte|
41154036|NCT00210288|BIOLOGICAL|SC599|
40808320|NCT06283394|BEHAVIORAL|Storefront Choice Architecture|An Instacart storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible)
40808321|NCT06283394|BEHAVIORAL|Fresh Funds|The treatment groups will each receive a $160 subsidy per month for 3 months to be used on produce through Instacart.
40808322|NCT06283394|BEHAVIORAL|Loss Framing|They will receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following end of the month).
40808323|NCT06450964|OTHER|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and the mitochondrial DNA mutation heterogeneity level was determined.|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and some granulosa cells, trophoderm cells, embryo culture fluid, embryo biopsy fluid, and embryo trophoblast cells were collected. Placenta and umbilical cord blood samples of some fetuses were collected after delivery, and the mitochondrial DNA mutation heterogeneity level was determined.
41154037|NCT05389254|DEVICE|continuous glucose monitoring system|use real-time CGM system to check and adjust blood glucose
41154038|NCT05389254|DEVICE|capillary blood glucose monitoring|monitor blood glucose with finger blood; real-time CGM is blind to both participants and researchers
41154039|NCT06194929|DRUG|Defactinib|Defactinib will be administered at 200 mg twice daily orally per arm description.
41154040|NCT06194929|DRUG|Avutometinib|Avutometinib will be administered at 3.2 mg twice a week orally per arm description.
41154041|NCT06194929|DRUG|Encorafenib|Encorafinib administered orally per arm description.
41154042|NCT06565221|DEVICE|Heat and negative pressure|Heat and negative pressure applied to the feet
41154043|NCT01594697|DRUG|Metformin|
41154044|NCT02511171|OTHER|Cranial osteopathic manipulative therapy|
41154045|NCT01372202|DRUG|Paclitaxel|Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
41479475|NCT03138447|DEVICE|Basal Insulin Titration Application|"Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose."
41325855|NCT04286828|OTHER|Position Sense|Knee position sense was evaluated with a Acumar dual digital inclinometer. Each participant was asked to wear shorts and to lie down in supine position treatment table. The lower extremity of the participant was positioned in neutral for the knee flexion movement. The placement of the digital inclinometer's attachment was the lateral ridge of the femur and tibia. We actively assisted the participant's knee to the target angle and asked the participant to hold it there for 5 seconds before returning the knee to the starting position. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. This procedure was repeated 3 times for each limb (non-dominant and dominant). We measured the absolute difference between the target angle and the observed angle and calculated the absolute error score by averaging the 3 trials.
41325856|NCT04286828|OTHER|Balance|"To measure postural stability and Limits of Stability this study used a balance device, the Biodex Balance System.~Postural Stability: The participants were focused on a characteristic dot (COP, centre of pressure) on the monitor screen. The participant's task was to balance the body in such a way that the dot was in the centre of a circle displayed on the monitor at the point of intersection of the coordinate axes. Test consisted of three 20-second trials, each separated by 10-second breaks. Measurements were repeated three times while their eyes were open/close and analyzed by calculating the average value of measurements.~Limits of Stability: The participants are asked to complete the directional tasks displayed on a screen as quickly as possible, with the directions displayed at random. A total of 3 tests were performed, at intervals of 10 s."
41325857|NCT04286828|OTHER|Dual Task Performance|"The timed up and go test (TUG) was used in the evaluation of dual task performance. For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. TUG test was performed initially without task, and then with cognitive and motor tasks, respectively. Cognitive task given during the test is counting three backwards from 100 or counting the names starting with the letter A, and motor task given is to carry three glasses of water on a tray. The time elapses between standing up from the chair and sitting back to chair was recorded as the test result. As time increases, dual task performance decreases."
41325858|NCT04572763|DRUG|Copanlisib|Intravenous infusion
41325859|NCT04572763|DRUG|Venetoclax|Tablet taken orally
41325860|NCT03307863|DRUG|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
41325861|NCT03307863|DRUG|Topiramate-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
41325862|NCT03307863|DRUG|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
41325863|NCT06368791|BEHAVIORAL|Box Breathing|Participants are guided to find a quite and comfortable spot to sit and unwind. They are then directed to inhale deeply for four seconds, hold that breath for another four seconds, and then exhale slowly over four seconds. Following a brief four-second pause, they begin the next cycle of breathing. To assist with this exercise, participants will have access to a video featuring a red dot tracing a square pattern, moving at the pace needed for the breathing technique.
41479476|NCT04132401|DIAGNOSTIC_TEST|algorithm|The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
41479477|NCT03394755|BIOLOGICAL|Thrombosomes|Freeze-dried platelets
41479478|NCT04740931|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
41479479|NCT04740931|DRUG|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
41479480|NCT04740931|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
41479481|NCT04706923|DRUG|BCV|Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.
41479482|NCT01974024|DRUG|methylprednisolone|Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).
40808324|NCT04532294|DRUG|BGB DXP593|Administered intravenously (IV) as specified in the treatment arm
41325864|NCT06368791|BEHAVIORAL|Breathing and Mindfulness Exercise|The second intervention involves a 10-minute session of guided breathing exercises that blend elements of mindfulness meditation with gentle body movements and controlled breathing. Participants are advised to find a quiet space, sit comfortably, and adopt an upright posture. They are then led through a series of brief exercises, incorporating mild stretches for the upper body and focused, mindful breathing.
41479483|NCT01936519|DRUG|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
41479484|NCT01936519|DRUG|Calcineurin Inhibitor|Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
41479485|NCT01176643|OTHER|Standard care plus Yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
40808325|NCT04532294|DRUG|Placebo|Placebo to match BGB-DXP593
41154046|NCT01372202|DRUG|Cisplatin|"Paclitaxel and cisplatin:~* Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~* Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~* Cisplatin 75 mg/m² days 1, 29."
40808327|NCT04150939|PROCEDURE|Core Biopsy|Undergo core biospy
40808328|NCT04150939|PROCEDURE|Cryosurgery|Undergo cryoablation
41154047|NCT01372202|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 days 1, 15, 29.
40808329|NCT04150939|DRUG|Immunotherapeutic Agent|Receive standard of care immunotherapy
41009538|NCT00129233|DRUG|Valsartan|valsartan 80 to 160 mg daily
41009539|NCT00129233|DRUG|Amlodipine|Amlodipine 5 to 10 mg daily.
41009540|NCT04452188|OTHER|Normoxia (with controlled re-oxygenation)|"Participants will receive lower levels of oxygen during surgery and after surgery on the ventilator.~As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation with an FiO2 of 50% or less (unless clinically necessary) to achieve oxygen saturation and PaO2 goals that fit within the expected range for the participant's physiology:~1. Single ventricle patients (PaO2:35-45 and oxygen saturation 75%-85%)~2. Two ventricle patients (PaO2: 60-100 and oxygen saturation \>92%)"
41009541|NCT04452188|OTHER|Standard of care ventilation|As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation per standard protocols. Ventilation will be continued in the ICU and adjusted per standard goals per the intensivist.
41325865|NCT06368791|BEHAVIORAL|Everyday life control|Participants are instructed to not perform the anti-stress intervention and to proceed with their daily activities as usual.
41325866|NCT04915326|PROCEDURE|rectal resection|every patients will undergo to the appropriate rectal resection
41325867|NCT00516412|DRUG|everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
41325868|NCT00516412|GENETIC|molecular response by PCR|Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
41154048|NCT01372202|DRUG|5-Fluorouracil|"Oxaliplatin and 5-fluorouracil:~* Oxaliplatin 85 mg/m2 days 1, 15, 29.~* 5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~* Cisplatin 75 mg/m² days 1, 29."
41325869|NCT04137419|DIETARY_SUPPLEMENT|Probiotic lozenges|Probiotic strains
41325870|NCT04137419|OTHER|Placebo|Similar to ProlacSan lozenges in taste in colour
41325871|NCT06355401|DRUG|Tamoxifen 20mg|maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT
41325872|NCT04559087|PROCEDURE|Laparoscopic Surgery|"NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall."
41154049|NCT01372202|RADIATION|Radiotherapy|Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
41325873|NCT01225757|DEVICE|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
40808332|NCT04276493|BIOLOGICAL|ZW25|Administered as specified in the treatment arm
41325874|NCT02690324|BEHAVIORAL|cognitive stress (serial 7)|
41325875|NCT06100549|OTHER|No intervention|No intervention will be provided.
41325876|NCT06196918|DRUG|Rivaroxaban 10 MG|Patients with postoperative lower extremity dyskinesia are treated with rivaroxaban (10 mg/day) and compression stockings until 1 month after surgery.
41325877|NCT06196918|DRUG|Placebo|Patients with postoperative lower extremity dyskinesia are treated with placebo (10 mg/day) and compression stockings until 1 month after surgery.
41325878|NCT01747811|DEVICE|wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
41325879|NCT01747811|DEVICE|wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
41325880|NCT01664858|OTHER|3T CMR|3Tesla Cardiac Magnetic Resonance Imaging
41325881|NCT01664858|OTHER|SPECT|SPECT: Single Photon Emission Computed Tomography
41325882|NCT01664858|OTHER|CT calcium score|CT calcium score
41325883|NCT01664858|OTHER|CT coronary angiography|CT coronary angiography
41325884|NCT01664858|OTHER|X-Ray coronary angiography|X-Ray coronary angiography
41325885|NCT00214487|DEVICE|Bifocal Contact Lenses|Use of bifocal contact lenses of varying add powers to control the progression of myopia
41325886|NCT00214487|DEVICE|Placebo Control|Single vision soft contact lenses
41325887|NCT03289871|DEVICE|Excilor|
40808333|NCT04276493|DRUG|Docetaxel|Administered as specified in the treatment arm
40808334|NCT04276493|BIOLOGICAL|Tislelizumab|Administered as specified in the treatment arm
40808335|NCT04276493|DRUG|Capecitabine|Administered as specified in the treatment arm
40808336|NCT04276493|DRUG|Oxaliplatin|Administered as specified in the treatment arm
40808337|NCT04827901|DRUG|XEN1101|two 10 mg capsules
40808338|NCT04827901|DRUG|Placebo|matching placebo
41325888|NCT03289871|DRUG|Loceryl 5%|
41479486|NCT04568031|DRUG|AZD1222|For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2
41325889|NCT01429610|DRUG|Rituximab+mVPDL|"1. Induction:~   * Dauno 90 mg/m2/d by civ (d1-3)~  * Vinc 2 mg iv (d1, 8)~  * Pred 60 mg/m2/d po (d1-14)~  * for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)~  * Rituximab 375mg/m2/d (d8)~2. Consolidation A (cycle1)~   * D 45 mg/m2/day by continuous iv (d1, 2)~  * V 2 mg iv (d1, 8)~  * P 60 mg/m2/day po (d1-14)~  * for Ph(-): L-asp (d1-14) for Ph(+): Imatinib~  * Rituximab 375mg/m2/d (d8)~3. Consolidation B (cycles2\&4)~   * Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)~  * Eto 150 mg/m2/d iv over 3 hr (d1-4)~  * Rituximab 375mg/m2/d d8~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)~  * Leucovorin 50 mg/m2 iv every 6hr for 3 doses,~  * Rituximab 375mg/m2/d (d8\&22)~5. Maintenance (for 2 years)~   - for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd~6. Consider alloHCT"
41325890|NCT03002103|DRUG|EndoTAG-1|
41325891|NCT03002103|DRUG|Paclitaxel|
41325892|NCT03002103|DRUG|Gemcitabine Hydrochloride|
41325893|NCT04991272|OTHER|prewarming and warmed fluid infusion|prewarming with forced air warming system and warmed fluid infusion.
41325894|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
41325895|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
41325896|NCT00597909|DRUG|placebo solution (10% dextrose)|Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
41325897|NCT01183312|DRUG|Flumazenil|Sublingual flumazenil
41325898|NCT03515018|DRUG|hydroxyurea|pulse therapy
41325899|NCT03515018|DRUG|Imatinib|400mg qd PO per day
41325900|NCT00131677|DRUG|tenofovir disoproxil fumarate|study product taken daily
41479487|NCT04568031|DRUG|0.9% (w/v) saline|For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.
41479488|NCT03185234|DEVICE|anodal tDCS|2 mA, 10 min, 5 sessions
41479489|NCT03185234|DEVICE|sham tDCS|sham stimulation, 10 min, 5 sessions
40808339|NCT05705531|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
40808340|NCT05705531|OTHER|Electronic Health Record Review|Undergo medical record abstraction
40808341|NCT05705531|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40808342|NCT05705531|OTHER|Survey Administration|Complete surveys
41154050|NCT01372202|PROCEDURE|Esophagectomy|The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).
41325901|NCT00131677|DRUG|placebo|study product taken daily
41325902|NCT04219969|DRUG|Fludeoxyglucose F-18|Given IV
40808345|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m\^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
40808346|NCT03281369|DRUG|Leucovorin|Leucovorin: 100 mg/m\^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
40808347|NCT03281369|DRUG|Oxaliplatin|Oxaliplatin: 100 mg/m\^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
40808348|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
40808349|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
40808350|NCT03281369|BIOLOGICAL|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
40808351|NCT03281369|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
40808352|NCT03281369|BIOLOGICAL|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
41325903|NCT04219969|DEVICE|Magnetic Resonance Imaging|Undergo PET-MRI
41325904|NCT04219969|PROCEDURE|Positron Emission Tomography|Undergo PET-MRI
41325905|NCT01017341|DEVICE|PSU hip protector|hip protetor
41325906|NCT00388258|DRUG|Alvimopan|
41325907|NCT05905757|PROCEDURE|Dexmedetomidin + bupivacaine|dexmedetomidine was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
41325908|NCT05905757|DRUG|Tramadol + Bupivacaine|tramadol was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
41325909|NCT06364761|PROCEDURE|Bag in the lens cataract surgery|Cataract surgery using the Morcher 89A intraocular lens
41479490|NCT05624827|DIAGNOSTIC_TEST|Testing DNA methylation test for predicting prognosis of untreated CIN 2|After being diagnosed with CIN 2, patients will first be contacted by telephone and invited to participate in the study. If patients agree to participate in the research, they will sign a consent to participate in the research. After that, we will perform a colposcopy and take a cervical swab for analysis with the QIAsure Methylation Test Kit (Qiagen, Gaithersburg, USA), which will determine the methylation of tumor suppressor genes FAM19A4 and has-mir-124. Patients will complete a questionnaire. The total duration of tracking in both groups will be two years. The QIAsure Methylation Test will be performed to analyze methylation. It is a methylation-specific PCR test that detects hypermethylation of the tumor promoter suppressor genes FAM19A4 and has-mir-124. The samples on which we will use this test are bisulfite-converted DNA obtained by triage test for high-risk HPV - Hybrid Capture 2 HPV DNA Test (hc2, Qiagen, Gaithersburg, USA).
41479491|NCT01915719|PROCEDURE|Early non invasive ventilation|
41479492|NCT01915719|PROCEDURE|Oxygen therapy only|
41479493|NCT00650442|DRUG|Estradiol Transdermal System Placebo - Alternate Adhesive|single application
41479494|NCT00650442|DRUG|Estradiol Transdermal System Placebo - Current Adhesive|single application
41325910|NCT06206902|DRUG|After preconditioning with chemotherapy, F01 will be evaluated.|Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)
41325911|NCT03779633|DRUG|Linoladiol Estradiol|"Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
41325912|NCT03779633|OTHER|Placebo vaginal cream|"Initial dose (week 1): 1 application every day for the first week Maintenance dose 1 (week 2) : 1 application every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
41325913|NCT00903370|PROCEDURE|MVS|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
41325914|NCT00903370|DEVICE|Ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
41325915|NCT04771026|DRUG|Dexamethasone|Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
41325916|NCT00003129|DRUG|valrubicin|
41325917|NCT03751423|DRUG|PO Morphine|10-20mg oral morphine depending on such factors as weight (100-200mcg/kg), previous opiate exposure (opiate naïve vs opiate sensitized), and participant's previous experiences with opiate medications for painful procedures. Dosing will be determined at the discretion of the surgical provider in clinic that day, as per standard of care.
41325918|NCT03751423|DRUG|IV Fentanyl|0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.
41479495|NCT03605251|DRUG|TAS5315 low dose|Oral administration for 12 or 36 weeks
41325919|NCT03751423|DRUG|IV Ketamine|200-500mcg/kg IV over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached
41325920|NCT03751423|DRUG|PO Placebo|A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
41325921|NCT03751423|DRUG|IV Placebo|This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
41479496|NCT03605251|DRUG|TAS5315 high dose|Oral administration for 12 or 36 weeks
41479497|NCT03605251|DRUG|Placebos|Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)
40808353|NCT03281369|DRUG|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
41325922|NCT04218604|PROCEDURE|Personalized atrial fibrillation ablation|Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)
41325923|NCT01162304|DRUG|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
40808354|NCT03281369|DRUG|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
40808355|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
41325924|NCT01162304|DRUG|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
41479498|NCT05007184|BEHAVIORAL|Chilean Warning Labels|These labels were implemented in Chile in 2016. They are shown on those less-healthy food and beverage products that do not fall within thresholds that are defined for the following nutrients: sugar, sodium, calories and saturated fats. The original labels are in Spanish but the ones that we displayed were in Arabic.
41479499|NCT05007184|BEHAVIORAL|Nutri-Score Labels|These labels were implemented by the French government in 2017. They are shown on all food and beverage products and range from A to E with the corresponding colours moving from Green to Red (symbolizing best to worst). The scores and grades are calculated based on 7 different nutrients grouped into 2 categories i.e. nutrients to consume (such as fibre) and nutrients to avoid (such as sugar). We modified the labels by adding % sugar per serving on the right side of the labels.
41325925|NCT03855033|BEHAVIORAL|Media Aware Sexual Health - High School|Media Aware Sexual Health is a web-based comprehensive sexual health education program for high school students that uses a media literacy approach.
41325926|NCT01186003|DRUG|Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
41325927|NCT06240494|PROCEDURE|Maxillary nerve and mandibular nerve pulsed radiofrequency|"For maxillary nerve pulsed radiofrequency, the lineer transducer is placed distal and parallel to the zygomatic arch, bridging the coronoid and condylar processes and a 22 gauge 6 mm RF cannula was inserted into the target area. With sensory stimulation, patients experienced a distinct sensation in upper jaw, teeth, and palate. Then, PRF treatment was performed at 42 °C for 240 seconds.~For mandibular nerve pulsed radiofrequency, the transducer was placed distally and parallel to the zygomatic arch, bridging the coronoid and condylar processes. The pterygopalatine fossa was visualized and the needle was inserted to target area. With sensory stimulation, patients experienced a distinct sensation in the lower jaw and teeth. With motor stimulation, a throwing movement of the jaw was observed with contraction of the masseter and temporal muscles. PRF treatment was performed at 42 °C for 240 s."
41325928|NCT02877667|DEVICE|planar acoustic wave device|accessory to laser treatment
41325929|NCT05632029|DEVICE|active laser|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
41479500|NCT01914172|OTHER|online questionairres|see group descriptions
41479501|NCT02114957|DIETARY_SUPPLEMENT|800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0|
41479502|NCT02306057|PROCEDURE|Pre BCPC|Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection
41479503|NCT02306057|PROCEDURE|Pre TCPC|Routine catheterization before surgical procedure Total CavoPulmonary Connection
41479504|NCT02306057|PROCEDURE|BCPC surgery|Surgical procedure Bidirectional CavoPulmonary Connection
41479505|NCT02306057|PROCEDURE|TCPC|Surgical procedure Total CavoPulmonary Connection
41479506|NCT03363399|DIAGNOSTIC_TEST|Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection. The samples will be stored at 4°C overnight.~Blood samples containing at least 105 neutrophils will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8-color flow cytometer and analyzed using Becton Dickinson (BD) Fluorescence-activated cell sorting (FACS) Diva Software version 6. Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
41325930|NCT05632029|DEVICE|sham laser|32 lupus prediabetic women will receive laser acupuncture (sham laser, i.e power of device will be zero watt) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
41479507|NCT01568866|DRUG|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
40808356|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
40808357|NCT03281369|DRUG|Cisplatin|Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
40808358|NCT03281369|DRUG|Tiragolumab|Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.
41325931|NCT05463159|OTHER|Transcutaneous electrical nerve stimulation|All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
41325932|NCT03067194|DRUG|Celecoxib 100 MG|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
41479508|NCT01568866|DRUG|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
41479509|NCT01568866|DRUG|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
41479510|NCT05824117|OTHER|Individual Placement and Support (IPS)|"IPS is an evidence-based practice for helping people with severe mental illness to gain and maintain competitive employment or/and mainstream education with nine well defined key principles that can be reliably assessed by the IPS Fidelity Scale for Young Adults.~Interventions range from engagement techniques (i.e. motivational interviewing) to individualized education/employment searches and from experience-based educational/employment assessment to benefits in counseling/work incentives planning."
40808359|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
41154051|NCT04946097|OTHER|gross Myofascial Release|Gross Myofascial Release : is amanual technique in form of Stretch of the Posterior Cervical Musculature and Gross stretch of gross Myofascial Release upper quarter: Arm Pull for duration of 10-15 min per session each stretch position was healed for 90sec
41325933|NCT03067194|DRUG|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
41325934|NCT05904691|DRUG|OCU-10-C-110 for Injection|OCU-10-C-110 for Injection in one of 3 doses
41325935|NCT06526806|OTHER|Kahoot game strategy|"Students in the experimental group will be informed about the Kahoot game strategy. 1-7 and 9-15. After the end of each lesson in the following weeks (except the midterm exam week in the eighth week), students will play the Kahoot game consisting of a total of five questions for approximately 10 minutes in the classroom. The first five minutes will be planned as answering the questions, and the other five minutes will be planned as evaluating the results. Students' answers and score calculations will be automatically recorded in the system, allowing them to see correct and incorrect answers, and learning deficiencies will be identified. Measurements will be made with data collection tools in the first week, ninth (after the midterm exam) and eighteenth weeks (after the final exam) of the course."
41154052|NCT04946097|OTHER|conventional selected exercise program|stretching exercises for cervical muscles and pectoralis major and source of heat in form of hot packs for 15 minutes
41009542|NCT01259661|OTHER|A longitudinal intervention|In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
41325936|NCT03820726|DRUG|Nintedanib|Bid
41325937|NCT03917225|DRUG|MIN-102|Once-daily dosing with a volume specified by the pharmacokinetic specialist to achieve the desired plasma exposure. MIN-102 oral suspension, strength 15 mg/ml.
41325938|NCT03917225|DRUG|Placebo|Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.
41325939|NCT01351064|OTHER|CHICA ADHD Module|This module was added to CHICA to help diagnose and manage ADHD
41325940|NCT06051825|DIAGNOSTIC_TEST|Blood specimen collection for C-reactive protein (CRP) and WBC (white blood cells). Saliva specimen collection for analysis of CRP levels|Blood analysis of CRP and WBC levels Saliva analysis of CRP levels
41325941|NCT05630898|DIAGNOSTIC_TEST|CMV PCR|Saliva CMV PCR
41009543|NCT05829603|DRUG|Dimethyltryptamin (DMT) & Harmine|Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
41009544|NCT03218722|DRUG|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
41009545|NCT03218722|DRUG|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
41009546|NCT06224829|PROCEDURE|Pain Inducing Massage|60 seconds of direct pressure to the neck resulting in 5/10 pain . This will be repeated four times for a total of 240 seconds
41154053|NCT04946097|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of electrical current, the electrode placement on the course of pain for 15 minutes
41325942|NCT04178577|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
41325943|NCT02709772|BEHAVIORAL|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
41325944|NCT06093945|DRUG|SHR2554 tablet dosing|SHR2554 350mg taken on Day 1 and Day 10
41325945|NCT06093945|DRUG|Omeprazole tablet dosing|Omeprazole taken from Days 5 to Day 10
41325946|NCT05247541|DRUG|Definity|Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
41325947|NCT04443842|BEHAVIORAL|Financial and social incentives|"Participants will be credited with HK$1000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, participants will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.~The social incentives are peer comparison and social support. Participants receive feedback of their physical activity performance by assessing whether they met or exceeded their step count target, followed by positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support."
41154054|NCT02382913|BIOLOGICAL|aP booster|"Acellular pertussis vaccine:~Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine."
41325948|NCT05102513|PROCEDURE|Unilateral Cleft Lip Repair: Hybrid Technique|The rotation flap of the Millard II technique was expanded by extending the incision into the columella - similar to the well-known Mohler technique. The caudal part of the advancement flap of the Millard II technique was lengthened by a wave cut as known from the Pfeiffer procedure. For the vermillion a Noordhoff plasty is applied.
41154055|NCT02382913|BIOLOGICAL|TdaP booster|"Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
41325949|NCT05102513|PROCEDURE|Unilateral Cleft Lip Repair: Millard 2 Technique|A curved incision is marked skirting the philtral ridge. If more length is required a back-cut incision can be performed. The C-flap is outlined by the incision just marked and the incision along red-white border up to the base of the columella. On the cleft side an advancement flap is designed. For the vermillion a Noordhoff plasty is applied.
41325950|NCT03107598|DRUG|colloid preload|coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
41325951|NCT01103778|DRUG|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
41325952|NCT02467829|DEVICE|Increase in handle height|Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.
41325953|NCT04265898|DEVICE|The Digital Virginia Tech Carilion Cognitive Examination|Completion of a newly developed digital cognitive screen
41325954|NCT03272217|DRUG|Atezolizumab|Atezolizumab 1200 mg (flat dose) IV every 21 days
41325955|NCT03272217|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
41479511|NCT01474902|DRUG|Enoxaparin|Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
41479512|NCT06030349|DEVICE|Non-invasive ventilation|Non-invasive ventilation
41479513|NCT05732896|DEVICE|Nociception Leve Indeks|During TIVA-TCI, propofol (Schnider) effect site concentration (Ce) was titrated to BIS score between 40-60 and remifentanil (Minto) Ce to standard hemodynamic parameters in the control group and NOL index value between 10-25 in the study group.
41479514|NCT04403217|OTHER|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
41479515|NCT00695435|DRUG|TOBRADEX Ophthalmic Suspension|TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
41479516|NCT00695435|DRUG|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
41479517|NCT00695435|DRUG|TOBREX Ophthalmic Solution|TOBREX Ophthalmic Solution 1 drop each eye at baseline
41325956|NCT00936299|DRUG|Bupropion|Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy
41325957|NCT00936299|OTHER|Placebo|
41325958|NCT06418776|OTHER|Intensive therapy|Intensive chemotherapy courses (MEC, FLAG, FLAG-Ida, FLAG-Mito)
41479518|NCT02799238|BIOLOGICAL|ALECSAT|3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
41325959|NCT06418776|OTHER|Low intensity therapy|Low intensity therapy (Aza+Ven, Dac+Ven, LDARA-C+Ven)
41325960|NCT06530121|BEHAVIORAL|Toolbox trainings|Training given with a single page material, lasting between 10-15 minutes, aimed at on-the-job application.
41325961|NCT02251678|DIETARY_SUPPLEMENT|Elimune Capsules|2 capsules BID for 28 days
41325962|NCT03258463|OTHER|Change in Texas Law|The change in Texan laws occurring from July 2013-January 2014
41479519|NCT02799238|RADIATION|Radiotherapy|Radiotherapy 5 days/week for 6 weeks
41479520|NCT02799238|DRUG|Temozolomide|Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
41479521|NCT03704402|OTHER|Alcohol policy|Introduction of new mutual alcohol policy
41479522|NCT03664895|DRUG|Leuplin or zoladex|OFS(Leuplin or zoladex) add on to TMX
41479523|NCT02265172|PROCEDURE|Physiotherapy screening|Physiotherapy screening.
41479524|NCT02265172|PROCEDURE|Standard practice|Orthopaedic surgeon assessment
41479525|NCT04486755|RADIATION|Hypofractionated Radiation Therapy|All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.
41479526|NCT05160753|PROCEDURE|Laparoscopic gastric function preserving surgery combined with resection of the anterior lymphatic drainage area|A 4mL volume of double tracer is injected into the submucosa of the four quadrants of the primary tumor by intraoperative gastroscopic method., and 15 minutes after gastroscopic tracer injection, the green anterior lymph nodes were carefully dissected and removed from the surgical area and evaluated for lymph node metastasis by parallel intraoperative freezing.If all collected anterior lymph nodes are negative, laparoscopic gastric function preserving surgery will be performed.
41479527|NCT03117751|DRUG|Prednisone|Given orally (PO).
41479528|NCT03117751|DRUG|Vincristine|Given intravenously (IV).
41154056|NCT02382913|BIOLOGICAL|Licensed TdaP booster (Boostrix®)|"Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
41325963|NCT02539303|DRUG|Yamani-15/5 chemical solution|A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
41009547|NCT06224829|PROCEDURE|Pain Free Massage|60 seconds of direct pressure to the neck resulting in 0/10 pain . This will be repeated four times for a total of 240 seconds
41325964|NCT03923439|DEVICE|Multi-b diffusion sequence MRI|Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
41325965|NCT04324788|OTHER|Group 1|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
41325966|NCT04324788|OTHER|Group 2|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
41325967|NCT02527148|DEVICE|OtisMed® ShapeMatch® Technology|The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology
41479529|NCT03117751|DRUG|Daunorubicin|Given IV.
41479530|NCT03117751|DRUG|Pegaspargase|Given IV or intramuscularly (IM) .
40808363|NCT04530110|DRUG|Fremanezumab|"Participants weighing ≥ threshold will receive Dose A subcutaneously monthly.~Participants weighing \< threshold will receive Dose B subcutaneously monthly.~Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months."
41154057|NCT05595369|DRUG|Experimental: Paxlovid 25 day dosing|Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)
41154058|NCT05595369|DRUG|Experimental: Paxlovid 15 day dosing|Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)
41154059|NCT05595369|DRUG|Placebo Comparator: Control|Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
41154060|NCT03600090|BIOLOGICAL|EOC202|EOC202 will be SC injection.
41154061|NCT03600090|DRUG|Paclitaxel|Paclitaxol will be IV injection
41154062|NCT05130502|OTHER|Foam roller|The investigators use Foam roller to 3 muscle groups per leg then conduct a dynamic warm up program and conduct performance tests
41154063|NCT05130502|OTHER|Kinesiotape|The investigators use Kinesiotape to 3 muscle groups per leg, wait 45 minutes for bring out the effects then conduct a dynamic warm up program and conduct performance tests
41154064|NCT01818245|DRUG|LY2605541|
41154065|NCT05552014|BEHAVIORAL|Natural Psychotherapy|"Natural psychotherapy is based on Morita therapy and is a psychotherapy that fully reflects the characteristics of Chinese culture, taking into account the Chinese cultural background and actual clinical characteristics."
41154066|NCT05552014|BEHAVIORAL|Mental Health Education|Mental Health Education Seminar
41479531|NCT03117751|DRUG|Erwinase®|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
41154067|NCT05578976|DRUG|Epcoritamab|Subcutaneous Injection (SC)
40808375|NCT04507828|RADIATION|Treatment Planning using the DIBH Technique|Different radiation plans will be generated-one using a DIBH scan with corresponding target and normal tissue contour and a second using an expiration scan with corresponding target and normal tissue contours. The expiration scan can be an expiratory gating scan averaging the expiratory breathing phases or an expiration breath hold scan as determined based on patient performance during simulation and relative tumor displacement compared to the DIBH scan. Then a third plan will be generated conceptually combining the two previous plans, named the DIBH-expiration composite plan.
41009548|NCT06224829|PROCEDURE|Cold Water Bath|Participants will place their hand in a cold water bath maintained at 6 to 8 degrees Celsius for 60 seconds. This will be repeated four times for a total of 240 seconds.
41009549|NCT02755831|DEVICE|CPAP|Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea
41009550|NCT02755831|OTHER|Pre-natal care|Standard Pre-Natal Care
41009551|NCT03912233|DRUG|VX-121|Tablets for oral administration.
40808376|NCT05215665|DRUG|GEMOX Regimen|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
40808377|NCT05215665|DRUG|Lenvatinib|8/12mg PO QD continuously
40808378|NCT05215665|DRUG|Toripalimab|240mg IV d1 Q3W
40808379|NCT05958017|BEHAVIORAL|reSET|Participants in this group will use a mobile application that delivers treatment for substance use disorder. 31 required and 30 optional modules. Among many topics covered in the modules, some are substance use management, communication, emotion management, relationship skills, HIV/Sexually Transmitted Infections and triggers for risky sex. In the reSET app you will get the chance to earn rewards for two activities: (1) completing a module and (2) providing a negative urine drug screen in exchange for a motivational or monetary prize. You will have 12 weeks to complete as many modules as you like, about 4 modules per week. Each module takes approximately 10-15 min. Every 3-4 days you will meet with the same study team member to provide a urine drug screen from a place comfortable for you (e.g. home) which will be observed and read via Zoom.
40808380|NCT05958017|OTHER|Standard of care|Participants in this group will receive assistance connecting to an in person community-based outpatient treatment program.
41154068|NCT05578976|DRUG|Cyclophosphamide|Intravenous (IV) Injection
41154069|NCT05578976|DRUG|Rituximab|IV Infusion
41154070|NCT05578976|DRUG|Vincristine|IV Infusion
41154071|NCT05578976|DRUG|Doxorubicin|IV Infusion
41154072|NCT05578976|DRUG|Prednisone|Oral; Tablet
41154073|NCT04910061|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide (NMN-C)|Daily supplementation with NMN-C at 400 mg for 29 days in total
41009552|NCT03912233|DRUG|TEZ|TEZ tablet for oral administration.
41009553|NCT03912233|DRUG|VX-561|Tablets for oral administration.
41009554|NCT03912233|DRUG|TEZ/IVA|Fixed-dose combination tablets for oral administration.
41009555|NCT03912233|DRUG|IVA|Tablets for oral administration.
41009556|NCT03912233|DRUG|Placebo|Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
41009557|NCT05606068|DEVICE|Paxman Limb Cryocompression System (PLCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours."
41009558|NCT03612037|DIETARY_SUPPLEMENT|alpha lipoic acid|600 mg/day oral dose of alpha lipoic acid
41009559|NCT03612037|DIETARY_SUPPLEMENT|Cellulose|600mg/day oral dose of placebo cellulose
41009560|NCT00611702|PROCEDURE|Kidney biopsy|Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.
41009561|NCT03246958|DRUG|Nivolumab|Ipilimumab are types of immunotherapy Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
41479532|NCT03117751|DRUG|Cyclophosphamide|Given IV.
41479533|NCT03117751|DRUG|Cytarabine|Given IV or by subcutaneous injection (SQ).
41154074|NCT02445781|DEVICE|Glucose clamp|Different levels of hypoglycemia
41479534|NCT03117751|DRUG|Mercaptopurine|Given PO.
41479535|NCT03117751|DRUG|Dasatinib|Given PO.
41479536|NCT03117751|DRUG|Methotrexate|Given IV.
41325968|NCT02527148|DEVICE|Stryker Precision Knee Navigation|Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.
41154075|NCT04287816|OTHER|Zero hard-boiled egg at 0 h|No eggs will be consumed on test day along with spinach consumption
40808388|NCT04627025|DRUG|apraglutide|Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
41154076|NCT04287816|OTHER|One hard-boiled egg at 0 h|One egg will be consumed on test day along with spinach consumption
41154077|NCT04287816|OTHER|Two hard-boiled eggs at 0 h|Two eggs will be consumed on test day along with spinach consumption
40808391|NCT05613322|DIAGNOSTIC_TEST|Resistell Phenotech|Resistell Phenotech IVD device used to assess susceptibility of Gram negative bacteria to antibiotics.
40808392|NCT04728893|DRUG|Nemtabrutinib|Nemtabrutinib tablets administered PO QD.
40808393|NCT03602157|BIOLOGICAL|ATLCAR.CD30.CCR4 cells|Three dose levels are being evaluated: 2x10\^7, 5x10\^7, 1x10\^8
40808394|NCT03602157|BIOLOGICAL|ALTCAR.CD30 cells|Fixed dose level of 1x10\^8
40808395|NCT03602157|DRUG|Bendamustine|70 mg/m\^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion
40808396|NCT03602157|DRUG|Fludarabine|30 mg/m\^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion
40808397|NCT05633459|DRUG|Multiple ascending doses of QRL-201|Multiple ascending doses of QRL-201 will be intrathecally administered to individuals with sporadic ALS.
40808398|NCT05633459|DRUG|Multiple ascending doses of Placebo|Multiple ascending doses of placebo comparator will be intrathecally administered to individuals with sporadic ALS.
40808399|NCT05633459|DRUG|QRL-201|QRL-201 will be intrathecally administered to individuals with C9orf72 ALS.
40808400|NCT05633459|DRUG|Placebo|Placebo comparator will be intrathecally administered to individuals with C9orf72 ALS.
41009562|NCT03246958|DRUG|Ipilimumab|Nivolumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
41009563|NCT03217929|DEVICE|Active-taVNS|Stimulation will be performed using the Neurodyn II (Ibramed) equipment approved by the national regulatory agency (ANVISA). The following parameters will be used: 120 Hz (hertz) of frequency, 250 μs of pulse duration and 12 milliamperes of intensity for a continuous stimulation for 30 minutes. This intensity corresponds to a non-painful mild paresthesia without muscle contraction previously described and evaluated. The 25 cm² (centimeters) electrodes will be positioned over the retroauricular area. A total of 10 sessions (one session per day during 10 week-days) will be performed. Every session will be followed by an interview with a trained psychiatrist to evaluate possible adverse effects and guarantee safety issues regarding the study itself.
41009564|NCT03217929|DEVICE|Sham-taVNS|Regarding sham protocol, the device will be turned off after 60 seconds of stimulation without the knowledge of the patient. After this initial period, the referred paresthesia seems to diminish due to nerve accommodation.
41009565|NCT04046471|DIETARY_SUPPLEMENT|enhanced Stop Light Diet|Stop light diet enhanced with portion-controlled meals
41009566|NCT04046471|BEHAVIORAL|Group Remote|Participants will receive remotely delivered weight loss in a group setting.
41009567|NCT04046471|BEHAVIORAL|Individual In-Person|Participants will receive a weight loss intervention during individual, at-home visits.
41325969|NCT02527148|PROCEDURE|Total Knee Replacement|
41325970|NCT02527148|DEVICE|Stryker Triathlon® Total Knee System|"Prosthetic components to be implanted including~* Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;~* Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;~* Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon."
41325971|NCT01601951|OTHER|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
41325972|NCT02151968|PROCEDURE|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
41325973|NCT02151968|PROCEDURE|Ultrasound-Guidance|"Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance."
41325974|NCT01617512|DEVICE|LIS302DL accelerometer|Recording for 24 hours accelerations related to daily physical activity of the patient.
41325975|NCT00314080|DRUG|Botulinum AntiToxin|
41325976|NCT00314080|PROCEDURE|neuro-electrophysiologic study, repetitive nerve stimulation|
41325977|NCT00314080|PROCEDURE|Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
41325978|NCT03788187|OTHER|Blood test sample|
41325979|NCT03788187|OTHER|Peritumoral adipose tissue sample|
41325980|NCT03673696|DRUG|HEC74647PA Capsule|Capsule administered orally once daily
40808401|NCT04250155|DRUG|XmAb24306|Participants will receive intravenous (IV) XmAb24306.
40808402|NCT04250155|DRUG|Atezolizumab|Participants will receive IV XmAb24306 followed by IV atezolizumab
40808403|NCT04250155|DRUG|XmAb24306|Participants will receive IV XmAb24306 followed by IV atezolizumab.
40808404|NCT05327127|DRUG|K-877-ER|K-877-ER tablet
40808405|NCT05327127|DRUG|CSG452|CSG452 tablet
40808406|NCT05327127|DRUG|Placebo|Placebo tablet
40808407|NCT05644951|DEVICE|Hot AXIOS system used for EPASS|EUS-guided double-balloon-occluded gastrojejunostomy bypass with Hot AXIOS system
41154078|NCT04287816|OTHER|Three hard-boiled eggs at 0 h|Three eggs will be consumed on test day along with spinach consumption
41154079|NCT04287816|OTHER|One hard-boiled egg at 3 h|One egg will be consumed on test day three hours after spinach consumption
41154080|NCT04287816|OTHER|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption
41009568|NCT05713032|PROCEDURE|Pulsed radiofrequency on lumbar dorsal root ganglion|voltage of pulsed radiofrequency on DRG
41009569|NCT01797536|DRUG|Elbasvir|
41325981|NCT03673696|DRUG|placebo|Matching Placebo Capsule
41479537|NCT03117751|DRUG|Blinatumomab|Given IV.
41154081|NCT01339156|DRUG|P3914|"Part A:~The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product will be administered orally to each subject with 240 mL of water.~Part C:~Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.~For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
41154082|NCT01339156|DRUG|Placebo|"Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
41154083|NCT05709145|OTHER|Written recommendation|"Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within1 year.~The colonoscopy report will included that an adequate intestinal cleansing has not been achieved and therefore it is an invalid exploration. Additionally, a written recommendation indicating that the colonoscopy should be repeated within1 year will be included in the colonoscopy report. This recommendation is addressed both to the clinician who requested the colonoscopy and to the patient himself."
41154084|NCT03854071|OTHER|intravenous fluid challenge|Patients will undergo a receive a pre-load increasing stress test with intravenous fluids depending on tolerability
41154085|NCT01685307|DIETARY_SUPPLEMENT|Test meal|test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
40808416|NCT06294925|DRUG|Etrasimod|As provided in real world practice
41325982|NCT03994536|BEHAVIORAL|A Person-Centred Transition Program to Empower Adolescents With Type 1 Diabetes in the Transition to Adulthood: the STEPSTONES-DIAB Project|Behavioral: Transition program Participants will be part of a transition program that aim to prepare them for adult life and adult care wich includes eight key components: 1. A transition coordinator; 2. Education on diabetes, treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the adult diabetes service: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Preparation and transfer to adult diabetes service.
40808417|NCT02257853|OTHER|Stress reduction intervention|Gentle chair yoga and breath work
41154086|NCT00488761|DRUG|Tigecycline|
41154087|NCT04627064|DRUG|Abemaciclib|Tablet taken orally
41154088|NCT04627064|DRUG|MK-6482|Tablet taken orally
41154089|NCT06288711|BEHAVIORAL|Prolonged exposure therapy|Twelve weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions provided by therapists trained in prolonged exposure therapy.
41154090|NCT06288711|BEHAVIORAL|Financial incentives|Financial incentives contingent upon completion of prolonged exposure therapy sessions
41154091|NCT06288711|BEHAVIORAL|Treatment as usual|Continued standard buprenorphine or methadone maintenance treatment from current treatment provider.
41325983|NCT03994536|OTHER|Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
40808429|NCT06524401|DEVICE|Limpet|Limpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure.
40808430|NCT06524401|DEVICE|Control|Control participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care.
40808436|NCT05776225|PROCEDURE|Right heart catheterization (RHC)|RHC to evaluate pulmonary hemodynamics
40808437|NCT05006716|DRUG|BGB-16673|Orally administered
40808438|NCT04973605|DRUG|BGB-11417|Administered orally daily
40808439|NCT04973605|DRUG|Dexamethasone|Once weekly either orally or intravenously
40808440|NCT04973605|DRUG|Carfilzomib|Administered intravenously weekly
40808441|NCT01174121|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes (one to four days after the last dose of fludarabine).
40808442|NCT01174121|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses.)
40808443|NCT01174121|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X2 days over 1 hr.
40808444|NCT01174121|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
40808445|NCT01174121|DRUG|Pembrolizumab (Keytruda)|Arm 3: Pembrolizumab 2mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63 Arm 4: Pembrolizumab 2mg/kg IV over approximately 30 minutes (for patients who meet progressive disease per RECIST criteria and have resolved major toxicities after cell infusion or anytime during the post-treatment evaluation period; starting within 4 weeks of progression; may receive up to 8 doses every 3 weeks).
41154092|NCT00043407|DRUG|CPG 7909|In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
40808447|NCT06053112|OTHER|New infant formula with 6 HMOs blend|Infants are fed with HMO formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
40808448|NCT06053112|OTHER|Standard infant formula without 6 HMOs blend|Infants are fed with standard formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
41154093|NCT01257698|DRUG|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
41154094|NCT00113334|DRUG|ABT-510|100 mg subcutaneously twice daily
41154095|NCT06584708|OTHER|Low-volume high intensity interval training|"Week 1 \& 2:~Warm-up: 10 minutes at 50% THR Work: 1x4 minutes at 80% THR followed by 1\*4 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 23 minutes~Week 3 \& 4:~Warm-up: 10 minutes at 50% THR Work: 2x6 minutes at 80% THR followed by 1\*6 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 33 minutes"
41154096|NCT06584708|OTHER|Moderate intensity continuous exercise|"Week 1 \& 2:~Warm-up: 5 minutes at 50% THR Work: 20 minutes at 60% VO 2 THR Cool Down: 5 minutes at 50% THR Total exercise time: 30 minutes~Week 3 \& 4:~Warm-up: 5 minutes at 50% THR Work: 30 minutes at 60% THR Cool Down: 5 minutes at 50% THR Total exercise time: 40 minutes"
41154097|NCT04966351|BEHAVIORAL|Time-restricted feeding|Each subject will participate in both conditions (CM and CM+TRF)--one in which food is allowed during the nighttime period and one in which food will be restricted to the daytime only. Food intake will be matched across conditions and designed to keep participants weight stable.
41154098|NCT04966351|BEHAVIORAL|Circadian Misalignment|Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.
41154099|NCT03688022|DRUG|MT-7117|MT-7117
41154100|NCT03688022|DRUG|PPI|Proton pump inhibitor
41154101|NCT03688022|DIETARY_SUPPLEMENT|Acidic beverage|Acidic beverage
41154102|NCT06600581|BIOLOGICAL|IMM01-STEM|IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling. This intervention is given 2mL twice a week.
41154103|NCT06600581|OTHER|Placebo|Saline. This intervention is given 2mL twice a week.
40808460|NCT06384313|DIETARY_SUPPLEMENT|butyrate/hexanoate-enriched triglycerides|The oils are consumed two times a day for 24 weeks (six months).
40808461|NCT04116411|DRUG|Valganciclovir Tablets|Valganciclovir treatment of glioblastoma
40808462|NCT04116411|DRUG|Temozolomide 120 mg|Chemotherapy
40808463|NCT04116411|RADIATION|Radiotherapy 60 Gy|Radiation therapy
40808464|NCT04116411|DRUG|Placebo oral tablet|Placebo treatment of glioblastoma
41154104|NCT06600581|BIOLOGICAL|IMM01-STEM alternating with placebo (saline)|This intervention consists of IMM01-STEM given once a week and placebo given one a week. IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling.
40808465|NCT05456542|DIAGNOSTIC_TEST|Cuff Leak Test|Clinicians perform the cuff leak test (CLT) to help optimize extubation. The test requires deflation of the cuff at the end of the endotracheal tube (ETT) and auscultation for air passing around the ETT. If air movement is not audible on auscultation (a failed CLT) there is a potential presence of laryngeal edema (LE) that may cause post-extubation airway obstruction.
40808466|NCT05456542|DRUG|Dexamethasone 4mg|Dexamethasone, will be administered to those patients who fail the CLT in the intervention arm (4mg intravenous every 6 hours for 12-24 hours). Dexamethasone belongs to a class of drugs known as corticosteroids
41009570|NCT04465045|PROCEDURE|Laparoscopy-hysteroscopy|Under general anesthesia, we start by a first look in laparoscopy, to look for endometriosis mainly, tubal infertility, ovarian cysts or any abnormalities that may not have been suspected on the first exam. Then we check tubal patency after a look at the uterine cavity by hysteroscopy. Then we treat everything possible to treat to improve fertility, spontaneous or with ART.
41325984|NCT06147453|DEVICE|Aerobika OPEP device|16 week twice daily use of the Aerobika OPEP device
40808467|NCT06120140|DRUG|Amivantamab|Amivantamab will be administered as intravenous (IV) infusion or SC injection.
40808468|NCT06120140|DRUG|Lazertinib|Lazertinib tablet will be administered orally.
40808469|NCT06120140|DRUG|Doxycycline|Doxycycline tablet will be administered orally.
40808470|NCT06120140|DRUG|Minocycline|Minocycline capsule will be administered orally.
40808471|NCT06120140|DRUG|Clindamycin|Clindamycin lotion will be used as topical application on the scalp.
40808472|NCT06120140|DRUG|Chlorhexidine|Chlorhexidine solution will be used as topical application on hands and feet.
40808473|NCT06120140|OTHER|Noncomedogenic skin moisturizer|Noncomedogenic skin moisturizer will be used as topical application.
40808474|NCT05904496|DRUG|BGB-30813|Specified dose administered on specified days
40808475|NCT05904496|DRUG|Tislelizumab|Specified dose administered on specified days
41154105|NCT06013982|BEHAVIORAL|Anxiety Reduction Bundle|"The Anxiety Reduction Bundle intervention comprises the following resources:~* Stroke Support Group~* Anxiety Reduction Sheet~* Understanding Anxiety Disorder sheet~* Your body's response to anxiety sheet~* Relaxation Tip sheet~* Breathing Tip sheet and video~* A sigh of Relief video"
41154106|NCT05066178|BEHAVIORAL|CAS Treatment for Minimally Verbal Children with Autism|Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
40808485|NCT04188067|DEVICE|ACTIVE rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
40808486|NCT04188067|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
40808487|NCT04987489|DRUG|Etavopivat tablets|Etavopivat 400 mg once daily
41154107|NCT04950790|DRUG|Shuxinin injection|Shuxuening injection : 5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
41154108|NCT04950790|DRUG|Basic treatment|Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
41154109|NCT04950790|DRUG|Placebo|sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
40808491|NCT06531538|BIOLOGICAL|PG4|Multivalent pneumococcal conjugate vaccine.
40808492|NCT06531538|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
41154110|NCT03223935|OTHER|Corn nuts|Roasted corn nut snack
41154111|NCT03223935|OTHER|Chickpeas|Roasted chickpea snack
41154112|NCT03223935|OTHER|Yellow peas|Roasted yellow pea snack
40808496|NCT04301128|OTHER|Experimental|Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.
40808497|NCT04301128|OTHER|control|Patients in the control group were informed same informations verbally and given an education book.
41154113|NCT03223935|OTHER|Pinto beans|Roasted pinto bean snack
41154114|NCT03223935|OTHER|Soybeans|Roasted soybean snack
40808500|NCT05111626|DRUG|Bemarituzumab|Bemarituzumab will be administered as intravenous (IV) infusion.
41009571|NCT04382638|COMBINATION_PRODUCT|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
41154115|NCT03223935|OTHER|Almonds|Roasted almond snack
40808501|NCT05111626|DRUG|Nivolumab|Nivolumab will be administered as IV infusion.
41479538|NCT03117751|DRUG|Ruxolitinib|Given PO.
40808502|NCT05111626|DRUG|Chemotherapy|"mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally."
40808503|NCT05111626|OTHER|Placebo|Placebo will be administered as IV infusion.
40808504|NCT04994132|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40808505|NCT04994132|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40808506|NCT04994132|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40808507|NCT04994132|PROCEDURE|Bone Scan|Undergo bone scan
40808508|NCT04994132|PROCEDURE|Computed Tomography|Undergo CT
40808509|NCT04994132|DRUG|Cyclophosphamide|Given IV or PO
40808510|NCT04994132|BIOLOGICAL|Dactinomycin|Given IV
40808511|NCT04994132|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40808512|NCT04994132|PROCEDURE|Positron Emission Tomography|Undergo PET
40808513|NCT04994132|RADIATION|Radiation Therapy|Undergo radiation therapy
40808514|NCT04994132|DRUG|Vincristine Sulfate|Given IV
40808515|NCT04994132|DRUG|Vinorelbine Tartrate|Given IV
40808516|NCT04994132|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
40808517|NCT06345729|DRUG|MK-1084|Oral tablets
40808518|NCT06345729|OTHER|Placebo|Oral tablets
40808519|NCT06345729|BIOLOGICAL|Pembrolizumab|IV infusion
40808520|NCT03016377|BIOLOGICAL|iC9-CAR19 cells|Three dose levels are being evaluated: dose level -1 (1 x 10\^5), dose level 1 (5 x 10\^5), and dose level 2 ( 1x 10\^6)
40808521|NCT03016377|DRUG|Rimiducid|Subjects with CRS and ICAN will assign one of two dose levels (DL)s of rimiducid with the standard treatment: 0.05 mg/kg or 0.1 mg/kg for subjects with CRS and 0.01mg/kg or 0.1mg/kg for subjects with ICAN. Subjects will first be enrolled on DL 1 and then enrolled on DL 2, and 0.4mg/kg rimiducid will be given to subjects who did not respond to the initial dose.
40808522|NCT03016377|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
40808523|NCT03016377|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
40808524|NCT05997914|BEHAVIORAL|Storytelling Intervention|Participants assigned to the intervention group will watch videos presenting stories of African American patients about their experiences with using anticoagulation or blood thinners throughout a 90-day period.
40808525|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy
40808526|NCT04097145|DRUG|Optimal Medical Therapy|Optimal Medical Therapy alone in patients with tricuspid regurgitation
40808527|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT
40808528|NCT04870944|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40808529|NCT04870944|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
40808530|NCT04870944|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40808531|NCT04870944|PROCEDURE|Echocardiography|Undergo ECHO
40808532|NCT04870944|DRUG|FACT Complex-targeting Curaxin CBL0137|Given IV
41479539|NCT03117751|DRUG|Bortezomib|Given IV or subcutaneously (SQ).
41154116|NCT04389983|DIETARY_SUPPLEMENT|Medium Chain Triglyceride oil|Bulletproof Braine Octane MCT oil
41154117|NCT01631318|PROCEDURE|Dynamic contrast-enhanced ultrasound imaging|Ultrasound imaging procedure
41154118|NCT01631318|DEVICE|Optical Tracking Device|Optical Tracking Device, manufactured by Atracsys LLC, Switzerland.
41479540|NCT03117751|DRUG|Dexamethasone|Given PO.
41154119|NCT01631318|DEVICE|Electromagnetic Tracking Device|Electromagnetic Tracking Device, Ascension Technology Corporation, Milton, Vermont.
41154120|NCT01631318|DRUG|Perflutren|Perflutren lipid microsphere, IV 0.4 mL. Used as standard contrast agent, not the subject of the study.
41479541|NCT03117751|DRUG|Doxorubicin|Given IV.
41479542|NCT03117751|DRUG|Etoposide|Given IV.
41479543|NCT03117751|DRUG|Clofarabine|Given IV.
41479544|NCT03117751|DRUG|Vorinostat|Given PO.
41479545|NCT03117751|DRUG|Idarubicin|Given IV.
41479546|NCT03117751|DRUG|Nelarabine|Given IV.
41479547|NCT03117751|DRUG|Thioguanine|Participants with mercaptopurine-related pancreatitis. Given PO.
41009572|NCT04382638|DEVICE|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
41009573|NCT01927250|BEHAVIORAL|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
41009574|NCT01440309|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
41154121|NCT04501978|BIOLOGICAL|LY3819253|Participants are no longer being randomized to this intervention.
41154122|NCT04501978|DRUG|Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion
41154123|NCT04501978|BIOLOGICAL|Remdesivir|Provided to all study participants as SOC unless contraindicated for an individual patient.
41154124|NCT04501978|BIOLOGICAL|VIR-7831|Participants are no longer being randomized to this intervention.
41154125|NCT04501978|BIOLOGICAL|BRII-196/BRII-198|Participants are no longer being randomized to this intervention.
41154126|NCT04501978|BIOLOGICAL|AZD7442|Participants are no longer being randomized to this intervention.
41154127|NCT04501978|DRUG|MP0420|Participants are no longer being randomized to this intervention.
41154128|NCT04501978|DRUG|PF-07304814|250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention.
41154129|NCT02394171|BEHAVIORAL|Group Cohesion|See description in arm/group above
41154130|NCT01440699|BIOLOGICAL|Allogenic human adipose-derived stem cells|ALLO-ASC 1xE7 cells/mL is injected once along the fistula. If there is no safety issue for 4 weeks, 3 more people could be enrolled who are subject to ALLO-ASC 3xE7 cells/mL.
41479548|NCT03117751|DRUG|Asparaginase Erwinia chrysanthemi (recombinant)-rywn|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
41479549|NCT03117751|DRUG|Calaspargase Pegol|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
41479550|NCT02719106|DEVICE|Ultimaster stent|
41479551|NCT03720769|BEHAVIORAL|Step-by-Step|Guided self-help programme delivered through an app/website for the treatment of depression
41009575|NCT01440309|DRUG|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
41009576|NCT03090256|DEVICE|AcrySof® IQ PanOptix™ IOL|Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
41009577|NCT04452266|OTHER|questionnaire assesment|Each patient will to answer questions about their medical history.
41154131|NCT00927537|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
41325985|NCT03457480|OTHER|Computer-Assisted Intervention|Read computer messages
41154132|NCT00927537|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
41154133|NCT02596542|OTHER|Water immersion|Different temperatures of cold water immersion will be assessed
41154134|NCT05317299|OTHER|3 different type of exercise|Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training
41154135|NCT03306693|BEHAVIORAL|Emotional skills|2-hour 3 group sessions
41154136|NCT03306693|BEHAVIORAL|Relaxation and talking group|2-hour 3 group sessions
41154137|NCT00076063|BIOLOGICAL|ALVAC-HIV (vCP1452)|experimental vaccine
41154138|NCT00076063|BIOLOGICAL|LIPO-5|experimental vaccine
41154139|NCT02896218|OTHER|Pharmacists consultation|Pharmacists consultation of vancomycin individualized dosing strategy
41325986|NCT03457480|BEHAVIORAL|Focus Group|Attend focus group
41325987|NCT03457480|OTHER|Informational Intervention|Receive text messages
41479552|NCT03720769|BEHAVIORAL|Enhanced care as usual|Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)
41479553|NCT02479542|OTHER|Standard Gauze Dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
41479554|NCT02479542|DEVICE|WiCare NPWT dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
41479555|NCT01435447|DRUG|FLu-Bu-Cy|Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
41479556|NCT02827890|DRUG|Januvia Tab. 100mg|Januvia Tab. 100mg\*1T/day for 5days, QD, PO
41479557|NCT02827890|DRUG|Januvia Tab. 100mg + Duvie Tab. 0.5mg|Januvia Tab.100mg + Duvie Tab. 0.5mg\*1T/day for 5 dyas, QD, PO
41479558|NCT00228241|DEVICE|AAI vs. DDD vs. BIV pacing in different patients groups|
41479559|NCT02017730|DRUG|BMS-986020|
41479560|NCT02017730|DRUG|[11C]BMT-136088|
41479561|NCT00423995|DRUG|Loratadine/montelukast combination|
41479562|NCT06204419|DRUG|XH-S002 （A）|XH-S002 powder will be administered orally as per assigned treatment regimen.
41479563|NCT06204419|OTHER|Placebo（B）|XH-S002 Placebo (matched) will be administered orally as per assigned treatment regimen.
41325988|NCT03457480|OTHER|Survey Administration|Complete surveys about experience
41009578|NCT05000749|BEHAVIORAL|DBT-SG|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
40808534|NCT05873153|BEHAVIORAL|Health Education|Education materials on high blood pressure, lowering sodium, starting an exercise program, and weight management.
40808535|NCT05873153|OTHER|Home Blood Pressure Monitor|Blood pressure cuff for home use
40808536|NCT06482099|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
41009579|NCT05000749|BEHAVIORAL|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
40808537|NCT05840159|DRUG|Doxycycline|Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.
41009580|NCT04962568|DIAGNOSTIC_TEST|DTEE|endexpiratory diaphragm thickness in mm
41009581|NCT04962568|DIAGNOSTIC_TEST|DTEI|endinspiratory diaphragm thickness in mm
41009582|NCT04962568|DIAGNOSTIC_TEST|DEx|diaphragm excursion during rest and diaphragmatic excursion during maximal inspiration in mm
41009583|NCT00160316|DRUG|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
41009584|NCT00151814|DRUG|Olmesartan medoxomil|Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
41009585|NCT05905458|DRUG|HRS9950 tablets|HRS9950 tablets, oral, once a week, low dose
41325989|NCT05466734|DRUG|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
41325990|NCT05466734|DRUG|PMR Tablet 135 mg|Single oral dose (total daily dose of 270 mg)
41325991|NCT05444985|OTHER|Pain Management|Regional anesthetic techniques for peri-operative pain management after surgery.
41325992|NCT02866734|OTHER|Free screening group|The intervention provide Diabetic Retinopathy screening without charging a fee.
41325993|NCT02866734|OTHER|Pay screening group ($150)|The intervention is charging HK$150 for the Diabetic Retinopathy screening.
41325994|NCT02866734|OTHER|Pay screening group ($300)|The intervention is charging HK$300 for the Diabetic Retinopathy screening.
41325995|NCT05764876|DRUG|Linezolid Oral Tablet|Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.
41325996|NCT05764876|DRUG|Azithromycin Oral Tablet|Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
41325997|NCT03447821|DRUG|400 mg Rifamycin SV dosage|
41325998|NCT03447821|DRUG|800 mg Rifamycin SV dosage|
41325999|NCT03447821|DRUG|1200 mg Rifamycin SV dosage|
41326000|NCT04397029|DEVICE|SureTouch|"The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch."
41326001|NCT02358564|PROCEDURE|Gastrointestinal Permeability Test|This test will involve ingesting a solution followed by urinalysis
41326002|NCT02358564|PROCEDURE|Upper Endoscopy|
41009586|NCT05905458|DRUG|HRS9950 tablets|HRS9950 tablets, oral, once a week, high dose
41479564|NCT05195866|DIAGNOSTIC_TEST|CRP POCT (C-reactive protein point of care test)|"CRP POCT equipment will be supplied at healthcare centers, along with a short training in use and interpretation supporting the clinical evaluation of the child. It will be communicated that CRP levels less than 10 indicate that the disease is not severe, and antibiotics is most likely not needed, if between 10 and 50, that antibiotics might be needed, and if more than 50 that it is likely that they are needed. With CRP between 10-50 the HCW are instructed to take the clinical picture into account together with the value of the test.~The training will also include knowledge of CRP pharmacodynamics and cases where a low CRP might need to be interpreted cautiously, e.g. a history of fever lasting less than 24 hrs. HCWs will be instructed to use CRP POCT for all patients in the intervention group and use the information to guide diagnosis and treatment choice. We will use Aidian (Copenhagen, Denmark) QuickRead go CRP POCT set-up."
41326003|NCT02358564|PROCEDURE|Rectal Barostat and Infusion of Fats|Feeding tube will be placed, as well as a small balloon in the rectum.
41326004|NCT04294654|DRUG|Vortioxetine|Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.
41326005|NCT00549510|DRUG|COREG CR and lisinopril (FDC)|
41479565|NCT00643734|DRUG|azithromycin sustained release|azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
41479566|NCT00643734|OTHER|placebo|placebo
41479567|NCT00643734|DRUG|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
41479568|NCT00643734|OTHER|placebo|placebo
41479569|NCT01092078|BEHAVIORAL|MINT|Motivational interviewing for lifestyle changes associated with treating hypertension
41479570|NCT01092078|BEHAVIORAL|Patient Navigation|Patient navigation for colonoscopy.
41479571|NCT02680418|DRUG|FDL169|
41479572|NCT06331741|PROCEDURE|Anterior cruciate ligament reconstruction, using graft, augmented with collagen membrane|Wrapping graft (tendon of the long fibular muscle) with collagen membrane before implantation
41479573|NCT06331741|PROCEDURE|Anterior cruciate ligament reconstruction, using graft, not augmented with collagen membrane (control group)|Implantation of the native graft (tendon of the long fibular muscle) without any augmentation method
41479574|NCT06331741|PROCEDURE|Resection arthroplasty of the first metatarsophalangeal joint with the introduction of a collagen membrane into the joint cavity|Arthroplasty with consequent collagen membrane implantation
41009587|NCT05905458|DRUG|HRS9950 placebo tablets|HRS9950 placebo tablets, oral, once a week.
41479575|NCT00859001|DRUG|FM+R|Fludarabine-Mitoxantrone-Rituximab
41479576|NCT00859001|DRUG|Zevalin (Ibritumomab Tiuxetan)|
41479577|NCT00280176|DRUG|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
41479578|NCT00280176|DRUG|fluorouracil|225mg/m2 given weekly, up to 6 weeks
41479579|NCT00280176|RADIATION|radiation therapy|180 cGy, every 5 days, up to six weeks
41479580|NCT03828266|OTHER|No intervention|Patients will undergo routine clinical practice. There is no additional intervention.
41479581|NCT05243186|DEVICE|Treadmill workstation|walking on a treadmill workstation next to desk with computer and screen
41479582|NCT05243186|DRUG|Methylphenidate|Using prescription drug
41009588|NCT05839665|DEVICE|Humidified high-flow nasal oxygen|Humidified high-flow oxygen delivered via the Optiflow device
41009589|NCT05839665|DEVICE|Standard nasal cannula|Oxygen delivered with high flows via a standard nasal cannula
41009590|NCT05839665|DEVICE|Facemask|Oxygen delivered with facemask
41009591|NCT01993108|DRUG|Methylphenidate|One dose 40mgs of methylphenidate one hour before fMRI scanning.
41009592|NCT01993108|DRUG|Naltrexone|One dose 40mgs of naltrexone one hour before fMRI scanning.
41009593|NCT01993108|DRUG|Placebo|One dose of placebo one hour before fMRI scanning.
41479583|NCT04729465|DRUG|Propofol|Propofol
41479584|NCT04729465|DEVICE|Bispectral Index Monitor|Bispectral Index Monitor
41479585|NCT04718129|BEHAVIORAL|Youth Mindful Awareness Program (YMAP)|The Mindfulness Intervention is an internet-based program that involves a coach. It is 9 weekly sessions and involves practicing the skills between sessions.
41479586|NCT04339920|DIAGNOSTIC_TEST|Spermine Measuring Device|The Spermine Measuring Device (SMD) is a simple device, with automatic urine aspiration and also spermine level assessment. First about 30 cc urine will be freshly collected by a prepared collection device. Then the cap of the SMD will be removed and the aspiration tip of the device will be immersed into the urine specimen. After firmly pressed on the device, a small sample of urine will be aspirated into the SMD. The device will then automatically assess the urine spermine level. The result will then be read at a indicator window after about 5 minutes. If the level was below a pre-set cutoff, i.e. suggestive of having increase risk of prostate cancer, the indicator window will turn into red colour. However, if the spermine level is higher than the cutoff value, i.e. low risk of having cancer, the indicator window will turn blue.
41479587|NCT05855616|DEVICE|"Group chlorhexidine dressing"|Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.
40808538|NCT05840159|OTHER|Placebo|Placebo
41009594|NCT00000826|DRUG|Clarithromycin|
41009595|NCT00000826|DRUG|Rifabutin|
41009596|NCT00000826|DRUG|Sulfamethoxazole-Trimethoprim|
41009597|NCT00000826|DRUG|Dapsone|
41009598|NCT00000826|DRUG|Fluconazole|
41326006|NCT00006372|DRUG|gemcitabine hydrochloride|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
41326007|NCT00006372|DRUG|pegylated liposomal doxorubicin hydrochloride|Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
41326008|NCT00006372|DRUG|vinorelbine ditartrate|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
41154140|NCT05921929|DRUG|Fluoroethylnormemantine (FENM)|Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
41326009|NCT00821145|PROCEDURE|conventional surgery|AAA patients operated using a conventional incision
41326010|NCT00821145|PROCEDURE|laparoscopic AAA resection|laparoscopic AAA resection
41326011|NCT00821145|PROCEDURE|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
41326012|NCT05285033|DRUG|Lurbinectedin|Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
41326013|NCT06117917|DRUG|S-ketamine and pregabalin|"* Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
41154141|NCT03535493|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress.
41154142|NCT03535493|BEHAVIORAL|Float REST|A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
41154143|NCT03535493|BEHAVIORAL|ACT + Float REST|The combined intervention will combine ACT and Float REST. An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress. A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
41154144|NCT01694199|DEVICE|Pulsed Radiofrequency Energy (PRFE)|The intervention is pulsed radiofrequencyenergy (PRFE).
41154145|NCT01694199|DEVICE|No Pulsed Radiofrequency Energy (PRFE)|Sham (placebo) with no therapeutic device activity
41326014|NCT06117917|DRUG|Normal saline and placebo capsule|"* Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
41326015|NCT03148106|DEVICE|Somatosensory Electrical Stimulation|We will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
41154146|NCT04785742|DRUG|Almonertinib|Almonertinib
41154147|NCT06487897|DEVICE|Optimal laser keratoplasty|Laser
41154148|NCT02502851|DEVICE|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
40808548|NCT05853705|BEHAVIORAL|Strong Hearts Exercise Program|The participant will either begin at the easiest variation of each strength exercise (level A), or will be placed at a specific level for each strength exercise based on their assessment with physical therapy. Participants can progress to the next level of difficulty of a specific strength exercise based on their rating of perceived exertion (RPE) with the opportunity to move to the next level if they have RPE score of 6 or less and if their heart rates are at goal. Each participant will be provided with heart rate ranges based on the heart rate reserve (HRR) method using their baseline resting and peak heart rates obtained during their cardiopulmonary exercise testing (CPET) or percent predicted heart rate based on age if CPET is not available. HRR goals will be set individually for patients and adjusted per protocol to guide effort.
40808549|NCT06068478|DRUG|Qingzhu Granules|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.
40808550|NCT06068478|DRUG|Qingzhu Granules Placebo|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
41154149|NCT02502851|DEVICE|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
41154150|NCT06537219|OTHER|Assessment|Assessment of pain severity,pain thresold of the fascia, pain sensitivity
41154151|NCT06443541|BEHAVIORAL|High-intensity implementation strategies (HIS)-Students|Students in the HIS group will receive educational outreach in a pre-implementation in-person orientation to GlobalConsent, covering similar topics and three monthly one-hour learning sessions during implementation in which technical questions about program access or progression can be addressed; more intensive intervention to enhance adherence with more frequent email/Short Message Service (SMS), completion reminders; and demand generation encouraging program completion.
41154152|NCT06443541|BEHAVIORAL|Low-intensity implementation strategies (LIS) for Students|Students in the LIS group will receive basic implementation strategies of the GlobalConsent often used to deliver online programs at US universities with email/SMS completion reminders with a predetermined frequency for 12 weeks.
41154153|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Faculty|"* Passive access to web-based educational materials~* Town halls (3) with general faculty to define sexual violence; rates in young people; acute/chronic effects over the life course; primary-prevention evidence-based interventions (EBIs)"
41326016|NCT02448004|DRUG|JNJ-63623872|Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
41154154|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) for Faculty|Passive access to web-based educational materials
41326017|NCT01930929|PROCEDURE|Bariatric surgery|
40808559|NCT06235151|DRUG|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.
41009599|NCT00546715|DRUG|Daclatasvir|Oral Solution, Oral, Single Dose
41009600|NCT00546715|DRUG|Placebo|Oral Solution, Oral, Single Dose
41479588|NCT05855616|OTHER|"Group solution"|Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.
41479589|NCT05600205|BEHAVIORAL|GOAL!|GOAL! is a integrated support focused on a combination of lifestyle factors for achieving a healthier lifestyle for people with severe mental illness. The intervention consists of two year of guidance from a lifestyle coach and qualified professionals.
41479590|NCT01100879|DRUG|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
41479591|NCT03282968|DEVICE|REWIRE|First, the patient will play the Fruit Catcher (weight transfer) game on the 3rd level for 3 minutes, followed by 3 minutes of rest. Next, the patient will play the Horse Runner (squats) on the 3rd level for 3 minutes, followed by 3 minutes of rest. In the end, the patient will play the Animal Hurdler (standing on one leg) on the 3rd level for 3 minutes. During the games, the patient will be standing on the Wii Balance Board, holding to a firm support if necessary. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
41479592|NCT03282968|OTHER|Balance exercises|The patient will first practice balance transfer for 3 minutes (standing by a ladder, holding position on each leg for 3 seconds), followed by 3 minutes of rest. Next, the patient will be performing squats for 3 minutes, followed by 3 minutes of rest. In the end, the patient will practice alternatively lifting lower limbs (like stepping on a footstool) for 3 minutes. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
41479593|NCT01478282|DRUG|Rivaroxaban|20 mg/day, oral administration maintained for 5 days
41479594|NCT01478282|DRUG|Dabigatran|150 mg/12 hours, administered orally, treatment maintained for 5 days
41479595|NCT02438982|DRUG|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
41479596|NCT02438982|DRUG|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If \>5 B cells per mm3, it will be measured again after 1 week. If count is still \>5 B cells per mm3, third \& fourth doses of rituximab will be given.
41479597|NCT06446141|OTHER|Osteopathic technique|Patients will be positioned in a supine position. Osteopathic technique will consist of supoccibital release, soft tissue release of thoracic outlet, mobilization of cervical facet joints, stretching of scalene anterior, scalene medius, upper trapezius, and levator scapula, pectorals major and minor. Subsequently, cost vertebral and cost transverse joint mobilizations will be applied using rib elevation. Then, manipulation of the vertebrae the levels between C6 and T1 will be applied using thrust mobilization technique. Afterwards, mobilization of the first rib will be applied. Finally, mobilization of the upper cervical spine will be performed.
41479598|NCT00270049|DRUG|epoetin alfa|
41479599|NCT00788229|DRUG|AT01|eye drop for 12 weeks
41479600|NCT00788229|DRUG|AT02|eye drop for 12 weeks
41479601|NCT00788229|DRUG|AT03|eye drop for 12 weeks
41479602|NCT00788229|DRUG|AT04|eye drop for 12 weeks
41479603|NCT01570816|DEVICE|IRS-8 (8 channel implanted receiver stimulator)|Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
41479604|NCT06490575|OTHER|Educational Intervention Based on Protection Motivation Theory to Improve Knowledge and Promote Nonpharmacological Approaches to Prevent and Manage Hypertension among Adults|Participants in the intervention group attended four face-to-face workshops (one session per week). Each session took about 30 minutes and consisted of lectures with PowerPoint presentations, discussion, questions and answers, and the distribution of educational pamphlets and booklets.
41479605|NCT01521065|DEVICE|IRay|Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
41479606|NCT02624726|DRUG|5 Fluorouracil|5 Fluorouracil: 400mg/m2, bolus infusion in \<5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
41479607|NCT02624726|DRUG|Leucovorin|Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
41479608|NCT02624726|DRUG|Irinotecan|Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
41479609|NCT02624726|DRUG|Aflibercept|Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
41479610|NCT04070287|COMBINATION_PRODUCT|SMART Pack|The SMART pack is a re-branded and repackaged box for HIV self-testing kits. The intervention aims to promote distribution of HIVST kits through in institutions, vocational centers, and social media platforms. The intervention would also include a referral systems, where participants provided with the HIV self-testing kits are provided with information with youth-friendly health facilities for uptake of testing for sexually transmitted infections. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the SMART pack and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Yaba local government area in Lagos state.
41479611|NCT04070287|COMBINATION_PRODUCT|Luv Box|"The Luv box is packaged in two colors: blue and pink. The LUVBox would be made available in supermarkets, on-line stores, mini-marts, pharmacies, neighborhood stores and markets, for easy accessibility in hard to reach areas. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the Luv Box and the location where the pack can be obtained for individuals who are interested.For this pilot study, the intervention will be implemented in Yaba in Lagos state."
41479612|NCT04070287|COMBINATION_PRODUCT|Bili Vibes|The HIV self-testing kits will be available for interested individuals at the community youth events. These events and information the HIV self-testing kits will be on flyers that would be promoted at community centers and schools. For this pilot study, the intervention will be implemented in Ngenevu/Bunker communities in Enugu state.
41326018|NCT02752724|DRUG|Ketamine|Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
41326019|NCT02752724|DRUG|Methohexital|Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
41326020|NCT04197024|DEVICE|Exercise capacity test|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.
41326021|NCT04197024|DEVICE|Exercise capacity test in virtual reality|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.
41326022|NCT02294006|DRUG|Everolimus plus Octreotide LAR plus Metformin|Everolimus plus Octreotide LAR plus Metformin
41326023|NCT02626455|DRUG|Copanlisib (BAY80-6946)|"Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.~Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days."
41326024|NCT02626455|DRUG|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
41326025|NCT02626455|DRUG|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
41326026|NCT02626455|DRUG|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
41326027|NCT02626455|DRUG|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
41326028|NCT02626455|DRUG|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
41326029|NCT02626455|DRUG|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
41326030|NCT02626455|DRUG|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
41326031|NCT01924299|DRUG|Baricitinib|Administered orally
41326032|NCT01924299|DRUG|Ketoconazole|Administered orally
41326033|NCT01924299|DRUG|Fluconazole|Administered orally
41326034|NCT03919110|DIAGNOSTIC_TEST|Collection of biological samples|"Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses."
41326035|NCT03316677|PROCEDURE|Intraoperative testing of colorectal anastomoses|"1. Insert a Foley catheter through the anus into the rectum.~2. Insufflate the Foley balloon with 5 cc of air.~3. Air tight leak test with saline and insufflating air: fill the pelvic space with 500 CC of warm saline~4. Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~5. Remove the saline from the pelvic space.~6. Inject diluted dye (methylene blue) in to the rectum up to a pressure of 35 mmH2o measured by external manometer~7. Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
41326036|NCT03316677|PROCEDURE|Stapled colorectal anastomoses|After the resection we do the stapled colorectal anastomosis with a standard circular stapler as part of the regular procedure
41326037|NCT06495216|DEVICE|Pulsed Field Ablation by a Balloon Catheter with the TRUPULSE Generator|Pulsed field ablation balloon catheter and TRUPULSE generator will be used for PV ablation.
41479613|NCT04070287|COMBINATION_PRODUCT|BeterDoc|"The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the BeterDoc Safety Kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Ibadan, Dugbe and Agbowo in Oyo state."
41009601|NCT04900896|DEVICE|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
41009602|NCT03563768|PROCEDURE|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
41009603|NCT04490434|DRUG|DWP14012|DWP14012 40mg, bid
41009604|NCT04490434|DRUG|Celecoxib|Celecoxib 200mg, bid
41009605|NCT04490434|DRUG|Naproxen|Naproxen 500mg, bid
41009606|NCT04490434|DRUG|Meloxicam|Meloxicam 15mg, qd
41154155|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Leaders|"* Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials~* Monthly emails from trained internal facilitators to university leaders with updates on implementation progress~* One post-implementation webinar to share anonymized findings (by IS group); discuss plan for sustainment (including guidance on how to handle reporting of sexual violence in existing university counseling centers)"
41154156|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) for Leaders|"* Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials"
40808562|NCT06065657|DIETARY_SUPPLEMENT|Ketone Supplement|Ketone supplement 3x day with control diet for 3 days.
40808563|NCT06065657|OTHER|Control Diet|Control Diet breakfast, lunch, and dinner for 3 days.
40808564|NCT06065657|OTHER|Ketogenic diet|Ketogenic Diet breakfast, lunch, and dinner for 3 days.
40808565|NCT06065657|DRUG|Ethanol|After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
40808566|NCT04000607|DEVICE|APTURE transcatheter shunt|Transcatheter treatment of symptomatic left heart failure patients
41154157|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Implementation Team Members|"* Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual~* In-person leadership training to champion GlobalConsent with internal stakeholders (leaders, implementation teams, faculty, students); leadership styles; managing teams; influence without authority; managing conflict; emotional intelligence; negotiation; leading change~* Biweekly (six) 1-hr recorded quality-improvement team webinars to provide refresher training; assess implementation progress; assess modifications; build peer-network; provide anonymized data on implementation progress for discussion"
41154158|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) Implementation Team Members|"* Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual"
40808569|NCT02176967|PROCEDURE|Biopsy|Undergo biopsy
40808570|NCT02176967|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40808571|NCT02176967|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40808572|NCT02176967|DRUG|Carboplatin|Given IV
40808573|NCT02176967|OTHER|Clinical Observation|Undergo clinical observation
40808574|NCT02176967|PROCEDURE|Computed Tomography|Undergo CT
40808575|NCT02176967|DRUG|Cyclophosphamide|Given IV
41326039|NCT04225884|OTHER|DTx for pain software|Software with active intervention
41326040|NCT04225884|OTHER|Control software|Software without active intervention
40808576|NCT02176967|DRUG|Doxorubicin Hydrochloride|Given IV
40808577|NCT02176967|DRUG|Etoposide|Given IV
40808578|NCT02176967|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40808579|NCT02176967|PROCEDURE|Ultrasound|Undergo ultrasound
40808580|NCT02835313|BEHAVIORAL|FAST alone|Subjects participate in fast walking training 3x/week for 12 weeks.
40808581|NCT02835313|BEHAVIORAL|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
40808582|NCT02835313|BEHAVIORAL|SAM alone|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
41154159|NCT02464306|DRUG|fidaxomicin|Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
41154160|NCT04320602|BIOLOGICAL|Eculizumab|Participants must have been prescribed and be receiving a stable dose of eculizumab 1200 milligrams (mg) every 2 weeks (q2w) for at least 3 months prior to the Screening Period. During the Screening Period, participants will continue to receive eculizumab 1200 mg q2w.
41326041|NCT04225884|OTHER|Standard care|Pain medication
40808585|NCT00658814|DRUG|Azacitidine|Given IV or SC during induction; given SC during consolidation and maintenance
40808586|NCT00658814|DRUG|Gemtuzumab Ozogamicin|Given IV
40808587|NCT04838769|DEVICE|REZŪM|Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.
41326042|NCT03678584|OTHER|Medium Supplemented with Chaetoglobosin A|A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
41326043|NCT02141217|DRUG|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
41326044|NCT02141217|DRUG|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
41326045|NCT01127295|DRUG|Tamoxifen, Letrozole, Anastrozole or Exemestane|Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years
41326046|NCT00851253|RADIATION|stereotactic radiosurgery|Given in 2 fractionated doses or 5 fractionated doses
41326047|NCT01332604|DRUG|GDC-0980|Oral escalating dose
41326048|NCT01332604|DRUG|bevacizumab|Intravenous repeating dose
41326049|NCT01332604|DRUG|capecitabine|Oral repeating dose
40808588|NCT04838769|DRUG|alpha blocker and 5-alpha reductase inhibitor|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
41154161|NCT04320602|BIOLOGICAL|Ravulizumab|During the Treatment Period, participants will receive a loading dose of ravulizumab on Day 1, followed by maintenance doses on Day 15 and every 8 weeks, administered by intravenous infusion. Ravulizumab loading and maintenance doses will be based on participants' body weight per approved dose regimen.
40808590|NCT06226610|DRUG|Dupilumab|injection every two weeks while on study
40808591|NCT06226610|OTHER|Placebo|injection every two weeks while on study
40808592|NCT06557889|DRUG|Pembrolizumab + Cisplatin/Carboplatin + 5-FU|"* 4 cycles of combination treatment: 4 cycles of pembrolizumab (200 mg IV on Day 1 of each 3-week cycle) in combination with chemotherapy with platinum salts (cisplatin (100 mg/m2 IV on Day 1 of each 3-week cycle) or carboplatin (AUC 5 IV on Day 1 of each 3-week cycle), at the investigator's choice) and 5-FU (1000 mg/m2/day IV continuous from Day 1-4 of each 3-week cycle).~* Maintenance phase: pembrolizumab is continued as monotherapy for up to 24 months of treatment in total (from the first injection of cycle 1)."
40808593|NCT00769379|OTHER|Laboratory Biomarker Analysis|Correlative studies
40808594|NCT00769379|BIOLOGICAL|Trastuzumab|Given IV
40808595|NCT00769379|RADIATION|Whole Breast Irradiation|Undergo standard whole breast irradiation
41009607|NCT04409041|DRUG|Low-Dose Naltrexone|Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.
41009608|NCT01288534|RADIATION|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
41326050|NCT01332604|DRUG|mFOLFOX6|Intravenous repeating dose
41326051|NCT00980785|DRUG|Ramipril|Ramipril 5 mg/day
41326052|NCT00980785|DRUG|Placebo|Matching Placebo
41326053|NCT02566109|DIAGNOSTIC_TEST|Fast MRI|The fast MRI is a 10 minute MRI scan that will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
41326054|NCT05941663|OTHER|Dental implant surface|Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® or SLActive® surface
41326055|NCT04041141|DIAGNOSTIC_TEST|CT Scan|An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)
41326056|NCT04041141|DEVICE|Experimental Oral Stent Device|Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
41326057|NCT04938388|DRUG|Semaglutide Pill|All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.
41326058|NCT04938388|DIETARY_SUPPLEMENT|Fresh organic vegetables|Prescriptions of organic vegetables
41326059|NCT02356146|DRUG|Tacrolimus C12|
41326060|NCT00206778|DRUG|Lamotrigine|
41326061|NCT00206778|DRUG|Sodium Valproate|
41479614|NCT04070287|COMBINATION_PRODUCT|IUNGO|The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the HIV self-testing kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Akure South, Orita-Obele, Ipinsa, Ilara Mokin and Ijare in Ondo state.
41326062|NCT02715583|DRUG|11C-Acetate|
41326063|NCT00943254|OTHER|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
41326064|NCT00943254|OTHER|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
41479615|NCT04037930|BEHAVIORAL|multiple implant surgery|Patients older than 30 years who will undergo elective dental implant surgery.
41479616|NCT04867421|OTHER|No intervention|No intervention
40808596|NCT04539964|PROCEDURE|Implant Procedure|The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
40808597|NCT04539964|DRUG|Conventional Synthetic DMARD|All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
40808598|NCT04539964|DEVICE|Active stimulation|Active stimulation for 1 min once per day
40808599|NCT04539964|DEVICE|Non-active stimulation|Non-active stimulation for 1 min once per day
40808600|NCT06151964|DRUG|AZD9550|Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks
40808601|NCT06151964|DRUG|Placebo|Matching administration volumes for SC injection
40808602|NCT06077760|BIOLOGICAL|V940|IM injection
40808603|NCT06077760|BIOLOGICAL|Pembrolizumab|IV infusion
40808604|NCT06077760|OTHER|Placebo|IM injection
40808605|NCT06303440|OTHER|Routine Physical Therapy+ Balance Training|Each session will be begun with routine PT treatment and lasted for 45 minutes in total. To start, the participants will be asked to do warm-up exercises, sitting comfortably on a chair with their backs and feet well supported, the participants will be instructed to breathe in and out. Warm-up exercises will be carried out for 5 minutes. Stretching exercises will be performed for 15 minutes per session, and stretches were held for 30 seconds with four repetitions of each of the following areas, shoulder flexors, elbow and wrist flexors, hip flexors, hip adductors, knee flexors, and calf, 10 seconds of rest period will be added after stretching of one muscle group. Participants will have a 15 minutes session of exercises neck holding on form roller for 1 minute with two repetitions, astride-sitting on foam roller for 2 minutes with four repetitions, weight on both hands on gym ball for 1 minute with two repetitions and hip adductors strengthening for 1 minute with three repetitions.
40808606|NCT06303440|OTHER|Virtual Reality+ Routine Physical Therapy|The exercises will be selected, and the difficulty level will be gradually increased according to participant's performance. Starting from the penguin slide, they will progress to table tilt. Initially, each game will be played for 2 minutes per session. With the progression of performance, 4 minutes of table tilt will be added. While playing this game, a typical mobility pattern will be initiated, and balance will be improved. In the same week, the subjects performed single-leg extensions for 1 minutes. In the following weeks, Balance Bubble, Advanced step, and Basic Run will be added to the plan. The participants will perform these activities for 7 minutes per session. Treatment sessions then progressed to motor function games, including bowling, tennis, kicking, and boxing (least challenging to most challenging), with most treatment sessions ending with boxing will be provided for 7 minutes and routine physical therapy for 30 minutes as explained in control group.
40808607|NCT06303440|OTHER|Motor Imagery+ Routine Physical Therapy|"The 15 minutes of Motor Imagery session will be provided to participants. It's a three step process that will be used to incorporate the technique.~Step I, The self-recorded videos of the principal researcher performing a normal movements will be shown to participant.~Step II, The participants will be asked to imagine movement with eyes closed, and breathe deeply.~Step III The participants will be asked to perform the movement you watched in video and routine physical therapy of 30 minutes will be provided.~During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video."
40808608|NCT06565780|DEVICE|Device under test evaluation against references|"Subjects will be asked to stay seated while blood pressure and pulse rate measurements are taken at different timepoints with the device under test and references.~Device under Test: Aktiia.product-G0 References: Cuff for double auscultation for blood pressure and Electrocardiogram for pulse rate."
41154162|NCT06102525|DRUG|RZ-001|Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
41154163|NCT06102525|COMBINATION_PRODUCT|VGCV|VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.
41154164|NCT02284802|PROCEDURE|Confocal endomicroscopy|Confocal endomicroscopy examination during endoscopy
41154165|NCT00600223|BEHAVIORAL|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
41326065|NCT03277508|DEVICE|BCI Robot Assisted Hand Therapy|"18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of BCI Robot and 30 minutes of the standard hand therapy).~Session 1-3. Peg game: Lateral movement of gears/cups Session 4-6. Moving cups onto a shelf: Elevation process for the arm, small cups to be used.~Session 7-9. Carrying of basket: Heavier load to be used, patient to hold the basket by the handles at the side, not by its base.~Session 10-12. Opening bottle + pouring into a cup: Training of ADL Session 13-15. Eating: Use of a modified spoon to train ADL Session 16-18. Box and blocks: Precise index finger and thumb control"
41326066|NCT03277508|DEVICE|CPM Robot Assisted Hand Therapy|18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of Passive Robot and 30 minutes of the standard hand therapy).The procedure will include the following: Session 1-18: Continuous passive motion
41326067|NCT06323694|BEHAVIORAL|quality of life|data collection through questionnaire and interview
41326068|NCT00658710|BEHAVIORAL|physical therapy sessions|two physical therapy sessions per week for two months
41326069|NCT03657810|DRUG|CL-108 5 mg|hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
41326070|NCT03657810|DRUG|Norco|hydrocodone 5 mg/APAP 325 mg
41326071|NCT03657810|DRUG|Placebo|Placebo matching CL-108
41326072|NCT05693870|DEVICE|Fixed space maintainer|Appliance bonded with composite resin or/banded and cemented with glass ionomer cement
41326073|NCT00038272|DRUG|Mycophenolate mofetil|
41326074|NCT00038272|DRUG|Amdoxovir|
41326075|NCT05856669|DEVICE|Virtual reality gaming|This study aims to combine the motivational delivery of therapy which is an immersive virtual reality with the foundational concepts of mirror therapy. By utilizing a recalibration software, the participant will be able to achieve magnified movements on their screen as compared to the limited movement that is occurring in reality. The recalibration software takes each plane of movement of the gaming controller and magnifies the participant's range of motion in order to promote greater participation and success in the game that they are playing (Walkin VR). By using the fundamental concepts of mirror therapy in an immersive virtual reality setting, the investigators aim to mimic the results of mirror therapy while increasing motivation and adherence to the therapeutic program to increase overall upper extremity function.
41326076|NCT00873808|DRUG|clodronate disodium|
41326077|NCT00873808|DRUG|demeclocycline hydrochloride|
41326078|NCT00873808|DRUG|ibandronate sodium|
41326079|NCT00873808|DRUG|tetracycline hydrochloride|
41326080|NCT00873808|DRUG|zoledronic acid|
41326081|NCT00873808|OTHER|laboratory biomarker analysis|
41326082|NCT00873808|PROCEDURE|adjuvant therapy|
41154166|NCT00038961|DRUG|fondaparinux sodium|2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
40808618|NCT06307431|BIOLOGICAL|V940|IM injection
40808619|NCT06307431|BIOLOGICAL|Pembrolizumab|IV infusion
40808620|NCT06307431|BIOLOGICAL|Placebo|IM injection
40808621|NCT06112314|BIOLOGICAL|IMC-F106C|Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.
40808622|NCT06112314|BIOLOGICAL|Nivolumab|Concentrate for solution for infusion at a unit dose of 10 mg/mL.
40808623|NCT06112314|BIOLOGICAL|Nivolumab + Relatlimab|Concentrate for solution for infusion at a unit dose of 10 mg/mL.
41154167|NCT00038961|OTHER|placebo|placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
41154168|NCT04964609|DEVICE|EmbracePlus|"A device intended for use by researchers and healthcare professionals for continuous collection of physiological parameters in home and healthcare settings.~Parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter."
41154169|NCT03071874|DRUG|AZD2014|AZD2014 is a dual mTORC1/mTORC2 inhibitor
41154170|NCT02721420|DRUG|dihydroartemisinin-piperaquine|
40808628|NCT05624554|DRUG|Nemtabrutinib|65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met.
40808629|NCT05624554|DRUG|Fludarabine|25 mg/m\^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
40808630|NCT05624554|DRUG|Cyclophosphamide|250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
41326083|NCT00873808|PROCEDURE|computed tomography|
41326084|NCT00873808|PROCEDURE|dual x-ray absorptiometry|
40808631|NCT05624554|DRUG|Bendamustine|Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m\^2. Subsequent doses may be escalated up to 90 mg/m\^2, if applicable and as per local guidelines.
40808632|NCT05624554|BIOLOGICAL|Rituximab|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
40808633|NCT05624554|BIOLOGICAL|Truxima|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
40808634|NCT05624554|BIOLOGICAL|Ruxience|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
40808635|NCT05624554|BIOLOGICAL|Riabni|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
41154171|NCT02721420|OTHER|message(SMS) reminder|
40808639|NCT06295809|BIOLOGICAL|Pembrolizumab|IV Infusion
40808640|NCT06295809|BIOLOGICAL|V940|IM injection
40808641|NCT06295809|PROCEDURE|Surgery|Local resection of cancerous lesions of the skin
40808642|NCT06527755|DRUG|Eplontersen Solution for Injection|an autoinjector with 0.8 mL deliverable volume (at 56 mg/mL concentration) will be provided, total dose is 45 mg.
41154172|NCT02721420|OTHER|Health worker reminder|Health surveillance assistants reminders prior to each treatment course
40808644|NCT06568731|DRUG|Danuglipron|Danuglipron oral tablets
40808645|NCT03658343|DIAGNOSTIC_TEST|T2* Imaging|T2\* imaging sequences for MRI
41154173|NCT02721420|OTHER|short message(SMS) reminder|
41154174|NCT05676996|OTHER|attachment-based support|attachment-based support application; It includes video-based trainings on attachment via mobile application and breastfeeding and skin-to-skin contact support for mothers on postpartum day 0.
41154175|NCT01088347|DRUG|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
41326085|NCT00003595|BIOLOGICAL|filgrastim|
41326086|NCT00003595|BIOLOGICAL|rituximab|
41326087|NCT00003595|DRUG|CHOP regimen|
41326088|NCT00003595|DRUG|cyclophosphamide|
41326089|NCT00003595|DRUG|doxorubicin hydrochloride|
41326090|NCT00003595|DRUG|prednisone|
41326091|NCT00003595|DRUG|vincristine sulfate|
41326092|NCT05560178|OTHER|SEXUAL HEALTH EDUCATION|Women in the intervention group will be given sexual health education once a week for 4 weeks
41326093|NCT06165380|DRUG|Cardenilimab Combined With Chemotherapy|Cardenilimab Combined With Chemotherapy
41326094|NCT04587596|OTHER|Pain education|70 minute lecture about chronic pain and one focus group afterwards
41326095|NCT04154371|DEVICE|Electromyography-controlled virtual and augmented reality using serious gaming|Surface electrodes and a tracking marker are placed on the subject's affected upper extremity. Electrodes are placed on active muscle sites along the affected extremity determined by palpation. Electrodes are connected to an electromyography recording device, and signal acquisition and processing software are used to record EMG signals and display feedback. Myoelectric signals are used to control a virtual limb on the screen. The intervention consists of different steps: virtual reality, augmented reality, and serious gaming, which the participant must control with their muscle activity, record by EMG, in their affected limb.
41326096|NCT03027219|DRUG|Alprostadil|Vasodilator for anastomosis-site of free flap
41326097|NCT01055418|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
40808646|NCT06118515|DRUG|Letermovir|Letermovir is a novel inhibitor targeting the cytomegalovirus (CMV) viral enzyme, effectively disrupting the production of additional CMV virions. Letermovir has demonstrated potent, selective, and reversible inhibition of CMV activity in preclinical studies.
41154176|NCT01088347|DRUG|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
41154177|NCT01088347|RADIATION|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
41154178|NCT02269033|BEHAVIORAL|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
41154179|NCT02269033|BEHAVIORAL|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged \> 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
41154180|NCT01395706|PROCEDURE|ICG Fluorescence technique|"This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.~A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.~10 mg (5mg/ml)per injection are applicated"
41326098|NCT05737407|OTHER|LUS-guided choice of Peep|Choice of Peep guided by lung ultrasound to avoid atelectasis
41326099|NCT05737407|OTHER|Standard choice of Peep|Choice of Peep according to standard practice
41326100|NCT05129787|PROCEDURE|Surgical resection|Resection of metastasis
41326101|NCT05129787|PROCEDURE|Thermal ablation|Ablation of metastasis
41326102|NCT00367029|BEHAVIORAL|Individualized Print-Based Motivational Program|"Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.~Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff."
41009609|NCT00865722|PROCEDURE|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
40808668|NCT05500417|DRUG|ALFQ|ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's Phosphate Buffer. Full dose of AFLQ compromised of 200 microgram 3D-PHAD and 100 microgram QS-21, co-administered with main intervention.
40808669|NCT05500417|BIOLOGICAL|CJCV2|Vaccine comprised of C. jejuni capsule conjugated to Cross-Reactive Material 197 (CRM197), a non-toxic mutant protein of diphtheria toxin. CJCV2 will be reconstituted in 1 mL of sterile water for injection (SWI). The resuspended CJCV2 product will be diluted with sterile 0.9% Sodium Chloride for Injection. 3 dosages for administration: 1 microgram, 3 micrograms, and 10 micrograms.
40808670|NCT03126916|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HSCT
40808671|NCT03126916|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40808672|NCT03126916|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
40808673|NCT03126916|DRUG|Busulfan|Given IV
40808674|NCT03126916|DRUG|Carboplatin|Given IV
40808675|NCT03126916|DRUG|Cisplatin|Given IV
40808676|NCT03126916|PROCEDURE|Computed Tomography|Undergo CT scan
40808677|NCT03126916|DRUG|Cyclophosphamide|Given IV
40808678|NCT03126916|DRUG|Dexrazoxane Hydrochloride|Given IV
40808679|NCT03126916|BIOLOGICAL|Dinutuximab|Given IV
40808680|NCT03126916|DRUG|Doxorubicin Hydrochloride|Given IV
40808681|NCT03126916|PROCEDURE|Echocardiography|Undergo echocardiography
40808682|NCT03126916|DRUG|Etoposide Phosphate|Given IV
40808683|NCT03126916|RADIATION|External Beam Radiation Therapy|Undergo EBRT
40808684|NCT03126916|RADIATION|Iobenguane I-123|Given 123 I-MIBG
40808685|NCT03126916|RADIATION|Iobenguane I-131|Given IV
40808686|NCT03126916|DRUG|Isotretinoin|Given PO
40808687|NCT03126916|DRUG|Lorlatinib|Given PO
40808688|NCT03126916|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40808689|NCT03126916|DRUG|Melphalan Hydrochloride|Given IV
40808690|NCT03126916|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
40808691|NCT03126916|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40808692|NCT03126916|BIOLOGICAL|Sargramostim|Given SC
40808693|NCT03126916|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
40808694|NCT03126916|DRUG|Thiotepa|Given IV
40808695|NCT03126916|DRUG|Topotecan Hydrochloride|Given IV
40808696|NCT03126916|DRUG|Vincristine Sulfate|Given IV
40808697|NCT05468619|DRUG|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir.
41009610|NCT06368063|DRUG|Huaier granule|Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
41154181|NCT02420938|DRUG|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
41154182|NCT02420938|DRUG|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
41154183|NCT03015961|DRUG|EXPAREL and bupivacaine HCl|"Drug: EXPAREL EXPAREL and bupivacaine HCl~Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
41154184|NCT03015961|DRUG|Bupivacaine HCl|"Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
41154185|NCT01610622|DEVICE|COstatus cardiac output measurement with isotonic saline|"Isotonic saline, which is the indicator, is injected to obtain COstatus cardiac output measurements.~No other interventions are made for the purpose of the study."
41154186|NCT05733000|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41154187|NCT05733000|PROCEDURE|Computed Tomography|Undergo CT
41154188|NCT05733000|DRUG|Devimistat|Receive IV
40808706|NCT03186508|BEHAVIORAL|Optimize Sleep (OS)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
40808707|NCT03186508|BEHAVIORAL|Optimize Sleep-Plus (OS-Plus)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
41154189|NCT05733000|DRUG|Fluorouracil|Receive IV
40808709|NCT05029999|DRUG|PLD Chemotherapy|PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
40808710|NCT05029999|DRUG|CDX-1140|CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
41009611|NCT06368063|DRUG|chemotherapy drugs|"Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment)~· Gemcitabine combine with capecitabine~Gemcitabine 1000mg/m\^2 intravenous infusion for more than 30 minutes, day 1, 8, 15,repeat every 4 weeks for a total of 6 cycles.~· mFOLFIRINOX solution~Oxaliplatin 85mg/m\^2 intravenous infusion for 2 hours, day 1 Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1 Leucovorin calcium 400mg/m\^2 intravenous infusion for 2 hours, day 1 5-FU 2400mg/m\^2, continuous intravenous infusion for 46 hours, repeated every 2 weeks, administered until 24 weeks.~* Gemcitabine monotherapy~  1000mg/m\^2 intravenous infusion, day 1 qw x 7, rest for 1 week Afterwards, qw × 3, take a week off, and administer medication for 6 months.~* Tegio capsules monotherapy~Take tegio capsules orally, 80mg/d, day 1-28, repeated every 6 weeks, administered until 6 months."
41154190|NCT05733000|DRUG|Gemcitabine Hydrochloride|Receive IV
41154191|NCT05733000|DRUG|Hydroxychloroquine|Receive PO
40808711|NCT05029999|DRUG|CDX-301|CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
40808712|NCT02052882|BIOLOGICAL|romiplostim|
40808713|NCT05274971|OTHER|Active dietary management and aerobic exercise training.|Active dietary management and aerobic exercise training.
40808714|NCT06494761|DRUG|zongertinib|zongertinib
40808715|NCT06494761|DRUG|midazolam|midazolam
41154192|NCT05733000|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41154193|NCT04339543|OTHER|Cognitive dual-task walking|• The task will consist in walking while performing the phoneme monitoring task. The phoneme monitoring task will consist in listening to a text through headphones, and participants will be asked to i) answer ten questions regarding the content of the text after the task, and ii) count how many times two predefined words appeared in the text. During single and dual-task walking, participants will be asked to walk around the track at a speed that they feel would be comfortable while walking through the grocery store or walking to their car, with no instructions regarding the priority to give to each task (walking vs. cognitive task).
40808716|NCT06494761|DRUG|omeprazole|omeprazole
40808717|NCT06494761|DRUG|repaglinide|repaglinide
41154194|NCT02515097|DRUG|IDP-122 Lotion|Medicated topical lotion
41154195|NCT02515097|DRUG|IDP-122 Vehicle Lotion|Vehicle topical lotion with no active ingredient
41154196|NCT02115178|OTHER|Lithotomy or Prone position|The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
41154197|NCT01347281|PROCEDURE|Injection of [18F]HX4|"Injection of \[18F\]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~\[18F\]HX4 PET scans; 444 MBq (12 mCi) \[18F\]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of \[18F\]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): \[18F\]FDG PET in treatment position"
41154198|NCT03049306|DRUG|Propranolol Oral Tablet|Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
41154199|NCT03049306|DRUG|Placebo Oral Tablet|Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
41154200|NCT06584669|DIETARY_SUPPLEMENT|Krill oil|The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).
41154201|NCT06584669|OTHER|Placebo|The placebo capsules contain a medium-chain triglyceride (MCT) oil obtained by fractionation of coconut and palm kernel oil, which has no detectable levels of EPA, DHA, astaxanthin, or phospholipids.
41154202|NCT05954780|DRUG|Selinexor|Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC
41154203|NCT03878290|BEHAVIORAL|Resilience, Stress, and Ethnicity (RiSE)|Group based stress reduction program focused on helping minorities develop coping and empowerment skills
41326103|NCT06186804|DRUG|ABSK021|Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.
41479617|NCT04078438|DEVICE|neurofeedback augmentation|"Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.~The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.~To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study."
41479618|NCT04078438|DRUG|treatment as usual|The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
40808719|NCT03756051|OTHER|Prospective Longitudinal Data|We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have \~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.
41479619|NCT04078438|OTHER|psychotherapy placebo sessions|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.
41154204|NCT01485991|DRUG|TMC435|TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
40808720|NCT03756051|OTHER|Surveys and Semi-structured Interviews|"We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family)."
41154205|NCT01485991|DRUG|TVR|TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
40808722|NCT02265536|DRUG|LY3022855|Administered IV
40808723|NCT04220827|DRUG|Paclitaxel|Given IP
41154206|NCT05935098|DRUG|BGB-A3055|Administered intravenously
41326104|NCT00669032|DEVICE|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
41326105|NCT00669032|OTHER|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
41479620|NCT03093818|OTHER|Pharmacogenomic testing|"The pharmacogenomic panel to be used incorporates 48 genetic variants for the following 13 pharamacogenes: CYP2B6 (cytochrome P450), CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), NUDT15 (Nudix hydrolase), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex)."
41479621|NCT00375492|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
41479622|NCT00375492|DRUG|placebo|subcutaneous injection, volume equivalent to exenatide dose, twice a day
41154207|NCT05935098|DRUG|Tislelizumab|Administered intravenously
41154208|NCT04130373|PROCEDURE|Autologous fat grafting procedure|Surgical intervention based on the injection of autologous fat grafting after radical or conservative breast surgery and breast reconstruction.
41154209|NCT04130373|PROCEDURE|Breast reconstruction|Breast reconstructive procedures after oncological radical or conservative breast surgery
41154210|NCT05672576|DRUG|Cenerimod|Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.
40808729|NCT05702645|PROCEDURE|Biospecimen Collection|Patients undergo saliva/buccal and blood sample collection
40808730|NCT05702645|OTHER|Clinical Evaluation|Undergo a clinical assessment
40808731|NCT05702645|OTHER|Questionnaire Administration|Ancillary studies
41154211|NCT05672576|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
41326106|NCT05019651|DEVICE|Apollo Wearable System|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks. They will be asked to continue to wear the device until all study data is collected.
41326107|NCT06174961|DRUG|Unfractionated heparin|15,000 units of unfractionated heparin administered in the thigh
41326108|NCT06174961|BEHAVIORAL|Double-legged cycle ergometer exercise|One hour of double-leg cycle ergometer exercise
41479623|NCT00000374|DRUG|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
41479624|NCT00000374|DRUG|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
41154212|NCT05944133|OTHER|No intervention, observational retrospective study|No intervention
41154213|NCT00237900|DRUG|Gefitinib, 5-fluorouracil, leucovorin and radiotherapy|
41154214|NCT02951416|OTHER|patient registry (observation and biomaterial sampling)|data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected
41154215|NCT00292305|PROCEDURE|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
41326109|NCT06174961|BEHAVIORAL|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
41009612|NCT02468466|BEHAVIORAL|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
41009613|NCT02468466|BEHAVIORAL|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
41009614|NCT02287896|DRUG|ROLEDUMAB|See Arm description
41479625|NCT05206487|DIETARY_SUPPLEMENT|Polydextrose|PDX will be started 2 weeks before TIPS and taken daily for a 6 month period after TIPS.
41326110|NCT06174961|BEHAVIORAL|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the non-exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
41326111|NCT06174961|BEHAVIORAL|No exercise|No exercise
41479626|NCT03347136|DEVICE|CPAP|
41479627|NCT03347136|DEVICE|NIPPV|
41326112|NCT04157647|DEVICE|CytoSorb|The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.
41326113|NCT04157647|DEVICE|Control|No hemadsorption filter or other treatment will be included in the CPB circuit
41479628|NCT02343757|DEVICE|PET/MRI|
41326114|NCT03129633|OTHER|Intervention group|One-on-one contact with a promotor(a) over the 6 month intervention.
41326115|NCT03438578|DEVICE|Efficacy Safety Score monitoring|According to data gathered from ESS and monitoring, the patients will receive needed care.
41009615|NCT01345084|RADIATION|Radiation Therapy|66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
41009616|NCT01345084|DRUG|Nimotuzumab|200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
41009617|NCT01345084|DRUG|Cisplatin|75 mg/m2, IV, doses every 3 weeks (a total of three doses)
41009618|NCT03638986|OTHER|No intervention planned|No Intervention planned.
41009619|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by lavage)|
41009620|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by bolus)|
41326116|NCT06085287|DEVICE|Electromagnetic therapy|Electromagnetic therapy will be performed using an electromagnetic stimulator (Smart Cap). Chinese medicine practitioners who have at least 3 years of experience will conduct EMT after training. Each session of EMT will take 20-25 min, with 2-3 sessions per week, total of 30 sessions finished within 12 weeks.
41326117|NCT00884715|DRUG|Octreotide|short acting octreotide
41326118|NCT02322684|DEVICE|Air-Q|Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
41326119|NCT05668676|DRUG|Prednisone arm|2 tabs of 20 mg prednisone per day during 7 days added to usual care medications
41326120|NCT05668676|OTHER|Usual care|Usual care alone as per European guidelines, which includes oxygen in case of hypoxia, low dose furosemide (40mg or daily dosage), and iv nitrates if no contra-indication.
41326121|NCT00536848|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|
41009621|NCT03619421|DIETARY_SUPPLEMENT|Zinc supplement|25 mg
41326122|NCT00536848|DIETARY_SUPPLEMENT|Placebo|
41326123|NCT00536848|DRUG|Metronidazole|
41009622|NCT04181346|DRUG|Pregabalin|antipsychotic
41326124|NCT04568187|DEVICE|zeltiq|Zeltiq prototype device (Zeltiq Aesthetics, Pleasanton, CA) approved by FDA 2010
41326125|NCT04568187|DEVICE|placebo|radiofrequency with 3000 Hz
41326126|NCT02992704|DRUG|Peginterferon Alfa-2A|peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
41479629|NCT00513682|DRUG|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
41479630|NCT01862393|DEVICE|400 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
41479631|NCT01862393|DEVICE|700 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds
41479632|NCT01862393|DEVICE|1000 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
41479633|NCT01704430|DIETARY_SUPPLEMENT|Glutamine|Enteric L-Glutamine
41479634|NCT01704430|DIETARY_SUPPLEMENT|Maltodextrin|Enteric Maltodextrin
41479635|NCT01543555|DRUG|Atorvastatin|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
41479636|NCT01543555|DRUG|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
41479637|NCT00925301|DRUG|migalastat hydrochloride|Oral capsule QOD
41479638|NCT00925301|DRUG|Placebo|Oral capsule QOD
41479639|NCT00474435|DRUG|Emtricitabine/tenofovir/efavirenz|"Co-formulated in one tablet (taken once daily by oral administration):~* emtricitabine 200 mg~* tenofovir DF 300 mg~* efavirenz 600 mg"
41009623|NCT04181346|DRUG|Placebo|Placebo
41009624|NCT06114862|BEHAVIORAL|Stigma-reduction intervention|"Participants will be presented with a list of common reasons why people report not wanting to tell other people about their mental health concerns, drawing from research in this area. Participants will be asked to click on any reason that resonates with them or about which they are interested in learning more. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns. For example, if a participant replies that they wouldn't reach out to peers because others don't understand what I'm going through, we might present context showing that many of their peers have had similar challenges with mental health and have found peer support helpful. Participants will be able to click on as many reasons on this list that they would like to."
40808732|NCT05702645|OTHER|Survey Administration|Ancillary studies
41326127|NCT04179786|BIOLOGICAL|Sci-B-Vac™|Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by SciVac Israel Ltd under good manufacturing practices (GMP). It contains the 3 surface antigens of the Hepatitis B virus: HBs, pre-S1 and pre-S2. Each 1 ml dose contains sterile 10 μg Hepatitis B virus surface antigens. It is formulated for intramuscular injection supplied in single use vials containing 1ml suspension.
40808733|NCT05662540|DEVICE|Positron Emission Tomography/Magnetic Resonance (PET/MR)|18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
41326128|NCT03089658|DRUG|Avelumab|Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
41326129|NCT02407912|DRUG|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
41009625|NCT05178849|OTHER|Hypnosis|Hypnosis
41009626|NCT05178849|DRUG|Local anesthetic|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
41154216|NCT02942628|OTHER|Vegetarian diet followed by meat diet or vice versa|Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
41326130|NCT00804843|DRUG|Atorvastatin/niacin extended-release|80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
41326131|NCT00804843|DRUG|Atorvastatin|10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
41326132|NCT00804843|DRUG|Simvastatin|(Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
41326133|NCT00804843|DRUG|Simvastatin|(Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
41326134|NCT06202339|DEVICE|DaRT seeds|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
41326135|NCT02843919|OTHER|Electroencephalography and Electrocardiography|
41326136|NCT06418334|DIAGNOSTIC_TEST|Thoracal hyperkyphosis study form|Thoracal hyperkyphosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.
41479640|NCT03132194|DRUG|DPSG 7.5%|topical gel
41479641|NCT03132194|DRUG|Aczone|topical gel
41479642|NCT03132194|DRUG|Placebo|topical gel
40808745|NCT04589845|DRUG|Entrectinib|Adults and pediatric participants with a BSA \>/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).
40808746|NCT04589845|DRUG|Entrectinib|Adults and pediatric participants with a BSA \>/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).
40808747|NCT04589845|DRUG|Alectinib|Alectinib will be administered orally BID (twice a day) with food at a dosage of 600 mg (four 150-mg capsules).
40808748|NCT04589845|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged \>/=18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle.
40808749|NCT04589845|DRUG|Ipatasertib|For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants \>/= 35 and \< 45 kg, 400 mg for those \>/= 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
40808750|NCT04589845|DRUG|Trastuzumab emtansine|Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
40808751|NCT04589845|DRUG|Idasanutlin|"Idasanutlin will be administered at 250 mg QD (daily) PO for Days 1-5 of each 28-day cycle. Idasanutlin may be given without regard to meals and water can be given as often as necessary or desired. The daily doses should be administered 10-14 hours apart.~Note: Cohort G has been closed for enrollment."
40808752|NCT04589845|DRUG|Inavolisib|GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
40808753|NCT04589845|DRUG|Belvarafenib|Belvarafenib will be administered at a dose 400 mg (PO) BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
40808754|NCT04589845|DRUG|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).
40808755|NCT04589845|DRUG|GDC-6036|GDC-6036 will be self-administered by patients orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric patients. A treatment cycle consists of 3 weeks (21 days).
40808756|NCT04589845|DRUG|Camonsertib|Camonsertib will be self-administered by patients orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
41154217|NCT00889733|DRUG|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
40808758|NCT06556563|DEVICE|Optune® device|Optune® device delivering TTFields therapy at 200 kHz.
40808759|NCT06556563|DRUG|Temozolomide|Temozolomide per approved labeling.
40808760|NCT06556563|DRUG|Pembrolizumab|Pembrolizumab dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
41009627|NCT05984134|DRUG|NL005 Middle Dose|Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
41326137|NCT06418334|DIAGNOSTIC_TEST|Scoliosis graphy|Patients whose forward bending test and clinical evaluation results are compatible with hyperkyphosis and scoliosis radiographs are requested. Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.
41009628|NCT05984134|DRUG|NL005 High Dose|Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.
40808761|NCT06556563|DRUG|Placebo|Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
40808762|NCT03325296|DRUG|LEO 124249|Ointment containing LEO 124249
40808763|NCT03325296|OTHER|Ointment vehicle|Ointment without active ingredients
40808764|NCT05535244|DRUG|Cevostamab|Cevostamab will be administered by IV infusion in 21-day cycles.
40808765|NCT05535244|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
40808766|NCT06249048|BIOLOGICAL|STX-001|STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.
40808767|NCT06249048|BIOLOGICAL|Keytruda®|Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
41009629|NCT05984134|DRUG|Placebo|30 subjects will be randomly assigned to the placebo for 7 days
41009630|NCT04526795|DRUG|Cytarabine|Given IV
41009631|NCT04526795|DRUG|Fludarabine|Given IV
41009632|NCT04526795|DRUG|Pegcrisantaspase|Given IV
41009633|NCT03042234|OTHER|Group Insulin-Resistant|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
41009634|NCT03042234|OTHER|Group Insulin-Sensitive|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
41009635|NCT00623883|PROCEDURE|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
41009636|NCT00623883|PROCEDURE|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
41009637|NCT03536039|DRUG|NGR-hTNF|dose of 0.8 mcg/sqm
41009638|NCT03536039|OTHER|RITUXIMAB|dose of 375 mg/mq
41009639|NCT03536039|DRUG|Doxorubicin|dose of 50 mg/mq
41009640|NCT03536039|DRUG|Cyclophosphamide|dose of 750 mg/mq
41009641|NCT03536039|DRUG|Vincristine|dose of 1.4 mg/mq (max 2 mg)
41009642|NCT03536039|DRUG|Prednisone|75 mg
41009643|NCT06211816|OTHER|communication strategy|an intensive communication strategy on end-of-life practice was implemented, based on a framework developed by the International Delphi Conference.
41154218|NCT03770299|BIOLOGICAL|Nivolumab|Specified dose on specified days
41154219|NCT03770299|DRUG|Vinorelbine|Specified dose on specified days
41154220|NCT03770299|DRUG|Gemcitabine|Specified dose on specified days
40808768|NCT05612061|BEHAVIORAL|Indigenous Recovery Planning|"The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future."
41154221|NCT03770299|DRUG|Docetaxel|Specified dose on specified days
41154222|NCT03770299|DRUG|Pemetrexed|Specified dose on specified days
41154223|NCT03770299|DRUG|Cisplatin|Specified dose on specified days
41154224|NCT03770299|DRUG|Carboplatin|Specified dose on specified days
40808773|NCT06568003|DEVICE|Transcatheter Tricuspid Valve Intervention|Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
41154225|NCT03770299|DRUG|Paclitaxel|Specified dose on specified days
41154226|NCT03770299|OTHER|Observation|Observation by the investigator
40808776|NCT04461639|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Different prophylaxis regimens with damoctocog alfa pegol following approved local labels or any other regimen prescribed by the physician as part of normal clinical practice
41326138|NCT06418334|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help participant healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken."
41326139|NCT06418334|DIAGNOSTIC_TEST|Ultrasonographic Measurement|Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter-cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
41326140|NCT01778270|DEVICE|Body Bioimpedance Sensor|
41326141|NCT02467023|DEVICE|Muscle stimulation with Niveus medical stimulator|Subjects will be treated five days per week, for 30 minutes each session. Muscle stimulation will be conducted for four seconds every 15 seconds, thus the subjects will undergo four stimulations per minute. Muscle stimulation will be adjusted until there is a visible or palpable bilateral quadriceps contraction.
41479643|NCT05981248|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
41479644|NCT05566678|OTHER|Cigarette|Subjects who self-selected to continue smoking their own preferred brand of commercially available cigarettes.
41479645|NCT05566678|OTHER|THS|Subjects who self-selected to quit smoking during the study duration will switch from cigarettes to using THS.
40808783|NCT06566170|DRUG|Donanemab|Administered IV
40808784|NCT06566170|DRUG|Usual Care|Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.
40808785|NCT06052059|DRUG|IV Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
40808786|NCT06052059|DRUG|IV Placebo|Placebo matching IV tulisokibart
40808787|NCT06052059|DRUG|SC Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
40808788|NCT06052059|DRUG|SC Placebo|Placebo matching SC tulisokibart
40808789|NCT06481878|DIAGNOSTIC_TEST|faecal analysis|Collection of medical data and stool sampling
40808790|NCT06305767|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to 9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of every 3-week cycle for up to 4 neoadjuvant cycles, and up to 13 adjuvant cycles for Perioperative Cohort participants.
40808791|NCT06305767|BIOLOGICAL|V940|Administered via IM injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.
41479646|NCT05566678|OTHER|Smoking Abstinence|Subjects who self-selected to quit smoking may be prescribed Nicotine Replacement Therapy (NRT) to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
41479647|NCT03295695|DIAGNOSTIC_TEST|Fluoro-D-glucose-positron Emission Tomography|2-deoxy-2-\[18F\]Fluoro-D-glucose-positron Emission Tomography (FDG-PET): within 2 weeks of obtaining first echocardiogram; within two weeks of obtaining follow-up echocardiogram.
41479648|NCT03295695|BIOLOGICAL|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|"2-deoxy-2-\[18F\]fluoro-D-glucose (FDG) labeled autologous human erythrocytes (RBCs): Approximately 10 mls of packed human erythrocytes are collected from the patient and labeled with ≈5-10 milliCuries of commercially available United States Pharmacopeia (USP)-grade FDG (≈5-10 picograms FDG) (Vendor: Cardinal Health) under sterile conditions in a Good Manufacturing Practice (GMP)-certified laboratory.~Synthesized RBCs: The cell suspension is manually infused via syringe through an indwelling peripheral venous catheter over the course of 1 minute, using an infusion method approved by the Moffitt Cancer Center (MCC) radiation safety officer."
40808792|NCT06305767|OTHER|Placebo|V940 diluent only (saline and/or dextrose) administered via IM injection Q3W for up to 9 doses.
40808793|NCT06305767|BIOLOGICAL|Enfortumab Vedotin|Administered via IV infusion at a dose of 1.25 mg/kg on Day 1 and Day 8 of every 3-week cycle for up to 4 neoadjuvant cycles, and up to 5 adjuvant cycles for Perioperative Cohort participants.
41326142|NCT02467023|DEVICE|measurement of maximal isometric twitch strength|Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.
41326143|NCT02467023|PROCEDURE|Muscle Biopsy|"This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4 long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding."
41326144|NCT02467023|DRUG|Muscle Biopsy Medication: Lidocaine|Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
41326145|NCT02467023|DRUG|Muscle Biopsy Medication: Versed|Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
41326146|NCT02467023|DRUG|Muscle Biopsy Medication: Fentanyl|Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
41326147|NCT02467023|OTHER|Blood and Urine Sampling|Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.
41326148|NCT02467023|DEVICE|ineffective muscle stimulation|An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.
41326149|NCT01249963|DIETARY_SUPPLEMENT|T-Diet plus Atémpero|T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.
41326150|NCT01249963|DIETARY_SUPPLEMENT|AlitraQ (Abbott)|AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
41326151|NCT01957709|OTHER|Laboratory Biomarker Analysis|Correlative studies
41326152|NCT01957709|BIOLOGICAL|Recombinant Interferon Gamma|Given subcutaneously weekly for four weeks prior to surgery.
41326153|NCT01388868|OTHER|TOF count guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
41326154|NCT01388868|OTHER|T1/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
41479649|NCT03295695|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram: prior to start of chemotherapy; post-treatment regimen.
41479650|NCT04004117|DRUG|Fentanyl citrate solution sublingual|Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
40808794|NCT06305767|PROCEDURE|Surgery (RC plus PLND)|Curative intent surgery (RC plus PLND) will be administered to all participants in the Perioperative Cohort and will be done in accordance with the American Urological Association/American Society for Radiation Oncology/American Society of Clinical Oncology/Society of Urologic Oncology guidelines.
40808795|NCT06425159|DRUG|BHV-7000|BHV-7000 75mg. Participants will take blinded investigational product (IP) once daily
41479651|NCT04004117|DRUG|Placebo oral liquid|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
40808796|NCT06425159|DRUG|Placebo|Matching placebo taken once daily
40808797|NCT04171635|RADIATION|Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)|Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
40808798|NCT04171635|RADIATION|R2* Magnetic Resonance Imaging (MRI)|Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
40808799|NCT06116916|DRUG|KHK4951|KHK4951 eye drop for 36 weeks until end of the trial
40808800|NCT06116916|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
40808801|NCT06568237|DRUG|TEV-56286|TEV-56286 capsules administered orally
40808802|NCT06568237|DRUG|Placebo|Matching placebo administered orally
40808803|NCT05453578|OTHER|Placebo|0.9 percent sodium chloride
40808804|NCT05453578|BIOLOGICAL|WRAIR-PAM-CF1|Bacteriophage combination composed of the following phages: PaWRA01Phi11, PaWRA01Phi39, PaWRA02Phi83, and PaWRA02Phi87.
40808805|NCT06347133|DRUG|Plozasiran Injection|ARO-APOC3 Injection
40808806|NCT06347133|DRUG|Placebo|sterile normal saline (0.9% NaCl)
40808807|NCT04270682|DRUG|Blinded CDCA 250 mg TID|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
40808808|NCT04270682|DRUG|Placebo|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
40808809|NCT04270682|DRUG|Open-Label CDCA 250 mg TID|Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.
40808810|NCT04270682|DRUG|Rescue Medication CDCA 250 mg TID|CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
40808811|NCT04270682|DRUG|CDCA Weight-Based Dose TID|Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
40808812|NCT05913713|BEHAVIORAL|12-week Intervention Period|Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.
40808813|NCT05913713|BEHAVIORAL|12-week Observation Period|After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
40808814|NCT06102200|BEHAVIORAL|CBT4CBT|This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
40808815|NCT06102200|BEHAVIORAL|RC|Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.
40808816|NCT06102200|BEHAVIORAL|Sandard of care|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.
40808817|NCT03869385|DRUG|Albutein® 200 g/L or Plasbumin® 20|The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
41154227|NCT02921438|DEVICE|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
41479652|NCT05377593|DEVICE|eminoplasty with patient specific Zirconium dioxide onlay implant|Eminoplasties will be done for patient with chronic condylar dislocation using patient specific zirconium dioxide implants
40808820|NCT03562975|DRUG|Ocrelizumab|Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds
40808821|NCT05349890|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
40808822|NCT05349890|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
40808823|NCT05349890|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
41479653|NCT06097793|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
40808824|NCT06052566|DRUG|Efinopegdutide|Subcutaneous injection administered at a dose of 7 mg
40808825|NCT02470585|DRUG|Veliparib|Capsules for oral administration
40808826|NCT02470585|DRUG|Paclitaxel|Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
40808827|NCT02470585|DRUG|Carboplatin|Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.
40808828|NCT02470585|OTHER|Placebo to Veliparib|Capsules for oral administration
41479654|NCT06278038|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
41479655|NCT06278038|DRUG|Venlafaxine hydrochloride sustained-release tablets|75 mg or 150 mg or 225 mg orally once daily dosing for 8 weeks
41479656|NCT00125411|DRUG|satraplatin and docetaxel|"Satraplatin - oral administration within 2 hours of docetaxel infusion. Subsequent dosing will be on days 2-5 at approximate 24 hour intervals.~Docetaxel will be administered as intravenous infusion over 1 hour followed by saline flush."
41479657|NCT01280617|DRUG|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
41479658|NCT01280617|DRUG|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
41154228|NCT02775123|DEVICE|Cytosorb|A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
41154229|NCT02502487|PROCEDURE|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
41154230|NCT02502487|DRUG|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
41154231|NCT02502487|DRUG|Tetracaine|1% Tetracaine gel instilled into urethra
41154232|NCT00862225|DRUG|Placebo|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
41154233|NCT00862225|DRUG|Desloratadin|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
41154234|NCT00862225|DRUG|IG-RD-001 / Ze 339|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
41154235|NCT06422559|DEVICE|Transmagnetic stimulation|Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
41154236|NCT06422559|DEVICE|TMS|Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
41154237|NCT05022927|DRUG|ERY974|ERY974 vial
41479659|NCT00070616|DRUG|Palifermin 6 x 60 μg/kg/day|
41479660|NCT00070616|DRUG|Palifermin 2 x 180 μg/kg/day|
41479661|NCT00070616|RADIATION|radiotherapy|
41479662|NCT00070616|DRUG|Chemotherapy|
41479663|NCT01825122|DRUG|Nadolol|
41154238|NCT05022927|DRUG|Tocilicumab|Tocilizumab vial
41154239|NCT05022927|DRUG|Atezolizumab|Atezolizumab vial
41154240|NCT05022927|DRUG|Bevacizumab|Bevacizumab vial
41154241|NCT00396721|DRUG|ACE inhibitor + statin|sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
41154242|NCT00396721|DRUG|Sirolimus (study drug)+ACE inhibitor + statin|enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
40808844|NCT05675722|BIOLOGICAL|biologic vaginal-construct implantation|biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.
40808849|NCT06567340|DEVICE|StratCare|The StratCare app is a technology that collects data, processes inputs using a machine learning algorithm, and outputs a personalised treatment recommendation using automated decision rules. The inputs for the algorithm include patient-reported measures of depression, anxiety, functional impairment, personality traits, employment status and ethnic background. The algorithm calculates an expected prognosis (i.e., a probability of full remission of depression and anxiety symptoms after treatment), based on which patients are classified as standard (better expected prognosis) or complex cases. Standard cases are matched to low-intensity treatments and later have the option to move to high-intensity, whereas complex cases are matched directly to high-intensity treatments. In addition, the StratCare app is programmed to implement decision rules that ensure compliance with national clinical guidelines for the treatment allocation of patients with specific disorders.
41479664|NCT01825122|DRUG|Placebo|
41479665|NCT03050034|DEVICE|WIN @ Hospital system|WIN @ Hospital system is a wearable and wireless system (Medical Class IIA) that allows continuous and real-time vital signs monitoring, automatically calculating the NEWS score with a personalized alert system for the patient. It does not require the continuous presence of the nurse in front of the control room, but is working with alert on portable devices (ipad).
41479666|NCT03050034|OTHER|Traditional monitoring|Vital signs control performed by nurse staff each 6 hours or more, according to medical advice.
41479667|NCT05361291|DRUG|Lidocaine Hydrochloride|Inferior alveolar nerve block
41479668|NCT06443788|DIAGNOSTIC_TEST|transperineal ultrasound|"The following measurement will be recorded:~1. Amniotic fluid pooling assessment will be performed in sagittal and transverse planes. ,~   * Images will be evaluated for appearance of accumulated hypoechogenic fluid around cervix. Whenever collection is spotted, three largest dimensions of fluid will be measured (length, width, depth).~  * Fluid accumulations around the cervix that are clearly demarcated from surrounding tissues will be considered positive.~2. Cervical length: it will be measured between the internal os point to the external os point below. Cervical dilatation will be measured in a transverse plane from inner to inner.~3. Presence of fetal part prolapse and/or cord prolapse"
41154243|NCT04382183|BEHAVIORAL|Ketogenic weight loss maintenance diet|The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
41154244|NCT04382183|BEHAVIORAL|Isocaloric balanced weight loss maintenance diet|The isocaloric balanced weight loss maintenance group will undergo in a diet following the recommendations from the Norwegian Health Directorate for 1 year.
41154245|NCT02503488|BEHAVIORAL|Narrative Exposure Therapy for Forensic Offender Rehab|See arm description.
41326155|NCT01388868|OTHER|T2/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
41154246|NCT02503488|BEHAVIORAL|Treatment as Usual|See arm description
41154247|NCT06045364|DRUG|Glycopyrrolate|During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously
41154248|NCT06045364|DRUG|Anisodamine|During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.
41154249|NCT03216252|BIOLOGICAL|samples|Blood samples, oral smear and urine
41154250|NCT04632264|OTHER|Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery|The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride
41154251|NCT04632264|OTHER|Initiation of standard postpartum oxytocin immediately following placenta delivery|Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride
41154252|NCT04632264|OTHER|Saline Placebo|Saline placebo will be initiated post placenta delivery (within 15 seconds).
40808860|NCT06107816|BEHAVIORAL|Usual Care|Visit with a primary care provider and referral for diabetes self-management education and support (DSME/S) sessions
40808861|NCT06107816|BEHAVIORAL|F&V Rx alone|Usual Care plus four F\&V prescriptions that are independent of DSME/S attendance
40808862|NCT06107816|BEHAVIORAL|F&V Rx plus DSME/S|Usual Care plus four F\&V prescriptions that are dependent on DSME/S attendance
41154253|NCT04632264|OTHER|Saline Placebo|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).
41326156|NCT05169346|BEHAVIORAL|Active Closed Loop Real Time fMRI Neurofeedback|Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
41326157|NCT05169346|BEHAVIORAL|Sham Closed Loop Real Time fMRI Neurofeedback|Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
41326158|NCT03025893|DRUG|Sunitinib|Sunitinib, 300 mg administered orally in a weekly schedule.
41326159|NCT03025893|DRUG|Lomustine|Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
41326160|NCT03138512|BIOLOGICAL|nivolumab|Specified dose on specified days
41154254|NCT03715634|DRUG|INDV-6200|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
41154255|NCT03715634|DRUG|Placebo|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
41154256|NCT03715634|DRUG|SL Buprenorphine|All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability
41154257|NCT03715634|DRUG|Nalorex|Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
41154258|NCT02064361|OTHER|High intensity exercise|Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.
41154259|NCT01388621|DRUG|Panitumumab|Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
41326161|NCT03138512|BIOLOGICAL|ipilimumab|Specified dose on specified days
41326162|NCT03138512|DRUG|nivolumab placebo|Specified dose on specified days
41326163|NCT03138512|DRUG|ipilimumab placebo|Specified dose on specified days
41326164|NCT05711680|DEVICE|Device|To develop an e-health system to remotely monitor patients with chronic HIV infection and conduct early screening for COVID-19 through a telemonitoring, teleconsultation and periodic remote visit system.
40808883|NCT06430801|DRUG|IV Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
40808884|NCT06430801|DRUG|SC Tulisokibart|Humanized monoclonal antibody that binds human TL1A, administered subcutaneously
40808885|NCT06430801|OTHER|IV Placebo|Placebo matching IV tulisokibart
40808886|NCT06430801|OTHER|SC Placebo|Placebo matching SC tulisokibart
41154260|NCT01388621|DRUG|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
41154261|NCT01388621|DRUG|Carboplatin|Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
41154262|NCT01388621|DRUG|Gemcitabine|gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
41154263|NCT01388621|DRUG|Carboplatin|Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
41154264|NCT01388621|DRUG|Panitumumab|Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
41154265|NCT01585688|DRUG|hLL1-DOX (IMMU-115)|hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
41154266|NCT04980755|OTHER|Body Reprogramming|An educational intervention originally designed for patients with fibromyalgia.
41154267|NCT01841645|DIETARY_SUPPLEMENT|CLA depletion-repletion|
41154268|NCT05527509|BEHAVIORAL|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of RCMP trainers during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
41326165|NCT04984512|DRUG|Mitizodone Phosphate tablets|Mitizodone Phosphate tablets will be administered with food.
41326166|NCT04984512|DRUG|Placebo-matching tablets|Placebo will be administered with food.
41326167|NCT00605722|DRUG|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
41479669|NCT02413931|OTHER|Routine management practices applied|all patients will be treated according to routine procedures, no intervention
40808900|NCT06317649|DRUG|Azacitidine|Given IV or SC
40808901|NCT06317649|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40808902|NCT06317649|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
40808903|NCT06317649|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
40808904|NCT06317649|DRUG|Gilteritinib|Given PO
40808905|NCT06317649|DRUG|Venetoclax|Given PO
40808906|NCT06239064|DIAGNOSTIC_TEST|Genetic testing via blood collection|blood collection
40808907|NCT01925040|DEVICE|Placement of restoration|Placement of restorations
40808910|NCT02950155|DRUG|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
40808911|NCT02950155|DRUG|Sodium Chloride solution|A single infusion of Placebo/Sham.
41326168|NCT00605722|DRUG|erlotinib (Tarceva)|150 mg orally (po) daily.
41479670|NCT06036888|OTHER|questionaries completion|Answer to the DASH and SF-12 questionaries, for an estimated duration of 15 minutes.
41479671|NCT04400760|DRUG|DAPA Tx|The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
41479672|NCT04647383|DRUG|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
41154269|NCT05527509|BEHAVIORAL|Active Monitoring|Participants in the STC will be assessed for at least 66 months, via full assessments (i.e., self-report surveys, clinical interviews), monthly assessments (i.e., \~20 minute self-report surveys), daily assessments (i.e., \~1 minute self-report surveys), and biometric assessments. The self-monitoring and feedback should be inherently beneficial and should facilitate earlier access to evidence-based care, which is why the STC is considered an active comparator.
40808913|NCT06392230|DRUG|Oral [14C] PF-06821497|A single oral dose of \[14C\] PF-06821497 will be administered as an extemporaneous suspension in Period 1
40808914|NCT06392230|DRUG|Oral PF-06821497|A single oral dose of PF-06821497 will be administered as an extemporaneous oral suspension in Period 2
40808915|NCT06392230|DRUG|IV [14C] PF-06821497|A single IV infusion of \[14C\] PF-06821497 will be administered at the Tmax after administration of the unlabeled oral dose of PF-06821497 in Period 2
41326169|NCT03130439|DRUG|Abemaciclib|Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
41326170|NCT01875705|DRUG|GDC-0994|Escalating doses of GDC-0994 until maximum tolerated dose is reached
41479673|NCT04647383|DRUG|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
41479674|NCT04647383|DRUG|Placebo|COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
41479675|NCT04647383|DRUG|Lemborexant 10 mg|COPD: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
41479676|NCT01192984|BIOLOGICAL|KW-0761|Intravenously 8 times at 1-week intervals
40808916|NCT03541889|DRUG|FLT imaging and TK1 blood measurements|F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
41157205|NCT06245499|BEHAVIORAL|Aging Brain Care Virtual Program|The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.
41326171|NCT01875705|DRUG|GDC-0994|Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
40808919|NCT06384781|BEHAVIORAL|Peer Support Checklist|Peer support specialists are Certified Peer Support Specialists (CPSS) who have lived experience with Opioid Use Disorder (OUD) and OUD recovery. Peer support specialists offer consistent personalized recovery support and generalized social support. Peer support specialists will maintain contact and provide support for the participant for six-months post-baseline. CPSS will utilize the newly developed checklist from earlier phases of the project to provide patient support.
40808920|NCT01096368|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo conformal radiotherapy
40808921|NCT01096368|DRUG|Carboplatin|Given IV
40808922|NCT01096368|DRUG|Cisplatin|Given IV
41326172|NCT03682939|BIOLOGICAL|Bexsero® (meningitis B vaccine)|Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant
41479677|NCT03718741|RADIATION|Radiotherapy +/- CT|Adiuvant Radiotherapy +/- weekly cisplatin
40808923|NCT01096368|OTHER|Clinical Observation|Patients undergo observation
40808924|NCT01096368|DRUG|Cyclophosphamide|Given IV
40808925|NCT01096368|DRUG|Etoposide|Given IV
40808926|NCT01096368|BIOLOGICAL|Filgrastim|Given SC or IV
41326173|NCT03682939|BIOLOGICAL|Menveo® (meningitis ACWY vaccine)|Menveo® 0.5ml IM vaccine administered into dominant arm of participant
41479678|NCT00697606|DEVICE|Seprafilm®|Seprafilm® placed at time of primary cesarean
41479679|NCT00697606|OTHER|Control|no Seprafilm® used at primary cesarean
41479680|NCT03517254|DIETARY_SUPPLEMENT|Glutamine|At the beginning and at the end of the training session, the experimental group will receive by mouth 15 grams of glutamine dissolved in 120 milliliters of water. The aminoacid will be inside gray envelopes.
41479681|NCT03517254|OTHER|Strength training program|One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.
41326174|NCT04374266|DIAGNOSTIC_TEST|physical examination, and computerized tomography|physical examination, and computerized tomography was performed during routine follow-up
41326175|NCT01529814|DEVICE|Implant with new abutment connection|New abutment connection implant system
41479682|NCT03517254|OTHER|Placebo|Maltodextrin powder to mimic glutamine,
40808927|NCT01096368|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41326176|NCT01529814|DEVICE|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
41479683|NCT03517254|OTHER|Dietary recommendations|All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).
41479684|NCT00614809|DRUG|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
41479685|NCT05655247|PROCEDURE|Split-thickness non-advanced tunnel (Zabalegui et al. 1999)|A split-thickness non-advanced tunnel will be performed according to Zabalegui et al. (1999).
40808928|NCT01096368|DRUG|Mesna|Given IV
40808929|NCT01096368|DRUG|Vincristine|Given IV
41154270|NCT04661189|BEHAVIORAL|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
41154271|NCT04661189|BEHAVIORAL|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
41154272|NCT01679457|BEHAVIORAL|ACT-Focused ERP|
41154273|NCT01679457|BEHAVIORAL|TAU-ERP|
41479686|NCT05655247|PROCEDURE|Full-thickness coronally-advanced tunnel (Aroca et al. 2010)|A full-thickness coronally-advanced tunnel (Modified Coronally Advanced Tunnel - MCAT) will be performed according to Aroca et al. (2010).
41479687|NCT03421366|DRUG|Posaconazole|A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
40808935|NCT06078371|OTHER|Opioid-free pain treatment|Pain treatment includes any medications up to the medical team's discretion aside from opioids.
40808936|NCT05822635|DEVICE|SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System|Observational, prospective study for the clinical utility of the SpyGlass Discover Digital Catheter and the SpyScope DS Catheter during an intraoperative endoscopy procedure.
40808937|NCT05135559|DRUG|Concizumab|"Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.~Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose."
40808938|NCT06411327|DEVICE|Augmented reality|Augmented Reality Devices - data collected from the Guiding-Pad app will be fed to two AR devices (i.e. team leader and medication nurse), which will provide role-specific decision support for these two providers.
40808939|NCT06411327|DEVICE|LCD Screen|LCD Screen - data collected from the Guiding-Pad app will be fed to the LCD screen, which will be mounted on a wall, in clear view for the entire resuscitation team to see.
40808943|NCT05927519|DEVICE|airtraq video laryngoscope|airtraq video laryngoscope will be used for intubations
40808944|NCT06116890|DRUG|KHK4951|KHK4951 eye drop for 44 weeks until end of the trial
40808945|NCT06116890|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
40808946|NCT00309985|DRUG|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
40808947|NCT00309985|DRUG|docetaxel|Given IV
40808948|NCT05936359|DRUG|INCA033989|INCA033989 will be administered at protocol defined dose.
40808949|NCT05936359|DRUG|Ruxolitinib|Rux will be administered according to Prescribing Information/SmPC.
41154274|NCT02956876|DRUG|standard chemotherapy for colorectal cancer|standard chemotherapy for colorectal cancer
41154275|NCT02956876|OTHER|Nurse practitioner consultation|Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer
41154276|NCT02956876|OTHER|Medical practitioner consultation|Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
40808952|NCT06073821|DRUG|Sonrotoclax|Administered orally
40808953|NCT06073821|DRUG|Zanubrutinib|Administered orally
40808954|NCT06073821|DRUG|Venetoclax|Administered orally
40808955|NCT06073821|DRUG|Obinutuzumab|Administered intravenously
41154277|NCT04212559|OTHER|Received negative pressure ventilation|Patients who received a negative pressure during inspiratory phase.
41154278|NCT01714414|DRUG|FZD|
41154279|NCT01714414|DRUG|3TC|
41154280|NCT01714414|DRUG|EFV|
41154281|NCT01714414|DRUG|AZT|
41154282|NCT03165344|OTHER|Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)|the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.
41154283|NCT03165344|OTHER|Triamcinolone Acetonide (route of administration)|The control group will get local injection of triamcinolone acetonide in wound during the operation.
41154284|NCT03165344|OTHER|Prednisone (route of administration)|The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
41154285|NCT04170153|DRUG|M1774|M1774 will be administered orally throughout the study.
41154286|NCT04170153|DRUG|Niraparib|Niraparib will be administered orally throughout the study.
41154287|NCT03314389|DEVICE|Cochet bonnet esthesiometer|Cochet bonnet esthesiometer- To examine sensation
41154288|NCT00000647|DRUG|CD4-IgG|
41154289|NCT00000647|DRUG|Zidovudine|
40808970|NCT06503848|DRUG|Sumatriptan|Register the response to treatment and headache characteristics.
40808971|NCT03994796|DRUG|Abemaciclib|Given PO
40808972|NCT03994796|DRUG|PI3K Inhibitor paxalisib|Given PO
40808973|NCT03994796|DRUG|Entrectinib|Given PO
40808974|NCT03994796|DRUG|Adagrasib|Given PO
41154290|NCT00000647|DRUG|Interferon alfa-n1|
41154291|NCT00000647|PROCEDURE|Peripheral lymphocyte infusion|
40808977|NCT05718570|DRUG|Somapacitan|Sogroya therapy in participants with AGHD.
41154292|NCT00000647|PROCEDURE|Bone marrow transplant|
41154293|NCT04481334|OTHER|Collaborative occupational therapy interactive vaulting group|Children will participate in a weekly 60 minute group that focuses on the devilment of social skills by incorporating activities that require team work. Part of the intervention will incorporate the equine to better understand non-verbal body language. It should be noted that each child will have two agreed upon goals developed that are agreed upon by the child and the parent and will be of emphasis during each group.
40808980|NCT02122666|PROCEDURE|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
41154294|NCT01794650|DIETARY_SUPPLEMENT|Meal composition|
41154295|NCT00016237|BIOLOGICAL|tucotuzumab celmoleukin|
41154296|NCT00346242|DRUG|Zoledronic Acid|
41154297|NCT06115239|OTHER|Questionnaires|The patients will fulfill the EORTC-LC29 and HADS questionnaires in 5 different moments.
41154298|NCT03149887|DRUG|Liposomal bupivacaine|Liposomal bupivacaine solution (Exparel) for injection
41154299|NCT03149887|DRUG|Placebo|Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
41154300|NCT03037814|DEVICE|Compomer|Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.
41154301|NCT03037814|DEVICE|RMGIC|Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.
41154302|NCT03037814|DEVICE|Giomer|Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.
41154303|NCT03037814|DEVICE|Amalgam|Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
41154304|NCT01447251|BEHAVIORAL|PreDx Diabetes Risk Score|The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.
41326177|NCT02911623|DEVICE|Shockwave Lithoplasty® System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
41479688|NCT00251641|DRUG|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
41154305|NCT02423447|DEVICE|Electro-Flo Intervention|An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
41479689|NCT00251641|DRUG|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a \<25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
41479690|NCT03765086|PROCEDURE|Karydakis procedure|Pilonidal sinus will be excised by Karydakis procedure
41479691|NCT03765086|PROCEDURE|Limberg Flap|Pilonidal sinus will be excised by Limberg Flap
41154306|NCT02423447|DEVICE|G5 Intervention|An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
40808983|NCT06584916|DRUG|Orforglipron|Administered orally
40808984|NCT06584916|DRUG|Placebo|Administered orally
40808985|NCT05107011|DRUG|LBL-015 for Injections|Initial dose - MTD ; Q2W ; intravenous infusion
40808986|NCT04989556|OTHER|Interview|Participate in interview
40808987|NCT04989556|OTHER|Palliative Therapy|Receive standard symptom management by palliative care team
40808988|NCT04989556|OTHER|Palliative Therapy|Receive provider initiated remote contact
40808989|NCT04989556|OTHER|Quality-of-Life Assessment|Ancillary studies
40808990|NCT04989556|OTHER|Questionnaire Administration|Complete questionnaire
40808991|NCT06536517|DRUG|Methadone|Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)
41154307|NCT04285671|BIOLOGICAL|Necitumumab|Given IV
41154308|NCT04285671|DRUG|Osimertinib|Given PO
41326178|NCT06453187|DEVICE|Urinary Bladder Matrix (UBM) sheet device for Venous Leg Ulcers|Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
40808993|NCT06176690|BIOLOGICAL|C7R.CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
40808994|NCT05549232|DEVICE|Hypoxic Red Blood Cells|Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced
41326179|NCT06453187|DEVICE|Urinary Bladder Matrix (UBM) sheet device for Diabetic Foot Ulcers|Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
41326180|NCT06453187|DEVICE|AmnioExcel Plus for Venous Leg Ulcers|Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
40809002|NCT06503250|DRUG|Atezolizumab|Observational Study
40809003|NCT06503250|DRUG|Bevacizumab|Observational Study
40809004|NCT06503250|RADIATION|Transarterial Chemoembolization|Observational Study
40809005|NCT06345001|DRUG|BAY3630942|IV, Single administration
40809006|NCT06345001|DRUG|BAY3547922|IV, Single infusion
41154309|NCT04285671|OTHER|Quality-of-Life Assessment|Ancillary studies
41154310|NCT04285671|OTHER|Questionnaire Administration|Ancillary studies
41154311|NCT04285671|BIOLOGICAL|Trastuzumab|Given IV
41154312|NCT00294879|PROCEDURE|pressure support ventilation at 0, 5, and 10% IRT|
41154313|NCT01802476|DRUG|Oral Drug Formulation of PD-0332991|Treatment A consists of a single 125 mg oral dose of PD-0332991.
41154314|NCT01802476|DRUG|Intravenous Formulation of PD-0332991|Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
41154315|NCT04186884|OTHER|Quality-of-Life Assessment|Ancillary studies
41154316|NCT04186884|OTHER|Questionnaire Administration|Complete questionnaires
41009644|NCT05157594|BIOLOGICAL|Blood sample|Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.
41009645|NCT00417183|DRUG|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
41154317|NCT03869541|OTHER|Mobilization|Physical rehabilitation
41154318|NCT00472069|PROCEDURE|transplantation of the squeletic muscular cells|transplantation of the squeletic muscular cells
41154319|NCT01032200|DRUG|Armodafinil|Given orally
41009646|NCT00417183|DRUG|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
41009647|NCT06452524|DEVICE|axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT)|Non-cycloplegic and cycloplegic refraction, best corrected visual acuity (BCVA), axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT) macular and OCT subfoveal choroidal measurements were performed in all cases.
41154320|NCT01032200|OTHER|placebo|Given orally
41154321|NCT01630161|BEHAVIORAL|Usual Care|Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (\<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
41009648|NCT01631474|DRUG|CB-03-01|Topical cream, applied once a day
41009649|NCT01631474|DRUG|Vehicle|Topical cream, applied once or twice a day
41154322|NCT01630161|BEHAVIORAL|Smoking Relapse Prevention for Cancer Patients (SRP-CaP)|The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
41154323|NCT05202327|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
41154324|NCT05202327|DRUG|Placebo|The placebo contained corn starch.
40809017|NCT05600894|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal samples
40809018|NCT05600894|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40809019|NCT05600894|DRUG|Decitabine and Cedazuridine|Given PO
40809020|NCT05600894|DRUG|Venetoclax|Given PO
41154325|NCT06128434|OTHER|zinc carbonate nano-hydroxyapatite toothpaste|Participants will brush their teeth with zinc carbonate nano-hydroxyapatite toothpaste twice daily.
41154326|NCT06128434|OTHER|8% arginine toothpaste|Participants will brush their teeth with 8% arginine toothpaste twice daily.
41154327|NCT06128434|OTHER|Fluoride toothpaste|Participants will brush their teeth with Fluoride toothpaste twice daily.
41154328|NCT00276783|DRUG|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
41154329|NCT01464671|DRUG|Bivalirudin|Anticoagulation during percutaneous coronary intervention
41154330|NCT01464671|DRUG|Heparin|Anticoagulation during percutaneous coronary intervention
41154331|NCT03269149|OTHER|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period. Classes begin with a 20-minute standing warm-up followed by partnering and rhythmic exercises. Next, novel step elements are introduced and participants will be taught how to combine the new steps with previously learned steps via improvisation. Caregivers will dance with each other or undergraduate /graduate student volunteers. Music will be played throughout classes and artistic expression, i.e., attention to aesthetics, and improvisation, will be encouraged.
40809028|NCT06215859|DRUG|MR-107A-02|tablet
40809029|NCT06215859|DRUG|Tramadol|over-encapsulated tablet
40809030|NCT06215859|DRUG|Placebo|over-encapsulated tablet and/or tablet
40809034|NCT03871257|DRUG|Carboplatin|Given IV
40809035|NCT03871257|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40809036|NCT03871257|OTHER|Quality-of-Life Assessment|Ancillary studies
40809037|NCT03871257|OTHER|Questionnaire Administration|Ancillary studies
40809038|NCT03871257|DRUG|Selumetinib Sulfate|Given PO
40809039|NCT03871257|DRUG|Vincristine Sulfate|Given IV or IV push
40809042|NCT05645107|DRUG|Xembify|SC infusion pump
40809043|NCT05645107|DRUG|Placebo|SC infusion pump
41009650|NCT01631474|DRUG|CB-03-01|Topical cream, applied twice a day
41009651|NCT03235024|BIOLOGICAL|B244|B244 suspension
41009652|NCT03235024|BIOLOGICAL|Vehicle|Vehicle suspension
41009653|NCT02214147|DRUG|Alisertib|Alisertib will be supplied as enteric coated tablets.
41009654|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
41009655|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
41009656|NCT00993785|DEVICE|Costar Coronary Stent Delivery System|
41009657|NCT02889354|BEHAVIORAL|Cognitive-behavioral therapy|
41009658|NCT03341052|OTHER|Normal Diet|The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
41009659|NCT03341052|OTHER|High Fat Diet|The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
41009660|NCT03341052|OTHER|Low Fat Diet|The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
41009661|NCT06467526|DRUG|Hydroxychloroquine|Oral hydroxychloroquine (400mg/day) for 2 months
40809046|NCT04633252|DRUG|ADT|For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.
40809047|NCT04633252|DRUG|Prednisone|For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.
40809048|NCT04633252|DRUG|M7824|M7824 (2400 mg) will be administered as a 1 hour intravenous (IV) infusion once every three weeks.
40809049|NCT04633252|DRUG|Docetaxel|Docetaxel 75mg/m\^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
40809050|NCT04633252|DRUG|M9241|M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.
41154332|NCT03269149|BEHAVIORAL|Educational lectures|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks. Classes will also be 1.5 hours long and will involve lecture, partnered and group learning and extensive Q\&A will be encouraged.
41154333|NCT00522678|DRUG|GW685698X|Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
41154334|NCT00522678|DRUG|Placebo|Subject will receive Placebo matching GW685698X via DISKUS.
40809054|NCT06097078|DEVICE|Eso-SPONGE®|minimally invasive treatment and prevention of anastomotic leakages and perforations in the upper gastrointestinal tract (upper GIT)
40809055|NCT05636124|DEVICE|Kaneka i-ED coil|The study device is the Kaneka i-ED coil T, FDA cleared under 510K number K192068. The coil is indicated for use in the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
40809056|NCT05671718|OTHER|Nurse-Led Treatment in Primary Care|At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
41154335|NCT03807271|DEVICE|Calculated and graphically produced depth of anesthesia (Smart Pilot® View)|Smart Pilot® View is a device integrated in the ventilator used under general anesthesia. The depth of anesthesia is calculated based on age, weight, height and the medication given - both volatiles and intravenous. The device does not control the supply of medication directly, but provides an estimate of anesthesia depth that can help the anesthesia team to control the supply of anesthetic agents under general anesthesia, ie indirectly.
40809058|NCT04279847|DRUG|INCB057643|INCB057643 dose escalation and dose expansion.
40809059|NCT04279847|DRUG|Ruxolitinib|Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.
40809060|NCT05189756|DRUG|Aprepitant 80 mg|Encapsulated capsule of aprepitant 80mg to make it look alike to the placebo.
40809061|NCT05189756|DRUG|Placebo|Encapsulated placebo capsules for optical, acoustical and haptic blinding.
41154336|NCT01481701|DRUG|Oxaliplatin|85 mg/m² / 14days
40809063|NCT04361136|DRUG|Delgocitinib cream|Cream for topical application
40809064|NCT04361136|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
40809065|NCT04730635|DRUG|Donepezil|Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.
40809066|NCT04730635|DRUG|Placebo|Dose matched placebo capsule QD, orally for Days 1-56.
40809067|NCT05724953|BEHAVIORAL|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
41009662|NCT06467526|DRUG|Steroid|Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)
41009663|NCT04560634|DRUG|Norepinephrine|Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes
41154337|NCT01481701|DRUG|oxaliplatin|oxaliplatin
40809068|NCT03781973|BEHAVIORAL|Data platform +Quality Performance feedback reports|Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
40809069|NCT05389514|DRUG|Cyclophosphamide|Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.
40809070|NCT05389514|DRUG|Gemcitabine|Patients will receive a single dose of gemcitabine 600 mg/mg2 IVPB over 30 minutes on Day -2.
40809071|NCT05389514|DRUG|Pembrolizumab|Patients will receive the anti-PD-1 immune checkpoint inhibitor pembrolizumab 200 mg IV over 30 minutes on Day -1 and will be dosed every 3 weeks.
40809072|NCT05389514|BIOLOGICAL|Cell Infusion|"Patient's T cells will be administered at a dose of between 1 x 10\^9 to 5.0 x 10\^10 TCR-transduced lymphocytes, which is a dose of genetically modified T cells that can be safely administered and is capable of mediating tumor regression in some patients with metastatic cancers.~The cells are to be infused intravenously over approximately 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping."
40809073|NCT03070223|DRUG|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
40809074|NCT03070223|DRUG|Placebos|One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
40809075|NCT02308163|DRUG|Peficitinib|oral
40809076|NCT02308163|DRUG|Placebo|oral
40809077|NCT02308163|BIOLOGICAL|Etanercept|subcutaneous injection
40809079|NCT03523416|DEVICE|Transcatheter Atrial Shunt System|Transcatheter treatment of symptomatic left heart failure patients
41154338|NCT02973945|DEVICE|High Flow Nasal Cannula|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the intervention arm will receive oxygen trough High Flow Nasal Cannula (HFNC) at 50 lpm and 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
41157206|NCT06620757|DRUG|Single antiplatelet therapy (SAPT)|Observational study of effectiveness and safety of SAPT (either with acetyl-salycilic acid or clopidogrel) after LAAO with Lambre device in patients with high risk of bleeding
40809082|NCT06097728|DRUG|Volrustomig|MEDI5752: Administered as IV infusion
41009664|NCT04560634|DEVICE|ClearSight®, Edwards Lifescience, Irvine, CA|"All patients are connected to a ClearSight® monitor (ClearSight®, Edwards Lifescience, Irvine, CA) by an inflatable finger cuff placed on the midphalanx of hand middle or ring finger with no radial artery catheter and its heart reference system (HRS) is zeroed at the level of the patient's midaxillary line.~The ClearSight® monitoring is started in the pre-anaesthesia room and calibrated for 5 minutes before recording. The monitoring continues throughout the procedure until patient transfer in the recovery room. All data are anonymously collected on a USB pen for statistical analysis."
41009665|NCT04924777|OTHER|Brisk Walk|1-Brisk walk for 30 minutes 2-5 days a week 3-3months
41009666|NCT04924777|OTHER|Strength training|1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months
41009667|NCT04924777|OTHER|Aerobic Exercises|1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
41009668|NCT05256433|OTHER|Group-A|IASTM Certified IASTM practitioner will be performing the technique with emollient lubricant in which brushing and sweeping stroke will be applied for plantar fascia and fanning and sweeping stroke technique for calf muscles for the duration of 10 minutes to eliminate the inflammation. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury. The frequency stretching will be 5 repetitions for each with 10 seconds hold.
41009669|NCT05256433|OTHER|Group-B|Manual massage includes transverse friction massage for plantar fascia, flexor digitorum brevis, and deep massage for calf muscle for the duration of 10 minutes to eliminate the tightness and increase the blood flow. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury.
41009670|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
41326181|NCT06453187|DEVICE|AmnioExcel Plus for Diabetic Foot Ulcers|Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
41479692|NCT03336320|DEVICE|ICT Multidomain Intervention Training|Intervention composed of cognitive training (reasoning and memory training), nutritional counselling (advices to raise awareness about the importance of promoting a diversified and balanced diet), and physical exercises (program and monitoring of progression). The access of control group to the website will be limited to general information about eMIND study and links to the website of health authorities regarding to the healthy ageing topics.
40809083|NCT06097728|DRUG|Pemetrexed|Alimta: Administered as IV infusion
40809084|NCT06097728|DRUG|Carboplatin|Paraplatin: Administered as IV infusion
40809085|NCT06097728|DRUG|Cisplatin|Platinol: Administered as IV infusion
40809086|NCT06097728|DRUG|Nivolumab|Opdivo: Administered as IV infusion
40809087|NCT06097728|DRUG|Ipilimumab|Yervoy: Administered as IV infusion
41009671|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
41009672|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
41009673|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
41326182|NCT06453187|PROCEDURE|Standard of Care|Participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
41479693|NCT01843686|DEVICE|Magellan®|Autologous Platelet Rich Plasma Prepared Using the Magellan System
41479694|NCT01843686|OTHER|Placebo Saline Gel and Usual and Customary Standard of Care|
40809088|NCT05633654|DRUG|Sacituzumab govitecan-hziy (SG)|Administered intravenously
40809089|NCT05633654|DRUG|Pembrolizumab|Administered intravenously
41326183|NCT06140277|PROCEDURE|extraction with chitosan particles as a replacement for bone graft with collagen membrane|to replace the bone at the extraction site we will put either chitosan or allograft particles
41326184|NCT06140277|PROCEDURE|extraction with placing of allograft particles with collagen membrane|to replace the bone at the extraction site we will put allograft particles
40809090|NCT05633654|DRUG|Capecitabine|Tablets administered orally
40809091|NCT04801849|DRUG|Vitamin E|Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks
40809092|NCT04801849|DRUG|Placebo|Participants will take a placebo vitamin E capsule daily for 24 weeks
41154339|NCT02973945|DEVICE|The Venturi Mask|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the control arm will receive oxygen trough The Venturi Mask (VM) at 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
41154340|NCT05695950|DRUG|GLPG3667|GLPG3667 capsules will be administered per dose and schedule specified in the arm description.
41154341|NCT05695950|DRUG|Placebo|Placebo matching to GLPG3667 capsules will be administered per schedule specified in the arm description.
40809096|NCT05517980|DRUG|KP104|Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
41154342|NCT02161185|DRUG|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
40809098|NCT05787899|OTHER|Hypothermia Protocol|Subject's who will be treated with the hypothermia protocol for Hypoxic Ischemic Encephalopathy as standard of care.
40809099|NCT02989584|DRUG|Atezolizumab|
40809100|NCT02989584|DRUG|Gemcitabine|
40809101|NCT02989584|DRUG|Cisplatin|
40809102|NCT03556592|DRUG|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
40809103|NCT03556592|DRUG|Caffeine|1x 100 mg tablet
40809104|NCT03556592|DRUG|Warfarin|2x 5 mg tablets
41009674|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
41009675|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
41326185|NCT06140277|PROCEDURE|tooth extraction only|hopeless tooth will be extracted without any intervention
41326186|NCT03763799|PROCEDURE|PCR-based microbiological diagnosis strategy|A multiplex PCR-based testing, will be used in addition to standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
41326187|NCT03763799|PROCEDURE|Standard microbiological diagnosis strategy|Standard strategy will be based on with standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
41326188|NCT04095442|DEVICE|Cepacol|Twice-daily use of Cepacol per the manufacturer's guidelines
41326189|NCT04095442|DEVICE|Tom's Natural Mouthwash|Twice-daily use of Tom's Natural Mouthwash per the manufacturer's guidelines
41479695|NCT00765011|DRUG|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
41479696|NCT00765011|PROCEDURE|H&N surgery|Rescue surgery
41479697|NCT05758220|DEVICE|MRI|Structural MRI volumetry, resting functional MRI \& MR spectroscopy
41479698|NCT05917028|DEVICE|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
40809105|NCT03556592|DRUG|Omeprazole|1x 20 mg capsule
40809106|NCT03556592|DRUG|Metoprolol|1x 100 mg tablet
40809107|NCT03556592|DRUG|Midazolam Hydrochloride|1 mL of 2 mg/mL oral solution/syrup
41009676|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
41157207|NCT04440514|PROCEDURE|endoscopic preperitoneal repair of parastomal hernia|repair of parastomal hernia after the Sugarbaker principle with TAR and preperitoneal mesh reinforcement
41326190|NCT01619592|DEVICE|webbased education (telemonitoring)|"Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon."
40809110|NCT06251375|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
40809111|NCT06251375|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
40809112|NCT00516906|DRUG|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
40809113|NCT00516906|DRUG|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
41009677|NCT01256710|DEVICE|Trifecta™ aortic bioprosthesis|Surgical aortic valve replacement with the Trifecta™ valve.
41009678|NCT04462705|PROCEDURE|Usual physiotherapeutic intervention and Abdominal Massage|Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
41326191|NCT02487134|DEVICE|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
41479699|NCT05365841|DRUG|Mepolizumab 100 MG|Patients with SEA eligible to receive anti-IL5 treatment, which is a biologic treatment for SEA
41479700|NCT02588066|PROCEDURE|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
41479701|NCT01964170|DRUG|degarelix|subcutaneous
41479702|NCT01964170|DRUG|Goserelin|subcutaneous
40809114|NCT05502718|OTHER|Stretching and Strengthening Exercises|The patients in the study group will be given exercise videos. These exercise videos will be selected in accordance with the patient's cervical dystonia type (Torticollis, laterocollis, retrocollis, anterocollis). During the exercises, stretching exercises will be applied to the muscle groups that cause dystonia, and isometric strengthening exercises will be applied to the contralateral muscle groups. Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week. Patients will be asked to mark after each exercise on the exercise chart prepared to determine continuity and compliance with exercise. Patients will be called and followed up on a weekly basis with the exercise chart given to the patients and by telephone.
41326192|NCT02487134|DEVICE|Control|Closure of the abdomen with conventional technique
40809115|NCT05502718|OTHER|Breathing and Rhythmic Coordination Exercises|The patients in the study group will be given exercise videos prepared in the Department of Physical Medicine and Rehabilitation of Ankara University Faculty of Medicine. . Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week.
41154343|NCT00907699|GENETIC|DNA analysis|DNA is extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways.
41154344|NCT00907699|GENETIC|RNA analysis|RNA is extracted from tumor samples. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
41326193|NCT06415838|BEHAVIORAL|Brief Behavioral Activation|"A five-session brief behavioral activation treatment delivered face-to-face in the participants' home.~Session outline:~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan."
40809118|NCT05471843|DRUG|BGB-11417|Administered orally
41326194|NCT06415838|OTHER|Care as Usual|Care as Usual provided by primary care and/or municipal care.
41326195|NCT05854069|BEHAVIORAL|FAMS-T1D|"FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.~Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly."
41326196|NCT05854069|BEHAVIORAL|Digital resources for diabetes|Quality digital resources about diabetes management provided upon enrollment and during the study.
41326197|NCT00821665|DIETARY_SUPPLEMENT|Sucrose consumption|Sucrose
41154345|NCT00907699|GENETIC|fluorescence in situ hybridization|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
41326198|NCT00821665|DIETARY_SUPPLEMENT|water consumption|water
41154346|NCT00907699|GENETIC|gene expression analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
40809121|NCT05596409|DRUG|Elacestrant|Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.
41157208|NCT01191697|DRUG|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
41157209|NCT01191697|DRUG|trastuzumab|Given intravenously on day 1 of each treatment cycle
41157210|NCT01191697|DRUG|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
41326199|NCT04783285|BEHAVIORAL|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 32 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants with psychotic disorders.
41326200|NCT03398733|DEVICE|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.
41326201|NCT05269472|PROCEDURE|Trigeminal Electrophysiology|This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.
41326202|NCT02204813|DRUG|Placebo|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours."
41326203|NCT02204813|DRUG|Lo-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours."
41009679|NCT01900470|BEHAVIORAL|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
41009680|NCT02483234|DRUG|secukinumab|
41009681|NCT04520425|PROCEDURE|Osteopathic manipulative therapy|"1. Mandibular: the clinician applies gentle pressure bilaterally to the subject's mandible, in the direction of the patient's clavicles.~2. Frontal: the clinician applies gentle pressure bilaterally to the subject's forehead, in a direction halfway between the parietals and ears.~3. Temporal: the clinician applies gentle pressure bilaterally to the subject's temples, in the direction of the patient's occiput.~4. Parietal: the clinician applies gentle pressure bilaterally to the subject's parietal bones, in the direction of the patient's occipital atlanto joint.~5. Occipital: the clinician applies gentle pressure to the subject's occipital bone, in the direction of the patient's neck."
41326204|NCT02204813|DRUG|Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours."
40809122|NCT04746924|DRUG|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
40809123|NCT04746924|DRUG|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
40809124|NCT04746924|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
41326205|NCT02204813|DRUG|Extra Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours."
41326206|NCT00407173|DRUG|HCV-796|HCV-796 1000mg single dose
40809125|NCT04746924|DRUG|Placebo|Placebo infusions will consist of a sterile, normal saline solution.
40809126|NCT05634785|BIOLOGICAL|ATLCAR.CD30 Cells|The cellular product consists of ATLCAR.CD30 cells will be administered via intravenous injection, over 5 - 10 minutes after lymphodepletion. The expected volume will be 1 - 50 mL, the prescribed dose will be 2 × 108 CAR-T cells per meter square and the maximum dose will be 5 × 108 CAR-T cells per meter square.
40809127|NCT05634785|DRUG|Cyclophosphamid|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes 300 mg per square meter of intravenous cyclophosphamide.
40809128|NCT05634785|DRUG|Fludarabine|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes daily 30 mg per square meter of intravenous fludarabine infusion for 3 days.
40809129|NCT05052255|DRUG|RVU120|RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
41154347|NCT00907699|GENETIC|mutation analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
40809131|NCT03734016|DRUG|Zanubrutinib|160 mg orally twice daily
40809132|NCT03734016|DRUG|Ibrutinib|Ibrutinib 420 mg orally once daily
41154348|NCT00907699|GENETIC|polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
41326207|NCT04426994|DRUG|proton pump inhibitor use|Patients using long term proton pump inhibitor
41326208|NCT06310837|DRUG|Adalimumab Biosimilars Injection|Adalimumab biosimilars: 80 mg was subcutaneously injected for the first time in the first week, and then 40 mg was subcutaneously injected every two weeks from the first week to the 48 th week.
41479703|NCT05101226|BEHAVIORAL|Yoga attended in person|One or two weekly yoga classes taught and attended in person with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
41479704|NCT05101226|BEHAVIORAL|Yoga attended online|One or two weekly yoga classes taught and attended online with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
40809134|NCT06342375|OTHER|Outbound phone call|Participants will receive either a live or pre-recorded outbound phone call
41157211|NCT01191697|DRUG|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
41326209|NCT06310837|DRUG|Corticosteroid|Patients received no less than 1 mg / kg.d glucocorticoid at week 0, then implemented according to the standard reduction scheme.
41326210|NCT06310837|DRUG|Immunosuppressive Agents|Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid
41326211|NCT02811796|OTHER|angio-based FFR estimation|The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
41326212|NCT00278096|BEHAVIORAL|occupational therapy|
41154349|NCT00907699|GENETIC|reverse transcriptase-polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
41154350|NCT00907699|OTHER|laboratory biomarker analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
41154351|NCT04488809|OTHER|Exercise|Exercise sessions will include 10 minutes of warming up, 30 minutes of loading, and 10 minutes of cooling down. The exercises will be performed two times in a week for eight weeks.
41154352|NCT01657071|DRUG|YH14659|YH14659 capsule by oral
41154353|NCT01657071|DRUG|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
41154354|NCT01502787|DRUG|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
40809140|NCT04797273|BEHAVIORAL|Internet-based cognitive behavior therapy|12 week Internet-based cognitive behavior therapy, delivered via an online treatment platform. The treatment includes components such as exercises in conducting recuperating activities, methods to improve sleep, exposure, and behavioral activation. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
41326213|NCT02988401|DRUG|Insulin|All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.
41326214|NCT02988401|DRUG|Placebo (Sterile diluent)|All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
41326215|NCT02384772|OTHER|Survey|
41326216|NCT00014911|PROCEDURE|Islet Transplantation|Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
41326217|NCT00014911|DRUG|Sirolimus|Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
41326218|NCT00014911|DRUG|Tacrolimus|Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
41326219|NCT00014911|DRUG|Daclizumab|Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
41326220|NCT00014911|DRUG|Sulfamethoxazole|An antibacterial used to prevent opportunistic infections
41326221|NCT00014911|DRUG|Ganciclovir|An antiviral used to kill viruses and stop viral replication
41326222|NCT00014911|DRUG|Trimethoprim|An antibacterial used to prevent opportunistic infections
41326223|NCT00014911|DRUG|Pentamidine|An antiprotozoal used to prevent disease
41326224|NCT03444571|PROCEDURE|revision surgery|If DNA based diagnosis detects infection, standard revision surgery will be conducted
41326225|NCT01189799|BEHAVIORAL|Motivational therapy|Twelve, 60 minute weekly structured manualized therapy sessions.
41326226|NCT01189799|BEHAVIORAL|Dual Recovery Anonymous/Tx as usual|Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
41326227|NCT01677507|DRUG|Variation in eye pressure response to timolol and latanoprost treatment|Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
41326228|NCT04673487|DIAGNOSTIC_TEST|1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test|Evaluation of 11 different Typhoid Rapid Diagnostic Tests that are commercially available internationally and use Blood culture as standard for comparison
41326229|NCT02016222|PROCEDURE|tears sampling|
41326230|NCT03619291|OTHER|Aerobic Exercise|walking on a treadmill at moderate intensity, total duration 15 minutes
41326231|NCT03619291|OTHER|High-intensity functional training|functional exercises in circuit format at 20/10 s (work/rest) intervals, total duration 15 minutes
41326232|NCT03619291|OTHER|control|physical inactivity, reading sports science literature, total duration 15 minutes
41479705|NCT06074302|DEVICE|RHA Redensity|RHA Redensity will be injected in a microdroplet technique to bilateral cheeks.
40809141|NCT04797273|BEHAVIORAL|Internet-based structured treatment-as-usual|This is a 12-week treatment, delivered via an online treatment platform. The treatment components in this treatment are designed to be similar to what is typically provided in primary care to these patients and includes information about stress and how different factors such as eating habits, physical exercise, and alcohol can contribute to stress problems. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
40809142|NCT05828589|DRUG|BGB-21447|BGB-21447 will be administered orally
41479706|NCT02592759|DEVICE|Smart Glove Treatment|Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
41479707|NCT06322394|DRUG|high-dose BXOS110|3.0 mg/kg, maximum dose not exceeding 300 mg，Participants received one administration by intravenous infusion.
41479708|NCT06322394|DRUG|low-dose BXOS110|2.0 mg/kg, maximum dose not exceeding 200 mg，Participants received one administration by intravenous infusion.
41479709|NCT06322394|DRUG|Placebo|Does not contain any test drug active ingredients，Participants received one administration by intravenous infusion.
41479710|NCT00269542|DRUG|Zinc and iron folic acid - Intervention|The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
41479711|NCT00269542|DRUG|Iron Folic Acid alone - Placebo|The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
41479712|NCT00283322|OTHER|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
41479713|NCT05820867|PROCEDURE|Single-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have both of their lower mandibular third molars extracted during a single appointment. This group will be used to compare the impact of single-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
41479714|NCT05820867|PROCEDURE|Two-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have their lower mandibular third molars extracted during two separate appointments. This group will be used to compare the impact of two-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
41479715|NCT05391334|DEVICE|Qumea|Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
41479716|NCT05802108|DRUG|Evolocumab combined with statins|The experimental group was treated with evolocumab combined with statin for lipid-lowering
41479717|NCT05802108|DRUG|Statin|the control group was treated with statin only for lipid-lowering
41479718|NCT04109313|DRUG|LOU064|Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
41479719|NCT03680287|DRUG|Within-Subject test of blinded study medication|On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.
41479720|NCT04158336|DRUG|ZN-c3|ZN-c3 is a study drug
41479721|NCT02041091|DRUG|Tabalumab Auto-Injector|Administered SC
41479722|NCT02041091|DRUG|Tabalumab Prefilled Syringe|Administered SC
41479723|NCT00606359|BIOLOGICAL|Inactivated, split-virion influenza virus|0.1 mL, Intradermal. 2 vaccinations 12 months apart
41479724|NCT00606359|BIOLOGICAL|Inactivated, split-virion influenza virus|0.5 mL, Intramuscular. 2 vaccinations, 12 months apart
41479725|NCT04107155|DIETARY_SUPPLEMENT|Weight Management Formulation|Saffron extract and Gynostemma extract with hesperidin
41479726|NCT04107155|DIETARY_SUPPLEMENT|Placebo|Placebo
41479727|NCT04107155|OTHER|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
41479728|NCT04107155|OTHER|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
41479729|NCT03896282|OTHER|Mobilization at a dedicated daycare facility|"All THA's are performed using a standard posterolateral approach with simple posterior soft-tissue repair. No infiltration anesthesia (LIA) is used in THA's. All TKA's are performed with a standard medial parapatellar approach without the use of tourniquet. Physiotherapy is started as soon as possible after surgery in the dedicated day care facility. Time till first mobilization is recorded as is total time mobilized supervised by a physiotherapist before discharge.~Patients are discharged if fulfilling the discharge criteria before 8 pm. Number of hours spent in hospital in total is recorded."
41479730|NCT02792348|OTHER|Laboratory biomarker analysis on urine sample|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
41479731|NCT04860596|BEHAVIORAL|collaborative health management model|nursing education program
41479732|NCT00106938|DEVICE|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
41479733|NCT00106938|PROCEDURE|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
41479734|NCT03965637|DRUG|vitamin C|water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection
41479735|NCT02549573|DRUG|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
41479736|NCT02549573|BEHAVIORAL|Physical Therapy|All subjects will participate in a standardized PT intervention
41479737|NCT05670106|DRUG|[177Lu]Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
41479738|NCT05670106|OTHER|Best supportive/best standard of care (BS/BSOC)|Best supportive/best standard of care as defined by the local investigator
41479739|NCT05670106|DRUG|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
41479740|NCT03142516|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
41479741|NCT03142516|DRUG|Irinotecan|Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
41479742|NCT03142516|DRUG|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
41479743|NCT03142516|DRUG|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
40809146|NCT02621151|BIOLOGICAL|Pembrolizumab|
41154355|NCT01502787|DRUG|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
41326233|NCT04093687|OTHER|Endoscopist's training|"The training session will be divided into two parts: theoretical and practical. Trainees will be blinded to the criterion of being chosen due to their performance status.~During the first, theoretical part, the body of research on the phenomenon of colonoscopy pain will be presented. Aspects on how to deliver a painless colonoscopy (patient characteristics, insertion technique, endoscope characteristics, non-technical skills, additional manoeuvres) will be discussed. This part will be based on the findings from Phase I.~The second, practical part of the training, will consist of a one-day session of 7 colonoscopies. Participants will be matched with each other. Each participant, will perform one colonoscopy with an oversight of a matched partner, then in turn oversee the colonoscopy of another participant. The rest of the participants will observe a live transmission of each colonoscopy in a separate room, with a commentary from study coordinator."
41479744|NCT05773157|BEHAVIORAL|Online Modules|Participants receive modules to improve responsive feeding practices of caregivers
41479745|NCT03459352|OTHER|ePRO|"Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms.~These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit.~Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction."
41479746|NCT02058082|PROCEDURE|Intracytoplasmic sperm injection|
41479747|NCT00335335|DRUG|iodixanol|
41479748|NCT02768038|OTHER|Observational|Blood, stool ja biopsy specimens
41479749|NCT05618145|OTHER|Clinical information|The investigators will recruit PSC patients and collect important clinical information and laboratory investigation, together with biological samples.
41479750|NCT00017537|BIOLOGICAL|MVF-HER-2(628-647)-CRL 1005 vaccine|
41479751|NCT01418716|OTHER|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
41479752|NCT01418716|OTHER|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
41479753|NCT02804555|OTHER|Oxygen|Oxygen administration
41479754|NCT00303875|BEHAVIORAL|behavioral dietary and exercise intervention|
41479755|NCT06030089|OTHER|Pharmacokinetic sampling|4 blood withdrawals ( before treatment, Day 5, Day 9 and relapse or 12 months after start of treatment) for the plasma dosage of VEN and inhibition of its Bcl-2
41479756|NCT06030089|OTHER|Vital status determination|Survival situation 12 months after start of treament
41479757|NCT06030089|OTHER|Toxicity assessments|Toxicity events
41154356|NCT01502787|PROCEDURE|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following handgrip exercise (described below), and following Angiotensin II infusion (described below).
41154357|NCT01502787|PROCEDURE|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
41154358|NCT01502787|PROCEDURE|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
41479758|NCT06030089|DRUG|Venetoclax and azacitidine combination|Response to treatment
40809147|NCT02621151|PROCEDURE|Transurethral Resection of Bladder Tumor|
40809148|NCT02621151|DRUG|Gemcitabine|
40809149|NCT02621151|RADIATION|External Beam Radiation Therapy|
40809150|NCT03926572|OTHER|A biobank will be created from blood samples taken at admission, days 3 and days 7|A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
40809151|NCT06296199|OTHER|VR|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to watch and listen with VR headphones to a concert by a group of musicians playing music."
40809152|NCT06296199|OTHER|Music only|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to listen with conventional headphones to a concert by a group of musicians playing music."
41154359|NCT01502787|PROCEDURE|Lower body negative pressure|Lower body negative pressure increases sympathetic nerve activity. Therefore, investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and after rhythmic handgrip exercise plus lower body negative pressure (LBNP) for 2 minutes.
41154360|NCT01502787|DRUG|Angiotensin II|Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and during intravenous infusion of Angiotensin II at the dose of 1, 2, and 3 ng/kg/min for 15 minutes at each dose.
41154361|NCT00195416|DRUG|Etanercept|Etanercept 25mg Injection, 2 times/week
41154362|NCT03939416|OTHER|Experimental|"STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease~POLD~1. Rhythmic transversal muscle mobilization in posterior chain musculature.~2. General vertebral decompression from the sacrum and pelvis~3. Metameric subcutaneous mobilization~4. Rhythmic vertebral mobilization from the spinous processes."
40809155|NCT06517277|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. Relapses will be collected up to 3 months after Haemophilus influenzae pneumonia first episode.
41154363|NCT03939416|OTHER|Control|"STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease"
41326234|NCT01193816|DRUG|loxapine|Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.
41326235|NCT01193816|DRUG|Placebo|Placebo
41326236|NCT01164592|DEVICE|adaptive servoventilation (ASV)|Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
41326237|NCT01167153|DRUG|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
41326238|NCT01167153|DRUG|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
41326239|NCT02894528|DRUG|BioMend and ReproBone|Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
41326240|NCT02894528|DRUG|BioMend without ReproBone|Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
41326241|NCT01147406|DRUG|N6022|This is an injectible formulation which will be given at 5, 15 \& 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
41326242|NCT01147406|DRUG|Placebo|This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
41326243|NCT03620435|DRUG|Atezolizumab|Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year
41326244|NCT01225120|OTHER|Gait Training|12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
41326245|NCT01312324|DRUG|neoadjuvant docetaxel/cisplatin|3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
41326246|NCT00004938|DRUG|fluconazole|
41326247|NCT02174783|OTHER|Control group|Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
41326248|NCT02174783|OTHER|Mediterranean diet|Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
41326249|NCT02174783|OTHER|Protein-Sparing Modified Fast (PSMF)|"Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.~Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.~Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards."
41326250|NCT00333697|OTHER|Comprehensive Duplex Ultrasound (diagnostic study)|A sigle duplex ultrasound examination of the deep venous system of the leg(s) suspected of deep vein thrombosis. Deep veins of the leg are examined for evidence of thrombosis from the inguinal ligament to the level of the malleolus.
41326251|NCT03461185|DRUG|EGFR-TK Inhibitor|EGFR-TKIs include but are not limited erlotinib, gefitinib
41326252|NCT03461185|DRUG|Anti-Angiogenic Drugs|Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
41326253|NCT01548794|PROCEDURE|spinal anesthesia|To receive 2 ml heavy bupivacaine + 0,6 ml saline
41326254|NCT01548794|PROCEDURE|spinal anesthesia|To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
41326255|NCT01548794|PROCEDURE|infiltration anesthesia|To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
41326256|NCT00222417|PROCEDURE|myringoplasty|Myringoplasty is an operative procedure to close tympanic membrane perforations.
41326257|NCT00222417|PROCEDURE|Stapes surgery|Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
41326258|NCT01525303|BEHAVIORAL|Behavioral Treatment for Chronic Headache- Exercise Version|This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
41479759|NCT01930175|DRUG|VAY736|
41479760|NCT01930175|DRUG|Placebo|
41479761|NCT06209801|BEHAVIORAL|Mirror therapy|60 seconds of intervention
41479762|NCT06209801|DEVICE|Neuromuscular electrical stimulation|60 seconds of intervention
41479763|NCT06209801|BEHAVIORAL|Motor imagery|60 seconds of intervention
40809156|NCT05734443|BEHAVIORAL|non-treadmill trip training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after tripping.
40809157|NCT05734443|BEHAVIORAL|treadmill trip training|Sudden treadmill changes in speed (from standing) induce trip-like losses of balance, after which participants take steps to recover balance and establish a stable gait pattern. This is repeated over a range of speeds to both provide training variability and to individualize training to each participant's capability.
40809158|NCT05267470|DRUG|Bemarituzumab|Intravenous (IV) infusion
41009682|NCT06571695|PROCEDURE|Anatomic Long Head of Biceps Tensioning Technique|The standard mini-open subpectoral approach will be made. The myotendinous junction of the long head of the biceps tendon and its location within the intertubercular groove will be marked using electrocautery. The surgeon will then turn to the glenohumeral joint and perform the biceps tenotomy.The long head of the biceps tendon will be retrieved.The tendon is tagged with a running, locking number 2 fiberwire suture at the mid substance of the myotendinous junction using the previously made electrocautery marks to set the tension. The tendon is shortened. The sutures from the biceps are passed through the Arthrex cortical button.The pectoralis major tendon is retracted and 2 centimeters proximal to the distal insertion a unicortical bone tunnel is drilled in the bicipital groove with a 3.2 millimeter drill.The wound is irrigated and the biceps button is threaded into this tunnel and then flipped.The suture is tensioned, securing the biceps against the groove
41154364|NCT01338051|BIOLOGICAL|Gardasil|"Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.~DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe."
41154365|NCT00562484|BIOLOGICAL|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
41154366|NCT00562484|BIOLOGICAL|Placebo|Placebo
41154367|NCT03011671|DRUG|Acetazolamide|ACZ will be given at an initial dose of 250 mg twice a day (BID) and then escalated to 500 mg BID after 1 week. ACZ will be given on days 1-21 of each cycle.
41326259|NCT04981977|BEHAVIORAL|Care Transitions Intervention|CTI is delivered by a trained Care Transitions Coach (Coach) who works closely with patients to ensure a smooth transition from hospital to home following an acute hospitalization. The patient, caregiver, and Coach work together to maximize the involvement of interdisciplinary experts, ensuring that the appropriate professionals are involved, issues are addressed, goals are understood, and the discharge care plan is executed correctly. There are three aspects to CTI; the first is the initial hospital visit, followed by an in-home visit, concluding with telephone follow-up over a 28-day period. During these visits, the Coach focuses on four conceptual areas, referred to as pillars (i.e., Personal Health Record, Medication Management, Red Flags, and Physician Follow up). The Coach ensures the patient understands and utilizes the Personal Health Record to facilitate communication and ensure continuity of care plan across providers and settings.
41326260|NCT04981977|BEHAVIORAL|Care Transitions Intervention and Peer Support|The PS intervention for this study is based upon the principles of motivational interviewing, which is a person-centered, goal-directed method to enhance intrinsic motivation for change by exploring and resolving ambivalence. A recent meta-analysis found the mean effect size for MI to be significantly larger for racial and ethnic minority samples (0.79 vs. 0.26) as compared to non-Hispanic Whites, highlighting its potential benefit and cultural relevance for minority populations. Patients in this arm of the study will receive the 28-day CTI intervention with a 2-month long Peer Support (PS) intervention provided by trained peer educators (PEs).
41326261|NCT04981977|OTHER|Usual Care|The researchers will follow a control group of patients who meet study inclusion criteria. These older adults will participate in the traditional discharge case-management offered by the hospital where they were admitted and discharged. UC at our three partner hospitals consists of: (1) routine inpatient nurse intake that includes screening about housing, substance abuse, and functional status; (2) medication reconciliation performed by treating practitioners; (3) discharge patient education provided by inpatient nurses; (4) a list of resources for safety-net clinics and community-based services; and (5) for patients with severe chronic illness (e.g. heart failure) there may be a planned home visit by a nurse practitioner.
41326262|NCT03720301|PROCEDURE|Osteopathic Manipulation Treatment|"All techniques with patient supine and physician at head of the bed:~1. Soft tissue massage to the posterior cervical musculature for approximately 1 minute~2. Muscle energy to the muscles of neck extension approximately 1 minute~3. Muscle energy to the Occipital Atlanto (OA) joint 1 minute~4. Muscle energy to the jaw. Approximately 1 minute~5. Occipital decompression approximately 1 minute~6. With time remaining complete another round of soft tissue massage.~Intraoperative techniques:~1. Myofascial Steering wheel Technique~2. Sibson's Fascia Release~3. Occipital decompression"
41326263|NCT03720301|PROCEDURE|Sham|"Sham protocol:~Patients randomized into the sham arm of the study will undergo a controlled trial tested sham treatment that was shown to induce no statistical improvement in cervical pain or mobility with zero adverse effects with the subjects unable to tell the difference between sham and actual protocol treatment."
41326264|NCT03320538|OTHER|Hou Gu Mi Xi|Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).
41326265|NCT03320538|OTHER|Placebo|The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
41326266|NCT03320538|DRUG|Rabeprazole|Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
41326267|NCT03649334|DRUG|ketamine-ketorolac|The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
41326268|NCT03649334|DRUG|fentanyl- ketorolac|The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
41326269|NCT04271670|OTHER|Ginger powder footbaths|20-minute footbath with 12 liters of 40°C warm water and an additive of 80g dried ginger powder (reaching up to mid-calf level)
41326270|NCT04271670|OTHER|Mustard powder footbaths|20-minute footbath with 12 liters of 40° C warm water and an additive of 80g dried mustard powder (reaching up to mid-calf level)
40809159|NCT05267470|DRUG|Docetaxel|IV infusion
40809160|NCT05267470|DRUG|Pembrolizumab|IV infusion
40809161|NCT05267470|DRUG|Carboplatin|IV infusion
40809162|NCT05267470|DRUG|Paclitaxel|IV infusion
40809163|NCT05267470|DRUG|Nab-paclitaxel|IV infusion
41009683|NCT06571695|PROCEDURE|Traditional Long Head of Biceps Tensioning Technique|Diagnostic arthroscopic shoulder scope will occur to assess the long head of the biceps for tendinopathy. Tenotomy will occur at the junction of the supraglenoid tubercle with arthroscopic scissors. Subsequent tensioning and tenodesis will be based on surgeon's preference
40809164|NCT05732935|BEHAVIORAL|Time Restricted Eating intervention|"In the TRE intervention, participants will be asked to fast for a target of 16 hours per day for a period of 24 weeks. The first few weeks will involve of a ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 16 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Participants will be asked to record the time of first and final food/drink consumption each day.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
41009684|NCT02566915|DEVICE|CPET submaximal with EPAP|The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
41009685|NCT05727358|BEHAVIORAL|Group-based Acceptance and Commitment Therapy|G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.
41009686|NCT03748940|DRUG|LY3074828|Administered SC
41009687|NCT03748940|DRUG|Placebo|Administered SC
41009688|NCT03748940|DRUG|LY900021|Administered SC
41009689|NCT00170079|BEHAVIORAL|Smoking Cessation Intervention|"A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:~Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;~Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and~Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition."
41009690|NCT00231608|DRUG|topiramate|
41009691|NCT00053430|DRUG|Thalidomide|Tablet taken orally daily
41009692|NCT00053430|DRUG|Thalidomide placebo|Placebo tablet taken orally daily
41009693|NCT01280929|PROCEDURE|Panretinal Photocoagulation (PRP)|
41009694|NCT01280929|DRUG|Intravitreous injection of ranibizumab|
41009695|NCT00675116|DRUG|GW823296|
41009696|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 2-week intervals
41009697|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 4-week intervals
41009698|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 three times at 2-week intervals
41009699|NCT01575327|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
41009700|NCT01575327|DEVICE|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
41009701|NCT02422433|DEVICE|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
41009702|NCT00347152|DRUG|Divalproex|Divalproex, 8-20% taper
41326271|NCT04271670|OTHER|Warm water only footbaths|20-minute footbath with 12 liters of 40° C warm water without any additive (reaching up to mid-calf level)
41009703|NCT00347152|DRUG|Divalproex|Divalproex, 8-20% taper
41009704|NCT01854021|PROCEDURE|intravenous anesthesia|intravenous anesthesia
41009705|NCT01854021|PROCEDURE|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
41009706|NCT01854021|PROCEDURE|inhalational anesthesia|inhalational anesthesia
41009707|NCT01451424|DRUG|Proellex|vaginal suppository, daily, for 12 weeks
41326272|NCT05215119|PROCEDURE|natural cycle endometrial preparation|Cycles will be monitored from either day-10 or-12, according to patient's menstrual cycle length, with serial analysis of blood serum LH and progesterone levels and assessment of dominant follicle growth. In a spontaneous cycle, ovulation will be determined by a LH surge (\>20 IU/L) and a corresponding rise in progesterone (\>0.8 ng/ml). In a triggered cycle, ovulation will be determined by the administration of an hCG trigger when the dominate follicle reached \>16 mm (and LH was \<20 IU/L).
41326273|NCT05046678|DIAGNOSTIC_TEST|Control|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking
41326274|NCT05046678|DIAGNOSTIC_TEST|Smokers with periodontally healthy|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
41326275|NCT05046678|DIAGNOSTIC_TEST|Non-smokers with gingivitis|without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking
41009708|NCT02842502|PROCEDURE|Collection of supernumerary biopsies during skin graft pellet procedure|
41009709|NCT06409468|PROCEDURE|Subperiostal tunnel in conjunction with Novomatrix|An intrasulcular incision on the tooth with recession and on each adjacent tooth. Subperiosteal pouches dissected apically for about 6-8 mm facial to the 3 teeth and connected by extension of the subperiosteal dissection into the interdental areas to create a tunnel. NovoMatrix trimmed to a vertical dimension of 7-8 mm and a horizontal length to completely over the exposed roots and extend laterally to the root line angles of the adjacent teeth. The graft inserted into the tunnel and aligned. Both the overlying tissue and graft positioned 1mm coronally to the level of the cementoenamel junction and secured with a 6-0 resorbable sling suture.
41009710|NCT05192837|BEHAVIORAL|Intensive preoperative smoking cessation counselling|"The study intervention consists of an interview by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery with individual counselling and offered nicotine substitution. The intervention meeting is based on the Chronic Care Model (CCM) to improve quality of ambulatory care.~In brief, the intervention includes:~* Informative content about advantages of smoking cessation~* Scheduling service for a motivational interview by a TSS in office to implement a treatment plan~* For participants willing to quit smoking a preoperative quit day will be scheduled after the first intervention meeting 2-3 weeks before surgery~* Patients will be encouraged by a TSS to use nicotine replacement. Bupropion or Vareniclin will be provided on an individual basis~* TSS will schedule repeated follow-up meetings to support smoking abstinence or nicotine reduction before and after surgery for all patients"
41009711|NCT02822508|DRUG|BLI801 Laxative|BLI801 oral laxative
41009712|NCT02822508|DRUG|BLI801 Placebo|BLI801 oral laxative placebo
41009713|NCT04550624|DRUG|Pembrolizumab Injection [Keytruda]|200mg IV on day 1 of each cycle
41009714|NCT04550624|DRUG|Lenvatinib Mesylate|20mg PO daily days 1-21 of each cycle
41009715|NCT02098161|OTHER|Laboratory Biomarker Analysis|Correlative studies
41009716|NCT02098161|OTHER|Questionnaire Administration|Ancillary studies
41009717|NCT02098161|DRUG|Smac Mimetic LCL161|Given PO
41009718|NCT04379167|DRUG|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma. PI3K-δ signaling pathways are frequently hyperactive in B-cell cancers, making inhibition of PI3K-δ a promising target for B-cell malignancies. YY 20394 has high potency against PI3K-δ, but with markedly improved selectivity in in vitro assays compared to idelalisib. This higher selectivity for PI3K-δ may decrease the risk of serious infection seen with idelalisib and duvelisib (a PI3K-γ/δ dual inhibitor) due to strong immune suppression.
41009719|NCT00624117|BEHAVIORAL|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
41009720|NCT00260234|BIOLOGICAL|Allogeneic Cultured Islet Cells (human); Encapsulated|
41009721|NCT04719910|OTHER|Visual exposure to taped food preparation|Patients in the study group can watch the preparation of the the type of food she prefers to eat normally.
41326276|NCT05046678|DIAGNOSTIC_TEST|Smokers with gingivitis|without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
41479764|NCT03261882|OTHER|Nativity|Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
41009722|NCT04719910|OTHER|Visual exposure to topics not related to food|Patients in the placebo group can choose a video that is relaxing but not related to food.
41009723|NCT01456325|DRUG|Erlotinib|Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
41009724|NCT01456325|DRUG|Onartuzumab (MetMab)|Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
41009725|NCT01456325|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
41009726|NCT05491603|BIOLOGICAL|DBI-001|Topically administered
41009727|NCT05491603|BIOLOGICAL|DBI-002|Topically administered
41326277|NCT05046678|DIAGNOSTIC_TEST|Non-smokers with periodontitis|interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and nonsmokers if they had no previous history of smoking
41326278|NCT05046678|DIAGNOSTIC_TEST|Smokers with periodontitis|interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
41326279|NCT01090219|PROCEDURE|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
41009728|NCT05491603|BIOLOGICAL|Aqueous Gel|Topically administered
41009729|NCT03268616|DEVICE|inspiratory threshold load device and NPPV|"before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive"
41009730|NCT00273403|BEHAVIORAL|Maintenance in Care Services|
41009731|NCT00273403|BEHAVIORAL|Access to Care Services|
41009732|NCT00431249|DRUG|Cilostazol|
41009733|NCT02584309|DRUG|Dexrazoxane|
41009734|NCT02584309|DRUG|Doxorubicin|
41009735|NCT03978481|COMBINATION_PRODUCT|Helicobacter pylori eradication (combination therapy)|Antibiotic eradication therapy (triple or quadriple regimen)
41154368|NCT03011671|DRUG|Temozolomide|For cycle 1 of the maintenance phase, TMZ will administered at 150 mg/m2 on days 1- 5 followed by 23 days with no drug. For cycles 2- 6, TMZ can be increased to 200 mg/m2 at the discretion of the treating investigator.
41157212|NCT00788879|BEHAVIORAL|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
41326280|NCT03468049|BIOLOGICAL|Topical App. of Allium Cepa Extract|Topical Application of Allium Cepa Extract (oil)
41326281|NCT03468049|BIOLOGICAL|Phonophoresis of Allium Cepa Extract|Phonophoresis of Allium Cepa Extract (oil)
41479765|NCT00000674|DRUG|Pyrimethamine|
41479766|NCT00000674|DRUG|Leucovorin calcium|
41479767|NCT00000674|DRUG|Clindamycin|
41479768|NCT04921124|DRUG|Teriparatide|PTH(1-34) cartridge and pen device
41479769|NCT02262793|DRUG|telmisartan|
41479770|NCT02262793|DRUG|ASA/ER-DP|
40809165|NCT05732935|BEHAVIORAL|Successful Aging Comparison Group (LEARN)|"In the Successful Aging Comparison Group (LEARN), participants will attend lectures on topic relevant to healthy aging at the same frequency as the group meetings in the TRE intervention.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
40809166|NCT04480736|DRUG|Placebo|Matching placebo will be administered orally.
40809167|NCT04480736|DRUG|JNJ-64281802 High dose|JNJ-64281802 high dose will be administered orally.
40809168|NCT04480736|DRUG|JNJ-64281802 Medium dose|JNJ-64281802 medium dose will be administered orally.
40809169|NCT04480736|DRUG|JNJ-64281802 Low dose|JNJ-64281802 low dose will be administered orally.
40809170|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen X|JNJ-64281802 dosing regimen X will be administered orally.
40809171|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen Y|JNJ-64281802 dosing regimen Y will be administered orally.
41009736|NCT03675048|DIETARY_SUPPLEMENT|BioGaia Protectis drops|food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
41009737|NCT03675048|DIETARY_SUPPLEMENT|Placebo|Contains same excipients as study drug, without the active ingredient L. Reuteri.
41009738|NCT00479908|DRUG|Sildenafil citrate|
41009739|NCT00479908|DRUG|Glyceryl trinitrate|
41009740|NCT00191997|DRUG|Olanzapine|
41009741|NCT05330650|DRUG|Coated Vicryl+|We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
41009742|NCT05330650|DRUG|Vicryl|We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
41009743|NCT06084208|DEVICE|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Cone Beam Computed Tomography (CBCT)
41009744|NCT00184899|DRUG|Intravenous infusion of Intralipid/heparin|
41326282|NCT03468049|BIOLOGICAL|Raw Mashed Allium Cepa Application|Raw Allium Cepa (onion bulb) Mashed
41326283|NCT03468049|OTHER|Standard Physiotherapy Group (SPG)|This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke
41326284|NCT04377672|BIOLOGICAL|Anti-SARS-CoV-2 Human Convalescent Plasma|"1-2 unit (200-250 mL per unit) of plasma with anti-SARS-CoV-19 titers of ≥1:320.~The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL."
41326285|NCT00378976|DRUG|valacyclovir|500 mg twice-daily oral
41326286|NCT00378976|DRUG|matching placebo|twice daily as per experimental drug
41479771|NCT03801941|DEVICE|wearing ATLAS device during evaluation at 4th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
40809172|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen Z|JNJ-64281802 dosing regimen Z will be administered orally.
40809173|NCT06469359|DEVICE|Nasal tissue-resident memory T and B cells|Nasal tissue-resident memory T and B cells are quantified using flow cytometry.
40809174|NCT06469359|DEVICE|Nasal fluid sampling|Nasal fluid is collected using strip (Hunt Development) in both nostrils
40809175|NCT06469359|DEVICE|Saliva sampling|Saliva is collected using Oracol (Malvern Medical Developments)
40809176|NCT06469359|OTHER|Blood sampling|Isolation of peripheral blood mononuclear cells (PBMC) and serum from blood
40809177|NCT06469359|DIAGNOSTIC_TEST|ELISA|ELISA to measure antibody responses in mucosal fluids and blood
41326287|NCT00141037|DRUG|Daclizumab|"Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)~Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)"
41479772|NCT03801941|OTHER|wearing ATLAS device during evaluation at 5th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
41479773|NCT01254682|DEVICE|Ostenil|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.
40809178|NCT06469359|DIAGNOSTIC_TEST|Neutralization test|Neutralization test to measure neutralizing antibody responses in mucosal fluids and blood to measure neutralizing antibody responses in mucosal fluids and blood
40809179|NCT06469359|DIAGNOSTIC_TEST|ELISPot|ELISPot to measure cellular responses in blood
41009745|NCT00184899|DRUG|Intravenous infusion of Glycerol/heparin|
41009746|NCT04808479|BEHAVIORAL|imFREE mCBT|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
41009747|NCT04808479|BEHAVIORAL|mHealth ED|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
41009748|NCT01196767|DRUG|Ropivacaine (in one arm); catheterization (in both).|"Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine."
41009749|NCT05769894|OTHER|No intervention given|No intervention is planned. Blood samples will be taken at different stages.
41009750|NCT03354494|DRUG|Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa|
41009751|NCT03945981|DRUG|Dolutegravir + Lamivudine FDC|Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
41326288|NCT00141037|DRUG|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m\^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m\^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
41326289|NCT00141037|DRUG|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing \<40 kg and 1.5 mg/kg/day in subjects weighing \>40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
41479774|NCT01254682|PROCEDURE|Standard arthroscopic procedure|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
41479775|NCT02098421|DRUG|Oxytocin|Use of oxytocin while the Foley bulb is in place
41479776|NCT04702347|DIAGNOSTIC_TEST|Urine biomarker|Bladder urine samples (\> 10 ml) will be collected for cytology and for the methylation test before cystoscopy. Prior to semirigid and flexible ureteroscopy, urine specimens from the upper urinary tract will be obtained via a ureteral catheter.
41326290|NCT00141037|DRUG|Tacrolimus|Taken orally from immediately preoperatively to those\>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects \<age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) \&5-7 ng/mL \>= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 \& 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
41326291|NCT00141037|DRUG|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
41326292|NCT00141037|DRUG|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
41326293|NCT00141037|DRUG|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
41326294|NCT03137017|DRUG|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods.
41326295|NCT03137017|DRUG|GRT7014 - Abuse Deterrent Tablet|Single oral dose in one of the four cross-over trial periods.
41326296|NCT03682406|BEHAVIORAL|CAMS-G|Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.
41326297|NCT00154219|DRUG|Lumiracoxib (drug)|
40809180|NCT06469359|DIAGNOSTIC_TEST|Transcriptomics|Transcriptomics to quantify the gene expression of immunological markers in blood
40809181|NCT05095727|DRUG|mRNA-3745|Sterile frozen liquid dispersion for injection
41154369|NCT01386411|GENETIC|BRCA testing and questionnaire assessments|If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.
41326298|NCT04628273|PROCEDURE|encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy|
41326299|NCT01907776|DRUG|ME1100 inhalation solution|ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
41326300|NCT01907776|DRUG|ME1100 placebo inhalation solution|Vehicle placebo
41326301|NCT01010854|DRUG|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
41326302|NCT04441554|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI of cervical spine
41326303|NCT02500368|DEVICE|silicone hydrogel lens (test)|contact lens
41326304|NCT02500368|DEVICE|enfilcon A lens (control)|contact lens
41326305|NCT05648981|OTHER|Inferior Alveolar Nerve Block administration with laser irradiation|Patients will receive inferior alveolar nerve block local anesthesia followed by laser irradiation after completion of the operative procedure.
40809183|NCT04017819|DRUG|18F-C-SNAT4|Radiotracer- Dose 10 mCi
40809184|NCT04017819|DEVICE|Positron emission tomography (PET)/Computed tomography (CT) Scan|Positron emission tomography (PET)/Computed tomography (CT) Scan
41479777|NCT06440187|DRUG|Gemcitabine+ nivolumab|Gemcitabine+ nivolumab q 2wks
41479778|NCT04425889|DIAGNOSTIC_TEST|COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)|a blood sample is drained for detection of IgG and IgM antibody
41479779|NCT06083402|DIETARY_SUPPLEMENT|HyaCera™|1 Ritual HyaCera capsule once daily
41479780|NCT06083402|DIETARY_SUPPLEMENT|Placebo|1 placebo capsule once daily
41479781|NCT05946174|OTHER|Intervention Set A|exercise sessions and meals over approximately 12 weeks
41479782|NCT05946174|OTHER|Intervention Set B|exercise sessions and meals over approximately 3 weeks
41479783|NCT05946174|OTHER|Intervention Set C|meals over approximately 3 weeks
41479784|NCT02053129|OTHER|TB screening Questionnaire|All subjects will be screened with the questionnaire which assesses TB symptoms.
41479785|NCT02053129|OTHER|Sputum smear and culture (only in HIV negative women who are symptomatic)|specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
41479786|NCT05512520|COMBINATION_PRODUCT|Intensity-modulated radiotherapy concurrent with capecitabine|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks.
41479787|NCT01108666|DRUG|Nelfinavir|Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.
41154370|NCT01779427|BEHAVIORAL|AIM|An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
41326306|NCT05648981|OTHER|Inferior Alveolar Nerve Block administration|Patients will not receive any laser irradiation after administration of inferior alveolar nerve block local anesthesia.
41326307|NCT02515708|DEVICE|Normothermic Liver perfusion Device|The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
41326308|NCT01718964|DRUG|Cortisol 20 mg|
41009752|NCT06034210|DEVICE|Customised 3D-printed insoles|Based on measurements from the 3D scanning procedure, and factoring in individual data such as age, weight, and activity preferences, custom insoles are designed using the ZOLA software. The insoles are then 3D-printed by Zoles ApS in Espergærde (Denmark), using BCN3D printers (Barcelona, Spain) and a TPU (Thermoplastic Polyurethane) filament material from Recreus (Alicante, Spain). The printed insoles are tailored for optimal support, performance, and comfort, with varying densities for areas like the arch and heel. They are finished with an OnSteam® microfiber cover for added durability and comfort. The insoles are intended for regular insertion into participants' shoes to align with their unique biomechanical needs. (Information translated and adapted from: https://www.zoles.eu/da/processen-bag-saalerne/)
40809190|NCT05492500|DRUG|Main cohort (Cohort A): Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
41009753|NCT01982422|BEHAVIORAL|Whole Food, Nutrient-Dense Dietary Intervention|The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
41009754|NCT01982422|BEHAVIORAL|Standard of Care|Normal standard-of-care for pregnancy.
41009755|NCT00574405|DRUG|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
41009756|NCT00574405|DEVICE|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
41009757|NCT05157100|DRUG|Ingrezza Pill|Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
41009758|NCT03929835|DRUG|Cannabis oil|T1/C20 CBD
41009759|NCT03929835|DRUG|Placebo|Olive oil with chlorophyl
41009760|NCT00240071|DRUG|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
41009761|NCT00240071|DRUG|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
41009762|NCT06131515|DEVICE|extra corporeal shock wave therapy device|"Patients were seated in a relaxed position with their forearm and finger placed on the table. The median nerve was identified at the pisiform level of the proximal carpal tunnel, with the palm facing upwards. rESWT was delivered with the Physio Shock Wave Therapy system .The rESWT probe was located and oriented perpendicularly on the median nerve, and treatment comprised graduated shots at a bar pressure of 4 and a pulse repetition frequency of 5Hz for each patient ( The treated area was parallel to the median nerve from the pisiform level to 2 cm proximal to the inlet of the carpal tunnel with equal diffusion of 800, 900, 1000, 1100 shots from first to fourth session respectively. The procedure was painless, and there was no need for additional anesthesia or analgesia.~In the control group, sham rESWT just made the same sound without energy emission"
41326309|NCT01718964|DRUG|Mannitol|Mannitol used as placebo
41326310|NCT01053702|DRUG|R475|IV
41326311|NCT01053702|DRUG|Placebo|Placebo
41326312|NCT02277522|BIOLOGICAL|RNA anti-CD19 CAR T cells|intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19)
41326313|NCT06527261|OTHER|Real-time electronic data input into REDCap|"During usual care sessions, clinicians will real-time capture information about the intervention session into REDCap. This information is related to the multi-dimensional dose articulation framework e.g., content of the session and difficulty of the task, session length, episode length, and number of repetitions.~The usual care motor upper limb intervention the patient receives is determined by the clinician providing the care. The therapy may include but is not limited to strength training, task specific retraining, constraint induced movement therapy, mirror box, and electrical stimulation."
41326314|NCT03040817|PROCEDURE|Gastric peroral endoscopic pyloromyotomy (G-POEM)|"G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point."
41326315|NCT03040817|DRUG|Esomeprazole + Mosapride|Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
41479788|NCT01712919|RADIATION|Intensity-modulated radiotherapy|Patients will be given intensity-modulated radiotherapy(IMRT)
41479789|NCT01712919|DRUG|Concurrent chemotherapy with paclitaxel and nedaplatin|Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
41009763|NCT02661438|DRUG|Placebo to Ciprofloxacin DPI (BAYQ3939)|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
41009764|NCT02857127|BEHAVIORAL|Walking program|To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
41154371|NCT03856424|PROCEDURE|Modality 1|Pressure support ventilation (PSV) modality
41154372|NCT03856424|PROCEDURE|Modality 2|T-Piece modality
41326316|NCT00444964|DRUG|Nutropin AQ|0.0125 mg/kg/day
41326317|NCT04836507|BIOLOGICAL|CRC01|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
41326318|NCT04836507|DRUG|Fludarabine|Administered according to package insert
41326319|NCT04836507|DRUG|Cyclophosphamide|Administered according to package insert
41326320|NCT04117568|OTHER|Blood sampling|Blood sampling at 3-5 occasions per admission
41326321|NCT05496218|DIAGNOSTIC_TEST|Blood samples|At study entry, we will collect morning blood samples from fasting women. participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS). In addition, women will be asked to report about their usual weekly food consumption in the previous year. Information on the diet will be based on a reproducible and valid food frequency questionnaire. Energy and mineral and macro-and micronutrient intakes will be estimated using the most recent update of an Italian Food Consumption Database.
41326322|NCT04562532|DEVICE|Microport Firehawk stent|MicroPort Firehawk biodegradable polymer rapamycin target eluting stent
41326323|NCT04562532|DEVICE|2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)|"* Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)~* Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)~* Sirolimus eluting stents (Orsiro- Biotronik)"
41326324|NCT06245369|BEHAVIORAL|learning modules (within app)|"Behavioral:~Participants will have access to a weekly learning module created as Kahoot courses. Each module will include some or all (as applicable) of the following:~* A brief educational video discussing the week's topic~* A brief video sharing ideas for applying the educational content into daily life~* PDF of meal swap examples~* A weekly goal or challenge~* Recipes"
41326325|NCT06245369|BEHAVIORAL|SWITCH app (self-regulation features) - Experimental|"Behavioral:~Diet (track by in app database). App homepage displays dietary intake graph -circles -. Participants will see an empty circles for the goal nutrients at the start of each day, which will fill up as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely full."
41326326|NCT06245369|BEHAVIORAL|SWITCH app (self-regulation features) - Comparator|"Diet (track by in app database). App homepage displays dietary intake graph -circles -.~Participants allocated to the control group, tracking intake of nutrients to lower, will see a full circle at the start of each day which depletes, or empties, as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely empty and the reported totals below the intake circles will display the current intake totals."
41326327|NCT03365947|DRUG|ARO-HBV|sc injection
41326328|NCT03365947|OTHER|Sterile Normal Saline (0.9% NaCl)|sc injection
41326329|NCT03365947|DRUG|JNJ-56136379|oral tablets
41326330|NCT06108245|BEHAVIORAL|Values Clarification Mobile Application|Participants in the intervention group will be asked to answer a series of values clarification writing prompts twice a day over four weeks.
41009765|NCT05851352|DIAGNOSTIC_TEST|serum anti-endometrial antibodies|- Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .This assay employs the qualitative enzyme immunoassay technique
41009766|NCT02121691|BEHAVIORAL|Walk by Faith|The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
41154373|NCT03856424|PROCEDURE|Modality 3|High-flow oxygen
41009767|NCT05045963|OTHER|Electronic Health Record Review|Medical record reviewed
41154374|NCT00002388|DRUG|Abacavir sulfate|
41326331|NCT06108245|BEHAVIORAL|Self-Reflection Mobile Application|Participants in the psychological placebo group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to clutter and organization.
41326332|NCT03141892|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Blood Glucose Monitoring
41009768|NCT02460224|DRUG|LAG525|LAG525 was administered via intravenous (i.v.) infusion
41009769|NCT02460224|DRUG|PDR001|PDR001 was administered via i.v. infusion
41009770|NCT05355636|BEHAVIORAL|Fertility Management Counseling|counseling
41009771|NCT05709821|DRUG|IMM60|IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion
41009772|NCT05709821|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
41009773|NCT01800916|DEVICE|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
41154375|NCT02157688|OTHER|no intervention : case control study|
41154376|NCT01107912|DRUG|prasugrel|administered orally, daily for 12 days
41154377|NCT01107912|DRUG|clopidogrel|Administered orally, daily for 12 days
41154378|NCT05343988|DEVICE|Percutaneous Electrical Nerve Field Stimulation (PENFS) device application|PENFS device will be used to treat children with paroxysmal sympathetic hyperactivity (PSH) due to acute severe brain injury.
41154379|NCT04631341|DIETARY_SUPPLEMENT|Melatonin|Melatonin 5mg every night, for one year
41154380|NCT04854616|BEHAVIORAL|CoSTED Intervention|Brief smoking cessation advice, the provision of an e-cigarette starter kit and training in its use, and referral to stop smoking services.
41154381|NCT00555334|PROCEDURE|RFA|radiofrequency ablation
41154382|NCT00555334|DRUG|lamivudine or entecavir|lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
41326333|NCT01797315|DRUG|Sirolimus|
41326334|NCT02452268|DRUG|NIZ985|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
41154383|NCT04734171|BEHAVIORAL|Digital social activity video intervention|A 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends during the COVID-19 pandemic. Two friends meet via zoom instead of in person and share their experiencing supporting each other.
41326335|NCT02452268|DRUG|PDR001|• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
41326336|NCT02146833|DRUG|Selinexor|Comparison of different dosages and dosing schedules of drug.
41479790|NCT01712919|BIOLOGICAL|Cetuximab|Patients will be given cetuximab weekly during radiation therapy
41479791|NCT02464826|DRUG|Nailprotex|Nailprotex apply to the abnormal nail twice daily
41479792|NCT03093272|DRUG|Leuprolide Acetate|a GnRH agonist
41479793|NCT03093272|DRUG|Prednisone|Prednisone is a corticosteroid
41479794|NCT03093272|DRUG|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
41479795|NCT03093272|DRUG|Apalutamide|The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
41479796|NCT04461132|OTHER|Manual Lymphatic drainage (MLD)|MLD vith vodder technique was applied to leg
41479797|NCT04461132|OTHER|Skin Care|Wound was cleaned with salin and covered by dressing without including active products
41479798|NCT04461132|OTHER|Exercise|breathing and foot pump exercise was prescribed
41479799|NCT04461132|OTHER|Shame Manual Lymphatic drainage|manual lymphatic drainage was applied with light touch instead of real mld techniques
41479800|NCT01408563|DRUG|Fludarabine|30 mg/m2/day IV x 6 days
41009774|NCT01800916|DEVICE|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
41009775|NCT01800916|DEVICE|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
41326337|NCT04048538|OTHER|Precare|an innovative patient education platform using animated videos created by using up-to-date evidence-based informaiton
41479801|NCT01408563|DRUG|Melphalan|100 mg/m2/day IV x 1 day
41479802|NCT01408563|RADIATION|Total Body Radiation|200 cGy on Day 0
41009776|NCT01800916|DEVICE|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
41009777|NCT06251076|DRUG|Teclistamab|Teclistamab is an antibody therapy (bispecific T-cell engager \[BiTE\]) that binds to two target proteins on different cells; CD3 on healthy T cells and B cell maturation antigen (BCMA) on myeloma cells. This brings healthy T cells and the myeloma cells close together so the T cells can more effectively kill them. Teclistamab is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
41154384|NCT04734171|BEHAVIORAL|Informational sheet|An informational sheet to learn about the COVID-19 outbreak (standard).
41154385|NCT04734171|BEHAVIORAL|Stigma awareness video intervention|A video aimed at sensitizing participants to COVID-19 related stigma. A COVID-19 + individual share their experience.
41154386|NCT02520414|DEVICE|Symphion® Bipolar Hysteroscopic Tissue Resection System|
41479803|NCT01408563|BIOLOGICAL|Cord Blood|2 cord blood units IV
41479804|NCT06011876|OTHER|Acute Intermittent Hypoxia (AIH)|AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).
40809191|NCT05492500|DRUG|Main cohort (Cohort A): Ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
40809192|NCT05492500|DRUG|Main cohort (Cohort A): ponsegromab high dose|Ponsegromab high dose subcutaneous injection
40809193|NCT05492500|OTHER|Main cohort (Cohort A): Matched placebo|Matched placebo subcutaneous injection
40809194|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab low dose|ponsegromab low dose subcutaneous injection
41154387|NCT04004169|DEVICE|Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
41154388|NCT04004169|DEVICE|Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
41154389|NCT04004169|DEVICE|Stimulation-ON Active Control|Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
41326338|NCT04048538|OTHER|usual standard of care|individuals will receive treatment as per the usual standard of care
41326339|NCT05379868|PROCEDURE|Posterior column osteotomy|Apical full facet joint resection. Study intervention does not involve a device.
41326340|NCT05379868|PROCEDURE|No osteotomies|Standard treatment
41326341|NCT05364229|RADIATION|MR-guided Radiotherapy Boost|IMRT/VMAT prostate whole gland SBRT to 30 Gy in 5 fractions. MRL focal boost of 15 Gy in 1 fraction will be delivered either before or after whole gland SBRT.
41326342|NCT00866515|DRUG|Ketoconazole + GW642444M|Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
41326343|NCT00866515|DRUG|Placebo + GW642444M|Placebo to match D1-6 + GW642444M 25ug single dose on D5
41326344|NCT04977154|OTHER|Primary prevention|The primary prevention that the trainers put in place for the hockey players
41326345|NCT05366192|DRUG|Nirmatrelvir and ritonavir stage 1|Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
41479805|NCT06011876|OTHER|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).
41479806|NCT06011876|OTHER|Sham AIH|A single session of sham AIH with episodes of normal room air (21% O2).
41479807|NCT05715554|OTHER|Homeopathy|Individualized homoeopathic medicines on impregnated lactose pellets was prescribed based on totality of physical, emotional, and mental symptoms.
41479808|NCT02373670|BEHAVIORAL|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
41479809|NCT02373670|BEHAVIORAL|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
41479810|NCT00951184|BEHAVIORAL|telephone-based intervention|
41479811|NCT00951184|OTHER|screening questionnaire administration|
41479812|NCT00951184|OTHER|study of socioeconomic and demographic variables|
41479813|NCT00951184|PROCEDURE|assessment of therapy complications|
41479814|NCT00951184|PROCEDURE|psychosocial assessment and care|
41479815|NCT02664857|DRUG|Vitamin D|Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
41479816|NCT02664857|DRUG|Placebo|Group P will not take orally during 12 weeks. This group will only observe by researchers.
41479817|NCT04995757|DEVICE|Stent Retriever|Stent Retriever for acute ischemic stroke
40809195|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
41009778|NCT06251076|DRUG|Tocilizumab|Toclilzumab is an interleukin inhibitor approved for the treatment of patients with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and other indications.
41154390|NCT03043950|DRUG|Panitumumab|Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.
41326346|NCT05366192|DRUG|Nirmatrelvir and ritonavir stage 2|Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
41326347|NCT05102331|OTHER|Lavender Oil Aromatherapy|"Participants will be given a dental bib to wear. Three drops of the lavender oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~The lavender oil is produced by doTERRA and has Gas Chromatography Mass Spectrometry analysis showing 35.66% linalool without any contaminants"
41326348|NCT05102331|OTHER|Placebo oil|"Participants will be given a dental bib to wear. Three drops of the placebo oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~Refined jojoba oil which has no color or smell"
41326349|NCT05102331|PROCEDURE|BMAB procedure|SOC BMAB procedure. The procedure takes approximately 20 minutes to complete and is performed on the posterior superior iliac crest of the pelvic bone. Between 5 and 10 mL of 1% lidocaine will be injected into the site of the BMAB 5 minutes prior to the procedure beginning. No systemic premedications will be allowed including opioids or benzodiazepines. If during the procedure, participants continue to report severe anxiety or pain, the practitioner may consider providing 1mg of lorazepam or morphine as a rescue medication. The aspirate needle and core biopsy needle will be the standard needle provided by the BMAB kit
41326350|NCT04549415|DRUG|Metformin Hydrochloride|"patients were divided into 2 groups: 1st group was on lifestyle modification (LSM), 2nd group on regimen LSM+ metformin (1000 g b.i.d) during 12 months"
41326351|NCT04549415|OTHER|lifestyle modification|Lifestyle modification Standard Principles
41326352|NCT06448026|DRUG|Cemiplimab|Given by IV
41326353|NCT06448026|DRUG|Cetuximab|Given by IV
41326354|NCT04166656|BIOLOGICAL|Trumenba®|Trumenba® (Pfizer): Suspension for intramuscular injection in 0.5 mL single-dose prefilled.
41326355|NCT04166656|BIOLOGICAL|Bexsero®|Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe
41326356|NCT05059938|BEHAVIORAL|MyFitnessPal user|Patients will be counseled on how to use the MyFitnessPal application to help with the patient's weight loss goals. The physician will monitor the patient's weight, blood pressure, and waist circumference over up to a six month period with visits at 1, 3, and 6 months. Patients will be asked about the patient's use of the application at the end of the study.
41326357|NCT01315002|DRUG|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
41479818|NCT02795637|DRUG|dasotraline|dasotraline 8mg capsule/day
40809196|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab high dose|Ponsegromab high dose subcutaneous injection
40809197|NCT05492500|DRUG|Optional Cohort C: Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
40809198|NCT05492500|OTHER|Optional Cohort C: Matched placebo|Matched placebo subcutaneous injection
40809199|NCT05492500|DRUG|Optional Cohort D: Ponsegromab high dose|Ponsegromab high dose subcutaneous injection
40809200|NCT05492500|OTHER|Optional Cohort D: Matched placebo|Matched placebo subcutaneous injection
41009779|NCT04171414|BIOLOGICAL|CT-P17 SC AI (adalimumab)|Subcutaneous Injection of Adalimumab 40mg once every two weeks
41009780|NCT00858390|DIETARY_SUPPLEMENT|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
41009781|NCT05928650|OTHER|Evaluation of menstrual function|Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.
41009782|NCT03221985|OTHER|questionnaires|questionnaire with application on smartphone
41479819|NCT03674502|DRUG|ADU-1604|anti-CTLA-4 monoclonal antibody
41479820|NCT05266079|DRUG|Intervention Group|Gan Mai Bai He Di Hung Tang, Tian Wang Bu Xin Dan,Shugan Granules,Liu Wei Di Huang Pill and Er Zhi Pill , You Gui pill and Li Zhong pill addition and subtraction
41479821|NCT05266079|DRUG|Control Group|Er-Xian decoction
41479822|NCT03338842|DEVICE|Distractor and Lower limb VR|In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.
41479823|NCT04734834|DIETARY_SUPPLEMENT|"Prodovite® VMP35"|"Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo"
41479824|NCT05720520|OTHER|Technological education method|Students in the experimental group will play the mobile application developed for stoma and peristomal skin care and are expected to learn the skill in this way. The students in the control group, on the other hand, will learn stoma and peristomal skin care on a model in the traditional skill laboratory and are expected to learn the skill in this way. Afterwards, the knowledge and skill scores of the two groups will be compared and the results will be reported.
41479825|NCT06427525|OTHER|Mobile application-based adolecent obesity education|Mobile application-based adolecent obesity education
41009783|NCT01158924|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
41009784|NCT00203450|DRUG|Zonegran|zonisamide
41009785|NCT00203450|DRUG|Placebo|Placebo pill
41154391|NCT03425045|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Patients randomised in Arm 1 will receive stimulation of the dorsolateral prefrontal cortex (frequency 25 Hz; 300 pulses; 80% resting motor threshold=RMT) and primary auditory cortex on both sides (1 Hz; 1000 pulses; 110% RMT) will be stimulated in patients in rTMS stimulation group for 5 consecutive days. No medication therapy will be provided for patients in this arm.
41154392|NCT03425045|PROCEDURE|Sham stimulation|Sham stimulation will be performed in patients randomised in Arm 2 of the study for 5 consecutive days. No medication therapy will be provided for patients in this arm.
41154393|NCT03425045|DRUG|Ginkgo Biloba Extract|Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.
41154394|NCT02166788|PROCEDURE|Inguinal Lymphadenectomy|
41479826|NCT03204474|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
40809201|NCT05242224|OTHER|Evolutionary Nutrition Package|The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
41326358|NCT01315002|DRUG|Placebo patch|Placebo patch
41326359|NCT02939599|DRUG|QCC374|0.015mg and 0.06mg
41326360|NCT05096702|DRUG|Tafenoquine|Tafenoquine 300 mg (2x150mg tablets)
41326361|NCT05096702|DRUG|Primaquine|Daily primaquine adjusted by weight (0.5 mg/kg/day for 7 days)
41326362|NCT05096702|DRUG|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
41326363|NCT00856986|DRUG|liraglutide|Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
41479827|NCT03204474|DRUG|Lacosamide (LCM) solution for infusion|Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
41479828|NCT00197522|BIOLOGICAL|CD34+ derived DCs|
41479829|NCT03046498|BEHAVIORAL|Evidence-Based Program|DSMP and DPP
41479830|NCT00052026|DRUG|carvedilol|low-dose carvedilol administered twice daily for 8 months
41479831|NCT00052026|DRUG|placebo|administered twice daily for 8 months
41009786|NCT05492058|OTHER|tactile stimulation group|The tactile stimulation group will be asked to touch their own abdomen during the NST procedure.
41154395|NCT02166788|PROCEDURE|Ilio-inguinal Lymphadenectomy|
41154396|NCT03570996|PROCEDURE|Esophagectomy|"Esophagectomy with minimally invasive approach of the chest including:~3 hole with R video-assisted thoracoscopic surgery (VATS), Ivor Lewis R VATS, Transhiatal"
41154397|NCT03570996|PROCEDURE|Transversus abdominis plane catheter|TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine
41326364|NCT00856986|DRUG|insulin detemir|Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
41479832|NCT00052026|DRUG|carvedilol|high-dose carvedilol administered twice daily for 8 months
41479833|NCT03589248|DIAGNOSTIC_TEST|GIF score|assessment by GIF score
41479834|NCT03589248|DIAGNOSTIC_TEST|US score|assessment by ultrasonography score
41479835|NCT03721302|OTHER|Main study clinical sepsis|No intervention-Observational study
41479836|NCT03721302|OTHER|Microbiology sub study|Analysis of Bacterial isolates
41479837|NCT01996384|PROCEDURE|Classical Acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
41009787|NCT05492058|OTHER|listen music|Pregnant women in the music group will listen to a song they want with headphones during the NST procedure.
41009788|NCT05492058|OTHER|virtual reality group|Pregnant women in the virtual reality group will be shown a nature walk video with nature sounds (stream, bird, etc.) during the NST procedure.
41009789|NCT03326427|BEHAVIORAL|Skill Training Group of the Dialectical Behavior Therapy|A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
41009790|NCT03326427|OTHER|Treatment as Usual|Conventional protocol using only medication (including drug adherence).
41009791|NCT01054703|DEVICE|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
41326365|NCT00856986|DRUG|metformin|Metformin tablets, at least 1500 mg/day
41154398|NCT03570996|PROCEDURE|Epidural|Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
41009792|NCT04132557|DRUG|Methylphenidate|Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.
41009793|NCT04132557|DRUG|Lisdexamfetamine|Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.
41009794|NCT04132557|DRUG|Atomoxetine|Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
41009795|NCT04132557|DRUG|Amphetamine|Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
41009796|NCT04132557|DRUG|Dextroamphetamine|Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
41009797|NCT06297356|DEVICE|Stress ball|Stress balls are soft sponges with a diameter of 2-4 cm. The lightest starting level was preferred for the patients. Patients were allowed to take the stress ball in any hand they wanted. They were asked to squeeze and loosen the ball in their palm at 2-3 second intervals.
41009798|NCT01451775|DRUG|Empagliflozin|high dose of empagliflozin after overnight fasting for at least 10 h
41009799|NCT01451775|DRUG|Empagliflozin|low dose empagliflozin after overnight fasting for at least 10 h
41009800|NCT01451775|DRUG|Empagliflozin|high dose of empagliflozin after a standardised high fat breakfast
41009801|NCT00882531|DRUG|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
41009802|NCT00882531|DRUG|placebo|
41009803|NCT05234515|DIAGNOSTIC_TEST|Microbiology swab|Patients will have swabs taken from the nose, mouth, umbilical skin, groin skin, fistula(e), stoma(s) and vascular access device prior to surgery. Patients will be followed for 90 days postoperatively for surgical site infection (SSI) as defined by the centre for disease control (CDC) criteria 2021. Patients who develop an SSI will have both preoperative and postoperative samples sent for genome sequencing.
41009804|NCT05234515|OTHER|Questionnaire|Patients will complete baseline preoperative questionnaires which will be repeated at 30 days and 90 days. These will evaluate generic and wound specific quality of life as well as decision conflict/decision regret.
41009805|NCT00211471|DRUG|anecortave acetate|
41009806|NCT04292158|DEVICE|SomnoTouch|"The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis."
41154399|NCT06296888|PROCEDURE|Radiofrequency balloon catheter ablation|Radiofrequency balloon ablation using the HELIOSTAR™ ablation catheter.
41326366|NCT03385408|DEVICE|HIRO® 3.0|Patients will receive pulsed Nd:YAG (yttrium aluminum garnet) laser, produced by HIRO 3.0 device (ASA, Vicenza, Italy). The total energy deliver to the patient during one session will be 3.000 J through three phases of treatment. HILT will be applied for a total of 4 weeks (three sessions/week).
41326367|NCT03385408|DEVICE|Sham laser|For sham laser, the patient will attended the physical therapy clinic three times a week for 4 weeks and receive sham laser. It is applies the same time than experimental one but with 0 W.
41009807|NCT04292158|DEVICE|MOX|"The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis."
41009808|NCT03550924|PROCEDURE|low flow passive oxygenation|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
41009809|NCT03550924|PROCEDURE|high flow passive oxygenation|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
41154400|NCT03548272|PROCEDURE|Percutaneous Coronary Intervention with stent implantation|PCI with BiOSS LIM C or rDES depending on the randomization
41154401|NCT02065895|DEVICE|HIGH error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
41326368|NCT04209400|BIOLOGICAL|Sci-B-Vac®|Sci-B-Vac® vaccine-10 μg of HBsAg, intramuscular injection of 10 μg/ml
41326369|NCT04209400|BIOLOGICAL|Engerix-B®|Engerix-B® vaccine-20 μg of HBsAg, intramuscular injection of 20 μg/ml
41326370|NCT04295356|BIOLOGICAL|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via AI on Day 1 followed by 10 weeks
41326371|NCT04295356|BIOLOGICAL|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via PFS on Day 1 followed by 10 weeks
41326372|NCT03289741|DRUG|Octreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
41326373|NCT03289741|DRUG|LAR Lanreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
41326374|NCT03289741|BEHAVIORAL|Questionnaires|Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
41326375|NCT02168803|DRUG|Evacetrapib|Administered orally
41009810|NCT05705908|OTHER|Hot Foot Bath 1|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water)."
41326376|NCT01769495|OTHER|2-3 day return appointment|2-3 appointment in geriatric clinic following ED discharge
41326377|NCT01729572|OTHER|Tele-medicine monitoring of medication adherence|
41326378|NCT01287546|DRUG|LY2875358|Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
41479838|NCT01996384|PROCEDURE|Non-classical acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
41479839|NCT01996384|DRUG|Lidocaine|Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
41479840|NCT01997021|OTHER|US|US is a 5-hour intervention/condition where participants will be required to sit quietly for 5 consecutive hours.
41479841|NCT01997021|OTHER|IW|IW is a 24-hour intervention/condition where participants interrupt sedentary time with short 1.5 minute walking bout.
41479842|NCT01997021|OTHER|CW|CW is a 24-hour intervention/condition where participants perform a 36 minute continuous walking bout and are seated the remainder of the time.
41479843|NCT05441995|OTHER|Cryotherapy|Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
40809203|NCT04829682|BEHAVIORAL|ACT for Life|ACT for Life is a brief recovery oriented individual inpatient Acceptance and Commitment Therapy treatment protocol consisting of four modules typically administered in three to six inpatient sessions and one to four outpatient sessions in the 30 days following discharge from inpatient care. The immediate goals of ACT for Life are to increase the participant's psychological flexibility and readiness to cope effectively with future suicidal crises.
41009811|NCT05705908|OTHER|Hot Foot Bath 2|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).~* 3 drops of lavender essential oil were dripped in the water"
41009812|NCT00178438|DEVICE|Capsule Endoscopy|
41009813|NCT02110992|DRUG|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
41009814|NCT02110992|RADIATION|Stereotactic Radiation|SBRT will be given over 5 fractions separated by \> 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
41009815|NCT04894617|DRUG|Amantadine|200 mg Amantadine daily for a total of 5 days.
41009816|NCT04894617|DRUG|Lactose monohydrate|Lactose monohydrate two tablet daily for a total of 5 days.
41009817|NCT01620606|BEHAVIORAL|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy \& Social Learning
41326379|NCT01287546|DRUG|LY2875358 + erlotinib|Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
41479844|NCT02350582|DEVICE|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
41479845|NCT01176019|DEVICE|Information about Prenatal Screening and Diagnosis|15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
41479846|NCT04722159|DEVICE|Renal denervation|Catheter-based inhibition of renal sympathetic nerve traffic.
41326380|NCT01287546|DRUG|LY2875358 at Part A highest dose|Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
41326381|NCT01287546|DRUG|LY2875358 at Part A highest dose + trametinib|Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
41326382|NCT04742920|DEVICE|Middle Meningeal Artery Embolization|MMA embolization using the Onyx™ non-adhesive liquid embolic agent within 72 hours after randomization in addition to standard management
41326383|NCT04742920|PROCEDURE|Standard Management|"Procedure : Surgical Management Surgical evacuation of the subdural hematoma~Other: Conservative Management Standard medical management: drug treatment and/or observation"
41479847|NCT03346070|DRUG|Sugammadex 2 mg/kg ABW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex (2 mg/kg by ABW) for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of a second twitch (T2) in response to TOF stimulations."
41479848|NCT03346070|DRUG|Sugammadex 2 mg/kg IBW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex (2 mg/kg by IBW) for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of T2 in response to TOF stimulations."
41479849|NCT03346070|DRUG|Sugammadex 4 mg/kg ABW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex (4 mg/kg by ABW) for reversal of deep NMB.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
41326384|NCT02190617|BEHAVIORAL|Enhanced Clinic+ Unified Plan + CHW|"* Unified asthma management plan and asthma support team coordination: A support team will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan.~* Home visit intervention: Community health workers will provide in-home tailored asthma support and conduct follow-up to support patient actions to improve asthma control based on unified asthma management plan.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
41326385|NCT02190617|BEHAVIORAL|Enhanced Clinic+ Unified Management Plan|"* Unified asthma management plan and asthma support team coordination: A support team (clinicians, CHWs and plan care managers) will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan and enhancing communications among care team.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
41326386|NCT02190617|BEHAVIORAL|CHW Home Visit Only|-Home visit intervention: Community health workers will provide in-home tailored asthma support: assess asthma self-management knowledge and skills, conduct a home environmental assessment focused on asthma triggers, and conduct follow-up visits to support patient actions to improve asthma control based on unified asthma management plan.
41009818|NCT01620606|BEHAVIORAL|Education and Support|Education about the GI system, nutrition and food safety
41326387|NCT01051115|DRUG|Dasatinib|Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
41326388|NCT03701204|BEHAVIORAL|DynamiCare Rewards|"Participants assigned to the DynamiCare Rewards group will receive the following:~1. App on their smartphone~2. Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~3. Next Step debit card to receive financial incentives~4. Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~5. Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~6. The amount of coins and funds are available on a progressive variable reward schedule."
41326389|NCT04371627|DRUG|Viaskin Peanut|Daily epicutaneous delivery
41326390|NCT03379896|OTHER|Collect peripheral blood sample|Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.
41326391|NCT06027879|BIOLOGICAL|Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
41326392|NCT00106288|DRUG|Micafungin|IV
41326393|NCT00106288|DRUG|Liposomal Amphotericin B|IV
41326394|NCT04794556|DEVICE|tight-fitting of KF94 mask with clip|The general-fitting method involved wearing a mask with ear loops, and the tight-fitting method involved wearing a clip that connected ear loops on the occiput after wearing a mask according to the general method
41326395|NCT05343741|OTHER|Psychological Intervention|The CPA provides outpatient psychological services to individuals: children, adolescents and adults, couples and families. At the CPA, care is carried out through the co-therapy model, which involves the participation of a professional clinical psychologist and a trainee. Psychotherapists with diverse theoretical and clinical backgrounds (mainly psychodynamic, cognitive, systemic and integrative), but a common constructivist approach, work in the center. The following elements are transversal in their practice: therapeutic alliance, healing environment, and a collaborative procedure between the client, the psychotherapist and the trainee co-therapist.
41479850|NCT03346070|DRUG|Sugammadex 4 mg/kg IBW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants will receive a single i.v. bolus of Sugammadex (4 mg/kg by IBW) for reversal of deep NMB.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
41009819|NCT01229475|PROCEDURE|Ablation with stepwise approach|Stepwise approach for repeat AF ablation
41009820|NCT01229475|PROCEDURE|Linear ablation|Linear ablation for AF ablation
41009821|NCT05552313|PROCEDURE|kinesio tape|kinesio tape will be applied while patient is in sitting position. Y strip will be applied along C1 till T1.while patient's cervical spine is in contalateral side bending and rotation. same will be performed on the other side. on top of it, an I strip will be applied horizontly along C1 to C4. Both strips will be applied with 15% to 20% stretch.
41009822|NCT05552313|PROCEDURE|standard therapy|Thoracic manipulation along with conventional including Tens, stretching and strengthening exercises of entire neck musculature
41009823|NCT03651791|COMBINATION_PRODUCT|USPIO labeled MSC injection|USPIO labeled MSC injection
41009824|NCT02777762|BEHAVIORAL|Fun First|8 weekly interactive small-group sessions with a health coach
41009825|NCT02777762|BEHAVIORAL|Close at Hand|8 weekly check-ins with a state of the art, engaging mobile app
41009826|NCT04199429|BEHAVIORAL|Relationship-Based Care|
41009827|NCT04042883|PROCEDURE|Acute normovolemic hemodilution|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
41154402|NCT02065895|DEVICE|NO error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL and glucose-value-used-for-control equal to the true glucose value.
41154403|NCT02065895|DEVICE|LOW error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 0.8 times the true glucose value (analogous to lower gain higher target).
41326396|NCT00885885|DRUG|Panitumumab+FOLFOX-4|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle~* Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2~* 5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2"
41326397|NCT00885885|DRUG|Panitumumab+FOLFIRI|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle~* Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1~* 5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle."
41326398|NCT05464472|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Guideline/ FDA approved implantation of a Transcatheter Aortic Valve Implantation (TAVI)
41326399|NCT05279716|DRUG|Eybelis ophthalmic solution 0.002%|Ophthalmic eye drop
41326400|NCT00051129|DRUG|Anecortave Acetate 15 mg sterile suspension|0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
41326401|NCT00051129|OTHER|Anecortave Acetate Vehicle|Administered as a posterior juxtascleral injection
41326402|NCT02789826|PROCEDURE|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.
41326403|NCT02789826|PROCEDURE|Open gastrectomy|patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy
41326404|NCT06131229|BEHAVIORAL|Structured emotional education program (PEE)|The principal investigator, together with the class-tutor of the experimental groups, conducts the 20 activities of which the program is composed during the hour dedicated to tutorial action. The sessions are held at Lauro School on Monday mornings in the respective classrooms, with the possibility of using the courtyard and other multipurpose rooms if the activities so require. Each session lasts one hour and is held throughout the school year 23-24.
41326405|NCT06131229|BEHAVIORAL|Incidental tutorial action based on the school's regular curriculum (PCO)|One hour tutorial action per week according to the regular school curriculum. This curriculum contemplates the incidental approach to the problems that arise in daily life and the work with the KIVA program.
41326406|NCT02679495|BEHAVIORAL|Active measures of lifestyle modification|
41326407|NCT02287870|DRUG|Chloroprocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 3% chloroprocaine.
41326408|NCT02287870|DRUG|Lidocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 2% lidocaine.
41009828|NCT03886064|OTHER|Multi-behavioral intervention|The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
41326409|NCT03411577|OTHER|Behavioral Intervention|
41326410|NCT00212485|PROCEDURE|Power Doppler Sonography|Power Doppler with gray-scale sonography is used to detect and quantify alterations in vascularity inside knee, elbow and ankle joints.
41326411|NCT00212485|PROCEDURE|MRI|Magnetic Resonance Imaging with intravenous gadolinium contrast will be done using a standardized protocol, including a spin echo T2 weighted image and gradient echo images.
41326412|NCT03746808|BEHAVIORAL|EMA + App/Treatment Messages|"This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use."
41326413|NCT01208571|OTHER|"Booster session"|Motivational interview
41326414|NCT00003809|BIOLOGICAL|cetuximab|
41326415|NCT00003809|DRUG|cisplatin|
41326416|NCT03538132|OTHER|dental regenerative techniques|dental regenerative techniques
41326417|NCT02527941|DRUG|Metronidazole|Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.
41326418|NCT02472795|DRUG|Matching placebo|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
41326419|NCT02472795|DRUG|Cenerimod|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
41326420|NCT04896190|OTHER|Evaluation of Q angle and Quadriceps muscle activation on dynamic balance position|Evaluation of Q angle, Quadriceps muscle activation, static and dynamic balance and functionality of all individuals was done.
41326421|NCT02666508|OTHER|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
41326422|NCT02666508|OTHER|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
41326423|NCT04263779|BEHAVIORAL|Order of Options|Relevant providers who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.
41326424|NCT04263779|BEHAVIORAL|Default Option|Both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. The optional P-SNF advantage video will be included and the link to it highlighted.
41326425|NCT03009240|DRUG|Decitabine|Given IV
41326426|NCT03009240|OTHER|Laboratory Biomarker Analysis|Correlative studies
41479851|NCT03346070|DRUG|Neostigmine + Glycopyrrolate|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 µg/kg; 5 mg maximum) and Glycopyrrolate (10 µg/kg; 1 mg maximum), dosed according to participant ABW for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of T2 in response to TOF stimulations."
41479852|NCT03346070|DRUG|Rocuronium or Vecuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide or Vecuronium Bromide administered via i.v. infusion and dosed according to participant ABW. NMBAs were concomitant medications used per label as adjunct to general anesthesia.
41479853|NCT06124274|BEHAVIORAL|Protein tracer drink|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13 Carbon(13C)\]-leucine.
41479854|NCT03754751|PROCEDURE|Laparoscopic cholecystectomy with the implementation of modified ERAS program|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient informing and brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Low-pressure pneumoperitoneum (8-9 mmHg)~2. Trocar wound and intraabdominal anesthesia with 0.25% ropivacaine~3. PONV prophylaxis in patients of risk~Postoperative care~1. Early mobilization (2 h after surgery)~2. Early fluid intake (2 h after surgery)~3. Early liquid food (6 h after surgery) Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
41326427|NCT03009240|DRUG|Pevonedistat|Given IV
41326428|NCT03009240|OTHER|Pharmacological Study|Correlative studies
41326429|NCT04172337|BEHAVIORAL|Healthier Choice Symbol|The HCS is intended to improve diet quality by signaling to consumers which products are healthier options within a specific category (e.g., which are the healthier biscuits or the healthier beverages). Manufacturers must meet category-specific criteria before a product can display the HCS and an associated tagline. The labels were displayed at the bottom of the product images.
41326430|NCT04172337|BEHAVIORAL|Physical Activity Equivalent label|"For the study, we designed a simple PAE logo (Appendix Figure A1) and added a description encoded into the NUSMart user interface to ensure that participants would understand the contents of the label. Participants saw the following description whenever their cursor hovered over the PAE label: The Physical Activity Equivalent (PAE) refers to the number of minutes that a typical adult would need to jog to burn off the calories associated with one serving of the product. Previous studies have shown this labelling approach to be effective.~The labels were displayed at the bottom of the product images."
41479855|NCT03754751|PROCEDURE|Laparoscopic cholecystectomy with standard perioperative treatment|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient oral informing. No brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Standard CO2 pressure (12-14 mmHg)~2. No additional anesthesia~Postoperative care~1. Mobilization in 4-6 h after surgery~2. Fluid intake in 6 hours~3. Liquid food intake in 12 hours Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
41326431|NCT03678376|OTHER|complaint, cognitive and functional assessments|"The evaluation with their GP is composed of (1-) Clinical impression, (2-) GP-Cog part 2 with patient or their informal caregiver and (3-) 6-CIT test.~The identification of patients at risk of NCD with the new strategy applied by the GP will be compared to the gold standard for diagnosis of NCD at the Memory Clinic, established according to Diagnosis and Statistical Manual of mental disorders (DSM-5) criteria and based on a clinical, neuropsychological evaluation and functional abilities. If needed, a secondary etiological diagnosis procedure will be undertaken following the HAS 2011 recommendation including brain MRI and biology."
41326432|NCT04776564|OTHER|Participation in the couple enhancement program|Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)
41326433|NCT01025687|DIETARY_SUPPLEMENT|water with noncalorie sweetener|
41326434|NCT01025687|DIETARY_SUPPLEMENT|water with glucose|
41479856|NCT06390202|OTHER|no intervention|there is no intervention in this study
41479857|NCT03180801|BIOLOGICAL|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
41479858|NCT03180801|BIOLOGICAL|adjuvanted placebo|Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
41326435|NCT01025687|BEHAVIORAL|TV program showed while feeding|
41326436|NCT01025687|BEHAVIORAL|TV program showed while feeding|
41326437|NCT03524911|BEHAVIORAL|CHFFF nutrition education|
41326438|NCT05247125|COMBINATION_PRODUCT|Blue light exposure + Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed. Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
41326439|NCT05247125|DRUG|Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed.
41326440|NCT05247125|DEVICE|Blue light exposure|Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
40809204|NCT04829682|BEHAVIORAL|Present Centered Therapy|PCT is an evidence-based treatment for PTSD but its principles can be applied to psychotherapy for a wide range of difficulties. The standard PCT manual was originally adapted for suicide prevention by Craig Bryan and his colleagues. Our study team made additional minor revisions to prepare the manual for use as an active control condition in the current efficacy trial. PCT includes two initial sessions focused on discussion of current symptoms, psychoeducation, and the rationale for PCT. Current life problems become the focus of the remaining sessions. PCT is expected to consist of three to six, 60-90-minute inpatient sessions and one to four outpatient sessions in the 30 days following discharge. Discontinuation will occur when the participant attends an individual outpatient mental health appointment or 30 days after discharge, whichever occurs first. PCT participants will receive caring communications from their therapist for 12-months following inpatient discharge.
40809205|NCT04901195|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
40809206|NCT06204900|DEVICE|Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during a standard Transforaminal Lumbar Interbody Fusion (TLIF).
41154404|NCT04983147|OTHER|Obesity Training Based on Health Belief Model|Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.
41326441|NCT05247125|COMBINATION_PRODUCT|Placebo|Placebo light exposure will be performed by using lamp turned off; and placebo pill will be given in the evening
41154405|NCT04983147|OTHER|Post-training follow-up|"After 7 weeks of training to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.It will be made by phone call.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days."
41326442|NCT03393689|DRUG|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
40809209|NCT05099003|PROCEDURE|Biopsy|Undergo a biopsy
40809210|NCT05099003|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
40809211|NCT05099003|RADIATION|Radiation Therapy|Undergo radiation therapy
40809212|NCT05099003|DRUG|Selinexor|Given orally
41009829|NCT06021392|PROCEDURE|Z plasty and minimal excision of pilonidal sinus|"The investigators will perform a  Z plasty  procedure and Minimal excision procedure for patients complaining of pilonidal sinus and the investigators will compare the outcomes and rate of recurrence of these two procedures"
41479859|NCT03180801|OTHER|Influenza challenge|On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.
41479860|NCT02065713|DRUG|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
41479861|NCT02065713|DRUG|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
40809213|NCT06578156|DEVICE|Nasal High Flow Cannula|High flow nasal cannula is a device that provides heated and humidified high flow gases. In-person. Depending on participant's availability, up to 6 times
40809214|NCT06578156|DEVICE|Nasal Low Flow Cannula|Low flow nasal cannula is a device that provides low flow gases. In-person. Depending on participant's availability, up to 6 times
41009830|NCT01898793|DRUG|Fludarabine|
41009831|NCT01898793|DRUG|Cyclophosphamide|
41009832|NCT01898793|PROCEDURE|Leukapheresis|
41479862|NCT02065713|DRUG|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
41479863|NCT03202901|DIETARY_SUPPLEMENT|B-turmactive|"The treatment consists of daily administration of B-TURMACTIVE®.~Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
41009833|NCT01898793|BIOLOGICAL|Cytokine-induced killer cells|
41009834|NCT01898793|BIOLOGICAL|IL-2|
41009835|NCT01898793|DRUG|ALT-803|
41009836|NCT01898793|PROCEDURE|Peripheral blood for correlative studies|-Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
41009837|NCT01898793|PROCEDURE|Bone marrow for correlative studies|-Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
41009838|NCT01218997|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
41009839|NCT01218997|DRUG|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
41009840|NCT03967470|BIOLOGICAL|Bacterial spray|Bacterial spray containing bacteria that do not cause underarm malodor
41009841|NCT00352612|DRUG|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
41009842|NCT00352612|DRUG|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
41009843|NCT06189456|DEVICE|BLUgel A|BLUgel A: Hyaluronic Acid Eye Drops 0.30%
41326443|NCT05190744|DRUG|PB|500mg twice daily (BID) followed by 1000mg BID. The dose of PB inducing the maximal increase in urine osmolality will be continued for up to three months providing that no side effects are observed including clinical and laboratory surveillance.
41326444|NCT04207268|BEHAVIORAL|Gardening and Nutrition Advice|Participate in gardening activities, gardening instructions and nutrition advice
41326445|NCT04207268|BEHAVIORAL|Nutrition Advice|Participate in only nutrition advice
41326446|NCT04101669|DEVICE|RESET Liner|The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.
40809215|NCT04450706|OTHER|Precision Medicine|"The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening. Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy. After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician. Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician. Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician. If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed informed. While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression."
40809216|NCT04450706|OTHER|Physican Decision Making|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
40809217|NCT05232916|BIOLOGICAL|Placebo|0.9% Normal Saline
40809218|NCT05232916|BIOLOGICAL|GLSI-100|500 mcg/mL GP2 and 125 mcg/mL GM-CSF
40809219|NCT06414954|DRUG|NMD670|Tablets taken twice a day for 21 days
40809220|NCT06414954|DRUG|Placebo|Tablets taken twice a day for 21 days
41154406|NCT04737499|BEHAVIORAL|CASCADe|Culturally tailored diabetes self-management and education sessions with mHealth integration
41154407|NCT05724797|DRUG|NRS-033|A single dose of NRS-033 will be administered
41154408|NCT05724797|DRUG|Placebo|A single dose of matching placebo will be administered
41154409|NCT05596045|DRUG|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
40809225|NCT00560651|PROCEDURE|CCL (Corneal Cross Linking)|Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
41154410|NCT05596045|DRUG|Placebo|Participants will be randomized to receive placebo
41326447|NCT04101669|OTHER|Sham|Patient receives upper endoscopy but no treatment
41326448|NCT02245867|DRUG|Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4|The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
41326449|NCT05126940|DIAGNOSTIC_TEST|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis|Patients were placed in a semi-recumbent or supine position depending on their respiratory tolerance. For each side of the chest, 4 zones have to be assessed : 2 anterior and 2 lateral. The operator should calculate the number of B-lines when present .
41326450|NCT01541501|DEVICE|Pachymetry|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
40809226|NCT04603495|DRUG|Pelabresib|"Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).~Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF."
41154411|NCT05872984|DIAGNOSTIC_TEST|adjustment of dry weight based on absolute blood volume measurement|adjustment of dry weight based on absolute blood volume measurement
41154412|NCT05880771|OTHER|Immediate Implant Placement|Tooth extraction followed by immediate implant placement. One group will have Allograft graft in the buccal gap, the other will have Xenograft graft.
41326451|NCT04451317|OTHER|Questionnaire, phone call|phone call and 3 questionnaires on a digital platform
41154413|NCT05004688|BIOLOGICAL|Biological/Vaccine: Bacillus Calmette-Guerin (BCG)|Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10\^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
41154414|NCT01973179|RADIATION|Radiation therapy|Radiation therapy with protons
41326452|NCT00358501|DRUG|Defibrotide|Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
41154415|NCT05253547|BEHAVIORAL|Healthy climate-friendly dietary guidelines|Personalised climate-friendly healthy dietary recommendations
41326453|NCT04848415|OTHER|Point-of-Care Ultrasound|Patients admitted to the ED with abdominal pain and suspicion of bowel obstruction : realization of a Point-of-Care Ultrasound after clinical exam by the Emergency Physician in charge as a standard of care. Beside usual findings, the investigators will search for signs of bowel obstruction: dilated and incompressible small bowel loop, back-and-forth peristalsis sign. Determination of probability of small bowel obstruction. Realization of a computed tomography in search of small bowel obstruction.
41326454|NCT00610285|OTHER|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
41479864|NCT03202901|DIETARY_SUPPLEMENT|Placebo|"The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.~Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
40809227|NCT04603495|DRUG|Ruxolitinib|Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
40809228|NCT04603495|DRUG|Placebo|Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
40809229|NCT06163326|DRUG|Ritlecitinib|Ritlecitinib 50 mg capsule once daily
41009844|NCT06189456|DEVICE|BLUyal A|BLUyal A:Hyaluronic Acid Eye Drops 0.15%
41009845|NCT02595736|DRUG|Placebo (SC)|Administered SC
41009846|NCT02595736|DRUG|LY3200327 (SC)|Administered SC
40809230|NCT06163326|DRUG|Ritlecitinib 100 mg|Ritlecitinib 100 mg capsule once daily
40809231|NCT06163326|DRUG|Placebo|Matching capsule once daily
41009847|NCT02595736|DRUG|LY3200327 (IV)|Administered IV
41009848|NCT02595736|DRUG|Placebo (IV)|Administered IV
40809232|NCT06337318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41154416|NCT05253547|BEHAVIORAL|Healthy dietary guidelines|Personalised healthy dietary recommendations
41154417|NCT00588991|DRUG|Carboplatin|Given IV
41154418|NCT00588991|OTHER|Laboratory Biomarker Analysis|Correlative study
41154419|NCT00588991|DRUG|Topotecan Hydrochloride|Given IV
41154420|NCT00588991|DRUG|Veliparib|Given orally
40809233|NCT06337318|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT scan
40809234|NCT06337318|BIOLOGICAL|Mosunetuzumab|Given SC
40809235|NCT06337318|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
40809236|NCT06337318|BIOLOGICAL|Rituximab|Given IV
40809237|NCT06337318|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
41154421|NCT02146729|PROCEDURE|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
41009849|NCT00270972|DEVICE|Bilayered Cellular Matrix (OrCel)|
41009850|NCT06278597|DIAGNOSTIC_TEST|NACA Estimator|Grading of peripheral anterior chamber width with the Narrow Anterior Chamber Angle (NACA) Estimator
41009851|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
41009852|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
41009853|NCT04069403|OTHER|Automated Reports on prescription patterns for their patients|de-identified aggregate reports
41009854|NCT05811104|DEVICE|Sequential bilateral theta burst stimulation|Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol
41009855|NCT06052774|PROCEDURE|Non-Surgical periodontal therapy|Supra and Subgingival debridement for all patients except periodontally healthy individuals
41009856|NCT05572502|BEHAVIORAL|plant-based diet|For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
41154422|NCT02146729|PROCEDURE|Open Treatment|Midline posterior incision with instrumentation.
41326455|NCT00229229|OTHER|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
41326456|NCT00229229|OTHER|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
41326457|NCT00229229|OTHER|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
41326458|NCT00229229|OTHER|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
41326459|NCT01998438|DRUG|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
41326460|NCT05493540|DRUG|Ibuprofen oral suspension|"The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics~An additional course of Ibuprofen may be offered if there is:~1. Moderate/Severe PDA on Echocardiography~2. Prolonged ventilation or Increased ventilatory setting~3. Prolonged use of inotropes or vasopressors or escalating dose~   * Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
41154423|NCT02297529|DRUG|Talimogene Laherparepvec|Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
41479865|NCT02283164|BEHAVIORAL|Hazardous materials online education and study feedback|Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
41479866|NCT02166320|DEVICE|Partially covered SEMS|
41009857|NCT05091528|DRUG|SBT6050|Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles
41009858|NCT05091528|DRUG|trastuzumab deruxtecan|5.4 mg/kg by intravenous (IV) infusion in 21-day cycles
41009859|NCT05091528|DRUG|tucatinib|300 mg by mouth (PO) twice daily (BID)
41009860|NCT05091528|DRUG|trastuzumab|8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles
41009861|NCT05091528|DRUG|capecitabine|1000 mg/m2 PO BID for 14 days of each 21-day cycle
41009862|NCT05091528|DRUG|trastuzumab deruxtecan|6.4 mg/kg by IV infusion in 21-day cycles
41479867|NCT02166320|DEVICE|Fully covered SEMS|
41479868|NCT02692482|DEVICE|hydrocellular polyurethane foam multilayer dressing|Application of hydrocellular polyurethane foam in the sacral region within 24 hours of admission and replaced when detaches or gets wet or dirty in addition to standard care
41479869|NCT02692482|PROCEDURE|standard care|Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.
41154424|NCT02551471|OTHER|Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|"This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries."
41009863|NCT02407106|DIETARY_SUPPLEMENT|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
41009864|NCT01243346|DRUG|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
41009865|NCT02232659|DEVICE|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
41009866|NCT02388997|DRUG|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
41009867|NCT02388997|BIOLOGICAL|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
41009868|NCT01148953|DRUG|ALN-TTR01|Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
41009869|NCT01148953|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
41009870|NCT03056131|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
41009871|NCT00325234|DRUG|Pemetrexed|600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
41009872|NCT00325234|DRUG|Carboplatin|AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
41009873|NCT00325234|DRUG|Gemcitabine|1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
41009874|NCT00325234|DRUG|Vinorelbine|30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
41009875|NCT03465293|OTHER|Bacterial composition and activity after bowel preparation|Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
41009876|NCT04213898|DRUG|SHR-1210+Albumin-bound paclitaxel + epirubicin|Neoadjuvant therapy：SHR-1210, 200mg,iv, q3w, for 6 cycles; Albumin-bound paclitaxel: 125 mg/m2, iv, d1, d8, and d15, 21 days as a cycle, for 6 cycles; Epirubicin: 75mg / m2, iv, d1, 21 days as a cycle, for 6 cycles; The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
41009877|NCT04395716|BIOLOGICAL|ResCure™|Patients will be treated with nebulized ResCure™
41009878|NCT04750122|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning|The choice of chemotherapy is based on the PTC drug sensitivity results.
41009879|NCT06122324|DRUG|Lidocaine Hydrochloride|Patients in Group 1 will receive 40 mg of lidocaine HCl solution 5 minutes before endotracheal intubation.
41009880|NCT03240575|DRUG|Tiotropium|Fixed Dose Combination
41009881|NCT03240575|DRUG|Olodaterol|Fixed Dose Combination
41009882|NCT03240575|DRUG|Fluticasone propionate|Fixed Dose Combination
41009883|NCT03240575|DRUG|Salmeterol|Fixed Dose Combination
41479870|NCT06468423|DRUG|Deferasirox (DFX)|Oral DFX at a dose of 30mg/kg daily advised for a duration of 6 months.
41479871|NCT06468423|DRUG|Deferoxamine (DFO)|DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week for a duration of 6 months.
41479872|NCT03351231|DRUG|BMS-986242|Specified dose on specified days
41479873|NCT03351231|BIOLOGICAL|Nivolumab|Specified dose on specified days
41479874|NCT03883282|OTHER|Not Provided|Not Provided
41326461|NCT05493540|DRUG|Placebo|"Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~1. Prolonged Ventilation or Escalating Ventilatory Setting~2. Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~1. After 5 days of recruitment~2. Moderate/Severe PDA on Echocardiography~3. Prolonged ventilation or Increased ventilatory setting~4. Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
41326462|NCT00184158|PROCEDURE|decompression|Conservative, simple decompression and nerve transfer
41479875|NCT02936687|DRUG|NOS Inhibition|NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology. L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment. Systemic delivery of L - NMMA has been shown to elevate blood pressure \~8-15 mmHg that is within the range observed during exercise.
41479876|NCT02936687|DRUG|ET-1 Inhibition|ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
41479877|NCT02936687|DRUG|NOS Inhibition Placebo|Saline will be infused at the same rate and quantity as the corresponding drug visit.
41479878|NCT02936687|DEVICE|3 Tesla MRI|A 3 Tesla MRI will be used to quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits (at baseline and during treatment conditions).
41479879|NCT02936687|DEVICE|Intravenous Catheter|A blood sampling IV catheter will be used to draw up to 15 mL blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin as well as for markers of inflammation and oxidative stress.
41479880|NCT02936687|OTHER|Oral Glucose Tolerance Test|The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.
41479881|NCT02936687|DRUG|ET-1 Inhibition Placebo|Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
41479882|NCT02327507|BEHAVIORAL|Toothpaste & Telephone Support|Mailed toothpaste, messages and telephone support.
41479883|NCT03912402|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
41479884|NCT03912402|BIOLOGICAL|Bevacizumab|IV infusion
41479885|NCT03912402|DRUG|Paclitaxel|IV infusion
41154425|NCT02551471|OTHER|MDT (Multidisciplinary team) meeting observation|"3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading)."
41154426|NCT02551471|OTHER|Semi-structured exploratory interviews and focus group with MDT health professional attendees|Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
41154427|NCT01304251|OTHER|Short-term fasting|Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy
41154428|NCT01304251|OTHER|Healthy nutrition|Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
41326463|NCT04099849|DIETARY_SUPPLEMENT|Diet-ZnBfR: Zinc biofortified rice-based diet|Diet-ZnBfR: Zinc biofortified rice-based diet
41326464|NCT04099849|DIETARY_SUPPLEMENT|Diet- CR: Conventional rice-based diet|Diet- CR: Conventional rice-based diet
41326465|NCT04099849|DIETARY_SUPPLEMENT|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
41479886|NCT03912402|DRUG|Cisplatin (or carboplatin)|IV infusion
41479887|NCT04669470|PROCEDURE|bariatric endoscopy, mainly intragastric baloons, plication of stomach too|bariatric endoscopy, mainly intragastric baloons, plication of stomach too
41479888|NCT00472797|DRUG|Rebif New Formulation Non Titrated|human interferon beta 1a - Rebif New Formulation
41479889|NCT00472797|DRUG|Rebif New Formulation Titrated|Human interferon beta 1a Rebif New Formulation
41479890|NCT00364806|DRUG|Prochlorperazine|
41479891|NCT00364806|DRUG|Metoclopramide|
41479892|NCT04439773|DRUG|placebo|the control group will be given the same volume of saline.
41479893|NCT04439773|DRUG|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
41479894|NCT03946020|PROCEDURE|Guided bone regeneration with or without autologous bone|Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.
41479895|NCT02957188|OTHER|13C eicosapentaenoic acid and 13C arachidonic acid|Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
41479896|NCT04287894|DRUG|Durvalumab|The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg
41479897|NCT04287894|DRUG|Tremelimumab|Per day 75mg
41479898|NCT04287894|DRUG|Pemetrexed|500 mg/m2 on day 1 every 3 weeks for 2 cycles
41479899|NCT04287894|DRUG|Cisplatin|6 mg / m2 on day 1 every 3 weeks for 2 cycles
41479900|NCT04287894|RADIATION|chemo radiotherapy|Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.
41479901|NCT04287894|PROCEDURE|Resection|After CIT-CRT
41326466|NCT01536652|DRUG|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
41326467|NCT03714009|BEHAVIORAL|Fasting|"Periodic fasting last for 4weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. Patients should take adequate water and non calorie beverages intake daily (2-3 liters)."
41326468|NCT03714009|BEHAVIORAL|No fasting|Patients will not fast . But they will take balanced food and drink 2 to 3 liters of water and non caloric drinks all the day for 4 weeks
41326469|NCT05570799|OTHER|Augmented Reality and Kahoot game learning|"* An augmented reality (AR) mobile application with image based will be used by the participants in the experimental group.~* Also, students will participate in Kahoot game. Students will participate in the game using their own devices by going to https://kahoot on their phones and entering their password and password."
41326470|NCT06539949|BEHAVIORAL|Rapid Planning Method (RPM)|RPM is a three day immersive seminar. Subjects will be exposed to a variety of mind-body exercises and psycho educational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
41479902|NCT04422119|PROCEDURE|Multi-Foam dressing|Application of a multi-layer foam dressing with Safetac in surgical wound
41479903|NCT04422119|PROCEDURE|Usual care|Care of surgical wound with povidone-iodine and a gauze dressing with plaster.
41479904|NCT03438227|DRUG|Iron dextran|Single intravenous infusion of iron dextran 1000mg.
41479905|NCT03438227|DRUG|Ferrous sulfate 325mg|Oral iron supplementation with ferrous sulfate 325mg one to three times daily
41479906|NCT05329493|DEVICE|Cooling digit device application|Cooling digit device will be applied on subject's right hand ( fifth finger).
41009884|NCT00548808|DRUG|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
41009885|NCT00548808|DRUG|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
41479907|NCT06221267|DRUG|Rimegepant|No intervention. The study will record the usage, timing, frequency, and dosage of rimegepant in a real-world clinical setting.
41479908|NCT00561314|OTHER|questionnaire administration|
41326471|NCT06539949|BEHAVIORAL|Journaling|Subjects will be keeping a weekly to-do list.
41326472|NCT04263194|DEVICE|rTMS|25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).
41326473|NCT04263194|DEVICE|Sham rTMS|Placebo intervention will consist in the same procedure but using a sham rTMS coil.
41326474|NCT00397878|DRUG|saracatinib|Given orally
41326475|NCT00397878|OTHER|laboratory biomarker analysis|Correlative studies
41326476|NCT04698109|OTHER|Biological sample collection|Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
41326477|NCT04698109|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
41326478|NCT04698109|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
41326479|NCT00408759|BEHAVIORAL|hypnosis|
41326480|NCT04030897|BEHAVIORAL|Parent-Directed Online Single-Session Program|Online, 15-minute self-administered program for parents
41326481|NCT04030897|BEHAVIORAL|Youth-Directed Online Single-Session Program|Online, 30 minute self-administered program for youths
41326482|NCT04030897|BEHAVIORAL|Information/Psychoeducation/Referral|Usual care at pediatric primary care clinics participating in this study
41326483|NCT04231513|DRUG|E2814|E2814, intravenous infusion.
41326484|NCT04231513|DRUG|E2814-matched placebo|E2814-matched placebo, intravenous infusion.
41326485|NCT06525870|DRUG|85%TCA topical application|85%TCA topical application is done at cervical lesion and transformation zone. Application of TCA will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of TCA will be applied to cover the lesion and transformation zone.
41326486|NCT06525870|DRUG|3% acetic acid|3% acetic acid topical application is done at cervical lesion and transformation zone. Application will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of acetic acid will be applied to cover the lesion and transformation zone.
41326487|NCT03626740|OTHER|TheraCal|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with TheraCal
41326488|NCT03626740|OTHER|MTA|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with MTA
41479909|NCT00561314|PROCEDURE|biopsy|
41479910|NCT00561314|PROCEDURE|high-intensity focused ultrasound ablation|
41479911|NCT00561314|PROCEDURE|magnetic resonance imaging|
41479912|NCT00561314|PROCEDURE|quality-of-life assessment|
41479913|NCT01706874|OTHER|Periodontal prophylaxis|Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
41479914|NCT00676325|PROCEDURE|Surgical treatment of Anterior Vaginal Prolapse|seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
41009886|NCT00548808|DRUG|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
41009887|NCT03218111|OTHER|MR Imaging|All subjects will undergo six sessions of MR imaging over a 10-12 hour period
41479915|NCT00676325|DEVICE|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
41479916|NCT00676325|PROCEDURE|surgical treatment for anterior vaginal wall prolapse|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
41479917|NCT01021241|BIOLOGICAL|Uricase-PEG 20|Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
40809245|NCT00018057|BEHAVIORAL|Attention Bias Modification Training|The intervention is computer-based. The active and control treatments have two components. In one component of the active intervention, subjects are asked to indicate the identity of a letter that appears behind a neutral face, opposite from an angry face. In another component of the active intervention, subjects are asked to identify numbers that are hidden within a puzzle, in locations distal from angry faces. In both components of the active intervention, subjects implicitly learn to shift their attention away from angry faces. This is because the faces are systematically arranged to be far removed from letters and numbers that need to be identified. The control arm of the intervention involves similar components. However, unlike in the intervention arm, angry faces appear in various locations near letters and numbers. Therefore, attention is not shaped in the control arm. This intervention requires five minutes per session and is administered before weekly psychotherapy sessions.
40809246|NCT00018057|DRUG|Fluoxetine|Randomized assignment.
40809247|NCT05072314|DRUG|lidocaine 2% and 10%|"Lidocaine infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 2% lidocaine (2.5 mg/kg).\*~2. Followed by a 2% lidocaine intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 10% lidocaine infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only"
40809248|NCT05072314|DRUG|Placebo|"Placebo infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 0.9% Saline solution.\*~2. Followed by a 0.9% Saline solution intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 0.9% Saline solution infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only"
41154429|NCT01751451|DRUG|Abiraterone acetate|Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
41154430|NCT01751451|DRUG|Abiraterone acetate plus degarelix|Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
41154431|NCT01751451|DRUG|Degarelix|Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
41326489|NCT04961086|OTHER|energy drink|An easily available 250 ml branded energy drink will be randomized to the partcipants after informed consent. Before and thirty minutes after drinking the given energy drink the participant cognition, heart rate, blood pressure and blood glucose will be measured.
41009888|NCT03218111|OTHER|CT-guidance|All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
41009889|NCT01352390|BEHAVIORAL|Planning Prompt|A prompt to have their child their health test reminder mailing to color
41009890|NCT01352390|BEHAVIORAL|Control Condition|A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
41009891|NCT03704181|DRUG|Colchicine 0.5 MG twice day for one year|placebo twice day for one year
41009892|NCT03704181|DRUG|Placebo Oral Tablet|placebo twice day for one year
41009893|NCT05784428|RADIATION|Single fraction SABR|"Participants randomized to this arm will receive SF SABR~Treatment recommendations are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory OAR constraints are met: 30 Gy in 1 fraction~Lung: Within 2 cm of mediastinum or brachial plexus 20 Gy in 1 fraction~Bone, Spine, Adrenal, lymph node/soft tissue: 20 Gy in 1 fraction~Liver: 30 Gy in 1 fraction~Brain: dose as per institutional policy"
41017838|NCT04205279|OTHER|Experimental: Overground training|"Slips and trips could be induced under either of the limbs. The specialized walkway consists of two sliding platforms, each of which is mounted on two rows of low friction linear bearings (friction coefficient = 0.02). The base plate of each platform is bolted separately onto the top of a force platform embedded in the floor. An electronic-mechanical latch system is used to control the 2 states of the support platform; that is, the locked state for regular walking and the release state to initiate slipping are carefully controlled. The sliding top of the platform is released after the heel strike (vertical force to exceed 2% of the body weight). The slip distance would be adjusted between 30 to 60 centimeters depending upon the different population and their physical capacity."
41479918|NCT05369468|DRUG|dexmedetomidine as adjuvant with bupivacaine|to assess efficacy of adding dexmedetomidine as adjuvant with bupivacaine in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
41479919|NCT05369468|DRUG|Bupivacain only|to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
41479920|NCT00608517|BIOLOGICAL|anti-thymocyte globulin|Given IV
41479921|NCT00608517|DRUG|cyclophosphamide|Given IV
41479922|NCT00608517|DRUG|fludarabine phosphate|Given IV
41479923|NCT00608517|DRUG|methylprednisolone|Given IV
41479924|NCT00608517|RADIATION|total-body irradiation|Given daily for 1-4 days
41479925|NCT00055484|DRUG|zonisamide|
41009894|NCT05784428|RADIATION|Multiple fraction SABR|"Participants randomized to this arm will receive MF SABR:~Dose/Fractionation are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory organ-at-risk (OAR) constraints are met: 48 Gy in 4 fractions (12 Gy/#), 54 Gy in 3 fractions (18 Gy/#), daily or every second day~Lung: Within 2 cm of mediastinum or brachial plexus 60 Gy in 8 fractions (7.5 Gy/#), 50 Gy in 5 fractions (10 Gy/#), daily~Bone: Any bone except spine: 35 Gy in 5 fractions (7 Gy/#), daily~Liver: 54 Gy in 3 fractions (18 Gy/#) or 5 fractions (10.8 Gy/#), daily or every second day~Spine: 24 Gy in 2 fractions (12 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Adrenal: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Lymph node/soft tissue: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Brain - dose per institutional policy for stereotactic lesions (no whole brain RT)."
41009895|NCT05784428|OTHER|QoL reporting alone|Participants randomized to this arm will complete the EQ-5D-5L and FACT-G at baseline and each follow-up visit
41009896|NCT05784428|OTHER|QoL reporting, symptom screen and healthcare provider intervention|Participants randomized to this arm will complete the FACT,G, EQ-5D-5L, radiation-symptom screen and receive healthcare provider-guided intervention based on their symptom reports.
41154432|NCT00965302|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
41326490|NCT01707329|DRUG|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
41326491|NCT01707329|DRUG|Icotinib+chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
41479926|NCT01660191|DRUG|Pitavastin 4mg|
41479927|NCT01660191|DRUG|Atorvastatin 20mg|
41479928|NCT01660191|DRUG|Rosuvastatin 5mg|
41479929|NCT05962450|BIOLOGICAL|iNKT Cells|the iNKT cells will be intravenous infused every two weeks as a course of treatment for up to six courses , the reinfusion dose is determined according to the patient's body surface area, which was about 108\~109cells/m2.
41479930|NCT05962450|DRUG|PD-1|Intravenous infusion, according to the drug instructions.
41326492|NCT04503863|DRUG|NPC-22|Single administration of middle dose NPC-22
41326493|NCT04503863|DRUG|NPC-22|Single administration of high dose NPC-22
41326494|NCT04503863|DRUG|NPC-22 Placebo|Single administration of NPC-22 Placebo
41326495|NCT06129942|DEVICE|Bright light box|The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The experimental group is treated with 10,000 Lux intensity. The treatment time is 1 hour each day from 09:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
41479931|NCT05962450|DRUG|Regorafenib|Oral administration, according to the drug instructions.
41479932|NCT01322126|DEVICE|ultrasound probe|we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
41479933|NCT03477552|DEVICE|Accuvein V400 device|Sickle cell patients who need a new vein puncture in order to infuse them will benefit of AccuveinV400 device to illuminate their venous network
41479934|NCT03477552|OTHER|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
41479935|NCT05664282|DEVICE|Damon self-ligating brackets|
41479936|NCT05664282|DEVICE|Victory self-ligating brackets|
41479937|NCT04343703|BEHAVIORAL|Telephone-based management|The intervention consists of a series of phone calls aimed at providing follow up care of individuals at risk. At each phone call the case manager collects information regarding the current treatment, adherence to mental health services, and current life stressors.
41479938|NCT04343703|BEHAVIORAL|iFightDepression for Suicide|The iFD-Survive is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iDF tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. The iFD-S also provides telephone guidance (2h per participant).
41154433|NCT00965302|BEHAVIORAL|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
41154434|NCT06584773|DRUG|Everolimus|mTORi added as the fourth maintenance immunosuppressive drug in recipients
41154435|NCT06584773|DRUG|standard maintenance immunosuppression|standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone
41154436|NCT01103271|OTHER|Open-label Placebo|Participants take open-label placebo pills - two twice daily for four weeks.
41154437|NCT02684942|DRUG|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
40809258|NCT03122899|DEVICE|SIJ fusion with iFuse-3D|Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
40809259|NCT06648798|DEVICE|Limber Limb|Participants will be involved for two months using a non-inferiority design in which the participant will be assessed using their normal device (1 month) and the study device (1 month).
40809260|NCT06433687|DEVICE|HekaHeart platform medication management and remote monitoring|Onboarding to the HekaHeart platform which includes a personalized GDMT management plan along with remote monitoring kits including a scale, blood pressure cuff, and heart rate monitor. Patients engage in video and phone calls with clinicians who will use established standardized clinical protocols to guide medication and vital optimization. Once patients are determined to be maximally titrated on all GDMT, they are transitioned back to standard clinical care.
41154438|NCT02684942|DRUG|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
41009897|NCT03077503|DRUG|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
41326496|NCT06129942|DEVICE|Dim Light box|The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The control group is treated with 300 Lux intensity. The treatment time is 1 hour each day from 09:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
41154439|NCT00449917|DRUG|lutein|
41154440|NCT00449917|DRUG|DHA|
40809264|NCT05494697|DRUG|Rintatolimod|Rintatolimod (poly I : poly C12U)
41154441|NCT00449917|DRUG|vitamins|
40809266|NCT06400472|DRUG|LY4170156|Intravenous
41326497|NCT00309257|DRUG|ACE I, ATA II and Statins|
41326498|NCT00309257|DRUG|Benazepril, Valsartan and Fluvastatin|"Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate."
41154442|NCT02213458|BEHAVIORAL|Navigated Care|"Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a dashboard functions as a patient care management system used by Care Team Navigators (CTNs)."
41154443|NCT00850993|DRUG|Stannsoporfin|Stannsoporfin administered as a single IM injection
41154444|NCT00850993|OTHER|Placebo|Placebo (sterile saline solution) administered as a single IM injection
41154445|NCT00850993|OTHER|PhotoTherapy (as needed)|PT standard care administered as needed, based on bilirubin levels throughout the treatment period
41154446|NCT01579461|DRUG|mirabegron|oral
41154447|NCT05363098|OTHER|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during assisted mechanical ventilation. No intervention is planned.
40809269|NCT06283810|BEHAVIORAL|psychotherapy of interpersonal relationships|"Group KIPT will be 1 session per week and each session will last 90 minutes. There will be 7 sessions in total, and a completion session will be held 2 weeks after the completion of Group KIPT. In order for the students in G1 to understand which group they are in, they will also be informed about the points to be considered regarding laughter therapy. An unstructured laughter intervention will be applied at the beginning or at the end of the sessions in which group IPT is applied.~Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect). Within the scope of work packages 3 and 4, KIPT application and other measurements will be made."
40809270|NCT06283810|BEHAVIORAL|laughter therapy|"Laughter therapy is 1 session per week and each session will last 40 minutes. A total of 8 sessions will continue. Each session will start with warm-up and deep breathing exercises and will continue with applause and childish games. Afterwards, games specific to each session will be added. Unstructured interviews will be conducted with G2 at the beginning or at the end of the session, suggesting that they were subjected to group CIPT. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect) when the interviews start."
41009898|NCT03077503|DRUG|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
41326499|NCT00875303|BEHAVIORAL|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
41326500|NCT00875303|BEHAVIORAL|Control|Routine primary care.
41009899|NCT03077503|DRUG|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
41009900|NCT03077503|DEVICE|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
41009901|NCT00866632|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
41009902|NCT00866632|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
41009903|NCT00646204|DRUG|Memantine|10 mg bid
41009904|NCT00646204|DRUG|placebo|2 tabs bid
41154448|NCT06358703|DRUG|Caplacizumab|Early Caplacizumab use
41326501|NCT00889811|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
41326502|NCT05500183|BEHAVIORAL|Cognitively enriched walking program|The PA+CA program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
41326503|NCT05500183|BEHAVIORAL|walking program|The PA only program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
41326504|NCT01268943|DRUG|Capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
41326505|NCT01268943|DRUG|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
41326506|NCT01268943|DRUG|Capecitabine|oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
41326507|NCT01268943|DRUG|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
41009905|NCT04911426|BEHAVIORAL|Telehealth|The telehealth intervention is delivered with an app developed for this research. The intervention features live video calling, messaging, appointment reminders; clinical support is provided by licensed clinicians.
41009906|NCT04169295|OTHER|Gynecologists' feedback on ART-Birth rates|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.
41009907|NCT04169295|OTHER|Control group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
41009908|NCT05526872|OTHER|Best Practice|Receive usual care
41154449|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
41326508|NCT03179410|DRUG|Avelumab|10 mg/kg intravenously every 2 weeks
41479939|NCT04343703|BEHAVIORAL|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
40809271|NCT06283810|BEHAVIORAL|Plasebo|"After the initial data are collected, unstructured interviews about the interpersonal relationships of the person will be conducted by conducting individual interviews with each student for 2-3 sessions at the beginning of the study in case the student does not understand which group he/she is in. Afterwards, unstructured random interviews and laughter intervention will be conducted for a total of 8 sessions lasting 40 minutes, 1 session per week. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week, 8th week and 12th week (long-term effect) when the interviews start."
40809272|NCT05061550|DRUG|Durvalumab|Participants will receive Durvalumab via intravenous route.
40809273|NCT05061550|DRUG|Oleclumab|Participants will receive Oleclumab via intravenous route.
41479940|NCT04343703|BEHAVIORAL|Self Awareness of Mental Health|The SAM consist of five, face-to-face, individual sessions designed to raise awareness about depression, anxiety and suicidal behaviors as well as to enhancing skills to effectively cope with stressful life events and mood.
41479941|NCT05940623|DEVICE|Standard care and home IOP telemonitoring with smart phone-based intervention|We expect that (1) GAT measurements over 30 months of follow-up for patients randomized to Management Paradigm I to be smaller compared with those randomized to Management Paradigm II; and that (2) the rates of RNFL/GCIPL thinning would be slower for those randomized to Management Paradigm I compared with those randomized to Management Paradigm II
40809274|NCT05061550|DRUG|Monalizumab|Participants will receive Monalizumab via intravenous route.
40809275|NCT05061550|DRUG|Dato-DXd|Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.
40809276|NCT05061550|DRUG|AZD0171|Participants will receive AZD0171 via intravenous route.
41154450|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
40809277|NCT05061550|DRUG|Carboplatin|Carboplatin as chemotherapy
41154451|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
40809278|NCT05061550|DRUG|Cisplatin|Cisplatin as chemotherapy
40809279|NCT05061550|DRUG|Pemetrexed/Cisplatin|Pemetrexed/Cisplatin as chemotherapy
40809280|NCT05061550|DRUG|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin as chemotherapy
40809281|NCT05061550|DRUG|Carboplatin/Paclitaxel|Carboplatin/Paclitaxel, as chemotherapy
40809282|NCT05061550|DRUG|Volrustomig|Participants will receive Volrustomig via intravenous route.
41154452|NCT04083690|DEVICE|Reprogramming of CRT Device Settings to Optimal Electrical Synchrony|Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.
41154453|NCT01461161|DRUG|bardoxolone methyl|oral, single dose
41154454|NCT05434533|DRUG|Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)|IV 1gm
41154455|NCT02503839|DRUG|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
40809287|NCT04759586|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
40809288|NCT04759586|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
40809289|NCT04759586|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
41154456|NCT02503839|BIOLOGICAL|H56:IC31|Therapeutic and prophylactic TB vaccine
41479942|NCT04792359|DEVICE|Equinometer|Measurement of dorsiflexion of the ankle will be reproduced three times on each ankle in two positions, with a force applied
41479943|NCT04880720|OTHER|Blood sampling|Blood sampling - 10mL
40809290|NCT04759586|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40809291|NCT04759586|DRUG|Cyclophosphamide|Given IV
40809292|NCT04759586|DRUG|Doxorubicin Hydrochloride|Given IV
40809293|NCT04759586|PROCEDURE|Echocardiography|Undergo ECHO
40809294|NCT04759586|DRUG|Etoposide Phosphate|Given IV
40809295|NCT04759586|BIOLOGICAL|Filgrastim|Given SC
40809296|NCT04759586|PROCEDURE|Lumbar Puncture|Undergo LP
40809297|NCT04759586|BIOLOGICAL|Nivolumab|Given IV
40809298|NCT04759586|BIOLOGICAL|Pegfilgrastim|Given SC
41154457|NCT05834972|DEVICE|Ultrasound-guided percutaneous dilatational tracheosyomy|All of the participants will be examined two times. First, the landmark-guided technique will be performed. Then, the ultrasound-guided technique will be performed.
41154458|NCT06313944|DIAGNOSTIC_TEST|Registry|Clinical data collection of patients scheduled for on-label treatment
41154459|NCT03320642|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
41154460|NCT03320642|DRUG|Calcineurin inhibitor|The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.
41154461|NCT06586606|DRUG|MK-1708|Oral administration
41154462|NCT06586606|DRUG|Itraconazole|Oral administration
41154463|NCT03302559|OTHER|Retinol Complex 0.5|Retinol Complex 0.5 topically in the evening.
41154464|NCT03302559|OTHER|Facial cleanser|Facial cleanser in the morning and in the evening.
41154465|NCT03302559|OTHER|Moisturizing lotion|Fragrance free moisturizing lotion in the morning and in the evening.
41154466|NCT03302559|OTHER|Sunscreen|Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.
41154467|NCT03302559|DEVICE|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500
41479944|NCT02080832|DRUG|Citalopram|20 mg or 40 mg daily for 8 weeks
41479945|NCT02080832|DRUG|Placebo|Placebo daily for 8 weeks
41326509|NCT04592848|OTHER|Questionnaires|"Four Questionnaires in French will be sent to participants :~* 1 questionnaire about sexual and urinary symptoms before and after the surgery ;~* 1 validated questionnaire Female Sexual Function Index to assess sexual function over the past 4 weeks ;~* 1 validated questionnaire Body Image Scale to assess body image during the past week ;~* 1 validated questionnaire Stoma Quality of Life, only for patients with incontinent urostomy.~If the questionnaires are not returned 15 days after sending, a follow-up phone call will be made by one of the investigators.~The data collection will include both the answers to the questionnaires and the patients' computerized medical data:~* Pathology responsible for the urological disorders and date of onset of the disorders~* Date and Type of surgery performed~* Patient's age at the time of surgery~* Post-operative complications within one month of surgery"
41326510|NCT01058733|OTHER|Internet|new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
41326511|NCT06014580|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
41326512|NCT04228887|DIAGNOSTIC_TEST|Respiratory Muscle Strength|Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
41326513|NCT04228887|DEVICE|Balance Training|Balance training will provide with Biodex® Balance Training System
41326514|NCT04228887|DEVICE|Inspiratory Muscle Training|15 minutes twice a day, 5 times a week for 8 week with Threshold IMT device
41326515|NCT01621854|DRUG|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days
41326516|NCT05838547|DRUG|64Cu-25%-CANF-Comb|Patients treated with OMT alone that are not treated with CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit and at 18 months.
41326517|NCT05838547|DRUG|64Cu-25%-CANF-Comb|Patients treated with OMT and CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit.
41326518|NCT02553317|BIOLOGICAL|Caplacizumab|"* First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
41326519|NCT02553317|BIOLOGICAL|Placebo|"* First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
41326520|NCT04368468|OTHER|biomarker evolution|analysis of a list of biomarkers on triple negative breast tumors samples before and after neoadjuvant therapy
41326521|NCT05145712|DIAGNOSTIC_TEST|Bowel readiness|"During the examination, the endoscopic physician required to stay in place while rinsing, and the lens could only be withdrawn after rinsing.~During the examination, the recorder should record the time points of the right colon, transverse colon, and left colon, as well as the time of irrigation.~If both are considered to be properly, then second colonoscopy was performed immediately.~If both results agree or either side agrees that the gut is not well prepared, the review will be carried out within a year"
41326522|NCT02224638|DEVICE|TheraHoney HD|Honey
41326523|NCT02224638|DEVICE|SkinTegrity|Hydrogel
41326524|NCT00002257|DRUG|Ganciclovir|
41326525|NCT05264558|DEVICE|Xpert HCV Viral load finger stick point of care test (Cepheid)|Xpert HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Appropriate pre and post testing counselling will be provided to participants.
41326526|NCT05264558|DRUG|Epclusa 400Mg-100Mg Tablet|Same day HCV test and treatment
41326527|NCT05264558|OTHER|Standard of care|Clinical services will receive additional education and have the option of providing incentives to attendees of service.
41326528|NCT00226967|DRUG|Sandostatin|Calculated per patient
41479946|NCT01202877|DRUG|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
41479947|NCT01202877|DRUG|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
41479948|NCT04211142|PROCEDURE|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)|Laparoscopic inguinal hernia repair
41479949|NCT04211142|PROCEDURE|Open Inguinal Hernia Repair (Lichtenstein repair)|Open Inguinal Hernia Repair
41479950|NCT01194102|BEHAVIORAL|Community Based Exercise Program|Three supervised exercise sessions per week, including individual and group sessions aimed at strengthening, flexibility and cardiovascular exercise.
40809299|NCT04759586|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40809300|NCT04759586|DRUG|Prednisolone|Given PO
40809301|NCT04759586|DRUG|Prednisone|Given PO
40809302|NCT04759586|RADIATION|Radiation Therapy|Undergo radiation therapy
40809303|NCT04759586|BIOLOGICAL|Rituximab|Given IV
41479951|NCT01194102|OTHER|Living with Stroke Education program|Weekly 1 hour long education sessions on living with stroke, aimed at helping participants take better care of their health after a stroke.
40809304|NCT04759586|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
40809305|NCT04759586|DRUG|Vincristine Sulfate|Given IV
40809306|NCT06443463|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily
41326529|NCT05885009|GENETIC|Liquid Biopsy|Patients with metastatic prostate cancer in disease progression or not receiving active systemic therapy will undergo a liquid biopsy
40809307|NCT06443463|DRUG|BHV-7000|BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily
41154468|NCT05558761|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics. PTX exerts anti-inflammatory effects by inhibiting phosphodiesterase and activating the adenosine 2 receptor
41154469|NCT06538675|OTHER|Psychotherapy|Patients are assigned to a therapist and will receive psychotherapy
41154470|NCT01323335|DRUG|IV Uric Acid|
41154471|NCT01323335|DRUG|IV Rasburicase|
41154472|NCT06057259|DEVICE|Joint position sense measurement|The participants' wrist joint position sense was evaluated.
41009909|NCT05526872|BEHAVIORAL|Health Education|Receive educational materials
41326530|NCT05885009|GENETIC|Archival Tumor DNA sequencing|Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
41326531|NCT00987090|BIOLOGICAL|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
41326532|NCT00987090|RADIATION|MRI|intervention at the inclusion and 18 months after
41326533|NCT00987090|PROCEDURE|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
41326534|NCT00987090|BIOLOGICAL|Apolipoprotein E genotyping|genotyping at the inclusion
41326535|NCT00987090|BIOLOGICAL|Study of cerebrospinal fluid|intervention at the inclusion
41326536|NCT00148421|DRUG|Darbepoetin alfa and Epoetin alfa|
41326537|NCT03694158|DRUG|Dupilumab|anti-IL4 receptor antagonist
41009910|NCT05526872|OTHER|Interview|Ancillary studies
41009911|NCT05526872|OTHER|Planned Notification|Receive planned reminders to schedule mammogram
41326538|NCT03694158|OTHER|Placebo|Placebo for Dupilumab (packaged/administered the same as the active drug)
41326539|NCT03367442|OTHER|no intervention|no intervention
41326540|NCT03979846|OTHER|Best Practice|Receive usual care
41326541|NCT03979846|OTHER|Computer Application|Use computer-based symptom reporting system
41326542|NCT03979846|OTHER|Questionnaire Administration|Ancillary studies
41326543|NCT03979846|OTHER|Quality-of-Life Assessment|Ancillary studies
41326544|NCT04070118|PROCEDURE|Measure niche thickness with ultrasound|in patients with previous cesarean section who applied to the emergency department with pain and underwent surgery; Measure niche thickness before operation
41326545|NCT02301754|BIOLOGICAL|INVAC-1|intradermal injection combined with electroporation
41326546|NCT01570933|DEVICE|NivNava|Non-invasive Nava ventilation mode on nasal cannula
41326547|NCT01570933|DEVICE|Cpap|nasal Cpap on nasal cannula
41326548|NCT01179347|DRUG|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
40809325|NCT05707377|DRUG|Zanubrutinib|Participants will receive zanubrutinib once daily
41326549|NCT01179347|DRUG|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
41326550|NCT00165581|DEVICE|High Dose Intracavitary Brachytherapy|
41326551|NCT00801138|DRUG|saline|2 ml 0.9% saline (placebo)
41326552|NCT00801138|DRUG|Dexamethasone|dexamethasone 8 mg (2 ml)
41326553|NCT00801138|DRUG|ropivacaine|30 ml 0.5% ropivacaine
40809326|NCT05707377|DRUG|Tacrolimus|Participants will receive tacrolimus twice daily
40809327|NCT05707377|DRUG|Zanubrutinib|Participants will receive zanubrutinib twice daily
40809337|NCT05222620|OTHER|Questionnaire Administration|Ancillary studies
40809338|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo single fraction SRS
40809339|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo fractionated SRS
40809340|NCT05222620|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40809341|NCT05536141|DRUG|casdatifan|Administered as specified in the treatment arm
40809342|NCT05536141|DRUG|Cabozantinib|Administered as specified in the treatment arm
41009912|NCT05526872|OTHER|Survey Administration|Ancillary studies
41009913|NCT02690961|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
41009914|NCT02690961|DRUG|placebo multiple doses|
41009915|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q4W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
41326554|NCT00801138|DRUG|Bupivacaine|30 ml 0.5% bupivacaine
40809343|NCT06255002|BIOLOGICAL|Fibrinogen concentration by the qLabs®FIB Monitoring system|A drop of blood (\~15 μL) is taken from the blood sample for the complete haemostasis assessment (prothrombin level, activated partial thromboplastin time, fibrinogen). This assessment is part of the usual management of severe postpartum haemorrhage. It is carried out urgently in the hospital's medical biology laboratory at the start of treatment (T1) and during or at the end of treatment of the haemorrhage (T2). This drop of blood will allow the measurement of the fibrinogen concentration by the qLabs®FIB Monitoring system for the study at these two times.
40809344|NCT06360354|DRUG|AMG 193|Administered Orally
40809345|NCT06360354|DRUG|Gemcitabine|Administered IV
40809346|NCT06360354|DRUG|Nab-paclitaxel|Administered IV
40809347|NCT06360354|DRUG|Modified FOLFIRINOX|Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
41154473|NCT06537570|BEHAVIORAL|Guided Imagery Practice|"Before the guided imagery application, the language translation of the guided imagery usage steps guide prepared by Owen (2010)27 was done by a translation center in a certified manner. Then, a relaxing, soothing, soft and slow-paced CD consisting of mixed nature sounds, photographs and music lasting 15 minutes and 50 seconds was prepared in the sound recording studio with the psychological counselor.~Data collection forms were filled in by the researcher using face-to-face interview technique for the women who agreed to participate in the study. The guided imagery video was shared with the women and they were made to watch it once a day for 12 weeks in a quiet, calm, uncrowded, dimly lit room in their homes. The women in the control group did not receive any interventions other than routine interventions during outpatient follow-up."
41154474|NCT03658694|PROCEDURE|Conventional rTMS - study 1|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
41154475|NCT03658694|PROCEDURE|Sham rTMS - study 1|Patients will be undergoing to sham transcranial magnetic stimulation session
40809351|NCT06651112|DRUG|Antipsychotic drugs|Any Antipsychotic drugs prescripbe as standrd of care for this specific populaton
40809352|NCT06651268|DRUG|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
40809353|NCT06651281|DRUG|Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
41009916|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
41009917|NCT04630522|DRUG|Drug: JMT103- 180 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
41009918|NCT04630522|DIETARY_SUPPLEMENT|Dietary Supplement: Calcium Dietary Supplement: Vitamin D|Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
41009919|NCT02941679|DRUG|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
41009920|NCT02941679|DRUG|HGP1011|Boehringer Ingelheim
41009921|NCT02941679|DRUG|HCP0910|GlaxoSmithKline
41009922|NCT03676452|BEHAVIORAL|Active@Home exergame training|The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
41154476|NCT03658694|PROCEDURE|Conventional rTMS - study 2|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
40809354|NCT06651281|DRUG|Placebo to tulisokibart|Placebo matching SC tulisokibart
41154477|NCT03658694|PROCEDURE|Patterned rTMS - stage 2|Patients will be undergoing to theta-burst transcranial magnetic stimulation session
41154478|NCT05197153|BIOLOGICAL|Half dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of half of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
41009923|NCT05864313|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|10 Hz rTMS for 5 seconds over the frontal eye fields with 25 second intertrain interval for 10 trains (500 pulses) at 90% of the resting motor threshold,
41009924|NCT05864313|BEHAVIORAL|Gait training|Subjects will practice stepping on virtual targets with real-time feedback of their foot position displayed on a screen while walking on a treadmill.
41009925|NCT05864313|BEHAVIORAL|Gaze training|Subjects will perform gaze stabilization and gaze shifting exercise via a virtual reality headset.
41009926|NCT05864313|DEVICE|Sham rTMS|Sham rTMS stimulation will produce discharge noise and vibration without stimulating the cerebral cortex.
41009927|NCT01994304|BEHAVIORAL|SCC|The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce intrapartum mortality (still births and very early neonatal deaths).
41009928|NCT05894681|OTHER|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS
41154479|NCT05197153|BIOLOGICAL|Full dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
41326555|NCT03350841|PROCEDURE|Platelet rich plasma PRP|blood sample is collected to prepare platelet rich plasma injected in the canal
41009929|NCT04623333|DRUG|TQB2450|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
41009930|NCT06336772|DEVICE|Restylane Shaype|Half (50%) of study participants will receive Restylane Shaype for the treatment of mild to severe chin retrusion
41009931|NCT06336772|DEVICE|Juvéderm Volux|Half (50%) of study participants will receive Juvéderm Volux for the treatment of mild to severe chin retrusion
41009932|NCT03192839|OTHER|Low dose PUFA|Low dose PUFA
41009933|NCT03192839|OTHER|High dose PUFA|High dose PUFA
41009934|NCT03192839|OTHER|Placebo|Placebo
41009935|NCT02658110|DIETARY_SUPPLEMENT|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
40809357|NCT06651151|DRUG|LTX-315 + pembrolizumab|LTX-315 as intratumoral injection once weekly for a maximum of 5 dosing days, in combination with pembrolizumab as intravenous infusion, 200 mg every 3 weeks for a maximum of 18 doses
41154480|NCT05197153|BIOLOGICAL|AZD1222|Approximately 240 participants will receive 1 doses of AZD1222 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
41154481|NCT05197153|BIOLOGICAL|Half dose of mRNA-1273|Approximately 240 participants will receive 1 doses half of mRNA-1273 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
41154482|NCT04635241|DRUG|Unfractionated heparin|Inhaled nebulised 6 hourly
40809361|NCT05170204|DRUG|Alectinib|Participants will receive oral alectinib twice daily with food.
41154483|NCT06440980|DRUG|Orforglipron|Administered orally
41326556|NCT03350841|PROCEDURE|root canal treatment|conventional root canal treatment and obturation with guttapercha
41326557|NCT01454479|DRUG|Lapatinib and ixempra|Ixabepilone 40 mg/m2 Lapatinib 250 mg
41326558|NCT03962712|OTHER|Increase Minimum Wage to $15-an-hour|Increase in minimum wage to $15-an-hour
41326559|NCT03962712|OTHER|No Increase in Minimum Wage|No increase in minimum wage
41326560|NCT03842215|DEVICE|smart physical exam|Use smart physical exam to collect functional performance
41326561|NCT02780479|DRUG|Dexamethasone|at 24 hours from the first Dexamethasone dose given in ED.
41326562|NCT02780479|DRUG|Prednisone|at 24 hours from the first Dexamethasone dose given in ED.
41326563|NCT01329289|DRUG|SOM230|60 mg intramuscularly (IM) on day 1 of each 28 day cycle
41326564|NCT01329289|DRUG|Bortezomib|1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
41326565|NCT01329289|DRUG|Dexamethasone|20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
41326566|NCT01551472|DEVICE|3DKnee™ System with Vitamin E UHMWPE Tibial Inserts|This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
41326567|NCT05731232|DIETARY_SUPPLEMENT|Vivatlac Synbiotikum|Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
41326568|NCT02915887|OTHER|Cervical Taping|Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
40809362|NCT05170204|DRUG|Entrectinib|Participants will receive oral entrectinib once daily, with or without food.
40809363|NCT05170204|DRUG|Durvalumab|Participants will receive IV durvalumab every 4 weeks.
40809364|NCT05866029|DRUG|Denosumab|Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
40809365|NCT05866029|DRUG|Teriparatide|Teriparatide was sequentially treated with Denosumab
40809366|NCT06482229|PROCEDURE|application for postoperative analgesia|three different methods will be applied to reduce patients' postoperative pain
41154484|NCT00826527|DRUG|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
41326569|NCT02111967|OTHER|Questionnaire administration|
40809367|NCT05834400|BEHAVIORAL|The Optimal Lymph FLow (TOLF)|Participants in TOLF intervention will complete initial in-person 40-minute session on TOLF lymphatic exercise training and daily monitoring, and 3 virtual 15-minute telehealth sessions to enhance their skills over the course of 4 weeks. These sessions will be conducted by the TOLF interventionist of the study. For 4-week study duration, participants will be asked to practice the set of 8 lymphatic exercises twice a day.
40809368|NCT05834400|BEHAVIORAL|Daily Monitoring|Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
40809369|NCT06210594|COMBINATION_PRODUCT|Mupirocin + Nozin + chlorhexidine gluconate|Education/household supplies + antibiotic + antiseptic regimen
40809370|NCT06210594|BEHAVIORAL|Education + Household supplies|Education/household supplies
40809371|NCT05878769|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W
41154485|NCT05626478|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
41154486|NCT05626478|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.
41326570|NCT02111967|OTHER|Laboratory biomarker analysis|
41479952|NCT01194102|OTHER|YMCA membership|Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
41326571|NCT02581982|OTHER|Laboratory Biomarker Analysis|Correlative studies
41326572|NCT02581982|DRUG|Paclitaxel|Given IV
41326573|NCT02581982|BIOLOGICAL|Pembrolizumab|Given IV
41326574|NCT01241955|BEHAVIORAL|video decision aid|video of CPR
41326575|NCT04782037|DRUG|L-Methylfolate Calcium|Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
41326576|NCT04255017|DRUG|Abidol hydrochloride|Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
41326577|NCT04255017|DRUG|Oseltamivir|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
41154487|NCT05626478|DRUG|Prolensa 0.07% Ophthalmic Solution|Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
41154488|NCT04453709|BEHAVIORAL|Problem Management Plus for Immigrants at family settings|"PMP-I is a 5-week, peer-led, culturally tailored psychoeducation, behavioral activation (90 minutes), breathing and yoga intervention (90 minutes) in a family setting. PMP-I will use a structured approach, including once a week face-to-face sessions, breathing and yoga practices.~1. Managing Stress: Breathing and yoga practices, stress-management sessions, and behavioral activation exercises to strengthen positive coping strategies.~2. Managing Problems: Practice exercises to identify the problems, develop solutions, and plan a strategy to carry out those solutions.~3. Get Going, Keep Doing: Communication skill sessions and practice exercises to identify and carry out pleasant tasks.~4. Strengthening Social Support: Social skills session and practice exercise to identify social support.~5. Staying Well: Make a plan that helps to create supportive family environment."
41326578|NCT04255017|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
41326579|NCT06034015|DRUG|APL-1202 and APL-1501 (Single ascending dose)|Period 1 drug adminstration (APL-1202 IR tablet , single dose of 375mg will be administered orally on Day 1; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered as single dose on Day 4.
41154489|NCT04453709|BEHAVIORAL|Talk program with Community Support Service Pamphlet (CSS)|Pamphlet including list of community support service institutions
41326580|NCT06034015|DRUG|APL-1202 and APL-1501 (Multiple Ascending dose)|Period 1 drug adminstration (APL-1202 IR of 375mg will be administered thrice a day (TID) orally from Day 1 to Day 5; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered twice daily (BID) from Day 9 to 13.
41326581|NCT02769078|DRUG|dabigatran|
41326582|NCT02769078|DRUG|rivaroxaban|
41326583|NCT02769078|DRUG|apixaban|
40809379|NCT06350500|BEHAVIORAL|Patient Navigation|Receive patient navigation
40809380|NCT06350500|OTHER|Questionnaire|Ancillary studies
40809381|NCT06444867|DRUG|LEO 158968|SC injection
40809382|NCT04793204|DRUG|fezolinetant|oral
40809383|NCT02591472|PROCEDURE|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
40809384|NCT02591472|PROCEDURE|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
40809385|NCT02591472|OTHER|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
41009936|NCT02658110|OTHER|Mixed Macronutrient Breakfast Meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
41009937|NCT02658110|OTHER|Mixed Macronutrient Lunch Meal|A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
41009938|NCT03447015|OTHER|ambulation|"Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
41326584|NCT02769078|DRUG|warfarin|
41326585|NCT03026049|DEVICE|deep venous stenting|Deep venous stent
41009939|NCT01448850|BIOLOGICAL|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
41009940|NCT01448850|OTHER|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
41009941|NCT02893293|DRUG|Ferumoxytol-enhanced magnetic resonance imaging|Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
41009942|NCT02893293|DEVICE|Magentic Resonance Imaging|Both arms will receive MRI
41326586|NCT04829942|BEHAVIORAL|positive health behavior|Training on nutrition, physical activity, first aid, individual hygiene, violence and bullying will be provided to the initiative group.
40809386|NCT02591472|OTHER|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
40809387|NCT02591472|OTHER|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
40809388|NCT02591472|OTHER|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
40809389|NCT02591472|OTHER|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
40809390|NCT02591472|OTHER|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
40809391|NCT02591472|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
40809392|NCT02591472|OTHER|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
40809393|NCT03268954|DRUG|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
40809394|NCT03268954|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
40809395|NCT05563805|DEVICE|Virtual Reality-based physical activity intervention|The V-RATE intervention will be delivered through a 360-degree non-mobilized treadmill in a university clinical laboratory for 6-8-weeks (1-2 days/week, 30 minutes/session) totaling 6 sessions. The V-RATE program will be focused on creating a safe and immersive environment supportive of physical activity. The treadmill enables an individual can walk and run at self-paced speed, moving in 360-degrees (i.e., forwards, sideways, and backwards) without risk of falling. The core feature of the self-paced treadmill is a concave walking platform with an adjustable waist hardness that enables a safe, smooth, natural gait while adults with elevated BMI engage in an immersive walking and running motion. During the V-RATE intervention, participants will self-pace their locomotor action (walking/running/bending/ jumping) while they wear the VR headset and experience immersive VR adventure games using the Omniverse VR system.
41154490|NCT01732055|BEHAVIORAL|Partner-Assisted Interpersonal Psychotherapy|
41326587|NCT01153906|OTHER|Data collection|New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
41326588|NCT05385627|PROCEDURE|Ankle block|Injection of local anaesthetics at the level of the ankle blindly (local infiltration analgesia). The dose, volume, and type of local anaesthetic will be registered.
41326589|NCT03760276|DRUG|Voriconazole Oral Product (Vfend®)|To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
41009943|NCT02592473|DEVICE|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
41009944|NCT00276718|BIOLOGICAL|bleomycin sulfate|
40809400|NCT01974206|BIOLOGICAL|ASP0113|intramuscular injection
40809401|NCT01974206|DRUG|Placebo|intramuscular injection
40809402|NCT06510777|DEVICE|PICO Treatment|"PICO 7 is a single-use Negative Pressure Wound Therapy System consisting of a small portable pump, 2 AA batteries, 1 or 2 dressings, and fixation strips. The dressing is changed when the dressing is saturated or after 7 days of treatment.~PICO Treatment will be given in addition to compression therapy.~If the wound is healed and until the wound healing confirmation visit, Venous Leg Ulcers (VLUs) allocated to the PICO group may be covered using a protective dressing.~If the wound meets the wound improvement criteria as assessed by the PI during the monthly visits, PICO treatment may be stopped."
40809403|NCT06510777|DEVICE|Standard of Care (SOC) Treatment|"Application of an appropriate wound primary dressing according to its intended purpose and chosen appropriately according to wound healing stage:~1. Dressing choice should take wound condition into consideration but may also consider subject's comfort (including pain) and HCP's preference.~2. Sequential treatment:~   * Debridement stage: alginate, hydrogel, absorbent, or hydro-detersive dressings~  * Granulation stage: wound contact layer, foam, petrolatum, or hydrofiber dressings~  * Epithelialization stage: wound contact layer, hydrocolloids~  * Other: dressings for specific clinical situations (e.g. fragile skin, infection; hemorrhagic wound, malodorous wound)~3. Application of appropriate venous compression therapy based on Ankle Brachial Pressure Index (ABPI) value."
41009945|NCT00276718|DRUG|carboplatin|
41009946|NCT00276718|DRUG|etoposide|
41009947|NCT00276718|PROCEDURE|conventional surgery|
41009948|NCT06205927|RADIATION|Standard carbon ion beam radiotherapy|The standard treatment arm will receive carbon ion beam radiotherapy of 77Gy (RBE equivalent) per 22 fractions for gross tumor volume.
41009949|NCT06205927|RADIATION|Carbon ion beam radiotherapy simultaneously dose boost|The hypoxic lesions dose boost arm will receive 77Gy (RBE equivalent) per 22 fractions for gross tumor volume and a simultaneously dose boost of 83.6Gy (RBE equivalent) per 22 fractions for hypoxic lesions detected by 18F-Misonidazole PET/CT.
41009950|NCT00000252|DRUG|0% N2O|
41009951|NCT00000252|DRUG|10% N2O|
41009952|NCT00000252|DRUG|20% N2O|
41009953|NCT00000252|DRUG|30% N2O|
41009954|NCT00000252|DRUG|40% N2O|
41009955|NCT06080152|DEVICE|Mobility Tool|An A-Linker device will be given to 12 patients 3 months before their total knee arthroplasty
40809404|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 2|"Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10\^5 cells/kg~Dose Level 2: 1×10\^6 cells/kg~Dose Level 3: 5×10\^6 cells/kg"
40809405|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 1|"Patients will receive one of the following doses:~Dose Level one: 1x10\^5 cells/kg~Dose Level 2: 5x10\^5 cells/kg~Dose Level 3: 1x10\^6 cells/kg"
41154491|NCT01732055|OTHER|Treatment as Usual|Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
41154492|NCT01138189|PROCEDURE|Wavefront-guided LASIK|Wavefront-guided LASIK in one eye using the Allegretto excimer laser
41154493|NCT01138189|PROCEDURE|Wavefront-optimized LASIK|Wavefront-optimized LASIK in one eye using the Allegretto excimer laser
41326590|NCT03291158|DRUG|Minocycline|Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
41326591|NCT05814913|BEHAVIORAL|CaCBT for psychosis|The CaCBT intervention is based on the intervention manual developed by David Kingdon and Douglas Turkington, and culturally adapted by our group. CaCBT aims to take a collaborative approach to gaining an understanding of the symptoms
40809412|NCT06340451|DEVICE|iovera° system|subjects will receive ultrasound-guided iovera° system treatment
40809413|NCT06340451|DEVICE|sham iovera° system treatment|subjects will receive ultrasound-guided iovera° sham system treatment
40809414|NCT06372652|DRUG|TE-8214 - SAD|Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg
40809415|NCT06372652|DRUG|Placebo|Single subcutaneous dose of matching placebo across the cohorts
40809416|NCT05647772|BEHAVIORAL|UseIt! App|The UseIt! app is a parenting app with evidence-based parent management content. The app runs on both Android and iOS devices. It includes a digital library of parent management skills, a trouble-shooting guide, a behavior diary, a point counter, and a skills-alarm.
40809417|NCT05647772|BEHAVIORAL|Coach|The coach is be a bachelor's level paraprofessional with a degree in psychology or an allied discipline (e.g., social work) who provides support to parents. The coach will provide motivation and accountability but will not provide therapeutic/clinical support. The primary goal of the coach is to increase participant engagement with the UseIt! mHealth system.
40809418|NCT05647772|BEHAVIORAL|SmilingMind App|The control app is a mindfulness app called SmilingMind. It is available for both Android and iOS devices.
40809419|NCT05111002|DRUG|Lefamulin|600mg tablet orally twice daily
40809420|NCT05111002|DRUG|Doxycycline|100mg tablet orally twice daily
41009956|NCT05608785|DRUG|IBI315|IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
40809421|NCT02689466|DRUG|[18F]FP-TZTP|radioligand
40809424|NCT06482567|BEHAVIORAL|iCOVER|"The term iCOVER is an acronym that summarizes the six specific steps of the intervention: (1) identify that an individual is experiencing an ASR; (2) Connect with the individual through word, eye contact, and physical touch to draw them back to the present moment; (3) Offer commitment so that the individual feels less psychologically isolated and withdrawn (e.g., I'm right here with you); (4) Verify facts - ask simple fact-based questions to engage the individual in deliberate cognitive activity; (5) Establish order of events - briefly review what has happened, what is happening, and what will happen to orient the individual; and (6) Request action to re-engage the individual in purposeful behavior."
40809425|NCT06482567|BEHAVIORAL|Physical Presence with Reassurance|The RA who performed randomization, initially approached the individual, and obtained assent will stay with the participant for the length of the iCOVER intervention (in order to ensure matching of the amount of time spent with individuals who receive the iCOVER intervention, which takes 60-120 seconds). During this time, the RA will provide supportive but passive statements. The RA will leave the participant after the length of the iCOVER intervention has elapsed. A separate blinded RA will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
40809426|NCT04436640|DRUG|Bimekizumab|Subjects will receive bimekizumab at prespecified time-points.
40809427|NCT05216263|DRUG|Atogepant|Oral Tablet
41009957|NCT05608785|DRUG|Oxaliplatin|Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
41009958|NCT05608785|DRUG|Capecitabine|Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
40809428|NCT05269771|DRUG|Ruxolitinib|Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.
40809429|NCT06397443|OTHER|5-day sailing activity|"* Sailing activity (4 h/die)~* Stretching exercises pre and post-sailing activity~* Post-activity debriefing"
40809430|NCT05540561|OTHER|blood collection|Biological analyses in the framework of care with conservation of blood samples
40809431|NCT06521463|DEVICE|WATCHMAN FLX Pro LAAC Device|WATCHMAN FLX Pro LAAC Device Implantation
41009959|NCT05608785|DRUG|TST001|TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.
40809435|NCT05835986|DRUG|RO7507062|RO7507062 solution for injection will be administered SC as specified in each treatment arm.
41009960|NCT05608785|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
40809436|NCT05835986|DRUG|Tocilizumab|Tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
41154494|NCT03168750|DEVICE|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.|Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
41154495|NCT05822245|DRUG|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
41154496|NCT05822245|DRUG|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
40809440|NCT04523818|DRUG|Capecitabine|Given PO
40809441|NCT04523818|DRUG|Fluorouracil|Given IV
40809442|NCT04523818|RADIATION|Radiation Therapy|Undergo radiation therapy
40809443|NCT04523818|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard of care surgery
40809444|NCT04200755|DRUG|Dupilumab 300Mg Solution for Injection|First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)
40809445|NCT04200755|OTHER|Placebo|First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
40809446|NCT05486572|OTHER|Abbreviated Magnetic Resonance Imaging with serum AFP|Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
40809447|NCT05486572|OTHER|Abdominal Ultrasound Screening with serum AFP|abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
40809448|NCT05779241|DRUG|LYN-005|Risperidone long-acting oral capsule
40809449|NCT05779241|DRUG|Risperidone|Risperidone immediate release (IR) oral tablets
41326592|NCT05814913|BEHAVIORAL|Culturally adapted Family Intervention (CulFI) for psychosis|CulFI intervention comprises of Family psychoeducation; cognitive-behavioural skills training for stress-management, coping and problem solving; crisis intervention and suicide risk management; relapse prevention; education and support regarding the family environment, including communication training. The components are designed to facilitate an understanding about psychosis, the emotional impact of the illness on family relationships, to promote more adaptive coping strategies and minimize relapse risk.
41326593|NCT05996380|DRUG|SHR-3167|SHR-3167, Single administration
41326594|NCT05996380|DRUG|SHR-3167 Placebo|SHR-3167 Placebo Single administration
41326595|NCT00970268|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
41326596|NCT00970268|DRUG|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
41326597|NCT01972854|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
41154497|NCT05822245|DRUG|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
41154498|NCT00269126|DRUG|fluticasone propionate/salmeterol combination DISKUS|
41154499|NCT00269126|DRUG|salmeterol xinafoate|
40809453|NCT03201965|DRUG|Cyclophosphamide|Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.
40809454|NCT03201965|DRUG|Bortezomib|Participants will receive 1.3 mg/m\^2 of bortezomib as an subcutaneous (SC) injection.
40809455|NCT03201965|DRUG|Dexamethasone, 40 mg|Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.
40809456|NCT03201965|DRUG|Daratumumab|Participants will receive 1800 mg of daratumumab subcutaneously.
40809457|NCT06297616|DRUG|LY3841136|Administered SC
40809458|NCT06297616|DRUG|LY3841136-Placebo|Administered SC
40809459|NCT06297616|DRUG|Tirzepatide|Administered SC
40809460|NCT06297616|DRUG|Tirzepatide-Placebo|Administered SC
41326598|NCT01972854|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
41326599|NCT01972854|DEVICE|KXL System|30mW/cm2
40809461|NCT05772455|DRUG|XZB-0004|Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with Penpulimab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.
40809462|NCT04350138|BIOLOGICAL|Meningococcal Group B Vaccine|A combination vaccine consisting of rMenB and OMV NZ.
40809463|NCT04350138|OTHER|Placebo|150mM sodium chloride (0.9% saline solution).
41154500|NCT01661244|DRUG|RV568 single dose|Safety and tolerability of single escalating doses in normal human volunteers
40809465|NCT03636438|OTHER|No Intervention|No Intervention
41154501|NCT01661244|DRUG|RV568 matching placebo single dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
41154502|NCT01661244|DRUG|RV568 repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
40809468|NCT06539338|GENETIC|INT2104|INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)
41154503|NCT01661244|DRUG|RV568 matching placebo repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
41154504|NCT00972686|DRUG|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
41154505|NCT04705883|DRUG|Prasterone (DHEA), Micronized|Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
41326600|NCT03120728|DRUG|Etonogestrel/ethinyl estradiol contraceptive vaginal ring|"Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section."
40809471|NCT06574126|DRUG|Group 1: Dara-VRD followed by apheresis and cilta-cel infusion|In Group 1, 10 eligible participants will undergo a maximum of two 28-day induction cycles with Dara-VRD. Participants in Group 1 are considered enrolled as the date of signing the Informed Consent Form. This will be followed by apheresis according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom apheresis or manufacturing fails will be allowed a second attempt of apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
40809472|NCT06574126|DRUG|Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion|In Group 2, 10 eligible participants will undergo apheresis first, according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Study enrollment is defined as the date of signing Informed Consent Form. The apheresis will be followed by a maximum of two 28-day induction cycles with DARA-VRD. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom the apheresis or manufacturing fails will be allowed a second attempt at apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
40809473|NCT03784911|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. SOZO measurements will be performed before the start of cancer treatment, at the 1/4, 1/2, and 3/4 time points of treatment, and after completion of treatment. Participants be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes.
40809474|NCT03784911|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
40809475|NCT04261972|GENETIC|Next generation sequencing (NGS)|NGS
40809476|NCT03450343|DRUG|Oral azacitidine|Azacitidine can be taken with or without food at the same time every day.
40809477|NCT03450343|DRUG|R-ICE|R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
40809478|NCT06224140|PROCEDURE|Heparin Anticoagulation|Conventional dialysis with heparin as anticoagulant treatment
40809479|NCT06224140|PROCEDURE|Regional Anticoagulation Procedure (RAP)|Dialysis without heparin as anticoagulant but based on the use of a calcium-free dialysis bath. Calcium is then restored by reinjection of a 10% calcium chloride solution.
41154506|NCT05990309|DIAGNOSTIC_TEST|skin biopsy|skin biopsy for immunohistochemical staining and assessment of tissue expression of tristetraprolin
41154507|NCT00974402|BEHAVIORAL|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
41154508|NCT05845099|DEVICE|Polymethyl Methacrylate-Based Complete Removable Dentures.|The patients will receive Complete Removable Dentures processed by Heat cured acrylic resin.
41154509|NCT05845099|DEVICE|Photopolymerized Methacrylate- Based Complete Removable Dentures.|The patients will receive a 3D-printed removable denture digitally manufactured using a 3d printer device with light polymerized resin.
41154510|NCT03965481|RADIATION|Dynamic Enhanced CT|Undergo standard CECT
40809484|NCT06551350|OTHER|Data Collection|Collection of medical data from MICU intervention file and the medical records of patients at the destination hospital
40809485|NCT05083884|OTHER|No Intervention|This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
40809486|NCT06451614|DEVICE|SpaceIT Hydrogel System|"SpaceIT Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceIT Hydrogel System to reduce the radiation dose delivered to the anterior rectum. The SpaceIT Hydrogel System is composed of a radiopaque, biodegradable material designed to maintain space for approximately 12 weeks and be absorbed in about 6 months, sufficient time to support the intended use.~SpaceIT has an iodinated PEG powder making it radiopaque."
41479953|NCT03393871|DIAGNOSTIC_TEST|absolute blood flow measurement|Absolute maximum flow will be measured, using the RayFlow® multifunctional monorail infusion catheter. (This measurement takes a few minutes per artery, does not require any additional drug, but only 50-100 ml of saline per artery, and is not associated with any additional risk for the patient compared to the regular invasive procedure.
41479954|NCT00114621|DRUG|Anthrax Vaccine|
41479955|NCT00114621|PROCEDURE|Blood Chemistry|
41479956|NCT00114621|PROCEDURE|Hematology|
41479957|NCT00114621|PROCEDURE|Urinalysis|
41479958|NCT05372276|OTHER|Assessment 1|Mental Toughness Questionnaire in Sport
41479959|NCT05372276|OTHER|Assessment 2|Sport Imagery Questionnaire
41479960|NCT05372276|OTHER|Assessment 3|The Pittsburgh Sleep Quality Index
41479961|NCT05372276|OTHER|Assessment 4|The Perceived Stress Scale (PSS)
41326601|NCT02424006|DEVICE|RHCIII-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
40809487|NCT06451614|DEVICE|Commercially available Boston Scientific Spacer|Boston Scientific's commercially available SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System to reduce the radiation dose delivered to the anterior rectum. SpaceOAR and SpaceOAR Vue are both perirectal spacers. SpaceOAR Vue specifically has an iodinated PEG powder making it radiopaque. SpaceOAR does not contain iodinated PEG powder and is not radiopaque. The SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System maintains space during prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
41009961|NCT05608785|DRUG|Anrotinib|Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
41009962|NCT01872871|DRUG|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
41009963|NCT01872871|DRUG|Topical anaesthetic drop with placebo|
41154511|NCT03965481|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI scan
41009964|NCT06424886|OTHER|Landing error scoring system (LESS)|Each group will perform two training blocks of 10 drop vertical jumping (DVJ) tasks. Knee joint position sense (KJPS), frontal plane projection angle (FPPA), and Landing Error Scoring System (LESS) assessments will be performed before and after the training blocks, and follow-up assessments will be performed 1 week later. The dominant limb of the participants (the side limb they use when kicking the ball) will be taken into account during the measurement.
41009965|NCT01659424|RADIATION|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
41326602|NCT02424006|DEVICE|Donor cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
40809491|NCT00060541|PROCEDURE|Laboratory tests|
40809492|NCT00060541|PROCEDURE|Radiological exams|
40809493|NCT04964986|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
41009966|NCT04301167|BEHAVIORAL|befriending|Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
41009967|NCT03866616|BEHAVIORAL|Brain Builders Parenting Class|Brain Builders Parenting Class group sessions goal is to increase parental knowledge of brain development and increase responsive parenting
41009968|NCT03866616|BEHAVIORAL|Control (Usual care)|"This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
41009969|NCT04072484|OTHER|Mild hypoxia|The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
41009970|NCT03457012|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
41009971|NCT04751591|PROCEDURE|Endoscopic resection|Endoscopic submucosal dissection (ESD) or endoscopic full-thickness resection (EFTR) for patients with 2-5cm gastric GISTs
41009972|NCT04751591|PROCEDURE|Laparoscopic partial gastrectomy|Laparoscopic partial gastrectomy for patients with 2-5cm gastric GISTs
41009973|NCT05516251|DEVICE|Transcutaneous Supraorbital Nerve Stimulator|SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.
41009974|NCT05516251|DRUG|Topiramate 25Mg Tab|Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
41009975|NCT03302858|DEVICE|BARRX™ Anorectal Wand|"The radiofrequency ablation (RFA) or Barrx™ Ablation System used in this protocol comprises an RFA generator (Barrx™ FLEX) and the Barrx™ Anorectal Wand. The generator and wand are cleared by the FDA for human use and the wand is specifically cleared for treatment of anal neoplasia. The present FDA indication for use statement is: The Barrx™ catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, gastric antral vascular ectasia, and radiation proctitis."
41009976|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution as a single dose.
41009977|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution given twice daily.
41154512|NCT03965481|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI scan
41154513|NCT05490680|DRUG|Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg|Sildenafil Oral Film containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil as citrate, flexible-dose
41154514|NCT05490680|DRUG|Placebo|Placebo Oral Film
41154515|NCT02599870|GENETIC|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
41154516|NCT04225234|OTHER|Financial incentives|"Depending on their level of participation or weight loss outcomes, participants will have the opportunity to receive between $60-$120 (over 12 months), on average, regardless of program assignment.~Regardless of which incentive program that participants are randomized to, they will receive the incentaHEALTH weight loss program intervention. incentaHEALTH is an technology-supported multi-component coaching intervention for weight loss includes a website, objective weight assessment using HIPAA-compliant kiosks, daily social cognitive theory-based email and text message support, and online access to health coaches. The intervention encourages increased intake of fruit, vegetables, lean protein, and complex carbohydrates while monitoring portion sizes."
41154517|NCT01257048|DRUG|Formoterol Turbuhaler|9 microgram on visit 5 single dose
41326603|NCT04006912|PROCEDURE|phacoemulsification and Toric intraocular lens implantation|A clear corneal incision is made in a different position
41326604|NCT05808842|OTHER|CeraVe|"* CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* CeraVe lotion (CeraVe; New York, NY) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
41326605|NCT05808842|OTHER|CeraVe and Calecim|"* CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* Calecim® Professional Serum (CellResearch Corporation; Singapore) to be used morning and evening~* Calecim® Restorative Hydration Cream (CellResearch Corporation; Singapore) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
41326606|NCT04189991|DEVICE|Free 02|"With the manual oxygen titration, the physiotherapist adjust manually the oxygen flow using the FreeO2 device during a titration 6 minutes walk test.~With the automated adjustment oxygen titration, the flow will be self adjusted by the FreeO2 device during a titration 6 minutes walk test. In that hase, the median flow rate and the 95th flow rate will be evaluated during the validation 6 minutes walk test."
41326607|NCT06229587|PROCEDURE|furlow with buccinator flap|Assessment of speech and the middle ear function of patients between the age of 3 and 7 years surgically treated by ARC (Furlow z-palatoplasty with a buccinator myomucosal flap) was done
41326608|NCT02823080|DRUG|Cetrorelix|study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
41326609|NCT02810951|GENETIC|FCX-007|FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.
41326610|NCT02924688|DRUG|FF/UMEC/VI (100/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily \[QD\] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
40809494|NCT03635424|DEVICE|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
41154518|NCT01257048|DRUG|Budesonide/Formoterol Turbuhaler|320/9 microgram twice daily during 8 weeks
41009978|NCT01341184|DRUG|Rifabutin|Rifabutin 300 mg orally on days 20-41
41009979|NCT01341184|DRUG|Rifampin|Rifampin 600 mg orally on days 20-41
41009980|NCT01341184|DRUG|TMC207|TMC207 400 mg orally on days 1 and 29
41009981|NCT05680766|OTHER|Cardiovascular endurance training|Based on the results of a maximal effort test, investigators will provide a personalised training program. Results of a submaximal effort test after 6 weeks, will allow for adaptation of the training program for the remaining training period.
41009982|NCT05740839|BEHAVIORAL|HIIT Exercise Program|Exercise program with stationary bike via the Zoom platform.
41009983|NCT05740839|BEHAVIORAL|Control Group|Usual Activities
41009984|NCT05103943|OTHER|SPECT MPI|SPECT MPI including dynamic acquisitions for stress, rest MBF and MFR
41009985|NCT05790434|DIAGNOSTIC_TEST|Laboratory test|including white blood cell count, C-reactive protein, erythrocyte sedimentation rate, percent of polymorphonuclear leukocytes, albumin, and globulin
41009986|NCT05790434|DIAGNOSTIC_TEST|History taking and physical examination|including fever, joint pain, local swelling and redness, sinus
41154519|NCT01257048|DRUG|Formoterol Turbuhaler|9 microgram twice daily during 8 weeks
40809495|NCT04644237|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
41154520|NCT04301063|OTHER|RV3278A|RV3278A is a non-rinsed cosmetic cream intended to be used every day on adolescents and young adults with acne-prone skin.
41326611|NCT02924688|DRUG|FF/UMEC/VI (100/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
41326612|NCT02924688|DRUG|FF/UMEC/VI (200/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
41326613|NCT02924688|DRUG|FF/UMEC/VI (200/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
41326614|NCT02924688|DRUG|FF/VI (100/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
41009987|NCT05790434|DIAGNOSTIC_TEST|biopsy|including arthrocentesis culture，and frozen section
41009988|NCT00320281|DRUG|botulinum toxin A|Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
41009989|NCT00320281|OTHER|placebo|Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
41009990|NCT02653677|OTHER|intake of the specific kind of bread|To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
41009991|NCT02262728|DRUG|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
41009992|NCT02262728|DRUG|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
41009993|NCT02262728|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
41009994|NCT02201797|OTHER|DCE MRI|
41009995|NCT04903691|BEHAVIORAL|Cardiac Exercise Program|Participants who enrolled in cardiac exercise program
41009996|NCT05892627|DIETARY_SUPPLEMENT|PoZibio|PoZibio (50 x 10\^9 CFUs/ CAPSULE)
41009997|NCT05892627|DIETARY_SUPPLEMENT|Placebo|Placebo
41009998|NCT06038591|BEHAVIORAL|Sleep Tight|The sleep intervention focuses on enhancing young children's sleep by providing parents with behavioral strategies and support. Interventionists will work with parents on establishing consistent soothing bedtime routines; behavioral regulation to manage bedtime resistance and nighttime wakings; goal setting, problem solving, and action planning; self-monitoring via daily sleep logs; and stimulus control of child's sleep environment.
41009999|NCT01482780|DEVICE|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
41010000|NCT05104372|OTHER|Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)|Nasal washout and gargles
41010001|NCT03595111|PROCEDURE|myocardial biopsy|Myocardial cell edema either focal or diffuse was detected in histopathological examination
41010002|NCT05000645|BEHAVIORAL|Grocery delivery|Each food delivery will contain approximately $35 worth of fresh fruits, vegetables, dairy products, and whole grain foods. These foods are not meant to supplant regular meals, rather make healthy eating more convenient.
41010003|NCT05000645|BEHAVIORAL|Unsweetened beverage delivery|Participants will receive unsweetened beverages to replace normal sugar-sweetened beverage intake.
41326615|NCT02924688|DRUG|FF/VI (200/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
41479962|NCT02467608|DRUG|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
40809496|NCT03390504|DRUG|Erdafitinib|Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
40809497|NCT03390504|DRUG|Vinflunine|Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.
40809498|NCT03390504|DRUG|Docetaxel|Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.
40809499|NCT03390504|DRUG|Pembrolizumab|Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
40809500|NCT03390504|DEVICE|Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)|FGFRi CTA will be used to determine molecular eligibility.
40809501|NCT05083403|DEVICE|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
40809502|NCT05083403|OTHER|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
40809503|NCT03301220|DRUG|Daratumumab SC: daratumumab + rHuPH20|Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 \[2000 U/mL\]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
40809504|NCT03287024|DEVICE|BeGrow Stent System|All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
41010004|NCT05114941|DEVICE|immunosorbent column|Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.
41010005|NCT05114941|DRUG|intravenous immunoglobulin|Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
41010006|NCT05337878|DRUG|Placebo|Pelacarsen-matching placebo administered by SC injection.
41010007|NCT05337878|DRUG|Pelacarsen|Pelacarsen administered by SC injection.
41010008|NCT02460198|BIOLOGICAL|Pembrolizumab|IV infusion
41010009|NCT05721417|PROCEDURE|Tricuspid valve surgery|Surgical treatment of tricuspid regurgitation, that may be performed by repair or replacement
41326616|NCT02924688|DRUG|Fluticasone/salmeterol (FSC)|Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
41326617|NCT02924688|DRUG|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
41326618|NCT02924688|DEVICE|ELLIPTA DPI|The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
41479963|NCT02467608|DRUG|HRZE|the same as experimental group,without the excipient of HUEXC030 only
41479964|NCT03097588|DRUG|Netupitant|300 mg, Given PO, QD
41479965|NCT03097588|DRUG|Palonosetron Hydrochloride|0.5 mg, Given PO, QD
40809505|NCT03652064|DRUG|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.
40809506|NCT03652064|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.
40809507|NCT03652064|DRUG|Lenalidomide|Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.
40809508|NCT03652064|DRUG|Dexamethasone|Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.
41010010|NCT03649555|DRUG|[18F]-FTC-146|Two 5 mCi \[18F\]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
41479966|NCT03097588|OTHER|Questionnaire Administration|Ancillary studies
41479967|NCT04918641|OTHER|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
41479968|NCT03252327|OTHER|Multiple Sensory Integrations|breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.
41479969|NCT00001007|DRUG|Zidovudine|
41010011|NCT00739336|BEHAVIORAL|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
41010012|NCT01424488|DRUG|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
41326619|NCT02924688|DEVICE|DISKUS DPI|The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
41326620|NCT02924688|DEVICE|METERED-DOSE INHALER (MDI)|Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
40809509|NCT06268873|DRUG|Baxdrostat/dapagliflozin|"baxdrostat tablet~dapagliflozin tablet"
40809510|NCT06268873|DRUG|Dapagliflozin in combination with placebo|"dapagliflozin tablet~placebo tablet"
40809511|NCT06211764|DRUG|TAR-200|Participants will receive TAR-200 intravesically.
40809512|NCT06211764|DRUG|Mitomycin C|Participants will receive MMC intravesically.
40809513|NCT06211764|DRUG|Gemcitabine|Participants will receive gemcitabine intravesically.
41154521|NCT03282071|BEHAVIORAL|Joyful Parenting Intervention|"* Two-session interactive talks for parents to promote praise \& appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing)."
41154522|NCT05199597|DRUG|0.01% atropine|0.01%, room temp, Lab A
41154523|NCT05199597|DRUG|0.05% atropine|0.05%, room temp, Lab A
41010013|NCT01424488|DRUG|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
41154524|NCT05199597|DRUG|0.05% atropine|0.05%, refrigerated, Lab A
41326621|NCT05308758|OTHER|Game-based High-Intensity Interval Training|There will be two training sessions each week. In each training session, there will be four sets of training programs separated by 3 minutes of passive recovery in accordance with a previous study.Each set of activities will last for around 5 minutes; therefore, the total duration of each training session will be approximately 30 minutes. A small group size (4-6 children per group) will be adopted to facilitate individual supervision and adaption of the exercise program.
41326622|NCT05308758|OTHER|GameSAE|Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week. Six to eight stations of multidimensional exercises will be set up for each session. Adopting the train-the-trainer (TTT) model, training will be provided by front-line healthcare providers or trained helpers. Children will be instructed to finish the exercises in all stations one after another in a predetermined order.
41326623|NCT00225680|DEVICE|drug eluting coronary stent|
41326624|NCT02818140|PROCEDURE|Ropivacaine TQL block|Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure
41326625|NCT02818140|PROCEDURE|Saline TQL block|Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure
41154525|NCT05199597|DRUG|0.05% atropine|0.05%, room temperature, Lab B
41154526|NCT01939483|DRUG|irinotecan hydrochloride|Given IV
40809519|NCT05466955|DEVICE|Free eye glasses for un or under-corrected myopia|All participants randomised to the intervention group will be provided with free eye glasses
40809520|NCT04819893|BIOLOGICAL|Maternal blood sampling|5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
40809521|NCT04819893|BIOLOGICAL|Umbilical cord blood sampling|0.5mL sample from the umbilical cord after childbirth standard protocols
40809522|NCT04819893|BIOLOGICAL|Placenta sampling|Sampling of 3 cotyledons by cutting across the thickness of the placenta
40809523|NCT04819893|OTHER|Data collection|Newborn, Maternal and Premature Retinopathy Screening Data Collection
40809524|NCT04113733|OTHER|Sample Collection|Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
41154527|NCT01939483|OTHER|laboratory biomarker analysis|Correlative studies
41154528|NCT00523926|DRUG|TMC207|
40809527|NCT02523014|DRUG|Vismodegib|Given PO
40809528|NCT02523014|DRUG|FAK Inhibitor GSK2256098|Given PO
40809529|NCT02523014|DRUG|Capivasertib|Given PO
40809530|NCT02523014|DRUG|Abemaciclib|Given PO
41326626|NCT02818140|DRUG|Ropivacaine|
41326627|NCT02818140|DRUG|Saline|
40809533|NCT05099133|DRUG|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
40809534|NCT05099133|DRUG|LEO 138559 Placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.
41326628|NCT02818140|DEVICE|Ultrasound|
41010014|NCT03646721|DRUG|DA-1241|"\[Part1\] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~\[Part2\] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)"
41010015|NCT03646721|DRUG|Placebo|\[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.
41010016|NCT03646721|DRUG|Sitagliptin|\[Part2\] Administration of Sitagliptin 100mg once daily for 56 days.
41010017|NCT05597527|DRUG|Fluzopari and apatinib|Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
41010018|NCT02720913|DEVICE|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
41010019|NCT02720913|PROCEDURE|Standard Suture Tying|Standard Suture Tying
41010020|NCT05963542|BEHAVIORAL|ACT for tinnitus|The intervention will be based on the ACT model and adjusted for tinnitus.
41010021|NCT05963542|OTHER|Customized sound therapy|The music will be modulated through a smartphone app using a set program to generate customized tinnitus relieving sound.
41010022|NCT01245855|DRUG|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
41010023|NCT05498194|DIAGNOSTIC_TEST|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (\~ 1cm3 ) are collected during surgery
41010024|NCT01395472|BEHAVIORAL|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
41010025|NCT01395472|BEHAVIORAL|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
41010026|NCT04708197|DEVICE|rTMS (repetitive transcranial magnetic stimulation )|applying high frequency TMS over the damaged hemisphere in chronic post stroke aphasic patients
41010027|NCT03059381|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
41010028|NCT01002144|OTHER|blood sampling|
41010029|NCT00283660|DIETARY_SUPPLEMENT|10 mg zinc oxide|10 mg zinc oxide
41326629|NCT02424812|BEHAVIORAL|Lifebuoy School of Five Handwashing Intervention|
41326630|NCT00436982|DEVICE|Cemented Triathlon total knee system|Orthopaedic implant
41326631|NCT00436982|DEVICE|Duracon total knee system|Orthopaedic implant
41326632|NCT02814864|DRUG|Mesenchymal Stromal Cell (MSC) injections|12 patients suffering of PRD (LENT-SOMA scale\>2) will receive Mesenchymal Stromal Cell (MSC) injections
41010030|NCT00283660|OTHER|Placebo|Placebo pill taken five days a week for six months.
41010031|NCT02710604|DRUG|CMX157|tablet
41010032|NCT02710604|DRUG|TDF|300mg tablet
41010033|NCT02089750|OTHER|Orthotics|
41010034|NCT02089750|OTHER|Orthotics Plus Chiropractic Care|The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
41010035|NCT02089750|OTHER|Wait List|
41010036|NCT01377974|DRUG|Miltefosine|1 Capsule of 50mg, taken orally 2 times a day for 28 days
41010037|NCT01377974|DRUG|Standard Treatment Meglumine antimoniate|20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
41010038|NCT05147857|DEVICE|Dilapan s|"is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually."
41010039|NCT05147857|DRUG|Misoprostol|Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, cause an abortion, and treat postpartum bleeding due to poor contraction of the uterus. Misoprostol is taken by mouth when used to prevent gastric ulcers in persons taking NSAIDs.
41010040|NCT01612546|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
41010041|NCT01612546|OTHER|Laboratory biomarker analysis|Correlative studies
41010042|NCT01612546|OTHER|Pharmacological studies|Correlative studies
41326633|NCT02171949|BIOLOGICAL|Infusion of bone marrow mononuclear cells.|Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
41326634|NCT05250518|PROCEDURE|argon plasma coagulation|After hot snare polypectomy, participants will be randomized assigned to the APC group for argon plasma coagulation to prevent colorectal post-procedure bleeding.
41326635|NCT05250518|PROCEDURE|clip closure|After hot snare polypectomy, participants will be randomized assigned to the Clip group for complete closure(spacing between adjacent clips \< 1cm) to prevent colorectal post-procedure bleeding.
41326636|NCT04469816|BEHAVIORAL|Family Check-Up 4 Health|A parent-training intervention to improve child health, school readiness and manage obesity.
41479970|NCT01078129|BEHAVIORAL|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
41479971|NCT01078129|BEHAVIORAL|non-CRT|waiting list
41479972|NCT06415266|OTHER|Quality of life questionnaire (QLQ)|Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).
41479973|NCT06415266|OTHER|Satisfaction survey|The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).
41479974|NCT06415266|OTHER|Assessment of patient needs in the field of oncosexology|Assessment of patient needs in the field of oncosexology during a face-to-face or virtual interview at inclusion and every 6 months for 2 years. If a need is identified, an oncosexology consultation will be organised. Following this, a personalised care plan may be proposed.
41479975|NCT03392493|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of worm-up exercise and 40 minute of robot-assisted hand exercise. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task and robot-assisted task.
41479976|NCT03392493|BEHAVIORAL|Standard treatment|Standard treatment only group: 60 min standard treatment. 20 minute of worm-up exercise and 40 minute of traditional occupational therapy. Traditional occupational therapy include spasticity-reducing activity, bilateral hands activity and hand training task.
41479977|NCT03867955|OTHER|Collection of datas|Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
41479978|NCT04715360|COMBINATION_PRODUCT|autologous activated platelet-rich plasma|Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient
41326637|NCT04469816|OTHER|Services as Usual|Services/Treatment as usual.
41326638|NCT00267371|DEVICE|PFO Closure with Premere investigational device.|PFO Closure with Premere investigational device.
41479979|NCT04715360|DRUG|Avigan|Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
41479980|NCT06335459|OTHER|epidemiology|Analysis of 2000 AP WB radiographs of Foot in Upper Egypt For Random People and determind cases of Hallux valgus and calculate the prevalence
41479981|NCT04399876|COMBINATION_PRODUCT|Microdevice|"Surgery Cohort: Placement of 1-6 microdevices: Drugs chosen have all been FDA approved for the treatment of cancer (so therefore safe) and there are phase 2 or 3 data that the drug has efficacy in prostate cancer. Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations~Ex vivo Cohort: Placement of multiple microdevices with miniature drug reservoirs but no drug is loaded into the removed prostate"
41479982|NCT00337441|DRUG|Epoetin Alfa (drug)|
41479983|NCT04686656|OTHER|nasal oxygen|Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.
41479984|NCT04686656|OTHER|buccal oxygen|Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.
41479985|NCT05294419|DEVICE|CVD Integrated Risk Test|CVD IRT (IVD regulations with a software device)
41479986|NCT03421041|DRUG|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet，0.75mg/tablet
41479987|NCT01796158|BEHAVIORAL|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
41326639|NCT00267371|DRUG|Medical management/current medications per standard of care by personal physician.|Medical management with current medications per standard of care by personal physician.
41479988|NCT01796158|BEHAVIORAL|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
41479989|NCT01046552|PROCEDURE|preoperative ERCP and LC|preoperative ERCP followed by LC
41479990|NCT01046552|PROCEDURE|Intraoperative ERCP and LC|LC and intraoperative ERCP
41479991|NCT06234319|DIAGNOSTIC_TEST|CXCR4|Patients with clinical suspected primary glioma will receive a CXCR4 PET imaging.
41326640|NCT04697602|DRUG|Stepwise dose titration of febuxostat and low-dose colchicine|Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
41326641|NCT04697602|DRUG|Fixed dose febuxostat and low-dose colchicine|Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
41479992|NCT00292188|DRUG|pregabalin|pregabalin
41479993|NCT00292188|DRUG|Placebo|placebo
41479994|NCT06226701|DEVICE|Cryolipolysis device|"-Cryolipolysis device~1max cool shaping device ( inform china korean technology).Is used for fat lipolysis ,with no harm to the skin.The device consist of Cool sculptor applicator head , cool gel pad its alarge gel pad it should be adherent to the area to be treated before applying the cool sculptor applicator to protect the skin from bruising or ecchymosis. The device uses vacuum suction which can be adjusted according to the patient tolerance. Duration of session 45min at each of treatment session ,1session every 2weeks for 3months."
41479995|NCT01166555|DRUG|PF-04236921|single subcutaneous dose
41479996|NCT03804398|DEVICE|compliance guided an optimal Positive End-Expiratory Pressure|The study groups received an alveolar recruitment maneuver(increase inspiratory pressure to 30cmH2O for 10s) at the 10min after one-lung ventilation. After the alveolar recruitment maneuver,the study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained.
41154529|NCT05668442|BEHAVIORAL|Online exercise and group meetings|"The intervention consists of 8 weeks of 30 minutes of online supervised high intensity physical exercise followed by 30 minutes of online group meeting once a week in Microsoft Teams. The program consist of a short warm-up, followed by interval.-based physical activity including bodyweight aerobic and strength training, followed by stretching.~Following the online exercise session, participants will be sent out in smaller break-out rooms in Microsoft Teams. The online group meeting sessions are intended to serve as a platform for group discussion evaluation of weekly physical acitvity.~Each online group will be facilitated by a participant. All participants will be encouraged to set physical activity goals to increase habitual physical activity As a part of the intervention, participants will wear a Garmin Vivofit 4 activity watch or a Garmin 245 watch."
40809539|NCT05735184|DRUG|Ziftomenib|Oral Administration
40809540|NCT05735184|DRUG|Venetoclax|Oral Administration
40809541|NCT05735184|DRUG|Azacitidine|Subcutaneous or Intravenous Administration
40809542|NCT05735184|DRUG|Daunorubicin|Intravenous Administration
40809543|NCT05735184|DRUG|Cytarabine|Intravenous Administration
41326642|NCT00286364|DRUG|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
41326643|NCT05506917|PROCEDURE|periodontal treatment|Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
41326644|NCT04721977|DRUG|Tucatinib|Tucatinib 300 mg administered BID via oral tablet
41326645|NCT04721977|BIOLOGICAL|Trastuzumab|Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose, administered via IV infusion
41326646|NCT04721977|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 administered BID via oral tablet
41326647|NCT06281405|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
41326648|NCT06281405|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
41326649|NCT06281405|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
41326650|NCT01225367|DEVICE|ultrasound doppler monitoring|Regular noninvasive chest echo monitoring
41326651|NCT06048653|OTHER|A computer based cognitive rehabilitation program (Rehacom system)|"Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction~* Patients will receive training for four weeks, two sessions per week.~* Each patient will assume a comfortable sitting position on a chair in front of the screen.~* A report will be generated at the end of the session. It will be used for follow up.~* Session duration will range from 45 to 60 min. including rest period."
41479997|NCT03804398|DEVICE|PEEP level of 5 cmH2O|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
41479998|NCT03043118|OTHER|Variety Intervention|Vegetable flavor variety created with multiple herb and spice blends
41479999|NCT06257420|DRUG|Rapamycin|Once weekly oral rapamycin
41480000|NCT03149458|OTHER|dance|dance program
41326652|NCT06048653|DEVICE|Vagus nerve stimulation|stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.
41480001|NCT03149458|OTHER|control|upper limb rehabilitation
41480002|NCT03290287|DRUG|Aclidinium bromide|Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
41326653|NCT04093362|DRUG|TAS-120|TAS-120 is an oral FGFR inhibitor
41326654|NCT04093362|DRUG|Cisplatin/Gemcitabine|Cisplatin/Gemcitabine is currently 1st line standard of care
40809549|NCT06407869|OTHER|Functional Progressive Strength Training|The Functional Progressive Resistance Exercise (FPRE) protocol is designed to improve functional strength through structured workouts. It begins with a 3-minute warmup involving stretching and range of motion exercises, followed by progressively intense sit-to-stand exercises over six weeks. Participants also perform half-kneeling, standing up, and side-step-up exercises, with 20 minutes of total activity and rest intervals. The session ends with a 2-minute cooldown. Weights are gradually increased up to 15 times the initial load, with a minimum of one-minute rest between sets. The regimen is tailored through trial and error to find the maximum load participants can effectively manage.
40809550|NCT06407869|OTHER|Control|conventional physical therapy techniques will be applied
40809551|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
40809552|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
41326655|NCT00357422|PROCEDURE|Operation|No drug needed
40809553|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
40809554|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
40809555|NCT03669757|DRUG|LEO 134310 vehicle|Active substance: none
41326656|NCT00357422|PROCEDURE|Percutaneous ethanol injection therapy|99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
40809556|NCT03669757|DRUG|0.1% betamethasone valerate ointment (class III steroid)|Active substance: betamethasone valerate
40809557|NCT04216472|DRUG|Alpelisib|Given PO
40809558|NCT04216472|DRUG|Nab-paclitaxel|Given IV
41154530|NCT01109602|OTHER|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
41154531|NCT01811823|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|"The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~* A/California/7/2009 (H1N1)pdm-like virus~* A/Victoria/361/2011 (H3N2)-like virus~* B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
41154532|NCT02194777|DRUG|BIBN 4096 BS - in single rising doses|
41154533|NCT02194777|DRUG|Placebo|
40809563|NCT04763200|DEVICE|Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®|Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI \<20 kg/m2 or body weight \<60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.
40809564|NCT04763200|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
41154534|NCT04727242|DRUG|Gemcitabine|Hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine. Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.
41154535|NCT04727242|DRUG|Dacarbazine|Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles given IV
40809567|NCT06017609|DRUG|JTT-861 Capsules|Active drug capsules containing JTT-861
40809568|NCT06017609|DRUG|Placebo Capsules|Placebo capsules matching in appearance to the active drug capsules
40809569|NCT04781855|DRUG|Ibrutinib|Given PO
40809570|NCT04781855|BIOLOGICAL|Ipilimumab|Given IV
40809571|NCT04781855|BIOLOGICAL|Nivolumab|Given IV
40809572|NCT02863172|BEHAVIORAL|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
41480003|NCT03290287|DRUG|Other COPD medication|"Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol"
41480004|NCT03274713|DEVICE|Electro-acupuncture|"Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity."
40809573|NCT02863172|PROCEDURE|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
40809574|NCT01534299|DEVICE|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
40809575|NCT04869059|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
40809576|NCT04869059|DEVICE|sham tDCS|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
41154536|NCT04727242|PROCEDURE|Cytoreductive Surgery|Surgery for cancer removal
40809580|NCT05970640|DRUG|BI 3006337|BI 3006337
40809581|NCT05970640|DRUG|Placebo matching BI 3006337|Placebo matching BI 3006337
40809582|NCT05903911|OTHER|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
40809583|NCT05812963|DIAGNOSTIC_TEST|IVUS-guided PCI group|In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
40809584|NCT05812963|DIAGNOSTIC_TEST|FFR-guided PCI group|In FFR-guided PCI group, FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis \>90%, we will judge FFR value of ≤0.80.
40809585|NCT05352919|DRUG|Litifilimab|Administered as specified in the treatment arm.
40809586|NCT05352919|DRUG|Litifilimab-matching placebo|Administered as specified in the treatment arm.
40809587|NCT06477952|DRUG|Dronabinol|Open label Dronabinol treatment for two weeks.
41154537|NCT04727242|BEHAVIORAL|Functional Assessment of Cancer Therapy (FACT) G questionnaire|Preoperative and Postoperative FACT G questionnaire to assess QoL
41154538|NCT04727242|PROCEDURE|Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan|Radiologic imaging after Cycle 3 and 6 and at each follow up visit
40809590|NCT02438683|DRUG|BI 409306|high dose, single dose, oral administration
40809591|NCT02438683|DRUG|BI 409306|low dose, single dose, oral administration
40809592|NCT02438683|DRUG|Placebo|single dose, oral administration
41154539|NCT04727242|DRUG|Gadolinium|Contrast Agent
41154540|NCT00556296|DRUG|NRP104|NRP104 30mg capsule once daily in a.m.
40809595|NCT06156176|OTHER|COVIDEx|The COVIDEx intervention was developed by triangulating patient preferences/needs, clinicians' expertise, and best current evidence specific to Long COVID and adapted from interventions for other complex fatigue disorders, which are consistent with evidence informed practice. The program is delivered by trained instructors and comprises of two 50-minute sessions each week for eight weeks. The intervention is designed to be delivered virtually in groups of 6 patients, to eliminate travel requirements for the study. The components of the program are: (i) warm-up (1 min), (ii) cardio training (5 min), (iii) rest (3 min), (iv) balance training (5 min), (v) breathing exercises (3 min), (vi) cognitive training (5 min), (vii) strengthening training (5 min), and (viii) stretching (10min). The COVIDEx program will be paced in order to prevent post-exertional malaise (PEM) in participants.
41154541|NCT00556296|DRUG|NRP104|NRP104 50mg capsule once daily in a.m.
41480005|NCT03274713|DEVICE|Manual acupuncture|Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
41010043|NCT00748943|OTHER|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
41010044|NCT02399150|OTHER|No intervention as observational study|
41010045|NCT04539028|PROCEDURE|Emergency Abdominal surgery|Emergency Abdominal surgery
41480006|NCT00621036|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
41480007|NCT00621036|BIOLOGICAL|sargramostim|
40809597|NCT06570512|DEVICE|transcutaneous posterior tibial nerve stimulation|Over three weeks, the TPTNS group underwent ten sessions of electrical stimulation along the course of the posterior tibial nerve behind the medial malleoli using cup electrodes, with a width pulse of 250 microseconds, and a frequency of 20 Hz. The TENS group used a sham device with the same parameters, but the electrodes were placed behind the lateral malleoli with underpowered amplitudes.
41154542|NCT00556296|DRUG|NRp104|NRP104 70mg capsule once daily in a.m.
41010046|NCT04795414|BIOLOGICAL|SARS-CoV-2 Vaccine(Vero Cell), Inactivated|The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)
41480008|NCT00621036|DRUG|methotrexate|
41154543|NCT00556296|DRUG|Placebo|Placebo
41010047|NCT03730935|DEVICE|Respiratory muscle endurance training|Respiratory muscle endurance training performed over the duration of 4 weeks
41010048|NCT01204866|BIOLOGICAL|Valortim and selected Components|"* Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.~* Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.~* Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1~* Histamine (1 mg/mL), positive control~* Saline (0.9%), negative control"
41480009|NCT00621036|DRUG|thiotepa|
40809600|NCT06540703|DIETARY_SUPPLEMENT|Therapeutic Ketogenic Diet (TKD)|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
41154544|NCT01511744|BIOLOGICAL|Inactivated influenza split vaccine|3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
41154545|NCT01870999|DRUG|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
41010049|NCT01204866|DRUG|Valortim and Selected Components|"• It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~* Only one subject will be skin tested in a single day.~* The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively"
41154546|NCT01870999|DRUG|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
41154547|NCT02368977|DEVICE|Third Eye Panoramic device|A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
41480010|NCT00621036|RADIATION|radiation therapy|
41480011|NCT02208115|DIETARY_SUPPLEMENT|Meal composition - Low versus high GI.|
41480012|NCT05895721|OTHER|Virtual Reality|Virtual Reality as adjunct treatment
41480013|NCT06096714|DRUG|Nicotine|Nicotine will be infused using a pump.
41480014|NCT06096714|OTHER|Saline|Saline with be used to compare Nicotine, Saline will be infused using a pump
41480015|NCT02826291|DEVICE|RD-100i, OSNA|quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
41154548|NCT06154798|BEHAVIORAL|World Digital Detox Women's Health Program|World Digital Detox Women's Health Program incorporates gradual steps, including mindfulness exercises, setting boundaries on digital usage, decluttering digital spaces, promoting offline connections, and encouraging mindful technology use.
41154549|NCT04498871|DRUG|Nilotinib|Nilotinib is recommended to be administered orally on a continuous schedule at a dose of 400 mg twice daily. The patient should be instructed to take each morning dose of nilotinib 2 hours after a light breakfast (e.g., toast and jam), with no oral intake other than water for 1 hour after dosing. It is recommended that the patient take nilotinib doses every 12 hours with a glass of water. The evening dose of nilotinib should be taken at least 2 hours after dinner with no oral intake other than water for 1 hour after dosing.
41154550|NCT01747616|DEVICE|Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)|1 drop of the medical device in 1 randomly chosen eye
40809606|NCT06401668|BEHAVIORAL|Community health worker (CHW) strategy|CHWs will offer participants personalized support to assist in overcoming barriers and leveraging facilitators to PRx uptake. CHWs are trained lay members of the communities they serve. The CHW strategy is an evidence-based.
41326657|NCT02906956|BEHAVIORAL|Preferred music playlist|Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
41326658|NCT01360853|DRUG|ON 01910.Na|ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
40809607|NCT06401668|BEHAVIORAL|PRx Program|The PRx Program provides free fruit and vegetables and nutrition education to patients with T2D and food insecurity.
41480016|NCT03218891|BEHAVIORAL|Cardiac Rehabilitation|"The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:~* 5 minutes warm up~* 30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;~* 10 minutes of localized exercises;~* 5 minutes of relaxation."
40809608|NCT05352061|BEHAVIORAL|CBT for Syndemics and Adherence Factors|Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
41326659|NCT01360853|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
41326660|NCT01360853|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
41326661|NCT05535764|DRUG|Pegylated interferon alpha2a|PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.
41326662|NCT04649619|PROCEDURE|GASTRIC BYPASS MODIFIED IN ROUX-EN-Y AS A THERAPEUTIC OPTION IN PATIENTS WITH INDICATION OF BARIATRIC AND / OR METABOLIC SURGERY|"Roux-en-Y gastric bypass:~Stapling and reduction of the gastric chamber of approximately 18 cm, followed by anastomosis with a deviated bowel, and another bowel anastomosis with a bowel in a lower portion, for deviation of biliopancreatic secretions. Maintenance of a gastro-gastric communication of approximately 1 cm between the functional gastric pouch and the excluded stomach for endoscopic access."
40809609|NCT05504291|PROCEDURE|Biospecimen Collection|Undergo aqueous humor and tissue sample collection
40809610|NCT05504291|DRUG|Carboplatin|Given IV
40809611|NCT05504291|DRUG|Etoposide|Given IV
41326663|NCT06252857|DRUG|Imiquimod Topical|Topical application of imiquimod (once daily, 5 days a week, during 6 weeks) versus surgical excision.
41326664|NCT05271903|BEHAVIORAL|MAMA Intervention|"The MAMA intervention will be based on PRONTO International's simulation training program to improve obstetric care delivery. The PRONTO curriculum is based on simulation and debrief of clinical scenarios, case-based learning, skills stations, and interactive teamwork and communication activities. Through the training, providers review and learn clinical skills related to obstetric care and emergencies, while reflecting on and practicing principles of respectful maternity care. The simulation exercises give providers and opportunity to act as the patient and develop empathy for the patient experience, and debriefing after simulation includes a reflection and discussion about RMC principles. The training will be two full days, followed by a refresher training in the clinical setting after one month."
41480017|NCT05506722|DEVICE|Testes shocker|It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
40809612|NCT05504291|PROCEDURE|Examination Under Anesthesia|Undergo imaging of the eye during EUA
40809613|NCT05504291|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41154551|NCT01747616|OTHER|Physiological saline solution|1 drop as placebo in the other eye not receiving the medical device
41480018|NCT05609916|BEHAVIORAL|Cognitive Behavioral Therapy|"During Phase I, participants will receive open label (no blinding) CBT during their study participation for 12 to 18 weeks.~During Phase II, participants will continue receiving CBT maintenance sessions every two weeks for the first 4 weeks, followed by sessions every four weeks. They will also meet with the study physician every 2 weeks via telepsychiatry appointments for clinical and scalar assessment."
41480019|NCT00093951|DRUG|SGS742|
40809614|NCT05504291|DRUG|Melphalan|Given I-VITRE
40809615|NCT05504291|PROCEDURE|Ultrasound Biomicroscopy|Undergo UBM during EUA
40809616|NCT05504291|DRUG|Vincristine|Given IV
40809617|NCT03503097|PROCEDURE|Biospecimen Collection|Provide saliva samples
40809618|NCT03503097|OTHER|Genetic Counseling|Undergo counseling
40809619|NCT03503097|OTHER|Genetic Testing|Undergo genetic testing
40809620|NCT03503097|OTHER|Laboratory Biomarker Analysis|Correlative studies
40809621|NCT03503097|BEHAVIORAL|Questionnaire|Complete questionnaire
41154552|NCT04970654|DRUG|somapacitan|Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
40809623|NCT05932654|DRUG|BSI-045B|Patients will be treated with BSI-045B.
40809624|NCT04023591|PROCEDURE|Surgery/Occupational Therapy|Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
40809625|NCT06495268|OTHER|Individualised data-driven hearing rehabilitation|"HA fittings will be conducted with the Real-Ear Measurements (REM) method that is recommended by the latest ISO-standard (21388:2020) and by the preliminary results of the BREM study at KUH. After the fitting of the HAs, participants' auditory-related outcomes will be immediately assessed using DigiKuulo and re-fitting is performed if needed based on the following criteria:~1. The absolute improvement in the DIN test is less than 1,5dB (SNR), OR~2. The participant is unsatisfied with the HA fitting~Participants are invited to intervention-related monitoring appointments at 3 and 6 months after the primary HA fitting. At these visits, auditory outcomes of the rehabilitation are assessed via DigiKuulo and re-fittings are performed as needed."
41154553|NCT04970654|DRUG|Norditropin®|Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
41326665|NCT02681185|OTHER|Virtual Care|"Virtual Care consists of the following services and resources:~1. Have a virtual consult through online methods or telephone with one of the study endocrinologists~2. Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods~3. Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic~4. Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support."
41326666|NCT02681185|OTHER|Standard of Care|Standard of care offered in the patient's community. May involve in-person education at a diabetes centre and consultation with a healthcare professional.
41480020|NCT03544398|OTHER|robot assisted gait training|we use two types of robot assisted gait training and we will compare two groups.
41010050|NCT03135522|DRUG|Zinc Acetate 50 Mg Oral Capsule|"* Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~* Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~* Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)"
41154554|NCT06041334|BIOLOGICAL|Collection of a urine sample|Collection of a urine sample for analysis of urinary biomarkers and urinary metabolomics (Inclusion and 1 year)
41154555|NCT06041334|DIAGNOSTIC_TEST|Magnetic Resonance Imaging of the bladder|Magnetic Resonance Imaging of the bladder (10 adults patients only) (Inclusion and 1 year)
41154556|NCT01704859|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
41154557|NCT01704859|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
41154558|NCT01704859|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
41154559|NCT01704859|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
41154560|NCT03053908|PROCEDURE|Actigraphy|Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days
41154561|NCT03053908|PROCEDURE|Nocturnal Polysomnograpahy (NPSG)|N1 habituation and N2 data collection
41154562|NCT06030258|DRUG|IN10018|orally taken once daily
41154563|NCT06030258|DRUG|Tislelizumab|200mg D1, Q3W, intravenously
41326667|NCT02883777|BEHAVIORAL|High Protein and Low Glycemic Index Diet|It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
41326668|NCT02883777|BEHAVIORAL|Conventional Diet|Conventional diet over 1 year after transplantation.
41326669|NCT02584465|DRUG|Tamoxifen|Tamoxifen: 40 mg/day
41480021|NCT02447159|BEHAVIORAL|Conditional Cash Transfers|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
41480022|NCT00103038|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
41480023|NCT00103038|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DCE-MRI
40809626|NCT06495268|OTHER|Standard care hearing rehabilitation|HA will be fitted with automatic algorithms by HA manufacturers and REM-fitting is only applied in complex cases based on the hearing rehabilitator's clinical judgement. Three months after the HA fitting, participants will be contacted via phone call to inquire about the status of the rehabilitation. Additional monitoring visits may be offered based on the participant's feedback. After the 3-month monitoring phone call participants will be advised to further contact the study team if they are dissatisfied with the amplification or for any other problem with their device.
40809627|NCT03988621|BEHAVIORAL|ViCCY|Virtual Caregiver Coach for You
40809628|NCT06649942|DRUG|KP-001|KP-001 100 mg + placebo
40809629|NCT06649942|DRUG|KP-001|KP-001 400 mg
40809630|NCT06649942|DRUG|Moxifloxacin 400 mg|moxifloxacin 400 mg tablet
40809631|NCT06649942|DRUG|Placebo|Placebo
40809632|NCT06649929|BEHAVIORAL|Couples-based treatment- Patient|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
40809633|NCT06649929|BEHAVIORAL|Couples-based treatment- Partner|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
40809634|NCT06649929|OTHER|Information control- Patient|Information only plus treatment as usual
40809635|NCT06649929|OTHER|Information control- Partner|Information only plus treatment as usual
41154564|NCT06030258|DRUG|Carboplatin|AUC 5 mg/ml/min, D1, Q3W, intravenously
41480024|NCT00103038|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DSC-MRI
41480025|NCT00103038|DRUG|Ferumoxytol|Given IV
41480026|NCT00103038|DRUG|Gadolinium|Given IV
41480027|NCT00103038|PROCEDURE|MRI-Based Angiogram|Undergo MRA
40809636|NCT06653764|OTHER|Chest physiotherapy and aerobic exercise training|Chest Physiotherapy including Percussion, vibration and shaking; along with it aerobic exercises such as walking up and down stairs, bedside ambulation, step walking
40809637|NCT06653803|PROCEDURE|Rhomboid Intercostal Block (RIB)|Intraoperative Ipsilateral Ultrasound-guided RIB
40809638|NCT06653803|PROCEDURE|Retrolaminar Block (RLB)|Intraoperative Ipsilateral Ultrasound-guided RLB
41154565|NCT06030258|DRUG|Etoposide|Etoposide 100 mg/m2, D1-D3, Q3W, intravenously
41154566|NCT02978235|DRUG|TAS4464|Intravenous (IV) Infusion
41154567|NCT00382408|BIOLOGICAL|DR-5001|All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
41154568|NCT00382408|OTHER|Placebo|All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
41154569|NCT02246387|PROCEDURE|Manchester Operation|A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
40809641|NCT06312579|BEHAVIORAL|12-week home based exercise|Consistent with current physical activity recommendations for older adults, participants randomized in this arm will be prescribed 5 days/week of exercise, with seated cycling exercise performed on 3 days a week (Monday, Wednesday and Friday), and strength/balance exercise performed 2 days a week (Tuesday and Thursday).
41154570|NCT05204771|OTHER|Ultrasound exam|Ultrasound exam
41154571|NCT05204771|OTHER|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
41154572|NCT05204771|OTHER|Pediatric Follow up|Pediatric Follow up
41326670|NCT02584465|DRUG|Regorafenib|Stivarga; 120mg/day
41326671|NCT06177119|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
41326672|NCT06177119|DRUG|Placebos during SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning with the first SRP session.
41326673|NCT06177119|DRUG|Placebos after SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning after the last SRP session.
41326674|NCT06177119|DRUG|Metronidazole during SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning with the first SRP session.
41326675|NCT06177119|DRUG|Amoxicillin during SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning with the first SRP session.
41326676|NCT06177119|DRUG|Metronidazole after SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning after the last SRP session.
41480028|NCT05678231|DEVICE|Zero Degree Knee Positioner|The Zero Degree Knee (ZDK) positioning device is a knee extension pillow designed to simplify knee extension exercise following TKA surgery.
41480029|NCT03465436|DRUG|Lasmiditan|100 mg administered orally (PO)
41480030|NCT03465436|DRUG|Lasmiditan|400 mg administered PO
41480031|NCT03465436|DRUG|Placebo|Placebo administered for lasmiditan or moxifloxacin
41480032|NCT03465436|DRUG|Moxifloxacin|400 mg moxifloxacin administered PO
41326677|NCT06177119|DRUG|Amoxicillin after SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning after the last SRP session.
40809642|NCT06312579|BEHAVIORAL|12-week standard of care|Participants in this group will be provided with guidance on the current standard of care. This includes guidance that these patients should slowly increase ambulation with appropriately fitted footwear.
41154573|NCT04905511|BIOLOGICAL|natural human collagen arteriovenous graft for hemodialysis access|The True Vascular Graft will be implanted in the forearm or upper arm in a straight or curved configuration.
41326678|NCT01599702|DRUG|Iron Isomaltoside 1000|1500-3000mg IV depending on HB level, sex and body weight
41326679|NCT00523653|OTHER|blood test|looking at DNA
41326680|NCT03688685|DRUG|CAD-1883|Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.
41326681|NCT03918642|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
41326682|NCT03918642|BEHAVIORAL|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
41326683|NCT03984838|DRUG|JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet|JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
41326684|NCT05281848|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment includes periodontal prophylaxis and root planning. No other methods or any of drugs will be used.
41326685|NCT01778400|PROCEDURE|radiofrequency ablation|radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
41326686|NCT01778400|PROCEDURE|Ethanol ablation|ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
41326687|NCT00306241|BIOLOGICAL|HPV-16/18 L1 VLP AS04|
41326688|NCT02485548|DRUG|Raltitrexed|Patients will receive IMRT and concurrent raltitrexed and cisplatin
41326689|NCT02485548|DRUG|5-fluorouracil|Patients will receive IMRT and concurrent 5-Fu and cisplatin
41480033|NCT02678442|DEVICE|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
41480034|NCT02678442|DEVICE|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
40809643|NCT06651775|DEVICE|High intensity laser therapy|lumbosciatalgia mode of the HILT device
40809644|NCT06651775|DEVICE|Sham Comparator|sham mode of the HILT device
41154574|NCT00721019|OTHER|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
40809646|NCT06653153|DRUG|Remternetug|Administered SC
40809647|NCT06653153|DRUG|Placebo|Administered SC
41154575|NCT00721019|OTHER|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
41154576|NCT05398653|DRUG|MIL62|An intravenous (IV) infusion of 600 mg of MIL62 will be administered at Week 1，Week 3.If the treatment is effective, MIL62 will continue be administered at W25，W27.
41154577|NCT05398653|DRUG|Cyclosporine|Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d, divided into 2 doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks ±3 days until the target blood concentration of 125\~175 ng/ mL was reached.Cyclophosphamide will be maintained for 12 months, after which the dose was reduced by about 1/3 to 1/2 of the original dose each month, and discontinued after 2 months.
41154578|NCT01631799|DEVICE|Femoral catheter|Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
41326690|NCT02485548|DRUG|Cisplatin|All patients will receive concurrent cisplatin.
41326691|NCT02485548|RADIATION|IMRT|All patients will receive IMRT
41326692|NCT05557123|DEVICE|MEDI-app|MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
41326693|NCT05557123|DEVICE|conventional treatment|conventional treatment with rivoxaban
41326694|NCT04172311|OTHER|Modified Atkins Diet|Modified Atkins diet is a type of ketogenic diet which is less restrictive
41326695|NCT04172311|DRUG|Levetiracetam|Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
41326696|NCT00179517|DRUG|Anastrozole 1mg|
41326697|NCT00179517|DRUG|Placebo Oral Tablet|
41326698|NCT05456152|DRUG|Sublingual Tablet|Sublingual zolpidem - 1 sublingual tablet 30 minutes before bed time.
41326699|NCT01154595|DIETARY_SUPPLEMENT|Plumpy Doz(r) - Ready-to-Use Food|47g Plumpy Doz(r) per day per child
41326700|NCT01154595|BEHAVIORAL|Food-for-Training|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
41326701|NCT02562950|DRUG|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
41326702|NCT02562950|DRUG|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
41480035|NCT06037278|DEVICE|MyPAO|use of MyPAO surgical guide to support periacetabular osteotomy procedures for treatment of acetabular dysplasia
41154579|NCT01631799|DEVICE|Epidural catheter|The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
41326703|NCT02562950|DRUG|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
40809649|NCT05709223|DEVICE|Categorical loudness scaling based fitting using the Nexus Research System.|The Nexus Research system is used in combination with other devices as part of a hearing implant system. It is intended to create and modify hearing profiles, to monitor the performance of the system and to facilitate Firmware updates of the system. It is also intended to be used with other devices of a hearing implant system to make volume adjustments to the processing unit, to download pre-defined MAPs and to collect data from tests and questionnaires using a compatible device.
40809650|NCT05709223|DEVICE|Behavioural fitting using Custom Sound Suite (CSS 6.3) Software|The comparator is the commercially available fitting method (i.e., the behavioural measurement of active channels) using Custom Sound Suite (CSS 6.3) software
40809651|NCT03609216|DRUG|Gemcitabine Hydrochloride|Given IV
40809652|NCT03609216|DRUG|Cisplatin|Given IV
41010051|NCT03135522|DRUG|Placebo oral capsule|"* Day 0 (randomization) to day 3 Placebo (one capsule per day)~* Day 4 to day 7 If well tolerated: placebo (two capsules per day)~* Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)"
41010052|NCT04038489|DRUG|Aspirin|325 mg aspirin daily during AC-T chemotherapy
41010053|NCT04038489|DRUG|Tamoxifen Pill|Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
41010054|NCT04038489|DRUG|Doxorubicin|Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
41010055|NCT04038489|DRUG|Cyclophosphamide|Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
41154580|NCT01540071|DRUG|NRX 194204|NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
41326704|NCT04950192|DEVICE|ICE Image guidance|ICE image guidance will be used on all patients undergoing planned cardiac catheterization procedures
41326705|NCT00640952|DRUG|acamprosate|333 mg 2 tabs tid
41326706|NCT00553345|DRUG|selenium|
41010056|NCT04038489|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
41326707|NCT00553345|DRUG|vitamin E|
40809653|NCT03609216|BIOLOGICAL|Pegfilgrastim|Given SC
40809654|NCT03609216|PROCEDURE|Conventional Surgery|Undergo bladder sparing
40809655|NCT03609216|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
40809656|NCT03609216|OTHER|Chemoradiotherapy|Undergo chemoradiotherapy
41154581|NCT01357564|OTHER|Tailored Activity Program|The interventionist, an occupational therapist, meets with the caregiver and introduces the intervention goals. The OT provides and reviews written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed is The 36 Hour Day. The OT interviews the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT also observes interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale.
40809658|NCT06319820|COMBINATION_PRODUCT|TAR-210|TAR-210 will be administered intravesically.
40809659|NCT06319820|DRUG|Gemcitabine|Gemcitabine will be administered intravesically.
40809660|NCT06319820|DRUG|MMC|MMC will be administered intravesically.
41010057|NCT00121771|BIOLOGICAL|FP9 CS|
41010058|NCT00121771|BIOLOGICAL|MVA CS|
41010059|NCT02920268|OTHER|Dance and yoga intervention|
41010060|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 2 saliva samples at inclusion.
41010061|NCT05928442|BEHAVIORAL|Completion of a self-questionnaire|Completion of a self-questionnaire on symptom and quality-of-life at inclusion.
41010062|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 1 saliva sample at the follow-up visit.
41010063|NCT04510935|PROCEDURE|general anesthesia|the patient will receive general anesthesia during surgery in this group.
41010064|NCT04510935|PROCEDURE|local anesthesia|the patient will receive local anesthesia during surgery in this group.
41154582|NCT01357564|OTHER|Attention Control|Caregivers in this group received bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers were provided information about dementia and strategies for disease management. Each telephone contact began with a brief overview the session purpose, followed by a description of key facts, and concluded with a question and answer period. The attention control group intervention was delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
41154583|NCT03604653|DEVICE|HIPEC|Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes
41154584|NCT03604653|DRUG|Mitomycin c|MMC 30mg@ T0, 10mg@T45 min
41154585|NCT03604653|DRUG|CDDP 50|50mg/m2@T0
41326708|NCT00553345|PROCEDURE|chemoprevention|
41326709|NCT02826993|DEVICE|CCE in incomplete Colonoscopies|When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
41326710|NCT05285436|DEVICE|CloudCath System|The CloudCath System enables drainage and measures turbidity, reported as a numeric score, in peritoneal dialysate effluent.
41326711|NCT04343209|DIAGNOSTIC_TEST|Myocardial Perfusion Imaging Study|Evaluation of myocardial perfusion via PET imaging agent
41326712|NCT04343209|DRUG|AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]|Cardiac PET imaging agent
41154586|NCT03604653|DRUG|CDDP 75|75mg/m2@T0
41154587|NCT03604653|DRUG|Doxorubicin|15mg/m2@T0
41326713|NCT04668092|OTHER|Functional dry needling|functional dry needling applied to hamstring for 1 minute and post interventional data collected
41326714|NCT01752972|DIETARY_SUPPLEMENT|Spirulina|10 g/day orally for 12 weeks
41326715|NCT05321095|DIAGNOSTIC_TEST|Albuminuria test|During participation, subjects are asked to collect one or more urine samples for albuminuria determination.
41326716|NCT05321095|DIAGNOSTIC_TEST|HbA1c test|During the screening visit, HbA1c will be measured with a point-of-care test (Affinion HbA1c, Abbott).
41154588|NCT05422859|OTHER|MobiDig|"The application will contain the following modules:~1. information and knowledge about heart failure;~2. vital sign diary, which can be sent to the certified HFU~3. pedometer (individualized step-goal), cardiac home training videos~4. frequently asked questions and connection to a certified HFU provider by a heart failure hotline"
41326717|NCT05321095|DIAGNOSTIC_TEST|Creatinine test|During the screening visit, creatinine will be measured with a point-of-care test (i-STAT Alinity handheld analyser, Abbott).
41480036|NCT00195013|DRUG|glutamine|10 grams three times a day (orally) for four days and then stop
41480037|NCT00195013|DRUG|Placebo|10 grams three times a day (orally) for four days and then stop
41480038|NCT05768126|DRUG|Rivastigmine Transdermal Product|The patches will be administered (first four weeks 4.6 mg and then 9.5. mg).
41480039|NCT05768126|OTHER|Sham|The sham patches will be administered during the same period of time as the rivastigmine.
41480040|NCT01435031|DEVICE|CTO Treatment Device|"Subjects receiving at least 1 of the following for the treatment of CTO:~* XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~* HT PROGRESS and/or HT PILOT guide wires in recanalization~* MINI-TREK Coronary Dilatation Catheter in predilatation"
41480041|NCT00355472|DRUG|KW-0761|IV administration at 4 escalating dose levels.
41010065|NCT01886794|DRUG|Postmenopausal, topical vaginal estrogen cream|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
41326718|NCT00866892|PROCEDURE|Irrigation|irrigation
41326719|NCT00866892|PROCEDURE|No irrigation|no irrigation
41326720|NCT01565590|DRUG|Dexmedetomidine|0.2-1.5 mcg/kg/hr
41480042|NCT00804141|DRUG|N-methylnaltrexone bromide (MOA-728)|MOA-728 will be administered as per the dose and schedule specified in the arm.
41480043|NCT03496857|DEVICE|Light emitting diode|Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention.
41480044|NCT03496857|OTHER|Bath Therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
41480045|NCT00537108|BEHAVIORAL|Home visiting and care management|Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support \& skills-building for school continuation, higher education, and job readiness.
41010066|NCT01886794|DRUG|Placebo Comparator: Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
41010067|NCT03930316|DEVICE|NOX T3|portable sleep study device
41154589|NCT02864342|DEVICE|Arm 1: BreatheMate device with application|The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.
41326721|NCT01565590|DRUG|propofol|5-80 mcg/kg/min
41326722|NCT05155657|BIOLOGICAL|Conventional therapy plus low dose UCMSCs treatment|Patients will receive the conventional therapy plus low dose UCMSCs treatment (0.5×10\^6 UCMSCs/kg body)
41326723|NCT05155657|BIOLOGICAL|Conventional therapy plus medium dose UCMSCs treatment|Patients will receive conventional therapy plus medium dose UCMSCs treatment (1×10\^6 UCMSCs/kg body)
41326724|NCT05155657|BIOLOGICAL|Conventional therapy plus high dose UCMSCs treatment|Patients will receive conventional therapy plus high dose UCMSCs treatment (2×10\^6 UCMSCs/kg body)
41326725|NCT00559416|DRUG|Cell Transfer|
41480046|NCT03857672|BEHAVIORAL|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT intervention will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention (more than the sum of CT and hypnosis) that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience).
41480047|NCT01360866|DRUG|OPC-34712|Tablet
41480048|NCT01360866|DRUG|Escitalopram|Tablet
41480049|NCT01360866|DRUG|Fluoxetine|Capsule
41010068|NCT01528241|DRUG|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
41010069|NCT04135638|PROCEDURE|Cover Group|"Cover when the ILM flap is everted over the MH gap in a single layer"
41010070|NCT04135638|PROCEDURE|Fill Group|"Fill when the ILM is folded into multiple layers within the MH"
41326726|NCT03155633|OTHER|Athletics track|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
41326727|NCT03155633|OTHER|Elliptical machine|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
41480050|NCT01360866|DRUG|Paroxetine CR|Controlled-release tablets
41326728|NCT02570646|BEHAVIORAL|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
41326729|NCT03029858|OTHER|No interventions will be taken in this Observational study|TAGRISSO(osimertinib/AZD9291）
41326730|NCT05340322|DEVICE|Colposcopy using pocket colpscope and thermocoagulator|If HPV+, visualization with pocket colposcope and treatment with thermocoagulator
41326731|NCT03508661|OTHER|SPIN-SSLED Program|The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 \&7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
41326732|NCT02819349|BEHAVIORAL|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. Content is guided by components of the Assertive Community Treatment (ACT) and focuses on facilitating improved patient-provider communication, promoting medication adherence, helping people self-monitor their early warning signs, and promoting self-management of symptoms.
41326733|NCT01104363|PROCEDURE|Snow white plaster 2|Test. Plaster impression not splinted.
41326734|NCT01104363|PROCEDURE|Primopattern LC gel + PVS|Control PVS impression
41326735|NCT01011218|BEHAVIORAL|BBT-I|Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone
41326736|NCT01011218|BEHAVIORAL|Control|Control behavioral intervention is a sleep hygiene handout completed by participant.
41326737|NCT01011218|DRUG|Armodafinil|150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.
41326738|NCT03703687|BEHAVIORAL|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
41326739|NCT03742206|DEVICE|Parasacral Transcutaneous Electrical Stimulation|Electrical stimulation with surface electrodes on the sacral roots of S3 that produce inferior urinary tract neuromodulation.
41326740|NCT03742206|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation|Electrical stimulation with surface electrodes through the activation of peripheral afferent nerves that produce inferior urinary tract neuromodulation
41326741|NCT05247385|DRUG|Prasugrel|Compared platelet inhibition and adenosine levels at baseline and after 15 days
41326742|NCT05247385|DRUG|Ticagrelor|Compared platelet inhibition and adenosine levels at baseline and after 15 days
41326743|NCT06461312|PROCEDURE|Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block|Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block
41326744|NCT02584868|DRUG|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
41326745|NCT02584868|DRUG|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
41480051|NCT01360866|DRUG|Sertraline|Tablets
41326746|NCT05445479|DRUG|Doxycycline|Patient with doxycycline treatment during COVID-19 waves
41326747|NCT00828503|DRUG|Certican (everolimus) + valganciclovir|"Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)~MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)"
41326748|NCT00828503|DRUG|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
41326749|NCT01272817|PROCEDURE|Nonmyeloablative Allogeneic Transplant|Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
41326750|NCT01272817|PROCEDURE|Nonmyeloablative Allogeneic Transplant|Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
41326751|NCT00574457|OTHER|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
41480052|NCT01360866|DRUG|Duloxetine|Delayed-release capsules
41480053|NCT01360866|DRUG|Venlafaxine XR|Extended-release capsules
41480054|NCT01762826|DIETARY_SUPPLEMENT|Myo-inositol|Dietary control plus Myo-inositol
41480055|NCT01762826|DIETARY_SUPPLEMENT|D-chiro-inositol|Dietary control plus D-Chiro-Inositol supplementation
41480056|NCT01762826|DIETARY_SUPPLEMENT|D-Chiro / Myo-inositol|Dietary control Supplementation with myo and d-chiro inositol
41326752|NCT02475395|DEVICE|TRAK device|Use of TRAK to attain sperm concentration measurement
41326753|NCT00961870|PROCEDURE|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
41326754|NCT05768425|DIAGNOSTIC_TEST|Real-time quaking-induced conversion (RT-QuIC)|RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.
41326755|NCT05768425|DIAGNOSTIC_TEST|Cognitive test|Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)
41326756|NCT05768425|DIAGNOSTIC_TEST|Motor examination|Unified Parkinsons Rating Scale (UPDRS)
41326757|NCT00933192|DEVICE|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
41326758|NCT05559073|PROCEDURE|Radiofrequency ablation|pulmonary vein isolation using radiofrequency ablation.
41326759|NCT06393894|DIAGNOSTIC_TEST|Near infrared spectroscopy|Near infrared spectroscopy (NIRS) is an intravascular imaging technique. Patients after coronary angiography with or without angioplasty will undergo NIRS if deemed suitable by the interventionalist. NIRS has a high sensitivity and specificity for lipid core plaque detection.
41480057|NCT01762826|DIETARY_SUPPLEMENT|Placebo|Dietary control plus folic acid 400 mcg daily
41480058|NCT00192270|BIOLOGICAL|CAIV-T|Each dose of the vaccine was formulated to contain approximately 1 x 10\^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of \~3 x 10\^7 TCID50 per dose.
41480059|NCT00373191|DRUG|chemotherapy|N/A- not dictated by study
41326760|NCT06393894|GENETIC|Genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 mutations and niR-126, -145 and -155 expression.|Patients without explicit atherosclerosis risk factors and known genetic disorders will undergo genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 genes in order to evaluate the presence of gene variations as a cause for early atherosclerosis. MiRNA-126, -145 and -155 expression in patients serum samples will be evaluated and correlated with plaque lipid core in near infrared spectroscopy (NIRS) imaging.
41326761|NCT02423460|OTHER|Threonine|Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
41326762|NCT00525785|DRUG|5-Fluorouracil|"2.2 Gm/m\^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump."
41326763|NCT00525785|DRUG|Folinic Acid|200 mg/m\^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
41480060|NCT00373191|DRUG|endocrine therapy|N/A- not dictated by study
41480061|NCT00373191|GENETIC|DNA methylation analysis|laboratory analysis
41480062|NCT00373191|GENETIC|protein analysis|laboratory analysis
41480063|NCT00373191|OTHER|laboratory biomarker analysis|laboratory analysis
41480064|NCT00373191|OTHER|questionnaire administration|questionnaire
41480065|NCT00373191|PROCEDURE|adjuvant therapy|N/A- not dictated by study
41154590|NCT02864342|DEVICE|Arm 2: BreatheMate device without application|"The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.~The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone."
41480066|NCT00373191|PROCEDURE|conventional surgery|N/A- not dictated by study
41154591|NCT03233204|DRUG|Olaparib|Given PO
41154592|NCT03549299|BIOLOGICAL|LSC2|Topical application of IMP on target eye
41326764|NCT00525785|DRUG|Oxaliplatin|"100 mg/m\^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m\^2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week)."
41326765|NCT00525785|RADIATION|Radiotherapy|45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
41326766|NCT00525785|PROCEDURE|Surgery|4-6 weeks after completion of chemoradiotherapy, restaged \& surgical resection of the primary tumor and lymph nodes attempted.
41326767|NCT00703859|DRUG|Dichloroacetate (DCA)|DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
41326768|NCT05682313|DIAGNOSTIC_TEST|Elastography arm|Renal ultrasound elastography to detect and classify the degree of fibrosis
41480067|NCT00373191|RADIATION|radiation therapy|N/A- not dictated by study
41480068|NCT00841360|OTHER|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
41480069|NCT00841360|OTHER|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
41480070|NCT00794482|DRUG|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
41480071|NCT04445064|BIOLOGICAL|IO102|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
41480072|NCT04445064|BIOLOGICAL|IO103|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
41480073|NCT01797484|DRUG|Ranolazine|Improvement of myocardial microcirculation
41480074|NCT01465282|DRUG|CT327 0.05%|0.05% CT327 (w/w) ointment
41480075|NCT01465282|DRUG|CT327 0.1%|0.1% CT327 (w/w) ointment
41480076|NCT01465282|DRUG|CT327 0.5%|0.5% CT327 (w/w) ointment
41480077|NCT01465282|DRUG|Placebo|Placebo
41480078|NCT05616403|OTHER|No intervention|This is an observational study without any intervention
41480079|NCT01202071|DRUG|Rabeprazole sodium, 5 mg Tablets|"Rabeprazole sodium Tablets, 5 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
41480080|NCT01202071|DRUG|Rabeprazole sodium, 10 mg Tablets|"Rabeprazole sodium Tablets, 10 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
41480081|NCT01202071|DRUG|Rabeprazole sodium, 20 mg Tablets|"Rabeprazole sodium Tablets, 20 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
41480082|NCT01202071|DRUG|Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)|"Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water, \>=2 hours after the completion of breakfast."
41480083|NCT04719104|DEVICE|Transcutaneous Bilirubin Meter - 'Bilimeter'|Taking a transcutaneous (TcB) measurement will involve using a 'biliflash'. This is a non-invasive measurement that involves flashing a light against the helix of the infant's ear and can be done at the cotside. This process takes approximately 1-2 minutes and does not cause the baby discomfort. The meter gives an immediate bilirubin level.
41480084|NCT00098228|DRUG|QAB149|
41480085|NCT05690074|DEVICE|Spectra Wave Writer™ Spinal Cord Stimulator System|Device: 5-6-5 Specify electrode Device: Restore Advance Pulse Generator
41480086|NCT03050918|BEHAVIORAL|Follow-up Phone Call|Patients will receive a first call attempt within 72 hours discharge.
41480087|NCT04128202|BEHAVIORAL|Sunnyside|The Sunnyside intervention is an online intervention (an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
41480088|NCT04128202|BEHAVIORAL|Sunnyside Plus|Sunnyside Plus will build upon the Sunnyside intervention, plus include additional education and support to promote breastfeeding. Breastfeeding education and skills will be provided during the 6weeks of online lessons during pregnancy; each lesson takes approximately 10 minutes to complete. Breastfeeding support will continue through 6 weeks postpartum. This postpartum support will involve weekly online lessons(each taking approximately 10 minutes to complete), text support messages(3 sent during weeks 1 and 2, 2 sent during weeks 3 and 4, 1 sent during weeks 5 and 6), and video support calls with a Lactation Educator (LE)provided on an as-needed basis(exception: at least 1 video call is required during both week 1 postpartum and week 2 postpartum).
41480089|NCT02531607|OTHER|blood and bile|20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
41480090|NCT03659721|BEHAVIORAL|FACAM|Support person
41480091|NCT03659721|BEHAVIORAL|Care as Usual|Usual care
41010071|NCT05649163|DRUG|Disitamab Vedotin|Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
41326769|NCT05242263|BEHAVIORAL|Attention Control Training (ACT) with ABV feedback|At the beginning of each session, participants will complete 45 standard dot-probe trials as described above. Participants' ABV on these trials will be calculated and set as their personal baseline (see below for ABV calculation). In the following 165-training trials, participants will receive feedback: when their online-calculated ABV will be below their baseline screen background will be green whereas its color will be red when their online ABV score will be higher than their baseline. Patients will be instructed to try to keep the background green for as long as possible.
41480092|NCT03659721|BEHAVIORAL|COS-P|Attachment based therapy
41154593|NCT03538223|OTHER|Music Listening|Participants will undergo two different types of music before radiotherapy sessions
41480093|NCT02610764|PROCEDURE|Blood Test for CTC evaluation|
41017839|NCT04205279|OTHER|Experimental: Surefooted training|During the first minute of each block, subjects would experience no perturbations followed by 3 minutes of single or multi-directional perturbations. A one minute break between each condition would be provided. Subject's fatigue would be assessed by Fatigue severity scale to determine the tolerability of 30 minute training protocol. The expected duration to complete the test would be a maximum of 1 hour including the preparation and training time.
41154594|NCT03538223|RADIATION|Radiotherapy|All participants will undergo radiotherapy according to breast cancer post surgery protocol
41480094|NCT06411340|OTHER|Observation|Observation
41480095|NCT03926481|BEHAVIORAL|Evaluate Healthy Lifestyle Program on cognitive outcomes|The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.
41480096|NCT03163433|BEHAVIORAL|Feedback in the consultation|Patients will complete electronic Patient Reported Outcome Measures (PROM) before the consultation at the hospital. The results are fed back to physicians. In the consultation patients will systematically participate in a dialogue with their physician about issues that are most important for the patients.
41480097|NCT01468376|DIETARY_SUPPLEMENT|GLU-01|14 day dosing
41480098|NCT01468376|DIETARY_SUPPLEMENT|GLU-02|14 day dosing
41480099|NCT01468376|DIETARY_SUPPLEMENT|GLU-03|14 day dosing
41326770|NCT05242263|BEHAVIORAL|Attention Control Training (ACT) with yoked sham feedback|Participants in this group will be exposed to the same task as in the active group but will receive sham feedback that is unrelated to their ABV during task performance. They will be presented with a feedback that is yoked to the one given to a participant in the training group.
41326771|NCT02578472|DRUG|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.
41326772|NCT02578472|DRUG|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
41326773|NCT02578472|DRUG|Placebo|Matching Placebo will be administered orally.
41480100|NCT01468376|DIETARY_SUPPLEMENT|GLU-04|14 day dosing
41480101|NCT01468376|DIETARY_SUPPLEMENT|GLU-05|14 day dosing
41480102|NCT01468376|DIETARY_SUPPLEMENT|GLU-06|14 day dosing
41480103|NCT06001723|BEHAVIORAL|Forest Therapy|Forest healing activities are guided by professionals, allowing participants to engage in a two-hour sensory experience within the forest environment. This includes activities such as stacking leaves and stones, closing their eyes to listen to sounds, engaging in physical stretches, blindfolded tree identification, connecting with tree companions, creating earth mandalas, and partaking in tea ceremonies and sharing insights.
41010072|NCT02896127|DRUG|Secukinumab|"Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment."
41326774|NCT02182297|DRUG|BI 201335 NA in single rising doses|
41480104|NCT03444272|DRUG|Sofosbuvir and Daklatasuvir|HCV Treatment (Sofosbuvir and Daklatasuvir)
41326775|NCT02182297|DRUG|Placebo|
41326776|NCT04624217|DRUG|SHR-1701|PDL1/TGFβ
41326777|NCT05684588|DIAGNOSTIC_TEST|Magnetic Resonance|After enrollment a Magnetic Resonance without medium contrast, at 1 year from previous hospitalization
41326778|NCT06528210|DRUG|Gonadotropin Releasing Hormone Agonists and Antagonists|Given PO, IM, Sub-Q injection or Sub-Q implant
41326779|NCT06528210|DRUG|Bicalutamide|Given PO
41326780|NCT06528210|PROCEDURE|Biopsy|Undergo prostate biopsy
41326781|NCT06528210|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41326782|NCT06528210|PROCEDURE|Computed Tomography|Undergo CT scan
41326783|NCT06528210|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41326784|NCT06528210|BIOLOGICAL|Pembrolizumab|Given IV
41326785|NCT06528210|OTHER|Questionnaire Administration|Ancillary study
41326786|NCT06528210|RADIATION|Radiation Therapy|Undergo radiation therapy
41326787|NCT06528210|PROCEDURE|Bone Scan|Undergo bone scan
41326788|NCT03165864|DRUG|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
41326789|NCT03165864|OTHER|Placebo|Saline .9%
41326790|NCT01309867|DEVICE|Investigational Toric Lens|Bausch \& Lomb investigational toric contact lens worn on a daily wear basis for 2 weeks.
41326791|NCT01309867|DEVICE|PureVision Toric Lens|Currently marked Bausch \& Lomb PureVision Toric Lens worn on a daily wear basis for 2 weeks.
41480105|NCT01494441|PROCEDURE|rhBMP-2/BCP|The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
41480106|NCT01494441|DEVICE|rhBMP-2/BCP/TSRH® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
41480107|NCT01494441|DEVICE|Autograft/TSRH® Spinal System|The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
41480108|NCT03648242|BEHAVIORAL|Interruptive Clinical Decision Support|"An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~* One-click addition of elevated BMI to problem list~* Reminder to utilize Suggested PowerPlan~* One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~* Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~* Links to existing, evidence-based childhood obesity screening and management guidelines"
41480109|NCT01706848|OTHER|Celotres|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
41010073|NCT02896127|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
41010074|NCT04647058|PROCEDURE|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
41326792|NCT04526067|BEHAVIORAL|CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home on weekly visits to cue adaptive behaviors and establish healthy habits.
41326793|NCT04526067|BEHAVIORAL|R-CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home using remote weekly visits to cue adaptive behaviors and establish healthy habits.
41326794|NCT05186987|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
41326795|NCT05186987|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
41010075|NCT04647058|PROCEDURE|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
41326796|NCT04759677|OTHER|Exercise with active video games|45-minute exercise in which individuals played pre-selected games from Nintendo Wii while keeping in mind their functional level, skills and needs. Four Nintendo Wii games were chosen: Island Cycling, Tilt Table Balance Board, Soccer Heading and Boxing. Each and every individual played these given four games consecutively in one session.
41326797|NCT02540772|BEHAVIORAL|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
41326798|NCT05278286|BEHAVIORAL|Crawling stimulation with the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5 minutes session everyday at home with a trained therapist. During each session the infant is prone wrapped on the crawliskate and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the therapist.
41326799|NCT05278286|BEHAVIORAL|Tummy time without the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5-minutes session everyday at home with a trained therapist. During each session the infant is prone directly ona mattress and cannot benefit from any assistance from the therapist to move forward.
41480110|NCT01706848|OTHER|Surgical Closure by Standard of Care|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
41480111|NCT04719741|OTHER|Parallel Assignment|Prospective, Triple blinded, randomized, controlled trial
41010076|NCT01086579|DEVICE|IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)|Coronary Artery Bypass Graft (CABG)
41326800|NCT03487328|PROCEDURE|Sacrospinous-Sacrotuberous fixation|Sacrospinous-Sacrotuberous fixation
41326801|NCT02111512|DRUG|Administration of Live attenuated influenza vaccine (LAIV)|
41326802|NCT01804114|PROCEDURE|Pain management following hernia repair|Continuous infusion of local anesthetic via pain pump following hernia repair
41326803|NCT01804114|PROCEDURE|Placebo for pain management following hernia repair|Continuous infusion of placebo via pain pump following hernia repair
41480112|NCT05339269|PROCEDURE|Laparoscopic splenectomy|The laparoscopic splenectomy is performed by the same surgical team.
41010077|NCT01086579|DEVICE|Taxus (Paclitaxel eluting stent)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
41010078|NCT03394391|BEHAVIORAL|Daily ART-adherence SMS reminder|Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
41010079|NCT03394391|BEHAVIORAL|Standard Adherence Counselling/Patient experience group chat|"All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges."
41010080|NCT01544972|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
41010081|NCT01544972|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
41154595|NCT00040521|DRUG|Recombinant Human Interleukin-11 (rhIL-11)|
41154596|NCT04466917|DRUG|ABP 215|ABP 215 will be administered at a dose of 15 mg/kg IV
41326804|NCT04942119|OTHER|Multifactorial intervention|"1. Correction of magnesium and/or potassium deficit and the underlying disease.~2. Education reinforcing optimal diet and exercise, in addition to, post-nutrition assessment , diabetes self-care activities and adherence will be given at each follow up visit by a specialized dietitian.~3. Comprehensive medication therapy management by clinical pharmacist, and medication adherence will be measured by adherence questionnaire as well as fixed medication possession ratio (FMPR)."
41326805|NCT02486367|DRUG|Clopidogrel|Standard ADP receptor blockade
41326806|NCT02486367|DRUG|Ticagrelor|High potency ADP receptor blockade
41326807|NCT05165550|DRUG|Elsulfavirine|Elsulfavirine (Elpida®) 20 mg capsules for oral administration
41480113|NCT02752841|DIETARY_SUPPLEMENT|Nutritional vitamin D repletion and maintenance|Ergocalciferol (50,000 IU weekly for 12 weeks) for vitamin D repletion, ergocalciferol (50,000 IU monthly) or cholecalciferol (1000 IU daily) for maintenance of vitamin D
41480114|NCT04587102|OTHER|whole body viberation|vibration training in the form of whole body vibration for 20-30 minutes per session, 3 sessions per week for 8 weeks. The vibration training was performed on a whole body vibration platform
41480115|NCT04587102|OTHER|Traditional program(balance exercises and resisted exercises)|balance exercises and resisted exercises
41480116|NCT02180698|OTHER|Laboratory Biomarker Analysis|Correlative studies
41326808|NCT06271928|DRUG|Yijing Keli|Once enrolled, participants will be administrated Yijing Keli
41326809|NCT05871593|GENETIC|Molecular genetic diagnostic|With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.
41480117|NCT02180698|RADIATION|Radiation Therapy|Undergo radiation therapy
41326810|NCT00030355|DRUG|homoharringtonine|
41480118|NCT02180698|DRUG|TLR4 Agonist GLA-SE|Given intratumorally
41480119|NCT04380675|OTHER|Music|Music listening during ESWL
41480120|NCT05845294|PROCEDURE|Routine Care|Routine care for patients undergoing colorectal cancer stoma
41480121|NCT05845294|PROCEDURE|Short-term structured psychological Care|Short-term structured psychological care for colorectal cancer stoma patients based on conventional care
41326811|NCT00030355|PROCEDURE|chemotherapy|
41326812|NCT02451540|RADIATION|HRCT scan|HRCT scan of thorax, at baseline and after 3 months
41480122|NCT04065776|RADIATION|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
41480123|NCT03932123|DRUG|Piperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin，cefotaxime|Efficacy and safety of antibiotics
41480124|NCT05392374|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2
41480125|NCT04636242|PROCEDURE|Skin Biopsy|A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
41010082|NCT02782650|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: focus group interviews to further perform in-depth exploration of prenatal counseling preferences"
41326813|NCT02451540|DRUG|Placebo of Roflumilast|Placebo, once a day in the morning during 3 months
41326814|NCT02451540|DRUG|Roflumilast|Roflumilast, once a day in the morning during 3 months
41480126|NCT04636242|DRUG|5 Aminolevulinic Acid + Phototherapy|5 aminolevulinic acid solution will be placed on the skin of the shoulder and the participant will receive Photodynamic therapy on the morning of surgery
41480127|NCT03106558|DEVICE|Total Knee Arthroplasty using Manual Instrumentation|
41154597|NCT04466917|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg IV
41326815|NCT01585493|OTHER|Treatment as usual|Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary
41154598|NCT04466917|DRUG|Paclitaxel|Paclitaxel will be administered 175 mg/m2 IV
41326816|NCT01585493|BEHAVIORAL|Care coordinator|Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
41480128|NCT03106558|DEVICE|Total Knee Arthroplasty using Robotic Arm|
41480129|NCT02786719|DRUG|Topotecan|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
41480130|NCT02786719|DRUG|Cyclophosphamide|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
41480131|NCT02786719|DRUG|Cisplatin|Cycle 3+5 (given daily x 4 days)
41480132|NCT02786719|DRUG|Etoposide|Cycle 3+5 (given daily for 3 days)
41480133|NCT02786719|DRUG|Vincristine|Cycle 4+6 (given daily for 3 days)
41480134|NCT02786719|DRUG|Cyclophosphamide|Cycle 4+6 (given daily for 2 days)
41480135|NCT02786719|DRUG|Doxorubicin|Cycle 4+6 (given daily for 3 days)
41480136|NCT02786719|DRUG|Sargramostim|Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
41480137|NCT00302302|DRUG|L-arabinose|
41480138|NCT02214420|DRUG|Simeprevir|
41480139|NCT02214420|DRUG|Sofosbuvir|
41480140|NCT02214420|DRUG|Ribavirin|
41480141|NCT02249221|BIOLOGICAL|Quadrivalent cell-culture based influenza vaccin|GC3106, 0.5ml, intramuscular, a single dosing at Day 1
41480142|NCT02249221|BIOLOGICAL|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
41480143|NCT03505814|DEVICE|High Flow Nasal Cannula Oxygen therapy (OPTIFLOW®)|High flow and humidified oxygen support for new borns and young infants for post-extubation care
41480144|NCT03505814|DEVICE|Conventional oxygen therapy|conventional oxygen support for new born and young infants in post-extubation care
41010083|NCT04354259|DRUG|Peginterferon Lambda-1A|Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
41326817|NCT01585493|BEHAVIORAL|CHANGE|"Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.~CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change."
41326818|NCT01078519|DRUG|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
41326819|NCT03924310|DEVICE|FeetBack System Active|Commercially available hand prosthesis with feedback device turned on
41010084|NCT04354259|OTHER|placebo|injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
41326820|NCT03924310|DEVICE|FeetBack System Passive|Commercially available hand prosthesis with feedback device turned off
41154599|NCT04466917|DRUG|Carboplatin|Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
41326821|NCT01610206|DRUG|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
41326822|NCT01610206|DRUG|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
41326823|NCT00003735|DRUG|topotecan hydrochloride|given by mouth
41010085|NCT04439240|DRUG|FGFR Inhibitor AZD4547|Given PO
41326824|NCT03742115|DRUG|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
41326825|NCT03742115|DRUG|Dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
41326826|NCT03742115|DRUG|Etoposide|150 mg/m2 weekly
41326827|NCT03742115|DRUG|IVIG|0.5 g/kg, once every 4 weeks
41326828|NCT01948869|DEVICE|Phoenix II (BAY81-2996)|
41326829|NCT01948869|DEVICE|Phoenix I (BAY81-2996)|
41326830|NCT03801811|PROCEDURE|Study of the efficacy of using skin glue in the application of Port a cath|The use of glue as a device in the implantation of central venous catheters has recently been introduced into European clinical practice. It is possible that the surgical incision created for the insertion of the PORT may be subject to complications such as: local bleeding, which if not properly treated may last even a few days, infections or surgical wound outbreaks. This possibility of bleeding occurs more easily in patients suffering from coagulation problems or when appropriate preventive measures have not been taken at the time of implantation of the device. A solution to this problem could be the application of the cyanoacrylate dermal glue on the edges of the surgical wound, after intradermal suture. The glue would have the purpose of sealing the surgical wound so as to immediately seal the skin incision with hemostatic effect and create a potential barrier against bacterial infections.
41326831|NCT05178693|DRUG|ASTX727|Cedazuridine 100mg + 35mg decitabine
41154600|NCT05315817|DEVICE|multiPlus dialysate|Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
41154601|NCT06192797|PROCEDURE|HAIC|administration of gemcitabine and oxaliplatin via the tumor feeding arteries every 3 weeks.
41154602|NCT06192797|DRUG|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
41154603|NCT02115542|DRUG|Regorafenib|Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\<30% fat) breakfast.
41326832|NCT05178693|RADIATION|Lutathera|Peptide receptor radionuclide therapy (PRRT)
41480145|NCT03344978|OTHER|Cardboard Cot Care|Infant maintained in reflective film-lined cot for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. Infant may be moved to incubator or radiant warmer. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
41010086|NCT04891224|OTHER|Pathway Platform mobile app|The pathway platform intervention involves 3 components: 1. The patient facing app which will: a) Gather health information related to depression management and patient-Provider engagement. b) Clinical data collection; PHQ-9, WHO-5, PDQ-D-5, medication adherence and side effects, goal setting and goal tracking. c) Research data; Patient Activation Measure -13\[PAM-13\], CollaboRATE, and Work and Social Adjustment Scale \[WSAS\]. 2. Electronic Medical Record Integration - a) Data collected in the app is accessible to care team in real time. b) Provide a longitudinal summary to assist in decision making and depression management. 3. Educational Scaffolding - a) Training program describing how the Pathway Platform can support care team members in clinical processes related to measurement-based care and shared-decision making. b) Includes ongoing feedback with up to three audit cycles.
41326833|NCT06507085|RADIATION|Radio-guided interventions to correct heart rhythm disorders|"All patients in the cohort will be undergoing one of the following radio-guided procedures :~* Insertion of a single-chamber pacemaker with lead~* Insertion of a dual-chamber pacemaker with lead~* Implantation of a multi-site pacemaker~* Implantation of a single-chamber endovascular defibrillator~* Implantation of a dual-chamber endovascular defibrillator~* Placement of multi-site defibrillator~* Typical Primary Atrial Flutter Ablation: Cavotricuspid Isthmus only~* Primo Ablation tachycardia by intra nodal re-entry~* Accessory pathway ablation~* Paroxysmal atrial fibrillation ablation (4 pulmonary veins only, all technologies combined~* Primo Ablation Persistent atrial fibrillation (4 pulmonary veins ± lines ± substrate"
41326834|NCT02016898|PROCEDURE|Placement of the sponge|
41326835|NCT02016898|DRUG|Mitomycin-C|
41326836|NCT03024671|OTHER|Patch test application|test patch with cosmetic product will be applied to the back
41326837|NCT00028106|DRUG|[131]I-MIBG|
41326838|NCT00028106|DRUG|6-[18F]Fluorodopamine|
41326839|NCT00028106|DRUG|[123]I-MIBG|
41326840|NCT00897936|GENETIC|DNA methylation analysis|
41326841|NCT00897936|GENETIC|comparative genomic hybridization|
41326842|NCT00897936|GENETIC|fluorescence in situ hybridization|
41326843|NCT00897936|GENETIC|microarray analysis|
41326844|NCT00897936|GENETIC|polymerase chain reaction|
41326845|NCT00897936|OTHER|diagnostic laboratory biomarker analysis|
41326846|NCT00897936|OTHER|immunologic technique|
41326847|NCT02375984|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Patients will receive an IV adoptive transfer of at least 10\^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
41326848|NCT04806633|DRUG|Dapagliflozin 5mg|Patients randomized in this arm will receive dapagliflozin at a dose of 5mg once daily.
41326849|NCT04806633|DRUG|Placebo|Patients randomized in this arm will receive placebo.
41326850|NCT05400356|PROCEDURE|On-pump valve surgery or CABG|On-pump valve surgery or coronary arterial bypass grafting
41480146|NCT03344978|OTHER|Incubator Care|Infant maintained in standard incubator for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
41326851|NCT04217083|DIAGNOSTIC_TEST|Breath sampling|The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes
41326852|NCT00871572|DRUG|LY2409021|4 capsules by mouth taken once daily for 12 weeks
41326853|NCT00871572|DRUG|Placebo|4 capsules by mouth once daily for 12 weeks
41326854|NCT02640066|OTHER|acupuncture|
41326855|NCT03086681|DRUG|Endostar|Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles
41326856|NCT03086681|DRUG|DDP|DDP: 40mg /m2，per week, for 5 cycles
41154604|NCT01033279|OTHER|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
41326857|NCT03713606|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
41326858|NCT03396978|OTHER|GnRHag|Ovarian Hormone Suppression - the purpose of the intervention is not to study the drug, but the impact of the loss of ovarian hormones.
41326859|NCT02372097|DRUG|SYR-472|SYR-472 25mg, 50mg
41326860|NCT03436771|GENETIC|JCAR017|No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
41326861|NCT03436771|GENETIC|JCARH125|No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
41326862|NCT01249534|OTHER|gastroesophageal cancer surgery|gastroesophageal cancer surgery
41326863|NCT02394808|DEVICE|senofilcon A|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
41326864|NCT02394808|DEVICE|lotrafilcon B|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
41326865|NCT05069805|PROCEDURE|PECS II block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to PECS II block
41326866|NCT05069805|PROCEDURE|ESP block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to ESP block
41326867|NCT00013455|DEVICE|Hearing|
41480147|NCT01221246|DRUG|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
41480148|NCT01221246|DRUG|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
41480149|NCT05613725|OTHER|Blood sample collection|Blood sample collection
41010087|NCT04833166|DEVICE|CMAC D-blade videolaryngoscope with full or partial glottic view|Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms
41010088|NCT02544893|DRUG|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
41010089|NCT02544893|DRUG|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
41326868|NCT05222295|OTHER|Supervised Pulmonary Telerehabilitation|For pulmonary rehabilitation to be applied in the simultaneous telerehabilitation method, digital blood pressure measurement device, digital finger pulse oximeter device will be given to severe COPD patients for safe exercise and they will be informed about confidence intervals and how to use saturation and heart rate monitors. The relevant program and points to be considered will be delivered to the patients in the form of an online PDF brochure.
41326869|NCT05222295|OTHER|Cognitive Telerehabilitation|These patients will be asked to do a standardized pulmonary telerehabilitation program three times a week for 8 weeks by watching videos consisting of commands and exercise videos transmitted to them, some of them by actively doing, imagining.
41326870|NCT02877849|DEVICE|MRI: Brain Imaging data collection|This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
41326871|NCT06507345|OTHER|Opioid Analgesia (OA) [Multimodal analgesia including opioid drugs]|In line with current standard care, discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs given at regularly scheduled intervals) and opioid tablets 'as needed' for breakthrough pain (i.e., pain that erupts while patients are already taking analgesics). Non-pharmacological pain interventions (i.e., icepacks, music, meditation.) may be recommended by some surgeons as part of standard practice. Given the pragmatic nature of the trial, the specific around-the-clock analgesia and rescue opioid regimens and other non-pharmacological interventions will be determined by the patient's surgeon discretion considering the breast procedure undertaken, co-morbidities, and patient preference.
41326872|NCT06507345|OTHER|Opioid-Free Analgesia (OFA) [Multimodal analgesia not including opioid drugs]|Discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs). In case of breakthrough pain, rescue analgesia may be provided by (1) using evidence-based non-pharmacological pain interventions (i.e., icepacks, music, and meditation), (2) adding non-opioid drugs not included in the initial regimen, or (3) switching drugs targeting individual variances in analgesia response. The specific around-the-clock and rescue OFA regimens will be determined by the patient's surgeon considering the type of procedure, co-morbidities, and patient preference.
41326874|NCT03487393|DEVICE|magnetic facial nerve stimulation|Magnetic stimulation of facial nerve.
41326875|NCT00037544|DRUG|ReFacto AF|
41326876|NCT03336762|DIAGNOSTIC_TEST|Intra spinal pressure monitoring|Sub dural pressure monitoring using a FDA approved intracranial pressure monitor
41326877|NCT03336762|DIAGNOSTIC_TEST|Intra spinal microdialysis monitoring|Sub arachnoid microdialysis monitoring using a FDA approved hepatic microdialysis catheter
41326878|NCT03028584|BEHAVIORAL|Survey|Subjects (cancer patients and clinicians) will complete up to 2 surveys.
41326879|NCT00769808|DEVICE|Bausch & Lomb 217z Excimer Laser|LASIK correction of myopia and myopic astigmatism
41326880|NCT02406053|GENETIC|oxidative and antioxidant biomarkers|the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
41326881|NCT05363670|DRUG|ARS-1|ARS-1
41010090|NCT02544893|DRUG|serum physiologic|21 ml serum physiologic is applied paravertebral space
41010091|NCT06453993|OTHER|Exhaled VOC breath test|To determine longitudinal variation in exhaled VOC concentrations during intended curative therapy for EC cancer.
41010092|NCT00064441|DRUG|OPC-6535 Tablets (drug)|
41010093|NCT04471584|DEVICE|Insertion of ILR device|All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.
41010094|NCT06139952|DRUG|Atorvastatin 80mg|Atorvastatin 80mg taken Once before coronary angiography
41010095|NCT06139952|DRUG|N-acetyl cysteine|200mg 3 times daily 2 days before coronary angiography
41010096|NCT06139952|OTHER|Normal Saline|adequate hydration using Normal Saline (1ml/kg/hr)
41010097|NCT05413928|BEHAVIORAL|Time Restrictive Eating- late|Eating window will be 10 hours or less, starting 3 hours after waking up. Same monitoring as Baseline phase.
41010098|NCT05413928|BEHAVIORAL|Time Restrictive Eating- early|Eating window will be 10 hours or less, starting 30 min after waking up. Same monitoring as Baseline phase.
41010099|NCT05413928|BEHAVIORAL|Time Restrictive Eating- early with early caloric intake|Same as TRE-early, but concentrating caloric intake early in the eating window Same monitoring as Baseline phase.
41326882|NCT05363670|DRUG|Albuterol MDI|180 mcg
41326883|NCT05363670|DRUG|Placebo|Placebo
41326884|NCT01659268|OTHER|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
41480150|NCT02651142|PROCEDURE|Patients receive SLNB|Patients receive sentinel lymph node biopsy
41480151|NCT03051139|BEHAVIORAL|Multi-component LTVV implementation strategy|Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
41480152|NCT02412462|DRUG|AB-16B5|
41326885|NCT01659268|OTHER|Exhibition-dialogued class|"The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.~Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes."
41326886|NCT02255617|BIOLOGICAL|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donors
41326887|NCT05987189|DIAGNOSTIC_TEST|miLungDx|At study enrollment a blood sample will be drawn prior to any invasive diagnostic study or treatment. On this blood sample a novel lung cancer test relying on small RNA signatures will be performed and evaluated.
41326888|NCT03625141|DRUG|Cobimetinib|60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.
41326889|NCT03625141|DRUG|Atezolizumab|"Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1)."
41326890|NCT03625141|DRUG|Vemurafenib|Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
41326891|NCT03258632|BEHAVIORAL|Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
41326892|NCT06145893|DRUG|Hemay005|Hemay005 tables 60mg bid p.o;
41326893|NCT06145893|DRUG|Hemay005|Hemay005 tables 45mg bid p.o;
41326894|NCT06145893|DRUG|Placebo|placebo to Hemay005 tables bid p.o
41480153|NCT04922684|BEHAVIORAL|Mimic facial expressions|16 times (4 times a week, last 4 weeks) of mimicking facial expressions.
41480154|NCT00325208|DEVICE|partial-vacuum milk bottle|
41480155|NCT00325208|DEVICE|anti-vacuum milk bottle|
41326895|NCT04833920|DEVICE|transcranial dirrect current brain stimuation|tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days (one session /day),
41480156|NCT00602134|DRUG|6-Mercaptopurine|
41480157|NCT00317642|DRUG|clofarabine (IV formulation)|clofarabine (IV formulation) infusion 40mg/m\^2 / day up to 3 cycles
41480158|NCT00317642|DRUG|placebo|placebo (sodium Chloride) 1-hour IV infusion
41480159|NCT00317642|DRUG|cytarabine|cytarabine IV infusion 1g/m\^2/day for up to 3 cycles
41010100|NCT05413928|OTHER|Macronutrient-controlled meals|Meals with a determined amount of protein, carbohydrates, and fat.
41010101|NCT03289104|DEVICE|Steel Wires|Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
41010102|NCT03289104|DEVICE|ZipFix Sternal Closure System|Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
41480160|NCT01904006|PROCEDURE|New Culture Condition|Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
41480161|NCT01904006|PROCEDURE|Standard Culture Condition|Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
41480162|NCT00772135|DRUG|sildenafil citrate|capsule of 50 mg , 90 minutes before exercise study
41480163|NCT04892121|OTHER|Prevention exercises|Participants will have to follow a warm-up prevention program (15 minutes) twice a week
41480164|NCT00384007|PROCEDURE|Hydrodiscectomy with Spinejet|
41480165|NCT05495113|DEVICE|YMS-201B (Device: Mind STIM)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
41480166|NCT05495113|DEVICE|Sham stimulation using YMS-201B|Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
41480167|NCT03858426|OTHER|no intervention|no intervention
41480168|NCT03827434|DEVICE|Continuous glucose Monitoring Devices and Clarity Software|Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
41480169|NCT03827434|OTHER|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
41010103|NCT00503685|BIOLOGICAL|IMC-A12|10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
41010104|NCT00503685|BIOLOGICAL|cetuximab|Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
41010105|NCT04906642|DEVICE|Next Science|Solution is a clear, colorless, aqueous solution that is used to remove debris, including microorganisms, from wounds via hydrodynamic shear across the wound. This aids in the removal of foreign material such as, microorganisms, dirt, and debris.
41480170|NCT03964636|DIAGNOSTIC_TEST|OCT-A (optical coherence tomography)|Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
41154605|NCT03045549|DEVICE|Digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session"
41154606|NCT03045549|OTHER|Conventional home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-6) Soft tissue massage Active assisted mobilization of the hip joint to increase range of motion (avoiding internal rotation and adduction) Gait training with bilateral assistive devices Isometric exercises progressing to open chain, low-impact, concentric exercises with strengthening of hip abductors and flexors Ice pack application STAGE 2 (weeks 7-8) Soft tissue massage Gait training with progressive withdrawal of assistive devices Balance exercises with progression to one-leg support Open-chain strengthening exercises against resistance with progression to closed-chain exercises Ice pack application"
41154607|NCT06210178|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI scans including abdominal 4D Flow MRI.
41154608|NCT01233492|DRUG|boron phenylalanine|
41010106|NCT04906642|OTHER|Standard of Care|Normal Saline will be used in place of Next Science for irrigation
41010107|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
41010108|NCT00827411|DEVICE|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
41010109|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
40809665|NCT05910372|OTHER|Color Comparison Task|Participants are presented with a series of colored squares and are instructed to compare the colors of two sequentially presented stimuli.
40809666|NCT05910372|OTHER|N-back Task|Participants are presented with a sequence of letters and they must indicate whether the current stimulus matches the one presented 2 steps back in the sequence.
41154609|NCT01233492|DRUG|mannitol|
41154610|NCT01233492|OTHER|biologic sample preservation procedure|
41154611|NCT01233492|RADIATION|radiation therapy treatment planning/simulation|
41154612|NCT05465499|PROCEDURE|ERAS|This study is a cross-sectional observational study by distributing questionnaires regarding the readiness to implement ERAS at Dr Soetomo General Hospital to the subjects, so there is no treatment whatsoever on the subjects.
41480171|NCT03438539|BEHAVIORAL|Normative Feedback|Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
41480172|NCT03438539|BEHAVIORAL|Inhibitory Control Training|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control.
41480173|NCT03438539|BEHAVIORAL|Working Memory Training|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task.
41010110|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
41010111|NCT00827411|DRUG|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
41010112|NCT01049724|OTHER|Tear collection|Tear collection
41010113|NCT02932397|DRUG|Intravenous dose of 0.5 mg/kg of propofol|
41010114|NCT02932397|DRUG|Intravenous dose of 0.05 mL/kg of saline solution|
41010115|NCT00554749|BEHAVIORAL|Interventions at home, in the kindergarten/school|Weekly interventions including behavior techniques (stimulus fading)
41010116|NCT03057145|DRUG|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
41010117|NCT03057145|DRUG|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
41010120|NCT02888028|PROCEDURE|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
41010121|NCT02888028|OTHER|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
41010122|NCT06250101|BEHAVIORAL|Enhanced Conversational Recast treatment|In the context of child-friendly activities, the clinician prompts the child to attempt to use the grammatical form targeted in the treatment. The clinician immediately restates the child's attempt (i.e., the recast), correcting any ungrammatical elements. Clinicians elicit and recasts 24 utterances per session.
41010123|NCT04524403|DRUG|Miricorlilant|Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing
40809672|NCT05851534|BEHAVIORAL|Preoperative optimisation program|Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
40809673|NCT02257528|OTHER|Laboratory Biomarker Analysis|Correlative studies
41010124|NCT04524403|DRUG|Miricorlilant|Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing
41010125|NCT04524403|DRUG|Placebo|Placebo for once-daily oral dosing
40809674|NCT02257528|BIOLOGICAL|Nivolumab|Given IV
41154613|NCT04809545|OTHER|Acusticare|Acusticare is an internet connected speaker which delivers an environmental intervention by playing sounds to adjust the soundscape in the room.
41154614|NCT04809545|OTHER|Treatment as usual|Usual care provided on the Specialized Dementia Unit
41154615|NCT05401201|DEVICE|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
41154616|NCT05401201|OTHER|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self care.
41154617|NCT00759681|DEVICE|ArterX Surgical Sealant|Apply at the suture site.
41154618|NCT00759681|DEVICE|Gelfoam and Thrombin|Apply at the suture site.
41010126|NCT01026870|DRUG|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
41010127|NCT01026870|DRUG|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
41010128|NCT01172691|PROCEDURE|Inhaled Nitric Oxide (iNO)|iNO or placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
41010129|NCT01179594|DRUG|entecavir|0.5 mg orally daily, 24 weeks (weeks 12-36)
41010130|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 48 weeks
41326896|NCT05779605|DEVICE|Home-based training|Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.
41154619|NCT00662883|DRUG|PMI-150 (intranasal ketamine HCl); mometasone furoate|"* 1 dose PMI-150 (intranasal ketamine HCl); day 1~* mometasone furoate, daily; days 2-15~* 1 dose PMI-150 (intranasal ketamine HCl); day 15"
41154620|NCT02065726|DIETARY_SUPPLEMENT|Whey protein|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins
41154621|NCT02065726|OTHER|Nutritional counseling|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
41154622|NCT00102271|DRUG|Oxypurinol|
41010131|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 96 weeks
41010132|NCT01179594|DRUG|placebo|orally daily, 24 weeks (weeks 12-36)
41010133|NCT04828655|BEHAVIORAL|Use of a mobile application based on machine learning with the aim of improving health and body composition parameters.|Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
41154623|NCT00102271|DRUG|Sodium Nitrite|
41154624|NCT02316821|DRUG|RTA 402|
41154625|NCT02316821|DRUG|Placebo|
41154626|NCT06344949|DRUG|Ciprofol|The sedation before tracheal intubation with Ciprofol
41154627|NCT06344949|DRUG|Propofol|The sedation before tracheal intubation with Propofol
41154628|NCT00441493|DRUG|fluvastatin|
41154629|NCT01149499|DRUG|Valacyclovir|1000 mg Tablet
41154630|NCT01149499|DRUG|Valacyclovir|1000 mg Tablet
41154631|NCT00529555|DRUG|minocycline HCl 2.1%|Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
41154632|NCT00529555|PROCEDURE|Scaling and root planing|scaling and root planing
41010134|NCT00968110|DRUG|omalizumab|Dosing table established for omalizumab
41010135|NCT01455675|DRUG|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
41010136|NCT01455675|DRUG|Placebo|Placebo, 70 ml gargling solution, once daily
41010137|NCT02268097|PROCEDURE|Patellar resurfacing with freehand technique|Preparing patellar resurfacing during total knee arthroplasty with freehand
41154633|NCT02642471|PROCEDURE|no systematic pelvic lymphadenectomy|systematic pelvic lymphadenectomy is omitted in surgical treatment
41154634|NCT00390936|DRUG|Brivanib|Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
41154635|NCT02325752|OTHER|Intervention|"A multidisciplinary team delivered the transitional care program.~Our transitional care program focused on four key areas:~1. Post discharge surveillance of the patient to ensure adherence to care plans.~2. Coordination of follow-up visits with specialist care providers.~3. Patent education and care giver training.~4. Activation of community and social services.~Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge."
41010138|NCT02268097|PROCEDURE|Patellar resurfacing with resection guide technique|Preparing patellar resurfacing during total knee arthroplasty with a resection guide
41010139|NCT03414242|OTHER|Cervical spine musculature|Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
41010140|NCT03240627|DRUG|LH-8|LH-8 cutaneous solution
41326897|NCT05779605|DEVICE|Center-based training|Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.
40809695|NCT06253195|DRUG|BGB-43395|Administered orally.
40809696|NCT06253195|DRUG|Fulvestrant|Administered via intramuscular injection.
40809697|NCT06253195|DRUG|Letrozole|Administered orally.
41154636|NCT04721132|BIOLOGICAL|Atezolizumab|Given IV
41154637|NCT04721132|BIOLOGICAL|Bevacizumab|Given IV
41154638|NCT04721132|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40809701|NCT06655181|DEVICE|Respiratory Muscle Training|Expiratory muscle training will be performed with POWERbreathe EX1 Medic (POWERbreathe®) device and inspiratory muscle training will be performed with POWERbreathe Medic Classic device.
40809702|NCT06655792|OTHER|Educational Program on Mental Illness Stigma Reduction|The intervention consists of an 8-session educational program designed to reduce stigma towards mental illness among primary healthcare providers. The program includes lectures and multimedia presentations on mental health, stigma, and its effects. It engages participants in role-playing exercises to simulate the experience of stigma and improve communication skills. Group discussions allow participants to reflect on personal beliefs and attitudes, and case studies provide real-world examples of stigma and intervention strategies. The program spans four days, with two sessions per day, each lasting 50-60 minutes.
40809703|NCT06655558|DEVICE|custom knee orthosis|The custom knee orthosis will be worn for 8 weeks.
41154639|NCT00571558|DRUG|aminolevulinic acid hydrochloride|Given PO
41154640|NCT00571558|DRUG|photodynamic therapy|Undergo photodynamic therapy
40809706|NCT06655363|OTHER|Anatomical description|Anatomical description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
40809707|NCT06655363|OTHER|Radiological (MRI) description|Radiological (MRI) description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
41010141|NCT03240627|DRUG|Placebo|Placebo cutaneous solution
41010142|NCT02472756|DRUG|Chemotherapy|The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
41010143|NCT02472756|DRUG|Rituximab|The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
41010144|NCT04862091|DRUG|Abiraterone Acetate Tablets (I)|Abiraterone Acetate Tablets (I)
41010145|NCT04862091|DRUG|ZYTIGA®|ZYTIGA®
41010146|NCT03509129|BEHAVIORAL|TECH (Technology)|"Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.~Device: Fitbit Alta HR"
41010147|NCT03509129|BEHAVIORAL|TECH+COMP (Technology + Competition)|"Participants will receive the same intervention components as the TECH group, as well as a team competition. The competition will be based on the following two aspects: total daily steps accumulated relative to group size and total number of points retained for achieving weekly physical activity challenges.~Device: Fitbit Alta HR"
41010148|NCT01531959|DRUG|Midodrine|Patients will be randomized to blinded to 20 mg of midodrine
41010149|NCT01531959|DRUG|Placebo|Patients will be randomized to blinded placebo control
41326898|NCT00798577|DRUG|Vigamox Ophthalmic Solution|Moxifloxacin 5mg/mL 3 times daily for 7 days
41326899|NCT00798577|DRUG|BSS placebo|Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
41326900|NCT03230617|DEVICE|Mechanical ventilator|Mechanical ventilation, in the healthcare setting or home, helps patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide. Depending on the patient's condition, mechanical ventilation can help support or completely control breathing.
41010150|NCT02036034|DEVICE|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
41154641|NCT00571558|OTHER|laboratory biomarker analysis|Correlative studies
41154642|NCT06406387|DIAGNOSTIC_TEST|ATRX/DAXX immunohistochemistry|Immunohistochemistry will be performed using an Autostainer Leica (Leica Biosystems) according to the manufacturer's instructions. Four μm formalin-fixed paraffin-embedded sections will be immunostained with antibodies for Cytokeratin AE1/AE3 (AE1-AE3, 1:100 dilution, Novocastra/United Kingdom) Chromogranin A (DAK-A3, 1:2500, Dako/Denmark), and Synaptophysin (27G12, 1:100, Novocastra), Ki67 (MIB1, 1:100, Dako/Denmark), ATRX (1:400, Sigma-Aldrich), DAXX (1:200, Sigma-Aldrich). After antigen retrieval, immunostaining will be performed in an automated Bond instrument (Vision-Biosystem, Leica, Milan, Italy) using a sensitive peroxidase-based 'Bond polymer Refine' detection system.
41010151|NCT02036034|DEVICE|warming blanket|warming blanket placed on torso of patient under the drape.
41154643|NCT06146790|PROCEDURE|endovascular treatment|For the subjects randomized to endovascular treatment (EVT) treatment initiation is defined as the date and time of arterial puncture. Ideally, femoral artery puncture will occur within 30 minutes of randomization and no longer than 60 minutes after the completion of the qualifying imaging. Treatment initiation (arterial puncture) must occur before 24 hours since the subject was last known well.Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two (2) hours of arterial access. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
41154644|NCT06146790|OTHER|Standard medical management|Standard medical management
41154645|NCT05876364|BIOLOGICAL|QTP104 1ug|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
41154646|NCT05876364|BIOLOGICAL|QTP104 5ug|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
41154647|NCT05876364|BIOLOGICAL|QTP104 25ug|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
41326901|NCT03852121|BEHAVIORAL|Bibliotherapy|"Bibliotherapy is the use of reading materials for therapeutic benefits. In this study, an evidence-based modified manual will be used as the reading material. The manual adopts the self-directed problem-solving approach to dementia caregiving, examples of how other caregivers solve the specific problem for each chapter is included in the corresponding chapter. Bibliotherapy also involves guided learning by reading written information, enabling caregivers to solve their caregiving problems step-by-step, so telephone coach is designed to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves."
41326902|NCT05106218|DEVICE|SurroundScope|The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
41326903|NCT05106218|DEVICE|Standard Laparoscope|The procedure will be performed according to the institution's standard of care, using the Standard laparoscope for visualization.
41326904|NCT00547898|DRUG|Crofelemer 125 mg|Crofelemer 125 mg
41326905|NCT00547898|DRUG|Crofelemer 250 mg|Crofelemer 250 mg
41326906|NCT00547898|DRUG|Crofelemer 500 mg|Crofelemer 500 mg
41326907|NCT00547898|DRUG|Placebo|Placebo
41326908|NCT05521464|OTHER|cast|Application of a short arm cast from just below the elbow to the finger's knuckles. The cast was from a Plaster of Paris bandage over a cotton pad. The participants who received this treatment modality were considered group 1 (control group)
41326909|NCT05521464|OTHER|Robert Jones Bandage|Modified RJ bandage (firmly applied two layers of bulky cotton layers alternating with two layers of elastic bandage in the following order: bandage - cotton - bandage - cotton - bandage). It was applied from below the elbow to the finger's knuckles. The participants who received this treatment modality were considered group 2 (trial group).
41480174|NCT05288036|OTHER|Proprioceptive Neuromuscular Rehabilitation group|The PNF technique was performed in the supine position with the hip joints of the patients in 30° flexion and the lower extremities in semi-flexion. The application was performed in 2 different diagonal and 4 different patterns (flexion-abduction-external rotation/extension-abduction-internal rotation, and flexion-adduction-external rotation/extension-abduction-internal rotation) of the upper extremity. When starting the exercise, the muscles were first brought to their longest position and the patient was asked to move in the direction of the pattern with resistance (concentric contraction) and to maintain this position for 6 seconds at the end of the pattern (isometric contraction). Then, while the therapist was taking the patient's arm to the starting position, the patient was asked to prevent movement (eccentric contraction). All of these moves counted as one repetition. 3 sets of 8-12 repetitions were performed for each pattern.
41010152|NCT00006279|DRUG|Nevirapine|
41010153|NCT02046434|DRUG|Glycerol Phenylbutyrate|
41010154|NCT00002604|DRUG|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
41010155|NCT00002604|DRUG|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
41010156|NCT00002604|DRUG|chemosensitization/potentiation therapy|
41010157|NCT02703103|OTHER|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
41010158|NCT02703103|DEVICE|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
41326910|NCT04051476|OTHER|3-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.
41326911|NCT04051476|OTHER|6-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.
41326912|NCT04051476|OTHER|12-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.
41326913|NCT04051476|OTHER|Warm water footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
41326914|NCT06185413|OTHER|Participatory system dynamics approach|First, local health profiles of children will be collected and used to engage key leaders and stakeholders from intervention communities and municipal administrations in participatory processes. These will be used to develop a systems map of drivers of PA behaviour in schoolchildren aged 6-12 years in the local communities. Second, based on the systems map, stakeholders from the civic and private sectors will be involved in developing and implementing actions to promote healthy PA behaviour through system changes.
41326915|NCT05246241|DEVICE|magnetic resonance imaging|Preoperative magnetic resonance imaging
41326916|NCT03114878|OTHER|TRT / EMDR|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Eye Movement Desensitization and Reprocessing:~This is a scientifically, psychotherapeutic approach, developed in 1987 by Francine Shapiro. EMDR represents a specific method within a wider theoretical model called 'Adaptive Information Processing (AIP)'. Within the treatment bilateral stimulation is used i.e. visual, auditory and tactile stimuli can be used to stimulate both the left - and the right hemisphere."
41326917|NCT03114878|BEHAVIORAL|TRT / CBT|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Cognitive Behavioral Therapy:~CBT is the combination of behavioral therapy with interventions that have been developed from cognitive psychology. The founders of CBT are Aaron Beck and Albert Ellis. The core idea is the assumption that so-called negative cognitions are responsible for dysfunctional behavior. The techniques used in the cognitive behavioral therapy focus on changing the content of these irrational cognitions."
41326918|NCT04257227|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be performed in a dedicated rTMS patient room on the PC unit, where the patient can remain in their bed seated upwards at a 45 degree angle, or seated in a chair.~The stimulation intensity for treatment will be determined by measuring the resting and active motor threshold (rMT and aMT) using single pulse TMS over the motor cortex using standard techniques as in previous trials. Investigators will use left-sided intermittent theta burst stimulation (iTBS). The trained team member will locate the left DLPFC using the BeamF3 technique. For the open-label dose-finding study, this region will be stimulated intermittently at 3 TMS pulses every 200 milliseconds for 2 seconds (i.e. 30 stimulations). This procedure is repeated every 10 seconds for a total duration of 3 minutes during which 600 total pulses are delivered. Participants will receive up to 8 3-minute sessions daily at 45 minute intervals for 5 days (consecutively or in a seven-day window if need be)."
41326919|NCT03574415|DRUG|DWP14012|DWP14012 tablets
41326920|NCT03574415|DRUG|Placebo|DWP14012 placebo-matching tablets
41326921|NCT02790463|BEHAVIORAL|Pharmacist-Led Intervention|Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
41326922|NCT01567891|BIOLOGICAL|NYESO-1c259 T cells|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
41326923|NCT02073903|BEHAVIORAL|Patient Survey|
41326924|NCT02073903|BEHAVIORAL|Provider Survey|
40809709|NCT06655532|BEHAVIORAL|Exercise Program|Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training twice weekly.
41326925|NCT02174861|DRUG|Erenumab|Administered by subcutaneous injection once a month
41326926|NCT03428256|DEVICE|Optiflow and THRIVE technique|Nasal high flow humidified oxygen
41326927|NCT03428256|DEVICE|Standard anaesthetic face mask|Oxygen delivery via an anaesthetic facemask
40809710|NCT06655532|BEHAVIORAL|Usual Care|Patients allocated to this arm will receive standard medical treatment plus explicit recommendations for 12-week home-based moderate-intensity aerobic and strength training. They will also receive a weekly phone call and an in-person monthly visit to monitor exercise training performance.
41010159|NCT01626261|DEVICE|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
41010160|NCT01546948|DRUG|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
41010161|NCT01546948|DRUG|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
41326928|NCT05835713|DRUG|Remimazolam besylate|Remimazolam group is induced general anesthesia using remimazolam besylate injection (0.2mg/kg bolus). General anesthesia is maintained using remimazolam infusion at a rate of 1mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min. After recovering spontaneous respiration during emergence, remimazolam group receive flumazenil injection (0.5 mg)
41010162|NCT01655836|RADIATION|Brachytherapy|Undergo high dose rate brachytherapy
41010163|NCT01655836|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
41010164|NCT01655836|PROCEDURE|Quality-of-life assessment|Ancillary studies
41010165|NCT01655836|OTHER|Questionnaire administration|Ancillary studies
41326929|NCT05835713|DRUG|Propofol|Propofol group is induced general anesthesia using propofol injection (2 mg/kg bolus). General anesthesia is maintained using propofol infusion at a rate of 4-8 mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min.
41010166|NCT06424080|PROCEDURE|laparoscopic partial nephrectomy|cases amenable for partial nephrectomy
41010167|NCT06424080|PROCEDURE|robotic partial nephrectomy|cases amenable for partial nephrectomy
41480175|NCT05288036|OTHER|Progressive Resistance Exercise Group|"Strengthening exercises targeting the upper extremity main muscles were applied to the PRE group with progressive resistance. Dumbbells and sandbags were used as resistance equipment. resistance intensity; 50-80% of a repetition maximum (RM) was determined according to the patient's tolerance. The exercises were applied as 8-12 repetitions and 3 sets. A rest period of 60-90 seconds was allowed between each set. After the 4th week of the training, 1 RM was measured again and the resistance density was updated. The 8 strengthening exercises to be applied were created by taking examples from the literature and in accordance with the Guidelines for implementing exercise programs exercise programs for cancer patients. These exercises are: dumbbell fly, triceps extension, biceps curl up, one-arm bent over row, dumbbell sides rise, lifting the arm forward, wrist curl and side lying shoulder internal -external rotation."
41480176|NCT05288036|OTHER|Control Group|The patients in the control group were instructed to continue their usual daily lives (not changing their physical activity levels, diet, drug use, etc.) until the date of re-evaluation after the initial evaluation. Information was given about the upper extremity normal range of motion exercises that they could apply at home, and a brochure was given.
40809711|NCT06655298|DEVICE|US guided block|"Group Q; (28 patients) Quadratus lumborum block group; patients will receive general anesthesia initially then bilateral QLB type III (anterior subcoastal approach) with a volume of 30 mL of bupivacaine 0.25% for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg) \[9\].~✓ Group E; (28 patients) Erector spinae plane block; patients will receive general anesthesia initially then bilateral ESPB with a volume of 30 mL of bupivacaine 0.25 % for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg"
40809712|NCT06654700|BIOLOGICAL|Recombinant Zoster Vaccine (CHO Cell)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection
40809713|NCT06499415|DRUG|5FU-Calcipotriol|topical 5FU-CAL, twice daily, during 4 or 6 consecutive days, depending on the treatment location
40809714|NCT06499415|DRUG|5-FU 50 MG/ML Topical Cream|topical 5FU, twice daily, 7 days a week, during 4 weeks
41154648|NCT03824145|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is a 16-week cognitive-behavioral intervention that addresses key changes in diet and PA behaviors to promote positive body composition changes.
40809716|NCT05547399|DRUG|Zanubrutinib|Administered orally as a tablet or capsule
41326930|NCT02729077|DEVICE|Pulse Oximetry|Use of pulse oximetry device for 48 hours after surgery.
41326931|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
40809717|NCT06592911|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and cognitive training program and written language training program.
41010168|NCT03979443|PROCEDURE|Discharge on the day of surgery|Patient discharge on the day of the surgery, usually within 6-8 hours after procedure
41480177|NCT01846273|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab
40809718|NCT06597058|DRUG|MAR|Once-daily tablet
41326932|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
41326933|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
41326934|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
41480178|NCT01846273|DRUG|Verteporfin PDT|Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
41010169|NCT06330194|DEVICE|2nd Generation Automated Insulin Delivery (AID) system|The AID system will initially commence delivery by insulin pump post-randomisation without the AID in operation and with predictive low glucose suspend activated for a period of two weeks. Once safety has been established, the autocorrect function can be activated and the setpoint reduced to 5.5 mmol/L. Throughout the study insulin pump uploads will be reviewed twice weekly initially and at least weekly thereafter.
41010170|NCT03120013|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
41010171|NCT03120013|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
41154649|NCT03824145|BEHAVIORAL|Attention Control|The attention control participants will receive a home/work organization intervention:
41154650|NCT00764010|DIETARY_SUPPLEMENT|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
41326935|NCT00210379|DRUG|rituximab|
41326936|NCT00210379|DRUG|CHOP|
41326937|NCT00210379|DRUG|intrathecal methotrexate|
41480179|NCT01846273|DRUG|Sham PDT|Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
41154651|NCT00764010|DIETARY_SUPPLEMENT|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
41480180|NCT04244201|DEVICE|Vaporous Hyperoxia Therapy|1 hour of treatment, 4 times per week
41480181|NCT04099979|OTHER|No Intervention|There is no intervention for this study
41480182|NCT04641793|DEVICE|Motion and Emg Control|"We will consider two methods for integrating motions and EMG signals:~1. Direct methods. Signals extracted from the latent EMG space will directly contribute to the control of the external device. We will integrate EMG and IMU in two ways. In a first scenario, EMG and IMU will be given variable weight in the control. In a second scenario (perturbative method) the distance of ongoing muscle patterns from a desired set of strategies will modulate the mapping from body to cursor motions in the form of assistive (i.e. the cursor moves faster towards the target) or resistive (i.e. the cursor slows down) influences on cursor movement.~2. Indirect Methods. Signals extracted by EMG will modulate the feedback offered to the learner to penalize deviations from desired muscle patterns. When multiple ways to perform a movement are offered by redundancy, (i.e., by the multiplicity of muscles compared to task demands), the brain chooses solutions that minimize noise and uncertainty."
41480183|NCT04323020|DIAGNOSTIC_TEST|CT Perfusion|CT Perfusion
41480184|NCT00028535|BIOLOGICAL|trastuzumab|Given IV
41480185|NCT00028535|DRUG|paclitaxel|Given IV
41480186|NCT00028535|BIOLOGICAL|recombinant interleukin-12|Given SC
41480187|NCT03971578|OTHER|No Intervention Provided|No Intervention Provided
41154652|NCT00764010|DIETARY_SUPPLEMENT|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
41154653|NCT00572299|DRUG|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
41326938|NCT00210379|PROCEDURE|radiotherapy|
41326939|NCT05730374|BEHAVIORAL|Benson's Relaxation technique|Each child in the study group had an individual interview with researchers, who demonstrated the Benson relaxation technique while teaching them. The child was then asked to demonstrate it. sit quietly in a comfortable position in separate room., close eyes, deeply relax all muscles, beginning at the feet and progressing up to the face and breathe through nose. Become aware of breathing pattern. As breathes out, say the word one silently to child. For example, breathe in, and then out, say one, in and out, and repeat one. Breathe easily and naturally. It is Continue for 10 minutes and repeated two times.
41326940|NCT05730374|BEHAVIORAL|Music therapy|"* The child lessen to a Mozart's music, which is played before and throughout the blood transfusion procedure. Ambient noise can be reduced by using headphones. As a result, it is easier to see how the intervention has succeeded.~* This intervention was done using an MP3 player during the blood transfusion procedure and immediately following the completion of the intervention to prevent the transmission of infections headphones were cleaned with disinfectant after each -use."
41326941|NCT01027013|DRUG|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
41326942|NCT01027013|DRUG|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
41326943|NCT01867567|PROCEDURE|abdominal bandage|
41326944|NCT06342570|OTHER|There is no Intervention name to describe.|There is no Intervention name to describe.
41480188|NCT03144817|OTHER|Dialysate Sodium Lowering|Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
40809721|NCT06591572|PROCEDURE|Single-port robotic transanal total mesorectal excision|Rectal resection by transanal TME with single-port robotic surgery
40809722|NCT06591572|PROCEDURE|Laparoscopic transanal total mesorectal excision|Rectal resection by transanal TME with Laparoscopic surgery
41154654|NCT02042170|DRUG|human growth hormone self-injection|
41154655|NCT05658575|DRUG|Dapansutrile|An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
41154656|NCT05658575|OTHER|Placebo Tablet|An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.
41154657|NCT01404377|PROCEDURE|infiltration with ropivacaine solution|Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
41326945|NCT06088407|DRUG|with Tranexamic acid|Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively
41326946|NCT05516160|DIAGNOSTIC_TEST|diagnostic of optical aberrations|diagnostic of optical aberrations with new device
41326947|NCT02807844|DRUG|MCS110|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
41326948|NCT02807844|DRUG|PDR001|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
41326949|NCT02294422|DEVICE|PBP|the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.
41326950|NCT02294422|DEVICE|LOR|
41480189|NCT05499013|DRUG|SLN124|SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).
41480190|NCT05499013|DRUG|Placebo|sodium chloride, solution for injection
41480191|NCT03220126|BIOLOGICAL|LY3074828|Administered IV
41480192|NCT03220126|BIOLOGICAL|LY900021|Administered SC
41480193|NCT04801667|BIOLOGICAL|Coronavac|The CoronaVac is manufactured by Sinovac Life Sciences Co., Ltd. This vaccine contains the inactivated SARS-CoV-2 virus antigen and is administered intramuscularly.
41480194|NCT03271606|COMBINATION_PRODUCT|ERAS|The investigators mainly used enhanced measures perioperatively in mediastinal surgery as these used in other surgery
40809723|NCT06587386|DRUG|First patient Bupivacaine liposome|This study was conducted using the biased coin method, where each patient's use of bupivacaine liposome concentration depended on the previous patient's response. Based on previous research and our past experience, the first recruited patient used a concentration of 0.443% w/v (15ml). Subsequently, if motor function was preserved, the next patient received a lower concentration (increased by 0.05% w/v) with a probability of b=0.11; or the same concentration with a probability of 1-b=0.89. If motor function was blocked, the next patient received a lower concentration (decreased by 0.05% w/v).
41480195|NCT03271606|COMBINATION_PRODUCT|Traditional measures|The investigators mainly used traditional measures perioperatively in mediastinal surgery as these used in other surgery
41480196|NCT02066337|PROCEDURE|scaling and root planing|
41326951|NCT02294422|DEVICE|Aneroid manometer|The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
41326952|NCT06041685|PROCEDURE|local warming|local warming on the site for arterial catheterization using forced air warmer
41480197|NCT02066337|DRUG|placebo gel|
41480198|NCT02066337|DRUG|Ozonated olive oil gel|
41480199|NCT05793814|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri 3613|Daily for 6 month
41480200|NCT05793814|DIETARY_SUPPLEMENT|Placebo|Daily for 6 month
41480201|NCT02540499|RADIATION|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
41480202|NCT00724373|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
41480203|NCT00724373|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
41480204|NCT01020799|DRUG|AZD7268|15 mg, oral, twice daily (BID)
41480205|NCT01020799|DRUG|Escitalopram|20 mg, oral, once daily (QD)
41154658|NCT04638088|OTHER|assessment of urinary function and erectil function before and after prostatectomy|assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete
41154659|NCT06444347|DEVICE|Biosynthetic Mesh|The biosynthetic mesh group will undergo hiatal hernia repair with Phasix Mesh (Becton Dickinson, Franklin Lakes, NJ) reinforcement, secured with permanent suture.
41154660|NCT06444347|PROCEDURE|Hiatal Hernia Repair|The non-mesh group will undergo hiatal hernia repair with permanent suture only.
41154661|NCT01116453|PROCEDURE|acupuncture|acupuncture on the acupoints of ST44 and ST43 of bilateral feet for 2 months, then followed-up for another 2months
41326953|NCT04234763|BEHAVIORAL|Strategies to lower postprandial hyperglycemia in T2D patients|T2D patients will undergo a 14-day chronic feeding trial intervention where the strategies to lower postprandial hyperglycemia will be educated. For example, to control portion of carbohydrate, incorporate low GI food and diabetes-specific formula, promote physical activity and practice consistent meal timing. After that, patients will undergo MCT again to evaluate the difference before and after the intervention.
41326954|NCT04234763|BEHAVIORAL|Control group|Assess nutritional status and no active intervention is conducted.
41326955|NCT02911818|BEHAVIORAL|CMS-recommended lifestyle counseling|21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
41480206|NCT01020799|DRUG|Placebo capsules|Placebo capsules to match AZD7268
41154662|NCT01116453|PROCEDURE|usual care|usual care with medication and behavior therapy for 2 months, followed by acupuncture for additional 2 months
41154663|NCT00745069|DRUG|tapentadol HCl|
41154664|NCT00915460|DRUG|Interferon beta-1a (Avonex)|dosage and frequency as per Biogen Idec protocol
41326956|NCT02911818|DRUG|Liraglutide 3.0mg|Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.
41480207|NCT01020799|DRUG|Placebo tablets|Placebo tablets to match encapsulated escitalopram
41480208|NCT04665206|DRUG|VT3989|25, 50, 100,150 or 200 mg capsules for oral administration.
41480209|NCT00208117|DRUG|Sertraline (Zoloft)|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
41480210|NCT00208117|DRUG|Simvastatin (Zocor)|The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
41480211|NCT02692729|PROCEDURE|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
41480212|NCT02692729|PROCEDURE|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
41480213|NCT03331237|PROCEDURE|scalene block|scalene block using 5ml of ropivacaine
41480214|NCT03331237|PROCEDURE|ISO block|ISO block is a combined block of suprascapular nerve and brachial plexus cords using a single puncture
41480215|NCT01304758|DEVICE|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
41480216|NCT01478737|DRUG|Intravitreal dexamethasone implant|Intravitreal Ozurdex after vitrectomy
41480217|NCT01478737|PROCEDURE|Vitrectomy|Vitrectomy only
41480218|NCT02594371|DRUG|Oraxol|
41480219|NCT02594371|DRUG|IV paclitaxel|
41480220|NCT02196740|DRUG|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
41480221|NCT02196740|DRUG|creosote|Pulp removal,Root canal irrigation and disinfection
41480222|NCT05416463|PROCEDURE|Intra-Operative Device for THA|The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
41480223|NCT00898534|DEVICE|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
41010172|NCT06142812|OTHER|Kahoot!™ Group|The theoretical concepts of each subject were taught over a period of four months, with a total duration of 30 hours. Of the total theoretical concepts of the subject, 50% were randomly selected to receive reinforcement through Kahoot! Each of the theoretical concepts chosen at random was consolidated through a Kahoot! questionnaire. which consisted of 15 questions, with three answer options. This questionnaire was administered at the end of the theoretical explanation of each section, with the objective of strengthening the learning of the contents just presented. After students answered each question in Kahoot!, the teacher clarified any questions related to that question and provided explanations as to why one answer was correct and the other two were incorrect. This process offered immediate feedback to students.
41010173|NCT00115596|OTHER|Formal Curriculum; Low-Fidelity Simulation|The intervention was a formal procedural skills training curriculum consisting of didactic lectures and simulation training.
41010174|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
41010175|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
41010176|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
40809724|NCT06587386|DRUG|Next patients Bupivacaine liposome|This study was conducted using the biased coin method, where each patient's use of bupivacaine liposome concentration depended on the previous patient's response. Based on previous research and our past experience, the first recruited patient used a concentration of 0.443% w/v (15ml). Subsequently, if motor function was preserved, the next patient received a lower concentration (increased by 0.05% w/v) with a probability of b=0.11; or the same concentration with a probability of 1-b=0.89. If motor function was blocked, the next patient received a lower concentration (decreased by 0.05% w/v).
41154665|NCT05312021|DRUG|IMR-687|150 mg and 200 mg tablets
41154666|NCT05312021|OTHER|IMR-687 Placebo|Matching placebo to IMR-687
40809727|NCT06586216|DRUG|PF-07817883|Experimental
41154667|NCT00767286|DRUG|flutamide|
40809729|NCT04778631|DEVICE|Heat therapy|Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.
40809730|NCT04778631|DEVICE|Cryotherapy|Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
40809731|NCT06604143|BEHAVIORAL|Quality Training|Participants will engage in piano playing tasks using their affected hand and fingers. The training focuses on specific aspects of finger movement, and participants will receive feedback related to their playing. They will wear a wrist brace for support, and their hand and arm positions will be monitored to ensure proper technique.
40809732|NCT06604143|BEHAVIORAL|Goal Training|Participants will engage in piano playing tasks using their affected hand and fingers. The training emphasizes learning to play and producing music. Feedback will be provided on various aspects of performance such as speed and accuracy, but specific details about finger movement or technique will not be given. The use of a wrist brace and monitoring of hand and arm positions will be consistent with standard practice.
40809733|NCT06592833|DRUG|Psilocybin|Psilocybin, 25mg, given once orally.
40809734|NCT06592833|DRUG|Pimavanserin|Pimavanserin, 34mg, given once orally
41326957|NCT02911818|OTHER|Portion-Controlled Diet|A 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
41480224|NCT02777684|OTHER|Qualitative study|
41480225|NCT04180176|OTHER|Blood Draw|Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
40809735|NCT06592833|DRUG|Placebo|Matching placebo.
40809736|NCT05570760|DEVICE|Adaptos®Ortho Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
40809737|NCT05570760|PROCEDURE|OWHTO without bone grafting|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation, without bone grafting. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
41010177|NCT04865497|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.
41010178|NCT01611571|DRUG|Risedronate|weekly risedronate
41010179|NCT01611571|DRUG|Teriparatide|daily teriparatide
40809738|NCT05570760|DEVICE|chronOS® Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
40809739|NCT05810571|PROCEDURE|preoperative remifentanil consumption|continuous remifentanil infusion will applied for peroperative analgesia
41010180|NCT01611571|DRUG|Placebo Teriparatide|daily placebo of teriparatide
41010181|NCT01611571|DRUG|placebo Risedronate|weekly placebo of Risedronic Acid
41010182|NCT06393192|PROCEDURE|Epidural analgesia (EA) only group|The epidural needle will be inserted into the lumbar epidural space at the level of L2-3 intervertebral space.
41010183|NCT06393192|PROCEDURE|Quadratus lumborum block (QL2)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side behind the QL muscle, resulting in a total of Sixty mL
41154668|NCT00767286|DRUG|goserelin acetate|
41326958|NCT02911818|DRUG|Placebo Oral Tablet|
41326959|NCT02911818|DRUG|Phentermine 15 MG|
41326960|NCT02911818|BEHAVIORAL|Extension Study CMS-recommended lifestyle counseling|4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
41326961|NCT01039636|DRUG|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
41480226|NCT03707041|DRUG|P218 (1000 mg) Oral Capsules|1000 mg P218 (4 x 250 mg capsules)
40809740|NCT05810571|PROCEDURE|postopeartive controlled anlagesia with morphine|postoperative morphine patient controlled analgesia will be applied for postoperative analgesia
41154669|NCT00767286|RADIATION|low-LET cobalt-60 gamma ray therapy|
40809742|NCT05304585|PROCEDURE|Biopsy|Undergo tumor biopsy
40809743|NCT05304585|PROCEDURE|Bone Scan|Undergo bone scan
40809744|NCT05304585|PROCEDURE|Computed Tomography|Undergo CT scan
40809745|NCT05304585|DRUG|Cyclophosphamide|Given IV
40809746|NCT05304585|BIOLOGICAL|Dactinomycin|Given IV
41010184|NCT06393192|PROCEDURE|Quadratus lumborum block 3(QL3)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side among the QL muscle and the psoas major, resulting in a total of Sixty mL
41010185|NCT06393192|PROCEDURE|Quadratus lumborum block 2+3 QL(2+3)|0.2 percent bupivacaine solution of fifteen milliliters were administered at each injection site, with the needle being inserted once on each side
41010186|NCT04313166|DRUG|Cu(II)ATSM|cooper-containing synthetic small molecule
41010187|NCT00375193|DRUG|Amrubicin|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
41010188|NCT01900613|BEHAVIORAL|Ninos Sanos Familia Sana|
41010189|NCT05349448|DRUG|Hylase plus Triamcinolone plus sterile isotonic saline|transforaminal fluroscopic epidural injection
40809747|NCT05304585|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
40809748|NCT05304585|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40809749|NCT05304585|RADIATION|Radiation Therapy|Undergo radiation
40809750|NCT05304585|DRUG|Vincristine|Given IV
41010190|NCT05349448|DRUG|Hylase plus Dexmedetomidine plus Triamcinolone|transforaminal fluroscopic epidural injection
41480227|NCT03707041|DRUG|Placebo Oral Capsules|Placebo capsules matched to the P218 capsules with regard to appearance and taste
40809751|NCT06095115|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
40809752|NCT06095115|DRUG|Placebo|Placebo will be administered orally
40809753|NCT05366816|DRUG|Sunitinib|37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle.
40809754|NCT05366816|DRUG|Regorafenib|120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle.
40809755|NCT05630066|DRUG|60 mg QD Alogabat|"Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.~I"
40809756|NCT05630066|DRUG|40 mg QD Alogabat|Participants aged 10-14 years receiving the equivalent of the adult 60 mg alogabat dose.
41010191|NCT05459493|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
41010192|NCT01501812|BEHAVIORAL|Generalization pattern|"During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new"
41010193|NCT04031885|DRUG|Abemaciclib|Administered orally
41010194|NCT04031885|DRUG|Fulvestrant|Administered IM
40809757|NCT05630066|DRUG|7 mg QD Alogabat|Participants aged 5-9 years receiving the equivalent of the adult 20 mg alogabat dose.
40809758|NCT05630066|DRUG|Part 2 Adult Alogabat High Dose (aged 15-17)|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
40809759|NCT05630066|DRUG|Alogabat|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
40809760|NCT05630066|DRUG|Alogabat|"If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, additional participants may be recruited in any of the of the 3 age-groups in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2."
40809761|NCT05630066|DRUG|Part 2 Optional Cohort|"If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, participants from any of the 3 age-groups may enroll in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2"
40809762|NCT04973683|DRUG|AL101|Given IV
40809763|NCT04973683|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
41010195|NCT04031885|DRUG|Standard Chemotherapy|Standard chemotherapy of physician's choice administered according to product label.
41010196|NCT00917332|BEHAVIORAL|"relaxation (breathing and muscles) and guided imagery (safe place)"|intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
41010197|NCT00461539|OTHER|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
41154670|NCT00767286|RADIATION|low-LET photon therapy|
41154671|NCT04695249|BEHAVIORAL|Exposure intervention using 360 degree videos|The intervention consists of eleven sessions. The first five sessions are dedicated to functional assessment and psychoeducation. The second five sessions are dedicated to exposure in 360-degree videos. The last session is provided for relapse prevention.
41154672|NCT05915884|OTHER|SGLT-2 inhibitors|This study is an observational study. It is not planned to do an interventional activity.
41154673|NCT00021021|BIOLOGICAL|anti-FLT-1 ribozyme|
41154674|NCT04685759|OTHER|In-Person Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes per in-person session.
41480228|NCT03707041|DRUG|P218 (100 mg) Oral Capsules|100 mg P218 (2 x 50 mg capsules)
41480229|NCT03707041|BIOLOGICAL|PfSPZ Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
41480230|NCT01314378|BEHAVIORAL|Mindfulness Training|Eight session intensive behavioral training program for smokers
41010198|NCT00461539|BEHAVIORAL|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
41010199|NCT00806468|DRUG|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
41010200|NCT03178058|OTHER|Questionaire|"Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
41010201|NCT00073671|BEHAVIORAL|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
41010202|NCT00073671|OTHER|Usual care|Participants receive usual care
41010203|NCT02011048|PROCEDURE|Endoscopic components separation|Endoscopic components separation hernia repair
41010204|NCT03488576|PROCEDURE|Complete Macular Peeling|A complete peeling of the internal limiting membrane was performed
41010205|NCT03488576|PROCEDURE|Macular Peeling with Foveal Sparing|A partial peeling of the internal limiting membrane was performed, sparing the fovea.
41010206|NCT02995915|OTHER|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
41480231|NCT01314378|BEHAVIORAL|Cognitive-Behavioral Therapy|Eight session intensive behavioral intervention for smokers
41010207|NCT02995915|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
41010208|NCT02995915|BEHAVIORAL|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
41010209|NCT02995915|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
41010210|NCT02995915|BEHAVIORAL|Mobile Monitoring|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
41154675|NCT04685759|OTHER|Virtual Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes each virtual session. A TheraBand (resistance band) will be provided to patients in this group to be used for resistance and flexibility training.
41480232|NCT02165618|OTHER|Medication review, based on but not limited to the RASP list|"Systematic approach:~1. Medication reconciliation~2. Applying the RASP list~3. Expert review (not based on the RASP list)~4. Multidisciplinary discussion"
41010211|NCT05349422|BEHAVIORAL|Electronic Health Record (EHR) Enabled Teamlets|The intervention consist of four components: 1) patients with hypertension will be automatically screened for low medication adherence using linked EHR-pharmacy data at the time of a PCP encounter; 2) MAs will deliver a validated, rapid, survey of common causes of non-adherence; 3) MAs and/or RNs will address barriers to adherence tailored to survey response, including delivery of brief health coaching based on motivational interviewing; and 4) PCPs will address specific barriers to adherence based on survey response.
41010212|NCT03142503|DIETARY_SUPPLEMENT|Diet + supplementation|Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
41480233|NCT05978908|DRUG|FC-12738|Retro enversio pentapeptide of thymopentin
41010213|NCT03142503|DIETARY_SUPPLEMENT|Diet + placebo|Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
41010214|NCT03142503|DIETARY_SUPPLEMENT|Placebo|Supplementation of 1g soybean oil, 3 times a day.
41010215|NCT05268471|DEVICE|Positional device (PD)|OSA treatment with PD for 6 months
41010216|NCT05268471|DEVICE|Continuos Positive Airway Pressure (CPAP)|OSA treatment with CPAP for 6 months
41326962|NCT00637377|DRUG|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
41480234|NCT05978908|DRUG|Saline|placebo
41480235|NCT04108559|PROCEDURE|Kinesiologic Tape Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures.The kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. The patients will be invited after one week for removing the sutures.
41480236|NCT04108559|PROCEDURE|Drain Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures. A plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa. The patients will be invited after one week for removing the sutures.
41010217|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
41010218|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
41010219|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
41010220|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
41010221|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
41010222|NCT06437405|DIETARY_SUPPLEMENT|Vinegar liquid|one pill daily
41010223|NCT06437405|DIETARY_SUPPLEMENT|vinegar pill|One pill daily
41010224|NCT06341465|OTHER|Just Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
41010225|NCT06341465|OTHER|Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
41010226|NCT06341465|OTHER|Taping|Kinesiological taping will be applied as a tone enhancer or tone reducer according to the the concave and convex sides of the curve.
41010227|NCT02537964|OTHER|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
41010228|NCT02240381|PROCEDURE|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
41010229|NCT02240381|PROCEDURE|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
41010230|NCT02240381|OTHER|laboratory biomarker analysis|Correlative studies
41326963|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
41010231|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with L-PRF|"Partially edentulous patients in need of a single-tooth extraction in the premolar region\[ (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with elevators and then carefully extracted with forceps without raising a flap.~L-PRF group will use 2-5 PRF clots, depending on the size of the socket, which will be inserted and compressed with a large plunger until they reach the alveolar crest. The site will thereafter be covered with L-PRF membranes. Then, crossed horizontal mattress suture will be placed followed by single interrupted sutures for stabilization. No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.~After 4 months of socket preservation, a dental implant will be inserted into the socket. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
41010232|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with Xenogenic bone and collagen membrane.|"Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap.~In the control group, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures will be placed to stabilize the collagen matrix. Sutures will be removed at 7-10 days. The grafted socket will then be left to heal for a period of 4 months.~The xenogenic material will be Bio-Oss Collagen® and collagen matrix Bio-Gide® .~After 4 months of socket preservation, a dental implant will be placed. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
41010233|NCT00349596|DRUG|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
41010234|NCT02153775|BEHAVIORAL|Progressive Muscle Relaxation|Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
41010235|NCT05219136|OTHER|Modified Fasting Group|a new fasting protocol is applied to subjects.
41010236|NCT05219136|OTHER|Conventional Fasting Group|a conventional fasting protocol is applied to subjects.
41154676|NCT01486277|DRUG|Quisinostat, 12 mg|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
41326964|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
41154677|NCT05310734|DRUG|Spinosad Topical|A topical suspension indicated for the treatment of scabies is used for this PK and Safety Study
40809765|NCT06656390|DRUG|ALK201|Administered intravenously, once every 3 weeks
40809766|NCT06657352|DIETARY_SUPPLEMENT|ACS Topical Treatment Group|The topical group applied the ACS cream to the face twice daily (morning and night) for 4 weeks.
41010237|NCT00554827|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
41010238|NCT00554827|DIETARY_SUPPLEMENT|Folic Acid|"1 mg orally~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered daily throughout the study and for at least 30 days after last dose of pralatrexate."
41010239|NCT00554827|DRUG|Pralatrexate|Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or
41010240|NCT05218174|OTHER|Exercise Prescription|In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.
41010241|NCT00968175|PROCEDURE|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
41010242|NCT05801159|DIAGNOSTIC_TEST|Positron Emission Tomography-Computerised Tomography (PET-CT)|Injection of the 18F-fluoropivalate (18F-FPIA) radiotracer followed by a whole brain static PET-CT scan.
41010243|NCT03611634|OTHER|BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|collection of saddles
41010244|NCT02285985|DRUG|Saxagliptin|Tablets: 5 mg
41010245|NCT02285985|DRUG|Placebo|Tablets: 5mg
41326965|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
41326966|NCT05979714|OTHER|Patient-centered injection site|CAB-RPV LA will be delivered in a trans-friendly injection clinic at Bridge HIV, which is centrally located in SF. The clinic is staffed by physicians, nurses, and peer navigators who are experienced working with the trans community and are experts in delivery of injectable formulations. For patients unable to attend follow-up clinic visits, arrangements will be made for a clinical provider and peer navigator to conduct a home visit for injection delivery. This implementation strategy will overcome structural barriers where it is difficult to get a visit appointment, and when appointments are missed, even harder to re-schedule. The central location in a quiet, safe and trans-affirming clinical site will make injections easy-to-access. Because the Bridge HIV clinic is not a primary care site, injections can be delivered with minimal wait times due to low patient load relative to clinical capacity.
41010246|NCT06142916|OTHER|Vırtual Realıty Traınıng On Mental Health Lıteracy And Stıgma|Nurses in the intervention group will be taken to a suitable room on the ward and virtual reality glasses will be worn. Mental health literacy training prepared by researchers by scanning the literature will be given using virtual reality glasses. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. Animations will be prepared for each topic. The training is planned to last 45 minutes.
41017840|NCT03031912|BIOLOGICAL|V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine|The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
41017841|NCT03031912|OTHER|Saline|Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
41154678|NCT03097458|BEHAVIORAL|Short-term Counselling for Families|Counselling for Families which can take up to 6 weeks, with regular meetings under the guidance of a trained psychotherapist.
41154679|NCT06336941|DEVICE|Ultrasound|Ultrasonographic scan with a 70 MHz probe
41154680|NCT04682223|BEHAVIORAL|Semantically-focused therapy tasks|1) Semantic feature analysis (SFA; Boyle \& Coelho, 1995; Boyle, 2004). For each pictured stimulus the participant is prompted to name the picture. Then, s/he is encouraged to produce semantically related words that represent features similar to the target word. 2) Semantic barrier task. This approach includes features of the Promoting Aphasics' Communication Effectiveness (PACE; Davis \& Wilcox,1985). The goal of the task is for one participant (e.g., person with aphasia) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. 3) Verb network strengthening therapy (VNeST; Edmonds et al., 2009; 2014) targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the participant to generate verb-noun associates with the purpose of strengthening the connections between the verb and its thematic roles.
41480237|NCT04108559|OTHER|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
41480238|NCT03326674|DRUG|Tesetaxel and Capecitabine|Tesetaxel plus reduced dose of Capecitabine
41480239|NCT03326674|DRUG|Capecitabine|Capecitabine alone at approved dose
41480240|NCT02604472|OTHER|CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
40809767|NCT06657352|DIETARY_SUPPLEMENT|Topical Placebo Group|The topical group applied the cream (without ACS) to the face twice daily (morning and night) for 4 weeks.
41480241|NCT02604472|OTHER|IC+CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
41326967|NCT05979714|BEHAVIORAL|Patient-centered adherence support|A Trans peer navigator will support trans women living with HIV receiving long-acting injectable treatment through our delivery model. Peer navigators will reach out to trans women using our highly effective mobile SMS platform to provide additional support before and between visits. This platform provides automated weekly check-ins for streamlined support and bi-directional asynchronous texting with a peer navigator. Peer navigators will use this SMS platform to send appointment reminders, assess needs for re-scheduling, answer questions and triage concerns regarding CAB-RPV LA, and offer support for transportation or scheduling a home visit. This approach has demonstrated efficacy in improving ART adherence and viral suppression in people living with HIV as well as retention in care and adherence to PrEP.
41326968|NCT05979714|OTHER|Provider education|To support effective outreach to and education of providers on novel evidence-based practices, SFDPH has utilized public health detailing (brief educational visits via a nurse practitioner) to ensure providers are prepared to implement new interventions. This strategy has been effective in expanding the implementation of PrEP, RAPID ART initiation, and comprehensive STI screening across clinics in SF. For this study, we will develop educational materials on the CAB-RPV LA regimen, including a summary of results from Phase 3 trials (ATLAS20, FLAIR21), the FDA labeling indication, and details about SFDPH's implementation of CAB-RPV LA within our safety-net system and our new delivery model. These materials will include information on which patients will be eligible for this treatment modality and eligible for referral to our new delivery model, and how to make these referrals.
41480242|NCT03236142|PROCEDURE|SIPS Operation|The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.
41480243|NCT03236142|PROCEDURE|Standard Duodenal Switch Operation|
41480244|NCT01559987|OTHER|Manual Toothbrush only|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
41480245|NCT01559987|OTHER|MTB + Waterpik Ultra Water Flosser 'High'|MTB + Waterpik Ultra Water Flosser 'High'
41480246|NCT01559987|OTHER|MTB + Floss (MTB+Floss)|MTB + Floss (MTB+Floss)
41480247|NCT05749679|OTHER|training and audit|"An evaluation of the practices with clinical audit before and after the management will be carried out.Every 3 months for 2 years, the investigating physicians of the intervention group will report for these patients the modifications or cessation of treatment, modification or implementation of interventions such as physical activity or implementation of nutritional modifications. Physician investigators will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers.10 possible actions to be deployed :~1. Hygienic and dietary measures~2. Physical activity~3. Smoking cessation~4. Avoidance of nephrotoxic substances~5. Treatment of hypertension~6. Proteinuria reduction~7. Oral antidiabetics; choice~8. Optimal HBA1c~9. Statin~10. Compliance"
41480248|NCT05749679|OTHER|Routine care|"Physicians in the control group will receive training on the study procedures. An evaluation of practices with a clinical audit before and after the treatments will be carried out. Every 3 months for 2 years, the investigating physicians in the control group will report for these patients the modifications or cessation of treatment, the modification or implementation of interventions such as physical activity or the implementation of modifications in terms of nutrition. The investigating physicians will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers. Physician investigators in the control group will continue their care as usual."
41480249|NCT04508036|DIAGNOSTIC_TEST|Withdrawal of blood samples for D-Dimer|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for D-dimer levels.
41480250|NCT04508036|DIAGNOSTIC_TEST|Withdrawal of blood samples for Fibrinogen|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for Fibrinogen levels.
41480251|NCT04508036|DIAGNOSTIC_TEST|Echocardiographic Examination|At postnatal 3rd, 7th and 14th days, Ductus Arteriosus will be echocardiographically examined to obtain calculations and confirm status of ductal patency or closure.
41480252|NCT06082674|DEVICE|Vayu bCPAP|The Vayu bCPAP uses a constant flow of dry oxygen from the source with an adjustable flow meter. Oxygen is blended by Venturi blender with ambient air to create a source of oxygen-enriched air of adjustable concentration.
41480253|NCT06082674|DEVICE|Mechanical Ventilator Driven CPAP|Mechanical Ventilator Driven CPAP
41480254|NCT05884879|BEHAVIORAL|Tinnitus simulation|The control group will perform speech perception tests and listening effort tests in the absence and presence of a simulated tinnitus percept using a bone vibrator.
41326969|NCT05979714|BEHAVIORAL|Improved clinic communication strategies|For SFDPH clinics, Bridge HIV providers will communicate with primary care providers through EPIC, SFDPH's electronic health record (EHR), and one of the most common EHR systems used across clinic systems in the US. For this study, secure email and/or telephone encounters within EPIC will be used to facilitate efficient referrals of TGW living with HIV from their primary providers to the Bridge HIV injection clinic and ongoing secure communication between Bridge HIV clinicians and the primary care team. For non-SFDPH clinics, communication will be via secure email or other secure communication strategies.
41326970|NCT01390480|DRUG|Cholecalciferol|weekly dose (based on 70 IU/kg bodyweight/day) orally
41326971|NCT01688635|DRUG|LY2963016|Administered subcutaneously
41326972|NCT01688635|DRUG|US Approved Lantus|Administered subcutaneously
41326973|NCT03956888|DRUG|N-acetylcysteine|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
41480255|NCT00059787|DRUG|paclitaxel|Given IV
41480256|NCT00059787|DRUG|carboplatin|Given IV
41480257|NCT00059787|DRUG|erlotinib|Given PO
41480258|NCT05028231|PROCEDURE|Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|Each patient will complete 2 cycles of neoadjuvant therapy. After evaluating the curative effect, decide whether to operate or not. Patients with and without surgery enter the survival follow-up period.
41480259|NCT04780932|DRUG|Macitentan 10mg|Macitentan 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
40809768|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Treatment Group|The combination group used both the topical and oral ACS products for 12 weeks.
40809769|NCT06657352|DIETARY_SUPPLEMENT|ACS Oral Treatment Group|The oral group ingested one ACS capsule twice daily after breakfast and dinner for 12 weeks.
40809770|NCT06657352|DIETARY_SUPPLEMENT|Oral Placebo Group|The oral group ingested one capsule (without ACS) twice daily after breakfast and dinner for 12 weeks.
40809771|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Placebo Group|The combination group used both the topical and oral products without ACS for 12 weeks.
41154681|NCT04682223|BEHAVIORAL|Phonologically-focused therapy tasks|1) Phonological components analysis task (PCA; Leonard et al., 2008). The participant first attempts to name a given picture and then to identify the phonological features of the target words. 2) Phonological production task focuses on the identification of phonological features of targeted, imageable nouns and verbs. It requires the participant to sort picture stimuli based on the number of syllables and then to identify a hierarchy of phonological features. Once each targeted feature is identified for the pair of words, the participant is required to blend the syllables/sounds together. 3) Phonological judgment task relies on computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features (e.g. # of syllables, initial phonemes, final phonemes, rhyming).
41154682|NCT01306409|DRUG|cera, darbepoetin, epoetin-beta|Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
41154683|NCT01306409|DRUG|ESA|Sequential application of three different ESA
41326974|NCT04718584|DRUG|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
41480260|NCT04780932|DRUG|Placebo|Placebo 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
41154684|NCT01145859|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
41154685|NCT03937596|DRUG|D-cycloserine|Daily oral D-cycloserine 100mg during the blinded phase (10 days).
41326975|NCT03394079|PROCEDURE|PCI|Percutaneous Coronary Intervention
41326976|NCT03814005|DRUG|Azacitidine|Azacitidine subcutaneous or intravenous injection.
40809772|NCT06656052|OTHER|1. working memory task.|Arithmetic test (Backward counting with serial 3 subtraction and articulation): participants will be asked to count out loud backward with serial subtraction of 3 from each number, starting with a random number provided by the researcher.
40809773|NCT06656052|OTHER|2. Visual and Verbal Fluency Task|Stroop colour word test (modified Stroop test): participants will be asked to name the colour of ink that each word is printed in. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
40809774|NCT06656052|OTHER|3. Motor Task|Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
40809775|NCT06657638|DIAGNOSTIC_TEST|Thoracentesis|Aspiration of pleural effusion
41010247|NCT06142916|OTHER|Classical Education|Nurses in the control group will be given mental health literacy training using the classical method using brochures. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. The training is planned to last 45 minutes.
41010248|NCT00002335|DRUG|Emtricitabine|
41326977|NCT03814005|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
41010249|NCT05001789|OTHER|CogMed|20 sessions of Cogmed working memory training
41010250|NCT03438435|DRUG|QRH-882260 Heptapeptide|Imaging agent
41010251|NCT00802217|DRUG|Civamide|5 mg liquid filled softgel capsules
41010252|NCT00802217|DRUG|Civamide|5 mg x 2 liquid softgel capsules
41010253|NCT05838729|DRUG|RiMO-301|"A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions."
41010254|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (low) administered intravenously (into the vein)
41010255|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (medium) administered intravenously (into the vein)
41010256|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (high) administered intravenously (into the vein)
41326978|NCT06180668|PROCEDURE|Trauma Laparotomy|Emergency abdominal surgery through midline incision to access abdominal and / or pelvic organs, to access identified injuries or exploratory diagnostic reasons
41010257|NCT06222957|OTHER|None (Observational study)|Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.
41154686|NCT03937596|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
41154687|NCT03937596|DRUG|Placebo oral capsule|Daily oral placebo during the blinded phase (10 days).
41154688|NCT01938209|OTHER|seated thoracic manipulation|seated general thoracic spine manipulation
41326979|NCT05279105|BEHAVIORAL|Program support|The intervention to be evaluated in this study is program design and selection considerations by humanitarian organisations. It will comprise of factors that motivate organisations to chose certain delivery models in providing health care in conflict-affected settings
41010258|NCT03788733|DRUG|Melatonin 3 mg|1 time a day for 8 weeks
41010259|NCT03788733|DRUG|Placebo Oral|1 time a day for 8 weeks
41010260|NCT06309875|OTHER|PLAN CUIDARTE|Description Plan Cuidarte
41010261|NCT06309875|OTHER|Conventional care|Description Conventional care
41010262|NCT03261349|DRUG|Ledipasvir and sofosbuvir|To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
41010263|NCT02548013|OTHER|outpatient management|patients if stable will be discharged to continue treatment at home
41010264|NCT02548013|OTHER|Inpatient management|patients will continue there treatment in hospital till delivery
41010265|NCT05746546|DRUG|Transdermal Nicotine patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
41010266|NCT02099721|DEVICE|ICD or CRT-D Device|Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
41010267|NCT03898817|OTHER|taking of cutaneous cells|Taking of cutaneous cells by biopsy Sample of blood
41010268|NCT00888303|DRUG|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
41010269|NCT00888303|DRUG|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
41154689|NCT01938209|OTHER|supine specific thoracic spine manipulation|supine specific thoracic spine manipulation
41326980|NCT03130023|DEVICE|Pulse Oximeter with ORI|Pulse oximeter that measure Oxygen Reserve Index
41326981|NCT04939779|DRUG|LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)|Oral administration
41326982|NCT04939779|DRUG|LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)|Oral administration
41326983|NCT04202549|DRUG|intra-arterial cocktail therapy|Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.
41326984|NCT00497354|DRUG|Variation in volume of local anesthetic|
41326985|NCT00497354|PROCEDURE|Ultrasound-guided interscalene brachial plexus block|
41010270|NCT00888303|PROCEDURE|Thyroidectomy, total or partial|Surgical standard intervention
41010271|NCT01416194|DRUG|Bazedoxifene|Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
41010272|NCT01416194|DRUG|Bisphosphonate|Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
41010273|NCT01416194|DRUG|Raloxifene|Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
41010274|NCT05474144|DIETARY_SUPPLEMENT|SmartProbio C|Probiotic supplement consisting of 19 strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, subsp. Infantis Bi-07, Lactobacillus rhamnosus LR22, Lactobacillus acidophilus LA14, Lactobacillus rhamnosus LGG, Bifidobacterium lactis HN019, Bifidobacterium lactis Bl-04, Lactobacillus acidophilus LA 11 ONLLY, Lactobacillus rhamnosus HN001, Lactobacillus plantarum LP ONLLY, Lactobacillus casei LC18, Bifidobacterium breve BB8, Lactobacillus reuteri LE16, Bifidobacterium lactis BI516, Streptococcus thermophilus ST6, Bifidobacterium animalis BA77, Bifidobacterium bifidum BB47, Bifidobacterium longum BL88 ONLLY, Bifidobacterium infantis BI211) in different ratios. Probiotic mixture enclosed in HPMC (hydroxypropylmethylcelulose) capsule, 25 billion CFU (colony-forming units) in each capsule. As a filling agent mix of inulin and maltodextrin was used. Dosage twice a day.
41010275|NCT05474144|DIETARY_SUPPLEMENT|Placebo|Placebo. HPMC (hydroxypropylmethylcelulose) capsule filled with maltodextrin. Dosage twice a day.
41010276|NCT04605575|DRUG|Pyrotinib 320mg + Vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
41010277|NCT04605575|DRUG|Pyrotinib 400mg + Vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
41010278|NCT04605575|DRUG|Pyrotinib plus Vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
41010279|NCT01790906|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
41010280|NCT01790906|OTHER|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
41154690|NCT03265262|DIAGNOSTIC_TEST|The basophil activation test (BAT)|Single sample: 5 mL of venous blood
41154691|NCT01572493|BIOLOGICAL|rh IL-15 (10 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) intravenous (IV) for first 10 days of each cycle
41154692|NCT01572493|BIOLOGICAL|rh IL-15 (5 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle
41326986|NCT06001840|BEHAVIORAL|Promotion factors|In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.
41326987|NCT06001840|BEHAVIORAL|Mitigation strategies|"Health Communications. The first narrative describes a person unknown to the participant who purchases from the illegal market and experiences negative life outcomes (e.g., ill health from contaminants). The second narrative incorporates cognitive biases of social proof (i.e., portraying a choice as the opinion of the majority).~Availability of Nicotine Replacement Therapies (NRT): Transdermal NRT will be available in the LETM at two different prices. In one condition, transdermal NRT will be available at a 50% subsidy in the form of coupons. In the other condition, a five-day supply of NRT will be available for free.~Penalties: Penalties will be presented in different fine magnitudes along with a description of the consequences of illegal purchases (i.e., a criminal record)."
41326988|NCT01768312|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
41326989|NCT05812937|PROCEDURE|Intraabdominal ultrasound|To assess the diagnostic value of the intraoperative intrabaabdominal ultrasound (IIUS) for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
41010281|NCT01588782|DRUG|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
41010282|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
41010283|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
41010284|NCT03390907|DEVICE|Hybrid APC|Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
41010285|NCT03683134|BEHAVIORAL|Mediterranean diet|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
41010286|NCT03683134|DIETARY_SUPPLEMENT|Olive oil and mixed nuts|Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks. Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.
41010287|NCT03683134|BEHAVIORAL|American Heart Association|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
41010288|NCT00004317|DRUG|Leucovorin calcium|See arm descriptions
41010289|NCT00004317|DRUG|Pyrimethamine|See arm descriptions
41010290|NCT00004317|DRUG|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
41010291|NCT00004317|DRUG|Sulfadiazine|See arm descriptions
41010292|NCT02327208|DIETARY_SUPPLEMENT|Control|
41010293|NCT02327208|DIETARY_SUPPLEMENT|Protein|
41010294|NCT02327208|DIETARY_SUPPLEMENT|Carbohydrate|
41010295|NCT05653960|OTHER|EMR or ESD|Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms
41154693|NCT02134899|DRUG|Everolimus|Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
41154694|NCT02134899|DRUG|Calcineurin inhibitors maintenance|Usual treatment
41154695|NCT02965599|DRUG|GSK3117391|GSK3117391 (Dose A) is a white, opaque, gelatin capsule.
41154696|NCT02965599|DRUG|Placebo|Placebo is a white, opaque, gelatin capsule.
41154697|NCT01795183|DRUG|AMISULPRIDE|Pharmaceutical form: tablet Route of administration: oral
41010296|NCT00528528|DRUG|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
41010297|NCT00528528|DRUG|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
41010298|NCT00528528|DRUG|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
41010299|NCT00528528|DRUG|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
41010300|NCT00528528|DRUG|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
41010301|NCT03697811|DRUG|DE-117 Ophthalmic Solution|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
41010302|NCT03638817|DRUG|Eltrombopag|"Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is \< 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count"
41010303|NCT02102139|DRUG|DXM + Propofol|"After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.~The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP \> ±20% from baseline), the target concentration was increased by 0.5 ng mL-1."
41010304|NCT02102139|DRUG|Saline + Propofol|All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
41010305|NCT00668681|DEVICE|EndoRefix|
41326990|NCT05194501|OTHER|Nine Hole Peg Test, Jamar dynamometer, pinchmeter|"Hand grip and pinch strengths: Hand grip strengths and tip pinch strengths were measured using a Jamar type hand dynamometer and pinchmeter available in our clinic.~The Nine Hole Peg Test (NHPT): Hand dexerities were evaluated with the NHPT available in our clinic."
41326991|NCT06460168|OTHER|Mulligan(MWM) MobilizationTechnique|"Mulligan Mobilization program in MWM , a therapist-applied pain free accessory gliding force combined with active movement.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets."
41010306|NCT04041869|BEHAVIORAL|MapTrek|Participants will receive a Fitbit activity monitor and access to the MapTrek game which will be visible on monitors set up in the residential facility.
41010307|NCT05571059|DRUG|Ifetroban Sodium|Once daily oral ifetroban
41010308|NCT05571059|DRUG|Placebo|Matching oral placebo
41154698|NCT03612453|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
41480261|NCT06168435|OTHER|eIMPAQc|e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard.
41480262|NCT00206492|DRUG|Iressa|Iressa
41480263|NCT00206492|DRUG|Tamoxifen|Tamoxifen
41480264|NCT05863624|PROCEDURE|Open hernioplasty|Inguinal hernia is operated using open surgery
41480265|NCT05863624|PROCEDURE|TEP hernioplasty|Inguinal hernia is operated using laparoendoscopic technique
41480266|NCT02116699|OTHER|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
41010309|NCT01985516|OTHER|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
41010310|NCT01985516|OTHER|pouring the gel on the catheter's tip|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
41326992|NCT06460168|OTHER|Maitland Mobilization technique|"will receive (Maitland mobilization program manipulative physiotherapy in which chain of oscillatory joint mobilization grades l-lV based on the pathological limit of tissue are used) In this, the exercises will be performed in 3 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session)"
41010311|NCT02422030|DRUG|Lipitor Tab. 40mg|
41010312|NCT02422030|DRUG|Trilipix 135mg|
41010313|NCT00251394|DRUG|Rituxan|Given intravenously once weekly for four weeks.
41010314|NCT00251394|DRUG|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
41010315|NCT05896358|BEHAVIORAL|ketogenic diet|a low calorie ketogenic diet
41010316|NCT02093572|OTHER|3 standard meals/day|
41010317|NCT02093572|OTHER|2 meals/day (omit breakfast)|
41010318|NCT00775437|DRUG|Adalimumab|Adalimumab solution for injection for subcutaneous use.
41010319|NCT04834011|PROCEDURE|Laparoscopic right colonic resection with Complete Mesocolic Excision (CME)|
41010320|NCT04834011|RADIATION|3D CT angiography|
41010321|NCT05698095|DRUG|5-methoxy-N,N-dimethyltryptamine succinate salt|The 5-MeO-DMT drug product is comprised of the appropriate concentration of 5-MeO-DMT succinate salt drug substance in solution with 0.9% sodium chloride injection solution (USP) in a 5 mL glass vial, and is administered intramuscularly.
41326993|NCT02333006|OTHER|Questionnaires|Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
41326994|NCT00062647|DRUG|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
41326995|NCT00062647|DRUG|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
41326996|NCT02574858|DRUG|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
41326997|NCT00393003|DEVICE|Closed-loop anesthesia system|
41326998|NCT05583357|BIOLOGICAL|V-01D-351|One dose of V-01D-351 on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
41326999|NCT05583357|BIOLOGICAL|V-01D-351|One dose of V-01D-351 on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
41327000|NCT05583357|BIOLOGICAL|CoronaVac|One dose of CoronaVac on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
41327001|NCT05583357|BIOLOGICAL|CoronaVac|One dose of CoronaVac on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
41327002|NCT00303615|DRUG|Fluoxymesterone 10 mg|
41327003|NCT00303615|DRUG|Anastrozole 1 mg|
41327004|NCT02080156|DEVICE|CPAP|
41327005|NCT05409768|PROCEDURE|Short axis out of plane|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance short axis visualisation out of plane approaches.
41327006|NCT05409768|PROCEDURE|Anteroposterior short axis in plane|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance anteroposterior short axis visualisation in plane approaches.
41327007|NCT04318379|BIOLOGICAL|HCVax|HCVax is a lentiviral vector encoding several HCV antigens
41327008|NCT00489034|BEHAVIORAL|Quantitative Interview|Index participants will be interviewed every six months (with phone interviews focused on service utilization at each six month interval midpoint) for 18 months while network members will be interviewed at baseline and one year. Interviews will consist of in-depth face-to-face and audio computer-assisted interviews (ACASIs) and a structured diagnostic interview to assess engagement in care (number of clinical visits attended), substance use, attitudes about substance use, friend's substance use, sexual risk behaviors, PTSD (for index participants only), support of index participants care use (network participants only), attitudes about healthcare (network participants only), index participant's adherence (network participants only), own functioning (network participants only), and family functioning (network participants only). At Baseline only, a urine sample will be collected from index participants for drug testing to assess the agreement between urine and ACASI.
41327009|NCT00489034|BEHAVIORAL|Ethnographic Interview|Qualitative interviews will be conducted with a small sub-sample of index and identified network participants from each site at least monthly for a period of 18 months. Interviews will be ethnographic in nature and will rely on participants' life stories and narratives of social experience to supply their content and guide their progression.
41010322|NCT05698095|DRUG|Placebo|The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.
41010323|NCT00581282|RADIATION|PET scan|positron emission tomography PET scan
41010324|NCT00581282|OTHER|fMRI|functional magnetic resonance imaging fMRI
41327010|NCT00489034|BEHAVIORAL|Gender Interview|Qualitative interviews will be conducted with a sub-sample of index participants. These interviews will focus on issues of gender related vulnerabilities and will be used to develop a survey.
41327011|NCT06413680|DRUG|REGN10597|Administered as an intravenous (IV) infusion
41154699|NCT03612453|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
41327012|NCT04818541|DEVICE|PPCI|Closure of the femoral access site with PerQseal device at the end of the PPCI index procedure and removal of the Impella pump.
41327013|NCT04818541|DEVICE|Cardiogenic shock|Closure of the femoral access site with PerQseal device after removal of the Impella pump.
41327014|NCT04552717|OTHER|My Grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains four main sections: Learning, Self-assessment, Manage symptoms and Find support.
41327015|NCT00673686|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
41327016|NCT00673686|DRUG|Yasminelle (SH T 00186 D)|SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
41327017|NCT04618926|DEVICE|Device intubating Laryngeal Tube Suction Disposable|Resuscitation in covid 19 patients
41327018|NCT01889888|OTHER|Submucosal injection of ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
41327019|NCT00886717|DRUG|carboplatin|
41327020|NCT00886717|DRUG|paclitaxel-loaded polymeric micelle|
41327021|NCT00050960|DRUG|bexarotene with carboplatin and paclitaxel|bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
41480267|NCT02116699|OTHER|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
41327022|NCT00050960|DRUG|carboplatin and paclitaxel|carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.
40809778|NCT06655909|OTHER|consumption of maize porridge containing stable iron isotope|consumption of maize porridge containing stable iron isotope
41327023|NCT05594212|BEHAVIORAL|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
40809779|NCT06657599|PROCEDURE|Major Abdominal Surgery|Patients with ASA I-IV, over 18 years of age, undergoing major abdominal surgery, have gynecological and GIS tumor, expected to stay in postoperative care unit for more than 24 hours.
41010325|NCT06364124|DRUG|evolocumab|Preoperative subcutaneous injection of Evolocumab (420mg)，Atorvastatin 40mg per day
41327024|NCT03384225|DRUG|Cladribine|
41327025|NCT03384225|DRUG|Fludarabine|
41327026|NCT03384225|DRUG|Busulfan|
41327027|NCT03384225|DRUG|Cytarabine|
41480268|NCT05043064|PROCEDURE|Wet lab tasks|Robotic-assisted internal thoracic artery harvesting, mitral annulus sutures placement and atrial closure in porcine model
41480269|NCT01436565|DRUG|MM-121 (SAR256212)|"Pharmaceutical form:solution~Route of administration: Intravenous"
41010326|NCT06364124|PROCEDURE|standard post-treatment for STEMI|standard post-treatment for STEMI
41017842|NCT04856163|BEHAVIORAL|Telelactation support|Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
41480270|NCT01436565|DRUG|SAR245408|"Pharmaceutical form:tablet~Route of administration: oral"
41480271|NCT03361384|DRUG|Alcohol|
41017843|NCT04809662|DRUG|Imiquimod|"Patients with a diagnosis of actinic keratosis or warts that would be prescribed imiquimod as standard of care will be asked to apply 2 packets (or 2 full pumps) of imiquimod once daily before bedtime for two weeks and then leave on overnight for \~8 hours.~(a) A biopsy will be performed at the baseline visit on the pre-treatment skin and the skin where the medication will not be applied. The skin where the medication will not be applied will act as the negative control. A biopsy will then again be performed on day 10 of imiquimod treatment on the treated skin only, where the study drug was applied."
41017844|NCT00178958|DEVICE|Holter Monitor|
41017845|NCT04003597|OTHER|Usual-salt diet|Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
41327028|NCT00347893|PROCEDURE|Selective laser trabeculoplasty|
41327029|NCT02732353|DIETARY_SUPPLEMENT|Minced beef|Cow meat protein supplement
41327030|NCT02732353|DIETARY_SUPPLEMENT|Hydrolyzed beef|Cow meat protein supplement
41327031|NCT05306353|DRUG|Placebo for VIB4920|26 participants will receive VIB4920 placebo administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including tumor necrosis factor alpha inhibitor (TNFi) (double-blinded)
41480272|NCT03361384|OTHER|Placebo (non-alcoholic beverage)|
41010327|NCT04704089|OTHER|spectrophotometer|"* Calibration of the spectrophotometer (calibration of white and green color on the provided support),~* Placing the patient or witness in the chair,~* Placement of intraoral retractors,~* Photographs of the dental arch in occlusion as well as slightly open mouth to visualize the mandibular incisors,~* If MIH is suspected, occlusal images of the occlusal surfaces of the first molars will be taken with the help of a dental mirror,~* Shooting with the spectrophotometer centered on each of the teeth of interest in the anterior sector with verification of the good quality of the shot according to the axis (validated in green on the camera),~* Backup of images with coded identification number"
40809780|NCT06656663|BEHAVIORAL|Social Prescribing|SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and LW, based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have an excellent knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.
40809781|NCT06656663|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
41154700|NCT01275872|OTHER|Guided Imagery and Progressive Muscle Relaxation|4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
41154701|NCT01737034|OTHER|dietary intervention by varying GI diets|The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
40809784|NCT06656117|OTHER|Elliptical training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
40809785|NCT06656117|OTHER|Resistance training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
41154702|NCT06190145|DRUG|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments were made throughout the study based on individual platelet counts.
41154703|NCT02706834|DRUG|TAK-828|TAK-828 oral solution
40809788|NCT06650748|DRUG|Dalpiciclib|Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.
40809789|NCT06650748|DRUG|Letrozole|2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage
41154704|NCT02706834|DRUG|Placebo|TAK-828 placebo-matching oral solution
41327032|NCT05306353|DRUG|VIB4920 with TNFi|52 participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including Tumor necrosis factor alpha inhibitor (TNFi) (double blinded)
41010328|NCT04704089|OTHER|Biological (protein analysis by western blot or mass spectrometry of matrix proteins), structural (electron microscopy) and physico-chemical analyses|"* Chemical analysis of enamel mineral.~* Techniques of spectrometry and spectroscopy (Raman and FTIR)~* Atomic Probe Tomography and Protein Mass Spectrometry (ICP-MS)."
41327033|NCT05306353|DRUG|VIB4920 without TNFi|Participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 but discontinue necrosis factor alpha inhibitor (TNFi) while continuing all other background rheumatoid arthritis (RA) therapy (evaluator-blinded)
40809792|NCT03772834|BEHAVIORAL|Exercise Intervention|Undergo resistance training and walking
40809793|NCT03772834|DRUG|Methylphenidate|Given PO
41010329|NCT06032624|PROCEDURE|combined ultra-sound guided femoral and sciatic nerve block.|Femoral nerve block, The femoral area will be scanned behind the midpoint of the inguinal ligament and the depth of the image will be set at 3-5 cm, and a linear high frequency 8-12MHz) probe will be placed perpendicular to the course of the femoral nerve., the volume of 15 ml of bupivacaine will be injected to perform the block. Sciatic nerve block, A curvilinear low-frequency (3-9 MHz) probe will be used to do a scan of the sub-gluteal region below a line from the ischial tuberosity and greater trochanter which are seen as two hyperechoic bony prominences,A volume of 25 ml of bupivacaine will be injected to perform the block.
41010330|NCT01000051|DRUG|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
41010331|NCT01000051|DRUG|Placebo|Once a day, orally for 8 weeks.
41327034|NCT05725330|OTHER|Gamification and education with mobile game application|This study aimed to provide self-care management by playing mobile games to patients with type 2 diabetes.
41327035|NCT03470857|DIAGNOSTIC_TEST|Patients|The FDG PET/CT imaging will be performed as part of typical medical procedures related to the diagnosis and monitoring of cancers at the Oncology Center in Bydgoszcz, Poland
41327036|NCT01877785|DRUG|MHAA4549A|Single-ascending dose of MHAA4549A
40809794|NCT03772834|OTHER|Placebo|Given PO
41327037|NCT01877785|DRUG|Placebo|Placebo to MHAA4549A
41327038|NCT05066867|OTHER|Smart sharps bin - collects data on compliance|collects compliance data
41327039|NCT05167721|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells administered intrathecally
41327040|NCT05167721|OTHER|Placebo|Placebo administered intrathecally
41327041|NCT04976296|DIAGNOSTIC_TEST|MRD detection|The Geneplus OncoMRD lung assay is used to detect the MRD status.
41327042|NCT01078714|DRUG|bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
41327043|NCT04603040|DRUG|Toripalimab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
41327044|NCT04768530|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
41327045|NCT04768530|DRUG|Nitazoxanide hydrogel|Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
41480273|NCT04224727|BEHAVIORAL|Group Commitment Contract|A group contract where the primary individual, who will be tracked by the study, can invite peers to join the contract and form their group. To initiate a contract, a user must choose: the stakes, start date, and (for weight loss contracts) target weight, and and, optionally, to allow other members to have the power to invite other people to join the group.
41480274|NCT04224727|BEHAVIORAL|Individual Monetary Rewards|Individuals eligible for a $100 monetary reward (incentive) following verified smoking cessation or weight loss.
41327046|NCT03271307|BEHAVIORAL|Optimized PITC|Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
41327047|NCT03271307|DIAGNOSTIC_TEST|Facility HIVST|HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.
40809795|NCT03772834|OTHER|Quality-of-Life Assessment|Ancillary studies
40809796|NCT03772834|OTHER|Questionnaire Administration|Ancillary studies
41327048|NCT03271307|DIAGNOSTIC_TEST|Index HIVST|HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
41327049|NCT03703362|OTHER|Resistance training|30 supervised training-sessions over 12 weeks
41327050|NCT01828099|DRUG|Ceritinib|Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule. Ceritinib (LDK378) was the investigational treatment and is referred to as the investigational study treatment/drug.
41327051|NCT01828099|DRUG|Pemetrexed|Pemetrexed was administered at a dose of 500 mg/m2 as an iv infusion on Day 1 of each 21-day cycle to patients randomized to the chemotherapy arm.
41327052|NCT01828099|DRUG|Cisplatin|Cisplatin was administered by IV at a dose of 75 mg/m2 every 21 days for up to 4 cycles.
41327053|NCT01828099|DRUG|Carboplatin|Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles
41327054|NCT05718206|DEVICE|Magnetocardiography|Both arms underwent magnetocardiogram examination, and three experts interpreted magnetocardiogram results independently.
41327055|NCT01319916|DRUG|ATX-101|ATX-101 2mg/cm2
41327056|NCT05145400|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab :10 mg/kg intravenous will be administered in cycle 1-24.
41480275|NCT04224727|BEHAVIORAL|Individual Commitment Contract|Individuals will have the opportunity to create an individual commitment contract to quit smoking. They will have the option to set the stakes, start date, and (for weight loss contracts) target weight.
41010332|NCT02652533|DEVICE|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
41327057|NCT05145400|DRUG|Lenalidomide|"Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR \> 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR \< 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death."
41327058|NCT05145400|DRUG|Dexamethasone|Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
41327059|NCT06281379|PROCEDURE|Total mesogastrectomy|More extended resection type with better oncological outcomes when compared to standard technique
41327060|NCT00307242|DRUG|Adefovir Dipivoxil|
41327061|NCT05414149|PROCEDURE|preoperative intravitreal injections of ranibizumab or conbercept|IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.
41327062|NCT04462536|DRUG|Placebo|Vehicle only
41327063|NCT04462536|DRUG|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
41327064|NCT06352411|DRUG|BI 456906|Solution for injection
41327065|NCT06372808|OTHER|The Plyometric Exercise|The training group will perform plyometric exercises for eight weeks in addition to their regular training program.
41327066|NCT06372808|OTHER|The Regular Training|The control group's regular training includes basic strength training, cardiovascular training, technical and tactical training, and match-style wrestling.
41327067|NCT02729805|DRUG|Saline|10ml bolus injection of saline followed by intravenous infusion of saline during the operation
41327068|NCT02729805|DRUG|Ketamine 0.5mg/kg|0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
41327069|NCT02729805|DRUG|Ketamine 0.75mg/kg|0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
41327070|NCT06068179|DRUG|Mycophenolate Mofetil, Oral, 250 Mg|Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy
41327071|NCT06068179|DRUG|methimazole, oral, 10mg|Methimazole 15-30mg daily initially then titrate to maintenance dose.
41327072|NCT02401087|PROCEDURE|Anaesthesiological procedure|
41327073|NCT03034057|DRUG|Sayana Press|Sayana Press in the Uniject injection system
41327074|NCT06315205|DRUG|Letrozole LEBE 75 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg
41327075|NCT06315205|DRUG|Letrozole LEBE 150 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg
41327076|NCT06315205|DRUG|Letrozole LEBE 225 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg
41327077|NCT04335708|DIETARY_SUPPLEMENT|Postibiotic formulation|5 mL daily of edible gel with intracellular content of Lactobacillus casei CRL-431
40809797|NCT03772834|OTHER|Stretching|Undergo stretching
41010333|NCT01595620|OTHER|Thermal|Thermal sensation/pain testing
41010334|NCT01595620|OTHER|Electrical|Electrical sensation/pain testing
41010335|NCT01595620|OTHER|Capsaicin|Intradermal Capsaicin
41010336|NCT01595620|DRUG|THC|Active THC (0.01 mg/kg) administered over 10 minutes
41327078|NCT04335708|DIETARY_SUPPLEMENT|Placebo formulation|5 mL daily of edible gel without intracellular content of Lactobacillus casei CRL-431
41327079|NCT03234972|DRUG|Daratumumab|Daratumumab will be administered on Day 1 of Cycles 4-9, and then q4w thereafter.
41327080|NCT03234972|DRUG|Velcade|Velcade will be administered at a dose of 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.
41010337|NCT01595620|DRUG|THC|Active THC (0.03 mg/kg) administered over 10 minutes
41010338|NCT01595620|DRUG|Placebo|Control: small amount of alcohol with no THC, administered over 10 minutes
41327081|NCT03234972|DRUG|Dexamethasone|Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
41327082|NCT00615797|BIOLOGICAL|Intravenous immunoglobulin|intravenous immunoglobulin 2g/kg total given over 2 days
41327083|NCT00615797|DRUG|standard interventions penicillin VK and haloperidol|Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
41327084|NCT05082064|DIAGNOSTIC_TEST|arterial blood gases and serum electrolytes|arterial bloog gases parameters serum potassium serum sodium serum calcium
41327085|NCT01809925|DIETARY_SUPPLEMENT|psyllium fiber 6.8g|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
41327086|NCT01809925|DIETARY_SUPPLEMENT|placebo|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
41327087|NCT02227056|DRUG|Methylphenidate|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
41327088|NCT01486004|DRUG|TMC435|Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
41327089|NCT01486004|DRUG|Ovysmen|Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
41327090|NCT05766436|DRUG|Dexmedetomidine|receive placebo ODF and 3 µ/kg nebulized dexmedetomidine (Precedex™ rxlist) prepared in 0.9% normal saline to a final volume of 3ml. Nebulization was performed using a wall nebulizer and wall oxygen source on 4 l/min.
41327091|NCT05766436|DRUG|Melatonin|will receive placebo nebulizer and 0.4mg/kg of ODF melatonin (metacyst ™ nerhadou) orally allowing the film to dissolve in the patients Oro mucosal lining
41327092|NCT05766436|DRUG|Placebo|placebo ODF and 0.9% normal saline nebulizer
41327093|NCT01993615|PROCEDURE|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
41327094|NCT01993615|PROCEDURE|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
41327095|NCT02436733|PROCEDURE|pleurectomy/decortication|Lung sparing procedures consist of the resection of the pleura without removing the lung
41010339|NCT04216732|OTHER|Blood Pressure Measurement|Undergo blood pressure measurement
41327096|NCT02436733|DRUG|Pemetrexed/Cisplatin|On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
41327097|NCT01478295|BEHAVIORAL|CuidaCare Intervention|Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
41327098|NCT01478295|OTHER|Control Group/Usual Care:|"Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education"
41327099|NCT00425113|DRUG|Metronidazole|
41327100|NCT00425113|PROCEDURE|Blood Draw|
41327101|NCT00425113|PROCEDURE|CT Scan|
41327102|NCT00425113|PROCEDURE|PET Scan|
41327103|NCT01826526|DEVICE|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
41327104|NCT05950971|DRUG|Amiodarone, diltiazem or esmolol|Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.
41327105|NCT01188538|DRUG|Epiduo gel|Once daily application on the face in the evening for 12 weeks
41327106|NCT01188538|DRUG|BPO|Once daily application on the face in the evening for 12 weeks
41327107|NCT03174613|DRUG|LC51-0255|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
41327108|NCT03174613|DRUG|Placebo|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
41327109|NCT03889899|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
41327110|NCT04197141|RADIATION|Conventionally-fractionated WPRT|Total dose: 45 Gy in 25 fractions WPRT
41327111|NCT04197141|RADIATION|Hypofractionated WPRT|Total dose: 25 Gy in 5 fractions WPRT
41010340|NCT04216732|OTHER|Questionnaire Administration|Complete questionnaires
41010341|NCT05040711|BEHAVIORAL|Mindfulness Coach|"This study will use Mindfulness Coach, an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. The app provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness. To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
41327112|NCT04873869|DRUG|NBI-921352|Administered orally
41327113|NCT04873869|DRUG|Placebo|Administered orally
41327114|NCT04777318|OTHER|Conventional physiotherapy|A total of 12 sessions of conventional physiotherapy program for 4 weeks were applied 3 days a week. The conventional physiotherapy program included 20 min hotpack , 10 min ultrasound, 20 min conventional (Transcutaneous electrical nerve stimulation) TENS application.
41327115|NCT04777318|OTHER|Conventional physiotherapy and Muscle Energy Technique|In addition to conventional therapy, the muscle energy technique was applied to the individuals in the second group at the same frequency. Muscle energy technique was applied to the upper trapezius, sternocleidomastoideus , scalene (anterior-medius-posterior) and levator scapula muscles. According to the MET post-isometric relaxation method, each muscle was applied as one set (each set includes three repetitions). The patient was asked to perform a 7-second isometric contraction corresponding to 20% of the maximum isometric contraction force in the area where the restriction was felt. After the application, the patient was asked to breathe and relax, and the neck was brought back to the barrier point and the technique was repeated.
41480276|NCT04224727|OTHER|Information|"In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates."
41327116|NCT04777318|OTHER|Conventional physiotherapy and Cervical Mobilization Techniques|Cervical mobilization techniques were also applied to the individuals in the third group in addition to conventional physiotherapy at the same frequency. In the first few sessions, bridging and manual traction techniques were applied in 3-5 repetitions. In the next sessions, in addition to these techniques, rotation with 3-5 repetitions of manual traction, anteroposterior sliding with traction and cervical lateral shift techniques were applied. Vertebrobasilar InsufficiencyTest was applied to all participants to determine the appropriateness of cervical mobilization. Before mobilization, a deep friction massage was applied on painful spasmic nuchal muscles for 3-4 minutes in order to increase blood circulation and relax tense tissues.
41327117|NCT02120144|OTHER|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
40809798|NCT06652412|DRUG|Ultrafractionated RT and CGA Guided systemic treatment.|in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.
41327118|NCT02120144|OTHER|Reading|"A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer"
41327119|NCT00740324|DRUG|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
41327120|NCT00740324|DRUG|NPO-11|NPO-11 after administration of NPO-11
41327121|NCT00740324|DRUG|NPO-11|1 mg glucagons after administration of NPO-11
41327122|NCT02970227|OTHER|Observation|None, observation only
41327123|NCT01734096|OTHER|Lower body negative pressure (LBNP)|Lower limbs are put in in LBNP device for one hour (-30 mbar)
41327124|NCT01734096|DRUG|Candesartan cilexetil|candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
41327125|NCT01270958|DRUG|Avamys aqueous nasal spray 110mcg|"At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.~Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken."
41327126|NCT00829127|DRUG|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
41327127|NCT00829127|DRUG|Placebo|Oral suspension
41327128|NCT01181102|DRUG|edoxaban|
41327129|NCT01181102|DRUG|enoxaparin sodium|
41327130|NCT05218577|OTHER|high selenium functional food|HSFF was made from the liver of the cow, that participant could eat HSFF direcly.
41327131|NCT05218577|DIETARY_SUPPLEMENT|selenium supplement|20 microgram/day selenium suppplement powder.
41327132|NCT05218577|OTHER|Placebo|the placebo mocaf powder
41327133|NCT04932044|BEHAVIORAL|Early Sleep Facilitation Program|It is divided into two stages. The first stage is to provide sleep circadian rhythm training for preterm infants during hospitalization, and the second stage is to give the caregiver the nursing guidance to promote preterm infants' sleep before preterm infants discharged from the hospital. Moreover, continue to give nursing guidance and follow its implementation status within two months after discharge.
41327134|NCT04932044|OTHER|Routine care|Receives routine care and provide general discharge care and nursing guidance.
41327135|NCT05394103|DRUG|Q901|The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
41327136|NCT05394103|DRUG|KEYTRUDA® (pembrolizumab)|KEYTRUDA® (pembrolizumab) will be administered Q6W
41327137|NCT03487887|DEVICE|continuous glucose monitoring (CGM) iPro™2 Medtronic|A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
41327138|NCT02989311|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP and Iron)|Maize porridge fortified with MNP and labelled iron compound
41327139|NCT02989311|DIETARY_SUPPLEMENT|Fortified Maize porridge (MNP + Iron + GOS)|Maize porridge fortified with MNP + GOS and labelled iron compound
41010342|NCT05040711|BEHAVIORAL|Active Comparator|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
41327140|NCT01440907|OTHER|Care Coordination Program|The Care Coordination Program includes: (1) access to a secure online personal health record (PHR) that people can logon and manage their health information, as well as receive alerts and reminders about action items for them to take on their healthcare; and (2) depending on the patient's health care needs, nursing support (either in-person or by phone).
41010343|NCT05725603|OTHER|MRI imaging|Shoulder MRI will be performed at least 3 years after shoulder surgery
41327141|NCT02394795|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
41327142|NCT02394795|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
41327143|NCT03654755|DRUG|ASN002|Daily dose of ASN002 for up to 110 weeks
41327144|NCT02528253|BIOLOGICAL|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
41010344|NCT02326142|DRUG|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
41010345|NCT02326142|DRUG|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
41010346|NCT01739530|BIOLOGICAL|Repaircell|allogenic differentiated adipocyte
41010347|NCT03852316|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
41010348|NCT00079274|DRUG|irinotecan hydrochloride|Given IV
41010349|NCT00079274|DRUG|oxaliplatin|Given IV
41010350|NCT00079274|DRUG|leucovorin calcium|Given IV
41010351|NCT00079274|DRUG|fluorouracil|Given IV
41010352|NCT00079274|BIOLOGICAL|cetuximab|Given IV
41010353|NCT00079274|DRUG|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
41010354|NCT05900479|OTHER|PTSD Service Dog|According to the Americans with Disabilities Act (ADA), a service dog is a dog that is trained to perform specific tasks to mitigate a disability. For PTSD service dogs, examples include detecting and alerting to physical signs of distress to interrupt anxiety and panic attacks, waking up Veterans from nightmares, and retrieving medication. In addition to trained tasks, service dogs live with the Veterans to provide emotional value as a source of comfort and companionship. Under the ADA guidance, PTSD service dogs have pubic access and are legally allowed to accompany their person in public places such as grocery stores, workplaces, and schools. In the proposed study, service dogs will be sourced from two Assistance Dog International (ADI) accredited providers, including K9s For Warriors and Canine Companions for Independence. Both providers have an established track record of training and providing PTSD service dogs, as well as collaborating with the investigative team in research.
41010355|NCT02717533|OTHER|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
41010356|NCT00077168|DRUG|anastrozole|
41010357|NCT00077168|DRUG|tamoxifen citrate|
41010358|NCT00077168|PROCEDURE|adjuvant therapy|
41010359|NCT00077168|RADIATION|radiation therapy|
41010360|NCT03917134|DRUG|cephalosporin + Metronidazole Vaginal|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
41327145|NCT02528253|BIOLOGICAL|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
41327146|NCT02528253|BIOLOGICAL|Tanezumab 5 mg SC|Tanezumab 5 mg SC
41327147|NCT02528253|BIOLOGICAL|Tanezumab 10 mg SC|Tanezumab 10 mg SC
41327148|NCT02528253|BIOLOGICAL|Tramadol PR oral|Tramadol PR oral
41327149|NCT00502528|DRUG|Placebo|Peri-interventional
41327150|NCT00502528|DRUG|BQ-123|Peri-interventional
41480277|NCT02099604|DRUG|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin|Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
41480278|NCT00347113|DRUG|Albendazole and praziquantel|
40809799|NCT06652412|OTHER|data prospectively collected|in cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.
41327151|NCT04461028|DRUG|Liposomal bupivacaine|20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
41010361|NCT03917134|DRUG|cephalosporin + Placebos|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
41327152|NCT04461028|DRUG|Bupivacaine with Dexamethasone Solution|20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
41327153|NCT04384432|OTHER|Routine Physical Therapy with Thoracic mobility exercise|Combınatıon of routıne Routine Physical Therapy with Thoracic mobility exercise
41327154|NCT04384432|OTHER|Routıne Physıcal therapy|Exercise for Chronic Neck Pain
41327155|NCT03284346|BEHAVIORAL|Exercise Intervention|Undergo CARE
41480279|NCT02848066|PROCEDURE|Blood sample(10cc) collection|In both groups, serum haptoglobins to be collected and analyzed
40809800|NCT06652412|RADIATION|Ultrafractionated Radiotherapy|1Fx every 3 or 4weeks
40809801|NCT06652412|DRUG|Sintilimab|200 mg q3w
40809802|NCT06652412|DRUG|Fluorouracil|5-Fluorouracil or capecitabine
40809803|NCT06652412|DRUG|Raltitrexed|Raltitrexed
40809804|NCT06652412|DRUG|Oxaliplatin|Oxaliplatin
41010362|NCT02090816|PROCEDURE|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
41010363|NCT01507428|DRUG|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
41010364|NCT01507428|DRUG|Carboplatin|Given IV
41010365|NCT01507428|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
40809805|NCT06652412|DRUG|Irinotecan (CPT-11)|irinotecan
41010366|NCT01507428|PROCEDURE|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
41010367|NCT01507428|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
41010368|NCT01507428|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
41010369|NCT01507428|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
41010370|NCT01507428|OTHER|Laboratory Biomarker Analysis|Correlative studies
41327156|NCT03284346|BEHAVIORAL|Exercise Intervention|Undergo standard stretching program
41327157|NCT03284346|OTHER|Laboratory Biomarker Analysis|Correlative studies
41327158|NCT03284346|DEVICE|Monitoring Device|Receive Polar heart rate monitor
41327159|NCT03284346|OTHER|Quality-of-Life Assessment|Ancillary studies
41010371|NCT01507428|DRUG|Paclitaxel|Given IV
41327160|NCT03284346|OTHER|Questionnaire Administration|Ancillary studies
41327161|NCT04201938|COMBINATION_PRODUCT|Symbiter-Omega|Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera.
41327162|NCT04201938|DIETARY_SUPPLEMENT|Placebo|Placebo
41327163|NCT03199508|DIAGNOSTIC_TEST|the 3-day voiding diary|The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
40809806|NCT06653751|DEVICE|Reminder App|he purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
40809807|NCT03709745|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection is given as described in the arm description
40809808|NCT03709745|DRUG|Ranibizumab Injection [Lucentis]|Intravitreal injection is given as described in the arm description
40809809|NCT06605027|OTHER|Therapeutic Ketogenic Diet|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
41154705|NCT05207449|OTHER|Questionnaire|"The questionnaire will include:~1. The demographic data of the patients~2. Chronic disease related questions~3. Assessment of adherence to treatment by using Arabic validated version of Medication Adherence Report Scale (MARS)~4. Patients' beliefs about medication will be assessed using Arabic validated version of Beliefs about Medicines Questionnaire (BMQ)~5. Disease acceptance will be evaluated using: Arabic validated version of Acceptance to Illness Scale (AIS)~6. Assessment of health-related quality of life (HRQoL) using the Arabic version of the Pediatric Qualify of Life Inventory Generic Core Scale (PedsQL) 4.0 GCS~7. Assessment of readiness for transition to adult health care settings using The Transition Readiness Assessment Questionnaire (TRAQ)"
41327164|NCT03199508|DIAGNOSTIC_TEST|the 7-day voiding diary|The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights.
40809812|NCT06598787|DRUG|BL-B01D1 for Injection|Administration by intravenous infusion for a cycle of 3 weeks.
40809813|NCT06592664|DRUG|LSTA1|LSTA1 given as a slow IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
40809814|NCT06592664|DRUG|Nab-paclitaxel|nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
40809815|NCT06592664|DRUG|Gemcitabine|gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
41010372|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
41010373|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
41010374|NCT03081416|DRUG|Ketamine|Intranasal ketamine administration
41010375|NCT03081416|DRUG|Normal saline|
41010376|NCT03081416|DRUG|Metoclopramide|Standard therapy
40809816|NCT06592664|DRUG|Placebo matching LSTA1|Placebo given as a slow IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
40809817|NCT06592664|DRUG|LSTA1|LSTA1 given as a slow IV push over 1 minute when standard treatment(s) are given
41010377|NCT03081416|DRUG|Ketorolac|standard therapy
41010378|NCT03081416|DRUG|Dexamethasone|Standard therapy
41010379|NCT03081416|DRUG|Benadryl|Standard therapy
41010380|NCT02150122|DIETARY_SUPPLEMENT|Vitamin D3|
41010381|NCT05911399|DRUG|Tiratricol|Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous endoscopic gastrostomy (PEG), nasogastric or jejunal tube.
41010382|NCT02714049|BEHAVIORAL|sex therapy|60 minutes each time, in person or on the telephone
41010383|NCT02714049|DRUG|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
41010384|NCT03544983|BEHAVIORAL|Web + Streamlined Telephone Genetic Information|Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
41010385|NCT02960880|DRUG|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
41010386|NCT02960880|DRUG|Phenprocoumon (branded and generics)|Individually adjusted dose
41327165|NCT00475800|DRUG|Lumiracoxib|
41327166|NCT03788863|DRUG|Diflucortolone valerate (BAY866146)|Follow clinical administration
41327167|NCT01135017|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
41327168|NCT01135017|DRUG|Placebo (for Dronedarone)|"Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
41010387|NCT02373124|DRUG|infusion of NMDA antagonist|52 minute infusion
41010388|NCT02919670|DIETARY_SUPPLEMENT|Enterade|
41010389|NCT02919670|DIETARY_SUPPLEMENT|Placebo|
41010390|NCT02919670|OTHER|Standard Supportive Care|
41010391|NCT05293275|DEVICE|EaseVRx Virtual Reality Headset|Virtual reality device with 360 degree visualization of various scenery and interactive modules
41010392|NCT01987323|DRUG|Subconjunctival injection of liposomal latanoprost|
41327169|NCT05049343|DRUG|SAGE-904|SAGE-904 oral solution.
41327170|NCT05049343|DRUG|Placebo|Placebo oral solution.
41327171|NCT05049343|DRUG|Ketamine|Ketamine intravenous (IV) infusion.
41327172|NCT00873288|OTHER|Usual care mailing intervention|routine colposcopy reminder letter
41480280|NCT05333237|DIETARY_SUPPLEMENT|Intervention #1: ProvideXtra Drink|Fasted subjects will be offered 200 ml of ProvideXtra and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
40809818|NCT06592664|DRUG|Placebo matching LSTA1|Placebo given as an IV infusion over 4 hours when standard treatment(s) are given
41154706|NCT02899481|OTHER|Transabdominal and transperineal ultrasound|Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
41480281|NCT05333237|DIETARY_SUPPLEMENT|Intervention #2: Fresubin Energy Drink|Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
41154707|NCT01177228|DRUG|Vedolizumab|Vedolizumab for intravenous infusion
41010393|NCT01935011|OTHER|PD, DBS|PD DBS frequency on swallowing function
41010394|NCT05789732|DRUG|Placebo|Patients will receive placebo treatment once daily.
41010395|NCT05789732|DRUG|Silodosin|Patients will receive Silodosin 8 mg once daily.
41010396|NCT05789732|DRUG|Tadalafil|Patients will receive Tadalafil 5 mg once daily.
41480282|NCT05333237|DIETARY_SUPPLEMENT|Intervention #3: Generic Glucose Solution|Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
41480283|NCT05320848|BEHAVIORAL|cardiac rehabilitation|Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.
41154708|NCT01177228|DRUG|Placebo|Placebo intravenous infusion
41154709|NCT01670747|RADIATION|Chest computed tomography|
41010397|NCT05789732|DRUG|Silodosin and Tadalafil|Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.
41010398|NCT03212677|DIETARY_SUPPLEMENT|Ferrous sulfate|Standard-of-care therapy for iron deficiency anaemia
41010399|NCT03212677|DIETARY_SUPPLEMENT|IHAT|IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.
41010400|NCT03212677|DIETARY_SUPPLEMENT|Aspiron|Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.
41010401|NCT03212677|OTHER|Placebo|Cornstarch
41010402|NCT06182267|DRUG|L Arginine|toothpaste
41010403|NCT06182267|DRUG|Sodium Fluoride|toothpaste
41010404|NCT01363778|DRUG|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
41327173|NCT00873288|OTHER|CIS support mailing intervention|Mailed reminder plus provider recommendation to call CIS and sample questions to ask
41327174|NCT00650182|DRUG|fentanyl; naltrexone|
41327175|NCT01305304|OTHER|repeated long term endurance exercise|competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)
41327176|NCT01305304|OTHER|Other|No history of endurance sports activity
41327177|NCT00350311|DRUG|nicotine transdermal patch/lozenge|
41327178|NCT03750240|DIAGNOSTIC_TEST|Sodium (Na) Magnetic Resonance Imaging (MRI)|"Two Na data will be acquired:~1. FLORET without Inversion Recovery (IR), and~2. FLORET with IR"
41327179|NCT03750240|DIAGNOSTIC_TEST|Dynamic Contrast- Enhanced (DCE) MRI|DCE MRI will be acquired subsequent to Na MRI to prevent influence of the contrast agent on 23 Na data
41154710|NCT06167915|BIOLOGICAL|30μg dose of LYB002V14|30μg dose of LYB002V14 vaccine IM, on day 0
41154711|NCT06167915|BIOLOGICAL|60μg dose of LYB002V14|60μg dose of LYB002V14 vaccine IM, on day 0
41154712|NCT06167915|BIOLOGICAL|placebo|placebo IM, on day 0
41327180|NCT01672528|OTHER|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
41327181|NCT01672528|OTHER|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
41480284|NCT00043758|DRUG|Tolvaptan|
41480285|NCT03861663|DEVICE|Ultrasound|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
41327182|NCT04354779|DIAGNOSTIC_TEST|a specifically designed self-administered questionnaire|The questionnaire consists of the following items: questions related to personal health, traveling activities, living situation, as well as inquiries of symptoms and comorbidities.
41327183|NCT03674658|DRUG|Propafenone|oral, TID
41327184|NCT05780593|OTHER|Manual Therapy|After the baseline assessment, each intervention group will be given physical therapy treatment. The group A will receive Manual Mobilization of the Lumbosacral Spine followed by passive stretching of the hip abductors of both sides of the body. The patient then will be asked to stand on the inclined board for 01 minute with feet 3 to 4 inches apart hands placed on the wall at the level of shoulder joints. After 01-minute patient will be asked to leave the inclined board. The patient will be advised to do this 01-minute inclined board standing for three times a day at home. All the patients in Group A will receive this treatment regime for two weeks.
41327185|NCT05780593|OTHER|Inclined Board Standing|The patients in Group B will be asked to stick to their medications if advised and stand on the inclined board for 01 minute. Inclined boards will be provided to all patients and will be advised to follow the inclined standing for 01 minute for three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.
41154713|NCT04297436|BIOLOGICAL|4CMenB (Bexsero®) vaccine|Tthe 4CMenB vaccine (Bexsero®) contains the MeNZB OMV component plus three recombinant antigens (NadA, fHBP-GNA2091, and NHBA-GNA1030. The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.
41327186|NCT01754675|BEHAVIORAL|Soccer|Watching the soccer match at the time that the favorite team is playing
41327187|NCT01754675|BEHAVIORAL|Movie|Watching a movie at the time that the favorite team is playing
41327188|NCT05884281|DRUG|Roflumilast|0.5 mg once daily for treatment period
41327189|NCT05884281|DRUG|Placebo|Placebo for treatment period
40809828|NCT06655207|DEVICE|Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding|Oli is a non-invasive wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding, including postpartum haemorrhage.
40809829|NCT06654505|BEHAVIORAL|Paired Community Health Workers|Community Health Workers will promote maternal and child health services as paired female and male
41327190|NCT06222736|OTHER|Rocabado Exercises|Patients trained by Rocabado Exercises
40809831|NCT05340569|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
40809832|NCT02254278|DRUG|Cisplatin|40 mg/m2 IV (intravenously) weekly for 6 weeks
40809833|NCT02254278|RADIATION|IMRT 6 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy
40809834|NCT02254278|RADIATION|IMRT 5 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
40809835|NCT06657092|PROCEDURE|Erector Spinae Plane Block|Single-shot ultrasound (US)-guided ESP block with 20 ml 0.25% bupivacaine ( Marcaine ) at the T4 vertebral level will be performed.
40809836|NCT06657092|PROCEDURE|Standart therapy|Postoperative 0.5 mg/kg morphine and 1 gr paracetamol will be admistered intravenously in the operation theatre and intravenous patient controlled analgesia (PCA) will be performed in the plastic surgery ward postoperatively
40809837|NCT06657391|DRUG|recombinant humanized anti-CD25 monoclonal antibody|The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
40809838|NCT06656078|OTHER|1. WORKING MEMORY TASK:|Arithmetic task: backward counting with serial 3 subtractions out loud. Group 1 and Group 2 participants will be asked to count backwards with serial 3 subtractions out loud while walking 10 meters. There is considerable disruption of performance because of simultaneous articulatory suppression. However, when errors were observed they were calculated to be numerically close to the correct figure which suggests that performance was not completely disrupted by suppression of articulation.
41010405|NCT03427658|BEHAVIORAL|Sweet food consumption|Comparison of the impacts of sweet and non-sweet food consumption
41010406|NCT02311049|RADIATION|Hypofractionation|
41010407|NCT04902859|DRUG|Clonidine Oral Liquid Product|Clonidine prepared from pharmacy with 20 mcg/ml concentration.
41327191|NCT06222736|OTHER|Servical Core Exercises|Servical Core Exercises
41327192|NCT03558451|OTHER|Complex intervention in sexual health|EXIMe is a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
41327193|NCT03558451|OTHER|Usual care|According to available protocols applicable to the patient and the health service standardized portfolio
41327194|NCT02978664|PROCEDURE|Air insufflation|Air insufflation during colonoscopy including insertion phase
41327195|NCT02978664|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
41327196|NCT02978664|PROCEDURE|Water exchange|Water will infused and removed during insertion phase of colonoscopy
41480286|NCT01157897|BIOLOGICAL|VMP001|Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
41480287|NCT01157897|OTHER|P. vivax sporozoite challenge|P. vivax sporozoite challenge
41480288|NCT00433277|DRUG|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
41010408|NCT04902859|DRUG|Sterile water|Sterile water used as placebo
41010409|NCT03524027|PROCEDURE|Posterior Vertebral Column Resection (PVCR)|Posterior Vertebral Column Resection (PVCR) Surgical Technique for Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity
41480289|NCT05500040|BEHAVIORAL|Multimodal Rehabilitation|The rehabilitation measure is based on the biopsychosocial ICF model of the WHO. A multidisciplinary team of therapists looks after the patients during their stay in rehabilitation. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to their needs.
41480290|NCT04989777|DEVICE|IABP (Intra-aortic balloon pump ) implantation|Eligible AMI patients in SCAI-B stage will receive IABP implantation from the femoral artery
40809839|NCT06656078|OTHER|2. VISUAL AND VERBAL FLUENCY TASK|Modified Stroop test or Stroop colour word test: Participants are asked to name the colour of ink that each word is printed. It is the most frequent test used to show attention bias in anxiety patients. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
40809840|NCT06656078|OTHER|3. MOTOR TASK:|Carrying a tray with four glasses filled with water. Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
41154714|NCT06289868|DIAGNOSTIC_TEST|Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|"Samples will be tested by comparing Access anti-HAV assay results to final anti-HAV sample status, and Access anti-HAV IgM results to final anti-HAV IgM status, according to respective instructions for use (IFU) or study guide, as applicable, to determine to determine non-reactive (NR), reactive (R), Negative, Positive or Equivocal (EQ).~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT).~For evaluation of the clinical performance of Access anti-HAV IgM assay, all clinical samples, except pre- and post-vaccinated patient samples, will be tested with the reference assays Abbott - ARCHITECT® HAVAb-IgM, DiaSorin - LIAISON® Anti-HAV IgM, and SIEMENS Healthineers Atellica IM® Hepatitis A IgM (aHAVM)."
41154715|NCT06289868|DIAGNOSTIC_TEST|Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|"All samples will be tested pre- and post-vaccination by comparing Access anti-HAV assay results to final anti-HAV status, according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity.~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT)."
41154716|NCT02894359|DEVICE|cone beam imagery of cervical spine|
40809844|NCT06656923|DIAGNOSTIC_TEST|Biopsies|Analyze previous biopsies to quantify changes induced by Poly-L-Lactic Acid in Adipose Tissue
40809845|NCT06656650|BEHAVIORAL|Commensality groups|Participants will attend at least 3 out of 6 commensality groups over the course of 6 months.
41327197|NCT03499613|OTHER|Multidisciplinary rehabilitation program|The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
40809847|NCT06657118|PROCEDURE|Ultrasound guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* Transducer is placed over TMJ, parallel to the long axis of mandibular ramus. • Transducer is tilted until the optimal visualization is obtained.~* Disc is visualized as a thin homogenous, hypo-to-iso-echoic band lying adjacent to the inferior relation. The bony landmarks of the mandibular condyle and the articular eminence are visualized as hyperdense lines.~* Superior joint space located between the disc and articular eminence is the targeted point of the needle.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
41010410|NCT00901940|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
41010411|NCT00901940|BIOLOGICAL|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
41327198|NCT04735965|DRUG|Dexmedetomidine|Dexmedetomidine would be intravenously infused at a dose of 1μg/kg over 15 minutes 30 min before the end of surgery
41327199|NCT04735965|DRUG|Meperidine|Meperidine would be intravenously injected at a dose of 0.5mg/kg 30 min before the end of surgery
41327200|NCT04735965|DRUG|Placeb|Equal volume of normal saline to dexmedetomidine and meperidine group.
41010412|NCT04458064|OTHER|LMA i gel|insertion of LMA for maintaining airway during anesthesia
41010413|NCT02321865|DRUG|NPC-02|
41010414|NCT02093546|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor
41327201|NCT00126854|PROCEDURE|Magnetic Resonance Spectroscopy Imaging|
41327202|NCT02703987|OTHER|Fermented infant milk formula|
41480291|NCT01369602|DRUG|PF-04991532|single dose 300-mg
41480292|NCT01369602|DRUG|PF-04991532|single dose 300-mg
41010415|NCT02533921|OTHER|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
41010416|NCT02533921|OTHER|Standard of Care|Usual care defined as including both a PCP and neurologist
41010417|NCT03037151|DRUG|Grazaoprevir/Elbasavir|treatment naive
41480293|NCT01369602|DRUG|PF-04991532|single dose 300-mg
41480294|NCT01369602|DRUG|PF-04991532|single dose 300-mg
41480295|NCT03016338|DRUG|Niraparib|200 or 300 mg daily PO, for 21 day cycle
41480296|NCT03016338|DRUG|TSR-042|500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
41480297|NCT04457453|OTHER|Macintosh in sniffing position|Macintosh direct intubation in sniffing position
41327203|NCT02703987|OTHER|Non-fermented infant milk formula|
40809848|NCT06657118|PROCEDURE|Conventional anatomically guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* A line will be drawn from tragus of the ear to the outer canthus of the eye with ink.~* Double needled canula is inserted into superior compartment of the joint space 2mm below and 10 mm ahead of mid-tragal end of Holmund Hellsing's line.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
40809850|NCT06657651|PROCEDURE|immediate implant placement with dentin-derived membrane|immediate implant placement with dentin-derived membrane and allograft in mandibular molar area
40809851|NCT06657651|PROCEDURE|immediate implant with extended platelet rich fibrin membrane|immediate implant with extended platelet rich fibrin membrane and allograft in mandibular molar area
40809852|NCT06651385|OTHER|Remote digital therapeutic exercise program|Participants will be introduced to the digital therapeutic exercise program during Screening and Consent (Visit 0, V0). Participants will be provided with an orientation to the Vitala platform and assistance will be offered in the download and access to the application, as needed. The study team will ensure access has been obtained via the health care professionals' dashboard on the Vitala app. Information obtained in the assessments outlined above will inform the tailored exercise prescription to meet the participant's needs. Participants will be encouraged to complete a total of 150 minutes of remote exercise sessions each week for 12 weeks via the Vitala platform. Participants will receive daily notifications to remind them to complete their assigned daily exercises.
41154717|NCT00212888|BIOLOGICAL|Remune and ALVAC|"* Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);~* Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or~* Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20."
41154718|NCT05283525|DIETARY_SUPPLEMENT|Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches|0 - 90 Days of Treatment
41154719|NCT05283525|DIETARY_SUPPLEMENT|Oxygen Saturation|0 - 90 Days of Treatment
40809856|NCT06662084|DIAGNOSTIC_TEST|phenotype|"Eligible patients will receive orally the cocktail probe drugs ( via a naso-gastric tube at D3 after tMCS implantation or after the beginning of the cardiogenic shock for the control group) and via an oral administration at 14 days after tMCS explantation (or cardiogenic shock termination for the control group defined as: no need to use inortropic or vasopressive agent and absence of organ insufficiency). The phenotyping probe drugs of the Geneva Cocktail will be given as: one capsule containing the remaining probe 'cocktail' drugs. According to clinical experience in our intensive care unit department, inflammation related to tMCS peaks at D3 after tMCS implantation.~Blood samples will be collected from the central venous line 2 hours after drug administration for CYP phenotyping and genotyping. Inflammatory markers blood levels (Il-6, TNF-α, Il-1β, IFN-γ) will be measured at tMCS implantation or shock initiation and at the same time than CYP phenotyping."
41010418|NCT03037151|DRUG|Grazaoprevir/Elbasavir/RBV|treatment experienced
41327204|NCT06311110|OTHER|Vancouver symptom score for dysfunctional elimination symptoms Questionnaire|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016. The questionnaire is filled in by the parents of the child.
41480298|NCT04457453|OTHER|Macintosh in Trendelenburg position and Sellick position|Macintosh direct laryngoscopic intubation in Trendelenburg position and Sellick position
40809857|NCT06660979|BEHAVIORAL|Reinforcement learning|The intervention is a reinforcement learning program that personalizes EHR-based tools for PCPs to promote deprescribing high-risk medications over follow-up. The reinforcement learning intervention selects a tool for each provider based on an algorithm from an inventory of EHR tools and chooses tools that are predicted to motivate action for the individual provider. The inventory of EHR tools from which the algorithm will choose include the following potential factors: open encounter, order entry, cold-state outreach, simplification, and risk framing.
40809858|NCT06662279|DEVICE|Removable Rapid Palatal Expander|Removable palatal expander where expanders are changed to obtain up to .25mm expansion per expander
40809859|NCT06662279|DEVICE|Banded Palatal Expander|Palatal expander cemented into mouth where a screw is turned to obtain .25mm expansion per turn
41154720|NCT05283525|DIETARY_SUPPLEMENT|Total Blood Chemistry|0 and 90 Days of Treatment
41154721|NCT05283525|DIETARY_SUPPLEMENT|Adverse Event Monitoring|Adverse Event Monitoring Throughout the Study
41154722|NCT05283525|DIETARY_SUPPLEMENT|Body Weight Monitoring|0 - 90 Days of Treatment
41154723|NCT05283525|DIETARY_SUPPLEMENT|Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health|0 - 90 Days of Treatment
41154724|NCT04284722|DRUG|Metformin Hydrochloride|Perioperative continuation of oral metformin therapy according to the patient's normal dosage and dosage intervals
41154725|NCT03003884|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary.
41327205|NCT06311110|OTHER|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning. The questionnaire is filled in by the parents of the child.
41327206|NCT06311110|OTHER|Questionnaire concerning impaired toilettraining and comorbities|Unvalidated, complementary questions concerning impaired toilettraining and comorbidities. Questions were based on ICCS standardisation guidelines (Austin et al., 2015). The questionnaire is filled in by the parents of the child.
41327207|NCT00657722|OTHER|Angiography and Computed Tomography|Preoperative angiography and Computed Tomography
41327208|NCT01724112|DRUG|LY2940094|Administered orally
41327209|NCT01724112|DRUG|Placebo|Administered orally
41327210|NCT00071422|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
41010419|NCT04306510|PROCEDURE|Blood samples for immunoglobulins|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for immunoglubulins at a clinic visit every 4 months for up to 2 years.
41010420|NCT04306510|PROCEDURE|Blood samples for inflammatory markers|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for inflammatory markers at a clinic visit every 4 months for up to 2 years.
41010421|NCT04306510|PROCEDURE|Blood samples for anti-drug antibodies|Patients taking TEGSEDI as prescribed by their physician per the product label, patients will have additional blood samples for anti-drug antibodies at various time-points as indicated in the event of hypersensitivity reactions.
41010422|NCT04114552|OTHER|questionnaires|"6 weeks after the trauma,during the call, an oral questionnaire will be proposed to collect data on patients' management since they have left the emergency department.~After the call, socio-demographic characteristics, trauma mechanism, medics management will be extracted from the patient's medical records"
40809860|NCT06659679|DRUG|New use of oral semaglutide|New use of oral semaglutide dispensing claim is used as the exposure.
40809861|NCT06659679|DRUG|New initiation of sitagliptin|New use of sitagliptin dispensing claim is used as the reference.
41010423|NCT00360776|DRUG|tipifarnib|Given orally
41010424|NCT00360776|OTHER|laboratory biomarker analysis|Correlative studies
41010425|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
41010426|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule|Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,
41010427|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.
41010428|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule|Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
41010429|NCT04469361|OTHER|Navicular drop measurement|The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.
41327211|NCT00071422|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
41327212|NCT00071422|DRUG|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
41327213|NCT04913441|OTHER|Routine physical therapy|Patients in this group will get every session routine physical therapy of 30 minutes 3 times per week on alternative days for 12 weeks
41327214|NCT04913441|OTHER|Manual physical therapy with routine physical therapy|Patients in this group will get every session Manual physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
41327215|NCT04913441|OTHER|Stretching physical therapy with routine physical therapy|Patients in this group will get every session of Stretching physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
41327216|NCT02727660|DRUG|BFF MDI (PT009) 320/9.6 μg|Blinded Treatment
41327217|NCT02727660|DRUG|BFF MDI (PT009) 160/9.6 μg|Blinded Treatment
41327218|NCT02727660|DRUG|FF MDI (PT005) 9.6 μg|Blinded Treatment
41327219|NCT05658263|DIETARY_SUPPLEMENT|Standard Diet|Participants receiving only standard of care (SOC) nutrition advice, which is SOC Dietary Instructions, as provided by routine surgical consults and one protein shake per day for 4 weeks prior to surgery (SOC).
41327220|NCT05658263|DIETARY_SUPPLEMENT|BIG MACS Diet|Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
41327221|NCT04765618|PROCEDURE|bariatric surgery|laparoscopic sleeve gastrectomy,or gastric bypass
41327222|NCT00241163|PROCEDURE|Fibrinogen (human) + thrombin (human) (TachoSil)|
41480299|NCT04457453|OTHER|AceScope in Trendelenburg position and Sellick position|AceScope videolaryngoscopic intubation in Trendelenburg position and Sellick position
40809862|NCT06658379|DIAGNOSTIC_TEST|CD8+TEMRA|
40809863|NCT06660784|DRUG|Nitric Oxide|Depending on the indication, the subjects will be given NO treatment or not. In ECMO assisted mechanical ventilation + NO treatment group, the subjects will be randomly assigned to NO treatment via ventilator or membrane oxygenator.
41010430|NCT04469361|OTHER|Measurement of venous return parameters in supine|Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position
41010431|NCT04469361|OTHER|Measurement of venous return parameters in standing|In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.
41010432|NCT04469361|OTHER|measurement of midfoot pressure distrubition|In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
41010433|NCT04766879|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
41010434|NCT04766879|DEVICE|Placebo|Passive emanator with formulated inert ingredients
41154726|NCT03003884|DRUG|Propofol|Initial dose plus supplemental doses as necessary.
41154727|NCT00176761|DRUG|Interleukin-2 (IL-2)|
41327223|NCT01320956|BEHAVIORAL|Pre operative nurse consultation and Hypnosis|Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
41327224|NCT01320956|OTHER|Pre operative nurse consultation|Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
41327225|NCT00004732|PROCEDURE|Carotid Endarterectomy (CEA)|CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
41327226|NCT00004732|DEVICE|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
41480300|NCT04803188|DIAGNOSTIC_TEST|Magnetic Resonance|"Screening MRI examinations will be performed on an MRI General Electric (GE) 3 Tesla MRI using a 32-channel phased array pelvic coil. The imaging protocol will include: T2-weighted morphological and diffusion-weighted functional sequences.~All images will be reviewed by two radiologists experienced in urogenital imaging, who will be blinded to the patients' medical history. Both radiologists in charge will then assign a PI-RADS score (1 to 5) to each lesion for bi-parametric MRI, representing the likelihood of a clinically significant prostate lesion. For the generation of the overall PI-RADS score assigned to each lesion, the PI-RADS score algorithm for non-contrast MRI described in the PI-RADS version 2.1 recommendations will be applied. Lesions scored as bPI-RADS superior or equal than 3 will be directed to MRI-TRUS guided targeted biopsy."
41327227|NCT03823807|DRUG|SH-1028|Oral,100mg or 200mg ,QD, fasted
41327228|NCT01369849|DRUG|Akt Inhibitor MK2206|Given PO
41327229|NCT01369849|DRUG|Bendamustine Hydrochloride|Given IV
41480301|NCT06437418|DIAGNOSTIC_TEST|abdominal ultrasonography.|Evaluate the gallbladder ejection fraction (EF)
41480302|NCT01475253|DRUG|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
41480303|NCT01475253|OTHER|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
41480304|NCT01475253|PROCEDURE|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
41480305|NCT00965770|DEVICE|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
41480306|NCT04462471|DIAGNOSTIC_TEST|I-124 PET/CT lesion dosimetry|I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)
41480307|NCT04462471|DRUG|Vemurafenib|Dose level 1 \& 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid
41480308|NCT04462471|DRUG|Copanlisib|Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly
41480309|NCT00952549|PROCEDURE|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
41480310|NCT03301103|BIOLOGICAL|E. coli strain E1392-75-2A|After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
41480311|NCT03301103|DEVICE|PTM202|PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
41480312|NCT00594620|DIETARY_SUPPLEMENT|Flav-ein capsules|Soy/isoflavone supplementation
41480313|NCT00594620|DRUG|Placebo|Placebo
41480314|NCT04341376|BEHAVIORAL|Enhanced First Connections|Enhanced First Connections is a short-term home visiting program that includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation.
41480315|NCT01615042|DRUG|Lenalidomide|Oral capsule, daily, 50mg-100mg, one cycle (21 days)
41010435|NCT04232163|BEHAVIORAL|Arm Boot Camp|The intervention involves a combination of daily homework based upper limb exercises and feedback from an activity monitor to motivate use of the affected upper limb. Participants will be supported through virtual sessions with a therapist.
41010436|NCT03176732|DEVICE|Positive Airway Pressure|Participants will use Positive Airway Pressure (PAP) treatment
41010437|NCT06390475|DIAGNOSTIC_TEST|MR Direct Thrombus Imaging (MRDTI)|Both groups will get the same MRDTI, the study is a proof-of-concept study to investigate if MRDTI can reliable distinguish between acute and chronic splanchnic thrombosis.
41327230|NCT01369849|OTHER|Laboratory Biomarker Analysis|Correlative studies
41327231|NCT01369849|BIOLOGICAL|Rituximab|Given IV
41327232|NCT04854577|PROCEDURE|Opioid Free Anesthesia|Patients will be administered a combination of a pre-incisional pecto-intercostal fascial plane block and a standardized opioid free anesthetic regimen consisting of dexmedetomidine, esketamine and lidocaine.
41327233|NCT04854577|PROCEDURE|Traditional Anesthetic Regimen|Patients will be administered a traditional anesthetic regimen which is based on sufentanil dosage. The dosage is at the discretion of the attending anesthesiologist.
41327234|NCT00392119|DEVICE|MR-guided Laser Interstitial Thermal Therapy System|
41327235|NCT03792802|PROCEDURE|laparoscopic appendectomy port sites|one group will have classic port sites ;.Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent . one group will have same dermatome port sites ; One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port
41327236|NCT03685370|PROCEDURE|LOS|placement of epidural catheters with LOS technique
41327237|NCT03685370|PROCEDURE|X-ray placement|placement of epidural catheters with x-ray guide
41327238|NCT01300364|DRUG|Reboxetine|8mg/day.
41327239|NCT01300364|DRUG|citalopram (SSRI)|30mg/day
41327240|NCT02066519|BEHAVIORAL|Physical exercise programme using a rowing machine|3 sessions per week of individualized physical training using a rowing machine during 3 months.
41327241|NCT02267226|DRUG|Octafibrin|
41327242|NCT05479266|OTHER|Muscle Energy Technique|METS-Post isometric relaxation will be applied for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
41327243|NCT05479266|OTHER|Myofascial release|Myofascial Release will be done for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
41327244|NCT01716026|DRUG|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
41010438|NCT03671681|BEHAVIORAL|Mindfulness|The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
41480316|NCT01543659|DRUG|89Zr-DFO-huJ591|The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11-100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
41010439|NCT03671681|DRUG|Prophylactic|Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
41010440|NCT01400594|DRUG|HTU-520 Patch|Terbinafine hydrochloride patch
41010441|NCT01400594|OTHER|Placebo Patch|Treatment with Placebo Patch
41010442|NCT04095000|BEHAVIORAL|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
41010443|NCT04095000|BEHAVIORAL|Treatment as Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
41010444|NCT00145366|DRUG|Recombinant human thyrotropin (Thyrogen)|
41010445|NCT02459314|DIETARY_SUPPLEMENT|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
41010446|NCT02459314|DIETARY_SUPPLEMENT|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
41010447|NCT05483010|DRUG|Atorvastatin|Atorvastatin is commercially available.
41480317|NCT01751542|BEHAVIORAL|Mindfulness + Residential Treatment|
41327245|NCT06049615|DEVICE|CLAAS® System|The CLAAS® System delivers a plug to the ostia of the Left Atrial Appendage (LAA) and is designed to occlude the appendage to eliminate blood flow. It is designed to conform to the geometry of the LAA. The implant is designed to permanently seal off the LAA from the LA with an endothelial layer that forms across the LA face of the implant. The implant is available in two different sizes; Regular (27mm) and Large (35mm) to accommodate patient anatomy. Angiography and/or echocardiography may be used to determine the LAA ostium diameter to properly select the Implant size. The implant has an inner, cylindrical, Nitinol endoskeleton that provides the mechanical base structure. The Nitinol endoskeleton contains 10 face struts and 20 anchors (Regular) and 12 struts and 24 anchors (Large) facing proximally to engage the tissue to resist movement. The endoskeleton also provides the conformable structure to enable the foam cylinder to compress against the LAA tissue to facilitate sealing.
41327246|NCT06431178|OTHER|General Anesthesia|"General anesthesia will be induced by 6% sevoflurane with a face mask. An intravenous line(22-g cannula )will be inserted then fentanyl 1mcg-kg will be given . Endotracheal tube will be used to intubate the patient .Anesthesia will be maintained by 2%sevoflurane inhalation in an oxygen air compination 1:1 throught the operation . Crystalloid solution was used to replenish fluid according 4/2/1-rule. Monitoring during the procedure include , ejection fraction (EF),blood pressure, heart rate, respiratory rate, and O2 saturation are measured at baseline, after induction, 10 min after catheter insertion,30 min during procedure and post emergence."
41480318|NCT01751542|BEHAVIORAL|Residential treatment alone|
41010448|NCT05483010|DRUG|Rosuvastatin|Rosuvastatin is commercially available.
41010449|NCT06126484|PROCEDURE|transcatheter cardiac intervention|Balloon atrial septostomy, PDA stent implantation, Pulmonary valvuloplasty, Aortic valvuloplasty, Balloon angioplasty of coarctation, PDA closure in preterm neonates
41154728|NCT04934878|BIOLOGICAL|Referral information|first visit to our hospital/transfer from another hospital
41327247|NCT06431178|OTHER|Local anesthesia|A nasal cannula was placed and oxygen delivered at 2 to 3 L/minute. An intravenous line will be inserted (22-g cannula). The sedation regimen will include loading dose of dexmedetomidine (1 mcg/kg) and ketamine (1mg/kg) over 10 minutes . The patient will receive an infusion of dexmedetomidine at 0.7 mcg/kg per hour and ketamine 0.5 mg/kg/hr as maintenance sedation .Local infilteration of xylocaine 2% at dose 2mg/kg will be given for vascular access in cardiac catheterization . After completion of the procedure the infusion pump will be stopped to ensure that the patient is fully awake and vitally stable
41010450|NCT01006811|DIETARY_SUPPLEMENT|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
41010451|NCT01006811|OTHER|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
41010452|NCT02489981|DRUG|Spiriva|60 puffs
41010453|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
41010454|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
41010455|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
41327248|NCT06243315|DEVICE|Ellansé-S|It is indicated for subcutaneous implantation to correct moderate-to-severe NLFs
41480319|NCT05093465|BEHAVIORAL|Technology Intervention|"Participants were provided with sleep hygiene and stimulus control procedure plus procedures to reduce technology usage in bed (i.e., technology usage stimulus control).~In addition to the sleep hygiene and stimulus control procedures, participants were also given a set of procedures aimed at changing technology usage behavior at bedtime and throughout the day."
41480320|NCT05093465|OTHER|Active Control|Participants were provided with sleep hygiene and stimulus control procedures.
41480321|NCT02880748|OTHER|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
41480322|NCT02880748|OTHER|Air insufflation (AI) method.|Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
41480323|NCT01516866|PROCEDURE|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging|Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
41480324|NCT00752674|OTHER|Neuromuscular balance|
41480325|NCT01940094|DRUG|5 mg Prednisone|Subjects will remain on daily prednisone dose of 5 mg
41480326|NCT01940094|DRUG|0 mg Prednisone|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
41480327|NCT05290324|DRUG|Midazolam|Midazolam infusion will be given after the surgery as 0.25 mg/kg/min.
41010456|NCT05329740|DRUG|Methylprednisolone Injection|All eligible patients randomised to the glucocorticoid group will receive intravenous Methylprednisolone for 3 days after surgery. The dosage is 2mg/kg/d on post-operative day 1, 1mg/kg/d on post-operative day 2, and 0.5mg/kg/d on post-operative day 3. The daily dosage will be administered with two injections (12h interval).
41010457|NCT02828839|PROCEDURE|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
41010458|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
41010459|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
41010460|NCT06472804|OTHER|Non-Interventional Study|Non-interventional study
41154729|NCT00393198|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
41154730|NCT00393198|DRUG|Cytotec|Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
41154731|NCT00393198|DRUG|Placebo|Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
41327249|NCT01771367|BIOLOGICAL|Fluad|
41327250|NCT01771367|BIOLOGICAL|Agrippal|
41327251|NCT01771367|BIOLOGICAL|Placebo|
41327252|NCT04297410|RADIATION|177Lu-PSMA-I&T Radionuclide|Each patient will receive two single doses of 7.4 GBq 177-Lu-PSMA-I\&T treatments. The treatments will be given intravenously, 2 weeks apart starting 12 weeks prior to radical prostatectomy.
41327253|NCT00284739|DRUG|Alteplase|2mg or 4mg given twice daily for three days into loculated abscess
41327254|NCT00284739|OTHER|saline|saline injection twice daily for three days
41480328|NCT05248984|DRUG|Ketorolac|"Once the decision has been made by the primary obstetrics (OB) provider to proceed with cesarean delivery, participants will be randomized in to one of two groups:~* Single dose of intravenous (IV) Ketorolac 30mg Vs.~* Single dose of intravenous (IV) Ketorolac 60mg"
41480329|NCT01019876|DRUG|Fludarabine|
41480330|NCT01019876|DRUG|Cyclophosphamide|
41480331|NCT01019876|DRUG|Busulfan|
41480332|NCT01019876|DRUG|Alemtuzumab|
40809864|NCT06658184|BEHAVIORAL|sleep restriction and stimulus control|"Sleep restriction: a) Reduce bedtime to match actual sleep time, but ≥4.5 hours, and adjust bedtime according to sleep efficiency; b) Avoid daytime naps and maintain a regular wake-up time.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
41010461|NCT03344185|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention consisted of three low GI meals.
41010462|NCT03344185|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention consisted of three meals, all with a high GI value.
41010463|NCT00033384|DRUG|CI-1040|
41010464|NCT00864474|DRUG|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
41327255|NCT03482128|DEVICE|Coagulation management guided by SONOCLOT|Application of blood products guided by SONOCLOT measurements
41327256|NCT03482128|DEVICE|Standard coagulation management|Application of blood products based on clinical experience of the anesthesiologist in charge
41480333|NCT01019876|DRUG|Rabbit Anti-thymocyte Globulin|
41480334|NCT01019876|DRUG|Horse Anti-thymocyte Globulin|
41480335|NCT02632513|DEVICE|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
40809865|NCT06658184|BEHAVIORAL|sleep hygiene education|"Sleep hygiene education:~1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight."
41010465|NCT05546333|DEVICE|Electrical impedance tomography|Non-invasive measure of electrical impedance in the body, with data collected on electrodes on the surface of the body
41010466|NCT01818362|BIOLOGICAL|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
41010467|NCT01818362|BIOLOGICAL|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
41010468|NCT00237588|DRUG|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
41010469|NCT05996081|BEHAVIORAL|Adherence toolkit|The adherence toolkit consists of a flowchart of adherence intervention, a self-reported adherence questionnaire, and an intervention wheel as a decision support tool for a healthcare provider. The toolkit can guide HIV care providers to identify problems causing nonadherence and to tailor the effective interventions based on the individual problems. It is available in a Bahasa Indonesia version, accompanied by a user guide on the practical application of the intervention, and can be used digitally or printed on paper. The intervention wheel is an integrated HIV medication adherence influencing factors and effective adherence-promoting interventions derived from systematic reviews and meta analyses, including previous studies conducted in Indonesia.
41010470|NCT02556710|BIOLOGICAL|4 mL injection of AMPION™|4 mL Injection of Ampion
41010471|NCT02556710|DRUG|4 mL injection of Placebo|4 mL Injection of Placebo
41010472|NCT01233297|DRUG|Azithromycin|10 mg/kg peroral for 3 consecutive days
41327257|NCT06268587|COMBINATION_PRODUCT|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS &amp;gt; 3/10 on day one and who did not take analgesics.|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS \&amp;gt; 3/10 on D+1 and who did not take analgesics. The protocol consists of providing the patient with instructions at the time of discharge, analgesics for a maximum of two days with dosages and an explanatory booklet on pain management
41327258|NCT01767012|DEVICE|Polylens EC-HY10-PAL (coated)|hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
41480336|NCT02139917|BEHAVIORAL|Transitional community based palliative care|"transitional palliative care include:-~* telephone follow up for early identification of signs and symptoms~* relief of signs and symptoms encountered~* home visit with spiritual support"
41480337|NCT03465748|DEVICE|OrthoK|orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.
41480338|NCT05397743|OTHER|Quality of Life|Questionnaire Perceived stress scale (PSS) + Questionnaire Short form 36 (SF-36) + Questionnaire Visual functioning questionnaire 25 (VFQ-25)
41010473|NCT01233297|OTHER|Placebo mixture|Placebo mixture containing no active substance.
41154732|NCT05473221|BIOLOGICAL|CD33 CAR-T|CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
41154733|NCT02053402|DRUG|Vitamin D|Vitamin D daily for six months
41010474|NCT02361567|DRUG|Tramacet|Pain medication commonly used post-operatively
41010475|NCT02361567|DRUG|Percocet|Pain medication commonly used post-operatively
41010476|NCT02130375|PROCEDURE|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
41010477|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol.
41010478|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol. May be able to cross over and receive 6 additional treatments with the high dose of propofol.
41154734|NCT06108752|OTHER|Scapular stabilization exercises|The scapular stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
41327259|NCT01767012|DEVICE|Polylens EC-Y10-PAL (uncoated)|
41327260|NCT04693520|DRUG|ALZ-801|ALZ-801 265 mg twice daily (BID)
40809866|NCT06658002|DRUG|Cyclosporine A|Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
41010479|NCT00594256|DRUG|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
41327261|NCT04505150|BEHAVIORAL|Lifestyle changes, e.g., take part in regular exercise, quitting smoking, and reduce salt consumption|Intervention participants will receive ongoing counselling with evidence-based information with pictures, fact sheets, published literature about the harmful effect of smoking on hypertension and other cardiovascular diseases for the cessation of smoking and to take part in regular exercise.
41010480|NCT03613506|DRUG|Captopril 12.5 Mg|Taking captopril 12.5mg b.i.d for two months before radiotherapy.
41480339|NCT06094907|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in an ascending fixed-order of 15mg and 60mg.
41480340|NCT05423470|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
41480341|NCT05423470|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
41010481|NCT05323695|BEHAVIORAL|Depression Screening Intervention|All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.
41327262|NCT01136863|DRUG|Felodipine|
40809867|NCT06658002|OTHER|Placebo Comparator: Placebo|Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
40809868|NCT06661902|DRUG|Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio)|"Patients scheduled for prostate biopsy will be approached for the study. Following enrollment, participants will complete three questionnaires that assess their baseline pain and anxiety scores.~Patients will then be randomized to one of two arms for their local anesthetic: (A) 1% Lidocaine or (B) Buffered Lidocaine. The patient and urologist will both be blinded to the contents of the local anesthetic.~During the procedure, local anesthetic will be administered in the standard fashion. Patients will then complete a series of questionnaires asking about the pain associated with the local anesthetic and prostate biopsy as a whole. Complications will be assessed."
41010482|NCT05702320|OTHER|the heating procedure|The patients will undergo a heating procedure.
41010483|NCT02796807|DRUG|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
41010484|NCT03183791|BEHAVIORAL|RELAXaHEAD app|The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.
41010485|NCT03183791|BEHAVIORAL|Monitored Usual Care (MUC)|"The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app."
41010486|NCT05227924|DEVICE|Total hip arthroplasty (primary or revision)|Total hip arthroplasty with at least one medical device from the SYMBOL range
41010487|NCT03943810|OTHER|No intervention|There is no intervention
41327263|NCT01136863|DRUG|Placebo|
41327264|NCT05304819|DEVICE|AchilloCordPLUS™ System Implant|AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair
41327265|NCT01821547|DRUG|Hepatitis B vaccine|Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
41327266|NCT06528743|RADIATION|RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.|Patients will receive RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases. Enrolled patients will receive a fractionation scheme with increasing break length.
41327267|NCT05561712|OTHER|Laboratory method validation|Test several sampling conditions
41327268|NCT01932658|BIOLOGICAL|Hematopoietic stem cell transplantation|Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
41480342|NCT02522403|PROCEDURE|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
41480343|NCT02522403|DEVICE|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
41480344|NCT01045915|BIOLOGICAL|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
41010488|NCT04939623|DRUG|Probenecid|The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.
41327269|NCT01442701|OTHER|Removal of triclosan-containing cleaning products from household.|An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
41327270|NCT00274768|DRUG|capecitabine|A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
41327271|NCT04190212|BEHAVIORAL|High-intensity interval training + standard care|HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
41327272|NCT06387030|BIOLOGICAL|Blood sampling|3 tubes of blood for research purposes (maximum 9.6 mL for children weighing 5-12 kg, 16 mL between 12-20 kg, 24 mL between 20 and 30 kg, and 56 mL for those weighing over 30 kg) will be taken from the catheter necessary for general anaesthesia.
41480345|NCT05899322|BEHAVIORAL|Primary Care Intervention for PTSD Spanish Speaking Adolescents|This treatment ranges from 1-3 sessions which last 30-50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the adolescent with optional parent involvement. The first session will also teach the adolescent a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the adolescent's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that address the adolescent's symptoms. This treatment will be delivered via telehealth and all materials have been developed in both Spanish and English.
41480346|NCT05899322|BEHAVIORAL|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
41480347|NCT02135406|BIOLOGICAL|CART-19 T cells|
41480348|NCT04184661|OTHER|blood sample|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
41327273|NCT06387030|BIOLOGICAL|Esophageal biopsies|4 additional esophageal biopsies will be taken during digestive endoscopy, in the pathological zone or in the lower third of the esophagus by default.
41480349|NCT01506908|DRUG|oral nicotine|oral nicotine replacement product
41480350|NCT01506908|DRUG|Placebo|no active
41480351|NCT03354455|DEVICE|Repetitive transcranial magnetic stimulation|"Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot."
41480352|NCT00064584|DRUG|CT53518|
41480353|NCT00040430|DRUG|111In-DAC|
41010489|NCT02358824|DRUG|CKD-828|"Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)"
41480354|NCT00040430|PROCEDURE|Diagnostic|
41480355|NCT01838928|DRUG|Bupivacaine|
41480356|NCT04882917|DRUG|M4076|M4076 will be administered orally, in Part 1A and Part 1B.
41480357|NCT02792959|DEVICE|Functional Imaging previous the second course|Functional Imaging before and after 1 cycle of chemotherapy treatment, in the previous 4 days before the second course: PET1 and MRI1
41480358|NCT02792959|DEVICE|Functional Imaging previous the surgery|Functional Imaging after 4 cycles of chemotherapy treatment, in the 3 weeks after the chemotherapy, before the interval surgery: PET4 and MRI4 The RECIST evaluation will be done, usually, by scanner to 4 courses of chemotherapy before the surgery interval
41480359|NCT00179868|BEHAVIORAL|C-Reactive Protein levels|"Each patient enrolled in the study will have a serum quantitative c-reactive protein (crp) level drawn on the day of transplant, day 7 of transplant, and twice weekly after that until recovery of neutrophil count (approximately 20-25 days). Patients will be followed for 100 days post-transplant for the development of the following complications:~1. Sepsis- defined as fever, positive blood culture, need for fluid resuscitation and/or pressor support.~2. Acute GVHD \> grade II defined according to the Seattle criteria~3. VOD- defined according to the modified Seattle criteria"
41480360|NCT06302972|OTHER|Traditional treatment|Hot Pack will be applied at the beginning of the session for 10 minutes. Wall corner stretching exercises, neck isometric exercises and neck stretching exercises will be performed Cold pack will be applied at the end of the session for a few minutes.
41010490|NCT02358824|DRUG|Telmisartan|"- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)"
41327274|NCT06387030|BIOLOGICAL|Unstimulated saliva sampling|A esophageal brushing will be done during digestive endoscopy.
41327275|NCT06387030|BIOLOGICAL|Urine sampling|A urine sample will be collected during hospitalization for digestive endoscopy.
41327276|NCT06387030|BIOLOGICAL|Stool sampling|A stool sample will be collected during hospitalization for digestive endoscopy.
41327277|NCT02528968|BEHAVIORAL|Educational Package|Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
41010491|NCT02358824|DRUG|S-amlodipine|"- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)"
41010492|NCT01799356|DRUG|Moxifloxacin|daily 400 mg moksifloksasin
41010493|NCT01799356|DRUG|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
41010494|NCT01799356|DRUG|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
41010495|NCT02376166|DRUG|Metformin|850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade \> 1 toxicities)
41010496|NCT06154434|DRUG|Chlorpromazine HCl 100mg Tablets|single-dose administered after a 10-hour overnight fast.
41480361|NCT06302972|OTHER|IASTM and CCEP|"Instrument Assisted Soft Mobilization Technique (IASTM); For pectoralis major:~Subjects will be asked to lay supine with their thorax front side exposed. In abduction, restriction or adhesions will be located using scanning and gel will be applied. IASTM also address soft tissue restrictions and pain in levator scapulae, suboccipital muscles and sternocleidomastoid muscle.~The Comprehensive Corrective Exercise Program (CCEP) will be designed in three phases, including initial, improvement, and maintenance.. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board"
41480362|NCT03812991|DRUG|Miacalcin Calcitonin Salmon Nasal Spray|Miacalcin nasal spray is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily
41480363|NCT04251091|OTHER|Treadmill walking|Up to 5 bouts of 6 minutes walking on the treadmill with rest breaks allowed between sets
41010497|NCT01049659|BEHAVIORAL|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
41154735|NCT06108752|OTHER|Thoracic extension exercises|Thoracic extension exercises will be comprised of three exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
41010498|NCT03723694|DIETARY_SUPPLEMENT|650 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
41010499|NCT03723694|DIETARY_SUPPLEMENT|0 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
41010500|NCT03225794|DIAGNOSTIC_TEST|Simian foamy virus Infection|Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
41154736|NCT04266366|OTHER|Face-to-Face Rehabilitation program|In each hospital, two trained therapists will carry out a face-to-face rehabilitation program consisting of electroanalgesia and an exercise program that follows the Mckenzie method. The physiotherapists place the electrodes in the patients, for this they use 5x9 cm electrodes, which they place at the bilateral paravertebral level, in the patients who present with radicular pain, the electrodes will be placed in the path of the affected nerve. The duration will be sufficient to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal periarticular components of the spine.
41154737|NCT04266366|OTHER|Telemedicine program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
41154738|NCT02024399|OTHER|Exercise|Strength training, aerobic exercise and core strengthening, running
41154739|NCT01906658|DRUG|Repository corticotropin injection|Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
41010501|NCT04744727|DRUG|paracetamol-pethidine|100 ml containing 1000 mg paracetamol -50 mg pethidine HCL
41010502|NCT04252105|DIETARY_SUPPLEMENT|Antioxidant|Antioxidant-rich diet (added selected types of fruits, vegetables, nuts, cereals and oils)
41010503|NCT04165291|BEHAVIORAL|F4C|Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.
41010504|NCT04165291|BEHAVIORAL|BIP|The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
41010505|NCT01857258|DIETARY_SUPPLEMENT|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
41010506|NCT04173338|DRUG|Cabozantinib|start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
41010507|NCT04173338|DRUG|Pemetrexed|Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
41480364|NCT04251091|OTHER|Overground Walking|Up to 5 bouts of 6 minutes walking overground with rest breaks allowed between sets
41480365|NCT00444821|DEVICE|AneuRx AAA stent graft / Talent AAA stent graft|Catheter based stent graft inserted to seal off an abdominal aortic aneurysm
41480366|NCT03431974|DRUG|LD-Aminopterin oral capsule|anti-folate treatment
41480367|NCT03431974|DRUG|Placebo oral capsule|Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
41480368|NCT06234774|PROCEDURE|Robot-assisted laparoscopic surgery|
41480369|NCT06234774|PROCEDURE|Conventional (non-robotic) laparoscopic surgery|
41480370|NCT03744559|BEHAVIORAL|Retrieval Extinction Training (RET)|Retrieval extinction training (RET) is a behavioral intervention that involves cue-elicited retrieval followed by extinction training (i.e., massed unreinforced exposure to drug-associated cues). The first element of RET involves briefly presenting drug-associated cues to retrieve drug use memories. The second element, occurring after a brief interval, involves extinction training. It is argued that the initial retrieval of the memories prior to extinction training initiates a period of instability, which is followed by reconsolidation of the memories back into long-term storage. Extinction training during the period of instability is presumed to overwrite the original drug-associated cue with a non-drug-associated cue, to attenuate expression of drug-seeking behavior.
41480371|NCT03744559|BEHAVIORAL|Control Retrieval Extinction Training (RET)|The control retrieval extinction training (RET) for the NR-E arms serves as the control intervention to the RET behavioral intervention. The first element of the control RET involves briefly presenting retrieval cues that contain neutral, non-smoking content. The second element, occurring after a brief interval, involves extinction training. Based on findings from the previous NIDA-funded R21, the R-E arm reported a significant 25 percent reduction in cigarettes smoked per day during the follow-up period versus the control NR-E arm.
41480372|NCT03744559|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI) will identify patterns of brain activity associated with RET and potentially predictive of treatment outcomes. The fMRI is used during the baseline and 24-hour follow-up test sessions while participants complete a cue-reactivity task. The collection of fMRI data is based on findings from human fear conditioning fMRI studies, in which groups receiving RET in the reconsolidation window exhibited less fear that was associated with attenuated BOLD response in the amygdala, relative to the control. We propose that the R-E arm will evidence attenuated cue reactivity in medial prefrontal cortex, limbic regions and ventral striatum, and that greater reduction in BOLD response in regions of interest will predict decreased smoking.
41327278|NCT04789863|DEVICE|SMILe-Integrated Care Model|"Four self-management intervention modules will be delivered by human and technology: 1) monitoring \& follow-up; 2) infection prevention; 3) medication adherence; 4) physical activity.~Human. A CC will provide structured and tailored self-management and behavioural support regarding all 4 modules via 12 face-to-face meetings congruent with planned clinic follow-up visits. The CC will be connected with the patients via the SMILe technology, enabling rapid responses to early signs of health deterioration.~Technology. The SMILe technology consists of the SMILeApp and SMILeCare. The latter is the interface of the monitoring component to connect the patient with the CC supporting fast recognition of symptoms and health deterioration. The SMILeApp enables to daily record a set of medical, behavioural and symptom-related data. A lexicon provides self-management and behavioural information. All data will be transferred to the clinic to be monitored, with the patient's consent, via SMILeCare."
41327279|NCT04789863|OTHER|Usual Care|The control group (CG) participants will receive usual care, which includes no specific counselling. USB outpatient appointment frequency follows a standard schedule: during the first 3 months post-alloSCT, depending on their health status, most patients (73%) return 1 to 3 times per week for follow-up at the USB outpatient clinic, where they are mainly seen by a junior or senior physician. Depending on health status and recovery, follow-up intervals extend to weekly or monthly within 1 year post-alloSCT. A research assistant (RA) will just contact CG participants for data collection. If participants raise concerns about any symptoms, the RA will encourage them to contact their physicians.
41010508|NCT02904252|OTHER|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F\>2).
41010509|NCT02442830|DEVICE|Early Video Capsule Endoscopy|"The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.~Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue."
41010510|NCT03919045|DRUG|Saline injection|Half of the patients will be randomized to saline injections into the neck and head muscles
41327280|NCT03962556|OTHER|bimanual palpation|bimanual palpation....i..
41327281|NCT05897112|DRUG|Group A received cryotherpay|Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
41010511|NCT03919045|PROCEDURE|Placebo|Half of the group will be treated with needle stings without injections
41327282|NCT05897112|DRUG|Group B received 10% Potassium Hydroxide Solution|Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
41010512|NCT01157481|DRUG|Conventional therapy plus nifedipine|Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
41010513|NCT01157481|DRUG|Conventional therapy|Conventional therapy
41010514|NCT06055426|OTHER|bed bath application|Patients who agree to participate in the research and are assigned to the experimental group will receive a bed bath. In order to examine the short-term, medium-term and long-term effects of bed bath, it is planned to have the whole body bed bath performed by the researcher nurse xx three times a week, two days apart.
41327283|NCT03410927|DRUG|TAS0728|TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
41327284|NCT03379480|BEHAVIORAL|Yoga arm|Yoga module developed for patients with Schizophrenia
41327285|NCT03963713|RADIATION|Stereotactic radiotherapy|Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
41327286|NCT03963713|RADIATION|Conventionally-fractionated image- guided Intensity modulated radiotherapy|Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
41327287|NCT03182413|DRUG|Placebo|
41327288|NCT03182413|DRUG|Modafinil|
41327289|NCT03182413|DRUG|THN102|
41327290|NCT06073041|OTHER|Invitation to adopt|All eligible Prisma Health clinics will be invited to adopt EIMG. Adopting clinics will first be sent an instructional video as a part of a low touch initial onboarding. After 4 months, clinics will then recieve an in-depth standardized onboard training.
41327291|NCT04432844|PROCEDURE|Biplanar Ultrasound guided Internal Jugular Vein Cannulation|Using Philips EPIQ elite ultrasound system with a high-frequency 3D and 4D volume linear array transducer (USG XL 14-3) to obtain the biplanar imaging of Internal jugular vein cannulation.
41327292|NCT04369768|PROCEDURE|restoration of permanent molars affected with MIH|restore MIH affected molars using direct composite or preformed metal crowns
41480373|NCT03744559|OTHER|No functional magnetic resonance imaging (fMRI)|No functional magnetic resonance imaging (fMRI) serves as the control intervention to the fMRI intervention. Participants who are randomized to the no fMRI intervention or who have a contraindication to MRI will complete an identical cue-reactivity task in a cue-reactivity lab during the baseline and 24-hour follow-up test sessions.
41480374|NCT05697055|DRUG|Azvudine|5mg orally, once a day, for no more than 14 days
41480375|NCT05697055|DRUG|Nirmatrelvir-Ritonavir|Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR \< 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
41480376|NCT04337619|BEHAVIORAL|Behavioral Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
41480377|NCT04337619|BEHAVIORAL|Mindful Acceptance|Integration of acceptance and willingness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
40809869|NCT06661902|DRUG|1% Lidocaine HCL|"Patients scheduled for prostate biopsy will be approached for the study. Following enrollment, participants will complete three questionnaires that assess their baseline pain and anxiety scores.~Patients will then be randomized to one of two arms for their local anesthetic: (A) 1% Lidocaine or (B) Buffered Lidocaine. The patient and urologist will both be blinded to the contents of the local anesthetic.~During the procedure, local anesthetic will be administered in the standard fashion. Patients will then complete a series of questionnaires asking about the pain associated with the local anesthetic and prostate biopsy as a whole. Complications will be assessed."
40809870|NCT06660602|PROCEDURE|cardiac surgery|All kinds of cardiac surgeries
41154740|NCT02771184|DEVICE|Lung Sound Recording System|The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.
41010515|NCT06020716|DRUG|Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution|Three times daily
41010516|NCT06020716|DRUG|Placebo|Three times daily
41010517|NCT01766375|DRUG|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
41154741|NCT02357355|DEVICE|UIHC Driving Simulator|This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
41154742|NCT02274350|RADIATION|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
41154743|NCT00072826|DRUG|Oxypurinol|
41154744|NCT00072826|DRUG|L-NMMA|
41480378|NCT04337619|BEHAVIORAL|Values|Integration of values clarification and awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
41480379|NCT04337619|BEHAVIORAL|Mindful Awareness|Integration of mindfulness and present-moment awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
41480380|NCT05112419|DRUG|Zibotentan|All participants will receive a single oral dose of zibotentan capsule under fasted conditions.
41480381|NCT00500552|DRUG|Perhexiline/Placebo|
41154745|NCT00072826|DRUG|Acetylcholine|
41154746|NCT00331851|DRUG|liraglutide|
41480382|NCT04126616|DIAGNOSTIC_TEST|chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent|chest MRI will be performed at rest and after moderate exercise
41480383|NCT06175429|DIAGNOSTIC_TEST|Physical performance testing|Assessment of physical performance using established clinical tests and scoring systems
41480384|NCT06175429|DIAGNOSTIC_TEST|Breath sampling and VOC analysis|Sampling of exhaled breath and using Proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF) for VOC quantification.
41480385|NCT06175429|DIAGNOSTIC_TEST|Muscle ultrasound|Quantitative and qualitative assessment of different limb skeletal muscles using non-invasive ultrasound.
41154747|NCT00331851|DRUG|insulin glargine|
41154748|NCT00331851|DRUG|metformin|
41154749|NCT00331851|DRUG|glimepiride|
41327293|NCT05730257|PROCEDURE|Robot-Assisted Kidney Transplantation|Robot-Assisted Kidney Transplantation takes place with the patient under general anaesthesia. Several ports are placed in the lower abdomen, for the entry of the camera, surgical instruments and manuel access. The DaVinci robot is placed between the patient's legs and docked to the ports. The iliac vascular bed is prepared and a peritoneal cavity created laterally. The kidney is introduced through the handport, regional hypothermia obtained via iceslush in the cavity and the vessel lumens flushed with heparin. The vessels are blocked during suturing with the kidney graft vessels anastomosed end-to-side to the external iliac vessels. The kidney graft is placed in the retroperitoneal cavity and a ureterovesical anastomosis performed ad modem Woodruff over double J stent. The ureter is placed extra peritoneally, fascia closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
41327294|NCT05730257|PROCEDURE|Open Kidney Transplantation|Open Kidney Transplantation takes place with the patient under general anaesthesia. A jockey-stick (Gibson) incision is made in the left or right iliac fossa and the peritoneum is displaced. With the kidney under hypothermia, the iliac vascular bed is prepared, the vessel lumens flushed with heparin and a vascular clamp instrument is used to block the vessels during suturing. The kidney graft vessels are anastomosed end-to-side to the external iliac vessels and the ureterovesical anastomosis performed ad modem Woodruff over a double J stent. The kidney graft is placed in the cavity and the fascia is closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
41327295|NCT01277497|DRUG|Sevelamer carbonate|Sevelamer carbonate 1,600 mg three times daily with meals
41327296|NCT01277497|DRUG|Calcium acetate|Calcium acetate 1,334 mg three times daily with meals for 12 weeks
41327297|NCT02228564|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
41327298|NCT02228564|DEVICE|LIFESTREAM™ covered stent|Implantation of the LIFESTREAM™ covered stent
41327299|NCT04152642|DEVICE|Marketed Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
41327300|NCT04152642|OTHER|Water control|negative control
41327301|NCT04152642|DEVICE|Experimental Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
41327302|NCT01286701|DRUG|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
41327303|NCT05152277|DRUG|HRS9531|Administered SC once
41327304|NCT05152277|OTHER|placebo|Administered SC once
41154750|NCT00274846|BIOLOGICAL|aldesleukin|10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
41154751|NCT00274846|BIOLOGICAL|therapeutic allogeneic lymphocytes|Cells infused per kg. 1.5-8.0 x 10\^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10\^9
41154752|NCT00274846|DRUG|cyclophosphamide|Days -5 and -4: 60 mg/kg
41154753|NCT00274846|DRUG|fludarabine phosphate|Days -5 through -2: 25 mg/m\^2
41327305|NCT05152277|DRUG|HRS9531|Administered SC for multiple dose
41327306|NCT05152277|OTHER|placebo|Administered SC for multiple dose
41327307|NCT00648570|DRUG|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fasting
41327308|NCT00648570|DRUG|Lexapro® Tablets (20 mg|20mg, single dose fasting
41327309|NCT00795171|DRUG|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
41154754|NCT00274846|PROCEDURE|in vitro treated peripheral blood stem cell transplantation|Day 0 infuse natural killer cells
41154755|NCT00062270|DRUG|cisplatin|
41154756|NCT00062270|DRUG|docetaxel|
41154757|NCT00062270|DRUG|gefitinib|
41154758|NCT00062270|DRUG|gemcitabine hydrochloride|
41154759|NCT00062270|PROCEDURE|conventional surgery|
41154760|NCT00062270|PROCEDURE|neoadjuvant therapy|
41154761|NCT00062270|RADIATION|radiation therapy|
41327310|NCT00795171|DRUG|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
41327311|NCT00795171|DRUG|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
41327312|NCT04508062|PROCEDURE|pectopexy operation|Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.
41327313|NCT04508062|PROCEDURE|uterosacral ligaments plication operation.|At least 2/3 of the sacrouterine ligaments will be shortened with helical sutures, starting from the cervix and so douglas will be partially obliterated.
41327314|NCT02615067|DRUG|99mTc-MIP-1404 Injection|A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.
41327315|NCT02615067|DIAGNOSTIC_TEST|Whole-Body Planar and pelvic SPECT/CT scan|A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404.
41480386|NCT06175429|DIAGNOSTIC_TEST|Blood-based biomarker analysis|Blood sampling and assessment of different blood-based biomarkers of muscle integrity using Enzyme-linked Immunosorbent Assay (ELISA) and Electrochemiluminescence Immunoassay (ECLIA)
41480387|NCT05874440|DRUG|Tenofovir Disoproxil Fumarate and Entcavir|Regular registration of side effects of the drugs, cause of non-compliance to treatment
41154762|NCT02391116|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
41154763|NCT04420897|PROCEDURE|Arterial blood gas samples|Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.
41154764|NCT04090216|DEVICE|Primary Percutaneous Coronary Intervention|Primary PCI will be done for patients with STEMI in both groups of patients
40809876|NCT06660264|OTHER|Pharmacist Personalized Medication Review (PMR)|Pharmacist-provided review of current medications and assessment of potential medication related problems.
40809877|NCT06660264|OTHER|Discussion of Pharmacogenomic results during the PMR|Return of pharmacogenomic results and discussion of impact on medications.
41154765|NCT02156999|DEVICE|Ibandronic acid, vitamin D|
41154766|NCT02745184|BIOLOGICAL|Lung stem cells|Patients will receive 0.5-5x10\^6 (0.5-5 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
40809880|NCT06658964|DRUG|Cohort 1: JMKX003142 and itraconazole|"JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD"
40809881|NCT06658964|DRUG|Cohort 2: JMKX003142 and rifampicin|"JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD"
41154767|NCT05673616|OTHER|Mckenzie Extension Exercises|"After two weeks of initial consultation, the patient will be taught to perform slouch-overcorrect on day 1 followed by flexion on day 2 in lying position and accompanied by flexion for 5 days in sitting position and finally flexion in standing will be performed.~The exercises will be repeated for 10 times and followed by extension in standing exercises."
40809883|NCT06658990|PROCEDURE|buccal acupuncture|ultrasound positioning assisted buccal acupuncture
40809884|NCT06658990|DRUG|control|Sufentanil is used after surgery
41154768|NCT01797822|DRUG|Dexamethasone|
41154769|NCT01797822|DRUG|Artificial tear|
40809888|NCT06661343|BEHAVIORAL|C4 Program|The C4 intervention is a behavioral program designed to provide care coordination to address structural barriers to PrEP adherence among Black men who have sex with men (MSM). It includes personalized support services, focusing on healthcare access, mental health, and stigma reduction to promote consistent PrEP use. Participants will receive counseling sessions and follow-ups based on their individual needs.
40809889|NCT06661343|BEHAVIORAL|C4 + 3MV Program|This intervention combines the C4 care coordination with the 3MV behavioral program. The 3MV program focuses on behavior change, addressing self-efficacy, stigma, and promoting healthy practices. Through this combination, participants receive both structural and behavioral support to maximize their adherence to PrEP.
41154770|NCT03887871|DRUG|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration after meal
41154771|NCT03887871|DRUG|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration after meal
41154772|NCT06645782|BEHAVIORAL|Virtual, Group CF-CBT|Virtual, group CF-CBT is an online, tailored CBT program for adults diagnosed with CF. Participants will attend eight weekly sessions (90 minutes each) delivered online. The sessions include: Introduction to CBT; Relaxation Skills; Depression in CF: What Helps?; Adaptive Thinking Skills, Part 1; Adaptive Thinking Skills, Part 2; Taking Charge of My Health; Anxiety in CF: What Helps?; and Maintaining Positive Changes.
41154773|NCT03865940|DRUG|Lidocaine|6 mL of 1% lidocaine
41154774|NCT03865940|DRUG|Guanfacine|250 mcg
41154775|NCT00884884|DRUG|Double Placebo|1 capsule daily
41154776|NCT00884884|DRUG|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
41154777|NCT00884884|DRUG|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
41154778|NCT00884884|DRUG|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
41154779|NCT00884884|DRUG|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
41154780|NCT00884884|DRUG|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
41154781|NCT00884884|DRUG|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
41154782|NCT00884884|DRUG|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
41154783|NCT00884884|DRUG|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
41154784|NCT00884884|DRUG|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
41154785|NCT06080178|DRUG|Plasma-lyte|Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg
41154786|NCT06080178|DRUG|Norepinephrine|When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).
41154787|NCT06080178|DRUG|Plasma-lyte|"Plasmalyte will be administered intravenously:~(1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg."
41154788|NCT06080178|DRUG|Norepinephrine|"When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg."
41154789|NCT04136587|OTHER|Colonic fluid collection during endoscopy for analysis of the bacterial secretome|Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
41327316|NCT06047925|PROCEDURE|3D printed crown|Reduction will be performed on the occlusal surface using a flame stone or a wheel stone, to perform occlusal clearance by 1 mm. Reduction will be performed by 1 mm on the mesial, distal, buccal and lingual surfaces of the tooth. Impression for the preparation will be taken using putty and light poly vinyl siloxane material. Temporary crown will be placed above the preparation as temporisation.The impression will be sent to the lab .The preparation will be optically scanned in the lab and the restoration will be digitally designed using computer designing software.The crown will be printed using 3D printer using hybrid resin(micro-filled hybrid composite) material.The 3d printed crown is cemented with resin cement.
41154790|NCT06646835|BEHAVIORAL|Stress Ball Intervention|The stress ball is a simple and effective tool for reducing anxiety and relaxation as a non-pharmacological method (Yanes et al., 2018). Due to the limited pharmacological options available for pregnant women to reduce anxiety during cesarean section, alternative, complementary or supportive non-pharmacological methods and low-risk approaches are needed (Baltacı \& Başer, 2020). It is thought that squeezing the stress ball may be advantageous in reducing anxiety.
41154791|NCT03401788|DRUG|Belzutifan|120 mg once daily (three 40 mg oral tablets once daily).
41154792|NCT06647212|OTHER|introducing breathing exercises with the harmonica|In addition to regular breathing exercises, participants will perform harmonica exercises
40809894|NCT06658743|BEHAVIORAL|Shared Medical Appointments|Participants will attend 4 quarterly appointments. In addition to time with their clinician, they will also have group activities that address relevant topics.
40809895|NCT06658743|OTHER|Standard of Care|Multidisciplinary team based care every 3 months.
40809896|NCT06660238|OTHER|No interventions|No interventions
40809897|NCT06658938|DRUG|Blinatumomab|"Beginning 3 months after transplantation, 1 cycle of blinatumomab was performed every 3 months for a total of 4 maintenance cycles.~Dosage of blinatumomab: 9 ug/d D1-4, 28 ug/d D5-14"
41327317|NCT06047925|PROCEDURE|stanless steel crown|The occlusal surface of the tooth should be reduced by about 1.5 mm, maintaining its occlusal contour or until the tooth is out of occlusion with adequate room to fit a crown.Proximally, tooth reduction will be made through the mesial and distal contact areas, then roundation of line angles to avoid the creation of ledges or steps.The crown selection will be done by trial and error or by measuring the mesiodistal dimension of the tooth space with dividers. It can also be helpful to measure the dimension of the contralateral tooth. A correctly fitting crown should snap or click at try in.
41327318|NCT04813276|BEHAVIORAL|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants receive weekly notifications for 12 weeks alerting them that a new serious game session is available and encourage them to complete one session per week.
40809898|NCT06661538|BEHAVIORAL|Food Security Screening & Referral Program|The I-FRESH (Implementing Food Referrals for Equity and Sustained Health) program is the food security nutrition support program that involves some combination and form of: 1) screening and identification of families experiencing food insecurity; 2) discussions with families to determine readiness to engage with nutrition support programs and other community resources; 3) referrals and support to engage with a program; and 4) conducting follow-up assessments to determine fit of program, track utilization, and assess need for additional referrals. The exact implementation and workflow for this program will be optimized for each clinic.
41154793|NCT03145519|DEVICE|Vasofix Certo Catheter|Placement of IV-catheter
41154794|NCT03145519|DEVICE|OptiVein Catheter|Placement of IV-catheter
41154795|NCT00515112|DRUG|AndroGel|Androgel 1%, 10g daily
41327319|NCT04813276|BEHAVIORAL|Enhanced Care as Usual|A self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
41327320|NCT05974007|DRUG|Neoadjuvant immunochemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
41327321|NCT05974007|DRUG|Neoadjuvant chemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery
41327322|NCT01018511|DRUG|Placebo tamsulosin hydrochloride OCAS 0.4 mg|tablet
41327323|NCT01018511|DRUG|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg|tablet
41154796|NCT00515112|DRUG|placebo|placebo
41154797|NCT05285878|DRUG|Fingolimod|0.5 mg daily
41154798|NCT05285878|DRUG|Placebo|0.5 mg daily
41154799|NCT02068352|DRUG|OPA-15406|OPA-15406 topical ointment
41154800|NCT02068352|DRUG|Vehicle ointment|OPA-15406 1%-matching placebo topical ointment
41154801|NCT05832216|DRUG|Daratumumab|Daratumumab is a monoclonal globulin targeting the CD38 molecule of immune cells, which can eliminate antigen-presenting cells such as dendritic cells and macrophages, and indirectly reduce the production of autoantibodies. In addition, Daratumumab reduces autoantibody levels by targeting plasma cells, B lymphocytes and T lymphocytes.
41154802|NCT05291962|OTHER|Retrospective observational study|Data from anesthesia charts and electronic medical records of 14 patients with SMA type I, II and III who underwent procedural sedation,such as; the demographics data of the patients (age, gender, weight, American Society of Anesthesiologist (ASA) Physical Status), which anesthetic agent was used and their doeses, during of anesthesia, presence of scoliosis, by whom the procedure was performed etc. was reviewed.
41154803|NCT06159933|PROCEDURE|Supine positioning|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
41154804|NCT06159933|PROCEDURE|Early pronation|According to our local protocol, starting from January 2022, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
41010518|NCT05755828|BIOLOGICAL|ASCT+CAR-T Cell Infusion|CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d\*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was \> 2\*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
41010519|NCT00879671|DIETARY_SUPPLEMENT|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
41010520|NCT00879671|DIETARY_SUPPLEMENT|placebo|Placebo capsules identical in taste and appearance
41010521|NCT00343317|DRUG|Intrapartum Cefoxitin (2g) vs. placebo|
41327324|NCT01018511|DRUG|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg|tablet
41327325|NCT01018511|DRUG|tamsulosin hydrochloride OCAS 0.4 mg|tablet
41327326|NCT01018511|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|tablet
41327327|NCT01018511|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|tablet
41480388|NCT02947074|BEHAVIORAL|Yoga Meditation|Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
41480389|NCT06304909|DRUG|Dexmedetomidine injection|Dexmedetomidine group will receive 0.5 mcg/kg
41480390|NCT04595916|DRUG|Polyene phosphatidylcholine injection 930 mg QD|Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
41480391|NCT04595916|DRUG|Magnesium Isoglycyrrhizinate injection 200 mg QD|Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
41327328|NCT06230835|BEHAVIORAL|Intervention Group|Community Health Workers (CHWs) will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. CHWs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'. No any drugs will be used in the intervention group.
41480392|NCT02375919|OTHER|PERC based Strategy|work up for diagnosis of PE includes calculation of PERC
41327329|NCT04107558|DEVICE|Virtual Reality|Subjects will undergo painful stimuli without HVR followed by a session with HVR. Subjects are their own control
41327330|NCT03713216|DRUG|Naldebain|150 mg Nalbuphine sebacate
41327331|NCT03713216|DRUG|Morphine|Morphine
41480393|NCT04008693|DIETARY_SUPPLEMENT|Aged Garlic Extract|2.400 mg (four capsules) of a nutritional supplement of aged garlic extract (Kyolic® Hi-Po Formula - Kyolic)
41480394|NCT04008693|OTHER|Placebo|800 mg of maltodextrin (four capsules)
41480395|NCT02581072|DRUG|SB204 4%|Applied topically once
41480396|NCT02581072|DRUG|SB204 8% or 12%|Applied once topically
41480397|NCT02581072|DRUG|Vehicle|Applied topically once
41480398|NCT03993249|BIOLOGICAL|Nivolumab|standard of care chemoradiotherapy + Nivolumab
41010522|NCT03932942|DIAGNOSTIC_TEST|QIAstat at pediatric emergency room|Pediatric acute care nurses will obtain respiratory samples for testing from all patients with fever or any respiratory symptom.
41480399|NCT03993249|OTHER|chemoradiotherapy|standard of care chemoradiotherapy
41010523|NCT06218433|DIAGNOSTIC_TEST|Urothelial cancer screening using urine tumor DNA test|Urine sample DNA is analyzed using a targeted sequencing panel encompassing the coding regions of 21 genes that are recurrently mutated in urothelial cancer
41010524|NCT06218433|DIAGNOSTIC_TEST|Urothelial cancer screening using urine cytology (comparator)|Urine cytology sample
41010525|NCT04949438|DRUG|AZD4831|Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
41327332|NCT03568058|DRUG|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
41480400|NCT05666947|OTHER|Home-based exercise|Eight weeks of home-based exercise programs
41480401|NCT00551382|DRUG|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
41480402|NCT00551382|DRUG|Placebo|Look alike tablets or granules 1 per day for 12 weeks
41480403|NCT04751084|DRUG|Buscopan 20 milligrams/ML Injectable Solution|cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
41480404|NCT02441582|OTHER|Telemetry|
41480405|NCT02441582|OTHER|Non-telemetry|
41480406|NCT01125020|DRUG|gemcitabine and oxaliplatin|Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
41480407|NCT01125020|DRUG|doxorubicin, 5-Fu and cisplatin|Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
41480408|NCT04399265|DIETARY_SUPPLEMENT|Trehalose|A disaccharide sugar usually used as food preservative, but for this study it is given at a higher dose
41480409|NCT04399265|DIETARY_SUPPLEMENT|Maltose|Maltose power
41327333|NCT03568058|DRUG|Pembrolizumab|200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
41327334|NCT03755999|OTHER|The premature infant oral motor intervention (PIOMI)|The premature infant oral motor intervention (PIOMI) is an oral motor program that provides assisted movement to activate muscle contraction and provides movement against resistance to build strength in the areas of the mouth necessary for feeding. It is designed to increase the maturation of neural structures, improving their ability to suck and swallow.
41327335|NCT03841487|DEVICE|Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI). In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
41154805|NCT06159933|PROCEDURE|Late pronation|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
41010526|NCT03152318|DRUG|rQNestin|rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
41010527|NCT03152318|DRUG|Cyclophosphamide|Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
41327336|NCT04591496|BEHAVIORAL|Behavioral change intervention;|Behavioral change intervention: goal setting, regarding child's diet and parental feeding practices; self-monitoring, with observation and recording of the child's food intake and parental feeding practices; individualized feedback, based on preceding week monitoring and according to the defined objectives, regarding child's and parent's behaviors; modeling and direct suggestions by tailored parent figures; positive reinforcement associated to parents' accomplishment of the objectives; prompts, to remember the defined objectives and the main messages of the intervention.
41327337|NCT04591496|BEHAVIORAL|Health Education|Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
41327338|NCT05824455|COMBINATION_PRODUCT|JS109 combine with irinotecan|JS109 PO,QD, q3w combine with irinotecan(65mg/m2,IV,D1,8,Q3w)
41327339|NCT01847261|DIETARY_SUPPLEMENT|Soy Dairy Protein Blend|
41327340|NCT01847261|DIETARY_SUPPLEMENT|Positive Control (Dairy Whey Protein)|
41327341|NCT02521389|DRUG|PWT-143|phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
41327342|NCT02762799|BIOLOGICAL|Leucostim®|Leucostim® is filgrastim biosimilar.
41327343|NCT02762799|BIOLOGICAL|Neupogen®|
41327344|NCT02307838|OTHER|Assessments arm|Protocol required assessments not provided in standard of care
41327345|NCT05594368|DEVICE|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.
41327346|NCT00348413|DRUG|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
41480410|NCT01183325|DEVICE|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
41480411|NCT00255255|DRUG|Budesonide/Formoterol|
41010528|NCT03152318|PROCEDURE|Stereotactic biopsy|In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.
41010529|NCT03678142|DIAGNOSTIC_TEST|analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood|blood draw (4.7 ml EDTA) and sweat sample taken (Macroduct Sweat Collecting System)
41010530|NCT02056171|DRUG|quetiapine|Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
41010531|NCT02056171|OTHER|Placebo|Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
41154806|NCT01000584|BIOLOGICAL|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
41154807|NCT01000584|BIOLOGICAL|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
41327347|NCT02786108|PROCEDURE|left gastric artery embolization|
41327348|NCT02786108|BEHAVIORAL|healthy diet and exercise|
41327349|NCT03095404|DRUG|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
41327350|NCT03095404|DRUG|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
41327351|NCT05871021|RADIATION|Dose escalation of radiation dose beyond the therapeutic standard|Dose escalation to 75 Gy with concomitant radioprotectant bevacizumab
41327352|NCT01236859|DRUG|Gabapentin|Neurontin®, Pfizer
41327353|NCT06335498|DEVICE|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
41010532|NCT01245179|DRUG|panobinostat|"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~1. 15 mg MWF 3 weeks on, 1 week off (if needed)~2. 15 mg MWF every week (starting dose)~3. 20 mg MWF 3 weeks on, 1 week off~4. 20 mg MWF every week"
41010533|NCT04717128|OTHER|Breastfeeding Skills Workshop|Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
41327354|NCT06335498|DEVICE|Periodic ECG triggered measurement|Subject triggers AFGen1 to perform an extended measurement during wear period
41327355|NCT01259635|DEVICE|Biofeedback auditory stimulation|Whenever freezing episodes occures, a metronom sound will be heard.
41327356|NCT03475901|OTHER|Virtual Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
41327357|NCT05075707|OTHER|Electromagnetic therapy.|Electromagnetic therapy will be applied for 20 min/ session for (3 days/ week for two months) to the group intervention.
41327358|NCT05075707|OTHER|Low level laser therapy (LLLT)|Low level laser therapy (LLLT) will be applied for 20 min/session laser scanner for three days each week for two months to the group intervention.
41480412|NCT01434576|BIOLOGICAL|HGS1025|2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
41480413|NCT01434576|BIOLOGICAL|HGS1025|10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
41480414|NCT01434576|DRUG|Placebo|Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
41327359|NCT02741089|PROCEDURE|Indication for a flexible bronchoscopy|"The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient."
41327360|NCT02667457|RADIATION|99mTc-rhAnnexin V-128|
41327361|NCT03494426|PROCEDURE|radiofrequency thoracic sympathectomy|"Under fluoroscopic guidance thoracic sympathectomy will be done as follow~1. antroposterior view of upper thoracic vertebrae ,cephalo-caudal adjustment of C - arm until aliment of endplates of T2 and T3~2. oblique view 20 degree under tunnel view RF 10cm 20G 1mm active tip needle is introduced intimately related to vertebral margin~3. the depth of the needle will be determined under lateral fluoroscopic view the needle is advanced step by step hugging the lateral vertebra l margin until the tip of the needle situated at the middle of the vertebral body . RF lesion 2min 80c will be done and needle is rotated 90 degree on both sides and another two lesions will be done at the end of the procedure 2ml of lidocaine and 20mg of triamcinolone will be injected at each level Post procedure analgesic protocol consisted of either increase or decrease, according to intensity of pain by 50 mg pregabalin and 50 mg tramadole and 25 mg tryptazole, individualized for each patient."
41327362|NCT03494426|DRUG|pregabalin ,tramadol,and tricyclic antidepressants|patient will receive anti neuropathic medications
41327363|NCT00034203|DRUG|efalizumab|
41327364|NCT01566201|DRUG|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
41480415|NCT03996070|PROCEDURE|Laser therapy|Erbium YAG laser
40809904|NCT06660823|DRUG|L-thyroxine|"Patients who show signs of delayed recovery defined as either prolonged ventilation for 48 hours or delayed conscious level recovery for 48 hours despite exclusion of muscle relaxants and/or sedative drugs. Those patients will undergo CT brain, CT chest and neurological examination to exclude structural damage as per institutional protocols. Also, metabolic profile screening including full kidney function, full liver function, electrolyte to exclude correctable metabolic abnormalities. and thyroid profile (TSH, free T3, free T4) sick euthyroid patients who are having normal FreeT3, normal Free T4, low TSH and low level of free T3 or freeT4 will be included in the study according lab reference.Daily assessment of conscious level according to Glasgow Coma Scale (GCS) and spontaneous breathing trial by ICU consultant (the investigator) till ICU discharge.~Patients will receive levothyroxine via Ryle, dose of 25 to 50 ug/ day according to BMI."
41010534|NCT06390020|OTHER|MBSR|The MBSR training spans eight weeks and follows a standardized protocol. It consists of eight weekly sessions, each lasting 2.5 hours, a single 6-hour silent day, and daily home exercises. Additionally, the program incorporates personalized psychoeducation on high sensory processing sensitivity, covering its characteristics, scientific foundations, its relation with stress-related symptoms, and why mindfulness might be helpful.
41010535|NCT01138748|RADIATION|hypofractionated radiation therapy|hypofractionated radiation therapy
41010536|NCT01745029|DEVICE|Motilis-3D-transit|
41480416|NCT06231719|OTHER|Cold Spray|Using cold spray for injection site before the Anti-D immunglobulin injection. 2 sprays of cold spray are applied from a distance of 25 cm.
41010537|NCT04996992|PROCEDURE|MR-guided focused ultrasound|MR-guided focused ultrasound pallidothalamic tractotomy is a minimally invasive and effective procedure for thetreatment of Parkinson's disease(PD) patients.
41327365|NCT01566201|DRUG|placebo|water for injection
41327366|NCT03250156|BEHAVIORAL|MBAT with proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.
41327367|NCT03250156|BEHAVIORAL|MBAT with non-proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
41327368|NCT06182540|DIETARY_SUPPLEMENT|Mango puree|Mango puree 300g
41480417|NCT06231719|OTHER|Manuel Pressure|Using manuel pressure ( about 10 second ) before the Anti-D immunglobulin injection.
41480418|NCT06231719|OTHER|Standard Injection Procedure|Using any special method for injection
41010538|NCT00222495|DRUG|quetiapine|
41010539|NCT00222495|DRUG|olanzapine|
41010540|NCT00222495|DRUG|risperidone|
41327369|NCT03055572|OTHER|Olfactory Training with Essential Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Essential oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
41480419|NCT00732420|DRUG|topotecan|Topoisomerase I inhibition.
41480420|NCT00732420|DRUG|pazopanib|Tyrosine kinase inhibitor
41480421|NCT05880121|DIAGNOSTIC_TEST|MRI|brain MRI
41480422|NCT02287324|PROCEDURE|Manipulation|
41480423|NCT02287324|PROCEDURE|Manual Contact|
41480424|NCT04731584|BIOLOGICAL|Blood sample|Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke
41480425|NCT05844631|DIETARY_SUPPLEMENT|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
40809905|NCT06660823|DRUG|Placebo|patients will receive placebo in form of inert starch tablet
41154808|NCT06164041|BEHAVIORAL|The use of mobile applications promoted from the physical education classroom to improve adolescent health.|"Before starting the intervention, a total of 465 adolescents participated in pretest measurements (T1).~Researchers in charge of explaining how the apps worked were not involved in the measurements or subsequent analysis, as they knew which student belonged to each App and control group. Once each app had been described and its use explained, a training plan was drawn up to be followed during the period of mandatory use.~The adolescents were motivated to utilize the app for a duration of ten weeks, aiming for a minimum usage of three times per week.~After the mandatory intervention with the mobile apps, post-test measurements were carried out (T2). Then, a period of 10 weeks was provided in which the use of the app was neither mandatory nor promoted from the physical education subject, after which the post-test 2 measurements (T3) were taken."
41154809|NCT05680285|DEVICE|diode lazer|diode laser was applied during the pulpotomy procedure
41327370|NCT03055572|OTHER|Olfactory Training with Pure Fragrance Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Pure fragrance oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
41327371|NCT04404023|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
41327372|NCT00806078|DRUG|quinine sulfate|2 x 324 mg capsules (648 mg)
41480426|NCT05470764|DRUG|PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
41480427|NCT05470764|DRUG|TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
41480428|NCT03827928|BEHAVIORAL|Yoga/meditation|A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
41480429|NCT00755404|DRUG|PD Solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
41480430|NCT00755404|DRUG|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
41480431|NCT01538836|BEHAVIORAL|Weight loss with normal protein intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
41480432|NCT01538836|BEHAVIORAL|Weight loss with protein supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
41480433|NCT03353623|DEVICE|Serious Game|"Serious Game (SG) refers to the use of immersive virtual environments and wearable haptic devices during the treatment. Two SG were specifically developed to allow a playful training of different, targeted Upper Limb (UL) movement based on typical rehabilitation exercises (reach-to-grasp, linear path tracking, hand orientation). The child interacts directly with a virtual environment through haptic feedback provided to his/her fingertips. In particular, moneybox game focused on pincer grasp and reaching tasks with pronation/supination od the hand while marble labyrinth game focused on pointing and tracking movements requiring both eye-hand and upper limb inter-joint coordination."
41480434|NCT03353623|OTHER|Conventional Therapy|Conventional therapy (CONV) refers to the neurocognitive rehabilitation approach, with the purpose of improving pointing, tracking, reaching and grasping, and pronation/supination of the forearm. The therapeutic sessions were performed with the exception of the visual channel to ensure that the child focused his/her attention on tactile/kinesthetic information to complete the task. In particular, five different tasks have been proposed during the sessions: 1) recognize trajectories; 2) arm proprioception; 3) object manipulation; 4) recognize surfaces; 5) forearm orientation.
41480435|NCT01477814|BEHAVIORAL|Physician chart reminder|Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
40809908|NCT06661850|PROCEDURE|Fusion or TDR determined by investigator.|The surgical treatment will be decided by the treating investigator based on their clinical judgement.
41154810|NCT05680285|DEVICE|low level diode laser|Low-dose diode laser was applied during the pulpotomy procedure
41154811|NCT00790777|DRUG|Paliperidone ER|
41327373|NCT00806078|DRUG|quinine sulfate|2 x 324 mg capsules (648 mg)
41327374|NCT02624011|BEHAVIORAL|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
41327375|NCT06024213|PROCEDURE|Sentinel lymph node identification|Intervention description: Intraoperative identification of sentinel lymph node
41327376|NCT06024213|DRUG|indocyanine green|Intervention description: indocyanine green (5 to 10 mg \[ie, 2 to 4 mL of a 2.5 mg/mL solution\]) administered by periareolar or peritumoural route
41327377|NCT06024213|DRUG|methylene blue|1%), 2-5 mL administered by periareolar or peritumoural route
41480436|NCT01477814|BEHAVIORAL|chart reminder, educational mat'ls, FIT|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
41327378|NCT06024213|DRUG|Technetium (99mTc)|(99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route
41327379|NCT01887106|DRUG|GLPG1205 single ascending doses, oral suspension|Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
41327380|NCT01887106|DRUG|Placebo single ascending doses, oral suspension|Single dose, oral suspension matching placebo
41327381|NCT01887106|DRUG|GLPG1205, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
41480437|NCT01477814|BEHAVIORAL|CR,ed mat'ls, FIT, phone call|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
41480438|NCT01935934|DRUG|Cabozantinib S-malate|Given PO
41480439|NCT01935934|OTHER|Laboratory Biomarker Analysis|Correlative studies
41480440|NCT01935934|OTHER|Pharmacological Study|Correlative studies
41480441|NCT02896777|OTHER|Transfer embryo from pH 7.20±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.20±0.02.
41480442|NCT02896777|OTHER|Transfer embryo from pH 7.3±0.02 either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.3±0.02.
41480443|NCT02896777|OTHER|Transfer embryo from pH of 7.4±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.4±0.02 from day 0 to 5/6
41154812|NCT06647147|OTHER|Aerobic training|For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
41154813|NCT06647147|OTHER|Diaphragmatic breathing exercises|From the hook-lying position, the women will receive instructions to position their hands on the rectus abdominis muscle located under the anterior chest wall. They will be advised to inhale slowly and deeply, expanding their abdomen without causing any movement in their upper chest, while simultaneously relaxing their shoulders. Slowly, the women will expel every breath. Air will be inhaled via the nose, swelling the abdomen. After the breath ceased, the women will purse her lips and exhale from his mouth with half-opened lips and a hollow belly. A single respiratory cycle consists of a three-second intake, followed by a three-second pause, and concluding with a six-second expiration phase.
41154814|NCT00574171|DRUG|lapatinib|1250mg by mouth daily one hour before or after breakfast on a continuous basis.
41327382|NCT01887106|DRUG|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
41327383|NCT02683304|BIOLOGICAL|Plasma S100B levels at inclusion|Patients will have blood drawn to measure plasma S100B levels at inclusion.
41327384|NCT02683304|DEVICE|Magnetic resonance imaging|If not performed under emergency conditions, patients will have an MRI on days 2-4.
41480444|NCT00847106|DRUG|Daclizumab|
41480445|NCT00847106|BIOLOGICAL|Dendritic cells|
41327385|NCT04117412|OTHER|Exercise|Same participants will undergo different one bout of exercise protocols
41480446|NCT01685658|DRUG|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
41480447|NCT01685658|DRUG|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
41480448|NCT06015477|DRUG|Ticagrelor monotherapy|starting dose of ticagrelor was a single loading dose of 180mg (90mg x 2 tablets) and thereafter 1 tablet (90mg) each time, twice daily.
41480449|NCT06015477|DRUG|Dual Antiplatelet Therapy|Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.
41480450|NCT04068974|DRUG|Camrelizumab (SHR-1210)|Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 \[PD-1\]). Monoclonal antibodies like SHR-1210 that can block this pathway.
41480451|NCT04068974|DRUG|Apatinib|Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
40809910|NCT06659250|DRUG|PF-06414300|Participants will receive oral ascending doses.
40809911|NCT06659250|DRUG|Placebo|Participants will receive matching placebo.
41327386|NCT03921047|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41480452|NCT03257475|RADIATION|Brachytherapy|Intracavitary irradiation starts at the end of the external beam radiation using image-guided CT/SIM.CT/SIM (transverse axis) is done to complete 3/2D treatment planning. Measurement VRL, PIBS and PIBS ± 2cm, R-V were recorded; Brachytherapy plan: Point A: 24-30Gy/4-5f, or 21-28Gy/3-4f HR-CTV: ≥85Gy, IR-CTV 65Gy dose records
41480453|NCT00958126|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
41480454|NCT00958126|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
41327387|NCT03921047|OTHER|Laboratory Biomarker Analysis|Correlative studies
41327388|NCT05220371|DIETARY_SUPPLEMENT|Collagen|Participants ingest 15 grams of either specific collagen peptides or Placebo daily
41327389|NCT05220371|OTHER|Concurrent training|Both arms undergo a 12-week trainingintervention 3x/week
41327390|NCT02664207|PROCEDURE|Open Fetal Repair of Myelomeningocele|Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
41327391|NCT02836132|BEHAVIORAL|Weight Watchers Online|
41327392|NCT02836132|BEHAVIORAL|Experience Success Virtual Reality Platform|
41327393|NCT01459068|BEHAVIORAL|Common Elements Treatment Approach|"CETA components include:~1. Engagement (encouraging participation)~2. Psychoeducation (introduction)~3. Anxiety Management Strategies (relaxation)~4. Behavioral Activation (getting active)~5. Cognitive Coping/Restructuring (thinking in a different way, part I and part II)~6. Imaginal Gradual Exposure (talking about difficult memories)~7. In Vivo Exposure (Live exposure)~8. Suicide/Homicide/Danger Assessment and Planning (safety)~9. Screening and Brief Intervention for Alcohol (alcohol intervention)"
41327394|NCT03332901|OTHER|this is an observational study, no intervention required|this is an observational study, no intervention required
40809912|NCT06661655|DEVICE|Liver ultrasound|Hepatoscope is a point of care ultraportable ultrasound device that is capable of conventional grayscale ultrasound imaging, of 2D transient elastography (imaging + liver stiffness measurement), and of quantitative ultrasound properties measurement (ultrasound attenuation, backscattering coefficient, sound speed) related to liver steatosis.
40809913|NCT06660355|DRUG|Ruxolitinib|Ruxolitinib is a Janus kinase inhibitor.
40809914|NCT06660355|DRUG|Prednisone|Prednisone is a glucocorticoid.
40809915|NCT06659055|RADIATION|DXA Imaging|DXA imaging: lumbar spine, bi-lateral femoral necks
40809916|NCT06659055|RADIATION|EOSedge imaging|Full body or full spine image
41327395|NCT06094972|BEHAVIORAL|Adolescent Community Reinforcement Approach, A-CRA|A-CRA consists of eighteen treatment modules/procedures that is delivered in weekly sessions over 12-14 weeks. The overarching goal is to decrease substance use behaviours and other related, problematic behaviours such as acting out when experiencing anger, and to increase prosocial and sober behaviours, relationships and activities. The procedures are: 1) Introduction to A-CRA/treatment agreement, 2) Happiness scale and treatment goals, 3) Homework, 4) Systematic encouragement, 5) Functional analysis of substance use behaviour, 6) Functional analysis of prosocial/sober behaviour, 7) Increasing prosocial activities, 8) Drink/drug refusal, 9) Relapse prevention, 10) Sobriety sampling, 11) Communication skills, 12) Problem-solving, 13) Caregiver sessions, 14) Relationship skills, 15) Couple relationship skills, 16) Job-seeking skills, 17) Anger management, 18) Medication adherence and monitoring. Youths' individual goals and problems guide treatment planning.
40809917|NCT06658314|OTHER|Experimental interventional group 1(Kinesiotaping)|"Kinesiotape will be applied by using two I-bands application technique:~Short band: to apply this ask the patient to move your arm behind her back as much as possible, then apply kinesiotape at the anterior glenohumeral joint.~Longer band: to apply this ask the patient to horizontal adduct her arm as much as possible, than apply kinesiotape targeting the posterior side of glenohumeral joint.~Apply both these band with paper-off stretch for 3-5 days or as depending upon skin sensitivity and tape adherence.~Kinesiotape will be applied once a week for total time period of 3 weeks."
40809918|NCT06658314|OTHER|Experimental interventional group II (Graded exposure therapy)|"First week: gentle arm raises with 10 repetitions/day, slow and controlled stretch 25 to 50% force with 5 repetitions, passive internal and external rotations (with towel) with 5 repetitions each/day.~Second week: overhead arm raises (wall climbing) with 10 repetitions/day, pendulum exercises 10 repetitions/day, cross arm stretches 5 repetitions/day, active internal and external rotations with 5 repetitions each/day.~Third week: resistance exercises (initially with minimum weight or manual resistance), scapular squeezes 10 repetitions/day, gentle chest stretches 5 repetitions/day and gentle stretch with 75 to 100 % force 5 repetitions each/day."
41154815|NCT00574171|DRUG|Capecitabine|2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
41154816|NCT05729477|DEVICE|miCOR System|The miCOR system is a lens fragmentation device used to break up the cataract prior to IOL implantation during cataract surgery.
41154817|NCT05729477|DEVICE|Phaco Subject Cohort|Phaco Subject Cohort
41327396|NCT06094972|BEHAVIORAL|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care in Sweden. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT and PULS, a program for reducing violence and criminal behavior. Also, individually tailored interventions will be included, such as counselling or other psychological interventions. TAU will be thoroughly registered during the study since the sites in the trial differs slightly in what they offer.
41327397|NCT00289744|BIOLOGICAL|TWINRIX™ ADULT|2 doses IM injection in primary study
41327398|NCT00289744|BIOLOGICAL|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
41327399|NCT03549429|DEVICE|Medical tapes: TegadermTM and EyeGard®|TegadermTM and EyeGard® will be placed over patients' eyes during surgery with general anesthesia.
41327400|NCT02128594|BEHAVIORAL|Serosorting Intervention|Single session, behavioral intervention
41327401|NCT00781963|BEHAVIORAL|Manual-based cognitive behavioral therapy for insomnia|Manual-based CBT-I provided in 5 individual or group sessions by a non-clinician sleep coach.
41327402|NCT00781963|BEHAVIORAL|Non-directive sleep education|Manual-based non-directive sleep education provided in 5 group sessions by a health educator.
41327403|NCT01532570|DRUG|TA-650|TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
41327404|NCT06251869|PROCEDURE|total hip arthroplasty with electrocoagulation|using normal technique
41480455|NCT00958126|BIOLOGICAL|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
41480456|NCT01490320|BEHAVIORAL|AAP Handout entitled, Pulling the Plug on Violence.|This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics
41154818|NCT05868148|DEVICE|Shoulder iD™ Primary Reversed Glenoid|Device implant via reversed total shoulder arthroplasty
41154819|NCT02173249|DRUG|AC 170 0.24%|1 drop in each eye 2 times daily for 1 week
41480457|NCT01490320|BEHAVIORAL|Play Nicely Program|Multimedia program available at www.playnicely.org.
41480458|NCT01490320|OTHER|Control Group|Standard care in primary care clinic.
41154820|NCT01345188|DRUG|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
41154821|NCT01345188|DRUG|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
41327405|NCT06251869|PROCEDURE|total hip arthroplasty without electrocoagulation|using only scalpel and pean as hemostasis and incision
41327406|NCT06251869|PROCEDURE|total knee arthroplasty with electrocoagulation|using normal technique
41480459|NCT01261741|DRUG|Memantine|Each subject will receive memantine 10mg tablets once daily
41327407|NCT06251869|PROCEDURE|total knee arthroplasty without electrocoagulation|using only scalpel and pean as hemostasis and incision
41154822|NCT02876302|DRUG|Ruxolitinib|15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.
41154823|NCT02876302|DRUG|Paclitaxel|80 mg/m2, IV (in the vein) weekly for 12 weeks.
41154824|NCT02876302|DRUG|Doxorubicin|60 mg/m2, IV (in the vein) every 14 days for 4 doses.
41154825|NCT02876302|DRUG|Cyclophosphamide|600 mg/m2, IV (in the vein) every 14 days for 4 doses.
40809924|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the Left DLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. For stimulating the lDLPFC, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI).
40809925|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the right VLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the rVLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med)
40809926|NCT06658795|DEVICE|Sham stimulation group|The electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.
41154826|NCT06528314|DRUG|Efruxifermin|Administered by subcutaneous injection
41154827|NCT06528314|DRUG|Placebo|Administered by subcutaneous injection
40809929|NCT06660381|DRUG|Psilocybin|Participants will receive a moderately high dose (25mg) of psilocybin in week 5 of the 12-week counseling, and either another moderately high dose (25mg) or a high dose (35mg) in week 7.
41017846|NCT04003597|OTHER|Reduced-salt diet|Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (\<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
41154828|NCT00126061|DRUG|Tedisamil sesquifumarate|
41154829|NCT05276011|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
41154830|NCT05276011|BIOLOGICAL|Placebo Control|2 mL normal saline injection
41327408|NCT01379924|BEHAVIORAL|Parenting/Life Skills Intervention|Modules adapted from the Ansell-Casey Life Skills Assessment Curriculum, the Women's Negotiation Project Curriculum for Teen Mothers and the Nurturing Curriculum. Goal is to help teen mothers develop positive parenting skills, decrease repeat pregnancy and acquire skills of daily living. The series of five, one-hour long, structured, one-on-one interactive modules aims to help teens build positive, empathetic relationships with their children, while enhancing self-efficacy and increasing the sense of self- worth for parents and children. Domains addressed include child development/discipline, safety, house/money management, social relationships, career planning, substance abuse and community and interpersonal violence.
41327409|NCT01379924|OTHER|Teen-tot medical home|Medical, mental health, and social services provided to teen parents and their children
41327410|NCT03559192|DRUG|JNJ-67953964|JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
41480460|NCT01261741|DRUG|Placebo|Each subject will receive matching placebo tablets once daily
41154831|NCT05952583|DIAGNOSTIC_TEST|Ultrasound|Additional ultrasound measurements during pregnancy
41154832|NCT05750017|BIOLOGICAL|Low Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
41154833|NCT05750017|BIOLOGICAL|High Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
41327411|NCT03559192|DRUG|Placebo|Matching placebo will be administered as 2 capsules orally once daily.
41327412|NCT02514772|BIOLOGICAL|GP2013 - A Proposed biosimilar rituximab|
41480461|NCT05070702|DRUG|CT-1500|Hard Capsule
41480462|NCT05070702|DRUG|Placebo|Hard Capsule
41480463|NCT03510182|DEVICE|transcranial direct current stimulation|
41480464|NCT01778153|BEHAVIORAL|Equinox Personal Coaching|Specially designed strength and aerobic exercise training program that consists of 36 sessions over 12 weeks.
41480465|NCT02666352|DRUG|Uprifosbuvir|A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
41154834|NCT05750017|DRUG|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
41154835|NCT05563428|PROCEDURE|Free gingival graft|A free gingival graft will be carried out for recession treatment.
41154836|NCT05563428|PROCEDURE|Connective tissue graft|The pouch technique with a connective tissue graft will be carried out for recession treatment.
41154837|NCT03027999|OTHER|tight nursing follow-up|"In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~1. a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~2. A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP \> 2.7"
41480466|NCT02666352|DRUG|Ruzasvir|A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
41480467|NCT04960306|BIOLOGICAL|Fecal filtrate transplantation|"Patients will receive 5-8 encapsulated lyophilized fecal filtrate transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
41327413|NCT02514772|BIOLOGICAL|Originator rituximab - Rituxan ® or MabThera ®|
41480468|NCT04960306|BIOLOGICAL|Conventional fecal microbiota transplantation|"Patients will receive 5-8 encapsulated lyophilized conventional fecal microbiota transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
41480469|NCT04546932|PROCEDURE|Lung-protective mechanical ventilation|Patients were provided with a tidal volume of 7 ml/kg IBW and an intraoperative 10 cmH2O in PEEP. Simultaneously, the alveoli were recruited applying a stepwise increase in PEEP (from 4 to 10 cmH2O for 3 breaths, 10 to 15 cmH2O for 3 breaths, and 15 to 20 cmH2O for 10 breaths) with maximum PIP = 50 cmH2O \[24\]. The recruitment maneuvers were performed right after intubation, 30 minutes after CO2 insufflation, then every hour, and finally before extubation.
41480470|NCT00017394|BIOLOGICAL|bevacizumab|Given IV
41480471|NCT00017394|DRUG|vinorelbine tartrate|Given IV
41480472|NCT00017394|OTHER|laboratory biomarker analysis|Correlative studies
41327414|NCT03181841|DRUG|PF-06412562|double-blind oral intake of single doses of the aforementioned drug or placebo
41327415|NCT03181841|DRUG|Placebo|double-blind oral intake of single doses of the aforementioned drug or placebo
41327416|NCT02422082|DIETARY_SUPPLEMENT|L. reuteri|Dietary supplementation with L. reuteri twice daily for 12 months
41327417|NCT02422082|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo twice daily for 12 months
41327418|NCT05185648|BEHAVIORAL|standard trauma care taining|trauma care training
41327419|NCT05480839|PROCEDURE|M-IBCS|Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant
41327420|NCT05480839|PROCEDURE|ReLA-IBCS Early|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia
41327421|NCT05480839|PROCEDURE|ReLA-ISBCS|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia
41480473|NCT02499224|DRUG|YYB101|"Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development"
41480474|NCT02317679|DRUG|Bosentan|Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
41480475|NCT02317679|DEVICE|Pulsed dye laser (PDL)|A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject).
41480476|NCT01861236|DRUG|Firmagon® (degarelix)|Monthly subcutaneous injections
41480477|NCT02841748|DRUG|Pembrolizumab|200mg, every three weeks, iv, x 1 year
41480478|NCT02841748|DRUG|Placebo|iv, every three weeks, x 1 year
41480479|NCT03781024|COMBINATION_PRODUCT|Footwash|footbath/footwash can help cleanse the wound, remove dead tissue, increase circulation and puts the wound in direct contact with medication to promote faster healing.
41480480|NCT05303376|BIOLOGICAL|IBIO123|5 or 10 mg
41480481|NCT05303376|OTHER|Placebo|matching placebo
41480482|NCT03333954|DEVICE|PRIMA|"The PRIMA Bionic Vision System is a device for treatment of patients who have lost their sight through outer retinal degenerative conditions of the eye such as atrophic dry age related macular degeneration.~The PRIMA System is designed to provide partial restoration of the patient's visual function through electrical stimulation of the retinal neurons by a sub-retinally implanted stimulator that replace part of the degenerate photoreceptors"
41327422|NCT00128583|BIOLOGICAL|polyvalent melanoma vaccine|
41327423|NCT01125293|DRUG|Everolimus|
41327424|NCT01125293|DRUG|Rituximab|
41327425|NCT01125293|DRUG|Bortezomib|
41327426|NCT04779632|DIETARY_SUPPLEMENT|Experimental: Fish Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.
41017847|NCT01560624|DRUG|Treprostinil Diolamine|Active
41017848|NCT01560624|DRUG|Placebo|Placebo
41017849|NCT02877706|OTHER|no specific intervention|
41017850|NCT01416012|BEHAVIORAL|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
41017851|NCT01416012|BEHAVIORAL|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
41327427|NCT04779632|DIETARY_SUPPLEMENT|Comparator: Safflower Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing \~ 3000 mg of linoleic acid) for 4 weeks.
41327428|NCT03429322|BEHAVIORAL|Medical Care and Resource Facilitation|The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.
41327429|NCT03429322|OTHER|Usual Care|Participants will receive and provide usual and customary care in their communities.
41327430|NCT00004685|DRUG|albuterol|
41327431|NCT02967484|DEVICE|acupuncture|"1. Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).~2. Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).~3. Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.~The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)"
41480483|NCT02018094|DRUG|Co-amoxiclav|Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
41480484|NCT02018094|DRUG|Iodine|Intra-operative skin preparation prior to incision to skin.
41327432|NCT04655209|BEHAVIORAL|apply a-tDCS on the ipsilesional M1 followed by MT (M1-Seq)|The participants in the M1-Seq group will first receive a-tDCS over ipsi-lesional M1 without any active arm practice for 20 minutes. For the next 20 minutes, the participants will start the MT, while the electrodes will be remained on the scalp with the stimulator off (sham tDCS condition). Then the electrodes will be removed, and the participants will receive additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
41327433|NCT04655209|BEHAVIORAL|apply a-tDCS on the ipsilesional PMC followed by MT (PMC-Seq)|The procedures for the PMC-Seq group will be the same as the M1-Seq, except that a-tDCS will be applied on ipsilesional PMC but not M1.
41327434|NCT04655209|BEHAVIORAL|MT only with sham tDCS (MT)|For the MT group, the procedure will be the same as the other groups except that sham tDCS will be used for the first 40 minutes.
41327435|NCT04676542|OTHER|Exercise|One hour of a beginning martial art class ,and a one hour walk at 4.0 mph pace.
41327436|NCT02928380|DEVICE|Experimental Denture Adhesive|Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
41327437|NCT02928380|DEVICE|Reference (Marketed) Denture Adhesive|Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
41327438|NCT00973622|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)|All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
41327439|NCT00973622|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 20Hz|All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
41327440|NCT00973622|DEVICE|SHAM repetitive transcranial magnetic stimulation (rTMS)|The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
41327441|NCT05386927|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.
41327442|NCT05128526|BEHAVIORAL|exercise|Short foot exercises without respiratory exercises
41327443|NCT05128526|BEHAVIORAL|respiratory|Short foot exercises with respiratory exercises
41327444|NCT05275296|DEVICE|Intracranial stent for wide-necked aneurysms|Intracranial stent for wide-necked aneurysms
41327445|NCT06315582|PROCEDURE|Removal of uterine septum with hysteroscopic scissors without electrosurgery.|Hysteroscopic septoplasty utilizing scissors without electrosurgery followed by hysteroscopic morcellation of residual tissue
41327446|NCT06315582|PROCEDURE|Hysteroscopic septoplasty utilizing bipolar electrosurgery|Hysteroscopic septoplasty utilizing bipolar electrosurgery
41480485|NCT02018094|DRUG|Metronidazole|500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
41480486|NCT02018094|DRUG|Chlorhexidine|Alcoholic Chlorhexidine skin pre-op preparation
41480487|NCT02018094|DRUG|Teicoplanin|Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
41480488|NCT02018094|DRUG|Clindamycin|Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
41480489|NCT05684146|DEVICE|Emboliner Embolic Protection|Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
41480490|NCT05684146|DEVICE|Sentinel Cerebral Protection|The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
41480491|NCT04515082|DIAGNOSTIC_TEST|Stool-based SDC2 and SFRP2 DNA methylation test|A diagnostic device measuring syndecan 2 (SDC2) and secreted frizzled-related protein 2 (SFRP2) methylation status in stool DNA to detect colorectal cancer
41480492|NCT04515082|DIAGNOSTIC_TEST|FIT|Fecal immunochemical test
41017852|NCT01416012|BEHAVIORAL|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
41480493|NCT03656874|OTHER|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care
41017853|NCT01416012|BEHAVIORAL|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
41017854|NCT02341196|PROCEDURE|CEA|Patients in both groups received an intra-operative angiography
41010541|NCT05002322|OTHER|Systems Analysis and Improvement Approach|"Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.~Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel."
41010542|NCT05443477|DIETARY_SUPPLEMENT|Hericium Erinaceus Mycelium|participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.
41010543|NCT05443477|DIETARY_SUPPLEMENT|Probiotic|participants received two oral capsules containing Probiotic powder every day for the 3 months.
41327447|NCT04190589|DEVICE|Robot-assisted laparoscopic extended right colectomy|An extended right hemicolectomy with total mesocolic excision and meticulous central dissection as described by Hohenberger will be performed with the DaVinci Xi robot by one of two dedicated surgeons
41327448|NCT04026971|PROCEDURE|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
41327449|NCT04463446|BEHAVIORAL|Use of the CHD app|Use of the CHD app
41327450|NCT04463446|BEHAVIORAL|Nurse-led intervention|Teaching session with clinic nurse
41327451|NCT03588611|DRUG|Bivalirudin|0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
41327452|NCT03588611|DRUG|Bivalirudin|0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
41327453|NCT04213937|DRUG|nab-paclitaxel|Drug: nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles.
41327454|NCT04213937|DRUG|Topotecan|Drug: Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
41327455|NCT00927719|BIOLOGICAL|ACAM2000® smallpox vaccine|Previous vaccination, no vaccine is administered in this study.
41327456|NCT04153643|PROCEDURE|Arthroscopic Partial Meniscectomy|Surgical treatment for meniscus tear
41327457|NCT05820646|OTHER|Boswellia Sacra|"1. Boswellia Sacra used as an intracanal medicament for 3 days~2. Boswellia Sacra used as an intracanal medicament for 7 days"
41327458|NCT06047106|RADIATION|multiparametric MRI|"For the living donor, multiparametric MRI will be added in the day hospital: at the pre-transplant assessment and at the 12-month post-transplant assessment.~For the recipient: multiparametric MRI will be added in the day hospital at the time of the systematic assessment at 1 month post-transplant, and will be added in the day hospital at the time of the 12-month post-transplant assessment."
41327459|NCT06047106|PROCEDURE|kidney graft biopsy|Biopsy of the graft itself prior to transplantation in the recipient.
41327460|NCT06047106|BIOLOGICAL|blood samples|"For donors who are not selected to donate their kidney, a total of 2 mL of blood will be collected at inclusion.~For donors eligible to donate, a total of 4 mL of blood will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 26 mL of blood will be collected (pre-transplant, 1 month and 12 months post-transplant)."
41327461|NCT06047106|BIOLOGICAL|urine specimens|"For donors who are not selected to donate their kidney, a total of 15 mL of urine will be collected at inclusion.~For donors eligible to donate, a total of 50 mL of urine will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 65 mL of urine will be collected (pre-transplant, 1 month and 12 months post-transplant)."
41327462|NCT02700919|DRUG|BCT197|Capsules will be taken orally with fluids over a 5 day period after randomization
41327463|NCT02700919|DRUG|Placebo|Capsules will be taken orally with fluids over a 5 day period after randomization
41480494|NCT06027541|PROCEDURE|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, GnRHa, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
41327464|NCT01633229|PROCEDURE|Bone Marrow Stromal Cell Infusion|
41480495|NCT01869478|DRUG|Intravenous Thrombolysis|
41480496|NCT01869478|DEVICE|Endovascular Arterial Reperfusion|
41480497|NCT03340987|PROCEDURE|vestibular incision subperiosteal tunnel access|vertical vestibular incision will be made down to the periosteum followed by creating a tunnel without reflecting the interdental papilla. Then a free gingival graft will be optained from the palate and de-epithelialized extraorally. The connective tissue graft will then be applied through the tunnel and the gingival margin will be sutured and the sutures will be fixed to the tooth surface by flowable composite. Then the vestibular incision will be sutured.
41010544|NCT05443477|DIETARY_SUPPLEMENT|control|participants received two oral capsules containing control powder every day for the 3 months.
41010545|NCT01281488|PROCEDURE|fluorescence imaging|Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
41010546|NCT01281488|PROCEDURE|laparoscopic surgery|Undergo standard approach robot-assisted laparoscopic partial nephrectomy
41327465|NCT00708903|DRUG|neratinib|HKI-272
41010547|NCT01281488|DRUG|indocyanine green|Given IV
41010548|NCT00035906|DRUG|DEX PS DDS®|
41010549|NCT02699905|OTHER|phlebotomy|phlebotomy
41010550|NCT04298528|DRUG|Dronabinol|2.5mg 2 times a day for 30 days after total knee replacement
41010551|NCT04298528|OTHER|Placebo|2 times a day for 30 days after total knee replacement
41327466|NCT00708903|OTHER|Placebo|Placebo
41327467|NCT00708903|DRUG|Moxifloxacin|
41327468|NCT00732641|DRUG|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
41327469|NCT03743207|OTHER|Room temperature|These infants were fed with room temperature (22-24 °C) so that hypothesizing that they will have more feeding tolerance and therefore more co-existing morbidities.
41010552|NCT03427372|BEHAVIORAL|anxiety scale, depression scale|post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale
41010553|NCT01700179|DRUG|ACH-0143102|
41010554|NCT01700179|DRUG|Ribavirin|
41010555|NCT06113042|BEHAVIORAL|Health talks, learning packs|All participants can join the health talks and receive the learning packs.
41010556|NCT06113042|BEHAVIORAL|Lifestyle modification programme|"In Group 1: The programme includes both knowledge and activity/practicum sessions for children and parents. It will be carried out in district community hubs.~Group 2: The programme focuses on the knowledge sessions for parents. It will be carried out in schools.~Group 3: The programme focuses on the activity/practicum sessions for children and parents. It will be carried out in district community hubs."
41010557|NCT06113042|BEHAVIORAL|School healthy environment evaluation|Evaluation on school healthy environment will be carried out in Group 1 and Group 2 to enhance the schools to provide a healthy school environment to children.
41010558|NCT01752140|PROCEDURE|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
41327470|NCT03743207|OTHER|Warmer temperature|Fifteen NICU mothers volunteered and expressed their milk for rapid measurement of freshly expressed breast milk. The mean (± SD) temperature of freshly expressed breast milk was found to be 33±1.5 °C in these preliminary measurements. Confirming this finding, the investigators decided to feed these infants with milk at 32 - 34 °C to examine the effects of feeding temperature and the possible comorbidities with a hypothesis that warmer feeding at the temperature of freshly expressed breast milk may be better physiologically.
41327471|NCT03767998|OTHER|Respiratory muscle training for IMST|2 sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week, training with breathing trainer.
41327472|NCT03767998|OTHER|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
41327473|NCT03767998|OTHER|Respiratory muscle training for EMST|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
41327474|NCT00254878|DRUG|Methylphenidate hydrochloride|
41327475|NCT03299036|DEVICE|Taiwan ACE Beads with doxorubicin|Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
41327476|NCT06146842|DRUG|Bupivacaine Hydrochloride|Each subject will receive allocated dose of bupivacaine
41327477|NCT05134597|GENETIC|Genetic assessment|Blood samples will be collected in 3-mL K3 EDTA vacutainer tubes. Peripheral blood mononuclear cells will be isolated via density gradient centrifugation within 2 hours of sample collection. Primary CD4+ T cells will be purified from the peripheral blood lymphocytes using a magnetic cell sorting CD4+ T cell isolation kit, according to the manufacturer's instructions. RNA extraction will be performed. Total RNA will be quantified, and the quality of RNA will be assayed using formaldehyde agarose gel electrophoresis and by determining the 260/280 absorbance ratio. One microgram of total RNA from each sample will be subjected to reverse transcription. One microliter of cDNA will be amplified via real-time PCR and 10 pmol of primers specific to IL23R, IL17, SGK1, RANBP1, TFGB. Real-time PCR assays will be performed in triplicate The specificity of the PCR products will be determined via melting curve analysis.
41327478|NCT03481387|DEVICE|Aortic Valve Replacement with Perceval S sutureless heart valve|Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
41010559|NCT01752140|PROCEDURE|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
41010560|NCT04894981|DEVICE|Immersive condition (CAVE)|Driving course with obstacles in a CAVE system
41010561|NCT04894981|DEVICE|Immersive condition (HMD)|Driving course with obstacles with a virtual reality headset
41327479|NCT03483116|BIOLOGICAL|RV3-BB|Oral administration
41480498|NCT03340987|PROCEDURE|Coronally advanced flap|Two horizontal incisions will be made mesial and distal to the recession area followed by two oblique incisions extended to the alveolar mucosa and a full-split thickness flap will be elevated. De-epithelialization will be done to receive the connective tissue graft obtained from the palate by de-epithelializing a free gingival graft. Then the flap will be advanced coronally aand sutured without tension
41010562|NCT04894981|DEVICE|Non Immersive condition (Screen alone)|Driving course with obstacles on a screen with physical simulator
41010563|NCT04894981|DEVICE|Non Immersive condition (Screen with physical simulator)|Driving course with obstacles on a screen only
41010564|NCT00021307|DRUG|carboplatin|
41010565|NCT00021307|DRUG|temozolomide|
41017855|NCT06086184|BEHAVIORAL|ACT group therapy|"Participation in four sessions of the inpatient Compass Group and eight sessions of the inpatient Here-and-Now Group. This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan."
41327480|NCT03483116|BIOLOGICAL|Placebo|Oral administration
41327481|NCT01544478|BIOLOGICAL|V501|HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
41010566|NCT06411548|DEVICE|InsuLearn|InsuLearn is an artificial intelligence (AI)-algorithm that analyses collected participants data: CGM, insulin, and meal categories to learn the optimal insulin dose. InsuLearn will run offline in a study laptop to generate the optimal insulin dose for each meal category. The algorithm will generate an ambulatory glucose profile (AGP) report with new settings for the InPen™ meal estimation bolus calculator. The study physician will review the report and the algorithm recommendations. The study physician can accept or modify the algorithm recommendations as per his judgment. The new settings will be used during the intervention admission.
41010567|NCT03112434|DRUG|Botulinum toxin type A|Botox injection in upper extremity for spasticity in pediatric CP patients
41010568|NCT01383902|OTHER|Food type|1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
41010569|NCT05112497|OTHER|No intervention procedure|No intervention procedure
41010570|NCT02402010|BEHAVIORAL|Adjunctive Yoga|
41010571|NCT02402010|BEHAVIORAL|Enhanced Treatment as Usual|
41010572|NCT02017691|DEVICE|Near Infrared Spectroscopy|If crSO2 is \<10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable \>10th centile, or if crSO2 is \> 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
41010573|NCT02017691|DEVICE|Pulse-oximetry|If SpO2 remains \<10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is \>90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
41010574|NCT06139913|OTHER|aerobic exercise|moderate intensity aerobic exercise using treadmill
41010575|NCT03247439|DEVICE|Cartiva|Synthetic Cartilage Implant
41010576|NCT02388737|DRUG|Vonoprazan|Vonoprazan tablets
41010577|NCT02388737|DRUG|Lansoprazole|Lansoprazole capsules or tablets
41010578|NCT02388737|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
41010579|NCT02388737|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
41010580|NCT03417141|DRUG|Mechlorethamine 0.016% Top Gel|Valchlor, a 0.016% gel formulation of mechlorethamine. Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
41010581|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
41010582|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
41010583|NCT04150081|PROCEDURE|Surgery or Endoscopic treatment|All the patients in the cohort will receive surgery o local (endoscopic) treatment, in some cases additional surgical treatment will be performed after an endoscopic primary treatment. This decision will have been taken based on daily clinical practice and does not represent a study intervention.
41010584|NCT03734848|DRUG|Bilateral Ultrasound Guided Pectoralis Nerve Block.|Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
41010585|NCT02692157|DRUG|Placebo|Placebo for Neurokinin 1,3 antagonist
41010586|NCT02692157|DRUG|NT-814 50 mg|Neurokinin 1,3 antagonist 50 mg
41010587|NCT02692157|DRUG|NT-814 100 mg|Neurokinin 1,3 antagonist 100 mg
41480499|NCT00485927|BEHAVIORAL|stress|
41010588|NCT02692157|DRUG|NT-814 200 mg|Neurokinin 1,3 antagonist 200 mg
41010589|NCT04595006|OTHER|Cold Stimulation (CS)|Subject wear cooling vest to stay cool
41010590|NCT04595006|OTHER|Browning Nutraceutical (BN)|Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root
41010591|NCT04595006|OTHER|Cold Stimulation and Browning Nutraceutical (CSBN)|Subject wear a cooling vest and consume 2000mg of curcumin
41010592|NCT03258372|DRUG|Mifepristone|Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
41017856|NCT02311595|PROCEDURE|reduced port laparoscopic distal gastrectomy|
41017857|NCT04545814|DEVICE|Stereotactic Radiosurgery|Maximum Tumor Diameter ≤ 2 cm = 20-24 Gy; Maximum Tumor Diameter 2.1-3.0 cm = 18 Gy; Maximum Tumor Diameter 3.1-5.0 cm = 15 Gy
41154838|NCT03227432|DRUG|Dexamethasone|Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.
41480500|NCT05778955|GENETIC|detection and monitoring of cirulating tumor DNA|detection and monitoring of cirulating tumor DNA in pediatric soft tissue sarcoma
41480501|NCT00287859|DRUG|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
41480502|NCT02406638|OTHER|3D pelvic floor ultrasound|Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
41480503|NCT02903238|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
41480504|NCT02903238|DRUG|Placebo Oral Tablet|Lactose capsule
41010593|NCT04407728|OTHER|early ultrasound screening|"Women whose fetus is at high risk of congenital heart disease at the end of the 1st trimester screening ultrasound (EchoT1), will benefit from an early heart-centered morphological ultrasound (EchoMorpho-T1) by a referring sonographer between 11 and 14 SA +/- an early fetal cardiac ultrasound (EchoCoeur-T1) between 11 and 15 SA by a cardio-paediatrician in case of EchoMorpho-T1 abnormality.~The results of the early morphological and cardiac ultrasounds will be compared with those of the 2nd trimester ultrasound at 18-22SA (EchoMorpho-T2) and +/- of the fetal cardiac ultrasound between 18SA and 24SA (Gold standard) or, failing this, with the anatomopathological examination when it is available if a medical termination of pregnancy took place before the EchoMorpho-T2."
41010594|NCT02538497|BEHAVIORAL|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
41327482|NCT04686877|PROCEDURE|STAPLE|Stereotactic aspiration plus urokinase clot irrigation
41327483|NCT02375269|DEVICE|RIPC with a tourniquet|
41327484|NCT03970018|OTHER|Intra-peritoneal pressure|Measurement of intra-peritoneal pressure
41010595|NCT02538497|BEHAVIORAL|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
41010596|NCT05459870|BIOLOGICAL|4SCAR T cells|Infusion of 4SCAR T cells at 10\^6 cells/kg body weight via IV
41327485|NCT06054503|DEVICE|prototype of sensor|The investigational device is composed of a sensor placed on the respiratory line of the ventilated patients and connected to a ventilation measure unit which records the ventilation parameters
41327486|NCT06502145|DRUG|Azacitidine Level -1|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
41010597|NCT00458484|RADIATION|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions."
41010598|NCT00458484|PROCEDURE|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
41010599|NCT00458484|PROCEDURE|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
41327487|NCT06502145|DRUG|Azacitidine Level 0|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
41327488|NCT06502145|DRUG|Azacitidine Level 1|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
41327489|NCT06502145|DRUG|Iadademstat Level -1|75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.
41327490|NCT06502145|DRUG|Iadademstat Level 0|75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
41327491|NCT06502145|DRUG|Iadademstat Level 1|100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
41327492|NCT06017778|DEVICE|whole body vibration|patients will receive WBV training in addition to traditional training will be performed on a tri-planar (mostly vertical, Z axis) oscillating vibration platform (Power PlateR pro5™; Power Plate North America, Inc., Northbrook, IL,USA) for 20-30 minutes per session. WBV training will be supervised and performed in a clinic three days a week with at least one day between each session for four weeks (total of 12 sessions).
41327493|NCT06017778|OTHER|traditional exercise group|10 minutes warm-up (lower extremity stretching exercises), 20-30 minutes period of strength exercises with three sets of 10-15 repetitions (isometric quadriceps setting, knee extensions, double-legged wall squat), and 5 minutes cool-down (lower extremity stretching exercises). Lower extremity stretching exercises consisted of quadriceps, hamstring, gastrocnemius and iliotibial band stretching with 3 repetitions for 30 s each muscle.
41327494|NCT05885048|DIAGNOSTIC_TEST|Blood samples for analysis|Test hormone levels in blood
41327495|NCT05885048|DIAGNOSTIC_TEST|Sperm samples for analysis|Spermiogram
41327496|NCT05885048|OTHER|Satisfaction evaluation|Participant satisfaction assessment
41327497|NCT05885048|OTHER|Quality of Life questionnaire|The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)
41480505|NCT04950959|DEVICE|Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T|The system is used for trajectory planning and is intended to assist the physician in the positioning of an instrument, such as a needle, where CT imaging is used for target trajectory planning and intraoperative tracking. The XACT ACE Robotic System uses a computerized quantitative guidance system, which provides real-time, accurate needle guidance, including advancement and steering of the needle from the entry point on the subject's body to the target point within the body.
41480506|NCT04790123|PROCEDURE|Injection of autologous freshly collected adipose tissue|injection of fresh autologous fat, previously lipoaspirates from the patient's abdomen and centrifugated, into the fistulous tract, after curettage and closure of the internal opening.
41480507|NCT04790123|PROCEDURE|sham|curettage and closure of the internal orifice of the anal fistula and simulated intervention in the abdomen.
41480508|NCT03516136|DEVICE|EndoFast Reliant SCP|POP repair procedure with the EndoFast Reliant SCP system
41010600|NCT03768739|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves a flexible laryngoscope that contains a light source and video camera on the end through the open passages of your nose and to the back of the throat in order to visualize the swallowing mechanism.
41480509|NCT03113448|DRUG|0.075% Capsaicin Lotion|To apply 3-4 times per day, every day until 8 weeks then stop
41480510|NCT03113448|DRUG|placebo|To apply 3-4 times per day, every day until 8 weeks then stop
41010601|NCT05957068|BEHAVIORAL|Exercise Programme|Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.
41010602|NCT05957068|BEHAVIORAL|Control|Usual care group.
41010603|NCT01014507|DRUG|8 cycles BEACOPPesc plus oral contraceptive|
41010604|NCT01014507|DRUG|8 cycles BEACOPPesc plus Goserelin|
41010605|NCT03641573|DRUG|[14C] ASN002|\[14C\] ASN002
41010606|NCT06117267|DEVICE|Anatase Spine Surgery Navigation System|Collect images with the probe touching the target position before screw implantation
41010607|NCT00126295|DEVICE|'What you need to know about stroke' education package|
41010608|NCT03306264|DRUG|ASTX727|ASTX727 oral tablet
41010609|NCT03306264|DRUG|Dacogen|Decitabine 20 mg/m\^2 one-hour IV infusion
41010610|NCT06097234|DEVICE|Pelex Upp|Biofeedback-mediated pelvic floor trainer. It captures contraction and relaxation of the pelvic floor muscles during use by the subject, and represents these contractions and relaxations back to the subject to improve conscious control of the muscle groups.
41327498|NCT03980626|BEHAVIORAL|Walking|The exercise intervention is designed to improve cardiorespiratory fitness, a known correlate of cognition and brain health, and follows the American College of Sports Medicine exercise guidelines for cancer survivors. Participants will engage in small group, moderate-to-vigorous intensity walking sessions three times weekly. Sessions will begin with a warm-up and end with a cool down and be progressive in nature. Volume of exercise will increase across weeks such that participants will progress from 15-20 minutes of walking to 40-45 minutes by week 8, and from 40-55% of their estimated heart rate reserve (HRR) to 65% of their HRR by week 9. All sessions will be led by trained exercise specialists to ensure close monitoring of participant safety. Participants will wear heart rate monitors and be asked to rate their perceived exertion to ensure they are exercising within the prescribed range. Modifications to each participant's exercise prescription will be made as needed.
41327499|NCT05054179|DRUG|Ropivacaine 0.2% Injectable Solution Bolus|20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side
41327500|NCT05054179|OTHER|Normal Saline Infusion|3 mL/hour infusion of normal saline for 48 hours via parasternal multi-orifice catheters on each side of the sternum
41327501|NCT05054179|DRUG|Ropivacaine 0.2% Injectable Solution Infusion|3 mL/h infusion of Ropivacaine 0.2% for 48 hours via parasternal multi-orifice catheters on each side of the sternum
41480511|NCT02516904|DRUG|CD101 IV|antifungal
41010611|NCT06097234|BEHAVIORAL|Pelvic Floor Physical Therapy|A form of physical therapy whereby the subject is given instructions on how to identify the pelvic floor, how to coordinate the pelvic floor contractions and relaxations, as well as counseling on dietary changes that affect pelvic floor and pelvic organ function
41010612|NCT04953923|DRUG|Cedazuridine|Tablet for oral administration
41010613|NCT04953923|DRUG|Placebo|Capsule for oral administration
41010614|NCT04953923|DRUG|Moxifloxacin|Tablet for oral administration
41010615|NCT04902105|DRUG|ecopipam HCL|oral tablets
41010616|NCT04902105|DRUG|Mefenamic acid|oral capsules
41010617|NCT04902105|DRUG|Divalproex Sodium ER|oral tablets
41010618|NCT02985736|DRUG|Topicort Topical Spray|
41010619|NCT02129361|BEHAVIORAL|Adapted Screening and Brief Intervention (Adapted SBI)|
41010620|NCT02129361|BEHAVIORAL|Screening & Education Attention Control|
41010621|NCT04139785|OTHER|Moodbuster|"Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data."
41010622|NCT00216294|DRUG|RG1068 (Synthetic Human Secretin)|
41010623|NCT01509794|OTHER|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
41010624|NCT01509794|OTHER|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
41010625|NCT02897739|PROCEDURE|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
41480512|NCT02516904|DRUG|Placebo|normal saline
41480513|NCT04714970|DEVICE|iTBS|Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.
41480514|NCT04714970|DEVICE|Shame stimulation|TMS coil vertical to the brain surface, with same protocol as iTBS
41327502|NCT01670682|PROCEDURE|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
41327503|NCT01670682|PROCEDURE|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
41327504|NCT01670682|DEVICE|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
41327505|NCT02077504|OTHER|MEG and MRI|CONDUCTOME
41327506|NCT03581682|OTHER|Tele-Clinic Visits Using Parent-Acquired Echos|"Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other."
41327507|NCT00391781|PROCEDURE|Temperature of contrast medium|
41327508|NCT01500941|DIETARY_SUPPLEMENT|probiotics|a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
41327509|NCT01500941|OTHER|maltodextrin|sachets
41327510|NCT03947567|DRUG|Recombinant Human Coagulation FVIII|Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
41327511|NCT02284230|DRUG|Liraglutide|
41327512|NCT02284230|DRUG|Placebo|
41327513|NCT01792297|DIETARY_SUPPLEMENT|Bovine colostrum|
41327514|NCT01792297|DIETARY_SUPPLEMENT|Whey protein|
41327515|NCT06139536|DRUG|BAT4706 Injection|Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
41327516|NCT06139536|DRUG|BAT1308 Injection|Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
41327517|NCT03874195|BEHAVIORAL|Access to PCforMe for review|Intervention Arm subjects will receive access to PCforMe.
41327518|NCT03874195|BEHAVIORAL|Access to three nationally-recognized Palliative Care websites for review|Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care
41480515|NCT03466541|BEHAVIORAL|Riskbruk|The Riskbruk model incorporates alcohol screening through a widely employed alcohol screening questionnaire, the Alcohol Use Disorders Identification Test (AUDIT) and a standard alcohol biomarker, carbohydrate-deficient transferring in serum (CDT), with brief consultations using the motivational interviewing (MI) technique. MI is a collaborative conversation style used to increase awareness and reflection around one's own drinking habits, as well as strengthening the person's motivation for a lifestyle change. The conversation style includes expressing empathy through reflective listening, communicating respect and acceptance of the participants and their feelings, and open up for self-reflection and exploration around the drinking behaviour.
41327519|NCT00093756|RADIATION|3-dimensional conformal radiation therapy|
41327520|NCT00093756|DRUG|bortezomib|Given IV
41327521|NCT00093756|DRUG|paclitaxel|Given IV
41327522|NCT00093756|DRUG|carboplatin|Given IV
41480516|NCT03466541|BEHAVIORAL|Balance|Balance is a new Norwegian eHealth programme, and incorporates two approaches to behaviour modification interventions: a brief interventions and an intensive self-help programme. The intervention is based on cognitive-behavioural and self-help principles, and is given to the participants through multiple interactive sessions.
41480517|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
41480518|NCT01014962|DRUG|Placebo|Placebo oral once daily for 5 days
41010626|NCT02897739|BIOLOGICAL|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
41010627|NCT02897739|RADIATION|PET CT|PET study for metabolic pathway study
41010628|NCT02897739|BEHAVIORAL|Psychological assessment|Assessment by a psychologist
41327523|NCT04586296|OTHER|Telemedicine|IVR will consist of a 3 minute call at a decreasing interval from the time of surgery. Questions will assess pain control, signs of infection, prosthesis failure.
41327524|NCT00033592|OTHER|placebo|
41327525|NCT00033592|DRUG|bupropion hydrochloride|
41327526|NCT00033592|DRUG|nicotine|
41327527|NCT01743170|OTHER|Telemonitoring of self-measured blood pressure|In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
41327528|NCT02896192|DRUG|Setmelanotide|Once daily SC injection
41327529|NCT02896192|DRUG|Placebo|Once daily SC injection
41327530|NCT03118076|DRUG|0.3% ropivacaine and 50 μg dexmedetomidine|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
41327531|NCT03118076|DRUG|Ropivacaine|Nerve blocks were administered with 0.3% ropivacaine.
41327532|NCT01052181|DRUG|Cholecalciferol|Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
41327533|NCT01052181|DRUG|placebo|2 sachets monthly for an year
41327534|NCT05942664|BEHAVIORAL|Sleep|Sleep will be restricted to 60% normal sleep duration
41327535|NCT00382213|DRUG|Olmesartan medoxomil|
41327536|NCT00382213|DRUG|Placebo|
41327537|NCT02780596|OTHER|Item1|Does CHILD NAME often wake one or more times during the night?
41327538|NCT02780596|OTHER|Item2|Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?
41327539|NCT02780596|OTHER|Item3|Do you think CHILD'S SLEEP is a problem?
41327540|NCT02780596|OTHER|Item4|Do you think CHILD NAME has a sleep problem?
41480519|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
41480520|NCT01014962|DRUG|Placebo|Placebo oral every 12 hours for 5 days
41480521|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
41010629|NCT03968952|OTHER|SMARThealth Pregnancy|Education and Training package on high-risk pregnancies and the associated long-term cardiometabolic risks; An mHealth platform providing mobile decision support to Community Health Workers.
41010630|NCT01164852|PROCEDURE|Delivery|Termination of pregnancy (delivery)after completed corticosteroids
41010631|NCT00980954|DRUG|carboplatin|Given IV
41010632|NCT00980954|DRUG|cisplatin|Given IV
41010633|NCT00980954|DRUG|paclitaxel|Given IV
41010634|NCT05613439|PROCEDURE|Day-surgery|Standard surgical procedure but with planned discharge on day of surgery
40809932|NCT06658210|OTHER|soft tissue mobilization with pelvic floor muscle exercises|Group A will receive soft tissue mobilization and pelvic floor muscle exercises. Soft tissue mobilization technique will include abdominal myofascial release/trigger point release and deep scar mobilization to decrease pain and improve scar mobility
40809933|NCT06658210|OTHER|soft tissue mobilization without pelvic floor muscle exercises|Group B will receive soft tissue mobilization technique without pelvic floor exercises.
41154839|NCT03227432|DRUG|Pomalidomide|Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.
40809935|NCT06658912|OTHER|TOPS Classes|Attend Dietician-Led Sessions
40809936|NCT06659146|DEVICE|Superficial hyperthermia|Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)
41154840|NCT03227432|DRUG|Elotuzumab|Elotuzumab is an antibody, that stimulates the immune system to fight diseases
41010635|NCT05613439|PROCEDURE|High-risk patient|Standard fast-track procedure but with additional perioperative measures dependent on risk-profile.
41010636|NCT05613439|PROCEDURE|Main Group|Standard fast-track procedure according to usual standard of care and discharge when fulfilling functional discharge criteria
41010637|NCT04313920|OTHER|Nutritional Supplement|50 g Carbohydrate
41010638|NCT01981434|OTHER|Video game based obesity education|The intervention will be in the form of a videogame in which both parent and their children will participate. The game incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
41010639|NCT06198192|OTHER|Pilates Exercises|Ten repetitions of Pilates exercises will be performed with a 2-minute rest period between repetitions. Pilate group will receive the intervention program three times/week for total 10 weeks
41010640|NCT06198192|OTHER|Conventional Therapy and Balance Exercises|this group receive conventional therapy along with balance exercises. Standing with feet together while the therapist sitting behind and manually locking the child knees, and then slowly tilt him to each side, forward and backward. Step standing with therapist behind the child guiding him to shift his weight forward then backward alternately. High step standing and try to keep balanced. Standing with manual locking of the knees then tries actively to stoop and recover. Equilibrium, righting and protective reactions training. Open environment gait training will be conducted with the different obstacles. Session includes three times/week for total 10 weeks
41010641|NCT06320470|BEHAVIORAL|Educational Session|The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
41010642|NCT00296556|DRUG|Rivenprost (drug)|
41010643|NCT01123538|DRUG|Progesterone|200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
41010644|NCT01123538|DRUG|Chlormadinone acetate|5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
41327541|NCT02780596|OTHER|Item5|Do you have any concerns about CHILD NAME'S sleep?
41327542|NCT02281344|DRUG|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
41480522|NCT01014962|DRUG|Placebo|Placebo oral every 8 hours for 5 days
41154841|NCT03227432|DRUG|Nivolumab|Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer
41154842|NCT02241642|DEVICE|VIVASURE CLOSURE DEVICE™|Large hole vascular closure device
41154843|NCT03642288|DRUG|Gastrografin|Patients with CRE-induced SBO or ASBO both received GG challenge.
40809941|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 1|Creatine hcl
40809942|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 2|Creatine hcl
40809943|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 3|Creatine ethyl ester
40809944|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 4|Placebo
41154844|NCT05846841|BEHAVIORAL|Precision Treatment|Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.
41154845|NCT05846841|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
40809947|NCT06658704|BEHAVIORAL|Supervised exercise in a group setting|Participants are invited to a 16 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first two weeks and then two sessions per week for week 3-16.
41154846|NCT06015620|PROCEDURE|Mini gastric bypass surgery|Mini gastric bypass surgery is a common metabolic or bariatric surgery done world wide for patients suffering from morbid obesity not managed by non surgical modalities of treatment.
41154847|NCT02767596|DRUG|Lixisenatide|
41154848|NCT02767596|DRUG|Basal insulins|patients are on basal insulin treatment
41154849|NCT05032651|DEVICE|novel artificial intelligence assisted platform|Use of a novel artificial intelligence assisted platform
41154850|NCT01278511|OTHER|Canadian C-Spine rule|Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
41480523|NCT00472875|DRUG|Glibenclamide|
41327543|NCT06193694|BEHAVIORAL|Coaching|Formal coaching program followed by the Coaching Fidelity Tool, to be taken by the study group after program completion contains 12 questions, predominantly multiple choice and yes/no, although there is one question that requires a short answer as well as a place to write additional comments. These questions are meant to elicit responses about their experience with their assigned coach during their one-on-one coaching sessions.
41327544|NCT00921427|BEHAVIORAL|Vision Restoration Therapy (VRT)|30 min, twice a day, 3 days a week, 12 weeks
41327545|NCT00921427|DEVICE|Transcranial direct current stimulation (tDCS)|2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
41327546|NCT01213264|OTHER|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
41327547|NCT01213264|DRUG|Sugammadex|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling."
41327548|NCT01213264|DRUG|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling."
41327549|NCT04707378|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
41327550|NCT03380338|BEHAVIORAL|Combined aerobic and strength exercise|
41327551|NCT04132648|DRUG|Curcumin|Oral supplement one time at 2,000 mg
41327552|NCT04132648|OTHER|Placebo|Oral supplement one time at 2,000 mg
41327553|NCT01854489|DRUG|Placebo|The volunteers will be given Oral placebo at 20.00 for 7 days \[Phase 1 \]
41327554|NCT01854489|DRUG|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
41327555|NCT01854489|DRUG|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
41327556|NCT05750888|BEHAVIORAL|integrated exercise therapy with 3D printing exerciser for training intrinsic foot muscles|The therapeutic exercise program with a custom-made 3-D printing foot core exerciser, consisting of warm-up exercise, active range of motion in the foot and ankle joints, foot core system strengthening program using the 3D printing device, and stretching exercises for foot and ankle.
41327557|NCT05750888|BEHAVIORAL|regular exercises for the elderly|The regular exercise provided for the elderly in the dwelling community, including walking, simple aerobic exercises, stretching exercises
41327558|NCT05893121|OTHER|Cardiac coherence session|A cardiac coherence session consists of an exercise of six breaths per minute during five minutes.
41327559|NCT05893121|OTHER|Information note about MRI|explanatory note about MRI examination
41327560|NCT00129792|DRUG|Dietary supplement for weight loss|The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
41327561|NCT00129792|BEHAVIORAL|Education and counseling for weight loss|Hour and a half weight loss education session weekly for 12 weeks.
41327562|NCT01922245|DEVICE|Soterix 1x1 tDCS|Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.
41154851|NCT02029521|DIETARY_SUPPLEMENT|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
41327563|NCT00206401|DRUG|Lantus and short acting analogs Vs NPH and short acting analogs|
41327564|NCT03472599|OTHER|Genital Nerve Stimulation|Genital nerve stimulation activates sensory afferents that travel through the pudendal nerves and enters the spinal cord through the sacral dorsal root ganglia. Inhibitory spinal reflex pathways are activated, causing increased sympathetic outflow through the inferior mesenteric ganglion and hypogastric nerve and also decreased parasympathetic efferent drive through the pelvic nerve, resulting in inhibited bladder contractions.
41327565|NCT03946293|DIETARY_SUPPLEMENT|White Bread|White bread made with commercial white flour with bran/fibre removed
41327566|NCT03946293|DIETARY_SUPPLEMENT|Wholegrain bread|Wholegrain bread made with commercial wholegrain flour.
41327567|NCT03946293|DIETARY_SUPPLEMENT|Wholegrain Enzyme|Wholegrain bread made with enzyme-treated commercial wholegrain flour.
41327568|NCT04155658|OTHER|Experimental Toothpaste containing 1450ppm SMFP|Experimental Toothpaste containing 1450ppm SMFP
41327569|NCT04155658|OTHER|Toothpaste containing 1450ppm SMFP|Toothpaste containing 1450ppm SMFP
41327570|NCT04155658|OTHER|Toothpaste with no fluoride|Toothpaste with no fluoride
41327571|NCT02842788|PROCEDURE|Prone positioning|Turning the patient face down for several consecutive hours
41327572|NCT02581618|OTHER|remote ischemic preconditioning|Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
41327573|NCT03214926|DEVICE|Moving Through Glass intervention|
41327574|NCT02067741|DRUG|CR1447|400 mg, corresponding to two 4 g stick packs applications twice daily
41154852|NCT02029521|DIETARY_SUPPLEMENT|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
41154853|NCT05698511|DRUG|Psilocybin|Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.
41327575|NCT05211258|DEVICE|a novel portable upper gastrointestinal endoscopy system|Patients arrived at the hospital in the morning after an overnight fast (\>6 hours). The patients took oral dyclonine glue 15 mins before their examination. The doctors prepared the portable endoscopy system so that it was in working status and the disposable sheathed system was placed on the endoscope optical probe.
41327576|NCT04320290|DRUG|Direct Acting Antivirals|8 weeks of DAA treatment
41327577|NCT01425749|BIOLOGICAL|recMAGE-A3 + AS15 ASCI|Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
41327578|NCT06279663|PROCEDURE|Revascularization|revascularization
41327579|NCT03852160|DRUG|Esketamine 28 mg|Participants will receive 28 mg esketamine as nasal spray (Initial dose for elderly participants with 65-74 years of age on Day 1 and then uptitrated to 56 mg on Day 4).
41327580|NCT03852160|DRUG|Esketamine 56 mg|Participants will receive 56 mg esketamine as nasal spray (Initial dose for participants with 18-64 years of age) on Day 1. The dose may be increased/may remain same based on the efficacy and tolerability. Participants with 65 to 74 years of age will receive esketamine 56 mg from Day 4 onwards.
41327581|NCT03852160|DRUG|Esketamine 84 mg|Participants may receive 84 mg (maximum uptitrated esketamine dose). The dose may be decreased/may remain same based on the efficacy and tolerability.
41327582|NCT03852160|DRUG|Placebo|Participants will receive matching placebo as nasal spray.
41327583|NCT03852160|DRUG|Escitalopram|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for escitalopram is 5 mg once daily (for elderly participants) and 10 mg once daily (for adults). The dose may be increased to 10 mg (for elderly participants) and 20 mg (for adults) once daily at the discretion of treating physician/investigator.
41327584|NCT03852160|DRUG|Sertraline|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for sertraline is 50 mg once daily and may be increased up to 200 mg once daily.
41327585|NCT03852160|DRUG|Duloxetine|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for duloxetine is 60 mg once daily and may be increased to 120 mg once daily.
41327586|NCT03852160|DRUG|Mirtazapine|Mirtazapine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for mirtazapine is 15 to 30 mg once daily and may be increased to 45 mg once daily.
41327587|NCT03852160|DRUG|Agomelatine|Agomelatine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for agomelatine is 25 mg once daily and may be increased to 50 mg once daily after 2 weeks.
41327588|NCT03852160|DRUG|Bupropion|Bupropion can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for bupropion is 150 mg once daily and may be increased to 300 mg once daily after 4 weeks.
41327589|NCT03852160|DRUG|Trazodone Prolonged Release|Trazodone prolonged release can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for trazodone prolonged release is 75 to 150 mg once or twice daily and may be increased up to 450 mg (adults) and 300 mg (elderly).
41327590|NCT05445518|BEHAVIORAL|Jump Start Plus COVID Support|The Jump Start Plus COVID Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
41327591|NCT05445518|BEHAVIORAL|Healthy Caregivers-Healthy Children (HC2)|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom.
41327592|NCT01231126|DRUG|Misoprostol|Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
41480524|NCT04150198|DEVICE|TEP/IRM|All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
41480525|NCT05210452|BIOLOGICAL|Follicular stem cells|Cultured autologous follicular stem cells
41480526|NCT05210452|OTHER|Standard treatment according to the clinical protocols|Standard treatment of alopecia according to the clinical protocols
41480527|NCT05743231|PROCEDURE|interpectoral area block + serratus anterior area block group|The interpectoral and serratus anterior area blocks will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used for two blocks.
41480528|NCT03560687|DRUG|Sucrosomial Iron|CardioSideral 2 caps per day
41480529|NCT05748327|DEVICE|Alcasite restorative material|Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), conditioning with primer, mixing alcasite capsula, place restoration, polymerizing and finishing
41327593|NCT02692313|DRUG|Epinephrine|Dose response of epinephrine infusion
41327594|NCT02692313|OTHER|Saline infusion|Placebo
41327595|NCT03057132|DEVICE|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
41327596|NCT06371664|DRUG|Conventional Tray (1 mm)|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of conventional individualized bleaching trays (trimmed 1 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
41480530|NCT05748327|DEVICE|Bulk fill glass hybrid restorative material|Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), mixing bulk fill glass hybrid capsula, conditioning, place restoration, apply coating, polymerizing and finishing
41480531|NCT03977701|BEHAVIORAL|Phonological treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.
41327597|NCT06371664|DRUG|Extended Tray (3 mm)|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of extended individualized bleaching trays (trimmed 3 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
41327598|NCT04740333|OTHER|No intervention- observational study|No intervention- observational study
41327599|NCT02942706|DRUG|Cetuximab|anti-EGFR monoclonal antibody
41327600|NCT02942706|DRUG|mFOLFOX6|Oxaliplatin+LV5FU2
41327601|NCT02942706|DRUG|FOLFIRI|Irinotecan+LV5FU2
41327602|NCT03598569|OTHER|dyspnea|dyspnea assessment
41327603|NCT06165523|OTHER|Water|340 mL plain tap water consumed immediately following glycogen depleting exercise
41327604|NCT06165523|OTHER|Flavored Kefir|320 mL kefir consumed immediately following glycogen depleting exercise
41327605|NCT06165523|OTHER|Flavored Milk|240 mL flavored milk consumed immediately following glycogen depleting exercise
41327606|NCT03179930|DRUG|Entinostat|All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15
41327607|NCT03179930|DRUG|Pembrolizumab|pembrolizumab 200 mg IV on D1
41327608|NCT01920438|PROCEDURE|Percutaneous Endoscopic Gastrostomy|PEG
41327609|NCT01920438|PROCEDURE|Radiologically-guided insertion of Gastrostomy|RIG
41327610|NCT00083343|DRUG|MK0991, caspofungin acetate/Duration of Treatment: variable|
41327611|NCT01343017|OTHER|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
41327612|NCT00345540|DRUG|NOV-002|60 mg / mL / day / 20-23 Days
41327613|NCT00345540|DRUG|Carboplatin|AUC 5 following IV bolus administration of NOV-002
41327614|NCT06295406|OTHER|Neuropsychological assessment|Neuropsychological tests assessing reading abilities, skills of motor coordination, postural stability, manual dexterity, including graphomotor skills, and estimation of time will be performed
41327615|NCT00819104|DRUG|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
41327616|NCT00819104|DRUG|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
41327617|NCT00819104|DRUG|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
41327618|NCT00819104|DRUG|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
41327619|NCT00819104|DRUG|Amlodipine 5mg|tablet,oral,OD,8 weeks
41480532|NCT03977701|BEHAVIORAL|Morpheme treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of targeted morphemes following the methodology of Plante and colleagues. A minimum of 50 productions will be targeted per 1-hour session.
41480533|NCT01701037|DRUG|dabrafenib|150 mg given PO
41480534|NCT01701037|DRUG|trametinib|2 mg given PO
41327620|NCT05005442|BIOLOGICAL|Pembrolizumab/vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
41327621|NCT05928676|DIETARY_SUPPLEMENT|Vascanox® HP|Vascanox® HP is a proprietary formulation that combines dietary sources of nitric oxide and hydrogen sulfide aimed at increasing the levels and duration of nitric oxide biosynthesis. Vascanox® HP contains an advanced blend of berry extracts in addition to beet root powder, black garlic, vitamin C, and minerals known to influence nitric oxide biosynthesis and metabolism. Because of the particular combination of ingredients, Vascanox® HP is expected to affect both canonical and non-canonical pathways of nitric oxide production and to augment nitric oxide reservoir in the body leading to an increased and prolonged nitric oxide bioavailability.
41327622|NCT02403141|OTHER|Questionnaire|
41327623|NCT03384108|OTHER|5-13C-Glutamine|Intravenous infusion of 5-13C-Glutamine
41327624|NCT03384108|OTHER|Bone marrow aspiration|Bone marrow aspiration of bone marrow aspirate
41327625|NCT02312115|DRUG|Furosemide|Diuretic
41327626|NCT02312115|DRUG|Placebo|Saline
41327627|NCT05832099|RADIATION|Radiation|The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
41327628|NCT05141734|DIAGNOSTIC_TEST|The relationship between the vestibulo-ocular reflex (VOR) gains and the slow phase velocity (SPV)|The vestibulo-ocular reflex (VOR) gains were measured by video Head Impulse Test (vHIT) in both the study group and the control group. The slow phase velocity (SPV) values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
41327629|NCT03949998|DEVICE|Dry Needling|Comparison between dry needling and/or manual therapy of the cervical region.
41327630|NCT03949998|OTHER|Manual Therapy|soft tissue release, cervical traction and/or cervical mobilization
41327631|NCT00714298|OTHER|Measure of Initial heart fatty acid binding protein and ischemia modified albumin|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
41327632|NCT00250367|DRUG|risperidone|
41327633|NCT03037606|DRUG|Rabelis DDR 50 mg Capsules|Rabelis DDR 50 mg Capsules once daily for seven days.
41327634|NCT03037606|DRUG|Pariet 20 mg Enteric Coated Tablets|Pariet 20 mg Enteric Coated Tablets once daily for seven days.
41327635|NCT00259038|DRUG|Carperitide|
41327636|NCT00259038|DRUG|Placebo|
41327637|NCT03764579|BEHAVIORAL|sleep and diet intervention vs diet intervention|lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.
41327638|NCT00964262|DRUG|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
41480535|NCT01701037|OTHER|laboratory biomarker analysis|Correlative studies
41480536|NCT00677079|DRUG|Iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
41327639|NCT00964262|DRUG|Placebo|Plcacebo of each doasage, single subcutanoeus injection
41327640|NCT01947894|OTHER|Non Interventional Study|Non Interventional Study
41327641|NCT02858102|BEHAVIORAL|Physical activity program|The intensity of physical activity will be adapted to the possibilities of the participants making individualized proposals to encourage participants to acquire active lifestyle habits to improve their health. All sessions end with a routine of relaxation and passive stretching. Simultaneously self-employment is controlled outside the guided sessions.
41327642|NCT03990701|COMBINATION_PRODUCT|11C-Metomidate PET/CT Scan|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
41327643|NCT03044470|OTHER|cryotherapy|Role of cryotherapy in reduction of post operative pain
41327644|NCT04822311|BEHAVIORAL|Experimental: Investigate the effects of an exercise intervention on retired APF players|Enrolled participants will perform a 18 months exercise intervention which involves 90 exercise rehabilitation training visits. In addition, participants will also be tested on various measures of health and function both at baseline (prior to intervention), at 6 months, 12 months, and 18 months (post intervention).
41327645|NCT03850418|DRUG|azacitidine|azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated
41010645|NCT05696730|OTHER|Communication intervention about sexuality in people with COPD|"COSY is a communication intervention which consists of one face to face counselling (75 min) and two 30-min telephone call counselling.~Patients assigned to the intervention group will get the COSY communication intervention with a special focus on the positive impact of sexuality on wellbeing plus specific motivation for physical activity. Together with the patient, a personalized re-enforcement instrument, the COSY-Compass, is elaborated to set individual goals and motivation for physical activity over the whole intervention period (3 months).~Participants will learn to understand the positive effect of regular physical activity on physical, mental, and cognitive wellbeing and a more fulfilling sex life as well as get inspiration about the spectrum and possible expressions and manifestations of caring and intimacy with oneself."
41327646|NCT05048199|DEVICE|pressure regulated volume-controlled mode of ventilation|"Cardiac output non-invasive monitor for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, .... etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, .... etc), end of surgery (T6), and postoperative every 4h for 24 hours( P1-P6)."
41327647|NCT05048199|DEVICE|volume-controlled mode of ventilation|"Cardiac output non-invasive monitor will be used for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, .... etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, .... etc), end of surgery (T6), and postoperative every 4 hours for 24 hours (P1-P6)."
41327648|NCT00602381|DRUG|Lithium|
41010646|NCT05731726|DRUG|Serplilumab|"Serplilumab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w"
41010647|NCT05731726|DRUG|Capecitabine|Given PO
41010648|NCT05731726|DRUG|Oxaliplatin|Given IV
41010649|NCT05731726|DRUG|Celecoxib|celebrex
41010650|NCT00006374|BIOLOGICAL|filgrastim|
40809948|NCT06658704|BEHAVIORAL|Usual care (Physical activity on Prescription)|Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 16 weeks.
41327649|NCT06087588|DRUG|0.9%sodium chloride|PENG sham block with 20ml 0,9% normal saline
41327650|NCT06087588|DRUG|95% ethanol|PENG neurolysis with 2.5ml of 95% ethanol
41327651|NCT02706678|DRUG|Tacrolimus sustained-release capsule|Oral
41327652|NCT06369038|BEHAVIORAL|observation of level of dental anxiety in children|analysis of children's drawings using CD:H index
41327653|NCT03611049|DIETARY_SUPPLEMENT|High dose Vitamin D3|High dose arm- 5000IU given daily
41327654|NCT03611049|DIETARY_SUPPLEMENT|Low dose Vitamin D3|Low dose arm-800 IU given daily
40809949|NCT06661304|OTHER|Benson Relaxation Exercise|Benson relaxation exercise is based on the patient relaxing their body muscles by focusing on deep breathing and a word that means something to them.
41010651|NCT00006374|DRUG|cisplatin|
41010652|NCT00006374|DRUG|etoposide|
41010653|NCT00006374|DRUG|paclitaxel|
41010654|NCT00006374|DRUG|topotecan hydrochloride|
41010655|NCT02177240|DEVICE|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
41010656|NCT02177240|DEVICE|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
41010657|NCT04711304|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
41010658|NCT04711304|DEVICE|Hyaluronic acid|Intraarticular injection
41010659|NCT04711304|OTHER|Saline|Intraarticular injection
41010660|NCT03149640|DRUG|Inhaled amikacin|Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
41010661|NCT03149640|DRUG|Inhaled placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
40809950|NCT06661304|OTHER|Ongoing treatment|In addition to their medical treatment and care in the clinics, patients participate in activities such as group activities, leisure time and walking.
41010662|NCT01697657|DRUG|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
40809951|NCT06661967|DRUG|Lidocaine spray|Comparison of the success rate of endotracheal intubations between lidocaine spray and placebo
41010663|NCT01697657|DRUG|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
40809952|NCT06660940|DRUG|Keluoxin Capsules|Treatment period (52 weeks):Keluoxin Capsules, 4 capsules/time, swallow with warm water after meals, 3 times/day
41010664|NCT01697657|DRUG|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
41010665|NCT02536859|DRUG|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
41010666|NCT02536859|DRUG|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
41010667|NCT01324375|DEVICE|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
41327655|NCT04985240|DIETARY_SUPPLEMENT|Lettuce with no biofortification|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
41327656|NCT04985240|DIETARY_SUPPLEMENT|Intervention Molibdenum group|Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
41327657|NCT00636441|DRUG|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
41327658|NCT06532253|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)
41327659|NCT05895695|PROCEDURE|levator muscle resection|resection of levator muscle in congenital unilateral ptosis
41327660|NCT05895695|PROCEDURE|levator muscle plication|plication of levator muscle in congenital unilateral ptosis
41327661|NCT00802867|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)|0.5 mL, Intramuscular
41327662|NCT03154177|BEHAVIORAL|Group ANC/PNC|The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
41327663|NCT03154177|PROCEDURE|Ultrasound+Pregnancy Testing|"Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention."
41327664|NCT01084330|DRUG|AUY922|70mg/m2
41327665|NCT01084330|DRUG|Docetaxel|Docetaxel 75mg/m2
41327666|NCT01084330|DRUG|Irinotecan|Iriniotecan 350mg/m2
41327667|NCT04154657|PROCEDURE|conductance catheter measurement|biventricular parallel conductance catheter measurement at rest and stress conditions, + CMR at rest and stress
41327668|NCT03930303|BEHAVIORAL|Multimedia- based patient education|Patients will receive a 5 minutes video education before D\&C
41327669|NCT00142402|DRUG|Modafinil|
41327670|NCT03215667|DEVICE|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
41327671|NCT04705610|OTHER|Video-oculography / Social cognition tasks / Neuropsychological evaluations|"* Recording of eye movements with a video-oculography device during oculomotor paradigms (Fixations, horizontal and vertical reflex saccades, horizontal and vertical smooth pursuit, anti-saccades)~* Recording of eye gaze with a video-oculography device during emotions recognition tasks (Reading the Mind in the Eyes test (Baron-Cohen 2001); Ekman Faces task (1976))~* Neurological evaluation~* Neuropsychological evaluations~* Social cognitions tasks~* Behaviour assessment"
41327672|NCT04208646|BIOLOGICAL|Mesenchymal progenitor cells|Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use
41327673|NCT04208646|BIOLOGICAL|No mesenchymal progenitor cells|No mesenchymal progenitor cells for intra- articular use
41327674|NCT03312361|DRUG|15% oxygen|Participants will inhale 15% oxygen for 2 hours to see how it affects them.
41327675|NCT06304675|OTHER|no intervention|no intervention
41327676|NCT00582699|BEHAVIORAL|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
40809953|NCT06660940|DRUG|Keluoxin Capsule Simulants|Treatment period (52 weeks):Keluoxin Capsule Simulants, 4 capsules/time, swallow with warm water after meals, 3 times/day
40809954|NCT06660940|DRUG|Irbesartan|"1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD"
41327677|NCT02963415|BEHAVIORAL|Exergame|Participants will take part in the exergame, 3 times a week for a month. The session will start for 30-35 minutes of cycling on recumbent stationary cycles in session 1 and progress to moderate intensity for 50 minutes a session. Participants will do warm-up and cool-down activities before and after cycling. While cycling, participants will be playing virtual reality based games. An exercise interventionist will supervise the sessions and monitor participant's conditions and responses to ensure safety.
41327678|NCT02448797|DRUG|Icotinib|125 mg three times daily (375 mg per day) orally for two years.
41327679|NCT02448797|DRUG|Chemotherapy|Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.
41327680|NCT04159922|OTHER|questionnaire|Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
41327681|NCT03633591|DRUG|Tolcapone|Multiple doses of tolcapone tablets in the fasted state
41327682|NCT03633591|DRUG|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype in the fasted state
41327683|NCT03633591|DRUG|Tolcapone Divided Dose|Tolcapone (suspension) in equal divided doses in the fasted state
41327684|NCT03633591|DRUG|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
41327685|NCT05319223|BEHAVIORAL|patient blood management|three pillars of patient blood management will be applied
41327686|NCT00225056|DRUG|docetaxel and capecitabine|
41327687|NCT01053572|PROCEDURE|Adhesiolysis|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
41327688|NCT04565041|BEHAVIORAL|Social Support|Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
41327689|NCT04975672|OTHER|Myofuncional Therapy|Group 1, with myofunctional therapy and SN1 functional orthopedic appliances The participant underwent a myofunctional therapy session every month, for 9 months. In this group, a series of procedures and techniques are carried out to create and mechanize muscular and orofacial patterns at rest and in function, eliminate habits, correct muscular imbalance, improve the aesthetics of the patient and normalize the functions of the stomatognathic system. The myofunctional therapy performed will be by an expert speech therapist
41327690|NCT00003882|DRUG|anhydrovinblastine|
41327691|NCT03182127|RADIATION|Magnetic resonance imaging|MRI of the elbow is performed in either the supine or prone position A high-resolution surface coil is essential in order to obtain high-quality images . Elbow MRI scanning protocols consist of a combination of T1-weighted and fat-suppressed T2- or proton density-weighted images obtained in the axial, coronal oblique, and sagittal oblique imaging planes. Axial images should extend from the distal humeral diaphysis to the level of the bicipital tuberosity of the radius. From the axial images, coronal oblique images should be prescribed parallel to a line drawn through the centre of the humeral epicondyles, with sagittal oblique images prescribed perpendicular to this. Additional sequences may be helpful in certain circumstances; .
41327692|NCT03182127|DEVICE|Ultrasound|ultrasound is performed by patient in supine or setting position,applied superficial probe , 2D image and color doppler if indicated.
41327693|NCT04670224|OTHER|QLB anesthesia|The QLB is a bilateral locoregional anesthesia technique, performed after surgery, under general anesthesia and in right and then left lateral decubitus.
41327694|NCT04670224|OTHER|Intravenous anesthesia without QLB|only intravenous anesthesia
41327695|NCT04097015|DEVICE|Alpha-Stim M|Alpha-Stim M with and Ocular Interface and a Spinal Interface
41327696|NCT00274040|DRUG|Tiotropium|
41010668|NCT03113682|BEHAVIORAL|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
41017858|NCT06100614|DIAGNOSTIC_TEST|Presepsin|"Umbilical cord blood or blood from the first routine venous puncture within four hours after birth will be used for presepsin determination. Presepsin measurement can be performed in 100 μl plasma with PATHFAST™ Presepsin which is a rapid chemiluminescent enzyme immunoassay (Mitsubishi Chemical Medience corporation, Tokyo, Japan) with results available within 15 minutes."
41017859|NCT06100614|DIAGNOSTIC_TEST|Standard Care|Standard care according to the Dutch EOS guideline
41017860|NCT03623737|DRUG|neoadjuvant chemoradiation|"Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection"
41327697|NCT00274040|DRUG|Ipratropium|
41327698|NCT01641965|DEVICE|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 \< 45 mmHg and improve symptoms.
41327699|NCT00143988|BEHAVIORAL|Treadmill testing|Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded
41327700|NCT00143988|BEHAVIORAL|Ambulatory Blood Pressure and Heart Rate Monitoring|Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
41327701|NCT05226351|DRUG|Dronabinol 2.5 mg|single administration of 2.5mg Dronabinol oral (oily solution)
41327702|NCT05226351|DRUG|Placebo|single administration of placebo oral (oily solution)
41017861|NCT01075334|DIETARY_SUPPLEMENT|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
41010669|NCT05690737|BEHAVIORAL|Tai Chi training|The 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves.
41327703|NCT04871919|DRUG|Filgotinib|Tablets are administered in accordance with the product label
41327704|NCT04896307|OTHER|Survey|Survey
41327705|NCT00613717|DIETARY_SUPPLEMENT|folic acid + iron prenatally, vits A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
41327706|NCT00613717|DIETARY_SUPPLEMENT|folic acid + iron prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
41327707|NCT00613717|DIETARY_SUPPLEMENT|folic acid prenatally, vitamins A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
41010670|NCT05690737|DRUG|Standard prophylactic medication|Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
41010671|NCT03938116|OTHER|Healing Hearts Together|Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
41010672|NCT03211195|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
41010673|NCT06077188|OTHER|Gum group|Group chewing gum with xylitol
41010674|NCT04691466|PROCEDURE|Joint replacement|Routinely performed hip- or knee replacement
41010675|NCT04283175|OTHER|Posturological examination on KPlates and AMTI platforms|By an unique evaluator
41010676|NCT04283175|OTHER|Berg Balance Scale (BBS)|Falls and fera of falling, motor and sensory impairments
41010677|NCT01379326|DRUG|Mebendazole|All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
41010678|NCT06052904|BEHAVIORAL|mHealth-delivered music breathing therapy|"Parental caregivers in the intervention group will receive individual home-based music breathing therapy comprising eight 1-hour weekly sessions for 2 months delivered through Zoom, by a qualified music therapist based on a standardized and validated music breathing instruction manual. The music breathing therapy comprises four breathing phases, namely Discovery Breathing, Triangular Breathing, Silent Breathing, and Music Breathing. In each session, participants will practice breathing for approximately 20-25 minutes in silence or with music in a sitting position. Thereafter, the participants will be instructed to create a Mandala drawing to visualize the effects of breathing on their mental body image, emotions, and thoughts. Each session will end with a debriefing session, which will serve to verbally integrate and reflect the participants' experiences and mental states."
41010679|NCT06052904|BEHAVIORAL|Online educational modules|Participants in the control group will receive eight weekly online educational modules via email for 2 months. The content of the online educational modules will include medical information and advice about caring for a child who has been newly diagnosed with cancer.
41010680|NCT05802381|DIETARY_SUPPLEMENT|protein supplement|20 gram protein supplement per day
41010681|NCT05802381|BEHAVIORAL|nutrition counseling|nutrition counseling for guidance of food intake
41010682|NCT05685797|PROCEDURE|trigminal nerve block with RFT|trigminal nerve block with RFT
41010683|NCT01283048|DRUG|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
41327708|NCT00613717|DIETARY_SUPPLEMENT|folic acid prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
41327709|NCT02910583|DRUG|ibrutinib|ibrutinib administered orally once daily (three 140 mg capsules)
41327710|NCT02910583|DRUG|venetoclax|venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
41327711|NCT02910583|DRUG|Placebo|placebo capsules to match ibrutinib administered orally once daily
41327712|NCT03983226|PROCEDURE|Surgery|Tumor debulking surgery (surgery in recurrent ovarian disease)
41327713|NCT03983226|DRUG|carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...|Salvage chemotherapy
41327714|NCT03983226|DRUG|Niraparib|Niraparib maintenance therapy
41327715|NCT04019795|DEVICE|REVIAN 101|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light."
41327716|NCT04019795|DEVICE|REVIAN 102|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light."
41327717|NCT04019795|DEVICE|REVIAN 103|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light."
41327718|NCT04019795|DEVICE|REVIAN 100|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy"
41327719|NCT01605383|BIOLOGICAL|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
41327720|NCT01605383|PROCEDURE|Standard treatment|Isolated core decompression
41327721|NCT02322099|DRUG|Alendronate|alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
41327722|NCT02322099|DRUG|Placebo|Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
41480537|NCT00962988|DRUG|Cost-Free Pharmacotherapy Group|"Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months."
41327723|NCT02322099|DIETARY_SUPPLEMENT|calcium carbonate and colecalciferol|Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
40809956|NCT06662240|DEVICE|The effect of vibration anesthesia on pain, ecchymosis and comfort level in subcutaneous heparin injection|The patient in the experimental group received one vibrating injection and one non-vibrating injection into the abdomen. The patient in the control group received 2 standard subcutaneous injections in the abdomen without vibration.
41010684|NCT06468644|DRUG|chemoradiotherapy （CRT）+sintilimab 1|radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
41010685|NCT06468644|DRUG|CRT+sintilimab 2|radiotherapy (60Gy/2Gy/30f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
41010686|NCT06234371|BEHAVIORAL|Financial Incentive|The intervention is offering a $500 gift card as an incentive for completing 6 counseling sessions to eligible individuals randomized into the treatment group. Another $500 gift card will be given after completing 12 counseling sessions, and another $500 gift card will be given after completing 18 counseling sessions.
41327724|NCT02322099|DRUG|Tenofovir disoproxil|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
41327725|NCT06279325|BEHAVIORAL|Computerized cognitive stimulation program|"* The cognitive stimulation (CS) program, for the IG, will be previously designed by 2 Occupational Therapy (OT) of the team, and adapted to the computerized format through a platform specialized in cognitive neurorehabilitation. The activities will be designed under OT models: human occupation model and cognitive-perceptual model, so that the different professions, interests and roles are represented, and allow to express different levels of complexity, according to the level of Cognitive Reserve (CR).~* The cognitive aspects to be worked on are: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.~* In addition, reinforcement, EF, episodic memory, attention and information processing speed activities will be designed, also according to the CR level."
41327726|NCT06279325|BEHAVIORAL|Face-to-face training-explanatory session|The CG will undergo a group and face-to-face training-explanatory session, where the importance of maintaining the usual level of cognitive activity will be emphasized.
41480538|NCT00962988|OTHER|Prescription Only Group|Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
41010687|NCT05798507|DRUG|Avutometinib|Given PO
41010688|NCT05798507|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
41010689|NCT05798507|DRUG|Defactinib|Given PO
41010690|NCT05695157|DEVICE|Suture-TOOL|Suture device for fast and standardized closure of the abdominal fascia
41327727|NCT03903120|BEHAVIORAL|ASSIST|"Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice."
41480539|NCT02293291|DIETARY_SUPPLEMENT|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI"
41480540|NCT02668822|DRUG|ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)|Medicated vaginal ring
41266410|NCT00891202|DRUG|Eliglustat tartrate|PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 \[active moiety of ET in plasma\] trough plasma concentration \>=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration \<5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
41010691|NCT04268342|OTHER|Resistance guided treatment for gonorrhoea infection|For cases of gonorrhoea infection treated at the return visit, a nucleic acid assay will be used to determine individual eligibility for ciprofloxacin treatment
41010692|NCT03621137|OTHER|No study-specific intervention|Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice
41010693|NCT03341624|PROCEDURE|cataract surgery cataract extraction and intraocular implantation|
41010694|NCT05162872|DRUG|Niraparib，Sintilimab|Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W
41010695|NCT00285935|OTHER|Standard Clinical Care with an SSRI|"Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label treatment-as-usual manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.~Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®)"
41010696|NCT02351752|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR\>60)
41010697|NCT04277988|DEVICE|Ultrasonography|Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.
41010698|NCT01108549|DIETARY_SUPPLEMENT|Ribose|Ribose 5 grams PO TID was taken daily
41010699|NCT02105077|DRUG|Anesthesia with inhalative application of xenon gas|
41010700|NCT06014112|DEVICE|Freestyle Libre Pro iQ|"Freestyle Libre Pro iQ is a professional sensor, marketed by the Abbott laboratory, for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.~The study will be offered to any subject with an ACS. The installation of the Freestyle Libre Pro iQ sensor will be performed upon admission to intensive care Cardiology and left in place for the duration of hospitalization. In case of the Freestyle Libre Pro iQ sensor defective or removed before discharge from hospital, and if the patient tolerates it, a new the Freestyle Libre Pro iQ sensor will be placed. If the duration of hospitalization exceeds 14 days, a 2nd sensor will be placed."
41010701|NCT02676544|DEVICE|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
41010702|NCT03337633|BEHAVIORAL|Menu design|Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.
41010703|NCT05463367|DRUG|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|Subjects will receive a single dose of carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
41010704|NCT05463367|DRUG|Naproxen 500 Mg|Subjects will receive a single dose of naproxen 500mg alongside carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
41017862|NCT01075334|DIETARY_SUPPLEMENT|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
41017863|NCT02747316|OTHER|Stable iron isotope 57 (57Fe) labeled iron solution|test meal labeled with 12 mg 57Fe
41480541|NCT02668822|DRUG|Placebo vaginal ring|Placebo vaginal ring
41480542|NCT02668822|DRUG|Ibuprofen|Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
41480543|NCT05780021|BEHAVIORAL|Motivational Support Program Emotiv|A motivational support program including a motivational and self-assessment remote application in the form of a Smartphone application for chronic low back pain patients after multidisciplinary functional rehabilitation.
41017864|NCT02747316|OTHER|Stable iron isotope 58 (58Fe) labeled iron solution|test meal labeled with 12 mg 58Fe
41017865|NCT04932265|DIETARY_SUPPLEMENT|HRG80™ Red Ginseng|Capsules containing red ginseng preparation HRG80 capsules, 200 mg - reference product
41017866|NCT04932265|COMBINATION_PRODUCT|HRG80™ Red Ginseng + gamma cyclodextrin|Chewable tablets containing red ginseng preparation HRG80 (100 mg) incorporated in gamma-cyclodextrin (GCD) - experimental modified product
41017867|NCT06135493|DRUG|Losartan|Using losartan to prevent paclitaxel-induced peripheral neuropathy
41017868|NCT00965848|DRUG|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
41480544|NCT01912638|DEVICE|Ologen Collagen Matrix|Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
41480545|NCT01912638|DRUG|Provisc|Provisc is an cohesive viscoelastic.
41480546|NCT04390802|DRUG|5-aminolevulinic acid|Study participants who are deemed surgical candidates for management of their pituitary lesion will drink 20mg/kg 5-ALA 2-4 hours preoperatively. They will then be taken to the operation room and undergo general anesthesia. Intraoperative blood draw may occur from lines places for anesthesia purposes at any time during the operation. In alignment with the neurosurgeon's practice and discretion, the sella will be accessed and opened. During the surgical exploration of the sella, the surgeon will attempt to identify the pituitary mass. The location of the tumor will be assessed using the blue-light filtered microscope or endoscope. These steps will be documented photographically during the operation. A biopsy of the fluorescent region will be taken to confirm pituitary adenoma histopathology. The tumor will then be maximally resected. The tumor sample will be used for further clinical testing as part of the patient's routine care.
41010705|NCT05463367|DRUG|Opioids|Subjects will be pre-screened in regards to their opioid medication. They will receive a single dose of their opioid dose, when appropriate. This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
41010706|NCT04913428|OTHER|Interdigital exercise|Patient asked to sit in upright position interlocking their fingers with inhaling deeply bringing the arms up and exhaling through mouth while bring the arm down.
41327728|NCT01043848|PROCEDURE|external electric pudendal nerve stimulation|"intervention timing: twice daily for 20 minutes during 3 consecutive months.~intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).~intervention device: contic+~stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable)."
41010707|NCT04913428|OTHER|Blow-Bottle technique|For blow bottle 20cm of bottle filled with 10cm of water in which a tube of length 35- 40cm inserted with the inner diameter of ≥8mm(21).Patient is asked to form bubbles in bottle by exhaling in bottle performing Forced Expiratory Techniques.
41010708|NCT00667342|BIOLOGICAL|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
41327729|NCT01057134|DEVICE|Cutera Ultrasound Device|Pulse duration 10-100 ms, fluence greater or equal to 50 J/cm2, contact tip temperature 5-30 celsus, frequency 5-20 MHz.
41327730|NCT01225172|DRUG|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
41327731|NCT01225172|DRUG|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
41327732|NCT04060810|OTHER|MR CSF flowmetry|MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt
41010709|NCT00667342|DRUG|Cisplatin|Given IV.
41327733|NCT01453998|BIOLOGICAL|Infanrix hexa|Single dose, licensed formulation, intramuscular into right thigh
41327734|NCT01453998|BIOLOGICAL|Prevenar 13|Single co-administered dose, intramuscular into left thigh
41480547|NCT03762499|DIAGNOSTIC_TEST|Echocardiography scan|Non-invasive ultrasound imaging of the heart.
41480548|NCT00214331|DRUG|ciprofloxacin|ciprofloxacin 500 mg twice a day for five doses.
41480549|NCT00214331|DRUG|azithromycin|azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
41480550|NCT00214331|DRUG|gentamicin|a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
41480551|NCT03482219|OTHER|Occupational therapy|The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.
41010710|NCT00667342|DRUG|Doxorubicin|Given IV.
41010711|NCT00667342|DRUG|Methotrexate|Given IV.
41010712|NCT00667342|DRUG|Ifosfamide|Given IV.
41010713|NCT00667342|DRUG|etoposide|Given IV.
41010714|NCT00667342|PROCEDURE|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
41010715|NCT00667342|RADIATION|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
41010716|NCT04550481|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41010717|NCT04550481|DRUG|Lisinopril|Given PO
41010718|NCT04550481|PROCEDURE|Liver Ultrasonographic Elastography|Undergo transient elastography
41010719|NCT04550481|PROCEDURE|Magnetic Resonance Elastography|Undergo PDFF MRE
41010720|NCT04550481|PROCEDURE|Magnetic Resonance Imaging|Undergo PDFF MRI
41010721|NCT04550481|PROCEDURE|Proton Density Fat Fraction|Undergo PDFF MRI/MRE
41327735|NCT01453998|BIOLOGICAL|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
41327736|NCT00554463|DRUG|Filgrastim|5 mcg/kg/day IV (intravenous) days 4-13 and days 25-34 for a total of 20 doses.
41327737|NCT00554463|DRUG|Pegfilgrastim|6 mg via subcutaneous injection days 46 and 67
41010722|NCT04550481|OTHER|Questionnaire Administration|Ancillary studies
41010723|NCT02967952|DEVICE|supraglottic airway (SGA) V.S. endotracheal intubation (ETI)|already being described above
41327738|NCT00554463|DRUG|Etoposide|Concurrent: 120 mg/m\^2, IV on days 1-3 and days 22-24. Adjuvant: 120 mg/m\^2, IV on days 43-45 and days 65-66.
41480552|NCT03482219|OTHER|Home app intervention|The app consists of videos depicting each exercise and ability to track adherence to exercises.
41480553|NCT05955495|OTHER|Food|Post-operative feeding includes water, liquid diet, soft diet.
41480554|NCT02129647|DRUG|Axitinib|
41480555|NCT01123317|DRUG|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
41480556|NCT03173170|DRUG|TAK-954|TAK-954 Infusion
41480557|NCT03173170|DRUG|Itraconazole|Itraconazole Capsule
41480558|NCT02537847|DRUG|Sitafloxacin|The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
41480559|NCT02537847|DRUG|Ertapenem|Control group will be given ertapenem only for 10 days.
41327739|NCT00554463|DRUG|Cisplatin|Concurrent: 60 mg/m\^2, IV on days 1 and 22. Adjuvant: 60 mg/m\^2, IV on days 43 and 64.
41327740|NCT00554463|RADIATION|radiation therapy|A total of 61.2 Gy in 5 weeks: Once-daily 1.8 Gy fractions for 15 fractions over 3 weeks beginning on day 1 of chemotherapy, then twice-daily 1.8 Gy fractions for 10 fractions over 2 weeks.
41327741|NCT00901381|DRUG|Filgrastim|10 µg/kg subcutaneously once daily x 5 days
41327742|NCT02931526|DRUG|Tigecycline|Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
41010724|NCT01632501|DEVICE|Coronary stent - Tsunami|A coronary angioplasty was done
41010725|NCT04448470|OTHER|Questionnaire for recording daytime sleepiness over the course of the day|Questionnaire for recording daytime sleepiness over the course of the day
41327743|NCT00540306|DEVICE|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
41327744|NCT00848445|DEVICE|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
41010726|NCT04448470|OTHER|Anamnesis and physicial examination|Anamnesis and physical examination, e.g. medication, comorbidities, complaints
41327745|NCT00848445|DEVICE|Atrial pacing preference turned on or off|programing changes in the device
41480560|NCT03544814|DRUG|icotinib combined with pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
41010727|NCT04448470|OTHER|Questionnaire for quantifying daytime sleepiness|the Epworth Sleepiness Scale (ESS) questionnaire and the STOP BANG Questionnaire
41010728|NCT04448470|DIAGNOSTIC_TEST|Pulmonary function test|The measured values of spirometry/body plethysmography, CO diffusion and blood gas analysis are documented, if available.
41017869|NCT05905185|DRUG|Tocotrienol-rich fraction vitamin E (TRF)|The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
41327746|NCT02521298|OTHER|Strength Training|
41327747|NCT02521298|PROCEDURE|Placebo|
41327748|NCT02521298|DRUG|Cortico-Steroid Injection. Depomedrol 40mg/1ml.|
41327749|NCT02521298|PROCEDURE|Dry Needling|
41480561|NCT03544814|DRUG|first icotinib and then pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
41327750|NCT04850612|OTHER|Survey|Delphi Survey on core outcomes, CSDH definition and data elements
41327751|NCT06295068|DEVICE|Transcatheter Aortic Valve Replacement (TAVR)|Replacement of the aortic valve with use of the OpSens SavvyWire
41327752|NCT06295068|DEVICE|Balloon Aortic Valvuloplasty (BAV)|Dilation of the narrowed aortic valve by balloon inflation with use of the OpSens SavvyWire
41327753|NCT00293046|BIOLOGICAL|ALK Grass tablet - use of compliance device|
41327754|NCT05307627|DRUG|low-dose naltrexone|LDN doses \<20 mg/day
41327755|NCT03823040|DRUG|Oxiconazole Nitrate Cream 1%|Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
41480562|NCT04085536|PROCEDURE|Dental and medical treatment|If the dental cause of sinusitis is objective, if necessary, dental treatment combined with medical treatment will be carried out.
41480563|NCT01949948|DRUG|Tenecteplase|0.4 mg/kg single bolus intravenously
41480564|NCT01949948|DRUG|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
41327756|NCT03823040|DRUG|Oxiconazole nitrate SLNs loaded gel.|Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
41480565|NCT04267263|BEHAVIORAL|Self-guided lifestyle intervention|The intervention will consist of one 60-minute group based online session, adapted specifically for young men based previous work with young adults, followed by a self-guided program for 12-weeks. Participants will receive a tool kit that includes evidence-based resources (scale for self-weighing, handouts that will include free self-monitoring apps and strategies for no-cost exercise, sample meal plans and meal planning tips, and tips for healthy living that emphasize risk areas) to assist them during the self-guided phase, as well as weekly health risk text messages.
41154854|NCT06135779|BEHAVIORAL|A Lust for Life|A Lust For Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
41154855|NCT06135779|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life School programme.
40809960|NCT06658444|OTHER|Phonophoresis|Pulsed ultrasound will be used at a frequency of 1 MHz with an intensity of 0.5 W/ cm2 for 5 minutes.
40809961|NCT06658444|OTHER|sham ultrasound|sham ultrasound
40809962|NCT06659744|DRUG|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
40809963|NCT06659744|DRUG|New initiation of sitagliptin|New initiation of sitagliptin dispensing claim is used as the reference.
41154856|NCT03343509|DRUG|Metronidazole Oral|Oral Metronidazole
41154857|NCT03343509|DRUG|Metronidazole Ointment|Metronidazole Ointment
41154858|NCT03343509|DRUG|Placebo Oral Tablet|Placebo Tablet
41010729|NCT04448470|DIAGNOSTIC_TEST|Polygraphy|Polygraphy is a non-invasive portable examination method that the patient uses in the home environment at night to measure possible sleep-related breathing disorders. Typically, the following measurement signals are recorded: nasal airflow, thoracic and abdominal breathing excursions, snoring and breathing sounds via a microphone, pulse, oxygen saturation and position. The evaluation results and the findings are checked by a physician. Essential parameters include the apnoea-hypopnoea index, the number of obstructive, central and mixed apnoea/hypopnoea, the number and duration of desaturation, snoring or the association with a certain position.
41010730|NCT05052229|DRUG|Nitric Oxide|Nitric oxide gas for inhalation
41010731|NCT05052229|DRUG|Medical air|Medical grade air for inhalation (placebo)
41327757|NCT00812240|DRUG|Masitinib|
41327758|NCT00812240|DRUG|Imatinib|imatinib 400 mg or 600 mg per day, per os
41327759|NCT01040754|OTHER|Acupuncture|This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
41327760|NCT01838590|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
40809967|NCT06659692|DRUG|Gonadotropins Subcutaneous|Gonadotropins s.c. multiple dose
41010732|NCT00256659|BEHAVIORAL|Early assessment and referral to ancillary care services vs. standard care|
41154859|NCT03343509|DRUG|Placebo Ointment|Placebo Ointment
41327761|NCT01838590|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
41327762|NCT02890732|DEVICE|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
41327763|NCT03934710|DRUG|Placebo|Drug will be administered in solution form
41327764|NCT03934710|DRUG|Serotonin agonist - 13ug|13ug lysergic acid diethylamide
41327765|NCT03934710|DRUG|Serotonin agonist - 26ug|26ug lysergic acid diethylamide
41327766|NCT06027944|OTHER|Light exposure|Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)
41327767|NCT02621619|DRUG|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
40809971|NCT06659289|DEVICE|Efferon LPS|"Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~The hemoperfusion procedure is performed at the time of artificial circulation during cardiac surgery. The therapy (Efferon LPS hemoperfusion) is performed once. The duration of the procedure is limited by the time of artificial blood circulation."
41010733|NCT00095784|DRUG|Decitabine|Given SC
41010734|NCT00095784|OTHER|Laboratory Biomarker Analysis|Correlative studies
41010735|NCT03394872|PROCEDURE|Drainage of the pleural effusion|
41010736|NCT01403103|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
41010737|NCT01403103|PROCEDURE|biopsy|Correlative studies
41010738|NCT01403103|GENETIC|protein expression analysis|Correlative studies
41010739|NCT01403103|OTHER|enzyme-linked immunosorbent assay|Correlative studies
41010740|NCT01403103|OTHER|laboratory biomarker analysis|Correlative studies
41010741|NCT01403103|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
41010742|NCT01831310|DIETARY_SUPPLEMENT|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
41010743|NCT01831310|DIETARY_SUPPLEMENT|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
41010744|NCT01831310|DIETARY_SUPPLEMENT|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
41480566|NCT05189236|PROCEDURE|Control Group (Only Algorithm of Febrile Neutropenia Management)|"Common Procedure Steps~1. The child is admitted to the unit and evaluated.~2. The objective of the study is explained to the children and children's parents, and their consent is obtained after they have read and signed the informed consent form.~3. The inclusion and exclusion criteria are evaluated.~4. The group of the child to be included in the study is determined in accordance with the randomization order.~5. The first section of the patient information and follow-up form is filled out.~6. The algorithm of Febrile Neutropenia Management is applied. The room temperature is kept constant at 21-24 degrees.~Procedure Steps for Control Group:~1. Common procedure steps are followed.~2. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
41010745|NCT01831310|DIETARY_SUPPLEMENT|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
41010746|NCT01182077|DRUG|ASP015K|Oral
41010747|NCT01182077|DRUG|Midazolam|Oral
41010748|NCT05996250|OTHER|Immersive virtual reality task|participants will have to wear a virtual reality headset connected to a remote control and will have to perform submersive virtual reality tasks
41010749|NCT00550836|BIOLOGICAL|panitumumab|Given IV
41010750|NCT00550836|DRUG|erlotinib hydrochloride|Given orally
41010751|NCT00550836|DRUG|gemcitabine hydrochloride|Given IV
41010752|NCT00839839|PROCEDURE|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
41010753|NCT06254417|PROCEDURE|Diaphragmatic ultrasound|Diaphragmatic ultrasound will be performed to all patients with respiratory disease to evaluate diaphragmatic thickening and estimate thickening fraction and to evaluate diaphragmatic excursion. Measurements will be obtained at bedside with a portable ultrasound machine equipped with a linear probe (Logic P6 Pro, GE Healthcare). Diaphragmatic thickness measures will be performed on right Intercostal approach through the zone of apposition. Diaphragmatic excursion will be performed using curved-array probe (Logic P6 Pro, GE Healthcare) is positioned below right costal arch at the mid-clavicular line. The ultrasound study will be done and /or supervised by ultrasound expert
41010754|NCT04475393|DEVICE|Carmat Total Artificial Heart|Heart Replacement Therapy
41327768|NCT02621619|DRUG|Normal saline + 0.5 mg IV hydromorphone|100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
41327769|NCT05843812|DRUG|Magnesium Sulfate 10 MG/ML|Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management
41327770|NCT06144242|BEHAVIORAL|Feedback on RTD metric|Clinicians in the experimental arm will receive feedback on the RTD metric while clinicians in the No intervention arm will not.
41327771|NCT03682380|DRUG|Seltorexant High Dose|In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
41327772|NCT03682380|DRUG|Seltorexant Low Dose|In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
41327773|NCT03815123|DIAGNOSTIC_TEST|cardiac CT|The cardiac CT examinations are indicated by the referring physician. The participation in this study has no influence on the further diagnostic and therapeutic regimen.
41327774|NCT06396455|PROCEDURE|interscalene block group|The ISB group scanning was done by linear ultrasound probe just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle; the skin was disinfected, and the transducer was positioned in the transverse plane to identify the carotid artery. Once the artery was identified, the transducer was moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles. 3 ml lidocaine 1% was injected at puncture site The needle was then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction. After a careful aspiration, 20 ml of bupivacaine 0.25% was injected.
41327775|NCT06396455|PROCEDURE|Suprascapular nerve block group|After cleaning the skin with an antiseptic solution, an ultrasound probe was put in sagittal orientation at the superior medial border of the scapula to identify the pleura and then moved laterally; when it was parallel to the spine of the scapula, the transducer was moved cephalad and the suprascapular fossa was identified, and then the transducer was moved lateral to locate the suprascapular notch. The suprascapular nerve was a round hyperechoic structure beneath the transverse scapular ligament in the scapular notch. 3 ml lidocaine 1% was injected at puncture site then the needle was inserted along the longitudinal axis of the ultrasound beam, and 10 ml of bupivacaine 0.25% was injected.
41327776|NCT01676441|DRUG|cellgram-spine|Mesenchymal stem cells transplantation
41327777|NCT06214624|BEHAVIORAL|Two types of exercise interventions|"* HIIT. 3 times/week. This consists of a 4x4 HIIT (preferably in treadmill), 4 intervals of 4min at high intensity (85-95% HRmax) and 3 intervals of 3min of active resting at \~70% HRmax in between. All sessions including 10 min of warming-up and 10min of cooling down, resulting in 45min sessions. The first 2 weeks will progress from moderate-intensity training to HIIT for a better adaptation and acceptability of the program.~* HIIT + resistance. 3 times/week. The aerobic part consists of a 3x4 HIIT (preferably in treadmill), 3 intervals of 4min at high intensity (85-95% HRmax) and 2 intervals of 3min of active resting (\~70% HRmax) in between. The resistance part consists of 2 series of an 8-exercise circuit (combination of upper and lower body exercises using elastic bands and body weight) with a ratio of 20sec of effort - 40sec of resting. Sessions will have 5min of warming up in the treadmill and 5min of cooling down walking in the gym, comprising a total of 45min sessions."
41327778|NCT03544632|DRUG|Acellular Adipose Tissue (AAT)|"Participants (n=15) will be administered between 5cc and 20cc of AAT, depending on their assigned treatment group, via sterile subcutaneous injection into the target defect. The injection is intended to be permanent. After the 3-month study follow-up visit, participants will have the option to undergo additional AAT injection (up to 20cc per treatment) in order to fully correct the defect. Total injected AAT volume per patient will not exceed 40cc. Additional injection is dependent upon study- and patient-specific adverse / unanticipated events to date.~Each vial contains a 2 milliliter (mL) dose of the injectable AAT. This volume is similar to other commonly used injectable filler materials intended for soft tissue correction."
41327779|NCT06413368|DRUG|Maralixibat 9.5 MG/ML [Livmarli]|Within Study subjects receiving 2 weeks of treatment with Maralixibat 9.5 MG/ML \[Livmarli\] and compare to baseline treatment.
41327780|NCT06151860|OTHER|Static stretching|Stretching exercises performed by maintaining the point of muscular discomfort without changing position for a certain period of time.
41327781|NCT06151860|OTHER|Pilates stretching|Stretching exercises performed dynamically, following the six basic principles of Pilates: concentration, control, center, precision, breathing and fluidity.
41327782|NCT04766983|DIAGNOSTIC_TEST|bronchoalveolar lavage|BAL and ETA are performed as per clinical practice on clinical suspicion of VAP (Johanson score)
41327783|NCT01299610|DRUG|GW870086 2.0%|White to slightly colored opaque cream
41327784|NCT01299610|DRUG|GW870086 0.2%|White to slightly colored opaque cream
41327785|NCT01299610|DRUG|FP 0.05%|White cream
41327786|NCT01299610|DRUG|Placebo|White to slightly colored opaque cream
41327787|NCT04391088|OTHER|vaccine coverage assessment|vaccine coverage assessment
41327788|NCT06508944|DRUG|vaginal 17 beta-estradiol|"* Femiest® Haupt Pharma Munster GMBH, Muenster, Germany~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."
41327789|NCT06508944|DRUG|Placebo|"* Placebo is produced by Chulalongkorn University Drug and Health Products Innovation \& Promotion Center.~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."
41327790|NCT06508944|BEHAVIORAL|Behavioral modifications|Behavioral modifications for women with storage symptoms of lower urinary tract symptoms (LUTS) involve strategies such as regulating fluid intake, avoiding bladder irritants, practicing bladder training techniques (scheduled and delayed voiding), performing pelvic floor muscle exercises, managing weight, increasing dietary fiber, maintaining a bladder diary, setting a regular voiding schedule, utilizing stress management techniques, and educating patients about LUTS.
41327791|NCT05132075|DRUG|JDQ443|JDQ443 tablets, orally administered
41327792|NCT05132075|DRUG|docetaxel|docetaxel concentrated solution for infusion, intravenously administered
41327793|NCT01383187|PROCEDURE|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
41327794|NCT01383187|PROCEDURE|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
41327795|NCT00095511|DRUG|aripiprazole|
41327796|NCT00924729|DRUG|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
41480567|NCT05189236|PROCEDURE|Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)|"Procedure Steps for Experiment Group:~1. Common procedure steps are followed.~2. Cold steam is continuously applied until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).~3. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form from the time the patient is admitted until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
41480568|NCT01385306|DEVICE|AlphaCore System|Non-invasive neurostimulation of the vagus nerve
41480569|NCT03738176|DRUG|Sesame Oil|Sesame oil(80 gm NaCMC-20 gmSesame oil)
41010755|NCT01314924|DIETARY_SUPPLEMENT|Dark chocolate|70% cocoa
41327797|NCT00924729|DRUG|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
41327798|NCT04446871|DRUG|0.9% sodium chloride|Intravenous infusion of 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
41327799|NCT04446871|DRUG|Methylene Blue|Intravenous infusion of 100 mg methylene blue in 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
41327800|NCT01674192|DRUG|prucalopride|single dose of 2 mg prucalopride
41327801|NCT00702247|PROCEDURE|Hematopoietic Stem Cell Transplantation|
41327802|NCT00045487|DRUG|OSI-774|OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
41327803|NCT06011980|DRUG|Growth Inhibitor|growth inhibitors for 250-500μg/h, ivgtt. for 5 days
41327804|NCT00065442|BIOLOGICAL|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
41327805|NCT00065442|BIOLOGICAL|APC-Placebo|Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
41327806|NCT05475912|OTHER|Group A, excercises|Each group will receive treatment three times per week for 3 weeks total 7 sessions.
41327807|NCT00294827|PROCEDURE|Liver transplantation and colo-rectal cancer|Liver transplantation
41327808|NCT04804280|GENETIC|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1) will be investigated. Cord blood will be collected at birth for PT and FT, only for PT a peripheral blood sample will be collected at hospital discharge, during routine clinical procedures. Genomic DNA will be extracted from aliquots of 0. 2 ml of each blood sample with the GeneElute Blood Genomic DNA kit (Sigma) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
41327809|NCT04804280|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. a trained experimenter will apply tactile stimulation associated with affective touch characteristics to the child with a soft brush on the right anterior tibial region in proximal and distal directions. The length of the stimulated area will be measured to cover approximately 15 cm, and tactile stimulations will be applied at a rate of 5 cm/s for 15s, with randomized intervals between stimuli of 10-15s (resulting in 5 stimulations in a 15s block). A regular audio signal will help the researcher to keep a constant stroke velocity. Audio commands will also be used to direct the experimenter. Infant must be asleep (natural sleep) during the fMRI acquisition.
41480570|NCT03738176|DRUG|triamcinolone in orabase|triamcinolone 140 gm-Na CMC 50 gm
41154860|NCT02469051|DEVICE|Breathhold SPECT-MPI|Respiratory triggered SPECT myocardial perfusion imaging
41480571|NCT02253602|DRUG|Ferumoxytol|maximum rate of administration 1 ml/sec
41154861|NCT02469051|DEVICE|Standard freebreathing SPECT-MPI|Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging
40809974|NCT06661629|DEVICE|Nerve stimulation|The intervention is testing the effect of bilateral genioglossus muscle stimulation on upper airway collapsibility during drug-induced sleep endoscopy in patients implanted with the Inspire hypoglossal nerve stimulator
41154862|NCT02469051|DEVICE|Coronary CT angiography|Clinically indicated coronary CT angiography serving as standard of reference
41010756|NCT00460941|DRUG|Placebo|sc weekly
41010757|NCT00460941|DRUG|Taspoglutide 20mg|sc weekly
41010758|NCT00460941|DRUG|Taspoglutide 20mg-30mg|sc weekly
41154863|NCT00367445|DRUG|Inhaled Human Insulin (Exubera)|
41154864|NCT00367445|DRUG|Insulin Glargine (Lantus)|
41154865|NCT01545999|OTHER|Brain Stimulation via Transcranial Magnetic Stimulation|"PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task."
41154866|NCT00953199|DRUG|Lidocaine Hydrochloride|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
41154867|NCT00953199|DRUG|Normal Saline|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
41154868|NCT05933083|BEHAVIORAL|In-person cardiac rehabilitation|In-person exercise training, health education, and counseling
41154869|NCT05933083|BEHAVIORAL|Telehealth cardiac rehabilitation|Telehealth exercise training, health education, and counseling
41480572|NCT03885882|DRUG|E0302 SR1|E0302 SR1, oral tablet.
41154870|NCT04038034|DIETARY_SUPPLEMENT|CoQ10- MINIACTIVES|COQUN oral formulation 100 mg BID
41480573|NCT03885882|DRUG|E0302 SR3|E0302 SR3, oral tablet.
41480574|NCT03885882|DRUG|E0302 SR2|E0302 SR2, oral tablet.
41480575|NCT03885882|DRUG|E0302 IR|E0302 IR, oral tablet.
41480576|NCT01027741|BEHAVIORAL|Phone Referral|Participants receive phone referral to cancer control and prevention services.
41480577|NCT01027741|BEHAVIORAL|Tailored Cancer Communication|Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
41327810|NCT00870038|DEVICE|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
41327811|NCT00870038|DEVICE|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
41327812|NCT00870038|DEVICE|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
41327813|NCT05647629|PROCEDURE|Total hip arthroplasty|hip prosthesis surgery
41327814|NCT02286492|DRUG|TAS-102|At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
41327815|NCT05964504|PROCEDURE|Blood Specimen|Blood will be drawn via venipuncture
41327816|NCT01372449|DRUG|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but \<60 kg, and 6 mg for subjects weighing ≥ 20 kg but \< 40kg.
41327817|NCT01372449|DRUG|Placebo|
41327818|NCT04751968|OTHER|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
41327819|NCT04751968|BEHAVIORAL|Enhanced Treatment as Usual|Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
41327820|NCT03717116|DIAGNOSTIC_TEST|parathormone level|From the patients, blood will be taken preoperatively and postoperatively.
41327821|NCT04101734|DEVICE|Double Lumen Endotracheal Tube.|Intubation was performed with Double Lumen Endotracheal Tube.
41327822|NCT04101734|DEVICE|Double Lumen Video Endotracheal Tube.|Intubation was performed with Double Lumen Video Endotracheal Tube.
41327823|NCT04690257|OTHER|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of pictures designed as a book contains and given to children during the procedure and they take a picture as they favored.
41327824|NCT05249153|DRUG|low dose of dexmedetomidine with sufentanil|low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)
41327825|NCT05249153|DRUG|high dose of dexmedetomidine with sufentanil|high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)
41480578|NCT01027741|BEHAVIORAL|Cancer Control Navigator|A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
40809976|NCT06658080|DIAGNOSTIC_TEST|organoid drug test|Before initiating therapy, patients diagnosed with metastatic breast cancer patients with hydrothorax and ascite fluid. The hydrothorax and ascite fluid is utilized to establish organoids and conduct drug testing.
41154871|NCT04038034|DIETARY_SUPPLEMENT|Placebo|Placebo
41327826|NCT03998761|DRUG|Micronized Progesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone until 7 weeks of gestation.
41480579|NCT03866018|OTHER|Adapted physical activity|12 sessions of one hour of adapted physical activity.
41480580|NCT05672693|OTHER|Several Calculation Formulas of Intraocular Lens|Comparison of the accuracy of several intraocular lens calculation formulas
41480581|NCT00110695|DRUG|Nanoparticle albumin bound paclitaxel followed by FEC|Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. \[or if given with trastuzumab 75 mg/m2 IV over 15 min.\]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days
41154872|NCT01106586|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
41480582|NCT01824134|OTHER|Klean & Klear The Dandy Day Corp|
41154873|NCT01106586|DRUG|ATV|Atazanavir 300 mg capsule administered orally once daily
40809980|NCT06659562|DRUG|HER-096|Administered as a single dose via s.c. injection
40809981|NCT06659562|DRUG|HER-096|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
41480583|NCT01824134|OTHER|The Skin Gel Herbal Answers, Inc|
41480584|NCT03216694|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart
41480585|NCT00674401|PROCEDURE|Radiofrequency catheter ablation|"* In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~  1. Empirical pulmonary vein antrum circumferential isolation, or~ 2. High frequency sites ablation in the LA~* In case of Persistent AF, patients will be randomized into one of 2 in the study:~  1. Empirical circumferential PV antrum isolation w/out roof line, or~ 2. A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation."
40809982|NCT06659562|DRUG|Placebo|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
41010759|NCT00460941|DRUG|Taspoglutide 20mg-40mg|sc weekly
41154874|NCT01106586|DRUG|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
41154875|NCT01106586|DRUG|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
41154876|NCT01106586|DRUG|Stribild Placebo|Placebo to match Stribild administered orally once daily
41154877|NCT01106586|DRUG|ATV Placebo|Placebo to match ATV administered orally once daily
41327827|NCT03998761|DRUG|Micronized progesterone plus dydrogesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone plus 20 mg dydrogestetrone until 7 weeks of gestation.
41327828|NCT00796003|DRUG|JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
41327829|NCT00796003|DRUG|JNJ-30979754 20 mg/m2|Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
41327830|NCT02855138|DRUG|oral isotretinoin|
41327831|NCT04745078|OTHER|Caboxy30|carboxy30 to periorbital dark halos
41327832|NCT04745078|OTHER|Caboxy60|carboxy60 to periorbital dark halos
41327833|NCT04329000|DRUG|Esomeprazole 40mg|On-demand Esomeprazole 40 mg QD
41480586|NCT02407171|DRUG|MK-3475|200 mg every 2 weeks by IV infusion
41480587|NCT02407171|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
41480588|NCT00832221|DRUG|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
40809983|NCT06658262|OTHER|Tai Chi Exercises With Cycling Exercises|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. Participants will be assisted to safely mount the ergometer bicycle. The height of the seat will be adjusted to ensure postural balance, upright seating and firm contact of the feet with the pedals. Treatment for the cycling will last for 30 minutes per session.
41480589|NCT00832221|DRUG|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
41480590|NCT00832221|DRUG|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
41480591|NCT02307643|DRUG|MT-1303 Low dose|
41480592|NCT02307643|DRUG|MT-1303 High dose|
41010760|NCT06389968|DEVICE|Light stimulation|see arm description
41010761|NCT06389968|DEVICE|Sham light stimulation|see arm description
41010762|NCT04698824|PROCEDURE|Hypnosis session|"At least one session of hypnosis in the internal medicine unit at the hospital Groupe Hospitalier Mutualiste de Grenoble"
41010763|NCT01321801|DRUG|Pregabalin|Preoperative administration of pregabalin 600mg
41010764|NCT01321801|DRUG|placebo|Preoperative administration of a matching placebo
41010765|NCT06351605|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
41010766|NCT01545817|DRUG|Pazopanib followed by everolimus|All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
41154878|NCT01106586|DRUG|RTV Placebo|Placebo to match RTV administered orally once daily
41327834|NCT04329000|DRUG|Esomeprazole|Continuous Esomeprazole 40 mg QD
41480593|NCT03450395|OTHER|Hot Cereal|Intervention involves consumption of one hot cereal in the beginning of each day
41154879|NCT01106586|DRUG|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
41327835|NCT00387348|DRUG|escitalopram oxalate|escitalopram oxalate 10 mg once daily for 4 weeks
41327836|NCT00387348|DRUG|Placebo|one placebo pill identical in appearance to the escitalpram pill once daily
41327837|NCT02978209|DEVICE|7.5 %|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
41480594|NCT04535752|DRUG|ANX009|Single or multiple ascending dose
41480595|NCT04535752|DRUG|Placebo|Single or multiple ascending dose
41010767|NCT03252522|COMBINATION_PRODUCT|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks
41010768|NCT03252522|DIETARY_SUPPLEMENT|Placebo|40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
41480596|NCT03507478|DEVICE|BPI1000013|Foam insole
41480597|NCT03695848|DEVICE|MRI scan|Before decompresssion surgery, DTI and fMRI will be recorded by a FDA approved 3T MRI scanner (Philips Achieva)
41480598|NCT05742698|DRUG|Nabilone|Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
41480599|NCT05742698|DRUG|Placebo|The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
41480600|NCT02072824|DRUG|Pregabalin Dose Level 1|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
41480601|NCT02072824|DRUG|Pregabalin Dose Level 2|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
41327838|NCT02770118|BEHAVIORAL|Partial Sleep Restriction|4 hour time in bed (TIB), participants will go to bed 4 hours later than during the HS condition. Wake-up times will be the same. During the in-lab portion of the PSR, meals, fulfilling weight-maintenance energy requirements, will be supplied by the research staff as BOOST shakes.
41327839|NCT02770118|BEHAVIORAL|Total Sleep Deprivation|0 hour time in bed (TIB), participants will remain awake throughout the night. Meals will be provided as BOOST shakes at the same meal.
41327840|NCT02770118|BEHAVIORAL|Habitual Sleep|8 hours time in bed (TIB), for 3 nights, with fixed bed and wake times, while at home. During the 3-d HS phase, participants will be provided will BOOST meal replacement shakes in amounts required to achieve weight maintenance.
41327841|NCT06528899|BEHAVIORAL|Physical Therapy|Assessment and/or treatment by physitoherapist during the visit
41327842|NCT04453904|OTHER|"sequential radiochemotherapy in a sanwich mode"|Patients will randomized into two different modalities of radiochemotherapy.
41480602|NCT02072824|DRUG|Placebo|Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
41327843|NCT00218140|DRUG|nicotine transdermal system|
41327844|NCT02969694|OTHER|G-STAT questionnaire|"Patients will have a consultation with an addiction specialist physician. During the consultation, the physician ask the patient about these sexual practice and the use of psychostimulants. The patient will answer to the G-STAT questionnaire. This questionnaire allows the physician to perform an initial assessment of the patient's sexual addiction.~The entire consultation takes place in the usual practice of consultations for this addiction."
41327845|NCT04084340|PROCEDURE|Real transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Real transcranial direct current stimulation associated with therapeutic exercises for urinary incontinence~tDCS: 20 minutes, 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
41327846|NCT04084340|PROCEDURE|Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence~tDCS: 20 minutes (30 seconds ON), 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
41327847|NCT01913197|OTHER|An MRI-based technique to identify prostate cancer|
41327848|NCT03920865|DRUG|Risdiplam|5 milligram (mg) oral dose administered in fasted state
41480603|NCT06360068|DRUG|Sulfasalazine Tablets|All subjects who meet the inclusion/exclusion criteria will be given sulfasalazine 750mg/dose, twice a day. The dosage will be increased to 1000mg/dose within one month, twice a day if the patient tolerates well.
41480604|NCT03859128|BIOLOGICAL|TORIPALIMAB INJECTION(JS001 )|Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W
41480605|NCT00865618|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
41480606|NCT00865618|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
41327849|NCT01926470|PROCEDURE|anteroposterior approach group|anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
41327850|NCT01926470|PROCEDURE|oblique approach group|oblique approach group (n=104): same as anteroposterior approach group except using oblique view
41327851|NCT01383109|DRUG|14C-labeled Pyronaridine|Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
41327852|NCT05601908|OTHER|Virtual Reality Relaxation|Participants will undergo a 5-week course of 20-min sessions of VR relaxation. The VR device used will be the Oculus Quest wireless head mounted display (HMD) with two handheld controllers. The HMD and software have been provided by a Germany based company called Magic Horizons. Participants will be asked to wear the HMD and will wear headphones to hear audio. Each session will involve participants experiencing two virtual environments designed to promote relaxation, at least one of which will have a small interactive component to aid engagement. Environments will focus on nature and will be paired with soothing music or guided meditation. For example, scenes might include dolphins dancing underwater, a beach with rock pools, waterfalls, a rainforest, green meadows with flowers, mountains with lakes and/or a sandy desert. Participants will be seated throughout all sessions.
41480607|NCT06133075|DRUG|Mirabegron 50 MG|10 patients will receive drug for 8 weeks
41480608|NCT06133075|DRUG|Mirabegron 25 MG|10 patients will receive drug for 8 weeks
41480609|NCT00988689|OTHER|Dietary Intervention|soup with or without starch
41010769|NCT03132597|BEHAVIORAL|Mindfulness training|six weeks of 2 hours class of mindfulness training and orientations for home training
41010770|NCT01394575|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
41154880|NCT03214055|DRUG|Mannitol|The mannitol has been administered routinely to prevent renal dysfunction in patients undergoing robot-assisted laparoscopic radical prostatectomy. Participants will receive the mannitol as part of routine medical care, and we will evaluate the change in optic nerve sheath diameters before and after mannitol administration.
41480610|NCT05736536|BEHAVIORAL|Chance2Act|A Health education package that has been developed based on Transtheoretical Model to encourage behaviour change for weight loss among overweight/obese type 2 diabetes adults.
41480611|NCT05695755|DIAGNOSTIC_TEST|ECHO, Serum electrolytes|echocardiography, serum electrolytes and cortisol level for all patients
41480612|NCT02575274|PROCEDURE|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
41480613|NCT00024648|DRUG|LErafAON|
41480614|NCT02011919|DEVICE|Echopulse|HIFU Under ultrasound guidance
41327853|NCT05537610|BEHAVIORAL|CDT|In this condition, the clinician will alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. According to RaC2, alternating periods of reinforcer availability and unavailability for the alternative response will teach the participant that the alternative response alone produces reinforcement but not always. The investigators predict that resurgence of problem behavior will lower, shorter lasting, and with fewer participants experiencing resurgence than those in the control group.
41327854|NCT05537610|BEHAVIORAL|Control|This condition emulates a traditional approach to treatment in which the clinician does not alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. The investigators predict that resurgence of problem behavior will higher, longer lasting, and with more participants experiencing resurgence than those in the CDT group.
41327855|NCT03395756|DRUG|Depot-Medroxyprogestereone Acetate|Administration of 150 mg intramuscular depot medroxyprogesterone acetate
41327856|NCT01583985|OTHER|Opioid-intensive prescribing strategy|The opioid-intensive arm emphasizes early use of strong opioid analgesics. Medications will be individually adjusted according to patient preferences and responses.
41327857|NCT01583985|OTHER|Opioid-avoidant prescribing strategy|The opioid-avoidant prescribing strategy emphasizes non-opioid medications from several drug classes. Medications will be individually adjusted according to patient preferences and responses.
41480615|NCT03287973|BEHAVIORAL|Lifestyle modification|A caloric reduction of 10-20% in daily energy intake from the patient's usual diet (i.e. a deficit ≥ 200 calories per day) will be set as the general initial goal, which will be adjusted subsequently based on changes in body weight with target body mass index (BMI) towards 23 kg/m2.
41480616|NCT03287973|DEVICE|Continuous positive airway pressure (CPAP)|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
41327858|NCT05216913|BEHAVIORAL|Lifestyle modification|Could include all/some of the following: weight loss, increased physical activity, smoking cessation and reduction in alcohol intake
41327859|NCT05216913|DRUG|Cardiovascular Agents, Other|Could include all/some of the following: statins, antihypertensives, diabetic medication, levothyroxine
41327860|NCT05216913|OTHER|QRISK 3 Score|Could include a combination of lifestyle measures and/or cardiovascular agents as described above
41327861|NCT04347278|DRUG|Patients with the treatment agains COVID19|"Data will be collected from patients who receive any of the treatments included in the Technical Document. Manejo clínico del COVID-19: tratamiento médico of the Ministry of Health, and Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise."
41327862|NCT01319279|DRUG|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
41327863|NCT03634878|OTHER|perineal ultrasound|Ultrasound measurement of the size and position of the prostheses.
41327864|NCT05238987|DIETARY_SUPPLEMENT|Ferrous sulphate|Single dose of ferrous sulphate (120 mg of elemental iron)
41327865|NCT05752708|DIAGNOSTIC_TEST|Diagnostic Test|Evaluation of perioperative anxiety in parents of children undergoing thoracic surgery using standardized tests: The Amsterdam Preoperative Anxiety and Information Scale (APAIS), the State-Trait Anxiety Inventory (STAI).
41327866|NCT03388086|DRUG|Injection of Onabotulinum toxin|multiple injections of Onabotulinum toxin into the detrusor muscle
41327867|NCT02715999|PROCEDURE|Quadratus Lumborum Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
41327868|NCT02715999|PROCEDURE|Transversus Abdominis Plane Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
41327869|NCT02564029|DRUG|PF-06372865|Single dose
41480617|NCT02211014|DRUG|acalabrutinib|
41480618|NCT05222542|OTHER|Sampling of plasma and cerebrospinal fluid at specified time points|Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.
41327870|NCT02564029|DRUG|Placebo|Placebo for PF-06372865 and placebo for lorazepam
41010771|NCT06161454|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight:~40 mg for a participants weighing 40-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg"
41327871|NCT02564029|DRUG|Lorazepam|2 mg single oral dose
41327872|NCT02639403|RADIATION|Conformal three-dimensional Radiotherapy|Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
41017870|NCT05905185|DRUG|Placebo|50mg of Placebo
41017871|NCT03333005|DRUG|APX001 with Standard of Care anti-fungal agent|safety assessment
41480619|NCT04845906|DEVICE|StatLock™ Catheter Stabilization Device and the StatLock™ stabilization device accessory (Foam Strip)|Each participant will have 2 separate devices applied, one to each arm, with or without a Foam Strip.The participant will also wear a dressing over top of a StatLock™ compatible catheter, which will be connected to an extension set. For this study, the catheter will not be inserted into the study participant but instead will be shortened or modified and placed on the skin and secured with the StatLock™ Stabilization Device. The use of the catheters, extension set, and the dressing represents how the device would be used in a clinical setting.
41480620|NCT04625075|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with gadolinium and manganese contrast
41010772|NCT03968458|BEHAVIORAL|CON|. Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
41010773|NCT03968458|BEHAVIORAL|EX-30|Condition with an acute exercise set 30 minutes before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
41010774|NCT03968458|BEHAVIORAL|EX-90|condition with an acute exercise set 90 minutes before lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
41010775|NCT04841564|PROCEDURE|ultrasound approach of serratus anterior block|After induction of general anesthesia, the ultrasound probe will be placed longitudinally oblique just below the mid-clavicle. After identifying the second rib, the probe will be moved caudally and laterally (obliquely), towards the mid-axillary line to identify the 3rd, 4th and 5th ribs.. The fascial plane between the serratus anterior muscle and latissimus dorsi muscle will be identified over the 4th rib in the mid-axillary region. The block will be performed with a needle (22-G, 50-mm) introduced in-plane to enter deep to the serratus anterior muscle, and 30 ml 0.25 bupivacaine will be injected.
41010776|NCT04841564|PROCEDURE|open approach of serratus anterior block|After resection of the breast and identification of the serratus anterior muscle, the surgeon will be asked to palpate the ribs below the clavicle and localize the fourth rib. A 22-G, 50-mm needle will be introduced deep to the serratus anterior muscle contacting the rib, and 30 ml 0.25 bupivacaine will be injected.
41010777|NCT03869125|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure monitoring using automated office blood pressure measurement (AOBPM), office blood pressure measurement (OBPM), and 24-hour ambulatory blood pressure monitoring
41010778|NCT00685152|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)|6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
41010779|NCT04884516|DIETARY_SUPPLEMENT|Retinol gummy|Participants take one retinol gummy per day
41010780|NCT04546204|OTHER|vaginal delivery|normal vaginal spontaneous delivery
41327873|NCT01379170|DRUG|Euthyrox (levothyroxine)|A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
41327874|NCT03316872|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
41327875|NCT03316872|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT involves delivery of high doses of radiation therapy in smaller fractions
41480621|NCT04625075|DIAGNOSTIC_TEST|Cardiac CT|Cardiac CT to assess coronaries
41480622|NCT04625075|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|ECG to assess rhythm
41480623|NCT04625075|DIAGNOSTIC_TEST|Blood samples|renal function liver function full blood count, hematocrit glucose
41010781|NCT04840758|RADIATION|Stereotactic Ablation Radiotherapy|Stereotactic ablation radiotherapy was performed sequentially on the primary and secondary lesions. 50Gy/4F or 70Gy/10F were used according to the specific location of the tumor。
41010782|NCT04840758|DRUG|Sintilimab|Sintilimab was started 2 weeks after the end of radiotherapy. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles
41010783|NCT06439914|DRUG|[89Zr]Zr-DFO-emapalumab|Radiotracer \[89Zr\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started
41010784|NCT01976416|DRUG|Hydroxyurea|
41010785|NCT01976416|DRUG|Placebo|
41010786|NCT02586701|OTHER|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
41010787|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
41327876|NCT05249712|DRUG|Darolutamide 300 mg|600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.
41480624|NCT01693627|DEVICE|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
41327877|NCT05249712|OTHER|Androgen deprivation therapy|The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.
41327878|NCT01357980|BIOLOGICAL|Botulinum toxin type A|750 U intra detrusor injection on Day 1 (single dose)
41327879|NCT01357980|DRUG|Placebo|Intra detrusor injection on Day 1 (single dose)
41327880|NCT05161754|PROCEDURE|Hemostasis|Hot hemostasis include bipolar and monopolar diathermy. Cold hemostasis include surgical knotting of the tonsil pillar and compression.
41480625|NCT01693627|DEVICE|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
41480626|NCT01693627|DEVICE|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
41480627|NCT01693627|DEVICE|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
41010788|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
41010789|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
41480628|NCT03026972|BIOLOGICAL|Placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.
41010790|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
41010791|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
41010792|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
41480629|NCT03026972|BIOLOGICAL|Low dose adjuvant|Population I and polulation IV are coxal muscle injection of low dose adjuvant.
41480630|NCT03026972|BIOLOGICAL|High dose adjuvant|Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.
41010793|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
41010794|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
41327881|NCT02467855|OTHER|No Intervention|No intervention was administered in this study.
41480631|NCT03026972|BIOLOGICAL|Low dose vaccine|Population I and population IV are coxal muscle injection of low dose vaccine.
41480632|NCT03026972|BIOLOGICAL|High dose vaccine|Population II,population III and population IV are coxal muscle injection of high dose vaccine .
41480633|NCT00576641|BIOLOGICAL|autologous dendritic cells|
41480634|NCT04231734|OTHER|Ketogenic Diet|Prepared ketogenic meals, 3 per day for up to 12 weeks (Day 1 through Day 84)
41327882|NCT03624764|PROCEDURE|Laparostopic promontofixation using surgical glue|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)
41327883|NCT03624764|PROCEDURE|Laparostopic promontofixation using threads|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
41327884|NCT06397885|DEVICE|Milli Vaginal Dilator|Patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion
41480635|NCT01040884|OTHER|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
41480636|NCT06409650|DRUG|KX-826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
41480637|NCT06409650|DRUG|KX-826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
41480638|NCT06409650|DRUG|KX-826 dosed at 5 mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
41480639|NCT06409650|DRUG|KX-826 dosed at 5 mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
41480640|NCT06409650|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp once daily for 24 weeks
41010795|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
41010796|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
41010797|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
41010798|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
41010799|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
41010800|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
41010801|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
41010802|NCT02492906|OTHER|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
41480641|NCT06409650|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp twice daily for 24 weeks
41010803|NCT02492906|OTHER|Healthy|Healthy and non-symptomatic volunteers.
41010804|NCT03998124|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
41327885|NCT04322162|OTHER|ASAP Intervention Quality Improvement Protocol|The intervention program includes: (1) a systems redesign Virtual Collaborative, and; (2) data monitoring and is designed to aid each of the 6 participating VAMCs in developing, implementing, and evaluating the implementation of an acute OSA testing and treatment protocol for ischemic stroke/TIA patients. The sites will choose a diagnostic strategy (i.e., unattended polysomnography \[PSG\]/home sleep test \[HST\], in-laboratory PSG, direct to auto-titrating \[auto\]-PAP) and a therapeutic strategy (i.e., in-laboratory PAP titration, auto-PAP). The intervention will employ 3 implementation strategies: (1) local adaptation; (2) external facilitation, and; (3) audit and feedback.
41327886|NCT00744848|DRUG|Bupivacaine HCl|100 mg Bupivacaine HCl
41327887|NCT00744848|DRUG|SKY0402|Single administration 300 mg SKY0402 in a 40-mL injection volume
41327888|NCT06015568|DRUG|MCLA-129: 1500mg or 2000mg IV Q2W|Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs
41327889|NCT06015568|DRUG|Befotertinib: 75 mg or 100 mg Po QD|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD.~Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs."
41327890|NCT03890393|DEVICE|Electromyography|Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.
41327891|NCT05263687|DIAGNOSTIC_TEST|Maximal exercise test|Each participants will conduct a spirometry test and exercise test on treadmill (using Modified Bruce Protocol) or cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange, ECG, gas volume in addition rating of perceived exertion will be asked.
41480642|NCT05623631|OTHER|Survey|Surveys were distributed using REDCap, and participants were asked to complete these within 5 weeks of receiving the invitation.
41480643|NCT04714229|BIOLOGICAL|Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
41480644|NCT04714229|BIOLOGICAL|Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
41480645|NCT03276780|BEHAVIORAL|Counseling|Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
41480646|NCT03276780|DRUG|combination NRT|Both groups will receive combination NRT to help with smoking cessation
41480647|NCT01565265|DRUG|Pergoveris in long protocol with GnRH agonist|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
41480648|NCT01565265|DRUG|Pergoveris in GnRH antagonist protocol|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
41480649|NCT04798235|BIOLOGICAL|TSHA-101|AAV9 viral vector containing HEXA and HEXB genes to be administered via Intrathecal injection
41010805|NCT03998124|OTHER|Usual care|Staff-led social activity
41010806|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U.~≈ bolus protocol: From 6 pm until 6 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm~1 dose/h + 50 % s.c. (≈ bolus)."
41010807|NCT00497536|DRUG|Insulin Aspart (IAsp).|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
41010808|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
41010809|NCT02568488|DRUG|Metformin|850 mg orally twice daily for 6 months
41010810|NCT02331446|BEHAVIORAL|Physical exercise intervention|
41010811|NCT01096784|DRUG|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
41010812|NCT03604055|PROCEDURE|Endobronchial hamartomas treatment|General anesthesia was administered by an intravenous anesthesia technique. Patients were intubated with a rigid bronchoscope. Debulking procedures were performed by mechanical tumor resection (MTR) using the tip of the rigid bronchoscope, rigid pliers or argon plasma coagulation assisted MTR or cryorecanalization or electrocautery - snare probe. An innovation of our study was that cryotherapy was performed in the regions where the lesions originated after debulking
41010813|NCT04460664|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
41327892|NCT01743885|DRUG|Acebutolol|10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
41327893|NCT01743885|DRUG|Propanolol|3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
41327894|NCT05393674|DRUG|Fedratinib Oral Capsule [Inrebic]|400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
41327895|NCT05393674|DRUG|Nivolumab|240 mg every 2 weeks i.v. from cycle 2-n
41327896|NCT00489372|DRUG|Se-methyl-seleno-L-cysteine|Given orally
41327897|NCT00489372|OTHER|placebo|Given orally
41327898|NCT00489372|OTHER|pharmacological study|Correlative studies
41327899|NCT00489372|OTHER|laboratory biomarker analysis|Correlative studies
41327900|NCT02905916|DRUG|PEG-rhG-CSF|
41327901|NCT00603213|PROCEDURE|Blood Volume Analysis, Echocardiogram|"Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.~Echocardiogram is an ultrasound of the heart."
41327902|NCT05473104|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|Social training targeting adolescents with ASD and focused on making and keeping friends
41327903|NCT03434418|DRUG|osimertinib|80 mg oral administration daily
41327904|NCT06317220|BIOLOGICAL|Vedolizumab|Administered over 30 minute infusion at MGH main campus
41327905|NCT05750316|OTHER|Cowpea leaves mixed with Jam|6g of freeze-dried cowpea leaves, equivalent to 80g(a portion) of vegetables mixed with Jam and spread on bread
41327906|NCT05750316|OTHER|Jam mixed with green food colour|Jam with green food colouring spread on bread
41327907|NCT04509323|DRUG|Huperzine A for Injection|Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days
41327908|NCT06184542|BIOLOGICAL|DTacP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on Day 0
41327909|NCT06184542|BIOLOGICAL|DTacP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on the M3-M4-M5, M2-M3-M4, or M2-M4-M6 immunization schedule
41327910|NCT06184542|BIOLOGICAL|DT (one-dose booster)|Diphtheria-Tetanus Combined Vaccine of 0.5mL on Day 0
41327911|NCT06184542|BIOLOGICAL|DTaP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on Day 0
41480650|NCT03697330|DRUG|Ringer lactate|"Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood."
41480651|NCT04452695|DEVICE|Doctor Spot|Robotic platform (Boston Dynamics) controlled by clinician with video interface to facilitate telemedicine triage
41480652|NCT02356991|DRUG|Famitinib|
41480653|NCT02356991|DRUG|Placebo|
41010814|NCT02994342|DEVICE|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
41327912|NCT06184542|BIOLOGICAL|PENTAXIM (one-dose booster)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on Day 0
41327913|NCT06184542|BIOLOGICAL|DTaP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on an M3-M4-M5immunization schedule
41327914|NCT06184542|BIOLOGICAL|PENTAXIM (three-dose primary vaccination)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on the M3-M4-M5 or M2-M3-M4 immunization schedule
41327915|NCT04154917|OTHER|HOME|HOME's focus is on the person's functional ability, safety and transition from hospital to home. HOME will be delivered by a community-based clinician (OT who will be involved in the hospital discharge planning) trained by the PI. Training will include two sessions covering assessment of functional ability, goal setting and home safety. The clinician will keep a record of recommendations provided, length of home visit and any adverse events during the intervention. Twice over the course of the study, the PI leader will observe the clinician conducting HOME interventions to assess adherence to the study protocol using a fidelity checklist. The HOME intervention comprises 4 phases, which are described in the arms section.
41327916|NCT04639843|DRUG|CC-486 (5-azacitidine)|CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 8 cycles.
41327917|NCT04639843|DRUG|Duvelisib|Duvelisib by oral intake at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of the 1st cycle then days 1-14 of Cycles 2-8 of each 21- day cycle (max 8 cycles).
41480654|NCT01272115|BEHAVIORAL|Integrative health care model|The integrative health care model with an empowerment approach will address the care that should be given collaboratively by the health team in cooperation with the active participation of women. The IHCM will be provided under the leadership of the nurse who will coordinate with the health team members, promote preventive care, and incorporate cognitive-behavioral strategies, such as individual and group counseling. The IHCM will be provided for three months to each woman, followed by a three-month follow-up. Each woman will receive: monthly individual counseling by nurse; eight weekly (90-minutes) group counseling sessions and 2-9 consultations with psychologist defined in accordance to women individual needs and characteristics.
41010815|NCT06176833|PROCEDURE|Body Weight Supported Treadmill Training|For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.
41010816|NCT05703919|DRUG|Titrated Oxygen|Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%
41010817|NCT05703919|DRUG|Standard Oxygen|Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators
41010818|NCT06347081|PROCEDURE|Nd- YAG laser at 532nm wavelength|Nd-YAG laser at 532nm wavelength every 2 weeks for 14 sessions. patients will also receive standard medical care, nursing, physiotherapy
41327918|NCT04639843|DRUG|Romidepsin|Romidepsin (12mg/m2) will be administered on days 1 and 8 of each cycle through a peripheral or central intravenous catheter for 8 cycles.
41327919|NCT04639843|DRUG|Doxorubicin|Doxorubicin at 25 mg/ m2 by IV infusion on Day 1 of cycles 3-8.
41327920|NCT05651217|DEVICE|disposable urinary catheter|The trial group was intervened with disposable sterile urinary catheter. The model of the trial group includes two chamber type (Fr8, Fr10, Fr12, Fr14, Fr16, Fr18, Fr20, Fr22, Fr24) and three chamber type (Fr16, Fr18, Fr20, Fr22, Fr24).
41327921|NCT05651217|DEVICE|super smooth antibacterial urinary catheter|the control group was intervened with ultra smooth antibacterial catheter. The control group models include single chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr), double chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr, 28Fr, 30Fr), and three chamber (16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr)
41327922|NCT00356395|DRUG|ramipril, candesartan|
41327923|NCT05474807|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program, will be based on Miglianico et al.'s (2020) general framework, following the theorized five stages: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation.~As to increase participant engagement and motivation, gamification components will be embedded in several of these stages.~The entire intervention will be delivered online via an LMS software solution."
40809984|NCT06658262|OTHER|Tai Chi Exercises Alone|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. 5.Part the Wild Horse's Mane
40809985|NCT06660862|DRUG|Darolutamide|How darolutamide and hormone therapy affects the step count of older men who have prostate cancer
40809986|NCT06660862|DRUG|Physician choice Androgen Deprivation (Hormone) Therapy|How step count/physical activity affects certain quality of life changes these men experience such as differences in pain, mood, function, memory and fatigue
41154881|NCT00414219|BEHAVIORAL|Visual quality of patients with corneal eye injuries|Visual quality of patients with corneal eye injuries
41154882|NCT02449837|OTHER|Blood draw|Blood samples will be collected at up to 4 time points before and during radiation. Blood will be collected at least 4 to 12 weeks post-treatment. Additional post-treatment blood draws will be performed at each subsequent follow-up visit to UNC (roughly \~1 month interval), up until 24 months after completion of radiation.
41327924|NCT04568018|DRUG|Surfactant|Inhalation of surfactant emulsion at 150 mg
41327925|NCT00655057|DRUG|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
41327926|NCT00655057|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
41327927|NCT00655057|PROCEDURE|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
41327928|NCT05716815|DIAGNOSTIC_TEST|CT scans 2D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
41327929|NCT05716815|DIAGNOSTIC_TEST|CT scans 2D plus 3D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions plus a 3D reconstruction are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
41327930|NCT00119236|DRUG|tanespimycin|
41327931|NCT00119236|DRUG|irinotecan hydrochloride|
40809989|NCT06661291|DEVICE|Pip Care Digital Health Platform|Pip Care Digital Health Platform is a smartphone application granting access to a health coach who will assist the patient in completing a health intake, creating personalized perioperative care plans, and meets regularly with the patient to encourage goal accomplishments and supports healthy surgical recovery.
41010819|NCT03087279|BEHAVIORAL|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
41010820|NCT05346627|PROCEDURE|Personalized and mixed training program|Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
41010821|NCT05770037|DRUG|Alectinib|"Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
40809990|NCT06661291|OTHER|Standard of Care Protocol|Subjects in this intervention group will receive routine, standard of care throughout their surgery and hospital stay as determined by their acting clinical care team.
41327932|NCT03611998|BEHAVIORAL|Occupation-based programming|Group sessions consisted of specific tasks performed to completion that emphasized skills such as problem-solving, decision-making, frustration tolerance, appropriate pacing, attention, inquiring, sequencing, gathering, organizing, adjusting, responding, enduring, initiating and cooperating. Examples of tasks included projects that the women were specifically interested in learning such as jewelry making, holiday decorations, clay work and other home décor projects. Investigators observed these and other behaviors during the group sessions, and scored individuals using the OTTOS instrument.
41480655|NCT05656079|DRUG|Pegylated liposomal doxorubicin|Drug: Pegylated liposomal doxorubicin (35 mg/m2) will be administered by an intravenous infusion on day 1 of each21-day cycle.
41480656|NCT05656079|DRUG|Epirubicin|Drug: Epirubicin (90 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
41480657|NCT05656079|DRUG|Cyclophosphamid|Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
41010822|NCT02335138|BEHAVIORAL|Couples HIV Testing and Counseling (CHTC, CVCT)|Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
41010823|NCT02335138|BEHAVIORAL|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
41327933|NCT06291467|BIOLOGICAL|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 9:30 a.m. and fasting from midnight.
41154883|NCT02946827|DIETARY_SUPPLEMENT|Balanced low FODMAPs /gluten free diet|
40809992|NCT06659094|OTHER|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"Using a WeChat mini-program, we offer personalized OCD SC-ICBT remote services. Training is customized based on individual assessments, focusing on psychological education and homework to simulate CBT therapy. If a patient's YBOCS score drop from baseline isn't 25% after four therapist sessions (one week of theory, two sessions/week), they get three more weeks of online guidance.~The program includes four structured lessons over six weeks:~Lesson 1: Psychological Health Education on OCD and related disorders. Lesson 2: ERP theory, exposure item lists, and related info. Lesson 3: Daily ERP practice for about an hour, followed by two weeks of therapist guidance.~Lesson 4: Retrospection and relapse prevention."
40809993|NCT06659094|OTHER|Cognitive Behavioral Group Therapy (CBGT)|The CBGT group will receive cognitive-behavioral group therapy for 6 weeks, twice a week, each session lasting 2 hours, at the Shanghai Mental Health Center. The CBGT program follows a structured process for treating OCD. During the prep phase, therapists assess patients for 50 minutes, collect data, and set CBGT groundwork. In Session 1, families join to understand CBGT, with goals reinforced and OCD education provided. Session 2 reviews homework and develops ERP strategies. Session 3 initiates ERP practice. Sessions 4-11 continue homework review and group ERP practice. The final session involves families in a review, discussing challenges, celebrating achievements, and focusing on relapse prevention.
41010824|NCT01417832|DRUG|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
41010825|NCT01417832|DRUG|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
41010826|NCT05954234|OTHER|Postural re-education|"Each session of the experimental approach will be composed of 40 minutes of postural exercise. Participants will be asked to maintain two different postures to stretch both the anterior and posterior muscle chains. The first posture will consist of lying on the back maintaining the extension of the legs to release the respiratory diaphragm and stretch the anterior muscle chain. For the second posture, participants wiil be asked to lie on their back with their legs flexed to stretch the posterior chai. For each posture, the physical therapist will use verbal commands and manual contact to maintain alignment and make the necessary postural corrections to optimize the stretching and discourage compensatory movements.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
41010827|NCT05954234|OTHER|Spinal mobilization|"This approach will consist of 40 minutes of thoracolumbar spine mobilization. Two different mobilizations will be carried out. In the first one the patient will be in sitting position with both legs out of the bed and a mobilization in antero-posterior direction will be provide by the physiotherapist; the second one will consist in rotational mobilisation provide with the patient in lateral decubitus position.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
41010828|NCT05954234|OTHER|Perineal Exercises|Perineal Exercises will be performed in both the allocated approach. The protocol will consist in 10 minutes of perineal contraction and relaxation and 10 minutes of stretch-reflex for a total of 20 minutes of perineal exercises.10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks.
41010829|NCT02513589|DRUG|18F-PBR06|Positron Emission Tomography / Computed Tomography (PET-CT) using 18F-PBR06
41327934|NCT06291467|OTHER|questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Hetero-questionnaires will be administrated during a clinical interview conducted by a psychiatrist or psychologist at the inclusion.~* MINI 7.0 Mini-International Neuropsychiatric Interview :~* MADRS (Montgomery Asberg Depression Scale)~* C-SSRS (Columbia-Suicide Severity Rating Scale)~* FAST (Functioning Assessment Short Test)~Self-administered questionnaire will be completed by the participant at the inclusion and at the end of hospitalisation (D7+/- 2 days) :~* STAI-Y (State-Trait Anxiety Inventory )~* PPP-VAS (Visual Analog Scale to measure Psychological and Physical Pain)~* SHAPS (Snaith-Hamilton-Pleasure Scale )~* CTQ (Childhood Trauma Questionnaire)~* ESUL : Echelle de solitude de l'université de Laval~* BIS-11 : (Barratt Impulsiveness Scale)~* QIDS (Quick Inventory of Depressive Symptomatology)"
41327935|NCT03841526|DRUG|Glucagon RTU Injection With Insulin Pump Reduction|0.15 mg injection with 50% pump reduction
41010830|NCT06448234|OTHER|Standart supplementation therapy group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles
41154884|NCT02946827|DIETARY_SUPPLEMENT|Balanced gluten free diet|
41154885|NCT04047680|DRUG|Sofosbuvir / Velpatasvir Oral Tablet|Sofosbuvir/velpatasvir for 12 weeks
41154886|NCT04047680|DRUG|Sofosbuvir and Ledipasvir|Sofosbuvir and ledipasvir for 12 weeks
41154887|NCT04047680|DRUG|Sofosbuvir Tablets|Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks
41154888|NCT04047680|DRUG|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir for 12 weeks
41154889|NCT04047680|DRUG|Elbasvir / Grazoprevir Oral Tablet|Elbasvir/grazoprevir for 12 weeks
41154890|NCT04047680|DRUG|Glecaprevir and Pibrentasvir|Glecaprevir/pibrentasvir for 12 weeks
41327936|NCT03841526|OTHER|Vehicle for Glucagon RTU Injection With Insulin Pump Reduction|vehicle injection with 50% pump reduction
41327937|NCT03841526|DRUG|Glugaon RTU Injection Without Insulin Pump Reduction|0.15 mg injection without pump reduction
41327938|NCT01993056|BEHAVIORAL|"FIFA 11+"|
41327939|NCT01993056|BEHAVIORAL|"no FIFA 11+"|
41154891|NCT04263909|DRUG|Sublingual Tablet|sufentanil SL 30mcg administered sublingually to patients undergoing spine surgery before extubation and during recovery
41327940|NCT05369052|DRUG|contezolid acefosamil (IV)/contezolid (PO)|Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
41327941|NCT05369052|DRUG|Linezolid (IV and PO)|Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
41480658|NCT05656079|DRUG|Trastuzumab|Drug: Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
40809994|NCT06659094|DRUG|conventional medical treatment (TAU)|Drug therapy, managed by a deputy chief psychiatrist unaware of patient groupings, utilizes China Food and Drug Administration (CFDA)-approved SSRIs for OCD. These include fluoxetine, paroxetine, sertraline, fluvoxamine, and others, with tricyclic drugs like clomipramine and SNRIs such as venlafaxine. The maximum dosage adheres to the instructions. Benzodiazepines may assist with sleep, but usage is capped at two weeks; no other psychotropics are co-administered. Common side effects comprise dry mouth, constipation, nausea, indigestion, dizziness, fatigue, and sweating. The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual.
40809995|NCT06660394|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
40809996|NCT06660394|DRUG|Placebo|Participants will be administered with matching placebo orally or through G-tube/ PEG tube
40809997|NCT06661460|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|The intervention is a therapist-guided, internet-delivered cognitive behavioral therapy (ICBT) program primarily based on exposure therapy, involving the gradual confrontation of feared situations and/or stimuli. Treatment is accessed through a smartphone, tablet or laptop/desktop device. The 12-week intervention is available in two different versions depending on the participant's age: one for 8-12-year-olds and one for 13-17-year-olds. Each version consists of separate logins to 12 modules (chapters) for the child/adolescent and 12 modules for the caregivers. Both the child/adolescent and caregiver have individual contact with a trained therapist over the internet platform. The therapist provides feedback, responds to questions and sends reminders to complete the next module if required. Communication is carried out via text messages in the platform, via telephone (if deemed justified) and through a scheduled telephone or videoconference call approximately 4-5 weeks into treatment.
41010831|NCT06448234|OTHER|AI-guided supplementation therapy group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
41010832|NCT00167934|DRUG|Valproate|Depakote ER 500 mg to 3000 mg taken every night
41010833|NCT00167934|DRUG|Placebo|Placebo given at same frequency as Valproate
41480659|NCT05656079|DRUG|Pertuzumab|Drug: Pertuzumab (840 mg loading dose at first day only, then 420 mg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
41480660|NCT05656079|DRUG|Docetaxel|Drug: Docetaxel (75mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
41480661|NCT04651322|DEVICE|upper robot Robot assisted upper arm training(RAT)|"The training group received an additional upper robot Robot assisted upper arm training(RAT) with Armeopower® 5 times per week for 4weeks.~\*Robot Assisted Arm training + Conventional occupational therapy"
40809998|NCT06658860|PROCEDURE|Modified Socket Shield Technique|The modified socket shield technique involves partial retention of the buccal aspect of the tooth root during extraction to preserve the surrounding alveolar bone and soft tissue. This technique is used to optimize the condition for delayed implant placement by preventing resorption of the alveolar ridge.
40809999|NCT06658860|PROCEDURE|Conventional Tooth Extraction|Conventional tooth extraction involves the complete removal of the tooth without the use of the socket shield technique. This arm served as the control group, with alveolar ridge changes observed and compared with those in the experimental arm over time.
41010834|NCT04516122|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41010835|NCT04516122|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
41154892|NCT00828542|DRUG|etonogestrel implant|Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
41154893|NCT00828542|DRUG|depot medroxyprogesterone acetate|150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
41010836|NCT03001128|DRUG|Antiretroviral treatment pause|Antiretroviral treatment pause
41010837|NCT03087201|DRUG|nabiximols|"starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks"
41010838|NCT03087201|DRUG|placebo|analogous to experimental intervention
41010839|NCT04275128|DEVICE|Cooled radiofrequency ablation|Cooled radiofrequency thermal treatment uses the electrical current produced by radio waves to destroy a part of nerve tissue and relieve pain.
41010840|NCT04275128|DEVICE|Conventional radiofrequency ablation|Genicular nerve ablation involves using radiofrequency to heat up the genicular nerve until it dies, causing relief of pain. This is a minimally invasive treatment that does not require any medication.
41010841|NCT04797780|DRUG|Tamibarotene|Administered as specified in the treatment arm
41010842|NCT04797780|DRUG|Placebo|Administered as specified in the treatment arm
41010843|NCT04797780|DRUG|Azacitidine|Administered as specified in the treatment arm
41010844|NCT02488629|DRUG|SCB01A|This study is a single arm, open-label, Phase II trial
41010845|NCT02285751|DRUG|acetylsalicylic acid|
41010846|NCT02285751|DRUG|clopidogrel|
41010847|NCT02285751|DRUG|prasugrel|
41480662|NCT04651322|BEHAVIORAL|Conventional therapy|The control group received the usual conventional therapy \*Only Conventional occupational therapy
41480663|NCT06105320|OTHER|LCHF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%"
41010848|NCT02285751|DRUG|ticagrelor|
41010849|NCT01367808|DRUG|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
41010850|NCT01367808|DRUG|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
41010851|NCT01367808|DRUG|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
41154894|NCT06089083|OTHER|Physical function assessment|Physical assessments of frailty will be conducted in person.
41154895|NCT06089083|OTHER|Self-reported Assessments and Questionnaires|Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study
41480664|NCT06105320|OTHER|HCLF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%"
41480665|NCT04523402|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy with GEMOX regimen before liver resection
41480666|NCT02049021|DEVICE|MECTA SPECTRUM 5000Q ECT|
41327942|NCT04874688|DIETARY_SUPPLEMENT|Small-quantity lipid-based nutrient supplement|Small Quantity Lipid-based Nutrient Supplement (SQ-LNS) is a food supplement rich in both macro and micronutrients (calories, proteins, fat and multivitamin mix). SQ-LNS is not considered a regulated drug product in Zimbabwe, or by the United States Food and Drug Administration (FDA). It is commercially available for prevention of chronic malnutrition, produced by Nutriset (https://www.nutriset.fr/products/en/enov-nutributter2). Each child will receive a daily sachet of 20g SQ-LNS between 6-12 months of age, consumed directly from the sachet or mixed with porridge.
41010852|NCT01406691|DEVICE|Flashes|one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime
41010853|NCT02764749|DIETARY_SUPPLEMENT|cranberry (poly)phenol containing supplement|Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
41327943|NCT04874688|DIETARY_SUPPLEMENT|Provitamin A biofortified maize|Provitamin A Maize Meal is orange maize-meal processed from provitamin A-rich orange maize. PVA maize meal will be sourced from International Maize and Wheat Improvement Centre (CIMMYT). Children in the intervention arm will consume 13g - 128g of pro-vitamin A (PVA) maize meal, with added powders. Each family will receive a monthly ration of 5kg PVA maize and this ration takes into consideration of household sharing. Families with children in the IYCF arm will receive white maize meal.
40810002|NCT06660576|PROCEDURE|Cholecystectomy and histochemical analysis of Gallbladder stones|Cholecystectomy and histochemical analysis of Gallbladder stones
41154896|NCT06089083|PROCEDURE|Surgery (Standard of Care, Non-Interventional)|Surgical data will be reviewed via medical record
41154897|NCT02884921|DRUG|Paracetamol|Paracetamol
41154898|NCT02884921|DRUG|Paracetamol|Paracetamol
40810006|NCT06659627|BEHAVIORAL|Aerobic exercise therapy|Participants will follow an aerobic exercise therapy program for 16 weeks.
40810007|NCT06659627|BEHAVIORAL|Cognitive behavioural therapy|Participants will follow an cognitive behavioural therapy program for 12-16 weeks.
41327944|NCT04874688|DIETARY_SUPPLEMENT|NUA-45 biofortified sugar beans|NUA 45 bean powder is ground from roasted iron and zinc-rich biofortified sugar beans. NUA 45 bean powder will be sourced from Sky Brands Ltd Company. Children will consume a daily dose of 5g - 15g of NUA 45 bean powder added to complementary foods.
41327945|NCT04874688|DIETARY_SUPPLEMENT|Moringa oleifera|Moringa oleifera is an edible plant abundant in dry tropic regions including Zimbabwe. It is known to be rich in micronutrients and has been widely used in Zimbabwe and around the world both as a food and a herb. Moringa oleifera leaf powder, is a dried and ground powder produced from Moringa oleifera leaves using traditional methods. It has been widely used to fortify complementary foods in the African region with the aim of improving micronutrient status. Moringa oleifera leaf powder will be sourced from Lemex Products Company. Children will receive a daily dose of 5g - 15g of Moringa leaf powder added to complementary foods.
41480667|NCT02049021|PROCEDURE|Sham ECT|Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
40810008|NCT06659627|OTHER|Usual care|Participants do not follow a program, but continue with care as usual
40810009|NCT06661473|DEVICE|Avance Solo Negative Pressure Wound Therapy|Avance Solo NPWT 7-14 days after high-risk revision TKA or THA.
41154899|NCT02884921|DRUG|Placebo|Placebo
41154900|NCT04342910|DRUG|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
40810012|NCT06660173|DRUG|Maridebart Cafraglutide|Solution for subcutaneous injection.
40810013|NCT06660173|DRUG|Placebo|Solution for subcutaneous injection.
41010854|NCT02764749|DIETARY_SUPPLEMENT|Placebo comparator: cranberry (poly)phenol deprived supplement|Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
41010855|NCT02159547|DRUG|Dexketoprofen|50 mg intravenous arveles in 50 ml saline in 5 minutes
41010856|NCT02159547|OTHER|Normal Saline|50 ml normal saline
41154901|NCT04342910|DRUG|Apatinib Mesylate|250 mg qd
41154902|NCT04342910|DRUG|Paclitaxel|80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
41154903|NCT04342910|DRUG|Irinotecan|180 mg/m\^2 administered as IV infusion on Days 1, and 15 of each 28-day cycle.
41154904|NCT05099978|GENETIC|NGS analysis of ctDNA|Diagnostic Test: plasma circulating tumor DNA
41154905|NCT05762978|DEVICE|In-Check Dial|Patient will have their NIF measured with In-Check Dial
41154906|NCT05762978|DEVICE|Inhaler Device|Children will use inhaler per standard of care.
41154907|NCT02214836|DEVICE|Verasonics Data Acquisition System (VDAS)|Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified. Stone location and size will be determined and compared to clinical determination of stone location and size.
41154908|NCT00582192|OTHER|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
41010857|NCT02840877|BEHAVIORAL|DOT Adherence Monitoring|Study participants will meet with a study-employed DOT worker daily during weekdays throughout the course of their TB treatment
41010858|NCT00934206|BEHAVIORAL|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
41010859|NCT05714579|PROCEDURE|Transcatheter Aortic Valve Implantation|"The TAVI procedure is performed transfemorally under local anesthesia most often, or more rarely under general anesthesia via the subclavian or transaortic route. Identification is carried out under fluoroscopy in the cardiac catheterization room. The crossing of the aortic valve allows the establishment of a guide at the bottom of the left ventricle. Aortic valve predilation can be performed. The tightness of the device is checked by an aortography. Sometimes, post-dilation of the implanted bioprosthesis proves necessary, particularly in the event of under-deployment or significant para-prosthetic leakage.~The duration of the intervention is approximately 1 hour."
41327946|NCT04874688|DIETARY_SUPPLEMENT|Whole egg powder|Egg Powder is hydrolysed non-genetically modified organism (GMO), fine and unflavoured whole egg powder. It is processed with no additives, preservatives, lecithin, added sugar, soy or monosodium glutamate. Egg powder will be sourced from France (A \& D Food Ingredients - distributor in South Africa). Children in the IYCF-plus arm will receive a daily dose of 14g egg powder. A 15% extra amount of egg powder will be provided to families taking into consideration of household sharing. Egg powder will be provided in sealed plastic jars similar to that of peanut butter and households will receive promotion messages to store the powder in a cool, dry place and avoiding contact with water or moisture during use.
41010860|NCT02386202|OTHER|No intervention|No interventions
41010861|NCT03144492|BIOLOGICAL|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
41327947|NCT04874688|DIETARY_SUPPLEMENT|White maize meal|Commercial white maize meal will be provided monthly. Infants age 6-8 months will receive 45g (3 tablespoons) daily; infants aged 9-12 months will receive 71g (4.5 tablespoons) daily.
41327948|NCT05840978|DIETARY_SUPPLEMENT|Probiotics|Oral capsules
41010862|NCT01441427|DRUG|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
41010863|NCT01441427|DRUG|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
41010864|NCT01441427|DRUG|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
41327949|NCT05840978|DIETARY_SUPPLEMENT|Placebo|Oral capsules
41327950|NCT00158223|DRUG|Pimozide|Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
41327951|NCT00158223|DRUG|Placebo|Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
41327952|NCT00865189|DRUG|Bevacizumab|Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
41327953|NCT00865189|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m\^2) as a 2-hour IV infusion.
41327954|NCT00865189|DRUG|Folinic Acid|Folinic acid will be administered at a dose of 200 mg/m\^2 as a 2-hour infusion.
41327955|NCT00865189|DRUG|5-fluorouracil|5-fluorouracil will be administered at a dose of 400 mg/m\^2 as an IV bolus, then at a dose of 600 mg/m\^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m\^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
41327956|NCT00865189|RADIATION|Preoperative Radiotherapy|Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
41327957|NCT00865189|PROCEDURE|Surgery|Radical rectal excision based on the TME technique.
41327958|NCT04466787|DIAGNOSTIC_TEST|Spectral Photon Counting Computed Tomography (SPCCT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field of View (FOV) of 168 mm in-plane, and a z-coverage of 2 mm."
41010865|NCT01441427|DRUG|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
41010866|NCT01441427|DRUG|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
41010867|NCT00410696|DRUG|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
41010868|NCT00410696|DRUG|Pegfilgrastim|6 mg/day sc at day +1
41480668|NCT04944017|DRUG|Ketamine Infusion|Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry
41480669|NCT04944017|OTHER|Placebo - Saline Infusion|Participants will receive 6 infusions of saline administered over 40 minutes while on continuous cardiac monitoring and oximetry
41480670|NCT06453512|DEVICE|Doublebase Once|Emollient
41327959|NCT04466787|DIAGNOSTIC_TEST|Dual Energy CT (DECT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~DECT : IQon, Philips"
41480671|NCT05338021|PROCEDURE|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
41010869|NCT00169650|OTHER|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
41480672|NCT01644136|PROCEDURE|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
41480673|NCT01644136|PROCEDURE|regional lymph node dissection|Undergo pelvic lymph node dissection
41480674|NCT01644136|DEVICE|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
41480675|NCT02823860|OTHER|Collection of biospecimens and Quality of Life (QoL) assessment|Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
41480676|NCT06415942|OTHER|Maternal Outcome Monitoring and Support system|The Maternal Outcome Monitoring and Support system is a mobile health application that allows participants to choose symptoms they may be having that are warning signs of pregnancy related death. They then receive decision support about when they should seek medical care (call their provider or go to an emergency room).
41480677|NCT05336110|OTHER|Postponing surgery|Postponing surgery for patients with Sars-cov-2 infection
41480678|NCT02274207|DEVICE|NPWT application|NPWT mode is cyclic mode : -125\~-50 mmHg
41480679|NCT00553449|DRUG|rabeprazole|
41480680|NCT04039386|DEVICE|Cell Phone Based Cognitive Based Therapy (Pacifica App)|Cell phone application that provides support for individuals with psychosocial conditions.
41480681|NCT04039386|OTHER|Control|Subjects in the control group will receive standard care.
41480682|NCT01901874|DEVICE|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
41480683|NCT03511274|BEHAVIORAL|Hygiene based educational film|Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.
40810014|NCT06659731|OTHER|Quantitative Sensory testing (QST)|The QST protocol (Rolke et al., 2006; Blankenburg et al., 2010), implies the administration of 7 short sensory test in order to measure up to 13 parameters, which can be grouped as follows: thermal detection thresholds for the perception of cold, warm and paradoxical heat sensations, thermal pain thresholds for cold and hot stimuli, mechanical detection thresholds for touch and vibration, mechanical pain thresholds and sensitivity for pinprick and blunt pressure, vibration detection threshold and pressure pain threshold.
40810015|NCT06659731|OTHER|EEG|EEG recording at rest and while receiving heat stimuli to study cortical processing of salient thermal stimuli. Up to 30 painful thermal stimuli, will be delivered to the patients' hand dorsum in order to register contact heat evoked potentials (CHEPs).
41154909|NCT04248049|OTHER|Platelet rich fibrin|The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
41480684|NCT03438396|DRUG|tisotumab vedotin|All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
41480685|NCT05465642|OTHER|Collect stool and blood samples from patients|Collect stool and blood samples from patients
41154910|NCT06063564|BEHAVIORAL|PREVENT|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
41010870|NCT01931267|BEHAVIORAL|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
41010871|NCT01931267|BEHAVIORAL|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
41480686|NCT02218112|PROCEDURE|bariatric surgery (gastric bypass)|
41480687|NCT06091228|OTHER|tongue scraper|tongue cleaning with gentle strokes twice a day covering the whole surface of the tongue
41480688|NCT02050425|DEVICE|Placebo-CPAP device|short-term CPAP withdrawal by the use of Placebo-CPAP
41480689|NCT02050425|DEVICE|CPAP|Patients continue therapeutic CPAP therapy
41480690|NCT01888341|DRUG|Isotretinoin|Isotretinoin Capsules,20 mg
40810018|NCT06658431|BEHAVIORAL|music group therapy|90 minutes music group therapy
41010872|NCT04177108|DRUG|Atezolizumab|Atezolizumab was administered as per the dosage regimen mentioned in arm descriptions.
41010873|NCT04177108|DRUG|Ipatasertib|Ipatasertib was administered as per the dosage regimen mentioned in arm descriptions.
41010874|NCT04177108|DRUG|Paclitaxel|Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.
41010875|NCT04177108|DRUG|Placebo for Atezolizumab|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
41480691|NCT02006368|OTHER|Blood Collection and autologous re-infusion|"Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.~After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated."
41480692|NCT00891371|DRUG|lanreotide (Autogel formulation)|Autogel 120mg
41327960|NCT04086602|DRUG|IZD334|Active Drug
41327961|NCT04086602|DRUG|Placebos|Placebo to Match
41480693|NCT02783430|DRUG|Ketamine|One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
41480694|NCT02783430|DRUG|Milnacipran|One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
41480695|NCT02783430|DRUG|Placebo|One single perfusion during 40 minutes at the beginning of the inclusion
41480696|NCT05057026|OTHER|Training Program Adult Mental Health Practice Support Program|"The Adult Mental Health Practice Support Program (PSP) was designed in 2009 by the General Practice Services Committee (GPSC) to address needs expressed by the province's family physicians to improve patient care in British Colombia. Its content and delivery model has been designed using evidence-based key ingredients and implication factors understood to be important for effective stigma reduction. These include the following:~* the use of contact-based education,~* skills-building to increase confidence and provide another management option with or without drugs particularly if access to mental health support services is difficult or absent~* tools - using the principles of cognitive behavioural theory~The training will be delivered virtually over a total of 4 sessions two weeks apart, covering an 8-week period. A two hour virtually delivered booster session will be provided to students approximately one year after the delivery of the initial training."
41480697|NCT05102136|DRUG|REGN9933|Administered intravenously (IV) or subcutaneous (SC) per the protocol
41480698|NCT05102136|DRUG|Placebo|Placebo to match REGN9933 in same form; placebo administered IV or SC per the protocol
41480699|NCT06422338|OTHER|IMCI-enhanced by sTREM-1 levels (SoC + sTREM-1 POC)|IMCI-guidelines (standard of care) + Point-Of-Care Rapid Triage Test (POC-RTT) based on sTREM-1 quantification
41480700|NCT04943159|DRUG|Afamelanotide|Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.
41480701|NCT03257150|PROCEDURE|Irreversible Electroporation|Irreversible electroporation (IRE) is a process that uses the NanoKnife system to sent electrical currents to a cancer tumor which will disrupt the tumor cell and therefore causing the cell to die. Eligible patients will undergo in situ IRE performed via laparotomy surgery.
41480702|NCT03257150|DEVICE|NanoKnife System|A system consisting of electrode probes connected to a machine. The probes will be surgically placed around the tumor.
41480703|NCT06374966|DRUG|Zonisamide|This is a real-world study，so we prospectively enrolled patients with focal epilepsy suitable for taking zonisamide as an add-on medication
41480704|NCT01969474|DRUG|Cannabis|Cannabis capsules given once daily for a month
41480705|NCT01969474|DRUG|Placebo|Placebo
41480706|NCT01834781|DEVICE|Pulsed electromagnetic fields|
41480707|NCT01834781|DEVICE|w/o pulsed electromagnetic fields|
41327962|NCT01098825|OTHER|web-based survey|Anonymous web-based survey
41327963|NCT02596685|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
41327964|NCT02596685|OTHER|Electronic Cigarette|Given nicotine-free and flavor-free electronic cigarettes
41327965|NCT02596685|OTHER|Laboratory Biomarker Analysis|Correlative studies
41327966|NCT02596685|OTHER|Questionnaire Administration|Ancillary studies
41327967|NCT01141127|DRUG|Tranexamic Acid|Comparison of two dosage regimen of Tranexamic Acid
41327968|NCT00562016|DEVICE|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
41327969|NCT00562016|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
41480708|NCT04688580|DRUG|XW10172|Various formulations
41480709|NCT04691180|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given intravenously
41480710|NCT04691180|DRUG|Placebo|Placebo given intravenously
41480711|NCT05783648|DRUG|Use of tranexamic acid|Percentage of correct use according to POISE-3 criteria of tranexamic acid
41480712|NCT05132569|DRUG|Tolebrutininb|Pharmaceutical form: Film-coated tablet Route of administration: Oral
41480713|NCT05132569|DRUG|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral
41480714|NCT03138902|DIETARY_SUPPLEMENT|TRUTOL Glucose Tolerance Beverage|A caffeine-free, non-carbonated, glucose tolerance beverage
41480715|NCT03186703|BEHAVIORAL|Tailored knowledge translation|Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
41480716|NCT01606852|DRUG|Dexmedetomidine|loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
41480717|NCT06132633|DEVICE|Neospot vitals measurement|Vitals of participants in the intervention group will be measured using neospot alongside standard of care measurement.
41480718|NCT00371306|DRUG|Insulin versus glucovance (glyburide/metformin)|
41480719|NCT00542763|DRUG|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
41480720|NCT05228496|DRUG|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
41327970|NCT04291924|DIAGNOSTIC_TEST|Dynamometry|A test for maximal muscle strength and explosive power in the lower limbs
41327971|NCT06055127|PROCEDURE|osseodensifiction internal sinus lift / sticky bone graft material|"The osteotomy for the osseodensification internal sinus lift begins with a twist drill advanced at 800 rpm with saline irrigation to within 1-2 mm from the sinus floor. Next, a series of osteotomy drills are used in the same fashion at 800 rpm to widen the osteotomy. The final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation occurs haptic feedback at this point infracture of the sinus has taken place. After infracture, injection of the graft material into the osteotomy site will occur. The final osteotomy drill is used to guide the graft apically. This process is repeated in an incremental fashion to lift the membrane. Once enough space has been created below the antral membrane, implant insertion will occur then suturing."
41327972|NCT06055127|PROCEDURE|piezoelectric internal sinus lift / sticky bone graft material|"In the PISE technique, an ultrasonic piezoelectric device (acteon), to which a specialized tip is attached, is used to break the sinus floor. Developed for sinus lift by the crestal approach, the Intralift™ Kit makes it possible to undertake dental non invasive surgery in full safety.~The diamond-coated tips, of increasing diameters (from 1.35mm to 2.80mm), are designed to drill and gradually widen the access canal to the sinus membrane. The sterile spray cools the tips down to avoid any rise in temperature, which could lead to oral tissue damage.The membrane elevation is achieved using the TKW5 by means of microcavitation. Thanks to the ultrasonic frequency modulation, the risk of membrane damage is limited. Moreover, the cavitation effect enables excellent visibility of the operating field."
40810019|NCT06661382|BIOLOGICAL|Infiltrative treatment with CB-PRP|Injection of CB-PRP or placebo into the vulvar site. Three treatments are planned four weeks apart. Three and six months after the last treatment with CB-PRP/ placebo each participant will be re-evaluated by vulvoscopy and biopsy, and will be given validated questionnaires to assess satisfaction, symptoms, and quality of life, psychological state, and sexual function.
41010876|NCT04177108|DRUG|Placebo for Ipatasertib|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
41010877|NCT04535128|OTHER|No intervention|No intervention
41327973|NCT00091026|BIOLOGICAL|cetuximab|Given IV
41480721|NCT05228496|DRUG|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 1 cycle of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
41010878|NCT01291927|PROCEDURE|Pancreas-sparing duodenectomy|Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
41010879|NCT01291927|PROCEDURE|Pancreaticoduodenectomy|The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
41010880|NCT03380039|GENETIC|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
41010881|NCT03380039|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
41010882|NCT03380039|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
41010883|NCT02488785|BEHAVIORAL|Virtual Diabetes Self-Care and Education Program|Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
41010884|NCT02488785|DEVICE|Fitbit|Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.
41327974|NCT00091026|DRUG|gemcitabine hydrochloride|Given IV
41327975|NCT00091026|BIOLOGICAL|bevacizumab|Given IV
41327976|NCT00091026|DRUG|erlotinib hydrochloride|Given orally
41327977|NCT03958539|DEVICE|3D printed insoles for normal footware|"Imprints are low-cost, bespoke, 3D-printed orthotics designed to prevent diabetic foot ulceration by redistributing and lowering peak foot pressures. This is achieved by using different density zones designed specifically for the patient. The patient's foot shape and pressure zone are capture by a 3D imaging system. Once scanned the software automatically identifies the peak pressure zones, matches these with the correct material and stiffness (densities), fits the insole arch to the patient and generates the insole.~The imprints insole is divided into four pressure zones: heel, midfoot, metatarsal head region and toes. These zones are printed with different stiffness to account for the difference in loading between them. The design of the pressure zones is automatically matched to the shape of each individual foot with the help of the 3D scan."
41327978|NCT00326417|DRUG|Fludarabine|Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)
41327979|NCT00326417|DRUG|Cyclophosphamide 150mg|A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
41327980|NCT00326417|DRUG|Cyclophosphamide 100mg|A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
41327981|NCT00326417|DRUG|Cyclophosphamide 50mg|A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
41480722|NCT02740829|DRUG|Intranasal glucagon|Glucagon will be administered via a nasal dispenser
41480723|NCT02740829|DRUG|Intranasal placebo|Placebo
41480724|NCT00615654|OTHER|aquatic physical therapy|The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
41327982|NCT00376246|DRUG|Ezetimibe|
41154911|NCT06063564|BEHAVIORAL|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool.
41327983|NCT03083275|OTHER|Resistance Training|
41327984|NCT02915068|BEHAVIORAL|EHR-Physician Asthma Care Education Program|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
41154912|NCT00961597|PROCEDURE|Meniscus repair for red/white tears without PRP|Same operation as experimental, only without the use of platelet rich plasma.
41327985|NCT03618602|DRUG|Bisthianostat|Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
41327986|NCT02533193|PROCEDURE|ERAS perioperative cares|"1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)~7. Intravenous patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. No nasogastric tube~10. No drain insertion~11. Patients will be discharged at POD#4 if there's no problem"
41327987|NCT02533193|PROCEDURE|Conventional perioperative cares|"1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Drainage tube insertion if needed"
41480725|NCT04019184|DRUG|L-Alanyl/L-Glutamine|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
41480726|NCT04019184|DRUG|Placebo|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
40810020|NCT06661720|BIOLOGICAL|Pembrolizumab|Given intravenously
40810021|NCT06661720|DRUG|Tivozanib|Given orally
40810022|NCT06661720|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40810023|NCT06661720|PROCEDURE|MRI|Undergo MRI
40810024|NCT06661720|PROCEDURE|Computed Tomography|Undergo CT scan
40810025|NCT06661720|PROCEDURE|Biopsy|Undergo biopsy
40810026|NCT06661720|OTHER|Questionnaire Administration|Ancillary studies
41154913|NCT00961597|PROCEDURE|Meniscus repair with PRP|Meniscus repair with platelet rich plasma using vertical divergent suture techniques.
41154914|NCT01816100|OTHER|specifically design 6 month resistance training program|Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
41327988|NCT04117399|OTHER|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
41327989|NCT05355935|DRUG|Brensocatib|Oral tablet.
41327990|NCT05355935|DRUG|Moxifloxacin|Oral tablet.
41154915|NCT01816100|BEHAVIORAL|6 months weight resistance and balance program|3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
41154916|NCT03553459|DIAGNOSTIC_TEST|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine, or flat on the back with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
41154917|NCT04204707|OTHER|PROMS|Patient Reported Outcomes after different types of surgery for rectal endometriosis
41154918|NCT02494076|DRUG|EzPAP|
41154919|NCT02494076|OTHER|Standard Care|
41327991|NCT05355935|DRUG|Placebo|Oral tablet.
41327992|NCT04125173|OTHER|Pneumoperitoneum pressure = 15mmHg|Randomized pneumoperitoneum 1
41327993|NCT04125173|OTHER|Pneumoperitoneum pressure = 12mm Hg|Randomized pneumoperitoneum 2
41327994|NCT04125173|OTHER|Pneumoperitoneum pressure = 10mmHg|Randomized pneumoperitoneum 3
41327995|NCT04809272|BEHAVIORAL|ParentChat for parents of children ages 2-17|The programme will include text/audio messages, illustrated comics, videos, and activity assignments for parents to do with their children. Parents will be prompted to give feedback regarding successes and challenges applying these parenting skills via audio or text messages during the week.
41327996|NCT05736978|DRUG|Azacitidine|75mg/m2 d1-7
41327997|NCT05736978|DRUG|Venetoclax|d1 100mg, d2 200mg, d3-28 400mg
41327998|NCT05736978|DRUG|Selinexor|if MRD positive in C1D14, selinexor 60mg D15, D22
41327999|NCT03661892|DRUG|Syndros|"As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study"
41328000|NCT02157246|OTHER|Pimonidazole|
41328001|NCT02157246|OTHER|F-MISO PET|
41328002|NCT02157246|OTHER|pCT|
41328003|NCT02157246|OTHER|Functional MRI|
41480727|NCT04325152|DEVICE|FCSEMS plus Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
41480728|NCT04325152|DEVICE|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
41480729|NCT02701231|DEVICE|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
40810027|NCT06657820|PROCEDURE|Hypoxia in healthy individuals|"The subject will undergo a graduated desaturation procedure. Arterial saturation targets are as follows:~1. 100%~2. 99%~3. 96%~4. 93%~5. 90%~6. 87%~7. 84%~8. 81%~9. 78%~10. 75%~11. 72%~12. 69%~13. 99%"
41328004|NCT02157246|PROCEDURE|Biopsy|
40810028|NCT06657820|DEVICE|Cerebral Oximetry|Each subject will be continuously monitored with the cerebral oximetry device throughout the desaturation procedure.
40810029|NCT06657820|DIAGNOSTIC_TEST|Blood Gas Sampling|At each arterial saturation plateau venous and arterial blood gas measurements will be taken from the jugular bulb, and the radial artery respectively.
41154920|NCT03418701|BEHAVIORAL|Health Smart for Weight Loss|We will test the effectiveness of a culturally sensitive, evidence-based, multi-component, behavioral program for treating obesity called Health-Smart. This program will be implemented for 6 months in 20 UF Health Jacksonville primary care clinics by Community Health Workers (CHWs) with Black women patients who have obesity, and followed by either of two physician-implemented behavioral counseling weight loss maintenance programs that are applied quarterly over 12 months to prevent weight gain. Specifically, we will compare the effects on weight-loss and weight-loss maintenance of (1) Health-Smart plus the Patient-Centered, Culturally Sensitive Weight Loss Maintenance Program (PCS-WLM), and (2) Health-Smart plus the Standard Behavioral Weight Loss Maintenance Program (SB-WLM).
41154921|NCT01224509|DRUG|Mifepristone|Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
40810032|NCT06659120|DRUG|Fremanezumab|Initiation of anti-CGRP mAb (fremanezumab) treatment according to the Summary of Product Characteristics (SmPC) during clinical routine as a treatment of their physician (no study-specific intervention). This means that patients have to fulfil criteria for treatment with anti-CGRP mAbs in Switzerland, i.e. they have at least 8 days of migraine per month in the last three months.
41154922|NCT01224509|OTHER|Non-treatment|Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
41154923|NCT02150109|DEVICE|Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH and WITHOUT diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
41328005|NCT02157246|PROCEDURE|Blood sample|
41328006|NCT01754077|BEHAVIORAL|LENA Linguistic Feedback Reports|LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
41328007|NCT01754077|BEHAVIORAL|Home Visiting Educational Session|A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
40810038|NCT06661174|PROCEDURE|Bariatric surgery|Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function
40810039|NCT06661174|OTHER|Non-surgical therapy|Diet management，exercise，metformin，GLP-1 receptor agonists and other drugs which can lose weight.
40810040|NCT06659965|DRUG|Intravenous Methocarbamol|At least 500 mg of intravenous methocarbamol administered within 2 hours after the end of elective spine surgery for acute postoperative pain management
40810043|NCT06661265|PROCEDURE|adjuvant tomotherapy +- chemotherapy after the reconstructive surgery with flaps|adjuvant treatment in locally-advanced head and neck cancers submitted to upfront surgery with flap reconstruction, evaluation of toxicity and flap status performed at San Raffaele Hospital between December 2017-December 2022.
41010885|NCT02488785|DEVICE|Smartphone|All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
41010886|NCT04269759|OTHER|Survey|pregnant women will answer to a survey regarding their oral health knowledge, attitudes and practices for themselves and their unborn child
41010887|NCT04269759|OTHER|dental care|pregnant women will have a dental care
41010888|NCT03612167|BEHAVIORAL|cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
41328008|NCT01754077|BEHAVIORAL|Childhood Nutrition Education|The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
41328009|NCT04183946|BEHAVIORAL|Online Cognitive Behavioural Therapy|"The Willkommen Mutterglück program is an 8-session, interactive web-based CBT intervention for prenatal and postpartum depression and anxiety. The sessions are administered online via audio and video images. Each weekly session has a duration of 40-50 minutes during which the participants are asked to actively participate through exercises and quizzes.~A SCID interview for screening will be conducted by a trained clinical psychologist and an experienced psychiatrist from our outpatient clinic will verify the diagnosis. Screened and consented participants will answer baseline questionnaires, provide sociodemographic information and receive a private login to access the program. After completing the 2nd, 4th and 8th intervention session participants will fill in psychological questionnaires.~During the intervention, participants will be contacted three times by telephone by coaches (psychotherapists in training) who follow a manualized script."
41328010|NCT05090683|BEHAVIORAL|Mind-body mobile application|Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.
41480730|NCT02701231|DRUG|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
41480731|NCT02701231|DEVICE|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
41480732|NCT04764955|DIETARY_SUPPLEMENT|Placebo|This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.
41480733|NCT04764955|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.
41480734|NCT02451098|DRUG|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
41480735|NCT02451098|DRUG|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
41480736|NCT02451098|DRUG|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
41010889|NCT03612167|BEHAVIORAL|nutritional group|12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
41010890|NCT01132521|DRUG|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
41480737|NCT02451098|DRUG|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
41010891|NCT01132521|DRUG|placebo|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
41328011|NCT03318601|PROCEDURE|Blood taking|"Blood taking in 2 times :~* J0 : 15 mL~* J14 : 5 mL 20 mL in total volume"
41328012|NCT04307173|DRUG|KBL693|"Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
41328013|NCT04307173|DRUG|KBL693|"Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
41328014|NCT02644837|DEVICE|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
41328015|NCT02644837|DEVICE|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
41328016|NCT02644837|DEVICE|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
41480738|NCT02451098|DRUG|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
41480739|NCT02451098|DRUG|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
41480740|NCT01633502|DEVICE|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
41480741|NCT01633502|DEVICE|Impella CP|Control group treated with Impella CP for a minimum of 48 hrs.
41480742|NCT04407078|DRUG|Sugammadex Injectable Product|Sugammadex of 2 mg/kg is injected.
41480743|NCT04407078|DRUG|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
41480744|NCT03024047|DEVICE|Pacemaker|
41010892|NCT00073905|DRUG|capecitabine plus gemcitabine|capecitabine plus gemcitabine
41010893|NCT03819231|DRUG|Oxytocin|A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.
41010894|NCT03819231|BEHAVIORAL|Mindfulness|Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
41480745|NCT03865537|PROCEDURE|Cold snare EMR|Participants will have their large polyp removed without electrocautery
41328017|NCT02644837|DEVICE|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
41328018|NCT02644837|DEVICE|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
41480746|NCT03865537|PROCEDURE|Hot snare EMR|Participants will have their large polyp removed with electrocautery
41328019|NCT02644837|DEVICE|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
41328020|NCT02644837|DEVICE|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
40810044|NCT06659666|DEVICE|COPD Optimiser|Patients will receive enhanced usual medical care as determined by their physician. The study visit is a standard consultation supported by the COPD Optimiser webtool. The extra elements added to the COPD consultation are the use of the COPD Optimiser and a short questionnaire directly following the consultation on the patient's experience with the COPD Optimiser. Patients can additionally consent to two optional elements: 1) a determination of blood eosinophil count using a point of care test and 2) a brief interview on their experience with the COPD Optimiser. this tool creates an overview of fac- tors and characteristics that may be associated with suboptimal COPD and provides GOLD guideline-based management suggestions. Implementation of the COPD Optimiser will sup- port healthcare professionals in providing optimal care for their COPD patients by providing individualized GOLD-guided management suggestions.
40810045|NCT06658626|DRUG|[¹⁴C]Enlicitide chloride|IV Injection
41010895|NCT03819231|DRUG|Saline Solution|A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
41010896|NCT03819231|BEHAVIORAL|Sham mindfulness|The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.
41010897|NCT05225961|DRUG|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.
41328021|NCT02644837|DEVICE|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
41328022|NCT04965168|PROCEDURE|phacoemulsification of the lens|all patients underwent phacoemulsification and IOL implantation for immature cataract extraction
41328023|NCT05113498|DIETARY_SUPPLEMENT|(-)-Epicatechin|Administration of a capsule with 150 mg of pure (-)-epicatechin after 48h low-flavanol diet.
41328024|NCT03015025|GENETIC|Acenocoumarol|A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
41154924|NCT02150109|DEVICE|Subjects WITH Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH diabetes use the Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
41328025|NCT02205918|OTHER|Active TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS."
41328026|NCT02205918|OTHER|Sham TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS."
41328027|NCT00755872|DRUG|Risedronate|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
41328028|NCT00755872|DRUG|Risedronate|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
41328029|NCT00755872|DRUG|Risedronate|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
41480747|NCT03865537|PROCEDURE|Eleview injection|Participants will have their polyp submucosally injected with Eleview
41480748|NCT03865537|PROCEDURE|Placebo injection|Participants will have their polyp submucosally injected with placebo
41154925|NCT00059735|DRUG|E7070|
41154926|NCT05068687|DIAGNOSTIC_TEST|high-resolution PET-CT specimen imaging.|"Included patients are given a single weight-dependent activity of 18F-FDG at the department of Nuclear Medicine. After administration, patients are brought to the operating room where standard of care surgical removal of the malignancy is performed.~The resected specimen(s) are brought to the imaging lab and scanned using a preclinical and/or a dedicated specimen PET/CT device. Following PET/CT imaging, the specimen is brought to the department of pathology, where it is sliced. Some of these slices are then rescanned using the preclinical PET/CT device. Moreover, frozen sections are made from one of these slices with macroscopically visible malignant tissue and placed on an autoradiograph overnight. Finally, the imaging results are then correlated to the results found during histopathological analysis of the specimens."
41328030|NCT00755872|DRUG|Risedronate|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
41010898|NCT05225961|DRUG|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
40810048|NCT06659848|OTHER|high intensity interval training|The subjects in the four groups performed 12 weeks of supervised HIIE program on a motorized treadmill (h/p/cosmos, Pulsar 4.0, Nussdorf-Traunstein, Germany) with a rate of three sessions weekly. The session commenced with a 5 min warming-up and concluded with a 5 min cooling down period. The exercise effort component consisted of 5 intervals of HIIT. Each interval continues for four min of HIIT with exercise intensity ranging from 75% to 90% of the peak heart rate. Each active recovery period between exercise intervals included moderate exercise at intensity of 50% to 60% of the peak heart rate. Every 3 weeks, the exercise intensity was increased by 5% starting with 75% of the HRmax in the first 3 weeks, 80% in the following 3 weeks and progressed to 90% the HRmax in the last 3 weeks. The subject's heart rate throughout the HIIT session was monitored using a polar heart rate monitor (Polar, Kempele, Finland).
40810049|NCT06661148|DRUG|EPI-003|Intravenous (IV) infusion.
41328031|NCT02814695|DIETARY_SUPPLEMENT|Vit E|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
41328032|NCT02814695|DIETARY_SUPPLEMENT|Yeast|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) yeast extraction and incubated at 37o C for 30 minutes.
40810052|NCT06661330|OTHER|Behavioral Treatment|Participants followed a 6-month hypocaloric Mediterranean-style diet, reducing energy intake by approximately 600 kcal/day. The diet emphasized fruits, vegetables, whole grains, and fish, while limiting red meat and processed foods. Additionally, participants were required to perform moderate physical activity, including 50 minutes of aerobic exercise, 3 times a wee
41328033|NCT02814695|DIETARY_SUPPLEMENT|Vit C 1|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
41328034|NCT02814695|DIETARY_SUPPLEMENT|Vit C 2|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.04 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
41328035|NCT02814695|DIETARY_SUPPLEMENT|Vit C 3|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.06 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
40810055|NCT06661525|DEVICE|Free Flap NIRS|Monitoring of tissue oxygenation after Free Tissue Transfer (FTT) surgeries.
40810056|NCT06660225|DEVICE|Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation]|Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Sham Stimulation=DBS OFF
40810057|NCT06660225|DEVICE|Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]|Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Therapeutic Stimulation= DBS ON
41010899|NCT01178970|BEHAVIORAL|Resistance training|
41010900|NCT06038838|DEVICE|Tioga TMVR System|A bioprosthetic mitral valve, as part of the Tioga TMVR System, is implanted percutaneously in a patient with MR via transfemoral-transseptal access.
41010901|NCT00325806|DRUG|Ramipril|
41010902|NCT00443183|BEHAVIORAL|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
41010903|NCT00443183|BEHAVIORAL|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
40810058|NCT06658522|DRUG|Sotatercept|Participants will receive open label subcutaneous sotatercept (starting dose, 0.3 mg per kilogram of body weight; target dose, 0.7 mg per kilogram) for 24 weeks
41154927|NCT00789399|DRUG|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
41154928|NCT00789399|OTHER|Placebo|subcutaneous equivolume isotonic saline
41010904|NCT03151356|DEVICE|Measurement of Prostate Health Index (PHI)|Use of a diagnostic tool to predict prostate biopsy outcome: measurement of total and free PSA as well as the \[-2\]proPSA and calculation of The Prostate Health Index according to the following formula: Prostate Health Index (PHI) = \[p2PSA /fPSA\] x √tPSA
41010905|NCT05576116|PROCEDURE|Sleeve Gastrectomy AND Pancreas after Kidney Transplantation (Staggered Approach)|"Participants will undergo sleeve gastrectomy a minimum of 3 months prior to Pancreas Transplant. SG will be performed using the standard technique.~Pancreas transplant will be performed as per standard procedure."
41010906|NCT05576116|PROCEDURE|Combined Sleeve Gastrectomy and Pancreas transplantation|Simultaneous SG and pancreas transplantation
41010907|NCT00373516|DRUG|Vehicle (Placebo) applied BID|
41010908|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied QD|
41010909|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied BID|
41010910|NCT02896400|BEHAVIORAL|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
41010911|NCT02896400|DRUG|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
41010912|NCT02896400|OTHER|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
41010913|NCT02896400|OTHER|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
41328036|NCT04391972|DEVICE|SAV|SAV multifocal intraocular lens is a implantable IOL which offers multifocal vision.
41154929|NCT02916745|DRUG|Porfimer sodium|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
41154930|NCT02916745|DEVICE|Fiber optic|A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
40810063|NCT06661486|BEHAVIORAL|Uniformed intervention group|The investigators provide lifestyle intervention through a health education programme which is in a group setting. The sessions consisted of short talks on a health-related topic targeting lifestyle factors associated with dementia risk, followed by group activities that required interactions, cognitive engagement, and the acquisition of certain skills (for example, how to read food labels, how to measure blood pressure, how to recognize signs of depression, et al).
40810064|NCT06661486|BEHAVIORAL|Individualised intervention group|On top of the uniformed intervention group, the individualised intervention group receives also 1:1 sessions every 3 months within 2 years. Participants will review the knowledge taught in the group sessions individually and the investigator will address the participant's concerns and provide advice to the participant for a better lifestyle accordingly.
41154931|NCT03829072|OTHER|Cooking Education|cooking Education and adapted physical activity on patients after allo stem cell transplantation
40810066|NCT06661863|PROCEDURE|alveolar ridge preservation with bioactive glass|Bioactive glass grafted into alveolar preservation.
41010914|NCT02636972|DRUG|OCPs|"Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra"
41010915|NCT01443442|DRUG|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
41010916|NCT01443442|DRUG|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
41010917|NCT02526992|DEVICE|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
41010918|NCT04688164|DRUG|REL-1017|REL-1017 tablet
41010919|NCT04688164|DRUG|Placebo|Placebo tablet
41010920|NCT03373175|DEVICE|Basal record|Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.
41010921|NCT03373175|DEVICE|PS 10 record|PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
41010922|NCT03373175|DEVICE|PS 15 record|PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
41010923|NCT03373175|DEVICE|PS 20 record|PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
41154932|NCT03829072|OTHER|adapted physical activity|cooking Education and adapted physical activity on patients after allo stem cell transplantation
41154933|NCT05001815|DEVICE|Continuous subcutaneous insulin infusion (CSII)|The CSII device used in this study has access to mobile phone, however, without CGM enhanced function
41328037|NCT01535612|DEVICE|PaQ™ insulin infusion device|Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
41328038|NCT03043209|GENETIC|Genomic sequencing|Genomic sequencing of DNA in Blood sample and myectomy tissue
41328039|NCT00858936|DRUG|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
41328040|NCT00858936|DRUG|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
41328041|NCT03012282|DIAGNOSTIC_TEST|Computed Tomography Perfusion Imaging|Undergo CT perfusion sequence
41328042|NCT01444898|DRUG|Exenatide|The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
41328043|NCT05995925|OTHER|Clinical Observation|Clinical Observation
41328044|NCT03954977|DIAGNOSTIC_TEST|PICC line ultrasound|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
41328045|NCT05632848|DRUG|Chidamide combined with Zimberelimab|Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.
41328046|NCT01313481|BEHAVIORAL|Group exercise|Otago exercise performed in groups of 4-8 patients, 2 times a week over 12 weeks
41328047|NCT01313481|BEHAVIORAL|Home exercise|Otago exercise performed as home exercise 3 times a weeks over 12 weeks. Individually tailored physical balance and muscle strength exercise
41328048|NCT00278941|DRUG|Quetiapine Fumarate Sustained Release|
41480749|NCT04619082|DRUG|Tenofovir alafenamide|Tenofovir alafenamide 25 mg once per day for one year
40810067|NCT06661863|PROCEDURE|alveolar ridge preservation with autologous bone|Autologous bone graft in alveolar ridge preservation.
40810068|NCT06658535|DRUG|dodecafluoropentane (0.025 mL/kg)|dodecafluoropentane (0.025 mL/kg)
40810069|NCT06658535|DRUG|dodecafluoropentane (0.032 mL/kg)|dodecafluoropentane (0.032 mL/kg)
40810070|NCT06658535|DRUG|dodecafluoropentane (0.050 mL/kg)|dodecafluoropentane (0.050 mL/kg)
41154934|NCT05001815|DEVICE|Multiple daily insulin injection (MDI)|Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.
40810072|NCT06661135|PROCEDURE|TLPD total laparoscopic pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the laparoscopy
40810073|NCT06661135|PROCEDURE|OPD open pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the open technique
41154935|NCT00003755|DRUG|MKC-1|
41154936|NCT06016725|OTHER|Exercise Intervention|Participate in online resistance training sessions
41328049|NCT02481596|BEHAVIORAL|REACH + FAMS|The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.
41154937|NCT06016725|OTHER|Informational Intervention|Given educational materials
41328050|NCT02481596|BEHAVIORAL|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).
41328051|NCT02481596|BEHAVIORAL|Helpline & A1c results|Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
41480750|NCT03693534|DIAGNOSTIC_TEST|Clinical Pregnancy Rate|The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS
41480751|NCT01421121|BIOLOGICAL|100U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
41480752|NCT01421121|BIOLOGICAL|200 U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
40810074|NCT06659458|OTHER|blood draw|A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.
41154938|NCT06016725|OTHER|Nutritional Assessment|Participate in online nutritional counseling
41480753|NCT01421121|BIOLOGICAL|400U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
40810075|NCT06659458|OTHER|Gene sequencing|Subjects will have their DNA sequenced within and around the EGFR gene.
41154939|NCT06016725|OTHER|Physical Performance Testing|Ancillary studies
40810077|NCT06659796|DEVICE|LifeVac|Removal of airway obstruction during choking emergency
40810078|NCT06662396|DRUG|MK-6552|Oral Gelatin Coated Capsule
40810079|NCT06662396|DRUG|Diltiazem|Oral Extended-Release Capsule
41154940|NCT06016725|OTHER|Quality-of-Life Assessment|Ancillary studies
41154941|NCT06016725|OTHER|Questionnaire Administration|Ancillary studies
41154942|NCT05456113|BIOLOGICAL|Cannabidiol|Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
41154943|NCT04946071|BEHAVIORAL|Arts-based HIV stigma intervention|The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.
41154944|NCT01914302|DEVICE|Delica Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
41154945|NCT01914302|DEVICE|Flash Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
41154946|NCT01914302|DEVICE|Easy Touch Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
41154947|NCT01914302|DEVICE|Glucoject Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
41480754|NCT01421121|BIOLOGICAL|200U EV71 vaccine without adjuvant|inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
41480755|NCT01421121|BIOLOGICAL|Placebo|0.5ml placebo, two doses, 28 days interval
41480756|NCT05990582|DIAGNOSTIC_TEST|CBCL|A questionnaire on behaviour
41480757|NCT05990582|DIAGNOSTIC_TEST|SDQ|A questionnaire on behaviour
41480758|NCT05990582|DIAGNOSTIC_TEST|CCC-2-NL|A questionnaire on communcational skills
41154948|NCT01914302|DEVICE|Microlet Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
40810082|NCT06661824|BEHAVIORAL|Aggression management care bundle|The aggression management care bundle consists of six components. All of these are high-evidence level interventions consisting of behavioral and nursing interventions aimed at managing aggression. These six interventions are: Risk Assessment, Cognitive Remediation Training, Social Skills Training, De-Escalation Techniques, Milieu Therapy, Improving Sleep.
41480759|NCT05990582|DIAGNOSTIC_TEST|MCH Feeding scale|A questionnaire on feeding problems
40810083|NCT06657924|DRUG|Tranexamic acid|1 gram IV bolus in 100ml of normal saline administered over 10 minutes at the start and end of the surgery for a total of 2 grams TXA
40810084|NCT06660524|DRUG|Sevelamer|Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
40810085|NCT06660524|DRUG|Calcium carbonate|Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
41480760|NCT05990582|DIAGNOSTIC_TEST|TRF|A questionnaire on behaviour
41154949|NCT01914302|DEVICE|Multiclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
41154950|NCT01914302|DEVICE|Fastclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
40810088|NCT06658717|DIETARY_SUPPLEMENT|Investigational product (IP): Natural orange extract|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
41328052|NCT00738829|DRUG|Lenalidomide|"Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.~During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage."
41480761|NCT05990582|DIAGNOSTIC_TEST|WISC-5-NL|An IQ test for children
40810089|NCT06658717|DIETARY_SUPPLEMENT|Group II: Placebo: Microcrystalline cellulose (MCC)|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
40810090|NCT06659341|DRUG|BAY3498264|Oral
41010924|NCT03814694|DIETARY_SUPPLEMENT|CRHP Diet|Dietary macronutrient composition of 30 E% from carbohydrate, 30 E% from protein and 40 E% from fat
41480762|NCT05990582|DIAGNOSTIC_TEST|Movement ABC|A test to assess motor function
41480763|NCT05990582|DIAGNOSTIC_TEST|CELF-5-NL|A test to assess language development
41010925|NCT03814694|DIETARY_SUPPLEMENT|CD Diet|Dietary macronutrient composition of 50 E% from carbohydrate, 17 E% from protein and 33 E% from fat
41010926|NCT05204134|DEVICE|Automated Insulin Delivery Settings Initialization and Adaptation Algorithm|All participants wearing the t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor, will have algorithm derived insulin delivery profile settings initialization and updates at regular intervals.
41010927|NCT02673775|OTHER|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
41480764|NCT05990582|DIAGNOSTIC_TEST|Emma Toolbox|Test of executive functions
41010928|NCT02673775|OTHER|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
41328053|NCT00738829|DRUG|Fludarabine|25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
41328054|NCT00738829|BIOLOGICAL|Rituximab|"Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.~Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage."
41328055|NCT03039738|DEVICE|Vital Sync IM & VPMP (Surveillance Monitoring)|The Vital Sync™ Informatics Manager (IM) \& Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
41328056|NCT03039738|DEVICE|Telemetry Monitoring|Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
41010929|NCT01814176|DEVICE|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
41010930|NCT00628550|DRUG|Vasopressin|One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
41154951|NCT01914302|DEVICE|Reli-On Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
41154952|NCT04623671|BIOLOGICAL|CAP-1002|100-mL (total volume) infusion of 150M CDCs in 5% Human Serum Albumin (HSA)
41154953|NCT04623671|BIOLOGICAL|Placebo|Matching placebo solution
41154954|NCT01651416|DRUG|Artemether-lumefantrine combination|
41154955|NCT01651416|DRUG|Dihydroartemisinin Piperaquine combination|
41154956|NCT01651416|DRUG|Amodiaquine plus sulphadoxine-pyrimethamine combination|
41154957|NCT06645470|OTHER|Standard Medical Care (SMC)|Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
41154958|NCT06645470|BEHAVIORAL|Monitoring Contacts|Participants will receive contacts with the research staff at weeks 6, 12, and 18.
41328057|NCT01068717|DRUG|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
41328058|NCT01068717|DRUG|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
41328059|NCT01068717|DRUG|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
41480765|NCT03881345|DRUG|Anticoagulants|anticoagulation according to the main diagnosis
41480766|NCT03881345|PROCEDURE|Open surgery|removal of blood clots with open surgery
41480767|NCT03881345|PROCEDURE|Thrombolysis|removal of blood clots with thrombolysis
41480768|NCT03881345|PROCEDURE|Venous stenting|elimination of vein obstruction by stenting
41480769|NCT02384850|DRUG|Selinexor|Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.
41480770|NCT02384850|DRUG|Oxaliplatin|85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle
41480771|NCT02384850|DRUG|5-FU|400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3
41480772|NCT02384850|DRUG|Folinic Acid|400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
41010931|NCT00628550|DRUG|Epinephrine|One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
41010932|NCT01852292|DRUG|Buparlisib|Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
41010933|NCT01852292|DRUG|Buparlisib matching Placebo|Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
41010934|NCT01852292|DRUG|Paclitaxel|Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
41010935|NCT05101564|DRUG|Alpelisib|Alpelisib 300 mg
41010936|NCT05101564|DRUG|Tamoxifen|Tamoxifen 20 mg
41328060|NCT01068717|DRUG|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
41328061|NCT04213508|DRUG|Isotonic Saline ( 0.9% Sodium Chloride Saline)|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
41328062|NCT04213508|DRUG|Hypertonic Saline ( 3% Sodium Chloride Saline)|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time). So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
41328063|NCT01511510|DRUG|PF-04958242|PF-04958242 0.05 mg oral solution Q24 hours for 14 days
41010937|NCT05101564|DRUG|Zotatifin|Zotatifin 0.10mg/kg (by weight)
41010938|NCT05101564|DRUG|Fulvestrant|Fulvestrant 500 mg
41480773|NCT01900496|BIOLOGICAL|Brentuximab vedotin|Day 1 every three weeks (weeks 0, 3, 6, 9, ... 27): 1.8 mg/kg IV. Ten doses maximum.
41480774|NCT01900496|BIOLOGICAL|Rituximab|Day 1 of weeks 12, 13, 14, 15, 18, 21, 24, and 27: 375 mg/m\^2 IV. Additional doses are given at three and six months post week 27.
41480775|NCT03898674|DRUG|Intra venous fluid|Volume of intra venous fluid administered during GDT protocol
41010939|NCT03860896|DRUG|GB004|GB0004 high dose
41010940|NCT03860896|DRUG|Placebo|Placebo
41480776|NCT03128684|OTHER|Small Green Lentil Muffin|Consumption of small green lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
41010941|NCT03860896|DRUG|GB004|GB004 low dose
41328064|NCT01511510|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
41010942|NCT03592641|DRUG|Savolitinib|Given PO
41010943|NCT02125539|BEHAVIORAL|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
41010944|NCT02125539|BEHAVIORAL|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
41328065|NCT01511510|DRUG|PF-04958242|PF-04958242 0.15 mg oral solution Q24 hours for 14 days
41328066|NCT01511510|DRUG|PF-04958242|PF-04958242 0.25 mg oral solution Q24 hours for 14 days
41010945|NCT05825482|PROCEDURE|Arm 1 Partial mastectomy with Savi Scout® localization and shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 1 randomization, the surgeons will be instructed to perform a partial mastectomy with routine cavity shave margins using Savi Scout® localization. The lesion will be removed in the routine fashion. The surgeons will use the Savi Scout® to perform routine cavity shave margins by extracting superior, lateral, inferior, medial, anterior, and posterior margins.
41010946|NCT05825482|PROCEDURE|Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 2 randomization, the surgeons will be instructed to perform a partial mastectomy with selective margins shave margins using Savi Scout®. The lesion will be removed in the routine fashion. The Savi Scout® localizer will be utilized to determine selective shave margins by examining the same margins on the excised tissue specimen. The surgeon will obtain selective margins if the margin of the tissue specimen is within 1mm of invasive cancer and 2mm within DCIS.
41010947|NCT04055636|DIAGNOSTIC_TEST|Echocardiography with speckle tracking analysis.|Transthoracic echocardiography with speckle tracking analysis.
41010948|NCT04055636|DIAGNOSTIC_TEST|48-hour ECG monitoring.|Ambulatory 48-hour electrocardiography monitoring.
41010949|NCT04055636|DIAGNOSTIC_TEST|Blood samples analysis.|Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
41010950|NCT01882127|DRUG|All-Trans Retinoid Acid(ATRA)|patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
41328067|NCT01511510|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
41328068|NCT03634917|DRUG|Acamprosate Calcium|1 capsule with 666 mg Acamprosate
41328069|NCT03634917|DRUG|Calcium Carbonate|1 capsule with 1500 mg Calcium Carbonate
41328070|NCT03634917|DRUG|Placebo|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
41328071|NCT03634917|DRUG|Placebo lead in|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
41328072|NCT02501902|DRUG|Palbociclib|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
41480777|NCT03128684|OTHER|Split Red Lentil Muffin|Consumption of split red lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
41480778|NCT03128684|OTHER|Wheat Muffin|Consumption of wheat muffin; consumption of ad libitum pizza test meal after 180 minutes
41480779|NCT03128684|OTHER|Small Green Lentil Chili|Consumption of small green lentil chili; consumption of ad libitum pizza test meal after 180 minutes
41480780|NCT03128684|OTHER|Split Red Lentil Chili|Consumption of split red lentil chili; consumption of ad libitum pizza test meal after 180 minutes
41010951|NCT01882127|DRUG|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
40810091|NCT06658041|BEHAVIORAL|Cognitive behavioural therapy (CBT)-based intervention with stepped-care|"After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]).~Mild symptoms (PHQ-9\<5) without major risks (\*see above): 4 weekly CBT-informed intervention sessions led by trained Emotional Support Assistants (Peer Supporters with 80hrs mental health training + 15hrs intensive clinical training).~Mild symptoms (PHQ-9\<5) with major risk factors or moderate-to-moderately severe symptoms (PHQ-9=10-19): 6 weekly CBT-based intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Individual CBT-based intervention will be provided to those unsuitable for group interventions.~In cases of non-remission (PHQ-9≥5): a second intervention trial will be provided. Those needing additional support will be referred to a partnered General Practitioner (if PHQ-9=10-19) or referred to more intensive psychological or psychiatric services as needed."
40810092|NCT06658041|OTHER|Care-as-usual|Following an initial interview session with research assessments, participants continue with their usual care at their primary care setting.
41154959|NCT06645470|BEHAVIORAL|Aerobic Training|Aerobic Training will be supervised exercise. It will occur on 3 days per week and will progress to 50 minutes per session (150 minutes per week). The intensity of the exercise will progress from 60%±5% to 70%±5% of age-predicted maximal heart rate (if taking beta-blocker medication intensity will progress from a Rating of Perceived Exertion of 11-13 to 12-14 based on the 6-20 Borg scale). While walking will be the preferred mode of exercise, alternative forms of cardiovascular exercise (upright cycling, elliptical, etc.) are allowed to accommodate any physical limitations that may be present for a participant. Heart rate will be monitored throughout these exercise sessions.
41010952|NCT04251559|OTHER|oral glucose loading test|oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
41010953|NCT04224766|PROCEDURE|Suprascapular Nerve Block with 5ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.
41010954|NCT04224766|PROCEDURE|costoclavicular Block 10ml bupivicaine 0.5%|transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%
41010955|NCT04224766|PROCEDURE|Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
41010956|NCT05362318|DRUG|Nicotine patch and lozenges|Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke \>10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke \<10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
41010957|NCT05362318|BEHAVIORAL|Telephone counseling sessions|Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.
41010958|NCT05362318|BEHAVIORAL|Access to a web-based video|"Participants will be given web-based access to the relapse prevention video Surviving Smokefree."
41010959|NCT05362318|BEHAVIORAL|Florida Tobacco Quitline|Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
41010960|NCT06336967|BEHAVIORAL|GUIDE|The GUIDE App is a wellbeing app designed for first responders and veterans that uses small group support, a learning management system, drivers of behavior change, and an anonymous member experience safeguarded by a leader in identity and login privacy, Okta (okta.com). It includes three main features: 1) Community, 2) Wisdom, and 3) Daily Practice. The Community feature connects app users with an online community of like folks, allowing for human support, encouragement, accountability and coaching. Online communities are moderated by GUIDE employees. The Wisdom feature includes tools and interactive media for personal growth. The Daily Practice feature includes simple, daily routines to maintain mental and emotional wellness.
41010961|NCT03041259|DRUG|Rejuveinix Low Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
41010962|NCT03041259|DRUG|Rejuveinix High Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
41010963|NCT01121211|DRUG|Testosterone|Testosterone 300mcg transdermal patch x 24 weeks.
41010964|NCT01121211|DRUG|Placebo|Placebo transdermal patch x 24 weeks
41010965|NCT00572650|DRUG|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
41010966|NCT00002082|DRUG|Azithromycin|
41480781|NCT03128684|OTHER|Rice Chili|Consumption of rice chili; consumption of ad libitum pizza test meal after 180 minutes
41480782|NCT00109759|BIOLOGICAL|RagweedMATAMPL|
41480783|NCT00109759|DRUG|Placebo|
41480784|NCT00775606|DRUG|Lopinavir 400 mg/ritonavir 100 mg|Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
41480785|NCT00775606|DRUG|Efavirenz|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
41010967|NCT00466960|BIOLOGICAL|sargramostim|Given SC
41010968|NCT00466960|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
41010969|NCT00466960|OTHER|laboratory biomarker analysis|Correlative studies
41010970|NCT00466960|OTHER|immunologic technique|Correlative studies
40810100|NCT06658418|PROCEDURE|Erector Spinae Plane Block|dexmedetomidine combined with bupivacaine versus dexamethasone combined with bupivacaine for ultrasound-guided ESPB for postoperative pain control in patients scheduled for abdominal surgeries.
40810101|NCT06662318|DRUG|Fentanyl Citrate|Fentanyl was given as a bolus of 1 µg/kg injected followed by a fentanyl infusion of 0.4 µg/kg/h. Fentanyl infusion was continued as Postoperative analgesia for 24 hours in a dose of 0.3 µg/kg/h.
40810102|NCT06662318|DRUG|Dexmedetomidine|Dexmedetomidine was given as a loading dose of 0.6 µg/kg, which was diluted to a total volume of 10 cc of normal saline and injected before induction of anesthesia over 10 minutes. Then, a DXM infusion prepared to provide 0.2-0.7 µg/kg/h was started Intraoperative; Postoperative DXM infusion was provided in a dose of 0.15 µg/kg/h for 24-h.
40810103|NCT06662318|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride was provided as 2 mg/kg slowly IV before induction of anesthesia and as an IV infusion at a rate of 3 mg/kg/h. Postoprative lidocaine infusion at a dose of 1.5 mg/kg/h was administered for 24 Postoprative hours.
40810104|NCT06659718|DRUG|Oral semaglutide|New use of oral semaglutide dispensing claim is used as the exposure.
40810105|NCT06659718|DRUG|Sitagliptin|New initiation of sitagliptin dispensing claim is used as the reference.
41154960|NCT06645470|BEHAVIORAL|Resistance Training|Resistance Training will be supervised exercise. It will occur 3 days per week and includes 8 exercises performed in a prespecified order. Week 1-2 sessions focus on familiarization to acclimate the participant to the equipment, proper form, to establish initial weight (load) for training, and with performing multiple sets per day. For Weeks 3-8, participants will engage in 2 sets per exercise with the weight adjusted to elicit muscle fatigue in 8-12 repetitions per set. This progresses to 3 sets per exercise from Week 9 until the end of the intervention period. When 12 repetitions for a specific exercise can be achieved, the resistance will increase for that exercise at the next session. There is a 90 second rest period between each set of an exercise. Heart rate will be monitored throughout these exercise sessions.
40810107|NCT06662136|BEHAVIORAL|motivational interview|Participants in the experimental group will be given motivational interviews about HPV at 4 different times and will also be given an educational brochure.
40810108|NCT06662136|OTHER|Control|Participants in the control group will not receive any intervention.
40810109|NCT06660836|DEVICE|Mouthguard|After the participants' records are taken with intraoral scanners, custom mouthguards will be prepared from soft EVA sheets in a dental laboratory setting.
40810110|NCT06660836|OTHER|Performance test|Participants will undergo the Yo-Yo performance test both while using and not using mouthguards prepared with a digital workflow.
41154961|NCT06645470|OTHER|Nutrition Education|A single counseling session to discuss the dietary recommendations when taking an obesity medication.
41154962|NCT04566744|OTHER|fRMI|The measurements performed will be the participant's brain activity, as well as behavioral measurements associated with the tasks performed (response time, correctness of the response). Brain activity measurements will be performed on the Siemens 3T system of the MRI department of CERMEP. The subject will perform the task under study while the level of brain activity is recorded. The functional examination will be subdivided into several parts according to its total length in order to spare the subject. The total duration of MRI acquisitions will be approximately 1 hour regardless of the axis.
41154963|NCT01442623|OTHER|Vestibular Rehabilitation|"The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.~Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program."
41154964|NCT00582985|DRUG|TRC105 chimeric anti-CD105 antibody|TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
41010971|NCT05067140|DRUG|ARV-766 Part A&B|"Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part B: Oral tablet(s) once daily in 28 day cycles."
41010972|NCT05067140|DRUG|ARV-766 + Abiraterone Part C&D|"Part C: Daily oral combination dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part D: Combination administered once daily in 28 day cycles.~Parts C\&D: Participants will also receive concomitant corticosteroid and ADT therapy of investigator choice/patient preference"
41328073|NCT02501902|DRUG|Nab-Paclitaxel|Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
41010973|NCT00512096|DRUG|Ifosfamide|1200 mg/m\^2 By Vein Over 2 Hours on Days 1-3
41010974|NCT00512096|DRUG|Paclitaxel (Taxol)|175 mg/m\^2 By Vein Over 3 Hours on Day 1
41010975|NCT00512096|DRUG|Cisplatin|25 mg/m\^2 By Vein Over 2 Hours on Days 1-3
41010976|NCT05186467|DRUG|intraperitoneal Magnesium sulfate|Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
41480786|NCT03078452|DEVICE|Power drill|Undergo bone marrow biopsy using power drill
41480787|NCT03078452|DEVICE|Jamshidi needle|Undergo bone marrow biopsy using Jamshidi needle
41154965|NCT02056873|DEVICE|Continuous DBS|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~The DBS system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for DBS. At 6 months, the investigators will determine whether or not the subject is a candidate for responsive brain stimulation (RBS). Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. Subjects who do not qualify or do not participate will continue to receive this intervention for the duration of the study. These subjects will been seen every 6 months for evaluation as part of normal clinical care for DBS."
40810117|NCT06658899|DRUG|CRD-4730|Oral CRD-4730 in tablet form
40810118|NCT06658899|DRUG|Placebo|Placebo to match CRD-4730 in tablet form
41154966|NCT02056873|DEVICE|Responsive Brain Stimulation (RBS Setting)|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~Six months post-surgery, the DBS system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for DBS.~Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention."
41154967|NCT04719273|DRUG|Extended-release Onapristone|Given PO
41010977|NCT05186467|DRUG|intravenous magnesium sulfate|Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
41010978|NCT00565279|DRUG|ASF1057|Twice daily, topical
41010979|NCT00565279|DRUG|ASF1057|Twice daily, Topical
41154968|NCT04719273|DRUG|Anastrozole|Given PO
41010980|NCT04279834|BEHAVIORAL|PAP Treatment|Motivational enhancement plus remote-monitoring and participant self-monitoring of PAP use.
41010981|NCT04279834|BEHAVIORAL|Sleep Education I|Motivational enhancement plus participant self-monitoring of sleep.
40810122|NCT06659042|DRUG|Tislelizumab|administered via Intravenous (IV) injection
41010982|NCT04300296|DRUG|secukinumab 300 mg Q4W|secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.
41010983|NCT04300296|DRUG|secukinumab 300 mg Q2W|secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.
41010984|NCT04300296|OTHER|Placebo|Matching placebo administered via a pre-filled syringe
40810123|NCT06659042|DRUG|Cisplatin|administered via IV infusion
40810124|NCT06659042|DRUG|Carboplatin|administered via IV infusion
40810125|NCT06659042|DRUG|Pemetrexed Disodium|administered via IV infusion
41010985|NCT05574348|OTHER|Osteopathic Protocol in 2 Sessions (PO2S)|"PO2S works on the principle that there is a concordance between the author's Preferential Torsion Pattern (PTP) and the rotatory direction of osteopathic dysfunctions.~The PO2S consists of two sessions of 30 minutes each, one week apart. A 13-item clinical examination is performed at the first session. It focuses on caused pain tests, and classifies patients in left or right PTP. During the first session 14 normalizations of joint, muscular, ligament and visceral dysfunctions are performed systematically. During the second session 10 normalizations of joint, muscular, ligament and visceral dysfunctions are performed .~PO2S is an innovative osteopathic protocol for back pain."
41154969|NCT04719273|OTHER|Quality-of-Life Assessment|Ancillary studies
41154970|NCT04719273|OTHER|Questionnaire Administration|Ancillary studies
41154971|NCT04719273|DIAGNOSTIC_TEST|Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)|Immunohistochemistry (IHC):Integral : Tissue
41154972|NCT04719273|DIAGNOSTIC_TEST|Progesterone Receptor Positive ( PGR Positive; PR Positive)|Immunohistochemistry (IHC)
41154973|NCT06396923|DIAGNOSTIC_TEST|Wingate test|Wingate Anaerobic Power Test is based on maximal pedaling on a bicycle ergometer against a predetermined constant load to provide the highest mechanical power for 30 seconds. During the test, measurements are made automatically at intervals of five seconds and six equal intervals. As a result of these measurements, some data are obtained that allow us to obtain information about anaerobic performance.
40810128|NCT06660875|DRUG|Serratus posterior superior intercostal plane block|Serratus posterior superior intercostal plane block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
40810129|NCT06660875|DRUG|Interscalene brachial plexus block and superficial cervical plexus block|İnterscalene brachial plexus block and superficial cervical plexus block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
41154974|NCT01349699|DRUG|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
41154975|NCT01349699|DRUG|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
40810132|NCT06661200|DEVICE|SMC signal recording|SMC recording involves collecting vibrations from the thorax using an antenna equipped with piezoelectric crystals. Subjects face the machine or stand with their backs to the machine, shirtless. Acquisitions last around ten seconds.
41154976|NCT01349699|DRUG|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
40810136|NCT06658652|DRUG|Enlicitide decanoate|Oral tablet
41154977|NCT01349699|DRUG|Placebo|"At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol."
41154978|NCT05417971|OTHER|Fludarabine|Reduced-intensity fludarabine with intermediate-dose TBI
41154979|NCT00558220|PROCEDURE|immunotherapy|"Given together with induction chemotherapy:~Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses"
41154980|NCT00558220|PROCEDURE|Induction treatment part 1|"cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.~3 cycles consisting of combination treatment of above mentioned drugs are given."
41328074|NCT04016688|PROCEDURE|ESPB and TAP block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
41328075|NCT05153447|BEHAVIORAL|M-Tech|M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.
40810137|NCT06661252|DEVICE|ABEL microsampler device|The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
41328076|NCT05153447|OTHER|Usual Care|Participants randomized to the usual care arm will receive standard of care.
41154981|NCT00558220|PROCEDURE|Induction treatment part 2 with PBPC collection|"Starts three weeks after last cycle of Induction part 1.~Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.~Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are \>20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood."
41154982|NCT00558220|PROCEDURE|Induction treatment part 3|"Part 3 of induction treatment is given approximately one week after the end of Part 2.~Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart."
41328077|NCT05185284|DRUG|Favipiravir|400 mg, lyophilizate for preparation of concentrate for solution for infusion
40810141|NCT06660732|DRUG|Rilonacept|320 mg subcutaneous (SC) loading dose delivered as two 2-mL, subcutaneous injections of 160 mg on the same day at different anatomical sites followed by once weekly 160 mg SC doses.
40810142|NCT06662032|DEVICE|LumbaCure®|LumbaCure® is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
40810143|NCT06662032|OTHER|Rehab program|Standard rehabilitation program
40810144|NCT06659237|DIAGNOSTIC_TEST|16s rRNA or shotgun metagenomics|16s rRNA or shotgun metagenomics on oral and fecal samples
41328078|NCT05185284|DRUG|Favipiravir|200 mg coated tablets
41328079|NCT05185284|DRUG|Remdesivir|100 mg, lyophilizate for preparation of concentrate for solution for infusion
40810147|NCT06659809|BEHAVIORAL|Tele-care video-feedback intervention (TVFI)|The TVFI 6 weekly sessions are organized in two subsequent phases: 4 sharing the focus sessions and 2 integration sessions. Sharing the focus sessions are dedicated to the discussion between the psychologist and the mother of specific themes related to parenting and parent-infant interaction: physical stimulation, responsiveness, teaching, and parenting experience. The goal of the sharing the focus sessions is to develop insights about the infants' behavioral signals, the best ways to provide stimulations and get in touch, strategies to promote emotion regulation, and to sustain cognitive and behavioral achievements. In the subsequent two integration sessions, the mother plays with the infant while the psychologist provides guidance based on topics previously discussed during the first four sessions. The goal is to promote a pragmatical translation of the insights developed during the sharing the focus sessions into the interactive exchanges between the mother and the infant.
41010986|NCT05931848|OTHER|Warm-up and Cool-down Program|"Each exercise in the warm-up and cool-down protocols consisting of active movements and static stretching exercises will be performed as 1 set and 10 repetitions. Active movements will be performed for 10 seconds. The detailed protocol is shown below.~Neck flexion/extension/lateral flexion Circles made with the head chin-tuck Backward bilateral shoulder circumduction Shoulder external rotation with hands clasped at neck Circles with wrists clasped clockwise and counterclockwise Reciprocal upper extremity flexion-extension cat-camel Trunk lateral flexion with hands clasped overhead Trunk rotation in both directions Ankle dorsi/plantar flexion with knee extension Static Stretching Exercises Neck lateral flexor stretch Posterior capsule stretching Hands clasped trunk flexion lateral Trunk lateral flexion with hands clasped Trunk rotation in both directions Knee extensor and ankle plantar flexor stretching by reaching for toes"
41328080|NCT06185608|DRUG|0.25% ropivacaine|A total of 15 ml of 0.25% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
41328081|NCT06185608|DRUG|0.5% ropivacaine|A total of 15 ml of 0.5% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
41480788|NCT01208428|BEHAVIORAL|Conventional cognitive behavioral therapy|Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.
40810148|NCT06661707|PROCEDURE|Sonar guided Quadratus Lumborum block|The probe will be tilted down the lateral abdomen to identify a bright hyperechoic line that represents the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of (0.2 mL/kg of 0.25% bupivacaine per side) will be applied without exceeding the toxic dose 3 mg/kg
40810149|NCT06661707|PROCEDURE|Sonar guided Ilioinguinal/Iliohypogastric block|"The ultrasound linear probe will be placed over the anterior superior iliac spine with the superior margin of the transducer pointed directly in an oblique plane toward the umbilicus. The iliohypogastric nerve will be seen medial to the ilioinguinal nerve. The overlying skin will be prepared with antiseptic solution and 21 gauge 120mm Locoplex Sono Tap cannula will be advanced using an in-plane approach from a point just below the inferior border of the transducer toward the ilioinguinal nerve as it lies within the facial plane between the internal abdominal oblique and transverse abdominis muscles.~After negative aspiration, (0.2 mL/kg of 0.25% bupivacaine per side) will be injected without exceeding the toxic dose of 3 mg/kg"
41328082|NCT06185608|DRUG|1% ropivacaine|A total of 15 ml of 1% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
41328083|NCT06211127|DEVICE|Cold laser plaque ablation|Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
41328084|NCT06211127|DEVICE|The excimer laser|Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
41328085|NCT01807949|DRUG|Placebo|Matching placebo tablet
41328086|NCT01807949|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
40810150|NCT06659107|PROCEDURE|Closed reduction and fixation by K- wires|Fixation by k-wires with mutual linking technique
40810151|NCT06658288|OTHER|Rebound Training|12 participants will be in experimental group A giving them rebound training.
40810152|NCT06658288|OTHER|Theraband resistance exercise|12 participants will be in experimental group A giving them theraband resistance exercise with different band resistnce.
40810153|NCT06662188|GENETIC|JAG201|Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
41328087|NCT01807949|DRUG|Ivacaftor|Film-coated tablet
41328088|NCT04252248|DRUG|Dacogen|Intravenous (i.v.) infusion of 20 mg/m2 over 1 hour repeated daily for 5 days starting on day 1. Single repetition of cycle on day 29.
41328089|NCT00324688|DRUG|Viread|
41328090|NCT05306184|PROCEDURE|Electroconvulsive therapy (ECT)|ECT
41328091|NCT03410134|DEVICE|NeoMTA|NeoMTA™ Plus® root and pulp treatment material is a powder/gel system with no resin. The components are an extremely fine powder primarily tricalcium and dicalcium silicate plus a water-based gel.
41328092|NCT04911829|BEHAVIORAL|Psychotherapy|
41328093|NCT04616404|DIETARY_SUPPLEMENT|500 mg of artichoke extract|Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)
41328094|NCT04616404|OTHER|Placebo|Tablets with no active ingredient
41328095|NCT03999112|OTHER|Metacognitive Reflection and Insight Therapy (MERIT)|A psychological therapy aiming to increase the ability of individuals to synthesise perceptions about themselves and others; to then form complex narratives which recognise the occurrence of these within particular social contexts; and to use these to form responses to psychological problems.
41328096|NCT01874873|DRUG|Anlotinib|
41328097|NCT06071390|BEHAVIORAL|Animated- assisted video|"For the experimental group, 15 minutes prior to the endoscopy, the researcher provided insight into the procedure by showing them a 3-minute animated video titled Endocan. This video, crafted by Köse in 2019 for his doctoral dissertation, offers a succinct overview of the endoscopy procedure."
41328098|NCT03263741|DRUG|Paclitaxel + S-1 + Oxaliplatin|"Paclitaxel: 135 mg/m2, iv, 3h, at D1. S-1: S-1: 40mg twice daily for patients with a body surface area (BSA) \< 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to \< 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week.~Oxaliplatin: 85 mg/m2, iv, 2h, at D1."
41328099|NCT03046017|DEVICE|tDCS|Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.
41328100|NCT03046017|OTHER|Lidocaine cream|Lidocaine cream will be applied to reduce pain sensitivity (analgesia).
40810154|NCT06662188|GENETIC|JAG201|Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
41154983|NCT00558220|PROCEDURE|Consolidation treatment part 1: HD-chemotherapy with ASCT|"Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.~High dose chemotherapy (HD-chemotherapy) consists of:~BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.~On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery."
41010987|NCT05931848|OTHER|Strengthening Exercises|"The progression of the strengthening program will be achieved by gradually changing the number of repetitions, sets, resistance and the number of exercises.~1-6 Weeks Upper extremity strengthening in unilateral PNF D2 pattern, Scapulothoracic strengthening with shoulder extension in elbow extension, Scapulothoracic strengthening with shoulder extension in elbow flexion, hip flexor strengthening, Hip abductor strengthening in knee flexion, when sit on the chair fingertip ups and downs 7-12 Weeks Added exercises Scapular adductor strengthening with shoulders in horizontal abduction position, Shoulder adductor strengthening in elbow extension with trunk lateral flexion in arms overhead position, hip abductor strengthening 13-16 Weeks Added exercises Shoulder abductor/flexor strengthening in the scapular plane, Elbow flexor strengthening, Upper extremity strengthening in unilateral PNF D2 pattern with trunk rotation, Taking a lateral step in a mini-squat position"
41010988|NCT05931848|OTHER|Balance Exercises|"Balance exercises will be applied following the strengthening exercises. The exercises will be gradually made more difficult. Participants will be encouraged to complete the balance exercises by standing next to the grab bar and with as little support as possible.~1-6. Week Rising and falling on the heels Hands at waist trunk extension hip abduction 6-9. Week Hip abduction and extension without lowering the foot to the ground, respectively 5 sec stop on tiptoe 5 seconds standing on one leg 10-12. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~5 sec stop on tiptoe 10 sec stop on tiptoe 5 seconds standing on one leg 10 seconds standing on one leg 13-16. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~10 sec stop on tiptoe 15 sec stop on tiptoe 10 seconds standing on one leg 15 seconds standing on one leg"
41328101|NCT03046017|OTHER|Control cream|A neutral cream will be applied as a control.
41328102|NCT01770899|DRUG|Montelukast|
41328103|NCT01770899|DRUG|Placebo|Gelatin capsule given every 24 hours
41328104|NCT01726712|OTHER|Supportive Care|Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
41328105|NCT04886193|DRUG|FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)|"* FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W~* Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W~* Tiggio capsule (S-1) 40-60mg (BSA\<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA\> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;~* Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year."
41328106|NCT03443895|DRUG|AEF0117 oral capsule|0.6, 2 and 6mg of AEF0117
41328107|NCT03443895|DRUG|Placebo oral capsule|Matching placebo capsule
41328108|NCT02320968|OTHER|MedclineTM Sleep Assist Pillow|The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
41328109|NCT05516719|OTHER|Positron Emission Tomography (PET) scan using BU99008 tracer|A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
41328110|NCT05516719|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
41328111|NCT05516719|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
41328112|NCT05516719|OTHER|Lumbar puncture|A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
41328113|NCT04693923|PROCEDURE|Fluid challenge|Fluid challenge according to the assigned group
41328114|NCT00169910|DRUG|AUC monitored withdrawal of MMF or CNI|AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
41480789|NCT01208428|BEHAVIORAL|Religious cognitive behavioral therapy|Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
40810157|NCT06660888|BEHAVIORAL|• Fatigue Severity Scale (FFS). • Hamilton Rating Scale for Depression (HRSD-17). • Hamilton Anxiety Rating Scale (HAM-A).|"1. Fatigue Severity Scale The FSS is one of the most commonly used fatigue questionnaires in chronic diseases. It measures how fatigue affects motivation, exercise, physical functioning, carrying out duties, work, family, or social life.~2. Hamilton Depression Rating Scale The 17-item Hamilton Depression Rating Scale (HRSD-17) is the most popular depression measure in antidepressant clinical trials.~3. Hamilton Anxiety Rating Scale The HAM-A was one of the first rating scales developed to measure the severity of anxiety symptoms."
41328115|NCT06310070|DEVICE|3D Printed Personalized Ostomy Appliance|Study procedures will include getting your stoma scanned, receiving personalized ostomy appliances in the mail, receiving a personalized ostomy template, which will be printed using a 3D printer, in the mail, and completing a daily symptom diary along with a weekly survey for 4 weeks.3D printing is done using a machine that takes the 3D image from the computer and prints a replica of the image using plastic or other materials.
40810158|NCT06659978|DEVICE|Device tolerance|"After being fed (breastmilk or formula), video will be turned on and the infant is placed on the Gentle Touch Stimulator (GTS) in deactivated mode. After a baseline period of 5- minutes the device will be activated. It will be deactivated after 10 minutes or earlier if there are any signs of distress from the infant. A 10-minute washout observation period will be followed.~Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours."
40810159|NCT06659978|OTHER|Acceptability questionnaire|Parental and clinical staff acceptability of the device assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial. Interviews will be conducted by researcher following the intervention.
41154984|NCT00558220|RADIATION|Consolidation treatment part 2: Radiotherapy|Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (\>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
41154985|NCT05640102|DRUG|Zanubrutinib|Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling
41154986|NCT02586961|DRUG|0.9% saline solution|"Placebo:~Nebulized 0.9% saline solution"
40810163|NCT06662071|OTHER|Organoid culture|Organoid culture of tumor tissue obtained during patient surgery
40810164|NCT06658171|BEHAVIORAL|Relaxation training and stimulus control|"Relaxation training: Progressive muscle relaxation; Breathing relaxation; Imagery training; Mindfulness relaxation.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
40810165|NCT06658171|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
41154987|NCT02586961|DRUG|oral betamethasone placebo|placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
41154988|NCT02586961|DRUG|adrenaline|Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)
41154989|NCT02586961|DRUG|oral betamethasone|Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
41154990|NCT01601821|DRUG|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
41154991|NCT01601821|DRUG|CsA+MMF+CS|"The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS."
40810171|NCT06661915|PROCEDURE|Biospecimen Collection|Undergo buccal swab and blood sample collection
41154992|NCT01262794|BIOLOGICAL|CDP6038|100 mg/mL solution for injection, single dose
41154993|NCT01262794|BIOLOGICAL|Placebo|0.9% sodium chloride for injection Single-dose
41154994|NCT02061189|OTHER|Physical exercise in a swimming pool during 6 months|10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
41328116|NCT03519399|DEVICE|Monica AN24|Monica AN24 will be used to record maternal and fetal ECGs. The Zephyr will be used to determine maternal lie.
41154995|NCT05969119|DRUG|Pyridostigmine|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours or Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
41154996|NCT05969119|DRUG|Placebo|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
41328117|NCT06057636|BEHAVIORAL|Self-Administered Hypnosis|Participants will choose from one of three 20-minute prerecorded hypnosis audio files. Practices using the recordings will be documented on the hypnosis practice log.
41328118|NCT06057636|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recording for 6 weeks and will be encouraged to practice daily. Practices using the recordings will be documented on the hypnosis practice log.
41010989|NCT05931848|OTHER|Otago Home Exercise Program|"The exercises included in the Otago Home Exercise Program will be taught to the participants after the group exercise session held at the Social Life Center. At the same time, home exercise training will be supported by brochures and videos. In addition to the exercises in the program, participants will be asked to do 30 minutes of moderate-intensity walking 2 days a week. Participants will be asked to record the exercises they did during the week in the exercise diary given to them.~Balance Exercises~1. Knee bend (half squat)~2. Walking backwards~3. Walk and turn around~4. Sideways walking~5. Tandem stance~6. Tandem walking~7. Standing on one leg~8. Walking on the heel~9. Toe walking~10. Tandem walking backwards~11. Sit down~12. Going up and down stairs Strengthening Exercises~1. Knee extension 2. Knee flexion 3. Hip abduction 4. Ankle plantar flexion 5. Ankle dorsiflexion"
40810172|NCT06661915|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
41010990|NCT04217551|DEVICE|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
41010991|NCT06358391|DEVICE|TS-RF Transseptal Needle|Apply radiofrequency energy to the electrode tip via the TS-RF Generator and puncture the atrial septum
41010992|NCT06358391|DEVICE|BRK Transseptal Needle|Cross and puncture the atrial septum with the BRK Transseptal Needle
40810173|NCT06661915|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
41010993|NCT05283252|DEVICE|3-D printed Guide|Guided Endodontic micro-surgery
41010994|NCT05283252|OTHER|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
41010995|NCT05246605|OTHER|change in body position|changing from supine to prone position and the back to supine
41010996|NCT01632579|DRUG|LY3023703|Administered orally
41010997|NCT01632579|DRUG|Placebo|Administered orally
41010998|NCT01632579|DRUG|Celecoxib|Administered orally
41010999|NCT06477016|DEVICE|OsciPulse|Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
41011000|NCT06477016|DEVICE|Intermittent Pneumatic Compression|Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
41011001|NCT00654381|DRUG|BI 1356|5 mg/daily
41011002|NCT00654381|DRUG|BI 1356|10 mg/daily
40810174|NCT06661915|DRUG|Decitabine and Cedazuridine|Given PO
41011003|NCT00654381|DRUG|voglibose placebo|three times daily
40810175|NCT06661915|DRUG|Iadademstat|Given PO
41154997|NCT05966623|OTHER|Video Remote Interpretation|To assess the effectiveness of the VRI system in improving communication outcomes between Deaf patients and doctors Produce a VRI model addressing the challenges faced by Deaf people that will be tested, implemented, and sustained in Bogota Colombia.
40810177|NCT06660693|DRUG|Upadacitinib Oral Product|Upadacitinib oral 45mg once daily.
40810178|NCT06658093|DRUG|Rapamycin|mTOR inhibitor
40810179|NCT06658093|DRUG|Everolimus|mTOR inhibitor
40810180|NCT06658093|OTHER|Placebo|Inert placebo for rapamycin or everolimus
40810181|NCT06661785|PROCEDURE|large orbital floor fracture|Twenty two patients with large orbital floor fracture will be reconstructed with interlocking polyetheretherketone patient-specific implant
41328119|NCT05485012|DRUG|Marijuana|Double-blind administration of marijuana
41011004|NCT00654381|DRUG|BI 1356 placebo|once daily
41011005|NCT00654381|DRUG|voglibose|0.6 mg/daily
41011006|NCT04965142|BEHAVIORAL|Exercise Training|The intervention group will be asked to complete aerobic exercises 3 to 5 times per week (≥ 150 minutes of at least moderate aerobic intensity) and resistance training at least twice a week over a 12-week period.
41011007|NCT05107362|DIAGNOSTIC_TEST|untrained lay user performs investigational diagnostic test|Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.
41011008|NCT03096782|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
41011009|NCT03096782|DRUG|Busulfan|Given IV
41011010|NCT03096782|DRUG|Clofarabine|Given IV
41011011|NCT03096782|DRUG|Cyclophosphamide|Given IV
41011012|NCT03096782|BIOLOGICAL|Filgrastim-sndz|Given SC
41011013|NCT03096782|DRUG|Fludarabine|Given IV
41011014|NCT03096782|DRUG|Melphalan|Given IV
41011015|NCT03096782|DRUG|Mycophenolate Mofetil|Given IV or PO
41011016|NCT03096782|BIOLOGICAL|Rituximab|Given IV
41011017|NCT03096782|DRUG|Tacrolimus|Given IV
41011018|NCT03096782|RADIATION|Total-Body Irradiation|Undergo total body irradiation
41011019|NCT03096782|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo cord blood transplant
41011020|NCT03466502|DRUG|Oral Vancomycin|Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence
41328120|NCT05485012|DRUG|Opioid|Double-blind administration of an opioid agonist
41011021|NCT05078645|DEVICE|Maya|The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy
41011022|NCT05856552|BEHAVIORAL|CBT|Cognitive behavioral therapy delivered by community resource persons via home visits.
41011023|NCT05856552|BEHAVIORAL|Group Activities|Weekly hour-long group activities delivered by community resource persons in community spaces.
41328121|NCT04720495|PROCEDURE|One stage ridge splitting with simultaneous implant placement|"A full mucoperiosteal flap was raised using the sharp periosteal elevator to expose the bone crestally and buccally.~An inverted U-shaped bone cut, down to the cancellous bone, was done in the undercut area with a piezoelectric device.~The horizontal bone cut was made apical to the most concave point in the undercut area with a distance of 3 mm.~The two vertical bone cuts were placed at least 1 mm away from the adjacent roots and extended beyond the undercut area.~The released bone end was minimally elevated using a periosteotome through a greenstick fracture.~All implants were installed with the implant shoulders flush to the bone level using a low-speed drilling procedure."
41328122|NCT04720495|PROCEDURE|Two-stage ridge splitting with implant placement|"The first surgery is the same as one stage ridge splitting Four weeks later, after revascularization between the bone block and the mucoperiosteum, the second surgery will be performed.~A crestal incision was done and the envelope flap slightly elevated to preserve the blood supply.~The implants will be placed in the same manner as one stage ridge splitting"
41328123|NCT05652413|BEHAVIORAL|Adapted-Engage-PA|Enhanced motivation strategies for increasing walking using personal values assessment and value-guided goal setting, adapted from Acceptance and Commitment therapy. Strategic activity pacing to increase stamina and reduce pain flares when walking, using the Activity Rest Cycle, from Pain Coping Skills Training. Culturally sensitive elements for older adults who identify as African American such as linking motivation to spirituality, family, community, and other personally-meaningful values.
41328124|NCT05304598|DRUG|Dexmedetomidine|a single intravenous (i.v.) dose of dexmedetomidine, 0.2 mcg/kg over 10 minutes
41011024|NCT03214003|RADIATION|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
41011025|NCT03214003|RADIATION|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
41011026|NCT01122199|DRUG|RAD001 + AMG479|Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
41011027|NCT00788866|DIETARY_SUPPLEMENT|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
41011028|NCT00788866|DIETARY_SUPPLEMENT|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
41011029|NCT02444650|DEVICE|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
41011030|NCT02444650|DEVICE|tonometer|
41011031|NCT00004804|DRUG|interferon alfa|
41328125|NCT05304598|OTHER|Usual Care|routine awake intubation as per current unit standard of care,
41480790|NCT00652028|DRUG|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
41011032|NCT04252859|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
41480791|NCT03529643|DRUG|Dexmedetomidine|Anesthesia with sevoflurane-remifentanil-dexmedetomidine
41480792|NCT03529643|OTHER|Without dexmedetomidine|Anesthesia with sevoflurane-remifentanil
41480793|NCT00055133|DRUG|Micellar Paclitaxel for Injection|
41011033|NCT05554861|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
41480794|NCT04154150|DRUG|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
41480795|NCT04154150|BEHAVIORAL|Cognitive training|8 sessions of computer-based cognitive training
41154998|NCT04029727|DIETARY_SUPPLEMENT|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
40810184|NCT06659185|DIETARY_SUPPLEMENT|Exercise|The effects of placobo mouth rinsing on softball batting performance
40810185|NCT06661356|BEHAVIORAL|COMPrEP|Participants will be paired with peer lay workers and will meet with peer lay workers at private community location. They will discuss options for oral PrEP with peer lay workers and be provided provide daily oral PrEP or event-driven (2-1-1) PrEP. Participants will take part in rapid HIV testing at each visit. They will also meet with peer lay workers at private community location for follow-up at 1,3,6,9, and 12 months
41154999|NCT04029727|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
41328126|NCT04828369|PROCEDURE|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|(1) Standard diagnostic endoscopy was first performed. Fundal varices were assessed using the classification of Sarin's. (2) intraluminal water filling of the gastric fundus to use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. (3) Punctured the gastric fundal variceal vein at the lower esophagus near the cardia and placed the coil into the shunt and immediately injected with sclerosant and cyanoacrylate under the guidance of EUS. (4) Sclerosant and cyanoacrylate were injected into the gastric fundal varices by a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. (5) After the injection, use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
40810187|NCT06660511|DRUG|Disitamab Vedotin in Combination With Anlotinib Hydrochloride|"The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.~Main research endpoint: Objective response rate (ORR)~Secondary study endpoint:~1. Progression free survival (PFS)~2. Overall survival (OS)~3. Disease Control Rate (DCR)~4. Objective Duration of Response (DoR)"
40810188|NCT06661811|DRUG|CAR-T|CAR-T cells
41155000|NCT05122052|OTHER|Psychological session|Just before the oncology visit, each patient is invited to undergo a psychological session of 20-30 minutes. During the session with a psycho-oncologist the following tasks are addressed: 1) favor emotional expression identifying the most difficult issues to promote mechanisms of elaboration of living experiences; 2) offer a containment of intense emotions; 3) assess awareness of diagnosis and prognosis; 4) favor expression of fears of treatment expectancy; 5) favor expression of difficulties on the inability to cope with prior commitments after the disease; 6) assess family and friend network; 7) improve the patient medic communication and relationship. At the end of the session, the distress thermometer and ESAS-r scale are compiled together with the demographic characteristics. All outstanding issues that are relevant to the therapeutic plan are then discussed between the psychotherapist and the medic before the oncology visit together with delivery of the DT and ESASr scale result.
41155001|NCT01798238|DRUG|MP-513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
41328127|NCT04828369|PROCEDURE|balloon-occluded retrograde transvenous obliteration|(1)A balloon occlusive catheter was inserted into the shunt via the right femoral vein. (2)Investigators performed angiography to evaluate the size and location of GV and the shunt during balloon occlusion. Shunt was occluded by Fogarty balloon. The diameter of the balloon was chosen according to the diameter of shunt. (3)Then investigators injected sclerosant into the portosystemic shunt. (4)Finally, the balloon left in place for 24 hours was gradually deflated when complete occlusion of blood flow of the target shunt was achieved.
41328128|NCT04583761|BEHAVIORAL|questionnaire|Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems
41328129|NCT01125657|DRUG|YM150|oral
41328130|NCT05106335|DRUG|camrelizumab + famitinib|camrelizumab for intravenous injection; famitinib malate capsules for oral administration
41328131|NCT05106335|DRUG|famitinib|famitinib malate capsules for oral administration
41328132|NCT05106335|DRUG|docetaxel|docetaxel for intravenous injection
41328133|NCT06425263|BIOLOGICAL|adipose tissue fragmented|harvested from the case form buccal pad of fat
41328134|NCT05008068|DRUG|Simvastatin|Simvastatin with PRF at site of osteotome
41328135|NCT01494987|DRUG|Ranolazine|Ranolazine tablet(s) administered orally
41328136|NCT01494987|DRUG|Placebo|Placebo to match ranolazine for the duration of the study
41328137|NCT01494987|DRUG|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
41328138|NCT01494987|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
41328139|NCT01494987|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
41328140|NCT00939939|DRUG|sitagliptin|sitagliptin 100 mg/d for 10 weeks
41328141|NCT00939939|DRUG|glimepiride|glimepiride 1 mg/d for 10 weeks
41328142|NCT02746354|OTHER|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
41328143|NCT05163067|BEHAVIORAL|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
41328144|NCT00966693|DRUG|Dexamethasone|Given PO
41155002|NCT01798238|DRUG|Placebo|Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
41328145|NCT00966693|DRUG|Lenalidomide|Given PO
41328146|NCT00966693|DRUG|Thalidomide|Given PO
41328147|NCT05843071|DEVICE|Nasal sprays with sea salts|Nasal sprays for nasal congestion and dryness
41328148|NCT01637870|DEVICE|Prevena negative pressure wound system|Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
41480796|NCT04154150|BEHAVIORAL|Sham Training|8 sessions of computer-based sham training
41480797|NCT04593017|DIETARY_SUPPLEMENT|Active Probiotic|Lactobacillus Reuteri (DSM 17938 and ATCC PTA 4659
41480798|NCT04593017|OTHER|Placebo Probiotic|Placebo
40810190|NCT06660056|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Recurrent or Progressive Gliomas of the Brain|Use of Ommaya capsules
40810191|NCT06661928|PROCEDURE|Papilla preservation flap|"Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used.~Suturing will be performed with external vertical mattress sutures to achieve primary intention closure."
40810192|NCT06661928|PROCEDURE|Widman flap procedure|"Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures."
40810193|NCT06659861|OTHER|RV3278B-OS0386|Cosmetic product to be applied twice a day on the face during the whole study
40810194|NCT06659861|OTHER|RV4632A-RY1845|Cosmetic product to be applied in the event of facial skin discomfort only
41155003|NCT05789407|DIAGNOSTIC_TEST|Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry|1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry
41155004|NCT06388876|OTHER|Exercise|Members of the exercise group received an exercise intervention twice a week for six weeks accompanied by a physiotherapist.
41155005|NCT06388876|OTHER|lifestyle advice|At the beginning of the program, the members of the individuals were given lifestyle recommendations, both verbally and in writing (in the form of a brochure) within the scope of a common training initiative.The individuals groups received both written (brochure) and verbal training within the scope of lifestyle recommendations (the effects of planned and regular exercise, sleep problems, methods of coping with stress, etc.).
41155006|NCT05400226|DRUG|VGT-309|VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.
41155007|NCT05937971|OTHER|plantar sensitivity training|"Plantar sensory training protocol:~Applying a moisturizing cream by washing the feet with warm water and drying them (before coming to the session)~Dynamic gastro-soleus stretching (20 sec, 5 reps, 2 min)~Plantar fascia stretch (20 sec, 5 reps, 2 min)~Picking up sheets with feet (10 reps, 2 min)~Pushing the small roller under the foot back and forth (10 reps, 2 min)~Holding the spiny proprioception ball on the plantar surface of the foot while sitting, moving it in anterior-posterior and circular directions (2x2.5 min=5 min)~Keeping the carpet pieces of different softness and texture on the plantar surface of the foot and moving them in anterior-posterior and circular directions (2x2.5 min=5 min) Soft tissue mobilizations applied to the soles of the feet by the physiotherapist (2 minutes)"
40810198|NCT06661005|DRUG|Nitrous oxide|The Nitrous oxide group will receive instructions to arrive at clinic 30 minutes before her procedure in order to sign consent forms. She will not be given instructions to remain NPO and will not be required to have someone bring her to and from the appointment. No IV will be placed. Anesthesia induction will be done by an anesthesiologist with a nitrous oxygen mixture at a 70:30 ratio
40810199|NCT06661005|DRUG|IV Sedation|Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol. A pulse oximeter will be placed and oxygen will be administered through a nasal cannula and the patient will be instructed to breath.
40810200|NCT06662305|BEHAVIORAL|Kick-Nic! mobile phone application|The Kick-Nic! app has seven modules that cover core CBT strategies using skills, graphic illustrations, and interactive components to help adolescents quit using e-cigarettes.
40810201|NCT06662305|BEHAVIORAL|NCI Quit Vaping website|The NCI webpage provides quitting tobacco resources for youth, including for e-cigarettes. The information provided is similar to the CBT skills modeled by the Kick-Nic! app.
41155008|NCT05937971|OTHER|aerobic exercise training|Warm-up exercises; will consist of stretching exercises (20-30 s, 5 repetitions), breathing exercises (6-10 s, 5 repetitions) and range of motion exercises (8-10 s, 5 repetitions) for the whole body. Conventional exercises will include balance (10 s, 5 reps), coordination (5-10 s, 5 reps), stabilization (5-10 s, 5 reps) and strengthening exercises (8-10 s, 5 reps), specific to each patient. Aerobic exercise training was started at 40% of the maximum heart rate on the treadmill and gradually increased at three-week intervals (40% in weeks 1-3, 50% in weeks 4-6, 60% in weeks 7-9, and 70% in weeks 10-12). ) will be progressed. Cool-down exercises will include a gradual lowering of the treadmill speed (3 min) and ankle range of motion exercises. Plantar sensory training begins with a duration of 5 minutes and progresses from a sitting position to a standing position at three-week intervals (1-3 weeks 5 minutes, 4-6 weeks 10 minutes, 7-9 weeks 15 minutes, 10-12 weeks 20 minutes). will be.
41328149|NCT05097833|BEHAVIORAL|Enhanced Saint Francis Fatherhood FIRE Program|Fathers receive an enhanced series of pro-parenting, relationship, and economic stability workshops over 16 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success and the Nurturing Fathers enhancement program.
41328150|NCT05097833|BEHAVIORAL|Services as Usual Saint Francis Fatherhood FIRE Program|Fathers receive the services as usual approach which includes a series of pro-parenting, relationship, and economic stability workshops over 13 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success.
41011034|NCT05554861|DEVICE|Intermittent Theta Burst Stimulation (iTBS) Protocol|"It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTBS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
41011035|NCT05554861|DEVICE|Sham rTMS Protocol|"It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.~After the daily sham rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
41328151|NCT06527209|OTHER|Coffee and agave inulin-based beverage (A)|"Intervention beverage:~134 mL of cold-brew coffee 18 g of agave inulin Total beverage weight: 350 g"
41328152|NCT06527209|OTHER|Control beverage (B)|"Control beverage:~40 mL of cold brew coffee 5.4 g of agave inulin Total beverage weight: 350 g."
41011036|NCT01636141|DRUG|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
41011037|NCT01636141|DRUG|Placebo gel|
41011038|NCT06229574|OTHER|virtual reality glasses|The breastfeeding software developed will be applied in this group.
41011039|NCT02733510|DRUG|methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
41328153|NCT02629328|DEVICE|CardioCel|Treatment with CardioCel implant
41328154|NCT04396288|DEVICE|ultrasound imaging at the forearm and at the tibia|ultrasound imaging will be performed at the radius bone (forearm) and at the tibia, before, during, and after a change of intraosseous blood flow
41328155|NCT06530108|BEHAVIORAL|PLISSIT model based sexual health education|the PLISSIT model includes the steps of PLISSIT (P-Permission), LI-Limited Information, SS-Specific Suggestions, IT-Intensive Therapy. This model provides communication with the patient and Since it is a model that increases confidence and provides care interventions based on the patient's preference, it has the feature of guiding sexual education during pregnancy by establishing the bond between the pregnant woman and the midwife.
41328156|NCT01746810|RADIATION|Stereotactic body RT and IRGA|SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
40810209|NCT06658145|DEVICE|Vnotes surgery using fully visualised surgical instruments|Vnotes surgery using fully visualised surgical instruments
40810210|NCT06658145|DEVICE|Vnotes surgery using traditional surgical instruments|Vnotes surgery using traditional surgical instruments
41480799|NCT05861635|DRUG|Disitamab Vedotin combined with Tislelizumab|"Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle"
41155009|NCT00762554|DRUG|Depodur|Depodur 10mg given epidurally at end of cesarean section.
40810214|NCT06661447|PROCEDURE|Tridimensional Onlay autologous bone graft|A thick block from the ramus area of the mandible are cut longitudinally with a microsaw into two thin pieces with the same surface area. The two thin block are used to rebuild the two wall of the future alveolar crest and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
40810215|NCT06661447|PROCEDURE|Tridimensional Onlay xenogeneic bone graft|A tridimensional Onlay xenogeneic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
40810216|NCT06661447|PROCEDURE|Tridimensional Onlay allogenic bone graft|A tridimensional Onlay allogenic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
41328157|NCT05066633|DRUG|Metoprolol Succinate|Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.
41328158|NCT05066633|DRUG|Placebo|Placebo will be in the form of identical tablets and will be administered orally once daily.
41480800|NCT02268266|DEVICE|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
41011040|NCT01097837|OTHER|Non-interventional|This is an observational study conducted by anonymous survey. There is no intervention.
41011041|NCT05942248|OTHER|No Intervention|No Intervention
41011042|NCT00414050|BIOLOGICAL|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
41328159|NCT00137670|DEVICE|Video-based HIV/STD prevention intervention|
41480801|NCT05404074|DRUG|Cobitolimod 500mg|Rectal administration
41155010|NCT00762554|DRUG|Depodur|Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
41155011|NCT00762554|DRUG|Fentanyl|Epidural fentanyl infusion started after spinal bupivacaine used for the cesarean section.
40810219|NCT06658977|DRUG|Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)|One Triumeq tablet per day
41328160|NCT02669199|BIOLOGICAL|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
41328161|NCT05676801|DRUG|Photodynamic Therapy|PDT with methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
41328162|NCT01313832|OTHER|remote ischemic preconditioning (RIPC)|RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
40810220|NCT06660277|DEVICE|Super High-Flux Dialyzer|Dialyzer currently approved and available for use across Canada.
40810221|NCT06660277|DEVICE|High-Flux Dialyzer|Dialyzer that is widely used across Canada for hemodialysis treatments.
41155012|NCT00860522|DRUG|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
41011043|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
41011044|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
41011045|NCT01177098|DRUG|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
41011046|NCT01177098|DRUG|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
41011047|NCT04230642|DEVICE|The Quantum Surgical device|Robotic platform for needle placement
41011048|NCT05793385|OTHER|operative intervention|all patients were operated after being admitted to surgical ward for acute abdomen
41155013|NCT00860522|DRUG|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
41155014|NCT01444547|DRUG|paclitaxel and cisplatin|"Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
41155015|NCT00002347|DRUG|Saquinavir|
41155016|NCT00002347|DRUG|Nevirapine|
41155017|NCT00002347|DRUG|Zidovudine|
41155018|NCT00002347|DRUG|Zalcitabine|
41155019|NCT06608459|DRUG|PEX010-Assisted Therapy|The investigational medicinal product PEX010 is a capsule for oral administration that contains the drug substance PYEX.
41155020|NCT02490059|OTHER|bronchoscopy|Bronchoscopy for diagnosis of pulmonary nodules
41155021|NCT02811302|DEVICE|Capnostream Monitor|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
41155022|NCT02127645|PROCEDURE|SRT-TEM|SRT-TEM underwent 25 Gy RT followed by TEM
41011049|NCT06240208|BEHAVIORAL|Inactivity|Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
40810224|NCT06662253|DRUG|Anti-Xa Guided Dosing of Low Molecular Weight Heparin|Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.
41011050|NCT03600168|DEVICE|PuraStat®|Synthetic haemostatic material
40810225|NCT06662253|DRUG|Standard of Care Dosing|Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \&lt; 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
41155023|NCT02127645|PROCEDURE|LRT-TEM|TEM following 46 Gy RT
41155024|NCT02127645|PROCEDURE|Transanal Endoscopic Microsurgery (TEM)|Transanal Endoscopic Microsurgery (TEM)
40810228|NCT06661551|PROCEDURE|Miniscrew insertion in dynamic-computer guided surgery|"The intervention more executed in the literature is by using static computer-guided systems (s-CAS) . However, the s-CAS has limitations, including the time and cost associated with guide production, furthermore, the guide's bulk prevents its use in patients with limited mouth opening, and reduced irrigation potentially leads to overheating and bone burns during implant placement. Additionally, the inability to adjust the surgical plan intraoperatively, the lack of real-time visualization during implant site preparation and implant insertion, and the requirement for specific surgical kits for each implant system present further challenges.~Dynamic navigation systems offer several benefits as highlighted in the literature, including: real-time feedback of the position of surgical drill or implant, allowing intraoperative changes adjusting the implant position during the surgery, reduction of risk of injury to adjacent anatomical structures, promotion of accuracy in novices"
41155025|NCT02127645|PROCEDURE|Total Mesorectal Excision (TME)|Laparoscopic Total Mesorectal Excision
40810230|NCT06660251|OTHER|Egg intervention|Oral administration of three hard-boiled eggs to be ingested within 15 minutes on one occasion.
41011051|NCT04518735|OTHER|Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19|Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
41011052|NCT01550939|DEVICE|Ophthalmic Biometer|One complete biometry examination
41011053|NCT04900103|OTHER|ITV-Pal|Use of new technologies for volunteering
41011054|NCT02625493|OTHER|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
41328163|NCT04944381|BIOLOGICAL|SARS-Cov-2 mRNA vaccine immunization|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd and .
41011055|NCT02263638|DRUG|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
41011056|NCT03082794|DIETARY_SUPPLEMENT|NCD|Negative Calorie Diet
41011057|NCT03082794|DIETARY_SUPPLEMENT|LCD|Low Calorie Diet
41017872|NCT03836092|PROCEDURE|Radiofrequency ablation|RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).
41017873|NCT01038778|BIOLOGICAL|Aldesleukin|Given IV
41155026|NCT02260583|DEVICE|extracorporeal CO2 device|An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
41328164|NCT04944381|BIOLOGICAL|Inactivated SARS-Cov-2 vaccine immunization|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
41328165|NCT02899624|BIOLOGICAL|Extra blood draw samples|
41328166|NCT02899624|BIOLOGICAL|additional tissue samples|
41328167|NCT05399108|PROCEDURE|Ultrasound Guided Lateral Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. On the image are displayed the trapezius muscle and layers of skin. Just above the trapezius muscle using the in-plane technique is done puncture of the vein. By Seldinger's technique, catheterization is done. The whole procedure is done according to the newest international recommendations for central vein catheterization.
41480802|NCT03392675|BEHAVIORAL|Self-monitoring of BF and intervention|"Self-Monitoring: At discharge, mothers will complete daily diaries for self-monitoring to stimulate cognitive reframing on the occurrence, duration, and characteristics of nipple and breast pain, infants' latch and sucking pattern, positioning, length of each BF session, and the MAIBB.~Self-Regulation: To support self-regulation skills, mothers will be provided with several 5-minute video modules on pain and BF pain SM with additional resources links. After discharge mother will receive text message from a nurse 2X/week for BF support. Mothers may text the nurse for emergent BF support."
41017874|NCT01038778|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
41017875|NCT01038778|DRUG|Entinostat|Given PO
41017876|NCT01038778|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
41017877|NCT01038778|OTHER|Laboratory Biomarker Analysis|Correlative studies
41017878|NCT01038778|OTHER|Pharmacological Study|Correlative studies
41017879|NCT01038778|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
41017880|NCT04412135|OTHER|spirituality|Patients will take three questionnaires (FACIT-Sp, Euroqol 5 dimensions and ESAS)
41017881|NCT02939417|OTHER|Grape seed extract|Grape seed extract - collagen cross-linking agent
41155027|NCT05961488|OTHER|Coronary Calcium Score and Coronary CT angiogram|Introduction of early Coronary CT angiogram and Coronary Calcium Score in the first days after a resuscitated out-of-hospital cardiac arrest.
40810231|NCT06660251|OTHER|Meatball intervention|Oral intervention with 170 g meatballs to be ingested within 15 minutes on one occasion.
40810232|NCT06658054|DRUG|Adjuvant analgesia|Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.
40810233|NCT06658054|DRUG|Control (Standard treatment)|Patient will receive standard ESPB with bupivacaine and normal saline
40810234|NCT06661954|DEVICE|Bed A - supine|Hercules dream air surface in supine position
40810235|NCT06661954|DEVICE|Bed B - supine|Oncare Skinguard surface
40810236|NCT06661954|DEVICE|Bed A - head of bed at 30 degrees|Hercules dream air surface with head of bed at 30 degrees
40810237|NCT06661954|DEVICE|Bed B - head of bed at 30 degrees|Oncare Skinguard surface with head of bed at 30 degrees
41155028|NCT06379763|OTHER|diaphragmatic breathing exercise|15-minute diaphragmatic breathing exercise from a semi-Fowler's position. Patients will be instructed to position one hand on the chest and the other on the belly, gradually inhaling deeply through the nose, moving from functional residual capacity to total lung capacity, and holding the breath for three seconds. Patients will be advised to relax their shoulders, maintain quiet upper chest movement, and allow the abdomen to slightly rise. Subsequently, patients will exhale slowly through the mouth for up to five seconds. Diaphragmatic breathing exercises will be organized into three sets lasting 15 minutes, with 3 minutes of active exercise and a 2-minute rest period between sets. During rest intervals, patients will be instructed to breathe normally. If individuals experience dizziness or discomfort, the session will stop.
41155029|NCT06379763|OTHER|conventional physiotherapy exercise|conventional physiotherapy exercise such as ROM, stretching exercises for superficial neck muscles
41011058|NCT06399328|DIAGNOSTIC_TEST|Surface Enhanced Raman Spectroscopy|Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Serum samples were collected and placed in sterile tubes with subsequent freezing at -18°C. Immediately before analysis, samples were thawed at room temperature. For spectral analysis, each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried for 30 minutes. The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope (ADF U300, ADF, China). The spectra were excited in the near infrared range using a laser module with a center wavelength of 785 nm. Each of the obtained spectra represented a discrete set of 1700 parameters in the range of studied frequencies.
41155030|NCT01459523|PROCEDURE|Proximal placement|Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
41480803|NCT06405698|PROCEDURE|surgical closure of myelomeningocele defects by perforator flaps|closure of myelomeningocele defect by perforator island flap after complete incision of the flap all around based on perforator vessel .
41480804|NCT06405698|PROCEDURE|surgical closure of myelomeningocele defects by perforator-plus flaps|closure of myelomeningocele defect by perforator-plus island flap harvesting leaving skin bridge connecting to the flap and dissection of the perforator vessel
41155031|NCT01459523|PROCEDURE|Short axis ultrasound|Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
41155032|NCT01459523|PROCEDURE|Long axis|Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
40810242|NCT06661187|PROCEDURE|Cryoanalgesia|Patients who received cryoanalgesia: patients subjects underwent arterial puncture. patients in the intervention group had a small plastic bag filled with 12 oz of crushed ice applied to the radial artery puncture site for 3 min (timed with a stopwatch) without external compression or massage.
40810243|NCT06661187|PROCEDURE|Psychological instructions|Psychological interventions using verbal signals of the impending procedure, music distraction, visual distraction, and breathing interventions be used during arterial puncture in adults
40810244|NCT06661187|PROCEDURE|Routine care|No intervention deliver routine care
41155033|NCT01459523|PROCEDURE|Distal placement|Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
41155034|NCT06379451|DRUG|NKG2D Chimeric Antigen Receptor NK Cell Injection|Administer KN1102 cell injection three times on day 0, day 7, and day 14, respectively.
41155035|NCT01840696|DRUG|Regadenoson|Vasodilator stress testing
41155036|NCT00645099|DRUG|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
41155037|NCT00645099|DRUG|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
41155038|NCT01248143|DIETARY_SUPPLEMENT|Green tea|9 gram per day
41155039|NCT01248143|DIETARY_SUPPLEMENT|FPP|2 sachets twice daily
41155040|NCT02867371|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
41011059|NCT01234623|OTHER|UCS eyedrops|1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
41011060|NCT04603859|PROCEDURE|Elective induction of labor at 39 gestational weeks and 0 to 3 days|Elective induction of labor (eIOL) according to local policies
41011061|NCT03135223|BEHAVIORAL|Co-created intervention to promote physical activity|A working group of girls and researcher co-created a school-specific intervention to promote physical activity
41328168|NCT05399108|PROCEDURE|Ultrasound Guided Conventional Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. The cannulation is done by the conventional approach (middle approach - the most frequently used).
41328169|NCT06079034|PROCEDURE|Venovenous ECMO|Initial support type of venovenous ECMO via a dual-lumen on two-site VV ECMO cannulation strategy
41328170|NCT06079034|PROCEDURE|Venoarterial ECMO|Initial support type of venoarterial ECMO
41011062|NCT06015698|PROCEDURE|Laparoscopic tubal disconnection|"1. The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~2. The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~3. The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~4. Then, the tube is severed in the middle of the burn area with laparoscopic scissors~5. Ensure adequate hemostasis"
41328171|NCT02022956|DRUG|Lorcaserin|
41480805|NCT02235220|OTHER|Composite resin restoration|"Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.~A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted."
41011063|NCT06015698|PROCEDURE|Laparoscopic salpingectomy|"1. The tube will be removed from its anatomical attachements by progressive bipolar coagulation~2. Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~3. Removal of the tube through one of the ancillary ports using artery forceps~4. Ensure adequate hemostasis"
41011064|NCT06130176|PROCEDURE|Single-step Functional Sinus Endoscopy and Transoral Surgery|In each patient, the operation will be carried out by an otorhinolaryngologist and a maxillofacial surgeon. The procedures of the functional sinus endoscopy (FSE) will performed as follow: Under general anesthesia, the origin of the turbinate, and the lateral nasal wall will be conducted. The following stage will be infundibulotomy, which ensures that the uncinate process will be completely removed. The ostium will be dilated with a Stammberger dilatator starting with a 0-degree endoscope then shift to a 30- or 45-degree endoscope to clean the sinus. The cavity will be irrigated after removal of the odontogenic diseases and the purulent discharge will suctioned.In addition to FSE, the maxillofacial surgeon will conduct the necessary oral surgery procedures.The needed transoral procedures will be tooth extraction, oro-antral fistula closure or cystectomy.
41011065|NCT06130176|PROCEDURE|Functional sinus endoscopy|All patients in this group will only be treated with FSE, which will be conducted by an otolaryngologist. The FSE procedures will be carried out in the same way as the group of Single-step Functional Sinus Endoscopy and Transoral Surgery.
41328172|NCT03228498|DRUG|Choline alphoscerate|Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
41328173|NCT03228498|DRUG|Placebo|Placebo b.i.d plus Nimodipine 30 mg t.i.d
41011066|NCT06130176|PROCEDURE|Trans oral Surgery|Every patient in this group will only be treated with transoral surgical procedures to remove dental pathology. Oral and maxillofacial surgeons will undertake these treatments. The procedure will be either tooth extraction, oro-antral fistula closure, or cystectomy. If extraction is not needed, endodontic treatment will be performed to remove necrotic pulp. The oro-antral fistula will be closed in two layers using a buccal advanced flap and a palatal rotational flap. In the case of odontogenic cysts, the lesion will be removed by raising a trapezoidal flap.
41011067|NCT06413433|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
41011068|NCT06413433|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
41011069|NCT06413433|DRUG|Placebo|Placebo tablets, taken once daily
41011070|NCT02685774|DRUG|Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg|Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
41011071|NCT02685774|DRUG|CKD-395 0.25/500mg|CKD-395 0.25/500mg 2T oral administration
41155041|NCT03340766|DRUG|Blinatumomab|Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.
41328174|NCT02685995|DEVICE|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
41328175|NCT02685995|DEVICE|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
41328176|NCT01513863|DRUG|Metronidazole Topical Gel 1%|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
41328177|NCT01513863|DRUG|Metronidazole Topical Gel 1% (Metrogel)|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
40810251|NCT06659484|DIAGNOSTIC_TEST|Assessment|"Evaluation carried out during a day hospital at T0 (initial assessment) and T3 (after the exercise program at around 3 months) including:~1. Clinical assessment by a geriatrician~   * Medical history; systematic search for symptomatic elements (asthenia, anorexia, weight loss); research into antecedents (chronic pathologies, etc.), treatments, lifestyle, eating habits, sedentary lifestyle,~  * Complete clinical examination: particularly of the musculoskeletal system, morphological data (weight and height, calf circumference), analysis of risk of falls,~  * Current medical treatments~  * Autonomy for basic activities (ADL), instrumental activities of daily living (IADL), visual disorders, hearing impairment, etc.~  * Assessment of comorbidities (Charlson score)~  * Screening for sarcopenia (using the SARC-F questionnaire),~  * An inventory of falls and their traumatic consequences,~  * Assessment of frailty status using FRIED criteria,~2. Nutritional assessment :~   * nutritional status will also be asses"
40810252|NCT06659484|OTHER|Multicomponent exercise program|"After inclusion in the protocol, participants with mobility disability risk factors are assigned to specialized and experienced kinesiologists at the end of the medical consultation.~Patients will be invited to take part in group-based exercise sessions, in small groups of no more than 10 patients, under the supervision of a kinesiologist. There will be 20 sessions over 10 weeks, at a rate of 2 sessions per week, each lasting one hour. The Multicomponent exercise program included progressive resistance and balance training."
40918157|NCT04183361|DIAGNOSTIC_TEST|ABR and salivary cortisone testing|"Three saliva samples at the workplace will be collected immediately after the morning shift. The first saliva sample was given 3 days (Tuesday) before arrival at the research place, the second sample 2 days (Wednesday) before arrival, and the third sample 1 day (Thursday) before arrival at the research site. One hour before saliva sampling, a respondent should not brush his/her teeth nor eat nor drink. Fifteen minutes prior to sample administration, the subject should rinse his/her mouth with a cold water. Samples will be analyzed using High Performance Liquid Chromatography (HPLC) at the Translational Medicine Division of the Srebrnjak Children's Hospital.~2. Collaboration in the process of assessing hearing health at the research place. The assessment includes: otoscopy, tympanometry and audiometry. Subjects will be tested for auditory evoked brainstem response in only one ear, with a more regular hearing threshold."
41328178|NCT01513863|DRUG|Placebo|Placebo applied to affected area once a day for 70 days
41011072|NCT03882359|DIAGNOSTIC_TEST|Echocardiogram|"Images will be recorded in parasternal long, short axis, apical four, two, and three chamber views according to the American Society of Echocardiography (ASE) 17 segment model. Each assessment will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2) in each of the pre-specified windows according to the 2014 ASE Sonographer Guidelines.~A baseline echocardiogram will be performed prior to the administration of DEFINITY® or MVT-100. Assessments will be made three times, once from 0 - 1 ½ minutes following injection, once between 1 ½ minutes to 3 minutes following IV injection and once from 3 - 4 ½ minutes following IV injection. Assessments at each time point will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2). Each round will include the views in the following order: parasternal long, parasternal short, apical 4, apical 2 and apical 3."
41011073|NCT03882359|DRUG|MVT-100|After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
41011074|NCT03882359|DRUG|Definity|After randomization, Definity, the active comparator, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
41011075|NCT00881309|DRUG|Tripterygium|TW 90mg/d
41011076|NCT05283096|OTHER|Questionnaire|A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
41328179|NCT01797445|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
41011077|NCT01751503|PROCEDURE|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
41011078|NCT01751503|PROCEDURE|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
41011079|NCT03481959|DRUG|Methylphenidate|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
41155042|NCT03340766|DRUG|Pembrolizumab|One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
41155043|NCT04539938|DRUG|tucatinib|300 mg orally twice daily
41155044|NCT04539938|DRUG|trastuzumab deruxtecan|5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle
41328180|NCT01797445|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
41328181|NCT01797445|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
41155045|NCT02574949|RADIATION|Radiation: 15 FPS Cine 15 PPS|Radiation 15 FPS Cine 15 PPS
41328182|NCT01797445|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
41328183|NCT03448900|BEHAVIORAL|Multicomponent intervention|Motivational interview (50 minutes), on-line self-help material, support e-mail, group therapy, and second motivational interview (20 minutes)
41328184|NCT03448900|BEHAVIORAL|Brief advice|Brief advice (5-10minutes) and a self-help pamphlet
41328185|NCT04394143|DRUG|AD128|Oral administration of two capsules before sleep for 7 days.
41328186|NCT04394143|DRUG|Mannitol|Oral administration of two capsules before sleep for 7 days.
41480806|NCT05349578|DIAGNOSTIC_TEST|swab RUT|rapid urease test using swab instead of biopsied tissue
41155046|NCT02574949|RADIATION|Radiation: 7.5 low Frame rate|Radiation: Frame rate 7.5 FPS, Cine 15 PPS
40810253|NCT06659484|OTHER|Follow-up at T3 + 6 months and T3 + 12 months|"Follow-up at T3 + 6 months :~- After the T3 visit, patients will either be redirected to independent practice (booklet) or to relay structures. At T3 + 6 months (6 months after the 3-month visit), the kinesiologists will call each patient to assess their compliance with the program, any difficulties encountered, any falls (and their severity and consequences), fear of falling, their level of ADL/IADL autonomy, level of PA practice (RAPA), presence of frailty appreciation (FRIED), whether or not they have entered an institution.~Follow-up at T3 + 12 months :~At T3+12 months (12 months after the 3-month visit), patients will be seen again by the kinesiologists to make a final assessment of their physical and functional conditions, with measurements (Handgrip, SPPB, TUG, gait parameters, leg strength) and questionnaires (SarQol and FES-I).~Patients will only be seen again by the kinesilogists, as this is mainly a check-up and final advice visit, to continue the exercises performed since."
41155047|NCT02574949|RADIATION|Low Cine|Radiation: Frame rate 7.5 FPS, Cine 10 PPS
40810255|NCT06659302|BEHAVIORAL|I-inTERACT North Step 1|Initial questionnaires completed followed by initial meeting with therapist for baseline evaluation.
41155048|NCT03701581|DRUG|4-Aminopyridine|FDA-approved tablets.
41155049|NCT03701581|OTHER|Placebo|Placebo will be tooled to look similar to the study drug.
40810256|NCT06659302|BEHAVIORAL|I-inTERACT North step 2|Two online modules completed by family plus two online zoom coaching sessions with therapist.
40810257|NCT06659302|BEHAVIORAL|I-inTERACT North|Full program will consist of an additional 5 sessions with online modules and virtual coaching sessions with therapist.
40810258|NCT06658821|DIETARY_SUPPLEMENT|LDL557-HK capsule|Subjects will take once a day during the experimental period. one LDL557-HK capsule(Heat-killed Lactobacillus delbrueckii subsp. lactis LDL557 1x10\^10cell) within 30 minutes before lunch.
40810259|NCT06658821|DIETARY_SUPPLEMENT|Placebo Capsule|Subjects will take once a day during the experimental period. one placebo capsule within 30 minutes before lunch.
40810260|NCT06660121|PROCEDURE|Electrochemotherapy with bleomycin|Electrochemotherapy (ECT) with bleomycin is a localized treatment approach used for managing desmoid fibromatosis, a benign but locally aggressive tumor. This technique combines electrical pulses with the administration of bleomycin, a chemotherapeutic agent, to enhance drug uptake into tumor cells. The electrical pulses create temporary pores in the cell membranes, allowing bleomycin to enter more effectively, leading to increased cytotoxicity. ECT is typically performed on patients who have not responded to conventional therapies or for whom surgery is not feasible. ECT can lead to significant tumor shrinkage and improvement in symptoms, making it a promising option in the multidisciplinary management of desmoid fibromatosis.
40918158|NCT05539300|DIAGNOSTIC_TEST|PSMA-PET/CT response evaluation|PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront enzalutamide therapy
40918159|NCT00137878|DRUG|TNFerade™|
40918160|NCT03011944|OTHER|Quality Improvement Program|Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
41155050|NCT06270407|DRUG|Tranexamic Acid 100 MG/ML|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid
41155051|NCT06270407|DRUG|0.9%sodium chloride|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
40918161|NCT06460740|OTHER|4-7-8 breathing technique|Treatment will be given 18 exercise sessions per month (four to five times per week). The patient at first will be directed to sit or lie down, in which manner they feel sense of comfort. Then they are asked to exhale completely through mouth emptying their lungs. Then closing their lips and inhaling silently through nose while counting on the count of 4 seconds, holding their breath for a count of 7 seconds and exhale slowly through semi-closed lips making a Whoosh sound for a count of 8 seconds. Inhale, hold breath, and exhale ratio of 4:7:8. In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling.
40918162|NCT06460740|OTHER|Stationary Cycling|In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling
40918163|NCT03561688|DEVICE|Foot orthotics|Insoles for shoes
40918164|NCT03561688|DEVICE|Standard insole|Sham foot orthotic
40918165|NCT01051154|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
41011080|NCT03481959|OTHER|Matching Placebo|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
41011081|NCT02111616|BEHAVIORAL|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
40810261|NCT06661421|DEVICE|Dry Needling|This intervention combines Dry Needling Therapy (DNT) with routine physical therapy for children with spastic cerebral palsy. The experimental group will receive DNT alongside physical therapy, while the control group will undergo only physical therapy. Routine Physical Therapy includes a warm-up, stretching, and strengthening exercises like hamstring stretches and squats, adjusted over a month with increasing intensity. Dry Needling targets the gastrocnemius muscle using a fast-in, fast-out technique with sterile needles, applied weekly for 10 weeks. This combined approach aims to reduce spasticity, improve mobility, and enhance range of motion, distinguishing it from standard therapies.
40810262|NCT06661421|OTHER|Cerebral Palsy conventional Treatment|Sessions will include a 5-minute warm-up, stretching, and strengthening exercises. Hamstring stretches will be done with the child supine, one leg flat, and the opposite hip flexed to 90°. Active knee extension will be held for 5 seconds, followed by a 40-second assisted stretch, repeated five times. If a short psoas is detected, a prone psoas stretch will involve assisted hip extension for 5 seconds, followed by a 40-second hold, repeated five times. Strengthening exercises like squats, heel rises, and step-ups with a loaded backpack will target the lower extremities. The program will last one month, with three sessions per week, focusing on hamstring stretches and progressive resistance exercises.
40810263|NCT06661564|OTHER|Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42)|Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers
41328187|NCT00747539|DRUG|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
41480807|NCT00652756|DEVICE|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
40810264|NCT06661564|OTHER|Collection of a blood sample (5 mL) for blood biomarkers analysis|Collection of a blood sample (5 mL) for blood biomarkers analysis.
40918166|NCT01051154|DIETARY_SUPPLEMENT|Placebo|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
40918167|NCT04359901|BIOLOGICAL|SARILUMAB|Single dose of 400 mg subcutaneous sarilumab
41011082|NCT02111616|BEHAVIORAL|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
41480808|NCT00652756|OTHER|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
41480809|NCT02229565|DEVICE|Biopsy or prostatectomy|
41011083|NCT04311034|DRUG|RC48|Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.
41011084|NCT00103792|DRUG|mycophenolate mofetil|2000 mg mycophenolate mofetil per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
41011085|NCT00103792|DRUG|cyclophosphamide|2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
41011086|NCT06072430|DRUG|VBI-S|VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.
41011087|NCT05026463|PROCEDURE|Inspiratory support level|Inspiratory support is the pressure delivered by the ventilator during pressure support ventilation.
40918168|NCT02577887|DEVICE|Patients implanted with a St. Jude Medical pacemakers|
40918169|NCT00406562|BIOLOGICAL|Boostrix|
40918170|NCT03976804|OTHER|low dose CT scan|Lung cancer screening will be based on the analysis of a low dose CT scan
40918171|NCT03976804|OTHER|blood sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
40918172|NCT03976804|OTHER|faecal sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
40918173|NCT02482818|DRUG|Pregabalin|Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
40918174|NCT02482818|DRUG|Control-Placebo|A control substance, Lactose is administered in place of Pregabalin.
40918175|NCT04622943|BEHAVIORAL|firearms safety|interactive and engaging website with videos and educational games to teach children firearms, hunting and shooting safety
40918176|NCT04622943|BEHAVIORAL|nutrition|interactive and engaging website with videos and educational games to teach children about nutrition and exercise
40918177|NCT03597204|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
40918178|NCT00003497|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
40918179|NCT00119093|PROCEDURE|Laboratory and clinical monitoring regimens|
40918180|NCT00796523|BEHAVIORAL|Happiest Baby videotape|a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants
40918181|NCT00796523|BEHAVIORAL|control videotape|a videotape with general newborn care instructions
40918182|NCT04620213|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
40918183|NCT04620213|OTHER|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
40918184|NCT03557840|DRUG|temocillin|Drug dosing and blood sampling as per the protocol
40918185|NCT04268823|DRUG|QBW251|Capsule 300mg
40918186|NCT04268823|DRUG|Placebo|Capsule 300mg
40918187|NCT00811096|DRUG|Tinidazole|2gms, p.o. q.d. for 5 days
40918188|NCT00811096|DRUG|chloroquine|
40918189|NCT00178776|BEHAVIORAL|Transtheoretical Model Group Therapy|
40918190|NCT00178776|BEHAVIORAL|Education & Advice|
41155052|NCT05324605|PROCEDURE|Questionnaire and use of 3 D tools|Resulting computer tomography(CT) results are transferred to a 3 D projection. Patients will be asked to wear 3 D glasses to be able visualizing the diagnosed vascular pathology. The physician will explain the disaese and treatment. The patient is ask to fill out a questionnaire post 3D consulting
41155053|NCT04949789|OTHER|Placebo without Exercise|2 Capsules to be taken 30 minutes before breakfast.
41155054|NCT04949789|OTHER|Placebo with Exercise|2 Capsules to be taken 30 minutes before breakfast.
41155055|NCT04949789|OTHER|IP I|2 Capsules to be taken 30 minutes before breakfast.
41011088|NCT06468488|PROCEDURE|DIEP flap surgery without drain|Patients will undergo a breast reconstruction with a DIEP flap without the placement of drains.
41011089|NCT06468488|PROCEDURE|DIEP flap surgery with drains|Patients will undergo a breast reconstruction with a DIEP flap with the placement of drains.
41011090|NCT03256552|DRUG|Glycopyrronium MDI 28.8 micrograms|Glycopyrronium MDI 28.8 micrograms
41328188|NCT02681718|BEHAVIORAL|Community health worker education|Diabetes self-management education by community health workers
41480810|NCT04529330|PROCEDURE|fasciotomy|if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS
40810269|NCT06660290|DRUG|0.003% AR-15512 ophthalmic solution|Investigational ophthalmic solution for topical instillation
40810270|NCT06660290|DRUG|REFRESH® Classic ophthalmic solution|Commercially available ophthalmic solution for topical instillation
41155056|NCT04949789|OTHER|IP II|2 Capsules to be taken 30 minutes before breakfast.
41155057|NCT04949789|OTHER|IP III|2 Capsules to be taken 30 minutes before breakfast.
40810273|NCT06657950|BEHAVIORAL|Integrative hatha yoga and mindful self-compassion|12 weeks of integrative hatha yoga and mindful self-compassion training
40810274|NCT06660303|BEHAVIORAL|Comprehensive Preoperative Education for Enhanced Recovery in Colorectal Surgery|The intervention in this study involves preoperative patient education aimed at improving outcomes for individuals undergoing colorectal surgery. Patients in the study group will receive targeted educational sessions that focus on setting expectations, managing anxiety, understanding pain control, and preparing for the surgical process as part of the Enhanced Recovery After Surgery (ERAS) protocol. This educational approach is designed to empower patients, reduce anxiety, enhance satisfaction, and potentially improve post-surgical recovery compared to those receiving routine hospital care.
41011091|NCT03256552|DRUG|Glycopyrronium MDI 14.4 micrograms|Glycopyrronium MDI 14.4 micrograms
41011092|NCT03256552|DRUG|Glycopyrronium MDI 7.2 micrograms|Glycopyrronium MDI 7.2 micrograms
41011093|NCT03256552|DRUG|Placebo MDI|Placebo Inhalation Aerosol
41011094|NCT02066558|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
41328189|NCT02681718|BEHAVIORAL|Cell phone text messaging|Diabetes self-management education through cell phone text messaging
41328190|NCT04643665|PROCEDURE|Double-lung transplantation|
41328191|NCT03965871|DRUG|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
41328192|NCT03965871|DRUG|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
41328193|NCT03965871|DRUG|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
41328194|NCT03965871|DRUG|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
41480811|NCT03264820|DEVICE|Laser Doppler|- Laser measurements at the level of each finger at 47 °C and at ambient temperature
41480812|NCT03264820|DEVICE|Laser speckle|- Laser measurements at the forearm
41480813|NCT03264820|BEHAVIORAL|pain evaluation|Visual scale assesment pain
41480814|NCT03264820|OTHER|Blood pressure and heart rate|Measurement of blood pressure and heart rate
41480815|NCT03507413|DRUG|Metformin Glucophage 500mg (IR) tablets M90|oral metformin Glucophage treatment 500 mg daily (2-0-2) for 1 year
41480816|NCT03507413|DRUG|Placebo Oral Tablet|Placebo Oral Tablet M90 treatment twice daily (2-0-2) for 1 year
41011095|NCT02066558|OTHER|Placebo|
41011096|NCT04542629|DRUG|RiTUXimab Injection [Rituxan]|375 MG/M2 /WEEK INFUSION
41011097|NCT03987373|OTHER|non-interventional|This study is a non-interventional, observational study. After completing 12-month treatment from DACAB trial, investigators would not make any interventions or impact on subjects' therapeutic strategy.
41011098|NCT01994512|PROCEDURE|Decompression without fusion|Decompressive surgery of both central and lateral component of the stenosis.
41011099|NCT01994512|PROCEDURE|Decompression with fusion|Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
41155058|NCT00145496|DRUG|Asenapine|5-10 mg sublingually twice daily for up to 26 weeks
41155059|NCT00145496|DRUG|Olanzapine|5-20 mg by mouth once daily for up to 26 weeks
41155060|NCT06584942|DRUG|Suvorexant (20mg/day)|Participants will take 20mg suvorexant daily for 14 days.
41155061|NCT00666991|DRUG|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
41155062|NCT05382299|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
41155063|NCT05382299|DRUG|Paclitaxel|Administered intravenously
41155064|NCT05382299|DRUG|nab-Paclitaxel|Administered intravenously
41155065|NCT05382299|DRUG|Gemcitabine|Administered intravenously
41328195|NCT04839224|DRUG|carbogen|Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.
41328196|NCT04839224|DRUG|phenylephrine|Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
40810275|NCT06660303|OTHER|Routine hospital care|The control group, designated as Group II, will receive standard hospital care, encompassing the usual preoperative and postoperative procedures provided by the hospital. This includes typical preparation and recovery guidelines without any added specialized preoperative education or targeted nursing instructions. This routine hospital care serves as a baseline, allowing for a direct comparison of outcomes against the intervention group, which will receive comprehensive preoperative education aimed at enhancing recovery and improving surgical outcomes.
41480817|NCT02323165|OTHER|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
41480818|NCT02640365|DRUG|MM-398|unresectable Advanced non-colorectal cancer
41480819|NCT02640365|DRUG|Irinotecan|unresectable metastatic colorectal cancer
40810276|NCT06661603|BEHAVIORAL|GSY Yoga Intervention|In the GSY yoga intervention, where participants received 90 minutes/week yoga intervention for duration of 10 weeks.
41155066|NCT05382299|DRUG|Carboplatin|Administered intravenously
41155067|NCT04763863|OTHER|Body Assessment Tool|Assessment tool to evaluate stoma to find proper ostomy products
40810279|NCT06659003|OTHER|Pilot Implementation of Network Canvas into HBH Partner Services|Our team deployed our network data capture software - Network Canvas - into Partner Services at HBH to examine feasibility and acceptability and to provide initial evidence of efficacy (examining impacts on data quality, number of partners notified, and timeliness). Further, our team worked closely with HBH on developing implementation strategies, a Network Canvas interview protocol, evaluation measures, and training materials for their staff. Finally, we provided the HBH team technical support, and regular coaching, supervision, and evaluation.
40810280|NCT06660043|OTHER|physical activity|40 min circuit training session
40810281|NCT06660043|OTHER|analgesic physical therapy|physical therapy with massage and Transcutaneous Electrical Nerve Stimulation in a 40min session
40810282|NCT06660043|OTHER|analgesic physical therapy AND physical activity|25 min circuit training session and 15 min physical therapy
41155068|NCT04763863|OTHER|Clinical usability evaluation of the Body Assessment Tool|"The stoma care nurses evaluated the clinical usability of the Body Assessment Tool, which included answering the following questions:~Does the tool offer value in clinical practice? Does it provide a good starting point when choosing ostomy product(s)? Does it help raise the quality of care? Participants provided their responses on a 6 point-scale (1-6), where 1 indicated the lowest satisfaction and 6 the greatest satisfaction with the tool."
41155069|NCT01189617|DEVICE|Formula PD-F-7619|Off-White to Beige Lotion
40810285|NCT06662214|OTHER|Refined maize flour|Meal made form refined maize flour
40810286|NCT06662214|OTHER|Whole grain flour|Meal made form whole grain maize flour
41328197|NCT01860963|PROCEDURE|Anal Pap smear and HPV DNA testing|Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
40810288|NCT06660108|GENETIC|blood draw|Multiple blood draw for genomic and transcriptomic investigations
41480820|NCT02640365|DRUG|Leucovorin (LV)|unresectable metastatic colorectal cancer
40810289|NCT06660914|PROCEDURE|Flexible Ureteroscopy|Ureteroscopic lithotripsy
40810290|NCT06658808|BEHAVIORAL|Promoting Community Conversations About Research to End Suicide|Promoting Community Conversations About Research to End Suicide (PC CARES) trains local community health workers to facilitate a series of five 3-hour Learning Circles (LCs) over \~6 months to develop a 'community of practice' (CoP), whereby trusted adults of youth (a) learn about SPBPs; (b) tailor the SPBPs to their culture and community; (c) build cross-sector relationships (parents, teachers, etc.), and (d) do more to prevent suicide. Each session shares evidence-based, actionable ways to enhance social support, reduce harm/risk, and promote help seeking, which participants adapt and apply in their daily interactions with youth.
40810291|NCT06661408|BEHAVIORAL|Intervention group 1|The women assigned to this group will be shown the newborn bath application video prepared by the researchers in groups of 2-4 people in the form of a projection presentation.
40810292|NCT06661408|BEHAVIORAL|Intervention group 2|In groups of 2, the researcher will first explain the stages of newborn bathing application by the researcher in the form of a projection presentation, and then the pregnant women will be provided to perform the newborn bathing application on the newborn bathing model and tools simultaneously with the researcher.
41328198|NCT02501837|DRUG|Syntocinon-Spray|Intranasal administration of 24 IU Oxytocin
41328199|NCT05752071|DEVICE|Gastric electric pacemaker|Mounting of a temporary gastric pacemaker
41328200|NCT00289549|DRUG|forodesine hydrochloride (BCX-1777)|experimental, forodesine oral dose 200 mg administered daily.
41480821|NCT02640365|DRUG|5-fluorouracile (5-FU)|unresectable metastatic colorectal cancer
41328201|NCT03998904|PROCEDURE|Muscle preservation|Muscle preservation during graft preparation of hamstring graft
41328202|NCT03998904|PROCEDURE|No muscle preservation|No muscle preservation during graft preparation of hamstring graft
41328203|NCT02818127|PROCEDURE|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
41328204|NCT05987345|DEVICE|PEF|PEF device treated in the trial.
41480822|NCT02640365|DRUG|bevacizumab|unresectable metastatic colorectal cancer
41480823|NCT02640365|DRUG|MM-398|unresectable metastatic colorectal cancer
41480824|NCT02881060|DIETARY_SUPPLEMENT|Alcohol|
41480825|NCT02881060|DIETARY_SUPPLEMENT|Placebo|
41011100|NCT06129812|DRUG|Neoadjuvant treatment|Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
41480826|NCT05253365|BEHAVIORAL|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
41480827|NCT00127517|DRUG|peptide-nucleic acid solution AVR118|
41480828|NCT03153618|OTHER|VALIDATE system|Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
41480829|NCT01713179|DRUG|Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)|
41480830|NCT03339505|DIETARY_SUPPLEMENT|Salovum|Dietary supplement with high concentration of anti-secretory factor
41480831|NCT03339505|DIETARY_SUPPLEMENT|Placebo|Placebo for Salovum
41480832|NCT05009966|DRUG|SYSA1801 for injection|SYSA1801 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
41480833|NCT05703243|DIAGNOSTIC_TEST|Comprehensive liquid molecular panel test|Lab test
41011101|NCT03837496|OTHER|STRIDE|STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
41011102|NCT03837496|OTHER|Medication Monitoring Control|Care provided as standard by the hospital and medication monitoring
41011103|NCT00960700|DEVICE|Visual Acuity|Assessment of visual acuity
41011104|NCT00960700|DEVICE|Contrast sensitivity|Assessment of contrast sensitivity
41011105|NCT00960700|DEVICE|Reading Speed|Assessment of reading speed
41011106|NCT00960700|PROCEDURE|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
41011107|NCT01280188|DRUG|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
41011108|NCT01280188|DRUG|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
41011109|NCT05156229|BIOLOGICAL|CDK-003|CDK-003 administered subcutaneously
41011110|NCT05686304|BEHAVIORAL|Internet-based self-help money management program|The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation.
41011111|NCT06531863|DIETARY_SUPPLEMENT|Curcumin|Curcumin is a bioactive compound found in turmeric (Curcuma longa), known for its potent anti-inflammatory, antioxidant, and antimicrobial properties. Its therapeutic effects are primarily attributed to its ability to modulate various molecular targets and signaling pathways within the body
41480834|NCT05703243|OTHER|EORTC QLQ-30|Quality of life questionnaire
41011112|NCT06531863|DIETARY_SUPPLEMENT|Epigallocatechin Gallate|Epigallocatechin gallate (EGCG) is a type of catechin, a natural phenol, and antioxidant found predominantly in green tea. EGCG is known for its potent health-promoting properties, including strong antioxidant, anti-inflammatory, and anti-carcinogenic effects.
41011113|NCT06531863|OTHER|Placebo|Placebo to be consumed after randomization.
41011114|NCT05301335|DEVICE|SCONE|The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes
41011115|NCT01728467|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
41480835|NCT04979273|DRUG|Dextrose 40 % in Water|injection of adrenaline 1:20.000, followed by dextrose 40% spray
41480836|NCT04979273|DRUG|Adrenaline 1 Mg/mL Solution for Injection|injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
41480837|NCT04979273|PROCEDURE|argon plasma coagulation|Thermocoagulation
41480838|NCT04979273|PROCEDURE|Hemoclip|Hemoclip
41480839|NCT01427166|OTHER|Non invasive venous ultrasound|Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
41480840|NCT03604341|DRUG|Dronabinol 5mg Cap|Subjects randomized to Dronabinol 5mg Cap and ibuprofen 800mg for pain
41480841|NCT03604341|OTHER|Placebo|Subjects randomized to placebo and ibuprofen 800mg for pain
41480842|NCT00657228|DRUG|Intravenous heparin|"Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.~To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone."
41480843|NCT00657228|DRUG|Saline|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) and saline.
41480844|NCT02291471|DRUG|T0001，10mg|
41480845|NCT02291471|DRUG|T0001，20mg|
41480846|NCT02291471|DRUG|T0001，35mg|
41480847|NCT02291471|DRUG|T0001，50mg|
41480848|NCT02291471|DRUG|T0001，65mg|
41480849|NCT02291471|DRUG|T0001，75mg|
41480850|NCT03433365|OTHER|MRD analysis|To collect 2 samples for MRD analysis in patients treated with Lenalidomide
41480851|NCT01784354|OTHER|Acupressure|
41480852|NCT01784354|OTHER|Acupressure dilatation|
41480853|NCT01784354|BEHAVIORAL|education|
40810293|NCT06661395|DEVICE|Wingate Anaerobic Test with Virtual Reality|"Wingate Anaerobic Power Test Protocol, commonly used for assessing anaerobic capacity, involves a warm-up followed by testing. The warm-up includes 5 minutes of dynamic cycling, incorporating sprints. During the test, the athlete pedals at maximum effort for 30 seconds with added weight. Heart rate is monitored, and power output is measured every 5 seconds. Peak and average power values are calculated.~This protocol will be gamified for VR goggles. The warm-up simulates cycling in a forest. Athletes sprint for 5 seconds every minute to escape a train, with prompts on the screen. The testing phase includes a simulated race, with athletes pedaling at maximum effort for 30 seconds to compete against rivals, signaled by flares and a countdown."
41155070|NCT06646029|DEVICE|RMO flexion orthosis (splint)|RMO flexion is an orthosis fabricated by hand therapists made of thermoplastic material design to position the involved finger in relative flexion at the metacarpal joint compared to adjacent fingers to facilitate PIP extension during daily activity use.
41155071|NCT06646029|OTHER|Standard of care|Treatment includes finger stretches, active range of motion (AROM), passive range of motion (PROM), thermal modalities, LMB finger extension orthosis.
41328205|NCT05987345|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody administered on Day 7 then routinely.
41011116|NCT01728467|DRUG|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
41011117|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 1|daily intake of the content of one 45 mL bottle containing the product
41011118|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 2|daily intake of the content of one 45 mL bottle containing the product
41328206|NCT00818311|DEVICE|LED GentleWaves®|primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
41328207|NCT03071380|DRUG|Repatoxaban|1 tablet contains 10 mg rivaroxaban
41328208|NCT03071380|DRUG|Xarelto|1 tablet contains 10 mg rivaroxaban
41328209|NCT02198651|BIOLOGICAL|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
41328210|NCT02198651|OTHER|Placebo|Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
41328211|NCT04946162|DRUG|Tadalafil Pill|Each patient will be given tadalafil 40 mg one time
41328212|NCT00965146|DEVICE|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
41328213|NCT02481063|OTHER|Control|3 Consecutive Days Running at 80% Maximus Heart Rate
41328214|NCT02481063|OTHER|Eccentric Overload|Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
41328215|NCT02855242|BEHAVIORAL|Lifestyle Counseling|Participation in weekly group sessions over a period of 10 weeks, with information on healthy nutrition and exercises promoting weight loss
41328216|NCT02855242|OTHER|Controls Group|Subjects not participating in any lifestyle counseling
41328217|NCT03748342|DEVICE|Second-Generation Laryngeal Mask Airway|A second-generation LMA will be used for airway management (instead of ETT).
41328218|NCT01277471|BEHAVIORAL|Meal frequency (6 meals vs. 2 meals/day)|6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
41480854|NCT06126965|DRUG|KX-826-（5%） BID|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized active drug would be administered to the scalp once in the morning and once in the evening.
41480855|NCT06126965|OTHER|Placebo|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized matching placebo would be administered to the scalp once in the morning and once in the evening.
41480856|NCT05587335|BEHAVIORAL|PREP|Relationship intervention to improve communication and conflict resolution for couples
41480857|NCT05587335|BEHAVIORAL|OurRelationship|Relationship intervention to improve communication and conflict resolution for couples
41011119|NCT02778581|DIETARY_SUPPLEMENT|Placebo|daily intake of the content of one 45 mL bottle containing olive oil
41011120|NCT05822011|PROCEDURE|Rhomboid intercostal subserratus plane block|Fascial plane block
41328219|NCT01277471|BEHAVIORAL|6 meals/day followed by 2 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
41328220|NCT04595357|PROCEDURE|Iris shelf technique|Removal of posterior segment intraocular foreign bodies through corneal incision combined with phaco-vitrectomy
41328221|NCT01877941|DEVICE|Pulmonary Artery Catheter (PAC)|A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
41328222|NCT01877941|DEVICE|Endotracheal Cardiac Output Monitor (ECOM)|An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
41480858|NCT05451732|PROCEDURE|Nanofat grafting|Naofat grafting in the urethral stricture. The autologous adipose tissue is transferred by injection and in this way, the access to the urethral stricture is carried out with a minimal incision of the male urethra while in the female urethra is transferred exclusively with injections, without incision of urethral tissue.
41480859|NCT05240131|DRUG|GB1211|GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
41480860|NCT05240131|DRUG|Placebo|Placebo is administered orally twice a day.
41011121|NCT05822011|PROCEDURE|Erector spinae plane block|Fascial plane block
41011122|NCT05822011|PROCEDURE|Thoraccic Epidural analgesia|Neuroaxial block
41011123|NCT03296163|DRUG|MB02 (Bevacizumab Biosimilar Drug)|15 mg/kg IV every 3 weeks on Day 1
41011124|NCT03296163|DRUG|EU-approved Avastin®|15 mg/kg IV every 3 weeks on Day 1
41011125|NCT03296163|DRUG|Carboplatin|Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles
41011126|NCT03296163|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
41011127|NCT03023488|PROCEDURE|flexible ureteroscopy|Flexible ureteroscopy is an endourological procedure performed for kidney stones. The flexible ureteroscope is a device used to reach the renal cavities through the natural urinary tract in a retrograde fashion. During the operation, irrigation fluid is used to expand the cavities to provide space for movement of the device and also to provide clear vision.
41011128|NCT03023488|DEVICE|Doppler Ultrasound examination|peak systolic velocities (PSV) and end diastolic velocities (EDV) of the arteries will be measured and then resistive index (RI) and pulsatility index (PI) will be calculated.
41011129|NCT03023488|DEVICE|laser lithotripsy|The laser fiber extending into the cavities through the working channel of the ureteroscope is used to fragment the stones. Laser energy is generated by the laser machine and transmitted to the stones via the laser fiber.
41011130|NCT01045226|PROCEDURE|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
41011131|NCT01045226|OTHER|Quality-of-Life assessment|Quality of Life Assessment
41328223|NCT01877941|DEVICE|Estimated Continuous Cardiac Output (esCCO)|Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
41011132|NCT01045226|OTHER|Questionnaire Administration|Questionnaire Administration
41328224|NCT01385267|PROCEDURE|aspiration of amniotic fluid|a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
41011133|NCT05932199|DRUG|Durvalumab / tremelimumab|"Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
41011134|NCT05932199|DRUG|Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab|"Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
41328225|NCT06219928|PROCEDURE|Control Group|After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline
41480861|NCT05240131|DRUG|Atezolizumab|Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
41480862|NCT04810442|OTHER|Nap|45-minute nap between scanning procedures
41480863|NCT03116321|DRUG|Eslicarbazepine acetate (ESL)|Oral Tablet of 800 mg and 200 mg of ESL
41480864|NCT05302570|RADIATION|Hypofractionated Proton Beam Therapy|5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
41480865|NCT02698865|DEVICE|MONOVISC|Two (2) intra-articular injections of 4 ml MONOVISC, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
41011135|NCT02575781|DRUG|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
41011136|NCT02550964|PROCEDURE|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
41011137|NCT04485481|DRUG|ADX-914|Single dose from 0.1mg/kg to TBD
41328226|NCT06219928|PROCEDURE|Ketamine Group|After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.
41328227|NCT06219928|PROCEDURE|Dexmedetomidine|After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.
41328228|NCT05726448|BEHAVIORAL|Telehealth solution|Mobile-friendly nutrition education platform
41328229|NCT02670915|DRUG|Faster-acting insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
41328230|NCT02670915|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
41480866|NCT02698865|DEVICE|Saline|Two (2) intra-articular injections of 4 ml saline, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
41480867|NCT01083017|DRUG|chlorthalidone|chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
41480868|NCT01083017|BEHAVIORAL|motivational intervention for non-compliant individuals|motivational interview(s) vs. repeated calls vs. no particular intervention
41480869|NCT01083017|DRUG|standardized anti-hypertensive treatment|olmesartan, amlodipine, chlorthalidone, +- spironolactone
41011138|NCT04485481|DRUG|Placebo|Matching single dose placebo
41011139|NCT04485481|DRUG|ADX-914|Multiple dose from TBD to TBD
41011140|NCT04485481|DRUG|Placebo|Matching multiple dose placebo
41011141|NCT05438082|DRUG|Antibiotic Prophylaxis|This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg
41011142|NCT05438082|OTHER|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
41155072|NCT05681845|DRUG|NNC0365-3769 (Mim8)|Participants will receive a single dose of Mim8 subcutaneously in the abdomen.
41155073|NCT00586807|OTHER|Stable amino acid isotopes|Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
41155074|NCT06193486|BIOLOGICAL|MSGV1-PSCA-8T28Z|Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.
41155075|NCT06193486|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
41155076|NCT06193486|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
41328231|NCT02670915|DRUG|insulin degludec|For subcutaneous (s.c., under the skin) injection once daily.
41328232|NCT05405907|OTHER|PuraBond haemostatic agent|Application of Purabond to surgical field
41011143|NCT04564976|BEHAVIORAL|Social support image|An image of a social support figure specific to each participant (provided by the participant) will be present while participants undergo a fear acquisition procedure. Specifically--the image will be presented alongside a neutral image that is either consistently paired with shock (CS+) or never paired with shock (CS-), so that assessment of whether there are differences in fear responding (evaluated via SCR) due the shock pairing can be assessed. This is a typical fear acquisition procedure, and a typical outcome would be for SCR to be higher for the CS+ compared to the CS- toward the end and following the procedure, indicating that the CS+ is now associated with the aversive shock and is bringing about a fear response (in this case indexed by increased sympathetic nervous system activity preparing the body to fight or flee).
41011144|NCT02619409|DRUG|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
41011145|NCT02619409|DRUG|EPI25|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
41011146|NCT02619409|DRUG|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
41011147|NCT02619409|DRUG|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
41011148|NCT02619409|DRUG|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
41011149|NCT04537806|DRUG|Brexanolone|Administered as IV infusion.
41011150|NCT04537806|DRUG|Placebo|Administered as IV infusion.
41011151|NCT00625599|OTHER|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
41011152|NCT00587587|DEVICE|Apligraf|Application at Day 0, potential re-application at Week 4
41011153|NCT00587587|OTHER|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
41011154|NCT05900427|DRUG|Liposomal bupivacaine|Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
41011155|NCT05900427|DRUG|Bupivacaine|Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
41011156|NCT05165121|DEVICE|MDHearing smart hearing aid|air conduction hearing aid with app support
41011157|NCT02180425|DRUG|Tretinoin or Adapalene|Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
41011158|NCT02180425|DRUG|Isotretinoin|Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
41328233|NCT06528184|DIAGNOSTIC_TEST|Self-sampled HPV DNA testing|Participants will be offered HPV DNA testing done through self-sampling (using self-sampling HPV DNA kits to obtain a mid-vaginal swab)
40918191|NCT03035877|BEHAVIORAL|Multisystemic Therapy-Emerging Adults|MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
41328234|NCT06528184|DIAGNOSTIC_TEST|Clinician-sampled HPV DNA test|Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)
41328235|NCT01969942|BIOLOGICAL|allogeneic stem cell transplantation|
41328236|NCT01969942|DRUG|Clyclophosphamide|
41328237|NCT01969942|DRUG|Fludarabina|
41328238|NCT01969942|DRUG|Busulfan|
41328239|NCT01969942|DRUG|Melphalan|
41328240|NCT04883567|DIAGNOSTIC_TEST|The use of artificial intelligence system Cerebro|The artificial intelligence system Cerebro would be used during OGD
41480870|NCT01613950|DRUG|AUY922|AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
41480871|NCT01613950|DRUG|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
41480872|NCT03907800|DRUG|Nab-paclitaxel|125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
41480873|NCT03907800|DRUG|Carboplatin|AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles
41480874|NCT03907800|DRUG|Herceptin|In case of HER2-positive, patients receive Herceptin weekly during all cycles.
40918192|NCT03035877|BEHAVIORAL|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
40918193|NCT03069729|OTHER|no intervention|This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
40918194|NCT03028454|DIETARY_SUPPLEMENT|Ginger Root|Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
40918195|NCT03028454|DIETARY_SUPPLEMENT|Placebo|Capsules containing rice flour powder.
40918196|NCT02816827|DIETARY_SUPPLEMENT|AG-01|Product to increase mental alertness
40918197|NCT02816827|DIETARY_SUPPLEMENT|AG-05|Product to increase mental alertness
40918198|NCT02816827|DIETARY_SUPPLEMENT|AG-06|Product to increase mental alertness
40918199|NCT02816827|DIETARY_SUPPLEMENT|AG-07|Product to increase mental alertness
40918200|NCT05674097|OTHER|no intervention|no intervention
40918201|NCT00920803|DRUG|Placebo|Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.
40918202|NCT00920803|DRUG|SRT501|SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
40918203|NCT02206789|DRUG|Prednisolone acetate1%,|efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
40810297|NCT06658223|OTHER|Exercise with virtual reality|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person's condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
40810298|NCT06662123|DRUG|Anifrolumab|Participants will receive a single SC or IV dose of anifrolumab at day 1
40810299|NCT06659081|PROCEDURE|socket shield technique|partial extraction therapy : sectioning the root and keeping part of it in contact with labial plate of bone
40810300|NCT06659081|PROCEDURE|subepithelial connective tissue graft|A connective tissue graft harvesting from maxillary tuberosity area
40810301|NCT06659081|PROCEDURE|implant placement|implant placement
41155077|NCT05682040|DIAGNOSTIC_TEST|Bedside Compression Ultrasonography|Point of Care Ultrasound (Bedside Compression Ultrasonography) vs formal lower extremity Doppler
40810303|NCT06659510|OTHER|education|ACCORDING TO THE RESULTS AFTER THE SURVEY APPLICATION, TRAINING WAS PROVIDED TO THE ADDICTIVE STUDENTS IN THE EXPERIMENT GROUP AND MESSAGES WERE SENT FROM WHATSAPP APPLICATION IN THE FOLLOWING 2 MONTHS AFTER THE TRAINING.
40810304|NCT06662110|DIAGNOSTIC_TEST|PSRscore|PSRscore calculated based on baseline serum immune proteomics
41011159|NCT05287464|DRUG|pembrolizumab plus axitinib|collect global experiences with the use of immuno-combinations in patients with metastatic RCC
41011160|NCT04011059|BIOLOGICAL|Wharton's jelly-derived mesenchymal cells|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
41328241|NCT04754113|OTHER|prone position|patient was helped into the prone position, patient received instructions of end expiratory occlusion lasting at least 10 seconds and, 1 seconds after the start, a bolus of 10 mL of 5% NaCl solution was injected via the central venous catheter
41328242|NCT04088708|OTHER|Aerobic Exercise Training|Each session will last 20 to 60 minutes depending on the stage of progression (shorter duration in the first few weeks). Sessions will occur on nonconsecutive days of the week. Moderate-intensity, continuous aerobic exercise will be used to target large muscle groups (e.g., legs) with the principal goal of increasing cardiorespiratory fitness. Exercise intensity will be gradually increased. To mitigate stagnation and support continued improvement of cardiorespiratory fitness, high-intensity interval exercise will be added in later weeks of the intervention.
41328243|NCT04088708|OTHER|Attention Control|The flexibility/toning control condition will be delivered using the same frequency as the aerobic condition (i.e., 3 times per week) and use light resistance bands of least difficulty. The flexibility/toning sessions will last about 40 minutes, be led by trained exercise specialists. Flexibility/toning activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, and ankle/foot. The progression of activities over the 10-week period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands (i.e., Thera-bands) that provide minimal resistance.
41480875|NCT05603455|DIETARY_SUPPLEMENT|Bifidobacterium adolescentis|Supplement with Bifidobacterium adolescentis twice/day in morning and tonight for 6 months
41480876|NCT05603455|DIETARY_SUPPLEMENT|Placebo|Placebo
40810305|NCT06660810|DRUG|Talimogene Laherparepvec|"Talimogene laherparepvec (HSV-1 \[strain JS1\]/ICP34.5-/ICP47-/hGM-CSF) is an oncolytic immunotherapy, formerly known as OncoVEXGM-CSF, an immune-enhanced, oncolytic herpes simplex virus type 1 (HSV-1)~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
40810306|NCT06660810|RADIATION|Neoadjuvant Radiation|"Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given.~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
41011161|NCT05584501|OTHER|Care Navigator|The Dental Team will have a Care Navigator as an added resource to assist with offering, implementing, and counseling for HIV testing; providing PrEP education and linkage; and providing linkage and re-linkage to HIV care.
41011162|NCT05584501|OTHER|Health Information Supported Ending the HIV Epidemic (ETE) Activities in Dental Setting|Dental Teams will receive a Best Practice Alert (BPA) when they have a patient who should be offered HIV testing. Dental Teams will also be notified when they have a patient known to be HIV positive but out of HIV care.
41011163|NCT05524402|BEHAVIORAL|TOR-C 1|TOR-C 1 is an active intervention, adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program with weekly sessions and home practice.
41155078|NCT00511147|BIOLOGICAL|IGIV3I Grifols 10%|IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
41155079|NCT05797116|OTHER|Survey|29-item Dutch survey about the implementation and practice variation of preoperative multidisciplinary team (MDT) meetings for high risk noncardiac surgical patients in the Netherlands.
41328244|NCT00734812|PROCEDURE|Laparoscopic supracervical hysterectomy|Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
41328245|NCT00734812|PROCEDURE|Total laparoscopic hysterectomy|Patients will be randomized to either removal or retention of cervix
41328246|NCT06317922|DEVICE|Thealoz Duo;|THEALOZ DUO is a solution containing trehalose (3%), sodium hyaluronate (0.15%), sodium chloride, trometamol, hydrochloric acid, and water for injections; Hydraback is a solution containing a sodium chloride 0.9 %, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, water for preparations for injection.
40810307|NCT06660810|PROCEDURE|Surgery|Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care
41155080|NCT00348283|BIOLOGICAL|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
41328247|NCT06317922|DEVICE|sham (Hydrabak)|Hydrabak is an ophthalmic solution containing: sodium chloride 0.9%, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, and water for injectable preparations
41328248|NCT04939870|DIAGNOSTIC_TEST|Biochemical parameters evaluation|selected biochemical parameters
40810311|NCT06660212|DEVICE|Photobiomodulation|The laser therapy will be delivered in progressively higher doses, based on individual participants. Each stage will follow this sequence of applications: (1) perineum application (DUO-240 red and infrared array in the surface of the perineum) and (2) LDR-100 probe on the vestibula more generally. Doses will increase from 40%-100% power over the course of the intervention
40810312|NCT06660212|DEVICE|Sham photobiomodulation|The laser therapy will be delivered in progressively higher doses, based on individual participants tolerance. Each stage will follow this sequence of applications: (1) perineum application (DUO-240 red and infrared array in the surface of the perineum) and (2) LDR-100 probe on the vestibula more generally. . Doses will always be set to 1% power over the course of the intervention
41011164|NCT05524402|BEHAVIORAL|TOR-C 2|TOR-C 2 is an active intervention teaching educational information on key modifiable factors relating to recovery after concussion, such as return to activity, the role of nutrition and sleep, and the relationship between concussion and anxiety. The format is a 4-week program delivered over live video with weekly sessions.
41480877|NCT06304649|DEVICE|Cast or brace alternative|Waterproof alternative to a cast or brace for broken bones
41011165|NCT06192771|BEHAVIORAL|ESSI-SURG|Patients will receive 3 face-to-face sessions with a speech-language pathologist (SLP), each with a specific goal, namely: pre-surgical educational, a post-operative day 3 therapy, and post-operative day 7 therapy. Following discharge from hospital, participants will be seen by an SLP for 4 weekly sessions, offered via telehealth or face-to-face depending on the patient's clinic schedule and/or availability.
41328249|NCT05494983|OTHER|Screening visit|The participants will be screened for inclusion and exclusion criteria and will be asked to fill the following questionnaires : Pittsburgh Sleep Quality Index, State and Trait Anxiety Questionnaire, Pain Catastrophizing Scale Fear of Pain Questionnaire, Perceived Stress Scale, Beck Depression Inventory, and questionnaires to assess their health status and the use of medications. A blood sample (to measure pro- and anti-inflammatory cytokines and perform metabolomic analyses) will be obtained. Enrolled participants will be given a wearable actimeter to assess daily total sleep duration during one week before the first experimental session. They will also be requested to complete daily a sleep diary during one week before each experimental session, and a food diary before the first experimental session. A fecal sample (to assess gut microbiota composition and perform metabolomic analyses) will be collected between the screening visit and the first experimental session.
41480878|NCT04291807|BEHAVIORAL|Video education|Procedure was presented to the cases via a video showing the steps in ERCP and questions had been answered by an experienced nurse
41480879|NCT05727475|PROCEDURE|Minimal invasive restorative treatment|Composite veneer facing without drilling or removal of enamel
41480880|NCT05727475|PROCEDURE|Fluoride gel application|Fluoride gel application 1.23%
41480881|NCT05023577|DRUG|Rabeprazole|20mg bid
41480882|NCT05023577|DRUG|Bismuth potassium citrate|0.6g bid
41480883|NCT05023577|DRUG|Metronidazole|0.4g qid
41480884|NCT05023577|DRUG|Clarithromycin|0.5g bid
41480885|NCT05023577|DRUG|Levofloxacin|0.5g qd
41011166|NCT06192771|BEHAVIORAL|Standard-of-Care|Participants will receive the current standard of care, which includes a referral to SLP in response to suspicion of a swallowing problem from either assessment by the medical team and/or patient report.
41011167|NCT06285539|DRUG|Filgotinib|Filgotinib
40810313|NCT06660212|PROCEDURE|Multimodal physiotherapy|A total of 10 sessions of multimodal physiotherapy interventions will be provided to each of the participants in the multimodal physiotherapy (mPT) and multimodal physiotherapy combined with photobiomodulation treatment (mPT+PBM) groups. In general, each session will take place in the following order:1) Subjective assessment of the condition and screening for adverse effects or deterioration of the condition, 2)Education, 3) Relaxation Techniques, 4) Pelvic Floor Muscle Exercises, 5) Manual techniques, 6) exercises with accommodators, 7) Global exercises, 8) Assessment of the post-treatment condition and 9) adjustment of the weekly exercise program to be done at home. Each of these 9 treatments will be adjusted and tailored to each participant and progressed based on individual preference and response to treatment under the discretion of the study physiotherapist.
40810314|NCT06661512|OTHER|Neurorehabilitation program|"Participants will participate in a neurorehabilitation program, consisting in a structured, interdisciplinary approach designed to help individuals improve their functional abilities following acquired brain injury. The goal is to optimize the individual's physical, cognitive, emotional, and social functioning to enhance their quality of life~The neurorehabilitation program includes, physical rehabilitation, occupational therapy, speech therapy and neuropsychological rehabilitation (cognitive, emotional and behavioral)."
41011168|NCT04915859|OTHER|Hand Cooling at 12-15 degrees celsius|hand cooling at 12-15 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
41011169|NCT04915859|OTHER|Hand Cooling at 16-20 degrees celsius|hand cooling at 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
41011170|NCT04915859|OTHER|hand and back cooling at 12-15 or 16-20 degrees celsius|hand and back cooling at 12-15 or 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature while also wearing the back wrap cooling device set to this temperature
41011171|NCT04915859|OTHER|Passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
41011172|NCT06087172|DIAGNOSTIC_TEST|Six Minutes Stepper Test (6MST)|Patients were applied two 6MST and 6MWT. 6MWT was conducted to test convergent validity of 6MST.
41011173|NCT05124639|BEHAVIORAL|Group self-management support program for anxiety disorders|The group SMS manualized program for anxiety disorders (https://monrelief.ca) aims at improving self-management capabilities through weekly 2.5-hours sessions with 10-15 patients over a 10-week period.This trial will focus solely on the virtual format of the program. The SMS program covers the following themes: getting to know your anxiety; building self-awareness; reconsidering your lifestyle habits; adopting a problem-solving method; avoidance and exposure; acceptance and committed action; seeing things differently; managing your emotions; receiving support from others; and consolidating your toolkit.
41480886|NCT02794259|DEVICE|tDCS|
41480887|NCT02794259|DEVICE|sham-tDCS|
41328250|NCT05494983|OTHER|Peripheral sensitization session|The extent of neurogenic inflammation induced by topical capsaicin will be used as a measure of the susceptibility to sensitize at peripheral level. A solution of capsaicin will be applied to the skin of the left or right volar forearm for 30 minutes. The capsaicin-induced neurogenic inflammation can be quantified by assessing the intensity, extent and duration of the capsaicin-induced cutaneous flare response using thermal infrared imaging. Using heat stimuli delivered to the treated skin and surrounding skin, the intensity and duration of the capsaicin-induced hyperalgesia will also be assessed. The experimental session will last approximately two hours.
41480888|NCT03237533|DRUG|Dexamethasone|Dexamethasone will be applied locally on the lesion
41480889|NCT02265341|OTHER|Laboratory Biomarker Analysis|Correlative studies
41011174|NCT04737642|PROCEDURE|Papillary ballon dilatation|Trans cystic papillary ballon dilatation during cholecystectomy
41011175|NCT03006666|BEHAVIORAL|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention."
41480890|NCT02265341|DRUG|Ponatinib Hydrochloride|Given PO
41480891|NCT02265341|OTHER|Quality-of-Life Assessment|Ancillary studies
41480892|NCT02192749|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
41480893|NCT05023382|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection
41480894|NCT00594646|DRUG|TRUVADA + Raltegravir|TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
41155081|NCT00348283|BIOLOGICAL|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
40810316|NCT06661746|DRUG|Multimodal IV analgesia|Multimodal IV analgesia of lidocaine, ketamine and MS
40810317|NCT06661746|DRUG|epidural analgesia|Opioid-based and epidural analgesia
40810318|NCT06658769|OTHER|Theta Burst Stimulation|Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation (NIBS) technique that involves modulating brain excitability and activity, which can increase or decrease depending on the parameters used. Theta Burst Stimulation (TBS) mimics the brain's natural firing patterns more closely and may have greater effects on cognitive performance.
40810319|NCT06658769|OTHER|Theta Burst Stimulation Sham|Theta Burst Stimulation simulated with 90º coil orientation with lower part external to the scalp.
41155082|NCT00348283|BIOLOGICAL|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
41155083|NCT06416111|DEVICE|NIRS|Near Infra-Red Spectroscopy (NIRS) is a non-invasive monitoring modality which measures regional tissue oxygenation defined as percentage (%).
41155084|NCT06416111|OTHER|Pinprick Test|"With the pinprick test, the practitioner gently touches the skin with the pin and asks the patient whether it feels sharp or blunt .Test begins distally and then move proximally (aiming to test each dermatome and each main nerve).~Assessment of sensorial blockade uses 3 grade system. Grade 0.Sharp pain Grade 1.Analgesia ,numbness Grade 2.Anesthesia ,no feeling"
41480895|NCT03044236|PROCEDURE|Stretching|The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
40810324|NCT06660069|DRUG|Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)|Toothpaste containing 0.454 percent (%) weight by weight (w/w) SnF2.
40810325|NCT06660069|DRUG|CPC Mouthwash (Parodontax Active Gum Health Mouthwash)|Mouthwash containing 0.07% w/w CPC.
40810326|NCT06660069|DRUG|Regular Fluoride Toothpaste (Crest Cavity Protection)|Toothpaste containing 0.243% w/w sodium fluoride.
40810327|NCT06660069|DRUG|Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)|Toothpaste containing 0.454% w/w SnF2.
41480896|NCT04072276|BIOLOGICAL|EV71 vaccine|EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study
40810329|NCT06661369|OTHER|Sensory Perceptual Motor Training on Group|"1. Sensory Input~   * Wheelbarrow walks, swimming, and drying off.~2. Proprioceptive~   * Climbing, pushing, pulling, and carrying heavy objects.~3. Vestibular~   * Swinging, trampolining, and playground games.~4. Tactile~   * Stereognosis training, textured paths, and messy play (mud, sand).~5. Motor Planning~   * Statue spinning, crawling through/under objects, and quick movements.~6. Balance and Posture~   * Various balance positions (e.g., hands and knees).~7. Ocular Control~   * Catching and tossing balls.~8. Bilateral Coordination~   * Activities using both sides of the body (e.g., stick ball).~9. Visual-Spatial~   * Walking, stair climbing, and puzzles.~10. Fine Motor Skills~    * Puzzles, bead stringing, and drawing.~11. Gross Motor~    * Standing, walking, running, and throwing games."
40810330|NCT06661369|OTHER|Sensory Perceptual Motor Training on Individual|"1. Sensory Input~   * Wheelbarrow walks, swimming, and drying off.~2. Proprioceptive~   * Climbing, pushing, pulling, and carrying heavy objects.~3. Vestibular~   * Swinging, trampolining, and playground games.~4. Tactile~   * Stereognosis training, textured paths, and messy play (mud, sand).~5. Motor Planning~   * Statue spinning, crawling through/under objects, and quick movements.~6. Balance and Posture~   * Various balance positions (e.g., hands and knees).~7. Ocular Control~   * Catching and tossing balls.~8. Bilateral Coordination~   * Activities using both sides of the body (e.g., stick ball).~9. Visual-Spatial~   * Walking, stair climbing, and puzzles.~10. Fine Motor Skills~    * Puzzles, bead stringing, and drawing.~11. Gross Motor~    * Standing, walking, running, and throwing games."
41011176|NCT03006666|BEHAVIORAL|Data Only|The teams randomly allocated will not have access to Community Health Workers.
41011177|NCT04901455|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
41480897|NCT01348984|DRUG|transdermal fentanyl patch|TFP = transdermal fentanyl patch (50 microgram/hour)
41480898|NCT01348984|DRUG|placebo patch|group 2 = placebo patch
41480899|NCT00049842|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg Weekly QW SC for 36 months
41480900|NCT03269799|DRUG|Vitamin C 500 MG Oral Capsule|non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
41480901|NCT03269799|OTHER|placebo|non surgical periodontal treatment+placebo for 2 months
41480902|NCT00971737|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|Given intradermally
41480903|NCT00971737|BIOLOGICAL|trastuzumab|Given IV
41480904|NCT00971737|DRUG|cyclophosphamide|Given IV
41480905|NCT01124357|DEVICE|NovaSure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
41480906|NCT01124357|DEVICE|thermachoice|ThermachoiceTM III thermal balloon ablation
41480907|NCT03401450|DRUG|ACB within true AC with bupivacaine 0.5% 20cc|The adductor canal block (ACB) is more commonly being used to provide post-operative analgesia since it provides a sensory block with minimal motor block.
41155085|NCT06416111|OTHER|Modified Bromage Scale|"Assessment of motor blockade uses 4 point Modified Bromage Score. 0.Normal motor function with full extension and flexion of elbow, wrist and fingers~1. Decreased motor strengths with ability to full flexion elbow and move fingers but inability to raise arm~2. More decreased motor strengths with inability to move elbow but ability to move fingers 3.Complete motor block with inability to move elbow, wrist, and fingers."
41155086|NCT06416111|DRUG|Bupivacaine|Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
40810333|NCT06661668|DEVICE|Gastric pacemaker (Enterra system) implantation|Laparascopic implantation of a gastric pacemaker (Enterra system) for patients with therapy refractive gastroparesis
40810334|NCT06660368|DRUG|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.
40810335|NCT06660368|DRUG|Venetoclax|Venetoclax will be administered orally, once daily, with food.
40810336|NCT06659068|DIETARY_SUPPLEMENT|Seluang fish oil (Rasbora argyrotaenia) and synbiotic|The patients received seluang fish oil (Rasbora argyrotaenia) and synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation
40810337|NCT06659068|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
40810338|NCT06657872|PROCEDURE|water vapor therapy under general anesthesia|Water vapor procedure will be performe under conscious intravenous sedation with anesthesia team
40810339|NCT06657872|PROCEDURE|water vapor therapy under local anesthesia|Water vapor procedure will be performe under local anethesia administrated with Schelin® catheter via the trans-urethral route : injection of 20cc of lidocaine 2% intra-prostatically via the schelin catheter at 4 injection points (3cc at 1h, 3cc at 11h, 7cc at 4h, and 7cc at 8h).
40810340|NCT06659172|DEVICE|taVNS|transauricular vagus nerve stimulation
40810341|NCT06661772|DIAGNOSTIC_TEST|Vancomycin trough concentration method|A blood sample for VTL was drawn 30 minutes before administration, prior to the fourth dose of vancomycin, under a complete aseptic technique, unless otherwise ordered by the medical team. Vancomycin serum concentrations were measured using a Human vancomycin ELISA Kit.
41155087|NCT06416111|DRUG|Prilocaine|Prilocaine is an amide local anesthetic secondary amine with an intermediate length of duration and quick onset of action.
41155088|NCT05664061|DRUG|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|twice daily inhalation throughout the treatment period
41011178|NCT05907356|OTHER|sciatic nerve slider technique in slump lying position|The patient will be sitting at the edge of the couch with the posterior aspect of the knee at the edge, the thighs parallel to each other, and flexion at the thoracic and lumbar spines (slouch position). The therapist will be standing at the bedside of the patient with a proximal arm over the patient's shoulder and one hand guiding the neck movements of the patient and the other hand guiding the knee movements, passively performing cervical neck flexion with knee flexion (stretching the nerve proximally and relaxing at the distal end) and then moving into cervical extension with knee extension. Provide five sets in every session: the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions; and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes
41155089|NCT05664061|DRUG|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the treatment period
41155090|NCT05664061|DRUG|Placebo|twice daily inhalation throughout the treatment period
41328251|NCT05494983|OTHER|Central sensitization session|The extent of secondary mechanical hyperalgesia induced by high-frequency electrical stimulation (HFS) of the skin of the left or right volar forearm will be used as a measure of the susceptibility to develop central sensitization. The stimulation will be delivered using a multi-pin electrode designed to preferentially activate epidermal free nerve endings. The strength, spatial extent and duration of the HFS-induced changes in pinprick sensitivity will be characterized by using calibrated mechanical pinprick stimuli. The experimental session will last approximately one hour.
40810346|NCT06658301|OTHER|plyometric push up exercises|The subjects will starts with push-up position with hands on the floor, place slightly wider than shoulder width apart and their feet together. Keeping their back flat, slowly lower the body toward the ground. Then in one explosive movement, push-up and away from the floor as quickly as possible, bring their hands off the floor.
40810347|NCT06658301|OTHER|swiss ball push up exercises|. The subjects will start with kneeling position so that they will face the ball. Place their hands on top of the ball so that they can bend their elbows towards the body. Straight the legs out and raise themselves slightly higher so that they can be on their toes. Stay in neutral position. Straighten their arms at the elbows, so that they can push themselves up from the ball.
41328252|NCT04029324|PROCEDURE|tooth extraction|Under local anesthesia, tooth will be extracted atraumatically.
40810349|NCT06660667|BIOLOGICAL|SAR402663|Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection
40810350|NCT06660667|DRUG|Diluent|Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection
41328253|NCT04029324|PROCEDURE|Implant placement|Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
41328254|NCT04029324|PROCEDURE|Bone augmentation|Bone substitute will be used to augment or maintain the bone contour.
41328255|NCT04029324|PROCEDURE|Coronally repositioned flap|After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
41155091|NCT06248021|BEHAVIORAL|Ecological Footprint Awareness Program|The program was conducted for four weeks, one day each week, for 40 minutes. Each week, a different topic was addressed such as waste evaluation, water and energy usage, food consumption, and transportation. The program was created in line with expert opinions and literature. The sessions were based on the principles of the Social Cognitive Learning Theory, developed by Bandura, which includes mutual determinism, symbolization, anticipatory capacity, vicarious learning, self-regulation capacity, and self-judgment capacity. During each session, various techniques such as animation, drawing, storytelling, memory cards, and games were employed. To ensure the program's content was appropriate for children's development, the opinions of two experts from the child development department of the university were obtained.
41155092|NCT00683514|DRUG|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 28 days :~* 50 mg/m2 oral vinorelbine d1, d8, d15~* 20 mg/m2/d cisplatin from d1 to d4"
41155093|NCT00683514|DRUG|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 21 days :~* 60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2~* 80 mg/m2 cisplatin d1"
40810355|NCT06659640|DRUG|ALN-6400|ALN-6400 will be administered subcutaneously (SC)
40810356|NCT06659640|DRUG|Placebo|Placebo will be administered subcutaneously (SC)
40810357|NCT06662344|BEHAVIORAL|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
40810358|NCT06662344|BEHAVIORAL|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
40810359|NCT06662344|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
40810360|NCT06658392|OTHER|cognitive tasks|no intervention in a medical sense, only observing changes of BOLD signal during different experimental conditions in cognitive tasks (arithmetic, attention, inhibition)
40810361|NCT06660992|DRUG|HSK31858, tablet|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis
40810362|NCT06660992|DRUG|Placebo|the placebo comparator of study
41328256|NCT01035008|PROCEDURE|Endoscopic Ultrasound (EUS)|The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
41328257|NCT04662411|DIETARY_SUPPLEMENT|Placebo|acute intake of 0 mg butyrate and hexanoate
40810368|NCT06657989|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
40810369|NCT06657989|BEHAVIORAL|Walking|Overground walking
40810370|NCT06660329|DRUG|Janus Kinase Inhibitor|Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.
40810371|NCT06659029|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
40810372|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Floragyn® probiotic tablets (Lapi, Indonesia)|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~One tablet Floragyn contains Lactobacillus rhamnosus and lactobacillus reuteri, bacteria that are normal flora (good bacteria) of the vagina."
40810373|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Cal95|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~Cal 95 is a supplement containing multivitamins and minerals including: Calcium, Zinc, Boron and Magnesium. This tablet is used to help meet calcium needs and maintain bone health in menopausal women."
40810374|NCT06659380|DIETARY_SUPPLEMENT|Floragyn® probiotic tablets (Lapi, Indonesia)|Given to the control group to ensure the ability of probiotics to maintain a healthy vaginal ecosystem and not the opposite.
40810375|NCT06660680|DRUG|Methylene Blue|Received MBI treatment to their surgical incisions upon completion of surgery
40810376|NCT06662162|DEVICE|i-Lumen AMD|i-Lumen AMD transpalpebral microcurrent stimulation system
40810377|NCT06659991|DRUG|alcohol condition|Ethanol
40810378|NCT06659991|OTHER|control condition|sparkling water
40810379|NCT06658691|OTHER|Multidisciplinary approach|"The study investigated a multidisciplinary approach consisting of an endocrinologist, a diabetes specialized nurse, and a clinical pharmacist to assess and improve diabetic foot care by systematic screening, patients' risk categorization, therapy optimization, and tailored education.~Risk of Diabetic Foot Ulcer (DFU) occurrence was assessed and evaluated by the endocrinologist, and the nurse based on the 2019 International Working Group on Diabetes Mellitus (IWGDF). At that point, only the clinical pharmacist knew about patients' allocations.~According to risk stratification, the clinical pharmacist provided intervention patients with educational sessions and tailored materials during scheduled three months follow-up interviews at Jordan University Hospital (JUH) DFU-related clinics.~Moreover, the study evaluated the impacts of the multidisciplinary approach on health-related Quality of Life (QoL) at baseline and at the end of the study. Economic impacts were also further analyzed."
40810380|NCT06661694|DRUG|Treatment A|Single 875 mg dose of mevrometostat standard tablet formulation
40810381|NCT06661694|DRUG|Treatment B|Single 875 mg dose of mevrometostat alternative tablet formulation
40810382|NCT06661694|DRUG|Treatment C|Single 875 mg dose of mevrometostat alternative tablet formulation
40810383|NCT06661694|DRUG|Treatment D|Single 875 mg dose of mevrometostat alternative tablet formulation
41155094|NCT06646900|BEHAVIORAL|Culturally adapted CBT (CaCBT) based guided self-help manual|The intervention consists of seven modules including cognitive restructuring, problem solving, behavioural activation and conflict management. Three additional modules focus on interpersonal relationships, mental health wellbeing and self-care. Each module is delivered over one week. The intervention uses culturally appropriate stories, drawings, examples from local folklore and religious context to describe the concepts of CBT.
40810385|NCT06660160|OTHER|Exercise program supported by audiovisual media|"The intervention group will perform the group exercise protocol during HD sessions. The videos with the exercises will be broadcast on all televisions simultaneously, so that the volunteers perform the exercises along with the person in the video.~* The first level of difficulty includes 5 exercises for the lower limbs and 3 exercises for the upper limbs. One set of 10 repetitions will be performed for each exercise per session.~* The second level includes 3 exercises for the lower limbs and 2 exercises for the upper limbs. These consist of proprioceptive neuromuscular facilitation diagonals for both the lower and upper limbs. One set of 10 repetitions will be performed for each exercise, once per week, for 3 weeks.~* The third level includes 8 combined lower and upper limb exercises performed simultaneously. One set of 20 repetitions will be performed for each exercise.~Exercises will be performed 3 times per week over a 4-week period, for a total of 12 planned exercise sessions."
40918204|NCT02206789|DRUG|Prednisolone acetate1%, cyclosporine 2%|penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
40918205|NCT01865552|BIOLOGICAL|SB4|SC administration
41328258|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 1|acute intake of 650 mg butyrate and hexanoate
41328259|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 2|acute intake of 1325 mg butyrate and hexanoate
41328260|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 3|acute intake of 2000 mg butyrate and hexanoate
41328261|NCT02024841|DRUG|Intraperitoneal docetaxel|Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
41328262|NCT05491044|DRUG|orelabrutinib|Orelabrutinib 150mg po qd d1-28, up to 2 years or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
40918206|NCT01865552|BIOLOGICAL|EU sourced Enbrel|SC administration
41328263|NCT02916810|DEVICE|Active rTMS stimulation|Participants will receive two rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two rTMS sessions.
40918207|NCT01865552|BIOLOGICAL|US sourced Enbrel|SC administration
40918208|NCT05755061|BEHAVIORAL|GEMS Plus|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS
40918209|NCT05755061|BEHAVIORAL|GEMS|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS
40918210|NCT03153384|PROCEDURE|Blood Culture|For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
40918211|NCT05439213|DRUG|Adrenaline 0,33 Mg/mL Solution for Injection|adrenaline dosage
40918212|NCT05439213|DRUG|Adrenaline 1 Mg/mL Solution for Injection|adrenaline dosage
40918213|NCT06109818|DRUG|ICP-488 Tablets|ICP-488 will be administered as tablet
40918214|NCT06109818|DRUG|ICP-488 Placebo|ICP-488 Placebo will be administered as tablet
41328264|NCT02916810|DEVICE|Sham rTMS stimulation|Participants will receive two sham rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two sham rTMS sessions.
41155095|NCT06646900|BEHAVIORAL|Standard CBT Manual|The standard CBT manual will follow conventional CBT techniques without specific cultural adaptations
41328265|NCT00719862|DRUG|Placebo nasal spray|Placebo
40810387|NCT06661876|RADIATION|5 Gray Whole Heart external beam radiotherapy|EBRT will be delivered with photon energies restricted to 6 Megavoltage (MV) using intensity modulated radiotherapy (IMRT) or Volumetric modulated arc therapy (VMAT). Patients will be treated with a single fraction treatment up to a dose of 5Gy prescribed to the 95% PTV-encompassing isodose line (PTVD95% ≥5Gy). The near-maximum dose is limited to 5.35Gy (PTV D2% ≤ 5.35Gy). The treatment can be performed both as an inpatient or outpatient procedure.
41328266|NCT00719862|DRUG|0.15% azelastine hydrochloride Nasal Spray|0.15% azelastine hydrochloride 822 mcg
40810388|NCT06657976|BEHAVIORAL|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
40810389|NCT06657976|BEHAVIORAL|Attention Control|This group will attend weekly one-hour educational sessions either on Zoom or in-person for 12 weeks. These sessions are on topics of interest to the typical PAD patient and may be led by study staff, physicians, or other health care workers.
40810390|NCT06657976|COMBINATION_PRODUCT|Nitrate-Rich Beetroot Juice + supervised exercise therapy|Participants randomized to this group will drink nitrate-rich beetroot juice while engaged in supervised exercise.
41328267|NCT05753007|DRUG|Cannabidiol (CBD)|Custom-formulated full-spectrum solution high in cannabidiol
40810391|NCT06657976|COMBINATION_PRODUCT|Placebo + supervised exercise therapy|Participants randomized to this group will drink placebo while engaged in supervised exercise.
40810392|NCT06660927|DEVICE|liac Bifurcation Stent Graft System|to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA)
41328268|NCT05753007|DRUG|Placebo|Placebo solution
41328269|NCT02727517|PROCEDURE|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table
41328270|NCT02727517|PROCEDURE|Delayed (≥ 180 seconds) cord clamping|If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
41328271|NCT01376401|DRUG|Bendamustine|
41328272|NCT01376401|DRUG|Velcade|
41155096|NCT04361916|OTHER|home care monitoring|home care active monitoring of patients with suspected of confirmed COVID-19
40918215|NCT05865041|DRUG|Farudodstat|Farudodstat tablets administered orally
40918216|NCT05865041|DRUG|Placebo|Placebo tablets administered orally
40918217|NCT06286189|DRUG|Placebo oral tablet|Placebo capsule taken 30 min before sleep
41328273|NCT01376401|DRUG|Prednisone|
41328274|NCT00661570|DEVICE|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
41328275|NCT02783144|PROCEDURE|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is added to levopubivacaine
41328276|NCT02783144|OTHER|TAP Block and saline|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and saline is added to levopubivacaine
41328277|NCT02783144|DRUG|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is injected intravenously
41328278|NCT03185416|OTHER|Palliative Care Training|The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
41328279|NCT00347412|DRUG|Paclitaxel|"Paclitaxel is dosed at 200 mg/m2, as a 3 hour infusion.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first."
41328280|NCT00347412|DRUG|NOV-002|"* Two 60 mg intravenous boli given 3 hours apart administered the day prior to the first administration of paclitaxel and carboplatin cycle one~* For each nominal 21-day paclitaxel and carboplatin cycle:~  * 60 mg given intravenously on Day 1, given one hour prior to paclitaxel and carboplatin~ * followed by 60 mg subcutaneously daily for the next 20 days. If there is a delay in chemotherapy cycles, the patient will continue with daily, subcutaneous administration of NOV-002 until the next cycle of chemotherapy begins~Patients randomized to NOV-002 Group A, will receive NOV-002 until disease progression, unacceptable NOV-002 related toxicity, or discontinuation of paclitaxel and carboplatin, whichever comes first."
40918218|NCT06286189|DRUG|Trazodone Hydrochloride|Trazodone 100 mg 30 min before sleep
40918219|NCT01284491|DEVICE|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
40918220|NCT01284491|DEVICE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
41155097|NCT04024371|BEHAVIORAL|Self-rating Questionnaires|"* Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~* Behavioral avoidance/inhibition Scales (BIS/BAS)"
41480908|NCT03401450|DRUG|ACB proximal to true AC with bupivacaine 0.5% 20cc|Patients will receive ultra-sound guided single femoral triangle block injection with 20 mL of 0.5% bupivicaine
41480909|NCT01534637|DRUG|aprepitant|Given PO
41480910|NCT01534637|DRUG|gemcitabine hydrochloride|Given IV
41328281|NCT00347412|DRUG|Carboplatin|"Carboplatin is dosed at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.~The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel, as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing."
41328282|NCT05317702|OTHER|Moderately Painful Massage|Participants will be seated in a chair with his or her shirt on. Participants will receive 60 seconds of manual pressure applied to the myofascial trigger point identified in the participant's upper back. The researcher's thumb or index finger will apply a deep manual pressure such that the participant rates the pain = 50/100 on a 101-point numeric pain rating scale with 0 indicating no pain and 100 indicating the most severe pain imaginable. The participant will be asked to rate his or her pain during the massage so the pressure may be adjusted to maintain the 50/100 related pain. Massage will be applied for 60 seconds, 4 times for a total contact time of 240 seconds. During each 30 second break in which manual pressure is released, Pressure Pain Threshold (PPT) to the foot will be examined. PPT will be assessed 2 times immediately after each of the 4 massage applications.
41480911|NCT01534637|DRUG|capecitabine|Given PO
41328283|NCT01896388|DRUG|Ifenprodil Tartrate|
41328284|NCT01896388|DRUG|Placebo|
41328285|NCT00719225|DRUG|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
41328286|NCT01972594|PROCEDURE|Targetted protocol with pedometer|12 week protocol based on targetted steps are given to the patient along with a pedometer.
41480912|NCT01534637|DRUG|fluorouracil|Given IV
41480913|NCT01534637|PROCEDURE|radiation therapy|Undergo radiation therapy
41480914|NCT01534637|OTHER|questionnaire administration|Ancillary studies
41480915|NCT01534637|PROCEDURE|quality-of-life assessment|Ancillary studies
40810394|NCT06658327|OTHER|Dynamic stretching|Group A will receive 2\*10 repetitions of dynamic stretching of hamstrings and calf muscles in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
40810395|NCT06658327|OTHER|Static stretching|Group B will receive 2\*10 repetitions of static stretching of hamstrings and quads in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes. The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
40810396|NCT06662331|PROCEDURE|Bilateral Sagittal Split Osteotomy|A surgical procedure to correct dentofacial deformities
41328287|NCT01972594|DEVICE|Accelerometer(ActivPAL)|
41328288|NCT05453448|DRUG|tenofovir alafenamide|Antiviral therapy
41328289|NCT05453448|DRUG|Entecavir|entecavir
41328290|NCT02581670|RADIATION|stereotactic radiation therapy (SRT)|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach
41328291|NCT04334512|DRUG|Hydroxychloroquine|Treatment with hydroxychloroquine
41328292|NCT04334512|DRUG|Azithromycin|Treatment with azithromycin
41480916|NCT01534637|PROCEDURE|nausea and vomiting therapy|Receive aprepitant
41480917|NCT01534637|PROCEDURE|management of therapy complications|Receive aprepitant
41480918|NCT05946902|DRUG|tolterodine|tolterodine 4 mg per day
41480919|NCT05946902|DRUG|mirabegron|mirabegron 25 mg per day
41480920|NCT05946902|DRUG|tolterodine , mirabegron|tolterodine 4 mg and mirabegron 25 mg per day
41480921|NCT06192836|PROCEDURE|Manual Removal 1|"1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed"
41480922|NCT06192836|PROCEDURE|Manual Removal 2|"1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed"
41480923|NCT06192836|PROCEDURE|Controlled Cord Traction 1|"1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed"
41480924|NCT06192836|PROCEDURE|Controlled Cord Traction 2|"1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed"
41328293|NCT04334512|DIETARY_SUPPLEMENT|Vitamin C|Treatment with vitamin C
41328294|NCT04334512|DIETARY_SUPPLEMENT|Vitamin D|Treatment with vitamin D
41328295|NCT04334512|DIETARY_SUPPLEMENT|Zinc|Treatment with Zinc
41480925|NCT06192836|PROCEDURE|Controlled Cord Traction+Uterine Massage 1|"1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed after placental delivery"
41480926|NCT06192836|PROCEDURE|Controlled Cord Traction+Uterine Massage 2|"1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. Additional uterine massage for one minute duration will be performed after uterine incision is closed"
41480927|NCT01401387|OTHER|Timing of start treatment with pancreatic enzymes|Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
41480928|NCT01401387|OTHER|Timing of start treatment with pancreatic enzymes|Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
41011179|NCT05907356|OTHER|sciatic nerve slider technique in supine position|.The patient will be in a supine position. The therapist will hold the patient's limb passively and then move the hip into flexion with the ankle in plantar flexion and the knee in extension, stretching the nerve at the hip and relaxing at the ankle, Then reversing the movement with the hip into extension, maintaining the knee in extension and the ankle in dorsiflexion, relaxing the nerve at the hip and stretching at the ankle. Provide five sets in every session; the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions, and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
41155098|NCT04024371|BEHAVIORAL|Measures of Reward processing/reinforcement learning|"* Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)"
41328296|NCT01046656|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
41328297|NCT05376995|DIAGNOSTIC_TEST|Graston technique|Graston technique among patient of knee osteoarthritis
41328298|NCT05376995|DIAGNOSTIC_TEST|muscle energy technique|muscle energy technique among patient of knee osteoarthritis
41155099|NCT04024371|BEHAVIORAL|Additional Schizophrenia-specific Questionnaires and Interviews|"* Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)~* Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)"
41155100|NCT02039596|OTHER|Diet|
41155101|NCT06647173|BEHAVIORAL|Blued+ Service Platform|During the intervention period, participants received the enhanced version of the Blued app. The free HIV prevention services were integrated into the Blued app: health messaging, in-home HIV testing, linkage to care for those testing HIV positive, condoms, lubricants, in-app screening, and provision to PrEP.
41155102|NCT04393779|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
41155103|NCT06057870|OTHER|Application on Apple watch|To determine the feasibility and engagement with remote management of acutely decompensated cirrhosis patients using CirrhoCare® App, CyberLiver ART App, and remote monitors by assessing patient adherence to the monitoring device and the Apps over a 3-month period.
41155104|NCT00701597|DRUG|bosentan|Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days
41155105|NCT00101062|DRUG|celecoxib|
41155106|NCT00101062|DRUG|letrozole|
41328299|NCT05957588|OTHER|Proning group|"Patients were educated about self-proning, and instructed to self-prone every 2 hours. The patient documented their position on the checklists every 2 hours.~Upon initiation of the initial proning, the patient was monitored by the research team RN for adverse effects for 15 minutes (such as inability to tolerate position or signs of respiratory distress).~If the patient tolerated the proning well, the RN entered the patient's oxygen saturation into the EMR, and documented the initial position (prone or supine) on the checklist. O2 saturation was documented at least every 4 hours per unit protocol.~The checklists were placed in a binder at the nurses' station at the end of each shift and collected daily by a member of the research team.~This intervention for each proned patient continued until either of the following occurred: ei the patient was discharged to a lower level of care or 14 days had passed."
41328300|NCT05957588|OTHER|Control group|A retrospective chart review was completed by the research team to ascertain length of stay, oxygenation, and pressure injuries for the control group on the acute care, telemetry monitored unit.
41480929|NCT02239198|OTHER|Nutrition bar|The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
41480930|NCT05334264|PROCEDURE|Cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
41480931|NCT02972502|DRUG|Metoclopramide|Patients receive 10 mg of intravenous (IV) metoclopramide.
41011180|NCT05907356|OTHER|Conventional physiotherapy|The patient will receive conventional physiotherapy, which includes: a moist hot pack, TENS, and back strengthening exercises (as a home program).
41011181|NCT04865679|DEVICE|Axoguard Nerve Cap®|Entubulation of the nerve stump into the Axoguard Nerve Cap® following surgical excision of symptomatic neuroma
41155107|NCT02259296|PROCEDURE|Lower eGFR for AVF construction|Lower eGFR patients (eGFR\<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR\<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
41155108|NCT02259296|PROCEDURE|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
41155109|NCT06049888|BEHAVIORAL|Restricted Social Media|Participants (N = 500) will be randomly assigned to either have no study-imposed restrictions on social media use (naturalistic social media condition) or have no access to social media apps on their phones (restricted social media condition). This manipulation will last three months, after which both groups will have no study-imposed restrictions on social media for three more months.
41480932|NCT02972502|DRUG|Haloperidol|Patients receive 2.5 mg of IV haloperidol.
40918221|NCT04966663|DRUG|Nivolumab|Antineoplastic agent
41328301|NCT06028425|DRUG|LOXO-783|Administered orally.
41328302|NCT03724617|DRUG|umbilical cord mesenchymal stem cells combined with collagen scaffold|3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.
41328303|NCT01433120|DIETARY_SUPPLEMENT|Lactobacillus paracasei ssp paracasei F19|10\^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)
41480933|NCT02972502|OTHER|Normal Saline|All patients receive a 1-liter bolus of normal saline (NS)
41480934|NCT02972502|DRUG|Diphenhydramine|All patients receive 25 mg of intravenous (IV) diphenhydramine.
41155110|NCT04533971|OTHER|Whole body cryotherapy|The WBC procedure consisted of 2-3 min walk in the cryogenic chamber at -110℃. Immediately before the WBC procedures, the patients were provided with a special treatment suit, they were instructed as to how to protect the parts of the body that are particularly vulnerable to frostbite, on the proper way of moving and breathing during the treatment. Excluding Saturdays and Sundays, the WBC treatments were performed daily for the next four weeks. Each time after the WBC the subjects participated in 15-minute kinesitherapy exercises conducted in groups of 5-6 people. The exercises were of general improvement nature and took into account the mobility of the subjects.
41155111|NCT03959579|DIAGNOSTIC_TEST|systematic endomyocardial biopsy.|"We sought to compare the long term survival of HTx recipients followed with or without systematic endomyocardial biopsy. Second, the sensibility and specificity of cardiac echo to diagnose acute allograft rejection will be analyzed.~To show the safety of non-invasively monitoring HTx recipients without systematic endomyocardial biopsy"
41155112|NCT03427645|BEHAVIORAL|Decision tool|A tailored web-based stroke decision support intervention. This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.
41328304|NCT01433120|DIETARY_SUPPLEMENT|Flax seed fibres|10 grams of flax seed fibres per day (baked into two breakfast buns)
40810397|NCT06661031|BEHAVIORAL|Motivational Enhancement Therapy plus Ecological Momentary Intervention|Two Motivational Enhancement Therapy (MET) sessions (1st, \~45 minutes; 2nd, \~30 minutes) between counselor and participant occur one week apart. MET sessions are personalized, interactive, face-to-face, and delivered according to a manual. MET session discussion topics include triggers for cannabis use, life goals/values, and development of a change plan. Participants then complete a 2-week Ecological Momentary Intervention (EMI) period. Survey prompts are sent 4x/day (3x/day at quasi-randomized times, 1x/day at fixed time; \~2 mins each) that ask about the participant's recent cannabis use. Depending on answers reported, the participant can receive tailored messages that support their self-efficacy and prompt use of coping strategies.
40810398|NCT06661031|BEHAVIORAL|Enhanced Usual Care|Participants meet with a study counselor 1-on-1 via videoconference to review a brochure containing cannabis information and treatment resources.
41155113|NCT03097302|PROCEDURE|Laser keratotomy|Penetrating femtosecond laser assisted keratotomy to treat preexisting corneal astigmatism during lens surgery.
41155114|NCT05080803|DRUG|intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone|intravitreal administration
40810401|NCT06660082|PROCEDURE|Experimental treatment: Head movements|"These are gaze stabilisation exercises under vHIT control, between post-operative days 1 to 6.~The patient sits facing a wall 2 metres away. The investigator places the vHIT device on the participant's head and ensures that it fits properly.~This is followed by an initial calibration phase (the patient must follow a laser dot with his eyes).~Then comes stimulation phase: the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The investigator then performs a series of low-amplitude, high-speed head movements in the plane of the lateral canals and on the side of the vestibular deficit.~The patient is encouraged to resume fixation of the visual target as quickly as possible.~For each treatment session, patients should perform a minimum of 10 impulses and a maximum of 30 impulses on the deafferented side. Each"
40810402|NCT06660082|PROCEDURE|Sham treatment: only eye movements|"These are visually guided saccade exercises under vHIT device control but without head movements (saccade module), between post-operative days 1 to 6.~For this sham treatment, the modalities are identical to the experimental treatment session, up to the calibration phase described above.~For the stimulation phase, the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The target then jumps horizontally to trigger visually guided saccades or slides horizontally to trigger an eye-tracking movement. The investigator stabilises the patient's head to prevent any head movement. The patient is encouraged to resume or maintain fixation of the visual target as quickly as possible.~A minimum of 5 horizontal saccade sequences and 5 horizontal eye-tracking sequences will be performed. Each training session lasts approxi"
40810403|NCT06658782|DIAGNOSTIC_TEST|non contrast enhanced MRI|6 monthly non contrast enhance MRI
40918222|NCT04966663|DRUG|Pemetrexed|Antineoplastic agent
41011182|NCT00568308|DRUG|PI-88|160mg subcutaneous injection
41011183|NCT00568308|DRUG|placebo|matched placebo
41011184|NCT03596424|DRUG|Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
41011185|NCT03596424|DRUG|Dexmedetomidine Hydrochloride|Intraoperative bolus and infusion (see arm description)
41011186|NCT03596424|COMBINATION_PRODUCT|dexmedetomidine Hydrochloride and Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
41155115|NCT05155553|DEVICE|QIAstat-Dx® Meningitis/Encephalitis (ME) Panel|The performance of QIAstat-Dx® Meningitis/Encephalitis Panel will be evaluated in comparison with another validated comparator method, followed by bidirectional sequencing using residual specimens of cerebrospinal fluid (CSF) obtained by lumbar puncture from subjects with signs and symptoms of meningitis and/or encephalitis.
41155116|NCT04228276|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 8 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
41328305|NCT01433120|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin is dissolved in a glas of water once per day
41328306|NCT00891761|DRUG|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
41480935|NCT01211782|DRUG|caprylic triglyceride|oral, 20 gm, daily x 6 months
41480936|NCT01211782|DRUG|long-chain triglyceride|oral, 14 gm, daily x 6 months
41480937|NCT00010413|DRUG|cyclophosphamide|
41480938|NCT00010413|DRUG|filgrastim|
41480939|NCT02536235|OTHER|heat|activated heating pad to lower abdomen
41155117|NCT04731506|BEHAVIORAL|Family Connections|The program starts with 2 small group support sessions spaced one week apart that guides participants through developing an action plan; followed by 10 IVR calls (5-10 minutes) beginning with weekly (4), biweekly (4), and monthly (2) calls. During each IVR call parents provide information on current physical activities, and food consumption that is used to provide feedback on success in subsequent IVR calls.
41155118|NCT06644417|DRUG|TQA3605 tablets plus NAs|TQA3605 tablets is core protein regulator
40810406|NCT06660420|DRUG|Cyclophosphamide|Given by IV
40810407|NCT06660420|DRUG|Fludarabine|Given by IV
40810408|NCT06658574|DRUG|Acetaminophen|Arm 1: Once cleared for oral intake - acetaminophen tablets 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days\&#39; dispensed as unit-dose tablets Arm 2: Once cleared for oral intake - acetaminophen liquid (160 mg/5 mL) 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days; 650 mg = 20.3 mL, dispensed as a unit-dose cup
41155119|NCT06644417|DRUG|TQA3605 Placebo plus NAs|Placebo without drug substance
41155120|NCT03867123|DRUG|LAM561|Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles
41011187|NCT01902485|OTHER|Timing of Contraceptive Initiation in Medical Abortion|
41480940|NCT00620659|DRUG|Comparator: MK0249|Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
41480941|NCT00620659|DRUG|Comparator: placebo|Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
40810411|NCT06662266|DEVICE|Induce XT™ is a mixture of human cortical bone fibers and microparticulates that have been processed into Natural Matrix Protein® (NMP®) to which cancellous bone microparticulates have been added|"Bone graft material is required for successful foot and ankle fusion surgery. Current bone grafting materials include autogenous bone, Augment Bone Graft and demineralized bone matrix (DBM), each of which have limitations.~Induce XT is a novel bone graft material that can potentially be used in foot and ankle fusions that may overcome some of these limitations."
40810412|NCT06660966|PROCEDURE|M TAPA block|Grup M: The patients who underwent M-TAPA block were placed in the supine position. The right upper quadrant of the abdomen was cleaned with antiseptic solution. For the block procedure, 20-30 ml of 0.25% bupivacaine, 22G 8.5 cm stimuplex needle and 10-14 Hz high frequency USG were prepared for the procedure. The USG probe was determined in the costochondral area at the mid-clavicular line, and the internal and transversus abdominis muscles were determined. The needle was advanced with the in plane technique from cephalad to caudal, passing through the skin, subcutaneous, external and internal oblique muscles, respectively, and then over the transversus abdominis fascia. After the target was confirmed with 2 ml of saline, 0.3 mg / kg bupivacaine (20-30 ml) was administered.
40810413|NCT06660966|PROCEDURE|ESP block group|"In Group E, patients who were to undergo ESP block were placed in the lateral position with the right side up. The T8-T10 dorsal region was cleaned appropriately with antiseptic solution. For the block procedure, 20-30cc %0.25 bupivacaine, 22G 8.5cm stimuplex needle and 10-14Hz high frequency USG were prepared for the procedure.~The USG probe is first determined in the sagittal direction, the spinous process of the T10 thoracic vertebra is then followed 1-2 cm above the transverse process, with the in plane technique, the skin, subcutaneous tissue and erector spina muscle are passed, the needle is touched to the transverse process and the target is confirmed with 2cc saline, then 20-30 cc (0.5 mg / kg bupivacaine) of local anesthetic is administered and the procedure is terminated."
40918223|NCT04966663|DRUG|Gemcitabine|Antineoplastic agent
40918224|NCT04966663|DRUG|Cisplatin|Antineoplastic agent
40918225|NCT04966663|DRUG|Carboplatin|Antineoplastic agent
40918226|NCT04966663|PROCEDURE|ctDNA blood test|Blood will be collected for ctDNA testing
40918227|NCT06428071|OTHER|standard physical therapy|All Patients in the three groups will receive supervised systematic exercise therapy that was performed effectively in previous work. This program consisted of lower limb static, dynamic, and flexibility exer¬cises that targeted the quadriceps, hamstrings, and gluteus muscles; and core strength training for 20 minutes per day. This program will be applied 3 times per week for 6 weeks to all the participants
40918228|NCT06428071|OTHER|knee Decompression|continuous mechanical decompression using 20% of the body weight as a traction force for 15 minutes.
40918229|NCT06428071|OTHER|hot pack|hot pack over the treated knee joint will be applied for 20 minutes. this application will be performed while the patient is receiving the decompression session
41011188|NCT02960984|OTHER|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
41011189|NCT04541758|PROCEDURE|surgical treatment|surgical treatment and Conservative treatment
41155121|NCT03867123|RADIATION|RT|In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy
41155122|NCT03867123|DRUG|TMZ|Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
41155123|NCT04394078|OTHER|Online survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess depression (Zung depression Scale) and quality of life (WHO Qualiy of Life - Bref version).
41155124|NCT03899285|DRUG|Citalopram 20mg or 40 mg (phase 2)|For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.
41480942|NCT00620659|DRUG|Comparator: modafinil|Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
41155125|NCT04501354|DRUG|Mesenchymal Stem Cell|Mesenchymal Stem Cell + NaCl 0,9% 2ml
41155126|NCT05104853|DRUG|CNP-104|CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.
41155127|NCT05104853|DRUG|Placebo|CNP-104 Placebo
41155128|NCT03794128|PROCEDURE|Blood collection for research (next-generation sequencing [NGS])|Participants will have whole blood collected for next-generation sequencing (NGS).
41480943|NCT05314894|BEHAVIORAL|Education|Giving training to the students in the initiative group to quit smoking in three sessions, sending messages via whatsapp program and telephone counseling
41155129|NCT03794128|PROCEDURE|Blood collection for research (HLA typing)|Participants will have whole blood collected for HLA typing.
40810417|NCT06658366|DIAGNOSTIC_TEST|impression of the teeth|Only conventional and digital impressions (comparable with taking videography) are taken of the patients teeth.
41155130|NCT05071378|BEHAVIORAL|Our Family, Our Voices|Many Men, Many Voices (3MV) is a seven-session, group-level intervention developed to prevent HIV and sexually transmitted diseases (STDs) among black men who have sex with men (MSM) who may or may not identify themselves as gay. The intervention addresses factors that influence the behavior of black MSM: cultural, social, and religious norms; interactions between HIV and other STDs; sexual relationship dynamics; and the social influences that racism and homophobia have on HIV risk behaviors. Our Family, Our Voices seeks to create an adaptation of Many Men, Many Voices specifically tailored to young people who are members of the house ball community by incorporating elements of family support and resilience afforded to participants in the intervention.
41155131|NCT00538616|DRUG|Dexmedetomidine|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
40810420|NCT06659926|OTHER|68Ga-PSMA-PET/CT scan|68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis. At clinical progression, each patient will undergo a second 68Ga-PSMA-PET/CT to determine the location of disease progression and assess the value of 68Ga-PSMA-PET/CT imaging as a response measure
41155132|NCT00538616|DRUG|Propofol|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
41155133|NCT03110432|DRUG|PCSK9 Inhibitor [EPC]|drug use according to the respective product labelling
41155134|NCT03110432|DRUG|Standard lipid lowering therapy|drug use according to the respective product labelling
40810424|NCT06661057|DEVICE|Vivally system stimulation|During the first month, participants will do the stimulation at different time points: 1) supine while in bed, 2) seated in the morning, 3) sitting in the afternoon, and 4) sitting in the evening. Participants will measure the circumference of their ankle prior to each use. Participants will use the System for an additional 2 months with the preferred stimulation parameters based on the study team's recommendations from the first month of use.
40810425|NCT06662357|BEHAVIORAL|Behavioral Treatment|"Family Connections Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
40810426|NCT06659757|DRUG|KIT2014|KIT2014 will be administered by inhalation with a nebuliser
40810427|NCT06659757|OTHER|Placebo|Placebo will be administered by inhalation with a nebuliser
41155135|NCT03735147|BIOLOGICAL|Live attenuated influenza vaccine (LAIV)|Single dose of LAIV
41011190|NCT04541758|PROCEDURE|Conservative treatment|Conservative treatment
41011191|NCT03824197|OTHER|EVOO|Extra-virgin olive oil that is rich with oleocanthal and other phenols.
41011192|NCT03824197|OTHER|OO|Olive oil low in oleocanthal and other phenols.
41011193|NCT00452881|DRUG|gemcitabine|Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
41011194|NCT00452881|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
41011195|NCT00452881|DRUG|Cisplatin|Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
41011196|NCT00413413|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
41011197|NCT00413413|DRUG|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
41011198|NCT00413413|DRUG|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
41011199|NCT04122248|OTHER|standard radiographic imaging|standard radiographic imaging
41480944|NCT03813693|OTHER|towels impregnated with 2% chlorhexidine gluconate|"The first TICHG should be used on the neck, chest and abdomen; The second TICHG should be used on the right upper limb, start at the shoulder; The third TICHG was intended for the upper left limb; The fourth TICHG should be used on the neck and chest; The fifth TICHG was for the right lower limb; The sixth TICHG should be used on the lower left limb.~2) Time of application: use six TICHGs the night before surgery and the six remaining on the morning of surgery.~3) After the hygiene of each member, discard the TICHG. After use of TICHG, allow the product to dry on the skin. Do not use bath towels to dry yourself and wear clean clothes."
41011200|NCT01433224|GENETIC|DNA methylation analysis|
41011201|NCT01433224|GENETIC|RNA analysis|
41011202|NCT01433224|GENETIC|mutation analysis|
41011203|NCT01433224|GENETIC|nucleic acid sequencing|
41011204|NCT01433224|GENETIC|polymerase chain reaction|
41011205|NCT01433224|GENETIC|polymorphism analysis|
41011206|NCT01433224|OTHER|laboratory biomarker analysis|
41011207|NCT01433224|OTHER|medical chart review|
41011208|NCT00214994|DRUG|Gabitril|
41011209|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
41011210|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
41011211|NCT00763659|DIETARY_SUPPLEMENT|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
41155136|NCT03151161|DRUG|Icotinib,Pemetrexed,Carboplatin|Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression
41155137|NCT03151161|DRUG|Icotinib|Single drug: Icotinib 125mg, three times a day, continuous until disease progression.
41155138|NCT02061215|OTHER|CMV viral load|
41155139|NCT04369664|DRUG|Statin|Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
41011212|NCT06072066|DIETARY_SUPPLEMENT|Skin Barrier Oral Supplement|Supplment powder
41011213|NCT03842787|OTHER|Biological analysis|"Biological and research analysis:~Quantification of ficolin-3, anti-ficolin-3 antibodies, ficolin-2, anti-ficolin-2 antibodies~Purification of patients' antibodies (anti-ficolin-3 and -2)~Evaluation of effects of anti-ficolin-3 and anti-ficolin-2 purified antibodies Investigation of ficolin-3 and ficolin-2 deposition in renal biopsy"
40810429|NCT06658548|OTHER|Isometric handgrip exercise training with resistance exercise|The subjects will perform 24 consecutive days, an isometric handgrip exercise at 30% Maximum Voluntary Contraction (M.V.C)continue the exercise protocol for another 48 consecutive days.
40810430|NCT06658548|OTHER|Resistance Exercise|The subjects will undergo outpatient training intervention during a period of 8 weeks will be using a hypertrophic maximum strength training method, which will divided into three phases: (1) muscle habituation training (2 weeks), (2) hypertrophic training I (5 weeks), and (3) hypertrophic training II, with intensified eccentric work (5 weeks).
40810431|NCT06660030|OTHER|No intervention|No intervention
40810432|NCT06658730|DEVICE|Endovascular|TEVAR - thoracic endovascular aortic repair
40810433|NCT06658925|DRUG|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
40810434|NCT06661122|DRUG|Darolutamide (BAY1841788) + docetaxel + ADT|Follow clinical practice/administration. ADT=androgen deprivation therapy.
40810435|NCT06662422|DEVICE|Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System|The Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System is a single-use electrode placed on and around the ear which provides transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN).
40810436|NCT06658639|DEVICE|Ultrasound lipolysis|Ultrasound lipolysis uses a Luvitra device to emit low-frequency ultrasound pulsed waves. The abdominal area is divided into two sections and the patient is placed in a comfortable supine lying position. The cavitation head is applied slowly to each segment in small circular movements. The treatment lasts 30 minutes on each side, with each session lasting 60 minutes. The same abdominal area is treated every two weeks for three months. The procedure involves cleaning the skin with alcohol cotton.
40810437|NCT06658639|DEVICE|Cryolipolysis|The study utilized Lipocool, a cryolipolysis apparatus from Korea, with a thermoelectric cooling element. Participants were treated with thermal coupling gel on their abdomen, and the tissue was drawn into the applicator with a moderate vacuum. The device was used for 40-50 minutes, with energy extraction controlled by sensors. The system stopped cold exposure and the clinician released the vacuum. Participants underwent cryolipolysis sessions every 2 weeks for 3 months.
41011214|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation X|see Treatment Arms
41011215|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation Y|see Treatment Arms
41011216|NCT04916327|DIETARY_SUPPLEMENT|Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
41011217|NCT04916327|DIETARY_SUPPLEMENT|Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
41011218|NCT04935151|PROCEDURE|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser
41011219|NCT04935151|PROCEDURE|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
41011220|NCT05568394|OTHER|Manual therapy combinded with therapeutic exercise|"The treatment includes cervical mobilization and specific therapeutic exercises: craniocervical and cervical flexors and extensors, axioscapular muscles, and postural correction (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
41011221|NCT05568394|OTHER|Routine physical therapy|"The treatment includes routine physical therapy (e.g., modalities, range of motion and/or gentle stretching exercise) (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
41011222|NCT00466765|DEVICE|Brava Autologous Fat Transfer System|Number of procedures is based on patient need
41328307|NCT00891761|DRUG|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
41011223|NCT02290587|OTHER|Brain MRI - Clinical and cognitive evaluation|"Neuropsychological evaluation :~* Questionnaire for depression and anxiety~* Evaluation of executive functions~* Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~* morphological MRI~* functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention"
41011224|NCT02290587|DEVICE|MRI|
40810438|NCT06658639|OTHER|Low Caloric Diet|A low-calorie diet is a structured plan that restricts daily caloric intake, often used for weight loss. It involves consuming 1,200 to 1,500 calories daily, creating a calorie deficit. However, it requires discipline and safety. The diet is low in fat (20-25%), high in complex carbohydrates (60%), and sufficient in protein (25-50%).
41155140|NCT04369664|DRUG|PCSK9 inhibitor|Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.
41011225|NCT05690295|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
41155141|NCT04369664|DRUG|Ezetimibe 10mg|Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.
41155142|NCT01613573|DRUG|somatropin AQ|somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period
41328308|NCT00891761|DRUG|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
41328309|NCT00891761|DRUG|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
41328310|NCT00891761|DRUG|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
41011226|NCT05973838|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately six weekly core sessions (approximately 30 minutes-1 hour), and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention."
40810440|NCT06661239|BEHAVIORAL|benson relaxation|"The benson relaxation consisted of the following steps: (1) Sitting or lying down quietly in a comfortable position; (2) Closing eyes; (3) Deeply relaxing all muscles, beginning at the feet and progressing up to the face. Keeping them relaxed; (4) Breathing through the nose. (5) Maintaining a passive attitude and permitting relaxation to occur at its own pace; (6) Continuing for 15 minutes. When finished, sit quietly for several minutes, at first with eyes closed and later with eyes opened. Do not stand up for a few minutes.~According to the agreement, the patients in both groups were required to perform the Benson relaxation technique regularly twice daily (morning and evening) for seven days in a row. Each session lasted 15 minutes"
41011227|NCT05046782|DEVICE|restriction spectrum imaging (RSI)|detect prostate cancer better than a standard-of-care MRI
41011228|NCT03281811|DRUG|Aminolevulinic Acid Hydrochloride|Given topically
41011229|NCT03281811|DRUG|Photodynamic Therapy|Undergo PDT
41011230|NCT03281811|OTHER|Quality-of-Life Assessment|Ancillary studies
41011231|NCT03281811|RADIATION|Radiation Therapy|Undergo RT
41011232|NCT00773097|BIOLOGICAL|MUC1 - Poly ICLC|The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
41011233|NCT01885442|DEVICE|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
41011234|NCT03992690|DEVICE|Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol|Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.
41011235|NCT03992690|DEVICE|Training with traditional physiotherapy protocol|Stretching
40810441|NCT06661239|BEHAVIORAL|Routine care in unit|The routine care include in the unit will be delivered to control group
41011236|NCT06203405|PROCEDURE|Titrating sedation targeting both optimal P0.1 and appropriate arousal level|"* Sedation will be adjusted initially to target light sedation (RASS 0 to -2).~* Sedative drugs include IV fentanyl (25-75 mcg/h), midazolam (0.02- 0.1 mg/kg/h), propofol (5-50 mcg/kg/min), dexmedetomidine (0.2-0.7 mcg/kg/h).~* Deep sedation and neuromuscular blocking agents are allowed to facilitate mechanical ventilation adjustment in patients with refractory hypoxemia.~* Dose of cisatracurium is 0.15-0.2 mg/kg intravenous bolus, then continuous infusion at 5 -20 mg/h.~* Then sedation adjustment will be guided by P0.1 measurement.~* If P0.1 value of 1.5-3.5 cmH2O is achieved, no further adjustment is required.~* If P0.1 value \<1.5, sedation will be reduced.~* If P0.1 value \>3.5, sedation will be increased.~* If P0.1 value is still \>3.5 with deep sedation, cisatracurium will be allowed and titrated until P0.1 value \<3.5 cmH2O.~* The study protocol will be continued for 48 hours or until the patients are considered ready for weaning."
41011237|NCT06203405|DRUG|Fentanyl|Continuous intravenous infusion of fentanyl 25-75 micrograms/hour
41011238|NCT06203405|DRUG|Midazolam|Continuous intravenous infusion of midazolam 0.02 - 0.1 milligrams/kilogram/hour
41011239|NCT06203405|DRUG|Propofol|Continuous intravenous infusion of propofol 5 - 50 micrograms/kilogram/minute
41011240|NCT06203405|DRUG|Dexmedetomidine|Continuous intravenous infusion of dexmedetomidine 0.2 - 0.7 micrograms/kilogram/hour
41011241|NCT06203405|DRUG|Cisatracurium|Continuous intravenous infusion of cisatracurium 5 - 20 milligrams/hour
41011242|NCT01270945|DRUG|CV-18C3|3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
41328311|NCT05886309|DIAGNOSTIC_TEST|Collection of Blood samples|"The following samples will be drawn from each study participant immediately after the venipuncture performed for the whole blood donation:~* 1 sample with no anticoagulant (5 ml) for SF measurement with the CDMS method~* 1 EDTA (Ethylendiamintetraazetat) sample (7,5 ml) for a complete blood count with red blood cell indices and reticulocytes~* 1 EDTA sample (2,7 ml) for the measurement of hepcidin~* 1 Li-Heparin-Gel sample (4.7 ml) for the measurement of SF with the ECLIA (Electrochemiluminescence-enzymeimmunoassay) and of the complete set of iron biomarkers (Transferrin Saturation, serum iron, Soluble Transferrin Receptor)~* 1 Li-Heparin-Gel sample (4.7 ml) for the measurement of CRP (C-reactive Protein)~* 1 sample with no anticoagulant (5 ml) for the measurement of SF with the CMIA (Chemiluminescence Immunoassay)~* 1 sample with no anticoagulant (5 ml) for storage"
40810442|NCT06658886|OTHER|No intervention|No intervention
41155143|NCT01613573|DRUG|pegylated somatropin|Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection
41011243|NCT01270945|PROCEDURE|Standard of Care|
41011244|NCT05073406|OTHER|Altitude exposure in hypobaric normoxic condition|Altitude exposure with oxygen supplementation to achieve normoxia at altitude
41011245|NCT05073406|OTHER|Altitude exposure in hypobaric hypoxic condition|Altitude exposure with air supplementation to obtain a sham comparator arm
41011246|NCT05682482|DRUG|LT3 (liothyronine)|Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
41011247|NCT05682482|DRUG|Placebo|Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
41011248|NCT00002794|DRUG|carboplatin|
41011249|NCT00002794|DRUG|vincristine sulfate|
41011250|NCT00079105|BIOLOGICAL|bleomycin sulfate|Treatment
41011251|NCT00079105|DRUG|cyclophosphamide|Treatment
41011252|NCT00079105|DRUG|etoposide|Treatment
41011253|NCT00079105|DRUG|mitoxantrone hydrochloride|Treatment
41011254|NCT00079105|DRUG|prednisolone|Treatment
41011255|NCT00079105|DRUG|procarbazine hydrochloride|Treatment
41011256|NCT00079105|DRUG|vinblastine sulfate|Treatment
41011257|NCT01122966|DRUG|intraocular injections of bevacizumab|intracameral and subconjunctival injections
41155144|NCT03038152|PROCEDURE|Axillary Lymph Node Dissection|Undergo targeted axillary lymph node dissection
41155145|NCT03038152|PROCEDURE|Localization|Undergo axillary lymph node localization
41155146|NCT03038152|DEVICE|Medical Device|Receive Magseed via ultrasound guided injection
41155147|NCT05953818|DIAGNOSTIC_TEST|Chinese version of the Montreal Cognitive Assessment Scale (MoCA) and brain magnetic resonance high resolution structural imaging|Chinese version of Montreal cognitive assessment scale and brain magnetic resonance high resolution structural imaging
41155148|NCT00355602|DRUG|Cefuroxime|
40810449|NCT06660186|DEVICE|Rigid Sternal Fixation|The surgeon will close the sternum (breastbone) using the SternalPlate system. The SternalPlate System consists of implants and instruments used to hold the two halves of the sternum together.
40810450|NCT06660186|DEVICE|Wire Cerclage|The surgeon will close the sternum (breastbone) using Wire Cerclage. Wire Cerclage consists of stainless steel wires used to hold the two halves of your sternum together.
41011258|NCT06248216|DEVICE|Relievrx|The RelieVRx program is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.
41155149|NCT00355602|DRUG|Ciprofloxacin|
41155150|NCT00355602|DRUG|Clarithromycin|
41155151|NCT00355602|DRUG|Cotrimoxazole|
40810454|NCT06659263|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
40810455|NCT06657963|DIETARY_SUPPLEMENT|Opuntia ficus-indica Supplementation|Participants are required to consume oral supplementation of OFi fine powder packaged in individual sachets (LifeGreenTM, LifeTree Asia, Selangor, Malaysia) at the dosage of 1500 mg once daily for 3 months.
41011259|NCT06248216|OTHER|Audio Mp4|Audio Mp4 modules ranging from 3-15 minutes with guided meditation.
41011260|NCT06404177|DRUG|Dexketoprofen|An intravenous perfusion of eunantyum with an intramuscular isotonic saline
41011261|NCT06404177|DRUG|Piroxicam|intramuscular injection of piroxicam with a perfusion of isotonic saline intravenous
41011262|NCT01346384|DEVICE|laryngeal tube (VBM Medizintechnik)|laryngeal tube number 4
41011263|NCT01917929|DEVICE|Secur-Fit Advanced Hip Stem|Straight femoral stem intended for cementless, press-fit application.
41011264|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
41328312|NCT04024462|DRUG|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.
41328313|NCT04024462|DRUG|Trastuzumab IV|Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
41011265|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
41011266|NCT01465802|DRUG|Doxycycline|Doxycycline or Doxycycline placebo BID for 4 weeks
41011267|NCT01465802|DRUG|Probiotic|VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
40810456|NCT06660563|DRUG|JNJ-80948543|JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection.
40810457|NCT06660563|DRUG|JNJ-75348780|JNJ-75348780 will be administered as SC injection.
40810458|NCT06662058|PROCEDURE|Audiometric Test|Undergo audiometry
40810459|NCT06662058|PROCEDURE|Audiometric Test|Undergo close to home audiometry
40810460|NCT06662058|PROCEDURE|Audiometric Test|Undergo self-administered remote audiometry
40810461|NCT06662058|OTHER|Interview|Ancillary studies
40810462|NCT06660758|DEVICE|Feeding tube (Entarik)|Feeding tube placement will be verified using multiple methods in the duodenum and stomach.
41155152|NCT00355602|DRUG|Coamoxiclav|
41011268|NCT01465802|DRUG|Alclometasone cream|Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
41155153|NCT00355602|DRUG|metronidazole|
41328314|NCT04024462|DRUG|Pertuzumab and Trastuzumab FDC SC|The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
41328315|NCT04024462|DRUG|Doxorubicin|Doxorubicin 60 milligrams per meter squared of body surface area (mg/m\^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
41155154|NCT00355602|DRUG|neomycin|
41155155|NCT00355602|DRUG|rifaximin|
41155156|NCT00355602|DRUG|Vancomycin|
41155157|NCT00355602|DRUG|Doxycycline|
41155158|NCT03029611|DRUG|Carboplatin|Given IV
41155159|NCT03029611|PROCEDURE|Gynecological Surgical Procedure|Undergo cytoreductive surgery
41155160|NCT03029611|OTHER|Laboratory Biomarker Analysis|Correlative studies
41155161|NCT03029611|DRUG|Paclitaxel|Given IV
41155162|NCT03029611|BIOLOGICAL|pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine|Given ID
41155163|NCT01792206|DRUG|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
41155164|NCT01792206|DRUG|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
41155165|NCT04723784|OTHER|Initial Assessment|In this phase the evaluation of the participants will be done, with the application of the instrument presented in outcome measures' section. According to the age of the person, specific questionnaires will be used to gather information more concrete about the skills for mobility. This assessment will allow determining the specific needs, demands and capabilities of participants. The assessment process will be done by professionals of research groups in rooms of collaborators centers.
41328316|NCT04024462|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m\^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
41480945|NCT03813693|OTHER|chlorhexidine gluconate 2% liquid|Spread the product on the skin during the bath and massage for 3 minutes, so that it is distributed equally to all parts of the body (except the face, hair and intimate area). Then rinse with water and dry with a clean, dry towel, and wear clean clothes.
40810464|NCT06658496|DEVICE|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 72 hours after birth to monitor regional tissue oxygenation.
40810465|NCT06661096|PROCEDURE|TMJ arthroscopy|level I and level II TMJ arthroscopy
40810466|NCT06659016|DRUG|Fosfomycin 3 g|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months.
41011269|NCT04832373|DEVICE|Interaction with humanoid robot|A humanoid robot will be installed for 30 days in children. It has a touchscreen tablet, allowing manual interaction complementing the voice interaction. The robot speaks, hears, and has facial and voice identification.
41480946|NCT05702879|DRUG|Ozanimod|Start of standard therapy
41480947|NCT05702879|DRUG|TNF Inhibitor|Start of standard therapy
41480948|NCT05702879|DRUG|Steroids|Start of standard therapy
41480949|NCT05702879|DRUG|Vedolizumab|Start of standard therapy
41480950|NCT05702879|DRUG|Ustekinumab|Start of standard therapy
41480951|NCT05449509|DIAGNOSTIC_TEST|Abdominal aortic Duplex ultrasound|All patients will undergo bedside Duplex ultrasound in order to measure infrarenal abdominal aortic diameter.
41011270|NCT04540432|OTHER|Stool collection at the patient's home.|Stool samples will be taken from each patient to look for changes in intestinal microbiota. These collections will be made on Day 0 +24h, 24 hours before the 1st follow-up visit after 1 month of treatment with non-steroidal anti-inflammatory drugs, 24 hours after the second follow-up visit (between months 3 and 4) and finally, at the end of treatment.
41011271|NCT04540432|DIAGNOSTIC_TEST|Blood test|7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
41328317|NCT04024462|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m\^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.
41480952|NCT00679913|PROCEDURE|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
41480953|NCT00679913|PROCEDURE|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
41480954|NCT02581878|DRUG|BAY1862864|Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
41480955|NCT06414239|DEVICE|Use of a VR mask|Virtual reality mask
41480956|NCT06414239|OTHER|Standard of care|Without any premedication or anesthesia
41480957|NCT00906113|DRUG|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
41480958|NCT00906113|DRUG|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
41480959|NCT04036149|DEVICE|Intraocular lens|Implantation as part of cataract surgery
40810467|NCT06659016|DIETARY_SUPPLEMENT|Uroxin 4G|Dietary supplement of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
40810468|NCT06659016|DRUG|Combination of dietary supplement and fosfomycin|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months, combined with an oral formulation of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
41011272|NCT02477020|DRUG|TAK-063 20 mg|TAK-063 tablet.
41011273|NCT02477020|DRUG|Placebo|TAK-063 matching-placebo tablet.
41011274|NCT00475007|DEVICE|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
41328318|NCT04024462|PROCEDURE|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
41480960|NCT05649735|DEVICE|Logusgyn ovules|"LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
41480961|NCT05649735|DEVICE|Logusgyn Lavander|"LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
41480962|NCT05649735|OTHER|Placebo|Sterile saline solution
41328319|NCT04024462|RADIATION|Post-Operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
41480963|NCT00906373|BIOLOGICAL|IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle
40810469|NCT06658158|BEHAVIORAL|Cognitive correction and stimulus control|"Cognitive correction:~a) correcting unrealistic sleep expectations; b) maintaining a natural sleep onset; c) avoiding worry about losing control oversleep; d) not associating nocturnal dreaming with adverse daytime consequences; e) avoiding feelings of frustration due to one night of poor sleep; f) developing tolerance to the impact of insomnia and avoiding compensatory behaviors.~Stimulus control:~1. Minimize wakefulness during time in bed and establish a positive association between sleepiness and the bed.~2. Use the bed only for sleep and sexual activities.~3. Go to bed only when feeling sleepy at night or at the designated sleep time.~4. If unable to fall asleep within approximately 20 minutes of being in bed, leave the bedroom, engage in relaxing activities, and return to bed when feeling sleepy. Repeat this process if unable to fall asleep within approximately 20 minutes.~5. Wake up at the same time every morning, including weekends."
40810470|NCT06658158|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
41155166|NCT04723784|OTHER|Implementation of assistive technology in the daily life of participants|The professionals of collaborator centers, supported by the research groups, will carry on the training in the use of AT by the participants, facilitating its incorporation during the performance of activities of daily living.
41155167|NCT04723784|OTHER|Application of outcome measures|After the process of implementation of AT (the next 2 and 6 months), members of the research group and the professionals of collaborators centers will apply the measurement instruments to determine the possible improvements in the level of functional independence (FIM scale) of people with disabilities, the impact that the AT has had on their lifes (PIADS scale) and the level of matching between person and AT (ATD PA - MPT model).
41155168|NCT05644041|DRUG|Gemcitabine|Gemcitabine will be administered intravesically at a dose of 2000 mg.
41011275|NCT05607992|BEHAVIORAL|Brief exposure-based CBT|The 5-week intervention is psychologist-guided and delivered via text-based interactive online treatment modules, where patients complete weekly homework assignments and have regular online contact with psychologists with training in CBT for cardiac disease. Key components include imaginal exposure of the ACS event, interoceptive exposure through at home physical activity that stimulats the CV system, exposure in-vivo to reduce avoided situations, and activities to enhance physical activity wellbeing. Labeling (i.e., describing cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure.
41011276|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
41011277|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
41011278|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
41011279|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
41011280|NCT03079804|OTHER|Experimental MWM|Mobilization with Movement
41011281|NCT03079804|OTHER|Experimental Thrust|Mobilization grade 5 (Thrust)
41155169|NCT00220116|DRUG|Capecitabine, Oxaliplatin|
41155170|NCT04658537|RADIATION|Radiation Therapy|Cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumours
41155171|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
41155172|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
41155173|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
41155174|NCT00117650|OTHER|Saline (Placebo Control)|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
41328320|NCT04024462|DRUG|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
41328321|NCT02126670|DRUG|ACT01|
41328322|NCT02126670|DRUG|Comp01|
41155175|NCT02959255|DRUG|Esomeprazole|dosage difference
41155176|NCT05067543|DEVICE|Tornier Perform Humeral - Stem|The PERFORM Humeral System - Stem is a non-constrained prosthesis intended for the total or partial replacement of the glenohumeral articulation.
41328323|NCT02126670|DRUG|Comp02|
41328324|NCT02126670|DRUG|Comp03|
41328325|NCT02126670|DRUG|Comp04|
41328326|NCT00143962|BEHAVIORAL|Low Carbohydrate Diet|
41328327|NCT00695500|DRUG|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
41328328|NCT00695500|DRUG|Placebo|Placebo tablets, 0 mg per day for 3 weeks
41328329|NCT03125018|DEVICE|LNCS ADTX Sensor|Noninvasive pulse oximeter sensor.
41328330|NCT03373110|BEHAVIORAL|Online Mindfulness Based Cognitive Therapy|see arm description
41328331|NCT03373110|BEHAVIORAL|Online Cognitive Behavioral Therapy|see arm description
41328332|NCT03373110|BEHAVIORAL|Fitbit Alone|see arm description
41328333|NCT00082329|DRUG|AMD 3100 (Mozobil plerixafor)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
41480964|NCT00906373|BIOLOGICAL|IMC-A12 (cixutumumab) - 20 mg/kg|intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle
41480965|NCT00906373|DRUG|Sorafenib|400 milligrams (mg) twice per day orally
41480966|NCT02182128|DRUG|BIBF 1120|
41480967|NCT06007651|DRUG|LY3885125|Administered SC
41480968|NCT06007651|DRUG|Placebo|Administered SC
41480969|NCT02087124|OTHER|Whey protein|Different amounts of whey protein dissolved in 200 mL water.
40810474|NCT06658834|DRUG|Dexamethasone Combined with romiplostim N01|Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection once a week for up to 6 months.
40810475|NCT06658834|DRUG|Dexamethasone monotherapy|Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
41155177|NCT05307120|DEVICE|Diameter integrated in secondary diabetes care|Regular T2DM treatment in secondary care will be complemented with the Diameter: a mobile application on smartphones that enables continuous monitoring of physical activity (via activity tracker Fitbit and self-reported activities) and nutrition (via food diary) and blood glucose values (via Freestyle Libre sensor). The Diameter also provides autonomous lifestyle coaching via daily coaching messages, short weekly e-mails and exercises aimed at goal achievement.
40810477|NCT06660134|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
40810478|NCT06661317|OTHER|no intervention|no intervention
41155178|NCT02367339|OTHER|ESBL|Evaluation of the prevalence of ESBL-Enterobacteriaceae colonization among ICU staff
41155179|NCT05203510|DRUG|Parenteral Treprostinil|Parenteral treprostinil will be administered per schedule specified in the arm description.
40810481|NCT06660017|DRUG|Placebo|Patients in this arm will receive unmedicated syrup solution dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
40810482|NCT06660017|DRUG|Ketamine Topical|Patients in this arm will receive ketamine oral rinse dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
40810483|NCT06660641|DEVICE|TaurolockTMHep100|1.35% taurolidine containing catheter losk solution
40810484|NCT06660641|DEVICE|0.9 % saline|placebo
40810485|NCT06658119|PROCEDURE|cataract surgery|The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Synergy ZFR00).
41011282|NCT03079804|OTHER|Placebo|Procedures similar to Experimental MWM group, but without aplly any force
41011283|NCT03684200|OTHER|Copenhagen adductor exercise|The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
41155180|NCT05203510|DRUG|Oral Treprostinil|Oral treprostinil will be administered per schedule specified in the arm description.
41155181|NCT00675519|BEHAVIORAL|Motivational enhancement therapy|Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
41155182|NCT02515500|BEHAVIORAL|Gradual Cessation|
41328334|NCT00082329|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
41328335|NCT05130372|OTHER|Static Stretching Method Group|Static stretching has been the most common stretching method applied to the ankle in healthy older adults, and different protocols have proven to increase ankle range of motion. In this study, the static stretching method was actively applied while standing.
41328336|NCT05130372|OTHER|PNF Stretching Method Group|The contract-relax technique was used in the PNF stretching method.
41328337|NCT05130372|OTHER|Myofascial Relaxation Method Group- Roller Massage|A theraband roller massager (Theraband®, The Hygenic Corporation, Akron, OH) was used for the myofascial relaxation method.
41328338|NCT04087408|DRUG|Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial|"1. Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~2. doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~3. Trigger will be done using HCG followed by OPU 36 h later.~4. Retrieved oocytes will be fertilized by ICSI.~5. LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6. GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~7. Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~8. Quantative BHCG will be performed 14 days after OPU."
41480970|NCT02736682|DRUG|Single dose antibiotic|Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
41480971|NCT02736682|DRUG|Multiple dose antibiotic|Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
41480972|NCT05847439|DRUG|[14C]BMS-986419|Specified dose on specified days
41480973|NCT04821765|DRUG|PD-1 antibody|200mg, d1, q3W
41480974|NCT04821765|RADIATION|Chemoradiation|50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week
41480975|NCT04821765|DRUG|Albumin-Bound Paclitaxel|150mg/m2, d1, q3W
41155183|NCT02515500|BEHAVIORAL|Gradual Cessation w/ Quitbit|
41480976|NCT04821765|DRUG|Cisplatin|75mg/m2, d1, q3W
40810486|NCT06658119|PROCEDURE|cataract surgery|The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Symfony ZXR00).
40810487|NCT06660719|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
40810488|NCT06660719|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
41328339|NCT00461422|DRUG|Ganirelix|sc injection of Ganirelix 0.25 mg per day
41328340|NCT00048009|DRUG|Dual Integrin Antagonist|
41328341|NCT00633802|DRUG|Risperidone|1 mg/d risperidone for 10 weeks or placebo
41480977|NCT00911807|DRUG|Cerebrolysin + donepezil|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
40810489|NCT06662019|DRUG|N-IP-00001 inhalation solution|Multiple ascending dose (MAD) study. Over the 2 dosing days participants will receive a total of 6 inhaled doses of 5 ml of N-IP-00001 at increasing concentrations, ranging from 0.5mg/ml to 16mg/ml (total volume loaded in the nebuliser is 6 ml per dose).
40810490|NCT06662019|DRUG|0.9% NaCl isotonic saline solution|Nebulized treatment consisting of 0.9% saline solution.
41328342|NCT05818384|BEHAVIORAL|Wakaya: Rising Up for Choctaw Youth Curriculum|An experiential, outdoor, nature-based program grounded in Choctaw values. It is a multi-level intervention that increases individual motivation and leadership skills to make healthy behavioral choices for behavior and exercise.
40810491|NCT06661018|DRUG|Coenzyme Q 10|participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks
40810492|NCT06661018|DRUG|Placebo|participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
40810493|NCT06659913|BEHAVIORAL|Exercise training|Session 1: Consist of high intensity interval training performed on spinning bikes. An exercise physiologist will supervise the participants to perform a light 10 min warm-up, followed by 4 min working periods (intervals) interspersed by 3 min active breaks. The intensity should be 85-95% of estimated peak heart rate, corresponding to approximately 16 on the Borg scale (17). There will be a maximum of 10 participants in each group, depending on how many patients who are recruited for each of the two inclusion periods.I In addition, participants are encouraged to participate in the physical education at school and encouraged to perform exercise during the weekend, either with their family or friends.
41328343|NCT03731546|PROCEDURE|Delayed cord clamping|Cord clamping 60 seconds after delivery of fetus in preterm infants
41480978|NCT00911807|DRUG|Cerebrolysin + placebo|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks)."
41480979|NCT00911807|DRUG|Donepezil + placebo|"Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
41328344|NCT03437213|DRUG|Total intravenous anesthesia group|Induction of general anesthesia with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h. to be modified according to analgesic needs and hemodynamics. 10mg atracurium when the 2nd twitch of train of four appears.
41480980|NCT04954378|DIAGNOSTIC_TEST|radiomics|
41480981|NCT00680186|DRUG|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
41480982|NCT00680186|DRUG|Dabigatran etexilate|150mg bid
40810494|NCT06661213|DRUG|Tapinarof|A thin layer of tapinarof cream is applied to affected areas once daily.
41328345|NCT03437213|DRUG|Total intravenous plus block group|Ultrasound guidance identifies the paravertebral space using a linear high-frequency (10-12 MHz) probe in the transverse plane in the midline, rotate the probe to the longitudinal plane, and scan in a medial-to-lateral direction. Locate the desired segment shift from the cephalad aspect of the sacrum. The transverse scan will show a hyperechoic outline of the vertebral spinous and transverse processes. Use the loss of resistance technique. Bilaterally inject (5ml) bupivacaine 0.5% for each segment. Induction of anesthesia after 30 minutes with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg),then prone position.
41328346|NCT02078661|DRUG|PG101|A topical gel containing either 1% or 0.25% PG101 active.
41328347|NCT05340101|BEHAVIORAL|ROGRESSIVE MUSCLE RELAXATION EXERCISE|"In the application, Relaxation Exercises CD Audio Recordings prepared by the Turkish Psychological Association were used. In the the second part of 30 minutes were explained with the sound of the PKGE stream and verbal instructions. Audio recordings in the second part were used in this study. In line with the PCGE sound recordings, each muscle group starting from the hands to the feet, and then the facial and whole body muscles were stretched for about 10 seconds. The exercise was applied by taking deep breaths while tensing each muscle group, and releasing this breath slowly during relaxation. The relaxation lasted 10-20 seconds before the next muscle group was stretched. In this way, the muscles groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, face and whole body were voluntarily stretched and relaxed, respectively, and the students were relaxed."
41155184|NCT00495612|DRUG|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
40810496|NCT06659536|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device|Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar URO device using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the symptomatic treatment of urge incontinence in adults with overactive bladder in accordance with the approved labelling.
41011284|NCT02053727|DRUG|Abatacept|Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
41155185|NCT00495612|DRUG|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
41155186|NCT00442026|DRUG|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
41011285|NCT02053727|DRUG|Placebo|
41011286|NCT00649181|DRUG|Metolazone Tablets 5 mg|2x5mg, single dose fasting
41328348|NCT04801394|PROCEDURE|hernioplastic and insertion of FLaPp® composite mesh|"After the reduction of the large incisional hernia, the polypropylene transparent film of this mesh (lower flap) was sutured to the margins of the residual peritoneum and posterior rectus sheath as a neo-peritoneum; the macroporous light polypropylene layer (upper flap) was then sutured circumferentially with full-thickness transabdominal stitches in the retromuscular space."
41328349|NCT03342456|DRUG|Doxycycline Hyclate Enteric-Coated Capsules|group 1,0.1g\*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.
41480983|NCT03060759|DEVICE|Light Therapy box|"The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs."
41480984|NCT05270928|DRUG|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
41480985|NCT02459665|BIOLOGICAL|Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
41011287|NCT00649181|DRUG|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
41480986|NCT02459665|DRUG|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
41480987|NCT02459665|BIOLOGICAL|Vaginal Lcr35-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
41328350|NCT03342456|DRUG|Amoxicillin Capsules|group 2,0.5g\*24 capsules/box, produced by United Laboratories（Zhuhai）
41328351|NCT03342456|DRUG|Ilaprazole Enteric-Coated Tablets|group 1 and group 2,5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc
41480988|NCT00521274|BIOLOGICAL|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
41480989|NCT00521274|DRUG|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
41480990|NCT06137755|BIOLOGICAL|CVI-VZV-001|Investigational Product
41328352|NCT03342456|DRUG|Furazolidone Tablets|group 1 and group 2,0.1g\*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
41480991|NCT06137755|BIOLOGICAL|Shingrix|Investigational Product
41328353|NCT03342456|DRUG|Potassium Citrate Tablets|group 1 and group 2,110mg\*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
41155187|NCT00442026|DRUG|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
41155188|NCT00442026|DRUG|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
41155189|NCT01084408|DEVICE|SeQuent®Please (Paclitaxel coated balloon)|PCI of de-novo lesions
41011288|NCT05593224|DEVICE|Intracranial Stent (Tonbridge)|The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
41011289|NCT05453838|DIETARY_SUPPLEMENT|oral intake of one serving of the original and new product|1) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
41011290|NCT00682019|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
41011291|NCT00682019|DRUG|Placebo|matching placebo
41011292|NCT04812379|DRUG|Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)|The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.
41011293|NCT04115358|PROCEDURE|Hyaluronic acid: Gengigel teething|Applying of 0,54% hyaluronic acid for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
41155190|NCT01084408|DEVICE|Taxus™Liberté™ (Paclitaxel eluting stent)|PCI of de-novo lesions
41328354|NCT02177175|DRUG|Carvedilol|
41328355|NCT02177175|OTHER|placebo|
41155191|NCT05039047|OTHER|Standard stroke acute care and rehabilitation|According to Swiss national guidelines and local protocols
41155192|NCT04643496|PROCEDURE|Laparoscopic or open Ileocolic resection|Laparoscopic or open Ileocolic resection
41155193|NCT03148301|OTHER|Survey|Survey
41155194|NCT02366702|DEVICE|Lower Limb Powered Knee-Ankle Prosthesis|
41328356|NCT05542693|BIOLOGICAL|RNA MCTI CIMATEC HDT 5µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
41328357|NCT05542693|BIOLOGICAL|RNA MCTI CIMATEC HDT 10µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
40810505|NCT06658236|OTHER|Proprioceptive Neuromuscular Facilitation|Group A will follow a PNF-based training protocol to enhance strength, flexibility, and coordination. The exercises include two main movement patterns: flexion-abduction-external rotation with the elbow extended and extension-adduction-internal rotation with the elbow extended. These patterns target the muscles around the shoulder and upper chest. A yellow Thera-Band adds light resistance, increasing muscle engagement. The protocol also employs the reversal of antagonists technique, alternating between opposing muscle groups for balanced development and improved coordination. Participants will complete three sets of ten repetitions per session, with a 60-second rest between sets. The program spans 12 weeks, with three weekly sessions, allowing for consistent progress and muscle recovery. This structured approach aims to improve functional mobility and the performance of activities involving similar movements, offering a comprehensive training strategy through PNF and resistance.
40810506|NCT06658236|OTHER|Chest Expansion Exercises|Group B participants followed a breathing-coordinated exercise protocol using a yellow Thera-Band to improve upper extremity function. The protocol began with subjects breathing generally at rest. They were then instructed to synchronize their movements with their breathing: performing upper extremity flexion, abduction, and external rotation during inhalation, followed by extension, adduction, and internal rotation during exhalation. This coordination between breathing and movement aimed to enhance muscle activation and control. Each session included three trials of ten repetitions for each exercise, with a 1-minute rest between trials. The protocol was conducted three times per week over 12 weeks. This approach was designed to promote strength, flexibility, and coordination in the upper body while integrating breath control, which may also support relaxation and better movement efficiency. The structured schedule ensures consistent practice and gradual improvement over the 12 weeks
41328358|NCT05542693|BIOLOGICAL|Covishield® - AstraZeneca|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer)
40810507|NCT06658249|OTHER|Core Stabilization Exercises with Foot-Ankle Strengthening Program|Core Stabilization Exercises and Foot-Ankle Strengthening Program with the frequency of 3 sets of 10 repetitions 3 times per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
40810508|NCT06658249|OTHER|Foot-Ankle Strengthening Program|Foot-Ankle Strengthening Program along with common conventional treatment with the frequency of 3 sets of 10 repetition thrice per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
41328359|NCT05542693|BIOLOGICAL|Comirnaty® - Pfizer|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer and (Covishield - Oxford/Astrazen).
41328360|NCT00053638|DRUG|efavirenz|
40810509|NCT06662149|OTHER|Pleasant Smell|The participants will be in an environment with an assumed pleasant smell while consuming the meal.
41011294|NCT04115358|PROCEDURE|Formocresol Buckley formula: Formacresol|Applying of 1/5 diluted formocresol for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
41328361|NCT00053638|DRUG|tenofovir|
41328362|NCT00053638|DRUG|abacavir/lamivudine|
41328363|NCT03922893|OTHER|Family History Information|The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.
41328364|NCT03922893|GENETIC|ORAGENE|Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.
41328365|NCT03922893|GENETIC|Blood|For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis
41328366|NCT03922893|OTHER|Skin Biopsy|In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.
41328367|NCT00189787|DRUG|tacrolimus|
41328368|NCT05915325|PROCEDURE|Physical training|"1. Supervised Physical Training in SeniorGym for 12 weeks: 1) Aerobic exercise: Patient-tailored intensity-modulated ergometer training for the limbs; 2) Resistance exercise: Patient-tailored resistance exercise by Theraband for the limbs~2. Nutrition intervention for 24 weeks: Dietitian consultation, education and intervention for 24 weeks"
41328369|NCT04903548|PROCEDURE|SIRT with Y-90 resin microspheres|Selective internal radiation therapy (SIRT) with Y-90 resin microspheres (Y-90 resin SIRT) is an intra-arterial, catheter-based locoregional therapy that has been used to treat patients with unresectable HCC
41328370|NCT06345599|RADIATION|Radiotherapy|This study is a phase I clinical study. The study is divided into phases Ia and Ib. Phase Ia is a dose-escalation experiment, divided into two cohorts based on radiotherapy dose, with 3+3 patients per cohort for a total of 12 patients. The first group undergoes two cycles of radiotherapy: 24Gy:8Gy3f d4-d6. The second group undergoes one cycle of radiotherapy: 40Gy:8Gy5f d3-d7. Phase II consists of 40 patients who choose the radiotherapy dose based on the results of phase I.
41328371|NCT06345599|DRUG|Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab|GM-CSF treatment: GM-CSF 200μg was started on the day of radiotherapy, and was subcutaneously injected daily for 7 consecutive days; d1-d7 Cadumilimab: use 375mg of cadumilimab within one week after radiotherapy
40810510|NCT06662149|OTHER|Unpleasant Smell|Participants will be in an environment with an assumed unpleasant smell while consuming the meal.
41328372|NCT06345599|DRUG|Chemotherapy:Albumin-bound paclitaxel、Gemcitabine|Albumin-bound paclitaxel 125mg/m2 d1, d8 Gemcitabine 1000mg/m2 d1, d8 After 3 cycles of neoadjuvant combination treatment with cadumilimab, the patient's surgical status will be evaluated. If surgery is possible, the patient will continue with another 3 cycles of treatment post-operation.
41328373|NCT04969432|OTHER|Client-centered|Rehabilitation
41328374|NCT04403529|DRUG|Traditional Chinese Medicine Formulation|"The prescription for breast cancer Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption."
41328375|NCT04403529|DRUG|Placebo Formulation|"Placebo granules contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption."
41328376|NCT00313248|DRUG|Sagopilone (ZK 219477)|All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
41155195|NCT04238299|DIAGNOSTIC_TEST|Multiparametric renal MRI|Localiser scans; Kidney volume; Longitudinal (T1) relaxation time mapping; Diffusion weighted imaging (DWI); Phase Contrast MRI; Arterial spin labelling (ASL); Blood Oxygen Level Dependent (BOLD) mapping
41155196|NCT03287375|DRUG|PIPAC|
41155197|NCT05289778|OTHER|Survey|Students will complete structured questionnaires in classroom settings, and parents will complete telephone interviews in the absence of their children.
41328377|NCT00313248|DRUG|Sagopilone (ZK 219477)|Patients will receive 22mg/m2 as intravenous infusion.
40810513|NCT06659549|DRUG|GAL-101|Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
40810514|NCT06659549|DRUG|Placebo|Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
41155198|NCT05723029|OTHER|Bowen Technique|A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position.
41328378|NCT05405218|DEVICE|CTR-US|Carpal Tunnel Release with Ultrasound Guidance
40810517|NCT06658106|BEHAVIORAL|Thera-Band Elastic Band-Assisted Progressive Resistance Training|Thera-Band Elastic Band-Assisted Progressive Resistance Training: This intervention involves a structured exercise program using Thera-Band elastic bands for resistance training, conducted three times a week for 12 weeks. Each session lasts approximately 50 minutes and includes exercises targeting major muscle groups, such as upper arms, shoulders, chest, lumbar, and lower limbs. Participants will perform each exercise for 8-12 repetitions in 2-3 sets with 1-minute intervals, aiming for an intensity of 60%-80% of their maximum heart rate. The program is designed to improve strength, balance, and overall physical function, thereby reducing frailty in older adults with diabetes.
40810518|NCT06658106|BEHAVIORAL|Conventional Diabetes Management|Conventional Diabetes Management: Participants in this arm will receive standard care for diabetes management, which includes health education covering diet, medication adherence, exercise recommendations, and routine health monitoring. This arm serves as a comparator to assess the effectiveness of the progressive resistance training intervention.
40810519|NCT06662006|DRUG|nal-IRI,5-fu,LV, benmelstobart, anlotinib|liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT
40810520|NCT06659406|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 will be given once daily, 200mg for the period of 3 months
40810521|NCT06660706|BEHAVIORAL|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
40810522|NCT06660199|BEHAVIORAL|Text-based intervention|Parents randomized to the texting intervention will receive up to 3 messages each day for 6 weeks: The intervention is comprised of adolescent-centered (A-C) texts focusing on parental adherence to recommended suicide prevention strategies to promote adolescents' safety and parent-centered (P-C) texts focused on improving parents' own well-being.
41328379|NCT05405218|PROCEDURE|mOCTR|Mini Open Carpal Tunnel Release
41328380|NCT02472015|PROCEDURE|telemedicine|psycho-behavioural care by telemedicine
41328381|NCT00996593|BIOLOGICAL|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)|Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
40810523|NCT06661499|OTHER|establish an artificial neural network model|to establish an artificial neural network model for pathogen diagnosis in ICU pneumonia
41328382|NCT02408185|DRUG|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
40810526|NCT06660342|DRUG|Vonoprazan|Oral tablet.
41011295|NCT04115358|PROCEDURE|Ferric sulfate: ViscoStat|Applying of 20% ferric sulfate for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
40810527|NCT06662370|OTHER|Replacement of the esophagus with a decellularized human esophagus graft|The Decellularized Human Esophagus (DHE) will be surgically implanted under general anesthesia via right or left thoracotomy or cervicotomy, depending on the location of the stenosis, to replace the esophageal defect created by resection of the stenosis. An omentoplasty is performed laparoscopically beforehand to provide secondary coverage of the graft area. A temporary esophageal stent is placed endoscopically to cover the DHE and the two anastomoses for a period of 3 months, to prevent the development of an anastomotic fistula and stenosis of the graft area.
40810528|NCT06661070|DEVICE|Electrolysis Percutaneous Therapeutic (EPTE)|EPTE device (Ionclinics, Valencia, Spain)
40810529|NCT06661070|OTHER|Dry Needling|A dry needle with size 0.30 × 40 (Agupunt, Barcelona, Spain)
40810530|NCT06659770|DRUG|Zevorcabtagene Autoleucel|Zevorcabtagene Autoleucel is a novel fully human BCMA-targeting CAR-T therapy
41155199|NCT05723029|OTHER|Post Isometric Relaxation|Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles.
40810533|NCT06658275|OTHER|Constraint-induced movement therapy|During the first routine checkup, therapists will educate caregivers on how to perform the exercises and activities at home. Caregivers will place the childrens less-affected hands in slings and guide them through exercises designed to engage their weaker, paretic hands. The sling will be fastened around the childrens trunks, with the end securely closed.After the initial session, the intervention will be provided by the caregiver at home, with progress monitored by the therapist through Zoom meetings or WhatsApp video calls. Children will engage in play-based activities as part of the CIMT program to improve upper limb functions.These activities will include painting, pin the tail on the donkey for sensory awareness and proprioception, card games, bubble activities, squeezing sponges, building towers with blocks, playing a curtained box game, using tongs, and picking up coins. Exercises will be gradually progressed from easier to more challenging tasks as the child improves.
40918230|NCT00668993|BEHAVIORAL|EFT - the Emotional Freedom technique|"EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published"
41155203|NCT03878147|BEHAVIORAL|Cognitive Games Training|Brain Powered Games (BPG) uses games for neurocognitive assessment and training, using images and sounds more familiar to African children. As a computerized cognitive rehabilitation training (CCRT) program designed for Sub-Saharan African school-age children, it can help children infected affected directly or indirectly by HIV. BPG consists of 5 core games evaluating different cognitive abilities (learning, memory, language, attention). Each game includes a visual tutorial, several adjustable settings on the administrative side (Admin), and records game play data for research purposes. Village Builder (VB) is a pro-social reasoning/planning world building strategy type game intended to evaluate frontal lobe executive functions in a culture-friendly and enjoyable game manner. It consists of many of the village artistic components as used in BPG but orchestrated into a village setting where children must gather resources and protect them in order to expand the capacity of the village.
41328383|NCT02408185|DRUG|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
41328384|NCT04301583|DIETARY_SUPPLEMENT|procyanidin B2 enriched cocoa|Volunteers will intake 5 grams per day of dietary supplement for 10 weeks
41328385|NCT06025617|OTHER|Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders|The intervention consists of being examined at the Diagnostic Clinic for Functional Disorders. If an FSD diagnosis is established, the patient receives feed-back of on the FSD diagnosis and patient education about the condition. Subsequently, the clinic provides guidance to the GP regarding recommended management and treatment options tailored to each individual patient.
41328386|NCT06025617|OTHER|Diagnostic as usual|"Diagnostic as usual consists in being referred to be examined at another existing specialist clinic in the secondary sector, as specified by the patient's GP."
41328387|NCT02051738|DRUG|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
41155204|NCT04694300|DRUG|Naproxen|"440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days."
41155205|NCT04694300|DRUG|Acetaminophen|1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
41155206|NCT04694300|DRUG|Tramadol|50 mg by mouth every 6 hours as needed for pain
41155207|NCT02524951|DRUG|MSI-1436C|Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
41328388|NCT02051738|DRUG|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
41328389|NCT05979155|BIOLOGICAL|NWY001|Part 1: Participants will be given a single-dose of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
41328390|NCT05979155|BIOLOGICAL|NWY001|Part 2: Participants will be given RP2D of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
41328391|NCT05053126|DRUG|Pregabalin 300mg|Participant will receive an oral dose of pregabalin 300 mg
41328392|NCT05053126|DRUG|pregabalin 450 mg|Participant will receive an oral dose of pregabalin 450 mg
41328393|NCT05053126|DRUG|Pregabalin 300 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg
41328394|NCT05053126|DRUG|pregabalin 450 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg
41328395|NCT05053126|DRUG|oxycodone 20 mg|Participant will receive an oral dose of oxycodone 20 mg
41328396|NCT05053126|DRUG|Placebo|Participant will receive an oral dose of placebo
41328397|NCT05668637|OTHER|Artificial Intelligence-based Decision support|Decision support to optimise invasive mechanical ventilation settings
41328398|NCT04681924|OTHER|Diet intervention|Low carb diet group are compared to low fat diet group and followed up for 6 months
40810534|NCT06658275|OTHER|Hand Arm Bimanual Intensive Training -HABIT|For the Bimanual Intensive Training group, a strategy similar to HABIT will be used. At the first routine checkup, therapists will educate caregivers on the exercises, which will then be conducted at home. Caregivers will guide children through specially designed bimanual activities without slings, focusing on tasks like reaching, grasping, manipulation, releasing, and bearing weight on the upper limb. Progress will be monitored remotely through Zoom or WhatsApp video calls.Exercises will include catching and throwing a ball to improve reaching, grasp, and release; squeezing a textured ball for sensory awareness and sustained grip; stabilising and reorienting paper while drawing and cutting to enhance forearm supination and wrist extension. Additional tasks like sticker peeling for pincer grip and dough playing for hand manipulation will also be included.Exercises will progress from easy to more difficult as the child improves
41328399|NCT05482035|DEVICE|wrist blood pressure monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
41328400|NCT05484427|OTHER|Telemedicine|Replacement of the regullar meeting with diabetologist by remote communication only
40810535|NCT06662175|DRUG|Hyperbaric bupivacaine|Group A (Unexposed) will received 2 ml of intrathecal bupivacaine
41328401|NCT05561894|OTHER|pulse pressure variation index guided fluid therapy|maintainence intraoperative fluid therapy (ringer's acetate) will be given guided by either two goals of pulse pressure variation index, either \>12% or \>16%
41328402|NCT04142749|DRUG|Oltipraz|Total 90mg, By mouth, TID
41328403|NCT04142749|DRUG|Placebos|Total 90mg, By mouth, TID
41480992|NCT03142035|DRUG|Dienogest 2 MG|Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions
41480993|NCT03142035|DRUG|gonapeptyl|gonadotropic releasing hormone agonist
41480994|NCT03142035|PROCEDURE|IVF/IVF+ART|In-vitro fertilization +/- assisted reproductive technology
40810536|NCT06662175|DRUG|hyperbaric bupivacaine and dexmedetomidine|Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion
41328404|NCT01985971|RADIATION|PET/CT Imaging|
41480995|NCT05311917|OTHER|home vision therapy|a group of vision therapy procedures in home to improve convergence insufficiency
41480996|NCT05311917|OTHER|base in prism prescription|base in prism prescription according to sheards criterion
41480997|NCT05311917|OTHER|conventional placebo|using near glasses with aimless eye training
41480998|NCT05999721|PROCEDURE|superficial parasternal intercostal plane block|Injection of 60 mL of bupivacaine 0.25% and epinephrine 2.5 µg mL-1
41480999|NCT05999721|OTHER|Standard care|"Anaesthesia will be induced using midazolam (0.1-0.15 mg kg-1), fentanyl (5-10 μg kg-1), and rocuronium (0.6-1.2 mg kg -1); then, after tracheal intubation, anaesthesia will be maintained using isoflurane at one MAC, along with continuous fentanyl (3-5 μg kg-1 h-1) and midazolam (20-50 μg kg-1 h-1). Moreover, patients will receive intravenous multimodal analgesics, including paracetamol 1 g, tramadol 100 mg, and dipyrone 1 g.~In the cardiothoracic intensive care unit, anaesthesia will be maintained using continuous fentanyl (2-5 μg kg-1) until tracheal extubation. After tracheal extubation, patients will receive intravenous multimodal analgesic drugs around the clock, including paracetamol 3 g day-1, tramadol 300 mg day-1, and dipyrone 3 g day-1. If the patients are still in pain, rescue doses of intravenous morphine 5 mg will be administered."
41481000|NCT00313443|PROCEDURE|Fat tissue needle aspiration|Small fat tissue sampling performed by needle aspiration.
41481001|NCT01817465|DRUG|Motilitone ®|
41481002|NCT01817465|DRUG|Pantoline®|
41481003|NCT01817465|DRUG|Motilitone® and Pantoline®|
41328405|NCT05706961|OTHER|Power Walking|"For 1- 2 Week 60% of the target heart rate with 5,000 to 7,500 steps/day Total 30 min Session The exercise intensity was set at 60% of the target heart rate during the first 2 weeks.~For 3- 4 week 70 % of the target heart rate with 7,500 to 10,000 steps/day Total 30 min Session B) Progressive increase walk according to 6MWD as improved Low intensity"
41481004|NCT02240563|PROCEDURE|Low-level laser therapy|
41481005|NCT02240563|PROCEDURE|Non laser ordinary red light|
41328406|NCT05706961|OTHER|Standardized Outpatient Cardiac Rehabilitation|"For 1- 2 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 60 % of of target heart rate, resistive ex with 1- 3 kg of weight for 20 min and 10 min of cool down)~For 3 - 4 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 70 % of target heart rate, resistive ex with 2- 3 kg of weight for 20 min and 10 min of cool down)"
41328407|NCT00944216|DRUG|Salkera Emollient Foam|application of the Salkera emollient foam twice a day during the 12 week study period.
41328408|NCT02216890|DRUG|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
41328409|NCT00112684|DRUG|alvocidib|Given IV
41328410|NCT00112684|OTHER|pharmacological study|Correlative studies
41328411|NCT00112684|OTHER|laboratory biomarker analysis|Correlative studies
41328412|NCT03009812|PROCEDURE|Longitudinal uterine incision|
41328413|NCT03009812|PROCEDURE|Transverse uterine incision|
41328414|NCT01867645|DRUG|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
41328415|NCT01867645|DRUG|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
41155208|NCT05399667|OTHER|Early stimulation|Preterm born children submitted to skin-to skin care (kangaroo care ) plus massage therapy by their mothers. This group received tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
41155209|NCT05399667|OTHER|Conventional care|Preterm born children submitted to skin-to skin care by their mothers (kangaroo care), associated to standard care according to the routine care in the Neonatal Intensive Care Unit (NICU).
40810539|NCT06657859|DRUG|GLM101|GLM101 IV infusion
40810540|NCT06659159|DIAGNOSTIC_TEST|Gastric ultrasound|"The sequence in which the study is conducted will be as follows, the first examination (baseline examination) will take place immediately before the appointment and prescription of GLP-1 Analoga (before the first injection). During the examination the gastric content (quality/quantity) will be determined, secondly, a baseline for gastric emptying time after oral intake of 500ml of water is collected (patient drinks water, the stomach emptying will simultaneously be tracked with gastric ultrasound).~In accordance with the first endocrinological control examination (6-8 weeks after therapy initiation) the same gastric ultrasound examination is performed."
40810541|NCT06661759|BEHAVIORAL|Clinic-based and technology-supported sleep intervention|CATS sleep intervention: The in-person sleep education and consultation will consist of 3 face-to-face, one-on-one sessions held 3 months apart during the child's routine clinic visit.The digital component of the sleep intervention will extend in-person education by providing ongoing support. Participants will receive one digital session per week for four weeks after the baseline, 3-month, and 6-month clinic visits, totaling 12 sessions.
41011296|NCT06457022|OTHER|Modified Constraint Induced Movement therapy|patient wears a restraint instrument in his unaffected hand, then applying massed practice to his affected upper extremity. The patient wears padded glove in his unaffected upper extremity for restraining the patient from using his unaffected upper extremity for about 3 hours per day including the treatment session and the home program. So, by this way the patient is reinforced to use his affected upper extremity during this period of time to achieve his activities of daily living. Finally, the total time, the patient spends it during the day wearing the glove should be recorded each day.
41155210|NCT04132388|OTHER|Electronic Reporting|"The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 \& 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
41155211|NCT04132388|DRUG|Adalimumab|Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks
41011297|NCT06457022|OTHER|Dual task training in the form of cognitive - motor task|Verbal fluency: Ask the hemiparetic patient to title many words of specific type as fruits, vegetable or animals. Mental tracking: as the hemiparetic patient to subtract serial 3 between number 90 and 100.
41011298|NCT06457022|OTHER|Conventional physiotherapy rehabilitation program|Ultrasound on shoulder. Graduated active exercises for shoulder. Prolonged stretching for spastic muscles
41155212|NCT06451224|OTHER|Questionnaire|Online Questionnaire
41155213|NCT05828602|OTHER|Conventional treatment|Conventional treatment
41155214|NCT05828602|OTHER|TeleRehabilitation|TeleRehabilitation
41328416|NCT04416945|OTHER|Household Reactive Case Detection|Within 7 days of the index case notification, all members of the index case's household and everyone in the neighboring five households will then be invited to participate in the study. After consenting, a finger stick blood sample will be collected for each consenting individual for testing with the HS-RDT for P. falciparum, a standard combination RDT, and four blood spots on filter paper.
41481006|NCT01957072|BEHAVIORAL|Behaviour change intervention|"The behaviour change intervention consists of~1. feedback via a web-based food diary~2. 'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails."
41481007|NCT00693225|DRUG|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
41155215|NCT05306613|BEHAVIORAL|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
41155216|NCT05306613|BEHAVIORAL|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
41155219|NCT00948103|DRUG|Nitrous Oxide|nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
41155220|NCT00948103|DRUG|Oxygen|oxygen
41155221|NCT04018534|BEHAVIORAL|Standard Verbal/Written Education|This patients as control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society (BOS) educational goals.
41155222|NCT04018534|BEHAVIORAL|Video Assisted Education|The video training consisted of two separate sessions, each one lasting 5 minutes, one about the treatment materials and the other about the oral hygiene successively and in compliance with the British Orthodontics Society (BOS) educational obligations. All of the candidates were allowed to rewind and watch the video presentation until they reach all of the educational goals. The accomplishment of the educational goals was documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics.
41481008|NCT04683419|DEVICE|Modified Thoracoscopic pleural Cryobiopsy|"Thoracoscopic pleural biopsy will be taken with a modified technique raising of the parietal pleura by injection of saline, adrenaline and xylocaine, then taking the biopsy via a cryoprobe"
41481009|NCT01032772|BEHAVIORAL|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
41481010|NCT01032772|BEHAVIORAL|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
41481011|NCT06196021|OTHER|Intra-articular hyaluronic acid injection|"Hyaluronic acid was injected into the symptomatic knees of the patients a total of 3 times, once a week for 3 weeks.~Injections were administered by the physician using a lateral approach with the patient lying on his back and the knee in full extension.~After each injection, patients were warned to apply cold to avoid possible local reactions and not to overload for 24 hours.~Hyaluronic acid preparation was in the form of 2.5 ml solutions obtained biotechnologically, containing 10 mg sodium hyaluronan in each milliliter.~The hyaluronan in solution was of medium molecular weight (0.9 million daltons) but still lower molecular weight than the hyaluronan in normal healthy synovial fluid."
41481012|NCT01025674|BEHAVIORAL|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
41328417|NCT04416945|OTHER|RACD of cases' co-workers/co-travelers|"Index cases will be screened by the VMW at their households at the time of case investigation to determine if they have traveled or worked in a forest or forest-fringe area within the past 30 days. If eligible, the case will trigger two reactive recruitment strategies to screen and treat others who recently traveled or worked with the case in a forest or forest-fringe location:~1. Peer-referral RACD (PR-RACD): In this strategy, the case will identify specific co-travelers or co-workers resident in their village who had spent the night with the case at a forest or forest-fringe area and spent the night there in the past 30 days.~2. Venue-based RACD (VB-RACD): In this strategy, co-workers will be recruited directly from (accessible) forest or forest-fringe work sites where the index case worked and spent at least one night in the past 30 days."
41481013|NCT04892797|OTHER|Covid-19+ observational|This is observational--there is no intervention
41481014|NCT04435106|DRUG|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
41481015|NCT04435106|DRUG|Standard of Care|Study participants received Standard of Care
41481016|NCT05143931|BEHAVIORAL|Home food environment and grocery delivery (AVOID)|Participants (Arms 2 \& 4) will receive 6 months of coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices
41481017|NCT05143931|BEHAVIORAL|Inhibitory control training (RESIST)|Participants assigned to RESIST (Arms 3 \& 4) will receive 6 months of coaching (Zoom and/or email/text) and gamified inhibitory control training.
41481018|NCT05143931|BEHAVIORAL|WW|Participants assigned to all arms will receive 6 months of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.
41481019|NCT00305552|DRUG|THALIDOMIDE|THALIDOMIDE
41481020|NCT02448849|BIOLOGICAL|Percutaneous injection|percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.
41481021|NCT02448849|OTHER|Percutaneous injection|Percutaneous implantation of placebo in patients with nonunion fracture.
41481022|NCT05258331|GENETIC|CT303|"1. Cohort 1 : Single-dose administration, intravenous injection~   * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~  * Dose 2 : 2.0\*10\^6 cells/kg~  * Dose 3 : 3.0\*10\^6 cells/kg~2. Cohort 2 : Multiple-dose administration, intravenous injections (Week 0, Week 4)~   * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~  * Dose 2 : 2.0\*10\^6 cells/kg~  * Dose 3 : 3.0\*10\^6 cells/kg"
41155223|NCT04018534|BEHAVIORAL|Hands-on Training|The hands-on training consisting of two separate sessions was performed by one of the authors (E.A). The first is about the treatment materials and the second one is about the oral hygiene successively. They are in accordance with the British Orthodontics Society (BOS) educational obligations. All of the patients were allowed to ask questions freely until they reach all of the educational goals. The accomplishments of the educational goals were documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics. The time requirements for all three different educational interventions were recorded separately.
41481023|NCT04710537|OTHER|AlloDerm|Enrolled patients will have one of their breasts reconstructed with AlloDerm at the time of their breast reconstruction surgery.
41481024|NCT04710537|OTHER|DermACELL|Enrolled patients will have one of their breasts reconstructed with DermACELL at the time of their breast reconstruction surgery.
40810544|NCT06659900|OTHER|CORE Plus (+)|CORE PLUS intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials, a voucher for a medication starter kit PLUS support from a Community Health Advisor who will serve as a connector to primary care for HTN management and send reminder text messages.
41155224|NCT00515281|DRUG|inhaled nitric oxide|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
41481025|NCT01179126|PROCEDURE|complete multivessel revascularization|After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission
40810545|NCT06659900|OTHER|CORE|CORE intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials and a voucher for a medication starter kit
41481026|NCT01179126|PROCEDURE|stress echocardiography and revascularization if required|after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
41481027|NCT01820351|OTHER|static stretching exercise on 3 times a week during 8 weeks. Sets number: three of 30 seconds with intervals of equal duration|
41481028|NCT06201416|BIOLOGICAL|SBT777101|Experimental treatment
41481029|NCT04555681|DIAGNOSTIC_TEST|Collection of subgingival dental plaque|Identification and quantification using q-PCR of the 21 bacteria most frequently found in the dental plaque (including the periopathogenic bacteria) and Candida albicans.
41481030|NCT05540821|DIAGNOSTIC_TEST|Hysterosalpingo-contrast sonography and sonoPODography|"Before operation, phloroglucinol 40mg of antispasmolysis was injected intramuscular, and then cervical dilation was performed according to aseptic operation requirements. A 12G double-lumen catheter was inserted into the uterine cavity, and 1.5-1.8ml of normal saline was injected into the sacculus.~Transvaginal 2/3/4D hysterosalpingo-contrast sonography: One operator extracted 2ml of Sonovue and injected 18ml of normal saline through a dual-lumen catheter, and the other operator started the four-dimensional ultrasound mode to collect dynamic volume data.~sonoPODography: Sterile saline was injected into the intrauterine cavity, with an upper limit of 20ml. The normal saline flowed from the intrauterine cavity into the pelvic cavity through the bilateral fallopian tubes, forming a good acoustic window. Pelvic observation was then performed."
41481031|NCT00196131|DRUG|morphine|only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
41481032|NCT02619136|PROCEDURE|Transfusion|Red Blood Cell Transfusion
41481033|NCT04877171|OTHER|telemedicine neurology consultation|consultations via phone-only at 12-14-day post-discharge. Consultations via phone both audio and video at 1, 3 and 6 months
41481034|NCT04877171|OTHER|in-person neurology consultation|consultation in-person at Hospital Internacional de Colombia
41481035|NCT01921621|BEHAVIORAL|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
41481036|NCT01921621|BEHAVIORAL|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
41481037|NCT04056975|BIOLOGICAL|Recombinant Anti-CD19m-CD3 Antibody Injection|Intravenous Infusion
41481038|NCT02635217|DEVICE|Carbon dioxide insufflation|using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
41481039|NCT02635217|DEVICE|room air insufflation|using standard care room air will be infused on demand
41481040|NCT02635217|PROCEDURE|EGD (Esophagogastroduodenoscopy) before Colonoscopy|the order of endoscopies will be randomized as well
41155225|NCT00515281|DRUG|oxygen|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
41481041|NCT02635217|PROCEDURE|Colonoscopy before EGD (Esophagogastroduodenoscopy)|
41155226|NCT02567227|OTHER|Cognitive Remediation|This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
41155227|NCT02567227|OTHER|Active Control|Computer, multimedia and group based health education programs.
40810549|NCT06659952|OTHER|HIV-positive heart transplant|Receipt of heart from HIV-positive deceased donor only as part of this study
41155228|NCT04054193|DRUG|Fosaprepitant Dimeglumine|Participants received IV fosaprepitant dimeglumine ≤115 mg on Day 1 and ≤80 mg on Days 2 and 3 (dose adjusted for age).
41481042|NCT00453778|DRUG|FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)|
41481043|NCT00299845|DRUG|Lansoprazole|
41481044|NCT04146831|DRUG|Sintilimab|Sintilimab: intravenous, 200mg, every 3 week. Course of treatment: Stop the treatment until clinical or radiographic progression occurs.
41481045|NCT03150823|PROCEDURE|Upward Direct Current (Ascending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the ascending stream direct current (Ascending effect) the proximal cathode and distal anode are placed, a excitatory effect on the nervous system being described in theory.
41481046|NCT03150823|PROCEDURE|Downward Direct Current (Descending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the descending stream direct current (Descending effect) the proximal anode and distal cathode are placed, a sedative and analgesic effect on the nervous system being described in theory.
41155229|NCT04054193|DRUG|5-HT3 antagonist|All participants received an oral 5-hydroxytryptamine (serotonin; \[5-HT\]) 3 receptor antagonist on Day 1 and had the option to take on Days 2-3. The dose was as per product label or standard of care.
41155230|NCT04054193|DRUG|Dexamethasone|Participants received optional oral dexamethasone at the investigator's discretion according to product label or standard of care.
41155231|NCT06584565|OTHER|microbiome; metabolomics; proteomics|post-stroke change of microbiome; metabolomics; proteomics
41155232|NCT00642499|DRUG|Dronabinol|2.5 mg to 40 mg
41155233|NCT00642499|DRUG|Placebo|placebo
41481047|NCT03150823|PROCEDURE|Sham Direct Current|Installation of electrotherapy equipment off (Sham tratment).
41481048|NCT03200691|RADIATION|3-DCRT or IMRT radiation|Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.
41481049|NCT03200691|DRUG|anti-PD-1 antibody SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.
41481050|NCT05714566|DIAGNOSTIC_TEST|Clostridioides difficile toxin detection|Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.
41481051|NCT03425279|BIOLOGICAL|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
41481052|NCT03425279|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
41481053|NCT03477955|PROCEDURE|PEEK interspinous spacer|To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.
41481054|NCT00350649|BEHAVIORAL|Standard CBT|Manualized delivery of CBT by trained clinicians
41155234|NCT01740999|PROCEDURE|silicone arthroplasty|silicone arthroplasty
41011299|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration|The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
41011300|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only|The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
41011301|NCT06013371|DRUG|PF-07038124|topical PDE4 inhibitor
40810551|NCT06660537|PROCEDURE|Balloon-blowing exercises in 90/90 bridge position with a ball.|In this group patients will undergo balloon-blowing exercises in the 90/90 bridge position with a ball. In this intervention, patients lie on back with feet against a wall and knee bent at 90 degrees, holding a ball between their knees. While extending one arm overhead and holding a balloon in the other hand, perform a pelvic tilt without lifting their back off the mat. Inhale through the nose, exhale into the balloon for four breaths, then remove the balloon and repeat the sequence four times. The 4-week protocol includes three supervised sessions per week, each supervised by a physiotherapist. Progress will be monitored regularly to evaluate improvements throughout the intervention.
40810552|NCT06660537|PROCEDURE|Buteyko breathing exercises management|In this group, patients will receive Buteyko breathing exercises, which consist of two main exercises; the control pause and the maximum pause. For control pause, patients exhale, plug the nose, and hold their breath until they feel the urge to breathe, then inhale and breathe normally for 10 seconds. In Maximum pause, patients exhale, plug their nose, and hold their breath as long as possible, aiming for double the control pause time, then inhale and breath normally for 10 seconds. This is a 4-week protocol with three sessions per week. Pre- and post-intervention values will be recorded to assess progress.
40810553|NCT06657937|OTHER|Questionnaire|"An initial questionnaire is completed on D0, the day of the patient's admission to the emergency department, by the practitioner in charge of the patient, and covers the patient's anamnesis, clinical examination, radiological examinations and treatment.~A follow-up telephone visit is then carried out at 30 days by an investigator, to gather information on the clinical and therapeutic evolution, and to evaluate the recovery and evolution of symptoms experienced by the patient in relation to the initial management."
41155235|NCT01740999|PROCEDURE|arthrodesis|arthrodesis
41011302|NCT06013371|DRUG|Placebo Ointment|matching placebo
41011303|NCT03116165|BEHAVIORAL|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
41011304|NCT03116165|BEHAVIORAL|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
41011305|NCT01540370|OTHER|No Treatment|No treatment
41011306|NCT05508633|DRUG|Alverine Citrate|Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.
41011307|NCT04705545|DEVICE|transpalatal arch group|transpalatal arch is a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands.
41011308|NCT04705545|DEVICE|Nance button|Nance button is a 1.0mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands
41011309|NCT05074550|DRUG|PPMX-T003|As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
41011310|NCT04971031|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
41011311|NCT04971031|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
41481055|NCT00350649|BEHAVIORAL|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
41011312|NCT01938534|DRUG|Helicobacter pylori eradication|
41011313|NCT06569303|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
41011314|NCT06569303|BEHAVIORAL|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
41011315|NCT00326911|BIOLOGICAL|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
41011316|NCT00326911|BIOLOGICAL|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
41011317|NCT00326911|DRUG|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
41011318|NCT00326911|BIOLOGICAL|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
41011319|NCT03794115|PROCEDURE|Treatment for ovarian cancer|The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.
41155236|NCT00002216|DRUG|Lamivudine/Zidovudine|
41155237|NCT00002216|DRUG|Abacavir sulfate|
41155238|NCT00002216|DRUG|Amprenavir|
41155239|NCT00002216|DRUG|Nelfinavir mesylate|
41155240|NCT00489151|DRUG|adefovir dipivoxil|
41155241|NCT00489151|DRUG|lamivudine|
41155242|NCT05744557|OTHER|num Vapocoolant|Spray will be administered for 4 to 6 seconds from a distance of 3 to 6 inches to desired sites of skin
41155243|NCT05401149|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
41481056|NCT00350649|BEHAVIORAL|CM/abstinence|Contingency Management
41481057|NCT00350649|BEHAVIORAL|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
41481058|NCT03335579|COMBINATION_PRODUCT|inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil|Different combination of opioids and anesthetics
41481059|NCT00109837|BIOLOGICAL|filgrastim|As needed per physician discretion
41481060|NCT00109837|DRUG|cyclophosphamide|Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
41481061|NCT00109837|DRUG|cytarabine|Induction 2: 3 g/m2; IV over 3 hrs; days 1-5 Consolidation: 75 mg/m2/d; IV push; days 2-5 and 16-19 Post-consolidation course 3: 75 mg/m2/d; IV push; days 3-6 and 10-13
41481062|NCT00109837|DRUG|daunorubicin|Induction: 60 mg/m2/d; IV; days 1, 2, and 3
41481063|NCT00109837|DRUG|dexamethasone|Induction 2: 0.1% QID; eye drops; days 1-6 Post consolidation course 2: 10 mg/m2/d; PO; days 1-28
41481064|NCT00109837|DRUG|doxorubicin|Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
41481065|NCT00109837|DRUG|leucovorin|For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC \< 3,000
41481066|NCT00109837|DRUG|mercaptopurine|Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
41481067|NCT00109837|DRUG|methotrexate|Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
41481068|NCT00109837|DRUG|mitoxantrone|Induction 2: 80 mg/m2; IV; day 3
41481069|NCT00109837|DRUG|Asparaginase|Induction: 2,000 IU/m2; IM or IV; day 15
41481070|NCT00109837|DRUG|prednisone|Induction: 60 mg/m2/d; PO or IV; days 1-35
41481071|NCT00109837|DRUG|thioguanine|Post-consolidation course 3: 60 mg/m2/d; PO; days 1-14
41481072|NCT00109837|DRUG|vincristine|Induction: 1.4 mg/m2/d (2 mg max); IV; days 1, 8, 15, 22
41481073|NCT00109837|RADIATION|radiation therapy|For CNS during consolidation: cranial radiation after blasts are no longer present in spinal fluid. Total dose of 1800 cGy over 2 wks in 10 fractions of 180 cGy 5 days/wk.
41481074|NCT00109837|DRUG|allopurinol|300 mg/d PO Days 1-7
41481075|NCT00109837|DRUG|bactrim|1 double strenth tablet 2x/d, 2x/wk, PO, begin with prednisone
41481076|NCT06321003|DEVICE|OCT (Optical Coherence Tomography)|OCT diagnosis in oral carcinogenesis
41481077|NCT03755479|DEVICE|Hybrid Closed Loop Insulin Pump Minimed 670G|Five Day Group Education on Minimed 670G
41481078|NCT03964610|DIAGNOSTIC_TEST|color fundus photography (CFP) and OCT-A|Included patients will have an ophthalmologic assessment (OCT-A and CPF) after stabilization and at 3 months follow-up.
41481079|NCT03037034|DEVICE|Forcep|"Following the injection around a submucosal tumor, the adjacent mucosa or submucosa was grasped with the forceps and pulled away to form a tent. The tissue was dissected using an electrocoagulating current."
41481080|NCT04300829|DRUG|cicaderma + simple hygiene rules|Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
41481081|NCT04300829|OTHER|Simple hygiene rules and a maximum of one topical treatment|Simple hygiene rules according to the site recommandations including eventually a maximum of one topical treatment
41481082|NCT05801653|DIETARY_SUPPLEMENT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
41481083|NCT05002413|DIAGNOSTIC_TEST|Resistell AST|The Resistell AST is intended for rapid antibiotic susceptibility testing of most common clinically relevant Gram-negative bacteria causing bloodstream infections (BSI) (bacteremia). In the scope of this study, the Resistell Phenotech device will be used to test the susceptibility of Gram-negative bacteria, in particular Escherichia coli and Klebsiella pneumoniae to ceftriaxone and ciprofloxacin.
40918231|NCT00660686|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
41011320|NCT02443376|DEVICE|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
41011321|NCT02443376|DEVICE|BCM- Body Composition Monitor|"BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)"
41155244|NCT05692232|OTHER|Pressure biofeedback guided DCFM strength training|A pressure biofeedback guided DCFM strength training was carried out according to the Jull protocol. Keeping the participant's cervical spine in a neutral position and ensuring a stabilizer pressure biofeedback unit placed beneath the cervical lordosis. The pressure sensor was inflated at 20mm Hg. The participants were asked to nod their heads slowly. As the DCFM is activated, the cervical lordosis gently flattens, and the pressure sensor measures an increase in pressure. The activation score is the maximum pressure that can maintain for 10 seconds.
41481084|NCT00773942|BEHAVIORAL|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
41481085|NCT00773942|BEHAVIORAL|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
41481086|NCT01842126|BIOLOGICAL|BG00010 IV|Ascending Doses intravenous (IV) of BG00010
41481087|NCT01842126|BIOLOGICAL|BG00010 SC|Ascending Doses subcutaneous (SC) of BG00010
41481088|NCT01842126|DRUG|Placebo IV|Ascending Doses intravenous (IV) of Placebo
41481089|NCT01842126|DRUG|Placebo SC|Ascending Doses subcutaneous (SC) of placebo
41481090|NCT00117403|DRUG|Vitamin E, Vitamin C, and Alpha-lipoic Acid|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
41481091|NCT00117403|DRUG|Coenzyme Q|400 mg, compounded as a wafer, two wafers three times per day with meals
41481092|NCT00117403|DRUG|Placebo capsules|one placebo capsule three times per day with meals
41481093|NCT00117403|DRUG|Placebo wafers|two placebo wafers three times per day with meals
41481094|NCT02883517|GENETIC|Cytogenetic and molecular studies|Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.
41481095|NCT05123677|DIAGNOSTIC_TEST|Non-invasive haemodynamic assessment|Maternal non-invasive haemodynamic assessment: a pressure cuff (similar to the one used to measure blood pressure) is applied to the arm and thigh, and a further neck sensor applied. Information about the function of heart and major blood vessels are recorded
41481096|NCT05123677|DIAGNOSTIC_TEST|Maternal ophthalmic artery doppler|Maternal ophthalmic artery doppler: an ultrasound probe is applied gently over the eyelid for a few seconds to study the blood flow of the main artery to the eye
41481097|NCT05927831|DRUG|Grape Seed Extract|Grape seed extract will be applied in the form of a gel on the tooth surface
41481098|NCT05927831|DEVICE|Low-level laser therapy|The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode
41481099|NCT06233019|OTHER|Glycolic Acid Plus Salicylic Acid in Treatment of Plane Wart|Prior to the procedure, patients will be instructed to avoid sun exposure during the treatment and to use broad spectrum sunscreen The treatment was started once daily over the entire face and maintained for two months. A fine layer of Glycolic Acid Plus Salicylic Acid face gel was applied on the whole surface where the warts were present, avoiding the eyelids and lips. In children 7 to 10 years of age, face gel was applied by their parents. Clinical controls were performed at Weeks 2, 4, 6, and 8.
41481100|NCT03893734|DRUG|methadone|Patients in the methadone group will receive a syringe of methadone at induction of anesthesia and a syringe of saline at the end of anesthesia
41481101|NCT03893734|DRUG|Hydromorphone|Patients in the hydromorphone group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
41481102|NCT01005706|DRUG|rapamune, mycophenolate mofetil and steroid|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
41481103|NCT01005706|DRUG|tacrolimus, sirolimus and steroid|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
40810555|NCT06657885|DRUG|his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi|"cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48"
41328418|NCT04416945|OTHER|Case Management and Follow-up|"All individuals who test positive by either HS-RDT or Standard RDT will be told of their results and treated on site per national guidelines:~* Individuals with P. falciparum infection will be treated with an age-appropriate course of artemether-lumefantrine (AL) and a single low dose of primaquine (SLD-PQ). Weight-based dosing is described in Tables 2 and 3 below.~* At all study sites in Lao Peoples Democratic Republic, patients with a P. vivax infection identified by RDT (both febrile and asymptomatic) will be given a unique coded and signed informational letter directing them to the nearest district hospital (or other testing facility) for G6PD deficiency testing and possible radical cure administration depending on results. At the health facility, G6PD normal individuals will be treated with AL and a 14-day course of PQ, whereas G6PD deficient individuals will receive AL alone as per the national guidelines and referred to a hospital for further primaquine management decisions."
41481104|NCT00507546|DRUG|Ramelteon|8 mg nightly
41481105|NCT00507546|DRUG|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
41481106|NCT01799317|DRUG|Vitamin D2|These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
41481107|NCT03499002|OTHER|Simulated Learning Environment|Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.
41481108|NCT01589861|DRUG|BKM120 + lapatinib|BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
41481109|NCT02406430|PROCEDURE|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
41481110|NCT02964819|OTHER|exercise|
41481111|NCT02964819|DEVICE|Interferential current therapy|
41481112|NCT02964819|DEVICE|Therapeutic Ultrasound|
41481113|NCT03415984|DIAGNOSTIC_TEST|Color retinography|Color retinography
41481114|NCT03415984|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography
41481115|NCT03415984|DIAGNOSTIC_TEST|Fundus autofluorescence imaging|Fundus autofluorescence imaging
40810556|NCT06660615|BEHAVIORAL|MIDWIFE-LED CARE|The birth process will be followed by the same midwife from the beginning of the intrapartum period until the birth of the baby and placenta. In this process, positive respectful maternal care will be included in line with the recommendations of WHO (İsbir \& Sercekuş, 2017).
41155245|NCT05692232|OTHER|Manual therapy|A manual therapy, including a slow, sustained elongation of muscles with a holding period of 7-10 seconds and a superficial oscillatory mobilization (grade-I) with 1-2 oscillations per second for 30 seconds per session was performed on the DCFM and at the cervical spine (C0-C5), respectively. The participants were asked to lie supine and prone while delivering stretching and mobilization, respectively.
41011322|NCT02672735|OTHER|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
41328419|NCT04908241|OTHER|TRAIL|"Each week has a specific focus for lower extremity rehabilitation:~Week 1) Building a base: 8 exercises, 10-15 repetitions x 2-3 sets~Week 2) Increasing repetitions: 8 exercises, 15-20 repetitions x 3 sets~Week 3) Building exercise tolerance:10 exercises, 15-20 repetitions x 3 sets~Week 4) Maximizing repetitions: 10 exercises, 30 seconds as many reps as possible x 2 sets~At the end of the second exercise session each week, the therapist and participants work collaboratively to develop an independent exercise action plan to be completed before the first session of the next week. The self-managed plans includes exercises selected from TRAIL, agreed upon by the participant and therapist, that are safe to perform without therapist oversight. The aims of the exercise action plan are to: i) Add exercise volume without using program resources (e.g., therapist time); and ii) Build capacity for self-management for long-term health and well-being after TRAIL has ended."
41155246|NCT05692232|OTHER|Conventional intervention|A hot pads was applied for 20minutes underneath the cervical spine covering either side of shoulder in a relaxed supine position.
41155247|NCT01367613|DRUG|SC Methylnaltrexone|
40810560|NCT06658756|BEHAVIORAL|internet-CBT|10 modules on line of I-CBT for OCD
40810561|NCT06658509|BEHAVIORAL|HIIT|High-intensity interval training
41011323|NCT04689737|DRUG|Doravirine|Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
41011324|NCT01299831|BEHAVIORAL|72 hour fast|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
41481116|NCT06032455|BEHAVIORAL|Multisystemic therapy|Multisystemic Therapy (MST) is an intensive, evidence-based treatment aimed at preventing out-of-home placement of adolescents with severe behavioural problems. The intervention is home-based and focuses not only on the adolescent, but also on the various systems surrounding the adolescent, such as the family, neighbourhood, school, and friends. MST helps parents increase their parenting competencies such as parental monitoring and find (more) social support in their environment. MST also helps adolescents improve their relationship with their parents, school participation, and social activities, and promotes contact with pro-social peers. These goals are achieved by working together with key figures in the family's environment. MST treatment duration is three to five months. In MST, a family can contact a therapist 24/7.
41481117|NCT06032455|BEHAVIORAL|Multisystemic therapy - intellectual disabilities|Multisystemic therapy - intellectual disabilities (MST-ID) is a specialisation of standard MST (see above), tailored to the needs and skill deficits of families in which the adolescent and/or parent(s) has/have a known or suspected ID. In MST-ID, among others, simplified language and visual support are used, and extra attention is paid to the generalisation of what has been learned in the treatment sessions.
41481118|NCT05212064|DEVICE|high-flow oxygen nasal cannula therapy|Heated and humidified oxygen of 40L/minute through high-flow nasal cannula (HFNC) therapy machine.
41481119|NCT05212064|OTHER|nasal cannula oxygen therapy|Heated and humidified oxygen of 6L/minute through high-flow nasal cannula (HFNC) therapy machine.
41481120|NCT00725530|DEVICE|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
40810562|NCT06658509|BEHAVIORAL|SIT|Sprint interval training
41011325|NCT01299831|BEHAVIORAL|control, 12 hour fast|The 12 hour fast will be used as a basic metabolic control
41011326|NCT01299831|DRUG|Growth hormone|Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
41011327|NCT01299831|DRUG|Olbetam|"The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours."
41481121|NCT00725530|DEVICE|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
41481122|NCT01575717|DRUG|Vitamin D3 4000 IU|Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
41481123|NCT01575717|DRUG|Vitamin D3 2000 IU|Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
41481124|NCT06305351|DRUG|K-757 and K-833 QD|Both administered orally once daily
41481125|NCT06305351|DRUG|K-757 and K-833 BID|Both administered orally twice daily
41481126|NCT06305351|DRUG|Matching placebo to K-757 and K-833 QD|Both administered orally once daily
41481127|NCT06305351|DRUG|Matching placebo to K-757 and K-833 BID|Both administered orally twice daily
41481128|NCT05020249|DRUG|bimekizumab|Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
41481129|NCT05020249|OTHER|Placebo|Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
41011328|NCT00422565|DEVICE|Endeavor, Medtronic|Zotarolimus-eluting stent
41011329|NCT00422565|DEVICE|Cypher, Cordis|Sirolimus-eluting stent
41011330|NCT00422565|DEVICE|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
41011331|NCT06232733|BEHAVIORAL|Healthy Lifestyles Project e-intervention|Virtual lifestyle behaviour change support.
41011332|NCT06383039|DEVICE|Transcranial Direct Current Stimulation|"Evaluations will be made in the presence of a physiotherapist. Individuals; For demographic information~• Demographic Information Form~For Static Balance Evaluation:~* Wii-Fit~* Balance Error Scoring System~For Dynamic Balance Assessment:~* Star Balance Test~* Timed Get Up and Go Test"
41011333|NCT05641740|DEVICE|Single-session of Radiofrequency|"The experimental group continue with their usual conservative and pharmacological treatment and will receive a single-session of monopolar dielectric capacitive radiofrequency in their hands. An Biotronic Advance Develops® (ABD-S25v) with a carrier wave frequency of 800-900 KHz of 850 KHz will be used. Patients will be placed in a seated position, with the forearms supinated and resting on a wooden table. An almond oil conductor will be applied to the hands. The application will be carried out with a circular head of 5 cm2 and for a total of 10 minutes on each of the palms of the hands.~They will be evaluated at baseline and post-session."
41328420|NCT04908241|OTHER|EDUCATION|"EDUCATION has a specific focus on:~Week 1) What is stroke (e.g., gaining an understanding of the function of the brain, types of stroke and how stroke affects physical function) and introduction to self-management;~Week 2) What is self-management;~Week 3) Self-management for post-stroke complications (e.g., activities of daily living);~Week 4) Self-management for secondary prevention (e.g., blood pressure, diet, medication, stress management).~Education therapists will be provided with lesson plans and manuals to be circulated with the participants, and will facilitate the educational session through interactive Powerpoint presentations. In addition, participants will be asked to complete 30-60 minutes of educational homework, which will be discussed at the commencement of the following session."
41328421|NCT04141215|BIOLOGICAL|BIOBank bone paste|BIOBank bone paste (PPT322)
41328422|NCT04141215|BIOLOGICAL|BIOBank cortico-cancellous bone powder|BIOBank cortico-cancellous bone powder (PPT6)
41328423|NCT06105203|PROCEDURE|Robotic-assisted total mesorectal excision|TME will be performed with the assistance of robot in rectal cancer
41328424|NCT06105203|PROCEDURE|laparoscopic-assisted total mesorectal excision|TME will be performed with the assistance of laparoscopy in rectal cancer
41328425|NCT04994704|DRUG|Propfol group|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.
41328426|NCT04994704|DRUG|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.
41328427|NCT00000384|BEHAVIORAL|Cognitive Behavior Therapy|
41328428|NCT00000384|BEHAVIORAL|Educational Support|
41328429|NCT00000384|DRUG|Sertraline|
41328430|NCT01577355|RADIATION|Drug|Single 30 mg oral dose containing 100 micro curies of LY2784544
41328431|NCT03810521|BIOLOGICAL|umbilical cord derived-mesenchymal stromal cells|Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
41328432|NCT00422903|DRUG|lapatinib|1500 mg administered orally daily
41011334|NCT05641740|DEVICE|Control Placebo single-session of Radiofrequency|"The control placebo group continue with their usual conservative and pharmacological treatment and will receive a placebo single-session of radiofrequency. This group will follow the same protocol and treatment time, but they will receive a placebo treatment (the device remains in paused mode), so that radiofrequency will not be applied.~They will be evaluated at baseline and post-session."
41011335|NCT03722329|DRUG|Eculizumab|Eculizumab Injection. 300 mg, single dose
41011336|NCT06340035|OTHER|TENS|The TENS group is subjected to transcutaneous current. Two surface electrodes are inserted at the level of the superior gluteal and inferior gluteal nerve tract. A protocol of 10 stimulations x 10 seconds of stimulations x 10 times is performed with a 10 second rest between each repetition. A maximum contraction evoked without pain is sought.
41155248|NCT02273180|DRUG|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by deep subcutaneous (SC) injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour post prandial plasma glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
41328433|NCT00422903|DRUG|letrozole|2.5 mg administered orally daily
41328434|NCT00422903|OTHER|placebo|1500 mg administered orally daily
41328435|NCT02674165|BEHAVIORAL|HART|Skills based sexual education intervention plus PTSD awareness
41328436|NCT06527196|BEHAVIORAL|Team Communication Training|Participants in the experimental arm will receive enhanced Team Communication Training developed during Aim I of the trial. This will occur over a period of six months.
41328437|NCT06527196|BEHAVIORAL|Early Identification Universal Depression Screening|Providers in the early identification universal depression screening condition will be asked to continue communications and response to depression screening as currently implemented.
41328438|NCT05982834|DRUG|Disitamab Vedotin combined with fruquintinib and Tislelizumab|Disitamab Vedotin 2.5mg/m2 ivgtt d1,15, fruquintinib 4mg qd po d1-21 and Tislelizumab 300mg ivgtt,q4w
41328439|NCT03911869|DRUG|encorafenib|taken orally
41328440|NCT03911869|DRUG|binimetinib|taken orally
41328441|NCT00505752|DRUG|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
41481130|NCT01973023|OTHER|Motion analysis|Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
41011337|NCT06340035|OTHER|Percutaneous Peripheral Nerve Stimulation|In the pPNS group, the superior gluteal nerve and inferior gluteal nerve are stimulated percutaneously. The nerves are localized at an ultrasound-guided level and with respect to the vascular-nervous package two acupuncture needles are inserted, one for each nerve. The stimulation is the same as the TENS group: 10 stimulations x 10 times x 10 seconds, evoking the maximum contraction without pain.
41328442|NCT00505752|DRUG|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
41328443|NCT00505752|DRUG|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
41328444|NCT00505752|DRUG|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
41155249|NCT02273180|DRUG|Humalog|Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
41155250|NCT02273180|DRUG|Insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
41328445|NCT00505752|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to \[\>=\] 18 millimeter \[mm\], two or more additional follicles with a diameter of \>= 16 mm, and Estradiol \[E2\] levels will approximately 150 picogram per milliliter \[pg/mL\] per mature follicle).
41328446|NCT05501288|DRUG|Huashi Baidu granule|Patients were given HSBDG the day after randomization, with a dose of 2.5g for age 3 to 6 years, 5 g for age 7 to 12 years, and 10 g for age 13 to 18 years, twice daily for 5 consecutive days.
41328447|NCT05501288|DRUG|compound pholcodine oral solution|Patients were given compound pholcodine oral solution (Bright Future Pharmaceuticals Factory, Hong Kong, CHN) the day after randomization, with a dose of 5 ml for age 3 to 6 years and 10 ml for age 7 to 18 years, three times daily for 5 consecutive days.
41328448|NCT01431261|OTHER|Education and training|Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times
41481131|NCT02239107|DRUG|N-Acetyl cysteine|
41011338|NCT03780179|BIOLOGICAL|MMRvaxpro|MMRvaxpro vaccine
41011339|NCT03780179|BIOLOGICAL|Placebo|Placebo
41011340|NCT02042976|BEHAVIORAL|Mindfulness-based cognitive therapy|
41011341|NCT02042976|BEHAVIORAL|Pulmonary rehabilitation|
41011342|NCT04335344|OTHER|Observation of suPAR plasma and salivary levels|Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease
41011343|NCT00214955|DRUG|ORAVESCENT Fentanyl Citrate|
41011344|NCT02145039|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
41011345|NCT02145039|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
41011346|NCT02145039|RADIATION|Total Body Irradiation|TBI 200cGy on day -1 before transplant.
41011347|NCT02145039|BIOLOGICAL|Haploidentical stem cell transplant|Non-T-cell depleted bone marrow infusion
41011348|NCT01479621|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
41011349|NCT01479621|DRUG|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
41011350|NCT01479621|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
41011351|NCT01479621|DRUG|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
41155251|NCT02543697|RADIATION|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
41481132|NCT02239107|PROCEDURE|laparoscopic ovarian drilling|
41481133|NCT01237353|DIETARY_SUPPLEMENT|betaine hydrochloride|betaine hydrochloride 1500mg po x 1 on day 5
41011352|NCT06316414|BIOLOGICAL|Omalizumab|Administration of Omalizumab at the doses indicated for asthma in the EMA information leaflet.
41481134|NCT01237353|DRUG|Rabeprazole|rabeprazole po daily x 5 days
41011353|NCT05581212|OTHER|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack|Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
41011354|NCT00887900|PROCEDURE|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
41011355|NCT00887900|PROCEDURE|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
41011356|NCT00028028|DRUG|temsirolimus|Given IV
41155252|NCT06192693|DRUG|Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution|"1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day).~FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%."
41155253|NCT06192693|DRUG|Capsulized placebo transfer containing dilution solution|"1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day).~Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%."
41155254|NCT05521555|PROCEDURE|Total knee arthroplasty|First intention total knee arthroplasty
41155255|NCT02686359|BIOLOGICAL|sample|
41328449|NCT01431261|BEHAVIORAL|Pain management|Educational sessions in pain management 4 times
41328450|NCT05578768|OTHER|No intervention|Patients will receive standard of care.
41328451|NCT03140683|DEVICE|non-stress test|antepartum fetal monitoring
41328452|NCT03094611|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
41328453|NCT00994162|DEVICE|EZCare/V1STA Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
41155256|NCT00999271|OTHER|Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)|"two different dosages:~* 0.8 pmol/kg/min~* 1.5 pmol/kg/min for 300 minutes"
41155257|NCT05840224|BIOLOGICAL|GS-4528|Administered intravenously
41155258|NCT05840224|DRUG|Zimberelimab|Administered intravenously.
41328454|NCT02474823|OTHER|polysomnogram|all participants will undergo PSG for assessment of OSA
41328455|NCT02474823|OTHER|home sleep test|all participants will undergo HST for assessment of OSA
41011357|NCT00028028|OTHER|pharmacological study|Correlative studies
41011358|NCT00028028|OTHER|laboratory biomarker analysis|Correlative studies
41155259|NCT06003868|OTHER|traditional physiotherapy|Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises
41328456|NCT02474823|OTHER|Easy Sleep Apnea Predictor|all participants will undergo ESAP for assessment of OSA
41328457|NCT04001309|OTHER|Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions|Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
41328458|NCT02414971|OTHER|There is no intervention|There is no intervention
41328459|NCT00877006|DRUG|bendamustine|
41011359|NCT02665728|DRUG|BLI400 Laxative|
41011360|NCT04931225|DRUG|Landiolol|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
41011361|NCT06218004|DRUG|Envafolimab combined with chemotherapy|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
41011362|NCT04076644|DEVICE|TMS treatment|TMS using either a standard 10hz 20min or 3 min theta burst protocol
41328460|NCT00877006|DRUG|rituximab|
41328461|NCT00877006|DRUG|vincristine|
41328462|NCT00877006|DRUG|prednisone|
41328463|NCT00877006|DRUG|cyclophosphamide|
41328464|NCT00877006|DRUG|doxorubicin|
41328465|NCT02889757|DRUG|Acteylcysteine|randomized into three arms
41328466|NCT00578604|DEVICE|diffuse near infrared spectroscopy measurements|Measure blood flow to diabetic wounds
41328467|NCT02565498|RADIATION|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
41328468|NCT02565498|RADIATION|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
41328469|NCT04401397|PROCEDURE|Intensive early mobilization techniques|"Pulmonary techniques: lung mechanics and breathing pattern restoration, mucus clearance techniques, breathing control and cough techniques.~Musculoskeletal techniques: strengthening and functional exercises, active assistive moving techniques."
41328470|NCT06376838|DEVICE|DLMR01|Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
41011363|NCT05857605|OTHER|Exercise for Knee Osteoarthritis|Standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
41155260|NCT06003868|OTHER|hippotherapy-assisted physiotherapy|"The patients will be placed on the simulator and the starting position will be taught. your simulator before the application and in order to maintain the starting position throughout their movements.~they will be warned during the applications.. Hippotherapy simulator is almost like walking.~pattern and will be run in the 1st stage of the 3-stage speed level."
41328471|NCT06376838|DEVICE|Rejuran|Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
41328472|NCT00373412|BIOLOGICAL|VCL CT02 pDNA vaccine|
41328473|NCT00373412|BIOLOGICAL|Towne CMV vaccine|
41155261|NCT01389609|DRUG|Doxazosin 4 mg Japanese marketed IR tablet|Immediate release tablet, 4 mg, single dose
41155262|NCT01389609|DRUG|Doxazosin 4 mg ODT with water|Orally-disintegrating Tablet , 4 mg, single dose with water
41328474|NCT03019705|OTHER|Observation|
41328475|NCT00789646|PROCEDURE|Lidocaine/NSS|First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection
41328476|NCT00789646|PROCEDURE|NSS/Lidocaine|First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
41328477|NCT00430963|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|
41328478|NCT00430963|DRUG|Placebo|
41328479|NCT04600843|OTHER|Physical therapy with Patient education|patient manual was translated and validated in Urdu which was provided to patients so that they can follow it at home
41328480|NCT04600843|OTHER|Physical Therapy without patient Education|Group B was only treated with proper physical therapy treatment protocol according to patient presenting condition
41328481|NCT04249167|DRUG|Atezolizumab|Given IV
41328482|NCT04249167|PROCEDURE|Cryosurgery|Undergo cryoablation of the primary tumor
41328483|NCT04249167|DRUG|Nab-paclitaxel|Given IV
41328484|NCT00841269|DRUG|Uridine|Uridine 500 mg by mouth twice per day for 6 weeks
41155263|NCT01389609|DRUG|Doxazosin 4 mg ODT without water|Orally-disintegrating Tablet , 4 mg, single dose without water
41155264|NCT06253689|DEVICE|Defecation Posture Modification Device|Patients assigned to the experimental arm will be asked to use the defecation posture modification device to aid with bowel movements during the postoperative period.
41155265|NCT02625571|BEHAVIORAL|Phase-based treatment of sexual behavior problems of children|
41328485|NCT05371938|PROCEDURE|Volar locking plate|Volar locking plate is the intervention
41155266|NCT00998114|BEHAVIORAL|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
41328486|NCT05371938|PROCEDURE|external fixation|surgery with external fixation
41328487|NCT06229483|DRUG|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|Tranexamic acid 20 mg/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, for the duration of surgery. Treatment is blinded.
41328488|NCT06229483|OTHER|Placebo|0.9% normal saline 20ml/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 ml/kg/hr infusion of 0.9 % sodium chloride for the duration of surgery. Treatment is blinded.
41328489|NCT04801797|DRUG|Cytarabine|Intravenous infusion
41328490|NCT04801797|DRUG|Idarubicin|Intravenous infusion
41328491|NCT04801797|DRUG|Daunorubicin|Intravenous infusion
41328492|NCT04801797|DRUG|Liposomal daunorubicin and cytarabine|Intravenous infusion
41328493|NCT04801797|DRUG|Venetoclax|Orally by mouth
41328494|NCT04801797|DRUG|Azacitidine|Intravenous infusion
41328495|NCT00396825|BEHAVIORAL|Video-based coping skills training with telephone coaching|Subjects will view the 10 modules of Williams LifeSkills Caregiver Video, do Workbook exercises for each module, and receive telephone coaching to enhance their ability to apply the skills taught in each module to caregiver situations.
41328496|NCT04203940|PROCEDURE|Cyanoacryale|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue
41328497|NCT04203940|PROCEDURE|Suture|mesh fixation was done with polypropylene 2/0 sutures
41328498|NCT03371251|DRUG|BOS161721|SC administration
41328499|NCT03371251|DRUG|Placebo|SC administration
41328500|NCT04656392|DIAGNOSTIC_TEST|Breath test (eNose) followed by uTNE.|All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
41328501|NCT03552627|DRUG|Oxygen|Medical Oxygen
41011364|NCT05857605|DEVICE|Compact seated elliptical exercise machine- Cubii JR-1|Compact seated elliptical machine exerice program in conjunction with standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
41011365|NCT03629015|BIOLOGICAL|Stemchymal®|ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
41155267|NCT00996619|PROCEDURE|An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination|"An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects seen by the endoscope"
41155268|NCT06476834|DRUG|Deucravacitinib|Specified dose on specified days
40810565|NCT06660407|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40810566|NCT06660407|PROCEDURE|Computed Tomography|Undergo CT
40810567|NCT06660407|OTHER|Immunotherapy|Given immunotherapy
40810568|NCT06660407|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
40810569|NCT06660407|RADIATION|Spatially-fractionated Radiation Therapy|Undergo grid radiation therapy
41155269|NCT05292170|OTHER|Heat acclimation|10 consecutive days of heat acclimation
41155270|NCT01369706|DEVICE|Hand-held metal detector|2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
41155271|NCT01854164|DIETARY_SUPPLEMENT|HGE (hydrolyzed ginseng extract)|
41155272|NCT01854164|DIETARY_SUPPLEMENT|Placebo|
41155273|NCT06539468|OTHER|Best Practice|Receive SOC treatment
41155274|NCT06539468|OTHER|Educational Activity|Watch an educational video on AS for LR-BCC
41155275|NCT06539468|OTHER|Patient Observation|Undergo active surveillance
41328502|NCT06342648|DRUG|Sterile Water Injection|Injection of intracutaneous sterile water
41328503|NCT06342648|DRUG|Diclofenac Sodium injection|Injection of intramuscular diclofenac sodium
41328504|NCT03154307|DEVICE|Low frequency repeated TMS (LF-rTMS)|Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
41328505|NCT04145713|DIETARY_SUPPLEMENT|Probiotic mixture|The experimental intervention will consist in administrating a high-dose multi-strain probiotic (SIVOMIXXTM) for 30 days in addition to hypothermic therapy. The administration of probiotics will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
41328506|NCT04145713|OTHER|Placebo|The comparison intervention will consist in administrating placebo for 30 days in addition to hypothermic therapy. The administration of placebo will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
41328507|NCT04079387|DEVICE|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°"
41328508|NCT04079387|DEVICE|ENDOTRACHEAL TUBE ALONE|intubating the trachea with an endotracheal tube alone
41155276|NCT06539468|OTHER|Survey Administration|Ancillary studies
41155277|NCT05278442|OTHER|LaserArc|LaserArcs.com is an online arcuate incision nomogram calculator initially developed on the basis of 12 months of data tabulation of patients undergoing femtosecond surgery with arcuate incisions
41328509|NCT00362050|DRUG|Treatment with 3 dose groups of RBx11160 over 7 days|
41328510|NCT05771506|OTHER|Balance Assessment|"Balance assessment will be done with the Biodex Balance System® (Biodex Medical Systems, Shirley, New York, United States). Postural stability test overall score, stability limits test overall score, and sensory integration test of balance composite score will be recorded."
41155278|NCT02085408|DRUG|Daunorubicin|Given IV
41155279|NCT02085408|DRUG|Cytarabine|Given IV
41155280|NCT02085408|DRUG|Clofarabine|Given IV
41155281|NCT02085408|DRUG|Decitabine|Given IV
40810572|NCT06659588|OTHER|Plasma, urine and stool collection|"During a consultation for follow-up, we will take an extra-volume during a blood sample taken as part of the care. We will also collect stool and urine.~There will be no biological collection for these samples. Organ biopsies carried out as part of the care (liver, kidney, digestive tract, spleen, lymph node) will also be studied as part of this research."
40810573|NCT06661278|DIAGNOSTIC_TEST|Exercise tolerance test|Clinical routine exercise tolerance test using an exercise treadmill, according to the arrhythmia protocol (15 minute protocol utilising increasing speed and incline with a 6 minute recovery)
41155282|NCT02085408|OTHER|Observation|Undergo clinical observation
41155283|NCT02085408|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
41155284|NCT04283097|DRUG|KPG-818|The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg. Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The treatment of study is divided into 6 cycles.
41155285|NCT05597306|DRUG|Bomedemstat|Bomedemstat will be administered orally once daily via capsule.
41155286|NCT05597306|DRUG|Venetoclax|Venetoclax will be administered orally once daily via tablet.
41155287|NCT05743114|DEVICE|Elemind Neuromodulation (ENMod)|The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.
41155288|NCT01243658|DRUG|Oxytocin|Oxytocin
41155289|NCT01243658|OTHER|placebo|placebo
41155290|NCT03216915|DRUG|Gilenya®; Novartis Pharmaceuticals Corporation|This is a prospective cohort-based study. Eligible are all patients planned for a treatment with fingolimod at the Hamburg University Hospital who are willing and able to participate in an observational study.
41328511|NCT05771506|OTHER|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) in accordance with ATS/ERS criteria. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
41011366|NCT04942275|DRUG|Pre-therapeutic imaging test|The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
41011367|NCT04138927|DRUG|Fostamatinib disodium|Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
40810574|NCT06661278|OTHER|Physical activity & heart rate monitoring|Physical activity monitoring over two weeks using Actiheart and Pro-Diary monitors to record heart rate, heart rhythm, activities engaged in and estimated intensity of activities.
40810575|NCT06658678|OTHER|Receiving an educational intervention|Patient not receiving any educational intervention
41155291|NCT06361810|DRUG|Pembrolizumab|"Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.~Pembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase."
41155292|NCT06361810|DRUG|177Lu-PNT2002|"177Lu-PNT2002 given intravenously every 8 weeks will be administered at 3.4 GBq, 6.1 Gbq, or 6.8 Gbq in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks until the maximum tolerated dose is reached during the dose escalation phase.~177Lu-PNT2002 given intravenously every 8 weeks will be administered at the determined maximum tolerated dose for a maximum of 4 cycles in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks for a maximum of 17 cycles."
41155293|NCT06361810|DRUG|(F-18)-DCFPyL|Patients will be administered 18F-DCFPyL as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.
40810579|NCT06659471|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
40810580|NCT06659471|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
41328512|NCT05771506|OTHER|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
41328513|NCT05771506|OTHER|Peripheral muscle strength test|Peripheral muscle strength will be assessed by measuring M. Quadriceps muscle strength with a digital handheld dynamometer (MicroFET® Hoggan Scientific; USA). The test will be done in three measurements for the dominant side lower extremity. The average of the obtained values will be recorded in kilograms.
40918232|NCT00660686|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
41155294|NCT02669888|DRUG|Indigo naturalis ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
41155295|NCT02669888|DRUG|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
41155296|NCT02970721|DRUG|Antipsychotic|Antipsychotic monotherapy
41155297|NCT02970721|DRUG|Antidepressant|Antidepressant monotherapy
41328514|NCT05771506|OTHER|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
41328515|NCT05771506|OTHER|Cognitive assessment|Cognitive function will be assessed with the Montreal Cognitive Assessment (MoCA) test. The MoCA test is a questionnaire developed to evaluate different cognitive functions and mild cognitive impairment. The maximum score that an individual can obtain from the test is 30, and a score of 21 or above is considered as mild cognitive impairment. Test; will be administered by a certified physiotherapist who has received training on practice and scoring directives
41328516|NCT05072756|OTHER|Applying a questionnaire|The participants have to answer a questionnaire addressing their opinion on menopausal hormone replacement therapy
41328517|NCT02825147|DRUG|Pegaspargase|
41328518|NCT02825147|DRUG|Methotrexate|
41328519|NCT02825147|DRUG|Dexamethasone|
41328520|NCT02825147|DRUG|Etoposide|
41328521|NCT02825147|RADIATION|radiotherapy|
41328522|NCT03194620|OTHER|Thearubigins|Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
40918233|NCT06196671|DRUG|H101|H101 15x10\^11vp intratumorally injection starts at day 1.
40918234|NCT06196671|DRUG|Camrelizumab|Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.
41011368|NCT01639170|RADIATION|chest radiograph|"All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.~All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.~The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the"
41011369|NCT03265119|DRUG|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
41011370|NCT03265119|DRUG|Placebo|Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
41155298|NCT02970721|DRUG|Antipsychotic and Antidepressant|Polytherapy
41328523|NCT03194620|OTHER|Theaflavins|Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
41328524|NCT03194620|OTHER|Procyanidin Dimer B2 (DB2)|Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.
41011371|NCT00646412|DEVICE|A-Part® Gel|10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
41011372|NCT03811730|DIAGNOSTIC_TEST|Transesophageal echocardiography|Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
41011373|NCT02130765|DEVICE|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
41011374|NCT03191916|DEVICE|transcranial direct current stimulation|2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
41011375|NCT03191916|DEVICE|Sham (for transcranial direct current stimulation)|For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
41011376|NCT03675958|OTHER|Johnstone's Pressure Splint|the intervention consists in the application of two tools used for the treatment of spasticity post - CVD. Johnstone's Pressure Splint added Stretching
41011377|NCT03675958|OTHER|Stretching|the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
41328525|NCT03194620|OTHER|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of 120 µmol of (-)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
41328526|NCT03194620|OTHER|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of 120 µmol of (-)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
41155299|NCT03771378|DRUG|rhTPO|After enrollment, all subjects receive TPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
41155300|NCT03771378|DRUG|eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd. blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
40810583|NCT06660771|PROCEDURE|Functional orthodontic treatment|"The patients were treated with Twin block and Herbst functional appliances. Alginate impressions and a protrusive wax bite were taken for the construction of each appliance. Each device was fitted and then reviewed 4-6 weeks later. First group was treated with Twin block which was manufactured basically according to the original design described by Clark. The overjet was measured from the patients in centric relationship and maximum protrusion position, and construction bite was recorded with 70% of the total advancement capacity of the mandible and 2-4 mm above the freeway space vertically. Overjet measurements were made at each session and active treatment was terminated when a normal overjet in the retracted position was recorded.~Second group was treated with the stainless-steel crown Herbst appliance, included crowned maxillary first molars and mandibular first premolars. The construction bite was recorded with the mandible forward by edge-to-edge incisor position."
41155301|NCT04634812|DRUG|KBP-5074|a single oral dose of \[14C\]-KBP-5074
41155302|NCT01514864|DRUG|Dasatinib|Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
41011378|NCT05216367|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral dose on the morning of day 1 under fasting conditions
41011379|NCT01234467|DRUG|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
41011380|NCT01234467|DRUG|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
41011381|NCT04791800|DIAGNOSTIC_TEST|Malaria/CRP combination test|Testing with a malaria/CRP combination test, in parallel with a standard malaria RDT (to guide case management), preparation of thin/thick films for expert malaria microscopy, and collection of venous blood for subsequent CRP quantification.
41011382|NCT01860417|BIOLOGICAL|Allogenic Mesenchymal Stromal Cells|
41011383|NCT01860417|DRUG|Mepivacaine|
41011384|NCT04176770|PROCEDURE|ESP Block|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
41011385|NCT04176770|PROCEDURE|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
41011386|NCT00767676|DEVICE|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
41011387|NCT00654524|DRUG|gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin|The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.\& Livial 1.25-2.5mg p.o. q.d.) if needed.
41011388|NCT04298710|BEHAVIORAL|Arm Cycling|20 minutes of arm cycling exercise at light to moderate intensity.
41011389|NCT04298710|BEHAVIORAL|Leg Cycling|20 minutes of leg cycling exercise at light to moderate intensity.
41011390|NCT04298710|BEHAVIORAL|Sitting|Remain seated for 20 minutes.
41155303|NCT03524547|DEVICE|J shaped stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.
41155304|NCT03524547|DEVICE|60-degrees stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
41155305|NCT02409823|DRUG|Atypical Antipsychotics|any atypical antipsychotic
41155306|NCT01882088|DRUG|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
41155307|NCT01829685|DRUG|Entecavir, Adefovir|
41328527|NCT03194620|OTHER|(-)-Epicatechin (EC)|Single oral intake of 120 µmol of (-)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
41328528|NCT03194620|OTHER|(-)-Epigallocatechin (EGC)|Single oral intake of 120 µmol of (-)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
41328529|NCT03194620|OTHER|Control|Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
41011391|NCT03735394|DIAGNOSTIC_TEST|ultrasonic probe|apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
41155308|NCT01789229|OTHER|Tumor tissue collection|"Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.~Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.~Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger."
41155309|NCT01789229|OTHER|Sampling of ascites and pleural effusion|Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
41155310|NCT01789229|OTHER|Collecting urine samples|Patient is asked to give a urine sample. Urine is collected in urine beaker.
40810589|NCT06659211|BEHAVIORAL|Mentalisation-Based Therapy|MBT is conducted according to the treatment manual developed by Bateman \&amp; Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.
40810590|NCT06659211|OTHER|Treatment as Usual (TAU)|The TAU group will receive treatment as usual, which in mental health services might include medication, supportive counseling, short therapy, and other limited psychotherapeutic treatments such as DKT. There is no requirement for a frequency of visits for the usual psychiatric care of the TAU group, as this would not be realistic in the current service system, and the usual treatment would not be the usual treatment currently provided.
40810591|NCT06660628|RADIATION|Large Segmentation Radiotherapy|Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold
40810592|NCT06660628|DEVICE|DIBH|Deep Inspiration Breath Hold
41011392|NCT05043324|DRUG|AntiCov-220 (1)|The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.
41328530|NCT04297293|DRUG|Ramosetron|Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)
41328531|NCT03949621|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
41328532|NCT03945903|DRUG|Golimumab|Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.
41328533|NCT02428907|BEHAVIORAL|simulation training|teamtraining of endoscopy staff
41328534|NCT06253234|BIOLOGICAL|personalized dendritic cell injection ZSNeo-DC1.1|Sequence A: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 3 weeks as a dosing cycle, a total of 6 dosing cycles Sequence B: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 2 weeks as a dosing cycle, a total of 6 dosing cycles
41328535|NCT06272630|DRUG|DWJ1464|DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
40810593|NCT06660628|DEVICE|Surface guided radiation therapy|The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.
40810594|NCT06660628|DEVICE|laser alignment|Laser systems for virtual simulation and patient positioning in radiotherapy
40810595|NCT06660628|BEHAVIORAL|free breathing|Patients breathe calmly while radiotherapy instead of holding their breath.
41155311|NCT01789229|OTHER|Collecting saliva sample|Saliva sample is collected by spatula from the mouth cavity of the patient.
41155312|NCT01789229|OTHER|Collecting sputum|Patient is asked to produce sputum into a 50ml lab tube.
41155313|NCT01789229|OTHER|Collecting stool samples|Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.
41011393|NCT05043324|DRUG|AntiCov-220 (2)|The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.
41011394|NCT01602276|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
41328536|NCT06272630|DRUG|Placebo of DWJ1464|Placebo of DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
41328537|NCT05377307|GENETIC|Pell's lentiviral-based gene-edited immune cell therapy|No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.
41011395|NCT00731328|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
41011396|NCT05457309|PROCEDURE|malignant fungating wounds care regimen|1) Preliminary construction of regimen: The researchers summarized the literatures and guidelines about malignant fungating wounds care, and then formed a preliminary draft of the regimen.2) Expert consultation: Experts in malignant fungating wound care, breast cancer and rehabilitation were consulted by email, and the researchers revised the protocol according to the experts' comments, and the final draft was determined after multiple rounds of consultation with experts. 3) Pre-experiment: The researchers investigated the enrolled patients to assess the feasibility of the protocol, and adjusted the content based on the feedback.4) Final Determining: including health records establishment, the intervention time, implementers, location, method and frequency. A wound care team was formed, interventions were carried out in terms of somatic care, wound home care, psychological support, and rehabilitation guidance, and the enrolled patients would be regularly followed by the researchers.
41328538|NCT05129761|DRUG|Syrup Hydryllin|( Syrup Hydryllin \& Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan \& Diphenhydramine)
41328539|NCT05163717|COMBINATION_PRODUCT|INP105|A single 5 mg dose of POD-OLZ (Precision Olfactory Delivery \[POD®\]-olanzapine)
41328540|NCT05163717|COMBINATION_PRODUCT|Placebo|A single dose of POD-placebo (Precision Olfactory Delivery \[POD®\]-placebo)
41328541|NCT04575831|BEHAVIORAL|Exercise, Nutrition, and Palliative Symptom Management|"1. Exercise: The exercise intervention is a 12-week group-based program, with 1 weekly 75 minute session focused on strength, balance, flexibility and aerobic capacity.~2. Palliative Symptom Management: Palliative symptom management will focus on symptoms that contribute to reduced QOL, limit ability to engage in exercise, or present barriers to oral intake.~3. Nutrition: A Registered Dietitian (RD) team will provide feedback and tailored nutrition advice based on a pre-study food recall evaluation, recommending interventions based on the nutrition assessment feedback form, such as oral nutritional supplementation or target daily protein and caloric intake."
41328542|NCT01047046|OTHER|Retrospective chart review|"This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.~The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out."
41481135|NCT03384017|OTHER|Transcutaneous Spinal Cord Stimulation and Gait Training|"TSCS will be applied using a midline electrode placed on the skin between spinous process T11 -T12 and two electrodes placed symmetrically on the skin over the lower abdomen as anodes. A symmetrical biphasic rectangular waveform, at 50 Hz and 1 millisecond, is used to provide 30 continuous minutes of stimulation.~Subjects will participate in 24 two-hour sessions of physical therapy over eight weeks. In each session, subjects will receive TSCS continuously for 30 minutes, using the parameters outlined above. During stimulation, subjects will participate in strengthening, segmental task practice, and gait-based interventions. Participation in gait training will continue following the stimulation period for the duration of the session."
41481136|NCT05402462|DIAGNOSTIC_TEST|upper endoscopy|detect esphageal motility disorder by upper endoscopy and esophageal manometry
41481137|NCT04223999|PROCEDURE|Skullremodeling surgery|"Strategically placed cranial burrholes in order to improve the TTField dose focally in the tumor."
41481138|NCT04223999|OTHER|Control|Tumor treating fields combined with best medical treatment.
41481139|NCT02431819|DEVICE|contention socks|Patients wear contention socks during 15 days.
40810599|NCT06659328|PROCEDURE|Structured Walking Intervention for Children with Autism Spectrum Disorder|"Participants: Thirty children with ASD will participate in the walking sessions.~Conditions: Each child will walk under three different speed conditions:~Normal Speed: 120 beats per minute (bpm) Slow Speed: 100 bpm Fast Speed: 140 bpm~Social Interaction: Each child will walk with two different types of adult companions:~Familiar Adult: A caregiver or individual known to the child. Unfamiliar Adult: An adult not known to the child. Procedure: The walking distance will be 10 meters. The adult will wear a metronome in an earbud to ensure that they maintain the prescribed walking speed, which the child will be instructed to follow. Each child will experience all combinations of walking speeds and social interactions, allowing for a comprehensive assessment of how these factors influence gait parameters.~Gait Parameters: The following parameters will be recorded during each walking session using video analysis software (Kinovea©):~Stride length Step time Cadence Velocity Joint amplitudes"
41481140|NCT05163197|PROCEDURE|Transperineal Laser Ablation of Prostate Cancer|Minimal invasive transperineal laser ablation treatment for prostate cancer
41481141|NCT05086718|OTHER|Endoscopic ear surgery|Endoscopic approach without posterior meatal flap elevation will be employed in the ear with dry chronic suppurative otitis media. Tympanoplasty utilizing composite cartilage-fascia graft will be performed. After three months of time period successful outcome will be taken as closure of air bone gap on pure tone audiometry.
40810600|NCT06658561|PROCEDURE|cold snare polypectomy|Place the special cold snare in the normal mucosa 1-2mm away from the polyp edge. Tighten the snare at a constant speed and gently lift it up and then excision.
40810601|NCT06658561|PROCEDURE|hot snare polypectomy|According to evaluation of the polyps, directly place the snare on the edge of the polyp including a clear margin of normal tissue (1-2 mm) or after submucosal injection. Tighten the snare at a constant speed and gently lift it up.Use the electrocoagulation and electroscission mode, power on for several seconds until the polyp is cut off.
41011397|NCT03040258|OTHER|Health-E-PALS-Pilot|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
41011398|NCT00058331|BIOLOGICAL|epoetin alfa|
41011399|NCT05610813|DRUG|VER-01|Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
41328543|NCT05441540|DEVICE|Internal Jugular Vein Compression Collar|The current FDA approved internal jugular vein compression collar, marketed as the Q collar, is manufactured by Q30 Innovations Home. It is designed to be worn around the neck of individuals aged 13 and older. It functions by lightly compressing the internal jugular vein's bilaterally, safely increasing intracranial volume and intracranial pressure. The FDA approved neck collar device is made of a thermoplastic elastomer that is specifically fitted to an individual to provide mild internal jugular vein compression. The product was developed and confirmed with ultrasonography to confirm appropriate fit and compression of the vein based on an athlete's neck circumference.
41328544|NCT04746560|DEVICE|TEG®6S device with its Platelet mapping® cartridge|Platelet function monitoring using the TEG®6S device with its Platelet mapping® cartridge
41328545|NCT05220098|DRUG|TAK-280|Participants will receive TAK-280 as IV infusion.
41328546|NCT01343355|DRUG|Tamibarotene|Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
41328547|NCT05135351|DIETARY_SUPPLEMENT|Resistant Starch|A prebiotic nutritional supplement available at commercial grocery and health food stores. Specifically, we will be using Bob's Red Mill® potato starch.
41328548|NCT05135351|DIETARY_SUPPLEMENT|Maltodextrin|A starch commonly used as a placebo in prebiotic trials that is digested in the stomach and rapidly absorbed
41328549|NCT00175162|DEVICE|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
41328550|NCT03330600|BEHAVIORAL|aquatic physicotherapy|Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
41155314|NCT01789229|OTHER|Lavage/Irrigation|Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
41155315|NCT06210737|BIOLOGICAL|PCV13|3 doses of PCV13 intramuscularly at Months 0, 2, and 4 and a booster dose at Month 10
40810604|NCT06661083|DIETARY_SUPPLEMENT|EGCG, FA, HA, B12|EGCG + FA + HA + B12 (1 cps /die)
40810605|NCT06662383|DRUG|Retatrutide|Administered SC
40810606|NCT06662383|DRUG|Tirzepatide|Administered SC
40810607|NCT06658197|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg) plus mechanical thrombectomy
40810608|NCT06658197|DRUG|Alteplase|Alteplase 0.9 mg/kg administered as 10% bolus +90% infusion/1 hour (maximum dose 90mg) plus mechanical thrombectomy
41155316|NCT06210737|BIOLOGICAL|PCV13|2 doses of PCV13, and a booster dose
40810610|NCT06660797|OTHER|Group1: A matching gutta-percha master cones will be used in up and down motion 2mm amplitude at a frequency of 100 strokes during approximately 1 min in each prepared canal.|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by matching gutta percha master cone , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
40810611|NCT06660797|OTHER|Group2: XP-endo Finisher activation: The XP-endo Finisher instrument will be used in continuous rotation for 1 mintute|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by XP-endo Finisher used in continuous rotation for 1 minute , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
40810612|NCT06660797|OTHER|Group 3:EasyClean system activation : EC instrument coupled to the countrangle handpiece and operated with a micromotor at approximately 20,000 rotations per minute in continuous rotation.|after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by EasyClean system activation , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
41155317|NCT06210737|BIOLOGICAL|PCV13|2 doses of PCV13
41155318|NCT06210737|BIOLOGICAL|PCV13|single dose of PCV13
41011400|NCT05610813|DRUG|Opioid therapy|The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.
41011401|NCT05124873|DEVICE|Moisture Management Liner|A prototype liner designed to reduce heat that builds up on the limb.
41011402|NCT02100267|DRUG|Methacholine Chloride (SK-1211)|Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
41011403|NCT01870128|DRUG|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
41011404|NCT01870128|DRUG|Methotrexate|Methotrexate 15 to 25 mg PO per week
41011405|NCT01870128|DRUG|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
41011406|NCT03050905|DRUG|VEKIRAX|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"
41155319|NCT03103178|OTHER|Quality of life questionnaire|Measurement of quality of life
41155320|NCT01150500|DEVICE|MDT-4107 Zotarolimus-Eluting Coronary Stent|
41155321|NCT02233504|DRUG|Exjade® (deferasirox, ICL670)|
41155322|NCT03117842|OTHER|Automated text and voice messages|Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
41155323|NCT04067206|OTHER|RECORDED MOTHER'S VOICE|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
41328551|NCT03330600|BEHAVIORAL|immersion|The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
41328552|NCT04757922|PROCEDURE|Opportunistic salpingectomy / bilateral salpingectomy|An opportunistic salpingectomy refers to removal of the salpinges without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases. Therefore, a so-called opportunistic salpingectomy is a method of female sterilization.
40810615|NCT06662097|DRUG|Bevonescein|Bevonescein is a sterile solution that is intravenously administered
40810616|NCT06659497|BEHAVIORAL|web-based patient education|"The web-based training, which will provide the following information about the IUI treatment process, will last a total of 60 minutes.~MODULE 1: General Information About Fertility MODULE 2: Diagnostic and Therapeutic Methods in Infertility / Insemination Treatment MODULE 3: Drugs Used in Insemination Treatment and Their Application MODULE 4: Things to Consider After Insemination"
41328553|NCT03874351|DEVICE|non-invasive transcranial direct current stimulation (tDCS)|"Active tDCS: transcranial direct current stimulation at intensity 1.5mA for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.~Sham tDCS: transcranial direct current stimulation at intensity 1.5mA for 30seconds followed by 0 mA current for remaining time of the 20-minute intervention per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right."
41328554|NCT05345444|DEVICE|IRE & MRgRT|Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)
41328555|NCT04394689|BIOLOGICAL|Measles Rubella Vaccine (MRV-SC)|One dose as subcutaneous injection of a WHO prequalified MR vaccine
41328556|NCT04394689|BIOLOGICAL|MRV-MNP|One standard dose of Measles and Rubella vaccine delivered intradermally as a dissolving microneedle patch
41328557|NCT04394689|OTHER|PLA-MNP|One placebo dose of a dissolving microneedle patch
41328558|NCT04394689|OTHER|PLA-SC|Placebo saline as subcutaneous injection
41328559|NCT03079245|OTHER|Education Plus (E+)|Education Plus was an intervention developed by the study team based on the Center for Disease Control (CDC) 12 Step Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. The study team provided Education Plus quarterly to prescribers at the three sites (NICU A, B, C) randomized to this intervention. Examples of topics presented were an overview of antimicrobial stewardship principles, epidemiology of healthcare-associated infections (HAIs), prevention of surgical site infections, antimicrobial susceptibility testing, and pharmacokinetic principles. Educational formats included didactic lectures, participation via the audience response system, case vignettes, and panel discussions.
41328560|NCT03079245|OTHER|Clinical Decision Support|The CDS tool was an intervention developed in consultation with neonatologists and pediatric infectious disease physicians from NICU A and B. Algorithms for empiric and targeted antimicrobial therapy for common pathogens and common clinical scenarios using local antimicrobial susceptibility patterns were developed. The CDS tool also provided additional components to facilitate antimicrobial prescribing, e.g., patient weight, day of life, previous culture results, antimicrobial orders, and selected laboratory results including white blood cell and platelet count, C-reactive protein, creatinine, and therapeutic drug levels. NICUs A and B also received E+
41328561|NCT03079245|OTHER|Prescriber Audit and Feedback|The prescriber audit and feedback (PAF) intervention was developed by the study team which held focus groups with neonatologists at NICU A (the site randomized to this intervention) to determine the feedback parameters and feedback format as previously described. Neonatologists at NICU A were provided aggregated prescribing data bimonthly that described inappropriate use as described below and prolonged therapy (\>7 days) for culture-negative late onset sepsis. NICU A also received CDS and E+.
41328562|NCT00001127|BIOLOGICAL|Influenza virus vaccine (CAIV-T)|
41328563|NCT05057741|BEHAVIORAL|Multimodal prehabilitation|"Patients who will receive a multimodal prehabilitation program consisting of guided self-care activities at home that include exercise, nutrition and relaxation. Information Will be share by e health. Monitored by telephone daily during the first week and three times a week between the second and fourth week.~The final evaluation of the program will be performed one working day after the control appointment with surgery, which will be scheduled ten days after hospital discharge; and the satisfaction survey will be applied. At 30 days after surgery, a telephone follow-up will be made to inquire about complications and mortality. On that day, self-care recommendations will be given."
41328564|NCT02899377|RADIATION|18F-FDG PET/CT Imaging|pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG
41328565|NCT02899377|RADIATION|11C-MET PET/CT Imaging|"Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.~Other Name:11C-MET"
41328566|NCT02899377|PROCEDURE|MRI Imaging with intravenous contrast with gadoterate meglumine|Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.
41155324|NCT04067206|OTHER|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
41011407|NCT03050905|DRUG|EXVIERA|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)"
41155325|NCT04067206|OTHER|MiniMuff|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
41155326|NCT04299581|DRUG|Camrelizumab|a PD-1 immune check inhibitor
41155327|NCT04299581|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
41011408|NCT04122443|DRUG|Acetaminophen|Acetaminophen 650mg
41011409|NCT04122443|DRUG|Oxycodone|Oxycodone 10mg
41328567|NCT02899377|PROCEDURE|Minor Salivary gland (labial) biopsy|A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.
40810622|NCT06660498|DRUG|Pomalidomide 2 mg|Participants will receive pomalidomide 2 mg/d concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
40810623|NCT06660498|DRUG|Placebo|Participants will receive placebo concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
40810624|NCT06660498|DRUG|Aspirin 75 mg|Auxiliary Medicinal Product
40810625|NCT06659198|PROCEDURE|total hip replacement|minimally-invasive hip replacement
41155328|NCT06500013|BEHAVIORAL|Self-designed messages|Messages designed by participants
41328568|NCT00122304|DRUG|eculizumab|
41328569|NCT05456412|OTHER|JAK inhibitor treatment|Standard care
41011410|NCT06097507|BEHAVIORAL|Educational intervention|The consented patients will be given an information packet containing an infographic about the climate impact of inhalers, a letter explaining the option of changing inhalers (which clearly outlines that the Bricanyl Turbuhaler will not cost them more money than the Ventolin) and a pre-filled prescription for Bricanyl Turbuhaler.
41328570|NCT04466072|DIAGNOSTIC_TEST|Stool test for microbial analysis|Fecal samples will be analyzed by shotgun metagenomics and sample from the high ventricular arrhythmia burden will be compared with those from comparable control patients with low ventricular arrhythmia burden.
41328571|NCT01165697|OTHER|Fluorescein angiography|Fluorescein angiography once every 6 months for 3 years
41155329|NCT06500013|BEHAVIORAL|Standardized messages|Messages designed by researchers based on behavioral change theories
41155330|NCT05348642|DIETARY_SUPPLEMENT|pasteurized A. muciniphila|pasteurized A. muciniphila - oral daily dose
40810629|NCT06658847|OTHER|Night Cream Usage|Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. The investigational night cream will be used daily in the evening/at night.
40810630|NCT06658847|OTHER|No Night Cream Usage|Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. No night cream will be used.
41155331|NCT05348642|DIETARY_SUPPLEMENT|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
41011411|NCT04463381|PROCEDURE|choledochotomy techniques during LCBDE|
41011412|NCT05958875|DRUG|Clozapine|Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.
41328572|NCT06280612|OTHER|Pet therapy|The patients were allowed to spend time with an animal (cat/robotic cat) for 20 minutes twice a week for 12 weeks.
41011413|NCT05958875|DRUG|Second-line Antipsychotics (treatment as usual)|Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
41011414|NCT05543213|BEHAVIORAL|Action Observation Therapy|A video clip of a series of exercises is shown to the patients, then they practice them according to mirror neurons and observational learning.
41011415|NCT04897542|DRUG|Gallium-68 NODAGA-JR11|Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
41011416|NCT02553681|DEVICE|roflufocon D contact lenses|HPT treated rigid contact lenses
41011417|NCT02553681|DEVICE|RGP contact lenses made from roflufocon D|
41011418|NCT00199745|DRUG|atorvastatin|
41011419|NCT05702073|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
41328573|NCT05633680|DIAGNOSTIC_TEST|Peripheral blood sampling for circulating tumor cells|Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.
41328574|NCT00313755|PROCEDURE|Narrow Band Imaging|
41328575|NCT02655406|OTHER|Class 2 compression stockings|
41328576|NCT06053619|OTHER|GaitTrainer and Virtual Reality|"Realization of Gait Trainer-assisted robot walking rehabilitation sessions without and with the addition of an immersive VR device. The proposed virtual stage will be a natural space (i.e. forest) of 360°. The subject will be able to explore the environment without moving. The created scene represents a straight path crossing a landscape composed of different natural elements. A fluid movement is obtained with the help of two sensors (trackers) of the HTC Vive device, placed at the level of the subject's feet. Moreover, thanks to these sensors the individual has a virtual representation of his lower limbs.~Post-stroke patients will perform 3 conventional sessions (Gait Trainer alone) and 3 sessions with the immersive VR device (Gait Trainer + VR)."
41328577|NCT02790710|DRUG|Propanolol|Active treatment
41328578|NCT02790710|DRUG|Placebo|
41328579|NCT04539691|DEVICE|Magnet|Magnet or Sham is worn by subject in close proximity to their described maximum pain site
41328580|NCT05019495|BEHAVIORAL|PrOMOTE|This is an opt-out, proactive approach to tobacco treatment by a clinical pharmacy specialist. The pharmacist will call patients and offer an individualized pharmacotherapy prescription. The patient must opt-out for it not to be sent to their pharmacy. The patient will also receive brief motivational interviewing and behavioral counseling from the pharmacist.
41328581|NCT01691287|BEHAVIORAL|Michael Method|
40810634|NCT06659653|DRUG|PRG2302|Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
40810635|NCT06660953|PROCEDURE|Erector Spinae Plane Block|For ESP, high frequency linear ultrasound probe was planned transversely to the midline and spinous features were visualized. Cervical C7 and T7 vertebrae at the lower end of the scapula, which were accepted as landmarks, were determined and marked with a sterile surgical drawing pen. According to these landmarks, the USG probe was moved 2-3 cm laterally towards the points where kidney transplantation was planned at the T10 vertebral level, and the transverse parts, trapezius, latissimus dorsi, serratus and erector spina muscles were visualized. Using the block needle that can be visualized on USG with in-plane surgery, the skin, subcutaneous tissue and trapezius, latissimus dorsi, serratus and erector spina muscles were passed in a cranio caudal direction and the needle location was confirmed by hydrodissection with 2-5 ml of serum. The distribution of the block procedure and the spread of local anesthetic were linearly visualized with 10 ml bupivacaine and 10 ml 0.9% saline.
41011420|NCT05702073|DRUG|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
41011421|NCT03245021|DRUG|Opdivo|"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
41011422|NCT02063997|DRUG|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
41011423|NCT02063997|DRUG|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
41011424|NCT02063997|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
41011425|NCT02063997|DRUG|Placebo|Placebo tablets once daily for 12 weeks
41011426|NCT02063997|DRUG|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
41011427|NCT00774488|OTHER|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
41011428|NCT00976534|DRUG|AZD1386|90 mg, capsules, oral, during 3 weeks
41011429|NCT00976534|DRUG|Placebo|capsules, oral, during 3 weeks
41011430|NCT00826267|DRUG|lapatinib|lapatinib tablets 1500 mg daily
41011431|NCT00826267|DRUG|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
41328582|NCT03736811|DEVICE|Polyglactin 910 or polydioxanone|Vicryl or PDS II
41328583|NCT03736811|DEVICE|Polyester or polypropylene|Ethibond Excel or prolene
40810636|NCT06660953|PROCEDURE|Quadratus Lumborum Block (QLB)|The QL block II was done under aseptic technique, in lateral position with the side intended to block side up. A high frequency ultrasound linear probe covered in sterile sheath was placed anterior and superior to the iliac crest. The three anterior abdominal muscles were visualized. The external oblique muscle was followed posterolaterally until its posterior border was identified. Subsequently, the probe was tilted towards the attachment site of both the internal and external oblique muscles over the quadratus (QL) muscle until the midline of the thoracolumbar fascia was seen as a bright hyperechogenic line located between the posterior border of the quadratus lumborum muscle and the middle thoraco-lumbar fascia (anterior to latissiumus dorsi and erector spinae muscles). A 22-gauge Facet-tip SonoPlex needle of appropriate length estimated from the depth and length of required needle trajectory during scout scanning was inserted via in-plane technique. The needle was directed from a
40810637|NCT06658353|DRUG|VC004 Capsules|VC004 Capsules BID
41011432|NCT00826267|DRUG|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
41011433|NCT01772498|BEHAVIORAL|heart rate variability biofeedback|
41011434|NCT01996969|DRUG|Regorafenib|Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
41011435|NCT00027430|DRUG|TheraDerm|
41011436|NCT01548456|PROCEDURE|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
41011437|NCT01548456|PROCEDURE|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
41011438|NCT01115426|DRUG|Ramipril or losartan|Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
41011439|NCT05172505|DEVICE|prefrontal tDCS|2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
41328584|NCT04730310|PROCEDURE|NSQIP Lower Extremity Open (LEO) procedure-targeted dataset (i.e. undergoing Lower extremity open revascularization) from 2014-2019|Infrainguinal, open lower extremity revascularization procedures
41328585|NCT01403831|OTHER|Daily text messages|2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
41328586|NCT03950999|OTHER|Placebo|Sugar pill
41328587|NCT01039818|RADIATION|Radioiodine|A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
41328588|NCT01039818|RADIATION|Radioiodine|A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
41328589|NCT02865265|PROCEDURE|Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
41481142|NCT05368441|DRUG|Midazolam|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given.Before the patients were given muscle relaxants, the patients were evaluated with the Han scale.
41481143|NCT05368441|DRUG|Saline|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's grading scale.
41481144|NCT03676517|RADIATION|preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
40810638|NCT06658951|BIOLOGICAL|Anti-HER2 CAR-T cells|All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.
41481145|NCT05333484|OTHER|Programed Pilates|The 60 min Pilates sessions were held twice a week for 12 weeks. Each session included three stages: 10 min of warm-up exercises, 40 min of floor-based Pilates training, and 10 min of cool-down exercises. Each stage was adjusted according to the participants' physical capacity. Only participants with an attendance rate of \> 80% were included in the final sample. The content of the exercise program was determined according to their muscular strength, flexibility, and fitness levels. The training course was divided into three levels: elementary, intermediate, and advanced. Each motion was performed in conjunction with a specific breathing pattern for effective muscle activations of each exercise.
41481146|NCT03481413|DEVICE|Ablation|Ablation therapy for cardiac arrhythmias
41481147|NCT00941057|DRUG|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
41481148|NCT00941057|DRUG|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
41481149|NCT00941057|DRUG|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
41481150|NCT05562193|BEHAVIORAL|Physical activity intervention coupled with standard post-cancer directed treatment care|CCS will participate in a 16-week physical activity program. CCS will be instructed to start with a session duration of \<15-min, three days per week at low intensity (e.g., activities expending \>1.5 to 3 METs or intensity \<5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize CCS' success. CCS will receive a Fitbit at the beginning of the intervention.
41481151|NCT05562193|OTHER|Standard post-cancer directed treatment care control|CCS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations and the International Pediatric Oncology Exercise Guidelines will be offered to CCS following completion of 16-week follow-up. Moreover, CCS will receive a Fitbit following completion of 16-week follow-up
41155332|NCT04478799|DEVICE|Transcutanous Posterior Tibial Nerve Stimulation|children were managed by bilateral TPTNS following the procedure described in 2006 by Queralto et al(11). A positive auto-adhesive electrode was applied 1.5 inch above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Electrical stimulation device (EMS physio Ltd, OX129 F, England) was connected to both electrodes. This device delivers a low frequency current (10 Hz), and the intensity was gradually increased till flexion of the big toe or spread out of the other toes in a fan shape occurred. Then the intensity was lowered to (10 Hz) again to avoid the motor response of the toes. Intensity was determined by the child's sensitivity. The procedure was done for 20-30 minutes and repeated2 times per week for 3 months
41155333|NCT04478799|DEVICE|Sham Transcutanous Posterior Tibial Nerve Stimulation|Sham transcutaneous stimulation Patients also had twice-weekly 20-30-min sessions for 3 months. The same self-adhesive electrodes as used for group A were employed, placed in a similar position. The stimulator was briefly switched on for 30 s to induce only a minor electrical sensation in the skin, and was then turned off for the rest of the treatment. This short duration was given for only for a few seconds to avoid lower limb stimulation. Patients in all TWO groups were told that they may or may not have any perception of the electrical stimulation. Without prior knowledge of what to expect from treatment, this enabled the sham group to act as a control. In order to improve on the blinding effect of the study, the electronic display window of the stimulators was shielded from the patients in the TWO groups. All patients underwent therapy in individual screened cubicles to prevent comparison between patients of the treatment being administered.
41481152|NCT05373121|BEHAVIORAL|Online Peer Support|Signposting to online peer support groups and forums
41481153|NCT06004778|BEHAVIORAL|Motivational Support Program|In studies conducted on adolescents with poor sleep quality, no study using motivational interviewing technique was found.
41481154|NCT06004778|BEHAVIORAL|Educational support|educational support
41481155|NCT01631513|DRUG|Nucynta ER|100 to 250 mg every 12 hours
41155334|NCT03998423|BIOLOGICAL|Fecal Microbiota Transplant|Double-encapsulated Fecal Microbiota Transplant Capsules
41155335|NCT03282799|DRUG|etonogestrel implant|The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
40810642|NCT06660654|DRUG|Raludotatug deruxtecan|IV administration Q3W
41155336|NCT04501107|DRUG|Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Administration of IMP1 during a 12-hour euglycaemic clamp.
41155337|NCT04501107|DRUG|Administration of Ready-to-use BioChaperone insulin lispro (IMP2)|Administration of IMP2 during a 12-hour euglycaemic clamp.
41155338|NCT04501107|DRUG|Administration of US-approved Humalog® (IMP3)|Administration of IMP3 during a 12-hour euglycaemic clamp.
41155339|NCT04501107|DRUG|Administration of EU-approved Humalog® (IMP4)|Administration of IMP4 during a 12-hour euglycaemic clamp.
41155340|NCT00243217|DRUG|SPM 936|
41155341|NCT02429232|DRUG|Pioglitazone|Pioglitazone 30mg/tablet once daily
41481156|NCT01843348|DRUG|Everolimus|
41481157|NCT01843348|DRUG|Tacrolimus|Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
41481158|NCT01843348|DRUG|Cyclosporin A|Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
41481159|NCT01843348|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
41481160|NCT01843348|DRUG|Mycophenolate mofetil (MMF)|Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
41481161|NCT01843348|DRUG|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
40810643|NCT06659354|BEHAVIORAL|Pregnant Body Project (PBP)|The Body Project is typically delivered as four 1-hour weekly sessions consisting of written, verbal, and behavioral exercises. The sessions aim to induce cognitive dissonance by encouraging participants to challenge the thin-ideal, a theoretically and empirically supported component of ED prevention. This adapted version of the Body Project (the Pregnant Body Project; PBP) consists of 6 1-hour, weekly group sessions delivered via Zoom. Since the target population consists of individuals with histories of an ED or disordered eating behaviors, PBP also includes elements from a treatment intervention (i.e., the Body Project Treatment 8.0 manual). PBP was adapted iteratively with a needs assessment, expert stakeholder input, and participant feedback following a mock trial with individuals with lived experience (i.e., individuals with histories of an ED who have given birth). This condition will be peer-delivered by facilitators with lived experience.
41011440|NCT04073095|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
41155342|NCT02429232|DRUG|Linagliptin|Linagliptin 5mg/tablet once daily
41155343|NCT00563433|DRUG|ofloxacin|400 mg twice a day for 14 days
41155344|NCT00563433|DRUG|MSI-78|1%/2% topical cream twice a day for 14 days
41481162|NCT01843348|DRUG|Simulect|Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
41481163|NCT03348748|OTHER|Laboratory Biomarker Analysis|Correlative studies
41481164|NCT03348748|OTHER|Quality-of-Life Assessment|Ancillary studies
41481165|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo lowest-dose of SBRT
41481166|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo lowest- or higher-dose of SBRT
41481167|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo highest-dose of SBRT
41481168|NCT03348748|PROCEDURE|Thoracic Surgical Procedure|Undergo thoracic surgery
41155345|NCT05360290|DEVICE|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
41155346|NCT03235401|OTHER|37-items questionnaire|Patient will answer the PAH-DBoQ questionnaire
41155347|NCT05973357|PROCEDURE|Sub-crestal implant|Patients receiving delayed implant placed 2mm sub-crestal level with immediate provisionalization
41481169|NCT00999180|PROCEDURE|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
41481170|NCT00999180|PROCEDURE|Saline and Kinesiotherapy|Saline and Kinesiotherapy
41481171|NCT03500497|DIAGNOSTIC_TEST|RetHe measurement (Sysmex)|RetHe measurement is done from blood samples gained during standard patient care perioperatively
41481172|NCT00344214|BEHAVIORAL|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
41481173|NCT00344214|BEHAVIORAL|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
41481174|NCT01374139|DRUG|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
41481175|NCT01374139|DRUG|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
41481176|NCT04633421|DIETARY_SUPPLEMENT|PRECISe protocol EN 8g protein/100kcal|Enteral feed containing 8g protein/100kcal
41481177|NCT04633421|DIETARY_SUPPLEMENT|PRECISe protocol EN 5g protein/100kcal|Enteral feed containing 5g protein/100kcal
41481178|NCT01780779|OTHER|MRI|"MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment."
41481179|NCT03892213|DRUG|Benznidazole|Benznidazole single dose (2.5 mg/kg) at Day 1. Benznidazole single dose (2.5 mg/kg) at Day 9\*. Benznidazole multiple dose (2.5 mg/kg twice daily) from Day 12\* until Day 15.
41481180|NCT03892213|DRUG|E1224|"E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15).~On Day 9 and from Day 12 to Day 15, E1224 and benznidazole will be given concomitantly."
41481181|NCT01045993|DEVICE|Heat Device|8-Hour Heatwrap
41481182|NCT01045993|DEVICE|Sham Device|Inactive wrap worn for 8 hours
41481183|NCT01045993|DRUG|marketed analgesic|2 x 200 mg ibuprofen tablets
41481184|NCT01045993|DRUG|Placebo|2 x placebo tablets
41481185|NCT03546803|OTHER|3M™ Cavilon™ Advanced Skin Protectant|liquid skin protectant on skin to protect from radiation dermatitis
41481186|NCT04336839|PROCEDURE|Portal vein resection / reconstruction|Portal vein resection and reconstruction, with or without concommitant arterial resection
41328590|NCT05411328|DEVICE|virtual reality|All children in the two groups received physical therapy protocol for 30 minutes in addition to virtual reality game traditional physical therapy group traditional physical therapy group
41328591|NCT05320380|DRUG|Anti-CD123 ADC IMGN632|Given IV
41481187|NCT00488670|DRUG|Escitalopram|See Detailed Description.
41481188|NCT00905788|PROCEDURE|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
41155348|NCT05973357|PROCEDURE|Equi-crestal implant|Patients receiving delayed implant placed equi-crestal level with immediate provisionalization
41155349|NCT05041439|BEHAVIORAL|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 6 months.
41328592|NCT05320380|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
41328593|NCT05320380|DRUG|Cytarabine|Given IT and IV
41328594|NCT05320380|DRUG|Fludarabine Phosphate|Given IV
41155350|NCT01039597|DRUG|ORE1001|Oral capsules containing 300 mg of the active, study drug
41155351|NCT01039597|DRUG|Placebo|placebo capsules
41328595|NCT05320380|DRUG|Hydrocortisone Sodium Succinate|Given IT
41328596|NCT05320380|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
41328597|NCT05320380|DRUG|Methotrexate|Given IT
41328598|NCT05320380|DRUG|Prednisolone|Given IT
41328599|NCT03465384|BEHAVIORAL|Comet|The intervention is a behaviorally based and manualized parent training program.
41328600|NCT06446518|DEVICE|Virtual reality exposure|Assessing immersive virtual reality as a distraction tool in anxiolysis and pain modulation.
41328601|NCT02629614|DEVICE|Cala ONE Device|The Cala ONE device is a wrist-worn stimulator which applies transcutaneous electrical stimulation non-invasively to the median and radial nerves of an individual through disposable hydrogel electrodes.
41481189|NCT02801084|BEHAVIORAL|Reduced environmental stimulation|"Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.~Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Floats 3 \& 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Each float will occur approximately 1 to 7 days apart."
41481190|NCT02642796|DEVICE|transcutaneous electric nerve stimulation|"The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.~Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound."
41481191|NCT01956695|DRUG|Lenalidomide|
41481192|NCT01956695|DRUG|Rituximab|
41481193|NCT02017860|DRUG|Everolimus|Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.
41481194|NCT02333487|DRUG|Lu AF35700|5 mg tablets for oral administration
41155352|NCT03055819|DEVICE|Brow Lift|Minimally Invasive Brow Lift
41155353|NCT01136733|DRUG|Lenvatinib|taken orally, once a day
41155354|NCT01136733|DRUG|Everolimus|taken orally, once a day
41328602|NCT04586556|DIAGNOSTIC_TEST|Polyps detection by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedback (polyp detection, tracking, and pathology prediction) will be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp or the information to predict pathology
41328603|NCT00927329|BIOLOGICAL|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
41481195|NCT03602963|DEVICE|Dexcom G5 Mobile CGM system|The accuracy and usability ot the Dexcom G5 mobile CGM system will be evaluated
41328604|NCT03060967|BEHAVIORAL|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities of food and control images
41328605|NCT00391807|DRUG|Norethindrone acetate/ethinyl estradiol|one tablet per day
41328606|NCT02980692|DRUG|SUNPG1623 I|injection
41328607|NCT02980692|DRUG|SUNPG1623 II|injection
41328608|NCT02980692|DRUG|SUNPG1623 III|injection
41328609|NCT02980692|DRUG|SUNPG1623 IV|injection
41328610|NCT02980692|DRUG|PLACEBO|injection
41328611|NCT05759546|DRUG|Fluzoparib|Parp inhibitor
41328612|NCT05759546|DRUG|Dalpiciclib|CDK4/6 inhibitor
41328613|NCT05759546|DRUG|Fulvestrant/AI|Endocrine therapy
41481196|NCT05608681|DRUG|EP-104IAR|Long-acting fluticasone propionate for injection
41481197|NCT02234752|DRUG|Galantamine ER|
41481198|NCT02234752|DRUG|Memantine XR|
40810644|NCT06659354|BEHAVIORAL|Pregnancy Health Education (PHE)|This time- dose- and attention- matched control condition accounts for the potential effects of time spent and support from group members and facilitators. Participants assigned to the PHE group will also be asked to attend 6, 1-hour, weekly group sessions via Zoom. During the sessions participants receive psychoeducation on body image and disordered eating during pregnancy but will not engage in any dissonance-inducing exercises. Participants will also receive lifestyle education specific to pregnancy (e.g., proper nutrition, sleep, physical activity), tied back to body image and disordered eating.
41011441|NCT04073095|OTHER|modified-thoracolumbar interfascial plane block (Group T)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
41011442|NCT05654324|OTHER|pelvic floor muscle exercises|Before the pelvic floor exercises are taught to all women participating in the study, a brief informational training about the function and structure of the pelvic floor and pelvis will be given using visuals. The application protocol will be given by experienced specialist physiotherapists who have received special training on pelvic floor muscle training. In this study, the training protocol described by Mørkved et al and Bø et al will be used. An exercise series will consist of slow and fast muscle contractions of the pelvic floor muscles. The exercise series will include 10 reps of maximum pelvic floor muscle contraction held for 6 seconds followed by three rapid muscle contractions. A 10-second rest period will be given between each exercise series. A total of 5 minutes, 4 repetitions of pelvic floor muscle contraction series will be applied, including the rest period.
41266411|NCT00891202|DRUG|Placebo|PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
41328614|NCT04687488|OTHER|Fluorescein|For droplet visualization, we will use fluorescein, which has been used for many years in medicine for diagnostic purposes and is safe upon topical administration, as a tracer. There are no local or systemic side effects of topical sodium fluorescein (5). Fluorescein is routinely used in the mouth to stain dental plaque (6). Through the lacrimal duct, the nasal cavity is exposed to fluorescein when it is used for ophthalmological purposes (7). Allergic reactions have been described to intravenous injection, which is not part of our trial. In the setting of head-and-neck and otolaryngological surgeries, coating the mouth with fluorescein has been used to quantify droplet spread, to assess for risk of transmission of COVID-19 (8). Hence, fluorescein can be safely applied to nasal and oropharyngeal cavities. We will use a similar approach, coating the nasal cavity, to study droplet spread from the nose during naso-gastric intubation for motility or reflux testing.
41328615|NCT04687488|OTHER|Particle measurement|Quantification of aerosol will be done using a medical particle counter, as used for hospital safety measurements.
41328616|NCT02846051|PROCEDURE|venous mapping|clinical examination + doppler echo
41328617|NCT06122987|DRUG|Angiotensin II and hydrocortisone sodium succinate|Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
41328618|NCT02479438|OTHER|Diagnosed with GERD|Recording of patient outcomes
41328619|NCT01646801|DEVICE|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
41481199|NCT00287300|DRUG|Sulfadoxine-Pyrimethamine|
41481200|NCT00287300|DRUG|Azithromycin|
41481201|NCT00287300|DRUG|Artesunate|
41481202|NCT05695092|BEHAVIORAL|Progressive muscle relaxation|Progressive Muscle Relaxation (PMR): This method involved efficiently relaxing global muscles of body with the objective of mental and physical relaxation.
41011443|NCT02348242|DEVICE|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
41481203|NCT05695092|OTHER|control|control group will not receive any intervention
41481204|NCT02013375|PROCEDURE|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
41481205|NCT02013375|DRUG|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
41481206|NCT02013375|RADIATION|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
41481207|NCT02013375|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
41481208|NCT02013375|DRUG|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
41011444|NCT02348242|DEVICE|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
41011445|NCT02348242|DEVICE|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
41011446|NCT02343510|OTHER|PCR for chlamydia DNA in primary tubal cancer|PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
41011447|NCT02871375|DEVICE|Delefilcon A multifocal contact lenses|Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
41266412|NCT03619213|DRUG|Dapagliflozin|10 mg tablets given once daily, per oral use.
41266413|NCT03619213|DRUG|Placebo|Placebo matching dapagliflozin 10 mg
41328620|NCT02938546|RADIATION|18F-FDG|18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
41328621|NCT01322451|DRUG|GLPG0259 fumarate|single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
41328622|NCT01322451|DRUG|GLPG0259 free base|single oral dose, GLPG0259, 50 mg solid formulation
41328623|NCT02349737|OTHER|Exposure to BIA interference with the ICD|Exposure to BIA interference with the ICD
41328624|NCT02195609|DIETARY_SUPPLEMENT|Omega-3|600 mg oral twice a day
41328625|NCT02195609|DIETARY_SUPPLEMENT|Soy Isoflavones|54.4 mg oral twice a day
41328626|NCT02420301|OTHER|Tuina exercises|
41328627|NCT02420301|OTHER|Placebo Tuina exercises|
41481209|NCT01576874|DRUG|Oxytocin|40 IUs of oxytocin administered intranasally one time
41481210|NCT01576874|DRUG|placebo|placebo administered intranasally one time
41011448|NCT02871375|DEVICE|Habitual multifocal contact lenses|Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
41011449|NCT01714310|DRUG|lisdexamfetamine|Titration and open label treatment from baseline visit for 12 week study.
41011450|NCT01714310|DRUG|Placebo|Initiated at end of study week 4 and continued to study week 12.
41011451|NCT01714310|DRUG|fluoxetine|Initiated at end of study week 4 and continued to study week 12.
41011452|NCT04877262|OTHER|weight maintenance diet (WMD)|A diet meeting the participant's weight maintenance energy needs will be provided.
41011453|NCT04196166|OTHER|preoperative blood tests|
41266414|NCT03828487|DEVICE|Masimo O3 Neonatal Sensors|Regional Oximetry sensor for Neonates
41266415|NCT03828487|DEVICE|510(k) cleared sensor|Cleared Regional Oximetry sensor for Neonates
41266416|NCT05841940|DRUG|[14C]HLX208|Carbon-14 labeled HLX208
41266417|NCT00252330|DRUG|SR58611A|
41266418|NCT01349309|BEHAVIORAL|Swallowing Exercise Group|"Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds."
41011454|NCT03784950|BEHAVIORAL|Rating tool|eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
41328628|NCT04992546|DRUG|PRN473 (SAR444727)|White to off-white gel suspension
41328629|NCT04992546|DRUG|Placebo|White to off-white gel suspension
41328630|NCT02617017|DRUG|Buspirone|Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
41328631|NCT02617017|DRUG|Placebo|Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
41328632|NCT04576247|BEHAVIORAL|Combined aerobic and resistance exercise|"The 12-week intervention will build upon an ongoing resistance exercise program for cancer patients and survivors at the University of Colorado's Anschutz Health and Wellness Center. Resistance exercise will be led by certified cancer exercise specialists who provide individualized exercise programs to cancer patients and survivors. Exercise sessions are progressive, target all major muscle groups, are 50 minutes in duration, and completed 2x/week.~The intervention will also include 3 self-directed moderate-intensity aerobic exercise sessions/week, building to 50 minutes at 60% heart rate maximum (determined at baseline). Target exercise will be achieved by a gradual progression of exercise duration over the first four weeks of the program."
41328633|NCT00444470|DRUG|Tranexamic acid|"Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid."
41328634|NCT00444470|DRUG|Placebo|"Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo."
41328635|NCT03297333|OTHER|Resistance training|The resistance training group
41481211|NCT04689763|BEHAVIORAL|Training|The programs contain sequential cognitive and exercise training, health lectures, and groups of daily living participation. We plan to assess the participants before and after the intervention programs. We expect that elders receiving training will improve on outcome measures. The results of the study will provide evidence of interventions for elderly with cognitive decline.
41481212|NCT01244061|DRUG|Varenicline|Varenicline 1mg twice daily
41481213|NCT01244061|DRUG|Placebo|Matched placebo twice daily
41481214|NCT00350402|BEHAVIORAL|Respiratory muscle strength training|The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
41481215|NCT02493920|OTHER|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm).
41481216|NCT02493920|DEVICE|mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).|
41481217|NCT00775541|DIETARY_SUPPLEMENT|Vitamin C|One IV infusion of 2 gm vitamin C
41481218|NCT03891017|OTHER|vacuum casting|Participants will be cast using vacuum casting (Ottobock Harmony) method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
41481219|NCT03891017|OTHER|hydrostatic casting|Participants will be cast using aqua casting method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
40810645|NCT06657833|DEVICE|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon
41266419|NCT02858427|BEHAVIORAL|eye tracking|"several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.~Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.~Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.~Picture Scanning: participant is instructed to freely watch pictures with different emotional valence."
41328636|NCT03297333|OTHER|Aerobic interval training|The aerobic interval training group
41328637|NCT01148693|DRUG|gentamicin|10mg per 10ml of contrast media
41328638|NCT01148693|DRUG|Placebo|Distilled water
41328639|NCT05274828|DEVICE|H7-Coil Deep TMS for CUD|The Study group will receive dTMS treatment three times a day for ten days.
41328640|NCT03230513|OTHER|Self Epley Manoeuvre|The patient has to position himself long sitting on the bed, then turn his head 45 degrees to the problematic side. When in this head position, he will rapidly lie himself supine with a pillow under his shoulders. He then turns his head 90 degrees to the opposite direction followed by turning of his body to the same side before returning to a sitting position at the edge of the bed. Each position should be kept for 30 seconds each, and the patient is required to perform 3 cycles of this manoeuvre just prior to going to bed daily for 2 weeks.
40810646|NCT06657833|DEVICE|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent
40810647|NCT06659133|OTHER|Music intervention|"The women participating in the study were divided into control and experimental groups.~The control group included women who underwent pipelle endometrial biopsy with routine care, and the experimental group included women who underwent pipelle endometrial biopsy accompanied by music. Pipelle endometrial biopsy was performed by the same physician working in the Department of Obstetrics and Gynecology at the hospital. Patients in both groups were interviewed 10 minutes before the endometrial biopsy procedure and the Personal Information Form and State and Trait Anxiety Scale were applied. The application of the GKO was explained to the patients before the pipelle endometrial biopsy procedure. Before the pipelle endometrial biopsy, all patients were routinely given local anesthesia with 8 cc of 2% lidocaine solution and waited for 5 minutes after the application of local anesthesia.~During the pipelle endometrial biopsy, the experimental group was given a music recital from an mp3 play"
41481220|NCT02615171|BEHAVIORAL|Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
41481221|NCT02615171|BEHAVIORAL|Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity|Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
41481222|NCT02662231|PROCEDURE|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
41481223|NCT04551820|PROCEDURE|Regular Hours|The regular hours cohort includes cholecystectomies performed during the day shift at the Institution during Monday through Friday, not inclusive of national holidays.
41481224|NCT04551820|PROCEDURE|After Hours|The after hours cohort includes cholecystectomies performed outside of the day shift at the Institution during Monday through Friday, on the weekend, or during a national holiday.
40810648|NCT06661733|DRUG|AZD5462|Participants will receive AZD5462 orally.
40810649|NCT06659887|DEVICE|nasal cannula|After induction, bag-mask ventilation with 100% oxygen and flow rates of 6 L/ min will be carried out until the expired oxygen concentration will be \>90%, SpO2 was 100%, and end tidal CO2 was 30-40 mmHg. Once this will be reached, bag-mask ventilation will be stopped and apneic oxygenation will be initiated for 3 minutes
41266420|NCT02858427|BEHAVIORAL|neuropsychological assessement|the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
40810651|NCT06658587|DIAGNOSTIC_TEST|No interventions|No interventions
41266421|NCT02858427|BEHAVIORAL|psychiatric assessment|this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
41266422|NCT02858427|BEHAVIORAL|sociological interview|this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
41266423|NCT05699720|DRUG|Nebulized Magnesium Sulphate|Group A received 250mg of MgSO4 /dose given through nebulizer four times a day, while group B did not. The groups will be followed for five days to see the results in terms of in-hospital outcome, whether the patient is discharged after fulfilling the set criteria or needing assisted ventilation.
41266424|NCT02493647|BEHAVIORAL|Love, Sex, & Choices|Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.
41266425|NCT00643630|DEVICE|Tetrix|Twice daily topical application
41266426|NCT00643630|DEVICE|Tetrix|Twice daily topical application
41266427|NCT02237690|DRUG|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
41266428|NCT04569838|DRUG|Bendamustine hydrochloride injection|Bendamustine is a bifunctional alkylating agent. It cross-links DNA single strand and double strand by alkylation,then destroys the function and synthesis of DNA, and makes the DNA and protein, protein and protein cross-linking, has potential to treat various tumors
40810652|NCT06347068|BIOLOGICAL|iC9-CAR.B7-H3 T Cell Therapy|iC9-CAR.B7-H3 T cells will then be administered intravenously
40810653|NCT06347068|DRUG|cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
40810654|NCT06347068|DRUG|fludarabine|fludarabine 30 mg/m2 IV will be given.
40810655|NCT06388148|DRUG|Medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
40810656|NCT06388148|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
40810657|NCT04846868|DRUG|Iclepertin|Iclepertin
40810658|NCT04846868|DRUG|Placebo|Placebo
41155355|NCT05731414|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis (CBTp)|Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness. This approach has demonstrated moderate to large improvements on symptoms and small to moderate effects on functioning. The first four sessions are devoted to building therapeutic rapport and developing collaborative treatment goals. The following phase focuses on developing formulations of why difficulties persist and using cognitive and behavioural change strategies. A longitudinal formulation is then offered to better understand how their difficulties developed. The final 2-4 sessions focus on consolidating the learning that occurred during treatment so that participants can maintain their improvement. Therapy homework is collaboratively assigned at the end of sessions to promote new learning in between sessions.
41155356|NCT05731414|BEHAVIORAL|Cognitive Remediation Therapy (CR)|Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials. ABCR involves practicing computerized training exercises with difficulty level dynamically titrated to improve neurocognitive abilities. Then participants engage in strategy discussions with other group members to develop new cognitive strategies. Finally, participants complete role-play simulations of real-world activities to practice their cognitive strategies in simulations of everyday life. ABCR is more effective for improving functioning than traditional approaches to CR. Homework consists of additional cognitive training and practicing cognitive strategies in everyday life.
41155357|NCT05731414|BEHAVIORAL|Befriending|Befriending will be delivered according to a manual validated to control for the non-specific effects of CBT, such as duration of therapeutic contact, client expectancy effects, therapeutic alliance, and therapist warmth. Befriending consists of 1-hour individual sessions once per week and involves a series of conversations similar to those one might have with a social acquaintance. These conversations involve discussion of neutral topics without problem-solving, coping strategies, or exploration of emotion. If emotional or mental health-related topics are brought up therapists redirect back to a neutral topic.
41266429|NCT03835741|DEVICE|FreeO2|an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
41266430|NCT03835741|OTHER|manual titration|a manual adjustment of oxygen during patient hospitalisation by hospital staff
41266431|NCT06481137|DIAGNOSTIC_TEST|Electrophysiological study (EP study)|Electrophysiological study: A second EP study 30-45 days after TAVI will be performed in the group of patients with positive EP study 3-7 days after TAVI.
41266432|NCT06481137|DIAGNOSTIC_TEST|ePatch (extended Holter Monitoring)|Continuous cardiac rhythm monitoring using the ePatch (Philips) will be performed during 4 weeks after TAVI
41266433|NCT00434967|DRUG|Candesartan cilexetil|32 mg oral tablet
40810667|NCT06606327|DRUG|Diazoxide, 3 mg/kg per dose|Insulin anti-secretagogue taken for 8 doses over 4 days
40810668|NCT00499330|PROCEDURE|lobectomy|
40810669|NCT00499330|PROCEDURE|segmentectomy or wedge resection|
40810674|NCT03604991|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
40810675|NCT03604991|DRUG|Carboplatin|Given IV
40810676|NCT03604991|PROCEDURE|Computed Tomography|Undergo CT scan
40810677|NCT03604991|BIOLOGICAL|Ipilimumab|Given IV
40810678|NCT03604991|BIOLOGICAL|Nivolumab|Given IV
40810679|NCT03604991|DRUG|Paclitaxel|Given IV
40810680|NCT03604991|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40810681|NCT03604991|RADIATION|Radiation Therapy|Undergo radiation therapy
40810682|NCT06592014|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L
40810683|NCT06604767|BIOLOGICAL|parainfluenza virus type 3 vaccine (PIV3)|Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular
40810684|NCT06604767|BIOLOGICAL|RSV/hMPV/PIV3 vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
40810685|NCT06604767|BIOLOGICAL|RSV/hMPV vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
40810686|NCT06604767|BIOLOGICAL|RSV vaccine 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
40810687|NCT06604767|BIOLOGICAL|RSV vaccine 2|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
40810688|NCT06589791|OTHER|No treatment given|Online self-completion survey
40810689|NCT06601686|DEVICE|Transcranial electrical stimulation (TES)|TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
40810690|NCT06601686|DEVICE|Transcranial electrical stimulation with temporal interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
40810691|NCT06601686|DEVICE|Sham stimulation|TES-TI sham includes receiving stimulation from all electrodes at the same frequency. Sham TES will include administration of transcranial random noise stimulation (tRNS), random oscillating current.
40810692|NCT06601699|DEVICE|Transcranial electrical stimulation (TES)|TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
41481225|NCT04551820|DEVICE|Robotic-assisted Cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
41481226|NCT06028503|BEHAVIORAL|Acceptance and Commitment Therapy|"Approximately 3 hours of ACT will be administered based on Gregg et al.;s (2007) protocol:~1. What is ACT?~2. Coping and Stress Management~3. Acceptance and Action"
40810693|NCT06601699|DEVICE|Transcranial electrical stimulation with temporal interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
41266434|NCT00434967|DRUG|Hydrochlorothiazide|25 mg oral tablet
41266435|NCT00434967|DRUG|Candesartan/HCT 32/25 mg|
41266436|NCT00888667|OTHER|Pacing interventions|10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
41266437|NCT03151486|DRUG|JNJ-55308942 0.5 mg|Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.
41266438|NCT03151486|DRUG|JNJ-55308942 1.5 mg|Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
41266439|NCT03151486|DRUG|JNJ-55308942 4 mg|Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
41266440|NCT03151486|DRUG|JNJ-55308942 12 mg|Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
41266441|NCT03151486|DRUG|JNJ-55308942 36 mg|Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.
41266442|NCT03151486|DRUG|JNJ-55308942 100 mg|Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.
41266443|NCT03151486|DRUG|JNJ-55308942: Fed State|Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
41266444|NCT03151486|DRUG|JNJ-55308942: MAD Part|Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
41266445|NCT03151486|DRUG|Placebo|Participants will receive matching placebo in all cohorts.
41266446|NCT01007526|OTHER|CCRT followed by VIDL chemotherapy|CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
41266447|NCT01786317|DEVICE|High resolution manometry|Anorectal High resoltion manometry using electronic sensors
41266448|NCT04488458|DIAGNOSTIC_TEST|MIC or MBEC+MIC based treatment algorithm|"i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks.~ii) Non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks."
41266449|NCT00570245|DRUG|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
41266450|NCT00570245|DRUG|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
41266451|NCT05332860|PROCEDURE|Congenital Cardiovascular Surgery|Relationship between perioperative and postoperative hemodynamics, laboratory, oxygenation parameters and demographic data with extubation times in pediatric cardiac surgery cases taken in our hospital.
41266452|NCT02759042|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
41266453|NCT05973136|OTHER|Telerehabilitation program based on cardiorespiratory principles|The intervention consists of a hybrid program. The participant will receive rehabilitation sessions in presence (aerobic component of the intervention based on maximal oxygen uptake measured before intervention by means on a ergospirometric test) and at home via a telerehabilitation platform. The length of the intervention is 12 weeks. For the in-presence sessions, they are going to be 75 minutes, 2x/week. For the at-distance sessions, they are going to be 45 minutes, 1x/week in groups of 3 to 4 participants. The intervention will consist of a warm-up, endurance, postural, and strengthening exercises, cool down and respiratory exercises. An exercise book with final recommendations is provided to the participants at the end of the intervention.
41266454|NCT05728840|OTHER|Immersive virtual reality gamified cognitive activities|This intervention will include 20 sessions of training with the experimental rehabilitation program using immersive VR cognitive gamified activities, in addition to the standard of care.
41266455|NCT05728840|OTHER|Double neuropsychological standard activities|This intervention will include 20 sessions of training using a standard neuropsychological rehabilitation program, in addition to the standard of care.
41266456|NCT01384292|DRUG|NKTR-118|12.5 mg oral tablet once daily
41266457|NCT01384292|DRUG|NKTR-118|25 mg oral tablet once daily
41266458|NCT01384292|DRUG|Placebo|Oral treatment
41155358|NCT05731414|BEHAVIORAL|Sham Cognitive Remediation|Sham CR was developed by Dr. Best and Dr. Bowie (CI) to control for the non-specific effects of CR such as computer practice and group discussion. Participants practice similar computerized exercises to ABCR, however, the exercises do not increase in difficulty. Participants then discuss enjoyment of the exercises but any discussion of cognitive strategies is redirected back to a neutral topic. We have previously found this condition to be an effective control for CR, with similar engagement to the active training group.
40810695|NCT06596616|OTHER|Radiology|Radiology - MRI Scans
40810696|NCT06596616|OTHER|Gadopiclenol|Gadopiclenol is a new macrocyclic gadolinium-based contrast agent (GBCA)
41155359|NCT04390971|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
41155360|NCT03256760|BIOLOGICAL|Endotoxin|Endotoxin
41155361|NCT03256760|BIOLOGICAL|Placebo|Placebo
41155362|NCT01359514|DRUG|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks
40810701|NCT06586515|DRUG|LY3962673|Administered orally.
41328641|NCT03230513|OTHER|Brandt-Daroff Exercise|The patient has to sit at the edge of the bed, turn his head laterally 45 degrees to one side and move rapidly into the side lying position, keeping his head in the same position. He then returns upright and turns his head to the opposite direction and the same movement is repeated on the other side. Each position is held for at least 30 seconds and the patient is required to perform it for 5 repetitions, three times a day, daily for 2 weeks duration.
41328642|NCT03052387|OTHER|assigned intervention|"\* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.~chin block graft~* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.~* Low vestibular incision exposing the symphysis area to the inferior border of the mandible.~* Using fissure bur to harvest the graft for the defect.~* Closure using vicryl 3-O sutures."
41328643|NCT02538367|DRUG|YH12852 IR 0.05mg|
41328644|NCT02538367|DRUG|YH12852 IR 0.1mg|
41328645|NCT02538367|DRUG|YH12852 IR 0.3mg|
41328646|NCT02538367|DRUG|YH12852 IR 0.5mg|
41328647|NCT02538367|DRUG|YH12852 IR 1mg|
41328648|NCT02538367|DRUG|YH12852 IR 2mg|
41328649|NCT02538367|DRUG|YH12852 IR 3mg|
40810702|NCT06586515|DRUG|Cetuximab|Administered intravenously.
40810703|NCT06586515|DRUG|Gemcitabine|Administered intravenously.
40810704|NCT06586515|DRUG|nab-paclitaxel|Administered intravenously.
40810705|NCT06586515|DRUG|Oxaliplatin|Administered intravenously.
40810706|NCT06586515|DRUG|leucovorin|Administered intravenously.
40810707|NCT06586515|DRUG|Irinotecan|Administered intravenously.
40810708|NCT06586515|DRUG|5-fluorouracil|Administered intravenously.
41155363|NCT01359514|DRUG|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
41155364|NCT06244706|COMBINATION_PRODUCT|Opioid drug + CNS-acting add-on drug|Patients suffering from persistent pain (pain lasting for at least three months), already treated with an opioid medication (treatment A) and to whom the treating physician is about to prescribe a CNS-acting add-on drug such as an antiepileptic, an antidepressant, a benzodiazepine or an alpha2-agonist (treatment B: the combination treatment).
41328650|NCT02538367|DRUG|YH12852 DR1 0.5mg|
41328651|NCT02538367|DRUG|YH12852 DR1 1mg|
41328652|NCT02538367|DRUG|YH12852 DR1 2mg|
41328653|NCT02538367|DRUG|YH12852 DR1 4mg|
40810714|NCT03598244|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40810715|NCT03598244|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
40810716|NCT03598244|DRUG|Savolitinib|Given PO
40810717|NCT03598244|PROCEDURE|X-Ray Imaging|Undergo X-ray imaging
40810718|NCT01677598|DRUG|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
41328654|NCT02538367|DRUG|YH12852 DR2 8mg|
41328655|NCT02538367|DRUG|Prucalopride 2mg|
41328656|NCT02538367|DRUG|Placebo|
41328657|NCT04758598|DEVICE|Direct Selective Laser Trabeculoplasty (DSLT)|DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
40810719|NCT03296137|BIOLOGICAL|Autologous tumor-infiltrating lymphocytes|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
40810720|NCT03296137|DRUG|Ipilimumab|One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
40810721|NCT03296137|DRUG|Nivolumab|4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
40810722|NCT03296137|DRUG|proleukin|2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
40810723|NCT03296137|DRUG|Cyclophosphamide|2 doses (60 mg/kg) prior to TIL infusion
40810724|NCT03296137|DRUG|Fludara|5 doses (25 mg/m2) prior to TIL infusion
40810727|NCT06611345|DEVICE|Tumor Treating Fields|Tumor treating fields will be used each day.
40810728|NCT06611345|DRUG|Durvalumab|Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).
40810729|NCT06611345|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
40810730|NCT06611345|DRUG|Cisplatin|Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
41155365|NCT01598389|OTHER|Feeding study|In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
41155366|NCT04093583|PROCEDURE|Exodontia|Atraumatic exodontia followed by simple suture
40810734|NCT04726592|DRUG|Clorazepate Dipotassium|Clorazepate Dipotassium : 20 mg intravenous injection
40810735|NCT04726592|DRUG|Placebo|Placebo IV
40810736|NCT04726592|DRUG|Ketoprofen|Ketoprofen 100 mg IV
40810737|NCT04726592|DRUG|Metoclopramide|Metoclopramide 10 mg IV
41011455|NCT03784950|BEHAVIORAL|Feedback|eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
41155367|NCT04093583|DRUG|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
41011456|NCT05621239|BIOLOGICAL|BNT162b2|BNT162b2 half dose and full dose
41155368|NCT04093583|DEVICE|Preparation of PRGF using Endoret technology|Preparation of PRGF using Endoret technology following manufacturer instructions
41266459|NCT03547557|DEVICE|Exablate 2000 strappable system|
41266460|NCT00836550|BEHAVIORAL|Video|The participants saw a 6 minute video
41266461|NCT00836550|BEHAVIORAL|in-person HIV pre-test counseling|
41266462|NCT04850729|OTHER|non-intervention|non-intervention
41266463|NCT01486030|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
41266464|NCT05641701|DEVICE|System On|The DBS system will be turned on, and the individual's stutter will be assessed.
41266465|NCT05641701|DEVICE|System off|The DBS system will be turned off, and the individual's stutter will be assessed.
41266466|NCT01451619|DRUG|Laropiprant|One 100-mg tablet orally once daily for 4 weeks
41266467|NCT01451619|DRUG|Placebo for Laropiprant|One tablet orally once daily for 4 weeks
41266468|NCT01775748|OTHER|Active Concord Grape Juice 12 oz per day|Grape Juice 12 oz per day
41266469|NCT01775748|OTHER|Placebo Grape Juice 12 oz per day|Placebo Grape Juice 12 oz per day
41266470|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - high intensity interval training (HIIT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 4x4-min high intensity aerobic intervals at a rating of perceived exertion 15-17 (hard to very hard), interspersed by a 3-min active recovery at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (4-min) and cool-down (3-min) at a light intensity.
41266471|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - moderate intensity continuous training (MICT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 34-min of continuous aerobic exercise at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (3-min) and cool-down (3-min) at a light intensity.
41266472|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - control|Participants will receive exercise advice in line with usual hospital discharge procedures. This involves exercise physiologists providing verbal and written information on achieving the national physical activity guidelines (150min/week of moderate intensity exercise) 60 and range of movement exercises for surgical patients with sternotomy. However, no structured or supervised exercise training program or other contact with participants will be provided after hospital discharge, to reflect the usual care process for patients that decline cardiac rehabilitation.
41266473|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - observational|During cardiac rehabilitation (12-weeks), program frequency and exercise training protocol will align with clinical care decisions and/or patient choice rather than random assignment.
41266474|NCT04201743|DRUG|Acellular amniotic membrane derived allograft injection (NuDYN)|Injectable acellular amniotic membrane derived allograft (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) in the treatment of knee osteoarthritis.
41266475|NCT02071433|PROCEDURE|Saphenous nerve blockade|
41266476|NCT02071433|PROCEDURE|Femoral nerve blockade|
41266477|NCT02840851|DEVICE|MRI|Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
41266478|NCT02840851|DEVICE|TCD|Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
41266479|NCT00001676|DRUG|SQ Fludarabine|
41266480|NCT00723684|OTHER|Placebo EEG Neurofeedback|"The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects."
41328658|NCT04758598|DEVICE|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
41155369|NCT06539936|DEVICE|Glide|Glide is a myoelectric prosthesis control strategy which enables multifunctional control using a limited set of input EMG signals (as few as two). The Glide control strategy uses the relative contributions of multiple electrode inputs to create a virtual cursor, calculated from a vector summation of multiple EMG channels, to select the type and speed of a movement from a circular map.
40810740|NCT05081219|DRUG|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
40810741|NCT05081219|DRUG|Empagliflozin 10 MG|Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.
40810742|NCT05081219|DEVICE|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
40810743|NCT05081219|DRUG|Placebo (Insulin Diluent)|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
40810744|NCT05081219|DRUG|Placebo (Capsules)|Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
41155370|NCT06539936|DEVICE|Direct Control|Direct Control (DC) is the most common method of control for powered prostheses, which directly links the activity recorded from a single electromyography (EMG) electrode to a prosthesis action. Typically, a pair of EMG electrodes are placed over a pair of agonist/antagonist muscle groups to operate a single DOF (e.g., for transradial amputees the flexor muscles in the forearm may be mapped to the prosthetic hand closing and the forearm extensor muscles mapped to hand opening).
41155371|NCT02409121|BEHAVIORAL|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
41155372|NCT04994314|DRUG|nCaF2 primer|Calcium fluoride nanoparticles was added to conventional orthodontic primers to develop bioactive primer. This primer was examined previously for its biological and physical properties
41155373|NCT04994314|DRUG|Control primer|Conventional orthodontic primer
41155374|NCT02270606|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
41155375|NCT02270606|DRUG|fluorouracil|Given IV
41155376|NCT02270606|DRUG|oxaliplatin|Given IV
41155377|NCT02270606|DRUG|leucovorin calcium|Given IV
41155378|NCT02270606|PROCEDURE|therapeutic conventional surgery|Undergo total mesorectal excision
41155379|NCT02592928|OTHER|Inclusion of Spirometry into the Electronic Health Records|Inclusion of the Forced Spirometry into the Electronic Health Records
41155380|NCT03451994|OTHER|Breath test|Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
41155381|NCT05765409|OTHER|TIMCA|"TIMCA is an individual therapy that will include the parents at certain points in the therapy .~It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.~Out of 10 sessions, there will be three with the parents and the adolescent together."
41155382|NCT05765409|OTHER|Treatment as Usual|"TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.~Each therapist will be asked to specify the approach used as well as the therapeutic axes."
41328659|NCT03271957|PROCEDURE|Manual rotation|Rotation of the fetal head to an anterior position at time of fuel dilation that is part of routine care
41328660|NCT01045928|DRUG|lenalidomide|Given orally
41328661|NCT01045928|BIOLOGICAL|rituximab|Given IV
41328662|NCT01045928|GENETIC|polymerase chain reaction|Correlative study
41155383|NCT05204316|OTHER|Digital Analysis of Speech|Recordings will be transcribed manually to written digital text formats, on which NLP tools such as tokenisation and lexical analysis will be performed.
40810759|NCT06586138|OTHER|STAI (State-Trait Anxiety Inventory) Scale : Psychological inventory of 20 self-report items on a 4-point scale|Patient completed STAI Scale in the 24 hours before Maintenance of Wakefulness Test during the hospitalization
40810760|NCT06598670|OTHER|tDCS|tDCS will be applied to the M1 area for 20 minutes with 5x7 cm electrodes. The intervention will be applied for eight weeks on alternate days
40810761|NCT06598670|OTHER|Conventional treatment|Breathing exercises will be performed
41155384|NCT04214548|OTHER|No Intervention|There is no intervention for this study
41155385|NCT04593771|DRUG|BCG-PPD|BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
41155386|NCT01580735|DRUG|ARQ 197|"ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd"
41155387|NCT03973645|OTHER|Patient presenting peritonitis managed with fungal research during year 2016|Patient presenting a peritoneal fungal with panfungal PCR and BDG compared to Peritonitis score (PS) and microbiological (ED direct fungal examination)
41155388|NCT02326740|DRUG|gevokizumab|
41155389|NCT02326740|DRUG|Placebo|
41155390|NCT02326740|DRUG|gevokizumab open-label|
41155391|NCT05541276|DRUG|Melatonin|Melatonin for injection 1 mg/mL
41155392|NCT05541276|DRUG|Isotonic sodium chloride solution|Sodium chloride 0.9 % for injection
41155393|NCT02498418|DRUG|Rifaximin|Tablets, generic formulation of the brand product.
41155394|NCT02498418|DRUG|Xifaxan®|Tablets, brand product.
41155395|NCT02498418|DRUG|Placebo Tablet|Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
41328663|NCT01045928|GENETIC|nucleic acid sequencing|Correlative study
41328664|NCT01045928|GENETIC|polymorphism analysis|Correlative study
41328665|NCT01045928|OTHER|flow cytometry|Correlative study
41328666|NCT01045928|OTHER|laboratory biomarker analysis|Correlative study
41328667|NCT03363919|DEVICE|NeuroStar TMS Therapy® System|The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that produces and delivers brief duration, rapidly alternating (pulsed) magnetic fields to induce electrical currents in localized regions of the cerebral cortex. It is a non-invasive tool used for the treatment of Participants with Major Depressive Disorder (MDD) who have not achieved sufficient clinical benefit from antidepressant pharmacotherapy.
41328668|NCT03363919|DEVICE|NeuroStar XPLOR®|NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS Therapy System that provides features necessary to conduct randomized controlled trials and other TMS research.
41328669|NCT01273987|PROCEDURE|rONB|Neobladder posterior wall suspended with round ligament of uterus after radical cystectomy in female with bladder cancer
41328670|NCT05656287|OTHER|SMS texts + incentives + Wisepill device for medication monitoring|For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if \>90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if \>90% medication adherence.
41328671|NCT05656287|OTHER|SMS texts only + Wisepill device for medication monitoring|For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders. All participants will also receive a Wisepill device for medication monitoring.
41481227|NCT06028503|DEVICE|Abbott FreeStyle® Libre® 3|The Abbott FreeStyle® Libre® 3 (FDA approved) consists of a single use disposable electrochemical sensing unit which is placed on the upper arm and an App for smart phones where the participant can view their glucose data, including their current glucose reading, their 'trend arrow' so participants can see how glucose is changing, and their glucose history. The FreeStyle system does not require user calibration. A sensor log will be maintained for accountability of all sensors received as well as used sensors (including the lot/serial number, expiration date, and the date). Sensors will be stored at manufacturers recommendations.
41481228|NCT06028503|OTHER|Generic Education|Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy. These sessions will also include education on diabetes nutrition guidelines and improving self-management through better food and lifestyle choices.
41481229|NCT04390321|OTHER|LLMcare|Participants will undergo 20 sessions of computerized cognitive and physical training, during a 2 month period. Both components have a duration of 30 minutes and are consecutive, but their sequence is pseudo-randomized. All sessions are conducted under supervision. Cognitive training uses the greek adaptation of the BrainHQ software (Posit Science Corporation), utilizing audiovisual stimuli, and targets memory, attention, cognitive-processing speed, orientation and social skills. Physical training is based on the WebFitForAll protocol and uses the motion sensor device Kinect. It consists of warm-up, aerobic, flexibility, strength, balance and cool down exercises.
41011457|NCT03901924|OTHER|Volume Support Mode Mechanical Ventilation|This is a spontaneous mode of mechanical ventilation that depends on the patient's efforts. A target volume (6 cc/kg of IBW), PEEP and FiO2 are set by the medical team, and the ventilator varies the inspiratory pressure support with each breath to achieve the target volume. The respiratory rate is fully dependent on the patient. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
41155396|NCT03159065|OTHER|Bilberry|Fruit beverage with bilberry and fermented oatmeal
41328672|NCT05656287|OTHER|Wisepill device for medication monitoring only|Participants (54) in the Control arm will not receive SMS reminders or mobile money. All participants will also receive a Wisepill device for medication monitoring.
41328673|NCT02084069|DRUG|Atorvastatin|
41155397|NCT03159065|OTHER|Blackcurrant|Fruit beverage with blackcurrant and fermented oatmeal
41155398|NCT03159065|OTHER|Mango|Fruit beverage with mango and fermented oatmeal
41155399|NCT03159065|OTHER|Beetroot|Fruit beverage with beetroot and fermented oatmeal
41328674|NCT02533687|PROCEDURE|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
41328675|NCT02533687|PROCEDURE|Bipolar TURP-2|Bipolar TURP
41155400|NCT03159065|OTHER|Rose hip|Fruit beverage with rose hip and fermented oatmeal
41328676|NCT02533687|PROCEDURE|Monopolar TURP|Monopolar TURP
41328677|NCT03714503|DEVICE|Retina re-attachment repair using C3F8 gas tamponade|Assigning a one day post-operative head positioning
41481230|NCT04303650|DEVICE|Ultrasound measurement of quadriceps muscle layer thickness|With patient in supine position ultrasound will be performed using a 12MHZ Transducer connected to Sonosite M Turbo machine. The probe will be placed perpendicular to the long axis of the thigh on its anterior surface at the two thirds of the length between the anterior superior iliac spine and the upper border of the patella. After identifying the muscle tissue, the thickness of the quadriceps muscle will be obtained by measuring the distance between the cortex of femur and the most superficial muscular fascia. Measurements will be performed by applying maximal compression on the probe without inflicting pain to prevent underestimation of muscle wasting linked to subcutaneous edema. measurements will be made on both sides repeatedly on ICU days 1, 3, 7, and 10. Every time three ultrasound measurements will be taken per site and the average of three measurements for each site will be used and combined to provide total muscle depth
41481231|NCT02164734|DEVICE|Endotracheal intubation|
41481232|NCT02164734|DEVICE|Laryngeal mask airway|
41328678|NCT01788280|DRUG|Fluciclitite , PET imaging, and Bevacizumab|\[18F\] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
41481233|NCT02164734|DRUG|remifentanil|additional premedication in the endotracheal intubation/INSURE arm
41328679|NCT00860119|DRUG|alprazolam sublingual tablet|1 mg alprazolam sublingual tablet, given as a single dose to each subject
41328680|NCT00860119|DRUG|alprazolam oral tablet|1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
41481234|NCT04799652|OTHER|Survey|Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.
41328681|NCT04735393|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
41328682|NCT04735393|DRUG|Placebo Comparator|Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
41328683|NCT04735393|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
41328684|NCT04735393|DRUG|Placebo Comparator|Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
41328685|NCT05127291|OTHER|Dual-task|In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
41328686|NCT01061736|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
41328687|NCT01061736|DRUG|Placebo (for sarilumab)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
41328688|NCT01061736|DRUG|Methotrexate|Same weekly dose as received prior to enrollment
41328689|NCT01061736|DRUG|Folic Acid|According to local standard
41328690|NCT05720767|DRUG|HMPL-523|HMPL-523 is a selective small-molecule SYK inhibitor.
41328691|NCT05720767|DRUG|Itraconazole|Itraconazole is an FDA approved synthetic triazole antifungal agent
41328692|NCT05720767|DRUG|Rifampin|Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
41481235|NCT01594450|BIOLOGICAL|Biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
41155401|NCT03159065|OTHER|Glucose drink|A reference glucose drink
41328693|NCT02373241|DRUG|Losartan|Standard dosing
41328694|NCT02373241|DRUG|Losartan|Experimental dosing
41328695|NCT06164613|DRUG|Cinnamomum Verum oil extract|one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
41328696|NCT06164613|DRUG|Placebo|400 mg PO Canola oil soft gel capsule
41328697|NCT01618422|OTHER|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
41328698|NCT01618422|OTHER|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
41328699|NCT06015412|DIAGNOSTIC_TEST|Radiographic classification|disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system
41155402|NCT00586430|DRUG|lorazepam|single 2 mg dose of lorazepam
41155403|NCT00586430|DRUG|placebo|single dose of placebo
41328700|NCT05794789|BEHAVIORAL|Social Identity|This group will receive the same content as the education+planning as well as two additional sessions. This includes short overviews of the benefits of PA as a family, brainstorming how a family can each assist each other in PA, and an activity for developing a family PA action plan. Behavior change techniques such as identity salience, identity similarity, and identity fit and contrast are included in the coaching session include. This will be supplemented by an organization of fun family PA roles for all members (e.g., activity planner, goal setter, supporter, etc.) to instill involvement as well as items (creation of a family PA t-shirt, family PA photos and display, etc.) to instill distinctiveness, which is a central feature of a social identity. Worksheets and discussion will be included. The second session will involve only the parent(s) to focus on parental support identity and the content is based on the behavior change principles of self-identity theory.
41328701|NCT00671983|PROCEDURE|Neurocognitive Testing|
41328702|NCT00105560|RADIATION|radiation therapy|Radiation therapy with proton beam to standard doses
41481236|NCT01594450|PROCEDURE|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
41481237|NCT00209586|DRUG|fospropofol disodium|
41328703|NCT03157921|RADIATION|transvaginal ultrasound|assessment of ovarian volume and antral follicle count
41481238|NCT05791682|DRUG|Sealant, Fissure|FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT
41481239|NCT01453894|BEHAVIORAL|Reminder and Outreach Intervention|This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
41481240|NCT04704141|DRUG|Hormone replacement therapy|A hormone replacement regimen using any medication of a number of standard treatment options
41481241|NCT04918303|DEVICE|SKNA recording|"The coupled recording of the sympathetic nervous activity of the skin and of an ECG will be carried out using the ME6000 device, CE marked, from the Bittium company.~It will be performed for a maximum period of one hour at Day 1, Post-procedure between Day 1 and discharge from hospital, and month 6"
41481242|NCT01099059|DRUG|Amantadine|Amantadine 100-150 mg depending on weight (100 mg/day for \<30 Kg and 150 mg/day for \>30 Kg)
41011458|NCT03901924|OTHER|Assist Control Mode Mechanical Ventilation|This is a controlled mode of mechanical ventilation that is independent of patient's efforts. A tidal volume (6 cc/kg of IBW), respiratory rate, PEEP and FiO2 are set by the medical team. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
41155404|NCT04200547|OTHER|Immunomonitoring-based follow-up|"Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. 3 months after the surgery, serum levels of adalimumab will be measured:~* If the level is below 5ug/mL, adalimumab treatment will be increased to every other week until the end of the study.~* If adalimumab level in the serum is above 5ug/mL, the treatment's frequency will be maintained until the end of the study."
41155405|NCT04200547|OTHER|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. If clinical relapse (CDAI \> 220 together with an increase of 70 points) and biological relapse (CRP \> 10mg/mL and fecal calprotectin \> 100 ug/g) occur, frequency of adalimumab treatment will be increased to once a week.
41155406|NCT05885464|BIOLOGICAL|BEAM-201|A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
41011459|NCT04163393|PROCEDURE|Percutaneous Coronary Intervention|PCI with robotic assistance
41481243|NCT01099059|DRUG|ritalin|ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)
41155407|NCT03847389|DRUG|Clobetasol propionate 0.05% Topical Oil|thin film application of the oil twice daily
41155408|NCT05577689|OTHER|Tissue|Tissue will be derived from patients during a standard of care procedure
41155409|NCT00357747|DRUG|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
41155410|NCT00357747|DRUG|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
41155411|NCT00092456|BIOLOGICAL|rotavirus vaccine, live, oral, pentavalent|Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
41328704|NCT03157921|DIAGNOSTIC_TEST|Hormonal levels|follicle stimulating hormone level, luteinizing hormone level and anti-mullerian hormone level
41011460|NCT04163393|DEVICE|Percutaneous Coronary Intervention using R-One assistance|PCI with robotic assistance
40810779|NCT05422534|DIETARY_SUPPLEMENT|CoQ10|Participants will receive 1800 mg/day for 12 weeks
41011461|NCT04317742|DEVICE|Sleep Healthy Using the Internet (SHUTi) Intervention Group|"SHUTi is a fully automated, interactive and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is presented in six Cores, metered out over time."
41011462|NCT04317742|DEVICE|Online Patient Education (PE) Control Group|The online PE program provides static information about: insomnia symptoms; the impact, prevalence, and causes of insomnia; when to see a doctor; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
41011463|NCT00189371|DRUG|paclitaxel, carboplatin, epoetin alpha|
41011464|NCT00003589|DRUG|cisplatin|
41011465|NCT00003589|DRUG|gemcitabine hydrochloride|
41011466|NCT00003589|DRUG|paclitaxel|
41011467|NCT04368923|DEVICE|Oxygen Therapy|Patients receive oxygen therapy
41011468|NCT04368923|PROCEDURE|Physical Therapy|Patients receive physical therapy
40810780|NCT05422534|DRUG|Placebo|Participants will receive placebo or CoQ10/day for 12 weeks
40810781|NCT05422534|BEHAVIORAL|HB-HIIT|Participants will be performed on non dialysis days. It will be video supervised exercise sessions with self directed exercises using pre-recorded bodyweight and strength exercise videos.
40810782|NCT05422534|BEHAVIORAL|Observational|Participant regular activities
40810783|NCT06614855|DRUG|C134|Initial Treatment . C134 Dose #1
40810784|NCT06614855|DRUG|C134|2nd Treatment. C134 Dose #2
40810785|NCT06614101|OTHER|Exhaled air analysis|The patient takes two breaths into two different Module In a Box devices (one measurement per device) which will give two measurements of the volatile organic compounds in the exhaled air. No estimate of blood glucose by breath will be displayed: the Module In Boxes will be set to only display the indication valid measurement/invalid measurement.
40810786|NCT04435639|OTHER|Manual lymph drainage.|"Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period."
40810787|NCT04435639|PROCEDURE|Coban compression bandage..|Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.
40810788|NCT04435639|DEVICE|Adjustable Compression Sleeve|Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
41155412|NCT00092456|BIOLOGICAL|Placebo|"Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"
41155413|NCT05788081|DRUG|golcadomide|BMS-986369 is an orally administered Cereblon-modulating compound
41155414|NCT05788081|DRUG|Nivolumab 10 MG/ML|Nivolumab is a fully humanised IgG4 blocking monoclonal antibody against PD-1.
41155415|NCT05788081|DRUG|Rituximab|Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions
41155416|NCT00365183|DRUG|Motexafin gadolinium and pemetrexed|1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
41011469|NCT01081808|BIOLOGICAL|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
40810792|NCT05332639|BEHAVIORAL|Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool|We will develop a web-based, personalized risk estimation for CD (PRE-Crohn's) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI); smoking history; NSAID use; intake of fruit, fiber, and added sugar; oral contraceptive use (females); antibiotic use; breast-feeding; pets in home; and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
40810793|NCT05332639|BEHAVIORAL|Standard Crohn's Disease Education|The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-Crohn's tool as well.
41011470|NCT02338947|PROCEDURE|Off-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions, an absorbable hemostat will be used in the sternal bone marrow. An automatic autotransfusion system will be used to recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time \>200s. The proximal anastomosis will be performed according to our guidelines. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.
41011471|NCT02338947|PROCEDURE|On-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time \>480 s. Heparin will be neutralized with 1:1 protamine sulfate. The automatic autotransfusion system will be used just in massive blood loss to recovery the red blood cells. Surgical techniques will be performed according to our guidelines.
41011472|NCT02123407|DRUG|Carbon Nanoparticles|Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
41155417|NCT02929706|GENETIC|Pre-genotype NUDT15 and optimize azathioprine dosage|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
41155418|NCT00295100|DRUG|Tamoxifen|
41155419|NCT04665349|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
41155420|NCT00246129|DRUG|Campath|Monoclonal antibody induction therapy
41155421|NCT00246129|DRUG|Daclizumab|Monoclonal antibody induction therapy
41155422|NCT01855997|DRUG|Peg-IFN alfa-2a|Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
41481244|NCT02439671|BEHAVIORAL|McGill Transition Support Program|"The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:~* Social communication (e.g. listening, perspective taking)~* Self-determination (e.g. problem-solving, self-advocacy)~* Working with others (e.g. knowing your context, teamwork)~Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.~The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages."
41328705|NCT04075539|OTHER|Home-based cycling program|"Usual care (i.e. standardized prescription of 6 sessions of outpatient physiotherapy), and~* 1 supervised session of cycling aimed at explaining how to use the connected ergometric bicycle and at designing a personalized home-based cycling program~* a 12-month home-based cycling program using connected ergometric bicycles which intensity and dose are self-determined~* 3 phone or email contacts with a care provider to deliver positive feedbacks and encouragements"
41328706|NCT04075539|OTHER|usual care|A prescription of 6 sessions of outpatient physiotherapy
41328707|NCT05082506|BEHAVIORAL|Acupressure|Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief.
41328708|NCT04666025|PROCEDURE|Biospecimen Collection|Undergo collection of nasopharyngeal swabs, blood, and saliva samples
41328709|NCT04666025|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
41328710|NCT04666025|OTHER|Electronic Health Record Review|Medical charts are reviewed
41481245|NCT00003138|BIOLOGICAL|Erythropoietin|Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.
41481246|NCT00003138|BIOLOGICAL|Filgrastim|G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.
41481247|NCT00003138|PROCEDURE|Transfusion|Red cell and platelet transfusions
41481248|NCT00376974|BEHAVIORAL|American Academy of Ophthalmology Glaucoma Educational Tape|
41481249|NCT03463993|DRUG|Tranexamic Acid|TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.
41481250|NCT03463993|DRUG|Oxytocin|5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
41481251|NCT05630092|DIAGNOSTIC_TEST|Maximal 6-minute Walk Test (Max_6MWT)|Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.
41481252|NCT05630092|DIAGNOSTIC_TEST|Normal speed 6-minute Walk Test (Nor_6MWT)|Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.
41481253|NCT04975321|DEVICE|Nu Smile Zirconia crown|Placement of an anterior primary crown restoration
40810794|NCT01051531|DRUG|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
41481254|NCT04975321|DEVICE|Nu Smile Pre Veneered crown|Placement of an anterior primary crown restoration
41481255|NCT04975321|DEVICE|Composite strip crown|Placement of an anterior primary crown restoration
40810795|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
41155423|NCT01509599|PROCEDURE|Cryotherapy: Cooling gel wrap|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy: cooling gel wrap during the home-based intervention
41328711|NCT04666025|OTHER|Questionnaire Administration|Complete questionnaire
41328712|NCT06094179|DRUG|Monoclonal antibody BAT6026|300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
41328713|NCT06094179|DRUG|sodium chloride injection|300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
41328714|NCT04172701|DRUG|Long-acting Muscarinic Antagonists (LAMA)|drug
41328715|NCT04172701|DRUG|Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)|drug
41328716|NCT06134869|PROCEDURE|Bone augmentation|Dense PTFE membranes covering an allograft biomaterial were used without any attempt to passivate the flap
41481256|NCT02138136|DRUG|Lubiprostone|12 or 24 mcg soft capsules for oral administration
41328717|NCT04137146|DEVICE|Sacral Nerve Stimulation|"Implantation of a sacral nerve neurostimulation system: A single electrode (Interstim® model 3889-28; Medtronic, Minneapolis, MN) was inserted bilaterally into the sacral foramen (S3), connected to an internal pulse generator (Medtronic Interstim~® II 3058)"
41328718|NCT04893928|OTHER|QUECOMIICAT survey|IBD-related knowledge. It will be assessed using the recently validated QUECOMIICAT (Qüestionari Coneixements Malaltia Inflamatòria Intestinal Catalunya) questionnaire (27) originally developed in Spanish. Compared with the most well-known CCKNOW (Eaden JA et al in 1999)(28), it incorporates IBD updated data (29).
41328719|NCT04893928|OTHER|Self-Efficacy for Appropriate Medication Use Scale|Treatment adherence and compliance. It will be assessed using the Self-Efficacy for Appropriate Medication Use Scale (SEAMS), a 13-item self-administered scale previously translated into Spanish and validated by Bozada-Gutiérrez K et al on a Mexican population (3). According to 13 situations asked by the items, patients stratify the level of confidence about correctly taking their medications: 1, not at all confident; 2, somewhat confident; 3, very confident. The sum of results ranges from 13 to 39 points, where higher scores indicate optimal self-efficacy for taking the pharmacological treatment.
41328720|NCT04893928|OTHER|ICTs preferences and barriers survey|"Information and communication technologies (ICTs) preferences and barriers. It will be assessed using an ad-hoc inventory designed by the authorship. It has 45 questions mainly answered through a 5-points Likert scale. This inventory was inspired by the surveys used by Mauer M et al on an international population with urticaria (11), and those used by Reich J et al (30) and Chowdhary TS et al (31) on American patients with IBD. Survey approaches aspects related to:~* Frequency of use of ten different ICTs for personal purposes;~* Frequency of use of ten different ICTs for IBD-related purposes;~* A free question about others ICTs that the patient uses for IBD-related purposes;~* Eight specific IBD-related purposes ICTs are used to;~* Assessment of ICTs for eight IBD-related purposes;~* Eight Features an IBD-related App must comprehend."
41328721|NCT04893928|OTHER|Focus group and IBD mobile App for health support (MAHS) development and validation|In stage II, a qualitative study will be performed using focus group discussion to explore the experiences and perceptions of patients with IBD using ICTs for health support in different contexts. Focus groups will be established following the Krueger and Casey guidelines (32). Collected data will address the development of an IBD MASH. The developed IBD MASH will be validated on a randomised pilot study along stage III. Methodology and ethical aspects of stage II and III will be defined in another proposal, after stage I preliminary findings.
41328722|NCT03000634|DRUG|Elotuzumab|Administered through a small tube that goes directly into the vein
41328723|NCT03000634|DRUG|Bortezomib|Administered as a subcutaneous injection under the skin
41328724|NCT03000634|DRUG|Lenalidomide|Capsule taken by mouth
41328725|NCT03000634|DRUG|Dexamethasone|Taken by mouth
41328726|NCT05868980|OTHER|vital signs by postpartum position|Evaluation of vital signs and NIRS values in 4 different positions after birth
41328727|NCT04020406|BIOLOGICAL|Antibacterial Activity|Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates
41328728|NCT00515580|PROCEDURE|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
41328729|NCT04060576|PROCEDURE|Dry needling treatment with a thinner needle|We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.
41328730|NCT04060576|PROCEDURE|Dry needling treatment with a medium-sized needle|We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.
41328731|NCT04060576|PROCEDURE|Dry needling treatment with a thickest needle|We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.
40810796|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
40810797|NCT06542978|DEVICE|40Hz stimulation|Exogenous 40HZ stimulation is a physical intervention that can drive oscillations in the gamma range, and the oscillations and pulses caused at the corresponding frequency can lead to a significant reduction in β-amyloid, reverse tau hyperphosphorylation, and thereby improve the cognitive function of patients.
40810798|NCT06342492|OTHER|Coronary Sinus Lead Revision|Coronary Sinus Lead Revision
41011473|NCT02123407|PROCEDURE|Gastrectomy with D2 dissection|In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
41155424|NCT01509599|PROCEDURE|Usual care|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap (sham) during the home-based intervention
41328732|NCT05008172|PROCEDURE|Splenic Artery Embolization|The decision for proximal or distal (selective) embolization is at the discretion of the Interventional Radiologist. For patients with angiographically evident injury, the choice of embolization site will be left to the discretion of the operator. For patients without angiographically evident injury, proximal splenic embolization will be performed with approved materials (coils or plugs for most patients) within the main splenic artery. The embolization endpoint will be hemostasis in the main splenic artery.
41328733|NCT02494219|PROCEDURE|Rapid Immunochromatographic streptococcal test|Throat swab obtained for rapid strep test in addition to throat culture,in order to check the accuracy of Rapid Immunochromatographic streptococcal test in detection of streptococcal pharyngitis
41481257|NCT05009836|DRUG|Savolitinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
41481258|NCT05009836|DRUG|Placebo|Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse
41155425|NCT02580019|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
41155426|NCT05335343|OTHER|no intervention|no intervention
41155427|NCT01047306|OTHER|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
41155428|NCT01767636|DRUG|Pazopanib Hydrochloride|Given PO
41328734|NCT04409301|OTHER|My Special Aflac Duck (MSAD)|The hospital Child Life Specialist or research team member will introduce the child and parent to My Special Aflac Duck MSAD), with instructions on how to use the duck. MSAD is a robotic toy with an associated app. Children can use MSAD for play, exploring feelings, and describing medical procedures. Intervention hospitals are permitted to provide their standard of care from Child Life with the exception of providing stuffed animal-like objects. Data will be recorded by Child Life or research team member on what tools are used outside of the MSAD.
41328735|NCT04409301|BEHAVIORAL|Standard of care control|Sites will follow their individual standard of care from Child Life. Data will be recorded by Child Life on what tools are used. After completion of the 3-month survey, patients at hospitals assigned to not initially receive MSAD will each receive a MSAD.
41328736|NCT02923908|OTHER|Noldus Facereader 7|A video recording of a subject's facial expressions while tasting a sweet, bitter, and neutral flavored liquid will be analyzed using Noldus Facereader 7 software.
41328737|NCT02923908|OTHER|Voice Recording|A voice recording will be made for the duration of the tasting period.
41481259|NCT05410366|OTHER|Safe harbor clinical practice guideline|A safe harbor is a special type of clinical practice guideline which, under existing federal law, may serve as the legal standard of care, not just evidence of the standard of care. If a patient with a safe harbor condition satisfies all safe harbor inclusion criteria and does not meet any exclusion criteria, no imaging is required, and the patient may be discharged with specific instructions. If a patient is excluded from the safe harbor, then imaging decisions are per customary practice. The safe harbor clinical practice guidelines are provided to treating ED physicians, but they are not obligated to use them. The safe harbor pathways do not limit the diagnostic and therapeutic approach patients and physicians undertake during a clinical encounter. They have the liberty in this decision to proceed jointly down a clinical pathway most appropriate to the individual clinical circumstance.
41328738|NCT02923908|OTHER|5-Point Facial Hedonic Scale|A 5-point facial hedonic scale will be given to the participant to complete prior to the administration of any test substances and about 5, 10, and 30 minutes after the administration of each test substance.
41155429|NCT04283058|DRUG|Ketamine|d. Ketamine 0.5mg/kg\* dose IV in 50 mL NS will be infused at a set non-titratable rate over 40 minutes or Ketamine 1mg/kg\* dose IV in 50 mL NS will be infused at a set rate non-titratable over 90 minutes. The dose that the subject will receive will be determined by the Intensive Care Unit Attending based on patient symptoms. Ketamine administered at these doses may result in the following adverse reactions such as excessive sedation or drowsiness, or unpleasant hallucinations, agitation or dysphoric reaction, nausea or increased oral secretions.
41011474|NCT01362907|DEVICE|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
41328739|NCT02923908|OTHER|Follow-Up Questionnaire|Participants will be asked a few questions about each test agent after tastings.
41328740|NCT00444080|PROCEDURE|Trabeculectomy|"Standard trabeculectomy procedure~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of a limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Creation of fistula 1mm x 2mm in size~5. Iridectomy~6. Suturing the scleral flap~7. Repositioning of conjunctiva with sutures After procedure, antibiotics \& steroids are administered topically; eye is covered with a pad - patient is discharged."
41155430|NCT02596178|DEVICE|Electrical Impedance Tomography|Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
41011475|NCT01362907|DEVICE|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
41011476|NCT02510846|BEHAVIORAL|Intensive educative management|5 hours a week
41011477|NCT05699668|DEVICE|OCT Angiography|"2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds."
41011478|NCT02880371|DRUG|ARRY-382|ARRAY-382 will be taken by mouth once daily at a fixed dose.
41011479|NCT02880371|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
41328741|NCT00444080|DEVICE|Ex-PRESS mini shunt|"Ex-PRESS implantation procedure:~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus~5. Prior to implantation, a thorough mobility check should be performed~6. Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision~7. Withdrawal of introducer~8. Tucking plate under the scleral flap, and verification of its position~9. Suturing scleral flap After implantation procedure, antibiotics \& steroids administered topically; eye is covered with a pad - patient is discharged."
41328742|NCT03258593|DRUG|Durvalumab|Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
41011480|NCT05352022|BEHAVIORAL|Monthly Unconditional Financial Incentive|No requirements will be placed on how or where funds will be spent.
41011481|NCT05352022|BEHAVIORAL|Weekly Food Purchasing Financial Incentive|Incentive for healthy food purchases
41011482|NCT05352022|BEHAVIORAL|Glycemic Control Financial Incentive|Incentive for absolute drop in HbA1c
41011483|NCT05352022|BEHAVIORAL|Diabetes Education|mailed education information
41011484|NCT01111656|DRUG|Interferon beta-1b group|Patients receive interferon beta-1b 250ug subcutaneously every other day
41011485|NCT01111656|DRUG|Interferon beta-1b/Atorvastatin group|Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
41011486|NCT00884234|OTHER|Vehicle Control|Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2
41155431|NCT01838499|BIOLOGICAL|MEDI8968|SC injection at baseline, Week 4 and Week 8
41155432|NCT01838499|BIOLOGICAL|Saline|SC injection at baseline, Week 4 and Week 8
41328743|NCT03258593|DRUG|Vicineum|Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
41328744|NCT03258593|DRUG|Acetaminophen|Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.
41328745|NCT03258593|DRUG|Antihistamine|Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.
41328746|NCT03258593|PROCEDURE|Bladder Biopsy|Bladder biopsy at screening and every 3 months before each cystoscopy per schema.
41481260|NCT03145831|DRUG|Somavaratan|All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
41481261|NCT01462318|DRUG|Midazolam|5 mg
41481262|NCT01462318|OTHER|Caffeine|200 mg
41481263|NCT01462318|DRUG|S-warfarin|10 mg
41481264|NCT01462318|OTHER|Vitamin K|10 mg
41011487|NCT00884234|DRUG|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 at Baseline (Day 0) and Week 2
41011488|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-free diet|The probiotic and gluten-free diet group (PRO-GFD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses, comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175, and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
41481265|NCT01462318|DRUG|Omeprazole|40 mg
41481266|NCT01462318|DRUG|Dextromethorphan|30 mg
41481267|NCT01462318|BIOLOGICAL|BIIB019 (Daclizumab)|150 mg in 1 ml PFS
41481268|NCT00345020|PROCEDURE|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
41481269|NCT03795831|DEVICE|ClearSight feasibility testing|A cuff is placed on a finger of the patient. The ClearSight system uses a volume clamp technology allowing measuring of continuous blood pressure waveform. Note: There will only be observational recordings, no interventions
41481270|NCT03064438|DRUG|ACCU-D1|ACCU-D1
41481271|NCT03064438|DRUG|Vehicle|Placebo Comparator
41481272|NCT04527328|DEVICE|AKST1210|AKST1210
41481273|NCT04527328|OTHER|Sham Control (No Intervention)|A covered surrogate object of similar size and shape as the investigational device
41481274|NCT04527328|PROCEDURE|Hemodialysis|Hemodialysis
41155433|NCT04675671|OTHER|Preoperative and postoperative anxiety measurement [Spielberger's State Anxiety Scale (STAI-S)] and [ Spielberg's State-Trait Anxiety Inventory (STAI-T) ]|The postoperative pain is measured and evaluated by Visual Analog Scale (VAS= 0 = no pain to 10 = worst pain)
41155434|NCT06042257|DRUG|Guanfacine Hydrochloride Immediate Release|0.5 mg capsules
41155435|NCT06042257|DRUG|Placebo|Matching placebo capsule
41155436|NCT00273650|DRUG|methylcobalamin|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
41328747|NCT03258593|PROCEDURE|TURBT|Transurethral resection of a bladder tumor (TURBT) at screening and every 3 months before each cystoscopy per schema.
41328748|NCT03258593|PROCEDURE|Cystoscopy|Urine cytology at screening and every 3 months before each cystoscopy per schema.
41328749|NCT03258593|DIAGNOSTIC_TEST|Urine cytology|Urine cytology at baseline and every 3 months before each cystoscopy per schema.
41481275|NCT05225974|DRUG|Liraglutide injection|At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection
41481276|NCT05225974|DRUG|Liraglutide injection(Victoza®)|At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection
41481277|NCT03293381|DEVICE|additional biopsies|additional biopsies
41481278|NCT03254602|DEVICE|Intense Therapeutic Ultrasound Treatment|
41481279|NCT01405131|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
41481280|NCT01405131|DRUG|methylprednisolone|tablets 32 mg single dose
41481281|NCT03376620|DRUG|1,4-Diaminobutane|Daily application to surgical breast scars of 1,4 diaminobutane on the active side
41481282|NCT03376620|DRUG|10% Urea cream|Daily application to surgical breast scars of 10% Urea cream on the sham side
41481283|NCT03639519|DRUG|Ascorbic Acid 500Mg Chew Tab|Ascorbic acid will be administered at the night before surgery and will be continued for five days
41481284|NCT03639519|OTHER|Carbonated orange beverage|The carbonated orange beverage will be administered at the night before surgery and will be continued for five days
41481285|NCT04519034|OTHER|no intervention|There will be no intervention
41481286|NCT02725775|DIETARY_SUPPLEMENT|100% Florida OJ|
41481287|NCT02725775|DIETARY_SUPPLEMENT|Placebo Equicaloric Orange Drink|
41481288|NCT00562770|DRUG|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
41481289|NCT00562770|DRUG|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
41481290|NCT03219931|DRUG|Bifidobacterium breve BR03 and Bifidobacterium breve B632|This is the active product containing 108 viable cells/strain
41481291|NCT03219931|DRUG|Placebos|This is the placebo product containing a similar product without bifidobacterium inside.
41481292|NCT00280878|DRUG|gemcitabine|
41481293|NCT00280878|DRUG|vinorelbine|
41481294|NCT00280878|DRUG|ifosfamide|
41481295|NCT00280878|DRUG|rituximab|
41481296|NCT02147249|DRUG|antibiotic treatment|Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
41155437|NCT00273650|OTHER|saline placebo|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
40810802|NCT06517017|DRUG|Isatuximab|Subcutaneous isatuximab will be administered weekly on a 28-day cycle during the first two cycles, and every two weeks of a 28-day cycle thereafter. Dexamethasone will be administered on the days of isatuximab administration and can be discontinued after two cycles of therapy, or continued at discretion of investigator. Lenalidomide, will be added after two cycles of therapy have been completed.
41155438|NCT00003359|DRUG|batabulin sodium|
41155439|NCT03264599|DEVICE|transabdominal ultrasound|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk
41011489|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-free diet|The placebo and gluten-free diet group (PLA-GFD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
41011490|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-containing diet|The probiotic and gluten-containing diet group (PRO-GD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
41011491|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-containing diet|The placebo and gluten-containing diet group (PLA-GD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
41155440|NCT00935129|DEVICE|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
41155441|NCT00935129|DEVICE|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
41155442|NCT02213224|DRUG|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
41011492|NCT05190458|OTHER|High Velocity Nasal Insufflation|High velocity nasal insufflation (HVNI), a form of HFNC that utilizes a small bore nasal cannula to generate higher velocities of gas delivery than HFNC which uses large bore cannula, has the ability to accomplish complete purge of extra thoracic dead space at flow rates of 35 litres/min and may be able to provide ventilatory support in patients with respiratory failure in addition to oxygenation support in patients with overlap syndrome.
41328750|NCT03258593|DIAGNOSTIC_TEST|Electrocardiogram|Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.
40810811|NCT03763656|DRUG|Oral Hydroxyurea (100 mg/mL) Solution|Participants received Oral Hydroxyurea 15 mg/kg once daily. Escalated by 5 mg/kg/day every 8-12 weeks until maximum tolerated dose achieved, up to a maximum 35 mg/kg/day.
41328751|NCT03258593|DIAGNOSTIC_TEST|CT|Computed tomography (CT) at screening and every 12 months while on study.
41328752|NCT03258593|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) at screening and every 12 months while on study.
41328753|NCT04733872|DIETARY_SUPPLEMENT|placebo|subjects drank 50 ml , 1 bottle a day for 8 week
41328754|NCT04733872|DIETARY_SUPPLEMENT|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
41481297|NCT01250483|OTHER|PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography|
41011493|NCT05190458|OTHER|Non-invasive mechanical ventilation|Noninvasive ventilation (NIV) refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube).
41011494|NCT01040429|DRUG|Clonidine|"Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients \< 35 kg; 50 microgram (2 capsula) x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients \< 35 kg; 25 microgram (2 capsula) x 2/day for patients \> 35 kg."
41011495|NCT01040429|DRUG|Lactose capsula|"Day 1-56 (week 1-8): 1 capsula x 2/day for patients \< 35 kg; 2 capsula x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients \< 35 kg; 1 capsula x 2/day for patients \> 35 kg"
41011496|NCT06107491|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
41011497|NCT06107491|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
41011498|NCT00394966|DRUG|SCH 619734 Dose 1|SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
41011499|NCT00394966|DRUG|SCH 619734 Dose 2|SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
41011500|NCT00394966|DRUG|SCH 619734 Dose 3|SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
41328755|NCT02299713|DEVICE|Electroacupuncture|Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
41328756|NCT01928563|DRUG|Dapoxetine|
41328757|NCT01928563|DRUG|Udenafil|
41328758|NCT01928563|DRUG|Udenafil+Dapoxetine|
41328759|NCT06527625|BEHAVIORAL|Cultural Arts Program|9-session group art program using Chinese calligraphy as the channel for gaining emotional awareness and facilitating expression
41328760|NCT06527625|BEHAVIORAL|Treatment as usual|Treatment as usual provided in local community aged care centres
41328761|NCT03061812|DRUG|Rovalpituzumab tesirine|Powder for solution for infusion in vials.
41328762|NCT03061812|DRUG|Topotecan|Powder or solution for infusion in vials. Topotecan is commercially available as both a powder and solution for infusion. Availability will vary by region.
41328763|NCT03061812|DRUG|Dexamethasone|Oral tablet.
41328764|NCT05741060|DRUG|S-equol|Experimental drug
41328765|NCT05741060|DRUG|Placebo|Placebo - 10 mg per day for 24 months of tablets that will be the same size/shape/color as the s-equol tablets.
41328766|NCT05149612|OTHER|Heat Therapy|Patients in the intervention group will be treated with hot water bags twice, 20 minutes in the morning and 20 minutes in the evening, starting four hours after the operation until discharge. In accordance with the literature, the water bag filled with 55 ± 2°C hot water will be wrapped with 2 towels. The water bag will be applied to the shoulder area while the patient is in the fawler or semi-fawler position. After 20 minutes, the hot application will be terminated. Pain and physiological parameters of the patients will be evaluated at the 0th minute, 30th minute, 4th hour, 12th hour, 24th hour and 48th hour postoperatively. At the same time, when individuals have pain, analgesics will be administered at the request of the physician.
41328767|NCT00099788|DRUG|Ranolazine|IV to oral transition.
41481298|NCT00161382|BEHAVIORAL|HIV, STD, and pregnancy prevention curriculum|"This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits."
41481299|NCT00161382|BEHAVIORAL|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
41011501|NCT00394966|DRUG|SCH 619734 Dose 4|SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
41328768|NCT00099788|DRUG|Placebo|IV to oral transition.
41328769|NCT01451398|DRUG|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
41011502|NCT00394966|DRUG|Placebo|Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
41011503|NCT00779454|DRUG|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
41011504|NCT00779454|DRUG|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
41011505|NCT04433897|OTHER|Questionnaire|"All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale"
41011506|NCT03689127|DEVICE|Heated breathing circuit on|Heated breathing circuit will be turned on.
41011507|NCT03689127|DEVICE|Heated breathing circuit off|Heated breathing circuit will be turned off.
41011508|NCT00835497|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
41011509|NCT00835497|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
41011510|NCT00200226|DRUG|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
41011511|NCT00200226|DRUG|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
41011512|NCT06333626|DIETARY_SUPPLEMENT|multi-vitamin carbohydrate|oral multi-vitamin carbohydrate beverage
41011513|NCT00261482|DRUG|norelgestromin + ethinyl estradiol|
41011514|NCT05493267|DRUG|Vγ2Vδ2 T lymphocyte-based immunotherapy|Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
41011515|NCT05493267|DRUG|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
41011516|NCT03474718|BIOLOGICAL|Platelet-rich Plasma Left Side|Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
41011517|NCT03474718|BIOLOGICAL|Platelet-rich Plasma Right Side|Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
41011518|NCT05430789|BEHAVIORAL|5As brief advice|"Participants will receive brief face-to-face advice following a 5As model at baseline:~1. Ask: Smoking patients will be asked about their smoking status.~2. Advise: Smoking patients will be advised to quit in a clear and personalised manner, with a focus on smoking-related diseases.~3. Assess: Smoking patients will be assessed for their readiness to quit by assessing their self-efficacy and perceived importance.~4. Assist: Those who are ready to quit will be assisted in setting a quit plan.~5. Arrange: Refer to smoking cessation services."
41011519|NCT05430789|BEHAVIORAL|Self-help e-booklet|"A 12-page generic self-help smoking cessation e-booklet via IM apps, including:~1. Highlights of the absolute risk of death due to smoking;~2. Smoking and diseases management;~3. Ten horrible pictorial warnings of health consequences of smoking and second-hand smoking;~4. Benefits of quitting;~5. Methods to quit and handle. withdrawal symptoms."
41011520|NCT05430789|BEHAVIORAL|Nurse-led mHealth intervention|Participants will receive real-time mHealth behaviour and psychosocial support for 12 weeks after baseline through IM apps. mHealth intervention consists of two main parts: regular instant messaging on smoking cessation and personalized real-time mHealth chatting on smoking and disease (including active referral to smoking cessation service)
41011521|NCT05430789|BEHAVIORAL|Regular intervention|Participants will receive text messages using IM app with content on general health and reminding the importance of participating in the follow-up surveys and biochemical validation for quitting.
41011522|NCT03872180|DRUG|Bendamustine|Given IV
41011523|NCT03872180|BIOLOGICAL|Obinutuzumab|Given IV
41011524|NCT03872180|DRUG|Venetoclax|Given PO
41011525|NCT01879696|DEVICE|ECSPRESS catheter with active vacuum|
41011526|NCT05709184|COMBINATION_PRODUCT|Lyophilized fecal microbiome transfer|Five days of vancomycin followed by five days of lyophilized fecal microbiome transfer, administered in a loading dose of 15 capsules, and a daily maintenance dose of 10 capsules.
41011527|NCT05709184|DRUG|Vancomycin|Ten days of oral vancomycin 125 mg four times daily
41011528|NCT01563250|DEVICE|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
41011529|NCT04296175|DRUG|Epirubicin|90mg/m2, d1 every 2 or 3 weeks
41011530|NCT04296175|DRUG|CTX|600mg, d1 every 2 or 3 weeks
41011531|NCT04296175|DRUG|Paclitaxel|80mg/m2,d1,d8,d15, every 3 weeks
41328770|NCT01451398|DRUG|Technosphere Powder|Placebo Comparator
41011532|NCT04296175|DRUG|ddEpirubicin|90mg/m2, d1 every 2 weeks
41011533|NCT04296175|DRUG|ddCTX|600mg, d1 every 2 weeks
41011534|NCT04296175|DRUG|Paclitaxel(with carbo)|80mg/m2,d1,d8,d15, every 4 weeks
41011535|NCT04296175|DRUG|Carboplatin|AUC=2,d1,d8,d15, every 4 weeks
41011536|NCT00544596|DRUG|R-(-)-gossypol acetic acid|Given orally
41328771|NCT04717778|DIETARY_SUPPLEMENT|Comparison of salivary pH after consuming milk of origin vegetable vs cow's milk|They were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).
41011537|NCT00544596|DRUG|cisplatin|Given IV
41011538|NCT00544596|DRUG|etoposide|Given IV
41011539|NCT05410652|DIAGNOSTIC_TEST|Detection of fecal samples with diagnostic kit|The 23S rRNA mutation site of clarithromycin and gyrA mutation site of levofloxacin were detected by Helicobacter Pylori fecal Gene Mutation Detection Kit.
41011540|NCT05410652|DIAGNOSTIC_TEST|Sanger Sequencing group|Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing
41155443|NCT02213224|DRUG|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
41328772|NCT02854553|PROCEDURE|Transversus abdominis plane block|ultra sound guides Transversus abdominis plane block
41011541|NCT05410652|DIAGNOSTIC_TEST|Bacterial culture and drug sensitivity test of gastric mucosa samples|First, a sample of the patient's gastric mucosa will be obtained through gastroscopy. Then, Helicobacter pylori culture and drug sensitivity test can be carried out. Finally, the resistance data of Helicobacter pylori to clarithromycin and levofloxacin will be obtained.
41011542|NCT03409692|DIAGNOSTIC_TEST|Gene Expression Profiling|SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling.
41011543|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
41011544|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
41011545|NCT06187545|DEVICE|Minimum viable prototype|Deep sedation in critical ill patients using minimum viable prototype
41011546|NCT06187545|DEVICE|Usual care|Deep sedation without minimum viable prototype
41011547|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
41011548|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
41011549|NCT06509100|DEVICE|Device: Altitudes USA|Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self- care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
41011550|NCT02126254|DEVICE|Hemodynamic group|NICAS guided treatment
41011551|NCT00602303|DRUG|Torsemide|
41011552|NCT01455116|PROCEDURE|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
41011553|NCT00669357|DEVICE|Abiocor Implantable Replacement Heart|Replacement of heart
41155444|NCT02213224|DRUG|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
41155445|NCT00184496|DRUG|Methadone|To methods for switching morphine to methadon. Stop-and go versus overlap
41328773|NCT02854553|PROCEDURE|rectus sheath block|ultrasound guided rectus sheath block
41328774|NCT02521857|DRUG|ALKS 5461|Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
41328775|NCT02223429|DRUG|Oxytocin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
41328776|NCT02223429|DRUG|Vasopressin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
41328777|NCT02223429|DRUG|Placebo|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
41155446|NCT01953471|OTHER|Allergic rhinitis|Questionnaire
41328778|NCT01679561|DRUG|intralipid|intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
41328779|NCT04035538|DRUG|CKD-320, D012|R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
41328780|NCT02747446|DIETARY_SUPPLEMENT|added sugar|isocaloric substitution of added sugars (honey or FG) for starch
41155447|NCT05952908|OTHER|Proficiency-Based Progression simulation training|The simulation-based training curriculum is delivered - with proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
41011554|NCT06250738|BEHAVIORAL|Mindfulness-based Stress reduction program: Virtual|Through mindfulness meditation and a series of carefully crafted exercises, MBSR equips individuals with powerful tools to manage stress, reduce anxiety, and enhance their overall well-being. Participants will complete 4 weekly virtual sessions covering topics like introduction to stress and its consequences, awareness of sensations, and thoughts, mindful eating, and mindful walking.
41011555|NCT06250738|BEHAVIORAL|Home exercises|Following each virtual session, participants will be given home exercises like practicing awareness of breathing, awareness of thoughts, and awareness of eating.
41011556|NCT01844258|PROCEDURE|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
41011557|NCT01844258|PROCEDURE|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
41011558|NCT05692141|DEVICE|ultrasound|For each lesion, ultrasound Elastography would be performed using a Linear probe ;
41011559|NCT03667339|PROCEDURE|Direct Anterior Total Hip Arthroplasty|Direct Anterior Total Hip Arthroplasty
41011560|NCT02213276|OTHER|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
41011561|NCT02213276|OTHER|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
41011562|NCT02086435|PROCEDURE|Extracorporeal morcellation|"patients treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
41011563|NCT02086435|PROCEDURE|Intracorporeal morcellation|patients treated with standard intracorporeal morcellation, using reusable electronic device
41011564|NCT01285206|DEVICE|Carbon polymer warming blanket|Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
41011565|NCT02869971|DEVICE|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
41011566|NCT02869971|DRUG|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
41011567|NCT02872636|DEVICE|Spinal catheter insertion with extracorporeal filtration of CSF|Extracorporeal filtration of CSF
41011568|NCT04484246|OTHER|Prevalence of sarcopenia in older patient with prostate cancer|All patients are screened for sarcopenia with the SAR-F questionnaire test score ≥4/10 suspected of sarcopenia will undergo a dual-X-ray exam to dertemine their skeletal muscle mass and the prevalence of sarcopenia before oncological treatment.
41011569|NCT02317159|DRUG|Imatinib|400mg imatinib qd PO
41011570|NCT05508061|DRUG|Insulin Lispro Cartridge [Lyumjev]|Administration of Lyumjev in combination with the AP system
41011571|NCT05508061|DRUG|Insulin Lispro Cartridge|Administration of Humalog in combination with the AP system (standard therapy)
41328781|NCT02678637|OTHER|MRI and muscle dynamometer|
41011572|NCT00850200|RADIATION|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
41011573|NCT00850200|RADIATION|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
41011574|NCT00850200|RADIATION|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
41011575|NCT05421208|DIAGNOSTIC_TEST|Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls|Inflammatory and immune profile of post-COVID-19 POTS patients. Reduced PNS activity (vagal tone) in relation to persistent inflammation.
41011576|NCT05421208|DIAGNOSTIC_TEST|Levels of inflammatory cytokine ( IL-6) in controls|Inflammatory and immune profile of healthy controls. Controls are the subjects who recovered from COVID-19 infection with no sequelae.
41011577|NCT05421208|DIAGNOSTIC_TEST|Effect on inflammation after chronic PNS stimulation|Inflammatory biomarkers after restoring PNS function in post-COVID-19 POTS patients, by chronic transcutaneous vagus nerve stimulation (tVNS) in post COVID-19 POTS patients
41011578|NCT04186910|BEHAVIORAL|Control group|The control group will carry the Fitbit for the entire period of the recovery but will receive no feedback and will not have the app downloaded onto the telephone.
41011579|NCT04186910|BEHAVIORAL|Feedback group|The feedback group will carry the Fitbit for the entire period of the recovery and will receive daily feedback on amount of physical activity carried out and percentage completed of target behavior at the end of the day from an app downloaded on their telephone. The feedback group will also participate in weekly one hour meetings focused on enhancing behavioral strategies to increase self-efficacy and motivation. They will also have their fitbit data analyzed and an agreed upon target of daily activity level increase.
41155448|NCT05952908|OTHER|Traditional simulation training|The simulation-based training curriculum is delivered - without proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
41155449|NCT03741309|OTHER|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks.
41155450|NCT03741309|OTHER|Calcium sodium phosphosilicate|Calcium sodium phosphosilicatand VAS score assessed at Baseline, 2weeks, 6 weeks.
41155451|NCT03741309|OTHER|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
41155452|NCT01765699|DEVICE|Primary knee arthroplasty|Patients undergoing primary knee arthroplasty
41328782|NCT01027104|OTHER|Education|Firearm injury prevention anticipatory guidance curriculum
41328783|NCT03920878|DRUG|Aflibercept injected Pre- and Post-operatively|Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).
41155453|NCT05740371|DRUG|Argatroban|"Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.~If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.~In cases ACT \> 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.~As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.~Depending on clinical relevancy further ACT assessments were possible."
41155454|NCT03068676|BEHAVIORAL|Space from Depression|internet-delivered CBT
41155455|NCT03068676|BEHAVIORAL|Space from Anxiety|internet-delivered CBT
41155456|NCT05069844|DIETARY_SUPPLEMENT|Gum chewing for 2 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
41155457|NCT05069844|DIETARY_SUPPLEMENT|Gum chewing for 4 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
41155458|NCT03086070|DRUG|Omeprazole 20mg|omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
41011580|NCT01578044|BEHAVIORAL|Intervention|"1. Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~2. Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.~3. Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
41011581|NCT01578044|OTHER|Control|Usual care
41011582|NCT04394416|DRUG|Imatinib|Therapeutic
41155459|NCT03086070|DRUG|Placebo oral capsule|Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
41155460|NCT02806817|DRUG|ME-344|ME-344 is a synthetic small molecule mitochondrial inhibitor based on the isoflavan ring structure. ME-344 is a chiral compound, and is manufactured predominantly as a single stereoisomer that is dextrorotatory. As a stereoisomeric drug with two chiral centers, ME-344 is one of four potential stereoisomers. The current manufacturing process produces a racemic mixture of two of those stereoisomers, which are enantiomers, and ME-344 is separated from the levorotatory enantiomer by chromatography in the final step.
41155461|NCT02806817|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
41155462|NCT02806817|OTHER|Normal saline|Use saline as placebo
41155463|NCT00774306|DRUG|phenytoin|Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
41155464|NCT00774306|DRUG|valproate|Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
41155465|NCT00774306|DRUG|levetiracetam|Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
41155466|NCT04512560|BEHAVIORAL|Surgical Training using Structured Remote Surgical Coaching in addition to Conventional Surgical Training|General surgery residents (PGY 1-5) will provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon. The coach will identify key moments or themes for discussion on how to improve technical skills and reduce intra-operative errors during five, 30-45 minute remote coaching sessions .
41155467|NCT04512560|BEHAVIORAL|Surgical Training using Conventional Training Program|General surgery residents (PGY 1-5) will continue their usual residency training.
41155468|NCT03630458|OTHER|Pearl millet couscous - made in Senegal|Pearl millet couscous (made in Senegal) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
41155469|NCT03630458|OTHER|Pearl millet couscous - made in USA|Pearl millet couscous (made in USA) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
41155470|NCT03630458|OTHER|Pearl millet thick porridge|Pearl millet thick porridge was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
41155471|NCT03630458|OTHER|Wheat couscous|Wheat couscous was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
41155472|NCT03630458|OTHER|White rice|White rice was tested as a comparator for gastric emptying rate, glycemic response, fermentability, and appetitive response.
41155473|NCT06376344|OTHER|myofascial release with tennis ball|Movement of the Tennis Ball on the Sole of the Foot: The tennis ball is moved under the foot by back and forth movements and by applying pressure. The aim is to briefly keep the pressure of the ball on the body and the stress indicated by the massage on.
41155474|NCT00927316|BIOLOGICAL|E. coli 83972|"Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml."
41328784|NCT03920878|DRUG|Aflibercept injected intraoperatively|Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
41328785|NCT01961089|DEVICE|Galilei Lens Professional|Measurement device
40810826|NCT05041907|DRUG|Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7
40810827|NCT05041907|DRUG|Nitazoxanide|Nitazoxanide 1.5g BD 7/7
40810828|NCT05041907|DRUG|Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7
40810829|NCT05041907|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg D0 BD and 400MG OD for a further 6/7
40810830|NCT05041907|OTHER|No treatment|No treatment (except antipyretics- paracetamol)
41011583|NCT04394416|DRUG|Placebo oral tablet|Placebo
41011584|NCT02143843|DRUG|Bimatoprost|Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
41328786|NCT01961089|DEVICE|IOLMaster|Measurement device
41328787|NCT01961089|DEVICE|Lenstar|Measurement device
41328788|NCT04582604|DRUG|modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine|Day -15 to -14 ： Decitabine 20 mg/m2/day, Ruxolitinib 70mg bid; Day-10： Cytarabine 1.6 g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9： Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 to -7： Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 50mg bid; Day-6: Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid; Day-4： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 20mg bid; Day-3： Carmustine 250mg/m2/day iv, Ruxolitinib 10mg bid; Day-2： Ruxolitinib 5mg bid; Day-1： Ruxolitinib 5mg qd;
41328789|NCT03905668|OTHER|Video Monitoring|Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
41328790|NCT03905668|OTHER|Accelerometer Monitoring|Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
41328791|NCT03905668|OTHER|Electromyographic Monitoring|Patients may have electromyographic monitoring for up to seven days while in the ICU.
41328792|NCT03905668|OTHER|Noise Level Monitoring|Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
41328793|NCT03905668|OTHER|Light Level Monitoring|Patients may have light level monitoring for up to seven days while in the ICU.
41328794|NCT05679609|DEVICE|incentive spirometry|It is flow-oriented that has 3 chambers, (600, 900, and 1200 cc/s) and it has a mouthpiece and a ball in each chamber. After a quiet exhalation, each participant was instructed to take slow full inspirations and to keep as long as he can for at least 5 seconds, then he slowly expires. The device is used every hour at least 5 to 10 times in the session during wake time.
41328795|NCT00247559|BIOLOGICAL|Botulinum toxin type A|
41328796|NCT02760160|OTHER|Reconstituted grape powder|To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) \[114, 217, 343, 500, 619, 848\].
41328797|NCT04159818|DRUG|Nivolumab|240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards
41328798|NCT04159818|DRUG|Cisplatin|40mg/m2, weekly for two weeks
41328799|NCT04159818|DRUG|Low dose doxorubicin|15mg flat dose, weekly for 8 weeks
41328800|NCT01248403|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
41328801|NCT01248403|DRUG|RAD001|RAD001 10mg (2 x5 mg tablets / day) d1-d28
41328802|NCT04491214|OTHER|quality of live assessment|quality of live assessment 3 moth and 6 moth after ointensive care hospitalisation using SF36.
41328803|NCT06301594|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week"
41328804|NCT01410162|DRUG|Tacrolimus|tacrolimus extended release capsules vs Prograf
41328805|NCT00607126|DEVICE|Lokomat|locomotor training using body weight support on a treadmill
41328806|NCT00607126|PROCEDURE|resistive training|resistive training using theraband and/or weights
40810831|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
41328807|NCT05889195|DIAGNOSTIC_TEST|Cxbladder urine test|Cxbladder tests uses mRNA and DNA biomarkers in the urine to direct the management of UC from diagnosis to surveillance for disease recurrence.
41155475|NCT02350127|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
41155476|NCT02350127|BEHAVIORAL|Usual Care|Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
41155477|NCT02042625|PROCEDURE|Nasopharyngeal|
41328808|NCT00346255|DRUG|BB-10901|dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.
41328809|NCT03097029|DRUG|Pancreatic Enzyme|All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
41481300|NCT04235699|OTHER|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
41481301|NCT00876018|OTHER|Nutritional supplement|Fortified nutritional powder
41481302|NCT00876018|OTHER|Placebo|Un-fortified nutritional powder
40810832|NCT05041907|DRUG|Fluoxetine|Fluoxetine 40mg OD for 7/7
40810833|NCT05041907|DRUG|Molnupiravir|Molnupiravir 800mg BD for 5/7
40810834|NCT05041907|DRUG|Sotrovimab|Sotrovimab 500mg given once on D0
40810835|NCT05041907|DRUG|Ensitrelvir|Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7
40810836|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
40810837|NCT05041907|DRUG|Favipiravir|Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7
40810838|NCT05041907|DRUG|Ivermectin|Ivermectin 600micrograms/kg/day for 7/7.
40810839|NCT05041907|DRUG|Remdesivir|Remdesivir 200mg D0 and 100mg for a further 4/7.
41328810|NCT03421574|DEVICE|MR-guided Focused Ultrasound|Focused Ultrasound allows for non-invasive thermal ablation of soft tissue virtually anywhere in the body. Treatment begins by acquiring a series of magnetic resonance (MR) images of the target tissue. The physician then reviews the images on the system workstation, identifies the target, delineates treatment contours, and reviews the treatment plan. Therapy planning software calculates the parameters required to effectively treat (e.g. ablate) the defined region. During treatment, the patient wears a helmet equipped with multiple sources of ultrasound which generate a point of focused energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, causing a thermal coagulation effect.
41328811|NCT02209038|BEHAVIORAL|Expanded AD Choice|
40810840|NCT05041907|DRUG|Atilotrelvir/ritonavir|Atilotrelvir 150mg BD for 5/7 Ritonavir 100mg BD for 5/7
40810841|NCT05041907|DRUG|Metformin|Metformin 500mg TDS 5/7
40810842|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 300mg BD for 5/7 Ritonavir 50mg BD for 5/7
40810843|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 150mg BD for 5/7 Ritonavir 50mg BD for 5/7
40810844|NCT05041907|DRUG|Nirmatrelvir|Nirmatrelvir 300mg BD for 5/7
40810845|NCT04580836|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40810846|NCT04580836|OTHER|Questionnaire Administration|Ancillary studies
40810847|NCT04580836|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
40810848|NCT04379570|OTHER|Educational Intervention|Receive online educational information about ET medication
40810849|NCT04379570|OTHER|Text Message-based Navigation Intervention|Receive text messages
40810850|NCT04379570|BEHAVIORAL|Motivational Interviewing|Receive motivational interviewing counseling sessions
40810851|NCT04379570|OTHER|Best Practice|Attend usual care clinic visits
40810852|NCT04379570|OTHER|Questionnaire Administration|Ancillary studies
40810853|NCT04379570|OTHER|Quality-of-Life Assessment|Ancillary studies
40810854|NCT06608511|OTHER|Blood draw for the laboratory assessment|Participants will have 50 milliliters (3.5 tablespoons) of blood drawn
40810855|NCT06607029|DRUG|the opioid-based control group|Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.
40810856|NCT06607029|DRUG|the opioid-free anesthesia group|The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.
41155478|NCT04303598|DRUG|FNC|3mg, 1 tablet，QD
41328812|NCT02209038|BEHAVIORAL|Expanded Life-sustaining Therapy Choice|
41481303|NCT06229821|DEVICE|Intrapulmonary Percussive Ventilation|IPV applied at increasing intervals, starting every 6 hours, and ending at every 24 hours, for a total of 7 days.
40810857|NCT06605599|DRUG|ABBV-932|Oral Capsule
40810858|NCT06605599|DRUG|Placebo for ABBV-932|Oral Capsule
41481304|NCT05435482|BEHAVIORAL|Education|Participants will receive two small group meetings and two follow-up calls
40810859|NCT06604858|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered every three weeks intravenously on day 1 of each cycle.
40810860|NCT06604858|DRUG|Carboplatin|Carboplatin: area under the curve (AUC) 1.5, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
40810861|NCT06604858|DRUG|Paclitaxel|Paclitaxel: 80 mg/m2, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
41155479|NCT04303598|DRUG|3TC|300mg, 1 tablet，QD
41155480|NCT04303598|DRUG|TDF|300mg, 1 tablet，QD
41155481|NCT04303598|DRUG|EFV|200mg, 1 tablet，QD
40810865|NCT06588322|OTHER|Blood samples will be taken on several times (36 mL of blood taken at each time):|"* Inclusion visit (T0): prior to initiation of Olaparib treatment~* Follow-up period (T1 to T8): every 3 months for a maximum of 24 months~* End of study (Tx): on definitive cessation of Olaparib treatment for any reason (progression, toxicity or definitive cessation of treatment after 2 years)."
41155482|NCT04303598|DRUG|FNC placebo|1 tablet，QD
41155483|NCT04303598|DRUG|3TC placebo|1 tablet，QD
41155484|NCT05865782|BEHAVIORAL|Schoolyard reconstruction|The current study will be designed as a quasi-experimental stepped-wedge intervention where schools undertaking schoolyard reconstruction will act as both control and intervention schools. By using the stepped-wedge study design, with internal control schools, will enable the control for the seasonal variation in children's physical activity levels and for the age-related decline in physical activity throughout childhood. That is, without control schools we would be unable to attribute a change in physical activity to the reconstruction of the schoolyards - as any difference in physical activity before and after the schoolyard reconstruction in the intervention group could be explained by the natural change in physical activity over time.
40810870|NCT02287090|OTHER|Observational Cohort|
40810871|NCT06615661|DEVICE|C-Rex Instrument|The C-Rex Instrument is a manual ophthalmic surgical instrument used for ab interno goniotomy and inner wall trabeculotomy.
40810874|NCT06434337|DIAGNOSTIC_TEST|"Novel point-of-care diagnostic test for detecting HPV (Rice HPV test)"|Given by Diagnostic Test
40810875|NCT02701283|DEVICE|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
40810876|NCT02701283|DEVICE|Surgical Aortic Valve Replacement (SAVR)|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
40810877|NCT04544202|DRUG|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~* Dabrafenib, 150 mg, twice daily (BID);~* Trametinib, 2.0 mg, once daily (QD)"
40810878|NCT04544202|DRUG|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
41155485|NCT05095233|BEHAVIORAL|Young Adults Culturally Adapted Manual Assisted Psychological Therapy (YA-CMAP)|"YA-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behavior Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the suicide risk mainly suicidal ideation, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking, relapse prevention strategies, training on interoceptive awareness, mood management and behavior."
41328813|NCT02015806|BEHAVIORAL|RxTimerCap|The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
41328814|NCT02015806|BEHAVIORAL|Take-N-Slide|The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
41328815|NCT02015806|BEHAVIORAL|Pillbox|The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
41328816|NCT05424185|BEHAVIORAL|different type of scapular dyskinesis|rapid arm elevation to see the different of EMG rise and force development
41481305|NCT05435482|OTHER|COVID-19 testing kits|Participants will receive two COVID-19 at-home antigen test kits.
41481306|NCT05435482|OTHER|Instruction|Participants will receive a written guide and a video clip guide to the test kit.
40810879|NCT04544202|DRUG|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
41155486|NCT05095233|DEVICE|Min Plan Tool|Self-help Tool are common evidence-based methods to help deal with mental health problems.The 'MIN PLAN APP' aims to support people at risk of suicide by letting them create a safety plan based on cognitive therapeutic intervention and behavioral techniques.
41011585|NCT01045291|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
41155487|NCT05579587|DEVICE|Transoral Incisionless Fundoplication|Transoral incisionless fundoplication (TIF) is a minimally invasive, endoscopic fundoplication technique. Transoral Incisionless Fundoplication (TIF) is an FDA approved endoluminal fundoplication technique which utilizes EsophyX device to restore the valve at the gastroesophageal junction. The EsophyX device (EndoGastric Solutions, Redmond, Wash, USA) is an FDA approved procedure for chronic of refractory GERD.
41155488|NCT03039088|OTHER|Follow-up after 12 weeks after TNF alpha blockers initiation|
41155489|NCT05653921|OTHER|In vivo confocal microscopy (IVCM)|In vivo confocal microscopy (IVCM) allows for visualization of the corneal structures at the cellular level, allowing for assessment of corneal nerves. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
41328817|NCT05778019|OTHER|Case Scenarios of complications to be ranked / classified according to classifications (for the severity grading of events)|Test the feasibility, applicability and logic of a novel instrument for the grading of unexpected events in pediatric surgery (Clavien-Madadi classification) compared to the Clavien-Dindo classification for the grading of postoperative complications in general surgery
41328818|NCT02091947|DEVICE|FMS (Magstim rapid2)|5 Hz FMS, over bilateral sacral roots.
41328819|NCT01234896|DRUG|Nicotine Medicated Gum|Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes
41328820|NCT01234896|DRUG|4 mg Nicotine Gum|Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes
41328821|NCT01234896|DRUG|2 mg Nicotine Gum|Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes
41328822|NCT01234896|DRUG|4 mg Nicotine Lozenge|Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
41481307|NCT04076670|OTHER|Psychological intervention for family caregivers of patients at the end of life|The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
41481308|NCT01389934|DRUG|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
41481309|NCT01389934|DRUG|Placebo|Women of this group be infused saline 2 ml / h for 48h.
41155490|NCT00220571|DEVICE|Coronary Angioplasty (PTCA)|
41155491|NCT04768751|DIAGNOSTIC_TEST|kidney assessment|Urea, BUN, and Creatinine BLOOD LEVELS
41155492|NCT06326216|OTHER|Non-Interventional Study|Non-interventional study
41481310|NCT02793570|OTHER|observational|
41481311|NCT00762931|DEVICE|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation
41481312|NCT02032251|DRUG|oral administration of ginger|Oral administration of ginger in patients with infertility.
41481313|NCT02032251|DRUG|Placebo|
40810884|NCT06616740|OTHER|Cricoid pressure|Cricoid pressure will be applied during LMA ProSeal insertion.
40810885|NCT06616740|OTHER|Paratracheal pressure|Pratracheal pressure will be applied during LMA ProSeal insertion.
40810886|NCT05097677|OTHER|Not applicable (observational study)|Not applicable (observational study)
40810890|NCT05034627|PROCEDURE|Biopsy|Undergo biopsy
41011586|NCT00283725|OTHER|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).
41011587|NCT06187103|DEVICE|HyperSight Imaging|Patients receive standard of care radiation treatment on a Varian TrueBeam system equipped with HyperSight CBCT imaging. Images acquired for daily patient positioning from two different treatment fractions - typically one near the beginning of the treatment course and one at about the halfway point - will be analyzed for the study.
41328823|NCT02538510|OTHER|Laboratory Biomarker Analysis|Correlative studies
41328824|NCT02538510|BIOLOGICAL|Pembrolizumab|Given IV
41328825|NCT02538510|DRUG|Vorinostat|Given PO or via PEG
41328826|NCT03163108|DEVICE|Closed-loop automatic oxygen control (CLAC) fast in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
41328827|NCT03163108|DEVICE|Closed-loop automatic oxygen control (CLAC) slow in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
41328828|NCT04712357|DRUG|Vitamin C 500 MG Oral Tablet|Vitamin C 500 MG per day for 10 days
41328829|NCT04712357|DRUG|Tenofovir disoproxyl fumarate 300 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG per day for 10 days
41328830|NCT04712357|DRUG|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days
41481314|NCT05638841|OTHER|After radiofrequency ablation of atrial fibrillation|This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.
41481315|NCT02608970|DRUG|BMS-986177|
41481316|NCT02608970|OTHER|Placebo|
41481317|NCT01421342|DRUG|Switching: Bupropion-SR|Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
41481318|NCT01421342|DRUG|Augmenting: Antidepressant + Bupropion-SR|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.~And~Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
40810891|NCT05034627|DRUG|Calaspargase Pegol-mknl|Given IV
40810892|NCT05034627|DRUG|Cobimetinib|Given PO
41011588|NCT00714259|DRUG|Fludarabine|Fludarabine 30 mg/m2/day x 3 days
41011589|NCT00714259|RADIATION|Total Body Irradiation|TBI 200cGy x1 dose on transplant day
41155493|NCT06255288|OTHER|SNAK intervention|The intervention consists of structured dialogue, patient information, and a protein supplement. The structured dialogue part of the intervention consists of an A3 poster with illustrations and keywords which will be hanging in the outpatient clinics. The poster will be utilized by nurses, patients, and their relatives to facilitate a dialogue regarding nutrition and wound healing. The patient information part of the intervention consists of a leaflet with easy-to-read information, which patients and their relatives can bring home after their visit to the outpatient clinic. The leaflet will consist of general information as well as food categories and recipes they can use to enhance their daily protein intake. For the protein supplement part of the intervention, the patients will have access to protein supplement beverages while they are in the outpatient clinic waiting room. Furthermore, they will receive prescriptions for protein drinks, that they can pick up at their local pharmacy.
41155494|NCT03360071|DRUG|Allergen Immunotherapy Extract|Allergen Immunotherapy treatment mixture to be delivered subcutaneously
41328831|NCT00000324|DRUG|Tryptophan|
41011590|NCT00714259|OTHER|Infusion of Stem Cells|On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10\*6 CD34+ cells per kilogram of recipient weight.
41328832|NCT03411707|DIAGNOSTIC_TEST|Stool DNA test|Stool DNA test could detect specific gene methylation in stool DNA. Blood mRNA test could detect specific set of gene expression in blood.
41328833|NCT05269732|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group Cognitive Behavioural Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists. This intervention was developed by Dr. Van Lieshout (Principal Investigator) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced each week. The first half of each session is devoted to core CBT content, including cognitive restructuring. The second half is devoted to group discussions co-led by participants on topics relevant to mothers with PPD (e.g., sleep, supports, role transitions). Homework is assigned at each session.
41328834|NCT06121362|DIETARY_SUPPLEMENT|Protocatechuic Acid or PCA|PCA 1000 mg capsule
41328835|NCT06121362|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
41328836|NCT01925612|DRUG|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
41328837|NCT01925612|DRUG|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
41328838|NCT01925612|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
41328839|NCT01925612|DRUG|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
41328840|NCT01925612|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
41155495|NCT03360071|DRUG|Allergen Immunotherapy Control|Allergen Immunotherapy Control Solution to be delivered subcutaneously
41155496|NCT06286033|DRUG|AG-181|AG-181 tablets
41155497|NCT06286033|DRUG|Placebo|AG-181 matched-placebo tablets
41155498|NCT03302871|DRUG|Botulinum toxin type A|
41155499|NCT03302871|DEVICE|transcranial direct current stimulation|
41155500|NCT03302871|OTHER|hybrid training model of CIMT and BIT|
41155501|NCT03302871|OTHER|usual care|
41155502|NCT02480244|BEHAVIORAL|Behavioral Intervention|Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
41155503|NCT02480244|OTHER|Control|Control arm receives no health-related behavioral intervention
41155504|NCT00579657|OTHER|control diet, supported by dietary supplement twice daily|control diet, see above
41328841|NCT01925612|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
41328842|NCT01925612|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
41328843|NCT05520918|DIAGNOSTIC_TEST|the LIT test|The retained functional capacity of leukocytes (primarily neutrophils) to produce ROS in response to PMA in whole blood samples could provide a rapid 10-minute detection method for objectively determining onset or occurrence of severe COVID-19 and monitoring progression and treatment of COVID-19.
41328844|NCT03521661|PROCEDURE|Kyphoplasty|Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter
41328845|NCT00722709|DRUG|Ropivacaine|"In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
41481319|NCT01421342|DRUG|Augmenting: Antidepressant + Aripiprazole|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.~And~Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
41481320|NCT05720975|DEVICE|iNstroke|Patients to undergo thromboaspiration with iNstroke.
41481321|NCT01940328|DEVICE|Transchoracic ultrasound Doppler|
41481322|NCT04957420|DRUG|Neupro|Rotigotine Patches
41481323|NCT06398613|DIAGNOSTIC_TEST|PSMA PET/CT|Prostate-Specific Membrane Antigen Emission Tomography/Computed Tomography (PSMA PET/CT) will done preoperatively
40810903|NCT04926636|BEHAVIORAL|Health and Wellness Coaching|An enhanced mobile application that allows for participation in health coaching features. Participants will be assigned to a health coach and will have coaching sessions scheduled.
41155505|NCT00579657|OTHER|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
41155506|NCT00579657|OTHER|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
41155507|NCT00579657|OTHER|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
41155508|NCT02936193|PROCEDURE|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
41481324|NCT01720199|OTHER|Diario della Salute (DDS)|"DDS is composed by~1. tools for children and their parents on health and social and emotional well-being issues:~   1. a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),~  2. a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);~2. five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers."
41155509|NCT02936193|PROCEDURE|Distal gastrectomy|Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
41155510|NCT03924596|DRUG|AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)|AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma
41155511|NCT03924596|DRUG|Potassium Sodium Hydrogen Citrate|Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)
41155512|NCT06645756|OTHER|Test meal|Test meal consisting of fries, chicken nuggets and eggs
41155513|NCT02481349|OTHER|Best Practice|Undergo standard of care
41155514|NCT02481349|OTHER|Informational Intervention|Receive DVD for home practice
41155515|NCT02481349|OTHER|Quality-of-Life Assessment|Ancillary studies
41155516|NCT02481349|OTHER|Questionnaire Administration|Ancillary studies
41155517|NCT02481349|OTHER|Yoga|Complete couple-based Hatha yoga program
41155518|NCT04165317|DRUG|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
41155519|NCT04165317|DRUG|Bacillus Calmette-Guerin|Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
41155520|NCT06646822|DRUG|Stimulant|observational study
41155521|NCT03487302|OTHER|Brain MRI|Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans
41328846|NCT00722709|DRUG|0.9% Saline|"In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.~At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
41328847|NCT05452109|OTHER|Blood Flow Restriction|Blood flow restriction with low load (30-50% 1RM) for 2 sessions in a week for 6 weeks during classical training will be applied.
41328848|NCT05452109|OTHER|Classical Training Alone|Classical training same as Group 1with moderate to high load (70-90% 1RM) for 2 sessions in a week for 6 weeks will be applied without blood restriction.
41328849|NCT01367314|DRUG|NVC-422|Dermal Gel applied 3 times per day for 7 days
41328850|NCT01009021|DRUG|potassium diclofenac|potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
41328851|NCT01553071|DRUG|Fenretinide (4-HPR) plus Intravenous Safingol|"A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects."
41328852|NCT03943108|DIAGNOSTIC_TEST|Gait analysis|Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.
41328853|NCT05923892|DRUG|OPS-2071|There are 3 dose groups of OPS-2071，OPS-2071 tablets, 50 mg、100mg、200mg. Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
41328854|NCT05923892|DRUG|placebo|Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
41328855|NCT02954302|PROCEDURE|PrPD with proximal Roux-en-y gastrojejunal anastomosis|the distal antrum was divided about 1 to 2 cm proximal to the pylorus ring, preserving more than 95% of the stomach. The proximal jejunum was divided approximately 2 to 4 cm distal to the duodeno-jejunal junction. After completion of the resection, the proximal end of the first loop of jejunum was then brought through the transverse mesocolon, and the gastrojejunal anastomosis (GJA) was performed in two layers by using 3-0 PDS sutures and 4-0 silk sutures in an end-to-side fashion. The jejunum was then divided 35 to 40 cm distal to the GJA, and the distal limb was brought separately through the transverse mesocolon to be placed in the duodenal bed for reconstruction of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA).
41328856|NCT02954302|PROCEDURE|conventional PrPD|After completion of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA), a hand-sewn, isoperistaltic GJA was performed 25 to 30 cm distal to the HJA in two layers by using 3-0 polydioxanone (PDS) sutures and 4-0 silk sutures.
41328857|NCT01378299|DRUG|Testosterone Cypionate|"Testosterone cypionate was administered at 200 mg by intramuscular injection every 2 weeks.~DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.~Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-, (178)-. Its molecular formula is CvH400a, and the molecular weight of 412.61."
41328858|NCT05871372|DEVICE|Brain Stimulation|Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care, respectively, The depression cohort will also have deep brain stimulation (DBS) leads implanted as part of their trial. We will deliver stimulation via the DBS and sEEG electrodes. We will adhere to well known safety parameters.
41328859|NCT05871372|DEVICE|sEEG Stimulation|Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care. We will deliver stimulation via the sEEG electrodes. We will adhere to well known safety parameters.
41328860|NCT06108128|OTHER|Executive functioning observational tasks|Interventions take place solely at the measurement level, where children will be seen in observational tasks of general executive functioning and executive functioning around eating in which various food and non-food stimuli are presented and children's responses to task instructions are recorded.
41328861|NCT02425280|BEHAVIORAL|Narrative Exposure Therapy|
41328862|NCT02425280|BEHAVIORAL|Treatment as Usual|
41328863|NCT02407314|PROCEDURE|Percutaneous Peripheral Intervention|Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.
41155522|NCT03487302|OTHER|Neuropsychological test battery|"1. Mini Mental State Examination (MMSE), Measso et al. (1993);~2. Frontal Assessment Battery (FAB), Appollonio et al. (2005);~3. Symbol Digit Test, Amodio et al. (2002);~4. Digit Cancellation Test, Della Sala et al. (1992);~5. Trial Making Test (TMT A-B), Giovagnoli et al. (1996);~6. Weigl's Sorting Test, Laicona et al. (2000) and Inzaghi (2010);~7. Digit Span, Orsini et al (1987);~8. Corsi block-tapping test, Orsini et al. (1987);~9. Babcock story recall test, Carlesimo et al. (2002);~10. Phonemic verbal fluency in MDB, Caltagirone and Carlesimo (2010);~11. Semantic verbal fluency, Novelli (1986);~12. Imitating gestures, De Renzi et al. (1980);~13. Coloured Progressive Matrices (CPM47), Measso et al. (1993)."
41155523|NCT00420797|DRUG|10% Phenylephrine hydrochloride gel|
41328864|NCT02407314|DEVICE|Optical Coherence Tomography|This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
41328865|NCT02407314|OTHER|Ankle Brachial Index|This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
41328866|NCT02407314|OTHER|Six minute walk distance|Assessment of the walking distance in 6 minutes.
41328867|NCT02407314|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid \[ASA\], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
41328868|NCT02407314|DRUG|Aspirin + Ticagrelor|This is a combination of drugs (Aspirin + Ticagrelor). Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
41328869|NCT05994963|DRUG|sisunatovir|Administered as either capsules in fasted state or tablet in fasted or fed state.
41328870|NCT05289856|DRUG|combination of Avelumab and Cabozantinib|Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months
41328871|NCT02685657|DRUG|Drug: Selumetinib|
41328872|NCT02685657|DRUG|Doxorubicin|
41328873|NCT02685657|DRUG|Cyclophosphamide|
41328874|NCT02685657|DRUG|Docetaxel|
41328875|NCT01709981|DRUG|Colchicine|Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later
40810915|NCT04989309|DEVICE|Transcranial Magnetic Stimulation|TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.
41328876|NCT01709981|DRUG|Placebo|Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
41328877|NCT03396926|BIOLOGICAL|Bevacizumab|Given IV
41328878|NCT03396926|DRUG|Capecitabine|Given PO
41155524|NCT03797326|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
41155525|NCT03797326|DRUG|Lenvatinib|Administered orally once a day during each 21-day cycle.
41328879|NCT03396926|OTHER|Laboratory Biomarker Analysis|Correlative studies
41328880|NCT03396926|BIOLOGICAL|Pembrolizumab|Given IV
41155526|NCT03792035|DRUG|Tongxinluo|tid, po.
41328881|NCT04781452|OTHER|standard treatment|there ist no Intervention but our standart Treatment in the center
41155527|NCT03792035|DRUG|Placebos|tid, po.
41155528|NCT02189122|DRUG|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
41328882|NCT02428673|OTHER|Assisted Standing Treatment Program|
41481325|NCT00599898|DRUG|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
40810916|NCT06412978|PROCEDURE|absorbable subcuticular polyglycolic acid staples (INSORB)|Insorb absorbable staples are used for skin closure
40810917|NCT06412978|PROCEDURE|subcuticular, polyglecaprone suture (Monocryl)|Monocryl absorbable staples are used for skin closure
41155529|NCT02189122|DRUG|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
41155530|NCT02189122|DRUG|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
41155531|NCT02189122|DRUG|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
41155532|NCT02189122|DRUG|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
41155533|NCT02189122|DRUG|Placebo|Subjects will take matching placebo for five days.
41155534|NCT06098443|OTHER|Acupressure|Acupressure is effective on anxiety and depression management. acupressure therapy at K1, ST36, and SP6 acupoints significantly reduced anxiety \& depression in patients with ESRD.
41328883|NCT05789849|DEVICE|Collecting blood pressure measurements with noninvasive blood pressure device|Noninvasive blood pressure measurements will collected based on the recommendations of the International Organization for Standardization (ISO) 81060-2:2018+A1:2020 Non-invasive sphygmomanometers -Clinical investigation of intermittent automated measurement type. This study has only 1 arm; investigational NIBP measurements will be collected using a NIBP Auscultatory Algorithm with alternating NIBP measurements collected using a reference sphygmomanometer.
41155535|NCT06098443|DEVICE|Transcutaneous electrical nerve stimulation|TENS lead to meaningful reduction of pain in patients suffering from difficult to treat phantom limb pain. This treatment has a high success rate and is associated with high satisfaction rates and no reported adverse events. The suggested duration of treatment is at least 30 minutes and may be extended up to 45 minutes. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extra segmental analgesia. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extrasegmental analgesia. (Vathakul et al., 2022).
41155536|NCT05642663|DEVICE|Stapler|Stapling performed with ALTUS Powered Stapler
41328884|NCT05374837|BEHAVIORAL|Infant and young child feeding voice messaging intervention|A mobile voice and text messaging intervention aimed at improving IYCF practices will be delivered to mothers and fathers with young children (6-23 months). A total of 16 voice and text message, with the same content, will be sent over a 16-week period (1 voice + 1 text messages (with same content) per week x 16 weeks). Two types of messages will be included: 1) eight scripted and 2) eight unscripted messages from positive deviants. The content of the messages include: breastfeeding until two years of age, consuming a variety of foods within a given meal, the consistency of porridge (thick rather than thin), limiting sweets and fried foods, the importance of animal source foods, consuming vitamin A rich fruits and vegetables, consuming leafy greens, handwashing and feeding infants and young children fruits and vegetables produced by the household.
41328885|NCT05274594|RADIATION|Radiotherapy|Patients who are candidate for radiotherapy and received neoadjuvant chemotherapy for breast cancer were evaluated after neoadjuvant chemotherapy. Cases that do not have clinical response received radiotherapy before surgery in order to increase complete response.
41328886|NCT03076918|DEVICE|FLEXITHERALIGHT PDT|Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
41328887|NCT03076918|DEVICE|Aktilite® Galderma|Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
41328888|NCT05816291|DIETARY_SUPPLEMENT|Time to Exhaustion at velocity at VO2max|During a familiarization trial prior to supplementation and before and after each supplementation period at the beginning of each study visit, participants will complete a standardized warm-up consisting of walking on a treadmill for 5 minutes, a series of whole-body dynamic movements (high knees, butt kicks, walking lunges, straight-leg marching, etc.), and a self-prescribed period of jogging on the treadmill for no more than ten minutes. The speed on the treadmill will then be set at the velocity upon which 100% VO2Peak was achieved. Participants will be instructed to run at this velocity for as long as they can. No feedback in terms of duration, pacing, etc. will be provided, and participants will be provided verbal encouragement to run for as long as possible.
41328889|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR22|4SCAR19 and 4SCAR22
41328890|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR38|4SCAR19 and 4SCAR38
41328891|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR20|4SCAR19 and 4SCAR20
41328892|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR123|4SCAR19 and 4SCAR123
41328893|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR70|4SCAR19 and 4SCAR70
41328894|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR30|4SCAR19 and 4SCAR30
41328895|NCT00295737|PROCEDURE|bronchoscopy, allergen/endotoxin instillation|
41328896|NCT05572346|OTHER|Home-based telerehabilitation program delivered through digital devices|To evaluate the effects of digital home-based telerehabilitation program on functional and spirometric measures as well as on quality of life in patients with chronic respiratory disease
41328897|NCT04063072|PROCEDURE|ERAS protocol|In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
41011591|NCT06102421|DEVICE|BTL-6000 FSWT|Low-energy focused extracorporeal shockwave therapy will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy can vary between 0.12-0.20 mJ/mm2 based on the pain toleration, frequency 5 Hz, total number of shocks 2x2000. The application of the first set of shocks will be semi-static at the location of the largest USG defined pathology in the patellar tendon and the second set of shocks will be performed dynamically to the proximal tendon. These parameters were selected in accordance to ISMST guidelines.
41011592|NCT02366481|DIETARY_SUPPLEMENT|Placebo|Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
41328898|NCT04559269|OTHER|No intervention|patients have benefited from maintenance wakefulness tests as part of their clinical evaluation
41328899|NCT03134924|BEHAVIORAL|Women's and Sexual Health [WASH]|The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
41328900|NCT03134924|BEHAVIORAL|Enhanced Standard of Care|"The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP."
41155537|NCT01568021|OTHER|No Intervention|No intervention was administered in this study.
40810925|NCT02625480|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|
40810926|NCT02625480|DRUG|Fludarabine|Administered intravenously
40810927|NCT02625480|DRUG|Cyclophosphamide|Administered intravenously
41011593|NCT02366481|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
41011594|NCT02366481|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
41011595|NCT02432716|DRUG|Insulin glulisine|Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
41328901|NCT01861145|DEVICE|Bed Alarm|The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
41328902|NCT01861145|DRUG|Nasonex|Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
41328903|NCT05388955|OTHER|None, transplantation recipients|None, observational
40810928|NCT06615817|DIETARY_SUPPLEMENT|Intermittent Fasting|In this group, a diet based on intermittent fasting will be administered - with 14 hours of nocturnal fasting and 10 hours of feeding with a low glycemic index Mediterranean diet.
41155538|NCT06589453|DEVICE|Nasal elevator with digital nasoalveolar molding in bilateral cleft lip and palate infants|This is a unique nasal elevator aiming to improve nasolabial esthetics in conjunction with digital nasoalveolar molding appliance when used in bilateral cleft lip and palate infants.
41155539|NCT06589453|DEVICE|Nasal stent with digital nasoalveolar molding in bilateral cleft lip and palate infants|Nasal stent that is used in conjunction with digital nasoalveolar molding in bilateral cleft lip and palate infants
41328904|NCT02119468|DRUG|ixazomib citrate|Given orally
41328905|NCT02119468|DRUG|dexamethasone|Given orally
41155540|NCT01670032|DRUG|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
40810932|NCT06072183|DRUG|Ritlecitinib|100mg Capsule
40810933|NCT06072183|DRUG|Ritlecitinib|50mg Capsule
41011596|NCT02432716|DRUG|Saline|Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
41011597|NCT01856972|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
41011598|NCT01856972|PROCEDURE|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
41328906|NCT02119468|DRUG|pomalidomide|Given orally
41328907|NCT06456515|DRUG|Regorafenib and Sintilimab in combination with electroacupuncture|Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing cycle.
41328908|NCT04871581|DEVICE|NTI-tss|FDA cleared device for prophylactic treatment of medically diagnosed migraine pain
41328909|NCT04871581|DEVICE|Placebo|Similar to Device, but having no influence on clenching intensity
41328910|NCT03222622|DRUG|Icotinib hydrochloride cream|Apply topically twice daily for 12 consecutive weeks
40810934|NCT06072183|DRUG|Placebo|Matching capsule
40810935|NCT04739813|BIOLOGICAL|obinutuzumab|administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
40810936|NCT04739813|DRUG|prednisone|administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
40810937|NCT04739813|DRUG|Revlimid|administered orally, days 1 and 14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
40810938|NCT04739813|BIOLOGICAL|Polatuzumab|administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
40810939|NCT04739813|DRUG|ibrutinib|administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
41328911|NCT03222622|DRUG|Placebo cream|Apply topically twice daily for 12 consecutive weeks
40810940|NCT04739813|DRUG|venetoclax|administered orally, days 2-14, at a dose of 800 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
41011599|NCT01856972|OTHER|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
41011600|NCT01389440|DRUG|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
41155541|NCT01670032|DRUG|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
41155542|NCT01670032|DRUG|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
40810943|NCT06621732|PROCEDURE|cutanous biopsy and blood sample|cutanous biopsy and blood sample
40810944|NCT06623994|BEHAVIORAL|Task sharing with Epilepsy Medical Record Systems|Training multiple cadres of healthcare workers in epilepsy treatment and management to enable a team-based approach to address access to care. Task sharing will be supported by epilepsy medical records system with patient tracking data to support care retention
41155543|NCT01670032|DRUG|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
41155544|NCT04273854|DEVICE|OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®|The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. This is overseen and any change is approved by physicians who can review the uploaded readings and respond to tele-monitored abnormal readings in a timely fashion.
41155545|NCT03327051|DRUG|Omeprazole|Proton pump inhibitor (PPI) that suppresses gastric acid secretion
40810948|NCT06608212|DRUG|Finerenone (Kerendia, BAY948862)|Follow clinical practice/administration.
40810949|NCT06608212|DRUG|Others except finerenone|Follow clinical practice/administration. The non-use finerenone treatment strategy will require individuals to be free of finerenone use.
40810950|NCT00211757|DRUG|Divalproex sodium|Study drug.
40810951|NCT00211757|DRUG|Placebo|Placebo comparator.
41155546|NCT03327051|DIETARY_SUPPLEMENT|VSL #3|Probiotics
41155547|NCT03327051|DRUG|Placebo|Placebo to match omeprazole
41328912|NCT02476344|OTHER|experiment protocol|"each subject will perform the following 3 days experiment protocol, consisting of army training exercises:~1. sack carrying exercise.~2. crawling exercise.~3. combined exercise: sack carrying, crawling and sprints.~heart rate, core temperature, lactic acid and CPK levels will be monitored continuously."
40810954|NCT04669262|DRUG|BGB-DXP604|Administered as intravenous (IV) infusion over 30 to 60 minutes
40810955|NCT04669262|DRUG|BGB-DXP593|Administered as intravenous (IV) infusion over 30 to 60 minutes
40810956|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP593
40810957|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP604
40810958|NCT06626321|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming visit and encourage the patient to ask their provider about receiving the vaccine.
41011601|NCT03189251|OTHER|Dietary intakes|Analysis of association between consumption of high excess free fructose (EFF) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice)
41155548|NCT06595706|DRUG|Lucid-21-302|Capsule containing a small molecule inhibitor of hypercitrullination
41155549|NCT06595706|DRUG|Placebo|Capsule containing only Silicified Microcrystalline Cellulose
41155550|NCT05109117|DRUG|CAP Unscented|Sunscreen lip balm.
41155551|NCT04318587|DIAGNOSTIC_TEST|Allosure|Blood is collected from the patient, packaged, and shipped at ambient temperature to CareDx for testing. Donor-derived cell-free DNA is measured via targeted amplification and sequencing of a set of carefully selected and validated SNPs. The AlloSure bioinformatics software calculates the percent dd-cfDNA in the sample tested and applies the QC criteria. The AlloSure results will be compared to the episodes of acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry in the subjects medical records. Transbronchial biopsies and spirometry are standard of care for lung transplant recipients.
41155552|NCT06032702|PROCEDURE|tooth alignment|Alignment will be assessed by Little's Irregularity Index
41155553|NCT00244751|DRUG|GI262570 0.5 mg|GI262570 0.5 mg
41155554|NCT00244751|DRUG|GI262570 1.0 mg|GI262570 1.0 mg
41155555|NCT00244751|DRUG|Placebo|Placebo
41155556|NCT04546971|BEHAVIORAL|Brief Intervention|Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking
41155557|NCT04546971|BEHAVIORAL|Telehealth Counseling|5 sessions of counseling on alcohol use based on Motivational Interviewing.
41155558|NCT04546971|BEHAVIORAL|Text messaging|A daily and then monthly text messaging program designed to help participants monitor drinking, set goals, and reinforce successful reduction or abstinence.
41155559|NCT06055920|DEVICE|FlowTriever System|Mechanical Thrombectomy for pulmonary embolism
41328913|NCT02099487|RADIATION|Radiation|hypofractionated IMRT
40810959|NCT06626321|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patients upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
40810960|NCT06626321|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention
40810961|NCT06626321|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
40810962|NCT06626425|OTHER|Healthy Minds Program App|An 8-week meditation-based well-being training containing content for each of the four pillars of the training program: Awareness, Connection, Insight, and Purpose.
40810963|NCT06626425|OTHER|Hydro Coach App|The Hydro Coach app (HC). A smartphone-based wellness app to ensure proper hydration.
40810964|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The patient's back was prepared for surgery. They were positioned on their side, with the operative side facing upward. The L3-4 spinal interspace was identified, and numbed, and a thin spinal needle was inserted. After confirming Cerebrospinal Fluid (CSF), 12.5 mg of isobaric bupivacaine 0.5% was injected into the spinal canal.
40810965|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The L3-4 spinal interspace was identified, numbed, and a thicker needle (Tuohy needle) was inserted. After confirming Cerebrospinal Fluid (CSF), a thin catheter was inserted into the spinal canal and secured. An initial dose of 1 ml isobaric bupivacaine 0.5% was injected, followed by additional doses as needed to maintain the block height.
40810966|NCT06625606|DRUG|Isoflurane Inhalant Product|General anesthesia was initiated with propofol and rocuronium. Anesthesia was maintained with isoflurane, with additional rocuronium and fentanyl as needed. Breathing was controlled by the ventilator, and muscle relaxation was reversed at the end of surgery.
40810967|NCT06625138|DEVICE|Latex Band|Hemorrhoid banding with latex band
40810968|NCT06625138|DEVICE|Non-Latex Band|Hemorrhoid banding with non-latex bands
40810969|NCT06315322|DRUG|Brivaracetam Film-coated tablet|Drug: Brivaracetam Film-coated tablet Pharmaceutical form: Film-coated tablet Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.
40810970|NCT06315322|DRUG|Brivaracetam oral solution|Pharmaceutical form: Oral solution Route of administration: Oral use Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.
41011602|NCT00225355|DRUG|Rosiglitazone|
41011603|NCT00568984|DRUG|repaglinide|
41155560|NCT06055920|DRUG|Anticoagulation Agents|"Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot."
41155561|NCT04838145|DRUG|Ribavirin + Pleconaril|Randomized to treatment with study drugs (ribavirin and pleconaril)
40810973|NCT05151445|BEHAVIORAL|mHealth dietary app + health coaching intervention|"The Lose-It app will be set up with Gmail accounts with unique unidentifiable codes developed by the research team. Participants be trained to enter their dietary intake and physical activity daily for 12-weeks. Participants will monitor their vegetable intake, fat intake, carbohydrate intake, weight, and blood pressure. Wi-Fi connected weight scales and blood pressure cuff will be supplied for weight and blood pressure monitoring. Participants will be taught how to sync the data from the scales and blood pressure cuff to the app for the research team to access. Participants will perform a return demonstration to confirm that they can record their dietary intake daily, physical activity, weight, and blood pressure using the Lose-It app. We also review with the participant the My Plate method for proper nutrition and the steps to distance conversion chart."
40810974|NCT04957992|OTHER|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
40810975|NCT04957992|OTHER|Control Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
40810976|NCT04957992|OTHER|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
40810977|NCT04957992|OTHER|Experimental Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
40810978|NCT04957992|OTHER|Human Milk|Ad libitum or as instructed by HCP
40810979|NCT04957992|OTHER|Human Milk Supplemental Formula|Ad libitum if consuming supplemented formula; feeding period up to 12 months of age
40810980|NCT04957992|OTHER|Human Milk Toddler Drink|\~16 fl oz per day if providing supplemental nutrition other than HM; feeding period from 12 to 24 months of age
40810981|NCT04505553|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
40810982|NCT04505553|PROCEDURE|Acupressure Therapy|Undergo acupressure
40810983|NCT04505553|PROCEDURE|Oral Cryotherapy|Undergo oral cryotherapy
40810984|NCT04505553|OTHER|Questionnaire Administration|Ancillary studies
41011604|NCT00568984|DRUG|metformin|
41011605|NCT00568984|DRUG|glicazide|
41011606|NCT03815162|DIETARY_SUPPLEMENT|High Flavanol Cocoa extract|Experimental group
41011607|NCT03815162|DIETARY_SUPPLEMENT|Alkalised cocoa|Control group
41011608|NCT00001368|PROCEDURE|cytokine and leukocyte activation profile|
41011609|NCT05108181|OTHER|Muscle typology + exercise training|Exercise training: Participants perform 9 weeks of strength training at 60% of their 1RM.
41011610|NCT05108181|OTHER|Muscle typology + training frequency|Training frequency: leg A and arm A of the participants train 3 times per week, leg B and arm B train 2 times per week.
41155562|NCT04838145|DRUG|Placebos|Randomized to treatment with placebo
41155563|NCT01585597|DEVICE|Zoll- Coolgaurd 3000|Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
41155564|NCT02650388|BEHAVIORAL|Cognitive fuction, quality of life|To test the above score in patients undergoing TAVI
41328914|NCT04077229|BEHAVIORAL|Intervention arm: Text Message Intervention|Participants will receive a combination of messages promoting both psychological well-being and education /support around health behavior adherence, such as physical activity or diet. In the first part of the study, participants will receive 28 fixed text messages that alternate between physical activity and PP (Positive Psychology) messages. In the second part of the study, participants will first receive a set of 14 pre-selected daily messages that contain a broad range of attributes to allow sufficient participant feedback to clearly identify preferences. After the first 14 messages, new messages will be selected based on the prior preferences of participants.
41481326|NCT00599898|DRUG|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
40810985|NCT04505553|OTHER|Quality-of-Life Assessment|Ancillary studies
40810986|NCT05300568|OTHER|No Intervention|This is a non-product related survey.
41011611|NCT01570075|PROCEDURE|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
41481327|NCT05959434|BEHAVIORAL|Cognitive Processing Therapy + Relapse Prevention|Cognitive-Behavioral Therapy that integrates Cognitive Processing Therapy for PTSD with Relapse Prevention for alcohol use disorder
40810987|NCT06239220|BIOLOGICAL|PD-L1 t-haNK|Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.
40810988|NCT06239220|DRUG|Cetuximab|Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
40810989|NCT06239220|BIOLOGICAL|N-803|Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.
40810990|NCT02359565|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
40810991|NCT02359565|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo standard MRI
40810992|NCT02359565|PROCEDURE|Diffusion Tensor Imaging|Undergo DTI
40810993|NCT02359565|PROCEDURE|Diffusion Weighted Imaging|Undergo MR diffusion imaging
40810994|NCT02359565|PROCEDURE|Dynamic Contrast-enhanced MR Perfusion|Undergo DCE permeability MRI
40810995|NCT02359565|PROCEDURE|Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging|Undergo DSC perfusion MRI
40810996|NCT02359565|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
40810997|NCT02359565|BIOLOGICAL|Pembrolizumab|Given IV
41011612|NCT01570075|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
41011613|NCT05397379|DRUG|HEC96719|Oral tablets
41011614|NCT05397379|DRUG|Placebo|Comparator
41011615|NCT02422381|DRUG|MK-3475|Investigational drug.
41155565|NCT00500539|DRUG|omalizumab|The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
41155566|NCT05055141|OTHER|Care to Share poster|The Care to Share poster enabled patients to share written information about who they are as people with their hospital caregivers.
41155567|NCT04475016|DRUG|Albumin-Bound Paclitaxel|260 mg/m² IV over 30 minutes on Day 1
41155568|NCT04475016|DRUG|Ifosfamide|1200 mg/m² IV over 2 hours on Days 1-3
40811002|NCT06619392|DRUG|HRS-2129|HRS-2129
40811003|NCT06619392|DRUG|HRS-2129 Placebo|HRS-2129 Placebo
41155569|NCT04475016|DRUG|Cisplatin|25 mg/m² IV over 2 hours on Days 1-3
41155570|NCT04475016|DRUG|Nimotuzumab|400 mg IV on Day 1
41155571|NCT04475016|DRUG|Triprilimab|240 mg IV on Day 1
41155572|NCT05123144|BEHAVIORAL|BHS+ORCHID|"At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises."
41155573|NCT01198067|DRUG|Pomalidomide|Given PO
41155574|NCT04226183|OTHER|pregnancy workout|"Procedure of pregnancy workout has been legalized by the Ministry of Health of Indonesia act 2014 No.97.~100 ml fresh guava juice without sugar"
41155575|NCT02725359|DRUG|Placebo|Group Placebo: will receive a placebo pill 1 hour before surgery
41155576|NCT02725359|DRUG|Tizanidine|Group T: 6 mg tizanidine1 hour before surgery
40811012|NCT01258933|DRUG|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
40811013|NCT06626334|DEVICE|Bright Blue Light|Bright blue light will be administered using a Day-Light Classic Plus Light Therapy Lamp fitted with a LEE filter (#132, Medium Blue) and mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended). The light intervention will be administered at bedside for 4 hours daily during the morning/early afternoon hours, repeated for up to 3 days.
41011616|NCT02422381|DRUG|Gemcitabine|Standard care drug.
41011617|NCT00448058|DRUG|GSK372475|daily administration during the 10-week treatment phase
41011618|NCT00448058|DRUG|venlafaxine|daily administration during the 10-week treatment phase
41155577|NCT02725359|DRUG|Bupivacaine|Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
41155578|NCT02725359|DRUG|Saline|USG guided SCPB with saline bilaterally 10 ml each side
41481328|NCT05959434|BEHAVIORAL|Relapse Prevention|Cognitive-Behavioral Therapy that targets alcohol use, specifically
40811014|NCT06626334|DEVICE|Bright Full-Spectrum (White) Light|Bright full-spectrum (white) light will be administered using a Day-Light Classic Plus Light Therapy Lamp fitted with a LEE filter (#211 0.9 ND) and mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended). The light intervention will be administered at bedside for 4 hours daily during the morning/early afternoon hours, repeated for up to 3 days.
40811015|NCT06626334|DEVICE|Usual Ambient Light|"Across all arms, the usual ambient light in the inpatient room will not be modified.~For the Bright Blue Light and Bright Full-Spectrum (White) Light arms, light will be added to the environment using a Day-Light Classic Plus Light Therapy Lamp as specified in the corresponding intervention descriptions.~For the Usual Ambient Light arm, a Day-Light Classic Plus Light Therapy Lamp mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended) will be positioned at a 12-14 inches from eye level with the on/off switch in the off position. The lamp will be positioned in this manner for 4 hours daily during the morning/early afternoon hours, for up to 3 days."
40811016|NCT06625515|DRUG|ATX-559|DHX9 tablets will be taken orally
40811017|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management in in person group Format|The CBSM sessions will be delivered to participants in groups of ten, totaling eight sessions, each focused on a specific theme related to stress management. All participants will attend the complete sessions in person.
40811018|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management Hybrid Format|The CBSM (hybrid) sessions will be offered to participants online, including a total of eight video modules, each dedicated to a specific theme related to stress management. Participants will also have access to three interactive virtual sessions, summary sheets in PDF format, and audio recordings for relaxation.
40811019|NCT06625099|OTHER|Mechanical Ventilation (MV) with Low PEEP|Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and 5cmH2o PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.
40811020|NCT06625099|OTHER|Mechanical Ventilation (MV) with Optimum PEEP|"Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and optimum PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.~The optimum PEEP will be adjusted by titrating to the highest compliance with the open lung strategy."
40811021|NCT01638013|DRUG|Peficitinib|Oral Tablet
40811022|NCT05396222|DEVICE|3D-printed custom-made non-rigid biomimetic implant|We developed a 3D printed, custom-made, biomimetic prosthesis, with non-rigid structure, which has been tested in biomechanical study and porcine model, showing good bone formation and less stiffness as well. Therefore, we proposed a prospective clinical study to investigate safety, subsidence, and fusion of this prosthesis.
40811023|NCT06628323|BEHAVIORAL|Virtual Reality-based Intervention employing Neurofeedback|Virtual Reality-based intervention augmented with real-time EEG-based neurofeedback targeting auditory hallucinations in schizophrenia
40811024|NCT06628323|BEHAVIORAL|Virtual Reality-based Intervention|Virtual Reality-based intervention targeting auditory hallucinations in schizophrenia
40811025|NCT06239441|DRUG|IL5/IL5R Antagonists|Treatment with IL5/IL5R antagonists for one year
40811026|NCT06502977|DRUG|Tarlatamab|IV infusion
40811027|NCT03777657|DRUG|Tislelizumab|200 mg IV on Day 1 during each 21-day cycle
40811028|NCT03777657|DRUG|Placebo|Placebo to match tislelizumab on Day 1 during each 21-day cycle
40811029|NCT03777657|DRUG|Cisplatin|80 mg/m² IV on Day 1 during each 21-day cycle
41011619|NCT00448058|DRUG|placebo|daily administration during the 10-week treatment phase
41011620|NCT05325086|OTHER|Adapted information arm|A adapted booklet will be delivered to patients at the start of the stay. This booklet contains adapted information about the pulmonary rehabilitation targetting the characteristics of the openness to experiences personality traits
41011621|NCT05325086|OTHER|Neutral information arm|A neutral booklet will be delivered to patients at the start of the stay. This booklet contains neutral information about the pulmonary rehabilitation
41481329|NCT05925504|DRUG|Luspatercept|The starting dose is 1.75mg/kg once every 3 weeks by subcutaneous injection. For rapid hemoglobin rise after 2 consecutive doses at the 1.75mg/kg starting dose, decrease the dose of Luspatercept or interrupt treatment. Otherwise, continue treatment with the dose of 1.75mg/kg once every 3 weeks.
41011622|NCT05495412|OTHER|Rebound therapy|Exercise therapy delivered twice weekly for 6 weeks, during Phase B of an ABA single case study design.
40811030|NCT03777657|DRUG|Oxaliplatin|130 mg/m² IV on Day 1 during each 21-day cycle
40811031|NCT03777657|DRUG|Capecitabine|1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) during each 21-day cycle
40811032|NCT03777657|DRUG|5-FU|800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle
40811033|NCT05967741|OTHER|Erythritol|Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)
40811034|NCT05967741|OTHER|Aspartame|Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.
41011623|NCT01713868|BEHAVIORAL|Safe Sleep Nursery Education|Nursery-based program for safe sleep
41011624|NCT01713868|BEHAVIORAL|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
41011625|NCT01713868|BEHAVIORAL|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
41155579|NCT06297876|BEHAVIORAL|Storytelling|Narrative stories will be videos that are 2-3 minutes long and will show community members speaking based on community identified themes.
41155580|NCT06297876|BEHAVIORAL|Learn More (Active Comparator)|Informational videos that are of similar length and on the same topic as the storytelling videos.
41155581|NCT05306223|DRUG|Bedaquiline|Bedaquiline uncoated tablets will be administered orally.
41155582|NCT05306223|DRUG|Levofloxacin|Levofloxacin filmcoated will be administered orally
41155583|NCT05306223|DRUG|Linezolid|Linezolid tablets will be administered orally
41155584|NCT05306223|DRUG|Cycloserine|Cycloserine capsules will be administered orally.
41328915|NCT04377269|OTHER|Taping and Bandaging|Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon
41481330|NCT05093374|DRUG|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF."
41155585|NCT05306223|DRUG|Clofazimine|Clofazimine capsules will be administered orally.
41155586|NCT05306223|DRUG|Pyrazinamide|Pyrazinamide tablets will be administered orally.
41328916|NCT02278991|DEVICE|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
41328917|NCT00503542|DRUG|Terazol or oral fluconazole for candidal vaginitis|Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
41328918|NCT00503542|DRUG|Metronidazole or Clindamycin for Bacterial Vaginosis|Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
41328919|NCT00503542|DRUG|Flagyl for definitively diagnosed vaginal trichomoniasis|Metronidazole 2 gms po x 1
41328920|NCT00503542|OTHER|Empiric Management|In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
41328921|NCT00627770|DEVICE|bioimpedance spectroscopy ImpediMed SFB7 Brisbane Australia|edema evaluation using bioimpedance
41328922|NCT04183387|DRUG|Simvastatin 40mg|
41328923|NCT06377072|DRUG|Shenqi Sherong Pill|two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
41328924|NCT06377072|DRUG|Placebo|two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
41481331|NCT05093374|DRUG|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
41481332|NCT05218382|DEVICE|Virtual reality|immersive virtual reality technology
40811037|NCT03958747|DIAGNOSTIC_TEST|Ultrasound - Serial and Tibial Nerve|Participants will undergo a serial and tibial nerve ultrasound
40811038|NCT03958747|PROCEDURE|Skin Biopsy|Two skin biopsies will be obtained as 4.0 mm punch biopsies at distal end of leg in sural nerve territory (10 cm above lateral malleolus) and from the thigh
40811039|NCT03958747|OTHER|Abbreviated Neurologic Exam|Exam to include strength assessment of the tibialis anterior and gastrocnemius and deep tendon reflex exam of the Achilles on the limb to be examined by nerve conduction velocity and ultrasound.
40811040|NCT03958747|OTHER|Blood draw|12 ml blood sample will be taken
40811041|NCT03958747|DIAGNOSTIC_TEST|Nerve Conduction Study|Sural and tibial nerve assessments
40811042|NCT03958747|OTHER|QLQ-CIPN20 Questionnaire Administration|Self-reported neuropathy scoring questionnaire completed same day as blood draw.
40811043|NCT05273255|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of CI.
41011626|NCT01713868|BEHAVIORAL|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
41011627|NCT04888000|OTHER|Educational Intervention|Professional development program provided to small groups of health care professionals in three different sessions over a period of one month with additional independent individual work to be completed between sessions.
41328925|NCT03522194|DRUG|Sevoflurane|Anesthesia maintenance with Sevoflurane
41328926|NCT03522194|DRUG|Propofol|Anesthesia maintenance with Propofol
41155587|NCT05306223|DRUG|Protionamide|Protionamide enteric-coated tablets will be administered orally.
41155588|NCT01896921|DRUG|Switch to Maraviroc + Raltegravir or Dolutegravir|Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
41155589|NCT05983328|DRUG|HUYPS-1 one tablet|After 7-day washout time, subjects will receive HUYPS-1 1 tablet.
41155590|NCT05983328|DRUG|HUYPS-1 nine tablets|After 7-day washout time, subjects will receive HUYPS-1 9 tablets.
41155591|NCT01391533|DRUG|SAR125844|"Pharmaceutical form:solution~Route of administration: intravenous"
41328927|NCT03032510|DRUG|Eravacycline|
41328928|NCT03032510|DRUG|Ertapenem|
41328929|NCT03032510|DRUG|Placebo|
41328930|NCT03032510|DRUG|Levofloxacin|
41328931|NCT02847845|DIETARY_SUPPLEMENT|red ginseng powder capsule|usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
41328932|NCT02847845|DIETARY_SUPPLEMENT|Placebo|Control (Placebo) : red ginseng powder capsule(placebo) usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
41328933|NCT05200429|DRUG|Trikafta|Highly Effective CFTR Modulator Therapy
41328934|NCT01349972|DRUG|alvocidib|Given IV
41328935|NCT01349972|DRUG|daunorubicin hydrochloride|Given IV
41328936|NCT01349972|DRUG|mitoxantrone hydrochloride|Given IV
41328937|NCT01349972|DRUG|cytarabine|Given IV
41328938|NCT06104319|DRUG|GSK4532990|GSK4532990 will be administered
40811044|NCT06002906|DRUG|Indocyanine green|Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediately followed the injection of indocyanine green by an anesthesiologist. A subjective score of 1-5 for perfusion will be assigned by operating surgeons. The RYGB will then be completed by the operating surgeon in their routine fashion.
40811045|NCT06002906|DEVICE|Stryker 1688 AIM system|The Stryker 1688 AIM system used during laparoscopic surgery which is sensitive in the visible and infrared spectrum. ICG (SPY AGENT™ GREEN) is used with the SPY mode in the Stryker 1688 AIM fluorescence imaging system to perform intraoperative fluorescence angiography.
40811046|NCT05980104|BEHAVIORAL|Empowered Relief|The participants will attend an online pain relief skills intervention (Empowered Relief). The two-hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
41155592|NCT03503643|DEVICE|Hemigland Cryoablation|Hemigland cryoablation for the treatment of prostate cancer
41155593|NCT04593641|BIOLOGICAL|CT-P59|administered
41011628|NCT01728155|DRUG|chemotherapy|
41328939|NCT04355494|BIOLOGICAL|eculizumab|Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)
41011629|NCT06116422|BEHAVIORAL|Grocery intervention - unrestricted|Receives financial support in an unrestricted fashion (i.e., can use the money for whatever they need).
41011630|NCT06116422|BEHAVIORAL|Grocery intervention - restricted|Receives financial support restricted to the purchase of items at a grocery store, and with monthly grocery shopping coaching from a trained nutrition expert.
41328940|NCT06376370|OTHER|Application of computer-assisted cognitive rehabilitation program|Since the program will respond to the patient's specific needs, the activity may become easier or more difficult depending on the patient's performance. Epilepsy patients will be encouraged by researchers during the exercises and will be able to give feedback on progress at the end of the session. After determining the appropriate time and day for each patient in the experimental group, the intervention will continue for 6 weeks with 45-minute sessions once a week.
41328941|NCT02521909|DEVICE|ProMark (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
41011631|NCT05405673|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|A kind of stool test
41328942|NCT02521909|DEVICE|Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
41011632|NCT02069561|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
41328943|NCT02521909|DEVICE|NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
41328944|NCT00593658|DRUG|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
41481333|NCT05218382|DEVICE|No virtual reality|Virtual reality with blank screen
41481334|NCT03001219|DRUG|Anti-TNF-alpha|Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
41481335|NCT03001219|DRUG|Methotrexate|Participants will continue their pre-trial methotrexate therapy at a stable dose.
41481336|NCT03001219|DRUG|Placebo|Participants will receive intravenous infusion of placebo.
41481337|NCT03001219|DRUG|RO7123520|Participants will receive intravenous infusion of RO7123520.
41481338|NCT01077882|BEHAVIORAL|education on skin disease conditions|information about several skin diseases skin function recommendation on care of skin
41481339|NCT01077882|BEHAVIORAL|Stress-reduction techniques|Physical Training yoga mindfulness-based stress reduction
40811051|NCT04644471|DIAGNOSTIC_TEST|CT scanner|1 conventional low dose inspiratory acquisition and 1 ultra-low-dose inspiratory acquisition
40811052|NCT04644471|DIAGNOSTIC_TEST|Lung MRI|3 UTE sequences (free breathing, inspiratory and expiratory) and 1 T2 sequence
40811053|NCT04647253|DEVICE|AGENT DCB|Drug coated PTCA balloon catheter
40811054|NCT04647253|DEVICE|PTCA balloon catheter|PTCA balloon catheter
40811055|NCT04884035|DRUG|CC-220|CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
40811056|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
41481340|NCT01077882|BEHAVIORAL|Lifestyle factors and psycho-education|by dietician and psychiatrist
41481341|NCT01077882|OTHER|no educational program|standard care without educational program
41481342|NCT02595008|DRUG|DSXS|Active treatment
41481343|NCT03091413|DIAGNOSTIC_TEST|diaphragm ultrasound|"For each patient intubated and ventilated in our ICU we will performed diaphragm ultrasound during the weaning process.~We will performed the measurement of diaphragmatic maximum excursion during a maximal inspiration using an abdominal standard preset with M-mode, with the so called anatomical M-mode.~We will put the probe in the right subcostal window to use the hepatic window to assess the movement of the diaphragm. We will performed the measure of the diaphragm excursion with patient in semi-recumbent position and through a transhepatic transverse oblique scan while the patient is on mechanical ventilation and undergo a Pimax maneuver, that consists in a temporary occlusion of the airway with an expiratory pause.~We will performed the measure three times, and we will take into account the best one made by the patient."
41481344|NCT00975962|DRUG|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
41481345|NCT00975962|PROCEDURE|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
40811057|NCT04884035|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
40811058|NCT04884035|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
40811059|NCT04884035|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
40811060|NCT04884035|DRUG|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
41011633|NCT04154280|DIAGNOSTIC_TEST|PET/MR scan|"* The PET will be performed with 68Ga-PSMA tracer.~* The 3 tesla magnet of the MRI will be used with sequence allowing MRS acquisition, additional sequences will include T2-weighted contrast and diffusion weighted contrast.~* Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV) or Ki (in case dynamic PET protocol will be applied). In addition, content relationship between metabolic entities detected will be extracted.~Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity."
41011634|NCT03464344|OTHER|neurological, neuropsychological and MRI evaluation|neurological, neuropsychological and MRI evaluation
41011635|NCT06319599|BEHAVIORAL|Routine therapy|During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
41266481|NCT00723684|OTHER|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
41266482|NCT01007214|PROCEDURE|Prostatectomy|Elective prostatectomy
41266483|NCT02893345|BEHAVIORAL|Safe@Home Intervention Group|For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
41266484|NCT02893345|OTHER|Usual Care Group|Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
41266485|NCT05487794|DRUG|Testosterone Cypionate 100 MG/ML|Testosterone is also responsible for increasing hematocrit by stimulating erythropoiesis (Velho et al., 2017). In cisgender men, who are hypogonadal and do not adequately produce testosterone, treatment with the use of testosterone is associated with stimulation of erythropoiesis, which can potentially increase blood viscosity, resulting in secondary erythrocytosis (Hajjar et al., 1997).
41266486|NCT01639326|DRUG|Irinotecan high doses|Irinotecan dose of 300 mg / m² in patients UGT1A1 \* 1 / \* 1 and 260 mg / m² in patients UGT1A1 \* 1 / \* 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
41266487|NCT01639326|DRUG|Irinotecan standard doses|Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
40811061|NCT04884035|DRUG|CC-99282|CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
40811062|NCT04884035|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
40811063|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
40811064|NCT05638802|DRUG|DS-7011a|20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
40811065|NCT05638802|DRUG|Placebo|Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
41266488|NCT04975802|OTHER|Placebo|10 oz (296 ml) cherry flavored still beverage
41481346|NCT05963191|DEVICE|Colorectal cancer screening with CAD EYE colonoscopy|"The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. A colonoscopy is considered complete if the endoscope reaches the appendicular orifice or the terminal ileum. In line with recommendations, water lavage (using a lavage pump) and aspiration of food residues will be performed on ascent and/or descent to visualize the entire colonic mucosa.~In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on. When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately. Then polyps will be removed by polypectomy or mucosectomy. Removed polyps are then sent for anatomopathological analysis."
41481347|NCT04572282|DEVICE|Mentora app|Remote monitoring mobile app
41155594|NCT06254079|PROCEDURE|video based education|The patients in the experimental group will be shown a video containing information about the operating room environment and care during surgery. The video content includes the following details: the operating room temperature being maintained at 18-24°C; the patient being placed on the operating table by the staff in the presence of an anesthesia technician; the establishment of intravenous access by the anesthesia technician; monitoring of blood pressure, pulse, respiration, and EKG indicators; the insertion of a urinary catheter by the surgical nurse after the patient is anesthetized; post-awakening transfer to the postoperative recovery unit with the anesthesia technician and personnel; reception and monitoring of vital signs, pain assessment, intervention, and observation for a period by a nurse in this unit; and finally, transfer to the General Surgery Service.
41155595|NCT01718613|DRUG|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
41481348|NCT02907541|OTHER|QI4U learning|Learners will have access to 8 QI methods modules on QI4U
41481349|NCT02907541|OTHER|Facilitated learning|Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops
41011636|NCT06319599|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41011637|NCT06319599|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
41011638|NCT06319599|BEHAVIORAL|placebo injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41011639|NCT05886764|OTHER|Digital Intervention|Digital messages (email, text, etc.) which include general educational information about clinical trials and available resources.
41011640|NCT05886764|OTHER|Community Outreach|Invitation to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial.
41481350|NCT02907541|OTHER|QI4U and Facilitated learning|Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
41481351|NCT02774486|DEVICE|IQP-AK-102|IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.
41481352|NCT04420221|BIOLOGICAL|Sa-5Ag half dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1, administered intramuscularly.
41481353|NCT04420221|BIOLOGICAL|Sa-5Ag full dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1, administered intramuscularly.
41155596|NCT01718613|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
41155597|NCT03617458|DRUG|Metformin|Metformin is a drug has been on the market for several decades and is considered first line therapy for diabetes mellitus type 2.
41155598|NCT03617458|DRUG|Placebo|A treatment with no active ingredients or therapeutic effect.
41266489|NCT04975802|DIETARY_SUPPLEMENT|Coffeeberry|10 oz (296 ml) cherry flavored still beverage
41266490|NCT04975802|DIETARY_SUPPLEMENT|Caffeine|10 oz (296 ml) cherry flavored still beverage
41266491|NCT04664348|OTHER|Posteroanterior mobilization (neutral)|"Positioning of the patient: Prone position with the lumbar area uncovered.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.~Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment."
41481354|NCT04420221|BIOLOGICAL|Sa-5Ag half dose adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1, administered intramuscularly.
41481355|NCT04420221|BIOLOGICAL|Sa-5Ag full dose adjuvanted|A series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61), administered intramuscularly.
41481356|NCT04420221|BIOLOGICAL|Placebo|One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo groups 1 to 3 and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo groups 4 and 5, administered intramuscularly.
41481357|NCT06223217|OTHER|Surveys and Questionnaires|The intervention consists of completing the Chinese version of Vascu-QoL scale and the modified version of Vascu-QoL scale
41481358|NCT01170910|PROCEDURE|Static incubation|"Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.~."
41155599|NCT03617458|DEVICE|mHealth Intervention|Our Health Insurance Portability and Accountability Act (HIPAA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.Subjects assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
41328945|NCT01090869|BEHAVIORAL|12 weeks of lifestyle change|Participants were randomly assigned to a 12-week intervention in one of four groups: Training (T), energy-reduced Diet (D), Training and increased- Diet (T-iD) or Control (C). The interventions consisted of: T: increased physical activity through daily endurance training equivalent to 600 kcal/day, unchanged diet; D: sedentary lifestyle, reduced diet by 600 kcal/day primarily through reducing serving sizes and substituting energy dense with less energy dense nutrients; T-iD: increased physical activity through daily endurance training equivalent to 600 kcal/day, increased diet by 600 kcal/day primarily through increasing serving sizes and consuming energy dense nutrients; C: sedentary lifestyle and unchanged diet.
41481359|NCT01170910|PROCEDURE|Pulsatile perfusion|Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
40811074|NCT05839730|DEVICE|Pacemaker PLR + TRT ON|RAMware modified implantable pulse generator (IPG) with personalized lower rate (PLR) and tachycardia remodeling therapy (TRT) ON
40811075|NCT05839730|DEVICE|Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.|RAMware modified implantable pulse generator (IPG)
40811076|NCT04720755|DEVICE|Low-Intensity Extracorporeal Shock Wave Therapy|Twice-weekly treatments for 6 weeks, of 0.2mL/mm\^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.
40811077|NCT00977574|BIOLOGICAL|Bevacizumab|Given IV
40811078|NCT00977574|DRUG|Carboplatin|Given IV
40811079|NCT00977574|DRUG|Ixabepilone|Given IV
40811080|NCT00977574|OTHER|Laboratory Biomarker Analysis|Correlative studies
40811081|NCT00977574|DRUG|Paclitaxel|Given IV
40811082|NCT00977574|DRUG|Temsirolimus|Given IV
40811083|NCT04195399|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40811084|NCT04195399|PROCEDURE|Computed Tomography|Undergo CT
41481360|NCT03968198|DRUG|Autologous ASC (for Adipose-derived Stem/Stroma Cell)|After adipose tissue aspiration (liposuction) by an authorized person, ASCs were isolated and cultured during 14±2 days by the French Blood Establishment. Then, patients receive intramuscular injections of ASCs.
41481361|NCT00303394|DRUG|IL-1Ra|
40811085|NCT04195399|PROCEDURE|Echocardiography|Undergo ECHO
41481362|NCT01757574|DRUG|Alemtuzumab infusion|
41481363|NCT03418506|BEHAVIORAL|SMOKELESS TOBACCO AWARENESS PROGRAM|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
41481364|NCT06219486|DIAGNOSTIC_TEST|D-dimer|The investigators will measure a D-dimer test on participants and randomize on informing the physician on the value.
41481365|NCT01665924|DRUG|GLPG0634 100mg capsule once a day for 10 days|
41481366|NCT06493903|BEHAVIORAL|Positive Minds, Strong Joints|In this10-week physical and mental health intervention, participants will receive recommended exercise intervention and evidence-based mental health intervention for pain, depression and anxiety.
40811086|NCT04195399|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40811087|NCT04195399|DRUG|Nirogacestat|Given PO
40811088|NCT04195399|OTHER|Quality-of-Life Assessment|Ancillary studies
40811089|NCT04195399|OTHER|Questionnaire Administration|Ancillary studies
40811090|NCT04195399|PROCEDURE|X-Ray Imaging|Undergo x-ray
41155600|NCT03617458|DEVICE|Usual Care|Our HIPAA data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.
41155601|NCT01245803|DRUG|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
41155602|NCT01245803|DRUG|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
40811094|NCT06292637|BEHAVIORAL|Cognitive Behavioral Faith Fellowship to Improve Thy Health (CB-FAITH)|CB-FAITH is a behavioral depression intervention set inside a cognitive behavioral framework, and Afrocentric paradigm and informed by faith-based principles, designed to treat major depressive disorder among African American adults. The 13-treatment modules focus on increasing knowledge of depression and healthy coping behaviors. It is designed to be co-delivered by licensed mental health clinicians and pastors at churches.
40811095|NCT06411912|DRUG|NIDO-361|Tablets containing 100mg of NIDO-361 for oral administration.
40811096|NCT06411912|DRUG|Placebo|Placebo oral tablets
41155603|NCT02868788|DIETARY_SUPPLEMENT|dietary fiber|Fiber one supplement (32 grams of fiber) will be consumed with 910 Calorie HFHC meal
41155604|NCT02868788|OTHER|HFHC meal|910 Calorie HFHC meal
41011641|NCT05320029|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
41155605|NCT03364283|PROCEDURE|Surgical position|
41155606|NCT00629642|DRUG|Solifenacin Succinate|Oral, 10mg
41155607|NCT00629642|DRUG|Solifenacin Succinate|Oral, 5mg
41155608|NCT00629642|DRUG|Oxybutynin Hydrochloride|Oral, 15mg
41155609|NCT00629642|DRUG|Placebo|Oral
41155610|NCT02828592|DRUG|Fludarabine|30 mg/m2 IV QD x 5 days (Days -6 to -2)
41011642|NCT05320029|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
41155611|NCT02828592|DRUG|Cyclophosphamide|14.5 mg/kg/day IV x 2 doses (Days -6 \& -5)
40811100|NCT04470908|DRUG|Zanubrutinib|Single oral dose of 320 mg
40811101|NCT04470908|DRUG|Rifabutin|Oral dose of 300 mg once daily
41155612|NCT02828592|RADIATION|Total Body Irradiation|300 cGy x1 dose (Day -1)
41011643|NCT05448001|DRUG|JP-1366 20mg|JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
40811103|NCT02905591|DRUG|Radiation Therapy|Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days
41011644|NCT05448001|DRUG|Lansoprazole 30mg|JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
41011645|NCT04768036|OTHER|IMPROVE DD VTE Tool|"Universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry incorporated into required admission and discharge EHR workflow."
41011646|NCT01046955|DRUG|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
41011647|NCT02187016|DEVICE|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
41011648|NCT02187016|DEVICE|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
41011649|NCT02187016|DEVICE|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
41011650|NCT02187016|DEVICE|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
41011651|NCT01929668|DRUG|polyethylene glycol|
41481367|NCT04476966|DRUG|Bladogra|1 tablet contains 25 mg Mirabegron
41481368|NCT04476966|DRUG|Myrbetriq (first dosing)|1 tablet contains 25 mg Mirabegron
40811104|NCT02905591|DRUG|Paclitaxel|"Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered~* the dose is 45 mg/m2 (standard dose)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standardized dose reductions are used"
40811105|NCT02905591|DRUG|Carboplatin|"Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.~* Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standard dose reductions are used"
40811106|NCT02905591|DRUG|Ascorbic Acid|"Administered intravenously~* 75 grams per infusion; each infusion is about 2 hours~* 3 infusion per calendar week~* The infusion is actively running for at least 20 minutes when radiation begins~* May be given while chemotherapy is delayed due to low counts~* Dose reductions are not used~* Given for 6 to 7 weeks, depending on when radiation starts"
40811107|NCT06034873|DRUG|Propofol injection and fentanyl|The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
40811108|NCT06034873|DRUG|Bupivacain|Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
40811109|NCT06247254|BEHAVIORAL|Intensive Clinic Management|The ICM arm includes BP management at in-person follow-up visits occurring every 2 months when BPs are at target and if not in target, monthly visits. Medications will be adjusted to lower BP to the target using evidence-based guidelines and in the context of whether the participant can effectively manage their medications and BP. ICM participants will receive a COMPASS Care plan, which will evaluate social and functional factors for managing stroke recovery.
41011652|NCT01929668|DRUG|Ascorbic Acid|
41011653|NCT00808938|DEVICE|MST|Magnetic Seizure Therapy
41011654|NCT05724498|BEHAVIORAL|Brief CBT-I|4 session CBT-I
41011655|NCT05724498|BEHAVIORAL|Standard CBT-I|Standard VA 6 session CBT-I
41011656|NCT03976921|DIAGNOSTIC_TEST|Integration of CCTA with stress CTP when indicated|When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
41011657|NCT03976921|DIAGNOSTIC_TEST|Standard of care approach|(a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
41011658|NCT02541266|OTHER|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
41011659|NCT03444142|DRUG|Exenatide LAR|2 mg, once weekly subcutaneously before breakfast during 4 weeks.
41011660|NCT03444142|DRUG|Dulaglutide|.75 mg once weekly subcutaneously before breakfast during 4 weeks.
41011661|NCT05353192|DRUG|Recombinant human growth hormone|Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
41011662|NCT03063359|DRUG|Intranasal fentanyl + Oral Placebo|Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
41011663|NCT03063359|DRUG|Oral Morphine + Intranasal Placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
41011664|NCT00653107|PROCEDURE|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
41011665|NCT00653107|RADIATION|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
41155613|NCT02828592|DRUG|Rabbit ATG|1.5 mg/kg/day x 3 days (Days -3 to -1)
41155614|NCT02828592|DRUG|Cyclophosphamide|Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
41155615|NCT02429037|DRUG|rAd-p53|multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10\^12 viral particles (VP) in a 21-days cycle.
41155616|NCT02429037|RADIATION|radiation|radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
41155617|NCT02429037|DRUG|Cisplatin|Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
41481369|NCT04476966|DRUG|Myrbetriq (second dosing)|1 tablet contains 25 mg Mirabegron
40811110|NCT06247254|BEHAVIORAL|Intensive Tailored Telehealth Management|The ITTM intervention involves a comprehensive, multi-dimensional approach to using real-time BP data to manage BP after stroke. ITTM includes an in-person visit during which participants will complete a series of questionnaires within the COMPASS-CP® web application and will receive a COMPASS-BP Action Plan home safety checklist, BP Matters documents, and referrals to local resources, as needed.
41011666|NCT00653107|RADIATION|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
41155618|NCT03612492|DRUG|Esmolol|Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.
40811112|NCT04234646|BEHAVIORAL|Patient Navigation (PN) 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
40811113|NCT04234646|BEHAVIORAL|One-on-one Patient Navigation (PN)|The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
41155619|NCT03612492|DRUG|Lidocaine|Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
40811115|NCT03206918|DRUG|Zanubrutinib|Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)
40811116|NCT04673942|BIOLOGICAL|AdAPT-001|Oncolytic virus administered by intratumoral injection
40811117|NCT04673942|DRUG|Checkpoint Inhibitor, Immune|Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
40811118|NCT06318273|DRUG|ABBV-969|Intravenous (IV) Infusion
40811119|NCT01087294|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cell transplant
40811120|NCT01087294|BIOLOGICAL|Anti-CD19-chimeric-antigen-receptor-transduced T cells|"Patients receive T cells genetically engineered to express an anti-CD19 CAR. The cells are cultured in media containing IL-21, IL-7, and TWS119.~TWS119 is a glycogen synthase 3 inhibitor"
40811121|NCT01087294|PROCEDURE|Leukapheresis|Donors will undergo leukapheresis
40811122|NCT02629120|DRUG|Alemtuzumab|Transplant Conditioning Drug: Monoclonal antibody that targets recipient and donor T-cells to prevent graft verses host disease. Not an IND. This is a well studied drug, and is not under an IND.
40811123|NCT02629120|DRUG|Busulfan|Transplant Conditioning Drug: Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under an IND.
41155620|NCT01266499|DRUG|Colistin (Polymyxin E) 100mg x 4/d|Colistin (Polymyxin E) 100mg x 4/d
41155621|NCT01266499|DRUG|both medications|PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
41155622|NCT01266499|DRUG|will not receive PO treatment|will not receive PO treatment - will receive plecebo treatment
41155623|NCT01266499|DRUG|PO Garamycin 80mg x 4/d|PO Garamycin 80mg x 4/d
41155624|NCT05769361|BEHAVIORAL|UNST|Strength and balance training using different destabilizing devices
40811124|NCT02629120|DRUG|Sirolimus|Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
41155625|NCT05769361|BEHAVIORAL|ST|Strength and balance training over firm surfaces
41155626|NCT06388785|OTHER|No Intervention|This is a non-interventional study.
41155627|NCT02245971|PROCEDURE|Partial precutting|Partial precutting will be performed prior to dissection during the ESD.
41155628|NCT02245971|PROCEDURE|Whole precutting|Whole precutting will be performed prior to dissection during the ESD.
41155629|NCT05196035|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 180±7 days
41155630|NCT05196035|DRUG|Placebo|Placebo to finerenone, treatment duration will be 180±7 days
41155631|NCT05043688|DRUG|Camrelizumab|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
41328946|NCT00648661|DRUG|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
40811125|NCT02629120|DRUG|Cyclophosphamide|Post transplant cyclophosphamide given to prevent graft verses host disease. This is a well studied drug, and is not under an IND.
40811126|NCT02629120|RADIATION|Total Body Irradiation|Transplant Conditioning Total Body Radiation (300cGy in 2 fractionated doses), given only to patient receiving matched unrelated donor cells, to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow.
40811127|NCT02629120|BIOLOGICAL|Peripheral blood stem cells|Donor Peripheral blood stem cells, either matched unrelated donor or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
40811128|NCT02311374|OTHER|Brain connectivity and physiology|Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2\*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.
40811129|NCT02311374|OTHER|Brain Wave|ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages
41328947|NCT00648661|DRUG|Lexapro® Tablets 20 mg|20mg, single dose fed
41155632|NCT05043688|RADIATION|radiotherapy|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
41328948|NCT03039920|OTHER|Electronic cigarette|Smoking of electronic cigarette
41481370|NCT02110017|OTHER|fMRI social cognition task|fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
41328949|NCT03039920|OTHER|Conventional cigarette|Smoking tobacco cigarette
41328950|NCT00976729|DRUG|NOX-E36|single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
41328951|NCT00976729|DRUG|NOX-E36|single SC doses, at safe and tolerable dose level
41328952|NCT00976729|DRUG|Placebo|
41328953|NCT02145832|DRUG|Fluconazole|
41328954|NCT02145832|DRUG|Micafungin|
41481371|NCT03621319|DEVICE|Hybrid argon plasma ablation (HAPC)|-The assigned HAPC ablation will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
41155633|NCT05466942|DEVICE|Pulse Oximeter, Respiratory Rate, Heart Rate|Measurement of physiological parameters
41328955|NCT02045251|DRUG|Pylera based reduced regimen|Patients with H. pylori infection will be treated with a 10 day course of reduced Pylera based regimen.
41328956|NCT01019252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
41328957|NCT01670136|DRUG|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
41328958|NCT06445465|DRUG|[18F]MNI-1216|\[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
41328959|NCT01929213|DRUG|Udenafil|Udenafil is administered
41481372|NCT03621319|DEVICE|Radiofrequency ablation (RFA)|-The assigned RFA procedure will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
41481373|NCT01635062|DRUG|Calcitriol|Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
41481374|NCT01635062|DRUG|Placebo|Subjects will receive placebo for 3 weeks.
41481375|NCT02277704|DRUG|TNX-102 SL|
41481376|NCT02277704|DRUG|Placebo|
41481377|NCT00206765|DRUG|Risperidone|
41481378|NCT00206765|DRUG|Paroxetine|
41155634|NCT00024102|DRUG|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 \& 8 and 5-FU 600 mg/sq m IV push d 1 \& 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
41155635|NCT00024102|DRUG|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
41328960|NCT01929213|DRUG|Bosentan|Bosentan is administered
41328961|NCT01929213|DRUG|Udenafil/Bosentan|Udenafil and Bosentan are administered
41328962|NCT00188968|PROCEDURE|Nasal Continuous Positive Airway Pressure|
41328963|NCT00188968|PROCEDURE|Synchronized Nasal Positive Pressure Ventilation|
41328964|NCT02136511|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
41328965|NCT02136511|DRUG|Rituximab|Rituximab administered intravenously starting at 375 mg/m\^2 at Week 0 and continuing with a dose of 500 mg/m\^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
41328966|NCT05599412|DRUG|Lorviqua|As provided in real world practice
41328967|NCT02505815|PROCEDURE|Surgery|
41328968|NCT02505815|PROCEDURE|Cortisol Level Measurement|
41328969|NCT02505815|PROCEDURE|Neurocognitive Testing|
41328970|NCT02958904|OTHER|using questionnaires|using questionnaires International Index Erectile Function and Beck Depression Inventory.
41328971|NCT02191280|DRUG|Antistax®, low dose|
41328972|NCT02191280|DRUG|Antistax®, high dose|
41328973|NCT02191280|DRUG|Placebo|
41328974|NCT01882777|BEHAVIORAL|Household drinking water filters and cookstoves|The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
41328975|NCT04725539|PROCEDURE|hypoxic exposure|"Administration of different hypoxic doses.~Intermittent hypoxia:~days 1-5 duration of breathing periods 5\*3min (FiO2 14-21%) days 8-12 duration of breathing periods 4\*4min (FiO2 = 12%) and 3\*3 min (FiO2 = 21%) days 15-19 duration of breathing periods 5\*5min (FiO2 = 10%) and 4\*3 min (FiO2 = 21%)~one night at 1900m"
41481379|NCT05937321|BEHAVIORAL|Share plus intervention|"Participants will receive the Share plus intervention:~* Set up Follow app~* Start Share plus intervention~* Communication and problem-solving strategies~* Detailed action plan including glucose targets~* Review communication and problems~* New communication content~* Revise action plan as needed for communication and problem-solving hypo- and hyperglycemia,~* Dyadic glucose pattern management training using Clarity, set automatic Clarity downloads~* Dyad set goals for regular times to discuss glucose trends and problem-solving~* Dyadic review of glucose targets after an in-depth analysis of CGM data and dyadic treatment strategies to improve glucose TIR"
41481380|NCT05937321|BEHAVIORAL|Control group|Diabetes self-management education materials
40811137|NCT03907046|DRUG|Apixaban|Apixaban is an oral anticoagulant of the Factor Xa inhibitor class.
40811138|NCT03907046|DRUG|Aspirin|Aspirin is an oral antiplatelet drug.
40811139|NCT06062667|OTHER|accompany the birth|Fathers will accompany their husbands during the birth process
41155636|NCT02475733|DRUG|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
41155637|NCT02475733|DRUG|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
40811142|NCT05751668|DRUG|Paclitaxel|Given IV
40811143|NCT05751668|DRUG|Monosialotetrahexosylganglioside|Given IV
40811144|NCT05751668|OTHER|Questionnaire Administration|Ancillary Studies
40811145|NCT05751668|OTHER|Quality-of-life assessment|Ancillary Studies
40811146|NCT05751668|DRUG|Placebo Administration|Given IV
40811147|NCT04851119|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40811148|NCT04851119|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
40811149|NCT04851119|DRUG|Tegavivint|Given IV
40811150|NCT04851119|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
41155638|NCT02475733|DRUG|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
41155639|NCT00412828|DRUG|CR011-vcMMAE|administered as an intravenous infusion of 250 mL over 90 min
41155640|NCT05959109|DRUG|Peresolimab|Administered SC
41155641|NCT01350388|DRUG|Febuxostat|80 mg/day of febuxostat for 24 weeks
41155642|NCT01350388|DRUG|Placebo|1 placebo tablet per day for 24 weeks
41328976|NCT05082402|DIAGNOSTIC_TEST|Swept Source Optical Coherence Tomography Angiography|The PLEX Elite 9000 is an FDA cleared research device for use in ocular imaging obtained by Northwestern University by way of a purchase agreement with the manufacturer, Carl Zeiss Meditec, Inc. It is currently unavailable outside of participation in the ARI Network, a cloudbased storage and image processing platform using deidentified information shared between academic institutions. The ARI Network is managed by a group of physicians and scientists from around the world that are working to better understand eye diseases.
41481381|NCT01173913|DRUG|ModraDoc001 10mg capsules|Bi-daily administration. One cycle will last 7 days
41155643|NCT00957671|DRUG|Recombinant human growth hormone|200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
41155644|NCT05897125|OTHER|Virtual at Home Medication Reconciliation Visit(s)|Patients will have their medications reviewed by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
41155645|NCT05897125|BEHAVIORAL|Virtual At Home Medication Education Visit(s)|Patients will be provided with inhaler education by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
41155646|NCT05897125|OTHER|COPD advanced practice nurse Inpatient Consult|Patients will receive a COPD consult by an advanced practice nurse as part of standard of care
41155647|NCT05897125|OTHER|Inpatient Medication Reconciliation|Patients will have their medications reviewed by member(s) of the clinical care team as part of standard of care
41155648|NCT05897125|OTHER|Post-discharge nurse 48 hour phone follow-up call|Patients will receive a post-discharge nurse 48 hour phone follow-up call as part of standard of care
41155649|NCT05897125|OTHER|Post-discharge follow-up advanced practice nurse outpatient visit|Patients will be scheduled for a 1-2 week post-discharge visit with the COPD advanced practice nurse as part of standard of care
41155650|NCT05312190|DRUG|ZhenQi BuXue KouFuYe|Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
41155651|NCT05312190|DRUG|Progesterone Capsules|The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
40811172|NCT05359822|OTHER|Image-Based Report|Participants will receive the new coronary artery calcium score risk report plus the old report
41155652|NCT06016179|DRUG|Tocilizumab|Each patient will receive four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.
40811176|NCT04832802|BEHAVIORAL|ACCESS|ACCESS-Vets is a customized employment intervention adapted for use in VA healthcare to help Veterans with SCI achieve competitive integrated employment. ACCESS-Vets includes the following elements: discovery, customized employment planning, job development, customized employment negotiation, and accommodations and job retention supports.
40811177|NCT04832802|BEHAVIORAL|IPS|IPS is an evidenced-based practice of supported employment that helps persons with disabilities find and maintain integrated competitive employment. IPS follows eight standardized principles: zero exclusion, integrated services, rapid job search, competitive employment, worker preferences, systematic job development, benefits planning, and time-unlimited supports.
40811180|NCT06542874|DRUG|NNC0487-0111 subcutanous|NNC0487-0111 administered subcutanously (under the skin)
40811181|NCT06542874|DRUG|Placebo (NNC0487-0111 subcutanous)|NNC0487-0111 placebo administered subcutanously (under the skin)
40811182|NCT06542874|DRUG|NNC0487-0111 oral|NNC0487-0111 administered orally (in the mouth)
40811183|NCT06542874|DRUG|Placebo (NNC0487-0111 oral)|NNC0487-0111 placebo administered orally (in the mouth)
40811184|NCT02518087|DEVICE|oXiris®|"oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[oXiris® (Baxter Gambro)\].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
40811185|NCT02305849|DRUG|Peficitinib|oral tablet
40811186|NCT02305849|DRUG|Placebo|oral tablet
40811187|NCT02305849|DRUG|Methotrexate|Oral tablet/capsule
41155653|NCT04257786|PROCEDURE|1ry cyto-reductive surgery|1ry surgery then chemotherapy
41155654|NCT04257786|COMBINATION_PRODUCT|Neoadjuvant chemotherapy followed by surgery|chemotherapy then surgery
41155655|NCT05041478|PROCEDURE|Cold Snare Endoscopic mucosal resection with adjuvant snare tip soft coagulation|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare. Following this defect margins are treated with electrocautery to create a rim of ablated tissue.
41155656|NCT05041478|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare.
41155657|NCT03494907|DRUG|Seltorexant|Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.
40811193|NCT06094218|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.
41155658|NCT03494907|OTHER|Placebo Matched to Seltorexant|Participants will be administered matching placebo to seltorexant tablets on Day 1.
41155659|NCT03494907|OTHER|Placebo Matched to Moxifloxacin|Participants will be administered oral dose of moxifloxacin placebo tablet on Day 1.
41155660|NCT03494907|DRUG|Moxifloxacin Dose 1|Participants will be administered oral dose 1 of moxifloxacin on Day 1.
41155661|NCT03915951|DRUG|encorafenib|self-administered orally
41155662|NCT03915951|DRUG|binimetinib|self-administered orally
41155663|NCT06423976|OTHER|Sequencing study|Sequencing of tumour samples for microbiome analysis and molecular charcterisation.
41155664|NCT03092323|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
41155665|NCT02266589|DRUG|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
41328977|NCT05803369|BEHAVIORAL|Regulating Together (RT)|Regulating Together is an intensive outpatient group treatment targeting emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
41328978|NCT05803369|BEHAVIORAL|Achieving Independence and Mastery in School (AIMS)|AIMS is a school-based program developed to help students with social-communication challenges (such as autism spectrum disorder) achieve academic success. It is well-established and has been used with autistic youth, both in schools and in outpatient settings.
40811194|NCT06094218|BEHAVIORAL|Treatment as usual (TAU)|Behavioral health treatment as it is typically provided at the treatment site.
40811195|NCT04627675|DRUG|CORVax|DNA-encodable coronaviral vaccine
40811196|NCT04627675|DRUG|IL-12 plasmid|cytokine
40811197|NCT04627675|DEVICE|Cliniporator|electroporation system
41155666|NCT04127383|DEVICE|Assessment of Burden of Chronic Conditions (ABCC)-tool|The tool consists of a questionnaire, a visualisation using balloons, and treatment advice. A patient completes the questionnaire before consultation. The questionnaire measures the experienced burden of the chronic condition(s), and several risk factors. The questionnaire consists of a generic part and disease-specific parts. The generic questionnaire will be combined with any amount of disease-specific questionnaires (i.e. COPD, asthma, diabetes type 2 and heart failure), to form a single personalised scale and balloon chart for each individual patient. Outcomes of the questionnaire are visualised using balloons. The healthcare provider opens the visualisation during consultation. A balloon represents a domain, and the colour and height indicate a score on that domain. If a patient and healthcare provider select a balloon by clicking on it, treatment advice is shown by means of pop-ups. Based on the discussion following treatment advice, personal care plans can be determined.
41155667|NCT05041842|DRUG|Tucatinib|300 mg orally twice daily
40811198|NCT05629065|OTHER|Clinician Nudge Email|"-Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit"
40811199|NCT05629065|OTHER|Patient Nudge Letter and Share questionaire|"Involves patient nudge consists of a letter and SHARE questionnaire~- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit."
40811200|NCT04837118|OTHER|Educational Intervention|Receive handouts containing dietary recommendations
40811201|NCT04837118|OTHER|Quality-of-Life Assessment|Ancillary studies
40811202|NCT04837118|OTHER|Questionnaire Administration|Ancillary studies
40811203|NCT04837118|OTHER|Resistance Training|Participate in a resistance training program
40811204|NCT04444778|DEVICE|CPAP|Continuous positive airway pressure
40811205|NCT05063565|DEVICE|TheraSphere Y-90 glass microsphere therapy|TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.
41155668|NCT05041842|DRUG|Pertuzumab|Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
41155669|NCT05041842|DRUG|Trastuzumab|"Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly"
41155670|NCT05041842|DRUG|Hormone therapy|Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
40811206|NCT05063565|DRUG|Durvalumab (Imfinzi) immunotherapy|"1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met:~* Absence of clinical symptoms or signs indicating clinically significant disease progression~* No decline in performance status~* Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention~* No other treatment discontinuation criteria are met"
40811207|NCT05063565|DRUG|Tremelimumab immunotherapy|300 mg, single administration
41328979|NCT03156855|DRUG|14-day sequential therapy|D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
41328980|NCT03156855|DRUG|Bismuth quadruple therapy|D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
41328981|NCT06480188|DEVICE|deep brain stimulation|Group A was the GPi-DBS stimulation group； Group B was the STN-DBS stimulation group
41328982|NCT00003203|BIOLOGICAL|filgrastim|Given IV
41328983|NCT00003203|DRUG|carboplatin|Given IV
41328984|NCT00003203|DRUG|cisplatin|Given IV
40811208|NCT06398626|DRUG|Etrasimod|As provided in real world practice
40811209|NCT05554393|DRUG|Azacitidine|Given IV or SC
40811210|NCT05554393|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40811211|NCT05554393|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41328985|NCT00003203|DRUG|cyclophosphamide|Given IV
41328986|NCT00003203|DRUG|vincristine sulfate|Given IV
41328987|NCT00003203|PROCEDURE|adjuvant therapy|
41328988|NCT00003203|RADIATION|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT\*
41328989|NCT04639908|OTHER|Interview|interview with patient
41328990|NCT03106012|PROCEDURE|Hysteroscopy|rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
41328991|NCT03106012|PROCEDURE|Laparoscopy|Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
40811212|NCT05554393|DRUG|Cytarabine|Given IV
40811213|NCT05554393|DRUG|Daunorubicin Hydrochloride|Given IV
40811214|NCT05554393|DRUG|Venetoclax|Given PO
41155671|NCT05041842|DRUG|Pertuzumab/ Trastuzumab|"Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly"
41328992|NCT00104156|PROCEDURE|External Qigong therapy|
41328993|NCT03958994|OTHER|Qualitative interviews|What are the roles of organisational factors, education and policy in shaping the experiences of staff and carers who care for people with dementia?
41328994|NCT06066840|DRUG|Basiliximab|Basiliximab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
41328995|NCT06066840|DRUG|Vedolizumab|Vedolizumab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
41328996|NCT03917082|DRUG|Tamoxifen Citrate|current standard of care is 5 years endocrine therapy after early breast cancer. Intervention will test if 2 years is adequate for population with low recurrence risk based on genomic tissue based test
41328997|NCT03326869|DEVICE|Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
41328998|NCT04146337|BIOLOGICAL|FMT|Fecal microbiota in frozen capsules
41328999|NCT06138990|DIAGNOSTIC_TEST|Pharmacoscopy|Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.
41329000|NCT06138990|DRUG|Clinical standard-of-care (physician's choice)|Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
41329001|NCT02533219|DRUG|18 F-DOPA|Subjects will undergo PET imaging with \[18F\]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of \[18F\]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
41155672|NCT05903625|DIETARY_SUPPLEMENT|Control Group - Standard White Bread|Participants consume commercially available standard white bread, serving as the control intervention.
40811215|NCT02882620|BEHAVIORAL|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
40811216|NCT02882620|BEHAVIORAL|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
40811217|NCT02882620|BEHAVIORAL|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
40811218|NCT06062238|BIOLOGICAL|M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine|Participants will receive an intramuscular dose of M72 (recombinant fusion protein) reconstituted with AS01E-4 (an adjuvant system), on Day 1 and Day 29.
40811219|NCT06062238|BIOLOGICAL|Placebo|Participants will receive an intramuscular dose of normal saline (0.9 percent \[%\] sodium chloride \[NaCl\]), on Day 1 and Day 29.
41155673|NCT05903625|DIETARY_SUPPLEMENT|Lysine Group - Lysine-Fortified Bread|Participants consume bread fortified with lysine, an essential amino acid, in a specified dosage, frequency, and duration.
41155674|NCT05903625|DIETARY_SUPPLEMENT|Phosphorus Group - Phosphorus-Fortified Bread|Participants consume bread fortified with phosphorus, an essential mineral, in a specified dosage, frequency, and duration
41329002|NCT01303458|BEHAVIORAL|Basic Needs Surveillance (BNS) protocol|The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
41329003|NCT00663598|DRUG|Levitra (Vardenafil, BAY38-9456)|Treatment according to US PI
41329004|NCT04742972|RADIATION|SABR|SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.
41329005|NCT04742972|OTHER|SOC|"Three options:~1. Continuation of Enzalutamide~2. Observation~3. Switch to next line treatment"
41329006|NCT06316687|OTHER|questionnaire for food consumption frequency|questionnaire about Food consumption frequency, Screen time , Dental neglect scale
41329007|NCT00209872|DRUG|Gabapentin|
41329008|NCT00209872|DRUG|Lidocaine|
41329009|NCT00209872|DRUG|S-ketamine|
41155675|NCT05903625|DIETARY_SUPPLEMENT|Lysine and Phosphorus Group - Double Fortified Bread|Double Fortified Bread: Participants consume bread fortified with both lysine and phosphorus in specified dosages, frequencies, and durations.
41155676|NCT01862614|DRUG|Articaine Hydrochloride + Epinephrine|
41155677|NCT01862614|DRUG|Buffered Articaine Hydrochloride + Epinephrine|
41155678|NCT06227442|DIAGNOSTIC_TEST|KDIGO criteria of 2010|They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.
41155679|NCT01334905|DRUG|YM178|oral
41329010|NCT00209872|PROCEDURE|Epidural analgesia|
41329011|NCT04716478|OTHER|Clinical and radiological data collection|No specific intervention. Data of the usual care will be collected as the demographic data, the medical history, imaging report, etc.
41155680|NCT06150222|OTHER|Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)|The aim is to include all patients with (induced) oligo metastatic and oligo recurrent settings, irrespective of whether treated with concurrent chemoradiation, systemic chemotherapy, or with other locally directed therapies (like surgery, ablation, etc.)
41329012|NCT05285267|BEHAVIORAL|Behavioral Parent Support|Parent training on effective child management strategies
41329013|NCT05285267|BEHAVIORAL|Shared Parent-Child Activities|Structured parent-child activities
41329014|NCT05285267|BEHAVIORAL|COACHES|This intervention involves practice of parenting strategies with facilitator monitoring and support.
41329015|NCT00961116|DRUG|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
41329016|NCT00961116|DRUG|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
41329017|NCT05182125|BIOLOGICAL|AdC6-HIVgp140|"The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB)."
41329018|NCT05182125|BIOLOGICAL|AdC7-HIVgp140|"The products is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.6 mL for AdC7-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC7-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the IB."
41155681|NCT05006703|BEHAVIORAL|Breathe for Teens (Breathe4T)|A digital, self-management intervention for adolescents to control their asthma using breathing retraining. The mobile-friendly website provides information about asthma, how it affects the lungs, and how breathing patterns can be dysfunctional. Information is presented using short (30sec-2min) video clips featuring physiotherapists, researchers and adolescent role models. Users are given tips about their practice, including choosing a suitable time and place and building up gradually. Users can plan and log their practice and record their confidence in using the breathing techniques. There are 8 sessions including peer-led videos demonstrating breathing exercises with voiceovers and step-by-step instructions. All features and sessions can be accessed via a main dashboard where users can tailor the intervention to allow parental involvement, reminders and a preferred format for notifications (email/text). Other features include frequently asked questions (FAQs) and a progress chart.
40811227|NCT04765644|DRUG|Celecoxib|Two 200 mg capsules per day (400 mg/day) for 7 days
40811228|NCT04765644|OTHER|Placebo|2 capsules/day for 7 days
40811229|NCT04765644|OTHER|L-arginine + placebo|L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
40811230|NCT04765644|OTHER|L-arginine + celecoxib|L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
40811231|NCT06514742|DRUG|Aticaprant|Aticaprant tablet will be administered orally.
40811232|NCT06514742|OTHER|Placebo|Placebo tablet will be administered orally.
40811233|NCT04085653|DRUG|alpelisib|"Alpelisib will be provided as 50 mg, 125mg and 200 mg film coated tablets as individual patient supply, and will be dosed on a flat scale of mg/day not to be adjusted to body weight or surface area.~In Adult patients, alpelisib will be administered at a starting dose of 250 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.~In Pediatric patients, alpelisib will be administered at a maximum starting dose of 50 mg orally once daily on a continuous dosing schedule and can be interrupted for toxicity per the recommendations in this treatment plan; no dose reductions are allowed."
41155682|NCT03238326|DRUG|Brexpiprazole|Once daily, oral tablets
41155683|NCT04158453|DRUG|AUT00201|Oral dose of AUT00201
41155684|NCT04158453|DRUG|Placebo|Oral dose of placebo
41011667|NCT05555472|BEHAVIORAL|Halt-intervention|The main aim of the Halt-intervention is to reduce the risk for reoffending. Seven sub-goals are implemented to work towards this main aim: (1) youths gain insight in (the consequences of) their behaviour; (2) strengthening youths' social skills; (3) youths are able take responsibility for the consequences of their behaviour; (4) victim-offender reconciliation; (5) youths are able to access support from own social network and, if necessary, access to formal support; (6) parents gain insight their child's behaviour; and (7) if youths complete the intervention, they do not receive a registration on their criminal record. With a compulsory screening and risk assessment at the start of the intervention, it is determined which sub-goals fit the adolescents' needs. The intervention gives Halt professionals the opportunity to identify adolescents (and families) in vulnerable circumstances and to guide them towards formal support, like youth care organisations or addiction treatment centres.
41329019|NCT05182125|BIOLOGICAL|CH505TF gp120|"CH505TF gp120 is formulated in 20 mM sodium phosphate, 150 mM NaCl, 0.02% polysorbate 80 (PS80), pH 6.5, supplied as a frozen liquid in 2 mL glass vials. Each 2 mL vial contains 0.75 mL of formulated gp120 at a concentration of 0.8 mg/mL and is stored at ≤ -65°C.~The study product is described in further detail in the IB."
41011668|NCT05555472|BEHAVIORAL|Youth Initiated Mentoring (YIM) approach|"The YIM approach focuses on strengthening naturally existing relationships between youth and non-parental adults within their own social network (Van Dam \& Schwartz, 2020). It stems from the idea it takes a village to raise a child (Educational Civil Society), which implies that other adults are co-responsible for the development of youth in their environment (Bowers et al., 2015). The YIM approach can be implemented in a formal context; expertise from the own social network is then combined with expertise from professionals (Van Dam \& Verhulst, 2018). Professionals support youth in identifying and positioning a YIM as part of a broader intervention (Van Dam \& Schwartz, 2020). Youths are responsible for asking their YIM and once agreed upon, the YIM is positioned. The YIM offers advice/support and plays a role during the intervention followed by the youth. Youth, parents, YIMs and professionals work together to set expectations and goals for the engagement of the YIM."
41155685|NCT05213117|BEHAVIORAL|Co-Localization with Nursing|Co-localize 15 residents to one of 6 general medical floors to complete all 8 weeks of general medicine on this floor
41155686|NCT00692523|OTHER|Recreational therapy activities|Recreational therapy sessions will include leisure activities such as playing cards and/or doing arts and crafts.
41155687|NCT00692523|OTHER|Nintendo Wii|The Nintendo Wii gaming system, released in 2005, introduced a new style of virtual reality by using a wireless controller that interacts with the player through a motion detection system. Nintendo Wii involves the incorporation of 3-dimensional accelerometer technology that can respond to changes in direction, speed, and acceleration, down to the most delicate movements. Specifically, the controllers use embedded acceleration sensors to enable players' wrist, arm, and hand movements to interact with the games. Tilt measurements allow users to move characters, while the accurate three-axis acceleration sensing easily transforms the controller into a virtual sword, gearshift, or musical instrument
40811244|NCT04900792|DRUG|Ferumoxytol injection|Ferumoxytol is an iron replacement product FDA approved for treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). This trial uses the FDA approved dosage (512 mg iron) for iron-deficiency anemia in CKD.
40811245|NCT04900792|DRUG|Pharmacological ascorbate|Intravenous ascorbate
40811246|NCT04900792|RADIATION|External beam radiation therapy|Photon based, focal radiation therapy delivered consistent with national guidelines, standard for treatment of GBM.
40811247|NCT04900792|DRUG|Temozolomide|Temozolomide is a cytotoxic alkylating agent administered orally that penetrates well into the central nervous system. It is a standard-of-care treatment for GBM.
40811258|NCT04068519|DRUG|Tislelizumab|Administered intravenously
40811259|NCT04186416|OTHER|Mostcare® device|The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.
41011669|NCT04122833|OTHER|Next generation sequencing|observational study
41011670|NCT00192452|DRUG|MEDI-507|
40811260|NCT04186416|OTHER|Transthoracic cardiac ultrasound|Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
40811261|NCT05086224|DRUG|Hematoma Local Anesthetic Block Procedure with 1% Lidocaine|Inject anesthetic into the hematoma site, 20 mL of 1% lidocaine without epinephrine.
41011671|NCT01297673|PROCEDURE|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
41011672|NCT04891549|PROCEDURE|Tension band fixation|Fracture fixation of the patella fracture with tension band.
41011673|NCT04891549|PROCEDURE|Plate fixation|Fracture fixation of the patella fracture with a plate.
41329020|NCT05182125|BIOLOGICAL|GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])|The GLA-SE adjuvant will be provided as vials containing 20 mcg/mL GLA in a 4% oil-in-water emulsion. Each sterile, single use vial contains 0.4 mL of product. Product appears as a milky-white liquid. GLA-SE must be stored at 2° to 8°C and must not be frozen. The study product is described in further detail within the IB.
41011674|NCT01482104|DRUG|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
41011675|NCT01482104|DRUG|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
41011676|NCT05321303|OTHER|Serious Game|"Each participant of the Serious game group played 1 scenario of MetaHospital, a screen-based simulation on the management of diabetic ketoacidosis. Immediately after the serious game was played, 5 open-ended questionnaires were sent to the students to evaluate the game usability."
41011677|NCT05321303|OTHER|Standard Patients|Each participant of the standardized patient's group played 1 scenario on the management of diabetic ketoacidosis and then a 30-minute analysis session with the trainer joined.
41011678|NCT04140994|DEVICE|rTMS device|Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
41011679|NCT00853658|DRUG|Enalapril|Enalapril 10 mg film-coated tablet and administered orally.
41011680|NCT00853658|DRUG|Aliskiren|Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
41011681|NCT00941733|DEVICE|IN.PACT Amphirion|Balloon Angioplasty
41329021|NCT05182125|BIOLOGICAL|Placebo|Placebo will be Sodium Chloride for Injection, 0.9%, will be used as the placebo. It must be stored as recommended by the manufacturer.
40811262|NCT05086224|DRUG|Bier Anesthetic Block Procedure with 1% Lidocaine|Intravenous anesthetic infusion, a maximum lidocaine dosing of 3 mg/kg.
40811263|NCT06520462|PROCEDURE|Pharmacopuncture|The physicians will decide the specific methods of pharmacopuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
40811264|NCT06520462|PROCEDURE|Acupuncture|The physicians will decide the specific methods of acupuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
41155688|NCT01333137|DRUG|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 \& 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
41155689|NCT01333137|DRUG|P276-00 along with Gemcitabine and carboplatin|In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 \& 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
41011682|NCT00941733|DEVICE|Standard PTA|Balloon Angioplasty
41011683|NCT03835260|DEVICE|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
41011684|NCT01449916|OTHER|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
41011685|NCT06018961|OTHER|Post-operative ileus surgery|Collection of ileus events, items of IFEED score and surgical complications
41011686|NCT04226716|BEHAVIORAL|Assessment of postural control, body perception and psychosocial factors|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception and psychosocial factors (incl. perceived harmfulness of daily activities, pain-related fear of movement, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress, optimism/pessimism, pain coping and coping with stressful life events)
41011687|NCT00622427|DRUG|Ramelteon|8 mg tablets every night for 2 weeks
41011688|NCT00622427|DRUG|Placebo|placebo tablets for every night for 2 weeks
41011689|NCT02360618|DRUG|Metformin|See Group Description
41011690|NCT02360618|DRUG|Simvastatin|See Group Description
41011691|NCT01375049|DRUG|Aztreonam for Inhalation Solution (AZLI)|AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
41011692|NCT01126541|DRUG|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
41155690|NCT00672347|DRUG|Clonidine|1 mcg/kg
41155691|NCT00672347|DRUG|Morphine|20 mcg/kg
41155692|NCT00672347|DRUG|Bupivacaine plus clonidine and morphine|"bupivacaine 0,166% 1 ml/kg~clonidine 1 mcg/kg~morphine 20 mcg/kg"
41155693|NCT00672347|DRUG|Bupivacaine|Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
41155694|NCT04225247|DRUG|Single Bond Universal|Single bond universal (by 3M ESPE) is a seventh generation bonding agents used as desensitizers in the present study.
41329022|NCT04914871|BEHAVIORAL|Protocol UN Lifeguard Kids in the Tunja version|"The experimental protocol UN Lifeguard Kids in the Tunja version done by the researcher following the guidelines of International organizations such as the American Heart association and European Resuscitation Council.~The intervention consists of 3 sessions of 60 minutes of theoretical and practical exercises on BLS, developed within the usual class schedule."
41329023|NCT04914871|BEHAVIORAL|Educational session accident prevention and wound management|It will be provided to the control group
41329024|NCT04089436|DIAGNOSTIC_TEST|CSF sampling|CSF sampling by lumbar puncture
41329025|NCT04089436|DIAGNOSTIC_TEST|Blood sampling|Blood sampling by blood test
41329026|NCT04089436|DIAGNOSTIC_TEST|Nasopharyngeal and rectal sampling|Nasopharyngeal and rectal sample by swabbing
41329027|NCT04259047|BEHAVIORAL|Diabetes Regulation for Eyesight and Memory|Participants randomized to DREAM will have 11 in-home visits over 2 years with a CHW, and 4 telehealth visits with a DM nurse educator.
41329028|NCT04259047|BEHAVIORAL|Enhanced Usual Care|Participants in this group will have 11 in-home CHW visits over 24 months to control for attention. During these visits, the CHW will provide general diabetes education. There will be no telehealth visits.
41329029|NCT03326583|DRUG|Patiromer|Patiromer will be orally self-administered by participants.
41329030|NCT02326389|BEHAVIORAL|Exercise|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.
41329031|NCT02326389|BEHAVIORAL|Cognitive Remediation|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
41329032|NCT03381209|DRUG|Sugammadex|sugammadex given based on 3 measurements of body weights
41329033|NCT03256409|OTHER|Adherence mold and yeast and mesophyll aerobe|Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.
41329034|NCT03256409|OTHER|Surface Roughness (Ra)|The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.
41329035|NCT04814472|DRUG|BLD-0409|Randomized to active product.
41329036|NCT01255306|OTHER|Optical coherence tomography|"Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~1. On 7th postoperative day~2. On 30th postoperative day~3. On 90th postoperative day~4. On 180th postoperative day"
41011693|NCT03736824|PROCEDURE|endoscopy|All endoscopy was performed by qualified gastroenterologists or endoscopic physicians in Renji hospital,Shanghai Jiaotong University School of Medicine.
41011694|NCT06114576|OTHER|Orange juice enriched with vitamin D3 and encapsulated probiotics|25 high cardiometabolic risk volunteers will be asked to consume 250 ml orange juice enriched with 2000 IU vitamin D3 and 10\^8 cfu/ml encapsulated probiotics (Lactocaseibacillus casei shirota and Lactocaseibacillus rhamnosus GG) daily, for 8 weeks, without any other change in their dietary habits and physical activity.
41481382|NCT01173913|DRUG|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
41481383|NCT01173913|DRUG|ModraDoc006 10 mg tablet|Bi-daily administration. One cycle will last 7 days
41481384|NCT05291832|OTHER|Brain.fm Music|Experimental arm
41481385|NCT05291832|OTHER|Spectrally-matched Noise|Active control arm
41481386|NCT03903458|DRUG|Tinostamustine|First-in-human administration of the combination of Tinostamustine and Nivolumab.
41481387|NCT03036774|PROCEDURE|Ultrasonic measurement of antral area|"Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent.~Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4.~Antral area will correspond to the average of the three measures."
41481388|NCT03748355|GENETIC|Pharmacogentic Analysis|Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
41481389|NCT02426047|DIETARY_SUPPLEMENT|betaquik®|Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
41155695|NCT04225247|DRUG|Bifluorid 12|it is a fluoride varnish by VOCO.
41481390|NCT02350634|DRUG|18F-AV-1451|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie \[mCi\]) of 18F-AV-1451.
41011695|NCT06114576|OTHER|Conventional orange juice|25 high cardiometabolic risk volunteers will be asked to consume 250 ml conventional orange juice daily, for 8 weeks, without any other change in their dietary habits and physical activity.
41011696|NCT05550675|OTHER|Questionnaires|Disease specific questionnaires
41155696|NCT04225247|DRUG|Xeno V+|Xeno V+ (by Dentsply) is a seventh generation bonding agents used as desensitizers in the present study.
40811268|NCT05416372|BEHAVIORAL|Religious Engagement in Health Intervention|Religious Engagement in Health Intervention for blood pressure (BP) includes three evidence-based components: (1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, (2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and (3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
41155697|NCT03386799|DEVICE|E-motion device|Powered assisted Wheelchair with the E-motion device. Outdoor and indoor runs
41155698|NCT04402021|BEHAVIORAL|Outdoor Walking|Unsupervised outdoor walking will be the mode used for moderate-intensity aerobic exercise. The walking intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
41155699|NCT04402021|OTHER|Quiet Rest|The quiet rest condition will consist of watching a nature documentary in a quiet room. The quiet rest intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
40811272|NCT06525077|DRUG|FT218|Sodium oxybate for extended-release oral suspension
40811273|NCT06525077|OTHER|Placebo|Matched placebo equivalent for oral suspension
41011697|NCT01410110|BEHAVIORAL|Cognitive Training + Work Therapy|Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
41011698|NCT01410110|BEHAVIORAL|Work Therapy|20 hours per week of work therapy
41011699|NCT06081218|OTHER|activity test|Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
41011700|NCT01484470|BIOLOGICAL|StemEx|"For patients allocated to StemEx® arm:~* Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~* Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~* Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~* Day 1: StemEx® transplantation.~* Day 2 to 3 years: Post transplant follow-up."
41011701|NCT04978129|BEHAVIORAL|Online and Text Messaging Intervention|The online and TM intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS.
41011702|NCT06360549|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation (TEAS) is a treatment that combines acupoint theory of traditional Chinese medicine with modern electrical stimulation techniques. It achieves the purpose of acupoint stimulation by applying a weak current to a specific part. TEAS operate just like ordinary electrodes with non-invasive, safe, portable, adjustable and other advantages.
41011703|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) active stimulator|In tDCS the electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
41011704|NCT06155786|DEVICE|transcranial random noise stimulation (tRNS)|Here, an alternating electrical current is applied at a mix of frequencies it is called transcranial random noise stimulation (tRNS), which can be delivered in low (between 0.1-100 Hz) or high (between 101-640 Hz) frequency stimulation
41011705|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) sham stimulator|Here a sham electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
41011706|NCT02208791|DRUG|Sirolimus|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
41481391|NCT00922558|OTHER|Evaluation of postural control|Children will be measured once using a Tetra-aximetric posturography method
41481392|NCT03977831|PROCEDURE|Radical Cystectomy|Participants are randomly and blinded assigned
41481393|NCT02328742|BIOLOGICAL|Hysteroscopy + endometrial biopsy|"The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study."
40811274|NCT06350097|DRUG|Osimertinib|"Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet ."
41011707|NCT02208791|DRUG|No intervention|
41011708|NCT05224492|DRUG|Sulforaphane|40 mg of Sulforaphane powder once daily.
41011709|NCT05224492|OTHER|Placebo|Placebo
41481394|NCT02328742|OTHER|Telephone call|"Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study."
41481395|NCT02328742|BIOLOGICAL|Resection + endometrial biopsy|"If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study."
40811275|NCT06350097|DRUG|Datopotamab Deruxtecan|Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
41155700|NCT02478762|PROCEDURE|Normal glycemic control|Use diet, physical exercise of insulins to reach normal glycemic control.
40811277|NCT04658862|BIOLOGICAL|Cetrelimab|Participants will receive intravenous Cetrelimab.
40811278|NCT04658862|DRUG|TAR-200|Participants will receive intravesical TAR-200.
40811279|NCT04658862|DRUG|Cisplatin|Participants will receive cisplatin intravenously.
40811280|NCT04658862|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously.
41155701|NCT02478762|PROCEDURE|Low glycemic control|Use diet, physical exercise of insulins to reach low glycemic control.
41155702|NCT02672137|BEHAVIORAL|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
41155703|NCT01863537|BEHAVIORAL|Multimedia Connect|
41155704|NCT01863537|BEHAVIORAL|Traditional Connect|
41011710|NCT00782652|DRUG|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
41329037|NCT01255306|DRUG|Local medical treatment of raised intraocular pressure|"In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added."
41329038|NCT06426498|DEVICE|Brainsonix Bx Pulsar machine tFUS|This is a tFUS device, delivering ultrasound at a dose within the FDA safety guidelines.
41329039|NCT04122586|DRUG|Tongxieyaofang(granule)|Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
41329040|NCT00518843|BEHAVIORAL|FBT-BN|Mobilizing parents to curtail binge eating and purging
41329041|NCT00518843|BEHAVIORAL|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
41329042|NCT01999907|DIETARY_SUPPLEMENT|Vitamin D|100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
41329043|NCT01999907|DIETARY_SUPPLEMENT|daily vitamin D supplement|Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
41329044|NCT01999907|OTHER|Placebo|placebo given in a 2ml dose by mouth at baseline.
41329045|NCT00259467|BEHAVIORAL|Home-Based Behavorial Intervention|
41329046|NCT01683084|DRUG|Telmisartan|
41329047|NCT01683084|DRUG|Placebo|
41329048|NCT04281017|DRUG|TIVA|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)
41329049|NCT04281017|DRUG|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg
41329050|NCT01915017|BEHAVIORAL|Cognitive Behavior Therapy for Psychosis|The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
40811281|NCT04658862|RADIATION|Conventional radiation therapy|Participants will receive conventional radiation therapy for bladder (64 gy).
41011711|NCT00782652|DRUG|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
41011712|NCT05603104|DRUG|Clozapine|See arm description
41329051|NCT01915017|BEHAVIORAL|Cognitive Adaptation Training|CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
41329052|NCT01915017|BEHAVIORAL|Multi-modal Cognitive Therapy|A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
41329053|NCT01915017|OTHER|Treatment as Usual|Standard medication follow up and limited case management
41329054|NCT02197598|DRUG|nalmefene|
41329055|NCT02274415|BIOLOGICAL|Vaccination with the combined vaccine (Prevenar13 ®)|
41011713|NCT05603104|DRUG|Esketamine Nasal Product|See arm description
41011714|NCT05603104|DRUG|Escitalopram|See arm description
41329056|NCT02274415|BIOLOGICAL|Vaccination with the polysaccharide vaccine (Pneumo 23 ®)|
41329057|NCT05586815|DRUG|Colistin|150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days
41329058|NCT05586815|DRUG|Minocycline|200 mg every 12 hours orally for at least 7 and up to a maximum of 28 days
41329059|NCT05586815|DRUG|Placebo|Capsule without active compound
41329060|NCT02785146|DRUG|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
40811282|NCT04658862|RADIATION|Hypo-fractioned radiation therapy|Participants will receive hypo-fractioned radiation therapy for bladder (55 gy).
41011715|NCT05603104|DRUG|Sertraline|See arm description
41011716|NCT05603104|DRUG|Venlafaxine|See arm description
41329061|NCT02785146|DRUG|Oxaliplatin|85 mg/m², ivdrip, D1
41329062|NCT02785146|DRUG|Calcium folinate|Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
41329063|NCT02785146|DRUG|5-fluorouracil|400 mg/m², iv, D1; and 2400mg/m², civ, 48h
41329064|NCT00006190|DRUG|Nelfinavir mesylate|
41011717|NCT05603104|DRUG|Lithium|See arm description
41011718|NCT05603104|DRUG|Valproate acid|See arm description
41011719|NCT05603104|DRUG|Quetiapine|See arm description
41011720|NCT05603104|DRUG|Second-line Antidepressants|See arm description
41011721|NCT05603104|DRUG|Second-line Antipsychotics|See arm description
41011722|NCT05603104|DRUG|Ketamine Hydrochloride|See arm description
41011723|NCT05603104|DRUG|Esketamine hydrochloride|See arm description
41011724|NCT00236938|DRUG|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
41011725|NCT00236938|DRUG|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
41329065|NCT00006190|DRUG|Stavudine|
41329066|NCT00006190|DRUG|Lamivudine|
41329067|NCT00006190|DRUG|Efavirenz|
41329068|NCT03970941|OTHER|Cost evaluation|The cost for the hospital of the strategy of management will be evaluated.
41329069|NCT03970941|OTHER|Questionnaire|The quality of life of patients will be measured.
40811283|NCT04120883|DRUG|Hydroxychloroquine lower dose|The participants weight will be measured and converted to kilograms. The participants will receive 4 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.
40811284|NCT04120883|DRUG|Hydroxychloroquine higher dose|"The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).~The participants in this group will receive 5 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily."
41481396|NCT02328742|BIOLOGICAL|Follow-up hysteroscopy + endometrial biopsy|"For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study."
41329070|NCT02468141|DRUG|SJDBT|Sipjeondaebo-tang
41329071|NCT02468141|DRUG|Placebo|Placebo
41011726|NCT05826067|OTHER|collection of bacterial strains|Urine (and blood) samples will be collected following SOC procedures for diagnostic purposes, at each visit of the patient (initial visit, follow up study or visit for new episode. For patients needing a catheter, urine sample will be collected before the insertion of the catheter, and before renewal of the catheter. Catheter tips will also be collected and sonicated to isolate bacteria. E. coli will be stored for analysis.
41011727|NCT01960231|OTHER|OGTT|
41329072|NCT03986242|DEVICE|rolling|use non- vibration rolling and the total time is 20 minutes.
41011728|NCT02647034|OTHER|no intervention|no intervention
41011729|NCT03609294|DRUG|Treatment A (Fimasartan, Linagliptin)|Co-administration of Fimasartan and Linagliptin
41011730|NCT03609294|DRUG|Treatment B (Fimasartan/Linagliptin)|Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
41011731|NCT00679341|DRUG|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
41011732|NCT00679341|DRUG|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
41011733|NCT00679341|DRUG|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m\^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
41329073|NCT03986242|DEVICE|Vibration rolling|use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.
41329074|NCT03986242|OTHER|static stretching|static stretching and the total time is 20 minutes.
41481397|NCT03974750|DEVICE|Bimanual motor skill learning with the REAplan(R) rehabilitation robot|REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
41481398|NCT05622136|DRUG|Regorafenib Oral Product|Dose escalation strategy
41481399|NCT01748331|OTHER|Fluid restriction|Patients will be randomized to strict fluid restriction \< 1 L/day versus moderate fluid restriction \< 2.5 L/day
41329075|NCT01608607|OTHER|Fructose-containing sugar sweetened beverages|Oral dietary fructose-containing sugar sweetened beverages in isocaloric exchange for other sources of carbohydrate (isocaloric trials) or hypercaloric exchange for beverages containing a non-nutritive sweetener or added to a control diet as a source of excess energy (hypercaloric trials)
40811286|NCT04559022|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
41329076|NCT02918656|OTHER|Infographic presentation of health information|"The students in this group will read Cochrane systematic review summary in infographics format.~Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs."
41329077|NCT02918656|OTHER|PLS presentation of health information|The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.
41329078|NCT02918656|OTHER|Scientific abstract presentation of health information|The students in scientific abstract group will read the the text written for the academic population and practitioners.
41329079|NCT04614350|BIOLOGICAL|Markman Biologics Microsurfaced ADM|an ADM which has been scored (microsurfaced)
41329080|NCT04614350|BIOLOGICAL|AlloDerm|AlloDerm tissue matrix
41481400|NCT01659736|DEVICE|TMS|Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
41329081|NCT01734707|DIETARY_SUPPLEMENT|Allicor|
41329082|NCT01734707|DRUG|Placebo|Sugar pill manufactured to mimic Allicor 150 mg tablet
41329083|NCT01141218|OTHER|internet-based protocol and physician referral|collection and review, dna and lab biomarker analysis, gene mapping
41329084|NCT06185478|DIAGNOSTIC_TEST|MRI scan|MRI scan
41329085|NCT04354441|DRUG|hydroxychloroquine sulfate 200 MG|Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days. Participants will be couriered the medication upon giving consent and will start taking the medication immediately.
41329086|NCT04354441|DRUG|Placebo oral tablet|Placebo that is identical in appearance to the study medication will be taken twice a day for 10 days. It will be couriered to participants upon giving consent. They will start taking the medication immediately.
41329087|NCT00278863|DRUG|S-1|
41329088|NCT00278863|DRUG|Capecitabine|
41329089|NCT06271694|OTHER|Vestibular Rehabilitation|Standard vestibular rehabilitation
41329090|NCT02379312|DIETARY_SUPPLEMENT|Very low energy aerated beverage|
41329091|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 1|
41329092|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 2|
41329093|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 3|
41329094|NCT02539719|DRUG|SC-003|
41329095|NCT02539719|DRUG|SC-003 in combination with ABBV-181|
41329096|NCT03343782|COMBINATION_PRODUCT|Expanded autologous bone marrow-derived mesenchymal stem cell|Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
41329097|NCT00505804|DRUG|dexmedetomidine|Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
41329098|NCT00505804|DRUG|haloperidol|Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
41329099|NCT06398574|OTHER|Real dry needling|With the subject lying supine, a dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made
41329100|NCT06398574|OTHER|Sham dry needling|With the subject lying supine, a sham dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made, simulating the real technique
41329101|NCT01847898|PROCEDURE|Vertebral Body Stenting (VBS)|Vertebral Augmentation with a Stent
41329102|NCT01847898|PROCEDURE|Balloon Kyphoplasty|Vertebral Augmentation with a Balloon (device not specified)
41329103|NCT03889964|OTHER|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
41011734|NCT02103478|DRUG|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
41329104|NCT03608046|DRUG|Avelumab|Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week
41329105|NCT03608046|DRUG|Cetuximab Injection|Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).
41329106|NCT03608046|DRUG|Irinotecan|Irinotecan will be administered every 2 weeks (180 mg/m2)
41011735|NCT02103478|DRUG|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
41329107|NCT04917120|DEVICE|Virtual Reality|The procedure will consist of a virtual reality program associated with suggestions of hypnoanalgesia, be added to usual care. Included patients will benefit from the Virtual Reality program combined with hypnoanalgesia suggestions for a period of 20 minutes. We will use a helmet with a built-in screen and an audio headset connected to a control room. Patients will watch an Virtual Reality sequence while listening to narratives designed for the hypnoanalgesia of the present pain.
41329108|NCT03958318|OTHER|Exercise plus nutritional suplementation|For 6 months, all participants in the exercise plus nutritional supplementation group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
41329109|NCT03958318|OTHER|Exercise|For 6 months, all participants in the exercise group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
41329110|NCT05690672|DIAGNOSTIC_TEST|Delirium Screening|Either 3D-CAM or 4AT
41329111|NCT02834312|DRUG|Estetrol|All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
41329112|NCT02834312|DRUG|Placebo|1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
41011736|NCT02103478|DRUG|ASTX727 Fixed-Dose Combination|Fixed-dose investigational product
41329113|NCT02468960|DEVICE|Predilatation with OPN NC balloon catheter.|Target lesion will be prepared by predilatation with OPN NC balloon catheter.
41329114|NCT02468960|DEVICE|Predilatation with standard compliant balloon.|Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
41329115|NCT02468960|DEVICE|Absorb BVS implantation.|After lesion preparation implantation of BVS Absorb scaffold will be performed.
41329116|NCT02468960|PROCEDURE|Treated segment visualization by OCT.|Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
40811290|NCT06440967|DRUG|Fezolinetant|oral
40811291|NCT06440967|DRUG|Placebo|oral
40811292|NCT06440967|DRUG|Tamoxifen|oral
40811293|NCT06440967|DRUG|Aromatase inhibitor|oral
40811294|NCT04956640|DRUG|LY3537982|Oral
40811295|NCT04956640|DRUG|Pembrolizumab|Intravenous
41329117|NCT02468960|OTHER|Clinical FU at 12 months.|All patients will be clinically followed for 12 months.
41329118|NCT02337686|OTHER|Laboratory Biomarker Analysis|Correlative studies
41329119|NCT02337686|BIOLOGICAL|Pembrolizumab|Given IV
41481401|NCT01669473|OTHER|EHR Based Strategy to promote Safe and Appropriate Drug Use|"The printed tools presented in the intervention include:~1. Medication Review: a consolidated list of the medications a patient is currently taking.~2. Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.~3. Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen"
41481402|NCT05329506|OTHER|patient population|questionnaires, standard of care
41481403|NCT03997071|OTHER|functional outcome measurement|functional outcome measured in terms of joint position sense analysis, isokinetic muscle strength measurements, gait analysis, drop jump and single leg hop tests, and balance tests
41481404|NCT06073535|PROCEDURE|Extraction of mandibular third molar|"After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle.~An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary."
41481405|NCT06073535|DEVICE|i-PRF|20 ml of venous blood will be drawn from the ante-cubital vein of all patients and collected in 2 plastic tubes (Vacutainer, Becton\& Dickinson, Rutherford, NJ) containing no anticoagulant or gelling agent. The tubes will be placed in a centrifuge (DUO Centrifuge, Nice, France) at 700 round per minute for 3 min, at the end of which time the blood will be separated into 2 fractions: the layer of injectable liquid i-PRF, which is more superficial, and the layer of red blood cells, in the deep part. From each tube, i-PRF will be withdrawn using a sterile syringe and it will be infiltrated into the lesion.
40811296|NCT04956640|DRUG|Cetuximab|Intravenous
40811297|NCT04956640|DRUG|Pemetrexed|Intravenous
40811298|NCT04956640|DRUG|Cisplatin|Intravenous
40811299|NCT04956640|DRUG|Carboplatin|Intravenous
40811300|NCT05278104|DRUG|Zentiva®|Zentiva®
40811301|NCT05278104|DRUG|Placebo|Placebo
40822928|NCT05137457|OTHER|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The DOZE app is a unique digital CBTi intervention that can be used on any mobile phone, tablet or computer, using the iPhone Operating System (iOS) or Android software. It is an innovative program that consists of an integrated smart phone app and web self-management system (DOZE) to help adolescents and young adults to sleep better. It allows data capture through entries in a sleep diary and calculation of specific clinical indices. The acquisition of baseline sleep health data over a two-week period is then used to provide personalized targets and tailored therapeutic interventions during the treatment phase. The app also includes a self-monitoring tool that fosters goal setting and provides feedback on sleep and goal attainment. DOZE allows for real time assessment of sleep related behaviors and customized reports and graphs from the young adults' data. The app provides reminders about specific goals and positive feedback (increasing scores) for each step towards a goal."
40822929|NCT05137457|OTHER|Sleep diary|The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
40822930|NCT03610503|OTHER|Music|Participants in this arm will listen to music during the EMG testing
40822931|NCT01045941|DRUG|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
41329120|NCT02337686|OTHER|Pharmacological Study|Correlative studies
41329121|NCT02337686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41329122|NCT04679558|DRUG|Chlorhexidine varnish added to the preventive protocol|Antibacterial agent varnish added to the preventive protocol
41329123|NCT04679558|BEHAVIORAL|Preventive protocol|Preventive protocol
41329124|NCT06442657|OTHER|Hydrocellular dressing|Application of hydrocellular dressings to at-risk areas prior to prone positioning. Assessment of pressure sores and their stage after prone positioning.
41329125|NCT06442657|OTHER|Hydrocolloids dressing|Application of hydrocolloids dressings to at-risk areas prior to prone positioning.
41329126|NCT05767372|OTHER|Coherent Breathing Exercise|"Step 1: Focus on your natural breathing and count the time of your inhale and exhale.~Step 2: Sit in a comfortable position to practice the coherent breathing technique. Gently place one hand on your stomach.~Step 3: Inhale for four seconds and then exhale for four seconds. Repeat this for one minute.~Step 4: Repeat the above step but lengthen your inhales and exhale for five seconds.~Step 5: Repeat the above step but extend the breaths to six seconds. Once you're able to do this for five minutes, gradually work your way up to 20 minutes.~During this breathing exercise, keep your hand on your stomach. Using diaphragmatic breathing can help you feel your breaths."
41481406|NCT00545207|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
41481407|NCT00545207|DRUG|Placebo|po monthly for 2 years
41481408|NCT05387174|BEHAVIORAL|: Nursing intervention in two risk factors of the Metabolic Syndrome, abdominal obesity and arterial hypertension and quality of life in the climacteric period.|Nursing intervention with technological support (Metamorphosis) in two risk factors of Metabolic Syndrome, abdominal obesity and hypertension and quality of life in the climacteric period, developed in 3 months, in the experimental group that includes individual nursing counseling, group education virtually and physical activity sessions for 12 weeks virtually.
41011737|NCT05863754|DEVICE|Networked Neuroprosthesis Device|The Networked Neuroprosthesis Device is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals.
41011738|NCT06573671|DIAGNOSTIC_TEST|Chitotriosidase|The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
41011739|NCT06573671|DIAGNOSTIC_TEST|Mass spectrometry|to show PVP presence in histiocytes of injecting drug users compared to controls
41481409|NCT04842500|BEHAVIORAL|Demand Informed Moderator Analysis|This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).
41481410|NCT01651546|BEHAVIORAL|Intermittent catheterization test|I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
41481411|NCT00627471|DRUG|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
40811304|NCT04046016|DRUG|Paclitaxel|Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
40811305|NCT05203211|PROCEDURE|Testicular sperm extraction (TESE)|During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.
40811306|NCT05130905|DIETARY_SUPPLEMENT|RiteStart Supplement|RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity \[6, 7, 8\]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
40811307|NCT05712785|DEVICE|Use of shuotong ureteroscopy|Treatment of patients with ureteral stones using the Shuotong-scopy
40822932|NCT01045941|PROCEDURE|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
41011740|NCT06573671|DIAGNOSTIC_TEST|X-ray spectromicroscopy|to show PVP presence in histiocytes of injecting drug users compared to controls
41011741|NCT06573671|DIAGNOSTIC_TEST|Fluorescence microscopy|to show PVP presence in histiocytes of injecting drug users compared to controls
41011742|NCT06573671|DIAGNOSTIC_TEST|Transcriptomics|To describe pathologic signals of PVP-exposed in vitro histiocytes of injecting drug users compared to control samples
41011743|NCT00855140|OTHER|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
41011744|NCT00008346|DIAGNOSTIC_TEST|Full Field Digital Mammography|Radiologic test to screen women for Breast cancer using digital detectors
41011745|NCT00008346|DIAGNOSTIC_TEST|Screen Film Mammography|Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
41011746|NCT02130401|DEVICE|TNM (thermoneuromodulation device)|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
41481412|NCT00627471|DRUG|Insulin Glargine|"In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG\<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic."
40822933|NCT06607198|DIAGNOSTIC_TEST|grading &amp; staging|To investigate the following pathological features of PitNET cell lineage-specific transcription factors, cell type specification by hormone production, proliferative index, p53, mitotic count, expression of somatostatin receptors
41011747|NCT02384824|PROCEDURE|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
41011748|NCT05151939|DIAGNOSTIC_TEST|Identification or discharge visualization of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos by an expert endoscopist|An expert endoscopist will select a dataset of mediastinal and abdominal EUS videos (one per patient). An expert endoscopist will identify or discharge visualization of the following organs correctly: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein.
40811308|NCT02684058|DRUG|Dabrafenib|Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients \< 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients \< 12 years old and \< 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and \<19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)
40811309|NCT02684058|DRUG|trametinib|"Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients \<6 years old and \<26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients \<6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg \< 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)"
40811310|NCT02684058|DRUG|Carboplatin|"Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m\^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m\^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle."
40811311|NCT02684058|DRUG|Vincristine|"Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing."
40811312|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy + Hiatal hernia repair|To evaluate the role of concomitant hiatal hernia repair in laparoscopic sleeve gastrectomy for morbidly obese patients.
40811313|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy alone|Current mainstay and standard surgical treatment for morbidly obese patients.
40811314|NCT05525052|OTHER|Trans-Facet fixation|Trans-facet fixation (TFF) under local anesthesia and double fluoroscopic and CT guidance is a minimally invasive technique involving the placement of screws through the posterior facet joints, improving spinal stability.
40811315|NCT05435807|BEHAVIORAL|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
40811316|NCT02191878|DRUG|TKM-080301|TKM-080301 intravenous infusion
41329127|NCT05767372|DEVICE|Inspiratory muscle training|"The patient was in the comfortable sitting position and then put the nose clip on the patient's nose~1. After setting the maximum training; the user recognized the load at which they could effectively execute ten breaths at greatest resistance relying upon the patient's pace of apparent effort.~2. Training was begun with a load at low intensity 20-30% of the patient maximum 10 repetition method using inspiratory muscle training (IMT) device.~3. Progress slowly and monitor carefully.~4. As the inspiratory muscle became stronger the inspiratory load was progressed to 50% of maximum effort over 3 weeks as tolerated.~5. Patient took full breath in (maximal and deep inspiration) then longer and slow expiration. Continue this breathing pattern for 10-20 breath.~6. Repeated step (5), 4-6 times or about 10-15minutes with rest in between 30 seconds.~7. The session was repeated three times per week for 12 weeks."
41329128|NCT00089999|DRUG|Lapatinib|
41329129|NCT05182424|BEHAVIORAL|Myndlift BPT App & As-Needed Therapist Support|"BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods to facilitate positive behaviors in their child and reduce challenging behaviors. Myndlift BPT translates established content and processes into a digital format to be delivered through a mobile app. Myndlift content consists of 10 components, designed to be completed in a self-directed manner by parents, over the course of approximately 10 weeks (total weeks depends upon parent's pace through the program).~In this project, trained and supervised doctoral- and masters-level students will serve as study therapists and meet with parents via a secured, password-protected Zoom platform to introduce parents to the Myndlift BPT (first session before start of the BPT), to support and problem solve BPT skills acquisition (during the Myndlift BPT), and at the end of the Myndlift BPT (to review the intervention content and consider the maintenance of skills)."
41329130|NCT00829777|DRUG|6β-Naltrexol escalating doses from 0.05-0.5 mg IV|"Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:~Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo."
41329131|NCT00022958|DRUG|Iodine-131 Anti-B1 Antibody|
41329132|NCT01960426|OTHER|Measurement of drug (Adalimumab/Infliximab)|Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.
41329133|NCT01960426|OTHER|Intensify treatment with the existing drug|Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
41329134|NCT06403748|DIETARY_SUPPLEMENT|Dietary supplement formulated with components of natural origin: artichoke, danshen, bergamot, folic acid, chromium and excipients.|The study will be conducted in male and female subjects, at least 18 and less than 70 years of age, with suboptimal level of LDL-Cholesterol (LDL 115-190 mg/dL) randomized into two groups to receive a preconstituted food supplement (NUT) combination containing (Red yeast rice 160 mg + Berberis aristate 449,7 mg + Folic acid 200 μg and others) in combination with a standard Mediterranean diet at low cholesterol content (\<200 mg/day) (Standard of Care - SOC) \[group 1\], or a PLACEBO in combination with hypo-cholesterol diet (healthy Mediterranean diet following the indication of the European Atherosclerosis Society guidelines) \[group 2\].
41329135|NCT06403748|OTHER|Placebo|Placebo
41329136|NCT05138341|DEVICE|Minimally invasive surgical (MIS) intracranial hemorrhage Evacuation|"Patients randomized to MIS group will be undergoing an intervention will get Minimal Invasive Surgical treatment.~The market approved Artemis Device (MIS group) will be used. The Artemis Device, Aspiration Pump, and endoscope are used to rinse (irrigate) this area and to gently suction out the rinsing fluid and any blood or clot in brain. The Device is also designed to prevent clogging during the suction of fluid and blood."
41329137|NCT02335203|DRUG|Depot medroxyprogesterone acetate|One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
41329138|NCT02335203|OTHER|Placebo|One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
41329139|NCT02576925|OTHER|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
41329140|NCT06396572|PROCEDURE|IVR-Procedure|Using immersive virtual reality to learn urinary catheterisation procedure
41329141|NCT06396572|PROCEDURE|Nursing Clinical Laboratory practice|Using nursing clinical laboratory sessions to learn urinary catheterisation procedure
41329142|NCT02522650|DRUG|Amiloride|5mg twice a day for 8 weeks
41329143|NCT02522650|DRUG|Triamterene|50mg twice a day for 8 weeks
41329144|NCT00567060|DRUG|Piracetam|
41329145|NCT00388167|DRUG|Caspofungin|The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment
41329146|NCT01499719|BEHAVIORAL|Checklist introduction / Pause|Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
41329147|NCT02679794|BEHAVIORAL|Egg consumption|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
41329148|NCT02679794|BEHAVIORAL|Control|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil.
41329149|NCT02879981|DRUG|Guaifenesin|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
41329150|NCT02879981|DRUG|Sulfamethoxazole|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
41329151|NCT02879981|DRUG|Trimethoprim|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
41329152|NCT00334646|DRUG|Oral GW679769|150mg oral, once daily on days 1-3
41329153|NCT00334646|DRUG|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
41329154|NCT05841108|DEVICE|force feedback rehabilitation robot (SEM™ Glove)|In the experimental group, the therapists were asked to illustrate and demonstrate the motor points of the cylindrical grasping and spherical grasping movements, and the patients were instructed to imitate them with nonparalytic hand, while the latter patients wore SEM™ Glove were used for task-oriented training, such as inserting pegs, grasping a ball into a barrel, and drinking water exercises. The difficulty of task-oriented training can be adjusted according to the patient's actual condition, such as changing the shape, weight, size of the target or changing the distance, duration, and so on during training
41329155|NCT05841108|OTHER|assisted by a therapist|The control group received task-oriented training assisted by a therapist to complete the same task as the experimental group. Therapists need to instruct patients to try to grasp items and give appropriate assistance to guarantee their completion of the grasping task. If finger extension is weak, the therapist assists the patient in extension of the digits before grasping the items, and if the finger flexion angle does not meet the grasp function needs, it should assist in flexion finger movements
41329156|NCT03685526|DEVICE|Cinenses Lung Volume Reduction Reverser System|Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
41329157|NCT04083118|DIAGNOSTIC_TEST|clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI|Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta
41329158|NCT04083118|DIAGNOSTIC_TEST|Repeat 18F sodium fluoride PET/MRI|as per first study visit but without the PET/CT
41329159|NCT02549963|DEVICE|WATCHMAN Left Atrial Appendage Occlusion Device|
41329160|NCT02549963|DRUG|Rivaroxaban|
41329161|NCT02794623|DEVICE|Tinnitus masking|Tinnitus masking via CI system
41329162|NCT00908622|PROCEDURE|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
41329163|NCT00908622|PROCEDURE|Cardiac revascularization|Cardiac revascularization
41329164|NCT01072448|DRUG|Indacaterol 75 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
41329165|NCT01072448|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
41329166|NCT05291572|BEHAVIORAL|speech therapy only|fluency shaping technique
41329167|NCT05291572|DEVICE|hyperbaric oxygen therapy|chamber system using oxygen with pressure
41329168|NCT05291572|DRUG|medical treatment|brain stimulant
41329169|NCT05647018|PROCEDURE|Primary Percutaneous coronary angiography|Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries in patients presenting with myocardial infarction, through which installment of stents or intracoronary injection of drugs can take place.
41329170|NCT05446623|DRUG|Dexmedetomidine|Opioid free anesthesia (OFA) consists in the simultaneous administration of alpha2-agonist (for example the dexmedetomidine), sodium channel blocker (lidocaine), and NMDA antagonists receptors (Ketamine). Its aim is to control de cardiovascular nociceptive response to the surgical stimulation.
41329171|NCT05446623|DRUG|Sufentanil|The one in the OA group will be given a bolus of Sufentanil before and during the surgery.
41329172|NCT03108625|DRUG|Vortioxetine|Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
41329173|NCT00833677|BEHAVIORAL|Chinese Coping Skills Training|Six-week group behavioral intervention: Chinese Coping Skills Training
41329174|NCT02628951|DRUG|Ramucirumab|Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
41329175|NCT02628951|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
41329176|NCT02979366|DRUG|S64315 once a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
41329177|NCT02979366|DRUG|S64315 twice a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
41329178|NCT03337425|BEHAVIORAL|Psychoeducational group therapy|The group-based psychoeducational program consists of 10 sessions, run over 10 consecutive weeks. Each session consist of a lecture, given by a recruited expert on the topic of the session (20 minutes) with a following discussion of the topic (45 minutes), facilitated by the course leader. All sessions are organized and led by the course leader, which also includes keeping structure in time, discussion and closing of the session. Psychoeducation comes in addition to standard treatment (ADHD treatment as usual).
40811317|NCT02762656|DRUG|Lidocaine|Lidocaine drip during surgery
41329179|NCT03337425|BEHAVIORAL|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
41329180|NCT03337425|OTHER|Standard treatment|Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.
41329181|NCT05445882|DRUG|Bintrafusp alfa|Bintrafusp alfa (1,200 mg) will be given via IV infusion every 2 weeks for up to 3 years.
41329182|NCT05445882|DRUG|N-803|N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.
41329183|NCT05445882|BIOLOGICAL|BN-Brachyury|BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury). MVA-BN-Brachyury subcutaneous injection will be given as 2 priming doses 2 weeks apart. FPV-Brachyury subcutaneous injection will follow MVA-BN-Brachyury injection 2 weeks later every month for 6 months total, then every 3 months until reaching 2 years. After 2 years FPV-Brachyury may be continued at 6-month dosing intervals for up to 3 years.
41329184|NCT05588180|PROCEDURE|FVD/FAD ratio guided|Ultrasound-guided ratio
41329185|NCT05588180|PROCEDURE|PPV|PPV
40811318|NCT01224340|BEHAVIORAL|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
40811319|NCT01224340|BEHAVIORAL|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
41329186|NCT05625633|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20
40811320|NCT01224340|OTHER|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
40811321|NCT01879462|DRUG|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
40811322|NCT01879462|DRUG|Placebo|Visually matching GSK2878175
40811323|NCT00000593|PROCEDURE|blood transfusion|
40811324|NCT04842149|DIETARY_SUPPLEMENT|Bif195 capsules|1 capsule daily for 8 weeks
40811325|NCT04842149|DIETARY_SUPPLEMENT|Placebo capsules|1 capsule daily for 8 weeks
40811326|NCT04075890|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
40811327|NCT06516146|BEHAVIORAL|Exercise|The intervention will involve online (via University of British Colombia (UBC) Zoom videoconferencing) 1-hour moderate to high intensity exercise classes 3 times a week for 6 months
40811328|NCT06516146|BEHAVIORAL|Meditation|"The intervention will involve 15 minute guided mediation following exercise classes as well as mindfulness classes.~Mindfulness classes will consist of 1.5 hour Mindfulness Based Stress Reduction (MBSR) classes for the first 2 months, followed by 1 month of 1 hour bi-weekly discussions and practice, then MBSR 2.0 for months 4 and 5, and 1 hour bi-weekly discussions and practice for the remaining month of the intervention."
40811329|NCT06516146|BEHAVIORAL|Diet|The intervention will involve biweekly 1-hour nutrition and cooking classes with a dietician.
40811330|NCT04894344|BEHAVIORAL|Education group|Is taught to choose low-sodium foods
41329187|NCT05625633|OTHER|Normal Saline|0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
41329188|NCT02490943|OTHER|Warm Compress Before Injection|Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
40811331|NCT00000293|DRUG|Nefazodone|
40811332|NCT02454439|OTHER|CRT implantation|
40811333|NCT04150237|OTHER|Simulation training in gastroscopy|Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
40811334|NCT02301546|BEHAVIORAL|computerized cognitive exercises|Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
40811335|NCT04676087|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
40811336|NCT04676087|BIOLOGICAL|Mogamulizumab|Given IV
40811337|NCT04676087|OTHER|Quality-of-Life Assessment|Ancillary studies
40811338|NCT05534659|DEVICE|Programmable valve|Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.
41329189|NCT02490943|OTHER|Cold Compress After Injection|Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
41329190|NCT06359704|BEHAVIORAL|Caregivers Of dementia Processing Emotions (COPE) program|a dual-modal (face-to-face and online approaches), client-customized Caregivers Of dementia Processing Emotions (COPE) program
41329191|NCT05970978|DRUG|regular treatment|IBI112 200mg s.c. at week 0, 12, 24 and 36.
41329192|NCT05970978|DRUG|Intensive treatment|IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
40811339|NCT05534659|DEVICE|Non-programmable valve|Non-programmable valve used in the study was Medtronic CSF-flow control valve.
40811340|NCT00115479|DRUG|intensive insulin therapy to maintain normoglycemia|
40811341|NCT01081704|DRUG|ustekinumab|Single dose of 45 mg subcutaneous injection
40811342|NCT01081704|DRUG|ustekinumab|Single dose of 90 mg subcutaneous injection
40811343|NCT04927247|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
40811344|NCT04927247|DRUG|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
40811345|NCT05847660|DRUG|Progesterone antagonist|Group (A): Women in progesterone primed (PPOS) will prescribed 30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until triggering day. Vaginal sonography will be done for all patients since the 6th day of the cycle.
40811346|NCT05847660|DRUG|conventional antagonist protocol|Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
40811347|NCT01087658|DRUG|Glutamine|Per os
40811348|NCT01087658|DRUG|Calcium and Magnesium|Intravenous
40811349|NCT02063867|DRUG|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
40811350|NCT04187794|OTHER|Interview patient|to investigate an association between literacy level and medication adherence in patients with rheumatic diseases.
40811351|NCT05223348|OTHER|Meditation practice|Our intervention will involve two meditation exercises. 1) the experimental condition (body scan meditation). 2) the active comparator condition (listening task)
41329193|NCT00259246|DRUG|Peptide YY infusion|
41329194|NCT02660866|DRUG|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
41329195|NCT02660866|DRUG|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
41329196|NCT02963896|DRUG|gentamicin|intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
41329197|NCT01896856|DRUG|SGI-110 Dose Escalation|"* Dose level 1 (DL1): 45 mg/m\^2 administered as a subcutaneous injection~* Dose level 1G (DL1G): 45 mg/m\^2 administered as a subcutaneous injection + growth factor support~* Dose level -1 (DL-1): 30 mg/m\^2 administered as a subcutaneous injection~* Dose level -1G (DL-1G): 30 mg/m\^2 administered as a subcutaneous injection + growth factor support"
41329198|NCT01896856|DRUG|Regorafenib|160 mg taken orally
40811352|NCT05553340|OTHER|Education for caregivers|The intervention will aim to equip the family caregiver to assist the elderly in activities of daily living after discharge, and will be carried out by two researchers, through an online course. The course includes the skills required and included in the scales that assess the caregiver's knowledge and performance. The course is divided into 12 modules that can be accessed as many times as needed by caregivers, in random order, according to the care needs of the elderly and the caregiver.
40811353|NCT00210457|DRUG|Lanreotide (Autogel formulation)|
40811354|NCT04482400|BEHAVIORAL|NEAT!2|8 week sedentary reduction program
40811355|NCT04482400|BEHAVIORAL|MyKneeGuide|8 week surgery recovery education program
40811356|NCT01775579|DRUG|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
40811357|NCT06300151|DEVICE|Ultrasound Real-time Guidance combined with Dural Puncture Epidural Labor Analgesia|Ultrasound real-time guidance technology has great advantages over traditional blind exploration technology in terms of accuracy, success rate, and reduction of puncture damage in intervertebral space positioning through operational visualization, greatly improving the effectiveness and safety of spinal block.
40811358|NCT06300151|DEVICE|Dural Puncture Epidural Labor Analgesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
40811359|NCT03011970|DRUG|Oxytocin|
40811360|NCT03011970|DRUG|Placebo|
40811361|NCT04147429|BEHAVIORAL|Early Literacy Intervention|Similar to the standard Reach out and Read model, parents will be given a high-contrast board book, Cluck and Moo, and education about the importance of and how to engage with newborns in early shared reading behaviors. This will include instructive information for families about using books to stimulate newborns through pictures and spoken words.
40811362|NCT00054327|DRUG|busulfan|Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
40811363|NCT00054327|DRUG|cyclophosphamide|Given IV
40811364|NCT00054327|DRUG|cytarabine|Given IV
40811365|NCT00054327|RADIATION|radiation therapy|Patients undergo total body irradiation
40811366|NCT00054327|DRUG|Etoposide|infusion
40811367|NCT00054327|PROCEDURE|Stem Cell Transfusion|
40811368|NCT02779088|OTHER|exercise and nutrition|Exercise:muscle strengthening exercise Nutrition: 7.2 g branched chain amino acid every day and 1200 mg Ca+800 IU Vitamin D3
40811369|NCT02493803|BEHAVIORAL|Dietary Advice|Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
40811370|NCT02241213|DEVICE|Transcranial Magnetic Stimulation (TMS-r)|"10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil placebo for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI)."
40811371|NCT02241213|DEVICE|Placebo Transcranial Magnetic Stimulation|10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
40811372|NCT05798936|DRUG|Polidocanol|Polidocanol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
40811373|NCT05798936|DRUG|Alcohol|Alcohol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
40811374|NCT01487174|DRUG|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
40811375|NCT01487174|DRUG|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
40811376|NCT04357730|DRUG|Alteplase 50 MG [Activase]|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (\>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but \<50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
40811377|NCT04357730|DRUG|Alteplase 50 MG [Activase]|wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
40811378|NCT03010774|BEHAVIORAL|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
40811379|NCT03010774|BEHAVIORAL|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
40811380|NCT02101801|OTHER|vegetables from fresh or recycled water|
40811381|NCT02101801|OTHER|receives vegetables from fresh water or recycled waste water farms|
40811382|NCT02030925|DRUG|IW-3718|
40811383|NCT02030925|DRUG|Matching Placebo|
40811384|NCT00132756|DRUG|Doxil and Estramustine|
40811385|NCT00015860|DRUG|daunorubicin hydrochloride|
41329199|NCT01896856|DRUG|TAS-102|35 mg/m\^2 taken orally
40811386|NCT00015860|DRUG|imatinib mesylate|
40811387|NCT00015860|DRUG|prednisone|
40811388|NCT00015860|DRUG|vincristine sulfate|
40811389|NCT02481648|OTHER|Exercise|
40811390|NCT04645654|BEHAVIORAL|Hypnosis|Three sessions of 30 minute hypnosis, based on standardised script, focused on pain management.
40811391|NCT00005841|BIOLOGICAL|MART-1 antigen|
40811392|NCT00005841|BIOLOGICAL|gp100 antigen|
40811393|NCT00005841|BIOLOGICAL|incomplete Freund's adjuvant|
40811394|NCT00005841|BIOLOGICAL|progenipoietin|
40811395|NCT00005841|BIOLOGICAL|tyrosinase peptide|
40811396|NCT02545881|OTHER|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
40811397|NCT06552546|DRUG|Icodextrin|Eligible participants were admitted to the hosptial ward and used one icodextrin bag (single-dose icodextrin) or two icodextrin bags (double-dose icodextrin) on the first day, depending on their choice. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange(s), the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with two or three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single- and double-dose icodextrin were provided.
40811398|NCT03408418|PROCEDURE|Platelet-rich fibrin|The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
40811399|NCT01253694|DRUG|injection of 0.5 mg of Intravitreal Ranibizumab|Following the sterile technique, intravitreal injection of anti-VEGF is applied
40811400|NCT01885208|DRUG|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
40811401|NCT01885208|DRUG|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
40811402|NCT02065843|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
40811403|NCT02065843|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
40811404|NCT02065843|DRUG|Passiflora incarnata|100 mg/single dose/1 hour before dental surgery
40811405|NCT02065843|DRUG|midazolam|15 mg/single dose/1 hour before dental surgery
40811406|NCT03736057|OTHER|Delayed results of pharmacogenomic results|"1:1 randomization schedule for delayed knowledge of pharmacogenomic results to clinician and patient. Results are released to prescriber at \<1 week (unblinded) or 12 weeks (blinded). When genomic results are available upon receipt, unblinded clinicians select an FDA-approved drug from the recommended drugs when possible. Blinded prescribers provide the intended prescription when notified of blinded status. At 4 weeks, 1° outcome measures, NPI-Q and side effects ratings are collected. Clinicians make a GO/NO-GO decision for continuation based on those measures. A NO-GO decision is unblinding and an alternative drug may be prescribed. At 12 weeks, 1° outcomes are collected again. Previously blinded clinicians will be unblinded and may decide to continue or revise the treatment plan based on the clinical outcomes and the genetic results. After the 12 week visit, results of the genetic tests will be entered in the EHR. Further clinical follow-up is based on need."
40811407|NCT01179828|DRUG|Oxycodone 15mg|15mg single administration p.o.
40811408|NCT01179828|DRUG|Clobazam|20mg single administration p.o.
40811409|NCT01179828|DRUG|Imipramine|75mg single administration p.o.
41329200|NCT01896856|DRUG|SGI-110|45 mg/m\^2 administered as a subcutaneous injection
40811410|NCT01179828|DRUG|Tolterodine|1 mg single administration p.o.
40811411|NCT02832557|OTHER|Salivary collection|Collection of saliva via swab for miRNA processing
40811412|NCT02832557|OTHER|Vineland Adaptive Behavior Scale-III Assessment|
40811413|NCT02832557|OTHER|Medical history questionaire|
40811414|NCT02832557|OTHER|Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)|
40811415|NCT02832557|OTHER|Mullen Scales of Early Learning|
40811416|NCT00801073|PROCEDURE|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
40811417|NCT02119195|PROCEDURE|Sealant|resin-based sealant (Clinpro Sealant, 3M ESPE)
40811418|NCT02973347|OTHER|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
40811419|NCT02973347|OTHER|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
40811420|NCT03883347|DRUG|Dexmedetomidine|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia and 0.6 mcg / kg / h after performing regional anaesthesia until the end of the surgery
40811421|NCT03883347|DRUG|Remifentanil|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
40811422|NCT05896098|OTHER|Ultrasound|Measurement of the airway by ultrasound in obese patients.
40811423|NCT00210353|DRUG|chlorambucil (drug)|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
40811424|NCT00210353|DRUG|rituximab+chlorambucil|rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
41329201|NCT01896856|DRUG|Irinotecan|125 mg/m\^2 administered IV
41329202|NCT03290170|PROCEDURE|Measured Resection|Bony landmarks are used to set femoral component rotation.
41329203|NCT03290170|PROCEDURE|Gap Balancing|Relies on ligament releases prior to bone cuts.
41329204|NCT01262599|DEVICE|Sham PEMF Device|Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
40811425|NCT00210353|DRUG|rituximab|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
41011749|NCT05151939|DIAGNOSTIC_TEST|Recognition of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos using artificial intelligence (AI)|Using the same previous dataset of mediastinal and abdominal EUS videos, the EUS-AI model will recognize the following organs: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein. Considering each patient (and not data frame videos) as the study unit, a contingency table per each mediastinal and abdominal organ/anatomic stricture will be designed.
41011750|NCT01086553|DRUG|budesonide|9mg budesonide OD
41011751|NCT01086553|DRUG|budesonide|3mg budesonide TID
41011752|NCT01872572|DRUG|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
41011753|NCT01872572|DRUG|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
40811426|NCT06018493|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
40811427|NCT06018493|DEVICE|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
40811428|NCT03023579|OTHER|The star excursion balance test|
40811429|NCT01420692|DRUG|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
40811430|NCT01420692|DRUG|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
40811431|NCT00439543|DRUG|Iloprost inhalation|
41011754|NCT01872572|DRUG|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
41011755|NCT01872572|DRUG|Subcutaneous RB006 2.0 mg|"* Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~* Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration."
41011756|NCT01872572|DRUG|Placebo|Placebo
41011757|NCT04341181|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
41011758|NCT04341181|DRUG|Atezolizumab|Atezolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab might be expected based on their molecular tumor profile.
41011759|NCT04341181|DRUG|Avelumab|Avelumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Avelumab might be expected based on their molecular tumor profile.
41329205|NCT01262599|DEVICE|Ivivi Torino II PEMF Device|"The PEMF device to be employed in this study is FDA cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours. Supplied by Ivivi Health Sciences, LLC."
41329206|NCT00776321|DRUG|Eprotirome|
41329207|NCT00776321|DRUG|Placebo|
41329208|NCT00349037|BIOLOGICAL|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
41329209|NCT01664156|DRUG|Korean red ginseng|Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
41329210|NCT01664156|DRUG|Placebo|
41329211|NCT06167083|DIAGNOSTIC_TEST|Machine Learning to Estimate Mortality|Using deep learning we try to develop an algorithm and anticipate mortality
41329212|NCT06221072|DRUG|JMT103|120 mg by subcutaneous injection every 4 weeks
41329213|NCT06221072|DRUG|zoledronic acid|4 mg by intravenous drip (100mL:4mg) every 4 weeks
41329214|NCT03915106|DEVICE|Brace|Wear a rigid brace
41329215|NCT03915106|PROCEDURE|Surgical correction using implants|Surgical correction of spine using implants (metallic rods and metallic screws)
41329216|NCT00525239|DRUG|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
41329217|NCT04169113|OTHER|Group 1 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
41329218|NCT04169113|OTHER|Group 2 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
40811432|NCT00867802|BEHAVIORAL|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
40811433|NCT02121106|BEHAVIORAL|Cognitive Remediation|
40811434|NCT02121106|BEHAVIORAL|Sham Cognitive Remediation|
40811435|NCT05806515|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40811436|NCT05806515|DRUG|Carboplatin|Given IV
40811437|NCT05806515|PROCEDURE|Chest Radiography|Undergo chest X-ray
40811438|NCT05806515|PROCEDURE|Computed Tomography|Undergo CT
40811439|NCT05806515|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40811440|NCT05806515|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
41329219|NCT05609851|OTHER|Short Physical Performance Batary|"The SPPB includes usual walking speed over 4 m, five chair-stands test, and balance test. A score (scale: 0-4) was assigned to performance on time to rise five times from a seated position, standing balance, and 4-m walking velocity. Individuals received a score of 0 for each task they were unable to complete. Participants coded in the unable to perform category included (a) those who tried but were unable and (b) the interviewer or participant felt it was unsafe. Summing the three individual categorical scores, a summary performance score was created for each participant (range: 0-12), with higher scores indicating better lower body function."
41329220|NCT05609851|OTHER|Occupational Balance Self-Assessment|"The Occupational Self-Assessment (OSA) is a self-reported assessment tool consisting of 21 items in which the patient rates their occupational competence (i.e., how well they do) and value (i.e., how important it is to them). The first 11 items are related to skills and occupational performance, the next five items concern habitation (including habits and roles), and the last five items correspond to volition (including personal causation, values, and interests). In the OSA, each item is scored on two separate 4-point scales, one for occupational competence (1 = I have a lot of problems doing this; 4 = I do this extremely well) and the other for value (1 = This is not important to me; 4 = This is most important to me).~The individual item scores are summed to obtain separate total scores for competence and value. Higher total scores indicate higher occupational competence and value."
41329221|NCT00005806|DRUG|carboplatin|
41329222|NCT00005806|DRUG|gefitinib|
41329223|NCT00005806|DRUG|paclitaxel|
41329224|NCT05903950|DEVICE|Air cleaners with HEPA filter|PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters
41011760|NCT04341181|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
41011761|NCT04341181|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Erlotinib might be expected based on their molecular tumor profile.
41329225|NCT05903950|DEVICE|Air cleaners without HEPA filter|Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.
41329226|NCT05300646|BEHAVIORAL|Prenatal mindfulness-based stress reduction|An adapted mindfulness-based stress reduction (MBSR) program with a particular focus on pregnancy and early motherhood.
41329227|NCT00425126|DRUG|Epoetin Alfa|
41329228|NCT04447924|DIETARY_SUPPLEMENT|Bif195|Daily intake of Bif195 dietary supplement
41329229|NCT04447924|OTHER|Placebo|Daily intake of Placebo
41011762|NCT04341181|DRUG|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib plus Cobimetinib might be expected based on their molecular tumor profile.
41329230|NCT00103597|DRUG|Fludrocortisone|
41329231|NCT00103597|DRUG|Domperidone|
41329232|NCT00103597|BEHAVIORAL|Conservative Measures for Orthostatic Hypotension|
41329233|NCT05625880|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place
41329234|NCT01371344|DRUG|Tacrolimus granules|oral
41329235|NCT01371344|DRUG|Tacrolimus capsules|oral
41329236|NCT06055972|OTHER|Educational Letter Post CT Examination|"Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination which will include the following:~1. Their calcium score, brief educational content explaining what the calcium score means and how the presence of coronary calcifications is associated with an increased risk of a cardiac event.~2. Guidance on what actions could be taken to decrease the risk of a heart event, including blood cholesterol management, smoking cessation, weight loss, dieting, exercise, and blood pressure control.~3. For patients with CAC\>0, the letter will encourage the patient to pursue a shared decision- making discussion with his/her primary care physician or cardiologist regarding risk reduction strategies.~4. Links to American Heart Association (AHA) and phone number for study research coordinator."
40811441|NCT05806515|PROCEDURE|Surgical Procedure|Undergo surgery
41329237|NCT05720273|DRUG|palicalcitol|This study does not interfere with the clinical medication of the researchers, and the usage and dosage of the drugs will be recorded according to the actual use. The recommended starting dose of palicalcitol may be based on body weight, baseline iPTH, or combined with prior medication. Dose adjustment should be determined according to pre-dialysis iPTH, Ca and P. iPTH levels should be maintained at 150-300pg/ml, while Ca and P levels should be closely monitored. If hypercalcemia occurs, the dose should be reduced or medication should be discontinued until these parameters return to normal; Subsequently, the dose of palicalcitol should be restarted at a lower dose. If PTH levels decrease as a result of treatment, the dose of medication may need to be reduced accordingly. The dose adjustment interval is 2-4 weeks, and the dose can be adjusted immediately for safety reasons.
41329238|NCT00838721|OTHER|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
41329239|NCT00400439|DRUG|dalcetrapib (RO4607381)|900mg po daily for 24 weeks
41329240|NCT00400439|DRUG|placebo|po daily for 24 weeks
40811442|NCT06108726|DRUG|Envafolimab Injection|Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
41011763|NCT04341181|DRUG|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab plus Pertuzumab might be expected based on their molecular tumor profile.
40811443|NCT02422836|OTHER|Three Product Anti-Aging Treatment Regimen|Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
40811444|NCT04060069|OTHER|Ringer Lactate|Fluids
40811445|NCT04743336|OTHER|Measuring pocket depth|Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
40811446|NCT05420311|OTHER|MedDiet Arm|A balanced hypocaloric diet in macronutrients (MedDiet)
40811447|NCT05420311|OTHER|KetoDiet Arm|A very low carbohydrate diet (KetoDiet).
40811448|NCT05420311|OTHER|IF Arm|An intermittent fasting (IF) approach
40811449|NCT01794663|DRUG|OPN-305|Intravenous infusion for 1 hour at start of transplant procedure
40811450|NCT01794663|DRUG|Placebo|Intravenous infusion for 1 hour at start of transplant procedure
40811451|NCT01945411|DEVICE|the length between incisor and mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle
40811452|NCT01945411|DEVICE|the length between mouth corner-mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
40811453|NCT02527226|BEHAVIORAL|Facial exercises|A series of self-administered facial movements and expressions.
40811454|NCT00979342|DEVICE|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
41329241|NCT05246475|DIAGNOSTIC_TEST|PET-MRI|Simultaneous PET-MRI measurement
41329242|NCT03796234|OTHER|Dietary and physiotherapy|3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
41329243|NCT03796234|OTHER|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
41329244|NCT04988321|PROCEDURE|Prolonged continuous theta burst stimulation (pcTBS)|Non-invasive brain stimulation (transcranial magnetic stimulation or TMS) which consists of a stimulating coil being held over the head. When this coil delivers a painless magnetic pulse, it feels like a quick, light tap on the head. Two different coils will be used to perform TMS. One coil will be used to determine stimulation parameters for the pcTBS protocol. The second coil will be used to implement pcTBS, which is a repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on the head. Participants will receive two procedures during one session, one with active stimulation and one with inactive stimulation.
40811455|NCT03781895|DRUG|Cholecalciferol|"• Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)"
40811458|NCT05725005|DRUG|ASN51|ASN51 formulation for oral capsule
40811459|NCT05970003|OTHER|Copenhagen exercises|"Group A performs copenhagen exercises~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
40811460|NCT05970003|OTHER|Holmich exercises|"The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period.~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
40811461|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at home|LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program
40811462|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at facility|LHWs will identify SAM as per 'Standard CMAM program' (MUAC \< 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
41011764|NCT04341181|DRUG|Trastuzumab emtansine|Trastuzumab emtansine treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab emtansine might be expected based on their molecular tumor profile.
41011765|NCT04341181|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vismodegib might be expected based on their molecular tumor profile.
41011766|NCT04341181|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Niraparib might be expected based on their molecular tumor profile.
40811463|NCT06094361|PROCEDURE|Iontophoresis Intervention|Iontophoresis was applied with a Chattanooga Physio (DJO Global, Herentals, Belgium) brand device. The galvanic current mode was selected for the intervention. Intervention area was cleaned to prevent irritation and active electrode pad (cathode-5 cm2) was immersed in 75 mg diclofenac sodium solution. The current intensity of the application for 10 minutes was 0.1-0.2 mA/cm2.
40811464|NCT06094361|PROCEDURE|Phonophoresis|Phonophoresis was performed with a Chattanooga brand ultrasound device (Chattanooga, Intelect Legend Ultrasound, TN, USA). 75 mg gel containing 1% diclofenac sodium was applied to the shoulder area. The ultrasound was conducted continuously for 6 minutes with frequency of 1 MHz and an intensity of 1.5 watts/cm2.
40811465|NCT06094361|PROCEDURE|Conventional Therapy|All groups received a treatment program consisting of hot pack, Transcutaneous Electrical Nerve Stimulation and Shoulder girdle exercises for 30 minutes.
40811466|NCT00487942|DRUG|armodafinil|50 mg/day armodafinil
40811467|NCT00487942|DRUG|armodafinil|100 mg/day armodafinil
40811468|NCT00487942|DRUG|armodafinil|200 mg/day armodafinil
40811469|NCT00487942|DRUG|placebo|placebo
40811470|NCT05611567|PROCEDURE|POSE2.0 procedure|The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
40811471|NCT05611567|BEHAVIORAL|Life style and behavioral intervention|The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
40811472|NCT01311128|DEVICE|T-line hemodynamic monitoring device (placement and use)|The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This procedure will be repeated, for a second two-hour period, in the ICU postoperatively.
41011767|NCT04499534|BIOLOGICAL|Seasonal influenza vaccine|To evaluate immune function in BRCA1/2 mutation carriers without cancer following seasonal influenza vaccination
41329245|NCT00749268|DEVICE|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
41329246|NCT00749268|DEVICE|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
41329247|NCT03819218|DRUG|MC2-01 cream|MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
41329248|NCT02571972|DRUG|Dorzolamide-timolol|On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
41329249|NCT04828356|OTHER|Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applied to the reflex points, the energy blockages are broken and this energy flow is distributed in a balanced way to the relevant organs.
41329250|NCT01984736|DRUG|Experimental: EVP-6124|
41329251|NCT04154956|DRUG|SAR408701|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: intravenous (IV) infusion
41329252|NCT04154956|DRUG|Docetaxel|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: IV infusion
41329253|NCT06178900|DIAGNOSTIC_TEST|Assisted by the AI-Gatekeeper software group|The group will be received a AI-Gatekeeper software report on the probability of having coronary artery stenosis (≥50%) based on the routine test.
41329254|NCT04749576|DIETARY_SUPPLEMENT|saffron supplement for IBD|anti inflammatory effect
40811473|NCT04234529|DIETARY_SUPPLEMENT|AMATEA™|"AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee).~Total of 1.35g of AMATEA containing 270mg of caffeine."
40811474|NCT04234529|DIETARY_SUPPLEMENT|Caffeine|1.08g of microcellulose and 270mg of caffeine.
40811475|NCT04234529|OTHER|Placebo|1.35g of microcellulose
40811476|NCT05055518|DRUG|APL-102 Capsules|"Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102."
40811477|NCT00779428|DRUG|Tanespimycin|"Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)"
40811478|NCT00869791|DRUG|IPX066|experimental drug product: extended-release carbidopa-levodopa capsules
40811479|NCT00869791|DRUG|IR CD-LD|active comparator: immediate-release carbidopa-levodopa capsules
40811480|NCT03430024|OTHER|Association of Myosin VI with oestrogen receptor|"1. Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~2. Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~3. Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues."
40811481|NCT03161912|DRUG|Aflibercept (Eylea, BAY86-5321)|As per the treating physicians discretion.
40822934|NCT06607198|DIAGNOSTIC_TEST|PitNET morphology analysis|Revision of the pre-surgical magnetic resonance images (MRIs): tumor maximum diameter, volume, sites of tumor extensions and invasion, and grading of cavernous sinus invasion
40822935|NCT06607198|DIAGNOSTIC_TEST|Radiomics|To investigate radiomics features of PitNETs
41011768|NCT02259491|OTHER|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
41329255|NCT06056765|DEVICE|"Minilith, Storz, Swiss"|shock waves
41329256|NCT03555071|BIOLOGICAL|Vaccine manufactured at commercialized scale|Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0
41481413|NCT02527499|BEHAVIORAL|Ride-On Cars with Bimanual Training Program (ROCBT)|The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
41481414|NCT02527499|BEHAVIORAL|Early Mobility Training Program|Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
40811482|NCT04593849|OTHER|Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)|We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
41481415|NCT02527499|BEHAVIORAL|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
40811483|NCT01178944|OTHER|Laboratory Biomarker Analysis|Correlative studies
40811484|NCT01178944|DRUG|Oxaliplatin|Given IV
40811485|NCT01178944|DRUG|Pralatrexate|Given IV
40811486|NCT04821102|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided
40811487|NCT04821102|DRUG|Saline|saline, 1 time injection under ultrasonic guided
40811488|NCT01713504|BIOLOGICAL|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
40811489|NCT00142805|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
40811490|NCT00142805|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
40811491|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
40811492|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
40822936|NCT06607198|DIAGNOSTIC_TEST|Molecular test: proteomics|To investigate on PitNets of molecular biomarkers Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor Receptor (EGFR), somatostatin receptors 1-5 (SSTRs), Fibroblast Growth Factor (FGF), mTOR (mammalian target of rapamycin), Programmed cells Death 1 (PD1) and its ligands (PD-L1), and Cytotoxic T Lymphocyte Associated protein 4 (CTLA4)\]
41329257|NCT03555071|BIOLOGICAL|Vaccine manufactured at trial-scale|Single subcutaneous injection of the control live attenuated varicella vaccine (0.5 ml) on Day 0
41011769|NCT05843877|BIOLOGICAL|Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy|Islet cells are isolated from patients healthy pancreatic tissue. Following total pancreatectomy, these autologous cells are injected into the portal vein, to implant in the liver and produce insulin.
41329258|NCT04871230|DIAGNOSTIC_TEST|3G DBS|Collection of capillary blood samples for the 3G q-PCR test
41329259|NCT04871230|DIAGNOSTIC_TEST|Sputum Test|Collection of sputum for test culture, microscopy, GeneXpert
41329260|NCT04871230|DIAGNOSTIC_TEST|3G Veinous Blood|Collection liquid veinous blood for the 3G q-PCR test
41329261|NCT04948814|BIOLOGICAL|Fecal microbiota transplantation|FMT utilizing stool from healthy children
41329262|NCT04948814|DRUG|Vancomycin|40mg/kg/day
41329263|NCT04857788|OTHER|Pandah Application smartphone only|Patients will have an application on their smartphone to help them do their homework
41329264|NCT06305221|DRUG|Opioid-free Analgesics (esketamine, dexmedetomidine)|opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
41011770|NCT05843877|PROCEDURE|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)|As a standard procedure, the tumor-affected region of the pancreatic head with surrounding tissue and lymph nodes is removed during surgery. Reconstruction is performed by pancreaticojejunostomy.
40811493|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
40811494|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
40811495|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
41011771|NCT05928338|BEHAVIORAL|Peer-supported, WhatsApp-assisted lifestyle modification intervention|The lifestyle modification intervention, supported by peers and WhatsApp voice calls aimed to assist participants in making dietary modifications, increasing physical activity, and achieve a weight loss of 5% of their initial body weight as well as avoid weight gain. A trained nutritionist delivered the intervention after the baseline assessment individually or in groups that covered six sessions related to dietary modifications, physical activity, set-up goals and action plans, and peer assignments and then once monthly for a year using WhatsApp voice calls to the participants and peers.
41011772|NCT04112433|DEVICE|PURE EP 2|Enrolled patients receiving cardiac ablation treatment using the current standard of care with additional monitoring and intracardiac electrogram signal collection via the PURE EP 2 system.
41011773|NCT05621421|PROCEDURE|FFR and IVUS guided PCI|PCI to the long lesion guided with FFR and IVUS
41011774|NCT02036905|OTHER|Cervical and thoracic mobilization|Described in arm description
41011775|NCT02036905|OTHER|cervical and thoracic manipulation|described in arm description
41011776|NCT03680729|BEHAVIORAL|Adapted Brothers Saving Brothers (aBSB)|This information is listed in the arm description.
41011777|NCT03680729|BEHAVIORAL|Standard Street Outreach|This information is listed in the arm description.
41329265|NCT06305221|DRUG|Opioid Anesthetics (sufentanil and remifentanil)|Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
41011778|NCT04953767|DEVICE|Blue light therapy|Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.
41011779|NCT04953767|OTHER|White light|White light is used as sham control.
41011780|NCT06348511|DEVICE|XTics|XTics is a gamified protocol of behavioral treatment for tic disorders. The participant's tics are monitored in real-time and they are reflected as achievements in a game that the participant plays at the same time. The rewards aim to counteract processes that consolidate the tic. XTics is compatible with ERP treatment, and it includes an introductory psychoeducation session and three behavioral training sessions.
41329266|NCT02186561|DEVICE|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
41329267|NCT04876586|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive degenerative disc disease
41329268|NCT02309814|DEVICE|eyelid motion sensor device (Hall-probe)|all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
41011781|NCT02897141|DEVICE|Health Management App with symptom strategies|The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.
41011782|NCT02897141|DEVICE|Control App|The attention control group will receive an app which asked them about their symptoms but did not provide symptoms strategies
41011783|NCT03757182|OTHER|Wearable activity monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR)
41011784|NCT01715103|PROCEDURE|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
41011785|NCT05951244|DEVICE|Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)|Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.
41011786|NCT00869648|PROCEDURE|Extension|After anaesthesia induction the head is placed in extension
40811496|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
40811497|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
40811498|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
40811499|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
40822937|NCT04621214|DEVICE|Audio-Visual Triage System (AVT)|Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
41011787|NCT00869648|PROCEDURE|Neutral head position|After anaesthesia induction the head is placed in neutral position
41011788|NCT00869648|PROCEDURE|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
41011789|NCT00485316|PROCEDURE|Laparoscopic assisted resection of colorectal carcinoma|
41011790|NCT03798431|BEHAVIORAL|M-ROCC|"1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks \& 120 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
41329269|NCT01639456|BIOLOGICAL|CD3-/CD19- natural killer cells|Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
41329270|NCT01639456|BIOLOGICAL|CD3-CD56+ natural killer cells|Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
40811500|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
40811501|NCT04467658|DIAGNOSTIC_TEST|Korean ADHD rating scale|The KARS is a standardized screening tool for ADHD in Korean children and rating scale completed by the parents.
41329271|NCT01639456|DEVICE|CliniMACS® CD3 and CD19 Reagent System|In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
40811502|NCT04467658|DIAGNOSTIC_TEST|Korean Version of Diagnostic Interview Schedule for Children Version IV|The DISC-IV is a structured diagnostic tool that was developed for use in epidemiological studies in children and adolescents
40811503|NCT05806541|BEHAVIORAL|laughter therapy|Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
40811504|NCT03926533|OTHER|Telehealth|Telehealth visits will be conducted from a private telehealth lab room in the Vanderbilt ICU Recovery Center using a live and interactive approach where providers and patients interact and communicate in real-time using Zoom, a secure video-conferencing platform recommended by Vanderbilt Telehealth.
40811505|NCT06010641|OTHER|head-down position|-20° Trendelenburg as an adjunct to guideline-based treatment,
40811506|NCT00118846|DIETARY_SUPPLEMENT|25 gm soy protein supplement|25 gm soy protein supplementation administered in equally divided dosage twice daily (12.5 gm)
40811507|NCT00118846|OTHER|Placebo|Milk protein administered twice daily
40811508|NCT00101920|DRUG|ABX-EGF|2.5 mg/kg by an infusion pump over one hour
40811509|NCT02336685|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
40811510|NCT02336685|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
40811511|NCT02336685|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
40811512|NCT02336685|DRUG|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
40811513|NCT00455091|DRUG|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/\> 105 copies/mL and ALT \> 2.0 x UNL
40811514|NCT01017744|DEVICE|Anesthetic Conserving Device|"* Ventilation in PSV with the Anesthetic Conserving Device with remifentanil~* Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
40811515|NCT03467893|DRUG|Antacids|number aof antacids treatment after PPI stop
40811516|NCT03084094|DEVICE|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
40811517|NCT00887367|DRUG|GSK598809|Two 175 mg doses of GSK598809 will be given.
40811518|NCT00887367|OTHER|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
41329272|NCT01639456|DEVICE|CliniMACS® CD56 Reagent System|CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
40811519|NCT00937742|DIETARY_SUPPLEMENT|Tomato products|Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
40811520|NCT03625947|OTHER|Argon Plasma Coagulation|Patients will be treated with Argon Plasma Coagulation. Argon plasma coagulation (APC) is a form of non contact electrocoagulation. APC utilizes electrically conductive argon plasma as a medium to deliver high-frequency current via a flexible probe. The argon plasma flow transfers electricity between the probe and the target tissue. Tracheobronchial access is obtained by passing the probe through the working channel of the bronchoscope. On arrival to the tissue, the application of energy causes uniform zones of desiccation, coagulation and devitalization in the areas receiving treatment, thus inducing hemostasis.
40811521|NCT00033566|DRUG|S-3304|
41481416|NCT03143478|DEVICE|M-MARK|"M-MARK will be used by therapists for assessment of the upper limb, and stroke participants will be asked to use M-MARK whilst performing individually tailored and prescribed exercises for a minimum of 5 days/week.~A set of tailored arm exercises using M-MARK (including targets for repetitive and functional activities) will be prescribed which the participant will be asked to practice independently at home for four weeks.~During the four weeks, the patient (with support from their carer as required) will be encouraged to don the M-Mark garment and log-on to the M-Mark computer tablet each day to carry out their programme of exercises. They will be asked to use M-Mark to repeat as many exercise sessions per day as prescribed to them by their research therapist."
40811522|NCT05213637|BIOLOGICAL|Expanded Activated Lymphocytes (EAL)|12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.
40811523|NCT05213637|PROCEDURE|transarterial chemoembolization (TACE)|After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
41011791|NCT00797992|DRUG|Injection|Intravitreal injection of 1.25 mg bevacizumab
41011792|NCT05472259|DRUG|Nanoliposomal irinotecan|In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
41011793|NCT05472259|DRUG|5 FU|In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
41011794|NCT05472259|DRUG|Leucovorin|In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
41011795|NCT05472259|DRUG|Oxaliplatin|Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
41329273|NCT01639456|DRUG|Cyclophosphamide|Infused intravenously 60 mg/kg x day -5
41329274|NCT01639456|DRUG|Fludarabine|Fludarabine 25 mg/m2 x days -6 through -2
41329275|NCT01639456|DRUG|Aldesleukin|IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
41329276|NCT03149926|OTHER|Stimuli presentation|Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
41481417|NCT03252418|DRUG|Ascorbic Acid 500 MG|ascorbic acid is vitamin that can cause gingival depigmentation
40811524|NCT01040091|DRUG|Emtricitabine (FTC)|200 mg once a day
40811525|NCT01040091|DRUG|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
40811526|NCT01040091|DRUG|Efavirenz (EFV)|600 mg once a day
40811527|NCT01040091|DRUG|Truvada|200 mg emtricitabine + 300 mg TDF once a day
40811528|NCT04251897|DEVICE|Novel support surface|This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
40811529|NCT04756999|BEHAVIORAL|massage therapy|Reflexology is massage therapy used to maintain and improve health, as well as relieve some symptoms.
41011796|NCT03139656|BEHAVIORAL|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
41481418|NCT03252418|DEVICE|diode laser|diode laser is soft tissue laser case photothermolysis of melanoctes
40811530|NCT03007329|DRUG|Exenatide|Exenatide will be combined with Dapagliflozin
40811531|NCT03007329|DRUG|Exenatide matching Placebo|Exenatide matching Placebo will be combined with Dapagliflozin
40811532|NCT03007329|DRUG|Dapagliflozin|Dapagliflozin, in both arms
40811533|NCT05073796|DEVICE|Cochlea Implant|"* examination and documentation of vital signs and concomitant medication~* application of an cochlea implant loan processor (external body surface) with varying stimulus pattern for vestibular stimulation by means of basal, medial and apical electrodes~* attraction of an special mask to determine the subjective visual vertical (SVV)~* assessment of the vertical spatial axis with all electrodes turned off~* assessment of the vertical spatial axis with all electrodes turned on~* assessment of the vertical spatial axis while using basal (12-16) and medial (6-11) electrodes~* assessment of the vertical spatial axis while using basal (12-16) and apical (1-5) electrodes~* assessment of the vertical spatial axis while using medial (6-11) and apical (1-5) electrodes"
40811534|NCT02776462|DEVICE|EyeBox CNS|
40811535|NCT03182946|DIAGNOSTIC_TEST|Platelet mapping Thromboelastography|These diagnostic tests will be acquired in patients with brain injury, to determine prediction of clinical, functional and psychological outcome.
41329277|NCT00156910|BIOLOGICAL|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
41481419|NCT04729647|PROCEDURE|Mastectomy|Mastectomy for breast cancer Blood sample for Complete Blood Cell Count and other blood parameters (Delta Neutrophil Index, Immature Granulocyte Count)
41481420|NCT04487002|PROCEDURE|surgical resection|
41481421|NCT05574894|DRUG|Growth hormone|Growth hormone is supplemented during the ovarian stimulation till the day of trigger
40811536|NCT00759265|OTHER|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
40811537|NCT02459431|OTHER|21 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
40811538|NCT02459431|OTHER|22 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
40811539|NCT01142778|DRUG|Bevacizumab|Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
40811540|NCT01142778|DRUG|Docetaxel|Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
40811541|NCT01142778|DRUG|Trastuzumab|Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
40811542|NCT01142778|PROCEDURE|Surgery|All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
40811543|NCT01142778|RADIATION|Radiotherapy|All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
40811544|NCT01142778|DRUG|Hormonal Therapy|Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
40811545|NCT04178525|DEVICE|ChitoCare gel|ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
40811546|NCT04178525|DEVICE|Placebo gel|Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
40811547|NCT02120300|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
41481422|NCT05574894|DRUG|GnRH antagonist|GnRH antagonist protocol for ovarian stimulation
41481423|NCT06358287|PROCEDURE|cryogenic auriculotherapy|Compressed nitrogen is used to create a 'cryonic needle', using a cryopunctor device. An orifice is placed in appropriate acupoint and nitrogen flow is used to cool and activate the point.
41481424|NCT05818748|DEVICE|virtual reality|virtual reality distraction
41481425|NCT04048941|PROCEDURE|One Needle Hand Acupuncture with Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
41481426|NCT04048941|PROCEDURE|One Needle Hand Acupuncture without Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to lay quietly on the examination table.
41481427|NCT04048941|PROCEDURE|Control Acupuncture with Movement|Control acupuncture at acupoint LI4 is performed, which should not have a large affect on pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
41481428|NCT04473521|DEVICE|Investigational denture adhesive cream|The denture adhesive application will be controlled by weight (1.00g +/-0.05g) applied to the maxillary denture only.
41481429|NCT04473521|DEVICE|Super Poligrip Free|The denture adhesive application will be controlled by weight (1.00g +/- 0.05g) applied to the maxillary denture only.
41481430|NCT04969861|DRUG|Bempegaldesleukin|Specified dose on specified days
41481431|NCT04969861|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
40811548|NCT02120300|DRUG|SOF|400 mg tablet administered orally once daily
40811549|NCT02120300|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
40811550|NCT02973204|DRUG|Sorafenib|
40811551|NCT02973204|PROCEDURE|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
40811552|NCT02973204|DRUG|Everolimus|
40811553|NCT02973204|DRUG|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
40822938|NCT06490068|DRUG|LTC004+Toripalimab|"LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W."
41329278|NCT00156910|OTHER|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
41329279|NCT01072968|DRUG|BF2.649|1 capsule per day in the morning before the breakfast
41329280|NCT01072968|DRUG|Placebo|1 capsule per day in the morning before the breakfast
41329281|NCT03923075|DRUG|Dexmedetomidine|INFUSION BEFORE INDUCTION OF ANAESTHESIA
41329282|NCT03923075|OTHER|0.9% saline|INFUSION BEFORE INDUCTION OF ANAESTHESIA
41481432|NCT01252875|PROCEDURE|Target : 100 mg/dL (+/-10 mg/dL)|Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.
40811554|NCT04207593|DRUG|Oxygen|Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2\>90% or pO2 \>60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
41011797|NCT03139656|BEHAVIORAL|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer \& Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
41011798|NCT03139656|BEHAVIORAL|Combined|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When \[I encounter the specified obstacle\], I will do \[X\] and remember \[values-based statement or image identified during values clarification exercise\]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
41011799|NCT05892458|BEHAVIORAL|Abdominal massage|To perform abdominal massage, patients should keep their upper body in an upright or semi-decumbent position. Using their right four fingers or palm, they should apply pressure to the middle point of the lower margin of the right upper abdominal ribs, which corresponds to the opening of the gallbladder and common bile duct. The pressure should be firm, with a depth of approximately 3-4 cm and a length of 5-10 cm, and should be applied at least once a day for 10-15 minutes per session.
41011800|NCT02583256|BIOLOGICAL|Adjuvanted QIV (aQIV)|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
41329283|NCT03331224|DEVICE|OTSC|OTSC placement
40811555|NCT02529462|GENETIC|NEUROPHARMAGEN-Guided Treatment|NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
41011801|NCT02583256|BIOLOGICAL|Non-adjuvanted QIV|Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
41011802|NCT04068675|BEHAVIORAL|Group pre-operative counseling|Enrolled patients will participate in a group pre-operative counseling session on the online conferencing platform BlueJeans® prior to their surgery. The sessions will not replace any portion of the pre-operative standard counseling and is designed to review and re-enforce the counseling already provided. The sessions will not review or discuss the specifics of any one individual's cancer or surgery. Rather the counseling session will focus on the universal instructions provided to all patients undergoing major surgery for a known or suspected gynecologic malignancy. The sessions will be led by a physician on a weekly basis with a minimal of three (3) enrolled patients per session and last approximately one (1) hour.
41011803|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
41011804|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
41011805|NCT05651009|PROCEDURE|TKA|Total knee artroplasty with medial parapatellar incision and mechanical alignment without navigation
41011806|NCT04040101|DEVICE|smartphone-based balance training system|use smartphone application to training balance
41011807|NCT06042088|OTHER|Regular Size Glove and Bigger One|Different sizes of surgical gloves will be worn by participants
41329284|NCT03331224|DEVICE|Endoscopic Standard therapy (combining two methods)|endoscopic standard therapy (two methods, e.g. clip and injection)
41329285|NCT02854007|DEVICE|Coronary angioplasty with implant of bioresorbable device|Percutaneous coronary intervention
41481433|NCT01252875|PROCEDURE|70 mg/dL|Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
41011808|NCT05707858|OTHER|Development of the NAPFA score|In subjects with suspected food allergy we will evaluate main anamnestic, and clinical features to develop the NAPFA score
41329286|NCT02876679|DRUG|Cyclophosphamide|GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
41329287|NCT02876679|DRUG|Anti-Thymocyte Globulin|GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
41329288|NCT02876679|DRUG|Conditioning regimen|30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
41329289|NCT02808507|OTHER|Active TB case finding|Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
41481434|NCT01893645|DEVICE|Pronto-7|A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
41481435|NCT02943967|PROCEDURE|CXL + PRK group|Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye
41481436|NCT02943967|PROCEDURE|PRK group|Photorefractive keratotomy alone was performed in contra lateral eyes
41329290|NCT00360048|DRUG|oxytocin|
41481437|NCT00767338|BEHAVIORAL|Timed intercourse|Timed intercourse
41329291|NCT02401802|DIETARY_SUPPLEMENT|Low-residue diet|Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
41329292|NCT02401802|DIETARY_SUPPLEMENT|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
41329293|NCT02673723|DRUG|Docozine|dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
41329294|NCT02673723|DRUG|Saline|The same amount of saline is given for 10 seconds after surface anesthesia
41329295|NCT05660213|DRUG|Huaier granule|Treatment period: Huaier Granule, oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment. After disease progression, whether to continue the medication or not should be determined by the researcher and patient together.
41329296|NCT05660213|DRUG|Atezolizumab + Bevacizumab|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
41329297|NCT05660213|DRUG|Camrelizumab+Apatinib|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
41329298|NCT05660213|DRUG|Sintilimab+Bevacizumab|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
41329299|NCT04605159|BIOLOGICAL|RSV MAT|One dose of RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm at Day 1.
41329300|NCT04605159|DRUG|Placebo|One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
41011809|NCT06422988|DIETARY_SUPPLEMENT|Probiotics|Any exposure to probiotics in first 14 days of life
41011810|NCT03112317|OTHER|Prevention of hypothermia|Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
41011811|NCT06538688|PROCEDURE|Orthodontic extrusion of the impacted mandibular third molar by using the maxillary miniscrew and cross arch elastic power chain as a temporary anchorage device before extraction|Orthodontic extrusion of the impacted mandibular third molar of high-risk for nerve injury using maxillary TAD.
41011812|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
41011813|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
41011814|NCT05120219|DRUG|FDC tablet|single and multiple doses of HR20033 FDC tablet
41011815|NCT04376645|PROCEDURE|Mandibular Setback with maxillary impaction|Occlusal bite force will be measured after surgery to correct vertical disproportions
41011816|NCT04376645|PROCEDURE|Mandibular setback only|Occlusal bite force will be measured after surgery without changing vertical disproportions.
41011817|NCT06399276|BEHAVIORAL|Weight Loss|Participants are instructed to perform a modified fast (\~500 kcal) on 3 days/week with ad libitum intake the other 4 days/week. Group-based behavioral support sessions will be held by an experienced Registered Dietician. Participants will attend BfitBwell exercise sessions in person and virtually to receive individualized support to progress to 150 min/wk of moderate-intensity physical activity
41011818|NCT04848766|DRUG|De-escalation Treatment Strategy of dual antiplatelet therapy|Patients receive de-escalation treatment of dual antiplatelet therapy after percutaneous coronary intervention
41011819|NCT03852329|DEVICE|Lateral skull base navigation|"Patient preparation: The participant is prepared for the surgery according to clinical standards.~System setup: The hardware components of the investigational device are set up~Tripod fixation: The tripod with integrated registration fiducials is fixed on the participant's skull.~CBCT imaging: A CBCT image of the participant is acquired~Image processing: The CBCT data is loaded on the navigation platform. The registration fiducials are automatically detected in the image data and relevant anatomy is segmented using an otologic planning software.~Measurements: The navigation software is started, and the fiducial positions and segmentations loaded. The measurements are conducted.~Treatment: The surgery is conducted by the surgeon according to clinical standards"
41011820|NCT03372148|DIAGNOSTIC_TEST|pHRMi|Pharyngeal High Resolution Manometry and Impedance swallowing function evaluation
41011821|NCT00830193|DRUG|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
41329301|NCT03878225|DIETARY_SUPPLEMENT|H.V.M.N. Ketone Ester|The ketone mono ester will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
41329302|NCT03878225|OTHER|Placebo|The placebo will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
41329303|NCT00271271|DRUG|oxaliplatine / gemcitabine / Vinorelbine|
41329304|NCT04569084|DRUG|MT-1186|Oral edaravone
41329305|NCT04569084|DRUG|Placebo|Oral
41329306|NCT03459404|COMBINATION_PRODUCT|Sufentanil NanoTab PCA System|15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
41329307|NCT03776097|OTHER|observational study|Observational study
41329308|NCT02800772|DIETARY_SUPPLEMENT|acetic acid|
41329309|NCT02800772|DIETARY_SUPPLEMENT|saline|
41329310|NCT06580470|BEHAVIORAL|Tailored Cognitive Behavioral Therapy for Menopause|Cognitive Behavioral Therapy for Menopause (CBT-Meno) is an evidenced-based intervention that includes psychoeducation, cognitive, and behavioral strategies for coping with common menopause symptoms and experiences. In Aims 1 and 2, CBT-Meno materials and procedures will be tailored for women Veterans through an iterative process involving: a) data from preliminary studies and a pre-pilot trial; b) input from content area experts; and c) stakeholder advisory panels. This tailored version of CBT-Meno will then be test in this clinical trial.
41329311|NCT02023112|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
41329312|NCT02023112|DRUG|Ribavirin|Capsule
41329313|NCT05031429|OTHER|Time Limited Eating|Includes an 8-hour feed/16-hour fast for 7 days per week, with consumption of all of calories in the afternoon/evening. Can consume non-caloric beverages (water, tea, coffee) during the fasting period. No caloric restriction will be used.
41329314|NCT01118715|DEVICE|Compression glove|A compression glove worn during recovery from distal radius fracture
41329315|NCT02428972|DRUG|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
41329316|NCT02428972|DRUG|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
41329317|NCT05507645|DRUG|Recombinant Human Prourokinase for Injection (rhPro-UK)|15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.
41329318|NCT05507645|DRUG|standard medical treatment|Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.
41329319|NCT04188002|BEHAVIORAL|Intervention Physical Activity|4 tailored newsletters focused on improving healthy diet and physical activity delivered at weekly intervals.
41329320|NCT04188002|OTHER|Usual Care|4 non-tailored newsletters focused on issues relevant to cancer survivors (e.g. returning to work)
41329321|NCT00085488|BIOLOGICAL|autologous tumor cell vaccine|
41329322|NCT00085488|BIOLOGICAL|therapeutic autologous dendritic cells|
41329323|NCT03722472|BIOLOGICAL|ID93 + GLA-SE|The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.
41329324|NCT04687007|BEHAVIORAL|SMART-ALD|At the beginning of SMART-ALD, a multi-professional team evaluates participant's current health status and develops an individual treatment plan together with the participant. The SMART-ALD intervention offers medical, psychological, and social counseling, as well as a physical fitness and disease-specific nutritional program carried out via video consultation. Thus, scope and intensity of SMART-ALD intervention is initially tailored to individual needs and continuously adapted to changes during intervention.
41329325|NCT04687007|BEHAVIORAL|Waiting list|At the beginning of the study, patients of the waiting list (WL) control condition receive one medical consultation via video consultation, including recommendations to contact their local treating physician if necessary. Individuals are instructed not to seek any other medical or psychological treatment for X-ALD symptoms without informing the study staff. All WL patients are guaranteed 6 months of SMART-ALD intervention after a waiting period of 6 months.
41329326|NCT00315978|DEVICE|Heart-to-Heart Decision Aid|
41329327|NCT02902822|PROCEDURE|Screening|"The screening visit consists in a general dermatological examination of the subject, with special focus on the onset of the following skin diseases during the follow-up period:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma)."
41329328|NCT02902822|DEVICE|Tele-dermatology|"The system consists in a simple web-based/smartphone application through which subjects can send pictures of recently onset non-widespread skin lesions with special focus on the following diseases:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).~A dermatology will judge online pictures based on a standard scale. Each subject who will use the system will be also seen by routine clinical visit to confirm the online diagnosis. Subjects who will not send any picture will be seen for a dermatological examination at the end of each year."
41329329|NCT02284022|DEVICE|Brain computer interface|Recording the P300 Testing the device Using the device with a speller
41329330|NCT01607294|DRUG|ETC-1002|ETC-1002 Daily for 4 weeks
41329331|NCT01607294|DRUG|Placebo|Placebo Daily for 4 weeks
41329332|NCT03702426|DRUG|GMCSF|GMCSF 1.5mcg/Kg
41329333|NCT03702426|DRUG|Norfloxacin|Tablet Norfloxacin 400 mg
41329334|NCT02907086|OTHER|blood collection|Patients will receive a research draw for circulating tumor material analysis with standard clinical labs
41329335|NCT00445250|DRUG|Calcipotriol|
41329336|NCT02899741|DRUG|Omega-3|1000mg every day for 90 days
41481438|NCT00767338|PROCEDURE|Microsurgical varicocelectomy|Microsurgical varicocelectomy
41329337|NCT03411668|OTHER|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
41481439|NCT00767338|PROCEDURE|Intrauterine insemination|Intrauterine insemination
41481440|NCT04560465|DRUG|Tranexamic acid|intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
41481441|NCT00140660|DRUG|rituximab|375 mg/m2 on D1
41481442|NCT04356118|DRUG|Recombinant Human Endostatin|endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.
40811556|NCT02529462|DRUG|Treatment As Usual|Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
40811557|NCT04739670|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody of IgG1 isotype PD-L1. It is used across a number of tumour types, both as a single-agent and in combination with other therapies such as chemotherapy.
40811558|NCT04739670|DRUG|Bevacizumab|Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
41329338|NCT02806947|DRUG|Sirolimus|Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m\^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.
41329339|NCT02806947|DRUG|Prednisone|Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
41329340|NCT03096444|DRUG|Ketamine Hydrochloride|2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
41329341|NCT03096444|DRUG|Amitriptyline Hydrochloride|2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
41329342|NCT03096444|DRUG|Lidocaine Hydrochloride|2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
41329343|NCT03096444|COMBINATION_PRODUCT|Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
41329344|NCT03096444|DRUG|Lipoderm Cream|2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
41329345|NCT00003777|DRUG|amifostine trihydrate|
41329346|NCT00003777|DRUG|cisplatin|
41329347|NCT00003777|DRUG|fluorouracil|
41329348|NCT00003777|PROCEDURE|surgical procedure|
40811559|NCT04739670|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy drug
41011822|NCT00830193|DRUG|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
41329349|NCT00003777|RADIATION|radiation therapy|
41329350|NCT04042038|BEHAVIORAL|Cognitive-behavior therapy (psychological treatment)|Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
41329351|NCT02573337|DEVICE|Emervel Classic Lidocaine|Treatment of wrinkles and folds
41481443|NCT04356118|DRUG|intrathcal methotrexate|Intrathecal chemotherapy specified dose on specified days.
41481444|NCT04356118|DRUG|Targeted drugs for non-small cell lung cancer|EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .
41481445|NCT00304720|DRUG|Tacrolimus and MMF|
40811560|NCT04739670|DRUG|Carboplatin|Carboplatin is platinum based chemotherapy drug
41329352|NCT02573337|DEVICE|Emervel Deep Lidocaine|Treatment of wrinkles and folds
41329353|NCT00884221|DRUG|Highly purified menotrophin|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
41329354|NCT00884221|DRUG|Recombinant FSH|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
41329355|NCT04108819|DIETARY_SUPPLEMENT|Ketogenic Diet|Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.
41329356|NCT06365372|DIAGNOSTIC_TEST|Western blot|Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.
41329357|NCT03036111|DRUG|Trimebutine|Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.
40811561|NCT03445377|DEVICE|Real-time continuous glucose monitoring|Subjects randomised to Real-time continuous glucose monitoring will be given a Dexcom G5 or similar, training on its use, and HbA1c measurements taken at the start and end of the study. They will also be given validated questionnaires to complete.
41011823|NCT04007952|PROCEDURE|Anterior Gastropexy|Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
41011824|NCT04527068|DRUG|Bevacizumab|7.5 mg/kg intravenously every 3week
41011825|NCT04527068|DRUG|Tripleitriumab|240mg intravenously every 3week
41011826|NCT05208567|DIAGNOSTIC_TEST|Echocardiogram|Cardiac Ultrasound Scan - using an abbreviated protocol
41329358|NCT03036111|PROCEDURE|Hemorrhoidectomy|Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
41329359|NCT01924962|DEVICE|revascularisation|revascularisation of chronic occluded coronary artery
41481446|NCT05015920|GENETIC|BD211 Drug Product|Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.
41481447|NCT05474274|OTHER|Machine learning algorithms|Machine learning techniques to rank order physiologic variables obtained via the wearable and handheld devices as well as remove low-importance and redundant variables to accurately determine postoperative pain intensity in outpatients
40811562|NCT03445377|DEVICE|Self-monitoring of blood glucose|Subjects randomised to self monitoring of blood glucose will be given a masked CGM which will be applied for one week, during Week 1, 4 and 8. HbA1c measurements will be taken at the start and end of the study. They will also be given validated questionnaires to complete.
40811563|NCT05475743|OTHER|Pain Informed Movement program|The patients included in the experimental group attended an 8-week Pain Informed Movement program in addition to standard medical care. The program was led by a physical therapist with experience in treating patients with chronic pain. This program consisted of 2 face-to-face sessions per week, and they were asked to complete two sessions at home weekly. The first face-to-face session was a group session with 3-6 participants, and the second face-to-face session was individual. Both sessions lasted approximately 1 h. In the group sessions, pain neuroscience education was conducted. In the individual sessions, an individualized functional exercise program was performed by each patient, as well as relaxation techniques. Patients were asked to perform the functional exercises and relaxation techniques at home. Participants were asked to record their compliance with the program and their progress.
40811564|NCT05475743|OTHER|Standard medical care and leaflet education|In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
40811565|NCT04750226|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
41329360|NCT01814826|DRUG|MLN4924|"MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~* MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles"
41329361|NCT01814826|DRUG|Azacitidine|"Azacitidine (IV) or subcutaneously in AML participants in a 28-day cycle:~- Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles"
41329362|NCT05918588|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
41329363|NCT05918588|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
40811566|NCT03465397|DIAGNOSTIC_TEST|biomarkers driven immunosuppressive therapy|the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
40811567|NCT02728648|DRUG|Oxycodone|Pain Management
40811568|NCT00405392|DRUG|Ibandronate (SB743830HD)|
40811569|NCT01222117|BIOLOGICAL|Plasmin|Plasmin prepared in 0.9% saline for injection
40811570|NCT01222117|BIOLOGICAL|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
41481448|NCT00463242|DRUG|Agomelatine|Either 25 mg or 50 mg agomelatine orally once daily
40811571|NCT01222117|OTHER|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
40811572|NCT03134495|OTHER|all children with at least one prescription of PPI|all children with at least one prescription of PPI
40811573|NCT03134495|OTHER|all children with no prescription of PPI|all children with no prescription of PPI
40811574|NCT06159244|OTHER|stool withdrawal|stool withdrawal at day 0 and day 7
40811575|NCT02337998|OTHER|load carriage|
41011827|NCT02111486|OTHER|breakfast|
41155705|NCT05347602|DIETARY_SUPPLEMENT|Gold Factor (Gold Nanoparticles, AuNPs)|AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
41155706|NCT05347602|DIETARY_SUPPLEMENT|Placebo|For the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.
41329364|NCT01790789|BEHAVIORAL|Daily stress reduction program|Subjects will participate in activities of a daily stress reduction program.
41329365|NCT01790789|OTHER|Attention control|Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.
40811576|NCT05348356|DRUG|Nirogacestat|nirogacestat oral tablet
40811577|NCT00551343|DRUG|Exenatide|10ug Exenatide single s.c. injection
40811578|NCT05967403|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
41481449|NCT00463242|DRUG|paroxetine|
41481450|NCT00463242|DRUG|placebo|
40811579|NCT05967403|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
40811580|NCT01519544|DRUG|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
40811581|NCT01519544|DRUG|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
40811582|NCT00623233|DRUG|Gemcitabine|Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
41481451|NCT03967587|DEVICE|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
41481452|NCT04810520|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
41329366|NCT06090448|DEVICE|EarSwitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
41329367|NCT05094076|RADIATION|chest x ray|The chest radiographs obtained will be classiﬁed according to the International Labor Organization (ILO) System for Classiﬁcation of Radiographs for Pneumoconiosis \[ILO, 1980\]. Film quality, profusion, and shape and size of opacities will be evaluated by this method. Radiographic evidence of silicosis was deﬁned as a profusion score of 1/0 or greater
41329368|NCT04830410|DIETARY_SUPPLEMENT|Fructan reintroduction|Patients will reintroduce fructan powder after 14-day of a low FODMAP diet
40811583|NCT00623233|DRUG|Bevacizumab|"Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
40811584|NCT03216343|DRUG|Chiauranib|CS2164
40811585|NCT03079934|DEVICE|Absorb-BVS|BVS patients undergoing optical coherence tomography examination at follow-up
41329369|NCT04830410|DIETARY_SUPPLEMENT|Placebo reintroduction|Patients will reintroduce placebo powder after 14-day of a low FODMAP diet
41329370|NCT03753815|DEVICE|19G FNA needle|Puncture of AIP under Endoscopic Ultrasonography, with a 19-gauge FNA needle
41329371|NCT03753815|DEVICE|20G FNB needle|Puncture of AIP under Endoscopic Ultrasonography, with a 20-gauge FNB needle
41329372|NCT00830154|DRUG|pagoclone|0.30 mg BID, 0.60 mg BID
41329373|NCT00830154|OTHER|placebo|placebo
41329374|NCT03900741|PROCEDURE|Submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a submerged healing protocol
41329375|NCT03900741|PROCEDURE|Non-submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a non-submerged healing protocol
41481453|NCT04810520|OTHER|Point-of-care ultrasound without tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
40811586|NCT04590430|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.
40811587|NCT04590430|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
40811588|NCT04136093|OTHER|the MED|The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.
41011828|NCT04118322|OTHER|aromatherapy (peppermint oil)|"The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)"
41155707|NCT02648282|DRUG|Cyclophosphamide|200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg/m2 as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 6 months for an additional 4 doses.
41329376|NCT00653328|DRUG|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
41329377|NCT00653328|DRUG|doxil|50 mg/m2 intravenously every 28 days
41329378|NCT00054184|DRUG|docetaxel|
41329379|NCT00054184|DRUG|paclitaxel poliglumex|
41329380|NCT00702910|DRUG|Placebo|comparator
41329381|NCT00702910|DRUG|GW642444|investigational drug or placebo
41329382|NCT00702910|DRUG|Magnesium Stearate|Magnesium Stearate
41329383|NCT00250081|PROCEDURE|Upper Extremity Tendon transfer|
41329384|NCT00250081|PROCEDURE|Botulinum Toxin injections in Upper Extremity|
41329385|NCT00250081|PROCEDURE|Regularly ongoing therapy|
41329386|NCT00191737|DRUG|Atomoxetine|
41329387|NCT05114148|DEVICE|Holmium-166 radioembolization|Individualized 166Ho-RE will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
41329388|NCT05742841|DRUG|moderate- or high-intensity statin/ rosuvastatin|moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
41329389|NCT01525056|RADIATION|ct and mri scans|ct and mri scan preradiation and postradiation
41329390|NCT01525056|RADIATION|ct, mri and pet scan|ct, mri and pet scans preradiation and postradiation
41329391|NCT01525056|RADIATION|ct, mri and pet scans|single arm with ct, mri and pet scans pre and post radiation
41481454|NCT05234320|DRUG|CG-SpikeDown, intranasal formulation|The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
41481455|NCT05234320|DRUG|Vehicle (Placebo)|patients will receive active drug or placebo in addition to standard of care
41481456|NCT05234320|DRUG|Standard of core (type of therapy is depend of decide of the site)|patients will receive active drug or placebo in addition to standard of care
40811589|NCT04136093|OTHER|the DASH|The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.
40811590|NCT04136093|OTHER|Control diet|"The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal."
40811591|NCT00868140|DRUG|pioglitazone|pioglitazone 45 mg
41011829|NCT05138380|DEVICE|Foot orthoses|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: inbuilt.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Orthoses are fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
41011830|NCT05138380|DEVICE|Flat shoe insert|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: no.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
41481457|NCT00979381|BIOLOGICAL|influenza vaccine|influenza vaccination
41481458|NCT03896464|PROCEDURE|Soft tissue hamstring autograft|Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.
41481459|NCT03896464|PROCEDURE|Quadriceps tendon autograft|Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
41481460|NCT05053347|DIETARY_SUPPLEMENT|Flaxseed oil capsule|The participants were asked to take flaxseed oil capsule 5d/day(ALA 2.5g/d). The intervention period is about 6 months separated by a one-month washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
41481461|NCT05053347|DIETARY_SUPPLEMENT|Corn oil capsule|The participants were asked to take corn oil capsule 5d/day. The intervention period is about 6 months separated by a one-month washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
41481462|NCT04481178|OTHER|Laser (QS, Picosecond laser)|QS-Nd Yag Laser, Picosecond laser
40811592|NCT00868140|DRUG|Placebo|placebo daily
40811593|NCT01028768|DRUG|Teduglutide|10 mg, one-time subcutaneous
40811594|NCT04769271|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
40811595|NCT04769271|DRUG|Scaling and Root Planing with tea tree oil|Supra- and sub-gingival calculus and debris were removed and 5% tea tree oil was applied
40811596|NCT04339933|DIAGNOSTIC_TEST|FGFR test|Detection of FGFR gene mutations in the tumor tissue and urine of patients
40811597|NCT03839849|PROCEDURE|: i-PRF|The description of this intervention has been already given before
40811598|NCT03839849|PROCEDURE|saline|The description of this intervention has been already given before
41481463|NCT00996931|DRUG|lenalidomide|2.5 mgs per day orally for 12 weeks
41481464|NCT02138942|DEVICE|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
41481465|NCT04529226|DRUG|Clozapine|Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week
41011831|NCT05439850|PROCEDURE|arthroscopic rotator cuff repair|This procedure is the standard of care for rotator cuff tears who fail conservative treatment options.
41011832|NCT05439850|BIOLOGICAL|Bioinductive implant|A bioinductive implant that is designed to promote healing of the torn rotator cuff tendon after surgery.
41011833|NCT05439850|DIAGNOSTIC_TEST|Ultrasound Imaging|An ultrasound will be performed on each patient one year postoperatively.
41011834|NCT01223716|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
41011835|NCT01223716|BEHAVIORAL|Video Game|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
41011836|NCT01223716|BEHAVIORAL|Crossover (Occlusion therapy + Video Game)|"Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).~Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks)."
41011837|NCT06250686|BEHAVIORAL|combined exercise and nutrition intervention|Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.
41011838|NCT03863366|DRUG|Prucalopride|1mg prucalopride tablet, encapsulated in white capsule
40811599|NCT05807256|OTHER|collection and analysis of treatments and procedures already performed by normal clinical practice|The patients' anthropometric variables; laboratory test results; PMA techniques (types of fertilization/drugs used for stimulation) and the outcome of the eventual pregnancy (ongoing treatment during the pregnancy itself, development of maternal/fetal complications, such as hypertension, preeclmpsia, thrombotic events, renal failure, disease flare, neonatal outcome) and data on the type of ovarian stimulation drug treatment.
40811600|NCT04630860|DRUG|LY03003|Rotigotine,extended-release microspheres
40811601|NCT03235895|OTHER|Educational material|Educational material given as a part of CME activity as through enhanced internet method
40811602|NCT01905046|DRUG|metformin hydrochloride|given PO
40811603|NCT01905046|OTHER|placebo|given PO
40811604|NCT00443872|DRUG|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
40811605|NCT00987428|PROCEDURE|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
40811606|NCT00987428|PROCEDURE|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
40811607|NCT04429386|PROCEDURE|Bariatric surgery|Laparoscopic bariatric surgery including gastric bypass and sleeve gastrectomy
40811608|NCT06088173|OTHER|exercises|Patients in both group will use Kleinert splint. Sessions will start with ice application if there is edema and continue with scar tissue massage. After general hand massage, passive flexion, active extension exercises; tenodesis exercise and passive punch will be performed for the postoperative (postop) first two weeks. In postop 3-4 weeks, four finger sliding exercises, active half fist and NMES (Neuromuscular electrical stimulation) will be performed. In postop 5-6 weeks, blocking exercises, full punch, grappling hooks and small on-digits holding and releasing exercises will be performed additionally.
40811609|NCT06088173|OTHER|Exercises and Education|In addition to the same treatment as the patients in the first group, in the first postoperative (postop) two weeks, the gmi will be explained to the patients and lateralization will be started. lateralization refers to right-left discrimination and the patients will be presented with visuals with the help of the noi recognise app and they will have to decide whether the visual is right or left hand. In the postop 3-4th weeks, the motor imagery stage will be started and imagery will be practiced with the help of the same app. In postop 5-6 weeks, mirror therapy will be practiced with the help of a mirror box.
40811610|NCT02160665|DRUG|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G \& W Laboratories, Inc.)
40811611|NCT02160665|DRUG|Vehicle|Vehicle of Test product (G \& W Laboratories, Inc.)
40811612|NCT02160665|DRUG|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
40811613|NCT03296748|PROCEDURE|trans-obturator tape inside-out usingsoft tapes.|trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
40811614|NCT03296748|PROCEDURE|anterior colporraphy|
40811615|NCT00630006|GENETIC|TNF-alpha and IL-10|
40811616|NCT02933424|DIETARY_SUPPLEMENT|Protein Powder|
40811617|NCT05859412|OTHER|Neurodynamic exercises|The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.
40811618|NCT05859412|DRUG|Steroid injection (Depomedrone 40mg)|Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
40811619|NCT05859412|OTHER|Advice|Group receiving advice but no additional treatment
40811620|NCT01766063|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
40811621|NCT01098188|DRUG|LFB-R603|intravenous administration, dose-escalation study
40811622|NCT04652258|DRUG|Actemra|Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
40811623|NCT05743556|DEVICE|HILT laserotherapy|application of high intensive laser therapy on cervical muscles
40811624|NCT05743556|DEVICE|TRT therapy|application of radiofrekvention therapy on cervical muscles
40811625|NCT06402526|OTHER|Mobile Epilepsy Education Package|"MEEP education section contains a range of topics. After completing the relevant section at the end of each week, participants complete the end-of-section test and switch to the next week's topic. Completion of the first part will take approximately 90-120 minutes per week for a total of 4 weeks of use.~Parental Monitoring Section, parents can actively record information on the mobile application related to their child's diagnosis (anonymous); treatments; timing and frequency of the seizures; and appointments; and schedule treatment and examination reminders to optimize compliance. Completion of this second part will take approximately 1-2 minutes and depends on the parental choice to use and how much information they would like to share. The second part, together with the first part, will be evaluated for a total of 1 month."
40811626|NCT06402526|OTHER|Standard care consisting of epilepsy education|This standard care includes the information and education provided by nurses and physicians during visits and hospitalisations. Standard information and education include topics such as: counseling by the neurologist regarding seizure safety precautions, prognosis, and sudden unexpected death in epilepsy (SUDEP); provision of paper or electronic resources regarding epilepsy; and telephone support provided by neurology clinic nurse regarding any issues or concerns). Information and education is usually provided orally and through printed brochures.
40811627|NCT03789435|DIAGNOSTIC_TEST|Questionnaire|"A questionnaire from which the session dedicated to the evaluation of the stump pain, the phantom limb and the sensation of the phantom limb has been extracted will be administered: this is the Prosthetic Evaluation Questionnaire (PEQ) validated in Italian by Ferrero et al. 2005.~In the questionnaire sent to patients will be asked also for anthropometric data (weight, height) in addition to the characteristics of the worn prosthesis and if they have followed a period of rehabilitation.The time of use of the prosthesis will be evaluated through the Houghton Scale of Prosthetic Use in People with Lower- Extremity Amputations (19)"
40811628|NCT00416494|BIOLOGICAL|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
40811629|NCT00416494|DRUG|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
40811630|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
40811631|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
40811632|NCT00153140|DRUG|polyethyleneglycol3350|
40811633|NCT03540589|DEVICE|Buzzy specific vibration device|It is a device that produces vibration
40811634|NCT03540589|BEHAVIORAL|Distraction|The distraction will be obtained through tablet with videos
40811635|NCT03866317|DRUG|Secukinumab|All subjects will receive secukinumab 300 mg injections subcutaneously at week 0, 1, 2, 3, 4, then every 4 weeks until week 12.
40811636|NCT03623321|DRUG|Pimavanserin|• Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
40811637|NCT03874741|DRUG|SCT200|"Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200"
41011839|NCT03863366|OTHER|Placebo|Lactose placebo tablet, encapsulated in white capsule
41329392|NCT03161782|OTHER|PNF stretching|For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
41329393|NCT03161782|OTHER|Static Stretching|For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
41329394|NCT03161782|OTHER|Exercise|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.
41329395|NCT03161782|OTHER|Cold Therapy|Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
41329396|NCT02972957|BIOLOGICAL|Nasovac-S|one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
40811638|NCT04556591|BEHAVIORAL|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
40811639|NCT04556591|BEHAVIORAL|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a three-month (90 day) period
40811640|NCT03686306|DRUG|Sildenafil|"Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
41329397|NCT02972957|DRUG|Azithromycin|a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
41329398|NCT06380790|PROCEDURE|Laser-aided csf|Laser-aided csf before leveling and alignment
41329399|NCT06380790|OTHER|placebo laser-aided csf|placebo laser-aided csf before leveling and alignment
41329400|NCT02037451|PROCEDURE|rhythmic auditory stimulation|Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
40811641|NCT03686306|DRUG|Placebo|"Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
40811642|NCT04227275|BIOLOGICAL|CART-PSMA-TGFβRDN|Intravenous administration of genetically modified autologous T cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA), as well as a dominant negative TGFβ receptor
40811643|NCT04227275|DRUG|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
40811644|NCT04227275|DRUG|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
40811645|NCT04227275|DRUG|Anakinra|In applicable cohorts, patients will receive anakinra prophylactically starting on the day of administration of investigational product, CART-PSMA-TGFβRDN genetically modified T cells
40811646|NCT05342012|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
40811647|NCT05342012|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|(Nitrate depleted beetroot juice
40811648|NCT02926027|DRUG|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
40811649|NCT02926027|DRUG|placebo|placebo
40811650|NCT01557257|DRUG|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
40811651|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
41011840|NCT00885872|DRUG|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
41329401|NCT01254578|OTHER|Laboratory Biomarker Analysis|Correlative studies
40811652|NCT01557257|DRUG|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
40811653|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
41329402|NCT01254578|DRUG|Lenalidomide|Given orally
41329403|NCT01254578|OTHER|Pharmacological Study|Correlative studies
41329404|NCT00764946|DRUG|Comparator: raltegravir|400 mg tablets taken twice daily. Total treatment period is 48 weeks.
41329405|NCT02790294|DEVICE|Magnetic Resonance Imaging|The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
40811654|NCT01557257|DRUG|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
40811655|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
40811656|NCT05872542|DRUG|Silver Diamine Fluoride (SDF)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.
41011841|NCT06514092|OTHER|anti-TNF therapy and seton drainage|Crohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.
41481466|NCT04529226|DRUG|haloperidol, pimozide, olanzapine, risperidone, amisulpride|Treatment as usual using first-generation or second-generation antipsychotics
41481467|NCT04666519|DIAGNOSTIC_TEST|Zonulin Biomarker|During revision hip and knee surgery, discarded fluid/blood will be tested for the presence of zonulin biomarkers
41481468|NCT03564301|DRUG|Placebo oral capsule|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
41481469|NCT03564301|DRUG|Metronidazole 250 MG|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the antibiotic to be taken during the following days will be given to the patient.
41481470|NCT00842478|PROCEDURE|Toothbrushing|
41481471|NCT01332578|DRUG|Paracetamol|Present in both test and active comparator
41481472|NCT01332578|DRUG|Phenylephrine|Test product
41481473|NCT01332578|DRUG|Ascorbic Acid|Test product
41481474|NCT03407430|DRUG|Pregabalin|During the first chemotherapy cycle, the patient will receive pregabalin 75mg (1 capsule) BID x 4 days before pegfilgrastim 6mg subcutaneous (SC) x1; then pregabalin 150mg (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive placebo in the same dosing scheme.
41481475|NCT03407430|DRUG|Placebo|During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
41481476|NCT00949689|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
41481477|NCT04085471|DIAGNOSTIC_TEST|CTHRC1 biomarker level in rheumatoid arthritis|measurment of levels of CTHRC1 in patients diagnosed as RA
41329406|NCT00518401|BIOLOGICAL|Mesendo|Intramuscular injection of 0.5 cc per site of the combination stem cell mixture in approximately 40 different ischemic sites of the gastrocnemius area of the calf.
41481478|NCT02370225|OTHER|aerobic exercise|"Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).~The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end."
40811657|NCT05872542|OTHER|Glass Ionomer Restoration (GI)|Application of GI restoration necessitates removal of carious tissue using round bur rotating on low-speed contra and excavation of infected carious dentin. Followed by restoring the prepared cavity with glass ionomer restoration according to the manufacturer's instructions. The restoration will be checked for any high spots and occlusal interference (if any) will be corrected.
40811658|NCT05872542|OTHER|Sodium fluoride varnish with nano-sliver particles (NaF-AgNP)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply NaF-AGNP to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Continue to isolate the site for up to three minutes.
40811659|NCT05252013|OTHER|Experimental: Bean Hull Bread|The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.
41011842|NCT05460624|OTHER|Egg-containing breakfast|Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.
41011843|NCT05460624|OTHER|Typical American-style breakfast excluding eggs|Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
41011844|NCT00440271|DRUG|tipranavir|
41011845|NCT00440271|DRUG|ritonavir|
41011846|NCT00440271|DRUG|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
41329407|NCT00223288|DRUG|Lexapro|
41329408|NCT05839847|DEVICE|Low-intensity focused ultrasound|A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can reduce reactions to sensory stimuli.
41481479|NCT00852566|DRUG|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
41481480|NCT00852566|DRUG|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
41481481|NCT05468788|BEHAVIORAL|Intervention: Integrative Community Therapy-based Psychodrama|Participants produce theatre scenes depicting issues that they have experienced. Group leaders then use a guide to facilitate a discussion of participants' feelings, coping strategies, and sharing of local knowledge.
41481482|NCT05468788|BEHAVIORAL|Control: Improvisational Theatre|Participants play improvisational theatre games.
41481483|NCT03325985|BEHAVIORAL|Nurse-led telephonic case management|Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
41481484|NCT03325985|BEHAVIORAL|Facilitated,outpatient specialty palliative care|In-person or telehealth palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
41481485|NCT05515393|DRUG|XY03-EA|The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.
41481486|NCT05515393|DRUG|XY03-EA Placebo|XY03-EA Placebo
41329409|NCT05839847|DEVICE|Low-intensity focused ultrasound - sham|A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
41481487|NCT03911921|DRUG|RSYRT decoction|Compound granules of traditional Chinese medicine
41481488|NCT03911921|DRUG|Astragalus membranaceus|One herb
41481489|NCT04242394|PROCEDURE|ERCP|Routine ERCP procedures with gallbladder in situ patient
41481490|NCT05051202|OTHER|Sugars from Fiber|Proprietary blend of Sugars from Fiber baked into 50 g flapjack
41481491|NCT05051202|OTHER|Resistant Maltodextrin|Resistant Maltodextrin baked into 50 g flapjack
41481492|NCT05579483|DIETARY_SUPPLEMENT|Prebiotics|The prebiotics consists of three non-digestible carbohydrates (40% acacia gum, 20% partially hydrolyzed guar gum, and 40% resistant starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
41481493|NCT05579483|DIETARY_SUPPLEMENT|Placebo|The placebo consists of two digestible carbohydrates (20% maltodextrin and 80% corn starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
41011847|NCT02472665|DRUG|plasma-derived FVIII/VWF concentrate|1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
41329410|NCT00323024|DRUG|NX1011|
41329411|NCT00859807|DRUG|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
41329412|NCT00859807|DRUG|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
41329413|NCT04348539|OTHER|Balance training|32 sessions will be held twice a week, with each session taking an average of 45 minutes
41329414|NCT04970849|OTHER|observation|IBD doctors who perform the endoscopy perform the questionnaire
41329415|NCT01994317|OTHER|Algorithm|IV sedation dosing calculated by algorithm
41329416|NCT01994317|OTHER|Standard care|IV sedation dosing calculated by standard care.
41329417|NCT04749563|DRUG|IGC AD1|IGC AD1 oral Solution
41329418|NCT04749563|DRUG|Placebo|Placebo of IGC AD1 oral Solution
41481494|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Starting Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
41481495|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Low Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
41481496|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Middle Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
41481497|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 High Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
41481498|NCT04471038|BIOLOGICAL|SAB-176|Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
41011848|NCT04035772|OTHER|Wiki101 and WikiTrauma|Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
41481499|NCT04471038|OTHER|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm
41481500|NCT01112813|DRUG|Lithium Carbonate|0.4-0.8 mmol/L for 2 months
41481501|NCT04997395|DRUG|MediCabilis Cannabis sativa 50|Already described
40811660|NCT05252013|OTHER|Experimental: Plain Bread|The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
41011849|NCT00434668|DRUG|cisplatin/docetaxel|
41011850|NCT00434668|DRUG|cisplatin/vinorelbine|
41011851|NCT06572085|DRUG|Butylphthalide and Sodium Chloride Injection|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
41329419|NCT03457311|DRUG|G.S.P. Oral Solution 400 mg/ml|Oral 1.25 ml/kg BW G.S.P. oral solution after fasting for 6 hours.
41329420|NCT00602511|DRUG|Bortezomib|"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
41329421|NCT00602511|DRUG|Thalidomide|"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
41329422|NCT02897869|DRUG|POL7080|7 doses of POL7080 alone over 2.5 days
41329423|NCT02897869|DRUG|Amikacin|3 doses of Amikacin alone over 2.5 days
41329424|NCT02897869|DRUG|POL7080 + Amikacin|7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
41329425|NCT00260429|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
41329426|NCT06157372|DIAGNOSTIC_TEST|targeted next-generation sequencing (tNGS)|To provide rapid etiological diagnosis of patients by means of targeted next-generation sequencing.
41329427|NCT02859987|PROCEDURE|PICC Placement by Landmark Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
41481502|NCT06451393|DRUG|Neoadjuvant chemotherapy with radical tumor resection surgery|All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).
41329428|NCT02859987|PROCEDURE|PICC Placement by Ultrasound-guided Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
41329429|NCT02859987|DEVICE|Ultrasound Scan|Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
41329430|NCT01886885|BEHAVIORAL|Mindfulness Based Chronic Pain Management Intervention|Mindfulness-Based Chronic Pain Management (MBCPM) is an intervention developed by Jackie Gardner-Nix, MD for individuals suffering from chronic pain. The focus of MBCPM is to teach clients skills that will facilitate the development of detached observation and reduce the experience of suffering through cognitive re-appraisal. The activities used within MBCPM include mindfulness meditation, gentle stretching/mindful movement, guided imagery, art techniques, psychoeducation, and discussion. There are daily homework assignments of just 5-30 minutes a day in MBCPM. Each class is two hours long with a break in the middle.
40811661|NCT03440151|PROCEDURE|contralateral submental flap for tongue cancer defect|"Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted."
40811662|NCT03440151|PROCEDURE|primary closure for tongue cancer defect|Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
41329431|NCT01125540|DEVICE|Acuvue (Standard Daily Disposable Contact Lens)|
41329432|NCT01125540|DEVICE|CIBA Dailies Aquacomfort Plus (Contact Lens - enhance lubricating)|
41329433|NCT01441791|PROCEDURE|Lung protective strategy ventilation|Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
41329434|NCT05015738|OTHER|Traditional education|Diabetes education will be given by the trainer for 10 weeks, 2 hours of presentation.
41329435|NCT05015738|DEVICE|Diabetes Education supported by digital tools|Diabetes education will be given for 10 weeks with 2-minute animations. At the end of the course, learners' knowledge was measured with a knowledge test using the Kahoot app.
41329436|NCT04238572|DEVICE|Audiovisual distraction device|Evaluate the impact of an audiovisual distraction device on the peroperative opioid consumption
40811663|NCT01997606|OTHER|use of Purotex treated bedding covers|Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
40811664|NCT01997606|OTHER|placebo|
40811665|NCT01877486|PROCEDURE|Ablation|Pulmonary vein isolation following dofetilide
40811666|NCT06274034|OTHER|Electronic Health Record Review|Ancillary studies
40811667|NCT06274034|OTHER|Medical Device Usage and Evaluation|Wear MUSE S headband
41011852|NCT06572085|DRUG|Saline Solution|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
41011853|NCT06573112|DIAGNOSTIC_TEST|ultrasound assessment for catheter-related thrombosis.|Patients with newly inserted central venous catheter will be assessed with vascular ultrasound for the presence of catheter-related thrombosis
41011854|NCT01268644|DRUG|Leptin|weight based sub-cutaneous injection twice daily of Leptin
41155708|NCT02648282|DRUG|GVAX Pancreatic Cancer Vaccine|2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of 8 doses. In the extended treatment phase, eligible patients may receive 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells administered one day after CY every 6 months for an additional 4 doses.
41329437|NCT04238572|DEVICE|Analgesia nociception index|ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
41329438|NCT01535768|DRUG|Aqueous Suppressant Eye Drops|"Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)"
40811668|NCT06274034|PROCEDURE|Meditation Therapy|Participate in meditation
40811669|NCT06274034|OTHER|Survey Administration|Ancillary studies
41011855|NCT00833924|DEVICE|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
41011856|NCT02247349|BIOLOGICAL|BMS-986012 (anti-fucosyl-GM1)|
41011857|NCT02247349|BIOLOGICAL|Nivolumab|
41011858|NCT03436472|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
41011859|NCT03436472|DRUG|placebo|normal saline infusion
41481503|NCT06415617|OTHER|Psychoeducation|"The content of psychoeducation is based on Five Ways of Well-being which covers Be active, Connect, Take Notice, Keep learning and Giving . The participants will be engaged in psychoeducation through group discussion, individualised goal setting and reflective exercises."
40811670|NCT05064358|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
40811671|NCT05933356|BEHAVIORAL|playing exergames|"will be provided with the individual brain training exergames three times a week and 30 minutes each time"
40811672|NCT05933356|OTHER|scheduled activities|scheduled activities
40811673|NCT05614258|DRUG|ADG206|All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years.
40811674|NCT03688334|DRUG|Oxygen 40 %|Oxygen supplementation (40%) via Venturi mask
40811675|NCT03688334|DRUG|Medical air (sham O2)|Medical air supplementation via Venturi mask
40811676|NCT04343170|DRUG|Placebo|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
40811677|NCT04343170|DRUG|ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
40811678|NCT01326884|DEVICE|ZLP|ZLP Graft
40811679|NCT05265234|DRUG|Dupilumab|IL-4 antagonist to improve moderate-severe atopic dermatitis
41329439|NCT04733001|DRUG|HSG4112|Once-daily oral administration
41329440|NCT06507761|OTHER|Sham|An unrefrigerated room temperature Cold Pack will be wrapped in a towel and applied to the patient's posterior neck and back for 15 minutes while the patient is lying face down.
41329441|NCT06507761|OTHER|Hot Pack|Hot pack (55-60 degrees) application will be wrapped in a towel and applied to the back side neck and back of the patient for 15 minutes while the patient is lying face down.
41481504|NCT06415617|OTHER|Attention control|The content of the sessions mainly focuses on physical health information, such as healthy eating, physical exercise, prevention of falls, and pain management.
41481505|NCT04707976|DEVICE|Navina Smart|CE-marked NavinaTM Smart including Navina Smart App.
41481506|NCT04707976|OTHER|Standard Bowel Care|Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
41481507|NCT05166954|PROCEDURE|LSG|Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
41481508|NCT05166954|PROCEDURE|RYGB|Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
40811680|NCT05265234|DEVICE|Optical Coherence Tomography|OCT is a noninvasive imaging device that can be used to monitor inflammatory skin disorders.
40811681|NCT05265234|DEVICE|Reflectance confocal microscopy|RCM is a noninvasive imaging device, with resolution approaching that of histology, which can monitor structural changes in the epidermis and superficial dermis, monitor inflammatory cells, and can overcome the limitations of a traditional biopsy.
40811682|NCT06306911|DIETARY_SUPPLEMENT|Aronia Melanocarpa extract|Aronia Melanocarpa extract (AME) consisting of a mixture of anthocyanins and other polyphenols
41155709|NCT02648282|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg as a 30 minute IV infusion every 21 days for an additional 9 doses.
41155710|NCT02648282|RADIATION|SBRT|Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX Pancreas Vaccine).
41481509|NCT00896155|DRUG|Tamoxifen|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
41481510|NCT00896155|RADIATION|Radiotherapy|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
41481511|NCT06138470|DIETARY_SUPPLEMENT|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
40811683|NCT06388096|DIAGNOSTIC_TEST|Pattern Electroretinogram|Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.
40811684|NCT05351177|OTHER|Exercise Training|Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
41155711|NCT02214017|DEVICE|A videotelephone, TandBerg E20,|
41155712|NCT02214017|BEHAVIORAL|Behavioral motivation|Optimization of medical care in diabetes
41329442|NCT06507761|OTHER|Cold Pack|Cold pack application (2-4 degrees) will be wrapped in a towel and applied to the patient's back side neck and back for 15 minutes while the patient is lying prone.
41329443|NCT04169685|PROCEDURE|bronchoscopy|during flexible bronchoscopy
41329444|NCT04629638|OTHER|Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores|The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.
41329445|NCT01119157|BIOLOGICAL|influenza vaccine|whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration
41329446|NCT01069367|BIOLOGICAL|Emulsion, Cell Culture-based, influenza HA vaccine H1N1|Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
41329447|NCT02581124|DRUG|JTZ-951|
41329448|NCT02581124|DRUG|Lapatinib|
41481512|NCT06138470|DIETARY_SUPPLEMENT|Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
41329449|NCT05193877|PROCEDURE|autologous bone marrow aspirate concentrate by centrifugation|"50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.~Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.~Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.~The separated MNCs is administered intra-articularly immediately after centrifugation."
41329450|NCT00971633|DRUG|Comparator: Treatment A (Zofran, ondansetron)|an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
41329451|NCT00971633|DRUG|Comparator: Treatment B (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the U.K., taken PO
41329452|NCT00971633|DRUG|Comparator: Treatment C (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
41329453|NCT00751179|DRUG|rocuronium|A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.
40811685|NCT06020391|OTHER|Collaborative drug review|"1. Structured, clinical drug review including medical history, physical examination, and supplementary tests. The work-up will be aimed at evaluating whether current medications are indicated, whether the patient's medical conditions are satisfactorily compensated, whether dosages are appropriate, whether the patient has adverse drug effects, and whether drug-drug or drug-disease interactions are present or likely to occur. The MipAC physicians will receive clinical supervision from a consultant in geriatric medicine.~2. The MipAC physician will offer the patient's FP a telephone meeting with the purpose of combining the assessments of the MipAC physician and the competence of the FP in a common drug review. The two physicians will review the patient's drug list systematically and discuss if any adjustments should be done, as well as the patient's need for further follow-up."
40811686|NCT03922672|BEHAVIORAL|Group piano training|The group piano training is scheduled over 4 months of a two-hour weekly group piano lesson. There is also a 3-hour weekly practice at home.
40811687|NCT02242214|DRUG|Misoprostol|
40811688|NCT05524623|OTHER|percutaneous microelectrolysis in myofascial trigger points of the trapezius|percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius
41329454|NCT00751179|DRUG|sugammadex|At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.
41329455|NCT00751179|DRUG|succinylcholine|A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
41329456|NCT01966861|OTHER|weaning guided by LUS (lung ultrasound)|Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score \>14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required \[CPIS\>6\], hemglobin\>8g/dl triggers transfusion)
41329457|NCT04443296|DRUG|CCRT+TIL|Cisplatin based chemotherapy concurrently with radiotherapy, then TIL infusing following concurrent chemoradiotherapy
41329458|NCT05193968|OTHER|Sympathoexcitatory stressors|Muscle sympathetic nerve activity will be measured continuously at baseline and in response to sympathoexcitatory stressors, including a Valsalva maneuver, isometric handgrip exercise, a cold pressor test, and stepped hypercapnia.
41329459|NCT05193968|DRUG|Sodium Nitroprusside|Sodium nitroprusside, used to test endothelium-independent vasodilation, will be infused through a brachial artery catheter at 0.25, 0.5, 1.0 and 2.0 ug/100ml tissue/min.
41329460|NCT05193968|DRUG|Acetylcholine|Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min
41329461|NCT05193968|DRUG|Terbutaline|Terbutaline, a β2-Adrenergic selective agonist, will be infused through a brachial artery catheter at 0.1, 0.5, 1.0, and 2.0 μg/100ml tissue/min.
41329462|NCT05193968|DRUG|Norepinephrine|Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
41481513|NCT06138470|DIETARY_SUPPLEMENT|Saffron and Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
41481514|NCT06138470|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Food supplements are taken during 6 weeks by healthy volunteers
41481515|NCT02286219|DRUG|FS102|Experimental
41481516|NCT04642859|BEHAVIORAL|Computerized Cognitive abilities training battery for reading (CATB-R)|Specially designed Arabic computerized training program for dyslexia
41481517|NCT03648034|PROCEDURE|ropivacaine|To perform scalp nerve blocks with ropivacaine
41481518|NCT03648034|PROCEDURE|saline|To perform scalp nerve blocks with saline
40811689|NCT03812341|OTHER|Experimental|KeraKlear Non-Penetrating Keratoprosthesis The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity
41155713|NCT03711825|DRUG|LYN-057|Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
41481519|NCT05834530|OTHER|3D Printed Complete Dentures|Denture bases printed from a pre-polymerized block via additive technique, using photon S desktop 3D printer\* that relies on SLA technology and post cured by post curing unit.
41481520|NCT00597116|DRUG|Vinorelbine|
41481521|NCT00597116|DRUG|Vandetanib|once daily oral dose
41481522|NCT06128694|DIETARY_SUPPLEMENT|NUTRICAN|Per serving/sachet NUTRICAN (±81g) contains 350 kcal energy, 9 g fat, 20 g protein, 48 g carbohydrate, 400 mg DHA, 300 mg EPA, 0.92 g Omega-3, 1 g L-Valine, 1.1 g L-Isoleucine, 2.1 g L-Leucine, 75 mg sodium, 12 vitamins and 9 minerals.
41481523|NCT03957187|DIAGNOSTIC_TEST|Ferritin, iron and iron binding capacity, high sensitive C-reactive protein (CRP) measurement|"Ferritin, iron and iron binding capacity will be measured for evaluation of ID using Cobas c-e and Elecsys.~The relation of inflammation to iron deficiency will be evaluated by high sensitive C-reactive protein measurement."
41481524|NCT03712241|DRUG|K-285|Topical
41481525|NCT03712241|DRUG|Indomethacin|Capsule
40811690|NCT04157153|DEVICE|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
40811691|NCT02791516|DRUG|Romosozumab|Administered by subcutaneous injection once a month (QM)
41155714|NCT03711825|PROCEDURE|Imaging Assessment (MRI)|Imaging assessments \[MRI\] will be performed on specified days according to protocol
41329463|NCT02313415|PROCEDURE|UC-MSCs therapy|Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
41155715|NCT03711825|PROCEDURE|Imaging Assessment (U/S)|Imaging assessments (abdominal U/S) will be performed on specified days according to protocol
41329464|NCT04593875|DEVICE|Active LIFUP Treatment|Low intensity focused ultrasound pulsation will be administered to the internal globus pallidus in 20 sonications at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5%, duration 30s with 30s spacing between sonications. For active LIFUP, the device will be used with a gel pad that allows the ultrasound to pass through.
41329465|NCT04593875|DEVICE|Sham LIFUP Treatment|The device will be aimed at the internal globus pallidus and turned on with the same settings as the active condition; however, in this case, the device will be used with a gel pad that blocks the ultrasound from passing through, such that no ultrasound is actually being administered to the brain.
40811692|NCT02791516|DRUG|Placebo|Administered by subcutaneous injections once a month
40811693|NCT05995678|BEHAVIORAL|STEP-Home-SP|This group will meet for \~1.5 hours/week for 12 weeks. The core skills of Emotional Regulation (ER) and Problem Solving (PS) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention training augments ER and PS skills and is interspersed throughout the group and individual sessions. Additional 30-minute individual skills building and goal setting sessions occur up to 6 times based on individual Veteran needs. STEP-Home staff will work in pairs to run workshops per established protocols. Workshops will be conducted via VA approved video telehealth.
41329466|NCT04630626|DEVICE|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
41329467|NCT04630626|OTHER|ACDF|Historical ACDF control data
41329468|NCT06155240|BEHAVIORAL|Therapeutic yoga|Yoga interventions include yoga poses, breathing, and meditation
41329469|NCT00344760|DRUG|Enfuvirtide|subcutaneously twice a day
41481526|NCT03977974|DRUG|LY3526318|Administered orally
41481527|NCT03977974|DRUG|Placebo|Administered orally
40811694|NCT05995678|BEHAVIORAL|Transition Assistance Program|Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
40811695|NCT05995678|BEHAVIORAL|VA Solid Start|VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
40811696|NCT06414135|BIOLOGICAL|Relma-cel|All participants will receive Relma-cel once at different dose levels: 25×10\^6 CAR+ T cells、50×10\^6 CAR+ T cells、75×10\^6 CAR+ T cells
41155716|NCT03501524|DEVICE|VATS evacuation|the patient will be randomized to a Video-Assisted thoracoscopy for retained haemothorax
41155717|NCT03501524|DEVICE|thoracostomy tube|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
41155718|NCT00010322|DRUG|atamestane|
41155719|NCT00010322|DRUG|toremifene|
41155720|NCT03623399|PROCEDURE|low gas pressure laparoscopy|To apply different CO2 entrance and intraoperative pressures
41155721|NCT00607737|DRUG|insulin detemir|3 cutaneous injections
41329470|NCT00344760|DRUG|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
41329471|NCT03201367|DRUG|Rivaroxaban|Rivaroxaban 10 mg/12 hour
41155722|NCT00607737|DRUG|saline|3 cutaneous injections
41155723|NCT04764864|PROCEDURE|Angioembolization|"Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.~In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.~The material used will vary depending on the characteristics of the injury and the availability of the materials."
41329472|NCT03201367|OTHER|symptomatic therapy for ascites, abdominal pain|
41329473|NCT02858284|DEVICE|TUG|Therapeutic Ultrasound for Glaucoma
41329474|NCT02858284|DEVICE|Sham|
41329475|NCT03135288|DEVICE|Cell-phone|a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits.
41481528|NCT04273919|DEVICE|HTC Vive with Karuna Virtual Reality Program|HTC Vive head-mounted display and an HTC Vive body tracker adhered to a belt on the patient's low back, which will be placed 2 inches below the waist
41481529|NCT04273919|DEVICE|HTC Vive with Lumen Program|HTC Vive head-mounted display with Lumen program
41329476|NCT02234557|BEHAVIORAL|Tai Chi|"6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.~Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Practice will consist of warm up, followed by practice of selected pieces of the form.~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention)."
41329477|NCT05569564|PROCEDURE|Ridge splitting followed by ossedensificaion|Ridge splitting followed by ossedensificaion with osseodensifying burs.
41329478|NCT05569564|PROCEDURE|Osseodensification|Pilot drill is used to make the initial osteotomy to the desired depth, then osseodensifying burs will be used in sequence, gradually wider diameter in a counterclockwise rotation and bouncing motion under profuse saline irrigation
41329479|NCT04458363|BIOLOGICAL|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria), an ABO compatible product will be identified. The CP dose administered will be 10mL/kg/dose (up to 2 units per dose) times two doses per patient for a total dose of 20 mL/kg. Patients will be followed for adverse events and clinical response. Research blood testing will be obtained prior to infusion (baseline) and serially weekly afterwards until clinical resolution. Patients will receive 2 doses equaling 20 mL/kg (if available) of ABO compatible CP over 24-48 hours if they do not experience grade 3-5 adverse events that are possible, probably, or definitely attributed to CP after the first dose. Patients will be followed for adverse events for a minimum of 28 days after the last infusion of CP.
41329480|NCT04458363|DRUG|Standard COVID-19 therapies|If clinical status permits, administration of additional COVID-19 therapies should be delayed 48 hours or more from CP infusion completion. Supportive care will be administered by best clinical practice.
41329481|NCT04880265|DEVICE|BraveHeart wearable life sensors|Collection of EKG data
41329482|NCT06114004|DRUG|Selinexor 20 MG|After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor
41329483|NCT06114004|DRUG|Gemcitabine|Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.
41329484|NCT05713825|PROCEDURE|Endovascular embolization or surgery|"* Endovascular embolization may be done with coils, remodeling technique (coils and balloon), stent and coils, flow-diverter, endosaccular devices. The access is through the femoral or radial artery.~* Surgery is considered the standard neurosurgical procedure of aneurysm clipping."
41329485|NCT01253187|DRUG|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
41329486|NCT01253187|DRUG|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg / L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
41329487|NCT01253187|DRUG|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
41329488|NCT05592418|DRUG|Rintatolimod|100 to 400 mg twice weekly
41329489|NCT05592418|OTHER|Placebo / Normal Saline|40 to 160 mL twice weekly
41329490|NCT00003085|PROCEDURE|laparoscopy|
41329491|NCT00003085|PROCEDURE|ultrasound imaging|
41481530|NCT02599259|DEVICE|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
41481531|NCT00759239|DRUG|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
40811697|NCT01133756|DRUG|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
41329492|NCT00651612|DRUG|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution|Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
41329493|NCT00651612|DRUG|Concurrent brimonidine 0.2% and 0.5% timolol|Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
41481532|NCT00759239|DRUG|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
41481533|NCT03182582|DEVICE|Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
41481534|NCT03182582|PROCEDURE|Scalpel/Curette Debridement|Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
41481535|NCT00190242|DRUG|group1|Havrix at 1440IU was administrated à weeks S0, S4 and S24
41481536|NCT00190242|DRUG|group2|Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
41481537|NCT03852459|DRUG|S-Ibuprofen|Topical Gel 5%
41481538|NCT03852459|DRUG|Vehicle|Vehicle Gel
40811698|NCT01133756|DRUG|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
40811699|NCT01133756|DRUG|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
41329494|NCT02061579|BEHAVIORAL|Structured Group Exercise|The study intervention is a 6-month exercise program with structured group sessions conducted in a clinical setting. Group sessions include Aerobic Training and Combined Training. Once-Weekly participants will attend one Combined Training session while thrice-weekly participants will attend two Combined Training sessions and one Aerobic Training session per week. Participants in both groups will attend three exercise evaluations during the intervention period. Participants will also use provided logs to track their daily exercise activities outside of group sessions. Physical activity will be assessed by group session attendance, exercise resistance and intensity, and exercise frequency data collected from exercise logs, surveys, and evaluations.
41481539|NCT03021252|DEVICE|High intensity IEMT|Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
40811700|NCT05449340|DEVICE|BEAUTIFY application|Interview with the coordinating nurse in the postoperative period to install the BEAUTIFY application on the patient's smartphone and to train her to record any Patients will monitor their symptoms weekly. In case of toxicity grade \> 2, the nurse will contact the patient for further information.
40811701|NCT03429985|BEHAVIORAL|FRRM Intervention|Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
41329495|NCT02043236|BEHAVIORAL|Healthy bones pamphlet|written educational material
41329496|NCT02043236|BEHAVIORAL|Bone Health Care Coordinator|The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
41329497|NCT02043236|BEHAVIORAL|Letter to GP|The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
41329498|NCT04590560|DIAGNOSTIC_TEST|screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice|women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
41329499|NCT04376515|BEHAVIORAL|HOPE intervention|Online peer support community of peers trained in behavior change science
41329500|NCT03278652|OTHER|Consumption of drugs for analgesic use|"* Regular assessment of pain~* Drug data will be collected (name, dosage, route of administration, time of delivery)"
41481540|NCT03021252|DEVICE|Sham IEMT|5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.
41481541|NCT04254939|DRUG|CS3007 (BLU-285)|"A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days."
41481542|NCT00393471|DRUG|Etanercept|
41481543|NCT04117737|OTHER|Virtual reality combined with anti-gravity treadmill|"The system is composed of three major parts: the treadmill, the antigravity system and the virtual reality system.~The treadmill is the base of the device. It is a rounded and concave structure that permits to walk in all direction. For simulate anti-gravity, a harness and pulley system allow to regulate the weight. Finally, the virtual reality system enables participants to simulate an experience of daily life."
41329501|NCT03368599|PROCEDURE|Bronchoscope guided advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the bronchoscope-guided method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Pass the fiberoptic bronschoscope through a bronchial lumen of Lt. DLT.~3. Secure the pathway into the Lt. main bronchus by advancing the bronchoscope into the Lt. main bronchus.~4. Lt. DLT can be advanced through the guide of the bronchoscope into Lt. main bronchus.~5. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
41329502|NCT03368599|PROCEDURE|Conventional advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the conventional method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Rotate Lt. DLT 90 degrees to the left side.~3. Advance Lt. DLT blindly to main bronchus level.~4. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
41329503|NCT01125618|OTHER|Health and development intervention package|The timing and sequence of intervention vary by site, but include improved access to seed-fertilizer to increase agricultural production; improved market and capital access; proven maternal-newborn-child health interventions delivered free of cost at the point of service; improvements to school number and quality; and access to basic infrastructure including safe water, sanitation, electricity, transport and communication.
40811702|NCT02676947|DRUG|Tocilizumab|
41329504|NCT01125618|OTHER|Routine services|Routine services and programs currently being administered using prevailing resources, at the current pace and with established partnerships. There is no attempt to limit the introduction of new interventions or agencies into comparison sites.
41329505|NCT05212402|DIETARY_SUPPLEMENT|Cannabinol|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
41329506|NCT05212402|OTHER|Placebo|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
40822939|NCT06604936|OTHER|Fibromyalgia group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Functional status of the patients will be evaluated with the Fibromyalgia Impact Questionnaire. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
41155724|NCT04764864|PROCEDURE|Preperitoneal Pelvic Packing|"Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.~Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.~A second intervention is required to remove the material in 24-48 hours."
40811703|NCT05208606|BEHAVIORAL|Wawokiya Health Advocate|"Study visits 1 and 2 will follow the same broad procedures. Subsequent visits will be structured around needs. WHAs will cover multiple domains of assessment utilizing a visit guide.~Visit 1: Specific topics covered in this visit will include; 1) an explanation of palliative care, study, and WHA role and 2) mapping of providers/family/caregivers The WHA will arrange dates and times for future visits.~Visit 2: Occurs 1 week after the first visit. WHAs will begin to assess patient needs utilizing a needs assessment tool. Specific topics covered will include: 1) Documentation of disease history 2) Needs assessment screen~Following Visits: After visit 2, activities will be based on needs assessed. Activities may entail: 1) Review of palliative care and WHA role, 2) Assessment of needs, 3) Addressing needs 3) Exploring goals of care.~We anticipate patients will receive an average of 2-3 WHA visits per month. Investigators will hold regular supervisory meetings with the WHA."
40811704|NCT03526393|DEVICE|Survey training equipment|The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.
40811705|NCT03526393|DEVICE|Attack and serve training equipment|The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.
41329507|NCT05817955|DRUG|Azacitidine (AZA) with Ruxolitinib|"1. Antibiotics: Antibiotic treatment is positively given when symptoms related to infection, and other support treatment is strengthened.~2. Blood products: Infuse the blood products according to the patient's blood routine test. Drugs that need to be used by other diseases must be recorded in detail in the case report form, including the general name of the drug, the dosage of the medication, and the frequency of administration. Drugs are not allowed to be combined: Avoiding the use of granulocyte colony-stimulating factor (G-CSF), there may be risk of spleen rupture."
40811706|NCT03526393|DEVICE|Pass training equipment|The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
41329508|NCT02313922|DRUG|etanercept combined with methotrexate or etanercept combined with placebo|
41329509|NCT00364819|DRUG|rituximab|rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
41329510|NCT04776915|DIAGNOSTIC_TEST|Ultrasound and Hysterosalpingography|Ultrasound and Hysterosalpingography
41329511|NCT00340834|DRUG|Fingolimod 1.25 mg|"Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
41329512|NCT00340834|DRUG|Fingolimod 0.5 mg|"Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily."
41329513|NCT00340834|DRUG|Interferon β-1a 30 µg|"Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
41329514|NCT05666440|PROCEDURE|Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.|A superior limbal-based conjunctival flap and a paracentesis. A superficial rectangular scleral flap 4×4 mm was fashioned and dissected forward toward the limbus. A deep sceral flap (2×2 mm) was then created toward the limbus underneath the superficial flap exposing the scleral spur and deroofing SC. Viscoelastic (Healon GV, Pfizer, NY) was injected (using a standard 30 G viscocanalostomy cannula) into the ostia of SC Then, the 5/0 polypropylene suture tip was cauterized into a blunt tip (to ensure atraumatic probing of SC). The tip was inserted into the left ostium of SC using a microsurgical forceps and advanced through the whole circumference of the canal. When the tip presented to the right ostium the AC was filled with a viscoelastic through the paracentesis and traction was applied to approximate both ends of the 5/0 polypropylene suture, thus creating a visco-360-degree trabeculotomy.
41329515|NCT05666440|PROCEDURE|Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.|A fornixbased conjunctival incision followed by creation of a partial thickness (about 50% thickness) triangular (4×4×4 mm) scleral fap, followed by localization of Schlemm's canal by radial incisions straddling the limbus. High viscosity sodium hyaluronate (Healon GV, Pfzer) was then slowly injected into both ends of Schlemm's canal. Trabeculotomy was completed using the standard Harm's trabeculotome (Geuder Instruments), the scleral fap was then secured tightly with interrupted 10/0 Nylon sutures and conjunctival closure ensued.
41329516|NCT00611611|BIOLOGICAL|fluzone|once
41329517|NCT00611611|BIOLOGICAL|pneumovax|once
41329518|NCT01906957|OTHER|high intensity interval training (HIIT)|High-intensity interval exercise (HIIE) session This HIIE session will be based on a previous study conducted in our laboratory that compared physiological, psychological and electrocardiological tolerance of four different single bouts of HIIE in coronary patients (Guiraud et al. 2010). The selected HIIE session represented the best compromise between safety, time spent at a high level of VO2peak and psychological adherence. This HIIE session consists of a 10-min warm-up at 50% of MAP, followed by two sets of 10 min composed of repeated bouts of 15 s at 100% of MAP interspersed by 15 s of passive recovery. Four minutes of passive recovery were allowed between the two sets, as well as a 5-min cool-down after the last 15-s exercise bout. A total duration of 35 minutes will be employed for this session for coronary artery disease patients, and 22 minutes for chronic heart failure patients (Guiraut et al. 2010 b).
41011860|NCT03945500|DEVICE|Investigational Mobile Medical Software Application & IT Dashboard Application, FDA approved Bluetooth spirometer, FDA approved pulse oximeter|"Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet, an FDA approved Bluetooth spirometer, an FDA approved pulse oximeter. HIPAA compliant data will be sent to an Investigational IT dashboard maintained at the Central Monitoring Institute Server.~Volunteers will train in-center or remotely \& perform baseline testing with the SHS method along with a baseline laboratory-based spirometry test (if practicable).~Pre-Surveillance Phase: Daily home spirometry method testing for 4 to 10 weeks to enable normal range calibration.~Surveillance Phase: At least weekly home spirometry method testing for 2-10 months of participation. Volunteers will maintain a test log during study team directed SHS software pathway functionality testing."
41011861|NCT06240897|DEVICE|CURATE.Dtx|CURATE.Dtx is a self-guided digital multitasking game that involves a combination of four subtasks played simultaneously, targeting different cognitive domains.
41011862|NCT06240897|DEVICE|Optional games|The patient will first be asked how he/she feels and what they have done that day. The patient then selects a digital local pet (dog, cat, bird) and can customize its appearance, name and background location. The player can interact with their pet via several actions such as feed, bathe, train and accessorize. Playing with digital pets can help reduce stress and anxiety in the elderly. It can be a positive distraction in alleviating the elderly's worries and discomforts. In order to purchase accessories for their digital pet, they are encouraged to play short games that include Grocery Snap, Down Memory Lane and Pet Escape. These games are aimed at improving memory and reduce cognitive decline.
41011863|NCT02534610|DRUG|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
41329519|NCT01906957|OTHER|moderate intensity continuous exercise training|Moderate Intensity Continuous Exercise (MICE) session This exercise session will be based on the recommendations of the American Heart Association on exercise prescription in cardiac rehabilitation (Balady et al. 2007), suggesting that exercise intensity should lie between 50% and 80% of maximal aerobic power (MAP). We opted for an intensity of 70% of MAP. Duration will be adjusted to match total energy expenditure of the HIIE, according to the previous methodology method (Guiraud et al. 2010 b). A total duration of 28.7 minutes will be employed in healthy elderly patients, coronary artery disease patients and patients with metabolic syndrom; and 16 minutes in chronic heart failure patients.
41329520|NCT02382653|DRUG|oral perixicam|Oral adminstration of buccal perixicam
41329521|NCT04655053|BEHAVIORAL|Goal intention|Researcher instructs participants to adopt and learn the goal intention requesting them to write it three times and verbally repeat once.
41329522|NCT04655053|BEHAVIORAL|Implementation intention to initiate the behavior|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
41329523|NCT04655053|BEHAVIORAL|Implementation intention to manage the goal preference (avoiding behavior or not)|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
41329524|NCT05646888|BIOLOGICAL|Blood sampling|the blood sample will be taken during a planned blood sampling
41481544|NCT00586482|DRUG|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
41011864|NCT02534610|DRUG|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
41329525|NCT03705312|DEVICE|Transcatheter mitral valve repair|Transcatheter mitral valve repair performed using the MitraClip device
41329526|NCT03705312|OTHER|Guideline-directed medical therapy|Standard medical therapy for heart failure as recommended by HF guidelines
41481545|NCT00586482|DRUG|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
41481546|NCT00586482|BEHAVIORAL|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
41329527|NCT02285504|DRUG|SAGE-547|Intravenous injection
41481547|NCT05701644|DRUG|C1K 150mg|Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
41481548|NCT05701644|DRUG|C1K 300mg|Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
41481549|NCT05701644|DRUG|Placebo with the same volume of C1K 300mg|Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15
41481550|NCT05701644|DRUG|C1K 600mg|Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
41481551|NCT05701644|DRUG|Placebo with the same volume of C1K 600mg|Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15
41481552|NCT05701644|DRUG|C1K 900mg|Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
41481553|NCT05701644|DRUG|Placebo with the same volume of C1K 900mg|Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15
41481554|NCT05701644|DRUG|C1K 1200mg|Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
41481555|NCT05701644|DRUG|Placebo with the same volume of C1K 1200mg|Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15
41481556|NCT01827124|DRUG|Carbetocin|
41481557|NCT01827124|DRUG|oxytocin|
41481558|NCT06406439|DEVICE|Smart Insulin Pen|The subject allocated to the intervention or control group through randomization will visit hospital maximun 5 times during the 12-week application period, including the baseline visit, in the following process.
41481559|NCT00908921|DRUG|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
41481560|NCT04718194|BEHAVIORAL|ESTEEM iCBT|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
41481561|NCT04718194|BEHAVIORAL|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
41481562|NCT00485030|DEVICE|Cypher|sirolimus-eluting stent
41481563|NCT00485030|DEVICE|Xience-V|everolimus-eluting stent
41481564|NCT03580122|DRUG|Arginine Aspartate|Asparten
41481565|NCT05545761|OTHER|music therapy|Feedback will be received via WhatsApp that the participants have listened to the maqam conveyed to them.Before applying music therapy in the experimental group, they will be asked to fill out the questionnaires.At the end of the music therapy application, the questionnaires made at the beginning will be applied to the experimental group again.No application will be made to the control group, and data collection forms will be applied twice with an interval of 4 weeks.
41481566|NCT00027742|BIOLOGICAL|pegylated interferon alfa|
41481567|NCT00027742|DRUG|temozolomide|
41011865|NCT04409028|PROCEDURE|Coronal restoration|A restorative material like composite resin is condensed into the cavity of teeth.
41329528|NCT05550896|DIAGNOSTIC_TEST|Echocardiogaphy|Assessment of high velocity low amplitude signals on Doppler echocardiography
41481568|NCT04813315|OTHER|Kendall exercise|consist of stretch of pectoralis major and neck extensor strengthening of deep neck flexors and scapular retractor
41481569|NCT04813315|OTHER|Gong's mobilization|it is combination of glide along the facet joint and concurrent movement of cervical spine
41481570|NCT03841890|DEVICE|the Clarus Video System as a video stylet|video-guided intubation
41481571|NCT03841890|DEVICE|the Clarus Video System as a lightwand|The endotracheal tube will be initially guided into larynx in the dimly lit operating room by a bright glow moving in the anterior soft tissue of the neck and finally by the image of the trachea rings on the video screen.
41011866|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
41011867|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
41011868|NCT01529528|DRUG|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
41011869|NCT00000410|PROCEDURE|Diskectomy|The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
41329529|NCT00646113|DEVICE|OsseoSpeed™ TX 3.0S|OsseoSpeed™ TX 3.0 mm diameter
41329530|NCT01504971|OTHER|symptom questionaire|GerdQ questionaire
41329531|NCT01504971|PROCEDURE|pH monitoring|24-hour pH monitoring
41329532|NCT01504971|PROCEDURE|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
41481572|NCT03841890|DEVICE|direct laryngoscope|Macintosh laryngoscope size 3
41329533|NCT01504971|DRUG|rabeprazole|10mg, bid, p.o.
41329534|NCT03431909|DRUG|Human urinary kallidinogenase (HUK)|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
41329535|NCT03431909|DRUG|aspirin® , clopidogrel® , atorvastatin®|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
41329536|NCT03124901|DEVICE|DCI pulse oximeter sensor|
41329537|NCT03558971|DRUG|Cortisol|Participants determine when to administer 5-day regimens of cortisol
41329538|NCT01934933|DRUG|celebrex|
41329539|NCT01934933|DRUG|Enbrel|
41329540|NCT01934933|DRUG|Enbrel plus Celebrex|
41329541|NCT00587301|DEVICE|Lap-Band|Obesity and adolescents
41329542|NCT04104373|OTHER|Observational Cohort|
41329543|NCT05730101|OTHER|Cognitive-behavioral treatment (CBT)|In the first individual session (CBT1), together with the therapist, participants develop a behavioral and conditional model of their procrastination behavior. In the next 2 group sessions (CBT2 and CBT3), participants receive psychoeducation on procrastination. The focus is on learning the method of starting on time. In the third group session (CBT4), participants identify key procrastination-promoting thoughts and are supported to develop alternative thoughts; deepened in the second individual session (CBT5). In the next 2 group sessions (CBT 6 and CBT7), participants are informed about action planning with focus on learning to plan realistically. The last group session is a concluding session: Experiences with the methods learned and an outlook on further steps and goals are discussed. At the end of both individual sessions (CBT1 and CBT5), participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
40811707|NCT05793255|BEHAVIORAL|Social Phone Calls|Following the collection of baseline data, the study participant will be randomly assigned to a student volunteer to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6weeks. Each phone call is expected to last around 1 hour with flexibility to be shorter or longer. The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer. If the stroke survivor and student volunteer wish to speak more than the designated one call a week, that will be allowed if both parties agree. The same student volunteer will conduct all six sessions
40811708|NCT04291196|OTHER|VR-ECT 360o Video|Patients in the VR arm will be immersed in the ECT process in first person utilizing Google Cardboard headsets. Patients will experience in 360 entering the procedure room, IV insertion, pretreatment checks, anesthetic induction followed by induction of seizure, and recovery. The experience will also have voice-over narration simultaneously describing the procedure and its risks and benefits.
41329544|NCT05730101|OTHER|Imaginary pill treatment (IP)|In the first session (IP1), participants will be asked about the nature of their procrastination behavior and receive a procedure to take an imaginary pill following a rationale of 5 steps. In the second IP session (IP2), experiences with taking the IP are discussed and the procedure of taking the IP is adapted according to previous experiences and current needs. The rationale of the second session encompasses the same five steps with small modifications: 1) discussing IP sensitive problem and adapting it if necessary, 2) building trust/belief/reality of the IP, 3) discussing the personally meaningful IP and adapting it if necessary, 4) taking the IP, 5) adapting the procedure for self-administering the IP in real life on daily basis if necessary and building adherence. At the end of both sessions, participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
41329545|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.
41329546|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are heterozygous carriers of c.1236G\>A or c.2846A\>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.
41329547|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.
41329548|NCT02260895|DIETARY_SUPPLEMENT|Almond pre-test snack|unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
41329549|NCT03264833|OTHER|TempTraq|no intervention
41481573|NCT02442271|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
40811709|NCT04291196|OTHER|Standard Treatment|Patients will receive preparation for their ECT as per standard of care, i.e. a discussion with a Psychiatrist.
40811710|NCT05243745|OTHER|3% PVM/MA + 5% KNO3 Combination|Toothpaste containing 3% PVM/MA + 5% KNO3 as combination will be used as test product.
40811711|NCT05243745|OTHER|3% PVM/MA only|Toothpaste containing 3% PVM/MA only will be used as comparator 1 product.
40811712|NCT05243745|OTHER|5% KNO3 Only|Toothpastes containing 5% KNO3 only will be used as comparator 2 product.
40811713|NCT05243745|OTHER|Regular Fluoride|Toothpaste containing regular fluoride will be used as negative control.
40811714|NCT02910401|BIOLOGICAL|Rhinovirus (GMP RV16 HRV-16)|300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only
40811715|NCT05486325|DEVICE|Endolumik Gastric Calibration Tube (EGCT)|"Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.~The portions of the sleeve gastrectomy operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric sleeve~* To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.~The portions of the gastric bypass operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric pouch~* To calibrate closure of the gastrojejunal anastomosis~* To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia."
40811716|NCT02834117|OTHER|natural cycle|Ovulation is not induced by drugs
40811717|NCT02834117|DRUG|moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
40811718|NCT03249909|DEVICE|Exufiber Ag+|gelling fibre dressing with silver
40811719|NCT03249909|DEVICE|Exufiber|gelling fibre without silver
40811720|NCT03249909|DEVICE|Aquacel Ag Extra|gelling fibre with silver
40811721|NCT02321319|DRUG|Hydromorphone HCl ER Tablets|Hydromorphone hydrochloride (HCl) extended release tablet
40811722|NCT00241410|BIOLOGICAL|OralvacB2MPL|Comparison of different dosages of drug
41329550|NCT00830115|DRUG|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
41329551|NCT01206790|BEHAVIORAL|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
41329552|NCT00385034|DEVICE|Interactive computer based health-risk survey before doctor's visit|
41329553|NCT00222248|BEHAVIORAL|Pelvic floor muscle training and bladder training|
41329554|NCT00888615|DRUG|Elesclomol Sodium|Given IV
41329555|NCT00888615|DRUG|Paclitaxel|Given IV
41329556|NCT03409419|DRUG|[18F] CFA|pilot study to evaluate the bio-distribution of \[18F\] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.
41329557|NCT00247572|DRUG|NRP104|
41481574|NCT02442271|DRUG|ribavirin|Tablet
41011870|NCT00000410|PROCEDURE|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
41011871|NCT05862025|DIAGNOSTIC_TEST|Echocardiography evaluation|"Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset."
41011872|NCT05195320|BEHAVIORAL|Reinvention with MS|A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
41011873|NCT04296812|BEHAVIORAL|Self-Love Model|"The model is a visual illustration shaped as a triangle.~* The bottom left line is title Zero Self-Love, moving upward are characteristics identified from zero self-love along the line.~* The bottom right side is titled Self-Love moving upward are characteristics identified from having self-love.~* At the top of the triangle is a circle with the letter R within for relationship.~* Two small lines project horizontally, from the circle, left and right.~* At the end of the Left line is a circle with the word break-up in the middle, surrounded by terms: drugs, alcohol, self-harming, suicide, and sex as the consequence of zero self-love.~* At the end of right line is a circle with the word break-up in the middle surrounded by terms: support system, coping skills, spirituality reflection as the consequences of having self-love.~The strategies being discussed:~* Exploring self-esteem strategies.~* Importance of self-worth in relationships.~* Importance of self-awareness."
41011874|NCT05750641|OTHER|removing milk and dairy products from diets without medical treatment|A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment
41011875|NCT05750641|OTHER|According to current standard algorithms and guidelines, appropriate treatment for FD types.|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
41011876|NCT04272190|OTHER|clinical routine treatments|The cohort stratified by four factors: preoperative treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy); surgical approach (laparoscopic, abdominal, vaginal, robotic); hysterectomy types (type A, type B, type C1, type C2), primary treatment (Radical hysterectomy + pelvic lymph node dissectionp; radiochemotherapy)
41011877|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
41011878|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
41011879|NCT04983394|OTHER|Virtual Realty Exercises|motion-controlled video game
41011880|NCT04983394|OTHER|Aerobic exercises|cycling activity
41011881|NCT04983394|OTHER|conventional exercises|stretching, strengthening and endurance exercises
41011882|NCT04245488|OTHER|taste test|rate intensity of sour solutions and fatty acid solutions
41011883|NCT05207813|DEVICE|Intracept Procedure|Intraosseous Basivertebral Nerve (BVN) Ablation
41011884|NCT06050590|DEVICE|NeuroGlove|Study participant with PTSD will undergo daily at home treatment using the NeuroGlove.
41011885|NCT06061770|OTHER|Adapted physical activity program|Rehabilitation
41011886|NCT06061770|OTHER|Adapted physical activity self-program|Rehabilitation
41011887|NCT01823393|DRUG|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
40811723|NCT05128864|PROCEDURE|High Tibial Osteotomy|Surgery procedure - High Tibial Osteotomy
41011888|NCT01823393|DRUG|NaCl|valvuloplasty is performed without heparin (placebo injection)
41011889|NCT02616250|DRUG|Brimonidine 0.33% gel (Br)|
41011890|NCT02616250|OTHER|CD07805/47 (Br) placebo gel|
41329558|NCT05210972|RADIATION|Cardiac catheterization|All the study population will be exposed to diagnostic coronary angiography and invasive coronary intervention as per standard guidelines.
40811724|NCT03006458|DEVICE|comfilcon A|toric contact lens
40811725|NCT03006458|DEVICE|omafilcon B|toric contact lens
41011891|NCT02616250|DRUG|Ivermectin 1% cream (IVM)|
41011892|NCT02616250|OTHER|CD5024 (IVM) placebo cream|
41011893|NCT03145727|DEVICE|Placebo Group|In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
41011894|NCT03145727|DEVICE|Low Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
41011895|NCT03145727|DEVICE|High Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
41011896|NCT03777189|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
41011897|NCT00810121|DRUG|ketoprofen 100 mg|100 mg b.i.d. for 5 days
40811726|NCT05221632|DEVICE|Accelerated transcranial magnetic stimulation with real coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation.
40811727|NCT05221632|DEVICE|Transcranial magnetic stimulation with real coil|The stimulation mode of TMS is 1-Hz repetitive Transcranial magnetic stimulation .
40811728|NCT05221632|DEVICE|Transcranial magnetic stimulation with sham coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation, but without active stimulation.
41011898|NCT00810121|DRUG|ketoprofen|150 mg b.i.d. for 5 days
40811729|NCT02453152|OTHER|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
40811730|NCT02453152|OTHER|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
40811731|NCT02453152|OTHER|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
41011899|NCT05725174|OTHER|Sample Collection|Patients will have breath samples collected by blowing into a bag, and sweat samples collected by gauze. These samples will be collected at various timepoints whilst the patients are admitted on the ward.
41011900|NCT03377335|DRUG|Dapagliflozin 10mg|"The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
41011901|NCT03377335|DRUG|Metformin|"All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
41011902|NCT01024400|BIOLOGICAL|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
41011903|NCT00917813|DRUG|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
41011904|NCT00917813|DRUG|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
41011905|NCT00128258|PROCEDURE|Injection of bone marrow cells in the heart|Biological implant into the heart
41329559|NCT03351478|DRUG|Sotagliflozin|Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.
40811732|NCT02453152|OTHER|Peak cough flow|Subjects' strongest coughs will be measured.
40811733|NCT02453152|OTHER|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
40811734|NCT02453152|OTHER|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
40811735|NCT02453152|OTHER|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
40811736|NCT02774200|DRUG|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
41011906|NCT00128258|BIOLOGICAL|Biological bone marrow cell therapy|Biological implant into the heart
41329560|NCT03351478|DRUG|Empagliflozin|Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.
40811737|NCT03763240|DIETARY_SUPPLEMENT|BSE|"BSE powder will be provided as dry mixtures in sealed, non-transparent portion size bags. Each BSE bag contains 150 μmole, equal to 0.26 g, sulforaphane at a minimum. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning. BSE should be stored at room temperature in dry conditions.~The doses of sulforaphane contained in the BSE is not possible to get by eating fresh broccoli, thus it has to be given as an extract."
41011907|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|Arthroscopic reconstruction of damaged Medial Meniscus using Fast-Fix (Smith \& Nephew) implant.
41011908|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|Arthroscopic reconstruction of damaged Medial Meniscus using Fiber-Stitch (Arthrex) implant
41011909|NCT05291390|DRUG|Pyronaridine Tetraphosphate|Via oral capsules.
41011910|NCT05701800|BIOLOGICAL|mRNA-1468|Sterile liquid dispersion for injection
41011911|NCT05701800|BIOLOGICAL|Placebo|Sterile liquid for injection
41011912|NCT05701800|BIOLOGICAL|Shingrix|Sterile suspension for injection
41011913|NCT04300400|OTHER|Delphi questionnaire|Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.
41011914|NCT05691140|OTHER|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy targeting Intolerance of Uncertainty
41329561|NCT03351478|DRUG|Placebo|Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
41011915|NCT01675713|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
41011916|NCT02381392|DEVICE|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
41011917|NCT02358694|DIETARY_SUPPLEMENT|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
41011918|NCT02358694|OTHER|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
41011919|NCT05732285|BEHAVIORAL|CRT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
41011920|NCT05732285|BEHAVIORAL|CBT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
41011921|NCT05732285|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
41011922|NCT05732285|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15 minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
40811738|NCT03763240|DIETARY_SUPPLEMENT|Placebo|Placebo powder will be provided as dry mixtures in sealed, non-transparent portion size bags. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning.
41011923|NCT02621970|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
40811739|NCT02118181|DIETARY_SUPPLEMENT|HMB|
40811740|NCT00639041|DIETARY_SUPPLEMENT|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
40811741|NCT00639041|DIETARY_SUPPLEMENT|Placebo|dairy products without special oils
41011924|NCT02621970|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1
40811742|NCT03077438|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate|0.5 milliliter (mL), Intramuscular
41011925|NCT02621970|DRUG|Docetaxel|Docetaxel 60mg/m2, D1
41155725|NCT06645847|OTHER|Ketone ester|"* 37.5 mL tropical flavored KE beverage containing 12.5 g/day of ketone ester will be consumed for the first 7 days, with the first meal of the day.~* 75 mL tropical flavored KE beverage containing 25 g/day of ketone ester will be consumed for week 2 (for 1 week) also with the first meal of the day.~* 112.5 mL tropical flavored KE beverage containing 37.5g/day of ketone ester will be consumed from week 3 (for 1 week). 25g (75mL) with the first meal of the day and 12.5g (37.5mL) with the last meal of the day.~* 150 mL tropical flavored KE beverage containing 50g/day of ketone ester will be consumed from week 4 (for 17 week). 25g (75mL) with the first meal of the day and 25g (75mL) with the last meal of the day."
41329562|NCT03351478|DRUG|Placebo|Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
41329563|NCT03550742|OTHER|Fuco-N-Tetraose|Daily bolus of Fuco-N-Tetraose
41329564|NCT01753830|DEVICE|Durolane|4.5 mL
41329565|NCT01753830|DEVICE|PBS|4.5 mL
41329566|NCT00975026|PROCEDURE|Massages ± Stretches|Chair Massage
41329567|NCT05276765|PROCEDURE|cad/cam socket sealing abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
41329568|NCT05276765|PROCEDURE|standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
41329569|NCT06527508|OTHER|Non-Interventional|This study has a observational design
41329570|NCT00861380|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
41481575|NCT00648024|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fasting
41481576|NCT00648024|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fasting
40811743|NCT03077438|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, Intramuscular
40811744|NCT03625778|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.
41011926|NCT02621970|DRUG|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
41011927|NCT02621970|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
41329571|NCT00861380|BIOLOGICAL|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|"3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.~Control 3+1 and Control 2+1 groups, only for children \< 12 months of age at the time of first study vaccination."
41329572|NCT00861380|BIOLOGICAL|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children \>= 12 months of age at the time of first study vaccination.
41329573|NCT01146548|DRUG|FLUOXETINE|20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
41329574|NCT02998892|BEHAVIORAL|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
41329575|NCT02998892|BEHAVIORAL|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
41329576|NCT01250652|DRUG|Levocetirizine|20 mg levocetirizine for 5 days
41329577|NCT01250652|DRUG|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
41329578|NCT05724017|BEHAVIORAL|Street Games Intervention|The children to be included in the study will be grouped in groups of 10 according to their age groups. Groups of 10 people consist of six sessions in total, two days a week for three weeks. Applications will be made in the school garden. In the meetings, games that attract the attention of children will be discussed, suitable games will be played, origami, painting and story sharing will be made. In the study, the independent variable street games intervention will be applied.
41329579|NCT06178094|BEHAVIORAL|Video Training|The participants in the Training Group is to sent a total of eight episodes of the Diabetes Training Videos prepare by the researcher, twice a week, through smartphones after the first interview
41329580|NCT01960829|DRUG|Everolimus|
41011928|NCT04431232|DEVICE|Endoscopic Band Ligation|Band ligation of the gastric body for weight loss
41011929|NCT01322204|DRUG|Codeine|One single oral dose of 1 mg/kg of codeine
41011930|NCT05105269|OTHER|Treatment from a physiotherapist|Any treatment provided by a physiotherapist e.g. exercise, advice and massage
41011931|NCT05351008|OTHER|Cognitive Functional Therapy|A physicaltheapy approach combining cognitive techniques, func-tional movement training, functional integration and Lifestyle Changes.
41011932|NCT05351008|OTHER|Exercise program:|Core strengthening program
41011933|NCT03022149|DEVICE|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
41011934|NCT03022149|DEVICE|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
41011935|NCT05943444|PROCEDURE|Parks technique|compare different operational styles of low rectal cancer
41011936|NCT05943444|PROCEDURE|Bacon technique|Bacon technique
41011937|NCT00762489|OTHER|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
41011938|NCT06481488|DRUG|E2086|E2086 tablets.
41011939|NCT06481488|DRUG|Placebo|E2086 matched placebo tablets.
41011940|NCT06573502|COMBINATION_PRODUCT|Prp with prf or prp or prf|Combination
41011941|NCT00507039|PROCEDURE|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
41011942|NCT06087939|DEVICE|Mechanical ventilation|Mechanical ventilation (MV) is a life support technique that is routinely used in the intensive care units (ICUs) for patients with life-threatening conditions.
41011943|NCT05430516|OTHER|No intervention|No intervention
41329581|NCT01549457|OTHER|Cell phone text messages|Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
41329582|NCT04759313|BEHAVIORAL|Image Narrative|Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
41329583|NCT05103475|BEHAVIORAL|Rage Against the Pain (RAP)|The sets of body positions used in the RAP program will mirror those used in the Hatha Yoga classes, but the RAP program will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the body positions (rather, positions will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the savasana exercise typically used in yoga practice).
41329584|NCT05103475|BEHAVIORAL|Control|The control group will comprise a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
41011944|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
41011945|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
41011946|NCT03304379|DRUG|Fasinumab|Solution for injection in pre-filled syringe
41011947|NCT03304379|OTHER|Diclofenac|NSAID active comparator (capsule)
41011948|NCT03304379|OTHER|Celecoxib|NSAID active comparator (capsule)
41329585|NCT01545024|DRUG|Sitagliptin, 50 mg once per day per os|Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
41329586|NCT05879757|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
41329587|NCT00878891|DEVICE|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
41329588|NCT00089102|DRUG|gemcitabine hydrochloride|1,000 mg/m2/dose in 250 cc of NS IV over 30 minutes on Days 1 and 8 of each 21 day cycle
41011949|NCT03304379|DRUG|Matching placebo|Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
41011950|NCT04906434|DRUG|60mg ABSK-011capsule|Three 20mg capsules,QD for oral administration
41011951|NCT04906434|DRUG|120mg ABSK-011capsule|One 20mg capsule and one 100mg capsule,QD for oral administration
41011952|NCT04906434|DRUG|180mg ABSK-011capsule|One 100mg capsule and four 20mg capsules,QD for oral administration
41011953|NCT04906434|DRUG|240mg ABSK-011capsule|Two 100mg capsules and two 20mg capsules,QD for oral administration
41011954|NCT04906434|DRUG|320 mg ABSK-011capsule|Three 100mg capsule and one 20mg capsule,QD for oral administration
41011955|NCT04906434|DRUG|400mg ABSK-011capsule|Four 100mg capsules,QD for oral administration
41011956|NCT01464320|DRUG|ABT-614|Active
41011957|NCT01464320|DRUG|Placebo Comparator|Placebo
41011958|NCT01948375|DEVICE|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
41011959|NCT01948375|DEVICE|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
41011960|NCT04403022|DEVICE|Robotic Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in complex colorectal procedures such as low anterior resection procedure or right colectomy with or without total mesorectal excision
40811745|NCT03625778|DRUG|Placebo|Placebo will be administered subcutaneously daily according to the Placebo cohorts.
40811746|NCT01364454|OTHER|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
40811747|NCT02881931|BEHAVIORAL|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
40811748|NCT03621176|OTHER|Home-based exercise|A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
40811749|NCT03849053|OTHER|Mézières Therapy for Low back pain|Spinal muscular global stretching
40811750|NCT02387333|PROCEDURE|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|"After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin."
40811751|NCT02387333|PROCEDURE|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
40811752|NCT05683938|DEVICE|Intermittent self-catheterisation|GentleCath™ Air intermittent catheter
40811753|NCT04502264|DEVICE|Hand of Hope|A virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot.
40811754|NCT04502264|DRUG|Botulinum toxin type A injection|A safe agent representing the gold standard treatment for focal spasticity.
40811755|NCT04559893|BEHAVIORAL|Collaborative Care|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In our model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care.
40811756|NCT03305081|DEVICE|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
40811757|NCT00884962|DEVICE|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
41011961|NCT03798808|OTHER|Consumption of fruits, vegetables and dairy products|Family Nutriathlon was an eight-week, family-based nutrition program where children and their parents were encouraged to reach individual and team goals with respect to the quantity and variety of fruit, vegetable and dairy product consumption.
41011962|NCT01693601|DRUG|Panobinostat|PO TIW QOW or PO TIW QW
41011963|NCT01693601|DRUG|Ruxolitinib|PO BID x 28 days
41011964|NCT06572657|OTHER|cognitive stimulation|cognitive stimulation
41329589|NCT00089102|DRUG|irinotecan hydrochloride|100mg/m2/dose in 500 cc of D5W or NS IV over 90 minutes on days 1 and 8 of each 21 day cycle
41329590|NCT05831527|DRUG|ARMRA™ Bovine Colostrum|"Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks."
41011965|NCT06572657|OTHER|physical exercise|physical exercise
40811758|NCT06387927|OTHER|home exercise program|Patients in group B were taught the core stability exercise in the first visit they received Arabic printed booklet for exercise description repetitions with diagrams in addition to Arabic illustration videos, they received a weekly telephone call to ensure their compliance to the exercise \& motivation.
41011966|NCT01050595|DRUG|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance \<30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
41011967|NCT01050595|DRUG|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
41329591|NCT06326671|DRUG|Tiotropium Bromide Inhalation Powder|It's a generic product of Spiriva HandiHaler.
41011968|NCT02707614|PROCEDURE|Robotic vs open prostastectomy|robotic minimal invasive surgery
41011969|NCT01734226|DIETARY_SUPPLEMENT|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
41329592|NCT06326671|DRUG|Spiriva HandiHaler|Tiotropium Bromide Inhalation Powder RLD, which binds to M3 receptors, and blocks the action of acetylcholine to relieve spasm of bronchial smooth muscle.
41329593|NCT00006030|DRUG|tamoxifen citrate|
41329594|NCT00006030|PROCEDURE|conventional surgery|
41329595|NCT00006030|RADIATION|radiation therapy|
41329596|NCT00435357|DEVICE|mobile-bearing TKA|
41329597|NCT00435357|DEVICE|fixed- bearing TKA|
41329598|NCT02079519|DRUG|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
41329599|NCT01307553|DEVICE|Pericardium Covered Stent|Percutaneous implantation of pericardium covered stent
41329600|NCT03148964|BIOLOGICAL|blood sampling|Blood Sampling at J0, M1, M3, M6, M12, M24 and every 12 months until the end of the study
41329601|NCT05971888|BEHAVIORAL|Food system and demand generation|GAIN's program to increase dairy consumption among BoP children and workers will include components to increase demand, improve access, and support the enabling environment. In Amhara, the demand generation component will share messages through radio, community influencers, and community conversations led by health extension workers targeting rural BoP households with children 6 months up to 7 years. GAIN will train milk houses and cooperatives on dairy safety and quality assurance and better business practices and will assist with cold chain and milk dispensing technology to improve milk availability and access. In industries and large-scale farms, GAIN will use a demand generation strategy to inform workers about the importance of dairy products and other nutritious foods and to encourage them to purchase them at their workplaces. GAIN will work with local businesses to launch and maintain dairy dispensers and arrange provision of other nutritious foods at work sites.
41329602|NCT01059396|DRUG|propranolol|GPVH ≥ 10 mmHg - responders: propranolol.
41329603|NCT01059396|DRUG|carvedilol|GPVH ≥ 10 mmHg nonresponders: carvedilol.
41329604|NCT01059396|DRUG|placebo|placebo propranolol / carvedilol
41329605|NCT03506100|OTHER|Water Walking|Practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®.
41329606|NCT06386211|DRUG|MAGNE-B6 Oral Solution|Oral solution.
41329607|NCT06386211|DRUG|MAGNE-B6 New Formulation Tablet|New formulation tablet.
41329608|NCT03573440|OTHER|mindful education on eating|Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
41329609|NCT00347477|DRUG|HyperHAES vs. RA-solution/NaCl|
41329610|NCT00326157|DRUG|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
41329611|NCT02666040|DEVICE|ULTRAPRO® meshes|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
41329612|NCT02666040|DEVICE|"Prolene® meshes"|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
40811759|NCT06387927|OTHER|the core stability exercise|supervised conventional core stability exercise
40811760|NCT05240157|DRUG|Corticosteroid Derivatives|observational
40811761|NCT00146016|DRUG|Amantadine|
41011970|NCT01734226|DIETARY_SUPPLEMENT|Placebo|Placebo (3.94g/day)
41011971|NCT05845125|OTHER|Physiotherapy alone|Physiotherapy focusing on increasing the shoulder range of motion.
41329613|NCT02666040|PROCEDURE|Detecting the mode of admission to hospital|Ordinary admission or day surgery
41329614|NCT02666040|PROCEDURE|Duration of surgery|Time operating room
41329615|NCT02666040|PROCEDURE|Anesthesia volume and type used|Anesthesias used: infiltration, followed by spinal, general, epidural.
41329616|NCT00577915|OTHER|Radiology/MRI scan|MRI spectroscopy
41329617|NCT03982745|DEVICE|bonfils|bonfils intubation
41329618|NCT03663140|DIAGNOSTIC_TEST|gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection|GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
41329619|NCT05191732|COMBINATION_PRODUCT|Platelet-Rich Plasma; Bone marrow concentrate|Platelet-rich plasma (PRP) (Dosage form: APA-15) Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
41329620|NCT05038787|DRUG|LY3473329|Administered orally.
41329621|NCT05038787|DRUG|Placebo|Administered orally.
41329622|NCT00418899|BEHAVIORAL|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
41329623|NCT05924516|BEHAVIORAL|Adhera® Fatigue Digital Program|The Adhera® Fatigue Digital Program is delivered via a mobile application and includes personalized educational and interactive content. The program is designed to support the wellbeing of people living with type 2 diabetes, including self-management education and support. This also includes a focus on diabetes-related fatigue.
41329624|NCT05849896|DEVICE|Acquisition of HD sEMG signals using the WPM-SEMG device|The WPM-SEMG-V2 device will be placed over the muscle of the participant to be investigated. A reference electrode over a bone close to the muscle of investigation will be applied. A sensor combing an accelerometer, gyroscope and magnetometer integrated in the WPM-SEMG-V2 device will be also used for the acquisition of body movement measures. An additional component for trapezoidal force measurement will be used during the acquisition in static contractions to measure the force. The participant will be instructed by the investigator how to execute the static or the dynamic exercises. Visual feedback will help the subject to track the trajectory.
41329625|NCT00533611|DRUG|MK0524A, /Duration of Treatment : 4 Weeks|
41481577|NCT04029987|PROCEDURE|Bilateral Ultrasound-Guided Transmuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoa Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
41481578|NCT04029987|PROCEDURE|Bilateral Ultrasound-Guided intra smuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
41481579|NCT04029987|PROCEDURE|Control|Conventional analgesia
41481580|NCT05954182|BEHAVIORAL|Cognitive Intervention|This is a virtual, group cognitive intervention. 12 live, weekly sessions will occur during the first 3 months of the study. Groups will be made up of 5-10 participants and will be led by a neuropsychologist. These sessions will include education on the brain and cognitive function as it relates to epilepsy, as well as compensatory strategies for use in daily life. After the 12 sessions, participants will be asked to continue to practice what they learned for the next nine months until their participation ends.
41481581|NCT02712801|DRUG|Zidovudine|Dose will be adjusted according to the child's weight.
41481582|NCT02712801|DRUG|Nevirapine|Dose will be adjusted according to the child's weight.
41481583|NCT02712801|DRUG|Lamivudine|Dose will be adjusted according to the child's weight.
41481584|NCT02712801|DRUG|Lopinavir/ritonavir|Dose will be adjusted according to the child's weight.
41481585|NCT03666481|BEHAVIORAL|Motivational Physical Activity Intervention (MPAI)|"MPAI was carried out during 6 consecutive months. The sessions were directed by sport sciences professionals, who were trained in the application of motivational strategies based on self-determination theory.~The frequency of training, as well as the duration of the sessions, was increasing throughout the 6 months. The contents of the sessions could be directed in two ways: sessions with activities to develop cardiorespiratory fitness and muscular strength, and playful sessions to enhance psychosocial aspects. Nevertheless, motivational strategies were implemented in both types of sessions."
41481586|NCT05265819|DEVICE|X-BOX kinetic360|1) Exergaming The practice of exergaming was performed using the Xbox 360 Kinect console,The volunteers carried out 36 exergaming sessions, with progressive increase in the duration of the games according to their tolerance,and reached a maximum duration of 50 minutes per session, included the realization of the games and the rest between activities. The exergaming protocol was performed two to three times a week, for a total of 12 weeks.
41481587|NCT05265819|DIETARY_SUPPLEMENT|mediterranean diet|Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
41481588|NCT05265819|DRUG|thyroid hormone replacement therapy|thyroid hormone replacement therapy
41481589|NCT01147978|BEHAVIORAL|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
40822940|NCT06604936|OTHER|Healthy group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
41481590|NCT03046134|BIOLOGICAL|PCV13|Conjugated pneumococcal vaccine
41329626|NCT00533611|DRUG|Comparator : niacin /Duration of Treatment : 1 Weeks|
41481591|NCT06141161|DRUG|corticosteroids|inhailed or oral corticosteroids
41329627|NCT02693327|OTHER|Biological Sample|A one time sample will be collected.
41329628|NCT02693327|OTHER|Blood Sample|A one time blood sample will be collected.
41329629|NCT05109078|DRUG|[14C]- Rongliflozin|Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1
41329630|NCT06306326|DIAGNOSTIC_TEST|3dMD technology|By taking photos using 3dMD, we obtained preoperative, immediate postoperative, and long-term postoperative three-dimensional data of patients. The software automatically fused the data to obtain the volume difference of facial volume at different time points, and then divided it to obtain the objective data of facial volume improvement rate. To improve the reliability of the measurements, two researchers measured independently and took the average value.
41329631|NCT01917240|OTHER|Comprehensive Chromosome Screening|On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
41329632|NCT00653094|DEVICE|Halevy kit|the use of Halevy kit in Crohn patients with Fistulas
41011972|NCT05845125|DRUG|Glenohumeral injection of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine coupled with physiotherapy|"The patient will lie supine on the radiology table. Proper skin disinfection will be done with Soluprep x 3 and sterile draping will be applied. An anterior view of the shoulder will be obtained with the fluoroscopic C-arm. Location of the injection site will be obtained with a radio-opaque stylus. Proper local anesthesia will be performed using approximately 1cc of 0.5% Bupivacaine intradermal. A 22G 3.5 spinal needle will be placed in the glenohumeral joint under fluoroscopic guidance using the anterior approach. A small amount (1cc) of iodine-based contrast agent (Omnipaque) will be injected under live fluoroscopic imaging to confirm the intra-articular position of the needle in the glenohumeral joint. In the event of a known iodine contrast allergy, no contrast agent will be used. A combination of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine will be injected into the glenohumeral joint."
41011973|NCT04979728|OTHER|At Home Self-Collections|Directly observed at home self-collection of blood samples
41011974|NCT01511380|BEHAVIORAL|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
41011975|NCT01511380|BEHAVIORAL|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
41011976|NCT03951129|PROCEDURE|hemodialysis catheter insertion|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) scoring will be performed after informing all groups and after the procedure
41011977|NCT05854693|DEVICE|transCranial direct current stimulation|The intervention consisted of 20 daily 20-min sessions of bilateral prefrontal tDCS
41011978|NCT05854693|DEVICE|sham stimulation|The sham group consisted of 10 daily 20-min sessions of sham stimulation
41011979|NCT05784701|DRUG|TSCV (Full-strength)|TSCV (Full-strength)
41011980|NCT05784701|DRUG|TSCV (Half-strength)|TSCV (Half-strength)
41329633|NCT06297798|OTHER|Telerehabilitation|"The telerehabilitation program will be implemented using Whatsapp and Zoom applications for 40 minutes, 5 days a week. Posture and stabilization exercises will be performed, and the exercises will be performed for 10 weeks.~Posture and Stabilization Exercise Program:~1. Stretching of neck flexor, extensor, and lateral flexor muscles (30 seconds each)~2. Pectoral muscle stretching (30 seconds, 3 repetitions)~3. Isometric neck exercises (10 seconds, 10 repetitions)~4. Rhomboid strengthening exercise (bringing shoulder blades closer together against resistance using a TheraBand) (10 seconds, 10 repetitions)~5. Stretching of hamstring, lumbar lordosis and gastrocnemius muscles (sitting and standing) (30 seconds, 3 repetitions)~6. Pelvic posterior tilt exercise (10 seconds, 10 repetitions)~7. Bridge exercise (20 seconds, 10 repetitions)~8. Single-leg bridge exercise (Right-Left) (10 seconds, 10 repetitions)~9. Plank (starting with 60 seconds, increasing by 10 seconds each week)"
41329634|NCT00438464|DRUG|Finasteride|Given PO
41329635|NCT00438464|OTHER|Placebo|Given PO
41329636|NCT00438464|PROCEDURE|Prostatectomy|Undergo prostatectomy
41329637|NCT00438464|OTHER|Laboratory biomarker analysis|Correlative studies
41329638|NCT02194556|DRUG|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
40811762|NCT02479087|DRUG|Plasma-derived FVIII/VWF concentrate|"The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of \> 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma)."
40811763|NCT06288854|OTHER|weight gain each group|weight gain after 12 Weeks
40811764|NCT04845009|BEHAVIORAL|progressive muscle relaxation|progressive muscle relaxation
40811765|NCT04845009|BEHAVIORAL|Usual care|Usual care
40811766|NCT03932864|BIOLOGICAL|MGTA-145|MGTA-145 will be given in various doses intravenously
40811767|NCT03932864|BIOLOGICAL|plerixafor|240 µg/kg subcutaneously
40811768|NCT03932864|BIOLOGICAL|Placebo|Placebo will be given in various doses intravenously
40811769|NCT04524715|DEVICE|Non-invasive red LLLT treatment to chest of patient.|Expose patient to LLLT light while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
40811770|NCT04524715|DEVICE|Sham Device Treatment|Expose patient to sham device while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
40811771|NCT04353999|PROCEDURE|Socket sealing by diode laser photocoagulation|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed using 980 nm diode laser photocoagulation applied in a non-contact mode with a poer output of 1 watt in a continuous wave mode for 3-5 minutes
40811772|NCT04353999|PROCEDURE|socket sealing with dense polytetrafluroethylene membrane|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed by a non-resorbable dPTFE membrane that is stabilized by suturing to the soft tissue margins of the socket
40811773|NCT01223651|PROCEDURE|two step hyperinsulinaemic glucose clamp study.|Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
40811774|NCT01664611|PROCEDURE|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
40811775|NCT01664611|PROCEDURE|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
40811776|NCT00675623|DRUG|Dimebon|Dimebon, 5 mg orally three times daily for six months
41329639|NCT02194556|DRUG|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
41329640|NCT02929628|DEVICE|Beijing PINS Programming|Using the programming control the Stimulator to change the parameter
41329641|NCT06249009|DEVICE|Non invasive ventilation|CPAP and increasing flows of HFNC will be compared during a 30-minutes period each
41329642|NCT02185248|BEHAVIORAL|Wellness Action Plan|The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
41329643|NCT01285063|OTHER|Multidisciplinary intervention: physical activity, dietary instructions and behavioral treatment.|"3 months intervention. Nutritious plan: includes 6 meetings of the child and his or her parents with a dietician from the center.~Physical activity: physical trainings of 60 minutes each will be held twice a week.~behavioral treatment: all the participants will take part it a 45 minutes meeting of movement therapy once a week. The goal of such meeting is to strengthen nutritious and physical activity habits and to assimilate positive change in the participants' lifestyle."
41329644|NCT00259350|DRUG|Skin disinfection|
41329645|NCT00071851|BIOLOGICAL|VRC-HIVDNA009-00-VP|
41329646|NCT00002707|DRUG|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
41329647|NCT00002707|DRUG|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
40811777|NCT00675623|DRUG|Dimebon|Dimebon 20 mg orally three times daily for six months
40811778|NCT00675623|DRUG|Placebo|Placebo three times daily for six months
40811779|NCT00235235|PROCEDURE|Biopsy|core biopsy
40811780|NCT00235235|PROCEDURE|Serum Collection|serum collection
40811781|NCT00235235|PROCEDURE|Urine Collection|urine collection
40811782|NCT00235235|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
40811783|NCT00235235|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
40811784|NCT00235235|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
40811785|NCT00235235|DRUG|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
40811786|NCT00235235|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
40811787|NCT01402557|BEHAVIORAL|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
41329648|NCT00002707|DRUG|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
41011981|NCT05784701|DRUG|Typbar-TCV|Typbar-TCV
41329649|NCT00002707|DRUG|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
41329650|NCT04920539|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
40811788|NCT01402557|BEHAVIORAL|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
40811789|NCT01402557|BEHAVIORAL|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
40811790|NCT02882061|PROCEDURE|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
40811791|NCT00097227|BIOLOGICAL|Cetuximab|"(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B."
40811792|NCT00097227|DRUG|Carboplatin|(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
41329651|NCT04342429|RADIATION|Proton-beam Therapy for Small Cell Lung Cancer|The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
41329652|NCT05024617|OTHER|conservative treatment|All patients had rehabilitation for a total of three months, including activity modification, splinting and exercises.
41329653|NCT05142449|DRUG|Amoxilan|Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day
41329654|NCT05142449|OTHER|Placebo|Patients receive 8 capsules placebo perioperatively and for the next 3 days 6 capsules per day
41329655|NCT02193672|DRUG|[18F] Fluciclatide|\[18F\] Fluciclatide given by vein before PET/CT scan.
41329656|NCT02193672|PROCEDURE|PET/CT Scan|PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
41329657|NCT02193672|BEHAVIORAL|Phone Calls|Phone call to participants by study staff about 24 hours after each PET/CT is performed.
41329658|NCT00398307|DRUG|S-1/Cisplatin|"S-1 administration will be determined by degree of renal impairment as follows:~Group A (Control): 30 mg/m2 BID Group B (Mild renal dysfunction): 30 mg/m2 BID Group C (Moderate renal dysfunction): 20 mg/m2 BID Group D (Severe renal dysfunction): 20 mg/m2 QD~Pharmacokinetic Phase (Part 1):~On Days -2 and 14 of the Pharmacokinetic Phase, patients will receive a single dose of S-1 administered orally in the morning.~Treatment will be followed by 1 week of recovery (Days 15 through 21).~Extension Phase (Part 2):~S-1 will be administered orally for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
41329659|NCT02458677|DRUG|PRX003|
41329660|NCT02458677|OTHER|Placebo|
41329661|NCT00654212|PROCEDURE|endo-laparoscopic approach|endoluminal stenting followed by laparoscopic resection
41329662|NCT00654212|PROCEDURE|open approach|emergency open surgery
41329663|NCT01191632|RADIATION|one time radiation|"Radiation: one time Radiation with an intensity of~0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery"
41329664|NCT01191632|RADIATION|No Radiation|Control group with 0Gy
41329665|NCT01153841|BIOLOGICAL|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
41329666|NCT01153841|BIOLOGICAL|Infanrix hexa™|Intramuscular, 3 doses
41481592|NCT06436352|PROCEDURE|Capsulotomy and fixation|"Firstly, Guide wire insertion passing anterior to the GT and the neck is done. then passing a pointed Schanze 5 or 6 ± scalpel, under X-ray in AP-lateral views until reaching the capsule (intra trochanteric line). Aspiration of hematoma with suction was done.~Then we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex."
41481593|NCT06436352|PROCEDURE|Fixation only|"we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex."
41481594|NCT05752682|DIAGNOSTIC_TEST|Diagnostic pathway|Each included patient will undergo to the faint and fall protocol, to assess the effectiveness of a patients' flow pathways developed in accordance with the most recent guidelines on syncope of the European Society of cardiology and of guidelines on falls of the American and British Geriatrics Societies.
41481595|NCT04793035|DEVICE|Omega-Cuff|An omega-shaped nitinol device to be placed and secured on the Lower Esophageal Sphincter area
41481596|NCT05011630|OTHER|Pancreaticoduodenectomy|The incidece of IAA after pancreaticoduodectomy; to validate the risk factors of IAA
41481597|NCT04476628|DRUG|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
41481598|NCT04476628|DEVICE|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
41481599|NCT04476628|DEVICE|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
41481600|NCT05154058|PROCEDURE|Medial Subperiosteal Release with Sharp Dissection|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This is commonly performed both via scalpel (aka sharp medial peel) or electrocautery
41481601|NCT05154058|PROCEDURE|Medial Subperiosteal Release with Electrocautery|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This group will receive this procedure using electrocautery.
40811793|NCT00097227|DRUG|Paclitaxel|225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
41329667|NCT02680392|PROCEDURE|Pulsed and Continuous Radiofrequency|"Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.~The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.~The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution."
41481602|NCT01583517|PROCEDURE|Biliary sphincterotomy|Cutting of the biliary sphincter muscle.
40811794|NCT05081518|DRUG|Lu AG06466|Lu AG06466 - capsule
40811795|NCT05081518|DRUG|Placebo|Placebo - capsule
41011982|NCT05784701|DRUG|Placebo|Placebo
40811796|NCT00515606|DRUG|helium:oxygen|
40811797|NCT05895331|DIAGNOSTIC_TEST|Thiol/Disulphide Homeostasis|An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).
41155726|NCT06645847|OTHER|Placebo Comparator: Non-ketone placebo|"* 37.5 mL tropical flavored, non-ketogenic canola oil, beverage containing 12.5 g/day of canola oil will be consumed for the first 7 days, with the first meal of the day.~* 75 mL (25 g/day) of canola oil will be consumed at week 2 (for 1 week) also with the first meal of the day.~* 112.5 mL (37.5g/day) of canola oil will be consumed from week 3 (for 1 week). 25g (75mL) with the first meal of the day and 12.5g (37.5mL) with the last meal of the day.~* 150 mL (50g/day) of canola oil will be consumed from week 4 (for 17 week). 25g (75mL) with the first meal of the day and 25g (75mL) with the last meal of the day."
41481603|NCT01583517|PROCEDURE|Pancreatobiliary sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
41481604|NCT01583517|PROCEDURE|Sham|No sphincterotomy is performed in patients randomized to sham with normal SOM.
41481605|NCT05195749|DRUG|101-PGC-005 ('005) + SOC|Three consecutive days of '005 administration
41481606|NCT05195749|DRUG|Placebo + SOC|Three consecutive days of placebo administration
41481607|NCT00136318|DRUG|Escitalopram|
41481608|NCT00136318|DRUG|Placebo|
41481609|NCT00136318|DRUG|Peginterferon alfa-2a|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
40811798|NCT06054152|DRUG|PD-1 inhibitor based immunotherapy|Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.
41011983|NCT04210154|DEVICE|Haemodiafiltration|pre-dilution and post-dilution Haemodiafiltration
41011984|NCT01352520|DRUG|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
41155727|NCT06554288|DRUG|Trihexyphenidyl|6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose
41155728|NCT04264416|DEVICE|WB-EMS|16 weeks of WB-EMS
41011985|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One Fast Release Tablet containing 1000 mg acetylsalicylic acid
41481610|NCT00136318|DRUG|Ribavirin|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
41481611|NCT04746599|PROCEDURE|Autologous Fat Grafting|The trochanteric area or the periumbilical abdominal region represents the donor sites. Following Coleman's technique and after the administration of modified Klein solution, a skin incision is performed in the selected area. Adipose tissue is harvested and after suture the area is managed with an elastic-compressive dressing, to be kept in place for 5 days to prevent hematoma formation. The adipose tissue is the centrifuged at 920 × g for 3 min in sterile conditions. Only the intermediate layer containing adipocytes and stromal vascular component will be then injected using a blunt cannula. The terminal branches of the patient's leg arteries are mapped to facilitate graft placement. Under local anesthesia multiple injections of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries.
41481612|NCT06062797|DEVICE|Mixed Reality Viewer|The Mixed Reality Viewer from Brainlab (Germany) enables the visualization of the fracture via a 3D hologram. In contrast to virtual reality, where the user is in a completely virtual world, the user of the mixed reality viewer sees the 3D hologram implemented in his real environment.
41481613|NCT06062797|DEVICE|X-ray or CT scan|X-ray or CT scan enables the visualization of the fracture in 2D.
41481614|NCT06277141|BEHAVIORAL|Standard message|Participants will receive standard messaging based on the Cancer Association of South Africa (CANSA) recommendation on breast cancer screening and a reminder to screen for breast cancer.
41481615|NCT06277141|BEHAVIORAL|Radiology booking site link.|Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site.
40811799|NCT02637414|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
40811800|NCT04840485|DRUG|SHR-1314|SHR-1314 high dose
41329668|NCT02680392|DRUG|Continuous Adductor Canal Block|"The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.~To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution. It will be always possible to crack the code and find out to which group the patient belongs"
41155729|NCT00003611|DRUG|acitretin|
41329669|NCT04813978|OTHER|Music|For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
41329670|NCT00429390|BEHAVIORAL|Ramadan Fasting|
41329671|NCT05037669|BIOLOGICAL|PACE CART19|PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.
41329672|NCT05401591|DIETARY_SUPPLEMENT|Protein shake|Participant will drink a protein shake made using each of the four protein types.
41329673|NCT00271934|BIOLOGICAL|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
41329674|NCT00200512|DRUG|apomorphine HCl injection|
41329675|NCT01924156|BIOLOGICAL|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
41329676|NCT01892644|DRUG|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
41329677|NCT01892644|OTHER|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
41329678|NCT01892644|DRUG|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
41329679|NCT05351463|PROCEDURE|papila suture technique|simple interupted vs internal horoizontal matress suture
41329680|NCT01705587|DRUG|teriparatide|20 microgram once-daily subcutaneous injection
41481616|NCT06277141|BEHAVIORAL|Radiology practice telephone numbers|Participants will receive a reminder to screen for breast cancer together with a list and telephone numbers of radiology practices
41481617|NCT06277141|BEHAVIORAL|Radiology site link and telephone numbers|Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site and a list and telephone numbers of radiology practices
41481618|NCT05613517|OTHER|Eye examination|"* orthoptic assessment (visual acuity, refraction, stereopsis test, Cover-test, evaluation of the disparity of fixation and ocular dominance, measurement of the inter-pupillary distance~* ocular biometry~* corneal topography~* monocular photographs in photopic condition"
40811801|NCT04840485|DRUG|SHR-1314|SHR-1314 low-dose
40811802|NCT04840485|DRUG|Placebo|Placebo
40811803|NCT04207411|DRUG|Bupivacaine|Injection of anesthetics blocks once a week during 4 weeks.
40811804|NCT04207411|DRUG|Lidocaine|Injection of anesthetics blocks once a week during 4 weeks.
40811805|NCT06361394|OTHER|mindfulness course|"The experimental group will enroll in the elective course named Mindfulness and Happiness, which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course."
40811806|NCT01910324|BEHAVIORAL|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
41155730|NCT00003611|OTHER|placebo|
41329681|NCT03966495|OTHER|Sustainability of a research program in risk management|"No intervention will be implemented in the present study.~The investigators will evaluate of the sustainability of a research program in risk management in pluriprofessional primary care offices:~* Qualitatively assessed safety culture and Sustainability of the PRisM RM program in the offices by interviews of professional belonging to the offices.~* Quantitatively assessed safety climate in the offices measured by the Medical Office Survey on Patient Safety Culture (MOSPS) Questionnaire (fill in by the professionals of the offices)"
41329682|NCT00418730|DRUG|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
41329683|NCT02232594|DRUG|Berodual®|
41329684|NCT05969912|OTHER|Graston Technique (Instrumented assisted soft tissue mobilization)|"They would received Graston technique (Instrumented assisted soft tissue mobilization) as follow:~Using lubricant (Vaseline) on the skin then a stainless steel instrument to relax the fascia and muscles. Frequency: 60 reps per min for 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Graston technique (Instrument assisted soft tissue mobilization)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
40811807|NCT01910324|BEHAVIORAL|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
41329685|NCT05969912|OTHER|Bowen's Technique(Soft tissue technique)|"They would received Bowen's technique (Soft tissue technique) as follow:~Bowen moves (15 - 20 times) with 2 mins gap between each set. Frequency: 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Bowen's technique (Soft tissue technique)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
41329686|NCT05931133|OTHER|NO INTERVENTION|NO INTERVENTION WILL BE GIVEN
40811808|NCT00634725|DRUG|capecitabine|
40811809|NCT00634725|DRUG|erlotinib hydrochloride|
40811810|NCT00634725|DRUG|gemcitabine hydrochloride|
40811811|NCT00634725|OTHER|laboratory biomarker analysis|
41329687|NCT02919735|DRUG|CG 428 cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
41329688|NCT02919735|DRUG|Placebo cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
41329689|NCT03583788|BEHAVIORAL|Hypnotherapy|The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.
41329690|NCT03583788|OTHER|Motivational Interviewing|The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
41481619|NCT00749502|DRUG|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
41481620|NCT00085774|DRUG|albuterol aerosol by HFA MDI|albuterol HFA MDI 160 mcg
41481621|NCT00085774|DRUG|albuterol aerosol by HFA BOI|albuterol HFA BOI 160 mcg
41481622|NCT00085774|DRUG|placebo aerosol by HFA|placebo HFA
41481623|NCT00000824|DRUG|Lymphocytes, Activated|
41481624|NCT04317599|OTHER|Non Interventional study|Non Interventional study
40811812|NCT00634725|RADIATION|radiation therapy|
40811813|NCT01208961|DRUG|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
40822941|NCT06603064|DEVICE|Active continuous theta burst stimulation|This intervention involves an active form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
40811814|NCT01208961|DRUG|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
41329691|NCT03614819|PROCEDURE|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
41481625|NCT04934150|DEVICE|navigated repetitive Transcranial Stimulation|High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.
41481626|NCT01888575|DRUG|Risk of low dose aspirin discontinuation|PPI continuous use; No PPI usePPI
41481627|NCT03338179|BEHAVIORAL|Judgement of learning evaluation|The hardware consists of two lists of 30 pairs of French words, each pair of words being composed of a word index and a target word (names of concrete objects). Among the 60 word pairs, 30 are strongly associated items (or easy items, the other 30 being weakly associated or difficult items.
41481628|NCT03603938|DRUG|potassium losartan|treated with bedtime or awakening doses of potassium losartan
41481629|NCT02314572|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
41481630|NCT04597398|DEVICE|Evaluation of blood flow with indocyanine green|
41481631|NCT04669717|DRUG|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
41481632|NCT04669717|DRUG|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
41481633|NCT04669717|DRUG|1/d 500 mg Azithromycine Pfizer for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
41481634|NCT02247219|BEHAVIORAL|Counselling and education individually and in groups|The counselling method is based om Motivational Interviewing
41481635|NCT06482671|DRUG|Rikkunshi-to|Kampo medicine (Herbal). ikkunshito is composed of the following eight herbal medicines: extracts of Atractylodes lancea Rhizome, Ginseng, Pinellia tuber, Poria sclerotium, Jujube, Citrus unshiu Peel, Glycyrrhiza, and Ginger. Among these, the extracts of the Atractylodes lancea Rhizome, Ginseng, Poria sclerotium, Pinellia tuber, Citrus unshiu Peel, and Glycyrrhiza
41481636|NCT06482671|OTHER|Placebo|inactive drug, The matching placebo contains Corn Starch (vehicle), Lactose Hydrate (vehicle), Dextrin (vehicle), Magnesium Stearate (lubricant), FD\&C Blue No.1 Aluminum Lake (coloring agent), FD\&C Yellow No.5 Aluminum Lake (coloring agent), and Red Ferric Oxide (coloring agent).
41481637|NCT03639974|OTHER|PEP in a blow-bottle device|A 500-milliliter enteral nutrition vial will be used, which will contain a hole in the side, where two silicone tubes of 20 centimeters long will be inserted together with tape on the bottleneck of the vial. To perform the exercise, the vial will be filled with water leaving a water column of 10 cm high. Deep inspirations will be requested at a volume greater than the tidal volume and less than the total lung capacity that can be performed via nasal or oral, then with the mouth connected to the extensors, the patient will exhale slowly, avoiding to totally empty the lungs. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA.
41481638|NCT03639974|OTHER|EPAP|The Vital Signs ® EPAP kit will be used. Exercises will be performed in the bed, and as soon as the patient is released by the medical team to leave the bed, they can be performed in the sitting position or in orthostasis. For performing the exercise, the EPAP mask will be connected to the face of the patient. The expiratory pressure will be adjusted to 10cmH2O. Deep inspirations will be requested at a volume greater than the tidal volume and below the total lung capacity, then the patient will exhale slowly. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA, as described in the conventional physiotherapy group.
40811815|NCT02258750|DIETARY_SUPPLEMENT|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
40811816|NCT02258750|OTHER|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
40811817|NCT03269916|OTHER|Anti Mueller hormone|used to assess ovarian reserve parameters
40811818|NCT03269916|OTHER|Estrogen|used to assess ovarian reserve parameters
40811819|NCT03269916|OTHER|Follicle-Stimulating Hormone|used to assess ovarian reserve parameters
41155731|NCT03586752|OTHER|On-line program|18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
40811820|NCT03269916|OTHER|Antral alveolar cell count|used to assess ovarian reserve parameters
40811821|NCT00005643|DRUG|pegylated liposomal doxorubicin hydrochloride|
40811822|NCT04334135|DIETARY_SUPPLEMENT|MitoQ|Four to eight 20mg capsules (depending on body mass)
40811823|NCT03788642|PROCEDURE|Control LED shoe arm|Patients with DFU will wear LED shoe 30 minutes once daily
41011986|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
41329692|NCT03614819|PROCEDURE|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
41329693|NCT05851794|PROCEDURE|endomanometric guided LNF|use of endomanometry during LNF
41329694|NCT05851794|PROCEDURE|laparoscopic Nissen fundoplication alone|laparoscopic Nissen fundoplication alone
41329695|NCT01887756|DEVICE|Tele Rehabilitation|
41329696|NCT04501835|OTHER|Diagnostic and treatment evaluation|No intervention, description of the diagnostic evaluation and the treatment
41329697|NCT04309838|COMBINATION_PRODUCT|Treprostinil via implanted pump|Patients, diagnosed with PAH classified in stagnating intermediate-risk status after triple therapy including Selexipag for at least three months will receive the implantation of LENUS pro that enables permanent infusion of Treprostinil.
41329698|NCT02645591|PROCEDURE|Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
41481639|NCT03639974|OTHER|conventional physiotherapy|Conventional physical therapy consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resisted lower limb exercises; stretching, cough and walking guidelines. Initially the exercises will be performed in the bed, as soon as this is withdrawn and the patient is released by the medical team to leave the bed, the progression of the exercises to be performed in the sitting position, orthostasis, and ambulation is performed, this usually occurs on the 2nd postoperative day, after the removal of the mediastinal drain . Under supervision of the physiotherapist, the protocol will be performed twice daily, two sets of ten repetitions.
41329699|NCT02645591|BIOLOGICAL|AmnioFix®|Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
41481640|NCT01370213|DRUG|Preparative Regimen|"Preparative Regimen:~1) fludarabine 40 mg/m\^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,"
41481641|NCT01370213|BIOLOGICAL|NK Cells|CD3\^- CD19\^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
41481642|NCT01370213|DRUG|Interleukin-2|Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion
41481643|NCT01370213|BIOLOGICAL|CD34 Graft/Anti-thymocyte globulin|Single donor filgrastim mobilized CD34+ selected peripheral blood stem cell graft (minimum cell dose of 5 x 10\^6/kg) on day 0. Rabbit anti-thymocyte globulin (ATG) will be administered on day -1 (0.5 mg/kg) and day +1 and +2 (2.5 mg/kg) pretransplant per institutional guidelines. ATG dosing not identical for all patients.
40811824|NCT03788642|PROCEDURE|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes once daily
40811825|NCT00189332|DRUG|852A|
40811826|NCT05849194|DIAGNOSTIC_TEST|POCUS examination|Point of care ultrasound examination
40811827|NCT01386489|BIOLOGICAL|VRC-HIVDNA016-00-VP|
40811828|NCT01386489|BIOLOGICAL|VRC-HIVADV014-00-VP|
40811829|NCT02335047|OTHER|Impaired passivity test|Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
41011987|NCT03560713|DEVICE|Functional Electrical Stimulation (FES)|Participants will perform 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant). during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
41011988|NCT03560713|OTHER|Functional Electrical Stimulation (FES) sham|Participants will perform 12 weeks of Functional Electrical Stimulation (FES) sham (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
41329700|NCT02645591|BEHAVIORAL|Questionnaire|Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
41329701|NCT03385694|DIAGNOSTIC_TEST|Assessment|Pelvic coronal X-ray, proprioceptive test with Delos system, questionnaires administration, orthopaedic, physiatric and prosthetic assessment
41481644|NCT01370213|BIOLOGICAL|Donor TCR α/β-depleted Graft/ATG|Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10\^6/kg) on day 0. ATG will be administered on days -6 and -5 (3mg/kg) for most patients.
41481645|NCT00750022|BEHAVIORAL|Individualized IC treatment|Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
40811830|NCT01380197|DRUG|Morphine|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
40811831|NCT01380197|DRUG|Nubain|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
41011989|NCT00938431|DRUG|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
41011990|NCT05379959|DRUG|MDMA|Participants will be given 125 mg of MDMA.
41329702|NCT06124885|DIAGNOSTIC_TEST|AKI risk screening using RenaFAST POCT test kits|"Based on the type and duration of drug therapy, a maximum of 5 time-point urine samples will be collected and real-time biomarker measurement will be done using the RenaFAST POCT kits. Additionally, Trefoil factor 3 (TFF3) biomarker levels will also be quantified using developed POCT kits.~Patients with all 3 biomarker (Clusterin, MCP1 and ß2MG) levels higher than the study cut-off will be identified as high-risk for AKI. The nephrology consultants within the research team will perform a medical chart and physical review (where required) of these patients, detailing potential actions to be taken in research data collection forms. No actual intervention (other than a patient review) will be performed."
41329703|NCT00561587|DRUG|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
41329704|NCT05599113|DEVICE|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and non-invasive muscle pain treatments
41329705|NCT01062009|DRUG|Zinc sulfate|Zinc sulfate 200 mcg/ml in Normal Saline
41329706|NCT06314997|DRUG|panitumumab (EGFR inhibitors)|Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression
41329707|NCT03962946|OTHER|Questionnaires to assess Patient reported Outcomes|Adolfsson-Score questionnaire quantifies the patient's utility of the hand. Suhm Score questionnaire quantifies the independency of a patient in his daily life.
41329708|NCT03962946|OTHER|wrist function test|wrist function assessed by the range of motion (ROM) for both the affected and the unaffected side.
41329709|NCT00305604|DRUG|sitagliptin phosphate|Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
41329710|NCT00305604|DRUG|Comparator: Placebo|sitagliptin matching placebo for up to a 24-wk treatment period.
41329711|NCT02088541|DRUG|Selinexor|Selinexor oral tablet.
41329712|NCT02088541|DRUG|Hydroxyurea|
41329713|NCT02088541|DRUG|Ara-C|Ara-C Subcutaneous Injection.
41329714|NCT05089448|DRUG|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 6:00-10:00.
41329715|NCT05089448|DRUG|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 20:00-24:00.
41329716|NCT02839824|PROCEDURE|Bowel preparation|Bowel preparation for bowel cleansing in a real clinical practice
41011991|NCT05379959|DRUG|Methamphetamine|Participants will be given 20 mg of MA.
41011992|NCT05379959|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
41011993|NCT06008925|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
41329717|NCT03267771|DRUG|Progesterone Suppositories Vaginal|progesterone vaginal suppository
41329718|NCT03267771|DRUG|Dydrogesterone Oral Tablet|oral progesterone drug
41329719|NCT03267771|DEVICE|doppler ultrasound|pulsed doppler ultrasound
41329720|NCT04492787|DRUG|Changkang Granule|Take Changkang granule before meals twice a day , one bag for each time
41329721|NCT04492787|DRUG|Changkang Placebo Granule|Take Changkang Placebo granule before meals twice a day , one bag for each time
41329722|NCT02657187|DEVICE|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
41329723|NCT02657187|DRUG|Rocuronium|The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
41329724|NCT04989088|DEVICE|ProComp5 Infiniti System w/BioGraph Infiniti Software|Left theta/beta NF training in combination with right beta/theta NF training in temporo-parietal regions, for 40 minutes (with a 20-minute break period)
41011994|NCT06008925|DRUG|Nivolumab Injection|Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.
41011995|NCT03427918|BEHAVIORAL|Mindfulness-Based Sex Therapy|Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.
41011996|NCT02117063|BEHAVIORAL|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
41011997|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
41011998|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel QD
41011999|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
41012000|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
41012001|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel BID
41329725|NCT04989088|DEVICE|ProComp5 Infiniti System w/recorded videos|Sham NF training using pre-recorded videos, for 40 minutes (with a 20-minute break period)
41329726|NCT06530238|PROCEDURE|Russian Currents|Currents are delivered in rectangular bursts. The electrode placement will be at the Tibialis Posterior muscle. Treatment will be given for 10 minutes, 30 minutes during the 3 consecutive days / 4 weeks.
41481646|NCT00750022|BEHAVIORAL|Usual Care|Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
41481647|NCT06133803|DRUG|Lovenox|A low-molecular-weight heparin, 40mg daily injection.
41329727|NCT06420999|OTHER|Diaphragmatic ultrasound and data collection|At the inclusion visit, anamnestic data available in the medical record and clinical data (vitals, chest X-ray) will be collected. At the same time, a diaphragmatic ultrasound will be performed in the half-seated position to measure diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm at rest. A follow-up visit will be made on the day of discharge from intensive care, during which diaphragmatic ultrasound will be performed At D90 (+/- 15 days), the following information will be collected by consulting the electronic medical record, or by telephone if the information is not available in the record: date of discharge from hospital, date of death, date and reason for readmission to hospital or intensive care, possible introduction of long-term non-invasive ventilation, new respiratory complication after discharge from intensive care (pneumonia, atelectasis).
41329728|NCT03465176|OTHER|Aromatherapy Blend|The essential oil intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
41329729|NCT03465176|OTHER|Placebo|The placebo substance is an odorless vegetable oil derived from avocados.
41329730|NCT04018703|DRUG|Dexmedetomidine|loading dose 0.5-2.5ug/kg followed by continuous infusion 0.2-0.5ug/kg/h
41329731|NCT04018703|DRUG|Midazolam|loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
41329732|NCT04950205|DRUG|Sevoflurane inhalant product|propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
41329733|NCT04969211|DRUG|VHX-896 and iloperidone|oral tablet
41329734|NCT04969211|DRUG|Iloperidone and VHX-896|oral tablet
41329735|NCT02899806|OTHER|Written Information|A written information on peridural anesthesia is delivered
40811832|NCT03091517|BEHAVIORAL|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
41329736|NCT02899806|OTHER|Video Information|A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
41329737|NCT01946412|DRUG|Ivacaftor|
41481648|NCT06133803|DRUG|Aspirin|Aspirin 81mg daily tablet.
41481649|NCT06133803|PROCEDURE|Embryo transfer|Embryo transfer
41481650|NCT04544020|DIETARY_SUPPLEMENT|NG feeding|NG feeding
41481651|NCT04614493|DEVICE|SonoCloud-9 (SC9) device|"daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months) with 6 concomitant Blood Brain Barrier opening sessions by ultrasound~+ 9 Blood Brain Barrier opening sessions by ultrasound without any associated drug"
41481652|NCT04614493|DRUG|Temozolomide according Stupp protocol|daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months)
41481653|NCT04785508|DEVICE|neuromuscolar tape|neuromuscalar tape application in decompression technique (hand and arm)
41481654|NCT04785508|BEHAVIORAL|antigravity arm position|antigravity arm position
41481655|NCT04375930|OTHER|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION: It is consist of skills, discharge, compilation and algorithm education.
40811833|NCT00620256|DRUG|AL-37807 ophthalmic suspension, 0.1%|
40811834|NCT00620256|DRUG|Timolol gel forming solution, 0.5%|
40811835|NCT00620256|OTHER|AL-37807 ophthalmic solution vehicle|
40811836|NCT00620256|DRUG|Latanoprost ophthalmic solution|
41329738|NCT02671955|DRUG|JNJ-61610588|Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
41481656|NCT04375930|OTHER|Control|It consists of only skills and discharge education
41481657|NCT06426173|OTHER|Resistance Training Program|The resistance training program will be individualized and divided into four stages of increasing complexity. It will be conducted for approximately 40 minutes per day, three times a week, for 12 weeks, under supervision. Each patient will begin the program at the stage corresponding to their functional capacity. The resistance load will be set at 50% of the maximum resistance (1RM) obtained in the initial assessment. Throughout all stages of the exercise program, the target intensity will range from light (≤ 12) to moderate (≤ 15) on the Borg scale.
41481658|NCT06426173|OTHER|Standard Treatment Group|Patients will receive the standard treatment provided by the hospital inpatient unit, which includes guidance on reducing sedentary time, encouragement to walk, and performance of active and breathing exercises when necessary.
41481659|NCT03785535|DEVICE|Vibrotactile stimulation|The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.
40811837|NCT01530178|DRUG|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
41329739|NCT04493593|BEHAVIORAL|SilverCloud|"'Space for Sleep' is a seven-module online CBT-based intervention for sleep. The structure and content of the programme modules follow evidence-based CBT principles for insomnia. Each module is structured to incorporate introductory quizzes. videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.~As per normal service provision, each participant will be assigned a clinician (PWP) who will monitor participants' progress through the program. Every one to two weeks, the PWP will login and review participants' progress, leaving feedback for them and responding to the work they have completed."
41329740|NCT05820009|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with the GORE® VIABIL® Biliary Endoprosthesis.
41481660|NCT04925713|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or lymph nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
40811838|NCT01530178|DRUG|Placebo Oral Tablet|
40811839|NCT05305118|PROCEDURE|TSCS Mapping|"Prior to TSCS Intervention, participants will undergo TSCS Mapping.~Electrode location, pulse frequency will be maintained while the stimulation intensity is ramped from 10 to 200 mA. Brachial blood pressures and symptoms will be monitored and recorded at each ramping interval and will continuously monitor and record beat-to-beat heart rate and blood pressures to determine the optimal site and frequency for further TSCS intervention~TSCS electrodes will be placed at two vertebral levels in the and back and pulse frequency will be set at 30 to 240 Hz to determine the optimal site and frequency for further TSCS intervention."
40811840|NCT05305118|DEVICE|Transcutaneous spinal cord stimulation|"TSCS will be used as an adjunct intervention to promote blood pressure stability in conjunction with daily physical and occupational therapy in the inpatient rehabilitation gym. Stimulation will be added to therapy 3-5 times per week as needed for the duration of inpatient hospitalization following SCI.~TSCS stimulation will be delivered using Digitimer DS7A, DS8R stimulators and Chattanooga Continuum (DS7A has FDA 510(k) clearance #K051357; Chattanooga Continuum is a Class 2 device)."
40811841|NCT01439971|BIOLOGICAL|PF-05280602|0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
40811842|NCT01439971|BIOLOGICAL|PF-05280602|4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
40811843|NCT01439971|BIOLOGICAL|PF-05280602|9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
40811844|NCT01439971|BIOLOGICAL|PF-05280602|18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
40811845|NCT01439971|BIOLOGICAL|PF-05280602|30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
40811846|NCT01027234|DRUG|AZD8418|Single oral dose
40811847|NCT01027234|DRUG|Placebo|single oral dose
40811848|NCT01942161|DRUG|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
40811849|NCT01942161|DRUG|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
40811850|NCT01942161|DRUG|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
40811851|NCT02331589|DRUG|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
40811852|NCT02331589|DRUG|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
40811853|NCT03707990|DRUG|NNC0165-1875|Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.
40811854|NCT03707990|DRUG|Placebo (NNC0165-1875)|Participants will receive a single dose of s.c. placebo injection.
40811855|NCT03707990|DRUG|Semaglutide|Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.
41481661|NCT00027859|DRUG|docetaxel|
40811856|NCT01207076|BIOLOGICAL|90Y-AHN-12|"The intervention consists of two parts.~1. The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.~   * Dose escalation of nonradiolabeled AHN-12:~   Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg~2. Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.~   * the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy."
40811857|NCT06243003|RADIATION|HA-WBRT plus SBRT|hippocampal-avoidance whole brain radiotherapy (WBRT) followed by stereotactic body radiotherapy (SBRT)
40811858|NCT03223922|RADIATION|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
40811859|NCT05192928|DEVICE|Ripple Health Smart Pill Cap|The device is a smart medical device created to allow physicians to have better access to patient compliance data, and intervene on the patient's health through the use of a text message, phone call, or email.
41481662|NCT00027859|DRUG|estramustine phosphate sodium|
41481663|NCT00027859|DRUG|ketoconazole|
41481664|NCT00027859|DRUG|therapeutic hydrocortisone|
41012002|NCT01222585|DRUG|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with \>=14 postnatal days and every 24 hours for infants \<14 postnatal days.
41012003|NCT05466396|BEHAVIORAL|smoking|Smoking history and spirometry are used to define groups
41012004|NCT06471933|DEVICE|Juläine|Dermal filler (PLLA)
41329741|NCT05820009|DEVICE|GORE® VIABIL® Short Wire Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with GORE® VIABIL® Short Wire Biliary Endoprosthesis
41329742|NCT01090102|DRUG|Mesalamine (5-aminosalicylic acid, Apriso)|"Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
41481665|NCT03250299|DRUG|Microtubule-Targeted Agent BAL101553|Given PO
41481666|NCT03250299|RADIATION|Radiation Therapy|Undergo radiation therapy
41481667|NCT01598519|BEHAVIORAL|suicide intervention|"universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.~indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net."
40811860|NCT03811392|PROCEDURE|Hernioraphy/Caudal block|30 patients will receive a caudal block after induction of general anaesthesia
40811861|NCT03811392|PROCEDURE|Hernioraphy/Quadratus Lumborum block|30 patients will receive ultrasound guided quadrates lumborum block
40811862|NCT03890354|PROCEDURE|Hand-Sewn Repair|gastotomy to identify and remove gastric subepithelium tumor and hand sawn repair
41012005|NCT00864500|DRUG|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
41012006|NCT00864500|DRUG|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
41012007|NCT06574308|DIAGNOSTIC_TEST|Blood cells classification|Comparison of the classification of peripheral blood and bone marrow cells with optical microscope reading with pre-classification using Scopio technology (AI based)
41012008|NCT02052479|OTHER|Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)|
41012009|NCT02729922|DEVICE|Cardiomems|Eligible patients will undergo implantation of a pulmonary artery sensor (CardioMEMS), a wireless implantable hemodynamic monitoring system in the cardiac catheterization laboratory. This system has a passive wireless, radiofrequency sensor without batteries or leads. Patients transmit data through a device in their home that interacts wirelessly with the sensor. Clinicians retrieve this data via a web interface to use in making management decisions for patients.
41012010|NCT06051773|OTHER|muscle involvement|evaluation of muscle involvement
41012011|NCT00023816|DRUG|carbendazim|
41012012|NCT02479919|DEVICE|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
41012013|NCT02479919|DEVICE|Magstim® Sham TBS|Sham stimulation
41012014|NCT00016094|BIOLOGICAL|bevacizumab|Given IV
41012015|NCT00016094|OTHER|laboratory biomarker analysis|Correlative studies
41012016|NCT05925894|DRUG|Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma|60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
41329743|NCT01090102|DRUG|Placebo|"Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
41329744|NCT05668026|DRUG|Venetoclax|In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.
41329745|NCT02131545|DRUG|Quetiapine 25 mg gel applied topically|Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
41329746|NCT02131545|DRUG|Quetiapine 25 mg tablet by mouth|Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
41329747|NCT02131545|DRUG|Quetiapine 25 mg rectal suppository|Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
41481668|NCT03314662|BIOLOGICAL|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
41155732|NCT03586752|OTHER|Standard program|60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
41329748|NCT02131545|DRUG|Quetiapine 25 mg gel applied topically|Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
41329749|NCT02035579|BEHAVIORAL|Aerobic Training Intervention|
41329750|NCT02035579|BEHAVIORAL|Stretching Intervention|
40811863|NCT00448851|BIOLOGICAL|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
40811864|NCT01000883|OTHER|biologic sample preservation procedure|approximately 16-20 milligrams of tumor tissue per core will be obtained for research purposes.
40811865|NCT01000883|OTHER|laboratory biomarker analysis|Evaluation of biomarkers will occur as questions are asked in subsequent correlative studies.
40811866|NCT01000883|PROCEDURE|biopsy|cancer tissue will be taken from the primary breast cancer site as well as the metastatic tumor sites. Two tubes of whole blood will also be collected.
41155733|NCT06646666|DRUG|All-trans retinoic acid|10mg，tid，po (After apheresis and continued until post-infusion)
41155734|NCT06646666|DRUG|zanubrutinib|160mg，bid，po (prior to apheresis and continued until post-infusion)
41155735|NCT06646666|RADIATION|radiotherapy|If the patient's specific lesions are suitable for radiotherapy
41329751|NCT01771536|OTHER|Decision Aid|
41329752|NCT01939964|OTHER|Activation Mist|Activation Mist topical spray
41155736|NCT06646666|DRUG|CAR-T|CAR-T cell therapy
41329753|NCT02025803|DRUG|TAS-114/capecitabine|"Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle)."
40811867|NCT02552745|DRUG|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
40811868|NCT04573153|DRUG|Hydroxychloroquine + Metabolic cofactor supplementation|Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
40811869|NCT04573153|DRUG|Hydroxychloroquine + Sorbitol|Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
40811870|NCT00776672|DRUG|Fosinopril 40mg Tablets|
40811871|NCT02551094|DRUG|colchicine|0.5 mg tablet taken once a day
41329754|NCT04226287|DEVICE|Monterey Pneumatic Compression Device|The MontereyInvestigational System is a compact pneumatic compression device used for the treatment of either primary or secondary lymphedema. The primary intention in this study is to gather usability design feedback. This will be done by observing how a patient uses the device after a brief demonstration from the clinician. Errors and difficulties will be noted by the ResMed representative observing the trial. The qualitative interview with the patient at the end of the trial will yield additional understanding of the patient experience with the device.
41329755|NCT01469091|BEHAVIORAL|Smoking intervention.|Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
41329756|NCT01052519|OTHER|Goal directed fluid therapy|Fluid will be administered to reach maximal stroke volume during the intraoperative period.
41329757|NCT05875246|BEHAVIORAL|Micro-interventions|Group 1: No intervention Group 2: Brief stress reduction messages Group 3: App based stress reduction audio activity
40811872|NCT02551094|DRUG|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
41329758|NCT02945800|DRUG|nab-Paclitaxel|nab-Paclitaxel: 125 mg/m\^2 intravenously (IV)
41329759|NCT02945800|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m\^2 intravenously (IV)
41329760|NCT00047008|DRUG|cisplatin|100 mg/m\^2 intravenously on days 1, 22
41329761|NCT00047008|RADIATION|Standard fractionation RT|Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
41481669|NCT03314662|BIOLOGICAL|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
41155737|NCT06646666|DRUG|PD-1 inhibitor|IV 200 mg on D1, Q3W
41155738|NCT03601949|DEVICE|SInergy Cooled Radiofrequency|ablation of low back pain
41155739|NCT03601949|OTHER|Medical Management|physical therapy, medications, lifestyle changes
41155740|NCT02338206|DRUG|Growth hormone|
41155741|NCT01725087|DRUG|Matching Placebo|
41155742|NCT01725087|DRUG|Low Dose GRT6005|
41329762|NCT00047008|RADIATION|Accelerated fractionation radiation therapy|Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.
41329763|NCT00047008|PROCEDURE|Conventional surgery for select patients|"Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made."
41329764|NCT00498849|DEVICE|CPAP|
41329765|NCT02595268|DRUG|Pitavastatin|Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.
41329766|NCT02595268|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
41329767|NCT06089070|DEVICE|FreeStyle Libre Continuous Glucose Monitor System|Continuous Glucose Monitor System for people with Type 2 Diabetes
41329768|NCT04506944|OTHER|No intervention|No specific exposure is explored.
41329769|NCT05322915|OTHER|line dancing|The intervention included 60-minute sessions, two days a week for four weeks for a total of eight sessions. All sessions were administered by the physiotherapist who has 26 years of experience in dance therapy. The dance was performed on a one to one basis with minimal support from the therapist. The line dancing sequence, which was specially created for this training program, was designed as a structured goal-oriented dance. Line dancing movements/steps are comprised of moving forward and backward, or sideways and turns and scuff. In addition, the fact that one foot is always in contact with the ground makes it ideal for patients with multiple sclerosis, who may have balance problems.
41329770|NCT02633046|DRUG|Acthar Gel|Acthar Gel 80 U/mL solution for subcutaneous injection
41329771|NCT00048789|PROCEDURE|Extracorporeal Photopheresis|
41329772|NCT06122246|BEHAVIORAL|Community Health Worker (CHW)|Participants will receive the additional support of a Community Health Worker (CHW).
40811873|NCT02985918|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
40811874|NCT02985918|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
40811875|NCT00271856|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
40811876|NCT00271856|BEHAVIORAL|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
40811877|NCT00464061|DRUG|Volinanserin|oral administration
40811878|NCT00464061|DRUG|Placebo|oral administration
40811879|NCT02106949|DEVICE|SMS contact with patient after discharge in intervention group|
40811880|NCT03468751|DRUG|HLX10|recombinant humanized anti-PD-1 monoclonal antibody against solid cancers
40811881|NCT01312493|DRUG|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
40811882|NCT01312493|RADIATION|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
41329773|NCT06122246|OTHER|Remote Blood Pressure (BP) Management Program (RBPM)|Participants will receive a medical model of remote BP management (RBPM).
41329774|NCT04381572|BEHAVIORAL|High fidelity simulation training|At the beginning of scheduled classes in the simulation center, students were placed sitting at rest for 30 min. In each team a leader was chosen. Other team members were also assigned detailed functions. Before starting the scenario, participants were oriented for 10 -15 minutes by a physician instructor about the simulation room setup and manikin features. The simulated scenarios were performed using a high fidelity computer-based manikin simulator, with the possibility of remote control of vital signs. All medications and equipment required during the clinical scenarios were available. The scenario used was prepared and validated by experienced simulation instructors. All student groups were given the same standardized scenario.
41329775|NCT03094819|BEHAVIORAL|Financial Incentive|Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
41329776|NCT03094819|BEHAVIORAL|Retinal Care DR|Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
40811883|NCT06215105|DEVICE|Intracranial Aneurysm Devices|Intracranial Aneurysm occlusion
40811884|NCT04268329|OTHER|Educational website|A website is used to educate patients and family members about head and neck cancer.
41155743|NCT01725087|DRUG|Medium Dose GRT6005|
41155744|NCT01725087|DRUG|High Dose GRT6005|
41155745|NCT01725087|DRUG|Tapentadol|
40811885|NCT03589989|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
41012017|NCT05259449|BEHAVIORAL|Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
40811886|NCT03589989|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
40811887|NCT04044053|DRUG|PF-06865571 400 mg Immediate Release (IR) in Fed State|400 mg IR dose in fed state
40811888|NCT04044053|DRUG|PF-06865571 50 mg Modified Release (MR) in Fed State|50 mg MR in fed state
40811889|NCT04044053|DRUG|PF-06865571 400 mg MR in Fed State|400 mg MR in fed state
40811890|NCT04044053|DRUG|PF-06865571 400 mg MR in Fasted State|400 mg MR in fasted state
40811891|NCT01397110|OTHER|respiratory and exercise therapy|Conventional therapy with specific respiratory and physical therapy plus mental walking training
40811892|NCT04678986|OTHER|ER2|No intervention, data analysis only
41012018|NCT05259449|OTHER|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
41012019|NCT05259449|OTHER|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
41012020|NCT04083872|DRUG|Reference drug|D744 Cap. 1 Cap., single oral administration under fasting condition
41155746|NCT00517270|DRUG|Rabeprazole 20mg twice daily|
41329777|NCT00351169|DRUG|Quetiapine SR|
41329778|NCT00351169|DRUG|Escitalopram|
41329779|NCT01395355|BEHAVIORAL|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
41329780|NCT01395355|BEHAVIORAL|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
41329781|NCT03024255|DRUG|BBI-4000 gel, 5%|BBI-4000 gel, 5% applied once to each axilla daily
40811893|NCT01258790|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
40811894|NCT01258790|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
40811895|NCT00729495|DRUG|celecoxib|dose form
40811896|NCT00443053|DRUG|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
40811897|NCT00695916|PROCEDURE|Breast MRI|
40811898|NCT00862758|DRUG|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
40811899|NCT04847752|PROCEDURE|carotid artery stenting|common treatments for carotid artery stenosis
41012021|NCT04083872|DRUG|Test drug|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
41329782|NCT03024255|DRUG|BBI-4000 gel, 10%|BBI-4000 gel, 10% applied once to each axilla daily
41329783|NCT03024255|DRUG|BBI-4000 gel, 15%|BBI-4000 gel, 15% applied once to each axilla daily
41329784|NCT03024255|DRUG|Vehicle (Placebo)|Placebo, applied once to each axilla daily
41329785|NCT04661267|DIETARY_SUPPLEMENT|Stem Cell Support Formula|This liquid supplement contains the following ingredients: chondroitin sulfate, glucosamine sulfate, vitamin C (ascorbic acid), curcumin and Bioperine®, resveratrol, L-carnosine, bitter melon, and vitamin D.
41329786|NCT04661267|DIETARY_SUPPLEMENT|Placebo|The placebo comparator will look and taste similar without the active ingredients of the Stem Cell Support Formula.
40811900|NCT04847752|PROCEDURE|carotid endarterectomy|common treatments for carotid artery stenosis
41329787|NCT05886179|OTHER|cross-sectional study|analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger.
41329788|NCT00907972|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3
41329789|NCT00907972|OTHER|Placebo|Placebo
41329790|NCT00609804|DRUG|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
41329791|NCT00609804|DRUG|Erlotinib|Erlotinib 150 mg once daily by mouth
41329792|NCT01223040|OTHER|SYSTANE® Balance Lubricant Eye Drops|Subjects will be dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
41329793|NCT00047307|DRUG|alvocidib|Given IV
41329794|NCT00047307|DRUG|gemcitabine hydrochloride|Given IV
41329795|NCT00047307|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
41329796|NCT00047307|OTHER|laboratory biomarker analysis|Correlative studies
41329797|NCT00463879|DRUG|Galantamine|
41329798|NCT03385499|BIOLOGICAL|blood additional samples|additional samples of mother's blood and umbilical cord at delivery
41329799|NCT03288740|DRUG|Semaglutide 0.5 mg|A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
41155747|NCT05752955|OTHER|SMARThealth Pregnancy|"At each visit, the CHW will:~* Update history and contact details~* Check haemoglobin with a point of care device.~* Check BP~* Check iron folic acid (IFA) supply and compliance~* Brief screen for mental health problems~An electronic decision support platform will provide advice if referral is needed. At the Primary Health Centre, doctor/s will be issued a tablet computer with a version of the SMARThealth Pregnancy App to:~* Generate an automated list of all patients in the community who require review, with the dates of testing and referral, and with two-way communication back to the CHW.~* Suggest management based on current Indian guidelines for the diagnosis and management of anaemia, hypertension and diabetes in pregnant and non-pregnant adults."
41329800|NCT03288740|DRUG|Placebo (semaglutide 0.5 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
41012022|NCT03146650|BIOLOGICAL|Ipilimumab|Given IV
41012023|NCT03146650|OTHER|Laboratory Biomarker Analysis|Correlative studies
41155748|NCT03745651|DRUG|Ruxolitinib cream|Ruxolitinib 0.75% or 1.5% cream.
41329801|NCT03288740|DRUG|Semaglutide 1.0 mg|A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
41329802|NCT03288740|DRUG|Placebo (semaglutide 1.0 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
40811901|NCT04847752|DRUG|Aspirin|the dosage and duration
41012024|NCT03146650|BIOLOGICAL|Nivolumab|Given IV
41155749|NCT03745651|DRUG|Vehicle cream|Ruxolitinib matching vehicle cream.
41329803|NCT00091962|BEHAVIORAL|Psychoeducation; Treatment recommendations|Counseling program
41329804|NCT00091962|DRUG|Pharmacotherapy|Recommendations to patients' PCP for medication to treat depression
41329805|NCT00091962|OTHER|Usual Care|Physicians' Usual care
41329806|NCT00829218|OTHER|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
41329807|NCT00829218|OTHER|Placebo diet|Juice with nothing added.
41329808|NCT02549248|OTHER|BAL|Patients with idiopathic and non idiopathic interstitial lung diseases
40811902|NCT04847752|DRUG|Clopidogrel|the dosage and duration
40811903|NCT04847752|DRUG|Anticoagulant|the dosage and duration
40811904|NCT04847752|DRUG|Statin|the dosage and duration
40811905|NCT04847752|DRUG|PCSK9 inhibitor|the dosage and duration
41012025|NCT05448664|BEHAVIORAL|Family HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students and their parents in the following 24 weeks.
41329809|NCT02549248|OTHER|BW|Patients with idiopathic and non idiopathic interstitial lung diseases
41012026|NCT05448664|BEHAVIORAL|Adolescent HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students in the following 24 weeks.
41012027|NCT05448664|BEHAVIORAL|Adolescent e-pamphlets|The contents of e-version of three pamphlets, published by Department of Health (http://www.toothclub.gov.hk/en/en_index.html) will be distributed in an electronic form and sent via a mobile message.
41012028|NCT02049489|BIOLOGICAL|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
41012029|NCT04866134|DRUG|ERAS-007|ERAS-007 will be administered orally as specified in Arm description.
41012030|NCT04866134|DRUG|ERAS-601|ERAS-601 will be administered orally as specified in Arm description.
41012031|NCT02804503|BEHAVIORAL|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
41329810|NCT02549248|OTHER|EAC|Patients with idiopathic and non idiopathic interstitial lung diseases
41329811|NCT02549248|OTHER|blood specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
41329812|NCT02549248|OTHER|Urine specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
41329813|NCT04138212|DRUG|Paclitaxel, Cisplatin|Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles
41329814|NCT04138212|RADIATION|neoadjuvant chemoradiation therapy|Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d\*23
41329815|NCT02482012|OTHER|Survey|This was a survey
41329816|NCT02299648|OTHER|Molecular profiling|molecular profiling, patient derived cells, fresh or FFPE
41329817|NCT01229514|OTHER|fMRI|fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
41329818|NCT06353360|DEVICE|Tumor Treating Fields|Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day, starting on the Day 1 of cycle 1 (C1D1), throughout the entire course of treatment.
41329819|NCT06353360|DRUG|Tislelizumab|Tislelizumab will be given 300 mg intravenously every 4 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. The Tislelizumab treatment should be continued until confirmed PD, unacceptable toxicity, or finished Tislelizumab treatment for other reasons.
40811906|NCT01985711|DEVICE|web-based collaborative care|"Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months."
40811907|NCT01985711|OTHER|wait-list|Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
40811908|NCT01985711|BEHAVIORAL|usual diabetes outpatient care|
41329820|NCT06353360|DRUG|Temozolomide (TMZ)|The patients will carry out 6 cycles of TMZ adjuvant chemotherapy according to the instructions. The dosage of TMZ is 150-200 mg/(m2·d), daily for 5 days followed by 23 days without treatment, the treatment cycle is 28 days. The initial dose of cycle 1 is 150 mg/(m2·d), if patients do not experience TMZ chemotherapy toxicity, the dose should be increased to 200 mg/(m2·d) in subsequent treatment cycles. After 6 cycles of TMZ adjuvant chemotherapy, if the patients do not experience disease progression, it is recommended to continue TMZ adjuvant chemotherapy, or treated according to investigators' recommendations. The TMZ treatment should be continued until confirmed progressive disease (PD), unacceptable toxicity, or finished TMZ treatment for other reasons.
41329821|NCT02176304|DRUG|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
41329822|NCT02176304|DRUG|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
41329823|NCT01579552|BEHAVIORAL|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
41329824|NCT01579552|BEHAVIORAL|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
41329825|NCT03357666|DRUG|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
41329826|NCT03357666|DRUG|HUDC_VT (Glucose 400mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
41329827|NCT03357666|DRUG|HUDC_VT (Glucose 400mg)|Vaginal administration, two tablets once a day for 7 days
41329828|NCT03357666|DRUG|HUDC_VT (Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
41329829|NCT03357666|DRUG|Placebo|Vaginal administration, two tablets once a day for 7 days
41481670|NCT03314662|BIOLOGICAL|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
40811909|NCT04945707|DRUG|Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]|Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg
40811910|NCT04945707|DRUG|Placebo|Normal saline
40811911|NCT03524963|DRUG|Cilostan CR Tab.|Cilostan CR Tab. 200mg once a day for 5 days
41012032|NCT02804503|BEHAVIORAL|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
41012033|NCT02804503|BEHAVIORAL|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
41012034|NCT03109275|OTHER|Single complete MRI intervention|MRI examination will comprise conventional T1 and FLAIR sequences, and advanced sequences such as rs-fMRI and High angular resolution MRI (HARDI).
41012035|NCT01164748|RADIATION|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
40811912|NCT03524963|DRUG|Pletaal SR Cap.|Pletaal SR Cap. 200mg once a day for 5 days
40811913|NCT06234579|DIAGNOSTIC_TEST|Biopsy (tissue or liquid)|"At the time of diagnosis, all newly diagnosed ALK+ NSCLC patients eligible for first line treatment with alectinib or brigatinib or lorlatinib will be considered for the study.~In case of progression, a multidisciplinary team (oncologists, interventional pneumologists and radiologists, surgeons) will discuss case-by-case the feasibility to procure an adequate biopsy from progressing lesions. Repeat biopsies will be performed within 2 weeks from multidisciplinary evaluation and before the start of subsequent treatment. If repeat biopsies are not technically or safely feasible or fail to yield sufficient material for genomic analysis, we will collect a whole blood drawn by venepuncture for the analysis of ctDNA."
40811914|NCT00006447|PROCEDURE|Social Support|
40811915|NCT06104878|OTHER|No Intervention|No Intervention will be administered in this study.
40811916|NCT01424748|DIETARY_SUPPLEMENT|Tahitian Noni Juice|noni fruit juice
40811917|NCT01424748|DIETARY_SUPPLEMENT|Placebo|Placebo juice
41329830|NCT06402903|OTHER|Observation|"The clinical, post-surgical and anthropometric variables of the patients, as well as the time spent in the Intensive Care Unit and on the hospital ward (in days) were collected in the Clinical Histories.~The collection of data from the Clinical Histories will be carried out by the principal investigator, an employee of the Hospital Universitario Central de Asturias, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the patients whose data were collected.~The data from the Clinical Histories will be exported to an Excel file which will subsequently be anonymised. Access to the Excel file will require a password access that will be managed from a computer of the University of Oviedo (Department of Surgery and Medical-Surgical Specialties)."
40811918|NCT04933045|DEVICE|Arthrex InternalBrace|Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
41329831|NCT05816694|DRUG|NAB-Paclitaxel plus Cisplatin|NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
41329832|NCT05816694|DRUG|Cisplatin plus Epirubicin plus Cyclophosphamide|Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
41329833|NCT04965870|DRUG|Trifluridine/Tipiracil|Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
41329834|NCT06248697|BIOLOGICAL|αPD1/CTLA4-MSLN-CAR T cells|BZE2209 is prepared by non-viral vector technology consisting of autologous CD3+T cells expressing mesothelin-specific chimeric antigen receptor (CAR), PD1 nanoantibody and CTLA4 antibody with dimethyl sulfoxide as medium. It can be used for direct intravenous infusion. Autologous CD3+ T cells were transfected with plasmids expressing anti-mesothelin-specific CAR, anti-PD1 nanoantibody and anti-CTLA-4 antibody by electroporation in vitro. Mesothelin-specific CAR is a single-domain antibody (VHH) derived from alpaca, which is composed of a binding domain and a CD28 and CD3ζ chain signal transduction domain.
41329835|NCT03659760|OTHER|Group Isolated|Eyes closed with patch and ears plugged between 24:00-06:00
41329836|NCT01037972|BEHAVIORAL|Conventional physiotherapy|3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
41329837|NCT01037972|BEHAVIORAL|Whole body vibration|3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
41329838|NCT04505878|DRUG|Vitamin C|Vitamin C is a first-line antioxidant that directly scavenges free radicals, inhibits reactive oxygen species (ROS) producing enzymes and recovers other cellular antioxidants
41329839|NCT04454138|DEVICE|XEN-45 gelatin microstent|Placement either in the subconjunctival space or supratenon's area
41329840|NCT03966729|OTHER|Time (outcome)|
41329841|NCT01573403|DRUG|DLBS2411|1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
41329842|NCT01573403|DRUG|DLBS2411|2 caplets of DLBS2411 @250 mg, once daily
41329843|NCT01573403|DRUG|Placebo DLBS2411|2 placebo caplets of DLBS2411, once daily
40811919|NCT00788931|DRUG|IV LBH589|
40811920|NCT00788931|DRUG|Oral LBH589|
41012036|NCT00233025|DRUG|Duloxetine|
41329844|NCT03395223|DRUG|Methylene Blue|Administration of Methylene Blue to treat acquired methaemoglobinaemia
41012037|NCT00233025|DRUG|Placebo|
41329845|NCT04857892|DRUG|GSK3640254|GSK3640254 will be administered via oral route.
41329846|NCT04857892|DRUG|DTG|DTG will be administered via oral route.
41329847|NCT04857892|DRUG|GSK3640254/DTG|GSK3640254/DTG will be administered via oral route.
41329848|NCT02613702|PROCEDURE|Free Gingival Graft|Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
41012038|NCT02995395|DEVICE|Mucosal Impedance Balloon catheter|"During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.~o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded."
41012039|NCT04522297|DRUG|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
41481671|NCT04090970|DEVICE|Briagen|Natural complex carbohydrate wound dressing for skin wounds
41481672|NCT00522340|BEHAVIORAL|Aerobic Exercise Program|Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
40811921|NCT00788931|DRUG|trastuzumab|
40811922|NCT00788931|DRUG|paclitaxel|
40811923|NCT03447210|BEHAVIORAL|Assisted Partner Services|Contact tracing for sexual and drug-sharing partners to notify about exposure to HIV and offer HIV and hepatitis C testing with linkage to care and partner services for those who test positive.
40811924|NCT04880746|DRUG|BEAC|Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
40811925|NCT04880746|DRUG|Cladribine combined with BEAC|Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
40811926|NCT05804656|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
40811927|NCT05804656|DRUG|Botox®|Intramuscular injection Botox®
40811928|NCT00602004|DRUG|losartan|losartan 50 mg a day
40811929|NCT02446678|DEVICE|PillCam ESO2|Capsule endoscopy
40811930|NCT00370760|DRUG|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
40811931|NCT00370760|DRUG|placebo|
40811932|NCT03482648|DRUG|BBT-401-1S, Single dose|Single dose of BBT-401-1S, 7 dose levels, oral capsule
40811933|NCT03482648|DRUG|BBT-401-1S, Multiple doses|Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule
41329849|NCT02613702|PROCEDURE|Original Free Gingival Graft technique|Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area
41329850|NCT02613702|PROCEDURE|Modified Free Gingival Graft technique|Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
40811934|NCT03482648|DRUG|Placebo|Placebo matched to BBT-401-1S, oral capsule
40811935|NCT05761106|OTHER|Oculomotor Therapy|It will consist exercise of a convergence technique and an accommodative technique.
40811936|NCT05761106|OTHER|Therapy for Temporomandibular Disorder|It will consist exercise of a ATM and cervical spine.
41329851|NCT02598505|DRUG|Indacaterol|
40811937|NCT03772028|DRUG|cisplatin|HIPEC with cisplatin after cytoreductive surgery
41329852|NCT02598505|DRUG|Placebo|
41329853|NCT04376099|DIAGNOSTIC_TEST|Transcutaneous oxygen pressure measurement during the treadmill test|"Calculation of the decrease from rest of oxygen pressure (DROP) throughout the period of rest exercise and recovery.~The DROP is calculated as chanegs on each limb probe minus changes on a chest reference probe from rest.~Analysis of the recovery period of the recordings will be done to seach for recovery 50% and 90% from the minimal DROP observed Evaluation of calf and non calf pain during the tests. Evaluation of calf and non calf (buttock or thigh) ischemia during the tests. Ischemia being defined as a monimal DROP lower than minus 15 mmHg."
40811938|NCT01184638|DRUG|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
40811939|NCT01184638|DRUG|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
40811940|NCT02399540|DEVICE|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
41329854|NCT05023850|PROCEDURE|TLIPB|Patients will receive TLIPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
41329855|NCT05023850|PROCEDURE|ESPB|Patients will receive ESPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between erector spinae muscle and transverse process of a vertebra.
40811941|NCT02399540|DEVICE|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
40811942|NCT02399540|DEVICE|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
40811943|NCT02399540|DEVICE|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
40811944|NCT04122911|DRUG|Temozolomide|pharmacological
40811945|NCT02112474|DEVICE|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
40811946|NCT02112474|DEVICE|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
41329856|NCT01613508|PROCEDURE|Direct Anterior Approach|
41329857|NCT01613508|PROCEDURE|Mini-Posterior Approach|
41329858|NCT05236959|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Following an initial interview session, patients are offered eight weekly group-based session, delivered via videoconferencing, and asked to engage in regular daily home practice of mindfulness meditation
40811947|NCT02112474|DEVICE|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
40811948|NCT00003783|BIOLOGICAL|filgrastim|
40811949|NCT00003783|DRUG|asparaginase|
40811950|NCT00003783|DRUG|cyclophosphamide|
40811951|NCT00003783|DRUG|cytarabine|
40811952|NCT00003783|DRUG|daunorubicin hydrochloride|
40811953|NCT00003783|DRUG|dexamethasone|
40811954|NCT00003783|DRUG|etoposide|
40811955|NCT00003783|DRUG|idarubicin|
40811956|NCT00003783|DRUG|leucovorin calcium|
40811957|NCT00003783|DRUG|mercaptopurine|
40811958|NCT00003783|DRUG|methotrexate|
40811959|NCT00003783|DRUG|prednisone|
40811960|NCT00003783|DRUG|vincristine sulfate|
40811961|NCT00003783|RADIATION|radiation therapy|
40811962|NCT03441035|OTHER|General anesthesia and surgery (liver transplantation)|The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.
40811963|NCT03219034|DEVICE|oral appliance - A ; washout; oral appliance B|Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
41012040|NCT04522297|DRUG|Nor-epinephrine|Intravenous infusion norepinephrine
41012041|NCT03925792|BEHAVIORAL|Lifestyle Medicine|diet, sleep, exercise and mindfulness
41012042|NCT02291627|DEVICE|MAC|direct laryngoscopy
41012043|NCT02291627|DEVICE|Coopdech|Video laryngoscopy
41329859|NCT05236959|OTHER|Treatment as Usual|Following an initial interview session, patients continue with their usual care
41329860|NCT04262141|DRUG|IMG-7289|Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.
41329861|NCT02134067|DRUG|TAS-119|
41329862|NCT02134067|DRUG|Paclitaxel|A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
41329863|NCT04630964|DRUG|Psilocybin|psilocybin 25 mg Single Oral Dose
41329864|NCT04630964|DRUG|Niacin|niacin 100mg Single Oral Dose
41329865|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine (TVDV)|Low dose delivered intramuscularly on Study Days 0, 30 and 90
41329866|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
41329867|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)|High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
41329868|NCT03825510|RADIATION|Stereotactic Body Radiotherapy|"All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to \<=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy."
40811964|NCT03219034|DEVICE|oral appliance - B; washout; oral appliance A|Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
40811965|NCT04985201|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 60 mg/m\^2 on Day 1,8 of each 21-day cycle.
40811966|NCT04985201|DRUG|Simvastatin|Simvastatin 40 mg daily oral tablet taken.
40811967|NCT04344860|DRUG|Recombinant Von Willebrand factor|Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
40811968|NCT04344860|DRUG|Tranexamic Acid Injection [Cyklokapron]|Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.
40811969|NCT03588806|DRUG|Xtampza ER (oxycodone)|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
40811970|NCT05983198|DRUG|225Ac-PSMA-R2|PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide
40811971|NCT05983198|RADIATION|68Ga-PSMA-R2|Kit for radiopharmaceutical preparation
40811972|NCT05983198|RADIATION|68Ga-PSMA-11|Kit for radiopharmaceutical preparation
40811973|NCT03171519|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
40811974|NCT03171519|BEHAVIORAL|Acupuncture|The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
41329869|NCT05625646|OTHER|quality assurance program|The program consists of an online quiz using a multiple choice questionnaire (MCQ) design. The participants are expected to complete the online MCQ at 3, 6, 9, and 12 months following baseline. The MCQ includes still-pictures and video sequences of the 10 application specific POCUS examinations from the course curriculum. Through 15-20 questions, the quiz tests the OSAUS dimentions Each question has four possible answers of which up to three answers are correct. Each MCQ will have ten questions pertaining to pathologies within the ten applications of the curriculum. Further, there will be five to ten questions relating to image recognition, image optimisation, ultrasound artifacts. Once each MCQ is finalized, the participating GP's will receive feed-back on the answers with suggestions for improvement and guidance toward continuing self-directed learning.
41329870|NCT02468206|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
41329871|NCT02468206|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
41329872|NCT02468206|DRUG|N-butyl-2-cyanoacrylate|
40811975|NCT00949923|DIETARY_SUPPLEMENT|tea capsule|3 tea capsules daily for 3 weeks
40811976|NCT04563234|BEHAVIORAL|COFLEX neurocognitive training|The COFLEX training group will then be provided with the cognitive training module and participants will be required to complete a targeted 30-minute daily training until the day of surgery, and then after the surgery, for a total of 6 weeks.
40811977|NCT04563234|BEHAVIORAL|Crossword puzzles|The control (crossword puzzles) group will be given a training module, where they can access crossword puzzles on the same platform, and can do puzzles whenever they desire over the 6-week time period.
41012044|NCT02291627|DEVICE|AirTraq|optical laryngoscopy
41012045|NCT04961892|PROCEDURE|surgical treatment|Anatomical contraction and termination reconstruction of the lateral ligament
41012046|NCT04961892|PROCEDURE|conservative treatment|Rehabilitation intervention training
41012047|NCT03756766|DIAGNOSTIC_TEST|RSV point of care testing|Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
41012048|NCT02782897|DRUG|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
41012049|NCT02782897|OTHER|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
41329873|NCT02468206|DRUG|Lauromacrogol|
41329874|NCT05968872|BEHAVIORAL|no intervation|it is observational, no intervention was taken
41329875|NCT02755142|BIOLOGICAL|Gliolan|
40811978|NCT00620178|DRUG|Candesartan Cilexetil|oral once daily dose
40811979|NCT00620178|DRUG|Losartan|once daily oral dose
40811980|NCT03403361|DEVICE|Siemens Somatom Definition Edge|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
40811981|NCT03403361|DEVICE|Philips Brilliance Big Bore CT/simulator|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
40811982|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat|A preparation of autologous microfat (5mL) will be injected intra-articularly.
40811983|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.
41329876|NCT05541523|BEHAVIORAL|cognitive behavioural therapy|The three therapists in the cognitive behavioural group therapy condition were two students of master's degree of nursing with formal education in cognitive therapy and one psychological specialist nurse working in a palliative care unit. There was no evidence of significant deviation from the protocol.
41329877|NCT05541523|BEHAVIORAL|mindfulness-based therapy|The two therapists in the mindfulness-based stress reduction condition were one clinical psychologist and one student of master's degree of nursing with formal education in mindfulness.Both interventions were manualized. To assure adherence to the study protocol meetings between the therapists and the researchers were organized regularly and the therapists detailed the content of each group session in clinical records which were frequently monitored by a research assistant.
41329878|NCT02904187|OTHER|Positron Emission Tomography (PET)|
41329879|NCT02904187|OTHER|Electroencephalogram (EEG)|
41329880|NCT04202978|DRUG|Camrelizumab|Camrelizumab ：200mg intravenous injection d1 q3w
41329881|NCT04202978|DRUG|Apatinib Mesylate|Apatinib：250mg/d P.O ,qd ,3weeks
41481673|NCT05790421|OTHER|Foot Muscle Energy Technique|Starting from the preparation position, at the restriction barrier, the patient is asked to exert a small effort (no more than 20% of available strength) towards plantarflexion, against unyielding resistance, with appropriate breathing. The patient produces isometric effort contracts either gastrocnemius or soleus (depending on whether the knee is unflexed or flexed). This contraction is held for 7-10 seconds together with a held breath. The exercise was repeated until the full range of movement was obtained.
41481674|NCT05790421|OTHER|Conventional Physical Therapy Program|Graduated active resisted range of motion exercises for both UL and LL and graduated gait training
41481675|NCT03527251|DRUG|Ipilimumab|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
41481676|NCT03527251|DRUG|SHR-1210|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
41481677|NCT00210899|DRUG|ceftobiprole medocaril|
41481678|NCT00210899|DRUG|Vancomycin plus Ceftazidime|
41481679|NCT00513552|DRUG|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
41481680|NCT05307887|DEVICE|Sync VR Medical PICO G2 4K Virtual Reality Technology|Virtual reality headset and software
41481681|NCT04447937|OTHER|No Interventions|There are no interventions associated with the study.
41481682|NCT06094452|OTHER|Computerized Cognitive Training|Participants in intervention group will receive a multidomain, adaptive computerized cognitive training program (www.66nao.com) and will be required to complete at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks. Multidomain coverage paradigms include working memory, calculation, processing speed, attention, executive function, and short-term and long-term memory.
41481683|NCT06094452|OTHER|Treatment As Usual|Patients in control group will receive TAU for 24 weeks, which includes (1) regular medication management from the Memory Clinic, if applicable; (2) basic health education at each follow-up (face to face) and twice per month on the internet .
41481684|NCT03023514|DIETARY_SUPPLEMENT|Oral Lipoic acid|300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
41481685|NCT03023514|DRUG|Vaginal Progesterone|200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
41481686|NCT06533462|DIETARY_SUPPLEMENT|Multiallergen powder|OIT multiallergen powder.
41329882|NCT04202978|DRUG|Capecitabine|capecitabine:850mg/m2 P.O ,bid ,d1-d14
41329883|NCT04202978|DRUG|Oxaliplatin|oxaliplatin:130mg/m2 intravenous injection d1 q3w
41481687|NCT00753818|OTHER|DHA and ARA|various levels of DHA and ARA
40811984|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat and platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
41012050|NCT04276350|PROCEDURE|Acupuncture|Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
41012051|NCT04276350|PROCEDURE|Best Medical Therapy|Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily
41012052|NCT06532812|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
41329884|NCT04202978|RADIATION|radiofrequency ablation|radiofrequency ablation:between first cycle and second cycle percutaneous
41329885|NCT03825172|DIAGNOSTIC_TEST|Caudal Epidural Ultrasonography|Ultrasonographic Measurement
41481688|NCT00753818|OTHER|Control|
41481689|NCT06104241|BIOLOGICAL|BGT007 Injection|BGT007 injection (d0) were infused intravenously once, and the dose group was 5.0× 10\^7 cells,1.0 ×10\^8 cells, 3.0× 10\^8 cells,1.0 × 10\^9 cells,3.0 ×10\^9 cells.
41481690|NCT05828121|BEHAVIORAL|POINT1|Receiving treatment
41481691|NCT04079127|DEVICE|Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.|Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.
41481692|NCT06320405|BIOLOGICAL|Axatilimab|Given IV
41481693|NCT06320405|PROCEDURE|Biopsy|Undergo tumor biopsy
41481694|NCT06320405|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41481695|NCT06320405|PROCEDURE|Computed Tomography|Undergo CT scan
41481696|NCT06320405|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41481697|NCT06320405|DRUG|Paclitaxel|Given IV
40811985|NCT00803400|DRUG|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
40811986|NCT00803400|DRUG|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association)."
40811987|NCT01321918|OTHER|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
40811988|NCT01321918|OTHER|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
41012053|NCT06532812|DRUG|Cyclophosphamid|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
41012054|NCT06532812|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
41329886|NCT06333236|OTHER|Food for Special Medical Purposes: Kron®|Citicoline 40mg/ml + Nicotinamide 15 mg/ml oral solution
41329887|NCT05933798|OTHER|ICOPE|The ICOPE approach with locally adapted care pathways was implemented by trained integrated care managers (ICMs) advised by multi-disciplinary teams, delivered in primary care settings
41329888|NCT05933798|OTHER|Usual Care|Participants in the Control Group would have their care plan after assessment and seek health and care services as usual without additional advice or support on implementing the care plan
41329889|NCT01359852|DRUG|[11C] JNJ-42491293|Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
41329890|NCT01359852|DRUG|[11C] JNJ-42491293 + JNJ-40411813|Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
41329891|NCT01359852|DRUG|[11C] JNJ-42491293 + JNJ-40411813|"Part D:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain"
41329892|NCT01359852|DRUG|[11C] JNJ-42491293|Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
41329893|NCT03159013|OTHER|Exposure|"Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31."
41329894|NCT06556667|DEVICE|biphasic defibrillator with maximum energy of 200J (® Zoll)|Cardioversion
41329895|NCT06556667|DEVICE|biphasic defibrillator with maximum energy of 360J (® Physio-Control)|Cardioversion
41329896|NCT03516955|DRUG|Rosuvastatin|Superstat ® Tablets 10mg, 20mg
41329897|NCT04294095|OTHER|My Baby My Move +|This is a community-based, peer-led 12-week wellness intervention to decrease excessive gestational weight gain.
41329898|NCT04294095|OTHER|Control|This is a 12-week basic prenatal education class.
41012055|NCT06532812|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
41329899|NCT04489004|PROCEDURE|Driver ablation+CPVI|Patients receive driver ablation and CPVI (circumferential pulmonary vein isolation).
41329900|NCT04489004|PROCEDURE|Stepwise ablation|Patients receive stepwise ablation.
41012056|NCT06532812|DRUG|Pembrolizumab|Intravenous (IV) infusion
41329901|NCT03483831|BEHAVIORAL|Intervention group|Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.
41329902|NCT00445731|BEHAVIORAL|exercise intervention|
41329903|NCT00445731|PROCEDURE|management of therapy complications|
41329904|NCT00445731|PROCEDURE|observation|
41329905|NCT03872193|OTHER|Exercise|Virtual Reality Exercies
41481698|NCT06320405|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41481699|NCT06320405|BIOLOGICAL|Retifanlimab|Given IV
41481700|NCT00431158|OTHER|Different Mechanical Ventilation Protocols|"OLA Group: Open lung approach protocol and recruitment maneuvers~ARDSnet Group: ARDSnet protocol"
41329906|NCT05034471|DEVICE|Mi-Chord™ Device Technologies|Mi-Chord™ System consists of LS-5™ ePTFE suture, the Mi-STITCH™ suturing device, the Mi-KNOT™ device and the Mi-KNOT™ titanium fastener. Mi-Chord™ system is designed to replace the chordae tendineae in order to enable mitral valve repair. These sub-devices (ePTFE suture, Mi-STITCH™, Mi-KNOT™ device, Mi-KNOT™ titanium fastener) can be considered as one system and refer to different aspects of the overall technology.
41329907|NCT00554476|DRUG|Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting|
41329908|NCT03432611|OTHER|Self-care information feature|The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.
41012057|NCT04404959|OTHER|fascia iliaca compartment block with ropivacaine|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of ropivacaine 0.25%)
41329909|NCT03432611|OTHER|Self-acupressure feature|The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.
41329910|NCT05304962|DRUG|RGT-419B|oral capsules
41329911|NCT05304962|DRUG|RGT-419B in combination with hormonal therapy|RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
41329912|NCT05263544|OTHER|measuring uterocervical angle and uterine dimensions|in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured
41329913|NCT03217201|DEVICE|Light Glasses (Experimental)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
41329914|NCT03217201|DEVICE|Light Glasses (Comparison)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
41481701|NCT06395376|OTHER|Bikram Hot Yoga Intervention|"Active participants engage in a yoga intervention which entails participating in a minimum of 60-minutes of hot yoga (Bikram sequence), 3x per week in a heated room at 40 degrees C. The intervention will be 6-weeks of active intervention when they are participating in yoga, followed by an 6-week washout period where they will be asked to not practice yoga. Participants will be asked to give blood at 9 timepoints throughout the 12-week study, including baseline, week one, midpoint, end of Hot Yoga Intervention (Week 6) and after Washout (Week 12)"
41481702|NCT06395376|OTHER|Hot Yoga Washout|"The Washout period consists of 6-weeks occurring immediately after the Hot Yoga Intervention during which the participants do not perform any hot yoga."
41481703|NCT02939014|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
41481704|NCT04332848|DRUG|ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
41481705|NCT04332848|DRUG|SGT|Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
41481706|NCT04038086|DIAGNOSTIC_TEST|oral glucose tolerance test|Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.
41012058|NCT04404959|OTHER|fascia iliaca compartment block with placebo|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of normal saline)
41012059|NCT04686097|PROCEDURE|treatment: puncture of coagulation|ultrasound-guided puncture of coagulation
41012060|NCT04686097|PROCEDURE|treatment: sclerosing agent injected|ultrasound-guided sclerosing agent injected
41329915|NCT05834101|OTHER|Myofacial Release|Illiopsoas , quadriceps, hamstrings, hip adductors, hip abductors ,tensor fasciae lata and gluteus, Foot flexors and extensors received thirty seconds flexibility by foam rolling.Although there appears to be a correlatiomuscle goups between higher SMR length and bigger impact size, the exact link between SMR duration and effect size is uncertain. The time was 30 seconds each muscle group was chosen since it is more realistic than the 60 seconds utilized by MacDonald et al., and it was also used by Peacock et al. Similar to the Grid roller, a commercially available foam roller had net diameter of 12.7 cm and a 5-mm thick empty core of plastic coated with a 12-mm layer of dense foam. In this study, participants were instructed to do the motions in sequenced and save manner, covering the complete muscular area, applying consistent pressure that was felt comfortable. For a total of 16 minutes, the therapy lasted 8 minutes on one leg and 16 minutes on both legs
41329916|NCT05834101|OTHER|Dynamic streching|The regimen included ten dynamic workouts lasting 10 minutes and varying in intensity from medium to high. At a distance of 13 meters, each Dynamic stretching exercise was completed. Before each workout, the subjects were given a 10-second rest time. During the exercises, the participants were given verbal comments on their posture, and video recordings of the activities were displayed to them. Dynamic stretching included High knee walk, Straight-leg march, Hand walk, Lunge walks, Backward lunge, High-knee skip, Lateral shuffle, Back pedal, Heel-ups, and High-knee run
40811989|NCT04426149|DIETARY_SUPPLEMENT|trehalose|patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily
41329917|NCT06124092|OTHER|neurocognitive tests|Cohort study: all parents and participants will have questionnaires to complete, based on participant's age.
40811990|NCT05894980|DEVICE|active tDCS stimulating left DLPFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
40811991|NCT05894980|DEVICE|active tDCS stimulating right OFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
40811992|NCT05894980|DEVICE|sham tDCS|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
40811993|NCT02855957|OTHER|Free α-Hb pool analysis|
40811994|NCT00257582|DRUG|Cetirizine Dry Syrup|
40811995|NCT01377610|DRUG|oral naltrexone|Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
40811996|NCT01377610|DRUG|Buprenorphine|Following detoxification with buprenorphine \[8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)\] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
40811997|NCT01377610|DRUG|Vivitrol|dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
41481707|NCT04038086|OTHER|circadian rhythm|Blood and CSF will be collected five times throughout the day.
40811998|NCT00528502|DRUG|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
40811999|NCT00528502|DRUG|Saline|Saline is misted into the air that you breathe during the surgery.
40812000|NCT03968029|PROCEDURE|suturing meniscal augmented|meniscal tear sutured + bone marrow injection/collagen membrane
40812001|NCT03968029|PROCEDURE|suturing meniscal|meniscal tear sutured
40812002|NCT01956097|DIETARY_SUPPLEMENT|HX106 590mg|
40812003|NCT01956097|DIETARY_SUPPLEMENT|HX106 1180mg|
40812004|NCT01956097|DIETARY_SUPPLEMENT|Placebo|
41481708|NCT04038086|DRUG|effect of insulin on peptide transport|Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
41481709|NCT04774341|DRUG|anticoagulation treatment|Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
40812005|NCT02024360|BEHAVIORAL|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
41481710|NCT00653484|BEHAVIORAL|Physical Activity|
41481711|NCT00653484|BEHAVIORAL|Energy Restriction|
40812006|NCT06394544|DIETARY_SUPPLEMENT|Brazil Nut|The intervention, for each participant, is estimated to last a total period of six months , which will be divided into three two-month stages, with data collection after each stage. Volunteers will be monitored to control possible side effects, doubts and check compliance. In addition, the telephone number and an email will be made available for contact during business hours, for possible clarifications.
40812007|NCT04955223|DRUG|Yinhu Qingwen Granules|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
40812008|NCT01406938|DRUG|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
40812009|NCT01406938|DRUG|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
40812010|NCT02390440|DRUG|EXPAREL|
40812011|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
40812012|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
40812013|NCT04570605|DEVICE|parasacral transcutaneous electrical nerve stimulation (PTENS)|electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.
41481712|NCT00653484|BEHAVIORAL|Physical Activity and Energy Restriction|
40812014|NCT04570605|OTHER|Standard Urotherapy|standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
40812015|NCT02305017|DRUG|BIA 9-1067|BIA 9-1067 50 mg
41481713|NCT05535439|PROCEDURE|EBUS-TBNA using 22 G EBUS-FNB Device OR 19 G EBUS-FNA needle|Both arm will be interventional where mediastinal lymph nodes will be sampled by two typs of needle
40812016|NCT02305017|DRUG|Paracetamol|Paracetamol 1g
40812017|NCT06428916|PROCEDURE|tucking position during endotracheal suctioning|, the staff nurse will perform the endotracheal suctioning while the researcher will carried out the intervention
40812018|NCT02135328|BEHAVIORAL|Radio Story|"For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management."
41329918|NCT05751694|PROCEDURE|Visceral manual treatment|The patient will be placed in a reclining sitting position and triple flexion of the lower limbs to keep the abdominal region relaxed. The therapist will be placed to the right of the patient at the height of the abdomen, with the hands placed in the epigastric area. He will make a skin fold that reduces tension in the area, so that the contact is focused on the visceral tissue of the area. The patient will be asked to take deep breaths, and during the exhalation, the therapist will perform a zigzag movement with vibration of the hands while pulling the tissue caudally. This procedure will be performed for 5 minutes.
41329919|NCT05751694|PROCEDURE|Respiratory listening|The patient and the therapist will be placed in the same position as in the experimental group. The therapist will place his hands in contact with the lower rib cage, and the patient will be asked to take a deep breath. The therapist will not exert any pressure, nor place restrictions on the tissues or movements of the ribcage.
40812019|NCT02135328|BEHAVIORAL|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
40812020|NCT00331994|DRUG|Bacillus clausii|3 bacillus clausii vials/day for one month
41329920|NCT00023712|DRUG|bortezomib|Given IV
41329921|NCT00023712|OTHER|laboratory biomarker analysis|Correlative studies
41329922|NCT00023712|OTHER|pharmacological study|Correlative studies
41481714|NCT03947736|DIAGNOSTIC_TEST|cfDNA was detected by dPCR|Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.
41481715|NCT01227655|DRUG|BIA 9-1067|Capsules will be used.
40812021|NCT00331994|DRUG|Metronidazole|3 Metronidazole tablets/day for one week
40812022|NCT02777047|OTHER|Anticoagulation Coordinated Care|see above
40812023|NCT00613002|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
41329923|NCT00436020|DEVICE|TMS|Transcranial Magnetic Stimulation
41329924|NCT00436020|DEVICE|Sham TMS|Sham Transcranial Magnetic Stimulation
41329925|NCT03130569|BEHAVIORAL|Web-based Module Group|
41329926|NCT02174016|DIETARY_SUPPLEMENT|Ketogenic diet|
41329927|NCT05589129|DIETARY_SUPPLEMENT|Whey Protein Supplement|Participants assigned to the intervention will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
41481716|NCT01227655|DRUG|Placebo|comparator
41481717|NCT01227655|DRUG|Levodopa|
41481718|NCT01227655|DRUG|Carbidopa|DOPA decarboxylase inhibitor (DDCI)
41481719|NCT01227655|DRUG|Benserazide|DOPA decarboxylase inhibitor
41481720|NCT05417360|DIETARY_SUPPLEMENT|Akkermansia muciniphila|"During the weight management period (weeks 8 to 32), the pasteurized A. muciniphila product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks) capsules. It appears as a white homogenous powder.~."
41481721|NCT05417360|DIETARY_SUPPLEMENT|Placebo|During the weight management period (weeks 8 to 32), the placebo product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks). It appears as a white homogenous powder.
40812024|NCT00613002|DRUG|placebo gel|once daily transdermal placebo gel
40812025|NCT01813058|DRUG|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~1. placebo i.e. saline 0.9% (intravenous injection)~2. intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
40812026|NCT01813058|DRUG|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~1. Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~2. TXA as previously described."
40812027|NCT02921217|DIETARY_SUPPLEMENT|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
40812028|NCT02921217|DIETARY_SUPPLEMENT|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
40812029|NCT02921217|DIETARY_SUPPLEMENT|Control|Placebo: 300 mg maltodextrin.
40812030|NCT05127824|BIOLOGICAL|Autologous alpha-DC1/TBVA vaccine|"Dendritic cells (DC) are derived from autologous (the subject's own) mononuclear cells in the peripheral blood obtained from the PRBC. In this case, biologic product and biologic substance are the same. The vaccine will be manufactured in the HCC-IMPCL, under cGMP conditions."
40812031|NCT05127824|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
41481722|NCT02556372|DRUG|JKB-122|Orally administered capsules of JKB-122 which will be taken once daily with dose escalation from 5mg up to 40mg depending on the monthly response.
40812032|NCT00397852|PROCEDURE|Kirschner-wires or not|
41012061|NCT02843282|BEHAVIORAL|Advanced Reasoning Training|This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
41329928|NCT05589129|DIETARY_SUPPLEMENT|Carbohydrate Placebo Control|Participants assigned to the placebo control will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
41329929|NCT02945306|PROCEDURE|Adenotonsillectomy|
41329930|NCT02945306|DRUG|Watchful waiting with supportive care|Use of widely prescribed medicines to treat associated conditions
41329931|NCT04866095|DEVICE|Transthoracic echocardiogram|Transthoracic echocardiogram (TTE) is a widely used and validated imaging technique which involves the study of the heart and great vessels through multiple examination windows. In particular, the subcostal window represents the gold standard for evaluating the diameter of the inferior vena cava (IVC) and its compliance, allowing the physician to obtain valuable information on the volume status of patients. Acquiring images in the subcostal window with a transthoracic echocardiogram (TTE) can be, in some cases, difficult or impossible due to the presence of drainages or surgical wounds: in such cases an alternative could be represented by the trans-hepatic window. This has not been validated in the scientific litterature.
41329932|NCT04866095|DEVICE|Clear Sight system|"The Clear Sight System is a non-invasive blood pressure (BP) monitoring system, where the CO is determined analysing the photo-plethysmography curve by a miniaturized pressure cuff and infrared LEDs.~Its main advantage is to assess CO continuously in a completely non-invasive way, following its variations and thereby contributing to the detection of hypovolaemia. Other visualized parameters are: the stroke volume (SV), the systemic vascular resistance (SVR) as well as the BP and the heart rate (HR)."
41329933|NCT03465046|COMBINATION_PRODUCT|intensive therapies(CIMT/BIT): protocol 1 or protocol 2|"The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family"
41329934|NCT04239170|DRUG|Camrelizumab(SHR-1210)|Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin
41329935|NCT03010722|DRUG|Regorafenib|"Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets."
41329936|NCT04606641|OTHER|functional tasks with mirror therapy|In this group a mirror will be placed in the sagittal plane of patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror. Then the patient will be asked to perform functional tasks
41329937|NCT04606641|OTHER|functional tasks without mirror therapy|The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks
41329938|NCT06000436|OTHER|Cardiovascular disease risk assessment|"Cardiovascular disease risk assessment~Training and Consultancy Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. By using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the working hours of the participants.~Mobile Application To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Monitoring Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application."
41329939|NCT06000436|OTHER|Training and Consultancy|Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. Using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the participants' working hours.
41329940|NCT06000436|OTHER|Mobile Application|"To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Text Messages Week 2 Tobacco use causes 6 million deaths in the world. The risk of death is reduced by 90% in those who stop using tobacco. Alcohol use causes damage to the heart muscle, arrhythmia, and stroke. For a healthy life, you should stay away from smoking and alcohol. ' Week 4 '' Inadequate physical activity increases the risk of death from all causes. Physical activity reduces the risk of hypertension, stroke, and depression. 30 minutes of moderate-intensity physical activity daily is recommended.~Week 6 Adequate consumption of vegetables and fruits reduces the risk of cardiovascular disease. Saturated and trans fats increase the risk of cardiovascular disease. It is recommended to consume \<5 g less per day to prevent cardiovascular diseases."
41329941|NCT06000436|OTHER|Monitoring|Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.
41329942|NCT01652937|DRUG|BIIB057|Oral
41329943|NCT01652937|DRUG|Placebo|Oral
41329944|NCT05566288|DRUG|Cytisinicline|compressed film-coated tablet containing 3 mg cytisinicline
41329945|NCT05566288|DRUG|Placebo|Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline
41329946|NCT05566288|DRUG|Moxifloxacin|400 mg tablets
41329947|NCT00103571|DRUG|Olanzapine|
41329948|NCT00103571|DRUG|Aripiprazole|
41329949|NCT03807076|OTHER|GIP-A|GIP-A
41481723|NCT04277871|BEHAVIORAL|Pelvic floor muscles training (PFMT) combined with yoga|All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
41481724|NCT02823483|OTHER|Sunscreen Lotion (BAY987521)|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.
41481725|NCT02823483|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
40812033|NCT02744495|DRUG|Betamethasone|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
40812034|NCT02744495|DRUG|Droperidol|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
40812035|NCT03130621|DIAGNOSTIC_TEST|Gene detection|Next-generation sequencing
40812036|NCT06495060|OTHER|No intervention (Only observation)|No intervention
40812037|NCT04491682|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
41329950|NCT03807076|OTHER|Placebo|Placebo
41329951|NCT05628155|OTHER|Oral diet including n-3 PUFA intake|menus to cover the recommended intake of n-3 PUFAs (ALA =1% of total energy intake, i.e. 2.1 g/d, and EPA+DHA = 500 mg/d) (n-3 PUFA MENU), based on mass-market products that guarantee the n-3 PUFA RDAs and are available from the catering sector
41329952|NCT01779596|DRUG|Bosentan|
41329953|NCT01779596|DRUG|Placebo|
41329954|NCT01624688|PROCEDURE|Tattoo Removal|Tattoo removal with q-switched laser treatment, repeated q-switched laser treatment, repeated q-switched laser treatment with fractional ablative laser treatment, and repeated q-switched laser treatment with fractional ablative laser treatment and then topical urea
41329955|NCT03638115|DEVICE|VaSecure™|Drug Coated PTA Balloon Catheter
41329956|NCT04914767|DRUG|Nigella|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
41329957|NCT04914767|DRUG|Placebo|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
41329958|NCT00282867|DRUG|IV glucose insulin and potassium, GIK|The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
41481726|NCT03091660|BIOLOGICAL|BCG Solution|Given intravesically
41481727|NCT03091660|BIOLOGICAL|BCG Tokyo-172 Strain Solution|Given intravesically
41481728|NCT03091660|BIOLOGICAL|BCG Tokyo-172 Strain Vaccine|Given ID
40812038|NCT04491682|DRUG|Rosuvastatin|At a dosage of 10 mg/day
41329959|NCT00282867|OTHER|standard care|usual care
41329960|NCT01624610|OTHER|Dietary intervention|After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
41329961|NCT04681729|DRUG|Dupilumab SAR231893|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
41329962|NCT04681729|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
41329963|NCT04681729|DRUG|Non sedating H1-antihistamine|Pharmaceutical form: Tablet Route of administration: Oral
41329964|NCT01455415|DRUG|pregabalin|150 - 300 mg/day in divided dose (3 time a day) for 6 weeks
41329965|NCT01455415|DRUG|placebo|matching placebo 3 time a day
41329966|NCT00168909|DRUG|alfacalcidol|alfacalcidol 1 µg once daily, oral, for 3 years
41329967|NCT00168909|DRUG|placebo|placebo once daily, oral, for 3 years
40812039|NCT04788004|OTHER|Online survey|There are no interventions planned for this study. This is an observational study only.
40812040|NCT04873141|DRUG|Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)|Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).
40812041|NCT04104191|DEVICE|L-1000AF System|The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
40812042|NCT00857831|DIETARY_SUPPLEMENT|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
40812043|NCT02014506|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -2
40812044|NCT02014506|DRUG|Cyclophosphamide|50 mg/kg IV on day -3 and -2
40812045|NCT02014506|BIOLOGICAL|anti-thymocyte globulin|
41012062|NCT04425499|OTHER|Learning running subcuticular sutures on the Gamified Educational Network|Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
41012063|NCT02877550|DRUG|Obinutuzumab|Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6
41329968|NCT03448042|DRUG|Runimotamab|Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
41329969|NCT03448042|DRUG|Trastuzumab|Trastuzumab will be administered via IV infusion
41329970|NCT03448042|DRUG|Tocilizumab|Participants will receive IV tocilizumab if needed
41329971|NCT01012349|DRUG|Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)|1 tablet in an episody of headache
41329972|NCT01012349|DRUG|Aspirin - Bayer|1 tablet in an episody of headache (Aspirin 500mg)
41329973|NCT03256071|DRUG|Decitabine plus Modified BUCY|"Decitabine:20 mg/m²/day on day -14 to -10;~Modified BUCY:~1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
41481729|NCT03091660|OTHER|Laboratory Biomarker Analysis|Correlative studies
41329974|NCT03256071|DRUG|Modified BUCY|"1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
41329975|NCT03419910|DRUG|BMS-986165|Specified dose on specified days
41155750|NCT03326193|DRUG|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (\>=) 77 kg and Baseline platelet count of \>=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (\<) 77 kg and/or Baseline platelet count of \<150,000/μL will take 200 mg (2X100 mg) at each dose administration.
41329976|NCT03419910|DRUG|Cyclosporine|Specified dose on specified days
41329977|NCT04833868|OTHER|hippotherapy and schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week hippotherapy intervention combined with Schroth exercise
41329978|NCT04833868|OTHER|schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week of Schroth exercise
41329979|NCT02030587|PROCEDURE|Radiofrequency Ablation|
41329980|NCT02030587|PROCEDURE|Laparoscopic Adrenalectomy|
41329981|NCT00087048|DRUG|topotecan hydrochloride|
41329982|NCT00002718|BIOLOGICAL|anti-thymocyte globulin|
41329983|NCT00002718|BIOLOGICAL|filgrastim|
41329984|NCT00002718|DRUG|cyclophosphamide|
41329985|NCT00002718|DRUG|cytarabine|
41329986|NCT00002718|DRUG|methylprednisolone|
41329987|NCT00002718|DRUG|thiotepa|
41329988|NCT00002718|PROCEDURE|in vitro-treated bone marrow transplantation|
40812046|NCT02014506|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
40812047|NCT02014506|RADIATION|Total body irradiation|200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 \& -4 (severe aplastic anemia)
41329989|NCT00002718|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
41329990|NCT00002718|RADIATION|radiation therapy|
41329991|NCT04869670|PROCEDURE|Gastric peroral endoscopic myotomy.|Under propofol anesthesia, EndoFLIP will be used to assess pyloric diameter and distensibility, prior to and after G-POEM, performed by an endoscopist skilled in this technique. After the procedure, the patient will be observed in the hospital for 2 days. Patients will undergo an upper GI series the next day to rule out perforation. If the patient develops a complication from the procedure, he or she will be managed per standard clinical practice by the treating (unblinded) endoscopist.
41329992|NCT04869670|PROCEDURE|Sham Gastric peroral endoscopic myotomy.|Patients assigned to the sham procedure will be treated identically as above, except for the performance of the G-POEM. Endoscopy and EndoFLIP will be performed and sedation will be stopped when the upper endoscopy is completed. Since sham endoscopy is expected to take less time than G-POEM, the patient should remain in the endoscopy procedure room for a minimum of 30 minutes (including the time required to complete the upper endoscopy). After the procedure, the patient will be observed in the hospital for 2 days. All patients will undergo an upper GI series radiographic examination the next day to rule out perforation in order to maintain study blind.
41329993|NCT02590419|DEVICE|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
41329994|NCT04994080|DRUG|Paricalcitol|Paricalcitol QD Treatment
41329995|NCT04994080|DRUG|Placebo|Placebo QD or TIW
41329996|NCT02901340|DIETARY_SUPPLEMENT|one to two liters of water daily|
41329997|NCT04884672|DEVICE|SMILE|Small incision lenticule extraction, a refractive surgery procedure for the corrcetion of myopia with or without astigmatism
41329998|NCT04488081|DRUG|Remdesivir|Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
40812048|NCT02014506|PROCEDURE|TCRαβ-depleted hematopoietic cell transplantation|
40812049|NCT02014506|DEVICE|CliniMACS|Immunogenetic depletion of TCRαβ cells
40812050|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS plus GOS|
40812051|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS|
40812052|NCT01031316|OTHER|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
40812053|NCT01031316|OTHER|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
40812054|NCT01922947|BEHAVIORAL|Motivational Interviewing w/Social Network Counseling|This is the active arm of the study.
40812055|NCT01922947|BEHAVIORAL|Active Control Condition|20-minute health counseling
40812056|NCT00904046|DRUG|Pioglitazone|30 mg orally daily for 6 months
40812057|NCT00904046|DRUG|Placebo|Placebo taken orally once a day for 6 months.
40812058|NCT01601756|DEVICE|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
40812059|NCT01601756|DEVICE|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
40812060|NCT01454609|DRUG|0.9% Normal saline|Saline
40812061|NCT01454609|DRUG|Bupivacaine|Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
41329999|NCT04488081|DRUG|Imatinib Mesylate|Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
41330000|NCT04488081|DRUG|Dexamethasone|6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
41330001|NCT04488081|DRUG|Cenicriviroc|Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
41330002|NCT04488081|DRUG|Icatibant|Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
41330003|NCT04488081|DRUG|Apremilast|oral, 30 mg bid × 14 days.
41330004|NCT04488081|BIOLOGICAL|dornase alfa|"For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first."
41330005|NCT04488081|DRUG|Celecoxib|Oral: 400 mg BID for 7 days.
41330006|NCT04488081|DRUG|Famotidine|Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
41330007|NCT04488081|BIOLOGICAL|IC14|intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
41330008|NCT04488081|DRUG|Aviptadil|Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
41330009|NCT04488081|BIOLOGICAL|narsoplimab|Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
41330010|NCT04488081|DRUG|Cyproheptadine|4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.
41330011|NCT04488081|DRUG|Cyclosporine|Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
40812062|NCT01454609|DEVICE|Bupivacaine with clonidine (combination)|"Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours~Clonidine - 0.5 - 1 microgram/ kg"
40812063|NCT00253513|DRUG|fludarabine|30 mg/m2, IV for 5 days
40812064|NCT00253513|DRUG|treosulfan|12 or 14 g/m2, IV for 5 days
40812065|NCT00253513|PROCEDURE|allogeneic blood or bone marrow transplantation|bone marrow or peripheral blood stem cells
40812066|NCT01252186|DRUG|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
40812067|NCT01252186|DRUG|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
41330012|NCT02572011|OTHER|Home-based Games Console Balance Training|The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
41330013|NCT04787211|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
41330014|NCT04787211|DRUG|Placebo|Placebo given by intravenous administration
41330015|NCT05187585|DIAGNOSTIC_TEST|radiograph interpretation without the support of the RAYVOLVE app|"Phase 1 does not involve any intervention: residents, emergency physicians, and radiologists will interpret the x-rays without the support of the RAYVOLVE application.~The emergency physician interprets the x-ray and manage the case as per protocol, all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated."
40812068|NCT01252186|DRUG|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
40812069|NCT02557451|OTHER|Surgery|
40812070|NCT02557451|OTHER|Intravitreal injections of gas|
40812071|NCT02557451|PROCEDURE|injections of an antiangiogenic|
40812072|NCT02680041|DRUG|18F-fluciclovine PET CT|Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
40812073|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (reproducibility)|The experienced examiner performed tests on 20 healthy subjects
40812074|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (availability)|Two examiners performed the test on one healthy subject with both devices for ten consecutive days.
41330016|NCT05187585|DIAGNOSTIC_TEST|radiograph interpretation with the support of the RAYVOLVE app|The residents interpret the X-ray with the RAYVOLVE application's support and indicate the presence or not of a fracture without sharing it with the senior emergency physician. A senior emergency physician manages the case as usual, and all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated
41330017|NCT01781871|BIOLOGICAL|Prevenar13|Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
41330018|NCT01781871|BIOLOGICAL|Pneumovax|0.5ml Pneumovax injected intramuscularly at day 1.
41330019|NCT04952051|DRUG|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
41330020|NCT04952051|DRUG|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
41330021|NCT04078529|OTHER|5 day falls prevention training|Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.
41330022|NCT04078529|OTHER|Home exercise programme|A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
41330023|NCT04078529|OTHER|Environmental Assessment|Use of the Homefast assessment tool to reduce risk of falls at home.
41330024|NCT04313088|DRUG|Eluxadoline 100 mg|Eluxadoline 100mg by mouth twice daily with food
41330025|NCT01779648|DEVICE|DVT-3000|
41330026|NCT01779648|DEVICE|SCD Express|
41330027|NCT01699412|DRUG|Clobetasol|Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
41330028|NCT01699412|DRUG|Dexamethasone|Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
41330029|NCT02299804|DRUG|Levophencynonate Hydrochloric|this drug is M receptor inhibitor
41330030|NCT02299804|DRUG|Placebo|No active ingredient
41330031|NCT02293941|DRUG|JKB-122 5mg|Participants were randomized to receive JKB-122 5mg for 12 weeks
41330032|NCT02293941|DRUG|JKB-122 15mg|Participants were randomized to receive JKB-122 15mg for 12 weeks
41330033|NCT02293941|DRUG|JKB-122 35mg|Participants were randomized to receive JKB-122 35mg for 12 weeks
41330034|NCT02293941|DRUG|Placebo|Participants were randomized to receive comparable placebo for 12 weeks
40812075|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (Accuracy)|200 ACL rupture and 200 healthy subjects were recruited as contrast to compare the accuracy of the devices in diagnosing ACL rupture.
41330035|NCT05862948|DEVICE|ENDO-Aid by Olympus|Colonoscopy assisted by ENDO-AID device
41330036|NCT01311895|DRUG|H2O|2 mg IV hydromorphone
41330037|NCT01311895|DRUG|1+1|"1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
40812076|NCT06341296|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle, 8 cycles.
40812077|NCT06341296|DRUG|5-FU|5-FU 400mg/m\^2, then 2400mg/m\^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.
40812078|NCT06341296|DRUG|LV|400mg/m\^2, d1, 14 days per cycle, 8 cycles.
41330038|NCT03819270|DRUG|LY3372689|Administered orally
41330039|NCT03819270|DRUG|Placebo|Administered orally
41330040|NCT03848676|DIAGNOSTIC_TEST|Evaluation of patients resistance to immunotherapies in Multiple Myeloma|There are only collections of the samples.
41330041|NCT02661464|BIOLOGICAL|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
41330042|NCT02661464|BIOLOGICAL|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
41330043|NCT06282536|DRUG|Iruplinalkib|60 mg on days 1-7, if tolerable, 180 mg from day 8 onwards.
41330044|NCT06282536|PROCEDURE|surgery|Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
41330045|NCT05652972|OTHER|Ketogenic diet|1700 kcal ketogenic diet (fat: protein: carbohydrate ratio of 70:20:10)
41330046|NCT05652972|OTHER|Control diet|1700 kcal standard diet (fat: protein: carbohydrate ratio of 20:30:50)
41330047|NCT01699646|DEVICE|Neoventa S 21 ST-ANalysis of fetal heart|"Application of gold-trace scalp electrode"
41330048|NCT01699646|PROCEDURE|CTG + FBS|Cardiotocography and fetal blood sampling on/from fetal skalp
40812079|NCT06341296|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle, 8 cycles.
41330049|NCT04392869|BEHAVIORAL|The CRAFT program (adapted due to COVID-19)|"The CRAFT program was created by P. Posadas, PhD (Posadas 2017). This program aims to cultivate positive emotions toward oneself and others, engaging socio-emotional processes and activating traits such as empathy, motivation and creativity. It has been previously implemented in other Higher Education Institutions (Rull et al 2019, Posadas 2018, 2019).~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: Consciousness, Relaxation-Breathing-Regulation, Mindfulness/Full Attention, Bliss, Transcendence, Communication as Connection, Mindfully, Consciously and Blissfully Living our Daily Lives, My Work of Art My Wonderful Craft Work Here and Now, Time and Energy Management, Passion and Compassion in the COVID context."
41330050|NCT04392869|BEHAVIORAL|The MBSR program (adapted due to COVID-19)|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA.~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: The Underpinnings of MBSR, The Perception of Reality, Emotion Regulation, Understanding Stress: The Mind-Body Relation, Responding to Stress, Communication and Personal Relations, Daily Life Management, My Personal Plan: The First Week of the Rest of my Life, Time and Energy Management, Emotion Regulation in the COVID context."
41330051|NCT02178306|DRUG|Telmisartan low dose|
41330052|NCT02178306|DRUG|Telmisartan high dose|patients switch to high dose if mean SBP \>= 85 mmHg after 4 weeks of treatment
41330053|NCT02178306|DRUG|Placebo|Run-in phase
41012064|NCT02877550|DRUG|Venetoclax|p.o. once daily according to dose level (DL) or MTD
41330054|NCT05622357|RADIATION|short course radiation therapy followed by 6 cycles of CAPOX then surgery|Short course RT 5 x5 Gy followed by 6 cycles CAPOX then surgery
41330055|NCT00716326|DEVICE|Transcutaneous Nerve Stimulation (TENS)|Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises. The TENS will be used during 3-4 weeks of hospitalization. If patients want to continue the use of TENS/placebo-TENS at home, they will be offered to borrow equipment for 4 months.
41330056|NCT00716326|DEVICE|Cefar Primo Pro TENS device|"Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.~Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold."
41330057|NCT00912340|DRUG|Everolimus|
41330058|NCT00912340|BIOLOGICAL|Trastuzumab|
41330059|NCT04429321|DRUG|Nivolumab|Nivolumab 3 mg/kg IV every four weeks, first in combination with capecitabine then alone
40812080|NCT03392831|OTHER|Peripherally inserted central catheter (PICC)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center
40812081|NCT03392831|OTHER|Central venous catheter|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
41012065|NCT06242808|BEHAVIORAL|Medically tailored groceries and food resource coaching|Patients will meet with a food resource coach who will explain basic coaching principles including how to respond to financial crises, how to access various food resources, and the importance of consistent utilization of food resources. After the coaching session, the food resource coach will help patients select medically tailored groceries from the free community food market inventory.
41012066|NCT06242808|OTHER|Free community food support|Usual services include selecting up to 21 meals for each person in the household from Crossroads nutritious market once per month (e.g., approximately 100 pounds \[$250 United States dollars\] of food for a family of four)
41012067|NCT04376034|BIOLOGICAL|Convalescent Plasma 1 Unit|"Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma."
41330060|NCT04429321|DRUG|Ipilimumab|ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, in combination with Nivolumab
41330061|NCT04429321|DEVICE|bland embolization|Lipiodol:ethanol embolization of their primary or target tumor
41330062|NCT05572788|PROCEDURE|EUS-guided fine needle aspiration of pancreatic cysts|Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
41330063|NCT03525457|PROCEDURE|Non Surgical Periodontal Therapy|Non Surgical Periodontal Therapy in 2 to 3 sessions
41330064|NCT03203954|BEHAVIORAL|Standard Learning|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
41330065|NCT03203954|BEHAVIORAL|Guided Learning: Instructed statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
41330066|NCT03203954|BEHAVIORAL|Guided Learning: Changing statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
41330067|NCT00082043|DRUG|Dutasteride|
41330068|NCT00082043|DRUG|Placebo oral capsule|
41330069|NCT06580860|DRUG|Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids|Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
41330070|NCT01541111|DRUG|Magnesiun|75mg pills; each 12h; 12wk
41012068|NCT04376034|BIOLOGICAL|Convalescent Plasma 2 Units|"Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma."
41012069|NCT04376034|OTHER|Standard of Care|Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
41330071|NCT04902898|DEVICE|Circumcision in adults using sterile single-use circular stapling device|Circumcision in adults using sterile single-use circular stapling device CIRCCURER II (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
41012070|NCT00548860|DRUG|Ferric Carboxymaltose|
41330072|NCT04902898|PROCEDURE|Circumcision in adults|Circumcision in adults
41330073|NCT01754597|DRUG|Peptide Natriurétique de type B|Peptide Natriurétique de type B
41330074|NCT03636113|DEVICE|Clarity RMS Electronic Sensor|The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
41330075|NCT03655392|BEHAVIORAL|Individualized educational program|IG patients were submitted to three 30-minutes intervention of a individualized shortterm educational program delivered by a nurse, were given explanations about general aspects of the disease, prevention methods and about the importance and correct use of inhaled corticosteroids, with an educational video showing the use of the device
41330076|NCT03655392|DIAGNOSTIC_TEST|Induced sputum collection|All participants performed induced sputum collection
41330077|NCT03655392|DIAGNOSTIC_TEST|Spirometry|All participants performed spirometry test using a Koko spirometer. Pulmonary function was assessed by spirometry prebronchodilator, after withholding short-acting beta-agonists for ≥ 6 hours and long-acting beta-agonist for ≥ 24hours. Forced expiratory volume in one second (FEV1) % predicted was used as a proxy variable for overall lung function.
41330078|NCT03655392|DIAGNOSTIC_TEST|Nitric oxide measure|All participants performed nitric oxide measure in three Mylar bags and measure was performed in a NOA280 Sievers equipment. For collection the patients blew in the balloons through a sterile nozzle in the equipment collector without prejudice or damage to the patient.
41481730|NCT02121561|BEHAVIORAL|Self-Acceptance Group Therapy|SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
41481731|NCT02865395|DRUG|Belladonna and Opium Suppository|
41481732|NCT02865395|PROCEDURE|Rectal Exam|
41012071|NCT00548860|DRUG|Standard Medical Care (SMC)|
41012072|NCT02030678|DRUG|irinotecan|Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
41012073|NCT04805983|DRUG|BMS-984923|Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
41330079|NCT03655392|OTHER|Questionnaires ACT, ACQ, AQLQ, BDI|All participants answered standardized questionnaires about asthma symptoms and depression: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI)
41330080|NCT03655392|OTHER|Symptoms Diary|All participants were instructed to note in the morning and evening before the use of routine inhaled corticosteroids, asthma symptoms (coughing, wheezing, shortness of breath, use of emergency inhaled corticosteroids) and three measures of peak expiratory flow (individual, provided to patients) and to return this completed diary at each study visit
41330081|NCT03655392|DIAGNOSTIC_TEST|Peak flow measure|All participants registered three peak flow measures in the symptoms diary by morning and night before the use of routine inhaled corticosteroids. Peak flow was measured by the electronic peak flow meter (Mini-Wright).
41330082|NCT03655392|DIAGNOSTIC_TEST|Exhaled breath condensate air measurement|Exhaled breath condensate was collect during 15 to 20 minutes in a Turbo DECCS equipment (Medivac SRL, Italy) in a sterile buccal of the own apparatus with the aid of a nasal clip with the participant breathing normally without any effort or damage.
41330083|NCT02648243|BEHAVIORAL|Structured intervention at discharge and tailored follow up post discharge|"At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.~The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge."
41330084|NCT03714347|DEVICE|cerebral oxygen monitoring|probes will be placed on eyebrows on forehead
41330085|NCT03714347|DEVICE|routine monitoring|We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
41330086|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 500 ug
41330087|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1000 ug
41330088|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1500 ug
41330089|NCT01883804|DRUG|Methyldopa|6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
41330090|NCT00807014|DRUG|Duac Gel|Duac® Gel will be applied to the face once daily at night, for 12 weeks.
41330091|NCT00807014|DRUG|Differin gel|Differin Gel will be applied to the face once daily at night, for 12 weeks.
41330092|NCT04447534|DRUG|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine
41330093|NCT04447534|DRUG|zinc|Zinc tablets
41330094|NCT06380764|PROCEDURE|Greater Occipital Nerve Block|"The occipital artery was localized, while the patient was setting with flexed neck, at the point of meeting of the medial third and the lateral two-thirds of a line drawn extending from the ipsilateral mastoid process to the external occipital protuberance and the GON was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline.~For assurance of GON localization, pressure was applied and the resultant tenderness indicated the site of the nerve. Injection procedure was performed as distal injection at the site of nerve localization and proximal injection was performed at 1.5 cm lateral to the sagittal plane and 3 cm below to the level of the external occipital protuberance."
41330095|NCT06380764|PROCEDURE|Bilateral suboccipital intramuscular injection|Sub-occipital intramuscular injection of the prepared solution was carried out on both sides while the patient was setting with maximally flexing the neck to expose these muscles.
40812082|NCT04666103|PROCEDURE|Intraoperative thermal ablation|"After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
40812083|NCT02192060|OTHER|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
41012074|NCT00958880|BEHAVIORAL|Group Cognitive Behavioral Therapy|"5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy."
41012075|NCT00958880|DRUG|Yohimbine Hydrochloride|Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
41330096|NCT06380764|PROCEDURE|Epidural Blood Patch|Patients showed manifestations of block failure within 24-h after block, received lumbar Epidural blood patch under non-invasive monitoring in the theater. Patient was positioned in the lateral decubitus position, lumbar area was sterilized and the epidural space previously used for receiving the previous neuraxial anesthesia was identified. Fifteen ml of venous blood was obtained aseptically and slowly injected while patient was monitored for the extent of pain severity until complete pain relief.
41330097|NCT06380764|DRUG|Normal Saline 10 mL Injection|Placebo drug
41330098|NCT06380764|DRUG|Lidocaine 2% Injectable Solution|Lidocaine is the main drug used in the interventions as it was injected to achieve bilateral block or intramuscular infiltration
40812084|NCT02192060|OTHER|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
40812085|NCT05586503|DIAGNOSTIC_TEST|ECG-gated CTAs|ECG-gated CTAs will be performed instead of static CTAs comparing to standard of care
40812086|NCT03585036|DRUG|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
40812087|NCT03585036|DRUG|Tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
41481733|NCT02378441|DRUG|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
41481734|NCT02378441|DRUG|CJ-30056 20/750mg|fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
41481735|NCT01453413|OTHER|Blood Glucose meter|Staff tested subject Blood Glucose using a Blood Glucose meter.
41330099|NCT04066946|DEVICE|Microcurrent therapy|Micro current therapy is a therapy to treat humans / animals using electric current with amperages flowing in the μA range. The device offers 2 treatment methods: manual treatment, which requires manual input corresponding to the mentioned parameters, and automatic treatment which, depending on the clinical picture and the currently measured resistance between the electrodes, allows the device to automatically change the mentioned parameters. For this study the investigators use an automatic treatment with predefined settings. This automatic programme consists of a variation of 20 different frequency settings during 17 minutes. This programme is repeated one time which leads to a total treatment time of 34 minutes. The intensity setting for the treatment is between 200 and 350 µA. The treatment is applied 5x per week in the first 6 weeks. The treatment is stopped after six weeks.
41330100|NCT04066946|OTHER|Standard of care|"Standard of Care consists of:~During the first two weeks:~* Histoacryl glue to close the surgical incisions.~* Suture strips to keep the wound closed.~* Isobetadine Dermicum as anti-septic treatment~* Dry wound dressings during the first 2 weeks.~* Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet."
41330101|NCT03406364|DRUG|MG005|"Phase I:~Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy."
41330102|NCT02409056|BEHAVIORAL|Workplace-tailored CDSMP|This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
41330103|NCT02409056|BEHAVIORAL|Chronic Disease Self-Management Program|This is the standard CDSMP which has been implemented in community settings.
41330104|NCT05565014|DRUG|Virus Activated Killer immune Cells|The VAK made from Pleural Effusion should be given to treat Malignant Pleural Effusion.The VAK made from Peritoneal Effusion should be given to treat Malignant Peritoneal Effusion.
41330105|NCT05565014|DRUG|Saline|The use of saline was the same as VAK group.
41330106|NCT05438251|DRUG|Fespixon Cream|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (approximately 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 12 weeks"
41012076|NCT00958880|DRUG|Sugar Pill|Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
41012077|NCT04209088|OTHER|Pulmonary ultrasounds|"Two ultrasounds will be performed by the same pediatrician for each child included: the first at nine days of life +/- two days, the second at fifteen days of life +/- two days.~A blind replay of ultrasound images to calculate the score will be performed by a another investigator."
41012078|NCT00896545|BEHAVIORAL|5-keys counseling|5-session small group intervention
41012079|NCT00896545|BEHAVIORAL|Lifestyle counseling|5-session small group behavioral intervention
41012080|NCT00687505|DRUG|FP-1039|Intravenous weekly administration
41012081|NCT00854087|DRUG|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
41330107|NCT03098524|PROCEDURE|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.
41330108|NCT03098524|PROCEDURE|No ventilation (noV arm)|During cardiopulmonary bypass, no mechanical ventilation is performed.
41330109|NCT03098524|PROCEDURE|Lung recruitment manoeuver|"An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit)."
41330110|NCT05016804|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41155751|NCT03326193|BIOLOGICAL|Bevacizumab|Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.
41330111|NCT00051090|DRUG|Telbivudine|Administered orally at a daily dosage of 600 mg for a period of 48 weeks
41330112|NCT00051090|DRUG|Lamivudine|Administered orally at a total daily dosage of 300 mg for Weeks 24-48
41012082|NCT00854087|DRUG|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
41012083|NCT03835442|DRUG|Baclofen|baclofen 10mg tid for 4 weeks
41012084|NCT03835442|OTHER|Placebos|placebo tid for 4 weeks
41012085|NCT02293785|DRUG|Oxycodone-Naloxone|
41012086|NCT02476396|PROCEDURE|Carotid Endarterectomy or Stenting|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic~Carotid stenting uses a expandable metal coil to prevent the artery from narrowing."
41012087|NCT01810978|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
41012088|NCT01810978|DIETARY_SUPPLEMENT|Maltodextrin|same amount of maltodextrin per day will be given as placebo
41155752|NCT06205576|DEVICE|DCB catheter|Trade name of DCB catheter：Acoart Orchid＆Dhalia
41155753|NCT04398355|COMBINATION_PRODUCT|acupuncture|acupuncture
41155754|NCT04398355|COMBINATION_PRODUCT|Liu-Zi-Jue Gongfa|Liu-Zi-Jue Gongfa
41330113|NCT00051090|DRUG|Efavirenz|Administered orally at a daily dose of 600 mg
41330114|NCT00051090|DRUG|Didanosine|Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
41330115|NCT00051090|DRUG|Abacavir|Administered orally twice daily in doses of 300 mg
41330116|NCT01997697|OTHER|behavior change program|behavior change program among patients with obesity
41330117|NCT04088331|DEVICE|AMS 800 Artificial Urinary Sphincter|The AMS 800 Artificial Urinary Sphincter (AUS) is an implantable, fluid filled, solid silicone elastomer device used to treat stress urinary incontinence due to reduced urethral/bladder outlet resistance (intrinsic sphincter deficiency). It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by opening and closing the urethra under the control of the patient.
41330118|NCT03587584|DRUG|liposomal bupivacaine|Experimental
41330119|NCT03587584|DRUG|Bupivacaine|Active Comparator
41330120|NCT01645085|DRUG|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
41330121|NCT01645085|DRUG|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
41330122|NCT01645085|DRUG|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
41330123|NCT01645085|DRUG|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
41330124|NCT01562678|DRUG|Liraglutide|In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
41330125|NCT01562678|DRUG|Placebo|In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
41330126|NCT06252246|DEVICE|Phacoemulsification machine|type of phacoemulsification machine is different
41330127|NCT03768895|RADIATION|MRI|"The technique used was coronal and axial T1 and T2\*WI sequences of the pelvis and femurs.~The MRI machine used is a HITACHI AIRIS-II1 model, with permanent vertical magnetic field of 0.3 Tesla, and the used sequences areT1, T2\*WI."
41330128|NCT01236794|BEHAVIORAL|Lifestyle Education Sessions and Youth Exercise Sessions|The intervention will include a \~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (\~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
41330129|NCT00125437|DRUG|spironolactone|
41330130|NCT01267604|DRUG|Recombinant FSH (rFSH)|225IU
41330131|NCT01267604|DIETARY_SUPPLEMENT|rFSH + Inositol + Melatonin|225IU rFSH, 4g Inositol, 3mg Melatonin
41330132|NCT01317693|DEVICE|Low intensity shock waves|1500 shocks, Energy Density - 0.09 mJ/mm2
41330133|NCT01467661|DRUG|SPD422 (anagrelide hydrochloride)|Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
41330134|NCT01115088|DIETARY_SUPPLEMENT|Aspartame|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
41330135|NCT01115088|DIETARY_SUPPLEMENT|Sucrose|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
40812088|NCT03585036|DRUG|Placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
40812089|NCT00998322|BIOLOGICAL|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
41012089|NCT00428545|DRUG|Bevacizumab|Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
41330136|NCT01115088|DIETARY_SUPPLEMENT|Stevia|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
41330137|NCT03509623|DIAGNOSTIC_TEST|Blood sampling through direct peripheral venous puncture|Fasting blood samples will be collected 10-15 minutes before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection using a 19-gauge needle under minimum stasis. Blood coagulation parameters will be evaluated.
41330138|NCT04518345|DRUG|Azacitidine|Given IV
41330139|NCT04518345|DRUG|Dubermatinib|Given PO
41330140|NCT02522572|DRUG|plerixafor|Plerixafor will be dosed subcutaneously and administered based on group assignment.
41330141|NCT02522572|DRUG|Bortezomib|Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.
41330142|NCT02522572|OTHER|plasmapheresis|Plasmapheresis will be administered based on group assignment.
41330143|NCT03902041|DRUG|Eltrombopag|The patients will receive Eltrombopag treatment after transplantation
41330144|NCT00141180|DRUG|CP-481,715|
41481736|NCT03673319|PROCEDURE|Dry needling with positives expectation|"DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
40812090|NCT00998322|DRUG|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
41330145|NCT00861588|DRUG|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
41012090|NCT00428545|DRUG|Bortezomib|Starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days
41330146|NCT00861588|DRUG|placebo|starch placebo
41330147|NCT01263314|DRUG|MK-8266|Oral capsules, 0.1 mg potency
41330148|NCT01263314|DRUG|Placebo|Oral placebo capsules to match MK-8266 capsules
41330149|NCT00003635|DRUG|nelarabine|
41330150|NCT03276572|DRUG|225Ac-J591|225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
41012091|NCT00005638|DRUG|cisplatin|
41330151|NCT01808404|BEHAVIORAL|Web-Based Guided Self-Help|"The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness."
41330152|NCT03136484|DRUG|Semaglutide|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
41012092|NCT00005638|DRUG|irinotecan hydrochloride|
41012093|NCT00005638|RADIATION|radiation therapy|
41012094|NCT02520531|DEVICE|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
41012095|NCT02520531|DEVICE|Scorpio NRG PS|Implantation of total knee prosthesis
41012096|NCT03387800|BEHAVIORAL|Basic health education messages|Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.
41012097|NCT03387800|BEHAVIORAL|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
41155755|NCT03347773|DIETARY_SUPPLEMENT|ReGen 18%|ReGen 18% is a kind of oral nutritional supplement, designed for patients under regular hemodialysis. One can of ReGen 18% contains 237ml, 425 Kcal, 19.1g protein, 22.7g lipid and 37.9g carbohydrate.
41330153|NCT03136484|DRUG|Canagliflozin|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
41330154|NCT03136484|DRUG|Placebo (canagliflozin)|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
41330155|NCT03136484|DRUG|Placebo (semaglutide)|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
41330156|NCT01841294|DRUG|Intravenous Lidocaine|Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
41330157|NCT01841294|DRUG|Normal saline infusion|Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
41330158|NCT05678270|DRUG|ICP-192|ICP-192 is a round, uncoated tablet, 5mg, orally.
41330159|NCT01867866|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
41330160|NCT01867866|DRUG|Trifluridine|35 mg/m2, orally, single dose
41330161|NCT01602549|DRUG|GSK962040 (25 mg tablet)|25 mg tablet
41330162|NCT01602549|DRUG|Placebo|matching placebo tablet
41330163|NCT04397692|DEVICE|Nitric Oxide delivered via LungFit™ system|Patients will receive inhalations of 80 ppm for 40 min 4 times a day
41330164|NCT04868227|DIETARY_SUPPLEMENT|FULTIUM D3 VITAMIN D3|VITAMIN D3 SUPPLEMENT
41330165|NCT02894255|DEVICE|Coronary artery bypass grafting|
41330166|NCT02894255|PROCEDURE|Percutaneous coronary intervention|
41330167|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every week
41330168|NCT01101243|RADIATION|Broadband UVB|UVB dose: 4 SED every second week
41330169|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every second week
41330170|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every month
41330171|NCT01101243|OTHER|Control group|No intervention
41330172|NCT00002204|BIOLOGICAL|HIV p24/MF59 Vaccine|
41481737|NCT03673319|PROCEDURE|Dry needling with neutral expectation|"DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
41330173|NCT04589338|OTHER|Endurance training|This group will perform aerobic type exercises. Initially, patients will perform continuous exercises of progressive intensity in order to adapt to this kind of effort. Next, we will introduce interval exercises.
41330174|NCT04589338|OTHER|Resistance training|Patients in this group will perform lower limb strengthening exercises to improve the maximum strength of different muscle groups.
41012098|NCT05447949|PROCEDURE|Adjuncts to levobupivacaine in Erector Spinae Plane Block|The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
41012099|NCT04991740|DRUG|JNJ-78306358|JNJ-78306358 will be administered.
41012100|NCT01132144|PROCEDURE|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~* Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~* Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~* Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
40812091|NCT03309319|DRUG|Rosiglitazone|rosiglitazone is added to the primary treatment
41481738|NCT02614313|PROCEDURE|Open breath test with fructose|Open randomised fructose 35g during breath test
41012101|NCT01132144|PROCEDURE|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
41012102|NCT05724602|DRUG|Xevinapant|3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy
41012103|NCT05724602|DRUG|Placebo|3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
41012104|NCT06133621|OTHER|dosage dRVVT|Blood test dRVVT assay on two tubes of blood in the haemostasis laboratory of the Center de Biologie et de Pathologie Est
41330175|NCT00006299|DRUG|Celebrex|
41481739|NCT02614313|PROCEDURE|Breath test with sweet placebo (Assugrin)|Double-blind randomised breath-testing with sweet placebo (Assugrin)
41481740|NCT02614313|PROCEDURE|Breath test with neutral placebo (still water)|Double-blind randomised breath-testing with neutral placebo
40812092|NCT01795495|DRUG|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
40812093|NCT01795495|DRUG|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
41330176|NCT04671069|DRUG|MGL-3196|Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
41330177|NCT04671069|DRUG|Clopidogrel|After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
41330178|NCT00216268|DRUG|Ribavirin|
41481741|NCT02614313|PROCEDURE|Blinded breath test with fructose|Double-blind randomised fructose 35g during breath test
41481742|NCT02527018|DEVICE|Sphygmomanometer|Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
41481743|NCT00046449|DRUG|Investigational Seasonal Affective Disorder (SAD) Drug|
41481744|NCT05651555|BEHAVIORAL|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution|Psycho-educational program EHPAD caregivers / Pact \& Pad for caregivers with a parent in an institution
41481745|NCT00666848|DRUG|Placebo|Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
41481746|NCT00666848|DRUG|Enalapril 5mg|Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
40812094|NCT01795495|DRUG|Remifentanil|
41330179|NCT04262908|OTHER|Telephone call|Patients who did not return to work after the SL prescribed initially and had an extension of the SL will be called at 4 months postoperatively to collect infomation
41012105|NCT01709318|DRUG|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
41330180|NCT05953207|OTHER|Medical hypnosis|Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
41012106|NCT01709318|DRUG|Etonogestrel (ENG)|Daily release of 75, 100, 120 or 125 μg
41330181|NCT05953207|OTHER|Standard Of Care|Sleep hygiene and safety education session
41330182|NCT02048267|PROCEDURE|Frey's procedure/Pylorus preserving pancreatoduodenectomy|Duodenum preserving head resection
40812095|NCT05505396|OTHER|Sampling of blood and cerebrospinal fluid|Blood HbA1c, insulin, C-peptide and IL-6 measured at admission. Glucose and lactate measured every 4 hours during intensive care stay. Daily sampling of CSV analysed for glucose and lactate in patients with EVD.
41012107|NCT01709318|DRUG|Ethinyl estradiol (EE)|Daily release of 15 μg
41012108|NCT01709318|DRUG|Estradiol (E2)|Daily release of 300 μg
41330183|NCT04112771|DRUG|Penehyclidine hydrochloride|Penehyclidine hydrochloride was administered before anesthesia induction.
41330184|NCT04112771|OTHER|No penehyclidine hydrochloride|Penehyclidine hydrochloride was not administered before anesthesia induction.
40812096|NCT02340247|OTHER|Water|
41155756|NCT01509040|OTHER|Standard Care|"Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.~Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.~Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.~Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours."
41330185|NCT01082978|DEVICE|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
41330186|NCT01082978|DEVICE|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
41330187|NCT01914783|OTHER|ultrafine particles|exposure to ultrafine particles
41330188|NCT01914783|OTHER|ultrafine particles and ozone|exposure to ultrafine particles and ozone
41330189|NCT01914783|OTHER|clean air|Exposure to clean air.
41330190|NCT06175767|DRUG|MT101-5|Tablet
41330191|NCT01565811|PROCEDURE|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
41330192|NCT06349850|DIAGNOSTIC_TEST|serum uric acid level to plasma HDL-c level ratio (UHR)|high UHR is considered to be a risk factor for development of DKI in type 2 DM
41330193|NCT03549117|DEVICE|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
41481747|NCT00666848|DRUG|Enalapril 10mg|Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
41481748|NCT00666848|DRUG|Sitagliptin|Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
40812097|NCT02340247|DRUG|Ursodeoxycholic Acid|
41012109|NCT06464588|BIOLOGICAL|Allogeneic Neonatal mesenchymal stromal cells (nMSCs)|nMSCs will be administered intravenously in the predefined dose per each group. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels.
41481749|NCT00429520|DRUG|Hyaluronic acid filler/IMD1 basic|
41330194|NCT03549117|OTHER|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
41330195|NCT04811001|DRUG|Osimertinib|TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets
41330196|NCT04811001|DRUG|Dacomitinib|Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets
41330197|NCT00606853|BEHAVIORAL|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
41330198|NCT04406012|PROCEDURE|paravertebral block|paravertebral block group
41330199|NCT02829008|DRUG|low-dose-bevacizumab/pemetrexed|Bevacizumab is administrated at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too.
41481750|NCT02103270|DRUG|Peanut Protein 4,000mg|"Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity."
41481751|NCT02103270|DRUG|Oat Flour|"Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
40812098|NCT02340247|DRUG|Chenodeoxycholic Acid|
41481752|NCT02103270|DRUG|Peanut Protein 300 mg|"Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
41481753|NCT03175289|OTHER|Best Practice|Undergo therapy session conducted by a speech pathologist
41481754|NCT03175289|OTHER|Educational Intervention|Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
41481755|NCT03175289|OTHER|Exercise Intervention|Perform prescribed home exercises
41481756|NCT03175289|OTHER|Expiratory Muscle Strength Training|Participate in EMST
41481757|NCT03175289|OTHER|Quality-of-Life Assessment|Ancillary studies
41012110|NCT04747938|DEVICE|Energy accumulator|All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.
41481758|NCT03175289|OTHER|Questionnaire Administration|Ancillary studies
40812099|NCT00382421|DRUG|bisoprolol|
40812100|NCT00382421|DRUG|amlodipine|
40812101|NCT00382421|DRUG|molsidomine|
40812102|NCT00382421|DRUG|acetylsalicylic acid|
40812103|NCT03400865|DRUG|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
40812104|NCT02774746|OTHER|35-week delivery|Induction at 35 weeks gestational age
40812105|NCT02774746|OTHER|38-week delivery|Observation to spontaneous delivery or induction at 38 weeks gestational age
40812106|NCT02991495|BIOLOGICAL|Stamaril, Sanofi Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
40812107|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Bio-Manguinhos|"1. Full dose~2. Fractional dose: one fifth (1/5)"
41012111|NCT04747938|BEHAVIORAL|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
41012112|NCT03197220|OTHER|fish|300 gr/week fish
41330200|NCT02829008|DRUG|Treatment of physician's choice|The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
41481759|NCT00826579|PROCEDURE|Sentinel lymph node procedure|After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
41481760|NCT00826579|PROCEDURE|Bone marrow aspiration|Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
41481761|NCT05396131|DEVICE|Lung Sealant|The Aeriseal System uses a polymer foam to block or seal fissures, peripheral airways, alveoli, and collateral channels to achieve lung volume reduction.
41155757|NCT01509040|DEVICE|Low Volume Hemofiltration|"Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required."
40812108|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
40812109|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
41012113|NCT03197220|OTHER|walnut|18 walnut per week
41012114|NCT03197220|OTHER|fish-walnut|150 gr fish and 9 walnut per week
41012115|NCT02956213|OTHER|HEPA portable air filter|A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.
41330201|NCT02155894|BEHAVIORAL|Disease control, Telemedicine, doctor|"Control of disease activity by a telemedicine consultation carried out by a doctor.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
41330202|NCT02155894|BEHAVIORAL|Disease control, Telemedicine, nurse|"Control of disease activity by a telemedicine consultation carried out by a nurse.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
41330203|NCT03526315|OTHER|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
41330204|NCT03526315|OTHER|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily.
41330205|NCT03526315|OTHER|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after tooth brushing, twice daily.
41330206|NCT02856906|OTHER|occlusal adjustment|
41330207|NCT04653389|DRUG|Sintilimab Injection|Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
41330208|NCT04653389|DRUG|TACE|The first TACE and Sintilimab Injection will be initiated simultaneously.
40812110|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
40812111|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
40812112|NCT04842630|DRUG|SHR-1916|All participants receive SHR-1906 alone
40812113|NCT00485758|DRUG|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
40812114|NCT00485758|DRUG|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
40812115|NCT04736212|DEVICE|Bed sensor monitoring system|Respiratory patterns in the post-anesthesia care unit will be assessed using a validated, modified under bed weighing scale placed under the patient's bed in the PACU.
40812116|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206641A|One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
40812117|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206640A|One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
40812118|NCT01999842|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
40812119|NCT04183127|OTHER|No intervention|ACPs, qualified or in training, will be invited to participate by email. Interested participants will be provided with study materials and asked to complete an online eligibility questionnaire; if eligible, contact details will also be recorded. Participants will be invited to take part in a focus group about their experience in developing clinical competence and their opinions on role identity. Data collection will consist of focus groups.
40812120|NCT02543281|DEVICE|Adaptive cardiac resynchronization therapy|The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.
40812121|NCT02543281|DEVICE|Conventional Cardiac Resynchronization Therapy|CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
40812122|NCT04697537|DRUG|Ultrasound guided regional anesthesia|Applied perineurally preoperatively ultrasound guided regional anesthesia
40812123|NCT04697537|DRUG|Local infiltration analgesia|Applied in the wound intraoperatively from the orthopedics
40812124|NCT03492957|OTHER|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
40812125|NCT02580123|BEHAVIORAL|Intervention taught by trained educators|
40812126|NCT00000149|DRUG|Beta Blocker|
40812127|NCT00000149|PROCEDURE|Trabeculectomy|
40812128|NCT00000149|PROCEDURE|Argon Laser Trabeculoplasty|
40812129|NCT04607304|DEVICE|ABCA2 GIRMS|Two systems (ABCA-C and ABCA-D) with run order randomized
41330209|NCT04653389|RADIATION|Radiotherapy|Use Cone Beam computor tomography(CBCT) locates the lession before the therapy.
40812130|NCT05790798|OTHER|occupational therapy-based instrumental daily living activities intervention|Occupational therapy-based instrumental activities of daily living intervention were applied to 9 people with disabilities in the intervention group, with sessions consisting of 45 minutes twice a week (totally 8 weeks/16 sessions). While the activity intervention program was being created for the intervention group, the problem areas in the ADL and IADL determined by the evaluations made before the intervention were identified. Ten occupation kits including 2 ADLs (dressing and feeding nutrition), and 8 IADLs (laundry, meal preparation, light cleaning, paperwork, use of technology, lifting and carrying, fine motor and gross motor leisure groups) were used as interventions. Various materials (jar, shirt, spoon, teapot, play dough, stapler, plastic bag, sponge, etc.) were prepared to be used in each occupation kit and to simulate daily activities.
40812131|NCT05790798|OTHER|Quite recreation activity|For the control group, information about the scope, duration and requirements of the research was shared throughout the process. During this period, reading activities continued. The final evaluation of all participants was made at the end of the 8th week of the study and the study was completed.
40812132|NCT01780246|DRUG|nusinersen|Administered by intrathecal (IT) injection
40812133|NCT03515733|DRUG|PF-04995274|PF-04995274 tablets
40812134|NCT03515733|DRUG|Placebo Oral Tablet|Placebo tablet, identical appearance to experimental tablet
40822942|NCT06603064|DEVICE|Sham continuous theta burst stimulation|This intervention involves an sham form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
40822943|NCT03387943|DRUG|PLD|intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.
41330210|NCT03148587|BEHAVIORAL|Self-assessment: MLPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.
41330211|NCT03148587|BEHAVIORAL|Self-assessment: LSPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.
41330212|NCT02702947|DIETARY_SUPPLEMENT|Prunus domestica extract|Prosman 1 capsule twice a day
41330213|NCT05185817|BIOLOGICAL|Pasocovac vaccine|All enrolled post-Allo-SCT participants who meet the inclusion criteria are recruited to study from 3 to 12 months after Allo-HSCT and vaccinated with 2 doses of Pastucovac, with a 4-week (±7 days) interval and a booster dose at an 8-week (±7 days) interval from the second dose.
41330214|NCT01349985|OTHER|AGATE|AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
41330215|NCT01349985|OTHER|SASED|Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
40812135|NCT05707442|PROCEDURE|Stent Implantation|Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to \> 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
41330216|NCT01727557|PROCEDURE|regional anesthesia|Regional anesthesia will be compared to local anesthesia
41330217|NCT01727557|PROCEDURE|local anesthesia|Regional anesthesia will be compared to local anesthesia
40812136|NCT05707442|DRUG|Acetazolamide-based medical therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
41330218|NCT01854671|OTHER|family planning counseling let by community health workers|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
41330219|NCT00036062|DRUG|Sivelestat|
41330220|NCT04167514|BIOLOGICAL|Alpha-1 antitrypsin (AAT)|AAT is a lyophilized product for intravenous administration
41330221|NCT04167514|DRUG|Placebo|Albumin solution administered intravenously
41330222|NCT03457740|DIETARY_SUPPLEMENT|Formula 1|Dietary supplement for strength, testosterone, sexual function, quality of life
41330223|NCT03457740|DIETARY_SUPPLEMENT|Formula 2|Dietary supplement for strength, testosterone, sexual function, quality of life
41330224|NCT03457740|DIETARY_SUPPLEMENT|Placebo|Placebo comparison
40812137|NCT05707442|BEHAVIORAL|Weight loss|The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
41330225|NCT04962672|DRUG|Propofol group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
40822944|NCT03387943|DRUG|Cisplatin|cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles.
41330226|NCT04962672|DRUG|Sevoflurane group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
41330227|NCT04077411|OTHER|Observational|This is an observational study with no interventions.
41330228|NCT02687360|DEVICE|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
40812138|NCT02121769|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
40812139|NCT02482597|DEVICE|Whole Body Periodic Acceleration|A bed that translates back and forth at different frequencies while the subject lies supine
40812140|NCT06058429|OTHER|no intervention|This is an observation study after vaccination, no intervention will be used
40812141|NCT01181999|DRUG|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
41330229|NCT02687360|DEVICE|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
41330230|NCT01110226|DRUG|KML-001|"KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off."
41330231|NCT01110226|DRUG|Cisplatin|Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
40812142|NCT00234663|DRUG|PTC124|
41012116|NCT02956213|OTHER|Sham Control/Active Comparator|A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place. Then at cross over, there will be an active HEPA portable air filter used
41012117|NCT03292822|DIETARY_SUPPLEMENT|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
41330232|NCT05579119|DRUG|Sitagliptin 100mg|Sitagliptin 100 mg po once daily.
41330233|NCT05579119|DRUG|Glargine|Glargine once daily.
41330234|NCT05579119|DRUG|Lispro|Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
41012118|NCT03292822|DRUG|Paclitaxel|chemotherapeutic drug
41330235|NCT00812604|DRUG|Ping On Ointment|Ping On Ointment
41330236|NCT00812604|DRUG|Vaseline|Placebo
41330237|NCT01988597|OTHER|Dry eyes|
41155758|NCT01509040|DEVICE|High Volume Hemofiltration|"Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required."
40812143|NCT05343689|PROCEDURE|Pneumatic compression|Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
41155759|NCT04966247|OTHER|Microdialysis|Monitoring real-time cerebral biomarkers using microdialysis method
41330238|NCT03957356|DEVICE|HLBLS-200|The amount of HLBLS-200 applied will be determined by the investigator based on the resection area.
41330239|NCT02399904|OTHER|california tri-pull taping|To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
41481762|NCT05396131|DEVICE|Endobronchial Valve (EBV)|The Zephyr EBV System are one way valves inserted into the airways to reduce lung hyperinflation.
41012119|NCT00003255|DRUG|carboplatin|
40812144|NCT01289275|DRUG|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
40812145|NCT01289275|BEHAVIORAL|Telephone Counseling|Up to 5 proactive counseling sessions from California Smokers' Helpline.
40812146|NCT01289275|BEHAVIORAL|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
40812147|NCT01114971|DRUG|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
41155760|NCT02905877|OTHER|Behavioural study|reaching studies and other behavioural studies.
41155761|NCT02396550|BEHAVIORAL|Positive Expectations|Give positive expectation of the treatment efficacy to patients
41155762|NCT02396550|PROCEDURE|Mobilization with movement|Give neutral expectation of the treatment efficacy to patients
41012120|NCT00003255|DRUG|topotecan hydrochloride|
41012121|NCT00963729|DRUG|cyclophosphamide|Given IV
41012122|NCT00963729|DRUG|docetaxel|Given IV
41012123|NCT00963729|DRUG|epirubicin hydrochloride|Given IV
41012124|NCT00963729|DRUG|fluorouracil|Given IV
41012125|NCT00963729|DRUG|letrozole|Given orally
41012126|NCT05705102|OTHER|Coronary intervention|Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for \<24h.
41481763|NCT01358552|OTHER|Néevo®/ NéevoDHA®|Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
41481764|NCT01034787|DRUG|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
41012127|NCT04147338|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
41012128|NCT06572514|DRUG|immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin|The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
41330240|NCT04080492|OTHER|QOL Survey|The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
40812148|NCT01114971|DRUG|Labetalol|"Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
41012129|NCT04684797|BEHAVIORAL|Virtual T-maze task|Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
41012130|NCT03285321|DRUG|Nivolumab|480mg
41330241|NCT04928391|DRUG|Dexmedetomidine|A single dose of 0.5 µ/kg IV dexmedetomidine at the end of surgery
41330242|NCT04928391|DRUG|Nalbuphine|A single dose of 0.1 mg/kg IV nalbuphine at the end of surgery
41330243|NCT04928391|OTHER|0.9% saline|Same volume of saline placebo IV at the end of surgery
41481765|NCT05683327|DIETARY_SUPPLEMENT|UltraHA® 75 mg/capsule|Take 2 capsules per day at any time.
41481766|NCT05683327|DIETARY_SUPPLEMENT|UltraHA® 40 mg/capsule|Take 2 capsules per day at any time.
40812149|NCT01114971|DRUG|Esmolol|"Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
40812150|NCT03957421|OTHER|aquatic exercise, land based exercise|general warm up and cool down. general exercises and treadmill training at self-selected intensity.
40812151|NCT05546697|OTHER|Online- Yoga-based Intervetion|See arms description
41012131|NCT03285321|DRUG|Nivolumab|240mg
41012132|NCT03285321|DRUG|Ipilimumab|1mg/kg
41012133|NCT01738152|OTHER|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
41330244|NCT02150213|PROCEDURE|MRI, CT or ultrasound was permitted if MRI was contraindicated|MRI/CT/ultrasound of abdomen
41330245|NCT02150213|PROCEDURE|Dexamethasone Supression Test|Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
41330246|NCT02150213|PROCEDURE|Sonogram|Sonogram of the uterus (females only)
41330247|NCT02150213|PROCEDURE|Biopsy|Uterine endometrial biopsy (females only)
41330248|NCT02150213|DRUG|BGG492|No study-drug was administered in this study
41481767|NCT05683327|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules per day at any time.
41481768|NCT03521648|PROCEDURE|PAE|Prostatic artery embolization
41481769|NCT03521648|PROCEDURE|TURP|Transurethral resection of the prostate
40812152|NCT05546697|BEHAVIORAL|Online- BA|See arms description
41481770|NCT03521648|PROCEDURE|Other|Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate
41481771|NCT04750135|DRUG|metformin 500 mg TID Oral Tablet|biguanides derivatives
41481772|NCT04750135|DRUG|Placebo|Placebo
41330249|NCT02992301|DRUG|Alirocumab|Injectable prescription medicine called a PCSK9 inhibitor.
41330250|NCT00198094|DRUG|Sertraline and Alprazolam XR|
41481773|NCT03512951|OTHER|Digital signal processing algorithms|The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).
41481774|NCT00992368|PROCEDURE|reduction mammaplasty|patients submitted to reduction mammaplasty
41481775|NCT00788502|BEHAVIORAL|Healing Touch|
41481776|NCT00788502|BEHAVIORAL|Desensitization Therapy|
41481777|NCT02469779|BEHAVIORAL|Surveys|At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
41481778|NCT02469779|BEHAVIORAL|ASPIRE Website|Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped
41481779|NCT02469779|BEHAVIORAL|ASPIRE Text-Based Website|Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
41481780|NCT02469779|BEHAVIORAL|Follow Up Survey|Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
41481781|NCT01016093|DRUG|Zoledronic acid|Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
41481782|NCT01016093|DRUG|Placebo|Placebo
41481783|NCT01847820|DEVICE|AmniSure ROM test|Comparison of AmniSure ROM test to clinical diagnosis of ROM.
41481784|NCT05355038|BEHAVIORAL|lifestyle modification (dietary modification)|low glycemic index diet the researcher gave detail information about (importance of LGI diet, component of food, number of meals and snake, example of food taken in breakfast, lunch, dinner and snake in between, food allowed and not allowed). After that, the researcher required from the woman to make an example of food for one day according to her income level, if correction of the content of food needed, the researcher will explain this point again.
40812153|NCT03150966|DRUG|Nanocurcumin|Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period
41481785|NCT05355038|BEHAVIORAL|lifestyle modification (physical activity)|health teaching about choose between two types of exercise to be selected according to the ability of GDM women to perform : brisk walking or seated arm exercise or selected both. Brisk walking should be performed for at least half an hour three time /week, while, seated arm exercise done three time after each meal for10 minute in each time. The researcher given a detail information about both types and its importance in decreasing blood glucose level, also how to perform and what should be done in case of appearance of fatigue manifestation during exercise, and the women have choice for perform both or selected one to perform according to your health condition.
41481786|NCT05355038|BEHAVIORAL|lifestyle modification( self glucose monitoring)|self-glucose monitoring the researcher explain the important of monitoring blood glucose level and instruct the women about how to perform self- glucose measuring, recording way of the result in schedule and to bring this result in the next antenatal visit. The women who have digital blood glucose monitoring instructed to measure it at least 5 time/day. while, the women who didn't have digital blood glucose monitoring measure went to nearest pharmacy to measure blood glucose at least one time per day especially when the woman felt the signs and symptoms of hypo or hyperglycemia and recorded the result in paper or sent the result in whatsapp for the researcher if you have whatsapp application. In addition to give the woman instruction about sings symptoms of hypoglycemia and hyperglycemia and the proper ways for management
41481787|NCT04689100|DRUG|JMT101|Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)
40812154|NCT03150966|DRUG|Placebo|Patients will take placebo in the form of capsules daily during 6 months study period
40812155|NCT02876237|OTHER|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
41330251|NCT00989612|BIOLOGICAL|Influenza investigational vaccine GSK2340274A|Two intramuscular injections on Day 0 and Day 21, respectively
41330252|NCT03091426|DRUG|Omiganan|Omiganan 1%
41330253|NCT03091426|DRUG|Omiganan|Omiganan 1.75%
41330254|NCT03091426|DRUG|Omiganan|Omiganan 2.5%
41330255|NCT03091426|DRUG|Placebo|Vehicle
41330256|NCT00649051|DRUG|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
41330257|NCT00649051|DRUG|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
41330258|NCT02140892|PROCEDURE|respiratory physical therapy manual technique- Autogenic Drainage|
41330259|NCT02140892|DEVICE|respiratory physical therapy technique- IPV|
41330260|NCT04783870|DRUG|Dapagliflozin|Dapagliflozin 10 mg PO QD
41330261|NCT04783870|DRUG|Placebo|Placebo
41330262|NCT00239356|DRUG|Aripiprazole|Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
41481788|NCT04689100|DRUG|JMT101|IV infusion Q2W (28-day cycles)
41481789|NCT04805918|BEHAVIORAL|VIPP-SD|Parenting program
41481790|NCT00164541|BEHAVIORAL|Arts Based Program|
41481791|NCT00164541|BEHAVIORAL|Curriculum|
41481792|NCT04340817|DIAGNOSTIC_TEST|Proteomics|Mass-spectometry proteomics
40812156|NCT02876237|RADIATION|Radiotherapy|standard radiotherapy
40812157|NCT00423982|DRUG|Rifampin-combination therapy|Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.
40812158|NCT00423982|DRUG|Monotherapy|Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
40812159|NCT02819258|OTHER|Endodontic treatment|
40812160|NCT00675441|DRUG|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
40812161|NCT03981757|DEVICE|NeurOS|NeurOS system pads will be placed on patients' head for monitoring.
40812162|NCT05659043|OTHER|overnight fasting|All blood samples were taken on the day of cardiac catheterization after overnight fasting.
41155763|NCT05532319|COMBINATION_PRODUCT|HAIC sequential TAE combined with lenvatinib and tislelizumab|Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
41481793|NCT04340817|DIAGNOSTIC_TEST|Transcriptomics|Next generation sequencing
41481794|NCT04340817|GENETIC|Genomics|Targeted genetics
41481795|NCT03364166|PROCEDURE|surgical excision|"* Under general anaesthesia, the buccal squamous cell carcinoma which invaded the buccinator muscle will be excised with the skin of the cheek. This will be done by a safety margins in the soft tissue and the mandible may be resected according to the plan and the invasion of the tumour.~* A neck dissection will be done in all cases of negative or positive neck lymph node.~* Reconstruction of the soft tissue will be done immediately by a major pectorals flap with the skin, also bony reconstruction may be done by a reconstructed plate at the time of surgery then the patients will be prepared for bone graft in another surgery."
41481796|NCT02972177|PROCEDURE|Radiofrequency ablation|Transbronchial radiofrequency ablation will be performed under the guidance of navigation bronchoscopy.
41481797|NCT02972177|PROCEDURE|Microwave ablation|Transbronchial microwave ablation will be performed under the guidance of navigation bronchoscopy.
40812163|NCT04233398|DEVICE|Device: Echopulse (HIFU ablation)|High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ
40812164|NCT06251466|DEVICE|iHealth Gluco-Smart application|iHealth Gluco-Smart is an application where blood glucose measurements can be registered. This application can be coupled to a platform in the hospital, called Dharma, that enables the researchers to evaluate these blood glucose levels.
40812165|NCT05934994|OTHER|Bone scan|the bone scintigraphy will include 3 stages: study of perfusion then early tissue uptake and finally late bone fixation
41155767|NCT06316778|BEHAVIORAL|Pelvic floor muscle training|12 weekly sessions of 60 minutes with an experienced physiotherapist, including pelvic floor muscles (PFM) exercises with biofeedback, teaching home exercises and education.
41481798|NCT05077436|DRUG|Vamifeport Formulation 1|Vamifeport Formulation 1 is available as 60 mg oral capsules
41481799|NCT05077436|DRUG|Vamifeport Formulation 2|Vamifeport Formulation 2 is available as 60 mg oral capsules
41481800|NCT03122340|DRUG|Ropren|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
41012134|NCT01738152|BEHAVIORAL|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
41012135|NCT03142295|PROCEDURE|urine transfusion|Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
41012136|NCT04109950|DRUG|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily
41012137|NCT03026673|OTHER|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
41012138|NCT04575402|OTHER|Wearable Activity Monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
41012139|NCT01866189|OTHER|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
41012140|NCT04532112|DEVICE|Biocontainment Device For Aerosol Generating Procedures (Biobox)|The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.
41012141|NCT04532112|DEVICE|Control for aerosol generating procedures|There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
41012142|NCT04374474|OTHER|Olfactory retraining|Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.
41012143|NCT04374474|DRUG|corticosteroid nasal irrigation|Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).
40822945|NCT04284735|OTHER|Quantitative ATX and LPA determination in plasma and sputum|"Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients (cases) and in plasma and sputum from RA patients without ILD (controls) after sputum induction using hypertonic saline inhalation"
41012144|NCT04374474|OTHER|smell household Items|Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items
41012145|NCT04374474|OTHER|Nasal Irrigation|Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
41012146|NCT01114516|DRUG|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
41330263|NCT06388135|DRUG|Serplulimab Combined With Nab-paclitaxel and Cisplatin|Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle.
41330264|NCT06388135|DRUG|nab-paclitaxel，Cisplatin|nab-paclitaxel，Cisplatin
41330265|NCT01789658|OTHER|Cryotherapy|Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
41330266|NCT05073172|DRUG|Calendula Ointment|Applied topically
40822946|NCT04155346|BEHAVIORAL|Exercise, nutritional optimization, and psychoeducation|Multimodal prehabilitation including exercise, nutrition, and stress-management delivered via a facility-based or home-based model
40822947|NCT05536089|DIAGNOSTIC_TEST|a multi-locus blood-based assay|Colorectal tumor-specific plasma ctDNA methylation markers detection
41012147|NCT06028867|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
41330267|NCT05073172|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied topically
41330268|NCT05073172|OTHER|Polyethylene Glycol Hydrogel|Applied topically
41330269|NCT05073172|DRUG|Silicone-based Film Forming Topical Gel|Applied topically
41330270|NCT05073172|DRUG|Silver Sulfadiazine|Applied topically
41330271|NCT05073172|DRUG|Topical Hydrocortisone|Applied topically
41330272|NCT03012633|DEVICE|Lysis timer|Lysis Timer compared with standard laboratory test to diagnose hyperfibrinolysis during liver transplantation.
41330273|NCT02460978|DRUG|Dapagliflozin|Tablets
41330274|NCT02460978|OTHER|Placebo for dapagliflozin|Tablets
41330275|NCT00480207|DIETARY_SUPPLEMENT|folic acid|
41012148|NCT02653196|PROCEDURE|Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
41012149|NCT02653196|DRUG|Keratinocyte Growth Factor|KGF 60 mcg/kg IV: 6 doses
41012150|NCT02653196|DRUG|Alemtuzumab|Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
41012151|NCT02653196|DRUG|Thiotepa|Thiotepa 300 mg/m2 IV: 3 doses
41012152|NCT02653196|DRUG|Etoposide|Etoposide 100 mg/m2 IV: 3 doses
41012153|NCT02653196|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV: 3 doses
41012154|NCT02653196|DRUG|Melphalan|Melphalan 70 mg/m2 IV: Day 2 doses
40812166|NCT04746118|BEHAVIORAL|DIET CHANGE|Nutritional supervision will be carried out individually based on the Food Guide for the Brazilian Population, ensuring an accessible, hygienic and contextualized diet according to the subject's culture and physiology. The protocol includes an initial assessment to define the meal plan and individual reassessments every four weeks. In the first evaluation participants will receive an eating plan with a 20% reduction in the total calories consumed or even the equivalent of their daily energy needs with a distribution of macronutrients comprised of 65% carbohydrate, 15% protein and 20% fat. The intention is to promote a reduction in weekly consumption by about 2000 kilocalories (Kcal). The prescription and diet control plan will include and be conducted by a team coordinated by a clinical nutritionist.
40812167|NCT04746118|BEHAVIORAL|PHYSICAL ACTIVITY|The physical activity program will consist of daily walking sessions performed outdoors and on a flat surface suitable for hiking. Each session will last 70 minutes and will be performed between 55% -60% of the maximum oxygen consumption (VO2), six times a week, for 24 weeks, with alternate on-site supervision on odd days and remote monitoring on even days. On-site supervision will be carried out by a team coordinated by a Physical Education teacher and implemented at two times in the morning and another two in the afternoon with meeting points previously defined. At the end of each supervised walking session, 20 minutes of exercise will be performed using the equipment available at the Senior Citizens Academy set up in public squares in the region so that the total expenditure of calories spent weekly with physical activities reach about 2000 kilocalories.
41012155|NCT02653196|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
41012156|NCT02653196|DRUG|Cyclosporine A|Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age \> 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
41012157|NCT02653196|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
41012158|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
41012159|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 20 µg per dose
41012160|NCT03962881|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 60 µg per dose
41012161|NCT03592472|DRUG|Pazopanib|All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
41012162|NCT03592472|DRUG|Abexinostat|The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
41012163|NCT03592472|OTHER|Placebo|The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
41012164|NCT03738904|COMBINATION_PRODUCT|ERAS|Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
41012165|NCT03738904|COMBINATION_PRODUCT|Standard of care|Oxcodone PO Ketorolac IV only (intraop)
41012166|NCT02772068|DRUG|Istaroxime|Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
41012167|NCT02772068|OTHER|Exercise|
41012168|NCT05114603|DRUG|HLX208|level 1:600mg po Bid level 2:900mg po Bid
41012169|NCT05768867|OTHER|FRAnçaise du PEYronie's Disease QUESTionnaire|Complete an online FRAnçaise du PEYronie's Disease QUESTionnaire
41012170|NCT05832034|DRUG|Immune Globulin Intravenous (Human)|IVIg is 2 g/kg over 2 to 5 days at baseline, followed by 2 g/kg IV in 2 to 5 days after 4 and 8 weeks. The rate of infusion is controlled by means of an infusion pump. The first dosage (30 grams IVIg) will be administered on the neurology ward.
41012171|NCT05832034|DRUG|Placebo|Placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks.
41012172|NCT05249725|DRUG|Irsogladine Maleate|Orally administration of irsogladine maleate 4mg/day, for 8 weeks.
41330276|NCT00480207|DIETARY_SUPPLEMENT|omega-3|
41330277|NCT00480207|DIETARY_SUPPLEMENT|vit B12|
41330278|NCT00480207|OTHER|folic acid placebo|
41330279|NCT00480207|OTHER|omega-3 placebo|
40812168|NCT04746118|OTHER|INTEGRATIVE PRACTICES|The health integrative practices will includes Mind-Fullness, auriculotherapy and laying on of hands. A suitably qualified professional, using it use a practical manual so that the practice became uniform among the subjects, will apply the practice of Mind-Fullness in weekly 1-hour sessions to individuals. The practice of auriculotherapy will be applied to individuals by a professional qualified to perform the technique, which consists in the selection of auricular points according to the health problems presented and the therapeutic objectives that are to be achieved, followed by the insertion of the mustard seed at specific points in the ear over a six-month period. The laying on of hands will be carried out by properly trained individuals.
41012173|NCT05249725|DRUG|Hydrotalcite|Patients were given 1 g hydrotalcite every morning, afternoon and evening for 8 weeks.
41012174|NCT03556631|DRUG|live combined Bifidobacterium and Lactobacillus Tablets|take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day
41012175|NCT01075659|DRUG|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
41012176|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
41330280|NCT04720690|DEVICE|Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output|Measurement of arterial stiffness and cardiac output
41155768|NCT05087797|DRUG|nicorandil|Patients in the nicorandil group were also given nicorandil (Tohoku Nipro Pharmaceutical Corporation, Japan) orally 5 mg three times per day for 3 months
41155769|NCT06402851|DRUG|Anticoagulant Oral|Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
40812169|NCT01350752|BEHAVIORAL|RDTs & Provider Training on Malaria Diagnosis and Treatment|In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
40812170|NCT01350752|BEHAVIORAL|Extended provider training (Cameroon only)|2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
40812171|NCT01350752|BEHAVIORAL|School based malaria education (Nigeria only)|Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
40812172|NCT04813614|DEVICE|STYLAGE M Lidocaine|Injection in the lips
40812173|NCT04813614|DEVICE|Active control group|Injection in the lips
41012177|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
41012178|NCT04670016|OTHER|This study does not include an intervention.|This study does not include an intervention.
41012179|NCT00109564|DRUG|ispronicline (nicotinic acetylcholine receptor agonist)|
41012180|NCT05508113|OTHER|ozone autohemotherapy|After autologous blood is mixed with ozone in vitro, the blood is injected into the patient through intravenous infusion
41012181|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
41155770|NCT04012099|DRUG|BMT101|Intradermal injection to each of 3 dose-groups.
41330281|NCT04720690|DEVICE|NICaS|Measurement of cardiac output
41330282|NCT04720690|DEVICE|Echocardiography and ultrasound of arteries|Measurement of cardiac output; measurement of intima-media thickness of arteries
41330283|NCT00781872|BIOLOGICAL|Injection of autologous bone marrow derived mesenchymal stem cells|60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously
41012182|NCT00559962|DRUG|placebo|3 capsules each evening for each 4-week period
41012183|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
41012184|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
41012185|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
41481801|NCT03122340|OTHER|Oil|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
41481802|NCT00181220|DRUG|valproic acid|
41012186|NCT00559962|DRUG|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
41012187|NCT00559962|DRUG|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
41481803|NCT03983174|PROCEDURE|Drainage seton with flap|Seton is placed around the external sphincter then mucosal advancement flap will be constructed
41481804|NCT03983174|PROCEDURE|EAS sparing seton|Rerouting of the seton around the internal sphincter only sparing the external sphincter
41330284|NCT05884476|OTHER|Treatment-as-usual|Veterans in the TAU-only control condition will remain engaged in their normal standard of mental health care throughout their participation in this study. Veterans in the TAU condition will have access to and receive referrals for any of the following services normally afforded to patients at this VA hospital: VA Office of Connected Care web-based training programs and mobile mental health applications; primary care appointments; PCMHI consultation; outpatient mental health individual and group therapies; psychiatry appointments; inpatient hospitalization in the event of a suicidal crisis during study participation; and post-discharge mental health follow-up appointments following inpatient hospitalization for medical or mental health reasons.
41330285|NCT05884476|BEHAVIORAL|Re-Evaluating Suicidal Thoughts|"REST is a brief, computerized intervention designed to mitigate psychological inflexibility associated with the experience of suicidal ideation. Most individuals complete the intervention in under one hour. REST provides psychoeducation to correct common misconceptions about suicidal ideation and help Veterans de-catastrophize the occurrence and meaning of these thoughts. This includes information about the prevalence of suicidal ideation among Veterans, a conceptualization of suicidal ideation as a response to stress, normalizing emotional reactions to suicidal ideation, and framing suicidal ideation as thoughts and conjectures as opposed to truth and reality. These components were chosen to directly address emotional distress related to suicidal thoughts, which is central to the construct of psychological inflexibility. Veterans randomized to receive REST will have access to and be encouraged to utilize any and all of these options described in the TAU-only condition."
41330286|NCT05934721|OTHER|Questionnaire and physical assessments|Participants will complete self-report questionnaires assessing pain (CSI) and RA severity (patient global VAS), as well as undergoing physical assessments of RA severity (physician global VAS, swollen/tender joint counts) and cognition (MoCA).
41330287|NCT01203722|DRUG|Fludarabine|Fludarabine 30 mg/m2/day
41330288|NCT01203722|DRUG|Cytoxan|Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day
40812174|NCT04654624|DRUG|SDF|Steps of SDF 38% application were carried out following the manufacturer's instructions. Eligible primary carious teeth were first dried and isolated using cotton rolls and gauze. Adjacent soft tissues were isolated using petrolleum gelly in order to prevent any irritation or staining from SDF that was directly placed into the carious lesion using a microbrush, allowed to absorb for 2 minutes, then dried with air. Parents were instructed that children should not eat for one hour after treatment. The second application was done after 6 months.
40812175|NCT04654624|DRUG|ART|Steps of ART caries removal were carried out following the Frencken et al. criteria where the cavity opening was widened using the tip of a dental hatchet. The carious dentin was then removed using a spoon excavator starting at the enamel-dentin junction, unsupported enamel was removed using the hatchet, and finally the cavity was cleaned using a wet cotton pellet and dried. After complete removal of infected dentin, the cavity walls and floor were conditioned for 10 seconds, washed and dried with cotton pellets, then restored with chemically cured glass ionomer cement that was applied under finger pressure, then coated with petroleum jelly.
41330289|NCT01203722|RADIATION|Total Body Irradiation|400 cGy TBI administered in a single fraction
41330290|NCT01203722|PROCEDURE|Allogeneic Blood or Marrow Transplant|
41330291|NCT01203722|PROCEDURE|Peripheral Blood Stem Cell Transplant|
41330292|NCT01203722|DRUG|Mycophenolate Mofetil|15mg/kg by mouth three times daily
41330293|NCT01203722|DRUG|Sirolimus|Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
41330294|NCT01203722|DRUG|Tacrolimus|Tacrolimus 1mg intravenously, daily
41481805|NCT00216645|DRUG|doxorubicin hydrochloride|
41481806|NCT02880657|DIETARY_SUPPLEMENT|SODB®|Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
41481807|NCT02880657|DIETARY_SUPPLEMENT|Placebo|Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
41481808|NCT05403736|OTHER|Cardiac Aggressive Risk MitigAtion Plan|Cardio-oncology consultation along with long-term collaborative cancer care visits during standard of care radiation therapy that will occur weekly for up to 6 weeks followed by 6-week and 3-month follow-up visits. Health will be monitored with biosensor monitoring devices.
40812176|NCT03453619|DRUG|APL-2|APL-2 administered as a daily subcutaneous infusion for 48 weeks
41481809|NCT03996551|BEHAVIORAL|ExeRTiOn online resource|This is a 12-week online resource, specifically designed for new kidney transplant recipients. It includes dietary advice, physical activity advice, and recognized behavior change techniques. The participant will be monitored by a specialist physiotherapist and will receive messages of encouragement a 6 weeks and 12 weeks.
41481810|NCT04690036|DRUG|toripalimab injection|when EBV-DNA is positive after allo-HCT, and EBV infected T/NK cell, one dose of toripalimab 3mg/kg would be used, the same dose would be repeated 4 weeks later.
40812177|NCT02806219|DEVICE|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
41012188|NCT00559962|DRUG|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
41155771|NCT05656807|BEHAVIORAL|Go NAPSACC Enhanced|Centers will receive the Go NAPSACC program as well as an online weight management intervention that focuses on personal weight management strategies. Participants will have access to materials that will support their adoption of evidence-based strategies for their weight management or loss goal. Behavior change strategies used are meant to increase intervention adherence and improve weight loss.
41330295|NCT02479295|DEVICE|Tenckhoff catheter|Peritoneal dialysis catheters for long term use
41330296|NCT00510068|DRUG|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
41330297|NCT00510068|DRUG|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
41481811|NCT00361114|DRUG|sulphadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
40812178|NCT02806219|DEVICE|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
40812179|NCT06533501|OTHER|Dietary Leucine Intakes|Participants consume 8 hourly meals that contain the assigned test leucine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
40812180|NCT02281110|DEVICE|iFR/FFR|• The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
40812181|NCT01578642|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components:~an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer."
40812182|NCT02164357|PROCEDURE|EVT (endovascular treatment )|
40812183|NCT02164357|PROCEDURE|IVT (intravenous thrombolytic therapy)|
40812184|NCT03530254|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
41481812|NCT00361114|DRUG|Chlorproguanil/dapsone|Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
40812185|NCT03530254|DIAGNOSTIC_TEST|ERA Test|The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
40812186|NCT05160168|DRUG|THE-630|Oral THE-630 administered once daily in a continuous regimen
40812187|NCT00980512|BEHAVIORAL|Parent Training|16 weeks of parent training led by trained group facilitator
40812188|NCT04470804|DRUG|Sirolimus|Sirolimus treats in experimental group
40812189|NCT04470804|DRUG|Cyclosporine A|Cyclosporine A uses for active comparator group.
40812190|NCT01684696|BEHAVIORAL|Virtual experience|
40812191|NCT01684696|BEHAVIORAL|Videos|
41330298|NCT01376362|DRUG|Interferon Gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
41330299|NCT05287607|DIAGNOSTIC_TEST|Urine sample for carbonic anydrase (I) levels|Point of care diagnostic device used routinely for non-invasive estimation of serum bilrubin level.
41481813|NCT00361114|DRUG|Sulfadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
41481814|NCT05033912|DRUG|CST-2032, matching placebo for CST-2032, CST-107|CST-2032 and matching placebo oral liquid; CST-107 white capsules
40812192|NCT00633568|DRUG|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
40812193|NCT00633568|DRUG|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
40812194|NCT04982328|DIAGNOSTIC_TEST|Th17 cytokine profile|Screening for the components of metabolic syndrome
40812195|NCT04982328|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
40812196|NCT04982328|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
40812197|NCT00306293|DRUG|valacyclovir|valacyclovir
40812198|NCT00151684|DRUG|Diazoxide|
41330300|NCT03529929|DRUG|Methylprednisolone|6 day dosing as dictated by Medrol 6 Day Dose Pack
41481815|NCT04298645|OTHER|Glycaemic response to high GI carbohydrates consumed at morning versus evening meals.|Controlled nutrition trial on the glycaemic response to morning and evening meals with high glycemic index carbohydrates among students with early and late chronotypes.
40812199|NCT02290691|BIOLOGICAL|Influenza Vaccine|Influenza Vaccine
40812200|NCT01597908|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily orally
40812201|NCT01597908|DRUG|Vemurafenib|Vemurafenib 960 mg twice daily orally
40812202|NCT01597908|DRUG|Trametinib|Trametinib 2 mg once daily orally
40812203|NCT00182715|BIOLOGICAL|cetuximab|
40812204|NCT00182715|DRUG|capecitabine|
40812205|NCT00182715|DRUG|fluorouracil|
40812206|NCT00182715|DRUG|leucovorin calcium|
40812207|NCT00182715|DRUG|oxaliplatin|
40812208|NCT06268678|OTHER|Phase of the menstrual cycle|Follicular or luteal phase
40812209|NCT06056336|DRUG|Tislelizumab|Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
40812210|NCT02497365|DRUG|Besifloxacin|
40812211|NCT02497365|DRUG|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
40812212|NCT02094378|DRUG|Esketamine|84 mg esketamine administered intranasally
40812213|NCT02094378|DRUG|Placebo|Placebo administered intranasally
40812214|NCT05742906|DEVICE|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
40812215|NCT05607511|OTHER|Probiotics baby immunity formula (SIM03)|Daily oral intake of a probiotics sachet
40812216|NCT03551405|RADIATION|CBCT scan|CBCT is a standard image guidance procedure for patient setup in image-guided radiation therapy at the Department of Radiation Oncology, UTSW. Our study will deliver three additional CBCT scans to each patient in only one fraction. These additional scans will increase radiation doses to the patients, which elevate the radiation-associated risks of secondary cancer.The other risk involved in this study is a possible violation of patient confidentiality. The imaging data will be completely anonymized, since the patient related information is not needed for this study.
40812217|NCT04030546|DRUG|Ivabradine|Ivabradine capsule
40812218|NCT01685242|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
41481816|NCT03914768|BIOLOGICAL|Immunomodulatory DC vaccine to target DIPG and GBM|This study will inject DC vaccine cells near lymphoid tissue close to the tumor. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day. The cells will be repeatedly infused every month for six consecutive months depending on the response and the condition of the patient. The amount of DC vaccine cells per injection is based on prior report at 5-10x106. An initial dose escalation scheme will be imposed.
40812219|NCT01685242|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
40812220|NCT01940367|DEVICE|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
40812221|NCT01940367|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation)|"TENS therapy will be administered as follows:~* Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~* The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~  * Mode: Burst~ * Cycle: 10 seconds~ * Frequency: 10 Hz~ * Pulse Width: 250 µs~ * Intensity: to subject comfort level"
41481817|NCT04063982|OTHER|none, only assessment at different time points|assessment at different time points
41481818|NCT00289003|DRUG|Soluble beta-1,3/1,6-glucan|
40812222|NCT00693537|BEHAVIORAL|Exercise training|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
40812223|NCT04019106|DRUG|Budesonide in bovine lipid extract surfactant (BLES)|Budesonide in bovine lipid extract surfactant
40812224|NCT04322474|DEVICE|Catheter-based left atrial appendage occlusion|Catheter-based implantation of left atrial appendage occluder
40812225|NCT03554941|DEVICE|noise stimulation|noise stimulation
40812226|NCT01713673|DRUG|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
41481819|NCT00442000|PROCEDURE|Prostatectomy|Patients undergoing prostatectomy.
40812227|NCT01713673|DRUG|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
40812228|NCT01576146|DRUG|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
40812229|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
40812230|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
40812231|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
41481820|NCT05174676|DEVICE|Dextreme|"A unique robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the movement.~The setting of stroke patients in a simulated environment enhances patient motivation and participation. The completion of games (tasks) is a great indicator for the patients that they are progressing in the treatment and are on their way to recovery."
40812232|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
40812233|NCT04537208|BIOLOGICAL|CoV2 preS dTM (high-dose) without adjuvant|Pharmaceutical form: liquid; route of administration: intramuscular injection
40812234|NCT04537208|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: liquid; route of administration: intramuscular injection
40812235|NCT05551741|BIOLOGICAL|IBC-Ab002|An anti-PD-L1 monoclonal antibody
40812236|NCT05551741|OTHER|Placebo|Normal Saline
40812237|NCT02491242|OTHER|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
40812238|NCT03804463|PROCEDURE|endometrial cancer radical surgery|Take hysterectomy and bilateral adnexectomy.
40812239|NCT03804463|PROCEDURE|fertility-sparing surgery|Take endometrectomy , preserve uterus and bilateral ovaries.
40812240|NCT03804463|PROCEDURE|ovarian preservation surgery|Take hysterectomy,preserve bilateral ovaries.
40812241|NCT04823923|OTHER|blood sampling for ITK dosage|Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)
40812242|NCT02604368|DRUG|SC411|Soft gelatin capsule
40812243|NCT02604368|DRUG|Placebo|Soft gelatin capsule
40812244|NCT00883818|DRUG|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
40812245|NCT03441867|BEHAVIORAL|Cognitive Behavioral Therapy for Seizures|CBT-informed psychotherapy for patients with PNES and PTE
40812246|NCT03441867|OTHER|Standard Medical Care|Observational - standard medical care
40812247|NCT02533986|DIETARY_SUPPLEMENT|Berry peel drink|
40812248|NCT02533986|DIETARY_SUPPLEMENT|Control drink|
40812249|NCT01289288|BEHAVIORAL|Mailed printed materials and in-office training|"1. Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster~2. Two sessions of in-office training with two standardized patients"
40812250|NCT05851079|DIAGNOSTIC_TEST|TCT test|These tests were performed on cervical exfoliated cells.
40812251|NCT05851079|DIAGNOSTIC_TEST|Vaginoscopy|To obtain the results of the patient's pathology report.
40812252|NCT05851079|DIAGNOSTIC_TEST|High throughput HPV typing and integration detection methods|This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
40812253|NCT05851079|DIAGNOSTIC_TEST|Cobas HPV test|To obtain HPV typing results.
40812254|NCT03241680|DIAGNOSTIC_TEST|Search of anal citology alterations|"All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE)."
40812255|NCT04751994|DIETARY_SUPPLEMENT|Iron drops/Ferrous sulphate|participant will consume daily drops of iron
40812256|NCT04751994|DIETARY_SUPPLEMENT|Placebo drops|Participants will consume daily drops of placebo
40812257|NCT03852992|DRUG|Post-Laser Minoxidil 2%|2ml of 20mg/ml sterile solution, applied post-laser procedure
40812258|NCT03852992|DRUG|At-Home Minoxidil 5%|2ml of 50mg/ml foam q24 h for duration of study
40812259|NCT03852992|DEVICE|Laser|Fractional ablative, deep mode, 5% fractional coverage
40812260|NCT03852992|DRUG|Post-laser 5mg minoxidil|0.25ml of 20mg/ml sterile solution, applied post-laser procedure
40812261|NCT03852992|DRUG|Post-laser 10mg minoxidil|0.5ml of 20mg/ml sterile solution, applied post-laser procedure
40812262|NCT03852992|DRUG|Post-laser 20mg minoxidil|1ml of 20mg/ml sterile solution, applied post-laser procedure
40812263|NCT03402204|DRUG|Simvastatin 10 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
40812264|NCT03402204|DRUG|Simvastatin 40 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
40812265|NCT03150550|BEHAVIORAL|Mindfulness practice|Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.
40812266|NCT03150550|BEHAVIORAL|Relapse prevention|It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
40812267|NCT06153849|DIAGNOSTIC_TEST|urine sample collection|Urine samples from patients receiving BCG instillation was collected for LC-WGS to evaluate CIN and urinary microbiome.
40812268|NCT06073912|PROCEDURE|Open sinus lifting|Sinus lateral window to graft the floor of the sinus using sinus red diamond stone
40812269|NCT06073912|PROCEDURE|Collecting blood sample|Blood sample is collected to harvest PRP and PRF
41330301|NCT04250376|DEVICE|Focused Transcranial Ultrasound|The FDA has determined the power intensity limits that are safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion (for example for hippocampal targets, there will be a delayed recall memory test).
41330302|NCT04839393|DRUG|PF-06882961 followed by PF-06882961/PF-06865571|Treatment A - PF-06882961 20 mg single dose followed by Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose. There will be a washout interval between periods of at least 3 days.
41330303|NCT04839393|DRUG|PF-06882961/PF-06865571 followed by PF-06882961|Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose followed by Treatment A - PF-06882961 20 mg single dose. There will be a washout interval between periods of at least 3 days.
40812270|NCT06073912|PROCEDURE|Bone graft harvesting|Bone graft harvesting from the chin area
41481821|NCT06127368|DRUG|GB-5001A|Depending on the cohort, volume will be varied to administer, and the dosage and route of administration may be varied.
40812271|NCT06073912|PROCEDURE|Autogenous corticocancellous block graft|Simultaneous implant placement with sinus lifting and grafting using autogenous corticocancellous block, stabilized inside the sinus using clamp or screws that will be removed before closure
40812272|NCT06073912|PROCEDURE|Mineralized plasmatic matrix graft|Simultaneous implant placement with sinus lifting and grafting using mineralized plasmatic matrix that is formed using PRP of the patient mixed with particulate autogenous graft from the chin area
40812273|NCT06073912|DEVICE|Centrifuge|Centrifuge will be needed to get the PRP in the Comparator group and PRP in both groups
40812274|NCT06073912|DEVICE|ACM bur|Auto Chip Maker will be used to collect the autogenous particulate bone graft for the sticky bone graft
40812275|NCT04915118|OTHER|Decompensation event|NT-proBNP (N-terminal pro B-type natriuretic) peptide distribution in patients with HFrEF who had a previous decompensation event.
40812276|NCT06464705|DEVICE|PEMF treatment|Pulsed electromagnetic field (PEMF) therapy is an emerging modality for the treatment of musculoskeletal disorders. Time-varying magnetic pulses are generated by passing an electrical current through a coil. PEMF has been shown to be effective in vitro and in vivo studies for tissue repair and accelerating muscle regeneration. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
40812277|NCT06464705|DEVICE|Placebo treatment|In this study the placebo group uses the same PEMF machine, but it does not generate any electrical current that have treatment effect. As the active PEMF device does not produce heat or cause any sensation to the tissue, participants are blinded to the treatment. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
40812278|NCT04310982|DEVICE|The G-Walk sensor system (G-Walk)|The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
40812279|NCT00916201|DRUG|URB597|10 mg / d for 5 days, orally
40812280|NCT00916201|DRUG|intranasal Insulin|160 IU / d for 5 days, intranasal
40812281|NCT00916201|DRUG|Cannabidiol CR|320 mg / d for 5 days, orally
41481822|NCT06127368|DRUG|GB-5001D|Depending on the cohort, volume will be varied to administer.
41481823|NCT06127368|DRUG|Oral cohort|Single dose of Aricept tablet.
40812282|NCT01232504|DRUG|rhGM-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
40812283|NCT01232504|DRUG|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
40812284|NCT01232504|DRUG|rhG-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
40812285|NCT06186245|OTHER|Early feeding with an oral diet|Participants in the treatment arm will be initiated on a clear liquid diet on day 1 of medical ICU admission. Diet will be progressed on day 2 to full liquid diet or diabetic diet as patient tolerates based on which diet the patient would prefer.
40812286|NCT01407835|BIOLOGICAL|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
40812287|NCT02970630|DRUG|Tacrolimus|once a day
41481824|NCT01302613|DRUG|Capecitabine|Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
41481825|NCT01302613|DRUG|5-FU|5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
41481826|NCT01302613|DRUG|Leucovorin|Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
41481827|NCT01302613|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 IV on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
41330304|NCT04839393|DRUG|PF-06882961 + PF-06865571|Period 1: PF-06865571 300 mg single dose (Day 1), Period 2: PF-06882961 10 mg twice daily dose titration up to 200 mg twice daily dosing (Days 3-46), Period 3: PF-06865571 300 mg single dose (Day 47) and PF-06882961 200 mg twice daily dosing (Days 47-48), Period 4: PF-06865571 300 mg twice daily dosing and PF-06882961 200 mg twice daily dosing (Days 49-62)
41330305|NCT00006063|DRUG|pancrelipase with bicarbonate|
41330306|NCT06060756|OTHER|questionnaires completion|"Patients will complete the following questionnaires at 3, 6 and 12 months after start of the treatment for Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS):~* Pain-related questionnaire~* Endometriosis-specific questionnaire~* Hospital Anxiety and Depression scale~* Questionnaire McGill on Quality Of Life~* Insomnia-related questionnaire"
41330307|NCT01144195|DRUG|Panitumumab + FOLFIRI|Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.
41481828|NCT01302613|RADIATION|radiation|"28-30 fractions of radiation, given once a day, five days per week (Monday-Friday, except for holidays). The prescribed fraction dose is 180 cGy; the total radiation dose is thus 5040-5400 cGy. The primary treatment fields will be treated with 25 fractions of 180 cGy/fraction with a boost of 3-5 fractions of 180 cGy subsequently delivered."
41481829|NCT01302613|PROCEDURE|total mesorectal excision|Optimal surgical technique involving use of total mesorectal excision (TME) is mandated. The type of surgery, either low anterior resection with sparing of the sphincter mechanism or sphincter-eliminating abdominoperineal resection (APR), will be at the discretion of the attending surgeon.
41481830|NCT04551911|DRUG|Rayaldee|30 mcg calcifediol Extended-Release (ER) Capsule
40812288|NCT02970630|DRUG|Everolimus|twice daily
40812289|NCT05366712|DEVICE|Stryker Trident® II HA coated cementless acetabula component|New acetabula component.
41330308|NCT00033371|DRUG|Celecoxib|Given 400 mg PO twice a day
41330309|NCT00033371|OTHER|Placebo|Given PO to match DFMO
41330310|NCT00033371|DRUG|eflornithine|Given PO at 0.5 gm/m\^2/day rounded down to the nearest 250 mg dose (BSA of \< 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of \> 2.6 = 1,250 mg/day).
41481831|NCT04551911|DRUG|Placebo|0 mcg calcifediol Extended-Release (ER) Capsule
41481832|NCT05094752|DEVICE|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
41481833|NCT05094752|DEVICE|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
41330311|NCT00033371|OTHER|Laboratory biomarker analysis|Correlative studies
41330312|NCT00033371|OTHER|Questionnaire administration|Ancillary studies
41330313|NCT03091595|DRUG|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
41330314|NCT03091595|DRUG|20 mcg EE/3 mg DRSP|20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
40812290|NCT03397433|OTHER|Information Technology physician assist|The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
41481834|NCT04816630|DEVICE|CBC-Diff Monocyte Volume Width Distribution|MDW is part of the CBC-Diff and will be collected but not reported to the physician. MDW will not impact standard of care.
41481835|NCT01300923|DRUG|Acamprosate|
41330315|NCT04045626|PROCEDURE|corneal cross-linking|Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
41330316|NCT03601793|BEHAVIORAL|Alcohol Help Center|An internet intervention based on CBT consisting of about 20 modules aimed at helping people with drinking problems
41330317|NCT03601793|BEHAVIORAL|Assistance from a health educator|This entails email contact with a health educator that guides the participant through the Alcohol Help Center during the first two weeks
41330318|NCT04925947|DRUG|KN046|KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
41330319|NCT00709124|DEVICE|Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
40812291|NCT04510987|DRUG|BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5|Tablet, oral
40812292|NCT04510987|OTHER|BAY2433334 on dialysis treatment day|Tablet, oral
40812293|NCT02855866|PROCEDURE|thyroidectomy|
40812294|NCT02855866|OTHER|cryotherapy|
40812295|NCT02855866|DRUG|cortisone aerosol|
41330320|NCT00709124|DEVICE|Sham|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
41330321|NCT02558985|PROCEDURE|Casting|Serial casting is used to partially correct the deformity before beginning bracing. A cast can be considered a full-time brace which cannot be removed.
41330322|NCT03831737|BEHAVIORAL|stretching exercises|"Head/neck stretches~* Head tilt side to side~* Cross-chest stretch Torso stretches~* Side stretch~* Mid-back stretch Lower limb~* Standing quadriceps stretch~* Standing hamstring stretch"
40812296|NCT02855866|DRUG|Dexamethasone acetate|
40812297|NCT02855866|DRUG|paracetamol|
40812298|NCT00003675|DRUG|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
40812299|NCT01707654|DEVICE|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
40812300|NCT00885586|DEVICE|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
40812301|NCT00885586|DRUG|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
40812302|NCT00885586|PROCEDURE|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
40812303|NCT02710981|DRUG|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
40822948|NCT03142555|BEHAVIORAL|Health talk plus intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
41330323|NCT03808428|DEVICE|Ankle Group|Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.
41330324|NCT02895412|BIOLOGICAL|Donor-derived WT1-CTL and P-CTL|"Donor-derived WT1-CTL and P-CTL.~P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses."
41481836|NCT02790034|DRUG|Sarizotan low dose|2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 5 mg bid (≥13 years of age and weighing ≥25 kg). Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
41481837|NCT02790034|DRUG|Sarizotan high dose|5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 10 mg bid (≥13 years of age and weighing ≥25 kg) Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients
41481838|NCT02790034|DRUG|Placebo|Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
41481839|NCT05120102|DEVICE|Diode laser|K2 diode laser of 980nm wavelength
41012189|NCT05343611|BEHAVIORAL|Combination of High Protein Diet and Physical Exercise protocol|"A high Protein Diet (HPro) will be provided to maintain individual caloric endpoint and to adjust protein intake to 0.9-1.0 g/Kg ideal body weight. Each participant will receive a tailored diet (taking into account personal preference) which will follow common general guidelines. Servings of food high in polyphenols will be limited to one per day.~Physical exercise will be undertaken three times each week for about 50 minutes per session. The intervention will consist of both aerobic and strength training exercises. Aerobic exercise will consist of walking on a treadmill with 4 x 4 minutes at (85-95% of HRmax), interrupted by 3-minute active recovery periods (60-70% of HRmax). Strength exercise consists of maximal strength training, using a seated leg press with 4 sets of 4 repetitions at \~90% of maximal strength (1RM). Rest periods between the sets will be 3-4 min."
41012190|NCT05343611|DIETARY_SUPPLEMENT|HPP Choko|Participants add to their diet with 30 g/day of 85% dark chocolate high in polyphenols
41012191|NCT05343611|DIETARY_SUPPLEMENT|HPP/VE Choko|Participants add to their diet 30 grams of 85% dark chocolate high in polyphenols, functionalized with 100 mg of Vitamin E per day.
41330325|NCT00571688|DRUG|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score \> 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
41330326|NCT00571688|DRUG|Treatment as usual|Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
41330327|NCT03886441|DRUG|Beclomethasone propionate|Beclomethasone propionate inhaled twice daily during radiotherapy
41481840|NCT06456437|DEVICE|Post-conditioning Balloon dilation and contraction|The balloon was filled at a pressure of no more than 4 atm at the original occlusion of the vessel to block blood flow for 2 minutes (confirmed by angiography), and then contracted to reperfuse the blood flow for 2 minutes, and the above steps were repeated 4 times to complete the in situ ischaemic post-acclimatisation intervention.
41481841|NCT01286389|OTHER|medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
41481842|NCT01286389|BEHAVIORAL|caloric restriction|Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
40812304|NCT02710981|DRUG|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
40812305|NCT04654169|PROCEDURE|Ultrasound-guided IAI|Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.
40812306|NCT04654169|PROCEDURE|Ultrasound-guided SSNB|Ultrasound-guided SSNB was carried out with a supraspinatus fossa level in-plane injection technique
40812307|NCT01805908|OTHER|111In-Pertuzumab + SPECT-CT|111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
40812308|NCT01900132|DEVICE|EIM testing|EIM device is placed on the muscle and a high frequency current is delivered to the skin.
40812309|NCT01900132|DEVICE|Nerve &amp; muscle ultrasonography|Ultrasound waves to examine the muscles and nerves
40812310|NCT01900132|DEVICE|Nerve conduction studies|Small metal disk electrodes attached to wires onto skin to measure how fast nerves conduct electrical impulses and the strength of the connection between nerves and muscles.
41012192|NCT01285765|DRUG|RCHOP21|Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
41012193|NCT00902356|DRUG|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
41012194|NCT00902356|DRUG|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
41012195|NCT04214691|DRUG|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
41481843|NCT03715998|DRUG|Ramipril|1 or 2 capsules administered orally, twice daily
41481844|NCT03715998|DRUG|Firibastat|1 or 2 capsules administered orally, twice daily
41481845|NCT03951584|OTHER|ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset as primary outcome, to evaluate the damage and prognosis of vestibular function.
41012196|NCT01494311|DRUG|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
41330328|NCT03536923|DEVICE|Leva Incontinence System For Pelvic Floor Muscle strengthening|The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
41330329|NCT01833741|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
41330330|NCT00756704|BEHAVIORAL|Smoking cessation guideline implementation|"1. a tutorial on brief cessation counseling for ED nurses and physicians~2. use of an ED algorithm that includes recommended tobacco counseling items~3. fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~4. group feedback to ED staff"
41330331|NCT00742846|DRUG|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid"
41330332|NCT00742846|DRUG|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space"
41481846|NCT06027138|OTHER|blood flow resistance training|Muscle size and explosive power was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press ,vertical jump test and timed push ups and pull up tests .secondly treat the arm and thigh muscles to to blood flow resistance training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles.
40812311|NCT01900132|DEVICE|Electromyography (EMG)|Thin needle placed into muscles to record electrical activity-adults only
40812312|NCT01355679|DEVICE|Guided Therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
40812313|NCT02379988|RADIATION|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
40812314|NCT03784131|DRUG|P-TEV|Replacement of vein with failing valves with personalized tissue engineering vein containing functional valves
40812315|NCT00833963|DRUG|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
40812316|NCT00833963|DRUG|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
40812317|NCT00833963|DRUG|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
41012197|NCT01494311|DRUG|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
41012198|NCT01494311|DRUG|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
41012199|NCT01494311|DRUG|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
41012200|NCT00433693|DRUG|R744|50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25\~300μg(i.v.)/4 week
41012201|NCT00993213|PROCEDURE|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
41330333|NCT00742846|DRUG|Lidocaine|"5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection"
41330334|NCT00742846|DRUG|Lidocaine|"5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection"
41330335|NCT00471003|DRUG|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
41330336|NCT03136900|DIETARY_SUPPLEMENT|Nutrilon without lactose® fortified by concentration|enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
41330337|NCT03136900|DIETARY_SUPPLEMENT|Nutrilon without lactose® fortified by Maltodextrin and oil supplementation|enteral diet with cow milk protein-based infant formula without lactose 14%
40812318|NCT01145001|BEHAVIORAL|Cognitive Behavioural Therapy|Weekly CBT for all subjects
40812319|NCT01145001|BEHAVIORAL|Contingency Management|incentives given for abstinence based on urine analysis
41330338|NCT01732107|DRUG|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
40812320|NCT01145001|DRUG|Nicotine Transdermal Patch|14mg ir 21mg doses based on weight and #cigs/day
40812321|NCT04679623|COMBINATION_PRODUCT|Midazolam|Midazolam Injection, 10mg
40812322|NCT04679623|DRUG|Seizalam|Seizalam, 10 mg
40812323|NCT00722722|DRUG|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
40812324|NCT02412891|DEVICE|UroShield device|The UroShield device is Consists of two units:Actuator and Driver.
40812325|NCT02412891|DEVICE|Sham UroShield device|
40822949|NCT03142555|BEHAVIORAL|Health talk plus less intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
41012202|NCT00993213|OTHER|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
41012203|NCT00401336|DEVICE|Magnetic resonance imaging multiecho gradient-echo sequence|Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
41012204|NCT00436306|BEHAVIORAL|Individualized Intervention|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
41012205|NCT00436306|BEHAVIORAL|Computer-based contraceptive information|Contraceptive method information is provided on a computer.
41012206|NCT04010110|DIAGNOSTIC_TEST|visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence|The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
41012207|NCT03093805|DIETARY_SUPPLEMENT|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
41012208|NCT01997086|PROCEDURE|Percutaneous transforaminal endoscopic discectomy (PTED)|Percutaneous transforaminal endoscopic discectomy
41012209|NCT01997086|PROCEDURE|Microendoscopic discectomy (MED)|Microendoscopic discectomy
41012210|NCT00054613|DRUG|Methoxsalen|
41012211|NCT00054613|PROCEDURE|Extracorporeal Photopheresis|
41012212|NCT03001895|DRUG|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT
41330339|NCT03288025|BEHAVIORAL|Nutrition and Exercise|5 times a week exercise training and biweekly diet counseling for 12 weeks.
40812326|NCT04661371|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
40812327|NCT00206128|DRUG|Seroquel SR|
40812328|NCT04553744|OTHER|Survey Administration|Complete survey
40812329|NCT00455819|PROCEDURE|home treatment|
41330340|NCT04983810|DRUG|Fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
41012213|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (active C-tDCS)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
41012214|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (sham stimulation)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.
41012215|NCT05089539|DRUG|Angiotensin Receptor-Neprilysin Inhibition|Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.
41012216|NCT05089539|DRUG|Placebo|Placebo \[100 mg\] bid). Continuous treatment was maintained for at least three months.
41012217|NCT03779997|BEHAVIORAL|Video-based DOT Application|Participants will be asked to record daily videos of themselves confirming daily ingestion of their buprenorphine. Clinical staff (i.e. physicians, nurses and medical assistants) of patients enrolled in the intervention group will be given training and the opportunity to review medication taking videos.
41012218|NCT04065919|DRUG|Liposomal bupivacaine|20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
41012219|NCT04065919|DRUG|0.25% Bupivacaine with epinephrine|0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
40812330|NCT05468086|DEVICE|VR Solace|Participants will use the VR audio and visual head-mounted device. The device is a standalone VR headset. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
40812331|NCT05546658|DRUG|Psilocybin|Psilocybin administration under supportive conditions
40812332|NCT00488020|PROCEDURE|stem cells transplant|
40812333|NCT06459999|DIAGNOSTIC_TEST|Urine and circulating blood biomarkers|Urine and circulating blood biomarkers in all cohorts
40812334|NCT01295840|DEVICE|Cardiac Resynchronization Therapy Defibrillator|Cardiac Resynchronization Therapy Defibrillator
40812335|NCT02723916|BEHAVIORAL|ezParent Program|Tablet-based behavioral parent training program.
41012220|NCT01304888|OTHER|Cash + nutrition education|Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
41155772|NCT05656807|BEHAVIORAL|Go NAPSACC|Go NAPSACC is an online evidence-based behavioral intervention that supports centers as they adopt center-wide healthy weight practices. It anticipates producing change in the child care environment through fostering best practices in center provisions, practices, policies, and professional development around child nutrition and physical activity and in turn foster healthier habits in the children in their care.
40812336|NCT02723916|BEHAVIORAL|Health-e Kids Control App|Tablet based health promotion information App
40812337|NCT01218958|DRUG|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
40812338|NCT01218958|DRUG|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
40812339|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
40812340|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
40812341|NCT05716178|BEHAVIORAL|Maternal health education|The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion.
40812342|NCT03184935|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
40812343|NCT03184935|DRUG|Decitabine|Decitabine，20mg/m\^2/d
40812344|NCT03522324|DRUG|Cannabis Edible|Self-Directed Use (ad-libitum)
40812345|NCT03548025|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-FR2000 Device
41330341|NCT03644108|DRUG|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg ER Bi-Layer tablet
41330342|NCT03791268|PROCEDURE|Gastric cancer surgery|Gastric cancer surgery is performed according to the Japanese Guidelines. Patients will intraoperative evaluate the edema, fibrosis and exudation.
41330343|NCT05892263|OTHER|early feeding|Enteral force feeding with 5% dextrose injection within 24 hours after operation
41330344|NCT00958516|DRUG|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
41330345|NCT01742533|BIOLOGICAL|human umbilical cord mesenchymal stem cells|
41330346|NCT01742533|BIOLOGICAL|hUCMSCs and hCBMNCs|
40812346|NCT05366621|DRUG|Anti-osteoporosis medications|Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
40812347|NCT04249297|DRUG|Duphaston® (Dydrogesteron)|No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).
40812348|NCT02217423|OTHER|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
40812349|NCT02217423|OTHER|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
40812350|NCT01228136|DRUG|Tranexamic Acid|10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
40812351|NCT01228136|OTHER|normal saline solution|normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
40812352|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
40812353|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
40812354|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
40812355|NCT01809509|PROCEDURE|Endometrial biopsy|
40812356|NCT04410562|DRUG|Hydroxychloroquine|Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).
40812357|NCT04410562|DRUG|Placebo|Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
40812358|NCT00704483|DRUG|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
40812359|NCT00704483|DRUG|Sevelamer HCl|0.8 g tid
40812360|NCT00704483|DRUG|SBR759|1.5 g tid
41330347|NCT01742533|BIOLOGICAL|human cord blood mononuclear cells|
40812361|NCT00704483|DRUG|Sevelamer HCl|1.6 g tid
40812362|NCT03106441|DEVICE|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
40812363|NCT03106441|DEVICE|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
40812364|NCT01964157|DRUG|LDK378|LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
40812365|NCT01937663|DRUG|KWA-0711|
40812366|NCT00123162|DRUG|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
40812367|NCT00123162|DRUG|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
40812368|NCT05030610|BEHAVIORAL|BeatIt-ASD|BeatIt-ASD, designed to be implemented with autistic individuals, is an adaptation of BeatIt. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
41012221|NCT01304888|OTHER|Food basket + nutrition education|Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
41155773|NCT06541262|DRUG|Silmitasertib|Capsules
41155774|NCT06541262|DRUG|Irinotecan|IV
41330348|NCT01742533|DRUG|Hormone Replacement Therapy|
41330349|NCT06173661|DRUG|Fremanezumab|The intervention will be active medication.
41330350|NCT06173661|OTHER|Placebo|The intervention will be placebo injection.
40812369|NCT01235845|BIOLOGICAL|Biological: DC activated CIK combined with DC|"Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.~DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations."
40812370|NCT06481371|DRUG|zuojinwan|In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.
40812371|NCT06481371|DRUG|Rabeprazole sodium enteric-coated tablets|For epigastric pain syndrome
40812372|NCT06481371|DRUG|mosapride citrate|Postprandial discomfort syndrome
40812373|NCT00791479|DRUG|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
41330351|NCT05004350|DRUG|Encorafenib|oral hard capsule
41330352|NCT05004350|DRUG|Cetuximab|intravenous infusion
41330353|NCT05004350|DRUG|FOLFIRI|"Combination of:~irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion"
40812374|NCT00791479|DRUG|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
40812375|NCT02719691|DRUG|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
40812376|NCT02719691|DRUG|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
40812377|NCT06553651|DEVICE|Cryotechnology Necrosectomy Procedure|Subjects undergo necrosectomy with 1.7 mm flexible cryoprobes, either concurrently with stent placement or post-placement, at the Investigator's discretion. The cryoprobe will freeze the necrotic tissue and extracted en-bloc. A maximum of 4 cryotechnology procedures will be performed, with each procedure aiming for significant debris removal and clinical improvement of walled-off pancreatic necrosis (WOPN) symptoms.
40812378|NCT03515135|BEHAVIORAL|Metacognitive Executive Function Training|Training the executive funtions of preshcool ADHD children through tasks and games repeatly but with fun. Giving the parents strategies to help the prechool ADHD childred coping the symptoms and develop EF in the reallife.
40812379|NCT00499512|BEHAVIORAL|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
40812380|NCT00094159|DRUG|SNS-595|
40812381|NCT02003638|DRUG|Niacin|Niacin titrated to 6000 mg daily
40812382|NCT02003638|DRUG|Placebo|Placebo provided in the same pill quantity as niacin arm
40812383|NCT03092986|DRUG|Paclitaxel|paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
40812384|NCT03092986|DRUG|Carboplatin|carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
40812385|NCT03092986|DRUG|Cisplatin|cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
40812386|NCT03092986|DRUG|Vinblastine Sulfate|Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
40812387|NCT03092986|RADIATION|three dimensional conformal radiotherapy|three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
40812388|NCT02841683|BEHAVIORAL|Tabac Info Service|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
40812389|NCT04757480|PROCEDURE|Thoracolumbar Interfascial Plane Block (TLIP)|(20ml) (plain bupivacaine 0.25% on each side toward the LG-MF interface.
40812390|NCT04757480|PROCEDURE|Bilateral Erector Spinae plane Block (ESB)|Will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the eighth thoracic segment (T8).
40812391|NCT05295784|DRUG|Caffeine citrate|A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
40812392|NCT00606541|DRUG|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
40812393|NCT00606541|DRUG|Placebo|Placebo
40812394|NCT04088240|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
40812395|NCT04088240|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
40812396|NCT04088240|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
40812397|NCT04054479|DRUG|Penehyclidine|Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
40812398|NCT04054479|DRUG|normal saline|Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
41012222|NCT01304888|OTHER|Food basket w/o nutrition education|A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.
41012223|NCT01304888|OTHER|Control|No benefits were provided
41155775|NCT06541262|DRUG|Temozolomide|Oral
41155776|NCT06541262|DRUG|Vincristine|IV
40812399|NCT04243577|DEVICE|Tele-EaT Sensors|Two iterations of a wearable surface EMG (sEMG) sensors patch we developed will be tested against commercially available wired devices. The first iteration of the wearable sensor patch is an ultrathin patch with a honeycomb-inspired design that included sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The second iteration is a more durable slightly thicker flexible, non-stretchable, and double-sided thin sEMG patch. Participants will perform standardized swallow tasks while wearing the device.
40812400|NCT04243577|DEVICE|Conventional Sensors|Conventional sensors will include snap-on wired electrodes as the control condition. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.
40812401|NCT03673085|DRUG|CN128|CN128
40812402|NCT03673085|OTHER|placebo|The tablets without CN128
41155777|NCT03731572|OTHER|Power Training|Hip abductor-adductor resistance exercises at maximum execution speed
41155778|NCT03731572|OTHER|Strength Training|Hip abductor-adductor resistance exercises at reduced execution speed
41330354|NCT02670018|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg \* 2 tablets, for 1 day
41330355|NCT02670018|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 25mg/metformin HCl extended release 1000mg \* 2 tablets, for 1day
40812403|NCT05536557|OTHER|Bilateral External Oblique İntercostal (EOI) Plane Block|External Oblique İntercostal (EOI) Plane Block will be provided for postoperative pain for Laparoscopic Cholecystectomy with Bupivacaine. And patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
41330356|NCT01742078|DRUG|LY2541546 - IV|Administered IV
41012224|NCT05953077|BEHAVIORAL|Conversational recasting|The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.
41012225|NCT05941897|DRUG|Ceralasertib|Participants will receive ceralasertib oral tablets.
40812404|NCT05536557|OTHER|Standard perioperative and postoperative multimodal analgesia|Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol for Laparoscopic Cholecystectomy.
40812405|NCT02665663|DEVICE|medical device|
40812406|NCT04692649|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
41155779|NCT00262769|DRUG|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
41330357|NCT01742078|DRUG|LY2541546 - SC|Administered SC
41330358|NCT01742078|DRUG|Placebo|Administered IV or SC
41330359|NCT00395213|DRUG|Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications|Treatment with SSRIs or SNRIs
41330360|NCT06362447|DRUG|Gentamicin Injectable Solution|Gentamicin (10 mg/kg) will be administrated once weekly for 3 months
41330361|NCT00503737|BEHAVIORAL|National Colorectal Cancer Roundtable Toolbox|
41330362|NCT01766219|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
41330363|NCT04401904|DRUG|Dapagliflozin 10 mg|10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth
41330364|NCT04401904|BEHAVIORAL|Nutritional counseling|10 participants randomized to receive 12 weeks of weekly counseling on nutrition
41330365|NCT04415619|PROCEDURE|Xenograft bone substitute (Osteo-biol)|Xenograft bone substitute will be placed over the implant to cover the bone defect after extraction.
41330366|NCT01319019|DRUG|GSK961081|Comparison of different doses and dosing regimens of the drug
41330367|NCT01319019|DRUG|Salmeterol|Positive control
41330368|NCT01319019|DRUG|Placebo|Placebo arm
41330369|NCT04183894|BEHAVIORAL|Personalized Intervention|Participants will receive a personalized intervention based on their personalized network.
41330370|NCT03600493|DRUG|Dexmedetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
41330371|NCT03600493|DRUG|Lidocaine|Lidocaine given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
40812407|NCT04692649|OTHER|cross body stretch|crossbody stretch performed by an individual
40812408|NCT04202406|DRUG|Acetaminophen and codeine and caffeine|The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
40812409|NCT04202406|DRUG|Acetaminophen|The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
40812410|NCT04202406|DRUG|Placebo|The patient will receive placebo (starch) 1hour before treatment.
40812411|NCT06199375|BEHAVIORAL|Routine treatment|The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)
40812412|NCT06199375|BEHAVIORAL|Rehabilitation training|The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
41012226|NCT05941897|DRUG|Durvalumab|Participants will receive durvalumab as an intravenous infusion
41155780|NCT00262769|DRUG|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
41155781|NCT01406171|DRUG|Isavuconazole|oral
41155782|NCT01406171|DRUG|Midazolam|Oral
41155783|NCT02259569|OTHER|Pressure-controlled ventilation|
41330372|NCT03339401|OTHER|Standard of Care|Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
41330373|NCT03339401|DRUG|Brincidofovir|Brincidofovir (BCV) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
40812413|NCT06199375|BEHAVIORAL|Modified mirror therapy|The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
40812414|NCT05042323|BEHAVIORAL|TF-CBT-Short|Participants receive either 4-5 sessions of TF-CBT-Skills or TF-CBT-Narr. If the participant still has significant PTSS they are provided with step two which is the components provided in the arm they did not receive.
40812415|NCT02083341|DEVICE|Lelo® Siri vibrator|external vibration device
40812416|NCT02083341|DEVICE|Lelo® Siri vibrator with vibration component removed|external vibration device - sham
40812417|NCT00669825|DRUG|ALV003|Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
40812418|NCT00669825|DRUG|Placebo|Placebo to be administered via intragastric tube
40812419|NCT05358522|OTHER|Opioid Prescribing Report Cards|"Initial comparison: Clinicians will receive an initial peer comparison feedback report by email in which their post-operative opioid prescribing for patients undergoing their top 3 procedures is compared to the guideline recommended doses and the mean prescribing doses by other University of Pennsylvania Health System (UPHS) prescribers for each of those 3 procedures since the start of the baseline period.~Furthermore, in an attached report, for each of the 3 procedures, the mean patient reported ability to manage pain one week at home after the procedure will be displayed for those who received guideline compliant dosages of opioids relative to those who received higher than guideline recommended amounts.~Monthly comparison: On a monthly basis clinicians will get a report providing similar peer comparison feedback as above but with a monthly trend line of their performance since the start of the intervention."
40812420|NCT03951831|DRUG|REGN2810|Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
41012227|NCT02912286|DEVICE|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
41012228|NCT02912286|DEVICE|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
41330374|NCT04560140|BEHAVIORAL|Narrative and Skills-building Intervention|The intervention is grounded in Narrative Theory and Bandura's principles of Self-efficacy and Outcome Expectation. It will consist of eight individual sessions over six months delivered by a facilitator. Participants will be facilitated to narrate their survival experiences and rebuild core life skills.
41330375|NCT04517227|DRUG|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
41330376|NCT04517227|PROCEDURE|Transcatheter Hepatic Arterial Chemoembolization (TACE)|TACE techniques have been described in the NCCN and ESMO-ESDO guidelines, including cTACE and DEB-TACE.
41330377|NCT04517227|PROCEDURE|Ablation|In this study, thermal ablation could be conducted with radiofrequency (RFA) or microwave (MWA).
40812421|NCT03951831|DRUG|Degarelix|Degarelix is administered subcutaneously (SC) at a dose of 240mg once.
41330378|NCT06056128|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways for the purpose of biopsying lung lesions
41012229|NCT02912286|DEVICE|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
41330379|NCT01570608|DRUG|Ranibizumab|intravitreal injection 3 monthly injections thereafter as needed
41330380|NCT01570608|DRUG|Verteporfin|Verteporfin photodynamic therapy standard fluence
41330381|NCT02538939|DRUG|Sodium thiosulfate|
41330382|NCT03712527|OTHER|Injection of Platelet rich plasma|The blood of the PRP patients group will be centrifuged by the nurse using the dedicated device. A single centrifugation is required to separate the red and white blood platelets and plasma. This method of centrifugation is carried out using specific kits (Mini-GPS System III, Zimmer Biomet Company). The PRP is then collected by the nurse into a syringe that will be provided to the injector physician. Duration of preparation: 20 to 25 minutes. After a standardized sterile preparation, a local anaesthesia will be performed. Then, the injector will inject a volume of 2 mL of PRP into the median portion of the suspected disc under radiographic guidance.
41330383|NCT03712527|OTHER|Injection of NaCl|The placebo will be a single-dose of saline solution which corresponds to NaCl 0,9% ProAmp 10 ml (Laboratoire Aguettant). The vials will be kept at room temperature (≤ 25°C) within the local pharmacy of each centre. 2 mL of this solution will be intra-discal injected.
40812422|NCT03951831|DRUG|Leuprolide Acetate|Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.
41012230|NCT03787849|DRUG|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
41155784|NCT02259569|OTHER|Volume-controlled ventilation|
41330384|NCT03249948|PROCEDURE|Vector change defibrillation|Defibrillation using pad placement in anterior-posterior position.
41012231|NCT03787849|DRUG|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
41012232|NCT00720876|BIOLOGICAL|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
41330385|NCT03249948|PROCEDURE|Double-sequential defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
40812423|NCT03951831|DRUG|Docetaxel|Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.
40812424|NCT01887938|BIOLOGICAL|HGT-1110|Participants will receive IT injection of HGT-1110.
40812425|NCT01132651|OTHER|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
41012233|NCT00720876|DRUG|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
41012234|NCT05496725|DRUG|Micafungin|Pharmacokinetic study under fasting conditions
41012235|NCT05670821|DRUG|Spesolimab|Spesolimab
40812426|NCT01132651|OTHER|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
41330386|NCT03212807|DRUG|Durvalumab|Investigational Medicinal Product
40812427|NCT05224076|OTHER|Home Air Quality|This study will assess the feasibility and usability of ecological momentary assessment (EMA) to capture the context of real time behaviors and environmental exposures that impact indoor environments. In addition, the study will assess the feasibility and usability of providing participants with a readily available indoor home air quality monitor to continuously capture total volatile organic compounds (VOCs) and particulates (PM2.5).
40812428|NCT06283641|DRUG|Liraglutide|Participants will be treated with commercially available Saxenda® according to routine clinical practice at the discretion of the treating physician, following approved label in Taiwan. The decision to initiate treatment with commercially available Saxenda® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
40812429|NCT02793349|DEVICE|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
40812430|NCT00037518|DRUG|AMG 073|
41012236|NCT03678012|DRUG|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
41012237|NCT03678012|DRUG|Hydrogen Peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
41012238|NCT03678012|DRUG|Water|Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
41012239|NCT03884972|DRUG|Trabectedin|Given IV
41330387|NCT03212807|DRUG|Lenalidomide|Investigational Medicinal Product
41330388|NCT05735613|PROCEDURE|osteotome crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. The drills can be sequentially used to widen the osteotomy site to the same level (1 mm short of the sinus floor), an osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level, the osteotome will be tapped gently to fracture up the sinus floor.Clinical check for membrane still intact, blocking the patient's nostrils and asking the patient to blow through his or her nose. Xenograft will be added as the grafting material and pushed to the sinus through the osteotomy site until the desired height of sinus elevation will be gained, the implant fixture will be inserted. Smart peg will be placed on implant and Ostell will be used to record ISQ.
40812431|NCT01236066|OTHER|Database analysis|Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children \<5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
40812432|NCT04723472|DRUG|Cefuroxime containing bismuth quadruple treatment|"Cefuroxime containing bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days."
40812433|NCT04723472|DRUG|Classic bismuth quadruple treatment|"Classic bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days."
41012240|NCT03884972|DRUG|Venetoclax|Given PO
41012241|NCT05210036|DEVICE|Ultrasound Therapy (US)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
41012242|NCT05210036|DEVICE|High-Intensity Laser Therapy (HILT)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
40812434|NCT01106859|DRUG|zopiclone|7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
41330389|NCT05735613|PROCEDURE|osseodensification crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. Change the drill motor to reverse-densifying Mode (counterclockwise drill speed 800-1500 rpm with copious irrigation), Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor, use the next wider Densah Bur (3.0mm) in the same mode and advance it into the previously created osteotomy with modulating pressure and a pumping motion. When feeling the haptic feedback of the drill reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments, the next wider densah drills advance in the osteotomy.Clinical check for membrane still intact. Xenograft added and pushed to the sinus through the osteotomy site then the implant fixture will be inserted.
40812435|NCT01106859|DRUG|zolpidem tartrate sublingual tablet|3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
40812436|NCT01106859|DRUG|Placebo (sublingual tablet)|Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
41012243|NCT03897972|BEHAVIORAL|Non-personalised diet advice delivered via the eNutri app (control)|Non-personalised dietary advice to improve food choices based on standard population guidelines delivered by the eNutri app and irrespective of the dietary intakes from the food frequency questionnaire (control group).
41012244|NCT03897972|BEHAVIORAL|Personalised diet advice delivered via the eNutri app (intervention)|Personalised dietary advice to improve food choices based on adherence to an 11-item diet quality score, which is determined by the eNutri app in response to the dietary intakes from the food frequency questionnaire (intervention group).
41012245|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
41155785|NCT04627662|BEHAVIORAL|Tele-STELLA|Tele-STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent videoconference-based intervention designed to facilitate effective management of behavioral and psychological symptoms common to the later stages of dementia.
41155786|NCT00940914|DRUG|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
41330390|NCT05735613|PROCEDURE|piezoelectric crestal sinus lifting|initial osteotomy will be performed with a 2-mm twist drill to remove the cortical bone, then the intralift tips (Intralift; TKW1, TKW2, TKW3,TKW4, TKW5; Satelec). TKW1 to TKW4 tips have diameters of 1.35 mm, 2.1 mm, 2.35 mm, and 2.8 mm and will be used to gradually widen the access canal to the Schneider membrane, gentle pressure will be applied on the tips to deepen the pathway, and a sterile spray (80 mL/min) cooling the tips to avoid heat injury. The TKW5 tip will be then inserted into the access canal, and the ultrasonic activation for 5 seconds with internal irrigation of 40 mL/min and repeated at 50 mL/min and then 60 mL/min. The sinus membrane will be pushed upward by the hydraulic pressure, the floating of the sinus membrane will be evaluated, and then the TKW4 (Ø 2.8 mm) will be used again to widen the access canal to the sinus membrane before plugging the bone graft.xenograft added. Implant fixture inserted and flap statured
40812437|NCT01106859|DRUG|Placebo|Placebo matching zopiclone
40812438|NCT04361409|DRUG|Rituximab|375mg/m2 on Day-14 and Day-7
40812439|NCT04361409|DRUG|Cisplatin|70mg/m2 on Day1
40812440|NCT04361409|DRUG|Gemcitabine|1000mg/m2 on Day8
40812441|NCT03655054|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
40812442|NCT03831516|DIAGNOSTIC_TEST|Non Invasive Electroanatomical Mapping|All patients will undergo non contrast CT chest and be fitted with the Medtronic CardioInsight wearable 252 electrode vest. Non invasive electroanatomical maps of the ventricular arrhythmia will be created. All patients will be then brought to the electrophysiology laboratory and undergo an invasive electrophysiology study and ablation of the ventricular arrhythmia.
40812443|NCT00170768|DRUG|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
41155787|NCT03687359|OTHER|Standard of care|Treatment as per standard practice
40812444|NCT00170768|DRUG|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
40812445|NCT00170768|DRUG|Placebo|Placebo once daily tablet (sham titration)
40812446|NCT03684603|BEHAVIORAL|melody during motor training and slow wave sleep|sequence of tones which are presented to the patient using earphones
40812447|NCT03684603|BEHAVIORAL|melody only during motor training|sequence of tones which are presented to the patient using earphones
41012246|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
41012247|NCT00393172|BEHAVIORAL|exercise|5 days per week exercise for 4 months
41012248|NCT03099135|DRUG|No Treatment|No treatment will be given tp participants during this follow-up study of previous phase II and Phase III in which they have received Odalavir and AL-335 with or without Simeprevir.
40812448|NCT04588415|OTHER|Bereavement Virtual Support Group|"Family members who experience loss will be invited to attend a virtual support group (VSG) led by Bereaved Families of Ontario- Ottawa (BFO). In pre-COVID-19 times, BFO presented monthly Support and Share nights with guest speakers, followed by breakout peer support groups for all different types of losses: loss of child, spouse, parent, loss by suicide, etc. These groups are facilitated by trained volunteers with a shared loss and include between 75 and 150 participants. These Support and Share Nights serve as intake sessions- interested participants from the breakout groups can attend Closed Groups where a smaller group of participants (up to 12) explore their grief more deeply. These run over 8-10 consecutive weeks with the same group of participants. They are led by trained facilitators who have experienced similar losses. Each week has a different theme, based on evidence-based components of bereavement support (e.g. writing a letter to the deceased)."
40812449|NCT00733070|DEVICE|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
40812450|NCT01923363|DRUG|Piperacillin/Tazobactam Standard Dose to High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
40812451|NCT03392363|DEVICE|Recordings of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease.
40812452|NCT01247025|OTHER|No intervention|This study will not contain a specific intervention
40812453|NCT00129584|PROCEDURE|Emphasys Endobronchial Valve and procedure|
40812454|NCT03149354|OTHER|Assay of TSH, FT3 and FT4 by immuno-radiometric method|Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
40812455|NCT04930276|OTHER|Diet intervention|Professionals will guide participants to have a standard diet and require them to monitor blood glucose by themselves.
40812456|NCT06495970|DEVICE|Gradient Denervation System|The Gradient Denervation System delivers ultrasound ablation to planned locations in the pulmonary artery to down-regulate the sympathetic nervous drive. The system includes a sterile, single-use catheter that is designed to centrally position the transducer within the arterial target zone for consistency of ablation.
40812457|NCT00060801|DRUG|BIIL 283 BS (Amelubent)|
40812458|NCT02218697|BIOLOGICAL|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
40812459|NCT02218697|BIOLOGICAL|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
40812460|NCT02218697|BIOLOGICAL|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
40812461|NCT04343430|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
40812462|NCT04343430|PROCEDURE|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
40812463|NCT04343430|PROCEDURE|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
40812464|NCT04343430|PROCEDURE|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
40812465|NCT04343430|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
40812466|NCT00160017|BEHAVIORAL|Breakthrough collaborative|Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
40812467|NCT00316706|BIOLOGICAL|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
40812468|NCT00316706|BIOLOGICAL|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
40812469|NCT01651819|PROCEDURE|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
40812470|NCT01639573|DRUG|Campath|Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.
40812471|NCT00201422|OTHER|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
40812472|NCT00025064|BIOLOGICAL|bleomycin sulfate|
40812473|NCT00025064|DRUG|chlorambucil|
40812474|NCT00025064|DRUG|cisplatin|
40812475|NCT00025064|DRUG|dacarbazine|
40812476|NCT00025064|DRUG|doxorubicin hydrochloride|
40812477|NCT00025064|DRUG|etoposide|
40812478|NCT00025064|DRUG|ifosfamide|
40812479|NCT00025064|DRUG|melphalan|
40812480|NCT00025064|DRUG|prednisolone|
40812481|NCT00025064|DRUG|procarbazine hydrochloride|
40812482|NCT00025064|DRUG|vinblastine sulfate|
40812483|NCT00025064|DRUG|vincristine sulfate|
40812484|NCT00025064|PROCEDURE|peripheral blood stem cell transplantation|
40812485|NCT00025064|RADIATION|radiation therapy|
40812486|NCT00823433|DRUG|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
40812487|NCT00413894|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
40812488|NCT01924273|DRUG|Talaporfin sodium|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
40812489|NCT03779867|BEHAVIORAL|Exercise Intervention|Undergo acute exercise
40812490|NCT03779867|OTHER|Resting|Seated resting
40812491|NCT03779867|OTHER|Biomarker Analysis|Correlative studies
40812492|NCT03779867|OTHER|Questionnaire Administration|Ancillary studies
41330391|NCT03807245|BIOLOGICAL|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
41330392|NCT03807245|BIOLOGICAL|Placebo GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
41481847|NCT06027138|OTHER|slow motion strength training|We will use slow motion strength training method. Each exercise is performed by lifting weights for approximately 10 seconds, lowering the weight for another 10 seconds, and not resting between repetitions.before receiving treatment sample muscle size and explosive strength was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press (pre test).secondly treat the arm and thigh muscles to to slow motion weight training.weight training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles. (Post test).
41330393|NCT03807245|BIOLOGICAL|Placebo GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
41330394|NCT03807245|BIOLOGICAL|GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
41330395|NCT01700881|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
41012249|NCT06094348|PROCEDURE|Endonasal osteotomy|Patients will undergo median-oblique and lateral osteotomy, with conventional 2 mm guarded, straight osteotome.
41330396|NCT01700881|OTHER|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
41330397|NCT04404803|OTHER|questionnaire|Patients will be asked to complete a questionnaire about the reasons why they agree / decline to take part in research.
41330398|NCT01998880|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
41481848|NCT05907330|DRUG|CU104|CU104 will administer the study drug once a day after a meal
41330399|NCT01998880|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
41330400|NCT01998880|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
41330401|NCT01875510|DIETARY_SUPPLEMENT|Fish-oil emulsions|"Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg."
41330402|NCT01875510|DIETARY_SUPPLEMENT|soybean-oil emulsion|soybean-oil emulsion
41330403|NCT02706119|DRUG|Subcutaneous glargine insulin|Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
41330404|NCT02706119|DRUG|Regular insulin added to TPN bag|Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
40812493|NCT00422630|BEHAVIORAL|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
40812494|NCT00422630|BEHAVIORAL|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
40812495|NCT00422630|BEHAVIORAL|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
40812496|NCT03770325|DRUG|Berberine|Purified berberine (500 mg orally twice a day) in tablets for 12 weeks
40812497|NCT03770325|DRUG|Placebo|Placebo tablets, prepared with the same appearance, for 12 weeks
40812498|NCT05281276|DRUG|chidamide|During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .
40812499|NCT05281276|DRUG|celecoxib|During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
40812500|NCT04897230|BEHAVIORAL|Hatha Yoga|The yoga poses were chosen for providing a restorative session based on their purported relationship to restorative effects to best promote cardiac autonomic recovery from mental stress.
40812501|NCT04897230|BEHAVIORAL|Video Watching|The video was about the history of the Earth which encompasses the development of the planet Earth from its formation to the present day.
40812502|NCT00152477|DRUG|Carboplatin|"10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles."
40812503|NCT00152477|DRUG|Paclitaxel|6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
40812504|NCT00152477|DRUG|CDP791 10mg/kg|CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
40812505|NCT00152477|DRUG|CDP791 20mg/kg|CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
40812506|NCT05992844|OTHER|KB Exercises Program|"Kinesthetic Brain Exercises will carried out for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase."
40812507|NCT05992844|OTHER|Conventional Rehabilitation program|Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
40812508|NCT02851797|DRUG|givinostat|"The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below:~Givinostat or placebo starting dose~* \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid~* \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid~* \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid~* \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid~* \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid~* \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid~* \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid~* \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid~* \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid"
40812509|NCT02851797|DRUG|placebo|The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
40812510|NCT05097651|DRUG|Cannabidiol oral solution|Cannabidiol 100mg/mL in a sesame seed oil, strawberry flavored solution, taken orally at bedtime in self-titrated dose between 50mg and 600mg. Once a dose that results in relief of symptoms is reached, it will remain as the maintenance dose, not to exceed 600mg.
40812511|NCT05097651|DRUG|Inert sesame seed oil|Placebo will be identical strawberry flavored sesame seed oil-based solution without CBD.
41012250|NCT06094348|DEVICE|Piezo assisted osteotomy|Piezo is a system for cutting bone with micrometric ultrasonic piezoelectric vibrations, with varying frequency and cutting energy. The device consists of a platform with a powerful piezoelectric hand piece and employs a functional frequency between 25-29 kHz. The device is fitted with a cooling irrigation system with a 0-60 cc/min variable sterile solution flow. Specific inserts and scalpels act in a linear vibration pattern, with a spatial range between 60 and 210 microns, moved by an ultrasonic power that exceeds 5 watts, reaching up to 16 watts.
41012251|NCT00087633|DRUG|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
41012252|NCT00087633|DRUG|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
41012253|NCT03126981|OTHER|1.5 oz of whole, natural almonds|1.5 oz of whole, natural almonds
41012254|NCT03126981|OTHER|Low-fat, high refined starches/sugars|Low-fat foods, high in refined starches and added sugars
41481849|NCT05907330|DRUG|Placebo|Placebo will administer the study drug once a day after a meal
41330405|NCT00690417|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|low calorie (\~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
41481850|NCT02537873|DRUG|Lorcaserin|Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)
41481851|NCT02537873|DRUG|Cocaine Intravenous (IV)|Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions
41481852|NCT02537873|DRUG|Placebo comparator|Dextrose in gelatin capsule
41481853|NCT01833533|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
41012255|NCT05668767|DRUG|Surufatinib Durvalizumab EP/EC|Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w
41012256|NCT02909322|PROCEDURE|Bupivacaine and Hydromorphone|Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
41012257|NCT02909322|PROCEDURE|Ropivacaine and Hydromorphone|Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
41012258|NCT05492084|OTHER|without Intervention|without Intervention
41012259|NCT01815281|DEVICE|Foot Mechanical Stimulation (GONDOLA)|
41012260|NCT02502357|OTHER|Healing Statements|"Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:~Following this operation, \[the participant\] will feel very comfortable and \[the participant\] will heal very well.~Toward the end of the surgery, the study staff member will say 5 times:~The operation has gone very well. Following the operation, \[the participant\] will be hungry. \[The participant\] will be thirsty and urinate easily."
41012261|NCT00894075|BIOLOGICAL|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
41012262|NCT05087017|OTHER|Intervention group|Patients with medical condition to follow the rehabilitation program will be asked to answer questionnaires to assess their sleep quality.
41012263|NCT06144073|BEHAVIORAL|Intervention (Mandala art therapy) group|Personal Information Form, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied to the students in both groups before mandala art therapy. The students in the experimental group will be given mandala activity by the researcher two days a week for 12 weeks/total 24 times. Three months after the first interview, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be administered as a post-test. One month after the end of the study, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied again as follow-up evaluation.
41481854|NCT01833533|DRUG|Ribavirin|Capsule
41481855|NCT01833533|DRUG|Placebo for Ribavirin|Capsule
41481856|NCT05173246|DRUG|JS001|JS001 240mg, ivdrip, d1, Q3w
41481857|NCT05173246|DRUG|nab-paclitaxel|nab-paclitaxel 220 mg/m2,ivdrip, d1,d8,Q3w
41012264|NCT06027827|PROCEDURE|Addition of fusion device lateral bone graft|In addition to the central bone graft of the fusion cage, the lateral bone graft of the fusion cage was added.
41481858|NCT05173246|DRUG|Cisplatin|Cisplatin 75mg/m2, ivdrip,d1,Q3w
41012265|NCT02279641|DRUG|RDEA3170 10 mg|
41012266|NCT02279641|DRUG|allopurinol 300 mg|
40812512|NCT03938103|BEHAVIORAL|Enhanced Go NAPSACC|In the Enhanced delivery model, TA coaches will help centers create an implementation team and conduct a needs assessment to identify organizational strengths and challenges. TA coaches will also provide an orientation to Go NAPSACC and its online tools and help the team develop a plan to guide their Go NAPSACC efforts. The team will then work through 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly check-ins incorporating tailored support based on the results from the needs assessment. They will also organize 2-3 meetings among teams from different centers to reflect and share lessons learned.
41012267|NCT00674141|DRUG|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
41012268|NCT06207279|DIAGNOSTIC_TEST|rating|rating scales, test ANT
41012269|NCT05434312|DRUG|TGRX-678|Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
41012270|NCT04751305|BEHAVIORAL|Health Coaching|The weekly health coaching (HC) calls were structured to be participant-centered, built on a coach participant relationship, and include participant-determined goals, a self-discovery process to find solutions, patient accountability, and education. Before each HC call, the participants received a short questionnaire on fatigue, QOL, stress, loneliness, and social support which enabled tailoring the HC call to the individual. Educational topics are discussed in the following order: Goal Setting, Monitoring Behaviour, Barrier Management, Social Support, Stress Management, Adapting the Program, Self-Compassion, Sleep \& Nutrition, Reflection, Health Media, Remote Resources, and Maintaining Motivation. However, the order of the educational topics can be adjusted based on the specific participants' needs each week. At the half-way point of the intervention, the participant provided feedback on the HC calls, ensuring optimization of HC impact.
41481859|NCT05173246|DRUG|Carboplatin|Carboplatin AUC 5,d1,Q3w
41481860|NCT02047175|DRUG|Telmisartan/S-Amlodipine|Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days
41012271|NCT04751305|BEHAVIORAL|Online delivered Exercise Classes|The group based remote exercise program was delivered over the Zoom application (2x/wk for first 2 weeks; 1x/wk for the remaining weeks). Classes were one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretch. Each class was followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
41012272|NCT05801627|DRUG|SAL067|SAL067 6mg(2 tablet) and Metformin ≥1500mg
41012273|NCT05801627|DRUG|Placebo|Placebo (2 tablet) and Metformin ≥1500mg
41012274|NCT01933932|DRUG|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
41012275|NCT01933932|DRUG|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
41012276|NCT01933932|DRUG|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
41012277|NCT01933932|DRUG|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
41012278|NCT03917693|DIETARY_SUPPLEMENT|Phytin, rice extract|Consumption of a rice extract, called phytin for a period of 2 weeks
41012279|NCT03917693|OTHER|MCC, placebo|Consumption of MCC, a placebo, for a period of 2 week
41012280|NCT05728112|OTHER|Hydrogen Inhalation|The manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. The research executor will pay attention to the LINE group on the first day of installation, and obtain the pre-test basic value data through the google form After (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started.
41481861|NCT02047175|DRUG|Rosuvastatin|Rosuvastatin 20mg 1T PO, QD for 5days
41330406|NCT04297345|DEVICE|Hemodialysis|"Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure.~Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer.~This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances."
41481862|NCT02047175|DRUG|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days
41481863|NCT02047175|DRUG|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
41481864|NCT00217269|DEVICE|Coronary Artery Stenting|Endeavor Drug eluting stent
41481865|NCT00217269|DEVICE|Coronary Artery Stenting|Taxus Drug Eluting Stent
41481866|NCT02310646|DRUG|LEO 90100 Aerosol Foam|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
41481867|NCT02310646|DRUG|Daivobet® gel|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
41481868|NCT04944134|BIOLOGICAL|COVID-19 Vaccination|Receipt of full COVID-19 vaccination
41481869|NCT03064321|BEHAVIORAL|Insomnia Intervention|The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
41012281|NCT05728112|OTHER|Ordinary Air Inhalation|The control group was inhaled with the same machine as the experimental group, but the gas was only ordinary air, which was used as a placebo control.
41012282|NCT06027281|OTHER|Hamilton depression rating scale (HDRS)|Hamilton depression scale (HDRS) is the most commonly used instrument for assessing symptoms of depression.
41012283|NCT06027281|OTHER|Hamilton anxiety rating scale (HARS)|Hamilton anxiety rating scale (HARS) is a 14-item clinician-rated measure of the severity of perceived anxiety symptoms.
41012284|NCT06027281|OTHER|Mini international neuropsychiatric interview (MINI)|The Mini International Neuropsychiatric Interview (MINI) was designed as a brief structured diagnostic interview for the major psychiatric disorders in DSM-III-R, DSM-IV and DSM-5 and ICD-10.
41012285|NCT06027281|OTHER|Minnesota Multiphasic personality Inventory (MMPI)|The Minnesota Multiphasic Personality Inventory (MMPI) is used to assess personality traits and psychopathology.
41012286|NCT06027281|OTHER|The Symptom Check-List-90-R (SCL-90-R)|The Symptom Check-List-90-R (SCL-90-R) is a widely used psychological status symptom inventory.
41330407|NCT03771690|BEHAVIORAL|Standardised meal|A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
41012287|NCT06027281|OTHER|Socioeconomic scale (A.El Gilany, A.El Wehady and M.El Wasify)|An Arabic version of the socioeconomic scale consisted of four dimensions, namely, level of education, employment, total family monthly income, and lifestyle of the family.
41481870|NCT03064321|OTHER|Information Control|Information on websites that are general health promoting
41481871|NCT03251274|OTHER|machine bathing|machine bathing 20-min duration at evening
41012288|NCT06027281|OTHER|The female sexual function index (FSFI)|The female sexual function index is a brief multidimensional scale for assessing sexual function in women.
41012289|NCT02317302|DEVICE|FDG-PET/MR|
41012290|NCT02317302|DEVICE|FDG-PET/CT|
41012291|NCT03345602|DIAGNOSTIC_TEST|serum S100B protein assay measurement|serum S100B protein assay measurement within the 3 hours after head trauma
41012292|NCT03374826|DIAGNOSTIC_TEST|Dedicated axillary hybrid PET-MRI|All clinically node negative patients will undergo a hybrid PET-MRI axilla preoperatively, followed by breast surgery and SLNB.
41012293|NCT03569644|OTHER|qualitative study|Interviews
41481872|NCT03251274|OTHER|traditional bathing|traditional bathing
41481873|NCT00013494|PROCEDURE|Stroke Rehabilitation|
41481874|NCT05200962|DEVICE|transcranial direct current stimulation|In tDCS, direct electrical currents are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
41012294|NCT00040040|DRUG|Bupropion|
41012295|NCT01323569|DRUG|Sativex|Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
41012296|NCT01323569|DRUG|Sativex|Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
41012297|NCT01323569|DRUG|Sativex|Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
41012298|NCT01323569|DRUG|Placebo|16 placebo sprays and 4 placebo capsules
41012299|NCT01323569|DRUG|Marinol|Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
41481875|NCT00166153|DRUG|Mycophenolate Mofetil|
41481876|NCT03352141|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
41481877|NCT00683982|DRUG|Nitazoxanide|Nitazoxanide 15mg/Kg/day twice day for 3 days
41481878|NCT00683982|DRUG|Probiotic mix preparation|Probiotic preparation 1 gram twice a day for 5 days
41481879|NCT00683982|OTHER|Oral hydration solutions|Oral hydration solutions as needed
41481880|NCT05344651|DEVICE|Surgery/implantation|The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.
41481881|NCT03601546|OTHER|Clinical examination|Blood test and patient interview as for standard patient care
41481882|NCT04749472|OTHER|Sling|Participants wore six different shoulder slings in a randomized order.
41481883|NCT03146182|BEHAVIORAL|CRP-algorithm|a strategy based on CRP guided antibiotic stewardship
41012300|NCT01323569|DRUG|Marinol|Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
41012301|NCT04019912|OTHER|Gait Training plus music|GaitTrainer3 is a platform that integrates gait training via a treadmill and RAS. The device is indeed equipped with an instrumented deck that issues acoustic cues to determine the exact tempo and rhythm during gait training and visual real-time biofeedback to prompt patients to follow their gait pattern. In fact, the device provides online feedback, including step length, speed, and symmetry, to encourage patient progress and monitor patient performance. Patient footfalls were compared in real-time to the desired footfalls step by step and documented in a histogram.
41012302|NCT04019912|OTHER|Traditional Gait Training|The traditional training will be provided by a conventional treadmill.
41330408|NCT06409611|DEVICE|neuromuscular electrical stimulation|Application of neuromuscular electrical stimulation using the NeuroDyn III device (IBRAMED, Amparo - SP)
41012303|NCT06080620|PROCEDURE|Modified radical mastectomy for breast cancer|Modified radical mastectomy for breast cancer
41012304|NCT06080620|PROCEDURE|neoadjuvant therapy|"neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）"
41012305|NCT06080620|PROCEDURE|Systematic treatment|"chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）"
41012306|NCT05852457|DEVICE|DAT Clip|All patients scheduled to undergo endoscopic procedures as medically indicated will be considered for the study. Data will be prospectively recorded according to the data collection form. The use of the DAT clip will be performed as medically indicated and consistent with the indications for endoscopic clipping (e.g., management of bleeding, treatment of fistulas, perforations, tissue approximation). The investigators on this project will also oversee the medical care of all patients that will participate in the study. Therefore, follow-up will be carried out as medically indicated and no clinical visits will be needed specifically for the purpose of this study.
41012307|NCT03117387|DIAGNOSTIC_TEST|Measurements of the level of neuromuscular blockade|Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.
41012308|NCT01639079|BEHAVIORAL|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
41012309|NCT05448924|DIAGNOSTIC_TEST|Hormone panel tests|Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone
41012310|NCT00589108|DEVICE|Sigma Knee System|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
41012311|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
41330409|NCT04054102|OTHER|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
41330410|NCT04054102|OTHER|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
41330411|NCT02867722|DRUG|aminolevulinic acid HCl|Drug will be administered to consented patients
41330412|NCT03460288|BEHAVIORAL|Retraining (AAT)|The training program is based upon the approach-avoidance task (AAT) and can be easily performed on a computer, laptop or tablet. There is a total of 20 pictures, 10 slot-machine gambling related pictures and 10 neutral pictures that were already used in a prior study (Wittekind et al., submitted). The pictures appear on the computer screen and have to be either pushed or pulled. Pushing and pulling depends on a masked instruction (not related to the content of the pictures, but to the color of the frame). All gambling-related pictures are framed with the color that is instructed to be pushed, all neutral pictures are framed with the color that is instructed to be pulled.
41330413|NCT03005041|OTHER|Biotene mouthwash|Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.
41330414|NCT03005041|OTHER|Bottled mineral water|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
41330415|NCT00418210|RADIATION|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
40812513|NCT03938103|BEHAVIORAL|Basic Go NAPSACC|In the Basic delivery model, TA coaches will provide an orientation to Go NAPSACC and its online tools to the center director. The director will then work 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly brief check-ins.
40812514|NCT00280618|DRUG|Oxaliplatin|
41481884|NCT03146182|BEHAVIORAL|PCT-algorithm|a strategy based on PCT guided antibiotic stewardship
41481885|NCT03606421|RADIATION|SRS and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
41012312|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
40812515|NCT04496206|OTHER|No intervention|No intervention, it is retrospective study.
41012313|NCT03726112|DEVICE|SpotOn Specs|SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field
40812516|NCT02437630|PROCEDURE|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
40812517|NCT02437630|PROCEDURE|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
40812518|NCT02437630|OTHER|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
41012314|NCT03726112|DEVICE|Sham Specs|Sham device
41330416|NCT03246555|DRUG|Fimasartan or Fimasartan/Hydrochlorothiazide|The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
41330417|NCT03246555|DRUG|Perindopril or Perindopril/Indapamide|The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
41012315|NCT02206126|BEHAVIORAL|Energy Restriction|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
41330418|NCT00207012|DRUG|BMS-599626|
41330419|NCT04781907|PROCEDURE|Tissue Expansion|Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
40812519|NCT02437630|PROCEDURE|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
41330420|NCT00759083|DRUG|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
41330421|NCT03648463|PROCEDURE|arthroscopy of the affected knee/ Bone Marrow Concentrate Injection|Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
40918235|NCT04458480|COMBINATION_PRODUCT|Fast Inpatient Rehabilitation|Routine inpatient rehabilitation protocol, administered by licensed Physical Therapist, duration period of 1.5h-2h each time, 2 times for weekdays and 1 time for weekends, totally lasting for 1 week, are applied to the exposed group. After the fast inpatient rehabilitation for 1 week, the patients can get discharged if reaching to the rehabilitation goals of symptoms of pain and swell reduced, knee flexion ≥ 90° and knee extension ≥ 0°, quadriceps femurs and hamstrings muscle strength enhanced, recovery to aided standing and walking, and acquiring of rehabilitation training methods.
41012316|NCT06414499|DRUG|rhTNK-tPA|0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds.
41330422|NCT01560611|DEVICE|Near infrared spectroscopy|
41330423|NCT04430686|OTHER|Questionaires|Any validated functional rating scale, such as the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (if available)
41330424|NCT00745381|OTHER|questionnaire, Blood specimens|All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
41330425|NCT00141934|DRUG|AD 452|
41330426|NCT00246064|DRUG|infliximab|
40812520|NCT02437630|PROCEDURE|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
40812521|NCT02437630|OTHER|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
40812522|NCT02043912|DRUG|Haloperidol|
40812523|NCT06416358|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
40812524|NCT01663116|GENETIC|Stem cells|"1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
40812525|NCT01663116|GENETIC|Placebo|"1. first cohort: 20 ml administered at days 1, 8 and 15~2. second cohort: 40 ml administered at days 1, 8 and 15~3. third cohort: 80 ml administered at days 1, 8 and 15"
40812526|NCT01018329|PROCEDURE|Magnetic Resonance Imaging|
40812527|NCT01018329|PROCEDURE|Diffusion Tensor Imaging|
40812528|NCT01018329|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|
40812529|NCT01018329|PROCEDURE|Dynamic Contract-Enhanced magnetic resonance imaging|
40812530|NCT01018329|PROCEDURE|Diffusion-weighted magnetic resonance imaging|
40812531|NCT00682903|DEVICE|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
40812532|NCT00626509|DRUG|sunitinib malate|
40812533|NCT00626509|PROCEDURE|adjuvant therapy|
40812534|NCT00626509|PROCEDURE|neoadjuvant therapy|
40812535|NCT00626509|PROCEDURE|therapeutic conventional surgery|
40812536|NCT02348034|DEVICE|Prevena Dressing|Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
40812537|NCT01533337|PROCEDURE|Free dorsal digital flap|The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
40812538|NCT00183781|BEHAVIORAL|FITT: Family Intervention - Telephone Tracking|
40812539|NCT00113399|BIOLOGICAL|filgrastim|
41012317|NCT06414499|DRUG|Control group|Standard medical care according to the guideline (Stroke. 2019;50(12): e344-e418.). Antiplatelet therapy is chosen by researchers-Single/dual antiplatelet therapy can be chosen.
41330427|NCT02091921|DRUG|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
41330428|NCT05353868|OTHER|No intervention|No intervention
41330429|NCT01142193|DRUG|USL255|
40812540|NCT00113399|DRUG|cisplatin|
41012318|NCT06387303|DRUG|Methadone|Intravenous Methadone
41012319|NCT06387303|DRUG|Morphine|Intrathecal Morphine
41012322|NCT03895320|BEHAVIORAL|Sexual Health Risk Assessment|The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.
41330430|NCT01142193|DRUG|Placebo|
40812541|NCT00113399|DRUG|docetaxel|
40812542|NCT00113399|DRUG|fluorouracil|
41330431|NCT03825107|OTHER|patching|covering the fellow eye with an eyepatch to force use of the amblyopic eye
41330432|NCT03825107|OTHER|Dichoptic videos|watching contrast-rebalanced dichoptic videos to allow the two eyes to work together
40812543|NCT00113399|DRUG|paclitaxel|
40812544|NCT00113399|RADIATION|radiation therapy|
40812545|NCT06486662|DRUG|OM-85-IN|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN
40812546|NCT06486662|DRUG|Placebo|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo
40812547|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
40812548|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
40812549|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
40812550|NCT03764566|BEHAVIORAL|Questionnaires|The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
41012323|NCT03895320|BEHAVIORAL|Sexual Health Score|The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.
41330433|NCT01330641|PROCEDURE|Injection of Subacromial Bursa|Injection of steroid and anesthetic to relieve pain
41330434|NCT01856842|PROCEDURE|Angiography and embolotherapy|
40812551|NCT06439654|OTHER|Supportive care|The study model will utilize the accepted standard of care while implementing key enhancements to proactively reach high-risk patients as early as possible. Wrap around comprehensive care is defined as database screening, outreach, encouraging genetic testing for participants and their family members, and provide ongoing education, medical management (e.g., adherence to FDA-approved medications), routine laboratory testing, specialist referrals, Epic referrals to integrated care support such as pharmacy, nutrition, social work, and community health), and routine follow-up either in-person or using virtual visits. Consultations with pharmacists, nutritionists and genetic counselors or specialists to manage co-morbidities may be requested.
40812552|NCT02573896|DRUG|Dinutuximab|17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
40812553|NCT02573896|BIOLOGICAL|NK Cells|The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
40812554|NCT02573896|DRUG|Lenalidomide|25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
40812555|NCT05070819|DIAGNOSTIC_TEST|pro-ANP|pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.
40812556|NCT00579618|OTHER|Saliva or Blood samples|Extracting sample of saliva or blood only once.
40812557|NCT02910752|DRUG|CLAM+PBSC|Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
40812558|NCT05402163|DEVICE|Adaptive DBS|aDBS vs cDBS
40812559|NCT05402163|DEVICE|Continuous DBS|aDBS vs cDBS
40812560|NCT00158249|DRUG|citicoline|2 gm/day, 8 weeks treatment
40812561|NCT00158249|DRUG|placebo|matched for physical appearance
40812562|NCT04037449|PROCEDURE|TAP block|With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
40812563|NCT04037449|OTHER|Conventional analgesia|"Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.~Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)"
40812564|NCT06317259|BEHAVIORAL|Hypoxic breathwork plus music and messaging|Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. The audio track also includes dynamic music that accompanies the different stages as well as positive messaging encouraging self-determination.
40812565|NCT06317259|BEHAVIORAL|Hypoxic breathwork only|Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. Other than breathing instructions and pacing, the audio track is silent.
40812566|NCT06317259|BEHAVIORAL|Music and messaging meditation|Music and messaging meditation consists of dynamic music that is engaging and aids focus, as well as positive messaging encouraging self-determination.
40812567|NCT06249698|DIETARY_SUPPLEMENT|meal replacements and supplements|Consumed daily: 2 Nutrimeal Active meal replacement shake, 1 electrolyte replacement drink, 3 metabolism + supplements, 1 whole food meal, and whole food snacks consisting of fruits and vegetables. 1200-1600 calories per day
40812568|NCT05837611|BEHAVIORAL|Deposit Contract|A deposit contract requires individuals to put down money that is earned back contingently upon meeting their goals.
41012324|NCT03895320|BEHAVIORAL|Sexual Health Messaging|After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'
41012325|NCT03895320|BEHAVIORAL|Water SSB Quiz|The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).
41330435|NCT05188599|DIAGNOSTIC_TEST|İsokinetic assessment|Isokinetic assessments of hip flexor and extensor muscle strength and proprioception wiill be performed
41330436|NCT03043807|DRUG|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
41330437|NCT03043807|DRUG|Docetaxel|75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles. Dose may decreased in the following intervals: 65 mg/M2, 55 mg/M2, 35 mg/M2.
41330438|NCT03043807|DRUG|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
41330439|NCT03043807|RADIATION|Radiation|Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.
41330440|NCT03043807|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 mg / day may be given at the investigator's discretion.
41330441|NCT01223768|DRUG|Acetyl-l-Carnitine|2g per day
41330442|NCT01223768|DRUG|placebo|twice per day
41330443|NCT04390568|DRUG|Spesolimap|Spesolimap
41330444|NCT01242254|BIOLOGICAL|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
41330445|NCT03859960|DIAGNOSTIC_TEST|body composition|fat mass % (FM%) and fat-free mass (FFM%)% of arms, legs, trunk, android, gynoid and total body
41330446|NCT03859960|DIAGNOSTIC_TEST|glucose, insulin, glycohemoglobin|In the morning after 12 hours overnight fast, all individuals underwent a 75 gram (g) oral glucose tolerance test (OGTT). Blood samples were taken before loading glucose and then 30, 60, 90 and 120 minutes after taking glucose solution in order to measure serum glucose and insulin levels. Glycohemoglobin (HbA1c) was measured in blood samples taken before the OGTT. We calculated the Matsuda index and Homeostasis model assessment index (HOMA-IR) using glucose and insulin levels.
41330447|NCT01063218|OTHER|Emollient - Cetaphil Advanced|Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
41330448|NCT05468762|PROCEDURE|Transfemoral tranScatheter aortic valvE implantation|Transcatheter aortic valve implantation (TAVI) is an established treatment modality in patients ≥ 75 years old with severe symptomatic aortic stenosis after Heart Team evaluation
41330449|NCT00055575|DRUG|Scopolamine Nasal Spray|
41330450|NCT03625297|OTHER|shelter cat|families will adopt a shelter cat
41330451|NCT01347632|DRUG|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
41330452|NCT06506838|DRUG|Anlotinib|For patients with the soft tissue sarcoma, the standard doxorubicin monotherapy regimen involves administering 37.5 mg/m² intravenously on days 1-2 of every 3 week . The treatment includes 3 cycles of neoadjuvant chemotherapy before surgery and 3 cycles of adjuvant chemotherapy after surgery, totaling 6 cycles. Anlotinib is administered at 12mg/d QD，day1\~14, 21d/cycle. Neoadjuvant radiotherapy is conducted before surgery, starting after the second chemotherapy cycle, using stereotactic body radiation therapy (SBRT) with a dose of 4\*10 Gy. Radical resection surgery is performed after the third chemotherapy cycle.
41330453|NCT05148169|DRUG|SSRIs|One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
41481886|NCT03606421|RADIATION|WBRT and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
41481887|NCT01079832|RADIATION|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
41481888|NCT01079832|PROCEDURE|quality-of-life assessment|Ancillary studies
41012326|NCT03895320|BEHAVIORAL|Water SSB Score|The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
41012327|NCT03895320|BEHAVIORAL|Water SSB Messaging|After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'
41155788|NCT04427397|OTHER|Sulcular Bristle Tip Technique (SBTT)|Tooth brushing should begin on the distal of the most posterior tooth on one side of the mouth and proceed anteriorly and then posteriorly overlapping areas to the most distal surface of the most posterior tooth on the contra lateral side. The lingual is done in like fashion ending where the brushing began. The opposing arch is brushed in the same manner. When moving from one area to the next, disengage the brush bristles entirely off the teeth to allow them to straighten, and then reposition the brush in the next overlapping area. Do not to drag the bristle tips from one area to the next area. For the lingual of the anterior teeth, the narrow portion of the brush is used with the exact same technique as described above. For the lingual of the mandibular molars, the angulation of the toothbrush bristles to the tooth needs to be somewhat more perpendicular to the tooth than on the buccal to ensure that the bristle tips enter the gingival crevice.
41481889|NCT00325832|DEVICE|BpTRU|
41481890|NCT00325832|DEVICE|Conventional mercury sphygmomanometry|
41481891|NCT06434922|DEVICE|Prevention Strategies|Data collection sessions lasted approximately 1 to 1.50 hours, with education and foot care provided once a month. Subsequently, patients underwent monthly follow-ups for three months, during which they received guidance on foot examination, foot care, dietary habits, physical exercise, and stress management.
40812569|NCT05837611|OTHER|Transdermal Alcohol Monitoring|Using a SCRAM-Cam device participants will be monitored for their alcohol use.
40812570|NCT06205381|DRUG|AV078|Oral solution containing active ingredient, AV078
40812571|NCT06205381|DRUG|Placebo|Oral solution with no active ingredients
41012328|NCT03895320|BEHAVIORAL|STI Screening|All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
41012329|NCT05776277|BIOLOGICAL|Iltamiocel|Single external anal sphincter (EAS) injection of 300 x 10\^6 cells.
41012330|NCT05776277|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
41012331|NCT04257058|BEHAVIORAL|Electronic educational material|Electronic media via email
41012332|NCT04047290|DRUG|AK112|AK112 is a PD1/VEGF bispecific antibody.
41012333|NCT01461096|BIOLOGICAL|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
41012334|NCT01461096|BIOLOGICAL|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
41012335|NCT01461096|BIOLOGICAL|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
41012336|NCT00226603|BEHAVIORAL|Specific training programme (behavior)|
41012337|NCT01494233|DRUG|250 mg LX1033 tablets|250 mg LX1033 tablets administered orally
41012338|NCT01494233|DRUG|Placebo tablet|Matching placebo tablet administered orally
41012339|NCT01947530|PROCEDURE|Navigational Bronchoscopy|
41012340|NCT01947530|PROCEDURE|Standard Bronchoscopy|
41012341|NCT02837536|OTHER|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
41012342|NCT02837536|OTHER|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
41330454|NCT05148169|DIETARY_SUPPLEMENT|SSRI plus Sulforaphane|"One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN (ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.) is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
41330455|NCT01438307|DRUG|Cabazitaxel-XRP6258 (3-week cycle)|Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
41481892|NCT06434922|DEVICE|Standard Strategiies|Group were educated about DM management, medication adherence, dietary practices, physical exercise routines, and foot care through pamphlets
41481893|NCT05518266|PROCEDURE|US-guided Parasternal block|Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of sternum after skin closure under ultrasound guidance
40812572|NCT06205381|DRUG|Itraconazole|Once daily oral dose of 200 mg itraconazole administered for 9 days
40812573|NCT06205381|DRUG|Midazolam|2.5 mg midazolam administered orally on day 1 and day 18
40812574|NCT06205381|DRUG|Fexofenadine|120 mg fexofenadine administered orally on day 1 and day 18
41012343|NCT03226067|DRUG|GKT137831|GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
41012344|NCT03226067|DRUG|Placebo oral capsule|Matching capsules.
41155789|NCT05361304|DEVICE|senofilcon A contact lenses made with a novel manufacturing technology|TEST Lens
40812575|NCT03409705|DIETARY_SUPPLEMENT|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
40812576|NCT03409705|DIETARY_SUPPLEMENT|Control group|2,000 mg of starch was orally administered per day for 12 weeks.
41012345|NCT05444309|PROCEDURE|Quadratus lumborum (QL) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the quadratus lumborum block approach
41012346|NCT05444309|PROCEDURE|Pericapsular Nerve Group (PENG) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the Pericapsular Nerve Group (PENG) block
41012347|NCT05037396|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
41012348|NCT00961324|DRUG|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
41012349|NCT00961324|DRUG|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
41012350|NCT00117091|DRUG|Anakinra (Kineret®)|
41012351|NCT01980849|DRUG|Nadroparin, long term|
41012352|NCT01980849|DRUG|Nadroparin: short-term|
41012353|NCT00098839|DRUG|L-asparaginase|Given IM
41012354|NCT00098839|DRUG|doxorubicin hydrochloride|Given IV
41012355|NCT00098839|DRUG|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
41012356|NCT00098839|DRUG|vincristine sulfate|Given IV
41012357|NCT00098839|BIOLOGICAL|epratuzumab|Given IV
41012358|NCT00098839|DRUG|cytarabine|Given IT
41012359|NCT00098839|DRUG|prednisone|Given orally
41012360|NCT00098839|DRUG|pegaspargase|Given IM
41012361|NCT00098839|DRUG|dexrazoxane hydrochloride|Given IV
41012362|NCT00098839|DRUG|methotrexate|Given IT
41012363|NCT00098839|DRUG|etoposide|Given IV
41012364|NCT00098839|DRUG|cyclophosphamide|Given IV
41481894|NCT05518266|PROCEDURE|Surgeon-delivered parasternal block|Just before wiring of the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
40812577|NCT01893411|DRUG|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
41012365|NCT00098839|DRUG|leucovorin calcium|Given IV
41012366|NCT00098839|BIOLOGICAL|filgrastim|Given SC
41012367|NCT05198492|OTHER|Impact of air pollution|To assess the short- and long- term impact of air pollution
41012368|NCT01731704|RADIATION|Stereotactic radiosurgery (SRS)|
41012369|NCT01731704|RADIATION|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
41012370|NCT03511560|DRUG|Tacrolimus Extended Release Oral Tablet|Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
41012371|NCT03511560|DRUG|Tacrolimus|Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
41012372|NCT03536728|DRUG|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
41481895|NCT02519621|DEVICE|NPWT PRO without irrigation|NPWT PRO without irrigation.
41012373|NCT03536728|DRUG|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
41012374|NCT00996567|DRUG|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
41012375|NCT02258282|DRUG|Etanercept|
41012376|NCT02258282|DRUG|Control|
41012377|NCT03995758|DEVICE|MOSES|software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
41012378|NCT00436280|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
41012379|NCT00436280|DRUG|gemcitabine|1000 mg/m², IV, once, every two weeks, four to eight 2 week cycles
41012380|NCT00436280|DRUG|rituximab|375 mg/m², IV, once every 2 weeks, four to eight 2 week cycles
41012381|NCT00436280|DRUG|oxaliplatin|100 mg/m², IV, once every two weeks, four to eight 2 week cycles
41012382|NCT04720859|DRUG|Canagliflozin 300 MG Oral Tablet|Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
41012383|NCT00343187|DRUG|ACZONE (dapsone) Gel, 5%|
41012384|NCT00343187|DRUG|Vehicle Control|
41012385|NCT05494255|OTHER|Recruitment maneuver|In Group RM (intervention group) after skin closure, mechanical ventilation settings will be set to FiO2:100%, I:E=1:1, respiratory rate: 6, and then tidal volume will be increased gradually by 150 ml until reaching a plato pressure of 30 mmHg. After 3 breaths in this state, RM will be considered accomplished. LUS evaluation will be made just before and after the RM.
41012386|NCT02124291|DEVICE|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
41012387|NCT03833284|BEHAVIORAL|Participant Barriers to TVU Screening|Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.
41012388|NCT03833284|BEHAVIORAL|Provider Barriers to TVU Screening|Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
41012389|NCT00996762|DRUG|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
41481896|NCT02519621|DEVICE|NPWT PRO with irrigation|NPWT PRO with irrigation (saline)
41481897|NCT02519621|DEVICE|KCI Ulta|KCI Ulta NPWT without irrigation
41481898|NCT04546893|BIOLOGICAL|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
41012390|NCT02749903|DRUG|enzalutamide|oral
41012391|NCT05301205|DRUG|oral gabapentin|will be received oral gabapentin capsule 2 HOURS pre-operatively.
41012392|NCT05115994|DEVICE|Continous positive airway pressure|
41012393|NCT00727194|DRUG|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
41012394|NCT00727194|DRUG|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
41012395|NCT01119911|OTHER|Blood sampling from peripheral venous catheter.|Venipuncture is performed on the opposite limb of the peripheral venous catheter. Within 3 minutes, a second sample is taken from existing peripheral venous catheter used for fluid administration. Intravenous fluids are then stopped for 30 seconds and a tourniquet applied proximal to the device for another 30 seconds. A 2-mL syringe is attached and 0.5 mL of blood aspirated and discarded. Thereafter, 2 mL blood is slowly drawn during about 15 seconds, into a different 2-mL syringe, to allow a gentle pumping action that may reduce vacuum in the syringe and thus hemolysis rates. Afterwards, the intravenous device is flushed with 2 mL normal saline and infusion restarted.
41012396|NCT06430372|DRUG|Bev-ICG|Probe targeting VEGF-A that is topically administrated during the endoscopy
41012397|NCT06430372|DEVICE|NIR-II fluorescence endoscopy platform|An endoscopic detection device which can detect and visualize NIR-II fluorescent signal during the endoscopy
41012398|NCT00317681|DRUG|Tacrolimus ointment|
41012399|NCT02121340|BEHAVIORAL|Behavioral Activation|
41012400|NCT00954213|BEHAVIORAL|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
41012401|NCT04715984|OTHER|Neurophysiology recordings|Neurophysiology recordings will be performed during deep brain stimulation surgery and their relationship to performance on a working memory task evaluated
41012402|NCT04715984|PROCEDURE|Neural stimulation|Neural stimulation will be delivered during a working memory task and its impact on task performance quantified
41012403|NCT03085927|BEHAVIORAL|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
41012404|NCT03085927|BEHAVIORAL|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
41012405|NCT06020404|PROCEDURE|supine position|At the end of the PEEP trial (i.e. at PEEP 5 cmH2O), patients will lay in the supine position for 15 minutes arterial blood gases will be performed and then a one-breath derecruitment maneuver (5-second exhalation, respiratory rate \< 8 bpm) from PEEP 5 cmH2O to 0 cmH2O will be conducted to assess baseline functional residual capacity (FRC), defined as the EELI measured at 0 PEEP.
41012406|NCT06020404|PROCEDURE|prone position|"After the supine step, each enrolled patient will be placed in the prone position for 1 hour.~For safety reasons, enteral feeding will be interrupted 30 minutes before prone positioning and re-established after the study ending.~During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 30 minutes of prone positioning. After 30 minutes of PEEP 12 cmH2O (provided that plateau and driving pressures did not exceed 30 cmH2O and 15 cmH2O, respectively) to stabilize lung volumes, the same measurements applied for the supine step will be performed. Any further modifications in the MV settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.~In case of sudden worsening of the oxygenation impairment or haemodynamic, 100% FiO2 will be set, and the patient will be promptly positioned in the supine semi-recumbent position."
41012407|NCT04053374|OTHER|Blood sampling|Blood sampling +/- CSF sampling
41012408|NCT02442921|DRUG|Colchicine|up to 2mg of Colchicine daily
41012409|NCT02442921|DRUG|Placebo|Daily placebo
41012410|NCT01201252|PROCEDURE|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
41012411|NCT04026919|OTHER|OK EN CASA-ZAINDOO|Intervention based on cognitive- behavioural techniques offered in an online format.
41012412|NCT03490084|OTHER|Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
41012413|NCT03490084|OTHER|Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
41012414|NCT05506020|PROCEDURE|indocyanine green (ICG) fluorescence cholangiography|indocyanine green (ICG) fluorescence cholangiography during operation
41012415|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 14 days
41012416|NCT03555526|DRUG|Amoxicillin|amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)
40812578|NCT01893411|DRUG|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
40812579|NCT01893411|DRUG|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
41012417|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, bid, for 7 days (day 8-14)
41155790|NCT05361304|DEVICE|senofilcon A contact lenses made with the current manufacturing technology|CONTROL Lens
41481899|NCT06414278|OTHER|Non-Interventional Study|Non-interventional study
41012418|NCT03555526|DRUG|Levofloxacin 500mg|levofloxacin 250mg, bid, for 7 days (day 8-14)
41012419|NCT03555526|DRUG|Clarithromycin ER|clarithromycin 500mg, bid, for 7 days (day 8-14)
41012420|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 10 days
41012421|NCT03555526|DRUG|Dibismuth trioxide|Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
41012422|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, tid, for 10 days (day 1-10)
41012423|NCT03555526|DRUG|tetracycline|tetracycline 500mg, qid, for 10 days
41012424|NCT04919967|BEHAVIORAL|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.
41012425|NCT04919967|BEHAVIORAL|e-learning toolkit|A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
41012426|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
41012427|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
41012428|NCT04319315|OTHER|survey|online survey
41012429|NCT00947297|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
41012430|NCT05729620|DEVICE|Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
41012431|NCT00134875|DRUG|Buprenorphine/naloxone|Acute doses of buprenorphine/naloxone in each experimental test session. Doses delivered by either sublingual or parenteral routes, and are: 4/1, 8/2, 16/4 mg.
41330456|NCT01438307|DRUG|Cabazitaxel-XRP6258 (5-week cycle)|Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
41330457|NCT03358654|DRUG|mesenchymal stem cells from umbilical cord|inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.
41330458|NCT03286296|BIOLOGICAL|LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection|LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
41330459|NCT02932644|OTHER|Baseline serum vitamin D level below 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
41330460|NCT02932644|OTHER|Baseline serum vitamin D level at or above 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
41330461|NCT02147509|DRUG|0.02% Fm, SH|Sjogren's Syndrome patients with severe dry eye
41330462|NCT02147509|DRUG|0.02% Fm, SH, 0.05% CsA|Sjogren's Syndrome patients with severe dry eye
41330463|NCT02147509|OTHER|0.02% Fm, SH, tBCL|Sjogren's Syndrome patients with severe dry eye
41330464|NCT02147509|DRUG|0.02% Fm, SH, AS|Sjogren's Syndrome patients with severe dry eye
41012432|NCT02978690|DRUG|Spesolimab|Solution for infusion
41012433|NCT06534021|DRUG|IASO-782 injection|Each subject will be given only one dose of IASO-782. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
41012434|NCT06534021|DRUG|placebo|Each subject will be given one dose of placebo. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
41155791|NCT04573257|OTHER|Echocardiography and pulse wave velocity measurement|Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement
41155792|NCT04796389|OTHER|Music|Preferred music of the participant administered using headphones.
41330465|NCT05121831|DRUG|DGX-001Dose 1|Dose level 1 of DGX-001
41330466|NCT05121831|DRUG|DGX-001 Dose 2|Dose level 2 of DGX-001
41330467|NCT05121831|DRUG|DGX-001 Dose 3|Dose level 3 of DGX-001
41330468|NCT05121831|DRUG|DGX-001 Dose 4|Dose level 4 of DGX-001
41330469|NCT05121831|DRUG|MAD dose panel of DGX-001|Dose levels confirmed through SAD and MAD
41481900|NCT05406024|DEVICE|Digital platform|The digital platform consists of 84 exercise sessions of progressive intensity. Each day, the tool offers 8 exercise sessions of about 5 to 10 minutes each, spaced out over an hour. One session can represent several exercises. The patient is asked to perform them daily.
41481901|NCT04375839|DEVICE|Zirconia implant|Following standard surgical protocol, Zirconia implant will be placed in horizontally deficient ridge.
40812580|NCT02047773|OTHER|Duration|If bacterial load checked on day 7 is less than 10\^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10\^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
40812581|NCT02047773|DRUG|Colomycin|If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
41012435|NCT05870527|DEVICE|Electrical stimulator|Electrical stimulation will be used to stimulate the Arnold's nerve and measure pupil dilation. The electrical stimulator is part of the standard facial nerve monitoring unit that we utilize in cochlear implantation and will be setup prior to surgery in standard fashion. The device allows for constant current stimulation, with stimulus range between 0-30 mA.
41330470|NCT04667052|DRUG|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.
41330471|NCT04667052|DRUG|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
41481902|NCT04375839|DEVICE|Titanium implant|Following standard surgical protocol, Titanium implant will be placed in horizontally deficient ridge.
41481903|NCT02504346|DRUG|AZD9291|
41481904|NCT02434224|PROCEDURE|Music Therapy|2 to 3 sessions per week of individualized creative music therapy
41481905|NCT04352608|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
41481906|NCT04352608|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
41481907|NCT04352608|BIOLOGICAL|Two doses of placebo at the emergency vaccination schedule|Two doses of placebo at the schedule of day 0,14 and one dose of booster immunization with placebo 6 months after the schedule of day 0,14 in phaseⅡ.
41481908|NCT04352608|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ.
40812582|NCT02047773|DRUG|Meropenem|
40812583|NCT06114914|DIAGNOSTIC_TEST|Tap Talk online program|Online hand and speech motor testing
40812584|NCT00812409|DIETARY_SUPPLEMENT|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
40812585|NCT00812409|OTHER|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
40812586|NCT03308968|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
40812587|NCT03308968|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
40812588|NCT03001830|BIOLOGICAL|AAV2/8-HLP-FVIII-V3|Infusion of AAV2/8-HLP-FVIII-V3
40812589|NCT05627011|BEHAVIORAL|Improving Pediatric Obesity Practice Using Prompts (iPOP-UP)|EHR-based CDS tools refined through a formative evaluation and user-centered design process that immediately preceded this study.
40812590|NCT04261725|GENETIC|EGFR mutation|Searching the EGFR mutation in pulmonary biopsy
41155793|NCT03588299|DRUG|BAY2599023 (DTX201)|Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
41155794|NCT06034964|DRUG|Tislelizumab|Tislelizumab：200mg, iv, d1, 21 days per cycle, until disease progression or intolerable toxicity
41330472|NCT02064205|DIETARY_SUPPLEMENT|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
41330473|NCT02064205|DIETARY_SUPPLEMENT|glucose syrup|Glucose syrup is used a control product for the polydextrose
41330474|NCT01812122|DRUG|Glimepiride|
41330475|NCT01812122|DRUG|Vildagliptin|
41330476|NCT02722772|DRUG|Etanercept|Intra-articular injection of etanercept of 25mg/w/joint for 5 weeks.
41481909|NCT04352608|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ
41481910|NCT04352608|BIOLOGICAL|Two doses of placebo at the routine vaccination schedule|Two doses of placebo at the schedule of day 0,28 and one dose of booster immunization with placebo 6 months after the schedule of day 0,28 in phaseⅡ.
41330477|NCT02722772|OTHER|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 5 weeks
41330478|NCT02571608|DRUG|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
41155795|NCT06477562|OTHER|Endoscopy|surveillance endoscopy was routinely performed to the patients with proximal gastrectomy with double tract reconstruction group.
41330479|NCT02571608|DRUG|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
41330480|NCT00617838|OTHER|Optimal gluten introduction|Optimization of gluten introduction by nutritional counselling
41330481|NCT03672357|PROCEDURE|Laparoscopic liver resection|Laparoscopic hepatectomy
41330482|NCT03672357|PROCEDURE|Open liver resection|Traditional open hepatectomy
41330483|NCT03967509|BEHAVIORAL|Comet|
41330484|NCT03424317|BEHAVIORAL|Sodium intake reduction|Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively
41481911|NCT04352608|BIOLOGICAL|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
40812591|NCT05996965|OTHER|HemoVista|additional attatchment of non-invasive hemodynamic monitoring HemoVista with FloTrac
40812592|NCT02245269|DRUG|Tipranavir|
40812593|NCT02245269|DRUG|Ritonavir|
40812594|NCT02245269|DRUG|Atorvastatin|
41330485|NCT03424317|BEHAVIORAL|Exercise|Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
41330486|NCT03372564|PROCEDURE|Hip Capsule Repair|In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl).
41481912|NCT04352608|BIOLOGICAL|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
41481913|NCT04352608|BIOLOGICAL|Three doses of placebo at the emergency vaccination schedule|Three doses of placebo at the schedule of day 0,14,42
40812595|NCT02245269|DRUG|Maalox|Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
40918236|NCT04598191|DRUG|Iloprost|"Participants in Iloprost group will be administered aerosolized 20 μg iloprost in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
41155796|NCT04798508|OTHER|Evoked related potential - P3 paradigm|Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
41330487|NCT03168555|DRUG|chenodeoxycholic acid|1250 mg CDCA is given with a study meal
41330488|NCT06199505|DRUG|GZR101|Once daily
41481914|NCT04352608|BIOLOGICAL|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
41481915|NCT04352608|BIOLOGICAL|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
41330489|NCT06199505|DRUG|insulin degledec/insulin aspart|Once daily or twice daily
41330490|NCT01522443|DRUG|cabozantinib|Tablets taken orally once daily.
41330491|NCT01522443|DRUG|mitoxantrone|Given by IV once every 3 weeks.
41330492|NCT01522443|DRUG|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
41330493|NCT01353755|DRUG|Grass pollen specific immunotherapy|"* Strength 1 (0.78μg/mL)~* Strength 2 (6.25μg/mL)~* Strength 3 (50μg/mL)~* Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo."
41481916|NCT04352608|BIOLOGICAL|Three doses of placebo at the routine vaccination schedule|Three doses of placebo at the schedule of day 0,28,56
41481917|NCT06205433|OTHER|IHSS Basic Training|The intervention is the Center for Caregiver Advancements 30-hour IHSS Basic training course.
41481918|NCT03053336|BEHAVIORAL|App-technology to increase physical activity|Access to the smartphone-app during 12 weeks. A personal step goal is set for each individual in the app.
40812596|NCT04248244|OTHER|Palliative Care|Early PC Integration - Participants will meet with a member of the outpatient PC team, which consists of board-certified PC physicians, advance practice providers and nurse care coordinators, within three weeks of enrollment. Participants will be scheduled to meet with a PC provider at least once per month. Additional visits may be scheduled at the discretion of participants, oncologists or PC providers. All participants will receive routine oncologic care throughout the study period.
41012436|NCT05671679|OTHER|SNAQ app|SNAQ is a smartphone food analysis app that estimates the macronutrient content of a meal, based on a single image. The app first determines meal content in terms of food components with input from the user to correct or add further components (e.g. foods, ingredients, sauces, herbs or seasonings). Then, the total macronutrient and energy content of the meal is determined based on the estimated volume and information from a nutritional database. Of note, the application also allows for assessing nutritional content of packaged foods by means of a barcode scanning function. The user can always adapt proposed nutritional contents at their own discretion. Meal macronutrients alongside the food pictures are collected in a detailed log which allows users to review their dietary choices. The product is not conceived by its manufacturer to be used for medical purposes and can thus not be considered a medical device.
41330494|NCT01353755|DRUG|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
41330495|NCT05739357|DEVICE|NIRS, EEG|During the carotic clamp, if cerebral oxygenation decreased for more than 12 % on the operating side from the baseline value, simple interventions as, increasing arterial blood pressure, increasing arterial carbon dioxide tension or increasing oxygen inspiration concentration will be performed.
41481919|NCT02622113|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
41481920|NCT02622113|DRUG|Insulin|
41481921|NCT00056745|BIOLOGICAL|TBC-3B|
41481922|NCT04997655|DIAGNOSTIC_TEST|Ultrasound measurement|In the patient group who will undergo elective laparoscopic cholecystectomy, the diaphragmatic thickness values measured and recorded routinely at the pre-operative, post-extubation and post-operative 30th minute, at the end of inspiration and expiration, and the inspiratory amplitude in m-mode in the ultrasound measured from the right anterior axillary line subcostal area were observed as observational data. will be saved in our file.
41481923|NCT00781521|DRUG|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
41481924|NCT02217631|DRUG|BI 653048 BS H3PO4|
41330496|NCT06443749|PROCEDURE|appendectomy|the appendiceal stump will be closed with a polyper homologous clip or with an intracorporial node
41330497|NCT00991224|BIOLOGICAL|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
40812597|NCT04248244|OTHER|FACT-MM questionnaire|FACT-MM questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
40918237|NCT04598191|DRUG|Control (Normal saline)|"Participants in Control group will be administered aerosolized 5 ml of normal saline in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
40918238|NCT00421941|PROCEDURE|Tube feeding|
41330498|NCT00991224|BIOLOGICAL|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
41330499|NCT00991224|OTHER|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
41481925|NCT02217631|DRUG|Prednisolone low dose|
41481926|NCT02217631|DRUG|Prednisolone high dose|
41481927|NCT02217631|DRUG|Placebo|
41481928|NCT03043560|DRUG|Ezogabine|daily for 5 weeks
41481929|NCT03043560|DRUG|Placebos|placebo pill daily for 5 weeks
41481930|NCT03659461|DRUG|Sitagliptin|oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.
41481931|NCT02546349|DRUG|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
41481932|NCT05726760|BEHAVIORAL|Seeking informed consent for participation in the study.|The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. The Anaesthetist or researcher will conduct this process. A patient information leaflet will be provided for the parturients.
41481933|NCT05726760|DEVICE|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
41481934|NCT05726760|DEVICE|Covidien Mon-a-Therm skin temperature probes will be applied to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher will conduct the intervention in theatre. The probes will be removed in the recovery ward.
41481935|NCT05726760|DEVICE|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the ear.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
41330500|NCT02249026|DRUG|BZDs + opiate exposure treated with BPN|These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
41012437|NCT05671679|OTHER|Traditional carbohydrate counting|Patients will follow their traditional methods of carbohydrate counting during the control period. In addition to assess sustainability of the intervention, following the control period, the control group will also go an intervention period of 3 weeks using the SNAQ App.
41012438|NCT06313528|DRUG|LY3437943|Administered SC
41012439|NCT06313528|OTHER|Placebo|Administered SC
41012440|NCT01678534|DRUG|Allogenic mesenchymal stem cells from adipose tissue|
41012441|NCT01678534|DRUG|Placebo|
41012442|NCT01149798|DRUG|Abraxane and Cisplatin combination|"Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.~Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1."
41012443|NCT00394797|PROCEDURE|mitral valve annuloplasty|
41012444|NCT02081495|DRUG|DOXIL/CAELYX reference product (Treatment A)|Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
41012445|NCT02081495|DRUG|DOXIL/CAELYX test product (Treatment B)|Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
41012446|NCT03127228|OTHER|Standard mechanical debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
41012447|NCT03127228|DEVICE|Er:YAG laser-assisted debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
41012448|NCT04556305|BEHAVIORAL|Mind|See arm description.
41012449|NCT04556305|BEHAVIORAL|Move|See arm description.
41481936|NCT00607152|DRUG|Rasburicase|0.20mg/kg per day IV
41012450|NCT03475160|DRUG|Sildenafil Citrate vaginal suppositories|Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
41012451|NCT03475160|DRUG|Placebo vaginal suppositories|Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
41012452|NCT03475160|PROCEDURE|Uterine artery Doppler before treatment|Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
41012453|NCT03475160|PROCEDURE|Uterine artery Doppler after treatment|Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
41481937|NCT00607152|DRUG|Allopurinol|100mg tablets
41481938|NCT00998972|DRUG|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
41012454|NCT02309281|DRUG|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
41012455|NCT01703481|DRUG|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
41481939|NCT05143151|BIOLOGICAL|CD276 CAR-T cells|CD276 CAR-T cells infusion
41012456|NCT01703481|DRUG|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
41012457|NCT01703481|DRUG|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
41012458|NCT01703481|DRUG|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
40812598|NCT04248244|OTHER|HADS questionnaire|HADS questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
41012459|NCT00113113|DRUG|Rubitecan|
41012460|NCT02582840|DRUG|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
41481940|NCT02070302|DRUG|Botulinum Toxin Type A|40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
41481941|NCT02070302|DRUG|Placebo|Placebo (Normal Saline) divided into 2 injections of .4cc each
41481942|NCT03659474|OTHER|compression|compression by Game Ready
41481943|NCT03659474|OTHER|ice pack|cryotherapy for ice pack
41481944|NCT03659474|OTHER|immersion|immersion therapy
41481945|NCT00094081|DRUG|tirapazamine (SR259075)|
41481946|NCT00094081|DRUG|cisplatin|
41155797|NCT04531852|OTHER|CALSTI - Complex Active Lifestyle Intervention|"A group-based exercise (EX) and health empowerment program (HEP) conducted in the local area.~Structured, progressive resistance (55-60%), balance (10-15%), endurance (10-15%) exercise was delivered twice weekly for 12 weeks under supervision of a trained instructor.~HEP consists of 8 group sessions aiming to facilitate long-term behaviour change, by empowering older citizens to act on current risk behaviours (i.e. low physical activity/exercise, high sedentary behaviour, social isolation, poor dietary habits, incontinence). Four sessions were conducted during the exercise intervention period (phase 1 - intensive), and four sessions in the following 12 weeks (phase 2 - maintenance)."
41330501|NCT02249026|DRUG|Opiates exposure treated with BPN|These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
41330502|NCT05446194|DEVICE|Non invasive neuromodulation device pattern 1|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
41330503|NCT05446194|DEVICE|Non invasive neuromodulation device pattern 2|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
41481947|NCT00094081|PROCEDURE|Radiation Therapy|
41330504|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
40812599|NCT05069077|OTHER|Music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
40812600|NCT05069077|OTHER|No music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
41012461|NCT02582840|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
41012462|NCT02582840|DRUG|Placebo tablet|Placebo tablet. Oral dose
41012463|NCT06054672|DEVICE|Subthreshold Electrical stimulation|We will use a electrotherapy device to deliver subthreshold Electrical stimulation
41012464|NCT04577092|OTHER|Warm-up exercise|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips.
41012465|NCT04577092|OTHER|Motor-Cognitive exercise|After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
41330505|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
41330506|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
41330507|NCT01080612|DRUG|300 mg pregabalin immediate release|A single dose of 300 mg immediate release capsule will be administered in the fasted state
41330508|NCT05376527|BIOLOGICAL|Double Recombinant Vaccinia Virus VV-GMCSF-Lact|"Intratumoral injections:~1\*107 PFU (calculated at minimal ED on mice); 2\*107 PFU; 4\*107 PFU; 6\*107 PFU; 8\*107 PFU; 10\*107 PFU;"
41481948|NCT02801552|DEVICE|PRF|Regenerative Endodontic Procedure with PRF: autologous PRF will be used instead of blood clot in the second vist.
40812601|NCT05911360|DRUG|DTG/3TC|DTG/3TC FDC will be administered once daily.
41012466|NCT04577092|OTHER|Motor-Motor exercise|participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
41012467|NCT04577092|OTHER|Cool-down exercise|In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
41012468|NCT01422434|DRUG|LEO 90105 = calcipotriol + betamethasone dipropionate|Applied once daily for 4 weeks.
41481949|NCT00886041|PROCEDURE|laparoscopy|subjected to laparoscopy
41481950|NCT00886041|OTHER|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
41012469|NCT01422434|DRUG|Dovonex® = calcipotriol|Applied twice daily for 4 weeks.
40812602|NCT02351063|DRUG|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
40812603|NCT02428998|DIETARY_SUPPLEMENT|Korean Red Ginseng|
40812604|NCT02428998|DIETARY_SUPPLEMENT|Placebo|
41012470|NCT01422434|DRUG|Rinderon® - DP = betamethasone dipropionate|Applied once daily for 4 weeks.
41481951|NCT03979820|DRUG|BI 1467335|Film-coated tablet
41481952|NCT03979820|DRUG|Placebo|Film-coated tablet
41481953|NCT03979820|DRUG|Phenelzine sulfate|Film-coated tablet
41481954|NCT03979820|DRUG|Tyramine|Capsules
41481955|NCT05797584|DRUG|Dobutamine|Dobutamine 5.0 - 10.0 mcg/Kg/min ev
41481956|NCT05797584|OTHER|Passive leg raising|Passive leg raising for acute volume load
41481957|NCT03565913|DRUG|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
41012471|NCT02711800|DRUG|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
41330509|NCT03210220|PROCEDURE|Pecs II block|After identifying the axillary vein and artery, the ultrasound probe was positioned inferio-laterally, between the 3rd and 4th ribs, and then the pectoralis major and minor, and serratus anterior muscles were confirmed. The needle was advanced in a medio-lateral direction in-plane view of the ultrasound. For the Pecs II block, a total 30 mL of 0.5% ropivacaine was injected. First, the needle tip was advanced into the fascia between the pectoralis major and minor muscles and 10 mL of 0.5% ropivacaine was injected. Thereafter, the needle tip was advanced into the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL of 0.5% ropivacaine was injected in a similar manner.
41330510|NCT00782301|DRUG|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
41012472|NCT05060419|DRUG|Meropenem- FL058|"Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h"
41330511|NCT00782301|DRUG|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
41330512|NCT05808023|OTHER|FODMAP powder reintroduction|The FODMAP powders will be reintroduced in three different doses, each for three consecutive days.
40812605|NCT03647410|DEVICE|lumbopelvic fixation|Sacral fractures fixed with lumbopelvic fixation or novel adjustable plate were divided into two groups. Surgical time, intraoperative blood loss, frequency of intraoperative fluoroscopy, reduction quality, related complications, and functional outcome were reviewed.
41330513|NCT01600001|DRUG|KWA-0711|
41012473|NCT05060419|DRUG|Piperacillin -tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h
41012474|NCT05060419|DRUG|Saline|180min
41012475|NCT05060419|DRUG|Saline|30min
41330514|NCT01600001|DRUG|Placebo|
41330515|NCT06195904|OTHER|NA (No intervention)|NA (No intervention)
41330516|NCT01825226|OTHER|Enhanced-Homestead Food Production Program|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
41481958|NCT03565913|OTHER|CaAcS|CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
41481959|NCT06072495|OTHER|real time MRI|ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects
41481960|NCT01362465|PROCEDURE|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
41481961|NCT03297528|DRUG|donor lymphocyte infusion|Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
41330517|NCT05745025|DEVICE|Repeated Transcranial Magnetic Stimulation|rTMS will be delivered using a commercially available magnetic stimulator (Rapid2, Magstim Inc., Eden Prairie, MN) with a figure-of-8 Air Film coil at 10 Hz. Coil orientation will be optimized for stimulation of the abductor pollicis brevis. Stimulation targeting will be identified using motor-evoked potentials (MEP) of the first dorsal interossei that will be monitored using electromyography (EMG) (Motion Lab Systems Inc., Baton Rouge, LA). The motor threshold (MT) of the muscle will then be identified by systematically adjusting the pulse intensity. The MT will be considered the lowest stimulation intensity at which 5 out of 10 MEPs have a peak-to-peak amplitude of at least 50 microvolts. rTMS will be performed at the identified optimal location at 10Hz using an intensity that is 80% of the MT. Pulse trains will be delivered for 10 seconds, with a 30-second rest for 20 repetitions.
41330518|NCT05745025|DEVICE|Sham Repeated Transcranial Magnetic Stimulation|Sham rTMS will be performed using the same methods as the active group, but a sham Air Film coil (Magstim Inc., Eden Prairie, MN) will be used. This coil looks and sounds like the active coil, but it does not deliver magnetic pulses.
41481962|NCT02916693|DRUG|Mirabegron|FDA-approved, beta 3 agonist for over active bladder
41481963|NCT04745715|PROCEDURE|craniectomy|craniectomy outcomes and survival
41481964|NCT01046799|DRUG|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
41481965|NCT03238976|OTHER|Nature sounds|Nature sounds will be played for patients in the nature sounds exposure group.
41481966|NCT04135521|DRUG|Intraperitoneal chemotherapy|Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy
41481967|NCT04808830|OTHER|Evaluation of musculoskeletal pain prevalence|Prevalence of musculoskeletal pain will be evaluated over 9 body regions using The Nordic Musculoskeletal Questionnaire.
41012476|NCT01491321|PROCEDURE|Bee Venom Acupuncture Therapy|"Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
41012477|NCT01491321|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
41481968|NCT04808830|OTHER|Evaluation of quality of life|Quality of life will be evaluated using The EmPHasis-10 questionnaire and The Minnesota Living with Heart Failure Questionnaire.
41481969|NCT04808830|OTHER|Evaluation of functional exercise capacity|Functional exercise capacity will be evaluated using 6-min walk test.
41481970|NCT04808830|OTHER|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire- Short Form
41481971|NCT00145639|DRUG|Ifosfamide, Carboplatin, Doxorubicin|See Detailed Description for treatment plan.
41481972|NCT00145639|PROCEDURE|Limb Sparing|See Detailed Description for treatment plan.
41481973|NCT03777904|DIAGNOSTIC_TEST|Serum Ferritin level|Serum ferritin level will be collected with other clinical labs and measured in the research lab
40812606|NCT06154889|OTHER|consultations with a psychologist|Consultations with a sports psychologist to decrease kinesiophobia
40812607|NCT06154889|OTHER|Conventional reeducation|Conventional reeducation
41481974|NCT03777904|DIAGNOSTIC_TEST|Serum Ferritin iron content|Blood will be collected with other clinical labs and the iron content in the ferritin will be measured in the research lab
41481975|NCT03777904|DIAGNOSTIC_TEST|Urine Ferritin level|Urine will be collected non-invasively and analyzed for ferritin level
41481976|NCT03777904|DIAGNOSTIC_TEST|Urine ferritin iron content|Urine will be collected non-invasively and analyzed for iron content within the ferritin
41481977|NCT03130114|DRUG|Azithromycin|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
41481978|NCT03130114|OTHER|Placebo|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
41481979|NCT04904159|PROCEDURE|Thyroidectomy|total thyroidectomy
41481980|NCT04904159|PROCEDURE|Lobectomy|Lobectomy
41481981|NCT01617694|DRUG|dexmedetomidine|Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
41481982|NCT01617694|DRUG|Normal Saline|
41481983|NCT03799991|BEHAVIORAL|Vestibular physical therapy|Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
41481984|NCT03799991|BEHAVIORAL|Active control|Strength and flexibility exercises that do not involve head movements.
41481985|NCT00234182|DRUG|Interferon alpha-2b|
41481986|NCT00770692|DRUG|Eszopiclone 1 mg- Elderly|"Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
40812608|NCT01529515|DRUG|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
40812609|NCT01529515|DRUG|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
41012478|NCT01491321|PROCEDURE|Placebo|"Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
41012479|NCT04391582|OTHER|Tilapia skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage. These dressings were changed only if the tilapia skin did not adhere properly to the wound bed
41330519|NCT05745025|OTHER|Rehabilitation|"Rehabilitation will consist of education, value-based goal setting, Graded Motor Imagery (GMI) (3 components described below), and graded activity. Subjects will complete activities at treatment sessions and be asked to perform certain treatment activities at home.~Week 1: Pain education, functional value-based goal setting, laterality training (first component of GMI), one task for graded activity (task-based on patient goals)~Week 2: Continue week 1 activity, add graded motor imagery (second component of GMI), progress 1st graded activity, and initiate 2nd graded activity exercise.~Week 3- Mirror therapy (third component of GMI), assess knowledge and update education as needed, progress graded activity 1 and 2, and add 3rd graded activity if appropriate based on patient goals.~Week 4- Continue with week 3 activities. Discuss experience with meditation and progress graded activity as tolerated"
41330520|NCT06039995|PROCEDURE|Comprehensive Oral Care|"The intervention mentioned in this study involves a combination of oral care strategies for patients in the intervention group. These strategies include:~Chlorhexidine Mouthwash: Patients in the intervention group will receive Chlorhexidine mouthwash. Chlorhexidine is known for its effectiveness in maintaining oral hygiene.~Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.~Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.~These interventions aim to enhance oral care beyond traditional methods, potentially reducing the risk of Ventilator-Associated Pneumonia (VAP) and improving overall patient outcomes in the intensive care unit (ICU)."
41330521|NCT06039995|PROCEDURE|Traditional Oral Care|"In the control arm, patients receive the intervention known as Traditional Oral Care. This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene."
41330522|NCT06039995|DEVICE|Mechanical Tooth Brushing using 0.2% Chlorhexidine|Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.
41330523|NCT06039995|DEVICE|Moisturizing Gel|Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.
41330524|NCT06039995|DEVICE|Oral care using Cotton swab dipped in 0.2% Chlorhexidine|This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene
41330525|NCT01040338|DRUG|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
41330526|NCT00162526|DRUG|Tocopherol|
41330527|NCT00474825|DRUG|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
41330528|NCT00474825|DRUG|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
41330529|NCT00474825|DRUG|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
41330530|NCT00474825|DRUG|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
41330531|NCT00004999|DRUG|Lamivudine/Zidovudine|
41330532|NCT00004999|DRUG|Capravirine|
41330533|NCT00004999|DRUG|Nelfinavir mesylate|
41330534|NCT04532073|OTHER|Eurythmy Therapy|A mindfulness-oriented movement therapy
41330535|NCT04532073|OTHER|Tai Chi|A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics
41330536|NCT04532073|OTHER|Standard Care|Treatment process that a clinician should follow for a certain type of patient
41330537|NCT02062398|DEVICE|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
40812610|NCT01529515|DRUG|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
40812611|NCT01529515|DRUG|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
41330538|NCT05461183|OTHER|Retrospective database analysis|This study will review data provided by the BCPDR from April 1, 2008 to March 31, 2021.
41330539|NCT05565326|DEVICE|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system using CE marked low-field MR coils as provided by the company will be taken for volunteers in phase I. In phase II and III, after therapy beginning those images will be taken once per week per subject using CE marked low-field MR coils as provided by the company. This is done over the entire course of radiotherapy, which takes between 3 and 6 weeks.
41330540|NCT01170312|BIOLOGICAL|Autologous conditioned plasma (ACP)|ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
41330541|NCT01170312|OTHER|Normal saline|Normal saline injection
41481987|NCT00770692|DRUG|Eszopiclone 2 mg- Elderly|"Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
41481988|NCT00770692|DRUG|Eszopiclone 3 mg- Non-elderly|"Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
40812612|NCT01529515|DRUG|Placebo (20% Intralipid emulsion)|Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
41155798|NCT04531852|BEHAVIORAL|SEMAI - Self-Management Intervention|A low-cost enhancement of the existing preventive service where citizens are information about relevant health resources. Citizens allocated to SEMAI intervention are offered the health-empowerment program as outlined above, including four extra sessions dedicated to practical experiences with exercising. 24 weeks duration in total, with eight sessions in phase 1 and four sessions in phase 2
41330542|NCT00511849|DRUG|carboplatin + SU011248 (sunitinib) + paclitaxel|AUC of 6 mg\*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
41330543|NCT05005091|DIETARY_SUPPLEMENT|Oral carbohydrate|100 ml oral carbohydrate two hours ago preoperatively
41330544|NCT04867200|DRUG|Lixiana(D006)|NOAC(Factor Xa inhibitor)
41330545|NCT04867200|DRUG|CKD-344|NOAC(Factor Xa inhibitor)
41330546|NCT03670498|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
41330547|NCT03670498|DEVICE|2 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
41481989|NCT00770692|DRUG|Eszopiclone 2 mg- Non-elderly|"Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
41481990|NCT01918826|DEVICE|TENS|
41481991|NCT00474474|PROCEDURE|Virtual patient is NOT introduced|
41481992|NCT00003179|DRUG|medroxyprogesterone|
41481993|NCT03642522|DEVICE|repetitive transcranial magnetic stimulation|rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
41481994|NCT00034983|DRUG|aprepitant|
41481995|NCT00034983|DRUG|Comparator: paroxetine HCL|
41481996|NCT04171713|BEHAVIORAL|Mindfulness-Based Health Promotion + Treatment as usual|Structured and developed over eight weeks (8 sessions), participants meet weekly for an average of 2 hours to experience the techniques and conceptual learning about mindfulness and can be adapted to one or 1.5 hour sessions. to be applicable within the contexts of health, education, and organizations. Plus participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
41481997|NCT04171713|BEHAVIORAL|Attachment-based compassion therapy + Treatment as usual|It is a program based on one of the fundamental psychological constructs that explain individuals' interpersonal relationships, attachment styles. It lasts 8 weeks in which participants meet for 2 or 2.5 hours at each meeting.
41481998|NCT04171713|BEHAVIORAL|Treatment as usual|participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
41481999|NCT06441461|OTHER|Primary informal caregiver at work.|Employees becoming a primary informal caregiver for a child or an adolescent with mental health problems in the period from 2000 to 2018.
41482000|NCT05466175|DRUG|Olverembatinib|Given PO
41482001|NCT05466175|DRUG|Prednisone|Given Intravenous
41482002|NCT05466175|DRUG|Vincristine|Given Intravenous
41330548|NCT03870009|OTHER|ARDS patients|"The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation"
41330549|NCT03769337|DIAGNOSTIC_TEST|serum biomarkers|Measurement of Serum concentrations of IL-6, TREM-1, CCL2, MMP-9, OPN, IL-1RA, GP-130, C5a, sRAGE, urokinase and presepsin before revision surgery and after 2 and 7 days after surgery
41330550|NCT05648838|DEVICE|Pivot Balloon Catheter|mornitoring acute RV failure and reduction of Functional Tricuspid Regurgitation
41330551|NCT00125372|DRUG|erlotinib (Tarceva) and bexarotene (Targretin)|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
41330552|NCT01263093|DRUG|Clopidogrel|
41330553|NCT01263093|DRUG|LY2216684|
41330554|NCT03073408|DRUG|Propofol|Closed loop control for propofol administration guided by the BIS.
41330555|NCT03073408|DRUG|Propofol|Manual control group: Propofol administration adjusted manually.
41330556|NCT03145597|DEVICE|Laminate veneer of composite|Composite laminate veneers, 2-4-6 veneers per patient
41330557|NCT03145597|DEVICE|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
41155799|NCT06292832|PROCEDURE|Ultrasound-guided pain block|Ultrasound-guided pain block after cesarean section
41155800|NCT06292832|DEVICE|Ultrasound Machine|Ultrasound machine used to guide the nerve block.
41330558|NCT01690104|DRUG|Rifampicin|
41330559|NCT01690104|DRUG|Placebo|
41330560|NCT00767845|OTHER|questionnaire/survey administration|
40812613|NCT05993429|DIAGNOSTIC_TEST|The sampling method selected in patients with suspected hilar cholangiocarcinoma|The appropriate sampling approach was selected as EUS-FNA/B or ERCP with or without POCS-TB based on experts' overall evaluation. This study will compare the histopathological diagnosis of the selected sampling method with the final diagnosis.
40812614|NCT03207321|DIETARY_SUPPLEMENT|Upma|A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
41330561|NCT00438919|DEVICE|drug-eluting stent|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
41330562|NCT02667522|BEHAVIORAL|Parent Child Interaction Therapy (PCIT)|PCIT includes 12-16 sessions across two phases: the first focused on enhancing positive parenting during child-directed interactions, and the second focused on reducing harsh parenting during parent-directed interactions. Parents receive feedback and coaching on their interactions with the child during sessions.
41330563|NCT03148756|DRUG|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
41330564|NCT03148756|DRUG|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
40812615|NCT00479817|DRUG|AMG 386|10mg/kg
40812616|NCT00479817|DRUG|AMG 386|3 mg/kg
40812617|NCT00479817|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
41330565|NCT00056836|DRUG|rhuFab V2 (ranibizumab)|
41330566|NCT05189132|DIAGNOSTIC_TEST|Periodontal Diagnosis|All participants, in the test group and in the control group, will undergo an initial periodontal evaluation. The clinical evaluation will always be carried out by the same examiner, the author of the study, in order to guarantee calibrated observations. During data collection, intra-observer calibration will be performed, as recommended by the WHO (WHO, 1993), in order to minimize diagnostic variability and verify agreement
41330567|NCT05189132|DIAGNOSTIC_TEST|Microbiological analysis|"Microbiological analysis will be performed using a sample of subgingival bacterial plaque. The sample will be collected at the tooth and at the location with the highest probing depth values in each quadrant.~A sterilized paper tip from the microbiological kit will be introduced to the bottom of the bag, with the aid of tweezers, remaining in the same position for 10 seconds. After collecting the sample, the paper tip will be placed in an individual transfer tube, properly identified. Afterwards, the sample will be sent to the laboratory, where a polymerase chain reaction (PCR) test is performed to identify the following bacteria - A. actinomycetemcomitans, T. forsythia, T. denticola, P. gingivalis, P. intermedia and F. nucleatum."
41330568|NCT05189132|DIAGNOSTIC_TEST|Inflammatory mediators|"The evaluation of inflammatory mediators will be performed with the aid of an absorbent paper strip, which is placed inside the periodontal pocket, for about 30 seconds. The sample will be taken from the tooth that has the highest probing depth values.~The collected sample will be placed and stored in an individual transfer tube properly identified and in accordance with the laboratory's instructions. Afterwards, the sample will be sent to the laboratory, where the ELISA test is performed to quantify the following inflammatory mediators - IL-1β, IL-6 and TNF-α."
41330569|NCT04140604|OTHER|Lactobacillus salivarius AP-32|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
41330570|NCT04140604|OTHER|Bifidobacterium animalis subsp. lactis CP-9|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
41330571|NCT04140604|OTHER|Placebo|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
41330572|NCT01471639|DRUG|intranasal ketorolac|15 mg
40812618|NCT00479817|DRUG|AMG 386 Placebo|AMG 386 Placebo
40812619|NCT04074694|PROCEDURE|Sialoendoscopy|Sialoendoscopy
40812620|NCT05459649|DRUG|Cyclosporine Oral Product|A combination of cyclosporin with standard steroid in newly diagnosed ITP patients: cyclosporin was started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. The therapeutic serum level of cyclosporin was 75 to 150 ug/L. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count; standard steroid regimen included orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
40812621|NCT05459649|DRUG|Prednisone|Standard steroid in newly diagnosed ITP patients: orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
40918239|NCT03361683|DEVICE|High-flow nasal oxygen|Randomized patients will receive oxygen through a high nasal flow device capable of delivering humidified, heated air at an output rate of 40 L/min
40918240|NCT03361683|DEVICE|Venturi mask|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
40918241|NCT03920644|DRUG|Scopolamine Transdermal Patch [Transderm Scop]|Current Motion Sickness treatment, 1 patch behind the ear.
40918242|NCT03920644|DRUG|Scopolamine|IND, up to 6 administration of intranasal gel.
40918243|NCT03920644|DRUG|Placebo Patch|Placebo Patch, 1 patch behind the ear.
41330573|NCT04298931|OTHER|Series of ventilator settings|"Before a planned fluid administration, the investigators will apply a series of 10 ventilator settings for 30 seconds each.~The settings are the following combinations of respiratory rate (RR) and tidal volume (TV):~RR (min\^-1), TV (ml/kg predicted body weight)~31, 6~31, 8~24, 6~24, 8~17, 6~17, 8~10, 4~10, 6~10, 8~10, 10~(the order of the respiratory rates: 17 to 31, will be randomized. 10/min will always be last. Tidal volume is always applied from lowest to highest for each respiratory rate)."
41330574|NCT05186272|BEHAVIORAL|Stress reduction program 'A'|Participants will use stress reduction program 'A' app 10-20 min per day for 6 weeks.
41330575|NCT05186272|BEHAVIORAL|Stress reduction program 'B'|Participants will use stress reduction program 'B' app 10-20 min per day for 6 weeks.
41330576|NCT04625985|DRUG|Metformin Glycinate|Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment
41155801|NCT06552910|PROCEDURE|Nerve Block|Since this study was conducted retrospectively, the choice of anesthesia method was made based on our own experience. For every patient undergoing LEA under PNB, a popliteal sciatic nerve block was carried out. A saphenous nerve block was also carried out if the procedure was on a level that was close to the metatarsal bone. In some circumstances (distal surgery, such as the metatarsal bone), a sensory block on the surgical site was tried following the popliteal sciatic nerve block to demonstrate that the saphenous nerve's anatomic abnormalities required an additional saphenous nerve block. The related block was later carried out, if needed. Under ultrasound guidance, every PNB was finished.
41330577|NCT04625985|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
41330578|NCT05525832|OTHER|Normal saline|Nasopharyngeal washes with NaCl 0.9%
41330579|NCT01601704|DRUG|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
41330580|NCT01601704|DRUG|PBO|Placebo. Administered in addition to the weight management program.
40812622|NCT02700035|OTHER|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
40812623|NCT02569255|PROCEDURE|Pulmonary venous ostia isolation|Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.
40812624|NCT01848977|DEVICE|vascular occlusion test|Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
41330581|NCT01601704|BEHAVIORAL|Weight Management Program|A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
41330582|NCT02923050|BEHAVIORAL|Simple Suppers|Theory-based 10-week family meals program
40812625|NCT01848977|DEVICE|vascular occlusion test|Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
41012480|NCT04391582|DRUG|silver sulfadiazine cream 1%|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
41012481|NCT00764140|BIOLOGICAL|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
41330583|NCT02403713|DRUG|Fluticasone/formoterol BAI|Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
41330584|NCT02403713|DRUG|Formoterol|Formoterol
41330585|NCT02403713|DRUG|Fluticasone/formoterol PMDI without spacer|Fluticasone/Formoteral 125/5µg pMDI without spacer
41330586|NCT02403713|DRUG|Fluticasone/formoterol PMDI with spacer|Fluticasone/Formoteral 125/5µg pMDI with spacer
41330587|NCT02403713|DRUG|Fluticasone/formoterol PMDI without spacer low dose|Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
41482003|NCT02758522|DRUG|Once-daily Insulin|Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
41330588|NCT01977339|DRUG|Liposome Bupivacaine|10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline
41330589|NCT01977339|DRUG|Bupivacaine|20 cc of 0.25% bupivacaine
41330590|NCT03029676|DRUG|benzodiazepines|sedative
41330591|NCT03029676|DRUG|opioid|analgetic, sedative
40812626|NCT02820246|OTHER|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
40812627|NCT05336734|BEHAVIORAL|Psychotherapy|see group description
40812628|NCT01780337|DRUG|Oxytocin|Intranasal dose of 20 IU oxytocin
40812629|NCT01780337|OTHER|Saline|Intranasal dose of saline
40812630|NCT06310642|OTHER|Immediate descent from altitude.|Immediate descent from altitude for severe symptoms or anyone who wished to discontinue their participation in the study.
40812631|NCT06310642|DRUG|Diphenhydramine|Diphenhydramine was available to counteract any potential extrapyramidal side effects of the study drug. The use of Diphenhydramine for this purpose is well established.
40812632|NCT06310642|DRUG|Prochlorperazine 10 mg|Subjects in the Prochlorperazine arm were administered 10mg PO Prochlorperazine immediately prior to ascent
40812633|NCT02778542|BEHAVIORAL|Electronic Pill Bottle|Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
40812634|NCT02778542|BEHAVIORAL|Bidirectional Text Messaging|Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
40812635|NCT00640809|DRUG|Celecoxib|200 mg oral capsule twice daily for 2 weeks
40812636|NCT00640809|OTHER|Placebo|Matched placebo for 2 weeks
40812637|NCT00640809|DRUG|Ibuprofen plus Omeprazole|ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
41012482|NCT04809129|DEVICE|Weighted vest|Patients will wear a weighted vest following bariatric surgery with weight increased incrementally to maintain baseline weight. This vest will be worn for a minimum of 8 hours a day for three months postoperatively.
41012483|NCT02886585|DRUG|Pembrolizumab|
41330592|NCT03029676|PROCEDURE|spinal anesthesia|
41330593|NCT00188357|BEHAVIORAL|Education|
41330594|NCT02873208|DRUG|ALKS 3831|Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
41330595|NCT02452112|DRUG|5% Lidocaine patch|5% Lidocaine patch to be placed on the site of pain
40812638|NCT04249492|DEVICE|IOL implantation experimental (Isopure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
40812639|NCT04249492|DEVICE|IOL implantation active comparator (Micropure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
40812640|NCT05617989|OTHER|lung ultrasound|non-invasive ventilation and diuretic
40812641|NCT02643563|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
40812642|NCT02643563|DRUG|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
40812643|NCT02643563|DRUG|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
40812644|NCT05753033|DRUG|SR750 tablet|Ascending single and multiple doses of SR750 orally
40812645|NCT05753033|DRUG|Placebo|Ascending single and multiple doses of placebo orally
40812646|NCT03466281|BEHAVIORAL|Structured patient group education|Patient education in a group setting
40812647|NCT03466281|BEHAVIORAL|Education via Internet|Patient education via the internet
40812648|NCT03794726|PROCEDURE|Orthodontic Molar Protraction and PAOO|Molar Protraction with Orthodontic Tooth Movement and Adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO) Surgery was performed on all study sites in this arm in coordination with standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
40812649|NCT03794726|PROCEDURE|Orthodontic Molar Protraction|Standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
40812650|NCT05557851|COMBINATION_PRODUCT|Minnelide|Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
40812651|NCT02407080|DRUG|RG7388|RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
40812652|NCT02407080|DRUG|Pegasys|PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
40918244|NCT03920644|DRUG|Placebo Gel|Placebo Gel,up to 6 administration of intranasal gel.
41012484|NCT02886585|RADIATION|MRI|
41012485|NCT02886585|RADIATION|PET/CT|
41012486|NCT02886585|PROCEDURE|Stereotactic Radiosurgery|
41012487|NCT01978184|DRUG|gemcitabine|
41012488|NCT01978184|DRUG|abraxane|
41012489|NCT01978184|DRUG|hydroxychloroquine|
41012490|NCT00619697|DRUG|biphasic insulin aspart|
41330596|NCT02452112|DRUG|Placebo|Placebo patch to be placed on the site of pain
41330597|NCT00989404|DRUG|Zanamivir|Rotahaler placebo 10mg BID 5 days
41330598|NCT00989404|DRUG|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
41330599|NCT00989404|DRUG|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
41330600|NCT03379428|DRUG|Trastuzumab|8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
41330601|NCT03379428|DRUG|Ibrutinib 560 mg|560 mg by mouth daily
41330602|NCT03379428|DRUG|Ibrutinib 840 mg|840 mg by mouth daily
41330603|NCT03379428|DRUG|Ibrutinib 420 mg|420 mg by mouth daily
41330604|NCT03670901|BIOLOGICAL|JHL1101|JHL1101, 100mg/10mL
41012491|NCT00619697|DRUG|insulin glargine|
41012492|NCT00619697|DRUG|metformin|
41012493|NCT00619697|DRUG|glimepiride|
41012494|NCT02459691|BEHAVIORAL|Vida Sana|Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.
41012495|NCT02459691|OTHER|Usual Care Only|Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
41012496|NCT03339518|BEHAVIORAL|BRIM3 educational intervention|Breast Cancer risk education and counseling
41012497|NCT03339518|BEHAVIORAL|Wait List|Booklet at the end of study
41012498|NCT00556595|PROCEDURE|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
41012499|NCT00556595|PROCEDURE|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
41012500|NCT00860652|RADIATION|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
41012501|NCT00860652|RADIATION|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
41012502|NCT02381080|DRUG|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
41012503|NCT02381080|DRUG|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
41012504|NCT02381080|DRUG|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
40812653|NCT06486493|OTHER|Conventional treatment|Conventional medical treatment by their physicians, following the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.
41012505|NCT03160924|OTHER|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
41012506|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for anorexia nervosa patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
41012507|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for obsessional compulsive disorder patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
41012508|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for healthy volunteer|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
40918245|NCT06376903|OTHER|Pilates exercise - pelvic floor exercise - home advices|"Group (A) (Study group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform program of pilates exercises, 3 sessions/week (30 minutes a session ) for 12 weeks in addition to Kegel exercises (15min/three times per week/ for 12 weeks) and home care advices.~• Group (B) (Controlled group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform kegel exercises (15min/three times per week/ for 12 weeks) and home care advices as in group (A)."
41012509|NCT03152786|OTHER|Laboratory Biomarker Analysis|Correlative studies
41012510|NCT03152786|DRUG|Propranolol Hydrochloride|Given PO
41012511|NCT03152786|OTHER|Questionnaire Administration|Ancillary studies
41012512|NCT03152786|OTHER|Survey Administration|Ancillary studies
41012513|NCT00723606|DRUG|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
41155802|NCT05639946|DRUG|brivaracetam|Drug dosage will be individually titrated for each participant with a goal of 100mg BID according to the following dose escalation protocol that we use clinically: 50mg BID for 2 weeks, followed by 50mg TID for 2 weeks, followed by 100mg BID for 48 days as tolerated. Participants will be allowed to reduce the dose of brivaracetam if they experience unacceptable side effects defined as increased somnolence according to routine clinical practice with other drugs in this class used for pain.
41012514|NCT00723606|DRUG|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
41012515|NCT02306980|OTHER|Colostrum|Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
41012516|NCT03614793|PROCEDURE|Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome|Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.
41012517|NCT06363084|DRUG|Nimotuzumab|Nimotuzumab (400mg) was given weekly
41155803|NCT05639946|DRUG|Placebo|Participants will receive placebo drug
41155804|NCT02186496|DRUG|CKD-330 8/5mg|
41155805|NCT02186496|DRUG|Candesartan 8mg and Amlodipine 5mg|
41155806|NCT05980975|OTHER|Coffee|4th hour, 8th hour and 12th hour of after the surgery, the patients in the coffee group received 10 gr. granulated coffee.
41155807|NCT05980975|OTHER|Hot water|hot water group were given 200 ml of 50-60 C0 sugar-free hot water at the 4th hour, 8th hour and 12th hour of after the operation
41330605|NCT03670901|BIOLOGICAL|MabThera|Rituximab, 100mg/10mL
41012518|NCT06113718|PROCEDURE|Abdominal Exercise (digital rectal stimulation, abdominal massage)|"The recommended bowel exercise program consisted of three steps:~1. Patients will perform a 2-3 minute massage starting from the cecum approximately 20-30 minutes after breakfast, moving along the colon.~2. Patients will assume a suitable position and perform circular massage on the anal walls with their finger for approximately 30 seconds (digital rectal stimulation).~3. Patients will try to defecate while sitting on the toilet."
41012519|NCT06168526|BEHAVIORAL|Acute physical activity|Regarding the first aim, participants will go through five different conditions using a within-participants cross-over design in a randomized order: control group (quietly sitting), light intensity (40% VO2max), moderate intensity (63% VO2max), or vigorous intensity (100% VO2max) exercise. All conditions will last 16 minutes and 15 seconds. The exercise conditions will be organized following an interval protocol, which includes 22 bouts of 30 seconds running at the established intensity with 15 seconds of passive rest between bouts. In addition, to achieve the second aim, the active break will be designed taking into account the intensity of physical activity that proves to have the greatest benefits on cognition and well-being.
41012520|NCT03979716|DEVICE|fMRI|fMRI examination
41155808|NCT04143737|BEHAVIORAL|Healthy lifestyle intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
41330606|NCT04451291|BIOLOGICAL|Decidual Stromal Cells (DSC)|DSCs are involved in the immune system during pregnancy. The DSCs used in this study will come from laboratory grown allogeneic human decidual stromal cells obtained from donated placentas.
41330607|NCT01893684|BEHAVIORAL|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last \~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, \~30 min of resistance training, and finally, a \~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
41330608|NCT01893684|BEHAVIORAL|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; \~30% of energy intake) with a ratio of carbohydrate/protein of \<1.5 and dietary lipids at \~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
41330609|NCT01893684|BEHAVIORAL|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (\~ 18% of energy intake) with a ratio of carbohydrates/protein \> 3.5 and dietary lipids at \~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
41330610|NCT05159362|OTHER|Software Application|Access is granted to participants for 4 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
40812654|NCT06486493|OTHER|Playful Family Education Strategy|"Workshop based on national and international guidelines for managing overweight and obesity in school-aged children, by the Food and Agriculture Organization (FAO). Monthly sessions over six months for parents and children, followed by an 18-month post-intervention follow-up.~For parents:~* First session focuses on raising awareness about childhood obesity through counseling and nutritional advice, promoting water consumption over sugary drinks.~* Subsequent sessions use 'case study' technique to discuss common food and nutrition challenges.~For children:~* Sessions follow the 'Nutritional Guidance Intervention Guide' by the National System for Integral Family Development (DIF).~* First session encourages healthy eating habits through activities and educational games.~* Later sessions emphasize healthy eating patterns and physical activity."
40812655|NCT06486493|OTHER|Reinforced Playful Family Education Strategy|The previosuly created and INDAUTOR registered workshop, will be reinforced through two-week technological algorithms, such as videogames, educational videos, and digital challenges, for the children, that they must complete through their smartphone of tablet. Followed by an 18-month post-intervention follow-up.
40812656|NCT01736072|PROCEDURE|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
41330611|NCT01062828|DIAGNOSTIC_TEST|Citrulline samples|Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
41012521|NCT02649972|DRUG|Cobimetinib|Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
41012522|NCT01338116|OTHER|antibiotic treatment of by TREAT/PCR|Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
41330612|NCT00418717|DRUG|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
41330613|NCT04645823|DRUG|Fentanyl Citrate|Fentanyl citrate 20 µg in 2 ml of saline injected into csf
41330614|NCT04645823|DRUG|Lidocaine 1% Injectable Solution|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
41330615|NCT04645823|DRUG|Fentanyl Citrate|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
41330616|NCT03118453|BEHAVIORAL|Active implementation clinics|Physical therapy treatment as the physical therapist chooses
41330617|NCT03118453|BEHAVIORAL|Passive implementation clinics|Physical therapy treatment as the physical therapist chooses
41330618|NCT01306851|DRUG|Fibrin glue|In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
41330619|NCT01001728|RADIATION|Imaging investigations (with radiation)|
41330620|NCT00079820|BIOLOGICAL|ACAM3000 MVA Vaccine|Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
41330621|NCT00228943|DIETARY_SUPPLEMENT|Acute tryptophan depletion|L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)
41330622|NCT00228943|DIETARY_SUPPLEMENT|Half-strength tryptophan depletion (Control)|L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).
41330623|NCT05703139|PROCEDURE|TRIANGLE procedure|The Triangle procedure aims to develop a novel method for patients with locally advanced pancreatic cancer after neoadjuvant therapy and was described in 2017. The basis of this operation is the notice that after neoadjuvant therapy conventional imaging fails to differentiate between actual tumor encasement and only fibrotic residual tissue mainly to the arterial structures
41330624|NCT02357888|DRUG|V0018|Oromucosal - Single dose
40812657|NCT01736072|PROCEDURE|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
40812658|NCT02042586|OTHER|Analysis of movement before total hip replacement|
41012523|NCT04360824|DRUG|Intermediate dose thromboprophylaxis|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
41155809|NCT00111839|DRUG|Pemetrexed|Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
41330625|NCT02357888|DRUG|Placebo|Oromucosal - Single dose
41330626|NCT04587921|DEVICE|Digital oximeter monitoring|Digital oximeter and cardiac frequency monitoring.
41330627|NCT03226561|PROCEDURE|Phaco / Panoptix|Phacoemulsification with bilateral diffractive trifocal lens implantation
41330628|NCT01437267|BIOLOGICAL|Vi-CRM197 vaccine|
41330629|NCT01437267|BIOLOGICAL|Pneumococcal conjugate vaccine|
41330630|NCT01437267|BIOLOGICAL|Vi Polysaccharide (PS) vaccine|
41330631|NCT05837325|PROCEDURE|Oocyte Pick Up - Out of Study|Aspiration of follicles. search for the oocyte(s) All oocytes are grouped in one dish.
41330632|NCT05837325|PROCEDURE|Denudation - Out of Study|All oocytes are denuded together. Maturational stages are recorded.
41330633|NCT05837325|PROCEDURE|ICSI|One oocyte injected at a time.
41330634|NCT05837325|PROCEDURE|Culture|One embryo per culture drop. Individual follow-up of the embryo development.
41330635|NCT05837325|GENETIC|Biopsy|One embryo per culture drop.
41330636|NCT05837325|PROCEDURE|Vitrification|One embryo per vitrification straw.
41330637|NCT05837325|PROCEDURE|OPU - Study Group|Measure the size of the follicle and aspirate only one follicle and flush. The needle before moving to the second ovary. Oocyte included in the study will be cultured separately (each ovary separately too).
41330638|NCT05837325|PROCEDURE|Denudation - Study Group|Oocyte included in the study will be denuded separately. Maturational stages are recorded per follicle.
41330639|NCT02905825|DEVICE|BreathID® Hp System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
40812659|NCT02042586|OTHER|Analysis of movement after total hip replacement|
40812660|NCT00318318|DRUG|Premarin|
41330640|NCT02905825|DRUG|BreathID® Hp Lab System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
41330641|NCT02905825|DIAGNOSTIC_TEST|Stool Test|Each subject was asked to perform a stool test in parallel to the breath test.
41330642|NCT00815204|PROCEDURE|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
40812661|NCT03811769|OTHER|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
41330643|NCT00815204|PROCEDURE|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
41330644|NCT05845307|DRUG|Control Group|Given by PO
40812662|NCT03811769|PROCEDURE|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
40812663|NCT00116701|DRUG|Aranesp®|
40812664|NCT04414592|OTHER|human umbilical cord mesenchymal stem cells|Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
40812665|NCT05666934|DEVICE|Augmented Reality Storybook|The AR system was developed using a Vuforia Engine Package for Unity (PTC Inc, San Diego, CA), which enabled to create an application for children to view a storybook in their own homes. The children and caregivers could view eight scenarios (receiving a praise, broken toys, waiting in line at the playground, getting a vaccination, waiting for watching a video, hitting someone in an accident, grabbing a toy, understanding another person's feelings) and learn strategies for emotional events reflected in the tablet (Figure 1). This AR application supports a tablet size of 10.4 inches and is equipped with a Samsung Galaxy Tab A7.
41012524|NCT04360824|DRUG|Standard of Care thromboprophylaxis|Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
41482004|NCT02758522|DRUG|Twice-daily Insulin|Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
41330645|NCT05845307|DRUG|TTI-101|Given by PO
41330646|NCT01896739|BIOLOGICAL|Eutravac|
41482005|NCT02758522|DRUG|Triple-daily Insulin|Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
41482006|NCT04799678|OTHER|Recording voice samples|A maximum of 9 voice sample recording session will be carried out on their phones and take less than 2 minutes each
41482007|NCT02182869|DRUG|Combivent® HFA inhalation aerosol|
41482008|NCT02182869|DRUG|Combivent® CFC inhalation aerosol|
41482009|NCT03581071|DRUG|TS-143|
41482010|NCT06457737|DEVICE|IPS Empress Direct|Resin composite will be heated and used to lute a ceramic partial coverage restoration.
41482011|NCT06457737|DEVICE|Bisco Duo-Link Universal|Dual cure adhesive resin cement will be used to lute a ceramic partial coverage restoration.
41482012|NCT01184248|BEHAVIORAL|Sound stimulation|Listening to sound stimuli at the lowest audible level.
41482013|NCT00906984|DEVICE|TheraSphere|Given IV
40812666|NCT04771416|BIOLOGICAL|PBKR03|Single dose of PBKR03, via intra cisterna magna
40812667|NCT02600416|OTHER|AV port reversal|Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
40918246|NCT00717236|DRUG|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
40918247|NCT00717236|OTHER|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
41012525|NCT00337649|DRUG|Epothilone D|≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks
41330647|NCT06170281|BEHAVIORAL|Migraine Behavioral Treatment|Migraine Behavioral Treatment involving daily activities
41330648|NCT02959112|DRUG|Epinephrine|
41330649|NCT02959112|OTHER|Sterile water|
41330650|NCT02959112|DRUG|Indomethacin Rectal Suppository|
41330651|NCT00435994|DRUG|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
41330652|NCT00435994|OTHER|Nasal Washing|1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
41330653|NCT05133336|DRUG|Saroglitazar Magnesium 1 mg|Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment for the entire treatment period up to Week 52.
41330654|NCT05133336|DRUG|Saroglitazar Magnesium 2 mg|Subjects randomized to Saroglitazar Magnesium 2 mg arm are switched to Saroglitazar Magnesium 1 mg treatment up to Week 52
41330655|NCT05133336|DRUG|Placebo|Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
41482014|NCT04209205|DRUG|AIN457 6 mg/kg i.v.|AIN457 6 mg/kg delivered by i.v. infusion
41482015|NCT04209205|DRUG|Placebo|Matching placebo to AIN457 i.v. infusion
41012526|NCT00337649|DRUG|Herceptin|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
41330656|NCT02290340|DRUG|Placebo|Participants will receive placebo intramuscularly.
41330657|NCT02290340|DRUG|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
41330658|NCT02290340|DRUG|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
41012527|NCT05836038|BEHAVIORAL|Visio-Tactile Stimulation|They will see their virtual hand touched while simultaneously feel their opposite real hand touched in the same pattern.
41330659|NCT02290340|DRUG|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
41482016|NCT04209205|DRUG|AIN457 3 mg/kg|AIN457 3 mg/kg delivered by i.v. infusion
40812668|NCT05304975|BEHAVIORAL|diet|Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline visit. Participants will then meet online with the study nutritionist for around 90 minutes for personal dietary advice which will be based on the latest evidence from the MIND (Mediterranean-DASH diet Intervention for Neurodegeneration Delay) diet tailored for the target population. The nutritionist will support participants to set personal dietary goals and to monitor progress in changing towards the MIND diet. If weight loss is indicated, the nutritionist will also advise energy intake to facilitate 5-10% body weight reduction. Following the initial appointment, review meetings with the nutritionist will take place monthly in the first four months, either online or by telephone and lasting up to 60 minutes
40812669|NCT05304975|BEHAVIORAL|cognitive stimulation|Cognitive stimulation will be delivered using Brain HQ® (Posit Science), a computer based cognitive training platform, which utilises games to enhance attention, mental processing speed, learning, memory, and low mood. On 2 occasions during the first month participants will receive a 30-60min training. The aim is to familiarise participants with games and program processes to optimise engagement with the programme.The cognitive training application is available to download on a range of devices. Following training, participants will be asked to log in and complete the training session at least 4 days per week. Each session is expected to last 30 minutes. Individual cognitive training performance will be recorded centrally. Participants will receive feedback of percentage improvement in performance. The program allows remote monitoring of frequency of use and engagement. Therefore, performance, frequency, duration, and type of use will be recorded centrally throughout the study period
40918248|NCT05145218|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
40918249|NCT05145218|DRUG|Paclitaxel injection|Paclitaxel is a novel anti-microtubule agent.
41012528|NCT00351494|PROCEDURE|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.~Abdominal route 2.4 ml sonovue per injection / bolus"
41012529|NCT00351494|PROCEDURE|embolization|Intervention is described in the case report form for each patient
41012530|NCT00393055|DIETARY_SUPPLEMENT|xylitol|1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
41012531|NCT00393055|DIETARY_SUPPLEMENT|inactive lozenge|1g inactive lozenge, dissolved in mouth. Five/day for three years
41155810|NCT00111839|DRUG|Matuzumab|Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.
41155811|NCT01214499|PROCEDURE|Transmyocardial revascularization (TMR) with Holmium YAG laser|Transmyocardial revascularization (TMR) is a surgical procedure that uses a laser to create channels through the myocardial, so this laser stimulates local angiogenesis and provides blood in the ischemic area.
41330660|NCT02995122|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-090)"
41330661|NCT02995122|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
41330662|NCT01363258|BEHAVIORAL|Care-resistant mouth care (MOUTh)|The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.
41330663|NCT01363258|PROCEDURE|Evidence-based mouth care|Mouth care tailored to the needs of older adults, including care of dentures.
41330664|NCT04709718|PROCEDURE|hepatectomy|liver resection taking over the liver hemangioma
41482017|NCT00110006|BIOLOGICAL|rituximab|Rituximab IV over 3-6 hours. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
41482018|NCT00110006|DRUG|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
41482019|NCT00110006|DRUG|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
41482020|NCT00110006|DRUG|prednisone|Oral prednisone once daily on days 1-5. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
41482021|NCT00110006|DRUG|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
41330665|NCT05063617|DEVICE|SCI Step Together|The 8-week program features weekly blocks of content. Each week builds from the previous week and targets specific components related to the three basic psychological needs (autonomy, relatedness, competence). The overall cadence of each weekly block is maintained throughout. For example, each week contains: 1) education modules 2) a worksheet or guided practice to apply the strategies in their own goals for that week along with embedded questions to discuss with their community coach 3) behavioural support from the community coach and 4) peer support from the discussion group.
41330666|NCT00617591|DRUG|Lenalidomide|25 mg orally on days 1-21
41330667|NCT00617591|DRUG|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m\^2 intravenously on day 1 (reduced to 30 mg/m\^2 after the initial 29 patients were treated)
41330668|NCT00617591|DRUG|Dexamethasone|40 mg orally on days on 1-4
41330669|NCT05733260|BEHAVIORAL|Exercise|10 weeks of resistance training.
41330670|NCT01671891|RADIATION|radiation therapy|45-55Gy
41330671|NCT01671891|DRUG|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
41330672|NCT06561438|DRUG|Vortioxetine 20Mg Tab|20 mg oral vortioxetine tablet 2 hours before the procedure
41330673|NCT05004519|DRUG|Dexmedetomidine Injection [Precedex]|dexmedetomidine or remifentanil during laparoscopic gastric bypass
41330674|NCT05004519|DRUG|Remifentanil|dexmedetomidine or remifentanil during laparoscopic gastric bypass
41330675|NCT05685719|DRUG|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
40812670|NCT05304975|BEHAVIORAL|physical activity|The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise written resource that has been designed for older adults and adapted for the current study. It is expected that participants will begin with a basic level of exercise that will increase in frequency and intensity over the first 4 weeks to reach a core required level. In week one, participants will meet online with the trained exercise instructor for around 60 minutes to plan a personalised exercise programme. The instructor will explain the basics of exercise prescription, the foundations of the personal home programme and safety aspects. The instructor will facilitate appropriate exercise goal setting and demonstrate the exercises within the personal programme. Participants will be advised to wear the study pedometer to record their walking activity and complete the exercise diary to record overall step count and daily exercise.
41482022|NCT00110006|PROCEDURE|positron emission tomography|Beginning 1 hour after receiving fludeoxyglucose F 18, patients undergo whole-body positron emission tomography (PET) scanning. Patients undergo repeat \^18FDG-PET scanning between days 7-10 of course 1, between courses 3 and 4, and then at the completion of R-CHOP.
41482023|NCT00110006|RADIATION|fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (\^18FDG) IV.
41482024|NCT01456091|BEHAVIORAL|AIM 4 Teen Moms|The AIM (Adult Identity Mentoring) 4 Teen Moms program is a combination of individual and small group sessions intervention that encourages parenting young women ages 15-19 years old to delay rapid repeat pregnancies for 24 months or later.
41482025|NCT04912882|DIAGNOSTIC_TEST|Circulating tumor cell|detecting circulating tumor cell pre- and post operatively
41482026|NCT01251978|DRUG|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
41482027|NCT01251978|DRUG|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
41482028|NCT00366041|DRUG|Dermal substrate cellularised LG002 (10x10cm)|application depending on burn injury surface
41482029|NCT00366041|DEVICE|Dermal substrate uncellularised LG002 (10x10 cm)|depending on burn injury surface
40812671|NCT05304975|OTHER|risk factor management|Metabolic and vascular risk factor management. At each study visit (baseline, month 4, month 6 and month 9), participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary
40812672|NCT03890926|RADIATION|radioactive Iodine-125 seed implantation under the guidance of 3D template|3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment for patients with local recurrent rectal carcinoma. Retrospective data on the effectiveness and adverse effects of the past radioactive Iodine-125 seed implantation is collected.
40812673|NCT04396873|DRUG|11C-MC1|Injected IV followed by PET scanning
40812674|NCT04396873|DRUG|11C-PS13|Injected IV followed by PET scanning
40812675|NCT04396873|DRUG|18f-florbetaben|Injected IV followed by PET scanning
40918250|NCT05145218|DRUG|TQB2450 injection|TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
41330676|NCT05685719|DRUG|Itraconazole|A strong CYP3A4 inhibitor
41330677|NCT05685719|DRUG|Rifampin|A strong CYP3A4 inducer
41330678|NCT00689169|DRUG|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
41330679|NCT00689169|PROCEDURE|ASCT|ASCT : D0
41330680|NCT00689169|DRUG|Rituximab|Rituximab 250 mg/m² :D-21 D-14
41330681|NCT00067821|DRUG|2-Flourodeoxyglucose|
41330682|NCT04231032|OTHER|Asynchronous dual chamber pacing (DOO) with paced ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
41330683|NCT04231032|OTHER|Asynchronous atrial pacing (AOO) with intrinsic ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
41330684|NCT06200285|OTHER|Registry of patients with accidental hypothermia|
41330685|NCT05244538|DEVICE|Virtual reality distraction|Patients will be exposed to a virtual reality representing a forest walk. A reduction of at least 50 percent in the remifentanil and propofol doses required for oocyte retrieval is expected.
41330686|NCT05244538|DRUG|Propofol-remifentanil sedation|"Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml."
41330687|NCT04315597|DRUG|Laif® 900, BAY98-7108|1 x daily, 1 tablet, 900 mg
41330688|NCT04315597|DRUG|Placebo|1 x daily, 1 tablet, 900 mg
41482030|NCT00969319|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
41330689|NCT06210438|DRUG|SHR-A1921 + Bevacizumab|SHR-A1921 + Bevacizumab
41330690|NCT02135900|DRUG|Heliox|From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
41330691|NCT03134612|DRUG|Ondansetron 8 mg|
41330692|NCT03134612|DRUG|Lidocain 40 mg|
41330693|NCT02089503|OTHER|intravitreal injections of Lucentis|intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
41330694|NCT02285712|DEVICE|Vascular ultrasound system|
40812676|NCT01807169|PROCEDURE|Colonic polypectomy or endoscopic mucosal resection (EMR).|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
40812677|NCT00002873|RADIATION|brachytherapy|
41482031|NCT05729919|PROCEDURE|Free gingival graft technique|"A horizontal partial thickness incision will be trace at the MGJ to dissect the alveolar mucosa from the keratinized tissue. The alveolar mucosa will be dissected from the underlying periosteum to create an envelope of 4-5 mm apical to the bone dehiscence associated with the gingival recessions. The keratinized tissue coronal to the first incision and neighboring the recession will be de-epithelialized to expose the connective tissue and create a trapezoidal recipient bed having a large apical base at the MGJ and a narrower coronal base just coronal to the CEJ of the experimental units. The grafts will be taken from the palate.The grafts will be positionned with the coronal edge of the CEJ.~Interrupted sutures (6-0 polypropylene, prolene) will be positionned to stabilize the graft. Sling crossed sutures anchored to the periosteum apical to the graft and placed to ensure a tight adaptation of the graft to the root surface"
41482032|NCT03322384|DRUG|epacadostat|Epacadostat will be administered orally, in pill form, twice daily until disease progression.
40812678|NCT02383888|DRUG|BI 425809|
40812679|NCT02383888|DRUG|BI 425809|
40812680|NCT02383888|DRUG|Placebo|
40812681|NCT02383888|DRUG|BI 425809|
40812682|NCT04611347|DRUG|CBD|Topical CBD application for thumb basal joint osteoarthritis.
40812683|NCT04611347|DRUG|Shea Butter|Placebo Shae Butter for comparison
40812684|NCT04826107|DRUG|DP303c treatment|DP303c injection, every 3 weeks.
40812685|NCT04826107|DRUG|DP303c treatment（second-line of HER2-positive）|DP303c injection, every 3 weeks.
40812686|NCT04826107|DRUG|DP303c treatment （third-line of HER2-positive）|DP303c injection, every 3 weeks.
40812687|NCT04826107|DRUG|DP303c treatment（≥second-line of HER2 low expressing）|DP303c injection, every 3 weeks.
40812688|NCT04826107|DRUG|DP303c + PD-1/PD-L1 treatment|DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
40812689|NCT01954459|DEVICE|Insupatch|Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
40812690|NCT01954459|DEVICE|Continuous glucose sensor|Glucose sensor inserted without warming patch
41330695|NCT00886106|DRUG|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
41482033|NCT03322384|DRUG|SD-101|Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
41482034|NCT03322384|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.
40812691|NCT02664311|DEVICE|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
41330696|NCT00886106|DRUG|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
40812692|NCT02664311|DEVICE|Conventional ventilation|Conventional ventilator - control arm
40812693|NCT06454890|BIOLOGICAL|Anti-Trop2 CAR-NK cell|chemotherapy followed by Trop2 CAR-NK infusion
40812694|NCT04189965|OTHER|Validation of virtual environment and auditive stimulation with virtual reality glasses (Pilot phase)|The goal of this phase is the development of the experimental protocol in virtual reality. Virtual environment will be checked and auditive stimulation will be graduated.
40812695|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Principal Experimental phase)|This phase is the principal step of the study: during moving in virtual environment, electrical stimulation on one hand and auditive stimulation will be applied. EEG, ECG and skin conductance will be measured during conditioning phase and extinction phase (day 1, 30 minutes each phase). Behavioral measures will be done throughout the 3 sessions (day 1, day 2 and day 30)
40812696|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Secondary Experimental phase)|This phase is the same of the Principal Experimental phase except for the EEG that will not be performed.
40812697|NCT03017872|DRUG|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
40812698|NCT03017872|DRUG|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
40812699|NCT03017872|DRUG|Darunavir|800mg tablet by mouth once daily for 96 weeks.
40812700|NCT03017872|DRUG|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
40812701|NCT03679858|OTHER|Platelet function test|Ex vivo platelet aggregation analysis by Multiplate aggregometer
40812702|NCT04776187|DRUG|Gadodiamide|Gadodiamide Injection(OMNISCAN™)
40812703|NCT04776187|DRUG|Gadoteric Acid Meglumine Salt|Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
40812704|NCT01453205|DRUG|MEDI-551 2 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
41330697|NCT03109756|DRUG|OV101|Single-dose 5 mg OV101
41330698|NCT05823870|DRUG|DW6014|"Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast"
41330699|NCT02796612|OTHER|no intervention|Patients do not receive any interventions but are treated according to current standard of care.
41330700|NCT02796612|BEHAVIORAL|delivery of a take-home brochure|Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.
40812705|NCT01453205|DRUG|Rituximab|Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
40812706|NCT01453205|DRUG|ICE|ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
41330701|NCT02796612|BEHAVIORAL|patient care by a psychologically trained physician|The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
40812707|NCT01453205|DRUG|DHAP|DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
41330702|NCT03532776|DRUG|Podofilox Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
41330703|NCT03532776|DRUG|Condylox Topical Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
41330704|NCT03532776|DRUG|Placebo Gel|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
41330705|NCT05525312|PROCEDURE|"Open-lung protective ventilation strategy"|"In the open-lung group, the positive end-tidal pressure (PEEP) is titrated to match the best lung compliance. During a PEEP decrement trial, PEEP is decreased from 20 cmH2O to 4 cmH2O by steps of 2 cmH2O/minute, and the driving the transpulmonary pressure (PTP) is calculated at each level of PEEP. In the open-lung group, the targeted PEEP corresponds to the lowest driving PTP during the PEEP decrement trial, meaning the best lung compliance. Thereafter, the PEEP is set at this level and maintained until extubation."
41330706|NCT05525312|PROCEDURE|"Standard protective ventilation strategy"|"In the standard group, the positive end-tidal pressure (PEEP) is arbitrarily set at 5 cmH2O, since this is the currently recommended level of PEEP, commonly used in control groups of previous clinical trials."
41330707|NCT06302998|DRUG|DEX-PRESSIN|This group will receive vasopressin as the first-line vasopressor. DEX will be started after hemodynamic stabilization if the heart rate is \>90 beats per minute (bpm). NE infusion will be the second-line vasoactive drug.
41330708|NCT06302998|DRUG|Standard of Care|This group will receive conventional treatment according to the SSC 2021 guidelines. This group will receive vasopressin as the second line after NE and will not receive DEX.
41330709|NCT01753700|DIETARY_SUPPLEMENT|UHT treated milk|
41330710|NCT01999023|DIETARY_SUPPLEMENT|Low protein formula group|Low protein formula formula (28.5 g) twice a day
41330711|NCT01181440|DEVICE|Dermagraft(R)|Weekly application of Dermagraft(R) with conventional care
41330712|NCT01181440|OTHER|Conventional care|Weekly application of conventional care
41330713|NCT04982419|DEVICE|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
41482035|NCT03022474|BEHAVIORAL|Healthy Lifestyles Intervention|The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
40812708|NCT01453205|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
41330714|NCT04982419|DEVICE|Sham remote ischemic conditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
41330715|NCT06195098|OTHER|Nutritional educational intervention|The interventional activities were targeted to the local population, according to their educational level and culture and it was composed by a theoretical part and a more practical part. The objective was to improve nutritional knowledge and their awareness about the role of food in connection to the human health. According to the theoretical part: to make the activities more appealing, three informative graphic posters were drafted. According to the practical part: a cooking class activities were conducted, involving women of the Ampanithosa and Bevoko villages. The researchers teaching them how to use a bamboo steamer and how to process vegetables, grew up in the organic gardens built by the Kukula team. The activities were carried out in each village thanks to a local enumerators involvement.
40812709|NCT01453205|DRUG|MEDI-551 4 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
40812710|NCT00391430|DRUG|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
40812711|NCT00391430|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
40812712|NCT05210582|DRUG|Afamelanotide|Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.
40812713|NCT05129280|DRUG|RO7444973|RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.
40812714|NCT05129280|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
40812715|NCT05643001|OTHER|In-patient and out-patient electronic health record alert|Electronic health record best practice alert which suggests measurement of LDL and HbA1c (in-patient) and referrals to sleep study and audiology (out-patient)
40812716|NCT03593343|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 6 days
40812717|NCT05439174|OTHER|Intradialytic Parenteral Nutrition|"Intradialytic parenteral nutrition (IDPN) is compounded using a combination of dextrose (D70%) and amino acids (Prosol 20%, Clinisol 15%, or Plenamine 15%) with the option of adding lipids (Intralipid 20% prior to 8/2020, Clinolipid starting 8/2020 and after).~Each prescription is dosed based on patient height, weight, and other nutrition considerations including but not limited to presence of wounds, recent hospitalizations, electrolyte imbalance, etc. Adjustments to prescription are made on an as needed basis to increase or decrease goal infusion rate, adjust protein levels, and/or add or remove lipids."
40812718|NCT01159925|PROCEDURE|Serum sample|Serum samples collected
40812719|NCT01618045|DIETARY_SUPPLEMENT|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
41330716|NCT05359809|BEHAVIORAL|Graspin Palmar Reflex Stimulation|The grasping reflex is an involuntary response involving the hands and fingers. flexion-adduction movement. The reflex resembles the grasping movement of the hand. The reflex can be achieved by moving an object distally across the palm.
41330717|NCT03705260|OTHER|Usual Care|Usual care from Primary Care Physician and dietitian.
40812720|NCT04435301|DEVICE|DC-Stimulator, NeuroConn, Germany|Neurostimulation device
40812721|NCT01726400|DRUG|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
40812722|NCT01726400|DRUG|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
41330718|NCT03705260|BEHAVIORAL|Intensive Behavioral Intervention|The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
41330719|NCT03705260|OTHER|Monthly Screening for Risk|Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.
40812723|NCT04482530|OTHER|fruit paste matrice|Evaluation of the kinetics of the appearance of nutrients and the metabolic response induced by the consumption of fruit pastes (5 different matrices will be tested: 1 Original recipe, 1 maltodextrine recipe, 1 fructose recipe, 1 isomaltulose recipe and 1 mixed recipe comprising fructose and isomaltulose) in elderly healthy volunteers.
41330720|NCT03275428|DEVICE|transnasal humidified rapid-insufflation ventilator exchange|high flow nasal cannula with humidified oxygen
40812724|NCT05064176|OTHER|Usual care|"Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~* week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~* week 3-4: start physical therapy, 2 days/ week: exercises, skin care \& manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care \& MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up"
40812725|NCT05064176|PROCEDURE|Reconstructive lymphatic surgery|"For the procedure of LVA:~- Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly~For the procedure of LNT:~- Aim:~1. Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network;~2. Placed lymph nodes induce lymphangiogenesis"
40812726|NCT06304181|DRUG|Paracetamol and Mannitol Injection|Paracetamol and Mannitol Injection 500mg
40812727|NCT06304181|DRUG|Parecoxib|40mg of parecoxib
40812728|NCT00003434|BIOLOGICAL|carcinoembryonic antigen peptide 1|
40812729|NCT00003434|BIOLOGICAL|hepatitis B antigen peptide|
41330721|NCT04489537|BIOLOGICAL|MarzAA|A cross over design to assess the efficacy of a dosing regimen of 60 µg/kg of MarzAA compared with standard of care for the treatment of bleeding episodes.
41330722|NCT05887908|DRUG|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam
41330723|NCT05887908|DRUG|co-administration of aztreonam and nacubactam|2 g aztreonama and 1 g nacubactam
41330724|NCT05887908|DRUG|imipenem/cilastatin|1 g imipenem/1 g cilastatin
41330725|NCT01614912|DRUG|SM-13496|40 or 80 mg once daily orally
41330726|NCT06020833|DRUG|Roxadustat in combination with retinoic acid|Roxadustat 150mg po qod combined with retinoic acid 20mg po bid
41330727|NCT01328197|DEVICE|Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System|Stent-graft implant
41330728|NCT01274117|PROCEDURE|Transposition of the basilic vein and anastomosis with the brachial vein|One-stage vs two-stage transposition of the basilic vein
41330729|NCT01205919|BEHAVIORAL|Internet-based guided self-help for tinnitus|Internet-based guided self-help for tinnitus: provided via Internet, duration of 10 weeks
41330730|NCT01205919|OTHER|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
41482036|NCT02310282|DEVICE|Telemedicine|In-hospital telemedicine
41330731|NCT03981185|DEVICE|Accelerated theta burst treatment|"All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
41330732|NCT01077869|PROCEDURE|endoscopic examination|on a weekly basis during 7 weeks
41330733|NCT01077869|PROCEDURE|FDG-PET|once pre-radiotherapy and once 2 weeks after initiation of radiotherapy
41330734|NCT00728936|DRUG|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
40812730|NCT03695614|OTHER|Cognitive Remediation Therapy|Cognitive Remediation is a well-established psychotherapy that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.
40812731|NCT02965742|DEVICE|Stratos|A machine made by DMS group.
41330735|NCT00728936|DRUG|Saline placebo|saline placebo given subcutaneously
41330736|NCT04227067|DEVICE|TENS|An electrical impulse is delivered to the skin around the painful area using pads attached to an electric generator.
41330737|NCT04227067|DEVICE|SHAM TENS|A TENS generator without batteries is used. The pads are attached to the generator and to the skin around the painful area.
41330738|NCT05467488|PROCEDURE|photofunctionalization|UVA and UVC photofunctionalization of dental implants
40812732|NCT02965742|DEVICE|"Hologic QDR 4500A"|A machine made by Hologic inc.
40812733|NCT02965742|DEVICE|"Hologic HORIZON A"|A machine made by Hologic inc.
40812734|NCT01835574|BEHAVIORAL|Conditional cash transfer and cognitive-behavioral aftercare|The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete \>=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
40812735|NCT04013802|BIOLOGICAL|HLA-matched VSTs|"An alternative approach that bypasses the need to grow VSTs for individual patients is to bank closely HLA-matched allogeneic VSTs that could be available as an off the shelf product.~The HLA-matched VST product is to produce immune activity to CMV, Adv, BK virus and EBV in all recipients.~Most recently our group extended this off the shelf approach to five viruses using the T cell product manufactured in 10 days. The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. A single infusion produced a cumulative complete or partial response rate of 92% overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (human herpesvirus) (n = 3)."
40812736|NCT06538051|OTHER|lying positions|All patients were placed in supine, semi-fowler's and lateral positions, respectively. The effects of positions on hemodynamic parameters were examined.
40918251|NCT03642132|DRUG|Chemotherapy + avelumab followed by avelumab + talazoparib|"Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib"
40918252|NCT03642132|DRUG|Chemotherapy followed by talazoparib maintenance|"Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib"
41330739|NCT00042562|DRUG|duloxetine|
41330740|NCT05569616|OTHER|Hand massage|Hand massage is a simple comfort intervention that involves touch and conveys care that can easily be incorporated independently into routine nursing care activities. Hand massage is a western technique that includes five basic classical massage manipulations, including eufluorage, petrissage, friction, tapotman and vibration. Kolcaba et al. (2006) hand massage procedure will be applied with baby oil for 20 minutes, three times a week (12 times in total) for 4 weeks.
41330741|NCT05569616|OTHER|Play activity|The number of people for the Jenga game was determined as two people in order to strengthen the social relationship among the elderly and to strengthen their psychomotor skills. Each game will be played with two people. For this reason, the elderly will be divided into five separate groups, two people each.These groups will be played the Jenga game for one hour a week on a certain day of the week, accompanied by the researcher, during the activity hours determined by the nursing home. After the game activity (Jenga) application is completed at the end of the fourth week, the post-test scales will be re-administered to the elderly by the researcher.
41330742|NCT00436202|BEHAVIORAL|Iron supplement|
41330743|NCT00997555|PROCEDURE|bronchoscopy|Scheduled bronchoscopy.
41330744|NCT06077201|OTHER|HBCR hands-off|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance.
41482037|NCT03188718|DEVICE|WatchPAT Intervention|Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
40812737|NCT05527587|OTHER|Nature Connections Intervention|10 PLWD and their 10 caregivers will be examined for the effects of a park visit program on their behaviour and mood symptoms, cognition, and quality of life over the period of 8-weeks. If participants meet the study criteria, an initial education session on the health benefits of nature will be provided to the them. Participants will then be invited to participate in the park visit program which will have them visiting local parks or outdoors spaces with their caregivers. They will be encouraged to allocate approximately 120 minutes each week to outdoor park activities for 8 weeks. Participants will be provided with a visit passport to record a log of activities completed during the park visits. During the 8 weeks of intervention, participants will also participate in a weekly check-in meeting with other participants to discuss about their experiences with the park visits.
40812738|NCT02426567|OTHER|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
40812739|NCT02426567|OTHER|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
40812740|NCT03729583|BEHAVIORAL|Pulmonary Rehabilitation|A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
41012532|NCT04491630|BEHAVIORAL|Self-Hypnosis (SH)|"Participants assigned to this condition will listen to a 20-minute recording with instructions of SH adapted from one of our team member's proposed model. First, the audio recording will introduce and orient the participant to SH. Then instruction in SH will be provided, including: (a) how to self-induce a hypnotic induction; (b) specific self-suggestions for comfort and ability to manage intense sensations; and (c) post-hypnotic suggestions that the participant will be easily able to use these hypnotic strategies on their own at a later time (i.e., in this case, during the Cold Pressor Arm Wrap procedures that will follow).~A second 5-minute audio recording with instructions to guide the participant in SH will be provided during the second cycle of Cold Pressor Arm Wrap (CPAW)."
41155812|NCT01214499|PROCEDURE|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.|The system called PHOENIXTM consists of a laser probe with Holmium:YAG energy capable of creating transmural channels in the myocardium. Surrounding this fibre 3 needles with side holes are arranged so that the implantation of stem cells is done on the edges of the channel and not on the channel itself. This device is capable of distributing stem cells in those channels created by the laser, carrying out both procedures simultaneously.
41155813|NCT04397822|BIOLOGICAL|Blood samples|Blood samples will be collected in peripheral blood at the admission in intensive care unit or in standard care unit to compare platelet inflammasome NLRP3 and others markers
41330745|NCT06077201|OTHER|HBCR interactive|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
41330746|NCT05653856|DRUG|64Cu-PSMA I&T|Radiolabeled Receptor-Targeted Diagnostic Product
40812741|NCT00270088|DRUG|epoetin alfa|
40812742|NCT04380194|DIAGNOSTIC_TEST|nano-composite screening|Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
40918253|NCT03642132|DRUG|Chemotherapy + bevacizumab followed by bevacizumab|"Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab"
40918254|NCT00000679|DRUG|Zidovudine|
40918255|NCT00000679|DRUG|Zalcitabine|
41482038|NCT02818387|DRUG|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
41482039|NCT02818387|DRUG|Remifentanil|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
40812743|NCT02899754|BEHAVIORAL|Lung Cancer Screening Decision Tool|This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.
41330747|NCT04919746|OTHER|Systemic acupuncture|Systemic acupuncture will be performed on the lower limb, bilaterally, at points E36 (Zusanli) and BP6 (Sanyinjiao). Point location specificity will be determined using the anatomical and directional F-cun reference method. Stimulation of pre-defined points will be performed using needles with a threadlike, sterile, disposable character and size 0.25 x 30.0 mm, within a period of 20 minutes. The insertion of the needle will be at a depth of 0.5 inches, aiming to obtain the De Qi, sensation of energy at the point and in the corresponding meridian, referring to the effectiveness of systemic acupuncture.
41155814|NCT06453161|OTHER|Post-operative acute kidney injury|"Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file"
41155815|NCT05313529|DRUG|Liraglutide|Liraglutide will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study
41330748|NCT02574481|DEVICE|ELUVIA (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
40812744|NCT02899754|BEHAVIORAL|Control Intervention|This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
40812745|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system with bone cement.
40812746|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system without bone cement.
40812747|NCT04945278|OTHER|Double mirror device ALTER-EGO|"The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : who do you see more : him/her or yourself ?"
41330749|NCT02574481|DEVICE|Zilver PTX (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
40812748|NCT04945278|OTHER|EASE test|The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia
40812749|NCT01215643|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
40812750|NCT01215643|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
40812751|NCT01215643|DRUG|Ribavirin|RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
40812752|NCT05796921|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain|Patients allocated to the probiotic arm will take the dietary supplement, containing 15 billion of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain, once a day for 10 consecutive days.
40812753|NCT05796921|DIETARY_SUPPLEMENT|placebo|Patients allocated to placebo arm will take placebo capsules once a day for 10 consecutive days.
40812754|NCT02512874|OTHER|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
40812755|NCT02512874|DEVICE|Dynamometer|Grip Test
40812756|NCT02512874|RADIATION|DEXA|Body Composition Testing
40812757|NCT02512874|OTHER|Gait Speed Test|15 foot walk test
40812758|NCT02512874|DEVICE|Activity Monitor|Measures energy expenditure and activity
40812759|NCT02512874|OTHER|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
40812760|NCT03576196|OTHER|Preoperative Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
40812761|NCT03576196|OTHER|Usual Care|This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.
40812762|NCT05259137|DRUG|Intralesional enalaprilat injection|1.0 mL of 1.25 mg/mL enalaprilat
40812763|NCT02147730|PROCEDURE|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
41330750|NCT04203017|BIOLOGICAL|allogeneic fecal microbiota|All patients receive autoHSCT with RIC (Cyclophosphamide, Antithymocyte globulin, Rituximab). After immune system reconstitution (approximately starting D+60 up to D+120), patients will receive FMT from healthy donor via po capsules.
41330751|NCT06244537|RADIATION|MR-linac|Patients enrolled will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX chemotherapy.
40812764|NCT02147730|PROCEDURE|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
40812765|NCT00515658|DEVICE|theta-burst rTMS|
40812766|NCT02172131|DRUG|BI 1744 CL|
40812767|NCT02172131|DRUG|Placebo|
40812768|NCT01610557|DRUG|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
40812769|NCT01610557|DRUG|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
40812770|NCT00245050|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
41330752|NCT06020573|DEVICE|Clip-on electrode with fiber optics|The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.
41330753|NCT04114539|DRUG|Ecopipam|Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.
41330754|NCT05367557|PROCEDURE|laparoscopic cholecystectomy|removal of the gallbladder by laparoscopy at pneumoperitoneum pressure setting of 12 or 8 mmHg
41330755|NCT03418064|DEVICE|Fanfilcon A toric lens|Contact lens
41330756|NCT03418064|DEVICE|Lotrafilcon B toric lens|Contact lens
41482040|NCT02818387|DRUG|Midazolam|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
41330757|NCT01476761|DEVICE|Microcutter XPRESS and Microcutter XCHANGE|Surgical stapling devices
41482041|NCT01884428|DRUG|panobinostat|Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
41330758|NCT05316480|DRUG|Nimotuzumab|nimotuzumab 200mg/week
41330759|NCT03525626|BEHAVIORAL|Online Mindfulness-based Tic Reduction|8-week online group mindfulness-based intervention for tics
41330760|NCT00701103|DRUG|Dalotuzumab|IV infusion
41482042|NCT01884428|DRUG|Ifosfamide|Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
41482043|NCT01884428|DRUG|Gemcitabine|Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
41482044|NCT01884428|DRUG|Vinorelbine|Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
41482045|NCT01884428|DRUG|Prednisolone|Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
41482046|NCT01338987|PROCEDURE|First Allogeneic Bone Marrow Transplant (BMT)|First Allogeneic Bone Marrow Transplant
40812771|NCT00245050|DRUG|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
40812772|NCT00245050|DRUG|doxorubicin HCL liposome|IV, 40mg/m2
40812773|NCT01425450|DRUG|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
41330761|NCT01998399|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
41330762|NCT01998399|DRUG|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
41330763|NCT03738189|OTHER|Augmented Reality Video|Augmented Reality selfies will place a selection of denture teeth in pictures of the participants in order to enable the selection of their preferred teeth on their new denture.
41330764|NCT04121689|DIETARY_SUPPLEMENT|Milk Protein Concentrate|The macronutrient composition and energy of the milk protein beverage provided to participants is 38 g protein (3.46 g leucine), 4.17 g carbohydrate, and 1.4 g fat. The milk protein met all chemical and bacteriologic specifications for human consumption. The L-\[1-13C\]phenylalanine and L-\[1-13C\]leucine enrichments in the milk protein concentrate averaged 38.3 and 10.8 mole percent excess (MPE), respectively.
41482047|NCT01338987|DRUG|Leuprolide|Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients \<18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients \> 18 years and as a 3 month injection (adult preparation) for patients \< 18 years
41012533|NCT04491630|BEHAVIORAL|Mindfulness Meditation (MM)|"Participants in the MM condition will listen to a 20-minutes recording with instructions in the use and application of Vipassana MM, adapted from the manual developed by one of our team members. First, the audio recording will focus on introducing the idea of attention to their breath, and of non-judgmental monitoring and acceptance of the all events and stimuli. Then a guided MM (body scan) experience will be provided.~A second 5-minute audio recording with instructions to facilitate the MM (body scan) experience taught in the first audio recording will be provided during the second cycle of CPAW."
40812774|NCT01425450|DRUG|HF1020 placebo|Single dose: HF1020 placebo capsule
41012534|NCT04491630|BEHAVIORAL|Christian Prayer (CP)|"Participants in this condition will listen to a 20-minute recording with CP instructions. These instructions will be adapted from the existing on-line biblical meditations from the Society of Jesus (www.passo-a-rezar.net). First, the recording will introduce and orient the participant to CP. Then, a text of the Bible will be read twice, followed by a brief suggestion of prayer.~A second 5-minute audio recording with instructions to facilitate the CP experience taught in the first audio recording, including the recording of a text of the Bible followed by a brief suggestion of meditation and relaxing music, will be provided during the second cycle of CPAW."
41012535|NCT03025022|DRUG|14C-JNJ-42847922 40 mg|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
41012536|NCT03351049|DEVICE|LAL|Reactive support surface with a low air loss feature
41482048|NCT01338987|DRUG|18F FLT|For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
41482049|NCT01338987|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)
41012537|NCT03351049|DEVICE|Non-LAL|Reactive support surface without a low air loss feature
41012538|NCT05755373|OTHER|No treatment given|No treatment given
41482050|NCT01338987|DRUG|Methotrexate|Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
41482051|NCT01338987|DRUG|Tacrolimus|Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
41482052|NCT01338987|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
41482053|NCT01338987|DRUG|Busulfan|Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.
41482054|NCT01338987|DRUG|Fludarabine|Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
41482055|NCT01338987|PROCEDURE|Second Allogeneic Bone Marrow Transplantation|Second Allogeneic Bone Marrow Transplantation
41482056|NCT02867657|BEHAVIORAL|Mindfulness|Five days MBSR curriculum with meditation and yoga
41012539|NCT00000189|DRUG|Gepirone|
41012540|NCT01305031|OTHER|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%
41155816|NCT05313529|DRUG|Empagliflozin|Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
41155817|NCT05313529|DRUG|Linagliptin|Iinagliptin will be initiated at 5mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
41155818|NCT05956535|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
40812775|NCT03515226|BEHAVIORAL|ITS based training|Training using computerized adaptive training in addition to role play
40812776|NCT03515226|BEHAVIORAL|Traditional Training|Training using didactics and role plays
40918256|NCT03873740|BIOLOGICAL|EV71 inactived vaccine（Vero cells）|The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.
40918257|NCT03873740|BIOLOGICAL|EV71 inactived vaccine（Human diploid cells）|The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
41012541|NCT01305031|OTHER|100% oxygen|Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
41155819|NCT05956535|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
41482057|NCT04147988|OTHER|screening and diagnostic assessment DONALD T unit list|Screening and diagnostic assessment of the group of people awaiting assessment, and thus test the feasibility of a screening and diagnosis procedure for autism in adults without intellectual disabilities
41482058|NCT02860442|BEHAVIORAL|Smartphone brief intervention (SP-BI)|"Participants in the SP-BI group will receive a 20-30 minute intervention through an app program based on the FRAMES format: providing personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-efficacy regarding making changes. The intervention is designed to address the target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan."
41482059|NCT02860442|OTHER|Enhanced Usual Care (EUC)|Those assigned to EUC will receive an informational brochure with resources available to members of the military related to mental health and alcohol use. They will be contacted to complete 4-, 8-, and 12-month follow-up assessments.
41012542|NCT05780242|BEHAVIORAL|Self-questionnaire Eating Attitudes|self-diagnostic and quantitative questionnaire of 40 questions evaluating the behavior, severity and evolution of anorexia nervosa
41012543|NCT05780242|BEHAVIORAL|Situational Anxiety and Trait Anxiety|"assess anxiety as a personality trait (feelings of apprehension, tension, nervousness and worry that the subject usually feels), and anxiety as a ' emotional state linked to a particular situation"
41482060|NCT01487382|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
41482061|NCT04136418|DEVICE|COPDPredict mobile App|An App on a mobile device is used by the patient to track the status of their COPD and inform the patient's care team
41482062|NCT04136418|OTHER|Usual care|Patients self-manage their COPD using prescribed medication in accordance with basic guidance information
41012544|NCT05780242|BEHAVIORAL|Beck Depression Inventory (BDI) scale|a diagnostic self-questionnaire allowing a quantitative estimation of the intensity of depressive symptoms in adults and adolescents
41012545|NCT05780242|BEHAVIORAL|• Post-traumatic Check List Scale|questionnaire includes 20 items, each question is to be rated between 1 and 5 depending on the intensity and frequency of symptoms during the previous month.
41482063|NCT01366092|DRUG|Interleukin-2|Daily subcutaneous IL-2 (1 x 10\^6 IU/m\^2/day) for self-administration for 12 weeks followed by 4-week hiatus
41482064|NCT01939041|DEVICE|InMotion3 (IMT)|Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
41482065|NCT01939041|DEVICE|Bi-Manu-Track (BMT)|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
41482066|NCT01939041|BEHAVIORAL|Control intervention (CI)|he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
41482067|NCT02242318|DRUG|Telmisartan|
41482068|NCT02242318|DRUG|Valsartan|
40812777|NCT00730041|DEVICE|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
41482069|NCT02242318|DRUG|Placebo|
41482070|NCT00345735|DRUG|Fentanyl|
40812778|NCT00730041|DEVICE|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
40918258|NCT00575393|DRUG|gold sodium thiomalate|
40918259|NCT00575393|GENETIC|gene expression analysis|
40918260|NCT00575393|OTHER|fluorine F 18 fluorothymidine|
41482071|NCT02726893|OTHER|no intervention|
40918261|NCT00575393|OTHER|mass spectrometry|
40918262|NCT00575393|OTHER|pharmacological study|
41482072|NCT00953472|DRUG|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
41482073|NCT00953472|OTHER|no-added salt diet|instruction to reduce salt for one week prior to study
41012546|NCT00184340|DEVICE|eTherapy|secured e-mail system between patient and therapist
41330765|NCT05215314|BEHAVIORAL|mHealth Meditation|Participants will receive access to the 4-week Healthy Minds Program (HMP) Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
41330766|NCT05829395|OTHER|metaverse- based education|"The nursing process course will be conducted in a metaverse environment. A virtual classroom is designed in the metaverse space for the execution of this course.~Starting from the week following the pre-test application, online training will continue according to the Metaverse-based for a total of 3 weeks, two hours a week, for the intervention group. At the end of the 3 weeks, the Instructional Materials Motivation Scale and Academic Success Assessment (Quiz) will be re-administered as a post-test."
40812779|NCT05116319|DIAGNOSTIC_TEST|point-of-care HbA1c|The Afinion2™ (Abbott, Oslo, Norway), will be used for the current study as it is recently validated. According to American Diabetes Association (ADA), pre-diabetes (pre-DM) is diagnosed if HbA1c is 5.7-6.4% and diabetes (DM) is diagnosed if HbA1c is ≥6.5%
40812780|NCT05409053|PROCEDURE|open reduction|the displaced fractures will be treated with open reduction so as to achieve the near anatomical alignment
40812781|NCT05409053|PROCEDURE|Closed reduction|the non displaced fractures will be treated with closed reduction and percutaneous pinning
40812782|NCT05409053|OTHER|Conservative management|the non displaced fractures will be treated with closed reduction and castor slab
41012547|NCT02175069|PROCEDURE|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
41330767|NCT04796025|DRUG|Sintilimab; Bevacizumab Biosimilar|1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
41330768|NCT02306161|DRUG|Cyclophosphamide|Given IV
41482074|NCT00773695|DRUG|Aromatase Inhibitor|Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
41482075|NCT00773695|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
41482076|NCT00773695|DRUG|Epirubicine|Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
41482077|NCT00773695|DRUG|5-Fluorouracil (5FU)|Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
41482078|NCT00773695|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
41482079|NCT00773695|DRUG|Paclitaxel|Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.
41482080|NCT00773695|DRUG|Docetaxel|Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
41482081|NCT04595266|DRUG|FOLFOX regimen|"Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.~Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1"
40812783|NCT01345968|DRUG|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
40812784|NCT01345968|DRUG|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
40812785|NCT05359081|DRUG|SEP-363856|SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
40812786|NCT00925106|DRUG|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
40812787|NCT00925106|DRUG|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
41482082|NCT04595266|BIOLOGICAL|Anti-EGFR or Bevacizumab|"In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.~Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications."
40812788|NCT00925106|DRUG|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
40812789|NCT00925106|DRUG|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
40812790|NCT01126437|DRUG|tiotropium 18 mcg|HandiHaler
40812791|NCT01126437|DRUG|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
40812792|NCT01126437|DRUG|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
41012548|NCT02175069|DRUG|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
41330769|NCT02306161|DRUG|Doxorubicin|Given IV
41330770|NCT02306161|DRUG|Doxorubicin Hydrochloride|Given IV
41482083|NCT04595266|DRUG|LIVERPEARLS-Irinotecan|Chemoembolization of Irinotecan in 100 +/- 50 micron hydrogel microspheres. Irinotecan will be loaded at a dose of 100 mg. LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization. This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis. The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.
41482084|NCT05456711|DIAGNOSTIC_TEST|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
41482085|NCT04912336|DIAGNOSTIC_TEST|Standard coagulation profile|prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount
41482086|NCT04912336|DIAGNOSTIC_TEST|Specific coagulation tests|AT III, anti Xa, ACT, ROTEM
41482087|NCT04912336|OTHER|Bleeding Scores|Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)
41482088|NCT05103657|DRUG|BI 1358894|BI 1358894
41482089|NCT05103657|DRUG|Placebo|Placebo
41482090|NCT05115526|OTHER|PEEP setting|PEEP setting according to various methods
41482091|NCT03725865|BIOLOGICAL|Induction of neural stem cells|Brain injection iNSC
41482092|NCT00711841|DRUG|dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
41482093|NCT00711841|DRUG|Placebo|Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
40812793|NCT05439993|DRUG|Tepotinib plus paclitaxel|Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
40812794|NCT01694121|BEHAVIORAL|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
40812795|NCT01694121|BEHAVIORAL|Comparison|general health intervention for men, not inclusive of HIV or relationship health
40812796|NCT03203811|DRUG|HTI-2088|3 dose levels
40812797|NCT03203811|DRUG|Placebo|placebo oral tablet
40812798|NCT03195218|DEVICE|HRME examination|HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
40812799|NCT06219967|DRUG|Activated Charcoal|Activated charcoal alone
40812800|NCT06219967|DRUG|Activated Charcoal|Activated charcoal mixed with cola
41482094|NCT00711841|DRUG|dexamethasone|dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours
40918263|NCT06531434|COMBINATION_PRODUCT|"Docetaxel, Cisplatin, fluorouracil, Radiation"|Induction chemotherapy with Docetaxel, Cisplatin, and fluorouracil for 4 to 8 cycles, followed by concurrent chemoradiotherapy with Cisplatin and Radiation 30.6-40 Gy.
41482095|NCT03544879|BEHAVIORAL|Yoga Intervention|The 60-minute yoga sessions began with a brief breathing practice led by the instructor. The yoga instructor then led students through yoga poses at a gentle pace using chairs as props as needed. The pace of the class increased slowly over time as students became more familiar and more capable with the poses. Meditation and breathing was followed by chair poses (15-20 minutes), standing poses (10-15 minutes), floor poses (15 minutes), and lastly a supine resting pose (Savasana; 10 minutes). In the Silver Age Yoga method at that time, there were 73 available postures overall including: 35 Chair Postures, 18 Standing Postures, 20 Floor Postures, with a typical class covering 20-25 poses.
41482096|NCT03544879|BEHAVIORAL|Healthy Aging Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. The 90-minute sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion. The lecture titles for Weeks 1-10 were as follows: Introduction/ Exploring Communication, The Science of Successful Aging, Acupuncture 101: How it Works \& What it is Good for, Quality of Life/Quality of Well Being, Fighting Cancer With Your Fork, Forgiveness via Shakespeare's: A Winter's Tale, Better Eyesight in Minutes a Day, Brain Fitness, The Importance of Organic Foods/ Organic Gardening, How Dementia Can Be Modified. Lectures were provided by a mix of credentialed experts (physicians/psychologists, etc) and other clinicians. Instructors were asked not to talk about yoga or medication in their lectures. Content was not otherwise closely monitored.
41482097|NCT03244423|DRUG|Normal saline at induction|0.5 ml/kg
41482098|NCT03244423|DRUG|Normal saline infusion|1ml/kg/hr. during surgery for six hours
41482099|NCT03244423|DRUG|Intravenous tranexamic acid|50 mg/kg
41482100|NCT03244423|DRUG|infusion tranexamic acid|1mg/kg/hr infusionfor 6 hours
40918264|NCT00190255|PROCEDURE|CY2PC9 genotyping|CY2PC9 genotyping
41012549|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
41330771|NCT02306161|DRUG|Etoposide|Given IV
41330772|NCT02306161|DRUG|Etoposide Phosphate|Given IV
41330773|NCT02306161|RADIATION|External Beam Radiation Therapy|Undergo EBRT
41330774|NCT02306161|BIOLOGICAL|Ganitumab|Given IV
41330775|NCT02306161|DRUG|Ifosfamide|Given IV
41330776|NCT02306161|RADIATION|Stereotactic Radiosurgery|Undergo SBRT
41330777|NCT02306161|PROCEDURE|Therapeutic Surgical Procedure|Undergo surgery
41330778|NCT02306161|DRUG|Vincristine|Given IV
41330779|NCT02306161|DRUG|Vincristine Sulfate|Given IV
41482101|NCT03244423|DRUG|topical tranexamic acid|50 mg/kg added to the normal saline 2 ml/kg into the pericardial cavity before sternal closure
41482102|NCT03244423|DRUG|topical normal saline|2 ml/kg into the pericardial cavity before sternal closure
41012550|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
41012551|NCT02175069|DRUG|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
41012552|NCT02175069|PROCEDURE|Shoulder Surgery|As per individual requirement (patient-dependent)
41012553|NCT02504866|OTHER|Vigorous exercise|Exercise training of vigorous intensity
41482103|NCT05166681|PROCEDURE|surgical wound suturing|single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing
41482104|NCT04219735|DRUG|Minocycline|Minocycline 100mg BID
41012554|NCT02504866|OTHER|Light to moderate exercise|Exercise training of light to moderate intensity
41012555|NCT03025724|DRUG|Levulan Kerastick|Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
41012556|NCT03025724|DEVICE|blue light source|At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
41012557|NCT03025724|OTHER|participant satisfaction survey|Participants will be asked to fill out a satisfaction survey.
41012558|NCT05586399|BEHAVIORAL|Maximal strength training in COPD|Participate in a rehabilitation program for 4 weeks, with exercise 5 times a week. Supervised maximal strength training in a leg press machine for a total of 20 exercise sessions. Patients will participate in rehabilitation in one of two rehabilitations centers in Trondheim, Norway.
41012559|NCT05909722|DIAGNOSTIC_TEST|Gastrointestinal Dysfunction Score will be calculated|We collect routine daily data on GI signs and symptoms and calculate the score (GIDS). We collect serum phosphate values as measured in routine practice of participating sites.
41012560|NCT04453124|BIOLOGICAL|Topical antiseptic treatment|Prevent the development of bacterial cutaneous ulcers by applying antiseptic sap from Ficus septica tree on small wounds.
41482105|NCT04219735|DRUG|Placebos|Placebo
40918265|NCT06092944|PROCEDURE|Catheterization|Before the operation,the patient was placed in the left lateral position.The catheter（soft tip epidural catheter 20-gauge-100 cm） was placed at the rhomboid-intercostal plane under ultrasound guidance at the T5-T6 level, followed by ultrasound-guided catheter placed in the anterior serrated muscle plane at the T7-9 level。
41012561|NCT06382623|PROCEDURE|The percutaneous A1 pulley release|Ultrasound-guided percutaneous pulley release is a procedure aimed at loosening the pulley using various cutting instruments or hypodermic needles under ultrasound guidance.
41012562|NCT06382623|OTHER|The peritendinous Betamethasone group|USG-guided injection of corticosteroid between the A1 pulley and the flexor tendon sheath.
41012563|NCT06420115|DEVICE|different needle size for prostate biopsy|MRI Fusion Transperineal Prostate Biopsy
41012564|NCT05627895|OTHER|Neurofeedback|Participants will be shown their brain activity measured in real-time using an MRI scanner. They can then use mental strategies, such as imagination to influence and regulate this activity.
41012565|NCT05422248|DEVICE|Series Topical Oxygen Therapy|Standard care provided to the whole wound followed by intervention device care to the whole wound.
41012566|NCT05422248|DEVICE|Paired Topical Oxygen Therapy|Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
41012567|NCT03820947|DEVICE|VenaSeal™ Closure System|The VenaSeal™ closure system is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.
41012568|NCT03820947|DEVICE|Endothermal Ablation (ETA)|"ETA includes EVLA that uses laser or RFA that uses radiofrequency heating to close the vein. Heat is applied in both EVLA and RFA therapies to close the vein.~Subject can be treated with either EVLA or RFA if randomized to ETA arm per site's standard practice."
41012569|NCT03820947|PROCEDURE|Surgical Stripping|Surgical stripping involves stripping (removal) of the diseased vein via surgical procedures.
41482106|NCT00390702|DEVICE|transcatheter implantation of a VSD occluder (Nitinol coil)|transcatheter implantation, by first performing a arterial-venous loop through the defect
41012570|NCT05545852|PROCEDURE|GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)|Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
41012571|NCT05545852|PROCEDURE|COT(Conventional Open Thyroidectomy)|Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
41155820|NCT06537063|OTHER|G4 DNAm test|Detection of DNA methylation (DNAm) around G-quadruplex loci in cell-free DNA from blood.
41482107|NCT03642626|DRUG|KYMRIAH|FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
41482108|NCT03642626|DRUG|YESCARTA|CD19-directed genetically modified autologous T cell immunotherapy
41482109|NCT03642626|DRUG|Fludarabine 30mg/m2 4 doses|30 mg/m2 IV daily for 4 doses
41482110|NCT03642626|DRUG|Cyclophosphamide 500 mg/m2; 2 doses|500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
41482111|NCT03642626|DRUG|Fludarabine 30mg/m2 3 doses|30 mg/m2 IV daily for 3 doses
41482112|NCT03642626|DRUG|Cyclophosphamide 500 mg/m2; 3 doses|500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
41482113|NCT03642626|DRUG|Fludarabine 25mg/m2 3 days|25 mg/m2 i.v. daily for 3 days
41482114|NCT03642626|DRUG|Cyclophosphamide 250 mg/m2; 3 days|250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
41482115|NCT03642626|DRUG|Tecartus|TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
41482116|NCT03642626|DRUG|Abecma, Intravenous Suspension|Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
41482117|NCT03642626|DRUG|Cyclophosphamide 900 mg/m2; 1 day|Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
41482118|NCT03642626|DRUG|Breyanzi Injectable Product|Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
41012572|NCT02592733|DEVICE|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
41012573|NCT00529841|DRUG|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
41012574|NCT00349492|DRUG|IP|irinotecan+cisplatin
41330780|NCT01451151|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
41330781|NCT03267407|OTHER|Preemptive high-dose Fluconazole|Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.
41330782|NCT03858296|BEHAVIORAL|Internet-delivered emotional awareness training|Emotional awareness training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
41330783|NCT03858296|BEHAVIORAL|Internet-delivered Cognitive reappraisal training|Cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
41330784|NCT03858296|BEHAVIORAL|Internet-delivered awareness and reappraisal training|Emotional awareness and cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
41482119|NCT03734406|OTHER|Videoclips|The images contained in the videoclips show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
40812801|NCT06519513|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
40812802|NCT05126992|BIOLOGICAL|AZD1222|Covid-19 AstraZeneca Vaccine
40812803|NCT01557777|DRUG|Navitoclax|QD
40812804|NCT03103698|DEVICE|To demonstrate the monitoring of perioperative analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
40812805|NCT03103698|OTHER|Standard preoperative evaluation of analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
40812806|NCT01748461|BEHAVIORAL|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
40812807|NCT01748461|BEHAVIORAL|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
40812808|NCT00907608|DRUG|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
40812809|NCT03713398|BEHAVIORAL|T4C-SMI|T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
40812810|NCT03666780|DEVICE|LAmbre Occluder|All patients are implanted with Lifetech LAmbre occluder device.
41012575|NCT05144152|DIAGNOSTIC_TEST|M3|A panel of four bacterial gene markers (Fn, m3, Ch and Bc)
41012576|NCT05144152|DIAGNOSTIC_TEST|FIT|faecal immunochemical test
41012577|NCT00130767|DRUG|finasteride|
41482120|NCT01274806|OTHER|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
41482121|NCT04412148|DRUG|Triamcinolone Acetonide|intralesional injection of triamcinolone acetonide every 2 weeks for 6 sessions
41482122|NCT04412148|OTHER|saline|intralesional injection of saline
41012578|NCT04113252|OTHER|Possible Incentive for Tablet Return|Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
41012579|NCT04113252|OTHER|Incentive for Completed Diary|Subjects who return completed diary will receive a gift card.
41012580|NCT04113252|BEHAVIORAL|Coaching|Subjects will receive coaching prior to starting pain medication.
41330785|NCT02559557|OTHER|Educational Intervention|Participate in focus groups
41482123|NCT05032313|DIAGNOSTIC_TEST|IUO CLPD Limited Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease .
41330786|NCT02559557|OTHER|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
41330787|NCT02559557|OTHER|Quality-of-Life Assessment|Answer questionnaires
41330788|NCT02559557|OTHER|Questionnaire Administration|Answer questionnaires
41482124|NCT05334355|OTHER|Family history of hypertension|Presence or absence of a family history of hypertension in a cross sectional study design.
41482125|NCT00653965|DRUG|Rosuvastatin|
41012581|NCT02057107|RADIATION|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
40812811|NCT06326359|PROCEDURE|autologous stromal vascular fraction|autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
40812812|NCT06176430|DRUG|Ferrous Sulfate Oral Product|ferrous sulphate oral in the form of syrup
40812813|NCT05403372|DEVICE|PAS-C System|The InterShunt PAS-C System is a transcatheter system that creates a shunt by excising tissue from the interatrial septum resulting in a left to right atrial shunt that off-loads elevated left atrial pressure, potentially reducing symptoms and improving quality of life. The PAS-C System does not require a permanent implant to maintain patency of the interatrial shunt.
40812814|NCT03065621|DRUG|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
40812815|NCT03894982|OTHER|Group Classes|Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
40812816|NCT04309890|OTHER|Arabic version of the Overactive Bladder Symptom Score Questionnaire|All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
40812817|NCT01633632|BEHAVIORAL|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
40812818|NCT01633632|BEHAVIORAL|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
40812819|NCT04352088|PROCEDURE|Nasal provocation test|Allergen extract under controlled conditions will be applied into nasal mucous.
40812820|NCT02706275|OTHER|External warming|External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
41012582|NCT02057107|DRUG|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
41012583|NCT02057107|DRUG|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
41012584|NCT02889159|BIOLOGICAL|Candida albicans antigen|0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.
41012585|NCT02889159|BIOLOGICAL|histamine phosphate|0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.
41012586|NCT02889159|BIOLOGICAL|imiquimod 5% cream|Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
41012587|NCT02889159|PROCEDURE|Tape Stripping|At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
41330789|NCT05584904|OTHER|volunteer anesthesiologists and nurses|18 not expert in electroencephalography digestive endoscopy and operating room nurses, and 8 anesthesiologists interpreting EEGs obtained with a single electrode EEG
41330790|NCT00323310|DRUG|gadobenate dimeglumine|A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
41330791|NCT05552807|DRUG|SCT-I10A|Administered intravenously
41330792|NCT05552807|DRUG|SCT200|Administered intravenously
41330793|NCT05552807|DRUG|paclitaxel|Administered intravenously
41330794|NCT05552807|DRUG|docetaxel|Administered intravenously
41330795|NCT02565732|BIOLOGICAL|Botulinum toxin type A|Botulinum toxin type A, Dose A, Topical
40812821|NCT04345029|DIETARY_SUPPLEMENT|Dietary supplement consumption|"The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days."
40812822|NCT06138015|BEHAVIORAL|Exercise and Time-Restricted Eating|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks and a time-restricted eating following 16:8 protocol for 12 weeks.
41012588|NCT02465528|DRUG|Ceritinib (LDK378)|Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
41012589|NCT06410872|DIAGNOSTIC_TEST|BART Task|The Zuckerman's Sensation Seeking Scale version-V (SSS-V) - Four-factor score, The Barret Impulsiveness Scale (BIS), Gormally's Binge Eating Scale (BES), The World Health Organization-developed AUDIT (Alcohol Use Disorders Identification Test) screen, The CAGE questionnaire for substance abuse-adapted to include drugs, Gamblers Anonymous's 20 Questions (GA20), Hospital Anxiety and Depression Scale (HADS)
41012590|NCT04390152|DRUG|Wharton's jelly derived Mesenchymal stem cells.|IV Wharton's jelly derived Mesenchymal stem cells, two doses
41330796|NCT02565732|BIOLOGICAL|Botulinum toxin type A|Botulinum toxin type A, Dose B, Topical
41330797|NCT02565732|BIOLOGICAL|Placebo comparator|Placebo, Dose C, Topical
41330798|NCT05955157|BIOLOGICAL|Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy|DC+CIK immunotherapy will be administrated with S-1 chemo drug as maintenance treatment for patients with advanced PDAC
41330799|NCT05955157|DRUG|Tegafur Only Product|Tegafur (TS-1) will be administrated alone as maintenance treatment to control group as standard of care
41330800|NCT02822651|BIOLOGICAL|Blood sampling|Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.
41330801|NCT02822651|OTHER|self-administered questionnaire|Patients will fill a self-administered questionnaire the day of inclusion
41330802|NCT06015295|DIAGNOSTIC_TEST|18F-Fluciclovine (Axumin)|Given by Injection
41330803|NCT06015295|DIAGNOSTIC_TEST|Pet Scan|Scans
41482126|NCT00653965|DRUG|Atorvastatin|
41330804|NCT06506903|DEVICE|Medtronic Avalus Ultra|Surgical aortic valve replacement with the Medtronic Avalus Ultra bioprosthesis for management of aortic stenosis and regurgitation.
40812823|NCT06138015|BEHAVIORAL|Exercise only|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks only.
40812824|NCT00550810|DRUG|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
40812825|NCT01033006|PROCEDURE|Active Comparator: Arm 1: catheter injection|
40812826|NCT01033006|PROCEDURE|Active Comparator: Arm 2: transarterial injection|
40812827|NCT01033006|PROCEDURE|Active Comparator: Arm 3: catheter and transarterial injection|
40812828|NCT01121445|DEVICE|NeilMed nose and sinus irrigation|Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
40812829|NCT04413656|OTHER|ablation|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).
40812830|NCT04413656|OTHER|surgery|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).
41012591|NCT04390152|DRUG|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)|Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
41012592|NCT05933837|DIAGNOSTIC_TEST|Troponin I|Measurements of plasma Troponin I 6-12 hours and on the first four postoperative days after surgery.
41012593|NCT03528330|DEVICE|Rehabilitation with dental implant with internal hexagon connection|"All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
41155821|NCT00926952|DRUG|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
41155822|NCT00926952|DEVICE|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
41330805|NCT03954249|PROCEDURE|Erecto Spinae nerve block|The ESPB is a myofascial block alternative to the paravertebral block. It is performed by injecting local anesthetic in the plane between the erector spinae muscle and the spinal transverse process. The ESPB is thought to be safer than the paravertebral block because the transverse process acts as a barrier to the pleura. It has been postulated that local anesthetic spread reaches the paravertebral space and in fact, cadaveric studies have shown dye spreading to involve the ventral and dorsal rami of spinal nerves.
41330806|NCT03954249|PROCEDURE|Multimodal Analgesia|Patients in the control group will receive standard 100mg pregabalin PO, midazolam 2mg IV, fentanyl 100mcg IV.
41330807|NCT02036268|BEHAVIORAL|Standard|Standard ostomy education
41330808|NCT02036268|BEHAVIORAL|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
40812831|NCT01803178|DIETARY_SUPPLEMENT|Plant Sterols|
40812832|NCT01803178|DIETARY_SUPPLEMENT|Placebo Product|
41330809|NCT02036268|BEHAVIORAL|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
41482127|NCT03233425|BEHAVIORAL|multiprofessional group therapy|Behavioural therapy of lifestyle including activity, family and eating habits
41482128|NCT06526455|DRUG|Vonoprazan|oral drug 3-56 days after ESD.
41482129|NCT06526455|DRUG|Esomeprazole|oral drug 3-56 days after ESD.
40812833|NCT03828903|DEVICE|Cryoprobe|"* The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~* The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~* The frozen tissue is going to be extracted by gently pulling of the probe.~* Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~* The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~* The biopsy sample will be released from the probe by thawing in the saline.~* The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding."
40812834|NCT03386136|DRUG|100% Oxygen|To provide hospitalized ileus or pseudo-obstruction patient with 100% oxygen via non-rebreather face mask, for 6 hours
40812835|NCT01983384|OTHER|Processed EEG-guided anesthetic depth|Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
40812836|NCT04283214|OTHER|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
40918266|NCT06092944|PROCEDURE|Single nerve block|Before the operation,40milliliters of 0.3% ropivacaine was injected into the rhomboid-intercostal fascia plane and anterior serrated muscle plane respectively under the guidance of ultrasound.
40918267|NCT06092944|PROCEDURE|Continuous nerve block|After surgery,local anesthetics were injected continuously through catheters.Local anesthetic formula:Ropivacaine 300mg + normal saline, prepared into 150milliliters liquid, background dose 2milliliters/h.
41012594|NCT03528330|DEVICE|Rehabilitation with dental implant with conical connection|"All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
41012595|NCT01401491|DRUG|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
41012596|NCT01401491|DRUG|clozapine plus placebo|clozapine 300 mg/day plus placebo
41012597|NCT05941039|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 6 days, a 4-day washout period, and a 6-day no-training period.
41012598|NCT05941039|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
41012599|NCT05086692|DRUG|MDNA11|MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
41012600|NCT05086692|DRUG|Pembrolizumab (KEYTRUDA®)|MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
41012601|NCT03271879|DRUG|Empagliflozin at a dose of 10 mg/day|Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
41012602|NCT04607408|BIOLOGICAL|CH505TF gp120|HIV-1 CH505 transmitted/founder virus Env gp120 immunogen
41012603|NCT04607408|BIOLOGICAL|GLA-SE adjuvant|An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)
41012604|NCT04607408|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9% USP
41012605|NCT00527813|PROCEDURE|prone position|prone position for at least 16 hours per day
41012606|NCT06567652|DEVICE|catheter ablation|All patients underwent pulmonary vein isolation (and eventually left atrial posterior wall isolation) with the POLARx™ cryoballoon system
41012607|NCT03178656|DRUG|Sorafenib|continuous application of the drugs
41330810|NCT01085656|DRUG|OXi4503|"Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent."
41330811|NCT03908905|DIAGNOSTIC_TEST|Polysomnography|Sleep screening, neurocognitive assessment, activity monitoring questionnaires, blood sample
41330812|NCT02879370|PROCEDURE|Transanal Inspection and management of low ColoRectal Anastomosis|Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
41330813|NCT03687671|OTHER|Animal-assisted therapy|Animal-assisted occupational therapy, animal-assisted physiotherapy and animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
41330814|NCT03687671|OTHER|Treatment as usual|Speech therapy, occupational therapy or physiotherapy
41012608|NCT03178656|PROCEDURE|surgery|curative resection
41012609|NCT04549740|DIAGNOSTIC_TEST|salivary alpha amylase level measurement|Saliva samples will be obtained to estimate salivary alpha amylase
41012610|NCT06349616|OTHER|Intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment. At 2 time points in the experiment, participants will place their hands and forearms in a bucket of cold tap water for 10 minutes.
41330815|NCT02988219|DRUG|Bupivacaine-fentanyl|Local anesthetic
41330816|NCT02988219|DEVICE|Holter ECG monitor|3-chanel, CM5 leads
40918268|NCT06092944|PROCEDURE|PCIA|After surgery, the patient was given controlled intravenous analgesia. Analgesic pump drug formula:Sufentanil 50ug+ Dezocine 20mg+ Granisetron 10mg+150milliliters saline, continuous dose of 2milliliters/h intravenous pump, single injection dose of 2milliliters, locking time of 20 min
41012611|NCT06349616|OTHER|No intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment.
41012612|NCT03752723|DRUG|GX-I7|i.m.
41012613|NCT03752723|DRUG|Pembrolizumab(KEYTRUDA®)|i.v.
41012614|NCT03752723|DRUG|Cyclophosphamide|i.v.
41012615|NCT04299711|OTHER|Exposed to the novel coronavirus disease 2019|Exposed to the novel coronavirus disease 2019
41012616|NCT01331148|DRUG|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
41330817|NCT02988219|PROCEDURE|Open kidney cancer surgery|Lateral position
41012617|NCT01331148|OTHER|Placebo|placebo with daily calcium/Vitamin D soft chews
41012618|NCT05461885|BEHAVIORAL|Supervised exercise|The exercise sessions start with warm-up exercises, followed by 10-20 minutes resistance training (Part A), 10-20 minutes High Intensity Functional Training (HIFT) (Part B) and cool down. Instructors are allowed to make local adjustments as the delivery of the intervention is considered pragmatic. The participants can either perform the exercise together as one group, in pairs or one-by-one depending on individual needs and requests.
41330818|NCT02988219|PROCEDURE|General anesthesia|
41012619|NCT03610971|DRUG|Ruxolitinib|Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).
41330819|NCT02988219|PROCEDURE|Epidural Anaesthesia|
41330820|NCT04817761|DRUG|Calaspargase pegol (S95015)|"Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.~Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.~Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2.~Patients aged 40 to \< 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2."
41482130|NCT03022708|DEVICE|Xeltis Bioabsorbable Pulmonary Valved Conduit|Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit
41482131|NCT04010019|BEHAVIORAL|Enhanced Facebook Condition|The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.
41482132|NCT04010019|BEHAVIORAL|Control Facebook Condition|The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
41482133|NCT02244918|DRUG|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
41482134|NCT02244918|BEHAVIORAL|Smoking Cessation Counseling|
41482135|NCT05224934|RADIATION|ultra-hypofractionated radiotherapy|stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively
41482136|NCT05775822|DIAGNOSTIC_TEST|CT scan and blood sample collection|"Each enrolled patient performs:~* preventive clinical cardiology assessment visit, addressed to individualized risk profile assessment and addressed to chest CT scan.~* a blood sampling (1 citrate tube of 5 ml) will be done the same day just the chest CT scan and analyzed locally also for future research of biomarker discovery (single sample, for those patients who agree in ICF)~* CT scan"
41482137|NCT01463436|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
41482138|NCT01463436|DIETARY_SUPPLEMENT|control group|the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
41012620|NCT03610971|DRUG|BCR-ABL Tyrosine Kinase Inhibitor (TKI)|The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
41012621|NCT00024362|DRUG|BBR 3464|
41012622|NCT06236035|DEVICE|Analgesia nociception index|a device to assess patient's pain during surgery
41012623|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
41012624|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
41012625|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)|Minimal surgical margin \< 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
41012626|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)|Minimal surgical margin \< 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
41012627|NCT00716261|DEVICE|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
41330821|NCT00129207|DRUG|bortezomib|
41330822|NCT01809678|BEHAVIORAL|Smoking Cessation|Once weekly program of cognitive-behavioral therapy for smoking cessation
41330823|NCT01809678|BEHAVIORAL|Yoga|Twice weekly program of 1-hour Iyengar yoga classes
41330824|NCT01809678|OTHER|Wellness|Twice weekly program of 1-hour wellness classes on a variety of health topics.
41330825|NCT01373918|DRUG|Intralipid|The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
41330826|NCT01373918|DRUG|Intralipid|The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
41330827|NCT00124332|DRUG|Rimonabant (SR141716)|
41330828|NCT00124332|DRUG|Placebo|
41330829|NCT00546234|DRUG|tiotropium|18 mcg daily via Handihaler
41482139|NCT04910659|OTHER|acupuncture|P6, LI4 and LI 11 stimulation
41482140|NCT06158347|DEVICE|hyperbaric oxygen chamber|Hyperbaric oxygen therapy allows patients to breathe 100% oxygen through an O2 Fresh M50 (HBOT Medical, Wonju, South Korea) chamber. Upon entering the chamber, oxygen is supplied by gradually increasing the barometric pressure from normal pressure to 1.5 atmospheres absolute (ATA).
40812837|NCT00737854|PROCEDURE|Surgical resection|20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
41330830|NCT00546234|DRUG|long acting beta agonist|Turbohaler, 6 \& 12 mcg
41482141|NCT05991128|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
41482142|NCT05991128|DRUG|Placebo|n the placebo group, patients will receive the equivalent number of normal saline injections.
41482143|NCT06237387|OTHER|Periodontal examination|Determining the patient's oral hygiene status and the severity of gingivitis. For this purpose, the non-invasive Löe-Silness plaque and gingival index system will be used.
41482144|NCT01144728|DRUG|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
41330831|NCT03069898|BEHAVIORAL|TRUE Dads|The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
41330832|NCT04720339|GENETIC|Molecular monitoring by quantification of cell-free DNA|"Molecular monitoring by quantification of cell-free DNA (absolute value and variation from baseline) of two house-keeping genes (RPP30, TMEM11) by droplet digital PCR, during based-immunotherapy treatments of NSCLC patients.~Cell-free DNA will be extracted from 4 ml of plasma before treatments by immunotherapy, obtained from blood Streck® tubes.~Quantification of house-keeping genes (or mutated genes if some are previously routinely identified in tumor tissue) by ddPCR."
41482145|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
40812838|NCT00206050|DRUG|Esomeprazole|
40812839|NCT00206050|DRUG|pantoprazole|
40812840|NCT01709422|DRUG|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
41012628|NCT05022810|DRUG|New Paracetamol Oral Suspension (24 mg/ml)|After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
41012629|NCT05022810|DRUG|Panadol B&I Oral Suspension (24 mg/ml paracetamol)|After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
41012630|NCT05640908|DEVICE|iFuse Bedrock Granite Implant System|Surgical procedure of the spine with pelvic fixation/fusion using iFuse Bedrock Granite
41012631|NCT04368702|RADIATION|Viewray MRIdian® Linac|MR-image guided radiation will be administered per disease site standards.
41012632|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
41482146|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
41482147|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
41482148|NCT06178159|DRUG|Disitamab Vedotin Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
41482149|NCT06178159|DRUG|Pertuzumab Injection|Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks
40812841|NCT01709422|DRUG|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
41012633|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
41012634|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
41012635|NCT01035879|DRUG|Sitagliptin|tablets and capsule once daily
41012636|NCT01035879|DRUG|placebo|tablets and capsule once daily
41012637|NCT03394014|PROCEDURE|sciatic nerve block|blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
41330833|NCT04373213|DIAGNOSTIC_TEST|Pleth variability index|The usefulness of Pleth variability index in predicting fluid response in patients with COVID 19
41330834|NCT03170258|DEVICE|Neurofeedback (from fMRI and/or EEG)|During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired \~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
41330835|NCT02726126|DRUG|Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy|
41330836|NCT01611480|DRUG|Imiquimod (topical use)|
41482150|NCT06178159|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
41482151|NCT00833352|DEVICE|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
40812842|NCT01709422|DRUG|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
40812843|NCT01263678|BEHAVIORAL|Coaching|Decision support coaching will be provided after the participant has viewed the decision aid
40812844|NCT01263678|OTHER|Usual Care|Patient views DA and completes post DA survey.
41012638|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen).
41012639|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen).
41012640|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen).
41012641|NCT03194646|OTHER|Standard of care|Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)
41012642|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)
41482152|NCT03627741|DRUG|Triamcinolone Acetonide|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
41482153|NCT00004734|DRUG|pyridoxine|
41482154|NCT00004734|DRUG|cyanocobalamin|
41330837|NCT06178757|DRUG|TAPB|As soon as the surgical procedure is completed, TAPB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed at the level of the anterior axillary line between the 12th rib and the iliac crest, and the external oblique abdominal muscle, internal oblique abdominal muscle, and transverse abdominis muscle will be visualized. Then, using the in-plane technique, the needle will be advanced with the help of ultrasound until the needle tip reaches the space between the internal oblique and transversus abdominis muscles. After negative pressure aspiration, 5ml saline will be injected and the block location will be confirmed. Once the block location is confirmed, 20ml 0.25% bupivacaine (40ml total for each side) will be injected bilaterally.
41482155|NCT00004734|DRUG|folic acid multivitamin|
41482156|NCT00226421|DRUG|Oxymorphone Extended Release|
41012643|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)
41012644|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
41482157|NCT03692143|DRUG|Teriparatide|subcutaneous injection of teriparatide(20 mg) once daily
41482158|NCT03692143|PROCEDURE|PVP|With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously
41482159|NCT03692143|DRUG|Alendronate|Alendronate Sodium, oral, 70mg, once a week
41155823|NCT04414254|DRUG|Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)|"Subjects were allocated to one of two groups randomly and equally with a 3-day washout interval between the two periods.Cefprozil for Suspension® (125mg/5mL, 50mL/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.) and cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
41482160|NCT01048216|RADIATION|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
41482161|NCT02621034|PROCEDURE|Control|K-file hand instrumentation
40812845|NCT04751604|DIETARY_SUPPLEMENT|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide \[1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)\] for 4 weeks
40812846|NCT04751604|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
40812847|NCT02099877|DRUG|Fentanyl|Epidural analgesia will be initiated with 100µg of epidural fentanyl
40812848|NCT03333252|BEHAVIORAL|Intervention Condition|Caregivers will access caregiving related information. Care Recipients will access cognitive training program
41482162|NCT02621034|PROCEDURE|Reciproc|reciprocating rotary instrument
41482163|NCT02621034|PROCEDURE|One shape|full rotation protocol
41482164|NCT05101369|DRUG|INCB086550|INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
41482165|NCT04948229|OTHER|Blood serum samples|Blood serum samples will be taken.
41482166|NCT03077321|BEHAVIORAL|CARE plus Peer Mentor|A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
41330838|NCT06178757|DRUG|EOIB|As soon as the surgical procedure is completed, EOIB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath in the supine position, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the 6th rib in the mid-axillary line, at the line between the anterior superior iliac spine and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected between, the external oblique muscle and the rib, and the block location will be confirmed. After confirming the block location, 20 ml 0.25% bupivacaine will be applied to the plane between 6.,7., and 8. ribs and the muscles. The same procedure will be applied to the other side (a total of 40 ml 0.25% bupivacaine).
40812849|NCT03333252|BEHAVIORAL|Control Condition|Caregivers will access Nutrition and Health Promotion material. Care Recipients will access words and card games
40812850|NCT00316225|DRUG|pemetrexed|500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles
40812851|NCT01369472|DRUG|Dilatrend SR capsule|single oral administration in period 1 or 2, 3 for each sequential group.
40812852|NCT00079391|DEVICE|allogeneic hematopoietic stem cell transplantation|Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
40812853|NCT03907176|DRUG|HTX-011|300 mg
40812854|NCT03907176|DEVICE|Luer lock applicator|Applicator for instillation
40812855|NCT03907176|DRUG|Ibuprofen|600 mg
40812856|NCT03907176|DRUG|Acetaminophen|1 g
40812857|NCT02998203|DIETARY_SUPPLEMENT|Organic diet|Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
40812858|NCT03583268|OTHER|Exercise|The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
40812859|NCT01304069|DRUG|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
40812860|NCT01304069|DRUG|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
40812861|NCT01304069|DRUG|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
40812862|NCT02078180|DRUG|generic bupropion|We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
40812863|NCT03242564|DEVICE|Vevazz LED|Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
40812864|NCT06115473|DRUG|epinephrine|patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
40812865|NCT06115473|DRUG|isotonic fluid|patients will receive IV bolus isotonic fluid 500 ml
41330839|NCT00432211|DRUG|Avotermin|"Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.~Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration."
41330840|NCT00310349|BIOLOGICAL|23 valent pneumococcal polysaccharide vaccine|
40812866|NCT03807791|PROCEDURE|Blood sample|"A blood sample will be taken by the nurse of our unit within a week after their consent. It consists as a simple blood sample and it will be taken during the normal analysis planed by the chief of the service in order to avoid to collect two different samples.~The measurement method will use equipment from the Lyon Sud hospital laboratory. The samples need a pre-treatment in the 3 hours after taking the blood to avoid the oxidation of vitamin C and a result lower than expected."
40812867|NCT03230890|DEVICE|HIRREM|HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
40812868|NCT03723330|DIETARY_SUPPLEMENT|plant sterols|Consumption a healthy eating pattern diet with a plant sterols-enriched food product
40812869|NCT03723330|OTHER|healthy diet|Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
40812870|NCT01050920|BIOLOGICAL|Blood collection|
40812871|NCT01728558|OTHER|Early goal Directed Sedation|
40812872|NCT01728558|OTHER|Standard care sedation|
41155824|NCT01564134|BIOLOGICAL|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
41155825|NCT04134455|PROCEDURE|Mesh reinforcement|Once the surgery is over. The closure is made with the 4: 1 rule, then an onlay mesh is placed that exceeds 3 cm on each side the wound is fixed with suture.
40812873|NCT01824810|PROCEDURE|Intramuscular Stimulation|"Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle."
40812874|NCT01824810|PROCEDURE|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
40812875|NCT01824810|PROCEDURE|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
41330841|NCT01874119|DRUG|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
41330842|NCT02157012|DRUG|The effectiveness of Xeljanz in rheumatoid arthritis patients|
41330843|NCT03241667|DEVICE|HemoCartridge|Our goal is to apply MEMS (microelectromechanical systems) and nanotechnology to miniaturize the bioartificial kidney (BAK) into an implantable, self-monitoring, and self-regulating renal surrogate. The implantable BAK (iBAK) is a biocompatible cartridge containing stacks of hemofilter membranes (HemoCartridge) and renal tubule cell bioreactors (BioCartridge) combined to mimic nephron function. Here, we plan to test ONLY the material being used to construct the HemoCartridge, to be sure in humans when substituted for a standard hemodialysis filter, subjects don't develop any clinical problems or side effects during several hours of blood exposure to the material. The AK material will be engineered by the study team to allow the system to be substituted in place of a standard HD filter.
41330844|NCT04841694|DIETARY_SUPPLEMENT|Probiotic|Bacillus indicus
41330845|NCT02206321|PROCEDURE|Navigation total knee arthroplasty|computer assisted navigation total knee arthroplasty without femur intramedullary involvement
41330846|NCT02206321|PROCEDURE|Conventional total knee arthroplasty|conventional technique with femur intramedullary violation
41330847|NCT04683172|DEVICE|Active Transcranial Direct Current Stimulation|"tDCS consists of delivering a low-intensity (1 to 2 milliamperes) direct electrical current by means of a pair of electrodes (anode and cathode) applied to the scalp. Electrodes generally have a diameter (round electrode) or a diagonal (rectangular electrodes) ranging from 2 to 3.5 cm.~To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode. In this study, the stimulation intensity will be 1.5 mA using round sponge electrodes 3.5 cm in diameter."
41330848|NCT04683172|DEVICE|Sham Transcranial Direct Current Stimulation|"The tDCS device has a Sham mode that allows for true placebo stimulation. A simulated session is thus designed as a real stimulation session without its effects. Sensations similar to tDCS are created by generating currents only at the start of the session.~Same modalities as for the Active tDCS procedure will therefore be put in place: a pair of electrodes (anode and cathode) are applied to the scalp.To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode."
41330849|NCT01374672|OTHER|laboratory biomarker analysis|Correlative studies
41330850|NCT04858503|OTHER|internet-based cardiac rehabilitation enhancement intervention|Participants in the intervention group will receive a 12-week i-CARE intervention, which will be designed to cover the core elements of CAD self-care: self-care maintenance, self-care monitoring and self-care management. The intervention will comprise: 1) a single individualized face-to-face session and 2) an internet-based intervention through a mobile application. Various behaviour change techniques will be used to increase the self-efficacy of CAD patients in enacting self-care behaviours.
41330851|NCT00671723|DRUG|Normal saline:|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
41330852|NCT00671723|DRUG|Hypertonic Saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
41330853|NCT00671723|DRUG|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
40812876|NCT01824810|PROCEDURE|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
40812877|NCT05977309|DEVICE|Topical ozone therapy|the topical ozone therapy group received a concentration of 30 mg/L at a frequency of 30 minutes per day for 30 days. Participants received ozone therapy topically every three days for eight treatments.
40812878|NCT00258232|DRUG|capecitabine|
40812879|NCT00258232|DRUG|celecoxib|
40812880|NCT00258232|DRUG|irinotecan hydrochloride|
41330854|NCT05226897|DRUG|YYC405-T|Subjects take the investigational products once a day for 24 weeks.
41330855|NCT05226897|DRUG|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
41012645|NCT02652975|PROCEDURE|Venous occlusion plethysmography|To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
41012646|NCT02652975|PROCEDURE|SphygmoCor|"Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.~Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously."
41330856|NCT05226897|DRUG|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
41482167|NCT03077321|BEHAVIORAL|CARE|CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
40812881|NCT01352221|DRUG|ST10|30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
41330857|NCT05226897|DRUG|YYC405-T placebo|Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
41330858|NCT04147507|OTHER|Passive Music Therapy|Music group (N=15) will receive listen to music therapy passively for 20 minutes/day, 5 days/week for 4 weeks, along with lifestyle modifications. Music therapy will be provided via headphones in an isolated quiet non-disrupted room, with room temperature maintained between 20-22 degree Celsius and having medium light intensity. Participants would be instructed to listen to music with eyes closed in sitting position, back supported in comfortable position on a chair. The participants will be given 5 minutes' rest in sitting position before and after each music therapy session.
41330859|NCT04147507|BEHAVIORAL|Control|Control group (N=15) would receive only lifestyle modification. Handout of lifestyle modification according to the Seventh Joint National Committee (JNC VII) report guidelines will be given to all participants. Participants would be instructed to not participate in any form of physical activity and to focus only on two components from the guideline which includes practice the DASH eating plan (diet rich in fruits and vegetables, low fat dairy or unsaturated fat) and limit the daily sodium intake (less than 100 mmol per day).
41330860|NCT00606528|OTHER|No intervention|None. This is an observational study.
40812882|NCT01352221|DRUG|Placebo oral capsule|Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
41330861|NCT00605696|DRUG|Insulin|Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
41330862|NCT03652545|BIOLOGICAL|TAA-T|Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
41330863|NCT04467632|OTHER|Validation of the mobility assessment by IMU wearable sensors|"The validity of the mobility assessment by IMU wearable sensors will be verified in Work Package 3.~It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDS-UPDRS-III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale.~The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. A subset of minimal motor tasks allowing good prediction of the patient's motor status by the machine learning algorithm will then be selected for Work Package 4."
41330864|NCT04467632|OTHER|Testing in real-life conditions at patients' home in a small group of subjects|"Baseline Phase B1: Observation phase: 1-week wrist actigraphy and sleep diary to assess habitual activity/rest routines.~B2: Nocturnal sleep consolidation phase: 2 weeks: timed light exposure, constant sleep/wake routine and sleep restriction of 1 hour/night (based on habitual activity)."
41482168|NCT02642536|BEHAVIORAL|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
40812883|NCT06183294|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
40812884|NCT01092780|DRUG|MK-7288|one or two 10 mg capsules, orally, single dose
40812885|NCT01092780|DRUG|Placebo to MK-7288|one or two capsules, orally, single dose
40812886|NCT01092780|DRUG|Modafinil|two 100 mg tablets, orally, single dose
40812887|NCT01092780|DRUG|Placebo to modafinil|two 100 mg tablets, orally, single dose
40812888|NCT01965613|BIOLOGICAL|Xilonix|IV
40812889|NCT06411769|BEHAVIORAL|50K4LIfe|This intervention will consist of the Walking Challenge only.
40812890|NCT06411769|BEHAVIORAL|SMS Text Messaging|In this intervention, participants will received notifications onto the Pathverse app
41012647|NCT02652975|PROCEDURE|24hour blood pressure|24 hour blood pressure measurement
41482169|NCT02642536|BEHAVIORAL|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
41482170|NCT01648504|OTHER|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
41482171|NCT04965389|DRUG|BMS-986177 Oral Solution|Specified dose on specified days
41482172|NCT04965389|DRUG|[14C]BMS-986177 Solution for Infusion|Specified dose on specified days
41330865|NCT04467632|OTHER|Testing in real-life conditions at patients' home in a small group of subjects|"Intervention phase~* Phase A (11 days): subjects will receive one hour of morning and afternoon light exposure twice a day:~  * Day #1: baseline assessment of outcome measures;~ * Days #2 to #6: bright light in the morning (active treatment) + dim light in the afternoon (placebo), to progressively advance circadian phase of 30' per day (phase advance of 2.5 hours obtained at day 6);~ * Days #7 to #11: dim light in the morning + bright light in the afternoon to revert the circadian phase to the baseline of 30' per day.~* Washout: 6 days. No intervention during this phase, to stabilise the reverted circadian rhythm to baseline, for phase B to be held at the same conditions as phase A.~* Phase B (11 days): similar as in phase A:~  * Day #1: similar as in phase A;~ * Days #2 to #6: reverted conditions compared to phase A.~ * Days #7 to #11: reverted conditions compared to phase A."
41330866|NCT02627833|OTHER|observation|Record lung function, Lung clearance index, inflammatory status
41330867|NCT04348994|DEVICE|Non-ablative thermal-only Er:YAG laser therapy|"Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®).~Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions."
41330868|NCT03949010|OTHER|Kinesiotaping with space correction technique|Kinesiotaping with space correction technique twice per week for two weeks along with home exercise program
41330869|NCT03949010|OTHER|Kinesiotaping with muscle inhibition technique|Kinesiotaping with muscle inhibition technique twice per week for two weeks along with home exercise program
41330870|NCT03949010|OTHER|Home exercise program|Home exercise program which consists of stretching exercises towards neck area
41330871|NCT05959304|OTHER|brolucizumab|There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.
40812891|NCT06411769|BEHAVIORAL|Individual|In this Phase 2 individual-level intervention, participants will receive remote education modules and one-to-one monthly phone-based coaching.
40812892|NCT06411769|BEHAVIORAL|School|In this Phase 2 school-level intervention, participants will receive group educational sessions, school environmental modifications (floor distance markings, signage in corridors and breakrooms, promotional items), and participate in work time/weekend group walks/hikes.
40812893|NCT05790018|DEVICE|PREGNANT PILLOW|First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
40812894|NCT01747343|BEHAVIORAL|Underwear/Differential Reinforcement|Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
40812895|NCT05406739|OTHER|Test Meals|"For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute \[60 kcal\]; 2 slices of bread \[120 kcal\] with 30 g strawberry jam \[75 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute \[120 kcal\]; 4 slices of bread \[240 kcal\] with 60 g strawberry jam \[150 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water."
40812896|NCT02566785|OTHER|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
40812897|NCT05247970|DRUG|S-309309|Capsule administered orally
40812898|NCT05247970|DRUG|Midazolam|Syrup administered orally
40812899|NCT05247970|DRUG|Placebo|Matching capsule to S-309309 administered orally
40812900|NCT03093207|PROCEDURE|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
40812901|NCT03093207|OTHER|Placebo|Placebo pills over a period of 180 days
40812902|NCT03093207|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
40812903|NCT03093207|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
41330872|NCT03723499|OTHER|Medical data collection|Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes
41330873|NCT01992666|GENETIC|Blood sampling|Immunologic and genetic analysis from a single blood sample.
41330874|NCT01444508|DRUG|"Ringer-lactate SAD"|Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
41330875|NCT01444508|DRUG|HES 130/04|"Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD."
41330876|NCT01726816|DRUG|Probucol 250mg/day|Probucol 250mg + Placebo
40812904|NCT02174029|PROCEDURE|Ventilation- mandatory|Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
40812905|NCT02174029|PROCEDURE|Ventilation- voluntary mode only|Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
40812906|NCT02174029|PROCEDURE|Voluntary with preceding mandatory|Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
40812907|NCT01217879|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
40812908|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
40812909|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
40812910|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
40812911|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
40812912|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
41330877|NCT01726816|DRUG|Probucol 500mg/day|Probucol 500mg + Placebo
41330878|NCT01726816|DRUG|Placebo|Probucol matching placebo
41330879|NCT06112912|OTHER|REAL Essentials Advance|"REA is a relationship education curriculum developed by the Center for Relationship Education for high school-age youth. REA teaches youth critical relationship skills and practical approaches for navigating the social dynamics of friendship and love. The curriculum draws on several theories of behavior change, including social cognitive theory, theory of planned behavior, social inoculation theory, social norms theory, and behavior change theory.~REA includes 87 lessons organized into 10 units. The units cover topics such as healthy relationships, effective communication, commitment, planning for the future, job readiness, and sexual health."
41330880|NCT00665678|DRUG|paroxetine|treatment for three months with paroxetine
41330881|NCT00665678|DRUG|placebo|treatment for three months with placebo
41482173|NCT04965389|DRUG|BMS-986177 Spray-dried Dispersion Capsules|Specified dose on specified days
41482174|NCT01742559|PROCEDURE|Anterior middle superior alveolar|The AMSA technique is performed according to Friedman \& Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
41330882|NCT04186663|DRUG|Silver Diamine Fluoride|38% aqueous silver diamine fluoride \[Ag(NH3)\]2F, CAS RN 33040-28-7
40812913|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
40812914|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
40812915|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
40812916|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
40812917|NCT00964912|DRUG|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
40812918|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
41012648|NCT02652975|PROCEDURE|DEXA scan|Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
41155826|NCT04134455|PROCEDURE|RTL reinforcement|Once the surgery is finished, the ared is reinforced by placing a longitudinal suture parallel to the edge of the wound 0.5 cm, then the wound is closed with a 4: 1 rule but the suture enters lateral to the reinforcement suture
41330883|NCT06014957|DRUG|spinal anesthesia|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), immediately positioned supine with one pillow supporting the head and shoulders
41330884|NCT06014957|DRUG|saddle block|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), placed in the sitting position for ten minutes and then supine with one pillow supporting the head and shoulders
41330885|NCT06013267|OTHER|Chin tuck against resistance exercise|The experimental group will receive a four-week CTAR protocol and regular dysphagia care, while the control group will only receive routine dysphagia care. The routine dysphagia care is including dysphagia education, dietary precautions, oral hygiene, and swallowing training, etc. The CTAR protocol is first, the study nurses face-to-face teach dysphagia patients to perform CTAR exercises once, then the patient perform CTAR exercises three times a day, five days a week, and for four weeks. The CTAR exercise is to tighten a rubber ball which placed between the chin and the sternum, and to perform 3 cycles of isometric exercise and isotonic exercise.
41330886|NCT04643795|DRUG|MGL-3196|Once daily oral dose for 6 days
41330887|NCT01770041|OTHER|Paracetamol (observation of routine administration)|Normal administration of paracetamol as prescribed by operating surgeon
41330888|NCT05060172|DEVICE|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography, electrohysterography, as well as accelerometer data."
41330889|NCT02747771|BEHAVIORAL|Cognitive behavioral therapy|10 sessions Group therapy during 10-12 weeks. The first three sessions focus on habit reversal training, the fourth to sixth session on acceptance and commitment therapy and the last four sessions aims at integrating the two approaches.
40812919|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
40812920|NCT00438269|DRUG|Site-specific empiric regimens included: Meropenem|
40812921|NCT00438269|DRUG|Piperacillin/tazobactam|
40812922|NCT00438269|DRUG|Ciprofloxacin and cefazolin +/- metronidazole|
40812923|NCT02752685|DRUG|Pembrolizumab|
40812924|NCT02752685|DRUG|Nab-Paclitaxel|
40812925|NCT00516893|BIOLOGICAL|BG00002-E (natalizumab high titer)|
40812926|NCT02350166|PROCEDURE|laparoscopic surgery|laparoscopic-assisted small-incision surgery
40812927|NCT00920387|DRUG|200 mcg LSD|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
40812928|NCT00920387|DRUG|20 mcg LSD|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
40812929|NCT00920387|BEHAVIORAL|Therapy|Therapy provided by male and female co-therapists
40812930|NCT03726918|PROCEDURE|Surgery for implantation of a prosthesis|Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes
40812931|NCT01299220|DRUG|Acitretin|Acitretin 10 mg by mouth daily
40812932|NCT02312999|DRUG|Plasmalyte|
40812933|NCT02312999|DRUG|Volulyte|
41155827|NCT05414656|DEVICE|Saddle contoured metal matrix, Pre-contoured self-adhesive matrix|Saddle contoured metal matrix placed with the small clipper. The -contoured self-adhesive matrix has self adhesive ability.
41155828|NCT00737997|DRUG|Morphine|150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
41330890|NCT01768338|DRUG|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
41330891|NCT03621306|DEVICE|DXA and pQCT precision testing|The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
41330892|NCT00651313|DRUG|Lidocaine|Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
41330893|NCT00651313|DRUG|Placebo|Placebo vaginal gel administered once daily for 4 days
41330894|NCT00100646|BEHAVIORAL|Structured treatment interruption|Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
41330895|NCT00100646|DRUG|Lamivudine|300 mg tablet taken orally daily
41330896|NCT00100646|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
41012649|NCT02652975|BIOLOGICAL|Laboratory blood samples|"Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen."
41012650|NCT01455324|DEVICE|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
41330897|NCT00100646|DRUG|Stavudine|Dosage dependent on weight
41330898|NCT00100646|BIOLOGICAL|Rabies de novo antigen|Vaccine injected intramuscularly
41330899|NCT02277340|PROCEDURE|EAPA|Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
41330900|NCT06275997|DEVICE|Integration of Artificial Intelligence (AI) assistance to screening gastroscopy|"Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems."
41330901|NCT05340491|DRUG|Toripalimab|240mg, D1, every 3 weeks per cycle, three cycles with chemotherapy and eight cycles after IMRT
41330902|NCT05340491|DRUG|Chemotherapy|Gemcitabine: 1.0g/m2, D1 and D8, Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
41330903|NCT05340491|RADIATION|Intensity modulated radiotherapy|total 60-66Gy, 1.8-2.0Gy/f/day
41330904|NCT06401798|DRUG|placebo gel|Methylcellulose gel was applied topically to the pocket
41012651|NCT04163549|BEHAVIORAL|Safe at Home|Discussion-based intervention
41012652|NCT06265220|DRUG|AB-101|NK Cell Therapy
41012653|NCT06265220|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
41330905|NCT06401798|DRUG|CWP gel|Methylcellulose gel combined with CWP was applied topically to the pocket
41330906|NCT06401798|DRUG|NCWP gel|Methylcellulose gel combined with NCWP was applied topically to the pocket
41330907|NCT02354092|PROCEDURE|Local anesthetic for tenaculum placement|2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
41330908|NCT02354092|PROCEDURE|Sham|Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
41330909|NCT02354092|PROCEDURE|Paracervical Block|18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
41330910|NCT02354092|PROCEDURE|Dilator Placement|"Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference~Drugs:~Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.~Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter."
41330911|NCT02354092|BEHAVIORAL|Post-procedural assessment|15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
41482175|NCT01742559|PROCEDURE|Supraperiosteal technique|The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
41012654|NCT06265220|DRUG|Fludarabine|Lymphodepleting chemotherapy
41330912|NCT02354092|DRUG|Preprocedural pain control|800 mg Ibuprofen taken before dilator placement
41482176|NCT00449982|DRUG|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
41012655|NCT06265220|DRUG|Rituximab|Anti-CD20 antibody therapy
41012656|NCT06265220|DRUG|Obinutuzumab|Anti-CD20 antibody therapy
41155829|NCT00737997|OTHER|Saline|10 ml saline alone
41330913|NCT05382962|BEHAVIORAL|iCanCope Post Op Application|The iCanCope program is designed to enhance pain self-management and self-efficacy, defined as perception of one's ability to successfully produce a desired effect in a task or behavior affecting their life. The intervention will be delivered on the iOS or Android smartphone platform depending on the participant's device. Usage of app features will be centrally tracked by the research team using Analytics Platform to Evaluate Effective Engagement (APEEE), developed at the Centre for Global eHealth Innovation. Participants will receive alerts through iCanCope to complete a pain diary check-in once per week preoperatively, twice per day over the initial 2-week postoperative period, and once per day for the subsequent 2-week period.
41482177|NCT05310578|PROCEDURE|Posterior cervical foraminotomy (with our without laminectomy)|The aim of surgery is to decrease the compression of the affected nerve. In posterior cervical foraminotomy, the foramina is expanded to create more space and with posterior cervical laminectomy the lamina is removed to create space mainly for the spinal cord.
41482178|NCT02405663|PROCEDURE|manual removal|one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
41482179|NCT02405663|PROCEDURE|cord traction|one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
41482180|NCT01908413|DRUG|CUDC-427|CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
41482181|NCT04802707|COMBINATION_PRODUCT|deoxycytidine and deoxythymidine|The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over 3 taking/day for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 730. Doses was chosen according to the safety and efficacy doses used in the literature.
40812934|NCT02251834|BEHAVIORAL|Community Health Worker (CHW)|The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
40812935|NCT02251834|OTHER|usual care and health education brochures every 4 months.|Patients randomized to the control group will receive usual care.
40812936|NCT01331343|DEVICE|Guardian RT Telemetered Glucose Monitoring System|
40812937|NCT05311449|OTHER|Acupressure|The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
40812938|NCT05311449|OTHER|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
40812939|NCT00327015|DRUG|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
40812940|NCT00327015|DRUG|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
40812941|NCT00327015|DRUG|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
40812942|NCT00327015|DRUG|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
40812943|NCT00327015|DRUG|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
41330914|NCT00810810|BIOLOGICAL|Standard blood components|Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets
41330915|NCT00810810|BIOLOGICAL|Leukoreduced blood components|Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets
41330916|NCT00810810|BIOLOGICAL|Leukoreduced and irradiated|Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
41330917|NCT00133172|DRUG|Tacrolimus|IV
41330918|NCT00133172|DRUG|mycophenolate mofetil|IV
40812944|NCT06209138|DRUG|5 fluorouracil|5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein
40812945|NCT06209138|OTHER|Saline|Normal saline solution contains 0.9 percent sodium chloride (salt)
41330919|NCT00133172|DRUG|Prednisone|IV
41330920|NCT02441192|OTHER|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
41330921|NCT02441192|OTHER|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
41482182|NCT03017118|DIETARY_SUPPLEMENT|Turmeric|Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
41482183|NCT03017118|OTHER|Placebo|Subjects in the control group will receive a placebo 3 times per day for 6 weeks.
41482184|NCT03757780|OTHER|Questionaire|A questionaire will be made to pregnant ladies who take caffeine during pregnancy
41482185|NCT03412812|RADIATION|Dose Escalated Five Fraction Stereotactic Radiosurgery|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
41482186|NCT03456960|DRUG|TAK-438ASA|TAK-438ASA tablet.
41482187|NCT03456960|DRUG|TAK-438|TAK-438 tablet.
41482188|NCT03456960|DRUG|Aspirin|Aspirin enteric-coated tablet.
40812946|NCT03088930|DRUG|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
40812947|NCT02740062|DEVICE|NIBS system for evaluation and non invasive current stimulation|
41330922|NCT02441192|OTHER|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
41330923|NCT03518489|DRUG|Lappaconitine Adhesive Patch|to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain
41330924|NCT03518489|DRUG|standard care|Standard care will include mouth wash with antibiotics.
41330925|NCT04613271|DRUG|Favipiravir|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
41330926|NCT04613271|DRUG|Azithromycin|Azithromycin 500 mg once a day for 5 days.
41330927|NCT04374201|OTHER|2 zirconia FDPs|The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
41482189|NCT02006537|DRUG|GSK2256294|GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
41482190|NCT04365179|DRUG|Nerofe|"Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1."
41012659|NCT06349044|RADIATION|Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）|RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.
41330928|NCT04374201|OTHER|1 zirconia FDP|The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
41330929|NCT06168825|OTHER|Mind Over Matter (MOM)|"Each participant's involvement in the study will include:~* Attending a Pre-Program Orientation which will be held a week before the first MOM Session.~* Completing 5 weekly sessions of MOM~* Completing 2 surveys; one will be given before the start of the intervention (a pre-test) and the other will be given after the last MOM Session (a post-test)~Participants will also have the option to participate in an optional Focus Group session which will occur a week after the last MOM Session ends~Participants will spend about 6 weeks in this study. If they decide to participate in the optional session, they will spend about 7 weeks in this study.~Please note, this entire Intervention will be offered online. There will be no in-person sessions or visits."
40812948|NCT02302248|BEHAVIORAL|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
40812949|NCT02302248|BEHAVIORAL|Expressive writing intervention|3 week access to a web-based expressive writing platform.
41330930|NCT01938001|DRUG|Rituximab|Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
41330931|NCT01938001|DRUG|Lenalidomide|Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles
41330932|NCT01938001|DRUG|Placebo|Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
41482191|NCT01622686|BEHAVIORAL|PictureRx medication label|Reformatted medication labels that adhere to current best practices for label design and also include illustrations
40812950|NCT01164891|DRUG|RO5185426|Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
40812951|NCT04650568|DEVICE|Autologous Bone Marrow Derived Mesenchymal Stem Cells|Autologous Bone Marrow Derived Mesenchymal Stem Cells injected into the ACL allograft prior to graft implantation.
40812952|NCT04650568|OTHER|Sham incision|Small incision over the site where bone marrow aspirate would have been obtained
40812953|NCT02912494|DRUG|JR-131|
40812954|NCT02912494|DRUG|Darbepoetin alfa|
40812955|NCT04599855|DRUG|Esketamine 56 mg|Esketamine 56 mg will be self administered as nasal spray.
41482192|NCT00003592|DRUG|methotrexate|
41482193|NCT00003592|DRUG|paclitaxel|
40812956|NCT04599855|DRUG|Esketamine 84 mg|Esketamine 84 mg will be self administered as nasal spray.
40812957|NCT04599855|DRUG|Placebo|Matching placebo will be self administered as nasal spray.
40812958|NCT00361868|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
40812959|NCT00361868|DRUG|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
40812960|NCT02126553|OTHER|Laboratory Biomarker Analysis|Correlative studies
40812961|NCT02126553|DRUG|Lenalidomide|Given PO
41012660|NCT06349044|DRUG|Anti-PD-1 monoclonal antibody|Sintilimab 200mg d1 iv q3w
41012661|NCT06349044|DRUG|Oxaliplatin and Capecitabine|Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14
40812962|NCT00093899|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 6 months
40812963|NCT06404866|BEHAVIORAL|eMotion|Participants will complete one lesson per week. The weekly education is targeted to women and contains personalized content via a variety of diverse lesson narratives. Each week participants listen to scripted sessions they can complete on their own time regarding each of the weekly topics (lasting about 30 minutes). At the end of the week, they then meet individually with a study team member virtually to discuss the same subject.
41012662|NCT06349044|DRUG|Anti-VEGF 15mg/kg|Bevacizumab 15mg/kg d1 iv q3w
41012663|NCT06349044|DRUG|Anti-VEGF 7.5mg/kg|Bevacizumab 7.5mg/kg d1 iv q3w
41330933|NCT05395741|DRUG|Regorafenib|Patients will receive regorafenib orally at doses adjusted for age, body surface area and pharmacokinetics. Treatment with regorafenib will be continued for up to 1 year or until disease progression, patient death, unacceptable toxicity, or study closure. Pharmacokinetics and safety profile of the investigational product (IP) will be determined throughout the course therapy. In the event of progression or relapse, patients in the control group will have the option to receive the IP along with the standard treatment of the next line.
41330934|NCT05351905|DRUG|CBD oil ( MPL-001)|MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 50 mg/ml of CBD and 2 mg/ml of THC. The starting dose will be 1 mL per day (50 mg CBD) orally and gradually titrated to a maximum dose of 6 mL (300 mg CBD) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
41330935|NCT05351905|DRUG|CDB+THC oil (MPL-005)|MPL-005: which is a 5:1 Cannabidiol (CBD):∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 25 mg/ml of CBD and 5 mg/ml of THC. The starting dose will be 1 mL per day (25 mg CBD + 5 mg THC) orally and gradually titrated to a maximum dose of 6 mL (150 mg CBD + 30 mg THC) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
41482194|NCT05035342|BIOLOGICAL|Fecal Microbiota Transplantation (FMT) capsules|Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).
41482195|NCT05035342|BIOLOGICAL|Placebo capsules|"The placebo FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules."
41482196|NCT02307214|OTHER|BaroReflex Sensitivity, endothelial function measurement|no other
41482197|NCT04670666|DRUG|MADALENA ASSOCIATION|Madalena association coated tablet.
41482198|NCT04670666|DRUG|METFORMIN|Metformin 1000 mg extended-release tablet.
41482199|NCT04670666|DRUG|EMPAGLIFLOZIN + LINAGLIPTIN|Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
40812964|NCT04308239|BEHAVIORAL|Reactive balance training|Participants were exposed to simulated trips and slips under safe, controlled conditions in order to practice their reactive response to these common balance perturbations.
40812965|NCT04308239|BEHAVIORAL|Otago Balance Training|Balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support).
40812966|NCT00093197|DRUG|KAI-9803 for Injection|0.05 mg
40812967|NCT00093197|DRUG|KAI-9803 for Injection|0.5 mg
40812968|NCT00093197|DRUG|KAI-9803 for Injection|1.25 mg
40812969|NCT00093197|DRUG|KAI-9803 for Injection|5 mg
41012664|NCT06349044|DRUG|Gemcitabine and Cisplatin|Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w
41012665|NCT01989533|BIOLOGICAL|Ad4-mgag|Ad4 live virus vaccine with an HIV insert
41012666|NCT01989533|BIOLOGICAL|Ad4-EnvC150|Ad4 live virus vaccine with an HIV insert
41482200|NCT04670666|OTHER|MADALENA ASSOCIATION PLACEBO|Madalena association placebo tablet.
41482201|NCT04670666|OTHER|METFORMIN PLACEBO|Metformin placebo tablet.
41482202|NCT04670666|OTHER|EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO|Empagliflozin + linagliptin placebo tablet.
40812970|NCT00093197|DRUG|Placebo|
40812971|NCT02918461|BEHAVIORAL|Emerging from the Haze class|A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
40812972|NCT02456207|DRUG|SCT400|
40812973|NCT02456207|DRUG|Rituximab|
40812974|NCT00199472|PROCEDURE|Dynamic Contrast Enhanced CT & Diuretic Renogram|
40812975|NCT03135769|DRUG|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
40812976|NCT05770635|DEVICE|Embosphere and chemotherapy drug|chemotherapeutic drug + embolic Embosphere;Iodide is selected according to the subject's condition
40812977|NCT05770635|DEVICE|Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug|chemotherapy drug+Polyvinyl alcohol embolization microspheres (Huihe Medical);Iodide is selected according to the subject's condition
40812978|NCT02885740|OTHER|Quantification assay of adenosine and methionine cycle metabolites|
40812979|NCT02885740|GENETIC|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
40812980|NCT02885740|OTHER|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
40812981|NCT02885740|BIOLOGICAL|Blood sample|
41012667|NCT01989533|BIOLOGICAL|gp 120 Protein Boost|HIV protein boost
41012668|NCT04483804|COMBINATION_PRODUCT|Endocrine therapy|Endocrine therapy
41012669|NCT06127251|BEHAVIORAL|PATH Intervention|"The PATH intervention guides participants in making changes in their lifestyle and PA habits to support gradual improvement of PA. The health coach provides participants with access to the PATH website and instructions on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week.~Participants will use a combination of walking, dance, and abdominal core workouts to add at least 10 minutes of MVPA to their baseline PA every two weeks. The remote coach will encourage each participant to engage in at least 2 days of aerobic training (walking or dance sessions), and one day of abdominal core workouts."
40812982|NCT04501653|DRUG|Psilocybin|Psilocybin is a naturally occurring psychedelic compound produced by psilocybin mushrooms, and has been shown to have antidepressant and anti-anxiety effects after one dose of 25 mg. Common side effects are slight elevations in blood pressure and heart rate. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
40812983|NCT04501653|DRUG|Methylphenidate|Methylphenidate is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is used as an active control for this study because it is metabolized similarly to psilocybin and has similar effects on heart rate and blood pressure. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
40812984|NCT03991403|DRUG|Atezolizumab(Tecentriq)|Atezolizumab(1200 mg IV);Over 60 (± 15) min (for the first infusion); 30 (± 10) min for subsequent infusions if tolerated Frequency: Day 1 of every 21 days Induction: Four or Six Cycles Maintenance : until PD
40812985|NCT03991403|DRUG|Pemetrexed|"Induction Period (Four or Six Cycles)~(1) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w~Maintenance Period (Until PD) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w"
40812986|NCT03991403|DRUG|Bevacizumab|Bevacizumab(15 mg/kg IV);Over 90 (±15) min (for the first infusion); shortening to 60 (± 10) then 30 (± 10) min for subsequent infusions if tolerated
40812987|NCT03991403|DRUG|Carboplatin|Carboplatin(AUC 5 or 5.5 IV a); Over approximately 15-30 min
40812988|NCT03991403|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 IV); Over 3 hours
41012670|NCT06127251|BEHAVIORAL|Control Group|Study staff will have a Zoom meeting with each control group participant where they will be advised to use the Be Active Your Way handout and to self-monitor PA using ScanWatch. Additionally, the group will be introduced to www.health.com, a jargon-free website that focuses on general health topics (e.g., dry eye) and the latest medical news (e.g., vaccines). Every 2 weeks control participants will meet on Zoom with study staff to review their progress in the study so as to keep the contact between the groups as similar as possible.
41012671|NCT06127251|DEVICE|Physical activity tracker|Participants will be asked to wear a ScanWatch tracker on their non-dominant hand for the entire duration of the study using a 24-hour wear protocol.
41012672|NCT06127251|BEHAVIORAL|Dietary education|The research team will examine diet quality and provide all study participants with educational content curated to promote diet quality. To minimize participants' burden, both the intervention and control arms will receive an email with a brief PDF addressing new diet components every 4 weeks
40812989|NCT03991403|DRUG|Carboplatin or cisplatin|Carboplatin(AUC 5.5 IV);Over approximately 30-60 minutes on Day 1 q3W or Cisplatin(75 mg/m²) ; Over 1-2 hours on Day 1 q3w
41330936|NCT05351905|DRUG|Placebo oil|The starting dose will be 1 mL per day (contains no API) orally and gradually titrated to a maximum dose of 6 mL per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
41330937|NCT03167541|DRUG|Test|RB naproxen sodium tablets (2x220mg)
41330938|NCT03167541|DRUG|Reference|Aleve naproxen sodium tablets (2x220mg)
41330939|NCT04355026|DRUG|Bromhexine Oral Tablet and/or hydroxychloroquine tablet|bromhexine 16 mg TID hydroxychloroquine 200 mg BID
40812990|NCT00580034|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
41012673|NCT00286949|DRUG|Atomoxetine|Open Label uncontrolled active Drug intervention
41012674|NCT01976845|DRUG|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
41330940|NCT06283225|DEVICE|Pia-App|The dysmenorrhoea app (Pia-App) is evidence-based and helps patients to implement continuous multimodal (pain) treatment that is integrated into everyday life. Symptoms, events, influencing factors and examinations can be recorded in a specialised diary. Diary evaluations and learning modules on dysmenorrhoea and other relevant topics promote understanding of the condition and self-efficacy. An intelligent evaluation suggests suitable evidence-based and appropriate exercises. In the learning modules, patients can learn about the menstrual cycle, menstrual pain and self-management methods in a structured way. For example, there are structured courses on physiotherapy, yoga, stress reduction and relaxation methods such as progressive muscle relaxation and autogenic training.
41330941|NCT01923571|OTHER|intraoperative BGC measure|
41330942|NCT01684683|DRUG|Theophylline|Theophylline 0.1 bid
41330943|NCT01684683|DRUG|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
40812991|NCT00580034|PROCEDURE|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
40812992|NCT03910738|DRUG|Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
40812993|NCT03910738|DRUG|Placebo 4 mL Solution for Injection|Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
40812994|NCT03910738|PROCEDURE|MRI|Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
40812995|NCT03910738|BEHAVIORAL|Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
40812996|NCT03910738|BEHAVIORAL|Assessment of disability|EDSS (Baseline, week 30 and 66)
40812997|NCT03010137|PROCEDURE|Incisional Negative Pressure Wound Therapy|
40812998|NCT03010137|PROCEDURE|Standard Closure with Skin Glue|
41012675|NCT01976845|DRUG|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
41012676|NCT01976845|DRUG|Saline|Saline 2 ml IV, in the pre-op area as a premedication
41330944|NCT05531968|BIOLOGICAL|BMI2006|IM
41330945|NCT05531968|BIOLOGICAL|BOTOX®|IM
40812999|NCT03010137|DEVICE|PICO (Smith&Nephew)|Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.
40813000|NCT03010137|DEVICE|Dermabond|Final wound closure with skin glue.
40813001|NCT03286829|DRUG|"Tesomet High dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
40813002|NCT03286829|DRUG|"Tesomet Low dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
40813003|NCT03286829|DRUG|Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
40813004|NCT03286829|DRUG|"Tesomet High dose in fed condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
40813005|NCT01129765|DEVICE|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
40813006|NCT02997436|DEVICE|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
40813007|NCT00006003|DRUG|semaxanib|Given IV
40813008|NCT00006003|OTHER|laboratory biomarker analysis|Correlative studies
40813009|NCT05706233|PROCEDURE|Erector Spina Plane Group|ESPB had been applied postoperatively: from T8 level, 20mL bupivacaine %0,5 + 5ml %2 lidocaine was applied.
40813010|NCT05706233|PROCEDURE|IV analgesic intervention|IV analgesics had been applied: All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS \> 3, 20 mg if NRS \> 5, 30 mg if NRS \> 8. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied.
40813011|NCT00116064|DRUG|intranasal lorazepam|
40813012|NCT00116064|DRUG|intramuscular paraldehyde|
40813013|NCT01179217|DRUG|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
41012677|NCT04554433|DRUG|Ethanol with Asprin|"Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~1. Inhaling alcohol vapor through nostrils .~2. Inhalation of Alcohol vapor driven by Oxygen .~3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~4. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results ."
41012678|NCT00000415|PROCEDURE|Physical activity|
41012679|NCT00000415|DRUG|Calcium supplement|
41012680|NCT00935103|BEHAVIORAL|Psychoeducation|
41012681|NCT02526381|DRUG|Danlou Tablets|Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
41012682|NCT02526381|DRUG|Tongmai Yangxin Pills|Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
41012683|NCT05591677|DRUG|D-Cycloserine|D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time.
41482203|NCT05841290|PROCEDURE|Primary local anesthesia|Tooth will be anaesthetized using Local anesthesia containing Articaine with epinephrine 1:100,000.
41482204|NCT05841290|PROCEDURE|Supplemental local anesthesia|if needed
41482205|NCT05841290|PROCEDURE|Removal Of Caries and Access Cavity|• Access cavity will be performed using a carbide round steel bur and tapered diamond stone until complete deroofing.
40813014|NCT01179217|DRUG|Placebo|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
40813015|NCT00100997|DRUG|tanespimycin|
40813016|NCT02195999|OTHER|Magnetic Resonance Imaging (MRI)|It is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
40813017|NCT02195999|OTHER|Pulmonary Function Testing (PFT)|It is non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
40813018|NCT02195999|OTHER|Metabolic Exercise Testing using stationary bicycle|Metabolic exercise testing, including assessment of exercise capacity and MVO2, evaluates global cardiopulmonary functional status. This is performed with the use of a stationary bicycle.
40813019|NCT02195999|OTHER|Echocardiogram|The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure.
40813020|NCT05576168|BIOLOGICAL|overexpression STRA6/miRNA3|RBP4 express in patients with T2DM or not
40813021|NCT02450461|OTHER|no intervention|
41482206|NCT05841290|PROCEDURE|Rubber dam isolation of tooth|Rubber dam isolation of tooth using certain clamps .
40813022|NCT02464995|DEVICE|Bronchial thermoplasty with the Alair System|
40813023|NCT02123238|OTHER|bed positioning|
40813024|NCT05501080|OTHER|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
40813025|NCT05501080|DRUG|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
40813026|NCT00303654|PROCEDURE|biopsy|
40813027|NCT00303654|PROCEDURE|therapeutic conventional surgery|
40813028|NCT02578966|BEHAVIORAL|Motivational Interview|
40813029|NCT02578966|OTHER|Traditional health education|
40813030|NCT03341364|BEHAVIORAL|ACT-based group therapy|6 group therapy sessions over 6 weeks (one session à 2 hours weekly), plus one follow-up session 6 weeks after last session. The sessions are lead by a psychologist and a social worker. Each session containing discussions, experimental exercises and home-work assignment.
40813031|NCT03341364|BEHAVIORAL|ACT individual treatment|3-12 individual therapy sessions over 3-16 weeks, plus one follow-up session 6 weeks after last session, lead by a clinical psychologist. Each session containing discussion, experimental exercises and home-work assignment.
40813032|NCT05354895|DEVICE|Transcranial infrared laser stimulation|non-invasive, non-pharmacologic photobiomodulation device
40813033|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
40813034|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
40813035|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
40813036|NCT01208883|OTHER|repetitive per-treatment [18F]FDG-PET for treatment adaptation|repetitive per-treatment \[18F\]FDG-PET for treatment adaptation
40813037|NCT01979666|DRUG|nitrate patch|patients in the study group will get a nitrate patch
40813038|NCT01979666|DRUG|placebo patch|control group patients will get a placebo patch
40813039|NCT01979666|DEVICE|MRI scan|MRI scan after 6 weeks of treatment
40813040|NCT06117969|DRUG|Tibolone|1.25mg po qd
40813041|NCT06117969|DRUG|Xiangshao granules|4g po tid
40813042|NCT06117969|DRUG|Tibolone plus Xiangshao granules|Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid
40813043|NCT02326168|DRUG|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
40813044|NCT05570110|DRUG|Enoxolone|one capsule of active or placebo in the evening
40813045|NCT05749510|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
40813046|NCT00113672|BEHAVIORAL|Increase healthy activity and increase healthy eating|Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
40813047|NCT00113672|BEHAVIORAL|Decrease unhealthy activity and increase healthy eating|Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
40813048|NCT00113672|BEHAVIORAL|Increase physical activity and decrease unhealthy eating|Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
40813049|NCT00113672|BEHAVIORAL|Decrease sedentary activity and decrease unhealthy eating|Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
40813050|NCT04742803|DEVICE|Straberi Epistamp Microneedling Treatment|"The patient's entire face will be treated with the Straberi Epistamp needling device.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
40813051|NCT02321787|PROCEDURE|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
40813052|NCT01961297|DRUG|Sodium oxybate|Sodium oxybate
40813053|NCT05099705|BEHAVIORAL|Access to a Family Service Navigator and Treatment Support System|An RCT will be conducted. 40 participants will be randomly assigned to the intervention group and 15 participants to the non-personalized comparison group (i.e., information, training, and referral). The intervention group will have access to a navigator and the treatment support system.
40813054|NCT02086487|DRUG|Nilotinib 300 mg.|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript \> 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at \> 12 months; i.e (BCR-ABL1 0.1 -1%)"
40813055|NCT00877786|BEHAVIORAL|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
40813056|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
40813057|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
40813058|NCT03116802|DRUG|Stamaril (live attenuated yellow fever vaccine)|They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
40813059|NCT06358664|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy will be performed
40813060|NCT05529264|OTHER|Memory Tasks|Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.
40813061|NCT05529264|OTHER|Attention/arousal tasks|Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.
40813062|NCT05529264|OTHER|Language tasks|Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.
40813063|NCT05529264|OTHER|Visuospatial tasks|Participants will be asked to copy 3 dimensional designs or make judgements of angle size.
40813064|NCT05529264|OTHER|Auditory Tasks|Participants will be presented with short, approximately 8-minute clips of music from various genres ( i.e. classical, country, rock, etc.) with an attention task (modified sustained attention to response task) nested within each trial. Participants will receive approximately 8 music stimuli and 1 control stimulus (pink noise) twice over the course of two testing sessions ( 90 mins each). Additionally, participants will be asked to answer questions about their hearing, music preferences/training, and certain demographic information (age, handedness, and language proficiency).
40813065|NCT05529264|PROCEDURE|Brain Stimulation|A brain stimulator will be used to understand new functions of the brain. Participants will be presented with pictures on a computer screen and may be asked to tell researchers what is seen or remembered by participants. As pictures are viewed by the participants, the brain stimulator may be activated, which would not be something that would be felt by an individual participant.
40813066|NCT05529264|OTHER|Social Emotional Task|Participants will be asked to view presented pictures and videos of people engaged in social interaction. Additionally, participants will be presented with the standardized tasks that are designed to help the researchers with understanding the nature of emotions. Some of these images may be emotionally disturbing. If participants are not comfortable viewing such images, they will be asked to refrain from participation in this study.
40813067|NCT05529264|OTHER|Recording of facial expressions|Some participants may be asked permission to record the video of their facial expressions during performance of a research task. Generally, this will include only research tasks investigating brain representation of social/emotional information. Automated analysis of facial expression may be used in certain experiments to provide information on experience of emotional states such as happiness and sadness related to the images being presented.
40813068|NCT05529264|OTHER|Judgement/Impulsivity Task|Certain study participants may be enrolled into research tasks designed to activate regions important for judgment and impulse control. These tasks will present participants with choices of varying monetary rewards and ask them to make judgements to measure one's tendency to prefer immediate over delayed rewards.
40813069|NCT03886870|BEHAVIORAL|Lifestyle and work intervention|"The intervention period lasted for a year with three institution-based stays, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan. At all three stages: The intervention contains activity training with a focus on the joy of movement, strength- and cardio-training. There were lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. Exercise programs was designed to use at home. The Cognitive Information Processing model of career guidance was the mainframe for the work dimension. All participants had talks with the work consultant at baseline, 6 and 12 months. Two work lectures, Duties and rights as employees and Work as medicine. When needed the work consultant contacted the employer in order to facilitate changes."
41012684|NCT05591677|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.
41012685|NCT03009097|BIOLOGICAL|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
41012686|NCT03009097|DRUG|DFDBA with atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel
41012687|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #1|Vitamin K supplement : 2mg, once a day, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
41012688|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #2|Vitamin K supplement : 7mg, twice a week, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
41012689|NCT06034366|DRUG|0.01% atropine|0.01% atropine (3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks,
41012690|NCT06034366|OTHER|0.9% sodium chloride|placebo eye drops (0.9% sodium chloride, 3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks
41012691|NCT04136834|BIOLOGICAL|PT01 (Pegtomarginase)|PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
41012692|NCT02833740|DEVICE|Click-MUAC prototype & regular MUAC tape|Screening of children using Click-MUAC and regular MUAC tape
41330946|NCT02783417|OTHER|Strength Training|"G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).~G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion."
41330947|NCT06360471|OTHER|fertility preservation|If a patient have a desire to fertility preservation, oocyte freezing or embryo freezing will be offered.
41330948|NCT00535444|OTHER|Parish nurse visit|One visit with the parish nurse in 2 weeks
41330949|NCT05385575|DRUG|KN056 (0.1mg)|The participants will receive assigned single dose of KN056 on Day 1
41330950|NCT05385575|DRUG|KN056 (0.3mg)|The participants will receive assigned single dose of KN056 on Day 1
41330951|NCT05385575|DRUG|KN056 (1.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
41330952|NCT05385575|DRUG|KN056 (3.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
41330953|NCT05385575|DRUG|KN056 (6.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
40813070|NCT03886870|BEHAVIORAL|Lifestyle intervention|"The intervention period lasted for a year with three institution-based stay, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan.~At all three stages: The intervention contains activity training with focus on joy of movement, strength- and cardio-training. There was lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. They developed exercise programs designed to use at home."
40813071|NCT04838054|DRUG|Stabilized chlorine dioxide oral rinse|Patients received stabilized chlorine dioxide rinse associated with periodontal basic therapy.
40813072|NCT04838054|OTHER|Placebo|Patients received a rinse containing no active ingredients and periodontal basic therapy.
40813073|NCT06491641|OTHER|Care based on Kolcaba's comfort theory|During the application process, the babies in the experimental group will receive care based on Kolcaba's comfort theory during their stay in intensive care.
40813074|NCT04916353|DRUG|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain
40813075|NCT04916353|DRUG|Triamcinolone Acetonide.|Triamcinolone Acetonide 40mg/1ml injection
40813076|NCT00711048|DRUG|AZD1386|oral, single dose
40813077|NCT00711048|DRUG|Placebo|Oral solution, single dose
40813078|NCT05181709|DRUG|Sodium Chloride|Administered intranasal (IN) and intramuscular (IM) in combination
40813079|NCT05181709|BIOLOGICAL|NDV-HXP-S IN low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108\^8 EID50."
40813080|NCT05181709|BIOLOGICAL|NDV-HXP-S IM low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10\^8 EID50."
40813081|NCT05181709|BIOLOGICAL|NDV-HXP-S IN high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
40813082|NCT05181709|BIOLOGICAL|NDV-HXP-S IM high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
41012693|NCT03873285|GENETIC|Genetic diagnostic by mendeliome or genome|For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
41012694|NCT01429766|OTHER|Respiratory Training|"All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one Spiroball device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed~1. st visit Within one day of the date of simulation~2. nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)"
41330954|NCT05385575|DRUG|KN056 (12.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
40813083|NCT04042051|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 \[according to the dose escalation scheme\]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.
40813084|NCT04042051|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
41012695|NCT01532466|DRUG|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
41012696|NCT05882539|DEVICE|endotracheal tube material,Bite block Material|Exposure factors associated with tracheal intubation in patients that may influence the occurrence of oral mucosa pressure injurie, such as the material and fixation of the tracheal tube, the patient's own nutrition, the level of tissue perfusion and relevant treatment factors.
41012697|NCT03269279|DRUG|Mifepristone|Medication used in conjunction with misoprostol for abortion
40813085|NCT05805696|BEHAVIORAL|Impostor tasks|Tasks to do every week
40813086|NCT01180036|DRUG|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
41012698|NCT03269279|DRUG|Misoprostol|Medication used in conjunction with mifepristone for abortion
41012699|NCT02383446|DEVICE|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
41012700|NCT03019497|BEHAVIORAL|Specific Modules|Educational session about a specific related problem
41330955|NCT05385575|DRUG|KN056 (18.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
41330956|NCT06415162|OTHER|Cooling Pillowcases|No intervention will be given to the patients in the control group.
40813087|NCT01180036|DRUG|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine \>30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
40813088|NCT02284529|DRUG|Orectalip|Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
41482207|NCT05841290|PROCEDURE|Bleeding control|bleeding is controlled by using excavator for the removing the pulp tissue . using a piece of cotton soaked with Sodium hypochlorite. using local anesthesia with vasoconstrictor if needed and if suitable for the patient.
41482208|NCT05841290|PROCEDURE|Canal negotiation|Coronal patency of the coronal and the Middle part of the canal using file #10 Apical patency of the apical part of the canal using #10
41482209|NCT05841290|PROCEDURE|Coronal flaring|Coronal flaring using Orifice opener of a certain Rotary system in and out motion first then brushing motion touching all the canal walls
41012701|NCT03019497|BEHAVIORAL|Cognitive behavioral therapy|PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.
41012702|NCT04416035|BIOLOGICAL|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.
41012703|NCT04416035|BIOLOGICAL|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.
41482210|NCT05841290|PROCEDURE|Working Length Determination (W.L)|Working length determination (W.L) using #10 K File , working length is recorded using apex locator and confirmatory radiograph.
41012704|NCT04416035|DRUG|Carboplatin|Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
41482211|NCT05841290|PROCEDURE|Glide path|Glide path of the canal Using #10 ,15 ,20 ,25 K files till becoming Super-Loose Inside the Canal at the recorded w.l to create a path for the rotary file .
41482212|NCT05841290|PROCEDURE|Irrigation|Irrigation using 5.25% sodium hypochlorite introduced using side vented needle
41482213|NCT05841290|PROCEDURE|Cleaning and shaping using rotary system|Cleaning and shaping using rotary system plus irrigation and apical patency between every rotary file .
41482214|NCT05841290|PROCEDURE|Second w.l determination|Second w.l determination using electronic apex locator before using final finishing rotary file .
41012705|NCT04416035|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
41012706|NCT03078998|DEVICE|Leap Motion Based Exercises|Game based exercise
41330957|NCT02379611|PROCEDURE|fNIRS (Functional Near Infrared Spectroscopy)|fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
41330958|NCT00129194|DRUG|KP-1461|
41330959|NCT01925391|DRUG|Tono-pen XL Applanation tonometer + Ocu-film +|
41330960|NCT02574819|DRUG|Methylnaltrexone (MNTX)|MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
41330961|NCT02574819|DRUG|Placebo|Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
41330962|NCT05168852|OTHER|Formlabs Permanent CB Resin|Tooth-colored, ceramic-filled permanent resin that can be fabricated with a 3D printer
41482215|NCT05841290|PROCEDURE|Apical gauging|"Establish the depth of apical constriction - this is the zero reading on your apex locator. your working length will be 0.5mm - 1mm short of this.~After cleaning and preparing the canal system to your working length, passively insert 02 taper hand files, starting from #15. If the file goes past the apical constriction (your working length + 0.5-1mm), then choose the next largest file and repeat.~When a file passively binds short of the apical constriction, that will be the upper limit of the apical constriction diameter. The smaller file before that would be the lower limit.~Apical gauging helps with:~Choosing the best master cone that closely matches canal length and taper Achieving true tug back - as opposed to false tug back! Minimising gutta percha extrusions during obturation"
41482216|NCT05841290|PROCEDURE|Activation of the irrigant|Activation of the irrigant using Manual Dynamic Agitation and Ultra x or eddy tips for activation
41482217|NCT05841290|PROCEDURE|Master cone check|Master cone check Clinically and confirmatory radiograph
41482218|NCT05841290|DRUG|application of resin based sealer inside the canal in the resin based sealer group|application done by inserting inside the canal by spreader or master cone
41482219|NCT05841290|DIAGNOSTIC_TEST|application of the sillicon based sealer inside the canal in the sillicon based group|application done by injection inside the canal
41012707|NCT05106894|BEHAVIORAL|smartphone application to promote nurturing care|see arm description
41012708|NCT05106894|BEHAVIORAL|printed caregiving materials|see arm description
41012709|NCT05239624|DRUG|Enfortumab vedotin|Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles.
41012710|NCT05239624|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles.
41482220|NCT05841290|PROCEDURE|Obturation|done by lateral condensation technique
41482221|NCT05841290|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS)|"Pain is evaluated using visual analogue scale (VAS) which is a pain rating scale. Scores are based on measures that are self-reported of symptoms that are recorded through a single handwritten mark placed at one point along the length of a 10-cm line representing a continuum between the two ends of the scale; on the left end of the scale (0 cm) means no pain and the on the right end of the scale (10 cm) worst pain"
41012711|NCT02492451|OTHER|Endometrial Injury|Endometrial injury in luteal phase of preceding cycle by pipelle canula
41482222|NCT03196414|BIOLOGICAL|CART-138/BCMA/19/more|Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight
40813089|NCT00879151|BEHAVIORAL|Cognitive Behavioral Therapy for Adolescents|The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
40813090|NCT00879151|BEHAVIORAL|Supportive Psychotherapy|SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
40813091|NCT00879151|BEHAVIORAL|Family Based Therapy for Bulimia Nervosa|FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
40813092|NCT05276674|DEVICE|ZNN Bactiguard Retrograde Femoral Nail|Femoral fracture internal fixation.
40813093|NCT00705913|DEVICE|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
40813094|NCT00705913|DEVICE|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
40813095|NCT00338286|OTHER|Standard supportive care (packed RBC transfusion)|Per doctor prescription
40813096|NCT00338286|DRUG|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
41012712|NCT02492451|DRUG|progesterone (Crinone® %8 vaginal progesterone gel)|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
41012713|NCT04119089|OTHER|Gastric ultrasound|"A first gastric ultrasound will be performed in the supine and the right lateral (RLD) decubitus position, allowing a qualitative analysis of the gastric contents (empty, liquid, solid, solid-liquid). The antral area will also be measured in both positions. The volume of gastric fluid content will be calculated according to the following formula: volume (ml) = -7,8 + (0,035 x antral area in RLD (mm²)) + 0,127 x age (month).~This examination will be immediately followed by the aspiration of gastric contents through the nasogastric tube used for enteral feeding, into 50-ml syringes, by a nurse blinded to the result of the first ultrasound examination. A second antral ultrasound examination will then be performed, by the same investigator blinded to the volume aspirated.~The occurrence of regurgitation and / or vomiting occurring within the 12 hours before and after the examination will be recorded."
41012714|NCT03722017|OTHER|Deprescribing intervention|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
41330963|NCT05281068|DRUG|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
40813097|NCT00189800|DRUG|Solifenacin succinate|
40813098|NCT05289141|DEVICE|Use of high flow nasal oxygen therapy|Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83).
41012715|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
41330964|NCT05281068|DRUG|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
41330965|NCT01256983|BEHAVIORAL|Bright Light Therapy|10000 Lux for 30 Minutes according to sleep wake rhythm
41482223|NCT02856009|OTHER|completion of a quality of life questionnaire|
40813099|NCT05289141|DEVICE|Use of other non-invasive ventilation or high concentration oxygen masks|Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83).
40813100|NCT05613452|RADIATION|Carbon ion beam radiotherapy|Patients receive carbon ion radiotherapy of 12GyE per fraction, totally 4 fractions. Patients with tumors ≥4cm should receive at least 4 cycles of platinum-based doublet chemotherapy.
40813101|NCT00970892|DRUG|Warfarin dose titration|Dosage
40813102|NCT00001106|DRUG|Zidovudine|
40813103|NCT06076252|PROCEDURE|Modified Blumgart Anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
41012716|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
41012717|NCT01706250|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
41012718|NCT01706250|OTHER|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
41012719|NCT01706250|OTHER|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
41012720|NCT01706250|OTHER|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
41012721|NCT03830294|OTHER|different temperature-controlled breast prostheses|Two types of temperature-controlled breast prostheses were applied to patients in each group
41330966|NCT01256983|BEHAVIORAL|Wait-list intervention|10000 Lux for 30 Minutes according to sleep wake rhythm
40813104|NCT06076252|PROCEDURE|conventional Blumgart anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
40813105|NCT03826173|BEHAVIORAL|PPPA|The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.
40813106|NCT03826173|BEHAVIORAL|PA|The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
40813107|NCT02709551|BEHAVIORAL|HRV_Bfb|
41012722|NCT03652298|OTHER|Memory structuring intervention + Vagal breathing|"The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation"
41012723|NCT03652298|OTHER|support and attention (usual care)|support and attention (usual care)
41012724|NCT02950636|OTHER|Yoga|Restorative Yoga
41012725|NCT03905551|PROCEDURE|Cold Dialysis|Dialysate temperature reduced to 35oC for a period of 7 months.
41155830|NCT03188809|PROCEDURE|Adductor Canal Block|Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
41012726|NCT03905551|PROCEDURE|Typical Dialysis|Dialysate temperature is set at 37oC for a period of 7 months
41012727|NCT03905551|PROCEDURE|Exercise|Aerobic Intradialytic exercise training
41155831|NCT03188809|PROCEDURE|femoral nerve block|The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
41155832|NCT01073774|BEHAVIORAL|Side by side|
41155833|NCT01073774|BEHAVIORAL|couples control condition|
40813108|NCT02709551|BEHAVIORAL|MBI|
40813109|NCT02709551|BEHAVIORAL|MBI_HRV_Bfb|
40813110|NCT05277519|DEVICE|Vibrations|Sequenced muscle vibrations during 30 min., 3 times a week during 5 weeks
40813111|NCT00053976|BIOLOGICAL|Daclizumab|
40813112|NCT00053976|DRUG|methylprednisolone|
40813113|NCT00053976|DRUG|Placebo|
40813114|NCT03319459|DRUG|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
40813115|NCT03319459|DRUG|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
40813116|NCT03319459|DRUG|Trastuzumab|HER2/neu receptor inhibitor
40813117|NCT05031091|OTHER|standardised exposure questionnaire|A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
40813118|NCT04458441|OTHER|warm group/cold group|sequential randomization
40813119|NCT00501722|DRUG|satavaptan (SR121463B)|
40813120|NCT00802997|DEVICE|Sinergy|radiofrequency denervation
40813121|NCT00802997|DEVICE|Placebo sham|sham procedure
40918269|NCT02410343|DRUG|TV-1106|A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
41012728|NCT02726763|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
41012729|NCT02726763|BEHAVIORAL|Questionnaires|
41155834|NCT00126555|DRUG|Gefitinib|Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
40918270|NCT02410343|DRUG|Placebo|Placebo treatment was administered in a blinded fashion and titrated on weeks 4, 8, 12 and 16 to mimic the active treatment.
40813122|NCT05991115|BEHAVIORAL|Hospital to Home Transition (H2H)|The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
40813123|NCT01263431|PROCEDURE|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
40813124|NCT01263431|PROCEDURE|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
40813125|NCT00144248|DRUG|nevirapine|
40813126|NCT05128474|OTHER|Neuromuscular Control-Based Exercise Training Group|Exercises for the neuromuscular control of the shoulder will be progressed by starting with the body weight, and in the following phases, a program that progresses to exercises that will improve the dynamic stabilization, coordination and proprioception of the shoulder will be applied to train the sensorimotor system. The exercise program will be performed twice a week for 8 weeks (16 sessions).
40813127|NCT05128474|OTHER|Conventional Exercise Training Group|In this group, which will mainly benefit from conventional open kinetic chain strength exercises, a strengthening exercise program will be applied by advancing from body weight to elastic bands and weights. The exercise program will be performed twice a week for 8 weeks (16 sessions).
41330967|NCT00308321|DRUG|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
41330968|NCT00308321|DRUG|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
41330969|NCT03824535|PROCEDURE|Computed Tomography|Undergo PET/CT
41330970|NCT03824535|DRUG|Fludeoxyglucose F-18|Given IV
41330971|NCT03824535|DRUG|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
41330972|NCT03824535|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41330973|NCT04553367|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
41330974|NCT04553367|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
41330975|NCT04553367|DEVICE|ventilator|ventilator
41330976|NCT04150354|BEHAVIORAL|Cogito Companion|During the course of the study, the research application (Cogito Companion) will be installed on participants' mobile phone. The application on the participants' phone will be recording data about their behavior. Participants will also be asked to complete bi-weekly surveys via the app.
41330977|NCT00358709|BEHAVIORAL|Cognitive-Behavioral therapy and Symptom Management|A group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and comparison its effects to a known skills training approach and a control group.
41330978|NCT00881790|OTHER|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
41330979|NCT01320813|PROCEDURE|Robot-assisted thyroidectomy|Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
41330980|NCT01320813|PROCEDURE|Open thyroidectomy|Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
41330981|NCT00517413|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
40813128|NCT02894723|DIETARY_SUPPLEMENT|L-arginine|30 ml arginoline contains 5 gr l-arginine
40813129|NCT02894723|DIETARY_SUPPLEMENT|syrup|The same bottle of the experimental group, but without l-arginine
40813130|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
40813131|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
40813132|NCT00185380|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
40813133|NCT01524224|DRUG|LY2495655|administered intravenously
40813134|NCT00320905|BEHAVIORAL|Observational|No intervention
40813135|NCT06098911|DEVICE|MI varnish|delivers a powerful dose of fluoride, with the added booster effect of the calcium and phosphate ions through its patented Recaldent™ technology. High initial fluoride release. Minimizes tooth sensitivity and strengthens enamel. Neutral pH of 6,6 enhances enamel and dentin acid resistance and inhibits demineralization
40813136|NCT00298623|DRUG|XP13512 (GSK1838262)|
40813137|NCT00298623|OTHER|placebo|
40918271|NCT02576145|BIOLOGICAL|DT|Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show \>=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
41330982|NCT03177967|BEHAVIORAL|Sleep Restriction Therapy/Stimulus Control|Sleep Restriction Therapy focuses on forcing your available sleep time into a fixed window. The sleeper sets a bedtime and wake-up time and sticks to those times closely. The time allocated for being allowed in bed is determined from an estimate of how long the patient in average has been sleeping during the night, in the week before treatment. The goal is to have the patient sleeping the entire time he or she is in bed by making this period so restricted that the patient has no chance of sleeping enough. Once this goal is achieved, the time allocated for bed can be slowly increased, for example by 15 minutes at a time. After enough iterations, an equilibrium is achieved that the patient can keep maintaining after treatment has completed.
40813138|NCT02810912|OTHER|the effect of surgical position|Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
40813139|NCT01837446|DRUG|2% morphine solution|
40813140|NCT01837446|DRUG|Magnesium aluminum hydroxide|
40813141|NCT01837446|DRUG|2% viscous lidocaine|
40813142|NCT01837446|DRUG|Diphenhydramine|
41155835|NCT00126555|RADIATION|Radiotherapy|Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
41155836|NCT00126555|PROCEDURE|Conventional surgery|Undergo surgery
41330983|NCT03177967|OTHER|Discussions about adverse cognitions about sleep|Group discussions about insomnia, CBT-i treatment and it's effects
41330984|NCT03177967|OTHER|Psychoeducative advice about how to improve sleep|Learning about sleep and sleep hygiene tips. It also includes learning about stimulus control and sleep restriction.
41330985|NCT04414527|BEHAVIORAL|Standard counselling|"The control cohort will receive national standard counseling during four ante-natal care visits.~Women in the control group will receive additionally~1. national nutrition and health care including IFA supplementation,~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
41330986|NCT04414527|BEHAVIORAL|Health-Video|"The intervention cohort Health-Video will receive innovative video-based nutritional and hygienic education.~Women in this group will receive additionally:~1. National nutrition and health care including IFA supplementation~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
41330987|NCT06177171|DRUG|Olaparib|Given orally
41330988|NCT06177171|DRUG|ASTX727|Given Orally
41330989|NCT01734278|OTHER|No intervention|This is a non-interventional study.
41330990|NCT03872557|DIETARY_SUPPLEMENT|Tyrosine (TYR) Supplementation|L-Tyrosine dietary supplement will be provided as 500 mg capsules and 4 (four) 500 mg capsules are to be given before OGTT. The capsules are formed from animal gelatin, and the contents are formulated with magnesium stearate as a flow agent, but without binders, coatings or colorings and also have no added flavorings, sugars, salt, artificial sweeteners, preservatives or salicylates. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity.
41330991|NCT06380348|DRUG|JMT101 Injection|JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 days
41330992|NCT06380348|DRUG|Osimertinib tablet|Osimertinib 160mg once po everyday
40813143|NCT04130724|DIAGNOSTIC_TEST|Blood ketone testing|Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.
41155837|NCT00126555|OTHER|laboratory biomarker analysis|Correlative studies
41155838|NCT05256914|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
40813144|NCT04130724|DIAGNOSTIC_TEST|Breath ketone testing|Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.
40813145|NCT02358161|DRUG|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
40813146|NCT04776720|BEHAVIORAL|Yoga Practice Program|3 month group yoga classes
40813147|NCT04776720|BEHAVIORAL|Physical Conditioning Program|3 month group physical conditioning classes
40813148|NCT01185314|PROCEDURE|Testing for mutation status|EGFR mutation test
40813149|NCT00323960|DRUG|3 MPDN pulse + PDN|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
40813150|NCT00323960|DRUG|3 MPDN pulse + PDN + CSA|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
40813151|NCT00323960|DRUG|3 MPDN pulse + PDN + MTX|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
40813152|NCT05795569|PROCEDURE|Nasogastric Tube removal during extubation|The nurse in charge of the patient and under the cover of a medical prescription, will proceed to the systematic removal of the nasogastric tube during the extubation procedure
40813153|NCT05795569|DIAGNOSTIC_TEST|Yale Swallow Protocol|"The dysphagia will be evaluated in a systematic way between 1 hour and 6 hours post-extubation with the help of the Yale Swallow Protocol (YSP) by the caregivers trained to the passing of the YSP (nurse or physiotherapist or ICU doctor)."
40813154|NCT05795569|PROCEDURE|Classif Nasogastric Tube Management|The removal of the nasogastric tube will not be performed during the extubation procedure and the time of removal will be left to the discretion of the attending physician (as currently performed in the unit).
40813155|NCT05795569|DIAGNOSTIC_TEST|Classic swallowing test|"Post-extubation dysphagia will be assessed as we do in the unit. Currently, the caregivers in charge of the patient do a gel water test Nutrisens Hydra'Fruit level 4 when the attending physician prescribes it."
40813156|NCT03086291|DRUG|Simvastatin|Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days
40813157|NCT05872386|BEHAVIORAL|Buprenorphine uptake/retention via Telehealth|Bupe by the Book (BBB) randomly assigns unstably housed library patrons with opioid use disorder to a telehealth to receive buprenorphine (aka, Suboxone) treatment from Father Joe's Villages Health Center.
40813158|NCT05872386|BEHAVIORAL|Control group|unstably housed library patrons with opioid disorder are assigned randomly to a treatment as usual control group (in-person at the clinic)
40813159|NCT06368505|OTHER|ultrasound guided PRP injection|whole blood is initially collected in tubes that contain anticoagulants, such as citrate dextrose A to prevent platelet activation prior to its use. Then PRP is prepared by a differential centrifugation. Then 3ml of PRP will be delivered via the in-plane ulnar approach
40813160|NCT06368505|OTHER|ultrasound guided hydrodissection|5ml will be injected to detach the median nerve from the TCL (2ml saline, 2ml dexamethasone and 1ml lidocaine), the injectate will be delivered via the in-plane ulnar approach, and the median nerve will be hydrodissected from its undersurface while advancing the needle among the superficial surface of the median nerve and the TCL
40813161|NCT03438279|OTHER|Non-Interventional|Non-Interventional
40813162|NCT02392390|PROCEDURE|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
40813163|NCT02392390|DRUG|Metvixia cream|
40813164|NCT04998994|DIETARY_SUPPLEMENT|wheat sprouts supplement|Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy
40813165|NCT02603601|BEHAVIORAL|Mind-body lifestyle intervention|
40813166|NCT02603601|BEHAVIORAL|Standard lifestyle intervention|
40813167|NCT03226379|OTHER|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~1. Health system strengthening~2. Delivery of a co-designed education program tailored to frontline healthcare workers~3. Implementation of an algorithm for HIV-related meningoencephalitis~4. Infectious diseases/AHD mentorship and laboratory capacity building"
40813168|NCT03525301|RADIATION|standard treatment|3000 cGy in 10 daily fractions
41330993|NCT06380348|DRUG|Cisplatin injection|Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.
41482224|NCT02966665|OTHER|Maximum Exercise Tests|Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
40813169|NCT03525301|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
40813170|NCT01468233|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
40813171|NCT01468233|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
40813172|NCT06426563|PROCEDURE|Ablation treatment of thyroid nodule|Use Radiofrequency or Microwave ablation device to treat thyroid nodule
40813173|NCT05093595|DEVICE|SFC|The lubricated SFC passed nasally into the oropharynx under the visual guidance of visual laryngoscope to ensure that the cuff had passed through the posterior choanae and reached the oropharynx. The guide wire is removed and the balloon inflated with 5 ml normal saline. The catheter is then pulled slightly until the balloon is fixed and concealed by the soft palate . The ETT is anchored to the SFC with a cable tie .
40813174|NCT00426595|DRUG|Administration of omeprazole suspension|
40813175|NCT00426595|DRUG|omeprazole administered as a multi-unit-pellet system|
40813176|NCT06394479|OTHER|Outcome after bariatric surgery in patient with T1D|Retrospective evaluation of clinical data
40813177|NCT05447195|DRUG|CAN008|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.
41330994|NCT06380348|DRUG|Pemetrexed injection|Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.
41330995|NCT06410469|PROCEDURE|rug weaving-like plication technique|anterior vaginal wall repair with the rug weaving-like plication technique in cystosel
41330996|NCT03048357|DEVICE|Freedom Bed|Fully Integrated Lateral Rotation Bed System that automatically turns the patient to a specific angle in degrees between from 15-25 with dwell times between 1-120 minutes.
41330997|NCT03048357|OTHER|Standard hospital bed|Caregiver turning patients to one side then the other every 2 hours for pressure relief over bony prominence's.
41330998|NCT03332303|DRUG|Estrace® Cream|Estrace® Cream
41330999|NCT03332303|DRUG|Estradiol Vaginal Cream|Estradiol Vaginal Cream
41331000|NCT03332303|DRUG|Vehicle Cream|Vehicle Cream
40813178|NCT05447195|DRUG|Placebo|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
40813179|NCT05760131|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
40813180|NCT04685720|DEVICE|LungFit|LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
40813181|NCT06141538|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
40813182|NCT05936567|DRUG|Povorcitinib|oral; tablet
40813183|NCT05936567|DRUG|Placebo|oral; tablet
40813184|NCT03815695|DRUG|FT-4202/Placebo|Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
40813185|NCT01009437|DRUG|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I."
40813186|NCT01009437|PROCEDURE|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
41155839|NCT05256914|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
40813187|NCT01414101|DRUG|ISIS CRP Rx or Placebo|
40813188|NCT00822627|DRUG|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
40813189|NCT00822627|BEHAVIORAL|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
40813190|NCT01858142|BEHAVIORAL|Parental presence decision tool|
40813191|NCT01858142|BEHAVIORAL|Standard preparation|
40813192|NCT03374683|BEHAVIORAL|RR Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date."
40813193|NCT03374683|BEHAVIORAL|RR In-Person Workshop|Participants engage in a facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.
41155840|NCT02876003|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
41155841|NCT01190228|BIOLOGICAL|JE-CV Vaccine|0.5 mL (single dose), Subcutaneous
40813194|NCT03374683|BEHAVIORAL|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015)."
40813195|NCT03771638|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
40813196|NCT03771638|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
40813197|NCT05763420|DEVICE|AH Plus Bioceramic Sealer|A bioactive, calcium silicate-based sealer will be used in combination with the core root canal filling material (gutta-percha). It's premixed and is dispensed in the root canal via a fine disposable syringe.
41155842|NCT01190228|BIOLOGICAL|Varicella Vaccine|0.5 mL (single dose), Subcutaneous
41155843|NCT01309399|DRUG|Teriparatide|six weeks of teriparatide
41155844|NCT01309399|OTHER|placebo|placebo
41155845|NCT03463538|PROCEDURE|arthroscopic capsular release|surgical release of shoulder joint capsule
41155846|NCT03463538|PROCEDURE|Hydro-dilatation|dilatation of shoulder joint capsule using water pressure under local anesthetic
40813198|NCT05763420|DEVICE|AH Plus Sealer (resin-based)|A resin-based sealer will be used in combination with the core root canal material (gutta-percha). It consists of two pastes that are mixed together in equal amounts prior to application.
40813199|NCT01226641|DEVICE|Telemedicine|CPAP treatment with telemedicine system
40813200|NCT01226641|DEVICE|Standard care|Standard care, including CPAP
40813201|NCT02202213|DRUG|Placebo|
40813202|NCT02202213|DRUG|Lu AF11167|
40813203|NCT00435227|BIOLOGICAL|Motavizumab|A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
40813204|NCT00435227|OTHER|Placebo|A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
40813205|NCT03420508|DRUG|Ensartinib|Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
40813206|NCT03420508|DIAGNOSTIC_TEST|ALKATI by Customized Nanostring Assay|a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
40813207|NCT03998670|DEVICE|Prism Glasses|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses
41331001|NCT02661620|DEVICE|REDAPT Revision Femoral System modular stem|Medical record review for retrospective information and observational prospective data collection of standard of care items at 5 years and 10 years post operatively plus a 7.5 year post op telephone call to assess stem status and adverse events.
41331002|NCT02597491|BEHAVIORAL|TLC monthly|Tobacco longitudinal care monthly
40813208|NCT03998670|DEVICE|Non-Prism Glasses|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism
40813209|NCT04005508|DIAGNOSTIC_TEST|Overnight sleep study|The patients will undergo an overnight sleep study using Watch-PAT sleep study device
40813210|NCT05425394|BEHAVIORAL|Delay first bath|Newborns delay first bath to 8 hours after birth
40813211|NCT01830283|BIOLOGICAL|varicella vaccine|The providers would get varicella vaccine
41331003|NCT02597491|BEHAVIORAL|TLC quarterly|Tobacco longitudinal care quarterly
41331004|NCT02597491|BEHAVIORAL|MTM|Medication management therapy
41331005|NCT02597491|BEHAVIORAL|4 week assessment|4 week assessment
40813212|NCT00024024|DRUG|rebimastat|
40813213|NCT00680355|DIETARY_SUPPLEMENT|golden rice|An acute dose of cooked golden rice containing \~ 1 mg of ß-carotene
40813214|NCT00680355|DIETARY_SUPPLEMENT|corn oil 0g|0 g of corn oil in the golden rice meal
40813215|NCT00680355|DIETARY_SUPPLEMENT|corn oil 10g|10g corn oil in the golden rice meal
41155847|NCT05618054|BEHAVIORAL|Looming task|Participants will be asked to look at some pictures during an fMRI scan. Participants will press a button as soon as they see the image appear.
41331006|NCT02597491|BEHAVIORAL|8 week assessment|8 week assessment
41331007|NCT00904176|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
41331008|NCT00904176|DRUG|Warfarin|Tablets, Oral, 25 mg, Single Dose
41331009|NCT00904176|DRUG|Digoxin|Tablets, Oral, 0.25, Single Dose
41331010|NCT01466478|DRUG|Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
41331011|NCT01466478|DRUG|Ointment B: LEO 29102 2.5 mg/g ointment|once daily application, 4 weeks
41331012|NCT01466478|DRUG|Ointment C: Calcipotriol 50 µg/g ointment|once daily application, 4 weeks
41331013|NCT01466478|DRUG|Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
40813216|NCT00680355|DIETARY_SUPPLEMENT|coren oil 5 g|golden rice meal with 5 g corn oil
40813217|NCT00760942|DIETARY_SUPPLEMENT|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
40813218|NCT00760942|DIETARY_SUPPLEMENT|Similac human milk fortifier|Powdered human milk fortifier.
40813219|NCT01182805|DEVICE|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
40813220|NCT01182805|DEVICE|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
40813221|NCT01182805|DEVICE|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
40813222|NCT00939029|DRUG|nicotine replacement therapy (nicotine patches)|2- 21 mg patches per day for 8 weeks
40813223|NCT00939029|DRUG|placebo NRT|2 placebo patches (containing no active ingredient)per day for 8 weeks
40813224|NCT05665504|DIAGNOSTIC_TEST|DetermaRX|A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.
41331014|NCT01466478|DRUG|Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
41331015|NCT01466478|DRUG|Daivonex® ointment|once daily application, 4 weeks
41331016|NCT01466478|DRUG|Diprosone® ointment|once daily application, 4 weeks
41331017|NCT01149343|BIOLOGICAL|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
41331018|NCT06258863|PROCEDURE|incision type|Total mastectomy was performed using one of the four incision types
41331019|NCT05860998|DIAGNOSTIC_TEST|Presence of Toxoplasma gondii IgG Antibodies|Testing for the presence of Toxoplasma gondii IgG Antibodies in participants blood.
41482225|NCT02966665|DRUG|BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
41331020|NCT02972112|BEHAVIORAL|CBT|novel cognitive behavioral protocol for the treatment of tokophobia
41331021|NCT02972112|OTHER|Sham|standard birth preparation sessions.
41331022|NCT05595603|PROCEDURE|4mg ZOL loaded gentamicin PMMA|During surgery, 4mg ZOL will be mixed with gentamicin (1000mg) PMMA cement (40g) by surgeon under sterile conditions to prepare ZOL loaded bone cement, and then it will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
41331023|NCT05595603|PROCEDURE|gentamicin PMMA|During surgery, gentamicin (1000mg) PMMA (40g) was prepared by surgeon under sterile conditions and will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
41331024|NCT03909672|OTHER|Cupping Therapy|application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally
41331025|NCT00555282|DEVICE|central venous catheter|coated central venous catheter
41331026|NCT00555282|DEVICE|central venous catheter|standard central venous catheter
41331027|NCT05616039|PROCEDURE|Standard Liver Surgery|Standard liver surgery using naked eye examination +/- palpation and intra-operative ultrasound scan (IOUS) examination to identify and remove liver tumours
41331028|NCT05616039|DIAGNOSTIC_TEST|Indocyanine Fluorescent Image Guided Surgery (I-FIGS)|Use of I-FIGS in accurate identification of tumours and their margins
41482226|NCT02966665|DRUG|BQ-123|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
41482227|NCT02966665|DRUG|Fexofenadine, Ranitidine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
41482228|NCT02966665|OTHER|Angiotensin-II, Valsartan|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
41331029|NCT05412212|OTHER|LTBI video intervention|3-minute educational video about latent tuberculosis and importance of taking and completing treatment
41331030|NCT04628598|BEHAVIORAL|Antenatal care and prenatal education with a home visit|Providing prenatal education and care by home visits to pregnant women
41331031|NCT02067533|PROCEDURE|soft tissue repair in flexion position|
41331032|NCT02067533|PROCEDURE|soft tissue repair in extension position|
41331033|NCT02791360|OTHER|Brain MRI|
41331034|NCT00004226|RADIATION|radiation therapy|
41331035|NCT03753204|DRUG|Furosemide 40 mg|Blood pressure data from the monitors will be downloaded and the average of the systolic blood pressure of the day of salt loading, from 12 noon (end of the saline infusion) until 10 pm will be used as the BP for the salt-loading period of study. The average of the systolic blood pressure of the day of salt depletion, from 12 noon (second dose of furosemide) until 10 pm will be used as the BP for the salt-depleted period of study. A fall in systolic BP ≥10 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive.
41331036|NCT02653313|DRUG|Parvovirus H-1 (H-1PV)|"Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu."
41331037|NCT02720250|DIETARY_SUPPLEMENT|Omega-3 chicken eggs|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
41331038|NCT02720250|DIETARY_SUPPLEMENT|Regular chicken eggs|Intake of 3 regular chicken eggs per day for three weeks.
41331039|NCT01759160|PROCEDURE|Marsh Plasma TCI with high initial target|plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
41482229|NCT02966665|DRUG|Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
41331040|NCT01759160|PROCEDURE|Schnider Plasma TCI with high initial target|plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
41331041|NCT06034912|DEVICE|Low-Intensity Red Light Therapy|myopia and amblyopia comprehensive treatment instrument red light feeding treatment
40813225|NCT01491789|DEVICE|The VSail-Access simulator|You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
41331042|NCT00888680|DRUG|BGC20-1531|BGC20-1531 administered orally
41155848|NCT00183235|DRUG|aripiprazole (up to 15 mg/day) for 8 days|
41331043|NCT00888680|DRUG|Lactose|Placebo administered orally
41331044|NCT02843178|BEHAVIORAL|Vouchers|A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
40813226|NCT04190381|OTHER|FR-Mask|"The investigational medical product of this study is a biomedical repair mask, FR-MASK, acting like moisturizing lotion applied on breasts.~The FR-Mask is applied to users' radiation-irritated breast skin for 15 to 20 minutes every 3 days."
40813227|NCT04600505|DRUG|Treatment A|Participants will receive 2 inhalations of BGF MDI with propellant 1.
40813228|NCT04600505|DRUG|Treatment B|Participants will receive 2 inhalations of BGF MDI with propellant 2.
40813229|NCT04600505|DRUG|Treatment C|Participants will receive 2 inhalations of BGF MDI with HFA propellant.
40813230|NCT06232603|OTHER|Education of medication management|Video and handout materials will be provided
40813231|NCT03013504|DRUG|HD201|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
41331045|NCT06179706|DIAGNOSTIC_TEST|11C-choline PET/CT|In our study we evaluated the efficacy of high-dose RT guided by 11C-Choline PET/CT on bone metastases in prostate cancer patients with a limited number of metastases.
40813232|NCT03013504|DRUG|Herceptin|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
40813233|NCT03013504|DRUG|Docetaxel|75mg/m2 via i.v. infusion during cycles 1 to 4.
40813234|NCT03013504|DRUG|Epirubicin|75 mg/m2 via i.v. infusion during cycles 5-8.
41331046|NCT06360497|OTHER|mindfulness meditation intervention and loving-kindness and compassion meditation intervention|Interventions were conducted by two teachers separately. Mindfulness meditation group provided the knowledge and practice related with mindfulness, and loving-kindness and compassion meditation group provided knowledge and practice related with loving-kindness and compassion meditation.
41331047|NCT04425460|DRUG|Favipiravir|Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
40813235|NCT03013504|DRUG|Cyclophosphamide|500 mg/m2 via i.v. infusion during cycles 5-8.
41331048|NCT04425460|OTHER|Placebo|Placebo combined with supportive care recommended in the current National/Local guidelines. Placebo dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
41331049|NCT00873145|PROCEDURE|HMRS|Modular prosthetic replacement of the humerus and elbow.
41331050|NCT00005092|DRUG|Cyclophosphamide|IV over 2 hours on days 2 and 3
41331051|NCT00005092|DRUG|Psoralen|Psoralen treated T-cell allogeneic transplant on day 9
41331052|NCT00005092|DRUG|Thiotepa|IV over 2 hours on day 1
40813236|NCT00483366|DRUG|capecitabine|"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid"
40813237|NCT00483366|DRUG|gemcitabine hydrochloride|"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~1. 550 mg/m2~2. 550 mg/m2~3. 675 mg/m2~4. 675 mg/m2~5. 825 mg/m2~6. 825 mg/m2~7. 1000 mg/m2"
40813238|NCT00483366|DRUG|imatinib mesylate|"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~1. 400 mg/d~2. 400 mg/d~3. 400 mg/d~4. 400 mg/d~5. 400 mg/d~6. 400 mg/d~7. 400 mg/d"
40813239|NCT00483366|GENETIC|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
40918272|NCT02576145|DRUG|Daclizumab|The fifth dose (1 milligram per kilogram \[mg/kg\]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
40918273|NCT02576145|BIOLOGICAL|KLH|KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
40918274|NCT03148691|DRUG|A-101|Topical Solution
40918275|NCT04572152|BIOLOGICAL|AK119|Subjects will receive AK119 by intravenous administration.
41331053|NCT00005092|PROCEDURE|Allogeneic bone marrow transplantation|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
41331054|NCT00005092|PROCEDURE|In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
41012730|NCT04099524|DEVICE|tDCS|tDCS (LPG/C3-anode, orbitofrontal cortex/Fp2-cathode) will be administered for 4 weeks (1 session per weekday for 2 weeks, and then 2 sessions per week for 2 weeks, for a total of 14 sessions). All subjects will receive anodal tDCS stimulation for 20 minutes per session, on C3 and the cathode electrode on Fp2 using 10/20 EEG system. tDCS will be applied with a pair of 35 cm2 single-use sponges soaked in approximately 4mL of saline solution on each side (\~8mL per sponge) connected to the stimulator. During the 20-minute tDCS session, we will use online tDCS design (i.e., a subject will simultaneously work on the visual attention-oriented task.
41012731|NCT05524324|DEVICE|CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)|Patients randomized to the CRT ON / CRT OFF arm will undergo a first intervention to activate their device and then a second intervention for 3 months to inactivate their device.
41331055|NCT00005092|RADIATION|Radiation Therapy (RT)|Whole body radiotherapy on days 5-8.
41331056|NCT04705987|DRUG|Colchicine 0.5 MG|Colchicine 0.5 mg/24h Treatment 8 weeks
41331057|NCT04705987|DRUG|Placebo|Placebo 1c/24h Treatment 8 weeks
41331058|NCT03027193|BIOLOGICAL|ChAdOx2 HAV|The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens
41331059|NCT03027193|BIOLOGICAL|MVA HAV|The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.
41331060|NCT01590212|OTHER|Mellow Bumps|Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
41331061|NCT01590212|OTHER|Chill-out in Pregnancy|Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
41482230|NCT02966665|DRUG|BQ-123, MitoQ, BH4|Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
41482231|NCT03255512|DRUG|Vericiguat (BAY1021189)|2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet
41482232|NCT03255512|DRUG|Placebo|Matching placebo
41012732|NCT05524324|DEVICE|CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)|Patients randomized to the CRT OFF / CRT ON arm will undergo a first intervention to inactivate their device and then a second intervention for 3 months to activate their device.
41012733|NCT04857866|DRUG|XmAb27564|Single ascending dose of XmAb27564
41012734|NCT04857866|DRUG|Placebo|Single dose of placebo
41012735|NCT02803697|OTHER|Patients|
41482233|NCT03255512|DRUG|Isosorbide mononitrate (ISMN)|30 mg/tablet or 60 mg/tablet
41482234|NCT02249676|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
40813240|NCT00483366|GENETIC|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
41012736|NCT01730495|DRUG|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
41012737|NCT00434096|DRUG|rimonabant (SR141716)|oral administration once daily
41012738|NCT00434096|DRUG|placebo|oral administration once daily
41012739|NCT04088461|DRUG|Linagliptin / Metformin Oral Tablet|Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
41012740|NCT04088461|DRUG|Metformin|Metformin 850 mg twice daily plus lifestyle modifications program
41012741|NCT05253482|PROCEDURE|wet cupping therapy|Vacuum cups will used on different acupuncture points to perform WCT: The one on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra was DU 14 (Dazhui) point; the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra interscapulum region were UB 42 (Pohu) bilateral points; and the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 7th thoracic vertebra were UB 46 (Geguan) bilateral points and additionally the patient's trigger points which we detect during the examination. There will be 5-7 points in total. The technique used will be triple S (Sucking, Scarification, Sucking) in all sessions.
41012742|NCT02639364|DEVICE|Nellcor Puritan Bennett 840 ventilator system|Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
41331062|NCT00557323|DRUG|Lanthanum carbonate|
41331063|NCT04113512|OTHER|Jalaneti|Sterilised and lukewarm isotonic salt water using neti pot was poured into one nostril, so that it leaves through the other. The procedure is then repeated on the other side, and the nose is dried by bending forward and by rapid yoga breathing
41331064|NCT04179019|DRUG|Amlodipine|Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks
41331065|NCT04787926|DEVICE|Locking Solution|The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.
41331066|NCT00291499|DRUG|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
41331067|NCT00291499|OTHER|Placebo|800 mg placebo/day for 6 months
41482235|NCT05852808|DRUG|Intra-articular steroid injections|"The patient will be placed in prone position and the facet joints will be imaged by pa-radiation path with attention to radiation protection. 20 mg Kenacort + 1 ml Bupivacain (2.5 mg/ml) will be injected into the affected facet joints. The patient is monitored after the intervention for another 30 minutes before leaving the hospital. In order to track the pain level, the patient will be instructed to keep a pain diary. The patient will be contacted via telephone 72h after the intervention and asked about the pain level.~The intervention is finished after one consultation."
40813241|NCT00483366|GENETIC|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
40813242|NCT00140283|PROCEDURE|Educational interactive intervention|
40813243|NCT03241940|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22-CAR T cells IV
40813244|NCT03241940|DRUG|Cyclophosphamide|Given IV
40813245|NCT03241940|DRUG|Fludarabine Phosphate|Given IV
40813246|NCT03241940|OTHER|Laboratory Biomarker Analysis|Correlative studies
41155849|NCT03740932|DIAGNOSTIC_TEST|Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
41331068|NCT03185312|DIAGNOSTIC_TEST|skin biopsy|"Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression."
40813247|NCT03241940|OTHER|Questionnaire Administration|Ancillary studies
40813248|NCT03887455|DRUG|Lecanemab|10 milligram per kilogram (mg/kg) biweekly (once every 2 weeks) administered as i.v. infusion.
40813249|NCT03887455|DRUG|Placebo|Biweekly (once every 2 weeks) administered as i.v. infusion.
40813250|NCT03887455|DRUG|Lecanemab|720 milligram (mg) weekly administered as subcutaneous injection.
40813251|NCT03887455|DRUG|Lecanemab|360 mg weekly administered as subcutaneous injection.
40813252|NCT02214888|DRUG|BIRB 796 BS, low dose|
40813253|NCT02214888|DRUG|BIRB 796 BS, high dose|
40813254|NCT02214888|DRUG|Placebo|
40813255|NCT04981639|PROCEDURE|IVPCA|Intravenous patient controlled analgesia will be performed.
40813256|NCT04981639|PROCEDURE|TAP|Transversus abdominis plane block will be performed.
40813257|NCT04981639|PROCEDURE|IMS|Intramuscular electrical stimulation will be performed.
40813258|NCT02550288|DRUG|Ezetimibe 10 mg|
40813259|NCT02550288|DRUG|Atorvastatin 10 mg|
40813260|NCT02550288|DRUG|Placebo for Ezetimibe 10 mg tablet|
40813261|NCT02550288|DRUG|Placebo for Atorvastatin 10 mg capsule|
40813262|NCT02550288|BEHAVIORAL|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
40813263|NCT02766439|DRUG|etanercept|25-mg etanercept injection subcutaneously twice a week
40813264|NCT06263907|PROCEDURE|Stellate gangalion block|The efficacy of Preoperative ipsilateral stellate gangalion block on the occurrence of postmastectomy depression and pain compared with no block
41331069|NCT03347240|PROCEDURE|Brain Lesioning|Stereotactic radiofrequency lesioning of the pallidum or thalamus
41331070|NCT03347240|PROCEDURE|Combined anterior and posterior lumbosacral rhizotomy|Combined anterior and posterior lumbosacral rhizotomy
41331071|NCT03347240|DEVICE|Deep brain stimulation|Bilateral DBS
41331072|NCT03347240|DEVICE|Intra-thecal baclofen infusion|Intra-thecal Baclofen infusion
40813265|NCT03016624|DEVICE|OCT guided PCI|oct guided
40813266|NCT03016624|DEVICE|Angiography guided PCI|angio guided
41331073|NCT05806112|BEHAVIORAL|Resiliency Training|"The Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) has been shown to be effective in improving resilience and reducing distress among individuals across different populations and settings. The SMART-3RP enhances resilience by 1) teaching tools to elicit the relaxation response (RR) to offset negative effects of chronic stress; 2) improving stress management and awareness; and 3) promoting growth enhancement and agency to effect positive change. It blends stress coping principles from mind-body, cognitive-behavioral, and positive psychology theory to teach skills to advance each of these resiliency processes. The training will be delivered in six 50-minute virtual group sessions with 2 optional booster sessions available for those who desire additional sessions to further consolidate the core resiliency skills."
40813267|NCT03263910|DRUG|NPO-11|20 ml NPO-11
40813268|NCT03263910|DRUG|Placebo|20 ml NPO-11(Placebo)
40813269|NCT00883545|OTHER|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
40813270|NCT00883545|OTHER|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
40813271|NCT00290771|DRUG|Imatinib tablets|Imatinib was supplied as 100 and 400 mg tablets by Novartis.
40813272|NCT00290771|DRUG|Hydroxyurea capsules|Hydroxyurea was supplied locally as 500 mg capsules.
40813273|NCT04887610|PROCEDURE|Ischemic preconditioning|Four 5-minute cycles of 200 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
41482236|NCT05852808|RADIATION|Low-dose radiation therapy|The treatment consists of an informing consultation, a planning CT scan and a series of 10 radiation sessions delivered over 3.5 weeks ( = 12 visits in total). The clinical target volume (CTV) will be defined based on the MRI and SPECT/CT. Planning target volume (PTV) will be expanded in all directions by 0.5 cm beyond the CTV. Patients will be treated in a supine position with minimum 6 MV photons and a 3D-technique or volumetric modulated arc therapy (VMAT)-technique. A kilovolt (kV) and in exception a cone-beam CT will be performed before each treatment for positioning accuracy. A dose of 0.5 Gy x 10 fractions (3 times per week) will be delivered over 3.5 weeks. Each radiotherapy treatment session takes approximately 15 minutes. If a second radiotherapy series will be done (NRS 4-10 at visit 4), the radiotherapy dose und fractionation will be the same as the first series.
41482237|NCT03248453|OTHER|CoPS|The COPS is an automated and objective computer-based program which generate a score/number after the colonoscope has reached the cecum. The participants are able to compare the score with experts.
41012743|NCT05015491|BEHAVIORAL|Noom Healthy Weight Program|"The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Users are encouraged to log their weight (Weight Logging) at least 1x/week and log their food and beverages (Food Logging) daily. Exercise logging (steps via automatic collection or manually added) is done daily. The Noom Food color grading system is founded on calorie-density (Volumetrics diet, Barbara Rolls) and is a simple and effective method for creating long lasting changes in diet and food choice. Coaches are contacted via In-app messaging or phone communication."
41012744|NCT00228527|DRUG|Esomeprazole (Nexium)|
40813274|NCT04887610|PROCEDURE|Ischemic preconditioning control|Four 5-minute cycles of 20 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
40813275|NCT04887610|DIETARY_SUPPLEMENT|Low fat meal|Meal containing 1006 calories, 1 g fat, 0.2 g saturated fat, 0 g trans fat, 20 mg cholesterol, 191 g carbohydrates, 60 g protein, 1560 mg sodium
40813276|NCT04887610|DIETARY_SUPPLEMENT|High fat meal|Meal containing 1030 calories, 62 g fat, 23 g saturated fat, 0.5 g trans fat, 445 mg cholesterol, 76 g carbohydrates, 41 g protein, 2080 mg sodium.
40813277|NCT00798460|DRUG|adefovir|adefovir 10mg
40813278|NCT00798460|DRUG|clevudine|clevudine 30mg
40813279|NCT00798460|DRUG|lamivudine|lamivudine 100mg
40813280|NCT02207049|BEHAVIORAL|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
40813281|NCT02207049|BEHAVIORAL|No Snacking|Caloric needs will be provided to preschoolers within three meals
40813282|NCT05974618|DIAGNOSTIC_TEST|Ultrasound|"A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age."
40813283|NCT04362488|PROCEDURE|Preoperative evaluation|"Preoperative evaluation using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
40813284|NCT04362488|PROCEDURE|Postoperative evaluation|"Postoperative evaluation at 4 months of follow up after surgery using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
40813285|NCT02227069|DRUG|M518101|
40813286|NCT02227069|DRUG|M518101 Vehicle|
40813287|NCT02227069|OTHER|sodium lauryl sulfate|
40813288|NCT02227069|OTHER|saline|
40813289|NCT04336046|PROCEDURE|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
41012745|NCT02662387|DEVICE|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
41482238|NCT03776292|OTHER|monitoring|Primary outcome; composite 1ry outcome \[1-Dynamic pulmonary compliance monitoring.2- Cardiac Index monitoring\] during and after surgical retractor application compared to the same variables reading prior retractor application and in between both groups. Secondary outcome: Static lung compliance, Cardiac output, Stroke volume SV - stroke volume variability (SVV)-Cardiac performance index, O2 delivery DIO2. Noninvasive Intraoperative hemodynamic (MBP, HR, O2 saturation)\] during and after surgical ring retractor application compared to the same variable reading prior retractor application and in between both groups.
40813290|NCT04336046|PROCEDURE|sham bilateral ultrasounded guided erector spinae block|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
41331074|NCT05806112|BEHAVIORAL|Task Sharing|"Task Sharing is a process involving health care workers in partnership with others in which workers retain many of their primary tasks, but some tasks are completed collaboratively or by other workers or volunteers in a shared effort. Study coaches will work with the group home directors and RCWs to identify shared tasks that may be conducted by peers or resident volunteers by task co-assignment with supervision and support. Task co-assignments will be discussed in routine house meetings occurring on a weekly basis and incorporated into a jointly developed house plan. The house plan will engage staff and residents to identify shared activities to reduce the burden on RCWs through task co-assignment and team-based efforts aimed at tasks that create unnecessary burden and stress for RCWs, yet do not require RCWs to complete them."
41331075|NCT05806112|BEHAVIORAL|Workplace Improvement Learning Collaborative|The Workplace Improvement Learning Collaborative (WILC) consists of identifying major sources of RCW burnout across the system and then instituting an organizational (agency-wide) measure to address the identified sources of burnout by restructuring tasks (e.g., reducing administrative burdens, increasing workflow efficiencies) through a virtual earning collaborative with group home leaders. Learning collaboratives commonly use a structured framework within which teams learn about research and best practices, apply quality-improvement methods, and exchange their experiences in making improvements with the widespread use of such collaboratives. Program Directors will participate in a learning collaborative facilitated by trained and certified study coaches to identify and collaboratively develop and implement effective strategies to address root causes of RCW burnout across group homes and program directors assigned to the WILC intervention.
41331076|NCT04980898|DEVICE|WoundEL medical device|"The WoundEl system is composed by: a class IIa device , a class IIb dressing electrode and a class I disperser electrode.~Applied to the leg ulcer, WoundEL® reproduces the endogenous electrical current to stimulate all the factors contributing to healing. Electrical current is evenly spread over the Dressing Electrode which also maintains a moist wound healing environment."
41331077|NCT04980898|OTHER|Standard cares|Cleaning and monitoring
41331078|NCT01361880|BEHAVIORAL|Reduce Infant Mortality|The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
41482239|NCT04075019|BEHAVIORAL|The Raising Healthy Children intervention, including teacher training, child skill development, and parent training|
41482240|NCT01588236|DRUG|high dose KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
40813291|NCT04336046|DRUG|normal saline|using 1 mg /kg normal saline
40813292|NCT04336046|DRUG|Bupivacaine|bupivacaine
40813293|NCT04254367|BEHAVIORAL|Learn-to-Cope|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
40813294|NCT05230446|DEVICE|PCI with OCT guidance|Procedure will be optimize using pre-and post-stent OCT imaging, to improve the accuracy of stent placement and reduce geographic miss, but also to prevent malapposition of the stent and to discover dissections.
40813295|NCT02814240|OTHER|NMR|
40813296|NCT02814240|BIOLOGICAL|Blood samples|
40813297|NCT02814240|OTHER|fibroscan|
40813298|NCT04639232|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
41155850|NCT03195127|OTHER|multimodal physical therapy|Consist of limb strengthening exercises, endurance training, and balance/coordination drills. These exercises and training maneuvers may involve the use of handheld weights, nautilus weight equipment, elastic exercise bands, stationary exercise machines (recumbent exercise cycles, hand ergometer cycles), or treadmills. If the subject is fit enough, Tai Chi may be added to as a training method to help improve your balance and strength. In addition, the subject will be asked to wear an accelerometer on their wrist
40813299|NCT04639232|DIETARY_SUPPLEMENT|Prob-milk|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
40813300|NCT04639232|DIETARY_SUPPLEMENT|Voluntas-Prob|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
40813301|NCT03824678|DRUG|CC-220|CC-220
40813302|NCT05726981|PROCEDURE|Fine needle aspiration biopsy (FNAB)|"Thyroid FNAB is a minimally invasive procedure performed routinely by an experienced sonographer.~It is a safe and brief procedure, performed with a 27G or 25G (very fine) needle (3 needles, i.e. 1 needle per pass)"
40813303|NCT02479685|PROCEDURE|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
41482241|NCT01588236|DRUG|lower dose KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
41331079|NCT05307341|DRUG|sufentanil|One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
41331080|NCT03242161|DIAGNOSTIC_TEST|LabPatch-alcohol|a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human subjects after they have consumed alcohol
41331081|NCT02548741|DRUG|Metformin Hydrochloride (500-mg capsule)|Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy \& David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
41331082|NCT02548741|DRUG|Calcium carbonate (placebo)|Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
41331083|NCT02548741|OTHER|Glucometer (One Touch glucometer), strips and lancets|Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
41331084|NCT02548741|OTHER|Urine container for 24-hour urine collection|During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
41482242|NCT01588236|DRUG|Placebo|3 capsules of placebo tid (morning, midday, and evening)
41331085|NCT05304572|DIAGNOSTIC_TEST|Multi-Detector CT angiography|Multiphasic CT within 4 weeks interval prior to TACE will be done including non-enhanced, arterial, portal and venous phases using IV bolus injection of a 75-100-mLiodinated contrast material iopamidol at a rate of 3.0 mL/s. The images of arterial phase will be transferred to workstation to produce 3D angiographic reconstruction images .
41482243|NCT05886439|DRUG|LK101 injection (personlized neoantigen pulsed DC vaccine )|LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.
41482244|NCT05886439|DRUG|Pembrolizumab|Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.
41482245|NCT05886439|DRUG|Durvalumab|Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.
41482246|NCT02676362|OTHER|Gingival crevicular fluid collection with filter paper|Gingival Crevicular Fluid Dynamics
41482247|NCT01591889|DRUG|Tinidazole|500 mg tablet
41482248|NCT01591889|DRUG|Tinidazole|500 mg tablet
41482249|NCT00326560|PROCEDURE|Pterygium excision and conjunctival autograft|
41482250|NCT04781036|DRUG|4%Chlorhexidine|4%Chlorhexidine was given to participants with foot odor for 2 weeks
41482251|NCT04645979|OTHER|Online survey|Participants will be invited to complete an online questionnaire about their experience of product use.
41482252|NCT02689063|DRUG|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
41482253|NCT02689063|DRUG|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
41482254|NCT02689063|DRUG|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
41482255|NCT02689063|DRUG|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
41482256|NCT05485519|DRUG|Dexmedetomidine|Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)
41482257|NCT05485519|DRUG|Midazolam|(1 mcg/kg/minute. up to a maximum of 5 mcg/kg/minute.
41482258|NCT05480826|GENETIC|study of the transmission of genetic variants|the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA
40813304|NCT04103151|DEVICE|Single lead ECG|Heart Rate Variability will be monitored using a single lead electrocardiogram
40918276|NCT04572152|BIOLOGICAL|AK104|On the same day subjects will receive AK104 by intravenous administration.
41482259|NCT01685541|OTHER|Maximum After Visit Summary Content|
41482260|NCT01685541|OTHER|Intermediate After Visit Summary Content|
41482261|NCT01685541|OTHER|Minimum After Visit Summary Content|
41482262|NCT01685541|OTHER|Usual AVS|
41482263|NCT00307034|BIOLOGICAL|GSK Biologicals' 10-valent pneumococcal conjugate vaccine.|Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
41482264|NCT00307034|BIOLOGICAL|Infanrix hexa.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
41482265|NCT00307034|BIOLOGICAL|Infanrix-IPV/Hib.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
41482266|NCT00618202|DRUG|Balsalazide|
41482267|NCT01859806|PROCEDURE|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
41482268|NCT01859806|PROCEDURE|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
40813305|NCT01532284|OTHER|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
40813306|NCT01124123|DRUG|Bilastine|20 mg oral tablet
40813307|NCT01124123|DRUG|Bilastine|10 mg endovenous bilastine
40813308|NCT05158335|DRUG|MBX 2109 (Part A)|Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg
40813309|NCT05158335|DRUG|MBX 2109 (Part B)|Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg
40813310|NCT05158335|DRUG|Placebo|Single SC dose or repeated SC doses of placebo.
40813311|NCT01895543|DRUG|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
40813312|NCT03221868|BEHAVIORAL|Exercise group|An exercise-based program following a 12-week periodization using mostly circuit-like activities.
40813313|NCT03221868|BEHAVIORAL|Control group|Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
40813314|NCT06382103|DIAGNOSTIC_TEST|ctDNA monitoring|The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay.
40813315|NCT06382103|DIAGNOSTIC_TEST|Plasma proteomic analysis|plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis
40813316|NCT02745704|DRUG|Peginterferon alfa|peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
40813317|NCT04354077|DEVICE|DBS of the NAc|Deep Brain Stimulation of the Nucleus Accumbens
40813318|NCT03871010|DEVICE|Midline catheter|Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.
40813319|NCT03126058|PROCEDURE|enhanced recovery after surgery|Patients will undergo enhanced recovery after surgery programs.
40813320|NCT02601235|DRUG|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
40813321|NCT02601235|DRUG|Afrin|2 pumps in each nostril every 12 hours.
40813322|NCT02275715|BEHAVIORAL|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
40813323|NCT04313374|DRUG|Morphine PCA 1 mg|PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
41012746|NCT02662387|OTHER|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
41012747|NCT03892720|OTHER|Quality-of-Life Assessment|Ancillary studies
41012748|NCT03892720|OTHER|Questionnaire Administration|Ancillary studies
41012749|NCT03892720|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41482269|NCT05814003|DRUG|hydroxylate flavones solid dispersion application|this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing
40813324|NCT04313374|DRUG|Morphine PCA 0,5 mg|PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
40813325|NCT04313374|DRUG|Placebo|the PCA will contain placebo
40813326|NCT03245268|PROCEDURE|Balloon pulmonary angioplasty|BPA is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
40813327|NCT03582553|DIETARY_SUPPLEMENT|Naringenin|An extract of Citrus Sinensis containing naringenin and its precursor naringin
40813328|NCT03582553|OTHER|Placebo|Cellulose
40813329|NCT02924246|BIOLOGICAL|cholera vaccination|Oral cholera vaccination on day 0 and day 14
40813330|NCT02924246|OTHER|raw milk|raw milk
40813331|NCT02924246|OTHER|pasteurized milk|pasteurized milk
40813332|NCT02924246|OTHER|UHT milk|UHT milk
40813333|NCT03459001|OTHER|Tube Feeding Product|a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
40813334|NCT03927547|DEVICE|Inclined Sleep|Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
40813335|NCT05742516|DIETARY_SUPPLEMENT|Bimuno Daily|Galactooligosaccharide supplement within Bimuno Daily
40813336|NCT05742516|DIETARY_SUPPLEMENT|Placebo|Maltodextrin powder
40813337|NCT02824770|BEHAVIORAL|Dimming of lights and decreasing noise level|The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
40813338|NCT02824770|DRUG|Bupivacaine (Bustesin®) via Pain Buster ® system|Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
40813339|NCT02824770|DRUG|Tramadol HCl (Tramosel®) via PCA system (Gemstar®)|Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
40813340|NCT02824770|PROCEDURE|Major abdominal surgery|Any major abdominal surgery (e.g. colectomy, gastrectomy)
40813341|NCT02789345|DRUG|Ramucirumab|Administered IV
40813342|NCT02789345|DRUG|Necitumumab|Administered IV
40813343|NCT02789345|DRUG|Osimertinib|Administered orally
40813344|NCT01907308|DRUG|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
40813345|NCT01907308|DRUG|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
40813346|NCT05835336|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
41012750|NCT03259711|DRUG|Hormonal therapies L02 in the ATC classification|Hormonal therapies L02 in the ATC classification
41012751|NCT03913078|BEHAVIORAL|Group Fitness|Traditional Group Fitness consisting of aerobic and strength exercises performed in a group setting and led by a trained instructor.
41012752|NCT03913078|BEHAVIORAL|PlayFit|Modified sports fitness exercise program consisting of games played in groups and led by a trained instructor.
41012753|NCT00002275|DRUG|Fat Emulsion 2%|
41012754|NCT00002275|DRUG|Fat Emulsion 20%|
41012755|NCT02993601|DEVICE|Heartfelt-1|The patients will stand in front of the Heartfelt-1 in order for images to be captured and the volume of their lower legs measured.
41012756|NCT02993601|DEVICE|Weighing scales|The patient will be asked to stand on standard medical weighing scales, to measure their weight.
41012757|NCT02993601|OTHER|Medical grading of oedema|A member of the research team will assess the severity of the peripheral oedema on a scale of 1-5.
41012758|NCT02993601|OTHER|Baseline assessements|At the point study participants are recruited, their age, sex, diagnosis, aetiology of heart failure, LVEF (Left ventricular ejection fraction), medical and device therapy, time since diagnosis, BNP (B-type Natriuretic Peptide), CRP (C-Reactive Protein), renal function (EGFR), Haemoglobin, albumin and urinalysis will be assessed unless recent (less that 6 months old) results are available. The number of Heart failure hospital admissions in the last 2 years, LACE score, co-morbidities will also be noted.
40813347|NCT05329480|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.
41012759|NCT02993601|DEVICE|Water displacement method|This will involve filling a gauge with lukewarm water (27-35oC +-2oC) up to the appropriate level. The appropriate level is determined by the water stabilising after some has flown out of the gauge into the waste bucket. Once the water level is stable the patient, who is sitting on a chair will be gently plunging the foot (naked) in the gauge until their foot is flat on the bottom on the gauge. The water flowing out of the gauge into the measuring bucket will be collected until the flow of water stops. Four small marks with non-toxic /non-permanent pen will be made on the lower leg of the patient to indicate where the water level was at. The water which has been collected in the measuring bucket will be weighted with precision scales to determine the volume of water displaced by the insertion of the foot. The patient's foot will then be dried.
40813348|NCT05329480|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin powder, 4 separate 5g doses per day for 7 days.
40813349|NCT00441142|DRUG|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
40813350|NCT00441142|DRUG|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
40813351|NCT00441142|RADIATION|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
40813352|NCT04281537|DRUG|Agalsidase Beta|Enzyme Replacement Therapy - Infusion every other week
40813353|NCT04281537|DRUG|Agalsidase Alpha|Enzyme Replacement Therapy - Infusion every other week
40813354|NCT03013101|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
40813355|NCT03888170|OTHER|No intervention|No intervention
41012760|NCT02993601|DEVICE|Callipers measurements|This will involve making 4 marks on one of the foot/lower leg (small cross) using non-toxic / non- permanent pen. The measurement will consist of making 6 measurements between those marks using callipers, and reporting the distance on a calibrated tape.
41012761|NCT02993601|DEVICE|Measuring tape|The measurements taken using a medical tape measure will involve the circumference of the ankle to be measured as well as the circumference at the level of the arch of the foot. The medical tape used will be a CE marked disposable medical measuring tape to minimise the risk of infection. The measurements will be done on both feet.
41012762|NCT01479634|DRUG|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
41012763|NCT01479634|DRUG|Study-Provided ART|"Study provided drugs:~1. Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]) PLUS~2. Efavirenz \[EFV\]"
41012764|NCT00965068|OTHER|Cholesterol|
41012765|NCT04766749|OTHER|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
41012766|NCT05294263|DRUG|Varenicline|Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype
40813356|NCT03968575|DEVICE|laser treatment|sub-threshold micro-pulse laser treatment
40813357|NCT00851981|OTHER|Placebo|TID
40813358|NCT00851981|DIETARY_SUPPLEMENT|SAMe|300 mg TID
40813359|NCT03973554|OTHER|pearl powder|natural product, support bone and joint health
40813360|NCT03973554|DRUG|CPP-ACP|Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
41012767|NCT05294263|DRUG|Placebo|Matching, inactive medication
40813361|NCT03428477|DRUG|Icosapent Ethyl|Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
41482270|NCT05814003|OTHER|Placebo|Dough inert material without any therapeutic action
40813362|NCT03428477|OTHER|Placebo|"Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day"
40813363|NCT00302172|DRUG|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
40813364|NCT01437579|PROCEDURE|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
40813365|NCT01437579|PROCEDURE|cystoscopy|cystoscopy under general anesthesia
40813366|NCT05850910|OTHER|Supine practice group|The practitioner's arm was placed in the mid-thoracic region from the opposite side of the individual's torso in the form of a half fist. In this position, the SPs coincide with the space in the middle of the half fist, while the TPs coincide with the fingertips and the thenar region. With the practitioner's other hand supporting the patient's elbows, a high-speed-low-amplitude thrust is applied from front to back.
40813367|NCT05850910|OTHER|Prone application group|the practitioner positions the hypothenar part of his hands above the TPs in the mid-thoracic segment. From this point, a high-velocity-low-amplitude thrust is applied from the back to the front.
40813368|NCT03397745|DEVICE|BIS|All patients applied BIS on both side (Left and Right)
40813369|NCT01891617|OTHER|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
40813370|NCT01656005|DRUG|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
40813371|NCT01656005|DRUG|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
40813372|NCT01656005|DRUG|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
41012768|NCT04454385|DIAGNOSTIC_TEST|Patients with well controlled asthma|"Patients with well controlled asthma~The following parameters are to be evaluated:~Blood eosinophils FeNO Findings on lung function test"
41331086|NCT05304572|PROCEDURE|Trans-arterial chemoembolization and DSA|Percutaneous arterial access is achieved through the common femoral artery (19 G needle) under local anesthesia with placement of a 5-Fr sheath. A 5-Fr Cobra (C2) or sidewinder (SIM1) catheter was used for catheterizing the coeliac trunk and SMA. Then celiac and superior mesenteric angiography was done by injecting 24 mL of iopamidol using forced manual injection method or using a pump at a rate of 6 mL/s according to the operator preferences.Then a microcatheter was used for selective and super-selective access of the hepatic arteries. The micro-catheter was placed in the feeding artery as close as possible to the tumor.The chemotherapeutic drugs (Doxorubicin 50 mg) solved within 5 ml of iodinated non-ionic contrast media and then mixed with 10 ml of iodized oil (lipiodol) will be delivered through the feeding hepatic artery and then embolized using Poly-vinyl Alcohol (PVA) particles.
41331087|NCT04521309|BIOLOGICAL|SARS-CoV-2 antibody based IVIG therapy|"Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics"
41482271|NCT02192008|BIOLOGICAL|Salmonella Typhi|
40813373|NCT01656005|DRUG|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
40813374|NCT01656005|DRUG|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
40813375|NCT03895580|OTHER|In-store POP education|Six in-store nutrition counseling sessions with a registered dietitian nutritionist.
40813376|NCT03895580|OTHER|Online POP education|Education on the use of an online grocery shopping, an online recipe tool, a grocery pickup service, a home grocery delivery service, and a phone application that promotes healthy food selection.
40813377|NCT04786704|DIAGNOSTIC_TEST|Stool-based SDC2 DNA methylation test|A diagnostic device measuring syndecan 2(SDC2) methylation status in stool DNA to detect colorectal cancer
41012769|NCT03431194|DRUG|midodrine|oral midodrine tablets 5 mg
41012770|NCT03431194|DRUG|Placebo|
41155851|NCT03106337|DEVICE|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
41155852|NCT04454489|DRUG|Pembrolizumab (immunotherapy)|Pembrolizumab 200 mg will be given every 3 weeks to tumor progression or treatment tolerance.
40813378|NCT04786704|DIAGNOSTIC_TEST|quantitative Fecal immunochemical test|A diagnostic device using immunoturbidimetric methods to measure fecal hemoglobin concentration
41331088|NCT03292341|OTHER|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs
41331089|NCT03292341|OTHER|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
41331090|NCT03292341|OTHER|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
41331091|NCT03292341|OTHER|Interviews with stakeholders|Interviews with stakeholders Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
41331092|NCT04884945|PROCEDURE|Open Pyeloplasty (OP)|Open approach for the surgical correction of UPJ obstruction
41331093|NCT04884945|DEVICE|Robotic-Assisted Laparoscopic Pyeloplasty (RALP)|Robotic approach with the da Vinci Surgical System for the surgical correction of UPJ obstruction
40813379|NCT01190475|DRUG|Active treatment with a high dose of BGS649|
40813380|NCT01190475|DRUG|Active treatment with a low dose of BGS649|
40813381|NCT01190475|DRUG|Placebo treatment to blind study|
40813382|NCT06172127|DRUG|Trastuzumab deruxtecan|10 mL type 1 amber borosilicate glass vial sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/aluminium yellow flip-off crimp cap. One vial of powder for concentrate for solution for IV infusion contains 100 mg of T-DXd. The drug product also contains L-histidine, L-histidine hydrochloride monohydrate, Sucrose, and Polysorbate 80.
40813383|NCT06172127|DRUG|Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection|20 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.
40813384|NCT06172127|DRUG|Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection|15 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 10 mL solution of 600 mg of pertuzumab and 600 mg of trastuzumab.
41482272|NCT02192008|BIOLOGICAL|Salmonella Paratyphi|
41482273|NCT03982576|OTHER|Nicotine replacement therapy (NRT)|4 weeks of Transdermal nicotine patches or nicotine gum
40813385|NCT02483923|DRUG|Ultrasound guided serratus anterior block with ropivacaine|After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
40813386|NCT02483923|DRUG|intravenous PCA only|same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
40813387|NCT02603458|DRUG|NRX-1074|Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
40813388|NCT02603458|DRUG|Placebo|Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
40813389|NCT00002858|DRUG|cisplatin|
40813390|NCT00002858|DRUG|cyclophosphamide|
40813391|NCT00002858|DRUG|doxorubicin hydrochloride|
40813392|NCT00002858|DRUG|etoposide|
40813393|NCT00002858|RADIATION|radiation therapy|
40813394|NCT02818023|DRUG|Pembrolizumab|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
40813395|NCT02818023|DRUG|Vemurafenib|"Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
40813396|NCT02818023|DRUG|Cobimetinib|Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.
40813397|NCT03928418|BEHAVIORAL|In-person counseling session|Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.
40813398|NCT03928418|BEHAVIORAL|Live phone call booster session|Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.
41331094|NCT01592006|DRUG|Peginterferon alfa-2a|Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
41331095|NCT01592006|DRUG|Ribavirin|Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
41331096|NCT01592006|DRUG|telaprevir|Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
41482274|NCT03982576|BEHAVIORAL|CS-CBT intervention|4 group sessions of a novel culturally specific, CBT-based intervention over 2 weeks
40813399|NCT03928418|BEHAVIORAL|Technology (IVR or SMS) booster session|Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
40813400|NCT01700998|DRUG|Magnesium|
40813401|NCT01700998|DRUG|Placebo|
40813402|NCT04961528|DRUG|Tranexamic Acid 500 MG|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days"
40813403|NCT04961528|DRUG|Terlipressin|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days"
40813404|NCT04961528|DRUG|Placebo|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days."
40813405|NCT03977025|DIAGNOSTIC_TEST|Lumbar punction|Patients will be evaluated prior to surgery with the Montreal Cognitive Assessment (MoCA) to determine the presence of cognitive impairment, and CSF samples, obtained by lumbar punction, will be analyzed by immunodetection of Aβ40, Aβ42, tau and ptau with multiplex technology
40813406|NCT01263418|DRUG|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
40813407|NCT01190761|DRUG|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions
40813408|NCT01190761|DRUG|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
40813409|NCT03379857|OTHER|Drug urinal test|Non Applicable
40813410|NCT05489354|OTHER|mHealth psychoeducational intervention|The mPEI program will be delivered through a mobile application (app). The app has five components which include: Breast cancer education, coping skills training, discussion forum, nurse-led consultation, and psychological support. Breast cancer education and coping skills training will be conducted by the principal investigator for 30 minutes per week for six weeks and will be delivered via text, audio and video on the mobile app. Group discussion will be moderated by the principal investigator in a text format for 30 minutes per week. Nurse-led consultation and psychological support will be provided by the oncology nurse on the research team through a 15-20-minute call in the first week, third week and fifth week.
40813411|NCT01283776|DRUG|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
40813412|NCT05208515|OTHER|independent obsteric operating center|send emergency cesarean section needing women from labor room to independent obstetric operating center
40813413|NCT05208515|OTHER|general operating center|send emergency cesarean section needing women from labor room to general operating center
40813414|NCT04660851|BEHAVIORAL|Coached|10-weeks of diet coaching weekly by telephone to improve dietary protein intake
40813415|NCT00239993|DRUG|glatiramer acetate|
40813416|NCT00239993|PROCEDURE|Warm compress prior to injection of glatiramer acetate|
40813417|NCT05099354|DIAGNOSTIC_TEST|autonomic nervous system testing|"* Autonomic tests, including heart rate variability (HRV) and baroreceptor sensitivity (BRS), are performed with a 10min ECG with non-invasive or invasive blood pressor measuring during rest. During the time at the stroke unit, this data will be calculated using the existing continuous monitoring.~* Valsalva maneuver during continuous ECG and blood pressure monitoring. The patient will be instructed to exhale against a mouthpiece with a defined resistance for 15 seconds.~* Assessment of the cerebrovascular reserve capacity will be done with continuous transcranial duplex sonography (TCD) and breath holding index (BHI). The patient will be instructed to hold his breath for 30 seconds, 4 times in a row with intervals of 4 minutes. This test will be performed only in responsive and compliant patients."
40813418|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
40813419|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
40813420|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
40813421|NCT01205932|DRUG|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
40813422|NCT00218634|BEHAVIORAL|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
40813423|NCT00218634|BEHAVIORAL|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
40813424|NCT06185907|OTHER|Surgery|We referr to resection as that performed in our hospital, and history of major abdominal surgery as interventional surgical procedures in the abdomen with therapeutic intent (e.g., resection) prior to the first hospitalization in our hospital.
40813425|NCT00950391|DRUG|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
40813426|NCT01651065|BEHAVIORAL|Microclinic Diabetes Education Program|"The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.~The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors."
40813427|NCT01651065|BEHAVIORAL|Control|
40813428|NCT00726791|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
40813429|NCT03325868|DRUG|Ulipristal Acetate|Ulipristal 5mg daily by mouth for 12 weeks
40813430|NCT01353443|PROCEDURE|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
40813431|NCT02628431|DEVICE|Elfi tech monitor|
40813432|NCT01639339|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
40813433|NCT01639339|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
40813434|NCT01639339|DRUG|Standard therapy|"The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
40813435|NCT00025207|DRUG|gefitinib|Given orally
40813436|NCT00025207|OTHER|laboratory biomarker analysis|Correlative studies
40813437|NCT03181061|OTHER|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
40813438|NCT05658848|OTHER|Collaborative infertility counseling|Collaborative infertility counseling for coping stratigies and marital satisfaction
40813439|NCT00610350|DRUG|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
41331097|NCT06162871|BEHAVIORAL|Presentations and interactive debate sessions, with intergenerational exchange|Intervention will consist of 12 sessions, each lasting about two hours, conducted on a weekly basis and delivered both in-person and remotely. The sessions will include presentations and interactive debate sessions, with a central focus on intergenerational exchange covering cultural, historical, and health-related topics. A key aspect is the active involvement of beneficiaries, individuals over sixty-five, who will be asked to prepare presentations with the support of project-provided facilitators. Simultaneously, the project will promote and enhance skills, organizational capabilities, and computer literacy.
41331098|NCT00004041|BIOLOGICAL|Ad5CMV-p53 gene|
41331099|NCT00004041|PROCEDURE|conventional surgery|
41331100|NCT00966069|OTHER|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
40813440|NCT00610350|DRUG|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
40813441|NCT06307522|DRUG|MRG-001|Patients will receive subcutaneous administration of MRG-001 at designated visits.
40813442|NCT03516773|DRUG|EB612 (EBP05)|Entera Bio's proprietary drug for the administration of PTH(1-34) orally
40813443|NCT03516773|DRUG|NATPARA/NATPAR|A PTH replacement (PTH \[1-84\]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
40813444|NCT04715204|OTHER|High Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. Formula with caloric density of \>1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.
40813445|NCT04715204|OTHER|Standard Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.
40813446|NCT04715204|OTHER|Formula-75/Formula-100|"Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml"
40813447|NCT00813865|DRUG|afegostat tartrate|
40813448|NCT06345950|DIETARY_SUPPLEMENT|Liposomal Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
40813449|NCT06345950|DIETARY_SUPPLEMENT|Standard Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
41331101|NCT00966069|OTHER|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
41482275|NCT03982576|BEHAVIORAL|Path2Quit|Path2Quit is a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP).
41482276|NCT03982576|BEHAVIORAL|Relapse prevention program|4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov
41482277|NCT03982576|BEHAVIORAL|SmokefreeTXT|NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7
41482278|NCT03168321|DRUG|IDP-123 Lotion|Tazarotene 0.045% Lotion
40813450|NCT06345950|DIETARY_SUPPLEMENT|New Micellar Glutathione (Lipomicel)|A maximum single dose of 600 mg glutathione (soft gel capsules)
40813451|NCT00446823|DEVICE|XCell cellulose wound dressing|
40813452|NCT00446823|DEVICE|Impregnated gauze dressing|
40813453|NCT00855933|DEVICE|Experimental Floss|Experimental Glide® floss with cetylpyridinium chloride (\~13% dry weight CPC)
40813454|NCT05053815|OTHER|Pharmacogenomic Testing|Pharmacogenomic testing is done via buccal swab. As this study is retrospective, data from PGx testing has already been collected as a part of routine care.
40813455|NCT06357091|PROCEDURE|ACL reconstruction with Shark Screw ACL®|ACL reconstruction with the Shark Screw ACL®, Investigation of tunnel widening
40813456|NCT06357091|PROCEDURE|ACL reconstruction with biocomposite screw (Mecta)|ACL reconstruction with biocomposite screw (Mecta), Investigation of tunnel widening
40813457|NCT06423495|DEVICE|low-intensity laser treatment|The experimental group will be subjected to a total of up to 24 sessions (2x a week for up to 12 weeks) of irradiation with red and infrared laser pulsed radiation, with 820mm wavelength, 60w power and 6 energy cages, applied in both nostrils and in 10 points under the tongue.
40813458|NCT01889264|OTHER|Observational|Observational, Translational non-treatment study
40813459|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
41017882|NCT03362840|BEHAVIORAL|Early Start Denver Model|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition. The objectives are monitored for progress during each session The sessions are conducted according to ESDM principles, and include weekly parent-coaching session, in which parents observe the therapist interact with the child while applying various teaching techniques, and then implement these techniques during the interaction with their child. Additionally, parents get acquainted with the daily objective sheet and are encouraged to work on these objectives at home as well. Finally, in this model, therapist adherence to the ESDM practices are monitored according to the ESDM fidelity rating system
40813460|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
40813461|NCT03927235|PROCEDURE|Transbronchial Cryobiopsy|Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
40813462|NCT03752346|OTHER|exercise group|"A step aerobics exercise lasted a total 30 minutes, including:~1. a warm-up with 10 minutes of stretching exercises.~2. A step aerobics exercise (step aerobics for 30 minutes; step by step, step exercise, or stepping the ground repetitively)23,24 a total of 30 minutes then cool down (5 minutes).~3. Resistance training (10 minutes), stretching and relaxation for 10-15 minutes."
40813463|NCT04181593|DRUG|Omega 3 fatty acid|Omega 3 fatty acid Softgels
40813464|NCT04181593|DRUG|Placebos|Mineral oil Softgels
40813465|NCT00920218|BIOLOGICAL|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
40813466|NCT00920218|BIOLOGICAL|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
40813467|NCT01858805|PROCEDURE|esophagectomy|
40813468|NCT01828606|DEVICE|coban 2 system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
40813469|NCT01828606|DEVICE|coban lite system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
40813470|NCT06339242|DRUG|Furmonertinib|After completion of all screening activities, eligible patients were confirmed to enter the study. All patients will receive study treatment, Furmonertinib tablets 160mg, oral, once daily, lateral ventricular chemotherapy with Ommaya capsule technique until disease progression, intolerable toxicity, death, withdrawal of informed consent.
40813471|NCT04534179|PROCEDURE|Vacuum myofascial therapy and physical activity program.|"This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program"
40813472|NCT04534179|OTHER|Physical activity program.|Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
40813473|NCT01258465|BEHAVIORAL|Pivotal Response Training|Naturalistic behavioral protocol designed to teach vocal communication.
40813474|NCT01258465|BEHAVIORAL|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
40813475|NCT05292924|PROCEDURE|Early SCC|Direct, immediate and uninterrupted contact of the infant with its mother's skin first 30 minutes delivery
40813476|NCT03368053|PROCEDURE|Blood sampling|Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
40813477|NCT01818739|PROCEDURE|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
40813478|NCT01818739|DRUG|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
40813479|NCT01818739|DRUG|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
40813480|NCT01818739|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
40813481|NCT01980836|BIOLOGICAL|Seasonal influenza vaccine|
41012771|NCT05294107|PROCEDURE|additional biopsies|"After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing."
41012772|NCT00295672|DRUG|Vinorelbine|
41012773|NCT00265616|DRUG|propofol|liquid, mg/kg.h, titrated after EEG
41331102|NCT05224440|BEHAVIORAL|TSMV Sponsorship Initiative|Consistent with preventive, universal and public health approaches to suicide, the VA's TSMV Sponsorship Initiative establishes public-private partnerships with federal and community organizations to provide TSMVs with one-on-one, certified and volunteer sponsors in their post-military hometowns. Sponsors are assigned approximately six months prior to discharge and help TSMVs to accomplish reintegration tasks pre-and post-discharge. After certification, sponsors are assigned to and managed by a community integration coordinator (CIC), which is a local organization. CICs recruit sponsors, manage sponsors and match sponsors with TSMVs moving to the local region. After being matched with a TSMV, sponsors then integrate their skills during regular contact with matched TSMVs and monthly video or in-person sessions and help TSMVs identify SMART goals and develop reintegration action plans and ensure TSMVs attend VA healthcare appointments.
41331103|NCT02097485|DRUG|Abametapir Lotion 0.74% w/w|200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
41482279|NCT03168321|DRUG|IDP-123 Vehicle Lotion|Vehicle Lotion
41012774|NCT00265616|DRUG|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
40813482|NCT05215808|DRUG|RBN-3143|Oral Administration of tablets
40813483|NCT01749657|DEVICE|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
40813484|NCT02142322|DRUG|MODIFIED FOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
40813485|NCT04812119|DIAGNOSTIC_TEST|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F; Robins, Fein, \& Barton, 2009) is a 2-stage parent-report screening tool to assess risk for Autism Spectrum Disorder (ASD). It is valid for children 16-30 months old.
40813486|NCT04812119|DIAGNOSTIC_TEST|The Autism Spectrum Quotient-Children's Version (AQ-Child)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 4-11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
40813487|NCT04812119|DIAGNOSTIC_TEST|The Autism-Spectrum Quotient (AQ)-Adolescent Version (AQ-Adolescent)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 12-15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
40813488|NCT04812119|DIAGNOSTIC_TEST|The Viking's Speech Scale|The Viking Speech Scale (Pennington, Virella, Mjøen, da Graça Andrada, Murray, Colver, ... \& Andersen, 2013) is used to classify children's speech production, specifically the ease at which children can make themselves understood using different methods of communication. The scale has four levels and is ordinal. The four levels include: (1) speech is not affected by motor disorder (2) speech is imprecise but usually understandable to unfamiliar listeners (3) speech is unclear and not usually understandable to unfamiliar listeners out of context (3) no understandable speech. It is intended for children above the age of 4 years.
40813489|NCT04812119|DIAGNOSTIC_TEST|The Functional Communication Classification System (FCCS)|The Functional Communication Classification System (Barty, Caynes \& Johnston, 2016) was designed to classify how children with cerebral palsy communicate on a daily basis. The tool focuses on how children typically communicate with familiar and unfamiliar communication partners. There are five classifications a child can be categorized in: (1) effective communicator in most situations (2) effective communicator in most situations, but does need some help (3) an effective communicator in most situations and can communicate small ranges of messages and topics to most familiar people (4) assistance is required in most situations, especially with unfamiliar people and environments. Communicates daily needs and wants to familiar people (5) communicates using undirected movement, vocalisation and/or behaviour, for interpretation by familiar people. The FCCS is valid for use in children up to 13 years.
40813490|NCT04812119|DIAGNOSTIC_TEST|Brief Infant Sleeping Questionnaire (BISQ)|The Brief Infant Sleep Questionnaire (BISQ; Sadeh, 2004) is used to assess sleep patterns, parent perception, and sleep-related behaviors in young children (0-36 months). The BISQ has been validated against actigraphy, daily logs, and has high sensitivity in documenting expected developmental trends in sleep.
41012775|NCT00571259|DRUG|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
41012776|NCT00571259|DRUG|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
41012777|NCT04952766|BIOLOGICAL|Biological samples|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to vaccination~* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
41012778|NCT06202638|DEVICE|HemoSphere monitor with Acumen Hypotension Prediction Index Software|Two concomitant courses of intraoperative data will be recorded: 1. the arterial waveform and pressure on the standard hemodynamic patient monitor and 2. the data from the HemoSphere monitor with Acumen Hypotension Prediction Index Software
41331104|NCT02097485|DRUG|Vehicle Lotion|control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
41331105|NCT03836352|OTHER|DPX-Survivac|SubQ injection (q9w)
41331106|NCT03836352|DRUG|Cyclophosphamide|PO (BID)
41331107|NCT03836352|DRUG|Pembrolizumab|IV Infusion (q3w)
41331108|NCT04636320|DEVICE|Contrast-enhanced CMR|Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.
41331109|NCT04636320|DIAGNOSTIC_TEST|Exercise test ECG|"A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls."
41331110|NCT04636320|BIOLOGICAL|Blood sample|"A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers."
41331111|NCT04636320|DIAGNOSTIC_TEST|Resting 12 lead ECG|A resting 12 lead ECG will be performed at Day 0 visit.
41331112|NCT04636320|DIAGNOSTIC_TEST|24 hour Holter ECG|A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
41331113|NCT01100645|DRUG|Sominex|Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
41331114|NCT01100645|DRUG|Placebo|Excipient
40813491|NCT04812119|DIAGNOSTIC_TEST|Pediatric Sleep Questionnaire (PSQ)|Pediatric Sleep Questionnaire (PSQ; Chervin, Hedger, Dillon, Pituch, 2000) has been designed to screen for sleep problems in children. The scale consists of 22 parent-reported items examining snoring and breathing problems, daytime sleepiness, inattention, hyperactivity, and other signs and symptoms of apnea including obesity and nocturnal enuresis. Those questions specifically relate to sleep-disordered breathing (SDB) in children. PSQ has been validated for children 2-18 years old.
40813492|NCT04812119|DIAGNOSTIC_TEST|The Eating and Drinking Ability Classification System (EDACS)|The Eating and Drinking Ability Classification System (EDACS; Sellers, Mandy, Pennington, Hankins, Morris, 2013) has been developed for people with cerebral palsy to describe five distinct levels of ability using the key features of safety and efficiency. The patient can be categorized in: (1) eats and drinks safely and efficiently, (2) eats and drinks safely but with some limitations to efficiency, (3) eats and drinks with some limitations to safety; maybe limitations to efficiency, (4) eats and drinks with significant limitations to safety or (5) unable to eat or drink safely - tube feeding may be considered to provide nutrition. The EDACS is valid for use in children above the age of 36 months.
40813493|NCT04812119|DIAGNOSTIC_TEST|Mini Manual Ability Classification System (Mini-MACS)|The Mini Manual Ability Classification System (Mini-MACS; Eliasson, Krumlinde-Sundholm, 2013) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 1-4 years of age.
40813494|NCT04812119|DIAGNOSTIC_TEST|Manual Ability Classification System (MACS)|The Manual Ability Classification System (MACS; Eliasson, Krumlinde Sundholm, Rösblad, Beckung, Arner, Öhrvall, Rosenbaum, 2006) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 4-18 years.
40813495|NCT04812119|DIAGNOSTIC_TEST|The Gross Motor Function Classification System - Expanded and Revised (GMFCS - E&R)|The Gross Motor Function Classification System - Expanded \& Revised (GMFCS - E\&R; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to \< 4 years, 4 to \< 6 years, 6 to \< 12 years, and 12 to 18 years.
40813496|NCT04812119|DIAGNOSTIC_TEST|The Visual Function Classification System (VFCS)|The Visual Function Classification System (Baranello et al, 2019) is a valid and reliable 5-level classification system of visual functioning for children with Cerebral Palsy. It describes the use of visual abilities in daily life, focusing on activity and participation.
40813497|NCT04812119|DIAGNOSTIC_TEST|The Early Childhood Oral Health Impact Scale (ECOHIS)|The ECOHIS measures the impact of oral problems and/or experience of dental treatment on the quality of life in children under 5 years old and their parents or other family members. It has 13 questions divided into two domains: one related to impact on the child (9 questions), and another to impact on the family (4 questions), measured using the Likert scale. In children with cerebral palsy and/or the ECOHIS has been validated for ages up to 6,5 years, in children with intellectual disability for ages up to 5 years and in children with special need for ages up to 9 years.
40813498|NCT04812119|DIAGNOSTIC_TEST|The Family Impact Scale (FIS)|The FIS evaluates the impact of a child's oral condition on family life. It consists of 14 items divided into three subscales: parental/family activity (PA), parental emotions (PE), and family conflict (FC). The financial burden subscale (FB) is the only one that is evaluated separately, since it comprises a single item and addresses economic rather than psychosocial or behavioural impact. It has been validated for children above the age of 12 years.
41331115|NCT03874416|OTHER|Specific rehabilitation|"Experimental rehabilitation of working memory:~3 sessions per week during 3 months, for a total 36 sessions."
40918277|NCT01452100|DRUG|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
40918278|NCT01452100|OTHER|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
40918279|NCT04704947|DRUG|nonselective beta blocker|nonselective beta blocker
41012779|NCT02851108|DRUG|Methylene Blue|50 patients will receive methylene blue
41012780|NCT02851108|DRUG|Primaquine|50 patients will receive primaquine
41012781|NCT01584947|DRUG|Bupivacaine|Bupivacaine lozenge taken 3 times a day for two weeks
41012782|NCT01584947|DRUG|Placebo|Placebo lozenge taken three times a day for two weeks
41012783|NCT02842268|DRUG|BAY987517|Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
41012784|NCT02364310|DEVICE|Baroreceptor stimulation with Barostim Neo TM|
41012785|NCT04678414|BEHAVIORAL|Healthcare Activity|Attend focus group
41331116|NCT03874416|OTHER|Non-specific rehabilitation|Usual non-specific rehabilitation treatment for moderate to severe TBI in healthcare facilities: 2-3 sessions per week for 3 months.
41482280|NCT04299659|DIAGNOSTIC_TEST|Landolt C entry method|Four different methods for entering the Landolt C gap position are compared
40813499|NCT04812119|DIAGNOSTIC_TEST|The Achenbach System of Empirically Based Assessment (ASEBA)|The Achenbach System of Empirically Based Assessment (ASEBA; Achenbach) is a collection of questionnaires used to assess adaptive and maladaptive behavior and overall functioning in individuals. The system includes report forms for multiple informants - the Child Behavior Checklist (CBCL) is used for caregivers to fill out ratings of their child's behavior, the Youth Self Report Form (YSR) is used for children to rate their own behavior, and the Teacher Report Form (TRF) is used for teachers to rate their pupil's behavior. The ASEBA seeks to capture consistencies or variations in behavior across different situations and with different interaction partners. The ASEBA exists for multiple age groups, including preschool-aged children, school-aged children, adults, and older adults. Scores for individuals in each age group are norm-referenced.
40813500|NCT04812119|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System Third Edition (ABAS-3)|The ABAS-3 (Harrison, Oakland, 2015) is a rating scale useful for assessing skills of daily living in individuals with developmental delays, autism spectrum disorder, intellectual disability, learning disabilities, neuropsychological disorders, and sensory or physical impairments. Rating forms are filled out by the parent and a teacher. The ABAS-3 covers three broad domains: conceptual, social, and practical, using 11 skill areas within these domains. Tasks focus on everyday activities required to function, meet environmental demands, care for oneself, and interact with others effectively and independently. On a 4-point response scale, raters indicate whether, and how frequently, the individual performs each activity.
40813501|NCT04246437|DRUG|[18F]FDOPA|Patients will receive a 3-D emission scan following a 6-8 mCi slow bolus injection of \[18F\]FDOPA over a 30 second period. Serial scans are started simultaneously with the bolus injection of radiotracer and are obtained for approximately 95 minutes.
40813502|NCT04246437|DRUG|Carbidopa 200mg oral dose|30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
40813503|NCT04246437|DRUG|Entacapone 400mg oral dose|30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
40813504|NCT03213938|DEVICE|Acupuncture|"For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.~Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
40813505|NCT03213938|DEVICE|Sham acupuncture|"For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.~Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
40813506|NCT05955820|DEVICE|Suspension system|Participants will be tested by four exercises designed for impingement syndrome using the suspension system
40813507|NCT05955820|DEVICE|Dumbbells|Participants will be tested by four exercises designed for impingement syndrome using Dumbbells
40813508|NCT06302400|DEVICE|166Holmium microspheres (QuiremSpheres®)|QuiremSpheres® are a biocompatible microsphere that contain the radionuclide holmium-166 (166Ho), which emits gamma-radiation (81 keV) and high-energy (1.81 MeV) beta-particles.
40918280|NCT04704947|DRUG|cardio-selective beta blocker group|cardio-selective beta blocker group
40918281|NCT04704947|DRUG|alendronate sodium|alendronate sodium
41012786|NCT04678414|OTHER|Survey Administration|Complete survey
41331117|NCT04586075|DIAGNOSTIC_TEST|Trio Whole Genome Sequencing and Participant-Specific Research|"The initial evaluation begins with short-read genome sequencing of DNA extracted from blood of affected individual(s) and participating family members (The most common approach will be trio whole genome sequencing, which involves the affected child + their parents).~Additional evaluation may include: functional assessments, animal modeling, reverse phenotyping (may require an interim visit), epigenetic profiling, or clinical database matching through selective sharing of coded patient data with external collaborators (e.g., via Matchmaker Exchange and Phenome Central), long read genome sequencing, de novo genome assembly, RNA sequencing, and novel bioinformatics analyses"
40813509|NCT06151613|DEVICE|continuous eCTG monitoring using the NFMS|Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring with NFMS. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
40813510|NCT05139719|DRUG|HEC585 dose A|taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage
40813511|NCT05139719|DRUG|HEC585 dose B|taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage
40813512|NCT05139719|DRUG|Placebo|taking Placebo orally once daily, up to 24 weeks in main stage
40813513|NCT03981887|DRUG|Nafithromycin|Nafithromycin 200 mg as IV infusion
40813514|NCT03981887|OTHER|Placebo|placebo administered as IV infusion
40813515|NCT05092282|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
40813516|NCT05092282|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
40813517|NCT03639636|OTHER|non surgical and surgical periodontal therapy|scaling and root planing periodontal flap surgery
40813518|NCT01854216|DRUG|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
40813519|NCT01854216|DRUG|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
40813520|NCT01854216|DRUG|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
41012787|NCT05459636|DEVICE|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
40813521|NCT01749124|DEVICE|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
40813522|NCT00853242|DRUG|Placebo|
40813523|NCT00853242|DRUG|Genz-644470|
40813524|NCT00853242|DRUG|Sevelamer carbonate|
40813525|NCT00656188|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
40813526|NCT00656188|DRUG|Placebo|Matching placebo
40813527|NCT01394692|PROCEDURE|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
40813528|NCT01394692|PROCEDURE|standard microsurgery|microsurgical tumor resection
40813529|NCT01237457|DRUG|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
40813530|NCT01941979|DRUG|5-FU, Capecitabine, Oxaliplatin, Leucovorin.|
40813531|NCT02490995|OTHER|Movie|Besides the anesthesist explanations the children will have a movie explanation.
40813532|NCT04717648|DIAGNOSTIC_TEST|Biochemical test|C Reactive protein and sodium
40813533|NCT05258578|BEHAVIORAL|Tele-CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets).
40813534|NCT05258578|OTHER|Self-Help Resources|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation.
40813535|NCT00011362|DRUG|Dexamethasone Early|Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
41012788|NCT05459636|DEVICE|Very-low-resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
40813536|NCT00011362|DRUG|Dexamethasone Late|Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was \>=2.4 on treatment day 14, or an additional two weeks of saline
40813537|NCT02414607|BIOLOGICAL|Elderberry Juice|
40813538|NCT02414607|OTHER|Placebo|
40813539|NCT00606034|DRUG|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
40813540|NCT01942668|DRUG|Estradiol|
40813541|NCT01942668|DRUG|Progesterone|
40813542|NCT01942668|DRUG|Placebo|
40813543|NCT03305796|RADIATION|Diffusion magnetic resonance imaging|Patients with suspected cholesteatoma will have diffusion magnetic resonance imaging
40813544|NCT03929952|OTHER|Neurofeedback treatment|"20 sessions of neurofeedback of 5 minutes each consisting of :~* The patient is equipped with an electroencephalography headset. The feedback visual has the form of a candle flame and is modulated by alpha synchrony.~* The height of the flame is proportional to the intensity of the patient's pain. The patient has to concentrate on the height of this flame by thought to modulate it and, at the same time, to decrease the intensity of his own pain."
40813545|NCT03929952|OTHER|functional magnetic resonance imaging (fMRI) scans|The patient in alpha synchrony related state and in rating state will undergo an fMRI
40813546|NCT02899455|DRUG|HGP0904|
40813547|NCT02899455|DRUG|HGP0608|
40813548|NCT02899455|DRUG|HGP0816|
40813549|NCT02899455|DRUG|HGP0904 Placebo|
40813550|NCT02899455|DRUG|HGP0816 Placebo|
41012789|NCT06089720|DEVICE|Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)|nine orthodontic patients each one will receive 2 coated zinc oxide nanoparticle molar tubes in split-mouth manner and will assess for antimicrobial effect on s. mutans \& lactobacillus after two weeks, in addition to evaluation of bond failure rate after three months.
41331118|NCT03402269|OTHER|Clavicle fracture injury- observation|The study is an observational study with assessments at 1 month, 3 months, 6 months and 1 year following injury. Assessments include range of motion, strength, patient reported outcomes and radiographic healing
41331119|NCT01261598|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
40813551|NCT02503358|OTHER|Laboratory Biomarker Analysis|Correlative studies
40813552|NCT02503358|DRUG|Paclitaxel|Given IV
40813553|NCT02503358|OTHER|Pharmacological Study|Correlative studies
40813554|NCT02503358|DRUG|Selumetinib|Given PO
40813555|NCT00660413|DEVICE|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
40813556|NCT00700544|DRUG|chemotherapy treatment (see arm) + norethandrolone|"oral form~Dosage:~10 mg in patients with a weight \< 60 kgs 20 mg in patients with a weight \> 60 kgs frequency: every day Duration: 2 years"
40813557|NCT00700544|DRUG|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
40813558|NCT03443479|DEVICE|Non-Invasive Ventilation|Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.
40813559|NCT03443479|DEVICE|High-Flow Nasal Cannula|Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher\&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
40813560|NCT01242839|DEVICE|CACICOL20|CACICOL20 is a solution of dextran \& poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
40813561|NCT01242839|DEVICE|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
41331120|NCT00064077|DRUG|Cisplatin|Given IV
40813562|NCT05667584|DEVICE|hypotension prediction index derived from non-invasive arterial pressure waveforms|The Hypotension Prediction Index (HPI) is an algorithm based on the complex analysis of features in high-fidelity arterial pressure waveform recordings developed to observe subtle signs that could predict the onset of hypotension in surgical and intensive care unit patients. HPI is a unitless number that ranges from 1 to 100, and as the number increases, the likelihood of a hypotensive event (MAP \<65 mm Hg for more than 1 minute) occurring in the near future increases. In a validation study on HPI conducted in patients under general anesthesia, the algorithm, at its optimal value, predicted hypotension with both sensitivity and specificity of 86% 5 minutes before the event. Measurement of the arterial pressure waveforms using a finger cuff (ClearSight) is well established.
40813563|NCT05667584|DEVICE|non-invasive arterial pressure waveforms|ClearSight is a non-invasive hemodynamic monitoring device using digital-cuff and volume-clamp technology to obtain a continuous arterial blood pressure waveform. Continuous finger blood pressure measurement is established by wrapping the cuff around the middle phalanx of a finger. The area under the waveform curve is analyzed using a unique algorithm that serves to calculate the arterial blood pressure, stroke volume (SV) and CO.
40813564|NCT05470179|DEVICE|Hybrid hyrax distalizer|class 2 Angle malocclusion
40813565|NCT05470179|DEVICE|Pendulum distalizer|class 2 Angle malocclusion
40813566|NCT06066021|OTHER|health educational sessions in diabetic patients type 2.|Professionals from different areas will be invited to carry out the sessions at Visit 2, namely on: mental health, physical activity, nutrition and self-care.
41331121|NCT00064077|DRUG|Gemcitabine Hydrochloride|
41331122|NCT00064077|DRUG|Paclitaxel|Given IV
40813567|NCT03367923|OTHER|Communication Intervention|Receive email/text
40813568|NCT03367923|OTHER|Counseling|Undergo exercise counseling
40813569|NCT03367923|OTHER|Fitbit tracker|Wear Fitbit tracker
40813570|NCT03367923|OTHER|Quality-of-Life Assessment|Ancillary studies
40813571|NCT03367923|OTHER|Questionnaire Administration|Ancillary studies
40813572|NCT03367923|BEHAVIORAL|Telephone-Based Intervention|Receive phone call
40813573|NCT03786081|DRUG|Tisotumab Vedotin|Given into the vein (IV)
40813574|NCT03786081|DRUG|Bevacizumab|Given via IV
40813575|NCT03786081|DRUG|Pembrolizumab|Given via IV
40813576|NCT03786081|DRUG|Carboplatin|Given via IV
41331123|NCT00064077|OTHER|Quality-of-Life Assessment|Ancillary studies
41012790|NCT06089720|DEVICE|orthodontic molar tubes (control)|nine orthodontic patients each one will receive two uncoated molar tubes in split-mouth manner and will assess for antimicrobial effect on S. mutans \& lactobacillus after two weeks, also, evaluation of the bond failure rate after three months period.
40813577|NCT01605604|BEHAVIORAL|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
41012791|NCT04963179|DEVICE|Womed Leaf|"Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated during approximately 5 days. It is degraded and discharged naturally through the cervix and vagina in less than 30 days."
41012792|NCT02501330|DRUG|Bosutinib|The recommended adult dose of bosutinib is 500 mg orally once daily with food. For newly-diagnosed chronic phase CML, the recommended dose is 400 mg. The dose may be adjusted appropriately according to the patient's condition; however, the maximum dose is 600 mg once daily.
40813578|NCT05596461|DEVICE|Transcranial magnetic stimulation|Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.
40813579|NCT05596461|DEVICE|Transcranial direct current stimulation|Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.
41331124|NCT00064077|DRUG|Topotecan Hydrochloride|Given IV
41331125|NCT00064077|DRUG|Vinorelbine Tartrate|Given IV
41331126|NCT04378257|BEHAVIORAL|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform.The link will direct the participant directly to a screen where they will be able to see and interact with the psychologist once a week. The sessions will be conducted in the Arabic or English languages.Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~* Acknowledging emotions and normalizing current stress~* Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~* Behavioral Activation Acceptance and Commitment Therapy (ACT)~* Grounding, Breathing, Acceptance of emotions, and de-fusion"
41331127|NCT04378257|BEHAVIORAL|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice. The participants will be requested to use this information to manage any distress that they might experience. On the sixth week, the participants in the control group will be assessed on their mood and anxiety symptoms. Participants will also be requested to provide information on other self-help remedies that participants used to improve or manage their functionality (example, access to other websites, communication with close friends or family etc.)
41331128|NCT03792165|OTHER|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
41331129|NCT03792165|OTHER|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
41482281|NCT05968534|BEHAVIORAL|MOSAIC Plus|"This is a single-arm study. Participants will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
41482282|NCT01242930|DRUG|Imetelstat (7.5 mg/kg)|Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
40813580|NCT06507436|DRUG|Herombopag tablets|Herombopag tablets; dose 1 or dose 2, for 5 days
40813581|NCT06507436|DRUG|Herombopag placebo tablets|Herombopag placebo tablets; dose 1 or dose 2, for 5 days
41331130|NCT04957303|DEVICE|sublingual microcirculation video recording|The sublingual microcirculation videos were recorded by video microscope
41331131|NCT00656084|DRUG|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.
41331132|NCT00656084|DRUG|mitoxantrone|"Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."
41331133|NCT00656084|DRUG|rituximab|"Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."
41331134|NCT03032250|OTHER|Communication Intervention|Attend interventionist sessions
41012793|NCT03746522|DRUG|Setmelanotide|SC injection of setmelanotide
41012794|NCT03746522|DRUG|Placebo|SC injection of placebo
41012795|NCT00393549|DEVICE|NeuroPath|
41012796|NCT01003431|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|\[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)\] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
41012797|NCT01003431|BIOLOGICAL|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
41331135|NCT03032250|OTHER|Watch video|Watch video on a DVD
41331136|NCT03032250|OTHER|Module completion of the Prepare to Care kit|Complete modules of the Prepare to Care kit
41012798|NCT01003431|BIOLOGICAL|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
41012799|NCT00226616|DRUG|Zinc|
41012800|NCT04154488|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
41012801|NCT00471913|DEVICE|Femoral Nailing with Different Entry Points|See Detailed Description.
41482283|NCT01242930|DRUG|lenalidomide standard of care|Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
41331137|NCT03032250|OTHER|Quality-of-Life Assessment|Ancillary studies
41331138|NCT03032250|OTHER|Survey Administration|Ancillary studies
41331139|NCT03032250|OTHER|Salivary cortisol collection|Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
41331140|NCT02970396|BEHAVIORAL|self-management|
40813582|NCT05852652|DEVICE|cryolipolysis and aerobic exercise|"the patients in this arm adjusted low calorie diet . According to the Recommended Dietary Intake (RDI), the low-calorie diet plan with three carefully calculated meals had a balanced macronutrient quantity of carbohydrate and protein, was low in fat, and was abundant in fruits, vegetables, and dietary fibres.~they got two cryolipolysis sessions,one session in the month ,they got two sessions in two months,then took our outcome measures with walking 60 minutes in the park"
41012802|NCT06162741|BEHAVIORAL|Primary Care Brief Mindfulness Training (PCBMT)|PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.
41155853|NCT04454489|RADIATION|Quad-shot palliative radiotherapy|"* Each cycle of quad-shot radiotherapy will be comprised of 14.8 Gy in 4 fractions (3.7 Gy per fraction) delivered twice daily (at least 6 hours apart) over two consecutive days.~* All patients will receive 1 cycle of quad-shot radiotherapy between ICI cycles 2-3.~* Subsequent cycles may occur between immunotherapy cycles 6-7 and 11-12, if more than 1 cycle can be safely delivered and the patient has experienced less than a partial response at protocol-specified tumor assessments (after C5 and C10). The eligibility for subsequent cycles will be at the discretion of the treating radiation oncologist.~Therefore, the total prescription dose will be:~* 14.8 Gy in 4 fractions for those that complete 1 cycle (all patients will receive 1 cycle)~* 19.6 Gy in 8 fractions for those that complete 2 cycles~* 44.4 Gy in 12 fractions for those that complete 3 cycles"
41155854|NCT06643052|OTHER|No intervention|No intervention
41331141|NCT03707262|BIOLOGICAL|Donor CD34+ and CD3+ cells|Infusion of GCSF-mobilized, Miltenyi-enriched CD34+ hematopoietic stem/progenitor cells (HSPCs) (≥ 5 million cells/kg) and CD3+ cells (5 million cells/kg) from an HLA-identical sibling living donor, following pre-conditioning regimen of rATG and TLI.
41331142|NCT01591811|RADIATION|Arm 1 Daily Boost of Radiation Therapy|Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
41331143|NCT01591811|RADIATION|Arm 2 Weekly Boost of Radiation Therapy|Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
41331144|NCT00638417|BEHAVIORAL|Maximal strength training|maximal dynamic strength training from 1 week after the operation, 5 training bouts a week for 4 weeks. The regimen consisted of 2 exercises, leg press and hip abduction, that included 4 series of 5RM involving the operated leg only. 5RM corresponds to approximately 85% of 1RM. When the patients managed to perform 6RM, the load was increased by 5kg. The series were separated by resting periods of 2 minutes.
41331145|NCT00638417|BEHAVIORAL|conventional rehabilitation|conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (\>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
40813583|NCT04208386|DRUG|JNJ-73763989|JNJ-73763989 will be administered SC under fasted condition.
41331146|NCT03295591|DIAGNOSTIC_TEST|Circulating tumor cell|Circulating tumor cell enumeration and sequencing
40813584|NCT00992199|DRUG|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
41331147|NCT06453772|PROCEDURE|Liposuction|Primary or secondary liposuction is performed by the surgical staff. The study analyzed variables including weight, height, BMI, preoperative hemoglobin, and aspirated volume. Additionally, preoperative hemoglobin (Hb), hematocrit (Hto), platelets, prothrombin time (Tp), partial prothrombin time (TpT), and International Normalized Ratio (INR) were evaluated. Hb and Hto levels were reassessed 24 hours post-surgery to monitor changes.
40813585|NCT05066152|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|One probiotic drop contained a formulation of 1x109 Cfu Lactobacillus rhamnosus GG (LGG; ATCC 53103)
40813586|NCT05066152|DIETARY_SUPPLEMENT|Placebo|Carrier material of probiotic product, not containing bacterial strain, similar appearance as the probiotic
40813587|NCT02431910|OTHER|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
40813588|NCT02431910|OTHER|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
40813589|NCT03721484|DIAGNOSTIC_TEST|CINtec PLUS|CINtec PLUS testing will be used to triage HPV positive women to colposcopy
40813590|NCT04926610|OTHER|proactive clinical ethics consultation|When the patients meet the initiation criteria of this study, the patients were randomly assigned to the intervention group (providing proactive clinical ethics consultation) and the routine care group (no proactive clinical ethics consultation) after obtaining the consent of the subjects.
40813591|NCT05984758|DIAGNOSTIC_TEST|AS-OCT imaging|Image acquisition with the Optovue RTVue OCT and the Heidelberg Spectralis OCT2 machines
40813592|NCT05984758|DIAGNOSTIC_TEST|Slit lamp examination|SLE of anterior chamber
40813593|NCT00726037|DRUG|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
40813594|NCT02196883|PROCEDURE|Transforaminal Epidural Steroid Injection|
40813595|NCT05457153|OTHER|Well-Being Process Program (WEBEPROP)|Technology-Based Well-Being Process Program (WEBEPROP)
40813596|NCT00765037|DEVICE|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
40813597|NCT06431672|OTHER|interpersonal group psychotherapy|Interpersonal psychotherapy (IPT) was developed by Stuart and O'Hara (1995). It addresses four domains of conflict. The intervention is an eight-session P-IPTG, which consisted of four sessions in pregnancy and four in postpartum.
40813598|NCT03491813|DEVICE|oscillometric device|"The blood pressure will be measured by the Automatic blood pressure monitor(Oscillometric) named the OMRON M2 basic® device was provided by Omron Healthcare company.~This monitor uses inflation by Fuzzy-Logic controlled by electric pump and an automatic rapid pressure release valve for the deflation , its cuff allows BP measurements in arm circumference of 22-42 cm. The device measure BP and pulse rate with a pressure range of 0-299 mmHg and pulse rate range of 40-180 beats/min."
40813599|NCT04832789|DEVICE|Venovenous ECMO|Venovenous ECMO
40813600|NCT03650374|OTHER|Standard of Care Rehabilitation|Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.
40813601|NCT03650374|OTHER|Experimental Strength Training|Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
41155855|NCT02222844|OTHER|Preoperative MRI scan|Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
41331148|NCT03940456|OTHER|Questionnaire|Questionnaire mainly focusing on low back pain, pain related disorders, psychosocial factors and the use of alternative treatments for pain
40813602|NCT00059943|DRUG|docetaxel|
40813603|NCT06127381|DRUG|Glycolic acid tetrasubstituted piceatannol (TGKP)|A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.
40813604|NCT02931513|OTHER|Blood samples|
40813605|NCT02931513|DEVICE|Fibroscan|
40813606|NCT02931513|OTHER|Questionnaires|
40813607|NCT02931513|BIOLOGICAL|Liver biopsy|Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
40813608|NCT02704702|DRUG|Fimasartan|
40813609|NCT02704702|DRUG|Rosuvastatin|
40813610|NCT02704702|DRUG|Fimasartan + Rosuvastatin|
40813611|NCT05988138|BEHAVIORAL|Family Promoting Positive Emotions|An 8-week dyadic intervention using cognitive and behavioral skills to up-regulate positive emotions in children and mothers
40813612|NCT05988138|BEHAVIORAL|Psychoeducation|An 8-week comparison condition that offers education in mental health, depression prevention, and accessing mental health resources
40813613|NCT00873041|DRUG|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
40813614|NCT00873041|DRUG|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
40813615|NCT02975739|DEVICE|Holmium-166 (poly L lactic acid) microspheres|Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
40813616|NCT06532526|OTHER|Predicta® Bioactive Desensitizer (PBD, PARKELL, EDGEWOOD, NY, USA)|A bioactive desensitizer gel that applied on teeth to reduce tooth sensitivity associated with dental bleaching.
41155856|NCT01890499|DIETARY_SUPPLEMENT|Low Residue diet arm.|Interventional arm is to provide low residue diet on postoperative day one.
41155857|NCT06379906|OTHER|Assessment|Baseline assessment
41155858|NCT00527696|PROCEDURE|transvaginal obturator tape|
41155859|NCT03793140|DRUG|CPI-613|CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)
41155860|NCT02988245|DRUG|Geneticure Panel for HTN therapy|Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension
41155861|NCT02988245|DRUG|JNC-8|Using JNC-8 guidelines to guide therapy
41331149|NCT00718523|DRUG|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
41331150|NCT00718523|DRUG|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
41331151|NCT00470678|DRUG|ranibizumab|
41331152|NCT06006780|DEVICE|Porcine acellular dermal matrix|Coronally advanced flap associated with the porcine acellular dermal matrix for root coverage
41331153|NCT06006780|OTHER|Coronally advanced flap (CAF)|Coronally advanced flap for root coverage
41331154|NCT03945448|DRUG|Single dose liposomal Amphotericin and Fluconazole|Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.
40813617|NCT06532526|OTHER|Gel with 1.23% sodium fluoride (EAZIGEL, VERICOM CO., LTD. SOUTH KOREA)|Fluoride gel that applied on the teeth to reduce tooth sensitivity
40813618|NCT06532526|OTHER|Placebo gel without any active ingredients.|Water-based glycerin gel is used as the Placebo gel without active ingredients
40813619|NCT01511614|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS), a type of Non-invasive Brain Stimulation (NIBS), has the potential to modify neuronal circuits by application of a subthreshold conductive current through the scalp. Two potential targets for tDCS as a smoking cessation aid are the dorsolateral pre-frontal cortex (dlPFC), a node of the ECN, and the ventromedial prefrontal cortex (vmPFC), a node of the DMN. tDCS can potentially strengthen the control of the ECN through excitatory stimulation of the dlPFC, and weaken the influence of the DMN (Lerman et al 2014) by inhibitory stimulation of the vmPFC. The tDCS model we will use is the neuroConn DC-Stimulator MR (neuroCare Group GmbH, Munchen, Germany).
40813620|NCT01511614|DEVICE|sham|Sham Comparator
40813621|NCT01511614|DRUG|Nicotine patch|Dose-match Nicotine for non-deprived scan
40813622|NCT01511614|DRUG|Placebo patch|Nicotine deprived
40813623|NCT01511614|DRUG|Varenicline Pill|Treatment
41331155|NCT03945448|DRUG|Fluconazole|Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
40813624|NCT01511614|DRUG|Placebo pill|Active comparator to varenicline
40813625|NCT01511614|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing for smoking cessation preparation
40813626|NCT06188286|OTHER|Transcutaneous electrical acupoint stimulation|The 4 patches of the transcutaneous acupoint electrical stimulator were pasted on two pairs of acupuncture points, the output frequency was adjusted to 2Hz, the intensity was up to 50ma, the single intervention time was 30 minutes, and another group of acupuncture points was replaced after completion, and the rest of the operations were the same as above, with a total intervention time of 1 hour.
40813627|NCT06188286|OTHER|sham Transcutaneous electrical acupoint stimulation|The patch is fixed on the acupuncture point to turn on the instrument, but there is no current output
40813628|NCT00083954|DRUG|Quetiapine Fumarate|
40813629|NCT00246051|BEHAVIORAL|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
40918282|NCT06007898|BEHAVIORAL|Parent self-help psychological resource|A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet.
41155862|NCT01249976|OTHER|blood culture|blood culture
41155863|NCT02264717|PROCEDURE|SPECT|Patients are randomized to either SPECT or Cardiac MRI
41331156|NCT03020212|DRUG|Oxygen|The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
40813630|NCT00246051|OTHER|Expert-Led Sleep Disorders Screening and Treatment|"Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.~1. Positive on the Berlin Questionnaire~2. Clinic visit, exam with a physician, given a home diagnostic device (HDD)~3. High risk on HDD, seen by physician, given a CPAP machine~4. Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed~5. Contacted by a sleep health clinic at 3, 6, 12 months~6. After 12 months subject will be referred to their primary care physician"
40813631|NCT00246051|OTHER|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
40813632|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; low dose
40813633|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; medium dose
40813634|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection, high dose
40813635|NCT06396429|DRUG|Placebo|blank preparation, participants received matching placebo.
40813636|NCT00625196|DRUG|Fluticasone foroate/ vilanterol|Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
40813637|NCT00625196|DRUG|Fluticasone foroate|Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
40813638|NCT00625196|DRUG|Vilanterol|Vilanterol will be available as dry powder inhaler.
40813639|NCT00625196|DRUG|Placebo|Placebo will be supplied as dry powder inhaler.
40813640|NCT03905239|DIAGNOSTIC_TEST|algorithm|clinical examination and procalcitonin assessment
40813641|NCT05091697|BEHAVIORAL|Multicomponent treatment VIRTUAL FIBROWALK + TAU|To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
40813642|NCT01414023|BEHAVIORAL|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
40813643|NCT01414023|BEHAVIORAL|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
40813644|NCT03167112|DRUG|Oxaliplatin|Patients receive Oxaliplatin 85 mg/m2 over 2 hours.
41331157|NCT03797508|DIAGNOSTIC_TEST|ultrasound|To evaluate the accuracy of ultrasound findings in comparison to serum CA125and progesterone in predicting fetal demise in cases of first trimester threatened miscarriage.
40813645|NCT03167112|DRUG|Irinotecan|Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.
40813646|NCT03167112|DRUG|Leucovorin|Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
40813647|NCT03167112|DRUG|Fluorouracil|Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
41331158|NCT02331641|PROCEDURE|Hepatectomy|Removal of a part of the liver
40813648|NCT00175630|PROCEDURE|Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description
40813649|NCT03542903|DEVICE|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg)."
40813650|NCT04793724|DEVICE|Simeox|"A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~* clearance of the upper airways before the physiotherapy session~* correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~* slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~* step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~* comfortable, relaxed sitting position with straightened spine~* controlled cough, which will be encouraged only when it is productive"
40918283|NCT04109508|DRUG|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
40918284|NCT00236704|DRUG|topiramate|
40918285|NCT00760799|PROCEDURE|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
40918286|NCT00975897|BIOLOGICAL|bevacizumab|
40918287|NCT00975897|BIOLOGICAL|cetuximab|
40918288|NCT00975897|DRUG|fluorouracil|
40918289|NCT00975897|DRUG|irinotecan hydrochloride|
41331159|NCT04907422|DIAGNOSTIC_TEST|CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction|new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
41331160|NCT04907422|DIAGNOSTIC_TEST|non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction|conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
41331161|NCT02537223|DRUG|BYL719|
41331162|NCT02537223|DRUG|Cisplatin|
41331163|NCT02537223|RADIATION|Intensity modulated radiation therapy (IMRT)|
41331164|NCT04429412|BEHAVIORAL|MCT+|Metacognitive training
41331165|NCT00138229|BIOLOGICAL|aldesleukin|
41331166|NCT00138229|BIOLOGICAL|filgrastim|
41331167|NCT00138229|BIOLOGICAL|therapeutic autologous lymphocytes|
41331168|NCT00138229|DRUG|cyclophosphamide|
41331169|NCT00138229|DRUG|fludarabine phosphate|
41331170|NCT03127436|DRUG|Acarovac|House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
41331171|NCT00659126|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
41331172|NCT00659126|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
41331173|NCT00659126|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
41482284|NCT01242930|DRUG|Imetelstat (9.4 mg/kg)|Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
41482285|NCT05192759|DEVICE|Transcranial Magnetic Stimulation|The stimulations were performed by MagStim Rapid2.
41331174|NCT00659126|DRUG|Ferumoxytol|Given IV
40918290|NCT00975897|DRUG|leucovorin calcium|
40918291|NCT00975897|DRUG|oxaliplatin|
40918292|NCT00975897|GENETIC|RNA analysis|
41331175|NCT00659126|DRUG|Gadolinium|Given IV
41331176|NCT00659126|PROCEDURE|High Field Strength Magnetic Resonance Imaging|Undergo 7T MRI
41331177|NCT00659126|PROCEDURE|Susceptibility Weighted Imaging|Undergo SWI
41331178|NCT02949713|BEHAVIORAL|Text messaging-motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviews
41331179|NCT03759028|DRUG|Ibuprofen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
41331180|NCT03759028|DRUG|Oxycodone|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
41331181|NCT03759028|DRUG|Acetaminophen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
41331182|NCT05641155|DEVICE|Focused Multipolar Stimulation (FMS) strategy|Adult cochlear implant recipients receiving different combinations of alternative modes and, sound coding parameters.
41331183|NCT03380026|DRUG|Triamcinolone|Apply up to three times daily on select lesions.
41331184|NCT03380026|DRUG|Valchlor 0.016 % Topical Gel|Apply valchlor nightly on select lesions.
41331185|NCT05240612|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
41331186|NCT05240612|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
41331187|NCT02626364|DRUG|crenolanib|single-agent crenolanib at 100 mg PO TID
41331188|NCT06060067|BIOLOGICAL|TDV|TDV SC injection on Day 1 and Day 90 of the study
41331189|NCT06060067|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study
41482286|NCT00974948|PROCEDURE|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
41482287|NCT03045237|OTHER|physical exercises classes|3 physical exercises classes, one of them in the pool.
41482288|NCT02547766|DRUG|Anakinra|Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
41331190|NCT01578538|PROCEDURE|inguinal hernia repair|strangulated hernias will be repaired surgically
41331191|NCT03023241|PROCEDURE|biopsy|cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection
41331192|NCT04019457|OTHER|Dietary intervention|Dietary intervention: Participants receive dietary fibers for a defined number of days.
41331193|NCT00628316|DIETARY_SUPPLEMENT|caffeine|caffeine daily intake will be reduced form 150 ml per day
41331194|NCT05440487|OTHER|Iron chelator|There is no treatment allocation. Patients administered approved Iron chelators by prescription that have started before inclusion of the patient into the study will be enrolled.
41331195|NCT05471206|OTHER|Milk and SmartPill intakes|During visit V2, the subject will ingest the SmartPill capsule. Then, subjects will drink milk.
41331196|NCT05031572|OTHER|dietary intervention|Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
41331197|NCT02784977|DEVICE|Positive Airway Pressure (PAP)|Treatment of OSA with PAP
41331198|NCT02784977|DEVICE|Intraoral device (IOD)|Treatment of OSA with IOD
41331199|NCT02784977|PROCEDURE|Uvuloplasty|Uvuloplasty
41331200|NCT02784977|OTHER|Conservative treatment|No active intervention
41331201|NCT04397796|BIOLOGICAL|BM-Allo.MSC|BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.
41331202|NCT04397796|BIOLOGICAL|Placebo|plasmalyte and human albumin
41482289|NCT02416011|BEHAVIORAL|GENERIC|The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
40813651|NCT04793724|DEVICE|PARI O PEP|"ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~* horizontal;~* low;~* transition of the device from the low position to the horizontal position;~* upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum."
40813652|NCT05393531|DEVICE|Mandibular advancement device (MAD)|Active therapy
40813653|NCT05393531|DEVICE|Continuous positive airway pressure (CPAP)|Active therapy
40813654|NCT04305509|OTHER|no intervention|no intervention
40813655|NCT00776594|DRUG|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
40813656|NCT00776594|DRUG|bicalutamide|50mg orally daily for 6 months
41331203|NCT05859360|OTHER|Physical performance and cardiovascular health measures|"* Retinal vessel analysis~* Muscle ultrasound~* Knee extension~* Voluntary activation~* spiroergometry"
40813657|NCT00776594|DRUG|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
40813658|NCT01555034|BEHAVIORAL|movement therapy|exercise, nutrition, movement therapy
40813659|NCT01555034|OTHER|exercise plus nutrition|exercise, nutrition
40813660|NCT00464373|DRUG|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
40813661|NCT00464373|DRUG|Placebo|4ml NaCl 0.9%
41331204|NCT04020276|RADIATION|SBRT|Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
41331205|NCT05277116|OTHER|Genome Informed Risk Assessment (GIRA) report|A Genome Informed Risk Assessment (GIRA) report that combines genetic (monogenic risks and polygenic risk scores), family history, and clinical risk information from participants.
41331206|NCT04191213|DIETARY_SUPPLEMENT|Acacia Senegal extract|Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks
41331207|NCT04191213|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
41331208|NCT04435561|OTHER|Standard physiotherapy rehabilitation and dry needling|The dry needling group receives 6 sessions of dry needling in the spastic muscles of the upper and lower hemiparetic limbs.
41331209|NCT04435561|OTHER|Standard physiotherapy rehabilitation|This group receives their traditional intervention, without dry needling.
41331210|NCT05610657|DRUG|Mitapivat|Mitapivat tablets
41331211|NCT04472637|DRUG|Atorvastatin|atorvastatin 10 mg, as one tablet /day for 24 weeks.
41331212|NCT04472637|DRUG|Placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 24 weeks)
41331213|NCT01946789|BIOLOGICAL|ALT-803|Intravenous infusion for dose level 1-5; subcutaneous injection for dose level 5a-8; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
41331214|NCT05426018|DRUG|SY-009 capsules|3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
40813662|NCT04165382|OTHER|Interventions in the guideline to infants receiving NIV|"Interventions in the guideline involve six components as~1. choice of right nasal interfaces and bonnet~2. use of skin protective dressing~3. alternate the nasal interfaces every 6 hours;~4. positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction~5. supportive care with more new interventions~6. regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV"
40813663|NCT04165382|OTHER|Usual care to infants receiving NIV|Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
40813664|NCT00040781|DRUG|gefitinib|Given orally
40813665|NCT00040781|OTHER|pharmacological study|Correlative studies
40813666|NCT00040781|OTHER|laboratory biomarker analysis|Correlative studies
40813667|NCT02376725|PROCEDURE|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
40813668|NCT02376725|PROCEDURE|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
40813669|NCT01069263|OTHER|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
40813670|NCT01069263|DRUG|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
40813671|NCT02959853|DRUG|Anastrazole|
40813672|NCT02959853|BEHAVIORAL|weight loss|
40918293|NCT00975897|GENETIC|cytogenetic analysis|
41331215|NCT03673956|DRUG|Mupirocin|30mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
41331216|NCT03673956|DRUG|Tobramycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
41331217|NCT03673956|DRUG|Levofloxacin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
41331218|NCT03673956|DRUG|Vancomycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
40813673|NCT03800446|DIAGNOSTIC_TEST|Point of care ferritin test|Point of care test that uses capillary blood sample from finger to determine ferritin level
40813674|NCT05972421|OTHER|High Intensity Proactive Outreach|phone calls + mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
40813675|NCT05972421|OTHER|Low Intensity Proactive Outreach|mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
41482290|NCT02416011|BEHAVIORAL|eTARGET|The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
41482291|NCT02758249|DRUG|Sevoflurane|patients are anesthetized by using sevoflurane inhalation
41482292|NCT02758249|DRUG|propofol|patients are anesthetized by using propofol infusion
40813676|NCT06322745|PROCEDURE|Suture renorrhaphy only for hemostasis of the tumor bed in laparoscopic partial nephrectomy|Suture renorrhaphy will be used in 2 layers; medullary and cortical, with Vicry 2/0 or 3/0 and secured with V-lock. Early unclamping will be done after hemostasis of the medullary layer. Renorrhaphy of the cortical layer will be continued after that.
40813677|NCT06322745|PROCEDURE|Thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy|A 2-μm continuous thulium laser with 365 μm laser fiber at 30-40 W will be used for coagulation of the tumor bed. Large vessels that may not be completely sealed with thulium beam will be closed by V-lock to achieve safe and stable hemostasis. Early unclamping will be done after hemostasis of the tumor bed. Suture renorrhaphy will be used in 1 layer to approximate the renal parenchyma.
40813678|NCT00771043|DRUG|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
40813679|NCT04044599|DRUG|Gynoflor|VAGİNAL GYNOFLOR
41331219|NCT04477915|OTHER|Core exercises|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises.
41331220|NCT04477915|OTHER|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles.
41482293|NCT04132336|DRUG|Naproxen sodium/Caffeine (BAY2880376)|Tablet, oral, single dose
41482294|NCT04132336|DRUG|Naproxen sodium (Aleve)|Tablet, oral, single dose
41482295|NCT04132336|DRUG|Caffeine|Tablet, oral, single dose
41482296|NCT04132336|DRUG|Placebo|Tablet, oral, single dose
41482297|NCT00308126|DRUG|Hydroxyethyl Starch 130/0.4 (Voluven)|
40813680|NCT00311740|DRUG|Valsartan|
40813681|NCT00311740|DRUG|Hydrochlorothiazide|
40813682|NCT06208293|BEHAVIORAL|KPZ Program (KPZ)|The KPZ package includes a culturally adapted approach to a co-designed safety plan. The assigned Peers will provide safety planning and Brief Contact Follow-Up. Contact follow up sessions will occur at the household level.
41331221|NCT01494415|DRUG|Paclitaxel for Injection（Albumin Bound）|concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
41331222|NCT01494415|DRUG|carboplatin|concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
41331223|NCT01494415|RADIATION|thoracic radiation therapy|66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
41482298|NCT00809965|DRUG|Rivaroxaban 2.5 mg|One tablet twice daily
41482299|NCT00809965|DRUG|Rivaroxaban 5 mg|One tablet twice daily
41482300|NCT00809965|DRUG|Placebo|One placebo tablet twice daily
41482301|NCT00809965|DRUG|Standard of care|
40813683|NCT06208293|BEHAVIORAL|Enhanced Usual Care (EUC)|Participants receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
40813684|NCT02382029|DRUG|Clonazepam|Active medical treatment for burning mouth syndrome
41482302|NCT05916521|DRUG|0.454% stannous fluoride|Brush two times daily
41482303|NCT05916521|DRUG|0.76% sodium monofluorophosphate|Brush two times daily
41482304|NCT05916521|DRUG|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
40813685|NCT02382029|OTHER|acupuncture|Traditional chinese acupuncture
40813686|NCT02485249|DRUG|Dexamethasone Phosphate Ophthalmic|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
40813687|NCT02110654|DRUG|Montelukast|
40813688|NCT02110654|DRUG|mometasone furoate nasal spray|
40918294|NCT00975897|GENETIC|fluorescence in situ hybridization|
40918295|NCT00975897|GENETIC|gene expression analysis|
40918296|NCT00975897|GENETIC|mutation analysis|
40918297|NCT00975897|GENETIC|protein expression analysis|
40918298|NCT00975897|OTHER|diagnostic laboratory biomarker analysis|
40918299|NCT00975897|OTHER|immunohistochemistry staining method|
40918300|NCT00975897|OTHER|questionnaire administration|
40918301|NCT00975897|PROCEDURE|cognitive assessment|
41482305|NCT00273741|DRUG|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
41482306|NCT00273741|DRUG|placebo comparator|placebo capsules
41482307|NCT02405949|GENETIC|Genetic test|Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
41482308|NCT02439203|DRUG|JM-010|
41482309|NCT02439203|DRUG|Placebo|
41482310|NCT01857960|BEHAVIORAL|Survey|A survey is directly applied to subjects who meet the inclusion and exclusion criteria
41482311|NCT00438477|DRUG|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
40813689|NCT03892057|BEHAVIORAL|Internet-based Positive Psychological Intervention|"The investigator's culturally-tailored internet-based Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well- being, e.g., mindfulness/meditation. The current 5-week Internet-based intervention will be delivered via a secure website which participants will access at home (or in a public setting with Wi-Fi) using an assigned username and password. The on-line program includes didactic material and home practice with participants logging into the website 3-4 times per week for 15 to 20 minute sessions. In addition to weekly on-line instruction, participants are assigned homework as a means of incorporating skills learned into their day-to-day activities."
40813690|NCT06090981|DRUG|Bovine surfactant|Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
41482312|NCT00438477|PROCEDURE|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
41482313|NCT00438477|RADIATION|Technetium Tc 99m sulfur colloid|"At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection."
41482314|NCT00111358|BEHAVIORAL|Lifestyle Modification|
41331224|NCT05260606|DIAGNOSTIC_TEST|F-18 FDG PET/CT|"1. 1st scan: pre-Tx, ICI Tx must be started within 35 days after 1st scan.~2. 2nd scan: interim~   * Pembrolizumab or atezolizumab: after the 2nd Tx cycle to before the start of the 3rd Tx cycle~  * Nivolumab: after the 3rd Tx cycle to before the start of the 4th Tx cycle~3. 3rd scan: optional (3rd scan can be performed when disease progression is suspected)~4. Imaging~   * Fasting: at least 6 hours~  * Blood glucose level: \< 200 mg/dL~  * F-18 FDG 0.14 mCi/kg (IV)~  * Image acquisition: 1 hr after FDG injection, CT images are acquired. After CT scan, PET images are acquired and attenuation-corrected PET images are reconstructed based on the CT image data.~  * PET/CT: Discovery MIDR or MI (GE Healthcare, Chicago, Illinois, USA)~  * First and second scans have to be performed with same scan."
41331225|NCT04919772|OTHER|Assessment|The participants walk 4-meter and 10-meter and 5-repetition sit-to-stand twice.
41482315|NCT00111358|OTHER|No lifestyle modification|
40813691|NCT04731298|DRUG|Emapalumab|"Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first."
40918302|NCT04405466|PROCEDURE|Blood sampling|Blood samples
40918303|NCT04405466|PROCEDURE|Throat swab|Throat swab
41012803|NCT06162741|BEHAVIORAL|Moving Forward (MF)|"Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act. The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion."
41155864|NCT02264717|PROCEDURE|Cardiac MRI|Patients are randomized to either SPECT or Cardiac MR
41155865|NCT05804526|DRUG|RC88|1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
41155866|NCT05804526|DRUG|Sintilimab Injection|Sintilimab 200mg by intravenous (IV) infusion，every 3 weeks
41482316|NCT03169920|PROCEDURE|Modified-Minimally Invasive Surgical Technique + PRF|
41482317|NCT03169920|PROCEDURE|Modified-Minimally Invasive Surgical Technique|
41155867|NCT00509925|DRUG|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
41482318|NCT05517161|BEHAVIORAL|INSIGHT|See Keegan et al., 2020
41482319|NCT01355354|DRUG|Digoxin|oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15
41331226|NCT00004898|BIOLOGICAL|filgrastim|
41331227|NCT00004898|DRUG|cyclophosphamide|
41331228|NCT00004898|DRUG|etoposide|
41331229|NCT00004898|PROCEDURE|peripheral blood stem cell transplantation|
41331230|NCT00004898|RADIATION|radiation therapy|
41482320|NCT01355354|DRUG|Fostamatinib|oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
41482321|NCT02071953|DEVICE|Experimental adhesive w/out phosphoric acid in post. rest.|Experimental adhesive without phosphoric acid in posterior restorations
41482322|NCT02071953|DEVICE|Experimental adhesive with phosphoric acid in post. rest.|Experimental adhesive with phosphoric acid in posterior restorations
41331231|NCT03345992|DRUG|Clarithromycin|Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
41331232|NCT03345992|DRUG|Water for injection|Water for injection 20 ml will be administered, diluted in D/W 5%, IV, once daily for four consecutive days
41331233|NCT01803711|DRUG|Desvenlafaxine|
41331234|NCT01803711|DIETARY_SUPPLEMENT|Omega 3 Fatty acids|
41331235|NCT01803711|DRUG|Placebo (for Omega 3 fatty acid supplement)|
41482323|NCT03987594|PROCEDURE|Transurethral fulguration of the Hunner lesion|Hunner lesion of the bladder is fulgurated with electronic surgical device under cystoscopic inspection. For the intervention, general or spinal anesthesia is required.
41482324|NCT03987594|PROCEDURE|Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion|Prior to Hunner lesion fulguration, bladder hydrodistension is performed for 8 minutes at pressure of 80cmH2O. And then transurethral fulguration is performed on the Hunner lesion.
41155868|NCT00509925|DRUG|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
41331236|NCT03228394|DRUG|Ganaxolone|Ganaxolone IV
41331237|NCT03228394|DRUG|Placebo|Placebo IV
41331238|NCT02061748|DRUG|Observational|Retrospective Chart Review
41331239|NCT00750178|DRUG|vorinostat (MK0683 )|"Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days"
41331240|NCT06149689|COMBINATION_PRODUCT|mFOLFIRINOX plus radiotherapy|Patients with advanced pancreatic adenocarcinoma will receive a modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 4\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.
41482325|NCT05800574|RADIATION|Radiation therapy (5 days for 7 weeks)|Mon-Fri (5 days for 7 weeks), total 35 fractions over 35 treatment days of radiation therapy (RT)
41155869|NCT00509925|DRUG|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
41155870|NCT02270463|DRUG|Tagraxofusp-erzs|Tagraxofusp-Erzs administered by IV infusion at doses of 7, 9, and 12 µg/kg/day
41155871|NCT06182800|DRUG|Adebrelimab Combined with Bevacizumab and Docetaxel|"Adebrelimab: 1200 mg Adebrelimab is given on day 1 of each cycle, with 1 dosing cycle every 3 weeks. The dosing time window may be ±5 days, but within 72 hours before each dose, subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing, in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.~Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle, with 1 dosing cycle every 3 weeks.~Docetaxel: 60-75 mg/m2 Docetaxel is given on days 1 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks."
41331241|NCT00510484|DRUG|Pancrelipase Delayed Release|24000 unit Capsule
41331242|NCT00510484|DRUG|Placebo Comparator|Placebo
41482326|NCT05800574|RADIATION|Radiation therapy (5 days for 6 weeks)|Mon-Fri (5 days for 6 weeks), total 35 fractions over 30 treatment days of RT (two doses 6 hours apart except for the last 6th Friday of the 6 weeks )
41482327|NCT05800574|DRUG|Cisplatin|Cisplatin, 40mg/m2 (weekly for 7 weeks)
41482328|NCT03185013|BIOLOGICAL|VGX-3100|1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
40813692|NCT04711369|DEVICE|Erbium:Yag laser|"Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2.~All sensitive/painful areas of the introitus will be treated, using 1-3 repetitions.~In postmenopausal women with signs of atrophy, additional irradiation of the vaginal wall will be performed."
40813693|NCT04711369|DEVICE|Sham Erbium:Yag laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same procedures. However, a specially devised placebo probe with a steel shutter, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic irradiation. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
40813694|NCT06125236|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
41482329|NCT03185013|BIOLOGICAL|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
41482330|NCT03185013|DEVICE|Electroporation (EP)|Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
41482331|NCT03458637|BEHAVIORAL|LITE Program and Usual Care|Family based lifestyle Intervention
40813695|NCT01591954|DEVICE|Video Augmentation|Assessment of value of video-based navigation system
40813696|NCT04695600|DRUG|Botulinum Toxin Type A Injection [Botox]|100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
40813697|NCT02377752|BIOLOGICAL|Olaratumab|Administered IV
41482332|NCT03458637|BEHAVIORAL|Usual Care|Usual care consisting of 3 visits to weight management clinic
41482333|NCT02470793|PROCEDURE|Descemet Stripping Automated Endothelial Keratoplasty|Descemet Stripping Automated Endothelial Keratoplasty
41482334|NCT02470793|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|Descemet Membrane Endothelial Keratoplasty
41482335|NCT01068379|PROCEDURE|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
41482336|NCT01068379|PROCEDURE|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
41482337|NCT05862194|DRUG|Lazertinib|Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
41482338|NCT05862194|DRUG|Platinum-based Chemotherapy|Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
41482339|NCT00845975|DEVICE|Erchonia Hearing Lasers #1 & #2|"Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.~Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site."
41482340|NCT00845975|DEVICE|Placebo Lasers|The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
40813698|NCT02377752|DRUG|Doxorubicin|Administered IV
40813699|NCT05968261|PROCEDURE|Real time 'near remote' guidance of regional blocks|Trainees who are to perform regional blocks will do so under expert guidance via tele-mentoring. This will be done using a novel technology consisting of a wirelessly linked iPad which will display the ultrasound image to the block operator/trainee. This image will be concurrently visualized by an expert mentor through their smartphone, who will then provide feedback/guidance in real-time to the operator/trainee.
40813700|NCT02141633|PROCEDURE|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
40813701|NCT02141633|PROCEDURE|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
41155872|NCT05686681|BEHAVIORAL|Brief Behavioral Activation for Improving Social Connectedness|"Brief Behavioral Activation for Improving Social Connectedness (BBAISC): BBAISC was developed to address social connectedness. Grounded in Behavioral Activation (Lejuez et al., 2011), BBAISC is a structured, 6-session skill-building intervention that has 4 key elements (Pepin et al., 2020):~1. Psychoeducation: Psychoeducation focused on homebound status, social connectedness, and associated changes in behavior.~2. Behavioral Activation intervention rationale: Framing how changing behavior can positively impact social connectedness (i.e., improve social connectedness and reduce loneliness).~3. Exploration of life areas, values, and activities: Focused on identifying life areas and values most relevant to the participant. Then, these values are used to generate activities that are aligned with those values.~4. Activity monitoring and planning: Participants are encouraged to schedule and organize their day based on what is important rather than their current mood or feeling state."
41155873|NCT02177435|DRUG|Telmisartan|
41155874|NCT02177435|DRUG|Telmisartan/Hydrochlorothiazide|
41482341|NCT00431782|DRUG|ATI-5923|
41482342|NCT02302521|DEVICE|Multiplex Sensitivity Encoding (MUSE)|It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
41482343|NCT00252174|DRUG|Stage 1 Active Methylenedioxymethamphetamine|"Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
40918304|NCT01429025|BIOLOGICAL|rituximab|IV
40813702|NCT02141633|DRUG|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
40813703|NCT02141633|DRUG|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
40813704|NCT01273116|OTHER|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~* will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~* a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~* will be discussed at least once in a multidisciplinary meeting;~* a structured medication review will be carried out by a geriatrician;~* is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~* may receive a consult of a geriatrician, if judged necessary;~* will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
40813705|NCT04815512|DIAGNOSTIC_TEST|Liver function tests.|serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.
40813706|NCT04815512|DIAGNOSTIC_TEST|kidney function tests|creatinine , urea and serum uric acid will be analysed in the serum.
40813707|NCT04011826|DEVICE|Device: Trial nasal mask (F&P)|This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
40813708|NCT00882583|DRUG|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
40813709|NCT00882583|DRUG|Dasatinib|Oral Dasatinib Days 8 through 64.
40813710|NCT00882583|DRUG|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
40813711|NCT00882583|RADIATION|Radiation Therapy|Standard Radiation Therapy.
40813712|NCT06302426|DRUG|INI-4001|INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.
40813713|NCT06302426|COMBINATION_PRODUCT|Nivolumab|During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.
40813714|NCT06302426|COMBINATION_PRODUCT|Pembrolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
41155875|NCT02177435|DRUG|Placebo|
41155876|NCT05935683|OTHER|Severe Uncontrolled Chronic Rhinosinusitis patients (CRS)|Obsertvation
41155877|NCT06329531|OTHER|Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)|Given by Questionnaire
41155878|NCT03965468|DRUG|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.
41155879|NCT03965468|DRUG|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
40813715|NCT06302426|COMBINATION_PRODUCT|Cemiplimab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
40813716|NCT06302426|COMBINATION_PRODUCT|Avelumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
40813717|NCT06302426|COMBINATION_PRODUCT|Atezolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
40813718|NCT06302426|COMBINATION_PRODUCT|Durvalumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
40813719|NCT03620578|DRUG|DA-EPOCH-R followed by Nivolumab|5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
40813720|NCT00451009|DEVICE|Viacell's product Media Kits|
41155880|NCT03965468|DRUG|Paclitaxel|A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
41155881|NCT03965468|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT of all oligo-metastatic lesions
41155882|NCT03965468|PROCEDURE|Surgical resection - definitive local treatment.|Surgical resection of primary tumour for patients with single station, non-bulky tumours.
41155883|NCT03965468|RADIATION|Radical radiotherapy - definitive local treatment.|Conventional or moderately hypo-fractionated radiotherapy to the primary tumour for other tumour stages, or in case of medical inoperability.
40813721|NCT06130449|DRUG|Natesto testosterone intranasal gel|A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
40813722|NCT06130449|DRUG|Ayr Saline Nasal Gel|A single dose of Ayr (one spray per nostril) will be administered to each participant.
40813723|NCT04251299|BEHAVIORAL|home-based, mentored vegetable gardening program|The mentored vegetable gardening program pairs each participant with a certified Master Gardener. The participant/Master Gardener dyads work together to plan, plant and tend to a vegetable garden at the participant's home throughout the year. Gardening supplies, plants and seeds are provided.
40813724|NCT02017938|PROCEDURE|Virtual Reality anti-fatigue ergo cycling training (Self-made)|To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
40813725|NCT00924430|DRUG|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
40813726|NCT00924430|DRUG|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
41331243|NCT04820153|DEVICE|Physical Activity Monitoring Device|Participants will be provided a Fitbit Alta HR and wall charger. Each participant will be assigned a unique ID# at baseline and used to set-up the data acquisition. The Fitbit app will be set up on their smartphone to allow self-monitoring of activity. The Fitbit device includes both an accelerometer and heart rate monitor, capable of continuous measuring and storing data up to 5 days. Fitbit data will be passively downloaded through smartphone connection to Fitabase, a research friendly application and data management program. The Fitbit will be worn on the wrist every day during the course of the 16-week study, with instructions on self- monitoring, usage and maintenance. Participants will be monitored for Fitbit compliance by weekly phone calls; and monitoring of passively downloaded Fitbit data through Fitabase. Follow-up phone call at 3-months post-study will assess continued use of the Fitbit activity monitor.
41331244|NCT04820153|BEHAVIORAL|Lifestyle Redesign Coaching|Participants will receive individualized goal setting and a guide to increase exercise at baseline and at week four visit. The Occupational therapist (OT) will administer a well published approach for promoting PA called Lifestyle Redesign which addresses physical, psychosocial and environmental barriers to health and incorporate self-care strategies and goal setting. Coaching will be administered by a bilingual OT and in Spanish. Based on studies examining PA and brain health, the OT will guide the participant through a goal setting process for moderate to vigorous intensity of physical activity including a specific guide plan to achieve these goals of 10,000 steps per day and/or 150 minutes/week of moderate to vigorous activity. Participants will also receive weekly calls from the study coordinator (overseen by OT) to review PA and goal setting for each week over the course of the 16-week study.
41331245|NCT04656288|DRUG|BI 764198 - Formula A|BI 764198
41331246|NCT04656288|DRUG|BI 764198 - Formula B|BI 764198
40813727|NCT01542697|DRUG|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
40813728|NCT03922347|DIAGNOSTIC_TEST|Screening program including 2 consecutive tests|visual acuity test by Snellen chart, fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)
41331247|NCT04656288|DRUG|BI 764198 - Formula C|BI 764198
40813729|NCT03922347|DIAGNOSTIC_TEST|Screening program with mobile health|Peek Acuity and Peek Retina installed on smart phones (Samsung Galaxy S8)
40813730|NCT00822419|DRUG|lidocaine|lidocaine cream 5%
40813731|NCT00822419|DRUG|ketamine|ketamine 5%
40813732|NCT00822419|DRUG|non-drug cream|will be put on the skin
40813733|NCT06383247|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
40813734|NCT03632993|DRUG|collagenase clostridium histolyticum (CCH)|Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.
41331248|NCT04656288|DRUG|BI 764198 - Formula D|BI 764198
40813735|NCT06170346|COMBINATION_PRODUCT|Antioxidants|30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%, Hydroxyectoine 0,01%, and vehicle) will be applied on tested area on each participant for four consecutive days.
40813736|NCT06170346|COMBINATION_PRODUCT|Vehicle|30 drops of topical vehicle (Aqua, Dipropylene glycol, Hydroxypropyl cyclodextrin, Polydextrose, 1,2-hexanediol, Butylene glycol, Propanediol, Caprylhydroxamic acid, Ethylhexylglycerin, Xanthan gum, Benzyl alcohol, Glyceryl caprylate, and Benzoic acid) will be applied on tested area on each participant for four consecutive days.
40813737|NCT01216709|DIETARY_SUPPLEMENT|ferrous sulfate|6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
40813738|NCT01216709|OTHER|iron-fortified infant formula (12.4 mg iron/L)|6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
40813739|NCT01216709|OTHER|iron-fortified infant formula (2.3 mg iron/L)|1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
40813740|NCT04319341|OTHER|To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS|ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.
40813741|NCT05617066|BEHAVIORAL|Cognitive behavioral therapy|With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
40813742|NCT05658159|DIAGNOSTIC_TEST|Vitamin D|Finger stick capillary blood sampling using test from ZRT Laboratories, Beaverton, OR
40813743|NCT05658159|DIAGNOSTIC_TEST|DXA scan|10 minute scan using scanner by GE Lunar, Madison, WI
40813744|NCT05658159|OTHER|Nutrition analysis|Analysis of 24-h recalls will be conducted by a registered dietician using Nutritionist Pro software by Axxya Systems, Redmond, WA
40813745|NCT02010333|DRUG|Ha44 Gel 0.74% w/w|HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
40813746|NCT03091998|DRUG|CD-NP|Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days
40813747|NCT03091998|OTHER|Placebo|Participants will receive an \~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
40813748|NCT04034719|OTHER|portage scarf|Parents will be carried their newborn with the portage scarf provided by the department.
40813749|NCT04034719|OTHER|usual practice|Parents will be carried their newborn as their usual practice.
40813750|NCT06329752|PROCEDURE|Ultrasound-guided Sciatic Nerve block (20 mL of 2% Lidocaine)|Patients will be scanned with the ultrasound machine to determine the technical feasibility of sciatic nerve blocks. If feasible, one of the following techniques will be performed a) popliteal sciatic nerve block, with either lateral or posterior approach; b) CAPS (crosswise approach to popliteal sciatic) block, with either lateral to medial or anterolateral to posteromedial approach; c) subgluteal sciatic nerve block; d) transgluteal sciatic nerve block. In all cases, 20 mL of 2% Lidocaine will be used.
40813751|NCT05222893|DIAGNOSTIC_TEST|Respiratory monitoring|Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation
40813752|NCT05222893|DIAGNOSTIC_TEST|Capnography|Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute
40813753|NCT05222893|DIAGNOSTIC_TEST|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
40813754|NCT05222893|DEVICE|Esophageal pressure|Measurement the pressure in the lower third of esophagus during inspiration and expiration
40813755|NCT06396169|OTHER|Yoga Exercise|Yoga Exercises
40813756|NCT06396169|OTHER|Calisthenic Exercise|Calisthenic Exercises
40813757|NCT04607512|DRUG|telaglenastat|glutaminase inhibitor
40813758|NCT04607512|OTHER|telaglenastat placebo|matching placebo for telaglenastat
40813759|NCT04607512|OTHER|moxifloxicin|positive control
40813760|NCT04693273|OTHER|Decision Aid for Surgical Modality Choice|A novel decision aid that helps surgical patients choose between Wide-Awake carpal tunnel release and traditional tourniquet surgery. It involves an orientation-memory-concentration test to test if patients are cognitively capable of making decisions, then the decision aid table that has similarities and differences between the two modalities, and a few survey questions that help the investigators know what the patients prefer. Finally, patients finish the decision conflict test to see how confident these patients are about their preference.
41331249|NCT03794713|DEVICE|Patient support tool|The patient support tool, a software app installed on the smart phones plus a wrist connected to the smart phones by Bluetooth. The wrist could monitor the pulse, which was recorded to the app in the smart phone. Meanwhile, the app could inform to patients about the importance of medication, remind on the medicine intake, share the patients' data with themselves, and warn the patients if the wrist don't wear.
41331250|NCT05186012|DRUG|APG-1252|APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.
40813761|NCT01905228|DRUG|CBL0137|"All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops"
40813762|NCT02309983|OTHER|Electrical Stimulation|Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.
40813763|NCT02309983|OTHER|Stand Retraining with Body Weight Support (BWS)|Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
40813764|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)|"Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
40813765|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B|"Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
40918305|NCT01429025|DRUG|bendamustine|IV
41331251|NCT05186012|DRUG|Chidamide|Chidamide 30mg orally BIW. Every 28 days as a cycle.
41331252|NCT06238115|DRUG|Tirofiban|Initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.
41331253|NCT06238115|DRUG|aspirin, clopidogrel|aspirin 100 mg/day, clopidogrel 75 mg/day
41331254|NCT02840526|PROCEDURE|Paravertebral blockade (PVB)|preoperative ThPVB performed unilaterally at Th10 level
41331255|NCT02840526|DRUG|Sopodorm|midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
41331256|NCT02840526|DRUG|Propofol WZF|propofol 2 mgkg-1intravenously (anesthesia induction)
41331257|NCT02840526|DRUG|Nimbex|cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
41331258|NCT02840526|DRUG|Fentanyl WZF|fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
41331259|NCT02840526|DRUG|Sevorane|sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
41331260|NCT02840526|DEVICE|Intubation|Intratracheal intubation with a single lumen endotracheal tube
41331261|NCT02840526|DRUG|Oxynorm|1 mgml-1 concentration oxycodone solution intravenously
41331262|NCT02840526|DRUG|Paracetamol Kabi|1g paracetamol intravenously every 6 hours
41331263|NCT02840526|DRUG|Ketonal|100 mg ketoprofen intravenously every 12 hours
41331264|NCT02840526|DRUG|Bupivacaine WZF|0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
41331265|NCT00443937|DRUG|enteric-coated mycophenolate sodium|oral
40813766|NCT04026009|DRUG|Placebo|Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
40813767|NCT04961541|BIOLOGICAL|ICC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
40813768|NCT04961541|BIOLOGICAL|qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
40813769|NCT04961541|BIOLOGICAL|SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
40813770|NCT04418492|BEHAVIORAL|Skills for Adaptive Functioning through Executive training (SAFE; tentative title)|An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
40813771|NCT04544930|BEHAVIORAL|therapist-guided|Therapist-guided Internet treatment comprises eight text modules on the Internet that include psychoeducation, tasks and exercises. Key elements are setting goals for treatment, identifying and challenging negative automatic thoughts through a number of exercises and behavioral experiments, as well as making a plan for relapse prevention. Therapist guidance is secondary to the self-help modules, and the therapist provides feedback to the patient online in the secured program once a week
40813772|NCT05927675|BEHAVIORAL|Physical activity|"The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises.~During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements."
40813773|NCT01841125|DRUG|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
40813774|NCT01841125|DRUG|Placebo|placebo 15mg, QD(once a day), Oral medication
40813775|NCT04860557|OTHER|cognitive skill, dual task and physical activity assessment|Montreal Cognitive Assessment Test, Trail Making Test (TMT) A \& B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
40813776|NCT06267469|DEVICE|Thermoplastic orthosis|The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.
41331266|NCT00443937|DRUG|everolimus|oral
41331267|NCT06449846|DIAGNOSTIC_TEST|circulating tumor cell DNA detection|circulating tumor DNA blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
41482344|NCT00252174|DRUG|Stage 1 Low dose Methylenedioxymethamphetamine|"Drug:~Dosage form: capsule~Dosage frequency and duration for the control arm (4 subjects):~Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg."
41482345|NCT00252174|BEHAVIORAL|Psychotherapy|Psychotherapy conducted with low or active dose MDMA
41482346|NCT00252174|DRUG|Stage 2 Active Methylenedioxymethamphetamine|"Administered open label Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
41482347|NCT05058534|DEVICE|Multiline Neo®|Multiperfusion neonatal system
41482348|NCT01159782|OTHER|Rhinovirus infection|All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
40813777|NCT03155087|DRUG|Metformin|
40918306|NCT01429025|DRUG|lenalidomide|PO
40918307|NCT06326983|DRUG|Dexmedetomidine|Dexmedetomidine (1mcg/kg bolus given intravenously at induction of anesthesia
41482349|NCT01634282|DRUG|OPC-262|Orally administered once daily
41482350|NCT05893381|DRUG|[177Lu]Lu-PSMA I&T|The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
41482351|NCT05893381|RADIATION|Stereotactic Radiotherapy|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
41482352|NCT02485821|DRUG|Estradiol|
41331268|NCT01089816|BIOLOGICAL|Local/Regional Public Health Notification|For any H5 positive results, notification of the result to the site's local/regional public health authorities.
41482353|NCT02485821|DRUG|Placebo|
41331269|NCT05308615|DIETARY_SUPPLEMENT|Rhea® Health Tone|Rhea® Health Tone
41331270|NCT01544686|DEVICE|3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV|Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
41331271|NCT00869219|DRUG|Nevanac|1 drop of NEVANAC at random eye
41331272|NCT00869219|DRUG|Acular LS|One drop of Acular LS
41331273|NCT01612442|BEHAVIORAL|nutrition and agricultural education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
41482354|NCT02485821|DRUG|Misoprostol|
41482355|NCT03738410|BEHAVIORAL|Mobile Health Messaging application|Mobile messaging sent to participants over a 12-month period.
40813778|NCT04627324|DEVICE|The smart toothbrush and smart mirror (STM) system (XiuSolution, Gyeonggi-do, Korea)|"The STM system comprises a smart mirror, which is integrated into a computer monitor, and a 3D motion-capture device inside of a modified toothbrush holder. The computer program displays a toothbrushing animation in the mirror. Toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis.~(used only during the test visits)~Participants had to brush their teeth at home (using toothbrushes with a flat-trimmed nylon bristle of identical type and length.) for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
40813779|NCT04627324|DEVICE|Conventional toothbrush|"toothbrushes with a flat-trimmed nylon bristle of identical type and length.~Participants had to brush their teeth at home for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
40813780|NCT00072930|BIOLOGICAL|MEDI-522|IV at a concentration of 50 mg/mL and 10mL vials
40813781|NCT00072930|BIOLOGICAL|Docetaxel + Prednisone* + Zoledronic Acid|IV 75 mg/m2 IV 3-4 mg 5 mg
40813782|NCT03539211|OTHER|Rotation Exercises|The subjects received 7 trunk rotation stability exercises x 10 reps each
40813783|NCT03539211|OTHER|Control Exercises|The subjects received 7 traditional exercises x 10 reps each
40813784|NCT02833090|PROCEDURE|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
40813785|NCT06398730|DRUG|GEH200520 Injection and GEH200521 (18F) Injection|Administration of GEH200520 Injection followed by GEH200521 (18F) Injection
41482356|NCT03738410|OTHER|Standard of Care Treatment|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat HIV/AIDS. SOC associated procedures and policies may vary across clinical settings.
41482357|NCT01916746|PROCEDURE|transvaginal resection of pregnancy tissue|Patient were under general anaesthesia, placed in a dorsal lithotomy position and the bladder emptied. Expose, grasp and traction the cervix. And adrenaline (600 ug/l; 10-20 ml) was injected submucosally at the level of the cervicovaginal junction. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted into the vaginal incision to retract the bladder upwards. The CSP was identified as a'purple bulge' located in the anterior part of the lower uterine segment. A transverse incision was made over the most prominent area of the bulge. Ectopic pregnancy tissue inside the bulge was removed, and suction curettage through the incision on the uterus isthmus was subsequently performed. The edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed with a continuous locking suture using 2-0 absorbable sutures.
41482358|NCT00853086|DRUG|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
40813786|NCT06398730|DIAGNOSTIC_TEST|Static - PET/CT scan|Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection
40813787|NCT02319616|DRUG|Clobetasol 0.05% ointment|Blinded, daily application to one arm for a period of fourteen (14) days
40813788|NCT02319616|DRUG|Placebo|Blinded, daily application to one arm for a period of fourteen (14) days
40813789|NCT00979966|DRUG|Temsirolimus|25 mg intravenously, once weekly infusion
40813790|NCT00979966|DRUG|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
40813791|NCT06442007|BEHAVIORAL|Behavioral Activation - single session intervention (BA-SSI)|Single session intervention
40813792|NCT06442007|BEHAVIORAL|4-session Mindset intervention|This is comprised of 4 sessions.
40813793|NCT05566691|OTHER|Positive thinking|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts.
41331274|NCT01612442|BEHAVIORAL|nutrition education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
41331275|NCT02279979|DEVICE|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
41331276|NCT05301803|DEVICE|Electrophysiology procedure|Electrophysiology testing and cardiac ablation of arrhythmia
41331277|NCT02264171|DRUG|Tamsulosin HCl|
41331278|NCT02264171|DRUG|Ketoconazole|
40813794|NCT05566691|OTHER|Positive thinking + Mood induction|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
40813795|NCT05566691|OTHER|Thought reevaluation|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts.
40813796|NCT05566691|OTHER|Thought reevaluation + Mood induction|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
40813797|NCT05414448|DEVICE|ENDOCUFF|ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
40918308|NCT06326983|DRUG|Acetaminophen|Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia).
40918309|NCT06326983|DRUG|Ketorolac|Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.
41331279|NCT04446442|DEVICE|tDCS|A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.
41331280|NCT02929862|DRUG|LYC-55716|For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
41331281|NCT01579149|DRUG|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
41331282|NCT01579149|DRUG|Placebo|Single subcutaneous (SC) dose of placebo
40918310|NCT06326983|DRUG|Morphine|Morphine (0.1mg/kg given intravenously at induction of anesthesia)
40813798|NCT03670654|OTHER|Pilates|The Pilates exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. The first two weeks will be spent learning the technique and, in the third week, patients will receive an exercise booklet for in-home training. Will be used the classical solo Pilates exercises, adapted for non-trained individuals. Before and after each session, patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
40813799|NCT03670654|OTHER|Muscle stretching|The muscle stretching exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. Patients will practice muscle stretching exercises for principal muscle groups, performed with 3 repetitions, 15 seconds sustain and 1 minute interval. Before and after each session, the patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
40813800|NCT02463084|OTHER|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
41012804|NCT06236958|DEVICE|Transnasal jejunal tube|A naso-jejunal tube was placed in the operation, which is placed 15 cm below Traitz's ligament. A short-peptide enteral nutrient solution was heated by an enteral nutrient pump and infused into the patients within 24 hours after the operation. Before and at the end of the infusion, physiological saline was given to flush the tube, and at the end of the infusion, the catheter was closed to prevent liquid reflux and blockage of the tube. The catheter should be clamped shut at the end of the infusion. During the infusion period, the patient's gastrointestinal tolerance was dynamically evaluated. According to the results of a regular review of nutritional indicators, including hemoglobin, albumin, electrolytes, liver and kidney function, etc., increase the amount of enteral nutrients; remove the nasojejunal tube when the patient has no abdominal distension after exhaustion and feeding; and change to feeding through the mouth.
41012805|NCT06236958|OTHER|Transvenous access|A uniform drip of nutritional solution was started 24 hours postoperatively. Configuration of nutritional solution: glucose and medium/long-chain fat emulsion as the main energy substances to provide calories, calculated at 30 \~ 35 kcal/(kg-d), glucose-fat ratio is 6:4, pancreatic glucose ratio for those without a history of diabetes mellitus is 1:6 \~ 8, and for diabetic patients depending on the level of glucose, pancreatic glucose ratio is 1:3 \~ 4, and then assisted with subcutaneous injections of insulin to control glucose, if necessary. Pay attention to the total amount of rehydration fluid, electrolytes, vitamins, and trace elements supplemented. Mix the nutrient solution evenly in the laminar flow clean table and infuse it through the route at 2500\~3000 ml/d; the infusion time is 8\~12 h/d. After exhaustion, start to eat through the mouth.
41012806|NCT05757375|OTHER|Mulligan Manuel Therapy Consept|Mulligan ankle taping is a noninvasive, painless, low-cost, and easily applicable technique of the Mulligan manual therapy concept. It is frequently used in cases of ankle instability. In healthy people, it is a method to prevent ankle sprains.
40813801|NCT02463084|OTHER|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
41012807|NCT02985242|DRUG|Empagliflozin|Empagliflozin film-coated tablet
41012808|NCT02985242|DRUG|Glimepiride|Glimepiride tablet
41012809|NCT02985242|DRUG|Empagliflozin placebo|Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
40813802|NCT01410175|DEVICE|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
40813803|NCT03655301|DRUG|Copanlisib (Aliqopa, BAY80-6946)|"The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8."
41012810|NCT02985242|DRUG|Glimepiride placebo|Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
41012811|NCT03211741|DRUG|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
41012812|NCT03966235|DRUG|Melatonin 3 mg|Melatonin was taken daily for 6 months.
40813804|NCT03655301|DRUG|Metformin|Single dose of 1000 mg is administered orally.
40813805|NCT04736368|OTHER|EDIP Diet Suggestions|CD participants will receive EDIP diet suggestions after random allocation.
41012813|NCT03966235|DRUG|Placebo|Placebo tablet was taken daily for 6 months.
41012814|NCT06164873|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362
41012815|NCT06164873|DRUG|Placebo|Once-weekly injections of volume-matched placebo
40813806|NCT04736368|OTHER|diet guidance|Control group will be given diet guidance according to routine experience under the participant's request.
41155884|NCT03965468|DRUG|Tremelimumab|Tremelimumab is a human mAb of the IgG 2 subclass that is directed against CTLA-4 (CD152), a cell surface receptor that is expressed primarily on activated T-cells and acts to inhibit their activation. Tremelimumab completely blocks the interaction of human CTLA-4 with CD80 and CD86, resulting in increased release of cytokines (interleukin-2 and IFN-γ) from human T-cells, peripheral blood mononuclear cells and whole blood.
40813807|NCT05169229|DRUG|Vancomycin + Tobramycin|1 g vancomycin (powder) diluted in 8 ml tobramycin (80mg/ml). Added to the prepared allograft before the allograft is used during the revision surgery.
40813808|NCT05169229|DRUG|Saline|As a placebo added to the allograft.
40813809|NCT04158037|BEHAVIORAL|mHealth App|The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station). If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.
40813810|NCT01490008|DRUG|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
40813811|NCT01490008|OTHER|Green Tea|"Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals"
40813812|NCT05970614|OTHER|Eye masks and ear plugs|Eye masks and ear plugs will be applied to patients for 3 days between 22:00 and 06:00.
40813813|NCT00597623|OTHER|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
40813814|NCT00597623|OTHER|Placebo|syringes under cutaneous vol = 8 ml
40813815|NCT02425228|DEVICE|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
40813816|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
40813817|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan to determine the actual AUC achieved using the population PK.
40813818|NCT05577312|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
41331283|NCT06045728|OTHER|Pilates exercises|Pilates is a group of low impact muscle exercises that strengthen abdominal muscles, back, hips and pelvic floor muscles. the exercise consists of 10 min warm up, 40 min exercise and 10 min cooling down. the exercises that will be included: spine twist, double leg stretch, double leg circles, side leg circle, curl up, shoulder bridges and pelvic curl.
41331284|NCT06045728|BEHAVIORAL|Mediterranean diet|it is a type of diet used for obesity management based on high vegetable intake, olive oil as a source of fat, the consumption of grains, legumes, and nuts with high amounts of pulp, low-medium consumption of fish, low consumption of red meat.
40813819|NCT02367001|OTHER|Normal invitation|No modification and signed by the coordinating doctor as usual
41012816|NCT01153035|DEVICE|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
40813820|NCT02367001|OTHER|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
40813821|NCT02367001|OTHER|Revised invitation signed by the attending physician|signature typed or typed + handwritten
40813822|NCT02010242|DRUG|GKT137831|1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
40813823|NCT02010242|DRUG|Placebo|1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
40813824|NCT00003191|DRUG|fenretinide|
40813825|NCT00260767|DRUG|HEC placebo gel|
40813826|NCT01222091|DRUG|Propranolol|Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
41012817|NCT01945515|DEVICE|tDCS|tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.
41331285|NCT00215241|DRUG|sertraline and risperidone|
41331286|NCT03528824|OTHER|Fenugreek wrap|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
41331287|NCT03528824|DRUG|Diclofenac Gel|Daily application of diclofenac gel, 4 weeks application
41331288|NCT02855112|BIOLOGICAL|Adipose derived mesenchymal stem cell|Allogeneic Adipose derived Mesenchymal Stem cell transplant
40813827|NCT01222091|DRUG|Placebo to Match Propranolol|
40813828|NCT01222091|DRUG|Remifentanil|Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
40813829|NCT02420288|BEHAVIORAL|Exercise Group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
40813830|NCT06331286|DRUG|dulaglutide injection|0.75mg Subcutaneous injection once a week for 24 weeks
40813831|NCT03418311|DEVICE|Cervical Pessary-Group|Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
40813832|NCT02930382|OTHER|Baroreflex assessment|
40813833|NCT05206188|BEHAVIORAL|Mastering the World of Work (MWW)|Mastering the World of Work (MWW) is a 29-session individual intervention comprised of 7 modules each covered in 4 sessions, and a wrap-up session. Participants in the randomized clinical trial will be offered to meet on a weekly basis with the MWW clinician assigned to work with them.
40813834|NCT02227082|RADIATION|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
40813835|NCT02227082|DRUG|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
40813836|NCT02895672|DRUG|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
41331289|NCT01398527|OTHER|Educ sessions & LTC Osteoporosis toolkit|Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
41331290|NCT04734977|DEVICE|High-intensity laser therapy (HILT)|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session.
40813837|NCT02645877|PROCEDURE|Prehospital care|The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
40813838|NCT06125925|PROCEDURE|Radiofrequency catheter ablation (RFCA)|Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
40813839|NCT06125925|DRUG|Medical Therapy|AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
40813840|NCT02352454|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
40813841|NCT05551923|OTHER|intestinal flora disturbance|To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
40813842|NCT00036855|BIOLOGICAL|rituximab|Given IV
40813843|NCT00036855|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
40813844|NCT00036855|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
40813845|NCT00036855|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
40813846|NCT00036855|BIOLOGICAL|filgrastim|Given subcutaneously
40813847|NCT00036855|OTHER|laboratory biomarker analysis|Correlative studies
40918311|NCT06317545|OTHER|Mulligan Taping|Mulligan taping involves the application of tape to the lateral aspect of the elbow to offload stress during movement of the extensor tendons.
41331291|NCT04734977|DEVICE|Sham high-intensity laser therapy (Sham HILT)|Sham High intensity laser therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device using a HIRO 3 device (ASA Laser, Arcugnano, Italy).
41331292|NCT04734977|OTHER|Therapeutic Exercise|"As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
40813848|NCT05155761|DEVICE|FeetMe® Monitor|"Each patient will be asked to go to 3 visits at the Cochin hospital, and to wear the soles after each of these visits during 3 days, at home, to record the data, so that it reflects walking patterns of the patient in his/her daily life and activities.~At each visit, clinical tests to assess fall risk will be performed (Timed Up and Go test, one foot stance, Short Physical Performance Battery and 6 minutes walking test ).~The patients will be supplied with a pair of FeetMe® Monitor insoles, return home and walking parameters will be recorded for 3 to 10 consecutive days."
41482359|NCT04275726|DEVICE|Myval THV Series|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
40813849|NCT02521753|DRUG|Metformin|Intervention also includes weight reduction diet and exercise therapy
40813850|NCT02521753|DIETARY_SUPPLEMENT|Magnesium|Intervention also includes weight reduction diet and exercise therapy
40813851|NCT02521753|DIETARY_SUPPLEMENT|PUFA|Intervention also includes weight reduction diet and exercise therapy
40813852|NCT03789136|OTHER|Not applicable, observational study|Not applicable, observational study
40813853|NCT02643615|DEVICE|VEP under TIVA|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
40813854|NCT02643615|DEVICE|VEP under balanced anesth.|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
41482360|NCT04275726|DEVICE|Contemporary Valves (Sapien THV Series and Evolut THV Series)|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
40813855|NCT02643615|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
41331293|NCT00004604|BIOLOGICAL|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
41482361|NCT06312514|BEHAVIORAL|LAFIYA|The Lafiya intervention is a comprehensive program designed to address the intersectional stigma and discrimination challenges faced by marginalized communities, particularly among Gay, Bisexual, and other Men who have Sex with Men (GBMSM). It aims to enhance HIV prevention, care, and treatment outcomes, with a focus on increasing HIV self-testing (HIVST) uptake among these key populations in Ghanaian urban slum settings.
41482362|NCT01101204|DRUG|Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg|Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
41482363|NCT04463498|BEHAVIORAL|Group-based cognitive behavioral therapy for insomnia|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques
41482364|NCT04463498|BEHAVIORAL|Group-based cognitive behavioral therapy for insomnia and additive bb-glasses|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques, bb-glasses worn from 3 hrs before bedtime.
40813856|NCT02643615|DRUG|Desflurane|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
41012818|NCT01945515|DEVICE|Robotic-assisted gait training|Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
41482365|NCT04463498|OTHER|8-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
40918312|NCT00947960|DRUG|Triheptanoin|1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
40918313|NCT00947960|OTHER|Vegetable Oil|1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
41012819|NCT00229684|DRUG|Tesaglitazar|2 mg once daily in oral form
41012820|NCT00229684|DRUG|pioglitazone|45 mg once daily in oral form
41012821|NCT00072345|DRUG|lomustine|
41012822|NCT00072345|DRUG|temozolomide|
41012823|NCT00072345|DRUG|thalidomide|
41012824|NCT00456092|DRUG|Apremilast|Capsules for oral administration
41012825|NCT00456092|DRUG|Placebo|Capsules for oral administration
40813857|NCT03574610|DEVICE|Transcranial Rotating Permanent Magnet Stimulator (TRPMS)|"TRPMS is a wearable non-invasive transcranial rotating permanent magnet stimulator. It has been determined to be a Non Significant Risk device by the FDA.~The amount and frequency of therapy are prescribed by the physician, and the device is custom configured to the patient to deliver the required amount of treatment. The device does not turn on until it is time for the treatment. It consists of three main parts: Neoprene cap with microstimulator(s), stimulator console (device controller box) and the tablet with TRPMS app which activates the console. The neoprene cap prevents the microstimulator(s) from coming in direct contact with the scalp. Microstimulators deliver the magnetic stimulation to the brain based on a prescription program uploaded in the stimulator controller."
40813858|NCT00510718|DRUG|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
40813859|NCT00308412|BIOLOGICAL|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
40813860|NCT00308412|BIOLOGICAL|Placebo|Placebo for rHPIV3cp45 vaccine
40813861|NCT00962741|DRUG|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
40813862|NCT02896491|RADIATION|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
40813863|NCT05803863|DRUG|Myatro|myopia control with 0.01% atropine drops
40813864|NCT05803863|DRUG|Myatro XL|myopia control with 0.05% atropine drops
40813865|NCT05223907|DRUG|Etomidate|Etomidate will be used for general anesthesia
40813866|NCT05223907|DRUG|Propofol|Propofol will be used for general anesthesia
40813867|NCT01032954|DRUG|Botulinum toxin|"Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~* Crow's feet wrinkles - 70 units~* Glabella - 50 units~* Forehead - 40 units~Mid face:~* Lower eyelid - 5 units~* Nasal wrinkles - 20 units~* Malar wrinkles - 10 units~Lower face:~* Peri-oral wrinkles - 15 units~* Asymmetric smile or gummy smile - 5 units~* Cellulitic chin - 20 units~* Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs."
40813868|NCT04105348|DIAGNOSTIC_TEST|HbA1c|patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2
40813869|NCT03183258|OTHER|Sentinel skin flap|Donor-derived vascularised composite allograft (sentinel skin flap)
40813870|NCT04637724|DEVICE|transcranial direct current stimulation (tDCS)|10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
40813871|NCT01824654|OTHER|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
40813872|NCT01824654|OTHER|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
40813873|NCT05556291|DRUG|Combinations of Oral Blood Glucose Lowering Drugs|Combination of Ertugliflozin and Sitagliptin
41155885|NCT01861795|OTHER|Preterm Neonates|Preterm Neonates
41331294|NCT00374270|BEHAVIORAL|Lifestyle Counselling; Opinion Leader Influence Statements|
40813874|NCT04015427|DEVICE|implant crown|After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
40813875|NCT03415451|DEVICE|Fiberscope-Guided Nasogastric tube insertion|Fiberscope-Guided Nasogastric tube insertion
40813876|NCT01541943|DRUG|Atorvastatin|Once daily, administered orally, 8 week
40813877|NCT01541943|DRUG|Losartan|Once daily, administered orally, 8 week
41155886|NCT02825719|DRUG|Ulipristal acetate|Ulipristal acetate 5mg daily will be prescribed
41331295|NCT02567357|BEHAVIORAL|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
41482366|NCT05432193|DRUG|[Ga-68]-PNT6555|\[Ga-68\]-PNT6555 IV administered as imaging agent for PET/CT
41482367|NCT05432193|DRUG|[Lu-177]-PNT6555|Patients with FAP-avid disease as determined by the \[Ga-68\]-PNT6555 screening PET/CT will receive \[Lu-177\]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.
41012826|NCT02598349|RADIATION|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
41012827|NCT02598349|DRUG|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
41012828|NCT02598349|PROCEDURE|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
41012829|NCT01863446|DEVICE|Lighting1|Ocular light exposure to a red wavelength light
41012830|NCT01863446|DEVICE|Lighting2|Ocular light exposure to a blue/green wavelength light
41012831|NCT04142541|DEVICE|Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System)|The Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection is indicated for improving the carotid luminal diameter in patients with clinically significant carotid artery stenosis and for the simultaneous capture and removal of embolic material during angioplasty and stenting.
41331296|NCT02567357|BEHAVIORAL|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
41331297|NCT01015820|PROCEDURE|EGD with EUS|EUS was performed in order to measure blood flow in duodenum.
41482368|NCT00080405|DRUG|Bortezomib|
41331298|NCT01015820|DEVICE|4D-ELF|During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
40813878|NCT01541943|DRUG|Placebo|Once daily, administered orally, 8 week
40813879|NCT01541943|DRUG|HL-040XC|Once daily, administered orally, 8 week
41155887|NCT02825719|OTHER|Placebo pills|Placebo pills will be prescribed
41482369|NCT01687582|DRUG|GLP-1 analog|GLP-1 analog treatment
41155888|NCT02825719|DRUG|Ferrous sulphate|Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
41155889|NCT02825719|DRUG|Tranexamic Acid|Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
41331299|NCT05444413|BIOLOGICAL|ultrasound-guided platelet rich plasma nerve block|selected persons are treated by ultrasound-guided platelet rich plasma nerve block and the regular medicine
41331300|NCT02268071|DRUG|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence|For patients with average of HBPM values \<135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
41482370|NCT01044654|GENETIC|SB-728-T|Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
41482371|NCT01069952|DEVICE|Deep Brain Stimulation System|In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
41331301|NCT01196312|BEHAVIORAL|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
41482372|NCT02759770|OTHER|no intervention|This is a clinical observational study, no intervention was included.
41482373|NCT05144347|DRUG|XL114|Tablets of XL114
41482374|NCT05362721|DIAGNOSTIC_TEST|Pressure-volume loop catheter|The cardiac catheterization procedure will be done according to standard protocol as part of the standard clinical care. This has become the standard of care in any patient in which it feasible and is performed with low risk.
41482375|NCT03236948|BEHAVIORAL|Women for Women International Intervention|
41482376|NCT05625087|DRUG|Alpelisib|Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days
41482377|NCT05625087|DRUG|Ribociclib|Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days
40813880|NCT04271488|DRUG|Tasurgratinib|Tasurgratinib oral tablet.
40813881|NCT04271488|DRUG|Tasurgratinib|Tasurgratinib oral capsule.
40813882|NCT00431522|DRUG|Valproic acid, sodium salt|
40813883|NCT03424967|BEHAVIORAL|ABM|Participants are trained with a dot-probe task including angry-neutral faces. In 80% of trials the probe appears in place of the neutral face, and in 20% of trials in place of the angry face.
40813884|NCT01443364|BIOLOGICAL|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
40918314|NCT04444856|DRUG|Eptacog alfa (activated)|The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
40918315|NCT04444856|OTHER|Standard of care|The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.
40918316|NCT02735135|DEVICE|AIRSOFT DUO for 1 day|The patient is placed on an AIRSOFT DUO mattress for 1 day.
40918317|NCT02735135|DEVICE|SENTRY 1200 for 1 month|The patient is placed on a SENTRY 1200 mattress for 1 month.
40918318|NCT02735135|DEVICE|SENTRY 1200 for 1 day|The patient is placed on a SENTRY 1200 mattress for 1 day.
40918319|NCT02735135|DEVICE|AIRSOFT DUO for 1 month|The patient is placed on an AIRSOFT DUO mattress for 1 month.
40918320|NCT02935283|PROCEDURE|MRI|MRI, fMRI, 1H MRS, DTI
41482378|NCT01592136|DRUG|ponatinib|Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
40813885|NCT05108454|DRUG|Multiple micronutrient supplementation|Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
40813886|NCT00122876|PROCEDURE|Photodynamic therapy|
40813887|NCT00122876|DRUG|Talaporfin Sodium|
40813888|NCT01066104|DRUG|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
40813889|NCT01066104|DRUG|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
40813890|NCT05514756|DEVICE|Active t-VNS|Active t-VNS at 8 Hz for up to 60 minutes will be applied to the left cymba conchae
40813891|NCT05514756|DEVICE|Sham t-VNS|Sham t-VNS at 8 Hz for up to 60 minutes will be applied to the left earlobe
40813892|NCT05514756|OTHER|Baseline assessments|Baselines assessments with no stimulation will serve as control in this three-part crossover design
40813893|NCT06028152|OTHER|"End-of-life conversation game called Hello"|"To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~Other Name: Previously named My Gift of Grace"
41482379|NCT06392204|PROCEDURE|CAD/CAM patient specfifc fracture reduction/plate guide and customized 3D grid plate|Mandibular angle fracture reduction and fixation using digitally designed and fabricated patient specific fracture reduction/plate positioning guide and customized 3D grid plate
41482380|NCT06392204|PROCEDURE|Champy's techqniue|Mandibular angle fracture reduction and fixation using a single superior border 2.0 miniplate
41482381|NCT05450328|DRUG|Combined Epoprostenol Sodium & Milrinone|"One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
41482382|NCT05450328|DRUG|Normal saline|"The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
41482383|NCT05513287|OTHER|On the period of covid 19|In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section
41482384|NCT04870723|BEHAVIORAL|eHealth for Covid-19 prevention and support|3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
41482385|NCT05768659|BEHAVIORAL|Fear Conditioning|"It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested.~Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered."
41482386|NCT01432574|BIOLOGICAL|Gardasil|The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
41482387|NCT01091272|DRUG|PF-04995274|Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
41482388|NCT01091272|DRUG|PF-04995274|Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
41482389|NCT01091272|DRUG|PF-04995274|Planned single PO 120mg and 210mg doses of PF-04995274
41482390|NCT01091272|DRUG|PF-04995274|single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
41482391|NCT00973765|DRUG|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
41482392|NCT00973765|DRUG|placebo|placebo 2 pills po BID x 7 days
40813894|NCT01667224|DIETARY_SUPPLEMENT|Actiponin|The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
40813895|NCT01667224|DIETARY_SUPPLEMENT|Placebo|Amount and calorie of placebo are same with Actiponin.
40813896|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
40918321|NCT02935283|BEHAVIORAL|Behavioral|Battery of executive function tasks
40813897|NCT04278768|DRUG|Venetoclax|Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.
41331302|NCT03380000|DRUG|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
40813898|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
40813899|NCT02539199|DRUG|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
40813900|NCT02539199|DRUG|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
40813901|NCT04342026|OTHER|Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors|Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
40813902|NCT04300361|GENETIC|Sequencing of DPYD gene|The DPYD gene of non-Western patients will be sequenced to identify DPYD variants that are possibly associated with an increased risk of developing severe fluoropyrimidine-related toxicity.
40813903|NCT03724383|BEHAVIORAL|Risk Factor Management Consult|Participants may be referred to an Internist to control risk factor management - this may require monthly visits until risk factor targets have been met.
40813904|NCT03724383|BEHAVIORAL|Diet Classes|Group nutrition sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention) delivered by a registered dietitian.
40813905|NCT03724383|BEHAVIORAL|Stress Management Classes|Group sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention). Techniques taught will include awareness, coping, and relaxation strategies.
40813906|NCT03724383|OTHER|Exercise Classes|Group sessions delivered two times per week (1 hr each), over 3 month period (months 3-6). Classes will include high intensity interval training, resistance training.
40813907|NCT03724383|OTHER|Home based exercise program|The interval and resistance training program will mirror the supervised exercise.
40813908|NCT03305549|OTHER|Conservative dialysis strategy|"Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):~* Blood urea nitrogen \>112 mg/dL (40 mmol/L)~* Serum potassium concentration \>6 mmol/L~* Serum potassium concentration \>5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)~* Arterial blood gas pH \<7.15 in a context of pure metabolic acidosis (PaCO2 \<35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate \<12 mmol/L~* Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate \>5 L/min to maintain SpO2 \>95% or requiring FiO2 \>50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy"
40813909|NCT03305549|OTHER|TIW dialysis strategy|Thrice-weekly acute intermittent hemodialysis schedule.
40813910|NCT03316287|DEVICE|Hearing aid|Smart hearing aid to allow collection of real time hearing aid usage data
40813911|NCT03316287|DEVICE|Mobile phone|Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests
40813912|NCT03316287|DEVICE|Sensor|Wearable biosensor for the collection of physiological data
40813913|NCT02778555|BEHAVIORAL|Questionnaires|
40813914|NCT03287934|DEVICE|selective laser sintered stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
40918322|NCT02862756|OTHER|diffusion-weighted MRI and clinical examination|
41331303|NCT03380000|DRUG|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
41331304|NCT03970707|OTHER|Small Number of Players training protocol A|8 participants each side game (4vs4), size of pitch area 25\*20 m. In total, 6 consecutive 4-minutes bouts interspersed by a 3-minutes rest between each bout will be executed.
41331305|NCT03970707|OTHER|Large Number of Players training protocol B|16 participants each side game (8vs8), size of pitch area 25\*20 m. In total, 3 consecutive 8-minutes bouts interspersed by a 1-minutes rest between each bout will be executed.
41331306|NCT06311357|DIETARY_SUPPLEMENT|Ensure|Ensure 6 scoops dietary supplement powder in 250 ml of water, 2 drinks per days for 12 weeks.
41331307|NCT05340062|DEVICE|bedside sonography|TCD and ONSD sonography twice a day per 2 days
41482393|NCT03623464|OTHER|Mobile health application and Fitbit + standard of care|Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
41482394|NCT03623464|OTHER|Standard of care|Post-operative standard of care information
41482395|NCT03634345|DRUG|Period 1 - Day 1: PF-04965842 administered|Period 1: Single administration of 100 mg PF 04965842.
41331308|NCT01152489|DEVICE|Device: Buzzy|"Buzzy, the vibrating cold pack, is held in place with a velcro strap or pressed by caretaker or nurse immediately prior and during immunizations. The vibration is activated and the device remains in place during the shot, moving locations if multiple shots are given. Distraction cards with pictures on one side and questions on the other are shown to the child while the caretaker asks the finding and seeking questions on the back."
41482396|NCT03634345|DRUG|Period 2: Cohort 1: Fluvoxamine & PF-04965842|Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
41482397|NCT03634345|DRUG|Period 2: Cohort 2: Fluconazole & PF-04965842|Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
40813915|NCT03287934|DEVICE|digital light processing(dlp)|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with digital light processing technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
40813916|NCT02427386|DRUG|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
40813917|NCT02427386|DRUG|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
41331309|NCT01152489|DEVICE|Buzzy: sham device|The identical device without batteries or a cold pack is held in place proximal to the site with a velcro strap or pressed by parent or nurse immediately prior to immunizations. The device remains in place throughout the procedure, moving locations to complete multiple shots.
40813918|NCT02995161|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-106)
40813919|NCT02995161|DRUG|SPF control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
40813920|NCT00666588|DRUG|idarubicin|Given IV
40813921|NCT00666588|DRUG|cytarabine|Given IV or IT
41331310|NCT05612594|DRUG|Bexagliflozin 20 mg|15mg once daily
41331311|NCT05612594|DRUG|Placebo|matching placebo once daily
41331312|NCT03667508|PROCEDURE|Rapid Maxillary Expanding Device|The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.
41331313|NCT03667508|PROCEDURE|Slow Maxillary Expanding Device|The expansion screw will be activated every five days until correcting the crossbite.
41331314|NCT02994381|DRUG|RPC1063|
41331315|NCT06402279|DEVICE|Efferon CT|"Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross- linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.~Hemoperfusion procedures were performed using the Efferon CT device no later than 6 hours after the start of invasive ventilation. Hemosorption was performed twice within 12 hours, with an interval of 24 hours between hemoperfusion."
41482398|NCT05278572|BEHAVIORAL|Stress Management and Relaxation Training/Expressive Supportive Therapy (SMART/EST)|Cognitive-behavioral stress management/expressive supportive therapy (CBSM+) group targeting depression
41482399|NCT06265207|OTHER|Virtual reality|Before the mammography, a 20-minute relaxing video featuring nature and forest views will be watched with VR SHINECON 360 degree glasses. Since it is seen in the literature that watching a video for 20 minutes provides effective results, the video viewing time was determined as 20 minutes.
41482400|NCT06265207|OTHER|routine maintenance|routine maintenance
41482401|NCT02487381|DRUG|delta-9-tetrahydrocannabinol|
41482402|NCT02487381|DRUG|Cannabidiol|
41482403|NCT02487381|DRUG|Placebo|
41482404|NCT03966391|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
41482405|NCT03185403|OTHER|paravertebral block|in the paravertebral block , the catheter was placed under ultrasound echography , at the right thoracic T4/T5 level
41482406|NCT03185403|OTHER|thoracic epidural block|in the epidural block the catheter was inserted without echography , at T4/T5 level
41482407|NCT03185403|DRUG|ropivacaine|
41482408|NCT03185403|DRUG|Sufentanil|
41482409|NCT01554826|BIOLOGICAL|Influenza Split Vaccine|0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart
41482410|NCT01554826|BIOLOGICAL|Inactivated Influenza Vaccine|0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
41482411|NCT00015028|DRUG|Buprenorphine/naloxone|
41482412|NCT05372783|DRUG|STI-9199|STI-9199 is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
41482413|NCT05372783|DRUG|Placebo|Diluent solution
41482414|NCT00003638|BIOLOGICAL|Detox-B adjuvant|
40813922|NCT00666588|DRUG|bortezomib|Given IV
40813923|NCT00666588|DRUG|etoposide|Given IV
40813924|NCT00666588|OTHER|laboratory biomarker analysis|Correlative studies
40918323|NCT01502215|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
41482415|NCT00003638|BIOLOGICAL|THERATOPE STn-KLH vaccine|
41482416|NCT00003638|BIOLOGICAL|keyhole limpet hemocyanin|
41482417|NCT00003638|DRUG|cyclophosphamide|
41482418|NCT03231319|PROCEDURE|Fascia iliaca compartment block with IV-PCA|1. Fascia iliaca compartment block: The injection was performed under ultrasound guidance. Surface landmark is identified on the line between anterior superior iliac spine and pubic tubercle. The injection site is at the medial one-third of the line. The needle is threaded medial to lateral and standardization of local anesthetic deposit is in the fascia plane between fascia iliaca and iliacus muscle. Anesthetic regimen: 2% xylocaine 15mL + 0.5% bupivacaine 15mL.
41331316|NCT01306032|DRUG|ABT-888|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
41331317|NCT01306032|DRUG|Cyclophosphamide|
41331318|NCT05721196|BEHAVIORAL|Culturally adapted Psychoeducation (CaPE)|This intervention consisted of 12 psychoeducation sessions, one session per week, that would be administered on an individual patient basis and to be added to treatment as usual. Each session lasted for approximately 1 h, beginning with a 20-30 min presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for relapse). The content is a reduced and modified version of the Barcelona Psychoeducation Program for bipolar disorders.
41331319|NCT05721196|DRUG|Treatment as Usual (TaU)|This group of patients will receive routine treatment, which in Nigeria means attending the outpatient clinic and taking prescribed medication.
41331320|NCT04819581|DRUG|SP-103|lidocaine topical system 5.4%
41331321|NCT04819581|DRUG|ZTlido|lidocaine topical system 1.8%
41331322|NCT00716339|BEHAVIORAL|motivation|
41331323|NCT01817114|DEVICE|Auto Remote Ischemic Conditioning (AutoRIC) device|
41331324|NCT01192711|DEVICE|Diabetes Interactive Diary (DID)|DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.
41331325|NCT01250457|DRUG|topical Timolol|topical Timolol 0.5% solution applied twice daily
41331326|NCT01221818|DRUG|E6007|E6007 25mg single dose or matching placebo
41331327|NCT01221818|DRUG|E6007|E6007 50mg single dose or matching placebo
41331328|NCT01221818|DRUG|E6007|E6007 100mg single dose or matching placebo
41331329|NCT01221818|DRUG|E6007|E6007 200mg single dose or matching placebo
41331330|NCT01221818|DRUG|E6007|E6007 400mg single dose or matching placebo
41331331|NCT01221818|DRUG|E6007|E6007 600 mg single dose or matching placebo
41331332|NCT01280019|PROCEDURE|alveolar recruitment manoeuvre|Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
40918324|NCT01502215|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
41012832|NCT06032286|DEVICE|Skinstylus microneedling device|Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.
41012833|NCT00000327|DRUG|Heroin Dependence|
41331333|NCT05201768|OTHER|balance tests,questionnaire|Individuals will be tested and recorded.
41155890|NCT05621720|OTHER|Case management|On enrolment, the nurse case manager will perform the initial comprehensive assessment based on the Omaha domains of environment, psychosocial, physiological and health-related behavior. The nurse case manager will execute the intervention scheme of teaching, guidance \& counseling, treatments \& procedure, case management, and/or surveillance, with the mutual goal set with clients to promote health and self-efficacy. Home visits and telephone calls will be employed. The referral network to health and social service will be activated as appropriate.
41331334|NCT05323487|DRUG|Bumetanide Injection|Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
41331335|NCT01269047|DRUG|Pramlintide|Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
41331336|NCT01269047|DRUG|Exenatide|Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
41331337|NCT01269047|DRUG|Insulin|Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
41331338|NCT04146051|DRUG|Descartes-08|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
41482419|NCT03231319|PROCEDURE|Femoral nerve block and lateral femoral cutaneous nerve with IV-PCA|"1. Femoral nerve block: The injection was performed under ultrasound guidance. Femoral nerve was identified in the femoral neurovascular bundle below or around inguinal ligament. The needle is threaded with lateral to medial approach. Local anesthetics will be deposited around the femoral nerve, the standardization of protocol is that femoral nerve should be lifted off from iliacus muscle. Anesthetic regimen: 2% xylocaine 10mL + 0.5% bupivacaine 10mL.~2. Lateral femoral cutaneous nerve block: The injection was performed under ultrasound guidance. Lateral femoral cutaneous nerve was identified in the fascia plane between sartorius muscle and tensor fascia lata muscle. Anesthetic regimen: 2% xylocaine 5mL + 0.5% bupivacaine 5mL"
41482420|NCT03231319|PROCEDURE|IV-PCA|IV-PCA was programmed and provided to the patient for optimize pain control
41331339|NCT03652272|BEHAVIORAL|EMC2|"1. Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~2. Patients will receive a Medication Guide + Summary with their After Visit Summary~3. Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~4. Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
41331340|NCT00094835|BIOLOGICAL|Panitumumab|9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
41155891|NCT05621720|OTHER|Social control call and usual are|Subjects in the control group will receive usual community service. in addition, a monthly social control call from trained community workers will be given to rule out the possible social effects of the intervention. These social calls will not be related the participants' health condition nor delivery of any health information.
41331341|NCT00094835|DRUG|Motesanib diphosphate|Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
41331342|NCT00094835|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 administered by IV infusion over 3 hours.
41331343|NCT00094835|DRUG|Carboplatin|Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
41331344|NCT02665195|OTHER|saliva specimen|
41331345|NCT02665195|BEHAVIORAL|questionnaire|
41331346|NCT00443846|BIOLOGICAL|RotaTeq®|Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.
41331347|NCT00443846|BIOLOGICAL|NeisVac-C®|Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.
41331348|NCT04571008|OTHER|Placebo|Intervention will last at least 16 weeks in the form of two capsules.
41331349|NCT04571008|DIETARY_SUPPLEMENT|Treatment|Intervention will last at least 16 weeks in the form of two or three NMN capsules (total of 300 or 450 mg/day).
41331350|NCT03983213|PROCEDURE|mpfl reconstruction|Harvested gracilis tendon is pulled through patella and femur in anatomic position and locked with interference screw.
41331351|NCT00004210|OTHER|loss of heterozygosity analysis|
41331352|NCT00004210|OTHER|microsatellite instability analysis|
41331353|NCT00004210|OTHER|mutation analysis|
41331354|NCT00004210|OTHER|counseling intervention|
41331355|NCT03504436|DEVICE|LEO +|LEO +: self-expanding intracranial stent
41482421|NCT05518630|BEHAVIORAL|Nomothetic Versus Idiographic Assessment in Chronic Pain|Participants with either endometriosis, vulvodynia, and/or fibromyalgia will answer a twice-daily diary for 42 days and a short weekly diary six times in total. In addition, they will answer two longer surveys at the start and at the end of the 42 days. These questionnaires ask about psychological flexibility, depression, catastrophizing, and pain interference. The data collected is only observational and does not include any intervention.
41482422|NCT06337825|BEHAVIORAL|Activity Tracker (Fitbit)|Wearable, activity tracker
41482423|NCT06337825|DIAGNOSTIC_TEST|HbA1C|Average blood glucose (sugar) levels reported as a percentage
41482424|NCT06337825|BEHAVIORAL|The PROMPT Questionnaire|The PROMPT Questionnaire which is a 30-question previously validated assessment for non-specific symptoms in PHPT, will be administered to patients preoperatively and at 2-weeks and 6-months postoperatively
41482425|NCT02605798|DRUG|Elbanovir|1 tablet contains 400 mg sofosbuvir
41482426|NCT02605798|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
41482427|NCT02605798|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
41331356|NCT05702398|DRUG|Vitamin A|1,000 μg retinyl palmitate twice a day for 6 months
41331357|NCT05702398|DRUG|Nicotinamide|500 mg NAM twice a day for 6 months
41155892|NCT06028230|DRUG|SAR444656 (KT-474)|Oral Tablet
41482428|NCT00003034|DRUG|doxorubicin hydrochloride|Given IV
41482429|NCT00003034|DRUG|ranpirnase|Given IV
41482430|NCT03501836|DEVICE|Rapid Rhythm Handheld 8-lead ECG Device|"We want to explore whether using 6 electrodes on the chest (as in the Rapid Rhythm Handheld 8-lead ECG device) can give the same diagnostic result to the standard 10 electrode (12-lead) ECG, which uses 6 chest electrodes plus 4 electrodes on the arms and legs.~To do this we need to compare measurements taken with the 6 electrode (8 lead) study device to those taken with the gold-standard 10 electrode (12 lead) method.~We want to find out whether the new equipment can detect the same heart rhythms as the standard method, so that ECG measurements might be made more quickly and easily in the future."
41482431|NCT04083586|OTHER|All investigations; laboratory and radiological, needed for diagnosis|mri brain, ct brain, drug screening
41155893|NCT06028230|DRUG|Placebo|Oral Tablet
41155894|NCT01596634|OTHER|questionnaire administration|Ancillary studies
41155895|NCT01596634|PROCEDURE|quality-of-life assessment|Ancillary studies
41331358|NCT05702398|OTHER|Other: Placebo|Identical placebo pills twice a day
41331359|NCT00852319|BEHAVIORAL|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
41331360|NCT00852319|BEHAVIORAL|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
41482432|NCT04612517|DRUG|ZP7570|Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.
41482433|NCT04612517|DRUG|Placebo|Placebo; corresponding volume
41155896|NCT01596634|OTHER|laboratory biomarker analysis|Correlative studies
41155897|NCT01596634|DIETARY_SUPPLEMENT|bovine lactoferrin|Given PO
41155898|NCT00035061|DRUG|pemetrexed|
41331361|NCT01022645|DEVICE|Mirena (Levonorgestrel IUD)|Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
41331362|NCT01022645|DEVICE|Paragard (Copper IUD ) or Tubal Ligation|Copper IUD placed to provide contraception for up to 10 years
41331363|NCT05294341|DRUG|Norethindrone Acetate 5 MG|As specified in arm design
41331364|NCT05294341|DRUG|Norethindrone 0.35 MG|As specified in arm design
41331365|NCT03758872|DIAGNOSTIC_TEST|cuff assisted colonoscopy(with cuff use of endocuff vision second generation)|this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps
41331366|NCT02566616|DEVICE|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
41482434|NCT01316302|DRUG|Pristiq|Flexible dose, 50-100mg QD, for 12 weeks.
41482435|NCT01316302|DRUG|Placebo|Matching placebo, taken QD for 12 weeks.
41482436|NCT03016221|OTHER|Axanova hot gel|Axanova hot gel is a topical product with a warming effect. It contains menthol, pine needle oil, wintergreen oil, rosemary oil, eucalyptus oil, incense oil.
40813925|NCT04056520|DEVICE|Medtronic Infinity Occipitocervical-Upper Thoracic System using the O-arm Imaging System and StealthStation Navigation system|"The INFINITY™ OCT System is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for the following acute and chronic instabilities of the craniocervical junction, the cervical spine (C1 to C7), and the thoracic spine from T1-T3:~* Traumatic spinal fractures and/or traumatic dislocations.~* Instability or deformity.~* Failed previous fusions (e.g. pseudarthrosis).~* Tumors involving the cervical spine.~* Degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/ or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability."
40813926|NCT06298617|PROCEDURE|Diagnostic laparoscopy|All women will undergo exploratory laparoscopy under general anesthesia
40813927|NCT06298617|DIAGNOSTIC_TEST|Full Blood Count (FBC)|Blood samples withdrawn from patients on EDITA tubes and gone through full blood count and differential leucocytic count
40813928|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
40813929|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
40813930|NCT01538979|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
40813931|NCT02681796|DRUG|Bupivacaine|
41482437|NCT03016221|OTHER|Axanova activ gel|Axanova activ gel is a topical product with a revulsive effect. It contains menthol, pine needle oil, orange oil, lemon oil, wintergreen oil, glycosaminoglycans.
40813932|NCT05529277|OTHER|Dementia Care Management|Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
40813933|NCT00144989|DRUG|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
41331367|NCT04447118|DRUG|Pyrotinib|400 mg, once daily (QD), will be administered with water within 30 minutes after completion of a meal, at approximately the same time each day on a continuous daily dosing schedule, with 21 days as a cycle.
41331368|NCT04447118|DRUG|Docetaxel|75 mg/m2, once every 3 weeks (Q3W), will be administered by intravenous infusion over 1 hour, with 21 days as a cycle.
41331369|NCT00832312|OTHER|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
41331370|NCT00832312|OTHER|placebo (saline)|Injection of 1cc of saline into the knee joint
41331371|NCT03725293|DEVICE|Angiodynamics BioFlo Midline Catheter|Placement of Angiodynamics BioFlo Midline Catheter.
41331372|NCT03725293|DEVICE|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
41331373|NCT04675736|PROCEDURE|brushing force|Using duplication method, vertical force was applied from 1-5.5 N in linear mesial-distal brushing motion at 4 strokes per second for 5 seconds Force was increase 0.5 N in every testing until plaque was completely removed from enamel surface
41482438|NCT03016221|OTHER|Perskindol Dolo Gel|Perskindol Dolo Gel is a topical product with a warming effect. It contains wintergreen oil, pine needle oil, aromatics, excipients.
41482439|NCT03016221|OTHER|Perskindol Classic Gel|Perskindol Classic Gel is a topical product with a revulsive effect. It contains menthol, wintergreen oil, pine needle oil, lemon oil, orange peel oil, lemon bergamot oil, rosemary oil, lavender oil, excipients.
41482440|NCT03016221|OTHER|Perskindol Cool Kühl-Gel|Perskindol Cool Kühl-Gel is a topical product with a cooling effect. It contains levomenthol, color E131, aromatics, excipients.
41482441|NCT03016221|OTHER|Dolor-X Hot Gel|Dolor-X Hot Gel is a topical product with a warming effect. It contains isopropyl alcohol, water, menthol, hyprolose, camphor, trometamol, paprika, wintergreen oil, excipients.
40813934|NCT00144989|DRUG|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
40813935|NCT03558269|BIOLOGICAL|Autlogous UCB infusion|Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
40813936|NCT00198393|DRUG|Gefitinib|250 mg/day, until progression
40813937|NCT00198393|DRUG|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
40813938|NCT00198393|DRUG|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
40813939|NCT04461691|PROCEDURE|Cryoballoon Pulmonary Vein Isolation|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
40813940|NCT00733291|DEVICE|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
40813941|NCT00733291|DEVICE|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
40813942|NCT00733291|DEVICE|FID 107027 solution|Commercially marketed solution for contact lens disinfection
40813943|NCT03220477|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
40813944|NCT03220477|DRUG|Guadecitabine|Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
41331374|NCT02691481|DIETARY_SUPPLEMENT|Oatmeal breakfast|
41331375|NCT02691481|DIETARY_SUPPLEMENT|Glucerna formula|
41331376|NCT02691481|DIETARY_SUPPLEMENT|Ultra Glucose Control formula|
41331377|NCT04157075|DRUG|Bupivacaine|Bupivicaine injection into uterosacral ligaments prior to colpotomy
41482442|NCT03016221|OTHER|Dolor-X Classic Gel|Dolor-X Classic Gel is a revulsive product. It contains water, isopropyl alcohol, menthol, spruce, hyprolose, trometamol, wintergreen oil, excipients.
41482443|NCT03016221|OTHER|Dolor-X Cool Gel|Dolor-X Cool Gel is a cooling product. It contains water, isopropyl alcohol, menthol, trometamol, color E131, excipients.
41331378|NCT02820558|DRUG|Substance P|
41482444|NCT03477019|DRUG|SonoVue|"consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol."
41482445|NCT03477019|PROCEDURE|Focused Ultrasound|ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
41482446|NCT00646620|DRUG|budesonide/formoterol (Symbicort)|
41482447|NCT00646620|DRUG|fluticasone/salmeterol (Advair Diskus)|
41482448|NCT00646620|DRUG|albuterol (Ventolin)|
41482449|NCT03642782|DEVICE|Electroretinogram Pattern (Diopsys® NOVA System)|it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
41482450|NCT03124862|DEVICE|ARM sensor|Acoustic Monitoring sensor that monitors respiratory rate
41482451|NCT04629261|BEHAVIORAL|Use of ECOBICI (public bicycle sharing program)|Use of ECOBICI program with and without incentive.
41482452|NCT05237440|BIOLOGICAL|Biological dosage|Metabolic, hormonal and psychometric evaluations will be carried out during inclusion inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out at inclusion
40813945|NCT03220477|DRUG|Mocetinostat|Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
41331379|NCT03620253|DRUG|Modafinil|Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
41331380|NCT03620253|DRUG|Placebo|Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
41331381|NCT02971527|DEVICE|Oste-scan 500A|The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).
41482453|NCT06331000|DRUG|elexacaftor-tezacaftor-ivacaftor treatment|Effect of one year elexacaftor-tezacaftor-ivacaftor treatment on glucose tolerance abnormalities in adult patients with cystic fibrosis
41331382|NCT02971527|DEVICE|SONOST3000|The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.
41482454|NCT04695756|OTHER|COVID-19 pandemic|The exposure of this observational study is the COVID-19 pandemic
41482455|NCT03602040|BEHAVIORAL|PISICC|"PISICC consists of:~1. Standard disease-specific information leaflet~2. Personalised lifestyle consideration form~3. 1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c)."
41482456|NCT04192123|DEVICE|HM242|HM242-Solution and HM242-Gel will be topically applied in an occlusive patch for 48h on healthy skin on the subject's outer part of the upper arm.
41482457|NCT00825136|BEHAVIORAL|relaxation|Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
41482458|NCT00825136|BEHAVIORAL|biofeedback (finger temperature biofeedback)|Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
41482459|NCT05892146|DRUG|Prevention therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
41482460|NCT05892146|DRUG|Rescue therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
41482461|NCT00887328|DRUG|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
41482462|NCT00887328|DRUG|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
41482463|NCT01621191|DRUG|Duloxetine|Administered Orally
41482464|NCT05130138|OTHER|Pharmaceutical intervention|Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.
41482465|NCT06331858|DEVICE|hip device-assisted concentric abductor strengthening (HDACAS)|All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
41482466|NCT06331858|DEVICE|knee device-assisted concentric flexor-extensor strengthening (KDACFES)|All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
41482467|NCT05393505|DRUG|Meropenem Injection|Given if patient has no known allergies at 1 g IV bolus within 1 hour of ED registration, then every 8 hours
41482468|NCT05393505|DRUG|Levofloxacin|Given if patient is allergic to beta lactam at 500 g IV in 100 mL 0.9% sodium chloride solution, infused over 1 hour started within 1 hour of ED registration, then every 24 hours. If the patient can tolerate oral drugs, 500 mg daily after the first IV dose.
40813946|NCT01293630|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
40813947|NCT01293630|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
40813948|NCT01293630|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
40813949|NCT02074345|BIOLOGICAL|TAK-816|TAK-816 intramuscular injection
40813950|NCT06485856|BEHAVIORAL|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Evaluation of the pain level of patients who are followed in intensive care and cannot speak during the procedural procedure with 3 different methods.
40813951|NCT01530035|OTHER|physical training|training
41155899|NCT04912102|DEVICE|high flow nasal oxygen device (HFNO)|it is a novel technique by which heated humidified oxygen is supplied via nasal prongs at flow rates ranging from 40 to 70 L/minute. The Fio2 ranges from 0.21 to 1.0.
41155900|NCT00254722|DRUG|Autologous bone marrow precursor cell harvest and transplant|Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10\^6 mononuclear cells/kg body weight, administered within 36 hours of injury
41331383|NCT03421509|OTHER|cutaneous silent period|In the upper limb the cutaneous silent period (CSP) is a brief transient suppression of the voluntary muscle contraction that follows painful stimulation applied to the finger (digits II-V, C6-C8 dermatomes)
41331384|NCT04328012|DRUG|Losartan|administered 14 days
41331385|NCT04328012|DRUG|Placebo|administered 14 days
41331386|NCT03846973|DRUG|Tranexamic Acid|intravenous infusion of 1 g infusion to be given and completed over 8 h in the hospital
41331387|NCT03846973|OTHER|Placebo|placebo (normal saline) infusion to be given and completed over 8 h in the hospital
41331388|NCT04798313|DRUG|MW031|Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.
41331389|NCT04798313|DRUG|Prolia®|Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
41331390|NCT02067572|OTHER|Saline mouthwash|
41331391|NCT02067572|OTHER|Salvia mouthwash|
41331392|NCT03904784|BEHAVIORAL|school withdrawal teenagers|The teenagers will have 4 interview with medical team alone or with his familly in order to have questionnaries, schools reports, psychological evaluation.
41331393|NCT06189248|BEHAVIORAL|Resourcefulness intervention|Teaching personal and social resourcefulness skills.
41331394|NCT02969967|DEVICE|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities for 50 minutes at least 3 times per week, followed by 10 minutes of grasp-release activities without the orthosis for 8 weeks. Will occur in participants' homes after discharge from inpatient rehabilitation with visit from principal investigator to progress program for 1 hour 3 times a week for the first 2 weeks and then once a week for 6 weeks.
41331395|NCT04571476|PROCEDURE|Ultrathin bronchoscope|Ultrathin bronchoscope (UTB) with an outer diameter no more than 3.0-mm and a 1.7-mm working channel.
40813952|NCT02724917|DRUG|APN1125|Oral solid dose form of APN1125
40813953|NCT02724917|DRUG|Placebo|Placebo to match
41331396|NCT04571476|PROCEDURE|Thin bronchoscope|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel.
41331397|NCT04571476|PROCEDURE|Virtual bronchoscopic navigation combined with endobronchial ultrasound|VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.
41331398|NCT04571476|PROCEDURE|Guide sheath|GS is a cannula with the thinnest outer diameter of 1.95 mm.
41482469|NCT05393505|DRUG|Amoxicillin Clavulanate|Given if patient has no known allergies at 1.2 g IV bolus within 1 hour of ED registration, then every 8 hours. If the patient can tolerate oral drugs, 1 g twice daily after the first IV bolus.
41331399|NCT06057610|DRUG|SHR-A1811 Injection|SHR-A1811 Injection
41331400|NCT06057610|DRUG|SHR-A1811 Injection ； Pertuzumab Injection|SHR-A1811 Injection ； Pertuzumab Injection
41331401|NCT06057610|DRUG|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
41331402|NCT02117804|OTHER|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
41331403|NCT02238288|DRUG|Aminocaproic acid|Crushed tablet in the dental socket
41331404|NCT02238288|OTHER|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
41331405|NCT02238288|DRUG|lidocaine and epinephrine|2%
40813954|NCT02168049|DEVICE|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
40813955|NCT02168049|DEVICE|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
40918325|NCT00995033|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
41331406|NCT02238288|DRUG|Paracetamol|750 mg
41331407|NCT06171815|BEHAVIORAL|Scenario-based simulation|Scenario-based simulation prepared for Respiratory Activity and Diabetes Management topics in the course curriculum
41482470|NCT05393505|DRUG|Antibiotic|"Any antibiotic for empirical therapy of common infections as recommended by the fifth version of Hospital Authority Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) guideline, with reference to previous bacterial sensitivity pattern"
41482471|NCT04850248|OTHER|no intervention, this is an observational study|no intervention, this is an observational study
41482472|NCT01953094|PROCEDURE|Screening Anal Pap Smear - No High Resolution Anoscopy|
41482473|NCT01953094|PROCEDURE|Screening Anal Pap Smear - With High Resolution Anoscopy|
41331408|NCT04511078|DRUG|Panitumumab-IRDye800|single dose infusion of panitumumab-IRDye800CW
41482474|NCT04284995|DRUG|RUC-4 Compound|All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.
41482475|NCT06056011|DEVICE|Connex CSVM with Timmy3 module|Connex Vital Signs Monitor with the Timmy3 Investigational module
41482476|NCT02688426|DEVICE|Sham Low-Level Laser Therapy (Sham LLLT)|perform with the machine off
40813956|NCT02168049|DEVICE|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
40813957|NCT04027803|BIOLOGICAL|BCD-148|single intravenous infusion of BCD-148 (900 mg)
40813958|NCT04027803|BIOLOGICAL|Soliris|single intravenous infusion of Soliris (900 mg)
41012834|NCT05913063|DEVICE|Structured Light Imaging Microscopy|Conducting the psychophysical task on the perception of OAM-coupled polarized light created using the experimental setup - Structured Light Imaging Microscopy (SLIM). Four types of vortex orbital angular momentum, differing by the number of fringes l=5;10; 15;20, will be presented for 0.5s per trial during which an azimuthally varying entoptic profile rotated clockwise or counterclockwise. A circular mask with a varying radius will be placed at fixation, thus the task will be performed at varying eccentricities. Circular obstruction of the area will be achieved due to the high refresh-rate structured light modulator. The threshold mask size will be changed by a 2up/1down staircase method (71% accuracy for the estimation of mask size).
41331409|NCT06406140|DRUG|Niacin tablets 500 mg|tablets used to treat hyperphosphatemia and lower lipoprotein a concentration in End-Stage Renal Disease Patients Undergoing Hemodialysis
41331410|NCT04835571|OTHER|Optimization of cardiovascular risk management|"Treatment goals were set according to current guidelines (Perk et al. Eur Guidelines on CVD prevention in clinical practice (2012). Eur heart J. 2012;33(13):1635-701):~* blood pressure \<140/90 mmHg~* Tot cholesterol \<5 mmol/l~* LDL \<1,8 mmol/l~* Waist circumference: men \<94 cm, women \<80 cm~* BMI \<25 kg/m2~* HbA1c without diabetes mellitus \<42 mmol/mol, HbA1c with diabetes mellitus \<52 mmol/mol~* Antithrombotic treatment (or anticoagulants, if indicated)~* Physical activity 30 min/day, 5 days/week, alternatively high-intensity training at least15 min/day, 5 days/week or a combination of the two.~* Healthy diet, including low levels of saturated fats, high intake of vegetables, fruits, whole-grain and fish~* Smoking cessation~* Low alcohol consumption~Patients were encouraged to follow the above recommendations through support of the study physicians, who made individual assessments of all patients and adjusted ongoing medical treatment to reach treatment targets."
41331411|NCT04539925|OTHER|Acute coronary syndrome|The effect of air pollution on acute coronary syndrome
41331412|NCT04612803|DRUG|Antihistamine|Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
41331413|NCT01228188|PROCEDURE|Inverted ILM Repositioning|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
41331414|NCT03771443|DRUG|experimental gluten free toothpaste|we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
41331415|NCT05169957|DRUG|Ipilimumab|Ipilimumab administered IV over 85-100 minutes at 3 mg/kg (combined with nivolumab administered IV over 30-60 minutes at 1 mg/kg) every 3 weeks for a total of 4 doses or until progression or unacceptable toxicity.
41331416|NCT05169957|DRUG|Nivolumab|Nivolumab administered IV over 30-60 minutes at 1 mg/kg (combined with ipilimumab administered IV over 85-100 minutes at 3 mg/kg) every 3 weeks for a total of 4 doses of the combination therapy or until progression or unacceptable toxicity. Subjects may receive maintenance dosing of nivolumab alone administered IV over 30-60 minutes at 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 52 weeks or until progression or unacceptable toxicity.
41482477|NCT02688426|DEVICE|6J Low-Level Laser Therapy (6J LLLT)|irradiation will be perform with 6J
41482478|NCT03828136|DEVICE|Novum Vitrium® Cervical Interbody Device|For spinal fusion procedure at one level (C3 to T1) of the cervical spine.
41482479|NCT03828136|DEVICE|Allograft Ring or Block|Standard of Care
41482480|NCT02979093|DRUG|Oxytocin|All women will receive a nasal spray containing oxytocin.
41482481|NCT02979093|DRUG|Placebos|All women will receive a nasal spray containing a placebo solution.
41482482|NCT02979093|PROCEDURE|Functional MRI scanning|Study participants undergo two functional MRI scans.
41482483|NCT03520868|DIAGNOSTIC_TEST|Monitoring Anti Factor Xa level|Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.
41482484|NCT04281979|DRUG|Study Agent|The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
40813959|NCT01631201|DRUG|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
40813960|NCT01631201|DRUG|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
40813961|NCT02531425|BIOLOGICAL|IT-pIL12-EP|Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
40813962|NCT00914446|PROCEDURE|hepatic biopsies|hepatic biopsies
41482485|NCT04281979|DRUG|Placebo|In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
41331417|NCT05169957|PROCEDURE|Stereotactic Body Radiation Therapy|24-45 Gy delivered in three fractions to up to 4 liver metastases
41331418|NCT06053970|OTHER|Assessing postural responses induced by visual stimulation (Visual Evoked postural responses, VEPR)|"The intervention will last 60 minutes and will include an assessment of the Berg Balance Scale (BBS), the collection of stabilometric data, the collection of the numerical difficulty scale, the Fast Motion Sickness Scale (FMS) and will end with a break after exposure to VR.~The various conditions will be carried out in this order:~* Eyes open with VR headset simulating a static environment~* Eyes closed with VR helmet off~* Eight measurements on a stabilometry platform will be taken for each of the VR signals, in random order"
41331419|NCT02759562|DRUG|Andecaliximab|Administered via subcutaneous injection
41331420|NCT02759562|DRUG|Placebo|Administered via subcutaneous injection
41331421|NCT00241878|BEHAVIORAL|Teacher-Delivered Weight Control Intervention|The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
41331422|NCT00241878|BEHAVIORAL|Teacher-Delivered General Health Intervention|The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
41331423|NCT02043184|BEHAVIORAL|Interactive Voice Response (IVR) Reminders|Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
41331424|NCT02006498|DRUG|Sillymarin|Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
41331425|NCT02006498|DRUG|Placebo|Placebo capsule with same appearances as study drug
41482486|NCT01530594|DRUG|Lenalidomide/Low dose Dex|Lenalidomide/Low dose Dex (LLD)
41482487|NCT01530594|DRUG|Bortezomib/Lenalidomide/ Low dose Dex|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
41482488|NCT01530594|DRUG|Lenalidomide|Lenalidomide/Low dose Dex (LLD
41482489|NCT02978820|OTHER|SEAS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
41482490|NCT02978820|OTHER|CS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
41482491|NCT01138111|DRUG|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
41482492|NCT03297372|DEVICE|IOL implantation|Implantation of monofocal IOL Micropure 1.2.3
41482493|NCT01064531|DEVICE|MIS Femoral Neck Stem implant|
41482494|NCT04798365|BEHAVIORAL|Intervention group|medical education and distribution of educations materials
41482495|NCT01457261|DRUG|Salbutamol|Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
41482496|NCT06053762|BEHAVIORAL|Peer-facilitated tobacco cessation|Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes
40813963|NCT01584791|DRUG|clopidogrel napadisilate + aspirin|clopidogrel napadisilate 75mg + aspirin 100mg
40813964|NCT01584791|DRUG|clopidogrel bisulfate + aspirin|clopidogrel bisulfate 75mg + aspirin 100mg
41482497|NCT06053762|BEHAVIORAL|Self-navigated tobacco cessation|Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves. Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
41482498|NCT03897647|DEVICE|General Electric (GE) VScan|This is a small, point-of-care, hand-held device used for ultrasound (POCUS). It uses sound waves to generate images without using any radiation.
40918326|NCT00995033|BIOLOGICAL|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
41331426|NCT01742091|DRUG|LY2541546 - SC|Administered SC
41331427|NCT01742091|DRUG|LY2541546 - IV|Administered IV
41331428|NCT01742091|DRUG|Placebo - SC|Administered SC
41482499|NCT05960474|OTHER|Outcomes for Patients with CMD|Our objective is to perform a retrospective/prospective descriptive study on the short term to longterm (up to 5 years of follow-up) outcomes of patients with coronary microvascular disease diagnosis invasively
41482500|NCT00496535|DRUG|TNFerade biologic|
41482501|NCT03654248|BEHAVIORAL|Let's Get Organized group intervention|Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
41482502|NCT03654248|DEVICE|Individual Occupational Therapy|Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
41482503|NCT03867799|DRUG|Nivolumab|Immunotherapy
41482504|NCT00556023|DRUG|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
41482505|NCT02429141|PROCEDURE|US-guided periarterial techique|The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery
41482506|NCT02429141|PROCEDURE|US-guided multi-injection technique|The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve
41331429|NCT01742091|DRUG|Placebo - IV|Administered IV
41331430|NCT03476382|DEVICE|Ultrasound Bone Growth Stimulator|Active device emits ultrasound signals.
41331431|NCT05553912|BEHAVIORAL|QBSafe|an intervention comprised of (a) a set of conversation cards (QBSafe ASK) designed to enable patients to identify aspects of life with diabetes important to them and to share them with their clinician to obtain their input; and (b) materials that help clinicians respond to patient concerns.
41331432|NCT00361023|DRUG|losartan|
41331433|NCT06394557|PROCEDURE|In-office Dental Bleaching Conventional|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 7 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
41331434|NCT06394557|PROCEDURE|In-office Dental Bleaching Alternative|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 2 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
41331435|NCT04591145|OTHER|Observational group|Patient receive the standard bowel preparation strategy and routine colonoscopy
40918327|NCT00995033|DRUG|Varenicline|Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
40918328|NCT00327821|BEHAVIORAL|calorie controlled diet|
41331436|NCT00583661|DEVICE|EXCOR Pediatric|Extracorporeal Ventricular Assist Device
41331437|NCT04550936|DRUG|Isavuconazole|antifungal agent
41331438|NCT03162029|OTHER|CBCT imaging|CBCT imaging of participants, then take measurement by radiomorphometric indices
41331439|NCT00383578|DRUG|Vildagliptin 100 mg qd|
41331440|NCT00383578|DRUG|Metformin 1500 mg daily|
41331441|NCT02592668|DEVICE|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
41331442|NCT01432093|OTHER|Intensive glycemic management|Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
41482507|NCT03273491|BEHAVIORAL|daily self-weighing|Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.
41482508|NCT03273491|BEHAVIORAL|daily temperature-taking|Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
41482509|NCT03314818|DEVICE|Ultrasound 3D Imaging|"Carotid artery ultrasound will be used to:~Determine plaque presence and plaque burden Presence of stenosis~Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.~Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism."
41482510|NCT04048343|DRUG|Biological: Experimental: Tezepelumab|Tezepelumab subcutaneous injection every 4 weeks
41482511|NCT04292366|PROCEDURE|Invitation procedure|Optimised invitation procedures in an organised colorectal cancer screening programme
41012835|NCT04662346|OTHER|Difficulty score system for robotic pancreatoduodenectomy|calculate the score for patient in you cohort
41482512|NCT04221607|OTHER|Sensate Focus exercise|Structured exercise to enhance intimacy
41482513|NCT00864617|DRUG|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
41482514|NCT00864617|DRUG|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
41331443|NCT01432093|OTHER|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
41331444|NCT04848012|DEVICE|Auto-titrating non-invasive ventilation|A non-invasive ventilator designed to auto-adjust the expiratory positive airway pressure according to expiratory flow limitation, measured using the forced oscillation technique.
41331445|NCT04379947|PROCEDURE|Fractional Flow reserve|Measurement of fractional flow reserve in the preoperative work-up for oronary artery bypass surgery
41482515|NCT02477774|DEVICE|ARISTA|According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
41482516|NCT00543452|OTHER|Oxygen|4 liters of oxygen a minute
41482517|NCT00543452|OTHER|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
41482518|NCT05723679|OTHER|HeO2 gas mixture|Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.
41482519|NCT05723679|OTHER|Room air gas mixture|Normal room air
41482520|NCT01829919|DRUG|Brisdelle (paroxetine mesylate)|All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.
41482521|NCT02620215|DEVICE|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
41482522|NCT02620215|DRUG|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
41482523|NCT02132754|BIOLOGICAL|MK-4166|
41482524|NCT02132754|BIOLOGICAL|Pembrolizumab|
41482525|NCT00635518|BEHAVIORAL|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
41155901|NCT05301192|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
41331446|NCT04099706|PROCEDURE|Autologous Fat Grafting / Fat Transplant|See arm descriptions.
41331447|NCT02568163|OTHER|Non surgical periodontal treatment|
41331448|NCT02957110|BEHAVIORAL|Laughter Frequency|Relationships between laughter frequency, momentary mood state, and pain will be observed.
41331449|NCT01115517|DRUG|Bevacizumab|1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
41331450|NCT01115517|DRUG|Mitomycin C|Mitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
41331451|NCT04679389|DRUG|Placebo|administered orally or enterally
41331452|NCT04679389|DRUG|Acetazolamide|administered orally or enterally
41331453|NCT05506696|DIETARY_SUPPLEMENT|Fultium|3200IU Fultium
41331454|NCT03043846|OTHER|Follow-up every 3 months during 1 year (data collection in eCRF)|
41331455|NCT03043846|OTHER|Follow-up every month to follow the pre-defined strategy|
41331456|NCT02053558|DRUG|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
41331457|NCT02053558|DRUG|TAP BLOCK with ropivacaine|TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
41331458|NCT03056807|OTHER|25° head-up position|Angle person is positioned for procedure.
41331459|NCT03056807|OTHER|55° head-up position|Angle person is positioned for procedure.
41482526|NCT01802749|DRUG|Bevacizumab|
41482527|NCT01802749|DRUG|Paclitaxel|
41482528|NCT01802749|DRUG|Carboplatin|
41482529|NCT01802749|DRUG|pegylated liposomal doxorubicin|
41482530|NCT01802749|DRUG|Gemcitabine|
41482531|NCT02334865|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
40918329|NCT03565328|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
41331460|NCT06336538|OTHER|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is a group-based psychological intervention for depression that combines mindfulness training with cognitive therapy.
41331461|NCT04373707|DRUG|Enoxaparin|"For example (Enoxaparin):~* 4000IU twice a day in patients \<50kg~* 5000IU twice a day in patients 50-70kg~* 6000IU twice a day in patients 70-100kg~* 7000IU twice a day in patients above 100kg"
41482532|NCT02334865|OTHER|Laboratory Biomarker Analysis|Correlative studies
41482533|NCT02334865|DRUG|Lenalidomide|Given PO
40918330|NCT00817596|DEVICE|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
40918331|NCT01489813|DRUG|Genistein|30 mg of genistein supplement by mouth three times daily (PO TID).
40918332|NCT01489813|DRUG|Sugar pill|Sugar pills will be taken by mouth three times daily (PO TID).
40918333|NCT02205840|DRUG|SI-614|1 drop in each eye
40918334|NCT02205840|DRUG|Vehicle|1 drop in each eye
41482534|NCT02334865|BIOLOGICAL|Sargramostim|Given SC
41482535|NCT02334865|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
41482536|NCT05667636|RADIATION|salvage SBRT|steretactic body radiation therapy in the setting of salvage radiotherapy for prostate cancer
41482537|NCT03061682|DEVICE|"Scharioth macula lens A45sml/A45smy"|Implantation of an add on intraocular lens to low vision patients
41482538|NCT00352235|DRUG|KRN7000|
41482539|NCT04698148|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
41482540|NCT04698148|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
41482541|NCT04698148|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
41482542|NCT04252222|DEVICE|Videolaryngoscopy with VL3|Tracheal Intubation aided by VL3 Videolaryngoscope
40813965|NCT01986231|DRUG|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
40813966|NCT05067023|DIAGNOSTIC_TEST|MRI scan|All participants will undergo 1 DCE-MRI scan.
41331462|NCT04373707|DRUG|Enoxaparin|For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.
41331463|NCT05966246|DRUG|Arm I : Experimental (Prucalopride succinate group)|Experimental group taking prucalopride succinate from day 1 to day 5 after surgery
41331464|NCT05966246|DRUG|Arm II : Control (Mosapride citrate group)|Control gourp taking mosapride citrate from day 1 day 5 after surgery
41331465|NCT05359445|BIOLOGICAL|IMA401 (Phase Ia)|Intravenous infusions in escalating dose levels
41331466|NCT05359445|BIOLOGICAL|IMA401 (Phase Ib)|Treatment at recommended dose for extension (RDE)
41331467|NCT00050622|DRUG|Methylphenidate 0.15 mg/kg|0.15 m/kg/dose immediate-release methylphenidate
41331468|NCT00050622|BEHAVIORAL|Low-Intensity BMOD|Lower-intensity behavioral treatment package.
41331469|NCT00050622|DRUG|Methylphenidate 0.3 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
41331470|NCT00050622|DRUG|Placebo|
41331471|NCT00050622|DRUG|Methylphenidate 0.6 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
41331472|NCT00050622|BEHAVIORAL|High Intensity BMOD|Comprehensive high-intensity Summer Treatment Program (STP)
41331473|NCT01559701|DRUG|PF-00345439|5-80 mg twice-a-day for 12 months
40813967|NCT02589652|DRUG|Pegylated interferon alfa-2a|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
40813968|NCT02589652|DRUG|Pegylated interferon alfa-2a plus Entecavir|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
40813969|NCT02589652|DRUG|Entecavir|ETV 0.5mg oral daily for 48 weeks
41155902|NCT05301192|DRUG|Saline|Saline will be used as the placebo comparator.
41331474|NCT04016987|BEHAVIORAL|Automated structured education intervention based on an app and artificial intelligence|In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
41331475|NCT03689868|BEHAVIORAL|Virtual Reality|Virtual Reality headset with calming scenery
41331476|NCT05704842|BEHAVIORAL|Exercise|Home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises.
41331477|NCT04406389|DRUG|Enoxaparin sodium|"Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours"
41331478|NCT04406389|DRUG|Unfractionated heparin|"Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol"
41331479|NCT04406389|DRUG|Fondapariniux|"Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~* If greater than or equal to 100 kg: 10 mg daily~* If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~* If less than 50 kg: 5 mg daily"
41331480|NCT04406389|DRUG|Argatroban|"Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol"
41331481|NCT03412123|BEHAVIORAL|group lifestyle-integrated functional exercise|Manualized teaching of balance and strength principles and integration of exercises and physical activity into daily routine during 7 sessions in a group of 8 to 10 participants with 2 trainers. The pilot intervention group will undergo the same strength and balance exercises and learn about the same physical activity enhancement strategies as described in the LiFE programme by Clemson et al. (BMJ 2012;345:e4547). However, instead of 7 home visits, gLiFE participants will attend seven group sessions (1 session/week). In these, LiFE contents are adapted to the group setting and enhanced by health psychological and behaviour change strategies fitting to the social structure and modalities of a group.
41331482|NCT03384004|DEVICE|Irrigation Technique 1|Irrigation of root canals for this group will be performed using EndoVac Pure, an Apical Negative Pressure Endodontic Irrigation System intended for the delivery and evacuation of endodontic irrigation solutions during root canal procedures. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid). This will be followed by Ultrasonic activation of the sodium hypochlorite solution using Minendo II ultrasonic unit.
41331483|NCT03384004|DEVICE|Irrigation Technique 2|Irrigation of root canals for this group will be performed using the EndoVac pure system without Ultrasonic irrigation. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid).
41331484|NCT01351311|OTHER|Exercise|Resistance Training exercise with swiss ball
41331485|NCT01351311|OTHER|Drug treatment|Drug treatment
41331486|NCT02451254|PROCEDURE|circumferential ablation|circumferential ablation of the pulmonary veins
41331487|NCT02451254|DEVICE|SVT ablation|SVT ablation
41331488|NCT03915912|BEHAVIORAL|Mindfulness meditation|The study intervention consists of seven mindfulness sessions (six 1-hour telephone sessions and one 1-hour in-person session). The six weekly telephone-based mindfulness sessions will occur in a one-on-one format and will be followed by one in-person, one-on-one session, which will occur at the post-chemoradiation standard of care clinic visit.
41331489|NCT00422123|DRUG|Quetiapine fumarate (Seroquel) SR|
41331490|NCT04261881|DIETARY_SUPPLEMENT|ATP-Fuel|5 capsules daily with breakfast and 5 capsules daily with lunch
41482543|NCT02109536|DEVICE|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
40813970|NCT03689491|BEHAVIORAL|rTMS|The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.
40813971|NCT03689491|BEHAVIORAL|visual feedback training|Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.
40813972|NCT03689491|BEHAVIORAL|traditional rehabilitation|30 min traditional rehabilitation. The traditional rehabilitation programs included balance training, postural training, muscle strengthening, ambulation training and etc..
40813973|NCT05379218|DEVICE|Remote Ischemic Conditioning|"Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected."
41331491|NCT04261881|DIETARY_SUPPLEMENT|ATP-II|3 capsules daily with breakfast
41331492|NCT04261881|DIETARY_SUPPLEMENT|ATP-II|3 capsules daily with breakfast and 3 capsules daily with lunch
41331493|NCT02069249|BEHAVIORAL|Healthy Sleep intervention|Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
41331494|NCT02069249|BEHAVIORAL|Healthy Nutrition intervention|Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
41331495|NCT03310437|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention in acute myocardial infarction patients
41331496|NCT02680106|DEVICE|SPINNER|The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous matrix is thus created.
41331497|NCT02680106|DEVICE|JELONET / IBU Biatain|The patient's DSW will be dressed by JELONET/IBU Biatain
41331498|NCT02150512|DEVICE|Transpulmonary Thermodilution|Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV \>10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still \>10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.
41331499|NCT02150512|DEVICE|Surviving Sepsis Guidelines (SSG)|Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
41331500|NCT03115788|OTHER|Heat induced pain|For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.
41331501|NCT03115788|OTHER|Cold Induced Pain|Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.
41331502|NCT03115788|DEVICE|iPad|
41331503|NCT00868335|DEVICE|Activ C disc prosthesis|cervical disc prosthesis
41331504|NCT00868335|PROCEDURE|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
41331505|NCT04898894|DRUG|Venetoclax|Given orally (PO)
41331506|NCT04898894|DRUG|Selinexor|Given Orally (PO)
41331507|NCT04898894|DRUG|Cytarabine|Given in to the vein (IV) or intrathecal (IT)
41331508|NCT04898894|DRUG|Fludarabine|Given in to the vein (IV) - Because of the ongoing nationwide shortage of fludarabine, this agent may be omitted during the dose expansion phase of the trial.
41331509|NCT04898894|BIOLOGICAL|Filgrastim|Given subcutaneous (SubQ, SC)
41331510|NCT04898894|DRUG|Methotrexate|Given intrathecal (IT)
41331511|NCT04898894|DRUG|methotrexate/hydrocortisone/cytarabine|Given intrathecal (IT)
41482544|NCT00001662|DRUG|CX516 (Ampalex)|
41482545|NCT03821363|BIOLOGICAL|SCT-I10A|Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
41331512|NCT06364384|COMBINATION_PRODUCT|PD-1 and CRT|Chemotherapy (/3w): 1)DDP 75 mg/m2, d1, intravenous infusion; 2)5-FU 1000 mg/m2, d1-4, continuous pumping intravenously; Immunotherapy (/3w): PD-1 monoclonal antibody(sintilimab) 200mg, d1, intravenous infusion; Radiotherapy (at 3rd week after first time of chemotherapy):Daily single dose of 2Gy, with a total dose of 50-54GY.
41482546|NCT04198636|DRUG|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
40813974|NCT02441153|OTHER|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
40813975|NCT03564522|PROCEDURE|cardiac catheterization|cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
40813976|NCT03564522|RADIATION|Cardiac MRI|If clinically indicated, the study will collect data from MRIs.
40813977|NCT06362330|OTHER|magnetic resonance imaging|Patients of bladder cancer underwent multiparameter magnetic resonance imaging before surgery
40813978|NCT04116983|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
40813979|NCT02720055|OTHER|Psychological workbook|
40813980|NCT02720055|OTHER|Basic information workbook|Basic rehabilitation information that represents current practice.
40813981|NCT03755674|PROCEDURE|CHRONOTYPE-ADJUSTED DIET|Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
40813982|NCT01818258|DRUG|ZDV+3TC+LPV/r|
40813983|NCT01037725|DRUG|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
41331513|NCT05301413|BEHAVIORAL|Culturally Tailored Diabetes Prevention Program|This intervention includes a culturally tailored DPP curriculum, class procedures, and handouts
41331514|NCT05301413|BEHAVIORAL|Culturally Tailored DPP Enhanced with Socioeconomic Supports|This intervention includes the culturally tailored DPP curriculum, class procedures, and handouts along with promotional items for class participation, opportunities to attend class in-person or virtually through a digital platform, and assistance from a community health worker to provide linkage to health care services and community resources
41331515|NCT05301413|BEHAVIORAL|Diabetes Prevention Program|This is the CDC TD2 evidence-based Diabetes Prevention Program
40813984|NCT01037725|DRUG|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
41331516|NCT01001858|OTHER|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
41331517|NCT01817660|PROCEDURE|Open repair of popliteal artery|
40813985|NCT00657293|BEHAVIORAL|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
40813986|NCT00657293|BEHAVIORAL|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
41012836|NCT03120065|OTHER|Electronic Dose Monitoring (MEMS)|The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
41012837|NCT00591448|OTHER|Virtual Reality (VR)|See above
41331518|NCT01817660|PROCEDURE|Endovascular repair of popliteal artery|
41331519|NCT03380507|DRUG|Triple therapy group|Refer to arms description
41331520|NCT02178163|OTHER|cytology specimen collection procedure|Correlative studies
41331521|NCT02178163|OTHER|laboratory biomarker analysis|Correlative studies
41331522|NCT04617899|DIAGNOSTIC_TEST|Intravascular imaging|Use of imaging catheter
41482547|NCT04198636|DRUG|Xgeva 120 MG in 1.7 ML Injection|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
41482548|NCT00732433|PROCEDURE|digital mammography|Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
41331523|NCT06067308|DIAGNOSTIC_TEST|Performance of CTPA|Exposure to CT scan and injection of IV contrast
41331524|NCT00436267|DRUG|fluorouracil|
41331525|NCT00436267|RADIATION|selective external radiation therapy|
41331526|NCT00436267|RADIATION|tomotherapy|
41331527|NCT00436267|RADIATION|yttrium Y 90 glass microspheres|
41331528|NCT00436267|RADIATION|yttrium Y 90 resin microspheres|
41331529|NCT00000608|BEHAVIORAL|diet, fat-restricted|
41331530|NCT00000608|BEHAVIORAL|diet, sodium-restricted|
41331531|NCT01927068|DEVICE|"Stellarex 0.035 Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)"|Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
41331532|NCT05071443|OTHER|Negative pressure wound therapy (NPWT)|"The therapeutic intervention being tested is the use of a negative pressure wound therapy (NPWT) device. Several medical devices are currently being used and are based on the same principle. They involve applying negative pressure, generally between -100 and -150 mmHg, to a wound using a dressing (mostly a polyurethane foam dressing with hydrophobic pores), which hermetically covers the wound's surface and is connected to a container for collecting the fluids drained off. These devices are widely available and used to treat post-operative wounds.~Duration of treatment: the use of NPWT will be maintained until the recovery of the skin has been achieved by the skin graft. An average duration of 3 weeks' treatment is expected in the intervention group."
41482549|NCT04731311|DEVICE|Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease|4 participants with undergo 4 usability evaluations each, inter-spaced by days when researchers will address design changes. 2 participants will be elderly healthy and 2 will have the early Alzheimer's disease. Each session will last up to 1 hour, during which participants will interact with tasks in the form of games. Games will be gradated in level of difficulty, increasing from session to session. They will be played with one game controller or with two controllers while participants wear an all-in-one head mounted display. The degree of cognitive engagement during tasks will be measured with custom biosensors and used in adjusting level of difficulty. Each participant will fill subjective evaluation form and a USE form assessing ease of use, usefulness, and perceived technology issues. Scores will be analyzed and data published, in conjunction with game performance data.
41482550|NCT04322578|DRUG|Crizotinib|Crizotinib 250mg po bid. Savolitinib 300mg po, qd.
40813987|NCT05998850|BEHAVIORAL|Community Health Worker Support with Resources|6-months of hands-on tailored support spanning the domains of social support, advocacy and navigation to achieve their action plans.
41482551|NCT04322578|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, ivgtt erery 21day.
41482552|NCT02478320|DRUG|Ilorasertib|200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
41482553|NCT03580564|DRUG|KL-A167|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
40813988|NCT03960086|OTHER|Podoactiva cutom-made foot orthoses|Children had to use the orthotics daily during the intervention period
41012838|NCT01698697|DRUG|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
41012839|NCT03840161|DEVICE|non-invasive tissue glucose prediction|Generation of non-invasive and invasive glucose readings for comparison with a standard laboratory reference glucose determination method (YSI glucose analyzer)
41482554|NCT05727917|DRUG|Hetrombopag|After hematopoietic stem cell reinfusion, the patients begin to take hetrombopag orally 7.5mg/d, until the patients reach complete platelet response.The treatment will stop when patients accept 21 consecutive days of treatment or reach the discontinuation criteria.
41482555|NCT05727917|OTHER|placebo|After hematopoietic stem cell transfusion, the patients will be only observed, and the observation during the treatment period will be ended after 30 days
41482556|NCT05500573|PROCEDURE|Sperm Sorting|Selection of gender specific spermatozoa using a multilayer density gradient solution
40813989|NCT03960086|OTHER|Podoactiva heel lifts|Children had to use the orthotics daily during the intervention period
40813990|NCT06538558|DRUG|Tezampanel|Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation
40813991|NCT06538558|DRUG|Placebo|Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.
41012840|NCT01769157|DRUG|L-carnitine|
41012841|NCT01769157|DRUG|Placebo|
41012842|NCT03611725|PROCEDURE|Distal radial artery|The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
41155903|NCT03747159|DRUG|Belimumab Injection|Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
41482557|NCT00004748|DRUG|colchicine|
41482558|NCT00004748|DRUG|methotrexate|
41482559|NCT00004748|DRUG|ursodiol|
41482560|NCT05906420|DIAGNOSTIC_TEST|ASTRAL prognostic score|ASTRAL prognostic score
41482561|NCT02122718|DRUG|Allopurinol|
41482562|NCT02122718|DRUG|Placebo|
41482563|NCT03494114|DRUG|Ga-EC2115|Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
40813992|NCT03664635|BIOLOGICAL|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL
40918335|NCT03227783|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
40918336|NCT04040322|DRUG|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
40918337|NCT04040322|DRUG|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
40918338|NCT03014999|DEVICE|High frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 10Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
40813993|NCT04587414|BEHAVIORAL|eHealth +counselling contacts|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.
41331533|NCT05071443|OTHER|Conventional dressing|"Conventional dressings will be performed from randomization to skin grafting and applied every day based on the methods normally used in the participating centres, and also until the recovery of the skin has been achieved by the skin graft.~This generally involves local care provided on a daily basis, ensuring gentle mechanical and chemical debridement by covering the wound with alginate type or other dressings, according to the condition of the wound. The methods used to apply these conventional dressings will be recorded."
41331534|NCT03212599|DRUG|Disulfiram|alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
41331535|NCT00905372|DRUG|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
40813994|NCT04587414|BEHAVIORAL|eHealth|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.
40813995|NCT04587414|BEHAVIORAL|Usual care|Usual care and councelling given to type 2 diabetics within the primary health care setting.
40813996|NCT03181217|OTHER|water 0|300 ml tap water at 0 ºC
40813997|NCT03181217|OTHER|water 22|300 ml tap water at 22 ºC
40813998|NCT03181217|OTHER|Glucose 0|300 ml tap water at 0 ºC with 75 grams of glucose added
40813999|NCT03181217|OTHER|Glucose 22|300 ml tap water at 22 ºC with 75 grams of glucose added
40814000|NCT00951236|DRUG|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
40814001|NCT00951236|DRUG|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
40814002|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
40814003|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
40814004|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
40814005|NCT05305222|DRUG|Risankizumab|Intravenous (IV) Infusion
40814006|NCT05305222|DRUG|Placebo|Intravenous (IV) Infusion
40814007|NCT04167059|BEHAVIORAL|Telehealth-delivered participation strategies to increase physical activity|Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
40814008|NCT02110537|PROCEDURE|Active Acupuncture|Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
40814009|NCT02110537|PROCEDURE|Sham acupuncture|For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
40814010|NCT02110537|DRUG|flecainide|Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
41331536|NCT00905372|DRUG|Placebo|intravenously (IV) every 4 weeks for 80 weeks
41331537|NCT02333669|OTHER|no intervention|no intervention
41331538|NCT03242304|OTHER|Behavioral tests|We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
41331539|NCT03383627|DEVICE|Continuous Glucose Monitoring|"* The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.~* CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.~* Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis."
41331540|NCT03650712|DIAGNOSTIC_TEST|Oral glucose tolerance test|oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus
41482564|NCT02813421|DEVICE|CGM Informed|
40814011|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
40814012|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
40814013|NCT00946608|DRUG|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
41482565|NCT01763918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
40814014|NCT06420856|OTHER|Assessment of the musculoskeletal system and its functions|Measurement of sub sole pressure sense, light touch sense, vibration sense and two-point discrimination sense. will be evaluated with. For the evaluation of proprioception, active joint position sense technique was used in plantar flexion (PF): 7°, 14° and 21°; In dorsiflexion (DF), 7° target angles will be used. An Dr. Goniometer will be used to determine target angles. To measure plantarflexion and dorsiflexion muscular strength and endurance will be used with the isokinetic system. Weight-Bearing Lunge test will be used to evaluate ankle mobility. For balance assessment, the Modified Star Excursion Balance Test will be measured using the anterior, posteromedial and posterolateral directions. American Orthopedic Foot and Ankle Society midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score , which are subjective evaluation methods, will be used to determine the functional level. A heel lift test will be performed to evaluate physical performance.
40814015|NCT00116675|DRUG|Resiquimod|
40814016|NCT05634694|OTHER|No interventions.|No interventions.
40814017|NCT00748397|DEVICE|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
40814018|NCT05300230|DEVICE|Neuro Zti cochlear implant and Neuro 2 sound processor|"The study will consist in 3 visits:~* Visit 1: it will be carried out the first contact and learning the measurement procedure.~* Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~* Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters."
40814019|NCT01453751|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)|ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
41331541|NCT03650712|DIAGNOSTIC_TEST|Continuous glucose monitoring|a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days
41482566|NCT01763918|DRUG|Placebo|Administered by subcutaneous injection
40814020|NCT02803177|BIOLOGICAL|BMC2012|
40814021|NCT02803177|DEVICE|beta-TCP Chronos® Synthes|
40814022|NCT00321074|DRUG|TACROLIMUS|Immunosuppression
40814023|NCT01129713|DRUG|Secretol|Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
40814024|NCT01129713|DRUG|Nexium|Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
40814025|NCT05720689|OTHER|using relaxing music|music diffusion during dental care under MEOPA
40814026|NCT05720689|OTHER|No relaxing music|dental care under MEOPA without music
40814027|NCT05360693|PROCEDURE|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done \& patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
40814028|NCT05360693|PROCEDURE|immediate implant placement with socket bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done and patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). In order to ensure standardization and reproducibility of the CBCT cross sectional images used in this study, superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
40814029|NCT02604602|OTHER|blood exam|laboratory test
40814030|NCT01372943|BIOLOGICAL|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
40814031|NCT06483282|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
40814032|NCT06483282|DRUG|Apatinib Mesylate|This product is an orally administered targeted therapy drug, with a recommended dosage of one tablet per day.
41331542|NCT03650712|DIAGNOSTIC_TEST|Dexa scan|low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis
41331543|NCT05678088|BEHAVIORAL|Oropharyngeal Exercises|The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles
41482567|NCT04754126|BEHAVIORAL|Amazing Me|The Amazing Me Program is an evidence-based program designed to help children between the ages of 9 and 11 build self-esteem, body confidence, and eliminate weight-based bullying and teasing. This school-based curriculum satisfies national educational health requirements and provides tools for teachers to implement in 4th and 5th grade classrooms.
41482568|NCT03181321|BEHAVIORAL|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
41482569|NCT02882685|PROCEDURE|Roux-en-y gastric bypass|
41482570|NCT02882685|PROCEDURE|Single anastomosis gastric bypass|
41482571|NCT01277718|DRUG|Cobimetinib|One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
40814033|NCT06483282|DRUG|Etoposide|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 100mg/m2, administered every 3 Weeks (Q3W).
40814034|NCT06483282|DRUG|Carboplatin|This product is administered by intravenously guttae. AUC=5, administered every 3 Weeks (Q3W).
41012843|NCT03611725|PROCEDURE|Radial artery|The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
41331544|NCT05678088|BEHAVIORAL|Sham Exercises|The participant will practice exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength.
40814035|NCT03913013|BEHAVIORAL|Family-Focused Treatment with MCC App|12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
40814036|NCT02554149|RADIATION|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
41331545|NCT01773798|DRUG|insulin degludec/insulin aspart 15|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
41331546|NCT01773798|DRUG|insulin degludec/insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
41331547|NCT01773798|DRUG|insulin degludec|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
40814037|NCT00960011|DEVICE|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
40814038|NCT00960011|DEVICE|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
40814039|NCT01325454|DEVICE|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
40814040|NCT06264089|PROCEDURE|Preservation Rhinoplasty Nasal Valve Angle and Area|The same group of patients who underwent Preservation Rhinoplasty will be followed and the nasal valve angles before and after surgery will be compared.
40814041|NCT04689906|OTHER|surgery|This is a retrospective study that includes patients operated for suspicion of acute appendicitis
40814042|NCT06501547|GENETIC|Leucocyte Telomere Length from blood draw|blood draw, PCR method to see leucocyte telomere length
40814043|NCT02130687|DRUG|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
41012844|NCT04515186|DRUG|Meglumine Antimoniate|Vials of a 5mL solution. Each vial contains 405 mg of Sb5+ corresponding to 8.1% Sb5+ (81 mg/mL).
41331548|NCT01773798|DRUG|insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
41331549|NCT01773798|DRUG|placebo|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
41012845|NCT04515186|DRUG|Miltefosine|50 mg capsule
41012846|NCT04515186|DEVICE|Thermotherapy machine|Localized Current Field radio-frequency generating device
41331550|NCT01699295|BEHAVIORAL|A+PAAC|academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
41331551|NCT01699295|BEHAVIORAL|CON|lessons taught by regular classroom teachers using traditional/regular sedentary lessons
41482572|NCT01277718|DRUG|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
41331552|NCT01708707|DRUG|Buprenorphine|"The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days."
41482573|NCT02780167|DRUG|PF-04965842|10 mg of PF-04965842 QD for 12 weeks
41482574|NCT02780167|DRUG|PF-04965842|30 mg of PF-04965842 QD for 12 weeks
41482575|NCT02780167|DRUG|PF-04965842|100 mg of PF-04965842 QD for 12 weeks
41482576|NCT02780167|DRUG|PF-04965842|200 mg of PF-04965842 QD for 12 weeks
41482577|NCT02780167|DRUG|Placebo|Placebo QD for 12 weeks
41482578|NCT02289859|PROCEDURE|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
40814044|NCT02130687|DRUG|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
40814045|NCT02130687|DRUG|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
41012847|NCT01251133|BIOLOGICAL|LBVH0101 (Hib vaccine)|0.5mL
41012848|NCT01251133|BIOLOGICAL|Hiberix™ Vaccine|0.5mL
41012849|NCT02753647|DRUG|Rituximab|
41012850|NCT02753647|DRUG|Cyclophosphamide|
41012851|NCT02753647|DRUG|Doxorubicin|
41482579|NCT02289859|PROCEDURE|Wound Closure without Undermining|One side of the wound will remain un-undermined.
41482580|NCT00446199|DRUG|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
41482581|NCT00446199|DRUG|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
40814046|NCT02130687|OTHER|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
40814047|NCT04186988|DRUG|Fluorine F 18 Ara-G|Given IV
40814048|NCT06112821|OTHER|Data collection in medical records|Data collection in medical records
40814049|NCT06112821|OTHER|Blood sampling|Blood plasma and serum collection for biobanking. Future laboratory analyses encompass the analysis of endothelial dysfunction markers and other markers implicated in APS.
40814050|NCT03086421|BEHAVIORAL|Questionnaires|Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
40814051|NCT06379035|DIAGNOSTIC_TEST|ELISA / PCR|"Multiplex PCR for confirmation of diagnosis of Blastocystis and Cryptosporidium infection.~Enzyme linked immunosorbent assay (Elisa) for detection of :~Different cytokines level in Colorectal cancer patients that may be involved in the tumor progression due to Blastocystis and Cryptosporidium infection."
40814052|NCT02191657|DRUG|Deferiprone|Oral iron chelator
40814053|NCT02526563|PROCEDURE|ropivicaine|Blood draws to measure serum ropivicaine
40814054|NCT04348318|OTHER|health related personal data extraction from digital medical records|health related personal data extraction from digital medical records (i.e. patient characteristics; start, end and duration of hospitalization and ICU stay; admitted from another hospital, nursing home or comes with emergency medical Service; formal data of written advance directives; data of unwritten advance directive; information on the contents of the advance directives (regarding life-worthy conditions, health care agents, resuscitation, pain management, artificial nutrition, hydration, surgeries, renal replacement, mechanical circulation, mechanical ventilation, pacemaker, administration of blood products, treatment of infections, organ donation, autopsy); patient history; clinical data; therapeutic features; outcome at discharge; knowledge regarding relatives and their level of information about the advance directives; discussion of euthanasia and self-determination of dying.
40814055|NCT05238207|DRUG|BBI-001|Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion
40814056|NCT05238207|DIETARY_SUPPLEMENT|Original Fibre Metamucil|Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion
41012852|NCT02753647|DRUG|Vincristine|
41012853|NCT02753647|DRUG|Prednisone|
41482582|NCT00446199|DRUG|Estradiol (E2 0.3mg)|One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
41012854|NCT02753647|DRUG|Chidamide|
41012855|NCT02071576|DEVICE|Proscan|One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
41012856|NCT00795691|BEHAVIORAL|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
41012857|NCT00795691|BEHAVIORAL|low-fat diet|low-fat diet in patients with type 2 diabetes
41331553|NCT01708707|DRUG|Morphine Sulfate|Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
41482583|NCT00446199|DRUG|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
41482584|NCT05881902|BEHAVIORAL|HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|"A total of 4 home visits and 2 phone calls will be made by giving awareness training based on the Health Belief Model to the participants in the Intervention 1 group in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made"
40814057|NCT00724685|DRUG|Naropeine (Ropivacaine)|
40814058|NCT00724685|DRUG|Placebo|saline
41012858|NCT00779766|BIOLOGICAL|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
41012859|NCT00779766|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
41331554|NCT00801892|DEVICE|Continuous Positive Airway Pressure (CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
41331555|NCT00801892|DEVICE|Sham- Continuous Positive Airway Pressure (Sham-CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
41331556|NCT00217009|PROCEDURE|Narrowband Ultraviolet B (TL-01UVB) Therapy|
41012860|NCT02851238|OTHER|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
41012861|NCT00852384|PROCEDURE|NIPPV and IRM|"* non invasive positive pressure support ventilation (NIPPV group)~* alveolar recruitment maneuver (IRM group)"
41012862|NCT02771639|PROCEDURE|Hip arthroplasty|Treatment with a hip arthroplasty (semi- or total hip arthroplasty) for a displaced femoral neck fracture
41012863|NCT05033964|COMBINATION_PRODUCT|Percutaneous Coronary Intervention with drug eluting stents|Coronary drug eluting stent implantation
41012864|NCT05555381|BEHAVIORAL|young-D program|"* needs detection by means of survey and interviews (mixed-methods)~* 6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
41012865|NCT00826085|DRUG|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
41012866|NCT01037790|DRUG|PD-0332991|Given orally, 125 mg QD on a 21-day
41155904|NCT03866434|DRUG|SPD422|Participants will receive 1 mg of SPD422 (2\*0.5 mg) capsule orally on Day 1 and 8 in fasted state.
41331557|NCT00217009|PROCEDURE|Topical Psoralen plus ultraviolet A (PUVA)|
41331558|NCT06332339|BIOLOGICAL|16055 NFL delta Gly4 trimer|200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each)
41331559|NCT06332339|BIOLOGICAL|Trimer 4571|100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each)
41331560|NCT06332339|BIOLOGICAL|Ad4-Env145NFL, 5 x 108 viral particles (vp)|to be administered intranasally (IN) (0.07 mL into 1 nostril)
41482585|NCT05881902|BEHAVIORAL|STANDART CANCER EDUCATİON|The participants in the intervention 2 group will be given the standard training applied by the Ministry of Health in KETEM for women's cancers during home visits, and a total of 4 home visits and 2 SMS reminders will be made.
41482586|NCT00161798|BIOLOGICAL|Tick-borne encephalitis vaccine|
41155905|NCT03866434|DRUG|Omeprazole|Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.
41331561|NCT05381207|DRUG|Montelukast Oral Tablet|Subjects in group A (study) will be treated with Fluticasone Furoate nasal: (50 micrograms/spray) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 months. Subjects group B (control) will receive only topical steroids in an identical regimen
40814059|NCT04082845|OTHER|Education|Web-based patient education
41331562|NCT03027388|DRUG|LB-100|LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m\^2.
41331563|NCT06300346|DRUG|Propofol|Ondansetron
41482587|NCT01602471|DRUG|[F-18]RDG-K5|Approximately fifteen (15) patients with carotid artery stenosis \> 69% will undergo an endarterectomy and will be imaged under PET/CT with \[F-18\]RGD-K5
40814060|NCT03082443|OTHER|Therapeutic group|"The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.~Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.~In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again."
41482588|NCT00761449|DRUG|lenalidomide|Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
40814061|NCT06205355|DEVICE|Analgesia/Nociception Index (ANI) monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to ANI monitor.
41331564|NCT01400139|DRUG|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
41331565|NCT04101344|OTHER|Two fiber-blend snack and four fiber-blend snack|All subjects will complete a 47-day, multi-phase feeding study to evaluate the effect of two snack prototypes containing two different fiber blends on gut community structure and features of host biological state (plasma proteome/ metabolome).
41331566|NCT06101316|DRUG|CB06-036|CB06-036 Capsule
41331567|NCT03392441|OTHER|Insulin Deprivation in Type 1 Diabetic Patients|Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)
41331568|NCT05245994|DRUG|Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy. Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator. The initial dose of olaparib is 300mg twice daily. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.
41331569|NCT05228756|OTHER|Accelerometer|Participants will complete 16 exercise sessions at home wearing an accelerometer
41331570|NCT05766293|DEVICE|extracorporeal shockwave device|Fibroblast cell lines (n=10) were subjected to Shockwaves from extracorporeal shockwave device
41331571|NCT05766293|OTHER|Fibroblast cell lines not subjected to shockwaves from extracorporeal shockwave device|Fibroblast cell lines (n=10) without shockwave exposure
41331572|NCT01616784|OTHER|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
41331573|NCT01616784|OTHER|MDI (levemir® & quick acting insulin) plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
41331574|NCT00531492|BEHAVIORAL|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
41331575|NCT00531492|OTHER|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
41331576|NCT01482572|PROCEDURE|biopsy|percutaneous lung biopsy and aspiration
41331577|NCT06236308|BIOLOGICAL|TTAX03 10mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
41331578|NCT06236308|BIOLOGICAL|TTAX03 25mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
41331579|NCT06236308|BIOLOGICAL|Placebo Comparator: Control Saline|2 mL Sterile, preservative free 0.9% NaCl
41012867|NCT06137833|DIETARY_SUPPLEMENT|APPOPRTAL®|1 sachet of APPORTAL® contains: Vitamin C 37,5 mg; Vitamin E 30 mg; Vitamin PP 18 mg; Vitamin B1 1 mg; Vitamin D 25 μg; Vitamin H 25 μg; L-arginine 1000 mg; L-carnitine 500 mg; Taurine 25 mg; Ginseng e.s. 100 mg; Eleutherococcus e.s. 50 mg; Magnesium 187,5 mg; Iron 14 mg; Zinc 1,5 mg; Iodine 75 μg; Selenium 27,5 μg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg
41155906|NCT03722485|DEVICE|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|Negative Pressure Therapy at -125mmHg for 3.5 hours followed by 10 minute dwell of saline solution for 6-9 days.
41331580|NCT05450744|DRUG|131I-IPA|131I-IPA: injection/solution administrated intravenously via infusion in ascending doses 18F-FET: injection/solution administrated intravenously
41331581|NCT00860990|OTHER|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
41331582|NCT04771546|DEVICE|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
41331583|NCT04202276|OTHER|diet assessment|Food frequency questionnaire to investigate differences in diet of children and adolescents with GERD compared to the age- and sex matched control group.
41331584|NCT05702970|DRUG|Sucrosomial iron|Sucrosomial iron group: administration of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once a day for 24 weeks.
41331585|NCT05702970|DRUG|Vitamin D|administration Vitamin D3 (100,000 IU load at time 0, then 2,000 IU daily) for 24 weeks in combination with of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once daily in Sucrosomial iron and vitamin D group
41331586|NCT05702970|DRUG|Ferric Carboxymaltose 50 MG/ML|Control group \[standard of care\]: administration of FCM (Ferinject®) with a dose between 500 and 2000 mg (depending on body weight and Hb values), to be administered in 1 or 2 doses (time 0 ± 6 weeks) with possible additional administration of 500 mg at week 12 in case of persistent ID.
41331587|NCT04584931|PROCEDURE|coronally advanced flap|flap surgery to achieve root coverage at gingival recession defect
41331588|NCT04584931|PROCEDURE|restorative intervention|colored composite restoration to camouflage the gingival recession defect
41482589|NCT02025751|DRUG|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
41482590|NCT02025751|DRUG|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
41331589|NCT01676792|DRUG|SR-T100 gel with 2.3% of SM in Solanum undatum plant extract|Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon \& before bed time. Medication should be reapply after bathing or cleaning.
41331590|NCT02251158|DRUG|Tipranavir oral solution|
41331591|NCT02251158|DRUG|Tipranavir capsules|
41482591|NCT02276768|DRUG|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
41331592|NCT02251158|DRUG|Ritonavir oral solution|
41482592|NCT02276768|DRUG|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
41482593|NCT02276768|DRUG|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
41331593|NCT02251158|DRUG|Ritonavir soft gel capsules|
41331594|NCT02251158|OTHER|High fat breakfast|
41482594|NCT02276768|DRUG|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
41012868|NCT06137833|OTHER|Placebo|Ingredients: Maltodextrin, acidifying agent: citric acid, flavours, anticaking agent: tricalcium phosphate, beetroot juice powder; sweetener: sucralose, anti-caking agent: silicon dioxide, colouring agent: beta-carotene
41331595|NCT03906175|DEVICE|Whole-body hyperthermia|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
41331596|NCT00555568|BEHAVIORAL|recovery oriented mental health peer support group|This is a recovery-focused mental health education and support group led by peer facilitators
41331597|NCT00555568|BEHAVIORAL|recovery-oriented mental health clinician-led group|This is a recovery-focused mental health education and support group led by a mental health clinician
41331598|NCT01620697|PROCEDURE|Colorectal surgery|Colorectal surgery
41012869|NCT04316182|DRUG|Cabozantinib|Cabozantinib 60 mg/day. Cabozantinib dose will be modified upon development of adverse events.
41012870|NCT03759093|DRUG|Bortezomib|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
41331599|NCT01674738|DRUG|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
41331600|NCT01674738|DRUG|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
41331601|NCT01674738|DRUG|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
41331602|NCT04984564|OTHER|None. As this was an observational study.|Observational study.
41331603|NCT00377533|DEVICE|wheelchair rear anti-tip device|assistive device
41331604|NCT06161857|OTHER|No intervention|There is no intervention this is an observational study to develop a diagnostic test
41331605|NCT04572581|OTHER|Donor Breast Milk|Donor breast milk will be given to the newborn if supplementation is required
41331606|NCT01153893|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
41331607|NCT01153893|BIOLOGICAL|InfanrixTM|Intramuscular injection, 1dose
41331608|NCT05750238|OTHER|no intervention|no intervention, survey was applied to the participants
41482595|NCT02276768|OTHER|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
41482596|NCT00441350|DRUG|OM 40|Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
41482597|NCT00441350|DRUG|OM/HCTZ 40/12.5|Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
41482598|NCT03987347|OTHER|Observational|People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
41482599|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 1|2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
41331609|NCT03082417|OTHER|Implementation|"The PAINFREE Initiative is a Multifaceted intervention:~1. Educating and providing point-of-care tools to nurses working at Emergency Department to improve pain management in older adults with fractures~2. Educating and providing point of care tools to Emergency Departments physicians working at Emergency Department to improve pain management in older adults with fractures~3. Inform the patients and their family about how to better manage the pain after a fracture"
41331610|NCT05799209|DEVICE|Float Pool|Participant floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
41482600|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 2|2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
41482601|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_ Dose level 3.|2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
41331611|NCT05799209|DEVICE|Float Chair|Participant floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
41331612|NCT05477446|BIOLOGICAL|CD207 CAR-T cells|Single dose of CD207 CAR-T cells administered IV
41331613|NCT05284058|OTHER|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
41331614|NCT05308160|DRUG|Dapagliflozin 10Mg Tab|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
41331615|NCT05308160|DRUG|Placebo|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
41331616|NCT06063512|OTHER|sweet orange oil inhalation|sweet orange oil with inhalers will be carried out in an open clinical setting. Three drops of sweet orange oil will be dispensed into a cotton wick of the inhaler, The children will be asked to inhale the aroma from the inhalers for 2 minutes followed by an induction period of 15 minutes
41331617|NCT00696436|DRUG|Azilsartan medoxomil|"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
41331618|NCT00696436|DRUG|Azilsartan medoxomil|"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
41482602|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_ Dose level 4|2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
41482603|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 5|2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
41482604|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 6|1 dose of study intervention is administered to participants intramuscularly.
41012871|NCT03759093|DRUG|Cyclophosphamide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
41012872|NCT03759093|DRUG|Dexamethasone|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
41012873|NCT03759093|OTHER|CURATE.AI-Guided dosage modulation|CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen
41012874|NCT03759093|DRUG|Thalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
41331619|NCT00696436|DRUG|Valsartan|"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
41331620|NCT00696436|DRUG|Olmesartan|"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
41331621|NCT00696436|DRUG|Placebo|Matching placebo, orally, once daily for up to six weeks.
41331622|NCT04282876|DRUG|Degarelix|Patients receiving Degarelix
41331623|NCT03230721|PROCEDURE|Thulium-fiber laser enucleation of the prostate|A high-power (120 W) thulium fiber laser (Urolase, IPG IRE-POLUS, Russia) with wavelength of 1940 nm was used for thulium laser enucleation. In our study, we used a 600-μm laser fiber. The operations were performed at power of 60 W energy of 1.5 J and repetition rate of 40 Hz. Laser power in the verumontanum zone was decreased to 30 W and repetition rate to 20 Hz.
41482605|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 7|1 dose of study intervention is administered to participants intramuscularly.
41482606|NCT06382311|DRUG|Placebo|2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 1 dose is administered to participants in Phase 2 Part B.
41331624|NCT03230721|PROCEDURE|Monopolar enucleation of the prostate|Monopolar enucleation was performed with a high-frequency generator (50-60 Hz), a pusher-electrode, and a hook-electrode.
41331625|NCT03230721|PROCEDURE|Ho:YAG laser enucleation of the prostate|Holmium laser enucleation of prostatic hyperplasia was performed with a 100 W laser (VersaPulse Powersuite 100, Lumenis, USA/Israel) with wavelength of 2100 nm and 550-μm fiber at the tip. The operation was performed at power of 70 W; it was decreased to 40 W when incisions were made at the verumontanum.
41331626|NCT00292955|DRUG|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
41331627|NCT01016808|DRUG|Q8003|Q8003 is a combination of morphine sulfate and oxycodone HCl
41331628|NCT01016808|DRUG|Morphine sulfate|One morphine sulfate 12 mg IR capsule q6h
41331629|NCT01016808|DRUG|Oxycodone HCl|One oxycodone HCl 8 mg IR Capsule q6h
41331630|NCT04841252|DEVICE|FDA approved GE LOGIQ E9 (LE9) ultrasound|Ultrasound
40814062|NCT06205355|DEVICE|Standard monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to the clinician's decision
40814063|NCT05311943|DRUG|olverembatinib|olverembatinib, 40mg, taken orally once every other day of a 28-day cycle
40814064|NCT00615225|PROCEDURE|Muscle biopsy|Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
40814065|NCT02661555|OTHER|Aerobic exercise|
40814066|NCT05523128|GENETIC|ZS802|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg.
41331631|NCT04841252|DEVICE|Alpinion clinical ultrasound machine|Ultrasound
41331632|NCT05223036|PROCEDURE|Biopsy|Undergo biopsy
41331633|NCT05223036|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41331634|NCT05223036|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
41482607|NCT01405287|DEVICE|PTCA with stent placement|PTCA with stent placement (Drug Eluting Stent)
40814067|NCT02137018|DEVICE|PPL fixation by BP|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
41331635|NCT05223036|BIOLOGICAL|Obeticholic Acid|Given PO
41331636|NCT05223036|DRUG|Placebo Administration|Given PO
41331637|NCT05223036|OTHER|Questionnaire Administration|Ancillary studies
41331638|NCT05946707|DRUG|restrictive oxygen supply|Oxygen supply will be limited to guarantee normoxia at the beginning of OLV.
41331639|NCT05946707|DRUG|liberal oxygen supply|Oxygen supply will be maximized to 100% at the beginning of OLV
41331640|NCT01000025|DRUG|PF-00299804|PF-804 45 mg PO, daily
41331641|NCT01000025|DRUG|Placebo|Placebo 45 mg PO, daily
41331642|NCT00778726|DRUG|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
41331643|NCT03928860|OTHER|OMT session|Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
41331644|NCT00279032|DRUG|GW406381|
41331645|NCT00606177|DRUG|Aripiprazole|oral, 24mg(4 tablets)/day
40814068|NCT02137018|DEVICE|PPL mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
40814069|NCT03378609|OTHER|Vocal Fatigue Index (VFI)|collection of 190 consecutive data sets, participants give separate consent for participating a retest or an interview, retest will be realised with the 10 following volunteers
40814070|NCT01851265|DRUG|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
40814071|NCT01851265|OTHER|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
40814072|NCT01851265|OTHER|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
40814073|NCT01851265|OTHER|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
40814074|NCT02899650|OTHER|exercise|acute downhill running
40814075|NCT02966145|OTHER|Observational Study|
40814076|NCT04177953|DRUG|Carboplatin AUC 5|chemotherapy iv
40814077|NCT04177953|DRUG|Cisplatin 75 mg/m2|chemotherapy iv
41331646|NCT00606177|DRUG|placebo|oral, 0mg(4tablets)/day
41331647|NCT05887557|OTHER|Active Referral|As an implementation science study, all clinical intervention components will be delivered as part of routine clinical care at participating clinical sites. Clinicians and staff at referral sites throughout San Francisco and Alameda counties (emergency departments, psychiatric emergency services, community clinics, care navigation and case management programs, and community-based services) will refer eligible patients who are out of care and are interested in linking to drop-in and/or mobile care services at one of the study sites. Clinical referrals will include basic patient information and contact/locator information to facilitate linkage to care. Referrals will be site-specific based on the site where the patient is interested in accessing care.
41331648|NCT05887557|OTHER|Drop-In Multidisciplinary HIV Care|Each site will independently implement a drop-in multidisciplinary site-based HIV care model. Core intervention features include drop-in care (no appointments), panel management to review clinical progress for all referred patients, and case management. Each site may include adaptations to the care model determined during Aim 1 formative work.
41331649|NCT05887557|OTHER|Mobile HIV Care|Each site will independently implement a mobile care model using site-specific resources. At a minimum, the mobile care team will include a clinical nurse with telemedicine (video visit) consultation with a clinician (MD/NP/PA). Mobile teams will also administer medications (including long-acting ART when available) and collect laboratory specimens (e.g. HIV viral loads)
41331650|NCT05887557|OTHER|Staged Care|Clinical decision rules to escalate/de-escalate care intensity will be finalized developed during Aim 1 formative work, though will be based on a combination of clinical assessment and patient preference.
41331651|NCT05887557|OTHER|Identify and prepare champions at referral sites|Identify implementation champions at each referral site. Champions will receive marketing materials to promote uptake of clinical referrals to a drop-in/mobile care site by referral site providers/staff. This strategy is aimed at improving referring provider confidence in the value of referral to the care model, reduce perceived referral complexity/improve provider capability to refer, and provide positive peer pressure to promote referrals.
41331652|NCT05887557|OTHER|Audit and feedback at referral sites|Investigators will provide monthly reports to implementation champions at each referral site on aggregate number of referrals and the success of referrals (proportion linking to care). This strategy is aimed at improving perceived value of the intervention and increasing provider motivation to refer.
41482608|NCT01875471|DEVICE|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
41482609|NCT01875471|DEVICE|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
41482610|NCT03504280|DRUG|Cholecalciferol|
41482611|NCT03036839|DRUG|LDV/SOF|90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
41482612|NCT00166270|DEVICE|ExAblate 2000|
41482613|NCT05291455|DRUG|Lacosamide|lacosamide will be given
41482614|NCT05291455|DRUG|Phenobarbital|phenobarbital will be given
41331653|NCT05887557|OTHER|Build a coalition among referral and clinical sites|Investigators will facilitate formation of a coalition of referral and clinic sites to improve cross-site collaboration and promote positive peer pressure to improve intra-site communication and increase referrals.
41482615|NCT05128370|OTHER|Visual observation of arm swing during walking|The gait pattern of the stroke patients will be scored based on a visual observation scale. Additional components concerning the arm swing have been added to an existing scale.
41482616|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose level 1 or 2|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
41482617|NCT03736928|OTHER|placebo|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
41482618|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose 3|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
41482619|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose 4|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
40814078|NCT04177953|DRUG|Pemetrexed 500 mg/m2|chemotherapy iv
41331654|NCT05887557|OTHER|Assess for readiness and identify barriers|Investigators will conduct patient in-depth interviews and clinical team focus group discussions to assess barriers to implementation of the clinical intervention. Findings from interviews and focus group discussions will inform site-specific implementation plans and adaptation of the intervention.
41331655|NCT05887557|OTHER|Promote adaptability|During a co-design workshop among drop-in/mobile care site teams and site-specific meetings, the study team will collectively finalize core clinical intervention components and outline site-specific adaptations (i.e. adaptable periphery of clinical intervention).
41482620|NCT03265067|DEVICE|autoRIC|Application of the autoRIC device
41482621|NCT00546572|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
41482622|NCT00546572|BIOLOGICAL|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
41482623|NCT00003517|DRUG|antineoplaston A10|
41482624|NCT00003517|DRUG|antineoplaston AS2-1|
41482625|NCT00003517|DRUG|bicalutamide|
41482626|NCT00003517|DRUG|flutamide|
41482627|NCT00003517|DRUG|leuprolide acetate|
41482628|NCT00003517|PROCEDURE|alternative product therapy|
41482629|NCT00003517|PROCEDURE|antiandrogen therapy|
41482630|NCT00003517|PROCEDURE|biological therapy|
40814079|NCT04177953|BIOLOGICAL|Nivolumab Injection|Human monoclonal antibody
40814080|NCT04405778|BIOLOGICAL|TAK-102|TAK-102 intravenous infusion
41482631|NCT00003517|PROCEDURE|biologically based therapies|
41482632|NCT00003517|PROCEDURE|cancer prevention intervention|
40814081|NCT03331601|DRUG|68GaNOTA-Anti-HER2 VHH1|Injection of the radiopharmaceutical and PET/CT 90 min post injection
40814082|NCT04378998|OTHER|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
41331656|NCT05887557|OTHER|Develop a formal implementation blueprint|With each drop-in/mobile care team, develop site-specific implementation plan that includes defining care team and leadership structure, clinic workflow, implementation timeline, and progress measures. This process, and the resulting blueprint, will incorporate site-specific barriers and facilitators to implementation.
41331657|NCT05887557|OTHER|Develop educational materials; conduct ongoing training|Compile a manual that includes detailed description of core intervention features, planned local adaptations, and implementation guidance. We will conduct site-specific meetings to provide training on this manual. We will also conduct regular (at least monthly) meetings between the study team and the clinic site to provide technical assistance and coaching.
41482633|NCT00003517|PROCEDURE|complementary and alternative therapy|
41482634|NCT00003517|PROCEDURE|differentiation therapy|
41482635|NCT00003517|PROCEDURE|endocrine therapy|
41482636|NCT00003517|PROCEDURE|hormone therapy|
41482637|NCT01072266|DRUG|INCB028060|10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
41482638|NCT00038337|PROCEDURE|Health Literacy|
41482639|NCT01612884|DRUG|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
40814083|NCT02285023|OTHER|CU-Q2oL|"The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire."
40814084|NCT03877315|DEVICE|Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
41155907|NCT03722485|BIOLOGICAL|Collagenase Ointment|Collagenase ointment applied daily to the wound and covered with secondary dressing for 6-9 days.
41331658|NCT05887557|OTHER|Create a learning collaborative|Create a cross-site learning collaborative with periodic meetings and workshops throughout the study period to facilitate cross-site communication, sharing of best practices and encourage positive peer pressure to support implementation.
41331659|NCT00086216|DRUG|Atiprimod|Oral, once a day, 14 days on 14 days off
41331660|NCT05698108|DEVICE|Instrument Assisted Soft Tissue Mobilization (IASTM)|Tools designed for soft tissue mobilization
41482640|NCT01612884|DRUG|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
41482641|NCT00463320|DRUG|Pazopanib eye drops and Allergen Refresh Plus eye drops|
41482642|NCT01991665|OTHER|Digital examination|
41482643|NCT01991665|OTHER|Sonography evaluation|
41482644|NCT04531657|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
41482645|NCT05645588|BEHAVIORAL|Pranayama assisted trauma-focused standard psychotherapy (TF-SPT)|To prepare patients for the TF-SPT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-SPT units.
40814085|NCT03877315|DEVICE|Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
40814086|NCT02035436|OTHER|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
40814087|NCT02035436|OTHER|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
40814088|NCT05364970|COMBINATION_PRODUCT|VR_Training_1PP|Immersive VR scenario of physical training with avatar embodiment
41155915|NCT02894385|DRUG|BAY1841788|600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
41155916|NCT02502721|DRUG|DWC20151|
41155917|NCT02502721|DRUG|DWC20152|
41482646|NCT05645588|BEHAVIORAL|Trauma-focused standard psychotherapy (TF-SPT)|Patients wait for 10 TF-SPT units and then are offered to learn pranayama
41482647|NCT00500175|DEVICE|TempTouchRM|
41482648|NCT00500175|DEVICE|Offloading|
41482649|NCT04102241|DRUG|15mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
41482650|NCT04102241|DRUG|Placebos|Placebos are the same as drugs, but contain no Hemay005.
41482651|NCT00793494|OTHER|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
41482652|NCT00793494|OTHER|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
41482653|NCT03763760|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
41331661|NCT05698108|OTHER|Conventional Physical Therapy|Moist Hot pack, Ultrasound, Deep Friction Massage, Stretching and Strengthening Exercises.
41331662|NCT01781663|DEVICE|KAM2904 Face Cream|
40814089|NCT05364970|COMBINATION_PRODUCT|VR_Training_3PP|Immersive VR scenario of physical training without avatar embodiment
40814090|NCT02292082|DRUG|Bupivacaine|
40814091|NCT02292082|DRUG|Morphine|
40814092|NCT02292082|DRUG|Methylprednisolone|
40814093|NCT02292082|DRUG|Cefazolin|
40814094|NCT02292082|DRUG|Normal saline|
40814095|NCT02292082|DRUG|Midazolam|
40814096|NCT02292082|DRUG|Propofol|
40814097|NCT02292082|DRUG|Dexamethasone|
40814098|NCT02292082|DEVICE|8 MHz. Chiba needle, 22 G / 4 inches|
40814099|NCT00431444|DRUG|Raloxifene|
40814100|NCT00431444|DRUG|Zoledronic acid|
40814101|NCT00431444|DRUG|Placebo oral pills|
40814102|NCT00431444|DRUG|Placebo intravenous (i.v.) infusion|
40814103|NCT05921266|DIETARY_SUPPLEMENT|Urolithin A|Participants in the intervention group will receive 500 mg of urolithin A twice daily for 4 weeks (1,000 mg daily in total). The supplement will be administered in the form of softgels (4 softgels daily).
40814104|NCT05921266|OTHER|Placebo|Participants in the control group will receive 0 mg of urolithin A twice daily for 4 weeks. The placebo will be administered in the form of inactive capsules (4 capsules daily).
41155918|NCT00703599|PROCEDURE|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
41331663|NCT01781663|DEVICE|KAM3008 Body Lotion|
41331664|NCT01781663|OTHER|petrolatum-based moisturizer|
41331665|NCT04009460|DRUG|ES101|ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
41331666|NCT04356209|OTHER|e-PRO Intervention|"Statements of symptoms and patients' health status (PROs) will be collected via a web interface, including access and use in patients with burden symptoms.~The platform will include four items concerning 7 side effects of fibrosis of grade \> 2 in breast cancer. Patients will be encouraged to evaluate on a 5-point Likert scale the frequency, the intensity and the repercussions on the daily life of some symptoms during the last 7 days, in particular on:~* general pain~* anxiety~* sadness~* texture of the treated breast~* Patients will also be invited to express themselves on the severity of two other symptoms of their choice, to their worst degree, by listing and rating them on a 5-point scale ranging from None to Very severe Finally, the aesthetic impact will be evaluated by patients on a visual analogue scale (VAS) of 0 to 100mm"
41331667|NCT04356209|DRUG|Pravastatin|All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
40814105|NCT00022204|DIETARY_SUPPLEMENT|vitamin E|
41155919|NCT05649904|DEVICE|IRRAflow with Active Fluid Exchange System|"IRRAflow® Active Fluid Exchange System is an intracranial drainage system intended for use by professional medical hospital personnel, trained and experienced in neurosurgical medical care.~The intracranial pressure is kept at a safe level by draining excessive intracranial fluid. The system incorporates an irrigation support mechanism, used to irrigate the system in a controlled, programmed manner to minimize catheter occlusion. Additionally, a manual bolus can be given to facilitate keeping the catheter clear of occlusion or to clear the catheter of occlusion if one is present. This mechanism works by producing a bolus pulse using short periods of high flow (i.e. flow pulses)."
41155920|NCT05649904|DEVICE|External Ventricular Drain|The External Ventricular Drain (EVD) is used standard of care at the study site for ventricular drainage.
41331668|NCT02591043|PROCEDURE|Outcome after surgery|Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
40814106|NCT00022204|DRUG|pentoxifylline|
40814107|NCT00022204|PROCEDURE|quality-of-life assessment|
40814108|NCT00820859|BEHAVIORAL|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
40814109|NCT00820859|BEHAVIORAL|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
40814110|NCT05610618|OTHER|Visual stimulation|Participants will be displayed with photographs of scenes and objects which predictability and sharpness will be manipulated
40814111|NCT04848220|DRUG|Temanogrel|Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)
40814112|NCT04848220|DRUG|Placebo|Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
40814113|NCT01670786|PROCEDURE|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
40814114|NCT05282030|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablets Route of administration: oral
40814115|NCT02503670|BEHAVIORAL|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
40814116|NCT02503670|OTHER|Control Group|Continue with standard care.
40814117|NCT05482529|OTHER|Integrative omics|Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT\&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
40814118|NCT00585442|DRUG|calcitriol|1.0 mcg daily
40814119|NCT00585442|DRUG|Placebo|Placebo
40814120|NCT04823702|BIOLOGICAL|Aldafermin|Biological: Aldafermin (NGM282) Subcutaneous Injection
40814121|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months and booster immunization at 18 months of age.
40814122|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months.
40814123|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax)|Performed booster immunization at 18 months of age.
40814124|NCT00416065|DEVICE|PET/CT imaging|
41012875|NCT03759093|DRUG|Bortezomib|Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
41012876|NCT03759093|DRUG|Cyclophosphamide|Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
41012877|NCT03759093|DRUG|Thalidomide|Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
41482654|NCT01427842|DRUG|DEVINE vancomycin regimen|The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
41482655|NCT01653613|GENETIC|DNA analysis|
41331669|NCT02408926|BIOLOGICAL|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
41482656|NCT01653613|GENETIC|fluorescence in situ hybridization|
41155921|NCT05783154|BIOLOGICAL|Autologous Adipose Tissue-Derived Mesenchymal Stem Cell|"After cleaning the knee with 10% povidone-iodine (Povidep10% solution, manufactured by Jayson Pharmaceuticals limited, Bangladesh) and draping it in a sterile manner, the injection site will be anesthetized with 0.5% bupivacaine (Inj. Bupi Heavy 0.5%, Manufactured by Popular Pharmaceuticals limited, Bangladesh) superficially outside of joint capsule.~Within one hour of preparation, the autologous AT-MSC will be injected into each knee joint through medial tibio-femoral compartment in group -I using a 38-mm 18- gauge needle"
41155922|NCT00900471|OTHER|biologic sample preservation procedure|
41155923|NCT00900471|OTHER|medical chart review|
40814125|NCT02632669|RADIATION|Hemigland focal LDR brachytherapy|The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre-treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine-125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks, 3, 6, 9, 12,18, 24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
40814126|NCT02545517|BIOLOGICAL|Rabipur|Participants in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm.
40814127|NCT02545517|PROCEDURE|Blood sampling|Blood samples were drawn from all participants at Day 1 and then at subsequent year intervals from extension study Day 1 onwards.
40814128|NCT02545517|BIOLOGICAL|Purified Chick-Embryo Cell Rabies Vaccine|1 booster dose of 1.0 mL of Purified Chick-Embryo Cell Rabies Vaccine intramuscular (IM).
40814129|NCT05457907|DEVICE|Ultrasound device|Low energy ultrasound therapy will be administered to the spleen
40814130|NCT05010486|PROCEDURE|rectal surgery|
41331670|NCT02408926|BIOLOGICAL|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
41331671|NCT02408926|BIOLOGICAL|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
41331672|NCT02408926|BIOLOGICAL|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
41012878|NCT03759093|DRUG|Dexamethasone|40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
41012879|NCT03759093|DRUG|Lenalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
41012880|NCT03759093|DRUG|Lenalidomide|Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.
41012881|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
41012882|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound in MV patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
41012883|NCT05740722|DIETARY_SUPPLEMENT|Nicotinamid riboside|500 mg x 2 po
41155924|NCT05662215|DRUG|CK-3828136|CK-3828136
41331673|NCT00967226|DRUG|propranolol|propranolol 0.5 mg/kg orally, 4 per day - 4-6 months
41482657|NCT01653613|GENETIC|gene expression analysis|
41482658|NCT01653613|GENETIC|microarray analysis|
41482659|NCT01653613|GENETIC|mutation analysis|
41482660|NCT01653613|GENETIC|polymorphism analysis|
41482661|NCT01653613|GENETIC|reverse transcriptase-polymerase chain reaction|
41482662|NCT01653613|OTHER|laboratory biomarker analysis|
41482663|NCT02495181|DRUG|Intravitreal Aflibercept|
41482664|NCT03065595|DIETARY_SUPPLEMENT|Ophiochepalus striatus extract|each sachet of ophiochepalus striatus extract is poured into 50 mL normal water and drink two times/day
41482665|NCT03065595|OTHER|Placebo|each sachet of placebo drug is poured into 50 mL normal water and drink two times/day
41482666|NCT03083821|DRUG|Baraclude|Specified dose on specified day
41482667|NCT02839486|OTHER|vancomycin pharmacokinetics|vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
41331674|NCT00967226|DRUG|Prednisolone|1.0 mg/kg orally, 2 per day 4-6 months
41331675|NCT04059991|BIOLOGICAL|Influenza Vaccination|Only subjects vaccinated against influenza will be enrolled. The study itself is observational
41331676|NCT04018586|DEVICE|AVACEN 100|AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes
41331677|NCT04018586|DEVICE|AVACEN 100 Heat Only|AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes
41331678|NCT04018586|DEVICE|AVACEN Sham|AVACEN 100 neither heats nor pulls a vacuum to hand
41331679|NCT06508437|BIOLOGICAL|Influenza Vaccination|Standard Dose QIV (15µg Hemagglutinin) - VaxigripTetra Suspension for injection, 0,5ml prefilled syringe
41331680|NCT06306352|OTHER|Vibrotactile feedback|The ABLE exoskeleton is accompanied by a vibrotactile feedback belt which users wear around their chest to receive real-time feedback during the double support phase. This feedback can assist them in their weight shift during the double support phase.
41331681|NCT01816256|PROCEDURE|Upper gastrointestinal endoscopy and Doppler ultrasound|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
41331682|NCT00249795|DRUG|Irbesartan|oral administration (tablets) once daily
41331683|NCT00249795|DRUG|placebo|oral administration (tablets) once daily
41331684|NCT04494958|DRUG|Combination, Palbociclib + Binimetinib|"Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily."
41331685|NCT05552859|DRUG|Insulin glargine 300 U/mL|Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
41331686|NCT05552859|DRUG|Insulin degludec 100 U/mL|Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
41331687|NCT05671315|DRUG|Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue|"1.Peginterferon alfa-2b injection: 180μg, subcutaneously inject, once a week, from week 1 to Week 48.~2, NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
41331688|NCT05671315|DRUG|Nucleos(t)ide analogue|"NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
41331689|NCT03014921|OTHER|iron injection|Injection of a 250mL saline solution added with 500mg of iron (Ferinject)
41331690|NCT03014921|OTHER|saline solution injection|Injection of a 250mL saline solution
41331691|NCT05221255|OTHER|spinal magnetic stimulation|"* Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~* Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~* Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds."
41331692|NCT00683007|OTHER|Volume resuscitation (Crystalloid)|Crystalloid vs. Hypertonic Saline Solution
41331693|NCT00683007|OTHER|Volume resuscitation (Hypertonic Saline Solution)|Crystalloid vs. Hypertonic Saline Solution
41331694|NCT02738762|OTHER|glutamine supplementation|glutamine supplementation guided by glutamine levels in plasma
41331695|NCT03419000|GENETIC|blood sample|Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes
41331696|NCT01040845|DRUG|Norethindrone/Ethinyl Estradiol|one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
41331697|NCT01040845|DRUG|Colchicine|0.6mg tablet every 12 hours on Days 8 to 21
41331698|NCT01040845|DRUG|Placebo (for Colchicine)|placebo tablet every 12 hours on Days 8 to 21
41482668|NCT02839486|OTHER|cefoxitin pharmacokinetics|cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
41331699|NCT06392750|BEHAVIORAL|Collection of tumor tissue specimens|Collection of tumor tissue specimens during surgery
41482669|NCT01207999|PROCEDURE|Collection of cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.
41482670|NCT01207999|OTHER|Data collection|Questionnaire completion
41482671|NCT04121650|BEHAVIORAL|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
41482672|NCT03721731|DEVICE|Obesity treatment with a Plication device|Plicating the stomach to treat obesity
41331700|NCT01512472|DRUG|degarelix|Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
41482673|NCT06010030|DEVICE|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. Anodal or sham tDCS will be administered.
41331701|NCT04965116|DRUG|Progestin Only Contraceptive Pills|Daily pill (placebo or active tablet)
41482674|NCT06010030|BEHAVIORAL|Speech Therapy|Participants will receive either semantic or phonological focused speech therapy
41482675|NCT04420338|BIOLOGICAL|Blood sample|rapid serological tests carried out
41482676|NCT04420338|BIOLOGICAL|Serum tube collection|SARS-COV2 seroconversion assay
41482677|NCT05315622|OTHER|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy
41482678|NCT05315622|OTHER|Placebo|"Manual tension without reaching the manipulation thrust"
41482679|NCT02596321|DRUG|Mitizax|Allergen extract
41482680|NCT02596321|DRUG|Placebo|Placebo tablet
41482681|NCT06375265|BEHAVIORAL|digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|Preoperative hybrid intervention (in-person or via phone/video) over 4 weeks using content from the CBT-I Coach app from Veteran Affairs.
41482682|NCT06375265|BEHAVIORAL|Sleep Health Education|Sleep Health Education materials provided
41482683|NCT05647226|COMBINATION_PRODUCT|Digital therapeutic and intensive lifestyle programme|Initial 12-week LED and behaviour education app.
41482684|NCT05647226|OTHER|Standard of care|Standard of care.
41482685|NCT03805308|PROCEDURE|Intra-arterial Therapy|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
41482686|NCT03374241|BIOLOGICAL|HM15211 or Placebo|Long-acting tri-agonist
41482687|NCT00004135|BIOLOGICAL|filgrastim|
41482688|NCT00004135|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41482689|NCT00004135|DRUG|cyclophosphamide|
41482690|NCT00004135|DRUG|fludarabine phosphate|
41482691|NCT00004135|PROCEDURE|peripheral blood stem cell transplantation|
41482692|NCT02612220|PROCEDURE|BioFoam® Surgical Matrix|Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.
41482693|NCT02612220|OTHER|Conservative hemostasis|Complete hemostasis will be achieved without the use of topical agents
41482694|NCT05889234|DEVICE|Modified Electroconvulsive Therapy|MECT is performed using the Thymatron System IV (Somatics LLC, LakeBluff, IL, USA) electroconvulsive therapy (ECT) machine. Prior to ECT, all patients undergo laboratory tests such as routine blood, liver, kidney and thyroid function and an ECG and remain fasted for 12 hours. Initial treatment power is considered by age: percentage of power = age x 0.7. Stimulation power is adjusted according to seizure duration. If the seizure duration is less than 25 seconds, the energy is increased by 5% in the subsequent treatments. Anaesthesia and muscle relaxation were administered with propofol (1.5-2 mg/kg) and succinylcholine (0.5-1 mg/kg), respectively, and subjects were awakened after ECT treatment and adverse effects, such as subjective memory impairment, headache or nausea/vomiting, were recorded. Frequency of ECT treatment: 3-4 times per week for a total of 6-8 sessions
41482695|NCT05889234|DRUG|Conventional pharmacotherapy|Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.
41482696|NCT00821873|OTHER|CR Plug|CR Plug will be placed in the harvest site
41331702|NCT05833555|BEHAVIORAL|MH task-sharing training|Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
41482697|NCT04872972|OTHER|Simulation based learning|Faculty development courses on simulation based learning
41482698|NCT01806818|DRUG|Epirisone 50mg or placebo TID|3 times a day after meals for 1 week
41482699|NCT00944268|DRUG|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
41482700|NCT02494700|RADIATION|External Beam Radiation Therapy|Undergo orbital EBRT
41482701|NCT02494700|DRUG|Orbital Radiation|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
41482702|NCT03082664|DEVICE|PICO Single Use Negative Pressure Wound Therapy|The PICO device will be placed over the closed cesarean section incision.
40814131|NCT03648177|BEHAVIORAL|IPGT|Behavioral Intervention for Patients with Chronic Pain
40814132|NCT03648177|BEHAVIORAL|Treatment as Usual|Standard Care
40814133|NCT00441428|DRUG|solifenacin|
40814134|NCT03883919|DRUG|5-FU|-Standard of care drug
40814135|NCT03883919|DRUG|Leucovorin|-Standard of care drug
40814136|NCT03883919|DRUG|Liposomal Irinotecan|-Standard of care drug
41331703|NCT05833555|BEHAVIORAL|Supervision|Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.
41331704|NCT05833555|BEHAVIORAL|Learning Collaborative|A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.
41331705|NCT05833555|OTHER|Technology Intervention|To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.
41331706|NCT04740060|OTHER|Augmented Feedback without Virtual Reality(VR|"For Walking Speed:One-minute fast walking with visual augmented feedback without VR interface (we ask participants to look at a screen where their walking speed and distance are tracked and increase their speed).~For Step Length: Maximum step length with visual augmented feedback without VR interface in which we ask participants to look at a screen where their step length is displayed and attempt to increase their step length up."
41331707|NCT04740060|OTHER|Augmented Feedback with Non-Game based VR|"For Walking Speed:One-minute fast walking with basic VR interface (we ask participants to look at a screen where their avatar walker representative will be represented in a virtual walking environment and try to make the avatar walk faster).~For Step Length: Maximum step length with basic VR interface in which we ask participants to look at their avatar feet in a virtual stepping environment and step with the avatar foot as far as possible."
41331708|NCT04740060|OTHER|Augmented Feedback with Game based VR|"For Walking Speed: One-minute fast walking with the VR Racing exergame (we ask participants to look at a screen where their avatar walker representative present in a virtual racing environment with other avatar racers and try to beat the avatar racers).~For Step Length: Maximum step length with the VR Stepping Exergame (we ask participants to look at their avatar legs and avatar animals in a virtual stepping environment and try to step over the avatar animals without touching the animal."
41331709|NCT03422640|DRUG|Apremilast|Open label treatment with apremilast
41331710|NCT01297946|DEVICE|Conventional continuous subcutaneous insulin infusion therapy|
41331711|NCT01297946|DEVICE|Dual-hormone closed-loop|
41331712|NCT03554850|DEVICE|Trevo® Retriever|Stent retriever procedure
40814137|NCT03883919|DRUG|Paricalcitol|-Investigational drug
40814138|NCT03883919|PROCEDURE|Serum and plasma blood samples|-baseline, day 1 of each cycle beginning with cycle 2
40814139|NCT03883919|PROCEDURE|Tumor biopsy|"* 5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~* After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible."
40814140|NCT03273452|DRUG|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
40814141|NCT01814878|DRUG|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours
41155925|NCT05662215|DRUG|Placebo for CK-3828136|Placebo for CK-3828136
41155926|NCT06647407|BIOLOGICAL|Pentavalent Meningococcal ABCYW vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
41155927|NCT06647407|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection in vial Route of administration: Intramuscular (IM)
41331713|NCT01917708|DRUG|Abatacept|All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
41331714|NCT03457766|DEVICE|HIFU|Ultrasound (Esaota MyLabSeven) imaging system using (SL2325) probe with (6-19 MHz) frequency
41331715|NCT04296916|DRUG|IOP lowering eye drops|"1. Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~2. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~3. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~4. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops."
41331716|NCT02623387|PROCEDURE|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
41331717|NCT03772340|DRUG|Tradipitant|Oral capsule
41331718|NCT03772340|DRUG|Placebo|Oral capsule
40814142|NCT01814878|DRUG|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
40814143|NCT03631004|DRUG|Olanzapine|olanzapine 10 mg is given before surgery
40814144|NCT05901675|OTHER|Lifestyle Management Program|The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.
40814145|NCT05901675|OTHER|Post-stroke Optimization of Walking using Explosive Resistance|POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
40814146|NCT06450834|DEVICE|Ostene|Soluble Bone Hemostasis Implant Material
41331719|NCT04092010|BEHAVIORAL|Problem-solving education (PSE)|PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.
41331720|NCT04092010|BEHAVIORAL|Engagement sessions|Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)
41331721|NCT04092010|BEHAVIORAL|Usual care|Normal services provided children and their mothers in Head Start
40814147|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
41331722|NCT04633031|DEVICE|Boston|
41331723|NCT04633031|DEVICE|Cheneau|
41331724|NCT03048942|DRUG|Cabazitaxel|3 weekly cyctotoxic chemotherapy
41331725|NCT03048942|DRUG|Paclitaxel|Weekly cyctotoxic chemotherapy
41331726|NCT00927758|DRUG|fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg|fluticasone propionate/salmeterol diskus
41482703|NCT03580174|OTHER|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed therapy protocol one hour in a session, 2 times in a week during 8 weeks. GDPT will be a structural protocol and consists of daily life activities as sit to stand and reach, treadmill exercises, balance exercises with bosu-ball, orthotics, home program, following with exercise-diary.
40814148|NCT00798239|OTHER|Iliac crest autograft|autograft
40814149|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
40814150|NCT06013358|GENETIC|AlloSeq cfDNA|An in vitro diagnostic medical device is employed for predicting damage to and rejection of transplanted organs (kidney, heart, liver, lung) by measuring the ratio of Donor-Derived Cell-Free DNA (dd-cfDNA) to total Cell-Free DNA (cfDNA) extracted from the plasma of patients who have undergone solid organ transplantation. This measurement is carried out using next-generation sequencing methods.
40814151|NCT04549779|PROCEDURE|Low volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%
41331727|NCT03162341|PROCEDURE|ultrasonography|The tophus volume will be assess using ultrasonography.
41331728|NCT03162341|PROCEDURE|DECT|The tophus volume will be assess using dual-energy computed tomography (DECT).
41331729|NCT00030030|DRUG|Silymarin (milk thistle)|
41331730|NCT01809197|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
41331731|NCT01809197|DEVICE|Senofilcon A contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
41331732|NCT01809197|DEVICE|OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)|Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
41331733|NCT01809197|DEVICE|Habitual Multi-Purpose Solution (MPS)|Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
41331734|NCT02465255|DRUG|Ketorolac|
41482704|NCT03580174|OTHER|Routine physiotherapy group|Ten children with CP will RPT applications will consist of unstructured stretching exercises, massage, passive range of motions, muscle strengthening, orthotics etc.) one hour in a session, 2 times in a week during 8 weeks.
41482705|NCT00569621|DRUG|Moxaverine|intravenous administration
40814152|NCT04549779|PROCEDURE|Intermediate volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%
40814153|NCT04549779|PROCEDURE|High volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
40814154|NCT01024972|DRUG|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
40814155|NCT01024972|DRUG|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
40814156|NCT05962632|DRUG|Fluoride based varnish (Dentkist Charm Fill Varnish )|topical Fluoride varnish administrated professionally every 3 months in the clinic
40814157|NCT05962632|DRUG|pro care gel remineralizing agent|topical remineralizing agent (Surface Pre-Reacted Glass ionomer filler SPRG based)SHOFU company
40814158|NCT05962632|DEVICE|Mobile application|examine the impact of Mobile application on caries prevention
40814159|NCT05962632|COMBINATION_PRODUCT|tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning,fluoride rinse OTC|interdental cleaning(dental floss),fluoride rinse OTC (B-FRESH MOUTH WASH )
41331735|NCT02465255|DRUG|Tramadol|
41331736|NCT02465255|DRUG|Acetaminophen|
41331737|NCT00587834|DEVICE|Gintuit|Application of Gintuit at Day 0 to the gingival bed
41331738|NCT00587834|OTHER|Autologous palatal tissue|Tissue will be harvested from the subject's palate and placed on the gingival bed
41331739|NCT03064347|DIETARY_SUPPLEMENT|Sucrose plus Whole Milk Powder in Enteric Coating|Single dose enteric coated sucrose plus whole milk powder will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
41482706|NCT00569621|DRUG|physiological saline|intravenous administration
41482707|NCT06026111|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Home-based, virtually supervised, aerobic exercise intervention at a high intensity in an interval fashion.
41331740|NCT03064347|DIETARY_SUPPLEMENT|Non coated Sucrose plus Whole Milk|Single dose sucrose plus whole milk powder with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
41482708|NCT06026111|BEHAVIORAL|Moderate-Intensity Continuous Training (MICT)|Home-based, virtually supervised, aerobic exercise intervention at a moderate intensity in a continuous fashion.
41482709|NCT02263235|BIOLOGICAL|administration of stable isotope-labelled leucine-|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
41482710|NCT02263235|OTHER|collection of CSF, blood, urine, saliva|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
41482711|NCT00312676|PROCEDURE|Rapid versus slow conversion|
41482712|NCT03260075|OTHER|cat|Cat living at the ward
41482713|NCT02944942|PROCEDURE|General anesthesia|Patients undergoing general anesthesia
41331741|NCT03064347|DIETARY_SUPPLEMENT|Sucrose in Enteric Coating|Single dose enteric coated sucrose will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
41331742|NCT03064347|DIETARY_SUPPLEMENT|Sucrose with Separate Enteric Coating Materials|Single dose sucrose with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
41482714|NCT05566964|DEVICE|ME&MGopen smartphone application|Smartphone application includes digital tests and e-questionnaires
41482715|NCT00040183|DRUG|Tarceva (erlotinib HCl, OSI-774)|
41482716|NCT01946360|DEVICE|Methacetin Breath Test in ACLF and ALF patients|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
40814160|NCT05800925|OTHER|Survey|Participants will be surveyed on demographics, medical history, and current psychiatric symptoms. Vital signs, urine drug screens, and urine pregnancy tests may be collected.
40814161|NCT03674073|BIOLOGICAL|Neoantigen Vaccines|HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
40814162|NCT03674073|PROCEDURE|Microwave Ablation|ALL the HCC patients will be treated by Microwave Ablation.
40814163|NCT05935657|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.1\~1.0 mg/kg/h continuous infusion
40814164|NCT05935657|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
40814165|NCT02185573|PROCEDURE|Bulk fill|This is one of the composite restoration application techniques
40814166|NCT02185573|PROCEDURE|SonicFill|This is the recent intervention under evaluation
40814167|NCT00167609|DRUG|dehydroepiandrosterone 100 and 400 mg|
40814168|NCT01647243|OTHER|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
40814169|NCT03923621|PROCEDURE|EPSiT|Specialised fistuloscope to indentify sinus tracts, cautery tracts, remove causative hair, irrigation.
41331743|NCT03064347|DIETARY_SUPPLEMENT|Whey Protein in Enteric Coating|Single dose enteric coated whey protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
41482717|NCT04958382|DRUG|ciprofol|intravenous infusion of ciprofol at 0.12 mg/kg, followed by 0.4-1.6 mg/kg/h for maintenance
41482718|NCT04958382|DRUG|medium/long chain fat emulsion injection (C8-24Ve)|at the infusion rate of 25-30 mL/h
41482719|NCT05056883|DRUG|K-237 0.3-0.4mg/kg (once daily)|Ivermectin 3mg tablet
40814170|NCT03923621|PROCEDURE|Excision|Surgery to remove all affected tissue, followed by wound closure.
40814171|NCT01513187|DRUG|Pazopanib + interferon alpha 2A|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
40814172|NCT05806034|OTHER|tractography MRI sequence protocol|tractography MRI sequence protocol does not require injection of contrast agent.
40814173|NCT05825430|PROCEDURE|Direct pecs block|"Patients will receive direct PECS block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
41012884|NCT05740722|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
40814174|NCT05825430|PROCEDURE|Ultrasound guided pecs block|"Patients will receive ultrasound guided pecs block after induction and before skin incision.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
41482720|NCT05056883|DRUG|Placebo 0.3-0.4mg/kg (once daily)|Placebo 3mg tablet
40814175|NCT05825430|DRUG|general anaesthetic technique only|All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
40814176|NCT01610219|BEHAVIORAL|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
40814177|NCT01610219|OTHER|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
40814178|NCT00744380|DRUG|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
40814179|NCT00744380|DRUG|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
40814180|NCT06108193|DRUG|topical minoxidil in Acne Vulgaris|Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.
40814181|NCT03803670|DIAGNOSTIC_TEST|evaluation of cerebrospinal fluid of ALL|We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
40814182|NCT05584163|DEVICE|Extracorporeal shock waves|3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.
40814183|NCT06552949|PROCEDURE|Emergent laparoscopic cholecystectomy guided by ICG cholangiography (ELC-ICGC)|Emergent conventional laparoscopic cholecystectomy
40814184|NCT01907321|BEHAVIORAL|Expiratory muscle strength training|Small hand held device that provides calibrated (cmH20) resistance to expiratory pressure. Once sufficient pressure is achieved (participant blowing out into the device) a valve is released, letting air flow through.
40814185|NCT01907321|BEHAVIORAL|Placebo expiratory training|Device with the same look and feel as the active EMST, but which provides no resistance to airflow.
40814186|NCT01907321|DRUG|Measures performed on all subjects|Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.
40814187|NCT01907321|BEHAVIORAL|Pulmonary function test|Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
41331744|NCT03064347|DIETARY_SUPPLEMENT|Whey Protein with Separate Enteric Coating Materials|Single dose whey protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
41331745|NCT03064347|DIETARY_SUPPLEMENT|Pea Protein in Enteric Coating|Single dose enteric coated pea protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
40814188|NCT01907321|RADIATION|Fluoroscopic swallow study|Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
40814189|NCT05377658|DRUG|AK104|10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
40814190|NCT05377658|DRUG|Albumin-Bound Paclitaxel|260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.
40814191|NCT05377658|DRUG|Carboplatin|AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
40814192|NCT03321864|PROCEDURE|Transrectal ultrasound scan of prostate|Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
40814193|NCT05237791|DRUG|Magnesium sulfate|magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
40814194|NCT05237791|DRUG|Placebo|normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
40814195|NCT03397524|OTHER|optima4BP|optima4BP will provide the treating physician with a treatment action recommendation for consideration.
41482721|NCT03913897|OTHER|distraction methods|The children in the groups were distracted by virtual reality goggles and kaleidoscope 2 minutes before venipuncture, until the process was over
40814196|NCT04378491|OTHER|Collection of clinical measurements|"Collection of clinical measurements:~* Active and passive range of motion (ROM) of the knee, hip and ankle Joint bilaterally.~* Passive patellar translation in 30° of flexion billaterally in quadrants of translation.~* Patellar apprehension test (Fairbank's Test) and the Moving Patellar Apprehension (MPAT) test for the diagnosis of patellar instability. The Fairbank's Test is performed in 30° of Flexion while the MPAT is performed while flexing the knee from 0° to 90°."
41012885|NCT05813743|DIAGNOSTIC_TEST|3 dimensional ultrasound|Detect the accuracy of 3D ultrasonography in prenatal detection of bladder wall involvement in abnormally invasive placenta (AIP) at 3rd trimester of pregnancy .
40814197|NCT04378491|OTHER|Collection of data for muscle strength|"Collection of data for muscle strength:~* Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic Flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (3 x 5 repetitions) Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight"
41012886|NCT05871073|DRUG|Ropivacaine 0.75% Injectable Solution|WOUND INFILTRATION AFTER SPINAL SURGERY
41012887|NCT05871073|DRUG|dexamethasone 8mg|WOUND INFILTRATION AFTER SPINAL SURGERY
41012888|NCT03074721|DEVICE|PCI Suite Software|PCI with PCI Suite Software
41012889|NCT03074721|OTHER|conventional PCI|conventional PCI without PCI Software
41012890|NCT03879681|DIETARY_SUPPLEMENT|Jelly confectionary Snakes|"The participants will be randomized by computer generated randomisation to receive either the jelly snake (n=120) or no intervention (n=120) apart from standard institutional management.~All children randomised into the snake group will be offered a chewy jelly snake once alert and cooperative in PACU or on the ward once University of Michigan Sedation Scale (UMSS) is 025,26. The UMSS is a simple observational tool that assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation).~The children randomized into the control group will receive a chewy jelly snake as a treat at discharge."
41012891|NCT02734017|OTHER|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
41012892|NCT01891734|OTHER|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
41012893|NCT01891734|OTHER|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
41012894|NCT04011878|PROCEDURE|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
41012895|NCT00890461|RADIATION|CT scan of the chest without contrast|Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
41012896|NCT02327429|BEHAVIORAL|A Chinese menu plan for type 2 diabetes|The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
41012897|NCT00427804|DRUG|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
41012898|NCT06404996|DEVICE|Smart-phone Voiding Diary|Smart-phone Voiding Diary
41012899|NCT06404996|DIAGNOSTIC_TEST|Paper voiding diary|Conventional Paper voiding diary
41012900|NCT06374433|PROCEDURE|Occipital tACS at IAF-2Hz|tACS applied to occipital areas at 2 Hz below the individual alpha frequency (IAF)
41012901|NCT06374433|PROCEDURE|Occipital tACS at IAF+2Hz|tACS applied to occipital areas at 2 Hz above the individual alpha frequency (IAF)
41012902|NCT06374433|PROCEDURE|Frontal tACS at 4-7 Hz|tACS applied to frontal areas at 4-7 Hz
41331746|NCT03064347|DIETARY_SUPPLEMENT|Pea Protein with Separate Enteric Coating Materials|Single dose pea protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
41331747|NCT04323150|DEVICE|Closed suction systems|Closed suction systems are using for prevention of the ventilator-associated pneumoniae
41331748|NCT04323150|DEVICE|Conventional suction system|The using of open (conventional) suctioning
40814198|NCT04378491|OTHER|Collection of EMG Data|"Collection of EMG Data:~* Surface electrodes will be placed bilaterally on the vastus medialis and lateralis rectus femoris, biceps femoris and semitendinosus muscles following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles). Simultaneously with the muscle strength measurements, EMG data will be collected using a 12-channel EMG system (myon AG, Schwarzenberg, Switzerland, sampling rate 2400 Hz)."
40814199|NCT04378491|OTHER|Collection of Clinical Scores|"Collection of Clinical Scores:~* patient's pain, range of motion and ability to perform daily living activities will be assessed using the Kujala Anterior Knee Pain Scale, Lysholm Knee Score, visual analog scale score (VAS) and the Tegner Activity Score"
41331749|NCT04090268|OTHER|Sport Therapy|Children and adolescent with malignant hemopathies will attend a 3 days/weekly combined training
41331750|NCT05334550|OTHER|Home Based Early Intervention by Parent|Through a video communication program called ZOOM, the parents of intervention group are educated once every two weeks for three months. Parent education consists of a program developed by our pediatric rehabilitation therapist to help premature infants develop motor skills. Parents provide daily exercise training to their children as educated.
41482722|NCT03227614|BEHAVIORAL|Support Person Intervention|The patient participant will have a support person of her choice accompany her during her abortion procedure.
41012903|NCT06374433|PROCEDURE|Occipital tRNS|tRNS applied to occipital brain regions
41012904|NCT06374433|PROCEDURE|Frontal tRNS|tRNS applied to frontal brain regions
41012905|NCT06374433|PROCEDURE|Sham/placebo tACS|tACS is activated only for 30 seconds and then turned off, thus resulting ineffective
41012906|NCT06374433|PROCEDURE|Sham/placebo tRNS|tRNS is activated only for 30 seconds and then turned off, thus resulting ineffective
41012907|NCT02200705|DEVICE|Ice-Sense3TM/ ProSenseTM|
41012908|NCT03310541|DRUG|AZD5363|AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
41331751|NCT05764460|DIAGNOSTIC_TEST|Neuropsychological tests|Neuropsychological tests for general cognition, social cognition and language.
41012909|NCT03310541|DRUG|Enzalutamide|Enzalutamide 160 mg PO once daily
41012910|NCT03310541|DRUG|Fulvestrant|500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
41012911|NCT03079336|BEHAVIORAL|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
41012912|NCT03079336|BEHAVIORAL|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
41331752|NCT03226548|OTHER|Paycheck Plus|A four-fold increase in the Earned Income Tax Credit
41331753|NCT04860011|DRUG|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin 10mg once daily
41331754|NCT04860011|DRUG|Metolazone Tablets|Metolazone 5MG or 10MG once daily
41331755|NCT05949268|DEVICE|Small bowel capsule endoscopy|Patients with gastrointestinal bleeding receive small bowel capsule endoscopy after bleeding could not be located in gastroscopy or colonoscopy.
41012913|NCT03079336|BEHAVIORAL|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
41012914|NCT05544968|DRUG|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
41012915|NCT05242965|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
41012916|NCT05242965|BIOLOGICAL|Sargramostim|Given ID
41331756|NCT02062242|OTHER|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
41331757|NCT02062242|OTHER|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
41331758|NCT02062242|OTHER|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
41482723|NCT02014077|PROCEDURE|VATS ( Video-Assisted Thoracoscopy )|the patients were randomized to a Video-Assisted thoracoscopy( VATS )for retained haemothorax
41012917|NCT05242965|PROCEDURE|Computed Tomography|Undergo CT
41012918|NCT05242965|PROCEDURE|Biopsy|Undergo biopsy
41012919|NCT05242965|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41012920|NCT01641588|BEHAVIORAL|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
41012921|NCT06573164|DRUG|Bacillus clausii tablets（Qipian®）|Take 4 tablets (0.3 mg each) orally three times daily.
41012922|NCT06573164|DRUG|conventional medication|Use conventional medication as needed based on the patient's condition.
41012923|NCT01922310|BEHAVIORAL|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
41331759|NCT02062242|OTHER|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
41331760|NCT06120309|DIAGNOSTIC_TEST|CRS scoring|For pathological evaluation, the omental specimens resected during the IDS were stained with haematoxylin and eosin (H\&E) and reviewed independently by two gynecologic pathologists, both blinded to the clinical data and each other's results. The pathology slide obtained from omentum, usually the site with the most viable tumor, was selected for CRS assessment according to the three-tiered CRS system recommended by 2019 ESMO ovarian cancer guidelines
41331761|NCT06120309|DIAGNOSTIC_TEST|Routine blood laboratory testing before treatment|The routine blood tests and tumor marker measurements, including CA125, HE4, and inflammation-related serum biomarkers including neutrophils, lymphocytes, monocytes, fibrinogen, and platelets, were conducted within three days before the first NACT.
41331762|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
40814200|NCT04378491|OTHER|Collection of Imaging Data - Radiological measurements|Collection of Imaging Data - Radiological measurements: Xrays and MRIs which were already performed as part of the original diagnostic and follow-up procedures pre- and postoperative will be reviewed and analysed.
40814201|NCT03590626|DRUG|Dulaglutide|0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks
40814202|NCT04985409|BEHAVIORAL|Feedback|The system uses Sonifi health (TV content and visualizations) and Fitabase (3rd party server to process Fitbit data and export to Sonifi). The system utilizes the patient's TVs to engage the patient and multidisciplinary team in monitoring ambulation status.
41331763|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
41331764|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
41331765|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
41482724|NCT02014077|PROCEDURE|Thoracostomy Tube reinsertion|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
40814203|NCT03723720|DEVICE|Colonoscopy|Endoscopic examination of large bowel
40814204|NCT00673205|DRUG|Bicalutamide|150mg p.o. daily
40814205|NCT00673205|DRUG|Placebo|
40814206|NCT01294306|DRUG|Akt Inhibitor MK2206|Given PO
40814207|NCT01294306|DRUG|Erlotinib Hydrochloride|Given PO
41331766|NCT06402786|DEVICE|Kitea ICP Sensor|Kitea ICP Sensor placed in brain during shunt surgery.
41331767|NCT00701246|DRUG|ferrous sulfate|
41331768|NCT00701246|DRUG|folic acid|
41331769|NCT00701246|DRUG|placebo (folic acid)|
41331770|NCT04698512|DEVICE|AVFistuloplasty with Sirolimus coated balloon|After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon
41331771|NCT03431142|DRUG|Clopidogrel|Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
41331772|NCT03431142|DRUG|Clopidogrel+aspirin|Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
41331773|NCT02198989|BEHAVIORAL|peer support and yoga music therapy|Patients in the intervention group will receive peer support and yoga music therapy before bed.
41482725|NCT02027870|DEVICE|EXCEL-II biodegradable polymer sirolimus-eluting stent|EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
41482726|NCT01301508|DRUG|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
41482727|NCT01301508|DRUG|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
41482728|NCT01301508|DRUG|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
41482729|NCT01301508|DRUG|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
40814208|NCT01294306|OTHER|Laboratory Biomarker Analysis|Correlative studies
40814209|NCT01294306|OTHER|Pharmacological Study|Correlative studies
40814210|NCT04218214|OTHER|LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)|Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
40814211|NCT02862483|DRUG|Tamsulosin 0.2mg|
40814212|NCT02862483|DRUG|Tadalafil 5mg|
40814213|NCT02862483|DRUG|Placebo for Tamsulosin|
40814214|NCT02229305|BEHAVIORAL|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
40814215|NCT02229305|BEHAVIORAL|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita \& Weisz, 2010).
40814216|NCT04463693|DRUG|Etonogestrel implant|Insertion of the contraceptive implant at an alternative insertion site located over the scapula
40814217|NCT03462017|DRUG|SAR247799|Pharmaceutical form:Capsule Route of administration: Oral
40814218|NCT03462017|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
40814219|NCT03462017|DRUG|Sildenafil|Pharmaceutical form:Encapsulated tablet Route of administration: Oral
41331774|NCT03770195|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
40814220|NCT03462017|DRUG|Acetylcholine|Pharmaceutical form:Solution Route of administration: Transdermal
40814221|NCT00051012|DRUG|ONTAK|
40814222|NCT00488449|DRUG|GSK256073A tablets|
41331775|NCT01767181|OTHER|Intensive light therapy|Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
41331776|NCT01767181|OTHER|Exercise|Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
41331777|NCT04126603|DRUG|Semaglutide|0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks
41331778|NCT04126603|DRUG|Placebos|Placebo injection
41331779|NCT05107518|BEHAVIORAL|Children Participation Assessment Scale|Evaluation is carried out to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
41331780|NCT02580838|DRUG|OnabotulinumtoxinA|Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
41331781|NCT02040155|DEVICE|Novel nano-scintillator fiber-optic dosimeter (nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
41331782|NCT02920281|OTHER|Polysomnography|
41331783|NCT04984213|DEVICE|Karma Posterior Fixation Device|Posterior Fixation
41331784|NCT06166888|DRUG|AK131|AK131 is an anti-PD-1 and CD73 bispecific antibody
41331785|NCT04083950|BIOLOGICAL|Vivotif Typhoid Oral Vaccine|One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.
41331786|NCT04083950|DRUG|Aspirin (Positive Control)|Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
41331787|NCT02249208|DEVICE|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
40814223|NCT00519324|DRUG|Everolimus|10 mg/day (2 tablets of 5 mg each)
40814224|NCT05347680|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
40814225|NCT05347680|DEVICE|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
41012924|NCT05487729|OTHER|ultrasonography and functional assessment and questionnaire survey|ultrasonography and functional assessment and questionnaire survey
41331788|NCT02249208|DEVICE|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
41331789|NCT02249208|DEVICE|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
41331790|NCT04433156|DRUG|Bortezomib|1.3 mg/m2, hypodermic injection on day 1 and day 4 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
40814226|NCT04153292|DEVICE|SAPIEN M3 valve and dock|During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.
40814227|NCT06010758|DRUG|Listerine Experimental Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
40814228|NCT06010758|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
40814229|NCT06010758|DRUG|Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
40814230|NCT06010758|OTHER|Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash twice a day, morning and night.
40814231|NCT03576404|OTHER|Patient-Centered Pharmacist Care|A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
40814232|NCT03571009|DEVICE|utilization of PAAS|utilization of real-time pain assessment and analysis system (PAAS) consists of wearing device and reporting a real-time pain using the device
40814233|NCT00234871|DRUG|trandolapril/verapamil|2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
40814234|NCT00234871|DRUG|Lotrel (amlodipine/benazepril)|5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
40814235|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
40814236|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
40814237|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
40814238|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
40814239|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
40814240|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
40814241|NCT03702348|OTHER|Resistance exercise|Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
40814242|NCT05052814|OTHER|root canal medicament-calcium hydroxide|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
40814243|NCT05052814|OTHER|root canal medicament-chlorhexidine gel|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
40814244|NCT05052814|OTHER|root canal medicament-calcuim hyroxide &chlorhexidine ge|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
40814245|NCT00778375|DRUG|Clofarabine|20 mg/m\^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
40814246|NCT00778375|DRUG|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
40814247|NCT00778375|DRUG|Decitabine|20 mg/m\^2 as a 1- to 2-hour infusion daily for 5 days.
40814248|NCT02402504|OTHER|Control|Non pulse extruded snack
40814249|NCT02402504|OTHER|Small particle size pea flour|Pulse extruded snack
40814250|NCT02402504|OTHER|Large particle size pea flour|Pulse extruded snack
40814251|NCT02402504|OTHER|Lentil flour|Pulse extruded snack
40814252|NCT02402504|OTHER|Navy bean flour|Pulse extruded snack
40814253|NCT02402504|OTHER|Pinto bean flour|Pulse extruded snack
40814254|NCT04683276|PROCEDURE|pars plana vitrectomy with ILM inverted flap|Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and \>2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.
40814255|NCT03729258|DRUG|Infex 400 MR|Infex (cefpodoxime) 400mg once a day (QD) for 10 days
40814256|NCT03729258|DRUG|Infex 200 IR|Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
41012925|NCT06569576|BEHAVIORAL|Wellness program|It combines seated yoga exercises, mindfulness, and social participation activities and discussions, and can be delivered in-person or via tele-health.
41012926|NCT03697200|OTHER|APA|Light touch using vaccaria seeds on specific points of the ear
41331791|NCT04433156|DRUG|Rituximab|375 mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
40814257|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
40814258|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
41012927|NCT03697200|OTHER|Sham APA control|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
40814259|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
40814260|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
40814261|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
40814262|NCT01551680|RADIATION|Radiation combined with iniparib (BSI-201)|"Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields."
41331792|NCT04433156|DRUG|Epirubicin|70 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
41331793|NCT04433156|DRUG|Cyclophosphamide|750 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
40814263|NCT06088394|DEVICE|Acupuncture|"Participants will be asked to assume supine lying position on the plinth and the following points will be located then needles will be inserted:~* CV3,4 \&5-40 mm needles at a depth of 1 cun perpendicular insertion.~* ST 25 bilaterally-40 mm needles at a depth of 1 cun oblique insertion.~* SP6 \& 9, K13\&7 bilaterally-25 mm needles at a depth of 0.5 cun perpendicular insertion. A total of 13 needles will be inserted at each session."
40814264|NCT06088394|OTHER|pelvic floor exercises|pelvic floor muscle exercises can help strengthen pelvic floor muscle, which provides better control of urinary urgency by interfering with urethral-detrusor reflexes and inhibiting detrusor contractions
40814265|NCT01519791|BIOLOGICAL|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
40814266|NCT01519791|OTHER|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
40814267|NCT01519791|BIOLOGICAL|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
40814268|NCT06279598|BEHAVIORAL|Prolonged Exposure therapy|This concerns a form of psychotherapy for PTSD.
40814269|NCT06279598|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|This concerns a form of psychotherapy for PTSD.
40814270|NCT06279598|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|This concerns a form of psychotherapy for PTSD.
40814271|NCT00099944|DRUG|vildagliptin|
40814272|NCT00099944|DRUG|Glimepiride|Glimepiride 4 mg qd
40814273|NCT00099944|DRUG|LAF237 placebo|
40814274|NCT00694837|DRUG|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
41331794|NCT04433156|DRUG|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles
41331795|NCT02433860|BEHAVIORAL|pharmacist nicotine cessation counseling using SCRIPT protocol|"Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.~Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.~Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.~At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately \> 36 weeks gestation or at delivery."
41331796|NCT01665872|BEHAVIORAL|Cognitive-Behavioral Group Therapy|CBT Group
40814275|NCT06373926|BIOLOGICAL|blood withdrawal|blood withdrawal
40814276|NCT04683549|DIAGNOSTIC_TEST|HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy|"Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have:~1. FDG PET Scan before treatment and 3 months after treatment~2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status~3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy,~4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy."
40814277|NCT04969601|BIOLOGICAL|vaccine COMIRNATY® (BNT162b2)|two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
40814278|NCT06046612|DRUG|Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment|The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.
40814279|NCT02789943|PROCEDURE|Cardiac Bypass Surgery|elective cardiac bypass surgery during which a sample of right atrial appendage and/ or aortic button can be removed
40814280|NCT04145921|PROCEDURE|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
40814281|NCT04145921|PROCEDURE|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
40814282|NCT04086693|DEVICE|Standard IV dressing|Polyurethane and clear tape dressing used to secure peripheral IV
40814283|NCT04086693|DEVICE|Standard IV dressing plus a tissue adhesive peripheral IV securement device|Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
41012928|NCT03697200|OTHER|Education control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
41331797|NCT03942237|PROCEDURE|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine is given immediately after the correct position of needle tip is verified."
40814284|NCT02330653|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standard by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
40814285|NCT02330653|BIOLOGICAL|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
41482730|NCT03490448|BEHAVIORAL|aerobic exercise and appropriate caloric control|The dietary was designed on the basis of ensuring the daily energy physiological requirement, and basal metabolic rate (BMR) was calculated to formulate diet project according to Harris-Benedict formula. The diet was composed of 20% protein, 30% fat and 50% carbohydrates.In the exercise, heart rate was monitored to ensure the small-medial load aerobic exercise. All kinds of sports were conducted indoor, twice per day, 6 days per week, and lasted for 2 hours every time.
41482731|NCT00771745|DRUG|Thymoglobulin|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
41331798|NCT03942237|PROCEDURE|Placebo Control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose 0.4ml/kg 0.9% NS is given immediately after the correct position of the needle tip is verified"
40814286|NCT02494518|BEHAVIORAL|Forced Exercise & Upper Extremity Repetitive Task Practice|
40814287|NCT02494518|BEHAVIORAL|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
40814288|NCT02494518|BEHAVIORAL|Stroke Education & Upper Extremity Repetitive Task Practice|
40814289|NCT05929391|PROCEDURE|Recycling orthodontic brackets|"T0: The adhesive removal will be performed by high-speed hand piece with tungsten carbide bur. the bur will be changed every five attachments. T1: Control group of T0. T2: The adhesive removal will be performed by sandblasting via Micro-etcher.~T3: Control group of T2."
40814290|NCT02748668|OTHER|Blood specimen collection|
41012929|NCT04428138|DIAGNOSTIC_TEST|In-office vascular visit|Every patient will undergo a complete physical examination in order to detect any clinical or sub clinical vascular disease.
41012930|NCT04428138|DIAGNOSTIC_TEST|Echo duplex scan of arterial system|Every patient will undergo a complete echo duplex scan in order to detect any morphological or hemodynamic alteration of aorta, carotid arteries and lower limb arteries.
41331799|NCT05848076|OTHER|TNE|McGill exercise focuses on the ability of the spine to stabilize in different positions 3 sets of 3 repletion with of each of muscle and briefly explains the patient about their pain
41331800|NCT05848076|OTHER|core stability|McGill exercises for the low back.
41331801|NCT05944159|BEHAVIORAL|Study Group|Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.
41331802|NCT05944159|OTHER|Control Group|Routin medication therapy was applied to the control group. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not.
41331803|NCT03924648|OTHER|Endocan levels|Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.
41331804|NCT03960658|DRUG|ketamine-enhanced prolonged exposure|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
41331805|NCT03729661|BEHAVIORAL|Nasal High Flow Therapy|Use of Nasal High Flow Therapy during CT and treatment
41331806|NCT03114098|OTHER|gene abnormalities|A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
41331807|NCT02517268|PROCEDURE|Pancreaticoduodenectomy|
40814291|NCT04660292|OTHER|Maitland's mobilization|Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades
40814292|NCT04660292|OTHER|Traditional Physical therapy|BASELINE TREATMENT INCLUDES TENS and Hot PACKS
40814293|NCT02687971|DRUG|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
40814294|NCT03750760|DRUG|Alirocumab|PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
40814295|NCT03750760|DRUG|Atorvastatin 80mg|3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
40814296|NCT03750760|DRUG|Ezetimibe 10mg|Cholesterol absorption inhibitor
40814297|NCT04115748|DRUG|Filgotinib|Tablets administered orally once daily with or without food
40814298|NCT04115748|DRUG|Adalimumab|Injection administered subcutaneously once every 2 weeks
41482732|NCT00771745|DRUG|Thymoglobulin|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
41482733|NCT06077331|DRUG|HS-10374 tablets 1mg|Administered orally QD for 12 weeks
41482734|NCT06077331|DRUG|HS-10374 tablets 5mg|Administered orally QD for 12 weeks
41482735|NCT06077331|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 12 weeks
41482736|NCT06383871|DRUG|HRS-7058 capsule/ HRS-7058 tablet|HRS-7058 capsule/ HRS-7058 tablet
41482737|NCT03358784|PROCEDURE|Hemi-shoulder Arthroplasty|Hemi-shoulder Arthroplasty treating three or four-part fractures of proximal humerus
41482738|NCT03358784|PROCEDURE|PHILOS Plate|PHILOS plate treating three or four-part fractures of proximal humerus
41482739|NCT04027374|PROCEDURE|Fetal surgery for MMC repair|Fetal surgery for MMC repair
41482740|NCT03095118|DRUG|Daratumumab|Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
40814299|NCT04115748|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food
40814300|NCT04115748|DRUG|Placebo to match adalimumab|Injection administered subcutaneously once every 2 weeks
41331808|NCT04105647|BEHAVIORAL|Lifestyle-integrated exercise|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and physical activity. The lifestyle-integrated exercise is modified from Zero-time exercise. It focuses on four exercise domains that patients with lung cancer could be done at home, including breathing, balance, aerobic, strength, stretching exercises
41331809|NCT04105647|BEHAVIORAL|Healthy living information|The control group will receive a face-to-face group session and a package healthy living instant messages, but not related to lifestyle-integrated exercise and physical activity.
41331810|NCT05966493|DRUG|lufepirsen|Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
40814301|NCT02119429|DIETARY_SUPPLEMENT|Pumpkin Seed Oil|2 grams per day, everyday for 12 weeks.
40814302|NCT02119429|DIETARY_SUPPLEMENT|Wheat Germ Oil|2 grams per day, everyday for 12 weeks.
40814303|NCT06214130|DRUG|Sodium valproate 500 MG|oral intake
40814304|NCT06214130|DRUG|Valproic Acid 500 MG|oral intake
40814305|NCT02302092|DRUG|Flomoxef|Flomoxef intravenous infusion
40814306|NCT02302092|DRUG|Cefepime|Cefepime intravenous infusion
40814307|NCT00566410|DRUG|Dichloroacetate|Continuous daily oral dosage (bid).
40814308|NCT04147377|BEHAVIORAL|behavioral intervention based on sensory cues|Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
40814309|NCT02161094|BEHAVIORAL|Give incentives to physicians based on their patient's HbA1c improvement|
40814310|NCT02161094|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|
40814311|NCT01579058|DRUG|bisoprolol|bisoprolol 5mg qd for 4 years
40814312|NCT01579058|DRUG|placebo|placebo for 4 years
40814313|NCT01404793|DRUG|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
40814314|NCT05460052|OTHER|Physical activity training program|"The physical activity training program will consist of 3 sessions per week for 6 weeks :~* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital~* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference."
40814315|NCT05460052|OTHER|Weekly phone call.|Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.
40814316|NCT05460052|OTHER|Personalized training plan.|After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.
40814317|NCT06580249|DEVICE|Repetitive transcranial magnetic stimulation|The true stimulus group acted directly, whereas the pseudo stimulus group reversed the head to produce no effect. Both groups were treated with sertraline medication。
40814318|NCT05215223|DEVICE|whole body vibration|the patients will stand on whole body vibration device with maintaining squatting position while keeping their trunk extended. The first training session will be consisted of three sets of 1 min and will be separated by a 1-min of standing rest. intensity will 1 mm. Then one set will be added every session
40814319|NCT05215223|DEVICE|Treadmill|Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks
41331811|NCT05966493|DRUG|Vehicle|Matching vehicle without lufepirsen.
41331812|NCT00979108|OTHER|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
41331813|NCT00979108|OTHER|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
41331814|NCT00979108|OTHER|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
40814320|NCT05434871|OTHER|Yoga training|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
40814321|NCT05434871|OTHER|Physiotherapy|The standard physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
40814322|NCT02975479|DRUG|ALK Diluent|
40814323|NCT02975479|DRUG|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
40814324|NCT05957393|OTHER|Quantity of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
40814325|NCT05957393|OTHER|Quality of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
40814326|NCT05957393|OTHER|Control|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
40814327|NCT03232645|DEVICE|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
40814328|NCT02180919|DEVICE|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
41331815|NCT03249753|DRUG|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
41482741|NCT05810558|PROCEDURE|glycine powder air-powered debridement|The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.
40814329|NCT02346643|DEVICE|Implantation with the commercially available Axium Neurostimulator|
41482742|NCT05810558|PROCEDURE|Ultrasonic instrumentation|The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste
41482743|NCT04739696|BEHAVIORAL|PEPRR|Briefly presented in the following order, sessions will include: 1) Overview and Introduction to Stress Management 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with work and caregiver stress, 5) Strategies for maintaining energy and stamina with caregiver and work demands, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs to employers and your loved ones, and 8) Getting the support they need including work accommodations and/or legal protections (e.g., Family Medical Leave Act, Americans with Disabilities Act)
41482744|NCT04739696|BEHAVIORAL|Pep-Pal|Pep-Pal program consisted of 11 sessions: 1) Introduction to stress management, 2) Stress and the mind body connection, 3) How thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty, 7) Managing changing relationships and communicating needs, 8) Getting the support they need; 9) Employment related challenges and resources for working caregivers; 10) Employment session one; 11) Employment session two
40814330|NCT02746887|OTHER|Preterm/term cohort|
41482745|NCT02991430|DEVICE|active neuromodulation for episodic migraine headache|Non-invasive brainstem neuromodulator. Active and placebo devices appear identical
41482746|NCT02991430|DEVICE|placebo neuromodulation for episodic migraine headache|Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical
41482747|NCT04320550|DIAGNOSTIC_TEST|abdominal ultra sound|non invasive tests to exclude pathological causes
41012931|NCT01663259|DRUG|Cetuximab|Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
41012932|NCT01663259|RADIATION|Radiotherapy|Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
41331816|NCT03249753|DRUG|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
41331817|NCT01485432|DEVICE|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measurements
41331818|NCT02562989|DRUG|[18F]MK-6240, ~185 MBq|IV dose of \~185 MBq \[18F\]MK-6240
41331819|NCT02562989|DRUG|[18F]MK-6240, ~160 MBq|IV dose of \~160 MBq \[18F\]MK-6240
41331820|NCT05467098|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
41331821|NCT00013767|BEHAVIORAL|Individual and Community education|
41482748|NCT00000734|DRUG|Sulfamethoxazole-Trimethoprim|
40814331|NCT03762889|DEVICE|Eyeprotx™ General Anesthesia Protective Goggles|Eyeprotx™ Protective Goggles have been designed specifically for use in the operating room or in any scenario where general anesthesia must be used, such as intubation in an emergency. The integral function is to reduce intraocular pressure while in place, prevent operating room bright light penetration, facilitate a swift placement preventative measure with straps, form a barrier against bacterial invasion and mechanical damage. This study would seek to examine this goggles' effectiveness as a preventative measure as vs. other measures.
40814332|NCT03762889|DEVICE|Eyelid Tape|Taping the eyelids during intubation is one of the standard techniques used perioperatively under general anesthesia. This intervention would be used for the Eyelid Tape Group.
40814333|NCT03762889|DEVICE|Eye Ointment|Another standard technique used perioperatively under general anesthesia is to apply an ointment to the eye for lubrication. This intervention would be applied to the Eye Ointment Group.
40814334|NCT03470324|DEVICE|[standard STN]|standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
40814335|NCT03470324|DEVICE|[STN+SNr]|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
40814336|NCT03470324|BEHAVIORAL|Swallowing therapy|Swallowing therapy with speech therapist
40814337|NCT02885480|BEHAVIORAL|questionnaires|
40814338|NCT02189044|OTHER|Pilates Exercise|"The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.~During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.~In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.~In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall."
40814339|NCT02030197|BEHAVIORAL|CRISP Program|Educational program to improve self-efficacy, loneliness and depression
40814340|NCT02030197|OTHER|Control Group|no treatment
40814341|NCT01106651|DRUG|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
40814342|NCT01106651|DRUG|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
40814343|NCT01106651|DRUG|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.
40814344|NCT01106651|DRUG|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
40814345|NCT04784052|DRUG|JSP191|Participants will receive a single IV dose at start of conditioning
41012933|NCT06490718|DRUG|USG ESPB|"After obtaining the appropriate sonographic window, under strict aseptic precautions, the block needle is inserted in the plane of the US beam in a caudad to cranial direction until the tip is in contact with the transverse process (TP) at its lateral aspect. A test bolus of 0.9% saline (1-2 ml) is injected and sonographic evidence of erector spinae muscle displacement (posterior) from the underlying TP is sought to ensure that the tip of the block needle is indeed at the erector spinae muscle plane. The study drug from the 25 ml syringe with the label 'study drug for ESPB' (containing either 25 ml of 0.5% levobupivacaine with 1:200,000 adrenaline or 0.9% saline depending on the group allocation) is injected in small aliquots over a minute. The anaesthesiologist performing the block and the patient is blinded to the group allocation.~Successful injection reveals a clearly delineated posterior displacement of the erector spinae muscle."
40814346|NCT04784052|DEVICE|CliniMACS Prodigy System|The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient
40814347|NCT04784052|BIOLOGICAL|Depleted Stem Cell Transplant|TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.
41012934|NCT06490718|DRUG|Intravenous Infusion|"Following ultrasound-guided erector spinae plane block (USG ESPB), patients will be transferred to the operating room. General anesthesia (GA) will be administered according to a standardized protocol.~Study Drug Infusion:~Immediately after securing the airway, an intravenous infusion from a 50 ml syringe labeled study drug for IVI will commence. The study drug contains either 30 ml of 2% lidocaine or 0.9% saline, depending on group allocation. The infusion begins with a bolus rate of 0.1 ml/kg over 10 minutes and continues at 0.1 ml/kg/hr until surgical wound closure."
41012935|NCT01849705|OTHER|No intervention|
41012936|NCT06572475|DIAGNOSTIC_TEST|USPIO enhanced MRI|Ferumoxytol (Feraheme©, AMAG pharmaceuticals, US) enhanced MRI
41012937|NCT01812044|DRUG|subtenons anesthetic - preservative-free bupivacaine 0.75%|
41012938|NCT01812044|DRUG|topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel|
41012939|NCT01812044|DRUG|topical control - 0.5 cc of Hypromellose 0.3% gel|
41012940|NCT01812044|DRUG|subtenons control - 0.5 cc of Normal Saline|
41331822|NCT02500277|DEVICE|Cryoprobe pleural biopsy first|Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).
41331823|NCT02500277|DEVICE|Flexible forceps biopsy first|Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
41331824|NCT03488238|DEVICE|ORi sensor|Noninvasive pulse oximeter sensor that is placed on the finger for measurement of ORi
41331825|NCT03261063|DEVICE|Evera MRI ICD System|Subjects are implanted with Evera MRI ICD System and exposed to MRI environment per study requirements
41331826|NCT05094895|PROCEDURE|Stretta|Radiofrequency energy delivered to the gastro-esophageal junction
41331827|NCT05094895|PROCEDURE|Sham|Patients that have the sham condition will have a procedure using a 24Fr Savary bougie dilator over the guidewire, with the same sedation.
41331828|NCT05380713|DRUG|Cyclophosphamide|Cyclophosphamide will be applied in the neoadjuvant setting
41331829|NCT05380713|DRUG|Tremelimumab|tremelimumab-durvalumab in adjuvant setting
41331830|NCT05380713|DRUG|Durvalumab|tremelimumab-durvalumab in adjuvant setting
41331831|NCT00331955|DRUG|doxorubicin hydrochloride|Given IV
41331832|NCT00331955|DRUG|vorinostat|Given orally
41331833|NCT00331955|OTHER|pharmacological study|Correlative studies
41331834|NCT00331955|OTHER|laboratory biomarker analysis|Correlative studies
41331835|NCT03057951|DRUG|Empagliflozin|once daily
41331836|NCT03057951|DRUG|Placebo|once daily
41482749|NCT00000734|DRUG|Zidovudine|
40814348|NCT04784052|BIOLOGICAL|Rabbit Anti-Thymoglobulin (rATG)|3 consecutive daily doses of rATG will be given by IV during conditioning
40814349|NCT04784052|DRUG|Cyclophosphamide|4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
40814350|NCT04784052|DRUG|Fludarabine|4 consecutive daily doses of fludarabine will be given by IV during conditioning
40814351|NCT04784052|DRUG|Rituximab|1 dose of rituximab will be given at the end of conditioning
40814352|NCT00152828|DRUG|Celecoxib|
40814353|NCT03792438|DIAGNOSTIC_TEST|Transvaginal 3D Power Doppler Ultrasound|Samsung H60 ultrasound machine with 4-9 MHz volume transducer using VOCAL system and Histogram Facility
40814354|NCT04597359|DRUG|Placebo Administration|Given PO
41012941|NCT02181231|DRUG|venlafaxine XR|slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
40814355|NCT04597359|OTHER|Quality-of-Life Assessment|Ancillary studies
41331837|NCT06290011|DEVICE|Pain key group|mixed real pain treatment software, pain treatment scenarios in MR
41331838|NCT03406715|DRUG|Nivolumab|Nivolumab (BMS-936558) is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. Induction Immunotherapy Phase (4 x 21 days cycles): Nivolumab on Day 1 of each cycle for 4 cycles. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: Nivolumab only on Day 1 of every 4 week period. Participants will continue to receive Nivolumab only on Day 1 of each additional 4 week period that they take part until their disease progresses. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
40814356|NCT04597359|OTHER|Questionnaire Administration|Ancillary studies
40814357|NCT04597359|DRUG|Sinecatechins|Given PO
41012942|NCT02181231|DRUG|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
41331839|NCT03406715|DRUG|Ipilimumab|Ipilimumab is an antibody (a type of human protein) that is approved to treat patients with metastatic melanoma. In this study, the use of ipilimumab is investigational. Induction Immunotherapy Phase (4 x 21 days cycles): Ipilimumab on Day 1 of each cycle for 4 cycles. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
41482750|NCT01372241|BEHAVIORAL|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
41482751|NCT04936828|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
41012943|NCT02181231|DRUG|Placebo|patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
41155928|NCT06647407|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Powder and solvent for injectable solution in a pre-filled syringe Route of administration: Intramuscular (IM)
41155929|NCT06647407|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
41155930|NCT06647407|DRUG|Paracetamol|Pharmaceutical form:Suspension-Route of administration:oral
41482752|NCT02870400|DRUG|REGN2477|Participants will receive ascending doses of REGN2477
41482753|NCT02870400|DRUG|Placebo|Participants will receive matching placebo
40814358|NCT04187144|DRUG|Gepotidacin|Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.
40814359|NCT04187144|DRUG|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.
40814360|NCT04187144|DRUG|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.
40814361|NCT04187144|DRUG|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
40814362|NCT04935190|DIAGNOSTIC_TEST|Vitalpercept|Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography
40814363|NCT05090826|DEVICE|Model ZFR00V|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
40814364|NCT05664659|DRUG|Oxytocin + misoprostol|600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution
40814365|NCT05664659|DRUG|Carbetocin|100 micrograms carbetocin
40814366|NCT02305472|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
40814367|NCT05917470|DRUG|ONCT-534|ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
40814368|NCT05690399|RADIATION|Radiotherapy|Effect of radiotherapy on patients
40814369|NCT03952468|DEVICE|Transcranial Magnetic Stimulation|Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
40814370|NCT03952468|OTHER|Brief Cognitive Behavioral Therapy|BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
40814371|NCT00281099|DEVICE|ICD (Implantable Cardioverter Defibrillator)|VVI 40 vs. MVP
40814372|NCT02964559|BIOLOGICAL|Pembrolizumab|Given IV
40814373|NCT00918775|OTHER|Follow-Up Care|Undergo follow-up
41331840|NCT03406715|BIOLOGICAL|Dendritic Cell based p53 Vaccine|Dendritic Cell based p53 Vaccine (Ad.p53-DC). The p53 vaccine will be made by inserting the p53 gene (a gene is a hereditary unit of all living organism within a cell) into a subset of the participant's own white blood cells. The insertion of the gene into their white blood cells will occur in the laboratory, after their cells have been extracted from their body through a procedure called leukopheresis (similar to dialysis). Induction Immunotherapy Phase (4 x 21 day cycles): Participants will receive the p53 vaccine on Days 1 and 15 of cycle 1 and then again on Day 8 of Cycle 2. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: p53 vaccine three additional times (every 4 weeks over a 12 week period).
40814374|NCT00918775|OTHER|Laboratory Biomarker Analysis|Correlative studies
40814375|NCT03260374|DEVICE|Electric compound action potential|The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
40814376|NCT03260374|DEVICE|electric stapedial reflex threshold|electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
41155931|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
41331841|NCT01505972|OTHER|Six and three time schedule|Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
41331842|NCT01505972|OTHER|Four and two time schedule|Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
41331843|NCT03527771|DEVICE|Video-assisted CPR|Emergency call using a Software capable of video Transmission for Video assistance in CPR
40814377|NCT03260374|DEVICE|electric auditory brain stem response|For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
41331844|NCT03527771|DRUG|telephone-assisted CPR|Emergency call with telephone assistance in CPR
41331845|NCT00880880|OTHER|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
40814378|NCT05484505|DRUG|Nicotine patch, Nicotine gums|"Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~* 14 mg: Next 4 weeks~* 7 mg: Last 4 weeks"
40814379|NCT05484505|BEHAVIORAL|Brief Advice (5 A's & 5 R's)|Brief Advice (5 A's \& 5 R's) at Day 0, 1 month, 3,6,9 \& 12 months
40814380|NCT05484505|DRUG|Nicotine Patch: Preloading for 4 weeks|Nicotine Patch: Preloading for 4 weeks - 21 mg: 4 weeks before quit date
40814381|NCT00957944|DRUG|rotigotine transdermal patch (Neupro®)|Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
40814382|NCT01060449|OTHER|LV stimulus intensity|"The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output"
40814383|NCT01210248|OTHER|BLOOD COLLECTION|BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
40814384|NCT03865745|DIETARY_SUPPLEMENT|Korean Red Ginseng|Take one pack of the product (3g) once a day for 24 weeks
40814385|NCT00108303|OTHER|Diagnostic|Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
40814386|NCT03015649|DEVICE|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
40814387|NCT04573699|DEVICE|CNT-HF|A modified CNT, will be delivered as a pacing sequence able to acutely influence sympathetic tone.
40814388|NCT03276026|DRUG|Sugammadex|Sugammadex is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
40814389|NCT03276026|DRUG|Neostigmine|Neostigmine is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
40814390|NCT02449889|DRUG|highly purified human chorionic gonadotropin|
40814391|NCT02449889|DRUG|recombinant human chorionic gonadotropin|
40814392|NCT03265002|DIETARY_SUPPLEMENT|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
40814393|NCT03265002|DIETARY_SUPPLEMENT|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
40814394|NCT03265002|DIETARY_SUPPLEMENT|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
40814395|NCT03265002|DIETARY_SUPPLEMENT|Inulin and psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
40814396|NCT01244594|OTHER|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
40814397|NCT04446507|DRUG|Saroglitazar magnesium|1 dose of 2mg and 4 mg Saroglitazar magnesium will be given to subjects on Day 1
40814398|NCT05804487|DEVICE|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
40814399|NCT05834088|OTHER|Myofascial release techniques|12 treatment sessions will be given in 12 weeks
40814400|NCT05834088|OTHER|Thiele massage|12 treatment sessions will be given in 12 weeks
40814401|NCT04154449|DRUG|Intranasal insulin|Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
40814402|NCT06454448|DRUG|Adebrelimab;decitabine;|Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2
40814403|NCT00592163|DRUG|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
40814404|NCT01823159|DRUG|retigabine|Single oral administration of a 400 mg tablet.
40814405|NCT01823159|DRUG|placebo|Single oral administration of a tablet
40814406|NCT00517348|BIOLOGICAL|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
40814407|NCT00347438|DRUG|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
40814408|NCT04606706|OTHER|Mobile health nutrition education intervention|Nutrition education will be given through mobile phone
40814409|NCT06473077|PROCEDURE|ETT beyond C7 level|Endotracheal cuff is placed deeper beyond C7 level, but above carina
40814410|NCT05908721|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
40814411|NCT02534558|BIOLOGICAL|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
41331846|NCT04327050|PROCEDURE|Magnetic anchored guided endoscopic submucosal dissection|Using magnetic anchoring technology, the magnetic pulling unit is anchored to the abdominal wall, and micro surgical tweezers are used. The tumor tissue is pulled indirectly, so that the mucosa is lifted up, which is beneficial to the peeling of the submucosa.
41331847|NCT01423955|DRUG|Erythropoietin zeta|The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.
40814412|NCT06454825|DRUG|Intravenous drug|medications were applied intravenously to the groups 30 minutes before end of the procedure
40814413|NCT01601106|DRUG|liposomal prednisolone|Two weekly dosages with 150 mg.
40814414|NCT01601106|DRUG|Placebo|
40814415|NCT00176488|DRUG|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
40814416|NCT00176488|DRUG|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
40814417|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|10 ml extrafascial interscalene brachial plexus block
40814418|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|20 ml extrafascial interscalene brachial plexus block
40814419|NCT05128513|DEVICE|DELP|The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
40814420|NCT04070716|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
40814421|NCT04070716|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
40814422|NCT04495257|DRUG|Nivolumab|Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
40814423|NCT04495257|DRUG|Ipilimumab|Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
40814424|NCT04495257|DRUG|APX005M|APX005M 0.3mg/kg intravenously (IV) every 3 weeks
40814425|NCT00737217|BEHAVIORAL|Behavioral assessment/questionnaire|Complete behavioral assessment/questionnaire
40814426|NCT04820010|DRUG|Topical Insulin|Patients were administered eyedrops enriched with insulin
40814427|NCT05876299|OTHER|95.1% Lean Pork|This intervention will contain 120 kcals, 4.4 g fat, and 20 g protein from low-fat ground pork.
40814428|NCT05876299|OTHER|81.16% Lean Pork|This intervention will contain 266 kcals, 20.6 g fat, and 20 g protein from high-fat ground pork.
41331848|NCT01423955|DRUG|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
41331849|NCT02120352|DRUG|CAB Oral Tablets|White to almost white oval shaped film coated 30 mg tablets for oral administration.
40814429|NCT05876299|OTHER|Carbohydrate Beverage|This intervention will contain 266 kcals and 73.3 g carbohydrate from a carbohydrate beverage.
40814430|NCT00070876|BEHAVIORAL|Mental health communication skills training|
40814431|NCT06604286|DRUG|In this group, patients received 8 mg IM dexamethasone injection into the masseter muscle after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the groups immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection in group 1 was made into the masseter muscle. injection; The margo anterior of the mandible was palpated and horizontally parallel to the occlusal level of the mandibular second molar tooth and 1 cm behind the margo anterior towards the mandibular ramus. Bone contact was not taken during the injection and the injection was made by taking negative aspiration.
40814432|NCT06604286|DRUG|8 mg IM dexamethasone injection into the pterygoid cavity after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the group immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection given to Group 2 was directed to the region between the margo anterior of the mandible and the raphe pterygomandibularis, 1 cm above the occlusal level of the mandibular 2nd molar tooth, and the direction of the syringe from the incisal top of the opposing mandibular canine tooth to this region, and then entering the pterygomandibular cavity.
40814433|NCT05066581|DEVICE|Live Chat|Subjects from the intervention group will be able to ask for a medical intervention if needed with the phisycians from the sleep unit. After the following period, we expect to see better sleep habits in this group when compared to the no intervention one
40814434|NCT00381511|DRUG|low molecular weight heparin|
40814435|NCT06575452|DIAGNOSTIC_TEST|Blood, urine and tumoral tissue samples|Blood, urine and tumoral tissue samples
40814436|NCT06575452|DIAGNOSTIC_TEST|Tumoral tissue samples|tumoral tissue samples
40814437|NCT01335893|DRUG|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
40814438|NCT00499291|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
40814439|NCT00499291|PROCEDURE|gene expression analysis|
40814440|NCT00499291|PROCEDURE|laboratory biomarker analysis|
40814441|NCT00499291|PROCEDURE|pharmacological study|
40814442|NCT00499291|PROCEDURE|polymerase chain reaction|
40814443|NCT01192269|DIETARY_SUPPLEMENT|DHA (docosahexaenoic acid)|1 x 950 mg capsules per day orally, each capsule providing \~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
40814444|NCT01005316|DRUG|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
40814445|NCT01005316|DRUG|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
40814446|NCT01005316|DRUG|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
40814447|NCT01005316|PROCEDURE|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
41012944|NCT05984589|BEHAVIORAL|RISE Personalized Self-Managament Training (PSMT)|Along with patient education and internalization of self-determination, the RISE intervention focuses on replacing unhealthy habits with health-promoting habits. Ongoing practice and guidance in generating and enacting SMART (specific, measurable, achievable, realistic, and time-bound) health goals is the centerpiece of the RISE intervention. Working one-on-one with the PI, participants will set goals and develop practical strategies to establish sustainable healthy behavior (HB) change. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create lasting change. The 6-week intervention includes 2 in-person visits and 4 videoconference sessions.
41155932|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
41155933|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Oral solution in tube Route of administration: oral
40814448|NCT01005316|PROCEDURE|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
40814449|NCT01005316|DRUG|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
40814450|NCT01005316|DRUG|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
40814451|NCT00336284|OTHER|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
40814452|NCT00336284|OTHER|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
40814453|NCT00578877|DEVICE|SILCS Diaphragm|SILCS Diaphragm used with 5 ml gel
40814454|NCT00578877|COMBINATION_PRODUCT|Nonoxynol-9 Gel|Gynol II (2% N-9 gel)
40814455|NCT00578877|COMBINATION_PRODUCT|Buffer Gel|Buffer Gel
40814456|NCT03541486|DRUG|Ascorbate|75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.
40814457|NCT03541486|DRUG|Gemcitabine|600 mg/m2 once weekly for up to weeks
40814458|NCT03541486|RADIATION|radiation therapy|Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
40814459|NCT06329063|DRUG|Vasopressin|Administration of vasopressin (20 IU) (oral spray)
40814460|NCT06329063|DRUG|Placebo|Administration of placebo (oral spray)
41155934|NCT06647407|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
41155935|NCT06647407|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
40814461|NCT06107842|BEHAVIORAL|Gerofit exercise|Individualized exercise prescription as well as a group exercise class based on physical function assessments offered 3x/week
41331850|NCT02120352|DRUG|CAB LA|Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
41331851|NCT02120352|DRUG|ABC/3TC Oral tablets|ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
41331852|NCT02120352|DRUG|RPV Oral Tablets|Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
40814462|NCT06107842|BEHAVIORAL|Health education|Scheduled monthly in-person health education discussion sessions covering 12 different health topics not including a physical activity/exercise promotion session
41331853|NCT02120352|OTHER|HAART|Higly-active antiretroviral therapy chosen by participant based on investigator recommendations and based on availability.
40814463|NCT03957499|DRUG|Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
40814464|NCT03957499|DRUG|Dexamethasone/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
40814465|NCT03957499|DRUG|Magnesium Sulfate/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
40814466|NCT05845333|OTHER|Decision task|Participants will complete a simple and/or moral decision making functional MRI task.
40814467|NCT05358418|OTHER|AIS,START with films transferring|Excluding patients with incomplete clinical data of treatment
40814468|NCT04028765|DRUG|Misoprostol|Oral misoprostol 50 mcg every 4 hours for up to 6 doses or until cervical ripening is no longer indicated
41331854|NCT02120352|DRUG|RPV|Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
41331855|NCT00948038|DIETARY_SUPPLEMENT|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
41482754|NCT04815421|OTHER|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The paste lasted for 24 hours and then peeled it rested the pasted region for 24 hours and changed another paste on the pain region. The therapy duration was 6 days.
40814469|NCT04028765|DRUG|Oxytocin|IV Oxytocin 2 milliunits (mU)/min, increased by 2mU/min q15 minutes per hospital protocol
40814470|NCT02692768|OTHER|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
40814471|NCT02692768|OTHER|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
40814472|NCT02692768|OTHER|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
40814473|NCT01610713|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
40814474|NCT02553551|DRUG|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
40814475|NCT02553551|DRUG|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
40814476|NCT03069248|DRUG|Rituximab|
40814477|NCT03069248|DRUG|Alpha Interferon|
40814478|NCT06290167|DEVICE|360° media|sessions with head mounted display in hospital and sessions with tablet at home
40814479|NCT06290167|OTHER|Treatment As Usual (TAU)|sessions of TAU rehabilitation in hospital and sessions TAU rehabilitation at home
40814480|NCT06290167|OTHER|In hospital sessions|sessions will be carried out under the supervision of a therapist
40814481|NCT06290167|OTHER|at home sessions|sessions will be carried out without the supervision of a therapist
40814482|NCT06290167|OTHER|Mild Cognitive Impairment|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
40814483|NCT06290167|OTHER|Subjective Memory Complain|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
40814484|NCT05073276|OTHER|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
40814485|NCT02805751|DEVICE|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
40814486|NCT02805751|OTHER|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
40814487|NCT02805751|OTHER|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
40814488|NCT01545791|DRUG|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
40814489|NCT05694312|DRUG|Ibrutinib 420 mg|Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
40814490|NCT02358200|DRUG|BMN-673|
40814491|NCT02358200|DRUG|Carboplatin|
40814492|NCT02358200|DRUG|Paclitaxel|
40814493|NCT04503135|DIAGNOSTIC_TEST|ultrasound|ultrasound of the central veins of the neck and chest and a (compression ultra-sound) CUS of the femoral veins will be performed bilaterally
40814494|NCT00762138|DEVICE|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
40814495|NCT06313502|DRUG|75gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 75gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 120 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
40814496|NCT06313502|DRUG|100gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 100gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 180 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
40814497|NCT06313502|DRUG|125gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 125gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 240 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
40814498|NCT00067964|BEHAVIORAL|small changes in physical activity and diet|
40814499|NCT04884217|DRUG|Pro-ocular™ Topical Gel|Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
40814500|NCT04884217|DRUG|Placebo Topical Gel|Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
40814501|NCT05418283|BEHAVIORAL|Exercise|1 hour of aerobic exercise will be applied 3 days a week for 12 weeks.
40814502|NCT01825148|OTHER|radiolabeled Exendin|
40814503|NCT05502107|BEHAVIORAL|PRESS Intervention|The study intervention is PRESS protocol training and educational delivered to EMS providers, followed by protocol implementation. EMS providers will be trained to screen all EMS patients for protocol eligibility and will start using the protocol at the beginning of the intervention phase. The PRESS EMS protocol includes 2 major components: 1) an evidence-based sepsis screening tool, and 2) a prehospital sepsis alert call to the receiving hospital for participants who screen positive. Upon arrival to the ED, ED providers will provide immediate medical assessment to the patient to determine whether there is concern for sepsis. If the treating provider determines there is concern for sepsis, the provider will deliver usual sepsis care per local hospital protocols, workflows, or care pathways. Sepsis treatment interventions will not be specified by this study protocol.
41155936|NCT01757171|DRUG|Cabazitaxel|20mg IV over 1 hour every 3 weeks
41155937|NCT00629161|DRUG|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
40814504|NCT00616018|DRUG|acetaminophen|4 g/day for 10 consecutive days
40814505|NCT02890303|DEVICE|Zepto System|Anterior Capsulotomy using the Zepto System.
40814506|NCT01120236|DRUG|Bicalutamide|Given PO
40814507|NCT01120236|BIOLOGICAL|Cixutumumab|Given IV
40814508|NCT01120236|DRUG|Goserelin Acetate|Given SC
40814509|NCT01120236|OTHER|Laboratory Biomarker Analysis|Correlative studies
40814510|NCT01120236|DRUG|Leuprolide Acetate|Given IM
40814511|NCT01120236|OTHER|Pharmacological Study|Correlative studies
40814512|NCT05858632|DRUG|Guselkumab|Guselkumab treatment for \~ 9 months
40814513|NCT01807559|DEVICE|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
40814514|NCT04810013|PROCEDURE|non-invasive measurement of cerebral autoregulation|Non-invasive measurement of the cerebral autoregulation in the postoperative period in 80 neonates and infants with complex congenital heart disease undergoing cardiopulmonary bypass surgery. A continuous, moving Pearson's correlation coefficient will be calculated between the arterial pressure and near-infrared spectroscopy signals and displayed continuously during surgery using a laptop computer and the ICM+ software (Cambridge Enterprise).
40814515|NCT05340712|DIETARY_SUPPLEMENT|new infant formula|New formula containing a prebiotic and a mix of probiotics, randomly assigned to infants during a 2-month period and allocated to all infants during the optional open-label follow-up period of 2 months.
40814516|NCT05340712|DIETARY_SUPPLEMENT|Standard formula|Standard infant formula containing no prebiotic nor probiotic, randomly assigned to infants during a 2-month period followed by an optional open-label follow-up period of 2 months with the new infant formula
40814517|NCT01287390|PROCEDURE|video fluoroscopy|video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
40814518|NCT01287390|PROCEDURE|extra imaging|For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
40814519|NCT01287390|OTHER|scoring acute toxicity|Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
40814520|NCT01287390|OTHER|scoring of late toxicity|Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
40814521|NCT01287390|OTHER|scoring quality of life (QOL)|Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H\&N 35).
40814522|NCT02043106|OTHER|plantar vibration|
40814523|NCT00406874|DRUG|omega 3 fats|1,000 mg daily
40814524|NCT00406874|DRUG|folic acid|800 micrograms daily
40814525|NCT05829447|DEVICE|G-EYE 760 R endoscope|The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
40814526|NCT05337111|OTHER|Cardiorespiratory fitness test|Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness
40814527|NCT05337111|OTHER|Resting measure of fat oxidation|Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest
40814528|NCT05337111|OTHER|Maximum fat oxidation test|Progressive exercise test to determine maximum fat oxidation during exercise
40814529|NCT02419222|BEHAVIORAL|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
40814530|NCT01660672|DRUG|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
41155938|NCT00629161|DRUG|placebo|12 months period of placebo plus 1 month period without placebo
40814531|NCT02978157|DRUG|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.
40814532|NCT02978157|DRUG|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
40814533|NCT03825146|BIOLOGICAL|Autologous Multi-lineage Potential Cells (AMPC)|"Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10\^8 (0.5 to 5.0 x 10\^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0."
40814534|NCT03199053|DRUG|Dapagliflozin|Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
41155939|NCT06538831|OTHER|Diet N-P-|Low in saturated fatty acids (SFAs), free sugar and sodium; Low in ultra-processed foods (UPFs)
41155940|NCT06538831|OTHER|Diet N+P-|Rich in SFAs, free sugar and sodium; Low in UPFs
41155941|NCT06538831|OTHER|Diet N-P+|Low in SFAs, free sugar and sodium; High in UPFs
41155942|NCT06538831|OTHER|Diet N+P+|Rich in SFAs, free sugar and sodium; High in UPFs
40814535|NCT03199053|DRUG|Saxagliptin|Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
40814536|NCT03199053|DRUG|Placebo|Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
40814537|NCT00654745|DRUG|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
41331856|NCT00948038|DIETARY_SUPPLEMENT|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
41331857|NCT05693688|DRUG|Atosiban|atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.
41331858|NCT01002742|DRUG|Mycophenolate Mofetil|"Oral dosing should be delivered in 250 mg units. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive MMF 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours."
41482755|NCT04815421|OTHER|the meridian group|Patients in the meridian group were treated with dredging the same side three yang meridian techniques(include the gliding techniques of deep tissue massage on three yang meridians of back hand (the second, fourth and fifth metacarpal bone); pinching and kneading the second, fourth and fifth phalanges of fingers of the affected side hand; Encourage the patient to try his best to roll his neck to the most tolerable degree during dredging the meridian) and the total time was about 3 to 5 minutes according the tolerance of every patient . The massage will not stop until the meridian route was relatively smooth, soft and thermal or light red. The sequence of massage is Hand Yangming meridian(LI) the first, Hand Taiyang meridian(SI) the second and Hand Sanjiao(SJ) the last. The frequency of massage was once a day.
41482756|NCT04528030|DEVICE|WAVE device|WAVE applies a transcutaneous vibration to the soles of the foot and palms of the hand to elicit nerve signalling from pressure and other limb proprioceptor sensors to pontine, cerebellar, and medullary brain areas that coordinate limb movement and reflexively activate brain areas controlling breathing. The WAVE device is a battery-operated product to reduce the episodes of Apnoea of Prematurity by vibratory stimulation to the hand and foot.
41482757|NCT00186043|DRUG|Quetiapine/Seroquel|Quetiapine/Seroquel
41482758|NCT00186043|DRUG|Placebo|Placebo
41482759|NCT02562482|BIOLOGICAL|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).
41482760|NCT02562482|OTHER|VRC-PBSPLA043-00-VP|VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.
41482761|NCT05757882|OTHER|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water.
41482762|NCT05757882|OTHER|2 hours of fasting time|Oral intake is not allowed for 2 hours before sedation including water.
41482763|NCT04987242|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
41482764|NCT04987242|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
41482765|NCT06224712|BEHAVIORAL|Arogya Sangama|Using human-centered design, the investigators will work wit the community to develop a prototype Arogya Sangama model to identify methods to bring GPTF and HWC service providers to create ideas, systems, processes, services, and delivery strategies for the GPTFs. They will help identify and prioritize interventions and address barriers to usability. There will also be capacity building of GPTFs to implement the interventions identified.
41331859|NCT01002742|DRUG|Placebo|"Oral dosing should be delivered in 250 mg units blinded placebo. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive placebo 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours."
41482766|NCT03784521|DEVICE|In-line filtration|In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.
41482767|NCT03784521|DEVICE|Standard care|Patients are treated with standard intravenous solutions and vascular access management
41482768|NCT02932020|DRUG|AlloGen-LI|interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
41482769|NCT02932020|DRUG|depomedrol|interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)
40814538|NCT00654745|DRUG|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
40814539|NCT00654745|DRUG|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
40814540|NCT05411588|DRUG|PF-07275315|Active drug
40814541|NCT05411588|DRUG|Placebo|Placebo
40814542|NCT04355442|PROCEDURE|Facial fractures reduction or osteosynthesis|Facial fractures reduction or osteosynthesis
40814543|NCT00825942|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
41331860|NCT05389384|DEVICE|Passive shoulder exoskeleton|Participants complete overhead working task with support of exo
41331861|NCT05389384|BEHAVIORAL|Fatigue protocol|Participants complete a fatiguing protocol
41482770|NCT02932020|DEVICE|MRI|contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)
41482771|NCT02932020|DRUG|0.5% marcaine|epidural injection of 2mL 0.5% marcaine
41482772|NCT05167604|DRUG|Adjuvants, Pharmaceutic|Patients with stage IB-IIA NSCLC after curative surgery were treated with adjuvant chemotherapy. The blood samples of the patients before and after adjuvant chemotherapy will be collected to examine the MRD status
40814544|NCT00201357|DRUG|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
40814545|NCT00964665|DRUG|albinterferon alfa-2b|
40814546|NCT00964665|DRUG|albinterferon alfa-2b|
40814547|NCT00964665|DRUG|albinterferon alfa-2b|
40814548|NCT00964665|DRUG|albinterferon alfa-2b|
40814549|NCT00964665|DRUG|Pegasys®|
41331862|NCT05389384|DEVICE|No exoskeleton support|Exoskeleton is worn, but no support provided
41331863|NCT05389384|BEHAVIORAL|No peripheral fatiguing protocol|Participants complete no fatiguing protocol
40814550|NCT06292416|OTHER|Experimental: Mirror therapy with sensory motor training.|"Block design, finding shapes in pictures, puzzles, matching geometric shapes and letters, numbers, and classification.~Pointing to the body parts, life-size drawing, turning left and right side and awareness of the body parts through touch.~feeling various textures, touching boards, and feeling shapes. Ocular-pursuit training, moving ball and pegboard activities During the sessions, subjects were asked to try and do the same movement with the paretic hand simultaneously The patients will be asked to repeat each movement 20 times per set for three sets, with a 2-minute break between sets.~Session will last for 45 mins"
40814551|NCT06292416|OTHER|Experimental: Mirror Therapy with motor training|the participant is asked to perform a forearm movement sting on the paretic side while the subjects look into the mirror, watching the image of their non-involved hand and thus seeing the reflection of the hand movement projected over the involved hand. During the sessions subjects were asked to try and do the same movement with the paretic hand simultaneously. movement was repeated 20 times per set for three sets, with a 2-minute break between sets
41155943|NCT00722488|DRUG|MLN4924|Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
41155944|NCT06001814|BEHAVIORAL|One-Mind One-Heart|One-Mind One-Heart will include mindfulness and behavior change skills to address psychological distress, physical activity, diet, and substance use.
41331864|NCT06070636|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
41331865|NCT06070636|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
41331866|NCT06070636|DRUG|Sintilimab|200mg intravenously every 32 weeks
41331867|NCT03628599|DEVICE|Delefilcon A contact lenses|Water Gradient silicon hydrogel daily disposable contact lenses
41331868|NCT03628599|DEVICE|Senofilcon A contact lenses|Silicon hydrogel daily disposable contact lenses with HydraLuxe™ Technology
41331869|NCT03734562|PROCEDURE|Ablation|Substrate-based radiofrequency catheter ablation
41331870|NCT03734562|DRUG|Antiarrhythmic drug|Amiodarone or sotalol therapy
41331871|NCT03700268|OTHER|Manual intervention to programme Cochlear Implant electrodes|The Clinician test the 22 electrodes so that the patient is able to hear the language
41331872|NCT03175874|PROCEDURE|Hip bone sampling|Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
41331873|NCT05145803|DEVICE|Polyvinylalcohol strip [diagnostic]|The investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using PVA test strips embedded in face masks (FMS) - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air. Utilizing this approach, the study aims to utilize the test results extracted from the masks to identify risk factors for SARS-CoV-2 transmission and timing of infectious period in exposed people (pre-symptomatic, asymptomatic, and symptomatic).
41331874|NCT04581863|DEVICE|pulse oximeter|Patients will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is \>3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
41331875|NCT04581863|OTHER|COVID Watch|Enrolled patients receive text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately.
41331876|NCT00545480|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
41331877|NCT00545480|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
41331878|NCT05428449|DRUG|GT20029 Gel|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
41331879|NCT05428449|DRUG|GT20029 Gel Placebo|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
41331880|NCT00028639|DRUG|bortezomib|
41331881|NCT01422512|BIOLOGICAL|seasonal influenza vaccine|Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
41331882|NCT04173039|DIAGNOSTIC_TEST|Serum anti-CarP antibodies detection|Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.
41331883|NCT03057912|BIOLOGICAL|TALEN|TALEN gel consists of TALEN plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
41331884|NCT03057912|BIOLOGICAL|CRISPR/Cas9|CRISPR/Cas9 gel consists of CRISPR/Cas9 plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
41331885|NCT00425100|DRUG|fesoterodine fumarate|12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
41331886|NCT01664819|DIETARY_SUPPLEMENT|Antioxidant|
41331887|NCT01664819|DIETARY_SUPPLEMENT|Placebo|
41331888|NCT01617928|DRUG|veliparib (ABT-888)|Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
41331889|NCT01617928|DRUG|carboplatin|Carboplatin will be administered on Day 3 of each cycle, intravenously.
41331890|NCT01617928|DRUG|paclitaxel|Paclitaxel will be administered on Day 3 of each cycle, intravenously.
41331891|NCT01170221|DRUG|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
41331892|NCT01170221|DRUG|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
41331893|NCT00026585|DRUG|Tamoxifen|
41331894|NCT00511121|DRUG|STI571 and PEG INTRON|
41331895|NCT04853589|DEVICE|Hyaluronic acid gel|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.
41331896|NCT04853589|DEVICE|Hyaluronic acid gel + carrier|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.
41331897|NCT02907671|PROCEDURE|carpal tunnel corticoanesthetic injection|Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
41331898|NCT00612989|DRUG|Temodar and O6-Benzylguanine|"O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose."
41331899|NCT05103241|DRUG|[14C] GP681|40 mg suspension containing 100μCi of \[14C\]GP681
41331900|NCT00535691|DRUG|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
41331901|NCT00535691|DRUG|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
41331902|NCT02650895|BIOLOGICAL|Efprezimod alfa|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
41331903|NCT02650895|DRUG|Saline|0.9% sodium chloride
41331904|NCT05325398|DIETARY_SUPPLEMENT|HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada|"The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.~All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)."
41331905|NCT05325398|DIETARY_SUPPLEMENT|placebo|"13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)"
41331906|NCT05474469|OTHER|Diaphragmatic breathing exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
41331907|NCT05474469|OTHER|Abdominal muscle strengthening exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
41331908|NCT05767229|DRUG|Carvedilol|Carvedilol 0.2 mg/kg for 1.5 hrs
41331909|NCT01367860|PROCEDURE|Open microdiscectomy|The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
41331910|NCT01367860|PROCEDURE|Percutaneous Diskectomy SpineJet|Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
41331911|NCT02699671|DEVICE|Bioresorbable Vascular Scaffold|
41331912|NCT04460248|DRUG|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|"Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-21;~2. Lenalidomide, 25 mg qd, po, day 2-11;~3. Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years."
41331913|NCT06211452|DRUG|ARM A: Active Comparator Drug|Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8, 15, 22; cytarabine 75 mg/m2/d, on days 3-6, 10-13, 17-20, 24-27, 31-34, 38-41; intrathecal cytarabine on days 1, 15, 29, 43; cyclophosphamide 500 mg/m2/d, days 29, 43.
41331914|NCT06211452|DRUG|ARM B: Blocks Therapy Drug|"Blocks AI Cytarabine 500 mg/m2 as 24 infusion infusion x 4 d; Idarubicin 7 mg/m2 on days 3 and 5; Intrathecal cytarabine on days 0 and 6.~haM Cytarabine 1 g/m2 every 12 hours for 3 days; Mitoxantrone 10 mg/m2 days 4 and 5; Intrathecal cytarabine days 6 and 15."
41331915|NCT00783172|DRUG|Gemcitabine|1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
41331916|NCT00783172|BIOLOGICAL|Opioid Growth Factor (OGF)|Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
41331917|NCT02533778|DEVICE|mechanical thrombectomy|Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
41331918|NCT06058884|DRUG|Alteplase|Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
41331919|NCT04913480|DRUG|Durvalumab|Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles
41331920|NCT04913480|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days.
41482773|NCT06367595|DRUG|Magnesium sulfate|IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine
41482774|NCT05730907|DRUG|Levosimendan|examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR
41482775|NCT03421782|BEHAVIORAL|Cognitive Behavior Therapy|Undergo PROSPECT internet-based CBT
40814552|NCT06292416|OTHER|Experimental: Motor Training|"1. Holding object with two hands, clapping, banging objects together.~2. Stabilize objects with one hand while the other is manipulating (holding paper while coloring, holding a container while putting objects in)~3. manipulate objects with both hands simultaneously (stringing beads, tying a knot),~4. ask child to padlock in which a key can be put into, markers with caps to put on, a box with a lid and objects to put inside the box~5. hold a cup with one hand while putting object in with other hand~6. Buttoning with both hands, tying a bow. doing craft project, fitting blocks together"
40814553|NCT00396136|DEVICE|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
40814554|NCT04135560|DRUG|PF-07038124 and Vehicle|PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
40814555|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
40814556|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
40814557|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
40814558|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
40814559|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
40814560|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle BID applied to 10% BSA
40814561|NCT04554966|DRUG|ABBV-382|Intravenous (IV) infusion
40814562|NCT04554966|DRUG|ABBV-382|Subcutaneous (SC) injection
40814563|NCT04554966|DRUG|Placebo for ABBV-382|Intravenous (IV) infusion
41155945|NCT06001814|OTHER|Education|Education will be provided on behavioral cardiovascular disease risk reduction strategies, such as increasing physical activity, reducing salt intake in diet, and reduce/stop alcohol and tobacco-use.
41331921|NCT05713942|DIAGNOSTIC_TEST|The Sport Concussion Assessment Tool 5th Edition (SCAT5)|The SCAT5 is a standardized tool for use by healthcare professionals in the evaluation of individuals 13 years old or older, who are suspected of having sustained a sports-related concussion. It comprises a neuropsychological test battery that assesses attention and memory function through 8 different domains 1) Symptom number, 2) Symptom severity, 3) Orientation, 4) Immediate memory, 5) Concentration, 6) Neurological examination, 7) Balance errors, 8) Delayed recall.
41331922|NCT05713942|DIAGNOSTIC_TEST|The Immediate Post-Concussion Assessment and Cognitive Testing tool version 4 (ImPACT)|The ImPACT is a computer-based neurocognitive test battery that provides an objective measure of neurocognitive functioning as an assessment aid in the management of concussion in individuals ages 12-80 years
41331923|NCT03638557|OTHER|Nutritious Lunch|"The intervention package consists of the following;~1. Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~2. Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
41331924|NCT05466981|BEHAVIORAL|Cognitive Behavioral Counseling|The intervention consisted of 12 weeks of HCV treatment combined with smoking cessation pharmacotherapy and brief behavioral counseling conducted by a LMSW. The brief behavioral counseling consisted of cognitive behaioral components and was provided by phone and in-person. The intervention followed these 5 phases: increase motivation to quit smoking, quit attempt, maintain short-term abstinence, and lapse and relapse prevention.
40814564|NCT05688215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
41331925|NCT06374862|OTHER|mobilization|specific mobilization on neuromuscular functioning, thanks to surface EMG, before and after a specific mobilization of the spine
41482776|NCT03421782|BEHAVIORAL|Exercise Intervention|Undergo POWER exercise intervention
40814565|NCT05688215|PROCEDURE|Computed Tomography|Undergo a CT scan
40814566|NCT05688215|PROCEDURE|Core Biopsy|Undergo core biopsy
40814567|NCT05688215|DRUG|Fluorouracil|Given IV
40814568|NCT05688215|DRUG|Irinotecan|Given IV
40814569|NCT05688215|DRUG|Leucovorin|Given IV
40814570|NCT05688215|DRUG|Leucovorin Calcium|Given IV
40814571|NCT05688215|DRUG|Oxaliplatin|Given IV
40814572|NCT05688215|DRUG|Quemliclustat|Given intravenously (IV)
40814573|NCT05688215|DRUG|Zimberelimab|Given IV
40814574|NCT05556057|OTHER|mindfulness meditation(MM)|Participants will be provided with a unique invitation code that will allow them to download and use the free research version of the Mindfulness Coach app that is designed to deliver mindfulness training developed by the Veteran Affairs' National Center for PTSD.The app is tailored to users who may be skeptical about meditation practices by providing simple instructions and brief meditation exercises. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes, with an average length of 10 minutes
40814575|NCT05556057|OTHER|Health Education (active control)|Participants will be asked to download and use the free TED Talk app.Each participant's account will include a list of over 80 TED Talks related to the six broad categories of sleep, nutrition, mood, relationships, chronic pain, and health behaviors. These talks range from 4 to 18 minutes and were reviewed/selected by the investigator team. The research coordinator(RC) will instruct them to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week. The RC will ask participants to complete weekly logs of their TED Talk app use
40814576|NCT04583787|DIAGNOSTIC_TEST|99mTc-sestamibi myocardial perfusion SPECT|82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
40814577|NCT04583787|DIAGNOSTIC_TEST|82Rb-Chloride myocardial perfusion PET with CCTA|stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
40814578|NCT06509997|DRUG|MRG003 combined with Dalpicicilip|MRG003, intravenous infusion, D1, once every 3 weeks; Dalpicicilip, taking orally, D1-21, once every 4 weeks, maintain use until progression or emergence of intolerable toxicity.
40814579|NCT05280652|BEHAVIORAL|Nutritional and culinary intervention|Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).
41331926|NCT06374862|OTHER|no effect|"a mobilization identified as no effect could modulate neuromuscular activity by a placebo effect."
41331927|NCT03349580|BEHAVIORAL|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
41331928|NCT03529370|RADIATION|optic nerve ultrasound|sonograhy of the optic nerve sheath diameter
41331929|NCT02705443|OTHER|No Intervention|Standard of Care Only
41331930|NCT05989295|DIETARY_SUPPLEMENT|probiotic LRa05|treatment about 12 weeks
41331931|NCT03883490|DIAGNOSTIC_TEST|ECG|A 12-lead ECG will be taken for each participant.
41331932|NCT03883490|DIAGNOSTIC_TEST|Blood test and biobanking|All patients will undergo venepuncture and blood sample will be taken for full blood count, renal function and plasma will be stored for future biomarker analysis.
41331933|NCT03883490|DIAGNOSTIC_TEST|Trans-thoracic Echocardiogram|A standard TTE will be undertaken to measure severity of AS as well as bi-ventricular function. Speckle-tracking data will be performed offline to assess diastolic function.
41331934|NCT03883490|DIAGNOSTIC_TEST|Vicorder recording|Measurement of carotid-femoral PWV will be made using the Vicorder technique.
41331935|NCT03883490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Patients will undergo a stress MRI scan of their heart and aorta on a 3T scanner, including 4D flow.
41331936|NCT03789968|DRUG|bictegravir/emtricitabine/tenofovir alafenamide|Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen
41331937|NCT06065345|DEVICE|BRight DCB|The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
41331938|NCT06144970|BIOLOGICAL|TG-C High Dose|High Dose - 1 mL of the combined TG-C cells
40814580|NCT05280652|BEHAVIORAL|Nutritional intervention|Participants will attend 6 1-hour nutritional workshops between May 2022 and February 2023. The workshops will be held in person, and will be given in groups of 10-12 families. In addition, during the intervention families will be given access to a web page with nutrition education materials (infographics, videos).
41331939|NCT06144970|BIOLOGICAL|TG-C Mid Dose|Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
40814581|NCT04567706|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
41331940|NCT06144970|BIOLOGICAL|TG-C Low Dose|Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
40814582|NCT00368381|DRUG|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
40814583|NCT02889289|OTHER|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
40814584|NCT00767663|DRUG|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
40814585|NCT00767663|DRUG|placebo|placebo twice daily, minimal three days pretreatment
40814586|NCT06457776|PROCEDURE|Dental management|The oral conditions of the included patients will be evaluated at baseline. When indicated, dental extractions will be performed before the beginning of Antiresorptive Therapy. Patients will then receive a six-months intervals follow-up, during which primary and secondary prevention of dental diseases will be performed.
40814587|NCT04164017|DEVICE|EUS-guided FNB with Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
41331941|NCT06144970|BIOLOGICAL|Sham Control|Single subcutaneous injection of normal saline
41331942|NCT03876145|OTHER|Minimal ovarian stimulation|After obtaining informed consent to participate in the study, the subjects will be randomly divided into the following 4 groups: The group of minimal ovarian stimulation with rec-FSH or HMG. The group of mild ovarian stimulation with rec-FSH or HMG. In all 4 experimental groups, after reaching at least three follicles the size of 12 millimeters (mm), daily administration of 0.25 milligram (mg) Cetrotide (antagonist GnRH) will be started and after reaching at least three follicles the size of 17 mm, 500 microgram Ovitrelle (recombinant Human curionic gonadotropin) will be prescribed. 36 hours later, ovulation process will be done. On the day of Ovitrelle administration, serum levels of estradiol and progesterone will be also evaluated. Based on the patient's condition and the quality of obtained oocytes and embryos, 2 embryos will be transferred.
41331943|NCT01924741|PROCEDURE|ALPPS|Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
41331944|NCT03274180|OTHER|Nursing consultation|travel preventive consultation was performed by nurse
40814588|NCT04164017|DEVICE|EUS-guided FNB without Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
40814589|NCT00484393|DRUG|tetracaine 4% gel|tetracaine applied prior to 1 injection
41331945|NCT01045434|DRUG|Omeprazole|Omeprazole Magnesium DR 20 mg Capsules
41331946|NCT03407170|BIOLOGICAL|pembrolizumab|200 mg by IV infusion Q3W for up to 24 months
41331947|NCT02398981|OTHER|Clinical decision support tool|
41331948|NCT00586638|BEHAVIORAL|Video game based training|36 one-hour sessions over 12 weeks
41331949|NCT04930211|DRUG|Dexamethasone-Lidocaine|Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.
40814590|NCT00484393|DRUG|Placebo|placebo applied prior to 1 injection
41331950|NCT00707460|BEHAVIORAL|Dietary Intervention (Macronutrient composition)|"The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size."
41331951|NCT04438772|OTHER|Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia|Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition
40814591|NCT00385281|BIOLOGICAL|FluMist|
40814592|NCT01045148|RADIATION|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
41331952|NCT05972395|OTHER|Localized vs Widespread Mechanical Pain Hypersensitivity|Based on pressure pain threshold mapping, participants will be classified as having either localized mechanical pain hyperalgesia (hyperalgesia limited to the lumbosacral region) or widespread mechanical pain hyperalgesia (hyperalgesia extending beyond the lumbosacral region).
40814593|NCT01045148|RADIATION|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
41331953|NCT05800509|BEHAVIORAL|Clips Intervention|A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners. There are pretest and posttest questions on the structured questionnaires of 22nd week and 35th week of pregnancy and 3rd month after delivery.
41331954|NCT05800509|DEVICE|Structured Questionnaire Only|A website of health education about gestational diabetes mellitus will be given to participants and their partners, then structured questionnaires and regular health service from the hospital continue to be given.
41331955|NCT04241172|DEVICE|Experimental: Immersive Virtual Reality (HIVR)|"the HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~* Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~* Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving a visual and auditory biofeedback."
41331956|NCT04241172|PROCEDURE|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~* exercises with a patients sitting on the swimming pool edge with lower limb immersed in the water;~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* water walking exercises."
41331957|NCT04241172|PROCEDURE|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~* exercises with a patient sitting on a chair (3 minutes per exercise):~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* walking (with and without aids)."
41331958|NCT05687708|OTHER|Non-Nutritive Sucking|NNS is stimulated by giving stimulus into the baby's mouth with the help of a finger wearing gloves.
41482777|NCT02724865|DEVICE|Somnodent® (Oral appliance therapy)|
41482778|NCT02724865|DEVICE|Herbst® (Oral appliance therapy)|
41482779|NCT02831959|DEVICE|NovoTTF-200M device|
41482780|NCT02831959|OTHER|Best Standard of Care|
41482781|NCT01402180|BIOLOGICAL|Nimotuzumab|
40814594|NCT06090539|DRUG|BMS-986458|Specified dose on specified days.
40814595|NCT06090539|DRUG|Rituximab|Specified dose on specified days.
40814596|NCT05968053|DIAGNOSTIC_TEST|biological samples analysis|biological samples analysis
40814597|NCT05807893|DRUG|Serplulimab combined with bevacizumab and first-line chemotherapy|Serplulimab combined with bevacizumab and first-line chemotherapy
40814598|NCT05719350|OTHER|Exercises for Knee|Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
40814599|NCT02013557|BEHAVIORAL|Text-message reminder|
40814600|NCT03441997|OTHER|Mind-body exercise|Exercise program.
40814601|NCT03441997|OTHER|Light mobility exercises|Modified mind-body program.
41482782|NCT01402180|RADIATION|Radiation therapy|
41482783|NCT01402180|RADIATION|radiation therapy|
41482784|NCT01402180|DRUG|chemotherapy|
40814602|NCT03745365|PROCEDURE|loop bipartition|A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.
40814603|NCT00002249|DRUG|Levofloxacin|
41482785|NCT01402180|DRUG|chemotherapy|
40814604|NCT00168636|DRUG|Vitamin A|
40814605|NCT01828619|PROCEDURE|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
40814606|NCT01278121|DIETARY_SUPPLEMENT|Diet A|3 days, 6 meals a day
40814607|NCT01278121|DIETARY_SUPPLEMENT|Diet B|10 days, 6 meals a day
40814608|NCT03526809|DIAGNOSTIC_TEST|MRI scan and FDG-PET scan|Scanning with MRI and FDG-PET
40814609|NCT04388319|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 12 weeks.
41012945|NCT05984589|BEHAVIORAL|Standardized Self-Managament Training (SSMT)|Participants randomized to the control condition will receive 6 standardized sessions from one of the OT interveners, matched to the PSMT for setting. At these visits, participants will be presented with slides containing pre-specified, standardized didactic content about the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) healthy behavior recommendations (HBRs). We hypothesize that these visits will control for the effect of research participation and increased knowledge about HBRs, and that simply providing standardized didactic content as an intervention modality without any personalization will have negligible effects on participants' healthy behaviors (HBs), self-efficacy, or quality of life. Content will follow the WCRF/AICR HBRs. Weeks 1-2 will focus on physical activity; weeks 3-4 will focus on diet and alcohol, and weeks 5-6 will focus on weight management and generalized strategies for HB change.
41012946|NCT03666598|DEVICE|Tourniquet|In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
41012947|NCT04355416|DRUG|curcumin Oral gel|application of curcumin oral gel after scaling and root planing
40814610|NCT04388319|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
41012948|NCT04355416|PROCEDURE|subgingival scaling and root planing|subgingival scaling and root planing without application of curcumin gel
41012949|NCT04068181|DRUG|Talimogene laherparepvec|Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.
41012950|NCT04068181|DRUG|Pembrolizumab|Intravenous (IV) infusion.
41012951|NCT05731219|BIOLOGICAL|B7-H3 target, CAR gene modified gdT cell injection|After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.
41012952|NCT05956418|DRUG|Centhaquine|Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
41012953|NCT05332262|DIAGNOSTIC_TEST|Assessment of platelet reactivity|Assessment of platelet reactivity and HPR status will be performed post-PCI. Platelet reactivity will be measured by VerifyNow P2Y12 and HPR status will be defined using a cut-off value of platelet reactivity units (PRU)\>208.
41331959|NCT01441518|OTHER|Home care|"Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia ."
41331960|NCT01441518|OTHER|Hospital care|"Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.~The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.~All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists."
41331961|NCT01024101|DRUG|Paclitaxel|Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
41331962|NCT00814307|DRUG|CP-690,550|5mg CP-690,550 BID PO for 6 months
41331963|NCT00814307|DRUG|CP-690,550|10 mg CP-690,550 BID PO for 6 months
41331964|NCT00814307|DRUG|Placebo|Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
41331965|NCT00814307|DRUG|Placebo|Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
41331966|NCT04790539|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
41331967|NCT05525741|OTHER|Non segmental vitiligo|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
41331968|NCT05525741|OTHER|Health Volunteers|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
41012954|NCT05332262|DIAGNOSTIC_TEST|Troponin measurement|Measurement of high sensitivity troponin for the assessment for the presence of myocardial infarction/myocardial injury will be performed post-PCI.
41012955|NCT01420302|PROCEDURE|Nurse directed|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
41012956|NCT01420302|PROCEDURE|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
41012957|NCT02707640|DRUG|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
41482786|NCT06367036|OTHER|Topical hypericum perforatum oil intervention|The research nurse working in the CICU applied 5-6 drops of hypericum perforatum oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied.
41482787|NCT03676699|DIAGNOSTIC_TEST|Ultrasound chest|Ultrasound detection of extravascular lung water
40814611|NCT04388319|OTHER|Halo G6 e-cigarette|G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
40814612|NCT05743842|DEVICE|TriSalus™ TriNav™Infusion System|Given by Infusion
40814613|NCT05743842|DIAGNOSTIC_TEST|Angiogram|X-ray photograph
40814614|NCT05743842|PROCEDURE|Y90-radioembolization procedure|procedure
40814615|NCT05515575|DRUG|Niraparib|Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.
40814616|NCT02894164|OTHER|No intervention|
40814617|NCT06315036|OTHER|Developmental gymnastics|The DG exercise program ran from September 15, 2021, to May 15, 2022, in a well-equipped gymnasium. Led by trained teachers and gymnastics experts, sessions were held twice weekly (Tuesday and Thursday) for 60 minutes. The program focused on stability, locomotor skills, and manipulation, introducing children to DG fundamentals. It included circuit and station training, obstacle courses, and gradually increased exercise complexity. Sessions comprised a 15-minute warm-up, a 40-minute main session with skill practice and conditioning, and a 5-minute cool-down. The atmosphere was positive and friendly, with kid-friendly music and adapted procedures from previous research.
40814618|NCT03830476|BEHAVIORAL|Acceptance- and Commitment therapy group for parents to children with disabilities|ACT groups adjusted for parents of children with (any kind of) disabilities.
40814619|NCT03830476|BEHAVIORAL|Treatment as usual.|Treatment as usual within outpatient disability services.
41482788|NCT02825329|DEVICE|TORAYMYXIN PMX-20R|Two (2) PMX cartridges will be administered approximately 24 hours apart. PMX Cartridge is an extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
40814620|NCT01127607|DRUG|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
40814621|NCT05978492|DRUG|TXN10128|Participants receive TXN10128 capsules orally once daily.
41012958|NCT02707640|DRUG|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
40814622|NCT00789594|BEHAVIORAL|laboratory monitoring alerts|laboratory monitoring alerts
40814623|NCT00789594|BEHAVIORAL|Result management module|Result management module
40814624|NCT04660825|OTHER|A resistance band exercise programme|A resistance band based exercise programme lasting six months
40814625|NCT04660825|OTHER|Control|Maintained usual physical activity
40814626|NCT05317715|OTHER|Group A, who will complete a questionnaire before receiving information about intrauterine devices|Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.
40814627|NCT05317715|OTHER|Group B who will answer a questionnaire after having the information about the intrauterine devices|Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.
40814628|NCT05556135|DIAGNOSTIC_TEST|level of serun adiponectin|estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
40814629|NCT01425359|DRUG|Ranolazine|
40814630|NCT01425359|DRUG|Ranolazine placebo|
41012959|NCT02707640|DRUG|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
41012960|NCT02660736|DRUG|Albiglutide Liquid Auto-injector|Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
41331969|NCT03029897|OTHER|My eReport France|"patients are educated to the use of My eReport France application"
41331970|NCT02050906|BEHAVIORAL|behavioral dietary intervention|Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
41331971|NCT02050906|BEHAVIORAL|exercise intervention|Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
41331972|NCT02050906|OTHER|behavioral activity counseling|Undergo behavioral activity and nutritional counseling
41331973|NCT02050906|BEHAVIORAL|telephone based counseling|Undergo behavioral activity and nutritional counseling
41331974|NCT02050906|PROCEDURE|quality-of-life assessment|Ancillary studies
41331975|NCT02050906|OTHER|questionnaire administration|Ancillary studies
41331976|NCT02722629|PROCEDURE|FEESST|Flexible Endoscopic Evaluation of Swallowing with Sensory Testing
41331977|NCT03466112|OTHER|endurance training|endurance training with stationary bicycles
41331978|NCT03466112|OTHER|balance and tone program|flexibility, core strength, balance, relaxation
41331979|NCT03990090|DRUG|TG103|Administered SC
41331980|NCT03990090|DRUG|Placebo|Administered SC
41331981|NCT03073343|DIETARY_SUPPLEMENT|Betaine (trimethyglycine)|Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
41331982|NCT02264015|DRUG|Cilobradine, low, film-coated tablets|
41331983|NCT02264015|DRUG|Cilobradine, high, film-coated tablets|
41331984|NCT02264015|DRUG|Placebo, film-coated tablets|
41331985|NCT02264015|DRUG|Moxifloxacin, film-coated tablets|
41331986|NCT05957848|DRUG|Guanfacine Extended Release Oral Tablet|Target dose 4 mg daily
41331987|NCT05957848|BEHAVIORAL|Residential withdrawal|4-14 days in residential withdrawal treatment
41331988|NCT05957848|BEHAVIORAL|Engagement with alcohol and other drug services|Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study
41331989|NCT05957848|DRUG|Placebo|Placebo capsule taken daily
41012961|NCT02660736|DRUG|Albiglutide Lyophilized DCC Pen Injector|Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
41012962|NCT02660736|DRUG|Placebo Liquid Auto-injector|Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
41482789|NCT01859130|DEVICE|Zimmer Persona Total Knee System|
41012963|NCT02660736|DRUG|Placebo Lyophilized DCC Pen injector|Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
41155946|NCT01114334|BEHAVIORAL|Guideline-Based Medical Management|We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
41331990|NCT04714489|OTHER|NO.|NO.
41331991|NCT04306978|OTHER|CareLink Express RM system|CareLink Express remote monitoring system consists of implantable pacemaker CareLink Express station for implanted Medtronic cardiac devices and provides remote data transmissions
41331992|NCT04306978|OTHER|Standard follow-up|Follow-up will be provided according to the standard guidelines (HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations; 2008)
41331993|NCT00263835|BEHAVIORAL|Empowerment|
41331994|NCT04702984|DEVICE|LID021201 contact lenses|Investigational silicone hydrogel sphere contact lenses for frequent replacement daily wear
41331995|NCT04702984|DEVICE|OPTI-FREE multipurpose solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
41482790|NCT01473121|OTHER|No Intervention|All treatment options (inc. surgery, TACE, drugs) will be registered.
40814631|NCT01844102|DEVICE|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
41331996|NCT06508177|OTHER|İnterfascial plane block|Interfascial plane blocks will be added to the routine analgesia plan as part of multimodal analgesia.
41331997|NCT06508177|OTHER|Standart analgesia plan|This is the routine analgesia plan applied in our clinic.
41331998|NCT00621088|PROCEDURE|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
41482791|NCT04146363|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
41482792|NCT04146363|OTHER|Placebo|Subcutaneous Injection
41482793|NCT02575976|BEHAVIORAL|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
40814632|NCT05627986|OTHER|No intervention|No intervention
41482794|NCT02575976|OTHER|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
41012964|NCT02039427|DRUG|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
41012965|NCT02039427|OTHER|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
41012966|NCT02039427|DRUG|Placebo|Normal saline 2 ml
41012967|NCT01464528|DRUG|Hyaluronan|single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
41012968|NCT04528563|DRUG|Ketorolac Tromethamine 10 MG/ML|Non-Steroidal-Anti-Inflammatory given intravenously.
41331999|NCT00248105|BEHAVIORAL|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
41332000|NCT06277583|BEHAVIORAL|Urban care farming|An intervention curriculum has been designed using horticulture therapy combined with urban farming techniques. The sessions will use plants and interaction with nature to engage and rehabilitate participants. Both the intervention and control group participants will undergo the intervention. But the intervention group will start with the urban care farming intervention first, and the control group will follow once the intervention group completes the program.
41332001|NCT04257604|DRUG|Perampanel|Perampanel tablets.
41482795|NCT02575976|OTHER|wait list control|No cardiac rehabilitation.
40814633|NCT01234740|DRUG|bafetinib|Given orally
41332002|NCT06344871|DEVICE|NeuroLF|NeuroLF Scan
40814634|NCT01234740|PROCEDURE|microdialysis|Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
40814635|NCT01234740|OTHER|pharmacological study|Correlative studies
40814636|NCT01234740|OTHER|liquid chromatography|Correlative studies
41332003|NCT06344871|DEVICE|Conventional PET scan|Scan on conventional PET system
41332004|NCT00500812|DRUG|Cethrin|
41332005|NCT01618526|DIETARY_SUPPLEMENT|Western Style Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.
41332006|NCT01618526|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
41332007|NCT05976932|DRUG|pegylated liposomal doxorubicin|All eligible subjects will receive the standard chemotherapy of pegylated liposomal doxorubicin monotherapy.
41332008|NCT06178887|DIAGNOSTIC_TEST|imaging|cardiac angioRMN
41332009|NCT00292578|PROCEDURE|NAET Testing Modalities|
41332010|NCT00799760|DRUG|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
41332011|NCT00799760|DRUG|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
41332012|NCT00799760|DRUG|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
41332013|NCT01297309|DRUG|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
41332014|NCT00484276|DRUG|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
41332015|NCT01639391|PROCEDURE|skin biopsy|biopsy 5mm maximum on healthy skin under local anaesthesia.
41332016|NCT01708616|DRUG|RO5285119|multiple doses
41332017|NCT01708616|DRUG|RO5285119 placebo|multiple doses
41332018|NCT01708616|DRUG|risperidone|single dose
41482796|NCT06278571|BEHAVIORAL|Educational intervention with App and web site education|This group will only receive intervention with access to the educational website from home, where they will review the different modules focused on diabetes care, nutrition and exercise. in addition to the usual medical care by your treating physician.
41332019|NCT01708616|DRUG|risperidone placebo|single dose
41332020|NCT02923310|BIOLOGICAL|Platelets Rich Plasma|
41482797|NCT06278571|BEHAVIORAL|Educational interventión with web site education|This group will receive, in addition to nutritional therapy, diabetes education through an educational site, to learn more about the most important aspects of diabetes care. In addition to the usual medical care by your treating physician.
41332021|NCT02923310|BIOLOGICAL|Leucocyte - Platelets Rich Plasma|
41332022|NCT02923310|DRUG|Hialuronic Acid|
41332023|NCT00389441|DRUG|AG-013736|AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
41332024|NCT00198458|DRUG|Vitrase|
41332025|NCT06453863|OTHER|Greater plantar feedback shoes|Shoes providing enhanced plantar feedback
41332026|NCT06453863|OTHER|Neutral gym shoes|Regular gym shoes
41332027|NCT06453863|OTHER|Barefoot|For the acute evaluation, barefoot will be considered as an active comparator for enhanced plantar feedback
40814637|NCT01234740|OTHER|mass spectrometry|Correlative studies
40814638|NCT01234740|OTHER|laboratory biomarker analysis|Correlative studies
40814639|NCT01234740|GENETIC|protein expression analysis|Correlative studies
40814640|NCT01234740|GENETIC|western blotting|Correlative studies
40814641|NCT01234740|OTHER|immunohistochemistry staining method|Correlative studies
40814642|NCT01234740|PROCEDURE|therapeutic conventional surgery|debulking craniotomy
40814643|NCT01460875|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
40814644|NCT01460875|OTHER|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
40814645|NCT01363921|DEVICE|HCO 1100|Dialysis treatment with HCO1100
40814646|NCT02613117|DEVICE|Potassium Oxalate Gel|Self applied
41332028|NCT02979444|BEHAVIORAL|Mothers and Babies Groups|"The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood."
41332029|NCT03358615|PROCEDURE|cesarean section|assessment of the indications of cesarean section according to Robson criteria
41332030|NCT01715272|DEVICE|TF037|
41332031|NCT01715272|DRUG|Fleet enema|
41482798|NCT06278571|OTHER|Control group with nutritional therapy|This group will receive only the usual medical care by your treating physician.
41482799|NCT03025490|DEVICE|Capnographic monitoring|Capnographic monitoring is used during the sedation.
41482800|NCT03613116|DIETARY_SUPPLEMENT|Vitamin D3|One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
40814647|NCT02613117|DEVICE|Potassium Oxalate Liquid|Professionally Applied
41332032|NCT01955395|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
41155947|NCT01114334|BEHAVIORAL|Motivational Interviewing for Depression|Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
41332033|NCT04340960|OTHER|Home Monitoring|Patients in this group will receive home monitoring for NIBP (non-invasive blood pressure), SPO2 (pulse oximetry), and pain scores. These will be monitored 4 times a day for 2 weeks following surgery.
40814648|NCT02613117|DRUG|Stannous fluoride paste|SnF2 Paste
41332034|NCT03431506|BEHAVIORAL|Vestibular rehabilitation|Vestibular Rehabilitation Exercises
41332035|NCT03432117|OTHER|Fixed respiratory rehabilitation|There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.
41332036|NCT03432117|OTHER|Responsive respiratory rehabilitation|The application provide responsive exercise program by changing type and numbers of exercise according to subject condition and exercise ability (This will be assessed with monitored O2 saturation, symptom of dyspnea and pulse rate during exercise)
40814649|NCT03267667|DIAGNOSTIC_TEST|2D Echocardiography and cardiac MRI|imaging of right ventricle by both modalities to assess right ventricle function accurately
40814650|NCT06523218|DIETARY_SUPPLEMENT|MindMD Supplement|Participants will take two capsules of the MindMD supplement once daily with their morning meal for a duration of 3 months. The supplement is designed to improve and maintain cognitive function and memory.
40814651|NCT06523218|OTHER|Placebo|Participants will take two capsules of the placebo once daily with their morning meal for a duration of 3 months. The placebo is designed to be indistinguishable in appearance and administration from the MindMD supplement to ensure blinding.
41155948|NCT00470041|DRUG|administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation|
41332037|NCT01952093|BEHAVIORAL|Home-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the home.
41332038|NCT01952093|BEHAVIORAL|Clinic-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the clinic.
41332039|NCT04402619|BEHAVIORAL|Cognitive behavior therapy|"The ten modules cover:~* Psychoeducation about sleep, sleep problems, and associations with alcohol~* How to keep and use a sleep diary~* Sleep hygiene~* Sleep compression~* Cognitive restructuring~* Emotional regulation~* Preparing for the future"
40814652|NCT02891902|OTHER|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
40814653|NCT00092703|DRUG|MK0663, etoricoxib|
40814654|NCT00092703|DRUG|Comparator: Diclofenac sodium|
40814655|NCT06019663|BEHAVIORAL|The Artificial Intelligence intervention for Self-Harm prevention Application (AISHA) is a mobile intervention based on Y-CMAP|"YCMAP is a Youth culturally adapted manual assisted psychological intervention based on CBT principles. The therapy focuses on current problems that contributed to the self-harm episode. Therapists and adolescent clients choose from a list of techniques those which are most relevant to the client's problems. Therapy is therefore adapted to fit with the client's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change."
41155949|NCT04290416|DIAGNOSTIC_TEST|Microwire electrodes|
41155950|NCT01244399|DIETARY_SUPPLEMENT|Inositol|
41155951|NCT05135156|BEHAVIORAL|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After two weeks, participants will gain access to the publicly available website (attention control) and will have an additional two weeks of access to both of these resources.
41332040|NCT03275415|DRUG|budesonide|Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
41332041|NCT03275415|DRUG|Saline|Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
41332042|NCT04602689|DRUG|Human fibrinogen concentrate|Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
41332043|NCT05022043|DIAGNOSTIC_TEST|Serum Presepsin|Estimation of Serum Presepsin at time of admission
40814656|NCT02899507|DRUG|Amoxicillin-Clavulanic acid|Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
40814657|NCT04176991|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
40814658|NCT04176991|BIOLOGICAL|Placebo|Placebo Comparator
40814659|NCT00801723|DRUG|Budesonide MMX 6 mg Tablet|Budesonide MMX 6 mg Tablet once daily.
40814660|NCT00801723|DRUG|Placebo Tablet|Placebo Tablet once daily.
40814661|NCT03604588|DIAGNOSTIC_TEST|HPV OncoTect™|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
40814662|NCT01497990|DRUG|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
40814663|NCT04201366|OTHER|No intervention|No intervention
40814664|NCT01428037|DRUG|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
40814665|NCT01428037|DRUG|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
40814666|NCT06330103|OTHER|Easy EF|AI was integrated into the application smartphone and used smartphone camera to recorded shot VDO clip of heart ultrasound in parasternal long axis view and returned cardiac function result to user.
40814667|NCT04077671|BIOLOGICAL|CHF6467 active|CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
40814668|NCT03278717|DRUG|Olaparib|Olaparib is a PARP inhibitor, targeting DNA repair processes.
40814669|NCT03278717|DRUG|Cediranib|Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.
41332044|NCT00216775|DRUG|interferon-alfa-2b and ribavirin|
41332045|NCT02691364|PROCEDURE|Blood withdrawal|
41332046|NCT05100108|BEHAVIORAL|Dog-assisted therapy|The program will involve 8 sessions, conducted once a week for 8 weeks. Each session will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to relaxation and say goodbye to the dogs.
40814670|NCT00728208|DRUG|GSK372475|1.5mg for 28 days
41332047|NCT00602069|BEHAVIORAL|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
41332048|NCT00602069|BEHAVIORAL|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
40814671|NCT03174405|DRUG|Avelumab|"All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.~Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)"
40814672|NCT04309370|DEVICE|20 Hz rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS modulates cortical activation depending on the stimulation parameters used. Physiological studies have provided evidence that suggests that high-frequency (HF) rTMS produces an increase in local cortical excitability. Studies have also demonstrated that rTMS may increase or decrease functional connectivity between separate but related cortical structures, utilizing high and low frequency stimulation, respectively.
40814673|NCT04348565|OTHER|Diabetes Care Programme|20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
40814674|NCT00167141|DRUG|injection of hormonal male contraceptive|testosterone injections 4 times
40814675|NCT04463186|OTHER|Muscle Static Stretching|Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Each static stretching (SS) trial involved varied repetitions of 30-seconds self-stretches and 20-seconds relax periods.
40814676|NCT02370485|DRUG|LY2801653|Administered orally
40814677|NCT05357989|DRUG|buntanetap/posiphen|HPMC (vegetarian source) capsule shells
40814678|NCT05357989|DRUG|Placebo|HPMC (vegetarian source) capsule shells
41012969|NCT04528563|DRUG|Morphine Sulfate 10Mg/1mL Injection|Opioid commonly used for acute abdominal pain given intravenously.
41012970|NCT03448003|OTHER|Cancer Prevention|Attend IO prevention program
41332049|NCT06114030|PROCEDURE|Deep margin elevation with composite resin and Lithium disilicate glass-ceramic crowns|Restoration of the deep margin by composite restorations such as: Filtek Supreme XTE, Tetric EvoCeram, Estelite Sigma Qquick followed by Lithium disilicate glass-ceramic CAD/CAM crowns (IPS e.max CAD).
41332050|NCT03584438|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)
40814679|NCT06542575|OTHER|DTx-guided HBCR|The Huaxiaoxin WeChat mini program incorporating the core components of guidelines are divided into two main sections. Section 1 comprises interventions such as exercise training, educational programmes and cardiovascular risk factor management. Section 2 provides a secure platform for individualized feedback, just-in-time two-way communication, remote data transmission, and data repository, allowing patients and healthcare providers to access all relevant files anytime and anywhere throughout the 12-month study period.
41332051|NCT03584438|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the sham coil (double blinded using the Universal Serial Bus key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
41332052|NCT01787955|PROCEDURE|PPPD with Braun anastomosis|making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
41332053|NCT01787955|PROCEDURE|conventional PPPD|
41332054|NCT05067712|PROCEDURE|Open Surgical Exposure Technique|"* A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed~* Follicular tissue is removed from the exposed crown area~* The flap is repositioned back and sutured~* The area over the exposed canine crown is excised leaving a window with the crown uncovered.~* If the tooth is deeply embedded in the bone, a dressing is placed over the uncovered crown and kept in place with sutures.~* The extraction of the primary canine (if present) is made before or in connection with the surgical exposure.~* Ten to fifteen days later the dressing and sutures are removed and the tooth is left to erupt autonomously.~* When the canine has spontaneously erupted above the palatal mucosa an attachment is bonded to the crown and the canine is moved into alignment in the dental arch above the mucosa with orthodontic appliances."
41332055|NCT05067712|PROCEDURE|Closed Surgical Exposure Technique|"* A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed.~* Follicular tissue is removed from the exposed crown area.~* An attachment with a chain is bonded to the exposed canine crown.~* The flap is repositioned back and sutured to cover the exposed crown leaving the chain through the palatal mucosa free in the oral cavity~* The extraction of the primary canine (if present) made before or in connection with the surgical exposure~* Ten to fifteen days later the sutures are removed.~* Within days, traction is applied to the canine with orthodontic appliances by means of the chain, and the canine is pulled through the palatal mucosa out to the oral cavity and into alignment in the dental arch."
41332056|NCT00601146|PROCEDURE|chest computed tomography scan|Once a year for three years
41332057|NCT05452317|OTHER|Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
41332058|NCT05452317|OTHER|Non-Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
41332059|NCT03957746|OTHER|Resistance training|3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
41332060|NCT03127579|BEHAVIORAL|Longer meal duration|Participants have 50% more time to eat than usual
41332061|NCT03419936|DIAGNOSTIC_TEST|Endoscopic biopsy|"1. Pre-operation (initial diagnosis) Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~2. Post-subtotal gastrectomy (After 6 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~3. Post-subtotal gastrectomy (After 12 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~4. Post-subtotal gastrectomy (After 24 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy."
41332062|NCT04397315|PROCEDURE|Pulpotomy to the level of canal orifices|Pulp tissue will be removed till the level of canal orifices.
41332063|NCT04397315|PROCEDURE|Pulpotomy up to superficial 2-3 mm of pulp chamber|Only superficial pulp from the chamber will be removed
41332064|NCT00211874|BEHAVIORAL|Nurse-management|bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
41332065|NCT00192595|DRUG|Tenofovir|
41332066|NCT00192595|DRUG|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)|
40814680|NCT03341078|DRUG|Ibudilast|Ibudilast capsules will be orally ingested twice daily for 6 weeks.
40814681|NCT03341078|DRUG|Placebo Oral Tablet|Placebo capsules will be orally ingested twice daily for 6 weeks.
41155952|NCT05135156|BEHAVIORAL|Publicly available transplant education resource (Attention Control)|Participants will access the publicly available education resource via their login to a secure website. After two weeks, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional two weeks of access to both of these resources.
41155953|NCT05021757|DEVICE|Shockwave C2 Coronary IVL|PCI procedure using a Shockwave C2 coronary IVL catheter
41332067|NCT04903704|DIAGNOSTIC_TEST|1 Minute Sit to Stand Test|Participants are asked to stand repeatedly from a chair for one minute without the use of their arms for support. The number of completed repetitions is counted.
41482801|NCT01835704|OTHER|Radio-frequency dennervation of facet joint|
41482802|NCT01835704|OTHER|Diagnostic nerve-blocks performed under direct x-ray vision|
40814682|NCT00874640|BIOLOGICAL|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
41482803|NCT05873361|OTHER|Questionnaire|The questionnaire is about hypocalcemia, dysphonia and anxiety. It will be carried out by phone call for 10 minutes
41482804|NCT01423136|DEVICE|Remote ECG monitoring Spacelab SL 1050|If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
41482805|NCT00005823|DRUG|cytarabine|
41482806|NCT00005823|DRUG|daunorubicin hydrochloride|
41482807|NCT00005823|DRUG|etoposide|
41482808|NCT00005823|DRUG|hydroxyurea|
41482809|NCT00005823|DRUG|idarubicin|
41482810|NCT00005823|DRUG|mitoxantrone hydrochloride|
41012971|NCT03448003|OTHER|Questionnaire Administration|Ancillary studies
41012972|NCT02537418|DRUG|durvalumab|
41012973|NCT02537418|DRUG|tremelimumab|
41482811|NCT00005823|DRUG|thioguanine|
41332068|NCT02109068|BEHAVIORAL|Weight Loss Counseling- Phone|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
41332069|NCT02109068|BEHAVIORAL|Weight Loss Counseling- In-Person|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
41332070|NCT02270801|DRUG|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
41332071|NCT03013257|DEVICE|Echopulse|Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
41332072|NCT01786863|PROCEDURE|Neuromuscular blockade|
41332073|NCT02052141|BIOLOGICAL|CINRYZE 500|500 Units of CINRYZE administered by IV injection
41012974|NCT03501797|BEHAVIORAL|Singing-based rehabilitation|The singing-based rehabilitation is a combination of group-training (16 weeks, 1 x week, 90 min), which utilizes a novel combination of traditional senior choir singing and singing-based speech training protocols, and home training (16 weeks, ≥ 3 x week, ≥ 30 min) in which the choir material is trained with a tablet computer.
41012975|NCT03501797|OTHER|Standard care|Standard care comprises all rehabilitation and care services (e.g. speech therapy, physical and occupational therapy, neuropsychological rehabilitation) received by the patients in the Finnish health care system
41012976|NCT01751464|BEHAVIORAL|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
41012977|NCT04230382|DIAGNOSTIC_TEST|Diagnosis of diabetes (OGTT)|Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
41155954|NCT05840016|DRUG|AK112, Carboplatin, Paxlitaxel|IV infusion,Specified dose on specified days
41155955|NCT05840016|DRUG|Tislelizumab, Carboplatin, Paxlitaxel|IV infusion,Specified dose on specified days
41332074|NCT02052141|BIOLOGICAL|CINRYZE 1000|1000 Units of CINRYZE administered by IV injection
41332075|NCT00139607|DRUG|Paracoxib|
41332076|NCT05386264|OTHER|Expanded autologous T regulatory cells|A 3+3 dose escalation design with expanded T regulatory cells administered on Day 1 and Day 15
40814683|NCT02613468|OTHER|collection of periodontal records|"1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester."
41482812|NCT00005823|DRUG|tretinoin|
41482813|NCT00005823|DRUG|valspodar|
41012978|NCT00947622|DEVICE|Transcranial direct current stimulation|Transcranial Direct current stimulation
41012979|NCT00382733|DRUG|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
41012980|NCT01328002|DRUG|Milnacipran|"Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.~Oral administration, twice daily dosing"
41012981|NCT01328002|DRUG|Placebo|matching placebo tablets daily
41012982|NCT01985984|RADIATION|Radiation alone|Radiation alone
41012983|NCT01985984|RADIATION|Radiation in combination with systemic therapy|Radiation in combination with systemic therapy
41012984|NCT01144338|DRUG|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
41155956|NCT01901302|DRUG|CB-5945|
41155957|NCT01901302|DRUG|Placebo|
41332077|NCT02518776|BEHAVIORAL|Neuropsychological tests|Neuropsychological tests
41012985|NCT01144338|DRUG|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
41332078|NCT04714944|DIETARY_SUPPLEMENT|Placebo|Supplementation period 12 weeks
41332079|NCT04714944|DIETARY_SUPPLEMENT|Whole fiber product|Supplementation period 12 weeks
41332080|NCT02762019|DEVICE|Laser therapy|Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.
41332081|NCT02762019|DEVICE|Sham therapy|Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.
41332082|NCT00390494|PROCEDURE|Hysterectomy|
41332083|NCT00390494|PROCEDURE|Myomectomy|
41012986|NCT02490137|BEHAVIORAL|Race Car Video Game|Repeatedly playing a race car video game
41012987|NCT04584567|DRUG|Doxycyclin|daily (100mg)
41155958|NCT00637325|DRUG|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
41332084|NCT00390494|PROCEDURE|Uterine Fibroid Embolization|
41332085|NCT02840513|OTHER|Smartphone app/CO self-monitoring|Smartphone app and carbon monoxide self-monitoring (personal device)
41332086|NCT05774197|BEHAVIORAL|Cognitive Behavioral Therapy for pain|Patient participating in this study will have survey assessments at baseline, 4 weeks (end of 4-week intervention period), and 6 weeks (end of 2-week post intervention period) assessing patient reported concerns, quality of life outcomes and usability of STAMP+CBT app. During this time, Patient will receive algorithm-based advice in response to their daily pain and mood surveys. These patients will be introduced to the extensive multi-media library of educational content covering medication support (e.g. using short and long-acting opioids, managing side effects, opioid safety); pain psychology (e.g. pain perception, pain and the stress response); health behaviors and pain (e.g. sleep hygiene); and skills training (e.g. activity pacing/ relaxation recordings).
41332087|NCT03658798|PROCEDURE|Functional Electrical Stimulation|Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
41332088|NCT05060796|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6/ kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
41012988|NCT02652624|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily with food
41012989|NCT02652624|DRUG|E/C/F/TDF|150/150/200/300 mg FDC administered orally once daily with food
41012990|NCT02652624|DRUG|ATV|ATV 300 mg capsules administered orally once daily with food
41332089|NCT05382702|OTHER|Test meal description changed|Using a within-subjects crossover design, on two separate mornings participants will eat yogurt described as 'high fat' and 'low fat.' In actuality, the meals will not differ.
41332090|NCT04379609|OTHER|Masticatory efficiency|"Two-color chewing gum mixing ability test was used to measure masticatory efficiency in the control group, before and after treatment in the experimental group.21 Commercial two-color chewing gum was used.The gum was left on the patient's tongue and he/she was asked to chew 20 times naturally.~After chewing, the gum was put in a transparent plastic bag and squeezed to 1 mm. Both sides of the sample were scanned at 300 dpi resolution on a desktop scanner (HP Deskjet, California, USA) in the same day to prevent the colors from deteriorating due to saliva. For each patient, two sides of scanned images were processed in ViewGum software (version 1.4, Dhal Software, Kifissia, Greece, www.dhal.com) using the method of Halozenitis et al. (2013).22 The value of VOH (variance of hue) was taken as the value of chewing activity. The highness of this value indicates low masticatory efficiency."
41332091|NCT06216197|DRUG|FENT group|Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).
41012991|NCT02652624|DRUG|RTV|RTV 100 mg tablets administered orally once daily with food
41012992|NCT02652624|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily with food
41012993|NCT02652624|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
41155959|NCT01945593|BIOLOGICAL|BAX855|Antihemophilic Factor (Recombinant), PEGylated
41155960|NCT04872634|BIOLOGICAL|SNK01 (Super Natural Killer Cells 01)|Investigational Product : SNK01 (Super Natural Killer Cells 01) Principal Component : Autologous Natural Killer Cell To induce anti-tumor immunity in Locally advanced or Metastatic Non-small Cell Lung Cancer Patients who have failed prior TKI therapy for EGFR, ALK, or ROS1 Gene Mutation and to strengthen the Antibody-Dependent Cellular Cytotoxicity (ADCC) of Cetuximab, 4x10\^9 or 6x10\^9 cells are infused through the veins of the subjects within 45 minutes (±15 minutes) per 100 mL total 8 times at intervals of one week.
41155961|NCT04872634|DRUG|GC|"Gemcitabine; 1000mg/m2, Day 1, Day 8, 4-cycle administration, Mixed with normal saline 50ml and administered into a vein for 30 min.~Carboplatin; AUC 5, Day 1, 4-cycle administration, Mixed with 5% Dextrose 200ml and administered into a vein for 1 hour."
41012994|NCT03962972|OTHER|Frailty evaluation|"It will be used a questionnaire that is called:The Centre of Excellence Self-Administered questionnaire (CESAM). The score of this questionnaire and its stratification of frailty in four levels with incident adverse health events in older community dwellers will be compare with validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index, Rockwood frailty index, 6-ietm brief geriatric assessment (BGA), Program of Research on the Integration of Services for the Maintenance of Autonomy (PRISMA-7) and b) two other frailty index developed over the COVID-19 pandemic which are Évaluation SOcio-GÉriatrique (ESOGER) and CriblAge et REcommandations (CARE)."
41482814|NCT05158218|BEHAVIORAL|Robotic Exoskeleton Gait Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will be completed in a 60-minute sessions with rests as needed. The key components of the therapy will include: 1) optimally challenging activities of variable intensity that emphasize motor planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints, 2) task specific overground movements that promote building a repertoire of mobility strategies that can be utilized in the community, and 3) motor tasks requiring active control that increase participant therapeutic engagement. An overhead body weight support system or a gait-belt may be used for some individuals during the robotic exoskeleton gait training blocks.
41012995|NCT01067352|DRUG|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
41012996|NCT05266326|OTHER|Western medicine conventional treatment +Bloodletting puncture|All acupoints are positioned according to the WHO standard acupuncture point locations in the Western Pacific Region. Operation: The patient is placed in a reasonable position, the acupuncture site is exposed, and the operator uses pushing, rubbing, squeezing and butterfly on or around the acupuncture site to collect blood at the acupuncture site before pricking, and then disinfects the acupuncture site with 75% ethanol. If more bleeding occurs, press with sterile dry cotton balls to stop the bleeding. The treatment was performed once daily for 7 days.
41012997|NCT05266326|OTHER|Western medicine conventional treatment|The patients in both groups were given conventional comprehensive treatment such as improving cerebral circulation, neuroprotection, antiplatelet aggregation, lipid regulation and symptomatic management after admission. Patients with hypertension, hyperglycaemia, hyperlipidaemia and coronary atherosclerotic heart disease were given individualised symptomatic treatment and advised to stop smoking, drinking alcohol and other adverse lifestyles as far as possible.
41012998|NCT00298896|DRUG|SNS-595|
41012999|NCT04007536|OTHER|No Intervention|No Intervention
41013000|NCT03231904|DIAGNOSTIC_TEST|Blood test|blood samples will be taken for maternal and fetal levels of ACTH and LIF
41013001|NCT00281840|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
41013002|NCT00281840|DRUG|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
41013003|NCT00281840|PROCEDURE|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
41013004|NCT00281840|RADIATION|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
41013005|NCT03950024|DIAGNOSTIC_TEST|functional brain MRI|The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
41013006|NCT05187533|OTHER|Osteopathic protocol of Sphenopalatine Ganglion Stimulation|Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness
41013007|NCT04377139|PROCEDURE|Prophylaxis|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
41013008|NCT04377139|PROCEDURE|Preemptive|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
41013009|NCT04140734|DEVICE|Spacer Graft|In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.
41013010|NCT02826889|DEVICE|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
41155962|NCT04872634|BIOLOGICAL|Cetuximab|"First administration: 400mg/m2 Subsequent administration: 250mg/m2 (Premedication before administration\*) Weekly Administration continues until the disease progresses or unacceptable toxicity develops.~400mg/m2: Administered into a vein for 120 minutes 250mg/m2: Administered into a vein for 60 minutes"
41155963|NCT00116584|DRUG|heliox|continuous heliox therapy
41332092|NCT06216197|DRUG|DEX group|The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
41155964|NCT00116584|DRUG|oxygen|continuous oxygen therapy
41332093|NCT01630941|DRUG|denosumab|Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
41013011|NCT02826889|DEVICE|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
41013012|NCT02753712|DRUG|Fluticasone/Formoterol BAI|
41013013|NCT02753712|DRUG|Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)|
41013014|NCT03331874|DIAGNOSTIC_TEST|Reflectance Confocal Microscopy|In-vivo microscope
41013015|NCT00838305|DRUG|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
41013016|NCT00838305|DRUG|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
41013017|NCT03075644|DRUG|somapacitan|Once weekly subcutaneous injections (s.c., under the skin)
41332094|NCT04984460|DIAGNOSTIC_TEST|Fluorescence morphological detection of liquid-based thin-layer film-making fungi|"Samples from outpatient or inpatient clinics to be tested for fungal vaginitis. A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.~Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd.~Samples are human vaginal secretions. Each sample should be the amount on one swab.~The sample is not in menstrual period. The sample subjects did not have vaginal irrigation, medication or sexual intercourse within 3 days."
41332095|NCT02983799|DRUG|OLAPARIB|300 mg olaparib tablets taken orally twice daily
41332096|NCT01461824|DRUG|Depot medroxyprogesterone acetate (DMPA)|75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
41332097|NCT00961662|DRUG|D-Tagatose|powder to be dissolved in water prior to dosage.
41332098|NCT00000248|DRUG|Pergolide|
41332099|NCT05694793|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
41332100|NCT01495923|PROCEDURE|epidural steroid injection|Injection of steroids and local anesthetic into the epidural space
41332101|NCT01495923|PROCEDURE|Sham epidural steroid injection|Injection of saline into the back muscles
41482815|NCT05158218|BEHAVIORAL|Physical Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. An overhead body weight support system or a gait-belt may be used for some individuals during the gait training blocks
41013018|NCT03075644|DRUG|Norditropin|Daily subcutaneous injections (s.c., under the skin)
41332102|NCT01495923|DRUG|Gabapentin|Titration of gabapentin to effect
41013019|NCT05313516|DEVICE|OKKO Health app|Use of OKKO Health app for home monitoring.
41013020|NCT02927691|DEVICE|EMST|
41013021|NCT02927691|BEHAVIORAL|smTAP|
41332103|NCT01495923|DRUG|Placebo gabapentin|Titration of placebo gabapentin
41332104|NCT03256838|DRUG|Ferric Citrate|Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.
41332105|NCT06049134|BIOLOGICAL|PCV20|Given by Injection into the muscle
41332106|NCT01635036|DEVICE|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
41332107|NCT06058936|OTHER|exercises using virtual reality technology|this is a one-dimensional therapy game using (Handle/ or Multiball) five games are available for the Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Applehunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week
41332108|NCT01229241|DRUG|local anesthetic|"postoperative 48h epidural continuous infusion,~1. ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~2. levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml"
40814684|NCT02613468|OTHER|pregnancy parameters|Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
40814685|NCT02613468|OTHER|Initial Periodontal Therapy|Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
40814686|NCT00605098|DRUG|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
41013022|NCT06469047|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-1β and NE levels were detected.
41013023|NCT00318487|PROCEDURE|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
41013024|NCT03348761|DEVICE|rTMS group|
41013025|NCT01117818|BIOLOGICAL|active: AFFITOPE AD02|vaccination
41013026|NCT01117818|BIOLOGICAL|control: Placebo|vaccination
41013027|NCT01885481|DRUG|Dexamethasone|epidural steroid injection using dexamethasone
41013028|NCT01885481|DRUG|Betamethasone|epidural steroid injection using betamethasone
41332109|NCT04593836|DRUG|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
41332110|NCT04593836|DRUG|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
41332111|NCT03209362|COMBINATION_PRODUCT|SI-613|SI-613 will be repeated intra-articularly administered.
41332112|NCT03209362|COMBINATION_PRODUCT|Placebo|Placebo will be repeated intra-articularly administered.
41332113|NCT01444313|DEVICE|narafilcon A contact lens|Soft contact lenses with UV protection
41332114|NCT01444313|DEVICE|nelfilcon A soft contact lenses|Soft contact lenses without UV protection
40814687|NCT00605098|DRUG|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
41332115|NCT05523804|PROCEDURE|interval cytoreductive surgery|cytoreductive surgery after 3-4 cycles of chemotherapy
41332116|NCT05523804|PROCEDURE|delayed cytoreductive surgery|surgery after \>5 cycles of chemotherapy
41482816|NCT03786133|DIAGNOSTIC_TEST|Analysis of microbiological tests|Collection and comparison of microbiological data
41482817|NCT04882566|OTHER|Paleolithic Diet|Advice to follow Paleolithic Diet for Inflammatory bowel disease Patients
41482818|NCT01771471|BIOLOGICAL|NuQu|Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
41482819|NCT01771471|OTHER|Placebo|0.9% w/v Sodium Chloride for Injection, USP
41482820|NCT02676713|DRUG|pre-ovulation Decoction|HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
41482821|NCT02676713|DRUG|post-ovulation Decoction|"BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.~All are made into granules."
41482822|NCT02676713|DRUG|pre-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
41482823|NCT02676713|DRUG|post-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
41482824|NCT03557528|PROCEDURE|Laparoscopic colorectal resection|Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes
41482825|NCT06224166|DIAGNOSTIC_TEST|Collection and use of tissue samples, blood and saliva|"For tissue collection, tumor and surrounding tissues will be used healthy specimens taken during surgical removal, according to clinical practice. Blood and saliva sampling will be carried out at different times:~i) the day before surgery; ii) the day after surgery (only for blood); iii) at the time of patient discharge (approximately 15 days after surgery); iii) during the check-up visit scheduled to monitor the follow-up (FU)"
41482826|NCT00207779|DEVICE|heparin impregnated central venous catheters|
40814688|NCT05935878|DEVICE|Cementless Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. Cementless components have a hydroxy-appatite coating to facilitate bone ingrowth. The cementless femoral component also has a smaller second peg, located anteriorly to the larger central peg that is also present of the cemented femoral component.
40814689|NCT05935878|DEVICE|Cemented Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. All cemented components will be secured using the same cement.
40814690|NCT02591667|PROCEDURE|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
40814691|NCT02591667|DRUG|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|"Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;"
40814692|NCT02591667|PROCEDURE|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
41332117|NCT05523804|OTHER|no surgery|no cytoreductive surgery (\>5 cycles of chemotherapy alone)
41482827|NCT03859141|BIOLOGICAL|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
41482828|NCT03859141|BIOLOGICAL|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
41482829|NCT03859141|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.
40814693|NCT06289920|DRUG|BR3005|One tablet administered alone, Once a day
40814694|NCT06289920|DRUG|BR3005-1|One tablet administered alone, Once a day
40814695|NCT06289920|DRUG|BR3005-2|One tablet administered alone, Once a day
41332118|NCT01457924|DRUG|Ofatumumab 3mg|3mg of investigational product
41332119|NCT01457924|DRUG|Ofatumumab 30mg|30mg of investigational product
41332120|NCT01457924|DRUG|Ofatumumab 60mg|60mg of investigational product
41332121|NCT01457924|DRUG|Placebo|Placebo
41332122|NCT04732819|BEHAVIORAL|High touch multi-pronged behavioral intervention|"In this intervention, facilities will work with our research team to accomplish the following:~1. Identify and engage a Facility Opinion Leader.~2. Employ Consenting Specialists to facilitate the clinical consent for vaccination process.~3. Engage well respected persons in the community who are willing to provide messages that promote trust in the vaccine and that will be distributed widely within a facility by email, website, text and/or social media.~4. Distribute buttons, T-shirts, and masks that promote awareness about vaccination (e.g., Ask me about the COVID-19 vaccine!) through facility leadership.~5. Acquire additional COVID-19 testing kits using funds provided by our research team."
41332123|NCT02638272|PROCEDURE|no debridement|It is a spinal surgery performed with isolated posterior instrumentation without debridement.
41332124|NCT01754285|DRUG|LF-PB and Placebo|
41332125|NCT01754285|DRUG|Placebo|
41332126|NCT01754285|DRUG|LF-PB|
41332127|NCT04763590|BEHAVIORAL|Cognitive Behavioral Therapy|"This study focuses on patients who are on a mechanical ventilator and who have been medically cleared to come off of it. The purpose of the study is to learn more about the possible influence of cognitive behavioral therapy in helping patients who are having some trouble getting off of the ventilator. Cognitive behavioral therapy is a highly effective intervention for anxiety and the investigators are evaluating whether cognitive behavioral therapy might be helpful in cases where it is difficult to come off of the ventilator.~Cognitive behavioral therapy is experimental for mechanical ventilation assistance as no research to date has evaluated whether it might be helpful."
41332128|NCT02046382|DRUG|IV Acetaminophen|1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
41332129|NCT02046382|DRUG|Placebo|100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
41332130|NCT00830804|DRUG|Raltegravir|400 mg tablet taken orally twice daily
41332131|NCT00830804|DRUG|Darunavir/Ritonavir|800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
41332132|NCT01563107|RADIATION|Plasma Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
41332133|NCT01563107|PROCEDURE|Exercise Capacity Test - Bicycle|subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
41332134|NCT01563107|PROCEDURE|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
41332135|NCT01414517|DIETARY_SUPPLEMENT|FructoOligoSaccharide|A mixture of 70% oligofructose and 30% inulin.
41332136|NCT01414517|DIETARY_SUPPLEMENT|Maltodextrin|a non-prebiotic carbohydrate
41332137|NCT00810589|DRUG|Levemir|0,4 IE per kg bodyweight
41332138|NCT00810589|DRUG|Humalog NPL Insulin|0,4 IE per kg bodyweight
41332139|NCT01018693|DRUG|VAK694; Alutard Avanz SQ|
41332140|NCT01018693|DRUG|VAK694 placebo infusion; Alutard Avanz SQ|
41482830|NCT03859141|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.
41482831|NCT03304028|DEVICE|Connected Devices for 3 months|Inclusion will be proposed at a follow-up visit by the child's or adult's referring doctor. A written informed consent form will be obtained. Quality of Life and Anxiety-Depression will be collected. Then, each included patient will be equipped with CDs-spirometer, oxymeter, scale and watch during 3 months for base-line.
41482832|NCT03304028|BEHAVIORAL|Educationnal Intervention|After a first statistical analysis and interpretation (5 months), alert parameters for each patient are then fixed. An educational visit will be scheduled with patients and a personnalized action plan will be defined..
41332141|NCT01018693|DRUG|VAK694 placebo infusion; Saline|
41332142|NCT04697862|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
41332143|NCT04697862|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
41332144|NCT00594087|DRUG|eszopiclone|eszopiclone 2mg or 3mg at bedtime
41332145|NCT00594087|OTHER|placebo|2 mg or 3 mg at bedtime
41332146|NCT00520299|DRUG|ADI PEG 20|Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
41332147|NCT00816283|DRUG|dasatinib|50 mg orally 2 times per day or 140 mg orally one time per day
41332148|NCT00816283|DRUG|vorinostat|100 mg orally 2 times per day
41332149|NCT00816283|GENETIC|cytogenetic analysis|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
41332150|NCT00816283|GENETIC|gene expression analysis|Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
41482833|NCT03304028|DEVICE|Connected Devices for 12 months|Each included patient will be re-equipped with CDs-spirometer, oxymeter, scale and watch during 12 months. If alerts occur, patients will be informed by email or SMS, with data transmission to the medical team who will not interfere. Patients should apply the shared action plan they learned. Quality of Life and Anxiety-Depression will be collected.
41482834|NCT03304028|OTHER|Interviews|At the end, semi-structured interviews will be completed to explore confidence on the CDs, impact on the doctor-patient relationship, change in the workload of medical team...etc.
41332151|NCT00816283|GENETIC|mutation analysis|Performed at baseline and at every bone marrow analysis on peripheral blood
41332152|NCT00816283|GENETIC|reverse transcriptase-polymerase chain reaction|Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
41332153|NCT00816283|OTHER|flow cytometry|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
41332154|NCT00816283|OTHER|laboratory biomarker analysis|Performed pre-treatment and day +14 of treatment
41332155|NCT03854851|DRUG|Naldebain|In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.
41332156|NCT03854851|DRUG|Morpine|In Morphine group, patients will receive morphine as needed after surgery.
41332157|NCT03428451|DRUG|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
41332158|NCT03428451|DRUG|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
41332159|NCT03428451|DRUG|NaCl 0.9% NS|Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
41332160|NCT05982145|OTHER|Individual interviews|Identify the needs and expectations of the users about the compression therapy; Identify the possible facilities and difficulties in link with the management of the venous leg ulcers; Identify care experiences; Identify experiences about the actual compressions systems
40814696|NCT06251661|OTHER|Cognitive multi-sensory Rehabilition|Kinetic awareness: Initially, only one joint will be moved at a time. Then the therapist will reposition the joint and ask the participants to report their perception of the joint position. Initially, the participants will distinguish between just two positions. If they reliably answer correctly, increase up to five points and integrate speed and dexterity in functional movements. Participants will be asked to relax and feel the movement during this training. Discrimination exercise: The therapist places a part of the participant's limb, the fingertip, on an external object (a block) and the participant will be asked to actively move his or her limb over the object and try to sense the shape of the object. If the participants differentiate between the two objects, then increase the number of objects (up to five). Functional training: The patient reaches toward many objects functionally (cup, ball, cane) from different angles, holds them, and relocates them again.
40814697|NCT06251661|OTHER|selected traditional physical therapy program.|The selected physical therapy program session will be occupational therapy training for the hand, strengthening exercises for the weak upper limb stretching exercises for short upper limb muscles, balance exercise, and gait training.
40814698|NCT00788099|DRUG|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
40814699|NCT00788099|DRUG|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
40814700|NCT00151710|DRUG|Pioglitazone|
41013029|NCT00906308|DRUG|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
41013030|NCT00906308|DRUG|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
41013031|NCT00906308|DRUG|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
41013032|NCT03052582|OTHER|Milk type|
41332161|NCT05982145|OTHER|Focus groups|Identify facilities and difficulties in link with the prescription and implementation of the compression therapy everyday
41332162|NCT05982145|OTHER|Questionary and measures|To take measurement of patients who lives in institution or at their home and take measure of hydration and some other measures like the Group Iso Resource (GIR) and the capacity of the person to getting out of the bed.
41332163|NCT04907864|COMBINATION_PRODUCT|Multi-modal intervention|Daily oral medications: ibuprofen 400 mg three times a day, omega-3-fatty acid 1 g twice a day, Bojungikki-tang 3.75g twice a day, oral nutritional supplement (HAMONILAN SOLN) 200 ml twice a day Weekly physical exercise by physiatrist (60 minutes per visit) Biweekly psychiatric intervention Nutritional counselling total four times during the study period
41332164|NCT02591888|DRUG|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
41332165|NCT02591888|DRUG|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
41332166|NCT05254652|DRUG|Duloxetine 30mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
40814701|NCT06312670|DRUG|EPI-7386|600 mg orally administered twice daily
41155965|NCT03959930|DEVICE|Transdermal Fluid Removal|"The Transdermal Fluid Removal (TFR) device is designed for use on the lower limbs of patients with Chronic Heart Failure and treatment resistant peripheral oedema.~The TFR device is intended to be applied on oedematous skin of eligible patients, for periods of up to 10 hours at a time, to gently remove excess fluid through the skin, over a period of a few days during exacerbations, thereby avoiding hospitalisation for intravenous diuretics.~The TFR device is designed to be used in conjunction with standard Negative Pressure Wound Therapy (NPWT) devices which are currently CE Marked and approved for use in both acute and homecare environment."
40814702|NCT06312670|DRUG|Enzalutamide|160 mg administered orally once daily, with or without food
41013033|NCT04284189|OTHER|Transition model|Transition of follow-up care of childhood cancer survivors to adult care
41013034|NCT03058406|DRUG|Eribulin mesylate|Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
41013035|NCT02621983|BEHAVIORAL|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
41155966|NCT00747149|DRUG|Rosuvastatin|Oral
41155967|NCT02985255|DRUG|Docetaxel|Neoadjuvant Arm
41013036|NCT02621983|BEHAVIORAL|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
40814703|NCT06312670|DRUG|Androgen Deprivation Therapy (ADT)|LHRH agonist/antagonist or orchiectomy
40814704|NCT03718572|PROCEDURE|Laparoscopic cholecystectomy|Surgical removal of Gall bladder using laparoscopy
41013037|NCT03227380|OTHER|thoracic densitometry with contrast|injected CT scan at 3 or 6 months after segmentectomy VATS
41332167|NCT05254652|DRUG|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
41332168|NCT00723671|PROCEDURE|MRI|
41332169|NCT01153308|OTHER|Observational Study|This is an Observational study
41332170|NCT03973203|DIETARY_SUPPLEMENT|Niacin|The dose for a slow-released form of niacin will be 750-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 3 months. The intervention time with the full niacin dose is 1 and 7 months for controls and patients, respectively, and subsequently total intervention time 4 and 10 months, respectively. At the end of the study, the daily dose will be decreased by 250 mg/month rate.
41332171|NCT03067480|DEVICE|iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
41332172|NCT02654470|DEVICE|Watchman FLX|Patients who are receiving the Watchman FLX device
41332173|NCT02391974|DEVICE|PERIOSYAL FILL|"Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.~Touch-up treatment provided at 3 and 6 weeks."
41332174|NCT05117749|DRUG|Saffron 100|to Mild and Moderate UC patients
41332175|NCT05117749|DRUG|Saffron 50|to Mild and Moderate UC patients
41332176|NCT05117749|DRUG|Placebo|to Mild and Moderate UC patients
41332177|NCT01537094|DIETARY_SUPPLEMENT|Placebo|
41332178|NCT01537094|DIETARY_SUPPLEMENT|Vitamin C 250 mg once daily|
40814705|NCT02657655|DEVICE|Kinesia 360|Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
41013038|NCT05120544|BEHAVIORAL|EXTEND Plus|The EXTEND Plus approach builds patient self-management capacity by focusing on knowledge, self-efficacy, and goal setting (using an RN-delivered, module-based approach). All material is at an 8th grade reading level. Module topics include, but are not limited to, use of self-monitoring of blood glucose (SMBG), BP monitoring, developing a diet plan, medication adherence, hypoglycemia and hypotension self-management, and self-managing insulin. In addition, this intervention component addresses diet and activity self-management during each encounter.
41013039|NCT05120544|BEHAVIORAL|EXTEND|EXTEND patients self-manage using data they collect during the study, and continue to receive standard behavioral counseling from primary providers.
41013040|NCT04990726|BEHAVIORAL|Assessment|Undergo medical assessments
41332179|NCT01537094|DIETARY_SUPPLEMENT|Vitamin C 1,000 mg once daily|
41013041|NCT04990726|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41332180|NCT01875913|BEHAVIORAL|Curiosity Message|Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
41332181|NCT01875913|BEHAVIORAL|Standard Message|"Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online)."
41332182|NCT02121444|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|
41332183|NCT02121444|DEVICE|BETACONNECT auto-injector.|
41332184|NCT04589962|OTHER|access axillary or brachial artery|access to the axillary or brachial artery during Transcatheter Aortic Valve Implantation (TAVI), Fenestrated/Branched-Endovascular Aortic Repair (F/BEVAR), chimney-EVAR (Ch-EVAR) or visceral side branches stenting
41332185|NCT00431496|DRUG|Cinacalcet|Cinacalcet tablets
41332186|NCT03815812|DRUG|IBI306|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
40814706|NCT03791281|BEHAVIORAL|BASIS|
40814707|NCT03791281|BEHAVIORAL|Attention Control|
41013042|NCT04990726|OTHER|Quality-of-Life Assessment|Ancillary studies
41013043|NCT04990726|OTHER|Questionnaire Administration|Complete questionnaires
41013044|NCT05848388|OTHER|Molar incisor malformation presence|the presence of radiographic features of molar incisor malformation
41013045|NCT05482945|OTHER|Noble gas Argon|Ventilation with Ar 70%/O2 30% in comatose patients resuscitated from OHCA with the use of an experimental mechanical ventilator.
41013046|NCT01890200|DRUG|Peginterferon alfa-2a|conventional treatment of Hepatitis C
41013047|NCT01890200|DRUG|Ribavirin|conventional treatment of Hepatitis C
41013048|NCT01890200|DRUG|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
41013049|NCT01890200|DRUG|Placebo|Placebo, without acting ingredient.
41155968|NCT02985255|DRUG|Cisplatin|Neoadjuvant Arm
41332187|NCT03815812|DRUG|placebo|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
41332188|NCT01819441|DRUG|Azelnidipine|8mg or 16mg
41332189|NCT01819441|DRUG|Perindopril|4mg or 8mg
41332190|NCT01819441|DRUG|hydrochlorothiazide|12.5mg or 25mg
41332191|NCT04750655|DRUG|Moxifloxacin (Topical)|We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
41013050|NCT06333444|BEHAVIORAL|four weekly psychological counselling intervention|four weekly psychological counselling intervention delivered by university students asking help to university counselling service in Southern Italy
41332192|NCT06376929|OTHER|oral carbohydrate containing fluid|administration of oral carbohydrate fluid and assessment of intraoperative blood glucose level and postoperative nausea and vomiting
41332193|NCT00456885|DRUG|exenatide|5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
41332194|NCT00456885|DRUG|Placebo|Twice daily injection of placebo
41332195|NCT05171881|OTHER|Intervention for cerebral hypoxia|For cerebral oxygen saturation measures below target range (cerebral hypoxia), a treatment algorithm with the following potential clinical interventions will be applied: fluid resuscitation, initiation of vasopressor/inotrope medication, change in mechanical ventilation or respiratory support, adjustment of fractional inspired oxygen, transfusion of red blood cells, acquisition of echocardiogram or cranial ultrasound.
41332196|NCT03990259|OTHER|Running the CSP Mountain Race|The runners completed a 107,6 km mountain race
41332197|NCT03999541|OTHER|Freeze-all policy|A policy of freezing all the embryos followed by subsequent thawed frozen embryo transfer
41332198|NCT02666690|DEVICE|CEUS (Contrast-enhanced ultrasound)|Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
41332199|NCT04282070|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
41332200|NCT04282070|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
40814708|NCT04917796|OTHER|Electroacupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
41013051|NCT02908997|OTHER|MindMate|A dementia-specific mobile reminding application
41013052|NCT01403207|OTHER|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
41013053|NCT00545831|DEVICE|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
41155969|NCT02985255|DRUG|5FU|Neoadjuvant Arm
41332201|NCT04282070|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
41332202|NCT04282070|DRUG|Albumin Paclitaxel|Maximum 6 cycles for combined therapy.
41332203|NCT00167362|BEHAVIORAL|Cognitive enhancement therapy (CET)|Using 80 to 100 hours of graduated exercises in computer assisted training, coupled with structured but unrehearsed in vivo social group interactions, CET tries to shift an early developmental reliance on effortful, serial and verbatim cognitive processing to a more gistful, less effortful and spontaneous abstraction of social themes. CET uses attention, memory and problem solving software from three exercises from Ben-Yishay's Orientation Remediation Module (the Attention Reaction Conditioner, Zero Accuracy Conditioner, and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision-making.
41155970|NCT02985255|RADIATION|Radiotherapy|Neoadjuvant Arm
41155971|NCT02985255|PROCEDURE|Glossectomy|Neoadjuvant Arm
41332204|NCT00167362|BEHAVIORAL|Enriched supportive therapy (EST)|EST is the commonly recommended (Spaulding 1992) treatment for control and experimental subjects in psychosocial trials. EST is a two-staged treatment that requires weekly one-hour sessions in Phase 1 and biweekly sessions in Phase 2. Some practice principles (e.g., psychoeducation and relaxation training) are provided during the group exercises for CET patients, but individually for EST patients. No attempt is made to control for hours of contact between EST and CET, since offering three hours of supportive therapy to EST subjects is neither logistically feasible nor faithful to the goals and methods of supportive therapy. Further, neurobiological hypotheses related to treatment specificity would be best tested by clear differences in treatment intensity and content.
41332205|NCT00422890|DRUG|5-Azacytidin|in case of decreasing CD34 chimerism
41013054|NCT00545831|DEVICE|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
41013055|NCT05724004|RADIATION|SBRT/SRS/radiation therapy|Consolidation radiation therapy (SBRT/SRS/moderately hypofractionated radiation therapy)
41155972|NCT02794428|DRUG|Eflornithine|Eflornithine\*, 2 tablets, Oral, Daily for 18 months
41155973|NCT02794428|OTHER|Eflornithine placebo|Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
41155974|NCT00000121|DEVICE|Prisms in Eyeglasses|
41155975|NCT00468884|DRUG|Increasing doses of GLP-1|
41155976|NCT00468884|DRUG|PYY3-36|
41155977|NCT06647420|BEHAVIORAL|Sedative Music|The participants will come twice in person and listen to 9 minutes of sedative music.
41155978|NCT06647420|BEHAVIORAL|Stimulative Music|The participants will come twice in person and listen to 9 minutes of stimulative music.
41332206|NCT03058848|DIETARY_SUPPLEMENT|PKU Start|"PKU Start is a powdered, phenylalanine-free, infant formula, containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and long chain polyunsaturated fatty acids (LCPs); Arachidonic acid (AA) and Docosahexaenoic acid (DHA). It is suitable for use from birth.~The recommended amount of the product for each participant will be determined and prescribed by a dietitian."
41332207|NCT05286996|DEVICE|Iovera - Cryoneurolysis|Iovera system delivers precise, controlled doses of cold temperature only to the targeted nerve through a handheld device.
41332208|NCT05286996|DRUG|Local anesthetic|Placebo - local anaesthesia
41332209|NCT01878097|BEHAVIORAL|Green Dot Bystander Intevention|Intervention allocated at the school level
41332210|NCT01878097|BEHAVIORAL|Control|Awareness Education
41013056|NCT03551470|PROCEDURE|Robotic one-stage colorectal and liver resection|
41013057|NCT00215826|DRUG|Alferon LDO|
41013058|NCT00179413|DRUG|PEG -Intron|
41013059|NCT00179413|DRUG|Colchicine|0.6mg twice a day
41013060|NCT04239534|DEVICE|Convergence Of Epicardial And Endocardial RF Ablation|The epicardial lesion pattern will be created using the EPi-Sense®-AF Guided Coagulation System with VisiTrax®. Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi- Sense-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.
41013061|NCT04646616|OTHER|Community popular opinion leader (POL) based intervention|A community popular opinion leader (POL) based intervention to promote measures to reduce COVID-19 risk, transmission, access to testing and treatment, reduction of the impact of COVID-19, and addressing the Substance Abuse, Violence, HIV/AIDS, and MEntal health (SAVAME) syndemic in the community. POLs will interact within their networks counseling regarding COVID-19 and SAVAME factors. The POLs will refer individuals to appropriate community services. POLs will record basic sociodemographic characteristics of all community contacts, the issue addressed, and their response to it. The first 300 community contacts will be invited to complete a baseline and 3-month follow up surveys (via internet or phone). The content of the surveys includes: 1) COVID-19 related questions (knowledge, impact, symptoms, risk factors, access to testing and care, acceptability contact tracing, vaccine) 2) Biological risk factors, 3) Social determinants of health, 4) SAVAME outcomes and access to services.
41013062|NCT04904510|DIAGNOSTIC_TEST|INDICAID™ COVID-19 Rapid Antigen Test|The diagnostic assay will be compared to a EUA SARS-CoV-2 assay
41013063|NCT00808600|BEHAVIORAL|resource-activating behavioural training programme|"Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report."
41013064|NCT00808600|BEHAVIORAL|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
40814709|NCT04917796|OTHER|Sham Acupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
41013065|NCT00808600|BEHAVIORAL|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
41013066|NCT00808600|BEHAVIORAL|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
41482835|NCT03304028|BEHAVIORAL|Refusal Questionnaires|Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal
41482836|NCT00988936|DRUG|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with \[F-18\]RGD-K5
41482837|NCT02188082|DRUG|IvabRadine hemisulfate Sustained-release Tablets|
41482838|NCT02188082|DRUG|placebo|
40814710|NCT06571708|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV
40814711|NCT06571708|DRUG|Cisplatin|Cisplatin 70 mg/m\^2 IV or renally-dosed split-dose cisplatin 35 m/m\^2 IV
40814712|NCT06571708|DRUG|Cemiplimab|Cemiplimab 350mg IV
40814713|NCT06571708|DRUG|Fianlimab|Fianlimab 1600mg IV
40814714|NCT01517165|DRUG|Pioglitazone|
40814715|NCT01517165|DRUG|Placebo|
40814716|NCT02839720|OTHER|Laboratory Biomarker Analysis|Correlative studies
40814717|NCT02839720|DRUG|Selumetinib Sulfate|Given PO
40814718|NCT03420391|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
40814719|NCT05740163|DIETARY_SUPPLEMENT|Egg product including egg white and yolk allergens|Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.
40814720|NCT00346606|DRUG|Denosin® and Xyzal®|
41013067|NCT02369133|DRUG|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
41013068|NCT02369133|DRUG|Placebo|
41013069|NCT04837794|DEVICE|Digital Pain-Management Tool|Digital Pain-Management Tool
41013070|NCT03597516|DRUG|RP-G28|powder for reconstitution for oral administration
41482839|NCT05477160|DRUG|STAR-0215 (SC)|STAR-0215 will be administered as an SC bolus injection.
40814721|NCT06179277|DEVICE|PrefGel® + Emdogain®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle
40814722|NCT06179277|DEVICE|PrefGel®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
40814723|NCT01842035|DRUG|regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
40814724|NCT00004495|DRUG|cyanocobalamin|
40814725|NCT00004495|DRUG|folic acid|
40814726|NCT00004495|DRUG|pyridoxine|
40814727|NCT05289271|BIOLOGICAL|Vaxelis™|Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.
40814728|NCT04328753|DRUG|Super Oxide water|Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .
40814729|NCT04328753|DRUG|Chlorhexidine mouthwash|CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity
40814730|NCT04328753|OTHER|Distilled water|act as a negative control in this study
40814731|NCT00753103|BIOLOGICAL|Infliximab|5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
40814732|NCT00753103|DRUG|Cyclophosphamide|Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
40814733|NCT00753103|DRUG|Prednisolone|Daily oral 1mg/kg tapered over 12 months
40814734|NCT00753103|DRUG|Azathioprine|Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
40814735|NCT00753103|PROCEDURE|Plasma exchange|Additional therapy for patients with severe vasculitis (creatinine \> 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
41013071|NCT03597516|DRUG|Placebos|powder for reconstitution for oral administration
41013072|NCT05451576|DIETARY_SUPPLEMENT|Zelnite®|2pc intravenous Zelnite® will be given for 7 weeks (5 days/week).
41013073|NCT05451576|DIETARY_SUPPLEMENT|Placebo|Placebo will be given for 7 weeks (5 days/week).
41013074|NCT01329497|OTHER|systemic dietary instruction|systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
41013075|NCT02082522|DRUG|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
41482840|NCT05477160|DRUG|Placebo (SC)|Placebo will be administered as an SC bolus injection.
41482841|NCT05477160|DRUG|STAR-0215 (IV)|STAR-0215 will be administered as an IV bolus injection.
41482842|NCT05477160|DRUG|Placebo (IV)|Placebo will be administered as an IV bolus injection.
41013076|NCT02082522|PROCEDURE|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
41482843|NCT05590156|PROCEDURE|Conventional Rehabilitation|Conventional treatment for the upper extremity will be applied according to the patient's individual needs. A physiotherapist will apply this method in the clinic for 60 minutes. The duration of treatment is 60x3x8 minutes/day/week. Other methods will be applied in addition to the conventional treatment program.
40814736|NCT00753103|DRUG|Mycophenolate mofetil|Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
40814737|NCT00753103|DRUG|Methylprednisolone|500 mg intravenous infusion daily for three days at lead physicians discretion.
40814738|NCT02599207|BIOLOGICAL|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
40814739|NCT04204694|OTHER|3-time blood sampling for septic shock patients|15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock
40814740|NCT04204694|OTHER|Only one blood sampling for controls patients|15 mL blood are sampled from a blood donation
41155979|NCT06419634|DRUG|BMS-986497|Specified dose on specified days
41155980|NCT03043170|DEVICE|Ultrasound Cardiac Output Monitor|a device for assessing haemodynamics continuously and non-invasively using Doppler wave ultrasound
41482844|NCT05590156|DEVICE|Robotic Rehabilitation (ExoRehab X)|Robotic Rehabilitation
41013077|NCT02082522|DRUG|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
41013078|NCT00507052|DRUG|N-acetylcysteine|
41482845|NCT05590156|PROCEDURE|Action Observation Therapy (AOT)|Action Observation Therapy (AOT)
41482846|NCT02199678|DRUG|Placebo|placebo
41482847|NCT02199678|DRUG|ketamine 25 mg|ketamine
41482848|NCT02199678|DRUG|ketamine 35 mg|ketamine
40814741|NCT03699059|OTHER|ExeRTiOn|REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
41013079|NCT04541446|OTHER|Dynamic Haptic Robotic Trainer (DHRT)|Device trains medical residents to safely perform the needle insertion portion of Central Venous Catheterization.
41482849|NCT02199678|DRUG|ketamine 50 mg|ketamine
41482850|NCT04395651|DEVICE|PET/CT|It is a prospective clinical study that will include patients known to have lung cancer and referred to nuclear medicine unit to perform 18F-FDG PET/CT for staging and therapy planning as well as patients referred for assessment of response of therapy and restaging.
41482851|NCT03143608|DEVICE|Esophyx|Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
41013080|NCT04541446|OTHER|Advanced Dynamic Haptic Robotic Trainer (DHRT+)|Device offers whole procedural training for medical residents to safely perform the procedure of Central Venous Catheterization.
40814742|NCT02934880|OTHER|immediate APA program|10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
41013081|NCT01306617|DRUG|ABT-450|tablets
41013082|NCT01306617|DRUG|ABT-333|tablets
41013083|NCT01306617|DRUG|ribavirin|tablets
41013084|NCT01306617|DRUG|ritonavir|capsules
41013085|NCT01470287|BIOLOGICAL|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
41013086|NCT06573268|DEVICE|robot surgery device|SPRA used da-Vinci SP system (SPRA) BABA used da-Vinci Xi system (BABA)
41013087|NCT04354922|BEHAVIORAL|Exercise intervention|Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.
41013088|NCT01142739|OTHER|Clinical variables|Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
41013089|NCT01142739|OTHER|Clinical variables|Demography, Biological variables.
41013090|NCT01142739|OTHER|Clinical variables|Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
41013091|NCT00061490|BEHAVIORAL|Behavioral weight control and lifestyle exercise|16 weekly educational meetings vs. waitlist control
41013092|NCT03049813|BEHAVIORAL|Virtual Reality Job Interview Training|Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.
41013093|NCT03049813|OTHER|Supported Employment (Services as Usual)|Standard supported employment services.
41013094|NCT03057691|OTHER|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
41013095|NCT05674487|DEVICE|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
41013096|NCT05674487|DRUG|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
41013097|NCT05559619|DRUG|Calcium carbonate|1000 mg of natural calcium carbonate once daily for 12 weeks
41013098|NCT05559619|DRUG|Vitamin D3|1000 IU vitamin D3 once daily for 12 weeks
41482852|NCT04252898|BEHAVIORAL|Front-of-pack nutrition label Nutri-Score|The intervention consists of displaying the Nutri-Score on dishes and pre-packed foods.
41155981|NCT05320861|DRUG|[14C]SJP-0008|Single oral dose of \[14C\]SJP-0008
41332211|NCT03991182|OTHER|SMAGs trained on ECD curriculum|50 volunteers (primarily SMAGs- Safe Motherhood Action Group members) associated with the health facility will be trained using a training -of-trainers approach on the e ECD (early childhood development) curriculum
41482853|NCT04962984|PROCEDURE|blood sampling|additional blood sampling for coagulation tests
41482854|NCT01211704|DRUG|Paliperidone Palmitate|NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
41013099|NCT05559619|DEVICE|laser acupuncture therapy|The patient was in crock lying for stimulation of acupoints in abdomen and lower limbs then asked to be in side lying for stimulation of acupoints in the back. After disinfection of the skin and careful localization of the acupoints, low level laser therapy (LLLT) (model: Lis 1050, SN: EM 13481014, manufactured by EME srl, Italy) was applied bilaterally on Dazhu (BL 11), Ganshu(BL 18), Pishu (BL20), Shenshu (BL23), Zusanli (ST 36), Sanyinjiao (Sp6), Jingmen(GB25), Yanglingquan (GB34) andXuanzhong (GB39) acupoints, while it was applied in the midline on Guanyuan (CV4) andMingmen (GV4) acupoints. Each acupoint was irradiated for 60 sec, with total duration of 20 min, wave length of 905 nm, average radiant power output of 12 mW, energy density of 2 J/cm2, pulse radiation of 200 ms and pulse frequency of 5000 Hz
40814743|NCT02934880|OTHER|delayed APA program|10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
41013100|NCT04484441|OTHER|Blood and placenta specimen collection.|Collection of maternal and paternal blood. Collection of infant cord blood and placenta.
41013101|NCT05964452|DRUG|Methimazole Tablets|Testing dosing algorithm for efficacy.
41013102|NCT02206113|BEHAVIORAL|Standing workstation|
41013103|NCT05418556|DRUG|aspirin|DAPT strategy
41332212|NCT03991182|OTHER|Head women trained on ECD curriculum|Each of the 50 trained SMAGs will train 10 head women on the ECD curriculum
41332213|NCT03991182|BEHAVIORAL|Head women led parent groups|Every two weeks 500 trained head women lead parent group meetings on childhood development and nutrition to caregiver-child dyads
41332214|NCT03991182|OTHER|Usual care of children 0-5 months|The traditional care and education of caregivers/parents for children 0-5 months
41332215|NCT04203108|DRUG|ATG|In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.
41482855|NCT01211704|DRUG|Placebo|Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
41482856|NCT05673213|OTHER|Three-stair positioning pillows group|The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with three-stair positioning pillows. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
40814744|NCT01984645|OTHER|Notification|Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
40814745|NCT05148013|OTHER|Pilates exercise|All participants will be given a basic introduction to the Pilates-based exercises and will be taught how to activate the core muscles, which entails isometric contraction of the transverses abdominis, pelvic floor, and multifidus muscles while exhaling during diaphragmatic breathing, before beginning the exercise program. The Pilates exercise program will consist of floor exercises on a mat, including the following exercises: one-leg kick, single leg stretch, shoulder bridge, the hundred, one leg circle, and swimming. All exercises progressed at three degrees of difficulty: basic, intermediate, and advanced. Depending on the patient's tolerance, each exercise will be done for 8-10 repetitions. The treatment plan included a five-minute warm-up, twenty minutes of exercise, and a five-minute cool-down.
41013104|NCT05833984|DRUG|IMM01|IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.
41013105|NCT05833984|DRUG|Tislelizumab|Tislelizumab 200mg Q3W IV
41013106|NCT04947033|DRUG|TJ210001 Injection|The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
41013107|NCT04634292|BEHAVIORAL|EEG|EEG + walking task + auditory task
41013108|NCT01340976|DRUG|LY2787106|Administered IV.
41013109|NCT01340976|DIETARY_SUPPLEMENT|Iron Supplementation|Administered orally.
41482857|NCT05337774|DRUG|[18F]PI-2620|The participant will be injected with 5 mCi (185 MBq) \[18F\]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.
41482858|NCT00563680|DRUG|AMG 479|AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
41482859|NCT01206816|DRUG|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
41482860|NCT05609123|DIAGNOSTIC_TEST|Endothelial glycocalyx damage assessment|Degradation products of endothelial glycocalyx will be assessed in the blood and urine.
41013110|NCT02651623|DRUG|Sertraline|Multiple doses of sertraline for 14 days
41013111|NCT02651623|DRUG|Moxifloxacin|A single dose of 400 mg Moxifloxacin
41013112|NCT02651623|DRUG|Drug - Placebo|Placebo administered for 14 days
41332216|NCT04203108|DRUG|CsA|In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
41332217|NCT04203108|DRUG|MTX|In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).
41332218|NCT04203108|DRUG|MMF|In both groups, MMF will be administrated at a dose of 1.0g/d.
41332219|NCT01232192|BEHAVIORAL|antenatal model|"Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:~* Midwife training~* Pregnant women campaigning~* Early detection with self pH detection~* Treatment of bacterial vaginosis"
41332220|NCT06203483|DRUG|Adductor canal block|A linear ultrasound probe will be placed medial to the patella, the probe will be advanced to cephalad, and the superficial femoral artery will be visualized. The block site will be confirmed by injecting 5 ml of saline around the saphenous nerve in the subsartorial region under ultrasound guidance. Then, 30 ml of local anesthetic solution containing 0.25% bupivacaine (Marcain 0.5% AstraZeneca, England) will be administered.
41013113|NCT05919394|DRUG|To compare in both treatment arms the percentage of patients controlled at week 52.|Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
41013114|NCT03575832|OTHER|Counseling|Complete nutrition counseling sessions
40814746|NCT05148013|OTHER|PNF exercise|The PNF techniques utilized in the PNF exercise group will include a combination of isotonics, rhythmic stabilization, and repeated stretch. The exercises which will be performed are; (1) Trunk rotation in sitting position (1a) Chopping to the left and right and (1b) Lifting to the left and right, (2) Rolling activity (2a) Resistance to pelvic anterior patterns 2(b) Resistance to posterior patterns, 2(c) Combination of scapula and pelvis, 2(d) Combination of scapula and pelvis (i.e. asymmetrical exercise for trunk extension: the scapula moves in posterior elevation, the pelvis in posterior depression) and (3) Bridging activity (3a) Stabilize the pelvis in its neutral position, 3(b) Bridging lower trunk rotation and, 3(c) Bridging on two legs in the supine position.
40814747|NCT06451692|OTHER|Clinical pharmacist|The clinical pharmacist calls the patients' GP 90 days after discharge for follow-up
41013115|NCT03575832|OTHER|Informational Intervention|Receive an exercise plan and printed materials
41013116|NCT03575832|OTHER|Quality-of-Life Assessment|Ancillary studies
41013117|NCT03575832|OTHER|Questionnaire Administration|Ancillary studies
41013118|NCT03575832|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching calls
41013119|NCT06374329|OTHER|Interceptive Slow Maxillary Expansion with removable plates|Interceptive Slow Maxillary Expansion with removable plates (see Willems et al 2023) https://doi.org/10.1093/ejo/cjad014
41013120|NCT06466395|DRUG|Venetoclax|Given by PO
41013121|NCT06466395|DRUG|Hyper-CVAD|Given by IV
41013122|NCT05217368|OTHER|mandala painting|In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
41013123|NCT05217368|OTHER|antenatal education|Routine antenatal education will be given.
40814748|NCT04117490|OTHER|Epiitalis|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
41013124|NCT03952533|DIETARY_SUPPLEMENT|Dav|Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
41013125|NCT04698005|DIETARY_SUPPLEMENT|25g Ketone monoester without added salts|oral supplementation of ketone monoester
40814749|NCT04117490|OTHER|Placebo|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
41013126|NCT04698005|OTHER|Placebo|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
41013127|NCT06035926|OTHER|questionnaire|questionnaire
41013128|NCT01518075|OTHER|Spontaneous Breathing|"Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size."
41013129|NCT01518075|OTHER|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
41013130|NCT02333578|PROCEDURE|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
41013131|NCT00004917|BIOLOGICAL|epoetin alfa|
41482861|NCT00603291|DRUG|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
40814750|NCT00236990|DRUG|pentosan polysulfate sodium|
40814751|NCT03542656|DRUG|amyloid PET|Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).
41013132|NCT00004917|DRUG|cisplatin|
41013133|NCT00004917|RADIATION|radiation therapy|
41013134|NCT02988063|DRUG|Polidocanol Endovenous Microfoam (PEM)|Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
41013135|NCT04865757|DEVICE|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
41013136|NCT05914584|DRUG|Baricitinib 4 MG|Reference drug
41013137|NCT01282216|BIOLOGICAL|Havrix|1440 ELISA units, or 1 mL, IM
41013138|NCT01282216|BIOLOGICAL|PCV13|0.5 mL IM
41013139|NCT01707004|DRUG|decitabine|Given IV
41013140|NCT01707004|DRUG|fludarabine phosphate|Given IV
41013141|NCT01707004|DRUG|busulfan|Given IV
41013142|NCT01707004|DRUG|cyclophosphamide|Given IV
41013143|NCT01707004|DRUG|tacrolimus|Given PO or IV
41013144|NCT01707004|DRUG|mycophenolate mofetil|Given PO
41013145|NCT01707004|BIOLOGICAL|filgrastim|Given SC
41013146|NCT01707004|RADIATION|total-body irradiation|Undergo total-body irradiation
41013147|NCT01707004|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
41013148|NCT01707004|OTHER|laboratory biomarker analysis|Correlative studies
41013149|NCT00851175|DRUG|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
41013150|NCT00851175|DRUG|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
41332221|NCT06203483|DRUG|PENG block|The probe will be placed at the anterior superior level of spina iliaca, parallel to the inguinal ligament. The probe will be scanned gradually towards the caudal. After the anterior inferior of the spina iliaca is visible, the probe will be slightly turned medially until the hyperechoic shadow of the superior pubic ramus is visible. The psoas muscle tendon will be visualized above the superior pubic ramus, then 5 ml of saline will be injected under the psoas tendon and the block location will be confirmed. After that 30 ml of 0.25% bupivacaine will be administered.
41332222|NCT04938271|DEVICE|HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve|Using a bluetooth connected iPhone, subject activates the HEAL-122 electroceutical device that is docked onto an e-textile sports knee sleeve worn on the osteoarthritic knee
41482862|NCT00603291|DRUG|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
41482863|NCT00603291|DRUG|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
41482864|NCT02399098|BEHAVIORAL|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
41482865|NCT00166036|DRUG|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
41482866|NCT00166036|DRUG|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
41482867|NCT03522571|BEHAVIORAL|Experimental gingivitis|Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.
41482868|NCT02494050|BEHAVIORAL|Behavioral Activation-Full|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
41332223|NCT01594567|OTHER|Dietary pulses|beans, peas, chickpeas, or lentils in whole or flour form
41332224|NCT05986825|OTHER|Verneuil questionnaire Validation|Request patient to Complete the questionnaire for validation of the French version
41332225|NCT06379438|COMBINATION_PRODUCT|Photodynamic therapy (indocyanine green+laser)|Photodynamic therapy with indocyanine green
41332226|NCT02851368|DEVICE|near infrared fluorescence imaging (NIFI)|The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules after receiving an injection of indocyanine green 1 day prior to planned surgery.
41332227|NCT02851368|DRUG|Indocyanine Green|Indocyanine Green will be administered intravenously 1 day prior to NIFI.
41332228|NCT05170672|BIOLOGICAL|Abatacept|
41332229|NCT04090983|BEHAVIORAL|Cognitive-behavioral therapy (Hesslinger protocol)|Cognitive-behavioral therapy in a group format focusing on improving symptoms of ADHD, specifically by using skills in counteracting hyperactivity and impulsiveness, and promoting mindful awareness.
41332230|NCT04090983|BEHAVIORAL|Cognitive-behavioral therapy (CADDI protocol)|Cognitive-behavioral therapy in a group format focusing on improving inattentive symptoms of ADHD, specifically by using skills in organizing, executing, and completing activity, and promoting mindful awareness.
41332231|NCT05221593|DRUG|Lithium Carbonate|400 mg tablet in controlled released formula
41332232|NCT01603212|DRUG|Vemurafenib|"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."
41482869|NCT02494050|BEHAVIORAL|Behavioral Activation-Short|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
41482870|NCT02494050|BEHAVIORAL|Bipolar Disorder Collaborative Care|This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
41482871|NCT00787579|DEVICE|Bifocal spectacles|+1.50D bifocal spectacles
41013151|NCT00544245|BEHAVIORAL|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
41332233|NCT01603212|DRUG|IL-2|"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
41332234|NCT01603212|DRUG|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
41332235|NCT00428883|DRUG|N-acetylcysteine (NAC)|
41332236|NCT03483376|PROCEDURE|Dental prophylaxis|Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.
41482872|NCT00787579|DEVICE|Prismatic bifocal spectacles|+1.50D bifocal spectacles combined with 3Δ base-in prisms
41482873|NCT03560349|DRUG|Lidocaine HCl Gel 2%|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
40814752|NCT00969592|DRUG|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
41482874|NCT03560349|DRUG|placebo gel|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
41332237|NCT03483376|DEVICE|Antimicrobial photodynamic therapy (aPDT)|Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.
40814753|NCT00969592|DRUG|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
41482875|NCT06394674|DRUG|Furmonertinib|Drug: Furmonertinib
41482876|NCT02302859|DRUG|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
41482877|NCT02302859|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
41482878|NCT02302859|OTHER|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
41482879|NCT02302859|BEHAVIORAL|Phone Counseling Sessions|"Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.~Participants also have access to additional counseling content on the smart phone, which can be used at any time."
40814754|NCT03392389|BIOLOGICAL|mRNA-1653|Escalating dose levels
40814755|NCT03392389|OTHER|Placebo|Saline
41332238|NCT03538275|OTHER|Monitoring test|Participants wear Zephyr BioPatch for three 24-hour periods and ZMachine Insight for three sleep periods.
41332239|NCT06403813|BEHAVIORAL|mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-A) for Adolescents|mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-A is designed for adolescents to self-evaluate and manage psychological wellbeing/mental health needs, as well as to gain resources and access and connect with adolescent peers.The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
41332240|NCT06403813|BEHAVIORAL|mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-P) for Parents|mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-P is designed for parents to self-evaluate their adolescent's development and mental health, gain awareness about their adolescent's mental health status, and learn strategies and resources to support adolescents' mental health. The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
41332241|NCT06403813|OTHER|Control Tooklit|The toolkit will have the same screening questions, with information, but without any decision support functions.
41482880|NCT02302859|OTHER|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
41013152|NCT05660616|DRUG|Gemcitabine|"The study includes patients with unresectable malignant pleural mesothelioma who received at least 4 cycles of first line platinum (Cisplatin or Carboplatin) and pemetrexed combination chemotherapy~* Response after first line treatment will be assessed by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1 for pleural mesothelioma.~* Patients will be randomized according to a (1:1) ratio to either Arm 1: Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care Arm 2 (control arm): best supportive care alone.~* Cases will be evaluated every cycle clinically and every three cycles radiologically with CTs."
41482881|NCT02302859|DEVICE|Smart phone|"Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone."
41482882|NCT04131049|OTHER|High GI calculated by CC (CHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
41013153|NCT05660616|OTHER|supportive care|supportive care
41482883|NCT04131049|OTHER|Low GI calculated by CC (CLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
41482884|NCT04131049|OTHER|High GI calculated by FII (FHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
41482885|NCT04131049|OTHER|Low GI calculated by FII (FLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
40814756|NCT04150666|DIETARY_SUPPLEMENT|Hydration|the same with arm descriptions
40814757|NCT01555853|DRUG|Abraxane|
41013154|NCT02023034|OTHER|Virtual exercises|The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
41013155|NCT03927157|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
41013156|NCT03927157|OTHER|Placebo|Placebo subcutaneous injection
41013157|NCT00861497|DRUG|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
41332242|NCT01766544|OTHER|Standard Practice Group (SPG)|The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
41332243|NCT01766544|OTHER|TISG|interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
41332244|NCT03810378|BEHAVIORAL|Mediterranean Diet (Med-Plus)|Participants will follow the Med-Plus diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
41332245|NCT03810378|BEHAVIORAL|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow the WFKD diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
41332246|NCT05187546|DRUG|[18F]-PI2620|\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
41332247|NCT06308146|DIETARY_SUPPLEMENT|Bacillus subtilis ATCC 122264|One capsule (5 billion CFU) per day for 8 weeks.
41332248|NCT06308146|DIETARY_SUPPLEMENT|Placebo|One capsule per day for 8 weeks.
41332249|NCT03931395|DIETARY_SUPPLEMENT|Honey|Will give patients and families included in the honey standard of care group 40 packets of hospital approved honey to implement in the tonsillectomy post-operative care of the child
41332250|NCT03931395|OTHER|Standard of Care|Patients will receive standard post operative medications per surgeon
41332251|NCT03446612|DRUG|Daprodustat|Daprodustat will be available as 1 mg, 2 mg and 4 mg oral tablets. Daprodustat will be administered once daily by oral route without regard for food.
41332252|NCT03446612|DRUG|Darbepoetin alfa|Darbepoetin alfa will be given as solution for injection for subcutaneous administration every 2 weeks.
41332253|NCT03446612|DRUG|Acetylcholine|Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
41332254|NCT03446612|DRUG|Sodium nitroprusside|Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
41332255|NCT03446612|DRUG|L-N-monomethyl arginine acetate (L-NMMA)|L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
41332256|NCT05610241|DEVICE|Compression Therapy System Prototype|A device designed to deliver compression therapy at a pre-set level to the lower leg for legs with a circumference between 30-50 cm. The device provides compression through a series of three air bladders and is controlled by a battery-powered electronic module that controls compression levels by monitoring bladder pressure.
41332257|NCT05610241|DEVICE|Standard Compression|Coban 2 represents the standard of care 2-layer compression wrap used to treat venous leg ulcers. The device consists of a comfort layer and a compression layer. A clinician applies the device to establish compression therapy.
41332258|NCT05373082|OTHER|questionnaire completion|Questionnaire to be completed by patients
41332259|NCT00002268|DRUG|Sevirumab|
41332260|NCT01688440|OTHER|#1 Respiratory Care Solution|Respiratory care solution.
41482886|NCT04324593|DEVICE|Peripheral intravenous analysis (PIVA) algorithm|An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
41482887|NCT02418117|OTHER|Stereolitographic template|Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
41482888|NCT00069186|DRUG|Creatine Monohydrate|
41013158|NCT04770480|BEHAVIORAL|Standard Care (SC)|No attempt will be made to change usual care practice after surgery
41013159|NCT04770480|BEHAVIORAL|Enriched Pain Management Pathway (EPM)|Enriched Pain Management Pathway will be delivered by physical therapists trained to integrate physical therapy and mindfulness techniques grounded in a biopsychosocial context. The intervention will be delivered within the context of the post-operative physical therapy routine (the mindfulness approach will be integrated into the post-operative physical therapy care).
41332261|NCT01902537|DRUG|Prucalopride; observational study|This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
41332262|NCT05425095|OTHER|Buteyko Breathing Technique|Group A will be treated with Buteyko Breathing Technique. Patient in a relaxed sitting position will ask to take a gentle breath in (2 sec), breath out (3sec) followed by pinching the nose with hands to hold the breath. The therapist will count the no. of seconds the patient can comfortably hold the breath until feels the need to breathe in again. Followed by releasing the nose and continue breathing.
41332263|NCT05425095|OTHER|Corpse-Pose Technique|Group B will be treated with Corpse-Pose Technique for 15-20 min.
41332264|NCT05191849|DIAGNOSTIC_TEST|Blood sample collection|Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2\~4 cycles of chemotherapy, or at the time of disease progression.
41332265|NCT01729104|DRUG|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I."
41332266|NCT01729104|DRUG|Lenalidomide|Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
41332267|NCT01729104|DRUG|Rituximab|Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
41013160|NCT01438190|DRUG|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
41332268|NCT05834699|BIOLOGICAL|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-low ABC
40814758|NCT04339998|DIAGNOSTIC_TEST|Point-of-Care Ultrasonography (POCUS)|"The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~1. B lines: absent (\< 3 lines), present (\> 3 lines), fused~2. Consolidation: yes or no~   a. Bilateral: yes or no~3. Pleural Effusion: yes or no~4. Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~1. Parasternal long axis~2. Parasternal short axis~   1. Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~  2. EPSS (E-point septal separation): normal (\<10 mm), abnormal (\>10 mm)~  3. Left ventricular (LV) mass approximation by septal thickness~  4. Left Ventricular Chamber Size by internal diameter at diastole"
41332269|NCT05003141|DRUG|PSB202|PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
41332270|NCT02074904|DRUG|Topiramate|
41332271|NCT02074904|DRUG|Placebo|
41332272|NCT05951543|OTHER|plyometric exercises|Experimental group will be given baseline exercises along with plyometric exercises such as Vertical jump, run and jump, drop jump (jump height between 40 and 50 cm) drop jump and horizontal jump with same height from 3rd week.particepents perform exercises carrying medicine balls. Participants will place their hands on the wall and performed foot stretches with the feet apart, 30 to 50 cm from the wall. Side row, biceps stretch and frontal row. Throwing and receiving, with a distance between 3 to 4 m.
41332273|NCT05951543|OTHER|dynamic balance group control group|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises
41332274|NCT03163173|DRUG|GC4419|30 mg (\~100 μCi) dose of \[14C\]GC4419
41332275|NCT03006081|DRUG|Intravitreal Aflibercept injection|Six number of injections at baseline, 1M, 2M, 3M, 4M, and 5M
40814759|NCT01116024|DEVICE|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
40814760|NCT02582073|BIOLOGICAL|Placebo (0.5ml)|
40814761|NCT02582073|BIOLOGICAL|Placebo (1.0ml)|
40814762|NCT02582073|BIOLOGICAL|Grass MATA MPL (0.5ml) 5100SU|
40814763|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 10200SU|
40814764|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 18200SU|
40814765|NCT02582073|BIOLOGICAL|Grass MATA (0.5ml) 5100SU|
40814766|NCT02410473|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
40814767|NCT02410473|OTHER|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
41013161|NCT01438190|DRUG|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
41013162|NCT04330079|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg once daily for 6 months.
41332276|NCT01765946|DRUG|Metformin|Metformin tablets 500 mg tris in die (tid)
41332277|NCT01765946|DRUG|placebo|
41332278|NCT03571503|PROCEDURE|Doin (conduction exercise)|An acupuncture physician will administer acupuncture at 4-8 acupoints in the low back and gluteal area (mandatory points: BL54, and GB30 ipsilateral to the dysfunctional site; and selective points: BL23, BL24, BL25, BL26, BL31, BL32, Ah-shi points, local acupuncture points and/or trigger points. Doin (conduction exercise) will be performed as active and passive movement with the needles in situ to the aim of effective treatment of pain and functional disability by increasing the hip joint range of motion (flexion and extension) with physician guidance and isometric resistance exercise (flexion and extension) as needed. Doin (conduction exercise) sessions will be performed 1 session/day for the duration of hospitalized treatment while the patient presents radiating leg pain (NRS≥1).
41482889|NCT06387459|DEVICE|Fabric-Type Knee Extensor Muscle-Mimicking Orthosis|The intervention device is a fabric-based orthosis incorporating shape-memory alloy springs designed to mimic the action of knee extensor muscles. The primary function of this orthosis is to provide supplementary support to the knee joint during walking, aiming to stabilize the gait of elderly individuals affected by muscle weakness or degenerative joint conditions. Material: The orthosis is made from a lightweight, flexible fabric that allows for breathability and comfort during extended wear. Mechanism: Embedded within the fabric are shape- memory alloy springs that function similarly to biological muscles.
41482890|NCT05415774|DEVICE|1 : S-C1-C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
41013163|NCT04330079|OTHER|Lifestyle modification|lifestyle modification (diet and exercise) for 6 months
41013164|NCT01782677|PROCEDURE|Bilateral Surgical Resection of Carotid Bodies|
41013165|NCT04612322|DEVICE|Assessment of microvascular function with intracoronary hemodilution|The pressure/temperature wire allows assessing coronary flow reserve, intracoronary pressure, and coronary flow to calculate multiple parameters of coronary macro- and microvascular function.
41013166|NCT05166291|DEVICE|Comfort-in injection system|local anesthesia applyed with comfort-in injection system
41013167|NCT05166291|OTHER|traditional anesthesia|local anesthesia applyed with dental syringe
41013168|NCT04996303|DRUG|Routine steroid administration group|Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
41013169|NCT04996303|DEVICE|Steroid pulse therapy group|Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg \~ 1g) pulse 3 days -\> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
41013170|NCT04139590|DEVICE|Panda|
41013171|NCT04139590|DEVICE|Visual Analogue Scale - Original|
41332279|NCT03571503|DRUG|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
41332280|NCT03571503|PROCEDURE|Chuna manual therapy|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered at the physician's discretion.
41332281|NCT03571503|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
41332282|NCT03571503|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
41332283|NCT03571503|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41332284|NCT03571503|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41332285|NCT03571503|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
41332286|NCT03571503|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
41332287|NCT00708747|DRUG|Albumin (5% serum-protein solution containing immunoglobulins)|5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
41332288|NCT00708747|DRUG|Biseko|Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
41332289|NCT03175562|OTHER|Facial micellar cleanser|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
41332290|NCT03175562|OTHER|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
41482891|NCT05415774|DEVICE|2 : S-C2-C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
41482892|NCT05415774|DEVICE|3 : C1 - S - C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
41482893|NCT05415774|DEVICE|4 : C1 -C2 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
41482894|NCT05415774|DEVICE|5 : C2 - S - C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
41482895|NCT05415774|DEVICE|6 : C2 - C1 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
40814768|NCT01162824|DRUG|Acetylcholine|Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
41482896|NCT06242002|PROCEDURE|Set up of sensor|Surgery is performed as usual for patients needing this medical procedure. At the end, the sensor is set up under the surgical dressing.
41482897|NCT04460196|OTHER|survey|Each admitted patient will complete a questionnaire
41482898|NCT06456944|OTHER|stretching exercises|stretching exercises of the plantar fascia, gastrocnemius and soleus
41482899|NCT06456944|DEVICE|ultrasound|therapeutic ultrasound upon the most painful point on the medial calcaneal tubercle. The parameters involved a pulsed mode (duty cycle 50%) using an intensity of 1.5 W/cm2 and a 1 MHz of frequency for 5 minutes
41482900|NCT06456944|OTHER|rigid tape|low-dye tapping will be done to provide mechanical correction to plantar fascia and medial longitudinal arch
40814769|NCT01162824|DRUG|Adenosine|Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
41482901|NCT06456944|OTHER|mobilization|mobilization techniques for the talocrural joint in weight bearing and non-bearing positions and subtalar joint
41482902|NCT06456944|OTHER|myofascial release|deep tissue release of the plantar fascia and flexor hallucis longus in a stretched position of the plantar fascia
41482903|NCT06456944|OTHER|strengthening exercise|strengthening exercise of the plantar intrinsic muscles using short foot exercise and strengthening of the Achilles tendon and windlass mechanism using unilateral heel raise exercises
41482904|NCT02251873|DRUG|TPV + RTV (low dose)|
41332291|NCT04530396|BIOLOGICAL|Gam-COVID-Vac|vaccine for intramuscular injection
41482905|NCT02251873|DRUG|TPV + RTV (high dose)|
41482906|NCT02251873|DRUG|ddl|
40814770|NCT01630928|PROCEDURE|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
40814771|NCT02021617|DEVICE|Intraosseous access|The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver-a small battery-powered drill-and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
40814772|NCT04913168|OTHER|Front Line Worker Pilot Project|13-month intervention targeting workplace policies and programs focused on changes to safety and ergonomics, job enrichment, and work intensity for front line food service workers practices,
40814773|NCT02350413|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
40814774|NCT02943330|OTHER|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
40814775|NCT03654040|BIOLOGICAL|arTreg|"Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes."
40814776|NCT03654040|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion."
40814777|NCT03654040|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
40814778|NCT03654040|DRUG|mesna|"Mesna is administered:~* Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and~* In conjunction with the cyclophosphamide, per institutional practice with CTX."
40814779|NCT03654040|DRUG|everolimus|EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.
40814780|NCT04867512|DIETARY_SUPPLEMENT|Liquid Tincture|Biocidin Liquid Tincture: 1 drop by mouth twice daily, increased by one drop each day until 15 drops twice daily have been reached. 15 drops by mouth twice daily will be maintained through the duration of the study.
40814781|NCT04867512|DIETARY_SUPPLEMENT|GI Detox|GI Detox: 2 capsules by mouth every evening and 1 hour away from all food maintained through the duration of the study.
40814782|NCT04867512|DIETARY_SUPPLEMENT|Olivirex|Olivirex: 2 capsules by mouth twice daily taken with Biocidin liquid tincture starting at week 10 until week 14 of the study for non-responders determined by symptoms and lactulose breath test results.
40814783|NCT03619096|PROCEDURE|tunnel technique for Root coverage with Porcine collagen Matrix|Tunnel technique for root coverage for multiple gingival recessions, using porcine collagen matrix
40814784|NCT03619096|PROCEDURE|extended fla technique for Root coverage with Porcine collagen Matrix|Extended flap technique for root coverage for multiple gingival recessions, using porcine collagen matrix
40814785|NCT05723562|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
41332292|NCT04530396|OTHER|placebo|placebo comparator
41332293|NCT01647425|BEHAVIORAL|physician assessment|"* Socio-economic conditions and general features: educational level, professional status...~* Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~* in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~* Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~* Assessment of current use of cannabis using the Cannabis Abuse Screening Test~* Psychiatric assessment using the MINI 5.0"
41332294|NCT02524535|OTHER|Therapeutic alliance|
41332295|NCT00195481|DRUG|Rapamune|
41332296|NCT02821091|OTHER|Interactive Dynamic Balance Training|
41482907|NCT03508414|BEHAVIORAL|ketogenic diet|Patients receive a ketogenic diet, which is carbohydrate-reduced with a high amount of fat.
41482908|NCT03508414|BEHAVIORAL|Intermittent therapeutical fasting|Patients fast for 1 week every six months. Additionally, the patients do an intermittent fasting, that is to say they do not eat for at least 14 hours a day.
41482909|NCT03508414|BEHAVIORAL|Active comparator|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
41482910|NCT01258166|PROCEDURE|Surgery or immobilization|
41332297|NCT01769625|DRUG|placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU|Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
41332298|NCT04285710|DEVICE|Phototherapy|The key intervention aspect of this study is the application of 15 J/cm2 of 410 nm pulsed light directly onto the infected diabetic wounds of subjects every week over the course of 3 months, allowing for the cumulative exposure of around 180 J/cm2 for the entire study. This 15 J/cm2 weekly dosage of blue light will split up into two sessions every week, with each session applying 7.5 J/cm2 of light treatment. Phototherapy will be applied twice per week, with one phototherapy session occurring directly following the debridement surgery during the first visit of the week and the other session occurring after the study clinician removes the subjects wound dressings at the second visit.
41482911|NCT05824741|BEHAVIORAL|Infant Cardiovascular Health (CVH) Promotion|The pilot infant CVH intervention will be delivered by Nurse-Family Partnership (NFP) staff starting no later than 1 month postpartum and lasting up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long. This pilot study will include an enhanced version of the NFP standard care plan delivered by trained nurses to promote cardiovascular health by targeting soothing, feeding, sleep, and physical activity behaviors during infancy. The intervention delivered by trained visiting nurses will include behavior change strategies (e.g., goal setting, problem solving barriers). This pilot study will also examine the feasibility and acceptability of a digital device (infant foot worn actigraphy) during this same time period.
40814786|NCT04943341|PROCEDURE|Eco-guided Triamcinolone-Acetonide injection|"The treatment consists in injecting 1 ml of Kenacort (corresponding to 40 mg of Triamcinolone Acetonide) diluted in about 1 ml of local anesthetic (Lidocaine) directly into the medial fold of the knee. Through an ultrasound guidance with in plane technique, the flute beak of the needle will be positioned between the two sheets of the synovial fold and the injection will be performed."
40814787|NCT03044119|BIOLOGICAL|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
40814788|NCT03044119|BIOLOGICAL|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
40814789|NCT04822896|BEHAVIORAL|Physical Exercise|"The videos will be prepared by the researchers and will be watched by the physical exercise group, which includes exercises such as shifting the jaw to the side, pushing the tongue forward, jaw opening, sliding the jaw with the tongue, opening the chin with the tongue, opening the chin by pressing the tongue against the palate and shifting the chin with the person's own resistance. Then they will be asked to do the exercises physically. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
40814790|NCT04822896|BEHAVIORAL|Kinesthetic Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as kinesthetic imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
40814791|NCT04822896|BEHAVIORAL|Visual Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as visual imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
40814792|NCT03293849|OTHER|Patient Navigation|The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
40814793|NCT02769338|OTHER|Quality Improvement Program|The Intervention is a QI Program that will include multiple components as described above.
40814794|NCT05354609|OTHER|MR-enterography|All patients will undergo a simplified MR-enterography, which includes four sequences, without bowel cleansing or injection. On the same day, the standard MR-enterography will be performed as in clinical practice, after ingestion of the usual oral preparation.
40814795|NCT03898466|DRUG|Fluticasone furoate|Inhaled corticosteroid
40814796|NCT03898466|OTHER|Matching placebo|Placebo inhaler
40814797|NCT02543866|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
40814798|NCT03951493|COMBINATION_PRODUCT|Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.~The first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.~The injections will be carried out either at the patient's home by the nurses or in the investigator centre."
40814799|NCT03951493|RADIATION|Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy."
40814800|NCT03603587|PROCEDURE|biopsy|Biopsy 4 to 5 mm from the distal part of the tips of the excision pieces. Three biopsies of 3 mm, made with punch, occipital hair zone (ZT) A completely painless sample, using a swab (soaked with a buffer solution) on the scalp of the ZH and ZT zone.
40814801|NCT03603587|DIAGNOSTIC_TEST|blood sample|Blood sample will be collected for performed for HIV serology, B and C hepatitis.
41482912|NCT02922101|BEHAVIORAL|Audit and Feedback|An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
41332299|NCT04285710|PROCEDURE|Debridement Surgery and Wound Dressing|All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.
41332300|NCT05333003|DRUG|Semaglutide|The semaglutide dose will start with 0.25 mg/week, and slowly increased every four weeks as tolerated up to a maximal dose of 2 mg/week
41332301|NCT05333003|OTHER|Placebo|Placebo will be provided to participants
41332302|NCT04712487|DIAGNOSTIC_TEST|Microbiological culture, viral PCR, histopathological analysis|"Intervertebral disc tissue was sent to the laboratory for further analysis:~Microbiological culture: Detection of bacterial growth Viral PCR: Detection of Herpes-Simplex-Type 1 virus, Herpes-Simplex-Type 2 virus, Cytomegalovirus Histopathological analysis: Inflammation signs of disc tissue"
41332303|NCT01599806|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
41332304|NCT01599806|DRUG|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
41332305|NCT01599806|DRUG|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
41332306|NCT01599806|DRUG|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
41332307|NCT03020264|DEVICE|glycemic sensor FREESTYLE Libre Pro|Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre Pro
41332308|NCT02904525|DEVICE|7 Tesla MRI, no contrast agent|Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
41332309|NCT01686100|PROCEDURE|No touch technique|The vein graft is harvested with its surronding tissues.
41332310|NCT01686100|PROCEDURE|Conventional technique|The vein graft is stripped from its surrounding tissues.
41332311|NCT01894763|DEVICE|Self-expandable metal stent|Placement of a self-expandable metal stent in the esophagus
41332312|NCT00432185|DRUG|PEP005|0.25% PEP005 Gel
41332313|NCT01482468|DRUG|continuous infusion of palonosetron added to prophylactic single injection of palonosetron|continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
41332314|NCT01482468|DRUG|continuous infusion of normal saline added to prophylactic single injection of palonosetron|continuous infusion of normal saline after single injection of palonosetron 0.075mg
41332315|NCT00901862|DEVICE|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
41332316|NCT00901862|DEVICE|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
40814802|NCT03603587|DIAGNOSTIC_TEST|questionnaire on sun exposure|Questionnaire on sun exposure will be completed by patients.
40814803|NCT03603587|DIAGNOSTIC_TEST|examination of the scalp|A complete examination of the scalp will be completed by dermatologist.
40814804|NCT03603587|DIAGNOSTIC_TEST|Norwood scale|Norwood scale measure the evolution of baldness. It will be completed by dermatologist.
40814805|NCT03603587|DIAGNOSTIC_TEST|questionnaire of clinicals signs|Questionnaire of clinicals signs will be completed by dermatologist and patient.
41013172|NCT03058068|BIOLOGICAL|Allo-hMSCs|1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)
41013173|NCT03058068|BIOLOGICAL|Placebo|1 peripheral intravenous infusion
41332317|NCT00092482|BIOLOGICAL|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years|
40814806|NCT03603587|DIAGNOSTIC_TEST|scinexa score|It's a assessment score of skin aging. It will be completed by dermatologist.
41332318|NCT06055049|OTHER|Intervention (Kinesio Taping) group|It is the group to which Kinesio Taping applied.
41332319|NCT06046365|DIAGNOSTIC_TEST|lymphoscintigraphy|lymphoscintigraphy
41332320|NCT06046365|DIAGNOSTIC_TEST|circumference measurement|circumference measurement
41332321|NCT06046365|DIAGNOSTIC_TEST|sonography|B-mode sono and elastography
41332322|NCT06046365|DIAGNOSTIC_TEST|DXA body composition analysis|DXA body composition analysis
41332323|NCT04637191|DEVICE|MentalPlus®|A digital game named MentalPlus will be used to evaluate the possibility of this game becoming a neuropsychological test.
41332324|NCT05849636|BEHAVIORAL|ALERTA CANNABIS|The intervention consists of preventive messages about the benefits of not consuming cannabis, reducing the positive attitudes and encouraging the negative attitudes towards cannabis use, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject cannabis use. This information is presented through different tailored messages. In addition, the participants will be able to choose avatars to accompany them during the intervention. The intervention consists of a short story about the cannabis use by adolescents.The stories take place in three different scenarios (at home, at school leaving, and in public places).
41332325|NCT01407848|DRUG|Furosemide|Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
41332326|NCT01407848|DRUG|Saline 0,9%|nebulised 0,9% saline 4x/d for max.3 days
41332327|NCT06212206|DEVICE|PillBot|The PillBot System uses active, motorized propulsion technology to facilitate the navigation and positioning of the capsule within the stomach anatomy for imaging of the gastric mucosa by an operator.
41332328|NCT03251872|DRUG|Olaparib|Olaparib tablets
41332329|NCT05037916|OTHER|laser speckle contrast imaging device|laser speckle contrast imaging device will be used for measurement of burn wound depth en to be compared to the golden standard the laser doppler imaging device
41013174|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for experimental vaccine is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
41332330|NCT01227304|DEVICE|PiCCO-parameter-guided volume challenge|Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
41332331|NCT05225480|BEHAVIORAL|Illness perception conversation|A conversation based on the indvidual's knee pain related illness perceptions
41332332|NCT05225480|BEHAVIORAL|research motivation conversation|A conversation based on the indvidual's motivation for participating in research
41332333|NCT00820807|OTHER|Novel dietary fiber|oral consumption in beverage
41013175|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 1 is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
41013176|NCT06344065|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 2 is through intramuscular injection of 0.5ml into the anterolateral side of the thigh or the upper arm.
41013177|NCT02082717|DRUG|potassium chloride replacement|
41013178|NCT02082717|DRUG|Experimental - 4% Sodium Bicarbonate|
41013179|NCT02550652|DRUG|Mycophenolate Mofetil/Mycophenolic Acid|MMF/MPA will be administered as per schedule specified in the respective arm.
41013180|NCT02550652|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
41013181|NCT02550652|OTHER|Placebo|Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
41013182|NCT02550652|DRUG|Methylprednisolone|Methylprednisolone IV will be administered as per schedule specified in the respective arm.
41013183|NCT02550652|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
41332334|NCT00820807|OTHER|Novel dietary fiber|oral consumption in beverage
41332335|NCT00820807|OTHER|Placebo|oral consumption in beverage
41332336|NCT01209975|PROCEDURE|Selective Laser Trabeculoplasty|Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
41332337|NCT01609725|DEVICE|Subgingival scaling and root planing|Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
41332338|NCT01609725|DEVICE|Oral prophylaxis|One session of supraginigval calculus removal
41013184|NCT01297842|DRUG|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
41013185|NCT01297842|DRUG|Meropenem or Imipenem|Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
41332339|NCT00203255|DRUG|Soy Isoflavones|
41332340|NCT02439736|OTHER|Blood draw within 12 hours of head injury|
41332341|NCT02577367|DRUG|Levothyroxine|Administer Levothyroxine
41332342|NCT06445010|OTHER|Creating Musical Playlist|Personal music playlist for therapeutic listening and sharing with other individuals in bereavement
41332343|NCT01800851|OTHER|Energy expenditure evaluation in calorimetric chamber|
41332344|NCT05649410|OTHER|mobilization with movement and conventional therapy|Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation
41332345|NCT05649410|OTHER|sleeper stretch along with conventional therapy|it will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
41332346|NCT00612339|DRUG|Avastin and Temozolomide|This is Phase II study with the combination of Avastin \& Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin \& Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI \& repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy \& requests discontinuation, patients will receive up to 4 cycles of Avastin \& Temozolomide, then proceed with standard XRT therapy, \& future therapy after 4 cycles will be at discretion of patient \& treating physicians.
41332347|NCT05134168|PROCEDURE|bone marrow mononuclear cell injection|bone marrow mononuclear cells were injected in the intersphincteric space and around the internal opening after ligation and division of the tract
41332348|NCT05134168|PROCEDURE|LIFT|The fistula tract is ligated in the intersphincteric space
41332349|NCT03202745|OTHER|Patient Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.
41332350|NCT03202745|OTHER|Prescriber Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.
41013186|NCT02618993|PROCEDURE|Realization of the V3 block in maxillofacial surgeries|bilateral mandibular block in maxillofacial surgeries
41013187|NCT05741918|DIAGNOSTIC_TEST|Fick's method|Cardiac output measurement by Fick method
41013188|NCT05741918|DIAGNOSTIC_TEST|Echocardiography|Cardiac output measurement by echocardiography
41332351|NCT03277625|PROCEDURE|modified omega-shaped single-loop|A double-layer, end-to-side, duct-to-mucosa PJ using interrupted polydioxanone 5-0 suture (PDS II, Ethicon, Somerville, USA) for the outer layer and interrupted polypropylene 5-0 suture (Prolene, Ethicon, USA) for the inner layer is the standard technique during PD at our Institution. For the modified omega-shaped single-Loop reconstruction the loop between PJ and HJ is left intentionally longer at about 25-30 cm and an additional side-to-side jejunojejunal anastomosis is performed at the lowest point between the afferent and efferent loops of the HJ This intestinal anastomosis is done in a double-layer continuous PDS 5-0 suture technique. Neither sealants, nor stents are being applied at the PJ. In cases of thin walled and tiny hepatic ducts, the HJ is splinted using an externally diverted T-tube.
41332352|NCT03460925|RADIATION|SBRT plus chemotherapy|Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox
41332353|NCT06047990|DEVICE|Cryobiopsy catheter|Comparison of endobiliary forceps biopsy and cryobiopsy of biliary stenosis during percutaneous transhepatic drainage.
41332354|NCT01953367|DRUG|Vantobra (tobramycin)|Inhalation
41332355|NCT01953367|DRUG|TOBI (tobramycin)|Inhalation
41332356|NCT00676156|DRUG|oral lipoic acid (LA)|A single 1200 mg dose of oral LA will be administered.
41332357|NCT00676156|DRUG|lipoic acid (LA) with fish oil and LA without fish oil|Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
41332358|NCT00676156|DRUG|R lipoic acid|A single oral dose of 1200mg R enantiomer LA will be administered.
41332359|NCT05462405|PROCEDURE|Experimental group|In the setting phase subjects will be in recumbent position. A microneurography needle (0.2mm diameter isolated Tungsten micro-electrode) will be placed under the skin. An identical (not isolated) reference needle tip will be inserted within 2 cm of the first electrode. These are connected to a recording system (ADInstruments PowerLab). Once sympathetic activity can be measured using the needles, a sympathetic specific test will be used to calibrate the measurement and recording system. In the testing phase sequential pacing and CNT delivery will be programmed for a few minutes, the whole procedure expected to last less than 2 hours.
41332360|NCT05703672|DRUG|Varenicline Tartrate|0.5 mg once daily for days 1-3, 0.5mg twice daily for days 4-7 and 1.0 mg twice daily from day 8 through week 12.
41332361|NCT05703672|DRUG|Placebo|One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.
41332362|NCT05703672|OTHER|Electronic cigarette|Nicotine salt pod based e-cigarette in 5% nicotine
41332363|NCT00415519|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
41332364|NCT00415519|DRUG|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
40814807|NCT03603587|DIAGNOSTIC_TEST|questionnaire of the history of the hair loss|Questionnaire of the history of the hair loss will be completed by dermatologist and patient.
40814808|NCT06398132|OTHER|Usual Care|Usual Care includes among others, over-the-counter or prescribed painkillers, treatment modalities such as physiotherapy and/or psychotherapy, privately accessed or via the National Health Service, exercise, etc.
41332365|NCT04618406|DEVICE|PICO VAC|PICO14 device from Smith and Nephew - Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager-sized) suction device/canister and provides a negative pressure of -80 mmHg for 14 days.
41332366|NCT04618406|OTHER|Standard care|Sterile surgical silicone foam dressing and soft dressing applied immediately postoperative and removed after 12 days
41332367|NCT05480761|BIOLOGICAL|Sucraid (sacrosidase) Oral Solution 8500 IU/mL|Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.
40814809|NCT03055728|DIAGNOSTIC_TEST|Rapid strep antigen detection test|Pharyngeal swab for rapid antigen detection of streptococcus
40814810|NCT03055728|DIAGNOSTIC_TEST|throat culture|Pharyngeal swab for culture for bacteria (specifically streptococcus) presence
41332368|NCT01721512|OTHER|Breastfeeding|
41332369|NCT01721512|OTHER|Infant formula|
41332370|NCT02384993|BEHAVIORAL|Enhanced Physical Activity|This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
41332371|NCT02281968|DRUG|Naproxen|Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
41332372|NCT02281968|DRUG|Placebo|
40814811|NCT03322176|OTHER|Genetic testing|LYNCH genetic testing
40814812|NCT02821442|DEVICE|Acupuncture|Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients
40814813|NCT02821442|DEVICE|Sham Acupuncture|Placebo needles appear to penetrate but do not actually penetrate the skin
41332373|NCT03514004|BEHAVIORAL|ICT-based intervention|"The ICT-based intervention, known as Project Clan, includes both a web-platform and a mobile application. Project Clan includes both informational and interactive features, ranging from traditional suicide prevention strategies (e.g., a chat with a psychologist, emergency phone hotline, and tips) that seek to reduce barriers to access quality, useful, and evidence-based information and rapid professional assistance, to components designed to increase interactions between participants and promote a sense of belonging and connection with the other Clan members."
41332374|NCT04084405|OTHER|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.
41332375|NCT04778371|OTHER|Almonds|64 g total dry roasted, unsalted almonds per day for a total of 12 weeks
41332376|NCT04778371|OTHER|Placebo|200 g total calorie matched granola bar per day for total of 12 weeks
41332377|NCT05718661|BEHAVIORAL|Watching video with virtual glasses|Using Mobile Virtual Glasses; In the preoperative period, after the patient is taken to the surgical service, a virtual reality video will be watched with mobile virtual glasses at the specified time (before going to the operating room on the day of surgery). Measurements will be made before and after the application. Necessary hygiene will be provided before the use of glasses, and the researcher will ensure hand cleaning before entering the patient's room.
41332378|NCT05718661|BEHAVIORAL|watching video without virtual glasses|The plain version of the video, which was shown to the intervention group by the researcher (SŞ) to the placebo group, will be watched over the phone with the naked eye and the stress level on the smart bracelet will be recorded.
41332379|NCT00220454|DRUG|Climara|
41332380|NCT00220454|DRUG|Hydrocortone|
41332381|NCT03466307|DEVICE|Ultrasonography|Ultrasonographic examination of shoulder
41332382|NCT00721617|OTHER|Intralipid 20%|Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
41332383|NCT00721617|OTHER|Normal Saline|Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
41332384|NCT00721617|OTHER|Oral fat load|Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
41482913|NCT02922101|BEHAVIORAL|Toolbox|A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
41482914|NCT00706381|DRUG|Sincalide|
41482915|NCT00706381|DRUG|Ursodiol|
41482916|NCT00706381|PROCEDURE|Fat Meal|600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate
41482917|NCT00706381|PROCEDURE|Carb meal|600 calorie meal containing 100% carbohydrate
41482918|NCT00706381|DRUG|Placebo|IV and/or oral placebo
40814814|NCT02664649|DRUG|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily"
40814815|NCT02664649|DRUG|Standard of care|VKA or Antiplatelet therapy
41332385|NCT03934541|BIOLOGICAL|MPER-656 Liposome Vaccine|Administered by intramuscular injection
41482919|NCT00250900|BEHAVIORAL|Prescription Fill Status|
40814816|NCT05150093|PROCEDURE|Deep Brain Stimulation|Clinically indicated DBS treatment for dystonia or tremor with simultaneous research electrocorticography (ECoG).
41332386|NCT03934541|BIOLOGICAL|Placebo for MPER-656 Liposome Vaccine|Administered by intramuscular injection
41332387|NCT02268136|DRUG|BIII 890 CL|
41332388|NCT02268136|DRUG|Placebo|
41482920|NCT06242561|BEHAVIORAL|Data collection from sepsis management|observational study
41482921|NCT04436978|DRUG|30-day DAPT|DAPT (aspirin + P2Y12 inhibitor) during the first 30 days following PCI. After 30 days, all patients will be treated with edoxaban and a P2Y12 inhibitor.
41482922|NCT04436978|DRUG|Guideline-directed therapy|Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)
41332389|NCT05521646|OTHER|Quality Improvement Collaborative|Explore if a Quality Improvement Collaborative can increase the proportion of immigrant women who choose an effective postpartum contraceptive method
41332390|NCT01422772|BIOLOGICAL|VM202RY|0.5mg intramuscular injection
41332391|NCT01422772|BIOLOGICAL|VM202RY|1mg intramuscular injection
41332392|NCT01422772|BIOLOGICAL|VM202RY|2mg intramuscular injection
41482923|NCT04988152|BIOLOGICAL|sotrovimab|sotrovimab IV infusion, single dose
41332393|NCT04545034|OTHER|water aerobic exercise|The EP would be formed by continuous session of dynamic water aerobic exercise which consisted of a dynamic warm-up period (5 minutes), an active exercise period at the established intensity of HR (35 minutes), and a cooldown period (5 minutes) to total 45 minutes, with a intensity of 75%HR.
41482924|NCT04988152|OTHER|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
41482925|NCT04988152|BIOLOGICAL|sotrovimab|Sotrovimab IM injection, single dose
41482926|NCT04988152|OTHER|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
41482927|NCT03529578|PROCEDURE|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
41482928|NCT02646449|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
41482929|NCT02646449|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
41482930|NCT01571076|GENETIC|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
41482931|NCT01571076|GENETIC|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
40814817|NCT05920681|PROCEDURE|Transanal irrigation|The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - d it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.
40814818|NCT05920681|COMBINATION_PRODUCT|Best supportive care|Diet modification, Loperamidum if needed, diapers, etc.
40814819|NCT05446766|BEHAVIORAL|Self-guided Exposure-based Digital Intervention for Health Anxiety|"An 8-week self-guided internet based CBT intervention which consists of text, exercises, examples and automated support. The format, potentially more accessible compared to traditional ICBT, will be developed with the aim to enhance treatment comprehension and motivation in the participants. The program consists of eight modules (chapters) where the main therapeutic focus is exposure with response prevention.~Participant will be interviewed before the program starts, after 8 weeks and 3 months after the program ends. If in need for technical support, participant will be able to ask for assistance via the program and will then be contacted by a clinician via telephone within a couple of days."
40814820|NCT04867720|DRUG|Everolimus|- Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.
40814821|NCT00703521|BIOLOGICAL|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
40814822|NCT05781061|OTHER|Screening for Eligibility|Asynchronous Screening for MA Eligibility
40814823|NCT06314958|OTHER|CENSURE|A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
40814824|NCT02478697|BEHAVIORAL|ProChange ExpertSystem|The computer program assesses stage of change and TTM constructs of temptations, decisional balance, and processes of change. Repeat intervention contacts occur at baseline, 3- and 6-months follow-up, providing iterative computerized feedback reflecting prior responses with encouragement for quitting smoking and relapse prevention.
40814825|NCT02899221|RADIATION|High-Dose Rate Brachytherapy|Undergo high dose rate brachytherapy
40814826|NCT02899221|PROCEDURE|Hyperthermia Treatment|Undergo interstitial hyperthermia treatment
40814827|NCT02899221|OTHER|Laboratory Biomarker Analysis|Correlative studies
40814828|NCT00742365|DEVICE|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
40814829|NCT00742365|DEVICE|Red light placebo|One hour of exposure to red light.
40814830|NCT01352442|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
40814831|NCT06412315|DRUG|Citalopram|Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
40814832|NCT06412315|DRUG|Placebo|Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
40814833|NCT01253148|DEVICE|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
40814834|NCT06161974|DRUG|Olutasidenib + TMZ|Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD
40814835|NCT01939002|DRUG|BIIB017|
40814836|NCT01939002|DRUG|naproxen|
40814837|NCT05587062|BIOLOGICAL|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) by intravitreal injection
40814838|NCT05587062|BIOLOGICAL|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) by intravitreal injection
40814839|NCT00949754|DRUG|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
40814840|NCT02083848|OTHER|7T MRI|Ultra high field magnetic resonance imaging
40814841|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel|
41482932|NCT01571076|OTHER|Prolonged culture|The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
41482933|NCT01571076|OTHER|Prolonged culture|Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
41482934|NCT01102374|DRUG|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
40814842|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan Vehicle|Inactive ingredients used as a placebo comparator
40814843|NCT02429219|DRUG|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
40814844|NCT02429219|PROCEDURE|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
40814845|NCT02429219|PROCEDURE|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
40814846|NCT00061815|BIOLOGICAL|cetuximab|400 mg/m2 IV
40814847|NCT00061815|DRUG|oxaliplatin|85 mg/m2 IV
40814848|NCT00061815|DRUG|leucovorin|200 mg/m2 IV
40814849|NCT00061815|DRUG|5-fluorouracil|400 mg/m2 IV
40814850|NCT00061815|DRUG|5-fluorouracil|600 mg/m2 IV
40814851|NCT00061815|BIOLOGICAL|cetuximab|250 mg/m2 IV
40814852|NCT02853812|OTHER|Functional brain MRI|Sound evoked functional MRI assessment on patients with single sided tinnitus
40814853|NCT06403306|DRUG|Ferric Sulfate (Viskostat; Ultradent, Utah, USA)|Widely used in pulpotomy treatment of primary teeth, provides hemostasis through a chemical reaction with blood. The metal-protein complex, formed due to contact with blood, creates a mechanical plug; thus, hemostasis occurs without clot formation.
40814854|NCT06403306|DRUG|Ankaferd Blood Stopper (Ankaferd Blood Stopper, Ankaferd Ilaç Kozmetik A.S, Istanbul, Turkey)|Recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. It consists of a standardized mixture of Thymus vulgaris (thyme), Alpinia officinarum (galangal), Vitis vinifera (vine), Glycyrrhiza glabra (licorice) and Urtica dioica (nettle).
40814855|NCT06403306|DEVICE|Er,Cr:YSGG laser (Waterlase MD, Biolase, USA)|Alternative technique introduced to clinical practice in recent years to provide hemostasis in vital pulp treatment is the usage of lasers in various wavelengths. Using lasers in pulpotomy provides many advantages such as tissue vaporization and coagulation, maintenance of a blood-free working field due to its property to close small blood vessels, minimal clot formation, and sterilization of the wound surface. Furthermore, laser systems were reported to induce cellular biostimulation. Er,Cr:YSGG lasers which belong to the Erbium laser family are the laser systems with the highest absorption rate by water, having a wavelength of 2780 nm. Besides, Erbium lasers manifest bactericidal effects.
41013189|NCT03794765|DRUG|Ceftriaxone|Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.
41013190|NCT03794765|DRUG|Metronidazole|Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day
41013191|NCT03794765|OTHER|Placebo infusion|Similar placebo infusion
40814856|NCT03902457|PROCEDURE|Maxillary sinus augmentation|Maxillary sinus augmentation procedures have become increasingly popular procedures before placement of dental implants in posterior maxillae that have suffered severe bone loss due to sinus pneumatization, alveolar bone atrophy, or trauma.
40814857|NCT06557057|OTHER|Non-Interventional Study|Non-Interventional Study
41013192|NCT06433414|OTHER|PAUSE App|Participants receiving the intervention will receive access to the PAUSE App, a self-management tool for SDMG intended for patients to use during an acute illness. The app asks users a series of questions regarding signs and symptoms that identify a qualifying sick day illness, and screens for 'red flags' that would require emergency, or HCP or urgent care referral, and help patients identify which of their medications they should temporarily withhold or adjusted, tailored to a patients' current medication list. This aims to provide patients with interactive support for managing medication during a sick day event. As part of the intervention, patients will also receive a SDMG patient handout. The intervention addresses the previously identified challenges described above via an interactive and individualized electronic application designed to facilitate provision of SDMG.
41013193|NCT06572410|DEVICE|EnVisio Navigation System|Patient will be undergoing BCS Breast Conserving Surgery treatment for DCIS or invasive breast cancer with EnVisio Navigation System.
41013194|NCT00048724|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
41013195|NCT02837887|BEHAVIORAL|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
41332394|NCT06164587|DRUG|K8|sustained released intravitreal implants
41332395|NCT00425074|DRUG|slow release acetyl salicylic acid|150 mg in capsules via oral, during 14 days.
41332396|NCT00425074|DRUG|ASA|normal release acetylsalicylic acid
41332397|NCT00425074|DRUG|SR-ASA|slow release acetylsalicylic acid 150 mg
41332398|NCT00981747|DRUG|Sildenafil|Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
41332399|NCT00981747|DRUG|Losartan|Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
41332400|NCT00981747|DRUG|Sildenafil and Losartan|Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
41332401|NCT00981747|DRUG|Placebo Oral Tablet|Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
41332402|NCT05446974|OTHER|Nursing Competency Enhancement Training Program in PTSD Intervention|This program was for nurses who work at the Mental Health Welfare Center and consisted of a workbook, self-learning online education, and workshop. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-learning guidelines for nurses to develop their capacity for PTSD intervention.
41332403|NCT06165861|OTHER|Experimental (with VR-G)|Watching video with using VR-G before undergoing open heart surgery
41332404|NCT02251171|DRUG|Tipranavir|
41332405|NCT02251171|DRUG|Ritonavir|
41332406|NCT02251171|DRUG|Rifabutin|
40814858|NCT02865954|DEVICE|iball (mhealth application)|mhealth application and associated device to support activation of the pelvic floor muscles.
40814859|NCT00918320|DRUG|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
41013196|NCT03174197|DRUG|Atezolizumab|Given IV
41013197|NCT03174197|RADIATION|Radiation Therapy|Undergo RT
41013198|NCT03174197|DRUG|Temozolomide|Given PO
41013199|NCT02905305|DEVICE|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
41013200|NCT02905305|DEVICE|Contour Advance electrode|Standard Contour Advance electrode
41013201|NCT04364633|OTHER|Voice Handicap Questionnaire (VHI)|Voice Handicap Index (VHI) self-questionnaire
41332407|NCT04648228|BEHAVIORAL|ACT+MBRP|Intervention is behavioral treatment group that combines Acceptance and Commitment Therapy (ACT) with Mindfulness-Based Relapse Prevention. The group focuses on living with long-term pain, ways to complete daily living activities when you experience pain, coping with opioid and other drug cravings, and training in mindfulness practices.
41332408|NCT04648228|BEHAVIORAL|Education control|Education control is behavioral treatment group that combines pain patient education with opioid and other drug education. The group focuses on experiences of long-term pain, instructions on how to function with this pain, and facts about opioids and other drugs.
41013202|NCT03032003|OTHER|Cysticlean|2 BID for 15 days
41013203|NCT03032003|OTHER|Placebo|2 BID for 15 days
41013204|NCT03440879|DRUG|Zoladex|Patients currently treated with Zoladex
41332409|NCT03300219|BEHAVIORAL|Cognitive Orientation to Occupational Performance|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
41332410|NCT05337150|BEHAVIORAL|Lifestyle Modification Intervention|For the first 12-weeks of the study, participants will complete weekly web modules in which they will learn cognitive-behavioral strategies to support lifestyle modification. Participants will also receive weekly phone coaching calls for the first 12-weeks of the study, and monthly coaching calls thereafter for the remainder of the 24-week study period.
41482935|NCT01102374|DRUG|Standard Dose Vitamin D|Vitamin D 12,000 IU monthly
41155982|NCT04059185|OTHER|Triple P-Level 2|Triple P-Level 2 (TPL2) consists of a brief, 30 minute, one-on-one consultation with a parenting professional followed by a phone call from that professional roughly 2 weeks later. TPL2 will be delivered on an individual level and consist of a brief, 20 to 40 minute, one-on-one parenting consultation. Parents will receive a positive parenting booklet. They also will be offered parenting tip sheets that are designed to provide basic information on the prevention and management of common behavioral, emotional and developmental problems. All materials are: 1) written in simple English; 2) understandable at a sixth grade reading level; 3) gender-sensitive; and 4) avoid technical and colloquial expression that may pose barriers from non-English speaking backgrounds. Participants will receive a follow-up phone call to check on the family's progress and offer any additional needed advice.
41332411|NCT05337150|BEHAVIORAL|Balanced Calorie Deficit Eating Plan|Participants will be prescribed a calorie target between 1200 and 1800 depending upon baseline weight and personal preference. Participants will be asked to monitor their dietary intake using MyFitnessPal and to submit food logs weekly. Calorie reduction content will be based primarily on the Diabetes Prevention Program protocol and adapted from existing behavioral treatment protocols. Individuals will receive general guidelines on eating a healthy diet, including reducing saturated fat, processed foods, refined sugars, and refined carbohydrates, and increasing intake of lean proteins, whole grains, and fruits and vegetables, but will be encouraged to flexibly decide which areas of their diet to modify to reduce calorie intake.
41332412|NCT05337150|BEHAVIORAL|Ad Libitum Whole Food Plant-Based Eating Plan|Participants will be prescribed a whole food plant-based (WFPB) low-fat vegan diet promoting intake of fruits, vegetables, starches, legumes, and whole grains. Participants will be encouraged to avoid processed foods, refined oils, and animal products (meat, fish, eggs, and dairy products), and to minimize consumption of high-fat plant-based foods. An adapted traffic-light diet chart will outline foods to eat daily, limit, and avoid. Participants will be advised to eat until satiation and not restrict energy intake. Participants will be asked to consume 50 μg vitamin B12 (methylcobalamin) daily. WFPB nutrition counseling content will be based upon existing successful programs. Each week, participants will complete a simplified dietary self-monitoring food frequency questionnaire aligned to correspond with the traffic light diet chart.
41482936|NCT01102374|DRUG|Placebo|Placebo monthly
41482937|NCT01102374|DIETARY_SUPPLEMENT|Usual Care|Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
41482938|NCT02836834|BIOLOGICAL|JS001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
41482939|NCT01566864|BEHAVIORAL|Improve clinic based measurement of blood pressure|This intervention seeks to improve BP control and reduce disparities through an organizational change and new skills development. To improve the reliability of BP measurement in clinics, new automated BP machines (Omron HEM-907XL) will be provided for each PCP. Medical assistants will be trained and certified in the proper use of the Omron machine by a master trainer. The will be trained to measure the arm circumference, choose the appropriate cuff and place it properly on the arm. They will be recertified yearly. Once activated, the Omron HEM-907XL will lead measurement for 5 minutes then perform a series of 3 BP measurements spaced by 30 seconds and present the man of these 3 measurements. The mean will be record in the electronic medical records.
41482940|NCT01566864|BEHAVIORAL|Provider education system to promote patient-centered care|The provider education intervention will address blood pressure control and disparities through audit and feedback. The intervention includes a hypertension dashboard and a linked provider-tailored education intervention. The latter aims to enhance provider communication skills during clinical encounters with hypertension patients, via teaching specific verbal behaviors with practice implications related to elicitation of hypertension treatment and adherence concerns. The dashboard is a web based tool linked to the electronic medical records that imports clinic measurements of BP and offers PCPs a quick assessment of the percentage of those achieving blood pressure control and receiving guideline-concordant care in their panel, clinic, and system overall and by patient race/ethnicity.
41482941|NCT01566864|BEHAVIORAL|Introduce care management system in clinics|The care management (CM) intervention will address blood pressure management and disparities through patient education, promotion of self-management, and the introduction of an organizational change through the addition of new team members. The CM team will contact patients with a BP of ≥140/≥90 (≥130/≥80 for patients with diabetes mellitus or chronic kidney disease) as identified through the electronic medical records for enrollment in care management services. Patients with a BP in these ranges will be referred to a CM program that emphasizes four key self-management behaviors: diet, physical activity, medication adherence, and self-monitoring. The self-management promotion program will consist of 3 one-on-one sessions either with a Pharm D. or R.D. over the course of 3 months.
41482942|NCT00663832|DRUG|LBH589 (i.v. panobinostat)|"i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle"
41482943|NCT01393730|DRUG|Abiraterone acetate|
41482944|NCT01393730|DRUG|Dutasteride|
41482945|NCT01393730|DRUG|Prednisone|
41482946|NCT05983913|BEHAVIORAL|cognitive-motor training|The cognitive-motor training program consists of five cognitive tasks related to concentration, reaction time, and executive function, combined with physical exercises using an interactive system. The five tasks include: (1) number sequence, (2) number-word sequence, (3) card matching games, (4) memorizing numbers, and (5) route-finding games.
41482947|NCT05983913|BEHAVIORAL|cognition training|The intervention consists of five cognitive tasks (memory, attention, spatial and temporal perception) with difficulty levels adapted to the individual's cognitive abilities.
41013205|NCT00365118|DEVICE|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
41332413|NCT03869671|BEHAVIORAL|PrEP uptake/adherence intervention|The interventionist will follow the manual to deliver informational and motivational strategies to participants to enhance their PrEP uptake (including completing clinical screening and obtaining/filling a PrEP prescription) and adherence (taking daily oral PrEP doses). The interventionist will assist participants in problem-solving around topics including limited transportation options, identifying local pharmacies, storing medications given complex living arrangements, coping with side effects, communicating with providers and pharmacists, and maintaining daily medication schedules with reminders and cues.
40814860|NCT06176794|DRUG|Immediate release torsemide 20mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
41332414|NCT03869671|BEHAVIORAL|Harm reduction standard of care|Participants will be provided with harm reduction supplies and health information and counseling according to routine practice at the community-based setting (harm reduction organization).
41332415|NCT02141113|DRUG|Guanfacine Hydrocholride|"1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)"
41332416|NCT02141113|DRUG|Guanfacine Hydrocholride|"1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)"
41332417|NCT01608529|DEVICE|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
41332418|NCT03086538|DRUG|Pemetrexed|Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
41332419|NCT03086538|DRUG|Tarceva 100Mg Tablet|Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
41332420|NCT06508853|OTHER|Qualitative research (no intervention)|Interviews are being conducted with support workers and managers.
41332421|NCT02670928|BEHAVIORAL|Lifestyle intervention|Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
41332422|NCT00377104|DRUG|alvocidib|Given IV
41332423|NCT00377104|OTHER|pharmacological study|Correlative studies
41332424|NCT00377104|OTHER|laboratory biomarker analysis|Correlative studies
41332425|NCT05954260|DIAGNOSTIC_TEST|Blood sampling|We will collect blood samples from the patients included in the study on ICU days 1, 3 and 5. We will measure gene expression (mRNA) and plasma levels of various elements involved in the immunological synapse.
41332426|NCT02426112|DRUG|Azithromycin|
41332427|NCT02426112|DRUG|Placebo|
41332428|NCT04751058|GENETIC|genetic analysis|"Intervention details: sampling in peripheral blood for the Methodology:~1. Automatic DNA extraction (ChemagicTM 360)~2. Mass sequencing using SeqCap EZ Choice Library capture technology (NimbleGen) and NextSeq sequencer (Illumina).~3. Bioinformatic analysis:.~   * Identification of point mutations and small deletions or insertions~  * Analysis of CNVs using the BEDtools program package~  * Search of the identified variants in the following public databases: 1000G, dbSNP, ExAC, EVS, GenomADm CSVS and DGV. Those with a MAF\> 1% have been considered benign, in public or private databases of our population.~The analysis process has focused exclusively on the genes described to date as associated with the pathology under study and included in the panel used. The reference sequences used for these genes are: determination of possible mutations, nucleotics, etc."
41332429|NCT03029949|BEHAVIORAL|ACT with VR|6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment
41332430|NCT03029949|BEHAVIORAL|self-treatment VR|booklet written on vestibular rehabilitation for self-treatment
41332431|NCT03029949|OTHER|clinical management|clinical management and pharmacotherapy as usual for chronic dizziness
41332432|NCT02658981|BIOLOGICAL|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
41332433|NCT02658981|BIOLOGICAL|Anti-PD-1|Given IV
41332434|NCT02658981|OTHER|Pharmacological Study|Correlative Studies
41332435|NCT02658981|OTHER|Laboratory Biomarker Analysis|Correlative Studies
41332436|NCT02658981|BIOLOGICAL|Anti-CD137|Given IV
41332437|NCT01313039|DRUG|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
41332438|NCT01138397|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
41013206|NCT02827292|OTHER|music|"A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.~A proper silent operative room environment will be maintained."
41332439|NCT01138397|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
41332440|NCT06112067|DEVICE|deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat mental disorders and to evaluate the efficacy and safety of DBS system.
41332441|NCT02267369|BEHAVIORAL|Media-assisted fitness program|Participants can register workshops online, track program participation, and receive promotional health messages online.
41332442|NCT02267369|BEHAVIORAL|Social network-assisted fitness program|Participants can register workshops online and track program participation. Participants are put into anonymous online social networks and receive real-time activity updates from 4-6 peers.
41332443|NCT02267369|BEHAVIORAL|Basic fitness program|Participants can register workshops online and track program participation.
41332444|NCT04263493|OTHER|Rehabilitation (physiotheraphy)|Time of loading, range of motion exercises, strength training
41332445|NCT05163834|BIOLOGICAL|Efgartigimod|intravenous infusion of efgartigimod
41482948|NCT02780427|DRUG|intranasal dexmedetomidine|"Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD)."
41482949|NCT03499418|OTHER|modified Silverman scale|Clinical assessment of severity of respiratory failure
41482950|NCT03499418|DIAGNOSTIC_TEST|echocardiography|echocardiographic evaluation of haemodynamic problems
41482951|NCT02041936|DEVICE|NanoKnife IRE System|
41482952|NCT00999765|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|eight-week (two hours a week) group therapy (8-12 patients per group)
41482953|NCT03003273|OTHER|stoppage of antibiotics|antibiotics will be stopped in arm - A on randomization, once child is afebrile for at least 24 hours and fulfills the inclusion criteria.
41482954|NCT03003273|OTHER|amoxycillin/clavulanic acid|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
41482955|NCT03003273|OTHER|levofloxacin|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
41482956|NCT05576623|BIOLOGICAL|AdCLD-CoV19-1 OMI (Part A)|20 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
41332446|NCT05163834|OTHER|Placebo|intravenous infusion of placebo
41332447|NCT05163834|BIOLOGICAL|PNEUMOVAX 23|PNEUMOVAX 23 vaccine
41332448|NCT03491930|DEVICE|VA MOVE! Coach app|The VA MOVE! Coach app promotes weight loss through positive feedback, nutritional education, calorie counts, graphs, charts, and encourages increased activity. Efforts will be supported through weekly phone coaching.
41332449|NCT03491930|BEHAVIORAL|Telephone Coaching|Weekly Telephone Coaching
41332450|NCT03491930|BEHAVIORAL|Standard of Care for weight loss.|"Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~* Vioscreen food frequency assessment and bionutritionist consult.~* Healthy eating nutritional pamphlets (during consult)~* Decrease daily caloric intake by 500 cal/day~* Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~* Dietary counseling by Clinician (monthly)"
41332451|NCT00156013|DRUG|CLOFARABINE|4 mg/m\^2 days 1-5 of every cycle for a maximum of 6 cycles
41332452|NCT05305001|GENETIC|Invitae Multi-Cancer Panel ®|Participants will have genetic testing.
41332453|NCT00045630|DRUG|carboplatin|
41332454|NCT00045630|DRUG|gemcitabine|
41332455|NCT00045630|DRUG|paclitaxel|
41332456|NCT00045630|PROCEDURE|surgery|
41332457|NCT00006234|PROCEDURE|peripheral blood stem cell transplantation|
41332458|NCT00006234|RADIATION|holmium Ho 166 DOTMP|
41332459|NCT05379205|BEHAVIORAL|Prehabilitation program (4 week before the surgery)|This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.
41482957|NCT05576623|BIOLOGICAL|AdCLD-CoV19-1 OMI (Part B)|250 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
41482958|NCT05576623|OTHER|Placebo (Part B)|50 participants will receive placebo via intramuscular injection in the deltoid muscle
41482959|NCT01678001|DRUG|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
41482960|NCT04002505|OTHER|Concussion and Brain Bleed App (CBB)|Tablet based decision aid that encourages shared decision making with the goal of educating patients to reduce unnecessary CT scans
41482961|NCT01969448|PROCEDURE|Inframammary Fold Incision or Lateral Radial Incision|
41482962|NCT01969448|PROCEDURE|Lateral Radial Incision|
41482963|NCT01969448|PROCEDURE|Inframammary Fold Incision|
41482964|NCT01969448|DEVICE|Laser-assisted fluorescence angiography|
41482965|NCT01969448|DRUG|Indocyanine Green|
41482966|NCT02494817|BEHAVIORAL|Male Couples Agreement Project|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
41482967|NCT04445779|DIETARY_SUPPLEMENT|Coenzyme Q10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure.
41482968|NCT02523196|DRUG|HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)|The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
41482969|NCT02523196|DEVICE|Hepatic Venous Pressure Gradient (HVPG)|Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
41482970|NCT00930254|PROCEDURE|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
41482971|NCT03867617|OTHER|Regulatory T cells|Single infusion of expanded regulatory T cells.
41332460|NCT05379205|BEHAVIORAL|Postoperative program (12 week after the surgery)|"This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.~NOTE: Both preoperative and postoperative programs will be administer to the participants assigned to the intervention group."
41482972|NCT03867617|DRUG|Tocilizumab|Treatment during first month post-transplant.
41482973|NCT03867617|OTHER|Bone marrow|Infusion of donor bone marrow cells.
41482974|NCT03867617|PROCEDURE|Kidney transplant|Living donor kidney transplantation.
41482975|NCT03867617|OTHER|Immunosuppressive drug therapy|Immunosuppressive drug therapy.
41482976|NCT05520593|DIETARY_SUPPLEMENT|Complex Carbohydrate Drink|Patients will drink a complex carbohydrate drink 3 hours before surgery. Drink to be given at the preoperative holding area.
41482977|NCT02254369|DRUG|GC021109|
41482978|NCT02254369|OTHER|Placebo|
41482979|NCT02980874|DRUG|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
41482980|NCT02980874|DRUG|suprachoroidal sham|suprachoroidal sham procedure
41482981|NCT02980874|DRUG|IVT aflibercept|2 mg intravitreal injection of aflibercept
41482982|NCT01684163|DRUG|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
40814861|NCT06176794|DRUG|Extended release torsemide 24mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
41013207|NCT02827292|OTHER|No music|Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.
41482983|NCT01684163|DRUG|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
41482984|NCT01684163|DRUG|Placebo|Intravenous administration of normal saline into arm.
41482985|NCT01762930|DRUG|Shanchol|Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
41013208|NCT02827292|PROCEDURE|Laparoscopic Surgery|Patients will undergo Laparoscopic Surgery as per the set protocol
41482986|NCT00622466|DRUG|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
41482987|NCT00622466|DRUG|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
41482988|NCT00507286|DRUG|combination of various doses of sildenefil and alprostadil|
41482989|NCT04149886|PROCEDURE|cardiac ganglion plexus ablation(cardioneuroablation)|Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.
41482990|NCT04149886|DEVICE|Permanent pacemaker implantation|DDD permanent pacemaker will be implanted in the paticipants.
41482991|NCT02494934|BEHAVIORAL|cognitive-behavioural therapy|The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
41482992|NCT02494934|BEHAVIORAL|physical therapy|The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
41482993|NCT04758663|BEHAVIORAL|Nap/wake conditions on memory|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities.
41482994|NCT04758663|BEHAVIORAL|Nap/wake conditions on overnight physiology|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities. On the nights of the nap and wake conditions, physiology will be recorded in habitual and non-habitual nappers.
41332461|NCT05379205|OTHER|Usual Care|Usual care group will follow the usual institutional pre-surgery care: (i) medication management, (ii) assessment of the surgery-derived risks, (iii) smoking cessation and peri-operative blood management. A trained nutritionist will evaluate the nutritional status of all patients at the baseline providing oral protein/vitamin supplementation, when necessary. Patients allocated to the control group will receive basic expert' advice on lifestyle changes.
41332462|NCT00947843|DRUG|aspirin + pregrel (Clopidogrel resinate)|
41332463|NCT00947843|DRUG|aspirin + placebo|
41332464|NCT00947843|DRUG|aspirin + plavix (Clopidogrel bisulfate)|
41332465|NCT00574444|PROCEDURE|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
41332466|NCT02213549|DIETARY_SUPPLEMENT|Placebo|
41332467|NCT02213549|DIETARY_SUPPLEMENT|Ume paste and ginger powder|
41013209|NCT00901329|DEVICE|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
41013210|NCT00901329|DEVICE|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
41332468|NCT03879993|OTHER|Exercise group|Resistance training 3 times per week (45-60 minutes of resistance training)
41332469|NCT03063398|DIAGNOSTIC_TEST|No intervention, this is an observational study|Assessment for exocrine pancreatic insufficiency
41332470|NCT00642967|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 mcg will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
41332471|NCT04562545|DEVICE|Modified Twin Block|a modified twin block design including jack screws to facilitate incemental advancement
41332472|NCT04562545|DEVICE|Twin Block Appliance set to maximum bite|a traditional twin block set to maximum bite advancement at start of treatment
40814862|NCT03575845|BEHAVIORAL|Occupational Therapy Informed Yoga|Occupational therapy informed yoga met weekly for six, 60-minute sessions. Each session started with a seated warm-up to coordinate breath and movement and promote upper extremity mobility. Standing postures followed to target balance. Sessions closed with restorative postures in seated and supine variations.
41013211|NCT05910385|PROCEDURE|laparoscopy|tubal ligation by laparoscopy or vnotes technique
41013212|NCT05910385|PROCEDURE|vnotes|tubal ligation by laparoscopy or vnotes technique
41013213|NCT00359450|DRUG|BMS-275183 (oral taxane)|
41013214|NCT01744444|DRUG|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
41332473|NCT04831567|RADIATION|MIBG-I131|Radiopharmaceutical
41013215|NCT01744444|DRUG|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
41332474|NCT02339857|PROCEDURE|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
41332475|NCT01708538|DRUG|CXL|corneal crosslinking
41332476|NCT01452724|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
41332477|NCT01452724|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
41332478|NCT01452724|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
41332479|NCT01452724|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
41332480|NCT03314012|DEVICE|Catheter-Based Carotid Body Ablation|The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
41332481|NCT05224817|OTHER|Necrotizing soft tissue infections (NSTIs)|There will be no direct interaction with subjects and involves no interventions; study is conducted completely via review of electronic health records. Our site will only collect data from the Methodist Dallas Medical Center.
41332482|NCT05381389|DRUG|Bupivacaine Hydrochloride in-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an in-plane approach to the brachial plexues
41332483|NCT05381389|DRUG|Bupivacaine Hydrochloride out of-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an out of-plane approach to the brachial plexues
41332484|NCT05320328|DEVICE|Radio frequency ablation|Radiofrequency ablation (RFA) uses heat to kill cancer cells. High-frequency electrical currents are passed through a special needle or probe called a needle electrode. The electrical current from the probe heats a small area containing cancer cells to high temperatures, killing the cancer cells. The area around the tumour is also usually treated because it may contain cancer cells.
41482995|NCT03970837|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.
41482996|NCT03970837|DRUG|Tofacitinib|Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.
41332485|NCT06294041|BEHAVIORAL|Sleep Restriction Therapy (SRT)|SRT is a manualised, adaptive, behavioural insomnia intervention that is a key active ingredient within multi-component CBT-I. Our SRT protocol involves standardising and (where required) limiting a patient's time in bed with the aim of increasing homeostatic sleep pressure, over-riding cognitive and physiological arousal, and strengthening circadian control of sleep. Those randomised to the SRT arm will receive two online sessions supported by two telephone calls over a 4-week intervention phase. The intervention will be delivered by trained research nurses
41332486|NCT06294041|BEHAVIORAL|Sleep Hygiene Education (SHE)|SHE will be delivered via a booklet that provides information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). Patients in the SHE condition will be instructed to implement the SHE advice over a 4-week period. One week after randomisation to SHE, the RA will telephone patients to check they understand the SHE advice and answer any questions they may have. SHE has successfully been used as a control condition in other trials evaluating SRT and does not have any therapeutic benefit for individuals with insomnia but is often part of usual care, so is a credible alternative to SRT.
41332487|NCT01522560|OTHER|Feedback group|"Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.~This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF)."
41482997|NCT03970837|DRUG|Placebo|Placebo matching GSK3196165 and Tofacitinib was administered.
41332488|NCT01522560|OTHER|Control group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
41482998|NCT00273481|DRUG|dorzolamide 2%/timolol maleate 0.5% fixed combination|
41482999|NCT00273481|DRUG|latanoprost 0.005%/timolol maleate 0.5% fixed combination|
41483000|NCT00273481|DRUG|timolol maleate 0.5%|
41483001|NCT00273481|DRUG|placebo|
41483002|NCT03956121|OTHER|injection of magnesium sulfate|The intervention consists to perform a study of the usual fetal heart rate with, in addition, comparison analysis of the short-term variability before and after injection of magnesium sulfate in the exposed group. Two successive short-term variability analyzes will be performed in fetuses of the control group.
41483003|NCT01053234|DIETARY_SUPPLEMENT|Standardised meals|
40814863|NCT04793451|BEHAVIORAL|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
41483004|NCT02973321|DRUG|SAR425899|Self-administered by SC injection using a solution for injection in cartridge.
41483005|NCT02973321|DRUG|Placebo|Self-administered by SC injection using a solution for injection in cartridge.
41483006|NCT02973321|DRUG|Liraglutide|Self-administered by SC injection using a pre-filled pen.
41483007|NCT02973321|DRUG|Metformin|Orally administered at a stable dose , \>=1500 mg daily stable dose or maximal tolerated dose.
41483008|NCT00031122|OTHER|No Intervention|There is no intervention in this study
41332489|NCT03305601|OTHER|application on smarthphone|application on smarthphone
41332490|NCT01374191|DRUG|onabotulinum toxin type-A|1 injection of Btx-A
41332491|NCT01374191|OTHER|placebo|1 injection of saline solution
41332492|NCT01374191|DRUG|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
41483009|NCT00198653|BEHAVIORAL|Newborn Thermal Care Practice|
41332493|NCT05235100|DRUG|Apatinib Mesylate|Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT
41483010|NCT01215513|DRUG|Degarelix|
41483011|NCT02844517|DEVICE|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
41483012|NCT02974036|OTHER|Patient education for osteoarthritis|Group sessions and optional supervised exercise.
41483013|NCT05121844|DEVICE|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
41483014|NCT02497313|DRUG|Isotonic saline|
41483015|NCT02497313|DRUG|Metformin placebo|
41483016|NCT02497313|DRUG|Cholecystokinin|
41332494|NCT05190107|DIAGNOSTIC_TEST|DASS-21 scale|"Each construct consists of 7 questions. The participants must select the answer that better represents their feelings over the last week in each scenario. Each question has a Likert scale of 4 options where 0 represents did not apply to me to 3 applied to me very much."
41332495|NCT00836303|BEHAVIORAL|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
41332496|NCT01939093|DRUG|Diazepam|If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
41483017|NCT02497313|DRUG|Metformin|
41483018|NCT04050150|BEHAVIORAL|Arm training in standing|Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
41013216|NCT05241223|OTHER|Behavior change intervention|This is an online intervention based on the transtheoretical model, along with self-determination theory strategies. This intervention will take place weekly summing up 12 online individual and/or group sessions of approximately 20 minutes. The sessions will be made through a platform and/or application that makes video calls privately. Each session will address a topic. In addition, in all sessions, the patients gain during the previous week will be recognized, as well as new goals will be set for the next week. The goals will always be individualized, realistic and achievable, based on the identification of each person's capacity and motivation. A Fitbit Zip will be used to propose objective goals aimed at increasing physical activity and reduce sedentary behavior. Additionally, a complex practice environment will be created around this device, such as the visualization of the number of steps evolution and competitions/games with other participants, among others.
41332497|NCT01939093|DIETARY_SUPPLEMENT|Vitamin B1-6-12|All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
41332498|NCT01939093|DRUG|Stugeron|All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
41332499|NCT06328660|DEVICE|Lens 1|Frequent replacement silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
41332500|NCT06328660|DEVICE|Lens 2|Daily disposable silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
41332501|NCT00596804|DRUG|veltuzumab|once weekly intravenous dosing for 4 weeks
41332502|NCT05948319|DIAGNOSTIC_TEST|Doppler ultrasonography|Doppler study was performed in all cases. perinatal outcomes were evaluated.
41332503|NCT00081328|DRUG|Metformin|capsule, 1000 mg bid
41332504|NCT00081328|DRUG|Rosiglitazone|capsule, 4 mg bid
41332505|NCT00081328|BEHAVIORAL|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
41332506|NCT01313078|DRUG|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m\^2 intramuscular or intravenously every 2 weeks
41332507|NCT01913171|OTHER|Exercise|
41332508|NCT00756678|DRUG|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days'
41483019|NCT05232084|DRUG|Bupivacaine + Fentanyl|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
41483020|NCT04259255|DRUG|Edaravone (Radicava®/Radicava ORS®)|"Participants will be followed from enrollment up to 24 weeks after treatment initiation (6 treatment cycles - 28 days per cycle, corresponding to a treatment period of approximately 24 weeks) or premature study discontinuation.~Biomarker testing and clinical assessments will be performed at baseline (at enrollment or before the start of cycle 1), and at cycles 1, 3, and 6. Dosing is 60 mg daily by intravenous infusion for 14 days for the initial treatment cycle, followed by daily dosing on 10 out of 14 days in subsequent treatment cycles."
41332509|NCT00756678|DRUG|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
41483021|NCT05676060|COMBINATION_PRODUCT|quasi|block facet joint in back pain due to afacet cause
41483022|NCT02334111|BEHAVIORAL|RESPECT-Plus|A RESPECT-Plus family specialist (FS) will deliver the intervention to subjects (mothers in treatment for opiate use disorder) recruited during their third trimester of pregnancy and randomized into the study's intervention arm post-delivery. During their infant's hospital stay, the FS will schedule a convenient time to meet the subjects (mothers) to educate them on infant soothing techniques. With permission from the mother, the FS will join the subjects during their infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between the subjects and FS.
41332510|NCT00354939|DRUG|Insulin glargine|
41483023|NCT04209673|OTHER|Multimodal Pain management including TENS unit|Patient receiving multimodal pain management strategies which includes the use of TENS.
41483024|NCT04209673|OTHER|Multimodal Pain management not including TENS unit|Patient receiving multimodal pain management strategies which does not includes the use of TENS.
41483025|NCT04566705|OTHER|Risks factors, maternal and neonatal outcomes/complications|Risks factors, maternal and neonatal outcomes/complications
41483026|NCT05306171|BEHAVIORAL|Online training for healthcare professionals|"The online training (4 modules) will use the technique of hybrid learning, combining meetings that will require the presence of participants and mediator at the same time and platform (live) with recorded meetings (interviews with experts) that will be watched by the participants at any time (from a distance).~Module 1: Self Care; Module 2: Stress and anxiety management; Module 3: Relationships; Module 4: Communication."
41483027|NCT02664233|BEHAVIORAL|Mobile and connected health|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
40814864|NCT04793451|BEHAVIORAL|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
41483028|NCT03493542|BIOLOGICAL|V501|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
41483029|NCT02016261|DRUG|Fluvoxamine|The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
40814865|NCT04806776|OTHER|24hrs dressings change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
40814866|NCT04806776|OTHER|7days dressings change|The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
40814867|NCT01152047|DRUG|oxytocin|40mU/min as infusion of oxytocin
41332511|NCT04743271|OTHER|High-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
41332512|NCT04743271|OTHER|Low-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
41332513|NCT01890317|PROCEDURE|Mild hypothermia|Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
41332514|NCT03838003|PROCEDURE|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
40814868|NCT04104815|OTHER|Experimental Thickener|Use to thicken liquids
40814869|NCT01115894|DRUG|Naltrexone|100 mg oral dosage daily for 12 weeks
40814870|NCT01115894|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
40814871|NCT01115894|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
40814872|NCT01115894|DRUG|Placebo|Placebo
40814873|NCT01097265|DRUG|capecitabine|
40814874|NCT01097265|DRUG|oxaliplatin|
40814875|NCT01097265|OTHER|active surveillance|
41483030|NCT05149443|BEHAVIORAL|theory-based mHealth-intervention (app)|Measuring the effect of the buddy and gamification components separately. During the A1 phase (baseline) and the A2 phase (reversal), participants will be asked not to use the 'Move it, Move ID' intervention: the app will be blocked. After an A phase, the app will be unblocked. During the B1 and B2 intervention phase, participants use the 'Move My it, Move ID' intervention only consisting of the buddycomponent. During the intervention period, adolescents and buddies are asked to wear an accelerometer. During the first AB pair we examine whether the buddy component has an effect on PA compared to no intervention. In the A2 reversal phase possible carryover effects can be measured. It will be informative to investigate whether some parts of the intervention are automatized or internalized and will still have some effect even when participants have no access to the intervention anymore (i.e. A2 phase). The study duration is 32 days; each phase will have a duration of minimum 5 days.
41483031|NCT05149443|BEHAVIORAL|theory-based mHealth-intervention (app)|"After the first study, other participants will be recruited. In a second study, the set-up remains the same, but the A1 and A2 phase this time consist of the buddy component (i.e. control phase) and in the B1 and B2 phase the gamification component will be added. This way, we can determine whether the gamification component has an effect on PA compared to the baseline buddy component intervention.~The study duration is 32 days for all participants. The duration of the 4 different phases of the design will vary between participants, but each phase will have a duration of minimum 5 days."
41483032|NCT04583020|DRUG|Camrelizumab|Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)
41483033|NCT04583020|RADIATION|radiation|60Gy/30
41483034|NCT04583020|DRUG|Temozolomide|Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles
41483035|NCT06398080|DRUG|aflibercept 8 mg|No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.
41483036|NCT00129051|PROCEDURE|Tomotherapy|
41483037|NCT05526859|OTHER|Kinsiotaping for wrist flexor muscles|The flexor muscles of the wrist area will be targeted.
41483038|NCT05526859|OTHER|Kinesiotaping for wrist extensor muscles|The extensor muscles of the wrist area will be targeted.
41483039|NCT05865808|OTHER|cervical spine mobilization|headache SNAGs, 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Eight weeks of treatment session will be provided and assessment of the improvement in cervicogenic headache will done at baseline, after 04, 06 and at the end of 8 week.
41483040|NCT05865808|OTHER|Rocabado 6x6|The Rocabado 6x6 program includes 6 types of exercises which are- rest position of the tongue, TMJ rotation control, upper cervical distraction, axial extension of cervical spine, shoulder girdle retraction, and rhythmic stabilization technique, which are to be performed 6 times in a day with 6 repetitions of each exercise in each session,
41483041|NCT05329298|DRUG|BPI-361175|Subjects will receive BPI-361175 until disease progression
40814876|NCT01097265|OTHER|laboratory biomarker analysis|
41013217|NCT05241223|OTHER|Educational program|The educational program will be delivered similarly to both groups through videos and booklets, which will be sent in all weekdays during de first week after the initial assessment. Later, one educational material will be sent every two weeks until de 11th week. In the first day, patients will receive a quick welcome video call, in which information will be provided on how this program will work. In the subsequent days, the material will be sent daily and the participants will be able to ask questions, if they want to. The program will cover information regarding the respiratory system, pathophysiology of asthma, asthma treatment, prevention strategies and medication instructions. It will also be briefly addressed the subjects: understanding physical activity and sedentarism, as well as the importance and benefits of being physically active and less sedentary.
41013218|NCT00145054|BEHAVIORAL|MoodHelper Internet program for Depression Self-Help|
41332515|NCT01240304|DRUG|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
41332516|NCT01240304|RADIATION|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
41332517|NCT01240304|PROCEDURE|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
41483042|NCT02031016|DRUG|Fentanyl|"fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
41483043|NCT02031016|DRUG|Remifentanil|starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
41013219|NCT04441450|DRUG|[14C]ICP-022|150mg suspension containing 100μCi of \[14C\]ICP-022
41013220|NCT00773175|DRUG|recombinant human hyaluronidase|150 Units in 1 mL
41013221|NCT04506151|BEHAVIORAL|Sleep-Opt|12-week behavioral intervention
41013222|NCT04506151|BEHAVIORAL|Healthy Living|Healthy Living
41332518|NCT01804257|OTHER|Digital Health Feedback System|The digital health offering passively collects and records medication-taking behavior and other habits of daily living
40814877|NCT01097265|PROCEDURE|adjuvant therapy|
40814878|NCT01097265|PROCEDURE|lymph node mapping|
40814879|NCT01097265|PROCEDURE|sentinel lymph node biopsy|
41483044|NCT02031016|DRUG|Fentanyl|fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
41483045|NCT04598048|BEHAVIORAL|Questionnaire|Patients will complete an EQ-5D questionnaire, medication and lifestyle questions
41483046|NCT02743143|BEHAVIORAL|Exercise therapy|
41483047|NCT02743143|OTHER|Follow-up care as usual|
41483048|NCT03970265|DIAGNOSTIC_TEST|extraction of ELF and ILF from explanted lung tissue; meropenem concentration in ELF and ILF; ELF on postoperative day 1-5 when bronchoscopy is performed within clinical routine.|Interventions will only be performed on explanted lung tissue ex vivo and on supernatant of bronchoscopy and are therefore non-invasive
41483049|NCT05183295|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food
41483050|NCT02199054|OTHER|wheat-safflower oil pretzels|Each serving (6 pieces) of the wheat-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, safflower oil, sugar, yeast, salt, and ascorbic acid.
41332519|NCT06436560|OTHER|STRIVE Peer Support Intervention|A virtual group-based peer support intervention led by trans peers who have had genital gender-affirming surgery.
41483051|NCT02199054|OTHER|soy-safflower oil pretzels|Each serving (6 pieces) of the soy-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, soy flour, soymilk, safflower oil, sugar, yeast, salt, and ascorbic acid.
41483052|NCT02199054|OTHER|control wheat pretzels|Each serving (6 pieces) of the control wheat pretzel contains 6 grams of vegetable shortening. Ingredients in the pretzel are high gluten wheat flour, vegetable shortening, sugar, yeast, salt, and ascorbic acid.
41483053|NCT03831763|DEVICE|ColdZyme|"ColdZyme® Mouth Spray is a CE-marked medical device with the following composition: glycerol, water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme® Mouth Spray consists of a 20 ml bottle, pump, spray nozzle and protective cap."
41483054|NCT02362984|DRUG|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
41483055|NCT02362984|DRUG|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
41483056|NCT00862017|DIETARY_SUPPLEMENT|MSg supplementation|
41332520|NCT02021851|DRUG|Dexamethasone and aprepitant|
41332521|NCT02021851|DRUG|Dexamethasone and ondansetron|
41332522|NCT04521920|DRUG|Suboxone|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
41332523|NCT04521920|DRUG|PrEP|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
41332524|NCT02910219|DRUG|Crofelemer|Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
41483057|NCT00862017|DIETARY_SUPPLEMENT|NaCl supplementation|
41483058|NCT05018520|DRUG|Six Courses of R-CHOP Plus Two Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 2 courses)
41483059|NCT05018520|DRUG|Four Courses of R-CHOP Plus Four Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 4 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 4 courses)
41332525|NCT03347617|DRUG|Ferumoxytol|Given IV
41332526|NCT03347617|OTHER|Laboratory Biomarker Analysis|Correlative studies
41332527|NCT03347617|PROCEDURE|Magnetic Resonance Imaging|Undergo ferumoxytol MRI
41332528|NCT03347617|BIOLOGICAL|Pembrolizumab|Given IV
41332529|NCT00961441|DRUG|Keppra XR|"Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days"
41332530|NCT04690712|BEHAVIORAL|Health Education|"All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy."
41332531|NCT05912036|BEHAVIORAL|CRT|CA-CRT treatment will entail exercises aimed to improve cognitive strategies, encourage subjects' reflection on their way of thinking, and explore the possibility of implementing new schemas in everyday life. The CA-CRT program will employ a range of cognitive exercises and tasks to address cognitive inflexibility and weak central coherence. The treatment will consist of 10 individual CA-CRT sessions, 2 times per week for 5 weeks, for a duration of 40 minutes per session with 15 individual CA-CRT sessions, 3 times a week for 5 weeks, with a duration of 30 minutes per session
41332532|NCT05459792|PROCEDURE|median nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
41332533|NCT05459792|PROCEDURE|radial nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
41332534|NCT05459792|PROCEDURE|local infiltration|intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle
41332535|NCT04016103|DEVICE|MY01 - Continuous Compartmental Pressure Monitor|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
41332536|NCT00005808|DRUG|motexafin lutetium|Given IV
41332537|NCT00005808|DRUG|photodynamic therapy|Undergo laser therapy
41332538|NCT00005808|PROCEDURE|loop electrosurgical excision procedure|Undergo LEEP
41332539|NCT00005808|OTHER|laboratory biomarker analysis|Correlative studies
41483060|NCT05507593|BIOLOGICAL|DLL3-CAR-NK cells|Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
41332540|NCT03481504|BEHAVIORAL|Acceptance & Commitment Therapy-Exposure and Perspective Taking|To increase patients' participation by improving their level of coping with chronic pain.
41483061|NCT00149188|DRUG|Lanreotide (Autogel formulation)|
40814880|NCT01028534|DRUG|Olmesartan and Azelnidipine|"1. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~2. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~3. Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months"
40814881|NCT00192660|DRUG|Lamivudine|
41013223|NCT06500078|BEHAVIORAL|Intermittent dietary restriction|"Intermittent dietary restriction will include the ILCD and ICR, which will be self-administered interventions in daily lives. The ILCD intervention will ask participants to restrict carbohydrate intake to ≤ 50 g/d on two consecutive or discontinuous days per week. The ICR intervention will ask participants to restrict caloric intake to 600 kcal/d for boys and 500 kcal/d for girls on two consecutive or discontinuous days per week.~At baseline, participants will receive face-to-face oral dietary instructions (e.g., principle of dietary restriction, sample menus, food list with macronutrients). Participants will receive the intervention booklets containing dietary advice and sample menus for diet according to the requirements of the dietary intervention.~Participants will be required to record dietary and physical activity data on a regular basis. The total intervention duration will be 12 months, including a 3-month intervention phase and a 9-month self-maintenance phase."
41332541|NCT03704805|BEHAVIORAL|Friendship bench intervention|The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.
41332542|NCT03704805|OTHER|Enhanced Standard of Care|Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
41332543|NCT06216106|PROCEDURE|Prepectoral breast reconstruction with polyurethane implants|Breast reconstruction in the prepectoral plane without elevate the pectoralis major muscle. We choose this type of reconstruction only in patients with mastectomy flap thickness of plus then 0.5 cm. We usally use silicone implants covered by an external layer of polyurethane so not to put directly in contact the silicone with the subcutaneus tissue.
41332544|NCT00005812|DRUG|temozolomide|
41332545|NCT04055467|DRUG|[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)|Brain imaging of alpha-7 nicotinic acetylcholine receptors
41483062|NCT03265366|DEVICE|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
41483063|NCT03265366|DEVICE|CT scan (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
41483064|NCT02206620|DRUG|Donepezil|
40814882|NCT00192660|DRUG|Stavudine|
41013224|NCT06500078|BEHAVIORAL|General health education|General health education based on dietary and physical activity guidelines for Chinese children and adolescents, will regularly send offline and online promotional materials to participants.
41332546|NCT04055467|BEHAVIORAL|Contingency Management|Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
41013225|NCT01701661|PROCEDURE|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
41013226|NCT01701661|OTHER|conservative treatment|Compression stockings class II
41332547|NCT04859972|DIAGNOSTIC_TEST|Diagnosis of IBS|Diagnosis of IBS according to ICD-10
41332548|NCT01920971|RADIATION|infrared therapy|wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
41483065|NCT00003851|BIOLOGICAL|proteolytic enzymes|
41483066|NCT00003851|DRUG|gemcitabine hydrochloride|
41483067|NCT00003851|PROCEDURE|Gonzalez regimen|
41483068|NCT04175743|DRUG|CT-044 HCl|CT-044 HCl is a reactive species decomposition accelerant
41483069|NCT00306163|DRUG|Ciclesonide|inhaled Ciclesonide 160 µg, once daily in the morning
41483070|NCT00306163|DRUG|Fluticasone|inhaled Fluticasone 100 µg, twice daily
41483071|NCT01362127|DRUG|Chemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
41483072|NCT01362127|RADIATION|Radiochemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
41483073|NCT05260164|DEVICE|HIFEM+RF|Combination of High-Intensity Focused Electromagnetic Field (HIFEM) and a high radio frequency (RF) field.
41483074|NCT05837572|OTHER|Standardized meal|"Assessment of the validity of the ES-LFPQ: Each participant will complete the ES-LFPQ in before (fasted state) and after a standardized meal (fed state).~Evaluation of the reproducibility of the ES-LFPQ: With at least one week of difference between tests, each participant will repeat the same protocol performed in the previous visit and under the same conditions."
41483075|NCT04154306|DIETARY_SUPPLEMENT|Red clover|2 weeks of Red clover
41483076|NCT04154306|DIETARY_SUPPLEMENT|Placebo|2 weeks of Placebo
41483077|NCT06020001|DIETARY_SUPPLEMENT|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
40814883|NCT00192660|DRUG|Didanosine|
40814884|NCT00192660|DRUG|Zidovudine|
41332549|NCT01977248|BEHAVIORAL|Sensorimotor Affect Relationship-based Therapy (SMART)|The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
41483078|NCT06020001|DIETARY_SUPPLEMENT|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
41483079|NCT06020001|OTHER|Placebo|Twice a day
41013227|NCT06449781|DRUG|Lutetium (177Lu) vipivotide tetraxetan|The intervention will consist of a single administration of 7,4 GBq of lutetium (177Lu) vipivotide tetraxetan
41332550|NCT02168881|DRUG|Misoprostol|
41332551|NCT02168881|DRUG|Dinoprostone|
41332552|NCT03320889|OTHER|Educational Intervention|Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.
41332553|NCT02969538|OTHER|Total etching time|Apply 35% phosphoric acid on dentin and enamel by 15 seconds.
41332554|NCT02969538|OTHER|Half-reduced etching time|Apply 35% phosphoric acid on enamel by 15 seconds and dentin by 7 seconds.
41332555|NCT04379323|DIAGNOSTIC_TEST|YuWell YE900 Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE900 Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer.
41332556|NCT01279980|OTHER|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
41332557|NCT01279980|OTHER|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
41332558|NCT03101449|OTHER|Finnish tube|Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
41483080|NCT04703582|DIAGNOSTIC_TEST|Activated clotting time|Relationship between elongated baseline activated clotting time and comorbidity
41483081|NCT02794857|DRUG|NP001|
41483082|NCT02794857|DRUG|Placebo|
41483083|NCT02796131|DRUG|RDX5791|
41483084|NCT02796131|DRUG|Placebo|Placebo
41483085|NCT01524250|DRUG|corticosteroids|1250mg of oral prednisone daily for 3 days
41483086|NCT01524250|DRUG|corticosteroids|1000mg IV methylprednisolone daily for 3 days
41013228|NCT00333112|DRUG|solifenacin succinate|Oral
41013229|NCT00333112|DRUG|tamsulosin|oral
41013230|NCT00333112|DRUG|placebo|oral
41013231|NCT01435005|OTHER|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
41013232|NCT01435005|OTHER|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
41483087|NCT00004402|DRUG|calcitriol|
41013233|NCT03150342|DIAGNOSTIC_TEST|myocardial perfusion imaging|dipyridamole-stressed MPI scan using thallium-201
41013234|NCT05022823|DEVICE|Compression sleeve, worn during exercise|Participants wear their daytime compression sleeve during the DPRE program.
41013235|NCT05022823|DEVICE|Adjustable Compression (AC) garment, worn during exercise|Participants wear an Adjustable Compression (AC) garment during the DPRE program. Participants will be fitted for an Adjustable Compression garment and instructed in its application by a physical therapist.
41013236|NCT05022823|DEVICE|Compression sleeve, daytime wear|Compression sleeve worn for at least 12 hours per day, seven days a week.
41332559|NCT03101449|OTHER|Staw phonation|Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
41332560|NCT05616169|DEVICE|Easy Flype/EasyHiFlype|Patients with stenosis or occlusion of the iliac artery, femoral artery and first third of the popliteal artery, implanted with at least one study device, the Easy Flype or the Easy Hi Flype.
41332561|NCT04436588|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
41332562|NCT01444872|DRUG|TRV120027|IV infusion
41332563|NCT01444872|DRUG|Normal Saline|IV infusion
41332564|NCT01207284|OTHER|Physical Therapy|strengthening passive and active stretching balance training gait training
41332565|NCT02227472|OTHER|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
41332566|NCT02227472|OTHER|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
41332567|NCT03222219|PROCEDURE|dental implant insertion|the registration of the torque values is discriminant for the group assignment after dental implant insertion
41332568|NCT00639262|DRUG|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
41332569|NCT00639262|DRUG|Temozolomide|For Cohort 2 - Gliomas only.
41332570|NCT00639262|RADIATION|Radiotherapy|Radiation Therapy (XRT)
41332571|NCT01369225|DRUG|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
41332572|NCT01369225|DRUG|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
41483088|NCT00004402|DRUG|interferon gamma|
41483089|NCT03167593|DIETARY_SUPPLEMENT|Lactobacillus coryniformis K8 CECT5711|Lactobacillus coryniformis CECT5711
41483090|NCT03167593|OTHER|Control placebo|Maltodextrin
41483091|NCT02960919|DRUG|oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin|
41483092|NCT02960919|DRUG|parenteral ampicillin/ penicillin|
41483093|NCT02960919|DRUG|gentamicin|
41483094|NCT03195036|BEHAVIORAL|Home-based ECD services|Health facilities will be randomized to intervention and control groups. The clients at clinics assigned to the intervention group will receive Home-based Early Childhood Development (ECD+) program. The clients at clinics assigned to the control group will not receive the Early Childhood Development (ECD) program.
41483095|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
41483096|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
41483097|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
41483098|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
41332573|NCT01369225|DRUG|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
41332574|NCT01369225|DRUG|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
41332575|NCT01369225|DRUG|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
41332576|NCT00032617|PROCEDURE|Prolonged Exposure|trauma-focused exposure therapy
41332577|NCT00032617|PROCEDURE|Present Centered Therapy|therapy that focuses on current problems
41332578|NCT04198519|OTHER|Weight Loss|The total energy value (TEV) of the diet prescribed for each study participant will be determined by subtracting 800 kcal / day from the total daily energy expenditure, which will be based on Dietary Reference Intake (DRI) recommendations. The distribution of macronutrients will be as follows: protein 15 to 20% of TEV, lipids 25 to 30% of TEV and carbohydrates 50 to 60% of TEV.
41332579|NCT04977973|BEHAVIORAL|Self-guided programme on body image|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
41332580|NCT04977973|BEHAVIORAL|Self-guided programme on cooperation|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
41332581|NCT03765710|OTHER|Recommended protein intake|Recommended protein intake in a mixed meal contained 13% protein, 54% carbohydrate, and 33% fat.
41332582|NCT03765710|OTHER|Elevated protein intake|Increased protein intake in a mixed meal contained 26% protein, 44% carbohydrate, and 30% fat.
41332583|NCT01569997|OTHER|MultiDisciplinary Team Meetings (MDTM)|The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
41332584|NCT03929523|DEVICE|End-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)|"In the experimental group, ECD liver grafts will first undergo a classical static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until transport to the transplantation center. They will then undergo a hypothermic oxygenated perfusion (HOPE) via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the back-table phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion Solution (Belzer-MPS, CE-certified)."
41332585|NCT03929523|DEVICE|classic static cold storage|The control group will consist of a classic static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold standard procedure in liver transplantation
41332586|NCT02228824|DRUG|Very low nicotine content cigarettes|0.07 mg nicotine delivery
41332587|NCT02228824|DRUG|Normal nicotine content cigarettes|0.8 mg nicotine delivery
41483099|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
41483100|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
41483101|NCT00004313|DRUG|dehydroepiandrosterone|
41483102|NCT01057381|DRUG|Dexmedetomidine 0.75 mcg/kg|Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
41483103|NCT01057381|DRUG|Morphine 50 mcg/kg|Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
41483104|NCT01057381|DRUG|Morphine 100 mcg/kg|Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
41483105|NCT01057381|DRUG|Dexmedetomidine 1 mcg/kg|Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
41483106|NCT04700280|DRUG|GLPG3970|GLPG3970 film-coated tablet.
41483107|NCT04700280|DRUG|Placebo|Placebo film-coated tablet.
41483108|NCT05862636|BEHAVIORAL|Mindfulness Training|"All participants will follow a mindfulness course consisting of group sessions of 2-3h duration that are organized (nearly) weekly and are spread over a period of eight weeks. The specific timeline and organisation of the course may differ between the participating sites but all courses will involve a comparable amount of contact hours with the mindfulness trainer. Each session consists of guided experiential mindfulness exercises (e.g., body scan, breathing space, breath focus, walk meditation), sharing of experiences of these exercises, reflections in small groups, psychoeducation, and review of home practices.~The mindfulness courses are based on one of the two most well-known MBIs, Mindfulness-Based Cognitive Therapy (Segal et al., 2002) and Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), or a combination thereof. Courses follow a standardised protocol with group sessions and daily homework tasks taught by experienced and certified mindfulness trainers."
41483109|NCT01758055|BIOLOGICAL|Autologous MSCs transplantation|Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
41483110|NCT06125496|OTHER|Pain management|Investigation of relationship between kinesiophobia, physical activity and disability level and pain management in patients with CLBP
41483111|NCT00324311|DRUG|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
41483112|NCT01081314|BEHAVIORAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
41483113|NCT01081314|BEHAVIORAL|PTSD Protocol|A modified version of Prolonged Exposure therapy for PTSD
41483114|NCT06405282|OTHER|Manual Lymphatic Drainage|MLD is a gentle manual technique used to decongest swollen areas and redirect lymphatic flow to non-congested areas
41483115|NCT06405282|DEVICE|Near infrared spectroscopy|Oxygen saturation measurement
40814885|NCT00192660|DRUG|Tenofovir|
40814886|NCT00192660|DRUG|Abacavir|
40814887|NCT00192660|DRUG|Efavirenz (EFV)|
41332588|NCT03001323|DRUG|Degludec|"Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
41332589|NCT03001323|DRUG|Standard long-acting|"Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
41483116|NCT06405282|DEVICE|Temperature|Thermal imaging
41483117|NCT06405282|DEVICE|Tissue Dialectic Constant|TDC captured by lymphatic fluid scanning device
40814888|NCT00192660|DRUG|Nevirapine|
40814889|NCT00192660|DRUG|Indinavir|
41483118|NCT05843799|DRUG|ILB-202|Single i.v. infusion
41483119|NCT05843799|DRUG|Placebo|Single i.v. infusion
41483120|NCT03806842|DEVICE|Easytech group|total shoulder replacement
41483121|NCT01297374|BEHAVIORAL|physical activities, dietician counseling and behavioral changes|One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes
41483122|NCT01461226|BEHAVIORAL|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
41483123|NCT01461226|BEHAVIORAL|Usual care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
41483124|NCT06000735|DEVICE|7-Day Continuous Glucose Monitoring with Abbott Freestyle Libre 2|All participants will go through the same intervention described above
41483125|NCT03822364|DRUG|009-1|Inhaled apomorphine via Staccato aerosol, Dose 1
41483126|NCT03822364|DRUG|active comparator|commercially available apomorphine injector
41483127|NCT03822364|DRUG|009-0|Inhaled placebo via Staccato device
41483128|NCT03822364|DRUG|009-2|Inhaled apomorphine via Staccato aerosol, Dose 2
41483129|NCT03822364|DRUG|009-3|Inhaled apomorphine via Staccato aerosol, Dose 3
41483130|NCT03822364|DRUG|009-4|Inhaled apomorphine via Staccato aerosol, Dose 4
41483131|NCT03822364|DRUG|009-5|Inhaled apomorphine via Staccato aerosol, Dose 5
40814890|NCT00192660|DRUG|Saquinavir|
41483132|NCT00400361|DRUG|RG1507|Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
41483133|NCT05341297|BEHAVIORAL|ParentKIT|The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms. The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
41483134|NCT02254018|DRUG|bivatuzumab mertansine|
41483135|NCT03832699|DRUG|Dydrogesterone 10 MG|Oral progesterone 10 mg TID
40814891|NCT00192660|DRUG|Amprenavir|
40814892|NCT00192660|DRUG|Ritonavir|
40814893|NCT00192660|DRUG|Nelfinavir|
40814894|NCT00192660|DRUG|Tipranavir|
40814895|NCT00192660|DRUG|enfuvirtide (T20)|
40814896|NCT03263130|OTHER|As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap|
40814897|NCT03257111|OTHER|activity monitors|activity monitors are worn on the wrist, much like a watch. Data from the activity monitors will be downloaded once a week and at discharge. Normal hospital and therapy activities will not be altered.
40814898|NCT03240367|OTHER|Coutery|Stapler line bleeding control with coutery
40814899|NCT04710550|DRUG|F18-3F4AP|PET Scan
40814900|NCT04486430|DRUG|Neu2000KWL|1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
40814901|NCT04486430|DRUG|Neu2000KWL|1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
41483136|NCT03832699|DRUG|Endometrin 100Mg Vaginal Insert|Vaginal Endometrin 100 mg twice daily
41483137|NCT06045819|BIOLOGICAL|Blood sampling for venetoclax drug dosage (venous puncture)|8 blood samples for venetoclax and azole antifungal drugs identification and dosage will be taken by venous and capillary punctures throughout management of patients
41483138|NCT01565772|RADIATION|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
41483139|NCT01565772|DRUG|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
41483140|NCT01565772|DRUG|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
41332590|NCT03193450|BEHAVIORAL|telephone-based re-education|Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
41332591|NCT03193450|BEHAVIORAL|First education at the clinic|Patients will receive an instruction card about the drug administration at the clinic by doctors.
41332592|NCT03347006|DIETARY_SUPPLEMENT|SPM Active|"Supplement or placebo will be administered orally between 9 am to 9:30 am.~* Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups \[this will be on a 1:1:1:1:1:1:1:1 ratio\]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval."
40814902|NCT04486430|DRUG|Neu2000KWL|1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
40814903|NCT04486430|DRUG|Placebos|1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours
41332593|NCT04253808|BEHAVIORAL|Carbohydrate-restricted, high-fat diet|"Diet composition was \~45% fats, \~30% carbohydrates, and \~25% proteins. Calorie needs were provided according to what the Bioelectrical Impedance (BIA) device gave as required to maintain bodyweight.~Sources of macronutrients:~* Carbohydrates: from whole grains, dairy products, legumes, fruits, and vegetables.~* Fats: from mono- and polyunsaturated fatty acids, including medium- and long-chain fatty acids.~* Proteins: plant-based proteins and lean animal-based proteins. All meals were provided to the participants throughout the study period and the diet was provided orally unless the patient was on a feeding tube or a feeding tube is ordered by a physician during the study period. Diet texture was according to patients chewing and swallowing abilities. If the patient is on a feeding tube or intake is insufficient, a formula with similar macronutrient composition + a protein supplement was provided."
41332594|NCT04253808|BEHAVIORAL|Regular composition diet|The regular composition diet contained approximately 50-52% carbohydrates, 30% fats, and 18-20% proteins
41332595|NCT04285853|DRUG|Oxycodone|5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
41332596|NCT04285853|DRUG|Placebo oral tablet|"Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets."
41332597|NCT03685110|DEVICE|CoreHip Total Hip Arthroplasty|Replacement of the Hip Joint
41332598|NCT02330445|DRUG|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
41332599|NCT00763243|BEHAVIORAL|Cogmed Working Memory Training Program|The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
41332600|NCT06076772|DRUG|Palbociclib|The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors
41332601|NCT01855945|BIOLOGICAL|Swine Influenza|Comparison of different dosages of vaccines
41332602|NCT01229891|DIETARY_SUPPLEMENT|plain yogurt drink|daily intake of two bottle of plain yogurt drink
40814904|NCT04569864|PROCEDURE|Hypothermic circulatory arrest with unilateral selective anterograde cerebral perfusion|Hypothermic circulatory arrest provides protection to cerebral and visceral organs.
40814905|NCT03974854|DRUG|XELOXIRI-3|chemotherapy with XELOXIRI-3 regimen
41013237|NCT05022823|BEHAVIORAL|Decongestive Progressive Resistance Exercise program|"Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format.~After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually."
41332603|NCT01229891|DIETARY_SUPPLEMENT|vitamin D fortified yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
41332604|NCT01229891|DIETARY_SUPPLEMENT|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
41483141|NCT03532113|BEHAVIORAL|Updating|Updating is trained across 12 sessions using N-back-type exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of the stimuli (numbers vs. symbols) is changed halfway in each session.
40814906|NCT03974854|DRUG|Gemcitabine|chemotherapy with Gemcitabine regimen
40814907|NCT03220932|PROCEDURE|Cytoreductive surgery combined with HIPEC|Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
40814908|NCT03220932|DRUG|Chemotherapy and bevacizumab (CT-BEV)|Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
40814909|NCT04245267|BEHAVIORAL|DIABEMPIC|Patients are attended by 9 diabetes health-care professionals every 2 weeks for 5 months in a shared medical appointment scheme, including individual and group sessions. Patients will be evaluated at the end of the program and 1 year after.
41332605|NCT06231030|OTHER|Validity, Reliability and Adaptation|Expanded Disability Status Scale (EDSS) will be applied by a neurologist to determine the disability level of the individuals included in the study. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be administered by an expert physiotherapist. The questionnaires and scales to be used in the study will be administered by face-to-face interview method twice in total with two weeks intervals. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be applied. The questionnaires and scales to be used in the study will be administered by face-to-face interview method 2 times in total with a 2-week interval.
41332606|NCT02255643|DEVICE|Change of PMT setting|The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
41332607|NCT02143323|DRUG|Augmentin tablet|
41332608|NCT00361218|DRUG|open-label selective serotonin reuptake inhibitor (SSRI)|Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
41332609|NCT04432740|PROCEDURE|Conservative Treatment of Distal Radius Fracture|The purpose of this prospective randomized study was to compare a new reverse sugar tong splint technique that does not immobilize the elbow with a below-arm cast, in terms of patient radiological and clinical outcomes and the ability to maintain fracture reduction.
41332610|NCT01963936|DEVICE|Supreme LMA|
41332611|NCT01963936|DEVICE|Facial mask|
41332612|NCT04807101|DRUG|midazolam alone|elimination of fentanyl from conscious sedation
41332613|NCT04606407|DEVICE|LungFit™|Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
41332614|NCT00228189|BIOLOGICAL|CEA-loaded dendritic cell vaccine|Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
41332615|NCT01967472|DRUG|amodiaquine-artesunate (AQAS) fixed-dose|
41332616|NCT01967472|DRUG|Artemether-lumefantrine combination (AL) dispersable|
41483142|NCT03532113|BEHAVIORAL|Inhibition|Inhibition is trained across 12 sessions with Stroop-like exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of stimuli (letters vs. numbers) is changed halfway in each session.
41483143|NCT03532113|BEHAVIORAL|General knowledge|General Knowledge is trained across 12 sessions. Participants complete four-choice questions relating to general knowledge and vocabulary and are provided with the correct answer and a short explanation. Questions are displayed one by one on a computer screen with a maximum of 20 seconds per question. Each session lasts 30 minutes and includes 2 blocks of 40 new questions each (about 220 seconds per block). Questions with wrong answers are displayed again at the end of each block.
41013238|NCT05022823|BEHAVIORAL|Home exercise program|Participants are provided with a home exercise program that follows the decongestive exercise sequence and instructed to perform the exercise sequence once daily for a 10-15 minute period.
41155983|NCT04059185|OTHER|Play Nicely|"Play Nicely is a brief, multimedia, computer-based educational program. The online program uses narrated modules to enhance parenting skills and promote effective parental responses to normal aggressive behavior in young children. The parent educational module presents a hypothetical situation of one child harming another. As the module progresses the viewer is given 20 different discipline options from which to choose. Participants are encouraged to click on all the options they wish to learn more about. The different options provide ways to respond to the situation and explain that there are discipline choices that are considered Great options, Good options after others have been tried, or There are better options. The length of the program is dependent on how many of the 20 discipline options the participant chooses to learn about, but generally it can be finished in 20-40 minutes."
41483144|NCT04216758|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
41013239|NCT00363987|DRUG|Ketosteril®|1 tablet Ketosteril/5kgBW/d
41155984|NCT04059185|OTHER|Usual care|"Our usual care control group participants receive a resource and referral list for local social services"
41332617|NCT04233710|COMBINATION_PRODUCT|Robot Rehabilitation + tDCS|Robotic therapy with Kinarm Exoskeleton Robot and 1 mA cathodal tDCS applied to contralesional M1 for 20 minutes.
41332618|NCT04233710|BEHAVIORAL|Robotic Rehabilitation + sham tDCS|Robotic therapy with Kinarm Exoskeleton Robot and sham tDCS.
41332619|NCT02070341|DRUG|Polyethylene Glycol|
41332620|NCT02070341|DRUG|Picosalax|
41332621|NCT02740218|OTHER|Patient questionnaire|Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
41013240|NCT00363987|OTHER|diabetic diet|Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
41332622|NCT00124813|DRUG|thalidomide|
41332623|NCT00124813|DRUG|idarubicin|oral idarubicin
41332624|NCT06276842|DRUG|Inferior Alveolar Nerve Block|Administration of a local anesthetic agent around the inferior alveolar nerve to achieve anesthesia in the mandibular region.
41332625|NCT06276842|DRUG|Buccal Infiltration|Administration of a local anesthetic agent into the tissue adjacent to the tooth being treated to achieve localized anesthesia.
41332626|NCT06276842|COMBINATION_PRODUCT|Inferior Alveolar Nerve Block and Buccal Infiltration|Utilization of both the Inferior Alveolar Nerve Block and Buccal Infiltration techniques simultaneously for anesthesia in the mandibular region.
41332627|NCT01978509|DRUG|Low volume prep (Prepopik)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
41332628|NCT01978509|DRUG|Moderate volume prep (Moviprep)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
41332629|NCT01978509|DRUG|High volume prep (Golytely)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
41332630|NCT05793684|DRUG|Period A|Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
41332631|NCT05793684|DRUG|Period B|Week 1: AD816 low dose; Week 2: AD816 high dose
41332632|NCT05793684|DRUG|Period C|Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
41332633|NCT00235664|PROCEDURE|Collection of stool and endotracheal aspirate samples|collection of samples
41332634|NCT01785108|BIOLOGICAL|GAD-Alum (Diamyd) 20 µg|
41332635|NCT01785108|BIOLOGICAL|GAD-Alum (Diamyd) 20 µg X 2|
41332636|NCT01785108|DRUG|Vitamin D|
41332637|NCT01785108|DRUG|Ibuprofen|
41332638|NCT05008146|RADIATION|Baseline [C-11]NOP-1A PET Scan|Radiotracer
41332639|NCT05008146|DRUG|Hydrocortisone|Intravenous, 1mg/Kg
41332640|NCT05008146|RADIATION|Post-hydrocortisone [C-11]NOP-1A PET Scan|Radiotracer
41332641|NCT03245502|BIOLOGICAL|Blood transfusion|The transfusion of erythrocyte suspension
41332642|NCT01614041|DRUG|Usual dose treatment of Tandospirone|Usual dose treatment of Tandospirone, oral, 30 mg/day
40822950|NCT06332664|COMBINATION_PRODUCT|Early Nutrition Intervention|This involves a multidisciplinary team intervention, including oncologists, nutritionists, and nurses. Additionally, the intervention introduces a team-developed mobile application (APP) for the purpose of regular patient follow-ups to identify nutritional risks promptly and facilitate timely interventions. Patients identified as at risk through the app follow-up will be referred to the nutrition clinic for consultation to address nutritional concerns. For advanced-stage cancer patients undergoing monthly chemotherapy hospitalizations, comprehensive assessments encompassing nutrition, psychological aspects, and other facets will be conducted during hospital stays. When deemed necessary, patients will receive dietary guidance and nutritional support.
41155985|NCT02232958|OTHER|Hyperbaric Oxygen Treatment|Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
41155986|NCT04845087|OTHER|Ozonized water|Irrigation of dental implants with ozonized water
41155987|NCT04845087|OTHER|Placebo|Irrigation of dental implants with water
41155988|NCT03126721|DRUG|midazolam|a single oral dose of 2 mg midazolam
41155989|NCT03126721|DRUG|PF-06751979|multiple oral doses of PF-06751979 100 mg a day
41155990|NCT02821689|DRUG|Pirfenidone|Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
41155991|NCT00912054|DRUG|DuoTrav APS|travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily
41155992|NCT00912054|DRUG|Xalacom|XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
41155993|NCT02584075|DRUG|Byetta (Exenatide)|Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
41155994|NCT02584075|DRUG|Glucophage ( Metformin Hydrochloride)|Metformin 500mg Tid
41332643|NCT01614041|DRUG|Comparative high dose of tandospirone treatment|Comparative high dose of tandospirone treatment, oral, 60 mg/day
41332644|NCT04258007|DRUG|Reversal Neostigmine|Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
41332645|NCT04258007|DRUG|Reversal Sugammadex|Interventional Arm Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
41332646|NCT02668952|DRUG|0.9% Normal Saline (0.9% Sodium Chloride) injection|
41332647|NCT02668952|DRUG|Isolyte S injection|
41332648|NCT00880607|DRUG|Intrathecal morphine|Morphine injection is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain.
41332649|NCT00880607|DRUG|Extended Release Epidural Morphine|DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
41332650|NCT05876104|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
41332651|NCT06313853|BEHAVIORAL|COACH-Cog|Oncology clinician intervention components: 1) a brief training video (completed once during the duration of the study following enrollment and randomization), 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments Patient/Care partner dyad intervention components: 1) Care partners (and patients if able) will participate in a one-time communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.
41332652|NCT00964600|PROCEDURE|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
41332653|NCT05167188|OTHER|no intervention|no intervention
41332654|NCT05158530|OTHER|Aerobic training|Aerobic training ( with cycle ergometer, 5-minute warm-up 15 - 30 minute cycle +5 minute cooldown) 40%-60% intensity calculated through Karvonen formula 3 days/ week
41332655|NCT05158530|OTHER|Pulmonary Exercises|"4 weeks protocol~1. Deep breathing Exercises\* 10 Reps 3 sets~2. Postural drainage (10 minutes \* 2 sets /day)~3. Incentive spirometry\* 10 Reps 3 sets~4. Bed activities (Active ankle and hand pumping exercise \* 10 Reps 3 sets)"
41332656|NCT02057068|BEHAVIORAL|SLEEP-E Dyads Intervention|Described in arm/group description
41332657|NCT00601679|OTHER|NT-proBNP guided care|knowledge of NT-proBNP results
41332658|NCT05370079|BIOLOGICAL|Collection of biological sample (blood and/or CSF)|"Blood sample will be collected one time for each patient:~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube~If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml)."
41332659|NCT05441943|PROCEDURE|Lymphovenous anastomosis|"Pre-operative planning prior to lymphovenous anastomosis using ICG lymphography and ultra high frequency ultrasound for mapping of applicable vessels.~During surgery, mapped vessels are freely dissected and anastomosed."
41332660|NCT05668325|OTHER|Mini trampoline exercise group|In this study, patients performed a 30-45 minute mini-trampoline exercise program 3 times a week for eight weeks (two months) under the supervision of the investigator.
41332661|NCT05668325|OTHER|Control group|In this study, patients were visited at home once a week for eight weeks and their feet were checked.
41483145|NCT04216758|DRUG|Gemcitabine|Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
40814910|NCT06318078|OTHER|eCHIS|The electronic Community health Information System (eCHIS) is a Government of Uganda owned application used by community health workers for quality health assessments and improved reporting. The eCHIS intervention allows for the registration of longitudinal profiles for client centered care as well as provides care guidance to aid decision making. For its users, the app has a task tab for schedule management and dashboards for performance help management and impact tracking by supervisors. This app is interoperable with national reporting tools such as DHIS2. The app has ten workflows including registration of households and new persons, death reporting, iCCM assessment, treatment and referral follow up, stock monitoring, data synchronization, pregnancy registration, ANC danger signs and follow up, family planning registration, and screening (tuberculosis, hypertension, sickle cell, tobacco use and net use).
40814911|NCT03505723|DRUG|Tranexamic Acid|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
40814912|NCT03505723|DRUG|Placebo (Saline)|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
40814913|NCT03505723|OTHER|Perioperative hypotension-avoidance strategy|"Perioperative hypotension-avoidance strategy includes:~1. Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,~2. Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg~3. Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery."
40814914|NCT03505723|OTHER|Perioperative hypertension-avoidance strategy|Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.
40814915|NCT00227344|DEVICE|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
40814916|NCT00227344|DRUG|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
40814917|NCT01762735|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
40814918|NCT01762735|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
40814919|NCT04883125|DRUG|Pioglitazone 15mg|pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
40814920|NCT03102047|DRUG|durvalumab|Within 3-7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
41013241|NCT01276899|PROCEDURE|Needle core biopsies|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect tumor samples.~A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
41155995|NCT06149156|BEHAVIORAL|Healthy Minds Program App|The four-week intervention comprises two introductory lessons and guided meditations followed by one week of content for each pillar of well-being. Each week includes two brief lessons (5-7 minutes) with education on the scientific research behind the practices, as well as examples of how to strengthen the skills of each pillar in daily life, along with three guided meditations for which the participant can select the practice length (5-30 minutes).
41155996|NCT06149156|BEHAVIORAL|Well-being Resources|List of well-being resources that comprises of online video links and books
41332662|NCT02098057|DIETARY_SUPPLEMENT|Gluten Healthy|Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
41483146|NCT04216758|DRUG|tegafur|Patients secondly receive tegafur Body surface area \< 1.25 m\^2, 60 mg/d;Body surface area ≥ 1.25 m\^2 to \< 1.5 m\^2, 80 mg/d;Body surface area ≥ 1.5 m\^2, 100 mg/d (po) on days 1-21 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
41483147|NCT00395174|BIOLOGICAL|Influenza Vaccination|0.5mL dose for intramuscular injection
41483148|NCT02219971|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
41483149|NCT04397445|DRUG|Ranitidine|Ranitidine 300 mg
41483150|NCT04397445|DRUG|Placebo|Oral placebo tablet
41483151|NCT04397445|OTHER|Low nitrite/NDMA meals|Meals containing low levels of nitrites and NDMA
41483152|NCT04397445|OTHER|High nitrite/NDMA meals|Meals containing higher levels of nitrites and NDMA
41483153|NCT03010982|DRUG|Tazemetostat and [14C] Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2.
41483154|NCT01997229|BIOLOGICAL|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
41483155|NCT01997229|DRUG|Placebo|Placebo
41483156|NCT01955655|DRUG|Baclofen|Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.
41483157|NCT01955655|OTHER|Placebo|
41332663|NCT02098057|DRUG|Placebo|"A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks."
41332664|NCT06065904|BEHAVIORAL|Nutrilect|This intervention involves a comprehensive approach that includes a thorough nutritional assessment and individualized nutrition plan for children with cerebral palsy (CP) and Autism Spectrum Disorder (ASD), addressing their unique dietary needs and challenges. It encompasses nutritional counseling, dietary modifications when necessary, and seamless integration with other therapies, including speech therapy and psychological consultation. The overarching goal is to optimize growth, muscle function, and overall well-being in these children by providing tailored nutritional support alongside a holistic care approach.
41013242|NCT01276899|PROCEDURE|Needle core biopsies of metastatic lesion|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect metastasis tumor samples.~Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
41332665|NCT01744457|DEVICE|Measurement of tear film osmolarity with the TearLab® instrument|
41332666|NCT01744457|OTHER|Schirmer I test|
41332667|NCT01744457|OTHER|Tear break up time|
41013243|NCT00953797|DEVICE|Enhanced External Counterpulsation|A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.
41332668|NCT01744457|DEVICE|Optical Quality Analysis System|Measurement of the objective scattering index (OSI)
41332669|NCT01744457|OTHER|Ocular Surface Disease Index|
41332670|NCT03615326|BIOLOGICAL|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
41483158|NCT02500641|DRUG|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration \> 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
40814921|NCT03955224|DEVICE|Basic Oral Care + active LLLT|"* Compliance with the Basic Oral Care Associated with~* Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
41332671|NCT03615326|BIOLOGICAL|Placebo|Solution for IV infusion on Day 1 of each 3-week cycle.
41332672|NCT03615326|DRUG|Cisplatin|80 mg/m\^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
41332673|NCT03615326|DRUG|5-FU|800 mg/m\^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.
41332674|NCT03615326|DRUG|Oxaliplatin|130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.
41332675|NCT03615326|DRUG|Capecitabine|1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
41332676|NCT03615326|DRUG|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.
41332677|NCT03615326|BIOLOGICAL|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
41332678|NCT04114344|PROCEDURE|TAPP|Trans Abdominal Pre Peritoneal approach
41332679|NCT04114344|PROCEDURE|TEP|Total Extra Peritoneal approach
41332680|NCT04507178|DRUG|Nadroparin Injectable Product|high dose LMWH compared to prophylactic dose LMWH
41483159|NCT02500641|DRUG|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration \>6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
41483160|NCT02500641|DRUG|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
41013244|NCT06067594|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement|Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.
41013245|NCT01809626|DRUG|Zolpidem|
41013246|NCT01809626|OTHER|Placebo|
41332681|NCT03842956|PROCEDURE|Primary wound closure in Allgower Technique vs. secondary open wound healing of pin-sides after removal of the fixated-externe|We compare the outcome of primary wound closure (Allgower) and secondary open wound healing by comparing infection-rates, use of antibiotics, reoperation-rates, satisfaction of the patients and optical results using the Vancouver scar scale
41332682|NCT03775174|DRUG|Mepsevii|
41332683|NCT02620735|DEVICE|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
41332684|NCT02620735|BEHAVIORAL|Exercise Only|12 week exercise program
41332685|NCT02620735|BEHAVIORAL|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
41155997|NCT05221216|OTHER|Collect data of medical record|Collect data of medical record: plasma concentrations of cotrimoxazole, demographic data (age, weight, height), data on the use of an extra renal replacement therapy (RRT) (date, type, number of sessions and duration of extra renal replacement therapy (RRT))
41483161|NCT02500641|DRUG|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
41483162|NCT02500641|DRUG|Omeprazole|Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
41483163|NCT03797820|OTHER|Our study type is observational|Our study type is observational
41483164|NCT03668821|OTHER|Questionnaire|Quality of life and frailty questionnaires
41483165|NCT02106650|DRUG|Folotyn and Leucovorin|
41483166|NCT02106650|DRUG|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
41483167|NCT02106650|DRUG|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
41483168|NCT04610463|DIAGNOSTIC_TEST|Cardiac flow measurement|Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
41483169|NCT04556552|DEVICE|Non invasive VN stimulation (nVNS)|"Stimulation of vagus nerve with active device. Participants will be administered nVNS using the electroCore GammaCore-S non-invasive VNS device. The intensity of the stimulus will be adjusted by the user, to the maximum tolerable level to ensure nVNS without causing excessive pain, the burst frequency to 5 kHz, and the envelope frequency to 25 Hz.~The duration of delivery will be 2 minutes, and the beginning will coincide with initiation of acquisition of the HR-PET scan which will be 90 seconds in duration; following an additional 8 minutes, a second VNS delivery will be administered, in conjunction with which another scan will be obtained."
41483170|NCT04556552|DRUG|Oxygen (15-O) Water|Injection of radiolabelled water. H2\[15-O\] is a radioactive material. Each patient will have eight H2\[15-O\] blood flow scans. For each O-15 water scan 20 mCi of H2\[15O\] will be injected as an intravenous bolus.
40814922|NCT03955224|OTHER|Basic oral Care + inactive LLLT|"* Compliance with the Basic Oral Care Associated with~* Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
40814923|NCT03955224|OTHER|Basic Oral Care|Compliance with the Basic Oral Care only
41013247|NCT05371587|OTHER|Autonomy and Perceptions Approach to Resistance Training (APART)|Alternative resistance training prescription based on trainees' autonomy and perceptions.
40814924|NCT03806556|DRUG|Tranexamic Acid|IV medication administered after patient meets inclusion/exclusion criteria
41013248|NCT05371587|OTHER|Standard prescription|Standard resistance training prescription, based on international organization's guidelines.
41332686|NCT02620735|BEHAVIORAL|Health Coaching|10 over the phone health coaching sessions.
41483171|NCT04556552|DEVICE|Sham Stimulation|"Sham stimulation of vagus during opioid cue exposure. Each subject in the SHAM group will undergo the action of administering the intervention, but the device will be programmed such that the stimulation will not activate the vagus nerve."
41483172|NCT01195272|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
41483173|NCT04153019|OTHER|Psychoeducational and rehabilitative intervention|Psycho-educational session: 3 weekly face-to-face consultations between a dyads and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
41483174|NCT02410356|DRUG|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
41483175|NCT02410356|DRUG|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
41483176|NCT05897268|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
41483177|NCT05897268|DRUG|Tislelizumab|a PD-1 immune check inhibitor
41483178|NCT05897268|DRUG|Lenvatinib|Lenvatinib capsules
40814925|NCT03806556|DRUG|Normal saline|IV medication administered after patient meets inclusion/exclusion criteria
40814926|NCT03028844|OTHER|Music therapy|The musical intervention will be played for ten minutes prior to venepuncture
40814927|NCT00072943|DRUG|anti-Interferon-gamma monoclonal antibody|
40814928|NCT01231542|DRUG|GSK1349572|GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
40814929|NCT01231542|DRUG|Rifampin|Rifampin is approved by the FDA for the treatment of tuberculosis.
40814930|NCT01231542|DRUG|Rifabutin|Rifabutin is approved by the FDA for the treatment of tuberculosis.
40822951|NCT03564964|DRUG|SUVN-502|Tablet
41332687|NCT01194869|DRUG|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
41332688|NCT01194869|DRUG|Cisplatin|75 mg/m² given IV
41332689|NCT01194869|DRUG|Paclitaxel|175 mg/m² given IV
41332690|NCT04570969|PROCEDURE|Erector spinae plane block|Insertion of bilateral catheters in the intersfacia space of erector spinae muscle
41332691|NCT00623285|DRUG|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
41332692|NCT00623285|DRUG|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
41332693|NCT04204798|DRUG|Dexmedetomidine|"1. Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.~2. For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.~3. For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events."
41332694|NCT04204798|DRUG|Placebo|"1. Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.~2. Propofol sedation is administered when considered necessary."
41332695|NCT06033690|BEHAVIORAL|multidisciplinary guide|use of the food guide for education, clarification of doubts
41332696|NCT06424392|OTHER|General Health Questionnaire (GHQ-28)|Anxiety and depression self-reported scales for both parents
41332697|NCT06424392|OTHER|State-Trait Anxiety Inventory (STAI-Y)|Anxiety and depression self-reported scales for both parents
41332698|NCT06424392|OTHER|Revised Children's Manifest Anxiety Scale (RCMAS)|Anxiety and depression self-reported scales for children
41332699|NCT06424392|OTHER|World Health Organization Quality of Life (WHOQOL-BREF)|Quality of life self-reported scales for parents
41332700|NCT06424392|OTHER|Quality of life measure for children (KIDSCREEN-27)|Quality of life self-reported scales for children
41332701|NCT06424392|OTHER|"Parental Educational Competence Self-Evaluation Questionnaire Questionnaire d'Auto-Évaluation de la Compétence Éducative Parentale (QAECEP)"|Parental Educational Competence Self-Evaluation self-reported Questionnaire for parents
41332702|NCT06424392|OTHER|Parental interview|The interview will only last about ten minutes and will take place during the first call, if the parents have agreed and are sufficiently available to answer. If the parents are not available, an appointment can be made at a later date
41332703|NCT02925208|OTHER|cochlear implant surgery|patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
41332704|NCT00182507|DRUG|Olanzapine|
41332705|NCT03123484|DRUG|β-elemene|β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days
41332706|NCT03123484|DRUG|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
41332707|NCT02844673|DRUG|Hydroxyurea|Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
41332708|NCT02844673|DEVICE|Mobile Directly Observed Therapy|Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
41332709|NCT00611988|BEHAVIORAL|Self-managed walking|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
41332710|NCT00611988|OTHER|Control group|Attention control group will receive routine follow-up phone calls
41332711|NCT01810380|DRUG|Placebo|Once daily as tablets and capsules, orally
41483179|NCT05816369|OTHER|Taste session of five ONS flavors|Patients will taste a small sample (30 mL) of five ONS flavors and report their taste experiences by completing questionnaires of each flavor during the taste session. Participants will also complete a malnutrition risk screening (MST), a three-day food diary, questionnaires of self-reported taste and smell changes (TSS), and quality of life (RAND-36).
41013251|NCT04989803|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
41332712|NCT01810380|DRUG|Brexpiprazole|2-4 mg/day, once daily, tablets, orally
41332713|NCT01810380|DRUG|Quetiapine extended release|400-800 mg/day, once daily, encapsulated tablets, orally
41332714|NCT01655069|DRUG|Solifenacin succinate suspension|Oral suspension
41332715|NCT01632072|DIETARY_SUPPLEMENT|Nutritional support|Nutritional support and counseling
41332716|NCT03470311|BIOLOGICAL|Benralizumab|30mg in 1mL pre-filled syringe
41332717|NCT03470311|BIOLOGICAL|Placebo|Matched placebo (1mL) in pre-filled syringe
41332718|NCT04038385|BEHAVIORAL|Multilevel Behavioral Intervention|Behaviorally-focused intervention grounded in the Social Ecological Model and Social Cognitive Theory to promote vegetable intake and the redemption of seasonal Farmers' Market Nutrition Program vouchers and monthly Cash Value Vouchers at farmers' markets.
41483180|NCT02593513|DEVICE|Daifert|
41483181|NCT02593513|PROCEDURE|Control Group|Control - Morphological Assessment
41013252|NCT04989803|DRUG|Fludarabine|Lymphodepleting chemotherapy administered intravenously
41013253|NCT04989803|BIOLOGICAL|KITE-363|A single infusion of CAR-transduced autologous T cells administered intravenously
41013254|NCT04989803|BIOLOGICAL|KITE-753|A single infusion of CAR-transduced autologous T cells administered intravenously
41013256|NCT06040502|BEHAVIORAL|The DICE Approach|Systematic guidance for care partners through assessment and management of the behavioral and psychological symptoms of dementia
41013257|NCT05203614|BEHAVIORAL|Household Contribution|Questionnaires
41013258|NCT05203614|BEHAVIORAL|Outside Contribution|Questionnaires
41013259|NCT05203614|BEHAVIORAL|Control|Questionnaires
41013260|NCT00001309|OTHER|Vitamin C|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
41013263|NCT06028022|DIETARY_SUPPLEMENT|Mushroom Extract|Given Reishi mushroom extract PO
41013264|NCT06028022|DRUG|Placebo Administration|Given PO
41013265|NCT06028022|OTHER|Quality-of-Life Assessment|Ancillary studies
41013266|NCT06028022|OTHER|Questionnaire Administration|Ancillary studies
41483182|NCT03095313|OTHER|18F-NaF|"At baseline a target dose of 125 MBq 18F-NaF will be administered intravenously to all subjects who will then undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. 125ml of iodine-based contrast agent (iohexol \[Omnipaque™\]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.~Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves."
40814931|NCT03046095|OTHER|Unilateral Resistance Exercise|Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
40814932|NCT03046095|PROCEDURE|Immobilization|During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
40814933|NCT02407340|DRUG|oxytocin|40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
41013274|NCT03783351|GENETIC|CYP2C19 genotype testing|CYP2C19 genotype testing will be conducted in a designated central laboratory.
41483183|NCT01349101|RADIATION|Total Body Irradiation|"Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)"
41332719|NCT04992637|BEHAVIORAL|ClockWork|ClockWork is a behavioral weight loss intervention comprised of coaching sessions as well as digital monitoring and feedback tools. It addresses 4 key behaviors related to the CTS, weight, and health and their Amount, Regularity \& Timing-the ART of ClockWork. Women will receive 12 tailored coaching sessions to review their digital monitoring of each key behavior, learn intervention content, and set goals, which are delivered in-person, by phone, or web to fit women's needs postpartum. Coaches will use women's baseline responses to tailor sessions around the key behaviors. The investigators will protocolize real-time monitoring to increase engagement and adherence, and to facilitate just-in-time adaptive reminders, recommendations, and coaching sessions.
41332720|NCT04992637|OTHER|Usual Care|Usual Care consists of the standard care that postpartum women receive without any additional intervention components.
41483184|NCT01349101|DRUG|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
41332721|NCT02314598|OTHER|No treatment|
41332722|NCT02418767|DRUG|MOD-4023|
41332723|NCT02418767|DRUG|Placebo|
41332724|NCT00385463|DRUG|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
41332725|NCT00005945|DRUG|cyclophosphamide|Given IV
41332726|NCT00005945|DRUG|cytarabine|Given IT
41332727|NCT00005945|DRUG|daunorubicin hydrochloride|Given IV
40814934|NCT02407340|DRUG|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
40814935|NCT05718167|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.
41483185|NCT01349101|DRUG|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
41483186|NCT01349101|DRUG|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
41483187|NCT01349101|DRUG|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
41483188|NCT01349101|DRUG|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
41332728|NCT00005945|DRUG|dexamethasone|Given PO
41332729|NCT00005945|DRUG|doxorubicin hydrochloride|Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
41332730|NCT00005945|DRUG|mercaptopurine|Given PO
41483189|NCT01349101|GENETIC|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
41483190|NCT03507348|DRUG|visits of tocilizumab injection (every 4 weeks, up to 5 visits)|every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).
41332731|NCT00005945|DRUG|methotrexate|Given PO and IT
41483191|NCT03507348|DRUG|Rituximab 375 mg/m2 at Day-30|Rituximab 375 mg/m2 at Day-30
41483192|NCT03507348|DRUG|Rituximab 375 mg/m2 at Day-15 (only for donors living)|Rituximab 375 mg/m2 at Day-15
41483193|NCT03507348|OTHER|Transplant Day-0|TRANSPLANTATION
41483194|NCT03653052|DRUG|Durvalumab|Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
40814936|NCT05718167|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.
40814937|NCT05718167|DRUG|Tislelizumab injection|Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
40814938|NCT00374946|DEVICE|THA|
40814939|NCT04123093|DEVICE|Noxsano Bandage (Healthy Volunteers)|Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
40822952|NCT03858335|OTHER|Constraint-induced movement therapy|The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
41332732|NCT00005945|DRUG|pegaspargase|Given IM
40822953|NCT00129701|PROCEDURE|Telephone consultation|
41332733|NCT00005945|DRUG|thioguanine|Given PO
41332734|NCT00005945|DRUG|vincristine sulfate|Given IV
41332735|NCT00005945|RADIATION|radiation therapy|Undergo radiation therapy
41332736|NCT02394418|DRUG|Sevoflurane|Treatment of delirium by inhaled sevoflurane
41332737|NCT02394418|DRUG|Propofol|Treatment of delirium by propofol i.v. infusion
41332738|NCT02394418|DRUG|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
41332739|NCT05610969|OTHER|Music|patients in this group will receive self-selected music after the golden moment has been completed between the patient, provider, and nursing staff
41332740|NCT05610969|DRUG|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
41332741|NCT00962754|PROCEDURE|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
41332742|NCT00753597|DRUG|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
41483195|NCT02957266|RADIATION|Volumetric Arc Radiotherapy|Volumetric Arc Radiotherapy
41483196|NCT02957266|RADIATION|Interstitial brachytherapy|Interstitial High Dose Rate Brachytherapy
41483197|NCT02957266|DRUG|Cisplatin|Weekly Cisplatin
41483198|NCT02957266|DRUG|Gemcitabine|Weekly Gemcitabine
41483199|NCT02957266|GENETIC|PIK3CA|PIK3CA mutations rate
41483200|NCT02957266|GENETIC|KRAS|KRAS mutations rate
41483201|NCT02957266|GENETIC|BRAF|BRAF mutations rate
41483202|NCT02957266|GENETIC|RRM1|RRM1 mutations rate
41483203|NCT03913260|DRUG|LY3375880|Administered SC
41332743|NCT05968716|OTHER|Social needs screening protocol|Pediatric hospital ward stakeholders will develop and implement a social needs screening protocol designed to screen families of hospitalized children for social risk factors and then provide resources to address their social needs. The intervention will consist of the protocol that is developed and implemented.
41332744|NCT02448017|DEVICE|The Herbst appliance|Orthodontic functional appliance
41332745|NCT02448017|DEVICE|Twin block appliance|Orthodontic functional appliance
41332746|NCT03356483|DRUG|Psilocybin (0.25mg/kg)|Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.
41332747|NCT03356483|DRUG|Niacin (250mg)|A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.
41332748|NCT00371540|OTHER|Home visit by community care coordinators|Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
41332749|NCT00517205|PROCEDURE|Non-contrast helical computerized tomogram (NCHCT)|
41332750|NCT03514888|PROCEDURE|HIPEC|40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
41332751|NCT05445141|BEHAVIORAL|Little ACF [in Swedish: Lilla ABC]|Little ACF is a modified version of the program called All Children in Focus \[in Swedish: Alla Barn i Centrum (ABC)\] that originally is developed for parents with children 3-12 years of age. The content is based on positive developmental psychology and involves role plays, discussions and exercises to try at home with the child. Printed material will be provided to the parents at each meeting/session. Little ACF is offered once a week during four weeks. Each session is 60 minutes, thereafter the parents can stay in the facility for 30 minutes to continue discussing with each other.
41332752|NCT05445141|BEHAVIORAL|Lectures|The lectures are pre-recorded and available during four weeks. Each lecture is 10 minutes and the content is similar to, but more superficial than, the content in Little ACF.
41332753|NCT00024193|BIOLOGICAL|filgrastim|
41332754|NCT00024193|DRUG|busulfan|
41332755|NCT00024193|DRUG|cisplatin|
41332756|NCT00024193|DRUG|cyclophosphamide|
41332757|NCT00024193|DRUG|doxorubicin hydrochloride|
41332758|NCT00024193|DRUG|etoposide|
41332759|NCT00024193|DRUG|melphalan|
41332760|NCT00024193|DRUG|vincristine sulfate|
41332761|NCT00024193|PROCEDURE|conventional surgery|
41332762|NCT00024193|PROCEDURE|peripheral blood stem cell transplantation|
41332763|NCT03771807|DIETARY_SUPPLEMENT|Beauty From Within|one scoop of product mixed in 8-16 ounces of water consumed once daily
41332764|NCT03771807|OTHER|Placebo|one scoop of product mixed in 8-16 ounces of water consumed once daily
41332765|NCT03771807|OTHER|Facial cleansing|All subjects will use a cosmetic instrument to clean on one half of their face daily
41332766|NCT05112484|DIAGNOSTIC_TEST|Measurement of concentrations of orally-used DMDs|"For effectiveness - the measured concentrations of orally used DMDs will be correlated with the clinical condition of patients with MS (usual clinical examinations such as physical assessment of clinical condition, evaluation of EDSS scale, MSQOL-54 quality of life questionnaire, and routine magnetic resonance imaging of the brain once a year). At the same time, the relationship between the measured concentrations of orally used DMDs and the concentrations of other biomarkers of MS, such as signs of axonal (so-called plasma neurofilament light chain - pNfL) and glial (so-called chitinase 3-like 1 - CHI3L1) damage, will be analyzed. concentrations of selected cytokines, concentrations of CD4 + and CD8 + T-lymphocytes, and the results of a genetic examination of drug transporters, again with an effect on the clinical condition of the patient."
41332767|NCT05112484|DIAGNOSTIC_TEST|Genetic testing|One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.
41332768|NCT05112484|DIAGNOSTIC_TEST|Parameters for routine use of DMDs|"For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs)."
41332769|NCT05112484|OTHER|Side effects of orally used DMDs|"For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed."
41332770|NCT06260904|DRUG|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) orally
41332771|NCT06260904|DRUG|Apremilast|Apremilast 30 mg twice daily orally
41332772|NCT06260904|DRUG|Methotrexate|Methotrexate 15 mg weekly orally
41332773|NCT01660230|BIOLOGICAL|3K3A-APC, diluted in 0.9% sodium chloride in water|
41332774|NCT01660230|DRUG|0.9% NaCl in water|
41483204|NCT03913260|DRUG|Buffer Matrix (No LY3375880)|Administered SC
41483205|NCT03913260|DEVICE|Autoinjector (AI)|AI used to administer LY3375880 or Buffer Matrix
40822954|NCT01069861|DRUG|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
41332775|NCT02925559|DRUG|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
41483206|NCT03913260|DEVICE|Manual Syringe|Manual syringe used to inject LY3375880
41483207|NCT02631018|BEHAVIORAL|Standard Weight Loss Intervention|18 session, group-based, 6-month, standard behavioral weight loss intervention
41483208|NCT02631018|BEHAVIORAL|Physical Activity Enhanced Weight Loss Intervention|18 session, group-based, 6-month, physical activity enhanced behavioral weight loss intervention
41332776|NCT02925559|DRUG|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
41332777|NCT02667392|PROCEDURE|Gait Training with Biofeedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded."
41332778|NCT02667392|PROCEDURE|Gait Training with Verbal Feedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation."
41332779|NCT05315141|OTHER|No Intervention|No Intervention
41332780|NCT00127088|DRUG|docetaxel|
41332781|NCT00127088|PROCEDURE|laparoscopic radical prostatectomy|
41332782|NCT01711541|DRUG|Carboplatin|Given IV
41483209|NCT00065455|DRUG|Vitamin A|
41483210|NCT05253274|DEVICE|Virtual Reality Glasses|In addition to the routine practice of the emergency service, the virtual reality (VR) group will watch a video with VR glasses during the emergency surgical intervention under local anesthesia. Before the emergency surgery, the patients will be asked to wear a VR glasses compatible with mobile phones with android operating system and a headset that minimizes sound loss. Patients will be shown their preferred 3D licensed video software with relaxing music in the background. VR glasses will be put on the patients before starting the emergency surgical procedure under local anesthesia and applied until the procedure was completed. Patients will be asked to refill the The State Anxiety Inventory at the end of the emergency surgical intervention. At the same time, blood pressure, heart rate, respiratory rate, SpO2 values will be monitored on a portable monitor.
41483211|NCT05397561|OTHER|Turkish Translation of Physical Activity Barriers and Facilitators Scale|Participants to be included in the study will be listed under a special code (traffic code of their city of birth, date of birth and order of participation). The socio-demographic characteristics, age, gender, body weight, height and Body Mass Index (BMI) of the participants will be evaluated and recorded with a specially prepared evaluation form. All participants in the study will complete the Turkish version of the PABFS, the Physical Activity Disability Scale (PADS), the Motivation for Participation in Physical Activity Scale (MPPAS), and the International Physical Activity Questionnaire (IPAQ) at their first visit. Participants will complete the BFYPA again after 7 days.
41483212|NCT01677923|DRUG|Metformin|Metformin 500 mg BID for 12 months
41483213|NCT04761874|OTHER|Telestroke|In the telestroke cohort, acute ischemic stroke patients at a single comprehensive stroke center received their stroke care and management exclusively via telestroke.
41483214|NCT04683757|OTHER|Establishment of a Survival Prediction Model|a nomogram to predict the survival of patients with ER positive / HER-2 negative advanced breast cancer
41483215|NCT00944112|BIOLOGICAL|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
41483216|NCT00944112|BIOLOGICAL|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
41483217|NCT02269163|BIOLOGICAL|Immune Globulin Intravenous|Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product
40822955|NCT02906215|BEHAVIORAL|Care Coordination Intervention|cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
40822956|NCT01656343|DRUG|Calcineurin inhibitors (CNI)|No Intervention
41332783|NCT01711541|DRUG|Cisplatin|Given IV
41332784|NCT01711541|DRUG|Fluorouracil|Given IV
41332785|NCT01711541|DRUG|Hydroxyurea|Given PO
41332786|NCT01711541|OTHER|Laboratory Biomarker Analysis|Correlative studies
41332787|NCT01711541|DRUG|Paclitaxel|Given IV
41332788|NCT01711541|OTHER|Placebo Administration|Given PO
41332789|NCT01711541|RADIATION|Radiation Therapy|Undergo radiation therapy
41332790|NCT01711541|DRUG|Veliparib|Given PO
41332791|NCT00832481|DRUG|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
41332792|NCT00832481|DRUG|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
41332793|NCT06206707|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Capsule FMT
40822957|NCT01656343|DRUG|Belatacept|No Intervention
40822958|NCT02438956|DIETARY_SUPPLEMENT|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
41332794|NCT06206707|PROCEDURE|Placebo|Placebo capsules
41332795|NCT06219668|PROCEDURE|Omentopexy group|Omentopexy and Clips on staple line during LSG
41332796|NCT00562640|BIOLOGICAL|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
41332797|NCT00562640|BIOLOGICAL|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
41332798|NCT00562640|DRUG|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
41332799|NCT00562640|OTHER|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
41332800|NCT06456138|DRUG|Trametinib|Trametinib will be administrated orally every day.
41332801|NCT06456138|DRUG|Anlotinib|Anlotinib will be administrated orally from day 1 to day 14 per 21-day cycle.
41332802|NCT06456138|DRUG|Tislelizumab|Tislelizumab will be administered at full dose (200mg, Q3W) on the patient who received the efficacy evaluation of stable disease (SD) or partial response (PR) or complete response (CR) after 2 cycles' treatment of trametinib plus anlotinib.
41332803|NCT04978480|OTHER|no intervention|There is no intervention. We are only collecting standard of care data.
41332804|NCT05195268|PROCEDURE|Intracardiac Catheter Ablation|Both arms will receive intracardiac catheter ablation procedures as described.
41332805|NCT00317876|DRUG|cyclophosphamide|
41332806|NCT00317876|DRUG|cyclosporine|
41332807|NCT00317876|DRUG|methotrexate|
41332808|NCT00317876|PROCEDURE|allogeneic bone marrow transplantation|
41332809|NCT00317876|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
41332810|NCT03405155|BIOLOGICAL|Nivolumab|Given IV
41332811|NCT05068388|DRUG|Z-Endoxifen|Z-Endoxifen
41332812|NCT05068388|DRUG|Placebo|Placebo
41483218|NCT02269163|BIOLOGICAL|Prometic's Immune Globulin Intravenous 10%|Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
41483219|NCT03344926|BEHAVIORAL|ACTsmart|"Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.~Treatment content is divided into four modules:~1. education about pain behaviors, exposure and acceptance and commitment therapy~2. education about pain physiology~3. exercises on changing behaviors, acceptance, mindfulness, defusion and exposure~4. value based exposure in the participant's daily life"
41483220|NCT04906252|DIAGNOSTIC_TEST|Echocardiography|Patients presenting in cardiac arrest will undergo echocardiography as is the standard of care at their institution
41483221|NCT04906252|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Patients presenting in cardiac arrest will undergo an electrocardiogram (ECG) as is the standard of care at their institution
41332813|NCT05565157|PROCEDURE|Zygomatic implants|A robotic assisted new strategy for positioning zygomatic implants will be performed and its efficacy and accuracy will be assess
41332814|NCT02884271|PROCEDURE|cardiopulmonary resuscitation|start cardiopulmonary resuscitation
41332815|NCT01721148|DRUG|ASLAN002( BMS 777607)|100mg, 200mg, 300mg, 450mg, 600mg
41332816|NCT03564236|DEVICE|Nasal High Flow Therapy|Nasal High Flow Therapy (nHFT) is an innovative therapy for patients with respiratory diseases. It supplies heated, humidified, and oxygen-enriched air at high flow rates through a nasal cannula. Because the air is provided through an open system with a nasal cannula, it is relatively easy to apply and suggested to be very comfortable for patients. The technique has been shown to be effective in the treatment of hypoxemic respiratory failure, mainly in neonates\[2\] and patients with acute hypoxemic respiratory failure on intensive care units (ICU).\[3\]
41332817|NCT03564236|OTHER|Standard care|Standard regular care of a COPD exacerbation
41332818|NCT01553721|DRUG|udenafil|"Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)"
41332819|NCT01553721|DRUG|placebo|Phase IIa - placebo Phase IIb - placebo
41332820|NCT01528995|DEVICE|Medtronic Interstim II-3058|impulse generator
41332821|NCT01528995|PROCEDURE|Anal bulking injection|"Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa"
41332822|NCT00565019|DRUG|Triamcinolone Acetonide|"* Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~* Doses will range from 60-120 mg depending on extent of the disease.~* Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~* PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: \>10 cm2, dosage 100-120 mg"
41332823|NCT04378439|BEHAVIORAL|Peer Navigation|"First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services.~Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention"
41483222|NCT00306423|PROCEDURE|Other: Exercise|exercise 3 times per week for 12 weeks
41483223|NCT02618408|DRUG|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
41013276|NCT06145282|DRUG|Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept|All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors.
41332824|NCT04378439|BEHAVIORAL|mHealth|"In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate in-real-time via social media about the process of participating in a syringe services program or accessing PrEP."
41332825|NCT04679441|DEVICE|The Computerized Functional Skills Assessment and Training Program|The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.
41332826|NCT04679441|DEVICE|Brain HQ Double Decision|Cognitive speed training program
41332827|NCT04840368|OTHER|Dancing|Participants randomized to the dance group will take part in a dance intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. Dance classes will be performed individually at home, guided by an expertise instructor, as live sessions online. They will include a variety of rhythms such as salsa, merengue, jazz dance, aerobics, etc. The dance sessions will include a warm up of approximately 10 min (posture, join mobility and dance technique), a main part of 40 min (practicing isolated dance moves and learning of specific choreographic routines), and a cool down of 10 min (muscle stretching and relaxation).
41332828|NCT04110184|OTHER|Systemic lupus erythematosus disease activity index (SLEDAI)|The SLEDAI score ranges between 0 and 105, and scores ≥8 represent active disease
41332829|NCT00102934|DRUG|Enfuvirtide-intensified HAART|90 mg tablet taken orally twice daily
41332830|NCT02082028|DEVICE|BGStar|
41332831|NCT02082028|DEVICE|glucose meter|
41332832|NCT06067750|DIAGNOSTIC_TEST|Narcotrend compared to Cerebral Function Analysing Monitor (CFAM)|All patients will receive Narcotrend and CFAM monitoring in this observational study
41332833|NCT01933321|BIOLOGICAL|Intrathecal autologous stem cell|Mobilization and collection of stem cells for intravenous and intrathecal administration
41332834|NCT03770676|DIETARY_SUPPLEMENT|Selenium-fortified biscuits|Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
41332835|NCT05022472|BEHAVIORAL|COVID-19 Individual Awareness and Education.|The 2VIDA! working group has developed culturally competent COVID-19 educational and outreach materials (available printed and electronically) in English and Spanish that are written at the 8th grade level (the average reading level of adults in the United States) that peer-health educators will distributed to community members during their visits to the participating SYH community centers, door-to-door, local supermarkets, and CBO's in the selected communities. These materials have general information on COVID-19 as well as educational information and resources regarding COVID-19 prevention, symptoms, testing, contact tracing, COVID-19 vaccine (how it works, technology used, administration \[2-dose series and importance of vaccine completion\]), safety concerns, benefits, dispelling common misconceptions and misinformation, and other topics identified based on community needs. This information will be updated monthly to ensure the most up to date information.
41332836|NCT05022472|BEHAVIORAL|COVID-19 Community Outreach & Health Promotion.|Peer-health educators will work with local CBO's and facilitate a combination of live broadcast sessions, pre-recorded webinars, social media posts, and other outreach activities in English and Spanish reaching community members with information on the above COVID-19 related topics as well as other identified needs such as what to do if a family member is infected and where you can get the COVID-19 vaccine. The goal is to reach 10,000 viewers (per session) in the various social media platforms in the three randomly selected communities.
41483224|NCT02618408|DRUG|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
41483225|NCT02618408|DRUG|Placebo|Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
41483226|NCT04107142|BIOLOGICAL|Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell|Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
41483227|NCT03045471|DRUG|R-EPOCH|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
41332837|NCT05022472|BEHAVIORAL|COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.|SYHealth will establish a COVID-19 Resource Center within the participating health centers in the three randomly selected communities (intervention sites only) providing individual COVID-19 related health education and linkages to medical and supportive services for patients and community members in need of additional education and support regarding COVID-19 disease and COVID-19 vaccine.
41332838|NCT05022472|BIOLOGICAL|Pop-up community vaccination sites|We will offer the COVID-19 vaccine at the participating SYHealth community health centers and pop-up vaccination stations that will be set-up in these communities (intervention sites) as part of the interventions efforts to increase access and uptake of the COVID-19 vaccine. We have identified various open spaces (e.g., public parks) in these communities to set-up the vaccination stations. Additionally, data will be collected to assess individual, social, and contextual factors related to access, acceptance, and uptake of the COVID-19 vaccine.The survey will last approximately 10-15 minutes and will be self-administered in both English and Spanish. Following the survey participants will be offered the COVID-19 vaccine and will be made an automatic appointment for the 2nd dose (4-week follow-up) and will be asked to complete a 5 min survey during the follow-up visit.
41332839|NCT05152667|DEVICE|levonorgestrel-releasing intrauterine device (LNG-IUS)|Intervention is administered proceeding the ICSI
41332840|NCT01335698|DRUG|Atazanavir Sulphate|
41332841|NCT01335698|DRUG|Ritonavir|
41332842|NCT05228197|DIAGNOSTIC_TEST|Biopsy & Imaging|H\&E stained prostate biopsy slides from standard of care treatment
41332843|NCT03305757|DRUG|Artiss|Application of ARTISS Glue to skin flaps after mastectomy
41332844|NCT03305757|PROCEDURE|vicryl sutures|Flap fixation with vicryl sutures after mastectomy
41332845|NCT03305757|PROCEDURE|Conventional|Conventional closure after mastectomy
41332846|NCT00704431|DRUG|SB-480848 (darapladib)|160 mg darapladib
41332847|NCT03684070|BEHAVIORAL|Self-Monitoring, peer support and motivational prompts|The intervention compares the effect of technologically delivered motivational messages, and peer support upon daily step counts.
41332848|NCT03684070|BEHAVIORAL|Self-monitoring|Self-monitoring of data from wearable step count tracker
41483228|NCT03045471|DRUG|R-CHOP|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
41483229|NCT05077371|BEHAVIORAL|Peer support program|The intervention will consist of 8 face-to-face peer social support sessions conducted by volunteers diagnosed with breast cancer who have finished their medical treatment (chemotherapy, radiotherapy, surgery) or who have been in a stable phase for at least two years and who are motivated to participate in this type of intervention.
40814940|NCT04123093|DEVICE|Noxsano Bandage (Wound Care)|Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
40814941|NCT01097317|DRUG|carboplatin|
40814942|NCT01097317|DRUG|vinorelbine tartrate|
40814943|NCT01097317|OTHER|neuromuscular electrical stimulation|
40814944|NCT01097317|OTHER|physiologic testing|
41332849|NCT03012594|DRUG|Lanreotide|Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
41332850|NCT00925145|PROCEDURE|Single Incision Laparoscopic Appendectomy|
40814945|NCT01097317|PROCEDURE|fatigue assessment and management|
40814946|NCT01097317|PROCEDURE|quality-of-life assessment|
40814947|NCT00632047|OTHER|active surveillance|
40814948|NCT00632047|OTHER|educational intervention|
40814949|NCT00632047|PROCEDURE|examination|
40814950|NCT00632047|PROCEDURE|long-term screening|
41332851|NCT03242590|DRUG|LPCN 1021|Oral testosterone undecanoate
41332852|NCT04125381|OTHER|Exposure to Arsenic by drinking water|People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.
40814951|NCT02765113|PROCEDURE|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
40814952|NCT02765113|PROCEDURE|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
40814953|NCT03220464|RADIATION|Ultra low dose chest computed tomography (ULDCT)|Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
40814954|NCT03220464|RADIATION|Chest X-ray|Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
40822959|NCT02438956|DIETARY_SUPPLEMENT|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
40822960|NCT00149994|DRUG|Cyclosporine A|
41332853|NCT05239312|DRUG|Antimicrobial|Implementation of antimicrobial protocol for empirical treatment which will be done according to the results of antibiotic susceptibility
41332854|NCT02726048|DEVICE|Simplus/Eson|Released product Simplus and Eson masks
41332855|NCT01714713|DRUG|EVP-6124|Arm 1, 2
41483230|NCT00649818|DRUG|Lorazepam Tablets 2 mg|2mg, single dose fasting
41483231|NCT00649818|DRUG|Ativan Tablets 2 mg|2mg, single dose fasting
41483232|NCT00626717|PROCEDURE|Riboflavin/UVA crosslinking|Removal of epithelium. Riboflavin eye drops. UVA exposure.
40822961|NCT00149994|DRUG|Tacrolimus|
41332856|NCT06087523|OTHER|Multidisciplinary discussion|"Multidisciplinary discussion: Participants will be diagnosed and categorized in regards of pulmonary disease on basis of medical record, PFT, HRCT, and questionnaires.~PFT: Participants will undergo body plethysmography (with diffusion) and six-minute walk test.~Analysis of circulating biomarkers: We will store glasses with serum and glasses with plasma and analyse them for circulating biomarker.~Questionnaires: Participants will complete Danish versions of three questionnaires.~* Saint George's Respiratory Questionnaire Interstitial Pulmonary Fibrosis~* Systemic Lupus Activity Questionnaire~* Lupus Impact Tracker~Review of medical record and clinical investigation with focus on SLE and pulmonary disease.~Thoracic and diaphragmatic ultrasound: The participants will undergo a 14 zone protocol, and be evaluated for b-lines and pleural thickening/irregularities. Diaphragm function will be evaluated according to the M-mode method, area method, and for thickening."
41332857|NCT01990703|DRUG|Levonorgestrel IUD|Timing of IUD insertion
41332858|NCT03669406|PROCEDURE|Autograft fat|autograft fat
41332859|NCT03817840|PROCEDURE|Treatment of Cushing's|Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism
41332860|NCT01709214|DRUG|Cebranopadol (GRT6005) Low-Dose Range|Capsules
41332861|NCT01709214|DRUG|Cebranopadol (GRT6005) High-Dose Range|Capsules
41013285|NCT03769116|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
41332862|NCT01709214|DRUG|Placebo|Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
41332863|NCT01709214|DRUG|Oxycodone CR|Capsules containing oxycodone CR 10 or 20 milligrams
41013286|NCT03769116|GENETIC|placebo|Single IV infusion of matching placebo
41013290|NCT01532362|DRUG|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
41013291|NCT05742802|COMBINATION_PRODUCT|Tozorakimab 1|Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.
41332864|NCT03358498|OTHER|The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It|"SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items.~."
41332865|NCT05688293|PROCEDURE|Connective tissue graft|non-surgical periodontal treatment and connective tissue graft
41332866|NCT05688293|PROCEDURE|Free gingival graft|will receive non-surgical periodontal treatment and partially de-epithelized free gingival graft
41332867|NCT05688293|PROCEDURE|Non surgical|non-surgical periodontal treatment only
41332868|NCT00561613|OTHER|SILCS and lubricant|
41013292|NCT05742802|COMBINATION_PRODUCT|Tozorakimab 2|Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.
41013293|NCT05742802|COMBINATION_PRODUCT|Placebo|Participants previously randomised to placebo in one of the predecessor studies will be re-randomised in a 1:1 ratio to the active dose of Tozorakimab or placebo.
41013294|NCT06290102|DRUG|TEV-56248|"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"
41013295|NCT06290102|DRUG|Fp MDPI|"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"
41013296|NCT02224781|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41013297|NCT02224781|PROCEDURE|Computed Tomography|Undergo CT
41013298|NCT02224781|DRUG|Dabrafenib Mesylate|Given PO
41013299|NCT02224781|PROCEDURE|Echocardiography|Undergo ECHO
41013300|NCT02224781|BIOLOGICAL|Ipilimumab|Given IV
41332869|NCT00561613|OTHER|SILCS and spermicide|
41332870|NCT05606380|DRUG|HLX60|HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks.
41332871|NCT04585672|OTHER|Ammonia infusion|Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)
41332872|NCT04853199|DRUG|Quercetin|Each patient should receive one tablet twice a day 30 minutes before the meal
41332873|NCT04853199|DRUG|Placebo|Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
41332874|NCT04443036|DRUG|Albumin-Bound Paclitaxel|"* 125mg/m2 IV d1、8，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity"
41332875|NCT04443036|DRUG|Toripalimab|"* 240 mg，IV d1，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months"
41483233|NCT00626717|PROCEDURE|Sham treatment|Fluorescein eye drops. Exposure with blue light
40822962|NCT00149994|DRUG|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
41013301|NCT02224781|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
41013302|NCT02224781|BIOLOGICAL|Nivolumab|Given IV
41013303|NCT02224781|OTHER|Quality-of-Life Assessment|Ancillary studies
41013304|NCT02224781|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
41013305|NCT06467084|DRUG|KVD900 75 mg|KVD900 Tablet 75 mg (1 x 75 mg)
41013306|NCT06467084|DRUG|KVD900 150 mg|KVD900 Tablet 150 mg (2 x 75 mg)
41013307|NCT06467084|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
41332876|NCT01449955|DRUG|Rapamycin|"Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.~a single dosage of 15mg will be administered during this study."
41332877|NCT01449955|DRUG|Placebo|Inactive
41332878|NCT01157455|PROCEDURE|Everolimus Drug Eluting Stent|Implantation
41332879|NCT01157455|DRUG|Aspirin|Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy
41332880|NCT01157455|DRUG|Clopidogrel|"A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.~75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy."
40814955|NCT03220464|DIAGNOSTIC_TEST|Interferon-gamma Release Assay (IGRA)|Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
41013314|NCT05070624|BEHAVIORAL|The Virtual Peer Support Program|Training: We have previously developed and beta-tested a virtual peer mentor training program adapted from the St. Jude's Research Hospital's (Memphis, USA) program for FCs of children with cancer for adults using HMV. Content \& Design of the Virtual Peer-Support Program: The program will be delivered by the aTouchAway™ App used for the LIVE program. Participants will be requested to access peer mentors ≥1 time/week. Participants can choose to interact with a peer mentor which will be assigned as well as other peer participants. Onboarding: Participants and mentors will create a personal profile of their caregiving situation (e.g., duration of care, family member age and diagnosis), to enable selection of mentors by the research team believed to be well suited to address support needs, questions, and concerns based on similar lived experience.
41013315|NCT05107310|PROCEDURE|Pedicle screws insertion by free hand technique|Spinal deformity correction. Pedicle screws are inserted using free hand technique with the help of intraoperative fluoroscopy if needed.
41013316|NCT05107310|PROCEDURE|Pedicle screws insertion using ARSN|Spinal deformity correction. Pedicle screws are inserted using augmented reality surgical navigation (ARSN) with the ClarifEye navigation system and the Philips Allura 2D/3D imaging system.
41013317|NCT05107310|PROCEDURE|Pedicle screws insertion using IRSN|Spinal deformity correction. Pedicle screws are inserted using infra-red surgical navigation (IRSN) with the Brainlab Curve 1.2 navigation system combined with the Medtronic O-arm 2D/3D imaging system.
41013321|NCT06444620|DRUG|DTG/3TC|This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine
41332881|NCT01157455|DRUG|Heparin or Bivalirudin|During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.
41332882|NCT05457738|OTHER|E-REVA® app|Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.
40822963|NCT00149994|DRUG|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
41013330|NCT05362032|DEVICE|Biopsy|Undergo transrectal MRI-targeted biopsy
41013331|NCT05362032|PROCEDURE|Endorectal Magnetic Resonance Imaging|Endorectal MRI
41013332|NCT05515523|GENETIC|Adipose Derived (AD) Stromal Vascular Fraction (SVF)|autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain and function associated with OA of the knee joint
41332883|NCT05457738|OTHER|No E-REVA® app|No use smartphone
41332884|NCT03854812|DRUG|Magnesium Sulphate|a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution
41332885|NCT03854812|DRUG|Fentanyl|loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
41332886|NCT03854812|DRUG|Propofol|0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
41483234|NCT01334710|DRUG|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
41332887|NCT01109550|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography transpapillary biopsies
41332888|NCT04326881|DRUG|SHR-1314|single dosing
41332889|NCT00720824|BEHAVIORAL|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
41483235|NCT06123442|BEHAVIORAL|Cognitive Resilience Intervention|Participants will have 12 weeks to complete the program, and then before the post-assessment, there will be a one-month feedback period \[22\]. This includes twelve components: 1) preliminary routine, 2) significance of knowing yourself, 3) interpreting events and stressors, 4) taking autonomy over events, 5) practicing mindfulness and self-compassion, 6) learning adaptation skills, 7) building connection , 8) purpose in life and personal growth, 9) Regulation and disclosure of emotions, 10) practicing gratitude, and 11) positive Communication both intra and interpersonal, 12) overcoming obstacles and moving forward (in the context of current problems) and the conclusion/retrospection are addressed in 12 sessions while closure and post assessment will be done after a month
41332890|NCT00720824|BEHAVIORAL|Office routine|Standard vaccine administration
41332891|NCT05420194|OTHER|Postural stability measurement|Postural stability of the participants will be evaluated with the NeuroCom Balance Master Static Posturography device. Evaluations will be carried out in the presence of two physiotherapists to prevent the patient from falling. Posturography devices allow us to quantitatively evaluate posture and balance and obtain objective results by measuring postural sway.
41332892|NCT05420194|OTHER|Timed Up and Go test|During the Timed Up and Go test, which is applied to evaluate dynamic balance and performance, the participant is asked to get up from the chair, walk 3 meters and sit back on the chair. The participant's time to complete the test is recorded. Completion of the test for more than 10 seconds indicates an increased risk of falling
41332893|NCT04362813|DRUG|Canakinumab|Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for \>80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
41483236|NCT04603911|DRUG|Liposomal bupivacaine|The liposomal bupivacaine used in the research study has been approved by the U.S. Food and Drug Administration (FDA) for use in humans for pain management. The specific approved uses are postsurgical single-dose wound infiltration analgesia and brachial plexus nerve block. In this study, we will be using liposomal bupivacaine in an additional way by infiltrating liposomal bupivacaine in a tissue plane to numb the nerves that provide sensation over the chest.
41332894|NCT04362813|DRUG|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
41483237|NCT04603911|DRUG|Bupivacaine, epinephrine, dexamethasone, and clonidine|The medications that are typically administered as a solution in this block include bupivacaine, epinephrine, dexamethasone, and clonidine.
41332895|NCT03056729|DRUG|BIIB076|Administered as single intravenous (IV) infusion
41332896|NCT03056729|DRUG|Placebo|Administered as single IV infusion
41332897|NCT03537092|DEVICE|Vaginal Film|"2 x 2 vaginal film with no active drug"
41483238|NCT00667082|DRUG|NPI-0052 (marizomib) + vorinostat|"NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle"
41013333|NCT03417297|DEVICE|High Intensity Focused Ultrasound|Participants will undergo high intensity focused ultrasound surgery utilizing magnetic resonance (MR) imaging guidance using a 3 Tesla scanner.
41332898|NCT03210064|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd po
41483239|NCT05500716|OTHER|Auricular Non-Invazive Vagus Nerve Stimulation + Traditional Rehabilitation Program for TMD|"In this application, vagus nerve stimulation is applied to the patients in addition to the traditional rehabilitation program. In our research, vagal nerve stimulation will be applied with the Vagustim Device and all applications will be applied at a frequency of 10 Hz, a pulse amplitude of 300 microseconds and for 20 minutes."
41013334|NCT05478174|DRUG|HSK3486|HSK3486 for induction of general anesthesia
41013335|NCT05478174|DRUG|Propofol|Propofol for induction of general anesthesia.
41332899|NCT03210064|DRUG|5-fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
41332900|NCT00002941|DRUG|carmustine|
41332901|NCT00002941|DRUG|cyclophosphamide|
41332902|NCT00002941|DRUG|etoposide|
41332903|NCT00002941|DRUG|mesna|
41332904|NCT00002941|PROCEDURE|peripheral blood stem cell transplantation|
41332905|NCT02023918|DRUG|pegvisomant|Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
41332906|NCT04163055|DEVICE|Moleculight i:X|This device is used to visualize the bacteria in the wound. Patients do not need consume any contrast agent prior to imaging. The device does not come in contact with the wound.
41483240|NCT05500716|OTHER|Traditional Rehabilitation Program|This intervention includes: Deep Friction Massage, Myofascial Trigger Point Compression Therapy, Temporomandibular Joint Mobilization, Rocabado Exercises, Muscle-Energy Techniques.
41483241|NCT04327713|DIETARY_SUPPLEMENT|fish oil supplement|daily fish oil supplement vs. placebo
41483242|NCT01303536|DRUG|Ondansetron|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
41483243|NCT04901013|OTHER|Affinity|Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM).
41483244|NCT00131872|DEVICE|Expedial Vascular Access Graft|
41483245|NCT03217396|PROCEDURE|lumbar puncture|lumbar puncture performed to detect OCB for diagnostic purposes
41483246|NCT04511052|DIETARY_SUPPLEMENT|Probiotic|Daily intake of 10 x 10\^9 CFU of a proprietary strain for a total duration of 10 weeks
41483247|NCT04511052|OTHER|Placebo|1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks
41483248|NCT04511052|DIETARY_SUPPLEMENT|Carotenoid supplement|1 capsule daily containing \~20 mg of total carotenoids for a total duration of 10 weeks
41332907|NCT04615780|OTHER|mouthwash with green tea|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily. For the preparation of the green tea mouthwash, green tea solution was made with 5 g (1 teaspoon) of green tea powder dissolved in 100 ml water to produce 5% green tea mouthwash, as described in a previous study (Eshghpour, et al., 2013). The green tea powder was ground from Camelia sinensis leaves and regularly provided by the researcher. The green tea solution is made for a single use and remade before rinsing each time. When patients return to the outpatient monthly, the researcher first confirms patients' compliance, then assists with solving difficulties and gives encouragement.
41332908|NCT04615780|OTHER|mouthwash with tap water group|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
41332909|NCT01969513|PROCEDURE|PROCEDURE: EPLEY MANOEUVRE|The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.
41332910|NCT01969513|PROCEDURE|PROCEDURE: SHAM MANOEUVRE|Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
40814956|NCT05047029|PROCEDURE|Transjugular intrahepatic portosystemic shunt implantation|Transjugular intrahepatic portosystemic shunt is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension (e.g., in liver cirrhosis)
41013336|NCT05556798|DRUG|Belantamab Mafodotin|Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg
41013337|NCT05556798|DRUG|Nirogacestat|1:1 randomization between nirogacestat 100mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100mg BID continuously during each cycle for all subjects.
41013338|NCT05556798|DRUG|Pomalidomide|After the 4-day run-in period, all patients will receive nirogacestat in combination with belantamab, mafodotin and pomalidomide. Pomalidomide was added for day 1-14 for cycle 1-3 and day 1-14 and day 21-35 for C4+.
41013345|NCT05714527|DEVICE|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
41013346|NCT05714527|DEVICE|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.
41332911|NCT01181310|DRUG|A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.
41332912|NCT01181310|DRUG|B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.
41332913|NCT01181310|DRUG|C: MK-3134 25 mg + Scopolamine 0.5 mg|A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.
40814957|NCT05047029|DIAGNOSTIC_TEST|Magnetic resonance imaging|Multiparametric cardiac and hepatic magnetic resonance imaging
41155998|NCT06640075|OTHER|Community co-produced action|"Participatory workshops will be conducted with community members by a multidisciplinary team with the aim to co-develop a strategy for cervical cancer screening adapted to the local setting (including primary HPV screening, triage of HPV-positive patients and treatment of patients triaged positive). This intervention is referred to as 'community co-produced action'. Possible strategies co-developed may include collaboration with community health workers or local associations, awareness campaigns, development of health education materials, integration of primary HPV screening at local integrated health centers, organization of group transportation to the district screening center, etc.~Using purposive sampling methods, approximately 15 participants will be invited to take part in the workshops in each health area of the intervention, including approximately 3 health care providers, 3 community health workers or members of women's associations, 3 men and 6 eligible women for screening."
41332914|NCT01181310|DRUG|D: Donepezil 10 mg + Scopolamine 0.5 mg|A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.
40814958|NCT01259648|DRUG|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
40814959|NCT01259648|DRUG|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
40814960|NCT01259648|DRUG|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
41013348|NCT03264131|DRUG|Brentuximab Vedotin|Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
41483249|NCT03592576|DRUG|Navitoclax|Tablet, Oral
41483250|NCT03592576|DRUG|Venetoclax|Tablet, Oral
41483251|NCT05696795|DRUG|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of sarcoidosis.
41483252|NCT00567736|DRUG|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
41013349|NCT03264131|DRUG|CHEP|"Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m\^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m\^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles."
41483253|NCT00567736|DRUG|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
41483254|NCT05068375|DIAGNOSTIC_TEST|Thrombophilia screening|Genetic thrombophilia and acquired thrombophilia screening
41483255|NCT02191475|DRUG|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
41483256|NCT02191475|DRUG|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
41483257|NCT02483832|BEHAVIORAL|Educational materials|Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
41483258|NCT02555020|DIETARY_SUPPLEMENT|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
41483259|NCT02555020|DIETARY_SUPPLEMENT|Allocated to Placebo group|Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
41483260|NCT02555020|DIETARY_SUPPLEMENT|Allocated to MN NPO group,|Patients received NPO from MN.
40814961|NCT01518998|DRUG|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
40814962|NCT03944356|DRUG|Dabrafenib and Trametinib|Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
40814963|NCT00178165|PROCEDURE|Skill Training Condition - problem solving training|
40814964|NCT00178165|PROCEDURE|REACH for TLC (Telephone Linked Computer) system|
40814965|NCT01975519|DRUG|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
41013350|NCT06109948|DRUG|ABX1100 injection for IV infusion|Centyrin protein-siRNA conjugate
41013351|NCT06109948|DRUG|Placebo injection for IV infusion|placebo saline injection
41013352|NCT06161532|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is administered IV at 10 mg/kg on days 1 and 8 of each 21-day cycle.
41013353|NCT06161532|DRUG|Atezolizumab|Atezolizumab is administered IV at 1200 mg on day 1 each 21-day cycle.
41483261|NCT02227654|PROCEDURE|Abnormal Ovarian Ultrasound|Ultrasound
41483262|NCT06163599|BEHAVIORAL|Transdiagnostic Telenovela Intervention|The intervention constitutes nine videos depicting the main character, Esperanza, who is struggling with anxiety and depression, undergoing therapy involving the a trandiagnostic treatment, and completing worksheets relating to the weekly therapy sessions.
41483263|NCT03819621|DEVICE|IRISS Medical Technologies mediGrid app|IRISS mediGrid is standalone software, loaded on a mobile electronic platform, which is intended to record and document ophthalmic and other bodily characteristics and to aid in the diagnosis of abnormalities.
41483264|NCT05639647|DRUG|ATM-AVI|A drug specifically designed to treat resistant gam-negative bacterial infections
41483265|NCT05639647|DRUG|BAT|BAT will be selected by the investigator and administered iv as appropriate for the selected drug(s)
41483266|NCT03119974|DRUG|Tpo-RA discontinuation|a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (\> 2 months) complete response (platelets counts \> 100 x 109/L) period on Tpo-RA treatment.
41483267|NCT00002473|PROCEDURE|conventional surgery|
41483268|NCT04976998|DIAGNOSTIC_TEST|imaging|imaging by ultrasonography and nerve conduction studies will be done for both grups
41483269|NCT02524587|DEVICE|standard polyethylene acetabular irradiated at 3 Mrad|
41483270|NCT02524587|OTHER|radio stereometric analysis (RSA) of the acetabular|
41483271|NCT02524587|DEVICE|acetabular polyethylene vitamys®|
41483272|NCT01465620|BEHAVIORAL|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by a 5 minutes phone call per week during 3 months
41332915|NCT01181310|DRUG|E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg|A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
41332916|NCT00789295|OTHER|Mediterranean diet and Low-Carbohydrates diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
41332917|NCT05185219|DRUG|Valerian|A natural plant
41332918|NCT01281189|DRUG|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
41332919|NCT01281189|DRUG|Placebo|Oral tablet twice daily for up to 18 months.
41332920|NCT06145659|BEHAVIORAL|Preschool and Me|Utilizes patient navigation services and a medical-educational care plan to support linkages between medical and educational systems
41332921|NCT06436209|BEHAVIORAL|Multitask Practice Intervention (MPI)|Multitask practice intervention (MPI) includes multiple behavioral testing sessions during which participants receive practice with multitasking two tasks using the psychological refractory period procedure.
41332922|NCT06436209|BEHAVIORAL|Single-task Practice Intervention (SPI)|Single task practice intervention (SPI) includes multiple behavioral testing sessions during which participants receive separate practice on two tasks.
41332923|NCT00822562|OTHER|PRFA or PMCT|PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
41332924|NCT00822562|PROCEDURE|surgery|only surgery
41332925|NCT06006442|BEHAVIORAL|Vaping|Subjects will be smoking the vapnig products that they admitted to using at baseline in the personal life prior to this study
41332926|NCT02733679|DRUG|Metformin|Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
41332927|NCT02733679|DRUG|Pioglitazone|Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
41332928|NCT00405717|DRUG|atorvastatin,pravastatin|
41332929|NCT01655745|PROCEDURE|FDG PET/MR|All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
41332930|NCT03862495|DIAGNOSTIC_TEST|C. trachomatis and N. gonorrhoeae|In vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhea in patient specimens utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of C. trachomatis and N. gonorrhoeae.
41332931|NCT03862495|DRUG|Azithromycin|Azithromycin 1g administered as a single oral dose
41332932|NCT03862495|OTHER|Partner notification and treatment|Pregnant women who test positive for Chlamydia will also be suggested to take Azithromycin home to treat their spouses
41332933|NCT01376245|DRUG|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
41332934|NCT01376245|DRUG|Placebo|matching placebo
41332935|NCT05434104|OTHER|Vaginal lactoferrin|Lactoferrin vaginal pessaries to insert nightly for seven nights
41332936|NCT05434104|DRUG|Usual care|Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
41332937|NCT03420313|DRUG|Buprenorphine/naloxone sublingual tablets|24-week maintenance with buprenorphine/naloxone sublingual tablets (plus other technology-assisted components described previously)
41332938|NCT03947255|DRUG|brentuximab vedotin|1.8 mg/kg given intravenously (IV)
41332939|NCT00086736|DRUG|bicalutamide|
41332940|NCT00086736|DRUG|eflornithine|
41332941|NCT00086736|DRUG|oral eflornithine placebo|
41332942|NCT00086736|DRUG|oral bicalutamide placebo|
41332943|NCT03916029|BEHAVIORAL|facilitator|Training and employment of community members to assist the diagnosis and management of otitis media
41332944|NCT00209326|DRUG|FE200440|
41332945|NCT01143714|DRUG|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
41332946|NCT01143714|OTHER|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
41332947|NCT00040469|DRUG|Campath -1H|
41332948|NCT00040469|DRUG|Dilantin|
41332949|NCT00040469|DRUG|Busulfan|
41332950|NCT00040469|DRUG|Cyclophosphamide|
41332951|NCT01783470|DRUG|beta3-adrenergic receptor agonist|single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
41332952|NCT04694716|OTHER|No intervention|No intervention will be applied.
41332953|NCT01250756|BIOLOGICAL|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
41332954|NCT01250756|BIOLOGICAL|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
41332955|NCT01250756|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
41332956|NCT04277832|DIAGNOSTIC_TEST|Questionary|All patients will answer two different questionary (TUPAST, TOPAS 2)
41332957|NCT01091051|DRUG|Ustekinumab|Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
41332958|NCT01091051|DRUG|Placebo (Soduim Chloride)|Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
41332959|NCT02077491|OTHER|High-protein diet and resistance training|The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
41332960|NCT02186457|DRUG|Polymyxin B in Normal Saline|Antibiotic irrigation via peritoneal lavage
41332961|NCT02186457|OTHER|Placebo: Normal Saline|Placebo irrigation via peritoneal lavage
41332962|NCT06090929|DEVICE|STN-DBS|STN-DBS was implanted according normal process
41332963|NCT00900445|DRUG|Daunorubicin Hydrochloride|Given IV
41332964|NCT00900445|OTHER|Pharmacological Study|Correlative studies
41013357|NCT03747484|BIOLOGICAL|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Given IV
41013358|NCT03747484|DRUG|Avelumab|Given IV
41013359|NCT03747484|BIOLOGICAL|Pembrolizumab|Given IV
41013360|NCT03747484|BIOLOGICAL|Interferon Gamma-1b|Given SC
41013362|NCT06148272|DRUG|LY3971297|Administered SC
41013363|NCT06148272|DRUG|Placebo|Administered SC
41013364|NCT06148272|DRUG|LY3971297 IV|Administered IV
41332965|NCT00900445|DRUG|Prednisolone|Given orally
41483273|NCT01465620|BEHAVIORAL|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by only one phone call
41483274|NCT03982563|BEHAVIORAL|Growth Mindset|Reading and writing activities designed to instill the belief that people can change.
40814966|NCT06132425|BEHAVIORAL|Exposure|All participants complete two study visits, each consisting of 8 exposure trials for durations of 1 minute each, resulting in a total of 16 exposures. For each exposure, participants are assigned a speech topic and given 1 minute to give an unprepared speech to two study confederates.
41332966|NCT00900445|DRUG|Prednisone|Given orally
41332967|NCT00900445|DRUG|Vincristine Sulfate|Given IV
41483275|NCT03982563|BEHAVIORAL|Gratitude|Reading and writing activities designed to practice noticing and appreciating good things in life.
41332968|NCT01191281|BEHAVIORAL|Diet/nutrition counsel+food aid|Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
41332969|NCT01191281|OTHER|Dietary/nutrition counsel|Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
41332970|NCT03853304|OTHER|+ Folic acid|Salt fortified with folic acid
41332971|NCT03853304|OTHER|+ Vitamin B12|Salt fortified with vitamin B12
41332972|NCT03853304|OTHER|DFS|Salt fortified with iron and iodine
41332973|NCT04165005|BEHAVIORAL|decentering|examined a mindfulness-based intervention focused on a decentering component, that is suitable for elders, aimed to influence on cognitive measures and psychological distress.
41332974|NCT04165005|BEHAVIORAL|guided imagery|relaxing guided imagery including breathing exercises.
41332975|NCT06153914|PROCEDURE|Sequential Adult Left Lateral Liver Transplantation|Hemihepatectomy combined with orthotopic left lateral lobe liver transplantation is performed first, and residual liver resection is performed after the graft has grown to a sufficient functional liver volume. After the two-stage surgery, we will follow up on all subjects for one year.
41332976|NCT00004234|PROCEDURE|management of therapy complications|
41013393|NCT04257578|DRUG|Acalabrutinib|Given PO
41013394|NCT04257578|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
41332977|NCT00004234|RADIATION|radiation therapy|
41332978|NCT06366334|DRUG|Ketamine Hydrochloride|See arm description
41332979|NCT06366334|DRUG|Normal saline|See arm description
41332980|NCT02944513|DEVICE|Quell|
41332981|NCT03943446|DRUG|TAK-018|TAK-018 immediate-release tablets.
41332982|NCT03943446|DRUG|TAK-018 Placebo|TAK-018 placebo-matching tablets.
41483276|NCT03982563|BEHAVIORAL|Behavioral Activation|Reading and writing activities designed to identify and schedule positive activities.
41483277|NCT03982563|BEHAVIORAL|Study Skills|Reading and writing activities designed to learn evidence-based study strategies.
41483278|NCT02514161|OTHER|Inspiratory Muscle training|This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
41483279|NCT02514161|OTHER|IMT + Manual Therapy and Motor Control Exercise|The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
41483280|NCT00632086|DRUG|PA32540|
41332983|NCT02471209|DRUG|Sevoflurane|general anesthesia with 2% followed by 3% sevoflurane
41332984|NCT04564703|DRUG|Iberdomide|IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
41332985|NCT04673188|PROCEDURE|Reconstruction of MPFL with or without tibial tuberositas osteotomy|Reconstruction of the medial patellofemoral ligament with autologous grafts with or without osteotomy and transfer of tibial tuberosities.
41332986|NCT00909519|DRUG|naproxcinod|naproxcinod 750 mg bid
41332987|NCT00909519|DRUG|Naproxen|Naproxen 500 mg bid
41332988|NCT00909519|DRUG|placebo|placebo
41332989|NCT00909519|DRUG|furosemide|furosemide
41332990|NCT04460040|BEHAVIORAL|Exercise training|"The first phase of the study will comprise two weeks of control phase when participants will not engage in any exercise training but will be monitored for total daily energy expenditure and its components (REE, SMR, and DIT) and assessed volume of metabolic organs and skeletal muscle efficiency.~Next, participants will start the active phase. In the first two weeks, participants will perform 150 - 200 min/week of a moderate intensity exercise so that they can adapt to the new regime and avoid injury. All exercise training will be monitored using heart rate sensor (HR) to track exercise adherence and HR range goals. Changes in daily non-exercise physical activity and sedentary behavior will be assessed for 10 days pre- and post-intervention by a tri-axial accelerometer. All study participants will be instructed to consume their habitual diet and to maintain the same caloric intake."
41332991|NCT05924126|OTHER|empiric antibiotic therapy|septic ICU patient given broad spectrum antibiotic therapy
41332992|NCT06380582|OTHER|Temperature and Airflow combination|23C 40%Relative Humidity (RH) low airflow, 23C 40%RH high airflow, 35C 40%RH low airflow, 35C 40% high airflow
41332993|NCT02382757|DRUG|insulin human|Children will receive conventional treatment with human insulin according to standard medical practice.
41332994|NCT02937688|DEVICE|Medtronic DBS Therapy for Parkinson's disease|Bilateral Deep Brain Stimulation (DBS) of the Subthalamic Nucleus or Globus Pallidus interna.
41332995|NCT06269718|OTHER|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
41332996|NCT06269718|OTHER|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
41332997|NCT06104722|OTHER|High-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
41332998|NCT06104722|OTHER|Low-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
41332999|NCT04181957|DRUG|Placebo oral tablet|Participants take one dose of placebo (lactose) tablet.
41333000|NCT04181957|DRUG|Lisdexamfetamine Dimesylate|Participants take one 50mg tablet of lisdexamfetamine dimesylate once.
41483281|NCT00632086|DRUG|aspirin component of PA32540|The 325 mg aspirin component of PA32540
41483282|NCT00632086|DRUG|Ecotrin|325 mg Ecotrin
41483283|NCT01825889|DRUG|Evacetrapib|
41483284|NCT00871741|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, three doses
41483285|NCT00871741|BIOLOGICAL|Infanrix hexa|Intramuscular, three doses
41483286|NCT00871741|BIOLOGICAL|Menjugate|Intramuscular, two doses
40814967|NCT06132425|BEHAVIORAL|Rehearsal|After every two exposures, participants will complete a rehearsal task where the participant is asked to use a positive or neutral approach to remember and recount the exposures they have just completed.
41333001|NCT02134041|OTHER|traumatic brain injury|mild TBI, GCS \>/=13 after traumatic brain injury
41333002|NCT04682678|PROCEDURE|Implantation of electrodes for Spinal cord stimulation|The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.
41333003|NCT05459207|OTHER|Moderate Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a normal/moderate fat meal.
41333004|NCT05459207|OTHER|High Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a high-fat meal.
41333005|NCT01693497|BEHAVIORAL|Dialogical exposure therapy|This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
41333006|NCT01693497|BEHAVIORAL|Cognitive Processing Therapy (German Adaptation)|This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
41333007|NCT01285752|DRUG|AK106-001616|
41483287|NCT02668848|DIETARY_SUPPLEMENT|water|If USG\>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
41483288|NCT02016313|OTHER|physiotherapy|
41483289|NCT01660399|DRUG|Boanmycin|Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
41483290|NCT01660399|DRUG|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1.
41483291|NCT02377063|DIETARY_SUPPLEMENT|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
41483292|NCT04097171|OTHER|Diet|Participants will consume each diet for 14 days in a crossover design.
41155999|NCT06640075|OTHER|Standard screening strategy|Recruitment of study participants will be coordinated centrally at district level (from the Bafoussam Regional Hospital) following procedures previously established in a cervical cancer screening program in the health district of Dschang. This standard procedure includes the training of 2 community health workers (CHW) by health area to raise awareness around cervical cancer. After an initial theoretical and practical training in cervical cancer prevention, CHWs recruit women by going door-to-door or through community meetings in their respective health areas. Through a system of nominal invitation vouchers distributed to eligible women, CHWs receive a financial incentive for each woman that shows up for cervical cancer screening. Twice a year, CHWs of all health areas are invited to a feedback session to discuss difficulties encountered on the field and propose solutions to face any identified challenges.
40822964|NCT00149994|DRUG|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
40822965|NCT04344496|OTHER|PAM50|PAM50 results is as one of the references for the physicians and the participants to choose adjuvant treatments.
41156000|NCT01573741|DRUG|Ketamine|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
41333008|NCT01285752|DRUG|AK106-001616|
41333009|NCT01285752|DRUG|Active comparator|
41333010|NCT02536157|DEVICE|Thermoplastic splinting|
41333011|NCT01855841|DRUG|Hemin|A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
41333012|NCT01855841|DRUG|placebo|A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
41333013|NCT05117593|DRUG|FBL-MTX|FBL-MTX is available as sterile liposomal dispersion for injection at nominal dose strength of 1 mg/mL of methotrexate free base. The dose of 0.1 mg was selected as starting dose in the present study. Three subsequent FBL-MTX dose levels are pre-planned: 0.33 mg, 1 mg and 2.5 mg.
41333014|NCT05117593|DRUG|Placebo|Placebo will consist of sterile saline 0.9% NaCl solution.
41156001|NCT04299971|DRUG|Methotrexate Tablets|"The methotrexate group is prescribed with methotrexate Tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of methotrexate is maintained for another 24 weeks, otherwise (resistant), patients would be given tofacitinib (5.0mg.bid.p.o.) for 24 weeks instead."
41333015|NCT00308243|DRUG|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
41333016|NCT03549468|DEVICE|Low level tragus stimulation|All patients will undergo sequentially: sham stimulation; LLTS (5Hz), LLTS (20Hz). The sequence will be repeated during atrial pacing at 100bpm
41333017|NCT01157546|PROCEDURE|Normal saline via TAP catheters|A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
41333018|NCT01157546|PROCEDURE|Lidocaine via TAP catheters|A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
41333019|NCT04814524|DEVICE|Fitbit|Wear Fitbit
41333020|NCT04814524|OTHER|Questionnaire Administration|Ancillary studies
41333021|NCT04814524|DEVICE|Virtual Reality Device|Use VR
41333022|NCT02964988|DRUG|Injection of PET tracer 68Ga-NOTA-AE105|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
41333023|NCT02964988|DEVICE|PET/CT|Whole body PET/CT
41333024|NCT01042938|DRUG|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
41333025|NCT01042938|DRUG|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
41333026|NCT04301193|DEVICE|Quantra Analyzer|Subjects blood will be manipulated in the lab and will be tested with the Quantra Analyzer
41333027|NCT03161171|OTHER|This is an observational study|This is an observational study
40822966|NCT01994863|DEVICE|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
41333028|NCT03025152|DIETARY_SUPPLEMENT|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
41333029|NCT03025152|OTHER|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
41333030|NCT02954445|BIOLOGICAL|Anti-BCMA-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
41333031|NCT05013294|OTHER|Intervention|Text messages through a basic phone or smart phone
41333032|NCT02066545|DRUG|CLS001 Topical Gel|
41333033|NCT02066545|DRUG|CLS001 Topical Gel Vehicle|
41333034|NCT05488704|DIAGNOSTIC_TEST|Stress Parameters Measurement|"Pre-Test (0-2 minutes before NST starts) - Measurement of vital parameters (Pre-Test)~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Starting NST by controlling the noise level Interim Test-(NST 10th minute) - Measurement of vital parameters (Intermediate Test)~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Termination of NST after 20 minutes Final Test(within 0-2 minutes after NST is over)~* Measurement of vital parameters~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory After Data Collection - Recording of data~* Centrifugation and analysis of saliva samples taken"
41483293|NCT03647046|DEVICE|Customized Scleral Lens|A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
41483294|NCT04727437|OTHER|No treatment|Withholding anticoagulation for at least 3 months.
41483295|NCT04727437|DRUG|Warfarin|anticoagulation drug given for at least 3 months.
41483296|NCT04727437|DRUG|direct oral anticoagulants|anticoagulation drug given for at least 3 months.
41483297|NCT04727437|DRUG|Low molecular weight heparin|anticoagulation drug, subcutaneous injection given for at least 3 months.
41333035|NCT04399824|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
41333036|NCT04399824|OTHER|Quality-of-Life Assessment|Ancillary studies
41333037|NCT04399824|OTHER|Questionnaire Administration|Ancillary studies
41333038|NCT04399824|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41333039|NCT01357889|BIOLOGICAL|albiglutide (GSK716155)|subcutaneous injection administered once a week
41333040|NCT01357889|BIOLOGICAL|albiglutide (GSK716155)|subcutaneous injection administered once a week
41333041|NCT04673669|DIAGNOSTIC_TEST|Posterior tibial tendon strength mesure|Posterior tibial tendon strength is assessed with a hand-held dynamometer by two independent observer and with an isometric dynamometer by one observer.
41333042|NCT03354572|DRUG|Acetyl cysteine|acetyl cysteine 150 mg/kg prior to surgery
41333043|NCT03354572|DRUG|Placebos|saline 0.9% prior to surgery
41333044|NCT00640276|DRUG|pitavastatin|Pitavastatin 2mg daily once
41333045|NCT00640276|BEHAVIORAL|Lifestyle Modification|conducting mainly exercises and diet
41333046|NCT01005199|DRUG|everolimus|Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
41333047|NCT01005199|DRUG|sorafenib tosylate|Sorafenib 2 x 400 mg daily
41333048|NCT04434105|DRUG|platlet rich plasma (PRP)|Platelet-rich plasma (PRP) promotes angiogenesis, neurogenesis, and nerve regeneration, also it could reduce swelling and inflammation of the flexor tenosynovitis.
41333049|NCT04434105|DRUG|Triamcinolone Acetonide|40 mg triamcinolone acetonide
41483298|NCT04094948|DRUG|Clenbuterol|20 mcg spiropent tablets will be overencapsulated (two 20 mcg tablets per capsule)
40814969|NCT05289817|DEVICE|Transcutaneous Vagus Nerve Stimulation (t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: cymba conchae at right ear (vagus branch nerve area); a clip electrode will be applied with its cathode on anterior cymba conchae, the anode placed behind.~Amplitude: from 2 times the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
40822967|NCT01994863|DEVICE|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
40822968|NCT05462990|DRUG|QUC398|QUC398 150 mg/mL, solution for s.c. injection (1 mL)
41333050|NCT04434105|DRUG|Saline|Saline
40822969|NCT05462990|DRUG|Placebo|Placebo 0 mg/mL, solution for s.c. injection (1 mL)
40822970|NCT02637427|BIOLOGICAL|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
41333051|NCT02556970|PROCEDURE|Single port VATS|Performing video-assisted thorascopic surgery through a single port
41333052|NCT02556970|DRUG|Paracetamol|1g intraoperatively
41333053|NCT02556970|DRUG|Diclofenac|75mg intraoperatively
41333054|NCT02556970|DEVICE|Camera (5mm diameter 30 degree videothoracoscope)|
41333055|NCT02556970|DEVICE|Forceps grasper|
41333056|NCT02556970|DRUG|0.25% Levobupivicaine intercostal nerve block|Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
41333057|NCT00088972|DRUG|celecoxib|Given orally
41333058|NCT00088972|OTHER|placebo|Given orally
41333059|NCT00602771|DRUG|tipifarnib|Given orally
41333060|NCT00602771|DRUG|etoposide|Given orally
41333061|NCT04583969|BIOLOGICAL|Lenzilumab|Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity.
41333062|NCT04583969|OTHER|Placebo|Placebo for lenzilumab is commercially sourced 0.9% sodium chloride.
41333063|NCT04583969|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
41333064|NCT05267145|COMBINATION_PRODUCT|blood preservation solution III|Blood bag added blood preservation solution III
41333065|NCT00527969|DRUG|HT1001 extract of Panax quinquefolius L|
41333066|NCT04096885|DIAGNOSTIC_TEST|Blood and urine samples, skin and stool swabs|Blood samples will be collected before surgery, on the first postoperative day and after 3-8 weeks. Urine samples will be collected after surgery and after 3-8 weeks. Stool and skin swabs will be collected before surgery.
41333067|NCT04814511|DRUG|InfectoScab 5 % Creme|InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
41333068|NCT04814511|DRUG|Permethrin 10 % Creme|Permethrin 10 % Creme also contains permethrin as the active ingredient, but in 10 % concentration. Permethrin 10 % creme is used exclusively for topical treatment in the second therapy cycle (escalation therapy).
41333069|NCT04814511|DRUG|Driponin 3 mg Tabletten|Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).
41333070|NCT03896269|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
41333071|NCT01719016|PROCEDURE|Cardiac PET, Coronary catheterization|"Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:~1. N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress~2. Lexiscan - stress agent for PET scan~Patients would also undergo Coronary catheterization including the following drug administration and device usage:~1. Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).~2. Adenosine - stress agent during catheterization, 140 ug/Kg/min"
41483299|NCT04094948|DRUG|Placebos|dextrose-filled capsules
41483300|NCT00026221|BIOLOGICAL|Recombinant Interferon Alfa|Given SC
41483301|NCT00026221|BIOLOGICAL|Bevacizumab|Given IV
40814970|NCT05289817|DEVICE|Transcutaneous Sympathetic Ganglion Electrical Stimulation (t-SES)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 5 Hz Number of channels: two Location and electrodes: cervicothoracic area (stellate ganglion region); first channel: new 5 cm x 5 cm self-adhesive electrodes will be applied at 1-1.5 cm both sides of the vertebral spinous processes, approximately from C7 to T4, upper cathode on the left side of C7 and lower cathode on the right side.~Amplitude: 2 mA above the muscle contraction threshold (individualized) at a comfortable, non-painful amplitude and to a maximum of 25 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of muscle contraction On-Off times: no trains, continuously delivered Duration: 20 minutes"
41013396|NCT04305431|BEHAVIORAL|Cooking Intervention|90-minute culinary education sessions.
41013397|NCT06632236|DRUG|Amivantamab|Amivantamab will be supplied in single-use 350 mg injectable solution, provided as a 7 ml per glass vial (50mg/ml), intended for IV infusion.
41156002|NCT04299971|DRUG|Tofacitinib tablet|"The tofacitinib group is prescribed with tofacitinib tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of tofacitinib is maintained for another 24 weeks, otherwise (resistant), patients would be given methotrexate (15.0mg.qw.p.o.) for 24 weeks instead."
41333072|NCT01324427|BEHAVIORAL|virtual medical visit|"At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits."
41333073|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
41333074|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
41333075|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
40822971|NCT05792839|PROCEDURE|Abdominoplasty with ventral hernia repair versus ventral hernioplasty.|We do surgical treatment for ventral hernia in the form of hernioplasty with surgical mesh placement or by means of abdominoplasty surgical technique.
40822972|NCT04840563|DEVICE|Kalifon A|Commercially available kalifilcon A lenses
40822973|NCT04840563|DEVICE|Dailies Total1|Dailies Total1
40822974|NCT04840563|DEVICE|Precision1|Precision1
41013398|NCT05132231|BIOLOGICAL|Brodalumab|Brodalumab
41013399|NCT05132231|BIOLOGICAL|Matched cohort|Matched cohort
41013400|NCT04677920|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 10g of grapeseed oil) 1 per day for 2 weeks
41156003|NCT03460496|BEHAVIORAL|neonatologists|will continue to be contact persons for the APN, even after hospital discharge, and will be available for 3 fixed outpatient consultations with the APN and families that have difficulty getting to a paediatrician, because they live in a rural area with no paediatrician.
40822975|NCT01938508|DRUG|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
40814971|NCT05289817|DEVICE|Sham Transcutaneous vagus nerve stimulation (Sham t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: scapha at right ear (non vagus innervated region); a clip electrode will be applied with its cathode on anterior scapha, the anode placed behind.~Amplitude: from 2 times above the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
40814972|NCT01364883|BIOLOGICAL|Vaccination Schedule One|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
40814973|NCT01364883|BIOLOGICAL|Vaccination Schedule Two|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
40814974|NCT01364883|BIOLOGICAL|Vaccination Schedule Three|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
40814975|NCT01364883|BIOLOGICAL|Vaccination Schedule Four|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
40814976|NCT01364883|BIOLOGICAL|Vaccination Schedule Five|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
41483302|NCT03983694|OTHER|Erythrocyte transfusion|The cerebro-vascular effects of a clinically prescribed erytrocyte (red blood cell) transfusion is examined. Before the transfusion, BabyLux sensor is placed on the neonatal fronto-parietal region and held in place by a self-adhesive bandage. A baseline prior to transfusion is established through a series of five repeated measurements of 1 minute taken during a stable period just before the transfusion is started. Once transfusion has ended, another series of five repeated measurements of 1 minute taken during a stable period are performed to determine the responses. Cerebral oxygenation as determined by a commercial spatially resolved NIRS device with neonatal sensor will be continuously recorded during transfusion.
40814977|NCT01364883|BIOLOGICAL|Vaccination Schedule Six|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
40814978|NCT01364883|BIOLOGICAL|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
40814979|NCT04960059|OTHER|No intervention|This is an observational study
40814980|NCT02839187|RADIATION|Neuroimaging|AV45-positron emission tomography
40814981|NCT01774097|BIOLOGICAL|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
40814982|NCT01774097|BIOLOGICAL|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
40814983|NCT02364115|RADIATION|Stereotactic Body Radiotherapy|
40814984|NCT04627623|DIAGNOSTIC_TEST|IgM and IgG antibodies assay|5 ml venous blood sample collection to assay IgM and IgM against COVID19
40814985|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Financial Incentive (FI)|Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
40814986|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Standard of Care (SOC)|Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
40814987|NCT01152918|BEHAVIORAL|Viral Suppression Component: FI|HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
40814988|NCT01152918|BEHAVIORAL|Viral Suppression Component: SOC|HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
41333076|NCT04777604|OTHER|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as neoadjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within patients with resectable pancreatic cancer after neoadjuvant chemotherapy, the investigators aim to strategize appropriate neoadjuvant chemotherapy before surgery, thus developing a platform to predict the outcomes of each patient.
41333077|NCT04104061|OTHER|iron profile|blood test
40814989|NCT01152918|BEHAVIORAL|Prevention for Positives Component: Counseling and SOC|Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
41156004|NCT03460496|BEHAVIORAL|psychological support|Psychological support will be standard for all families. In a first consultation, psychologist and family will decide about long-term psychological support. They will have at least 3 follow-up consultations during hospital stay and one before discharge; specific psychological interventions will be provided. The aim of the interventions is to re-establish emotional stability and improve the ability of parents to cope with the situation, to prevent parental and family adaptive disorders and child developmental disorders. Support focus on screening for psychological disorders. Techniques include family-centred, holistic interventions (e.g. activating parental resources and coping, crisis intervention, stabilization techniques etc.). Parents will receive outpatient psychological support.
41333078|NCT00274066|DRUG|Tiotropium + placebo|
41483303|NCT00845234|BEHAVIORAL|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
41483304|NCT04321954|DRUG|LENVATINIB|Orally
41483305|NCT02191007|DRUG|Calcipotriol Betamethasone ointment and Calcipotriol ointment|
41483306|NCT02191007|DRUG|Calcipotriol Betamethasone ointment|
41483307|NCT02191007|DRUG|Calcipotriol Betamethasone ointment and Urea Cream|
41483308|NCT00601874|DRUG|Pilocarpine|
41156005|NCT03460496|BEHAVIORAL|lactation consultant|during hospitalization, the lactation consultant will be involved more frequently than during standard care. Breastfeeding support will take a structured approach and will be performed in close collaboration with both parents. The main aims of structured breastfeeding support are strengthen parent-child bonding. Infants will be breastfed according to their needs. Parents will become competent in meeting their child's nutritional needs. After discharge, parents may schedule outpatient breastfeeding consultations.
41483309|NCT03566576|DRUG|Anlotinib|Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
40814990|NCT01152918|BEHAVIORAL|Prevention for Positives Component: SOC|Participants will receive SOC from their HIV care site.
40822976|NCT02947178|PROCEDURE|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
41483310|NCT03566576|DRUG|Pemetrexed|Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
41483311|NCT03566576|DRUG|Docetaxel|Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
41483312|NCT03591939|DIAGNOSTIC_TEST|laboratory test|role of T- regulatory cells in the patients of diabetic nephropathy
41483313|NCT02280226|DEVICE|magnetic resonance imaging (MRI)|
41483314|NCT01862315|DRUG|Floxuridine (FUDR)|
41483315|NCT01862315|DRUG|dexamethasone|
41483316|NCT01862315|DRUG|Gemcitabine|
41483317|NCT01862315|DRUG|Oxaliplatin|
41483318|NCT01862315|OTHER|MRI|
41483319|NCT01862315|OTHER|Research blood draws|These are optional
41483320|NCT03874494|DRUG|Brexpiprazole|Brexpiprazole 2-4 mg/day
41333079|NCT00274066|DRUG|Tiotropium + ipratropium|
41333080|NCT00274066|DRUG|Tiotropium + fenoterol|
41333081|NCT05920200|PROCEDURE|open non-mesh hernia repair|A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.
41333082|NCT05920200|PROCEDURE|open mesh hernia repair|"A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures."
41333083|NCT05920200|PROCEDURE|MIS hernia repair|"A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation ."
41333084|NCT01496170|DRUG|MK-8931|MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
41333085|NCT01496170|DRUG|Placebo|Placebo capsules, orally, once per day for 7 days
41333086|NCT05818072|PROCEDURE|One biopsy|To do one biopsy at the proximal part of the longest columnar-lined esophagus.
41333087|NCT05818072|PROCEDURE|Three biopsy|To do three biopsy at the proximal, middle and distal part of the longest columnar-lined esophagus.
41333088|NCT05818072|PROCEDURE|Seattle protocol|To do 4-quadrant biopsy every 1-2 cm at the esophagogastric junction. Seattle protocol has been considered as the gold standard biopsy protocol for patients with suspected Barrett's Esophagus.
41333089|NCT05818072|DEVICE|Endoscopy|The participants will receive meticulous endoscopic examination with narrow-band imaging.
41333090|NCT00198367|DRUG|Cisplatin-Gemzar|
41333091|NCT00198367|DRUG|Cisplatin-Navelbine-Radiotherapy|
41333092|NCT00198367|DRUG|Carboplatin-Taxol-Radiotherapy|
41333093|NCT00379236|DEVICE|EUFLEXXA™|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
41333094|NCT00379236|DEVICE|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
41333095|NCT06453447|DRUG|Prednisone|40 mg PO once daily for 14 days starting day of surgery
41333096|NCT06453447|DRUG|Placebo|Placebo tablet (cellulose) PO once daily for 14 days starting day of surgery
41333097|NCT02421146|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
41333098|NCT02421146|DEVICE|Transcranial direct current stimulation - Sham|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
41333099|NCT02254551|DRUG|LDE225|"Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
41333100|NCT02254551|DRUG|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
41333101|NCT03402282|PROCEDURE|embolization|upper rectal artery embolization with coils
41333102|NCT03402282|PROCEDURE|surgical repair|surgical repair through the classic technique (Milligan and Morgan technique)
41333103|NCT01395641|DRUG|gene therapy|AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
41333104|NCT04165733|DIAGNOSTIC_TEST|Online questionnaire|Clinical psychologists in Germany currently working with patients with mental disorders
41333105|NCT02104141|DEVICE|ROIA Interbody Cage with VerteBRIDGE plating|
41333106|NCT03147599|DRUG|Coloverin|Mebeverine hydrochloride 135 mg
41333107|NCT03147599|DRUG|Placebo|Placebo
41333108|NCT03028467|DRUG|GSK3196165 Dose 1|GSK3196165 is supplied as liquid and will be administered as SC injection.
41333109|NCT03028467|DRUG|GSK3196165 Dose 2|GSK3196165 is supplied as liquid and will be administered as SC injection.
41333110|NCT03028467|DRUG|GSK3196165 Dose 3|GSK3196165 is supplied as liquid and will be administered as SC injection.
41333111|NCT03028467|DRUG|Methotrexate|Methotrexate capsule/tablet 8-16 mg per week is given orally.
41333112|NCT03028467|DRUG|Placebo|Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.
41333113|NCT03028467|DRUG|Folic acid|Folic acid tablet 5 mg per week is given orally.
41333114|NCT02275520|DEVICE|NIO Adult device|IO access-1
41333115|NCT02275520|DEVICE|Bone Iniection Gun|IO access-2
41333116|NCT02275520|DEVICE|EZ-IO|IO access-3
41333117|NCT02275520|DEVICE|Jamshidi Intraosseous Needle|IO access-4
41333118|NCT02275520|DEVICE|Cook Intraosseous Needle|IO access-5
41333119|NCT00773851|PROCEDURE|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
41333120|NCT00773851|PROCEDURE|mesh fixation by staples|mesh fixation by staples
41333121|NCT00753961|OTHER|fermented dairy product|fermented dairy product (2 bottles/day during 16 weeks)
41333122|NCT00753961|OTHER|non fermented dairy product|non fermented dairy product (2 bottles/day during 16 weeks)
41333123|NCT01521572|DRUG|Salbutamol sulphate|bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
41333124|NCT01871415|DRUG|aleglitazar|150 mcg orally daily
41333125|NCT01871415|DRUG|metformin|pre-existing background regimen and dose
41013419|NCT05544461|BEHAVIORAL|eNutri personalised nutrition advice|eNutri is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex and dietary restrictions (such as whether they eat meat) so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutri Team, including a registered dietitian and registered nutritionist and are in line with UK dietary guidelines (primarily the EatWell Guide).
41013422|NCT04917575|OTHER|Mobile Game|An enhanced life-simulation prototype of a playable interactive game to increase HIV testing.
41013423|NCT04917575|OTHER|Mobile Application|A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information, and information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
41013424|NCT05448690|PROCEDURE|Two different approaches|Please refer to Groups
41013425|NCT05448690|PROCEDURE|Non-combined approach|Either transnasal, transcranial or a staged approach
41013427|NCT03979365|DRUG|Envarsus XR|Twice daily tacrolimus vs. Envarsus XR
41013428|NCT03979365|DRUG|Tacrolimus twice daily|Twice daily tacrolimus vs. Envarsus XR
41013429|NCT02473575|DIETARY_SUPPLEMENT|caffeine gum|Gum is consumed 30 minutes before commencement of run
41013430|NCT02473575|DIETARY_SUPPLEMENT|placebo gum|Gum is consumed 30 minutes before commencement of run
41013431|NCT06419608|DRUG|BHV-7000|BHV-7000 75 mg taken once daily for 6 weeks
41013432|NCT06419608|DRUG|Placebo|Matching placebo taken once daily for 6 weeks
41013434|NCT03736421|PROCEDURE|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
41013435|NCT03736421|PROCEDURE|Non-invasive fluid response measure|To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
41013436|NCT03736421|DIAGNOSTIC_TEST|Passive leg raise (PLR)|Test to predict cardiac output and fluid responsiveness
41013437|NCT05975541|OTHER|Observational|No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.
41483321|NCT03874494|DRUG|Aripiprazole|Aripiprazole 10-20 mg/day
41013438|NCT04992949|DRUG|CPX-351|"Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study~Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.~Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle"
41013439|NCT06166953|OTHER|digital technology-supported education|The education will include information about surgical process and care after surgery.
41013440|NCT03152812|PROCEDURE|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
41013441|NCT06360575|PROCEDURE|Biopsy|Undergo tumor biopsy
41013442|NCT06360575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41013443|NCT06360575|DRUG|Crizotinib|Given PO
41013444|NCT06360575|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
41013445|NCT06489301|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
41013446|NCT04403295|BEHAVIORAL|Collaborative Specialty Care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
41013447|NCT04403295|BEHAVIORAL|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
41013448|NCT05413304|DRUG|pre-operative abemaciclib|pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
41333126|NCT01871415|DRUG|placebo|matching aleglitazar placebo orally daily
41333127|NCT00054236|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
41333128|NCT00054236|BIOLOGICAL|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
41483322|NCT00326287|DRUG|Ceftobiprole medocaril|
41333129|NCT00054236|DRUG|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
41333130|NCT00054236|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
41333131|NCT00054236|PROCEDURE|umbilical cord blood transplantation|Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
41333132|NCT00054236|DRUG|methylprednisolone|Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
41333133|NCT00209170|BEHAVIORAL|Beating the Blues|Beating the Blues is a computerized cognitive behavioral therapy.
41483323|NCT00326287|DRUG|Ceftriaxone with or without Linezolid|
41013449|NCT05413304|DEVICE|Device for Cerebral Fluid Dialysate Collection|post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48-hours to assess CNS drug entry and targeted inhibition with abemaciclib
41013450|NCT05413304|DEVICE|Ashion Analytics GEM ExTra|resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets
41013451|NCT05413304|DRUG|abemaciclib + temozolomide|abemaciclib 150mg po BID and temozolomide 200mg/m2 po daily x 5 days in 28 day cycles (temozolomide 150mg/m2 po daily x 5 days for cycle 1)
41013454|NCT06070870|BEHAVIORAL|Patient Navigation|"Navigation will address the following 4 domains of barriers to screening:~* Individual~* Organizational~* Economic~* Sociocultural At the first visit, navigators will assess the participant's barriers in each of these domains. Any follow-up visits, if necessary, will be used to help the participant overcome these barriers to screening"
41013455|NCT01138124|DRUG|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
41013456|NCT03523559|GENETIC|bladder tissue of Interstitial Cystitis and normal bladder tissue|Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
41013457|NCT03079258|OTHER|Exercise|Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
41013459|NCT04667819|DRUG|Sodium Hyaluronate|We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
41013460|NCT06518551|DRUG|Elotuzumab|Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.
41013461|NCT06518551|DRUG|Iberdomide|A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.
41013462|NCT06518551|DRUG|Dexamethasone|Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.
41483324|NCT01338649|DEVICE|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
41483325|NCT01338649|DEVICE|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
41483326|NCT00136578|DRUG|SB-715992|SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
41013469|NCT06380270|DIETARY_SUPPLEMENT|Oral probiotic Streptococcus salivarius eK12 sachet|Bactoblis® EVOL (containing 10 bittion CFU of S. salivarius eK12)
41013471|NCT04666649|DRUG|Venetoclax and pegcrisantaspase|Therapeutic
41013478|NCT06251700|DEVICE|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonscopy
41013479|NCT06442267|DRUG|Enoxaparin Injectable Solution|Subcutaneous Enoxaparin will be dosed at 0.5 mg/kg twice daily
41013480|NCT06442267|DRUG|Argatroban, 1 Mg/mL Intravenous Solution|Intravenous Argatroban will be administered as a continuous infusion of 0.1-1 µg/kg/min with a target modified thrombin time measured using Hemoclot of 0,40 - 0,60 µg/mL.
41013481|NCT06442267|DRUG|Unfractionated heparin|Unfractionated heparin will be administered as a continuous infusion of 7.5-20 units/kg/h with a target Anti FXa calibrated for UFH of 0.3-0.5 u/mL.
41333134|NCT00209170|DRUG|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
41333135|NCT00209170|DRUG|Placebo|A sugar pill taken as one to two tablets daily for 6 months.
41013484|NCT06628362|DRUG|Placebo|Placebo will be volume-matched and administered subcutaneously (SC) once weekly.
41013485|NCT06628362|DRUG|CT-388|CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
41333136|NCT04229108|DEVICE|Medopad|Timed up and go module of Medopad application. About page explains how to perform test and conditions, subsequent page contains timer, once completed test, commence on final page which has a number of short questions to complete
41483327|NCT00136578|DRUG|carboplatin|Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.
41013486|NCT06157892|DRUG|disitamab vedotin|Given into the vein (IV; intravenous)
41013487|NCT06157892|DRUG|tucatinib|300mg given twice daily by mouth (orally)
41013493|NCT04147013|DRUG|Celecoxib|Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
41013494|NCT04147013|DRUG|Placebo|Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
41013495|NCT04677946|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 9g of linoleic acid) 1 per day for 8 weeks
41013496|NCT05915026|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
41013497|NCT04101526|BEHAVIORAL|Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference|Six sessions of Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference. Sessions address topics such as sleep education, sleep hygiene, sleep restriction, stimulus control, relapse prevention, and cognitive restructuring.
41013498|NCT06252285|BIOLOGICAL|RSVt Vaccine|Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
41013499|NCT06252285|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
41483328|NCT02885649|DRUG|Enzalutamide|Given PO
41483329|NCT02885649|OTHER|Laboratory Biomarker Analysis|Correlative studies
41013500|NCT02944578|DRUG|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
41013501|NCT02944578|DRUG|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
41156006|NCT03460496|BEHAVIORAL|physiotherapeutic interventions|physiotherapeutic interventions will also be structured. The physiotherapist will make an assessment during hospitalization, and decide which physiotherapeutic interventions are necessary. Each family will learn how to handle their premature child in everyday life, based on the child's developmental stage, in a single consultation.
41333137|NCT02736396|OTHER|fMRI|Functional MRI scan to be performed
41333138|NCT02736396|OTHER|Neuropsychological tests|Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.
41333139|NCT06067932|RADIATION|Foot X rays|Radiographs of ankle and foot anteroposterior/dorsoplantar were taken in standing position with a centralized beam on the ankle joint.
41333140|NCT06067932|DIAGNOSTIC_TEST|Clinical examination + scores|The American Orthopedic Foot and Ankle Society Score (AOFAS- midfoot section and 1st Forefoot ray, Forefoot ray 2-5) and the foot function index (FFI) were assessed
41333141|NCT05950555|OTHER|Saline|We used 0.9% isotonic sodium chloride.
41333142|NCT05950555|OTHER|Dexmedetomidine|We used the vial containing 200 mcg/2 ml i.v. concentrated infusion solution in 100 ml of 0.9% isotonic sodium chloride.
41333143|NCT05950555|OTHER|Ketamine|We used 500 mg/10 ml solution for injection in 0.9% isotonic sodium chloride.
41333144|NCT06422572|OTHER|No Intervention|No Intervention
41483330|NCT02885649|PROCEDURE|Nephrectomy|Undergo partial or radical nephrectomy
40814991|NCT04783779|DEVICE|Implant of STARgraft-2 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
40814992|NCT01073397|BEHAVIORAL|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
40814993|NCT01250184|OTHER|Physical therapy|Twelve sessions (3 per week)
40814994|NCT01250184|DRUG|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
40814995|NCT01250184|OTHER|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
40814996|NCT02398422|BEHAVIORAL|Listening Project Protocol|"The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention."
41483331|NCT05434377|OTHER|ergocalciferol supplementation|Participants in both groups will recieve ergocalciferol with different supplementation regimens for 6 months.
40814997|NCT04052789|OTHER|BioHPP PEEK copings veneered with composite resin|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.
40814998|NCT01535599|DRUG|AL-60371, 0.3% Otic Suspension|
40814999|NCT01535599|OTHER|AL-60371 Vehicle|Inactive ingredients used as a placebo comparator
40815000|NCT06172803|BEHAVIORAL|Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise|8 week exercise program. 20 minutes of home aerobic exercise most days, phone- based motivational exercise coaching and supervised exercise with our team exercise physiologist.
40815001|NCT06172803|BEHAVIORAL|Light Stretching/Breathing Exercises|The control group will receive 8-week, attention-matched, stretching and breathing exercises, supervised by a rehabilitation clinician (via 20-minute weekly video visits). Exercises performed 5 days a week will not increase HR significantly. Participants will record and track their HR with Apple watch and app; like RESToRE, fidelity of treatment will be objectively measured using HR data.
40815002|NCT05229211|DEVICE|Cardiac monitoring|Continuous ECG monitoring via VitalConnect patch worn on the chest.
40815003|NCT04236024|OTHER|Board game|The students in the experimental group will play board game to learn medication about 30-60 minutes.
40815004|NCT04236024|OTHER|Traditional lecture|The students in the comparison group will receive medication lecture using PPT slides about 30-60 minutes.
40815005|NCT01257568|DEVICE|Rejuvenate Modular Hip|Rejuvenate Modular Hip
40815006|NCT02052336|DRUG|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
40815007|NCT02052336|DRUG|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
40815008|NCT02052336|DRUG|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
40815009|NCT05017753|PROCEDURE|Thoracentesis|Thoracentesis will be performed according to local practice, either at the ward or at the radiology department, in addition to standard-of-care medical treatment.
40815010|NCT05017753|DRUG|Standard-of-care medical treatment|Standard-of-care medical treatment
40815011|NCT04182399|DRUG|Zonisamide Capsules|anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
40815012|NCT00110786|BIOLOGICAL|Ragweed MATAMPL|
40815013|NCT06412705|PROCEDURE|Tooth extraction, guided bone regeneration and dental implant|The arm received tooth extraction and contextual guided bone regeneration. After 4 months, a dental implant was inserted.
40815014|NCT02522585|OTHER|Conservative management|Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
40815015|NCT03172884|DRUG|Copanlisib (ALIQOPA, BAY80-6946)|12mg single dose, intravenous on Day 0
41483332|NCT05434377|OTHER|dialysis techniques|Both groups will have participants treated with maintenance hemodialysis and peritoneal dialysis.
41483333|NCT05434377|OTHER|sunlight exposure time|Both groups will be advised to receive similar hours of daily sunlight exposure time.
40815016|NCT03350256|DEVICE|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.|BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
40815017|NCT06294574|DEVICE|HydroMARK Plus Clip|Each patient will undergo a breast localization procedure, and a HydroMARK plus clip will be placed.
40815018|NCT03070171|DRUG|dabigatran etexilate|single dose
40815019|NCT01552551|BEHAVIORAL|Assessment and education|PA Healthy Steps program
40815020|NCT01552551|BEHAVIORAL|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
40815021|NCT01552551|BEHAVIORAL|Healthy Steps in Motion|Group exercise program
40815022|NCT03888040|OTHER|Exercise|The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
40822977|NCT02947178|BEHAVIORAL|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
40822978|NCT02947178|BEHAVIORAL|Pill Count|Patient reported as needed (prn) pain medication usage
40822979|NCT02947178|DRUG|Bupivacaine|
41333145|NCT06270563|OTHER|Postural advice|The patients received advice about maintaining good posture when sitting, standing, reading, driving, or lifting; taking breaks; sleeping on back or side with a pillow supporting head/neck; avoiding prolonged phone use; adjusting car seat; reading stand for upright posture; keeping objects close when lifting; and using pillows for support when breastfeeding.
41333146|NCT06270563|OTHER|Traditional exercise treatment|The exercise program included strengthening of deep flexor muscles and shoulder retractors while stretching of cervical extensors and pectoral muscles.
41333147|NCT06270563|OTHER|Scapular stabilization exercises|Scapular Stabilization exercise was composed of four exercise programs, including scapula retraction exercise, scapula mobilization exercise, and scapula dynamic stabilization exercise I and II.
41333148|NCT06270563|OTHER|High intensity Laser therapy|"There were two phases in every session, the wavelength is 1064 nm, size of spacer is 60 mm in both phases:~Phase I (analgesic phase): the application was made by moving the applicator perpendicular to the skin in continuous circular movements at trigger points detected by acupuncture, power was 8.00 w with a dosage of 5 J/cm2, surface area 50 cm2, frequency 25 HZ, treatment time in this phase was 3 minutes and total energy received at this phase was 250 J.~Phase II (bio stimulation): the application was made at the pain inflicting region by using continuous linear movements and prevent static application, The power was 8.00 w with a continuous frequency, dosage of 50 J/cm2, surface area 50 cm2, treatment time in this phase was 5 minutes and the total energy that was delivered to the patient during this phase was 2500 J."
41333149|NCT04883918|BIOLOGICAL|ASC930|4 intravenous doses of ASC930
41483334|NCT02782494|OTHER|Examination of latent TB by QuantiFERON-TB|Examination of latent TB by QuantiFERON-TB both QFT-plus QFT-GIT
41483335|NCT01784666|DRUG|Isradipine|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
41483336|NCT01784666|DRUG|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
41483337|NCT00301847|DRUG|sorafenib tosylate|
41483338|NCT03610568|BEHAVIORAL|Growing up GREAT! Intervention|The Growing up GREAT! intervention is built around the socio-ecological model. For young adolescents, a suite of materials provides information and prompts discussion about puberty, gender equality, healthy relationships, violence, and other related themes during weekly club sessions. For parents, group sessions featuring six testimonial videos foster discussion around non-violent parenting, equal sharing of household tasks, and girls' education. Other materials for teachers, health workers, and community members complement the core toolkit materials.
41483339|NCT00333879|DEVICE|Virtual Sound System|Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
40815023|NCT02019108|OTHER|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
40815024|NCT02019108|OTHER|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
40815025|NCT02461290|RADIATION|Chemotherapy|
40815026|NCT02461290|DRUG|Rituximab|
40815027|NCT02984241|BEHAVIORAL|eHealth Coping Skills Training|Access to a specialized coping skills training website
41333150|NCT01413828|DRUG|concurrent|Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
41333151|NCT01413828|DRUG|sequential|Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
41333152|NCT00686010|DRUG|Placebo|Placebo tablet, 3 tablets, oral, once daily after breakfast
41333153|NCT00686010|DRUG|JTT-705 300mg|JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
41333154|NCT00686010|DRUG|JTT-705 600mg|JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
41333155|NCT00686010|DRUG|JTT-705 900mg|JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
41483340|NCT01754116|DRUG|GSK1265744 30 mg oral|GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
41333156|NCT00000314|DRUG|M-CPP|
41483341|NCT01754116|DRUG|Midazolam 3 mg oral + GSK1265744 30mg oral|Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14
41483342|NCT01754116|DRUG|GSK1265744 400 mg (200 nm)|A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)
41483343|NCT01754116|DRUG|GSK1265744 400 mg (1 micro m)|A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)
40815028|NCT02984241|BEHAVIORAL|eHealth Usual Web Care|Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
40815029|NCT02984241|BEHAVIORAL|Coach Support|Access to a professional coach by phone
40815030|NCT01184313|PROCEDURE|aortic valve surgery with CPB|elective aortic valve surgery with CPB
40815031|NCT03900104|PROCEDURE|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
41333157|NCT06454162|OTHER|Modified Ketogenic Diet|the patients will receive KD after nutritional counseling, patients will instructed to start by limiting carbohydrate intake to just 20 g/day for 4 weeks in order to establish ketosis. Then, patients increase their carbohydrate intake by 5 g each week until they reach their individual maximum (approximately 40 g) to maintain stable ketosis. All carbohydrates relevant for elevating blood glucose are limited to 40-50 g/ day. In addition, the glycemic index and glycemic load of carbohydrates have to be below 50 and 60, respectively. This ketogenic diet is equivalent to a traditional ketogenic diet, but with a liberalized macronutrient composition of 70-80% fats, 15-20% proteins and 5-10% carbohydrates (compared to a traditional ketogenic diet with 90% fat, 6% proteins and 4% carbohydrates)+ exercise program
41333158|NCT06454162|OTHER|exercise program|the patients will receive exercise program in the form of aerobic training (10-30 minutes at moderate intensity) and resistance training (1-3 sets of 8-15 repetition maximum (RM)
40815032|NCT03900104|PROCEDURE|Cervical injection of technetium 99 m-labeled human albumin colloid particles|Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.
40815033|NCT02897037|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
41483344|NCT01754116|DRUG|GSK1265744 400 mg (5 micro m)|A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
41483345|NCT01632111|OTHER|Lung function measurement|Spirometry
40815034|NCT02897037|DRUG|heparin|heparin monotherapy
40815035|NCT02520869|PROCEDURE|swim-up technique|swim-up technique used
40815036|NCT02520869|PROCEDURE|zeta test technique|zeta test technique used
40815037|NCT01748812|DRUG|Osteomalacia|
40815038|NCT00145184|DIETARY_SUPPLEMENT|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
40815039|NCT00145184|DRUG|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
40815040|NCT06608927|DRUG|Quemliclustat|Administered as specified in the treatment arm
40815041|NCT06608927|DRUG|Placebo|Administered as specified in the treatment arm
40815042|NCT06608927|DRUG|Nab-paclitaxel|Administered as specified in the treatment arm
40815043|NCT06608927|DRUG|Gemcitabine|Administered as specified in the treatment arm
40815044|NCT05149651|DRUG|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
40815045|NCT05149651|DRUG|MTA|ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
41483346|NCT04328519|OTHER|observation|observation
41483347|NCT00530686|DRUG|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
41483348|NCT00362921|DRUG|Gliadel wafers in combination with O6-benzylguanine|
41483349|NCT03954314|DRUG|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
40815046|NCT01931488|OTHER|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
40815047|NCT01931488|DEVICE|SPECT imaging|
40815048|NCT00271921|BEHAVIORAL|Calorie controlled diet|
40815049|NCT01938924|DEVICE|GekoTM|electrical neuromuscular stimulation
41333159|NCT01350713|DRUG|povidone iodine|one local application of 10% povidone iodine ointment
41333160|NCT02867163|DRUG|Tranexamic Acid|Intravenous or local administration of TXA, in any dosage
40815050|NCT01543399|DRUG|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
40815051|NCT01543399|DRUG|Placebo|patients of the placebo group will use placebo one a day for 30 days
40815052|NCT03215992|DEVICE|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
40815053|NCT04568759|OTHER|Global postural re-education|GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
40815054|NCT02447250|DRUG|Varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning between 14 or more days from birth and at a corrected gestational age of 28w0d to 33w6d. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
40815055|NCT02873065|DRUG|Ilaprazole|
40815056|NCT02873065|DRUG|Esoprazole|
40815057|NCT01243372|GENETIC|mutation analysis|
40815058|NCT01243372|OTHER|laboratory biomarker analysis|
40815059|NCT04452071|RADIATION|periapical xray|periapical xray on the middle phalanax of the middle finger
40815060|NCT06241638|DRUG|Vitamin B12 0.5 MG/ACTUAT|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
40815061|NCT06241638|DRUG|Dapagliflozin 10mg Tab|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
40815062|NCT06283823|DEVICE|Thermoformed orthodontic retainer|compare the outcome of the retaining phase of the orthodontic treatment with two different thermoformed retainers
40815063|NCT01961856|DRUG|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
40815064|NCT01961856|DRUG|Ticagrelor|Ticagrelor 180mg loading dose
40815065|NCT00057733|PROCEDURE|psychosocial assessment and care|
40815066|NCT00057733|PROCEDURE|quality-of-life assessment|
40815067|NCT02152371|DRUG|Dulaglutide|Administered SQ
40815068|NCT02152371|DRUG|Placebo|Administered SQ
41333161|NCT00513994|DRUG|Nitroglycerin|MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
40815069|NCT02152371|DRUG|Insulin Glargine|Administered SQ
40815070|NCT02152371|DRUG|Metformin|Administered orally
41483350|NCT06138119|BEHAVIORAL|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/ she belongs. Stereotype threat manipulation will be performed on the male and female participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare fiberoptic intubation performance between male and female anesthesiologists. Additionally, we are investigating whether the high inclination of males towards computer games has any impact on their fiberoptic intubation success. The other participants (Control Group) will not be given any prior information."
40815071|NCT00066222|DRUG|Cisplatin|60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
41333162|NCT04011319|BEHAVIORAL|group culture|Four embryos were cultured in the same droplet by a special dish.
41333163|NCT01539213|DRUG|secukinumab (AIN457)|anti-IL-17 antibody
41483351|NCT05692076|DEVICE|High Velocity Nasal Insufflation|High-flow humidified oxygen with flow rates from 30 to100 L/min with high fraction of inspired oxygen( FiO2) is able to be delivered.
40815072|NCT00066222|DRUG|Etoposide|120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
40815073|NCT00066222|RADIATION|Radiation therapy|Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
40815074|NCT01054131|BEHAVIORAL|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
40815075|NCT02539173|OTHER|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
40815076|NCT02687555|BEHAVIORAL|Cognitive Bias Modification of Appraisals (CBM-App)|
41333164|NCT03366818|DEVICE|thrombectomy|mechanical thrombectomy
41333165|NCT02887365|DRUG|tegafur-uracil|
41333166|NCT00005969|DRUG|Chemotherapy|
41333167|NCT00005969|DRUG|Tretinoin Liposome|Liposome by vein (IV) over 30 minutes every other day for 28 days
41333168|NCT02589743|DEVICE|Sealant|Application of preventive agent
41333169|NCT02589743|DEVICE|Adhesive and Sealant|Application of preventive agent and technique for control moisture
41333170|NCT04161612|OTHER|Demographic characteristics, duration of spinal cord injury, spinal cord injurylevel, etiology, number of intermittent bladder catheterization (IC), number of night time|Observational clinical study
41483352|NCT04232813|DRUG|Estradiol 10 MCG Vaginal Tablet [VAGIFEM]|To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.
41483353|NCT04232813|DRUG|Promestriene Vaginal|To insert the cream the patient must use the applicator provided in the way explained in the prospectus.
40815077|NCT02687555|BEHAVIORAL|Peripheral Vision Task (control condition)|
40815078|NCT06414148|DRUG|Epcoritamab|Epcoritamab will be administered as a 28-day cycle. In Cycle 1 and 2, epcoritamab will be given with step up dosing in Cycle 1. From Cycle 3 onwards dosing will be on Day 1 and 15 of each cycle.
40822980|NCT02947178|DRUG|Liposomal Bupivacaine|
40822981|NCT02944227|DRUG|Lucentis|Lucentis fixed-treatment arm
40815079|NCT06414148|DRUG|Epcoritamab, lenalidomide and rituximab|"Treatment with epcoritamab will be administered following the same dosing schedule as Arm A. On days where rituximab and/or lenalidomide are also due, epcoritamab should be administered last.~Patients will receive lenalidomide once daily on Day 1-21 of each 28-day cycle, starting at Cycle 1 through to Cycle 6.~Patients will receive rituximab administered by intravenous (IV) infusion on Day 1, 8, 15 and 22 of Cycle 1 and on Day 1 only of Cycles 2-6."
41156007|NCT03460496|BEHAVIORAL|social workers|social workers will closely collaborate with the APN within the transitional model. They will be involved with every family and will assist the APN in establishing a network with social and medical services within and outside the clinic. They will also support families in coping with daily life and with their integration into society, family and work. Furthermore, they will give advice on social security issues and on asserting claims as well as clarify financial possibilities.
41333171|NCT04717895|DIAGNOSTIC_TEST|Rocking environment forward (B) followed by a translation environment|Start by the virtual reality session by viewing a rocking environment followed by a translation environment
41333172|NCT04717895|DIAGNOSTIC_TEST|Translation environment followed by a rocking environment|Start by the virtual reality session by viewing a translation environment followed by a rocking environment
40815080|NCT01516580|DRUG|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
41333173|NCT04605185|DRUG|Donafenib Tosilate Tablets|100mg Qd/150mg Qd/100mg Bid, po
40815081|NCT01516580|DRUG|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
40815082|NCT04699695|OTHER|Biologic therapy versus no biologic therapy|Biologic therapy administered per standard of care
40815083|NCT00002412|DRUG|Emivirine|
40815084|NCT00002412|DRUG|Hydroxyurea|
40815085|NCT00002412|DRUG|Stavudine|
40815086|NCT00002412|DRUG|Didanosine|
40815087|NCT04407026|BIOLOGICAL|biofluids|Gingival crevicular fluid, saliva and serum samples were obtained.
40815088|NCT02243618|DRUG|Polaprezinc|Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
41333174|NCT04605185|BIOLOGICAL|Toripalimab Injection|240 mg, iv drip,q3w
41333175|NCT00367432|DRUG|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
41333176|NCT02077803|DRUG|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
41333177|NCT02077803|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
40815089|NCT02243618|DRUG|Rebamipide|Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
40815090|NCT05966363|RADIATION|Nanodot|Radiation measurements using nanodots placed on the eyes, ears, neck and lower abdomen during an imaging examination.
41333178|NCT02077803|DRUG|CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
41333179|NCT02077803|DRUG|CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
41333180|NCT02882022|DEVICE|Continuous positive airway pressure|A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
40815091|NCT03020134|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
40815092|NCT03020134|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
41333181|NCT02793089|OTHER|Analysis of Ectopic Pregnancy incidence|Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
40815093|NCT03020134|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
40815094|NCT03020134|DRUG|Placebo|Placebo
40815095|NCT03121235|DIAGNOSTIC_TEST|PCR based detection of azole resistance in A. fumigatus|Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.
40815096|NCT04345861|DRUG|Hydroxychloroquine + placebo|hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)
40815097|NCT04345861|DRUG|hydroxychloroquine + azithromycin|Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
40815098|NCT04893239|BIOLOGICAL|LMN-201|Components of LMN-201
40815099|NCT02524275|DRUG|Capecitabine|Given PO
40815100|NCT02524275|DRUG|Docetaxel|Given IV
40815101|NCT02524275|OTHER|Quality-of-Life Assessment|Ancillary studies
40815102|NCT02524275|OTHER|Questionnaire Administration|Ancillary studies
40815103|NCT02549625|BIOLOGICAL|Autologous Bone Marrow-derived Mononuclear Cells|
40815104|NCT03094091|OTHER|News items with spin|Interpretation of news items with spin
40815105|NCT03094091|OTHER|News items without spin|Interpretation of news items without spin
40815106|NCT04652882|DRUG|Tasimelteon|oral capsule
40815107|NCT04652882|DRUG|Placebo|oral capsule
40815108|NCT00808613|DEVICE|Optetrak PS|Optetrak Posterior Stabilized total knee replacement
41333182|NCT03892434|DRUG|Intravitreal bevacizumab and dexamethasone implant Injection|Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.
41333183|NCT03892434|DEVICE|Intravitreal dexamethasone implant|Dexamethasone implant insertion using approved kit
41483354|NCT01272726|BEHAVIORAL|Education|Education on the genetics of ADHD and treatment options for ADHD
41483355|NCT03241381|DIAGNOSTIC_TEST|vitamin D serum assay study and control groups|Serum- vitamin D assay
40815109|NCT00808613|DEVICE|Optetrak Hi-Flex|Optetrak Hi-Flex total knee replacement
40815110|NCT04054869|OTHER|Bio-mechanically correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.
40815111|NCT04054869|OTHER|Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
40815112|NCT05870150|BIOLOGICAL|Salmonella Typhimurium|Salmonella Typhimurium oral challenge. Dose-escalating (1-5x10\^3 CFU, 1-5x10\^4 CFU, 1-5x10\^5 CFU, 1-5x10\^6 CFU)
40815113|NCT01689025|DRUG|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
41333184|NCT05840341|DRUG|QingyiHuaji optimized formula|Qingyihuaji Optimization Formula each bag contains: (1)Scutellaria barbata D. Don (Banzhilian); (2) Hedyotis diffusa Willd. (Sheshecao); (3) Amorphophallus rivieri Durieu (Sheliugu); (4) Amomi Fructus Rotundus (Doukou); (5) Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan); (6) Semen Coicis (Yiyiren); (7) Ganoderma lucidum (Curtis) P. Karst. (Lingzhi). One bag at a time, twice a day, rinsing with boiling water, continuous administration, oral administration in the morning and evening, every 3 weeks as a cycle.
40815114|NCT01689025|DRUG|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
41333185|NCT04555408|DEVICE|blue light|Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.
40815115|NCT01706497|DEVICE|Cerebral tissue oxygen saturation monitoring, blinded|
40815116|NCT00442442|DEVICE|mosquito coils|mosquito coil / night mosquito coil \& LLIN / night
40815117|NCT00442442|DEVICE|LLIN|Sleep under LLIN every night
40815118|NCT02213848|DRUG|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
41333186|NCT04555408|DEVICE|bright light|Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.
40815119|NCT02213848|DRUG|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
40815120|NCT01235923|DRUG|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
41333187|NCT04555408|DEVICE|dim light|Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
41333188|NCT02718391|BIOLOGICAL|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
40815121|NCT01235923|DRUG|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
40815122|NCT03354312|DRUG|Lidocaine Hydrochloride 1% Gel|Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.
40815123|NCT03354312|DRUG|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride|Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
40815124|NCT02606981|DEVICE|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
40815125|NCT02606981|DEVICE|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
40815126|NCT03360890|DRUG|Pembrolizumab|Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.
40815127|NCT03360890|DRUG|Docetaxel|Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.
40815128|NCT00169234|BIOLOGICAL|PCV7, Prevnar®|Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
40815129|NCT00169234|BIOLOGICAL|Pneumovax 23|Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
40815130|NCT00289068|PROCEDURE|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
41333189|NCT03454204|OTHER|Pharmacokinetic|Analysis of blood samples
41333190|NCT00541736|DRUG|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
41333191|NCT04182906|BEHAVIORAL|Care Coordination|Screening and referral for basic needs and adult mental health
41333192|NCT04182906|BEHAVIORAL|Resiliency Clinic|Mindfulness-based caregiver-child group medical care
41333193|NCT04182906|BEHAVIORAL|Usual Care|Usual Primary Pediatric Care
41483356|NCT03241381|DIAGNOSTIC_TEST|Photometry|Serum- Hemoglobin assay
41483357|NCT03241381|OTHER|Russels periodontal index|Clinical examination for periodontitis
41483358|NCT03324321|OTHER|Hypocapnia via Hyperventilation Protocol|90 seconds of hyperventilation using a metronome to lower levels of -5mmHg and -10mmHg below baseline EtCO2
41483359|NCT01917864|BEHAVIORAL|iPad Application|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
40815131|NCT00289068|PROCEDURE|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
40815132|NCT00289068|PROCEDURE|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
40815133|NCT03425435|OTHER|QoL and developed questionnaires for healthcare research|Questionnaires
40815134|NCT05210803|OTHER|No intervention.|All subjects that previously received RGX-314 in a parent study
40815135|NCT00974441|DRUG|Divalproex Sodium|500 mg Extended Release Tablet
40815136|NCT00974441|DRUG|Depakote®|500 mg Extended Release Tablet
40815137|NCT01396824|OTHER|No intervention|No intervention
40815138|NCT03549208|BIOLOGICAL|LBVE01|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
40815139|NCT03549208|BIOLOGICAL|LBVE02|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
40815140|NCT03549208|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
41013506|NCT05556876|DIETARY_SUPPLEMENT|Protein omega-3|An oral supplement with a high content of protein and with essential fatty acids
41013507|NCT06309082|PROCEDURE|Amputation|Amputation was performed on diabetic foot ulcer
41013508|NCT06309082|PROCEDURE|Debridement|Debridement of diabetic foot ulcers was performed
41333194|NCT06156904|DEVICE|Bone grafting for the treatment of surgically created bone defects or bone defects/voids resulting from traumatic injury to promote healing in the pelvis, upper and lower extremities.|"All patients enrolled in this clinical investigation will undergo a reconstruction of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone as per the standard of care at the investigational sites. Patients will be treated with b.Bone which will be used as a bone substitute in isolation or as a graft expander to promote healing in the pelvis, upper and lower extremities.~b.Bone is a bone substitute without initial mechanical properties, therefore it is to be used in conjunction with internal/external fixation devices suitable for primary stabilization."
41333195|NCT00204412|DIETARY_SUPPLEMENT|Flax lignan|543 mg SDG per day
41013512|NCT02135679|RADIATION|Radiotherapy|
41333196|NCT00204412|BEHAVIORAL|Exercise (walking)|walking 45 minutes per day 5 days per week
41333197|NCT03287869|DRUG|Brexpiprazole|Brexpiprazole tablets
41333198|NCT00915538|DRUG|pMDI budesonide/formotrol 160/4.5 is in group 1|The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
41333199|NCT00915538|DEVICE|Symbicort 160/4.5 plus Aerochamber Plus included in group 2|Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
41333200|NCT02081560|DRUG|Colistin|Colistin i.v. three times daily as long a necessary for infection treatment
40815141|NCT02994472|RADIATION|Gastric emptying scintigraphy using 99mTc-DTPA|
40815142|NCT02269813|OTHER|MammaPrint|
40815143|NCT02269813|OTHER|BluePrint|
40815144|NCT02269813|OTHER|TargetPrint|
40815145|NCT01151059|BIOLOGICAL|Trivalent subunit inactivated flu vaccine, Formulation 2010-2011|This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
40815146|NCT05617924|PROCEDURE|Physical Therapy|Therapy methods using physical agents in treatment
40815147|NCT02348879|DRUG|AMG 403|AMG 403 is for treatment of subjects with chronic pain
40815148|NCT02348879|DRUG|Placebo|contains no active drug
40815149|NCT05846880|DRUG|Lenalidomide|For first three cycles, taken orally once daily for 28 days at 10mg/day dose. After cycle 4, taken orally once daily at 15 mg/day dose
40815150|NCT05846880|DRUG|Maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, will start maintenance therapy with Monthly replacement with 50,000 IU
40815151|NCT05846880|DRUG|No maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, stop replacement and continue monitoring levels
40815152|NCT00284284|DEVICE|Use of a rehabilitation brace|
40815153|NCT03037476|BEHAVIORAL|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
40815154|NCT03037476|BEHAVIORAL|Assessment Only|The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
40815155|NCT02665351|DRUG|Peramivir|The two regimens of Peramivir were compared
41333201|NCT04393909|BEHAVIORAL|Diagnostic Uncertainty Educational Curriculum|"A Diagnostic Uncertainty Educational Curriculum will consist of an interactive, one-hour teach-the-teacher workshop delivered to resident-attending pairs early on during their inpatient medicine rotation. During the workshop, we will discuss the motivation behind teaching diagnostic uncertainty, review factors that may predict risk of diagnostic error during hospitalization, introduce the framework. Each resident-attending pair will work through a case-based exercise focused on managing learners' diagnostic uncertainty during rounds. Our research team will also conduct Training for clinical staff working on intervention units and will provide at-the-elbow support during the intervention period of the main trial."
41333202|NCT04393909|BEHAVIORAL|Diagnostic Timeout|"A Diagnostic Timeout is a structured pocket guide that clinicians may use to address uncertainty in a step-wise approach for patients who have risk factors for diagnostic error. This tool can be used during or after clinical rounds, inside or outside of a patient's room if the patient is agreeable. The Diagnostic Timeout will be introduced as part of the Diagnostic Uncertainty Educational Curriculum as well as Training."
41333203|NCT04393909|BEHAVIORAL|Patient Diagnostic (Dx) Questionnaire|"We will administer a survey, the Dx Questionnaire, to patients which asks a series of questions on communication regarding diagnosis with the care team. Patients admitted to inpatient units within the prior 24 hours will be approached after asking the patient's nurse to determine whether it is the appropriate time to approach for enrollment. Upon explaining the objectives of the survey and obtaining verbal informed consent, patients will be asked to complete the Dx Questionnaire via REDCap on an iPad. Alternatively, the research assistant administering the survey will go through the Dx Questionnaire with the patient and record their answers in REDCap on their behalf. If patients' answers indicate a gap in communication (i.e., an answer of No on a question), the Research Assistant will ask for permission to follow-up within the next few days and will relay the gap in communication to the patients' care team (i.e., nurse)."
41333204|NCT04393909|BEHAVIORAL|Enhancements to Epic-integrated Quality & Safety Dashboard|"Epic-integrated Quality and Safety Dashboard, currently in operational use at BWH, will be enhanced to include a new diagnostic safety column. Clinical staff will receive Training and at-the-elbow support by the research team upon implementation."
41333205|NCT03199742|BEHAVIORAL|Personalized App Coaching|All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress \& use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.
41333206|NCT03199742|BEHAVIORAL|Active Comparator|Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
41333207|NCT04029623|OTHER|Partnered Rhythmic Rehabilitation (PRR)|Partnered Rhythmic Rehabilitation (PRR) is moderate intensity, cognitively-engaging social dance that targets postural control systems. PRR involves learning complex stepping patterns and fosters tactile communication of motor goals between partners, enhancing social interaction's effect on cognition. Class sizes will consist of 10 or fewer pairs of participants with pAD and partners to maximize safety. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Classes include practicing previously-learned steps, a 20-minute standing warm-up, and partnering and rhythmic enhancement exercises.
41333208|NCT04029623|OTHER|Group walking (WALK)|WALK sessions consist of 10 minutes of warm-up, and evaluation/tips for practicing safe walking form mechanics (i.e., head up, shoulders relaxed, abdominals engaged, heel strike, roll and toe off; keep natural stride length, and speed up cadence if increased speed is desired), 55 minutes of walking with breaks, and 20 minutes of balance and stretching. WALK will take place in small groups with research assistants and trained family members and/or caregivers to control for social effects/contact of intervention. Participants of similar walking abilities will be 'buddied' with research assistants and trained physical therapy students who will act as group backmarkers, although participants will lead the pace. WALK participants will keep walking logs documenting their progress. WALK is expected to expend 3 metabolic equivalents (METs), like that of PRR.
41333209|NCT03867110|DRUG|Placebo|
41333210|NCT03867110|DRUG|Ezetimibe 10 mg|
41333211|NCT03867110|DRUG|Atorvastatin 10 mg|
41333212|NCT03867110|DRUG|Atorvastatin 20 mg|
41333213|NCT03867110|DRUG|Atorvastatin 40 mg|
41333214|NCT03867110|DRUG|Atorvastatin 80 mg|
41333215|NCT01586650|OTHER|aerobic training|The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
41333216|NCT01586650|OTHER|Stretching exercises|Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
41333217|NCT06481020|DIETARY_SUPPLEMENT|Plant sterols 2g/day|PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day) during 8 weeks
41333218|NCT06481020|DIETARY_SUPPLEMENT|Placebo|Sachet containing the powdered excipients of the dietary supplement during 8 weeks
41333219|NCT06508970|BEHAVIORAL|Experimental RAM-based virtual reality glasses|"RAM-based virtual reality glasses were applied to the experimental group for 4 weeks.~Video contents:~1. week; 1st sub-dimension (physiological domain)~2. weeks; 2nd sub-dimension (self-space) Three weeks; 3rd sub-dimension (Role function/function area) week 4; 4th sub-dimension (Independence and interdependence/autonomy)"
41333220|NCT06508970|OTHER|pre-post test|Adaptation Difficulty Assessment Scale in the Elderly, Life Satisfaction Scale in the Elderly , and Psychological Well-Being Scale in the Elderly
40815156|NCT01490736|DRUG|Lemuteporfin|lemuteporfin topical solution, 1%
40815157|NCT03257202|DRUG|Clindamycin 1% Gel|topical clindamycin
40815158|NCT03257202|DRUG|Benzoyl peroxide 5% gel|topical benzoyl peroxide
40815159|NCT03257202|DRUG|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
40815160|NCT05143749|OTHER|video tutorial|get video tutorial
40815161|NCT05296824|PROCEDURE|Cryoballoon ablation for the treatment of atrial fibrillation|Cryoballoon ablation for the treatment of atrial fibrillation
41333221|NCT03828500|BEHAVIORAL|Assistant-encouraged fasting up to ASA/CAS guideline limits|Research Assistant encourages patient to drink clear fluids up to 2 hour limit before surgery, in accordance with the latest ASA and CAS guidelines.
41333222|NCT04216706|DRUG|tailored pharmaceutical treatment|Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).
41333223|NCT01300585|OTHER|MRI|Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
41333224|NCT03989856|DEVICE|2-0 polyglican absorbable sutures|The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
41333225|NCT03989856|DEVICE|Diathermy|bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). I
41333226|NCT01661309|DIETARY_SUPPLEMENT|Inactive lozenge|Manufactured to mimic 1mg methylcobalamin lozenge
41333227|NCT01661309|DIETARY_SUPPLEMENT|Methylcobalamin|Aimed at reducing plasma tHcy.
41333228|NCT04547998|DEVICE|Control Intervention (UVB)|Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.
41483360|NCT05072821|DRUG|Botulinum Toxin Type A Injection [Botox]|After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.
41013513|NCT03995238|BEHAVIORAL|Error-augmentation gait training|Split-belt treadmill training to enhance between-limb asymmetry during treadmill walking, which is intended to force compensation and correction of step asymmetry during treadmill walking. The error-augmentation gait training program is delivered in 8 sessions over 4 weeks.
41013514|NCT03995238|BEHAVIORAL|Error-correction gait training|Metronome will be set to cue participants to overcorrect between-limb step asymmetry during treadmill walking, through use of asymmetrical metronome tones in a 2:1 ratio. The error-correction gait training program is delivered in 8 sessions over 4 weeks.
41013515|NCT03995238|BEHAVIORAL|Supervised walking|An active comparator intervention, in which a supervised treadmill walking program is delivered without attempt to correct step asymmetry. The supervised walking program is delivered in 8 sessions over 4 weeks.
41013516|NCT03660046|DRUG|Depot medroxyprogesterone acetate (DMPA)|Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
41013517|NCT03660046|DRUG|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
41013518|NCT03660046|DRUG|Levonorgestrel IUD (Lng-IUD)|The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
41013521|NCT05264974|BIOLOGICAL|Autologous total tumor mRNA loaded DOTAP liposome vaccine|"All participants will receive three doses of RNA-NP vaccine (1 dose every 2 weeks) intravenously.~The vaccine dose given will be determined by a 3 + 3 design. Participants will be given one of the following vaccine doses:~Dose level 0 (starting dose level): 0.00125 mg/kg mRNA in 0.01875 mg/kg LP; Dose level 1: 0.0025 mg/kg mRNA in 0.0375 mg/kg LP; Dose level 2: 0.005 mg/kg mRNA in 0.075 mg/kg LP; or Dose level 3: 0.01 mg/kg mRNA in 0.15 mg/kg LP~If 3 or more of the initial 6 subjects experience a dose-limiting toxicity, then the initial starting dose will be reduced (dose de-escalation) to 0.000625 mg/kg mRNA encapsulated in 0.009375mg/kg LPs (Dose level -1)."
40815162|NCT06488612|PROCEDURE|Minced skin grafts for donor site|"After harvesting of STSG using watson's knife and coverage of the recipient site, the excess graft edges will be trimmed and together with any unused graft pieces will be collected in saline filled plate to prevent graft dissecation. Graft pieces will be placed over a rigid surface such as dorsum of a stainless steal jar or pot. Mincing of these small grafts will be done manually using large blade (no. 25) and sharp scissors. The resulting pasty graft mass composed of a large number of minced skin graft particles and a small amount of saline solution will be spread onto one half of the donor site using small dressing forceps.~Minced skin grafts will not be used on the other half (control side). The entire donor site will be covered with non-adherent absorbable dressing in the form of Vaseline gauze and sterilized cotton-filled dressing followed by elastic compression bandage."
40815163|NCT03396367|BEHAVIORAL|PARTNER|The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.
40815164|NCT03396367|BEHAVIORAL|Education Intervention|The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
40815165|NCT01412450|DEVICE|nitinol stent|implantation of one Protégé EverFlex stent
40815166|NCT04282265|DIETARY_SUPPLEMENT|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 11 weeks
40815167|NCT04282265|DIETARY_SUPPLEMENT|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 11 weeks
40815168|NCT01792713|DRUG|Sertaconazole 2% cream|
40815169|NCT01792713|DRUG|Placebo|
40815170|NCT01369641|PROCEDURE|Insertion of Pressure Equalization (PE) Tubes|If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.
40815171|NCT01369641|DRUG|Sodium Thiosulfate (STS)|Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
40815172|NCT01369641|OTHER|Saline (Placebo)|Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.
40815173|NCT01369641|DRUG|Cisplatin|Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
40815174|NCT04624386|OTHER|Thiol disulfide level|Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
40815175|NCT06384508|BEHAVIORAL|SHINE-VR|"The SHINE-VR takes place after module 6 of TF-CBT and is followed by the rest of the regular treatment. It consists of the following 3 VR sessions à 45min:~* Introduction: getting acquainted with VR, playing a VR game developed for the feasibility study (Krupljanin et al., in preparation), receiving psychoeducation about seeking help.~* Shame: virtual group therapy setting, psychoeducation about shame, virtual peers sharing thoughts of shame and their learnings/positive affirmations.~* Self-compassion: practicing self-compassion using an immersive perspective-changing task in VR."
40815176|NCT05064020|DRUG|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.
40815177|NCT03732495|DRUG|Lenvatinib + Denosumab|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met"
40815178|NCT01679548|PROCEDURE|Single-port LAVH|LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.
40815179|NCT01679548|PROCEDURE|Three-port LAVH|Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
40815180|NCT03489655|BEHAVIORAL|Maintenance Phase Intervention|The CHW will utilize motivational interviewing techniques over phone calls to reinforce all asthma education provided in the AI phase, including asthma basics, triggers and reduction strategies, purpose of medications, and steps for proper medication use. The CHW will identify barriers the participant is facing in management of their asthma and set goals to overcome them. The CHW will encourage regular visits with the Primary Care Physician and assist with referrals for other medical and social services, as needed. CHWs will check-in with participants via phone, monthly for the first 6 months and bi-monthly in the remaining 6 months Participants will receive bi-monthly data collection follow-up phone calls by a Research Assistant.
40815181|NCT06283940|OTHER|Physiotherapist-led exercise based cardiac rehabilitation (PT-X)|Individually prescribed centralcirculatory aerobic exercise and muscular endurance training twice a week for 60 minutes each session over 12 weeks in a hospital-based setting, and two sessions of home-based exercise recorded in an exercise diary.
41483361|NCT05072821|DRUG|0.9% Sodium Chloride Injection|After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
41483362|NCT00131378|DRUG|Nutropin AQ growth hormone|Participants will give themselves injections of growth hormone every night for 6 months.
40815182|NCT06020066|DRUG|EGFR-TK Inhibitor|Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.
40815183|NCT06020066|RADIATION|Stereotactic radiotherapy|Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist.
41333229|NCT04547998|DEVICE|Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)|Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.
41483363|NCT00131378|DRUG|Placebo Growth Hormone|Participants will give themselves injections of placebo growth hormone every night for 6 months.
41333230|NCT02622438|OTHER|Followed with an initial assessment, six months and followed annually for 3 years corresponding to the usual follow-up of the patient.|
41333231|NCT05167968|OTHER|No intervention (Observational cohort)|"For each patient, evaluation and adhesion to diuretics at inclusion are recorded:~* Self-questioning of medication adherence: Girerd questionnaire~* Assessment of the Medication Possession Ratio~* Social and demographic data~* Comorbidities~* PH characteristics"
41483364|NCT04102852|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG ATCC 53103|probiotic administration at two different doses for 1 month
41013522|NCT06146569|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Current will be applied bilaterally from the tragus and turbinate parts of the ear with the VagustimTM device. The current frequency to be used in modulation mode is 10 Hz, and the pulse width is 300 μs (In modulation mode, the pulse rate and width are automatically changed in a loop pattern. The pulse width is reduced by 50% from its original setting in 0.5 seconds; then, the pulse rate is changed in 0.5 seconds, reduced by 50% from the original setting. Total cycle time is 1 second.). The current intensity will be applied for 5 minutes, keeping the current constant where the participant feels comfortable.
41483365|NCT05787470|BEHAVIORAL|Quantative sensory testing|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
41483366|NCT05787470|DIAGNOSTIC_TEST|Blood Draw|Sample of blood will be taken.
41013523|NCT06146569|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|For 5 minutes, sham applications will be applied using a current-free headset specifically designed for this purpose. Participants will observe the device's functionality, but it will not supply any current.
41333232|NCT00263250|PROCEDURE|watchful waiting or tension-free hernia repair|
41483367|NCT02363608|OTHER|standard post surgery care|
41483368|NCT02363608|BEHAVIORAL|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
41483369|NCT02363608|BEHAVIORAL|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
40815184|NCT05432362|OTHER|Aronia Juice|The intervention is based an the additional consumption of 200 ml natural juice a day for a period of six weeks. The participants are asked to drink the natural and commercially availabe juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
40815185|NCT05432362|OTHER|Placebo|A beverage is prepared according to a known recipe. It contains macro- and micronutrients in comparable amounts like the aronia juice. It is completely polyphenol free.
40815186|NCT05247957|BIOLOGICAL|CAR-NK cells|NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7
40815187|NCT00725192|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
41333233|NCT00055848|GENETIC|cytogenetic analysis|
41333234|NCT00055848|GENETIC|gene mapping|
41483370|NCT01120652|BEHAVIORAL|Mind-Body Skills Training (MBST)|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
41013535|NCT02666235|PROCEDURE|Remote ischaemic conditioning|Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
41333235|NCT00055848|GENETIC|microarray analysis|
41333236|NCT02187341|DIETARY_SUPPLEMENT|5-HTP|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
41333237|NCT02187341|DIETARY_SUPPLEMENT|Placebo|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
41483371|NCT01120652|BEHAVIORAL|Supportive Counseling (SC)|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
41483372|NCT04284514|DRUG|AKB-9778 Ophthalmic Solution|AKB-9778 Ophthalmic Solution
41483373|NCT04284514|DRUG|Placebo Ophthalmic Solution|Matched vehicle-control
41483374|NCT03816215|BEHAVIORAL|Volunteer experience|Participants will be assigned to a meaningful volunteer experience from a menu of local options (e.g., volunteering at an animal shelter or in a library) for 30 hours.
40815188|NCT00725192|BEHAVIORAL|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
40815189|NCT04506060|OTHER|serum withdrawal|Serum of the transplant patient. In the transplanted patient, the search for the BK virus is traditionally carried out during visits in the first year after transplantation.
40815190|NCT04826848|DIAGNOSTIC_TEST|Lactate|We will evauate the lactate clearance of the patients in 6 hours period. Lactate clearance = \[(Initial lactate - 6th hour lactate) / Initial lactate\] \* 100
40815191|NCT04053946|DEVICE|Next Science Wounds Gels|SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
40815192|NCT03324334|DIAGNOSTIC_TEST|Thyroid antibodies|Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
40815193|NCT03324334|DIAGNOSTIC_TEST|Thyroid sonography|Thyroid sonography to detect anatomical changes in thyroid
40815194|NCT05451706|BEHAVIORAL|Mental help-seeking self-persuasion|Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
40815195|NCT02428751|DRUG|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
40815196|NCT02428751|DRUG|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
40815197|NCT02428751|DRUG|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
41156008|NCT03460496|BEHAVIORAL|music therapy|music therapy with premature infants and their parents creates a new dimension of contact, and helps stabilize the child and supports their development through music. It also reduces the anxiety of parents, and enhances self-efficacy and makes them more sensitive to their child 74,75, thus enhancing the parent-child relationship. In standard care, music therapy is offered only during hospitalization. In the new model of care, after NICU discharge, the program will offer 10 follow-up sessions at the family's home or in the music therapists' private practice.
41483375|NCT06346002|BEHAVIORAL|Mindfulness-based intervention|The MBI program implemented comprised ten weekly sessions. Please refer to the arm/group descriptions for further details.
41483376|NCT03197558|COMBINATION_PRODUCT|Tymbion Iontophoresis and Tube Delivery System (TDS)|Subjects will receive active Tymbion iontophoresis and tube insertion using the Tube Delivery System in all ears indicated for tube placement.
41483377|NCT05009732|DRUG|GT0918|300mg once daily orally
41483378|NCT05009732|DRUG|Standard of care|Local standard of care per written policies or guidelines
40815198|NCT02428751|DRUG|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
40815199|NCT02428751|DRUG|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
40815200|NCT02428751|DRUG|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
40815201|NCT03911752|OTHER|Semi-structured interviews|Semi-structured interviews were used to obtain the main data in this study.
40815202|NCT03911752|OTHER|Canadian Occupational Performance Measure|The Canadian Occupational Performance Measure was used with the group of people with Acquired Brain Injury to know their occupational priorities.
41483379|NCT05009732|DRUG|Matching placebo|Matching placebo
41483380|NCT03559166|DRUG|BLD-2660|Randomized to active product or placebo
40815203|NCT05345574|DRUG|dexmedetomidine infusion|dexmedetomidine as anaesthetic adjuvant
40815204|NCT05345574|DRUG|remifentanil infusion|remifentanil as anaesthetic adjuvant
40815205|NCT00735826|DRUG|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
41013536|NCT02666235|PROCEDURE|Arm cuff placement, no inflation;|Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
41156009|NCT03460496|BEHAVIORAL|other health care professionals|the APN will contact and involve other health care professionals, like the family's paediatrician, the outpatient midwife, the community health care nurse or the mother and father counselling as soon as need becomes evident. The APN will help set up meetings between health care professionals and the family, and will keep them up-to-date on the family's situation.
41483381|NCT03938129|OTHER|Blood sample|1st trimester blood sample for bio-bank
41483382|NCT03938129|OTHER|Urine sample|1st trimester urine sample for bio-bank
41483383|NCT03938129|OTHER|Pregnancy, maternal health, and fetal health data|Pregnancy, maternal health, and fetal health data
41483384|NCT03985787|BEHAVIORAL|Resistance Training|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
41483385|NCT01684436|DEVICE|Punctal Plug|Punctal plugs inserted into the study eye on Day 1.
41333238|NCT04313101|OTHER|withdrawl of blood samples for thyroid function testing|"Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories~* Euthyroid ( Normal TSH, FT3 and FT4)~* Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3).~* Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4)~* Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels."
41333239|NCT04785937|DIAGNOSTIC_TEST|Ultrasound and Magnetic Resonance|liver ultrasound (US), including shear wave elastography (SWE) with liver stiffness measurement and US- fatty liver indicator (US-FLI), and a multiparametric unenhanced liver magnetic resonance examination including MR spectroscopy (MRS), Proton Density Fat Fraction (PDFF) and T2\* measurement with Multiecho technique, T1 mapping with Inversion Recovery method, and Intravoxel Incoherent Motion diffusion weighted imaging (IVIM-DWI), measuring different parameters.
41333240|NCT00728663|BIOLOGICAL|cetuximab|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
41333241|NCT00728663|DRUG|docetaxel|"75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
41333242|NCT01394367|OTHER|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
41333243|NCT04862741|DRUG|NX-13 250mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
41333244|NCT04862741|DRUG|NX-13 500mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
41333245|NCT04862741|DRUG|NX-13 500mg MR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
41333246|NCT04862741|DRUG|Placebo|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
41333247|NCT04266158|DEVICE|Myoelectric UE Device-UE Orthosis-No Device|all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects.
41483386|NCT01302522|BEHAVIORAL|Mental practice|All patients in the study will be administered a regimen of locomotor therapy (rehabilitative therapy working on walking). Half of the patients will also be administered a regimen in which they mentally rehearse the exercises that they have just physically performed.
41483387|NCT02044549|DRUG|carbetocin|Oxycontin analogue
41483388|NCT02044549|DRUG|Syntometrine|Uterotonins
41483389|NCT01490931|DRUG|Ketorolac Nasal Spray|15.75 mg nasal spray delivery to each nostril no more than every six hours
40815206|NCT05497531|DIAGNOSTIC_TEST|ctDNA Blood Collection|Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy
41156010|NCT03460496|BEHAVIORAL|interprofessional roundtable meetings|interprofessional roundtable meetings with health care professionals involved in the care of a specific family will be held every two weeks. The meeting is aimed at developing consensus on the best possible support in the care of preterm infants and their families. Parents will be invited to participate in these meetings, led by the APN. The meeting will focus on two family situations, and then determine and initiate supportive interventions in collaboration with the parents.
41483390|NCT01689662|DRUG|Tc 99m EC20|
41483391|NCT04414436|BEHAVIORAL|GYNEA- digital coping program for women after gynaecological cancer|6 modules with relevant information and tools for coping after cancer
41483392|NCT01834430|DIETARY_SUPPLEMENT|enteral nutrition|
41483393|NCT03342599|DIETARY_SUPPLEMENT|Alpha Lipoic Acid Supplement|Alpha lipoic acid ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
41483394|NCT03342599|DIETARY_SUPPLEMENT|Placebo|Cellulose fiber ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
41483395|NCT01874795|DEVICE|TENS|Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).
41483396|NCT01874795|DEVICE|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
41483397|NCT04542707|PROCEDURE|joint manipulation|Thrust manipulation to the spine, hand, and foot
41483398|NCT04542707|PROCEDURE|Exercise|Strength training, bike aerobic training, and yoga exercise
41483399|NCT04542707|DEVICE|Soft tissue massage|Graston tool
41483400|NCT02416024|DEVICE|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
41483401|NCT04111848|DRUG|Ketamine|"Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour."
41333248|NCT06042192|DRUG|TK-254RX|Two TK-254RX per day to predetermined application site
40815207|NCT02136758|BEHAVIORAL|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
40815208|NCT04187508|DRUG|AZD8154 nebulizer suspension, 20 mg/mL|Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
41483402|NCT04111848|DRUG|ketamine and magnesium|Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
40815209|NCT04187508|DRUG|Placebo|Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
40815210|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
41483403|NCT00102830|DRUG|AMG 386|
40815211|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
40815212|NCT06310967|DRUG|IG3018|Oral administration
40815213|NCT06310967|OTHER|Placebo matching IG3018|Oral administration
40815214|NCT04160286|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)"
40815215|NCT05664958|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block with liposomal bupivacaine and immediate release bupivacaine
41483404|NCT01941355|BEHAVIORAL|Exercise training component|The physical exercises consist of; deep breathing exercises and breathing exercises using incentive spirometry with expiratory positive pressure airway, cycling exercises during hospitalisation and an individualised exercise programme running from discharge to 4 weeks following surgery.
41483405|NCT01941355|BEHAVIORAL|Psycho-educative component|The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse. The last consultation will take place 4 weeks following surgery.
40815216|NCT05664958|DRUG|bupivacaine liposome injectable suspension|133 mg liposomal bupivacaine per side.
40815217|NCT05664958|DRUG|bupivacaine|20 ml bupivacaine 0.25% per side.
40815218|NCT05141708|DRUG|Talazoparib|Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
41333249|NCT04424316|BIOLOGICAL|RSVpreF|RSV vaccine (RSVpreF)
40815219|NCT01274923|DEVICE|"MEDISPEC treatment probe"|shock wave treatment
40815220|NCT03650803|DEVICE|3D MR Fingerprinting scan|"3D MR Fingerprinting technique is a non-contrast technique and generates quantitative information about MR-visible tumors without having to administer contrast.~MR Fingerprinting software is used in conjunction with a standard-of-care MRI scan."
40815221|NCT04880629|BEHAVIORAL|Baseline condition|In the baseline sleep condition, participants are instructed not to restrict their sleep on the night before completing an oral glucose tolerance test (OGTT). Participants are prescribed sleep-wake timings based on their preferred and averaged sleep durations measured over 2 weeks using a wearable sleep tracker. Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
40815222|NCT04880629|BEHAVIORAL|Sleep restriction condition|In the sleep restriction condition, participants are prescribed sleep timings to restrict their sleep by 1 to 2 hours on the night before completing an oral glucose tolerance test (OGTT). Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
40815223|NCT01944098|DRUG|Lidocaine|
40815224|NCT01944098|DRUG|Placebo|
41333250|NCT04424316|BIOLOGICAL|Placebo|Placebo
41333251|NCT04103242|OTHER|16s rRNA gene sequencing|High-throughput sequencing of the microbial 16s rRNA subunit to define the abundance of microbial phyla and genera
41333252|NCT03607071|DRUG|Prednisolone and taper|Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
41333253|NCT03067844|DRUG|Alirocumab|Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
41333254|NCT01855113|DEVICE|Invisalign|
41333255|NCT05872256|DRUG|0.045% Tazarotene/0.01% Halobetasol Lotion|FDA approved drug for psoriasis treatment
41333256|NCT01851863|DRUG|Omeprazole|Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
41333257|NCT01851863|DRUG|Flupentixol-Melitracen(psychological and GI) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
40815225|NCT04155086|BIOLOGICAL|the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis|The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
40815226|NCT06511453|DEVICE|Acupressure (using AcuWand or pencil eraser)|"The acupressure procedure will consist of medium-deep pressure as tolerated at each assigned point applied in a circular motion. Subjects will be trained in the appropriate performance of the treatment at all points and complete the first treatment under supervision. Acupressure treatment will last for 2-3 minutes per point and be administered remotely every other day for 5 weeks.~Acupressure will be performed using a tool (AcuWand) and a pencil (the pencil's eraser head will be used as an alternative/backup tool) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. In the event AcuWand/pencil is not available, participants can use fingers/thumbs for self-acupressure."
41483406|NCT04414306|OTHER|In-person cancer screening education|Participants will receive verbal instruction covering the key messages, including risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. These in-person programs will take place in a variety of settings such as community-based organizations (e.g., community businesses, libraries, faith-based organizations, senior centers), fairs and community events, and clinical centers (e.g., health centers, local hospitals). Depending on the setting, education will be facilitated with one or more of the following educational tools: inflatable colon exhibit, PowerPoint presentation, flip chart/flip book, written materials/handouts, and displays. Data will be collected via pre- and post-tests. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
40815227|NCT01031589|DRUG|TMC278 (Rilpivirine) LA; Placebo|
40815228|NCT02256384|DEVICE|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
40815229|NCT05808309|OTHER|Salivary sampling|Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)
40815230|NCT06429696|DRUG|PD-L1 inhibitor combined with apatinib|Every 3 weeks (21 days) is a treatment cycle. After 4-6 cycles of induction therapy, patients whose efficacy is evaluated as CR, PR or SD (according to RECIST 1.1) will enter maintenance therapy until the disease progresses and becomes intolerable. Toxic and side effects, death, withdrawal of information or the investigator's decision to withdraw the subject from the study, non-compliance with study treatment or other reasons specified in the study procedures or protocol, or treatment for up to 2 years. Maintenance treatment: PD-L1 inhibitor + apatinib 250 mg po qd, maintained for up to 2 years. Note: The specific PD-L1 inhibitor is selected by the researcher, such as adebelimab 1200mg iv, q3w; or atezolizumab 1200mg iv d1, q3w; or durvalumab 1500mg iv d1, q3w . The selection of PD-L1 inhibitors in the maintenance phase is consistent with the first-line standard treatment in the induction phase.
40815231|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|"In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged \> 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
40815232|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|"In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~1. Fit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~2. Unfit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~3. Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
40815233|NCT03720041|DRUG|R2: Lenalidomide plus placebo maintenance|"Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Placebo: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
41013539|NCT06155903|PROCEDURE|Selective Spinal Anesthesia|Selective Spinal Anesthesia will be performed at the L2-L3 or L3-L4 interspace with the patients lying in the lateral position (fractured side up). Anesthesiologists will determine the needling point for spinal anesthesia with reference to Tuffier's line, a virtual line connecting the tops of the iliac crests of a patient. A small dose of LA (4 ml of 1% lidocaine) will be injected into the skin and soft tissues at the planned site of spinal needle insertion. The correct path for spinal needle placement will be identified with the needle infiltration. The technique will be performed aseptically in the subarachnoid space after observing clear Cephalo-Spinal Fluid (CSF) in the spinal needle 25 Gauge, and without releasing the CSF. Selected patients will receive Hypobaric Bupivacaine 0.5% 10 mg and Sufentanil 5 µg and will maintain the lateral position for 15 min. At the end of these they will be gently placed in supine position.
41333258|NCT01851863|DRUG|Flupentixol-Melitracen(psychological) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
40815234|NCT03720041|DRUG|R2: Lenalidomide + ixazomib maintenance|"Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Ixazomib: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
40815235|NCT04293926|OTHER|Exercise|Resistance exercise program for 8 weeks, 3 times a week, with a 60 min session duration.
41333259|NCT01851863|DRUG|Flupentixol-Melitracen(without explanation) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
41333260|NCT00838370|DRUG|Capecitabine, 5-fluorouracil|"Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD\*2A. Patients heterozygous or homozygous mutant for DPYD\*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients."
41483407|NCT04414306|OTHER|Online educational video and website module|Participants will receive online education via a video and website. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
40815236|NCT01482169|DRUG|FFR Measurement with IV Adenoscan® then with Regadenoson|Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
41156011|NCT03460496|BEHAVIORAL|Advanced practice nurses' interventions|The APN will participate in comprehensively planning individual discharge, coordinating services, consulting with other healthcare professionals, assessing needs on a case by case basis, and coaching the family from birth to 6 months after discharge from the NICU. The APN will provide the Newborn Behavioral Observation (NBO), an infant-centred and family-focused method for building relationships, to parents and children, during and after hospitalization. The NBO helps sensitize parents to their infant's competencies and capabilities, teaching them to read their infant's signals and understand their behaviours. It promotes positive interactions between parent and preterm infant. The APN will also offer telephone support and follow-up Visits at home after discharge.
40815237|NCT05012631|DRUG|Losartan|Losartan dosing for participants \<16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
41333261|NCT03423563|DEVICE|Flexible fiberoptic bronchoscopy|Flexible fiberoptic bronchoscopy versus flexible intubation video endoscope regarding intubation time in obese patients
41333262|NCT03423563|DEVICE|Fexible intubation video endoscopy|Fexible intubation video endoscopy
41333263|NCT02967770|OTHER|Molecularly Tailored Second Line Therapy|This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.
41333264|NCT02967770|DRUG|Standard of Care Second Line Therapy|
41333265|NCT00469209|DRUG|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
41333266|NCT00469209|DRUG|Velcade (Bortezomib)|"Arm 1 (Level 1):~1.0 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."
41333267|NCT00469209|DRUG|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
41483408|NCT04414306|OTHER|Online educational video|Participants will receive online education via a video and website about lung cancer screening. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
41333268|NCT00469209|DRUG|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
40815238|NCT02483156|DRUG|Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg|The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
40815239|NCT02483156|DRUG|Sofosbuvir tablet (SOF) 400 mg - once daily|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
41156012|NCT02256488|BIOLOGICAL|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
41156013|NCT02256488|BIOLOGICAL|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
41333269|NCT03934203|DRUG|BI 409306|Film-coated tablet
41333270|NCT03934203|DRUG|Moxifloxacin|Film-coated tablet
41333271|NCT03934203|DRUG|Placebo matching to BI 409306|Film-coated tablet
41333272|NCT05211609|DIAGNOSTIC_TEST|Plasmatic 3-O-Methyldopa dosage|Plasmatic 3-O-Methyldopa dosage
41333273|NCT01256203|DRUG|Solar Protection Formula SPF® 60|Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
41333274|NCT01256203|PROCEDURE|Photobiological testing|Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.
41333275|NCT00537680|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients \> 45 kg/99 lbs: idebenone 900 mg/day
40815240|NCT02483156|DRUG|Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening|RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
40815241|NCT05501431|DEVICE|Verily Study Watch|The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.
40815242|NCT02856243|DRUG|new antiviral therapy|
40815243|NCT00760435|DRUG|Infliximab|5 mg/kg IV over 2 hours once
40815244|NCT00760435|DRUG|Placebo|Placebo (same volume as active drug)
40815245|NCT04506216|OTHER|cohort|"During a regular follow-up visit, the following data will be collected:~* questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)~* bio-electric impedance analysis~* insulin pump and sensor data collection"
40815246|NCT06362473|DRUG|Lipid-lowering treatments|
40815247|NCT05875636|OTHER|Esophagogastroduodenoscopy|All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.
40815248|NCT04192136|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
40815249|NCT04192136|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).
40815250|NCT04192136|OTHER|Exercise Intervention|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands.~On aerobic training days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.~On resistance training days, subjects will be given instructions to complete circuits of resistance exercises. Resistance training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group."
40815251|NCT00003234|DRUG|vinorelbine tartrate|
41156014|NCT02256488|BIOLOGICAL|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
40815252|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 40 minutes later.
41156015|NCT02256488|BIOLOGICAL|TIVf|Single IM administration dose of 0.5 mL of TIVf
41333276|NCT00537680|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
41333277|NCT00537680|DRUG|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
41333278|NCT00014001|DRUG|perphenazine|
41333279|NCT00014001|DRUG|olanzapine|
41333280|NCT00014001|DRUG|quetiapine|
41333281|NCT00014001|DRUG|risperidone|
41333282|NCT00014001|DRUG|ziprasidone|
41333283|NCT00014001|DRUG|clozapine|
41333284|NCT00014001|DRUG|fluphenazine decanoate|
41333285|NCT05754801|DRUG|Yunzhi Essence|Yunzhi Essence capsule
41333286|NCT05754801|OTHER|Placebo|Placebo capsules
41333287|NCT05564676|DIETARY_SUPPLEMENT|flaxseed oil and pomegranate dry extract|The flaxseed oil were yellow capsules with 1.0 g each and the pomegranate dry extract capsules were green with 0.6 g each.
41333288|NCT05564676|DIETARY_SUPPLEMENT|sunflower oil and microcrystalline cellulose|The sunflower oil were yellow capsules with 1.0 g each and the microcrystalline cellulose capsules were green with 0.6 g each.
41156016|NCT04345783|DRUG|Camrelizumab for injection, apatinib mesylate and tegio|Camrelizumab for injection: fixed dose of 200 mg, ivgtt for 30 minutes, given on D1, repeat for every 3 weeks; Apatinib mesylate: 250 mg, p.o, qd; Tegio capsule: p.o., bid, D1-14, repeat for every 21 days.
41156017|NCT01192672|BEHAVIORAL|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
41333289|NCT04023136|PROCEDURE|partial hepatectomy by laparotomy on healthy or pathologic parenchyma.|Preoperative flow and MRI + intraoperative measures of flow and pressures
41156018|NCT01192672|BEHAVIORAL|Control Writing|Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
41333290|NCT00290524|BEHAVIORAL|Oral alimentation started 12 hours after colorectal surgery|
41333291|NCT00145912|BEHAVIORAL|MI + CATCH-IT Internet Site|MI + CATCH-IT Internet Site
41333292|NCT00145912|BEHAVIORAL|BA (brief advice) + CATCH-IT Internet site|BA (brief advice) + CATCH-IT Internet site
41333293|NCT00132314|DRUG|IM risperidone|long-acting injectable risperidone
41333294|NCT00132314|DRUG|oral antipsychotic medication|doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
41333295|NCT06298188|DRUG|Risankizumab|Risankizumab
40815253|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment and fumigation|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 60 minutes later (when fumigation was finished)
40815254|NCT01331837|DRUG|Etanercept|Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
41333296|NCT02163668|OTHER|Yoga Group|8 months of Yoga training
41013540|NCT06155903|PROCEDURE|Peripheral nerve blocks|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during surgery.~Sciatic nerve blocks with para sacral approach will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the related muscles. Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.~Lateral femoral cutaneous, femoral and obturator nerve blocks, femoral will be performed with the ultrasound technique. After identifying the nerves, a needle will be inserted with an in plane approach and will be injected.~The anesthesia mixture will consist for all of :Ropivacaine 0.375% plus Mepivacaine 1% plus dexamethasone 4 mg.~The volumes of the 3 anesthesia mixtures will be respectively: 1ml, 15ml,5ml."
41333297|NCT06526598|PROCEDURE|PMI-targeted pressure support setting and adjustment|During PSV, the pressure support is set and adjusted to a PMI target between 0 and 2 cmH2O.
41333298|NCT06526598|PROCEDURE|VT/RR-targeted pressure support setting and adjustment|During PSV, pressure support is set and adjusted according to a VT/RR target of VT between 6 and 8 ml/kg predicted body weight, RR between 20 and 35 breaths/min, and no signs of respiratory distress.
41333299|NCT02057367|DRUG|Scalp block with 0.5% plain Marcaine|Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
41333300|NCT02057367|DRUG|Scalp block with 0.9% normal saline|Anterior scalp block will be done by using 0.9% normal saline 20 ml.
41333301|NCT00419367|DRUG|Comparator: vorinostat|Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treatment will continue until disease progression, intolerable toxicity, withdrawal of consent, or physician determines it is in best interest of patient to withdrawal.
41483409|NCT04414306|OTHER|Message from healthcare system and online educational video and website module|Patients at one or more healthcare systems will receive a message from their healthcare provider or healthcare system indicating that they are due or overdue for colorectal cancer screening and receive information on how to schedule a related care (e.g. appointment with primary care provider to discuss screening options) and have the option of receiving education via on online video and website module with or without research study participation. Only recipients of this information who opt into the study through a consenting process will be considered study participants. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
41483410|NCT00105573|BEHAVIORAL|Maternal interpersonal psychotherapy (IP)|Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.
41483411|NCT00105573|BEHAVIORAL|Infant-parent psychotherapy|Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
40815255|NCT01331837|DRUG|Tocilizumab|Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
40815256|NCT04014881|BIOLOGICAL|Third-generation anti-CD123 CAR-T cells|From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
40815257|NCT02882867|OTHER|Injuries in Swedish Youth Athletics. The KLUB-study.|
40815258|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
40815259|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
40815260|NCT01659996|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
40815261|NCT01000012|DEVICE|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
41333302|NCT02017457|BIOLOGICAL|Donor lymphocyte infusion|"On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .~* Patients with a sibling donor will receive:~* 5x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6~* Patients with an unrelated donor will receive:~* 1x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6"
41483412|NCT00105573|BEHAVIORAL|Informational meetings plus treatment as usual|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
41013541|NCT06155903|DRUG|Anesthesiological mixtures (Spinal anesthesia)|The anesthesia mixtures will be injected into the subarachnoid space for spinal anesthesia. It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 10 mg and Sufentanil 5 µg.
41013542|NCT06155903|DRUG|Anesthesiological mixtures (Peripheral nerve block)|The anesthesia mixtures will be injected into selected peripheral nerves . It will consist of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
41013543|NCT05962606|DRUG|AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
41013544|NCT05962606|DRUG|Placebo|Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
41013545|NCT02914964|BEHAVIORAL|Swank Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling to study participants to assist them in following the Swank Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
41333303|NCT02017457|DRUG|Azacytidine|"* Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.~* Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.~All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.~In case of stable disease or partial response, Azacytidine will be continued until progression.~In case of disease progression after cycle 6, Azacytidine will be stopped."
41333304|NCT06022172|DIAGNOSTIC_TEST|MOTIVATIONAL INTERVIEW BASED ON THE CALGARY FAMILY INTERVENTION MODEL IN PARENTS WITH A CHILD WITH CEREBRAL PALS.|"Motivational interview based on Calgary family intervention model in parents of children with cerebral palsy.~Introductory information form, caregiving burden, parent self-efficacy and stress coping styles scale will be used."
41333305|NCT06142968|DIAGNOSTIC_TEST|laboratory tests|Laboratory tests inform of Complete blood count , liver function tests , kidney function tests abdominal ultrasound
41333306|NCT05881512|DEVICE|Transcutaneous Upper Airway Stimulation Device|Multiple frequency stimulation of the hypoglossal nerve
41013546|NCT02914964|BEHAVIORAL|Wahls Elimination Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling using to study participants to assist them in following the Wahls Elimination Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
41013547|NCT06580821|PROCEDURE|mucogingigval surgery|Is a form of mucogingival surgery that attempts to improve the height of the keratinized tissue (KT), as well as augment the thickness of the gingival phenotype to facilitate meticulous oral hygiene.
41013550|NCT05735080|DRUG|INX-315|Oral administration
41013551|NCT05735080|DRUG|Fulvestrant|Fulvestrant will be combined with INX-315
41333307|NCT00565812|DRUG|SD-6010|200 mg tablets once a day for 2 years
41483413|NCT00823121|PROCEDURE|freezing embryos by vitrification|vitrification by Cryotop method
41483414|NCT00823121|PROCEDURE|fresh embryo transfers|fresh embryo transfers
41483415|NCT00823121|DRUG|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
41483416|NCT00823121|DRUG|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
41483417|NCT00823121|DRUG|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
41483418|NCT04435821|DRUG|[18F]FTC-146|Participants will be injected with 0.08 mCi/kg \[18F\]FTC-146. A whole-body PET/MRI scan will be performed after injection.
41013552|NCT01298024|OTHER|Early Neuromuscular Exercise|30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
41013553|NCT05407935|BEHAVIORAL|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
41013554|NCT05407935|BEHAVIORAL|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
41333308|NCT00565812|DRUG|SD-6010|50 mg tablets once a day for 2 years
41333309|NCT00565812|DRUG|Placebo|Placebo tablets once a day for 2 years
41333310|NCT00003340|DRUG|cyclophosphamide|
41333311|NCT00003340|DRUG|topotecan hydrochloride|
41333312|NCT05390307|DRUG|Liraglutide / Semaglutide|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection for 6 months.
41333313|NCT05390307|DRUG|Dapagliflozin|Dapagliflozin 5-10 mg once daily for 6 months.
41333314|NCT05390307|DRUG|Liraglutide or Semaglutide / Dapagliflozin|Combined treatment with Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months.
41333315|NCT05390307|DRUG|Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months combined with intensive lifestyle changes.
41483419|NCT06476366|DRUG|Azathioprine|azathioprine will be started at 0.3mg/kg. Anticipated response is after atleast 1 month so testing will be done thereafter ( after checking initial safety profile)
41483420|NCT06476366|DRUG|Methotrexate|Methotrexate will be started at 10mg/week and
41483421|NCT03436914|DRUG|PPI|After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
41483422|NCT02397642|PROCEDURE|IVF/ICSI|
41013557|NCT00065884|DRUG|Valproate|
41333316|NCT05390307|OTHER|Usual care|Usual standard care
41333317|NCT01858896|DRUG|Glucagon-Like Peptide- 1 (GLP-1) infusion|GLP-1 infusion during experimental period
41483423|NCT02397642|DRUG|Human Chorionic Gonadotropin|given in different doses and timing to support the luteal phase
41483424|NCT00416026|BEHAVIORAL|Educational/Counseling/Training|
41013564|NCT06532656|DRUG|Lenacapavir|Tablets administered orally without regard to food
41013565|NCT06532656|DRUG|BIC/LEN FDC|Tablets administered orally without regard to food
41013566|NCT05035069|DRUG|Ciprofol|Ciprofol infusion, starting with 0.8 \~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 \~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.
41013567|NCT05035069|DRUG|Propofol|Propofol infusion, starting with 4 \~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 \~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
41333318|NCT01858896|OTHER|Placebo Comparator: Saline Infusion|Saline infusion (placebo) during experimental period
41013569|NCT05879146|DRUG|Nirogacestat|Given by PO
41483425|NCT00916136|PROCEDURE|Femoral Traction|Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
41013570|NCT06075706|BIOLOGICAL|MC0518|MC0518 will be intravenously infused immediately after thawing.
41013571|NCT06075706|BIOLOGICAL|BAT|BAT including ECP, ATG, etanercept, infliximab or RUX will be administered based on Investigator's decision.
41013572|NCT06014255|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.
41333319|NCT05374291|DRUG|Dapagliflozin 10 mg/day (oral)|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
41483426|NCT00309764|BEHAVIORAL|Telemedicine|
41483427|NCT06359860|DRUG|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
41483428|NCT00254852|PROCEDURE|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
41483429|NCT00254852|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
41013573|NCT06014255|OTHER|Standard of Care|Radical prostatectomy within 4-8 weeks of randomization.
41013575|NCT01993407|BEHAVIORAL|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
41013576|NCT01993407|BEHAVIORAL|Control Task|Participants will complete four, one-hour training sessions in which they will perform a single task each session
41013577|NCT03616756|BEHAVIORAL|Authentic Connections|Authentic Connections support groups for nurse leaders who are also mothers. Meetings occur once a week for one hour.
41333320|NCT05374291|DRUG|Placebo|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
41333321|NCT00605072|DRUG|candesartan|orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
41333322|NCT00605072|DRUG|lisinopril|orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
41013578|NCT03616756|BEHAVIORAL|Protected time|Participants have one hour per week protected time scheduled on their calendar to do with what they choose.
41013579|NCT03004534|DRUG|darolutamide|Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
41013580|NCT01023659|DRUG|bupropion|bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
41013581|NCT01023659|DRUG|varenicline|varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
41013582|NCT01023659|BEHAVIORAL|motivational emails|brief motivational emails, sent weekly for 12 weeks
41013583|NCT02744846|DRUG|Antibiotics exposure|
41333323|NCT00605072|DRUG|hydrochlorothiazide|orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
41333324|NCT00605072|DRUG|nifedipine, long acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
41333325|NCT00605072|DRUG|metoprolol, long-acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
41333326|NCT04904380|OTHER|Active peer learning|HMS, HBS and peer learning in combination with AIR and PRISMS
41483430|NCT00254852|PROCEDURE|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
41483431|NCT00254852|PROCEDURE|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
41483432|NCT00254852|PROCEDURE|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
41483433|NCT02658513|OTHER|Lancet blood sampling|Blood samples will be obtained using a finger-prick (lancet) technique.
40815262|NCT01000012|DEVICE|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
40815263|NCT00531557|DRUG|Darunavir ritonavir|
40815264|NCT03857360|DIETARY_SUPPLEMENT|Pentabiocel|Pentabiocel is the trade name of the product containing the probiotic mixture of: Lactobacillus paracasei LMG P-17504, Lactobacillus plantarum CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500 and Bifidobacterium animalis subsp lactis Bi1 LMG P -17,502.
40815265|NCT03857360|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of maltodextrin which is easily digestible, being absorbed as rapidly as glucose. Maltodextrin listed by the U.S. Food and Drug Administration (FDA) as a safe food additive.
40815266|NCT06490731|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine
40815267|NCT06490731|DRUG|Ketamine|patients Will receive ketamine
40815268|NCT06239467|DRUG|OKI-219|Oral twice daily
40815269|NCT06239467|DRUG|Fulvestrant|Intramuscular injection
40815270|NCT06239467|DRUG|Trastuzumab|Intravenous (IV)
40815271|NCT01015495|DRUG|ranibizumab|0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
40815272|NCT05594017|DRUG|Scopolamine (0.4mg)|Patient receives a dose of scopolamine (0.4mg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
40815273|NCT05594017|DRUG|Placebo|Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
40815274|NCT05645978|DEVICE|Pacemaker insertion|Patients who underwent pacemaker insertion between January 2015 and December 2020
40815275|NCT03086707|OTHER|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
40815276|NCT00614445|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|up to 4 tablets daily, titrated according to the protocol
40815277|NCT00614445|DRUG|Placebo|2 to 4 tablets daily titrated according to the protocol
40815278|NCT03587025|DRUG|Amitriptyline|Amitriptyline compared with placebo for preemptive analgesia in women after abdominal hysterectomy.
40815279|NCT03587025|DRUG|Placebo|Placebo
40815280|NCT05929612|RADIATION|Ultra Low Dose 4 Gy Radiation|4 Gy in 2 fractions
40815281|NCT05852158|DRUG|Cefazolin 2 GM Injection|Single pre-op dose of 2g IV cefazolin
40815282|NCT05852158|DRUG|Cefazolin Injection|Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
41333327|NCT01755741|COMBINATION_PRODUCT|Placebo Vaginal Ring|a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.
41333328|NCT01755741|DEVICE|Condom|Male condom
40815283|NCT06077955|PROCEDURE|Mini-gastric bypass with stapled anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a linear stapler."
40815284|NCT06077955|PROCEDURE|Mini-gastric bypass with hand-sewn anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a fully manual suture."
40815285|NCT01378702|DRUG|mistletoe preparations|1 ampoule (1ml) twice per week subcutaneously
40815286|NCT01801436|DRUG|Bortezomib|Bortezomib 1.3 mg per (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
41333329|NCT03126279|PROCEDURE|Total Knee Replacement Surgery|All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
41333330|NCT03777085|DRUG|TQB2303|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
40815287|NCT05994703|DRUG|d-cycloserine|d-cycloserine (DCS) 100 mg taken orally, once a day for six weeks.
40815288|NCT05994703|OTHER|Juul e-cigarette|Juul use as often as the participant likes for 12 weeks.
40815289|NCT01612286|DRUG|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle \*4cycles
40815290|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (low dose)|Participants are administered 125 µg indacaterol + mometasonefluroate
40815291|NCT06067100|DRUG|Placebo|Participants are administered placebo
40815292|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (high dose)|Participants are administered 500 µg indacaterol + mometasonefluroate
40815293|NCT00227669|DRUG|docetaxel|
40815294|NCT00227669|DRUG|gemcitabine hydrochloride|
40815295|NCT03929653|OTHER|Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing|This study is to observe this therapy model outcomes
40815296|NCT02184091|DRUG|Nevirapine|
40815297|NCT01545934|BEHAVIORAL|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
40815298|NCT00484380|PROCEDURE|Coronary scanner|multislice spiral computed tomography coronary angiography
40815299|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
41333331|NCT03777085|DRUG|Rituximab|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
41013587|NCT06460727|OTHER|task oriented exercise training on dynamic surface|Following exercises will be performed in this group: Make the child bounce on swiss ball, reaching the toy with both hand kept over the head on platform swing, high sitting on swiss ball throwing ball with both hands, reaching the toy with one hand shifting the wait towards reaching side.
41333332|NCT00003613|DRUG|O6-benzylguanine|Given IV
41333333|NCT00003613|DRUG|carmustine|Given topically
41156019|NCT05450705|BIOLOGICAL|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
41156020|NCT06404086|DRUG|Modafinil|"Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks."
41333334|NCT00003613|OTHER|laboratory biomarker analysis|Correlative studies
41333335|NCT00929045|DRUG|Growth Hormone Replacement|
41333336|NCT06306924|RADIATION|Radiation therapy|Subjects with metastatic cancer receive radiation therapy.
41333337|NCT04836546|DEVICE|Blood glucose meter|First phase: SMBG for 6 months
41333338|NCT04836546|DEVICE|Eversense CGM System|Second phase: CGM for 6 months
41333339|NCT00268463|DRUG|capecitabine|"Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2"
41333340|NCT00268463|DRUG|floxuridine|Continuous hepatic arterial infusion of floxuridine 0.2 mg/kg on days 1-14 every 42 days for 4 cycles
41333341|NCT00268463|DRUG|oxaliplatin|"Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1~Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2"
41013588|NCT06460727|OTHER|task oriented exercise training on static surface|The children in this group will receive following TOET: Sit to stand from various cjair heights , standing and reaching indifferent directions for an object, Stepping forwards, backwards, and sideways onto blocks of various heights, walking forward , backward and sideways, Walking up and down stairs
41333342|NCT02143960|DEVICE|VelaShape III|Subjects will receive one treatment to their entire waist / love-handle/ flanks area in a split-waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
41333343|NCT02143960|DEVICE|CoolSculpt|Noninvasive Cryolipolysis
41333344|NCT04071171|DRUG|CVVH with Phoxilium® in the first 48h after randomization|After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
41333345|NCT04071171|DRUG|CVVH with Biphozyl® in the first 48h after randomization|After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
41483434|NCT02658513|OTHER|Standard intravenous blood sampling|Blood samples will be obtained using a standard intravenous technique.
41483435|NCT04905849|BEHAVIORAL|Adaptive Cognitive Control Trainer (ACCT)|"Module 1: Attention=\> This module demands an active scan of the screen in search for a target, much like traditional visual search tasks. Participants quickly identify the direction that a probe target is facing (up, down, left, right), and are aided by the presence of directional cue indicating where the location of the target will appear.~Module 2: Goal Management=\> Requires participants to rapidly switch their focus based on distinct rules. Participants are presented with exemplar objects along with a target, and are asked to indicate which exemplar presented is most like the target.~Module 3: Working Memory=\> Engages spatial working memory resources similar to the Corsi block task. Participants memorize the location of objects on screen followed by a 5-7 second delay period, with a correct response leading to a greater number of potential targets to be memorized on the next trial (and vice versa)."
41483436|NCT04905849|BEHAVIORAL|Active Control App|The app used here is undergoing expectancy-matching at the present time, will be updated with the final app characteristics when completed out of a list of several possibilities
40815300|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
40815301|NCT00408382|DRUG|atorvastatin, Lipitor|
40815302|NCT03618732|OTHER|Bilateral movement-based computer training|
40815303|NCT03618732|OTHER|Video-directed conventional training|
41333346|NCT04071171|DRUG|CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)|48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
41333347|NCT04071171|DRUG|CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)|48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
40815304|NCT00670618|DEVICE|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
40815305|NCT00670618|DEVICE|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
40815306|NCT00670618|DEVICE|Fluoride (Elmex Medical Gel)|Fluoride
41333348|NCT02755025|OTHER|Automated SOFA scoring calculator|Automated SOFA scoring will be activated within an existing electronic patient care dashboard for ICU patients.
41333349|NCT05448989|DRUG|1% atropine 5+3|A method for myopia control using high-concentration atropine
41333350|NCT02837809|RADIATION|Low dose CT|annual CT vs biennial CT
41333351|NCT00346138|PROCEDURE|Corneal transplantation|
41333352|NCT03486197|OTHER|Laboratory Biomarker Analysis|Correlative studies
41333353|NCT03486197|BIOLOGICAL|Pembrolizumab|Given IV
41333354|NCT03486197|RADIATION|Radiation Therapy|Undergo neutron radiation therapy
41333355|NCT00003000|DRUG|fentanyl citrate|
41333356|NCT00003000|DRUG|morphine sulfate|
41333357|NCT03121807|OTHER|Oliclinomel N4 Per bag 1.5 L|Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
41333358|NCT03121807|DRUG|Oxaliplatin|
41483437|NCT05918224|DRUG|Streptococcus salivarius K12|The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.
40815307|NCT03730831|BEHAVIORAL|Narrative Exposure Therapy|"8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling~-\> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder."
40815308|NCT04835805|DRUG|Belvarafenib|Twice daily (BID), continuous dosing
40815309|NCT04835805|DRUG|Cobimetinib|Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off
41333359|NCT03121807|DRUG|5Fluorouracil|
41333360|NCT03121807|DRUG|Leucovorin|
41333361|NCT04018612|DRUG|Acetaminophen|Acetaminophen is an analgesic and antipyretic
41333362|NCT04018612|OTHER|Placebo|Saline
41333363|NCT05945745|DRUG|Chemotherapy|different treatments based on the molecular analysis
41333364|NCT00805922|OTHER|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
41483438|NCT05918224|DRUG|Streptococcus salivarius K12 simulants|Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.
41483439|NCT01144364|DRUG|rituximab [Mabthera/Rituxan]|Intravenous repeating dose
40815310|NCT04835805|DRUG|Nivolumab|Once every 4 weeks (Q4W)
40815311|NCT02800694|DRUG|"bupivacainediluted with 1 ml of normal saline and 25 μg fentanyl "|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) diluted with 1 ml of normal saline and 25 μg fentanyl. Then, the parturients were placed in the supine position with left lateral displacement produced by placing a wedge under the right hip to prevent aortocaval compression and hypotension. Supplemental oxygen was applied using nasal cannula (2-4 L/min). Routine monitoring included maternal vital signs, uterine contractions and fetal heart rate tracing. The cardiotocogram was recorded continuously throughout the study period
40815312|NCT00433966|DRUG|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
40815313|NCT00433966|DRUG|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
40815314|NCT00433966|DEVICE|Bare metal stent|Uncoated bare metal stent
40815315|NCT00433966|DEVICE|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
41333365|NCT02352532|OTHER|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
41333366|NCT02352532|OTHER|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC\&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
41333367|NCT05018637|DRUG|WJ-MSC|"Other: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.~Other: intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months."
41333368|NCT05018637|DRUG|Teriparatide|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
41333369|NCT06109519|PROCEDURE|implant supported overdenture|patients would be delivered mandibular implant overdenture using conventional locator and Locator RTX attachments
41333370|NCT02988492|DEVICE|MRI perfusion imaging|Evaluate the sensitivity and specificity of whole---brain CTP in predicting 24 hour DWI---MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
41483440|NCT04368611|PROCEDURE|start with fundus|fundus first dissection then complete cholecystectomy as usual
40815316|NCT01179750|DEVICE|Ultrasonic Coagulating Shears|comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
41333371|NCT04266249|DRUG|Docetaxel|Given IV
41333372|NCT04266249|PROCEDURE|Lumpectomy|Undergo lumpectomy
41333373|NCT04266249|PROCEDURE|Mastectomy|Undergo mastectomy
41333374|NCT04266249|DRUG|Nab-paclitaxel|Given IV
41333375|NCT04266249|DRUG|Paclitaxel|Given IV
41333376|NCT04266249|BIOLOGICAL|Pertuzumab|Given IV
41333377|NCT04266249|RADIATION|Radiation Therapy|Undergo radiation therapy
41333378|NCT04266249|BIOLOGICAL|Trastuzumab|Given IV
41333379|NCT04266249|BIOLOGICAL|Trastuzumab Emtansine|Given IV
40815317|NCT04338139|PROCEDURE|bone regeneration|bone regeneration using bio-oss collagen
40815318|NCT01202019|OTHER|Circuit Resistance Training (CRT)|CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
40815319|NCT06538077|DRUG|Oral Branched chain Amino acid|The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 24 weeks
40815320|NCT06538077|DRUG|Rifaximin 550 MG|Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 24 weeks
40815321|NCT06538077|DRUG|Lactulose|Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day
40815322|NCT06538077|DRUG|Placebo for BCAA|A placebo comparator of 15 gm of skimmed milk powder will be used.
40815323|NCT06538077|DRUG|Placebo for Rifaximin 550mg|Identical placebo sugar pills will be used as a placebo.
41333380|NCT03290794|DRUG|Aflibercept (Eylea, BAY86-5321)|Intravitreal Aflibercept as prescribed by the treating Physician
40815324|NCT00346879|DRUG|fondaparinux|Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux
40815325|NCT05504265|DRUG|Preemptive flurbiprofen axetil|50mg once，30min before induction anesthesia
40815326|NCT05504265|DRUG|Postoperative flurbiprofen axetil|50mg bid
40815327|NCT05504265|DEVICE|Patient-controlled analgesia pump|Sufentanil 2.5 μg/kg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml/h, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.
40815328|NCT04622891|DRUG|Clarithromycin 500mg|clarithromycin 500
40815329|NCT04622891|DRUG|Azithromycin|azithromycin group
40815330|NCT04622891|DRUG|Placebo|control group
40815331|NCT01723293|BEHAVIORAL|Exercise group|"The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training."
41156021|NCT06404086|DRUG|Modafinil Placebo|"The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
41333381|NCT03514238|BEHAVIORAL|High Intensity Interval Aerobic Exercise (HIIT)|"Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min)."
41483441|NCT04368611|PROCEDURE|calot first dissection|start dissection by calot approach
41483442|NCT03394911|BIOLOGICAL|250mg healthy adult male facial skin surface lipid liquid pheromone|Human Pheromone provided p.o. to tox-screen verified opioid drug addict
41483443|NCT00655850|DRUG|Paclitaxel|"* Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~* Dexamethasone 20mg, intravenously (IV)~* Diphenhydramine 50 mg IV~* Ranitidine 50 mg IV~* Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~* The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~* Dose Level 1 ________80 mg/m2/weekly~* Dose Level -1 ________70 mg/m2/weekly"
40815332|NCT03706742|BEHAVIORAL|Mailed outreach|The investigators will randomize all baby boomer patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
40815333|NCT02825706|OTHER|Educational physiotherapy group|20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
40815334|NCT04399863|BEHAVIORAL|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
41333382|NCT03514238|BEHAVIORAL|Continuous Moderate Aerobic Exercise (MOD)|35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
40815335|NCT00820794|DRUG|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
40815336|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
40815337|NCT00820794|DRUG|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
40815338|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
40815339|NCT04742348|DRUG|Carbidopa Levodopa|Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
40815340|NCT04742348|DRUG|Placebo|Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
40815341|NCT02904629|BEHAVIORAL|Respecting the Circle of Life (RCL)|"Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT)."
41333383|NCT03514238|BEHAVIORAL|Control Sitting Condition (C)|Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).
40815342|NCT02904629|OTHER|Control Program|Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
41333384|NCT05595551|BEHAVIORAL|"The intervention Aan Tafel in 1, 2, 3 euro"|"The participants in this group are clients of Colruyt who are subscribed to the program Aan Tafel in 1 2 3 euro. They will receive two-weekly recipe booklets with 6 balanced and child-friendly recipes in each booklet. They are guaranteed a fixed price for each recipe, that will be given at the checkout counter, based on their loyalty card."
40815343|NCT03019328|OTHER|Peanut in diet|
40815344|NCT04964648|DEVICE|shear wave elastography|Shear wave elastography (SW-EG), a form of ultrasound elastography used in transabdominal ultrasonography, can measure tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI) The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals (kPa) or meters per second
40815345|NCT05083013|DIAGNOSTIC_TEST|Reverse transcription polymerase chain reaction (RT-PCR)|For SARS Corona Virus 2 (COV2) confirmation
40815346|NCT05083013|DIAGNOSTIC_TEST|Glycated haemoglobin (HbA1C)|Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control
40815347|NCT05083013|RADIATION|High Resolution Computed Tomography (HRCT)|with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation
40815348|NCT05083013|DIAGNOSTIC_TEST|Routine Laboratory investigations|"* Arterial blood gases (ABGs)~* Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)"
40815349|NCT05083013|DIAGNOSTIC_TEST|Random Blood Sugar (RBS)|Blood Sugar will be measured before each meal and before bed time during hospitalization.
40815350|NCT03215303|DEVICE|Continuous Positive Airway Pressure (CPAP)|In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
40815351|NCT01920568|BIOLOGICAL|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
40815352|NCT01920568|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
40815353|NCT01920568|DRUG|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
40815354|NCT01920568|DRUG|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
40815355|NCT01920568|DIETARY_SUPPLEMENT|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
41013589|NCT02211755|DRUG|Bortezomib plus Clofarabine|The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
40815356|NCT01920568|DIETARY_SUPPLEMENT|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
41333385|NCT01803113|DEVICE|Sofia hCG FIA|Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.
41333386|NCT00446758|DIETARY_SUPPLEMENT|Zinc|zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.
41333387|NCT02427100|BEHAVIORAL|Diet/Physical Activity|Diet/Physical Activity Intervention
41333388|NCT00435149|PROCEDURE|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
41333389|NCT00435149|PROCEDURE|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
40815357|NCT02117960|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
40815358|NCT02117960|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
40815359|NCT04277663|DRUG|IBI310+IBI308|In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
40815360|NCT04277663|DRUG|IBI308|In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
40815361|NCT04277663|DRUG|High-dose recombinant interferon a-2B|In this group, subjects will be given 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
41013590|NCT00895219|OTHER|Breathing re-training|Breathing re-training
41013591|NCT00895219|OTHER|Breathing re-training and musculoskeletal techniques|Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
41013592|NCT00075868|DRUG|octreotide acetate|
41013593|NCT00075868|OTHER|Placebo|
41333390|NCT05865210|OTHER|Kegel Exercise|Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
41483444|NCT00655850|DRUG|Gemcitabine|"Premedication~* Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~* Prior to receiving paclitaxel chemotherapy~* Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~* The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~* Dose Level 2 ________300 mg/m2/weekly~* Dose Level 1 ________200 mg/m2/weekly~* Dose Level -1 ________150 mg/m2/weekly"
41483445|NCT00655850|BIOLOGICAL|Avastin|"* The dose of Avastin is 10 mg/kg IV every 2 weeks~* It will be administered following the administration of chemotherapy~* The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~* It should not be administered or mixed with dextrose solutions."
40815362|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg(20mg once a day, fasted)
40815363|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
41483446|NCT06033365|BEHAVIORAL|care navigation|Dedicated care navigation throughout study enrollment and follow-up period. Care navigation consists of addressing social support needs (e.g. transportation, communication, housing).
41483447|NCT01304693|BIOLOGICAL|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
41483448|NCT01304693|BIOLOGICAL|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
41483449|NCT03035552|BEHAVIORAL|Pacifier activated music player|Therefore the immediate goal of the current proposal is to demonstrate that intensive NNS-training using reinforcement with mother's voice can improve the oral feeding outcomes of infants with CCHD using a randomized controlled trial (RCT) design, with wait-list controls to ensure that infants in the trial all benefit from a treatment with only demonstrated positive effects. Establishment of optimal NNS patterns in the first 6 months after birth in these infants will improve downstream feeding skills and may promote better motor and language outcomes by one year of age.
41483450|NCT01312311|DRUG|Docetaxel, Cisplatin|Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1
41483451|NCT01344174|DRUG|5 days dexamethasone therapy|dexamethasone 10mg, intravenously, po daily for the first 5 days
40815364|NCT01568450|DRUG|Oxycodone|Oxycodone 20mg/day (10mg twice a day, fasted)
40815365|NCT00332020|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
41333391|NCT05865210|OTHER|Myofascial release technique|Myofasical release will include deep pressure for 10-15 seconds to release the trigger points and also gentle, light soft tissue massage on the vaginal muscles and surrounding areas.
41333392|NCT00724815|DRUG|NP101 - Sumatriptan iontophoretic transdermal patch|Sumatriptan iontophoretic transdermal patch
41333393|NCT00724815|DRUG|Placebo|NP101 Placebo iontophoretic transdermal patch
41333394|NCT02142504|BIOLOGICAL|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
41333395|NCT02142504|DRUG|Placebo (Saline)|Placebo-matching norovirus bivalent VLP vaccine
41333396|NCT06338007|DEVICE|Hand Dynamometer|Hand grip strength will be measured using a hand dynamometer. Research has demonstrated that hand grip strength is correlated with muscle strength in the upper extremities, as well as overall body and pulmonary muscle strength.
40815366|NCT00332020|DRUG|Enoxaparin|40 mg enoxaparin syringe administered for 12 +/- 2 days
40815367|NCT00377845|PROCEDURE|Regular Tampax used in 3 hours|
40815368|NCT04011566|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
40815369|NCT02324205|DEVICE|DBT and FFDM|Subjects underwent breast imaging using each device: DBT and FFDM.
40815370|NCT04330391|BEHAVIORAL|Remote dietitian supervised weight loss intervention and mobile app|Please see intervention arm description for more details.
40815371|NCT02125851|OTHER|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
40815372|NCT02125851|OTHER|Honey|esophageal mucosal contact time of honey vs sucralose slurry
40815373|NCT04098367|DEVICE|VIVITY|Extended vision intraocular lens intended for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed by extracapsular cataract extraction
40815374|NCT04098367|DEVICE|SYMFONY|Extended range of vision intraocular lens indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed
40815375|NCT04098367|DEVICE|AT LARA|Extended depth of focus intraocular lens indicated for implantation for the visual correction of aphakia in patients with and without presbyopia in whom a cataractous lens has been removed by extracapsular cataract extraction
40815376|NCT04098367|PROCEDURE|Cataract surgery|Cataract removal by routine small incision surgery
40815377|NCT03100981|BEHAVIORAL|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
40815378|NCT03100981|BEHAVIORAL|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
40815379|NCT01280058|DRUG|Carboplatin|Given IV
40815380|NCT01280058|OTHER|Laboratory Biomarker Analysis|Correlative studies
40815381|NCT01280058|DRUG|Paclitaxel|Given IV
40815382|NCT01280058|BIOLOGICAL|Wild-type Reovirus|Given IV
40815383|NCT02584530|PROCEDURE|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
40815384|NCT03139643|OTHER|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
40815385|NCT03139643|OTHER|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
41333397|NCT06338007|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry is a physiological test that measures the ability to inhale and exhale air relative to time. Spirometry is a diagnostic test of several common respiratory disperses such as asthma and chronic obstructive pulmonary disease (COPD). It is also instrumental in monitoring the progression of various respiratory disorders. The main results of spirometry are forced vital capacity (FVC), forced expiratory volume exhaled in the first second (FEV1), and the FEV1/FVC ratio. Pulmonary Function Test analysis values (FEV1, FVC and FEV1 /FVC) will be used.
41333398|NCT06338007|OTHER|Modified Frailty Index|The modified frailty index is a valuable preoperative risk assessment tool that can be used to assess the risk of both morbidity and mortality in patients undergoing surgery. It is calculated based on 11 parameters.
41483452|NCT04199884|BEHAVIORAL|Active IU-focused Psychoeducation Intervention|This paradigm was an IU-focused psychoeducation intervention wherein participants were provided psychoeducation about the nature of IU and anxiety, given strategies to cope with fear of uncertainty, and provided examples and information as to how they can expose themselves to uncertainty.
41483453|NCT04199884|BEHAVIORAL|Health-focused Psychoeducation Intervention|This intervention is a health-focused psychoeducation intervention wherein participants learn ways to engage in healthy behaviors, such as getting adequate sleep, eating healthier, and exercising regularly.
41483454|NCT03578237|DEVICE|Cryoneurolysis (active)|Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature
41483455|NCT03578237|DEVICE|Sham cryoneurolysis procedure|"Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe.~Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature"
41013597|NCT00501540|DRUG|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
41483456|NCT04439084|OTHER|Prospective Chart Review|Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.
41013598|NCT05953584|DRUG|Etavopivat|Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.
41013599|NCT05953584|DRUG|Hydroxyurea|Participants will receive a stable dose of HU.
41013600|NCT04746937|DRUG|Nitazoxanide|nitazoxanide adjuvant to standard therapy
41333399|NCT01432457|DRUG|desvenlafaxine succinate sustained-release 50 mg/day|50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
41333400|NCT01432457|DRUG|desvenlafaxine succinate sustained-release 100 mg/day|100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
41483457|NCT03642353|DRUG|Triclosan|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
41483458|NCT03642353|DRUG|Placebo|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
41013601|NCT04746937|DRUG|Norfloxacin|Standard therapy
41013602|NCT01175382|BEHAVIORAL|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
41013603|NCT01175382|DRUG|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
41156022|NCT06404086|DRUG|Solriamfetol|"The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase."
41333401|NCT01432457|DRUG|placebo|50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
41333402|NCT02452710|OTHER|Placebo|Open-label placebo
41333403|NCT02077842|DEVICE|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
41483459|NCT05513586|DRUG|TAK-771|Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
41483460|NCT01000493|DRUG|orvepitant|Neurokinin-1 (NK-1) antagonist
40815386|NCT03139643|OTHER|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
41333404|NCT02077842|DEVICE|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
40815387|NCT01303718|DEVICE|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
40815388|NCT01303718|OTHER|Standard of Care|Usual care for LV dysfunction and heart failure (no CardioFit System implant)
40815389|NCT03737448|DRUG|Trimetazidine|Subjects with receive up to 60 mg daily
40815390|NCT05608993|OTHER|High Intensity Intervention|The High Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields.
40815391|NCT05608993|OTHER|Low Intensity Intervention|The Low Intensity intervention will include clinician education and EHR changes only.
40815392|NCT05129904|OTHER|Double plasma molecular absorption system|DPMAS is an extracorporeal procedure that combines two hemoperfusion machines. During the procedure, toxic plasma is separated and cleansed by perfusion over two absorbers, and the final cleansed plasma is then returned to patients. It does not require large volumes of plasma and nor does it bear the risk of plasma-associated allergic reaction or disease transmissions. DPMAS can attenuate the jaundice in a short term and decrease the bilirubin concentration, which then reduces the toxicities of bile acid and high levels of bilirubin on the hepatocytes
40815393|NCT00951080|DEVICE|Traditional NPWT System|Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
40815394|NCT00951080|DEVICE|SNaP Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
40815395|NCT06052254|DRUG|12 cm2 - 2 Active DMTS Patches|2 Active DMTS patches applied to the upper back followed 7 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
40815396|NCT06052254|DRUG|6 cm2 - 1 Active and 1 Placebo DMTS Patches|1 Active and 1 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
40815397|NCT06052254|DRUG|Placebo - 2 Placebo DMTS Patches|2 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
40815398|NCT02961933|OTHER|Apneic oxygenation|Nasal cannula apneic oxygenation
40815399|NCT02961933|OTHER|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
40815400|NCT02178852|DEVICE|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
40815401|NCT05635396|DEVICE|Wearable, non invasive sensor for seizure detection|The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
40815402|NCT05865340|BEHAVIORAL|oral health + MED diet|oral health + MED diet education
41333405|NCT05670249|PROCEDURE|suboccipital decompressive craniectomy|extensive bilateral suboccipital decompressive craniectomy with duraplasty
40815403|NCT05865340|BEHAVIORAL|oral health|oral health education
40815404|NCT05865340|BEHAVIORAL|MED diet|MED diet education
40815405|NCT00338208|BEHAVIORAL|Training in the Use of Low Vision Devices|
41333406|NCT01285336|GENETIC||
41333407|NCT03579030|DRUG|Placebo oral capsule|Placebo capsule matched to an RTA 1701 capsule
40815406|NCT02353702|PROCEDURE|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
40815407|NCT02353702|DRUG|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
40815408|NCT02353702|DEVICE|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
40815409|NCT02353702|DRUG|Infusion of placebo during 48 hours|
40815410|NCT02353702|DRUG|NaCl|
40815411|NCT04036474|OTHER|Smoking Prevention Education Program|"The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness."
40815412|NCT05064410|BEHAVIORAL|Educational Intervention|The colorectal cancer (CRC) educational activities will include the use of NCI CRC resources and materials, including a PowerPoint presentation, and CRC educational models and displays. The CRC education will be delivered in Spanish and English, and will consist of pre and post knowledge assessments including screening and behavioral intention questions. The educational intervention will take approximately 45 minutes-1 hour.
41333408|NCT03579030|DRUG|RTA 1701 capsules|Capsule containing RTA 1701, multiple dosages
41333409|NCT00232505|BIOLOGICAL|cetuximab|Given IV
41333410|NCT00232505|DRUG|carboplatin|Given IV
41333411|NCT01202760|DRUG|LY2127399|
41333412|NCT01202760|DRUG|Placebo|
41013604|NCT01175382|OTHER|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
41013605|NCT02321579|DIETARY_SUPPLEMENT|vitamin B-6|50 mg/d
41013606|NCT02321579|DIETARY_SUPPLEMENT|Glutathione|500 mg/d
41013607|NCT02321579|DIETARY_SUPPLEMENT|Dextrins|50 mg/d
41333413|NCT04220138|PROCEDURE|Anterior chamber illumination in cataract surgery|This will be a prospective interventional case series, patients with cataract and poor red reflex will undergo phacoemulsification assisted by anterior chamber illumination to overcome the problem of poor red reflex.
41333414|NCT00002004|DRUG|CD4 Antigens|
41013608|NCT05130775|OTHER|Transesophageal echocardiograpgy|3D acquisition of the right ventricle regurgitation volume
41333415|NCT00647972|DRUG|Olanzapine Tablets 20 mg|20mg, single dose fasting
41333416|NCT00647972|DRUG|Zyprexa® Tablets 20 mg|20mg, single dose fasting
41333417|NCT04463225|OTHER|Internet-Delivered Brief Intervention|The internet-delivered brief intervention developed for the study can be accessed via computers and mobile devices.. The intervention will employ assessment data to give study participants feedback on their drinking behavior and offer strategies to avoid risky behavior.
41333418|NCT00977587|DRUG|Saccharomyces Cerevisiae CNCM I-3856|Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
41333419|NCT00977587|DRUG|placebo|"Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
41333420|NCT00640146|DRUG|Methylnaltrexone bromide|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
41333421|NCT00640146|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
41333422|NCT02695576|PROCEDURE|Lumbar Fusion Surgery|Interbody fusion with fixation
41333423|NCT02695576|OTHER|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
41333424|NCT02695576|OTHER|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
40815413|NCT03197714|DRUG|OPB-111077|"Two dose schemas will be employed:~* Level 1: 200 mg daily~* Level 2: 250 mg daily"
40815414|NCT04324996|BIOLOGICAL|NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells|The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
41333425|NCT02808013|DRUG|NDS-446|
41333426|NCT02808013|DRUG|Placebo|
41333427|NCT00846469|PROCEDURE|CCTA (coronary computed tomography angiography)|A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.
41333428|NCT00846469|OTHER|Control section|Normal emergency room treatment for symptoms of chest pain.
41483461|NCT01000493|OTHER|Placebo|Inactive placebo to match orvepitant 60 mg dosage form
41013609|NCT02484105|BEHAVIORAL|Comforting Conversation|Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
41013610|NCT02484105|BEHAVIORAL|Standard Communication|Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
41156023|NCT06404086|DRUG|Solriamfetol Placebo|"The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
41333429|NCT01630798|DRUG|GI heptapeptide|Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
41333430|NCT03702140|DRUG|"Teriparatide, Forteo® or Teribon"|To examine the effects of terimaratide less than 6 months in osteoporosis
41333431|NCT01176240|DRUG|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
40815415|NCT04958993|DRUG|Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy|radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
40815416|NCT02135029|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
40815417|NCT02135029|DRUG|Atorvastatin|Atorvastatin PO QD
40815418|NCT02135029|OTHER|Placebo for Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
41013611|NCT04400305|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
41333432|NCT01176240|OTHER|Placebo|Placebo
41333433|NCT01869803|DRUG|gemtuzumab ozogamicin|Given IV
41333434|NCT01869803|OTHER|laboratory biomarker analysis|Correlative studies
41333435|NCT02788591|DRUG|Proton Pump Inhibitor (PPI) Therapy|Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
40815419|NCT02135029|OTHER|Placebo for atorvastatin|PO QD
40815420|NCT00522418|DEVICE|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
41333436|NCT02788591|DRUG|Sucralfate|Subject will take Sucralfate 4 times a day for 8 weeks.
41333437|NCT04374578|DRUG|Dulaglutide 1.5 MG/ML|Dulaglutide 1.5Mg qw sc injection for 4 weeks
41333438|NCT05857007|DEVICE|Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids|Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
40815421|NCT00522418|DRUG|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
40815422|NCT00395187|PROCEDURE|Photodynamic Therapy|
41013612|NCT03076554|DRUG|Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
41333439|NCT00706615|BIOLOGICAL|Ad-sig-hMUC-1/ecdCD40L vaccine|
41333440|NCT06318221|DIETARY_SUPPLEMENT|Experimental (Immunonutrition) Group|"Immunonutrition was given to the patients in the intervention group and ready-to-use liquid in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day as taken between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. The ready-to-use immunonutrition product was given to the patients in the intervention group."
41483462|NCT03245957|OTHER|Ischemic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
41483463|NCT03245957|OTHER|Haemorrhagic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
41483464|NCT04471402|DRUG|Precedex|Intranasal Precedex 3mcg/kg
40815423|NCT02441491|DRUG|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster."
40815424|NCT03081819|DRUG|SH003|Herbal medicine for cancer treatment
40815425|NCT04548934|DEVICE|Personal protective equipment (PPE)|Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)
40815426|NCT04548934|DEVICE|No Personal protective equipment (PPE)|Standard CPR without wearing PPE
40815427|NCT01644006|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
40815428|NCT02399280|BEHAVIORAL|Lunch as main meal(LM)+ Diet|Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.
40815429|NCT02399280|BEHAVIORAL|Dinner as main meal(DM)+ Diet|Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
40815430|NCT03971240|PROCEDURE|evacuation of traumatic acute subdural hematoma|craniotomy will be done with evacuation of the hematoma
40815431|NCT00777985|DRUG|bosentan|62.5 mg b.i.d for 4 weeks
40815432|NCT00777985|DEVICE|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
40815433|NCT02131103|OTHER|Percutaneous coronary intervention|"All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
40815434|NCT03018795|PROCEDURE|Decontamination of implant surfaces|Decontamination of implant surfaces in combination with regenerative surgery
40815435|NCT00017654|DRUG|anti-thymocyte globulin|
40815436|NCT00017654|DRUG|cyclophosphamide|
40815437|NCT00017654|DRUG|cyclosporine|
40815438|NCT00017654|DRUG|methylprednisolone|
41333441|NCT06318221|DIETARY_SUPPLEMENT|Active Comparator Group ( Standard enteral nutrition)|"Standard enteral nutrition was given to patients in the control group in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. Liquid standard enteral nutrition was given to the patients in the control group."
41483465|NCT01363804|DRUG|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
41483466|NCT00448136|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 every 3 weeks
40815439|NCT00017654|PROCEDURE|Allogeneic Bone Marrow Transplantation|
40815440|NCT00656149|PROCEDURE|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
40815441|NCT00656149|PROCEDURE|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
40815442|NCT06324422|OTHER|Aerobic exercise intervention|Participants in this arm are randomized to perform 12 weeks of supervised high intensity progressive aerobic exercise comprising continuous and/or interval cycling-, rowing- or cross-trainer sessions, increasing from 30 minutes towards 60 minutes with intensity increasing from 65 to 90% of individual maximum heart rate. The 12 weeks of aerobic exercise are followed by 12 weeks of habitual lifestyle (follow up period).
40815443|NCT06324422|OTHER|Resistance exercise intervention|Participants in this arm are randomized to a 24-week waitlist control group. The control group will continue their habitual lifestyle throughout the 24 weeks. After 24 weeks, the waitlist control group will begin a 12 week supervised resistance exercise intervention comprising machine exercises in 3 to 5 sets with 2-3 minutes rest in between and a decrease from 12 to 6 repetitions in parallel with intensity increasing from 15RM (repetition maximum) to 8 RM.
41483467|NCT00448136|DRUG|5 FU|400mg/m2/day iv on days 1-5 every 6 weeks
40815444|NCT04599023|DEVICE|MSPT|The MS Performance Test (MSPT) software tool and accompanied hardware is an iPad®-based assessment tool, developed via collaboration between Biogen and the Cleveland Clinic Mellen Center, and designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders.These assessment modules of the MSPT are self-administered by MS patients at the point of care and incorporate and expand upon previously validated measures of the MSFC.
40815445|NCT04892550|OTHER|Denneroll traction|The participants will be instructed to lie flat on their back on the ground with their knees slightly bent at 20-30° for comfort and arms gently folded across their stomach. The examiner will position the apex of the Denneroll in one of three regions: lower thoracic (T9-T12), mid-thoracic (T5-T8), and upper-thoracic (T1-T4) depending on the apex of each participant's thoracic kyphosis deformity. For lower thoracic kyphosis (T9-T12) the Denneroll is turned 180° so the peak contacts the lower thoracic spine (T10) while the tapered end supports the mid thoracic region
40815446|NCT04892550|OTHER|Multimodal Program|The multimodal program consists of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.
40815447|NCT05120765|BEHAVIORAL|The CONNECT Program|The CONNECT Program is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT). The group sessions take place once a week and they last 90 minutes each.
41483468|NCT00448136|DRUG|Streptozotocin|500mg/m2/day iv on days 1-5 every 6 weeks
41483469|NCT00448136|DRUG|Xeloda|1000mg/m2 po bid on days 1-14 every 3 weeks
41483470|NCT02799030|DRUG|BF-200 ALA 1%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
40815448|NCT04313400|DRUG|1.1% w/w AMTX-100 CF-part1|AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient
40815449|NCT04313400|DRUG|Placebo|Topical cream manufactured to mimic AMTX-100 CF3
40815450|NCT04313400|DRUG|1.1% w/w AMTX-100 CF3-part2|AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
40815451|NCT03453762|PROCEDURE|recruitment maneuver|Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
41156024|NCT06404086|DRUG|Melatonin|Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
41156025|NCT06404086|DRUG|Melantonin Placebo|Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
41156026|NCT06404086|DEVICE|Tailored lighting (TL) Active|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
41333442|NCT00092677|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
41333443|NCT00092677|DRUG|Comparator: Placebo|matching Placebo
41333444|NCT01215669|BIOLOGICAL|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
41333445|NCT01215669|BIOLOGICAL|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
40815452|NCT03453762|PROCEDURE|ultrasonography-guided recruitment maneuver|Recruitment maneuver is guided by ultrasonography.
41333446|NCT01215669|BIOLOGICAL|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
41333447|NCT01215669|BIOLOGICAL|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
40815453|NCT04236180|OTHER|Specialised Paediatric Palliative Care (SPPC)|All services provided to children/families by a member of the multiprofessional SPPC team in Zurich according to local guidelines will be considered as study intervention. This includes direct consultation of the patient/family, as well as patient-/family-related consultation of the frontline care team. Bereavement support is considered an integrated part of SPPC and after the death of a child, follow-up bereavement support is routinely offered at the individual or group level as appropriate for parents and siblings.
40815454|NCT00263042|DRUG|Rimonabant|Tablet, oral administration
40815455|NCT00263042|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
41333448|NCT01877590|DRUG|alpha-lipoic acid|
41333449|NCT04309604|BIOLOGICAL|IC14|monoclonal antibody directed against CD14
41333450|NCT04049812|DEVICE|PEMF|
41333451|NCT04049812|DEVICE|Hot pack|
41333452|NCT04049812|DEVICE|TENS|
40815456|NCT04103307|PROCEDURE|Dialysis cooling|Cooling the blood in the CRRT circuit during delivery
40815457|NCT00146809|DRUG|Minocyline|
40815458|NCT00624585|DRUG|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~* Dose Level and Dose of dasatinib:~  1. Starting dose (1-8 weeks)= 100 mg orally (po) daily~ 2. +1 (\<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~* Dose Level and Dose of dasatinib:~  1. Starting dose = 100 mg po daily~ 2. -1 = 70 mg po daily~ 3. -2 = 50 mg po daily~OR~* Dose Level and Dose of dasatinib:~  1. Starting dose = 150 mg po daily~ 2. -1 = 120 mg po daily~ 3. -2 = 90 mg po daily~ 4. -3 = 50 mg po daily"
40815459|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
41333453|NCT04049812|DEVICE|Sham PEMF|
41333454|NCT00134017|DRUG|Busulfan|Days -7 to -4: 4 mg/kg PO daily OR 3.2 mg/kg IV daily OR 160 mg/m\^2 daily (for pediatric recipients)
40815460|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
40815461|NCT00022360|DRUG|taurolidine|
41333455|NCT00134017|DRUG|Cyclophosphamide|Days -3, -2, +3, +4: 50 mg/kg IV daily
40815462|NCT01746511|PROCEDURE|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
40815463|NCT01746511|DRUG|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
40815464|NCT05862974|DRUG|LPM3480392|Intravenous infusion of 30min duration
41333456|NCT02527187|BIOLOGICAL|10 HEP/mL Betula verrucosa allergen extract|The investigational product contained 10 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
41333457|NCT02527187|BIOLOGICAL|25 HEP/mL Betula verrucosa allergen extract|The investigational product contained 25 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
41333458|NCT02527187|BIOLOGICAL|50 HEP/mL Betula verrucosa allergen extract|The investigational product contained 50 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
41483471|NCT02799030|DRUG|BF-200 ALA 3%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
40815465|NCT05862974|DRUG|Placebo|Intravenous infusion of 30min duration
40815466|NCT03222154|DEVICE|Experimental - Shock wave therapy|Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
40815467|NCT03222154|DEVICE|Placebo - Shock wave therapy|Simulation of shock wave therapy
40815468|NCT04925076|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
40815469|NCT04925076|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
41333459|NCT02527187|BIOLOGICAL|100 HEP/mL Betula verrucosa allergen extract|The investigational product contained 100 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
41333460|NCT02757092|OTHER|Home-based Pulmonary Rehabilitation|(1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
41013613|NCT05406544|OTHER|FD qualitative study on quality of life|Patients will be contacted and focus groups will be organized with 6 to 8 patients presenting different types of FD: monostotic, polyostotic, with or without craniofacial damage. Several focus-groups will be conducted with men only or women only. Patients will be led in a semi-directive manner by a moderator who will use an interview grid listing all the topics to be addressed: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The discussions will be recorded and transcribed verbatim. Data will be analyzed manually by 2 investigators and with the help of a semantic analysis software. The objective is to bring out common notions about the quality of life of patients, their psychological and emotional well-being, their difficulties in daily life and their coping strategies according to their condition. Differences or similarities between men and women will be investigated.
41013614|NCT05406544|OTHER|FD quantitative sudy on quality of life and olfaction.|Participants will receive 3 questionnaires to complete: the SF36 questionnaire (quality of life), the SELF-MOQ questionnaire (olfaction evaluation) and a demographic questionnaire. Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. For each questionnaire, scores will be calculated and compared between the different FD patient populations according to sex, age and type of FD.
41013615|NCT04931654|DRUG|AZD7789|anti-PD-1 and anti-TIM-3 bispecific antibody
41483472|NCT02799030|DRUG|BF-200 ALA 10%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
41483473|NCT04860050|DIETARY_SUPPLEMENT|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
41013616|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six weeks of strength training combined with patient education
41013617|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six to eight weeks of supervised home training
41156027|NCT06404086|DEVICE|Tailored lighting (TL) Placebo|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
41333461|NCT06153069|DRUG|Short-course regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
41333462|NCT06153069|DRUG|Standard regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
41483474|NCT04860050|DIETARY_SUPPLEMENT|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
41483475|NCT03660436|DRUG|BMS-986165|Specified dose on specified days
41483476|NCT03660436|DRUG|MMF|Specified dose on specified days
41483477|NCT05379855|DRUG|0.01% atropine eye drops|using 0.01% atropine eye drops for both eyes every night
41483478|NCT05379855|DRUG|placebo eye drops (0.1% sodium hyaluronate ophthalmic solution)|using placebo eye drops (0.1% sodium hyaluronate ophthalmic solution) for both eyes every night
41483479|NCT05379855|DRUG|0.05% atropine eye drops|using 0.05% atropine eye drops for both eyes every night
41483480|NCT03734211|DRUG|Evolocumab|420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
41483481|NCT03734211|DRUG|Placebo|Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
41483482|NCT03939299|PROCEDURE|OCT|Patients with coronary chronic total occlusion received successful stenting. Optimal coherence tomography imaged immediately and at 9-12 months after the index procedure to explore long-term vascular response and healing profile.
41483483|NCT00016718|DRUG|Didanosine (ddI)|Antiretroviral Didanosine (ddI) : 240 mg/m\^2 up to a maximum of 400 mg once daily
41156028|NCT02794558|DEVICE|ExAblate MRgFUS|"MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment."
41156029|NCT01062854|OTHER|Soft earplugs are worn during sleep study|"Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups."
41483484|NCT00016718|DRUG|Efavirenz (EFV)|Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
41483485|NCT00016718|DRUG|Emtricitabine (FTC)|Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
40815470|NCT06497062|DRUG|sonrotoclax|"Orally once daily, on D5-14. A 4-day dose ramp-up is required for the first induction. The dosing regimen will be determined in the Safety Run-in phase.~If a second induction is needed, dose ramp-up is not required. In the consolidation therapy phase, subjects in the group with favorable risk and MRD negative do not need to receive Sonrotoclax treatment, and subjects in the group with favorable risk and MRD positive, or with intermediate and adverse risk will receive sonrotoclax on D1-7 at the target dose determined in the safety run-in phase, dose ramp-up is not required.~In the maintenance therapy phase, subjects will receive once daily sonrotoclax on D1-14 at the target dose determined in the safety run-in phase."
40815471|NCT06497062|DRUG|idarubicin/daunorubicin|idarubicin: On D1-3, intravenously, 10 mg/m\^2 for subjects aged \<60 years, 6 mg/m\^2 for subjects aged ≥60 years daunorubicin: On D1-3, intravenously, 60 mg/m\^2 for subjects aged \<60 years, 40 mg/m\^2 for subjects aged ≥60 years
41483486|NCT01088282|PROCEDURE|Cataract surgery|Implantation of multifocal or monofocal IOL
41483487|NCT04232241|DRUG|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
41483488|NCT02337140|DEVICE|Pacemaker SORIN Group KORA DR|
40815472|NCT06497062|DRUG|Cytarabine|In induction therapy phase: intravenously, 100 mg/m\^2 on D1-7. In consolidation therapy phase: subjects with favorable-risk and MRD negative will receive cytarabine intravenously at 2 g/m\^2/q12h for those aged \<60 years, at 1g/m\^2/q12h for those ≥60 years on D1-3 or 3+7 regimen, and subjects with favorable-risk and MRD positive or intermediate or adverse-risk will receive cytarabine intravenously at 1 g/m\^2/d q12h on D1-3(in combination with sonrotoclax).
40815473|NCT06497062|DRUG|Azacitidine|75 mg/m\^2, subcutaneously, once daily, on D1-7
41333463|NCT05610722|DEVICE|DreaMed Endo Digital|The DreaMed Endo.Digital uses information gathered from glucose monitoring (sensor readings or capillary blood glucose measurements), insulin dosing and meal data during daily routine home care. Following a 5-minute data collection and analysis, the algorithm learns and suggests insulin dose adjustments and behavioral tips for optimization of glucose control. The algorithm is designed as an advisory tool for health care professionals.
41333464|NCT04192760|PROCEDURE|Stenting|Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions
41333465|NCT03612947|DRUG|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4
41333466|NCT03612947|DRUG|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
41333467|NCT01539278|PROCEDURE|Adenotonsillectomy|Tonsils and adenoids are surgically removed
40815474|NCT06497062|PROCEDURE|allo-HSCT|Per standard of procedure
40815475|NCT01703208|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
40815476|NCT01703208|DRUG|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
40815477|NCT02607475|DEVICE|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
40815478|NCT02607475|DEVICE|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
40815479|NCT01064102|DRUG|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
40815480|NCT05686746|DRUG|Baricitinib 4 MG|4 mg oral daily
41333468|NCT01539278|OTHER|Observation alone / no intervention|Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
41333469|NCT04019210|PROCEDURE|MODIFIED TRABECULECTOMY|Rectangular scleral flap
41333470|NCT03905876|OTHER|Questionnaire|Questionnaire to evaluate psychological experience
41333471|NCT02295306|DEVICE|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
41333472|NCT02561780|BEHAVIORAL|Curriculum|A mental health educational resource delivered in the classroom by trained educators
41333473|NCT02561780|BEHAVIORAL|eLearning Follow-up|An online mental health education module that students access individually
41333474|NCT00081939|DRUG|Velcade|Two cycles of induction on days 1,4,8,11 at 1.0mg/m\^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m\^2. Maintenance year one 1.0mg/m\^2 1,4,8,11 q 28 days.
41333475|NCT00081939|DRUG|Thalidomide|Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
41333476|NCT05196724|BEHAVIORAL|Mentalization Based Therapy MBT|The focus is on improving the core components of secure attachment, particularly by developing the reflective functioning for all professionals working with children in out-of-home care, which is subsequently proposed to increase the psychosocial adjustment of the child and decrease emotional and behavioral problems. MBT treatment consists of up to 12 weekly sessions with the foster parents and child covering three core components: 1) psycho-education about mentalizing, trauma, and attachment for foster parents; 2) support for reflective practice in the professional network, and 3) mentalization-based therapy for the foster family \[41\].
41333477|NCT05196724|BEHAVIORAL|Usual care|The control group will receive the usual care offered to foster families such as supervision
41333478|NCT05359679|BEHAVIORAL|Value Champion Training Program|Clinicians from primary care clinic sites randomized to the intervention arm of the study will complete a 6-month clinician value champion training program by participating in a series of 12 web-based training sessions. No intervention will be conducted at clinics in the control arm.
40815481|NCT05686746|DRUG|Baricitinib 2 MG|2 mg oral daily
40815482|NCT05686746|DRUG|MMF|1000 mg oral daily
40815483|NCT00251368|DRUG|9-Aminocamptothecin (9-AC)|
40815484|NCT05695261|BIOLOGICAL|Microbial Transplantation Therapy|Subjects randomized to the MTT/antibiotic arm will be administered oral MTT capsules over the course of 28 days.
40815485|NCT05695261|DRUG|Antibiotic|Subjects randomized to the MTT/antibiotic arm will receive oral antibiotics for 7 days prior to the MTT administration visit.
40815486|NCT05695261|OTHER|Placebo (in place of MTT)|Subjects randomized to the placebo arm will be administered oral placebo capsules in place of MTT over the course of 28 days.
40815487|NCT05695261|OTHER|Placebo (in place of antibiotics)|Subjects randomized to the placebo arm will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.
40815488|NCT06041711|PROCEDURE|General anesthesia with propofol induction and sevoflurane maintenance|Surgical procedure is performed under general anesthesia with propofol induction and mainteined with sevoflurane inhalation.
41333479|NCT05359679|OTHER|No Intervention|Usual clinical care - no value champion present at this clinical setting
41333480|NCT03146403|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
40815489|NCT06041711|PROCEDURE|Regional anesthesia with neuroaxial blockage|Surgical procedure is performed under regional anesthesia. Patients are sedated with 2 mg intravenous midazolam. Combined spinal epidural anesthesia or spinal anesthesia with PENG block is used for anesthesia and analgesia.
40815490|NCT06314373|DRUG|HSK39775 Monotherapy|HSK39775 will be administered orally once daily
40815491|NCT01897350|OTHER|Cardiac magnetic resonance imaging|
41333481|NCT03146403|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
41333482|NCT03146403|OTHER|0.9% normal saline|Placebo
41333483|NCT02656901|DEVICE|auto total endovenous anesthesia|a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
40815492|NCT01292356|DRUG|cetuximab|
40815493|NCT04136327|DRUG|GLPG1972 film-coated tablets|single oral dose of GLPG1972
40815494|NCT04136327|DRUG|[14C]-GLPG1972 solution for infusion|a 15-minute IV infusion \[14C\]-GLPG1972
40815495|NCT04136327|DRUG|[14C]-GLPG1972 oral solution|single oral dose of \[14C\]-GLPG1972
40815496|NCT02056886|PROCEDURE|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
40815497|NCT02018848|BEHAVIORAL|Attention Training Program|
40815498|NCT03871309|DEVICE|Tigertriever|Mechanical Thrombectomy
40815499|NCT06229028|OTHER|hand rehabilitation with verbal explanation|Patients in all groups will undergo a 12-week hand rehabilitation process that includes the use of appropriate orthoses if necessary, approaches to edema and pain, restoration of joint range of motion, strengthening, and functional return to work or activities. The application of the rehabilitation process will change according to the assigned group.
40815500|NCT06229028|OTHER|hand rehabilitation with patient information and exercise forms|hand rehabilitation with patient information and exercise forms
40815501|NCT06229028|OTHER|hand rehabilitation with video recording|hand rehabilitation with video recording
40815502|NCT01753869|PROCEDURE|Airways clearance and Hypertonic saline inhalation|
41013618|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S|"Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S:~1. The probiotics, Duolac7S, consist of 7 bacteria.~2. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~3. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (30 min after morning and evening meal)~4. Duration: 4 weeks of treatment period"
40815503|NCT02584543|BIOLOGICAL|HEV vaccine|
40815504|NCT02584543|BIOLOGICAL|HBV vaccine|
41333484|NCT02656901|DEVICE|Manual Desflurane anesthesia|General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40
41333485|NCT02656901|DEVICE|Manual Sevoflurane anesthesia|General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.
41333486|NCT02656901|DEVICE|Manual total endovenous anesthesia|In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
40815505|NCT05981001|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
41333487|NCT03600870|DRUG|Midodrine|Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
41483489|NCT02337140|PROCEDURE|transcatheter aortic valve implantation (TAVI)|
40815506|NCT05981001|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
41013619|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S-P|"Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
41483490|NCT04064814|DRUG|Flunarizine 5mg|Flunarizine 5mg once daily,orally for 12 weeks
41013620|NCT03606798|OTHER|3 Home visits made by a psychologist|Patient and caregiver interviews with a psychologist at home
40815507|NCT05981001|DRUG|Fludarabine|After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
41013621|NCT01312402|DRUG|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
41333488|NCT06332040|DRUG|Gentamicin|random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)
41333489|NCT01763983|BEHAVIORAL|Cognitive Behavioural Therapy|"CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.~Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study."
41333490|NCT01763983|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
41483491|NCT04064814|DRUG|Alpha lipoic acid 300mg|Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks
40815508|NCT05981001|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|"In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D."
40815509|NCT05981001|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
40815510|NCT05981001|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a fixed dose of 200mg IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
40815511|NCT05981001|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
41013622|NCT01312402|DRUG|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
40815512|NCT05981001|DRUG|Gemcitabine|Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
40815513|NCT05981001|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
40815514|NCT06355609|DRUG|sunvozertinib in combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle.
41013623|NCT06432010|OTHER|Group nutrition and physical activity coaching|Group nutrition and physical activity coaching consists of an initial health check-up, followed by nutrition and physical activity coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the group nutrition and physical activity coaching sessions.
41013624|NCT06432010|OTHER|Group cognition coaching|Group cognition coaching consists of an initial health check-up, followed by cognition coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the cognition coaching sessions.
41483492|NCT00283491|BEHAVIORAL|Active Lactobacillus plantarum 299v|10\^11 cfu/meal in 2 meals on 2 consecutive days
41013625|NCT00141063|DRUG|Focalin XR|
41483493|NCT00283491|DIETARY_SUPPLEMENT|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
41013626|NCT01824303|DRUG|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
41483494|NCT02133586|OTHER|Ozone|Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
41483495|NCT02133586|OTHER|Nitrogen dioxide|Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
41483496|NCT05802251|DIAGNOSTIC_TEST|Ultrasonographic parameters|cervical length. placental thickness. distance placental edge from internal os of the cervix
41483497|NCT00276952|DRUG|Gonyautoxin|
40815515|NCT06259487|BIOLOGICAL|Coordinated Vaccination|Coordinated Vaccination against Respiratory Syncytial Virus (RSV) and influenza provided by the research team (i.e., during cardiology visits)
40815516|NCT06259487|BEHAVIORAL|Following recommendations|Guidance on following the standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points).
40815517|NCT01685801|DRUG|Ivacaftor|150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
40815518|NCT01685801|DRUG|Placebo-matched-to-ivacaftor tablet|Orally every 12 hours up to 4 weeks.
40815519|NCT04605497|DIAGNOSTIC_TEST|Continuous glucose monitoring (CGM)|Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission \& discharge + additional 10 days during postpartum period
40815520|NCT04605497|DIAGNOSTIC_TEST|Self-Capillary Blood Glucose Monitoring (SCBG)|Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear
41013627|NCT01824303|OTHER|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
41013628|NCT06449157|OTHER|Inhalation induction with parosmia|"The experimental group will then be told that the patient's favorite smell will be put into the face mask via the magical machine. The patient will be asked to take a deep breath thinking about that smell and then introduce sevoflurane. The patient will be asked if the chosen flavor is smelled and their response will be noted."
40815521|NCT03455933|OTHER|Sham Comparator|The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
41333491|NCT04048629|DEVICE|Point-of-care (POC) viral load (VL) testing plus refresher training|VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
41013629|NCT06361511|OTHER|High Linoleic Acid Foods|Two food products containing 6g of high linoleic safflower oil each will be consumed each day for a total of 12g daily
41013630|NCT06361511|OTHER|High Oleic Acid Foods|Two food products containing 6g of high oleic safflower oil each will be consumed each day for a total of 12g daily
41156030|NCT01424189|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
40815522|NCT03455933|OTHER|Experimental Intervention|The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
40815523|NCT03455933|OTHER|Control Group|Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
40815524|NCT00734604|DRUG|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
40815525|NCT00734604|DRUG|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
41156031|NCT01424189|DEVICE|AcrySof® ReSTOR® Multifocal IOL Model SA60D3|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
40815526|NCT00734604|DRUG|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
41156032|NCT06646185|OTHER|Menstrual Pads|Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
40815527|NCT06464380|DIETARY_SUPPLEMENT|Saffranal|HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.
41013631|NCT06073327|DIETARY_SUPPLEMENT|dark chocolate|30g of dark or white chocolate was provided by the nutritionist for 30 days
41156033|NCT06646185|OTHER|Menstrual Cups|Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
41156034|NCT06646185|OTHER|Tampons|Participants adopt tampons to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
41156035|NCT06600815|PROCEDURE|preemptive stepwise infiltration anaesthesia(PSIA)|For PSIA patients, the anaesthetic is administered in stages. Initially, CA is injected at the incision site before the medial parapatellar incision. Following skin incision, more CA is injected into the subcutaneous tissue. After exposing the fascial layer and joint capsule, CA is used around the patellar tendon, and then CB is injected into the joint capsule and surrounding muscles. Additional CB is applied to the synovium and soft tissues after the joint cavity is opened, and more is used in the posterior joint capsule after bone resection.
41156036|NCT06600815|PROCEDURE|postoperative local infiltration analgesia(PLIA)|Before standardized TKA and implantation of the prosthesis, 30-40 mL of CB will be used to infiltrate the synovium and whole joint capsule. Subsequently, the joint cavity, subcutaneous tissue, and skin will be closed layer by layer using routine procedures. After the skin is closed, 30-40 mL of CA will be injected into the skin and subcutaneous tissue.
41333492|NCT04048629|OTHER|Standard of care central laboratory VL testing plus refresher training|VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
41333493|NCT00321009|DRUG|Enoxaparin|
41333494|NCT03550365|OTHER|Rye bran bread intervention|4 week dietary intervention rich in rye bran bread
41333495|NCT03550365|OTHER|Rye bread intervention|4 week dietary intervention rich in rye bread
40815528|NCT06464380|DIETARY_SUPPLEMENT|Placebo|HCC patients will receive Placebo in dose of once per day for six months.
41333496|NCT03550365|OTHER|Wheat bread diet|4 week dietary intervention rich in wheat bread as an active comparator for previous two interventions
41333497|NCT02269384|PROCEDURE|Experimental Noxious Stimulus|Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.
41333498|NCT02269384|BEHAVIORAL|Memory of Experimental Noxious Stimulus|Subjects will be asked to visualize previously experience experimental noxious stimulus
41333499|NCT02269384|BEHAVIORAL|Memory of Prior Significant Injury|Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
41333500|NCT02269384|PROCEDURE|Mental Challenge Test|Subjects will count backwards from 100 by specified amounts as rapidly as possible
41333501|NCT04464577|DRUG|Fluconazole|Specified Dose on Specified Days
41333502|NCT04464577|DRUG|Bupropion|Specified Dose on Specified Days
40815529|NCT03628482|PROCEDURE|CRF|For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
40815530|NCT03628482|PROCEDURE|PRF|The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
40815531|NCT00678769|DRUG|Cixutumumab|Given IV
40815532|NCT00678769|OTHER|Laboratory Biomarker Analysis|Correlative studies
40815533|NCT00678769|OTHER|Pharmacological Study|Correlative studies
40815534|NCT00678769|DRUG|Temsirolimus|Given IV
40815535|NCT05159492|DEVICE|PVI using PEF|PVI using PEF
40815536|NCT05159492|DEVICE|PVI using CFRF|PVI using CFRF
40815537|NCT05203757|PROCEDURE|ArthroCT scan|Conventional CT arthrogram as routine care
40815538|NCT05203757|PROCEDURE|CBCT|Cone Beam CT scan.
40815539|NCT03530774|DIETARY_SUPPLEMENT|powdered egg white protein supplement|consumption of egg white protein supplement daily for 6 months
41333503|NCT04464577|DRUG|Itraconazole|Specified Dose on Specified Days
41333504|NCT04464577|DRUG|BMS-986235|Specified Dose on Specified Days
40815540|NCT03530774|DIETARY_SUPPLEMENT|maltodextrin supplement|consumption of maltodextrin supplement daily for 6 months
41333505|NCT06231641|DRUG|Lemborexant 5 MG [Dayvigo]|Lemborexant 5 mg will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
41333506|NCT06231641|OTHER|Matching Placebo|Matching placebo will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
41333507|NCT01484561|DRUG|CP-690,550 or Placebo|CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
41333508|NCT01484561|DRUG|Placebo|Placebo BID orally, approximately 72 days
41333509|NCT00226278|DRUG|ORG 34517|
41333510|NCT03954067|BIOLOGICAL|ASP9801|Administered by intratumoral injection
40815541|NCT05286658|BEHAVIORAL|MEG/EEG|"The participant will sit still while their head is slid into the helmet-shaped bottom of the MEG device. The MEG contains sensors that passively detect weak magnetic fields outside the head produced by brain activity. The computer records the brain's electrical activity on the screen as wavy lines. The investigators will also ask you to wear sensors to capture eye-blinks (electrooculogram) and heartbeats (electrocardiogram) to facilitate removal from the MEG signal during analysis.~Participant will sit in front of a projector screen and be asked to put on a pair of headphones. Participant will be shown real words or nonsense words to read, the investigators may play sounds through headphones for the participant to repeat. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete."
40815542|NCT05286658|BEHAVIORAL|MRI|An MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures of organs and structures inside the body. The participant will be able to hear and speak to the research staff at all times during the MRI procedures. The MRI test will take about 15 minutes.
40815543|NCT05286658|BEHAVIORAL|Speaking Tasks|The participant may be asked to perform some of the tasks from MEG again, this time outside of the scanner. As before, the participant may see real words or nonsense words to read, and the investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
40815544|NCT01900171|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
40815545|NCT01900171|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
41333511|NCT03954067|COMBINATION_PRODUCT|Pembrolizumab|Administered by Intravenous Infusion
41333512|NCT00317057|PROCEDURE|Patient education and disease management|
41333513|NCT03114423|OTHER|EMDR-Therapy|The EMDR-protocol from Hase (2008) was used
41333514|NCT03114423|OTHER|Sham Intervention|For the training the COGPACK-program from Marker (2008) was used
41333515|NCT01488409|DRUG|Acipimox|250 mg by mouth (PO) three times daily
41333516|NCT01488409|DRUG|Placebo|0 mg by mouth (PO) three times daily
41333517|NCT04961827|BEHAVIORAL|Self-efficacy based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will utilize concepts in the Theory of self-efficacy to increase dietary self-efficacy among participants and hence improve dietary quality beyond that of conventional nutrition counseling.
40815546|NCT03528239|OTHER|Refugee patients|To investigate characteristics of outpatient visits of refugee patients
40815547|NCT02923830|OTHER|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
40815548|NCT02923830|DRUG|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
40815549|NCT01269229|DRUG|folfox|FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -\> 2400mg/m2 46hrs continuous
40815550|NCT01269229|RADIATION|short course Radiotherapy|After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.
40815551|NCT03654404|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 8-week period. The positive psychology program exercises includes three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
41013632|NCT06073327|DIETARY_SUPPLEMENT|White chocolate|30g of white chocolate was provided by the nutritionist for 30 days
41013633|NCT06252753|OTHER|Durvalumab-based combination therapies in observational study setting|Data on patients who initiated durvalumab-based regimens, including STRIDE (Single Tremelimumab Regular Interval Durvalumab), will be collected).
41013634|NCT06252753|OTHER|Durvalumab-based combination therapies in observational study setting|Data on patients who initiated durvalumab-based regimens, including durvalumab + chemotherapy combinations (e.g., Durvalumab + GemCis etc.) will be collected.
41013635|NCT04885517|DEVICE|Esophageal catheter|Patients are equipped with an esophageal catheter: positioning is performed after accurate nasopharyngeal anesthesia with lidocaine
41013636|NCT05501054|DRUG|Ipilimumab|Given by IV (vein)
41013637|NCT05501054|DRUG|Nivolumab|Given by IV (vein)
41013638|NCT05501054|DRUG|Ciforadenant|Given by PO
41013639|NCT02356159|BIOLOGICAL|Rituximab|Rituximab: 375 mg/m2 IV, day 1 for patients with CD20-positive disease
41156037|NCT03343288|DEVICE|Silver doped hydroxyapatite coated implants|In this study, CE marked, domestic manufactured standard orthopedic implants will be used in 30 patients after silver ceramic coating with electrospray method. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months.
41333518|NCT04961827|BEHAVIORAL|Knowledge based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will consist of information covered in nutrition counseling sessions, such as those related to serving sizes.
41333519|NCT02843750|BEHAVIORAL|Inspiratory Muscle Training-Rehabilitation|"The training will include the following components:~1. Breathing Awareness~2. Upper and Lower Extremity Exercise.~3. Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve~4. Practice at home"
41333520|NCT02843750|OTHER|Questionnaires|Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
41333521|NCT03785444|OTHER|WHODAS 2.0|WHO Disability Score
41333522|NCT03785444|OTHER|EQ5D|Health related quality of life measured with European Quality of Life 5 Dimensions 5 Level
41333523|NCT03785444|OTHER|IADL|The Lawton Instrumental Activities of Daily Living
41333524|NCT03785444|OTHER|Barthel-Score|Barthel Score of the patient
41333525|NCT03785444|OTHER|SF-36|Short Form Health 36
41333526|NCT03785444|OTHER|MoCA Blind|Montreal Cognitive Assessment
41333527|NCT00360685|DRUG|Tac+MTX|Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
41333528|NCT00360685|DRUG|TAC + MMF|Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
41333529|NCT04813302|PROCEDURE|Coronally advanced flap and connective tissue graft|CAF+CTG treatment will be performed by starting with two vertical releasing incisions lateral to the teeth to be treated and split-full-split thickness flap will be raised beyond the MGJ. The periosteum will be cut, and a blunt dissection into the vestibular lining mucosa will be carried out to eliminate muscle tension so that the mucosal flap can be passively positioned above the level of CEJ on the tooth. The papillae adjacent to the involved teeth will be de-epithelialized. CTG of 1mm in thickness will be harvested from the posterior palate by means of disepithelization of a free gingival graft, cut to the exact size of the defect, and placed over the dehisced defect, sutured to the interdental papillae and subsequently covered with CAF. Sling sutures will be placed to stabilize the flap in a coronal position about 1-2 mm above the CEJ , followed by interrupted sutures to close the releasing incisions.
41333530|NCT06207071|DIETARY_SUPPLEMENT|DHA|DHA supplementation
41333531|NCT00255996|DRUG|linezolid|
41333532|NCT01369407|OTHER|No Intervention|Not an interventional study
41333533|NCT01192204|DRUG|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
40815552|NCT06233682|OTHER|Enriched environment|In the experimental group (enriched environment), assistants will supervise participants sponatneoulsy engaging in activities, including listening to music, drawing, playing cards or board games, exercising the affected upper limb with constructions or puzzles, etc., in the living room and personal rooms. Posters and clocks will also aid in orientation and improve the physical environment.
40815553|NCT02516098|DRUG|hyoscine butylbromide|
41333534|NCT01192204|DRUG|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
41333535|NCT01879254|DEVICE|Deep Brain Stimulation|
40815554|NCT00721578|DRUG|voriconazole|Patients must have received (in the Intensive Care Unit \[ICU\] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
41333536|NCT04868136|BEHAVIORAL|Exercise|30 minutes of exercise at 80% of maximum predicted heart rate performed on an indoor stationary bicycle. Exercise was preceded by 10 min of gradually increasing cycling intensity in one of two exercise trials
41333537|NCT05960136|PROCEDURE|Sinus lift in patients with positive COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with positive COVID-19 history
40815555|NCT02982434|DRUG|Pharmaceutical composition containing botulinum toxin|
41483498|NCT03792360|DRUG|SVF (Stromal Vascular Fraction)|The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.
41483499|NCT04684303|PROCEDURE|Lumbar medial branch radiofrequency ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
40815556|NCT02982434|DRUG|0.9% normal saline|
41013640|NCT02356159|DRUG|Conditioning chemotherapy|Fludarabine:30 mg/m2 per day IV infusion over 30 minutes, daily On days -6, -5, -4, and -3; Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3 Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3; Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3
40815557|NCT02982434|PROCEDURE|Coronary artery bypass grafting|
40815558|NCT03474900|DEVICE|PLGA implant, Bioretec ltd. Finland|The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)
41483500|NCT04684303|PROCEDURE|Lumbar medial branch cryo ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
41013641|NCT02356159|DRUG|TMS|Tacrolimus: 0.02 mg/kg, start day 3. Continue IV or PO. Taper will begin at day +60 if no acute GVHD then at day +100 and discontinue at day +180 as tolerated. Methotrexate: 5 mg/m2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 60, followed by a taper if GVHD does not develop.
41013642|NCT02356159|DRUG|FLAG|Fludarabine: 25 mg/m2 per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m2 IV over 4 hours, on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy
40815559|NCT03474900|DEVICE|Titanium elastic stable nail|Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
40815560|NCT05655559|OTHER|Questionnare|Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).
40815561|NCT05655559|DEVICE|Moxy Muscle Oxygen Monitor|Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
40815562|NCT02497144|OTHER|NMES Group|Neuromuscular electrical stimulation
40815563|NCT02497144|OTHER|Control Group|Breathing exercises
40815564|NCT03558334|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
40815565|NCT03558334|DRUG|No transplantation of mesenchymal stem cell|Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.
40815566|NCT01405352|DIETARY_SUPPLEMENT|Vitamin A|"25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month"
40815567|NCT03979456|DRUG|Rituximab|After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
40815568|NCT02355652|DEVICE|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
40815569|NCT02355652|DEVICE|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
40815570|NCT03663127|DIETARY_SUPPLEMENT|Beauty Drink|"Subjects receive two bottles of Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks."
40815571|NCT03663127|DIETARY_SUPPLEMENT|Placebo|Subjects receive two bottles of placebo of similar appearance per day for 8 weeks of a stage. In addition, anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
40815572|NCT01076868|DRUG|Primaquine|Primaquine x 14 days
40815573|NCT05804513|DRUG|Placebo|s/c injection
40815574|NCT05804513|DRUG|Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector|s/c injection
40815575|NCT04286841|DRUG|Immunotherapy|Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
40815576|NCT00022763|DRUG|Enfuvirtide|
40815577|NCT00565149|BEHAVIORAL|PROOF|dietary overfeeding with high, low or normal protein content
40815578|NCT03897153|DEVICE|SONAS® Ultrasound Device|The SONAS® Ultrasound Device is intended for non-invasive transcranial ultrasound and used with a commercially approved contrast agent (e.g., Lumason®/SonoVue®).
40815579|NCT02327390|PROCEDURE|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
40815580|NCT02327390|BIOLOGICAL|X-ACT|Administered as an IV infusion
40815581|NCT03539822|DRUG|Cabozantinib|by mouth
40815582|NCT03539822|DRUG|Durvalumab|infusion
40815583|NCT03539822|DRUG|Tremelimumab|infusion
40815584|NCT03119181|DRUG|Tymbion Lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution
41013643|NCT02356159|DRUG|EPOCH-F|Fludarabine: 25 mg/m2 per day IV infusion over 30 minutes, daily on days 1-4. Etoposide: 50 mg/m2 per day continuous IV infusion over 24 hours on days 1-4. Doxorubicin: 10 mg/m2/day CIV, days 1-4. Vincristine: 0.4 mg/m2 per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide: 750 mg/m2 IV infusion over 30 minutes on day 5 Prednisone: 60 mg/m2 per day PO daily on days 1-5. Filgrastim: 5 mcg/kg per day SC or IV.
40815585|NCT03119181|COMBINATION_PRODUCT|Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution. The Iontophoresis System (IPS) will be used to deliver current to the Tymbion solution to facilitate drug penetration into the tympanic membrane (TM) tissue to anesthetize (numb) the TM
41013644|NCT02356159|PROCEDURE|Hematopoietic stem cell transplant|Hematopoietic stem cell transplant
41013645|NCT02356159|DRUG|Palifermin|Escalating doses of palifermin given during transplant phase
40815586|NCT03660202|DEVICE|Firesorb|Implantation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
40815587|NCT02604654|DRUG|Yiqitongluo granule|administered after dissolved
40815588|NCT03802305|DEVICE|computerized intraosseous technique (Quicksleeper™)|"The anesthetic solution is administered with a specific equipment allowing the injection step by step:~* anesthesia of the interdental papilla,~* positioning of the needle and perforating of the interdental space,~* Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment."
40815589|NCT03802305|DEVICE|loco-regional anesthesia (IANB technique)|The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
40815590|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D)
40815591|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D)
40815592|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D)
40815593|NCT02333682|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol)
40815594|NCT05705375|OTHER|Waterpipe size|Participants will have 3 lab visits where they are allocated (random order) to smoke a small waterpipe in one visit, smoke a medium waterpipe in a second visit and smoke a large waterpipe in a third visit.
41013646|NCT06497556|DRUG|Divarasib|Divarasib will be administered orally QD
40815595|NCT03252444|OTHER|Conscious control|Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
40815596|NCT03252444|OTHER|Conscious control+biofeedback|In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
40815597|NCT05846425|OTHER|Nose-breathing training|13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day
40815598|NCT05846425|OTHER|Mouth-breathing training|13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
41013647|NCT06497556|DRUG|Sotorasib|Sotorasib will be administered orally QD
41156038|NCT06223958|DRUG|OTX-TKI (axitinib implant)|Intravitreal Injection of OTX-TKI (axitinib implant)
41483501|NCT03353454|DRUG|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
40815599|NCT01814319|DRUG|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
41483502|NCT03353454|DRUG|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
41483503|NCT02099695|DRUG|Oxybutynin|The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.
40815600|NCT01814319|DRUG|Placebo|Matching placebo oral twice daily
40815601|NCT01444625|OTHER|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
40815602|NCT01444625|OTHER|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
40815603|NCT01377155|DRUG|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
41013648|NCT06497556|DRUG|Adagrasib|Adagrasib will be administred orally BID
41013649|NCT02568410|PROCEDURE|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
41013650|NCT02558608|PROCEDURE|DIPL|dissection of the inferior pulmonary ligament
41013651|NCT02558608|PROCEDURE|WR|wedge resection of the lung bleb
41013652|NCT02558608|PROCEDURE|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
41013653|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays with reservoir.|During bleaching using trays with reservoir.
41013654|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays without reservoir.|During bleaching using trays without reservoir.
41013655|NCT04189757|DRUG|Acalabrutinib|Given PO
41013656|NCT03058796|DEVICE|Contralaterally Controlled Functional Electrical Stimulation (CCFES)|The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.
41013657|NCT03058796|DEVICE|Hand Therapy Video Games|The use of video games with CCFES to encourage therapeutic hand movement at home
41013660|NCT06572826|OTHER|Cardiac Rehabilitation intervention|The cardiac rehabilitation program for post-CS patients includes respiratory physiotherapy, muscle strengthening and endurance training such as walking, treadmill exercises, and cycling, all tailored to the patient's capabilities. Cardiovascular training involves interval and continuous aerobic exercises to improve heart function. The program emphasizes secondary prevention strategies, including lifestyle changes and medication management. Neuromotor rehabilitation addresses sarcopenia and polyneuropathies through targeted exercises like balance training, gait retraining, and the use of advanced technologies like functional electrical stimulation (FES), robotic devices, and virtual/augmented reality. Cognitive-behavioral therapy (CBT) helps manage the psychological effects of severe cardiovascular events. The program also includes speech and occupational therapy, planning for home reintegration, and telerehabilitation to ensure long-term recovery.
41483504|NCT02099695|DRUG|Placebo|The quantity of tablets will increase due to the absence/ lack of therapeutic response.
41483505|NCT01649466|DRUG|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
41483506|NCT01649466|DRUG|Protaphane|Protaphane will be used as commercially available injection pens
41483507|NCT02496819|OTHER|Meta-cognitive self-regulated learning intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
41483508|NCT02496819|OTHER|Sensory integration intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
40815604|NCT02978547|DRUG|Metformin Hydrochloride 500Mg Tablet|In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
40815605|NCT05108272|PROCEDURE|Microneedling|Derma Pen is an electric device, used for microneedling. Derma pen has a Cartridge which has microneedles fitted. These needles penetrate the skin upto 2mm
41013661|NCT04655404|DRUG|Larotrectinib|"1. Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
41013662|NCT04655404|PROCEDURE|Larotrectinib surgical|"1. Surgical cohort: Larotrectinib x 3-5 days prior to definitive surgery followed by Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
41013663|NCT01087346|BEHAVIORAL|Reading Information|Reading information about risk factors for obesity among children
41156039|NCT06223958|DRUG|Aflibercept|Injection of 2mg (0.05mL) of aflibercept
41483509|NCT02496819|OTHER|Activity-based intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
40815606|NCT05108272|PROCEDURE|Percutaneous Collagen Induction|It is self-adhesive sheet made from medical graded Silicone. It has micropore technology which entraps moisture where it is needed on scared skin.
41483510|NCT02257294|DRUG|Alteplase|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
41483511|NCT02257294|OTHER|Placebo|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
41483512|NCT02558231|DRUG|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
41483513|NCT02558231|DRUG|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
41483514|NCT02558231|DRUG|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
41483515|NCT04783974|DEVICE|Dental implants|Treatment of total or partial edentulism through the placement of osseointegrated dental implants
40815607|NCT00426400|DRUG|The cessation of anti-aggregative treatment for 10 days|
40815608|NCT01260090|DEVICE|Vagus nerve stimulation;|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
40815609|NCT01260090|DEVICE|No stimulation|Vagus nerve stimulation
41013664|NCT05198674|DEVICE|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
41483516|NCT03376542|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary exercise testing on treadmill prior to coronary artery bypass grafting surgery
41483517|NCT04132895|OTHER|observational only, no interventions are prescribed in protocol.|"* Treatment will be given as per usual standard of care.~* No treatments are specified by this protocol."
40815610|NCT00244933|DIETARY_SUPPLEMENT|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
40815611|NCT00244933|DRUG|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 \& 8 every 21 days
40815612|NCT00244933|PROCEDURE|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
40815613|NCT06517394|BEHAVIORAL|Recovering Together after Cardiac Arrest|The intervention will teach resiliency skills (mindfulness, coping, etc.) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person or on Zoom/telephone, depending on the participant's preference and access to technology.
40815614|NCT04552210|DIAGNOSTIC_TEST|blood sample|Whole blood was collected on EDTA (1mg/ml) to prevent clotting and DNA degradation.
40815615|NCT06003543|BEHAVIORAL|Virtual Reality|Virtual Reality
40815616|NCT06230549|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy, online onboard adaptation of dose distribution with a specialist radiation oncologist and a medical physicist
40815617|NCT01803191|DRUG|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
40815618|NCT01803191|DRUG|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
41483518|NCT00470457|BIOLOGICAL|Allergen specific immunotherapy|
41483519|NCT00705692|DRUG|Levamisole|
41483520|NCT00705692|DRUG|Placebo|
41483521|NCT05210244|DIETARY_SUPPLEMENT|Beetroot Juice (BJ) acute supplementation|One serving of 70 mL of BJ (6.4 mmol of NO3) 3h before initiating the testing session
41483522|NCT05210244|DIETARY_SUPPLEMENT|Placebo Juice (PLA) acute supplementation|One serving of 70 mL of juice (0.005 mmol of NO3) 3h before initiating the testing session
40815619|NCT04990063|DRUG|Chemotherapy|Standard chemotherapy drug
40815620|NCT04990063|BIOLOGICAL|Adoptive TKC transfer therapy|TKC: co-cultured autologous NK cells and γδT cells
40815621|NCT02570152|PROCEDURE|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever \[body temperature ≥ 38°C/≥ 100.4°F\] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
41013666|NCT06573840|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand. NeuroGlove provides sensory stimulation in the form of pneumatic puffs of air.
41013667|NCT00001360|DRUG|0-15 Water|
41333538|NCT05960136|PROCEDURE|Sinus lift with negative COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with negative COVID-19 history
41333539|NCT04432467|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous adipose tissue-derived mesenchymal stem cells
41483523|NCT06069778|DRUG|BNT321 Dose Level 1|Intravenous infusion
41483524|NCT06069778|DRUG|BNT321 Dose Level 2|Intravenous infusion
41483525|NCT06069778|DRUG|mFOLFIRINOX|Intravenous infusion
41483526|NCT06069778|DRUG|BNT321 RP2D|Intravenous infusion
41483527|NCT02031952|PROCEDURE|hepatectomy combined with lymphadenectomy|
41483528|NCT02031952|PROCEDURE|hepatectomy alone|
41483529|NCT00428779|PROCEDURE|running during 24 hours without sleep|patients running during 24 hours without sleep
40815622|NCT05076409|DRUG|BI 425809|Period 1 and period 2
40815623|NCT05076409|DRUG|fluconazole|Period 2
40815624|NCT00415428|BEHAVIORAL|Patient adherence to national educational guidelines.|
41333540|NCT04432467|OTHER|standard treatment|standard treatment according to clinical protocols
40815625|NCT04641221|BEHAVIORAL|Weekly Yoga Classes|All participants are invited to attend weekly yoga classes.
40815626|NCT00653848|DRUG|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
40815627|NCT03892668|DRUG|Tranexamic Acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
40815628|NCT03892668|DRUG|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
40815629|NCT03892668|DRUG|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
40815630|NCT04771923|DRUG|Tranexamic acid|Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.
41333541|NCT03690947|DRUG|Intravitreal Ranibizumab|All subjections received 3 initial Ranibizumab injections
40815631|NCT04771923|DRUG|Adrenaline|Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.
41013669|NCT04184635|DEVICE|VA-ECMO|"* The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae.~* Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France)."
41013674|NCT01034397|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
41013675|NCT01034397|DRUG|placebo|iv every 4 weeks for 24 weeks
41013676|NCT01034397|DRUG|non-biological DMARDs|stable dose at investigator's prescription
41483530|NCT00428779|OTHER|no sleeping|patients without sleep during 24 hours
41483531|NCT03516084|DRUG|ZL-2306(nirapairb)|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
41483532|NCT03516084|DRUG|Placebo|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
41483533|NCT02310243|DRUG|Palbociclib|oral, once daily (125mg, 100mg or 75mg) for 21 days
41483534|NCT01352130|DRUG|Ondansetron|Intravenous Ondansetron 8 mgs
41483535|NCT01352130|DRUG|Granisetron|Intravenous Granisetron 1 mgs
40815632|NCT05311995|PROCEDURE|Only different trocar sites|Only different trocar sites in literature
40815633|NCT05658627|OTHER|active release technique|Hamstring active release technique-
40815634|NCT05658627|OTHER|conventional therapy|ultrasound therapy - stretching Exercise - Strengthening Exercise -
40815635|NCT05072223|PROCEDURE|Pericapsular nerve group block|A new nerve block guided by ultrasound that aims to block articular branches of the shoulder.
40815636|NCT05072223|PROCEDURE|Interscalene block|A common and rapid-onset nerve block method guided by ultrasound for pain control of patients undergoing shoulder surgery.
40815637|NCT00139542|OTHER|One shock per minute AED protocol|Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
40815638|NCT00139542|OTHER|Guidelines 2000 AED protocol|Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
40815639|NCT06061263|OTHER|follow up|collecttion of clinicopathological data from a prespectively collected databse, including survival data.
40815640|NCT05349409|DRUG|SHR-A1811|SHR-A1811 for Injection: Given IV.
40815641|NCT05349409|DRUG|Fluzoparib Capsule|Fluzoparib Capsule: Given PO.
41013679|NCT06360588|PROCEDURE|Biopsy|Undergo tumor biopsy
41013680|NCT06360588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41013681|NCT06360588|DRUG|Copanlisib|Given IV
41013682|NCT06360588|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
41333542|NCT03690947|PROCEDURE|Micropulse Laser|After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists
41333543|NCT03690947|DRUG|Intravitreal Ranibizumab as needed|After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
41333544|NCT04907162|DIAGNOSTIC_TEST|Beck depression inventory fast screen|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
41333545|NCT04907162|DIAGNOSTIC_TEST|German Pain Inventory|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
41483536|NCT05665920|RADIATION|Ultra-hypofractionated whole breast radiotherapy|Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week
41156040|NCT05426655|OTHER|Self management|"The program will consist of 3 sessions in which everything related to pain and its management will be explained. In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power Point presentation. In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle. A meditation session will also be held. In the third and last workshop, the game the painometer will be played and a meditation session will be held."
41156041|NCT00789932|BEHAVIORAL|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
41156042|NCT00789932|BEHAVIORAL|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
41156043|NCT05360342|DRUG|Vitamin K supplement|Single dose of vitamin K supplement
41333546|NCT04907162|DIAGNOSTIC_TEST|Brief Pain Inventory|Validated questionnaire for pain.
41333547|NCT04907162|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS)|Validated questionnaire for perceived fatigue
41333548|NCT04907162|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
41333549|NCT04907162|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
41333550|NCT04907162|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
41333551|NCT04907162|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
41333552|NCT04907162|DIAGNOSTIC_TEST|Myotonometer Assessment|Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
41333553|NCT04907162|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
41333554|NCT04907162|DIAGNOSTIC_TEST|Borg Scale|the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
41333555|NCT05293171|DRUG|1.25 mg/kg BL-8040 + BL-8040-matching placebo|Administered via subcutaneous (SC) injection
41333556|NCT05293171|DRUG|2 mg/kg BL-8040|Administered via subcutaneous (SC) injection
41333557|NCT05293171|DRUG|BL-8040-matching placebo|Administered subcutaneous (SC) injection
41333558|NCT05293171|DRUG|400 mg Moxifloxacin (1x400 mg tablet)|Administered orally
41333559|NCT00139841|DRUG|Bendamustine HCl|Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
41333560|NCT05215678|OTHER|Acceptance of invitation to trial participation|Individuals who are eligible for and accept participation in the INKA trial (NCT05172843)
41333561|NCT05215678|OTHER|Declining invitation to trial participation|Individuals who are eligible for participation in the INKA trial (NCT05172843) but decline the invitation to participate
41333562|NCT00158405|PROCEDURE|Structured Treatment Interruption|
41333563|NCT00158405|DRUG|Zidovudine (ZDV)|
41333564|NCT00158405|DRUG|Lamivudine (3TC)|
41333565|NCT00158405|DRUG|Efavirenz (EFV)|
41333566|NCT00158405|DRUG|Ritonavir (NRV)|
41333567|NCT00158405|DRUG|Indinavir (IDV)|
41333568|NCT01007513|PROCEDURE|Transvaginal ultrasound|A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
41333569|NCT01007513|PROCEDURE|Vaginal secretion sampling|Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
41333570|NCT00897091|GENETIC|comparative genomic hybridization|
41333571|NCT00897091|GENETIC|microarray analysis|
41483537|NCT05665920|RADIATION|Standard Radiation|Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage
41483538|NCT02733081|PROCEDURE|Simplified IUD Insertion|IUD Insertion with no bimanual pelvic exam or uterine sounding.
41483539|NCT05019820|OTHER|Knee strengthening exercises with isokinetic dynamometer|18 sessions of strengthening exercises around the knee with an isokinetic dynamometer 3 days a week
41156044|NCT05530083|BEHAVIORAL|group education|Group education is one of strategies and behavioural interventions of smoking cessation. Lectures, group meeting for mutual support, discussion of coping skills and suggestions for prevention relapse can help smokers quit smoking by providing support and encouragement from people in same condition.
41156045|NCT05530083|BEHAVIORAL|conventional smoking cessation management|Including regular follow-up of smoking status and giving advice of smoking cessation
41333572|NCT00897091|GENETIC|reverse transcriptase-polymerase chain reaction|
41333573|NCT00897091|OTHER|diagnostic laboratory biomarker analysis|
41156046|NCT04185142|COMBINATION_PRODUCT|cryoballoon ablation combining with left atrial appendage closure|cryoballoon ablation using either 1st or 2nd generation of cryoballoon and left atrial appendage closure using devices including WATCHMAN, Lefort and Lacbes.
41333574|NCT00805012|DRUG|docetaxel+CDDP|docetaxel+CDDP
41333575|NCT00805012|DRUG|docetaxel+S-1|docetaxel+S-1
41333576|NCT03590704|DEVICE|Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® neuromuscular bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region.
41483540|NCT05019820|OTHER|Strengthening around the knees with home exercise programe|18 sessions of strengthening exercises for the muscles around the knee at home, 3 days a week
41483541|NCT04160013|BEHAVIORAL|Discipline education|Discipline education using the Play Nicely program.
41483542|NCT04160013|BEHAVIORAL|Cavity Prevention|Cavity prevention using a 2 page handout.
41483543|NCT02213913|DRUG|lenalidomide|Given PO
41013685|NCT06571279|OTHER|Plant-based diet|"Participants will follow one week Western diet run-in where participants will consume a diet high in processed foods (e.g., fast food, chips, soda). Following the run-in phase, participants will consume plant-based meals and snacks for 5 weeks, which will be delivered directly to their homes or provided directly by the study team. Participants will be permitted to consume one cheat meal of up to 500kcal per week, which will all be reported to the study team."
41013686|NCT06571214|DRUG|Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)|As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.
41013687|NCT06571214|DRUG|Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)|This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.
41013691|NCT03866382|PROCEDURE|Bone Scan|Undergo bone scan
41013692|NCT03866382|DRUG|Cabozantinib S-malate|Given PO
41013693|NCT03866382|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT scan
41333577|NCT02645071|BEHAVIORAL|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
41333578|NCT00426933|DRUG|Daptomycin|
41013694|NCT03866382|BIOLOGICAL|Ipilimumab|Given IV
41013695|NCT03866382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41333579|NCT00426933|DRUG|Vancomycin|
41333580|NCT00889980|OTHER|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
41333581|NCT06343025|OTHER|Pilates Exercises Group|Individuals will perform clinical pilates exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of basic pilates exercises, 10 minutes of warm-up and 5 minutes of cool-down exercises.
41333582|NCT06343025|OTHER|Tai Chi Exercises Group|Individuals will perform Tai Chi exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of Tai Chi movements, 10 minutes of warm-up and 5 minutes of cool-down exercises.
41333583|NCT04273009|DEVICE|Renew VS PTNS|These will be prescribed and applied as described above.
41333584|NCT00175071|BEHAVIORAL|Comparison of cooking oils|30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
41013696|NCT03866382|BIOLOGICAL|Nivolumab|Given IV
41013697|NCT03866382|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
41013698|NCT06094959|OTHER|Suicide Prevention Package|The implementation package consists of co-designed and culturally adapted suicide prevention elements including suicide crisis response planning, contact follow up phone calls, and healthcare provider support mechanisms to optimize implementation.
41013699|NCT06572007|DIAGNOSTIC_TEST|Ultrasound|To investigate the thickness of the fascia tissue, the subjects will undergo an ultrasound examination using a clinical ultrasound system (S9, SonoScape Corporation, made in China) with a linear 5-14 MHz array of L14-5/38. The transducer with a cross-section of 6.24 cm2 will be aimed at points 2 cm lateral to the midline of the L2 and L3 vertebrae on both sides of the spine.
41013700|NCT06072612|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity
41013701|NCT06072612|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
41013702|NCT06072612|DRUG|Interferon infiltration of the inoculation site|Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
41333585|NCT02194517|DEVICE|ELKa|ELKa should be used for every meal preparation. After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving. No standard calculation of exchanges need to be performed.
41333586|NCT03846167|DRUG|Imaging Drug FluorThanatrace (FTT)|\[18F\]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
41483544|NCT02213913|DRUG|etoposide|Given IV
41483545|NCT02213913|DRUG|prednisone|Given PO
41013703|NCT06072612|DRUG|Retifanlimab|Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
41013704|NCT06072612|DRUG|Treatment of Physician's Choice|Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
41483546|NCT02213913|DRUG|vincristine sulfate|Given IV
41483547|NCT02213913|DRUG|doxorubicin hydrochloride|Given IV
41013705|NCT01600040|RADIATION|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
41156047|NCT06196229|OTHER|Action Observation Therapy|"During each training session, participants were asked to observe a specific object-directed daily action presented on a computer screen, and afterward they performed what they have observed, 5 repetitions of each task, time duration was noted .~16 motor tasks related to their daily living that were performed with their own hands which are following~1. Folding a towel~2. Cutting a toilet roll~3. Using scissors~4. Tightening shoelaces~5. Opening and closing a square airtight container~6. Opening a bottle top~7. Turning a faucet~8. Using a field of billfold~9. Drinking water~10. Setting a seal~11. Changing batteries~12. Opening and closing a zipper~13. Turning over pages of a book~14. Plugging the outlet~15. Spraying water with a sprayer~16. Sorting chopsticks and spoons and putting them in a box • The participants were advised to keep focusing on their affected arm/hand action observational tasks"
41013708|NCT01445509|DRUG|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
41156048|NCT06196229|OTHER|Action Observation Therapy combined with Virtual Reality|"In the VRT group, participants will execute VR-based activities conducted by the same therapist.~* 16 tasks will be assigned in each session. VR SHINECON 3D Glasses will be used~* The virtual environment was set in a 6 m2 physical space~* At the beginning of each session, the participant will sit in the center of the set zone and will be assisted to wear the VR glasses~* After the participant will confirm that the sight and sound is clear and comfortable, the tasks mentioned in action observation therapy will be done using virtual reality videos~* The Extrinsic feedback will be provided, including the time left, number of repetitions, and record number of repetitions"
41333587|NCT00190645|DRUG|Duloxetine|
41483548|NCT02213913|DRUG|cyclophosphamide|Given IV
41013709|NCT01445509|DRUG|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
41013710|NCT03754257|PROCEDURE|Experimental Electrical Stimulation|Experimental Electrical Stimulation (100Hz) during 40 minutes
41013711|NCT03754257|PROCEDURE|Sham Electrical Stimulation|Sham Electrical Stimulation (5Hz) during 40 minutes
41483549|NCT02213913|BIOLOGICAL|rituximab|Given IV
41483550|NCT02213913|OTHER|quality-of-life assessment|Ancillary studies
41013712|NCT03754257|OTHER|Conventional Physiotherapy|Active and passive exercises, and walking.
41483551|NCT02213913|OTHER|laboratory biomarker analysis|Correlative studies
41483552|NCT05799027|DIAGNOSTIC_TEST|Raman spectrum|The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.
41483553|NCT05372874|DRUG|Direct Acting Antivirals|hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
41483554|NCT01800526|DRUG|N-Acetylcysteine|Oral and Intravenous administration of NAC
41483555|NCT01832675|DRUG|Xylocain, cutaneous spray, solution|10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
41483556|NCT01832675|DRUG|Bupivacaine lozenge|25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
41483557|NCT03697265|DRUG|Sepranolone (UC1010) low dose|Subcutaneous (SC) administration
40815642|NCT01539733|DRUG|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
40815643|NCT01539733|DRUG|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
40815644|NCT05456373|DEVICE|ClearEdge device|ClearEdge tissue imaging device uses a new technology to detect tissue abnormalities at the surgical margins of a surgically excised breast tissue specimen. Adding the use of the imaging device has the potential to assist the surgeon in identifying DCIS or invasive cancer involved margins of the excised specimen.
40815645|NCT03277898|BEHAVIORAL|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
40815646|NCT03277898|BEHAVIORAL|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
40815647|NCT01390831|DEVICE|THERMOCOOL® Catheter|Catheter-based renal denervation
40815648|NCT03037359|BIOLOGICAL|Bivigam|Human immune globulin
40815649|NCT03037359|BIOLOGICAL|Other|Human immune globulin
40815650|NCT02954406|DRUG|TAK-659|TAK-659 immediate release tablet
40815651|NCT02954406|DRUG|Bendamustine|Bendamustine intravenous infusion
40815652|NCT02954406|DRUG|Rituximab|Rituximab intravenous infusion
40815653|NCT02954406|DRUG|Gemcitabine|Gemcitabine intravenous infusion
40815654|NCT02954406|DRUG|Lenalidomide|Lenalidomide capsule
40815655|NCT02954406|DRUG|Ibrutinib|Ibrutinib capsule
40815656|NCT03629340|DRUG|Metformin|500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
40815657|NCT03629340|DRUG|Placebo oral capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
40815658|NCT01642498|DEVICE|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
40815659|NCT05659017|GENETIC|Genetic analysis|The DNA will then be analyzed with a custom panel designed ad hoc to study the candidate gene by Next Generation Sequencing according to the protocols of the supplier of the kit.
40815660|NCT00557310|DRUG|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
40815661|NCT00663884|DRUG|Mitiglinide|mitiglinide 10mg three times a day before a meal
40815662|NCT00663884|DRUG|Voglibose|voglibose 0.2mg three times a day before a meal
40815663|NCT05905835|DEVICE|Synaptic Cryoablation System|The Synaptic Cryo Balloon must be used to isolate all targeted pulmonary veins. Entrance block will be confirmed in all targeted pulmonary veins (PVs) after a 20-minute waiting period or provocative testing with adenosine or isoproterenol. Any additional ablation in the LA beside PV isolation is not allowed in this protocol. Additional ablation of the cavo-tricuspid isthmus (CTI) with a conventional market-approved RF catheter is allowed only in case a typical atrial flutter is documented in prior patient history or occurs during the case (either spontaneously or inducible).
40815664|NCT02936310|BEHAVIORAL|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
41156049|NCT01545778|DRUG|Tapentadol IR|Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
40815665|NCT04850196|DEVICE|TEAS|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
40815666|NCT04850196|OTHER|control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
40815667|NCT03978052|DIETARY_SUPPLEMENT|EGCG|"FontUp capsules (100 mg of EGCG each)~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
40815668|NCT03978052|DIETARY_SUPPLEMENT|Placebo EGCG|"Placebo FontUp (same appearance as active).~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
40815669|NCT03978052|OTHER|Healthy lifestyle recommendations|Personalized advice on diet, physical activity, cognitive training, and social stimulation activities.
41156050|NCT01545778|DRUG|Oxycodone IR|Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
41156051|NCT05160402|DRUG|IGM-6268|Active comparator
41156052|NCT05160402|DRUG|Placebo|Placebo comparator
41156053|NCT04994483|DRUG|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.
41156054|NCT04994483|DRUG|Placebo|Matching placebo given b.i.d. for 52 weeks.
41483558|NCT03697265|DRUG|Sepranolone (UC1010) high dose|Subcutaneous (SC) administration
41483559|NCT03697265|DRUG|Placebo|Subcutaneous (SC) adminstration
40815670|NCT03978052|OTHER|Multimodal lifestyle intervention|"* Dietary intervention: personalized dietary recommendations based on MedDiet, 9 individual counseling sessions.~* Physical activity intervention: Guided gymnasium (aerobic, strength, and balance activities). Minimum one class/week the first 6months, and two classes/week from month 7 to 12). Achieve a physically active lifestyle (10,000 steps/day; individuals living with disability 8,500 steps/day). Achieve moderate physical exercise in older adults (150 to 210 minutes/week or 90 to 150 minutes depending on medical history.~* Cognitive training: NeuronUP, 3/week, 30 min sessions~* Psychoeducation: ten 90-minute sessions~* Social stimulation activities: ten to twelve 90-to-120-minute sessions."
40815671|NCT05483257|DEVICE|Multigene panel for next-generation sequencing|HLA-I genotyping based on next-generation sequencing for prognosis evaluation
40815672|NCT03643341|BEHAVIORAL|Family Healthy Living|Children aged 8-12 and at least one caregiver will meet for 10 weekly intervention sessions (1.5 hours per session), and 4 extra sessions to be chosen by families and intervention Leaders. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. Four biweekly maintenance sessions will follow the main program.
40815673|NCT02040350|DRUG|Pralidoxime|Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
40815674|NCT04446624|OTHER|Music therapy intervention|Group psychotherapy with music intervention
40815675|NCT00640380|OTHER|Nerve stimulation|CPVB with NS
40815676|NCT00640380|OTHER|Loss of resistance to air|CPVB with LOR
40815677|NCT00415337|PROCEDURE|endobronchial ultrasound|EBUS
41156055|NCT04187963|OTHER|Physical therapy|"The rehabilitation protocol for the IPT consisted of cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises. In addition, the GPT protocol followed the exact same pattern, except for 5-10 minute breaks for informal socialization between participants, at the beginning of the session, mid-session and at the end of the session.~Also, both groups had access to external cues, which were applied during a variety of tasks and environmental situations, like gait initiation and termination, heel strike and push-off, sideways and backwards stepping, walking while dual tasking, and walking over various surfaces and long distances."
41483560|NCT04190069|BEHAVIORAL|Behavioral interventions/modifications|UPMC Prescription for Wellness is an innovative physician/provider prescribed coaching and feedback program that improves patient engagement and outcomes in healthy behaviors; self-care of chronic disease and condition management; and shared decision-making. The resources available through this program are offered via a telephonic health coach, online or through a digital intervention based on the participant's convenience.
40815680|NCT02139878|OTHER|Wild blueberry juice|
40815681|NCT02139878|OTHER|Placebo wild blueberry juice|
40815682|NCT05984407|PROCEDURE|cytokine hemadsorption therapy|Observation of cytokine hemadsorption therapy in critically ill patients who have no microbiological findings and develop vasoplegic shock.
40815683|NCT01320319|OTHER|Placebo|Capsule form, 960 mg to be taken three times a day.
40815684|NCT01320319|DIETARY_SUPPLEMENT|Experimental: Nutritional Supplementation with EPA|Capsule form, EPA, 960mg to be taken three times a day.
40815685|NCT03824561|DRUG|Vedolizumab|Vedolizumab IV infusion
40815686|NCT04956276|DRUG|ALXN1830|Administered as an SC infusion.
40815687|NCT04956276|DRUG|Placebo|Administered as an SC infusion.
40815688|NCT00936533|DRUG|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
40815689|NCT00936533|DRUG|Placebo|Placebo preparation without active compound, administered as the active drug.
40815690|NCT04314999|DIAGNOSTIC_TEST|Examination of stool samples|Tests for diagnosis of parasitic diseases
41483561|NCT05502523|PROCEDURE|Pulmonary Artery-First Surgical Technique|Undergo pulmonary artery first surgical technique
41483562|NCT05502523|PROCEDURE|Biospecimen Collection|Correlative studies
40815691|NCT02519894|BEHAVIORAL|Dietary Scanning Calculator|
40815692|NCT04164095|PROCEDURE|lappg|Preservation of pylorus and vagus nerve by laparoscopy
40815693|NCT02974959|DEVICE|gammaCore active device|The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
40815694|NCT02974959|DEVICE|gammaCore sham device|The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
40815695|NCT00301392|OTHER|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
41483563|NCT03565393|COMBINATION_PRODUCT|Fibersol-2|A placebo-controlled, randomized; double-blind 2 arm trial
41483564|NCT03566264|OTHER|Non-Interventional|Non-Interventional
40815696|NCT00301392|DRUG|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
41483565|NCT02775136|DEVICE|HS-1000 recording|
40815697|NCT04557514|PROCEDURE|platelet rich plasma injection in post burn facial scar|"2 spins\>\>\>~1. st spin (separate plasma from blood) 2500 for 10 minutes~2. nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy"
41013718|NCT06136520|BEHAVIORAL|Baby massage|"After the first measurements are made and the groups are determined; Personal Information Form, Perinatal Attachment Inventory and Beck Depression Inventory will be applied to the experimental and control groups. Pregnant women in the experimental group were 32-40 weeks of pregnancy.~After baby massage training is given, 30-42 weeks after birth. between days and 60-72. Maternal Attachment Scale and Edinburgh Postpartum Depression Scale will be applied to the experimental and control groups on the following days. The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher."
40815698|NCT04557514|PROCEDURE|fat injection in post burn facial scar|Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .
41013727|NCT06498973|DRUG|Azacitidine|Given IV
41013728|NCT06498973|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41013729|NCT06498973|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
41013730|NCT06498973|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
41013731|NCT06498973|OTHER|Questionnaire Administration|Ancillary studies
41013732|NCT06498973|BIOLOGICAL|Tagraxofusp-erzs|Given IV
40815699|NCT00157196|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide \[L-BLP25\]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
41013739|NCT05970107|PROCEDURE|Axillary Lymph Node Dissection|"ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest."
41013740|NCT05970107|PROCEDURE|Axillary Reverse Mapping|Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND
40815700|NCT00157196|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
40815701|NCT00157196|OTHER|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
41013741|NCT05970107|PROCEDURE|Lymphaticovenous Bypass|Lymphaticovenous bypass/anastomosis (LVB/LVA) involves supramicrosurgery in which the blocked lymphatic vessel of an affected limb is connected to a nearby vein with the aid of ultra-fine instruments and a powerful operating microscope.
41013742|NCT03636490|BEHAVIORAL|Psychological Stress Intervention|Participant will be shown a series of words for five minutes and a research coordinator will ask him/her to name the color of each (Stroop Color-Word Conflict Task). Then, for another five minutes, the participant will be asked to count backwards out loud by sevens starting from 1,000 (Mental Arithmetic Task). The research assistant will ask the participant to work as quickly and accurately as possible for both tasks.
41013743|NCT05271929|BIOLOGICAL|Current standard of care and COVID-19 convalescent and vaccinated plasma|ABO compatible convalescent plasma infused intravenously on study day 1 (as soon as possible after randomisation) and the second on day 1 or day 2. Plasma obtained by apheresis from donors who have recovered from COVID-19 infection (at least 14 days after recovery) and have been vaccinated (at least 3 weeks after first dose of vaccine). A combination of both a SARS-CoV-infection and a SARS-CoV-2 vaccination of the donor is required - irrespective of the sequence of infection and vaccination. As far as the availability of CCP units allows, the two plasma units should have been donated by two different convalescents.
41013744|NCT05271929|OTHER|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~* Casirivimab~* Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~* Imdevimab~* Sotrovimab (Xevudy)~* Tixagevimab / Cilgavimab (Evusheld)~* Molnupiravir (MK-4482)~* Nirmatrevlir / Ritonavir (Paxlovid)~* Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
41013745|NCT04541017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41013746|NCT04541017|PROCEDURE|Computed Tomography|Undergo PET/CT or diagnostic CT
41013747|NCT04541017|BIOLOGICAL|Magrolimab|Given IV
41013748|NCT04541017|BIOLOGICAL|Mogamulizumab|Given IV
41013749|NCT04541017|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41013750|NCT04541017|PROCEDURE|Punch Biopsy|Undergo skin punch biopsy
41333588|NCT02360371|DRUG|Within-subject test of blinded study medication|Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.
41333589|NCT06396377|DEVICE|Reborn doll (Therapeutic object - OT)|If the resident is randomized to the intervention group, the investigating team will give the Reborn®doll to the resident, during a 45-minute to 1-hour workshop, twice a week for 3 weeks. The OTs, wrapped in a blanket, are presented to the residents by a member of the investigative team trained in reborning , in the resident's room. If the resident is not in his/her room, he/she will be taken back to receive his/her doll. In the case of double rooms, it will be necessary to assess whether or not to leave the room-mate in the room, in order to limit the loss of reference points for the resident concerned by the study. The caregiver lets the resident appropriate and recognize the OT, so that he or she can find meaning in it and awaken his or her sensory memory.In total, the patient will be exposed to OT 6 times.
40815702|NCT04222634|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions
40815703|NCT06014931|BEHAVIORAL|Telemedicine ICU Recovery Clinic Visit|Multidisciplinary clinic visit that encompasses a medical examination, medication management, neuropsychological exam with focused psychotherapy, case management, and patient-centered consultation.
40815704|NCT04302740|BEHAVIORAL|LEAP|The LEAP is a comprehensive, multidimensional, community-level intervention offered in Housing First settings that was developed using a CBPR framework. The LEAP principles, process, and components were conceptualized and operationalized by the CAB in the pilot study, and are outlined in a recently published articles in the American Psychologist and Journal of Community Psychology. Briefly, LEAP principles include recognizing and respecting community as a key unit of identity versus solely as individuals in a traditional research hierarchy; embracing cultural humility; practicing pragmatism and compassion; aiming to build equitable research partnerships with communities; acknowledging and promoting community strengths; and supporting relevant, sustainable, positive and community-led change.
41333590|NCT00005061|BIOLOGICAL|bevacizumab|
41333591|NCT03936478|RADIATION|MRIdian Radiation Treatment Unit|partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
41483566|NCT05343052|OTHER|Patient Reported Outcomes Surveys|"* Oslo Sports Trauma Research Center Hamstring Injury Screening Questionnaire (HaOS) at baseline~* Functional Assessment Scale for Acute Hamstring Injuries (FASH) within 7 days of injury and within 7 days of return to sport (RTS)"
41483567|NCT05343052|OTHER|Clinical Assessments|"* Injury History at baseline, within 7 days of injury, within 7 days of RTS~* Pain and Function Assessments within 7 days of injury, within 7 days of RTS"
41013752|NCT04455893|OTHER|Stratified Transplant Survival|The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs. Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ. excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
41013753|NCT05814627|DRUG|Upadacitinib|Oral Tablets
41013754|NCT05814627|DRUG|Adalimumab|Subcutaneous Injection
41013755|NCT05814627|DRUG|Upadacitinib Matching Placebo|Oral Tablets
41013756|NCT05814627|DRUG|Adalimumab Matching Placebo|Subcutaneous Injection
41013757|NCT03949387|OTHER|FES Cycling Exercise|FES cycling will use self-adhering surface electrodes (Pals Platinum, Fallbrook, CA) placed over the quadriceps, hamstrings, and gluteal muscle groups to deliver stimulation to the leg muscles.
41013758|NCT03949387|OTHER|Passive Leg Cycling|Passive leg cycling will not involve electrical stimulation
41013759|NCT04464226|DRUG|Darolutamide (Nubeqa, BAY1841788)|Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
41013760|NCT04097379|DRUG|LRX712|LRX712 intra-articular injections
41013761|NCT04097379|DRUG|Placebo|Placebo intra-articular injections
41013762|NCT04314401|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
41013763|NCT04314401|OTHER|Medical Chart Review|Medical charts are reviewed and data is collected
41013765|NCT03040297|DEVICE|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
41013766|NCT03040297|DEVICE|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
41013767|NCT03040297|DEVICE|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
41013768|NCT03552887|PROCEDURE|Cardiac Surgery|Any type of cardiac surgery
41013769|NCT03552887|PROCEDURE|Physiotherapy|Any type of physiotherapy intervention, performed by physiotherapists outside of the protocol
41013770|NCT02714452|BEHAVIORAL|Person-centred care|Person-centred and thriving promoting care
41013771|NCT00575588|DRUG|Metformin|open-label metformin
41013772|NCT00575588|DRUG|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
41013773|NCT00575588|DRUG|Saxagliptin|Saxagliptin 5 mg tablets
41013774|NCT03353428|BIOLOGICAL|LC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time
40815705|NCT04904276|DRUG|Fostamatinib|Fostamatinib disodium
41013777|NCT06183502|BEHAVIORAL|Quantitative survey|Quantitative surveys will be conducted through Alchemer, a HIPPA-compliant online survey system previously used by our group in collaborative research with CDC and supported by the Emory University Center for AIDS Research (CFAR). Surveys will be optimized for participants to take them through a personal computer, mobile phone, tablet, or the SMART study app. For participants who do not have any of these devices or prefer to not take the survey from their device, each city will have a research space where participants can schedule a convenient time to take the survey on a computer or tablet that the study will provide for that purpose.
41013778|NCT06183502|DIAGNOSTIC_TEST|HIV & STI testing|The research team has developed and validated procedures for self-collection of specimens for testing for STIs (syphilis, urethral, rectal, and pharyngeal gonorrhea/chlamydia) and HIV self-testing. All participants will be mailed self-collection kits to provide samples for STIs (urine, rectal swab, and pharyngeal swab for gonorrhea/chlamydia; dried blood spot (DBS) for syphilis testing) and HIV (HIV 4th generation testing on DBS specimens in a CLIA-certified laboratory). Participants will be asked to collect specimens for their STI and HIV testing (every 6 months) and return them to Molecular Testing Labs. For participants who prefer in-person procedures, they will meet study staff who will provide them with the STI and HIV self-collection kit and instructions and provide a room for participants to collect their specimens.
41156056|NCT05474378|DRUG|B7-H3CART|"B7-H3CART will be administered administered locoregionally (either ICV or both ICV and intratumorally (IT)) at one of the following doses:~Dose Level -1: 5 x 10\^6 CAR+ cells (+/- 20%) Dose Level 1: 10 x 10\^6 CAR+ cells (+/- 20%) Dose Level 2: 25 x 10\^6 CAR+ cells (+/- 20%) Dose Level 3: 50 x 10\^6 CAR+ cells (+/- 20%) Dose Level 4: 100 x 10\^6 CAR+ cells (+/- 20%)~B7-H3CART Dose Dose Level -1 (DL-1): 5 x 106 B7-H3CART+ cells (± 20%) Dose Level 1 (DL 1): 10 x 106 B7-H3CART+ cells (± 20%) Dose Level 2 (DL2): 25 x 106 B7-H3CART+ cells (± 20%) Dose Level 3 (DL3): 50 x 106 B7-H3CART+ cells (± 20%) Dose Level 4 (DL4): 100 x 106 B7-H3CART+ cells (± 20%)~Repeated every 28 days (-7 / +14 days) as long as infusion criteria are met for a total of 6 doses, with an option for an additional 6 doses, up to a total of 12."
41156057|NCT06646575|OTHER|Qualitative data, no intervention|This is a qualitative study
41156058|NCT06291584|OTHER|Exercise|In the exercise program, the first 5 minutes are for heating, and the last 5 minutes are for cooling. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. At the end of respiratory exercises, resistance exercise training will be started. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, hip extrudy, squat, and cat-decrease. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
41156059|NCT06646978|DRUG|Imatinib (STI571)|Imatinib-based regimen
41156060|NCT06065202|DIETARY_SUPPLEMENT|Nutrition Supplement|Total parenteral nutrition (TPN) will be administered within 72 hours of abdominal surgery. Nutritional shakes will be started with a liquid diet and given 3 times a day. This will continue for 4 weeks after discharge.
40815706|NCT01595230|PROCEDURE|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
40815707|NCT05678816|DEVICE|BREATHER|respiratory muscle trainer used to strength inspiratory an expiratory muscles through breathing in and out against aresistence which is determined individually according to each patient.
41333592|NCT06418568|DEVICE|Ultra-pulsed Shockwave Therapy Device by Shenzhen Lifotronic Technology Co., Ltd.|The intervention involves treating melasma using tranexamic acid (aminomethylbenzoic acid) delivered through ultra-pulsed shockwave therapy on one side of the face, while the other side receives topical application of tranexamic acid at the same concentration. The shockwave therapy parameters are tailored based on patient tolerance. Each patient undergoes 3 treatment sessions spaced 3 weeks apart, followed by a 4-week follow-up period. Facial skin is assessed using the VISIA system before each treatment and at the 4-week follow-up, evaluating the Melasma Area Severity Index (MASI). Patient and researcher satisfaction levels are rated on a scale of 1 to 5. Adverse reactions, including short-term effects like pain and swelling, and potential long-term effects such as allergic reactions and hyperpigmentation, are monitored after each treatment session.
41483568|NCT05343052|OTHER|Biomechanical and Neuromuscular Assessments|"* Eccentric Strength measure at baseline and within 7 days of RTS~* Sprinting Biomechanics at baseline and within 7 days of RTS"
41483569|NCT05343052|DEVICE|Conventional MRI|at baseline, within 7 days of injury, and within 7 days of RTS
40815708|NCT05678816|OTHER|physiotherapy prgramme for rehabilitation of stroke patients|"physiotherapy prgramme for rehabilitation of stroke patients which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training."
40815709|NCT00121758|BIOLOGICAL|LIPO-5|
40815710|NCT02439450|BIOLOGICAL|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
40815711|NCT02439450|DRUG|Nivolumab|Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
40815712|NCT02439450|DRUG|Pembrolizumab|The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
40815713|NCT02439450|DRUG|Pemetrexed|The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
40815714|NCT03867266|PROCEDURE|Ablation with radiofrequency|Ablation point by point on the cavo tricuspid isthmus guided by an index lesion
40815715|NCT03051880|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
40815716|NCT03051880|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
40815717|NCT00150319|DRUG|Vfend®; I.V.|
41156061|NCT05854160|PROCEDURE|Electrical Pulse Train Stimulation|sEEG provides the ability to stimulate neural circuits via implanted electrodes by delivering mild intra-cranial electrical stimulations in different brain structures to estimate their impact on cognitive tasks.
41333593|NCT00481741|DEVICE|SafeSeal(TM) Hemostasis Patch|
41156062|NCT02149576|PROCEDURE|Low Dose Computed Tomography Imaging|
41156063|NCT02149576|PROCEDURE|Chest Radiograph Imaging|
41156064|NCT05164718|BEHAVIORAL|Supervised home-based exercise|150-300 minutes of moderate intensity activity (55-75% of maximum heart rate in sinus rhythm or RPE 12-13 on the Borg Scale) or 75-150 minutes of vigorous intensity activity (75-90% of maximum heart rate or 14-16 on the Borg Scale) per week, or an equivalent combination of both, according to current general recommendations, including also those with established CVD. To maximize the potential for improvements in cardiorespiratory fitness, we encourage that at least 40-60 minutes per week (i.e. 2 sessions á 20-30 minutes) should be of vigorous intensity.
41333594|NCT02321072|DRUG|Oxygen|
41333595|NCT04876963|DEVICE|Holter-monitor|7-day holtermonitoring of each patient
41483570|NCT06070987|PROCEDURE|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 100 units. The dose range of each target muscle is as below:100 units in rectus femoris.
40815718|NCT04005560|OTHER|no interventional study|no interventional study
40815719|NCT05707078|PROCEDURE|Neck dissection|Based on PET/CT scan patients will undergo neck dissection.
40815720|NCT02050802|DRUG|Moxifloxacin 400 mg|
40815721|NCT02050802|DRUG|Macitentan 10 mg|
40815722|NCT02050802|DRUG|Macitentan 30 mg|
40815723|NCT02050802|OTHER|Placebo|
40815724|NCT03501004|DEVICE|Sterile acupuncture needles for single use|Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm\*25mm.
40815725|NCT06483191|BEHAVIORAL|Acceptance and Commitment Therapy|A half-day pre-operative virtual ACT group workshop, booster post-operative ACT text messages once a week for 6 weeks and a telephone follow-up with a physiotherapist at 6-8 weeks (all in addition to standard care).
40815726|NCT03300271|OTHER|Mobile application for self monitoring|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
40815727|NCT03300271|OTHER|Education|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
40815728|NCT03300271|OTHER|Mobile application for personal coaching|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
40815729|NCT04347213|BEHAVIORAL|Regular lifestyle in different circumstances|Participants' lifestyle will be followed over the years.
40815730|NCT03829462|DRUG|Regorafenib|regorafenib tab 40 mg i.e 160 mg/day
41156065|NCT05164718|OTHER|Usual care|Standard management according to usual practice at the respective participating centers, including medical therapy as per guidelines. Prior to randomization all will be provided an ICM (Confirm RX™). The UC group will receive information about general PA recommendations as per guidelines at study enrollment. No further supervision is given.
40815731|NCT03829462|DRUG|Irinotecan|irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
40815732|NCT00003603|DRUG|cyclophosphamide|
40815733|NCT00003603|DRUG|dexamethasone|
40815734|NCT00003603|DRUG|idarubicin|
40815735|NCT00003603|DRUG|lomustine|
40815736|NCT00003603|DRUG|melphalan|
40815737|NCT00003603|DRUG|prednisolone|
40815738|NCT01932229|DRUG|Afatinib treatment|
40815739|NCT03842969|DRUG|RO7234292 (RG6042)|Intrathecal injection
40815740|NCT00590174|DRUG|Aspirin|stopping clopidogrel at 1 year after DES implantation
40815741|NCT00590174|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
40815742|NCT04739553|DEVICE|His Pacing|The patients will receive a pacemaker implant with a traditional right ventricular pacing lead and an additional His pacing lead in a basal high septal position at the level of the proximal electrical conduction system (His). An atrial lead is implanted if dual chamber pacing is needed. All leads are connected to a biventricular pacemaker with the His lead in the LV port.
40815743|NCT04009694|OTHER|Pelvic Floor Muscle training|Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
40815744|NCT03967028|PROCEDURE|cesarean section|lower segment cesarean section either elective or emergency
40815745|NCT05103670|PROCEDURE|Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA|32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
40815746|NCT04277858|DRUG|Docetaxel|Subjects will be treated with neoadjuvant docetaxel and cisplatin for 3 cycles. This is followed by transoral robotic surgery (TORS) and neck dissection as definitive treatment, reserving radiotherapy for salvage.
40815747|NCT03178123|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
40815748|NCT03178123|BIOLOGICAL|high-dose recombinant interferon a-2B|15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
40815749|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (Fast Track)|The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
41156066|NCT06646406|BEHAVIORAL|Patient letter and clinician communication|Single mailing to patients from practice with a reminder that the influenza and COVID-19 vaccines are due, and monthly emailing to the patients' clinicians with information about how to make a strong recommendation for those vaccines
41156067|NCT05879991|DRUG|BI 1810631 (C-14) formulation 1|BI 1810631 (C-14) formulation 1
40815750|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (5 weeks)|The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
40815751|NCT05333627|BEHAVIORAL|Wellbeing Course (8 weeks)|The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
41483571|NCT06070987|OTHER|BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot after BoNT-A injected in the affected rectus femoris, then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
40815752|NCT06225375|DEVICE|Restorelle® Flat Mesh|Pelvic organ prolapse repair using Restorelle® Flat Mesh
40815753|NCT05952011|PROCEDURE|Left stellate ganglion block|patients will be positioned with head in midline position and mild extension of the neck. Cricoid cartilage will be identified by midline palpation of the neck and a 12 mega hertz ultrasound probe will be used. The airway will be identified by the shadow of the cricoid cartilage at the level of C6 vertebrae. The probe will be moved laterally to identify internal jugular vein, carotid artery and thyroid. Depth of ultrasound field will be adjusted to include the transverse process of the C6 vertebra. Following complete aseptic precautions, an echogenic insulated needle 5 cm long will be inserted under ultrasound guidance and directed toward the transverse process of the C6 vertebra. After the needle tip will make contact with the transverse process, it will be withdrawn 2 mm and 8 ml of 0.25% bupivacaine will be injected.
40815754|NCT00737568|DRUG|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
40815755|NCT00737568|DRUG|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
40815756|NCT00737568|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
40815757|NCT00737568|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
40815758|NCT04754191|DRUG|Enfortumab vedotin|Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
40815759|NCT06430580|DRUG|Hydrocortisone Oral|20mg hydrocortisone, single oral dose
40815760|NCT06430580|DRUG|Yohimbine Hydrochloride|54mg yohimbine hcl, single oral dose
40815761|NCT06430580|DRUG|Cornstarch Placebo 20mg|20mg cornstarch placebo, single oral dose
40815762|NCT06430580|DRUG|Cornstarch Placebo 54mg|54mg cornstarch placebo, single oral dose
41013779|NCT06183502|BEHAVIORAL|Qualitative Assessment|Focus group discussions (n=up to 48 men for 3 qualitative assessments; total n=up to 144 men) as a part of the study consisting of 9 to 12 focus group discussions (FGD) with an average of 8 (range 3-10) participants in each (3 per city). These focus groups will be conducted once during the first year of the study. FGD will be conducted by a trained moderator using a semi-structured interview guide developed in collaboration with CDC scientists. For the FGD, in each city, there will be one FGD with men who have never used PrEP, one with men who are using PrEP and report no adherence issues, and one with men who are currently using PrEP or used PrEP previously and report sub-optimal adherence. In-Depth Interviews (IDIs) A series of 90 in-depth interviews (same n=up to 45 men for each of 3 qualitative assessments) will be conducted over 18 months: up to 45 IDIs each 6 months apart, with up to 15 IDIs per city each wave.
41013780|NCT03920397|BIOLOGICAL|Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation|The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 \[T3\], 6 \[T6\], 12 \[T12\], 18 \[T18\], and 24 \[T24\] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.
41156068|NCT05879991|DRUG|BI 1810631|BI 1810631
41156069|NCT05879991|DRUG|BI 1810631 (C-14) formulation 2|BI 1810631 (C-14) formulation 2
40815763|NCT00045149|BIOLOGICAL|aldesleukin|
40815764|NCT00045149|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
40815765|NCT06325241|OTHER|No intervention|There is no intervention. This is an observational study.
40815766|NCT05301257|BEHAVIORAL|Intervention group SOSteniamoci|Intervention based on cognitive behavioural therapy principles and culturally adapted to Italian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
40815767|NCT00875485|PROCEDURE|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
40815768|NCT00875485|BIOLOGICAL|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (\< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
40815769|NCT00742989|OTHER|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
40815770|NCT00742989|OTHER|Sham OLT|Therapeutic massage performed
40815771|NCT04353375|DRUG|HMPL-453|Cohort_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)
40815772|NCT00945347|DRUG|Miglustat|Nasal instillation of miglustat
40815773|NCT00945347|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
40815774|NCT05820568|BEHAVIORAL|ICBT-IU|Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
40815775|NCT02187276|DRUG|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
40815776|NCT01950793|DRUG|triamcinolone acetonide|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only Steroid"
40815777|NCT01950793|DRUG|Hyaluronic Acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
40815778|NCT04545190|DIETARY_SUPPLEMENT|Glucose|To investigate the effects of glucose intake during resistance training on muscle biological adaptations
40815779|NCT05352516|BIOLOGICAL|HLX14|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects will be continue with a third dose of HLX14."
40815780|NCT05352516|BIOLOGICAL|Prolia®|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of Prolia® 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14."
40815781|NCT04657705|PROCEDURE|High power ablation|High power ablation parameters (50-55 W)
41156070|NCT05399082|DEVICE|Cryoprobe biopsy|A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
41333596|NCT05267418|DEVICE|Automated nasal O2 titration with FreeO2|The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)
41333597|NCT02773368|DRUG|insulin degludec/liraglutide|IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
40815782|NCT04657705|PROCEDURE|Standard ablation power|Standard ablation power parameters (40-45 W)
41333598|NCT02773368|DRUG|insulin glargine|IGlar will be given subcutaneously ( s.c., under the skin) once daily.
41333599|NCT03442504|DIAGNOSTIC_TEST|FES PET/CT|"There will be no premedication or other treatment before and after PET FES. PET / CT will be performed at the center level on a hybrid PET camera.~* The first TEP FES acquisition begins at the time of injection and continues for 30 minutes,~* The second acquisition of 20 minutes takes place 60 minutes after the injection is a total of 50 minutes of imaging and 1:30 in the service."
41333600|NCT02918955|PROCEDURE|up-front neck dissection|
41333601|NCT02918955|RADIATION|radiotherapy|70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)
40815783|NCT02559323|OTHER|Survey|
41156071|NCT05399082|PROCEDURE|Forceps biopsy|Biopsy forceps used to collect tissue
41156072|NCT05669339|DRUG|Irinotecan|All subjects will be given either 25 mg/m2 (dose level -1), 50 mg/m2 (dose level 0), or 75 mg/m2 (dose level +1) irinotecan intravenously every 7 days.
41013781|NCT04083456|BEHAVIORAL|Walking Biobehavioral Intervention|Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.
41013782|NCT04083456|OTHER|Attention Control|Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.
41013783|NCT02284737|PROCEDURE|PADN|Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
40815784|NCT06232018|DEVICE|Skin adhesive (Dermabond)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue (DERMABOND ADVANCED®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
41013784|NCT02284737|PROCEDURE|sham PADN|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
41013785|NCT02284737|DRUG|Sildenafil|Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
41013786|NCT05846009|DRUG|SAR442501|Subcutaneous injection
41013787|NCT05846009|DRUG|Placebo|Subcutaneous injection
41013788|NCT05536349|DRUG|Pirtobrutinib|Given by PO
41013789|NCT05536349|DRUG|Obinutuzumab|Given by (IV) vein
41013790|NCT05536349|DRUG|Venetoclax|Given by PO
41013791|NCT05536349|DRUG|Valacyclovir|Given by PO
41013792|NCT05536349|DRUG|Allopurinol|Given by PO
41013793|NCT04337554|DEVICE|Exoskeleton footwear|Assistive footwear
41013794|NCT04798261|DEVICE|Indigo Aspiration System|Indigo Aspiration System
41013799|NCT00607945|DRUG|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
41013800|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
41013801|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
41156073|NCT05669339|DRUG|Sonidegib|All subjects will take 200 mg sonidegib orally either every 96 hours (dose level -1), every 48 hours (dose level 0), or every 24 hours (dose level +1).
40815785|NCT06232018|DEVICE|skin adhesive + polyester mesh (Dermabond prineo)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue + polyester mesh ( DERMABOND PRINEO®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
41156074|NCT05669339|DRUG|Sorafenib|All subjects will take 200 mg sorafenib orally either every 48 hours (dose level -1), every 24 hours (dose level 0), or every 12 hours (dose level +1).
41483572|NCT06070987|OTHER|None BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot (do not inject BoNT-A in the affected rectus femoris), then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
41483573|NCT04516512|BIOLOGICAL|Blood draw|For each participants to the research a peripherical blood draw will be performed
41483574|NCT05994820|BEHAVIORAL|Happy Baby Programme -Vaccine Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi.
41483575|NCT05994820|BEHAVIORAL|Happy Baby Programme- Vaccine ++ Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi as part of a holistic healthy baby approach that includes nutrition and sanitation.
41483576|NCT00002321|DRUG|Aldesleukin|
40815786|NCT05868928|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image
41483577|NCT05575635|DRUG|fruquintinib + concurrent radiotherapy + chemotherapy|"mFOLFOX6: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days, continuous infusion.~fruquintinib: 3mg/d, qd po, for 7 weeks continuously.~Radiation Therapy: radiation 45.0\~50.0 Gy (1.8-2.0 Gy/day or 25 fractions weeks 3-7)"
41483578|NCT05834166|OTHER|Upper back strengthening and Postural correction|The treatment protocol will involve upper back strengthening exercises and postural correction exercises 3 times a week for 10 to 15 minutes. Upper back strengthening will involve exercises with light-to-moderate load of free weights (body weight or resistance bands) or with a stability ball. Postural correction will involve maintaining the correct posture.
41483579|NCT01829113|DRUG|OGX-427|Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
41483580|NCT01829113|DRUG|Placebo|Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
41483581|NCT01672944|OTHER|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
41483582|NCT01672944|OTHER|NCI-developed educational materials|"Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
41483583|NCT00560937|DRUG|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
41483584|NCT00560937|DRUG|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
41483585|NCT04719234|DEVICE|lung ultrasonography|Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)
41483586|NCT01846117|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside, vitamin D|SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
41156075|NCT04112355|OTHER|Blood Collection|Blood draw
41156076|NCT06646354|DRUG|Ezetimibe/Rosuvastatin/Candesartan/Amlodipine|PO, QD, 8 weeks
41156077|NCT06646354|DRUG|Candesartan/Amlodipine|PO, QD, 8 weeks
41483587|NCT03075319|PROCEDURE|Received perioperative photograph|"All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
40815787|NCT05868928|DIAGNOSTIC_TEST|Diffusion-weighted MRI|Diffusion-weighted MRI
40815788|NCT05868928|DIAGNOSTIC_TEST|Arterial spin labeling (ASL)|Cerebral blood flow imaging parameter
40815789|NCT05868928|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-MRI (DSC-MRI)|Cerebral blood volume and vessel architectural imaging parameters
40815790|NCT03969056|BEHAVIORAL|Artificial Intelligence (AI) Activity|The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
41013813|NCT06012435|DRUG|sigvotatug vedotin|Given into the vein (IV; intravenously) on Day 1 and 15 of a 28-day cycle
41013814|NCT06012435|DRUG|docetaxel|75 mg/m\^2 given into the vein (IV; intravenously) on Day 1 of a 21-day cycle
41156078|NCT06646354|DRUG|Candesartan/Rosuvastatin/Ezetimibe|PO, QD, 8 weeks
41156079|NCT05246618|DRUG|TUM012|Ex-vivo infusion
41156080|NCT05246618|DRUG|Placebo|Ex-vivo infusion
41156081|NCT05375383|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 lozenge|In this study, a lozenge will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
41483588|NCT03075319|PROCEDURE|Didn't receive perioperative photograph|"All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
41483589|NCT03130218|OTHER|Peppermint oil aromatherapy|Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
41483590|NCT03533374|DIAGNOSTIC_TEST|Electroencephalogram (EEG) and visual evaluation|Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).
41483591|NCT01586403|BIOLOGICAL|Dose 1|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight. Subject in cohort 1 will receive 2.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
41483592|NCT01586403|BIOLOGICAL|Dose 2|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 2 will receive 7.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
41483593|NCT01586403|BIOLOGICAL|Dose 3|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 3 will receive 2.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
40815791|NCT03969056|BEHAVIORAL|10,000 steps|The intervention provides participants with an automated daily 10,000 step goal intervention
40815792|NCT02082080|OTHER|Education|
40815793|NCT02082080|OTHER|Social support|
40815794|NCT02339142|RADIATION|External beam radiotherapy|100 Rads to each lateral orbit x 10 doses
41156082|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
40815795|NCT02339142|DRUG|intravenous corticosteroids (methylprednisolone)|Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
40815796|NCT02777606|DRUG|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
40815797|NCT06008418|BEHAVIORAL|The LINE Chatbot|The chatbot approach is selected as it uses artificial intelligence to simulate conversations with users. The information can be collected or distributed and even through these conversations trigger human actions. LINE is one of the most widely used freeware applications in Taiwan and its chatbot function is well-organized and relatively easy to modify, adapt, and use. The design of the chatbot aims at the two elements above, ensuring goal alignment and enhancing power sharing, by guiding participants to complete three activities: specifying their goals for today's discussions, providing patient-reported outcomes by self-rating their health-related quality of life, and learning question prompt list based on their needs.
40815798|NCT01965769|OTHER|No gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding.
40815799|NCT03393819|DRUG|DuraPrep|DuraPrep surgical solution
40815800|NCT03393819|DRUG|ChloraPrep|ChloraPrep surgical solution
40815801|NCT01608698|DRUG|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
40815802|NCT01608698|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
41156083|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
41156084|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotics A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
41333602|NCT02918955|DRUG|Chemotherapy (Cisplatin)|"100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension."
41333603|NCT02918955|PROCEDURE|Early Salvage Neck Dissection in case of less than cCR (Arm A only)|"Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.~In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure."
41333604|NCT01985919|OTHER|Obtaining human tissue for basic research or biospecimen bank|
41483594|NCT01586403|BIOLOGICAL|Dose 4|Subjects then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
41333605|NCT00018018|DRUG|CD34+ cells transduced with ADA retrovir|
41483595|NCT00107549|BIOLOGICAL|rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])|Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
41483596|NCT00107549|BIOLOGICAL|rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])|Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
41483597|NCT03828448|DRUG|Ublituximab|- anti-CD 20 monoclonal antibody administered via IV infusion
41483598|NCT03828448|DRUG|Umbralisib|- PI3K Delta Inhibitor oral daily dose
41483599|NCT01660334|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
41483600|NCT02238626|DRUG|Placebo (for MN-166)|
41483601|NCT02238626|DRUG|MN-166|
41483602|NCT02238626|DRUG|riluzole|Patient is given 50 mg riluzole twice daily.
41483603|NCT05865821|PROCEDURE|Negative pressure drainage|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
41483604|NCT05865821|OTHER|No pressure drain|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
41483605|NCT05943119|RADIATION|Radiotherapy in painting dose on histoscannographic mapping|"The target volumes to be delineated are as follows:~* High-risk CTV (Clinical Target Volume), corresponding to all initially invaded areas, as identified by comparison between the operative report and the anatomo-pathological report (ideally with histo-surgical mapping).~* Low-risk CTV, corresponding to naso-sinusal structures not initially invaded but at risk of recurrence, and located close to the high-risk target volume, including at least 5 mm around the high-risk volume and excluding non-risk areas (muscle, bone)."
41483606|NCT05943119|RADIATION|Standard pan-sinusal Radiotherapy|"The target volumes to be delineated are as follows:~* High-risk CTV, including the entire post-operative cavity,~* Low-risk CTV, adapted from the recommendations described by Lapeyre (Cancer/Radiotherapy 2005), and including at least 5 mm around the high-risk volume, excluding non-risk areas (muscle, bone)."
41483607|NCT03898830|DEVICE|eon™ FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
41483608|NCT05370755|DRUG|ICP-189|Administered orally
41483609|NCT04465552|OTHER|Patients received standard of care treatment during hospitalization|All patients admitted with covid-19 will be enrolled and followed for the duration of their hospitalization as well as during outpatient follow for up to 6 months, in those recovered, to assess clinical outcomes.
41483610|NCT05224284|OTHER|BPA levels|BPA (Bisfenol A) in blood and ejaculate samples
41483611|NCT03676166|DRUG|Cannabis|Inhaled cannabis
41483612|NCT00188227|DRUG|Midazolam (sedative)|
41483613|NCT00188227|DRUG|Piritramid (analgetic)|
41483614|NCT00188227|BEHAVIORAL|Cognitive exercises|
41483615|NCT04407494|BIOLOGICAL|Reporting of anosmia, ageusia and other clinical symptoms|Reporting of anosmia, ageusia and other clinical symptoms related to COVID-19 - CODA test - SARS-CoV2 RT-PCR and ELISA
41483616|NCT05884242|DRUG|Adalimumab|Adalimumab will be administered subcutaneously.
41333606|NCT02098005|OTHER|usual care evidence-based physiotherapy|Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.
41333607|NCT02098005|OTHER|modern neuroscience approach|Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
41483617|NCT05884242|DRUG|Lipopolysaccharide (LPS)|LPS will be administered intravenously.
41483618|NCT03832309|BEHAVIORAL|Do we speak to them in a way that convinces them to have the dream|During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug
41483619|NCT03832309|BEHAVIORAL|Speaking to them as a regualar person|During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.
40815803|NCT01796990|BEHAVIORAL|ACT|"The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
40815804|NCT01796990|BEHAVIORAL|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
41013815|NCT05590702|DRUG|First line therapy|"Patient with CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation will be identified in MCM (multidisciplinary collegial meeting).~Patients will be treated and managed according to the decision of their physicians and the related MDM. No treatment plan is recommended in the setting of this non-interventional study."
41333608|NCT02019498|BEHAVIORAL|Relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
41156085|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder|In this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
41483620|NCT00004175|DRUG|cyclophosphamide|
41483621|NCT00004175|DRUG|docetaxel|
41483622|NCT00004175|DRUG|doxorubicin hydrochloride|
41333609|NCT02019498|OTHER|ususal care|Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
41156086|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotic A|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
41333610|NCT00954057|DRUG|LIPO-102|intraorbital injection
41483623|NCT00004175|PROCEDURE|conventional surgery|
40815805|NCT00000886|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
41333611|NCT00954057|DRUG|Placebo|intraorbital injection
41333612|NCT05406440|DRUG|MK-8189|MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
41333613|NCT05406440|DRUG|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
41483624|NCT03869203|OTHER|Enhanced recovery after surgery (ERAS)|The patients in the ERAS group were given a pre-treatment drug \[300 mg (gabapentin, Neurontin 300mg) and 10 mg oxycontin (oxycontin, Oxycontin CR 10mg) and 2 mg prednisolone (prednisolone 10 mg, Solondo 5mg)\] on the evening before surgery. And pre-operative fasting should not exceed 6 hours, and clear liquid fasting should not exceed 2 hours. In addition, 400 ml of oral carbohydrate should be taken 2 to 4 hours before surgery to ensure adequate blood sugar and encourage regular diet (light meal) as soon as possible within a tolerable range after surgery. The initial pain after surgery is actively controlled by oral drugs such as celebrex and IR codon, and injections such as tramadol and demerol. On the first postoperative day, the urinary catheter is removed and CPM (continuous passive motion) rehabilitation is started.
41483625|NCT01391741|OTHER|Visual Cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
40815806|NCT06278506|PROCEDURE|Ablation|Microwave ablation, Radiofrequency ablation, Cryo ablation
41156087|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotic B|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
41483626|NCT01391741|OTHER|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
41483627|NCT04060342|DRUG|GB1275|Oral
41333614|NCT03926338|DRUG|Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) and Celecoxib (oral 200mg twice daily for 3 months) followed by surgical resection.
41333615|NCT03926338|DRUG|Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) followed by surgical resection.
41333616|NCT03926338|DRUG|Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) and Celecoxib (oral 200mg twice daily for 6 months) followed by surgical resection.
41333617|NCT03926338|DRUG|Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) followed by surgical resection.
41333618|NCT04600453|OTHER|Physical Exercise|The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day. The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM combined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
41333619|NCT00003852|BIOLOGICAL|filgrastim|
41333620|NCT00003852|DRUG|carboplatin|
41333621|NCT00003852|DRUG|cyclophosphamide|
41333622|NCT00003852|DRUG|epirubicin hydrochloride|
41333623|NCT00003852|DRUG|etoposide|
41333624|NCT00003852|DRUG|ifosfamide|
41156088|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotics A and B|In this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
41333625|NCT00003852|DRUG|paclitaxel|
41333626|NCT00003852|DRUG|thiotepa|
41333627|NCT00003852|PROCEDURE|bone marrow ablation with stem cell support|
41333628|NCT00003852|PROCEDURE|peripheral blood stem cell transplantation|
41333629|NCT01962857|BEHAVIORAL|Exercise|4-week supervised high intensity shuttle running intervention, 3 sessions per week (12 sessions in total)
41483628|NCT04060342|DRUG|nab-paclitaxel and gemcitabine|IV infusion
41156089|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges|In this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
41156090|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
41156091|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
41156092|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
41333630|NCT02519062|OTHER|No intervention|This is a retrospective study
41333631|NCT01922739|DRUG|Hydrocodone ER|Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
41483629|NCT04060342|DRUG|pembrolizumab|IV infusion
41333632|NCT01922739|DRUG|Placebo|During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
41333633|NCT00162513|BIOLOGICAL|Allogeneic tumor cell vaccine|
41333634|NCT02884128|DRUG|PEP02|PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
41333635|NCT02884128|DRUG|5-FU|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
41483630|NCT00054041|BIOLOGICAL|HspE7|Given subcutaneously
41483631|NCT00054041|PROCEDURE|therapeutic conventional surgery|Undergo large loop excision
41483632|NCT00054041|OTHER|laboratory biomarker analysis|Correlative studies
40815807|NCT06278506|PROCEDURE|Surgery|Partial or total nefrectomy
41156093|NCT01092936|OTHER|Rating Scale administration|Movement Disorder Society_Unified Parkinson's Disease Rating Scale will be submitted to the patient (with the help of the caregiver) in a single visit lasting about 40 minutes.
41156094|NCT01161706|OTHER|Vegetable Juice|Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
41333636|NCT02884128|DRUG|LV|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
41333637|NCT02575300|DRUG|Ibrutinib|Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
41333638|NCT01181141|DRUG|DU-176b (edoxaban)|
41333639|NCT01181141|DRUG|Enoxaparin sodium 20mg|
41333640|NCT02060968|DEVICE|Promus PREMIER|
41333641|NCT00049504|DRUG|cyclophosphamide|Given IV
41483633|NCT04731870|OTHER|Survey research|This is not an intervention study. It involves social science research of surveys and focus groups.
41483634|NCT05796063|DIAGNOSTIC_TEST|gastric point of care ultrasound|Patients will receive a gastric point of care ultrasound to evaluate for delayed gastric emptying. Gastric POCUS studies will be obtained using Kosmos, a handheld portable ultrasound that is FDA approved for clinical use. This product has already been validated for use, and this is not a novel application of the technology.
41333642|NCT00049504|DRUG|fludarabine phosphate|Given IV
41333643|NCT00049504|DRUG|tacrolimus|Given IV or orally
40815808|NCT01368172|BEHAVIORAL|Physical Activity Guidelines|Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
40815809|NCT02321228|PROCEDURE|Salpingectomy with delayed oophorectomy|Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.
40815810|NCT02321228|PROCEDURE|Risk-reducing salpingo-oophorectomy|This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
40815811|NCT06212115|DIAGNOSTIC_TEST|mNGS|metagenomics next generation sequencing
40815812|NCT05327842|DEVICE|New training simulator|Participants receive training with new simulator
40815813|NCT05327842|DEVICE|Traditional simulator|Participants receive traditional training
40815814|NCT04433689|DEVICE|Non-Contact measurement of corneal properties|Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.
40815815|NCT05598125|DEVICE|electronic cigarette (e-cigarette)|
40815816|NCT05598125|DEVICE|conventional tobacco cigarette|
41333644|NCT00049504|DRUG|mycophenolate mofetil|Given orally
41333645|NCT00049504|GENETIC|polymerase chain reaction|Correlative studies
41333646|NCT00049504|GENETIC|fluorescence in situ hybridization|Correlative studies
41333647|NCT00049504|GENETIC|polymorphism analysis|Correlative studies
41333648|NCT00049504|GENETIC|gene expression analysis|Correlative studies
40815817|NCT03695627|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
40815818|NCT00494650|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.
40815819|NCT00494650|BEHAVIORAL|Brief PTSD treatment|Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.
40815820|NCT03916185|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L Vaccine|10\^6 plaque-forming units (PFU); administered as nose drops
40815821|NCT03916185|BIOLOGICAL|RSV 6120/ΔNS2/1030s Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
40815822|NCT03916185|BIOLOGICAL|RSV 276 Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
40815823|NCT03916185|BIOLOGICAL|Placebo|Administered as nose drops
40815824|NCT06355596|OTHER|Virtual teaching|Virtual teaching of laparoscopic skills
40815825|NCT04574414|DIAGNOSTIC_TEST|Psychological testing and MRI imaging|"Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI."
40815826|NCT00633633|OTHER|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
40815827|NCT00633633|BEHAVIORAL|Exercise Training|Exercise training 3 times a week.
40815828|NCT00633633|BEHAVIORAL|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
40815829|NCT01689012|BEHAVIORAL|Facial Exercise|
40815830|NCT03401944|DRUG|TPN|
40815831|NCT03401944|OTHER|Control|
40815832|NCT04876066|DRUG|Ketamine|Weight-based ketamine dose will be prepared and delivered personally to study physician or study personnel by pharmacy personnel as is done during standard protocol for use of ketamine not part of a clinical study.
40815833|NCT00529347|DEVICE|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
41333649|NCT00049504|RADIATION|total-body irradiation|Undergo total-body irradiation
41333650|NCT00049504|PROCEDURE|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
41333651|NCT00049504|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
41333652|NCT03177785|BEHAVIORAL|EverydayMatters|
41333653|NCT03081598|DRUG|PBI-4050|Soft gelatine capsule containing 200 mg of the active ingredient per capsule
41333654|NCT03081598|OTHER|Placebo|Placebo soft gelatine capsule
41333655|NCT03007719|DRUG|Fluorine F 18 Ara-G|Given IV
41333656|NCT03007719|PROCEDURE|Positron Emission Tomography|Undergo PET/MR imaging
41333657|NCT03007719|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR imaging
41333658|NCT02818413|OTHER|Biospecimen collection and questionnaires|Biospecimen collection and questionnaires
41333659|NCT04491240|DRUG|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
41333660|NCT04491240|DRUG|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
41333661|NCT04491240|DRUG|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
41013817|NCT03317990|PROCEDURE|NeuroSAFE procedure|When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a significant positive margin (on more than one section from one side or in a single section but greater than or equal to 3mm) is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.
41333662|NCT05665660|BEHAVIORAL|CARE|CARE is a culturally tailored mammography education module.
41333663|NCT05665660|BEHAVIORAL|CARE + COACH|CARE + COACH is a culturally tailored mammography education module + access to an Apache paraprofessional women's health coach who functions as a patient navigator
41333664|NCT02996955|BEHAVIORAL|social support|behaviour change intervention
41333665|NCT02996955|BEHAVIORAL|treatment of illness perceptions|educational interview
41333666|NCT02996955|DEVICE|Activ8|wearing a move monitor
41333667|NCT02996955|OTHER|activity advice|walking or cycling 5 days a week during at least half an hour
41333668|NCT00603850|DEVICE|ForeseeHome|human factor
41013818|NCT03317990|PROCEDURE|Standard RARP|Patients will undergo the standard intervention - RARP without NeuroSAFE Frozen section analysis
41013819|NCT04062305|BEHAVIORAL|Hand Function Test|Complete tasks that test grip strength, pinch strength, and ability to use and feel with hands
41333669|NCT00947934|DEVICE|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
41483635|NCT03564418|PROCEDURE|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|"Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points.~Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that the needle is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
40815834|NCT03387007|BEHAVIORAL|Psychosocial support training for school teachers|The intervention for this study was schoolteachers' training on psychosocial support.A clinical psychologist provided 2-day training (a total of 16 hours) training on psychosocial support for the schoolteachers
40815835|NCT03262571|DIAGNOSTIC_TEST|Lung ultrasound|Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
41013820|NCT04062305|PROCEDURE|Navigated Transcranial Magnetic Stimulation|Undergo nTMS
41013821|NCT04062305|OTHER|Quality-of-Life Assessment|Ancillary studies
41333670|NCT02283957|DRUG|CNTX-4975|
41333671|NCT02283957|OTHER|Placebo|
41333672|NCT04124055|DIAGNOSTIC_TEST|Therapeutic drug monitoring (TDM)|Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted
41333673|NCT00854438|OTHER|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
41333674|NCT04983199|DEVICE|Hexoskin Medical System|Hexoskin is a smart shirt that can detect heart rates, lung function and physical activity of patients before and after radiotherapy.
41333675|NCT05151224|DIAGNOSTIC_TEST|microRNA 21|"Plasma microRNA 21 5p expression, by real-time polymerase chain reaction, before and after neoadjuvant systemic therapy.~Blood sample will be taken by a trained nurse, amount of blood will be 3 ml, and will be taken twice, one time before the start of the neoadjuvant systemic treatment , second time by the end of the neoadjuvant systemic treatment."
41333676|NCT06095544|PROCEDURE|Enhanced recovery for SPK recipients|Pre-operative, perioperative and post-operative were consisted of evidenced-based systematic optimization approaches.
41013822|NCT04062305|OTHER|Questionnaire Administration|Ancillary studies
41013823|NCT06394739|DEVICE|Thrombectomy|RevCore Thrombectomy to treat in-stent thrombosis
41013824|NCT04861623|OTHER|Orange juice|Orange juice will be purchased commercially.
41013825|NCT04861623|OTHER|Placebo juice (Fanta)|Fanta will be purchased commercially.
41013828|NCT06458049|BEHAVIORAL|Group Session|On-line educational session-3 modules-1 hour each for a total of 3 hours
41013829|NCT06458049|BEHAVIORAL|Coaching Call|Single Coaching phone call at one month
41013830|NCT06458049|BEHAVIORAL|Educational Materials|Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer
41333677|NCT03450993|OTHER|SMART Program|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology)
41333678|NCT00157170|BEHAVIORAL|supervised exercise|
41333679|NCT02678728|DRUG|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off
41483636|NCT03564418|PROCEDURE|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|"Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that it is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
41483637|NCT00885521|OTHER|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
41483638|NCT05712525|DIAGNOSTIC_TEST|G-Tech Wireless Patch System (WPS)|Noninvasive monitoring of myoelectrical signals
40815836|NCT06397651|BEHAVIORAL|Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application|"Participants will get access to Complement Theory's 24-week Live 1:1 Coaching program, focusing on Exercise and Meditation and supplemented with evidence-based information on Diet, Sleep, and other lifestyle practices, adjunct to the core treatment.~* Each week, up to five sessions of 45 minutes each will be offered, with a recommendation for participants to engage in a minimum of three sessions to ensure adequate program exposure and benefits.~* Each session will consist of 30 Minutes of Physical Exercise and 7 minutes of meditation. Each session will be a combination session focused on Aerobic and Strength, with flexibility and balance exercises included as supplements."
40815837|NCT06397651|BEHAVIORAL|Digital application with expert guidelines on lifestyle modification|24 weeks access to Digital application with expert guidelines on lifestyle modification focusing on exercise, meditation, as well as information on diet, sleep and other lifestyle practices.
40815838|NCT05721352|BEHAVIORAL|Virtual Reality Nature scene plus heart rate variability biofeedback phone application|phone app for slow- paced breath training with biofeedback in a virtual reality nature scene
40815839|NCT03773536|DRUG|Artesunate-amodiaquine given with single low dose primaquine|Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
40815840|NCT01969396|DEVICE|SonoBiopsy Catheter|Catheter utilized in dual role: sonohysterography and endometrial biopsy
40815841|NCT01969396|DEVICE|Endometrial biopsy catheter|Endometrial sample obtained without the assistance of sonohysterography
40815842|NCT02084706|PROCEDURE|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
40815843|NCT02084706|DRUG|2% Lidocaine|
40815844|NCT02084706|DRUG|Triamcinolone (20 g)|
41156095|NCT02423252|BEHAVIORAL|Massage, Relaxation, Guided imagery and music listening.|In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
41333680|NCT02678728|DRUG|normal saline|IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
41333681|NCT00007982|BIOLOGICAL|filgrastim|
41333682|NCT00007982|DRUG|carmustine|
40815845|NCT02084706|PROCEDURE|J-tip lidocaine administration|
41013839|NCT05814562|BEHAVIORAL|Remote Intervention|The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
41013840|NCT03449381|DRUG|BI 907828|Film-coated tablet
41333683|NCT00007982|DRUG|cisplatin|
41333684|NCT00007982|DRUG|cyclophosphamide|
41333685|NCT00007982|DRUG|etoposide|
41333686|NCT00007982|DRUG|thiotepa|
41156096|NCT02423252|OTHER|No Intervention|The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
41156097|NCT06525753|OTHER|Weaning off Parenteral Nutrition|pediatric intestinal failure patients who have been weaned off parenteral nutrition
41333687|NCT00007982|PROCEDURE|adjuvant therapy|
41333688|NCT00007982|PROCEDURE|autologous bone marrow transplantation|
41333689|NCT00007982|PROCEDURE|bone marrow ablation with stem cell support|
41333690|NCT00007982|PROCEDURE|peripheral blood stem cell transplantation|
40815846|NCT02084706|PROCEDURE|Triamcinolone (20 g) Injection over the A1 pulley.|
40815847|NCT00035607|DRUG|Darbepoetin alfa SC|Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
40815848|NCT00035607|DRUG|Darbepoetin alfa IV|Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
40815849|NCT02125916|OTHER|oxygen therapy|
40815850|NCT05705778|PROCEDURE|standard amblyopia treatment|amblyopia treatment following international guidelines and genetic tests.
40815851|NCT05964465|DRUG|Dupilumab|Monoclonal antibody blocking interleukin 4 and interleukin 13
40815852|NCT00368836|DEVICE|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
40815853|NCT04327427|OTHER|Aspirin|Outcome Analysis of Aspirin in liver transplantation
41333691|NCT05378776|DIETARY_SUPPLEMENT|sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of water. For this double-blind study, we replaced water with diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm. With the idea of correcting ketosis, we chose to provide the same amount of sugar as we do in hypoglycemia (0.4-0.5 g/kg of dextrose) to participants in the intervention group, which represents 1.5 ml/kg of the sucrose solution containing 0.4 g of sucrose/mL for a total of 0.6 g/kg of sucrose.
41333692|NCT05378776|DIETARY_SUPPLEMENT|Standard rehydration solution|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
40815854|NCT01779856|DEVICE|REVEAL Insertable Cardiac Monitor (ICM)|
40815855|NCT03139981|DRUG|ASN002|Daily dose of ASN002 for 28 days
40815856|NCT03139981|DRUG|Placebo Oral Tablet|Placebo for ASN002 for 28 days
40815857|NCT04120753|DRUG|OLOMAX 20/5/5mg|Tablets, Oral, QD
41333693|NCT03010904|OTHER|Dietary intervention|
41483639|NCT03150355|PROCEDURE|Arthroplasty or open reduction and internal fixation|fixation of proximal femoral fractures or replacement with prosthesis
40815858|NCT04120753|DRUG|OLOMAX 20/5/10mg|Tablets, Oral, QD
40815859|NCT04120753|DRUG|Olmesartan 20 mg/Amlodipine 5 mg|Tablets, Oral, QD
40815860|NCT04731480|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
40815861|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
40815862|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to Schneider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
40815863|NCT04731480|DRUG|Propofol|Manual propofol administration will be done using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
40815864|NCT02108327|PROCEDURE|surgical blade|Using surgical blade all the time of surgery
40815865|NCT02108327|PROCEDURE|electrocautery|Using electrocautery all the time except at skin incision
40815866|NCT04008641|OTHER|Pediatric consultation's survey|Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
40815867|NCT03692754|DRUG|Atorvastatin 20mg|Atorvastatin will be given in 20 mg po qn for 1 month
40815868|NCT03692754|DRUG|Atorvastatin 10mg|Atorvastatin will be given in 10 mg po qn for 1 month
40815869|NCT03692754|DRUG|Dexamethasone|Dexamethasone will be given in 40mg po qd for 4 days
40815870|NCT02591758|DEVICE|Hexoskin Vest|The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
40815871|NCT02591758|BEHAVIORAL|Cardiac rehabilitation program|A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
41333694|NCT02295800|OTHER|Standard of care|
40815872|NCT02591758|OTHER|Anxiety assessment as determined by the GAD-7|Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
40815873|NCT02591758|OTHER|Angina assessment with the angina diary, the SAQ and the SF-36|
40815874|NCT02591758|OTHER|Exercise stress test|Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
40815875|NCT02591758|OTHER|Holter monitoring|24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
41156098|NCT04013932|BEHAVIORAL|KUPAA Intervention Group (Culturally Tailored Family Psychoeducation)|"KUPAA is composed of 3 key components:~1-2 Joining sessions \[\~30 to 45 minutes each\] give the facilitator and participants a chance to get to know each other before KUPAA groups begin and allows time for questions.~Educational Workshop is an interactive, one day workshop offering information about biological, psychological and social aspects of mental illness; the nature, effects and side effects of psychiatric treatments; what families can do to help recovery and prevent relapse; and guidelines for managing mental illnesses.~12 Family psychoeducation group sessions \[\~1.5 hours each session\] occur weekly in multi-family groups. These sessions follow an empirically tested format and focus on solving problems that interfere with treatment, illness, and symptoms management and that support coping skills and personal care. Case management may also be provided."
41333695|NCT02295800|OTHER|Semi-structured interviews|
41333696|NCT02384304|BEHAVIORAL|Choice|A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions
41333697|NCT02384304|BEHAVIORAL|Messages|A self help program consisting of 8 modules and access to therapist guidance through messages
41333698|NCT02384304|BEHAVIORAL|Self help|A self help program consisting of 8 modules
41333699|NCT04959604|PROCEDURE|ICG-marking endoscopically|Preoperatively the participants will receive an endoscopic marking at four points around the tumour with the fluorescent dye indocyanine green.
41333700|NCT06508775|BIOLOGICAL|MB-CART19.1|Assessment of long-term safety and efficacy of MB-CART19.1 treatment.
41333701|NCT06508775|BIOLOGICAL|MB-CART20.1|Assessment of long-term safety and efficacy of MB-CART20.1 treatment.
41333702|NCT06508775|BIOLOGICAL|MB-CART2019.1|Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.
40815876|NCT03096093|BIOLOGICAL|ACIT-1|Cell suspension
40815877|NCT04485013|DRUG|TTX-080|Variable dose (Q3W)
40815878|NCT04485013|DRUG|TTX-080|Specified dose (Q3W)
40815879|NCT04485013|DRUG|pembrolizumab|Specified dose (Q3W)
40815880|NCT04485013|DRUG|cetuximab|Specified dose on specified days
40815881|NCT06087237|DRUG|Pentoxifylline|400 mg pentoxifylline oral tablets three times per day starting from the day before surgery till two weeks after the surgery.
40815882|NCT06087237|DRUG|Placebo|placebo tablets three times per day starting from the day before surgery till two weeks after the surgery.
40815883|NCT05474638|DEVICE|Isometric Thumb Force (isometric mechanomyography) compared to TOF-Watch SX (acceleromyography)|Comparison of mechanomyographic measurements of thumb adduction's force induced by 100 versus 200 Hz 5 seconds tetanic ulnar nerve stimulation during neuromuscular block spontaneous recovery monitored by acceleromyography on the controlateral arm.
40815884|NCT02829736|PROCEDURE|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
40815885|NCT02829736|PROCEDURE|Standard post-operative chest tube|A regular chest tube is left in the pleura.
40815886|NCT02829736|PROCEDURE|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
41333703|NCT04246125|PROCEDURE|Interventional radiology : skin dose measurements|"Therapeutic interventional radiology procedure for the following anatomical regions:~* cerebral (neuroradiology)~* thoracic (cardiology, lungs)~* abdominal~Assessment of peak skin dose and dose mapping with use of Gafchromic film dosimeter and the estimation of the absorbed dose to the skin with use of RDM software program."
41333704|NCT05985070|DIETARY_SUPPLEMENT|Oral Ferric pyrophosphate|30 mg capsule
41333705|NCT05985070|DIETARY_SUPPLEMENT|Oral Sodium ferric pyrophosphate|30 mg capsule
41333706|NCT05985070|DIETARY_SUPPLEMENT|Oral Ferric maltose|30 mg Tablet
41156099|NCT03600506|DRUG|Dexmedetomidine|Patients will receive infusion of study drug intravenously 10 minutes before induction of anesthesia as 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr till the start of wound closure.
41156100|NCT03600506|DRUG|Placebo|Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
41333707|NCT00519883|OTHER|Exercise|
41333708|NCT00519883|OTHER|Supportive Care|
41333709|NCT00161811|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
41156101|NCT06231550|DRUG|FC084CSA tablets|"FC084CSA accelerated doses at 100mg QD, and then started the conventional 3+3 design from 200mg QD."
41333710|NCT00161811|BIOLOGICAL|Egg cell-derived Influenza Vaccine|
41333711|NCT06508528|BEHAVIORAL|a 12-week growth mindset intervention|This is a 12-week growth mindset intervention for the nursing students during clinical rotation practice. It aims at promoting the core self-evaluation and professional sefl-efficacy for them. The intervention has 12 themes, with each intervention lasting 15 to 20 minutes. Intervention will be carried out through a combination of online and offline methods.
41333712|NCT06508528|OTHER|Hospital mentoring|The control group will receive guidance from the hospital. Including self-regulation of stress, self-protection in clinical practice, and so on
41333713|NCT01128881|BIOLOGICAL|Factor IX Concentrate (purified, virus-inactivated)|Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
41333714|NCT06242093|DEVICE|whole body vibrator|• WBVT and Conservative treatment Group A will receive WBVT with conservative treatment. The treatment will be given with the frequency of 34 times/week for 25-30 minutes with the help of Galileo vibration platform
41483640|NCT06310928|OTHER|Thermal Blanket|Thermal blankets, a passive heating blanket, have a silver surface to prevent heat loss through radiation. Thermal insulation is achieved thanks to the fact that they are covered with a reflective surface to reflect light radiation, i.e. thermal radiation. It is a cost-effective, easy-to-clean, flexible material that takes the desired shape. Thermal blankets generate heat by providing thermal insulation with infrared radiation and can provide thermal vasodilation or thermotherapy. In 2013, Lima et al. used infrared thermal blankets to provide thermal vasodilation and as a result, it was found to reduce vascular resistance. Therefore, FORCLAZ brand blanket, also known as emergency blanket, used in natural disaster management, peripheral vascular resistance studies and hypothermia prevention studies was used in this study.
41013850|NCT01063010|DRUG|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
41013851|NCT01063010|DRUG|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
41013854|NCT05305365|DRUG|QBS72S|QBS72S 18mg/m2 injection given intravenous once a month.
41013855|NCT06489522|BEHAVIORAL|THRIVE|THRIVE is a brief, parent child interaction therapy (PCIT) based telehealth intervention delivered over 6-sessions that has been tested in pediatric and community-based settings.
41013856|NCT06424301|DRUG|Targeting NUDT21 siRNA drugs|It is performed for intravitreal chemotherapy.
41013857|NCT06362798|OTHER|Financial Transfers|"Mothers assigned to the intervention group will be informed that they are eligible to receive financial transfers $160/week on a debit-card with a one-time label or scripted message that states: This money is intended to help you to spend more time visiting and caring for your infant(s) in the NICU. Financial transfers will begin 1 week after birth or when the mother is discharged (whichever comes later) until the infant is discharged, except in cases where the hospitalization lasts beyond 42 weeks corrected age."
41013861|NCT04304001|BEHAVIORAL|Community Health Advisor|"Intervention arm participants will receive one 45-minute face-to-face meeting followed by two phone calls in one-week intervals over a period of three weeks beginning within one month following baseline survey completion. These educational activities will include the use of National Cancer Institute colorectal cancer resources and materials, including a Screen to Save media presentation, and colorectal cancer brochures. The intervention will follow a conversation guide/standard script for intervention fidelity. Community Health Advisors will take notes following each interaction to document the call length and call details. Participants will receive an additional text message reminder once a week for an additional three weeks - with instructions for participants to text yes to confirm they received the message - for a total of six weeks of intervention delivery. The personalized text messages will include short messages about the benefits of colorectal cancer screening."
41013862|NCT04304001|BEHAVIORAL|Usual care|Control arm participants will receive a Fecal Immunochemical Test kit, a mailed targeted colorectal cancer brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
41013866|NCT04142437|DRUG|larotrectinib(Vitrakvi, BAY2757556)|In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
41013867|NCT03559686|DRUG|Certolizumab Pegol|The recommended maintenance dose of Cimzia® (Certolizumab Pegol) for adult patients with Rheumatoid Arthritis (RA) is 200 mg every 2 weeks (single 1 mL injection of 200 mg) .
41483641|NCT00002922|DRUG|paclitaxel|
41483642|NCT04549935|DRUG|Dextenza|Dextenza 0.4mg
41483643|NCT04549935|DRUG|Topical Prednisolone|Standard of care topical drop treatment
41483644|NCT03493776|BIOLOGICAL|VZV subunit vaccine|VZV subunit vaccine
41333715|NCT06242093|OTHER|GROUP B Pelvic floor muscle training (PFMT) and conservative treatment.|"Pelvic floor muscle training (PFMT) and conservative treatment.~Group B will receive (PFMT) with conservative treatment. The PMFT group will be educated to do each exercise in 3-4 set with 15-20 repetitions and a 60-second relax between each set.~Time: 3-4 Times/WEEK for 8 weeks"
41333716|NCT04008199|OTHER|Super Abbu|The investigators have developed, piloted, and propose to expand and to experimentally evaluate a speech-based service that connects expectant fathers to doctors and to each other over a simple phone call. This service is dubbed Super Abbu (Super Dad in English).
41333717|NCT03078959|OTHER|immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1
40815887|NCT03619707|DRUG|Progesterone|Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
41013868|NCT04776148|DRUG|pembrolizumab|IV infusion
40815888|NCT05275387|OTHER|observational study, no intervention|observational study, no intervention
40815889|NCT01175265|OTHER|respiratory biofeedback|In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
41333718|NCT01517412|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
41333719|NCT01517412|DEVICE|Self-injector pen device (OptiClik®)|
40815890|NCT02058511|DRUG|Anesthesia Premedication, Induction and Maintenance|"The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain."
40815891|NCT02058511|PROCEDURE|Pupillometry after administration of anesthetic drugs|"All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.~Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period~The administered drugs are:~Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia."
40815892|NCT02182063|DRUG|BIBF 1120 low dose|
41013869|NCT04776148|DRUG|lenvatinib|oral capsule
40815893|NCT02182063|DRUG|BIBF 1120 high dose|
40815894|NCT05210699|OTHER|Product A|Usual Brand (UB) filtered, menthol combustible cigarette
41013870|NCT04776148|DRUG|regorafenib|oral tablet
41333720|NCT01517412|DRUG|Metformin|To be kept at stable dose (≥1.5 g/day) throughout the study.
41333721|NCT05563051|DEVICE|i-ED COIL|The i-ED COIL System (i-ED COIL and detachment box) are intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
41333722|NCT03948269|BEHAVIORAL|group behavioral cognitive therapy|First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.
40815895|NCT05210699|OTHER|Product B|Flavor variant P1211216 of a 1.5% nicotine ENDS product
40815896|NCT05210699|OTHER|Product C|Flavor variant P1211217 of a 2.4% nicotine ENDS product
40815897|NCT05210699|OTHER|Product D|Flavor variant P1211222 of a 5.0% nicotine ENDS product
40815898|NCT05210699|OTHER|Product E|Flavor variant P1213616 of a 1.5% nicotine ENDS product
40815899|NCT05210699|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
40815900|NCT03135158|OTHER|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
41013871|NCT04776148|DRUG|TAS-102 (trifluridine and tipiracil)|oral tablet
41013872|NCT03064126|DEVICE|RANGER™ Paclitaxel Coated Balloon|"A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
41013873|NCT03064126|DRUG|Paclitaxel|The RANGER™ Balloon is coated with the drug Paclitaxel.
41013874|NCT03064126|PROCEDURE|Standard Balloon Angioplasty|"A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
41333723|NCT05906667|BEHAVIORAL|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks
41333724|NCT05062551|PROCEDURE|three steps hysteroscopic resection of an isthmocele|removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
41013875|NCT05925517|OTHER|Graded Motor Imagery (GMI)|"GMI includes three stages. Each session will be 30 minutes, and the GMI program will span over 8 weeks. The first 3 weeks will focus on lateralization, followed by 3 weeks of motor imagery, and the final 2 weeks will involve mirror therapy.~Lateralization: Patients will be asked to differentiate whether the extremities shown in the Recognise™ Knee application belong to the right or left side of their body.~Motor Imagery: Patients will be instructed to imagine slowly and smoothly moving their affected extremities to the posture depicted in the photos in the Recognise™ Knee application and then returning to the starting position.~Mirror Therapy: Using a mirror measuring 90x60 cm² placed between the lower extremities, patients will be instructed to progressively move only their unaffected extremity, then their affected extremity, and finally both extremities."
41333725|NCT01463657|DEVICE|Juvéderm® Ultra Plus|Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
41156102|NCT05117879|PROCEDURE|Cold snaring polypectomy/ Cold EMR/Hot EMR|"Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove \[small colonic polyps\] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue."
41156103|NCT02609035|BEHAVIORAL|Telephonic prompt|
40815901|NCT06007664|BEHAVIORAL|Tele-Video to Improve Daily Activity|Participants will be asked to meet individually with an Occupational Therapist (OT) via Zoom to assess activity performance, establish short-term activity goals, and outline an individualized home exercise program. Participants will also be asked to participate in 4 weekly one hour group sessions via Zoom that will include: 1) education; 2) OT facilitated discussion; and 3) activity demonstration, engagement and feedback. The following topics will be covered: mobility, physical activity, pain management, and energy conservation. Participants will be asked to meet individually with the OT via Zoom for 15-20 minutes weekly to answer questions. At the end, participants will be asked to again meet individually with the OT via Zoom to re-assess activity performance and revisit short-term activity goals and the individualized home exercise program. Advisory Committee Members will be asked to make note of intervention activities during their regular interactions with other participants.
40815902|NCT00461149|DRUG|Octreotide-LAR|
40815903|NCT04148196|OTHER|Progressive muscle relaxation exercise|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
40815904|NCT01220973|DRUG|atorvastatin calcium|
40815905|NCT01220973|DRUG|celecoxib|
40815906|NCT01220973|OTHER|laboratory biomarker analysis|
40815907|NCT06126718|DRUG|BR201|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
40815908|NCT06126718|DRUG|Cosentyx（Secukinumab ）|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
40815909|NCT02179424|BEHAVIORAL|Workshop|Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention
40815910|NCT02179424|BEHAVIORAL|Face-to-face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
40815911|NCT02179424|BEHAVIORAL|Phone counseling|Use motivational interview strategies through phone counseling to provide smoking cessation intervention.
40815912|NCT02179424|BEHAVIORAL|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
40815913|NCT02179424|BEHAVIORAL|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.
40815914|NCT02179424|BEHAVIORAL|SMS|Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
40815915|NCT01904474|OTHER|Next.Step - e-therapeutic intervention program|
40815916|NCT01904474|OTHER|Standard treatment protocol|
40815917|NCT03905265|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required
41156104|NCT05990075|BEHAVIORAL|self-monitoring|This research study will evaluate a self-monitoring intervention to increase awareness, provide support, and promote motivation to initiate treatment after referral to mental health. The proposed intervention is a user-driven program delivered online and by mobile text. This will be initially piloted for acceptability among Veterans referred to mental health service for depression treatment.
41333726|NCT01463657|DEVICE|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
41333727|NCT04777474|DIAGNOSTIC_TEST|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy - studied imaging technique
41483645|NCT01578135|DRUG|somatropin|Patients are to fill in a questionnaire at inclusion in registry
41013876|NCT05925517|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes. The current will be applied to the most painful area of the affected knee. The four self-adhesive electrodes will be positioned in a square pattern, approximately 5 cm apart, centered over the pain point. Conventional TENS will be applied for 30 minutes at a frequency of 100 Hz, pulse width of 100 μs, and intensity below 10% of the motor threshold.
41333728|NCT04777474|DIAGNOSTIC_TEST|Narrow band imaging|The study subjects will undergo narrow band imaging - comparator procedure
41333729|NCT04777474|DIAGNOSTIC_TEST|IMAGE1S imaging|The study subjects will undergo IMAGE1S imaging - comparator procedure
41333730|NCT06068504|OTHER|Arm-cranking exercise|Arm-cranking exercise
41333731|NCT06068504|OTHER|Heating|Immersion of the foot in warm water
41333732|NCT02999815|PROCEDURE|Human tetanus immunoglobulin|Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.
41333733|NCT02999815|PROCEDURE|Intramuscular antitoxin|First, adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin including a 0.05ml test dose (ie 75 units equine antitoxin or 12.5 IU human antitoxin). Second, participants will be randomized with sham procedure
41333734|NCT01425853|DRUG|Chondroitin/Glucosamine (Droglican)|Experimental
41333735|NCT01425853|DRUG|Celecoxib|Active comparator
41333736|NCT01906476|BEHAVIORAL|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
41333737|NCT01906476|BEHAVIORAL|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
41333738|NCT00254163|DRUG|Fludarabine|
40815918|NCT01265563|DRUG|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
40815919|NCT01265563|DRUG|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
41013877|NCT05925517|OTHER|Conventional Physiotherapy Program|The routine 60-minute program for OA patients in conventional physiotherapy includes warming up, core stability, pelvic and hip stability, gluteus medius strengthening, knee control and stability (knee flexion and extension control, lunge exercises), knee strengthening exercises (wall-assisted leg press with a ball, step-ups with elastic bands), and functional exercises.
41013878|NCT05925517|OTHER|Home Exercise Protocol|The home exercises will include a warm-up consisting of a 10-minute walk at a normal pace on a flat surface while gently stretching the hamstring and calf muscles. The exercises will also involve straight leg raises, terminal knee extension, isometric contractions of the quadriceps femoris and adductor muscles using a pillow for support, toe raises, single-leg standing, toe taps, and quadriceps strengthening exercises included in the session.
41333739|NCT00254163|DRUG|Cyclophosphamide|
41333740|NCT00254163|DRUG|Rituximab|
40815920|NCT01265563|DRUG|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
40815921|NCT01265563|DRUG|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
40815922|NCT01265563|DRUG|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
40815923|NCT06513429|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells by intravenous infusion.
41013880|NCT05856760|DRUG|Sparsentan|Target dose of 400 mg daily
41013881|NCT02841618|OTHER|High Linoleic Acid Healthy Cookies|
41013882|NCT02841618|OTHER|High Oleic Acid Healthy Cookies|
41333741|NCT00254163|DRUG|Pentostatin|
41333742|NCT02186756|OTHER|EMG-Biofeedback and Usual care|Please refer to arm description
41333743|NCT00695513|DIETARY_SUPPLEMENT|BENEO synergy1|50/50 v/v inulin/oligofructose 10 gram BID
41333744|NCT02319408|RADIATION|Preoperative radiation|Lobectomy for lung cancer following preoperative radiation
41333745|NCT04359225|OTHER|3D Telemedicine|Telemedicine using 3D broadcast to clinician
41333746|NCT04359225|OTHER|2D Telemedicine|Standard care with 2D telemedicine
41333747|NCT02747407|BIOLOGICAL|Hepatitis A Vaccine|
41333748|NCT02747407|OTHER|Laboratory Biomarker Analysis|Correlative studies
41333749|NCT02747407|BIOLOGICAL|Tetanus Toxoid Vaccine|
41333750|NCT02747407|BIOLOGICAL|Trivalent Influenza Vaccine|
41333751|NCT03273231|DRUG|Ketamine|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
41333752|NCT03273231|DRUG|Saline|0.9% saline solution
41333753|NCT06338046|OTHER|Corthellus Shiitake(Mushroom) Extract|topical treatment with Corthellus Shiitake(Mushroom) Extract
41333754|NCT06338046|OTHER|Placebo|topical treatment with a placebo cosmetic formula
41333755|NCT04095468|RADIATION|Preoperative Radio(Chemo)Therapy|Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
41333756|NCT06044129|DEVICE|Mri scan of fetal head and pelvis|The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.
41013884|NCT05615311|DIETARY_SUPPLEMENT|Vitamin D supplementation|Study participants assigned to the intervention group will receive 800 IU/ day of vitamin D plus 200-300 IU/day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
41013885|NCT05615311|OTHER|No additional vitamin D supplementation|Study participants assigned to the control group will receive 200-300 IU/ day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
41333757|NCT02750579|PROCEDURE|Percutaneous coronary intervention for revascularization|Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)
41333758|NCT05581485|PROCEDURE|Non-intubated Laryngomicrosurgery|Non-intubated LMS was performed with assistance of Optiflow(HFNO).
41333759|NCT01945268|DRUG|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
41333760|NCT01945268|OTHER|Sterile saline|0.5 ml dose injected intramuscularly
41333761|NCT05591651|DRUG|Treatment of damaged nipple skin: Preparation with hyaluronic acid|The active preparation will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
41333762|NCT05591651|DRUG|Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid|The neutral preparation, containing only white vaseline, will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
41333763|NCT03907592|DIETARY_SUPPLEMENT|L-carnitine supplementation|Supplementation of 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout the study period.
41333764|NCT03907592|DIETARY_SUPPLEMENT|Leucine supplementation|Supplementation of 4000 mg L-leucine per day throughout the study period.
41156105|NCT06329544|DIETARY_SUPPLEMENT|Fructose|12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
41156106|NCT06329544|DIETARY_SUPPLEMENT|glucose|12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
41156107|NCT05760300|DRUG|Bulevirtide (BLV)|Administered via subcutaneous (SC) injections
41333765|NCT03907592|PROCEDURE|Resistance training|Resistance training at the gym, twice a week for 24 weeks (48 training units in total).
41333766|NCT00064636|DRUG|VELCADE TM (bortezomib) for Injection, or PS-341|
41333767|NCT03012542|DIETARY_SUPPLEMENT|Diet 1|Diet controlled in amount and source of carbohydrates or fiber containing foods.
41333768|NCT03012542|DIETARY_SUPPLEMENT|Diet 2|Diet controlled in amount and source of carbohydrates or fiber containing foods.
41333769|NCT04825249|PROCEDURE|traditional suture bridge technique|(A) Limbs of the sutures from the medial anchor were passed through torn tendon (B) the suture limbs were tied in a horizontal mattress suture pattern (C) the lateral row pressed the free tails of the knotted line on the greater tubercle of the humerus (D) the effect after completion of the TSB technique
41333770|NCT04825249|PROCEDURE|modified suture bridge technique|(A) Limbs of the sutures from the medial anchor and 2 tendon sutures were passed through the same position of torn tendon (B) the lateral row pressed free tails of the two tendon lines on the greater tubercle of the humerus (C) after examination of sufficient tension and stable fixation, sutures of medial row was knotted (D) the effect after completion of the MSB technique
41333771|NCT02708992|DRUG|Azithromycin|
41333772|NCT02708992|DRUG|Cefixime|
41483646|NCT01578135|DRUG|somatropin|Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
41333773|NCT01146951|DRUG|Rufinamide (E2080)|"Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)"
41333774|NCT01146951|DRUG|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
41333775|NCT00486512|DRUG|0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
41333776|NCT00486512|DRUG|75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
41333777|NCT00486512|DRUG|placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
41333778|NCT00486512|DRUG|placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
41333779|NCT00486512|PROCEDURE|Colonoscopy|
41333780|NCT01670812|DRUG|FFP+HDMP+Rituximab|This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
41333781|NCT05430672|DEVICE|The Thoracic Aortic Stent Graft System (Zylox-Tonbridge Medical Technology Co., Ltd. )|This is a objective performance criteria-controlled study, all subjects meet the criteria will receive the same treatment using the thoracic aortic stent graft system (Zylox-Tonbridge Medical Technology Co., Ltd. ).
41333782|NCT04339322|OTHER|Follow up|Follow up to assess the outcome until complications, improvement, death or being transferred to another quarantine hospital.
41333783|NCT06357884|PROCEDURE|Callus debridement|Eligible patients will be seated on a podiatry couch. Standard skin preparation procedure will be done with 2% Chlorhexidine gluconate in 70% isopropyl cleansing to all areas of feet. The same researcher will perform sharp debridement in all participants to minimize the variance between procedures. The procedure will comply with Infection Control Guideline (Podiatry) . A sterile scalpel handle loaded with a single-use No. 15 blade will be used to carry out sharp debridement using aseptic technique. Hyperkeratotic tissue will be debrided until smooth transition with adjacent skin is achieved and underlying pinkish normal skin is visible. Used scalpel will be unloaded and disposed by a QlickSmart ® BladeFLASK scalpel blade remover.
41333784|NCT03914534|DRUG|Valproic Acid 500 MG|Administration of 500 mg of Valproic Acid
41483647|NCT04793074|COMBINATION_PRODUCT|Transforming nanoparticle dressing|Transforming nanoparticle dressing
41156108|NCT02676739|DRUG|Adderall XR|
41333785|NCT03914534|DRUG|Valcote 500 mg|Administration of 500 mg of Valproic Acid
41333786|NCT04535505|DIAGNOSTIC_TEST|Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology|This is an observational study and there are no interventions. The purpose of the study is to compare the accuracy （including sensitivity and specificity）of the new CPA platform based on CRISPR technology detection method and the gold standard in detecting pertussis patients.
41333787|NCT03848715|BIOLOGICAL|Endotoxin|Endotoxin
41333788|NCT03848715|BIOLOGICAL|Placebo|Placebo
41333789|NCT00002657|BIOLOGICAL|bleomycin sulfate|5 mg/m\^2
41156109|NCT03924661|DEVICE|Aortic Valve Replacement|SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
41333790|NCT00002657|BIOLOGICAL|recombinant interferon alfa|3.0 x 10\^6 IU/m\^2
41333791|NCT00002657|DRUG|cyclophosphamide|650 mg/m\^2
41483648|NCT04793074|COMBINATION_PRODUCT|Conventional compression dressing|Conventional compression dressing
41483649|NCT01235702|BEHAVIORAL|12-week lifestyle modification|
41156110|NCT06350071|BEHAVIORAL|Kangaroo Care|Kangaroo care will be applied so that the infant and mother will have skin-to-skin contact, and heel blood will be taken.
41156111|NCT06350071|BEHAVIORAL|Swaddling|Heel blood will be taken while the infant was swaddled in the maternal holding.
41333792|NCT00002657|DRUG|cytarabine|300 mg/m\^2
41333793|NCT00002657|DRUG|doxorubicin hydrochloride|25 mg/m\^2
41333794|NCT00002657|DRUG|etoposide|120 mg/m\^2
41333795|NCT00002657|DRUG|methotrexate|120 mg/m\^2
41483650|NCT02115217|DEVICE|Leukotape K|All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.
41483651|NCT02115217|DEVICE|Sham kinesiotape|KT put with no effects
41483652|NCT03760614|DRUG|Entinostat|Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.
41333796|NCT00002657|DRUG|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m\^2.
41333797|NCT00002657|DRUG|vincristine sulfate|1.4 mg/m\^2
41483653|NCT03760614|DRUG|FOLFOX regimen|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.
41333798|NCT00002657|PROCEDURE|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
41333799|NCT00002657|RADIATION|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
41483654|NCT01289665|PROCEDURE|Lubricating gel used during speculum insertion.|Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
41483655|NCT01289665|PROCEDURE|Water used during speculum examination.|Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
41483656|NCT02185313|OTHER|visual stimulus to follow|
41483657|NCT01698437|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
41483658|NCT03176459|DRUG|Exparel + Bupivacaine|EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
41333800|NCT01807767|DRUG|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
41333801|NCT01807767|DRUG|Myfortic and Tacrolimus|Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
40815924|NCT04823455|PROCEDURE|fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill-Sachs lesion|Between 2001 and 2018, a total of 12 consecutive patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.
40815925|NCT06084416|DRUG|Sovilnesib|Sovilnesib tablets will be given orally.
40815926|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
41333802|NCT04826913|DEVICE|Organoids|"Use of an innovative device to improve the management of patients with NSCLC for precision medicine.~The different drugs used can be conventional chemotherapy (cisplatin, carboplatin, pemetrexed), targeted therapies or immunotherapy molecules. It is also planned to use radiotherapy on our drug testing device."
41333803|NCT04486612|OTHER|spinal anesthesia|prospective observational study
40815927|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
40815928|NCT05039515|DRUG|IPN60130|Immediate-release capsule containing high dose of the drug substance.
40815929|NCT05039515|DRUG|IPN60130|Immediate-release capsule containing low dose of the drug substance.
41333804|NCT05967208|BEHAVIORAL|CONSORT referrals|"Participants will be offered SMS-based confidential social network referrals for HIV testing (CONSORT referrals) to extend to any of their social and sexual network contacts."
41483659|NCT03176459|DRUG|Bupivacaine|Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
41483660|NCT04378517|OTHER|psychosocial education in parents groups|psychosocial education
41483661|NCT04378517|OTHER|psychosocial parents support, interviews with APN|Family strength-oriented therapy conversation
41483662|NCT04375683|DRUG|Flumatinib|Flumatinib 600mg per day, taken on empty stomach
41483663|NCT06264245|OTHER|Audiological profile|Video otoscopy Tympanometry High-frequency tonal audiometry
41483664|NCT06264245|OTHER|Hearing self-assessments|Hearing skills questionnaire Subjective assessment of tinnitus using a visual analogue scale Self-questionnaire on the impact of tinnitus Hyperacusis self-questionnaire
41333805|NCT05967208|BEHAVIORAL|Card referrals|"Participants will be offered physical invitation cards (card referrals) to extend to any of their social and sexual network contacts."
41333806|NCT00706394|DEVICE|Endologix Powerlink 34 mm stent graft cuff|Endovascular abdominal aortic aneurysm repair
40815930|NCT05039515|DRUG|Placebo|Placebo will be supplied as powder filled hard capsules
40815931|NCT04999215|DRUG|F-choline intravenous injection|Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
41333807|NCT01735097|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (200 mg, soft capsule)
41333808|NCT01735097|DIETARY_SUPPLEMENT|Nigella sativa|Nigella sativa (200 mg, soft capsule)
41333809|NCT01735097|DIETARY_SUPPLEMENT|Placebo|Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
41333810|NCT02378493|BIOLOGICAL|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
41333811|NCT00456833|DRUG|RAD001|
41333812|NCT00456833|DRUG|erlotinib|
41333813|NCT03498092|DRUG|Bupivacaine-Dexmedetomidine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg
41333814|NCT03498092|DRUG|Bupivacaine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline in a volume of 0.5 ml/kg
41333815|NCT03498092|DRUG|General anesthesia|Normal saline in a volume of 0.5 ml/kg
41333816|NCT02687932|DRUG|LCZ696|
41333817|NCT02687932|DRUG|Valsartan|
41333818|NCT00929136|BIOLOGICAL|USP endotoxin|Continuous intra-arterial infusion
41333819|NCT03714061|OTHER|Pain Neuroscience Education|"The PNE will be administered following Explaining Pain concepts, initially contextualizing the importance of the program, addressing concepts of neuroscience and pain, incorrect information about what is pain, how the brain responds to nociception in a variety of situations, and how an experience of danger can trigger or aggravate a state of pain, coexistence of several potential protection systems, central sensitization and how to promote behavioral change, abandoning incorrect beliefs, proposing graded activity exposure.~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
41333820|NCT03714061|OTHER|Self-Management Education|"Concepts about pain, musculoskeletal pain, chronic pain and disability will be addressed. Participants will be guided on the process of chronic pain, associated suffering, conceptual model of fear-avoidance and clarified on avoidant and confronting profiles. In a third phase, strategies will be presented on how to deal with chronic pain, with advice on the harmful effects of restricting activities and the use of drug therapy in a careful way (Dupeyron et al, 2011).~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises (reinforcement) and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
41333821|NCT00272545|BEHAVIORAL|Normalization of Eating (NOE)|The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
41333822|NCT00272545|BEHAVIORAL|Treatment As Usual (TAU)|Treatment as usual will include standard care for a person with an eating disorder.
41333823|NCT03713983|OTHER|Observational study|Observational study
41333824|NCT00550992|BIOLOGICAL|anti-thymocyte globulin|
41333825|NCT00550992|DRUG|asparaginase|
40815932|NCT02888691|OTHER|Low carbohydrate diet|
41156112|NCT06075147|DRUG|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.
41333826|NCT00550992|DRUG|busulfan|
41333827|NCT00550992|DRUG|cyclophosphamide|
41333828|NCT00550992|DRUG|cyclosporine|
40815933|NCT02888691|OTHER|High carbohydrate diet|
40815934|NCT00535704|BEHAVIORAL|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
41333829|NCT00550992|DRUG|cytarabine|
41333830|NCT00550992|DRUG|daunorubicin hydrochloride|
41333831|NCT00550992|DRUG|etoposide|
41333832|NCT00550992|DRUG|leucovorin calcium|
41333833|NCT00550992|DRUG|melphalan|
41333834|NCT00550992|DRUG|mercaptopurine|
41333835|NCT00550992|DRUG|methotrexate|
41333836|NCT00550992|DRUG|mitoxantrone hydrochloride|
41333837|NCT00550992|DRUG|pegaspargase|
41333838|NCT00550992|DRUG|prednisolone|
41333839|NCT00550992|DRUG|prednisone|
41333840|NCT00550992|DRUG|therapeutic hydrocortisone|
41333841|NCT00550992|DRUG|thioguanine|
41333842|NCT00550992|DRUG|vincristine sulfate|
41333843|NCT00550992|PROCEDURE|allogeneic bone marrow transplantation|
41333844|NCT00550992|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41333845|NCT00550992|PROCEDURE|umbilical cord blood transplantation|
41333846|NCT04281836|BEHAVIORAL|Interoceptive breathing awareness through use of audio and visual virtual technology aid|Participants are asked to focus on their breathing while (a) listening to their breathing sounds with headphones and (b) watching the 3-D image of their lungs inhaling and exhaling in real-time using the Oculus Rift 3D virtual imaging equipment and plethysmography belt. During this time fNIRS and tQST data will be collected (more detail provided below).
41333847|NCT04281836|BEHAVIORAL|Interoceptive breathing awareness without use of audio or visual virtual reality|Participants are asked to focus on their breathing. During this time fNIRS and tQST data will be collected (more detail provided below).
41333848|NCT03895918|OTHER|Educational Activity|Undergo parenting skills intervention
41333849|NCT03895918|PROCEDURE|Patient Monitoring|Undergo medication adherence monitoring
41333850|NCT03895918|OTHER|Questionnaire Administration|Ancillary studies
41333851|NCT03886922|DRUG|Levcromakalim|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
41333852|NCT03886922|DRUG|Saline|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
41333853|NCT04956081|DEVICE|Neuro-navigated Transcranial Magnetic Stimulation (TMS)|TMS delivered to a target within the left- dorsolateral prefrontal cortex (L-DLPFC)
41333854|NCT01316939|DRUG|GSK1605786A|GSK1605786A 500 milligrams once daily
41333855|NCT01316939|DRUG|Placebo|Placebo
41333856|NCT01316939|DRUG|GSK1605786A|GSK1605786A 500 milligrams twice daily
40815935|NCT00535704|BEHAVIORAL|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
40815936|NCT03201926|DIETARY_SUPPLEMENT|mealworms|10g , 3 times a day , po, 2 months
40815937|NCT03201926|DIETARY_SUPPLEMENT|grain powder|grain powder, 10g ,3times one day,2months
40815938|NCT00984165|PROCEDURE|Single fraction radiation|8-Gy fraction of radiation
40815939|NCT00984165|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
40815940|NCT00984165|PROCEDURE|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
40815941|NCT04329390|DRUG|Anticoagulant drugs|Prescription of, or already on oral anticoagulant treatment.
41333857|NCT06054438|OTHER|Chinese medicine nutritional supplement Cs4|Cs4 will be provided by Chinese Pharm, produced by GMP standard manufacturing. The intervention will be given according to the product instruction. Each capsule is 0.4g. According to the product sheet, adults should take 3-4 capsules daily as a way to nourish and strengthen the lungs and kidneys. In our study, the participants are people with long-COVID symptoms. Therefore, in order to achieve maximum efficacy, we will follow the directions and let participants take the maximum amount allowed by the product which is 4 capsules daily. Participants will take one capsule (each 400mg) 4 times a day, for a total of 1.6g. Treatment will last 12 weeks.
41156113|NCT04450771|BEHAVIORAL|Family-based Treatment for ARFID|This treatment includes 14 1-hour sessions that will be conducted approximately weekly over a 4 month period. It is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior.
40815942|NCT00075114|BEHAVIORAL|Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
40815943|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
40815944|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
40815945|NCT02581046|DRUG|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
40815946|NCT02499900|DRUG|Copaxone®|Subcutaneous Injections
40815947|NCT01683747|DRUG|Tranexamic Acid|
41333858|NCT02785991|PROCEDURE|Balloon cryoablation|pulmonary vein cryoablation for atrial fibrillation
41333859|NCT05826990|DRUG|cefepime and enmetazobactam combination|Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation
40815948|NCT01683747|DRUG|Control Intervention (Carrier fluid only)|
40815949|NCT06356935|OTHER|RT|Resistance training
40815950|NCT06356935|OTHER|CON|Control group
40815951|NCT06056895|PROCEDURE|Biopsy|Undergo tumor biopsy
40815952|NCT06056895|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40815953|NCT06056895|PROCEDURE|Computed Tomography|Undergo CT/MRI
40815954|NCT06056895|PROCEDURE|Magnetic Resonance Imaging|Undergo CT/MRI
41156114|NCT04450771|BEHAVIORAL|Manualized Non-Specific Usual Care for ARFID|This treatment is a manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model. It consists of sessions with the child alone and 5 parent-only meetings, all of which are 1-hour over a 4 month period.
41333860|NCT00973180|OTHER|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
41333861|NCT01909609|OTHER|AAP Documents|
41333862|NCT01909609|OTHER|Parent Survival Guide|
41333863|NCT05131529|OTHER|Taste-focused labels|"We will implement taste-focused labels on plant-based dishes in each of the 3 treatment dining halls to re-brand dishes with attributes focused on the taste of the dish (e.g., renaming a Squash with Ginger side to Aromatic Thai Curry Kabocha Squash With Zesty Ginger)."
41333864|NCT05131529|OTHER|Carbon impact labels|We will add labels next to all dishes served in treatment dining halls that indicate whether production of the ingredients in the dish contribute a high, moderate or low amount of carbon emissions. These labels will be absent from the same dishes served in control dining halls. Labels will be added to point-of-service signs, digital menu boards, and menu information on a mobile app.
41333865|NCT05131529|OTHER|Changing default menu options|We will make red meat items an opt-in (as opposed to opt-out) item across all meal stations in treatment dining halls. All menu stations will exclude red meat by default, and dining hall patrons will have to request the addition of red meat to meals. At control dining halls, red meat items will be provided by default at meal stations as normal.
41483665|NCT06264245|OTHER|Objective and subjective audiological tests|Acoustic Omission Measurement of the stapedial reflex by tympanometry High-frequency tonal audiometry - exposed ear only Speech audiometry in noise Tinnitus and subjective discomfort thresholds Psychoacoustic intensity perception test
40815955|NCT06056895|BIOLOGICAL|Retifanlimab|Given IV
40815956|NCT06056895|DRUG|Tuparstobart|Given IV
40815957|NCT06056895|DRUG|Verzistobart|Given IV
40815958|NCT01271712|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
40815959|NCT01271712|DRUG|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
40815960|NCT01271712|DRUG|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
40815961|NCT03347526|DRUG|Cosyntropin Injectable Suspension, 1 mg/mL|Injectable
40815962|NCT03347526|DRUG|Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin|Injectable + oral solution
40815963|NCT03347526|DRUG|Vigabatrin|oral
40815964|NCT05230108|PROCEDURE|Advanced Triage|Advanced triage is an intervention that allows the emergency nurse to resolve health problems of low clinical complexity. All actions are aimed at resolving a health problem based on a protocol previously agreed upon by a multidisciplinary team.
40815965|NCT01522521|DRUG|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
40815966|NCT01522521|DRUG|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
40815967|NCT04149977|BEHAVIORAL|Physical Therapy with pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.
40815968|NCT04149977|BEHAVIORAL|Physical Therapy with placebo pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
40815969|NCT00255138|DRUG|Atomoxetine|
40815970|NCT01493102|DRUG|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
40815971|NCT01493102|DRUG|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
41333866|NCT04827615|BEHAVIORAL|Ambuja Cement Foundation's Non Communicable Disease Program|"Government level: Strengthening linkages with Govt; Ensuring availability \& affordability of NCD diagnostics and treatment; Establishing a follow-up mechanism with patients to ensure continuity of care \& medication compliance~Provider level: Capacity building of frontline workers; Promotion of interface between community \& service provider~Community level: Screening of hypertension \& diabetes for all adults ≥30 years in the village in coordination with Govt under 'population based screening'; Create awareness of modifiable risk factors and lifestyle change among high-risk population; Community mobilization \& active participation in various health marker days; Formation of support groups, women's groups, self help groups, with involvement of people living with NCDs~Individual level: Behavior change communication with messages on NCD risk factors; Nutrition awareness on healthy and unhealthy food practices"
41333867|NCT02307318|DEVICE|SoftSeal Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
41333868|NCT01784003|DEVICE|Powered ankle-foot prosthesis|
41333869|NCT05848180|OTHER|Ankle proprioceptive training (APT)|"APT comprise of exercises including towel curls, uni-leg stance on foam with activity, writing alphabets on gym ball with toes, picking marbles with toes.~BT includes tendem walk, side leg raises, sit to stand, side walk, back leg raise"
41333870|NCT05848180|OTHER|Balance training (BT)|Balance training exercises comprising of side walk, tandem walk, standing on one leg, walking with alternating arm raise up to 90 degrees
41333871|NCT01902004|DRUG|Escitalopram|All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.
41333872|NCT01902004|DRUG|Memantine|Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.
41483666|NCT06264245|OTHER|Self-assessment of exposure sound quality|A self-assessment of the sound quality of the manipulated sounds heard during the exhibition will be carried out during the second follow-up visit. The elements on which the participant will be asked to make a qualitative judgement will relate to intelligibility difficulties or not; background noise (these two items in the form of a mark between 0 and 10); the clear, muffled or shrill nature of the sounds, their resonant or saturated side.
41483667|NCT06186102|DIETARY_SUPPLEMENT|Spermidine|Spermidine capsule of 8 mg x 3 capsules daily.
41483668|NCT06186102|OTHER|Placebo|Placebo capsule. 3 capsules daily.
41483669|NCT03915665|DRUG|Chlorhexidine|Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments
41483670|NCT03915665|DEVICE|Air-powder|Erythritol powder using air-powder device
41483671|NCT03405558|OTHER|No intervention|As this is an observational study, we will only supervise testing and training sessions which were performed anyway during first rehabilitation as daily therapeutic routine
41483672|NCT00786279|OTHER|ethanol|15 gm ethanol daily for 6 months
40815972|NCT05051293|OTHER|serum concentration of estrogen (E1 and E2) and testosterone ratio measurement|To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
40815973|NCT03568448|OTHER|Response monitoring (no intervention)|Response monitoring (no intervention)
41333873|NCT01902004|DRUG|Placebo|Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
41333874|NCT05106595|DEVICE|Bimanual Arm Trainer|tabletop/desktop device that couples bilateral simultaneous upper extremity movement with virtual reality games or activities via computer monitor
41483673|NCT00786279|OTHER|Ethanol-free beverage|0 grams ethanol daily for 6 months.
41483674|NCT01681966|DRUG|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
40815974|NCT02363361|DRUG|Imatinib|Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day
40815975|NCT01044745|DRUG|rituximab|Given IV
40815976|NCT01044745|DRUG|mycophenolate mofetil|Given IV or PO
40815977|NCT01044745|DRUG|tacrolimus|Given IV
40815978|NCT01044745|DRUG|anti-thymocyte globulin|Given IV
40815979|NCT01044745|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
41333875|NCT00220857|DRUG|Rabeprazole|
41333876|NCT02995213|BEHAVIORAL|Accelerometer based feedback about paretic arm use|
41483675|NCT02216019|OTHER|Whole blood|preoparatoire whole blood and postoperative whole blood
41483676|NCT05973682|OTHER|Post-isometric relaxation and Conventional treatment|"The term refers to the effect of subsequent relaxation experienced by a muscle or group of muscles, after brief periods during which an isometric contraction has been performed. Post isometric relaxation technique was applied to levator scapulae for 5 repetition using 20% of maximal isometric contraction for 7-10 sec. with complete relaxation of all element, the stretch is maintained for 30 sec.~+ hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30 second hold. static stretching exercises two sessions per week for 3 weeks were given to each patient"
40815980|NCT01044745|OTHER|laboratory biomarker analysis|Correlative studies
40815981|NCT01044745|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
40815982|NCT01044745|DRUG|cyclophosphamide|Given PO or IV
40815983|NCT01044745|DRUG|fludarabine phosphate|Given IV
40815984|NCT01044745|DRUG|busulfan|Given IV
40815985|NCT01044745|RADIATION|total-body irradiation|Undergo TBI
40815986|NCT01044745|BIOLOGICAL|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
40815987|NCT01044745|BIOLOGICAL|immunosuppressive therapy|Undergo immunosuppressive therapy
41333877|NCT05068999|DEVICE|shear wave elastography|"Shear wave elastography (SWE) is an emerging technology that provides information about the inherent elasticity of tissues by producing an acoustic radiofrequency force impulse, sometimes called an acoustic wind, which generates transversely-oriented shear waves that propagate through the surrounding tissue and provide biomechanical information about tissue quality. Although SWE has the potential to revolutionize bone and joint imaging, its clinical application has been hindered by technical and artifactual challenges. Many of the stumbling blocks encountered during musculoskeletal SWE imaging are readily recognizable and can be overcome, but progressive advances in technology and a better understanding of image acquisition are required before SWE can reliably be used in musculoskeletal imaging."
41333878|NCT03032289|BEHAVIORAL|Active Transport|Active transport, most commonly walking or cycling, is the use of physical activity to commute.
41483677|NCT05973682|OTHER|Conventional Physical Therapy|Conventional Physical Therapy; hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30-second hold. static stretching exercises, two sessions per week for 3 weeks were given to each patient
41483678|NCT00986570|BIOLOGICAL|Botulinum Toxin A|100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
41483679|NCT03166553|DRUG|Elemene|
41483680|NCT03198975|DIAGNOSTIC_TEST|Magnetic resonance image|Histologically-diagnosed primary HCC after curative hepatectomy. The magnetic resonance image will be imported into the software ,and the radiomic textural features will be automatically extracted by the Analysis-Kit software.The high-throughput extracted features will be then selected and a prediction model will be developed in the training set in which patients were collected from a retrospective study. In this project, an independent validation set will be collected and used to validate the prediction accuracy of the model.
41333879|NCT03273504|OTHER|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
41483681|NCT06294184|DEVICE|tdcs lDLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
41483682|NCT06294184|DEVICE|tdcs rVLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
41483683|NCT06294184|DEVICE|Sham|The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.
41483684|NCT04586153|DRUG|Meplazumab for Injection|humanized antibody target CD147
41483685|NCT04586153|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
41483686|NCT04647669|DRUG|Remdesivir|200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.
41483687|NCT04647669|DRUG|Acalabrutinib|100 mg capsules twice daily every 12 h for 10 days taken with or without food.
41483688|NCT04647669|DRUG|Interferon beta-1a|Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6
41483689|NCT04647669|OTHER|Standard of Care|Treatment according to local hospital protocol
41483690|NCT04102631|DIAGNOSTIC_TEST|colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
41483691|NCT04102631|DIAGNOSTIC_TEST|colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
41333880|NCT03273504|OTHER|Placebo|The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
41333881|NCT03009149|OTHER|Aerobic exercise|Aerobic exercise will perform 3 days per week
41333882|NCT03241589|OTHER|Direct to patient facing mobile apps introduction|VA employees and Veterans begin use of OCC's direct to patient facing mobile app.
41333883|NCT00801346|OTHER|laboratory biomarker analysis|
41483692|NCT03562741|PROCEDURE|Fecal Microbiota Transplantation|Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
41483693|NCT05215717|BEHAVIORAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
41483694|NCT05215717|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
41483695|NCT05336552|OTHER|Validated questionnaire : Social Phobia Inventory ( SPIN ) questionnaire|Social Phobia Inventory ( SPIN ) questionnaire which is consisted of 17 items. . The answers of each item ranged from 0 ( Not at all ) to 4 ( Extremely ). The total score will be calculated to determine the severity of the problem .
41483696|NCT00912093|DRUG|Icatibant|Single subcutaneous injection of icatibant, 30 mg
41013902|NCT06641856|OTHER|Sample Collection|All participants will provide nasal and pharyngeal swabs for virome analysis. A subset of 30 elderly volunteers will also provide peripheral blood samples and undergo bronchoscopy under general anesthesia to collect upper and lower respiratory tract samples.
41013910|NCT05961098|DRUG|RBD1016|RBD1016 with NAs background treatment will be explored.
41013914|NCT00068003|DRUG|Anti-CD19 CAR PBL|
41333884|NCT00801346|OTHER|metabolic assessment|
41013922|NCT06003231|DRUG|disitamab vedotin|Given into the vein (IV, intravenous) every 2 weeks
41333885|NCT00801346|OTHER|questionnaire administration|
41333886|NCT00801346|PROCEDURE|assessment of therapy complications|
41333887|NCT00801346|PROCEDURE|fatigue assessment and management|
41333888|NCT00801346|PROCEDURE|quality-of-life assessment|
41333889|NCT04173390|DRUG|Pregabalin 150mg|Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day
41333890|NCT04173390|DRUG|Placebo oral tablet|Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day
41333891|NCT04924010|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|The CBT intervention will be delivered by a Senior Psychologist with seventeen years of hospital psychology experience, six in the treatment of chronic pain patients. Sessions are delivered in one hour, individual therapy appointments to patients, and there is an emphasis on relaxation training, cognitive restructuring, exercise and pacing, behavioral activation, improving sleep, and anger management. Standardized worksheets and homework assignments are an important part of CBT-CP and these will be given (post or email) to patients who will be asked to read and complete in terms of complementing the consultations. This intervention has been developed with reference to two sources: A successful national implementation of CBT for chronic pain (CBT-CP) using video teleconferencing format \[Connolly KS et al\] AND an evidence-based CBT manual specifically designed to treat chronic pain \[Murphy JL et al\].
41333892|NCT04924010|BEHAVIORAL|Education and Mindfulness|To control for differences in attention between the two interventions, patients in the mindfulness group will also have two meetings before the surgery and two meetings afterward. As the same person will be providing the CBT-CP and educational interventions, this confounding factor will be controlled for. The control intervention consists of discussing pain education, as derived from the self-management section of the chronic pain Ireland website (https://www.chronicpain.ie/our-services/self-management) and the persistent pain section of the pain toolkit website (https://www.paintoolkit.org/persistent-pain). Four mindfulness-based stress reduction exercises will be completed including an introductory session on mindful breathing, a guided meditation, progressive muscle relaxation, and a body scan. These sessions will last about half an hour.
41333893|NCT04516655|DRUG|chidamide combined with rituximab and high-dose methotrexate|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central nervous system lymphoma
41333894|NCT05387213|BEHAVIORAL|Team Huddles|Brief multidisciplinary meeting occurring twice a week for staff working at a LTC home led by a Nurse Practitioner. Huddles focused on discussing resident-care and staff-wellbeing.
41333895|NCT00498225|DRUG|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
41333896|NCT00498225|DRUG|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
41333897|NCT00498225|DRUG|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
41483697|NCT00912093|DRUG|Placebo|Single subcutaneous injection of matching placebo
41483698|NCT04765527|DIETARY_SUPPLEMENT|Turmeric Strength for Joint|Turmeric-based tablets
41483699|NCT04765527|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
41483700|NCT00191633|DRUG|Atomoxetine|
41483701|NCT03400072|OTHER|Unsupervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
41483702|NCT03400072|OTHER|Supervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
41483703|NCT00578981|BEHAVIORAL|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
41483704|NCT06032273|BEHAVIORAL|Investigator-designed lung transplant education website|Caregiver participants assigned to the intervention will access the investigator-designed educational resource via their login to a secure website.
41483705|NCT02890836|DRUG|Antihypertensiva, mainly Metyldopa|
41483706|NCT01727882|BEHAVIORAL|Brief feedback|A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
41483707|NCT01727882|BEHAVIORAL|Daily assessments|Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
41483708|NCT01460901|BIOLOGICAL|GD2 CAR modified Tri-virus specific cytotoxic t-cells|This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
41483709|NCT02931045|DRUG|Ticagrelor|Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
41483710|NCT02931045|DRUG|Clopidogrel|Comparison of clopidogrel with another antiplatelet drug (ticagrelor)
41483711|NCT00055614|DRUG|topotecan hydrochloride|
41483712|NCT00055614|PROCEDURE|adjuvant therapy|
41483713|NCT03486054|DEVICE|INTERCEPT|The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD
41483714|NCT03486054|DEVICE|Standard of Care|The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.
41483715|NCT01023295|DRUG|fosbretabulin|single dose, intravenous infusion
41483716|NCT01023295|DRUG|Saline|single dose, intravenous infusion
41483717|NCT04334486|OTHER|Super Smash Brothers Melee (Gamecube)|10 minutes of participation in Super Smash Brothers Melee prior to Eyesi Surgical Simulator evaluation of skills.
41483718|NCT02760264|DRUG|Vamorolone 0.25 mg/kg/day|Oral administration of 0.25 mg/kg/day daily for 14 days.
41483719|NCT02760264|DRUG|Vamorolone 0.75 mg/kg/day|Oral administration of 0.75 mg/kg/day daily for 14 days.
41483720|NCT02760264|DRUG|Vamorolone 2.0 mg/kg/day|Oral administration of 2.0 mg/kg/day daily for 14 days.
41483721|NCT02760264|DRUG|Vamorolone 6.0 mg/kg/day|Oral administration of 6 mg/kg/day daily for 14 days.
41483722|NCT01580813|DRUG|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
41483723|NCT01580813|DRUG|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
41483724|NCT02208232|PROCEDURE|cataract surgery|cataract surgery with implantation of intraocular lens
41483725|NCT03748849|PROCEDURE|Physiotherapy|
41483726|NCT01610453|PROCEDURE|ultrasound examination|transabdominal and transperineal ultrasound examinations
41483727|NCT01187199|DRUG|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
41483728|NCT01187199|DRUG|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
41333898|NCT05468723|DEVICE|Carecube Negative Pressure Isolation Chamber|Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters. Environmental data will be collected by physicians and nurses \[which may include physicians, physician assistants, Registered Nurses, Licensed Practical Nurses, medical technicians and emergency medical technicians (EMTs)\] . Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded on an hourly basis. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.
41483729|NCT01187199|DRUG|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
40815988|NCT05594927|DRUG|Icaritin|600 mg (6 x 100 mg capsules) icaritin administered orally twice daily (30 minutes after breakfast and dinner, respectively) until treatment discontinuation criteria are met.
40815989|NCT05594927|DRUG|Huachansu|1200 mg (4 x 300 mg tablets) huachansu administered orally three times a day (30 minutes after breakfast, lunch and dinner, respectively) until treatment discontinuation criteria are met.
40815990|NCT01431014|DRUG|"Dexamethasonelow-dose"|5mg
40815991|NCT01431014|DRUG|"Dexamethasonehigh-dose"|15 mg
41013929|NCT02511028|DRUG|Ferumoxytol|510mg (17mL) IV
41013930|NCT04162847|DEVICE|SilverCloud Health Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
41017883|NCT03362840|BEHAVIORAL|Eclectic preschool intervention|"The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.~Parents attend by-weekly counseling-sessions with a professional in order to receive input regarding their child's progress, and discuss issues concerning their child's functioning. All staff members receive supervision at various intensities. However, these usually do not adhere to a single structure and are not guided by official fidelity criteria."
41333899|NCT00005018|DRUG|Hydroxyurea|
41483730|NCT01187199|DRUG|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
41483731|NCT01187199|DRUG|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
41483732|NCT02244879|DIETARY_SUPPLEMENT|resveratrol|arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
41333900|NCT00005018|DRUG|Abacavir sulfate|
41483733|NCT02592109|BEHAVIORAL|Enhanced Counseling using CFR based on Linear Programming|
41483734|NCT03884374|BEHAVIORAL|Focused Breathing and Attention Training (BAT)|Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.
41483735|NCT03884374|BEHAVIORAL|Standard Breathing and Attention Training (BAT)|Standard BAT intervention will incorporate most of the general aspects of the Focused BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.
41483736|NCT03884374|DEVICE|Transcranial Direct Current Stimulation (tDCS)|A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges
40815992|NCT01089413|DRUG|bevacizumab [Avastin]|As prescribed by physician
40815993|NCT04308460|PROCEDURE|arthrocentesis|lavage of the temporomandibular joint was done
40815994|NCT04308460|PROCEDURE|operative arthroscopy|operative intervention inside the temporomandibular joint was done using arthroscope
40815995|NCT03255967|BEHAVIORAL|DSM-H|Multi-modal quality improvement program for improving the quality of care provided to person with dementia (PWD)-informal caregiver dyads through HHC
40815996|NCT03255967|BEHAVIORAL|Standard of Care|Subjects receive care through usual home healthcare assignment process.
41333901|NCT00005018|DRUG|Efavirenz|
40815997|NCT04348149|DIETARY_SUPPLEMENT|Lindera obtusiloba extract|One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.
41333902|NCT00005018|DRUG|Didanosine|
41483737|NCT03884374|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.
41483738|NCT03483207|DRUG|Warfarin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
40815998|NCT02576041|DRUG|Bilastine|Bilastine tablets once a day for 7+3 days
40815999|NCT02576041|DRUG|Placebo|Placebo tablets once a day during 7+3 days run in period
41333903|NCT05952960|OTHER|Placebo|Open Label Placebo + Rationale
41333904|NCT03412500|DRUG|Vancomycin equation-based method|Vancomycin dosage will be adjusted according to the equation-based method
40816000|NCT05139953|OTHER|No intervention|No intervention
40816001|NCT04094090|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
40816002|NCT03771131|BEHAVIORAL|Multi-domain cognitive training|Weekly sessions of multi-domain cognitive training, each lasting around one hour for an overall duration of the training of 3 months (13 sessions)
40816003|NCT06027996|DEVICE|Absorbable Antibacterial Matrix|Soft tissue support coated with antibiotics
40816004|NCT02727387|DRUG|TEMIRI|Window therapy frontline for VHR patients
40816005|NCT02727387|DRUG|ADM|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
41017884|NCT04929301|OTHER|Antenatal milk expression|Hand-expression of breast milk in pregnancy
41333905|NCT03412500|DRUG|Vancomycin trough concentration method|Vancomycin dosage will be adjusted according to the trough concentration method
41333906|NCT06347783|DEVICE|Insulin pump|Continuous subcutaneous insulin therapy.
41333907|NCT05490498|OTHER|Collection of breast milk|Collection of breast milk through a sterilized breastfeeding device. Once the collection is completed, the milk will be transferred to a sterile jar provided in a dedicated survey package for transport to the laboratory.
41333908|NCT04909216|OTHER|Mindful Attention Workshop|The 90-minute workshop will include a 15-minute break and include up to 15 participants. The workshop will be led by peer support staff, fire department psychologists, and/or fire department doctoral psychology practicum students. Each workshop will be facilitate by up to 3 workshop leaders. The workshop will provide (1) psychoeducation regarding common mental health concerns among firefighters, (2) introduction to the concept of mindful attention, why it is relevant to firefighters, and how it can prevent or decrease mental health symptoms, (3) 5 experiential mindful attention training exercises, and (4) discussion. Workshop co-leaders will teach 5 mindful attention exercises, and firefighters will practice each exercise and then engage in discussion about their experiences and provide feedback regarding the utility of the exercise for them personally and for firefighters, generally.
41483739|NCT03483207|PROCEDURE|MVT with failure of anticoagulation therapy|"patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded."
41483740|NCT03483207|DRUG|Heparin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
41013932|NCT05112835|OTHER|brolucizumab|There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study
41483741|NCT03575871|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
41483742|NCT03575871|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
41483743|NCT03575871|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
41483744|NCT02722148|DEVICE|Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy|A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
41333909|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir under fasted conditions
41333910|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions
41333911|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions
41333912|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions
41333913|NCT05515198|OTHER|Patient Education|Patients will be provided educational opportunities.
41333914|NCT05515198|OTHER|Nurse Navigation|A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.
40816006|NCT02727387|DRUG|IFO|Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
41333915|NCT05515198|OTHER|ChatBot|"A ChatBot will allow participants to directly and privately communicate through a smartphone (or other device) with an artificial intelligence-driven ChatBot, also known as a conversational agent, that will provide education and encouragement to manage their symptoms."
41333916|NCT02171819|BIOLOGICAL|IVACFLU-A/H5N1, 7.5 mcg|Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.
41333917|NCT02171819|BIOLOGICAL|IVACFLU-A/H5N1, 15 mcg|Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose
41333918|NCT02171819|OTHER|Placebo Comparator|PBS, pH 7.2 in 0.5 mL single-dose vials.
41333919|NCT00848770|DRUG|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min."
41333920|NCT00848770|DRUG|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
41333921|NCT00848770|DRUG|manipulation of SAP|Esmolol or NPS or NOR
41333922|NCT01092026|OTHER|cord blood transplantation|One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
41333923|NCT00054444|DRUG|Topotecan Hydrochloride Liposomes|Given IV
41333924|NCT00054444|RADIATION|3-Dimensional Conformal Radiation Therapy|
41333925|NCT00054444|DRUG|Cisplatin|Given IV
41333926|NCT02330913|PROCEDURE|Intracorporeal esophagojejunostomy|Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
41333927|NCT00897741|GENETIC|microarray analysis|
41333928|NCT00897741|OTHER|laboratory biomarker analysis|
41333929|NCT02685787|BEHAVIORAL|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
41483745|NCT00336765|DRUG|XL647|Tablets supplied in 50-mg strength administered orally daily
41483746|NCT00506818|OTHER|Multifactorial vascular-risk-factor-intervention|
41483747|NCT00212576|BEHAVIORAL|Video Interaction Project|While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.
40816007|NCT02727387|DRUG|CYC|Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
40816008|NCT02727387|DRUG|ETO|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
41333930|NCT02685787|BEHAVIORAL|Educational Intervention on AD|"The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions."
40816009|NCT02727387|DRUG|BUMEL|Consolidation phase
41333931|NCT06115057|DIETARY_SUPPLEMENT|Fiber|"Subjects in this study are to consume the study product twice daily during regular meals.~The fiber mix consists of different types of dietary fiber that are individually well tolerated for human consumption."
41333932|NCT06248463|DIAGNOSTIC_TEST|BP measurement in waiting room for 20 minutes|"Measured of BP will be performance in waiting room for 20 minutes every 3 minutes and report by an mobile app. After 24h-ABPM device will be implanted. Results of SBP and DBP obtained in office will be compared with 24-h, diurnal and nocturnal SBP/DBP mean.~BP will be measured automatically and repeatedly every 3 minutes in the waiting room for 20 minutes. Subsequently, a SpaceLab ABPM monitor will be implanted."
41333933|NCT05400538|OTHER|Biorepair Toothpaste + Mousse|Domiciliary application of the products twice a day.
41333934|NCT05400538|OTHER|Biorepair Toothpaste|Domiciliary application of the product twice a day.
41333935|NCT04631614|OTHER|Warm up|Warm up through a walk or exercise bike for 5 minutes with moderate intensity according to modified Borg scale (CR-10)
41333936|NCT04631614|OTHER|Passive calf muscle stretching|With the participant lying in the supine position, the physiotherapist will passively perform the ankle dorsiflexion movement to stretch the participant's calf to the limit tolerated by the participant. This procedure will be performed in two repetitions with 30 seconds of held in the stretching position and 30 seconds of rest between repetitions.
40816010|NCT02727387|DRUG|VIN|Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
41333937|NCT04631614|OTHER|Ankle joint mobilization - weight-bearing mobilization with movement (WB-MWM) technique|To perform the WB-MWM technique, the participant will be instructed to take a weight-bearing position with the tibia in a vertical position. The physiotherapist will be stay in front participant's ankle and will use the hands to stabilize the participant's foot as close as possible to the anterior region of the talus. A rigid belt will be placed on the participant's tibia and around physiotherapist´s hip. Then, the physiotherapist will project his hip backwards to produce a nonpainful anterior tibia glide. The participant will be asked to perform a forward lunge as far as possible without raising heel off the table and without reproducing knee symptoms. After achieving the maximum forward lunge, the participant will be instructed to hold this position for 5 seconds and then return to the starting position. This procedure will be performed in two sets of 10 repetitions with two minutes of rest between sets.
41333938|NCT04631614|OTHER|Clam exercise|The participant will side lying with trunk straight and both hips and knees at 45º and 90º of flexion, respectively. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the abduction and lateral rotation of the hip (keeping the heels in contact) against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
41483748|NCT00212576|BEHAVIORAL|Building Blocks Project|This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
41483749|NCT03285308|DRUG|Placebo|Placebo injected subcutaneously twice daily.
41483750|NCT03285308|DRUG|Relamorelin|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily.
41483751|NCT06007131|DEVICE|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
41483752|NCT05675241|DIAGNOSTIC_TEST|Clinical examination of a dental implant|Clinical examination includes bleeding on probing, pocket depth, gingival biotype, suppuration, gingival index
41483753|NCT05675241|DIAGNOSTIC_TEST|Radiological Examination|A standardized periapical radiograph in parallax technique will be taken.
40816011|NCT04824768|DEVICE|Tecar Therapy|"CRet is a non-invasive diathermy technique that provides high frequency energy generating a thermal effect on soft tissues. Functional massage (FM) is a non-invasive manual therapy technique that combines rhythmical passive joint mobilization with compression of the muscular belly with the muscle-tendon insertions to be treated.~In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min F.M with passive ankle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (180-250VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 8.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
40816012|NCT04824768|DEVICE|Sham Tecar Therapy|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min FM with passive ankle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 0.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
40816013|NCT01895439|BIOLOGICAL|Autologous Mesenchymal Stem Cells|
41483754|NCT05675241|DIAGNOSTIC_TEST|Peri-implant crevicular fluid sample collection|A sample of the peri-implant crevicular fluid will be collected using paper strip for 60 seconds. The sample of the fluid will be a resultant of inserting six different strips at the same time in six sites of the implant including mesiobuccal, midbuccal, distobuccal, distopalatal/distolingual, midpalatal/midlingual, mesiopalatal/mesiolingual sites of the implant.
40816014|NCT04017572|PROCEDURE|Automated peritoneal dialysis (APD)|Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
40816015|NCT03532854|DRUG|Valsartan|Valsartan P.O
40816016|NCT03532854|DRUG|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin P.O
40816017|NCT00006253|BEHAVIORAL|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
40816018|NCT00006253|BEHAVIORAL|Non-nurse coach|Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
40816019|NCT05992324|DEVICE|Caption LungAI|Caption LungAI is a software that is designed to help non-expert healthcare professionals acquire diagnostic quality images on an 8-zone lung protocol for both healthy patients and patients presenting with pathology such as B-Lines.
40816020|NCT03983265|OTHER|Bilateral Sagittal Split Osteotomy|after BSSO condyle will be re positioned by using computer guided device
40816021|NCT00733837|OTHER|Nonspecific, Innocuous, Mechanoreceptor Stimulation|A custom device will be used to provide light manual cervical traction
40816022|NCT00521690|DRUG|insulin detemir|
40816023|NCT02248441|OTHER|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
41017885|NCT04929301|OTHER|Education handouts|Educational breastfeeding handouts
41483755|NCT01558297|BEHAVIORAL|Motivational Interviewing|5 sessions of motivational interviewing over a period of 3 months.
41483756|NCT01558297|BEHAVIORAL|Nutritional Counseling|5 sessions of nutritional counseling over a period of 3 months.
41333939|NCT04631614|OTHER|Hip abduction exercise in side lying|The participant will side lying with trunk straight, both hips in a neutral position and both knee in extension. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the hip abduction against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
41333940|NCT04631614|OTHER|Knee extension exercise in a sitting position|The participant will be seated at the treatment table with the trunk straight and both knees in 90º of flexion. The external resistance will be positioned above the participant's ankle. The individual will be instructed to perform the knee extension at a protective angle (90º-45º of flexion), progressing to full extension (90º-0º of flexion) as long as the full knee extension does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
41333941|NCT04631614|OTHER|Squat exercise|The participant will be stand with the trunk straight, knees in extension and feet hip-width apart. Dumbbells will be used as external resistance.The individual will be instructed to perform the squat movement at a protective angle (0º-45º of knee flexion), progressing to a deep squat (90º of knee flexion) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
41333942|NCT04631614|OTHER|Forward lunge exercise|The participant will be stand with one lower limb in a long stride forwards of the other limb, trunk straight and both knee in extension. Dumbbells will be used as external resistance. From this position, the participant will be instructed to bend both knees to lower your body at a protective angle (0º-45º of knee flexion), progressing to a greater knee flexion (90º) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
41333943|NCT06040476|BIOLOGICAL|hUCB|hUCB
41333944|NCT03624439|DEVICE|Standard double-lumen tube|intubation using standard double-lumen tube with Macintosh laryngoscope
41333945|NCT03624439|DEVICE|Double-Lumen Tube Vivasight-DL|intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope
41333946|NCT01679522|PROCEDURE|single-port laparoscopic surgical staging|single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
41333947|NCT01679522|PROCEDURE|Four-port laparoscopic surgical staging|Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
41333948|NCT01080144|OTHER|Critical flicker frequency procedure|After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
41333949|NCT04594018|DRUG|Finlândia Association + finasteride placebo|Finlândia association hair lotion + finasteride placebo
41017886|NCT06074250|DIETARY_SUPPLEMENT|Fish oil|1500mg EPA +1000mg DHA daily
40816024|NCT03019653|DRUG|ANX-042|The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
40816025|NCT03019653|DRUG|Placebo|The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
41333950|NCT04594018|DRUG|Minoxidil + finasteride|Minoxidil hair lotion + Finasteride 1 mg
41013958|NCT03900533|BEHAVIORAL|Adjunctive group emotion regulation skills training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 7 weeks to adolescents and parents jointly together with treatment as usual
41013959|NCT03900533|BEHAVIORAL|Treatment as usual|Treatment as usual at the child- and adolescent psychiatric clinic is delivered during 7 weeks
40816026|NCT02480166|DRUG|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
40816027|NCT02480166|DRUG|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
40816028|NCT04740281|BEHAVIORAL|Footwear|Assessment of footwear
41017887|NCT06074250|DIETARY_SUPPLEMENT|Probiotics|Combination strain of lactobacillus and bifidobacteria
40816029|NCT06401889|OTHER|Non-Interventional Study|Non-interventional study
40816030|NCT01049230|RADIATION|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
40816031|NCT02439151|DEVICE|New lung ventilation strategy|New ventilation strateg: pressure assist control mode; inspiratory pressure was lowered to keep Ppeak less than 25cmH2O; set the PEEP at such a level that expiratory transpulmonary pressure stays between 0 and 5 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
40816032|NCT02439151|DEVICE|Conventional ventilation strategy|Conventional ventilation strategy: pressure assist control mode; keep the Ppeak between 20 and 25 cmH2O; set PEEP between 10 and 15 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
40816033|NCT01281254|DRUG|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
40816034|NCT01281254|DRUG|Placebo plus PLD|"Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)"
41017888|NCT06074250|BEHAVIORAL|Prebiotics|Dietary consult with follow-up to ensure target fiber intake is met.
41333951|NCT01844427|DRUG|Memantine|Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
41333952|NCT01844427|DRUG|Placebo|
41333953|NCT00028418|DRUG|Clofarabine|
41483757|NCT01558297|BEHAVIORAL|Treatment as usual with primary care physician|Participants will be encouraged to continue their care with their primary care physician.
40816035|NCT05142917|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
40816036|NCT05142917|BEHAVIORAL|Hand motor task|Various type of hand motor tasks are applied to stroke patients.
40816037|NCT02251704|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.
40816038|NCT02251704|DIAGNOSTIC_TEST|Assessment of body temperature|Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
40816039|NCT05959577|PROCEDURE|Stapled hemorrhoidopexy with anoplasty|The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty.
40816040|NCT05959577|PROCEDURE|Ferguson hemorrhoidectomy|Ferguson hemorrhoidectomy
41333954|NCT03718676|PROCEDURE|Ferric sulphate|Teeth were pulpotomized with ferric sulphate in this group.
41333955|NCT03718676|PROCEDURE|Ortho-MTA|Teeth were pulpotomized with Ortho-MTA in this group.
41333956|NCT03718676|PROCEDURE|Retro-MTA|Teeth were pulpotomized with Retro-MTA in this group.
41333957|NCT02880462|DIETARY_SUPPLEMENT|sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
41483758|NCT00571285|DIETARY_SUPPLEMENT|Vitamin D3|600 IU Vitamin D3 capsule daily
41017889|NCT06074250|BEHAVIORAL|Diet Quality|one time dietary consult at enrollment to discuss strategies to improve overall diet.
41017890|NCT05772065|BEHAVIORAL|CDC/NTCA guidelines only|The control group will have a link to US guidelines only.
41017891|NCT05772065|BEHAVIORAL|LTBI ASSIST and CDC/NTCA guidelines only|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool.
41017892|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
41333958|NCT02880462|OTHER|placebo|Placebo is made of starch
41333959|NCT06238011|DRUG|Dexmedetomidine|Dexmedetomidine(Precedex Pfizer) prepared in concentration 0.1 mcg/kg/ml total volume50 ml by nurse anesthetist at preprocedure room, start dexmedetomidine by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass (loading 1mcg/kg in 10 minutes then 0.5 mcg/kg/hour). Record patients data by nurse anesthetist
41333960|NCT06238011|DRUG|Normal saline|Normal Saline total volume50 ml prepared by nurse anesthetist at preprocedure room, start Normal Saline by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass. Record patients data by nurse anesthetist
41333961|NCT04194515|DRUG|YH1|YH1 treatment for one month
41333962|NCT04194515|DRUG|metformin|metformin treatment for one month
41333963|NCT01264068|DRUG|Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San|Take medicine every day 3 times, each time 4 grams.
41333964|NCT02122926|OTHER|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~1. Inpatient protocol for adjusting the discharge diabetes regimen;~2. Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~3. Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~4. Visiting nurse intervention after discharge;~5. Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~6. Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~7. Follow-up with PCP or endocrinologist within 1 week of discharge."
41333965|NCT00014547|DRUG|BBR 3464|
41333966|NCT06516458|DIAGNOSTIC_TEST|Camera Based Kinematic Analysis|Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis
41333967|NCT02169713|DRUG|Mirabegron|Oral
41333968|NCT02169713|DRUG|Solifenacin succinate|Oral
41333969|NCT02169713|DRUG|Tamsulosin HCl|Oral
41333970|NCT02169713|DRUG|Placebo|Oral
41333971|NCT05823792|DIAGNOSTIC_TEST|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery
41333972|NCT04933409|PROCEDURE|3D printed replica of the donor tooth|3D printed replica of the donor tooth.
41333973|NCT04933409|PROCEDURE|Conventional Autotransplantation of tooth|Conventional Autotransplantation of tooth without using the 3D printed guide
41333974|NCT04228107|DEVICE|Medication monitoring|This is an observational study of medication use patterns. The propeller health device has reminders for controller medication use and gives feedback regarding medication use to the participant, their guardian and their asthma provider
41333975|NCT01709968|DRUG|MAGNOX 520®|un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
41333976|NCT01709968|DRUG|placebo|Similarly looking placebo. Oral administration once daily for 4 weeks
41483759|NCT00571285|DIETARY_SUPPLEMENT|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
40816041|NCT01213147|DRUG|clomiphene citrate|100 mg per day oral for 7 days
40816042|NCT01213147|DRUG|buserelin|50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
40816043|NCT06493097|BEHAVIORAL|Gut-directed hypnotherapy via audio files|5 audio files 10-15 min each, min 5 times a week for 12 weeks
40816044|NCT01730664|DRUG|ertapenem|single dose of 2000mg ertapenem IV
41333977|NCT04998851|DRUG|Ocrelizumab|Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.
41333978|NCT04314492|PROCEDURE|Tonsillectomy|Intracapsular removal of tonsillar tissue (\>90%) with coblation
41333979|NCT04030949|OTHER|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
41333980|NCT02563925|RADIATION|Brain radiotherapy or Stereotactic Radiosurgery|
41333981|NCT02563925|DRUG|Tremelimumab|
41483760|NCT00571285|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given once a week
41156115|NCT05188729|DRUG|LTX-315 Part 1|LTX-315 once-daily dosing; starting total daily dose of 2 mg for the first subject. Ascending once-daily 1 mg dosing increments (eg, 2 mg on Day 1, 3 mg on Day 2). Subjects may be treated for a maximum of 2 weeks and a maximum total daily dose of 8 mg in Part 1. The starting dose will be escalated between subject cohorts in 1-mg increments after the previous cohort has completed Week 1 dosing (the DLT observation period).
41483761|NCT04978064|BEHAVIORAL|e-health psychological counselling|"Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application My Plan. The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model.~Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study)."
41483762|NCT04431882|PROCEDURE|optic nerve sheath fenestration|A standard medial transconjunctival orbitotomy was performed in all cases under general anesthesia. The medial rectus muscle was disinserted and reflected nasally with 6-0 synthetic polyester suture in typical fashion for eye muscle surgery. A traction suture was then placed through the insertion stump of the medial rectus in a baseball stitch fashion to facilitate abduction of the globe. The pupil was monitored at all times. A custom- made cupped orbital retractor was inserted along the medial scleral wall and used to retract the orbital fat and allow visualization of the optic nerve sheath. Retraction and globe abduction were relaxed if any changes in pupil size were noted. When adequate visualization was achieved, multiple dural sheath fenestrations approximately 3 mm in length. Expulsion of cerebrospinal fluid was invariably observed with the initial incision into the dural sheath.
41483763|NCT04322149|DRUG|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
41483764|NCT05255965|DIAGNOSTIC_TEST|level of IL-8+ initial T cells|5ml peripheral venous blood was taken before surgery or biopsy, and the levels of initial T cell with IL-8+, PLXND1+, PTK7+ or CR2+ were detected and recorded within 6 hours, respectively.
41483765|NCT05752565|DEVICE|SenseWear armband device|"Device: SenseWear armband device Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life"
41483766|NCT01320748|BEHAVIORAL|Dual Processing|A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
41483767|NCT01320748|BEHAVIORAL|Relapse Prevention|The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
41483768|NCT04732936|DEVICE|Temporary Peripheral Nerve Stimulator|Temporary Peripheral Nerve Stimulator to deliver 1-hr of electrical stimulation to injured nerves.
41483769|NCT03365011|DRUG|Nitrous oxide gas for inhalation|Nitrous oxide gaseous mixture (50% nitrous oxide and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
41156116|NCT05188729|DRUG|VP-315 Part 2|VP-315 once-daily dosing; Part 2 will be initiated upon completion of Part 1 to determine the optimal dosing regimen of VP-315. There were no DLTs observed in Part 1 of the study and the maximum dose of 8 mg was achieved. Therefore, the dose to be evaluated in Part 2 will be a total daily dose of 8 mg in 4 Cohorts.
41333982|NCT02563925|DRUG|HER2 directed therapy|
41156117|NCT02535598|BEHAVIORAL|Normal presentation|All the material will be presented as plain text.
41333983|NCT02563925|DRUG|Durvalumab|
41333984|NCT04503512|PROCEDURE|removal of fat pad|Removal removal of fat pad
41333985|NCT04503512|PROCEDURE|non removal of fat pad|non removal of fat pad
41333986|NCT01752725|DEVICE|BiCision®|
41333987|NCT01752725|DEVICE|Ultracision® Har-monic Scalpel(Ethicon)|
41333988|NCT03970824|BIOLOGICAL|CT-P17|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
41333989|NCT03970824|BIOLOGICAL|US-licensed Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
41483770|NCT03365011|DRUG|Placebo gas for inhalation|Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
41483771|NCT03512262|DRUG|Abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
41333990|NCT03970824|BIOLOGICAL|EU-approved Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
41333991|NCT01025297|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
41333992|NCT03175016|PROCEDURE|TACE|Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
41333993|NCT03175016|DRUG|Irinotecan|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
41333994|NCT03175016|DEVICE|eluting-bead|The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
41333995|NCT03895970|DRUG|Lenvatinib plus Pembrolizumab|Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.
41333996|NCT04950660|DRUG|Caffeine Tablet|Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
41483772|NCT03512262|DRUG|Placebo|Abaloparatide-matched placebo.
41333997|NCT04950660|DRUG|Placebo|Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
41333998|NCT00879983|DRUG|azithromycin (Zithromax)|"1. a single dose of azithromycin ER 2g~2. 3-day regimen of azithromycin tablet 500mg"
40816045|NCT05548712|DEVICE|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
41333999|NCT00879983|DRUG|azithromycin (Zithromax)|"1. 3-day regimen of azithromycin tablet 500mg~2. a single dose of azithromycin ER 2g"
41483773|NCT05042934|PROCEDURE|Fine-Needle Aspiration|Undergo fine-needle aspiration
41483774|NCT05042934|DRUG|Irinotecan|Given IV
41483775|NCT05042934|DRUG|Irinotecan Hydrochloride|Given IV
41483776|NCT05042934|DRUG|Lurbinectedin|Given IV
41483777|NCT03667079|OTHER|integrated delivery of deworming and vaccination|integrated delivery of mass drug administrations, one targeting humans (deworming) and one targeting animals (rabies vaccination)
41483778|NCT03667079|OTHER|Mass deworming only|Delivery of mass deworming to people only
41334000|NCT06579391|DIETARY_SUPPLEMENT|Essential amino acids|Twice daily consumption for two weeks before and one week after surgery.
41334001|NCT06579391|DIETARY_SUPPLEMENT|Alanine|Twice daily consumption for two weeks before and one week after surgery.
41334002|NCT01293084|DRUG|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
41483779|NCT03667079|OTHER|Mass vaccination of dogs|Delivery of mass vaccination of dogs only
41483780|NCT01722565|PROCEDURE|laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)|
41483781|NCT02263781|PROCEDURE|Blood draw|Blood draw
41017893|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
41334003|NCT01293084|DRUG|7% saline|5mL 7% saline inhaled once over 20 minutes
41334004|NCT05409846|DIAGNOSTIC_TEST|Alfa-galactosidase activity and genetic testing for Fabry diagnosis|Dry blood spot analysis and blood sample (if necessary)
41334005|NCT01495364|BIOLOGICAL|NBS10|dosage = 10 or more million CD34+ cells via intracoronary infusion
41334006|NCT01495364|OTHER|placebo|matching placebo
41334007|NCT01122888|DRUG|Cilengitide|Given IV
41334008|NCT01122888|OTHER|Clinical Observation|Patients undergo a 2-week rest period
41334009|NCT01122888|OTHER|Laboratory Biomarker Analysis|Correlative studies
41334010|NCT03481569|OTHER|Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use|Blood and cerebrospinal fluid pharmacocinetic samples at different time point
41334011|NCT02732184|DRUG|Co-ArgI-PEG modified human arginase I|
41017894|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
41017895|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
41334012|NCT01864317|DEVICE|7-Tesla MRI|High resolution functional and structural imaging of the visual pathway
41334013|NCT01864317|OTHER|Optical Coherence Tomography|Measurement of retinal nerve fiber thickness
41334014|NCT01864317|OTHER|Heidelberg Retina Tomography|Measurement of retinal nerve fiber thickness
41334015|NCT01864317|OTHER|Scanning Laser Polarimetry|Measurement of retinal nerve fiber thickness
41334016|NCT01864317|OTHER|Humphrey Perimetry|Visual Field Testing
41334017|NCT01864317|OTHER|Applanation Tonometry|Measurement of Intraocular Pressure
41483782|NCT02263781|PROCEDURE|muscle biopsy|Muscle biopsy during planned anesthesia/surgery
41483783|NCT00675064|DRUG|GSK369796|Anti-malarial
41483784|NCT00675064|DRUG|Placebo|Placebo matching GSK369796
41483785|NCT04629768|DEVICE|PuraStat|Purastat is applied to the EMR defect
41483786|NCT02278419|DRUG|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
41483787|NCT02278419|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
41483788|NCT03567382|DRUG|Tenofovir Disoproxil Fumarate|300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.
41483789|NCT03567382|BIOLOGICAL|Monovalent HBV vaccine|Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.
41483790|NCT06206083|GENETIC|Descriptive and analytical|Patients with EC endometroid
41483791|NCT05748119|DRUG|MEB-1170|Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
41483792|NCT05748119|DRUG|Placebo|Equivalent number and size of capsules containing placebo
41483793|NCT02914093|OTHER|IMT|Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
41156118|NCT02535598|BEHAVIORAL|Enhanced presentation|The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
41156119|NCT02535598|BEHAVIORAL|Normal support|Participants receive semi-standardized support once a week and there will be no formal training or competence.
41156120|NCT02535598|BEHAVIORAL|Enhanced support|Participants are offered daily support through the internet from trained therapists.
41334018|NCT03822338|PROCEDURE|Pneumoperitoneum preconditioning|Pneumoperitoneum preconditioning consists of three cycles of 5 min insufflation and 5 min desufflation, after complete anesthesia and successfully implanting the veress. This process will be induced by pneumoperitoneum machine, and the utilized gas will be carbon dioxide to maintain the intra-abdominal pressure at 15 mmHg. The whole duration will last 30 min.
41334019|NCT03822338|PROCEDURE|Sham-Pneumoperitoneum preconditioning|Sham-Pneumoperitoneum preconditioning consists of three cycles without insufﬂation and subsequent desufﬂation. The whole duration will also last 30 min.
41334020|NCT00567957|DRUG|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
41334021|NCT00567957|DRUG|Saline|same volume iv bolus before induction followed by same volume infusion
41334022|NCT00468611|DRUG|MBP8298|500mg MBP8298 IV every six months for a period of two years
41334023|NCT01520688|DRUG|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
41334024|NCT01520688|DRUG|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
41334025|NCT01520688|DRUG|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
41334026|NCT01520688|DRUG|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
41334027|NCT01520688|DRUG|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
41334028|NCT01520688|DRUG|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
41334029|NCT05455736|OTHER|Stereotactic salvage radiotherapy for macroscopic prostate bed relapse|Stereotactic prostate salvage radiotherapy administered on prostate bed macroscopic recurrence. Different techniques will be allowed provided that treatment respects doses and fractionation indicated per-protocol (35 Gy in 5 fractions)
41334030|NCT01332097|DRUG|BCT197|
41334031|NCT01332097|DRUG|Prednisone placebo|capsules
41334032|NCT01332097|DRUG|BCT197 placebo|capsules
41334033|NCT01332097|DRUG|Prednisone|capsules
41156121|NCT02176512|DRUG|BIBR 277 SE and HCTZ|Treatment A - fixed dose combination
41156122|NCT02176512|DRUG|BIBR 277 SE|Treatment B - Monocomponent
41156123|NCT02176512|DRUG|HCTZ|Treatment B -Monocomponent
41334034|NCT06507605|BIOLOGICAL|R21|R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.
41334035|NCT06507605|BIOLOGICAL|Pfs230D1-CRM197|Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.
41334036|NCT06507605|BIOLOGICAL|Pfs230D1-EPA|Recombinant Pfs230D1 conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA)
41334037|NCT06507605|OTHER|Matrix-M|Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.
41334038|NCT03713827|DEVICE|tooth restoration|restoration of non carious cervical lesions with two different restorative materials
41156124|NCT05928689|DRUG|Propranolol Hydrochloride tablet|Single dose of 40 mg propranolol tablet
41334039|NCT01567423|DRUG|ASAQ Winthrop® Sanofi Aventis|Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
41334040|NCT01567423|DRUG|Coartem®, Novartis|"artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:~1. tab/dose for children 5 to 14.9 kg (total 6 tabs)~2. tabs/dose for children 15 to 24.9 kg (total 12 tabs)"
41334041|NCT00371813|DRUG|Varenicline tartrate|
41334042|NCT00371813|DRUG|Placebo|
41334043|NCT03024385|BEHAVIORAL|Well Child Visits|Mothers of young infants will be screened for maternal behaviors that affect the outcome of future pregnancies. These behaviors are related to the following: family planning; smoking status, prenatal vitamin use and maternal depression. Mothers with positive screens will be offered appropriate resources. This will all take place during the child's routine well-child visit.
41334044|NCT01626534|DRUG|Clopidogrel|600mg loading dose then 75mg/day
41334045|NCT01626534|DRUG|trigagrelor|180 mg loading dose then 90 mg Twice a day
41334046|NCT06262594|DRUG|Lemborexant|Drug is administered
41156125|NCT05928689|BEHAVIORAL|Reminder|Reactivation of misophonia trigger memory
41156126|NCT05928689|BEHAVIORAL|Counterconditioning|Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards.
40816046|NCT05548712|DEVICE|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
41156127|NCT05928689|DRUG|Placebo|Matching placebo tablet
40816047|NCT03836833|DRUG|ABC/3TC/LPV/r granules (30/15/40/10 mgs)|"This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day"
40816048|NCT03836833|DRUG|LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day"
40816049|NCT06607965|DIETARY_SUPPLEMENT|Whey Protein and Carbohydrates|"Experimental Group:~6 hours before surgery, patients orally consumed 250 ml of a full-nutrition liquid (220 ml homogenized diet, 50 g; containing 31.4 g carbohydrates, 8 g protein, and 215 kcal).~2 hours before surgery, patients orally consumed 200 ml of a clear liquid (50 g enzymatically hydrolyzed rice powder + 0.5 g low-sodium salt; containing 47.7 g carbohydrates, 6.5 g whey protein, and 193 kcal).~After surgery, once there were no symptoms such as dizziness or vomiting, patients could start consuming clear liquids (containing 47.7 g carbohydrates, 6.5 g protein, and 221 kcal) orally every 30 minutes, 4 times on the day of surgery.~Starting from the first day after surgery, patients consumed 200 ml of fat-free nutritional liquid (50 g enzymatically hydrolyzed rice powder + 7.5 g isolated whey protein + 0.5 g low-sodium salt; 223 kcal) per serving, 4 to 6 times per day as needed."
40816050|NCT03271372|DRUG|Avelumab|Given IV
40816051|NCT03271372|OTHER|Peripheral Blood Collection|Correlative studies
40816052|NCT03271372|OTHER|Placebo|Given IV
40816053|NCT02138305|DEVICE|ComboMap XT Guidewire|Intracoronary pressure and flow measurements
40816054|NCT02138305|PROCEDURE|'SPY' NIRF During CABG|FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
40816055|NCT04694352|OTHER|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
40816056|NCT04694352|OTHER|Conventional Physical therapy|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour"
40816057|NCT04031664|DRUG|Qianjin Capsule of Gynaecology|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
40816058|NCT04628169|OTHER|no intervention applied|no intervention applied
40816059|NCT06162559|DRUG|Tucatinib|Tucatinib 300mg is taken orally twice daily
40816060|NCT06162559|DRUG|Trastuzumab|Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle
40816061|NCT06162559|DRUG|Pertuzumab|Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle
40816062|NCT01317576|BEHAVIORAL|Exercise intervention|Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.
40816063|NCT01357161|DRUG|adavosertib|Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
40816064|NCT01357161|DRUG|Placebo|placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
40816065|NCT01357161|DRUG|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
40816066|NCT01357161|DRUG|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
40816067|NCT01777217|DRUG|Solifenacin succinate|IGRT with VESIcare
40816068|NCT01777217|DRUG|Placebo|IGRT with placebo
40816069|NCT00480558|BIOLOGICAL|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10\^7
40816070|NCT00445107|DRUG|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
40816071|NCT04472117|OTHER|usual care|Interviews will be conducted in person or by telephone by an MD on the research team who does not have an ongoing treatment relationship with the patient, and has been trained by the qualitative methods specialist. Interviews will take place over the phone or in person and are anticipated to last approximately 20-30 minutes.
40816072|NCT04472117|OTHER|Educational video|Watch an educational video created by the research team and.will also complete the post-video survey. Those randomized to view the video must complete the post-video survey (Appendix 3), and all patients must complete the Post-Op Survey with the Patient Experience and Decision Regret Scale (Appendix 5) to be evaluable. If not completed, they will be replaced.
40816073|NCT02576535|PROCEDURE|Fractionated stereotactic radiosurgery|
40816074|NCT02576535|DEVICE|Leskell gamma unit|FDA approved device
40816075|NCT04664972|DRUG|Docetaxel +doxorubicin+ cyclophosphamide|The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.
40816076|NCT04664972|DRUG|Docetaxel +Cisplatin|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
41017896|NCT03105843|DRUG|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
41017897|NCT03105843|DIAGNOSTIC_TEST|Eucapneic Voluntary Hyperventilation (EVH)|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
41017898|NCT03105843|DRUG|Mannitol Inhalation Kit|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
41017899|NCT04065347|DEVICE|Digital Pill|Digital Pill over encapsulating tenofovir alafenamide ART
40816077|NCT04217135|DRUG|evidence-based medications vs. high-dose hydralazine + evidence-based medications|randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
40816078|NCT05195957|PROCEDURE|Robotic tranversus abdominis release operation|Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.
40816079|NCT05195957|PROCEDURE|Open transversus abdominis release operation|Original open TAR using midline incision.
40816080|NCT00322452|DRUG|Gefitinib|oral tablet
40816081|NCT00322452|DRUG|Carboplatin|IV
40816082|NCT00322452|DRUG|Paclitaxel|IV
40816083|NCT06606717|DIETARY_SUPPLEMENT|Creatine Whey Protein|3 grams creatine + 30 grams whey protein
40816084|NCT06606717|DIETARY_SUPPLEMENT|Whey Protein|30 grams Whey Protein
40816085|NCT02199314|DRUG|Desflurane|
40816086|NCT06178848|DRUG|propofol group|During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
40816087|NCT06178848|DRUG|remimazolam group|The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
40816088|NCT02542033|OTHER|treated apple juice with low sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
40816089|NCT02542033|OTHER|un-treated apple juice with normal sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
40816090|NCT04899999|BEHAVIORAL|Financial reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping leads to nothing. Don't let your money vaporize away.
40816091|NCT04899999|BEHAVIORAL|Health reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Dying for a vape? It hurts more than you know.
41013960|NCT06461520|OTHER|Maze Balance board|Every child will have their balance evaluated using the SWOC tool, CTSIB, and Pediatric Balance Scale. Patients performed a range of proprioceptive exercises, such as static one-leg standing, board balancing, squatting, and 20 minutes of straight-line walking on a hard surface before moving to a foam surface. For 20 minutes each session, proprioceptive exercises were conducted with open eyes first, followed by closed ones. The training program for the maze balancing board will next take place. There will be seven phases to the maze balance board training; each stage will last for two days and there will be three sessions per day, each lasting an hour.
41013961|NCT06461520|OTHER|Proprioceptive training|This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.
41013964|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose A)|Liquid formulation administered by intravitreal (IVT) injection
41013965|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose B)|Liquid formulation administered by intravitreal (IVT) injection
41013966|NCT05160805|PROCEDURE|Sham procedure|A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.
41013967|NCT04846140|DEVICE|transcranial electrical stimulation (tES)|Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.
41013968|NCT02531880|DRUG|Mangafodipir|Patients will be imaged interictally with a gadolinium enhanced MRI session. The administration of mangafodipir will be done as an inpatient during long-term video EEG recording, to ensure administration in the peri-ictal period.
41334047|NCT06262594|DRUG|Placebo|Drug is administered
40816092|NCT04899999|BEHAVIORAL|Self-efficacy graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping companies are targeting Black and Latino teens. Your life matters. Don't let them take it away.
40816093|NCT04899999|BEHAVIORAL|Social norms graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Just because vaping is common, doesn't mean it's cool. Stay woke. Don't smoke.
40816094|NCT06474507|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
40816095|NCT00460278|DRUG|XL418|
40816096|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge without oil|300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
40816097|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge with oil|300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
40816098|NCT01381276|OTHER|White cassava porridge with retinyl palmitate reference dose|300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
40816099|NCT00633074|BIOLOGICAL|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
40816100|NCT00633074|BIOLOGICAL|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
40816101|NCT02674919|OTHER|Nordic Hamstring|
40816102|NCT02674919|OTHER|Control|
40816103|NCT04122183|OTHER|iManage (my hearing loss)|An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
40816104|NCT03928938|DEVICE|Electronic patient reported outcomes|Electronic patient reported outcomes-tool
40816105|NCT04200196|PROCEDURE|"fabrique à histoire"|"Fabrique à histoire is a participatory entertainment method. Children of this arm going to create and listening a story before and during the venous puncture."
40816106|NCT04200196|PROCEDURE|Usual care|It is a passive entertainment method. Children of this arm going to do habitual activities before and during the venous puncture, like to sing, blow up a balloon, to play with recreational thing, etc.
40816107|NCT00274859|DRUG|gemcitabine hydrochloride|
41334048|NCT03374813|DEVICE|MimetikOss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
41156128|NCT05951777|BIOLOGICAL|Autologous HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
41156129|NCT05951777|DRUG|Normal Saline|Sterile Saline Solution 0.9%
41156130|NCT06645522|DRUG|Edaravone dexborneol|Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.
41334049|NCT03374813|DEVICE|Bio-Oss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
41334050|NCT00901589|DIETARY_SUPPLEMENT|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
41334051|NCT00901589|DIETARY_SUPPLEMENT|thistle oil|four capsules a day
41334052|NCT00901589|DIETARY_SUPPLEMENT|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
40816108|NCT00274859|DRUG|oxaliplatin|
40816109|NCT06086158|PROCEDURE|Nordic Reverse Protocol|The participant begins on their knees, with the trunk upright and fully aligned. At this moment, the soccer player slowly leans back, maintaining the starting position by means of a controlled flexion of the knees. This fall is executed at the lowest speed possible to maximize muscle load in the eccentric phase and reach the point of maximum flexion.
40816110|NCT04953819|OTHER|Revascularization|Percutaneous coronary intervention and/or coronary bypass grafting for coronary artery disease
40816111|NCT04953819|OTHER|Medical therapy|Optimal medical therapy for coronary artery disease
40816112|NCT00328562|DRUG|ZD1839 (Iressa)|
40816113|NCT00328562|RADIATION|Thoracic Radiotherapy|
40816114|NCT04089241|OTHER|Contrast 3D Ultrasound|an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
40816115|NCT03327220|DEVICE|iovera°|The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
40816116|NCT01194089|DRUG|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
40816117|NCT01194089|DRUG|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
40816118|NCT02603237|OTHER|Glucose tolerance test|Standardized oral glucose tolerance test (75 g oral glucose) and blood collection before and 2hrs after the glucose load
40816119|NCT02603237|OTHER|Fat tolerance test|Oral fat tolerance will be provided to fasting participants and blood samples will be collected before and 4 hrs after the fat load.
40816120|NCT05096247|DEVICE|TempSure|This device is an RF device.
40816121|NCT05096247|DEVICE|Icon|This device works with IPL (Intense Pulsed Light) handpieces.
40816122|NCT00899197|DRUG|tamoxifen citrate|
40816123|NCT00899197|GENETIC|gene expression analysis|
40816124|NCT00899197|GENETIC|protein expression analysis|
40816125|NCT00899197|OTHER|immunoenzyme technique|
40816126|NCT00899197|OTHER|laboratory biomarker analysis|
40816127|NCT01384630|DRUG|RA-18C3|200 mg subcutaneous injection
41156131|NCT06645522|DRUG|Placebo|Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.
41156132|NCT03684278|DRUG|Infusion of 5 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
41334053|NCT00901589|DIETARY_SUPPLEMENT|Thistle oil|Four capsules daily
40816128|NCT04153175|COMBINATION_PRODUCT|ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.
40816129|NCT04153175|COMBINATION_PRODUCT|Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).
40816130|NCT02213185|OTHER|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
40816131|NCT06438016|BEHAVIORAL|Stress Management Training|The intervention will comprise of 4 sessions delivered over 4 weeks. The training session will be structured as follows: Session 1 - Psychoeducation relating to stress and its effects. Session 2 - Behavioral techniques to cope with stress 1, Session 3 - Cognitive techniques to cope with stress and Session 4- Behavioral techniques to cope with stress. Both verbal and written means will be used to provide this training.
40816132|NCT01467037|OTHER|No intervention done|Not applicable because no intervention was done.
40816133|NCT01649674|DRUG|polyethylene glycole (PEG) solution|
40816134|NCT01649674|DRUG|sodium picosulphate and magnesium citrate solution|
40816135|NCT05422365|DRUG|Intravenous immunoglobulin (IVIG), 10% solution for infusion|The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
40816136|NCT04494542|PROCEDURE|Sustained Low Efficiency Dialysis (SLED)|sustained low efficiency dialysis (SLED)
40816137|NCT04494542|PROCEDURE|Continuous Renal Replacement Therapy|Continuous Renal Replacement Therapy
40816138|NCT06517225|BEHAVIORAL|Visual-acoustic biofeedback|Behavioral: Visual-acoustic biofeedback In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. The web-based software staRt will be used for intervention delivery.
40816139|NCT03227653|DRUG|Efavirenz|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
40816140|NCT03227653|DRUG|Nevirapine|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
41013969|NCT02788227|BIOLOGICAL|rVSV-Zebov GP vaccine|primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.
41013970|NCT05201794|DRUG|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
41013971|NCT05201794|DRUG|Placebo|Matching placebo for each dose level as tablet will be administered orally.
41013972|NCT02669251|DRUG|MPH966|"Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID~Phase 2 Cycle=28 days: MTD PO BID"
41013973|NCT03586999|DRUG|Nivolumab|Nivolumab injection is to be administered as an IV infusion.
41013974|NCT03586999|DRUG|Etoposide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
41334054|NCT00993304|DRUG|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
40816141|NCT03227653|DRUG|Lopinavir-Ritonavir Drug Combination|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
41013975|NCT03586999|DRUG|Prednisolone|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
41013976|NCT03586999|DRUG|Oncovin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
41334055|NCT00993304|DRUG|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
41334056|NCT04262791|DEVICE|Wrist Actigraphy Device|Wrist Actigraphy Device
41334057|NCT04262791|DEVICE|Sleep Headband|Sleep Headband
41334058|NCT05146037|OTHER|CO2 and saline flushing|TAVI valves will be prepared by flushing with CO2 to displace any retained air during manufacturing and preparation. The valves will then be flushed with saline as per IFU.
41334059|NCT05146037|OTHER|Saline flushing|TAVI valves will be flushed with saline only as per IFU.
40816142|NCT03761017|BIOLOGICAL|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
40816143|NCT04654611|DRUG|preservative free tafluprost 0.0015%|preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
40816144|NCT04437511|DRUG|Donanemab|Given IV
41334060|NCT05671237|OTHER|bilateral infraorbital+infratrochlear block|we will perform bilateral infraorbital+infratrochlear nerve block
40816145|NCT04437511|DRUG|Placebo|Given IV
40816146|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
40816147|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
40816148|NCT01960998|BEHAVIORAL|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
41334061|NCT06213610|DRUG|Perindopril tablet|Perindopril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril tert-butylamine.
41334062|NCT06213610|DRUG|Prestarium® A tablet|Prestarium® A is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine.
40816149|NCT01960998|BEHAVIORAL|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
40816150|NCT04802135|OTHER|Survey|directive questionnaire administered during an individual face-to-face interview
41334063|NCT05545878|DEVICE|Super enhanced single vision lens 01 for spectacles|This is a spectacle lens designed to have a small amount of positive power towards the bottom of the lens as this is the area that is in line with the eye when downwards for near tasks such as looking at a digital device.
41334064|NCT01933204|OTHER|Acupuncture|Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
41334065|NCT01933204|DRUG|Climen 21 Tablets|Climen Tablets are commonly used for menopausal symptoms
41334066|NCT02709109|DRUG|VX-371 + HS|
40816151|NCT01655121|DIETARY_SUPPLEMENT|High protein high fiber diet|"A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months."
40816152|NCT04342494|BEHAVIORAL|Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback."
41013977|NCT03586999|DRUG|Cyclophosphamide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
41013978|NCT03586999|DRUG|Hydroxydaunorubicin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
41013979|NCT06350864|DEVICE|High-flow nasal cannula (HFNC)|high flow cartridge and adult size nasal cannula: (flow range: 5-40L/minute, oxygen concentration (FiO2): 21-100%, temperature range: 33-39◦ C, humidity minimum of 12mg/liter)
41013980|NCT06350864|DEVICE|Conventional nasal oxygen therapy (COT)|Adult size, single use nasal cannula
41013981|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including gastroscopy|Upper gastrointestinal endoscopy (UGE) will be either diagnostic and/or therapeutic including variceal band ligation, endoscopic hemostasis as injection of bleeding peptic ulcers with adrenaline or bleeders control via either argon plasma coagulation (APC) or heater probe coagulation.
41013982|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including Endoscopic ultrasound (EUA)|Upper gastrointestinal endoscopy (UGE) will be diagnostic
41017900|NCT02442817|DRUG|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
41156133|NCT03684278|DRUG|Infusion of 10 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
41334067|NCT02709109|DRUG|Hypertonic saline|
41334068|NCT02709109|DRUG|Placebo|
41334069|NCT02709109|DRUG|Orkambi|
40816153|NCT04342494|DEVICE|Headspace app + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Headspace is an app designed to train the user in mindfulness practices."
41017901|NCT03125889|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
41017902|NCT01492140|PROCEDURE|Subdermal Injection|Injection of dermal filler
41156134|NCT03684278|OTHER|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
41334070|NCT02709109|DRUG|VX-371|
41334071|NCT02641639|DRUG|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
41334072|NCT02641639|DRUG|Placebo|Saline for infusion
41334073|NCT00219388|DRUG|Levosimendan|
41334074|NCT01302691|DRUG|losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
41334075|NCT01302691|DRUG|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
41334076|NCT01302691|DRUG|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
41334077|NCT01302691|DRUG|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
41334078|NCT01302691|DRUG|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
41334079|NCT01302691|DRUG|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
41017903|NCT01492140|DEVICE|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
41334080|NCT01673269|OTHER|Blood culture ( aerobic and anaerobic)|Blood culture 5 minutes and 30 minutes after the procedure
40816154|NCT04342494|DEVICE|Headspace app + Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Headspace is an app designed to train the user in mindfulness practices."
40816155|NCT04342494|DEVICE|SilverCloud + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
41483794|NCT03946254|OTHER|Effect of strength training on executive functions in elderly people with mild cognitive impairment.|Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 20 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The exercises will be controlled movements and not harmful, as guided machines will be used to facilitate the execution of actions. In addition, the largest amount of muscle groups to be able to generate strength gains in all muscle groups. The control group will perform breathing exercises and low intensity stretching during the same days and with the same duration as the experimental group
41483795|NCT01651143|DRUG|SAR100842|"Pharmaceutical form: tablets~Route of administration: oral"
41483796|NCT01651143|DRUG|Placebo (for SAR100842)|"Pharmaceutical form: tablets~Route of administration: oral"
41483797|NCT05960240|DRUG|AB-101|AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.
41483798|NCT05960240|DRUG|Placebo|A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.
41483799|NCT05960240|DRUG|Nucleos(t)ide Analogue|Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.
41483800|NCT05435716|DEVICE|C-wave™ peripheral seismic waveguide system|In the experimental group, if the target lesions did not show flow-limiting dissection or severe elastic retraction, drug-coated balloon was subsequently performed after lumen preparation by peripheral seismic catheterization system (IVL). If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
40816156|NCT04342494|DEVICE|SilverCloud app +Enhanced Feedback +Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
40816157|NCT01863173|DRUG|metoprolol|using B blocker in patient group
40816158|NCT01863173|DRUG|placebo|placebo to control group
40816159|NCT04588857|DRUG|Dexamethasone|The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.
40816160|NCT04588857|DRUG|Saline|The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.
41017904|NCT00131781|BEHAVIORAL|Cognitive Therapy|
41017905|NCT00131781|BEHAVIORAL|Supportive Therapy|
41156135|NCT06302010|BEHAVIORAL|Stress Ball Intervention|The stress ball has a soft plastic or silicone structure that can be held comfortably. Each ball is approximately 6 cm in diameter, in different colors, and is a soft toy that can be squeezed and manipulated with fingers to relieve stress and muscle tension and exercise the muscles (Apaydin Cirik et al., 2023). Squeezing a stress ball is a distraction and relaxation method. It is thought that squeezing a stress ball may be advantageous for reducing anxiety, considering its reliability, easy accessibility, effectiveness, low cost, sustainability, non-pharmacological and non-invasive properties.
41156136|NCT03377179|DRUG|ABC294640|Two 250 mg capsules of ABC294640 will be taken twice daily
41017906|NCT01888289|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
41156137|NCT03377179|DRUG|Hydroxychloroquine Sulfate 200 MG|HCQ tablets will be taken at a dose that will be determined
41334081|NCT02299271|DRUG|Ropivacaine|0.375% ropivacaine as a one-time, 60 milliliter injection
41334082|NCT02299271|DRUG|Saline|Saline as a one-time, 60 milliliter injection.
41017907|NCT02304042|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
41017908|NCT02304042|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
41334083|NCT03418272|DIAGNOSTIC_TEST|Culture/PCR Analysis|"Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species.~* Staphylococcus aureus (MSSA, MRSA)~* Pseudomonas aeruginosa~* Haemophilus influenza~* Streptococcus pneumonia~* Streptococcus Pyogenes Group B streptococci,~* Klebsiella pneumonia~* Moraxella catarrhalis"
41334084|NCT01911208|BEHAVIORAL|RECRUIT intervention|Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
40816161|NCT01581034|DRUG|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
40816162|NCT01581034|DRUG|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
40816163|NCT06140498|BEHAVIORAL|Self-Efficacy Training and Ecological Momentary Assessment|Participants receive 3 self-efficacy trainings per day, combined with Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week
40816164|NCT06140498|BEHAVIORAL|Control intervention: Ecological Momentary Assessment only|Participants receive Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week only
40816165|NCT05638269|OTHER|no intervention|Observational studies, no intervention
40816166|NCT05482477|OTHER|Transcutaneous acupoint electrical stimulation|Transcutaneous electrical acupoint stimulation (TEAS) is a new type of acupoint stimulation therapy that inputs low-frequency pulse current into human acupoints through electrodes pasted on the skin surface to achieve therapeutic purposes, which combined the preponderances of both acupuncture and transcutaneous electrical nerve stimulation (TENS). TEAS is non-invasive, easy to operate and acceptable to patients. Study showed that TEAS treatment can reduce the consumption of intraoperative anesthetic and improve postoperative nausea and vomiting (PONV) and postoperative recovery.
40816167|NCT02239835|DRUG|Tipranavir (TPV) low dose|
40816168|NCT02239835|DRUG|Tipranavir (TPV) high dose|
40816169|NCT02239835|DRUG|Ritonavir low dose|
40816170|NCT02239835|DRUG|Ritonavir high dose|
40816171|NCT02239835|DRUG|Saquinavir|
40816172|NCT03732677|DRUG|Durvalumab|Anti- PD-L1 Antibody
40816173|NCT03732677|DRUG|Cisplatin|Chemotherapy Agent
40816174|NCT03732677|DRUG|Gemcitabine|Chemotherapy agent
40816175|NCT03322267|DRUG|Pembrolizumab|Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18-26 Gy/10-13 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)
40816176|NCT05476237|BEHAVIORAL|Group Interpersonal Therapy for Adolescents (IPT-AG)|IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.
40816177|NCT05476237|BEHAVIORAL|Treatment as Usual (TAU)|Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).
40816178|NCT04216784|DRUG|Furosemide Injection|Patient will receive furosemide intravenously
40816179|NCT04216784|DRUG|Albumin Human|Patient will receive albumin (25%) 12.5 gm intravenously
40816180|NCT05704023|BEHAVIORAL|Reminder to exercise|Exercise support: Daily, at 7 p.m. patients will get a notification with a reminder to exercise. The app includes photographs of exercises, with instructions, that patients can look at and read if they forget which exercises they need to do and how.
40816181|NCT00362271|DRUG|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
40816182|NCT06046183|BEHAVIORAL|Process group|The medical student process group serves as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
40816183|NCT06458530|BEHAVIORAL|Vivo|Participants will meet virtually twice a week with their small group and certified trainer for 45 minutes exercise sessions for a 12-week period.
41017909|NCT06574347|DRUG|Vebreltinib|Subjects will receive Vebreltinib orally twice per day (BID).
41334085|NCT01911208|BEHAVIORAL|Control|Non-intervention control.
40816184|NCT01825486|BEHAVIORAL|accidental falls|
40816185|NCT02304887|DRUG|Bis, SERM Teriparatide, Denosumab|Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
40816186|NCT00412347|DRUG|Insulin Drip Therapy|
40816187|NCT04221737|DEVICE|APRV. General Electric Healthcare Engstrom ventilator system|APRV consist of an extended time at plateau pressure (a continuous positive airway pressure phase) comprising about 90% of the respiratory cycle, while providing very brief releases to enhance carbon dioxide removal. Time-controlled adaptive method requires interpretation of the expiratory flow curve to assess changes in lung elastance and, therefore, set the Time low to optimize carbon dioxide removal, but not at the expense of alveolar derecruitment and instability.
40816188|NCT04221737|DEVICE|Conventional. General Electric Healthcare Engstrom ventilator system|Lung protective ventilation consist of delivery of low tidal volumes (4-6 ml/kg PBW), high PEEP enough to avoid de-recruitment, titrated according to ARDSNet PEEP/fraction of inspired oxygen (FiO2) table, while avoiding excessive transpulmonary pressure.
41017910|NCT06574347|DRUG|Osimertinib|Subjects will receive Osimertinib 80mg orally once per day (QD).
41017911|NCT06574347|DRUG|PLB1004|Subjects will receive PLB1004 80mg orally once per day (QD).
41017912|NCT02780349|DEVICE|WIRION|Embolic Protection System
41017913|NCT04894474|DRUG|BI 767551 intravenous|BI 767551 intravenous
41017914|NCT04894474|DRUG|BI 767551 inhalation|BI 767551 inhalation
41017915|NCT04894474|DRUG|Placebo intravenous|Placebo intravenous
41017916|NCT04894474|DRUG|Placebo inhalation|Placebo inhalation
41017917|NCT01088516|DRUG|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
40816189|NCT05825534|OTHER|EIT monitoring|EIT monitoring (PulmoVista 500, Dräger, Lübeck, Germany) will be applied using a dedicated silicon belt with 16 electrodes placed at the level of the fifth intercostal space. The EIT system will be connected to the ventilator and data of gas flow, volume, airway pressure, and impedance will be synchronously collected at 40 Hz. The investigators will perform one simple pressure-volume (PV) curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O. During the low-flow insufflation, both ventilator and EIT-derived PV curves will be recorded. All PV curves will be analysed offline to detect complete and regional airway closures, and measure AOPs.
41334086|NCT04104295|DIAGNOSTIC_TEST|Ultrasound following X-ray|A short (less than 10 minutes) ultrasound (US) scan of the abdomen within 2 hours of the routine X-ray (XR). The performer will be a physician who received a focused training on relevant US views, blinded to the XR image and report.
40816190|NCT01500915|DRUG|Ranibizumab|0,5mg intravitreal ranibizumab
41334087|NCT06340672|OTHER|Augmented Reality Enhanced Preoperative Counseling|For patients undergoing AR enhanced preoperative counseling, headset-based AR holograms of standardized patient anatomy through AnatomyX as well as patient specific anatomy through SurgicalAR will be projected to assist the surgeon in educating the patient throughout preoperative counseling.
41334088|NCT06340672|OTHER|Standard preoperative counseling|Control patients will undergo standard preoperative counseling.
41334089|NCT00003408|BIOLOGICAL|aldesleukin|
41013985|NCT06189092|DRUG|Bleomycin|Using electroporation to infuse bleomycin in the lesion
41334090|NCT00003408|BIOLOGICAL|recombinant interferon alfa|
41334091|NCT00003408|BIOLOGICAL|sargramostim|
40816191|NCT04987996|DRUG|GR-MD-02|Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.
40816192|NCT04987996|DRUG|Placebo|Patients will receive up to seventeen doses of placebo intravenously over 85 Days.
40816193|NCT04987996|DRUG|Pembrolizumab|Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.
41013986|NCT04096560|DRUG|TAK-994|TAK-994 tablets.
41013987|NCT04096560|DRUG|Placebo|TAK-994 placebo-matching tablets.
41017918|NCT05911620|DEVICE|Magnetic resonance elastography (MRE)|Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
41334092|NCT04436783|DEVICE|Virtual Reality Epley Maneuver System (VREMS)|The VREMS system includes a smartphone placed inside virtual reality goggles worn by the participant. On the smartphone there is a virtual reality application. When viewed through the VR goggles the participants see a three-dimensional environment. Audio and text cues are presented in a 3D environment to help guide the patient through the Epley maneuver.
41334093|NCT04436783|OTHER|Instructional Handout (IH)|Patients randomized to the IH group will be given an instructional handout with image and text-based instructions on the steps involved in performing the Epley maneuver. They will then be given the chance to perform the Epley maneuver.
41334094|NCT01634113|DRUG|tiotropium-bromide|IMP
41334095|NCT01634113|DRUG|tiotropium-bromide|IMP
41334096|NCT01634113|DRUG|placebo|placebo matching tiotropium
41334097|NCT00492414|DRUG|Paroxetine CR|
41334098|NCT02646150|PROCEDURE|Magnetic Resonance Perfusion Imaging|
41334099|NCT00987610|DEVICE|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
41334100|NCT05825092|DRUG|Androgel Topical Product|AndroGel® will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
41334101|NCT05825092|DRUG|Placebo|Placebo gel will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of
41483801|NCT05435716|DEVICE|Peripheral vascular balloon dilatation catheter (PTA)|Subjects in the control group received balloon dilatation catheter in peripheral blood for lumen preparation, and if the target lesions did not show flow-limiting interlayer or severe elastic retraction, drug-coated balloon therapy was subsequently performed. If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
40816194|NCT06039176|DEVICE|HeartMate 3 (R) left ventricular assist device|No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
40816195|NCT04493333|DRUG|Vaginal Dehydroepiandrosterone|This is a vaginally administered suppository steroid indicated for the treatment of moderate to severe dyspareunia, a frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause.
40816196|NCT04493333|COMBINATION_PRODUCT|Vaginal Polycarbophil Moisturizer|This is an FDA cleared, over-the-counter personal lubricant for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. It is non-sterile, water-based, non-irritating, non-greasy, non-staining vaginal gel delivered as a long-lasting moisturizer for vaginal dryness.
40816197|NCT06006507|OTHER|control|no exercise will be given
41013994|NCT06582225|BEHAVIORAL|Internet-delivered exposure and response prevention (I-ERP)|"The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, emotions, healthy habits, the difference between repetitive behaviours in autism and OCD, how compulsions maintain the obsessions, and the rationale for ERP. The main focus of the treatment is ERP tasks based on the young person's individual goals. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of ERP. The final module includes a summary of the treatment and a relapse prevention plan.~The version for parents consists of the same content as the child treatment, but with elaborated psychoeducation, and additional focus on strategies on how to assist their child in the different exposure tasks."
41013995|NCT06582225|BEHAVIORAL|Internet-delivered stress management (I-SM)|"The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, healthy habits, and how stress is a contributor to OCD symptoms. The rationale is that targeting and reducing stress will have a beneficial impact on anxiety, obsessions, and compulsions. The main goal of the treatment is to learn how to reduce stress, mainly by using relaxation techniques such as deep breathing, progressive muscle relaxation, and imagery (cognitive) relaxation. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of relaxation tasks.~The version for parents contains psychoeducation, as well as strategies on how to assist their child in the different relaxation tasks."
41013997|NCT06357988|PROCEDURE|Biopsy|Undergo tumor biopsy
41013998|NCT06357988|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41013999|NCT06357988|PROCEDURE|Echocardiography|Undergo echocardiography
41014000|NCT06357988|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
41014001|NCT06357988|DRUG|Vismodegib|Given PO
41334102|NCT05825092|DIAGNOSTIC_TEST|Physical performance|"Physical performance at 3, 6 months and 1 year after ICU admission~6 minute walk distance 3 months after ICU admission, at 6 months and at 1 year Percentage of patients with Short Physical Performance Battery \< 10 at 3, 6 months and 1 year Physical component of SF 36 (Medical Outcomes Study 36 Item Short Form Health Survey) at 3, 6 months and 1 year"
41334103|NCT05825092|DIAGNOSTIC_TEST|Muscle strength|"Muscle strength at ICU discharge at 3, 6 months and 1 year after ICU admission~Handgrip: Kg and percent of the predicted force Medical Research Council testing (MRC)"
41334104|NCT05825092|DIAGNOSTIC_TEST|Muscular mass|"Muscular mass at 3, 6 months and 1 year after ICU admission~Mid-arm muscle circumference (MAMC)"
41483802|NCT01117766|DRUG|Pregabalin|Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
41483803|NCT01117766|DRUG|Placebo|BID dosing for 28 days
40816198|NCT06006507|OTHER|exercise|In line with the recommendation of the World Health Organization, the exercise group will do 150 minutes of moderate-intensity walking a week and strengthening exercises prepared by the physiotherapist two days a week. Strengthening exercises will be taught by the physiotherapist in a session with the people in the exercise group in groups of five, and then exercise lists will be given to the people on digital exercise platform, where there are video narrations of the exercises. In addition, the participants will be asked to do balance exercises and macular exercise.
40816199|NCT01424891|DRUG|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
40816200|NCT01424891|DRUG|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
40816201|NCT01424891|DRUG|Placebo|treatment with placebo over 8 weeks
40816202|NCT05711381|DRUG|HM15912|Drug: HM15912 Active 0.5mg/kg
40816203|NCT02156284|BEHAVIORAL|Empathic behaviour by nurses|"Control group: patients without specific empathic behaviour~Intervention group: patients who received the empathic behaviour was performed by a trained nurse."
41014004|NCT06216236|OTHER|Kinect intervention system combined with aerobic exercise training|A Kinect intervention system was used in the experimental group. The video displayed a skeletal simulation of the action. The participants could see their own actions and those of the teacher. After the video was completed, an accurate score for each action was displayed.
41334105|NCT05825092|DIAGNOSTIC_TEST|Test: Functional status|"Functional status at 3, 6 months and 1 year after ICU admission~• Composite score of 11 items of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)"
41334106|NCT05825092|DIAGNOSTIC_TEST|Oxygen muscular consumption|"Oxygen muscular consumption at ICU discharge and at 3 months after ICU admission~Ventilation free days at day 28 Length of stay in ICU Length of stay in hospital Mortality rate at day 28 Mortality rate at day 90 ICU mortality rate Hospital mortality rate"
41334107|NCT00568204|DEVICE|Mexyn-A|Atomised topical self-chilled pressurised spray
41334108|NCT04125875|DIAGNOSTIC_TEST|Electrogastrogram(EGG)|Heart Rate Variability
41334109|NCT04125875|DIAGNOSTIC_TEST|Heart Rate Variability(HRV)|Heart Rate Variability
41334110|NCT01866345|PROCEDURE|Surgically facilitated Orthodontic treatment|Surgically facilitated Orthodontic treatment in the mandibular anterior region
41334111|NCT01866345|PROCEDURE|Conventional orthodontic treatment|Conventional orthodontic Procedure
41334112|NCT05119088|OTHER|Return to Sport testbattery|At baseline, approximately 3 weeks before surgery and 6 months after surgery: patients conduct a testbattery consisting of 2 PROMs: the NPI-No and BPII2.0-No together with three physical tests: isokinetic strength tests, hop tests and Y-balance test. For the cross-cultural validation of NPI and BPII2.0 patients also conduct KOOS, IKDC 2000 and Tampa Scale.
41334113|NCT01589263|DRUG|onaBoNT-A + placebo|"200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo"
41483804|NCT03178565|OTHER|Mechanical insufflation-exsufflation|The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).
41014005|NCT06216236|OTHER|aerobic dance training|The control group used a video that did not show a skeletal simulation of the action and only saw the teachers movements.
41014006|NCT06096844|PROCEDURE|Biospecimen Collection|Undergo stool sample collection
41014007|NCT06096844|DRUG|Carboplatin|Given IV
41334114|NCT01589263|DRUG|Tamsulosin + placebo|0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
41334115|NCT04480541|BEHAVIORAL|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their own mobile phones/tablet
41334116|NCT04480541|OTHER|Wearable activity sensor|Caregivers and patients will receive a Fitbit wearable activity sensor
41483805|NCT03178565|OTHER|Standard Respiratory Physiotherapy|Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
41483806|NCT00302120|PROCEDURE|Contrast-enhanced MR mammography|
41483807|NCT06300788|OTHER|PPI and T50 dosing|Sampling for PPI determination and T50 in blood and urine.
41483808|NCT03393455|OTHER|not accurate|not accurate
41483809|NCT01855048|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
41483810|NCT01855048|OTHER|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
41483811|NCT00376025|DIETARY_SUPPLEMENT|Biological Antioxidant Supplementation|Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
41483812|NCT04346966|OTHER|Study Group|Video Based Exercises 64 young adults aged 18-40, who are socially isolated due to coronavirus, will be included in this group. A video-based exercise protocol was created for individuals to participate in the study. Each exercise session is planned as 30 minutes 7 days a week for 6 weeks. The protocol was planned to start with warm-up exercises and end with cooling exercises. The exercise protocol has also been determined as a combination of aerobic exercises, strengthening and posture exercises. Individuals will be classified at 4 levels according to their physical activity levels and will be shared with volunteers according to their level of exercise. Volunteers will be evaluated before and after 6 weeks of exercise.
41334117|NCT04480541|OTHER|Survey administration|Caregivers and patients will be asked to complete health-related quality of life surveys
41334118|NCT02366247|DRUG|PEG-Tα1|3.2mg/ml, once a week, taken subcutaneously
41334119|NCT02366247|DRUG|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
41483813|NCT00177502|BEHAVIORAL|behavioral exercise intervention|
41483814|NCT01705236|DRUG|Fingolimod|All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.
41483815|NCT04171557|BEHAVIORAL|Bicycling|Total bicycling is reported in categories of: (0 - reference), (\>0 to \<60), (≤60 to \>150), (≤150 to \< 300) and (≥300) minutes/week
41014008|NCT06096844|PROCEDURE|Computed Tomography|Undergo CT scan
41014009|NCT06096844|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41014010|NCT06096844|DRUG|Nab-paclitaxel|Given IV
41014011|NCT06096844|DRUG|Paclitaxel|Given IV
41014012|NCT06096844|BIOLOGICAL|Pembrolizumab|Given IV
41014013|NCT06096844|DRUG|Pemetrexed|Given IV
41014014|NCT06096844|PROCEDURE|Positron Emission Tomography|Undergo PET
41014015|NCT06096844|OTHER|Quality-of-Life Assessment|Ancillary studies
41014016|NCT06096844|OTHER|Questionnaire Administration|Ancillary studies
41014017|NCT04439188|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
41014018|NCT02381535|DRUG|Cisplatin|Given IV
41014019|NCT02381535|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41014020|NCT02381535|OTHER|Laboratory Biomarker Analysis|Correlative studies
41334120|NCT02366247|DRUG|Adefovir|10 mg, once daily, taken orally for 48 weeks
41334121|NCT06129136|OTHER|Nature-based exposure by biodiversity component in lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
41334122|NCT06129136|OTHER|Placebo group using colored lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
41014021|NCT02381535|DRUG|Onalespib|Given IV
41014022|NCT02381535|OTHER|Pharmacological Study|Correlative studies
41334123|NCT00971360|OTHER|conversion disorder|Proinflammatory cytokine levels in conversion disorder
41334124|NCT01230918|RADIATION|99mTc-NC100692|"HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.~Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images."
41334125|NCT02699853|OTHER|Questionnaire Administration|Ancillary studies
41334126|NCT02699853|PROCEDURE|Radical Cystectomy|Undergo RRC
41334127|NCT02699853|PROCEDURE|Radical Cystectomy|Undergo ORC
41334128|NCT03364491|DRUG|Tranexamic Acid|A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
41334129|NCT03364491|DRUG|Placebo|50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
41334130|NCT00440336|DRUG|Cosopt|
41334131|NCT00440336|DRUG|Xalatan|
41334132|NCT05410197|DRUG|Envofolimab|400mg by subcutaneous injection every 3 weeks
41334133|NCT05410197|DRUG|Lenvatinib|8 mg orally once a day
41334134|NCT05410197|DRUG|Gemcitabine|1000mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
41334135|NCT05410197|DRUG|Cisplatin|25mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
41334136|NCT00419458|PROCEDURE|inspiratory muscle strength training|
41014026|NCT05714202|DRUG|TAR-200|TAR-200 will be administered intravesically.
41014027|NCT05714202|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
41014028|NCT05714202|BIOLOGICAL|BCG Vesiculture|BCG will be administered intravesically.
41014029|NCT05894239|DRUG|Inavolisib|Participants will receive an inavolisib tablet to be taken orally (PO), once a day (QD), on Days 1-21 of each 21-day cycle, beginning on Day (D) 1 of Cycle (C) 1 of maintenance treatment.
41014030|NCT05894239|DRUG|Phesgo|Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
41014031|NCT05894239|DRUG|Placebo|Inavolisib-matching tablet taken PO QD on Days 1-21 of each 21-day cycle, beginning on D1 C1 of maintenance treatment.
41014032|NCT05894239|DRUG|Taxane-based Chemotherapy|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy will be administered after Phesgo.
41014033|NCT05894239|DRUG|Optional Endocrine Therapy of Investigator's Choice|Optional endocrine therapy (ET) is allowed at the discretion of the investigator, based on the standard of care. Allowed ETs are tamoxifen, or one of the specified third-generation aromatase inhibitor (AI \[anastrozole, letrozole, or exemestane\]), or fulvestrant. The investigator will determine and supply the appropriate luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
41334137|NCT01349296|DRUG|Everolimus + BIBF 1120|Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
41334138|NCT05065268|DEVICE|Immersive Virtual-Reality Stimulation|IVR stimulation every 2 days (± 1 day) at any time during the day (delivery).
41334139|NCT03132441|OTHER|Strength Training for Frailty|Cardiac Rehabilitation, abbreviated course
41334140|NCT02533661|OTHER|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
41334141|NCT03845114|OTHER|Continous exercise|60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
41334142|NCT03845114|OTHER|Interval exercise|Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
41334143|NCT03845114|OTHER|Reduction of basal insulin by 40%|Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.
41334144|NCT03845114|OTHER|Reduction of basal insulin by 80%|Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.
41334145|NCT00786097|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
41334146|NCT05242978|OTHER|Nutrition|acute single dose nutrition intervention
41334147|NCT05223699|BIOLOGICAL|MGTA-117|MGTA-117 will be administered as an IV infusion
41334148|NCT02894489|DEVICE|corneal lenses|wear corneal lenses on daily basis
41334149|NCT02894489|DEVICE|large diameter lenses|
41483816|NCT05690464|DIETARY_SUPPLEMENT|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
41483817|NCT05690464|DIETARY_SUPPLEMENT|placebo|placebo
40816204|NCT00772915|DRUG|dexamethasone|"Dose: -40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly."
40816205|NCT00772915|DRUG|lenalidomide|"25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described)."
40816206|NCT06092216|DRUG|Spesolimab|"900 mg of spesolimab intravenously (IV) administered every 4 weeks at Visits 2, 3, 4, 5, 6, 7, 8, 9.~If at visit 4 dosing schedule changes to every 3 weeks, Spesolimab will be administered at Visits 2, 3, 4, 5, 6, 8, 9, 10 and 11."
40816207|NCT03363087|DEVICE|Mapping and ablation|Ultra high density scar mapping Collection of impedance data during ablation
41334150|NCT05482555|PROCEDURE|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
41483818|NCT02917226|OTHER|Clinical decision support and monitoring system|
40816208|NCT03363087|DEVICE|Mapping|Omnipolar mapping of left atrial scar and pulmonary vein isolation lines
40816209|NCT02375737|BEHAVIORAL|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
40816210|NCT01663818|DEVICE|Tack-It Endovascular Stapler|
41334151|NCT05482555|PROCEDURE|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
41334152|NCT01180764|DRUG|Lovaza (Omega-3 acid ethyl esters)|1g capsules, 4 capsules po daily
41334153|NCT01180764|DRUG|Placebo|Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
41334154|NCT01952288|DRUG|simvastatin|simvastatin 40 mg/day for 12 months
41334155|NCT01952288|DRUG|Placebo Oral Tablet|placebo comparator
41334156|NCT04000022|DEVICE|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
41334157|NCT06081699|DRUG|TNP-2198|Oral
41334158|NCT06081699|DRUG|TNP-2198 Placebo|The placebo for TNP-2198 active drug
41334159|NCT00410904|DRUG|cediranib maleate|
41334160|NCT00410904|DRUG|pemetrexed disodium|
41334161|NCT03527316|DRUG|MDMA|125 mg MDMA per os, single dose
41334162|NCT03527316|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs.
41334163|NCT04310878|OTHER|Survey among perioperative nurses and surgeons|Online survey
41334164|NCT05433636|BEHAVIORAL|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
41483819|NCT00818129|DRUG|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
41483820|NCT00818129|DRUG|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
41334165|NCT05433636|BEHAVIORAL|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
41334166|NCT05433636|BEHAVIORAL|Mindfulness of Discomfort|Patients will listen to a 5-minute, audio-recorded mindfulness of discomfort practice.
41334167|NCT05433636|BEHAVIORAL|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
41334168|NCT05433636|BEHAVIORAL|Integrative Health Recording|Patients will listen to a 5-minute, audio-recorded description of integrative health.
41334169|NCT03000686|BIOLOGICAL|GSK2586881|GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
41334170|NCT03000686|OTHER|Placebo|Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
41334171|NCT02327312|DEVICE|Stents|Two Trabecular meshwork Micro-Bypass stents into the study eye
41334172|NCT02327312|PROCEDURE|Laser|Laser Trabeculoplasty
41483821|NCT06126666|DRUG|ABL103|ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
41483822|NCT02091141|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
41483823|NCT02091141|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
41483824|NCT02091141|DRUG|Erlotinib|Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
41334173|NCT02327312|DEVICE|Laser Trabeculoplasty|
41334174|NCT05199883|OTHER|TI.VA algorithm: decision support system|TI.VA algorithm uses BIS and MAP values as control variables to suggest the intervention on propofol and remifentanil levels.
41334175|NCT02136550|BEHAVIORAL|Smoking cessation|Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
41334176|NCT02197897|DRUG|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
41334177|NCT02157103|DRUG|Bevacizumab 25 mg in 1 ml subcutaneously daily|Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
41334178|NCT05863702|BEHAVIORAL|Penny|The chatbot will assist patients who have not been see for cancer follow-up care, with scheduling follow-up appointments, labs, scans, specialty appointments, and monitor compliance with the appointments made.
41334179|NCT04972825|BEHAVIORAL|Mind the Gap|This intervention will help parents with children newly diagnosed with autism or other neurodevelopmental disorders learn how to navigate the system of acquiring services for their child. These parents will be assisted by a coach, an employee at the child's agency, that will help them through this process.
41334180|NCT03228706|BEHAVIORAL|Know Your Medicine - Take It For Health (KYM-TIFH)|The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska \& Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen \& Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
41334181|NCT04968353|DEVICE|Incisally-beveled attachment|Incisally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
41334182|NCT04968353|DEVICE|Gingivally-beveled attachment|Gingivally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
41334183|NCT04968353|DEVICE|Optimized attachment|Optimized attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
41334184|NCT04968353|DEVICE|Horizontal attachment|Horizontal attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
41334185|NCT05474872|DEVICE|BIS monitoring|The depth of anesthesia will be monitored using Bispectral Index values.
41334186|NCT00501462|DRUG|GSK189075|single 250 mg dose of drug
41334187|NCT00660075|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
41334188|NCT00660075|DRUG|Placebo|Placebo for 6 weeks
41334189|NCT02682160|OTHER|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
41334190|NCT00003250|DRUG|fenretinide|
41334191|NCT02120560|PROCEDURE|Atrial Fibrillation Ablation|Both treatment arms will undergo atrial fibrillation ablation.
41334192|NCT00178061|BEHAVIORAL|Interpersonal Social Rhythm Therapy (IPSRT)|
41334193|NCT02569021|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes as a washout period~3. Biphasic pulse stimulation mode (assessment at 0.5hr)~4. Biphasic pulse stimulation mode (assessment at 1hr)~5. Biphasic pulse stimulation mode (assessment at 2hr)~6. Biphasic pulse stimulation mode (assessment at 3hr)"
41334194|NCT02569021|OTHER|Unified Parkinson's Disease Rating Scale|UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.
41334195|NCT02569021|OTHER|Tremor Rating Scale|TRS is used by neurologists to rate the severity of a tremor.
41483825|NCT02091141|DRUG|Vemurafenib|Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
41334196|NCT02569021|DEVICE|Kinesia accelerometer|The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.
41334197|NCT02569021|DEVICE|Trigno wireless system|The Trigno system measure muscle contractions.
41334198|NCT02569021|OTHER|GaitRite walking assessment.|GaitRite records a patients gait pattern.
41334199|NCT03936270|DRUG|Palbociclib 125mg|The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
41334200|NCT03936270|DRUG|Letrozole 2.5mg|Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
41334201|NCT00616291|BIOLOGICAL|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
41334202|NCT00968708|DRUG|Alogliptin|Alogliptin tablets
41334203|NCT00968708|DRUG|Placebo|Alogliptin placebo matching tablets
41334204|NCT01319513|OTHER|whey protein bolus|single dose of 25 g whey protein
41334205|NCT01319513|OTHER|whey protein pulses|10 2.5 g pulses of whey protein
41334206|NCT05229419|OTHER|complete blood count|complete blood count will be done for corrosive cases
41334207|NCT04467164|DEVICE|exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)|Non-painful exhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
41334208|NCT04467164|DEVICE|Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)|Non-painful inhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
41483826|NCT02091141|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
40816211|NCT02534935|BIOLOGICAL|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
41483827|NCT02091141|DRUG|Vismodegib|Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
40816212|NCT02534935|BIOLOGICAL|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
41483828|NCT02091141|DRUG|Alectinib|Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
41483829|NCT02091141|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
41483830|NCT00974974|DRUG|IPX066|extended-release carbidopa-levodopa capsules
41483831|NCT00974974|DRUG|IR CD-LD|immediate-release carbidopa-levodopa tablets
40816213|NCT00604643|DEVICE|TALENT Aortic Cuff Abdominal Stent Graft|Endovascular Aneurysm Repair
40816214|NCT00564902|DRUG|3R 3'R Zeaxanthin|8 mg per day during 12 months
40816215|NCT00564902|DIETARY_SUPPLEMENT|Lutein|9 mg of Lutein during 12 months
40816216|NCT00564902|DIETARY_SUPPLEMENT|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
41334209|NCT03117309|DRUG|Nivolumab 240 mg|PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment
41334210|NCT03117309|DRUG|Ipilimumab 1mg/kg|Ipilimumab 1 mg/kg every 3 weeks x 4
41334211|NCT03117309|DRUG|Nivolumab 3mg/kg|In combination with Ipilimumab
41334212|NCT03117309|DRUG|Nivolumab 360mg|Continue Nivolumab 360 mg IV every 3 weeks
41334213|NCT04090580|DIAGNOSTIC_TEST|Continuous glucose monitoring|"Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks (n=18) or 2000 mg metformin (n=18). Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit)."
41334214|NCT00004910|PROCEDURE|bowel obstruction management|
41334215|NCT00004910|PROCEDURE|quality-of-life assessment|
41334216|NCT00264667|DRUG|GW677954|
41483832|NCT05298878|OTHER|Intervention Group: Virtual home-based rehabilitation plus usual outpatient care|"14 supervised exercise virtual sessions with Kinesiologist and 10 independent exercise sessions. Each session lasts 40 minutes. The exercises consist of aerobic training; functional lower and upper body strengthening; balance; and flexibility exercises. During the first 10 minutes of the first session of each week, there is an educational session.~Week 1-2: three supervised virtual sessions Week 3-4: two supervised virtual sessions and one independent session. Week 5-8: one supervised virtual session and two independent sessions."
41483833|NCT05000970|DEVICE|blood pressure cuff PLUS tablet|all arms
41334217|NCT05462340|DRUG|[18F]ASEM|\[18F\]ASEM demonstrated excellent imaging properties, as was recently confirmed by others. \[18F\]ASEM is the 1st validated α7 human PET radiotracer to examine α7-nAChR characteristics in the living brain of SCZ patients. Previous α7 studies in the SCZ literature were done using brains harvested post-mortem, and under variable storage conditions. The proposed studies will also determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
41334218|NCT05462340|DRUG|[18F]AZAN|The most widely used PET radioligand for human imaging of α4β2-nAChR is 2-\[18F\]FA. Because 2-\[18F\]FA exhibits very slow brain kinetics, the investigators developed \[18F\]AZAN, a highly α4β2 specific tracer with optimal brain kinetics. Therefore, the proposed studies will utilize \[18F\]AZAN to determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
41334219|NCT01976169|DRUG|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
41334220|NCT01847079|OTHER|Procalcitonin|Procalcitonin to guide obtaining bloodcultures
41334221|NCT00092404|BIOLOGICAL|measles, mumps, and rubella virus vaccine live|
41483834|NCT05000970|OTHER|Telehealth Consult|Telehealth consult with an RN
41483835|NCT03651466|DRUG|Gx-G6|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
41483836|NCT03651466|DRUG|Placebo|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
41334222|NCT00092404|BIOLOGICAL|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
41334223|NCT02621255|DRUG|Sevoflurane|Anesthesia type of performed for patient which has femur fracture.
41483837|NCT04534218|DRUG|Regorafenib|"* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle."
40816217|NCT05143307|BIOLOGICAL|EBT-101|Long term follow up of participants who received EBT-101
41334224|NCT02621255|DRUG|Bupivacaine|Anesthesia type of performed for patient which has femur fracture.
41334225|NCT00703170|DRUG|Temsirolimus|
41483838|NCT04534218|DRUG|Cyclophosphamide|50 mg per os, daily, for 6 months
41483839|NCT04534218|DRUG|Capecitabine|625mg/m²/orally twice daily continuously for 6 months
41483840|NCT04534218|DRUG|Aspirin|75 mg orally and daily until progression
41483841|NCT00262041|BIOLOGICAL|MenACWY-CRM conjugate vaccine, adjuvanted|
41483842|NCT00262041|BIOLOGICAL|MenACWY-CRM conjugate vaccine, unadjuvanted|
41483843|NCT00262041|BIOLOGICAL|MenACWY polysaccharide vaccine|
40816218|NCT03295383|DRUG|Rituximab 1g IV|Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
40816219|NCT03295383|DRUG|Cyclophosphamide 50Mg Oral Tablet|"cyclophosphamide will be administered orally once daily at the following initial doses:~* patients younger than 75 years: 1.5 mg/kg/day, orally.~* patients older than 75 years: 1 mg/kg/day, orally."
41334226|NCT00703170|DRUG|Pegylated liposomal doxorubicin|
41334227|NCT01062919|PROCEDURE|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
41334228|NCT01062919|PROCEDURE|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
41483844|NCT01197417|DRUG|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
41483845|NCT01197417|DRUG|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
41483846|NCT03794518|DRUG|Pioglitazone Plus dapaglifliozin|Pioglitazone Plus dapaglifliozin
41483847|NCT03794518|DRUG|Placebo|(Beta blockers, ACEI, ARB, and aldosterone )
41483848|NCT01679106|OTHER|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
40816220|NCT03295383|DRUG|Placebo of Rituximab|Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
41334229|NCT03030014|BEHAVIORAL|educational programm|Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
41334230|NCT03030014|OTHER|no educational program|without oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
41334231|NCT06378060|DRUG|Modified transplantation system|Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA
41334232|NCT02361619|DRUG|Caffeine|probe
41014051|NCT05198791|DRUG|Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets|Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
40816221|NCT03295383|DRUG|Placebo Oral Tablet|cyclophosphamide placebo will be administered orally once daily
40816222|NCT06605547|PROCEDURE|Non-surgical periodontal treatment|The non-surgical periodontal treatment (scaling and root planing) was applied under local anesthesia using ultrasonic device and Gracey curettes. After scaling and root planing, periodontal pockets were irrigated using saline solution. Non-surgical periodontal treatment was completed in one or two sessions within 24 hours.
41014052|NCT05198791|OTHER|Stratification and standard care|Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
41483849|NCT01679106|OTHER|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
41483850|NCT02439749|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
41483851|NCT02439749|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
40816223|NCT06605547|DEVICE|Subgingival application of saline|For the subgingival saline application at the control sites, the insulin needle was filled with saline and the 29-gauge needle tip was gently placed into the periodontal pocket. The saline was injected into the periodontal pocket until it was seen to overflow from the gingival margin. Subgingival saline application was repeated on the 7th day.
41334233|NCT02361619|DRUG|Diclofenac|probe
41334234|NCT02361619|DRUG|Esomeprazole|probe
41334235|NCT02361619|DRUG|Metoprolol|probe
41334236|NCT02361619|DRUG|Midazolam|probe
41483852|NCT05005871|OTHER|Quadratus lumborum block after C-section surgery as postoperative pain management|To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.
40816224|NCT06605547|OTHER|Subgingival application of i-PRF|For subgingival application of i-PRF at the test sites, the i-PRF taken into the insulin syringe, the 29-gauge needle tip was gently placed into the periodontal pocket and the i-PRF was injected into the periodontal pocket until it reached the gingival margin (until it overflowed from the sulcus). Subgingival i-PRF application was repeated on the 7th day.
40816225|NCT03576066|DRUG|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
41334237|NCT02361619|DRUG|Dabigatran|probe
41334238|NCT02361619|DRUG|Clarithromycin|perpetrator
41483853|NCT04677855|DRUG|PCUR-101|50 mg capsules
41483854|NCT04677855|DRUG|Dutasteride 0.5 mg|0.5 mg capsules
41483855|NCT04677855|DRUG|Abiraterone and Prednisone|500 mg tablets Abiraterone with 5 mg Prednisone Tablets
40816226|NCT03576066|DRUG|SOC NUC|Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
40816227|NCT03576066|DRUG|Placebo Oral Tablet|Participants will receive placebo matching ABI-0731 tablets orally QD.
41483856|NCT05559112|OTHER|Vitamin D-enriched mushrooms|Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily (for a total of 168g per day) for 12 weeks.
41483857|NCT05559112|OTHER|Study Powder|Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily (2 tsp total per day) for 12 weeks. Study powder is a commercially available carbohydrate.
41483858|NCT06299852|DRUG|Trastuzumab emtansine|SRT for metastatic foci
40816228|NCT05594121|DRUG|Extended Release Subcutaneous Buprenorphine|Monthly subcutaneous injections of long-acting buprenorphine
41483859|NCT00775684|DRUG|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
40816229|NCT05594121|DRUG|Immediate Release Sublingual Buprenorphine|Daily sublingual fast-acting buprenorphine
40816230|NCT01827774|DEVICE|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
40816231|NCT00453700|PROCEDURE|Trypanosoma cruzi serology|
40816232|NCT06608498|BEHAVIORAL|SPARK Coping|SPARK Coping is a single-session intervention providing psychoeducation and structured practices related to stigma reduction, cognitive restructuring, behavioral activation, and effective coping. It is a self-guided website powered by research data capture software.
40816233|NCT06065059|DRUG|TNG348|Ubiquitin Specific Peptidase 1 (USP1) inhibitor
40816234|NCT06065059|DRUG|Olaparib|PARP inhibitor
40816235|NCT06482515|BEHAVIORAL|Time-restricted eating|Participants will be asked to eat all their food in a self-selected 10-hour eating window every day.
40816236|NCT06482515|BEHAVIORAL|Nutrition counseling|Participants will meet with a nutritionist to discuss their dietary habits and how they compare to the American Cancer Society nutrition guidelines.
40816237|NCT06405737|DRUG|Intranasal oxytocin|Subject assigned to receive intranasal administration of oxytocin (24 IU).
40816238|NCT06405737|DRUG|Intranasal placebo|Subjects assigned to receive intranasal administration of placebo (24 IU).
40816239|NCT03048890|BEHAVIORAL|Physical activity levels|Patients with severely low physical activity levels will be notified to consult their physician.
40816240|NCT05060549|DRUG|Cariprazine|Participants will receive 6 weeks of cariprazine treatment
40816241|NCT05762250|OTHER|Auricular Acupuncture|Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
40816242|NCT04491019|OTHER|Balance exercise group|Balance exercises will be carried out with a physiotherapist
40816243|NCT02446704|DRUG|Olaparib|
40816244|NCT02446704|DRUG|Temozolomide|
41334239|NCT01799304|PROCEDURE|no distractor control group|This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
40816245|NCT03939767|DRUG|Aflibercept (Eylea, BAY86-5321)|As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
41334240|NCT01799304|PROCEDURE|visual and sound attentional distractors|The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
41334241|NCT01799304|PROCEDURE|sound attentional distractor alone|In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
40816246|NCT03155529|PROCEDURE|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
40816247|NCT02060630|PROCEDURE|Open surgical revascularization|
41334242|NCT01799304|PROCEDURE|additional cognitive task|The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
41334243|NCT03508544|PROCEDURE|Lumbar ESP block|Lumbar ESP block will be performed at the begining of surgery under ganeral anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 4-6 cm lateral to L4 spinous process. The erector spinae muscles will be identified superficial to the tip of L4 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
41334244|NCT03508544|PROCEDURE|QLB bLock|QLB block will be performed at the begining of surgery under ganeral anesthesia. The convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest.The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscles, transverse abdominis muscles, internal and external oblique muscles and the quadratus lumborum muscles will be identified. A 15cm 22G insulated needle will be inserted on the posterior corner of the convex probe. 40 ml of local anesthetic mixture(bupivacaine and lidocaine ) will be administered between the quadratus lumborum and psoas muscles into the fascial plane. We observed the local anesthetic pressing down on the psoas muscle in the ultrasound image.
41334245|NCT03508544|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
41334246|NCT06304363|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
41334247|NCT03239639|BEHAVIORAL|Advance care planning education session|Administration of values clarification tool, elicitation of preference for treatment options, if preference for resuscitation, shown an educational video about cardiopulmonary resuscitation, summary document of values and preferences created by a facilitator to share with doctor
41334248|NCT03239639|OTHER|Wait list control|No intervention
40816248|NCT02060630|DEVICE|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
41483860|NCT00775684|DRUG|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
40816249|NCT05055388|OTHER|Multidrug-resistant bacteria|Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.
40816250|NCT00002705|DRUG|topotecan hydrochloride|
40816251|NCT02502435|OTHER|Observation|Observational study
40816252|NCT06607991|DRUG|Blinatumomab Treatment|Blinatumomab treatment for CNI-resistant/Intolerant pediatric steriod-resistant nephrotic syndrome Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
40816253|NCT03103204|COMBINATION_PRODUCT|One-stage full-mouth disinfection with chlorhexidine|"Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).~Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).~Oral hygiene instructions will be given for all participants."
40816254|NCT05865405|BEHAVIORAL|MS CATCH|Participants will respond to a set of surveys every month to increase communication on mood with their clinician.
40816255|NCT00978380|DRUG|catridecacog|Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
40816256|NCT01738607|DIETARY_SUPPLEMENT|Psyllium|
40816257|NCT01738607|DIETARY_SUPPLEMENT|Gum Arabic|Gum acacia dietary fiber
40816258|NCT01738607|DIETARY_SUPPLEMENT|carboxymethylcellulose|dietary fiber
40816259|NCT01738607|DIETARY_SUPPLEMENT|Placebo|
40816260|NCT05355259|DEVICE|GECKO Active Guidewire|The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.
40816261|NCT01335724|DRUG|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
40816262|NCT01335724|DRUG|Placebo gel|Placebo gel
40816263|NCT05005845|DRUG|NFX-179 gel|NFX-179 topical gel is the active investigational product being studied
40816264|NCT05005845|DRUG|Vehicle gel|NFX-179 vehicle gel is the placebo comparator for this study
40816265|NCT00481559|DRUG|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
40816266|NCT04827147|DEVICE|Multi-Periscopic Prism (MPP) glasses|Spectacles with multi-periscopic prisms mounted as oblique peripheral prism segments
40816267|NCT04827147|DEVICE|Fresnel Peripheral Prism (FPP) glasses|Spectacles with conventional permanent Fresnel prisms mounted as oblique peripheral prism segments
40816268|NCT00434733|BIOLOGICAL|Pandemic influenza vaccine|
41334249|NCT00502619|PROCEDURE|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
41334250|NCT00502619|OTHER|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
40816269|NCT01913028|DRUG|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
40816270|NCT01913028|DRUG|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
41334251|NCT01016678|DRUG|Treximet|85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
40816271|NCT00258765|DRUG|Zoledronic Acid|
40816272|NCT00258765|DRUG|Docetaxel|
40816273|NCT03581695|OTHER|Blood test|Blood test
40816274|NCT00491855|DRUG|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
40816275|NCT00491855|DRUG|Oxaliplatin|Starting dose level 25 mg/m\^2 given intraperitoneally on day 2.
41014057|NCT06526247|BEHAVIORAL|Strength at Home (SAH)|SAH is a group intervention that incorporates elements from interventions for violence and trauma. It is administered during 12 two-hour weekly sessions. The program uses a social information processing model based on the premise that trauma negatively impacts one's ability to interpret and respond to social situations effectively. It underscores the importance of cognitive behavioral strategies to monitor one's thoughts and responses to interpersonal situations.
40816276|NCT00491855|DRUG|Paclitaxel|Starting dose level 110 mg/m\^2 given continuous infusion on day 1 and 30 mg/m\^2 given intraperitoneally on day 8.
40816277|NCT01696019|OTHER|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
41014058|NCT06526247|BEHAVIORAL|Treatment as usual for IPV|Treatment as usual for IPV includes court-mandated interventions delivered over the 26 two-hour weekly sessions in Washington state.
41014059|NCT02464969|DRUG|Apixaban|Tablet or Solution
41334252|NCT01016678|DRUG|Placebo|Dummy pill comparator
41483861|NCT00775684|DRUG|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose \< 110mg/dl
41483862|NCT05787054|OTHER|Third trimester ultrasound|Third Trimester U/S on indication (TT-Indication) vs Late Third Trimester Protocol (Late-TT)(Trial n°2).
41483863|NCT03112980|DEVICE|Transcatheter aortic valve implantation|(TAVI)
40816278|NCT01696019|OTHER|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
40816279|NCT01696019|OTHER|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
40816280|NCT01696019|OTHER|Contact and testing only|
40816281|NCT03614481|GENETIC|Sampling|Sampling
40816282|NCT02974127|RADIATION|Radiotherapy|Multisession radiosurgery
40816283|NCT02347553|OTHER|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
40816284|NCT00065039|BEHAVIORAL|Promotion of a healthy diet and physical activity|
40816285|NCT00065039|BEHAVIORAL|Avoidance of Alcohol, Drugs, and Tobacco|
40816286|NCT05769855|DRUG|HR18034|HR18034 380mg
40816287|NCT05769855|DRUG|ropivacaine HCl|ropivacaine HCl 75mg.
40816288|NCT05769855|DRUG|Sodium Chloride Physiological Solution|Sodium Chloride Physiological Solution 20ml
40816289|NCT02225847|OTHER|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
40816290|NCT02225847|PROCEDURE|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
40816291|NCT02225847|BEHAVIORAL|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
40816292|NCT04445883|BEHAVIORAL|Feeding Assistance|Patients will be receiving assistance during mealtimes. This includes assistance by opening packages, listing/explaining the food products on the tray, providing encouragement and companionship during mealtimes and directly feed patients.
41014060|NCT02464969|DRUG|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
41014061|NCT05687110|PROCEDURE|Biopsy|Undergo tumor biopsy
41014062|NCT05687110|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41014063|NCT05687110|PROCEDURE|Diagnostic Imaging|Undergo medical imaging scans
41014064|NCT05687110|BIOLOGICAL|Novobiocin Sodium|Given PO
41483864|NCT03112980|PROCEDURE|Surgical aortic valve replacement|(SAVR)
41483865|NCT04026685|DRUG|Phenylephrine infusion|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure
41334253|NCT04116216|COMBINATION_PRODUCT|High frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
41334254|NCT04116216|COMBINATION_PRODUCT|Low frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
41483866|NCT04026685|DRUG|Phenylephrine infusion and Ringer-Acetate bolus|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL
41483867|NCT06425770|PROCEDURE|indirect digital impression and 3D printed cast|the provisional restoration will be scanned with intraoral scanner extraorally, based on which a virtual model will be created, from which a 3D printed cast will be created with manually fabricated gingival mask based on the provisional restoration
41483868|NCT06425770|PROCEDURE|direct digital impression|the emergence profile will be directly scanned with intraoral scanner at 0, 2, 10, and 20 minutes after removing the provisional restoration
41483869|NCT06425770|PROCEDURE|conventional impresion and cast|conventional impression with elastomer (silicon), from which a high-precision epoxi-resin cast with gingival mask will be created
41483870|NCT05645770|COMBINATION_PRODUCT|ECG, computerized task|ECG for cardiac waves computerized task for prospective memory
40816293|NCT02022761|DRUG|Laninamivir octanoate|40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
40816294|NCT02359045|DRUG|D1400147|Treatment A
40816295|NCT02359045|DRUG|D14000136|Treatment B
40816296|NCT02359045|DRUG|D14000137|Treatment C
40816297|NCT02359045|DRUG|Epanova®|Treatment D
40816298|NCT02132923|BIOLOGICAL|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
40816299|NCT02767726|DEVICE|non-invasive multimodal imaging|
40816300|NCT02684877|OTHER|Questionnaire|
40816301|NCT00292279|DRUG|Omega-3 fish oil emulsion (Omegaven )|Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
41014067|NCT04301089|DEVICE|Pico G2 4K Headset with Applied VR software|headset worn at time points defined in study
41014074|NCT05889182|DRUG|Upadacitinib|Oral Tablets
41014075|NCT05889182|DRUG|Placebo|Oral Tablets
40816302|NCT00292279|DRUG|long-chain triglyceride|the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
40816303|NCT05292911|DRUG|ALT-801|Injected subcutaneously (SC)
40816304|NCT05292911|OTHER|Placebo|Injected subcutaneously (SC)
41334255|NCT04116216|COMBINATION_PRODUCT|Sham repetitive transcranial magnetic stimulation|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
41334256|NCT01989572|OTHER|Laboratory Biomarker Analysis|Correlative studies
41334257|NCT01989572|OTHER|Placebo|Given GM-CSF placebo SC
41334258|NCT01989572|OTHER|Placebo|Given peptide placebo SC
41334259|NCT01989572|BIOLOGICAL|Sargramostim|Given SC
41334260|NCT01989572|BIOLOGICAL|Tyrosinase Peptide|Given SC
41483871|NCT01047930|BEHAVIORAL|Exercise|"Each 3-day experimental period will include one of the following conditions:~1. Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;~2. Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;~3. No exercise - subject will watch television or read and they will be required to remain sedentary."
41334261|NCT02347852|DRUG|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
41334262|NCT04359121|OTHER|Questionnaires for specific phobia|Questionnaires will be used.
41334263|NCT05645653|BEHAVIORAL|Motivational tteaching|A comprehensive assessment of adherence problems will be firstly conducted to identify the factors that affect adherence, including how and why these factors contribute to poor adherence. Medication-related knowledge and skills will be provided based on individual treatments and barriers to adherence. Motivational interviewing techniques will be used for a better understanding of patients' cognitive factors of adherence behavior.
41334264|NCT05833568|DEVICE|Active Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~tACS stimulation will be applied for 20 minutes for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the tACS condition."
41334265|NCT05833568|DEVICE|SHAM Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~SHAM stimulation will be applied for a 2-minute ramp-up, then the current will stop for 20 minutes, followed by a 2-minute ramp-down. This will be applied for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the ramp-up and down in the SHAM conditions."
41483872|NCT05422430|BEHAVIORAL|Rebreathing-induced hypoxia|Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.
41483873|NCT05422430|BEHAVIORAL|Spontaneous breathing|Participants will be spontaneously breathing during an oral glucose tolerance test.
40816305|NCT00190021|DRUG|donepezil|
40816306|NCT01309048|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
40816307|NCT03982719|OTHER|Brief protocol|This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.
41014078|NCT06411691|DRUG|KRAS Vaccine with Poly-ICLC adjuvant|"SLP mKRASvax with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22 in Cycle 1 (Prime Phase) and on day 1 in cycle 4 and every other cycle and beyond (Boost Phase). Up to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
41334266|NCT02690168|BEHAVIORAL|Fasting|72 hour fasting
41483874|NCT03585465|DRUG|Vinblastine|"* Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle~* Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see C"
41334267|NCT01080456|DRUG|Tacrolimus 1 mg capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
41334268|NCT04557618|DEVICE|Auricular Vagus Nerve Stimulation|Transcutaneous auricular vagal nerve stimulation
41483875|NCT03585465|DRUG|Cyclophosphamide|"* Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~* Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
40816308|NCT03982719|OTHER|Intense protocol|This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
40816309|NCT04556955|DEVICE|Graston technique|Experimental group included Graston technique :The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min.
40816310|NCT04556955|OTHER|post isometric relaxation|Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier
40816311|NCT00948233|BEHAVIORAL|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
41334269|NCT04557618|DEVICE|Sham Auricular Vagus nerve Stimulation|Transcutaneous auricular vagal nerve ear clip applied without current
41334270|NCT03708757|OTHER|Post isometric relaxation - Group I|Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
41334271|NCT03708757|OTHER|Eccentric Muscle contraction - Group II|and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
41334272|NCT00608842|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
41334273|NCT00608842|DRUG|Placebo|Matching vehicle placebo administered via intralipomal injection.
40816312|NCT00948233|BEHAVIORAL|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
40816313|NCT00948233|BEHAVIORAL|Surveys|Computer surveys taken at 4 points throughout the study.
40816314|NCT04017923|DIAGNOSTIC_TEST|measurement of nasal tip support in different age groups.|Nasal tip resistances , were measured in all age groups with a digital Newton meter.
40816315|NCT04655755|DRUG|Decitabine and Cedazuridine|Given PO
41334274|NCT05744323|OTHER|Functional training|Physical and motor function training for children,may use BOSU balls, medicine balls, balance mats, fitness steps, and other training equipment to improve gradually
41334275|NCT04727645|OTHER|Philips interventional MRI suite (Philips Healthcare, Best, the Netherlands)|iSuite is an an electroanatomical mapping system (EAM) designed to support real-time MRI guided interventional procedures.
41334276|NCT05761860|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone 5mg oral administration
41334277|NCT05761860|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oxycodone 2.5mg oral administration
41334278|NCT05761860|OTHER|Placebo oxyCODONE Oral Tablet|Oxycodone 0mg (placebo) oral administration
41483876|NCT03585465|DRUG|Capecitabine|"* Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~* Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
41483877|NCT03585465|DRUG|Nivolumab|"* Arm A, B or C (First stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle~* Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle"
41483878|NCT02890030|BEHAVIORAL|Questionnaire|"* Neurotoxicity~* Medications of interest~* General health~* Family history"
40816316|NCT04655755|DRUG|Venetoclax|Given PO
41334279|NCT05761860|DRUG|Oxytocin Nasal Spray (48 IU)|Intranasal oxytocin administration (48 IU)
41334280|NCT05761860|OTHER|Placebo Oxytocin Nasal Spray|Intranasal oxytocin placebo administration
41334281|NCT05512312|PROCEDURE|Conventional Esthetic crown lengthening|Conventional Surgical Esthetic Crown Lengthening
41334282|NCT05512312|PROCEDURE|Computer guided Esthetic crown lengthening|Computer guided Esthetic crown lengthening
41334283|NCT05883345|DIAGNOSTIC_TEST|Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin levels|Endoscopic biopsy
41334284|NCT00113711|BEHAVIORAL|smoking cessation|
41334285|NCT00113711|BEHAVIORAL|reducing diet|
41334286|NCT02126813|PROCEDURE|increased interventional threshold for urinary bladder catheterization (800 ml)|
41334287|NCT02126813|PROCEDURE|Current used interventional threshold for urinary bladder catheterization (500 ml)|
41334288|NCT02126813|DEVICE|Intermittent bladder catheter|
41334289|NCT02324738|DRUG|Mefloquine and Dihydroartemisinin-piperaquine|2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
41334290|NCT02324738|OTHER|Wash-out period|
41334291|NCT02324738|DRUG|Mefloquine|2 tablets of Mefloquine single dose
41334292|NCT02938507|DRUG|Formulation 1 solabegron|
41483879|NCT01415219|OTHER|Active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
41334293|NCT02938507|DRUG|Formulation 2 solabegron|
41483880|NCT02902718|DEVICE|mē|The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
41483881|NCT03274882|DRUG|S95005|The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
41483882|NCT05637437|BEHAVIORAL|Peer supported diabetes self-care intervention|"Participants in the intervention group will attend a multi-faceted 8 weeks peer supported diabetes self-care intervention through digital communication.~* Weekly group video telephony meeting facilitated by trained peer supporters.~* Support and assistance through instant messaging services between peer supporters and participants."
41483883|NCT05637437|OTHER|Usual care|Participants in the control group will receive the usual care of the hospital.
40816317|NCT00733161|OTHER|Passive leg cycle exercise with stretching and resistance training|Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
40816318|NCT00733161|OTHER|Stretching and resistance training|Stretching and resistance training everyday but no Passive leg cycle exercise
41334294|NCT02783209|PROCEDURE|Cataract surgery|
41334295|NCT02220361|DRUG|placebo|received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.
41334296|NCT02220361|DRUG|low dose dexmedetomidine|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.
41334297|NCT02220361|DRUG|high dose dexmedetomidine|"received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.~The infusion was completed in 30 minutes"
41334298|NCT00136838|BEHAVIORAL|Neutral or active cigarette cues|Packets of cigarettes or cigarette smoke.
41334299|NCT03079557|DRUG|Intragastric botulinum toxin type A|200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
41334300|NCT01287598|DRUG|Regorafenib (Stivarga, BAY73-4506)|BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
41334301|NCT01287598|DRUG|Warfarin|CYP 2C9 (warfarin) at Cycle 1
41334302|NCT01287598|DRUG|Omeprazole|CYP 2C19 (omeprazole) at Cycle 1
41334303|NCT01287598|DRUG|Midazolam|CYP 3A4 (midazolam) at Cycle 1
41334304|NCT01287598|DRUG|Rosiglitazone|CYP2C8 (rosiglitazone) at Cycle 1
41334305|NCT02293824|DRUG|Caffeine|Given per standard of care.
41483884|NCT02415569|DRUG|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
41483885|NCT02415569|DRUG|2L PEG-ELP and 10mg bisacodyl|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
41483886|NCT02415569|DRUG|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
41483887|NCT00069836|DRUG|Rosiglitazone/metformin|
41483888|NCT02548312|OTHER|Variations of financial competing interest statements|Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.
40816319|NCT05250635|DEVICE|electronic stethoscope|It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
41334306|NCT05845489|DRUG|Clopidogrel treatment group|Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.
41334307|NCT05845489|OTHER|No antiplatelet or anticoagulant group|Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.
41334308|NCT01024920|DRUG|BIBF 1120|VEGF inhibitor
41334309|NCT01024920|DRUG|sunitinib|VEGF inhibitor
41334310|NCT03949543|OTHER|Large Lunch Intervention|Participants were asked to consume 60% of their daily energy requirements as lunch, between 12:30 and 13:30. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as dinner.
41334311|NCT03949543|OTHER|Large Dinner Intervention|Participants were asked to consume 60% of their daily energy requirements as dinner, between 19:30 and 20:30, each day during their two dietary interventions. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as lunch.
41334312|NCT00305812|DRUG|dexamethasone|
41334313|NCT00305812|DRUG|lenalidomide|
41334314|NCT00305812|DRUG|melphalan|
41334315|NCT04131985|PROCEDURE|Erector Spina Block|After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
41334316|NCT00439725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
41334317|NCT00439725|DRUG|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
40816320|NCT02731677|OTHER|Acupuncture|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
41014079|NCT06411691|DRUG|Balstilimab|"75 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on day 1 and day 15 during Cycle 1 in Prime Phase and on day 1 and day 15 of every cycle in the Boost Phase beginning on Cycle 2 (for a maximum of 2 years from initial vaccination).~Drug: 75 mg IV"
41014080|NCT06411691|DRUG|Botensilimab|"240 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on Cycle 1 day 1 in Prime Phase and on Cycle 2 day 1 in the Boost Phase.~Drug: 240 mg IV"
41014081|NCT05487170|DRUG|RNK05047|RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
40816321|NCT01950351|OTHER|Laboratory Biomarker Analysis|Correlative studies
40816322|NCT01950351|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
40816323|NCT01950351|OTHER|Quality-of-Life Assessment|Ancillary studies
41334318|NCT01947647|BEHAVIORAL|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
40816324|NCT03269968|DEVICE|Negative pressure wound therapy (PREVENA Incision Management Therapy System)|After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
40816325|NCT03269968|DEVICE|Standard dressing|After cesarean delivery, women in the intervention group will receive standard dressing.
40816326|NCT05464641|OTHER|Oxford knee score|The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse
40816327|NCT04854525|RADIATION|Pre reconstruction Radiotherapy|Previous PMRT
40816328|NCT05641428|DRUG|ARI-0001|Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
40816329|NCT05641428|DRUG|Axi-cel|Infusion with a single target dose of 2.0 x 10\^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
40816330|NCT00886886|DRUG|MDMA|125 mg, single dose
40816331|NCT00886886|DRUG|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
40816332|NCT00886886|DRUG|Placebo|capsules identical to MDMA or Reboxetine
40816333|NCT00584090|DRUG|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
40816334|NCT00584090|DRUG|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
40816335|NCT03195348|OTHER|HBF Bed Rest|7 days of bed rest on hyper-buoyancy floatation (HBF)
41334319|NCT01947647|BEHAVIORAL|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
41334320|NCT00063310|DRUG|Leuprolide acetate|
41334321|NCT01390038|DEVICE|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
41483889|NCT02744131|DRUG|Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|
41483890|NCT02744131|DRUG|Metformin 1500mgs per day|
41483891|NCT00772720|DRUG|raltegravir|raltegravir 400 mg BID for 7 days
41483892|NCT00772720|DRUG|Placebo|Placebo BID for 7 days
41483893|NCT02582918|BEHAVIORAL|Outreach with patient education and patient navigation services|"* Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~* Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~* If results are normal, the patient is invited to repeat screening in 6 months.~* If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~* If CT/MRI is unremarkable, the patient is referred back for routine screening.~* If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~* All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic."
41014094|NCT02535702|OTHER|In vivo MRS|1H MR spectroscopy to assess brain metabolites.
41483894|NCT03356886|PROCEDURE|Spinal Manipulative Technique|1) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
41483895|NCT03356886|BEHAVIORAL|Pain Neuroscience Education|All participants in the PNE + SMT group will initially receive a workshop on PNE in which different concepts of pain neuroscience and pain reconceptualization will be discussed and a power-point presentation with metaphors and animated videos on the topic will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The topics of the intervention program will be divided into four thematic topics according to Explain Pain concepts.
41014095|NCT02535702|OTHER|fMRI|Three fMRI sessions to assess test-retest reliability of functional connectivity (FC) measures at rest and during task performance.
41483896|NCT03846713|PROCEDURE|non-thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.
41483897|NCT03846713|PROCEDURE|thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).
41014096|NCT02535702|OTHER|EEG/EOG|Electroencephalography or electrooculography (EEG/ EOG) sessions to record electrical activity of the brain or measure corneo-retinal standing potentials.
41483898|NCT04524052|DRUG|DWRX2003|Intramuscularly injection at pre-defined injection sites
41483899|NCT04524052|DRUG|Placebo|Intramuscularly injection at pre-defined injection sites
41483900|NCT00375570|DRUG|ME-609|Topical treatment 5 times daily for 5 days
41483901|NCT00001713|DRUG|Recombinant Tissue Plasminogen Activator|
41483902|NCT00001713|DRUG|Heparin|
41483903|NCT00001713|DRUG|Warfarin|
41483904|NCT00593632|DIETARY_SUPPLEMENT|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
41334322|NCT03563261|DIETARY_SUPPLEMENT|Collagen supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
41334323|NCT03563261|DIETARY_SUPPLEMENT|Placebo supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
41334324|NCT04037007|PROCEDURE|Fistulotomy - High experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
41334325|NCT04037007|PROCEDURE|Fistulotomy - Low experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
41334326|NCT04037007|PROCEDURE|Conventional (guidewire) cannulation- High experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
41334327|NCT04037007|PROCEDURE|Conventional (guidewire) cannulation - Low experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
41334328|NCT04238611|DEVICE|Microneedle|Lactate microneedle applied on the skin of participant
41334329|NCT04238611|DIAGNOSTIC_TEST|Blood lactate measurement|Serum lactate testing through conventional laboratory methods
41334330|NCT04238611|OTHER|Exercise regimen|Standardised aerobic exercise regimen
41334331|NCT03351010|BEHAVIORAL|Mindfulness training program|The mindfulness training program is a self-awareness mindfulness training program by performing the 15-position hand movement series
41334332|NCT03351010|DEVICE|Cancer pain educational program|A cancer pain education program by using Videos and personalized face-to-face techniques
41334333|NCT05801172|PROCEDURE|ketoprofen for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy
41334334|NCT05801172|PROCEDURE|ketoprofen plus infiltration anesthesia with lidocaine for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in intracervical administration at the start of the procedure
41334335|NCT05801172|PROCEDURE|ketoprofen plus paracervical block anesthesia with lidocaine for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in paracervical block at the start of the procedure
41334336|NCT06268483|DIETARY_SUPPLEMENT|HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg + cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group I: an oral preparation (capsule) of HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg once a day in the morning plus an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
41334337|NCT06268483|DIETARY_SUPPLEMENT|cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group C: an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
41334338|NCT06398444|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Participants will receive 7.4GBq (200mCi) Lutetium\[177Lu\] Oxodotreotide Injection every 8 weeks.
41334339|NCT05906992|BIOLOGICAL|CT-P53|Intravenous(IV) infusion
41483905|NCT06489938|BEHAVIORAL|Mirror therapy|In mirror therapy, a wooden mirror (41×50×33 cm3) will be positioned in the participant's sagittal midplane, blocking the participant's view of the affected arm performance. We will also provide a foldable bed tray table to ensure that the participants focus on the mirror reflection of the less affected arm. The mirror therapy will consist of movement and functional practices.
41334340|NCT05906992|BIOLOGICAL|US-Ocrevus|Intravenous(IV) infusion
41334341|NCT05906992|BIOLOGICAL|EU-Ocrevus|Intravenous(IV) infusion
41483906|NCT06489938|BEHAVIORAL|Task-oriented approach|The task-oriented approach will provide both bimanual common-goal and dual-goal tasks for the participants.
41483907|NCT06489938|BEHAVIORAL|Impairment-oriented approach|The impairment-oriented approach will focus on the movement components. Arm BASIS or Arm Ability training will be provided based on the severity of the participant's impairment.
40816336|NCT04864626|OTHER|semi-standardized interview|annual collection of the number of consultations and hospitalizations at the center, as well as the number of treatments
40816337|NCT04864626|OTHER|care experience questionary|questionary with 12 questions to rate the quality of the telephone reception and your feelings during the interview
40816338|NCT03170115|DRUG|Aspirin|chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
40816339|NCT03170115|DRUG|Placebo Oral Tablet|chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
40816340|NCT00426816|DRUG|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
40816341|NCT00426816|DRUG|Placebo|Placebo to match SB-649868
40816342|NCT00733200|PROCEDURE|Minor or Major Liver Resection|
40816343|NCT03344549|BEHAVIORAL|Renal nutrition teleconsultation|Renal Nutritional teleconsultation for patients with diabetic kidney disease without dialysis, monthly for 4 months.
40816344|NCT03344549|BEHAVIORAL|Face-to-face consultation of renal nutrition|Face-to-face consultation of renal nutrition for patients with diabetic kidney disease without dialysis, monthly for 4 months.
40816345|NCT00311194|BEHAVIORAL|6 months readmission rate to hospital|
40816346|NCT04767581|DRUG|KHK7791|oral administration
40816347|NCT04767581|DRUG|Placebo|oral administration
40816348|NCT01611363|DRUG|ASP1941|Oral
40816349|NCT01611363|DRUG|Placebo|Oral
40816350|NCT03735199|DEVICE|PCL-TCP scaffold|During the surgery, the scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
41334342|NCT01666860|PROCEDURE|Anterior Lumbar Interbody Fusion procedure|
41334343|NCT01109069|DRUG|PCI-32765|Dose based on parent protocol
41334344|NCT01646853|RADIATION|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
41334345|NCT01646853|DRUG|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
41334346|NCT00809861|PROCEDURE|volar locking plating|open reduction and internal fixation
41483908|NCT01698775|DRUG|Omarigliptin|Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
40816351|NCT03735199|DEVICE|Geistlich Bio-Gide collagen membrane|A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
40816352|NCT05598944|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
40816353|NCT05598944|BEHAVIORAL|Más Presente, the UGRComp program|"Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life."
40816354|NCT05598944|OTHER|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
40816355|NCT04607213|PROCEDURE|Advancement-rotation approach based on Millard' for repairing lip defect.|"patients were treated using Millard technique is the downward rotation of the medial part of the flap, and lateral advancement of the flap to close and fill the defect. if more lip height is needed; cut- as- you-go by adding a back-cut incision at the end of his rotation incision down toward the philtral ridge of non-clefted side. Moreover; C-flap is used to close nasal sill."
41334347|NCT00809861|PROCEDURE|external immobilisation|closed reduction and external fixation
41334348|NCT01712503|DEVICE|Phacoemulsfication cataract surgery and intra-ocular lens implant|
41334349|NCT02345044|DRUG|CS-3150|
41334350|NCT02345044|DRUG|placebo|
41334351|NCT02345044|DRUG|eplerenone|
41334352|NCT00719537|DRUG|Aspirin|Aspirin 81 mg once a day
41334353|NCT00719537|DRUG|Placebo Oral Tablet|Placebo 1 tab Daily
41334354|NCT00719537|DRUG|Progesterone|Oral Progesterone 200 mg Twice Daily
41483909|NCT01698775|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
41483910|NCT01698775|DRUG|Glipizide|Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
41483911|NCT01698775|DRUG|Placebo to glipizide|Matching placebo to glipizide daily
41483912|NCT01698775|BIOLOGICAL|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
40816356|NCT04607213|PROCEDURE|Straight-line approach|"patients were treated using Straight-Line design based on Fisher modification. C-shaped flap extend from the proposed nasal sill to the origin of philtral column of medial flap as a straight incision to the planned top of the cupid's bow. In addition, to the previous mentioned incision, small inlate incision is needed to length the cleft side on the medial flap.~On the other hand, on the lateral flap; two connected triangular incisions are used; one on the vermillion border at Noordhoff's point. And the other one just above the cutaneous margin to improve aesthetic outcome and diminish formed scar."
41334355|NCT05845008|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Acetaminophen/naproxen sodium fixed combination tablets, oral.
41334356|NCT01729663|BIOLOGICAL|CSF470 vaccine, BCG, Molgramostim|
41483913|NCT03014336|DEVICE|memsorb|memsorb is a CO2 filter replacing current chemical CO2 absorbers
41334357|NCT01729663|DRUG|interferon alpha 2b|
41334358|NCT03180242|BIOLOGICAL|EG12014|EG12014, single-dose IV infusion over 90 min at 6 mg/kg
41334359|NCT03180242|BIOLOGICAL|EU-sourced Herceptin|EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
41483914|NCT02140866|OTHER|Hand Exercise|
41483915|NCT02140866|OTHER|Compensatory Intervention Program (CIP)|
41334360|NCT03180242|BIOLOGICAL|US-sourced Herceptin|US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
41483916|NCT06052488|BEHAVIORAL|Strength After Breast Cancer|Individual physical therapy evaluation and 4 group-based exercise sessions led by a licensed physical therapist
41334361|NCT00255879|DRUG|Quetiapine|
41334362|NCT00255879|DRUG|Risperidone|
41334363|NCT00255879|DRUG|Olanzapine|
41334364|NCT05343585|DEVICE|PortionSize AI|For this pilot study, using a convenience sample, the investigators will recruit up to 25 adults to use the Nutrition AI technology in Openfit to identify and estimate portion size of foods provided in a laboratory setting at Pennington Biomedical Research Center (PBRC) and/or Louisiana State University (LSU). Laboratory members within the Ingestive Behavioral Laboratory will also test the ability of Nutrition AI to identify foods and to quantify foods provided in the laboratory. Meals will be simulated, and participants will not consume the foods provided.
41334365|NCT03489850|DRUG|Ibudilast|Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
41334366|NCT03489850|OTHER|Placebo|Placebo is matched to ibudilast active medication.
41483917|NCT03345394|BEHAVIORAL|Contingency Management|Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples
41483918|NCT03345394|BEHAVIORAL|Standard treatment|Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program
41483919|NCT05992376|BEHAVIORAL|Food system and demand generation|The Vegetables for All program will create FitFood Zones (FFZs) in low-income estates in urban and peri-urban areas with a minimum of 1,000 households and 10 mama mbogas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will support mama mbogas to source vegetables from Good Agricultural Practices (GAP)-compliant suppliers, support the uptake of digital solutions for mama mbogas to access vegetables, create business-to-business mentorship opportunities, and support county governments to improve market infrastructure. To encourage BoP parents of children 3-11 years to buy and consume more vegetables, the program will include a demand generation component. This will be implemented through a communication campaign, including above-the-line (ATL) activities (mass media such as radio and television), below-the-line (BTL) activities (market activations and others), and FFZ branding.
41483920|NCT03633448|DRUG|Children's Mucinex® Grape Flavor|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
41483921|NCT03633448|DRUG|Children's Mucinex® Grape Flavor|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
41483922|NCT02177136|DRUG|Obeticholic Acid (OCA)|
41483923|NCT02177136|DRUG|Placebo|
41483924|NCT06140121|BEHAVIORAL|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
41483925|NCT06140121|BEHAVIORAL|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
41483926|NCT00391079|DRUG|Sativex|"Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg."
41483927|NCT00391079|DRUG|Placebo|Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
41483928|NCT02511899|DIETARY_SUPPLEMENT|Mango fruit powder|Dietary supplement; Mango fruit powder
41483929|NCT02566993|DRUG|Lurbinectedin (PM01183)|
40816357|NCT06571591|DRUG|CT-L03 Group 1|tablets, QD, oral administration
40816358|NCT06571591|DRUG|CT-L03 Group 2|tablets, QD, oral administration
41334367|NCT05850013|DEVICE|Lifelight Junior|Lifelight® is an app developed by xim that measures VS including heart rate, respiratory rate and blood pressure. All you need to do to have these vital signs measured is look at your smartphone or tablet camera for 20-40 seconds. The app has used data from over 1 million heartbeats to learn how to measure these vital signs in adults. The technology is already available for doctors and nurses to use with adult patients in some specific scenarios
41334368|NCT03515213|DRUG|Fenofibrate|145mg of fenofibrate
41334369|NCT03515213|DRUG|Placebo|Placebo
41334370|NCT03214328|DIAGNOSTIC_TEST|Determination of causes of fetal death|Determination of causes of fetal death using systematic protocol testing
41334371|NCT01960504|DEVICE|Percutaneous Coronary Intervention (DREAMS) stenting|
41334372|NCT05270083|DIAGNOSTIC_TEST|NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)|Participants will receive an intravenous (IV) dose of 300 MBq of Neuraceq™ in a volume of 10 mL or less. A 30 minute duration PET image will be acquired starting immediately after Neuraceq™ injection. A second 20-minute duration PET image will be acquired starting 90 minutes after Neuraceq™ injection.
40816359|NCT06571591|DRUG|Placebo|tablets, QD, oral administration
40816360|NCT06571591|DRUG|Empagliflozin|tablet, QD, oral administration
41334373|NCT01879813|DIETARY_SUPPLEMENT|Phospholipid drink|Participant in an intervention parallel group will consume a drink with added phospholipids
41334374|NCT01879813|DIETARY_SUPPLEMENT|Placebo milk drink|Participant in an intervention parallel group will consume a drink without added phospholipids
41334375|NCT02305290|PROCEDURE|Endoscopic Mucosal Resection|
41334376|NCT04018157|DRUG|"Ketamine and dexmedetomidine and propofol and 0.9%saline"|patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
41483930|NCT02566993|DRUG|Doxorubicin (DOX)|
41483931|NCT02566993|DRUG|Cyclophosphamide (CTX)|
41483932|NCT02566993|DRUG|Vincristine (VCR)|
41483933|NCT02566993|DRUG|Topotecan|
41483934|NCT03212521|DRUG|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
41483935|NCT01524913|DRUG|Hyaluronic acid|1 cc hyalgan to be injected into superior joint space
41483936|NCT01524913|DRUG|Corticosteroid|1cc celestone (6 mg/cc) will be injected into the joint space
41483937|NCT01524913|DRUG|Lactated Ringers|1 cc lactated ringers solution will be injected into the joint space
41483938|NCT02482493|DEVICE|Sigma PFC|patients will receive either an all polyethylene tibial component or a metal- backed component
41483939|NCT00040248|DRUG|Daclizumab|
41483940|NCT05060133|PROCEDURE|Orthognathic Surgery|Surgical corrections of dentofacial deformities and malocclusions.
41483941|NCT04656730|DRUG|Iberogast® and Iberogast® N|Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
41483942|NCT06165666|OTHER|Approach by functional objectives|The therapeutic approach that will be administered to the EG will be based on the training of specific tasks aimed at functional objectives. Each session will begin with activities to activate the muscles of the trunk, pelvis and lower limbs, to modify atypical movement patterns and prepare the muscles for a more effective contraction. Subsequently, activity training will be carried out in a functional and meaningful context, aimed at specific and significant functional objectives for the participant and previously agreed upon with them.
41483943|NCT06165666|OTHER|Treatment protocol|The therapeutic approach of the participants assigned to the CG will be aimed at maintaining joint ranges and transfer work, passive mobilization of the paretic lower and upper limb, maintenance of sitting posture with/without assistance, transfer from sitting to standing, from standing to sitting. and coordination work. Subsequently, initiation of walking with a support product and/or help, if possible.
41483944|NCT03772431|OTHER|Female Voice|The survey was narrated by a female voice
41483945|NCT03772431|OTHER|Motivational Introduction|The survey introduction was worded to include motivational content
41483946|NCT03772431|OTHER|Male Voice|The survey was narrated by a male voice
41483947|NCT03772431|OTHER|Informational Introduction|The survey introduction was worded to include informational content
41483948|NCT04775420|DIAGNOSTIC_TEST|Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)|MPV and NLR are easily accessible and inexpensive tests
41483949|NCT00266526|BIOLOGICAL|Recombinant birch pollen|
41483950|NCT03329807|DEVICE|Transcranial Magnetic Stimulation|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.
41483951|NCT03329807|BEHAVIORAL|conventional sensory therapy|Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week.
41483952|NCT02664363|BIOLOGICAL|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
41483953|NCT02806258|RADIATION|Accelerated partial breast irradiation|To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.
41483954|NCT02806258|DRUG|Chemotherapy|minimum of six cycles of PST using anthracycline and/or taxane based regimens
41483955|NCT04906083|DRUG|Avatrombopag|"Avatrombopag:~PLT：30\~50×10\^9/L patients, 40 mg/d; PLT：\<30×10\^9/L patients, 60 mg/d."
41483956|NCT04906083|DRUG|Standard medical treatment|Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
41483957|NCT04146506|OTHER|Muscle stretching exercises|Muscle stretching exercises consisting of static stretching exercises of the knee flexors
41483958|NCT04691050|PROCEDURE|OrthoMTA (BioMTA)|Primary second molars without successors in which traditional root canal treatment with gutta-percha could not be performed was treated with OrthoMTA
41483959|NCT00407693|DRUG|[C-11]PRB28|
41483960|NCT04971044|BEHAVIORAL|COACH|Multi-Level Behavioral Intervention
40816361|NCT06571591|DRUG|Metformin|tablets, oral administration
41334377|NCT00635440|DEVICE|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
41483961|NCT04971044|BEHAVIORAL|School Readiness Intervention|Multi-Level Language and School Readiness Intervention (Control Group)
41483962|NCT04243408|OTHER|Autologous umbilical cord blood transfusion|single dose of an autologous umbilical cord blood transfusion
41483963|NCT04243408|OTHER|placebo|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml
41483964|NCT03735134|DRUG|Colchicine Loading Dose|Two milligrams of colchicine will be administrated in addition to the standard of care treatment
40816362|NCT05867420|BIOLOGICAL|ASKG915|ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
41334378|NCT00635440|DEVICE|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
41483965|NCT03735134|DRUG|Standard of care treatment prior to elective PCI|All medications normally given to patients prior to elective PCI
41483966|NCT01174082|BIOLOGICAL|KLH Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
41334379|NCT02131246|DRUG|Faster-acting insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
41334380|NCT02131246|DRUG|insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
41334381|NCT05721560|DEVICE|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
41334382|NCT03625089|DRUG|Atorvastatin|"Group 1 patients will be prescribed statin when FRS \> 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS\>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom."
41334383|NCT06167278|OTHER|Indirect bonding with two different digital bracket bonding transfer tray|"To achieve more precise and predictable result is the common aim in contemporary treatment. Digital indirect bonding (IDB) is used for this purpose in orthodontic treatment. The aim of this study is to compare the transfer accuracy of two different IDB trays.~Digital IDB was performed on a total of 30 patients, using one of the two designs: shell and bar trays; with 15 patients in each group. Trays were designed with the Appliance Designer software (3Shape A/S, Copenhagen, Denmark) as shell and bar types."
41334384|NCT05430204|DEVICE|Group 1: one-hour GCT|Group I will be comprised of one-hour 50g glucose challenge participants for diagnosis of GDM..Diagnosis will be based on 1-hour glucose challenge test results: 1-hour result ≤ 130 mg/dL, the participant will have passed the challenge test. 1-hour result ≥ 130 mg/dL will complete a three-hour 100g glucose tolerance test. If two out of three values are elevated per Carpenter Coustan criteria , the participant will be diagnosed with GDM and treated according to the standard of care. This group will also receive the CGM.CGM data will not be observed until completion of study and will not be available to provider. Participants will return transmitter at follow up visit after completion of 7 days.Group I will receive routine prenatal care follow-up depending upon one-hour glucose results as written above.
41334385|NCT05430204|DEVICE|Group 2: CGM placement|"CGM will consist of using the Dexcom G6 Pro device. The device will be placed on the abdomen or the arm.The Dexcom G6/G7 Pro App will be downloaded on the patient's phone. A patient profile will be created on the Dexcom Clarity portal .The patient will receive an email to link their portal to the clinic's portal.The patient will receive a message through Epic electronic medical records to remove the CGM 10 days after placement.The device will be reviewed by the Diabetes team 48 hours after CGM is removed. The recommended range for glucose during pregnancy is defined as 63-140 mg/dL .The time above range has been defined as ≥ 140 mg/dL, greater than 10% of total CGM placement time. The following criteria will currently be used to diagnose gestational diabetes in the CGM group:~* Time above range (≥140 mg/dL) ≥ 10% of the time while using CGM or~* Average glucose≥130 mg/dL or~* Any glucose value ≥200 mg/dL"
41334386|NCT00750217|DRUG|Buprenorphine patch and sublingual tablets|"Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.~Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake."
41334387|NCT00740363|DRUG|sitagliptin|Once daily sitagliptin. If GFR\>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
41334388|NCT00740363|DRUG|placebo|No active sitagliptin treatment for 4 weeks
41334389|NCT01274312|PROCEDURE|Xiao procedure|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
41334390|NCT01587274|DRUG|Naproxen|Naproxen 500mg twice/ day x 10 days
41334391|NCT01587274|DRUG|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
41334392|NCT01587274|DRUG|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
41483967|NCT01174082|BIOLOGICAL|KLH-id Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
41483968|NCT01174082|DRUG|GM-CSF|250 mcg/m2 subcutaneously daily for 4 days after each vaccine
41483969|NCT01174082|PROCEDURE|Apheresis|Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.
41483970|NCT01174082|PROCEDURE|Donor Lymphocyte Infusion (DLI)|Day 0, infusion to patient of collected donor cells.
40816363|NCT03004261|BIOLOGICAL|donor derived cytomegalovirus specific T lymphocytes|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
40816364|NCT03004261|DRUG|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
41483971|NCT03173053|DRUG|Doxycycline|tablet
41483972|NCT03173053|DRUG|Trimethoprim|tablet
40816365|NCT03004261|DRUG|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
40816366|NCT00090233|BIOLOGICAL|Rotateq™|3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
41483973|NCT03173053|DRUG|Sulfamethoxazole/trimethoprim|tablet
41014097|NCT02535702|OTHER|Stimulation tasks|To be used in the context of fMRI to study blood-oxygenation-level- dependent responses in the brain to sensory stimulation.
41014098|NCT02535702|OTHER|NSPRD|To be used in conjunction with pupillometry in the context of fMRI to study blood-oxygenation-level-dependent responses to selective neurostimulation of pain fibers.
41014099|NCT02535702|OTHER|Structural MRI|High spatial MRI and diffusion tensor imaging (DTI) to assess brain morphology and structural connectivity.
41014100|NCT06528340|PROCEDURE|spontaneous delivery|The women will be followed until the birth, in which the 3 traditional 3 methods will be carried out (spontaneous, vaginal operating, abdominal operation)
41334393|NCT00825149|DRUG|Bendamustine|Bendamustine will be administered as per schedule specified in the respective arm.
41334394|NCT00825149|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per schedule specified in the respective arm.
41334395|NCT00825149|DRUG|Doxorubicin|Doxorubicin will be administered as per schedule specified in the respective arm.
41334396|NCT00825149|DRUG|Fludarabine|Fludarabine will be administered as per schedule specified in the respective arm.
41334397|NCT00825149|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
41334398|NCT00825149|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
41483974|NCT03173053|DRUG|Clindamycin|tablet
41483975|NCT03173053|DRUG|Clarithromycin|tablet
41483976|NCT03173053|DRUG|Ciprofloxacin|tablet
41334399|NCT00825149|DRUG|Vincristine|Vincristine will be administered as per schedule specified in the respective arm.
41334400|NCT00416312|DEVICE|Patient-specific dosimetry|"Tumor absorbed dose calculation using patient-specific 3D-RD dosimetry software.~Patients receive dosimetric tositumomab IV over 60 minutes followed by iodine I 131 (\^131I) tositumomab IV over 20 minutes on day 0. Patients undergo PET/CT scans and SPECT/CT scans on days 0; 2, 3 or 4; and 6 or 7. Patients who have acceptable biodistribution receive therapeutic tositumomab IV over 60 minutes followed by \^131I tositumomab IV over 20 minutes on approximately day 7."
41334401|NCT00416312|DEVICE|conventional dosimetry|"Doses calculated using conventional dosimetry software.~Patients receive dosimetric rituximab IV followed by indium In 111 (\^111In) ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo positron emission tomography (PET)/CT scans and single-photon emission computed tomography (SPECT)/CT scans between 2-24, 48-72, and 90-120 hours after \^111In ibritumomab tiuxetan administration. Patients who have acceptable biodistribution receive therapeutic rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes between days 7-9."
41334402|NCT05955430|OTHER|Therapeutic exercise|It consists of strengthening exercises and gradual walking. The lower limb strengthening exercises are individualized and progressive for each patient for twelve weeks. There will be eight face-to-face sessions over four weeks. And then the patient will continue with those exercises for eight more weeks. In addition, they must perform twelve weeks of progressive walking until they are walking at least 30 minutes, 5 days a week at a moderate intensity (defined as moderate shortness of breath while walking).
41334403|NCT05955430|OTHER|Pain education|A therapeutic pain education program for patients will be implemented. There will be four 30-minute face-to-face sessions (one session per week). The objective is to change the participants' conceptualization of pain. From seeing pain as a marker of tissue damage to a marker of the body's perceived need for protection. Contents include basic structure of the nervous system, distinction between nociception and pain, peripheral and central sensitization, neuroplasticity and benefits of exercise.
41334404|NCT05955430|OTHER|Percutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four needles located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
41334405|NCT05955430|OTHER|Transcutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four patches located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
41334406|NCT05955430|OTHER|Placebo stimulation|To perform the dry needling placebo, modified needles will be used according to the validation performed by Mitchell et al. 2018, since they generate more puncture sensation than normal needles, which has been shown to generate more analgesia and to be more effective as a placebo. To perform placebo TENS, the protocol established by Rakel et al. 2010 will be used, which consists of applying a TENS of 100 Hz and 100 ms for 30 seconds and then lowering the intensity during the following 15 seconds. Eight sessions will be held during a month (two per week).
41334407|NCT03771495|OTHER|Joint Mobilization|Manual Therapy Intervention, commonly used by physiotherapists
41334408|NCT03771495|OTHER|Laying on of Hands|Sham Hip Joint Mobilization
41334409|NCT01160263|DRUG|SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM|"123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter."
41483977|NCT03173053|DRUG|Fusidic Acid|tablet or ointment
41483978|NCT03173053|DRUG|Rifampin|tablet
41483979|NCT03173053|DRUG|Chlorhexidine|Mouthwash or bodywash
41483980|NCT03173053|DRUG|Mupirocin|Nasal ointment
41483981|NCT03173053|DRUG|Betadine|Shampoo
41483982|NCT06219993|PROCEDURE|robot-assisted modified Kasai portoenterostomy|"1. A 1.0 cm incision was made around the umblilicus for the camera port. 1.Firstly, the Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, and indocyanine green (ICG) cholangiography were observed to confirm the BA diagnosis.~2. dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With electric scissors help, the fibrous plate was horizontally cut from the middle of the portal plate and transected from to the left and to the right sides which was the Glissonian systems enter the liver parenchyma until see the bile outflow by verified by ICG. The opening of microbile ducts and abundant bile outflow were clearly visible under 10× camera of Da Vinci robot."
41483983|NCT06219993|PROCEDURE|traditional open Kasai portoenterostomy|Dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With scissors help, the fibrous cone of the hilar region was transected from left to right (the level of transection depends on adequate bile outflow).
41483984|NCT03026855|BIOLOGICAL|Autologous PRP Gel and PRP Injection|"Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.~Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.~Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment."
40816367|NCT00090233|BIOLOGICAL|Comparator: Placebo|3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
40816368|NCT02513407|BEHAVIORAL|Behavioral Dietary Intervention|Attend healthy nutritional education session
41334410|NCT01350011|BEHAVIORAL|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
41483985|NCT03966482|BEHAVIORAL|Group before-after|The group was submitted to four weeks of speech therapy intervention with Semiocluded vocal tract exercise. The 12 participants were evaluated before and after the intervention with a multidimensional evaluation comprised of analysis of images generated by specialized videonasoendoscopy software, analysis of speech emissions by perceptual-auditory evaluation and acoustic analysis, and vocal self-assessment.
41334411|NCT01350011|BEHAVIORAL|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
40816369|NCT02513407|OTHER|Educational Intervention|Attend EML educational session
41334412|NCT02654275|OTHER|Proprioceptive Intervention|
41334413|NCT01937624|DEVICE|Diagnostic Ultrasound|
41334414|NCT01937624|RADIATION|X-ray imaging|
41334415|NCT04898127|DIAGNOSTIC_TEST|SARS-CoV-2 antigen rapid test|Rapid test before access to mass gathering event (concert), provided the test result is negative.
41483986|NCT04554797|OTHER|Regional Hypothermia|Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain
41483987|NCT04966364|DEVICE|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
40816370|NCT02513407|BEHAVIORAL|Exercise Intervention|Attend exercise educational session
40816371|NCT02513407|BEHAVIORAL|Exercise Intervention|Receive fitness tracker
40816372|NCT02513407|OTHER|Laboratory Biomarker Analysis|Correlative studies
41334416|NCT04902768|OTHER|This is an observational study, there is no intervention|This is an observational study, there is no intervention. Hence, this is not applicable.
41334417|NCT01949857|BIOLOGICAL|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
41334418|NCT01949857|BIOLOGICAL|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
41334419|NCT01949857|BIOLOGICAL|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose
41334420|NCT01949857|BIOLOGICAL|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose.
41483988|NCT04966364|DEVICE|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
40816373|NCT02513407|OTHER|Questionnaire Administration|Ancillary studies
40816374|NCT04271371|OTHER|Not yet developed|A prototype intervention will be developed over Phase 1 \& 2 and piloted in Phase 3 of this study.
40816375|NCT01882426|OTHER|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
40816376|NCT01882426|OTHER|Usual Care|usual step care practice
40816377|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
40816378|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
40816379|NCT05654441|BIOLOGICAL|Influenza vaccine|0.5 mL single-dose injection
40816380|NCT05654441|BIOLOGICAL|Placebo|0.5 mL single-dose injection with no therapeutic effect
40816381|NCT05955924|DRUG|Nicotinamide|Oral nicotinamide (500 mg) twice daily
40816382|NCT05955924|DRUG|Placebo|Matching placebo capsule twice daily
40816383|NCT01180894|DRUG|Iron sucrose|100 mg IV TIW
40816384|NCT01180894|DRUG|Placebo|
40816385|NCT02414945|DRUG|Cyclophosphamide|
40816386|NCT02414945|DRUG|Fludarabine|
40816387|NCT02414945|BIOLOGICAL|Autologous tumor infiltrating lymphocytes (TILs)|
40816388|NCT02414945|BIOLOGICAL|Interleukin-2|
40816389|NCT03023774|DRUG|Neupogen|neupogen 30 IU once intrauterine at the time of ovum pickup
40816390|NCT01498393|DEVICE|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
40816391|NCT02696733|DEVICE|Ultrasound|Ultrasound-guided obturator nerve localization
41334421|NCT05265962|DRUG|Decitabine plus Penpulimab|Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
41334422|NCT00077922|DRUG|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
41334423|NCT05369546|DIAGNOSTIC_TEST|q3CB|The q3CB/ncCEM/DBT acquisition protocol consists of a combination of DBT volume reconstructions and projection dual-energy mammograms acquired with a clinical contrast enhanced mammography (CEM) protocol, without contrast administration agent.
41334424|NCT05822648|BEHAVIORAL|Project Health|Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.
41334425|NCT05822648|OTHER|Educational Video Control|We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
41334426|NCT04800094|DEVICE|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
41334427|NCT02438046|PROCEDURE|Palatal wound bandage|Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
41334428|NCT04411706|DRUG|Sintilimab Combined With Apatinib and Capecitabine|"Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;~Drug: Apatinib,250mg po qd, for continuous medication;~Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;"
41334429|NCT01391338|DRUG|ASP3652|Oral
41483989|NCT05657236|OTHER|medical treatment|traditional medical treatment and regular follow-up
41483990|NCT05657236|OTHER|plyometric exercise|Each session starts with a 5-minute warm-up of flexibility exercises (active range motion and stretching exercises).The main plyometric exercise set will be applied for 20-30 minutes and consisted of 10 exercises directed at the lower body that gradually progress by increasing the set/repetition number in two exercise blocks, each continue for 1 month .The cool down period is 5 minutes and includes walking at self-preferred speed and static stretches of the major muscle groups.
41334430|NCT01391338|DRUG|Placebo|Oral
41334431|NCT02715596|DIETARY_SUPPLEMENT|EPA supplementation|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
41334432|NCT02715596|OTHER|Placebo|placebo in 15 cc emulsion stick-pack
40816392|NCT02696733|DRUG|lidocaine 2%|local anesthetic used to block the obturator nerve
41334433|NCT00457756|DIETARY_SUPPLEMENT|BiosLife Complete|
41334434|NCT00457756|DIETARY_SUPPLEMENT|Placebo|
41334435|NCT06127147|DEVICE|IMT|The IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 60% of each patient's maximal inspiratory pressure.
41334436|NCT06127147|DEVICE|Sham-IMT|The sham IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc) without intensity.
41334437|NCT00631618|DRUG|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
41334438|NCT03350971|OTHER|Virtual reality training|training with Wii games, ergometer exercise, ambulation, standing exercises
41334439|NCT03350971|OTHER|Control|chest physical therapy exercises
41334440|NCT05940441|DRUG|Capecitabine 500Mg Oral Tablet|650 mg/m² body surface area twice daily for 1 year
41483991|NCT04766541|OTHER|no intervention|There is no intervention.
41483992|NCT02540317|BEHAVIORAL|Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
41483993|NCT05236920|DEVICE|Resuscitative Endovascular balloon occlusion of the aorta using a REBOA catheter device|In-hospital use of a REBOA catheter device during advanced cardiac life support
41483994|NCT02630836|DRUG|XCEL-MT-OSTEO-BETA|XCEL-MT-OSTEO-BETA followed by endomedullary nailing
41483995|NCT02630836|PROCEDURE|Surgical treatment|Isolated endomedullary nailing
40816393|NCT02696733|DRUG|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
41483996|NCT00118131|DRUG|cisplatin|
41483997|NCT00118131|DRUG|docetaxel|
41483998|NCT00595686|DRUG|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
41334441|NCT01570309|DRUG|Ergocalciferol|Oral capsule, 50,000 units, once a week, 12 weeks
41334442|NCT01570309|OTHER|Sugar pill|Oral capsule, once a week, 12 weeks
41334443|NCT03381625|DRUG|BMX-010|Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.
41334444|NCT03381625|DRUG|Placebo|Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
41334445|NCT03068936|RADIATION|Intensity modulated radiotherapy|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
41334446|NCT03068936|DRUG|Cisplatin|Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
41334447|NCT06330974|OTHER|No intervention|No intervention
41334448|NCT03152396|OTHER|CV risk assessment and modification of global risk|Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
41334449|NCT06173609|PROCEDURE|CABG|"During coronary artery bypass surgery, the surgeon removes a piece of blood vessel from the leg, chest, arm, or belly. Then, the surgeon uses that piece of blood vessel (called a graft) to reroute blood around the blocked artery."
41334450|NCT06094114|DEVICE|pacemaker follow-up|Performance of an exercise test in patients previously implanted with Micra AV
41334451|NCT05583591|DEVICE|Combined cataract surgery with Hydrus microstent|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
41334452|NCT05583591|DEVICE|Combined cataract surgery with iStent Inject W|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
41483999|NCT04203121|RADIATION|low dose whole brain radiation to treat Alzheimer disease|"subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions"
41014109|NCT04524273|DRUG|inebilizumab|Participants will receive IV inebilizumab
41014110|NCT04524273|DRUG|IV Placebo|Participants will receive IV placebo matched to inebilizumab
41014111|NCT02522611|DRUG|Resiniferatoxin|Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
41014112|NCT01036581|DEVICE|MagPro X100 Magnetic Stimulator|Concurrent TMS-MRI acquisition allows us to investigate the acute effects of induced brain activity on BOLD signal and evaluate interference of the TMS pulse with the BOLD signal measurement.
41334453|NCT05897060|DEVICE|Venus Jugular O2 Saturation optical fiber|A continuous measurement of VjO2S, the usual reference measurement of the marketed devices, will be performed by implanting an optical fiber (CEVOX, PULSION Medical Systems) through an internal jugular catheter in addition to the classical catheter of the external electro-systolic drive probe. The following parameters will be recorded every 2 seconds: invasive blood pressure (systolic, mean and diastolic), heart rate, SaO2 on the pulse wave. VjO2S will be recorded continuously during the entire implantation procedure. The time of the beginning of the surgical incision, of the beginning of sinus tachycardia (overdriving) induced by external electro-systolic stimulation, of the beginning of inflation of the intravalvular aortic balloon, of the maximum occlusion of the balloon, of the end of complete deflation of the balloon, of the end of stimulation and of the end of skin closure will be recorded.
41334454|NCT05007223|DRUG|Doxycycline|200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
41334455|NCT04486989|BEHAVIORAL|Cardiovascular Conditioning Protocol|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
41334456|NCT04486989|OTHER|Voice Production Exercises|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
41334457|NCT05560152|DRUG|Yiqihuayu Decotion|Per os, twice a day, for 7 days.
41334458|NCT03429907|BEHAVIORAL|Mind-Body Exercises|Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.
41334459|NCT03429907|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
41334460|NCT03327519|BEHAVIORAL|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
41334461|NCT03327519|BEHAVIORAL|Emmi|The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
41334462|NCT01060098|DRUG|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
41334463|NCT02939651|DRUG|Pembrolizumab|Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
41484000|NCT00570882|DRUG|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
41484001|NCT00570882|DRUG|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
41484002|NCT05354830|OTHER|Foot Massage|Foot Massage
41484003|NCT00195234|BIOLOGICAL|HIV CTL MEP 1000 micrograms, 19 months per subject|
41484004|NCT02428686|DRUG|Epoetin beta (NeoRecormon)|Epoetin beta 60 000 IU/week
41014113|NCT01036581|DEVICE|Transcranial Rotating Magnetic Stimulator|Participants will undergo transcranial rapid rotating permanent magnetic stimulation (TRPMS), with the aim of evaluating the prolonged effect of TRPMS on motor cortex excitability. In another experiment, participants will undergo TRPMS with the aim of evaluating cortical excitability changes with TRPMS. These experiments will help interpret subsequent experiments investigating the effect of TRPMS on BOLD signal.
41014114|NCT01036581|DEVICE|Magnetom Prisma Fit 3T Scanner|Type: MRI Name: Magnetom Prisma Fit 3T Scanner (Siemens) Description: Functional and structural magnetic resonance imaging techniques are used for noninvasive mapping of brain physiology and pathology and to develop advanced magnetic resonance imaging and spectroscopy (MRI and MRS) techniques for neuroimaging studies related to addiction.
41014119|NCT03191149|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41014120|NCT03191149|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
41014121|NCT03191149|PROCEDURE|Echocardiography|Undergo ECHO
41014122|NCT03191149|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41014123|NCT03191149|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41014124|NCT03191149|DRUG|Osimertinib|Given PO
41014125|NCT01362803|DRUG|AZD6244|AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
41014127|NCT05898399|DRUG|ART6043|ART6043 will be given orally.
41014128|NCT05898399|DRUG|Olaparib|Olaparib will be given orally.
41014129|NCT05898399|DRUG|Niraparib|Niraparib will be given orally.
41014130|NCT04539366|PROCEDURE|Biopsy|Undergo biopsy
41014131|NCT04539366|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41014132|NCT04539366|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41014133|NCT04539366|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41014134|NCT04539366|DRUG|Cyclophosphamide|Given IV
41014135|NCT04539366|PROCEDURE|Echocardiography|Undergo ECHO
41334464|NCT04469257|BEHAVIORAL|Sunbathing|the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open.
41334465|NCT00937326|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
41334466|NCT00937326|DRUG|Placebo|Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
41334467|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
41334468|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
41334469|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
41334470|NCT03809247|OTHER||have no any intervention
40816394|NCT04689490|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Only diagnostic tests
41014136|NCT04539366|DRUG|Fludarabine Phosphate|Given IV
41014137|NCT04539366|BIOLOGICAL|GD2-CAR-expressing Autologous T-lymphocytes|Given IV
41014138|NCT04539366|PROCEDURE|Imaging Procedure|Undergo standard imaging scans
41014139|NCT04539366|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo cardiac MRI
41014140|NCT04539366|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41014141|NCT04539366|OTHER|Questionnaire Administration|Ancillary studies
41014146|NCT03500757|DEVICE|HoloLens|use the HoloLens to evaluate new 3D holographic guidance and navigation for percutaneous ablation of solid tumors
41014150|NCT06048120|DRUG|BAY2701250 IV|Single does, intravenous infusion
41334471|NCT02518542|PROCEDURE|Endoscopic intervention A|POEM: Per oral endoscopic myotomy
41334472|NCT02518542|PROCEDURE|Endoscopic intervention B|PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
41334473|NCT02518542|PROCEDURE|Endoscopic intervention C|Endoscopic balloon dilatation
41334474|NCT02518542|PROCEDURE|Laparoscopic Surgery|Laparoscopic Heller myotomy
41334475|NCT05817981|OTHER|Semi-structured interview|Before the questionnaire survey, 30 cancer survivors and 30 clinical oncology medical staff will respectively participate in different semi-structured interview individually.
41484005|NCT05772806|DEVICE|Electrocardiogram|"The electrocardiogram will help to diagnose atrial fibrillation and the electronic devices (App Fibricheck and Smart bracelet/watch) will help to detect an arrhythmic rhythm.~The echocardiography will be used for detecting criteria of atrial cardiomyopathy.~MRI may help to detect silent strokes."
41484006|NCT01641133|BIOLOGICAL|Synflorix (3-Dose)|3 doses administered intramuscularly
41484007|NCT01641133|BIOLOGICAL|Synflorix (2-Dose)|2 doses administered intramuscularly
41484008|NCT01641133|BIOLOGICAL|Synflorix (Single Dose)|1 dose administered intramuscularly
41484009|NCT01641133|BIOLOGICAL|Prevenar 13 (Single Dose)|1 dose administered intramuscularly
41334476|NCT05817981|OTHER|Questionnaires set|Except for participants who participated in semi-structured interviews, other cancer survivors who met the inclusion criteria will be asked to respond to the demographic information sheet, the cancer related sexual and reproductive health knowledge and attitudes questionnaire, and the access methods and demand for cancer-related fertility information.
41334477|NCT00813917|DRUG|varenicline|12 weeks of varenicline 1 mg by mouth twice per day
41484010|NCT01641133|BIOLOGICAL|Prevenar 13 (2-Dose)|2 doses administered intramuscularly
41484011|NCT02894866|DEVICE|hyperbaric oxygen|The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
41334478|NCT00813917|DRUG|placebo|12 weeks of placebo (double blinded) by mouth twice per day
41334479|NCT01843634|DRUG|ODSH|
41014151|NCT06048120|DRUG|Placebo IV|Matching placebo for BAY2701250 IV
41334480|NCT00206011|PROCEDURE|Endoscopic surgery|Open surgical intervention compared to endoscopic intervention
41334481|NCT06334172|DRUG|Oxytocin|Oxytocin
41334482|NCT06334172|OTHER|Placebo|Saline
41334483|NCT06233214|DEVICE|vein imaging device|"During the PIC application attempt, the parents of the children in the experimental group will be ensured to be with their children throughout the procedure.~PIC placement attempt will be performed on the experimental group with the help of a vein imaging device."
41334484|NCT00460629|PROCEDURE|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
41484012|NCT05918978|DRUG|Efgartigimod|Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
41484013|NCT03679052|DRUG|Mirtazapine|Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.
41484014|NCT03679052|DRUG|Clonidine|Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.
41484015|NCT03679052|DRUG|Placebo|Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
41484016|NCT04248348|DRUG|Low Molecular Weight Heparin|Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)
41484017|NCT06456619|OTHER|Tooth restoration|Comparison of composite resin and CAD-CAM supported restorations for hypomineralized molar teeth in children
41334485|NCT04163913|OTHER|Change in User interfaces of Cirvo compression device application.|Comparison of 2 versions of the Circo user interface
41334486|NCT04163913|OTHER|Change in Satisfaction in use of Cirvo device|Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
41334487|NCT00473044|BEHAVIORAL|Sisters in Motion|
41484018|NCT02867475|OTHER|Physical activity motivation|Physical activity motivation
41484019|NCT00819975|DIETARY_SUPPLEMENT|Casein|
41484020|NCT00819975|DIETARY_SUPPLEMENT|Whey Isolate|
41484021|NCT00819975|DIETARY_SUPPLEMENT|Whey Hydrolysate|
41014152|NCT06048120|DRUG|BAY2701250 SC|Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue
41014153|NCT06048120|DRUG|Placebo SC|Matching placebo for BAY2701250 SC
41014157|NCT03740438|DIAGNOSTIC_TEST|Hemoglobin concentration|Perioperative hemogloin concentration
41014158|NCT05446909|BEHAVIORAL|IBMT mindfulness|IBMT is an effortless mindfulness technique; health education is a class including health-related topics - exercise, sleep, nutrition, lifestyle, stress management
41014159|NCT05446909|BEHAVIORAL|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
41334488|NCT04307953|DRUG|AZD0530 Difumarate|AZD0530 for the duration of the trial
41334489|NCT04307953|DRUG|Matching placebo|Matching placebo during 6 month RCT, AZD0530 thereafter
41484022|NCT00819975|DIETARY_SUPPLEMENT|Alphalact-Albumin|
41484023|NCT00946348|DRUG|Dronabinol|Dronabinol 10 mg or 15 mg
41484024|NCT00946348|DRUG|Cannabis|Cannabis cigarette
41484025|NCT02843594|PROCEDURE|LEEP intervention|Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
41484026|NCT02843594|PROCEDURE|Standard Phaco Control|
41484027|NCT04135196|OTHER|voluntary forearm loading task|voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
41484028|NCT06333223|DIETARY_SUPPLEMENT|Mixture of (Poly)phenols and a probiotic supplement|Mixture of (Poly)phenols and a probiotic supplement
41484029|NCT06333223|DIETARY_SUPPLEMENT|Placebo comparator|Mixture of (Poly)phenols and a placebo maltodextrin comparator
41484030|NCT03022669|BEHAVIORAL|Text Message|Annie (VA text messaging program) or mobile Health manager (private text messaging program for non-VA female participants recruited at non-VA facility)
41484031|NCT03022669|BEHAVIORAL|Mobile Application|
41484032|NCT03022669|OTHER|Website|American Heart Association patient education website
41484033|NCT01826461|DRUG|PDI-192|
41484034|NCT01826461|DRUG|Vehicle|
41484035|NCT05486455|DIAGNOSTIC_TEST|Low-dose chest CT scan|baseline, 1-year, 3-year and 5-year low-dose CT scan
41484036|NCT06388031|DRUG|Immune checkpoint inhibitor|"Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles:~* Pembrolizumab 200mg;~* Tislelizumab 200mg;~* Camrelizumab 200mg;~* Toripalimab 240mg."
41484037|NCT05544565|DRUG|IV Antibacterial Agents|Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .
41484038|NCT05544565|DRUG|Orally antibacterial agents|Cotrimoxazole (sulfamethoxazole/trimethoprime) 30mg/kg/day (2 divided doses) OR Cefixime 8mg/kg/day (2 divided doses) during 7 days
41334490|NCT05939271|PROCEDURE|lower extremity amputation|"persons are defined as having a lower extremity amputation when an operation with removal of an extremity below the hips took place.~To identify those people with diabetes who underwent amputation, the following DBC's claims were extracted from the system: 038590; amputation upper leg, 038690; amputation lower leg, 038691; exarticulation of the lower leg, 038790; amputation of the tarsus, 038791; amputation or exarticulation of a toe, 038793; exarticulation of the foot, 038794; Chopart exarticulation, Lisfranc, respectively trans metatarsal amputation. Amputations were categorized into minor (038790, 038791, 038793, 038794) and major (038590, 038690,038691) amputations"
41484039|NCT05544565|PROCEDURE|Fecal/Rectal Swab|Collected by the nurse or the physician (D0,D3,D14) (and parents for D45), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.
41484040|NCT05544565|PROCEDURE|PCT assay|Dosage of procalcitonin (if not performed in standard care) at D0
41014161|NCT04002297|DRUG|zanubrutinib|Administered as two 80 mg capsules by mouth twice a day
41014162|NCT04002297|DRUG|bendamustine|Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
41334491|NCT03379376|OTHER|Questionnaire Administration|Receive questionnaire
41484041|NCT05544565|PROCEDURE|Renal scintigraphy|A DMSA scintigraphy (99mTc-DMSA) will be performed at 6 months (± 15 days) for evaluation of the kidney growth and renal scars
41484042|NCT04204759|DEVICE|Transcranial direct current stimulation|Non-invasive stimulation will be conducted using a tDCS device (StarStim, Neuroelectrics, Spain).
41484043|NCT04204759|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
41484044|NCT00234455|DEVICE|drug eluting-stent|PCI
40816395|NCT01734954|PROCEDURE|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
41014163|NCT04002297|DRUG|rituximab|Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
41014166|NCT04620603|RADIATION|Low Dose Rate Brachytherapy (LDR)|LDR on treatment day 1
41484045|NCT00234455|DEVICE|drug-eluting stent|PCI
41484046|NCT04795908|DEVICE|Transcranial Magnetic Stimulation|rTMS will be delivered using a MagStim Super Rapid2 TMS therapy system.
41334492|NCT03379376|PROCEDURE|Supportive Care|Undergo eHealth mindful moving and breathing
41334493|NCT02746770|OTHER|Experimental: Cawthorne and Cooksey exercises group|Experimental: intervention group. Patients assigned to the experimental group will perform the Cawthorne and Cooksey exercises for vestibular rehabilitation in addition to their habitual treatment.
41334494|NCT00212758|DRUG|Nutropin AQ|Nutropin AQ
41334495|NCT04961879|PROCEDURE|Reversed Cross Finger Flap|"distal dorsal finger defect will be reconstructed by reversed cross finger flap~- reversed cross finger flap is a modified cross finger flap harvested from an adjacent finger ."
41334496|NCT04961879|PROCEDURE|reversed island homo-digital flap|"distal dorsal finger defect will be reconstructed by reversed island homo-digital flap~- this flap is harvested from the same finger ."
41334497|NCT04128527|DEVICE|Placement of laryngeal mask|All participants are experienced in placement of laryngeal masks and placement will be performed according to standard clinical practice.
41334498|NCT03048409|OTHER|Enteral Formula|Enteral feeding with a peptide-based formula.
41334499|NCT05190536|PROCEDURE|Ho:YAG lasers|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um Ho:YAG laser fiber was used for lithotripsy.Kidney stones were fragmented by Ho:YAG lasers, and sucked out by the suction sheath.
41334500|NCT05190536|PROCEDURE|TFL|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um TFL fiber was used for lithotripsy.Kidney stones were fragmented by TFL, and sucked out by the suction sheath.
41334501|NCT04098263|BIOLOGICAL|LMN-101|variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
41334502|NCT02005783|DRUG|DBD|DBD:one dose of medicine twice per day, orally
41334503|NCT02005783|DRUG|Epirubicin|Epirubicin:90mg/m2, d1, q3w\*4
41334504|NCT02005783|DRUG|Cyclophosphamide|Cyclophosphamide:600mg/m2, d1, q3w\*4
41334505|NCT02005783|DRUG|Docetaxel|Docetaxel:75mg/m2, d1, q3w\*4
41334506|NCT02352103|PROCEDURE|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
41334507|NCT02352103|PROCEDURE|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
41334508|NCT02352103|DEVICE|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
41334509|NCT05241665|DEVICE|SpectraWAVE Imaging System|Coronary imaging
41334510|NCT00838695|DRUG|Phenylephrine|Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)
41334511|NCT05229991|DRUG|Lonafarnib|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
41334512|NCT05229991|DRUG|Ritonavir|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
41334513|NCT02842541|DRUG|EBI-031|
41484047|NCT04795908|BEHAVIORAL|Comprehensive behavioral intervention|Patients will receive CBIT with a therapist trained in CBIT. Each session will last about an hour and will be delivered remotely via telemedicine. Sessions will be tailed to the patient's individual needs.
41484048|NCT02351544|DRUG|Botulinum Toxin Type A|
41334514|NCT01569087|BIOLOGICAL|empegfilrastim|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.
41334515|NCT01569087|BIOLOGICAL|filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
41334516|NCT05073627|DRUG|Dicloxacillin|Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.
41484049|NCT02351544|PROCEDURE|Surgery|
41334517|NCT03636308|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
41334518|NCT03636308|DRUG|S1|S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.
41334519|NCT03636308|DRUG|Gemcitabine|Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
41484050|NCT02351544|OTHER|Daily headache diary|
41484051|NCT02351544|OTHER|Migraine Disability Assessment Test (MIDAS)|
41484052|NCT02351544|OTHER|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
41484053|NCT02351544|OTHER|Migraine-Specific Quality of Life Questionnaire (MSQ)|
41334520|NCT05618327|DRUG|JS203 for Injection|"2-steps:JS203 for Injection is administered on the first and eighth day of the first cycle and every 3 weeks thereafter.~3-steps:JS203 for Injection is administered on the first, eighth and fifteenth day of the first cycle and every 3 weeks thereafter.~4-steps:JS203 for Injection is administered on the first, eighth, fifteenth and twenty-second day of the first cycle and every 3 weeks thereafter."
41334521|NCT04874844|BIOLOGICAL|Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)|"The ratio of subjects in the experimental drug group to the placebo control group is 1:1, and you will have a 50% probability of receiving JY025 combined with gefitinib or erlotinib, and a 50% probability of receiving placebo combined with gefitinib Or erlotinib.~Blind people, researchers, nurses, research assistants, inspectors, applicants and blind statisticians involved in clinical trials."
41334522|NCT05073913|DIAGNOSTIC_TEST|Vascular remodeling characterization|Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with decrease in plasma of Iohexol
41334523|NCT00716989|BIOLOGICAL|Tuberculin antigen|2 intradermal injection of 50µl of antigen + 2 intradermal injection of 50µl of physiological serum
41334524|NCT05690698|DRUG|Quatiapine|Atypical antipsychotic
41334525|NCT05690698|DRUG|Haloperidol|Antipsychotic
41334526|NCT06300567|OTHER|data collection|"collection of data of generated by real world follow up"
41334527|NCT02221960|BIOLOGICAL|MEDI6383|Subjects will receive MEDI6383 until disease progression or adverse event.
41334528|NCT02221960|BIOLOGICAL|MEDI6383 and MEDI4736|Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
41334529|NCT02114489|DRUG|ibandronate|Unique perfusion of ibandronate 3 mg IV
41334530|NCT02114489|DRUG|Placebo|
41334531|NCT00414505|DEVICE|Intradermal Acupuncture Treatment|
41334532|NCT00004014|DRUG|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
41334533|NCT00223912|DEVICE|ERGYS BikeFunctional Electrical Stimulation Ergometry|A
41334534|NCT05197309|DIETARY_SUPPLEMENT|Metabolic Diet|Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.
41334535|NCT01757587|DRUG|Vildagliptin|50 mg, 2 tablets/day on 3 months, both periods of treatment
41334536|NCT01757587|DRUG|Placebo|50mg 2 tablets / day on 3 months, both periods of treatment
41334537|NCT01916187|DRUG|Imetelstat|
41334538|NCT06436820|PROCEDURE|Lumbar puncture|Lumbar puncture procedure performed within a clinical setting
41334539|NCT01271413|BEHAVIORAL|Computerized cognitively stimulating activities|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
41334540|NCT01213290|DEVICE|EUS - FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
41334541|NCT01213290|DEVICE|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
41334542|NCT03271060|PROCEDURE|Posterior lumbar interbody fusion|Lumbar fusion by screws and inter vertebral cage
41334543|NCT03271060|PROCEDURE|Inter transverse bone grafting|Inter transverse process bone grafting by bone graft from illiac crest or other sites
41334544|NCT04097080|DRUG|NBTX-001|Active drug group will receive 6 doses of NBTX-001 given three times a week.
41014167|NCT04620603|DRUG|Standard-of-Care Immunotherapy|Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.
41014168|NCT05827302|DEVICE|Health Gauge AI-Based Wearable Device - Model: Phoenix|Wearable device
41014169|NCT05197049|DRUG|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
41014170|NCT05197049|DRUG|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered by SC injection.
41014171|NCT05197049|DRUG|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered by SC injection.
41014172|NCT05197049|DRUG|Placebo|Placebo will be administered by SC injection.
41334545|NCT04097080|DRUG|Standard of Care|Placebo group will receive reconstituted air given three times a week.
41014179|NCT03663933|DRUG|Immunosuppression Only Conditioning|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -9 and -5, cyclophosphamide:5 mg/kg orally daily on days -9 through -2
41334546|NCT04822441|OTHER|data collection|Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord
41334547|NCT04019392|DEVICE|Game Ready® device|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
41334548|NCT04019392|OTHER|Wetted Ice Bag with Elastic Wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied using an elastic wrap to each participants' lower leg for 30 minutes. An elastic wrap applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half will be applied over the wetted ice bag.
41156138|NCT00588341|DRUG|Temozolomide|"At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.~Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.~After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient."
41156139|NCT03997708|OTHER|Med-LFD|All participants of this group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs).
41156140|NCT03997708|OTHER|Nutritional Guidelines of the British National Institute for Health and Care Excellence (NICE) Managing IBS|All participants of this group will be informed to follow a diet based on the nutritional guidelines of the British National Institute for Health and Care Excellence (NICE) for Managing IBS for 4 weeks.
41156141|NCT06645873|DEVICE|Continuous glucose monitoring (CGM) device|All included study participants recieve a CGM sensor (Dexcom G7) to monitor blood glucose. The treatment team is blind for the CGM values; the gold standard for glucose control (POC interval measures) will be followed.
41334549|NCT01405378|DEVICE|Robot therapy and transcranial direct current stimulation|"Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2)."
41334550|NCT02103881|DRUG|Ketamine|500 mg of intramuscular ketamine for severe pre-hospital agitation
41334551|NCT02103881|DRUG|Haloperidol|Haloperidol 10 mg intramuscular for severe prehospital agitation.
41334552|NCT04770298|OTHER|Halliwick Concept|Halliwick Concept: Water intervention Bobath Concept: Neurodevelopmental Treatment
41334553|NCT02915640|OTHER|Remote technology|Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
41334554|NCT03932019|DRUG|Jitongning tablet(High-dose )|Jitongning tablet,3tablets,bid,treat 12 weeks
41334555|NCT03932019|DRUG|Jitongning tablet(Low-dose )|Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks
41334556|NCT03932019|DRUG|Placebo|Jitongning tablet placebo,3tablets,bid,treat 12 weeks
41334557|NCT01192841|OTHER|Physician uniform|Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
41484054|NCT04043936|BEHAVIORAL|Cognitive Bias Modification Intervention for Help-Seeking Stigma|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
40816396|NCT01734954|PROCEDURE|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
41156142|NCT05336721|DRUG|Chiauranib|25mg/35mg/50mg orally once daily
41156143|NCT05336721|DRUG|capecitabine|1000mg/m2 on Days 1-14 in a repeating 21-day cycle
41156144|NCT03303547|DIAGNOSTIC_TEST|MRI mapping to guide pathological sampling of extranodal tumour deposits|Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
40816397|NCT01734954|DRUG|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
40816398|NCT01734954|DEVICE|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
41156145|NCT03777553|BEHAVIORAL|Narrative Exposure Therapy for Justice-Involved Veterans|Behavioral intervention that uses narrative therapy and exposure to address repeated or complex trauma.
41334558|NCT02911519|OTHER|Brief Group Psychoeducation|First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.
41334559|NCT02911519|OTHER|Treatment as Usual|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
41334560|NCT02420990|BEHAVIORAL|Medication Integration Protocol (MIP)|
41334561|NCT02420990|BEHAVIORAL|Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)|
41334562|NCT00430391|OTHER|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
41334563|NCT00430391|OTHER|Routine Control|Participants are assigned to the routine, standard consent.
41484055|NCT04043936|BEHAVIORAL|Placebo Cognitive Bias Modification (CBM-Placebo)|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
41484056|NCT04043936|BEHAVIORAL|Self-Directed Psychoeducation|Material presented with information on mental health literacy, mental health stigma, \& treatment options. This is based on the idea that increasing knowledge about psychiatric symptoms and treatment options encourages help-seeking behavior and engagement.
41484057|NCT00390130|DRUG|Pentacel (DPTaP+Hib)|
41484058|NCT00390130|DRUG|Prevnar (conjugated pneumococcal vaccine)|
41334564|NCT03733457|BEHAVIORAL|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
41334565|NCT02683707|OTHER|Removal of Fentanyl from peri-procedural analgesia|Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
41334566|NCT02683707|DRUG|Fentanyl|IV peri-procedural analgesia
41334567|NCT02683707|DRUG|Lidocaine|Local Anesthetic
41484059|NCT03257904|PROCEDURE|intracranial pressure monitoring|measurement of intracranial pressure
41484060|NCT02833376|OTHER|alcohol antisepsis|
41484061|NCT02833376|OTHER|chlorhexidine antisepsis|
41484062|NCT04376528|DRUG|Cyclosporin A|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with cyclosporin A)
41484063|NCT04376528|DRUG|Mycophenolate Mofetil|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with mycophenolate mofetil )
41484064|NCT03947424|DEVICE|LP Er:YAG|LP Er:YAG applied to oral mucosa
41484065|NCT03947424|DEVICE|SMOOTH mode Er:YAG|SMOOTH mode Er:YAG applied to oral mucosa
41484066|NCT03947424|DEVICE|sham|Er:YAG laser applied to oral mucosa with no energy
41484067|NCT05515016|PROCEDURE|chin enhancement with a fatty flap sculpted from the double chin|Under general anesthesia, an incision was made behind the submental crease followed by the excision of the skin excess. The preplatysmal fatty compartment was individualized through a subcutaneous dissection. Then, the lower part of the preplatysmal fat was cut to start its separation from the platysma muscle, thus obtaining a real vascularized fatty flap. This flap could be folded on itself, then easily turned over to be fixed on the muscular layer of the chin.
41484068|NCT00073021|DRUG|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
41484069|NCT00073021|DRUG|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
41484070|NCT06139718|BEHAVIORAL|ACT Guide Lite|ACT Guide Lite is a single session online mental health program that is designed to take 30-45 minutes to complete. The single session self-guided intervention includes a series of sections that teach key ACT skills.
41484071|NCT05626699|DEVICE|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
41334568|NCT02683707|DRUG|Midazolam|IV sedation
41334569|NCT01159821|DRUG|31001074/paroxetine|1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
41334570|NCT01094990|DRUG|Dexamethasone|dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
41334571|NCT00531895|DRUG|duloxetine|duloxetine 60 mg/d
41334572|NCT00289861|DRUG|Risperidone|
41334573|NCT00289861|DRUG|placebo|
41484072|NCT01646047|DIETARY_SUPPLEMENT|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
41484073|NCT01646047|DIETARY_SUPPLEMENT|multi-component dietary supplement|placebo capsules
41484074|NCT06052865|BEHAVIORAL|SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants. Additionally, for very preterm infants with advanced neurological injury, additional 1-2 sessions of weekly motor therapy are added to the SENSE-II program
41484075|NCT06052865|BEHAVIORAL|SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants.
41484076|NCT06052865|OTHER|Reference/ Standard of care|Infants in the Unexposed group receive the NICU standard of developmental care throughout hospitalization.
41334574|NCT03835988|DEVICE|Geniculate Artery Embolization|Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
41334575|NCT01001234|DRUG|rizatriptan|"For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity).~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
41334576|NCT01001234|DRUG|placebo|For participants randomized to placebo in Stage 1: a single placebo ODT was to be taken within 30 minutes of onset of qualifying migraine.
41334577|NCT01001234|DRUG|rizatriptan|"For participants randomized to rizatriptan in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder \[moderate or severe pain 15 minutes after dose\] to be randomized at Stage 2): a single 5 or 10 mg rizatriptan ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
41334578|NCT01001234|DRUG|placebo|For participants randomized to placebo in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder to be randomized at Stage 2) or allocated to placebo in Stage 2 (took rizatriptan in Stage 1 and was Non-Responder): a single placebo ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
41334579|NCT02595424|DRUG|Capecitabine|Given PO
41334580|NCT02595424|DRUG|Carboplatin|Given IV
41334581|NCT02595424|DRUG|Cisplatin|Given IV
41334582|NCT02595424|DRUG|Etoposide|Given IV
41334583|NCT02595424|OTHER|Laboratory Biomarker Analysis|Correlative studies
41334584|NCT02595424|DRUG|Temozolomide|Given PO
41334585|NCT05839639|DRUG|NrtIs|Subjects will receive NrtIs therapy for 24 weeks.
41334586|NCT05839639|DRUG|HH-003|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks.
41334587|NCT05839639|DRUG|HH-003+NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks. Subjects will receive NrtIs therapy for 24 weeks.
41334588|NCT01105780|DRUG|Placebo|Matching placebo
41334589|NCT01105780|DRUG|JNJ-41443532|250mg tablet once daily for 1 day
40816399|NCT01734954|DEVICE|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
41484077|NCT04929938|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This is a combination of cognitive-behavioural techniques oriented to improve the emotional regulation. The Unified Protocol is comprised of 8 modules and it is applied following The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders Manual (Barlow, 2017).
41484078|NCT02686203|DEVICE|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment"
41334590|NCT06305026|DIAGNOSTIC_TEST|Muscle- and skin biopsies|RA patients with and without concomitant fibromyalgia will be examined with muscle and skin biopsies.
41334591|NCT00185536|BEHAVIORAL|Packaging and identification of source|
41334592|NCT00645515|DRUG|Ziprasidone|Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
41334593|NCT00645515|DRUG|Risperidone|Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
41334594|NCT01174888|DRUG|midostaurin|Drug midostaurin, Given orally given twice daily days 1-14
41334595|NCT01174888|DRUG|Bortezomib|Bortezomib given IV on days 1, 4, 8, and 11
41334596|NCT01174888|DRUG|mitoxantrone hydrochloride|Patients receive mitoxantrone hydrochloride IV over 10 minutes
41334597|NCT01174888|DRUG|etoposide|Patients receive etoposide IV over 1 hour
41334598|NCT01174888|DRUG|cytarabine|Patients receive cytarabine IV over 6 hours on days 1-6
41484079|NCT05177172|OTHER|High beta glucans|higher dose betaglucans
41484080|NCT05177172|OTHER|Low beta glucans|lower dose beta glucans
41334599|NCT03617913|DRUG|Avelumab|Given IV
41334600|NCT03617913|DRUG|Cisplatin|Given IV
41484081|NCT05177172|OTHER|Low beta glucans + low polar lipids|low dose betaglucans in a combination with low dose of polar lipids
41484082|NCT05177172|OTHER|Polar lipids|low dose polar lipids
41484083|NCT05177172|OTHER|Control|No beta glucans or polar lipids
41334601|NCT03617913|DRUG|Fluorouracil|Given IV
41334602|NCT03617913|DRUG|Mitomycin|Given IV
41334603|NCT03617913|OTHER|Quality-of-Life Assessment|Ancillary studies
41334604|NCT03617913|RADIATION|Radiation Therapy|Undergo RT
41334605|NCT04125992|PROCEDURE|distal radial artery access in coronary angiography and angioplasty|"The patient grasps his thumb towards the palm to bring the radial artery up to the surface. The left hand is set on the right side of the groin toward the operator, who stands on the right side, with the dorsal surface of hand upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the distal radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, Safe Guard, is used for hemostasis."
41334606|NCT04125992|PROCEDURE|Forearm radial artery access in coronary angiography and angioplasty|"The right hand is set in the anatomical position, with the anterior surface of arm face upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the forearm radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, TR band, is used for hemostasis."
41334607|NCT05419947|DRUG|VERDYE powder for solution for injection 25 mg|Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.
41484084|NCT00313456|DRUG|Satraplatin|Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.
41484085|NCT03714360|DRUG|Tranexamic Acid|patients with ASA(American Society of Anesthesiologists grades) 1 to 2, scheduled to undergo lumbar decompressive surgery at Middelfart Hospital. Patients were randomized, in blocks of 10, to two groups: TXA or placebo. Anticoagulation therapy was discontinued 2-7 days preoperatively. Prior to the incision, patients received either a bolus of TXA (10mg/kg), or an equivalent volume of saline solution (placebo).
41484086|NCT03714360|DRUG|Sodium Chloride 0,9%|Sodium Chloride 0,9%
41484087|NCT00926016|DRUG|Pioglitazone (Actos)|pioglitazone 45 mg a day
41484088|NCT05964790|DRUG|HS-10380|Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days
41484089|NCT05964790|DRUG|Placebo|Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days
40816400|NCT01734954|DRUG|supplemental oxygen|supplemental oxygen during the block and/or during surgery
41484090|NCT02831218|PROCEDURE|QCA and Aspirin|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
40816401|NCT01734954|DRUG|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
40816402|NCT01734954|DRUG|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
41014180|NCT03663933|DRUG|Reduced Intensity Conditioning|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -11 and -7, cyclophosphamide:3 mg/kg orally daily on days -11 through -4 Busulfan IV, pharmokinetically dosed, on days -3 and -2.
41014181|NCT03663933|DRUG|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, Mesna: 25-50 mg/kg weight based dosing, Tacrolimus 0.02 mg/kg on days +5 through +90, and mycophenolate mofetil (MMF) 15 mg/kg on days +5 through +25
41014182|NCT03663933|PROCEDURE|Allogeneic HSC|Stem cell transplant
41014191|NCT06323304|OTHER|Auricular acupressure|Auricular acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds, which is an herb in traditional medicine. The acupoints on the ear that will be treated with auricular acupressure therapy are Shenmen (TF4), Internal nose (TG4), Lung (CO14), Wind stream (SF1,2i), Adrenal gland (TG2p). These acupoints are believed to be effective in the treatment of allergic rhinitis. The patches will be kept on the auricle for one week.
41014192|NCT06323304|OTHER|Sham acupressure|Sham acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds. The acupoints that will be treated with auricular acupressure therapy are Helix 2 (HX10), Shoulder (SF4), Clavicle (SF6), Anus (HX5) and Tooth (LO1). These acupoints are not used to treat allergic immune-related problems or respiratory diseases. The patches will be kept on the auricle for one week.
41014193|NCT06323304|OTHER|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of fluticasone propionate nasal spray as needed, and lifestyle modifications.
41156146|NCT05593016|BEHAVIORAL|Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)|"Participating in the SMILE arm of the study will consist of four, 60-minute sessions delivered over 6-8 weeks to patients in their homes using videoconferencing.~Intervention will provide training in behavioral symptom management skills (e.g.,relaxation training, activity-rest cycling) and include skills from ACT and MCP targeting avoidance of uncomfortable experiences (e.g., thoughts, emotions) and promoting engagement in value-directed activity."
41156147|NCT05593016|BEHAVIORAL|Education Control Arm|"The control arm will receive the NCI booklet, Taking Time: Support for People with Cancer, which provides basic strategies for symptom (e.g., pain, fatigue, stress) management, coping with negative emotions, and communication and will continue their usual medical care of advanced cancer."
41334608|NCT05666908|DEVICE|HFNO|After the patient's mask-assisted ventilation makes the end-expiratory oxygen concentration (EtO2) \> 90%, wear the HFNO device according to the pre-adjusted mode (temperature 34°C, oxygen concentration 100%, flow rate 50 litres per minute). The nasal cannula will remain in place until intubation is complete (including DLT intubation, direct FOB guidance, and DLT alignment with FOB). After securing the HFNO device, the glottis was exposed using a laryngoscope, and the DLT main tracheal cuff was passed through the glottis and paused under direct vision. Insert the DLT into the bronchial tube lumen of the DLT using the FOB, and then advance the DLT into the corresponding main bronchus under the guidance of the FOB. After confirming the appropriate depth of the catheter using the FOB, insert the DLT into the anesthesia machine to complete the intubation process. After the DLT was connected to the anesthesia machine and mechanical ventilation was started, the HFNO device was removed.
41334609|NCT00121680|DRUG|E7080|Oral.
41334610|NCT05621590|DRUG|MLC 901|MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components
41334611|NCT05621590|DRUG|Placebo|placebo capsules filled with stevia sweetened powder
41334612|NCT01391455|PROCEDURE|Isolation of the spermatic cord from mesh|The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
41484091|NCT02831218|PROCEDURE|QCA and Clopidogrel|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
41334613|NCT03549819|DRUG|Cannabidiol (CBD) Oil Capsules|"200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)"
41334614|NCT03549819|DRUG|Sunflower Lecithin Oil in Capsule|Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
41334615|NCT06423872|DRUG|ZT002|Participants will receive a single subcutaneous (SC) ZT002 injection.
41334616|NCT06423872|OTHER|Placebo|Participants will receive same volume as of the study drug.
41334617|NCT00741806|BIOLOGICAL|GHB04L1|single dose intranasal administration of GHB04L1
41484092|NCT02831218|PROCEDURE|Imaging guided and Aspirin|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
41334618|NCT00741806|OTHER|Placebo|SPGN buffer
41334619|NCT03203590|DRUG|Oral Navelbine + Carboplatin|The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
41334620|NCT03203590|DRUG|Gefitinib|The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
41484093|NCT02831218|PROCEDURE|Imaging guided and Clopidogrel|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
41484094|NCT06213870|DIAGNOSTIC_TEST|Surgical criteria|"In the MRI group, patients with FVH-DWI mismatch underwent EVT surgery or were otherwise treated with medication.~In the perfusion group, patients who meet the criteria of DEFUSE3 will receive EVT surgery, otherwise receive medication."
41334621|NCT04088565|OTHER|Paired-Associative Stimulation (PAS)|Simultaneous activation of connections in motor cortex via stimulation to the nerves and brain.
41334622|NCT04088565|OTHER|Vagus Nerve Stimulation (VNS)|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
41334623|NCT04088565|OTHER|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
41334624|NCT01126502|DRUG|alvespimycin hydrochloride|Given IV
41484095|NCT03476343|DEVICE|GE OPTIMA MR430s with HDx/GE Electronics|MRI scan
41484096|NCT03274622|BEHAVIORAL|Impact Parent Training|
41484097|NCT03274622|BEHAVIORAL|No Impact|
41484098|NCT03058653|PROCEDURE|Small fluid boluses of 50 ml|Participants will receive small 50ml boluses of fluid up to 250ml in total. The remainder will be given as infusion pump method at a rate of 1000ml/hour which will complete in 15 minutes. In total, the 500ml will be given over 25 minutes.
41484099|NCT03058653|DEVICE|LIDCORapid Monitor|Addition of the LIDCORapid Monitor to measure stroke volume
41334625|NCT01126502|OTHER|diagnostic laboratory biomarker analysis|
41334626|NCT01126502|OTHER|pharmacogenomic studies|
41334627|NCT01126502|OTHER|pharmacological study|
41334628|NCT03127553|DIETARY_SUPPLEMENT|Low-sodium diet with standard bread|low-sodium diet (2300 mg Na/die) with use of standard bread (750 mg Na/100g) for 6 months
41334629|NCT03127553|DIETARY_SUPPLEMENT|Low-sodium diet with low-sodium bread|low-sodium diet (2300 mg Na/die) with use of low-salt bread (280 mg Na/100g) for 6 months
41334630|NCT01998152|PROCEDURE|Nutritional counseling|Patients in the intervention-arm will receive individualized nutritional counseling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.
41334631|NCT03661255|BEHAVIORAL|PC CARES|PC CARES trains local residents to deliver the PC CARES curriculum in their own community. These facilitators will attend a 40 hour training, and then will deliver the 4 session PC CARES curriculum in their home village. To aid local facilitators, each session follows the same structure after a beginning ritual:(1) agreements/safe talk, (2)'small wins', (3)'what do we know?' (facilitator shares current research on suicide prevention or wellness) (4)'what do we think?' (participants have an opportunity to discuss their thoughts on the research presented), and (5)'what we want to do?' (participants identify what steps they can take in their village to make positive change).The content of learning circles (LCs) includes community-level conditions, evidence-based approaches, risk and protective factors that can prevent suicide and promote well-being.Each LC includes both primary and secondary prevention strategies.Teaching tools include charts, short films, and case studies.
41334632|NCT04283357|OTHER|Exercise|Short Foot Exercises
41334633|NCT04283357|DEVICE|Virtual Reality|Exercise with virtual reality
41334634|NCT00972972|DIETARY_SUPPLEMENT|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
41334635|NCT00972972|DIETARY_SUPPLEMENT|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
41334636|NCT03471104|OTHER|PAID in clinical diabetes consultations|"The intervention starts when participants complete PROMs before an annual consultation. The physician reviews the PAID (problem areas in diabetes scale) scores with the participant. Participants with one or more single PAID item(s) scored 3 or 4, or a PAID score ≥30, will be referred to extra follow-up which will consist of at least two diabetes nurse consultations. The nurses will follow a communication manual based on key elements from empowerment theory and self-determination theory.~The participants then complete the PROMs prior to the next annual consultation with the physician."
41334637|NCT00762268|DRUG|SAMe|"SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
41334638|NCT00762268|DRUG|Placebo|
41334639|NCT03472872|DRUG|Ketorolac|15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
41334640|NCT03472872|DRUG|Acetaminophen|1,000mg acetaminophen IVPB
41334641|NCT05999149|DRUG|Camrelizumab Plus Chemotherapy and Famitinib|camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib
41334642|NCT05999149|DRUG|Camrelizumab Plus Chemotherapy|Camrelizumab Plus Chemotherapy
41334643|NCT03454945|DRUG|Vibramycin|Antibiotic
41484100|NCT06166316|DEVICE|overdenture retained by locator attachments.|"• Implant-retained overdenture construction procedures:~1. Primary maxillary and mandibular impressions were made, and custom trays were fabricated using auto-polymerizing acrylic resin.~2. Definitive impressions were made with non-eugenol zinc oxide paste, and the impression copings were threaded to the implants, and polyether material was injected around the copings through the opening of the tray. Auto-polymerizing acrylic resin was used to pick up the copings with the tray. Implant analogs were screwed to the copings and the impressions was poured with stone.~3. Locator abutment (Dentium, Co. Ltd., Korea) screwed in the analogs. Jaw relations were recorded, and semi-anatomical acrylic teeth eeee arranged in balanced occlusion.~4. The locator housing and retentive clips were incorporated into the fitting surface of the overdentures during denture processing."
41484101|NCT05476120|BEHAVIORAL|BATHE|The BATHE interview technique was applied 3 times, once every 3 months, for 6 months.
41484102|NCT04918316|OTHER|Corneal gas permeable lens|Fit in corneal gas permeable contact lens first.
40816403|NCT01734954|PROCEDURE|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
41334644|NCT03454945|DEVICE|Phototherapy|UVA+Psoralen
41334645|NCT04926844|DRUG|Levetiracetam|Intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).
41334646|NCT04926844|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
41334647|NCT04926844|DRUG|Placebo|Intravenous isotonic saline (1.2 ml/kg) over 5 minutes
41334648|NCT02914197|OTHER|Full information|Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
41334649|NCT04516733|OTHER|supportive care|visit with supportiv unit and neuropsychologue every 3 months
41334650|NCT04556448|OTHER|Aligners|Clear aligners
41334651|NCT04556448|OTHER|Clear braces|Clear braces
41484103|NCT01753336|BIOLOGICAL|Botulinum toxin type A|Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
41484104|NCT03832036|DIAGNOSTIC_TEST|Paraspinal Mapping and Quantitative Sensory Pain Test|Participants will be tested at baseline.
41484105|NCT04448912|PROCEDURE|Damage control surgery|Surgery for non-traumatic abdominal emergencies using the damage control approach
41484106|NCT04448912|PROCEDURE|Conventional surgery|Conventional surgery for non-traumatic abdominal emergencies
41334652|NCT01085019|DIETARY_SUPPLEMENT|Cinnamon|2.8g/day of cinnamon in capsules during 4 weeks.
41334653|NCT01085019|DIETARY_SUPPLEMENT|Oregano|2.8g/day of oregano in capsules during 4 weeks.
41334654|NCT01085019|DIETARY_SUPPLEMENT|Ginger|2.8g/day of ginger in capsules during 4 weeks.
41334655|NCT01085019|DIETARY_SUPPLEMENT|Rosemary|2.8g/day of rosemary in capsules during 4 weeks.
41334656|NCT01085019|DIETARY_SUPPLEMENT|Black pepper|2.8g/day of black pepper in capsules for 4 weeks.
40816404|NCT04734418|DRUG|Remifentanil|Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min
41334657|NCT01085019|DIETARY_SUPPLEMENT|Placebo|2.8 g/day of placebo in capsules (corn starch) during 4 weeks.
41334658|NCT01762527|RADIATION|Adaptive Radiotherapy|CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
41334659|NCT04783714|DIETARY_SUPPLEMENT|Swisse Nutra+ Cholesterol Balance|Swisse Nutra+ Cholesterol Balance is a multi-ingredient nutraceutical composition contained in a brown soft-gel capsule format. Three capsules are required per dose.Swisse Nutra+ Cholesterol Balance is a multi-ingredient formulation containing artichoke extract, bergamot juice extract, hydroxytyrosol, an antioxidant derived from olive oil and sunflower oil-derived phytosterols. All ingredients target cholesterol reduction by different and complementing mechanisms, as evidenced by human clinical trials. These ingredients have been chosen to work synergistically to alleviate hypercholesterolemia and/or dyslipidemia through multiple pathways, whereby each ingredient works via a different mechanism to lower LDL-cholesterol in the body.
41334660|NCT04783714|DIETARY_SUPPLEMENT|Placebo|Matched brown soft-gel capsule placebo containing olive oil and palm olein - no therapeutic benefit.
41334661|NCT06045143|DEVICE|Patients undergoing DDD pacemaker implantation|compare the effect right ventricular apical versus septal pacing on left ventricular function by deformation imaging using 2D speckle tracking echocardiography.
41334662|NCT04039763|DEVICE|Dexcom G6|Realtime Continous Glucose Monitoring
41484107|NCT01094249|DRUG|divalproex sodium ER/paliperidone ER|Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
41334663|NCT04039763|DEVICE|Self monitoring of blood glucose|Finger prick self monitoring of blood glucose
41334664|NCT01022151|DRUG|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L \[group P\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
41334665|NCT01022151|DRUG|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL \[group A2\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
41334666|NCT01022151|DRUG|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL \[group A3\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
41334667|NCT01022151|DRUG|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL \[group A4\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
41334668|NCT01022151|DRUG|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL \[group A5\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
41334669|NCT01022151|DRUG|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL \[group D\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
41334670|NCT05214404|OTHER|Patients diagnosed with ulcerative colitis|Patients with ulcerative colitis diagnosed by endoscopy and histopathology
41334671|NCT01989819|OTHER|skin biopsy|
41334672|NCT00201760|DRUG|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
41334673|NCT00201760|DRUG|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
41334674|NCT00201760|DRUG|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
41334675|NCT04641910|OTHER|No intervention|No intervention
41334676|NCT03313856|DRUG|Guazuma Ulmifolia plus Tecoma Stans|Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
41484108|NCT06469489|OTHER|Liver Disease of all etiologies|No intervention
41484109|NCT04093869|BEHAVIORAL|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX condition has two integrated components: the CST component will systematically train patients in the use of coping skills for stress reduction and promote key transplant-specific health behaviors. The exercise component of the intervention will progressively increase participants exercise and promote daily physical activity through motivational interviewing strategies.
41484110|NCT04093869|BEHAVIORAL|Standard of Care plus Education (SOC-ED)|The SOC-ED condition provides support and enhanced post-transplant education. Participants will be given detailed educational information about post-transplant care, the importance of medication adherence, and maintenance of physical activity.
41484111|NCT01219413|DRUG|Aliskiren, Perindopril|Rasilez 300 mg Prestarium 10 mg
41484112|NCT00054548|BIOLOGICAL|oblimersen sodium|Given IV
41334677|NCT03313856|DRUG|Calcinaned magnesia|Calcined magnesia 400 mg per capsule
41334678|NCT04334772|DEVICE|Muscle belly Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application at the level of the muscular belly of the shortened hamstrings.
41334679|NCT04334772|DEVICE|Tendon Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application in the tendon of the shortened hamstrings.
41334680|NCT04334772|OTHER|Stretching exercises|5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each
41334681|NCT02693691|DEVICE|CardioMEMS HF System|Pulmonary Artery Pressure Monitoring
41334682|NCT00127699|PROCEDURE|Alcohol swab of umbilical cord|
41334683|NCT00187850|PROCEDURE|PP|Partial pulpotomy
41334684|NCT00187850|PROCEDURE|DPC|Direct pulp capping
41334685|NCT04114045|DIETARY_SUPPLEMENT|Experimental:Whey protein|Each participant in the protein group received 2 protein drinks immediately following exercise. The supplement was given using a relative quantity of whey protein isolate (0.3g/kg) and was chocolate flavoured.
41484113|NCT00054548|DRUG|paclitaxel|Given IV
41484114|NCT00054548|OTHER|laboratory biomarker analysis|Correlative studies
41484115|NCT00054548|OTHER|pharmacological study|Correlative studies
41484116|NCT03457649|BIOLOGICAL|ARGX-113|
41484117|NCT03457649|BIOLOGICAL|Placebo|
41334686|NCT04114045|DIETARY_SUPPLEMENT|Active Comparator: Isoenergetic control - Carbohydrate|Each participant in the carbohydrate group received 2 drinks immediately following exercise. The supplement was given using a relative quantity of maltodextrin (0.3g/kg), non-caloric chocolate flavouring was added to mask the drinks contents.
41334687|NCT04114045|OTHER|Placebo|Each participant in the water group received 2 drinks immediately following exercise. The water was provided in a similar volume using the same non-caloric chocolate flavouring as the other drinks.
41334688|NCT00001669|DRUG|rhIGF-1 (CEP-151)|
41334689|NCT06386744|DRUG|Dusquetide|1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks
41334690|NCT02525887|OTHER|Observation|Observation and evaluation of care provided to patients that received DNA tests to determine metabolic pathways.
41334691|NCT00571519|DRUG|Rivoglitazone HCl|0.5 mg tablets administered orally, once daily
41334692|NCT00571519|DRUG|rivoglitazone HCl|1.0 mg tablets administered orally, once daily
41334693|NCT00571519|DRUG|rivoglitazone HCl|1.5 mg tablets administered orally, once daily
41334694|NCT00571519|DRUG|placebo|placebo tablets matching rivoglitazone tablets administered orally, once daily
41334695|NCT00571519|DRUG|pioglitazone HCl|15 mg capsules administered orally, once daily
41334696|NCT00571519|DRUG|pioglitazone HCl|30 mg capsules administered orally, once daily
41334697|NCT00571519|DRUG|pioglitazone HCl 45 mg|45 mg capsules administered orally, once daily
41334698|NCT00571519|DRUG|placebo|placebo capsules for pioglitazone administered orally, once daily
41334699|NCT00571519|DRUG|metformin|Oral tablets. Rescue medication.
41334700|NCT01817452|DRUG|Trastuzumab|
41334701|NCT01817452|DRUG|Pertuzumab|
41334702|NCT01817452|DRUG|Paclitaxel|
41334703|NCT03255304|BEHAVIORAL|health mindest|groups be confronted with health aspects of food items
41334704|NCT03255304|BEHAVIORAL|palatability mindset|groups be confronted with palatability aspects of food items
41014206|NCT04412096|DRUG|Timolol 0.5% ophthalmic solution|1 drop BID
41334705|NCT00959881|DRUG|Donepezil plus placebo|5- and 10-mg tablets, single dose
41484118|NCT03866720|OTHER|Carbohydrate rich breakfast|A porridge breakfast meal fed at a carbohydrate delivery rate of 7.3 mg/kJ of each participants resting metabolic rate.
41484119|NCT03866720|DIETARY_SUPPLEMENT|Whey protein enriched breakfast|A porridge breakfast meal in which 15 grams of whey protein is substituted in place of carbohydrate and a small portion of fat.
41484120|NCT01124708|DRUG|TC-5619-238|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.
41484121|NCT01124708|DRUG|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
41484122|NCT06271720|OTHER|visceral manipulation|"visceral manipulation: A palpation technique will be applied till the barrier is felt and it will be applied until release is felt.~integrated neuromuscular inhibition: ischemic compression will be applied to trigger point of upper trapezius"
41484123|NCT06271720|OTHER|integrated neuromuscular inhibition|It involves applying direct sustained digital pressure to the TrP with sufficient force over dedicated time duration, to slow down the blood supply and relieve the tension within the involved muscle. The pressure is gradually applied, maintained and the gradually released
41484124|NCT05857826|OTHER|soft tissue release|Patient will be asked to lie in hook lying position using a clean glove will apply some water based lubricant gently sweep vaginal muscle from superficial to deep until find a trigger point press it and release it using circle motion for 1 to 2 minute until the trigger point is completely released.
41334706|NCT00959881|DRUG|Donepezil|5- and 10-mg tablets, single dose
41334707|NCT00959881|DRUG|Begacestat|6 x 50-mg capsules, single dose
41334708|NCT05620069|OTHER|Music listening|Participants are asked to select one of four music playlists and listen to it for appr. 30 minutes at bedtime during the intervention period.
41334709|NCT03437629|PROCEDURE|Temporary cement based on Calcium Hydroxide|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Calcium Hydroxide; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
41334710|NCT03437629|PROCEDURE|MTA temporary cement|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Mineral trioxide aggregate; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
41334711|NCT00471783|PROCEDURE|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
41334712|NCT02792049|DEVICE|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with integrated internal handle
41334713|NCT02792049|DEVICE|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
41334714|NCT01576120|OTHER|bowel prep regimen first boost 6 oz. and second boost 3 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)"
41334715|NCT01576120|OTHER|bowel prep regimen first boost 3 oz. and second boost 6 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)"
41484125|NCT05857826|OTHER|vaginal dilators|Vaginal dilators will be used according to the patient's condition starting from small sizes to the wider ones.
41484126|NCT02448121|PROCEDURE|Autologous bone marrow stem cell graft|All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
41334716|NCT00035477|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient
41334717|NCT00035477|DRUG|Placebo|placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
41334718|NCT02841592|OTHER|Flush rate oxygen|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.
41334719|NCT02841592|OTHER|Flush rate oxygen with assist|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
41334720|NCT01745913|DEVICE|CliniMACS® CD34 Reagent System|If a subject is randomized to the haplo-cord transplant group, their family member will undergo a stem cell collection. The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
41334721|NCT01745913|DRUG|Fludarabine|Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
41334722|NCT01745913|DRUG|Melphalan|Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
41334723|NCT01745913|DRUG|Rabbit ATG|Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
41334724|NCT01745913|PROCEDURE|Double Umbilical Cord Blood Transplantation|All subjects will receive an UCB dose of \> 3 x107/kg nucleated blood cells. It is expected that this will require co-infusion of two UCB in the large majority of cases. If two UCB are required, they will be at least 4/5 matched to the recipient.
41334725|NCT01745913|PROCEDURE|Haplo-Identical Cord Transplantation|"If randomized to the haplo-cord group, a family member will undergo a stem cell collection. In both arms, subjects will receive a conditioning regimen prior to transplantation. The conditioning regimen utilized in this study incorporates fludarabine-Melphalan and antithymocyte globulin (ATG). This regimen has the advantage of being nearly identical to the regimen utilized for our haplo-cord regimen is based on the experience of the Dana-Farber/Mass-General regimen."
41334726|NCT05362461|DIAGNOSTIC_TEST|Near Infrared Transillumination|Caries imaging detection technology.
41334727|NCT00568607|DRUG|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
41334728|NCT03039569|BEHAVIORAL|Text messaging|"The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages"
41484127|NCT00914459|BIOLOGICAL|Moroctocog alfa ( AF-CC)|Dosing is at the discretion of the Investigator
41484128|NCT00914459|PROCEDURE|Laboratory tests|Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody
41484129|NCT00804817|BEHAVIORAL|Control Group|Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
41484130|NCT00804817|BEHAVIORAL|SCION-HSCT program|"Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
41484131|NCT05032521|BIOLOGICAL|collection of biological data|collection of biological data
41014207|NCT04412096|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop QD
41484132|NCT05032521|OTHER|collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data|These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.
41334729|NCT03322397|BEHAVIORAL|Self-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.
41334730|NCT03322397|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
41334731|NCT03322397|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
41334732|NCT02096042|DRUG|Brentuximab Vedotin|"Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle."
41334733|NCT02096042|DRUG|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
41334734|NCT01070238|DIETARY_SUPPLEMENT|Isomaltulose|
41484133|NCT05032521|PROCEDURE|Standard treatment|usual management based on the use of drugs according to international recommendations
41484134|NCT05032521|PROCEDURE|stratified treatment according to algorithm|management based on arteriovenous CO2 gradient Stratification of drug use
41484135|NCT06395779|BEHAVIORAL|Neuromuscular Exercise Group|A 12-week Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization, balance training, muscle strength, breathing, and functional movement patterns will be created for the participants in Group 1.
41484136|NCT06395779|BEHAVIORAL|Dance Therapy Group|Participants in Group 2 will be given dance training by a dance instructor in the gym for 1 hour a day, 2 days a week, for a total of 12 weeks. In dance therapy practices, simple and basic movements are appropriate to the level of the participants, and special attention will be paid to the rhythm of the music not being fast. Latin dances were applied to the participants; selected rumba, merengue, bachata, and salsa movements. Dance therapy will start with a warm-up exercise (10 minutes), then dance exercises will be applied and the activity will end with a cool-down exercise (10 minutes).
41014217|NCT05559580|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
41014218|NCT05559580|DRUG|Placebo|Placebo
41484137|NCT00554307|DEVICE|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
41484138|NCT06406660|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
41014220|NCT04623216|BIOLOGICAL|Sabatolimab|Sabatolimab is a solution in vial for IV infusion
41014221|NCT04623216|DRUG|Azacitidine|Azacitidine comes in Vial for IV infusion or subcutaneous administration
41017919|NCT01049880|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL."
41156148|NCT06647355|OTHER|Effectiveness of physical exercise in preventing pain and improving plantar pressure distribution|At the beginning of the study, the participants underwent a baropodometric and photometric analysis. At the same time, anthropometric data and self-assessed body pain data were collected. For 12 continuous weeks, the participants completed a training programme that included specific exercises designed for each group. At the end, the baropodometry images were analysed again, which led to the final conclusion of the study.
41484139|NCT03131622|BEHAVIORAL|Digital Therapeutics|
41484140|NCT05389982|OTHER|mHealth (GetWell)|GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.
41484141|NCT05389982|OTHER|Standard Care|Office based pathway
41484142|NCT01449279|DRUG|Ipilimumab|Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
41484143|NCT01449279|RADIATION|Radiation Therapy|Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
41484144|NCT04166513|DEVICE|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the targeted region.
41334735|NCT02670850|OTHER|Family Caregiver Intervention Program|Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
41334736|NCT02959697|DRUG|Subcut. + Subconj. Xylocaine|Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).
41334737|NCT02959697|DRUG|Subcut. + Sham Subconj. Injection|Patient will receive the standard subcutaneous local anesthetic as well as a subconjunctival sham injection of Normal Saline.
41334738|NCT02959697|PROCEDURE|Blepharoptosis Repair|Patients will undergo blepharoptosis repair using an anterior approach.
41334739|NCT04864600|OTHER|Candle C|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
41334740|NCT04864600|OTHER|Candle 1|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
41334741|NCT01564602|DEVICE|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
41334742|NCT00632996|OTHER|Rehabilitation|Exercise, manual therapy, patient education, posture, home exercise program
41334743|NCT04559412|DEVICE|Sofusa DoseConnect|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
41334744|NCT04559412|DRUG|Enbrel|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
41484145|NCT04166513|DEVICE|Active Control Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the active control region.
41484146|NCT04166513|BEHAVIORAL|Phonologic-Focused Speech Therapy|Participants are asked to generate or choose from a list phonologic information about a target picture.
41484147|NCT04166513|BEHAVIORAL|Semantic-Focused Speech Therapy|Participants who have difficulty retrieving an object name are given hierarchical clues or asked questions about the objects function as a way of activating the semantic network for that object, leading to eventual retrieval of the target word.
41484148|NCT01264042|DIETARY_SUPPLEMENT|Ferrous Sulfate|60 mg with 200 mL water, single administration
41484149|NCT01746264|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
41484150|NCT00104091|DRUG|TP-38|TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
41484151|NCT01466452|DRUG|Aspirin|single-dose aspirin in 100 mg 1 tablet every 24 hours
41484152|NCT01466452|DRUG|Aspirin|single-dose aspirin 200 mg 1 tablet every 24 hours
41484153|NCT01466452|DRUG|Aspirin|double-dose aspirin 100 mg 1 tablet every 12 hours
40816405|NCT04734418|DRUG|Dexmedetomidine|Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
40816406|NCT00052611|DRUG|Celecoxib|
41156149|NCT04822337|DRUG|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin|Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I
41334745|NCT01113840|BEHAVIORAL|Exercise|Exercise classes three times per week in a controlled, supervised environment.
41334746|NCT01113840|BEHAVIORAL|Control|Control group continues daily life as prior to randomization.
41334747|NCT03125993|BEHAVIORAL|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: \> 10000 steps, \> five days, per week brisk walking.
41334748|NCT04364906|OTHER|Regional anesthesia|The effects of QLB 2, 3 interfascial plane blocks on post-operative analgesia after cesarean section surgery
41334749|NCT00083876|DRUG|Thalidomide|
41334750|NCT03619837|DRUG|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
41334751|NCT03619837|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|"Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks."
41334752|NCT02397590|DRUG|Fimasartan|
41334753|NCT02397590|DRUG|Atorvastatin|
41014222|NCT06331052|DEVICE|MR-guided Focused Ultrasound Ablation|3-D tractography Vim-FUSA -D tractography Vim-FUSA will be carried out as follows: (a) head shaving and placement of the stereotactic frame (Integra radionics frame, Integra Lifesciences, NJ, USA) secured to the skull with transcutaneous screws; (b) positioning on the procedure table and placement of the ultrasound transducer; (c) acquisition of conventional magnetic resonance (MR) imaging and co-registration with the CT head and 3-D tractography imaging acquired pre-surgically; (d) exploration of the target area with subtherapeutic sonications; (e) intraoperative monitoring with clinical testing of tremor and side effects with a standardized protocol. (f) Therapeutic sonications in the target area to deliver definitive ablation followed by clinical testing of tremor and side effects with a standardized protocol as described in section (e).
41156150|NCT06647030|DEVICE|CURATE.DTx sessions|"Participants will interact with CURATE.DTx twelve minutes per day for two weeks.~CURATE.DTx is a cognitive training DTx developed by our research team in The N.1 Institute for Health (N.1) and The Institute for Digital Medicine (WisDM). CURATE.DTx is comprised of CURATE.AI and a modified version of the Multi-Attribute Task Battery (MATB), Online MATB.~CURATE.AI is a small data AI-derived platform that can dynamically personalize treatment by modulating drug dose or therapy intensity. We previously implemented CURATE.AI into Online MATB - the modernized, online version of MATB, a flight deck simulator program developed by NASA and the United States Air Force."
41156151|NCT06647030|BEHAVIORAL|Interview|After the last DTx session (regardless of study completion by the participant), a 60-minute interview session will be conducted by a team member, either at the Institute for Digital Medicine (WisDM) in person or via Zoom. All responses will be audio-recorded and transcribed verbatim. We will use categorical analysis of anonymized transcripts to identify emerging or recurring themes. Data will be analyzed using NVivo. The analysis will begin with open/primary coding, where we will descriptively label data. Subsequently, we will group the labels into categories based on literature (i.e., secondary coding). These categories will then help create broader themes/assertions.
41014223|NCT04981509|BIOLOGICAL|Atezolizumab|Given PO
41484154|NCT05626439|DRUG|Staccato alprazolam|Study participants will receive single dose of Staccato alprazolam by inhalation at pre-specified time points.
41484155|NCT05626439|DRUG|Oral alprazolam|Study participants will receive single dose of oral alprazolam at pre-specified time points.
41484156|NCT00499174|PROCEDURE|conventional surgery|Radical prostatectomy
41014224|NCT04981509|BIOLOGICAL|Bevacizumab|Given IV
41156152|NCT05582135|DRUG|2 mg morphine sulfate|The parturients were administered 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
41156153|NCT05582135|DRUG|0.25mg/kg esketamine|The parturients were administered 0.25mg/kg of esketamine through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
41156154|NCT05582135|DRUG|0.25mg/kg of esketamine in combination with 2 mg morphine sulfate|The parturients were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
41156155|NCT05582135|DRUG|0.25mg/kg of esketamine in combination with 1 mg morphine sulfate|The parturients were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
41156156|NCT05115136|DRUG|Doxepin|25mg dose of Doxepin will be administered one time, by mouth
41484157|NCT00499174|RADIATION|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
41014225|NCT04981509|PROCEDURE|Biopsy|Undergo biopsy
41014226|NCT04981509|PROCEDURE|Biospecimen Collection|Undergo blood collection
41014227|NCT04981509|PROCEDURE|Bone Scan|Undergo bone scan
41014228|NCT04981509|PROCEDURE|Computed Tomography|Undergo CT without contrast
41014229|NCT04981509|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
41014230|NCT04981509|DRUG|Erlotinib|Given PO
41014231|NCT04981509|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41014232|NCT04981509|PROCEDURE|Positron Emission Tomography|Undergo PET
41156157|NCT05115136|DRUG|Diphenhydramine|50 mg dose of Diphenhydramine will be administered one time, by mouth
41156158|NCT00156975|DRUG|Capecitabine|
41156159|NCT00156975|DRUG|Oxaliplatin|
41156160|NCT04231266|DRUG|ManNAc|Oral N-acetyl-D-mannosamine monohydrate (ManNAc)
41156161|NCT04231266|OTHER|Placebo|Placebo
41156162|NCT06646250|DEVICE|NeoDoppler - CE certified|The NeoDoppler is small and light weighed constructed as a single element transducer, that can be gently fixed over the fontanelle. The system is fully compatible for cooccurring use with other intensive care equipment for neonates as well as caregiving from the parents. It is capable of measuring cerebral blood flow at different depths of the brain simultaneously. The Doppler velocity measurements arise from a cylindrical volume of tissue. It is therefore less sensitive to the exact position and angle of the probe over the fontanel to target the vessels of interest than standard hand-held Doppler. This means that the NeoDoppler system may be placed by healthcare professionals who do not have specialized training performing diagnostic ultrasound exams of the cerebral vasculature in neonates.
41014233|NCT04981509|DRUG|Sodium Fluoride F-18|Given F-18 sodium fluoride
41014234|NCT03011814|BIOLOGICAL|Durvalumab|Given IV
41014235|NCT03011814|OTHER|Laboratory Biomarker Analysis|Correlative studies
41014236|NCT03011814|DRUG|Lenalidomide|Given PO
41014239|NCT04064060|DRUG|Luspatercept|Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
41014242|NCT05950945|DRUG|Trastuzumab Deruxtecan|Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
41014243|NCT04145791|OTHER|Ice|ice packs
41014245|NCT05292950|DRUG|ARO-MUC5AC|single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution
41014246|NCT05292950|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
41014247|NCT00007150|PROCEDURE|Phlebotomy|Therapeutic phlebotomy, the periodic, frequent removal of the iron contained in the hemoglobin of red blood cells.
41014249|NCT06181669|DIAGNOSTIC_TEST|Pathogen and Host Directed testing|"This study will compare up to 6 pathogen-directed tests and 3 host biomarker tests. Pathogen-directed tests detect and identify the most common causes of bacterial pneumonia, while host biomarker tests assess the host's immune response to infection. Testing will occur at various testing centers.~Evaluable participant specimens will be sent to a central laboratory for distribution to the testing centers that will perform the index testing. Testing centers will be blinded to whether the samples were collected at baseline or clinical change. Further, each testing center will prepare and test the specimens according to documented procedures, then transfer the testing results to the ARLG Statistics and Data Management Center for analysis. Neither the study sites, participants, nor adjudicators will receive the results from the index testing. After the study, untested aliquots of specimens will be stored in the ARLG Physical Biorepository."
41014253|NCT03558828|BEHAVIORAL|Step 1: PA Monitor|The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.
41014254|NCT03558828|BEHAVIORAL|Step 1: PA Monitor + Text|"The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.~In addition, these participants will receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent."
41014255|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Calls|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
41017920|NCT01693224|DEVICE|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
41156163|NCT01638533|OTHER|Pharmacological Study|Correlative studies
41014256|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Meetings|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
41156164|NCT01638533|DRUG|Romidepsin|Given IV
41156165|NCT04388514|PROCEDURE|Medical Ozone procedure|The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.
41156166|NCT01295775|DRUG|sulodexide|"A (SULODEXIDE GROUP):~50 mg a day by oral route (1+1 capsules/day) for 360 days~B (PLACEBO GROUP):~Sulodexide placebo at the same schedule dosage and for the same lengths of time as group A."
41156167|NCT06619210|DRUG|HL231 Dose 1/2/3/4|HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer
41156168|NCT06646796|OTHER|Yoga|Yoga with certified teacher, 3 times a week during 3 months.
41156169|NCT06623409|BIOLOGICAL|GARDASIL®9 (G9)|Suspension administered via intramuscular (IM) injection
41156170|NCT06623409|BIOLOGICAL|V540B|Experimental vaccine and adjuvant administered via IM injection
41156171|NCT05268185|BEHAVIORAL|Moderna Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Moderna vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, Moderna booster (0.25 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
41334754|NCT03665207|DRUG|Insulin|When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
41334755|NCT03496441|OTHER|Fecal sample collection for analysis|Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.
41334756|NCT04432571|BEHAVIORAL|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
41334757|NCT04432571|BEHAVIORAL|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following per current MOH guidelines).
41014257|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Calls|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
41014258|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Meetings|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
41014259|NCT03558828|BEHAVIORAL|Step 3: PA Monitor|During Weeks 35-50, all women will receive enhanced physical activity monitors only.
41484158|NCT00499174|RADIATION|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
41484159|NCT00499174|PROCEDURE|Biopsies|Periodic repeat biopsies
41334758|NCT04432571|BEHAVIORAL|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV). SOC-REC is a stage 1 intervention (routine care) to prevent lapses in HIV engagement. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement. Trained peer navigators will develop rapport with the participants and provide psychosocial support, case management, and assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers. The peer navigator will meet with the participant at least monthly, and no more than weekly, until HIV care engagement is demonstrated.
41334759|NCT04432571|BEHAVIORAL|E-NAV/SOC-OIC|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
41334760|NCT04432571|BEHAVIORAL|E-NAV/CCT|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following current MOH guidelines).
41334761|NCT04432571|BEHAVIORAL|E-Nav/IP-NAV|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) has unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement by providing in person navigation and counseling to a cash incentive for on-time clinic attendance and/or viral load suppression (MOH guidelines). Trained peer navigators will provide psychosocial support, case management, assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers
41334762|NCT05527106|DIETARY_SUPPLEMENT|Citicoline|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.
41334763|NCT05527106|DIETARY_SUPPLEMENT|Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.
41334764|NCT05527106|DIETARY_SUPPLEMENT|Citicoline and Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.
41334765|NCT05527106|DIETARY_SUPPLEMENT|Vitamin C|Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.
41334766|NCT04306367|DRUG|Pembrolizumab|200 mg given intravenously.
41334767|NCT04306367|DRUG|Olaparib|300 mg given orally.
41014260|NCT04010968|DRUG|venetoclax and ibrutinib (I+VEN)|"The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~* if BM MRD at M9 \< 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~* if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above."
41334768|NCT03368352|DIETARY_SUPPLEMENT|Melatonin|Dietary supplement melatonin
41334769|NCT03368352|OTHER|Hypoxia|Sleep in a hypoxic tent simulating high altitude
41334770|NCT01398228|BEHAVIORAL|quality improvement initiatives|A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
41334771|NCT02205164|DRUG|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
41334772|NCT02205164|DRUG|Palonosetron|Aloxi 0.25mg
41334773|NCT04031924|OTHER|Assessment of: 1. Functional Capacity 2. Physical Fitness 3. Physical Activity Level 4. Balance 5. Kinesiophobia 6. Psychological Status 7. Fatigue Severity|All liver transplantation patients who underwent transplant at least one year ago and healthy subjects were evaluated the first day they came.
40816407|NCT04888689|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
40816408|NCT04888689|DEVICE|IMU|"IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes."
41334774|NCT00458367|DRUG|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
41334775|NCT01487707|BEHAVIORAL|Voluntary Health Worker (VHW) Program|Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
41334776|NCT01487707|BEHAVIORAL|Safe Birth Kit|A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
41484160|NCT04061642|DEVICE|Clinical Decision Aid|The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
41484161|NCT01089621|DRUG|Duloxetine|30 mg to 120 mg administered orally, daily for 12 weeks
41014261|NCT04010968|DRUG|FCR|"All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6."
41014262|NCT06283628|PROCEDURE|Radiofrequency ablation of lumbar medial branch nerves.|"Traditional approach:~The electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (SAP) and transverse process (TP) of the vertebral body to target the traversing medial branch nerve.~Parasagittal (new) approach:~The RF cannula is placed parasagittally and more dorsally. The remainder of the procedure does not differ from the traditional method."
41334777|NCT01487707|BEHAVIORAL|Community Folk Media Campaigns|Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
41334778|NCT01636453|DEVICE|Stent assisted coiling with the Liberty Stent|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
41334779|NCT01376895|BEHAVIORAL|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
41334780|NCT01376895|BEHAVIORAL|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
41334781|NCT02725268|DRUG|Paclitaxel|Paclitaxel intravenous solution.
41334782|NCT02725268|DRUG|Sapanisertib|Sapanisertib capsules.
41334783|NCT02725268|DRUG|MLN1117|MLN1117 capsules.
41334784|NCT05474755|DRUG|GP681 40mg|2X20mg tablets taken orally
41334785|NCT05474755|DRUG|Placebo|Placebo tablets matching GP681 40mg
41334786|NCT06140628|COMBINATION_PRODUCT|Fotona4D Pro® treatment followed by daily use of formulations containing MLYAAT-1002®|Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the active comparator on the randomly assigned side of split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 28 days.
41334787|NCT06140628|COMBINATION_PRODUCT|Fotona4D Pro® treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the placebo comparator on the randomly assigned side of split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 28 dayd.
41334788|NCT00088114|DRUG|STA-4783/paclitaxel|
41014287|NCT04958694|BEHAVIORAL|CEDARS|This intervention is intended to help adolescents cope with stress and improve positive affect.
41334789|NCT03472794|OTHER|"web portal:  Mon réseau cancer du sein  (My Breast cancer Network)"|"web portal:  Mon réseau cancer du sein "
40816409|NCT01887015|DEVICE|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
41014288|NCT04886804|DRUG|zongertinib|zongertinib
41014289|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
41334790|NCT04625361|DRUG|HEC122505MsOH|Part2：Mulltiple doses once daily, up to 8 days
41014290|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
41334791|NCT04227210|BIOLOGICAL|RSV vaccine MV-012-968 (dosage #1)|Single dose administered intranasally on Day 1
41014295|NCT02063165|DIETARY_SUPPLEMENT|High Linoleic Safflower Oil|2 tsp per day (\~10g of oil)
41014296|NCT03874858|DRUG|Nilotinib|Nilotinib oral 300 mg QD hard capsules
41014297|NCT03874858|DRUG|Nilotinib|Nilotinib oral 300 mg BID hard capsules
41014298|NCT03874858|DRUG|Asciminib|Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)
41014301|NCT00397111|DEVICE|7T Magnetic Resonance Imaging scanner|Non-significant risk device used for brain imaging
41014302|NCT05030441|DRUG|Ivosidenib|. Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.
41014303|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
41017921|NCT01693224|DEVICE|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
41017922|NCT01693224|DEVICE|Cepheid Xpert MTB/Rif assay|
41017923|NCT04709237|DEVICE|omafilcon A control lens|Participants were randomized to wear omafilcon A control soft contact lens for 10 days.
41017924|NCT04709237|DEVICE|omafilcon A test lens 1|Participants were randomized to wear omafilcon A test soft contact lens 1 for 10 days.
41334792|NCT04227210|BIOLOGICAL|RSV vaccine MV-012-968 (dosage #2)|Single dose administered intranasally on Day 1
41017925|NCT04709237|DEVICE|omafilcon A test lens 2|Participants were randomized to wear omafilcon A test soft contact lens 2 for 10 days.
41017926|NCT05003700|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin and raltitrexed via the tumor feeding arteries every 3 weeks.
41017927|NCT05003700|DRUG|Lenvatinib|8 mg once daily (QD) oral dosing.
41017928|NCT05003700|DRUG|Camrelizumab|200mg intravenously every 3 weeks.
41017929|NCT02977949|DRUG|Raloxifene|
41017930|NCT06533306|PROCEDURE|Surgery for cryptorchidism.|Patients previously operated on for cryptorchidism.
41017931|NCT03675659|DRUG|intra-articular injection|intra-articular injection with magnesium sulfate with four injections at weekly intervals
41334793|NCT04824105|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|A repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System will be used to deliver intermittent theta burst to ventromedial prefrontal cortex, and continuous theta burst to pre-supplementary motor area.
41334794|NCT00643799|DRUG|Celecoxib|200 mg oral capsule once daily for 6 months
41334795|NCT00643799|DRUG|Naproxen|500 mg oral capsule twice daily for 6 months
41334796|NCT00643799|DRUG|Placebo|Matched oral placebo for 6 months
41334797|NCT01071369|DRUG|Xylocaine|0.5% Xylocaine
41334798|NCT01071369|DRUG|Xylocaine and Celestone|non-particulate Celestone
41334799|NCT03499769|PROCEDURE|natural orifice|laparoscopic total colon surgery and patients who are removed from the natural orifice and conventional will gather
41334800|NCT01917890|DIETARY_SUPPLEMENT|Curcumin|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)"
41334801|NCT01917890|DIETARY_SUPPLEMENT|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)"
41334802|NCT05168176|DRUG|Dotilavir sodium tablet|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
41014304|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
41014305|NCT06319196|DRUG|Opdualag|Opdualag vial IV every 4 weeks (Q4W)
41014306|NCT06319196|DRUG|Nivolumab|Nivolumab 480mg IV Q4W
41014307|NCT06461572|OTHER|conventional therapy|This group will receive conventional physiotherapy, which will consist of manual resistance-based neck strengthening exercises. The exercises will last 30 minutes apiece and cover cervical flexion, extension, side flexion, side flexion with rotation, and pure rotation with moderate resistance. The power ball's effect on proximal muscle control and refractive error in children with developmental delays will also be discussed.
41017932|NCT04862052|PROCEDURE|Intravascular management of prior implanted coronary drug eluting stent restenosis|Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
41334803|NCT05168176|DRUG|Dotilavir sodium tablet(Tivicay@)|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
41334804|NCT00319683|DRUG|ADH300004|
41334805|NCT01692834|DRUG|Sandimmune® Injection|
41334806|NCT01692834|DRUG|NeuroSTAT®|
41334807|NCT02229253|DRUG|degarelix|
41334808|NCT03572153|BEHAVIORAL|Self-Administered Hypnosis|Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.
41334809|NCT03572153|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.
41334810|NCT02285517|PROCEDURE|modified Meek skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
41334811|NCT02285517|PROCEDURE|mesh skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
41017933|NCT06131411|OTHER|Health promotion|Co-created culture-tailored intervention of health promotion aimed to increase healthy diet, physical activity and compliance with treatment protocols for diabetes.
41017934|NCT06131411|OTHER|Usual care|Health promotion activities routinely performed by Diabetes clinics at the recruiting centres.
41017935|NCT03898804|DEVICE|BCI and FES|The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components. The device will be tested during research sessions spanning a 13-month period.
41017936|NCT02302105|RADIATION|IGRT|Image Guided RT to the prostate
41334812|NCT02560480|DEVICE|magnetic resonance imaging|to diagonose groin injury exactly in magnetic resonance imaging
41334813|NCT00111111|DRUG|Etanercept|
41334814|NCT00012207|BIOLOGICAL|aldesleukin|
41334815|NCT00012207|BIOLOGICAL|therapeutic autologous lymphocytes|
41334816|NCT00012207|DRUG|cyclophosphamide|
41334817|NCT00012207|DRUG|prednisone|
41334818|NCT00012207|DRUG|vincristine sulfate|
41334819|NCT00012207|PROCEDURE|adjuvant therapy|
41484162|NCT06341387|OTHER|Breath, urine and blood analysis|"breath sampling: all subjects exhale into two sterile Tedlar bags, connected to a mouthpiece, in a condition similar to traditional spirometry.~Urine will be collected usual urine container.~The blood sample (\~ 5 ml) will be taken with a serum separator tube."
41484163|NCT01699763|DEVICE|Contour® NEXT LINK BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
41484164|NCT01699763|DEVICE|OneTouch® UltraLink® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
40816410|NCT05935891|DRUG|CBD-dominant|product contains 2210 mg CBD and less than 0.3% THC per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
40816411|NCT05935891|DRUG|THC dominant|contains 375mg THC and less than 20mg CBD per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
40816412|NCT03096795|DRUG|MEDI3506|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 or Dose 2 or Dose 3 or Dose 4 or Dose 5 or Dose 6 subcutaneously and Dose 6 intravenously in Part 1. Participants with COPD will receive 3 administration of MEDI3506 Dose 4 or Dose 5 or Dose 6 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of MEDI3506 Dose 6 intravenously in Part 3.
40816413|NCT03096795|DRUG|Placebo|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.
40816414|NCT06606756|OTHER|Patient Registry without intervention|This is a patient registry that collects real world data without intervening with therapeutic decision
40816415|NCT06606756|OTHER|Digital Registry and Feedback on clinical data|The data is entered via a validated online platform and is provided back to the center in aggregated form
40816416|NCT04880083|DIETARY_SUPPLEMENT|Commercially Available Starter Infant Formula|Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
40816417|NCT04494347|PROCEDURE|MitraClip TMVR and Watchman LAAO|The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
40816418|NCT04748757|DRUG|recombinant human annexin A5|recombinant human annexin A5, manufactured as SY-005
40816419|NCT04748757|DRUG|Placebo|Normal saline 50 ml
41014308|NCT06461572|OTHER|conventional therapy along with standard therapy and stability exercises.|"Group B: In addition to standard care, this group will engage in power ball exercises for neck stability and strengthening. Gradually, the resistance will rise.~Three mints in each position for a total of fifteen mints of ball exercises. At first, Powerball progressively strengthened the muscle and reduced the pain , and with continued development, allowed them to move in a pain-free range."
41484165|NCT01699763|DEVICE|Nova Max Link® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
40816420|NCT00491270|DEVICE|VS Sense|An applicator to diagnose pH increase above 5.2
40816421|NCT01981941|DRUG|Gabapentin enacarbil|Oral
41017937|NCT02375412|PROCEDURE|Pre-operative measurement of heart rate variability|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
41017938|NCT01919385|DEVICE|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
41484166|NCT00396799|DRUG|bazedoxifene/conjugated estrogens|
41484167|NCT03572166|DIAGNOSTIC_TEST|Arginine infusion|Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
41484168|NCT03572166|DIAGNOSTIC_TEST|Hypertonic saline infusion|Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
41484169|NCT03834844|BEHAVIORAL|Meditation|Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
41334820|NCT03150199|BEHAVIORAL|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 8 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered step-wise within sessions (rather than intertwined).
40816422|NCT02918396|DEVICE|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (\>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as \<0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
40816423|NCT02918396|DEVICE|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
40816424|NCT02918396|DEVICE|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
40816425|NCT05131867|DRUG|nimodipine|(60 mg/4 hours) orally or via nasogastric tube
40816426|NCT05131867|DRUG|Oral Nimodipine and milrinone|Oral Nimodipine then after the diagnosis of vasospasm is confirmed, start milrinone bolus
40816427|NCT03447899|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|Attachment and Biobehavioral Catch-up (ABC) is an in-home, 10-session, manualized parent-training program for children ages 6 months through 2 years who have experienced early adversity. ABC utilizes parent-child interactions to enhance positive interactions with the child through live coaching with particular focus on nurturing behaviors, following the child's lead, non-frightening behaviors. These behaviors include appropriate soothing and comforting when a child is distressed, responding to or imitating a child in a contingent way, and displaying warmth.
40816428|NCT06155656|OTHER|Pea protein concentrate|Ingestion of a soup containing 25 g of protein from pea protein concentrate
40816429|NCT06155656|OTHER|Pea protein isolate|Ingestion of a soup containing 25 g of protein from pea protein isolate
40816430|NCT06155656|OTHER|Pea protein extrudate|Ingestion of a soup containing 25 g of protein from pea protein extrudate
40816431|NCT06155656|OTHER|Whey protein|Ingestion of a soup containing 25 g of protein from whey protein
40816432|NCT01730365|PROCEDURE|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
40816433|NCT06493305|BEHAVIORAL|Neurolinguistic programming|In the NLP application protocol, the visual, auditory and/or tactile representation system that the woman uses most frequently will be determined. Then, using the anchoring technique, the internal reactions and external reactions created by the woman's current symptoms and emotions and thoughts regarding the urination process will be combined using the anchoring technique. Existing negative emotions will be reduced and positive emotions will be reinforced. Then, with the swish technique, the intensity of the woman's existing negative emotions will be erased from the most frequently used visual, auditory or tactile representation system. Then, taking into account the representation system that the woman uses most frequently, the belief change model will be used in her negative thoughts about the current symptom, and her negative feelings and thoughts will be replaced by positive feelings and thoughts and reinforced.
41334821|NCT03150199|BEHAVIORAL|MI-based Health Education Intervention|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments. Motivational interviewing topics (e.g., pros and cons of behavior change, importance and confidence of behavior change, identification of barriers and resources to change) will be presented related to each health behavior.
41334822|NCT00105209|DRUG|Aspirin|
41334823|NCT00105209|DRUG|clopidogrel|
41334824|NCT02318745|BEHAVIORAL|Culturally Informed Family Treatment for Adolescents|Family Therapy, Psycho-educational Modules, Individual therapy sessions
41334825|NCT02318745|BEHAVIORAL|Individual Treatment|Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
41334826|NCT04685538|DRUG|Chloroprocaine 3%|"Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery."
41484170|NCT03834844|OTHER|AF Education|6 weekly education modules on topics related to AF
40816434|NCT04487535|OTHER|Cytokine level|Serum cytokine level will be measured before surgery, 72nd after surgery and 6 weeks after surgery
40816435|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
40816436|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
40816437|NCT06457230|DEVICE|10Hz rTMS based on cerebellum and FPC|We compare the efficacy of paired-pulse stimulation relative to single-pulse stimulation. Subjects will be randomly assigned to a cerebellar + frontal pole paired-pulse experimental group.
40816438|NCT06457230|DEVICE|10Hz rTMS based on cerebellum or FPC|Subjects will be randomly assigned to a cerebellar or frontal pole randomised control group.
40816439|NCT05120570|DRUG|VIC- 1911|25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.
41334827|NCT04685538|DRUG|Tetracaine 0.5%|"Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery."
41334828|NCT01089166|DRUG|Metformin|
41334829|NCT03126578|DRUG|LEO 32731|LEO 32731 is being developed by LEO Pharma.
41334830|NCT03126578|DRUG|Midazolam|Benzodiazepine
41334831|NCT03322085|PROCEDURE|radiofrequency ablation or cryoballoon|Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
41334832|NCT04661852|DRUG|Cabozantinib|PO (dose and schedule based upon dose level and nomogram)
41334833|NCT04661852|DRUG|Topotecan|IV, over 30 minutes (schedule based upon dose level)
41334834|NCT04661852|DRUG|Cyclophosphamide|IV, over 30 minutes (schedule based upon dose level)
41334835|NCT04661852|DRUG|Myeloid growth factor|subcutaneous filgrastim (daily until ANC ≥ 1,500/mm3 after nadir) or pegfilgrastim (once) must be given, with choice of agent per institutional standard or treating physician preference, starting on day 5, 6, 7 or 8 (depending upon chemotherapy timing)
41334836|NCT03491969|DRUG|Alpha-Lipoic Acid(α-LA)|200 mg, po, tid
41334837|NCT03491969|DRUG|Placebos|200 mg, po, tid
41334838|NCT03184116|BEHAVIORAL|Individual intervention|Individual intervention based on a cognitive-behavioral program Reasoning \& Rehabilitation
41484171|NCT03834844|OTHER|Phone Calls|Weekly phone call to discuss patient concerns or questions
40816440|NCT04300517|DRUG|Three sachet of protein supplement to be mixed in with water used daily|Three sachet of protein supplement to be mixed in with water used daily
41334839|NCT04969627|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
41334840|NCT04969627|DRUG|Exenatide|Use Exenatide for 3 months to treat PCOS
41334841|NCT04030468|OTHER|Educational intervention addressed to general practitioners|"* feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~* Continuous Medical Education (CME) course"
41334842|NCT04030468|OTHER|Informative intervention addressed to patients|• leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use
41484172|NCT03340753|DRUG|KBP-5074 Capsule|KBP-5074 (0.5 mg or 1.0 mg) capsule formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
40816441|NCT02762630|DEVICE|Carestream Health Inc. weight bearing cone beam CT scanner|
40816442|NCT02178254|DRUG|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
41334843|NCT04843072|DEVICE|Evolut R/PRO bioprosthesis|To compare Evolut R/PRO versus Sapien S3/Ultra in failing surgical bioprostheses
41334844|NCT04843072|DEVICE|Edwards Sapien S3/Ultra bioprosthesis|Edwards Sapien S3/Ultra bioprosthesis
41334845|NCT00844324|DRUG|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
41334846|NCT00844324|DRUG|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
41334847|NCT01179867|OTHER|Electronic Medication Reconciliation|"1. At admission the community drug list will be electronically retrieved from the public drug insurance administrative databases using a real-time interface, and the admitting team/pharmacist will verify the list, adding over-the-counter medications~2. At discharge the attending physician/resident will write the discharge prescription using the discharge reconciliation module, allowing the physician to simultaneously view the validated community drug list and the hospital pharmacy drug list for the patient~3. The discharge communication module will facilitate identification and transfer of information on discontinued and changed medication to the respective dispensing pharmacies and prescribing physicians along with the reasons for these changes"
41334848|NCT05941676|DIAGNOSTIC_TEST|Tumour immunoprofile evaluation|Tumour immunoprofile evaluation will be performed in patients with head and neck cancer.
41334849|NCT02556411|DRUG|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
41334850|NCT02556411|DRUG|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
41334851|NCT05970068|PROCEDURE|implantation of hydrophobic tubes for edema fluid drainage|1 - A 2-cm-long incision is made at the border of the hypogastrium or lumbar region 10 cm above the inguinal crease; 2- A 1.5-cm-wide and 100-cm-long metal tube tunneling device is introduced under the skin and bluntly passed in the subcutaneous tissue toward the thigh and internal aspect of the calf; 3- Incisions 2 cm long are made in the groin and calf, through which the tunneling device was passed; 4-The hydrophobic tube is passed upward through the tunneling device, after which the tunneling device is removed; 5-The upper and lower ends of the hydrophobic tubes are fixed to the fascia with absorbable sutures.
41484173|NCT03340753|DRUG|KBP-5074 Tablet|KBP-5074 (0.5 mg or 1.0 mg) tablet formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
41484174|NCT03801421|PROCEDURE|Mass continous suture with PDS|The surgical incision will be treated by mass continous suture with PDS.
41484175|NCT03801421|PROCEDURE|Interrupted suture with thread|The surgical incision will be treated by interrupted suture with thread.
41484176|NCT04158960|BEHAVIORAL|Equine-assisted activities|Participants performed riding-related activities on and off of a horse once per week for 8 weeks
41334852|NCT05970068|DEVICE|Best Medical Treatment|Compressive therapy, Phisioterapy, venous intervention
40816443|NCT02178254|DRUG|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
40816444|NCT02178813|DRUG|Administration of minocycline|"Administration of minocycline with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o."
41014311|NCT06274528|DRUG|Lemborexant 10 mg|Within FDA approved dose 10 mg; capsule; QD, 6 month duration
41014312|NCT06274528|DRUG|Lemborexant 20mg|20 mg; capsule; QD; 6 month duration
41334853|NCT03355404|OTHER|standing patient|patient goes standing to the surgery room
41014313|NCT06274528|DRUG|Placebo|0 mg; capsule; QD; 6 month duration
41334854|NCT04803019|COMBINATION_PRODUCT|DEB-TACE|"The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F).~TANDEM® embozene microspheres are available in three different sizes, in 2 ml and 3 ml volumes of product and are supplied in preloaded vials and syringes.The maximum loadable amount on the hydrospheres 50 mg of Doxorubicina for ml. The maximum injectable dose of Doxorubicin for each treatment is 150 mg and therefore the maximum amount of microspheres that can be used for each treatment is 3 ml. The size of microspheres that will be used in this study is up to 100 ± 25 μm."
40816445|NCT02797665|DRUG|corticosteroids|prednisone 0.6mg/kg/d
40816446|NCT02797665|PROCEDURE|biliary stent|placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
40816447|NCT02759107|DRUG|Tirzepatide|Administered SC
40816448|NCT02759107|DRUG|Placebo|Administered SC
40816449|NCT02759107|DRUG|Dulaglutide|Administered SC
40816450|NCT04703816|OTHER|Interpersonal Skills Multifaceted Training Program for the physician-patient relationship|The training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations based on communication theory like Process-Com® and the Four Habits Model.
41014315|NCT05421078|DRUG|Obicetrapib|tablet
41014316|NCT05421078|DRUG|Placebo|No active ingredient
41017939|NCT02681926|PROCEDURE|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
41017940|NCT00132444|DRUG|topical vaginal application of UC-781 gel|UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
41017941|NCT03262272|DEVICE|VIE A Hemodialyzer|polysulfon membrane coated with vitamin E
41017942|NCT03262272|DEVICE|Rexsys 27H hemodialyzer|polyethersulfon membrane with large surface area : 2,7m²
41017943|NCT03262272|DEVICE|Leoceed 21HX hemodialyzer|polyslfon membrane with gamma sterilization
41017944|NCT03262272|DEVICE|Polypure 22S+ hemodialyzer|polysulfon membrane with steam sterilization
41017945|NCT06435026|DRUG|FTC/TDF 200mg/300mg|Standard Dose
40816451|NCT03628144|DIETARY_SUPPLEMENT|Impact® Advanced Recovery|The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
40816452|NCT03628144|DIETARY_SUPPLEMENT|Boost® High Protein|The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
40816453|NCT03628144|RADIATION|Radiation Therapy|Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
40816454|NCT03628144|DRUG|Chemotherapy|Standard of Care: Chemotherapy as already planned for each participant.
40816455|NCT03628144|OTHER|Quality of life (EORTC-QLQ-30)|Participants will undergo pre- and post-treatment assessments.
40816456|NCT03628144|OTHER|Evaluation of Cognitive Function (FACT-Cog, v. 3.0)|Participants will undergo pre- and post-treatment assessments.
40816457|NCT03628144|OTHER|Mindfulness Questionnaire (FFMQ)|Participants will undergo pre- and post-treatment assessments.
40816458|NCT03502967|DRUG|Hyperpolarized [1-13C] Pyruvate|Bolus injection of study drug
40816459|NCT03502967|DRUG|Hyperpolarized [2-13C] Pyruvate|Bolus injection of study drug
40816460|NCT02255058|OTHER|No intervention|The study is a Prospective observational cohort study
40816461|NCT00467194|DRUG|Rapamycin|
41014323|NCT04071951|BEHAVIORAL|Pharmacist-led Hospital Discharge Care Intervention|"Pharmacists will address medication reconciliation, medication adherence, and polypharmacy issues as appropriate. Pharmacists will rely most on their prior training, but study investigators will also encourage the use of documentation templates with reminders, Beers list, deprescribing, motivational interviewing, the Medication Adherence and Literacy tool, and post-discharge phone calls.~Pharmacists will assess patient needs and customize accordingly. All patients will receive one discharge counseling visit and one post-discharge phone call, but pharmacists will find that some patients need further phone calls, interventions, referrals, or other interactions. Some or all of the pharmacist activities may take place over the phone."
41014324|NCT06210789|PROCEDURE|Surgical excision|Periodontal plastic reconstruction of the subsequent soft tissue dehiscence after the surgical excision of the localized gingival enlargement
40816462|NCT00467194|DRUG|Bevacizumab|
40816463|NCT01984463|DRUG|Fentanyl|Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
40816464|NCT01984463|DRUG|Morphine|Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
40816465|NCT05013918|OTHER|Observational study|No intervention
40816466|NCT06277986|OTHER|cachexia|Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.
40816467|NCT02654431|PROCEDURE|Breast Cancer patient|Samples
40816468|NCT02654431|PROCEDURE|Cancer patients|Samples
40816469|NCT05615675|OTHER|Virtual Reality Headset|Patient uses a virtual reality headset and support during prone pain procedure
40816470|NCT04364555|DRUG|Clobetasol Propionate|Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.
40816471|NCT04364555|DRUG|Placebo/Klobetasol APL oral gel 0.025%|Placebo/active
40816472|NCT04364555|DRUG|Placebo|Placebo/placebo
40816473|NCT03397394|DRUG|Rucaparib|Rucaparib will be administered daily.
40816474|NCT02388490|DRUG|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
40816475|NCT03643315|BEHAVIORAL|Exercise and Meal (EX)|30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal
40816476|NCT03643315|BEHAVIORAL|No-Exercise and Meal (NEX)|30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
40816477|NCT04202224|DRUG|Ibuprofen 400 mg and Acetaminophen 500 mg|Analgesia.
40816478|NCT04202224|DRUG|Glucose|Placebo.
40816479|NCT04202224|OTHER|No drug|Standard surgical procedure without any preoperative medication.
40816480|NCT03433833|DRUG|Digoxin|Digoxin oral route once daily for 24 weeks.
40816481|NCT00002938|PROCEDURE|conventional surgery|Salvage prostatectomy
40816482|NCT04118036|DRUG|Pembrolizumab|intravenously over 30 minutes every 21 days (+/- 3 days)
40816483|NCT04118036|DRUG|Abemaciclib|Oral 2 times a day
40816484|NCT00571870|DRUG|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
40816485|NCT00388388|DRUG|losartan, hydrochlorothiazide|Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
40816486|NCT05403593|OTHER|No Intervention|No intervention, prospective data collection
41484177|NCT04158960|BEHAVIORAL|GaitWay program|Participants performed riding-related activities on and off of a horse, along with brain-building activities including balance tasks, swinging, spinning, music therapy, and sensory tasks, all once per week for 8 weeks
40816487|NCT02292758|BIOLOGICAL|Bevacizumab|Given IV
40816488|NCT02292758|BIOLOGICAL|Cetuximab|Given IV
40816489|NCT02292758|DRUG|Irinotecan|Given IV
40816490|NCT02292758|OTHER|Laboratory Biomarker Analysis|Correlative studies
40816491|NCT02292758|OTHER|Placebo|Given IV
40816492|NCT04997109|OTHER|APPLES-tele|The APPLES-tele intervention is 5 weekly telehealth sessions of therapist-demonstrated tasks, delivered over a 6 week period. Infant participants wear a soft-constraint harness (C-Mitt) on their less affected arm for 6 hours per day, while their parent encourages them to use their more affected arm to complete play-based activities as instructed by the study therapist. As the infant experiences success, heavier objects are provided. During times when the C-Mitt is not worn, parents engage therapist-demonstrated bimanual play of increasing difficulty.
40816493|NCT04997109|BEHAVIORAL|Parent-centered Approach (PCA) Support Intervention|The PCA support intervention is 5 weekly telehealth sessions delivered over a 6 week period. The PCA curriculum includes 5 basic principles of positive parenting from Triple P: ensuring a safe engaging environment, creating a positive learning environment, using assertive discipline, having reasonable expectations, and looking after yourself as a parent. All of these elements, when taught to parents in an individualized manner, can help promote responsivity, structure and expectations that are tailored to their child's condition and developmental stage. In addition, a curriculum of CP-specific knowledge will address the challenges unique to parents of children with CP, such as understanding principles of infant learning of new movements, challenges and solutions for self-directed activity in infants with CP.
40816494|NCT04997109|BEHAVIORAL|Standard of Care|Participants will receive the usual care from being followed in high-risk infant follow-up (HRIF) programs in the Early Detection and Intervention (EDI) Network.
40816495|NCT03160274|GENETIC|Genetic screening|Germline and/or tumor samples will be screened for mutations
40816496|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India
41014333|NCT03916627|DRUG|cemiplimab|Administered intravenous (IV)
41014334|NCT03916627|DRUG|Platinum Doublet|Administered intravenous (IV)
41014335|NCT03916627|DRUG|fianlimab|Administered IV
41484178|NCT02662166|DEVICE|MR imaging|3 T MRI of the urinary bladder
40816497|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
40816498|NCT02059889|DEVICE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
40816499|NCT02059889|DEVICE|4-dimensional computed tomography|Undergo 4D CT
40816500|NCT02059889|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET
41484179|NCT03667014|DRUG|Dupilumab|Dupilumab treatment
40816501|NCT02059889|DEVICE|FDG-PET|Undergo FDG-PET
40816502|NCT06267937|PROCEDURE|Access to surgery|access to surgery after hip fracture
40816503|NCT06267937|OTHER|type of intitution|public or private health care facility
41014338|NCT00018044|DRUG|Clofazimine|
41014339|NCT04616781|DIETARY_SUPPLEMENT|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|nutritional ketone ester
41014340|NCT04616781|DRUG|Isocaloric dextrose placebo|Drink indistinguishable from ketone ester
41484180|NCT02198326|DRUG|BIBN 4096 BS- in single rising doses|
41484181|NCT02198326|DRUG|Placebo|
41484182|NCT03332927|OTHER|Egg based breakfast foods|Two eggs/day, 6 days per week provided as breakfast foods such as burrito-type roll-up, egg sandwich and omelet.
41484183|NCT03332927|OTHER|Non-egg based breakfast foods|Non-egg based control foods provided as breakfast foods 6 days per week such as waffles, ready-to-eat cereal, fruits and cheeses.
41484184|NCT03150914|DRUG|Sirolimus|mTOR inhibitor or placebo
40816504|NCT04633070|BEHAVIORAL|Gamification|Gamification (including, but not limited to a ranking system, badges and achievements, points, social media interaction, and leveling up) within mobile and web-based applications (also referred to as 'apps') for lifestyle modification (diet, physical activity, smoking cessation etc).
40816505|NCT05467332|DEVICE|HIGH FLOW NASAL OXYGEN|"BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES."
40816506|NCT03401658|DEVICE|Sensor light detector|The intervention is based on a sensor technology that gathers data and transmit it to another location for processing. The monitoring utilises an LED light source, an integral detector set which has variance from device to device and chromatic based algorithms for extraction of information from the detectors. The integration of these components into a system provides robustness and stability for operation. The availability of smartphones which possess high quality cameras and constant internet connectivity provides an ideal platform for multimedia clinical data collection and real-time patient-provider communication.
40816507|NCT06605326|DRUG|Subcutaneous Treprostinil|Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.
40816508|NCT04261400|BEHAVIORAL|MAMAACT|Improved communication regarding warning signs of pregnancy complications
40816509|NCT00568373|DEVICE|Enterra Gastric Pacemaker|Gastric Pacemaker
40816510|NCT06039930|BEHAVIORAL|Tele PROTECT|Tele-PROTECT is a behavioral intervention delivered virtually over nine 45-minute sessions for depressed elder abuse (EA) victims. It is designed to work in synergy with EA resolution services that provide safety planning, support services, and links to legal services.
40816511|NCT06039930|BEHAVIORAL|Depression Education|DepEd is designed as an intervention delivered virtually over nine 45-minute sessions with active therapeutic ingredients (education, support, empathy). It is designed to be what a good clinician providing education would do with an individual with depression.
41014341|NCT04616781|OTHER|Alcohol drinks|drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
41014342|NCT05057312|OTHER|Enhancing Accessibility to Health Care|Receive enhanced access to vaccination
41014343|NCT05057312|OTHER|Informational Intervention|Receive standard CDC information
41014344|NCT05057312|OTHER|Informational Intervention|Receive video narratives
41014345|NCT05057312|OTHER|Informational Intervention|Receive written narratives
41014346|NCT05057312|OTHER|Interview|Ancillary studies
41014347|NCT05057312|OTHER|Questionnaire Administration|Ancillary studies
41484185|NCT00590278|DRUG|Tomudex|
41484186|NCT00590278|PROCEDURE|Radiotherapy|
41484187|NCT00590278|PROCEDURE|Haematology|
41484188|NCT00590278|PROCEDURE|Biochemistry|
41014350|NCT05994157|DRUG|CD38-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.
41014351|NCT06556368|DRUG|Tarcocimab tedromer|Intravitreal injection
41014352|NCT06556368|DRUG|Tabirafusp tedromer|Intravitreal injection
41014353|NCT06556368|DRUG|Aflibercept|Intravitreal injection
41014354|NCT05686330|DEVICE|Apple Watch|Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
41017946|NCT06435026|DRUG|FTC/TDF 300mg/450mg|150% Standard Dose
41484189|NCT05051501|DIETARY_SUPPLEMENT|Probiotics C2P|Probiotics will supplement normal diet. Unlike other products available on the market, which are usually of bovine origin, our probiotic has been manufactured using human-stemmed lines. The supplements are composed of a mixture of naturally occurring human gut bacteria.
41484190|NCT05587114|DIAGNOSTIC_TEST|frozen blood plasma samples|Analysis of various biomarkers using frozen blood samples
40816512|NCT02662504|DEVICE|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
40816513|NCT02662504|PROCEDURE|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
40816514|NCT02662504|DRUG|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
40816515|NCT05304442|DRUG|Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]|Single Dose of IV Iron
40816516|NCT05304442|DRUG|Ferrous Sulfate 65 mg elemental iron (325 mg tablets)|Once daily by mouth for 42 days
40816517|NCT06601933|OTHER|Cognitive Training|"Participants (n=240) will be randomized to high dose crosswords, low dose crosswords, and health education at 1:1:1 ratio, stratified by site, age (\< 70 and 70 years), and MCI status (early MCI and late MCI). In the two crossword puzzles conditions, after initial training to use the web-based platform, the participant will be assigned to do 12 weeks of crossword puzzles four times per week or 12 weeks of crossword puzzles once per week at home. After these 12 weeks, booster sessions will be either four or one 30-minute session(s) completed over 1 week. These booster sessions will occur at weeks 20, 32, 42, 52, 64, and 78. In-person assessments will occur at 0, 12, 32, 52, 78 weeks with one crossword puzzle session, which will count toward the booster session.~Health education will involve reading chapters in a book on common illnesses and lifestyle, and a research staff member will review these chapters at the same assessment intervals as the crossword puzzles conditions."
40816518|NCT05732506|DRUG|Edoxaban|There are not intervention.
40816519|NCT04715802|PROCEDURE|Immediate breast reconstruction with implant|Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.
40816520|NCT04715802|PROCEDURE|delayed breast reconstruction with implant|The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
40816521|NCT04715802|PROCEDURE|delayed breast reconstruction with autologous fat transplantation|Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.
40816522|NCT03300154|BEHAVIORAL|Financial incentives|The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
40816523|NCT03300154|BEHAVIORAL|Framing (SMS)|After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
40816524|NCT03258281|DRUG|Evolocumab|Patients will receive evolocumab 420 mg administered subcutaneously
40816525|NCT03258281|DRUG|Placebo|Patients will receive placebo administered subcutaneously
40816526|NCT04962841|OTHER|Nutraceuticals|To observe the effect on cognitive and physical impairment.
41484191|NCT04271020|DEVICE|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
41484192|NCT04209335|OTHER|isometric core muscle endurance testing|holding previously described isometric positions until fatigue
41484193|NCT03878888|DRUG|Exparel 266 MG Per 20 ML Injection|patients receive Exparel in bilateral TAP blocks for open abdomen surgery
41484194|NCT00193427|DRUG|Docetaxel|30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles
41484195|NCT00193427|DRUG|Gemcitabine|1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles
41484196|NCT00193427|DRUG|Carboplatin|AUC = 1.5 weekly x 7
40816527|NCT05153369|BEHAVIORAL|Enhanced Care|Enhanced care aims to educate participants about bipolar disorder using a didactic approach, in addition to teaching and practicing DBT skills in an applied and relevant manner based on the participant's needs. Participants will receive a total of four sessions (approx. 60 minutes in duration), to occur once a month, at a minimum. The content will be split up into psychoeducation (2 sessions) and selected DBT skills (2 sessions). Psychoeducation will be specific to youth bipolar disorder, covering topics such as symptoms of depression and hypo/mania, medications used to treat bipolar disorder, the role of biology and the environment in emotions, and vulnerability and protective factors to emotion dysregulation and mood episodes. The content of skills sessions will be individualized and based on participant needs and goals (e.g., learning and applying skills to optimize their overall functioning, address problem behaviors and/or stressors, and/or maintain commitment to treatment).
40816528|NCT05153369|BEHAVIORAL|DBT Skills Training|In DBT Skills Training, participants will only receive skills training and can choose to do this individually and/or with their individual family unit by including their parent(s) and/or sibling(s). Participants will receive 20-25 sessions (approx. 60 minutes in duration), to occur at least biweekly. Skills training will include the five standard youth DBT modules: psychoeducation about DBT and bipolar disorder, mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path. The primary focus of the skills training is to impart knowledge and acquire and strengthen pragmatic skills to replace dysfunctional behaviors. If participants choose to include their family members, they will be encouraged to coach one another in effective use of skills.
40816529|NCT05153369|BEHAVIORAL|Dialectical Behavior Therapy Full Intervention|The DBT full intervention is based on Miller et al.'s DBT for suicidal youth, with modifications for youth with BD. DBT will be conducted over 1 year with approximately 40-50 sessions. Sessions will alternate between individual and skills training sessions. Family involvement in skills training will be strongly encouraged, however will be up to the participant to decide. Participants in Level 3 will complete diary cards tailored for this population, assessing daily mood, suicidality, sleep, and medication adherence. Participants will report use of specified DBT skills on the diary card, and individualized treatment goals will be incorporated into the diary card (e.g., alcohol use). In addition, Level 3 will include skills coaching by phone (via phone and/or text). These brief, structured calls and/or texts function to promote skills generalization by helping the participant and any participating family member(s) use skills to achieve goals and solve problems.
40816530|NCT03990415|BEHAVIORAL|Exercise|Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
40816531|NCT01839591|DEVICE|catheter ALAIR|Catheter ALAIR Radiofrequency 65°
40816532|NCT05503771|BEHAVIORAL|ISA-MI|Parents seen by clinicians randomized to the intervention group will complete the Infant Sleep Assessment (ISA), either prior to their visit using MyChart (Epic patient portal) or on a tablet computer in the exam room while they wait for their clinician; 2) a Clinical Decision Support (CDS) smart form is created in the EMR based on the assessment results, with risks and MI-informed strategies highlighted; this information will be derived from a pre-programmed algorithm and theory-based, tailored communication strategies and messages; 3) the clinician uses the CDS smart form to guide counseling with the parent during the visit, applying their training in MI-informed counseling skills; and 4) Clinician gives the parent an After Visit Summary (AVS) from the EMR (or informs them that they can access the AVS in MyChart if the parent or other caregivers use the patient portal, MyChart), which summarizes and reinforces the safe sleep counseling.
40816533|NCT05503771|OTHER|Standard of Care (SOC)|Parents seen by clinicians randomized to the control group will receive the usual practice that pediatric residents are taught which follows the American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age and developmentally based anticipatory guidance. As part of their training, residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.
40816534|NCT06444815|DRUG|VET3-TGI|Oncolytic vaccinia virus engineered with immunomodulatory transgenes
40816535|NCT06444815|DRUG|Pembrolizumab|anti-pd1 antibody
40816536|NCT05191888|DRUG|Vonoprazan and Amoxicillin|14-day vonoprazan high-dose two-in-one therapy
41334855|NCT04803019|DEVICE|TAE|"The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F). This medical device is available in various sizes; in this study, to avoid that the particle size exceeds the one used for the treatment of arm A, it will be possible to use microspheres with dimensions up to 100 μm (range 75 ± 125 μm).~Embozene microspheres are offered in vials containing 1 ml of suspended product in physiological saline solution for apyrogenic sterile transport. The total volume of the Embozene microspheres, including the transport solution, is about 7 ml. To this product it is necessary to add an appropriate amount of non-ionic contrast medium in order to obtain a homogeneous suspension and with good visibility during the injection under fluoroscopy."
41484197|NCT00193427|RADIATION|Radiation|To 63 Gy
41484198|NCT02192164|BEHAVIORAL|smoking questionnaire|patients fill in a smoking questionnaire about their smoking habits
41484199|NCT05499780|DEVICE|Sentinox|The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.
41484200|NCT01949753|BEHAVIORAL|Exposure therapy with pharmacological facilitation|Exposure with response prevention and pharmacological facilitation
41484201|NCT01949753|BEHAVIORAL|Exposure therapy|Exposure with response prevention without pharmacological facilitation
41484202|NCT02998450|DRUG|IMR-687|1 of 6 possible single doses administered orally following overnight fast
40816537|NCT05191888|DRUG|Vonoprazan, Amoxicillin and Clarithromycin|14-day vonoprazan triple therapy
40816538|NCT05191888|DRUG|Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole|14th Rabeprazole reverse mixed therapy
40816539|NCT01761318|DRUG|Liraglutide|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
40816540|NCT01761318|DRUG|Liraglutide - Placebo|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
40816541|NCT04640558|DEVICE|Muscle strength measurement|The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
40816542|NCT03800342|OTHER|Aerobic Exercise Training|see arm/group description
40816543|NCT04779567|DRUG|Acetaminophen|Acetaminophen 1 gr iv 4 times a day
40816544|NCT04779567|DRUG|Placebo|100 ml saline 0.9% iv 4 times a day
40816545|NCT05741476|DRUG|DBV712|DBV712 250 mcg epicutaneous system.
40816546|NCT05741476|OTHER|Placebo|DBV712 matching placebo epicutaneous system.
40816547|NCT05741476|DRUG|DBV712|DBV712 250 mcg epicutaneous system.
40816548|NCT01644695|PROCEDURE|Bony Anchoring Reinforcement System|Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
40816549|NCT00159328|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
40816550|NCT05299996|PROCEDURE|flexible ureterorenoscopy|stone disintegration stricture dilation tumor resection access guidance
40816551|NCT04971239|DRUG|topical methotrexate micoemulsion|The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
40816552|NCT04971239|DEVICE|Excimer light|the excimer laser will be done twice weekly for a total treatment course of 12 weeks.
41334856|NCT02768103|BEHAVIORAL|task-based training|The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
41484203|NCT02998450|DRUG|Placebo Oral Capsule|Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
41484204|NCT02516423|DRUG|ixazomib|oral
41484205|NCT02516423|DRUG|lenalidomide|oral
41484206|NCT02516423|DRUG|dexamethasone|oral
41484207|NCT02516423|DRUG|zoledronic acid|IV
40816553|NCT04971239|DEVICE|Narrow band ultraviolet B|the Narrow band ultraviolet B will be done twice weekly for a total treatment course of 12 weeks.
40816554|NCT06279364|DRUG|SKB264|IV Infusion
40816555|NCT06279364|DRUG|Paclitaxel|IV Infusion.
40816556|NCT06279364|DRUG|Nab-paclitaxel|IV infusion.
40816557|NCT06279364|DRUG|Capecitabine|Tablet. Oral route of administration.
40816558|NCT06279364|DRUG|Eribulin|IV infusion.
40816559|NCT06279364|DRUG|Carboplatin|IV infusion.
40816560|NCT02815696|DEVICE|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
40816561|NCT05958953|PROCEDURE|Induction of Labor IoL|Center-specific IOL protocols, based on international guidelines, will be used.
40816562|NCT02916641|DRUG|Fuzhenghuayu|
40816563|NCT02916641|DRUG|UDCA|
40816564|NCT00759356|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
40816565|NCT00759356|DRUG|KADIAN|2 x 100 mg, single-dose capsule
40816566|NCT02241655|DEVICE|a pragmatic EEG-guided anesthetic protocol|
40816567|NCT00964041|DRUG|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
41334857|NCT04478110|BEHAVIORAL|interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care.|The interactive group education was aimed to increase participant overall understanding of CRC, screening methods, and utilization of available resources such as home test kit and navigation services, with the ultimate goal of increasing screening rates. Clinical partners provided clinical support and ensured successful screening assessment and follow-ups by offering more flexible hours of clinic operation with bilingual medical staff on site. Patient navigation assistance was also offered based on participants' needs. The range of assistance included scheduling appointments with clinical partners for sigmoidoscopy/colonoscopy for screening and diagnosis after a FIT positive result, assisting paper.
41484208|NCT04201548|OTHER|Endurance Training|"These patients will perform an aerobic exercise with a moderate intensity cycle ergometer. The exercise session on an exercise bike will last 33 minutes at a constant load, starting from an intensity equal to the load of 60% of the maximum load (max watt) achieved at the incremental test.~Working volume = 60 X 33 = 1980"
40816568|NCT00964041|DRUG|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
40816569|NCT01257230|DRUG|tiotropium Respimat low dose|IMP
40816570|NCT01257230|DRUG|placebo Respimat|placebo representing comparator
40816571|NCT01257230|DRUG|tiotropium Respimat high dose|IMP
40816572|NCT04901442|DEVICE|Aetrex L700 Speed orthotic|An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
40816573|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 lozenges|In this study, a lozenge formulation containing dairy based S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
40816574|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 dairy free lozenges|In this study, a lozenge formulation containing dairy free S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
40816575|NCT02409004|DRUG|Ataluren|Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
40816576|NCT02409004|DRUG|Rifampin|Capsule 2x3oo mg Oral
40816577|NCT02720380|OTHER|Buteyko|Intervention will be held twice a week during 3 weeks.
40816578|NCT02720380|OTHER|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
40816579|NCT06572891|OTHER|Maxillary obturator|conventional acrylic obturator
40816580|NCT06572891|OTHER|Implant supported obturator|"Implants inserted as planned The necks of the implants were bent up to 15 degrees to be parallel.~* The maxillary obturator was adjusted on the poured mode, modified and access holes will be made above the abutment to be finally relined in the patient mouth at the correct vertical dimension of occlusion to allow for immediate loading protocol.~* Impressions were made"
40816581|NCT06314477|DEVICE|CPAP treatment|Subjects allocated to this arm will receive continuous positive airway pressure (CPAP)
40816582|NCT06314477|OTHER|Hygienic and dietary advice|Subjects allocated to this arm will receive hygienic and dietary counselling
40816583|NCT06430957|OTHER|The STOP-BANG questionnaire for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
40816584|NCT06430957|OTHER|ASA recommended criteria for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
40816585|NCT06430957|OTHER|Record of postoperative complications|Respiratory complications as laryngospasm/bronchospasm, apnea, hypoxia, duration and amount of need for additional oxygen support and recovery time (duration of modified aldrete score of 9 and above) will be recorded.
40816586|NCT02968160|DRUG|Telmisartan 40mg + Rosuvastatin 20mg|
40816587|NCT02968160|DRUG|Telmisartan 80mg + Rosuvastatin 20mg|
40816588|NCT02968160|DRUG|Telmisartan 40mg, 80 mg|
40816589|NCT02968160|DRUG|Rosuvastatin 20mg|
40816590|NCT00686985|DRUG|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
40816591|NCT00459875|DRUG|sunitinib malate|
40816592|NCT06523608|OTHER|Standard survillance protocol|Patients will be followed every 6 months. They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification.
40816593|NCT06523608|OTHER|Stratified survillance protocol|"Based on PLEASE and M10LS20 scores, patients will be followed every 3 or 12 months. Low-risk patients will be followed once per year, and high-risk patients every 3 months.~They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification."
40816594|NCT02589665|DRUG|Mirikizumab|
40816595|NCT02589665|DRUG|Placebo|
40816596|NCT05456568|DEVICE|LymphAssistTM Professional|An intermittent pneumatic compression (IPC) device that mimics manual lymphatic drainage. Participants use the device daily for 12 weeks alongside their usual and standard lymphoedema care
41017947|NCT06435026|DRUG|FTC/TDF 400mg/600mg|200% Standard Dose
40816597|NCT05878886|DIETARY_SUPPLEMENT|Emergency Food Product|Each subjects of treatment group consumed 50 g food bar during 15 days. Monitoring of compliance undertaken by home visit to recall daily food consumption three days a week and to record the food bar stocks at home during study, and also weekly weight measurement.
40816598|NCT04348747|BIOLOGICAL|Anti-HER2/HER3 Dendritic Cell Vaccine|Given ID
40816599|NCT04348747|BIOLOGICAL|Pembrolizumab|Given IV
40816600|NCT06607640|BEHAVIORAL|Increase outdoor activity time during specific time periods|"The specific time periods of outdoor activity found to be beneficial for myopia prevention will be used as the intervention target, and a one-year intervention will be initiated."
40816601|NCT05734001|DIAGNOSTIC_TEST|ROTEM Tests|"This group will undergo ROTEM based correction. ROTEM bcorrection will be based on the following protocol~1. EXTEM CT \> 80 sec - FFP will be transfused at 15 ml/kg MCF \< 35 mm- Platelet will be transfused at 10 ml/kg~2. FIBTEM MCF \< 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
40816602|NCT05734001|DIAGNOSTIC_TEST|Conventional Haemostatic Tests|"To prevent bleeding during the procedure, one group will receive prophylactic transfusion of either FFP, Platelet or Cryoprecipitate based on the following protocol~1. If INR: \> 2.5 FFP will be transfused at 15 ml/kg~2. If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~3. If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
40816603|NCT04975919|DRUG|Decitabine and Cedazuridine|Given PO
40816604|NCT04975919|DRUG|Venetoclax|Given PO
40816605|NCT01110330|DRUG|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
40816606|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
40816607|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
40816608|NCT06350136|BEHAVIORAL|With Tele-Nursing|no With Tele-Nursing
40816609|NCT01739686|OTHER|CASA Intervention|"CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
40816610|NCT05088083|DEVICE|Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon|After predilation, using drug-coated balloon catheter to cover the whole treated segment
41334858|NCT04478110|BEHAVIORAL|Education Session on General Health|Participants in the control group received a group education session in a similar format with that of the intervention group delivered by trained Korean community health educators. Different from the intervention group, the education focused on general health education and primary prevention issues, including routine health examinations and screening for various diseases such as cancer. Korean version of work and communication with a physician, and arranging transportation. standard printed materials and guidelines related to the education contents were also provided, including CRC screening guidelines.
40816611|NCT05869643|DRUG|Low-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
41334859|NCT04941157|PROCEDURE|Cerebrospinal Fluid Drain Placement|Prophylactic CSF Spinal Drain to be placed prior to surgery in patients randomized to the experimental arm of the study
41334860|NCT01082003|DRUG|Trental|Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
40816612|NCT05869643|DRUG|Medium-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
41334861|NCT05869786|DEVICE|Virtual Reality Mediated Upper Extremity Rehabilitation (SensoRehab®)|In the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the SensoRehab® sensor that can detect hand movements through gloves.
41334862|NCT05869786|OTHER|conventional rehabilitation program|conventional rehabilitation program
41334863|NCT05869786|BEHAVIORAL|Exercise|Participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist.
41334864|NCT05691712|DRUG|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
41334865|NCT05691712|DRUG|Placebo|Administered SC as add-on to the pre-trial background medication.
41334866|NCT03582852|PROCEDURE|Surgical treatment of genital prolapse|Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
41334867|NCT03926637|OTHER|Multiple Sclerosis Performance Test (MSPT)|Administered as specified in the treatment arm.
41334868|NCT02121314|DRUG|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
41334869|NCT02565953|DEVICE|Paclitaxel-releasing PTA balloon catheter|
41334870|NCT02565953|DEVICE|PTA balloon catheter|
40816613|NCT05869643|DRUG|High-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
40816614|NCT05869643|DRUG|Placebo|Matching placebo capsule, taken orally once daily after breakfast
40816615|NCT01581489|PROCEDURE|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
41334871|NCT00412113|DRUG|Amlodipine besylate|Amlodipine besylate 5 mg
41334872|NCT00412113|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
41334873|NCT00412113|DRUG|Amlodipine besylate|Amlodipine besylate 10 mg
40816616|NCT06395675|DIAGNOSTIC_TEST|ID NOW™|"The ID NOW™ CT/NG is an in vitro qualitative molecular assay for the rapid differential.~detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in urine, and self-collected vaginal swabs (SVS) in symptomatic and asymptomatic individuals."
40816617|NCT02553200|DEVICE|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
40816618|NCT02553200|DEVICE|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
40816619|NCT02553200|DEVICE|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
40816620|NCT02617394|OTHER|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
40816621|NCT02617394|OTHER|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
40816622|NCT04271748|OTHER|Time Restricted Feeding|The counseling on the regimen will involve instructing the subjects on study compliance and fasting times. Subjects will be instructed to choose an eight-hour eating window (e.g., 11:00am - 7:00pm) during which the patient will be able to eat his/her normal diet. During the 16-hour fasting window (e.g., 7:00pm - 11:00am), the participant will be able to drink regular water and black coffee.
40816623|NCT01983605|DEVICE|LARIAT Suture Delivery Device|LAA exclusion procedure
40816624|NCT01338350|DRUG|AZD5423|Inhalation, suspension
40816625|NCT01338350|DRUG|Placebo|Inhalation, solution
40816626|NCT05487651|GENETIC|KUR-502|KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity against CD19+ B-cell malignancies. Following intravenous (IV) infusion, the product is expected to kill CD19+ tumor cells by direct interaction with the chimeric antigen receptor (CAR), and activation of the NKT cells to kill tumor through their innate cell killing.
40816627|NCT05462444|OTHER|Skin prick test|Skin prick test with a standard pallete of inhalational and nutritional allergens
40816628|NCT06447623|DRUG|Apatinib|Apatinib is a kind of TKI inhibitor.
40816629|NCT06447623|DRUG|CDK4/6 Inhibitor|Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
40816630|NCT06447623|DRUG|Aromatase inhibitor and Fulvestrant|Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
40816631|NCT01794078|DRUG|Aminophylline 400 mg|Xanthine derivative
40816632|NCT01794078|DRUG|Ambrisentan 5 mg|Endothelin receptor antagonist
40816633|NCT01794078|OTHER|Placebo|
40816634|NCT06482697|PROCEDURE|total colpocleisis|Total colpocleisis refers to the process where, during the dissection of the anterior and posterior vaginal walls to remove the vaginal mucosa, no holes are left. When suturing, the anterior and posterior vaginal walls are completely interrupted with mattress sutures, and no holes are left on either side or at the top of the vagina.
41334874|NCT00412113|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
40816635|NCT06482697|PROCEDURE|partial colpocleisis (LeFort)|LeFort involves the removal of a rectangular piece of mucosa from the anterior and posterior walls of the vagina, leaving a strip of mucosa 2 to 3 cm wide on each side of the vagina. The dissection is carried out close to the vaginal mucosa while preserving the vaginal bladder fascia as much as possible, creating channels on both sides of the vagina.
40816636|NCT03479177|BEHAVIORAL|High Intensity Interval Training|The exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). The goal will be to engage in three exercise sessions per week. The participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. The exercise counselor will also engage in dialogue that will motivate the participant to exercise.
41334875|NCT06201169|PROCEDURE|implant placement|All patients received four implants in the lower arch
41334876|NCT03340311|DEVICE|iHealth Wireless Smart Gluco- Monitoring System (BG5)|Over the course of 8 weeks, participants collected serum glucose logs (SGL) for 4 weeks using usual care followed by SGL's log for 4 weeks using Bluetooth-enabled glucometers and the iGluco application.
41334877|NCT05800834|DRUG|Morphine Sulfate|"For the preparation of the gel formulated for the intervention, the proportion of an ampoule of dimorf® (morphine sulfate) in the injectable presentation of 10mg/ml will be used. Morphine sulfate is a strong, systemic opioid analgesic used for the relief of severe pain.~For the base of the compound, Curatec Hidrogel with Alginate® will be used. A transparent and viscous hydrogel, which provides a moist environment, preventing the dressing from adhering to the skin, preventing additional injuries generated by difficulty removing the dressing."
41334878|NCT05800834|DRUG|Lidocaine Hcl 2% Jelly|The control group will receive lidocaine® in gel (2% sterile jelly lidocaine hydrochloride) alone. Because it is a homogeneous, transparent gel, free of lumps and impurities, it has similar characteristics to the hydrogel (Curatec Hidrogel with Alginate®) used in the preparation of morphine gel, guaranteeing the blinding of the study.
40816637|NCT04049266|DRUG|KSI-301|Intravitreal Injection
41334879|NCT03582436|PROCEDURE|Kidney transplantation|"For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis"
41334880|NCT00085345|DRUG|arsenic trioxide|
41334881|NCT00085345|DRUG|ascorbic acid|
40816638|NCT04049266|DRUG|Aflibercept|Intravitreal Injection
41334882|NCT00085345|DRUG|melphalan|
41334883|NCT00085345|PROCEDURE|chemosensitization/potentiation|
41334884|NCT00085345|PROCEDURE|chemotherapy|
41334885|NCT02175303|BIOLOGICAL|Decidual stromal cell therapy|Decidual stromal cells from placenta will be infused intravenously at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals.
41334886|NCT02025049|DRUG|DP-b99|DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)
41334887|NCT02025049|DRUG|Placebo|mannitol-based DP-b99 look-alike
41334888|NCT04803604|BEHAVIORAL|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, lay coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training as well as monthly follow-up.
41484209|NCT04201548|OTHER|Long High Intensity Interval Training|"The patients assigned to the Long-HIIT group will perform a 32-minute interval work with 4x4 protocol (active phase x passive phase) performing 4 minutes at an intensity of 80-85% of the Max Watt (active phase) spaced from 4 minutes to 40% of the Max Watt (passive phase). The goal of high intensity work will be to bring the heart rate to a level close to 85-90% of the maximum cardiac frequency achieved in the incremental exercise test. If this target is not reached within the session, the load of the next one will be increased in the following session with 10 watt steps.~Working volume = 16 X 85 + 16 x 40 = 2000"
41484210|NCT04201548|OTHER|Short High Intensity Interval Training|"The patients assigned to the Short-HIIT group will perform an interval work with initial intensity equal to 100% of the Max Watt highlighted in the incremental exercise stress test in the phase (30 seconds) followed by a passive phase of 30 seconds at 50% of the Max Watt for a period of 26 minutes a day. The intensity will be gradually increased during the sessions with symptom-based progression, according to the protocol of Maltais et al. with steps of 10 watts each increment.~Working volume = 13 X 100 + 13 x 50 = 2050"
41484211|NCT02441244|DRUG|Visbiome|Visbiome probiotic
41484212|NCT02441244|OTHER|Placebo|Placebo
41484213|NCT03848169|OTHER|Radiofrequency|See previous page
41484214|NCT03024736|OTHER|buprenorphin|"if buprenorphine has better neonatal outcomes compared to methadone in~the treatment of opioid-maintained pregnant women"
40816639|NCT04049266|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
40816640|NCT05293613|DEVICE|extracorporeal shock wave lithotripsy|shock wave transmited from the device through patient body towards the stone to disintegrate it
41334889|NCT02945995|PROCEDURE|hip arthroscopy|Follow up after hip arthroscopy in pt with previous PAO. Follow up by questionnaires send til the cohort
41334890|NCT02944136|BEHAVIORAL|enhanced usual care|usual care from health providers
41334891|NCT02944136|BEHAVIORAL|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
41334892|NCT02608125|DRUG|PRN1371|
41484215|NCT01868711|BEHAVIORAL|Cognitive Behavior Therapy|
41334893|NCT04252261|DRUG|sulforaphane|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
41334894|NCT04252261|DRUG|placedo|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
41334895|NCT01020032|OTHER|"Individual receptive music therapy by U sequence method"|During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
41334896|NCT06339606|OTHER|Biospecimen collection|Biospecimens, including maternal blood and cervical mucus will be collected serially during pregnancy. After delivery tissue samples from the placenta and umbilical cord blood will be collected.
41334897|NCT01067651|DEVICE|Plaster of Paris (POP) casting using the Ponseti Method|
41334898|NCT01067651|DEVICE|Semi-Rigid Fiberglass softcast using the Ponseti Method|
41334899|NCT04509401|DRUG|Vitamin B 6 with Magnesium|Patients of intervention group will receive high dose of vitamin B6 with magnesium. This group will receive high dose of vitamin B6 with magnesium orally for 12 weeks.
40816641|NCT04085458|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
40816642|NCT04385472|RADIATION|3T MRI|The main method used will be 3 Tesla MRI, which is a high resolution imaging technique. The participants will be asked to undergo musculoskeletal MRI scanning (pelvis and lumbar spine).MRI is a non-invasive procedure which excludes the risk of radiation (in comparison to other imaging modalities: X-ray, CT
40816643|NCT04907773|OTHER|Capillary blood sampling|Each subject will have one to two capillary blood collections.
40816644|NCT04907773|OTHER|Venous blood sampling|Each healthy subject will also have a reference venous blood collection.
40816645|NCT04907773|OTHER|Arterio-venous blood sampling|Each hemodialysed subject will also have a reference arterio-venous blood collection.
41334900|NCT04509401|DRUG|placebo of vitamin B6 and magnesium|Patients of control group will receive oral placebo tablet in the same manner, schedule for 12 weeks.
41334901|NCT02953613|DEVICE|NIRS/IVUS|Cardiac catheterization using infraredx
41334902|NCT04383613|OTHER|Prone positioning|The intervention is prone positioning (i.e., instructing a patient to lie on their stomach while they are in bed) for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for \>24 hours or study outcome. Patients will be asked to aim for prone positioning four times per day for at least two hours each time, and will be encouraged to sleep on their stomach at night.
41334903|NCT00113412|DRUG|SP01A|
41334904|NCT03191812|OTHER|transcranial Direct Current Stimulation (tDCS)|There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
40816646|NCT01408550|DRUG|NPB-01|Intravenous immunoglobulin
40816647|NCT01408550|DRUG|Placebo|Physiological saline
40816648|NCT06232850|OTHER|Position sense and manual dexterity evaluate|Position sense and manual dexterity evaluate
40816649|NCT00834990|DRUG|divalproex sodium|delayed-release 500 mg tablet
40816650|NCT00834990|DRUG|Depakote®|delayed-release 500 mg tablet
40816651|NCT04052763|DIAGNOSTIC_TEST|FFR-CT|FFR-CT is a non invasive method using coronary CT images and 3 dimensional modelling to reconstruct coronary arteries and their stenoses, with subsequent calculation of fractional flow reserve (FFR) based on a mathematical algorithm.
40816652|NCT04052763|DIAGNOSTIC_TEST|FFRangio™|Angiography-derived FFR (FFRangio™) uses coronary angiography images and a mathematical algorithm to reconstruct a 3 dimensional model of coronary arteries with calculation of FFR without the use of a pressure guide.
40816653|NCT04549116|DRUG|Progesterone-IBSA Injectable Solution|Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours
40816654|NCT04549116|DRUG|Progesterone Vaginal Gel with Applicator|Crinone 8%, 90 mg, QD intravaginally
40816655|NCT04549116|DRUG|Placebo Vaginal gel with applicator|Vaginal gel Placebo, once daily (QD) intravaginally
40816656|NCT04549116|DRUG|Placebo injectable solution|Placebo injectable solution, BID SC Injection every 12 hours
40816657|NCT03915574|DEVICE|25G Dural Puncture Epidural|Dural puncture created with a 25 gauge spinal needle
40816658|NCT03915574|DEVICE|Standard Epidural|Control group - standard epidural (no dural puncture)
40816659|NCT06315907|OTHER|Responses to survey questions|All 400 participants will first complete a demographic information survey and the new food noise questionnaire. Of these 400 participants, 250 participants will then complete additional questionnaires to assess construct validity. The remaining 150 participants will be asked to complete the food noise questionnaire again in approximately 1 week to assess test-retest reliability.
40816660|NCT03659149|DRUG|CKD-333 formulation I|1 tablet administered before the breakfast(single-dose)
40816661|NCT03659149|DRUG|CKD-333 formulation II|1 tablet administered before the breakfast(single-dose)
40816662|NCT03659149|DRUG|CKD-330+D086|2 tablet administered before the breakfast(single-dose)
40816663|NCT03729037|OTHER|CPR self-training|
40816664|NCT00306657|PROCEDURE|Optic nerve sheath fenestration|
40816665|NCT02141399|DRUG|ALKS 5461|Sublingual tablet, taken daily
40816666|NCT01034566|RADIATION|Proton Beam Radiation Therapy|
40816667|NCT05940363|COMBINATION_PRODUCT|Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies|To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.
40816668|NCT02559934|DRUG|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
40816669|NCT03193086|DRUG|Alemtuzumab|Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.
40816670|NCT06375473|DRUG|Irinotecan liposome II combination therapy regimen|Irinotecan liposome II combination therapy regimen
40816671|NCT03539289|BEHAVIORAL|MUFA Diet|Control of patient MUFA Diet
40816672|NCT03539289|BEHAVIORAL|SFA Diet|Control of patient SFA Diet
40816673|NCT00562263|BEHAVIORAL|Lifestyle modification|Dietary modification and regular physical activity
40816674|NCT04726150|OTHER|ILR implantation|If LGE is present on CMR, ILR implantation will be proposed
40816675|NCT03150576|DRUG|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
40816676|NCT03150576|DRUG|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
40816677|NCT06056440|PROCEDURE|Virtual reality|"The VR intervention program for the experimental group will be carried out with a frequency of 3 sessions/week, duration of approximately 45 minutes, and for a total of 12 weeks, being performed in addition to the patient's usual treatment program.~The Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. Specifically, the specific functional rehabilitation program will be used, which comprises exercises that are easy to perform, with a playful component, and which encourage the patient's continuous attention to the task performed, acting as a distractor phenomenon in the face of restrictive movement factors such as fear of pain or movement. This software offers the possibility of adjusting the number of repetitions and characteristics of the exercises, thus allowing an individualized physical rehabilitation"
40816678|NCT06056440|OTHER|Control group|The control group will only receive their usual treatment program for the 12-week duration of the study.
40816679|NCT01341808|BIOLOGICAL|Epaxal Berna (virosomal hepatitis A vaccine)|standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
40816680|NCT05758389|DRUG|Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU|evaluate the efficacy and safety of immunotherapy combined with chemotherapy
40816681|NCT03315273|OTHER|Test battery to measure the motor imagery ability|Participants will perform 3 different tests to measure the motor imagery ability
40816682|NCT01974557|OTHER|Exercise|
40816683|NCT04547335|DRUG|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
40816684|NCT00564863|BIOLOGICAL|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
40816685|NCT02200003|BEHAVIORAL|attention bias modification for anxiety|
40816686|NCT04149158|DIETARY_SUPPLEMENT|Placebo|
40816687|NCT04149158|DIETARY_SUPPLEMENT|Sinetrol® Xpur|
40816688|NCT05943392|OTHER|EEG recording|EEG recording to assess cortical processing of non-painful tactile, auditory, and/or visual stimuli
40816689|NCT05943392|OTHER|Psychophysics (behavioural experiments)|Behavioural experiments to assess perception of non-painful tactile, auditory, and/or visual stimuli
40816690|NCT02965183|OTHER|Temperature measurements|
40816691|NCT06470919|OTHER|SMS reminders for upcoming vaccination(s)|All parents/caregivers of children in participating villages will receive access to a digital vaccine card. This will be used for record-keeping application (digital vaccine registry). Selected parents/caregivers of children will receive SMS messages and reminders related to vaccination.
40816692|NCT03652857|DRUG|Apatinib Combined With Vinorelbine|Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
40816693|NCT01242891|DEVICE|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
40816694|NCT02901002|OTHER|Sensory testing in the two hand|spontaneous sensations while watching a hand
40816695|NCT02901002|OTHER|Neuropsychological evaluation|Score to anxiety-depression scale
40816696|NCT01205061|DEVICE|Emervel Deep Lidocaine|20 mg/mL + 0.3% lidocaine
40816697|NCT01205061|DEVICE|Juvederm Ultra Plus|24mg/mL
40816698|NCT02453945|DEVICE|Adjustable Support Bra|A ClearPoint Medical support bra
40816699|NCT03317626|DIAGNOSTIC_TEST|Cold Stimulus (ice) Test|Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
40816700|NCT03404531|BEHAVIORAL|Social Media Messages Intervention Group|The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.
41484216|NCT03245645|OTHER|Dietary Intervention|Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
40816701|NCT03404531|BEHAVIORAL|Website Only Group|The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
40816702|NCT01781650|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
40816703|NCT01781650|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
40816704|NCT01781650|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
40816705|NCT05440591|DRUG|Dapagliflozin|Dapagliflozin 10mg tablets
41334905|NCT05300893|OTHER|No night splint|Instead of the usual treatment with a night splint for three months after percutaneous needle fasciotomy patients do not receive treatment with a night splint.
40816706|NCT05440591|DRUG|MetFORMIN 500 Mg Oral Tablet|Metformin 500 mg tablets twice daily
40816707|NCT05440591|DRUG|Dapagliflozin / metFORMIN Pill|Combination pill
40816708|NCT03860012|DRUG|Folic Acid|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
40816709|NCT05723731|DEVICE|taVNS|"Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)"
40816710|NCT05723731|DRUG|Laxative Agent|Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
41334906|NCT06180876|DRUG|remimazolam|continuous infusion
41334907|NCT06180876|DRUG|propofol|continuous infusion
40816711|NCT04566562|DIAGNOSTIC_TEST|Brain Imaging|Magnetic Resonance Imaging (MRI) using diffusion weighted pseudo-continuous arterial spin labeling (DW-pCASL) .
41334908|NCT01501734|DEVICE|watch-pat|"The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.~The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.~Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea."
40816712|NCT04566562|DIAGNOSTIC_TEST|Cognitive Testing|Wide Range Assessment of Memory and Learning (WRAML 2) and Montreal Cognitive Assessment (MoCA)
40816713|NCT04566562|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory Markers
40816714|NCT02725814|OTHER|24% Sucrose Solution|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
40816715|NCT00646321|DRUG|budesonide/formoterol (Symbicort)|
40816716|NCT00646321|DRUG|budesonide|
40816717|NCT02753907|DIETARY_SUPPLEMENT|Low LA|Individuals who replaced 10 mL soy oil with one apple
41334909|NCT02235168|PROCEDURE|six minute walking test|
41484217|NCT01440439|DRUG|Insulin glargine|Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
41484218|NCT01440439|DRUG|Insulin detemir|Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
41484219|NCT06280378|DRUG|KL003 Cell Injection Drug Product|Administered by intravenous infusion after myeloablative conditioning with busulfan.
41484220|NCT00855803|RADIATION|radiation|Given in 1 or 5 fractions
40816718|NCT02753907|DIETARY_SUPPLEMENT|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
40816719|NCT06204692|PROCEDURE|dental implant|consisted of 6 patients where computer guided dental implant placement
40816720|NCT05721326|OTHER|Sequential EHR Communications|The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
40816721|NCT02013206|DRUG|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
41334910|NCT06263660|DIETARY_SUPPLEMENT|Keto-like supplement|Participants will consume 9.25g stick packs of the keto-like supplement dissolved in water 3 times per day for 8 weeks.
41334911|NCT06263660|DIETARY_SUPPLEMENT|Placebo|Participants will consume 9.25g stick packs of placebo dissolved in water 3 times per day for 8 weeks.
40816722|NCT04434092|DRUG|Crovalimab|Crovalimab will be administered as specified in the respective arms.
40816723|NCT04434092|DRUG|Eculizumab|Eculizumab will be administered as specified in the respective arm.
40816724|NCT03863470|BEHAVIORAL|Early mobilization intervention|The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
40816725|NCT02438384|BEHAVIORAL|Video|This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
40816726|NCT02438384|BEHAVIORAL|Phone follow-up|The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
41334912|NCT04821960|BEHAVIORAL|Tailored Mindfulness Program for Fear of Memory Loss|The tailored mindfulness program has been specifically created to focus on fear of memory loss compared to general mindfulness lessons and activities.
41334913|NCT04821960|BEHAVIORAL|Conventional Mindfulness Program|Routine non-tailored mindfulness lessons and activities.
41334914|NCT01171014|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
41334915|NCT01171014|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
41334916|NCT01171014|DIETARY_SUPPLEMENT|Placebo|Placebo, once a day for 14 days
41334917|NCT01102140|DRUG|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
41334918|NCT01102140|DRUG|Sugar Pill|Matching sugar pill
41484221|NCT01957228|PROCEDURE|bone biopsies|
41484222|NCT03992794|DIAGNOSTIC_TEST|Measurement of MR-proADM|It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
41484223|NCT04866849|OTHER|examination|"The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
40816727|NCT05526664|OTHER|Genetic testing and Omics analysis|Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
40816728|NCT06220591|PROCEDURE|Superior trunk block|"The patient will receive selective supraclavicular nerve block, then will undergo blockage of superior trunk the fifth and sixth cervical nerves of the brachial plexus. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. Then ultrasound probe will be moved to scan the superior trunk the fifth and sixth cervical nerves in the scalene groove.15 cc of local anesthetics mixture will be injected in 0.5 cc aliquots to encircle the fifth \& sixth cervical nerve roots."
40816729|NCT06220591|PROCEDURE|Clavipectoral fascial plane block|"The patient will receive selective supraclavicular nerve block, then will undergo clavipectoral fascial plane block. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. The ultrasound probe will scan both the medial \& lateral ends of the clavicle. Then Local anesthetics mixture15 cc will be injected in 0.5 cc aliquots after negative aspiration between the periosteum of the clavicle and the clavipectoral fascia. The same technique will be conducted on both the lateral and medial ends of the affected clavicle."
40816730|NCT04407650|DRUG|Metformin|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
40816731|NCT04407650|DRUG|Ursodeoxycholic Acid|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
40816732|NCT04083508|OTHER|Mosquito bites|Successful feeding of 5 infected P. vivax mosquitoes
40816733|NCT06236984|OTHER|multiFiltratePRO with all CKRT treatment modes|Retrospective Data Analysis of CKRT treatments in adult mode with multiFiltratePRO
40816734|NCT05832515|DRUG|Fludarabine Phosphate for Injection|Intravenous injection of fludarabine phosphate at a dose of 30 mg/m2 from day -5 to day -2 of immunoablative conditioning regimen.
41334919|NCT04846972|BEHAVIORAL|FASTRACS intervention|"Intervention (4 steps) :~* Penultimate to last chemotherapy : patient will receive tools of the intervention~* 1 month after the end of oncological treatment (OT): patient will attend a general medicine consultation with the GP RTW checklist~* 2 months after OT: patient will attend a pre RTW visit with the OP RTW checklist~* 5 months after the end of OT: if the patient has not returned to work 10 months after inclusion, they will have a visit with an OP-RTW to work coordinator~Self-questionnaires will evaluate quality of life (EORTC QLQC30, BR23, Euroqol (EQ-5D-5L)), anxiety and depression (HAD), employment status, self-efficacy to return to work (RTW-SE11), pre-RTW and RTW visit with the OP, social support, care consumption, physical activity (short IPAQ), perceived performance (WRF), work conditions. The implementation and use of the intervention tools will also be assessed: the patient guide, the employer guide, RTW checklists for the GP and the OP."
41334920|NCT04708769|BEHAVIORAL|Smartphone App Participants (APP)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
41334921|NCT04708769|BEHAVIORAL|Diabetes Prevention Program Participants (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
41334922|NCT03366597|DRUG|Sevoflurane|1.5%-3% Sevoflurane will be given during the cardiac surgery except cardiopulmonary bypass.
40816735|NCT02537587|OTHER|Control 1|67g of control bar
40816736|NCT02537587|OTHER|Control 2|86g of control bar
40816737|NCT02537587|OTHER|15/0|66g of experimental bar 15/0
40816738|NCT02537587|OTHER|15/0LS|84g of experimental bar 15/0LS
40816739|NCT02537587|OTHER|15/5|75g of experimental bar 15/5
40816740|NCT02537587|OTHER|10/5|72g of experimental bar 10/5
40816741|NCT02537587|OTHER|10/10|80g of experimental bar 10/10
40816742|NCT00712036|BEHAVIORAL|Interim|Methadone maintenance with emergency counseling only for up to 4 months
40816743|NCT00712036|BEHAVIORAL|Comprehensive|Methadone treatment with counseling as usual
40816744|NCT00712036|BEHAVIORAL|Restored|Methadone maintenance with counseling provided by a clinician with a lower than usual caseload
40816745|NCT04614870|DIAGNOSTIC_TEST|DETEC® Esterase|DETEC® Esterase is a disposable diagnostic device that is used to indicate the presence or absence of infection based on the presence or absence of the evaluated level of leukocyte esterase by testing the freshly recovered wound dressing which are soaked with wound exudate.
40816746|NCT01847066|DEVICE|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
40816747|NCT01847066|DEVICE|Erbium 2940 plus cosmetics|laser
40816748|NCT02793817|DRUG|KPI-121 1% Ophthalmic Suspension dosed BID|
40816749|NCT02793817|DRUG|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
40816750|NCT00995397|DRUG|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
40816751|NCT00995397|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
40816752|NCT04651439|DRUG|Filgrastim|"Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~* 20 to \< 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~* 30 to \< 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 60 to \< 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* 90 to \< 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* \> 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)"
40816753|NCT04651439|DRUG|Placebo|"Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~* 20 to \< 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~* 30 to \< 60kg = 20mL of Glucose 5% solution (by IV)~* 60 to \< 90kg = 20mL of Glucose 5% solution (by IV)~* 90 to \< 120kg = 20mL of Glucose 5% solution (by IV)~* 120 to 150kg = 20mL of Glucose 5% solution (by IV)~* \> 150kg = 20mL of Glucose 5% solution (by IV)"
40816754|NCT04540666|DRUG|Propofol|Targeted Controlled Propofol Infusion will be set at 1 micro gram/ml.
40816755|NCT05392790|OTHER|Progressive resisted exercise training|Progressive resisted exercises will be started with the 8 maximum repetition test (8 RM) performed at progressive intensities. The subject will perform the 8 RM test at the beginning and the end of each cycle over the two-month training period. Each training session lasts sixty minutes and will be performed three times per week on alternate days.
40816756|NCT05392790|DRUG|Calcium and Vit D|Traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
40816757|NCT05392790|OTHER|Aerobic exercises|Aerobic exercises will be applied at 70 - 80% of their maximum heart rate. Trained health professionals supervised the exercise program. Each exercise session will begin with a 5-10-minute warm-up, will be followed by 20 -30 minutes of aerobic activity, and will be concluded with a 5-10-minute cool-down period.
40816758|NCT04047875|DRUG|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting
40816759|NCT04047875|DRUG|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
40816760|NCT03570918|BIOLOGICAL|MGD014|HIV-1 x CD3 bispecific DART molecule
40816761|NCT03822598|BEHAVIORAL|Teaching Recovery Techniques, TRT|TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
40816762|NCT00002114|DRUG|Procysteine|
41334923|NCT00671398|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally for one night only.
41334924|NCT00671398|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally for one night only
41334925|NCT00671398|DRUG|Placebo|Ramelteon placebo-matching tablets, orally for one night only
41334926|NCT04905823|DIAGNOSTIC_TEST|blood test|assessment of humoral, immune cell response and glycemia
40816763|NCT05763381|DEVICE|Photobiomodulation Therapy (PBMT)|Participants will receive PBMT with the PBM device over the course of three consecutive weeks (three treatments per week). PBM treatments will take approximately 5-10 minutes to administer at each session. Specific treatment parameters will be based on measurements of calf, ankle, and foot using pre-calculated treatment tables; participants will receive 10 J/cm2, 25W output power, and the length of the treatment will be dependent on treatment area (size). PBMT will be administered by a trained member of the study team using the LightForce® XPi therapy laser, provided by LiteCure, LLC/DJO Global (New Castle, DE). The LightForce® XPi therapy laser is an FDA cleared device for the treatment of pain. The trained team members will use the Smart Hand Piece technology, which achieves effective treatments and improves dosing accuracy by assessing the operator's speed and providing real-time visual (red - amber - green light) and sensory feedback.
40816764|NCT05763381|DEVICE|Sham-Photobiomodualtion Therapy (Sham-PBMT)|Sham-PBM treatment time will be calculated in the same way as the PBM treatment group, with the time of treatment dependent on the size of the treatment area. The sham-PBMT will be administered by rolling the massage ball over the plantar surface of the foot and dorsal aspect of the calf in contact with the participants' skin. Because emission of photons at the selected treatment parameters may cause participants in the treatment group to feel warmth, the massage ball will be warmed in the sham-PBMT. The device will be turned on, so the red aiming beam will be visible, but the operator will not activate the switch to emit photons.
41334927|NCT03698422|DIAGNOSTIC_TEST|Blood and urine samples|Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.
40816765|NCT04282096|OTHER|native and non native casein|selected participant will test the 3 treatments in a random order
40816766|NCT04801225|DEVICE|Non-invasive electromagnetic stimulation for acute stroke treatment|Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
40816767|NCT05894720|OTHER|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs."
40816768|NCT06369467|DRUG|linvoseltamab|Administered by intravenous (IV) infusion
40816769|NCT06369467|DRUG|dupilumab|Administered by subcutaneous (SC) injection
40816770|NCT05811520|OTHER|Scapular stabilization exercises with conventional therapy|The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec
40816771|NCT05811520|OTHER|Thoracic extension exercises with conventional therapy|Thoracic extension exercises consist of three exercise protocols
41334928|NCT03622541|DRUG|Sorafenib 200mg|Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
41334929|NCT01719679|BEHAVIORAL|School Located Vaccine (SLV) Program|A community vaccinator will administer vaccines to students whose parents consent for their child to participate
41334930|NCT05680818|DRUG|Encaleret|Administered as film-coated tablet for oral use
40816772|NCT06106061|DEVICE|Decompression + FFX®|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression associated with the use of FFX® implant
40816773|NCT06106061|PROCEDURE|Decompression alone|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression alone
40816774|NCT00491036|DEVICE|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
41334931|NCT05680818|DIETARY_SUPPLEMENT|Standard of Care|Calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)
41334932|NCT03979872|DIAGNOSTIC_TEST|MC1R Genetic Testing|\[See arm/group descriptions\]
41334933|NCT03979872|OTHER|Skin Cancer Education|\[See arm/group descriptions\]
41334934|NCT03979872|DEVICE|UV Photo|\[See arm/group descriptions\]
41334935|NCT01521806|DIETARY_SUPPLEMENT|Dietary Fiber|Dietary fiber will be added to snack foods
41334936|NCT00095719|DRUG|Aripiprazole|IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.
41334937|NCT00095719|DRUG|Placebo|IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
41334938|NCT01917552|DRUG|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
41334939|NCT02260388|DRUG|Nortriptyline|
41334940|NCT02260388|DRUG|Duloxetine|
41334941|NCT02260388|DRUG|Pregabalin|
41334942|NCT02260388|DRUG|Mexiletine|
41334943|NCT00499460|DIETARY_SUPPLEMENT|garlic powder tablets|Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
41334944|NCT00499460|DRUG|oxycodone|Single administration of three 5-mg oxycodone tablets or a 15-mg dose
41334945|NCT03892525|DRUG|Selicrelumab|escalated dose in intratumoral injection, every 3 weeks, for 3 cycles
41334946|NCT03892525|DRUG|Atezolizumab|1200mg IV every 3 week until progression or relapse for maximum 1 year
41334947|NCT00784082|DRUG|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
41334948|NCT04972266|DEVICE|AcumenTM Hypotension Prediction Index software|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
41334949|NCT03626480|OTHER|No treatment|No treatment
40816775|NCT06556095|DRUG|Dexamethasone 4mg/ml solution|The study intervention dexamethasone solution (4mg/ml) is used to hydrate bone allograft.
40816776|NCT03647150|DRUG|amoxicillin|At enrollment the child will receive a 1 week course of amoxicillin
40816777|NCT03647150|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
40816778|NCT03647150|BEHAVIORAL|Mother Care group|Nutrition education via mother care groups lead by a respected elder in the local community
40816779|NCT00725348|DRUG|Talarozole|1.0 mg oral dose per day
40816780|NCT06601517|DRUG|Repaglinide|Single dose; Administered orally
40816781|NCT06601517|DRUG|Atorvastatin|Single dose; Administered orally
40816782|NCT06601517|DRUG|Digoxin|Single dose; Administered orally
40816783|NCT06601517|DRUG|Rosuvastatin|Single dose; Administered orally
40816784|NCT06601517|DRUG|HDM1002|Administered orally
40816785|NCT06558422|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined either to maintain fasting serum insulin levels (MH protocol) or to reduce fasting serum insulin levels by approximately 50% toward euinsulinemia (RE protocol).
41014402|NCT04422912|BIOLOGICAL|DSG3-CAART or CABA-201|"Intravenous infusions of DSG3-CAART alone at different doses and different fractionations. Subjects may also receive varying doses of DSG3-CAART as part of a sub-study, which will employ pre-treatment with intravenous immunoglobulin, cyclophosphamide, and with or without fludarabine to potentially increase the in vivo expansion, persistence and activity of DSG3-CAART.~OR~CABA-201: Single intravenous infusion of CABA-201."
41334950|NCT06397534|OTHER|Education|"In the experimental group, students will be administered the Introduction Characteristics Form, Stoma Care Knowledge Assessment Form (pre-test), and the General Self-Efficacy Scale (pre-test). Subsequently, digital materials (such as stoma care presentation materials and stoma care demonstration videos) will be prepared by the researchers. The video content will be uploaded to the 'Edpuzzle' program, which is accessible via internet connection or downloadable to devices. The video content in the 'Edpuzzle' program will consist of stoma care procedural steps. Following this, students will apply the stoma care skill in the skills laboratory under the supervision of instructors. To reinforce the implementation in the experimental group, online activities such as word clouds and quizzes will be sent. After the implementation and 4 weeks later, the 'Stoma Care Knowledge Assessment Form (post-test)' and the 'General Self-Efficacy Scale (post-test)' will be administered online."
41334951|NCT04263415|DRUG|Semaglutide|semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks
41334952|NCT04263415|OTHER|Placebo|once-weekly injection with placebo pen for 16 weeks
41334953|NCT02512276|BEHAVIORAL|Telepharmacist intervention|The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
41334954|NCT04880681|DEVICE|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
41014403|NCT03946670|DRUG|MBG453|MBG453 is being administered i.v.
41014404|NCT03946670|DRUG|Placebo|Placebo is being administered i.v.
41014405|NCT03946670|DRUG|Hypomethylating agents|Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
41014406|NCT04777396|DRUG|Semagludtide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
41014407|NCT04777396|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
40816786|NCT06558422|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
40816787|NCT06558422|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
40816788|NCT06558422|DRUG|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
40816789|NCT06558422|DRUG|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
40816790|NCT06558422|DIAGNOSTIC_TEST|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
40816791|NCT06558422|DIAGNOSTIC_TEST|[1-13C1] sodium acetate|Stable isotope tracer administered to calculate de novo lipogenesis during pancreatic clamp.
40816792|NCT06558422|DIETARY_SUPPLEMENT|Nestle BOOST Plus|"Nutritional supplement will be administered to provide standardized mixed meals prior to the pancreatic clamp."
40816793|NCT06558422|DIETARY_SUPPLEMENT|KIND Bar|Energy bar snack will be administered the evening before the pancreatic clamp.
40816794|NCT06558422|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
40816795|NCT06558422|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
40816796|NCT00556608|DEVICE|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
40816797|NCT00556608|DEVICE|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
40816798|NCT03615872|DEVICE|pessary use|evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
41334955|NCT04880681|DEVICE|Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000)|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
40816799|NCT00811005|RADIATION|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
40816800|NCT00811005|RADIATION|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
40816801|NCT02375841|BEHAVIORAL|psychometric tests, questionnaires and neurocognitive assessments|
40816802|NCT05814393|DRUG|Treatment Period(JW0201)|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
40816803|NCT05814393|DRUG|Treatment Period(Placebo)|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
40816804|NCT05814393|DRUG|Extension Period(JW0201)|JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)
40816805|NCT01952548|DRUG|K-312|
40816806|NCT01952548|DRUG|Placebo|
40816807|NCT02694276|BEHAVIORAL|Internet-based cognitive behavior therapy|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
40816808|NCT02899234|OTHER|E-cigarette|A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
40816809|NCT02977936|DIETARY_SUPPLEMENT|Cartimotil Fort|1 to 4 capsules per day during 90 days
40816810|NCT02609841|DEVICE|Cardiac rhythm remote monitoring system|Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
40816811|NCT00025298|DRUG|amifostine trihydrate|
40816812|NCT00025298|DRUG|carboplatin|
40816813|NCT00025298|DRUG|cisplatin|
40816814|NCT00025298|DRUG|paclitaxel|
40816815|NCT00025298|RADIATION|radiation therapy|
40816816|NCT05045482|DRUG|Saroglitazar Magnesium 1 mg|Group-8: Total of 12 subjects will be enrolled in the Group-8. Group 8A (n=3, consist of mild hepatic impairment subjects); Group 8B (n=3, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
40816817|NCT05045482|DRUG|Saroglitazar Magnesium 2 mg|Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
40816818|NCT05042765|OTHER|self-reported entheogen use|self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
41156172|NCT05268185|BEHAVIORAL|Pfizer Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Pfizer vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, the Pfizer booster (0.30 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
41334956|NCT06274268|DIAGNOSTIC_TEST|Sarcopenia diagnostic test|the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.
41334957|NCT03438513|BEHAVIORAL|Occupational Therapy Assessment|The occupational therapy assessment includes a functional evaluation of the disorders impact (activities of daily living)
41334958|NCT03438513|BEHAVIORAL|Psychological Assessment|It consists of a detailed history of the patient's experience, an evaluation with the patient (cognitive, emotional, motivational ...), an interview with the caregiver to see the repercussions of the disorders on a daily basis, how they are managed, and how they cope in order to give information and advice.
40816819|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 25mg|Given PO
40816820|NCT04047706|DRUG|Nivolumab|Given IV
41334959|NCT03438513|BEHAVIORAL|Problem Solving Therapy|Problem-solving learning program for all situations of daily living, done in groups (10 people per group)
41334960|NCT03438513|BEHAVIORAL|Speaking group|Intervention, carried out in groups (10 people per group) which will consist of sharing experiences, sufferings, exchange and allow people who attend to share their experiences.
40816821|NCT04047706|RADIATION|Radiation Therapy|Undergo radiation therapy
41334961|NCT05265793|DRUG|Camrelizumab Combined With Apatinib|After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib. Treatment until disease progression and intolerable adverse reactions occur
40816822|NCT04047706|DRUG|Temozolomide|Given PO
40816823|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 50 mg|Given PO
40816824|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 100 mg|Given PO
40816825|NCT00791453|BEHAVIORAL|Education|Patients will receive literacy appropriate health information.
40816826|NCT00642434|DRUG|carvedilol|variable
41156173|NCT00263783|DRUG|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. \[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.\]
41334962|NCT00178698|OTHER|thermochemotherapy|cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
41334963|NCT00178698|DRUG|Cisplatin, Gemcitabine, Interferon-a|cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
41334964|NCT00178698|OTHER|thermochemotherapy|After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
41334965|NCT01769638|DRUG|SPO1101|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.
41334966|NCT01769638|DRUG|SPO1101D|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
40816827|NCT00642434|DRUG|metoprolol|variable
40816828|NCT00256035|PROCEDURE|Measuring IL-4 levels|
40816829|NCT03781323|DRUG|FOLFOX|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
40816830|NCT03878030|DRUG|nusinersen|Subjects will receive nusinersen and be observed with motor assessments for 24 months
40816831|NCT00346450|PROCEDURE|Cultivated conjunctival transplantation|
40816832|NCT05406219|DRUG|BAY2395840|Immediate release (IR) tablet, oral administration
40816833|NCT00904098|DRUG|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~1. A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~2. An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
40816834|NCT00904098|DRUG|Usual Care|Current treatment used to treat all migraine headaches
40816835|NCT02767089|DRUG|Prednisone|Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
40816836|NCT02767089|DRUG|Placebo|Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
40816837|NCT05137288|DRUG|Ondansetron , atropine and bupivacaine|"Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) ."
40816838|NCT05098964|DEVICE|pedometer home based rehabilitation|Home based pulmonary rehabilitation for 6 weeks using pedometer Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan)
40816839|NCT05098964|OTHER|Exercise training|Hospital based exercise training for 6 weeks
40816840|NCT02882789|DRUG|LCB01-0371|Cohort1 \& 3: Placebo-controlled, Single ascending dose administration
40816841|NCT02882789|DRUG|LCB01-0371 400mg|Cohort 2: Crossover designed administration
40816842|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (400mg of nitrate per serving)|Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
40816843|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (trace amounts of nitrate per serving)|Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
40816844|NCT01082874|DRUG|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
40816845|NCT01082874|DRUG|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
40816846|NCT01082874|DRUG|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
40816847|NCT01082874|DRUG|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
41334967|NCT06403293|PROCEDURE|Root canal treatment (AH Plus-NA)|Root canal treatment procedures explained in arm descriptions.
41334968|NCT06403293|PROCEDURE|Root canal treatment (AH Plus-EA)|Root canal treatment procedures explained in arm descriptions.
41334969|NCT06403293|PROCEDURE|Root canal treatment (BC-NA)|Root canal treatment procedures explained in arm descriptions.
41334970|NCT06403293|PROCEDURE|Root canal treatment (BC-EA)|Root canal treatment procedures explained in arm descriptions.
41334971|NCT01431651|DIETARY_SUPPLEMENT|probiotics,digestive enzyme|patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
41334972|NCT02152150|OTHER|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)
41334973|NCT02152150|OTHER|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
41334974|NCT02846857|OTHER|15-week intervention with sensor-augmented pump|A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
41334975|NCT02846857|OTHER|15-week intervention with single-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
41334976|NCT02846857|OTHER|15-week intervention with dual-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
41334977|NCT02846857|DEVICE|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
41334978|NCT02846857|DEVICE|Continuous glucose monitoring system|Enlite sensor®, Medtronic
41334979|NCT02846857|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
41334980|NCT02846857|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
41334981|NCT00212212|DIETARY_SUPPLEMENT|selenium|200 µg selenium as selenate
41334982|NCT00212212|DIETARY_SUPPLEMENT|selenium|400 µg selenium as selenate
41334983|NCT00212212|DIETARY_SUPPLEMENT|selenium|200 µg selenium as selenomethionine
41014418|NCT06171659|DRUG|FDG radiotracer|Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
41014419|NCT06171659|DEVICE|PET/MRI|positron emission tomography and magnetic resonance imaging
41014420|NCT06171659|DEVICE|PET/CT imaging|positron emission tomography and computed tomography imaging
41334984|NCT00212212|DIETARY_SUPPLEMENT|placebo|placebo tablet
41334985|NCT01570205|DRUG|XG-102|single intravenous infusion
40816848|NCT06210542|DRUG|ceftazidime avibactam|"Routine treatment dose for patients: the recommended intravenous dose for patients with creatinine clearance rate (eCrCL) \&gt; 50ml/min was 2.5g (2g/0.5g), once every 8 hours, and the infusion time was 2 hours.~Patients with renal injury adjust the dosage according to eCrCL"
40816849|NCT02523157|OTHER|Wellbeing Plan|The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
40816850|NCT02523157|OTHER|Control task|Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
41014421|NCT04975763|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
41156174|NCT00764855|PROCEDURE|Automatic administration of propofol and opiates during routine clinical practice|"The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device."
40816851|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
40816852|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
40816853|NCT04376840|OTHER|Blood sample and data record|Blood sample and data record
40816854|NCT02323685|BIOLOGICAL|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
41014422|NCT04975763|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
41014423|NCT03834961|DRUG|Larotrectinib Sulfate|Given PO or via NG or G tube
40816855|NCT02209545|DRUG|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
40816856|NCT02209545|DRUG|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
40816857|NCT06089460|OTHER|Beef|Fresh, locally-sourced, grass-fed, grass-finished ground beef sufficient to meet protein needs based on body weight for 8 weeks
41334986|NCT03953885|OTHER|Fire needle|"1. Participants wear eye masks and fully expose the lesions. After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation. After selecting an acupuncture needle with a specification of 0.4\*40mm and ignites the alcohol lamp, the operator continuously moves the needle from the needle root to the needle tip to burn the red needle to disinfect the needle in the outer flame of the alcohol lamp.~2. The operator ignites the alcohol lamp, and burns the needle tip and the needle body to the outer flame of the alcohol lamp until it is completely red (the length of the needle burning red is determined by the acupuncture depth), and then rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
40816858|NCT06089460|OTHER|Meat analogue|Commercially-available and purchased meat analogue sufficient to meet protein needs based on body weight for 8 weeks
41484224|NCT04788160|OTHER|Cervical SNAGs along with conventional therapy|"cervical SNAG half rotation technique will be performed with the patient sitting on a chair in the erect posture. The therapist placed his thumb over thumb over the transverse process of C1. Then, he glided ventrally with active rotation of the restricted site 10 times holding for 10 seconds with overpressure at end of the rotation with 30 second rest in between each repetition and 3 session/week for 4 weeks.~* Conventional therapy will include:~* Hot pack over the cervical region for 10 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions with 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be done 10 times in sitting position."
40816859|NCT06089460|OTHER|Beans/legumes|Canned beans/legumes sufficient to meet protein needs based on body weight for 8 weeks
40816860|NCT01988662|PROCEDURE|Neovascular Age-related Macular Degeneration|Blood measurement
40816861|NCT04694755|DRUG|Placebo|On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards
40816862|NCT04694755|DRUG|Traditional Chinese medicine prescription|Tianjiang brand formula granules, in line with GMP standards
40816863|NCT02421406|BEHAVIORAL|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
40816864|NCT02421406|BEHAVIORAL|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
41014431|NCT06576765|DRUG|AZD0780|Dose 1
41014432|NCT02048813|DRUG|Cyclophosphamide|Given IV
41014433|NCT02048813|DRUG|Fludarabine Phosphate|Given IV
41014434|NCT02048813|DRUG|Ibrutinib|Given PO
41014435|NCT02048813|OTHER|Laboratory Biomarker Analysis|Correlative studies
41014436|NCT02048813|OTHER|Pharmacogenomic Study|Correlative studies
41484225|NCT04788160|OTHER|Conventional Therapy|"* Patients in this group will undergo only conventional therapy which will include:~* Hot pack for 15 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions each 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be given to the patient by the therapist, 10 times in sitting position."
41484226|NCT03349528|BIOLOGICAL|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily
41484227|NCT03349528|BIOLOGICAL|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
40816865|NCT05463718|DEVICE|Virtual Reality|children treated by Virtual Reality for 15 min. besides the traditional physical therapy program
40816866|NCT01229254|DRUG|Amiodarone|Patients on Amiodarone
40816867|NCT01229254|DRUG|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
41014437|NCT02048813|OTHER|Quality-of-Life Assessment|Ancillary studies
41014438|NCT02048813|BIOLOGICAL|Rituximab|Given IV
41156175|NCT06644235|OTHER|Cold Application|Before DFU care, the patient was given an appropriate position and the materials (forceps, scalpel, sponge, pad, bandage, etc.) and the temperature of the 0.9% NaCl solution kept in the refrigerator for 24 hours were measured with an infrared thermometer (+4°C to +8°C) and taken to the treatment area. The solution was transferred to a 50 mL syringe in a sterile manner. The solution was instilled into the wound simultaneously with wound care (5-15 min).
41014439|NCT02512497|DRUG|Romidepsin|"Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
41017948|NCT02652780|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
41334987|NCT03953885|OTHER|Fire needle Placebo|"1. Participants wear eye masks and fully expose the lesions (no lesions on the head and face, external genitalia and skin folds). After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation, then selects an acupuncture needle with a specification of 0.4\*40mm to prepare for operation.~2. The operator rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
40816868|NCT01229254|DRUG|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
40816869|NCT01229254|DRUG|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
41334988|NCT01857024|DRUG|sevelamer carbonate (Renvela®)|800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
41334989|NCT02803814|PROCEDURE|Superior mesenteric artery approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the superior mesenteric artery approach
40816870|NCT03900858|DRUG|Isoniazid；Rifapentine|1 months (12 doses) of three-weekly rifapentine at a dose of 450mg plus isoniazid at a dose of 400mg given under direct observation
41334990|NCT02803814|PROCEDURE|Classic approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the classical approach
41334991|NCT01656811|DRUG|levalbuterol 90 mcg|90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
41334992|NCT01656811|DRUG|levalbuterol 180 mcg|180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
41334993|NCT01656811|DRUG|racemic albuterol 180 mcg|180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
40816871|NCT02487654|PROCEDURE|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
40816872|NCT02487654|PROCEDURE|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
41334994|NCT01656811|DRUG|Placebo|Placebo 2 actuations QID
41334995|NCT05477225|DEVICE|NovoSorb® BTM|a biodegradable polyurethane porous matrix adhered to a transparent sealing membrane. The sealing membrane is designed to physiologically close the wound limiting evaporative moisture loss during integration of the matrix.
41484228|NCT01524965|PROCEDURE|Immediate mobilisation after locking-plate osteosynthesis|"Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
40816873|NCT03055325|OTHER|Observational study of patients undergoing surgery|Cognitive testing, testing of heart rate variability and collection of blood samples
40816874|NCT06457646|GENETIC|Genetic polymorphism|The biological significance of HTR2A and DRD3 in bruxism remains unclear as molecular analyses, including genetic association studies, have not explored the mRNA expression of genes implicated in bruxism. This study aims to evaluate the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism to identify potentially associated genotypes. Additionally, it aims to investigate the expression of HTR2A and DRD3 to elucidate their biological significance in bruxism.
40816875|NCT03489434|BEHAVIORAL|Intervention|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
40816876|NCT05684757|BEHAVIORAL|Dietary Advice|Dietary Advice
40816877|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
40816878|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
40816879|NCT04362475|BEHAVIORAL|Community Health through Engagement and Environmental Renewal (CHEER)|FYI and ESPI intervention activities will be implemented in the overall study, CHEER. It will also allow us to examine possible synergistic effects of both interventions when implemented in the same neighborhoods. Separate sets of participants will be selected for the FYI comparisons and for the ESPI comparisons. Because the FYI intervention focuses on mothers and their children, participants for the FYI comparisons will be selected by Respondent Driven Sampling of eligible families from the neighborhoods in all four cells. The ESPI intervention targets the whole neighborhood, and thus a random sample of neighborhood residents will be enrolled in each of the four cells. Because the primary outcomes for FYI and ESPI are connected but differ from each other, the FYI samples will be assessed for the FYI outcomes in all four cells and the ESPI samples will be assessed for the ESPI outcomes in all four cells.
40816880|NCT06586320|DRUG|150% of their routine home dopaminergic medications dose right in the clinic|IPD subjects will be informed head of time not to take their dopaminergic medications and other Parkinson's non-dopaminergic medications such as anticholinergics, NMDA inhibitors, and adenosine blockers for at least 12 hours prior to their initial procedure. Immediately, after conducting both hand movement and eye movement tests, the patient will take 150% of their routine home dopaminergic medications dose right in the clinic. They will also take their non-dopaminergic medications doses similar to home dose with no change. This will be under the supervision of their treating movement disorders specialist and study PI.
41156176|NCT05862779|DIETARY_SUPPLEMENT|Placebo Group|The placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin.
41334996|NCT05477225|DEVICE|Human Cadaveric Allograft|"The donated human tissue (Allograft) used in this study are from Maxxeus Medical, Kettering, OH . Tissue grafts are recovered from deceased human donors. All tissue is recovered, processed, stored and distributed for use in accordance with the standards of the American Association of Tissue Banks (AATB). Tissue is manufactured in a clean room environment, following rigorous quality assurance standards. The procedures executed to manufacture this graft including recovery, donor screening, testing, processing, packaging, labeling, storage, and distribution were performed in compliance with all applicable local, state, and federal regulations, including the U.S. Food and Drug Administration (FDA) regulations published at 21 CFR Part 1271, and the current edition of the American Association of Tissue Banks Standards for Tissue Banking.~The current sizes that are available for this study: 103 sq cm., 154 sq cm and 232 sq. cm"
41334997|NCT00953004|DIETARY_SUPPLEMENT|fiber drink and fiber bread|fiber drink or fiber bread three times daily
41334998|NCT04663542|PROCEDURE|immobilization duration|brace immobilization duration after open surgery for Achilles tendon rupture
41334999|NCT01878227|DRUG|Coenzyme A|Coenzyme A 400mg per day
41335000|NCT01878227|DRUG|Fenofibrate 200mg|Fenofibrate 200mg per day
41484229|NCT01524965|PROCEDURE|Standard mobilisation after locking plate osteosynthesis|"Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
41484230|NCT01524965|DEVICE|Osteosynthesis with a locking plate (Philos)|Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
41484231|NCT02941276|DEVICE|Active Electrostimulator device|Patients who will receive a fully functioning device
41484232|NCT02941276|DEVICE|Sham Electrostimulator device|Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
41484233|NCT02909738|OTHER|Volunteer to pedal a bicycle|
41484234|NCT06002087|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The current researchers adapted the Unified Protocol (UP) treatment and used the adapted version in this study. UP outlines two complimentary modules for goal setting and psychoeducation followed by five core treatment modules: mindful emotion awareness, cognitive flexibility, countering emotional behaviors, awareness and tolerance of physical sensations, and emotion exposures, and an optional relapse prevention module to help people maintain their gains after treatment.
41484235|NCT04717102|DRUG|0.5 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.5 MAC desflurane with remifentanil infusion during spinal surgery.
41014440|NCT02512497|DRUG|Busulfan|Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI \>4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.
41014441|NCT02512497|DRUG|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
41484236|NCT04717102|DRUG|0.75 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.75 MAC desflurane with remifentanil infusion during spinal surgery.
41484237|NCT04717102|DRUG|1.0 MAC desflurane|On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
41484238|NCT01006941|BIOLOGICAL|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
40816881|NCT06586320|DEVICE|Evaluation of mathematical models|Evaluation of performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras
40816882|NCT00163943|BEHAVIORAL|Dietary weight loss +/- aerobic exercise|
40816883|NCT04071262|DRUG|Abemaciclib|Administered orally
40816884|NCT04071262|DRUG|Abiraterone Acetate|Administered orally
40816885|NCT04071262|DRUG|Prednisolone|Administered orally
40816886|NCT01035463|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplant
40816887|NCT01035463|DRUG|Carmustine|Given IV
40816888|NCT01035463|DRUG|Cytarabine|Given IV
40816889|NCT01035463|DRUG|Etoposide|Given IV
40816890|NCT01035463|DRUG|Lenalidomide|Given PO
40816891|NCT01035463|DRUG|Melphalan|Given IV
40816892|NCT01035463|BIOLOGICAL|Rituximab|Given IV
40816893|NCT03603899|DRUG|Hp 129Xenon|129 Xenon is a noble gas with no taste or smell. It will be made slightly magnetic (also called hyperpolarizing) and then inhaled into the lungs to provide better pictures of the lungs during MRI.
40816894|NCT00194584|BEHAVIORAL|7 week Building on Family Strengths Program|Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
40816895|NCT00296465|DRUG|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
40816896|NCT00296465|DRUG|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
40816897|NCT00296465|DRUG|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
40816898|NCT00296465|DRUG|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
40816899|NCT05039164|BEHAVIORAL|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
40816900|NCT05039164|BEHAVIORAL|CBT for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
41014442|NCT02512497|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
41014443|NCT02512497|DRUG|Thymoglobulin|Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
41156177|NCT05862779|DIETARY_SUPPLEMENT|Whey Protein + Placebo|The whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil.
41156178|NCT05862779|DIETARY_SUPPLEMENT|Omega 3 + Placebo|The omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin.
41156179|NCT05862779|DIETARY_SUPPLEMENT|Omega 3 + Whey Protein|The omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein.
41156180|NCT05581589|PROCEDURE|Lymphadenectomy|Undergo pelvic lymph node dissection
40816901|NCT05039164|BEHAVIORAL|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
40816902|NCT05039164|BEHAVIORAL|Initial Training (CC)|School personnel will participate in an initial live remote training.
40816903|NCT05039164|BEHAVIORAL|Initial Training plus Video (RV)|School personnel will participate in an initial live remote training and receive access to asynchronous video training modules.
40816904|NCT05039164|BEHAVIORAL|Initial Training plus Video plus Coaching (RV+)|School personnel will participate in an initial live remote training, receive access to asynchronous video training modules, and receive coaching support from study staff.
41156181|NCT05581589|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
41156182|NCT05581589|BIOLOGICAL|Sacituzumab Govitecan|Given IV
41156183|NCT06512181|OTHER|Conservative/Expectant Management|At time of caesarean section, participants will not have a hysterectomy, but will be treated clinically to preserve their uterus.
41484239|NCT01781520|BIOLOGICAL|DC-CIK Treatment|The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
40816905|NCT06292325|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard therapy for Obstructive Sleep Apnea. It consists of a machine that delivers a constant and steady air pressure through a mask worn over the nose or both nose and mouth during sleep. This continuous flow of air helps to keep the airway open, preventing episodes of airway collapse and obstruction characteristic of OSA. CPAP therapy is highly effective in reducing symptoms such as snoring, daytime sleepiness, and fatigue, as well as improving overall sleep quality and decreasing the risk of complications associated with untreated OSA, such as cardiovascular issues. It is considered the gold standard treatment for moderate to severe OSA and is often prescribed after a sleep study confirms the diagnosis. CPAP machines come in various designs and features to suit individual needs and preferences, and proper adjustment and compliance are essential for optimal treatment outcomes.
40816906|NCT06608849|OTHER|Blood samples|Blood sampling for proteomics and transcriptomics, suPAR measurement \&amp; isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \&amp; urea
40816907|NCT06608849|OTHER|Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms|Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
40816908|NCT03262766|OTHER|Acute Intermittent Hypoxia (AIH)|This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
40816909|NCT03262766|BEHAVIORAL|Upper extremity training|Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
40816910|NCT03262766|OTHER|Sham Acute intermittent hypoxia|This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
41335001|NCT04644484|BIOLOGICAL|SYN023|The finished product of SYN023 is a mixture of 3.0 mg/mL CTB011 and 3.0 mg/mL CTB012 at a ratio of 1:1. SYN023 is a sterile and preservative-free injection, and the excipient contains 25 mM histidine (3.879 mg/mL), 150 mM sodium chloride (8.766 mg/mL) and 0.02% polysorbate 80 (0.2 mg/mL) and pH of 6.0. Each vial contains 2.15 mL of SYN023, or 6.45 mg of monoclonal antibody. The glass bottle was closed with a 13 mm bromobutyl rubber stopper, a 13 mm aluminum crimping cap and a polypropylene flip-open lid.
40816911|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
40816912|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
40816913|NCT01632475|BIOLOGICAL|Pneumostem®|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg, High Dose Group (6 patients): 2 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study."
41335002|NCT04644484|BIOLOGICAL|Human Rabies Immune Globulin (HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin, which are derived from human plasma, and then purified and filled in the injectable vial form. The HRIG is indicated for the Post-exposure Prophylactic (PEP) of Rabies
41335003|NCT04644484|BIOLOGICAL|Rabies Vaccine|Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
41335004|NCT02463760|OTHER|Medical imaging|
41335005|NCT00758407|DRUG|Methylphenidate hydrochloride|sustained release, dosage according to an individual titration schedule
41335006|NCT00758407|DRUG|Placebo|dosage according to an individual titration schedule
41335007|NCT03447119|BEHAVIORAL|Living Well with a Disability|Implementation of an adapted health promotion program.
40816914|NCT01558492|DRUG|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
41335008|NCT01210755|DRUG|Rivaroxaban, Dabigatran|Rivaroxaban: One dose of 20mg (2 tablets of 10mg) then Dabigatran: One dose of 150mg(2 capsules of 75mg) two weeks later
41335009|NCT01210755|DRUG|Dabigatran; Rivaroxaban|Dabigatran: One dose of 150mg(2 capsules of 75mg) then Rivaroxaban: One dose of 20mg (2 tablets of 10mg)two weeks later
40816915|NCT01558492|DRUG|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
40816916|NCT02984150|DIETARY_SUPPLEMENT|dodecanoic acid|
40816917|NCT02984150|DIETARY_SUPPLEMENT|saline|
40816918|NCT03315897|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.
40816919|NCT03315897|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
41335010|NCT04735536|DRUG|CT1812|Active Treatment- CT1812 at a dose of 300mg
40816920|NCT03440736|DRUG|Secukinumab|Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)
41014469|NCT03609177|OTHER|Clinician Communication Skills Training|Communication skills training
41014470|NCT03609177|OTHER|Advance Care Planning (ACP) Decisions Videos Decisions Aids|ACP Decisions video decision aids
41014471|NCT03609177|OTHER|Video Declarations (ViDec)|Recording of patient advance care planning videos
41014472|NCT05779657|DRUG|Ketamine|Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)
41014473|NCT05779657|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
41014474|NCT05779657|DRUG|Placebo|Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
41014475|NCT03296696|DRUG|AMG 596|Drug
41014476|NCT03296696|DRUG|AMG 404|Drug
41014477|NCT04439149|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
41014478|NCT02962895|BIOLOGICAL|VAY736|VAY736
41014479|NCT02962895|OTHER|Placebo|Placebo control
41156184|NCT06106789|DRUG|Tobramycin inhalation solution|"Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital."
41156185|NCT02924532|BIOLOGICAL|immediate post operative bioassay of Parathyroid Hormone|
40816921|NCT03440736|BEHAVIORAL|Life-style intervention|A structured program to guide weight loss and increased physical activity
40816922|NCT01196468|OTHER|HIV test (serological or salivary)|"An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition"
41014480|NCT06051695|BIOLOGICAL|A2B694|Autologous logic-gated Tmod CAR T cells
41335011|NCT04735536|OTHER|Placebo|Placebo Comparator
41335012|NCT05419115|DRUG|SQIN-Furosemide|The investigational furosemide formulation (SQIN-Furosemide) is a Captisol®buffered solution of 80mg furosemide in 2.7 mL (30 mg/mL) at pH 7.4 (range: 7.0 to 7.8). SC infusion will be performed using the SQIN-Infusor which will deliver 2.7 mL of the SQIN-Furosemide formulation (80mg) over approximately 5 hours, using a biphasic delivery profile.
40816923|NCT01196468|OTHER|Interview|Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
40816924|NCT06608433|DRUG|semaglutide|semaglutide/Rybelsus will be administered as a single oral dose
40816925|NCT06608433|DRUG|Placebo|Placebo pills will be administered as a single oral dose
40816926|NCT06302140|DRUG|[14C]-Nanatinostat|A single oral dose administered on Day 1 in a fasted state.
41335013|NCT05419115|DEVICE|SQIN-Infusor|The investigational device (SQIN-Infusor) is an on-body delivery system that consists of a RU, DU, plus a charger (Figure 2). For the purpose of SUBCUT-HF II trial, the RU will be used for multiple infusions for a single participant. The DU will be used only once per infusion and disposed of. The RU must be charged after each use and will not restart for the next infusion without charging. Charging takes up to 15 minutes. SQIN-Infusor is a bespoke system, adapted from the design of a SC insulin pump. The RU consists of the drive-unit, the controllers, the rechargeable battery, and the user interface.
41335014|NCT01267344|DRUG|gemcitabine, oxaliplatin|GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks
41335015|NCT01267344|DRUG|cetuximab, gemcitabine, oxaliplatin|E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
41335016|NCT00044993|BIOLOGICAL|Ad5CMV-p53 gene|
41335017|NCT00044993|DRUG|docetaxel|
41335018|NCT00044993|DRUG|doxorubicin hydrochloride|
41335019|NCT00044993|PROCEDURE|conventional surgery|
41335020|NCT00044993|PROCEDURE|neoadjuvant therapy|
41335021|NCT05201482|DEVICE|SightPlus|SightPlus is a head-mounted, augmented reality low vision aid. SightPlus enables people with a visual impairment to use their remaining vision to see more clearly up close and at a distance. SightPlus is commercially available, non-invasive, CE marked, and a MHRA approved class 1 medical device.
41335022|NCT01211119|OTHER|No PRF|Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
41335023|NCT00978224|DIETARY_SUPPLEMENT|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
41335024|NCT00978224|DIETARY_SUPPLEMENT|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
40816927|NCT06302140|DRUG|Nanatinostat (free base) tablets in combination with Valganciclovir|Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
40816928|NCT06302140|DRUG|Nanatinostat mesylate tablets in combination with Valganciclovir|Treatment B: a single, oral dose of nanatinostat mesylate tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
40816929|NCT06302140|DRUG|Single-agent Nanatinostat (free base) tablets|40 mg once daily under fed conditions until disease progression or unacceptable toxicity, whichever occurs first.
40816930|NCT02762240|OTHER|DHQP 2016|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
40816931|NCT02762240|OTHER|DHQP 2018|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
40816932|NCT06277349|DEVICE|Toric multifocal IOL|Implant of Multifocal toric intraocular lens only
40816933|NCT06277349|DEVICE|Non-toric multifocal IOL|Implant of non-toric multifocal lens plus incisional surgery
40816934|NCT05125718|DRUG|0.85% synthetic antimicrobial peptide TAPS-18|commercially available synthetic antimicrobial peptide gel for periodontal disease treatment
40816935|NCT05125718|DRUG|0.9% normal saline|commercially available normal saline Sodium Chloride irrigation solution
40816936|NCT04403152|OTHER|Post-operative rehabilitation|Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.
40816937|NCT04403152|OTHER|Post-operative mobilization|Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
40816938|NCT06346691|DRUG|Doxofylline|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
40816939|NCT06346691|DRUG|Procaterol|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
40816940|NCT02555813|DRUG|Abraxane|Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity
40816941|NCT02555813|DRUG|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
41156186|NCT05254834|DIAGNOSTIC_TEST|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
41335025|NCT06156891|PROCEDURE|Toxicities reduced treatment|"Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-related patients.~Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) combined with concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-urelated patients."
41484240|NCT01781520|DRUG|S1|The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25-\<1.5 m2, 50 mg; and \>1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
41484241|NCT01781520|OTHER|Best supportive care|Best supportive care
41484242|NCT02836626|PROCEDURE|deep fascial mobilization|Pelvic and abdominal myofascial release techniques as described by Barnes will be performed to facilitate independent mobility between tissue layers as needed following the direction of palpated fascial tension. Following this, direct scar mobilization techniques as described by Manheim will be done, applying a stretch in the direction of palpated restriction . This involves applying deep pressure whose force and direction is dictated by the tightness the therapist palpates and the subject reports. These are each held until a release is felt (defined as a sudden relaxation of tissue tension), usually 60-120 seconds. Total treatment time will last 25 minutes. Treatments will include all the above techniques but the therapist will tailor each treatment to address palpated restrictions. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
40816942|NCT05810870|DRUG|MEN1611|MEN1611 is a potent, orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) with a novel structure which exhibits a strong inhibitory activity especially against the PI3K catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.
40816943|NCT05810870|DRUG|Eribulin|Eribulin mesylate (eribulin), a non-taxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastics, suppresses microtubule growth and sequesters tubulin into nonfunctional aggregates, preventing mitotic spindle formation with subsequent G2-M stop and apoptosis.
40816944|NCT02281786|DRUG|Placebo|Matching placebo to RO6926496
40816945|NCT02281786|DRUG|RO6926496|single, ascending dose, intravenous administration
40816946|NCT02879591|OTHER|Social Skills training with Avatar therapist|
40816947|NCT04131322|DRUG|Amgevita 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
40816948|NCT04131322|DRUG|HUMIRA 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
40816949|NCT05121220|DEVICE|fixed retainer|bonded lingual mandibular fixed retainer on frontal teeth 33-43
40816950|NCT05121220|DEVICE|removable retainer|thermoplastic vacuum-formed removable mandibular retainer
41156187|NCT05648500|DRUG|Cenerimod|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
41156188|NCT05648500|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
41156189|NCT05652036|BIOLOGICAL|Intradetrusor Botox Injections|100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.
40816951|NCT00010387|DRUG|cyclophosphamide|
40816952|NCT00010387|DRUG|filgrastim|
40816953|NCT00937144|DRUG|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
40816954|NCT00937144|DRUG|placebo|
40816955|NCT06608277|PROCEDURE|Group A active comparator|Group A placebo comparator. Stellate Ganglion Block plus placebo (.9 normal saline) infusion
40816956|NCT06608277|DRUG|Group B active comparator|Active Comparator: Group B = Sham Stellate Ganglion Block plus ketamine infusion
40816957|NCT06608277|COMBINATION_PRODUCT|Group C Experimental|Group C experimental Stellate Ganglion Block plus ketamine infusion
40816958|NCT06608277|OTHER|Group D Placebo Comparator|Group D Placebo Comparator: Sham Stellate Ganglion Block plus placebo normal saline
40816959|NCT05312632|DRUG|Safinamide Mesilate|Safinamide Mesilate oral tablets.
41156190|NCT02994264|RADIATION|adjuvant concurrent chemoradiation|
40816960|NCT03252249|OTHER|3 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
40816961|NCT03252249|OTHER|12 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
40816962|NCT00211835|BEHAVIORAL|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
40816963|NCT00211835|BEHAVIORAL|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
40816964|NCT01343186|DRUG|Peginterferon alfa|s,c, 45mcg of Ypeginterferon alfa-2a
40816965|NCT01343186|DRUG|Peginterferon alfa 2a|s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
40816966|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
40816967|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
40816968|NCT05480189|OTHER|Non-intervention|Non-intervention,with real world study
40816969|NCT05507021|DIETARY_SUPPLEMENT|Lactobacillus plantarum DSM 33464, MegaMetalliQ|Pour Lactobacillus Plantarum DSM 33464 sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
40816970|NCT05507021|DIETARY_SUPPLEMENT|Placebo|Pour placebo sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
40816971|NCT04880044|DIAGNOSTIC_TEST|EsoCheck/EsoGuard (EC/EG)|EC is a swallowed capsule on a tethered catheter that obtains a touch sample of the distal esophagus. The obtained sample is placed in a buffer and sent to a diagnostics lab for testing of methylated markers from extracted DNA. EG is a methylated DNA test . A positive EG is associated with Barrett's esophagus at all its stages.
40816972|NCT04880044|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|SOC diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum. Tissue samples collected.
40816973|NCT01407471|DRUG|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
40816974|NCT01407471|DRUG|Clobetasol + Placebo|One application 6 days a week during 4 weeks
40816975|NCT01407471|DRUG|Placebo + Spironolactone|One application 6 days a week during 7 weeks
40816976|NCT01407471|DRUG|Placebo + Placebo|One application 6 days a week during 7 weeks
41335026|NCT06156891|PROCEDURE|Conventional treatment|Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70.4Gy/32Fx) when responses to induction chemotherapy are less than 70% Partial Response (PR) regardless of HPV status.
41335027|NCT01852916|DEVICE|CPAP|Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
41335028|NCT01852916|DEVICE|NHFOV|Nasal High Frequency Oscillatory Ventilation
41335029|NCT02613988|DEVICE|3 Tesla magnetic resonance imaging|High resolution structural imaging (contrast-enhanced T1-weighted image, T2-weighted image, Fluid-attenuated inversion recovery)
41335030|NCT02613988|DEVICE|Chemical exchange saturation transfer MRI|Amide proton transfer-weighted image
41335031|NCT02613988|DEVICE|Diffusion weighted MRI|diffusion-weighted image with b value 0, 1000, and 3000
40816977|NCT06252961|DRUG|Levamisole 3 days|Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days
41335032|NCT02613988|DEVICE|Dynamic susceptibility contrast MRI|dual echo EPI sequence
40816978|NCT06252961|DRUG|Levamisole 5 days|Levamisole for 5 days (2,5 mg/kg)
41335033|NCT04053036|DRUG|MDMA|Participants will be given 1.5mg/kg of MDMA
41335034|NCT04053036|DRUG|Placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
40816979|NCT06252961|DRUG|Placebo|Placebo for 5 days
40816980|NCT02683070|PROCEDURE|Bilateral pudendal nerve block|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation
40816981|NCT02683070|DRUG|Intravenous tramadol|Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
40816982|NCT01926418|BEHAVIORAL|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
40816983|NCT04850391|OTHER|Mobile app|To compare changes induced by the movile app intervention among the three study groups
40816984|NCT01772524|BIOLOGICAL|ALD403|
40816985|NCT01772524|DRUG|Placebo|
40816986|NCT03117374|BEHAVIORAL|Team Nutriathlon intervention|8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
40816987|NCT03505294|OTHER|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks including lower extremity and upper extremity activities will be applied to the training group twice a week for 6 weeks."
40816988|NCT06305715|DEVICE|Radiation Therapy|Enrolled subjects will be given radiation doses, at the discretion of the treating physicians, that range from 24-60 Gy in 1-15 fractions with a minimum biologically effective dose (BED\^10) of 58 Gy.
41014481|NCT06051695|DIAGNOSTIC_TEST|xT CDx with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
41014486|NCT00309998|BIOLOGICAL|bevacizumab|
41014487|NCT00309998|DRUG|vinorelbine tartrate|
41014488|NCT00417560|BIOLOGICAL|inactivated influenza A/H5N1 vaccine|
40816989|NCT06305715|DRUG|Targeted TKI therapy|Immediately following radiation therapy, subjects with an actionable driver mutation will receive a standard-of-care TKI. The choice of TKI will be at the discretion of the treating oncologist.
40816990|NCT04714203|OTHER|sarcopenia assessment|evaluation of sarcopenia status
40816991|NCT04151927|DEVICE|Normobaric Hypoxia|Low oxygen exposure to mimic \~8500 feet elevation.
40816992|NCT04151927|DEVICE|Normobaric Normoxia|Normal oxygen exposure to mimic \~1000 feet elevation (sham comparator).
40816993|NCT06503497|BIOLOGICAL|chemotherapy sequential CAR-NK cell infusion|In each chemotherapy cycle, patients received 2 intravenous infusions of CAR-NK on days 2 and 3 after each chemotherapy was discontinued.
40816994|NCT04652375|OTHER|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
40816995|NCT04652375|OTHER|Lactated Ringer's Solution|Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.
40816996|NCT05223231|DRUG|LBL-019 Injection|initial dose-MTD
40816997|NCT05223231|DRUG|anti-PD-1 antibody injection|provide medicine base on needs
40816998|NCT00305032|PROCEDURE|gastric balloon insertion|patient would be offered endoscopic gastric balloon insertion
41014490|NCT03495986|DEVICE|Functional Electrical Stimulation Leg Cycle Ergometry|Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
41014491|NCT03495986|BEHAVIORAL|Diet|An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
41156191|NCT06038617|BIOLOGICAL|mRNA COVID-19 Vaccine|ACIP Recommended Vaccine
40816999|NCT01872195|OTHER|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
40817000|NCT01581749|RADIATION|"TrueBeam stereotactic body radiosurgery"|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
41156192|NCT06038617|BIOLOGICAL|Routine Childhood Vaccinations|ACIP Recommended Vaccines
40817001|NCT01678573|DRUG|Treatment A: abiraterone acetate|250 mg/day tablet administered orally on Day 1 of each treatment period.
40817002|NCT01678573|DRUG|Treatment B: abiraterone acetate|500 mg/day tablets administered orally on Day 1 of each treatment period.
40817003|NCT01678573|DRUG|Treatment C: abiraterone acetate|1000 mg/day tablets administered orally on Day 1 of each treatment period.
40817004|NCT00876850|DRUG|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
40817005|NCT00876850|DRUG|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
40817006|NCT04620382|DRUG|Midodrine|Midodrine 5-10 mg, single oral dose
40817007|NCT04620382|DRUG|Placebo pill|single oral dose
40817008|NCT04620382|DEVICE|Abdominal compression|abdominal compression up to 40 mmHg during head-up tilt
40817009|NCT04620382|DEVICE|sham compression|Sham abdominal compression during head-up tilt
40817010|NCT02901054|DRUG|Ondansetron|A single 15-min intravenous infusion of ondansetron
40817011|NCT02986672|DIETARY_SUPPLEMENT|Calanus oil|Omega-3 oil in form of calanus oil
40817012|NCT02986672|OTHER|Medical Paraffin|2ml per day
41014497|NCT05179954|OTHER|Metabolic testing|Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
41014498|NCT03532516|DRUG|Brivaracetam|"Patients will start on the individual Brivaracetam (BRV) dose that they had reached at the completion of the previous study. The BRV dose can be adjusted based on the individual patient's seizure control and tolerability; however, the BRV dose may not exceed 200 mg/day in divided (preferably symmetrical) morning and evening doses, taken with or without food.~Up- and down-titration steps should be performed in steps of maximum 50 mg/day on a weekly basis. The full down-titration should include a 1-week step at 20 mg/day."
40817013|NCT00294645|OTHER|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
40817014|NCT00294645|OTHER|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
40817015|NCT03775343|DIAGNOSTIC_TEST|Neurocognitive Test Battery|neurocognitive testing: preoperative(baseline), 6 and 24 hours postoperative.
40817016|NCT03775343|DIAGNOSTIC_TEST|Blood sampling|Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery, investigating plasma levels of S 100-B, CRP, vitamines, homocysteine and folic acid
40817017|NCT00541866|DRUG|Voreloxin injection and cytarabine|"Dose-escalation Phase~* Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~* Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous \[IV\] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~* Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~* Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)"
40817018|NCT06150534|OTHER|No Intervention|This is a non-interventional study.
40817019|NCT04924894|OTHER|no intervention|no intervention
40817020|NCT01888133|BEHAVIORAL|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
41335035|NCT04360772|DIAGNOSTIC_TEST|mHLA-DR|"* Before treatment/ At inclusion/Day 0 : Collection of gender, date of birth, comorbidities, pathology implicating treatment by corticosteroids and other treatment administered at the time of inclusion.~* At Day 0, Month 1, Month 3, Month 6 : Blood sampling (3mL) to proceed to mHLA-DR measurement. At those time-points, results from lymphocytes immunophenotyping, C-reactive protein and numeration will be collected.~* At Month 24 : Collection from medical report of~* any infectious events that would have occured during the follow-up~* course of the disease with corticosteroids~* survival or death at 24 months of follow-up."
41335036|NCT01930240|DRUG|TRIA-662|1-MNA Chloride
40817021|NCT01888133|BEHAVIORAL|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
41335037|NCT01930240|DRUG|Placebo|Double-blind placebo
41335038|NCT02661945|DEVICE|Near focus with narrow band imaging|
41335039|NCT02291445|DRUG|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
41014502|NCT06120075|DRUG|AB801|Administered as specified in the treatment arm
41014503|NCT06120075|DRUG|Zimberelimab|Administered as specified in the treatment arm
41014504|NCT06120075|DRUG|Docetaxel|Administered as specified in the treatment arm
41014505|NCT06376461|OTHER|Data collection|Sites will recruit all consecutive adult patients admitted to ICU, to a maximum of 120 patients or a maximum recruitment period of 8 weeks, whichever comes first
41014506|NCT01895751|PROCEDURE|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
41335040|NCT02291445|DRUG|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
41335041|NCT04042012|OTHER|Eccentric exercise|soleus eccentric exercise
41335042|NCT04042012|OTHER|PNE|the application of galvanic current
41335043|NCT04042012|OTHER|Combined|soleus eccentric exercise and PNE
41335044|NCT03822702|OTHER|Biofeedback Training|Biofeedback training targeted to goals that are relevant to the handwriting skills for children by using a force acquisitional pen.
40817022|NCT06117111|DEVICE|PaMo monitoring device|Comparison of the device to standard monitoring
40817023|NCT01345513|OTHER|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
40817024|NCT03051412|OTHER|No Intervention|No intervention
40817025|NCT05438212|PROCEDURE|Brain Surgery|Undergo surgery per standard of care
40817026|NCT05438212|OTHER|Quality-of-Life Assessment|Ancillary studies
41014507|NCT04502602|DRUG|Neratinib 160 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
41014508|NCT04502602|DRUG|Neratinib 200 mg|Determined RP2D dose
41014509|NCT04502602|DRUG|Neratinib 240 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
41014510|NCT04502602|DRUG|Niraparib 100 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
41014511|NCT04502602|DRUG|Niraparib 200 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
41014512|NCT04502602|DRUG|Niraparib 300 mg|Phase 1: Escalating doses to determine recommended phase 2 dose (RP2D)
41014513|NCT04502602|DRUG|Niraparib at RP2D|Phase 1b: Determined dose
41335045|NCT03822702|OTHER|Motor Training|Motor training targeted to goals that are relevant to the handwriting skills for children by using a personal designed motor training program.
41335046|NCT01978600|DRUG|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
40817027|NCT05438212|OTHER|Questionnaire Administration|Ancillary studies
40817028|NCT05438212|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
40817029|NCT01126268|DRUG|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
40817030|NCT04195438|PROCEDURE|CO Testing Pre/Post Hepatic Resection|Monitor CO in exhaled air of patients before liver resection, at 4 hours and 24 hours after PH
40817031|NCT04195438|DIAGNOSTIC_TEST|ABG Testing Pre/Post Hepatic Resection|Monitor carboxyhemoglobin(COHb) in the arterial blood gas of patients before liver resection at 4 hours and 24 hours after PH
41335047|NCT01978600|DRUG|Timolol Maleate 0.5%|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
41335048|NCT03587922|DEVICE|Fantom|Treatment of den ovo coronary lesions
41335049|NCT00000339|DRUG|Risperidone|
41335050|NCT01095341|OTHER|No intervention performed|
41335051|NCT00040950|BIOLOGICAL|rituximab|
41484243|NCT02836626|PROCEDURE|superficial fascial mobilization|This group will undergo four 25-minute sessions of gentle superficial effleurage to the abdomen and posterior trunk followed by superficial skin rolling to the scar. Each treatment session will be terminated a) after 25 minutes or 2) when the patient asks to stop due to discomfort. Reasons for termination will be documented. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
41484244|NCT04530552|DRUG|Apalutamide|Given PO
41484245|NCT04530552|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41484246|NCT04530552|OTHER|Quality-of-Life Assessment|Ancillary studies
41484247|NCT04303377|BIOLOGICAL|Evolocumab|Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)
41484248|NCT05404412|PROCEDURE|Epidural Steroid Injection|This intervention is applied mostly for cervical or lumbar radiculopathy. The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then a combined local anesthetic and glucocorticoids are delivered to the epidural space.
41484249|NCT02993770|PROCEDURE|Endoscopic DCR|Endonasal endoscopic technique as described by Wormold et al.
41484250|NCT02993770|PROCEDURE|External DCR|External DCR
41484251|NCT00704730|DRUG|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
40817032|NCT04195438|DIAGNOSTIC_TEST|CT Evaluations|Analyze the relationship between CO production and the extent of hepatic resection assessed by computed scans liver volumetric study at one and three months after PH, size and weight of the resected specimen and operative report
40817033|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
40817034|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
40817035|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
40817036|NCT06067685|OTHER|Observation|Prospective Observation only. Will record serum triglyceride, fingerstick blood triglyceride measurements, cord c-peptide, and neonatal body fat composition measurements in the first 6 months.
40817037|NCT03960411|DRUG|Doxycycline 100Mg Capsule|Doxycycline capsule
40817038|NCT03960411|DRUG|Placebo oral capsule|Capsule manufactured to mimic doxycycline 100 mg capsule
40817039|NCT03796390|BIOLOGICAL|CD123 CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
41014514|NCT04502602|DRUG|Neratinib at RP2D|Phase 1b: Determined dose
41335052|NCT00040950|DRUG|agatolimod sodium|
41335053|NCT05848973|OTHER|Healthy Diet|The targeted study participants will be given advice about healthy dietary intakes. This will entail promotion of foods rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; moderate in lean red meat and low-fat diary products). To be concrete, the study investigators will target energy (E%) from macronutrients as follows: 42 E% total fat (≥ 22 E% from monounsaturated fatty acids, 10 E% from polyunsaturated fatty acids and \<10 E% saturated fatty acids), 35 E% carbohydrate, 15 E% protein and ≤ E 5% alcohol. Importantly, this will meet all Recommended Dietary Intake requirements for adults.
41335054|NCT05848973|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is a skills-based intervention comprising a structured 8-week group intervention program to be delivered in groups of study participants, with an all-day practice session around week six and regular reunion sessions thereafter.
41335055|NCT02480504|OTHER|dietary intervention intermittent energy restriction|Randomized clinical trial
41335056|NCT02480504|OTHER|continuous energy restriction|
41335057|NCT04658810|OTHER|Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder)|Patients identified as women with cytomegalovirus (CMV) seroconversion during pregnancy will be called on the phoned and ask to participate to the study and to answer the Perinatal Post-traumatic Stress Disorder
41335058|NCT02854670|DRUG|Capsaicin patch|After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
41335059|NCT01574937|DRUG|Cabozantinib|28 day cycle
41335060|NCT01574937|DRUG|Abiraterone|28 day cycle
41484252|NCT00704730|DRUG|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
41484253|NCT03853018|DEVICE|CWAT intervention|Participant in the intervention group will wear an activity tracker for 12 weeks.
41014515|NCT06207110|BEHAVIORAL|Regulation of Cues|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to improve satiety responsiveness and decrease food cue responsiveness. This arm will include an experiential component, including hunger monitoring during a meal or snack and participating in exposure exercises.
41014516|NCT06207110|BEHAVIORAL|Family Based Behavioral Treatment|FBT provides nutrition and physical activity education, behavior therapy skills, and parenting skills targeting changes in energy balance.
41335061|NCT02565446|PROCEDURE|Magnetic Resolution Elastography (MRE)|Magnetic Resolution Elastography (MRE): Three-dimensional magnetic resonance elastography (3DMRE), Waves at frequencies of 30 Hz, 40 Hz, and 60 Hz.
41335062|NCT02294669|DEVICE|Turris Facet Fuser|Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
41484254|NCT03853018|DEVICE|CWAT + motivation intervention group|Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
41014517|NCT06207110|BEHAVIORAL|Regulation of Cues +|ROC+ includes all of the skills provided in ROC but integrates nutrition education and reducing energy intake
41014518|NCT06207110|BEHAVIORAL|Health Education|The HE program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
41014519|NCT01306019|BIOLOGICAL|Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector|Transduced cell product administered intravenously over approximately 30 minutes by authorized licensed personnel consistent with NIH Clinical Center Department of Transfusion Medicine's standard operating procedures for cellular products.
41014520|NCT01306019|DRUG|Busulfan|3mg/kg per day with drug levels obtained on Day -3. Busulfan dose on day -2 will be adjusted (if busulfan AUC result is available) to achieve targeted busulfan AUC 4500 min\*umol/L/day. If the result is not available in time to adjust, then proceed to give the standard 3mg/kg on the second day
41014521|NCT01306019|DRUG|Palifermin|Mucositis prophylaxis commenced- Infusion of keratinocyte growth factor (palifermin) at 60 mcg/kg/day before (Days -6 to Day -4) administration of busulfan and (Days +1 to +3) post-busulfan administration
41014528|NCT04456699|DRUG|Olaparib|300 mg BID, oral until progressive disease or end of study
41014529|NCT04456699|DRUG|5-FU|2400 mg/m\^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion
41014530|NCT04456699|DRUG|Bevacizumab|5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
41014531|NCT04456699|DRUG|Capecitabine|1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
41014532|NCT04456699|DRUG|Leucovorin/ levoleucovorin|400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
41335063|NCT00424346|DRUG|Canakinumab|
41335064|NCT00424346|DRUG|Placebo|
41335065|NCT00014170|DRUG|gefitinib|Given orally
41335066|NCT00014170|OTHER|pharmacological study|Correlative studies
41484255|NCT00891839|DRUG|Bendamustine|Bendamustine at 90 mg/m\^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
41335067|NCT00014170|OTHER|laboratory biomarker analysis|Correlative studies
41335068|NCT00014170|OTHER|questionnaire administration|Ancillary studies
41484256|NCT00891839|DRUG|Rituximab|Patients receive 375 mg/m\^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
40817040|NCT04564807|BEHAVIORAL|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
41014535|NCT06257264|DRUG|BG-68501|Planned doses administered orally.
41014536|NCT06257264|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
41014537|NCT03199469|GENETIC|Resamirigene bilparvovec|Resamirigene bilparvovec is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
41335069|NCT00014170|PROCEDURE|quality-of-life assessment|Ancillary studies
41335070|NCT03628495|DEVICE|compression|compression will be delivered using compression garment
41335071|NCT03628495|DEVICE|occlusion|occlusion will be delivered using silicone gel sheeting
41335072|NCT01526005|DRUG|Transdermal Nicotine Patch|1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
41335073|NCT01526005|DRUG|Transdermal Placebo Patch|1 patch per day; 8 weeks total
41335074|NCT01340560|PROCEDURE|Endometrial biopsy|Endometrial biopsy was performed with biopsy catheter
41335075|NCT04445350|OTHER|External Focus Of Attention|Instructions and feedback are used to direct the learner's focus to an external source (e.g. the effect the intended movement has) promoting long-term learning by stimulating automatic cognitive control processes.
41335076|NCT04445350|OTHER|Internal Focus Of Attention|In contrast, adopting an internal focus of attention (e.g. focus on specific body areal) can disrupt automatic control processes and interfere automatic movement.
41335077|NCT02798562|DEVICE|Native and dynamic contrast-enhanced CT|
41335078|NCT00134953|DRUG|Rivastigmine|
41335079|NCT01248364|DRUG|BI 10773|BI 10773 tablets once daily high dose
41335080|NCT01997281|DIETARY_SUPPLEMENT|dietary fiber-enriched cereal|"* provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)~* one serving of steamed egg is added for dinner and breakfast"
41335081|NCT01997281|OTHER|conventional cereal|"* provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)~* one serving (40g) of steamed egg is added for dinner and breakfast"
41335082|NCT04438304|DRUG|64Cu-SARTATE|64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.
41484257|NCT00183937|DRUG|PS 341|PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
41484258|NCT00183937|DRUG|Docetaxel|Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
41484259|NCT04650113|COMBINATION_PRODUCT|MTA material|Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
41335083|NCT00409916|DEVICE|BioZ Dx|
40817041|NCT04564807|BEHAVIORAL|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
41014551|NCT06369571|DRUG|Atorvastatin 10mg|Atorvastatin 10mg daily by mouth
41014552|NCT06369571|OTHER|Modification of dietary fat composition|Replace 10% of saturated fat intake with polyunsaturated fat
41014553|NCT06629181|OTHER|Education|"The researchers will conduct a 4-week intervention for the intervention group participants.~Technology Use Basic Information Training, MHRS and e-pulse Systems Usage Training Health literacy, mobile health application usage training Counseling Applications will be made at the end of the training"
41014554|NCT06630286|DRUG|ISL/LEN|Tablet administered orally
41014555|NCT06630286|DRUG|B/F/TAF|Tablet administered orally
41014556|NCT06630286|DRUG|PTM B/F/TAF|Tablet administered orally
41335084|NCT06109077|OTHER|Levator ani release|Patients will be treated with levator ani release exercises for pain (3 sets with 10 repetitions 3 times per week for 6 weeks).
41335085|NCT06109077|OTHER|Post isometric relaxion|Patients will be treated with Post isometric relaxation exercise and hold contractions for 10 seconds over 5 to 12 repetitions, 3 times per week for 6 weeks
41335086|NCT04213183|DIAGNOSTIC_TEST|Hepatobiliary Disorders|The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
41335087|NCT03969836|DEVICE|NeurOS system|NeurOS system pads will be placed on patients' head for monitoring.
41335088|NCT05151367|BEHAVIORAL|Text message reminder|Receipt of text messages notifying when the next HPV vaccine dose is due (either first or second)
41335089|NCT00115544|DRUG|Stanate|Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
41014557|NCT06630286|DRUG|PTM ISL/LEN|Tablet administered orally
41335090|NCT05387798|DRUG|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
41484260|NCT06422390|BIOLOGICAL|Platelet - Rich Plasma|Platelet - Rich Plasma is a biologic injection created from the patient's own blood. 52cc of the patient's blood is drawn then mixed with 8cc of anticoagulant. The blood mixture will be spun down using a centrifuge that can separate the platelet-rich plasma from the other contents in the blood. Once the centrifuge process is complete the Platelet - Rich Plasma is ready to be used.
40817042|NCT04137588|DRUG|Antiangiogenesis Agents|antiangiogenesis agents plus chemotherapy as first line treatment
40817043|NCT04137588|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor plus chemotherapy as first line treatment
41014563|NCT03559660|DRUG|Certolizumab Pegol|
41014564|NCT05575999|DRUG|Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination|The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
41335091|NCT06267807|DIAGNOSTIC_TEST|Dynamic contrast-enhanced lymphangiography|The subject is placed supine on a detachable MR imaging table, outside the scanning room. Both inguinal regions are prepared under sterile conditions. Using Ultrasound guidance, the thoracic duct outlet at the left venous angle is identified. Under US guidance, a small 25 gauge needle is placed at the corticomedullar junction of an inguinal lymph node on each side. The needle position is confirmed and checked that there is no extravasation at saline injection under US visualization. The subject is then transferred to the MR imaging machine. First, pre-contrast imaging is performed, this takes around 20 minutes.
41335092|NCT04537572|DIAGNOSTIC_TEST|comparison of sample collection methods|Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.
41335093|NCT00804986|DRUG|LY2428757|Once weekly for 12 weeks as a subcutaneous injection.
41335094|NCT00804986|DRUG|Placebo|1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
41335095|NCT06383689|OTHER|Seizure placebo pill|patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible acceleration of seizure occurrence during presurgical video-EEG
41335096|NCT06383689|OTHER|Well-being placebo pill|patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible improvement of emotional well-being during video-EEG
41335097|NCT04450641|OTHER|GuessWhat Mobile Application|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
41014565|NCT06003855|BEHAVIORAL|Supervised exercise therapy|Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
41156193|NCT05721378|PROCEDURE|Permissive Weight Bearing group|The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.
41335098|NCT05425303|DIAGNOSTIC_TEST|Exposure to risk for injury|Athletes will be examined in the preseason stage and will be monitored during the competitive season.
41484261|NCT04022928|OTHER|PRP|, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.
41014566|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin|"TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
41484262|NCT05042050|BEHAVIORAL|A-iMAPS|Imagery therapy targeting Psychosis-Related PTSD
41484263|NCT03347422|DRUG|sutimlimab (BIVV009)|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
41014567|NCT05834543|DRUG|Penpulimab injection, Paclitaxel, Cisplatin|"Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
41014568|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, TQB3617capsules|TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).
41014569|NCT05843643|DRUG|Upadacitinib|Oral Tablets
41014570|NCT05843643|DRUG|Placebo|Oral Tablet
41484264|NCT03347422|DRUG|placebo|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
41335099|NCT04107116|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
41335100|NCT04107116|OTHER|Usual Care|Usual care as provided by local oncologists
41335101|NCT01227720|DRUG|Experimental Nicotine Replacement Therapy (NRT) 2 mg|2 mg Single-dose of new NRT product (NSL2L)
41335102|NCT01227720|DRUG|Experimental Nicotine Replacement Therapy (NRT)|4 mg Single-dose of new NRT product
41335103|NCT01227720|DRUG|Marketed Nicotine Lozenge|2 mg Single-dose of marketed lozenge
41014573|NCT01703949|DRUG|Brentuximab Vedotin|Given IV
41014574|NCT01703949|OTHER|Laboratory Biomarker Analysis|Correlative studies
41014575|NCT01703949|BIOLOGICAL|Nivolumab|Given IV
41014576|NCT04016402|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Clinical transcranial magnetic stimulation administered as part of usual care for the study population
41335104|NCT01227720|DRUG|Marketed Nicotine Lozenge|4 mg Single-dose of marketed lozenge
41335105|NCT03948451|DRUG|[14C]AZD5718 Oral Suspension|200 mg dose of \[14C\]AZD5718 Oral Suspension
41335106|NCT01756638|DRUG|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
41335107|NCT01756638|DRUG|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
41335108|NCT05300854|PROCEDURE|Standard anesthesia in addition to serratus plane block|a US-guided SPB was performed after induction of general anesthesia with the patient lying supine.
41335109|NCT05300854|PROCEDURE|Standard anesthesia in addition to para-vertebral block|Standard anesthesia in addition to para-vertebral block
41335110|NCT00215592|DRUG|Zonegran|
41335111|NCT02455362|DRUG|Morphine sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
41335112|NCT02455362|DRUG|Placebo|
41335113|NCT05688072|OTHER|trunk oriented exercise|trunk oriented exercises include: stretching exercises, stabilization exercises (active or active-assisted), arm exercises in fixed trunk position, trunk-oriented exercises (active or active-assisted), trunk mobilization (sitting and lying position), and functional reaching exercises with different ranges of motion in shoulder elevation
41335114|NCT05688072|OTHER|whole body vibration|WBV application technique. The children assume a full squatting position on a vibration platform. The apparatus will set at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 min. The children were instructed to remain in squatting position after the vibration started and to report any discomfort that arose. At the end of 5 min, the vibration turned off automatically. Thereafter, the children rested for 1 min. They were then asked to stand on the vibration platform while supported by the therapist for 5 min, with the same parameters as those used in the squatting position. The total time of application of WBV in each session was 10 min.
41335115|NCT00614991|DRUG|Raltegravir|400mg BID
41335116|NCT00614991|DRUG|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
41335117|NCT00614991|DRUG|Ritonavir|100 mg BID or QD
41335118|NCT06349382|DIETARY_SUPPLEMENT|carbohydrate-rich beverage|Patients in the OCHL group will drink a high-carbohydrate beverage (12.6% carbohydrates, 50 kcal/100 mL, 285 mOsm/kg; PreOp®, Nutricia, Zoetermeer, The Netherlands) 800 mL in the evening before surgery (between 9 p.m. and 11 p.m.), and 400 mL two hours before the induction of anesthesia.
41335119|NCT00105183|BIOLOGICAL|Placebo|placebo infusion, single
41335120|NCT00105183|BIOLOGICAL|EZ-2053|single IV infusion, 9 mg/kg
41335121|NCT00105183|BIOLOGICAL|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
40817044|NCT01842165|DRUG|Intravenous injection of 177Lu-octreotate|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
40817045|NCT02834585|OTHER|Ultrasound|
40817046|NCT06315231|DRUG|Edaravone dexborneol sublingual tablet|Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks
41335122|NCT01703104|DRUG|Paludrine + Folic Acid|This is the combination of routine drugs for treating sickle cell disease
41335123|NCT01703104|DIETARY_SUPPLEMENT|Paludrine + Folic Acid + Jobelyn|Combination of routine drugs + Jobelyn
41335124|NCT03371927|OTHER|SINC Feeding Protocol|Safe individualized nipple-feeding competence protocol for premature infants
40817047|NCT06315231|DRUG|Placebo|Patients will receive one placebo twice daily for 24 weeks
40817048|NCT03263858|DEVICE|Stent|Implantation of coronary stent in de novo coronary artery lesions
41335125|NCT03221712|BEHAVIORAL|cardiac rehabilitation|cardiac rehabilitation in patients with chronic total occlusion of the coronary arteries.
40817049|NCT00092872|DRUG|MK0557|
40817050|NCT03487588|DRUG|A-101 Topical Solution|A-101 Topical Solution applied Day 1, Day 15 and Day 29
40817051|NCT01065194|DRUG|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
40817052|NCT01065194|DRUG|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
40817053|NCT03970096|RADIATION|Total-Body Irradiation|Undergo TBI
40817054|NCT03970096|DRUG|Thiotepa|Given IV
40817055|NCT03970096|DRUG|Fludarabine|Given IV
40817056|NCT03970096|DRUG|Tacrolimus|Given IV
40817057|NCT03970096|BIOLOGICAL|Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Given IV
40817058|NCT03970096|DRUG|Methotrexate|Given IV
40817059|NCT03970096|DRUG|Cyclophosphamide|Given IV
40817060|NCT03970096|BIOLOGICAL|Peripheral Blood Stem Cell|Given IV
40817061|NCT03970096|DRUG|Cyclosporine|Given IV
40817062|NCT03970096|DRUG|Sirolimus|Given IV
41335126|NCT03356808|BIOLOGICAL|Lung cancer-specific T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
41335127|NCT02540876|DRUG|Ilorasertib|Given PO
41335128|NCT02540876|OTHER|Laboratory Biomarker Analysis|Correlative studies
41335129|NCT03543527|OTHER|no intervention|no intervention
40817063|NCT03970096|DRUG|Busulfan|Given IV
41156194|NCT05721378|PROCEDURE|Restricted Weight Bearing group|The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.
41335130|NCT00260195|BEHAVIORAL|School-based cognitive behavioral support group|
41335131|NCT04916756|DRUG|Baricitinib 2 MG|baricitinib 2mg per day for 24 weeks
41335132|NCT04724681|DEVICE|WARD CSS|Wireless devices monitor vital signs continuously and transmit real-time data to an app that notifies clinical personnel when relevant deviations in vital signs occur This group will be monitored with standard Early Warning Score as well
41335133|NCT01459770|OTHER|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
41484265|NCT03174106|DEVICE|Smartphone-Application|Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
41484266|NCT00378716|DRUG|5-fluorouracil|
40817064|NCT03970096|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
41156195|NCT05173259|BEHAVIORAL|F|The participant will be asked to chew the two-coloured chewing gum naturally.
41156196|NCT05173259|BEHAVIORAL|R|The participant will be asked to chew the two-coloured chewing gum on the right-side.
40817065|NCT03970096|PROCEDURE|Echocardiography|Undergo ECHO
41335134|NCT01459770|OTHER|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
41335135|NCT01804660|OTHER|No study treatments administered|
41335136|NCT06085430|DEVICE|Kubota Glass|Kubota Glass employs white light producing micro-LEDs covered by masks which create a patterned target. The patterned images are defocused by micro-lenslets and projected to the retinal periphery by a central mirror. Parameters of interest to evaluate in this investigation include but are not limited to dioptric amount of defocus, brightness (cd/m2), spectrum of illumination, and shape of the target mask. In each scenario, right eyes will be exposed to the stimulus, whereas left eyes serve as controls. The order of exposures to the various stimuli will be randomized to participant and investigator.
41335137|NCT00931060|DIETARY_SUPPLEMENT|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
41014580|NCT05340686|BEHAVIORAL|Aerobic Physical Exercise|Moderate to vigorous physical exercise 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
41014581|NCT05340686|BEHAVIORAL|Relaxing Physical Exercise|Relaxing exercises (stretching, light yoga) 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
41014582|NCT05340686|BEHAVIORAL|Information about physical exercise|Written and oral information about physical exercise recommendations, on one occasion, by researcher
41156197|NCT05173259|BEHAVIORAL|L|The participant will be asked to chew the two-coloured chewing gum on the left-side.
41335138|NCT04908709|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo sMRI
40817066|NCT03970096|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40817067|NCT03970096|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40817068|NCT00518648|OTHER|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
40817069|NCT00518648|OTHER|Usual care|Usual care
40817070|NCT06606431|BEHAVIORAL|Multileveled-community approach|One-to-one delivered interaction at relational level (Interpersonal Relations, Volunteers) Socio-health interaction at personalized level (Social Work) Group delivered interaction for volunteers (Group Dynamics) Community-level interactions (Social Cohesion, Community Networks)
41335139|NCT04908709|DEVICE|Proton Therapy|Target volume treatment
41484267|NCT00378716|DRUG|leucovorin calcium|
41484268|NCT00378716|DRUG|tegafur|
41484269|NCT00378716|DRUG|uracil|
41484270|NCT00325195|OTHER|placebo|placebo by intravenous infusion every 2 weeks
41484271|NCT00325195|BIOLOGICAL|pegloticase|8 mg pegloticase by intravenous infusion
41484272|NCT03256084|PROCEDURE|Blood and tumor samples|Blood and tumor samples
41335140|NCT01886404|DRUG|Efavirenz|"HIV-infected subjects currently receiving efavirenz (EFV) containing antiretroviral therapy (ART) will be asked to provide plasma samples. In addition to blood samples for determination of EFV concentrations, we will collect whole blood samples for functional Single Nucleotide Polymorphism (SNP) discovery within known candidate genes of interest in drug metabolism and transport.~Subjects will be at steady state for efavirenz when blood samples are collected. EFV is usually taken during the evening hours. The study consists of 2 blood draws at 12 and 18 hours post EFV dose. At the first blood draw, venous blood will be obtained by venous puncture for plasma concentrations of EFV and pharmacogenetics. At 18 hours post EFV dose , a second blood draw by venous puncture will be obtained for EFV plasma concentrations.~Demographics and clinical parameters will be collected at the time of the first visit, Neuropsychological tests and questionnaires completed as well."
41335141|NCT03437291|PROCEDURE|Cesarean section|Lower segment CS with evaluation of Placental site, spontaneous separation, placental invasion into the bladder and other surrounding organs, Uterotonic administration, Bladder , ureteric or bowel injury, blood loss and blood transfusion
41335142|NCT03437291|DEVICE|Transabdominal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
41335143|NCT03437291|DEVICE|Transvaginal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
41335144|NCT05656391|DIETARY_SUPPLEMENT|Treatment vs control bread|Consumption of 200 grams per day of either treatment or control bread for eight weeks
41335145|NCT04024241|DEVICE|Flow Cytometer|high dose
41335146|NCT04024241|DRUG|Mitoxantrone|high dose
41335147|NCT04024241|DRUG|Cytarabine|high dose
41335148|NCT01386567|DRUG|Androxal (enclomiphene citrate)|"capsules oral 1x a day~1 year"
41335149|NCT01386567|DRUG|Testim (topical testosterone)|"topical~1 tube~1x a day~1 year"
41335150|NCT01478178|DRUG|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
41335151|NCT06158282|OTHER|Voluntary apnoea|Walking apneas at high lung volume with cycles of 15-10s (apnea - breathing) during 6 minutes
41335152|NCT05241938|PROCEDURE|PSLT|PSLT will be performed under topical anesthesia (proxymetacaine hydrochloride 5mg/ml eye drops) using a mirrored gonioscopy lens (Latina Ocular Instruments). A α2 agonist hypotensive eye drops (0.2% brimonidine tartrate) and 2% pilocarpine eye drops are applied 40 minutes before the procedure. After laser treatment, the patient will be instructed to use non-steroidal anti-inflammatory eye drops (thrice daily for 7 days).
41335153|NCT05241938|DRUG|Prostaglandin analogue eye drops|Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
41335154|NCT05256316|OTHER|Previously admitted COVID-19 patients in intensive care units|Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission
41335155|NCT00647946|DRUG|tenofovir DF|tenofovir DF 300mg once daily along with the other antiviral drugs
41335156|NCT00647946|DRUG|abacavir 300mg twice daily|abacavir 300mg twice daily along with the other antiviral drugs
41335157|NCT03616847|OTHER|Standard care|Hallux valgus/hallux rigidus surgery with the calf tourniquet remaining in situ until the wound is closed.
41335158|NCT03616847|OTHER|Tourniquet release|Hallux valgus/hallux rigidus surgery with the calf tourniquet released five minutes before the wound is closed.
41335159|NCT05765552|OTHER|Dual-Task Training|Motor-cognitive dual-task exercises will be applied for 2 days a week for 8 weeks.Sessions will last for 30 minutes.
41335160|NCT05765552|OTHER|Control Group|Upper and lower extremity range of motion exercises will be applied for 8-10 repetitions for 1 set 2 times a week for 8 weeks.
41335161|NCT00004360|DRUG|chlorothiazide|
41335162|NCT06196619|DIAGNOSTIC_TEST|SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level|Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.
40817071|NCT06303648|DRUG|Methylone|Oral dose of methylone
40817072|NCT03362060|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors
41335163|NCT01761994|DRUG|Anticoagulation with nafamostat mesilate|Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
41335164|NCT06397976|DEVICE|ANTERION investigational|Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)
41335165|NCT00004300|DRUG|bromocriptine|
41335166|NCT00004300|DRUG|sertraline hydrochloride|
41335167|NCT04429152|DRUG|Doravirine/Lamivudine/Tenofovir|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination
41335168|NCT05544071|DEVICE|Transcranial Magnetic Stimulation (TMS)|Compare active coil with sham coil.
41335169|NCT01009918|DRUG|Coreg CR®|Given orally
41335170|NCT01009918|DRUG|lisinopril|Given orally
41335171|NCT01009918|OTHER|placebo|Given orally
41335172|NCT03219801|BIOLOGICAL|mesenchymal stem cells|SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.
40817073|NCT03362060|BIOLOGICAL|PVX-410|PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
41156198|NCT05173259|BEHAVIORAL|G05|The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.
41335173|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The range of cases in which it can be used is wider than a simple reconstructive anatomical prosthesis. In fact, thanks to its anchoring plate, and if cephalic perfusion criteria are met, the modular nature of HUMELOCK II® means it is possible to retain the patient's native humeral head, even in cases of severe osteopenia.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus, a common occurrence in severely injured shoulders. The HUMELOCK II® shoulder system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II® shoulder prosthesis is a hemi shoulder and a total shoulder prosthesis."
41335174|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus). It is designed for use in complex shoulder reconstruction procedures in patients with stage 3 or 4 fragments in the proximal humerus - a common occurrence in severely injured shoulders. The HUMELOCK II® reversible system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed.~The HUMELOCK II reversible system is used when the rotator cuff is injured."
41335175|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System|Humelock Reversed® is a new generation of reversed prosthesis, designed for numerous shoulder pathologies: ranging from offset arthritis to a complex cephalotuberosity fracture. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post and the position of which is guided by an intuitive adaptive instrumentation. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible. Options of locking or cementing will allow the surgeon to position the prosthetic stem at the required height, according to the patient's indication and anatomy. The surgery is called total shoulder arthroplasty. It is also indicated in a failed hemi-arthroplasty or a failed total arthroplasty. It is indicated for significant rupture of rotator cuff-tear (first surgery or revision surgery)
41484273|NCT04375852|DIAGNOSTIC_TEST|Detection of autoantibodies|Blood was obtained from each patient for testing the endocrine functions and determination of a panel of autoantibodies to the following: Side-chain cleavage enzyme (SSC), Aromatic L-amino acid decarboxylase (AADC), Tryptophan hydroxylase (TPH),Tyrosine hydroxylase ( TH), 17α-hydroxylase (17α-OH), Cytochrome P450 1A2 (CYP1A2), 21-hydroxylase (21-OH), Potassium channel regulatory protein (KCNRG), Tyrosine phosphatase-like protein IA-2 (IA-2), Glutamic acid decarboxylase 65 (GAD65), NACT Leucine-Rich-Repeat-Protein 5 (NALP5), and Interleukin (IL) 22.
41484274|NCT02852642|OTHER|Exercise|Plyometric training
41484275|NCT05465096|PROCEDURE|Micro-fragmented adipose tissue injection|Intra-articular ultrasound-guided injection of MF-AT
41484276|NCT00735917|DRUG|saracatinib|Given PO
41484277|NCT00735917|OTHER|pharmacogenomic studies|Optional correlative studies
41484278|NCT00735917|OTHER|pharmacological study|Optional correlative studies
41156199|NCT05173259|BEHAVIORAL|G15|The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.
41156200|NCT05173259|BEHAVIORAL|G25|The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.
41156201|NCT00585208|DRUG|Ramelteon|Ramelteon 8mg daily
40817074|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\])
40817075|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
40817076|NCT00313313|DRUG|Glyburide|Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
41335176|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System|"EASYTECH Anatomical Shoulder System is indicated for use in total shoulder replacement to treat a severely painful and/or disabled joint resulting from osteoarthritis or rheumatoid arthritis.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. The surgery is called total shoulder arthroplasty. EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability"
41484279|NCT00735917|PROCEDURE|positron emission tomography|Optional correlative studies
41484280|NCT00735917|RADIATION|fludeoxyglucose F 18|Optional correlative studies
41156202|NCT00585208|DRUG|Placebo|matching placebo for ramelteon 8mg daily
41156203|NCT06646562|DRUG|Cabotegravir LA + Rilpivirine LA|Cabotegravir (CAB) LA 600mg and Rilpivirine (RPV) LA 900mg will be administered intramuscularly every 2 months after an induction phase with a single administration in months 1 and 2.
40817077|NCT00313313|DRUG|Placebo|Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
40817078|NCT00313313|DRUG|Glyburide|Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
40817079|NCT00313313|DRUG|Metformin|Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
41156204|NCT00167323|BEHAVIORAL|Adherence therapy|
41156205|NCT06611657|DRUG|Antirotinib hydrochloride|Oral antirotinib treatment was started 2 weeks before radiotherapy for brain metastases, stopped for 1 week after 2 weeks, and continued after radiotherapy until tumor progression
41156206|NCT04174378|DRUG|Decapeptyl 0.2mg|IM Decapeptyl o.2 mg was given 2 days before embryo transfer
41156207|NCT06285227|BIOLOGICAL|CM313 injection|CM313
41484281|NCT00735917|OTHER|laboratory biomarker analysis|Optional correlative studies
41484282|NCT04414839|DEVICE|Digital Intubation (Two-finger)|In the NGT Digital Intubation group (group B), the second and third fingers were placed in the posterior pharynx and depressed the tongue downwards. The NGT was passed through the nose into the posterior pharynx with the fingers in the pharynx to reach the esophagus. The thumb was placed under the jaw and pushed it forward to pave the way for tube insertion.
41484283|NCT04414839|DEVICE|Video Laryngoscopy|In the NGT Video Laryngoscopy group (group A), first, the GlideScope blade was inserted under direct visualization via color monitor through the patient's mouth by employing jaw-thrust maneuver to preserve the cervical spine and by raising the tongue to obtain better visualization of the larynx space. Then, NGT was inserted through the selected nostril, advanced through the esophagus under direct vision to meet the measured length, and fixed after confirmation.
41484284|NCT01029158|DRUG|Juvista (Avotermin)|250 ng, twice, intradermal injection, standard formulation
41484285|NCT01029158|DRUG|RN1006 (Avotermin)|250 ng, intradermal injection, twice
41484286|NCT01029158|DRUG|RN1006 (Avotermin)|205 ng, Intradermal injection, once
40817080|NCT05638334|DRUG|89Zr-S095012 tracer and S095012 will be administered via an IV infusion|"Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C."
40817081|NCT01471028|BIOLOGICAL|ELAD treatment|ELAD treatment consists of treatment with an extracorporeal liver assist system.
40817082|NCT01471028|OTHER|Standard of care (Control)|Control receives standard medical treatment.
40817083|NCT06257667|OTHER|Respiratory Support|Treatment with High Flow Nasal Cannula
41014611|NCT05007483|DIETARY_SUPPLEMENT|BodyBio Balance Oil|nutraceutical supplement
41014612|NCT05007483|DIETARY_SUPPLEMENT|Kirunal Fish Oil|nutraceutical supplement
41156208|NCT06091982|PROCEDURE|Renal Replacement Therapy (RRT)|Renal Support therapy which consist of procedure of intermittent hemodialysis (IHD) or continuous veno-venous hemofiltration/hemodialysis/hemodiafiltration (CVVH/CVVHD/CVVHDF)
41484287|NCT01029158|DRUG|RN1006 (Avotermin)|500ng, intradermal injection, once
41484288|NCT01029158|DRUG|Juvista (Avotermin)|250 ng, intradermal injection, twice
41484289|NCT01029158|DRUG|Juvista (Avotermin)|500 ng, intradermal injection, once
41484290|NCT01029158|DRUG|Juvista (Avotermin)|500 ng, intradermal injection, once
41484291|NCT01029158|DRUG|RN1006 (Avotermin)|500 ng, intradermal injection, twice
41484292|NCT01029158|DRUG|Placebo|Placebo
41484293|NCT05001711|DEVICE|Aria CV Acute PH System|The Aria CV Acute PH System is indicated for evaluation of hemodynamic responses (e.g. pulmonary arterial compliance, cardiac output, and effective arterial elastance) to an intravascular Balloon catheter temporarily placed in the pulmonary artery in symptomatic adult patients with WHO Group 2 or WHO Group 3 pulmonary hypertension and right ventricular dysfunction.
40817084|NCT01853579|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
40817085|NCT01853579|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
41484294|NCT00687310|BEHAVIORAL|Educational intervention|Tailored asthma education based on needs assessment
40817086|NCT01310543|BEHAVIORAL|Teens and Toddlers|The T\&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
40817087|NCT04170530|DRUG|mFOLFOXIRI|irinotecan\* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
41014613|NCT05007483|DIETARY_SUPPLEMENT|BodyBio PC|nutraceutical supplement
41014614|NCT05007483|BEHAVIORAL|Modified Paleolithic Elimination diet|"1. Complete elimination of all gluten-, dairy-, and egg-containing foods.~2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.~3. Consume 6-12 ounces/day protein including organ meats and fatty fish.~4. Consume fermented foods daily.~5. Consume daily servings of algae, seaweed, and nutritional yeast."
41014615|NCT05007483|BEHAVIORAL|Time Restricted Olive Oil Based (TROO) Ketogenic Diet|"1. Restriction of dietary carbohydrates to \< 50 grams/day.~2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to \>160 grams/day.~3. Consume \<100 grams/day protein.~4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).~5. Consume at least 3 servings/day non-starchy vegetables."
41014616|NCT05007483|BEHAVIORAL|Usual diet with Dietary Guidelines for Americans Diet information|"1. Limit sodium to \< 2,300 mg/day.~2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively.~3. Consume 5 servings of fruits and vegetables per day.~4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.~5. Consume 3 servings of reduced fat dairy per day.~6. Consume 6 ounces/day protein foods."
41014617|NCT05732831|DRUG|TNG462|TNG462, a selective PRMT5 inhibitor, will be administered orally
41014618|NCT05819398|DRUG|Spesolimab Formulation 1|Spesolimab Formulation 1
41014619|NCT05819398|DRUG|Spesolimab Formulation 2|Spesolimab Formulation 2
41014620|NCT05819398|DRUG|Placebo matching Spesolimab Formulation 1|Placebo matching Spesolimab Formulation 1
41014621|NCT05819398|DRUG|Placebo matching Spesolimab Formulation 2|Placebo matching Spesolimab Formulation 2
41484295|NCT04601038|DRUG|CORT108297|120mg of a selective glucocorticoid receptor antagonist, taken as 2 tablets daily for 2 weeks
41484296|NCT04601038|DRUG|Placebo|Placebo taken as 2 tablets daily for 2 weeks
41484297|NCT03126357|OTHER|Product A|Usual Brand Cigarette
41484298|NCT03126357|OTHER|Product B|FT21039 an electronic tobacco vapor product
41484299|NCT03126357|OTHER|Product C|FT21092 an electronic tobacco vapor product
41484300|NCT03126357|OTHER|Product D|FT21018 an electronic tobacco vapor product
41484301|NCT03126357|OTHER|Product E|4mg nicotine gum
40817088|NCT05092763|BEHAVIORAL|FIT4SURGERY|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls. Patients are asked to wear the Fitbit through the entire 9-12 weeks in which they are receiving neoadjuvant chemotherapy both when asleep and when awake. Patients are taught how to understand the Fitbit outputs on the application, for example, understanding how to monitor their steps and heart rate. Caregivers are also be encouraged to assist patients. Patients are provided with information about the benefits of physical activity and effective behavior change strategies for incorporating physical activity into their daily lives. These include things such as short bouts of activity by walking around the room during commercial breaks or planning to be dropped off a short walk from a destination.
40817089|NCT05092763|BEHAVIORAL|Healthy Lifestyle Control|Participants assigned to this study arm are instructed to go about their usual activities and receive education about physical activity and a healthy lifestyle for ovarian cancer patients. They are encouraged to download the free Cancer.Net mobile app and visit the cancer.net website for educational materials related to ovarian cancer and survivorship. At the end of the 9-12 week intervention, participants in the Healthy Lifestyle group receive a Fitbit for their optional, personal use after surgery.
40817090|NCT06198712|DRUG|Etavopivat|Participants will receive oral tablets of etavopivat once daily.
40817091|NCT04427995|DEVICE|OMNI surgical system|GATT + viscodilation
40817092|NCT03326414|PROCEDURE|Constant PEEP - low tidal volume|The respirator is set according to study protocol
40817093|NCT03326414|PROCEDURE|Constant PEEP - high tidal volume|The respirator is set according to study protocol
41014622|NCT02684006|DRUG|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
41335177|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)|"EASYTECH Reversed Shoulder System is indicated for primary total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation"
41335178|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)|"EASYTECH Reversible Shoulder System is indicated for revision total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation."
41484302|NCT06303713|DRUG|Carboplatin|Platinum coordination compound, premixed aqueous solution of 10mg/ML, via intravenous (into the vein) infusion per protocol.
41484303|NCT06303713|DRUG|177Lu-PSMA-617|Radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.
41484304|NCT02876926|BEHAVIORAL|"Smart home-based test for HIV"|A standard home-based HIV test kit, fit with a Bluetooth low energy beacon to allow remote monitoring.
41484305|NCT02876926|BEHAVIORAL|Home-based testing only|A standard home-based HIV test kit.
41484306|NCT02876926|BEHAVIORAL|Reminder letters for clinic-based testing|Letters reminding patients to get tested at a free clinic location
41484307|NCT04763018|DEVICE|iTEAR100|Neurostimulation external nasal nerve to stimulate tear production
41484308|NCT02849327|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
41484309|NCT02849327|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
41484310|NCT04860765|DEVICE|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
41484311|NCT01131572|DRUG|N-acetylcysteine NAC|N-acetylcysteine in the treatment of Bulimia Nervosa
41014623|NCT02684006|DRUG|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
41014624|NCT02684006|DRUG|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
41484312|NCT00290394|DRUG|rosiglitazone(drug), blood pressure lowering effect|
41484313|NCT03994549|DRUG|Dual GLP-1/GLP-2 Receptor agonists|Eight ascending doses of ZP7570
41484314|NCT03380559|DRUG|Injection, botulinum toxin + corticoid|"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
41484315|NCT03380559|DRUG|Injection, placebo of toxin + corticoid|"* Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
41484316|NCT03380559|DRUG|Injection, botulinum toxin + placebo corticoid|"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)"
41484317|NCT02516410|DRUG|VX-661 plus ivacaftor combination|
41484318|NCT02516410|DRUG|Ivacaftor|
40817094|NCT03326414|PROCEDURE|constant tidal volume - low PEEP|The respirator is set according to study protocol
41156209|NCT06279637|BEHAVIORAL|Joint Home-DM-BAT Intervention|8 weekly sessions of telephone-delivered, manualized education on diabetes management, problem solving of social needs, and behavioral activation.
41484319|NCT02516410|DRUG|Placebo (matched to VX-661 plus ivacaftor combination)|
41484320|NCT02516410|DRUG|Placebo (matched to ivacaftor)|
41484321|NCT04796636|DRUG|Sodium Ascorbate|As previously described
41335179|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible.
41335180|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals, in order to avoid the disadvantages of traditional reverse prostheses. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post, the position of which is guided by an intuitive adaptive instrumentation.A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability.The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible
41484322|NCT01801683|OTHER|Intervention-using PEARLS|The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
41484323|NCT05296382|DRUG|Tebipenem tablet form|Tebipenem tablets will be administered intact or crushed
40817095|NCT03326414|PROCEDURE|constant tidal volume - high PEEP|The respirator is set according to study protocol
40817096|NCT03804567|OTHER|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs such as chronic pain that are troubling them.
40817097|NCT03804567|OTHER|Routine low back pain management|Standard low back persistent physiotherapy management as recommended by national guidelines.
41484324|NCT05296382|OTHER|Tube feeds|Tebipenem tablets will be administered with or without tube feeds
41484325|NCT04487743|DRUG|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
40817098|NCT01537159|DEVICE|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
41014628|NCT05952037|DRUG|BGB-11417|Administered orally as a tablet.
41014629|NCT05952037|DRUG|Zanubrutinib|Administered orally as a tablet.
41014630|NCT06313866|DIETARY_SUPPLEMENT|control|Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.
41014631|NCT06313866|OTHER|Electronuchal acupuncture group treatment|Electronuchal acupuncture
41014632|NCT06313866|OTHER|Smell therapy group treatment|nasal suction intervention with volatile oil of Acorus calamus
40817099|NCT02028117|BIOLOGICAL|Enadenotucirev|Oncolytic Virus
40817100|NCT01711489|DRUG|isavuconazole|oral
41014633|NCT06313866|OTHER|Electronuchal acupuncture combined with smell and inhalation therapy group treatment|On the basis of electric nuchal acupuncture treatment, sniffing and inhalation therapy is given.
41156210|NCT06279637|BEHAVIORAL|Usual Care|Diabetes education materials will be mailed weekly and monthly according to the booster schedule
40817101|NCT01711489|DRUG|Mycophenolate mofetil|oral
40817102|NCT05969756|DRUG|Fluoride varnish|Thirty-eight permanent molars will receive 5% sodium fluoride varnish application every three months
41014634|NCT06313866|OTHER|Sham stimulation|In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture.
41335181|NCT04823546|OTHER|activity based therapy|Standing and reaching (2) Sit-to-stand (3) Stepping forward and backward onto blocks (4) Stepping sideways onto blocks (5) Forward step up onto blocks (6) Raising and lowering of heel (7) Standing with the base of support constrained with feet in parallel and tandem conditions Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise. (10) Walking on a treadmill; (11) Walking over various surfaces and obstacles;
41335182|NCT04823546|OTHER|Strength Training|Strength training included for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
41335183|NCT03439111|DIETARY_SUPPLEMENT|Standardized Lycium chinense Fruit Extract (LCF) capsules|All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).
41335184|NCT01204307|DRUG|Docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
41335185|NCT01204307|DRUG|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
41335186|NCT06022146|DRUG|Rifampin and Isoniazid|3HR regimen of isoniazid and rifampicin once daily for three months
41484326|NCT04487743|DRUG|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
40817103|NCT05969756|DRUG|Conventional etch and rinse sealant|Thirty-eight permanent molars will receive conventional etch and rinse sealant
40817104|NCT05969756|DRUG|Self-etch sealant|Thirty-eight permanent molars will receive self-etch sealant
40817105|NCT04041466|DIAGNOSTIC_TEST|AF detection by ECG|Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
41014639|NCT03128879|DRUG|Ibrutinib|Given PO
41014640|NCT03128879|DRUG|Venetoclax|Given PO
41014641|NCT03128879|DRUG|Acalabrutinib|Given BID
41156211|NCT03122405|DEVICE|RAM sensors|Noninvasive acoustic monitoring device
41156212|NCT02103426|DRUG|ASP0113|intramuscular injection
41156213|NCT02103426|DRUG|Placebo|intramuscular injection
41156214|NCT03982082|PROCEDURE|Physical Therapy|Undergo physical therapy
41484327|NCT02043665|BIOLOGICAL|CVA21/pembrolizumab|
41484328|NCT04412265|OTHER|Relation between frailty and clinical outcomes in elderly patients with COVID-19.|"To evaluate whether a tool built to measure frailty in elderly patients hospitalized in COVID + hospital departments are more accurate in predicting clinical outcomes compared to a clinical evaluation based on age and comorbidity. If the assessment of fragility were actually more accurate, the tool developed could be implemented in hospitals to support the clinician 's choices regarding the roof of care and actions to be taken undertake to prevent deterioration."
41335187|NCT06022146|DRUG|isoniazid and rifapentine|12-dose ultra-short TPT 1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month
41335188|NCT03224104|DRUG|TG02|"The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated."
41484329|NCT04310956|DEVICE|Y-Knot all-suture anchor|Y-knot all-suture anchor will be implanted to participants
41484330|NCT04310956|DEVICE|Biocomposite suture anchor|Biocomposite suture anchor will be implanted to participants
41484331|NCT06428318|DIAGNOSTIC_TEST|Conventional Sputum culture|Sputum culture was done to patients and they received Antibiotics According to its results
41484332|NCT06428318|DIAGNOSTIC_TEST|BioFire Pneumonia Panel (BFPP)|BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results
41484333|NCT00468650|DRUG|sildenafil citrate|Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
41484334|NCT01467206|BEHAVIORAL|Long term follow up by a coordinating physiotherapist|Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
40817106|NCT00607269|BEHAVIORAL|Voucher-Based Reinforcement Therapy|"Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).~Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol \<0.05) urine sample."
40817107|NCT01323088|OTHER|Control|Standard care control (no exercise)
40817108|NCT01323088|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
40817109|NCT01323088|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
40817110|NCT03896724|BIOLOGICAL|R21 adjuvanted with 25mcg Matrix-M|Vaccine
40817111|NCT03896724|BIOLOGICAL|Rabies Vaccine|Vaccine
41156215|NCT03982082|OTHER|Questionnaire Administration|Ancillary studies
41156216|NCT03982082|PROCEDURE|Ultrasound|Undergo ultrasound via MuscleSound technology
41156217|NCT06647121|BEHAVIORAL|ACT Psychoeducational Workshop|The 1-hour ACT psychoeducational workshop will introduce participants to Acceptance and Commitment Therapy and include guided practice of the mindfulness exercise that they will be asked to practice for two weeks.
41484335|NCT01467206|BEHAVIORAL|Standard care|Standard care as it is given to all stoke patients after stroke
40817112|NCT03896724|BIOLOGICAL|R21 adjuvanted with 50mcg Matrix-M|vaccine
40817113|NCT06287515|DEVICE|Stereotactic Radiosurgery|Given by Radiation Therapy
40817114|NCT01675297|DRUG|Risedronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination once a week
40817115|NCT01675297|DRUG|Risedronate|Risedronate once a week
40817116|NCT04875377|DIETARY_SUPPLEMENT|Reformulated pizza|Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).
40817117|NCT04875377|DIETARY_SUPPLEMENT|Control pizza|Control (placebo) meal to consume thrice weekly (no iodine supplementation).
40817118|NCT04875377|DIETARY_SUPPLEMENT|Seaweed capsule|Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).
41156218|NCT06647121|BEHAVIORAL|ACTaide Mobile App|The ACTaide mobile app is a novel app that is designed to support home practice of exercises from ACT via annotated image sequences and reminder notifications. A prototype version that features the dropping anchor mindfulness exercise will be investigated in this study.
41335189|NCT03224104|RADIATION|Radiation Therapy|For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks
41335190|NCT03224104|DRUG|Temozolomide|For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
40817119|NCT04875377|DIETARY_SUPPLEMENT|Control capsule|Empty capsules (placebo)
41335191|NCT00882830|PROCEDURE|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
41335192|NCT03457636|DRUG|Doxycycline Anhydrous 40 MG|One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals
41335193|NCT03457636|DRUG|Adapalene/Benzoyl Peroxide Gel 0.3-2.5%|Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
41335194|NCT01257672|DRUG|Ondansetron|ondansetron syrup (0,15 mg/Kg of body weight)
41335195|NCT01257672|DRUG|Domperidone|domperidone syrup (0,5 mg/Kg of body weight)
41335196|NCT01257672|DRUG|placebo|placebo
41335197|NCT00841672|DRUG|Aliskiren/amlodipine 300/10 mg tablet|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
41156219|NCT06647121|BEHAVIORAL|Reminders-only mobile app|This app will include only reminder notifications to encourage home practice of the dropping anchor mindfulness exercise in the comparator condition. It will not include the annotated image sequence for the exercise (i.e., the primary feature of the ACTaide app to be investigated in the intervention condition).
40817120|NCT01413906|DRUG|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
40817121|NCT00436423|DRUG|gemcitabine, TS-1|
40817122|NCT05659407|DRUG|Belimumab in SLE patients / Rituximab in RA patients|Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.
40817123|NCT01814098|DRUG|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
41335198|NCT00841672|DRUG|Amlodipine 10 mg capsule|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
40817124|NCT05716100|DRUG|XEN1101|XEN1101 Capsules
41156220|NCT05965726|DRUG|Paxlovid 25 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 30 days
41156221|NCT05965726|DRUG|Paxlovid 15 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 15 days then ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 15 days
41156222|NCT05965726|DRUG|Control|ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 30 days
41156223|NCT06646991|DEVICE|Nasal canula - up to 6 liters per minute|"Oxygen will be administered via nasal cannula up to 6 liters per minute during this period.~Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the peripheral oxygen saturation (SpO2) target (92% for non chronic obstructive pulmonary disease (non COPD) patient and 90% for chronic obstructive pulmonary disease (COPD) patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
41156224|NCT06646991|DEVICE|Nasal canula - up to 15 liters per minute|"Oxygen will be administered via nasal cannula up to 15 liters per minute during this period.~Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
41156225|NCT06646991|DEVICE|Open oxygen mask|"Oxygen will be administered via an open during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
41335199|NCT05711693|DEVICE|Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)|Patients scheduled for thoracic aorta MRI will have LDV measurement of ccPWV. Both techniques will be compared
41335200|NCT05711693|PROCEDURE|Blood pressure and heart rate measurement|"To all patients:~- blood pressure and heart rate will be measured"
41335201|NCT05711693|DEVICE|carotid to femoral PWW measurement|"To all patients:~- carotid to femoral PWW will be measured by LDV and tonometry for comparison"
41335202|NCT05711693|PROCEDURE|Questionnaire completion|All patients will complete a questionnaire of acceptability
41335203|NCT01954810|BIOLOGICAL|Japanese encephalitis chimeric vaccine (JECV)|Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
41335204|NCT01821404|DRUG|Atorvastatin|Capsules including 80 mg of atorvastatin
41335205|NCT01821404|DRUG|Placebo|Similar capsules as in the atorvastatin arm, but without the active ingredient
41335206|NCT00228410|DRUG|Tigecycline|
41335207|NCT00228410|DRUG|vancomycin with aztreonam|
40817125|NCT05716100|DRUG|Placebo|Placebo Capsules
40817126|NCT05096234|DRUG|[ 18F]F-AraG PET|Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
41335208|NCT03954379|DRUG|Standard of Care (ACB, SA, peri-op pain management)|"INTERVENTION BEFORE SURGERY~Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~INTERVENTION DURING SURGERY~IV propofol for sedation~INTERVENTION AFTER SURGERY~Injection of salty water through the tube in the thigh x 2"
41335209|NCT03954379|DRUG|IPACK and multi-modal analgesic regimen|"INTERVENTION BEFORE SURGERY~1. Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~2. iPACK block ( infiltration between Popliteal Artery and posterior Capsule of the Knee) - injection of freezing medication in the back of the knee~INTERVENTION DURING SURGERY~1. IV dexmedetomidine~2. IV ketamine Both for sedation~INTERVENTION AFTER SURGERY~1. injection of freezing medication through the tube in the thigh x 2~2. IV dexamethasone 8 mg 1 day after surgery"
41335210|NCT03954379|PROCEDURE|Periarticular Local Anesthetic Infiltration|INTERVENTION DURING SURGERY
40817127|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
40817128|NCT00191724|DRUG|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
40817129|NCT00191724|DRUG|Placebo|intravenous (IV), one infusion, over 12 hours
40817130|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
40817131|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
40817132|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
41014644|NCT06311591|DEVICE|Jaspr App|Jaspr was designed to improve delivery of evidence-based, personalized suicide care in the ED. Jaspr (Dimeff, R44MH108222) is rooted in EBPs, including Collaborative Assessment and Management of Suicide (CAMS) and Dialectical Behavior Therapy (DBT). Briefly, Jaspr provides a patient interface, optimized for a tablet computer provided to the patient, which uses an avatar to administer: (1) the CAMS Suicide Status Form (SSF), an evidence-based suicide risk assessment; (2) crisis stabilization planning (CAMS' version of safety planning) or Stanley-Brown Safety Planning Intervention, depending on site choice; (3) lethal means safety counseling. Further, Jaspr teaches behavioral skills from DBT to manage imminent distress and has a library of over 40 racially and culturally diverse, inspirational videos of people with lived experience. Finally, Jaspr@home provides access to these resources after the visit during the high-risk transition to outpatient care.
41156226|NCT06646991|DEVICE|Simple oxygen face mask|"Oxygen will be administered via simple oxygen face mask during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
41484336|NCT03738852|DEVICE|Continuous Glucose Monitor (CGM)|Continuous Glucose Monitor (CGM)
41014653|NCT01717573|PROCEDURE|Deferred stenting|
41014654|NCT01717573|PROCEDURE|Conventional treatment|
41335211|NCT03954379|DRUG|IV Dexamethasone 8mg at the end of surgery as standard of care|INTERVENTION DURING SURGERY
40817133|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
41335212|NCT05189704|DRUG|NSAID|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
41335213|NCT05189704|DRUG|Opioid|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
41335214|NCT04580160|DEVICE|Duo Venous Stent System|Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.
41335215|NCT02178072|DRUG|5-Azacitadine|
41335216|NCT03348566|OTHER|fish|fish intkae
41335217|NCT00218361|DRUG|Hydromorphone|
41335218|NCT00553657|DRUG|DETROL LA (drug)|
41335219|NCT00045812|DRUG|SCH-58235|
41335220|NCT06430645|DRUG|Esketamine|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.3mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
41335221|NCT06430645|DRUG|Esketamine|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.6mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
41335222|NCT06430645|DRUG|Saline|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). The same volume of 0.9% saline instead of esketamine will be given to the control group after stable plasma concentration of propofol deep sedation.
41335223|NCT01804491|OTHER|Motion Analysis|3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
41335224|NCT01628042|DRUG|Vibegron 100 mg|Vibegron tablets, orally, on Day 1
41335225|NCT00000345|DRUG|Lofexidine|
41335226|NCT04816045|PROCEDURE|Electrochemotheraoy|Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin
41335227|NCT04816045|PROCEDURE|Electroporation with saline (placebo)|Electroporation in the control group is performed endoscopically with saline
41335228|NCT05687916|DRUG|TAK-861|TAK-861 tablets.
41335229|NCT05687916|DRUG|Placebo|TAK-861 placebo matching tablets.
40817134|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
40817135|NCT01502878|DIETARY_SUPPLEMENT|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
40817136|NCT04452435|DRUG|C21|C21
40817137|NCT04452435|DRUG|Placebo|Placebo
40817138|NCT06605170|OTHER|Questionnaire|Translate and culturally adapt the original English version of the traumatic injuries distress scale to Turkish
41335230|NCT03432767|DEVICE|Non-invasive hemoglobin monitor|
40817139|NCT06179134|BEHAVIORAL|Goal Management Training|"The main objective of GMT intervention are to train individuals to periodically STOP what they are doing, attend to task goals, evaluate their performance and monitor or check outcomes as they proceed (Levine \& Stamenova, 2017)."
40817140|NCT03215758|DRUG|QAW039|QAW039 once daily
40817141|NCT03215758|DRUG|Placebo|Placebo once daily
41335231|NCT00152945|DRUG|Intravenous Intralipid|intravenous infusion
41335232|NCT00152945|DRUG|Intravenous leucine, glycerol|intravenous infusion
41335233|NCT03345368|DEVICE|rTMS|Patients will be stimulated in the dorso lateral frontal cortex. First, the motor threshold will be determined for each patient. To induce currents to the left primary sensory-motor cortex hand area (M1/S1) the coil will be placed over the scalp oriented at 45 ° from the mid-sagittal plane while subjects will sit comfortably on a chair. The coil will be systematically moved in this area until a contraction of the abductor will be identified. Motor evoked potentials (MEPs). MEPs will be registered with surface electrodes on the left hand abductor pollicis muscle using the same Magstim equipment. Then the parameters will be adjusted for the stimulation as was described before.
41335234|NCT03345368|DEVICE|sham rTMS|As well as the rTMS group, the motor threshold of each patient will be determined. They will experience a similar rTMS session with the difference that they not will be stimulated.
41335235|NCT03345368|OTHER|Diet|This intervention will be applied to both groups, rTMS and sham group, as a combined therapy. The diet is low in carbohydrates, like sugary foods, pasta and bread. Instead, patients eat food with protein, natural fats and vegetables.
41335236|NCT00823160|PROCEDURE|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
41335237|NCT00823160|PROCEDURE|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
41335238|NCT05316818|DRUG|FOLFOXIRI Protocol|Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
41484337|NCT03738852|DRUG|Insulin|standard insulin regimen
41484338|NCT06531369|DRUG|Flumazenil Injection（F1 group）|Flumazenil Injection（F1 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
41335239|NCT06059092|BEHAVIORAL|Adapt Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to coping strategies, locus of control, coping metacognition, positive psychology strategies. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
41335240|NCT06059092|BEHAVIORAL|Engage Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to goal setting, planning, strengths identification, motivation; goal pursuit metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
41335241|NCT06059092|BEHAVIORAL|Interact Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to social cognition, assertive communication and conflict resolution, proactive prosocial behaviors, interactional metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
41335242|NCT06059092|BEHAVIORAL|Control Group|Sessions will be devoted to serious game training cognitive and executive functions through individual and group activities based on board games.
41335243|NCT03254940|BEHAVIORAL|Charge|Text messaging-based study to determine effect of different components on weight loss.
41335244|NCT03696446|BEHAVIORAL|Virtual Cardiac Rehabilitation Program|This group will receive their Rehab program primarily online through a secure web-based platform with a trained facilitator.
41335245|NCT03696446|BEHAVIORAL|Case Managed Home Program|This group will receive their Rehab program over the phone with a trained facilitator
40817142|NCT02095873|DIETARY_SUPPLEMENT|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
41335246|NCT01643304|BEHAVIORAL|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
41335247|NCT03326661|PROCEDURE|Aspiration|Needle aspiration of pus from the peritonsilar abscess
41335248|NCT03326661|PROCEDURE|Tonsillectomy a chaud|Removal of tonsil(s) due to peritonsillar abscess
41335249|NCT03326661|DRUG|Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)|patients treated with aspiration will receive antibiotic treatment
41484339|NCT06531369|DRUG|Flumazenil Injection（F2 group）|Flumazenil Injection（F2 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by 0.3 mg flumazenil 25 minutes later.
40817143|NCT02095873|DIETARY_SUPPLEMENT|Placebo|Mannitol, 108 mg
40817144|NCT04397159|BEHAVIORAL|Combination Exercise|Flywheel Resistance Plus Aerobic Exercise
40817145|NCT00713349|DRUG|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
41014662|NCT05736731|BIOLOGICAL|A2B530|Autologous logic-gated Tmod CAR T-cells
41014663|NCT05736731|DIAGNOSTIC_TEST|xT-Onco with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
41014664|NCT03249038|OTHER|Measurement of external blood loss|
41014665|NCT03249038|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|
41014667|NCT04141462|GENETIC|blood sample|blood test
41156227|NCT06339385|BEHAVIORAL|PADIS assessment|Hospital and nursing records from the 24 hours preceding enrollment were examined to document the assessment rate of pain, agitation-sedation, and delirium.
41014668|NCT06192745|BEHAVIORAL|no screen control with dim light and calming activities|Non-screen-based quiet activities for 1 hour before bed in room lighting 40-50 lux
41156228|NCT00705614|BIOLOGICAL|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
41335250|NCT05488418|OTHER|Clinical, cognitive and biological tests|"Evaluations at 1, 3, 6 and 12 months post-inclusion will be performed, during which the subject will complete various clinical and cognitive tests.~A blood sample will be collected at each visit to study biological processes including the regulation of genetic and epigenetic expression, in particular the expression of the GPR56 and ELK1 genes in the blood.~For eligible subjects a brain MRI will be proposed at the first visit."
41335251|NCT00544804|DRUG|lapatinib ditosylate|
41335252|NCT00544804|GENETIC|gene expression analysis|
41335253|NCT00544804|OTHER|diagnostic laboratory biomarker analysis|
41335254|NCT05110599|DRUG|Bryophyllum 50% chewable tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g
41335255|NCT05110599|OTHER|Placebo|Lactose with adaption in appearance and tast
41335256|NCT02835898|OTHER|Conventional periodontal treatment|Conventional routine periodontal treatment will be done for patients in test group
41484340|NCT06531369|DRUG|Saline（C group）|Flumazenil Injection（F2 group）: Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
41484341|NCT02932228|OTHER|ImPACT|"The ImPACT team offers the following services:~* An intensive intake process, including a home visit if deemed appropriate~* Frequent contact (in-person, telephone, or secure messaging) tailored to a patient's needs~* After-hours access to on-call team member in order to avoid unnecessary emergency care~* Optimization of chronic condition management using evidence-based protocols~* Navigation of transitions between hospital and home~* Coordination of specialty care, including contact with specialists when indicated~* Rapid response to signs of health status deterioration or other stressful events~* Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment"
41014669|NCT06192745|BEHAVIORAL|unfiltered Bright tablet screen|Bright light screen media exposure will be delivered on an iPad Pro provided by the research team which will be set to the brightest light intensity setting for 1 hour before bed in room lighting 40-50 lux
41014670|NCT06192745|BEHAVIORAL|Filtered dim tablet screen|Filtered dim light screen media exposure will be delivered for 1 hour before bed in room lighting 40-50 lux on an iPad Pro provided by the research team. A blue light filter will be used to alter the spectral distribution of the emitted light and the screen brightness will be dimmed to the lowest possible setting
41014671|NCT06192745|BEHAVIORAL|Exciting content|We will create a 1-hour recording of movie clips containing exciting content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
41156229|NCT03705988|DEVICE|Cranial Electrotherapy Stimulation(CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The current intensity could be adjusted continuously from 500 μA\~2mA.
41156230|NCT03705988|DEVICE|sham Cranial Electrotherapy Stimulation( sham CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The sham CES devices were identical to the active device, except the ear clip electrodes emit electricity intensity of lower than 100 μA.
41156231|NCT06321601|DRUG|Avacopan|Oral administration
41014672|NCT06192745|BEHAVIORAL|Calming Content|We will create a 1-hour recording of movie clips containing calming content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
41156232|NCT04769895|DRUG|MaaT013|MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota
41156233|NCT02809677|OTHER|Non-Interventional|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
41335257|NCT02280486|DRUG|Saxagliptin|5 mg/d
41335258|NCT02280486|DRUG|Glimepiride|1mg/d, up titrated 1mg if FPG \>6.1 mmol/L (110mg/dL) till 6 mg
41335259|NCT02334553|DRUG|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
41335260|NCT02334553|DRUG|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
41335261|NCT01505660|BEHAVIORAL|Care management|The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at \~9 and 12 months after enrollment.
41335262|NCT04010162|OTHER|Mesh debate awareness survey|"A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute"
41335263|NCT01918683|RADIATION|TACE transarterial chemoembolization|
41335264|NCT01918683|RADIATION|stereotatic body radiotherapy (SBRT)|
41335265|NCT01936272|DEVICE|Chhabra Shunt Placement|
41335266|NCT01936272|PROCEDURE|ETV/CPC|
41484342|NCT03801395|OTHER|There is no intervention|No intervention
41484343|NCT02681146|OTHER|Multimodal intervention|Educational advice + physiotherapist treatment
41335267|NCT05094804|DRUG|OR2805|IgG1 monoclonal antibody that binds specifically to the CD163 protein.
41335268|NCT05094804|DRUG|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
41335269|NCT05094804|DRUG|Docetaxel|An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
41335270|NCT02336048|DRUG|Chlorambucil|Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
41335271|NCT02336048|DRUG|Obinutuzumab|Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
41335272|NCT02336048|DRUG|Placebo|Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
41335273|NCT02336048|OTHER|Standard Premedication|Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
41335274|NCT02336048|DRUG|Tocilizumab|Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
41335275|NCT00084604|DRUG|irinotecan hydrochloride|Given IV
41335276|NCT00084604|BIOLOGICAL|bevacizumab|Given IV
41335277|NCT00084604|DRUG|cisplatin|Given IV
41335278|NCT00084604|PROCEDURE|computed tomography|Correlative studies
41335279|NCT00084604|OTHER|laboratory biomarker analysis|Correlative studies
41335280|NCT01645865|BEHAVIORAL|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
41335281|NCT01645865|BEHAVIORAL|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
41014674|NCT04328493|DRUG|Chloroquine phosphate|"Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days"
41156234|NCT06645860|PROCEDURE|SDF+KI+LED Light 20s|After the silver diamine fluoride (SDF) and potassiım iodide (KI) application, 20-second LED light will be applied to the cavity.
41156235|NCT06645860|PROCEDURE|SDF+KI|Silver diamine fluoride (SDF) and potassium iodide(KI) will be applied.
41156236|NCT02134249|DRUG|Diosmin|2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
41335282|NCT02297646|BEHAVIORAL|Endurance Training|
41335283|NCT00800930|BIOLOGICAL|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
41335284|NCT00800930|BIOLOGICAL|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
41014678|NCT05802797|OTHER|Algae Oil Fortified Soymilk|Flavored soymilk beverage fortified with 0.4% algae oil with both EPA and DHA
41014679|NCT05802797|DIETARY_SUPPLEMENT|Algae Oil Capsule|Algae oil capsules with EPA and DHA
41014680|NCT05167344|BEHAVIORAL|Healthy Relationships Program-Enhanced|The Healthy Relationships Program-Enhanced (HRP-E) is a small group mental health promotion and healthy relationship program designed for vulnerable, at-risk youth. It is a trauma-informed, 16-session manualized program.
41156237|NCT02134249|DRUG|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
41156238|NCT00131690|DRUG|Nescafé Gold Blend (exposed)|
41156239|NCT00131690|DRUG|Nescafé Decaffeinated (controls)|
41156240|NCT05453396|BIOLOGICAL|Loncastuximab Tesirine|Given IV
41335285|NCT05603494|DEVICE|NuvoAir|Use of NuvoAir in pulmonary function monitoring during asthma attack
41335286|NCT01807091|DRUG|Chemotherapy|Receive outpatient induction chemotherapy
41156241|NCT03596099|DIETARY_SUPPLEMENT|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
40817146|NCT00713349|OTHER|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
40817147|NCT01477710|PROCEDURE|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
40817148|NCT01477710|PROCEDURE|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
40817149|NCT01477710|PROCEDURE|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
40817150|NCT02269553|DEVICE|TMJ(TM) NextGeneration|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
40817151|NCT02269553|DEVICE|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
40817152|NCT00926419|BIOLOGICAL|Varicella Vaccine|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
40817153|NCT00926419|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A virus vaccine, inactivated, Single dose
40817154|NCT05350228|DIAGNOSTIC_TEST|CNN based model|It is an automatic detector model based on convolution neural network created by computer science expert
41335287|NCT01529619|DRUG|Rivastigmine transdermal patch|
40817155|NCT05958394|BEHAVIORAL|SkillFlix for Parents|A Microskills video training library on communication skills for talking to youth about relationships and sexual health topics.
41335288|NCT00224003|DRUG|Sodium Ferric Gluconate Complex in Sucrose.|
41335289|NCT04630210|DRUG|Letrozole|Letrozole 2.5 mg/day oral until surgery
41335290|NCT04630210|DRUG|Atezolizumab|Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
41335291|NCT00114218|DRUG|Gemcitabine Hydrochloride|Given IV
41335292|NCT00114218|DRUG|Docetaxel|Given IV
41335293|NCT04745312|DEVICE|Visible light|Ambient room lighting will be supplemented with additional light from a task lamp.
41335294|NCT04836923|BEHAVIORAL|"LIver FrailTy intervention (LIFT)"|Novel physical therapy intervention to decrease frailty in pre-transplant patients
41335295|NCT04836923|BEHAVIORAL|"Realistic Effort Action Planning intervention (REAP)"|This intervention is an interactive behavioral interviewing process to engage patients in their care
41335296|NCT05246488|DIAGNOSTIC_TEST|American Orthopedic Foot and Ankle Association Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analog Scale (VAS)|All participants will receive two assessments, 7 days apart. After the demographic data of the patients are recorded with the form prepared by us, they will be evaluated with the AOFAS Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analogue Scale (VAS).
41335297|NCT06512831|DRUG|Isoniazid|Those with risk factors were recommended a 6-month prophylaxis regimen, consisting of INH (300 mg/d) and pyridoxine (10 mg/d to prevent INH-related neurotoxicity).
41335298|NCT01105936|DRUG|Paracetamol|665 mg sustained release paracetamol caplets
40817156|NCT06174454|OTHER|Respiratory Pediatric Physiotherapy|Prolonged slow expiration Tracheal pumping Controlled expiratory flow exercises Forced expiration technique
40817157|NCT06174454|OTHER|Control Group|Will be subject to muscle compressions of the upper limbs. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
40817158|NCT06605690|DRUG|Dalpiciclib and Letrozole Combined With Anlotinib|Dalpiciclib: 150mg orally, once daily, d1-d21, every 28 days as a cycle (3 weeks / 1 week off) Letrozole: 2.5mg orally once daily (continuous) Anlotinib: 12mg orally, once daily, d1-d14, every 21 days as a cycle (use 2 weeks/stop 1 week). One of the last cycles of the new auxiliary The combination of anlotinib is not included in the treatment regimen to ensure that the time interval between anlotinib withdrawal and surgery is more than 2-3 weeks.
40817159|NCT04754412|OTHER|Behavioral, Psychological or Informational Intervention|Write about stress and coping, emotional disclosure, and benefit finding
40817160|NCT04754412|OTHER|Behavioral, Psychological or Informational Intervention|Write about positive thoughts and feelings regarding their breast cancer experience
40817161|NCT04754412|OTHER|Best Practice|Write about facts regarding their cancer diagnosis and treatment
40817162|NCT04754412|OTHER|Quality-of-Life Assessment|Ancillary studies
40817163|NCT04754412|OTHER|Questionnaire Administration|Ancillary studies
40817164|NCT01643252|DRUG|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
40817165|NCT01643252|DRUG|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
41156242|NCT03596099|DIETARY_SUPPLEMENT|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
41014681|NCT03515148|PROCEDURE|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
41014682|NCT03515148|PROCEDURE|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
41335299|NCT01105936|DRUG|Placebo|Placebo caplets
41484344|NCT04838236|OTHER|MASP app + NRT|MASP is a mobile intervention that targets anxiety sensitivity among African American smokers (Mobile Anxiety Sensitivity Program for Smoking: MASP). Our intervention is framed within the cultural context of interoceptive stress among African American smokers, which is supported by theory, empirical evidence, and characteristics of this group. The MASP app employs a variety of features to educate its users on how to deal with stress, anxiety, and nicotine withdrawal symptoms. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos. MASP also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time.
41484345|NCT04838236|OTHER|QuitGuide app + NRT|Quitguide is a smartphone-based National Cancer Institute (NCI) app for standard mobile smoking cessation treatment. The app contains features that allows its' users to better understand their smoking patters, and build skills needed to becomes and stay smoke free. The app allows users to track their cravings, and delivers motivational messages to users for each craving they track.
40817166|NCT02446249|BIOLOGICAL|AAV2hAQP1|Infusion of gene therapy
40817167|NCT02872896|PROCEDURE|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
40817168|NCT04700345|DEVICE|Onyx|Embolization of the Middle Meningeal Artery using the liquid embolic material
40817169|NCT04700345|PROCEDURE|Burr-hole|Burr-hole drainage of subdural hematoma
40817170|NCT04700345|OTHER|Medical Management|best medical management
41014683|NCT05145920|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 5 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
41014684|NCT04726410|BIOLOGICAL|Cold Stored Platelets|early infusion of urgent release CSP
41484346|NCT05434858|OTHER|Dual-energy CT (DECT) and ultrasound|DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.
41484347|NCT06362382|BEHAVIORAL|tele-rehabilitation training|"During their stay in the hospital, the patients were accompanied by a rehabilitation trainer and a psychotherapist for a complete cycle of (7 days ± 3 days 1 week/times) standardized training.~After discharge from the hospital, patients in the rehabilitation group underwent 3-5 weekly daily （a total of 3 months）training sessions and intensive supervision and management by the online community at least once a week. All patients' routines were monitored by telemetry and data, photographs and video recordings were collected by a specialized agency.~The scheme of rehabilitation is impedance training. A specialized professional team including cardiologists, rehabilitation trainers, psychotherapists and radiologists were involved."
40817171|NCT05115474|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Participants will undergo MRI imaging with and without contrast.
40817172|NCT05978388|DIAGNOSTIC_TEST|Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation|Analysis of coronary CT angiography and CAC scoring and initiation of relevant derived treatment at the time of catheter ablation.
40817173|NCT00724854|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
41014685|NCT04726410|BIOLOGICAL|Standard Care|standard care including room temperature platelets
41156243|NCT04636879|OTHER|Positive expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding message.
41156244|NCT04636879|OTHER|Neutral expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
41156245|NCT04636879|OTHER|Negative expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
41156246|NCT05430074|DEVICE|HM Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of HM casts.
41156247|NCT05430074|DEVICE|Fibreglass Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of Fibreglass casts.
41156248|NCT04410003|BIOLOGICAL|Fecal microbial transplant|Fecal microbial transplant
41335300|NCT04963881|DIAGNOSTIC_TEST|Antibody testing|Blood samples were taken and analyzed for APS antibodies
41335301|NCT03253133|DRUG|Oxaliplatin|"Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 \* 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~\* Start level"
41335302|NCT03253133|DRUG|LV5FU or Folfiri|Association of chemotherapy by LV5FU or Folfiri according pratician choice
40817174|NCT00724854|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
41335303|NCT03253133|DRUG|Oxycodone|Oxycodone
41335304|NCT04989881|DEVICE|da Vinci Simulator|Single training session
41335305|NCT04989881|DEVICE|Laparascopic training box|Single training session
41484348|NCT06362382|BEHAVIORAL|health propaganda and education|"During their stay in the hospital, participants of the control group received health propaganda and education (7 days ± 3 days 1 week/times).~After discharge from the hospital, the control group followed their daily routine."
40817175|NCT04972682|PROCEDURE|Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy|Laparoscopic total hysterectomy, bilateral salpingo-oophorectomy (BSO), and sentinel lymph node (SLN) biopsy are executed by 1 of 5 experienced gynecologic oncologists. SLN mapping utilizes indocyanine green (ICG) at a standard concentration of 2.5 mg/mL - 1 mL is injected into the cervix at the 3 and 9 o'clock positions (total dose - 5 mg) to a depth of 5-10 mm, initiated right after general anesthesia induction. Diagnostic laparoscopy employs the Image 1S equipment (KARL STORZ©, Tuttlingen, Germany). Upon examination, fluorescence in the near-infrared spectrum is observed. Successful mapping is indicated by identifying a lymphatic vessel with at least one LN. Detected SLNs are then extracted, and the total hysterectomy with BSO is completed. SLN frozen section remains at the surgeon's discretion. If metastasis surfaces in the SLN either during the frozen section or routine assessment, the option for systematic LN dissection in a subsequent procedure exists although not mandatory.
41014686|NCT01812694|BEHAVIORAL|Enhanced standard care|Standard prenatal care plus education
41156249|NCT05372913|DEVICE|Woebot for Adolescents (W-GenZD) Mobile Application|"Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
41484349|NCT00757757|DRUG|MCS110|Anti-M-CSF antibody
41484350|NCT00281606|DRUG|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
41484351|NCT05046665|DRUG|89Zr-Girentuximab|Administration of 89Zr-girentuximab as per protocol.
41484352|NCT02240342|DRUG|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
41484353|NCT01168765|BEHAVIORAL|Tu Salud Si Cuenta Behavioral Intervention|A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
41335306|NCT01176188|OTHER|Comfort Care|The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.
41484354|NCT00061243|BIOLOGICAL|HIV-1 DNA vaccine with protein vaccine boost|Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
41484355|NCT00851643|BIOLOGICAL|Octavalent HPV with 15 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
41484356|NCT00851643|BIOLOGICAL|Octavalent HPV with 30 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
41484357|NCT00851643|BIOLOGICAL|Octavalent HPV with 60 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
41484358|NCT00851643|BIOLOGICAL|Octavalent HPV with 120 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
40817176|NCT02255448|DEVICE|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
41335307|NCT01176188|OTHER|Usual care|Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
41335308|NCT03186872|BEHAVIORAL|Digital behavioral program app|mobile app utilizing cognitive behavioral techniques to help alleviate anxiety
41335309|NCT04537754|DEVICE|bleaching device|activated bleaching
41014687|NCT01812694|BEHAVIORAL|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
41335310|NCT04814407|DIAGNOSTIC_TEST|Blood-derived DNA methylation detection|Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.
41484359|NCT00851643|BIOLOGICAL|Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
41484360|NCT01703936|OTHER|Agricultural and life skills training program|
41484361|NCT02593448|PROCEDURE|NIRS during VOT|"Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~1. 30 minutes after anaesthesia induction,~2. directly after the sternotomy,~3. during CPB - 20 minutes after aortic cross-clamping ,~4. 40 minutes after aortic cross-clamping,~5. 20 minutes after the release of the aortic cross-clamp,~6. 45 minutes after weaning of CPB."
41014688|NCT05562947|DEVICE|PDS with ranibizumab (100 mg/mL)|Patients randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 uL of the 100-mg/mL formulation of ranibizumab \[approximately 2 mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for patients randomized to the intravitreal arm. After the initial fill of the implant with ranibizumab, patients will receive implant refill-exchanges at fixed 24-week intervals.
41484362|NCT02593448|PROCEDURE|General anaesthesia with propofol use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60."
41335311|NCT03684941|DEVICE|Treatment Period One|LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
41335312|NCT03684941|DEVICE|Treatment Period Two|CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
41484363|NCT02593448|PROCEDURE|General anaesthesia with sevoflurane use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60."
41484364|NCT02804230|DEVICE|Neuro Ablation - Functional|MR-Guided Focused Ultrasound
40817177|NCT05757154|OTHER|Diet|All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
40817178|NCT04816136|OTHER|Sleep recording (already done)|Sleep recording (already done)
40817179|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
40817180|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
40817181|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
40817182|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
40817183|NCT01741025|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
40817184|NCT01741025|OTHER|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
40817185|NCT05666999|DEVICE|FibDex®|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
40817186|NCT05666999|DEVICE|Suprathel|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
40817187|NCT05666999|DEVICE|Aquacel Foam|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
41335313|NCT01901978|BEHAVIORAL|Caloric restrictive diet|Patients will meet weekly with a registered dietician.
41014689|NCT05562947|DRUG|Ranibizumab (10 mg/mL)|Patients in the intravitreal arm will receive their first intravitreal injection of 50 uL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, patients will receive intravitreal ranibizumab injections of 50 uL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44
41335314|NCT03610906|PROCEDURE|Tumor and Blood Specimens|If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
40817188|NCT05559840|DEVICE|S-Condom Uterine Tamponade|The condom catheter will be inflated with air
40817189|NCT05559840|DEVICE|Traditional condom catheter|The condom catheter will be inflated with saline following national protocol
41335315|NCT01832857|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
40817190|NCT03398642|BEHAVIORAL|French Lifestyle Redesign|Lifestyle Redesign® is a preventive occupational therapy intervention designed to promote meaningful and healthy activities. The French-Canadian Lifestyle Redesign® intervention was led by an occupational therapist (OT) who took the University of Southern California 6-hour online introductory training course and was supervised on a weekly basis. Weekly 2-hour group sessions were held over a six-month period.These sessions were based on 12 modules (e.g. occupation, health and aging; transportation and occupation) from the 2nd edition of the Lifestyle Redesign® Manual and involved didactic presentations, peer exchanges, reflective exercises, direct experience and personal exploration. Every month, one group outing was targeted and individual meetings with the OT were planned.
40817191|NCT06364813|OTHER|COMPANION eHealth Program|COMPANION consists of online, self-paced educational modules with information on a range of topics such as providing medical care, applying for financial aid and home aid, working on the relationship with the care recipient, dealing with mental health issues, and learning life skills.
40817192|NCT00434603|BEHAVIORAL|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
40817193|NCT04489147|DRUG|Metformin|metformin 850 mg orally twice daily along the cycle of ICSI
41014692|NCT05756647|DEVICE|Interventional Arm|The MAD arm will consist of participants given a fitted mandibular advancement device that they will wear for the length of the study.
41014693|NCT05756647|COMBINATION_PRODUCT|Conservative treatment Arm|Participant will undergo a nightly medicated nasal rinse that will occur for a 4 week period, prior to beginning of the other three conservative therapy interventions. The 4-part combination therapy will take place for 4 weeks total.
41335316|NCT05054231|OTHER|Blood sample collection|Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.
41335317|NCT01855425|RADIATION|Radiation|Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
41335318|NCT03919006|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
41335319|NCT03919006|OTHER|Gingival crevicular fluid, saliva and serum collection|GCF with filter paper using the intracrevicular method, saliva and serum collection
41484365|NCT03916523|PROCEDURE|Sustained lung inflation|"Preterm infants will receive a total of 15 sustained lung inflations during the first 4 days of life as follows:~1. On day 1 of life (a total of 6 sustained lung inflations, 20 cmH2O for 21 seconds each) once at enrollment and then once every 4 hours~2. On day 2 of life (a total of 3 sustained lung inflations, 15 cmH2O for 21 seconds each) once every 8 hours.~3. On day 3 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours.~4. On day 4 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours."
41484366|NCT03916523|PROCEDURE|Continuous positive airway pressure (CPAP)|Preterm infants will receive CPAP for respiratory support.
41014699|NCT06335771|OTHER|Dietary consultation weight loss intervention|Participants will meet with a member of the study team biweekly for about 6 months.
41014700|NCT06144502|BEHAVIORAL|5Ways@School|"The 5Ways@School intervention is a teaching material consisting of five elements; Take notice, Be active, Keep Learning, Connect, and Give. The intervention will be given in an ordinary classroom setting by the class' main teacher in two school hours of 45 minutes each week for six consecutive weeks, i.e., a total of 12 school hours. The teaching sessions will consist of presentations of the five elements, videos, reflection exercises, focused group discussions, creative group work, and giving the pupils small challenges to practice what they have learned between the weekly sessions."
41335320|NCT00845845|DRUG|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
41335321|NCT00845845|DRUG|Placebo|Daily placebo with dietary counseling for 24 weeks.
41335322|NCT00439504|DRUG|Lobeline|
41335323|NCT00655811|DRUG|Capsaicin|Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
41335324|NCT00655811|DRUG|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.)
41335325|NCT05099536|DRUG|3D011-08|participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).
41484367|NCT03916523|PROCEDURE|Mechanical ventilation|Preterm infants in this group will receive mechanical ventilation for respiratory support
41484368|NCT05770505|BEHAVIORAL|Exercise training using an e-health tool|Experimental: Exercise training will be guided by using the e-health tool MIA Health, with the possibility for digital communication between the participants and study personnel The participants will receive wearables that record heart rate. Participants will be encouraged to achieve 100 Personal Activity Intelligence (PAI) equivalents per week Control: No follow-up
41484369|NCT02156141|OTHER|Supervised high intensity training|8 weeks of supervised training
41156250|NCT05372913|BEHAVIORAL|CBT-Lite Teletherapy Group|The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
41484370|NCT02156141|OTHER|Optional training|8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.
41156251|NCT05306418|DRUG|Mim8|"For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin"
41484371|NCT02156141|OTHER|Control period|8 weeks with no training.
41484372|NCT02156141|OTHER|Unsupervised High intensity training|8 weeks of unsupervised high intensity training.
41484373|NCT01661179|DRUG|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
41484374|NCT02619877|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
41484375|NCT02619877|OTHER|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
41484376|NCT04158349|DRUG|Oxaliplatin|Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.
41484377|NCT04158349|DRUG|mFOLFIRI|mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
41484378|NCT03370731|PROCEDURE|adenotonsillectomy|Resection of adenoidal tissue or hypertrophy tonsils by radiofrequency ablation or other methods.
41484379|NCT03370731|OTHER|Nonsurgical management|Nasal Irrigation or inhaled corticosteroids, etc.
40817194|NCT03053986|DIETARY_SUPPLEMENT|Apple polyphenols|1 tablet per day at evening before sleeping
40817195|NCT03053986|OTHER|Placebo|1 tablet per day at evening before sleeping
41156252|NCT02375243|DRUG|dexmedetomidine|dexmedetomidine continous infusion 0.5 mcg/kg/h
41156253|NCT03877952|DRUG|14C-CORT125281|14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C
41484380|NCT04625595|DRUG|350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
41484381|NCT04625595|DRUG|700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
41484382|NCT04625595|DRUG|1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
41484383|NCT04625595|DRUG|1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
41484384|NCT06127914|BEHAVIORAL|Learning Early Infant Feeding Cues|"The LEIFc intervention includes individualized responsive feeding education and promotion using the SS-OO-PP-RR (or super, Setting the Stage, Observation and Opportunities to Embed, Problem Solving and Planning, Reflection and Review coaching approach as a guide. An interventionists interacts with mother-infant dyads during a feeding session at infant ages of 1, 2, 3, 4, and 5 months and coaches the mother on responsive feeding. In particular infant cues of hunger and fullness and tips to assist the mother in making decisions regarding feeding her infant. This will begin with milk based feedings (either breastmilk from breast or bottle, or formula from a bottle), and continue through the transition to solid (complementary) foods."
41484385|NCT03866915|DIAGNOSTIC_TEST|Aortic pulse wave velocity measurement|Aortic pulse pulse wave velocity (AoPWV) measured by photoplethysmography
41484386|NCT03866915|DIAGNOSTIC_TEST|6 minutes walking test|This test is performed routinely in the pre-rehabilitation units or in external anesthesiology consultations during the preoperative visit. In essence, it consists in measuring the maximum distance the patient is able to walk in 6 minutes, in a short walk in a corridor, simultaneously assessing the heart rate, oxygen saturation and the degree of dyspnea. In general, healthy people can walk between 400 and 700 meters in 6 minutes, depending on age, height and sex.
41484387|NCT03263039|DRUG|Pembrolizumab|Pembrolizumab 200 mg Q3W
41335326|NCT05355181|OTHER|Scar mobilization techniques|"Scar mobilization techniques include the gentle stroking and lifting of the scar as well as moving the scar tissue in different directions. It also includes rolling, C- grip, S-grip, and ram horn mobilization of the scar tissue.~Core stabilization exercises administered after cesarean section include the posture corrective exercises, abdominal draw-in, squatting, pelvis tilting, knee to chest, flexibility and stretching exercises, and bridges."
40817196|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 6 months in addition to standard of care
40817197|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 3 months in addition to standard of care
40817198|NCT04778163|BEHAVIORAL|Clinical use of humor|"Clinical study in psychiatry in young adult patients between 18 and 25 years old. The aim of the study is to evaluate the therapeutic impact of the clinical use of humor through 6 group sessions (group of 5 to 10 patients), at the rate of one hour session per week for 6 weeks.~The investigators will form 2 groups of 5 to 10 patients matched in terms of gender, education level and score on a scale measuring their sense of humor. The participants will be asked to complete a series of tests measuring their ability to use humor, psychiatric symptoms and well-being."
40817199|NCT05959538|BEHAVIORAL|Building Regulation in Dual Generations (BRIDGE)|The BRIDGE intervention includes 16 weeks of 20-30 minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use). The clinical team will consist of two Master's or PhD level clinical psychology trainees and a parent peer coach. Mood tracking will be completed using a brief weekly survey, including questions on depression, parenting stress, positive mood, and recent stressful experiences.
41156254|NCT06645496|OTHER|Evaluation of ehealth literacy|All patients undergoing radiotherapy at the Clinic for Radiotherapy (Campus Virchow Klinikum, Campus Benjamin Franklin) will be informed about the possibility of participating in the study (RO_eHEALTH I). If written consent is given, patients will be asked to complete the established questionnaires (EORTC QLQ-C30 and eHEALS) and a questionnaire to collect epidemiological data at their next visit to the respective clinics.
41335327|NCT05355181|OTHER|Core stabilization exercises|Core stabilization exercises
41335328|NCT03235726|DRUG|CCI15106|One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
41335329|NCT03235726|DRUG|Placebo|One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
41335330|NCT02585076|OTHER|Standard of care|As prescribed by treated physician
41335331|NCT05483660|OTHER|Lactobacillus plantarum|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
41335332|NCT05483660|OTHER|Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
41484388|NCT06339320|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG)|The ESG procedure uses the Apollo OverStitch endoscopic suturing device, which has received FDA authorization as a minimally invasive procedure to facilitate weight loss for adults with who have been unable to lose weight or maintain weight loss through more conservative measures such as diet and exercise. This procedure involves endoscopic suturing to reduce the volume of the stomach endoscopically by approximately 70% to 80% its original size. Using the Apollo OverStitch or APOLLO ESG and ESG SX Systems, the ESG procedure is performed be folding the stomach in on itself (endoscopically) and placing full-thickness sutures through the wall of the stomach to maintain this narrow, smaller size. Following the procedure, the new stomach appears similar to the surgical sleeve stomach, although the procedure is considered less invasive with fewer complications compared to a surgical sleeve gastrectomy.
41335333|NCT05483660|OTHER|Lactobacillus plantarum + Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
41335334|NCT05483660|OTHER|Placebo|Adult milk powder 15 g pertime, three times daily and half an hour before meal.
41014702|NCT05180474|BIOLOGICAL|GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.|GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
41014703|NCT06628609|OTHER|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
41014704|NCT06628609|DEVICE|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
41335335|NCT02204410|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|
41335336|NCT02204410|DRUG|ADHD Medication|
41484389|NCT06339320|DEVICE|Apollo OverStitch endoscopic suturing device|Apollo ESG is the first and only device to be authorized by the FDA to perform the ESG procedure to facilitate weight loss in patients with obesity (BMI 30 to 50 kg/m2). The FDA identifies this generic type of device as an Endoscopic suturing device for altering gastric anatomy for weight loss.
41335337|NCT03182621|BEHAVIORAL|THINK|The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
41335338|NCT03182621|BEHAVIORAL|SPARK|traditional YMCA program
41335339|NCT01402388|BEHAVIORAL|Group lifestyle programme|
41335340|NCT04797312|DRUG|Opioid Free Anaesthesia protocol|"The OFA protocol begins with a systematic preoperative premedication with clonidine, continues with an adapted intraoperative management without opioid administration, but associating several molecules (clonidine, magnesium, lidocaine, ketamine) and ends with a continued administration of xylocaine up to 1 hour postoperatively in PACU. The use of an opioid in preoperative or intraoperative phases is considered as a deviation from the protocol.~To these different molecules, the use of hypnotic molecules left to the choice of the practitioner and a curare will be systematically associated."
41335341|NCT04797312|DRUG|standard practice protocol based on the use of opioids (sufentanil or remifentanil)|Standard anesthetic practices can be summed up as the combination of a hypnotic, a morphinic (sufentanil or remifentanil) and a curare. The use of ketamine is allowed.
41335342|NCT02951455|BEHAVIORAL|Critical Dialogue|Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
41335343|NCT02951455|BEHAVIORAL|Capacity Building Project|Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
41335344|NCT02951455|BEHAVIORAL|Quality of Life Wheel|Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
41335345|NCT02951455|BEHAVIORAL|PF|Whether the intervention is delivered by a peer facilitator.
41335346|NCT02951455|BEHAVIORAL|LC|Whether the intervention is delivered by a licensed clinician.
41335347|NCT01009736|DIETARY_SUPPLEMENT|tomato-soy juice|
41335348|NCT01009736|OTHER|laboratory biomarker analysis|
41335349|NCT01009736|OTHER|pharmacological study|
41484390|NCT00278187|BIOLOGICAL|volociximab|
41484391|NCT00278187|DRUG|erlotinib hydrochloride|
41484392|NCT06420791|OTHER||
41484393|NCT04906317|DRUG|midazolam and dezocine|Midazolam (0.05 mg/kg) and dezocine(5mg) sedation during colonoscopy, targeted to a painless level
41014705|NCT06628609|DEVICE|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
41014706|NCT06628609|DEVICE|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
41335350|NCT01009736|PROCEDURE|therapeutic conventional surgery|
41335351|NCT03835013|DRUG|Saline 0.9%|Intravenous infusion of 0.9% saline
41335352|NCT03835013|DRUG|Glucagon (25ng/kg/min)|Intravenous infusion of glucagon 25ng/kg/min
41484394|NCT04906317|DRUG|Propofol|standard propofol (1.5mg/kg) induction during colonoscopy, targeted to a moderate sedation level
41484395|NCT05568693|BIOLOGICAL|0.3ml of mRNA vaccine|Subjects received 0.3ml of mRNA vaccine intramuscularly
41484396|NCT01918631|DRUG|tenofovir disoproxil fumarate|
41484397|NCT01918631|DRUG|Entecavir|
41484398|NCT01955213|DRUG|methylnaltrexone|Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
41014707|NCT06442527|DEVICE|Virtual Reality|Virtual reality gear and content will be used prior to TMS session as part of the provocation items
41014708|NCT06548451|DEVICE|Augmented reality guided localization|In this study, AR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
41156255|NCT00411463|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (IPSRT-BPII)|"IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.~Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms."
41335353|NCT03835013|DRUG|Glucagon (50ng/kg/min)|Intravenous infusion of glucagon 50ng/kg/min
41335354|NCT03835013|DRUG|Exenatide|Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes
41335355|NCT03010267|DRUG|DP-R213|Investigational product is prescribed to all of randomized subjects
41335356|NCT03010267|DRUG|Raloxifene|Investigational product is prescribed to all of randomized subjects
41335357|NCT03010267|DRUG|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
41335358|NCT06277492|DRUG|Single ascending doses SUL-238|PART 1: SUL-238 single ascending doses
41335359|NCT06277492|DRUG|Single dose Placebo|PART 1: Placebo single dose
41335360|NCT06277492|DRUG|Single dose SUL-238|PART 2: SUL-238 single dose for pharmacokinetics
41335361|NCT06277492|DRUG|Multiple ascending doses SUL-238|PART 3: SUL-238 multiple ascending doses
41484399|NCT02933970|OTHER|Telemedicine|Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
41484400|NCT06467773|RADIATION|Radiation: PET-MRI with [18F]-DPA-714|Radiation: PET-MRI with \[18F\]-DPA-714
41484401|NCT01805830|DRUG|MP513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
41484402|NCT01805830|DRUG|Placebo|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
41484403|NCT06240715|PROCEDURE|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
41335362|NCT06277492|DRUG|Multiple doses Placebo|PART 3: Placebo multiple doses
41335363|NCT00647257|DRUG|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
41335364|NCT00647257|DRUG|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
41335365|NCT04323423|BEHAVIORAL|interrupting sedentary behaviour with light physical activity|replacing sitting with light walking bouts at different frequencies/durations
41335366|NCT02685124|DIETARY_SUPPLEMENT|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
41335367|NCT05837650|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
41335368|NCT01503892|DIETARY_SUPPLEMENT|Metanx|Metanx- one tablet twice daily for twelve months
41335369|NCT01503892|DRUG|Placebo|Placebo- one tablet twice daily for twelve months.
40817200|NCT05959538|BEHAVIORAL|Dialectical Behavioural Therapy Skill Training|Participants in the DBT arm will participate in 16 weeks of DBT skills training only led by two Master's or PhD level clinical psychology trainees. Participants in the DBT Skills condition will participate in a skills group which follows the DBT Skills Training Manual 2nd Edition (Linehan, 2015) through weekly, synchronous 1.5-hour virtual group therapy sessions. Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness skill domains will be covered. Participants will be asked to complete worksheets between sessions to practice using skills, and will be asked to complete a Diary Card to track DBT skills use each week (Linehan, 2015). Mood tracking will be completed using a brief weekly survey including questions on depression, parenting stress, positive mood, and recent stressful experiences.
40817201|NCT01560637|DRUG|UT-15C (treprostinil diolamine)|UT-15C extended release oral tablet three times daily
40817202|NCT02174367|DEVICE|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
40817203|NCT00946764|DRUG|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
41014710|NCT02498600|BIOLOGICAL|Ipilimumab|Given IV
41014711|NCT02498600|BIOLOGICAL|Nivolumab|Given IV
40817204|NCT00946764|DRUG|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
40817205|NCT06608719|BIOLOGICAL|The study drug is SHED-CM manufactured by U-Factor|Patients diagnosed with ALS were administered SHED-CM
41335370|NCT03599544|BEHAVIORAL|Robot-Assisted Therapy (RT)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).
41484404|NCT02996760|DRUG|Growth Factor, Platelet-Derived|0,5 mL, vaginal use , 3 dose number
41484405|NCT05301530|DRUG|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
41484406|NCT05301530|DRUG|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
40817206|NCT00560534|PROCEDURE|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
40817207|NCT05525091|OTHER|Feeding Evaluation|Feeding Evaluation with Device
41335371|NCT03599544|BEHAVIORAL|Robot + Active Learning Program(RT-ALPS)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
41335372|NCT04483297|DRUG|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation. Ascending Dose.
40817208|NCT06439433|DRUG|Aminolaevulinic acid (500-mg bottle)|once a week for 6 weeks
40817209|NCT06439433|DRUG|Aminolaevulinic acid (750-mg bottle)|once a week for 6 weeks
41335373|NCT04483297|OTHER|Control|Local Autologous Bone + Posterior Fixation
41335374|NCT06337162|DRUG|INCB099280|400 mg Tablet
41335375|NCT05983042|GENETIC|Ibuprofen|Ibuprofen 400mg three times a day for three days
41335376|NCT04745468|DEVICE|CRP apheresis|Selective CRP apheresis by use of the PentraSorb-CRP adsorber
41335377|NCT00868543|PROCEDURE|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
41335378|NCT00868543|PROCEDURE|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
41335379|NCT05898750|DIETARY_SUPPLEMENT|MorDom|oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)
41335380|NCT02699125|DRUG|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
41335381|NCT02699125|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
41484407|NCT05301530|DRUG|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
41484408|NCT01945073|BEHAVIORAL|Educational Booklet (BK)|The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.
41484409|NCT01945073|OTHER|Formal Counselling (CB)|The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
41484410|NCT00408564|BIOLOGICAL|cetuximab|
41484411|NCT00408564|DRUG|capecitabine|
41484412|NCT00408564|DRUG|oxaliplatin|
41484413|NCT00408564|PROCEDURE|conventional surgery|
40817210|NCT06439433|DRUG|Placebo|once a week for 6 weeks
40817211|NCT00881764|PROCEDURE|Inguinal hernia surgery|Non-experimental procedure
40817212|NCT00881764|PROCEDURE|General anesthesia|Non-experimental procedure/treatment
40817213|NCT02660671|BEHAVIORAL|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
40817214|NCT02660671|BEHAVIORAL|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
41484414|NCT00408564|RADIATION|radiation therapy|
41484415|NCT00408564|DRUG|Gemcitabine|
41484416|NCT02526511|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo arterial spin labeled perfusion magnetic resonance imaging
41484417|NCT02526511|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging
41484418|NCT02526511|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging
41484419|NCT02526511|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo perfusion magnetic resonance imaging
41484420|NCT04003584|PROCEDURE|Coronary bypass surgery|Reviewed postoperative coronary bypass patients and compared postoperative pain levels
40817215|NCT02660671|BEHAVIORAL|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
40817216|NCT06306729|DIAGNOSTIC_TEST|Computed Tomography, Magnetic Resonance Imaging|Computed Tomography, Magnetic Resonance Imaging
40817217|NCT05078515|DIAGNOSTIC_TEST|PREDICT score|Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
41484421|NCT02579161|DRUG|cephalosporins|Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed
41335382|NCT00116987|DEVICE|Dual chamber cardiac pacemaker|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
41335383|NCT00116987|DEVICE|Single chamber cardiac pacemaker|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
41335384|NCT03561168|DIAGNOSTIC_TEST|Change in plan of care based on MRI results|"Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results."
41335385|NCT03638713|BEHAVIORAL|colonoscopy first|Received water exchange colonoscopy followed by EGD
41335386|NCT03638713|BEHAVIORAL|EGD first|Received EGD followed by water exchange colonoscopy
41335387|NCT01570062|DEVICE|HEPA Filter|"Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration)."
41335388|NCT01570062|DEVICE|HEPA Filtration Placebo|for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
40817218|NCT05858593|BEHAVIORAL|Virtual reality curriculum|Rather than rely on mere exposure to devices, participants in the treatment group will receive a curriculum that integrates the devices into traditional content delivered through the after school program.
41335389|NCT05793957|OTHER|Questionnaire Administration|Ancillary studies
41335390|NCT05793957|BEHAVIORAL|Telephone-Based Intervention|Use smartphone
41484422|NCT02579161|DRUG|Fluoroquinolones|If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance
41484423|NCT02579161|DRUG|Clindamycin|If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.
40817219|NCT05858593|BEHAVIORAL|No Virtual reality curriculum|Children will be able to use the same devices but will not have access to a curriculum that integrates the devices with traditional content delivered through the after school program.
41484424|NCT02579161|DRUG|Ampicillin/Gentamicin|5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin
41484425|NCT00952536|DIETARY_SUPPLEMENT|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable \& 2 fruit \& 2 berry capsule
41484426|NCT00952536|DIETARY_SUPPLEMENT|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable \& fruit \& placebo capsule
41014719|NCT04706624|BEHAVIORAL|High intensity contingency management|Participants receive 12 weeks of contingency management.
41335391|NCT05793957|OTHER|Virtual Technology Intervention|Use VR headset
41335392|NCT01510223|DIETARY_SUPPLEMENT|Olive oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase."
41335393|NCT01510223|DIETARY_SUPPLEMENT|Olive oil and fish powder|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase."
41484427|NCT00952536|DIETARY_SUPPLEMENT|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
41014720|NCT04706624|BEHAVIORAL|Low intensity contingency management|Participants receive 6 weeks of contingency management and 6 weeks of group education.
41014721|NCT04706624|BEHAVIORAL|SMS reminders|Participants receive two daily SMS reminders plus one weekly self-monitoring assessment.
41335394|NCT01510223|DIETARY_SUPPLEMENT|Olive oil and macadamia oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase."
41014722|NCT04706624|BEHAVIORAL|Matrix only|Participants attend 12 weekly Matrix group counseling sessions.
41014723|NCT04706624|BEHAVIORAL|Matrix + Contingency management|Participants attend 12 weekly Matrix group counseling sessions plus 12 weeks of contingency management.
41335395|NCT01510223|DIETARY_SUPPLEMENT|Deadaptation|A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
41335396|NCT01233180|OTHER|Gua Sha|Single Gua Sha treatment of the neck and shoulder region
41335397|NCT01233180|DEVICE|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region
41335398|NCT00646581|DRUG|Placebo|Placebo
41335399|NCT00646581|DRUG|Insulin (Humulin)|40 IU Intranasal Insulin will be administered once
41335400|NCT04390789|PROCEDURE|Non surgical Single visit Retreatment|Non-surgical endodontic retreatment will be carried out in single visit.
41335401|NCT04390789|PROCEDURE|Multi visit Retreatment with calcium hydroxide dressing|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
41335402|NCT00905268|DRUG|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
41335403|NCT00905268|DRUG|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
41335404|NCT03975712|OTHER|Not applicable, no intervention|Not applicable, no intervention
41335405|NCT00251589|DRUG|Vorinostat|Vorinostat 200 mg twice a day for 3 days a week.
41335406|NCT00251589|DRUG|Vorinostat|Vorinostat 300 mg once a day for 3 days a week.
41335407|NCT00251589|DRUG|Vorinostat|Vorinostat 300 mg twice a day for 3 days a week.
41335408|NCT00251589|DRUG|Vorinostat|Vorinostat 400 mg once a day for 21 out of 28 days.
41335409|NCT00251589|DRUG|erlotinib|erlotinib 150 mg once a day.
40817220|NCT03769818|DRUG|bupivacaine|Bilateral TAP block with 20 ml of 0.25% bupivacaine
41335410|NCT02746445|OTHER|No intervention|No intervention. This is a longitudinal study looking at subjects who received MeRT treatment.
41335411|NCT03375723|OTHER|Information on anatomy and physiology, and breathing technique|The patients in the treatment group receive information about what acute PE is regarding anatomy and physiology, a review of what causes the respiratory associated pain in acute PE and also a review of the breathing technique to manage their respiratory associated pain. The given information is standardized and the patient also receives written information with both text and pictures. Patients in the treatment group will meet the physiotherapist at day 1, 2 and the patients also has an opportunity to see the physiotherapist or talk to her at the phone if there are any questions concerning the study.
41335412|NCT03375723|OTHER|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
41335413|NCT00407550|DRUG|gemcitabine HCL|1250 mg/m\^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 \& 8 of each cycle (21 days) x6 cycles.
41335414|NCT00407550|DRUG|pemetrexed disodium|500 mg/m\^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
41335415|NCT00407550|DRUG|gemcitabine HCL|1500 mg/m\^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
41335416|NCT01782924|DRUG|KHK4827|
41335417|NCT00671619|DRUG|ESBA105|eye drops
41335418|NCT01709708|DRUG|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
41335419|NCT01709708|DRUG|Saline|Saline
41484428|NCT00957619|DRUG|pentoxyfilline|The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
41484429|NCT00957619|DRUG|Placebo|This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
41484430|NCT02811263|DRUG|Normal saline placebo|Equal volume of normal saline to be used as placebo
41484431|NCT02811263|DRUG|Erythropoietin|Epogen drawn from commercially available single dose 4000U/mL vials
40817221|NCT03769818|DRUG|dexamethasone|Bilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline.
40817222|NCT03769818|DRUG|placebo to dexamethasone|Bilateral TAP block with placebo to dexamethasone.
40817223|NCT03769818|DRUG|placebo to bupivacaine|Bilateral TAP block with placebo to bupivacaine.
40817224|NCT00616382|DRUG|Indomethacin|IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
40817225|NCT00616382|DRUG|Pentoxifylline|IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
40817226|NCT05950191|OTHER|long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)|Next-generation bed net combining insecticides with different modes of action
40817227|NCT05950191|OTHER|long lasting insecticidal nets with PBO-pyrethroid (PermaNet)|Next-generation bed net combining an insecticide with a synergist
41335420|NCT00550277|DRUG|LBH589|LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
41335421|NCT00441480|DIETARY_SUPPLEMENT|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
41335422|NCT00441480|DIETARY_SUPPLEMENT|placebo|4 gr of corn oil
41484432|NCT05886452|DEVICE|DT1fA contact lenses|Subjects will be fitted with DT1fA contact lenses
41484433|NCT05855486|DEVICE|Saline eye drops|Ocular drops used to facilitate the removal of ocular secretions in pediatric subjects
41484434|NCT05987462|OTHER|Green walking|The researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups. The first subgroup had their 50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval between green walks for both groups.
41484435|NCT03695861|DIAGNOSTIC_TEST|Whole-body 18F-FDG PET-CT scan|A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.
41335423|NCT01089569|DRUG|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
41335424|NCT01089569|DRUG|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
41335425|NCT03077243|RADIATION|Intensity Modulated Radiotherapy (IMRT)|60- 70 Gy at 2 Gy/fx
41335426|NCT03077243|DRUG|Cisplatin (or alternative)|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 -7 total doses.
41335427|NCT03077243|PROCEDURE|Assessment for surgical evaluation|Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
41335428|NCT00216515|DRUG|galantamine hydrobromide|
41335429|NCT02999191|DRUG|BI 1467335 (Treatment A)|
41335430|NCT02999191|DRUG|BI 1467335 (Treatment B)|
41335431|NCT02999191|DRUG|BI 1467335 (Treatment C)|
41335432|NCT04570514|PROCEDURE|PCI|percutaneous coronary intervention (PCI)
41335433|NCT04587960|PROCEDURE|Delayed primary closure of skin incision in Caesarean section in experimental group|Delayed closure of skin wound of emergency Caesarean section following wound dressing for 2-3 days in experimental group
41335434|NCT04587960|PROCEDURE|Primary closure of skin incision in Caesarean section in active comparator group|Primary closure of skin wound (incisional) at the time of emergency Caesarean section in active comparator group
41335435|NCT05766423|BEHAVIORAL|The PATTERN Intervention|"The intervention components include:~1. An adherence assessment that requests patients to self-report via MyChart about their medication use. The assessment provides a link between the health center and the patient ahead of a regularly scheduled clinic visit.~2. Care alert notifications directed to a nurse pool and/or member of the clinical care team when a medication adherence related problem is identified by the adherence assessment. The alert will also include the type of problem the patient is experiencing (cognitive, psychological, medical, regiment, social and/or economic). Once they receive these alerts, the care team can then activate appropriate staff and/or resources to respond."
40817228|NCT05950191|BEHAVIORAL|Social Behavior Change Communication|The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
40817229|NCT06576674|DIETARY_SUPPLEMENT|Dietary Fiber + Green Tea Extract|10g fiber + 750mg green tea supplement will be administered at experimental arm
40817230|NCT06576674|OTHER|Alcohol|alcohol administered up to a target BAC 60mg% during lab sessions
40817231|NCT06576674|OTHER|Aspartame Placebo Supplement|Aspartame sweetener mixed with water + aspartame capsule
41156256|NCT00411463|DRUG|Seroquel|"Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder."
41156257|NCT05364047|BIOLOGICAL|Low-dose of LVRNA009|25μg/person
41156258|NCT05364047|BIOLOGICAL|Middle-dose of LVRNA009|50μg/person
41156259|NCT05364047|BIOLOGICAL|High-dose of LVRNA009|100μg/person
41156260|NCT05364047|OTHER|Placebo|0.5ml/person
41335436|NCT02396693|DEVICE|NIPPV|Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) \< 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) \< 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
41335437|NCT02396693|DEVICE|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
41335438|NCT02396693|DEVICE|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
41335439|NCT05239884|OTHER|ENDS Product A with 1.5% nicotine|P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
41156261|NCT02046057|PROCEDURE|PNB of SLN|Percutaneous biopsy of sentinel node
41156262|NCT04679597|DRUG|Capecitabine|comparison of two treatments
41335440|NCT05239884|OTHER|ENDS Product B with 1.5% nicotine|P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
41335441|NCT05239884|OTHER|ENDS Product C with 1.5% nicotine|P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
41484436|NCT01856361|DRUG|Ramipril|Angiotensin Converting Enzyme Inhibitor
41335442|NCT05239884|OTHER|ENDS Product D with 1.5% nicotine|P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
41335443|NCT05239884|OTHER|ENDS Product E with 1.5% nicotine|P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
41335444|NCT05239884|OTHER|ENDS Product F with 1.5% nicotine|P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
41335445|NCT05239884|OTHER|ENDS Product G with 1.5% nicotine|P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
41335446|NCT05239884|OTHER|ENDS Product H with 1.5% nicotine|P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
41335447|NCT04337723|BEHAVIORAL|ABI/WIFI scoring|The initial ABI training workshop will be coordinated by the non-physician clinic staff champion, and all non-provider clinic staff will be asked to participate. The PI and a research assistant will conduct a 1.5-hour telemedicine training session instructing clinical staff in ABI measurement and WIfI and scoring, using the clinical scoring sheet. Following didactic teaching, participants will perform ABI tests under the guidance of the PI/research assistant and with the support of other participants. During each part of the workshop, specific attention will be directed to pitfalls and technical errors of the test. A pre-post assessment will be used to ensure comprehension of key concepts and performance of the ABI and WIfI tools.
41335448|NCT02003118|DRUG|AKR 202|
41484437|NCT01856361|DRUG|Placebo|Placebo pill that will match the treatment pill
41484438|NCT00173875|DRUG|Iressa|
41484439|NCT02603978|BEHAVIORAL|BASICS|A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
41484440|NCT02603978|BEHAVIORAL|Bystander and Social Norms|A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
41484441|NCT02603978|BEHAVIORAL|Combined BASICS and Bystander|A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
41335449|NCT02003118|DRUG|Placebo|
41335450|NCT06031376|DRUG|Fruquintinib|5mg once daily for 14 days on/7 days off, over a 21-day cycle
41484442|NCT01881113|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
41484443|NCT01881113|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
41484444|NCT00922987|DRUG|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
41484445|NCT04214925|OTHER|Tai Chi|Home exercises will include warm-up and cool-down exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles.
41484446|NCT03184259|DEVICE|Robotic ankle system|Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.
41484447|NCT03184259|DEVICE|Robotic knee system|Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
41484448|NCT06148064|OTHER|Collaplug with low level laser|Immediate implant placement with applying a collaplug material in the jumping gap followed by low level laser application using Siro laser (660 nm, avg. power density: 0.5-WATT) circular spot diameter and area: 0.71 cm/0.4cm2) applied in six points in contact mode with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before bone perforation and after suturing.
41484449|NCT06148064|OTHER|Collaplug|Implant of suitable diameter and height was placed in the fresh extracted socket immediately after extraction and the jumping gap was augmented by the collaplug followed by healing abutment placement.
41484450|NCT01917448|DRUG|Morphine|spinal morphine 0.15 mg
41335451|NCT06031376|DRUG|PD-1 inhibitors|The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.
41335452|NCT06031376|DRUG|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
41335453|NCT06031376|DRUG|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
41335454|NCT02130752|DEVICE|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
41335455|NCT02130752|DEVICE|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
41335456|NCT02002624|DEVICE|PSI|
41335457|NCT02002624|DEVICE|Conventional instrumentation|
41335458|NCT04439812|OTHER|Observation|The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
41484451|NCT01917448|OTHER|control|Patient receive only local infiltration without spinal analgesia
41484452|NCT05084664|DEVICE|electrical stimulation|premodulated current+ exercises
41335459|NCT03528590|DEVICE|size 3 i-gel supraglottic airway device|Use size 3 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
41484453|NCT05084664|DEVICE|electrical stimulation|diadynamic current+ exercises
41484454|NCT00982176|OTHER|Brain MRI and cerebral perfusion scintigraphy|"A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).~MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide."
41335460|NCT03528590|DEVICE|size 4 i-gel supraglottic airway device|Use size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
41335461|NCT02645461|DRUG|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
41335462|NCT02645461|DRUG|Riluzole|Riluzole 50 mg twice daily
41335463|NCT04935970|DIAGNOSTIC_TEST|diagnostic blood test|vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
41335464|NCT04935970|DIAGNOSTIC_TEST|neuropsychological test|neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
41335465|NCT00649168|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
41335466|NCT00649168|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
41335467|NCT00033111|DRUG|Cabergoline|
41335468|NCT00033111|DRUG|Placebo|sugar pill manufactured to mimic cabergoline 05mg tablet
40817232|NCT02904005|OTHER|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
40817233|NCT05365061|OTHER|periosteal electrical dry needling with no maintenance treatments|periosteal electrical dry needling
41156263|NCT02201368|DRUG|Triheptanoin (SpezialölÒ 107®)|"* Randomization: Treatment with Triheptanoin for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months"
41156264|NCT02201368|DIETARY_SUPPLEMENT|MCT (Medium-Chain Triglycerides)|"* Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with Triheptanoin for 6 months"
41335469|NCT02072746|DIETARY_SUPPLEMENT|Zinc|
41335470|NCT02072746|DIETARY_SUPPLEMENT|Placebo|
41335471|NCT01923649|DRUG|Lanreotide 90 mg slow release formulation|Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo
41335472|NCT01923649|DRUG|Placebo|Placebo for somatuline slow release 90 mg
41335473|NCT02434913|DEVICE|SR PIP Implant System|HUD for use in arthroplasty of the PIP joint
41335474|NCT00004772|DRUG|Immune globulin|
41335475|NCT03818711|BEHAVIORAL|Communication & Coping Intervention|Mothers receive a treatment manual and participate in individual phone calls aimed at reducing depressive symptoms and improving the quality of parental involvement. A concurrent secret Facebook group will have daily posts to reinforce concepts.
41335476|NCT03818711|BEHAVIORAL|Education & Check Ins|Mothers receive educational materials and participate in individual phone calls related to these materials. A concurrent secret Facebook group will have daily educational posts.
41335477|NCT02532569|BIOLOGICAL|Japanese encephalitis vaccine|Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.
41335478|NCT02327156|DRUG|dexmedetomidine|adding dexmedetomidine to the local anesthetic
41335479|NCT04943666|OTHER|Hemorrhoid Disease Questionnaire|a new patient specific questionnaire (HDQ) with appropriate sensitivity and specificity to use for screening of patients with haemorrhoids in Russia in clinical practice for wider screening of haemorrhoids in population and for increasing patients' awareness of the disease and prompting them to seek professional advice.
41335480|NCT01527110|DRUG|Intravenous (IV) zanamivir|Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
41156265|NCT04717362|DRUG|Natesto Nasal Product|Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
41156266|NCT02709798|DRUG|Shenfu Injection|
41156267|NCT02709798|DRUG|5% Glucose Injection|
41156268|NCT03432286|DRUG|Galcanezumab|Administered SQ
41156269|NCT03432286|DRUG|Placebo|Administered SQ
41335481|NCT02219217|DRUG|Dolutegravir, Elvitegravir and Cobicistat|
41335482|NCT06452368|DEVICE|facemask|Fixation of miniplates by four screws in the maxilla and protraction by using facemask
41335483|NCT03063853|OTHER|Removal of surgical clips at day 4 post operative vs day 8 post operative|Removal of surgical clips at day 4 post operative vs day 8 post operative
41335484|NCT03063853|PROCEDURE|Elective cesarean delivery|non emergent elective cesarean delivery
41335485|NCT02012881|BEHAVIORAL|Physical activity intervention|Physical activity during recess, in academic subjects, active transportation and PA home work
41335486|NCT02012881|BEHAVIORAL|Usual practice|Normal curriculum
41335487|NCT06082349|PROCEDURE|Lymphaticovenous anastomosis|Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to a adjacent vein of similar size, thereby facilitating the ouflow of lymphatic fluid in patients suffering from secondary lymphedema
41335488|NCT06082349|PROCEDURE|Sham surgery|Sham surgery involves the process of surgery, including local anesthesia and incisions, but no LVA is made.
41335489|NCT00205751|DRUG|Thalidomide/Dexamethasone vs Melphalan/Prednisone|
41335490|NCT05886244|DRUG|Eculizumab|Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.
41335491|NCT05204758|DRUG|TCM Formula|three packages of TCM preparations with each meal three times a day
41335492|NCT05204758|DRUG|Placebo|three packages of placebo preparations with each meal three times a day
41335493|NCT02715492|DRUG|LMWH|(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
41335494|NCT02715492|PROCEDURE|TACE|Trans arterial chemoembolization
40817234|NCT05365061|OTHER|periosteal electrical dry needling with maintenance treatments every other month|periosteal electrical dry needling with maintenance treatments every other month
40817235|NCT05365061|OTHER|periosteal electrical dry needling with monthly maintenance treatments|periosteal electrical dry needling with monthly maintenance treatments
40817236|NCT00349011|PROCEDURE|Personalized risk assessment|
40817237|NCT00349011|PROCEDURE|genetic counseling intervention|
41335495|NCT03678818|OTHER|Medium Supplemented with Latrunculin A|A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
40817238|NCT05519449|BIOLOGICAL|JANX007|JANX007 is dosed via IV in a 21- or 28-day cycle.
40817239|NCT03831191|DRUG|LY3375880|Administered SC
40817240|NCT03831191|DRUG|Placebo|Administered SC
40817241|NCT04225676|BIOLOGICAL|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients \> 50 kg body weight."
40817242|NCT04233307|DIAGNOSTIC_TEST|Telethermographic images|Infrared digital thermography photographs of fracture wound and contralateral limb before and after propofol infusion.
40817243|NCT05308017|DEVICE|Richard Wolf 24F Laser scope|24F Laser with HoLEP
40817244|NCT05308017|DEVICE|Karl Storz 28F Laser Scope|28 F Laser with HoLEP
40817245|NCT00000467|BEHAVIORAL|diet|
41335496|NCT01200160|DRUG|Niacin|
41335497|NCT00343109|BIOLOGICAL|HER-2/neu intracellular domain protein|Given ID
41484455|NCT03970486|PROCEDURE|Dry needling|For the needle manipulation technique, the needle will be pulled in and out (sparrow pecking) and redirected in small angles (coning) for 5-10 seconds. For the in situ technique, the needles will stay (in situ) in the left and right lumbar multifidus muscles for 10 minutes after the insertion of the needle.
41484456|NCT02312713|BEHAVIORAL|Internet Based Exercise Training|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
41484457|NCT02312713|BEHAVIORAL|Physical Therapy|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
41484458|NCT02773459|DRUG|MEK162+capecitabine|In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
40817246|NCT00000467|BEHAVIORAL|exercise|
40817247|NCT00000467|BEHAVIORAL|smoking cessation|
40817248|NCT00973544|OTHER|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
40817249|NCT06084754|DEVICE|pulsed electromagnetic field|pulsed electromagnetic field will be over the site of osteomyelitis where patient in supine lying position. the treatment parameters will be set as10 HZ frequency , 20 gauss amplitude, duration about 120 minutes.
40817250|NCT06084754|DRUG|Antibiotics|Vancomycin IV injection 1gm divided 250mg every 6hours
40817251|NCT03029078|DRUG|fecal microbiota transplant|We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
40817252|NCT04039711|PROCEDURE|Vaginal self-sampling|The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.
40817253|NCT01536665|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
40817254|NCT01536665|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
41156270|NCT01588847|PROCEDURE|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
40817255|NCT00797745|BIOLOGICAL|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
40817256|NCT00797745|DRUG|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
40817257|NCT00797745|DRUG|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
40817258|NCT00797745|DRUG|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
40817259|NCT06367686|DEVICE|IscAlert sensor|Insertion of an IscAlert sensor at the nasal mucosa
40817260|NCT06606808|DRUG|Risankizumab-800CW 4.5 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
40817261|NCT06606808|DRUG|Risankizumab-800CW 15 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
40817262|NCT06606808|DRUG|Risankizumab-800CW 25 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
41335498|NCT00343109|PROCEDURE|leukapheresis|Optional correlative studies
41335499|NCT00343109|OTHER|laboratory biomarker analysis|Correlative studies
41335500|NCT00343109|BIOLOGICAL|sargramostim|Given ID
41335501|NCT00343109|OTHER|immunologic technique|Correlative studies
41335502|NCT00343109|BIOLOGICAL|synthetic tumor-associated peptide vaccine therapy|Given ID
41335503|NCT01378819|PROCEDURE|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
40817263|NCT06606808|DRUG|Risankizumab-800CW optimal dose|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
40817264|NCT00125463|DRUG|Candesartan cilexetil|
40817265|NCT06605365|DEVICE|CX-HA and CS|Sterile Isotonic ophthalmic solution
40817266|NCT00199251|DRUG|RUPATADINE|
41335504|NCT01378819|PROCEDURE|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
40817267|NCT03401021|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
40817268|NCT01611116|DRUG|sodium chloride solution 0.9%|intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment
40817269|NCT01611116|DRUG|temsirolimus|intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
40817270|NCT04273165|DRUG|Etravirine Tablets|Daily etravirine BID with 100 or 200 tablets for 4 months
40817271|NCT06453941|OTHER|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion)|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion) is a newly compiled routine developed on the foundation of the traditional Baduanjin (Eight Pieces of Brocades), which is a traditional Chinese medical health exercise consisted of eight movements to be practiced by oneself.
40817272|NCT05489172|BEHAVIORAL|Hola Bebe|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
41335505|NCT00105755|DEVICE|personal dermal thermometer (DT)|
41335506|NCT00105755|DEVICE|Device|
41335507|NCT06120959|OTHER|Stabilization exercise|The exercise program included Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks. .
41335508|NCT06120959|OTHER|Pelvic floor exercise|The pelvic floor exercise protocol involved several steps. Prior to commencing the exercise, women were instructed to empty their bladders. The initial position for the woman was lying in a crook lying position. They were then guided to contract and hold their pelvic muscles for a duration of 5 to 6 seconds, followed by a relaxation period of 5 to 6 seconds. As the sessions progressed, patients were encouraged to perform the exercises in different positions: from a quadriped position, then sitting, followed by standing, and eventually while walking. Each session had a duration of 20 minutes, and the recommended frequency was three times a week for a span of 6 weeks. The repetitions were set at 10 to 15 per set, with two sets in total.
41335509|NCT03460613|OTHER|FODMAP diet|Patients with a diagnosed FODMAP intolerance (and a control with no FODMAP intolerance) by prior nutrient challenge testing are going on a FODMAP diet. In a first nutritional visit a specialized nutritionist will inform the patients about FODMAP containing foods and illustrate a FODMAP elimination diet. After 3 weeks of elimination diet another visit will take place and a stepwise reintroduction diet is initiated after successful elimination diet.
41335510|NCT04423757|DRUG|BI 1358894|125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
41335511|NCT04423757|DRUG|Placebo|Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
41335512|NCT00000937|DRUG|Antibiotics|
41335513|NCT00712933|DRUG|belimumab|"Recombinant, fully human, monoclonal antibody~Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days."
41335514|NCT05194111|DRUG|Sacubitril-valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
41335515|NCT05194111|DRUG|Valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
41484459|NCT03880760|OTHER|L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
41484460|NCT03880760|OTHER|Placebo|Taking 1 placebo capsule twice a day before meals for six months.
41335516|NCT01517906|BEHAVIORAL|Identity Intervention Program|Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
41335517|NCT01517906|BEHAVIORAL|Supportive Psychotherapy for the Eating Disorders|SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
41335518|NCT03374436|BEHAVIORAL|High-Carbohydrate Sedentary|Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
41484461|NCT01172483|PROCEDURE|general practice in primary care and education|education of chronic disorders in PC
41484462|NCT01172483|OTHER|Multimodal community program|The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
40817273|NCT02975011|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
40817274|NCT02975011|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
40817275|NCT02975011|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
40817276|NCT02975011|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
40817277|NCT02975011|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41014743|NCT06580158|DEVICE|AI-ECG Dashboard|Patients standard of care ECG's will be processed through the AI-ECG Dashboard
41014744|NCT06580158|DIAGNOSTIC_TEST|Point of care ultrasound (POCUS)|Patients will undergo a ultrasound to confirm diagnosis of atrial stenosis or diastolic dysfunction.
41014745|NCT04329962|OTHER|Blueberry Powder Food Product|Consume blueberry powder confection
41014746|NCT04329962|OTHER|Dietary Intervention|Consume blueberry extract confection
41014747|NCT04329962|OTHER|Questionnaire Administration|Ancillary studies
41014748|NCT05592015|DRUG|Ruxolitinib|Given PO
41335519|NCT03374436|BEHAVIORAL|High-Carbohydrate Active|"Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint snack) for a total of 8 active breaks."
41484463|NCT05532579|OTHER|Invasive Physiotherapy Group|The study participants corresponding to the intervention group will receive the treatment proposed by their medical doctor. In addition, and as the main part of the intervention, they will receive an invasive physiotherapy protocol consisting of 3 sessions of ultrasound-guided percutaneous neuromodulation, with a time margin of one week between the first and second session and two weeks between the second and third session. The session will last approximately 15 minutes. Each treatment session will consist of the application of a symmetric biphasic current of 3Hz frequency, 250µsec pulse width, 10 impacts of 10 seconds duration with 10 seconds of rest between them. This application will be performed with acupuncture needles placed in an echoguided manner in the proximity of the dorsal root of the last 3 lumbar levels and in the proximity of the sciatic nerve at its exit from the piriformis muscle.
41484464|NCT05532579|OTHER|Sham Group|Study participants corresponding to the sham group will receive the treatment proposed by their medical doctor. In addition, they will receive the application of the simulated transcutaneous electrical stimulation technique, placing the patches on the same points where the needles are located, remaining in prone position for the necessary time after the technique is performed until 15 minutes have elapsed. This technique has been studied as a placebo technique for neuromodulation interventions.
41484465|NCT04056871|DIAGNOSTIC_TEST|Frailty Screening Tools|This is an observational and prospective study of patients who are going for elective surgery, thus no intervention will be given.
41484466|NCT04293978|BEHAVIORAL|CalmPlace|Self-contained VR application allowing the user to build and custom a relaxation session, with options to vary session length (9-20 minutes), music/sound, relaxation exercises, and specific nature environment (three available) including time of day and events (e.g. rain). Delivered using an Oculus Go devices in kiosk-mode.
41484467|NCT01882920|DRUG|Goal Directed Intravenous Restrictive Fluid Therapy|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) \<2.5 l/min/m2, stroke volume index (SVI) \< 35 SVI ml/m2 and stroke volume variation (SVV)\> 15%. In the case of CI \<2.5 l/min/m2 and SVI \<35 ml/m2 with SVV \< 15%, an infusion with dopamine was initiated.
41484468|NCT01882920|DRUG|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
41484469|NCT01709279|BIOLOGICAL|adipose tissue derived stromal cells dosage|intra-coronary administration of autologous adipose tissue derived stroma cells
41484470|NCT03796039|BEHAVIORAL|Standing|Standing for an additional 100 minutes per week; 20 minutes Monday-Friday
41484471|NCT03865186|BEHAVIORAL|Psychoeducation Program|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
41484472|NCT03865186|BEHAVIORAL|no intervention|
41484473|NCT01690221|DRUG|VEN 307|VEN307 applied three times a day, in and around the anus, for 28 days.
41484474|NCT01690221|DRUG|Placebo|Placebo cream applied three times a day, in and around the anus, for 28 days.
41484475|NCT05262036|DIETARY_SUPPLEMENT|Anti-aging Supplement|Mixture of different vitamins and nutrients
41484476|NCT05262036|DIETARY_SUPPLEMENT|Placebo|Excipient powder
41484477|NCT02171676|DRUG|Docetaxel|
41484478|NCT02171676|DRUG|BIBW 2992|
41484479|NCT02205502|DRUG|Lidocaine|Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.
41156271|NCT01588847|PROCEDURE|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
41156272|NCT04727190|PROCEDURE|Transbronchial Cryobiopsy|The eligible patient will be randomized to TBCB group to receive transbronchial cryobiopsy.
41156273|NCT04727190|PROCEDURE|Transbronchial Forceps Biopsy|The eligible patient will be randomized to TBFB group to receive transbronchial forceps biopsy.
41484480|NCT02205502|DRUG|Normal saline|
41484481|NCT04062474|PROCEDURE|Epidural Intervention with TNF-α inhibitor|Epidural administration with TNF-α inhibitor
41484482|NCT03465917|COMBINATION_PRODUCT|Renal Denervation|Bilateral denervation of the renal arteries using extravascular administration of neurolytic alcohol
41484483|NCT02505490|OTHER|Television|The purpose is to determine whether television impacts liking of food.
41484484|NCT02505490|OTHER|No Television|The purpose is to determine whether the lack of television impacts liking of food.
41484485|NCT05406063|RADIATION|SBRT|Stereotactic multiple fraction radiotherapy
41484486|NCT06417138|OTHER|biological and targeted synthetic disease modifying anti rheumatic drugs (bDMARDs) and (tsDMARDs)|This is a registry-based study. It is an observational, retrospective trial. There is/are no interventional drug(s).
41156274|NCT05878249|PROCEDURE|wound lavage with normal saline|After removing caries and achieving hemostasis after removing caries and achieving hemostasis, wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds
41484487|NCT04859036|DIAGNOSTIC_TEST|24 hours ambulatory Holter monitoring|
41484488|NCT05203666|OTHER|percutaneous removable interspinous process|percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
41484489|NCT02145312|DRUG|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
41484490|NCT03880773|DEVICE|Stapler|for transection of the pancreas and pancreatic stump treatment
41484491|NCT03880773|DEVICE|ultrasonic shears|for transection of the pancreas and pancreatic stump treatment
41484492|NCT01186601|DRUG|PET tracer (BAY94-9392)|A radioactive dose of 300 MBq of the study drug with a total quantity of \</= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
41335520|NCT03374436|BEHAVIORAL|Low-carbohydrate Sedentary|Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.
41335521|NCT04322955|DRUG|Cabozantinib|2 x 20 mg capsules taken orally daily
41335522|NCT04322955|DRUG|Nivolumab|480mg IV on first day of each 28-day cycle
41484493|NCT01551641|OTHER|chemoradiotherapy|Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
41484494|NCT01551641|DRUG|thalidomide|Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
41484495|NCT01551641|OTHER|without thalidomide|Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
41484496|NCT00423319|DRUG|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
41484497|NCT00423319|DRUG|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
41335523|NCT04322955|PROCEDURE|Cytoreductive nephrectomy|Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.
41335524|NCT03747536|DRUG|Ipratropium bromide|ipratropium bromide via metered dose spray (21 micrograms per spray)
41335525|NCT03747536|OTHER|Placebo|normal saline delivered via metered dose spray
41335526|NCT02814448|DEVICE|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
41484498|NCT00423319|DRUG|Enoxaparin-matching placebo|Administered as injection
41484499|NCT00423319|DRUG|Apixaban-matching placebo|Administered as oral tablets
41484500|NCT05089318|DIETARY_SUPPLEMENT|Flexofytol PLUS|2 tablets in the morning and in the evening for minimum 6 weeks.
41335527|NCT02814448|DEVICE|CO2 standard cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
41335528|NCT02814448|DEVICE|Thermocoagulator|The use of heat produced by high-frequency electric current to bring about local destruction of tissues
41335529|NCT04855357|BEHAVIORAL|Resident counselling|One hour, one-on-one counseling for residents
41335530|NCT04855357|BEHAVIORAL|Staff Training|A two-hour training for PSH staff on how to provide referrals to smoking cessation programs using materials previously developed from UCSF's 'Rx for change' curriculum for service providers, directed toward empowering PSH staff to provide referrals to local cessation services using the ask, advise, and refer approach. The training will address nicotine addiction, tobacco use among PSH residents, pilot data, brief cessation counseling (ask, advise, and refer), and local resources for cessation. Because PSH resident-PSH staff encounters will take place as part of routine care, the study team will request permission from a random sample of staff and resident dyads (n=40) to record these interactions to assess fidelity.
41484501|NCT05964192|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|The theta burst stimulation (TBS) technique consists in administering bursts of transcranial magnetic stimulation (TMS) at very high frequency (50Hz) for 5 minutes (3 pulses of stimulation given at 50 hz; 10 bursts/1 s train; inter-train interval : 8 s; number of trains : 30; 100% resting motor threshold; number pulses/session : 900). Total number of sessions : 20 sessions (single daily session).
41484502|NCT03531801|OTHER|Pressure algometry and mapping referred pain areas|The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.
41484503|NCT01660464|BEHAVIORAL|CBT Based Self-help Workbook + Counseling Telepho|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
41484504|NCT05882916|DEVICE|HIV self-testing|Oral fluid-based HIV self-test kits for secondary distribution
41335531|NCT05960513|BEHAVIORAL|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
41335532|NCT02639923|PROCEDURE|Drawing of 7ml peripheral blood|puncture peripheral vein
41335533|NCT05421091|OTHER|Asciminib|Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study.
41335534|NCT03602989|DEVICE|AI-enabled Diabetic Retinopathy Screening Software|Color fundus images of both eyes are captured on site before being uploaded to and analyzed by the cloud-based Artificial Intelligence software
41335535|NCT01651312|DRUG|14C-labeled YM178|oral solution (1.85 MBq)
40817278|NCT02975011|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41335536|NCT02420795|DRUG|Akt/ERK Inhibitor ONC201|Given PO
41335537|NCT02420795|OTHER|Laboratory Biomarker Analysis|Correlative studies
41335538|NCT02420795|OTHER|Pharmacological Study|Correlative studies
40817279|NCT02975011|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
40817280|NCT02975011|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
40817281|NCT06506032|DRUG|Intravenous Vancomycin administration|Vancomycin was administered to the patients at the discretion of the physician
41335539|NCT01154738|DRUG|Lidocaine|"bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.~start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine"
41484505|NCT05882916|BEHAVIORAL|Behavioral economic 'nudges'|Salient information for men included with the self-test kit on clinic location and hours within their cluster, and pilot-tested messaging on the importance of early ART initiation, and the availability and benefits of PrEP
41484506|NCT02312063|DRUG|Sitagliptin|
41335540|NCT01154738|DRUG|Placebo|"NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00"
41335541|NCT03497611|PROCEDURE|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
41335542|NCT01263444|DRUG|Brinzolamide 1% / timolol 0.5% Fixed Combination|
41484507|NCT02312063|DRUG|Glimepiride|
41484508|NCT03726281|DRUG|Nivolumab|Nivolumab 240 mg, IV
41156275|NCT05878249|PROCEDURE|wound lavage with sodium hypochlorite|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds,Subsequently the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets
41335543|NCT01263444|DRUG|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
41335544|NCT05870670|DRUG|NNC0519-0130|Administered subcutaneously.
41335545|NCT05870670|DRUG|Placebo|Administered subcutaneously.
41335546|NCT03382262|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
41335547|NCT03382262|DRUG|TAcs 40 mg|Immediate-release 40mg TAcs IA injection
41335548|NCT03786406|OTHER|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
41335549|NCT02416778|DRUG|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion|
41484509|NCT00931268|DEVICE|Macrolane VRF 30|One administration
40817282|NCT06506032|OTHER|Standard postoperative therapy|The patients received standard postoperative therapy
41014752|NCT04388332|PROCEDURE|Structural allograft|Subjects that have received ACDF structural allograft with plates with autograft and/or allograft comprised of cancellous and/or corticocancellous bone chips
41014753|NCT04388332|DEVICE|Tritanium C|Subjects will receive the Tritanium C anterior cervical cage which is intended to be used with autogenous or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft
41014754|NCT06142422|PROCEDURE|stimulation device|"The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma.~The target is the left precuneus, which is defined by neuronavigation."
41335550|NCT03954990|DRUG|Metronidazole Oral|4 tablets (2 g of metronidazole)
41335551|NCT03954990|DRUG|Placebo Oral Tablet|4 tablets
41335552|NCT05811208|DEVICE|automated pupillometry|Automated pupillometry every 6 hours
41484510|NCT03589235|PROCEDURE|A free gingival graft|A free gingival graft will be used for the treatment of gingival recession
41484511|NCT03589235|DEVICE|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be applied in both donor and receiving sites after the free gingival graft.
41484512|NCT03589235|DEVICE|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be applied in both donor and receiving sites after the free gingival graft.
41484513|NCT00750308|DRUG|Ramipril|Ramipril 10 mg per day for three weeks
41484514|NCT00750308|DRUG|Tadalafil|tadalafil 10 mg every other day for three weeks
41484515|NCT00750308|DRUG|placebo|placebo matching ramipril
41484516|NCT00750308|DRUG|placebo|placebo matching tadalafil
40817283|NCT05925413|DRUG|Cadonilimab+TACE|Cadonilimab: 15mg/kg Q3W Day1 Select the best TACE treatment strategy. Traditional TACE (cTACE) or DEB-TACE can be selected. TACE treatment can be continued as needed based on disease control. The combination of cadonilimab is given 3 to 7 days after the first TACE treatment, and the subsequent administration of cardonilizumab is given once every 3 weeks, if the time overlaps with TACE treatment, it is generally administered 3 to 7 days after TACE treatment. Treatment was discontinued until intolerable toxicity, death, withdrawal of informed consent, initiation of a new antitumor therapy, or other reason specified in the protocol, whichever occurs first. Patients in this study received cadonilimab for up to 24 months.
41014755|NCT04135703|BEHAVIORAL|Risk Prevention Services + Housing|opioid and related prevention services in addition to 6 months of rental assistance
41335553|NCT05811208|DIAGNOSTIC_TEST|questionnaire|"CAM ICU questionnaire will be used for delirium screening the incidence of pain will be assessed using 3 valid scales. The Visual Analogue Scale (VAS), the Behavioral Pain Scale (BPS) and the Critical Care Observational Tool (CPOT) will be used.~questionnaires will be done the same time as pupillometry"
41335555|NCT04149847|PROCEDURE|inguinal hernia repair|patients 18 years and above presenting with primary inguinal hernia
41335556|NCT00179569|BEHAVIORAL|Relaxation response|8 weeks of relaxation response training
41335557|NCT01119963|DRUG|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
41335558|NCT01119963|DRUG|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
41335559|NCT00662389|DEVICE|Apsara Thermal Wand System|Single radiofrequency cycle to dermal tissue
41484517|NCT06236932|DIETARY_SUPPLEMENT|Mediterranean diet|Hypocaloric Mediterranean Diet consist of a nutritional regimen with customized daily energy intake, calculated considering the Basal Metabolism and Physical Activity Level (LAF) of each patient. The distribution of macronutrients will be worked out as follows: ≃ 55-60% Carbohydrates (of which 80% are complex carbohydrates, pasta, bread, rice, whole grains and 20% simple sugars), ≃ 10-15% Proteins (of which the 60% of animal origin (meat, especially white) and 40% of vegetable origin (beans, chickpeas, lentils and legumes in general), ≃ 25-30% of lipids (predominantly olive oil).
41484518|NCT06236932|DIETARY_SUPPLEMENT|Melatonin supplementation|Melatonin (supplement formulation in capsules, 1mg/die one hour before sleep) will be associated with mediterranean diet for 12 w.
41484519|NCT01007942|DRUG|everolimus|Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
40817284|NCT05538312|DRUG|vepdegestrant|Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant
41014756|NCT04135703|BEHAVIORAL|Risk Prevention Services Only|opioid and related prevention services for 6 months
41484520|NCT01007942|DRUG|Placebo|Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
40817285|NCT05538312|DRUG|Itraconazole|Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
41014759|NCT04870840|RADIATION|Proton Beam Radiation Therapy|Undergo radiation therapy
41014760|NCT04870840|OTHER|Quality-of-Life Assessment|Ancillary studies
41014761|NCT04870840|OTHER|Questionnaire Administration|Ancillary studies
41484521|NCT01007942|DRUG|vinorelbine|intravenous vinorelbine (25 mg/m2 weekly)
41484522|NCT01007942|DRUG|trastuzumab|intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
41335560|NCT05554718|BEHAVIORAL|Self-help Smartphone App|The app provides a 12-week adaptation of scientifically proven cognitive behavioral therapy techniques for the treatment of SAD and is intended for use as a mobile intervention. The app includes modules such as learning (e.g., creating a model, learning about the maintaining factors), changing the maintaining factors (e.g., safety behaviors), or behavioral experiments.
41335561|NCT05554718|BEHAVIORAL|Therapist-guided App Use|In addition to using the app, patients receive a total of 8 video-based therapy sessions over the course of 12 weeks. The sessions include topics such as video feedback and behavioral experiments.
41335562|NCT05965206|BEHAVIORAL|Follow-up phone interview|Follow-up phone interview within 7 business days after receiving intravenous chemotherapy
40817286|NCT00349921|DRUG|clonidine|Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
41335563|NCT05706818|OTHER|Validity and reliability study|Validity and reliability assessment of the Community Integration Questionnaire-revised
41335564|NCT05428553|PROCEDURE|Endoscopic resection: CSP/p-CSP|Patients in the experimental arm will be assigned to receive CSP/p-CSP.
41335565|NCT05428553|PROCEDURE|Endoscopic resection: EMR/EPMR|Patients in the historical control arm have already finished EMR/EPMR
41335566|NCT02979028|DEVICE|TEAS|Transcutaneous electrical acupoint stimulation
41335567|NCT04390997|PROCEDURE|Non-surgical Periodontal Treatment|Non-surgical periodontal treatment includes scaling and root planning by using curettes and ultrasonic devices only in the periodontitis group.
41335568|NCT06374524|PROCEDURE|greater occipital nerve block|Patients will receive an ultrasound-guided bilateral GONB (distal approach) of 5 mLs of injectate of bupivacaine 0.25% (5 mLs) + depomedrol 40 mg in 1 mL (3 mLs to each side).
40817287|NCT00349921|DRUG|adenosine|Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
41335569|NCT01458496|BEHAVIORAL|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
41335570|NCT03429764|PROCEDURE|CISS|continuous independent sling sutures will be placed with minimum two intact contact points at the surgical site
41335571|NCT03429764|PROCEDURE|VIMS|internal mattress suture will be placed with minimum two intact contact points at the surgical site
41335572|NCT03693404|DRUG|Marcaine, Duramorph , ketorolac|Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
41335573|NCT03693404|DRUG|Bupivacaine (Marcaine)|0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
40817288|NCT00349921|DRUG|placebo|inactive substance
40817289|NCT00349921|DRUG|placebo|inactive substance
41335574|NCT03693404|DRUG|General Anesthetics|Placebo group will only receive standard of care general anesthesia
40817290|NCT05137171|DRUG|AK105 and anlotinib|AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
41335575|NCT00519168|PROCEDURE|Urine sample|Standard of care
40817291|NCT01935583|BEHAVIORAL|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
40817292|NCT03495310|BEHAVIORAL|Mindfulness|Mindfulness is a method based on the concentration of attention, awareness and meditation, which has been used successfully to reduce stress, depression and anxiety in individuals with some pathology in the short term
41156276|NCT05878249|PROCEDURE|wound lavage with Ethylenediaminetetraacetic acid(EDTA)|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12% Ethylenediaminetetraacetic acid for 5minutes ,Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
41335576|NCT00519168|DEVICE|Electrode sleep recorder|Standard of care
41335577|NCT00519168|PROCEDURE|phlebotomy|Standard of care
41484523|NCT05982730|BEHAVIORAL|Sensory-Augmented Postural Training|To examine the safety and efficacy of postural training emphasized on the integration of multiple sensory information into motor control and to assess the effectiveness of postural training using Segway
41335578|NCT06154499|PROCEDURE|Radical prostatectomy|Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
41335579|NCT00149383|DRUG|Rosiglitazone|
41335580|NCT00149383|DRUG|Placebo|
41335581|NCT01627223|DRUG|Lamivudine|"Lamivudine 100 mg p.o. q.d.~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
41335582|NCT01627223|DRUG|Entecavir|"•Entecavir 0.5 mg p.o. q.d~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
41335583|NCT00318370|DRUG|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
41335584|NCT00318370|DRUG|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
41335585|NCT04269837|OTHER|Counseling|Receive sexual health counseling
41335586|NCT04269837|OTHER|Quality-of-Life Assessment|Ancillary studies
40817293|NCT05332587|DRUG|Rituximab|The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
41335587|NCT04269837|OTHER|Questionnaire Administration|Ancillary studies
41335588|NCT06006546|BIOLOGICAL|426c.Mod.Core-C4b|100 mcg and 300 mcg
40817294|NCT05291988|OTHER|Educational Intervention|Receive S2S education
40817295|NCT05291988|OTHER|Fecal Immunochemical Test|Receive FIT kit
40817296|NCT05291988|OTHER|Questionnaire Administration|Ancillary Studies
40817297|NCT06017921|DRUG|Eszopiclone 3 mg|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
40817298|NCT06017921|DRUG|Placebo|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
40817299|NCT01368783|DRUG|atazanavir|400 mg/day for 2 days
40817300|NCT01368783|DRUG|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
40817301|NCT01368783|DRUG|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
41335589|NCT06006546|OTHER|Adjuvant 3M-052-AF+Alum|5 mcg
41335590|NCT01433692|BEHAVIORAL|Brief Intervention|CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
41484524|NCT05325593|DRUG|romiplostim plus dexamethasone|Patients will be reviewed weekly for 8 weeks (56 days). After Week 8, patients will be reviewed every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
41484525|NCT05325593|DRUG|Dexamethasone|Patients will be reviewed weekly until the completion of dexamethasone cycles and for a minimum of 8 weeks (56 days). After that, every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
41335591|NCT03313804|DRUG|Immune checkpoint inhibitor|Standard of care immune checkpoint inhibitor
41335592|NCT03313804|RADIATION|Radiation Therapy|Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
41335593|NCT00083629|PROCEDURE|PET|
41335594|NCT06145087|DIETARY_SUPPLEMENT|"NOVOS Core supplement"|The supplement mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee once per day.
40817302|NCT01368783|DRUG|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
41335595|NCT06145087|DIETARY_SUPPLEMENT|Placebo|The placebo mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee.
41484526|NCT00140621|DRUG|Agalsidase beta|
41484527|NCT03732261|OTHER|Exercise and dietary|The 12-week study invention will take place between 6 to 8-weeks postpartum and 18 to 20-weeks postpartum, with a follow-up at one year postpartum. The six-week postpartum time point is to allow for exercise clearance from the participant's obstetrician. The exercise clearance is needed prior to the baseline laboratory measurement. Women will be randomized to an intervention group or minimal care group after all baseline measurements (anthropometrics, cardiovascular fitness test, human milk and blood samples and DXA) at six-weeks postpartum. A random numbers table will be used to stratify by parity and determine groups.
41484528|NCT03218163|DRUG|MEDI-551 Maintenance|Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
41484529|NCT05875922|DEVICE|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
40817303|NCT05382338|DRUG|Cisplatin|Given IV
40817304|NCT05382338|DRUG|Cyclophosphamide|Given IV
40817305|NCT05382338|DRUG|Lomustine|Given PO
40817306|NCT05382338|DRUG|Mesna|Given IV
41335596|NCT05032417|OTHER|implementation of evidence-based nutrition practice guidelines|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
41335597|NCT04344704|OTHER|Single chamber DAI device with floating atrial dipole|DAI for the detection of atrial signals with optimized programming, using Smart, Onset \& Stability, and Morphmatch methods
41335598|NCT04746209|DEVICE|Alpha/Beta T-cell and B-cell depleted HCT|Device: Alpha/Beta T-cell and B-cell depletion
41335599|NCT04746209|DRUG|Blinatumomab|28 day continuous infusion given on Day 100 post-HCT if no significant ongoing GVHD
41484530|NCT05875922|DEVICE|IOL implantation active comparator (TECNIS Eyhance)|Implantation of EDOF IOL TECNIS Eyhance
41484531|NCT01841775|DRUG|interferon α 2b + ribavirin|"1. interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks~2. ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks"
40817307|NCT05382338|OTHER|Quality-of-Life Assessment|Ancillary studies
40817308|NCT05382338|RADIATION|Radiation Therapy|Undergo radiation therapy
40817309|NCT05382338|DRUG|Sodium Thiosulfate|Given IV
40817310|NCT05382338|OTHER|Survey Administration|Ancillary studies
40817311|NCT05382338|DRUG|Vincristine|Given IV
40817312|NCT04368494|BEHAVIORAL|12-week home based exercise|Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.
40817313|NCT00664339|BIOLOGICAL|Flu Vaccine|Single dose of Flu vaccine by year (1)
41014772|NCT02439775|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
40817314|NCT00664339|OTHER|Conventional medical therapy for heart failure|According with the international guidelines
41014773|NCT02439775|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
41014774|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
41014775|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
41014776|NCT05061446|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks
41014779|NCT06455293|DRUG|Psilocybin|"Single dose of psilocybin ranging from low (microdose) to high delivered orally with psychological support and monitoring"
41014780|NCT04817241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41335600|NCT03476434|DEVICE|chromoendoscopy with indigo carmine|the lumen of the colon is sprayed in a segmental fashion using 0.4% indigo carmine delivered via a specially designed dye spray catheter (Olympus PW-5V1) or via the accessory channel with a 50cc syringe filled with indigo carmine and air.
41335601|NCT05375162|BEHAVIORAL|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the Opt2Move self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the 24-week study period. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the Opt2Move study app and provide Fitbit data to the study team in real-time.~The core Opt2Move study app will support YACS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
41335602|NCT05375162|BEHAVIORAL|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
41014781|NCT04817241|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
41014782|NCT04817241|DRUG|Cytarabine|Given IV
41014783|NCT04817241|DRUG|Daunorubicin|Given IV
41014784|NCT04817241|DRUG|Decitabine and Cedazuridine|Given PO
41014785|NCT04817241|DRUG|Venetoclax|Given PO
41014786|NCT03975647|DRUG|tucatinib|300mg given twice per day by mouth (orally)
41014787|NCT03975647|DRUG|placebo|Given twice per day orally
41014788|NCT03975647|DRUG|T-DM1|3.6 mg/kg given into the vein (IV; intravenously) every 21 days
41014789|NCT04111497|DRUG|Glasdegib|Given PO
40817315|NCT03692377|DEVICE|Virtual Reality|Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
40817316|NCT05021302|PROCEDURE|NOVAMAG NT-60|The Electromagnetic stimulation consists of 15 sessions with 20 minutes duration and three times a week. The total length of therapy is five weeks.
40817317|NCT05021302|BEHAVIORAL|Kegel Exercises|Self-supporting pelvic floor muscle strengthening exercises performed at home by contracting and relaxing quickly (2 seconds of contraction and 4 seconds of rest), followed by a slow contraction (contraction for 5 seconds, and rest for 10 seconds with five times each) five sets per day. The average length of exercise for each session is 2 minutes, with total exercise per day is 50 times. Thus, the total length of exercise is 10 minutes. It was done every day for eight weeks.
40817318|NCT00473668|BIOLOGICAL|Zilbrix-Hib|Intramuscular injection, 1 dose
40817319|NCT00473668|BIOLOGICAL|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
40817320|NCT04067297|OTHER|Lipid management toolbox|The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of \~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
40817321|NCT01521871|PROCEDURE|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
41484532|NCT04180553|DIAGNOSTIC_TEST|Point of Care Ultrasound (POCUS)|The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP \<90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
41484533|NCT04180553|OTHER|Usual Care|"The control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated."
40817322|NCT01521871|PROCEDURE|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
40817323|NCT05379517|DEVICE|Pulsed ectromagnetid field therapy|Pulsed electromagnetic field therapy is an innovative therapy. The technology is based on a high intensity electromagnetic field, which positively influences human tissue. It is a form of non-invasive treatment, with good tolerance by patients. High-intensity electromagnetic fields excite neural and muscle cells, which stimulates the human body.
40817324|NCT05379517|OTHER|Pulmonary rehabilitation program (PRP)|This type of physiotherapy program includes: respiratory muscle training, coughing exercises, diaphragmatic training, aerobic training and strength training.
40817325|NCT04500080|BEHAVIORAL|PE Intervention|"Each single exercise session will last for one hour and will consist of a combination of the following elements:~* Aerobic Exercise (AE): 20-30 minutes at moderate-high intensity, from 60 to 80% of the maximum heart rate (% HRmax).~* Resistance Exercise (RE): 30 minutes of strength activity of the major muscle groups.~* Neuromotor Exercise (NE): will be integrated with strength exercises and will consist of jumping, balance and coordination activities"
40817326|NCT06332768|DEVICE|Respiratory support|High-flow nasal oxygenation
41017949|NCT02652780|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
41017950|NCT01208233|DRUG|PF-03049423|1 mg of PF-03049423 daily for 90 days
41017951|NCT01208233|DRUG|PF-03049423|3 mg of PF-03049423 daily for 90 days
40918339|NCT03014999|DEVICE|Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed
40817327|NCT03199326|OTHER|Collaborative Care|CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
41014793|NCT04816006|BEHAVIORAL|Aerobic Exercise Training|Breast cancer survivors in the intervention group will participate in a 24-week moderate intensity exercise program led by community-based fitness center personal trainers. Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Treadmill walking is the primary mode of exercise. However, participants will be permitted to use other cardiovascular equipment (e.g., elliptical machines, stationary bicycles) as prescribed by their exercise trainer. The trainer will supervise three weekly exercise sessions in Weeks 1-2, two in Weeks 3-4, one in Weeks 5-8, biweekly across weeks 9-16, and monthly in Weeks 17-24 (N=20 supervised sessions).
40817328|NCT00262886|BIOLOGICAL|anti-thymocyte globulin|
40817329|NCT00262886|BIOLOGICAL|graft-versus-tumor induction therapy|
41014794|NCT04816006|OTHER|Health Education (Active comparator)|Breast cancer survivors in the Health Education group will participate in education sessions with a health educator and receive monthly newsletters/webinars (N=20 total contacts) across 24 weeks. The program will include cancer support and discussion of cancer-related wellness topics (e.g., stress management, coping). Control group participants will be offered a 6-month fitness center membership upon study completion.
40817330|NCT00262886|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40817331|NCT00262886|DRUG|cyclophosphamide|
40817332|NCT00262886|DRUG|fludarabine phosphate|
40817333|NCT00262886|DRUG|mycophenolate mofetil|
41017952|NCT01208233|DRUG|PF-03049423|6 mg of PF-03049423 daily for 90 days
40817334|NCT00262886|DRUG|tacrolimus|
40817335|NCT00262886|PROCEDURE|allogeneic bone marrow transplantation|
40817336|NCT00262886|PROCEDURE|peripheral blood stem cell transplantation|
40817337|NCT02222909|OTHER|Co-developed IT intervention|The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
40817338|NCT00685269|DRUG|Eszopiclone|Eszopiclone 3 mg QD
40817339|NCT00685269|DRUG|Placebo|Placebo tablet
40817340|NCT05279690|DRUG|Colchicine|Patients will receive 14 days of colchicine in the absence of prohibitive toxicity of disease progression
41017953|NCT01208233|OTHER|Placebo|Placebo of PF-03049423 daily for 90 days
41017954|NCT01181895|DRUG|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
41017955|NCT01181895|DRUG|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
41017956|NCT01181895|DRUG|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
41017957|NCT01181895|DRUG|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
41017958|NCT03955484|DIAGNOSTIC_TEST|Urinary Glycosaminoglycan|Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.
41017959|NCT06202261|DRUG|TQB2930 for injection|TQB2930 for injection is a HER2 bispecific antibody.
41017960|NCT06202261|DRUG|Paclitaxel for injection (albumin-bound)|It is an anti-microtubule chemotherapy drug
41017961|NCT06202261|DRUG|TQB3616 capsule|TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
41335603|NCT05375162|BEHAVIORAL|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the Opt2Move app.
41335604|NCT05375162|BEHAVIORAL|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the Opt2Move app.
41335605|NCT05375162|BEHAVIORAL|Buddy|Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the Opt2Move app modules the participant has access to for their assigned condition. The Opt2Move app will include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcasts (one every 3 weeks) during the first 12 weeks of the intervention. Each podcast will provide social support training and peer discussion of challenges and successes in providing YACS with MVPA support.
41335606|NCT06082375|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 in the form of cholecalciferol.
41335607|NCT06082375|DIETARY_SUPPLEMENT|Placebo|Vegetable oil.
41335608|NCT06479434|DRUG|Metformin|Females diagnosed with polycystic syndrome will be given metformin tablets for 8 weeks and followed up. Blood samples will be collected along with anthropometric data (weight (kg), height (m) etc)
41335609|NCT03261570|DRUG|Pyridostigmine|60mg by mouth
41335610|NCT03261570|DRUG|Digoxin|0.5 (500mcg) by mouth
41335611|NCT03261570|DRUG|Placebo|Lactulose 50mg by mouth
41335612|NCT02255760|DRUG|MEDI3902 - Dose 1|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
41335613|NCT02255760|DRUG|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
41014798|NCT04875806|DRUG|NC762|NC762 is an experimental antibody drug that may make the immune response more active against cancer
41335614|NCT02255760|DRUG|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
41335615|NCT02255760|DRUG|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
41484534|NCT05017974|BEHAVIORAL|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement|MBSR+PS
41335616|NCT02255760|OTHER|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
41335617|NCT03186261|DRUG|Nano silver fluoride solution|Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.
41335618|NCT03186261|DRUG|Cavity Cleanser|Moistens dentin surface after cavity preparation using a micro brush.
41335619|NCT02370550|DRUG|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
41484535|NCT05017974|OTHER|Treatment as Usual|TAU
41484536|NCT04737070|BIOLOGICAL|Prenatal test for Trisomy 21 screening|prenatal routine test for Trisomy 21 screening (blood test + nuchal translucency test)
41017962|NCT06202261|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol
41484537|NCT04391530|BEHAVIORAL|emotional freedom technique, breathing therapy|emotional freedom technique, breathing therapy
41484538|NCT00003972|BIOLOGICAL|filgrastim|
41484539|NCT00003972|BIOLOGICAL|sargramostim|
41484540|NCT00003972|DRUG|busulfan|
41484541|NCT00003972|DRUG|carboplatin|
41484542|NCT00003972|DRUG|cyclophosphamide|
41484543|NCT00003972|DRUG|melphalan|
40817341|NCT04137653|DRUG|nab-Paclitaxel+carboplatin|Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
40817342|NCT04137653|DRUG|Paclitaxel+carboplatin|Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
41484544|NCT00003972|DRUG|paclitaxel|
41484545|NCT00003972|DRUG|tamoxifen citrate|
40817343|NCT05496452|DIETARY_SUPPLEMENT|Beta-lactoglobulin|Beta-lactoglobulin (BLG) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
40817344|NCT05496452|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate (dextrose monohydrate) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
41014807|NCT06453590|PROCEDURE|Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
41335620|NCT02370550|DRUG|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
41014808|NCT06453590|PROCEDURE|Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
41335621|NCT02370550|DRUG|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
41335622|NCT02370550|DRUG|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
41335623|NCT02925312|OTHER|Diabetes Pathway|Medication algorithm, survival skills education, enhanced patient-provider communication facilitated by near, real-time blood glucose monitoring
41335624|NCT03639922|DRUG|Imatinib 400mg|2 tablets of Imatinib 400mg per day for 6 days
41484546|NCT00003972|DRUG|thiotepa|
41335625|NCT03639922|DRUG|Placebo Oral Tablet|2 tablets of placebo per day for 6 days
41017963|NCT06202261|DRUG|Capecitabine tablets|Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.
41017964|NCT06202261|DRUG|Vinorelbine tartrate injection|Vinorelbine is an anti-tumor drug of vinca alkaloids.
41335626|NCT00134407|PROCEDURE|Normal diet|
41484547|NCT00003972|PROCEDURE|peripheral blood stem cell transplantation|
41335627|NCT00134407|PROCEDURE|Nutrition via jejunal needle-catheter|
41335628|NCT00578422|OTHER|Ivus (Intravascular Ultrasound) of Amputation Specimens|Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques
41484548|NCT00003972|RADIATION|radiation therapy|
41484549|NCT00511992|DRUG|Avastin|"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles"
41484550|NCT00511992|DRUG|Paclitaxel|Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
41484551|NCT00511992|DRUG|Cisplatin|75mg/m2 IP day 2 every 21 days x 6 cycles
41484552|NCT01404871|DRUG|clomipramine|oral tablets, starting at 50mg/daily for 12 weeks including \> 8 weeks at 250 mg/daily
41484553|NCT01404871|DRUG|escitalopram|oral tablet, starting 10mg/daily 12 week treatment including \>8 weeks at max dose 50mg daily
41484554|NCT01404871|DRUG|duloxetine|oral tablets, starting dose 30mg daily 12 week treatment including \>8weeks at 120mg daily
41484555|NCT04960618|DRUG|Gemcitabine|Participants will receive gemcitabine 1000 mg/m2 on days 1 and 8 on 21-days cycles for up to 6 cycles
41484556|NCT04960618|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be introduced with cycle 2 and will be given on day 1 of each 21-day cycle for up to 35 cycles
40817345|NCT06262659|OTHER|Doppler Ultrasonography Assessment|"Preoperative data will be collected from the latest available data within the last month. Preoperative Doppler ultrasonography venous mapping for all patients will be performed by experienced Radiology Specialists.~AVF flow measurement will be performed intraoperatively and at the 6th week postoperatively using Doppler ultrasonography (B-Mode and duplex ultrasound on the LOQIC; GE Healthcare Technologies, Milwaukee, Wisconsin, United States). For each patient, AVF flows will be recorded by taking at least 3 measurements of AVF flow, depth, and vascular diameters at 2, 5, 10, and 15 cm proximal to the AVF anastomosis, and arithmetic averages will be calculated. AVF flow will be expressed in ml/min, and the vascular structure diameters and the distance of AVF from the skin will be indicated in mm. AVF depth will be calculated as the distance from the skin to the anterior wall of the AVF."
41014809|NCT06453590|PROCEDURE|Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
41014810|NCT04037527|DRUG|Gemcitabine|Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)
41014811|NCT04037527|DRUG|Docetaxel|Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
41014812|NCT04037527|RADIATION|Radiation|Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.
41014813|NCT04037527|PROCEDURE|Surgical Resection|Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.
41014814|NCT04037527|OTHER|Blood draws|Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
41335629|NCT00578422|PROCEDURE|IVUS (Intravascular Ultrasound)|Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
40817346|NCT03263728|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
41335630|NCT00427791|DRUG|Etoposide|60 mg/kg IV Daily Over 4 Hours for 1 Day
41335631|NCT00427791|RADIATION|Total Body Irradiation|3 Gy Daily for 4 Days
41335632|NCT00427791|DRUG|Rituximab|375 mg/m\^2 IV Weekly Over 4-8 Hours for 4 Weeks
41335633|NCT01498588|DRUG|Eribulin|Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
41335634|NCT01498588|DRUG|Doxorubicin|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
41335635|NCT01498588|DRUG|Cyclophosphamide|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
41335636|NCT01498588|DRUG|Pegfilgrastim|Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
41335637|NCT00914238|BEHAVIORAL|2 years OPUS treatment|2 years OPUS and transfer to standard treatment.
41335638|NCT00914238|BEHAVIORAL|OPUS 5 years|
41335639|NCT03993353|DRUG|Pembrolizumab|200 mg intravenously every 3 weeks
41335640|NCT03993353|DRUG|Tadalafil|10 mg by mouth daily
41335641|NCT05321693|DEVICE|Transcranial Pulsed Current Stimulation|Current has a peak pulse amplitude of 2mA, with a frequency range from 6 to 10 Hz. A battery-powered current stimulator will be used. This device provides stimulation through biphasic and alternating square wave pulse, with random pulse width range from 1 to 20 ms
40817347|NCT01595971|BEHAVIORAL|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
40817348|NCT01595971|OTHER|usual care|Received the usual care provided
41335642|NCT03289052|DEVICE|Restylane Volyme|Subcutis injection
41335643|NCT01927887|DRUG|Ferumoxytol|Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.
41335644|NCT01927887|DEVICE|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
40817349|NCT06354413|PROCEDURE|CABG during myectomy|To explore the effect of CABG during myectomy. No control group
40817350|NCT02813135|DRUG|Ribociclib|
40817351|NCT02813135|DRUG|Topotecan|
40817352|NCT02813135|DRUG|Temozolomide|
40817353|NCT02813135|DRUG|Everolimus|
40817354|NCT02813135|DRUG|Adavosertib|
40817355|NCT02813135|DRUG|Carboplatin|
40817356|NCT02813135|DRUG|Olaparib|
40817357|NCT02813135|DRUG|Irinotecan|
41335645|NCT01001572|DRUG|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
41335646|NCT01001572|DRUG|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
40817358|NCT02813135|DRUG|Vistusertib|
40817359|NCT02813135|DRUG|Nivolumab|
40817360|NCT02813135|DRUG|Cyclophosphamide|
40817361|NCT02813135|DRUG|Selumetinib|
40817362|NCT02813135|DRUG|Enasidenib|
40817363|NCT02813135|DRUG|Lirilumab|
40817364|NCT02813135|DRUG|Fadraciclib|
40817365|NCT02813135|DRUG|Cytarabine|
40817366|NCT02813135|DRUG|Dexamethasone|
40817367|NCT02813135|DRUG|Ceralasertib|
40817368|NCT02813135|DRUG|Futibatinib|
40817369|NCT02813135|DRUG|Capmatinib|
41014818|NCT05962905|OTHER|Blood sample|During the standard of care interventional or diagnostic cardiac catheterization, paired arterial and venous blood samples will be obtained. The venous sample will be obtained from 2 cm superior to the clavicle, which is beyond standard of care during the routine cardiac catheterization
41335647|NCT01001572|DRUG|Placebo|1 capsule or tablet taken orally once daily
41484557|NCT01944787|OTHER|Routine|IV Hydration at 125 cc hour
41484558|NCT01944787|OTHER|IV Hydration at 250cc hour|IV Hydration at 250 cc hour
41484559|NCT02030483|DRUG|Palbociclib|Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
41484560|NCT02030483|DRUG|Dexamethasone|20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
41484561|NCT02030483|DRUG|Lenalidomide|Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
41484562|NCT02399735|BIOLOGICAL|Low Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
40817370|NCT01858545|DEVICE|MatriStem|MatriStem MicroMatrix and MatriStem Wound Matrix
40817371|NCT01858545|DEVICE|Cellular Dermal Replacement Tissue|Cellular Dermal Replacement Tissue
40817372|NCT03666897|OTHER|DTI Images and Plasma Biomarkers|Additional Images added from standard of care MRI, Bio-markers identified
40817373|NCT04960904|DEVICE|Dental implant surgery with implants|Adult patients who have had dental implant surgery.
40817374|NCT05725486|DIETARY_SUPPLEMENT|N-3 PUFAs Chicken Meet|Intake of n-3 PUFAs enriched chicken meet for three weeks.
40817375|NCT05725486|DIETARY_SUPPLEMENT|Regular Chicken Meet|Intake of regular chicken meet for three weeks.
40817376|NCT00098046|DRUG|famciclovir|
40817377|NCT01357538|DRUG|Posiformin 2 %, bibrocathol|A strip of 5 mm eye ointment applied 3 times per day to the eye lid
40817378|NCT01357538|DRUG|Placebo Comparator|corresponding vehicle, eye ointment applied to the eye lid
40817379|NCT02471560|DRUG|dimethyl fumarate|As per the prevailing local label.
40817380|NCT02471560|DRUG|injectable MS DMT|As described above.
40817381|NCT01657890|DRUG|isavuconazole|oral
40817382|NCT06540963|DRUG|Tipifarnib|Tablet
40817383|NCT06540963|DRUG|Naxitamab|IV
40817384|NCT06277414|OTHER|collection of laboratory test results, imaging results and symptoms|collection of laboratory test results, imaging results and symptoms
40817385|NCT01743235|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
40817386|NCT01743235|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
40817387|NCT01743235|DRUG|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
40817388|NCT04397003|BIOLOGICAL|Neoantigen DNA vaccine|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM system, PapiVax Biotech). At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
40817389|NCT04397003|DRUG|Durvalumab|-Supplied by AstraZeneca
40817390|NCT04397003|DEVICE|TDS-IM v2.0 Device|-Integrated electroporation administration system
40817391|NCT04397003|PROCEDURE|Peripheral blood draws|-Pre-treatment, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Vaccine Day 1, Vaccine Day 29, Vaccine Day 85, Vaccine Day 141, on even numbers of cycles for durvalumab for one year following completion of vaccine
40817392|NCT03638531|DEVICE|Anodal tDCS|Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
40817393|NCT03638531|DEVICE|SHAM tDCS|SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
40817394|NCT06443177|DEVICE|Vectris trial leads and stimulation|The electrode is placed into the epidural space using standard epidural placement techniques with paramedian approach. The initial electrode settings have been adopted from prior studies. Should any significant discomfort be elicited from the stimulation, first the amplitude will be decreased to an acceptable level. If an acceptable level of stimulation is unable to be found, the stimulation will be discontinued.
40817395|NCT06443177|DEVICE|Sham|No electrode is placed.
41014819|NCT05962905|DEVICE|INVOS monitoring|During the standard of care interventional or diagnostic cardiac catheterization, INVOS monitoring will be used. INVOS™ regional oxygen saturation (rSO2) values will be compared to the calculated global field saturation of cerebral tissue determined from blood sample co-oximetry.
41014820|NCT03880578|DRUG|Levothyroxine Sodium|thyroid hormone replacement
41484563|NCT02399735|BIOLOGICAL|Normal Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
41484564|NCT02399735|BIOLOGICAL|Normal Dose NK cells ×8 times|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
41484565|NCT01208220|DEVICE|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
41484566|NCT01208220|BIOLOGICAL|Collagenase Ointment|Apply TIW
41484567|NCT03052413|DIETARY_SUPPLEMENT|Nutrafol|Eligible subjects will receive Nutrafol® to take daily for 180 days
41484568|NCT03052413|DIETARY_SUPPLEMENT|placebo|Eligible subjects will receive Placebo to take daily for 180 days
41484569|NCT05500118|OTHER|Patients Decision Aids|Patient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.
41014831|NCT04537715|DRUG|Tazemetostat|A single, oral, 400 mg dose of tazemetostat on Day 1, Day 15, and Day 36; and tazemetostat (oral 400 mg) tablets twice daily on Days 3 - 14 and Days 21 - 35.
41014832|NCT04537715|DRUG|Itraconazole|Oral 200 mg itraconazole once daily on Days 18 - 38
41335648|NCT02794025|DRUG|Esmolol|"patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm \< HR \< 100 bpm within 72 hours).~Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol."
41335649|NCT02794025|DRUG|natural saline|Control group also received natural saline via a micro pump,
41335650|NCT04246541|DRUG|Ketorolac|Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.
41335651|NCT04246541|DRUG|Oxycodone-Acetaminophen|Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.
41335652|NCT05276427|OTHER|Non Clinical procedure|Non clinical procedure- Informed consent completion and interview session
41335653|NCT02251067|DRUG|VPI-2690B low dose|Comparison of different doses of study drug
41335654|NCT02251067|DRUG|VPI-2690B medium dose|Comparison of different doses of study drug
41335655|NCT02251067|DRUG|Placebo to match VPI-2690B|
41335656|NCT02251067|DRUG|VPI-2690B high dose|Comparison of different doses of study drug
41335657|NCT05251298|OTHER|"Coordination through the online platform JamesAKTIV"|"Coordination of the treatment through the online platform JamesAKTIV that allows neurologists and therapists to select specialised therapies for the predominant symptoms of the patients and communicate easily about problems during the treatment"
41335658|NCT05812768|DEVICE|Suture-Tight Suture Delivery System|Implantation of the Suture-Tight Suture in the deployment of multiple nitinol sutures to provide augmented fixation and sealing between endovascular aortic graft and the native artery.
41335659|NCT04488757|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a one hour fMRI scan with pain-induction using heat-based QST protocol.
41335660|NCT04488757|OTHER|Allostatic Load Composite|All participants will be asked to provide saliva samples to measure cortisol response over time and dehydroepiandrosterone (DHEA) in addition to physiological measurements such as blood pressure/pulse, height/weight, and waist-hip ratio. Measurements will be taken at baseline and 4-month follow-up.
41335661|NCT03855241|BEHAVIORAL|Informational Sheet|The informational sheet details how use opioid medicines safely, and lists ways to properly dispose of leftover opioids
41335662|NCT03855241|BEHAVIORAL|DisposeRx Drug Disposal kit|DisposeRx is a powder that is activated with water and traps leftover drugs (i.e. pills, capsules, caplets, liquids or tablets) in a semi-solid gel. The trapped drug cannot be retrieved from the resulting gel material for misuse, abuse or to leach into landfills. The participant can then throw away the biodegradable solid material in the prescription bottle into the trash, as it is safe for the environment.
41014833|NCT04537715|DRUG|Tazemetostat|A single, oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 24 ; and tazemetostat (oral 800 mg) twice daily on Days 3 - 14 and on Days 17 - 23.
41014834|NCT04537715|DRUG|Rifampin|Oral 600 mg rifampin once daily on Days 17 - 25.
41014835|NCT06445959|DRUG|Olutasidenib|Given by PO
41014836|NCT06445959|DRUG|Venetoclax|Given by PO
41335663|NCT05166395|DEVICE|Er:YAG laser|2940 nm Er:YAG laser treatment spread over 3 sessions within 4 weeks on participant's scar on either the head/neck, trunk or extremities.
41335664|NCT05452824|OTHER|Tai Chi Prehabilitation|The intervention arm will be oriented to a WaQi (youthful vitality) program 8 weeks prior to their scheduled surgery date. The WaQi program uses a Tai Chi curriculum previously successfully implemented in older adults, and at the Memorial Sloan Kettering Cancer Center (MSKCC). It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting or standing. Intervention participants will also receive printed materials from Prostate Cancer Canada about prostate cancer management. These materials include information about how to cope with prostate cancer including pelvic floor exercise, physical activity, healthy eating, and mental wellbeing.
41156277|NCT05878249|PROCEDURE|wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid|fter removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes.Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
41484570|NCT03308539|RADIATION|echocardiography and cardiac magnetic resonance|transthoracic echocardiography and magnetic resonance imaging of the heart
41484571|NCT05160467|DIAGNOSTIC_TEST|Segmental multi-frequency bio electrical impedance analysis|"A segmental (eight-polar) multi-frequency bio electrical impedance analysis (Inbody S10, Seoul, Korea) is carried out at the initiation of the deresuscitation strategy, at day 1, 3 and 5, in lying posture with touch type electrodes. Raw and derived parameters are recorded. The measurement is performed 5 times for the first measurement and then one time at day 1, 3 and 5.~Measurement error is defined by the manufacturer as: reversed Impedance in different segment all between 5-500kHz; impedance over 50Ω in trunk, or over 700Ω in limb; sudden drop of impedance in trunk (more than 10Ω), or in limb (more than 50Ω). If it occurs, measurement is carried out three times maximum after solving potential technical issues to obtain a valid analysis."
41484572|NCT06014749|PROCEDURE|undergo|regional anesthesia
41484573|NCT06014749|DEVICE|ultrasound|ultrasound guided
41484574|NCT06014749|DRUG|Local anesthetic|local anesthetic
41484575|NCT02756247|DRUG|Buparlisib|
41484576|NCT02756247|DRUG|Ibrutinib|
41484577|NCT05321225|DIAGNOSTIC_TEST|the level of biomarker in bood|Elisa is used to test the level of biomarker in blood.
41484578|NCT00329472|DRUG|gemcitabine, cisplatin|
41484579|NCT03032861|OTHER|Orange juice|Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
41484580|NCT06371144|DRUG|Paracetamol|Analgestic
41484581|NCT04882631|DRUG|PBI-100 Topical Cream|A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.
41484582|NCT04882631|DRUG|Positive Control - Sodium laurel sulfate (SLS)|Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.
41484583|NCT04882631|OTHER|PBI-100 Topical Cream, Vehicle|Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.
41484584|NCT04882631|OTHER|Negative Control|A blank patch was applied daily (excluding weekends) as a negative control test site.
41484585|NCT03082170|DEVICE|FEES|FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
41484586|NCT03082170|DIAGNOSTIC_TEST|SDQ|The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
41484587|NCT03082170|BEHAVIORAL|data review|Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
41484588|NCT05065983|BIOLOGICAL|CHIKV VLP, adjuvanted|Adjuvanted formulation includes aluminum hydroxide
41484589|NCT00522171|DEVICE|The Harmonic™ ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
41484590|NCT00838435|DRUG|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
41484591|NCT02963311|DRUG|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
41484592|NCT02963311|DRUG|Standard of Care|Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
41484593|NCT05438407|DRUG|Leniolisib|The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
41484594|NCT03869853|BEHAVIORAL|Entrepreneurial stimulation and integrated education|one month cycle of stimulation of business with integrated education on nutrition, health, and gender empowerment
41484595|NCT03869853|BEHAVIORAL|control|no intervention
41484596|NCT00312819|DRUG|chemotherapy +/- disulfiram|
41156278|NCT00424723|DRUG|Pemetrexed|Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.
41335665|NCT05452824|OTHER|Usual care|Control arm participants will receive printed materials identical to intervention arm participants with general information on a healthy lifestyle. The control arm will receive an 8-week online Tai Chi teaching module subscription at the end of the study.
40817396|NCT04322331|OTHER|no intervention|no intervention
41335666|NCT00635245|BIOLOGICAL|figitumumab|
41335667|NCT00635245|OTHER|imaging biomarker analysis|
41335668|NCT00635245|OTHER|laboratory biomarker analysis|
41335669|NCT00635245|OTHER|pharmacological study|
41335670|NCT00635245|PROCEDURE|conventional surgery|
40817397|NCT04871893|DEVICE|multiECCO2R blood-gas exchanger|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
40817398|NCT02689739|PROCEDURE|venous duplex ultrasound|Venous duplex ultrasound
41014837|NCT06445959|DRUG|Decitabine|Given by IV
41335671|NCT00635245|PROCEDURE|magnetic resonance spectroscopic imaging|
41335672|NCT00635245|PROCEDURE|neoadjuvant therapy|
40817399|NCT04608409|DRUG|Lapatinib and Paclitaxel|Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.
41484597|NCT06062849|DEVICE|nephrostomy tube|we will investigate if a nephrostomy tube really necessary after PNL operations
41484598|NCT06062849|DEVICE|double J stent|we will investigate if a JJ stent really necessary after PNL operations
41484599|NCT06062849|PROCEDURE|totally tubless|we will not insert any device after the procedure and investigate if a nephrostomy tube or JJ stent really necessary after PNL operations
40817400|NCT01747408|DRUG|Human Albumin|"25% human albumin given in four escalating doses:~1. Group 1: .625g/kg infused over 3hrs daily X 7day~2. Group 2: 1.25g/kg infused over 3hrs daily X 7day~3. Group 3: 1.875g/kg infused over 3hrs daily X 7day~4. Group 4: 2.5g/kg infused over 3hrs daily X 7day"
40817401|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~* At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition).~* Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour.~* For at least 1 hour after the participant is returned to their incubator (post-intervention condition).~The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch."
40817402|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~▪ For 24 hours once the participant reaches 36 weeks corrected gestational age."
40817403|NCT03658200|OTHER|FAST start software delay|Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
41484600|NCT01598350|DEVICE|Supramalleolar Orthoses (Cascade)|Walk wearing supramalleolar orthoses - three trial
40817404|NCT03658200|OTHER|Manual bolus tracking delay|Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
40817405|NCT02664168|DEVICE|Aquacel Ag Surgical Dressing|
40817406|NCT02664168|DEVICE|Single-Use Negative Pressure Wound Therapy (PICO)|
40817407|NCT05625789|BEHAVIORAL|Postural control (weight shift) training|Visual cues to improve amplitude of weight shift prior to initiating gait.
40817408|NCT05625789|BEHAVIORAL|Steady state gait training|Auditory cues are provided to increase amplitude of movement (e.g., step length) during continuous walking, to determine its effects on gait initiation amplitude of movement.
40817409|NCT03159169|DEVICE|Spinal Cord Stimulation (SCS)|Implantation of SCS electrodes and stimulator according to clinical standards
41484601|NCT00003174|DRUG|bryostatin 1|
41484602|NCT00003174|DRUG|cladribine|
41484603|NCT04751539|DRUG|AND017 single dose|AND017 administrated as oral single-dose on Day 1 in Part A
41484604|NCT04751539|DRUG|AND017 multiple dose|AND017 administrated once daily from Day 1 to Day 10 in Part B
41484605|NCT04751539|DRUG|Placebo|Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
41484606|NCT04616547|OTHER|Questionnaire Administration|Ancillary studies
41484607|NCT04616547|RADIATION|Tin Sn 117m Pentetate|Given IV
41484608|NCT00679536|DRUG|Busulfan|Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.
41484609|NCT00679536|DRUG|Fludarabine|Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m\^2/day.
41484610|NCT00679536|DRUG|Thymoglobulin|The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.
41484611|NCT00679536|RADIATION|Total Body Irradiation|On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
41484612|NCT03265613|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
41484613|NCT01713426|DRUG|Qutenza|Cutaneous patch
41484614|NCT01713426|DRUG|Pregabalin|Oral capsule
40817410|NCT05924698|OTHER|Electrostimulation|Consisting of the use of NMES (biphasic symmetrical pulse, bipolar mode, 50Hz frequency, pulse duration 300 μs at 1:1 ratio) (S82®; Enraf-Nonius BV, Rotterdam, The Netherlands). The self-adhesive electrodes (8x5 cm2 Pals Platinum © type, Axelgaard Manufacturing Co. Ltd, Fallbrook, CA, USA) were placed on the quadriceps muscle. The positives electrodes placed distally on the rectus anterior and vastus externus and negative electrodes were placed proximally on the rectus anterior and vastus internus. The over current program consisted of 8 seconds (s) of work (ON phase) and 8 seconds of rest (OFF phase). The overcurrent program in the ON phase had a rise time of 2 s, a hold time of 4 s and a fall time of 2 s. The intensity of the electric current was increased to the maximum perceived tolerance, achieving a clear contraction without producing fatigue.
41335673|NCT05725200|DRUG|Alectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
40817411|NCT05924698|OTHER|Blood flow restriction therapy|To attain partial vascular occlusion, a PTS ii portable tourniquet system (Delphi Medical, Vancouver, BC, Canada) with a corresponding size-specific tourniquet was placed around the patient's proximal thigh. This system allows for precise control of cuff pressure throughout training despite the changes in muscle volume that naturally occur while performing exercises. Total limb occlusion pressure (LOP) was identified by determining the pressure required to eliminate a detectable pulse using Doppler ultrasound. Partial vascular occlusion was achieved by setting the tourniquet to 80% of the LOP. This ensured that venous occlusion was obtained while still allowing arterial inflow and was personalized to each patient despite variations in thigh girth, cuff size, and systolic blood pressure. An Easy-Fit Tourniquet Cuff (Delfi Medical, Vancouver, VC, Canada) was used with the PTS ii system.
40817412|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 30 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
40817413|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 60 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
40817414|NCT05704907|OTHER|gallbladder ultrasound|gallbladder ultrasound
40817415|NCT02906449|BEHAVIORAL|Meditation Technique|Alertness training or relaxation training
40817416|NCT03290417|DIETARY_SUPPLEMENT|Vitamin D|5000 IU/cap; One cap by mouth daily
40817417|NCT03290417|DIETARY_SUPPLEMENT|Omega-3|720 mg/cap; one capsule by mouth 3 times per day
40817418|NCT03290417|DIETARY_SUPPLEMENT|Turmeric|250mg/cap; two capsules by mouth 4 times per day
40817419|NCT01986192|DRUG|rivaroxaban|
40817420|NCT01986192|DRUG|Warfarin|
40817421|NCT05366426|OTHER|EMG biofeedback program:|Superficial electrodes and EMG-guided biofeedback will be applied to the perineal region 3 days a week for 8 weeks, so that patients can receive visual and auditory feedback during exercise.
40817422|NCT05366426|OTHER|Sham EMG biofeededback:|3 days a week for 8 weeks; Surface electrodes will be attached as in the EMG Biofeedback group, but unlike the EMG biofeedback group, they will exercise without any visual and auditory feedback (1).
40817423|NCT05366426|OTHER|Pelvic floor muscle training home exercise program:|Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
40817424|NCT04566393|DRUG|Ulixertinib (BVD-523)|Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor
40817425|NCT02891148|DRUG|BI 690517|
40817426|NCT05093673|DEVICE|Cathodal Cerebellar tDCS|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes.
41014842|NCT06448481|PROCEDURE|Intra-dermal purse-string closure|Sutures are placed below the skin surface around a circular surgical wound, and the ends are cinched together like a coin purse.
41014843|NCT06448481|PROCEDURE|Transcutaneous purse-string closure|Sutures are placed through the skin surface around a circular surgical wound, and cinched together like a coin purse.
41014846|NCT06464939|DRUG|KH001|Applications of KH001 over a 1 or 2-week period, and application of placebo
41014847|NCT06464939|DRUG|Placebo|Applications of water for injection
41335674|NCT05725200|DRUG|Cetuximab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335675|NCT05725200|DRUG|Crizotinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335676|NCT05725200|DRUG|Dasatinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41484615|NCT01835379|DEVICE|Oasis|Oasis Ultra will be applied once per week for up to 12 weeks.
41484616|NCT01835379|OTHER|Standard|
41484617|NCT06438536|BEHAVIORAL|Virtual Reality-based Social Cognitive Training|Virtual reality assisted social cognitive training embedded in cognitive behavioral therapy, that aims at enhancing social cognition and daily life functioning.
41335677|NCT05725200|DRUG|Everolimus|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
41484618|NCT00673933|DRUG|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
41014848|NCT06244316|DRUG|rhNGF concentration 1|Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
41014849|NCT06244316|DRUG|rhNGF concentration 2|Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
41014850|NCT06244316|DRUG|Vehicle (Placebo solution)|Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.
41014852|NCT05211947|DRUG|BI 425809|BI 425809
41014862|NCT01886872|DRUG|Bendamustine Hydrochloride|Given IV
41484619|NCT04952077|DEVICE|MRI|Magnetic Resonance Imaging (MRI)
41484620|NCT04124666|BIOLOGICAL|Granulocytes|Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.
41484621|NCT04569448|DRUG|Brexpiprazole|Adjunctive variable dose (1-3 mg/day) Brexpiprazole
41014863|NCT01886872|DRUG|Ibrutinib|Given PO
41014864|NCT01886872|OTHER|Laboratory Biomarker Analysis|Correlative studies
41014865|NCT01886872|OTHER|Quality-of-Life Assessment|Ancillary studies
41014866|NCT01886872|BIOLOGICAL|Rituximab|Given IV
41484622|NCT01087632|DIETARY_SUPPLEMENT|Armolipid Plus|Armolipid Plus 1 tablet QD for 18 weeks
41335678|NCT05725200|DRUG|Encorafenib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335679|NCT05725200|DRUG|Gemcitabine|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
41335680|NCT05725200|DRUG|Idelalisib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335681|NCT05725200|DRUG|Larotrectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335682|NCT05725200|DRUG|Methotrexate|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335683|NCT05725200|DRUG|Palbociclib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335684|NCT05725200|DRUG|Panobinostat|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335685|NCT05725200|DRUG|Pembrolizumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335686|NCT05725200|DRUG|Petrozumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335687|NCT05725200|DRUG|Trastuzumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335688|NCT05725200|DRUG|Talazoparib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335689|NCT05725200|DRUG|Venetoclax|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
41335690|NCT04152746|OTHER|Periostin level|The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.
41484623|NCT01721811|OTHER|Hyperoxia|
41335691|NCT01964287|DRUG|GEMBRAX|
41335692|NCT01964287|DRUG|FOLFIRINOX|
41335693|NCT04399252|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Participants will take 2 capsules per day of either LGG or placebo.
41335694|NCT04399252|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG Placebo|Participants will take 2 capsules per day of LGG placebo
41335695|NCT02393222|OTHER|Observing effect of routine HD|Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
41335696|NCT00493194|DRUG|sirolimus|
41335697|NCT00493194|DRUG|cyclosporine|
41335698|NCT00493194|DRUG|daclizumab|
41484624|NCT01721811|OTHER|Glucose|
41484625|NCT05177562|OTHER|No intervention|There is no intervention in this study
41484626|NCT00798187|BEHAVIORAL|Group Meetings|10 weekly group meetings lasting 2 hours.
41335699|NCT00423592|DRUG|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
41335700|NCT06218199|DRUG|Furosemide|oral administration
40817427|NCT05093673|BEHAVIORAL|Semantic Feature Analysis (SFA)|Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.
40817428|NCT05093673|DEVICE|Sham|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
40817429|NCT03924063|DEVICE|Hemiverse|Implantation of the hemiverse shoulderprothesis
40817430|NCT01856049|OTHER|Collection of umbilical cord blood|Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.
40817431|NCT05470543|BEHAVIORAL|Nurse-led supportive care|Nurse-led supportive care was given to primary caregivers of women with breast cancer. Nurse-led supportive care was applied to primary caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 30 minutes to interview with primary caregivers at the clinic.
40817432|NCT00380991|DRUG|lactoserum|
40817433|NCT01534260|DRUG|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
40817434|NCT05898308|DRUG|RiTUXimab Injection|"Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels."
40817435|NCT04378465|OTHER|Enhanced Recovery Program (ERP)|An evidence-based perioperative care approach, involving a multidisciplinary team work including surgeons, anaesthesiologists, dieticians, and nurses, which aim to reduce the surgical stress and metabolic responses as well as organ dysfunction, thus leading to a faster recovery after surgery
40817436|NCT01771692|OTHER|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
40817437|NCT01771692|OTHER|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
41335701|NCT06218199|DRUG|Torsemide|oral administration
41014875|NCT06400238|PROCEDURE|Biopsy|Undergo biopsy
41014876|NCT06400238|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41014877|NCT06400238|PROCEDURE|Computed Tomography|Undergo CT scan
41014878|NCT06400238|DRUG|Copanlisib|Given IV
41014879|NCT06400238|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41014890|NCT06105554|DRUG|Belumosudil mesylate|Given by PO
41014891|NCT06294509|DEVICE|in-house developed transcutaneous auricular Vagus Nerve Stimulation device|taVNS in this study involves short electric pulses (0.25 ms) delivered to the ear's skin to activate the auricular branch of the Vagus. The pulses are current-controlled to ensure stability and delivered in a bipolar fashion to prevent skin irritation. Before each session, taVNS is calibrated for each participant. Starting at 0.1 mA, the intensity is increased stepwise until a comfortable maximum (typically 1.5-2.5 mA) is reached. Stimuli are delivered in short trains lasting 0.5 seconds each, with 13 pulses (0.25ms each) per train. Participants receive a maximum of 150 stimuli per session, totaling a maximum of 75 seconds of cumulative stimulation. Participants adapt their movements over up to six sessions across two weeks. The robotic task facilitates accurate movement tracking and provides interactive real-time feedback.
41014892|NCT06211634|DRUG|HMB-001|HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.
41014893|NCT05000996|PROCEDURE|Bariatric Surgery|Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)
41014895|NCT05554406|DRUG|Azacitidine|Given SC or IV
41014896|NCT05554406|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41014897|NCT05554406|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41014898|NCT05554406|DRUG|Cytarabine|Given IV
41014899|NCT05554406|DRUG|Daunorubicin Hydrochloride|Given IV
41014900|NCT05554406|PROCEDURE|Echocardiography|Undergo ECHO
41014901|NCT05554406|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
41335702|NCT06218199|DRUG|Bumetanide|oral administration
41335703|NCT06218199|DRUG|sacubitril/valsartan|oral administration
41335704|NCT06218199|DRUG|Hydralazine|oral administration
41335705|NCT06218199|DRUG|Isosorbide Dinitrate|oral administration
40817438|NCT05834933|BEHAVIORAL|Individualized breast cancer risk assessment|Individualized breast cancer risk assessment: The Nigerian Breast Cancer Study (NBCS) absolute risk prediction model was used to predict the 5-year and lifetime breast cancer risks of the participants. The model utilized individual breast cancer risk factors.
40817439|NCT05834933|BEHAVIORAL|Individualized breast cancer risk counselling|Individualized breast cancer risk counselling: The Principal Investigator (PI) and other trained risk counsellors discussed the results of the NBCS risk prediction model with participants and counselled them about the risk of developing breast cancer. The
40817440|NCT01794312|DEVICE|T4020|
40817441|NCT01794312|DEVICE|Vehicle|
40817442|NCT05594498|DEVICE|StrataXRT|StrataXRT is a silicone-based film-forming topical gel that may help in reducing radiation dermatitis.
40817443|NCT01451931|OTHER|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
40817444|NCT01451931|RADIATION|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
40817445|NCT01451931|OTHER|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
40817446|NCT04351464|OTHER|physical therapy and reflexology|
40817447|NCT04950712|PROCEDURE|Blood sampling|Blood samples for HSV-2 testing and for HIV test are collected from patients at screening visit (first visit).
40817448|NCT04950712|PROCEDURE|Anogenital lesion swab collection|Anogenital lesion swab of all lesions are collected at screening visit (only for newly infected HSV-2 patients) and at first genital HSV-2 recurrence during the study period.
40817449|NCT02498886|DIETARY_SUPPLEMENT|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
40817450|NCT02498886|DIETARY_SUPPLEMENT|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
41014902|NCT05554406|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41014903|NCT05554406|DRUG|Venetoclax|Given PO
41335706|NCT04504461|OTHER|Analysis of feasibility and costs|Analyze the feasibility and costs of performing laparoscopic inguinal hernioplasty in an ambulatory surgery center
40817451|NCT04599959|DIAGNOSTIC_TEST|Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol|Kylt® for detection/confirmation of SARS-CoV-2 cobas® SARS-CoV-2 (PCR) test TaqPath™ COVID-19 CE-IVD RT-PCR kit
40817452|NCT06032949|OTHER|Vialize|Any patients undergoing surgeries involving a groin incision (e.g., femoropopliteal bypass, aortofemoral bypass, loop thigh graft, femoral exposure for delivery of device) will receive Vialize subcutaneously.
40817453|NCT05058573|OTHER|Control group (n=22)|Control group will be received only medical treatment
40817454|NCT03252886|PROCEDURE|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
40817455|NCT05852262|DRUG|Cephalexin|1000 mg PO QID for 7 days
40817456|NCT05852262|DRUG|Cephalexin|500 mg PO QID plus oral placebo for 7 days
41014914|NCT06332534|DRUG|Upadacitinib|Oral Solution/ Extended-Release Tablets
40817457|NCT05115240|BEHAVIORAL|Body Scan|The body scan intervention aims to raise one's awareness of one's own body. It is considered a relaxation, meditation or mindfulness intervention. During the body scan participants will walk through his or her body by focusing their mind on specific body parts without analyzing, judging or reacting.
40817458|NCT05115240|OTHER|Audio-book|Participants listen to an audio book for the same amount of time as the body scan groups
40817459|NCT06224439|PROCEDURE|hypobaric spinal anaesthesia|0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
40817460|NCT06224439|PROCEDURE|lumbar plexus block|ultrasound and nerve stimulator will be used for lumbar plexus block
40817461|NCT00521391|OTHER|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
40817462|NCT05145764|DRUG|Suvorexant|Encapsulated suvorexant (matched for color, weight, and size)
41014915|NCT06533631|DEVICE|Portable low-field MRI (pMRI)|Participants will receive a pMRI during the study visit.
41014916|NCT06533631|DEVICE|3T MRI|Gold standard MRI for WMH. Participants will receive a 3T MRI during the study visit.
41484627|NCT00798187|BEHAVIORAL|Questionnaire|Surveys
41484628|NCT02473783|DRUG|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
41484629|NCT02473783|OTHER|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
40817463|NCT05145764|DRUG|Placebo|Encapsulated placebo (matched for color, weight, and size)
41484630|NCT02933762|DRUG|JNJ-54175446|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
40817464|NCT06560554|OTHER|Fermented foods|Participants randomized to the intervention arm will begin to incorporate probiotic fermented foods into their diet during weeks 1-4 of the study (ramp up phase). They will start with one serving of fermented food of their choice a day, increasing to 6+/day as tolerated by the end of week 4. Weeks 5-12 will serve as the intervention maintenance phase, with the target of a daily intake of 6+ servings of fermented foods.
41335707|NCT01282567|OTHER|Blood samples|The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
41335708|NCT02771457|DRUG|Infliximab at weeks 0,2, and 6|
41335709|NCT02771457|DRUG|Infliximab at weeks 0,4, and 8|
41335710|NCT02771457|DRUG|Infliximab at weeks 0 and 8|For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
41335711|NCT00766064|DRUG|Paliperidone|"Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily\*, Week 6: fixed dose,~\*Criteria to increase the dose from 3 mg to 6 mg daily are 1\] absence of any side effects, 2\] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline."
41335712|NCT06423170|DRUG|Camrelizumab plus GEMOX|"1. Camrelizumab：200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : oxaliplatin 100mg/m2，D1, gemcitabine1000mg/m2，D1，intravenous infusion.~3. Carrilizumab and GEMOX chemotherapy will be intravenous infused atone day. Three weeks is a course of treatment,a total of 6-8 courses."
41335713|NCT04509362|DEVICE|Advanced Hybrid Closed Loop System|Evaluation of the use of an 8-day structured protocol to initiate patients from MDI to the AHCL system, in achieving safe glycemic control
41484631|NCT02933762|DRUG|Placebo|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
41484632|NCT02494102|DRUG|Modafinil|Atypical Psychomotor stimulant
41484633|NCT02494102|DRUG|Placebo|
41484634|NCT04968860|OTHER|This study is observational|"* Clinical evaluation of the oral health condition~* Microbiota evaluation by analyzing the collected saliva~* Application of questionnaires of quality of life"
41156279|NCT06512116|DRUG|SIBP-A17|"Strength: 1, 2, 4, 5, 6 or 8 mg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle.~The dose escalation stage, 1mg/kg and 2mg/kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored, and the dose exploration starting from 4mg/kg will adopt a 3+3 dose escalation design."
41484635|NCT04801953|DRUG|NiMODipine Injectable Solution|nimodipine solution is applied to cranial nerves during resection of vestibular schwannoma
40817465|NCT06560554|OTHER|Control|No information on incorporation of fermented foods will be provided for subjects in the control arm.
40817466|NCT05791565|DRUG|Salbutamol HFA-152a|Salbutamol HFA-152a will be administered.
40817467|NCT05791565|DRUG|Salbutamol HFA-134a|Salbutamol HFA-134a will be administered.
40817468|NCT06007170|DEVICE|SPIRION Laryngeal Pacemaker System Implantation and follow-up|"Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives"
40817469|NCT01329653|BEHAVIORAL|aerobic training|12 weeks of aerobic training, 4X/week
41156280|NCT05451810|DRUG|Epcoritamab|Subcutaneous Injection (SC)
41156281|NCT00448786|DRUG|AMG 706|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
41156282|NCT00448786|DRUG|AMG 706|Arm C - 75 mg BID 5-days on, 2-days off
41484636|NCT04801953|OTHER|Placebo|Sodium chloride solution is applied to cranial nerves during surgery
41484637|NCT04928534|DIAGNOSTIC_TEST|Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination|"1. Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.~2. Cognitive function tests, including RPQ, MMSE and MoCA.~3. Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination"
41484638|NCT03090997|DIETARY_SUPPLEMENT|vitamin C (500 mg / day) + placebo|Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
40817470|NCT01329653|BEHAVIORAL|Wait list|wait list control condition
40817471|NCT05997992|DEVICE|electroacupuncture|Electroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
40817472|NCT05997992|DEVICE|sham acupuncture|Acupuncture does not penetrate the skin, and the electroacupuncture machine is not plugged in.
40817473|NCT01906723|DEVICE|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
40817474|NCT05339490|DRUG|Progenitor Biological Bandages|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, PBB will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1. Old PBB will be replaced by new ones according to the local procedure.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
40817475|NCT05339490|DEVICE|Jelonet|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, Jelonet, as standard bandages, will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
40817476|NCT06483555|DRUG|Gemcitabine|1000 mg/m2, intravenously on day 1 and day 15, for subjects with basal-like cell type pancreatic carcinoma.
40817477|NCT06483555|DRUG|Nab paclitaxel|125 mg/m2 intravenously on day 1 and day 15 for subjects with basal-like cell type pancreatic carcinoma.
40817478|NCT06483555|DRUG|Erlotinib|50 mg per oral daily. for subjects with basal-like cell type pancreatic carcinoma.
40817479|NCT06483555|DRUG|NALIRIFOX|Subjects with classical pancreatic adenocarcinoma will receive. NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin. Dosing and plan will be decided by the treating physician.
40817480|NCT06483555|DRUG|Folfirinox|Subjects with classical pancreatic adenocarcinoma will receive. Dosing and plan will be decided by the treating physician.
40817481|NCT04984265|RADIATION|Stereotactic Body Radiation Therapy|SBRT targeting the area of the circuit of Ventricular Tachycardia
40817482|NCT03826654|DIETARY_SUPPLEMENT|fortified oil|35 g fortified sunflower oil
40817483|NCT03826654|DIETARY_SUPPLEMENT|Placebo|plain oil
40817484|NCT05279924|DRUG|Prophylaxis with Emicizumab|Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
41014919|NCT02073422|DEVICE|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
41014920|NCT02073422|OTHER|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
41014921|NCT06055075|DRUG|Forimtamig|Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
41014922|NCT06055075|DRUG|Carfilzomib|Carfilzomib will be administered via IV infusion in combination with forimtamig.
40817485|NCT04686084|DEVICE|Dual-energy computed tomography scan|Diagnostic CT scan
40817486|NCT04720040|DEVICE|Mind STIM|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
41014923|NCT06055075|DRUG|Daratumumab|Daratumumab will be administered via SC injection in combination with forimtamig.
41014924|NCT06276478|OTHER|AI-video|Video administration for the explanation of the dental procedures followed by verbal instructions.
41014925|NCT06276478|OTHER|Verbal instructions|Only verbal instructions will be administered for the explanation of the dental procedures
41014926|NCT05826353|DRUG|Ripasudil|K-321 ophthalmic solution
41014927|NCT05826353|DRUG|Placebo|Placebo ophthalmic solution
41156283|NCT00448786|DRUG|AMG 706|AMG 706 125 mg daily continuously (Arm A)
40817487|NCT06116539|DRUG|Cyanoacrylate|In the test group, a cyanoacrylate-based tissue adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
41335714|NCT03004976|BIOLOGICAL|Umbilical Cord Blood|Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10\^7 TNCC/kg.
41335715|NCT03004976|OTHER|Placebo|The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 \[pink\]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.
41484639|NCT03090997|DIETARY_SUPPLEMENT|resveratrol (500 mg / day) + placebo|Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
41484640|NCT03090997|DIETARY_SUPPLEMENT|vitamin C (500 mg / day) and resveratrol (500 mg / day)|Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
41484641|NCT01744119|DEVICE|Vascutek Anaconda™ Stent Graft System|
41484642|NCT05492370|DIETARY_SUPPLEMENT|EpiCor|2 gummies daily
41484643|NCT05492370|DIETARY_SUPPLEMENT|Placebo|2 gummies daily
40817488|NCT06116539|PROCEDURE|Suture|After harvesting the full-thickness connective tissue graft, the edges of the control group will be approximated with 4/0 non-absorbable monofilament nylon suture (Aragó, Barcelona, Spain).
40817489|NCT02946567|OTHER|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
41156284|NCT02509754|PROCEDURE|Atrial fibrillation catheter ablation|
40817490|NCT02946567|OTHER|Generic Game|Participants will play a generic game without any particular information about hearing health care.
40817491|NCT02743949|DRUG|Vonoprazan|Vonoprazan over-encapsulated capsules
40817492|NCT02743949|DRUG|Esomeprazole|Esomeprazole over-encapsulated tablets
40817493|NCT02743949|DRUG|Esomeprazole Placebo|Esomeprazole placebo-matching capsules
40817494|NCT02349191|PROCEDURE|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
40817495|NCT02109432|BEHAVIORAL|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
40817496|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
41156285|NCT02509754|PROCEDURE|Rate control|Composite of optimal medical therapy and device implantation
41335716|NCT03814681|OTHER|Colorectal Surgery|elective Colorectal Surgery
41335717|NCT04514588|DIETARY_SUPPLEMENT|caffeine consumption|In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight
41335718|NCT03174769|OTHER|Normal protein|Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
41335719|NCT03174769|OTHER|High protien|Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
41335720|NCT06161688|DRUG|Ensitrelvir|Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days
41156286|NCT03661749|OTHER|clean catch|clean catch technique applied to collect urine for PR/CR ratio
41156287|NCT00015171|DRUG|Buprenorphine/naloxone|
41335721|NCT06161688|OTHER|Placebo|Matching placebo for Ensitrelvir
41335722|NCT04629196|DRUG|Ustekinumab|A second IV weight-based induction dose of Stelara at week 8
41484644|NCT03875937|DRUG|Tranexamic 1 gram|To be administered intramuscularly (2 injections)
41484645|NCT03325972|DRUG|Dexmedetomidine|The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
41484646|NCT03325972|OTHER|Placebo Saline|Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
41484647|NCT04076384|BEHAVIORAL|Guided Self-Determination|Structured team-based consultations
41335723|NCT04629196|DRUG|Ustekinumab|A standard 90mg subcutaneous dose of Stelara at week 8
41335724|NCT04629196|DRUG|Ustekinumab|All patients will receive IV ustekinumab weight-based dose at 260mg (55kg or less), 390mg (more than 55kg to 85kg), or 520mg (more than 85kg) at time point 0
41335725|NCT03455062|OTHER|Questionnaire about fertility|"Recruitment of participants through the list of cardiac, renal, hepatic, pancreatic or pulmonary transplant patients collected from the the Organ Transplant Unit.~A letter from the the Organ Transplant Unit will initially be sent to patients informing them of the study and if they do not wish to participate they can report their opposition by email.~A fertility questionnaire will be send and that will have to be returned by the patient in order to be included in the study.~The questionnaires, anonymous, will be numbered according to their order of return."
41335726|NCT00087386|DRUG|tanespimycin|Given IV
41335727|NCT00087386|OTHER|laboratory biomarker analysis|Correlative studies
41335728|NCT05524558|DEVICE|Pulmonary artery catheter|PAC already in place
41335729|NCT05524558|DEVICE|Esophagal pressure|Esophagal pressure already in place
41335730|NCT04069624|BEHAVIORAL|MOUD Pre-Treatment Telehealth|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
41335731|NCT04069624|BEHAVIORAL|MOUD Pre-Treatment Telehealth and Peer Navigator|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
41335732|NCT04069624|OTHER|Services as Usual|Medications to treat opioid use disorder (MOUD) pre-treatment.
41335733|NCT01261260|DRUG|Uridine|1 gram tablets BID for 7 days
41335734|NCT03983460|DRUG|Dupilumab|Each single used prefilled syringe contains 300 mg of Dupilumab in 2 mL solution (150mg/mL) Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signaling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
41484648|NCT04076384|BEHAVIORAL|Standard care|Standard consultations
41335735|NCT03983460|DRUG|Optimized TCS treatment|Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
41335736|NCT03983460|PROCEDURE|Biopsies|"Four skin biopsies (5 mm diameter) and ten microbiopsies (2 \& 3 mm diameter) will be performed according the following schedule:~* Day 0~  * a 5 mm section biopsy from a non-lesional skin~ * a 5 mm section biopsy from an active lesion~ * a 3 mm section microbiopsies from a non-lesional skin~ * a 3 mm section microbiopsies from an active lesion~ * a 2 mm section microbiopsies from a non-lesional skin~ * a 2 mm section microbiopsies from an active lesion~* Day 28~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion~* Day 168~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non-lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion"
41484649|NCT05747521|DRUG|Anrotinib hydrochloride combined with adriamycin|To evaluate the efficacy of anrotinib hydrochloride combined with doxorubicin in the neoadjuvant treatment of high-grade soft tissue sarcoma
41484650|NCT00209846|DRUG|Gaboxadol|
41484651|NCT00455611|DEVICE|CPAP (Continuous Positive Airway Pressure)|
41484652|NCT05098002|BEHAVIORAL|Mindfulness program|6 week class designed to improve psychological well-being
41484653|NCT02608151|OTHER|massage with oil|Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
41484654|NCT02608151|OTHER|massage without oil|
41484655|NCT04975074|DRUG|Iron|One of each type of iron was taken orally according to the instructions and followed every two weeks
40817497|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
40817498|NCT01925118|BIOLOGICAL|Irradiated donor lymphocyte infusion|
41014928|NCT04411043|BEHAVIORAL|Molecular caracterization|Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T
41014929|NCT03056690|DRUG|ASP0819|Oral capsule
41014930|NCT03056690|DRUG|Placebo|Oral capsule
41017965|NCT06202261|DRUG|Eribulin mesylate injection|Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.
41017966|NCT06202261|DRUG|gemcitabine hydrochloride for injection|Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
41017967|NCT00149708|DRUG|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
41017968|NCT03766009|OTHER|Usual Care|Usual Care
41017969|NCT03766009|OTHER|Web-based decision aid|Web-based decision aid received prior to the surgical consultation
41484656|NCT04370951|PROCEDURE|Erector Spinae Plane Block - Ultrasound guided|20mls 0.25% Levobupivicaine ultrasound guided bilaterally
41335737|NCT03983460|PROCEDURE|Skin prick-test|"Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~* Negative control : saline solution~* Positive control : histamine solution~Positive criteria of prick tests results are:~* Positive control's diameter ≥ 3mm~* And negative control's diameter \< 3 mm~* And tested allergen with wheal ≥ positive control, i.e. 3mm"
41017970|NCT03194763|DIAGNOSTIC_TEST|coronary angiography|computed tomography acquisitions performed on a revolution CT
41335738|NCT03983460|PROCEDURE|Blood sample collection|"A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA."
41335739|NCT01324128|DRUG|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
41335740|NCT01324128|DRUG|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
41335741|NCT01324128|DRUG|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
40817499|NCT05898776|DEVICE|Lung transplantation after 10°C donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.
40817500|NCT05898776|DEVICE|Lung transplantation after standard ice cooler donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (\~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.
40817501|NCT05322512|DRUG|18F-FDG|All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
40817502|NCT05472909|OTHER|Standardized Relaxation Music|Participants listen to standardized relaxation music during surgery.
40817503|NCT05472909|OTHER|Personal Choice of Music|Participants listen to their preferred music during surgery.
41484657|NCT03812705|BIOLOGICAL|fecal microbiome transplantation|"1. Stop antibiotics treatment 1 day before fecal microbiome transplantation;~2. Fasting food 6 hours before fecal microbiome transplantation;~3. Give Ondansetron intravenously 1 hour before fecal microbiome transplantation for vomiting prevention;~4. Perform fecal microbiome transplantation under colonoscopy or gastroscopy;~5. Perform up to 4 times if patient response;~6. Stop if no response after twice fecal microbiome transplantation."
41335742|NCT02836080|BEHAVIORAL|Integrated Collaborative Care Team (ICCT)|An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.
41335743|NCT02836080|OTHER|Treatment as Usual (TAU)|Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
41335744|NCT03633513|DIAGNOSTIC_TEST|LBT-3627|Immunomodulatory agent
41335745|NCT03633513|DIAGNOSTIC_TEST|Immunological profiling|Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
41335746|NCT03002285|BEHAVIORAL|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
41335747|NCT03002285|BEHAVIORAL|Control group|Group with typical development that performed the Fitts law in a computer task
41335748|NCT03944304|DRUG|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
41335749|NCT00510107|DRUG|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
41335750|NCT00510107|DRUG|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
41335751|NCT00169039|DRUG|Clozapine|
41335752|NCT00169039|DRUG|Chlorpromazine|
41335753|NCT02583516|DRUG|vemurafenib and cobimetinib|Comparison between different treatment regimens
41335754|NCT02323399|DRUG|Phenylephrine|one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level\]; each initial treatment group will have two PK sampling schedules.
40817504|NCT06563180|BEHAVIORAL|Health-Promoting Lifestyle Profile II|"health promoting lifestyle behaviors (HPLBs). It included fifty-two elements within six dimensions: Physical activity, nutrition, spiritual growth, interpersonal relations, stress management, and health responsibility. Higher scores refer to higher adherence levels to healthier lifestyle behaviors. The total score ranged from (52 to 208). It used a four-point likert scale, ranged from one (never) to four (routinely) . The total score will be classified into four levels:~* Poor for the range 52-90~* Moderate for the range 91-129.~* Good for the range 130-168.~* Excellent for the range 169-208."
41335755|NCT02936336|OTHER|exercise|circuit exercise, aerobic dance and Tai Chi exercise
41335756|NCT05674604|PROCEDURE|Cryoneurolysis|This is on observational study. All participants are already candidate for cryoneurolysis. Cryoneurolysis uses a cold probe to generate an ice ball, which initiates Wallerian Degeneration, a process where axon is destroyed but the epineurium and perineurium remain intact. The treated nerve is able to regenerate over time due to this preserved tube.
41335757|NCT05308667|OTHER|Rehabilitation (modified constraint-induced movement therapy)|Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
41335758|NCT05308667|OTHER|non-invasive brain stimulation (intermittent theta-burst stimulation)|Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
41335759|NCT00405236|DRUG|tiotropium|
41335760|NCT02613091|DRUG|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
41335761|NCT00383708|DRUG|lanreotide (Autogel formulation)|120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
41335762|NCT00383708|DRUG|Pegvisomant|Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
41335763|NCT03647176|OTHER|Cold snare polypectomy|cold snare polypectomy (CSP), which does not include electrocautery to do a polypectomy with a snare
41335764|NCT06241820|PROCEDURE|Lumbar Sympathetic Ganglion Block|A needle will be inserted at the L3 on the side experiencing pain, either right or left, under fluoroscopy guidance. Once the needle is positioned in front of the desired vertebral body, its location is confirmed using a contrast medium. If the position is well visualized in lateral and anteroposterior (AP) views, 7 mL of 0.5% ropivacaine will be injected.
41335765|NCT04688411|BEHAVIORAL|MED-Go App|A novel multifunctional mobile app (MED-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
41335766|NCT01674816|DEVICE|Repeated Measurements of Knee Alignment and Kinematics|Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.
41335767|NCT01674816|DEVICE|Computer Guidance of Surgical Actions|Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
41484658|NCT05798156|DRUG|Glofitamab|Glofitamab is a fully humanized, engineered monoclonal bivalent antibody of the IgG1 isotype.
41484659|NCT05798156|DRUG|Rituximab|Rituximab is a genetically engineered chimeric mouse/human anti-CD20 monoclonal antibody
41484660|NCT05798156|DRUG|Obinutuzumab|Obinutuzumab is a fully humanized, glycoengineered type II monoclonal antibody of the IgG1 isotype that binds to an epitope on CD20
40817505|NCT04442126|BIOLOGICAL|NM21-1480|Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein
40817506|NCT02384473|PROCEDURE|Real-Time CEUS|Undergo real-time CEUS
40817507|NCT02384473|PROCEDURE|SWE|Undergo SWE
40817508|NCT02384473|DRUG|Definity Suspension for Injection|Participant will receive contrast agent by intravenous administration
40817509|NCT02384473|DEVICE|Philips Shear Wave Elastography|Type of equipment used for SWE
40817510|NCT02465723|DEVICE|MRI with IVIM DW-MRI|
40817511|NCT02465723|OTHER|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
40817512|NCT02169024|BEHAVIORAL|Expect With Me group prenatal care|Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.
40817513|NCT02169024|OTHER|Standard individual prenatal care|Standard of care- individual prenatal care
40817514|NCT04027049|DEVICE|Supine cycle ergometry of the lower extremities|The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
40817515|NCT06372171|DIETARY_SUPPLEMENT|Satge 1|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 1-10 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 11-20
40817516|NCT06372171|DIETARY_SUPPLEMENT|Stage 2|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 11-20 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 1-10
40817517|NCT04444986|DRUG|FAVIR 200 MG FT|FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
41335768|NCT05382988|DRUG|Sodium zirconium cyclosilicate|The experimental group was required to take SZC 10g at 6 am on the day of surgery.
41335769|NCT05556915|OTHER|Ultrasound-guided AVF cannulation method|For ultrasound-guided cannulation, the same ultrasound device will be used for all patients (TE5-POC ultrasound MINDRAY® system). The ultrasound device will identify the AVF aspect , the location including the depth (distance from the skin surface) , the vessel diameter and guide the cannulation in real-time. The device will be disinfected between uses and covered with a transparent adhesive film to avoid any direct contact with the patient. Sterile gel will be used for the cannulation.
41335770|NCT05556915|OTHER|Conventional AVF cannulation method|The AVF cannulation is carried out by palpation. This technique consists of manually evaluating the position, direction and depth of the fistula in order to determine the puncture site where the 2-dialysis catheters will be inserted. After local asepsis, the AVF is therefore needled at 2 points 5 cm apart.
41335771|NCT03198104|DEVICE|MRI|
41335772|NCT03385434|DEVICE|Endorings-2|292 patients with an indication for screening colonoscopy will be included. 146 patients will receive a standard colonoscopy and 146 patients will receive an Endorings-2 assisted colonoscopy (1:1 standard colonoscopy vs Endorings-2-assisted colonoscopy).
41335773|NCT01026350|DIETARY_SUPPLEMENT|colostrum enriched with anti flu antibodies|each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
40817518|NCT04444986|DRUG|AVIGAN 200 mg FT|AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
40817519|NCT05469815|BEHAVIORAL|Lost Children Society Game|36 online therapeutic role-playing sessions spread over 36 weeks, one session per week
40817520|NCT04916366|OTHER|Kinesio taping|Kinesio taping in a bandage to treat musculoskeletal pain.
40817521|NCT04916366|OTHER|Conventional bandage|It will be used a conventional bandage applicated in the same neck region than kinesio taping intervention.
41335774|NCT03309904|OTHER|Knee Control training program|10-minute training program to be performed at all team training sessions during the season.
41484661|NCT05798156|DRUG|Polatuzumab vedotin|Polatuzumab vedotin is an antibody-drug-conjugate that contains a humanized IgG1 anti-CD79b monoclonal antibody (MCDS4409A) and a potent anti-mitotic agent (MMAE) linked through a protease-cleavable linker.
41484662|NCT02857738|DRUG|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
40817522|NCT06132477|DRUG|GLP-1 receptor agonist|Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
40817523|NCT03584841|DIAGNOSTIC_TEST|Iontophoresis sessions in forearm of subjects with pilocarpine|The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.
40817524|NCT02615691|BIOLOGICAL|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII).
40817525|NCT02615691|BIOLOGICAL|ITI|Immune tolerance induction therapy
40817526|NCT01140997|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
40817527|NCT01140997|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
40817528|NCT04989205|BEHAVIORAL|Cannabis cessation Program|Lundqvist and Ericsson developed the 'Cannabis Cessation Program' (CCP, Nordic abbreviation: HAP) in Sweden in the 1990s. The method uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising \~15 individual sessions. It describes a medical, a psychological, and a social phase, in which the participant is helped to recognize and address typical problems related to each phase, e.g., physical and psychological withdrawal problems. The overarching aim of the program is to help cannabis users to reorganize thinking patterns that developed while they were using cannabis and increase their social and psychological coping skills in relation to quitting cannabis use. The CCP manual has been translated into eight languages, e.g., Norwegian.
40817529|NCT06354790|OTHER|Motor evaluations|Evaluation of patients motor function using motor scales (MFM32, RULM), Timed functioned tests (6MWT, Rise from floor, 4SCT, 10mWT), dynamometric strength evaluation (grip, pinch, flexion/extension)
40817530|NCT06354790|OTHER|Cognitive assessment|Patients cognitive evaluation (WPPSI-IV, WISC-V)
41335775|NCT03254862|PROCEDURE|CSS/AsynS|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Sequential Stimulation (ASynS) on the other leg
41335776|NCT03254862|PROCEDURE|CSS/AsynR|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Random Stimulation (ASynR) on the other leg.
41335777|NCT04798846|PROCEDURE|dorsal plating|Spanning Plate inserted dorsally below tendons Spanning External Fixator by rods inserted in distal radius and metacarpals
41335778|NCT02566876|DRUG|Mixture of three Bifidobacteria|This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
41335779|NCT05401903|OTHER|Chiropractic Maintenance Care|"Subjects will receive high-velocity, low amplitude (HVLA) chiropractic manipulations to areas of defined restriction in the upper cervical spine, thoracic spine, lumbar spine, and pelvis. The clinician will use motion palpation to determine spinal segments with joint restrictions. Subjects will schedule weekly chiropractic visits.~The clinician will not use passive care modalities. The exclusions of passive modalities include heat and cold therapies, electric stimulation, massage, acupuncture, and cupping therapies. Subjects will be encouraged to maintain normal exercise activity levels throughout the study. The clinician will provide instructions on homecare exercises as needed to promote range of motion of spinal segments between chiropractic visits. A single clinician will deliver the HVLA chiropractic manipulations to ensure consistency of chiropractic care throughout the study."
41335780|NCT02329145|PROCEDURE|renal denervation|
41335781|NCT04595409|DRUG|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive 1 subcutaneous (SC) injection of FYB202 at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
40817531|NCT06354790|OTHER|Pulmonary function test|Evaluation of patients' respiratory function (FVC, PCF, MIP, MEP, SNIP)
41335782|NCT04595409|DRUG|Stelara® (Ustekinumab)|Patients will receive 1 subcutaneous (SC) injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
41335783|NCT04140370|OTHER|There is no intervention|There is no intervention
41335784|NCT02456792|PROCEDURE|IVF|Women will undergo one IVF cycle
40817532|NCT06354790|OTHER|Cardiac evaluation|Evaluation of patients' cardiac function (ECG, Echo-cardiography)
40817533|NCT06354790|OTHER|Quality of life|Evaluation of patients quality of life with questionnaires and PROM
40817534|NCT06354790|OTHER|Spine X Ray|Evaluation of spinal deformities by X-ray
40817535|NCT06354790|OTHER|Muscular MRI|Evaluation of a qualitative whole-body muscle part and a quantitative lower limb muscle part by MRI
40817536|NCT06354790|OTHER|Biomarkers collection and analysis|Collection of blood and urinary sample for biomarkers research.
41335785|NCT02456792|PROCEDURE|LOD|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
41335786|NCT04752917|DEVICE|Noise Cancelling headphones|Use of headphones playing patients choice of music
41014981|NCT04948697|DRUG|Ociperlimab|900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
41014982|NCT04948697|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
41014983|NCT04948697|DRUG|BAT1706|15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
41484663|NCT02857738|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
41335787|NCT05904938|DEVICE|Lenodiar Pediatric|Medical Device made of natural substance
41335788|NCT05904938|OTHER|Placebo|Product appearance similar to verum without clinical efficacy
41335789|NCT05702372|OTHER|Glucose as reference food|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
40817537|NCT05016661|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
41335790|NCT05702372|OTHER|Cracker made by wheat flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by wheat flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
41335791|NCT05702372|OTHER|Cracker made by rye flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by rye flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
41335792|NCT05702372|OTHER|Cracker made by sunflower flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from sunflower flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
41335793|NCT03363165|DRUG|VM202|"Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with evidence of PAD. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
41335794|NCT03363165|OTHER|Placebo|"Participants randomized to placebo will receive calf muscle injections of placebo (the excipient buffer formulation minus the VM202) to each leg with evidence of PAD. Injections of placebo are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Placebo appears identical to the VM202 study drug and is administered in a pattern on the calf identical to that of the VM202 injections.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
40817538|NCT05643196|DEVICE|PLIFUS|The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.
41014985|NCT02091518|BEHAVIORAL|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
41335795|NCT02575989|OTHER|1: control group|Classic - current management of trauma patients by French medical teams
41335796|NCT02575989|OTHER|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~* Continuous monitoring of body temperature~* Ambulance warming (target : 30°C)~* Patient warming with dedicated blanket~* Infusion fluid warming (and temperature control)"
41014986|NCT02091518|DEVICE|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
40817539|NCT05643196|DEVICE|Sham PLIFUS|Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.
40817540|NCT05643196|DEVICE|MRI|A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
41014987|NCT06274554|DRUG|Fluconazole|Oral fluconazole capsules.
41014988|NCT06274554|DRUG|Placebo|Oral placebo capsules will be used as a comparator.
41014989|NCT06274554|BIOLOGICAL|IL-23 Therapy|Risankizumab (IL-23) or Ustekinumab (IL-12/23) as standard of care treatment.
40817541|NCT05556421|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
41014991|NCT03895853|OTHER|Best Practice|Receive standard of care
41014992|NCT03895853|DIETARY_SUPPLEMENT|early metabolic resuscitation|Given Intravenous
41014993|NCT05673720|DEVICE|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session for 5 times via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session for 5 times by a recorded meditation.
41014994|NCT05673720|DEVICE|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
41015003|NCT05414240|DRUG|Ibudilast|IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
41335797|NCT00396305|DRUG|Placebo|Sterile phosphate buffered saline solution.
41484664|NCT02754466|OTHER|Subjective vs objective criteria in selective excavation|Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions
40817542|NCT05634733|OTHER|Treatment of Sepsis|Patients will have standard care of sepsis
40817543|NCT02140008|DEVICE|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
41015004|NCT05414240|BEHAVIORAL|Medical management|All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.
40817544|NCT02140008|DEVICE|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
40817545|NCT02104596|DEVICE|Xylitol|
40817546|NCT02450448|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
40817547|NCT02450448|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
40817548|NCT06515184|DRUG|PharmaNord Bio-Quinone Active CoQ10 Gold 100mg|"Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
41015005|NCT05414240|DRUG|Placebo|Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
41484665|NCT02754466|OTHER|Glass-ionomer vs Bulk fill composites in the ART approach|High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
41484666|NCT02895815|COMBINATION_PRODUCT|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 \* 10\^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit \[SRAK-02 kit\] and third arm accessory).
41484667|NCT02895815|COMBINATION_PRODUCT|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 \* 10\^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
41484668|NCT00039026|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
41335798|NCT00396305|BIOLOGICAL|Trivalent Inactivated Influenza|The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
41484669|NCT00039026|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
41484670|NCT00039026|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
41484671|NCT00039026|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
40817549|NCT06515184|DRUG|PharmaNord Placebo|"Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
40817550|NCT06515184|DRUG|PharmaNord Bio-Quinone Active CoQ10 Gold 100mg|"Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
41015018|NCT06133582|BEHAVIORAL|Internet Based Psychodynamic Psychotherapy|"This is a 10-week intervention, delivered on a website called 'Iterapi' which was developed in Sweden. The programme involves creative and interactive web-based content- worksheets, audio, video, expressive writing exercises. Additionally, each participant is assigned a Therapeutic Support Worker (TSW). The TSW logs into the platform and views the questionnaires and other data provided by the participants that they are supporting. Each week, the TSW sends each of their participants a reflective message in response to the data they have provided when interacting with the programme over the last week. The participant can reply to this message.~The principal objective of the iPDT intervention is to reduce depressive symptoms through the promotion of emotional awareness and emotional experience. The intervention is an affect-focused therapy and draws on Malan's Triangle of Conflict (Malan, 1995)."
41015019|NCT04316546|DRUG|MK-7075 (miransertib)|MK-7075 (miransertib) is a small molecule developed by ArQule Inc., a wholly owned subsidiary of Merck Sharp \&amp; Dohme (Merck), that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a Phase 2 trial investigating the efficacy of miransertib as a treatment for adult and pediatric patients with Proteus syndrome.
41015020|NCT05563220|DRUG|Elacestrant|Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
41015021|NCT05563220|DRUG|Alpelisib|Alpelisib 250 mg or 300 mg once daily in cycles of 28 days
41015022|NCT05563220|DRUG|Everolimus|Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days
41335799|NCT02811172|OTHER|BEhavior of biomarkers during pregnanCy and lactatiOn|
41484672|NCT00010608|BEHAVIORAL|Transcendental Meditation|a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
41484673|NCT00010608|BEHAVIORAL|Health Education|didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake
41484674|NCT00793026|DRUG|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
41484675|NCT03955471|DRUG|Niraparib|Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
41484676|NCT03955471|DRUG|Dostarlimab|TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).
41015023|NCT05563220|DRUG|Ribociclib|Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
41015024|NCT05563220|DRUG|Palbociclib|Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days
41015025|NCT05563220|DRUG|Capivasertib|Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days
41015026|NCT05563220|DRUG|Abemaciclib|Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
41015029|NCT05281731|DEVICE|Sonobiopsy|Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy
41484677|NCT03766490|DRUG|Anlotinib Hydrochloride|Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle
41484678|NCT03766490|DRUG|Gefitinib|Tablet, P.O. 250mg qd
41484679|NCT03766490|DRUG|Icotinib|Tablet, P.O. 125mg tid
41335800|NCT05200728|DRUG|SIM1910-09|"Part A-single ascending doses， SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose."
41335801|NCT05200728|DRUG|Placebo|"Part A-single ascending doses， placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose."
41484680|NCT03424512|BEHAVIORAL|Group Metacognitive Therapy|Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
41484681|NCT02107326|DEVICE|Webdia Software|
41484682|NCT01400620|DRUG|IZN-6N4|Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
41484683|NCT02573753|BEHAVIORAL|Sleep restriction|
41484684|NCT02573753|DIETARY_SUPPLEMENT|Weight gain|
41484685|NCT05733520|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
41484686|NCT05733520|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
41484687|NCT04419623|DRUG|TL-895|TL-895, administered by mouth
41484688|NCT05104463|DRUG|CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107|CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
41484689|NCT03733210|DRUG|Panitumumab-IRDye800|30 mg administered intravenously (IV)
41484690|NCT03733210|DRUG|89-Zirconium (Zr-89) Panitumumab|0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
41484691|NCT03733210|DEVICE|Pinpoint IR IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
41484692|NCT03733210|DEVICE|SPY-PHI IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
41484693|NCT03733210|DEVICE|Explorer Air camera|Fluorescence camera manufactured by SurgVision
41484694|NCT03733210|DEVICE|PDE-NEO II camera|Medical infrared camera manufactured by Hamamatsu Photonics KK
41484695|NCT03733210|DEVICE|FIS-00 fluorescence imaging system (FIS)|Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
41484696|NCT03733210|DEVICE|Da Vinci Firefly Imaging System|Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
41484697|NCT03733210|DEVICE|IGP-ELVIS-v4 Macroscopic Specimen Imager|Macroscopic specimen imager manufactured by LI-COR Biosciences
41484698|NCT03733210|DEVICE|Vevo 3100 LAZR-X|Photoacoustic ultrasound imaging system manufactured by VisualSonics
41484699|NCT03733210|DEVICE|Pearl Triology Imaging System|Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
41484700|NCT03733210|DEVICE|Odyssey CLx Imaging System|Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
41484701|NCT03733210|DEVICE|Leica fluorescence microscope|Fluorescence microscope manufactured by Leica
41484702|NCT04160845|PROCEDURE|cardiac surgery|cardiac surgery with hypothermic cardiopulmonary bypass
41484703|NCT02479373|OTHER|Ren-Ex Machine|The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.
41484704|NCT02479373|OTHER|Dual-Emission X-ray Absorptiometry (DEXA) scan|To study body composition
41484705|NCT02479373|OTHER|Biodex dynamometer|To study muscle strength
41484706|NCT02479373|OTHER|Sub-maximal test|To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.
41484707|NCT02479373|OTHER|Quality of life questionnaires|
41335802|NCT03511300|BEHAVIORAL|Goal-Setting Instructions|"In the goal-setting instruction condition, participants will be asked to increase their performance by 20% from the previous similar test (e.g., On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter 'F.' Now, I want you to aim to generate at least 12 words for the letter 'F'.)"
41335803|NCT03511300|BEHAVIORAL|Standard Instructions|Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
41484708|NCT04190030|BEHAVIORAL|mindfulness training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
41015030|NCT05281731|PROCEDURE|Research blood|No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)
41015031|NCT05281731|GENETIC|Cancer Personalized Profiling|Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.
41015032|NCT05281731|DEVICE|Definity®|Being used off-label in this trial
41015036|NCT05032976|BIOLOGICAL|Tozinameran 12 Years of age and older|BNT162b2 (purple cap) is administered with dilution, while BNT162b2 (grey cap) is administered without dilution. Both formulations are administered by intramuscular injection (IM) of 0.3 mL. According to the approved and authorized label, the recommended dose of BNT162b2 is a series of two doses (1 day 1 dose, 0.3mL each) 21 days apart and administered IM.
41015037|NCT05032976|BIOLOGICAL|Tozinameran 5 to 11 Years of age|"BNT162b2 (orange cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, the recommended dose of BNT126b2 is a series of two dose (1day 1dose, 0.2mL) 21days apart and administered IM.~But, a third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised aged 5 to 11 years of age."
41335804|NCT02951897|PROCEDURE|lobectomy|
41335805|NCT02951897|PROCEDURE|segmentecomy|
41335806|NCT02951897|DRUG|chemotherapy（pemetrexed+CISPLATIN）|
41484709|NCT04190030|BEHAVIORAL|cognitive reappraisal training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
41484710|NCT02824718|DRUG|Teriparatide|human recombinant parathormone
41484711|NCT02824718|DRUG|Thiazide|Diuretic
41484712|NCT02824718|DRUG|Potassium sparing diuretic|Diuretic
41484713|NCT02824718|DRUG|Alfacalcidol|Belongs to the class of vitamin D and analogues
40817551|NCT06220864|DRUG|SNV1521|SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
41015038|NCT05032976|BIOLOGICAL|Tozinameran 6 months to 4 years of age|"BNT162b2 (maroon cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, it is recommended that the recommended dose of BNT162b2 is administered by intramuscular injection (IM) twice (once a day, each 0.2mL) at least of 21 days apart, and Dose 3 at least 8 weeks later.~Children who will turn from 4 years to 5 years of age between their doses in the vaccination course should receive their age-appropriate dose at the time of the vaccination and the interval between doses is determined by the child's age at the start of the vaccination course.~The interchangeability of BNT162b2 with COVID-19 vaccines from other manufacturers to complete the vaccination course has not been established.~BNT162b2 (6 months to 4 years of age) should be used only for infants and children 6 months to 4 years of age."
40817552|NCT03645421|DRUG|MEDI0382 100 μg|Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
40817553|NCT03645421|DRUG|MEDI0382 200 μg|Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
41015039|NCT05032976|BIOLOGICAL|Riltozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 1) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 1) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 1) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
41015040|NCT05032976|BIOLOGICAL|Famtozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
41015041|NCT05032976|BIOLOGICAL|Famtozinameran 5 to 11 Years of age|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age (orange cap) is administered after dilution by intramuscular injection (IM) of 0.2mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
41015042|NCT05032976|BIOLOGICAL|Raxtozinameran 12 years of age and older|"BNT162b2 OMI XBB.1.5 (grey cap) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.~For individuals who have previously been vaccinated with a COVID-19 vaccine, BNT162b2 OMI XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine."
41015043|NCT05032976|BIOLOGICAL|Raxtozinameran 6 months to 4 years of age|BNT162b2 OMI XBB.1.5 (maroon cap) is administered intramuscularly after dilution. For infants and children 6 months to 4 years of age without history of completion of a COVID-19, each 0.2 mL of dose is administered for a total of three vaccinations. The second dose is administered 3 weeks after the first dose followed by a third dose administered at least 8 weeks after the second dose. For infants and children 6 months to 4 years of age with history of completion of a COVID-19 primary course or prior SARS CoV-2 infection, a single dose of 0.2 mL is administered.
41015047|NCT01961869|OTHER|Fast release BRB confection|Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
41015048|NCT01961869|OTHER|Intermed release BRB confection|Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
41015049|NCT01961869|OTHER|Prolong release BRB confection|Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
41015050|NCT01852890|DRUG|Ascorbate|Intravenous infusion of high-dose ascorbate
41015051|NCT01852890|DRUG|Gemcitabine|Intravenous chemotherapeutic
41015052|NCT01852890|RADIATION|Radiation therapy|
41015053|NCT06535906|OTHER|kinesio taping|The 5 cm wide Kinesio tape (Kinesio® Tex Gold™, Albuquerque, NM) applied to the participants has the ability to stretch up to 140% of its original length. Moreover, it provides comfortable use for 3 to 5 days thanks to its latex-free, cotton, hypoallergenic and porous features. The skin will be cleaned with alcohol before applying Kinesio tape. To prevent muscle tension, the physiotherapist will apply the kinesio tape inhibition technique to the wrist flexor muscles with light tension (15-25% of the current tension) from the end point to the origin. We will use this inhibition technique to prevent muscle spasm. Kinesio taping will be applied immediately after exercise
40817554|NCT03645421|DRUG|MEDI0382 300 μg|Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
40817555|NCT03645421|DRUG|PlaceboA|1.0 mL liquid formulation per Vial
40817556|NCT03645421|DRUG|MEDI0382 50 ug|Solution for injection, 1.0 mL per vial, 50 ug
40817557|NCT03645421|DRUG|PlaceboB|Solution for injection in 1.0 mL pre-filled syringe.
41335807|NCT02951897|PROCEDURE|Lymphadenectomy|Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
41335808|NCT02951897|OTHER|CanPatrolTM to detect CTCs|CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E\&M-) CTCs.
41335809|NCT02556580|DRUG|Albumin 20%|Intervention: intravenious infusion Drug: albumin
41335810|NCT00966680|OTHER|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
41335811|NCT06287918|DRUG|3HP-2827|3HP-2827 will be administered orally once daily in 28-day cycles.
41335812|NCT02818270|DRUG|Salbutamol|Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
40817558|NCT05840952|DRUG|ALG-097558|single or multiple doses of ALG-097558
41335813|NCT02818270|DRUG|Acetylcysteine|Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
40817559|NCT05840952|DRUG|Placebo|single or multiple doses of placebo
40817560|NCT05840952|DRUG|Midazolam|Multiple doses of Midazolam
40817561|NCT05840952|DRUG|Itraconazole|Multiple doses of Itraconazole
41335814|NCT02870257|OTHER|Strengthening protocol with progressive load|Strengthening protocol for scapular and shoulder muscles
41335815|NCT02870257|OTHER|Strengthening protocol without progressive load|Strengthening protocol for scapular and shoulder muscles
41335816|NCT00300716|DRUG|Memantine|
40817562|NCT05840952|DRUG|Carbamazepine|Multiple doses of Carbamazepine
40817563|NCT05840952|DRUG|ALG-097558 in solution formulation|ALG-097558 in solution administered in fasted state
40817564|NCT05840952|DRUG|ALG-097558 in tablet formulation|ALG-097558 in tablet administered in fasted and fed state
40817565|NCT02224287|PROCEDURE|Technologist control of fluoroscopy|Technologist control of fluoroscopy
40817566|NCT02224287|PROCEDURE|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
40817567|NCT02617407|DRUG|Livionex® Dental Gel|Oral application Dental Plaque, Gingivitis and Oral Microbiome Control.
40817568|NCT02617407|DRUG|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Oral application for Dental Plaque, Gingivitis and Oral Microbiome Control.
41335817|NCT03476967|PROCEDURE|Panretinal photocoagulation|In cases of proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) is the first-line treatment. Although PRP reduces the risk of severe vision loss, it has been shown that laser energy can cause destruction to all layers of retina including the ganglion cells and the retinal nerve fiber layer (RNFL), and therefore generate visual field defects similar to that observed in glaucomatous damage. In such cases, visual field testing can be less helpful to evaluate glaucomatous damage in PDR patients treated with PRP.
41335818|NCT05417659|DIETARY_SUPPLEMENT|Exercise plus carbohydrate|A high carbohydrate drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise.
41335819|NCT05417659|DIETARY_SUPPLEMENT|Exercise plus niacin|A dose of niacin to be consumed 30 minutes prior to exercise, at onset of exercise and 30 minutes into exercise.
41335820|NCT05417659|OTHER|Placebo|A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
41484714|NCT04229524|PROCEDURE|Fluorescence angiography|After the tube and stomach were made during surgery, the predetermined anastomosis position was marked with sutures in advance according to the doctor's experience, and then 0.04ml / kg indocyanine green injection was injected into the central vein. Next, dynamic observation and recording of the tube-gastric anastomosis area in 136 seconds using a fluorescent imaging system with a fixed focal length till the fluorescence reaching range and intensity. If the average value of the fluorescence value of the anastomosis position is greater than 30, then the anastomosis position may be according to the original plan or moved to the proximal part. If the average fluorescence value of the predetermined anastomosis position is less than 30, the anastomosis must move to proximal part ensure anastomosis with fluorescence value at least\> 30.
40817569|NCT02617407|DEVICE|Kolibree Toothbrush|Electric Toothbrush
40817570|NCT00223405|DEVICE|crown placement|
40817571|NCT06177197|DEVICE|Physiomer|"Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
40817572|NCT06177197|DEVICE|Saline solution|"Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
40817573|NCT05416489|DEVICE|C-MAC videolayngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a C-MAC videolaryngoscopy.
40817574|NCT05416489|DEVICE|Laryngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a laryngoscopy
40817575|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
40817576|NCT02068690|DRUG|Placebo|Placebo
40817577|NCT02068690|DRUG|Placebo|Placebo
40817578|NCT02068690|DRUG|BI 425809 tablet|BI 425809 tablet
40817579|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
41015054|NCT06535906|OTHER|placebo kinesio taping|5 cm wide and 0.5 mm thick I-shaped Kinesio tape (Kinesio Tex® Gold) will be used. The tape will be applied in a plus-shaped, tension-free and technical sitting position. Kinesio taping will be applied immediately after exercise
41015055|NCT06535906|OTHER|manual lymph drainage|Participants will lie in a supine position with their knees bent. Manual lymphatic drainage will begin with abdominal lymph drainage followed by central lymph stimulation. Then, bilateral axillary lymph nodes will be stimulated and the fluid in the exercised arm will be directed to the axillary lymph nodes. While the patients are in the prone position, the axillary lymph nodes will be stimulated in the same way and each manual lymphatic drainage will be performed from the back to the axillary lymph node. Each treatment session will last approximately 30 minutes
41015056|NCT06535906|OTHER|placebo manual lymph drainage|Participants will lie in a supine position with their knees bent. It will only be moved in a stroking style with hand contact from the fingers towards the armpit.
41015057|NCT04266093|DRUG|GeneTherapy|Observation/ Gene Therapy Long-term Follow-up. Subjects who have received treatment on an applicable NCI CIO gene therapy protocol.
41015066|NCT06522451|OTHER|conventional physical therapy|Only conventional physical therapy (CPT) will be administered to this group. These regular workouts will include dynamic and static stretching, walking-specific functional exercises, passive mobilizations for pain-free mobility, balance modulation, and gait training. At baseline, the functional state of both groups will be evaluated. Treatment sessions will run for a total of 12 weeks, five days a week, for 45 minutes each. They will consist of four to six repeated exercises, six times on average, and use BSID-4 once the trial is over.
41015067|NCT06522451|OTHER|Conventional physical therapy along with cuevas medek exercises|In addition to regular physical therapy, this group will get Cuevas Medak exercises including head and trunk control (by stabilizing limb) and standing to sitting transition. For a duration of 12 weeks, five days a week, and 45 minutes, each session will be held. At the baseline, the functional state of both groups will be evaluated.
40817580|NCT03112512|DEVICE|optimal PEEP guided by EIT|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
40817581|NCT03112512|DEVICE|optimal PEEP guided by G5 ventilator|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
40817582|NCT02816021|DRUG|Azacitidine|300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
41015068|NCT05962398|GENETIC|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua in the study CSL222_2001 (NCT03489291) or CSL222_3001 (NCT03569891).
41015072|NCT05370885|BIOLOGICAL|VE202|VE202 is a rationally defined, live biotherapeutic product for oral administration.
41484715|NCT04241666|DIAGNOSTIC_TEST|renal scintigraphy|Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys
41484716|NCT04241666|DIAGNOSTIC_TEST|renal doppler sonography|doppler ultrasound of both kidneys
41484717|NCT00541164|DRUG|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
41484718|NCT00541164|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
41015073|NCT05370885|DRUG|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection
41015074|NCT05370885|OTHER|VE202 Placebo|VE202 Placebo
41015075|NCT05370885|OTHER|Vancomycin Placebo|Vancomycin Placebo
41015078|NCT04948333|DRUG|ABL001 40mg BID|One tablet of 40 mg will be taken orally twice a day (BID)
41015079|NCT04948333|DRUG|ABL001 80mg QD|Two tablets of 40 mg will be taken orally once a day (QD)
41015080|NCT04948333|DRUG|ABL001 200mg QD|Five tablets of 40 mg will be taken orally once a day (QD)
41015081|NCT05927571|DRUG|Cevostamab|Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.
41015082|NCT05927571|DRUG|Elranatamab|Elranatamab solution for injection will be administered SC as specified in each treatment arm.
41015083|NCT05927571|DRUG|Tocilizumab|Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
41015086|NCT02157324|DRUG|acalabrutinib|
41015087|NCT02157324|DRUG|ACP-319|
40817583|NCT02816021|DRUG|Pembrolizumab|200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
41015091|NCT03837899|DRUG|Durvalumab / Tremelimumab Combination Therapy|"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase."
41484719|NCT03992417|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
41484720|NCT03731871|DIAGNOSTIC_TEST|Ultrasonography|ultrasound to evaluate parameters of fetal maturity during pregnancy
40817584|NCT02450383|DRUG|Acellular Dermal Matrix|Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
41015092|NCT01856192|DRUG|Cyclophosphamide|Given IV
41015093|NCT01856192|DRUG|Doxorubicin Hydrochloride|Given IV
41015094|NCT01856192|OTHER|Laboratory Biomarker Analysis|Correlative studies
41015095|NCT01856192|DRUG|Lenalidomide|Given PO
41015096|NCT01856192|DRUG|Prednisone|Given PO
41015097|NCT01856192|BIOLOGICAL|Rituximab|Given IV
41015098|NCT01856192|DRUG|Vincristine Sulfate|Given IV
41015099|NCT02003209|DRUG|Aromatase Inhibition Therapy|Given at the investigator's discretion
41015100|NCT02003209|DRUG|Carboplatin|Given IV
41156288|NCT06585748|DRUG|Lidocaine spray|4 puffs of lidocaine spray was applied to the glans penis and urethral meatus, and after 5 minutes, the appropriate method and sterilization were used to apply a catheter gel, and a Foley catheter was placed in the bladder. After bladder catheterization, pain scores were evaluated by a neutral emergency medicine physician at 0 minutes (during the procedure), and at 15, 30, and 60 minutes post-procedure. The Face Legs Arms Cry Consolability Pain Scale (FLACC) and Wong-Baker pain scales were used for this evaluation.
41156289|NCT06585748|OTHER|Placebo|No medication/application will be administered as placebo.
41484721|NCT00197392|DEVICE|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
41484722|NCT00197392|DEVICE|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
41484723|NCT04802902|OTHER|home-based hospitalization|management in a hospital-at-home programme of patients treated by immunotherapy and chimiotherapy combo for bronchial cancer
41484724|NCT00324480|DRUG|alvocidib|Given IV
41015101|NCT02003209|OTHER|Cytology Specimen Collection Procedure|Undergo 2 core biopsies
41015102|NCT02003209|DRUG|Docetaxel|Given IV
41015103|NCT02003209|DRUG|Goserelin Acetate|Given SC
41015104|NCT02003209|OTHER|Laboratory Biomarker Analysis|Correlative studies
41015105|NCT02003209|BIOLOGICAL|Pertuzumab|Given IV
41015106|NCT02003209|OTHER|Quality-of-Life Assessment|Ancillary studies
41015107|NCT02003209|PROCEDURE|Therapeutic Conventional Surgery|Undergo lumpectomy or mastectomy
41015108|NCT02003209|BIOLOGICAL|Trastuzumab|Given IV
41015109|NCT02003209|RADIATION|Whole Breast Irradiation|Undergo whole breast irradiation
41484725|NCT00324480|DRUG|vorinostat|Given orally
41335821|NCT05380960|DEVICE|cbc coaglation profile|The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
40817585|NCT02450383|PROCEDURE|Autologous subepithelial connective tissue graft|Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
40817586|NCT06605781|BEHAVIORAL|AR/VR technology-based training|Students will receive AR/VR Technology and OSCE in a Virtual Clinical Environment to learn how to assess and manage patients with auditory hallucination. The course was designed as a diverse and interactive learning experience, integrating a virtual clinical environment for auditory hallucinations with the application of Objective Structured Clinical Examination (OSCE). The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum. Additionally, students will have access to the AR/VR materials for self-practice during the practicum.
41015110|NCT05003986|DRUG|Sparsentan|Population 1: 800 mg Sparsentan (oral suspension)
41015111|NCT05003986|DRUG|Sparsentan|Population 2: 400 mg Sparsentan (oral suspension)
41015112|NCT05003986|DRUG|Sparsentan|Population 3: 400 mg Sparsentan (tablets)
41335822|NCT04657354|PROCEDURE|Assessment|Early surgical assessment
41335823|NCT06298760|COMBINATION_PRODUCT|Knee Massage With Black Cumin Oil Group:|The patients received a knee massage with black cumin oil once a week for approximately 30 minutes for 6 weeks.
41335824|NCT06298760|COMBINATION_PRODUCT|Foot Reflexology Group With Black Cumin Oil|The patients underwent foot reflexology with black cumin oil once a week for approximately 40 minutes for 6 weeks.
41335825|NCT06298760|COMBINATION_PRODUCT|placebo group|Applications were made with vaseline
41335826|NCT04142710|DEVICE|Telemedicine: tablet and possibly tools to perform measurements|Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.
41335827|NCT03498118|DRUG|20 mL of bupivacaine 0.25%|"In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient's abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
41484726|NCT00324480|OTHER|pharmacological study|Correlative studies
40817587|NCT06605781|BEHAVIORAL|traditional vedio and discussion group|Students will receive a traditional course on auditory hallucination assessment, which includes watching educational videos and participating in a general discussion group on auditory hallucinations. The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the traditional course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum.
41015119|NCT03433456|BEHAVIORAL|Home visitation + HABITS program|The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
41015120|NCT03433456|BEHAVIORAL|Standard home visitation program|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
41156290|NCT00295048|BEHAVIORAL|Computer Assisted Cognitive Remediation (CACR)|
41156291|NCT02941432|OTHER|Black tea compress treatment|Wet compresses with black tea applied 4-5 times daily to the face for 6 days
41484727|NCT00675636|OTHER|study of socioeconomic and demographic variables|database, no intervention
41484728|NCT00675636|PROCEDURE|evaluation of cancer risk factors|database, no intervention
41484729|NCT00675636|PROCEDURE|study of high risk factors|database, no intervention
41335828|NCT02920450|DRUG|Gedatolisib|"During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg"
41335829|NCT02920450|DRUG|Paclitaxel|Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
41335830|NCT02920450|DRUG|Carboplatin|The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
41335831|NCT03959956|DIAGNOSTIC_TEST|Recording lung sound by a Smartscope|Lung sound will be recorded from four chest points by an electronic stethoscope called Smartscope which can also classify the recorded lung sound.
41335832|NCT06383819|DRUG|Longidaza®|dose 3000 IU intramuscularly once every 5 days, 15 injections
41335833|NCT06383819|DRUG|Placebo|intramuscularly once every 5 days, 15 injections
41335834|NCT05539872|DRUG|I004|Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
41335835|NCT05539872|DRUG|NovoLog|Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
41335836|NCT01843205|DRUG|Methamphetamine|The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
41335837|NCT01843205|DRUG|Placebo|The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
41335838|NCT04999007|OTHER|Artificial intelligence algorithm|Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.
41484730|NCT06437665|BEHAVIORAL|The intervention name in this study is ADAS-integrated driver simulation training.|The intervention involves providing older drivers (≥65 years of age) with training sessions utilizing a high-fidelity driving simulator. This training focuses on the integration and use of Lane Departure Warning (LDW), Cruise Control (CC), and Forward Proximity Warning (FPW) technologies, collectively referred to as ADAS. The training is designed to familiarize participants with these advanced driver assistance systems, enabling them to effectively utilize these features while driving.
41484731|NCT03452332|BIOLOGICAL|Durvalumab|Given IV
41484732|NCT03452332|OTHER|Laboratory Biomarker Analysis|Correlative studies
41484733|NCT03452332|RADIATION|Stereotactic Radiosurgery|Undergo SABR
41015127|NCT05795933|DRUG|Vitamin D3|A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
41015128|NCT06080789|DRUG|RABI-767|125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
41335839|NCT04703049|OTHER|Blood Viscosity Testing|we calculated WBV using the formula \[(0.12 × hematocrit) + (0.17 × (total protein - 2.07)\]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.
41335840|NCT06009861|DRUG|Tislelizumab|Dose: 200 mg Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
41335841|NCT06009861|DRUG|Albumin-Bound Paclitaxel|Dose: 260 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
41335842|NCT06009861|DRUG|Cisplatin|Dose: 60-75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
41335843|NCT00953225|DRUG|vitamin D3|4,000 IU daily for one year
41335844|NCT00953225|DRUG|Placebo daily for one year|Placebo
41335845|NCT00118469|BEHAVIORAL|Psychoeducation|
41335846|NCT00118469|BEHAVIORAL|Cognitive behavior therapy|
41484734|NCT03452332|BIOLOGICAL|Tremelimumab|Given IV
41484735|NCT03192241|OTHER|Pump|Intervention is providing mothers with a manual breast pump and instructions for when it could be used.
41484736|NCT03192241|OTHER|Book|Active control intervention is providing mother's with a children's book and information about reading to baby.
40817588|NCT06309017|OTHER|Nutrition specialist|Nutrition specialist to help improve nutritional status by diet, oral nutrition supplements or parenteral nutrition.
41335847|NCT04366713|DRUG|Neratinib|Administered orally once daily as a single daily dose of 240 mg
41335848|NCT04366713|DRUG|Capecitabine|Administered orally twice daily at 750 mg/m\^2 for 14 days of each 21 day treatment cycle
41335849|NCT04366713|DRUG|Loperamide|Administered orally for prophylaxis for 28 days and then as needed
41484737|NCT02440022|COMBINATION_PRODUCT|Lutonix DCB|
41484738|NCT02440022|DEVICE|Standard Balloon Angioplasty Catheter|
41484739|NCT02440022|PROCEDURE|Percutaneous Transluminal Angiography|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
40817589|NCT06309017|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition shakes|All study subjects, including subjects without malnutrition, will be given the Ensure Surgery Immunonutrition Shakes for prior to surgery as per standard of care. All subjects will also receive additional shakes starting as an inpatient when diet is advanced.
41335850|NCT05460689|OTHER|M-HEALTH APP|The intervention group will have in use a mHealth App for education and support of caregivers of children undergoing tonsillectomy and/or adenoidectomy in the perioperative process. An out-patient nurse will be in charge of instructing intervention group participants to mHealth App use and content options. The mHealth App will be available for intervention group families from the day of pre-admission visits to the 7th day post surgery or follow up visit.
41335851|NCT05460689|OTHER|Standard Care|The control group will receive information and education provided by nurses and physician in the preoperative visits and during hospitalization. Information and education will be provided orally or through printed booklets.
40817590|NCT00117715|PROCEDURE|Genotyping and Phenotyping using dextromethorphan and caffeine as probes|Single doses of dextromethorphan (0.3 mg/kg)and caffeine (3.0 mg/kg) are administered and urine is collected overnight for measurement of drug and metabolites to determine drug biotransformation activity.
40817591|NCT03900130|DIETARY_SUPPLEMENT|Preload|"In the 2 x 2 factorial design we vary two factors:~1. caloric load of the preload such that it is either high calorie or low.~2. protein to carbohydrate ratio of the preload such that it is either high or low"
41335852|NCT06118762|DRUG|Fruquintinib|Fruquintinib capsule is taken orally once a day, 5 mg each time, and taken for 2 weeks and stopped for 1 week, every 21 days (3 weeks) for a cycle. Raltitrexed: 3 mg/m2 intravenously, on the first day of each cycle, for a treatment cycle of 3 weeks. Combination treatment until toxicity becomes intolerable, disease progression, or death.
41335853|NCT01158638|BEHAVIORAL|Web Mediated Step Intervention|The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
41335854|NCT04721938|BEHAVIORAL|Systematic weight loss intervention|"Weight reduction through life style changes in diet and exercise by the following means:~* Counselling with a Nutritionist Nurse on diet and exercise~* Online Smartphone coaching program (Life-sum App)~* Motivational and adjustment dialogue and counselling with Nutritionist Nurse including anthropometric measures every month"
41335855|NCT03882723|DEVICE|Evaluated 4 masks used for NIV with mechanical ventilators|Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, \& 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
41335856|NCT06149754|DEVICE|BraiN20(R) monitoring of N20 somatosensory evoked potential|N20 monitoring will be carried out using the BraiN20 medical device and appropriate electrodes. The device measures one N20 wave per 33 seconds. Scalp electrodes will be located on band and wrist electrodes on a globe. The device provides an automatic reading of N20 and outcome prediction and do not require a specific training.
41335857|NCT05823610|DIAGNOSTIC_TEST|ultrasound|The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
41335858|NCT06119425|DIAGNOSTIC_TEST|blood-based CRC screening|For this study, a commercially available blood-based CRC screening test will be used. The selected test is Shield (Guardant Health, Redwood City, California, USA). The Shield test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, California, USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. The Shield test is currently commercially available as an laboratory developed test (LDT). Additionally, Guardant submitted the pre-market approval (PMA) application for the Shield test to the Food and Drug Administration (FDA) in March of 2023. Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of medical devices. To this end, the Shield test is currently under review by the FDA.
41484740|NCT02872363|OTHER|Intervention A - Behavioural Regulation|"SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'"
41484741|NCT02872363|OTHER|Intervention B - Priority|"SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'"
41484742|NCT03863483|DRUG|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
40817592|NCT03388866|DRUG|Mite extract sublingual immunotherapy (SLIT)|Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
40817593|NCT03388866|OTHER|Placebo|Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
40817594|NCT05254132|PROCEDURE|Liquid biopsy|Participants in the aRECIST group will undergo a blood draw for liquid biopsy analysis at baseline and follow up visits
41484743|NCT03863483|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
41484744|NCT03863483|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
41484745|NCT03863483|DRUG|Placebo|0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
41484746|NCT00325377|PROCEDURE|MME Procedure|
40817595|NCT05197530|DRUG|Indocyanine green|A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.
40817596|NCT05197530|DEVICE|MultiSpectral Imaging System|Once the ICG is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
40817597|NCT04848506|DRUG|Aficamten (5 - 20 mg)|Aficamten tablets administered orally. During titration phase, clinic visits will occur approximately every 2-6 weeks. In the maintenance phase clinic visits will occur every 24 weeks, with safety check-in occurring every 12 weeks between visits by phone or, if desirable, in the clinic.
40817598|NCT00615446|DRUG|SU011248; Gemcitabine|Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
41335859|NCT04869111|BEHAVIORAL|Brain Health Training|"1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.~3. Brain-Healthy Habits - daily reminders of habits you can track~4. BrainHQ - participants will gain temporary access to the exercise-based cognitive training of BrainHQ after completing their 3rd BrainHealth Index"
40817599|NCT04245670|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
40817600|NCT06607744|DRUG|Pharmacokinetic profiles of Selegiline TDS and EMSAM|Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.
40817601|NCT01631747|BEHAVIORAL|Lifestyle Intervention Group|Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet \& activity and use of pedometer
40817602|NCT01631747|BEHAVIORAL|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
41015137|NCT06511804|DEVICE|Intracranial Pressure Noninvasive Monitoring|Mespere sensors will be placed on the temporal areas of the head in patients with invasive intracranial pressure monitoring. Blood pressures, intracranial pressure, and Mespere parameters will be recorded.
41335860|NCT04242459|RADIATION|Adaptive Radiotherapy|Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning
41335861|NCT06153199|BEHAVIORAL|Self-management videos|Short video modules on self-management of back pain without medication and ergonomic adjustments for limiting back pain in nursery and landscape work
41484747|NCT02714933|OTHER|MRI sequence Advanced ZTE|Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
41484748|NCT04694326|DIAGNOSTIC_TEST|HbA1c|The participants' age, sex, education level, known diseases, unit of hospitalization and inpatient diagnosis were questioned and recorded. Height, weight and waist circumference measurements were taken. Fasting blood sugar and HbA1c measurements were made
41484749|NCT03285789|OTHER|Passing tests in dyslexics with reduced eva|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30."
40817603|NCT03233334|BEHAVIORAL|Purpose Project|The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
40817604|NCT04319029|BEHAVIORAL|Pharmaceutical care plan|"The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study."
40817605|NCT03789513|DIAGNOSTIC_TEST|HPV test with partial genotyping and VIA triage|HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
40817606|NCT03217877|DIAGNOSTIC_TEST|routine stress testing|In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9\~15 months after the procedure according to the practice pattern of each participating center.
40817607|NCT03217877|DIAGNOSTIC_TEST|No Routine stress testing|In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
40817608|NCT03469986|DEVICE|Marcus Autism Center Investigational Device|This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.
41015146|NCT04090567|DRUG|Cediranib|Given PO
41015147|NCT04090567|DRUG|Ceralasertib|Given PO
41015148|NCT04090567|DRUG|Olaparib|Given PO
41015149|NCT05475184|DRUG|JPI-547|"Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor.~* The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~* 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal."
41015154|NCT06489886|OTHER|Conventional Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless convential chicken breast meat together with 250mL of water
41015155|NCT06489886|OTHER|Regenerative Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless regenerative chicken breast meat together with 250mL of water
41156292|NCT06645574|OTHER|The multidisciplinary preventive approach among young people involved in intensive sports activities. Athlete will see doctor and physiotherapist.|"Athletes will have 2 times per years prevention examination:~* A standard medical examination~* A physiotherapy assessment with strength assessment~* They will complete psychometric evaluation self-questionnaires"
41156293|NCT02368366|BEHAVIORAL|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
41335862|NCT06153199|BEHAVIORAL|Check lists for ergonomic options|Guidance on ergonomic choices appropriate for work tasks not currently being used that are the most difficult due to back pain, using a checklist
41335863|NCT06153199|BEHAVIORAL|Text reminders|Reminders to implement choices using graphics and gifs as well as motivational messages
41015156|NCT03193294|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
40817609|NCT05964530|PROCEDURE|Surgery|Surgery procedures include LAR+ anal preservation or APR
40817610|NCT01112774|DEVICE|Transcranial direct current stimulation|Stimulation will be applied at 2 mA for a total of 20 minutes.
40817611|NCT03481166|OTHER|Education on breastfeeding pain|A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
40817612|NCT06608823|DEVICE|Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System|Transcatheter Aortic Valve Replacement (TAVR) with Trilogy Device
40817613|NCT06608823|DEVICE|SAVR|SAVR using commercially available surgical prosthetic valves.
40817614|NCT06606093|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
40817615|NCT06606093|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
41335864|NCT06153199|BEHAVIORAL|Video review|Participants will review videos of their movement during their most difficult work tasks to help problem solving to adjust ergonomic adjustments
41335865|NCT05378048|DRUG|PDO-guided treatment|"A biopsy of the tumour will be performed for PDO culture and Genome-guided drug screening.~An Multidisciplanary Tumour Board will review the drug screen results and recommend the use of a drug with a response in a PDO."
40817616|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
40817617|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
41015159|NCT06300554|DEVICE|Healthy Minds Program App|freely available well-being app
41015160|NCT04262856|DRUG|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
41015161|NCT04262856|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
41015162|NCT04262856|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
41335866|NCT05378048|DRUG|standard of care|the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
40817618|NCT01285570|DRUG|5% dextrose in water|Placebo
40817619|NCT05980273|BEHAVIORAL|Educational sessions|session for oral health education
40817620|NCT00364572|DRUG|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
40817621|NCT00364572|DRUG|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
41335867|NCT00852423|DRUG|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
41335868|NCT00852423|DRUG|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
41335869|NCT00852423|DRUG|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
41484750|NCT03285789|OTHER|Passing tests in controls|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.~test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.~All of these tests will be made during an unique visit of 1h30."
41484751|NCT04570397|DRUG|Ravulizumab|Patients will receive weight-based dosing of ravulizumab on Days 1, 5, 10, and 15 along with the standard care.
40817622|NCT00692614|DRUG|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
40817623|NCT05840887|PROCEDURE|Knee osteotomy associated with meniscal allograft transplantation|Patients will undergo knee osteotomy associated with meniscal allograft transplantation, which will be implanted by arthroscopic technique with body fixation by all-inside and transosseous sutures to the posterior horn and if necessary to the anterior horn.
40817624|NCT05840887|PROCEDURE|Knee osteotomy|Knee osteotomy
41484752|NCT04971213|DEVICE|Non invasive ventilation|Emergency and transport ventilator (Monnal T60, Airliquide, Antony, France)
40817625|NCT01933438|OTHER|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
40817626|NCT01933438|OTHER|Control|Standard treatment
41484753|NCT04971213|DEVICE|High-flow nasal cannula heated and humidified oxygen|AirVO2 device (Fisher and Paykel, New Zealand)
41484754|NCT00148330|DRUG|Triamcinolone acetate|When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\]) was injected into the vitreous under sterile conditions in a minor procedures area.
41484755|NCT00112346|DRUG|Cetuximab + platinum + gemcitabine|Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
41484756|NCT00112346|DRUG|Platinum + Gemcitabine|Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
41484757|NCT00379990|DRUG|GW274150|60 mg /day
40817627|NCT05750654|DEVICE|Small Phlebotomy Tube Group|"In the small tubes group, the recommended blood volumes are 0.5 mL for hematology and single chemistry tests, and 1 mL when multiple chemistry tests are needed. A, a non-formulary medication order will be placed in the electronic medical record to alert nurses to collect blood in small tubes. Participants will continue to use small tubes anytime they are in the ICU or IMU."
40817628|NCT05750654|DEVICE|Standard Phlebotomy Tube Group|In the standard tubes group, the recommended blood volumes are 4.0 mL for hematology and 3.0 for chemistry tests.
40817629|NCT00431886|PROCEDURE|64 multi-detector computed tomography|
40817630|NCT00491946|DRUG|Actinomycin-D|
40817631|NCT00491946|DRUG|Vincristine|
40817632|NCT04285866|DRUG|Durvalumab|Durvalumab after chemoradiotherapy
40817633|NCT00149136|DRUG|imatinib|
40817634|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
40817635|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
41484758|NCT00379990|DRUG|Prednisolone|7.5 mg/day
40817636|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
40817637|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
40817638|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
40817639|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
40817640|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
40817641|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
40817642|NCT04440397|OTHER|xbp-1 - endometriosis patients group|Patients diagnosed with endometriosis by surgery and ultrasound and whose xbp-1 level was examined
40817643|NCT05828394|PROCEDURE|DFGG|Depithelised free gingival graft harvesting technique
40817644|NCT05828394|PROCEDURE|SCTG|Subepithelial connective tissue graft harvesting technique
41484759|NCT00379990|OTHER|Placebo|Placebo
41484760|NCT02824471|OTHER|SCD Group|No Intervention. Use of discard blood/tissue
41484761|NCT00761865|DEVICE|Air Cast Stirrup Brace & High Tide Fracture Boot|Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
41015167|NCT06028711|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD.
41335870|NCT00852423|DRUG|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
41335871|NCT02778945|DRUG|Rocuronium 0.9 mg/kg|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
41335872|NCT02778945|DRUG|Rocuronium 0.6 mg/kg|Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
41335873|NCT00702260|DRUG|Ramipril|10 mg capsule
41335874|NCT03725449|OTHER|Best Practice|Receive standard of care
41484762|NCT00870649|BIOLOGICAL|Bilhvax vaccine (Sh28GST)|Four vaccine sc administrations over a year associated with chemotherapy (PZQ)
41484763|NCT00870649|BIOLOGICAL|placebo|Four placebo sc administrations over a year associated with chemotherapy (PZQ)
41015168|NCT06028711|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
41335875|NCT03725449|BEHAVIORAL|mySmartCheck|Receive access to mySmartcheck program
41335876|NCT03725449|OTHER|Survey Administration|Ancillary studies
41335877|NCT01475318|DRUG|mifepristone|200 mg mifepristone on day 1
41335878|NCT01475318|DRUG|Letrozole|Letrozole 10mg PO on day 1, day 2, and day 3
41335879|NCT01475318|DRUG|Misoprostol|misoprostol 800mcg PV on day 3
41335880|NCT03785470|OTHER|Fructose and physical inactivity|Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
41335881|NCT05837507|OTHER|Telerehabilitation solution (m-Rehab)|"Patients in the experimental group will have access to a multimodal digital platform (m-Rehab®). The solution includes a website and an application available on smart phones for the patient and caregivers. Patients and caregivers will have access to educational content about the condition and its treatments, NIV compliance data, digital group educational workshops, secure messaging and video conferencing.~All the professionals forming the patient's circle of care will be able to have access to the solution, after the patient's authorization. The circle of care, in a non-exhaustive way, includes specialist doctors, the general practitioner, the staff of the reference center of the Montpellier University Hospital, the physiotherapist, the speech therapist, the dietician and the psychologist."
41484764|NCT03045159|BEHAVIORAL|Strong Families Strong Forces|Parenting program
41484765|NCT03045159|BEHAVIORAL|Strong Parents|self-care program
41484766|NCT04236583|OTHER|Telehealth|Post-discharge virtual visit
41484767|NCT01487070|DRUG|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only."
41484768|NCT00598624|DRUG|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
41484769|NCT02000401|DRUG|Ketorolac Tromethamine|
41484770|NCT01764243|DRUG|MT-4666|low dose, high dose
41335882|NCT05837507|OTHER|Usual management including NIV.|Usual management including NIV.
41484771|NCT01764243|DRUG|Placebo|
41484772|NCT04866277|OTHER|Fast-track referral for reference services|Activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study.
41484773|NCT00377936|DRUG|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
41484774|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
41335883|NCT00129740|DRUG|Nilotinib|400 mg orally twice daily
41335884|NCT00790530|BEHAVIORAL|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
41484775|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
41484776|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
41335885|NCT00790530|OTHER|Usual Care|Usual Care
41335886|NCT01126684|DRUG|Atorvastatin|10 mg of atorvastatin once daily for six months
41484777|NCT02053675|DRUG|Vasopressin infusion|
41484778|NCT02563717|DEVICE|T-piece used for respiratory support (several manufacturers)|Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
41484779|NCT02563717|DEVICE|New system used for respiratory support|Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
41484780|NCT05445726|DEVICE|CPM Device|CPM device used in tangent with reference ECG for validation
41335887|NCT01126684|DRUG|Placebo|placebo once daily for six months
41335888|NCT03374761|OTHER|Families First Home Visiting Program|10 group sessions and 4 home visits with community facilitators emphasizing positive parenting
41484781|NCT04927026|BEHAVIORAL|Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)|The WIPT include weekly face-to-face group sessions including mindfulness-based training and solution focused brief therapy (SFBT) involving psychoeducation and structured life review therapy catered to the personal needs of the participants.
41484782|NCT05991830|PROCEDURE|General anesthesia|Older adults during elective surgery under general anesthesia with propofol, frontal EEG will recorded and a baseline plasma sample will be taken
41484783|NCT02658565|PROCEDURE|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
41484784|NCT01093664|BIOLOGICAL|AFFITOPE AD02|s.c. injection
41335889|NCT00821860|OTHER|talc|Talc pleurodesis
41335890|NCT00821860|PROCEDURE|therapeutic thoracoscopy|Talc pleurodesis via thoracoscopy
41335891|NCT00821860|PROCEDURE|therapeutic videothoracoscopy|Video-assisted thoracoscopic pleurectomy
40817645|NCT04331184|PROCEDURE|RFA using combined bipolar and monopolar energy deliver|RFA technique combining bipolar mode and switching monopolar mode using dual / Twin Cooled-wet electrodes is performed on residual tumors after transarterial chemo-embolization.
40817646|NCT06399185|DRUG|Normal saline|20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
40817647|NCT06399185|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml/h after anesthesia induction but before surgery.
40817648|NCT06399185|DRUG|Esketamine|Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
40817649|NCT06399185|DRUG|Combined dexmedetomidine-esketamine|Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
41335892|NCT00995813|BIOLOGICAL|Rotarix|A rotavirus vaccine (Rotarix) will be administered in two doses, 8 weeks apart, in infants between 6 and 14 weeks of age. The standard dosage is 1 mL administered orally or per gastrostomy tube.
41335893|NCT06192667|DEVICE|GC Geanial Injectable (Tokyo,Japan)|Highly filled composite resin
41484785|NCT01691820|PROCEDURE|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
40817650|NCT04775862|DRUG|investigator choice re-challenge with anti EGFR Rx|Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
40817651|NCT01314170|DEVICE|Susanna Implant|device
41015189|NCT05676034|DRUG|AMX0035|AMX0035
41015190|NCT06568146|DIETARY_SUPPLEMENT|Multivitamin Supplement|: Participants will take 2 capsules of the multivitamin supplement daily with the first meal of the day in the morning.
41015191|NCT02675452|DRUG|AMG 176|Study Drug
41015192|NCT02675452|DRUG|Azacitidine|Non-investigational product
41015193|NCT02675452|DRUG|Itraconazole|Non-investigational product
41015194|NCT04560712|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
41015195|NCT04560712|OTHER|Best Practice|Undergo usual care
41015196|NCT04560712|OTHER|Questionnaire Administration|Ancillary studies
41015197|NCT05116735|PROCEDURE|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
41015198|NCT01251796|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
41156294|NCT02368366|BEHAVIORAL|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
41335894|NCT06192667|DEVICE|3M Filtek Z250 Universal Restorative (Germany)|Conventional composite resin
41335895|NCT01158066|PROCEDURE|CT Cardiac|the patient will undergo cardiac CT
41335896|NCT02266004|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
41335897|NCT02266004|OTHER|locomotor training|An individualized dual-task walking program for approximately 30 minutes.
41484786|NCT01691820|PROCEDURE|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
41484787|NCT01691820|PROCEDURE|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
41335898|NCT06360536|BEHAVIORAL|Resistance Training|A home-based resistance training condition that is delivered through a web-based platform.
41335899|NCT02312011|DRUG|IONIS-DMPKRx|Drug
41335900|NCT02312011|DRUG|Placebo|Placebo
41335901|NCT04834050|PROCEDURE|Quadriceps femoris isometric home-based exercise|All 3 groups of participants were given 4-week (5 days/week) quadriceps-hamstring isometric home-based exercise training for their both knees. Exercises were performed (with maximal effort for 10 seconds) at a rate of 20 repetitions per day. Training was performed at outpatient clinic for 30 minutes.
41335902|NCT03865238|BIOLOGICAL|EV71vac|Subjects are to receive a 0.5 mL IM injection of EV71vac. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
41335903|NCT03865238|BIOLOGICAL|Placebo|Subjects are to receive a 0.5 mL IM injection of placebo. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
41335904|NCT02172846|RADIATION|Proton beam radiation therapy (PBT)|
41484788|NCT03801382|DEVICE|IntelliSpace Cognition (ISC)|Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
41484789|NCT03801382|DIAGNOSTIC_TEST|Paper-Pencil Tests|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
41484790|NCT02881164|OTHER|Low glycemic index|Subjects intake a low glycemic index breakfast
41484791|NCT02881164|OTHER|High glycemic index|Subjects intake a high glycemic index breakfast
41484792|NCT05469217|OTHER|fMRI brain imaging|Structural MRI of gray and white matter, functional MRI during performance of the N-back task
41484793|NCT02341833|DRUG|Sevoflurane|In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
41484794|NCT05925673|OTHER|Mirror Therapy|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
41335905|NCT02172846|DRUG|Paclitaxel|
41335906|NCT02172846|DRUG|Carboplatin|
41335907|NCT04795492|BEHAVIORAL|remote intervention|Medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided. Risk factor modification included lipid control, smoking and drinking cessation, BP monitoring, dietary change keeping a healthy weight and in our trial. There were also a lot of educational materials about coronary heart disease knowledge that were reviewed by cardiologists, and participants were free to provide them whenever and wherever they want.
41335908|NCT04795492|BEHAVIORAL|Routine outpatient follow-up|Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention.
41335909|NCT02542670|GENETIC|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
41335910|NCT03530618|DEVICE|Flexible tip straight guidewire|Use a flexible tip straight guidewire for ultrasound-guided central venous catheterization
41335911|NCT03530618|DEVICE|J-tip|Use a J tip straight guidewire for ultrasound-guided central venous catheterization
41335912|NCT03224260|DRUG|BMS-986177|Oral Suspension
41335913|NCT03224260|OTHER|Matched Placebo|Oral Suspension
41017971|NCT05580718|BEHAVIORAL|MI-CBT|"* Education Common reactions following MI and general lifestyle advice on e.g., physical activity. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation.~* Goal setting Identifying life areas impaired by MI-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Exposure therapy Exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity.~* Relapse prevention Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
41335914|NCT04804904|DRUG|TQ-B3101|TQ-B3101 oral capsule
41335915|NCT05183646|DRUG|DMX-200|DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.
41335916|NCT05183646|DRUG|Placebo|Patients will receive 120 mg capsules of Placebo twice daily
41335917|NCT05636904|DRUG|prostaglandin F2a analogue in vehicle solution high dose|Topical treatment for 24 weeks
41335918|NCT05636904|DRUG|prostaglandin F2a analogue in vehicle solution low dose|Topical treatment for 24 weeks
41335919|NCT05636904|DRUG|active ingredient-free vehicle solution to DLQ01|Topical treatment for 24 weeks
41335920|NCT05636904|DRUG|Minoxidil 5% Topical Solution|Topical treatment for 24 weeks
41335921|NCT05757024|DEVICE|high power laser therapy|m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths
41335922|NCT02447640|DRUG|ADX48621|ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
41335923|NCT02447640|RADIATION|[18F]FPEB|radiotracer used for PET scanning
41335924|NCT06305091|DIAGNOSTIC_TEST|Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples|Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples
41335925|NCT03816397|BIOLOGICAL|Adalimumab|Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody, a biologic, immunomodulatory drug. Adalimumab 20mg/0.8mL and 40mg/0.8mL is a clear, colorless solution provided in a pre-filled syringe for subcutaneous injection. The formulation is adalimumab, mannitol, polysorbate 80, and water for injection Each pre-filled syringe has a fixed 29-gauge thin wall and ½ inch needle with black protective cover and is intended for a single dose to a single patient.
41335926|NCT03816397|OTHER|Placebo|The placebo solution is a clear, colorless solution provided in a single-use, pre-filled syringe for subcutaneous injection. The placebo is designed to match the characteristics of the citrate-free adalimumab during injection.
41335927|NCT03723785|DRUG|Insulin icodec|Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
41335928|NCT00228033|DRUG|Elemental calcium (as carbonate)|
41335929|NCT01661946|DRUG|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
41335930|NCT01661946|DRUG|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
41335931|NCT05955872|DRUG|VX-147|Tablets for oral administration.
41335932|NCT01591993|PROCEDURE|10% lactic acid test|To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
41484795|NCT05925673|OTHER|Neuromuscular Stimulation (NMES)|Participants will use a portable NMES machine to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
41335933|NCT01591993|PROCEDURE|Placebo|To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
41335934|NCT03486561|DRUG|Ranolazine|Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
41335935|NCT00615212|DRUG|GSK376501|GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
41335936|NCT00615212|DRUG|Midazolam|Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.
41335937|NCT00615212|DRUG|Rosiglitazone|Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.
41335938|NCT00615212|DRUG|Flurbiprofen|Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
41335939|NCT01827241|OTHER|Chart Review|Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
41335940|NCT02562027|BEHAVIORAL|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|"* 30 quality of life questions for the participant to answer~* The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~* The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
41335941|NCT02562027|BEHAVIORAL|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|"* 13 quality of life questions for the participant to answer~* The answers range from 1 (Not at All) to 4 (Very Much)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
41484796|NCT05925673|OTHER|Mirror Therapy + NMES|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. During the exercises they will have a portable NMES machine set up to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
41484797|NCT05991648|PROCEDURE|Kangaroo Care (skin-to-skin contact)|Skin-to-skin contact between the mother and the child. The naked newborn, wearing only a diaper and a hat, is placed in a vertical position in direct contact between the mother's breasts. An elastic fabric support (made of cotton or synthetic elastic fiber) will be used to facilitate the position.
41484798|NCT04999930|DEVICE|Aerochamber|efficacy and patients satisfaction
41015200|NCT02785367|PROCEDURE|Cord blood samples|"After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.~The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth."
41015201|NCT03244228|DRUG|HTL0016878|Oral solution
41015202|NCT03244228|DRUG|Placebo - Concentrate|Matching placebo
41335942|NCT02562027|BEHAVIORAL|Modified Medical Research Council|"* Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
41335943|NCT02562027|BEHAVIORAL|EQ-5D|"* 5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~* The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
41335944|NCT02562027|BEHAVIORAL|Center for Epidemiological Studies Depression Scale|"* 20 quality of life questions for the participant to answer~* Answers range from Rarely or none of the time to Most or all of the time~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
41335945|NCT02562027|BEHAVIORAL|Medical Outcomes Study Social Support Survey|"* 19 quality of life questions for the participant to answer~* Answers from from 1 (None of the time) to 5 (All of the time)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
41484799|NCT04899817|DRUG|Granisetron|The drug is given after induction of general anesthesia
41484800|NCT00937820|DRUG|YM150|oral
41017972|NCT00403546|DRUG|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
41017973|NCT00403546|DRUG|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
41335946|NCT01789892|DRUG|methylprednisolone|Given IV
41335947|NCT01789892|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT scan
41335948|NCT01789892|PROCEDURE|positron emission tomography|Undergo FDG PET/CT scan
41335949|NCT01789892|PROCEDURE|computed tomography|Undergo FDG PET/CT scan
41335950|NCT00154193|DRUG|cyclosporine|patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
41335951|NCT03419845|DEVICE|Step Right Buddy|The Step Right Buddy, which is under investigation in this clinical study, is an elasticated band that attached by Velcro to the back legs of a standard walking frame. The purpose of the Step Right Buddy is to provide sensory feedback to standard walking frame users of how far to step in to the frame and to encourage them to move the frame forward.
41335952|NCT04725201|DRUG|Intravenous unfractionated heparin|See experimental arm description for intervention description.
41335953|NCT04725201|DRUG|Sham|See sham comparator arm description for intervention description.
41335954|NCT06039280|DRUG|N Acetylcysteine|NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.
41484801|NCT05079386|DEVICE|New Voice Prosthesis|Replacement of the current prosthesis with the experimental device and use the New Voice Prosthesis for the duration of two weeks with the option of leaving the device in situ until replaced for device failure or other reason, with a maximum of 12 months.
40817652|NCT06163625|DEVICE|Repetitive Transcranial Magnetic Stimulation|For those with depression where medication and psychotherapy have limited benefit, repetitive transcranial magnetic stimulation (rTMS) is an effective treatment. rTMS is a treatment that involves stimulating certain areas of the brain with magnetic field pulses. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region. This can be helpful in treating some kinds of psychiatric and neurological disorder, including MDD.
41335955|NCT06039280|DRUG|Dexamethasone|Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure.
40817653|NCT06163625|BEHAVIORAL|Research Interview, Questionnaires|"Research Interview: A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 30 minutes.~Research Questionnaires: A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. Questionnaires will be completed via pen and paper at each visit. These questionnaires will take approximately 90 minutes to complete."
40817654|NCT06163625|BEHAVIORAL|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes, and there will be a recovery period for 40 minutes. The participant will be given instructions about these tasks outside of the scanner. This brain scan will happen at St. Michael's Hospital.
40817655|NCT06163625|BIOLOGICAL|Saliva Samples|The participant will be asked to provide six 1mL saliva samples during the MRI scan and recovery period so that the investigators can measure molecular markers associated with depression. In order to provide the sample, the investigators will collect their saliva using a cotton swab and test tube. Each sample should take no more than 5 minutes.
41335956|NCT06039280|OTHER|Placebo|The placebo will be administered in the same way as the drug in the experimental group.
41484802|NCT00467636|PROCEDURE|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
41484803|NCT00467636|DRUG|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI \< 30 = 0.1 unit/kg. BMI \> 30 = 0.2 unit/kg)
41484804|NCT00944749|DRUG|h-ATG (ATGAM )|
41484805|NCT00944749|DRUG|Cyclosporine (Gengraf )|
41484806|NCT02901613|DEVICE|Negative-pressure wound therapy|
41484807|NCT04212533|DIETARY_SUPPLEMENT|Vitamin D|comparison between pre- and postoperative calcium and vitamin d level after vit d and calcium supplementation
41484808|NCT04212533|DIETARY_SUPPLEMENT|rice starch tablets|rice starch tablets as placebo
40817656|NCT01212679|DRUG|nerve growth factor|The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
41484809|NCT05485935|DEVICE|Investigational device - intermittent catheter with micro-hole zone|Intermittent male catheter with micro-hole zone for urinary drainage
41484810|NCT05485935|DEVICE|Comparator - standard intermittent catheter|SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.
41484811|NCT02164630|BEHAVIORAL|Hope Therapy|Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.
41335957|NCT01095939|DRUG|Placebo|Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
41015212|NCT02633475|GENETIC|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
41015213|NCT02133326|DRUG|Caldolor|Subject will be given Caldolor by IV prior to surgery.
41015214|NCT02133326|DRUG|Ofirmev|Subject will be given Ofirmev prior to surgery.
41335958|NCT01095939|DRUG|Benazepril hydrochloride|Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
41335959|NCT01095666|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
41335960|NCT01095666|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
41335961|NCT01095666|DRUG|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
41335962|NCT01095666|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
41335963|NCT01095666|DRUG|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
41335964|NCT00394693|GENETIC|Adenovirus Interferon gamma|intra-tumoral injections, 1 dose per lesion, up to 6 simultaneous lesions.
41335965|NCT06039969|OTHER||This is an obvertional study and there is no intervention
41335966|NCT03926260|OTHER|ctDNA analysis|blood sample at Baseline, 3weeks, 9 weeks after treatment, at progression if applicable
41335967|NCT04446299|DRUG|Bowel Prep|Orally ingested liquid bowel preparation
41335968|NCT01958554|BEHAVIORAL|Intervention Group|
41335969|NCT01052636|OTHER|Interdisciplinary intervention program|The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
41335970|NCT01153672|DRUG|vorinostat|Given PO
41015215|NCT04579913|OTHER|Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound|Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
41015216|NCT04666038|DRUG|LOXO-305|Oral LOXO-305
41015217|NCT04666038|DRUG|Idelalisib|Oral
41015218|NCT04666038|DRUG|Bendamustine|IV
41484812|NCT02164630|OTHER|Pain Education|Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
41335971|NCT01153672|OTHER|laboratory biomarker analysis|Correlative studies
41335972|NCT01153672|PROCEDURE|biopsy|Optional correlative studies
41335973|NCT01153672|RADIATION|F-18 16 alpha-fluoroestradiol|Correlative studies
41335974|NCT01153672|PROCEDURE|positron emission tomography|Correlative studies
41335975|NCT01153672|DRUG|anastrozole|Given PO
41335976|NCT01153672|DRUG|letrozole|Given PO
41484813|NCT00026286|DRUG|conjugated estrogens|
40817657|NCT01212679|DRUG|nomral saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
41015219|NCT04666038|DRUG|Rituximab|IV
41335977|NCT01153672|DRUG|exemestane|Given PO
41335978|NCT01153672|GENETIC|gene expression analysis|Correlative studies
41335979|NCT04260672|BEHAVIORAL|Child Centred Health Dialog (CCHD)|"The universal part of CCHD means a structured dialogue between the nurse and the child in presence of its parents using eight illustrations based on the most important practices associated with overweight in preschool children: fruit and vegetables consumption, intake of sweetened beverages and portion size, physical activity, sedentary behaviour tooth brushing and sleep routines. The health dialog is completed by demonstrating the BMI-growth chart to show BMI development to give parents an accurate weight perception, identify overweight and support parental readiness towards a healthy lifestyle.~When the child is identified with an overweight or obesity, the entire family is invited to participate in the targeted part of CCHD: the Family Guidance, a family consultation based on the evidence based Standardized Obesity Family Therapy (Nowicka, 2011)."
41335980|NCT02527902|DEVICE|Holter|measure of ANS in IgAN patients
41335981|NCT04246346|OTHER|An interactive chatbot for patient decision aid|A chatbot embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
41335982|NCT04246346|OTHER|Senior ophthalmologists|Senior ophthalmologists would communicate with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
41335983|NCT01378845|DRUG|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
41335984|NCT01378845|DRUG|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
41335985|NCT00035568|DRUG|Glucovance (metformin HCl/glyburide)|
41335986|NCT00035568|DRUG|or Metformin HCl alone|
41335987|NCT00035568|DRUG|or Glyburide alone.|
41484814|NCT00026286|DRUG|medroxyprogesterone|
41335988|NCT02776852|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: SR15-43-Y65-158)
41335989|NCT01415908|DEVICE|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
41335990|NCT01415908|OTHER|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
41335991|NCT03385525|DRUG|BIIB074|Administered as specified in the treatment arm
41335992|NCT03385525|DRUG|Valproic Acid|Administered as specified in the treatment arm
41335993|NCT01711658|RADIATION|IMRT|Intensity modulated radiation therapy (IMRT), 35 fractions over 6 weeks, 6 fractions per week for 5 weeks and 5 fractions per week for 1 week, 2 Gy per fraction to total dose of 70 Gy
41335994|NCT01711658|DRUG|Cisplatin|100 mg/m\^2 administered intravenously on days 8 and 29
41335995|NCT01711658|DRUG|placebo|1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
41335996|NCT01711658|DRUG|Lapatinib|1500 mg lapatinib by mouth or by feeding tube daily starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
41335997|NCT00490867|DRUG|Alpha lipoic acid|
41335998|NCT01749800|DEVICE|GVS|A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
41335999|NCT01749800|DEVICE|Sham GVS|Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
41336000|NCT01749800|DEVICE|Armeo Spring|A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
41336001|NCT04904341|DRUG|Cerebrolysin|neuroprotection treatment
41336002|NCT01248585|DRUG|Dexamethasone|2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
41484815|NCT03181698|DIAGNOSTIC_TEST|Magnetic resonance imaging|"A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.~The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls"
41484816|NCT03425487|BEHAVIORAL|Mindfulness based Intervention|MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
41484817|NCT03425487|BEHAVIORAL|Compassion based Intervention|ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
41336003|NCT01248585|DRUG|Placebo|2 placebo tablets taken once daily for 5 days
41336004|NCT03423862|OTHER|Mixed Meal Tolerance Test|"After a 10-hour overnight fast (not eating or drinking anything except water), participants will complete a mixed meal tolerance test (MMTT):~This involves participants drinking a Boost drink, like a milkshake, which will raise participants' blood sugar.~The amount of Boost will be based on participants body weight, up to a maximum of 360 mL or about 1 ½ cups, and should be consumed within 5 minutes.~An IV will be placed in participants arm and blood will be drawn from it. Blood will be drawn from the IV before and then 6 times over the next 2 hours after participants drink the Boost."
41336005|NCT05635370|DRUG|Pentoxifylline|Pentoxifylline claim is used as the exposure group.
41336006|NCT05635370|DRUG|Cilostazol|Cilostazol claim is used as the reference group.
41336007|NCT04520178|DRUG|5-Hydroxytryptophan 100 MG|100mg combined with 50mg carbidopa
41336008|NCT04520178|DRUG|5-Hydroxytryptophan|50mg combined with 50mg carbidopa
41336009|NCT04520178|DRUG|Carbidopa|50mg
41484818|NCT03425487|OTHER|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
41484819|NCT05034276|OTHER|MORE-VR|Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.
41484820|NCT06003751|DRUG|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
41484821|NCT06003751|DRUG|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
41484822|NCT06003751|DRUG|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
41484823|NCT02599636|OTHER|None intervention|Investigators will study the usual medical assistance
41484824|NCT02751359|DRUG|Cannabidiol|200, 400, or 800 mg Cannabidiol
41484825|NCT02751359|DRUG|Placebo|0 mg Cannabidiol
41336010|NCT04520178|DRUG|Placebo|Placebo
41336011|NCT05455307|DEVICE|Allium ureteral stent|observe the effficacy and safety of long-term self expanding ureteral stents for treating refractory ureteral stricture
41484826|NCT05355766|DRUG|CN128 Tablets|Iron chelator, oral tablets
41484827|NCT05813314|COMBINATION_PRODUCT|BMN 111 administration via Injector Pen|BMN 111 Injection will be given using an injector pen
41484828|NCT05813314|DRUG|BMN 111 administration via vial and syringe|BMN 111 Injection will be given using vial and syringe
41484829|NCT01791231|DRUG|Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)|A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
41336012|NCT03030768|DRUG|PrEP|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
41336013|NCT03030768|BEHAVIORAL|Counseling on timed condomless sex, ART and PrEP adherence|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
41015224|NCT05610800|DRUG|Exenatide 2 milligram (mg) Injection|Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
41015225|NCT05610800|DRUG|Placebo|Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
41015226|NCT05610800|DRUG|Nicotine patch|"Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke \>10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14."
41015227|NCT05610800|BEHAVIORAL|Smoking Cessation Counseling|Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
41015228|NCT02170753|PROCEDURE|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
41015229|NCT02170753|PROCEDURE|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
41015230|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
41015231|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
41015232|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
41015233|NCT05375513|OTHER|PMI@Home|"Personalized multidomain interventional program by combining tailored lifestyle interventions that targets 5 domains: physical activity, cognition, diet, sleep, and vascular risk factors. These interventions are tailored based on participants' baseline profile and progress in intensity following the principles of personalized medicine. All aspects of the PMI@home will be delivered remotely, at participants' homes, using a digital platform with scheduled bi-weekly 1-to1 coaching sessions. Delivery of interventions and assessments are centralized with 5 trained staff at the sponsor site (London) to assure logistics, standardization, and quality control."
41015234|NCT05375513|OTHER|Brain Health Pro|"Online Modules:~* Motivation, Self-Efficacy, Positive Health, Environment and Genetic risk~* Physical Activity~* Cognitively Stimulating Activities~* Diet~* Sleep~* Social and Psychological Health~* Vascular health~* Vision and Hearing~* Lifestyle Risk Impact Surveys~* Goal Setting"
41015235|NCT06572488|DEVICE|Non-ablative SMOOTH mode Er:YAG laser|Four intravaginal treatments within four months.
41015238|NCT00453505|DEVICE|TMS|\<=1 Hz TMS for up to 30mins and up to 115% of resting motor threshold intensity (MT).
41015239|NCT00453505|DEVICE|tDCS|tDCS up to 2 mA for up to 60mins.
41015240|NCT00453505|DEVICE|tACS|tACS up to 1 mA for up to 10 minutes.
41015241|NCT00453505|DEVICE|CPNS|CPNS alone with intensities below 130% of the peripherally-elicited-motor-threshold for up to 2 hours.
41015242|NCT06504017|PROCEDURE|COG-TB: Cognitive Fusion guided prostate targeted Biopsy|Cognitive Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
41015243|NCT06504017|PROCEDURE|FUS-TB: MRI-TRUS Fusion guided prostate targeted Biopsy|MRI-TRUS Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
41015245|NCT05130190|DEVICE|RF Treatment|ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.
41015246|NCT06538623|DRUG|Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin|Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);
41484830|NCT00907127|BEHAVIORAL|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
41015247|NCT06538623|DRUG|Tegodor|Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
41015248|NCT04360018|OTHER|Alcohol beverage|High-proof alcohol (e.g., Everclear) will be mixed with orange juice in an approximately 1:3 ratio and split evenly into two drinks. After splitting the orange juice into two cups, a small amount (approx. 6 ml) of high-proof alcohol will be floated on top of the beverage.
41015249|NCT04360018|OTHER|Placebo beverage|The final drink will have the same volume of liquid as the alcohol beverage.
41484831|NCT03096275|DRUG|MMF|Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
41484832|NCT03096275|DRUG|CYC|Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
40817658|NCT05401929|DEVICE|iTBS|Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
41015252|NCT06408285|DRUG|TQC3927 powder for inhalation|TQC3927 is a targeted inhibitor.
41015253|NCT06408285|DRUG|TQC3927 powder for inhalation placebo|TQC3927 powder for inhalation placebo contains no active substance.
40817659|NCT05401929|DEVICE|iTBS|Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
40817660|NCT03143907|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.
40817661|NCT03277430|PROCEDURE|Live donor uterus transplantation|Transplantation of uterus from a living donor.
40817662|NCT03277430|PROCEDURE|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
40817663|NCT03277430|DRUG|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
40817664|NCT05538806|DEVICE|TTFields|all patients will receive routine clinical care and TTFields
40817665|NCT01648296|DRUG|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
40817666|NCT02585024|DRUG|Cytisine|
40817667|NCT03727646|DIETARY_SUPPLEMENT|Nicotinamide riboside|nicotinamide riboside supplied as 250mg capsules
40817668|NCT06608693|OTHER|PNF stretching|Subjects lay supine on a treatment table, holding one knee to the chest and letting the other leg extend freely toward the floor at the end of the table. This protocol was adapted from previous studies. The hip joint was carefully and gradually lowered towards the floor, with the knee flexing at a 90-degree angle until the individual experienced a mild stretching sensation (Visual analog scale:4-6). Then, the subject performed a sub-maximal voluntary isometric contraction by utilizing the flexor muscles for 20 seconds while resisting the applied force exerted by an examiner through the utilization of a hand-held dynamometer (K-Force Muscle Control). The examiner proceeded to passively manipulate the leg to achieve the desired range of motion (ROM), maintaining it for 20 seconds. This process was repeated six times for each limb. The patient rested for 2 minutes before applying the same technique to the other side.
41336014|NCT05034614|DIAGNOSTIC_TEST|Papette brush collection|Cervical cell brush that gathers collects cervical cells during Pap smear collection
41336015|NCT05034614|DIAGNOSTIC_TEST|Spatula/cytology brush collection|Combination of extended-tip spatula with endocervical brush that collects cervical cells during Pap smear collection
41336016|NCT02820038|BEHAVIORAL|Medication Guides|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
41336017|NCT02820038|BEHAVIORAL|SMART Program|The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
41336018|NCT02820038|BEHAVIORAL|Drug Facts Boxes|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
41336019|NCT04815733|PROCEDURE|Mandatory ventilation|Use PCV-VG
41336020|NCT04815733|PROCEDURE|pressure support ventilation|Use PSVpro
41336021|NCT02758119|OTHER|Serious Game|
41336022|NCT02758119|OTHER|Online course|
41336023|NCT05467072|DEVICE|Annular closure|Lumbar discectomy patients treated with Annular Closure Device BARRICAID
41336024|NCT04538261|DEVICE|Fetal Pillow insertion|Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure
41484833|NCT03096275|DRUG|Glucocorticoids|Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
40817669|NCT06608693|OTHER|Static stretching group|While the patient was lying supine, the hip and knee joints on the non-stretch side were kept in 90⸰ flexion. A sandbag was positioned on the side to be stretched, specifically proximal to the patella, in order to induce a moderate sensation of stretching in the patient. Subsequently, a force was exerted in the direction of hip extension for a duration of 30 seconds. Afterward, the patient was instructed to relax. This process was repeated a total of six times, with a designated 20-second rest period between each repetition. The patient took a two-minute rest before the same technique was applied to the other side. There was no specific order on which side to apply the technique.
40817670|NCT05858450|BIOLOGICAL|Comirnaty|COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
40817671|NCT05858450|BIOLOGICAL|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines
41015254|NCT06199986|BEHAVIORAL|ADT Order Check Attestation (Or)|Clinical reminder order check in electronic health record
41336025|NCT01364857|GENETIC|search for polymorphisms of RASA1 gene|Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
41336026|NCT00882167|OTHER|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
41336027|NCT01529450|DRUG|LDE225|800-mg (4 200-mg capsules/day) capsule
41336028|NCT05021172|OTHER|Best Practice|Receive usual care
41336029|NCT05021172|OTHER|Informational Intervention|Receive Passport to Health booklet
41336030|NCT05021172|OTHER|Questionnaire Administration|Complete ePrognosis
41336031|NCT05021172|OTHER|Survey Administration|Ancillary studies
41336032|NCT05878691|DRUG|GRC 54276|"Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm."
41484834|NCT03096275|DRUG|MTX|Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
41484835|NCT03096275|DRUG|AZA|Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
41015255|NCT06199986|BEHAVIORAL|Provider Script (Sc)|Provider script added to progress note in electronic health record
41336033|NCT05878691|DRUG|GRC 54276 + Pembrolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
41336034|NCT05878691|DRUG|GRC 54276 + Atezolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
41336035|NCT02017704|RADIATION|Endo-HDR (if randomized to this arm)|Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
41336036|NCT02017704|DRUG|capecitabine and IMRT (if randomized to this arm)|Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
41336037|NCT02017704|RADIATION|IMRT (intensity modulated radiation therapy)|Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
41336038|NCT02017704|DRUG|FOLFOX6|"* Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion."
41336039|NCT02017704|PROCEDURE|Surgery|"After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis."
41336040|NCT00776490|DRUG|Glimepiride 1mg Tablets|
41484836|NCT04696107|BEHAVIORAL|Psychoeducative intervention|"This workshop is centred in psychoeducational and training action in emotional self-regulation in a group modality and participatory character, aimed at patients with mCNCP to acquire basic knowledge in:~* Neurology and psychoneuroimmunology.~* The role of beliefs in our manifestation of the disease.~* Body language and modulation of pain perception.~* Relaxation body-mind techniques.~* Creative visualization for pain management.~* Mirror feed-back.~The workshop will take place at the Hospital San Juan de Dios del Aljarafe, in four weeks, once a week, three hours each. Until now, the attendance was 24 patients per workshop. After the pandemic, we will reduce to 15 to increase safety distance. We will also conduct a telephone survey of each patient on symptoms of Covid infection in the 24 hours prior to the workshop."
41484837|NCT04449757|DRUG|Bicarbonated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
41484838|NCT04449757|DRUG|Lactated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
41015262|NCT04617093|DEVICE|PrismaLung+|Overall, up to 60 adult patients will be initiated on ECCO2R using PrismaLung+. A minimum of approximately 15 patients will be treated with ECCO2R using PrismaLung+ as stand-alone therapy and another minimum of approximately 15 patients (maximum of 20) will receive ECCO2R using PrismaLung+ in combination with CRRT.
41336041|NCT04516031|PROCEDURE|Posterior Component Separation with Transversus Abdominis Muscle Release|The posterior component separation technique with transversus abdominis muscle release was done as prescribed in Novitsky et al in 2012.
41336042|NCT04516031|PROCEDURE|Mesh-only repair|The prosthetic mesh only repair was done as described by Wantz in 1991.
41336043|NCT06269588|DEVICE|Nexpowder|Endoscopic hemostasis
41336044|NCT04153929|DRUG|BI 456906|Solution for Injection
40918340|NCT03014999|DEVICE|sham rTMS (repetitive Transcranial Magnetic Stimulation)|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
41336045|NCT04153929|DRUG|Placebo|Solution for Injection
41336046|NCT04153929|DRUG|Semaglutide|Solution for Injection
41336047|NCT02402621|DRUG|fentanyl|fentanyl with antiemetic drug
41336048|NCT02061904|RADIATION|DEXA: dual energy X-ray absorptiometry|Bone mineral density development measured with dual energy X-ray absorptiometry
41336049|NCT02061904|OTHER|Short Form Health Survey 12|questionnaire for general health monitoring
41336050|NCT02061904|OTHER|VAS-satisfaction|questionnaire for intervention satisfaction monitoring
41336051|NCT02061904|OTHER|VAS-pain|questionnaire for pain monitoring
41336052|NCT02061904|OTHER|Harris Hip Score|questionnaire for hip function monitoring
41336053|NCT05164263|DRUG|Empagliflozin|Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg
41336054|NCT02756546|DRUG|Cyclophosphamide|
41336055|NCT02756546|DRUG|Hydroxychloroquine|
41336056|NCT02756546|DRUG|Hydrocortisone|
41336057|NCT06034041|DRUG|Mediclore|After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.
41336058|NCT06034041|DRUG|Normal Saline|After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
41336059|NCT00688545|DRUG|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
41336060|NCT00688545|DRUG|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
41336061|NCT00053222|DRUG|arsenic trioxide|
41336062|NCT01501669|DRUG|Irinotecan, Capecitabine|"Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks"
41336063|NCT06037512|DIAGNOSTIC_TEST|subject|blood glucose measurement by subject
41336064|NCT06037512|DIAGNOSTIC_TEST|reference|blood glucose measurement with reference
41336065|NCT01562145|PROCEDURE|Blood sampling|Four mL venous blood samples were collected from all study participants after inclusion
41336066|NCT02477306|DRUG|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
41336067|NCT02477306|DRUG|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
41336068|NCT05537493|OTHER|Telerehabilitation|It will be followed by exercising on whatsapp
41336069|NCT05537493|OTHER|Face to face|It will be followed by face to face
41336070|NCT01116310|DRUG|Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
41336071|NCT01116310|DRUG|Placebo|Bottles containing 60 capsules.
41336072|NCT02411513|DEVICE|CEFALY|
41336073|NCT00702728|DRUG|Furosemide and matched saline hydration|Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
41336074|NCT00702728|DRUG|isotonic saline solution|Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
41336075|NCT00062205|DRUG|imatinib mesylate|
41484839|NCT04129320|BIOLOGICAL|enoblituzumab|anti-B7-H3 antibody
41484840|NCT04129320|BIOLOGICAL|MGA012|anti-PD-1 antibody
41484841|NCT04129320|BIOLOGICAL|MGD013|PD-1 X LAG-3 bispecific DART protein
41484842|NCT01490866|DRUG|Axitinib|5-mg tablets PO BID
41484843|NCT01490866|DRUG|Bevacizumab|5 mg/kg Days 1 and 15; IV
41484844|NCT01490866|DRUG|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
41484845|NCT01490866|DRUG|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
40817672|NCT05236452|OTHER|Training for traditional and modern care providers|The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
40817673|NCT05009641|DIETARY_SUPPLEMENT|L-carnitine|
40817674|NCT02354131|DRUG|Niraparib|Niraparib versus Bevacizumab-Niraparib combo
40817675|NCT02354131|DRUG|Bevacizumab|
40817676|NCT04571307|PROCEDURE|cryotherapy|comparison between cryotherapy and surgery
40817677|NCT00904462|DRUG|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
40817678|NCT00904462|DRUG|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
40817679|NCT01753219|PROCEDURE|Onstep|
41336076|NCT00145197|BEHAVIORAL|Improving the Delivery of Effective Care to Minorities|The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
41336077|NCT04658368|PROCEDURE|Primary TMR|TMR procedure as part of the primary major limb amputation surgery
41484846|NCT01490866|DRUG|Leucovorin|400 mg/m2 Days 1 and 15; IV
40817680|NCT01753219|PROCEDURE|Lichtenstein|
40817681|NCT04077346|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous spinal stimulation (TcStim): The 5-channel stimulator capable of generating (41) pain-free biphasic rectangular waveform of 0.3- to 1.0-ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels.~TcStim will be delivered in combination with activity based locomotor training in 5 - 10 minute of stimulation at sub-motor threshold daily (5x/week) for 60 sessions"
41336078|NCT04658368|PROCEDURE|Secondary TMR|TMR procedure subsequent to major limb amputation surgery
41336079|NCT02242760|DRUG|SB204 2%|Applied topically twice daily
41336080|NCT02242760|DRUG|SB204 4%|Applied topically daily
40817682|NCT04077346|OTHER|Transcutaneous Spinal Stimulator + Activity Based Locomotor Training|Participants will receive a combination of Activity-based locomotor training (AB-LT)+TcStim daily (5x/week) for 60 sessions and will consist of a minimum of 55-60 min on the TM for facilitated standing/stepping followed by 30 min of activities off TM in sitting, standing, or stepping.
40817683|NCT03575364|DEVICE|ClotTriever|Thrombectomy
40817684|NCT00005077|DRUG|oxaliplatin|
40817685|NCT01916252|DRUG|bortezomib (Velcade ®)|
41336081|NCT02242760|DRUG|Vehicle Gel|Applied topically twice and once daily
41336082|NCT02050451|DIETARY_SUPPLEMENT|Ensure Plus®|
41484847|NCT01490866|DRUG|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
41484848|NCT02139371|OTHER|Injection of 64Cu-DOTA-AE105|One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
41484849|NCT00488930|OTHER|Observational|data collection ONLY
41484850|NCT02214784|DEVICE|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
41484851|NCT02214784|DEVICE|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
41484852|NCT05355714|DEVICE|Sofwave|High-Frequency Non-Focused Ultrasound Device
41484853|NCT05355714|DEVICE|Ultherapy|Microfocused Ultrasound with Visualization
40817686|NCT01916252|DRUG|lenalidomide (Revlimid®)|
40817687|NCT01916252|DRUG|busulfan (Busilvex ®)|
40817688|NCT01916252|DRUG|Dexamethasone acetate|
40817689|NCT01916252|DRUG|Melphalan|
40817690|NCT02038140|DEVICE|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
40817691|NCT03817463|DRUG|Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
40817692|NCT03817463|DRUG|Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor|Dipeptidyl peptidase-4 (DPP-4) inhibitor
40817693|NCT03173976|DRUG|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
41336083|NCT02050451|DIETARY_SUPPLEMENT|Multivitamin|
41336084|NCT00052936|BIOLOGICAL|filgrastim|
40817694|NCT05655325|BEHAVIORAL|Home-based walking exercise|A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.
40817695|NCT05655325|OTHER|Attention control|Health education and stretching
40817696|NCT04117581|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU (125 μg) vitamin D3 capsules daily over 12 weeks (84 days)
40817697|NCT04117581|OTHER|Placebo|Inert filler capsules daily over 12 weeks (84 days)
40817698|NCT00221000|DRUG|Methoxsalen|
40817699|NCT00221000|PROCEDURE|Extracorporeal Photopheresis|
41336085|NCT00052936|BIOLOGICAL|rituximab|
41336086|NCT00052936|DRUG|CHOP regimen|
41336087|NCT00052936|DRUG|cyclophosphamide|
40817700|NCT05807477|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
40817701|NCT06033196|DRUG|Tocilizumab|"The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.~6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more"
40817702|NCT06033196|DRUG|Placebo for Tocilizumab|"Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)~Placebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses"
40817703|NCT03426462|DRUG|Propofol|Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.
40817704|NCT02070419|PROCEDURE|transarterial chemoembolization|Undergo TACE with doxorubicin-eluting beads
40817705|NCT02070419|RADIATION|stereotactic radiosurgery|Undergo SBRT
41336088|NCT00052936|DRUG|doxorubicin hydrochloride|
41336089|NCT00052936|DRUG|prednisone|
40817706|NCT02250807|DRUG|Simeprevir|Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
40817707|NCT02250807|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
40817708|NCT04110951|BEHAVIORAL|Pranayama Breathing Technique|Yogic Breathing Technique
41015271|NCT01747213|DRUG|BNC|
41015272|NCT01747213|OTHER|Placebo|Microcrystalline cellulose fiber
41336090|NCT00052936|DRUG|vincristine sulfate|
41336091|NCT00052936|RADIATION|radiation therapy|36Gy on BULK and extranodal involvement
41336092|NCT02955368|DRUG|DP-R212|DP-R212 + C1-R212 placebo + C2-R212 placebo
41336093|NCT02955368|DRUG|C1-R212|DP-R212 placebo + C1-R212 + C2-R212 placebo
41336094|NCT02955368|DRUG|C2-R212|DP-R212 placebo + C1-R212 placebo + C2-R212
41336095|NCT03596970|DRUG|TAC withdrawal|Everolimus (RAD001) with MMF and Steroids
40817709|NCT04110951|BEHAVIORAL|Relaxation technique|Progressive relaxation technique
40918341|NCT03050411|DRUG|Apatinib Mesylate Tablets|250mg, 500mg, 750mg, q.d., p.o.
40918342|NCT03050411|DRUG|EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)|EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
40918343|NCT03911102|BIOLOGICAL|DaxibotulinumtoxinA for injection|Intramuscular injection
40918344|NCT00329524|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
41336096|NCT03596970|DRUG|Everolimus with reduced TAC|Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
41336097|NCT05098418|DRUG|Poison|standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable
41484854|NCT04315870|OTHER|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
40817710|NCT00770497|DRUG|Pioglitazone|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks."
41017974|NCT00403546|DRUG|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
41017975|NCT02717091|DRUG|FOLFIRINOX|
41017976|NCT02717091|DRUG|gemcitabine + nab-paclitaxel|
41017977|NCT01175694|RADIATION|Interstitial multicatheter brachytherapy|Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
41017978|NCT01007461|DRUG|Sodium Sulfide (Na2S) for Injection|IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started \> 5 minutes but \< 20 minutes (approximately) prior to coronary artery reperfusion.
41484855|NCT02350244|BEHAVIORAL|Computer program|Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
41484856|NCT04375865|DRUG|AD-2111|celecoxib 200mg
41484857|NCT04375865|DRUG|AD-2112|Tramadol 150mg
41484858|NCT01328236|DRUG|Bortezomib|"INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
40918345|NCT05676918|BEHAVIORAL|Positive Psychology Intervention|PPI includes 2 modules: hedonic well-being and eudaimonic well-being.
40918346|NCT05676918|BEHAVIORAL|Cognitive Behavior Therapy|CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.
40918347|NCT05884749|BEHAVIORAL|Peer to Community (P2C) Model|The P2C model is an outreach model including peer support, occupational therapy and social work aimed at facilitating community integration through relationship building and meaningful activity engagement for individuals living with concurrent disorders following homelessness.
40918348|NCT05884749|BEHAVIORAL|Care as Usual (UC)|Participants in this group will receive care available typically in the community
40918349|NCT00367783|DRUG|CP-741,952|
40918350|NCT05825157|DEVICE|BioBridge|Fibralign BioBridge is a thread-like, multi-lumen scaffold consisting of highly aligned collagen fibrils, optimized to encourage the endothelial cell attachment,alignment and migration that are prerequisites to new vessel formation. BioBridge is a device made from highly purified, medical-grade porcine collagen.
40918351|NCT01931371|PROCEDURE|Anal Fistula Plug|Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
40918352|NCT01931371|PROCEDURE|Endorectal Advancement Flap|Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
40918353|NCT05822765|DRUG|Epinephrine concentration of 1:1000000|Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
40918354|NCT05822765|DRUG|Epinephrine concentration of 1:500000|Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter with same lidocaine and bicarbonate dose. lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
40918355|NCT00460291|DEVICE|Implantation of the ProVena vein graft during bypass surgery|
41017979|NCT01007461|DRUG|Placebo|0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
41017980|NCT05390866|OTHER|HIIT|A single HIIT on a bicycle ergometer
41017981|NCT01343160|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
41017982|NCT03009071|PROCEDURE|Doin (conduction exercise)|Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
41017983|NCT03009071|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
41017984|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using single needle approach|The primary outcome is to study the efficacy of the described technique which creates a lesion that we estimate to be 11.0-mm wide and 11.6-mm long along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score. Responder status was defined as a 30% or greater improvement in VAS pain score from the pre-procedural VAS pain score. Outcomes were summarized by means and standard deviations for continuous outcomes, and frequencies (%) for categorical outcomes.
41017985|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using three needle approach|The primary outcome is to study the efficacy of the described technique by maximizing the lesion size (compared to control group) along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score.
41017986|NCT05795387|OTHER|Video-based self-regulated training on the mental status exam|Authentic patient videos for self-regulated training as well as written e-course material, both on the mental status exam
41017987|NCT05795387|OTHER|E-course with written material on the mental status exam|Written material on the mental status exam
41017988|NCT00399334|DRUG|antipsychotic medications|as prescribed
41017989|NCT01922596|DRUG|Ropivacaine|
41017990|NCT01922596|DRUG|Placebo|
40817711|NCT00770497|DRUG|Pioglitazone and ramipril|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
41015278|NCT01273168|DRUG|Z-Endoxifen|Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit.
41015283|NCT04463719|BEHAVIORAL|Counseling using the electronic conversation aid|Patients receive counseling about thyroid biopsy with the use of the conversation aid.
41484859|NCT01328236|DRUG|Liposome doxorubicin|INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
41484860|NCT01328236|DRUG|Dexamethasone|"INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
41484861|NCT02777515|BEHAVIORAL|using electronic cigarette|"Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~1. A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~2. measurement of blood pressure~3. An electrocardiogram~4. A Holter-ECG 10 minutes~5. A transthoracic echocardiogram"
41484862|NCT01936623|BEHAVIORAL|Computerized Brief Intervention|No additional information needed.
41484863|NCT02381626|DEVICE|HEPA air purifier|air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
41484864|NCT02381626|BEHAVIORAL|questionnaires|
41484865|NCT02381626|OTHER|Log-book|PM and biological measurements
41484866|NCT02381626|OTHER|Urine sample|PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
41484867|NCT00102687|DRUG|azacitidine|"Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation."
41484868|NCT04896827|OTHER|Conditioned pain modulation test|Conditioned pain modulation (CPM) protocol consist of evaluating pain during a heat test, before and after one conditioning stimulus (cold water bath); 3 cameras will be capturing participants' facial expressions during the tests.
40817712|NCT00770497|DRUG|Ramipril|"Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
40817713|NCT02679144|DRUG|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
40817714|NCT05758181|OTHER|Apical Undermining|The skin at the tip of the wound will be freed to reduce tension.
41015284|NCT04463719|BEHAVIORAL|counseling by routine care|Patients receive counseling by routine care without the use of the conversation aid
40817715|NCT01320553|DRUG|SPARC1102 I|SPARC1102 I will be administered in both eyes
40817716|NCT01320553|DRUG|SPARC1102 II|SPARC1102 II will be administered in both eyes
41015285|NCT04219163|BIOLOGICAL|CLL-1.CAR T cells|"Dose escalation study with 3 dose levels:~DL1: 1x10\^7 cells/m2, DL2: 3x10\^7 cells/m2, DL3: 1x10\^8 cells/m2~If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10\^6 cells/m2"
41484869|NCT02340845|BIOLOGICAL|Bromelain and Comosain|Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
41015290|NCT06083753|DRUG|PIPE-307 Dose A|Subjects will receive daily oral doses of PIPE-307
41015291|NCT06083753|DRUG|PIPE-307 Dose B|Subjects will receive daily oral doses of PIPE-307
41015292|NCT06083753|DRUG|Placebo|Subjects will receive daily oral matching dose of Placebo
41015293|NCT05255289|PROCEDURE|Urodynamic investigations before and after a trans-obturator tape protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.)
41015294|NCT05255289|PROCEDURE|Urodynamic investigations before and after a tension-free vaginal tape-obturator (TVT-O)|Urodynamic investigations (stated above.)
41015295|NCT05255289|PROCEDURE|Urodynamic investigations before and after a mini Arc protocol.|Urodynamic investigations (stated above)
41015296|NCT05255289|PROCEDURE|Urodynamic investigations before and after an i-STOP mini adjustable sling protocol.|Urodynamic investigations (stated above)
41015299|NCT05967806|PROCEDURE|assessment|2 ml volume of blood withdrawal
41015300|NCT04346615|DRUG|Zavegepant (BHV-3500)|10 mg intranasal (IN) for 14 days
40817717|NCT01320553|DRUG|SPARC1102 III|SPARC1102 III will be administered in both eyes
40817718|NCT01320553|DRUG|Vehicle|Vehicle will be administered in both eyes
41015301|NCT04346615|DRUG|Placebo|Placebo Q8h for 14 days
41015304|NCT05412550|BEHAVIORAL|Exercise self-management|Six walking exercise self-management telehealth sessions will focus on behavior change techniques and personalized action plans. Peer support groups will be held every three months, and will be focused on supporting participants in attaining sustained exercise. Text message prompts will focus on encouraging exercise and health self-management.
41015305|NCT05412550|BEHAVIORAL|Attention control|The six individual telehealth sessions, six peer-group sessions, and text message prompts will focus on general health education. No prompts for exercise or health self-management will be given.
41015306|NCT05112601|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and/or blood samples
41015307|NCT05112601|PROCEDURE|Computed Tomography|Undergo CT
41015308|NCT05112601|BIOLOGICAL|Ipilimumab|Given IV
41015309|NCT05112601|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41015310|NCT05112601|BIOLOGICAL|Nivolumab|Given IV
40817719|NCT00322296|DRUG|Bexarotene 1% gel|
40817720|NCT02315612|BIOLOGICAL|CD22-CAR|CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
40918356|NCT02784639|OTHER|Plasma Analysis of circulating cell free DNA|
40918357|NCT02784639|OTHER|Tumor tissue analysis of circulating cell free DNA|
40918358|NCT03881761|BIOLOGICAL|CD19/CD20 bispecific CAR-T cells|collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg
41484870|NCT02169349|OTHER|laboratory biomarker analysis|
41484871|NCT02169349|OTHER|Next Generation Sequencing|
41484872|NCT02169349|GENETIC|DNA Analysis|
41484873|NCT01745705|OTHER|Cervical Spine Manipulation|
41484874|NCT01745705|OTHER|Manual Contact|
41484875|NCT00534014|DIETARY_SUPPLEMENT|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
41015311|NCT05091567|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
41015312|NCT05091567|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
41015313|NCT05091567|DRUG|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
41015314|NCT05091567|DRUG|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
41015315|NCT04473040|DRUG|alpelisib|Alpelisib is provided as 50 mg and 200 mg film coated tablets as individual patient supply, packaged in bottles. Alpelisib will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. Alpelisib will be administered at a starting dose of 300 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.
41015316|NCT05212259|DRUG|Collagen type II (40 mg/day)|4 capsules per day
41015317|NCT05212259|DRUG|Collagen type II (80mg/day)|4 capsules per day
41015318|NCT05212259|DRUG|Collagen type II (120 mg/day)|4 capsules per day
41015319|NCT05212259|DRUG|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day
41484876|NCT00940836|DRUG|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
41015320|NCT05212259|DRUG|Placebo|4 capsules per day
41015321|NCT01818336|DRUG|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
41336098|NCT03024710|BEHAVIORAL|Intervention cluster|The mother- infant pairs (the infant who has completed his/her 6 month of age from the date of birth along with their mother) of intervention clusters will receive the CF practice counselling in groups as soon as enrolment is completed by CHRW at fixed site clinic and refreshers will be arranged 3 months apart from first training in groups at same place and by same person. However CHRWs will also counsel each participant during her bimonthly household visit.
41484877|NCT00940836|DRUG|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
41484878|NCT00940836|DRUG|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
41484879|NCT05435339|BIOLOGICAL|GEN1053|GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
41484880|NCT00833742|BEHAVIORAL|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
41484881|NCT05050006|BIOLOGICAL|ITIL-168|ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.
41484882|NCT03338348|DRUG|Vosaroxin|Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
41484883|NCT03338348|DRUG|Azacitidine|"Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;~Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
41484884|NCT04710511|OTHER|Child and Youth Resilience Measure - Revised (CYRM-R)|(CYRM-R): questionnaire , answered by the child (PMK): questionnaire, answered by the parent
41484885|NCT04413136|BEHAVIORAL|Web-ORLA|
41015322|NCT02344368|OTHER|0.2 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
41336099|NCT01152411|OTHER|Autologous bone marrow stem cells|Bone marrow stem cells; Single dose; Interventional fluoroscopy-guided injection into the renal artery.
41336100|NCT00033982|DRUG|Posaconazole|
41336101|NCT00635557|DRUG|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
41336102|NCT05008133|BEHAVIORAL|Bicycle exercise|Stepwise increased exercise for 5 minutes at 0, 50, 100 and 150 Watts. One series lying flat in prone position, after 15 minutes of rest, series repeated at 70 degrees head up tilt.
41484886|NCT04413136|BEHAVIORAL|Control|
41484887|NCT02327117|DRUG|Tranexamic Acid|
41484888|NCT02327117|DRUG|Normal saline|
41484889|NCT03822507|DRUG|KHK7580|oral administration
41484890|NCT03822507|DRUG|Cinacalcet Hydrochloride|oral administration
41484891|NCT02681224|OTHER|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
41484892|NCT02681224|OTHER|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
41484893|NCT02681224|OTHER|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
41484894|NCT02681224|OTHER|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
41484895|NCT06471530|DRUG|TE-8105 SAD Cohort 1|Each participant will receive one dose of TE-8105 0.5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
41484896|NCT06471530|DRUG|TE-8105 SAD Cohort 2|Each participant will receive one dose of TE-8105 0.75 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
41484897|NCT06471530|DRUG|TE-8105 SAD Cohort 3|Each participant will receive one dose of TE-8105 1.5 mg or less than or equal to 2.5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
41484898|NCT06471530|DRUG|TE-8105 SAD Cohort 4|Each participant will receive one dose of TE-8105 3 mg or less than or equal to 5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
41484899|NCT06471530|DRUG|TE-8105 SAD Cohort 5 (Adaptive cohort)|Each participant will receive one dose of TE-8105 less than or equal to 6 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
41484900|NCT06471530|DRUG|TE-8105 MAD Cohort 1|Each participant will receive 5 doses of TE-8105 0.5 mg or less than or equal to 1.5 mg injection via SC injection into the abdomen on Day 1 and then Q2W for 5 doses.
40817721|NCT06362655|BEHAVIORAL|Intervention|Intervention study. In this intervention study for teachers, a 5-month continuous training program will be included that will improve teaching style and promote teaching training. It will also strengthen teaching competencies to create teaching improvement strategies affecting PEaH and interpersonal and personal factors. This is expected to improve schoolchildren's AB, even when they are not directly influenced. The program will be designed according to the results of the cross-sectional study. The greatest associations found between the three proposed factors (school, interpersonal and personal factors) and schoolchildren AB will be sought. In addition, the characteristics of the schools and the possibilities of time and physical spaces available will be taken into account. This information will be recorded through validated questionnaires and interviews in the pre-test, post-test 1 and after follow-up post-test 2.
40817722|NCT02944864|DRUG|TQ-B3395|TQ-B3395 p.o. qd
40817723|NCT02879643|DRUG|Marqibo|The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
41484901|NCT06471530|DRUG|TE-8105 MAD Cohort 2|Each participant will receive 5 doses of TE-8105 1 mg or less than or equal to 3 mg injection via SC injection into the abdomen on Day 1 and then Q2W for 5 doses.
40817724|NCT00438126|BEHAVIORAL|A lifestyle educational program|
41484902|NCT05789719|BIOLOGICAL|STEM-OA|Combination of autologous or allogeneic MSC(AT)s and fat
41484903|NCT00468078|PROCEDURE|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
41484904|NCT00468078|DRUG|F-18 FPCIT|5mCi, intravenous injection
41484905|NCT06263062|BEHAVIORAL|Awareness-Based Coping with Fear of Cancer Programme|The content of the Training Program was created by researchers based on MBSR, in line with high-level research results and international guides.Then, the necessary arrangements were made bytaking the opinions of 10 experts ( faculty members of the department of obstetrics and gynaecology nursing, psychiatry specialist, faculty members of the gynaecology oncology department, oncology clinic psychologist, obstetrics and gynaecology clinic charge nurse). Content concluded in accordance with the comments received.
40817725|NCT06024850|OTHER|Datas collected|"Datas collected by medical record: medical data (weight, height, smoking status, history) and socio-demographic data (age, occupation, type of injury) information, assessment of knee function before surgery, at 6 months and 1 year after surgery, magnetic resonance imaging (MRI) and radiological imaging at 1 year after surgery, results of the Iso-kinetic Muscle Assessment Test at 1 year after surgery to objectively determine the recovery of muscle function~The data collected will be used to perform a statistical analysis to evaluate the factors predicting a good long-term post-surgical evolution"
40817726|NCT03100916|DRUG|BI 690517|once daily
40817727|NCT03100916|DRUG|Placebo|once daily
40817728|NCT03100916|DRUG|BI 690517 (Reference)|Fasting
41336103|NCT06249022|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
41336104|NCT06249022|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
41484906|NCT02071849|DEVICE|HAART 200 Aortic Valve Annuloplasty Device|Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
41484907|NCT05442671|BEHAVIORAL|Exercise intervention|16-week home exercise intervention, enriched by mobile health technology
41484908|NCT01844999|BEHAVIORAL|Personal Patient Profile - Prostate (P3P)|Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
40817729|NCT03100916|DRUG|BI 690517|Non- fasting
41484909|NCT01844999|BEHAVIORAL|Standard prostate cancer information websites|Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
40817730|NCT02864888|RADIATION|Radiation|Children with a diffuse, intrinsic brain stem glioma will receive radiation.
40817731|NCT02864888|DRUG|Atengenal|Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
40817732|NCT02864888|DRUG|Astugenal|Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
40817733|NCT05777317|DEVICE|10 kHz SCS|Spinal cord stimulation programmed to a frequency of 10 kHz
41015323|NCT02344368|OTHER|0.5 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
41484910|NCT00492765|DRUG|Interferon-beta-1a|dosage and frequency as per label
41484911|NCT00492765|DRUG|Simvastatin|dosage and frequency as per Biogen Idec protocol
41484912|NCT00492765|DRUG|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
41484913|NCT02515760|PROCEDURE|Bone marrow aspiration from the iliac crest|
41484914|NCT02515760|DEVICE|Illinois bone marrow aspiration neddle|
41336105|NCT06249022|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
41336106|NCT01849562|DRUG|Sovaprevir|Nonstructural protein 3/4A protease inhibitor.
41336107|NCT01849562|DRUG|ACH-3102|Nonstructural protein 5A inhibitor.
41336108|NCT01849562|DRUG|Ribavirin|
41336109|NCT01849562|DRUG|Placebo|
41484915|NCT00367003|DEVICE|Deep Brain Stimulation|The deep brain stimulation system (consisting of a lead, extension wire, and implanted pulse generator) will be surgically implanted to stimulate the targeted area of the brain. Stimulation will be turned off for 4 weeks following implantation, then participants will use brain stimulation for 6 months. Participants will also take part in Behavioral Activation therapy during the 6 months of active stimulation. Participants will be followed for 10 years, or until the DBS device has been FDA approved, with adjustments made to the stimulator and medications as necessary.
41484916|NCT03763552|OTHER|arthroscopic wrist arthrodesis|Cases of midcarpal wrist arthritis treated surgically with arthroscopic partial wrist fusion with cannulated screws
41336110|NCT00432913|DRUG|Eicosapentaenoic Acid (EPA)|Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
41336111|NCT00432913|PROCEDURE|Endoscopy|At baseline, month 3 and month 6.
41336112|NCT00432913|PROCEDURE|Biopsies taken|9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
41336113|NCT00432913|PROCEDURE|Clinical chemistry|Full blood count at baseline, month 3 and month 6.
41336114|NCT00432913|PROCEDURE|Haematology|Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
41336115|NCT00432913|PROCEDURE|Physical examination|Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
41336116|NCT00432913|PROCEDURE|Vital signs|Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
40817734|NCT05777317|OTHER|CMM alone|Conventional medical management alone
40817735|NCT05076279|PROCEDURE|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
41015324|NCT02215070|DRUG|Pasireotide|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
41015325|NCT05209295|DRUG|Onureg|Specified dose on specified days
41015326|NCT04190745|DRUG|Toripalimab+Apatinib mesylate|Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
41336117|NCT00432913|PROCEDURE|Urine pregnancy test|For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
41336118|NCT00432913|PROCEDURE|Completion of patient diary card|Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
41336119|NCT05729269|DIAGNOSTIC_TEST|Sarcopenia_CT|measurement of skeletal muscle through abdominal computed tomography
41336120|NCT02116361|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
41336121|NCT02116361|DRUG|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
41336122|NCT05076097|DRUG|Orelabrutinib in in combination of rituximab and lenalidomide(OLR)|Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
41484917|NCT05543330|DRUG|M701 pleural infusion|M701 pleural infusion on Days 1,4,7 and 10.
41015327|NCT04190745|DRUG|paclitaxel|paclitaxel 80mg/m2, q3w
41484918|NCT05543330|PROCEDURE|Pleural drainage|Pleural effusion drainage via Ultra-sound guidance on Day 1.
41484919|NCT05543330|DRUG|Cisplatin pleural infusion|Cisplatin pleural infusion (30-50mg/m2) on Day 1.
41336123|NCT01442519|BIOLOGICAL|bacillus Calmette-Guerin|The BCG instillation consisted of 81 mg wet weight (10•2±9•0_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
40817736|NCT06399432|BEHAVIORAL|Mediterranean Diet|"In the Mediterranean Diet, all foods are included. Red meat will be limited to 1/week, poultry to ≤3 times/week and fish to 2-3 times/week. Supplementation with extra-virgin olive oil and nuts, providing 1 liter of olive oil per week and 30 gr a day of nuts.~The dietician will personalize the dietary advice by adapting it to the patient's condition, preferences and beliefs, will encourage adherence, and transmit a sense of empowerment. A change in diet with specific, attainable goals will be negotiated between the dietician and the participant.~Dieticians will conduct a phone call once in every 2-week period to assess dietary compliance using a 24-hour food recall, the Mediterranean Diet Adherence Form. MD patients will keep a diet diary for 3 days every two weeks, which they will discuss with the dietician during their scheduled dietician assessment. The Baseline Visit with the dietician can occur either in-person or via video communication software."
41336124|NCT01442519|DRUG|electromotive mitomycin|BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
41336125|NCT05078307|PROCEDURE|OHR VS OHV|"Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid.~Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid."
41336126|NCT04672070|OTHER|Selective Caries Removal|"Selective caries are removed only for secure sealing with a direct restoration, without removing deep caries next to the pulp.~If the pulp is exposed, pulpotomy will be performed instead and the tooth will be excluded from further analysis."
41336127|NCT04672070|OTHER|Pulpotomy|"Complete caries removal and excision of the coronal pulp to the level of the root canal orifices will be performed. After haemostasis, sealing with Biodentine® and restoration.~If the pulp is not exposed after complete caries removal, the tooth will be restored without further excavation and pulp exposure. If the pulp is assessed intra-operatively to be non-vital or not amenable to pulpotomy, root canal treatment will be performed instead. In both cases, the tooth will be excluded from further analyses."
41336128|NCT02795611|BEHAVIORAL|Family-centered occupational therapy|Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
41336129|NCT02795611|BEHAVIORAL|regular occupational therapy|regular occupational therapy
41336130|NCT02795611|OTHER|intervention done outside our hospital|intervention done outside our hospital
41336131|NCT01470365|PROCEDURE|quality-of-life assessment|Ancillary studies
41336132|NCT01470365|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
41336133|NCT01470365|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional CRT
41336134|NCT06376188|OTHER|communication training|The intervention group received a communication training session prior to the prebriefing and familiarization of the scenario, including advice on how to improve communication skills as well as how to create an optimal setting for difficult medical conversations. This communication training session has been created on the basis of an in-depth literature research.(Brock et al., 2019; Chumpitazi et al., 2016; Collins et al., 2018; Grant et al., 2016; Tobler et al., 2014; Vaidya et al., 1999; Yuan et al., 2019)
41336135|NCT00044642|DRUG|Lorazepam|
41336136|NCT01000519|OTHER|Aerobic Training|18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate
41336137|NCT01000519|OTHER|Progressive resistance training|18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
41336138|NCT00607919|DRUG|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
41336139|NCT00607919|DRUG|Placebo|oral, daily, for 16 weeks
41336140|NCT00481221|PROCEDURE|Observation of results from laboratory tests|Laboratory data summary only
41336141|NCT01379560|DRUG|unoprostone isopropyl|"1. unoprostone isopropyl (2 drops)~2. placebo (2 drops)"
40817737|NCT02436707|DRUG|Ibrutinib|
41336142|NCT01379560|DRUG|unoprostone isopropyl|"1. unoprostone isopropyl (3 drops)~2. placebo (3 drops)"
41336143|NCT05109611|DRUG|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
40817738|NCT02436707|DRUG|Rituximab|
40817739|NCT02436707|DRUG|Gemcitabine|
40817740|NCT02436707|DRUG|Dexamethasone|
40817741|NCT02436707|DRUG|Cisplatin|
40817742|NCT02436707|DRUG|Mesna|
40817743|NCT02436707|DRUG|Cyclophosphamide|
40817744|NCT02436707|DRUG|Etoposide|
40817745|NCT02436707|DRUG|G-CSF|
40817746|NCT02436707|DRUG|Selinexor|
40817747|NCT05350202|DRUG|Empagliflozin|Empagliflozin
40817748|NCT05647343|DRUG|Ciclopirox Olamine Oral|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
41015328|NCT02612207|DEVICE|Bilirubin Binding Capacity by Hematofluorometry Validation|Observation study
41015329|NCT02563340|OTHER|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
41484920|NCT01222390|DEVICE|Contour Profile Tissue Expander|The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
41484921|NCT05056766|BEHAVIORAL|questionnaires: Epworth Sleepiness Scale; Pichot fatigue questionnaire.|"Each patient will undergo 3 to 7 polygraphy recordings according usual practice of titration At the same time, Self-questionnaires will be conducted by the patient in order to evaluate Oral appliance efficacy.~Optimal titration of oral appliance will be done according subjectives parameters. (sleepeness Reduction and fatigue Reduction).~Neither the investigator nor the patient will know the polygraphy results (apnea-hypopnea index)"
41484922|NCT05582252|OTHER|Non-Invasive saliva sampling|"There are two types of intervention in this ambidirectional study.~1. Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~2. ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records."
41484923|NCT01856036|PROCEDURE|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
41484924|NCT06323486|DEVICE|active accelerated bilateral sequential theta burst stimulation and sham treatment|"We shall use the Magpro device (Magventure) employing the specialized Active/Sham B70 coil.~absTBS shall be administered consisting of 6 sessions daily (with a 50-minute interval between treatment sessions) on Mondays to Fridays or for a maximum of 5 working days of daily treatment. The target stimulation intensity will be set at 90 to 120% of the subject's resting motor threshold (RMT). Each session shall be composed of administration of continuous theta burst stimulation (triplet burst pulses at 50 Hz, repeated at 5 Hz, for a total of 600 pulses per session over 40 seconds administered on the right dorsolateral prefrontal cortex) and then intermittent theta burst stimulation (triplet burst pulses at 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, for a total of 600 pulses per session over about 3 min, administered on the left dorsolateral prefrontal cortex).~The sham treatment will be conducted for the same number of sessions and duration as the absTBS treatment sessions."
41484925|NCT05372133|DRUG|Morphine|Children will be provided with morphine for at-home pain management following supracondylar fracture repair
41484926|NCT03003949|DRUG|Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release|Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
41484927|NCT03003949|DRUG|Placebo Patch|Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
41484928|NCT03003949|DRUG|Progesterone Capsule|Micronized progesterone (200 mg) will be administered every day for 12 days during the 9th week of randomization and again following randomization at the 17th week
41484929|NCT03003949|DRUG|Placebo Oral Capsule|Matching placebo capsules will be administered orally every day for 12 days during the 9th week of randomization and again following randomization at the 17th week.
41484930|NCT03382314|COMBINATION_PRODUCT|HDDO-1614|"* Combination drug (Bazedoxifene + Cholecalciferol)~* Incrementally modified drug~* Not market authorized product"
41484931|NCT03382314|DRUG|Bazedoxifene / Cholecalciferol|Co- Administration of Bazedoxifene and Cholecalciferol
41484932|NCT04946565|DIAGNOSTIC_TEST|Semen analysis|Semen analysis according to WHO laboratory manual for the examination and processing of human semen, Fifth edition
41484933|NCT01876550|DRUG|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
41484934|NCT01876550|DRUG|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
41484935|NCT01876550|DRUG|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
41484936|NCT05182255|DEVICE|Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered|To aid in maintaining patency of the esophagus in cases of obstruction of the esophagus caused by an esophageal disease and to seal tracheoesophageal fistula.
41484937|NCT02809170|DIETARY_SUPPLEMENT|Arginine|Arginine is an amino acids
41484938|NCT02809170|DIETARY_SUPPLEMENT|Citrulline|Citrulline is an amino acid
41484939|NCT02030314|DRUG|Chlorthalidone|treatment of resistant hypertension in kidney transplant patients
41484940|NCT00238849|DRUG|Oxaliplatin|
41484941|NCT03893474|DIAGNOSTIC_TEST|OCT|Optical Coherence Tomography of study eye.
41484942|NCT03893474|DIAGNOSTIC_TEST|Visual Acuity|Visual acuity measured by ETDRS
41336144|NCT05109611|DEVICE|Nasal spray with isotonic saline|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
40817749|NCT05647343|OTHER|Placebo|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
40817750|NCT03494530|DRUG|Edoxaban 60 MG|Anticoagulant used to treat atrial fibrillation
41336145|NCT03046563|OTHER|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes
41336146|NCT03046563|OTHER|Pressing the Sham points|Pressing the sham points for eight minutes
40817751|NCT03494530|DRUG|Edoxaban 30 mg|Anticoagulant used to treat atrial fibrillation
40817752|NCT02513485|DRUG|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
40817753|NCT02513485|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
41015330|NCT02563340|OTHER|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
41336147|NCT03959345|DRUG|Combination therapy group|Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
41484943|NCT05402982|DEVICE|Electrical Cardiometry (EC) ICON|Electrical Cardiometry (EC) ICON (Osypka Medical, Berlin, Germany) is an FDA approved device used for non-invasive measurement of some hemodynamic parameters as cardiac output,cardiac index, stroke volume,stroke volume variation, systemic vascular resistance, thoracic fluid content, ICON (index of contractility), variation of ICON,corrected flow time and systolic time ratio.The set data of EC are the height, weight,hemoglobin, Oxygen saturation(SPO2),age, gender ,blood pressure and heart rate(HR) of the patient
41484944|NCT05402982|OTHER|Rohrich formula|Rohrich formula and the intraoperative fluid ratio (subcutaneous infiltration fluid plus intravenous fluid divided by total aspirate volume) will be 1.2
41484945|NCT04335175|OTHER|None - observational study|None - observational study
41484946|NCT02513836|OTHER|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
41484947|NCT02513836|OTHER|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. The questionnaire (POEM) will be tested again after this education on opioid knowledge on the same day.
41484948|NCT04626752|DRUG|BCMA CAR-T|Volunteers will be treated with BCMA CAR-T cells
41484949|NCT04626752|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
41484950|NCT04626752|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
41484951|NCT00618930|DRUG|Moviprep®|use of Moviprep®
41484952|NCT00618930|DRUG|Fleet|Use of Fleet
41484953|NCT04641065|OTHER|Music listening|An expert on the particular type of music will do the selection of the playlist of Traditional Turkish Military music, and this playlist will be listened to the patients by the researchers.
41484954|NCT01443936|BIOLOGICAL|Ad4-H5-VTN vaccination-tonsillar route|
40817754|NCT05175222|RADIATION|Laser therapy|Patients receive laser therapy in 7 points in oral cavity every day from the first day of conditioning chemotherapy till the second day post HSCT. Each point is irradiated for 1 minute.
40817755|NCT06099418|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.~A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
40817756|NCT06099418|DRUG|Atezolizumab Injection [Tecentriq]|Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.
40817757|NCT06099418|DRUG|Placebo|Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
41015331|NCT04544449|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
41015332|NCT04544449|DRUG|Ocrelizumab|Participants will receive ocrelizumab.
41336148|NCT03959345|DRUG|Standard therapy group|Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
41484955|NCT01443936|BIOLOGICAL|Ad4-H5-vaccination-oral route|
41484956|NCT01700166|BIOLOGICAL|Autologous Human Cord Blood derived Stem Cell injection|One time intravenous (in the vein) injection with two year follow-up
41484957|NCT04309214|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period
41484958|NCT04250948|DRUG|JS001|JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.
41484959|NCT04250948|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w
41484960|NCT04250948|DRUG|S1|S-1: 40\~60mg Bid，d1\~14, q3w
41484961|NCT04250948|DRUG|Capecitabine|Capecitabine: 1000mg/m2 Bid，d1-14, q3w
41484962|NCT02311920|BIOLOGICAL|Ipilimumab|Given IV
41484963|NCT02311920|OTHER|Laboratory Biomarker Analysis|Correlative studies
41484964|NCT02311920|BIOLOGICAL|Nivolumab|Given IV
41484965|NCT02311920|DRUG|Temozolomide|Given PO
41484966|NCT02341950|BEHAVIORAL|SCI Hard|The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
41484967|NCT02422914|BEHAVIORAL|Smoking cessation program TFC and activity tracker|Participants will receive a free TFC device and sufficient nicotine cartridges (8 mg/ml) to last the last of the procedure. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks. The nicotine cartridges use will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)
41015333|NCT04544449|DRUG|Placebo matched to ocrelizumab|Participants will receive ocrelizumab-matching placebo.
41015334|NCT04544449|DRUG|Placebo matched to fenebrutinib|Participants will receive fenebrutinib-matching placebo
41015335|NCT02020668|OTHER|Physiotherapy|
41015336|NCT02020668|OTHER|Wait list control|
41015337|NCT02336984|BIOLOGICAL|HER-2 pulsed DC1|Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
41015338|NCT02336984|DRUG|trastuzumab|The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
41015339|NCT02336984|DRUG|pertuzumab|Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
41484968|NCT02422914|BEHAVIORAL|Smoking cessation program TFC-free and activity tracker|"Participants will receive a free TFC device and a set of 10 ml flacons enough to complete the trial. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks.~The actual use of the device and smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)."
41484969|NCT02422914|BEHAVIORAL|Smoking cessation program and activity tracker|Participants undergo a motivational interview and low-intensity at distance counseling (the same counseling program of other groups) without any device.The actual smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
41484970|NCT06354491|DEVICE|Magnetic Resonance Imaging (MRI)|MRI procedures will include a 20-25 exam with periodic breath holds. The imaging series will be conducted twice to assess repeatability.
41484971|NCT06354491|DEVICE|Ultrasound (US)|In each ultrasound exam, each participant will be scanned by two sonographers to evaluate inter-operator variability. Each exam will take approximately 60 minutes to complete. The imaging series will be conducted twice to assess repeatability.
41484972|NCT04327856|PROCEDURE|Cataract Surgery|The cataract will be removed from patient's eye and artificial intraocular lens will be implanted
41484973|NCT01031966|BIOLOGICAL|MF59 adjuvanted H1N1 influenza monovalent vaccine|One/two single administration
41484974|NCT01031966|DRUG|Thymosin alpha 1|1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
41484975|NCT01031966|DRUG|Thymosin alpha 1|1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
41484976|NCT03056820|OTHER|25° head-up position|Participant will be positioned at 25° angle for procedure.
41484977|NCT03056820|OTHER|55° head-up position|Participant will be positioned at 55° angle for procedure.
41484978|NCT04453098|BEHAVIORAL|3-week residential program based on a tryptic (diet,|"3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education)."
41484979|NCT02828059|DRUG|Ropivacaine|Surgical wound Infiltration over 48 hours
41484980|NCT05106543|DEVICE|Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients|Kinesiological Taping
41484981|NCT00777413|DRUG|Minocycline 100mg Tablets|
41484982|NCT01769339|DRUG|Miconazole plus Hydrocortisone|Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
40817758|NCT05491070|DEVICE|Vascular closure device (Angio-Seal, Progilde)|In transfemoral TAVI, vascular closure devices were used for femoral artery wound closure, progilde and angio-seal can be used in wound closure. We aimed to compared the efficacy and safety of different vascular closure device in TAVI
41015340|NCT03444857|DEVICE|Continuous positive airway pressure|The optimal continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) settings will be determined during 1-2 nights within 7 days after pPCI.
41015341|NCT01176825|BEHAVIORAL|cognitive-behavior therapy (CBT)|14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
41336149|NCT05299138|BEHAVIORAL|Marriage and Relationship Enhancement Skills (MRES) Intervention|The Intervention group will be assigned a Case Manager and placed in the next available Marriage and Relationship Enhancement Skills (MRES) class that is convenient for their schedule. Intervention participants will attend classes weekly and meet with their Case Manager weekly, bi-weekly, or monthly, as needed. Study measures will be gathered from intervention participants at baseline, 10 weeks after baseline, and then 22 weeks after baseline. The following tools will be utilized at baseline and follow-up assessment: (1) REACH program eligibility screening (only conducted at baseline), (2) Information, Family Outcomes, Reporting, and Management (nFORM) system, (3) Family Environment Scale (FES), (4) Revised Dyadic Adjustment Scale (RDAS), and (5) Economic Self-Sufficiency Scale (ESS).
41336150|NCT04300881|DRUG|Eplerenone|Following intravitreal ocriplasmin therapy
41336151|NCT06166290|PROCEDURE|CO2 LASER Vaporisation|The CO2 LASER vaporization procedure is described as follows. Patient positioning will be done, and patient will be anesthetized. Local infiltration with 2% lidocaine, nerve block or general anesthesia will be given. The surgical field will be disinfected and draped. The perianal and anal area will be investigated for lesion. CO2 LASER from 20 cm distance in a continuous wave mode and 20 W power will be applied. After warts melts, necrotic tissue will be removed. After the operation was completed, residual debris will be wiped away with a piece of moist gauze. Bacitracin cream applied over the treated areas. Upon discharge acetaminophen 1-gram q8 and Ibuprofen 600 q8 for pain.
41484983|NCT03592342|DRUG|Clobetasol Propionate|Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
41484984|NCT04309253|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
41484985|NCT04309253|DRUG|AV45|F-18 AV45 PET Imaging
41484986|NCT01234792|DRUG|6 mg Experimental nicotine gum|A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
41484987|NCT01234792|DRUG|4 mg Nicotine Gum/|A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
41484988|NCT01234792|DRUG|2 mg Nicotine Gum|A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
41336152|NCT06166290|PROCEDURE|Electrosurgical Fulguration|The procedure is described as follows. Patient will be administered regional or general anesthesia, placed in prone jack-knife position. Prepping and draping will be done. The perianal and anal area will be investigated for lesion. The lesions will be excised, and the bases will be fulgurated. Electrosurgery device will be used in monopolar setting (30 Cut mode, 30 Coag mode). After procedure local analgesics total MERCAINE/EPI 0.25% 20 ml on both sides of the lesion. Bacitracin cream applied over the treated areas. Upon discharge 1000 mg of Tylenol every 8 hours along with 600 mg of ibuprofen every 8 hours.
41336153|NCT03717636|OTHER|medical evaluation|return of medical evaluation after discharge
41484989|NCT04594174|PROCEDURE|Fluid administration|"Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP \<65 mm Hg or a Systolic Blood Pressure \<90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase."
41484990|NCT03309007|DRUG|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
41484991|NCT03309007|DRUG|Placebo Oral Tablet|Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
41484992|NCT00973401|OTHER|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
41484993|NCT05289128|DEVICE|Experimental group|10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
41484994|NCT05289128|DEVICE|Sham Control|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
41484995|NCT05706194|DIAGNOSTIC_TEST|Early neurological prognostication with biomarkers, EEG and CT|Biomarker samples collected at 12, 24, 48 and 72 h after randomisation, CT and EEG performed as early as possible after 24 h post randomisation in patients still unconscious (defined as not awake and able to follow verbal commands)
41484996|NCT01610739|DRUG|Indigocyanine green dye|Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
41484997|NCT00937482|DRUG|cediranib maleate|Given orally
41484998|NCT00937482|RADIATION|whole-brain radiation therapy|Undergo whole-brain radiotherapy
41484999|NCT01431859|BIOLOGICAL|Allergovit Birch pollen|Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
41485000|NCT01431859|OTHER|Placebo|Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
41485001|NCT01112943|OTHER|Acupuncture|Acupuncture on predefined points for 20min once a week over seven weeks
41485002|NCT01112943|OTHER|Pulmonary Rehabilitation|a seven week pulmonary rehabilitation course
41485003|NCT01112943|OTHER|Pulmonary Rehabilitation|Twice a week for seven weeks. Each session lasting 2 hrs (1hr exercise and 1hr education
41485004|NCT03336957|PROCEDURE|periodontal treatment|non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction
41485005|NCT04309552|DRUG|18F-FMISO PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
41485006|NCT04309552|DRUG|18F-FLT PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
41485007|NCT03528785|DRUG|Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid|"* Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle~* Irinotecan Liposomal Injection \[Onivyde\] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle~* Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle~* 5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle"
41485008|NCT04133766|BEHAVIORAL|Community Based Nutrition Package (CNBP)|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
41015342|NCT04279444|DIETARY_SUPPLEMENT|BKR-017|BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
41485009|NCT05685901|DIETARY_SUPPLEMENT|High polyphenolic olive oil. (Early harvest olive oil).|High polyphenolic olive oil is normal olive oil obtained from early harvest olives, this early harvest olive oil has been widely used for culinary purposes for centuries. The investigators wanted to study if oromucosal immunoprophylaxis with small quantities of high polyphenolic olive oil (2 mL of olive oil equivalent to 5 mg of polyphenols) adiministered twice a day could have clinical mitigating effects on the disease caused by SARS-CoV-2 infection.The primary outcome was to determine the effect of high polyphenolic olive oil on Coronavirus disease incidence, duration and severity.
41485010|NCT05161806|DRUG|SOK583A1 (40 mg/mL)|SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
41485011|NCT05161806|DEVICE|Prefilled Syringe (PFS)|Prefilled Syringe (PFS)
41485012|NCT01289444|BEHAVIORAL|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care \& when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care \& prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
41485013|NCT01289444|BEHAVIORAL|Healthy Living Control|"Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides."
41485014|NCT01520974|OTHER|ProBiora3 mints|Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
41485015|NCT01520974|OTHER|Placebo tablet|Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
41485016|NCT02182791|DRUG|Nevirapine|
41485017|NCT02182791|DRUG|EE/NET|
41485018|NCT03827616|RADIATION|Hypofractionated IMRT using helical Tomotherapy.|70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
41485019|NCT03827616|RADIATION|Hypofractionated IMRT using helical Tomotherapy.|60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
41485020|NCT04623775|BIOLOGICAL|Nivolumab|Specified dose on specified days
41485021|NCT04623775|BIOLOGICAL|Relatlimab|Specified dose on specified days
41485022|NCT04623775|DRUG|Carboplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
41485023|NCT04623775|DRUG|Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
41485024|NCT04623775|DRUG|Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
41485025|NCT04623775|DRUG|Nab-Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
41485026|NCT04623775|DRUG|Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
41485027|NCT01547364|DRUG|Saline|Injection of 10 ml of normal saline into the caudal epidural space
41336154|NCT03049930|DRUG|Ketamine|Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
41336155|NCT03049930|DRUG|Sodium chloride|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
41336156|NCT00440141|DRUG|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
41485028|NCT01547364|DRUG|Dextrose|Injection of 10 ml or dextrose 5% in water into the caudal epidural space
41485029|NCT04761458|DIAGNOSTIC_TEST|Olfactory function testing|Olfactory function will be evaluated through the Burghart Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The extended version of this test will be used and consist of three tests of olfactory function, namely tests for odor threshold, odor discrimination and odor identification.
41485030|NCT04761458|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
41336157|NCT00440141|DRUG|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
41015343|NCT06118294|DIETARY_SUPPLEMENT|probiotics|\>30 billion CFU/capsule
41015344|NCT06118294|DIETARY_SUPPLEMENT|Placebo|Placebo
41336158|NCT02714608|DRUG|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
41485031|NCT04761458|DIAGNOSTIC_TEST|Clinical Frailty Scale|The Clinical Frailty Scale (CFS) uses clinicians' judgement to evaluate frailty. It comprises assessment of specific domains including comorbidity, function, and cognition. Score ranges from 1 (very fit) to 9 (terminally ill).
41485032|NCT04761458|DIAGNOSTIC_TEST|Neuropsychological test battery|Patients will undergo a neuropsychological test battery preoperatively and postoperatively. This test consists of a battery of psychometric assessments with the ability to objectively assess specific cognitive domains such as attention, executive function, learning and memory, language, perceptual-motor, or social cognition.
41485033|NCT04726319|OTHER|FHAMe Intervention|Patients will receive an invitation email prior to their scheduled clinical visit which includes information about the study, a link to the YouTube patient presentation, and a link to the consent form and questionnaire. Patients will be invited to fill out the questionnaire prior to their appointment. After patients complete the initial questionnaire, physicians will receive an EMR message on the day of patient's clinic visit alerting them that patient family history information is available and to complete the Family History Action Form. They will be prompted to respond to the message which will open the action form and ask what action the provider intends to take with this family history information. The form will then link to management support tools for use during the patient visit. All participants will attend their clinical visit after which they will receive a post-visit electronic survey regarding their clinical visit and whether family history was reviewed with their provider.
41485034|NCT00017719|DRUG|Lamivudine|
41485035|NCT00017719|DRUG|Lamivudine/Zidovudine|
40817759|NCT04594902|BEHAVIORAL|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
41336159|NCT02714608|DRUG|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
41336160|NCT02714608|DRUG|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
41336161|NCT04206670|DEVICE|In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
41336162|NCT04206670|DEVICE|Waiting Control In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
41336163|NCT05911737|BEHAVIORAL|Short video and Questionnaire|A 10-minute video in a foreign language (not English or Greek) with greek subtitles will be presented and a questionnaire will follow to assess the level of concentration during the video
41336164|NCT05184127|DRUG|MIR 19 ®|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
41336165|NCT05184127|COMBINATION_PRODUCT|Standard COVID-19 therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
41485036|NCT00017719|DRUG|Nelfinavir mesylate|
41485037|NCT00017719|DRUG|Nevirapine|
41485038|NCT00017719|DRUG|Zidovudine|
41485039|NCT02776514|DRUG|Triamcort|Fluoroscopic guided injection in the knee joint
41485040|NCT02776514|DRUG|Platelet-rich-plasma|
41485041|NCT02776514|DRUG|Suplasyn1|
41485042|NCT02776514|DRUG|Placebo|
41485043|NCT03924011|DEVICE|Photobiomodulation therapy (PBMT)|PBMT sessions will be planned 2x/week after RT.
41485044|NCT03924011|DEVICE|Sham laser|Sham laser sessions will be applied 2x/week after RT.
41485045|NCT03036241|DEVICE|Conventional angioplasty|Angioplasty with conventional balloon
40817760|NCT04594902|OTHER|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
40817761|NCT06588647|BEHAVIORAL|Improving Participation after Stroke Self-Management Program (IPASS)|The IPASS-R program is a group-based self-management intervention that aims to improve problem-solving, action-planning, and resource utilization skills for improved community living and participation. The Activity-Barriers-Changes-Doing-Evaluation (ABCDE) framework is a user friendly problem-solving and goal setting framework that is used repetitively in each session throughout the program. Participants are guided to identify (1) an activity that they want to improve or re-engage in (A); (2) individual and environmental barriers that hinder their engagement (B); (3) changes that they can make to deal with the barriers and improve their engagement (C); and (4) an action plan to pursue (D). After the action plan, participants come back in the next session and evaluate their performance in following through on their plans (E).
40817762|NCT06588647|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The program is facilitated by two trained leaders in small groups in a community setting with individuals who have chronic health problems and will follow the CDSMP protocol. Participants receive education on various health-related topics applicable to a range of chronic conditions, share experiences, and support one another.
41336166|NCT05499598|PROCEDURE|Experimental: Modified minimally invasive surgical technique with PRF and vitamins A and C|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.
41485046|NCT03036241|DEVICE|Angioplasty with drug-eluting balloon|Angioplasty with drug-eluting balloon
41485047|NCT05161650|DIETARY_SUPPLEMENT|Ketone monoester (3-OHB)|Commercially available ketone supplement
41485048|NCT05161650|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
41485049|NCT03142906|DIAGNOSTIC_TEST|Scan|The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
41485050|NCT03234894|DEVICE|SiteSeal Endovascular|to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.
41485051|NCT00831636|DRUG|CP-4055|D1-5 and D8(+2)-12(+2) q4w
41485052|NCT00831636|DRUG|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
41485053|NCT03972449|BEHAVIORAL|BEAT-Speech|BEAT-Speech integrates beatboxing techniques within speech-therapy services for individuals with speech sound disorders.
41485054|NCT03972449|BEHAVIORAL|Traditional Articulation Approach|The traditional approach to treating speech sound disorders focus on one or two sounds at a time until they are mastered by the client. Perceptual and production training are used with target starting at simple (isolation) and moving to more complex (sentences). A variety of cues such as shaping and phonetic placement cues are used.
41485055|NCT04082728|DRUG|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
41485056|NCT04082728|DRUG|Placebo oral tablet|Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
41485057|NCT05255926|DRUG|68Ga-pentixafor|All participants undergo intravenous administration of 68Ga-pentixafor (1.85-3.71 MBq/kg body weight).
41485058|NCT05255926|DEVICE|PET/CT|PET/CT imaging is performed 1 h after intravenous injection of 68Ga-pentixafor.
41485059|NCT04878614|DRUG|Levothyroxine Tablet|Standard clinical management
41485060|NCT04878614|DRUG|Levothyroxine Sodium|Liquid levothyroxine through enteral feeding tube
41485061|NCT00703508|DRUG|Metformin 500 mg tablet|Metformin 500 mg tablets; two tablets every 12 hours for 9 months
41485062|NCT02707861|DRUG|ibalizumab|Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
41485063|NCT02707861|DRUG|Optimized Background Regimen|An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
40817763|NCT02633254|DEVICE|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
40817764|NCT05043792|DRUG|TT-00920|TT-00920 Tablets
41336167|NCT05499598|PROCEDURE|Modified minimally invasive surgical technique with PRF|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. The resultant PRF clot will be placed into the intra-osseous defect.
40817765|NCT05043792|DRUG|TT-00920 Placebo|TT-00920 Placebo Tablets
41336168|NCT03942146|BEHAVIORAL|Information on smoking cessation|Smoking cessation is recommended 6 weeks before and after surgery
41336169|NCT01780324|DRUG|Lidocaine|Intervention - intraurethral lidocaine
41336170|NCT03908580|DRUG|Meditoxin|Meditoxin® (Botulinum toxin type A) was injected up to 360 U.
41336171|NCT05128695|OTHER|there is no intervention; the study is observational|there is no intervention; the study is observational
41336172|NCT04799704|DIAGNOSTIC_TEST|swabbing of conjunctiva|Each eye will be sampled with a single, sterile, nylon, flocked swab
41336173|NCT01112982|OTHER|Magnetic Resonance Imaging|An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
41336174|NCT01112982|DRUG|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is \> 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
41336175|NCT01112982|DRUG|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
41015345|NCT00948805|DRUG|GnRH agonist|3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
41015346|NCT00948805|DRUG|Control|250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
41336176|NCT00778310|DRUG|methylphenidate-OROS|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
41485064|NCT06074484|DRUG|RC48-ADC|4 preoperative cycles of RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 6 cycles of postoperative RC48-ADC（2.0 mg/kg，intravenous (IV) infusion，Q3W）
41485065|NCT06074484|DRUG|AK104|4 preoperative cycles of AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 14 cycles of postoperative AK104（10 mg/kg，intravenous (IV) infusion，Q3W）
41485066|NCT03533127|DRUG|LY01008|LY01008+Carboplatin/Paclitaxel
40817766|NCT03859440|DEVICE|DSiHy Silicone hydrogel soft contact lens|•Device: DSiHy (test lens) Silicone hydrogel soft contact lens for daily disposable wear.
40817767|NCT03859440|DEVICE|CE-marked Silicone hydrogel soft contact lens|"・Device: Silicone hydrogel soft contact lens CE-marked for daily disposable wear.~Other Name : MyDay"
40817768|NCT04613557|BIOLOGICAL|CYAD-211|Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
40817769|NCT04613557|DRUG|Endoxan|Preconditioning chemotherapy
40817770|NCT04613557|DRUG|Fludara|Preconditioning chemotherapy
41485067|NCT03533127|DRUG|Bevacizumab|Bevacizumab + Carboplatin/Paclitaxel
41485068|NCT03861793|BIOLOGICAL|ALKS 4230|SC injection administered in the back of the arm or the abdomen
40817771|NCT04676841|DEVICE|Conventional ventilation + instrumental tables with integrated laminar airflow|Surgical instruments protected from contamination by local laminar airflow
40817772|NCT04676841|DEVICE|Conventional ventilation + standard instrumental tables|Control
40817773|NCT04676841|DEVICE|Laminar airflow ventilation + standard instrumental tables|Control
41015348|NCT05514067|PROCEDURE|Electro-Acupuncture|A single application of EA at cardiac-related acupoints administered for 30 min prior to CABG surgery.
40817774|NCT02379221|DRUG|Injectable|20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
40817775|NCT02379221|DRUG|Topical|4% Topicaine gel
40817776|NCT00044837|DRUG|Medroxyprogesterone acetate|
40817777|NCT00044837|DRUG|Estradiol|
41015349|NCT05956314|DRUG|KM-001 cream 1% 12 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
41336177|NCT00778310|DRUG|Placebo|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
41336178|NCT00910728|DRUG|AZD1480|Oral capsule 2.5 mg, 10 mg and 40 mg
41336179|NCT05693103|DEVICE|High-Intensity Focused Electromagnetic therapy|"The HPM-6000UF is a non-invasive therapeutic device. The device produces electromagnetic field that interacts with the tissues of the human body.~The electromagnetic field delivered in the muscular or neuronal tissue area is triggering the stimulation and tonisation."
41336180|NCT03370198|BIOLOGICAL|NKR-2 cells|NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)
41336181|NCT04199546|OTHER|Chewing and swallowing rehabilitation|A home based chewing and swallowing training program (CST) will be applied by an experienced physical therapist. The Functional Chewing Training will be used to improve chewing function which has five steps including positioning the child and food, sensory stimulation, chewing training and adjustment of food consistency to improve chewing function. To support hyolaryngeal elevation, laryngeal mobilization will be performed. Hyolaryngeal mobilization will be performed by moving hyolaryngeal complex in right, left and up directions manually.
41336182|NCT06350006|DRUG|SHR-A1904; Adebrelimab|SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab
41485069|NCT03861793|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion over 30 minutes
41485070|NCT05671172|DRUG|Hyaluronidase|hyaluronidase will be applied as adjuvant to bupivacaine in transversus abdominis plane block to enhance the postoperative analgesic effect after CS
41336183|NCT06350006|DRUG|SHR-A1904; CAPOX; Adebrelimab|SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)
41336184|NCT05587634|BEHAVIORAL|Virtual Peer Health Coaching|"Intervention arm: weekly sessions (\~30 min each session) of physical activity counseling with an assigned peer health coach over the course of 12 weeks. The focus of the initial 2 calls is on rapport development and trust building with a focus around PA with discussion of physical activity goals and motives, where possible. The remainder of the call sessions follow a standardized format of a 30-minute call to 1) review the previous week, 2) integrate motivational strategies, and 3) develop action and support plans for the next week. The final call format includes a summary and evaluation of the intervention, discussion of short- and long-term goals, and relapse prevention strategies. Sessions guided by a call tracking form.~These participants receive an adaptive physical activity local guide including information on local adaptive sports opportunities, which the control group also receives."
41336185|NCT01689766|DRUG|Technetium Tc 99m EC20|
41336186|NCT06261476|DIETARY_SUPPLEMENT|Ashwagandha (Withnia somnifera)|Ashwagandha is the active ingredient in Withania somnifera (a medicinal plant in Indian medicine). Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
41336187|NCT00718250|BIOLOGICAL|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
41336188|NCT00718250|BIOLOGICAL|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
41336189|NCT00718250|BIOLOGICAL|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
40817778|NCT05849259|OTHER|Dementia Care Quality at Home|Each of the two HBPC practices will identify at least two trained Dementia Care Quality at Home Champions who will be trained in the intervention comprised of 1) a standardized assessment tool to assess PLWD and caregiver needs; 2) seven modules created to optimize the well-being of the PLWD and their caregiver; and 3) regular team-based review of persons participating in the program to address care challenges and a team-based case conference approach to solve these challenges.
41336190|NCT00718250|BIOLOGICAL|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
41336191|NCT00675688|DRUG|Bazedoxifene/Conjugate Estrogens (CE)|
41485071|NCT05671172|DRUG|Bupivacaine Injection|20ml bupivacaine will be injected without additives in the transversus abdominis plane block on each side for postoperative analgesic after CS
41485072|NCT03947671|DEVICE|Rapr Rounds Hyper/Hypothermia Wraps|Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature
40817779|NCT03520348|DRUG|PRO-167|"Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic"
40817780|NCT03520348|DRUG|Corneregel|Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
41336192|NCT00675688|DRUG|Raloxifene|
41336193|NCT00675688|DRUG|Placebo|
41336194|NCT00116324|DRUG|Montelukast|
41336195|NCT02998255|DRUG|Single dose of 2L PEG|Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
41336196|NCT02998255|DRUG|Split dose of 4L PEG|All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
41336197|NCT00454480|BIOLOGICAL|alemtuzumab|
40817781|NCT04545723|DEVICE|FibriCheck|FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
40817782|NCT04131387|DEVICE|LIPUS-1|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
40817783|NCT04131387|DEVICE|LIPUS-2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
40817784|NCT06606522|DIAGNOSTIC_TEST|Clinical model|Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.
40817785|NCT06606522|DIAGNOSTIC_TEST|Urinary biomarkers|Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
41017991|NCT04486287|DRUG|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo Stereotactic Ablation Brachytherapy. Sintilimab shall be started no later than 4 weeks after Stereotactic Ablation Brachytherapy."
41336198|NCT00454480|DRUG|arsenic trioxide|
41485073|NCT03947671|DRUG|Acetaminophen|Acetaminophen will be administered as it would be per standard of care
41485074|NCT04743856|BEHAVIORAL|ActiveGOALSv2|13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.
41336199|NCT00454480|DRUG|azacitidine|
41336200|NCT00454480|DRUG|busulfan|
41336201|NCT00454480|DRUG|clofarabine|
41336202|NCT00454480|DRUG|cytarabine|
41336203|NCT00454480|DRUG|daunorubicin hydrochloride|
41336204|NCT00454480|DRUG|fludarabine phosphate|
41336205|NCT00454480|DRUG|gemtuzumab ozogamicin|
41336206|NCT00454480|DRUG|melphalan|
41336207|NCT00454480|DRUG|tipifarnib|
41336208|NCT00454480|GENETIC|DNA methylation analysis|
41336209|NCT00454480|GENETIC|cytogenetic analysis|
41485075|NCT04743856|BEHAVIORAL|PAT|Participants will receive a physical activity tracker and encouragement to increase activity.
41485076|NCT00635115|DEVICE|a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|
41485077|NCT00635115|DEVICE|an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)|
41336210|NCT00454480|GENETIC|gene expression analysis|
41336211|NCT00454480|GENETIC|mutation analysis|
41485078|NCT05366465|OTHER|SMA adult patients|An online questionnaire aimed at collecting demographic and social data, and data concerning activity limitations, participation and quality of life of SMA patients from validated scales : QOLNMD, Rosenberg.
41485079|NCT05426304|DRUG|Agomelatine|agomelatine 25 mg/day for 180 days
40817786|NCT06058247|DIETARY_SUPPLEMENT|Active nutritional supplementation|"The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day.~NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active nutritional supplementation arm were protein supplementation at over 1.5 g/kg/day, calorie provision at over 20 kcal/kg/day, and energy adequacy of at least 80%. Energy target was estimated by multiplying the resting energy expenditure using the Harris and Benedict equation by an activity factor of 1.3 and a stress factor of 1.1. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%."
40817787|NCT06058247|DIETARY_SUPPLEMENT|Conventional nutritional supplementation|The participants in conventional nutritional supplementation arm received conservative nutritional management without specific protein or caloric targets.
41336212|NCT00454480|OTHER|diagnostic laboratory biomarker analysis|
41485080|NCT05426304|DRUG|Placebo Tablets|placebo 25 mg/day for 180 days
41485081|NCT02651454|DRUG|Daesiho-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
41485082|NCT02651454|DRUG|Chowiseungcheng-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
41485083|NCT02651454|DRUG|Placebo|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
41485084|NCT01882075|DRUG|Open loop|
41485085|NCT01882075|DEVICE|Closed-loop|
41336213|NCT00454480|OTHER|immunologic technique|
41336214|NCT00454480|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41336215|NCT00454480|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
41336216|NCT04749160|DEVICE|Connected device|Connected device is a smart watch (with accelerometer without location data).
41336217|NCT04973293|DRUG|sintilimab|Sintilimab 200 mg, 4 cycles of treatment before surgery
41336218|NCT04973293|DRUG|bevacizumab|bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
41336219|NCT02455388|DIETARY_SUPPLEMENT|High added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
41336220|NCT02455388|DIETARY_SUPPLEMENT|Low added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
41336221|NCT05193851|DRUG|ricolinostat|"This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period."
41336222|NCT00553761|DEVICE|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
41485086|NCT00642694|DRUG|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
41485087|NCT00642694|DRUG|Ramelteon|Ramelteon 8 mg qd
41485088|NCT00642694|OTHER|Placebo|Matching placebo qd
41485089|NCT02400424|RADIATION|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
41485090|NCT02767882|DRUG|Dexamethasone|Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.
41485091|NCT02767882|DRUG|Saline|Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
41485092|NCT04128475|OTHER|N/A - observational study.|N/A - observational study.
41485093|NCT01298713|DRUG|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
41015350|NCT05956314|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed as follows at screening and baseline, abbreviated after that (i.e., on Days 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort):~* The complete physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, gastrointestinal (GI), musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~* Symptom-directed physical examinations will be performed at all other trial visits.~* Height and weight measurement will be performed at screening only. An abbreviated examination including a comprehensive skin examination."
41336223|NCT04516577|OTHER|Assesssing the severity of pulmonary alveolar proteinosis|Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.
41336224|NCT05537961|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness instruction incorporated in classroom-based curriculum
41485094|NCT01298713|DRUG|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
41485095|NCT00317421|DRUG|Sildenafil citrate|
41485096|NCT02398357|DRUG|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
41485097|NCT06064292|DEVICE|INSPIRATORY MUSCLE TRAINING|After finishing the 8-week intervention period with IMT, CP patients stopped training with IMT and continued with their daily normal activities. During the following 24 weeks (without IMT), three evaluations of the respiratory parameters analyzed in the trial were made (MIP, MEP, FEV1, PEF). The first evaluation was made 4 weeks after the intervention was completed, the second 12 weeks and the third 24 weeks after finishing IMT.
41485098|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise HIIT|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
41485099|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise CME|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
41336225|NCT04128618|DEVICE|CyMedica e-vive NMES|Neuromuscular Electrical Stimulation (NMES) therapy
41485100|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Coaching Text Messages|The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.
41485101|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Control Text Messages|"The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group."
41485102|NCT00953108|DRUG|quetiapine|300 mg per day
41485103|NCT00953108|DRUG|escitalopram|escitalopram 10 mg per day
41485104|NCT03439852|BEHAVIORAL|Light-to-Moderate Physical Activity / Sedentary Time|12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
41485105|NCT02527928|OTHER|None intervention|
41336226|NCT02443805|BIOLOGICAL|300 IR|300 IR tablet of HDM Allergen Extracts
41485106|NCT03764436|BEHAVIORAL|LEAPS-NCHD Program|The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.
41485107|NCT00834652|DRUG|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
40817788|NCT05293041|DRUG|Argipressin|Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.
41336227|NCT02443805|BIOLOGICAL|Placebo|Placebo tablet
41336228|NCT05783492|DRUG|Intranasal ketamine|10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
41336229|NCT02031198|DRUG|AADvac1|Active immunization against pathological Alzheimer's disease tau protein
41336230|NCT02444936|DRUG|ZOSTAVAX|Shingles vaccine
41336231|NCT04061941|BEHAVIORAL|Cognitive Assessment|Assessment on cognitive dysfunction using standardised cognitive tests
41336232|NCT00763178|DRUG|Duloxetine|"Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose"
41015351|NCT05956314|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (oral body temperature, pulse, and resting systolic and diastolic blood pressure) will be measured at screening, on Days 1, 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort. Vital signs will be measured in supine position after at least 5 minutes of rest.
41336233|NCT05381675|OTHER|Tele-rehabillitation|"Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
41336234|NCT05381675|OTHER|Prescribed Exercise Program|"The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
41336235|NCT04843943|DRUG|Sintilimab|Sintilimab: 200mg IV Q3W D1
41336236|NCT04843943|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
41336237|NCT02356328|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
41336238|NCT00224783|BIOLOGICAL|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
41336239|NCT00224783|BIOLOGICAL|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
41336240|NCT06118554|OTHER|Irrigation head position|Patients irrigated their sinuses with once daily 2 mg mometasone using 240 mL NeilMed sinus rinse bottles for 8 weeks. The only factor that varied between groups was the head position patients irrigated in.
41485108|NCT00834652|DRUG|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
41485109|NCT04619992|DEVICE|Currently marketed Hydrophillic Intermittent Catheter|Currently marketed Hollister standard with tip hydrophilic intermittent catheter
41485110|NCT04619992|DEVICE|Test Hydrophilic Intermittent Catheter|Hollister standard with tip hydrophilic intermittent catheter with design enhancements
41336241|NCT01847690|DRUG|Hydrocortisone|Cortef 5 mg tablets per os, 2x5 mg, one day, one time
41336242|NCT00329394|DRUG|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
41336243|NCT04408170|DIAGNOSTIC_TEST|Point-of-care test for SARS-CoV-2|Throat and nose swabs and/or saliva samples and/or whole blood and/or finger stick samples may be taken to be tested on Point-of-care tests for SARS-CoV-2
41336244|NCT06144567|DRUG|Upadacitinib|As this is an observational study, AbbVie is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.
41485111|NCT02063243|PROCEDURE|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
41485112|NCT03559621|BEHAVIORAL|mobile-based lifestyle intervention|one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed
41485113|NCT06131827|OTHER|Neural mobilization|Neural mobilization will be performed with twenty oscillations per minute being repeated three sets of one minute respecting one minute interval of rest between each set for 4 days weekly for six week
41485114|NCT06131827|OTHER|Task based activities|Task based activities consisted of different types task which will be performed with the dosage of 45 minute session 5 days weekly for six week.
41485115|NCT04390659|PROCEDURE|myomectomy|The myomectomy was done by conventional technique but timing of myomectomy either before or after delivery of the baby varied between different cases .Infusion of oxytocin during the operation and for 24 h later.
41017992|NCT01792661|OTHER|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
41336245|NCT02100202|OTHER|Placebo|
41336246|NCT02100202|DIETARY_SUPPLEMENT|BioTurmin (Curcuma longa rhizomes extract)|
41336247|NCT02100202|DIETARY_SUPPLEMENT|BioTurmin-WD (Water dispersible curcuminoids)|
41336248|NCT02100202|DIETARY_SUPPLEMENT|MaQxan (Tagetes erecta flower extract)|
41336249|NCT03703960|OTHER|hypnotic analgesia|classic three-step hypnosis procedure (induction, trance and return to consciousness).
41336250|NCT03703960|OTHER|music|calm music conducive to relaxation
41336251|NCT02558283|DEVICE|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
41336252|NCT02558283|DEVICE|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
41336253|NCT00779363|DEVICE|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
41336254|NCT01448707|DRUG|Darunavir|Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
41336255|NCT01448707|DRUG|Ritonavir|ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
41336256|NCT01031199|DRUG|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
41015352|NCT05956314|DIAGNOSTIC_TEST|Serum chemistry|Approx. 5 mL whole blood will be collected after an ≥8 h fast for serum biochemistry assessments during screening, and on Days 1 (baseline), 7, 84 112, 140 or at an ET visit - where applicable, per cohort. Serum chemistry will include assessments of total and direct bilirubin, ALT, AST, gamma-glutamyl transferase (GGT), alkaline phosphatase, glucose (fasting), sodium, potassium, blood urea nitrogen (BUN/Urea), creatinine, chloride, calcium, uric acid, albumin, and total protein.
41485116|NCT02091323|PROCEDURE|gastric bypass surgery|With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 \~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
41485117|NCT01079884|DRUG|esomeprazole 40 mg|40 mg daily for 4 weeks
41485118|NCT00200759|DRUG|Cranberry juice and capsules|
41336257|NCT01031199|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
41015353|NCT05956314|DIAGNOSTIC_TEST|Hematology|Approx. 5 mL whole blood will be collected for complete blood count (CBC) during screening, and on Days 1 (baseline), 7, 84, 112, 140 or at an ET visit - where applicable, per cohort. The CBC assessments will include red blood cells (RBC), haemoglobin, haematocrit, reticulocyte count, platelet count, mean corpuscular haemoglobin (MCH), mean platelet volume (MCV), white blood cells (WBC), neutrophils (absolute \[abs.\]), lymphocytes (abs.), monocytes (abs.), eosinophils (abs.), and basophils (abs.).
41015354|NCT05956314|DIAGNOSTIC_TEST|Serology|Approx. 5 mL whole blood will be collected for serology assessments during screening. Serology will include HbsAg, HbcAb, hepatitis C antibody, and HIV antibody.
41015355|NCT05956314|DIAGNOSTIC_TEST|Urinalysis|General urinalysis will be performed, by dipstick, during screening, and on Days 1 (baseline), 7, and 84, 112, and 140, or at an ET visit - where applicable, per cohort. At least 7 to 10 mL of urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin, urobilinogen, and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
41015356|NCT05956314|DIAGNOSTIC_TEST|ECG test|A 12-lead, resting, ECG will be taken for each patient at screening, on Days 1 (baseline), 84, 112, and at day 140 (for Cohort 2), or at an ET visit - Where applicable. The measurement will be taken after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTc interval and QRS complex. The report will be printed out and signed by the investigator, who will record in the eCRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the patients will be reviewed.
41017993|NCT01792661|OTHER|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
41017994|NCT01792661|OTHER|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
41017995|NCT06152211|BEHAVIORAL|Choir|A choir for older adults is a musical/singing ensemble composed of individuals aged 65 and above. The choir rehearsals are weekly, 2 hours each and the length of the intervention is 16 weeks total.
41336258|NCT02019745|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
41336259|NCT01820767|DRUG|Paricalcitol|Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
41336260|NCT01820767|DRUG|Paricalcitol, atorvastatin|"Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks."
41485119|NCT02765217|DRUG|Lactobacillus reuteri DSM 17938|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
41485120|NCT02765217|DRUG|Placebo|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
41336261|NCT01820767|DRUG|Atorvastatin|Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
41336262|NCT00044213|DRUG|EDTA|Participants will receive 40 infusions of standard chelation solution.
41336263|NCT00044213|DRUG|EDTA Placebo|Participants will receive 40 infusions of EDTA placebo.
41336264|NCT00044213|DIETARY_SUPPLEMENT|High Dose Vitamin|
41336265|NCT00044213|DIETARY_SUPPLEMENT|High Dose Vitamin Placebo|
41336266|NCT02463318|DRUG|Melatonin|Melatonin is used for healthy subjects and multiple sclerosis patients
41015357|NCT05956314|DIAGNOSTIC_TEST|Pharmacokinetics Assessments|"Blood samples for PK will be collected during screening (Days -14 to 0) at any time during the visit, or on Day 1 (up to 30 minutes prior to the first dose, if not performed during Screening) and on Day 7 and at End of Treatment (EoT, Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28, 42, and 84 (for Cohort 2): 1 sample after the first dose, before the second dose, as late as possible in the visit, at End of Study (EoS, Cohort 1: Day 112; Cohort 2: Day 140), or at an ET visit: at any time during the visit.~* Altogether up to 15 samples, and approx. 30 mL of blood will be drawn for PK at screening or Day 1 and on Days 7, 28, 42, 84, EoT (84/112), and EoS (112/140), or at an ET visit, if applicable.~* Overall, up to a total of 85 mL of blood will be drawn during the trial for blood and PK assessments per patient in Cohort 1, and 95 mL of blood per patient in Cohort 2."
41015358|NCT05956314|DIAGNOSTIC_TEST|Clinical global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator during screening and on Days 1 (baseline, prior to first dosing), 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort).~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
41015359|NCT05956314|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS) pain scale|"The patient will enter the PPPK- or PC-related pain score (not any pain) using a VAS pain scale in the patient-reported diary, on a weekly basis starting on Day 1 through ET visit, prior to the second administration of the IMP (evening dose) at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The score will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, 140, and at an ET visit - where applicable, per cohort).~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
41015360|NCT05956314|DIAGNOSTIC_TEST|Peak pruritus-numerical rating scale (PP-NRS)|"The peak pruritus severity will be assessed using the PP-NRS, an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The PP-NRS will be entered by the patients on a weekly basis starting on Day 1 through ET visit, preferably after the evening dose, at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The scores will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort).~The PP-NRS was designed to measure peak pruritus, or worst itch, over the previous 24 hours based on the following question: On scale from 0 (no itch) to 10 (worst imaginable itch) how was your worst itch in the past 24 hours?"
41015361|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) as follows:~Since the start of the trial, my overall status has:~from, 1= very much improved to 7= very much worse"
41015362|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe"
41015363|NCT05956314|DIAGNOSTIC_TEST|Lesion photography|"High quality photographic documentation of the treated lesions will be performed during Screening and on Days 1, 7, 42, 63, 84, 112, and 140, or at an ET visit before treatment - where applicable, per cohort.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022)."
41015364|NCT05956314|DRUG|KM-001 cream 1% 16 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.
41015365|NCT05242497|PROCEDURE|pharmacopuncture|This is a pragmatic randomized controlled trials, so the physicians will choose pharmacopuncture treatment, including the type and doses, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
41015366|NCT05242497|PROCEDURE|conservative treatments (including physiotherapy)|This is a pragmatic randomized controlled trials, so the physicians will choose conservative treatment, including physiotherapy and pharmacological treatment, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
41015367|NCT03468530|PROCEDURE|Transurethral ablation|transurethral resection and/or coagulation with a bipolar loop under spinal or general anesthesia
41485121|NCT02765217|DRUG|Amoxicillin-Clavulanic Acid|All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
41015368|NCT04462302|BEHAVIORAL|Internet-based pain coping skills program|The purpose of this study is to determine if an 8-session Internet-based pain management program can help you better manage your cancer-related pain.
41336267|NCT02463318|OTHER|Hydrogen peroxide|Hydrogen peroxide is only used for healthy subjects
41015371|NCT05120193|DEVICE|Mapping and Ablation|Minimally invasive catheter mapping and ablation procedure
41336268|NCT02438761|DRUG|PF-05212384|"PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression."
41336269|NCT03044080|DRUG|IncobotulinumtoxinA|Three consecutive injections of 200-300 units of IncobotulinumtoxinA (Xeomin ®) under ultrasound guidance. The IncobotulinumtoxinA will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
41336270|NCT03044080|DRUG|OnabotulinumtoxinA|ree consecutive injections of 200-300 units of OnabotulinumtoxinA (Botox ®) under ultrasound guidance. The BoNT/A will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
41336271|NCT03793634|DRUG|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect
41336272|NCT05156333|DIETARY_SUPPLEMENT|Respecta|"Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed."
41336273|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose|3 doses of iNTS-TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose Group in Stage 1 (Europe).
41336274|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose|3 doses of iNTS-GMMA low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
41336275|NCT05480800|BIOLOGICAL|Typhoid conjugate vaccine (TCV) low dose|3 doses of TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
41336276|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose|3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 Group in Stage 2 (Africa).
41336277|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose|3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).
41336278|NCT05480800|BIOLOGICAL|Typhoid conjugate vaccine (TCV) full dose|3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).
41336279|NCT05480800|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly at Day 1 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
41336280|NCT05480800|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly at Day 57 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
41336281|NCT05480800|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly at Day 169 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
41336282|NCT05480800|DRUG|Placebo|3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo_Step 1 and Placebo_Step 2 in Stage 1 (Europe).
41017996|NCT06152211|BEHAVIORAL|Group Music Listening|A weekly collective music listening, 2 hours each for 16 weeks.
41015373|NCT06543394|BEHAVIORAL|Primer postcard|Mailed primer postcard
41336283|NCT05480800|OTHER|Saline|3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).
41336284|NCT05288855|DRUG|Voclosporin|calcineurin inhibitor
41336285|NCT05288855|DRUG|Placebo Oral Capsule|matching placebo capsule
41336286|NCT04125303|BEHAVIORAL|brief motivational psychoeducational therapy|The brief motivational psychoeducational therapy (BMPT) it lasted an average of 90 min and followed the following structure: (i) brainstorming the concepts of health, lifestyle, and substance-use prevention; (ii) analysis of a work accident at an international rock group concert, which was used to generate (iii), a debate on consumer habits (30 min); (iv) discussion of the substance types and classifications known by the participants; (v) Prochaska and DiClemente's stages of change and (vi), the consequences of drug use (50 min); and finally, (vii) a true/false quiz used to discuss myths and beliefs about drugs (10 min).
41336287|NCT04602819|DEVICE|PicoSure 755nm picosecond alexandrite laser with diffractive lens|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.
41485122|NCT05007847|DEVICE|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~Routinely once per day from the day of randomisation till the 12-month visit after AF Catheter Ablation (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
41485123|NCT05652959|DEVICE|Cerviron®|Cerviron® is a medical device manufactured by PFC Pharma Manufacturing SL formulated following the provisions of the European Regulation 2017/745 on Medical Devices. Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21. Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
41015374|NCT06543394|BEHAVIORAL|Control recruitment letter|Mailed recruitment letter with usual care message framing
41015375|NCT06543394|BEHAVIORAL|Behavioral theory-informed recruitment letter|Mailed recruitment letter with prospect-theory informed message framing
41336288|NCT04602819|DEVICE|ApolloVue® S100 Image System|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.
41336289|NCT04602819|DEVICE|Cutometer® dual MPA 580|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.
41336290|NCT04602819|DEVICE|VISIA®|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.
41336291|NCT03261141|COMBINATION_PRODUCT|(PV-RQOL),(APA) ,Acoustic analysis|"1. severity and character of dysphonia (measured by Auditory Perceptual Assessment using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~2. Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~3. the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
41336292|NCT03375970|OTHER|TCM|oral chinese herb, chinese topical ointment
41336293|NCT03375970|OTHER|Western medicine|oral steroid, oral antihistamine, topical steroid
41336294|NCT00390429|DRUG|docetaxel|Given IV
41336295|NCT00390429|DRUG|erlotinib hydrochloride|Given orally
41336296|NCT01150604|BEHAVIORAL|Self-help cognitive-behavioral online course|A self-help online course based on cognitive behavioral therapy for major depression.
41336297|NCT04115527|PROCEDURE|Extended Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes
41485124|NCT02296684|BIOLOGICAL|MK-3475 (neoadjuvant)|
41485125|NCT02296684|PROCEDURE|Surgery|Standard of care
41015376|NCT06543394|BEHAVIORAL|2 phone calls|Up to 2 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
41015377|NCT06543394|BEHAVIORAL|4 phone calls|Up to 4 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
41015379|NCT05499676|DEVICE|SilverCloud Health Mobile Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs, including one for anorexia nervosa developed by our team. Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
41015380|NCT05499676|DEVICE|Social Networking Intervention: Facebook|Facebook is a social networking site that will offer participants the opportunity to interact with study team posts, post themselves, and connect with others in the study experiencing similar struggles in a private group
41015384|NCT03455855|DEVICE|Jetstream System|including Atherectomy Console (Jetstream Console) and Atherectomy Catheter(Jetstream Catheter), intended for use in atherectomy of the peripheral vasculature and to break apart and remove atherosclerotic disease, debris, and thrombus from the SFA and/or PPA.
41015386|NCT06525935|DRUG|CT-388|CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
41015387|NCT06525935|DRUG|Placebo|Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
41015388|NCT05891236|BIOLOGICAL|MAM01 1.5 mg/kg|1.5 mg/kg MAM01 will be administered via IV route.
41015389|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via IV route.
41015390|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via SC route.
41015391|NCT05891236|BIOLOGICAL|MAM01 10 mg/kg|10 mg/kg MAM01 will be administered via IV route.
41015392|NCT05891236|BIOLOGICAL|MAM01 40 mg/kg|40 mg/kg MAM01 will be administered via IV route.
41015393|NCT05891236|BIOLOGICAL|MAM01 450 mg|MAM01 will be administered via SC route.
41015394|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via SC route.
41015395|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via IV route.
41015396|NCT05891236|OTHER|Control|No drug or placebo will be administered.
41015397|NCT05891236|BIOLOGICAL|MAM01 600 mg|MAM01 will be administered via SC route.
41015398|NCT05891236|BIOLOGICAL|MAM01 900 mg|MAM01 will be administered via SC route.
41015399|NCT01516190|BEHAVIORAL|Exercise|Supervised exercise sessions and independent exercise
41015400|NCT01516190|BEHAVIORAL|Surgical preparation program|Book, tapes, CD
41015401|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 1 (CPMSM)|Test group 1 will receive investigational product 1 (CPMSM: daily dose 25 mL contains: Hydrolyzed fish collagen 5 g, methylsulphonylmethane (MSM) 1,5 g, Biotin 150 μg, Vitamin B6 1,6 mg, Zinc 2 mg, Vitamin C 120 mg).
41015402|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 2 (HC+)|Test group 2 (TG2) will receive investigational product 2 (HC+: daily dose 25 mL contains: Niacin 16 mg, Pantothenic acid 6 mg, Biotin 500 μg, Vitamin B6 1,4 mg, Folic acid 200 μg, Zinc 2 mg, Pea sprout extract 100 mg, Horsetail aerial parts extract 70 mg, Ashwagandha root extract 40 mg, Saw palmetto fruit extract 40 mg, Nettle leaves extract 30 mg, Grape seed extract 10 mg).
41015403|NCT06174441|DIETARY_SUPPLEMENT|Placebo|Placebo group (PG) will receive placebo product without any of the active ingredients (PL, daily dose 25 mL: no active ingredients).
41485126|NCT02296684|RADIATION|Intensity modulated radiation therapy|Recommended, standard of care
41485127|NCT02296684|RADIATION|Image-guided radiation therapy|Recommended, standard of care
40817789|NCT05293041|DRUG|Placebo|Infusion of Normal Saline 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the placebo arm.
40817790|NCT01296711|BIOLOGICAL|CDP6038 (olokizumab)|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
40817791|NCT03352557|DRUG|BIIB092|Administered as specified in treatment arm.
41015404|NCT02622035|BEHAVIORAL|Provision of information|Information about fruit and vegetable feeding for children framed in gain vs. loss manner
41015405|NCT02622035|BEHAVIORAL|Emotion induction|Film clip designed to induce anger or fear
41336298|NCT04115527|PROCEDURE|Standard Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes
41336299|NCT04275999|DRUG|ivermectin|Subjects will be given the ivermectin with an electronic monitoring device attached with a return appointment at month 3 for end of study visit. Subjects will be instructed to use the ivermectin once daily.
41336300|NCT04275999|BEHAVIORAL|digital interaction|Subjects will receive weekly digital interaction; an electronic survey asking about their use of the ivermectin which will have the electronic monitoring device attached. Subjects will be instructed to use the ivermectin once daily. They will have a 3 month return appointment for end of study visit.
41336301|NCT04275999|DEVICE|GPSkin|Subjects in the GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin with the electronic monitoring device once daily. They will be scheduled for a 3 month end of study visit.
41336302|NCT02983513|BEHAVIORAL|Early Intervention|
41336303|NCT04713111|BEHAVIORAL|Lifestyle (Meditation)|Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace 2 or more times a week for a duration of 4 weeks.
41336304|NCT04713111|BEHAVIORAL|Lifestyle (Exercise)|Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks.
41336305|NCT05728762|DEVICE|Novel LEDs|LEDs with a continuous spectrum of 430-780 nm.
41336306|NCT04005807|DRUG|BPN-14967|BPN-14967 oral capsules
41336307|NCT04005807|DRUG|Placebo|Oral capsules
41336308|NCT05793112|DRUG|INF108F probiotic|Oral suspension
41336309|NCT05793112|DRUG|Placebo|Oral suspension
41336310|NCT04737980|DRUG|Liposomal bupivacaine|Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block
41336311|NCT04737980|DRUG|Bupivacaine Hcl 0.5% Inj|Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block
41336312|NCT04737980|DRUG|Ropivacaine 0.5% Injectable Solution|Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block
41485128|NCT02296684|DRUG|Cisplatin|Standard of care
41485129|NCT02296684|BIOLOGICAL|MK-3475 (adjuvant)|
41485130|NCT02296684|PROCEDURE|Peripheral blood|-Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery
41485131|NCT04306237|DRUG|IMB-1018972|IMB-1018972 200 mg tablet for oral administration
41485132|NCT04306237|DRUG|Placebo oral tablet|Matched placebo tablet for oral administration
41015406|NCT02622035|BEHAVIORAL|visual perceptual load|visual and interactivity-based load of virtual reality buffet environment
41015408|NCT05142358|DEVICE|Continuous Positive Airway Pressure|Use of CPAP device at the start of treatment planning.
41485133|NCT05533398|OTHER|Stress ball use|They were asked to use the ball for at least 10 minutes during the dialysis treatment and when they felt stressed or unwell at home/work. Patients with arteriovenous fistula or arteriovenous graft were instructed to use the stress ball with the other hand, where there was no vascular access.
41485134|NCT01568320|DEVICE|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
41485135|NCT00121147|DRUG|Travatan|
41485136|NCT00121147|DRUG|Azopt|
40817792|NCT03352557|DRUG|Placebo|Administered as specified in treatment arm.
40817793|NCT03351816|PROCEDURE|Ablation of atrial fibrillation|Pulmonary vein isolation by radiofrequency or cryoablation.
40817794|NCT03351816|PROCEDURE|Cardioversion|External electric shock delivery under general anesthesia.
40817795|NCT02042053|DEVICE|PET/CT|
40817796|NCT02042053|DEVICE|PET/MRI|
41015409|NCT05142358|OTHER|Deep inspiratory breath hold|Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments
41015410|NCT05142358|OTHER|Free Breath|Regular breathing
41015411|NCT03520491|DRUG|Nivolumab|Nivolumab 3 mg/kg or Nivolumab 1 mg/kg
41015412|NCT03520491|DRUG|Ipilimumab|Ipilimumab 3 mg/kg
41336313|NCT04737980|DRUG|Dexamethasone|Injection of 8mg (2ml) dexamethasone injectable as admixture
41336314|NCT01244204|DIETARY_SUPPLEMENT|Vitamin D|Daily dose of 800IU of vitamin D
41336315|NCT01244204|DIETARY_SUPPLEMENT|Placebo|Identically appearing capsules
41336316|NCT03464890|OTHER|P926 - LICHTENA DermAD CREMA VISO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
41336317|NCT03464890|OTHER|P927 - LICHTENA DermAD CREMA CORPO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
41485137|NCT00121147|DRUG|Alphagan P|
41485138|NCT05496543|DEVICE|acupuncture|All acupoints will be routinely sterilized at first. After the insertion of the needles, manipulations of lifting, twirling, and thrusting are performed on all needles to reach de qi, which is a sensation typically associated with needling including soreness, numbness, swelling, heaviness, and other feelings. This is considered to be an important component of the therapeutic effect of acupuncture.
41015413|NCT03520491|PROCEDURE|Radical cystectomy|RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)
41015414|NCT04216719|BEHAVIORAL|OCM-RISE|OCM RISE will comprise four phases (Exploratory, Preparation, Implementation, and Sustainment). During Exploration, staff will conduct readiness surveys, interviews and system mapping exercises to assess county context. In the Preparation Phase, the needs assessment data will inform county-specific action plans. Guided facilitation during this phase includes court development planning, practice/process improvement strategies, and training on data-driven decision-making to help IACTs operationalize the 10 OCM guidelines, assess performance, and fit the guideline to the local context. In the Implementation Phase, counties will roll out the OCM for 18 months with data feedback, support, and facilitation. Each IACT will receive reports on the performance of its OCM and complete two plan-do-study-act cycles. In the Sustainment Phase, implementation and feedback reports will continue for 6-18 months, but without other external facilitation.
41015415|NCT02803437|DRUG|Radium-223 dichloride (Xofigo, BAY 88-8223)|Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.
41015418|NCT06513819|BEHAVIORAL|Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique|Delivered by a clinical pharmacist who will employ IMB-MI in informational, participant-centered discussions in which the clinical pharmacist and the participant collaboratively discuss the harms of alcohol use (with or without concurrent use of cannabis) and polypharmacy (specifically neurocognitively active medications), the relationship of these exposures to fall risk and NCEs, and how to mitigate these harms. Together pharmacist and participant will develop a plan for change in alcohol and polypharmacy use, self-monitoring, medications of concern, symptoms, and any additional resources needed. The goal of the intervention being to help patients stop or decrease alcohol use and stop medications in situations where it is safe to do so and agreed upon by the primary provider (but substitutions will be made if necessary).
41015423|NCT05512221|OTHER|GBAT+I, GBAT+E - Phase I|Phase I is the development phase, which is informed by the study team's previous pilot study and autistic advisors. It will include the development of engagement booster materials. Booster materials will be tested in 2 groups (GBAT+I and GBAT+E) of six participants each. Groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions) and GBAT+Engagement Booster (GBAT+E; supplemental materials). The first 4-6 eligible adults recruited will participate in GBAT+I and the second 6 eligible adults recruited will participate in GBAT+E. Both groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities).
41015424|NCT05512221|OTHER|Watchful Waiting and Groups - Phase 2|"Phase 2a will include a watchful waiting (WW) condition and assignment to 1 of 2 treatment conditions: GBAT+I or GBAT+E.~Participants will be assigned to WW for 10 wks. They will not receive specific therapeutic services during WW, but a member of the study team will contact them at weeks 1, 2, 4, 6, and 8 to maintain engagement and monitor for clinical deterioration.~After WW, participants will be randomly assigned to one of the treatment conditions (GBAT+I or GBAT+E). All groups will consist of 10 weekly 60-90-minute GBAT group sessions. GBAT+I participants will attend four 30-minute individual booster sessions. GBAT+E participants will be asked to use booster materials between group sessions (e.g., worksheets, goal trackers, interactive learning activities)~WW group size is based on study feasibility and availability of resources. Additional participants will also be recruited at the end of the WW period to supplement group sizes."
41336318|NCT03464890|OTHER|P926 - LICHTENA DermAD CREMA VISO - PLACEBO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
41336319|NCT03464890|OTHER|Untreated control area|Untreated skin area of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
41336320|NCT00663689|DRUG|erlotinib|erlotinib 150mg qd until disease progression or unacceptable toxicity.
41485139|NCT05496543|DEVICE|sham acupuncture|"The placebo needles chosen for this study are flat-tipped needles without a tip, which could not be pierced into the skin. In the meanwhile, an external patch device will fix the needles, which are visually pierced into the skin. After the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball so that the patient can feel the pulling out of the needle."
41485140|NCT01376193|DRUG|Naratriptan|Collection of safety data
40817797|NCT04314765|PROCEDURE|lower third molar extraction|the extraction is performed with one of the two type of flap based non randomization.
41015425|NCT05512221|OTHER|GBAT+IE|"Phase 2b will include assignment to GBAT+IE, which includes components of both GBAT+I (individual sessions) and GBAT+E (supplemental materials)~All groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities). Participants in GBAT+IE will participate in both the individual sessions and use of booster materials."
41015426|NCT06259565|DRUG|Dexmedetomidine|Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in IMV that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium
41015427|NCT06259565|OTHER|Placebo Control|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
41336321|NCT05571904|PROCEDURE|thick STSG; thin STSG|"For all the patients, thick STSGs (at a depth of 0.7 mm) were harvested from the upper lateral thighs to repair skin defects at functional sites or joint sites. For patients in the thick STSG group, the surgeons harvested a larger size of thick STSGs than the size of recipient sites. The size of the donor site was 150% - 200% of the size of the recipient site. Part of the thick STSG was grafted onto the recipient site. Subsequently, the leftover skin was punctured (in 1.5:1 mesh ratio) and stretched to obtain expansion. The donor site was covered by the leftover skin completely. In other words, the donor site was reconstructed by resurfacing the large sheet of thick STSG in situ.~For patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with a large sheet of thin STSGs (at a depth of 0.4 mm) which were harvested from other parts of the patients."
41015432|NCT06073405|DEVICE|Colonic Polyp Measurement Assessment Via Artificial Intelligence|In this study, we collect colonoscopy video clips of polyps and, among the related clinical information, their estimated size using the gold standard technique, and we use them offline to evaluate the measurement performances of the novel virtual polyp sizing tool
41015433|NCT02502786|BIOLOGICAL|humanized anti-GD2 antibody|
41015434|NCT02502786|DRUG|GM-CSF|
41485141|NCT06255301|DIAGNOSTIC_TEST|EYEPRIM|Collection of conjunctival impressions using the EC(European Conformity )-marked EYEPRIM device . This device enables cells to be collected the superficial ocular surface cells by applying a membrane for few seconds to the ocular surface.
41485142|NCT03453671|BEHAVIORAL|Mindfulness|Participants will use mindfulness techniques while exercising
40817798|NCT05605275|DIAGNOSTIC_TEST|PCT levels|All patients will have their serum PCT level recorded on the day of the positive blood culture and in the next three days.
40817799|NCT05605275|DIAGNOSTIC_TEST|CRP levels|All patients will have their serum CRP level recorded on the day of the positive blood culture and in the next three days.
40817800|NCT05605275|DIAGNOSTIC_TEST|White blood cell count|All patients will have their white blood cell (WBC) count recorded on the day of the positive blood culture and in the next three days.
41485143|NCT03453671|BEHAVIORAL|Distraction|Participants will distract themselves while exercising
40817801|NCT05605275|DIAGNOSTIC_TEST|Platelet count|All patients will have their platelets count recorded on the day of the positive blood culture and in the next three days.
41485144|NCT03453671|BEHAVIORAL|Self-monitoring|Participants will use associative attentional focus while exercising
41485145|NCT02970435|BEHAVIORAL|Video Discharge Instructions|The video discharge instructions, will be provided to the patient at the time of surgical procedure.
41485146|NCT02970435|BEHAVIORAL|Telecommunication Reminders|Telecommunication reminders including text messages, email, or phone calls to remind participants how to access the video discharge instruction up to three times before follow-up
41485147|NCT02970435|BEHAVIORAL|Standard of Care|Standard of Care: verbal and written discharge instructions for patients after surgery
41485148|NCT05717855|DIAGNOSTIC_TEST|Displaying optic chiasm for screening septooptic dysplasia|Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia with ultrasound between 16-20 weeks of gestation
41485149|NCT01764282|BEHAVIORAL|comprehensive intervention components|ART promotion, Couple testing and consulting promotion, and Condom use promotion
41485150|NCT01408095|DRUG|LY2608204|Administered orally
41336322|NCT04424004|OTHER|COVID-19 PCR and serology testing|"1. PCR testing: participate will conduct at-home collection and return of self-administered nasal swabs for COVID-19 polymerase chain reaction (PCR) viral testing. Saliva specimens may replace the nasal swab specimen. Specimens will be collected at baseline and every 2 weeks in conjunction with questionnaire administration.~2. Serology testing: The same randomized participants will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies. Specimens will be collected by routine venipuncture at the MURDOCK Study office in Kannapolis, NC.Specimens for serology will be collected at baseline approximately 1 month after the first questionnaire and 2 weeks after the first nasal swab collection and COVID-19 PCR testing. Specimens for serology will be collected at least bi-monthly and up to monthly thereafter through a total study duration of 6, and up to 12, months."
41336323|NCT02394223|PROCEDURE|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
41336324|NCT06260800|OTHER|Validation CEQ|In initial assessment, EQ-5D-5L and HADS questionnaires were completed. After sessions 1 and 2, CEQ and WAI-S were filled. Finally, EQ-5D-5L was completed before the fourth session.
41485151|NCT01408095|DRUG|Glimepiride|Administered orally
41336325|NCT03204357|OTHER|Fresh Autologous whole Blood|Subjects randomized this arm will receive fresh autologous whole blood
41336326|NCT03204357|OTHER|Standard of Care Expectant management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
41485152|NCT03580291|OTHER|Mesenchymal stem cells|The group receive pulse infusion of MSCs once of 2 x 10\^6/kg body weight
41485153|NCT03580291|DRUG|Mycophenolate Mofetil|This group receive oral MMF of 2.0 g / d.
41485154|NCT03580291|OTHER|Placebo of Mesenchymal stem cells|The group receive placebo of Mesenchymal stem cells.
41485155|NCT03580291|DRUG|Placebo of Mycophenolate Mofetil|The group receive placebo of oral mycophenolate mofetil.
41485156|NCT05632341|DIETARY_SUPPLEMENT|Lactococcus lactis|1 capsule once a day
41485157|NCT05632341|OTHER|maltodextrin|1 capsule once a day
41485158|NCT04644094|OTHER|Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration|"A. Electrocardiographic (ECG) leads will be place in the patient for electrocardiogram (ECG) recordings.~B. Echocardiography (ECHO) will be performed by an expert member of the Neonatal Echocardiography team C. Heart Rate Variability (HRV): ECG recordings D. Growth trajectory: body weight, length, head circumference, length/weight ratio at 1-, 2-weeks prior treatment, 1-, 2-, 3-, 4-,6-,8-weeks after treatment, at 36-week PMA."
41485159|NCT00204958|DRUG|nutritional supplement|
41485160|NCT00204958|DRUG|glutamine popsicle|
41485161|NCT03437915|RADIATION|NIBB: accuboost|28.5 Gy delivered in 5 daily fractions
41485162|NCT03437915|PROCEDURE|Partial mastectomy|4-12 weeks post NIBB
41485163|NCT00801359|PROCEDURE|Phacoemulsification|
41485164|NCT00801359|DRUG|BSSPlus solution|
41485165|NCT00801359|DRUG|Lactated Ringer's solution|
41336327|NCT00683813|BEHAVIORAL|vCRP|The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
41336328|NCT05592041|DRUG|Banaba Leaf Extract|a herbal extract in the form of Bigel
41336329|NCT00356668|DEVICE|High Flow Nasal Cannula|30 minute blocks on varying flows of high flow nasal cannula
40817802|NCT04281225|BEHAVIORAL|Attention to Variability (ATV)|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and behavior that occur throughout the day, and to notice changes they experience with their hearing loss symptoms; noticing if it is better or worse and to ask why it may be.
40817803|NCT04281225|OTHER|Placebo|Participants are told that the device they will be testing will improve their hearing, when in fact the device is not a hearing aid but just a metallic earring.
41015439|NCT05133531|DRUG|Ravulizumab|Administered Intravenous (IV) per the protocol
41015440|NCT05133531|DRUG|Pozelimab|Administered IV and subcutaneous (SC) per the protocol
41336330|NCT02349204|BEHAVIORAL|Music - Mozart's sonata for 2 pianos in D-440|
40817804|NCT00503776|BEHAVIORAL|exercise intervention|Patients undergo low weight resistance training.
40817805|NCT00503776|DRUG|amifostine trihydrate|Given subcutaneously
41336331|NCT03256136|DRUG|Carboplatin|Chemotherapy
41336332|NCT03256136|DRUG|Nivolumab|will allow the body's immune system to work against tumor cells
41336333|NCT03256136|DRUG|pemetrexed|Chemo therapy
41336334|NCT03256136|DRUG|Ipilimumab|will allow the body's immune system to work against tumor cells
41336335|NCT05176860|DEVICE|CBCT Imaging|Two research CBCT images will be acquired per subject.
41336336|NCT02672618|OTHER||The IRS system is capable of precisely measuring and storing real-time thermal images with a resolution of 320×240 pixels (IRS S6md Shanghai,China). The camera has Focal Plane Array (FPA), Uncooled microbolometer detector, with a thermal sensitivity of 0.05 ℃ at 20℃ to 30℃. The thermal images were captured at a distance of one meter from the various body regions namely face and the images were analyzed by thermal software（version 1.0）.
41336337|NCT01002898|DRUG|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
41336338|NCT02470897|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo urethral-sparing IMRT planning
41336339|NCT02470897|RADIATION|SBRT|Undergo moderate dose SBRT with SIB
41336340|NCT02470897|RADIATION|SBRT|Undergo uniform dose SBRT
41485166|NCT02054130|DRUG|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
40817806|NCT00503776|PROCEDURE|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
40817807|NCT00616811|DRUG|vildagliptin|
40817808|NCT00616811|DRUG|Sitagliptin|
40817809|NCT06527144|DRUG|3mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
40817810|NCT06527144|DRUG|6mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
40817811|NCT06527144|DRUG|Placebo TQC3721 suspension for inhalation|Placebo without active drug substance.
41015441|NCT05133531|DRUG|Cemdisiran|Administered SC per the protocol
41015442|NCT05133531|DRUG|Eculizumab|Administered IV per the protocol
41015443|NCT03685331|DRUG|Palbociclib|Combination of palbociclib, olaparib, and fulvestrant.
41015444|NCT03685331|DRUG|Olaparib|Combination of palbociclib, olaparib, and fulvestrant.
41015445|NCT03685331|DRUG|Fulvestrant|Combination of palbociclib, olaparib, and fulvestrant.
41015449|NCT03057626|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine
41015450|NCT03057626|OTHER|Laboratory Biomarker Analysis|Correlative studies
41015451|NCT03057626|OTHER|Quality-of-Life Assessment|Ancillary studies
40817812|NCT06608251|DIAGNOSTIC_TEST|white matter lesion|According to the results of magnetic resonance, they were divided into white matter degeneration group and non-white matter degeneration group
40817813|NCT04124562|OTHER|Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals
40817814|NCT00350363|DRUG|Zymar|zymar qid
40817815|NCT03474848|OTHER|HABIT|Provision of individualized bimanual activities, individually chosen according to the child´s abilities, impairments and improvements in order to achieve success and to encourage bimanual use. Task difficulty is graded, focusing on enhancing the level of difficulty or speed, according to child's improvements. We use whole task practice (sequencing successive movements in the context of activities), part task practice (practice of specific components of the task in a repetitive sequence of time) and individualized functional goal training.
40817816|NCT03474848|OTHER|Conventional Occupational Therapy (OT)|Children will maintain the occupational therapy sessions with their therapists, without any change in their routine at the rehabilitation center. Strategies such as functional training, stretching and sensory stimulation are used.
41336341|NCT06103019|OTHER|conventional complete denture|conventional complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
41336342|NCT06103019|OTHER|3D complete denture|3D complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
41336343|NCT06294236|BIOLOGICAL|SC291|SC291 is an allogeneic CAR T cell therapy
41336344|NCT01609738|DEVICE|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
41336345|NCT05158179|DEVICE|Sensation testing|Sensation testing tactile aesthesiometer.
41336346|NCT00338260|DRUG|MK0954, /Duration of Treatment : 5 Years|
41336347|NCT00338260|DRUG|Comparator : atenolol /Duration of Treatment : 5 Years|
41336348|NCT01956058|RADIATION|brachytherapy remedial|brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
41336349|NCT05651984|DEVICE|Comparison between communication board and eye tracking|The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
41336350|NCT04889690|DRUG|Danicopan|
41336351|NCT04889690|DRUG|Placebo|
41336352|NCT02252757|DEVICE|CoVa|
41336353|NCT05651841|DRUG|Tezepelumab|"Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
40817817|NCT01761591|DEVICE|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
40817818|NCT01761591|DEVICE|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
41336354|NCT05651841|OTHER|placebo|"APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
41336355|NCT04767295|DRUG|Camrelizumab, Albumin Paclitaxel, Carboplatin|Intravenous administration of Camrelizumab (200mg/3weeks); Intravenous administration of albumin paclitaxel (260 mg/m2/3weeks); Intravenous administration of carboplatin (AUC 4/3weeks)
41336356|NCT05953324|OTHER|Kiwifruit|2 kiwifruit for 6 weeks
41485167|NCT02054130|DRUG|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
40817819|NCT05257460|DEVICE|Hybrid closed-loop using ultra-rapid insulin lispro|Hybrid closed-loop using ultra-rapid insulin lispro
40817820|NCT05257460|DEVICE|Hybrid closed-loop using standard insulin lispro|Hybrid closed-loop using standard insulin lispro
40817821|NCT06608420|OTHER|Gradient Boosting Survival Analysis (GBSA),|It is a non-deep learning method that effectively addresses data scarcity issues. GBSA adapts the gradient boosting machine algorithm for survival analysis, particularly accommodating censored data. In survival analysis, patients are represented by a triplet (xi, δi, Ti), where xi is the feature vector, Ti is the time to event, and δi indicates whether the observation is censored. Our goal is to estimate the survival function S(t), representing the probability of a patient surviving beyond time t, and the hazard function λ(t), indicating the instantaneous probability of an event occurring at time t.
41015458|NCT06416748|PROCEDURE|Minimally invasive simple hysterectomy|Patients with SHAPE inclusion criteria (FIGO 2018 stage IA2 and IB1 up to 2 cm, with limited stromal invasion: \&amp;amp;lt; 10 mm on LEEP/cone and \&amp;amp;lt; 50% depth on imaging) should undergo conization with surgical margins free from invasive disease or conization with involved surgical margins followed by MRI scan or expert ultrasound scan showing no residual disease. In case of residual disease at post conization imaging still fitting inclusion criteria, another conization is recommended. After these steps minimally invasive (laparoscopy or robotic) simple hysterectomy is performed with sentinel lymph node biopsy algorithm. Adjuvant therapy is given only in case of positive surgical margins, metastatic lymph nodes, and extensive LVSI with depth of stromal infiltration over 2/3.
41336357|NCT06337903|BEHAVIORAL|Self-compassion intervention (the Mindful Self-Compassion course)|An online 8-week mindful self-compassion course with weekly sessions.
41015462|NCT00663611|DRUG|Norditropin|Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.
41015463|NCT00663611|DRUG|Placebo|0.9% normal saline
41017997|NCT02112786|DEVICE|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
41017998|NCT02367313|DRUG|Vapendavir|Vapendavir 264 mg twice daily
41485168|NCT02054130|DRUG|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
41485169|NCT02054130|DRUG|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
41336358|NCT04979962|DEVICE|EW10-EC02 (Endoscopy Support Program)|EW10-EC02 is intended to automatically detect the location of suspected polyps in colonoscopy exams. Identified polyps are highlighted to the clinician in real-time during the exam, as a video image superimposed on the endoscope monitor. EW10-EC02 is limited to the detection of suspected findings, and should not be used in lieu of full patient evaluation or relied upon to make or confirm a diagnosis.
40817822|NCT06608420|OTHER|Concordance index|The survival model performance will be evaluated using the concordance index (c-index), a metric particularly suited for survival analysis. The c-index assesses the predictive accuracy of our model by comparing predicted and observed event times. A high c-index indicates that our model effectively predicts the order of patient hazard given its input features.
41336359|NCT02099760|DEVICE|STD testing (GC/Ct/trich)|
41336360|NCT01802541|DIETARY_SUPPLEMENT|diacylglycerol oil|
41336361|NCT01802541|DIETARY_SUPPLEMENT|triacylglycerol oil|
41336362|NCT01150760|DRUG|Alvimopan|At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
41336363|NCT00280605|DRUG|Alfuzosin|
41336364|NCT00288041|DRUG|carboplatin|Given IV
41485170|NCT05250674|DEVICE|CEM-guided biopsy|"The evaluation population consists of adult women, presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination (with no clear ultrasound or mammography correlation) and considered eligible for this procedure as per standard of care.~Eligible subjects undergo the clinically indicated breast biopsy procedure using the Pristina Serena Bright ® CEM-guided biopsy. Region of interest location is determined by using stereotactic pairs of CEM images after injection of iodinated contrast media. All necessary equipment and instrumentation, medications, or other devices required to complete the subject's clinically indicated procedure shall be used and are not expected to be influenced by evaluation participation."
41485171|NCT03923530|DRUG|Eplerenone|Eplerenone 50 mg daily
41485172|NCT04817566|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
41485173|NCT04817566|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
41336365|NCT00288041|DRUG|paclitaxel|Given IV
41485174|NCT04817566|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
41485175|NCT05054218|BIOLOGICAL|mRNA-1273|Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.
41485176|NCT00535587|BEHAVIORAL|Exercise|
41485177|NCT00535587|DRUG|pyridostigmine|
41336366|NCT00288041|DRUG|bortezomib|Given IV
41336367|NCT04382677|BEHAVIORAL|Promoting First Relationships ®|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 12 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
41336368|NCT04382677|OTHER|Resource & Referral|This condition consists of 1) Resource \& Referral assistance provided over the phone, and 2) Local Services Resource Packet. Throughout the intervention period, the provider makes monthly phone calls to offer further support to families, answer questions, and provide additional resources. The provider has at least four interactions with each family served. In addition, families in this condition have the Resource and Referral Specialist's phone number and they can call if an additional need arises. The resource packet includes local information organized by type of need or resource. These packets are updated regularly as services change over time.
41336369|NCT03157843|DRUG|low-molecular-weight heparin|
41485178|NCT00535587|DRUG|Placibo|
40817823|NCT03802344|DRUG|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
40817824|NCT03802344|DRUG|Cal/BDP combination|Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
40817825|NCT03802344|DRUG|Vehicle|Vehicle cream
41336370|NCT01351389|BEHAVIORAL|Brief Motivational Intervention (BMI)|The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
41017999|NCT02367313|DRUG|Vapendavir|Vapendavir 528 mg twice daily
41018000|NCT02367313|DRUG|Placebo|Placebo twice daily
41336371|NCT01351389|BEHAVIORAL|Brief Advice|Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
41336372|NCT06052189|PROCEDURE|Ultrasound|Ultrasonographic parameters: in the parasagittal plane (1cm from midline) with the patient lying supine, without a pillow, head, and neck in the neutral position, looking straight ahead with mouth closed and the tongue on the floor of the mouth without any movement.
41485179|NCT00535587|BEHAVIORAL|Attention Control|
41485180|NCT05565339|DEVICE|PMEIs|"To evaluate audiological outcomes post-operatively, the air-bone gap (ABG) was assessed.~To evaluate safety of the devices, adverse events were collected.A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated. To assess whether implantation of PMEI affected residual hearing pre- and post-operative bone conduction thresholds were evaluated."
41485181|NCT00120536|DRUG|vildagliptin|
40817826|NCT05059860|DEVICE|Tandem Control IQ Hybrid Closed Loop Insulin Delivery System|The Tandem Control IQ hybrid closed loop insulin delivery system is made up of an externally worn Tandem insulin pump which communicates wirelessly to the Dexcom G6 CGM worn as a patch on the skin. The CGM measures glucose levels transmitting them into the computer within the pump. The computer then calculates how much insulin is required then dose delivery completes the cycle. The Control-IQ™ advanced technology adjusts insulin delivery to avoid glycaemic excursions, while still allowing the user to manually bolus at mealtimes.
40817827|NCT01418703|DEVICE|Closed Loop Control (CLC)|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This Control to Range System uses two DexCom Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer used CGM values to make recommendations of insulin treatment based on the algorithms.
41485182|NCT00759902|DRUG|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
40817828|NCT01418703|DEVICE|Open Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects use their own pump. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
40817829|NCT02663466|PROCEDURE|erroneous off-midline closures|All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
40817830|NCT01175486|DRUG|Actos (Pioglitazone)|Actos 30 mg for 6 months
40817831|NCT01175486|DRUG|Acarbose|Acarbose 50 mg tid for 6 months
40817832|NCT02489708|BEHAVIORAL|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
40817833|NCT03479294|DRUG|Shenlingcao Oral Liquid|Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
41018001|NCT01956175|DEVICE|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
41336373|NCT05768542|DRUG|Metoprolol Injection|If heart rate below 60, give 5 mg IV. If heart rate above 60, give 5 mg IV and repeat until heart rate below 65 or 20 mg given in total or systolic blood pressure below 110 mmHg.
41336374|NCT05768542|DRUG|Saline|5 ml given IV
41336375|NCT01596192|OTHER|PETCT|"CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).~CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec."
41485183|NCT00759902|DRUG|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
41485184|NCT00809159|BIOLOGICAL|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
41485185|NCT00809159|DRUG|Placebo|Placebo to AIN457
41336376|NCT05678478|OTHER|semi-directed interview concerning the experience of adolescents and their parents on Lyme borreliosis and on the tick.|"semi-structured interview on the experience of adolescents and their parents on Lyme borreliosis and the tick.~The interviews will be semi-directed in physical presence. Three interviews will be conducted.~The minor will be questioned first, then the parent(s). And finally, the whole family in one interview. All interviews will be audio recorded with parallel note taking in order to best transcribe the visual expressions. The interviews will be transcribed in writing and pseudonymised."
41485186|NCT02564419|DEVICE|Medtronic Activa PC+S|Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
40817834|NCT04595630|OTHER|data collection from the hospital records|The clinical data from the patients enrolled in the study, such as the medical history, functional state, and EuroSCORE, and the hematological, basic renal, hepatic, and metabolic chemistry findings (including cTn as defined per the protocol), the operative data (operating time, blood loss, cardiopulmonary and cross-clamp time, number of arterial and venous grafts, the number of distal anastomoses, flow measured at all bypass grafts at the end of the intervention and the need for an assist device) and CCT scan data (at discharge from hospital facility) will be obtained from the hospital records. The data will be entered into a database.
41018002|NCT01956175|DEVICE|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
40817835|NCT03267719|DEVICE|laser therapy|Transvaginal erbium-laser treatment
41336377|NCT01135745|DEVICE|Reclaim® Deep Brain Stimulation|Implant of leads in pre-defined brain area; implant of neurostimulators
40817836|NCT06608563|PROCEDURE|Fissure sealant without adhesive system (NO BOND)|"1. Cotton roll isolation~2. Etching of the enamel surface: 17% phosphoric 15 seconds over the surface to be sealed (Phosphoric etchant gel - Vococid, VOCO)~3. Washing/drying: a 3-1 syringe will be used to rinse all etch material from the toothsurface.~4. Sealant application: a light-curing nano-hybrid fissure sealant material (Grandio Seal; VOCO) will be applied using the applicator tip.~5. Lightcuring: The material will be lightcured for 20 seconds."
40817837|NCT06608563|PROCEDURE|Fissure sealant with adhesive system (BOND)|"1. Cotton roll isolation~2. Etching of the enamel surface: 17% phosphoric 15 seconds over the surface to be sealed (Phosphoric etchant gel - Vococid, VOCO)~3. Washing/drying: a 3-1 syringe will be used to rinse all etch material from the toothsurface.~4. Adhesive system application: the adhesive system (Futurabond, VOCO) single dose capsule will be applied over the surface to be sealed for 5 seconds using a microbrush. The adhesive system will be air thin dried and lightcured for 10s before sealant placement.~5. Sealant application: a light-curing nano-hybrid fissure sealant material (Grandio Seal; VOCO) will be applied using the applicator tip.~6. Lightcuring: The material will be lightcured for 20 seconds."
41336378|NCT02394327|DEVICE|7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)|Endoscopic
40817838|NCT01666535|BIOLOGICAL|Influenza vaccination|
41336379|NCT02394327|DEVICE|7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)|
41336380|NCT06280053|DEVICE|HealiAid Collagen Wound Dressing|HealiAid is an absorbable collagen wound dressing. It is fabricated by fibrous collagen matrix, in which the collagen is purified from bovine Achilles tendons. HealiAid can be applied easily by covering directly to the clean wound sites.
41336381|NCT02944734|DRUG|Candesartan Cilexetil 8mg|Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
41336382|NCT02944734|DRUG|Candesartan Cilexetil 16mg|Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
40817839|NCT04991389|DRUG|129-Xe|Inhaled contrast for MRI
40817840|NCT05731908|DRUG|BI 690517|BI 690517
40817841|NCT03955250|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.
40817842|NCT03955250|BEHAVIORAL|Mobile app attention control|The control app provides ecological momentary assessment and psychoeducation about illness.
40817843|NCT06285201|DRUG|T|8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)
40817844|NCT06285201|DRUG|R|8 mg/kg IV of Test drug manufactured by Patheon Italia
40817845|NCT05957042|DRUG|Lumason|Up to 4.8mL administered intravenously
40817846|NCT01200407|DRUG|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
40817847|NCT03197987|DEVICE|Endocuff|Endocuff-assisted colonoscopy
41336383|NCT02944734|DRUG|Amlodipine 5mg|Amlodipine 5mg Daily oral administration for 8 weeks
40817848|NCT03197987|DEVICE|cap|Cap-assisted colonoscopy
41336384|NCT02944734|DRUG|Amlodipine 10mg|Amlodipine 10mg Daily oral administration for 8 weeks
41336385|NCT01006213|BEHAVIORAL|Motivational intervention|Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
40817849|NCT03091985|DEVICE|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
40817850|NCT03091985|DEVICE|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
40817851|NCT00952445|DRUG|T0903131 Besylate|Once daily, oral
40817852|NCT00952445|DRUG|Placebo|Once daily, oral
40817853|NCT06508489|BIOLOGICAL|SAR443579|Pharmaceutical form: Powder for solution for infusion Route of administration: intravenous infusion
41485187|NCT01484184|DRUG|SPINALON (buspirone + levodopa + cardidopa)|The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
41485188|NCT02772952|OTHER|Control Intervention|Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
41485189|NCT02772952|OTHER|Multimodal Intervention|Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
41485190|NCT00239655|DRUG|MK0812|
41485191|NCT02613325|DEVICE|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
41485192|NCT02613325|PROCEDURE|Standard of care surgical excision|
41485193|NCT02613325|DEVICE|Single cell photoacoustic microscopy|
40817854|NCT06508489|DRUG|venetoclax|Pharmaceutical form :Film coated tablet Route of administration: oral
40817855|NCT06508489|DRUG|azacitidine|Pharmaceutical form: Lyophilized powder for suspension for injection Route of administration: intravenous or subcutaneous
40817856|NCT01239381|RADIATION|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
40817857|NCT01340625|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
40817858|NCT01340625|DRUG|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
41156295|NCT02368366|BEHAVIORAL|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
41336386|NCT05543824|DRUG|Levobupivacaine|Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize
41336387|NCT02754661|DEVICE|COLON Capsule endoscopy|
41336388|NCT02754661|DEVICE|Computed Tomographic Colonography|
40817859|NCT05582707|DRUG|Pioglitazone 15mg|Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
40817860|NCT02939820|DRUG|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
40817861|NCT04761679|BEHAVIORAL|Applying the Mepilex foam|Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
40817862|NCT00417378|DEVICE|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
40817863|NCT00417378|DEVICE|Intraaortic Balloon Pump|Counterpulsation
40817864|NCT02080481|DEVICE|Infiniti Plus needle guidance system|The Infiniti Plus needle guidance system is designed to help physicians perform ultrasound guided nerve blocks.
40817865|NCT02080481|DEVICE|Conventional block needle|conventional block needle used for insertion of femoral nerve catheters.
41156296|NCT04072198|DRUG|Nivolumab|240 mg every 2 weeks for 8 cycles followed by maintenance
41156297|NCT04072198|DRUG|Bevacizumab|5 mg/kg every 2 weeks for 8 cycles followed by maintenance
41156298|NCT04072198|DRUG|Irinotecan|165 mg/m2 every 2 weeks for 8 cycles
41156299|NCT04072198|DRUG|Oxaliplatin|85 mg/m2 every 2 weeks for 8 cycles
41156300|NCT04072198|DRUG|Leucovorin|200 mg/m2 every 2 weeks for 8 cycles
41156301|NCT04072198|DRUG|fluoruracil|3200mg/m2 every 2 weeks for 8 cycles
41156302|NCT05406206|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.
41156303|NCT05406206|PROCEDURE|Hepatic Arterial Infusion Chemotherapy|HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m\*2 + 5-FU 2000 mg/m\*2, Q4W
41156304|NCT05177770|DRUG|SRF617|SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.
41156305|NCT05177770|DRUG|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
41156306|NCT05177770|DRUG|zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
41336389|NCT00331084|DRUG|antibiotic/steroid combination|1 gtt, 4x/day, 15 days
41336390|NCT00331084|DRUG|moxifloxacin / dexamethasone|1 gtt 4x/day, 15 days
41336391|NCT04731922|DRUG|TAK-510|TAK-510 solution.
41336392|NCT04731922|DRUG|TAK-510 Placebo|TAK-510 placebo-matching solution.
41336393|NCT00399867|DRUG|Simvastatin|
41336394|NCT03532724|DEVICE|Patient Self-Management of VKA therapy|Trained patients check weekly the INR using a portable coagulometer an decide by themselves the dosis of VKA
41485194|NCT05966220|DEVICE|Hip surgery with FH Ortho devices|"This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma.~In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons."
41485195|NCT03489161|DRUG|Buprenorphine|buprenorphine/naloxone 4mg/1 mg for Clinical Opioid Withdrawal Scale (COWS) scores between 8 and 12, or 8mg/2mg S/L ≥ 12 by the sublingual route
41485196|NCT00531141|OTHER|examination only|OCT performed twice
40817866|NCT06039449|DRUG|VYD222 (pemivibart)|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.
40817867|NCT06039449|DRUG|Normal saline|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.
40817868|NCT01476319|OTHER|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
40817869|NCT00460694|BIOLOGICAL|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
40817870|NCT05826418|DIETARY_SUPPLEMENT|MEND diet|Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
40817871|NCT05826418|DIETARY_SUPPLEMENT|mNICE diet|Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
41485197|NCT06357663|OTHER|Mindfulness practice with Calligraphy|The unique style of Art Meditation where mindfulness (heightened awareness) is achieved by combination of movement and focus on Chinese Tao Calligraphy while chanting a mantra. The practitioners repeatedly trace the lines of Tao calligraphy with fingers and chant the mantra. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age.
41485198|NCT03481218|OTHER|The World Health Organization Quality of Life (WHOQOL) -BREF|The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.
40817872|NCT06608550|OTHER|short video film|Children will be trained with a short movie to prepare for the endoscopy procedure. The content of the short movie video training will include; introduction of the outpatient clinic, things to be considered before the procedure, preparation for the procedure, introduction of the endoscopy room, introduction of the service to come after endoscopy, issues to be considered after the procedure. The short movie training is expected to last approximately 5 minutes.
41156307|NCT05284006|DIAGNOSTIC_TEST|Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.|This study includes 15 major assessments: clinical assessment procedures; anthropometric measurements; activity of daily living and quality-of-life questionnaires; gait kinematics and kinetics analysis; pulmonary function tests (PFT); skeletal radiographs and dual-energy x-ray absorptiometry (DXA); MRI in cervical spine, temporal bones, and hip; computed tomography angiography (CTA) for tracheal obstruction; CT for temporal bones; anesthetic encounters; joint mobility; hearing function; biochemical analyses; and pathological analyses.
41336395|NCT00956462|DRUG|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
41336396|NCT02053519|DRUG|Active Comparator: Vigantol Oil (Vitamin D3)|Vitamin D Oral oil 100.000iu in 5 mls
41336397|NCT02053519|DRUG|Mygliol Oil|Matched placebo comparator
41336398|NCT00073034|DRUG|EAA-090|
41336399|NCT01846689|DRUG|ESS (medical food/drug)|Prescription medical food erythropoietin stimulating system
41336400|NCT03105245|OTHER|Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)|The intervention in this study is the time interval between anaesthetic administration and ECT stimulus
41336401|NCT02703142|PROCEDURE|Patients after esophagectomy|postoperative endoscopic evaluation
41156308|NCT01295788|DEVICE|Simultaneous RT-CGM and Pump Initiation|Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
41336402|NCT00003110|BIOLOGICAL|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
41336403|NCT05646719|DRUG|Phentolamine Opthalmic Solution 0.75%|phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
41336404|NCT05646719|OTHER|Placebo|Vehicle for Phentolamine Ophthalmic Solution
41485199|NCT03481218|OTHER|The Satisfaction With Life Scale - SWLS|The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.
41485200|NCT03481218|OTHER|Big Five Inventory - BFI; John in Srivastava, 1999|The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.
41485201|NCT02322619|DRUG|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
41485202|NCT00336076|OTHER|Collection of blood and bone marrow|5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.
40817873|NCT05909410|OTHER|Survey investigating the CHC use and patients' perception about the relationship between CHC and cancer, diseases and symptoms|This survey investigated the CHC use (type and timing of administration) and patients' perception about the relationship between CHC and cancer, diseases and symptoms
40817874|NCT05853107|DEVICE|AuTNA I|AuTNA I means Au nanoparticle-decorated TiO2 Nanowire Arrays, a retinal prothesis designed for subretinal implantation.
40817875|NCT03617263|DRUG|Saroglitazar Magnesium 4 mg Tablet|Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
40817876|NCT03617263|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
40817877|NCT03227952|DEVICE|Vibrotactile stimulation|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
40817878|NCT01117740|BEHAVIORAL|MDASI Questionnaire|19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
40817879|NCT01029990|OTHER|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
40817880|NCT01029990|OTHER|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
40817881|NCT04392141|DRUG|Standard Treatment|Standard Treatment for COVID-19 based on National Recommendations
40817882|NCT04392141|DRUG|Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions|Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
40817883|NCT03170518|DRUG|Canagliflozin 100 mg|Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.
40817884|NCT03170518|DRUG|Canagliflozin 300 mg|Canagliflozin 300 mg tablet will be administered orally once-daily.
40817885|NCT03170518|DRUG|Placebo|Matching placebo tablet will be administered orally once-daily.
40817886|NCT05083546|DRUG|Gly-low|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
40817887|NCT05083546|OTHER|Placebo|sugar pill
40817888|NCT06215703|BEHAVIORAL|Music Playing Task|For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.
40817889|NCT03057041|DRUG|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
40817890|NCT03057041|DRUG|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
40817891|NCT04146961|DEVICE|Alcon PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the Alcon PanOptix or PanOptix Toric IOL in both eyes.
40817892|NCT03027856|DEVICE|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
40817893|NCT02260778|BEHAVIORAL|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
40817894|NCT00134992|DRUG|Prednisolone acetate|
40817895|NCT04839471|DRUG|BI-754091 plus afatinib|Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.
40817896|NCT00742287|DIETARY_SUPPLEMENT|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
41156309|NCT01295788|DEVICE|Delayed Initiation of RT-CGM|Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
41336405|NCT05646719|DRUG|Low dose pilocarpine|Pilocarpine hydrochloride ophthalmic solution 0.4%
41485203|NCT06139393|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28.
40817897|NCT00742287|DIETARY_SUPPLEMENT|Placebo|placebo
40817898|NCT00202709|BEHAVIORAL|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
41336406|NCT05646719|OTHER|Low dose pilocarpine vehicle|Vehicle for low dose pilocarpine
40817899|NCT03194568|DEVICE|Anterior Vertebral Tether|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
40817900|NCT00072293|PROCEDURE|Axillary lymph node dissection|Axillary lymph node dissection
40817901|NCT00072293|PROCEDURE|No axillary lymph node dissection|Therapeutic conventional surgery
40817902|NCT05704621|PROCEDURE|secondary cytoreductive surgery|Maximum effort cytoreductive surgery
40817903|NCT05704621|DRUG|chemotherapy|six cycles of bevacizumab \[10 mg/kg, days 1 and 15\] plus carboplatin \[AUC 5, day 1\] plus pegylated liposomal doxorubicin \[30 mg/m2, day 1\] every 4 weeks, followed by maintenance bevacizumab \[15 mg/kg every 3 weeks\]
40817904|NCT05449067|PROCEDURE|Group A and Group B|Group A: Participants receive APD for 12 weeks then switch to CAPD for another 12 weeks; Group B: Participants receive CAPD for 12 weeks and switch to APD for another 12 weeks.
40817905|NCT02719964|OTHER|Visual Attention Program (UCR Games)|This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
40817906|NCT02719964|OTHER|Speech Pathologist-Directed Therapy|This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
40817907|NCT02719964|OTHER|General Cognitive Rehabilitation Games (Lumosity)|Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
40817908|NCT04666129|DRUG|Relugolix|"(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.~(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day."
40817909|NCT04666129|DRUG|Abiraterone|Abiraterone acetate (1000 mg \[2 x 500-mg tablets\]) or fine-particle abiraterone acetate (500 mg \[4 x 125-mg tablets\]) will be administered orally once daily.
40817910|NCT04666129|DRUG|Prednisone|"(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.~(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required."
40817911|NCT04666129|DRUG|Methylprednisolone|For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
40817912|NCT04666129|DRUG|Apalutamide|Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
40817913|NCT04666129|DRUG|Docetaxel|Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
40817914|NCT05887544|OTHER|Exposure: Plant-based diet pattern|From dietary records average intake across food groups will be calculated and a plant-based diet index score will be generated to group participants.
41156310|NCT05313178|DIETARY_SUPPLEMENT|Bacillus Coagulans GBI-30, 6086|In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.
41156311|NCT00516178|DRUG|Fish oil emulsion|0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
41156312|NCT00516178|DRUG|Saline|3 infusions, perioperative or post-PTCA
40817915|NCT05887544|OTHER|Intervention: Fermented dairy products|1000g of the product to be consumed 1-2 days prior to spot urine sample.
41156313|NCT04054596|BEHAVIORAL|SME|The treatment group (TX) will complete 8 sessions of SME (2 sessions per week for 4 weeks), de-signed to teach the concepts of SG, SL and RP and the application of these techniques in daily life. Sessions are approximately 30-45 minutes long.
40817916|NCT05887544|OTHER|Exposure: individual foods and food groups|From the dietary records, average intake of specific foods or food groups will be calcualted.
40817917|NCT02110329|GENETIC|evaluation of the recurrence rate according to molecular analysis|
40817918|NCT06496295|DEVICE|Vaginal Speculum Exam|Evaluating the visibility of the cervix, ease-of-use, and comfort of a new vaginal speculum.
40817919|NCT00597311|RADIATION|radiotherapy|"1. Short term radiotherapy 5x5 Gy during 5 days~2. Chemoradiotherapy 50 Gy + 5Fu/Lv"
41015471|NCT02453594|BIOLOGICAL|pembrolizumab|IV infusion
41485204|NCT06139393|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28.
41485205|NCT03500653|DIETARY_SUPPLEMENT|Curcumin|4 gr curcumin
41485206|NCT03500653|DIETARY_SUPPLEMENT|Placebo|4 gr placebo
41485207|NCT00168311|DEVICE|Transcranial Magnetic Stimulation|Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.
41485208|NCT00168311|DEVICE|sham TMS|
41485209|NCT04262661|DRUG|NNC0472-0147|Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.
41485210|NCT04262661|DRUG|insulin glargine|Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts.
41485211|NCT04262661|DRUG|Placebo (NNC0472-0147)|Part 1: A single dose of placebo, dose increased in each cohort.
41015487|NCT03986944|DRUG|75 mg linzagolix tablet|For oral administration once daily
41015488|NCT03986944|DRUG|200 mg linzagolix tablet|For oral administration once daily
41015489|NCT03986944|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
41015490|NCT03986944|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
41156314|NCT05028647|DEVICE|Virtual reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a VR device (Oculos)
41015491|NCT03986944|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
41015492|NCT03986944|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
41015494|NCT04564755|DRUG|abrocitinib|Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
41015495|NCT02844816|DRUG|Atezolizumab|Given IV
41156315|NCT05028647|DEVICE|Augmented reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a AR device (tablet)
41156316|NCT04161547|DRUG|CSPCHA115 100 mg; Matching placebo 100 mg|CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
41015506|NCT06078735|DEVICE|Vascular closure with LockeT device|For subjects that are assigned to the LockeT device arm, the healthcare professional will place the LockeT with suture above the wound to achieve compression instead of manually holding pressure on the sutures. After hemostasis is achieved and prior to ambulation the LockeT will be removed followed by suture removal.
41015507|NCT05917873|DIETARY_SUPPLEMENT|LaKe Ester|Lactate and ketone body ester (one equivalent of S-lactate and one equivalent of 1,3-butanediol / D-β-hydroxybutyrate)
41015508|NCT05917873|DIETARY_SUPPLEMENT|Placebo|Taste and appearance matched noncaloric placebo
41336407|NCT05154578|BIOLOGICAL|GBS-NN/NN2 Vaccine|0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.
41336408|NCT05154578|BIOLOGICAL|Placebo|0.5 mL normal saline given by intramuscular injection
41336409|NCT04498468|DRUG|Sustained Release Dexamethasone, 0.4 mg|dexamethasone 0.4mg lacrimal insert
41336410|NCT04498468|OTHER|E-Caprolactone-L-Lactide copolymer (PCL) punctal plug|Control eye will receive a tear duct plug without the dexamethasone (EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL). Absorbs in 60 to 180 days. Size 0.5mm which is comparable to the study treatment)
41336411|NCT03625492|BEHAVIORAL|Reducing Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
41336412|NCT03625492|BEHAVIORAL|Adopting the USDA Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
41336413|NCT02409147|PROCEDURE|Uterine Transplant|Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
41336414|NCT03955055|DEVICE|Video Capsule Endoscopy|Patients will swallow a video capsule as soon as possible (immediately or within 10 hours, if patient is not fasting).
41018003|NCT04358484|BEHAVIORAL|Incredible Years - ASD and Language Delay®|"The IY - ASLD Program will consist of 22 weekly online group sessions for parents of children between 2-5 years of age with symptoms or a diagnosis of ASD or delayed language acquisition. The program will be conducted by a therapist and a co-therapist, trained in the model.~Fidelity to the intervention will be assessed in accordance with the regulations of the program. All of the therapists and co-therapists will be trained in the intervention by accredited trainers. The three main therapists will be supervised by accredited supervisors of the IY Program, seeking accreditation in the intervention. As the intervention IY - ASLD has not been translated into Spanish, the English materials will be used with simultaneous translation into Spanish language."
41156317|NCT04161547|DRUG|CSPCHA115 200 mg; Matching placebo 200 mg|CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
41336415|NCT02768389|DRUG|Bevacizumab|Subjects receive Bevacizumab as standard of care
41018004|NCT03102476|DRUG|Humalog|Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
41336416|NCT02768389|BEHAVIORAL|Modified Atkins Diet|The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (\< 20gm/day).
41015513|NCT06028061|PROCEDURE|Adjuvant-free Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
41018005|NCT00813761|DEVICE|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
41018006|NCT00813761|DEVICE|Proclear contact lens|control contact lens to be worn for entire length of study.
41018007|NCT00813761|DEVICE|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
41018008|NCT00813761|DEVICE|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
41336417|NCT03432572|DRUG|Pyridium|a urine discoloration agent
41336418|NCT03432572|DRUG|Riboflavin|a urine discoloration agent
41336419|NCT03432572|DRUG|Thiamine|active placebo not known to cause urine discoloration
41336420|NCT05830526|OTHER|Escape Room|"The next day, 56 students, who agreed to participate in the study, were divided into groups of 5, and they had to fill out a 10-question test, which includes the stages of the ERAS Protocol preoperative period, within the scope of the pre-test. A simulation room for students has been set up as an escape room. At the briefing on the theme of the escape room, it was explained that they would have 10 minutes to complete six missions using the clues given to them.~The 6 stations created in the room were numerically numbered from 1 to 6. There were question/answer cards at each station and a clue on the back of the correct answer card to reach the next station. The first clue was given by the observer who made the information in the information room.The student who could not get out of the room within 10 minutes was considered as unable to leave the escape room."
40817920|NCT06303089|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, tobacco-related knowledge, perceptions of tobacco harm. Smokers will be asked the history of smoking cessation sheet, the Fagerstrom Test of Nicotine Dependence, Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, Intention to Quit Smoking sheet, Motivation to Quit Smoking sheet, Alcohol Use Disorders Identification Test, and International Physical Activity Questionnaire.
41018009|NCT02369497|DEVICE|HRA|Humeral head resurfacing with the HRA device
41018010|NCT03760549|DRUG|Subjects were administered NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
40817921|NCT00274898|DRUG|celecoxib|
40817922|NCT00274898|DRUG|docetaxel|
40817923|NCT00274898|PROCEDURE|adjuvant therapy|
40817924|NCT00274898|RADIATION|radiation therapy|
40817925|NCT06106724|PROCEDURE|sphincterotomy|cutting the papilla and cannulation with sweeping of common bile duct by ballon and stent insertion
41018011|NCT00796861|DRUG|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
41018012|NCT06196723|PROCEDURE|transjugular intrahepatic portal shunt|TIPS was performed by experienced clinicians in the Gastroenterology/Hepatology Department according to standard operating procedures, utilizing 8 mm or 10 mm expanded polytetrafluoroethylene-covered stents at the discretion of the local physician.
41018013|NCT04420806|OTHER|HIT-exercise|13 months of high intensity endurance and resistance exercise, 3x 45 min/week - 3 months of COVID-19 induced exercise break
41018014|NCT04420806|OTHER|Sham intervention|Types of exercise (flexibility, relaxation) that did not affect the present outcomes
41485212|NCT05709041|OTHER|Individualized lung-protective ventilation|"Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal manometry.~The ventilator will be set to volume-controlled ventilation with a tidal volume of 6 mL/kg of ideal body weight, inspired oxygen fraction of 30%, inspiratory pause of 30%, inspiration-to-expiration ratio of 1:2, PEEP of 5 cm H2O, and flow of 3 L/min). The respiratory rate will be set to 12 breaths/min in the beginning then adjusted (within 10-20 breaths/ min) to maintain EtCO2 between 35 to 45 mm Hg.~The set PEEP will be then increased by 2 cm H2O every 2 minutes (up to a max of 30 cm H2O) to identify and maintain the lowest driving pressure, maximum compliance, and positive TPP. These steps will be performed every 30 minutes after intubation, and after instillation of the pneumoperitoneum, and after steep Trendelenburg positioning. These individualized PEEP settings will be maintained until the pneumoperitoneum is released."
41485213|NCT05709041|OTHER|Standard lung-protective ventilation|Ventilator settings will be adjusted to standard lung-protective settings according to the anesthesiologist's clinical judgement for the patient, their comorbodities, and the surgical procedure.
41485214|NCT01534923|BEHAVIORAL|surveys|The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
41485215|NCT02677649|OTHER|cranberry|the effect of cranberry on the gut microbiota
41485216|NCT02677649|OTHER|placebo|the effect of placebo on the gut microbiota
41485217|NCT02788149|DEVICE|Ultrasound Exam|Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver
41485218|NCT02788149|DEVICE|Polysomnography|"Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as \>50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.~Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:~Non-OSA : \< 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr."
41485219|NCT06156345|DEVICE|Conservative with Denneroll|Denneroll cervical traction orthodontic traction for 3 to 15 minutes once daily with conservative management of stretching and relaxation.
41485220|NCT06156345|OTHER|Conservative|conservative management of stretching and relaxation with placebo traction.
41485221|NCT00741936|DRUG|MaZiRenWan (MZRW)|MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
41336421|NCT00979719|BEHAVIORAL|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
41485222|NCT00741936|DRUG|Placebo|Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
41485223|NCT05378919|RADIATION|Radiotherapy 50 Gy|Radiotherapy 50 Gy 5 radiations per week of 2 Gy for 5 weeks
41485224|NCT05378919|DRUG|Fluorouracil/folic acid|Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
41485225|NCT05378919|DRUG|Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)|oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
40817926|NCT06106724|PROCEDURE|precutting of the papilla by knife needle|precutting of the papilla by knife needle
40817927|NCT00583414|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
40817928|NCT00144469|DRUG|peginterferon alfa-2a|
41018015|NCT02385955|PROCEDURE|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
41336422|NCT00979719|BEHAVIORAL|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. \& Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
41336423|NCT00131170|PROCEDURE|paravertebral block|
40817929|NCT00144469|DRUG|rivavirin|
41336424|NCT01733836|DRUG|Metformin|
41336425|NCT01733836|DRUG|placebo|
41336426|NCT04026945|DRUG|Lidocaine|Sustained-release lidocaine injection
40817930|NCT01240525|OTHER|CD4 DLI|Patients will receive CD4 DLI between day 70 to 115 post transplant
40817931|NCT01240525|OTHER|No DLI|Patients will not receive DLI as trial treatment
41485226|NCT05378919|RADIATION|Radiotherapy 50 Gy|"Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy.~FOLOFX4 will be administrated for 8 cycles over a 16 week period. Patients will undergo re-staging within 6 weeks of their 8th cycle of FOLFOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 8 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous fluorouracil."
41485227|NCT01408628|BEHAVIORAL|Internet Insulin Education|"Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of \< 7.0% using an established treat-to-target algorithm."
41485228|NCT05577819|DIAGNOSTIC_TEST|99mTc-pyrophosphate Scintigraphy|Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer
41485229|NCT03693573|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
41485230|NCT03693573|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
41485231|NCT03214341|RADIATION|MRI diffusion|using MRI diffusion to differentiate between benign and malignant mediastinal masses
41336427|NCT04134299|DIETARY_SUPPLEMENT|AXA4010|The study will initiate with approximately eight (8) adult subjects (≥18 y/o) with SCD (Cohort 1). Each subject will receive AXA4010 twice a day (BID) for 12 weeks. Safety and tolerability will be monitored, and study procedures will be performed. Analysis of safety, tolerability and laboratory assessments at week 12 would be performed. Based on the 12-week observations from at least three subjects in Cohort 1, subsequent Cohorts 2 and 3 in Part II may be initiated.
41336428|NCT03857607|GENETIC|Whole exome sequencing|Whole exome sequencing will be used to identify causative genes in ATP1A3 mutation negative patients, to confirm causality in ambiguous phenotypes and to identify modifier genes.
41336429|NCT01041404|DRUG|Trastuzumab|Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
41336430|NCT01041404|DRUG|Fluorouracil|800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
41336431|NCT01041404|DRUG|Cisplatin|80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
41336432|NCT01041404|DRUG|Capecitabine|1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
41336433|NCT00531908|DRUG|furosemide|furosemide
41336434|NCT01489267|OTHER|stem cell transplantation|The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).
41485232|NCT04355663|BEHAVIORAL|Motor program activating therapy|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
41485233|NCT04355663|BEHAVIORAL|Vojta's reflex locomotion|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
41018016|NCT02630771|PROCEDURE|Pressure pain threshold|Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
41018017|NCT03574025|OTHER|Questionnaire|To telephone the patient/family to look into how the patient is doing, moderate/severe brain damage.
41018018|NCT02282449|DEVICE|Power Injectable Port (AngioDynamics Smart Port CT Mini)|The subjects will all receive power injectable port.
40817932|NCT01643161|BEHAVIORAL|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
40817933|NCT01643161|BEHAVIORAL|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
40817934|NCT05730543|DRUG|Volbella or Juvederm Ultra XC filler|Hyaluronic acid filler
40817935|NCT04108845|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
40817936|NCT01997957|DRUG|S-1|Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
40817937|NCT03115853|DRUG|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
40817938|NCT03115853|DRUG|Placebo|Placebo tablet for Aliskerin
40817939|NCT03115853|DRUG|HCTZ|HCTZ 25mg every day for 18 weeks
40817940|NCT03115853|DRUG|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
40817941|NCT05478434|DEVICE|Cortico-cortical stimulation plus robot-assisted therapy|15 sessions of cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Paired-pulse stimulation (PAS) technique, with 5ms inter-stimulus time between the two areas (PPC to M1), will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To stimulate the M1 area, the coil will be placed tangentially to the scalp at a 45° angle to the midline, to stimulate the PPC area the center of the coil will be positioned over P4 (10-20 EEG system) tangentially to the skull with the handle pointing downward and slightly medial (10°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
40817942|NCT05478434|DEVICE|Sham cortico-cortical stimulation plus robot-assisted therapy|15 sessions of sham cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Sham paired-pulse stimulation (PAS) will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To simulate the real stimulation, the coils will placed in the same sites with different inclination respect to the scalp (90°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
40817943|NCT00003914|DRUG|dolastatin 10|
40817944|NCT03336801|PROCEDURE|Back Surgery|All patients undergo basic back surgery.
40817945|NCT03336801|DRUG|Propofol|Anesthesia on propofol alone.
40817946|NCT03336801|DRUG|Sevoflurane|Anesthesia on sevoflurane alone.
40817949|NCT04417218|DIETARY_SUPPLEMENT|Lysine|Lysine is an essential amino acid which is acquired from dietary sources.
40817950|NCT04417218|DIETARY_SUPPLEMENT|Controlled Diet|Individuals will be instructed to consume specific foods, to adhere to a controlled lysine diet.
41336435|NCT05166551|PROCEDURE|Acupressure|"This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the Gall Bladder (GB) 31 Fengshi acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine."
41485234|NCT04355663|BEHAVIORAL|Functional electric stimulation|Pacients uderwent two months' therapy. They used the whole time Functional electric stimulation during activities of daily living and underwent 2 individual sessions of Motor program activating therapy.
41485235|NCT04030182|DIAGNOSTIC_TEST|Level of Vitamin D|3 ml of venous blood will be taken to determine the level of vitamin D
40817951|NCT04659499|DRUG|Nab-paclitaxel in combination with pyrotinib|Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year
41336436|NCT05166551|PROCEDURE|Placebo Acupressure|Placebo Acupressure
41336437|NCT05263349|OTHER|Typical Dreams Questionnaire|"Each of the dreams was classified according to its thematic content (e.g., being involved in a chase, flying through the air, falling, being lost, losing one's teeth, drowning) in order to in a chase, flying through the air, falling, being lost, losing teeth, drowning) in order to determine the most determine the most frequent themes emerging from our sample. The instrument used used to carry out this classification is the Typical Dream Questionnaire of Zadra and Nielsen (1999), which has been validated with more than 600 patients suffering from sleep disorders and and 1200 adults (Nielsen et al., 1999; 2003)."
41336438|NCT05263349|OTHER|HAD Questionnaire|"The HAD scale is an instrument that screens for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D).~two scores (maximum score for each score = 21)."
41336439|NCT05263349|OTHER|Dream Booklet|The patient is asked to write down in a notebook every morning the description of the dreams made during the night and to comment on it if necessary
41336440|NCT00291187|DRUG|20 mg VEC-162|20 mg VEC-162
41336441|NCT00291187|DRUG|50 mg VEC-162|50 mg VEC-162
41336442|NCT00291187|DRUG|100 mg VEC-162|100 mg VEC-162
41336443|NCT00291187|DRUG|Placebo|Placebo
41336444|NCT01668134|RADIATION|Stereotactic radiation|
41336445|NCT03284021|DEVICE|Fractional erbium-glass 1550 nm laser|The fractional erbium-glass 1550 nm laser will be applied to the previously 100 cm2 determined area of the scalp with the following parameters: 5-10 mm tip, 5-10 mJ, pulse energy 500-1500 MTZ/cm2 density, one to twopasses, static mode.
41485236|NCT03396666|OTHER|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
41485237|NCT05726175|DRUG|Disitamab Vedotin|Disitamab Vedotin(RC48)：2.0mg/kg, iv, day1, q3weeks, 6 cycles in total;
40817952|NCT05051631|OTHER|Intervention plus 12 months maintenance|The intervention will include 2 months of data collection in the control period, 4 months of education and awareness training, and 12 months of data collection in the maintenance time period.
40817953|NCT05051631|OTHER|Intervention plus 10 months maintenance|The intervention will include 4 months of data collection in the control period, 4 months of education and awareness training, and 10 months of data collection in the maintenance time period.
40817954|NCT05051631|OTHER|Intervention plus 8 months maintenance|The intervention will include 6 months of data collection in the control period, 4 months of education and awareness training, and 8 months of data collection in the maintenance time period.
40817955|NCT05051631|OTHER|Intervention plus 6 months maintenance|The intervention will include 8 months of data collection in the control period, 4 months of education and awareness training, and 6 months of data collection in the maintenance time period.
41336446|NCT04936204|DEVICE|ConnettivinaBio Plus cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
41336447|NCT04936204|DEVICE|ConnettivinaBio cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
41336448|NCT03387891|DEVICE|Cortrium C3 device|Paired measurements of data from C3 device with golden standard methods or equipment
41336449|NCT03352128|DIETARY_SUPPLEMENT|Creatine|Participants will have to supplement themselves with creatine for 7 days (20g/day).
41336450|NCT03352128|DIETARY_SUPPLEMENT|Calcium lactate|Participants will have to supplement themselves with calcium lactate for 7 days (elemental calcium: 0.780g/day).
41336451|NCT01372644|DRUG|SOM 230 / Pasireotide|
41336452|NCT05177289|DEVICE|Theradome® LH80 pro|The Theradome LH80 pro is a wearable laser helmet device, which uses red laser light to stop hair loss, thicken existing hair and stimulate the growth of new hair.
41336453|NCT05177289|DEVICE|Scalp cooling|Scalp cooling is a standard treatment that is applied to prevent hair loss during chemotherapy.
41336454|NCT02976545|DEVICE|fMRI (functional Magnetic Resonance Imaging)|fMRI examination
41336455|NCT02976545|BEHAVIORAL|psychiatric evaluation|psychiatric evaluation
40817956|NCT05051631|OTHER|Intervention plus 4 months maintenance|The intervention will include 10 months of data collection in the control period, 4 months of education and awareness training, and 4 months of data collection in the maintenance time period.
40817957|NCT06604845|BEHAVIORAL|Group cognitive behavioural therapy (CBT)|"CBT based on Safren's manual CBT for ADHD/Mastering Your Adult ADHD20 adapted for group format. The program includes psychoeducation and cognitive restructuring and aims to improve ADHD symptoms, especially planning, organisation, attention and adaptive thinking. The CBT groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two clinicians."
41336456|NCT02883426|BIOLOGICAL|H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)|Approximately 10\^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
41336457|NCT02883426|BIOLOGICAL|H3N2v inactivated subvirion influenza vaccine|15 μg; administered intramuscularly
41336458|NCT02883426|BIOLOGICAL|Placebo|Administered by nasal spray
41336459|NCT03274245|BEHAVIORAL|Intervention Package|"* Community Level:~  * Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~ * Transect Walk: village walk to identify and mark feces in community;~ * Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~ * Wall painting: village map noting households that use latrines always.~* Sub-Community level:~  * Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~* Household Level:~  * Household visits: to those with latrines to motivate use;~ * Latrine repairs: for households with non-functional latrines to make functional."
41336460|NCT03274245|OTHER|Qualitative Research|"For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies."
41018019|NCT02282449|DEVICE|Non-Power Injectable Port (Cook Vital Mini Port)|The subjects will all receive non-power injectable port.
41336461|NCT04240912|DEVICE|CompuFlo Epidural Computer Controlled System|"The CompuFlo Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the physician to perform epidural anesthesia and epidural injections using standard methods. However, for the purpose of this study the instrument will be used only as a monitor to detect the occurrence of EPW.~The CompuFlo Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
40817958|NCT06604845|OTHER|Activity group|The Activity group is a structured manualised group intervention designed for this and planned future studies of psychosocial treatments for adults with ADHD and/or autism. The program includes group discussions, peer-sharing and social every-day life activities. The Activity groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two trainers.
41336462|NCT05825313|BEHAVIORAL|Podcast Using|Students in the experimental group listened to podcast episodes any time they desired following the course every week during the semester from February 2021 to June 2021.
41336463|NCT03609489|DRUG|Capecitabine|Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
41485238|NCT05726175|DRUG|Penpulimab|Penpulimab(AK105)：200mg, iv, day1, q3weeks, 6 cycles in total;
41485239|NCT02033330|DIETARY_SUPPLEMENT|phenolics form orange peel|
40817959|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
41485240|NCT00631852|DRUG|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
41485241|NCT05410158|DRUG|Ketamine in PECS block versus topical wound instillation|On arrival to the operating room, an intravenous line will be inserted in the contralateral upper limb to the side of surgery. Anesthesia will be induced for all participating patients with 2 μg/kg fentanyl, 2 - 3 mg/kg propofol and 1.5 mg/kg lidocaine. Endotracheal intubation will be facilitated by 0.15 mg/kg cis-atracurium.The patients will be randomly assigned into 2 groups ( pecs block group , topical instillation group) using a randomization-computer program . Anesthesia will be maintained by 1 - 1.5 MAC isoflurane in 50% oxygen/ air mixture and 0.03 mg/kg cisatrcurium, respectively, in ventilation parameters that maintain normocapnia. At the end of surgery, a reversal of the muscle relaxant will be done using neostigmine (0.04 mg/kg) and atropine (0.01 mg/kg). After extubation, all patients will be transmitted to the post anesthesia care unit (PACU) for follow up .
41485242|NCT03433716|OTHER|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
41485243|NCT02581163|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
41485244|NCT02581163|DRUG|Dasabuvir|Tablet
41485245|NCT02581163|DRUG|Ribavirin|Tablet
41485246|NCT00003144|DRUG|amifostine trihydrate|
41485247|NCT00003144|DRUG|cisplatin|
40817960|NCT02342717|DRUG|Itraconazole|multiple doses of Itraconazole capsules
40817961|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
41485248|NCT00003144|DRUG|gemcitabine hydrochloride|
41485249|NCT04570540|DIAGNOSTIC_TEST|Sleep Study|Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry
41485250|NCT04570540|DIAGNOSTIC_TEST|Pulmonary Function Test|Bodyplethysmographic assessment
41485251|NCT04570540|DIAGNOSTIC_TEST|Hypercapnic ventilatory response|Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag
40817962|NCT03833986|OTHER|Stress management program|Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
40817963|NCT06031428|BEHAVIORAL|MANAGe-DM - novel nurse case management|Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
40817964|NCT06031428|BEHAVIORAL|Monthly Educational Mailing|All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
40817965|NCT03922334|BEHAVIORAL|Patient Navigation Program|A postpartum patient navigation program is designed to reduce barriers to care, enhance access, and improve multiple postpartum health outcomes, including retention in care, contraception uptake, vaccination, and depression screening.
40817966|NCT05465798|DRUG|MC 3x3|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
40817967|NCT05465798|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
41485252|NCT04570540|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations
41485253|NCT01530763|DRUG|Ceftaroline fosamil|"Treatment Group 1:~Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Children \< 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)"
41485254|NCT01530763|DRUG|Ceftriaxone|"Treatment group 2:~75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)"
41018020|NCT03569956|OTHER|556 Razor|In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
41336464|NCT03609489|DRUG|Apatinib|Apatinib, 500 mg, administered orally (after breakfast) once daily from day 1 to day 21 (including day 21) with continuous administration. Every 21 days serve as a cycle. If after 2 dose adjustments, the subject is still unable to tolerate toxicity, he/she should be moved out of the group.
41336465|NCT02822157|DRUG|Olaparib|
41336466|NCT02822157|DRUG|carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly|physician's choice chemotherapy
41336467|NCT04884529|BEHAVIORAL|Chair-yoga program|8-week chair yoga program with gentle postures, breathing techniques, and mindfulness.
40817968|NCT06102122|DIETARY_SUPPLEMENT|Compleat|Patients well established and stable on a standard enteral tube feed with food derived ingredients will act as their own controls and make a product switch
41336468|NCT00634465|DEVICE|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
41485255|NCT01530763|DRUG|amoxicillin clavulanate|"Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)"
41018021|NCT04986059|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
41485256|NCT00804713|DRUG|BST|0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
41336469|NCT00650312|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
41336470|NCT00650312|DRUG|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
41336471|NCT05098704|DRUG|clopidogrel treatment|75 mg daily during 24 months
41485257|NCT00804713|DRUG|TST|Administer TB Skin test (TST)
41485258|NCT00804713|OTHER|QFT|Perform QFT TB test
41485259|NCT00804713|OTHER|T-spot|Perform T-Spot TB test
41485260|NCT01799122|DEVICE|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
41485261|NCT05342415|OTHER|Internally Focused Exercise|While performing the exercises participants will be instructed to focus on the muscle itself.
41485262|NCT05342415|OTHER|Externally Focused Exercise|While performing the exercises participants will be instructed to focus on the external target (towel, target line, etc.)
41485263|NCT02709252|DEVICE|PVI and deltaPP after trendelenburg position change|Comparison of hemodynamic parameters during surgery after position change
41485264|NCT01469702|DRUG|prednison and azithromycin|Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
41336472|NCT05098704|DRUG|Placebo|75 mg daily during 24 months
41336473|NCT05462457|PROCEDURE|Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)|Intraoperative excision of TAD lymph nodes followed by ALND in the same surgical session or secondary surgical intervention
41485265|NCT01469702|DRUG|prednison, azithromycin|Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
41485266|NCT01469702|DRUG|prednison, Azenil|Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
41485267|NCT01744093|DRUG|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
41485268|NCT01744093|DRUG|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
41485269|NCT05226559|PROCEDURE|Multimodal Physical therapy approach plus usual care|HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
41018022|NCT03060824|OTHER|Blood sampling|To explore changes in osmolality during coronary artery bypass grafting surgery with the aid of Cardiopulmonary Bypass by repeated measurements of osmolality and concentration shifts of sodium, glucose and urea in plasma.
41485270|NCT05226559|DRUG|Usual care|Standard pharmacological treatment alone.
41485271|NCT00577902|OTHER|Observation|Head and neck cancer patients receiving chemoradiation
41485272|NCT04024293|DEVICE|Goldfish (GF)|The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
41485273|NCT01938404|BIOLOGICAL|Octaplas|Octoplas infusion solution for IV administration
41485274|NCT01938404|DRUG|Standard Plasma|Plasma given as replacement fluid
41018023|NCT04019535|DEVICE|physiological assessment with Volcano Verrata pressure wire (iFR)|physiological assessment of the coronary lesion will be made with both iFR and dFR. all clinical decisions will be made based on the results of iFR
41018024|NCT06426797|DRUG|Cadonilimab plus anlotinib|cadonilimab (10mg/Kg, ivgtt, d1) and anlotinib (12mg, P.O., d1-d14) on a 21-day regimen for 3 cycles
41018025|NCT03167294|DEVICE|AquaBeam System|Aquablation
41485275|NCT00377507|DIETARY_SUPPLEMENT|catechin extracts|catechin extracts solution
41485276|NCT01622374|BEHAVIORAL|Music|Ten minutes of music or silence were applied prior to dental procedures
41485277|NCT04465630|DEVICE|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
41485278|NCT01356784|OTHER|Tailored Physical Activity|Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)
41015514|NCT06028061|PROCEDURE|Quadratus lumborum block III with Adjuvant|The same block was applied to this group too, but a different local anesthetic mixture was used.Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
41485279|NCT01356784|BEHAVIORAL|"Chronic Pain Self-management Programme"|Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)
41015515|NCT04983901|DRUG|Imipenem/Cilastatin/Relebactam|Given IV
41015516|NCT04983901|DRUG|Cefepime|Given IV
41336474|NCT03391076|DIAGNOSTIC_TEST|FilmArray Respiratory Panel|An Multi-PCR method which can detect 20 pathogens in 45 minutes.
41336475|NCT02705222|PROCEDURE|D&C|Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination
41485280|NCT01356784|BEHAVIORAL|Health counselling|Health guidance (1,5h)
41485281|NCT06261060|DRUG|Sirolimus|Given by PO
41015517|NCT04983901|DRUG|Meropenem|Given IV
40817969|NCT01218750|PROCEDURE|Triple therapy for diffuse diabetic macular edema|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
41015518|NCT04983901|DRUG|Piperacillin-Tazobactam|Given IV
41015519|NCT04983901|DRUG|Vancomycin|Given IV
41336476|NCT02705222|PROCEDURE|Hysteroscopy|Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
41336477|NCT00543868|DRUG|MK0782|
41336478|NCT04735809|DIETARY_SUPPLEMENT|Whole Cell Algae Fermentate|Contains at minimum 50% Beta Glucan
41336479|NCT04735809|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
41485282|NCT06428630|DRUG|dexamethasone oral rinse|"The study drug is FDA approved (NDC- 0054-3177) and will be used as it would be used in a standard of care setting. The rinse will be administered on the same therapeutic dose to OLP/OLR (0.5 mg/5ml of dexamethasone oral rinse once (rinse for 2 minutes or 5 minutes), then spit the excess into a cup.~The oral rinse dexamethasone 0.5 mg/5ml will be used only on the subjects who participated in the study."
40817970|NCT04872348|DEVICE|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
40817971|NCT00580580|DRUG|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
40817972|NCT00580580|DRUG|Definity|intravenous injection at 0.05-0.20 mL
41336480|NCT00109005|DRUG|Revlimid|oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
40817973|NCT00580580|DRUG|PESDA|intravenous injections dosage 0.05-0.20 mL
41015520|NCT04983901|DRUG|Daptomycin|Given IV
41015521|NCT04983901|DRUG|Linezolid|Given IV or PO
41015522|NCT06434207|OTHER|Collecting discarded blood samples|Discarded blood samples will be collected from routine clinical labs collected before and after surgery.
41018026|NCT03643523|DIAGNOSTIC_TEST|Albumine detection|Control of serum albumine levels in postoperatori of colorectal surgery
41336481|NCT01397045|OTHER|VATS|Video-assisted lung segmentectomy
41336482|NCT01397045|PROCEDURE|Mini thoracotomy|Mini muscle sparing thoracotomy for lung segmentectomy
41336483|NCT06374589|DEVICE|Closed-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
41336484|NCT06374589|DEVICE|Conventional|Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.
41336485|NCT02023268|DEVICE|T2762|1 drop in each eye 3 to 6 times daily during 84 days
41485283|NCT02639052|DRUG|Botox|10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.
41485284|NCT02639052|DRUG|Saline|10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.
41485285|NCT05335993|BIOLOGICAL|Oregovomab|2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.
41485286|NCT05335993|DRUG|Niraparib|300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is \<77 kg or platelet count is \<150,000 μL, the daily dosing will be 200mg.
41485287|NCT01946776|DEVICE|implantable heart rate monitor|Implantation of Reveal XT
41485288|NCT00223353|OTHER|Prosthetics, Orthotics and Physical Therapy|Gait Analysis.
41485289|NCT01566357|OTHER|Toothpaste|
41336486|NCT02023268|DEVICE|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
41336487|NCT05628402|OTHER|Semi-structured interview|The semi-structured interview will take place during a standard follow-up appointment with the therapist already treating the patient after the patient has agreed to participate in the study.
41336488|NCT01582867|DEVICE|ARTIS hemodialysis system|"Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01"
41336489|NCT01477138|PROCEDURE|pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)|Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
41336490|NCT04518722|RADIATION|CT Scan|Dual-energy mid-tibia CT, high-resolution single energy MDCT imaging of the distal tibia (ankle), and low radiation hip CT scans
41336491|NCT04518722|RADIATION|DXA Scan|Basic DXA scans will be performed to measure areal BMD and body composition measures at the whole body, spine, and hip
41336492|NCT04518722|OTHER|Steroid Intake Questionnaire|Questionnaire designed to quantify lifetime oral glucocorticoid intake
41336493|NCT00000361|DRUG|Corticosteroids|
41336494|NCT00000361|DRUG|Methotrexate|
41336495|NCT02949557|PROCEDURE|Decortication + bone grafts|
41336496|NCT00464711|DRUG|Escitalopram|Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.
41336497|NCT00524043|DRUG|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
41336498|NCT00524043|DRUG|Placebo|Once daily for 6 weeks
41336499|NCT00524043|DRUG|Paliperidone ER|6 mg tablet once daily for 6 weeks
41336500|NCT00425945|DRUG|Pine Bark Extract (Flavangenol®)|"Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks."
40817974|NCT04138914|DEVICE|Focal Cryotherapy|Ablation of the cancer focus within the prostate using cryotherapy
41336501|NCT03189407|DIETARY_SUPPLEMENT|Moringa oleifera tea|
41336502|NCT00159718|DRUG|amlodipine|
41336503|NCT00159718|DRUG|atorvastatin|
41336504|NCT00916396|DRUG|Dehydroepiandrosterone|100 mg of DHEA a day (50 mg twice a day) for six weeks
41336505|NCT00916396|DRUG|placebo|100 mg of Placebo a day (50 mg twice a day) for six weeks
41336506|NCT03905824|BIOLOGICAL|Allogenic stromal mesenchymal cells derived from the umbilical cord|Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus
41336507|NCT03905824|PROCEDURE|Debridement and microfracture|Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
40817975|NCT01326156|DEVICE|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
41156318|NCT04161547|DRUG|CSPCHA115 400 mg; Matching placebo 400 mg|CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
41156319|NCT04161547|DRUG|CSPCHA115 600 mg; Matching placebo 600 mg|CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
41156320|NCT01887418|DRUG|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
41336508|NCT05911113|OTHER|sensory re-education training|the patients will receive sensory re-education training in the form of texture discrimination training, limb position sense and tactile object recognition
41336509|NCT05911113|OTHER|traditional treatment|the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
41336510|NCT05515445|DRUG|Chiglitazar|Oral single dose 48 mg
41336511|NCT05051176|DIAGNOSTIC_TEST|2D usg and 3D/4D usg|IRD distance measured by a linear probe 2D usg. Pelvic floor muscle morphometry measured by 3D/4D usg
41336512|NCT05564208|DRUG|elafibranor|Oral Tablet
41336513|NCT05564208|DRUG|elafibranor|Oral Tablet
41336514|NCT06117904|DRUG|MEBO ointment|This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks
41336515|NCT06117904|DRUG|Symptomatic treatment only|"This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets)."
41336516|NCT04104841|BEHAVIORAL|Behaviorally Enhancing Adolescents' Mood in Schools|8-session modified behavioral activation intervention
41336517|NCT04104841|BEHAVIORAL|Usual Care|Referral to school mental health provider, social worker, or community care.
41336518|NCT01454024|DEVICE|FlexPen®|Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
41336519|NCT01454024|DEVICE|NovoPen® 3|Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
41336520|NCT05854797|OTHER|Normal Walking|"Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
41336521|NCT05854797|OTHER|Brisk Walking|"Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
41336522|NCT04368897|DIAGNOSTIC_TEST|CAG length <22|CAG repeat length in exon 1 of AR gene
41336523|NCT04368897|DIAGNOSTIC_TEST|CAG length >=22|CAG repeat length in exon 1 of AR gene
41336524|NCT02583711|DEVICE|Activity sensor (3 axis accelerometer)|Patient cohort will wear the activity sensor from pre-admission clinic until discharge after surgical procedure
41336525|NCT00005905|DRUG|hu Leptin (A-100)|
41336526|NCT05341284|OTHER|Questionnaire Survey and Cervical Cancer Screening|"A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36.~For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36."
41336527|NCT05057325|OTHER|Pulpectomy using single file system ( One Shape file)|Rotary file instrument for pulpectomy of primary molars ( One shape file)
41485290|NCT01566357|DIETARY_SUPPLEMENT|Milk|
41336528|NCT05057325|OTHER|Pulpectomy using single file system ( WaveOne Gold file)|Rotary file instrument for pulpectomy of primary molars ( WaveOne Gold file)
41336529|NCT02629536|DRUG|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
41336530|NCT03489070|COMBINATION_PRODUCT|Traumastem®|Intraoperative application as secondary hemostatic treatment
41336531|NCT03489070|COMBINATION_PRODUCT|Surgicel®|Intraoperative application as secondary hemostatic treatment
41336532|NCT04908969|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy for Chronic Tic Dosorder/Tourette Disorder|The treatment will be provided through a secure internet platform designed for internet-administered treatments (BASS-4). In the treatment, the patient works through modules of self-help material, each ending in a short quiz with questions about the material. The treatment is supported by a therapist through text-based communication via the platform as well as occasional phone calls when needed. The central component in the treatment is exposure and response prevention (ERP). In ERP, the patient exposes her/himself to situations that trigger premonitory urges (a type of bodily sensation that precede the tic) while practicing to resist the tic. By doing this systematically and repeatedly, the patient gradually learns how to tolerate the premonitory urges and increase the ability to control and resist doing tics. Beyond ERP the treatment consists of other components such as applied relaxation, counter-movements and interventions to decrease stressors in the patient's everyday life.
41336533|NCT03732521|OTHER|Educational therapy|educational intervention to the caregiver and individualization according to their family and social context
41336534|NCT00995267|BEHAVIORAL|parent-child interaction/activities based on Adler's methods|"Description of the Intervention:~5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories \& pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.~Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations."
41485291|NCT01566357|DIETARY_SUPPLEMENT|Fluoridated Milk|
41485292|NCT01566357|DRUG|Tooth Mousse|
41485293|NCT01566357|DRUG|MI Paste Plus|
41015523|NCT05968989|BIOLOGICAL|VRC-FLUMOS0116-00-VP( FLUMos-v2)|"The vaccine, FLUMos-v2, is composed of engineered pentamer yeast C. albican lumazine synthase assembled with 20 HA ectodomain trimers from the following 6 influenza strains:~Influenza A:~H1: A/Idaho/07/2018; H2: A/Singapore/1/1957; H3: A/Perth/1008/2019; H3: A/Darwin/106/2020~Influenza B:~B/Victoria lineage: B/Colorado/06/2017; B/Yamagata lineage: B/Phuket/3073/2013"
41336535|NCT03295604|PROCEDURE|SCTG+EMD|Miller class I-II gingival recession defects were operated with SCTG+EMD
41336536|NCT03295604|PROCEDURE|SCTG|Miller class I-II gingival recession defects were operated with SCTG only and
41336537|NCT04268303|DRUG|Sublingual film containing dexmedetomidine (BXCL501)|Sublingual film containing dexmedetomidine (BXCL501)
41336538|NCT04268303|DRUG|Placebo Film|Placebo Film for BXCL501
41485294|NCT01566357|DRUG|Elmex Erosion Protection|
41485295|NCT00210236|PROCEDURE|Conventional surgery|
41485296|NCT02790307|DEVICE|The Geko|transcutaneous tibial nerve stimulation (stick on patch)
41485297|NCT01359644|DRUG|PSI-7977|Tablets, oral, 400 mg, once daily
41485298|NCT01359644|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily
41485299|NCT01359644|DRUG|Ribavirin|Tablets, oral, 200 mg
41485300|NCT02848911|DRUG|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
41485301|NCT00311311|DRUG|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
41485302|NCT00311311|DRUG|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
41015524|NCT06419582|DRUG|BHV-7000|BHV-7000 75 mg taken once daily for 21 days
41015525|NCT06419582|DRUG|Placebo|Matching placebo taken once daily for 21 days
40817976|NCT00801034|DRUG|Calcium|tablets, 1 tablet 2 times per day in 28 days
41015528|NCT04609319|DRUG|Dacomitinib|This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC
41015529|NCT02944877|BEHAVIORAL|social media intervention|social media intervention
41015530|NCT06477796|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 120 minutes of waking up.
41015531|NCT06477796|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 120 minutes of waking up.
41336539|NCT00606294|RADIATION|fluorine-18-labeled fluoro-misonidazole (18F-FMISO)|
41336540|NCT00606294|DEVICE|18F-FMISO PET scan|
41336541|NCT00606294|DEVICE|MRI|
41336542|NCT00606294|DEVICE|FDG PET/CT scan|
41336543|NCT04992377|DRUG|R-EPOCH in Combination With Ibrutinib|"Induction:~(21-day per cycle) Ibrutinib:420mg given orally , once daily.~Details of R-DA-EPOCH are as follows:~Rituximab: 375 mg/m2 given intravenously (IV) on day 0 Etoposide: 50 mg/m2 given CIV from day 1-4 Doxorubicin: 10 mg/m2 given CIV from day 1-4 Vincristine: 0.4 mg/m2 given CIV from day 1-4 Cyclophosphamide: 750 mg/m2/day IV on day 5 Prednisone: 60 mg/m2 given orally bid on days 1-5. Patients who achieve CR after 4 cycles enter the consolidation treatment ; Patients with PR after 4 cycles would receive another 2 cycles of R-EPOCH + ibrutinib induction therapy, they could enter the consolidation treatment if they achieve CR ,withdrawn from the study if they achieve ≤ PR; Patients with SD/PD after 4 cycles of treatment are withdrawn from the study.~Consolidation:~2 cycles of R-EPOCH + Ibrutinib (dose as before) treatment~Maintenance:~Ibrutinib 420 mg/day for 24 months or until disease progression or intolerable toxicity"
41336544|NCT05768893|DEVICE|Long-Pulsed Nd:YAG Laser 1064nm & Er:YAG Laser 2940nm|Warts with this intervention treated firstly with the Er:YAG laser, followed by the Nd:YAG laser in the same session.
41336545|NCT05768893|DEVICE|Er:YAG Laser 2940nm|Warts with this intervention treated only with the Er:YAG laser.
41336546|NCT02435862|DRUG|1.0mg Luminate®|
41336547|NCT02435862|DRUG|2.0mg Luminate®|
41336548|NCT02435862|DRUG|3.0mg Luminate®|
41336549|NCT02435862|OTHER|Balanced Salt Solution for intravitreal injection in 0.10cc|
41336550|NCT04965285|BEHAVIORAL|quality assesment|"For each time-out procedure observed, the investigators will record compliance for each element of the time-out. Elements that are clearly verbalized by the member of the operating room team performing the time-out were considered compliant.~As each step of the time-out is verbalized by a team member, the operating room team members are expected to respond. The observations will be conducted by trained study staff using a standardized Checklist/ Proforma to assess surgical team compliance with the time-out protocol and to record general observations of the operating room environment. Any non-routine events that occurred during the time-out process will be recorded.~In each phase, the Checklist coordinator must be permitted to confirm that the team has completed its tasks before it proceeds onward."
41015534|NCT06147505|BIOLOGICAL|XS005 Injection|Treatment on this study includes XS005 infusions over an 16 week period. Phase 1： dose escalation (3+3); Phase 2 : dose of recommended phase 2 dose(RP2D).
41336551|NCT02048358|DRUG|2B3-201|
41336552|NCT02048358|DRUG|Placebo|
41336553|NCT02048358|DRUG|Methylprednisolone hemisuccinate|
41485303|NCT00311311|DRUG|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
40817977|NCT00801034|DRUG|Potassium|Tablets, 5 tablets 2 times per day for 28 days
40817978|NCT03136497|DRUG|400mg ABT-199|Oral dose daily until disease progression
40817979|NCT03136497|DRUG|Ibrutinib|Oral dose daily until disease progression
41015535|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
41015536|NCT05645627|DRUG|placebo /IBI112|placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
41015537|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
41156321|NCT01887418|DRUG|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
41156322|NCT01887418|DRUG|Delatestryl 200 mg IM Treatment C|Standard of care
41336554|NCT01526317|DRUG|Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)|For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
40817980|NCT03136497|DRUG|Rituximab|Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1
40817981|NCT03136497|DRUG|800mg ABT-199|Oral dose daily until disease progression
40817982|NCT03114579|DEVICE|Intraoperative heart rate measurement (reference method)|Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)
41156323|NCT00942513|OTHER|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
41156324|NCT00942513|OTHER|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
41156325|NCT00942513|OTHER|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
41156326|NCT00942513|OTHER|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
41156327|NCT00942513|OTHER|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
41156328|NCT00942513|OTHER|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
41156329|NCT00942513|OTHER|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
41156330|NCT03229096|DRUG|Apatinib plus XELOX|"three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks."
41156331|NCT05134948|DRUG|BMS-986213|Specified dose on specified days
41156332|NCT04614285|PROCEDURE|Partial excavation|"Operators sign up for participation at the homepage of Center for Pediatric Oral Health Research (ABC). The study will be carried out in a Practice-Based Research Network setting. All practitioners interested in participating in the study will get access to an online information about their participation after they signed up. The participation starts by answering a questionnaire on their treatment attitudes and experiences.~Patients will be identified during the routine dental examination. If a carious lesion in the primary molars is detected and in a need of a restoration, the children and parents will be asked to participate in the study.~The parents receive information about the study and give their consent. Allocation into treatment groups will be performed by random assignment by the homepage of ABC.~After the study is finished the participating dentist will be asked to answer the same questionnaire to investigate the effect of the participation on the operators attitude."
41156333|NCT05144802|PROCEDURE|acute hypoxia|Participants will be exposed to a 3-hour acute hypoxia
41156334|NCT00347802|DRUG|Bimatoprost 0.03%, Travoprost 0.004%|
41156335|NCT02608697|DRUG|CAT-2054|
41156336|NCT02608697|DRUG|Placebo|
41156337|NCT02608697|DRUG|Atorvastatin|
41156338|NCT03298347|DRUG|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP
41156339|NCT03298347|DRUG|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP
41156340|NCT05358184|DEVICE|High frequency Percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz
41156341|NCT01107249|DEVICE|Boston Scientific Ultraflex or Wallstent stents|Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.
41336555|NCT03736668|DIAGNOSTIC_TEST|echocardiography|One year after patient's inclusion, an echocardiography / doppler will be performed to evaluate any changes.Two years after the patient's inclusion, an investigating cardiologist will contact the physician, cardiologist and / or diabetologist treating the patient by telephone to find out if any cardiovascular events have occurred.
41485304|NCT00311311|DRUG|sirolimus|"The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.~On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant."
40817983|NCT03114579|DEVICE|NEXFIN HD|
41015539|NCT04877197|BEHAVIORAL|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
41156342|NCT04788472|DRUG|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
41156343|NCT01503515|DRUG|Caspofungin Acetate|Given IV
41156344|NCT01503515|DRUG|Fluconazole|Given IV or PO
41156345|NCT01503515|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41156346|NCT01503515|DRUG|Voriconazole|Given IV or PO
41156347|NCT04053517|OTHER|Medical Chart Review|Medical chart is reviewed
41156348|NCT04053517|OTHER|Quality-of-Life Assessment|Ancillary studies
41156349|NCT04053517|OTHER|Questionnaire Administration|Ancillary studies
41156350|NCT00470171|DRUG|Ursodesoxycholic acid|
41156351|NCT06487858|DRUG|BGB-R046|Intravenous administration
41156352|NCT06487858|DRUG|Tislelizumab|Intravenous administration
41156353|NCT06645587|DEVICE|Active HD-tDCS over pre-SMA|Active cathodal HD-tDCS over pre-SMA cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using small circular electrodes (diameter 1 cm) will be applied with the cathode placed centrally over Fz. The current intensity will be set at 0.5 mA for a total of 20 minutes (30 s ramp up/down).
41485305|NCT00311311|DRUG|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
41015540|NCT04877197|OTHER|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
41015541|NCT03919071|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41015542|NCT03919071|DRUG|Dabrafenib Mesylate|Given PO
41015543|NCT03919071|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
41015544|NCT03919071|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41485306|NCT00311311|DRUG|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
41156354|NCT06645587|DEVICE|Active HD-tDCS over left DLPFC|Active cathodal HD-tDCS over left DLPFC cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using small circular electrodes (diameter 1 cm) will be applied with the cathode placed centrally over F3. The current intensity will be set at 0.5 mA for a total of 20 minutes (30 s ramp up/down).
41156355|NCT06645587|DEVICE|Sham HD-tDCS|Sham HD-tDCS will be delivered over pre-SMA or left-dlPFC cortex for 10 days (3 sessions per week). The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness. Each Sham session will last 20 minutes.
41156356|NCT04348383|DRUG|Defibrotide|6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
41156357|NCT04348383|DRUG|Placebo|Placebo 250 cc every 6 hours for 7 or15 days
41156358|NCT06472011|OTHER|lean steak and potatoes|Participants will be fed \~400 kcal lean steak and potatoes on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
41156359|NCT06472011|OTHER|lentil and sweet potato chili|Participants will be fed \~400 kcal lentil and sweet potato chili on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
41156360|NCT06472011|OTHER|macaroni and cheese|Participants will be fed \~400 kcal macaroni and cheese on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
41156361|NCT06472011|OTHER|fish tacos|Participants will be fed \~400 kcal fish tacos on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
41156362|NCT06472011|OTHER|chicken and pea fried rice|Participants will be fed \~400 kcal chicken and pea fried rice on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
41156363|NCT06472011|OTHER|pita and hummus|Participants will be fed \~400 kcal pita and hummus on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
41156364|NCT06472011|OTHER|creamy pork pasta|Participants will be fed \~400 kcal creamy pork pasta on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
41156365|NCT05631379|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), muscle radiation attenuation (MRA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
41156366|NCT05631379|DIAGNOSTIC_TEST|GLIM malnutrition criteria|GLIM criteria (Global Leadership Initiative on Malnutrition) will be applied to assess malnutrition
41156367|NCT05631379|DIAGNOSTIC_TEST|EWGSOP2 sarcopenia criteria|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia
41156368|NCT05631379|DIAGNOSTIC_TEST|ESPEN-EASO criteria for sarcopenic obesity|The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) consensus criteria from 2018 will be applied to assess sarcopenic obesity
40817984|NCT02408861|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40817985|NCT02408861|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40817986|NCT02408861|PROCEDURE|Computed Tomography|Undergo CT scan
40817987|NCT02408861|BIOLOGICAL|Ipilimumab|Given IV
40817988|NCT02408861|BIOLOGICAL|Nivolumab|Given IV
40817989|NCT02408861|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40817990|NCT03011372|DRUG|Pemigatinib|"Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.~Participants will receive either the intermittent dose (as written) or continuous dosing."
41015545|NCT03919071|RADIATION|Radiation Therapy|Undergo RT
41015546|NCT03919071|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
41015549|NCT04665739|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
41015550|NCT04665739|PROCEDURE|Computed Tomography|Undergo CT
41015551|NCT04665739|DRUG|Everolimus|Given PO
41015552|NCT04665739|OTHER|Fludeoxyglucose F-18|Given FDG
41015553|NCT04665739|DRUG|Lutetium Lu 177 Dotatate|Given IV
41015554|NCT04665739|PROCEDURE|Positron Emission Tomography|Undergo PET
41015555|NCT04665739|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
40817991|NCT00754949|DRUG|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
40817992|NCT00754949|DRUG|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
41015567|NCT06167096|OTHER|Lavender essential oil|Lavender Oil; blend of two (2) pure lavender oil - Lavandula angustifolia from Bulgaria and Lavandula hybrida from France
41015568|NCT06167096|OTHER|Water|Water
41015569|NCT04085523|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
41015570|NCT04085523|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
41015571|NCT03887936|DRUG|Testosterone gel 1.62%|Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.
41015572|NCT03887936|DRUG|Placebo|Matching placebo gel, apply 2 pumps to upper arm and shoulder
40817993|NCT00754949|DRUG|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
40817994|NCT01790178|PROCEDURE|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
41015596|NCT00001168|BEHAVIORAL|Balanced diet|Dietary studies for the diagnosis of post-prandial hyperlipidemia will include a 3 week period while subjects are on a baseline, isoweight, 15% fat, 42% carbohydrate, normal polyunsaturated fat ratio (0.1-0.3) 250-300 mg cholesterol diet.
41018027|NCT05132335|OTHER|Imaging Biomarkers|"One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA(\[18F\]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water(\[15O\]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~\[18F\]-FTHA tracer injections \[15O\]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion"
41018028|NCT00334659|DRUG|apricitabine|
41336556|NCT05710770|DEVICE|Immunoadsorption|IA is a well-established, safe interventional therapy broadly applied for different indications. Medical complaints of the TheraSorb Ig apheresis system are rare and none led to a long-term impairment of the patient's health. In most treatments, the patients do not report any side effects. The Ig omni adsorbers specifically remove antibodies. Other components of the blood, except for an unspecific loss of plasma during the treatment, are not removed. Main adverse effects can occur due to the necessity of a Shaldon catheter and include accidental puncture of carotid artery. The procedure is performed under sonographic control and a chest-x-ray is performed afterwards to ensure integrity of lungs.
41336557|NCT02687607|DEVICE|WEB Aneurysm Embolization System|
41336558|NCT03177746|DRUG|Dapoxetine/Tadalafil 30/20 mg film coated tablet|"During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment."
41336559|NCT01582958|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
41336560|NCT01582958|OTHER|sham omt|Hands are placed on subjects the same as omt arm but no omt is provided.
41485307|NCT00311311|DRUG|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
41156369|NCT05631379|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
41156370|NCT05631379|DIAGNOSTIC_TEST|The high-sensitivity modified Glasgow prognostic score|The high-sensitivity modified Glasgow prognostic score (Hs-mGPS) is an inflammation-based score consisted of C-reactive protein level and serum albumin
41156371|NCT06647524|DRUG|THC|Participants will be administered 0.5g of vaporized THC cannabis (12% THC cannabis)
41156372|NCT06647524|DRUG|Placebo|Participants will be administered identical plant material from which all THC has been removed by solvent extraction.
41336563|NCT05370846|OTHER|Clinical pharmacy antimicrobial stewardship intervention|"A new AMS group will be introduced in Tauernklinikum in Zell am See, based on the S3-AWMF-guideline Strategien zur Sicherung rationale Antibiotika-Anwendung im Krankenhaus on antibiotic use in hospitals. As part of this, a new formulary will be developed and gradually introduced where we determined which AMS guidelines need to be incorporated. Antimicrobial use will be audited after set-up of the local formulary against the data from before implementation (using defined daily dose, DDD, as suggested by the WHO). Data on antimicrobial use will be obtained from a recently purchased and installed AMS programme called HyBase® by epiNET AG. AMS group will be provided with implementation material and toolkits, baseline data for antimicrobial use within hospital will be obtained."
41336564|NCT02599857|DEVICE|CONCOR smartphone application|
41336565|NCT01896661|DRUG|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
41336566|NCT01896661|DRUG|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
41336567|NCT05782374|DRUG|Ibrutinib|ibrutinib alone or in combination with R-CHOP or R-CHOP like
41336568|NCT00355134|DRUG|Fingolimod|Fingolimod capsules for oral administration
41336569|NCT00355134|DRUG|Placebo|Matching placebo capsules for oral administration.
41336570|NCT02527564|DRUG|Suvorexant|
41336571|NCT02527564|DRUG|Placebo|
41336572|NCT02108834|PROCEDURE|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
41336573|NCT02108834|PROCEDURE|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
41336574|NCT00742040|DRUG|Captopril|A rapid 3-day up-titration protocol
41336575|NCT00742040|DRUG|Captopril|A slower 9-day up-titration protocol
41336576|NCT01288586|DEVICE|Scandinavian Total Ankle Replacement System (STAR Ankle)|Total Ankle Replacement
41336577|NCT01197092|DIETARY_SUPPLEMENT|Mitochondrial preparations|"Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:~ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)"
41336578|NCT01197092|DIETARY_SUPPLEMENT|Infusion therapy|Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.
41485308|NCT04887233|OTHER|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
41485309|NCT04887233|OTHER|Placebo|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
41485310|NCT05066763|OTHER|Non-interventional|non-interventional
41485311|NCT05356143|DRUG|Rupatadine|Oral single dose 10 mg tablet
41485312|NCT03928314|DRUG|ORIC-101|ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle
41485313|NCT03928314|DRUG|Nab-paclitaxel|75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle
41485314|NCT03984292|PROCEDURE|Teaching of laparoscopic skills on a box simulator|The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
41156373|NCT06647459|DIAGNOSTIC_TEST|EP Study|To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
41336579|NCT01197092|DEVICE|Webermedical device|Intravenous-Blood-Laser-Therapy: the Webermedical device will be used
41336580|NCT01197092|BEHAVIORAL|Nutritional therapy|"Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts."
41336581|NCT01659359|DEVICE|Virtual reality glasses and Lidocaine|The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
41336582|NCT01659359|DRUG|Lidocaine|The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
41336583|NCT01369446|DEVICE|Eeva System Study|The Eeva System will image embryos through cleavage and/or blastocyst stage.
41336584|NCT01250743|DIETARY_SUPPLEMENT|ascorbic acid (vitamin C)|intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
41336585|NCT02578992|PROCEDURE|Head-lift position|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
41485315|NCT06132217|DRUG|Simmitinib|Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
41336586|NCT02578992|DEVICE|7cm high pillow|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
41336587|NCT04815538|BEHAVIORAL|the subscale of Health-Promoting Lifestyle Profile II|"Nutritional health behavior included the following nine items: choose a low-fat diet; limit the use of sugars; eat servings of bread, cereal, and rice; eat servings of fruit; eat servings of vegetables; eat servings of meat, poultry, fish, dietary guidelines"
41336588|NCT02449772|OTHER|No intervention|No intervention
41336589|NCT04373018|PROCEDURE|Sodium hypochlorite|Sodium hypochlorite irrigant will be used during biomechanical preparation.
41336590|NCT04373018|PROCEDURE|Chlorhexidine|Chlorhexidine irrigant will be used during biomechanical preparation.
41336591|NCT04373018|PROCEDURE|Chlorhexidine + Hydrogen peroxide|Chlorhexidine + Hydrogen peroxide irrigant will be used during biomechanical preparation.
41336592|NCT02680119|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA.|oral, crossover
41336593|NCT02680119|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, crossover
40817995|NCT05662774|DIAGNOSTIC_TEST|Ultrasound contrast agent (Sonovue)|Patients are diagnosed by intravenous injection of ultrasound contrast on the first day of admission and information is collected by diagnostic ultrasound instruments
41015604|NCT01810913|DRUG|Atezolizumab|Given IV
41015605|NCT01810913|PROCEDURE|Biopsy|Undergo biopsy
41015606|NCT01810913|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41015607|NCT01810913|BIOLOGICAL|Cetuximab|Given IV
41336594|NCT06031025|OTHER|Questionnaire, clinical examination|At each follow up visit, a clinical examination and anthropometric evaluation will be performed. Parents will fill a structured questionnaire to describe the occurrence and characteristics of functional gastrointestinal disorders.
41336595|NCT02321683|DEVICE|Taperloc|Femoral stem with electrochemical deposition of hydroxyapatite
41336596|NCT00509652|PROCEDURE|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
41336597|NCT00509652|PROCEDURE|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
41336598|NCT05065060|OTHER|Observation|Observation
41336599|NCT03030183|DRUG|Zilucoplan (RA101495)|0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
41336600|NCT01053403|DRUG|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
41336601|NCT03907449|DIAGNOSTIC_TEST|Preview Rapid Strep A test|Rapid assay for the detection of type A streptococcal infection of the throat.
41336602|NCT05944029|DIETARY_SUPPLEMENT|Pomegranate seed powder|10 g powder / day
41336603|NCT05968625|DEVICE|Thermoformed retainers|conventional thermoformed retainers fabricated on stone models.
41336604|NCT05968625|DEVICE|3D-printed retainers|3D-printed retainers fabricated directly by DLP printer.
41336605|NCT05621018|DEVICE|Maze Out|Play for 15 weeks, at list once a week the serious game: Maze Out
40817996|NCT05772663|OTHER|Personalized program of rehabilitation|"D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
41015608|NCT01810913|DRUG|Cisplatin|Given IV
41015609|NCT01810913|PROCEDURE|Computed Tomography|Undergo CT
41015610|NCT01810913|DRUG|Docetaxel|Given IV
41015611|NCT01810913|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41015612|NCT01810913|OTHER|Laboratory Biomarker Analysis|Correlative studies
41015613|NCT01810913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41336606|NCT01333462|BIOLOGICAL|NB-1008|NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
41336607|NCT01333462|OTHER|Control|The controls include PBS placebo control as well as Fluzone IN and IM active controls.
41336608|NCT04580888|PROCEDURE|early transthoracic echocardiography|In the intervention arm, echocardiography will be performed immediately and potentially repeated to confirm the need for additional fluid resuscitation up to 30 mL/kg in the presence of persisting hypovolemia, or not (e.g., severe ventricular dysfunction). A therapeutic algorithm will allow standardized impact on ongoing management according to the hemodynamic profile identified by early echocardiography. After the completion of initial fluid resuscitation up to 30 mL/kg if required, a new echocardiographic assessment will be systematically performed by the same operator to stop or not fluid resuscitation, and to potentially initiate another treatment according to both the hemodynamic profile and clinical context.
41336609|NCT04580888|PROCEDURE|standards of care|In the control arm, patients will be treated according to standards of care based on current SSC recommendations, including a fluid resuscitation of 30 mL/kg.
41336610|NCT02474914|DRUG|Octreotide|Octreotide will be given after PD
41336611|NCT02474914|DRUG|Placebo|Octreotide will NOT be given after PD
41336612|NCT04863313|DIETARY_SUPPLEMENT|Probiotic|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
41336613|NCT04863313|DIETARY_SUPPLEMENT|Placebo|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
41336614|NCT02883920|OTHER|Allergy and respiratory functional tests|
41015614|NCT01810913|OTHER|Quality-of-Life Assessment|Ancillary studies
41015615|NCT03832959|DEVICE|EnsoETM|The EnsoETM is a device with a esophageal probe that can provide temperature adjustment
41015623|NCT05446870|BIOLOGICAL|Pembrolizumab|200 mg by IV infusion on Day 1 of each 21-day cycle
41336615|NCT00546507|DRUG|TDS-943 (topical diclofenac sodium 4% spray)|
41336616|NCT00546507|DRUG|celecoxib|
41336617|NCT00546507|OTHER|placebo|
40817997|NCT05772663|OTHER|Routine program of rehabilitation|"Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
40817998|NCT02839447|DIAGNOSTIC_TEST|Diagnostic|Diagnostic
41336618|NCT01989871|BEHAVIORAL|Adjusted individual feeding|Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
41336619|NCT01496989|BIOLOGICAL|HIV-MAG (3,000mcg)|Delivered intramuscularly by in vivo electroporation
41336620|NCT01496989|BIOLOGICAL|GENEVAX® IL-12 (100mcg)|Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
41336621|NCT01496989|BIOLOGICAL|GENEVAX® IL-12 (1000mcg)|Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
41336622|NCT01496989|BIOLOGICAL|Ad35-GRIN/ENV|(2x10\^10vp) Delivered intramuscularly by standard needle injection
41485316|NCT06132217|DRUG|SG001|Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
41485317|NCT04744350|PROCEDURE|Treatment of FFP type IIb and IIc|Patients will either be randomized in the surgical or conservative group.
41485318|NCT03412786|BIOLOGICAL|Bcl-Xl_42-CAF09b vaccine|The vaccine consists of 0.05 mg peptide (bcl-xl_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion
41485319|NCT01117337|PROCEDURE|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
40817999|NCT05787093|DEVICE|transabdominal rectal ultrasound|transabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol
40818000|NCT02867813|BIOLOGICAL|Evolocumab|subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
40818001|NCT01467050|OTHER|Application of STOPP/START criteria|"The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's."
40818002|NCT01467050|OTHER|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
40818003|NCT04467229|BEHAVIORAL|Focus group|5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.
40818004|NCT05515588|DRUG|BI 690517 (C-14)|BI 690517 (C-14)
41015624|NCT05446870|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
41015625|NCT05446870|DRUG|Carboplatin|AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
41336623|NCT04833790|BEHAVIORAL|Free distribution of ORS|Provides will receive 3 months supply of ORS at the beginning of the study to dispense to their patients. They will be asked to dispense the ORS at the market rate and not to give it away to other providers.
41485320|NCT05921513|PROCEDURE|Free Gingival Graft Procedure|This procedure is done to increase the width of keratinized gingiva around teeth or dental implant. The healing of the palatal wound at the donor site will be recorded.
41485321|NCT05643248|DRUG|NEX-20A|Subcutaneous prolonged-release injection
41485322|NCT03521063|DRUG|Budesonide|Drug: Budesonide inhalation suspension
41485323|NCT03521063|DRUG|Poractant Alfa|Drug: Poractant alfa intratracheal suspension
40818005|NCT05515588|DRUG|BI 690517|BI 690517
40818006|NCT03707951|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)
41015626|NCT05446870|BIOLOGICAL|Avastin|According to local practice and at the choice of the investigator.
41015627|NCT05446870|BIOLOGICAL|MK-4830|800 mg by IV infusion on Day 1 of each 21-day cycle
41015628|NCT05446870|DRUG|Docetaxel|75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
41336624|NCT04833790|BEHAVIORAL|Standardized patient with ORS preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests ORS to treat their child's diarrhea.
41336625|NCT04833790|BEHAVIORAL|Standardized patient with Antibiotic preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests Antibiotics to treat their child's diarrhea.
41336626|NCT04833790|BEHAVIORAL|Standardized patient with no preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea.
41485324|NCT03521063|DRUG|Saline|Sodium chloride injection 0.9%
41485325|NCT01155453|DRUG|BKM120|
41485326|NCT01155453|DRUG|GSK1120212|
41485327|NCT03036553|OTHER|Diagnosis/Prognosis|The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
40818007|NCT03707951|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
41485328|NCT06217484|BEHAVIORAL|delayed feedback|participants learn through either immediate or delayed feedback during a computer task
41485329|NCT03805503|DRUG|Chloroprocaine 1% Injectable Solution|"standard CSE procedure in outpatients for inguinal hernia. The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. 2,5 microgram of sufentanil will be added for prolongation of the analgesia. The testing interval is 2 mg.~Efficacy of the analgesia will be evaluated:~Successful : sensory block at or above T6 dermatome bilateral at the beginning of surgery without additional analgesia during surgery. Unsuccessful: sensory block under T6 dermatome bilateral and/or VAPS is more than 10 mm at the beginning of surgery what necessitates additional epidurals analgesia.~Patients who indicate an ineffective result will receive a rescue treatment by the administration of 5 ml chloroprocaine 3% epidural every 5 minutes with maximum of 30ml. When CSE fails, general anesthesia will be performed."
41485330|NCT00845819|DRUG|rhEGF + povidone iodine, chlorhexidine, & nystatin|"Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) \& nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
41485331|NCT00845819|DRUG|Placebo + povidone iodine, chlorhexidine, & nystatin|"Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
41485332|NCT01524614|PROCEDURE|nasal mask|nasal mask use instead of face mask
41015639|NCT06339034|DIETARY_SUPPLEMENT|Lithium|5mg of elemental lithium/capsule
41015640|NCT06339034|OTHER|Placebo|Cellulose-filled capsules
41336627|NCT04833790|BEHAVIORAL|Standardized patient with no preference + no financial incentive|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea. In addition they will inform the provider that they are not going to purchase anything from the provider because they have an uncle with a drug shop where they can get a discount.
41485333|NCT03475264|DIAGNOSTIC_TEST|Lung MRI|Participants will be undergoing hyperpolarized xenon and proton lung MRI
41485334|NCT01970865|DRUG|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
41485335|NCT01970865|DRUG|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
41485336|NCT05262192|OTHER|nutrition education|Nutrition education will be given to the patients in the experimental group.
41485337|NCT02939950|DEVICE|Bausch + Lomb Samfilcon A Soft Contact Lens|soft contact lenses
41485338|NCT02939950|DEVICE|Bausch + Lomb Pure Vision Soft Contact Lens|soft contact lenses
41485339|NCT03744702|DRUG|Ascorbic Acid|Patients will receive IV ascorbic acid.
41015644|NCT05610111|DEVICE|CLC + BAM|Closed Loop Control with the Behavioral Adaption Module for 4 weeks
41015645|NCT05610111|DEVICE|CLC + ABC|Closed Loop Control with Adaptive Biobehavioral Control for 16 weeks
41485340|NCT02453906|OTHER|XNKQ|stimulation at 5 acupuncture points according to XNKQ acupuncture
41015649|NCT01218854|DEVICE|Needle angle measurement|The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
41015654|NCT04558476|BIOLOGICAL|Convalescent Plasma|2 units of convalescent plasma
41015655|NCT04558476|OTHER|Standard of Care|Gold Standards
41015656|NCT05464511|OTHER|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
41015658|NCT06112418|DEVICE|The Cleerly CAD Staging System|The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
41015659|NCT02376127|PROCEDURE|Dynamic contrast enhancement MRI|
41336628|NCT04220567|OTHER|Experimental: Exercise and Patient-centred education|"An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).~Patient-centred Education will follow the principles of transformative learning \& incorporate patients' narratives. It will precede 9 of the 24 exercise sessions and be delivered by the same physiotherapist"
40818008|NCT02652208|BEHAVIORAL|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
40818009|NCT02652208|BEHAVIORAL|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
40818010|NCT01007435|DRUG|Tocilizumab|Tocilizumab was supplied in vials.
41336629|NCT04220567|OTHER|Active Comparator: Exercise|An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).
41485341|NCT02453906|OTHER|Control 1|no stimulation at 5 acupuncture points according to XNKQ acupuncture
41485342|NCT02453906|OTHER|Control 2|stimulation at 5 control points
41485343|NCT02453906|OTHER|Control 3|no stimulation at 5 control points
41485344|NCT03072199|DRUG|RiTUXimab Injection|Single dose of Rituximab given intravenously within 48hours of myocardial infarction
41015660|NCT06022159|PROCEDURE|Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior to surgery.|"Early post-radiotherapy toxicity will then be assessed 1 month after the end of radiotherapy.~Post-operative follow-up: post-operative complications will be followed at 3 and 6 weeks post-surgery.~A visit at 6 months post-surgery will also be carried out to evaluate post-operative complications and late adverse effects of radiotherapy.~Long-term follow-up would also be performed every 6 months from the 6-month post-surgery visit up to 3 years post-surgery (M12, M18, M24, M30 and M36)."
41015661|NCT06022159|PROCEDURE|Patient will undergo surgery before receive the adjuvant hypofractionated radiation therapy (40 Gy in 15 fractions).|"Post-operative follow-up: postoperative complications will be followed at 3 and 6 weeks post-surgery (before the start of irradiation). Early post-radiotherapy toxicity will then be assessed 1 month after the end of radiotherapy.~A 6-month post-surgery check-up will also be carried out to assess post-operative complications and acute side effects of radiotherapy.~Long-term follow-up would also be performed every 6 months from the 6-month post-surgery visit up to 3 years post-surgery (M12, M18, M24, M30 and M36)."
41015662|NCT00044304|DRUG|Imatinib|The dosing regimen to be used initially (400 mg po qd in adults and 260 mg/m2/day in children with food and a glass of water) is identical to that recommended by the FDA for the treatment of the chronic phase of chronic myelogenous leukemia (CML) (Prod Info Gleevec ). In patients with ANC \<1500/mm3, platelet counts \< 75,000mm3 or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 300 mg po qD.
41015663|NCT00044304|DRUG|Ruxolitinib|The dosing regimen to be used initially (15 mg po bid) is identical to that recommended by the FDA for the treatment of myelofibrosis with platelet counts of 100-200,000/mm3 (Prod Info ruxolitinib). In patients with platelet counts \<100,000/mm3, moderate renal impairment (CrCl \<60 mL/min) or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 10 mg bid. The recommended guidelines for dose adjustment during therapy and discontinuation of therapy in myelofibrosis will be followed.
41015665|NCT05382559|DRUG|ASP3082|Intravenous Infusion
41485345|NCT04371328|OTHER|RECOP unit patient|"All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.~30 days after inclusion, virological status and mortality will be collect"
41485346|NCT03688282|DEVICE|Wearable vibration belt|The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
41015666|NCT05382559|DRUG|Cetuximab|Intravenous Infusion
41015667|NCT05382559|DRUG|Leucovorin|Intravenous Infusion
41336630|NCT06089707|DRUG|Naloxone Nasal Spray|IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
41485347|NCT03688282|DEVICE|Sham, wearing belt|The device is worn, for a specified time. It will not be turned on during this period. It is only sham.
41485348|NCT04841330|DEVICE|Securis™ Stabilization Device|A trained clinician will apply and remove, and participants will wear the Securis™ Stabilization Device for up to one week (7 days) on their forearm. A shortened catheter will be placed (not inserted) over the Securis™ device in accordance with the product Information for Use (IFU), and an extension set attached to the catheter and secured in place, to simulate clinical use.
40818011|NCT01007435|DRUG|Placebo to tocilizumab|Placebo to tocilizumab was supplied in vials.
40818012|NCT01007435|DRUG|Methotrexate|Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
40818013|NCT01007435|DRUG|Placebo to methotrexate|Patients received placebo to methotrexate orally once a week.
40818014|NCT02472418|DRUG|DFN-15 Dose A (treatment A)|DFN-15 Dose A administered
40818015|NCT02472418|DRUG|DFN-15 Dose B (treatment B)|DFN-15 Dose B administered
40818016|NCT02472418|OTHER|Placebo (treatment C)|Placebo administered
41336631|NCT01877031|DEVICE|Virtual Reality|A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
40818017|NCT00549900|BIOLOGICAL|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
41015668|NCT05382559|DRUG|Oxaplatin|Intravenous Infusion
41336632|NCT01877031|DEVICE|Ultrasound|Standard of Care - Ultrasound guided intervention
41336633|NCT05730127|OTHER|Conditioning stimulus|Pain stimulus on non-dominant side
41336634|NCT04957680|BEHAVIORAL|CCBT|computer-based treatment program for depressed adolescents
41336635|NCT00776334|DRUG|Fosinopril 40mg Tablets|
41485349|NCT05604248|OTHER|Intervention|Mother : 2.0 μmol 13C2 -retinyl acetate diluted in soybean oil Children : 1.0 μmol 13C2 -retinyl acetate diluted in soybean oil
40818018|NCT02241811|DRUG|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
40818019|NCT02241811|DRUG|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
40818020|NCT06562660|DEVICE|apnoeic|In group S, High-Flow Nasal Oxygen was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 95 %.
40818021|NCT01421303|DRUG|Enbrel|Enbrel
40818022|NCT01331382|DIETARY_SUPPLEMENT|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
40818023|NCT01331382|OTHER|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
40818024|NCT06102590|OTHER|Individualized red blood cell transfusion strategy|Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%.
40818025|NCT06102590|OTHER|European guidelines red blood cell transfusion strategy|RBCT according to ESICM guidelines
41336636|NCT02833818|DIETARY_SUPPLEMENT|CAKE-intervention|Increased protein and energy supplementation and conversations
41336637|NCT02833818|DIETARY_SUPPLEMENT|CAKE-control|nutrition according to established procedures
41485350|NCT04667260|PROCEDURE|Maxillary sinus membrane elevation|Maxillary sinus membrane elevation with blood coagulum
41485351|NCT04667260|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
40818026|NCT01905345|PROCEDURE|Training|
40818027|NCT05960331|BEHAVIORAL|Autonomy supported learning|The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.
40818028|NCT05960331|BEHAVIORAL|Practice with predetermined feedback|Learners practice the motor task, while the feedback is provided according to their counterpartner
40818029|NCT03457142|BIOLOGICAL|Abatacept|Given IV and SC
41015669|NCT05382559|DRUG|Fluorouracil|Intravenous Infusion
41015670|NCT05382559|DRUG|Irinotecan|Intravenous Infusion
41015671|NCT05382559|DRUG|Nanoparticle albumin-bound-paclitaxel|Intravenous Infusion
41015672|NCT05382559|DRUG|Gemcitabine|Intravenous Infusion
41336638|NCT06066606|DRUG|Vilanterol and Fluticasone Furoate (low dose)|Participants are administered 25 µg of vilanterol + fluticasone furoate
41336639|NCT06066606|DRUG|Vilanterol and Fluticasone Furoate (high dose)|Participants are administered 100 µg of vilanterol + fluticasone furoate
41336640|NCT06066606|DRUG|Placebo|Participants are administered placebo
41336641|NCT01577004|DIETARY_SUPPLEMENT|omega-3 fatty acid|Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
41336642|NCT00293241|DEVICE|Managed Ventricular Pacing programmed ON/OFF|Device programming
41336643|NCT00707538|DRUG|BMS747158|2 IV injection of \~11 mCi (total) F-18 labeled compound
41336644|NCT04949828|DRUG|CREON|Oral Capsules
40818030|NCT03457142|DRUG|Dexamethasone|Given PO
40818031|NCT03457142|DRUG|Ixazomib Citrate|Given PO
40818032|NCT03457142|OTHER|Laboratory Biomarker Analysis|Correlative studies
40818033|NCT03524690|DIETARY_SUPPLEMENT|Energy Balance|Energy Balance Sufficient food provided to maintain energy balance.
40818034|NCT03524690|DIETARY_SUPPLEMENT|Negative Energy Balance|Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
40818035|NCT02017392|DRUG|Compound Lidocaine Cream|Compound Lidocaine Cream ,1-2 grams per person.
40818036|NCT00318747|DRUG|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
40818037|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
40818038|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
40818039|NCT03840772|DRUG|Eribulin|Treatment with eribulin
40818040|NCT03350958|DIETARY_SUPPLEMENT|Alginate Bread|100g Alginate Bread, toasted with 20g of butter.
40818041|NCT03350958|OTHER|Control Bread|100g standard White Bread (control), toasted with 20g of butter.
40818042|NCT05569057|DRUG|SIM1811-03|SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
40818043|NCT06452641|OTHER|Jones technique|Strain counter strain technique also known as Jones technique will be performed with the patient lay supine on the treatment table, taking them to a position-of-comfort by extending, side-bending, and rotating the head away (ESARA) from the TP until the TP pain has reduced. Continues to monitor, maintaining the patient's position for 90 seconds. After 90 seconds has elapsed, the patient's head should be slowly and passively returned to a neutral position with 3 sessions/week for 6 weeks. In essence, the TP should be relieved by placing the patient in a position of comfort, holding this position for 90 seconds, and slowly returning the patient to a neutral position.
40818044|NCT06452641|OTHER|Cross-friction massage|Group B will get cross friction massage for 15-20 mins. Participants will be treated 3 times per week for 6 weeks. Pre and Post-treatment readings will be taken in 1st session and 6th week respectively.
40818045|NCT05771441|OTHER|neck stabilization exercise (nse)|neck stabilization exercise (nse)- exercise
40818046|NCT05771441|OTHER|NSE + HOT PACK THERAPY|NSE + HOT PACK THERAPY- exercise plus heat therapy
41336645|NCT04977024|BIOLOGICAL|COVID-19 Vaccine|Receive SOC mRNA SARS-CoV-2 vaccine IM
41336646|NCT04977024|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
41336647|NCT04977024|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1|Given IM
40818047|NCT05771441|OTHER|NSE + infrared therapy|NSE + infrared therapy- exercise plus heat therapy
40818048|NCT05771441|OTHER|NSE + ultrasound therapy|NSE + ultrasound therapy exercise plus heat therapy
41015675|NCT03617679|DRUG|Rucaparib|Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
41015676|NCT03617679|DRUG|Placebo Oral Tablet|Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
41336648|NCT03690674|BEHAVIORAL|Lifestyle Enhancement for ADHD Program|The LEAP intervention consists of 3 components: 1) an enhanced 8-week, group-based BMT curriculum, 2) parent and child use of the Garmin daily activity tracker accompanied by personalized goal setting, and 3) parent participation in a private Facebook group to encourage PA goal achievement and promote social support and positive parenting.
41485352|NCT03118388|BEHAVIORAL|Social Enterprise Intervention|The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months).
40818049|NCT03183323|BEHAVIORAL|Telerehabilitation|Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
40818050|NCT06152835|OTHER|Data and breast milk samples collection|Breast milk samples and, clinical, anamnestic and lifestyle data collection
40818051|NCT05280002|BIOLOGICAL|Adipose Tissue derived Total-Stromal-Cells (TOST)|Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
40818052|NCT02815657|DRUG|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
40818053|NCT02815657|DRUG|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
40818054|NCT01185418|DRUG|risperidone|
40818055|NCT01185418|DRUG|aripiprazole|
40818056|NCT01185418|DRUG|haloperidol|
40818057|NCT01185418|DRUG|amisulpride|
40818058|NCT01185418|DRUG|lactose|
40818059|NCT06606535|DIAGNOSTIC_TEST|validated questionnaires|Validated questionnaires for climacteric symptoms
41485353|NCT03118388|BEHAVIORAL|IPS|To implement the IPS at the host agency, one employment specialist, two case managers, and two clinicians were assigned the 22 available IPS cases among them at baseline. Over the 20 months, all IPS participants met individually with the employment specialist, one case manager, and one clinician at least weekly. Regarding job development in the community, the IPS employment specialist also spent about 40% of each week out in the community building relationships with new and existing employers.
40818060|NCT06606535|DIAGNOSTIC_TEST|functional MRI|functional MRI
40818061|NCT06606535|DIAGNOSTIC_TEST|Optical Coherent Tomography Angiography|OCT angiography, macular and peripapillary scans
40818062|NCT06606262|PROCEDURE|Tonsillotomy|Bilateral partial removal of the palatine tonsils to a level between the pharyngeal pillars and the tonsillar capsule. Surgery will be performed under general anesthesia using monopolar electrocautery.
40818063|NCT06606262|PROCEDURE|Tonsillectomy|"Bilateral extracapsular removal of palatine tonsils. Surgery will be performed under general anesthesia using cold knife dissection."
40818064|NCT01057576|DIETARY_SUPPLEMENT|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
41336649|NCT01082341|BIOLOGICAL|Immunization with P. vivax irradiated sporozoites|"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."
41336650|NCT00527072|BIOLOGICAL|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
41336651|NCT05410977|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
41336652|NCT05410977|OTHER|Electronic Health Record Review|Medical records reviewed
41336653|NCT04714723|BEHAVIORAL|Programmed smartphone intervention|Interactive programmed lifestyle education based on smartphone for six month
41336654|NCT04714723|BEHAVIORAL|Programmed smartphone plus dietitian intervention|Interactive programmed lifestyle education based on smartphone plus dietitians support for six month
40818065|NCT01057576|OTHER|Placebo|capsule, daily dosage
40818066|NCT06301724|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41015678|NCT06460701|OTHER|m-CIMT without Kinesio taping|Baseline treatment m-CIMT will be applied includeing ROM with a sling, e.g shoulder flexion, extension, abduction, and rotation. The elbow's flexion and extension, Forearm supination is the extension of the wrist and fingers. Functional Training Using a tiny toy ball, practice tossing and catching it from various angles. Play with modeling clay, constructing towers of the toy bricks using LEGOs,Using crayons, ripping a piece of paper towel,Grasping biscuits, Using a spoon, utilizing a glass to drink, comb hair, brush teeth,Using a bubble blower,With a toy in hand, putting cap, putting lotion.stretching to shoulder's extensors, adductor, and internal rotators ,wrist and elbow flexors. strengthening exercises e.g a ball above head position in various directions,Using paper adhered to the window or wall at varying heights for drawing. The session will go for one hour.
41336655|NCT02448914|DRUG|TRIGEL|All patients will receive TRIGEL. Treatment order is determined by randomization.
41336656|NCT02448914|DRUG|Duodopa|All patients will receive Duodopa. Treatment order is determined by randomization.
41336657|NCT01320969|BEHAVIORAL|Mindfulness-Based Stress Reduction course|an eight-week mindfulness-based stress reduction course
41336658|NCT02045056|DRUG|Gemfibrozil|
41336659|NCT02045056|DRUG|Placebo|
41336660|NCT01002404|PROCEDURE|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
41336661|NCT01003613|DRUG|Tranilast, and Tissucol|1.0%, 0.1 ml, subconjunctival route, single dose
41336662|NCT01003613|OTHER|Beriplast P|0.1 ml to attach graft
41336663|NCT02637648|DRUG|Sodium Oxybate|parallel Group administration
41336664|NCT02637648|DRUG|Placebo|parallel Group administration
41336665|NCT02376478|DRUG|TNF-alpha inhibitors|therapy for at least 6 months
41336666|NCT02376478|DRUG|Alternative/no medication|therapy for at least 6 months or no therapy
41015679|NCT06460701|OTHER|m-CIMT along with kinesiotaping|"Modified constraint-induced movement therapy along with kinesiotaping will be applied. m-CIMT protocol is baseline treatment and it is is same as in the other group.~This group also participated additionally in a kinesio taping program, which utilize KT with the goal of enhancing middle and lower trapezius function to increase stability in the scapula on the afflicted side. During the application of the tape, the shoulders were kept in a low and backward posture, and the scapular alignment was manually maintained. KT was administered at the acromion and positioned medially at the spinous processes (T2-T3 for the middle trapezius and T12 for the lower trapezius). For eight weeks in a row, there will be three sessions every week"
41336667|NCT02376478|OTHER|Alternative/no medication|phototherapy for at least 6 months
40818067|NCT06301724|DRUG|Lidocaine hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41336668|NCT02376478|DRUG|Purine/folic acid analogues|therapy for at least 6 months
41336669|NCT03568695|DIAGNOSTIC_TEST|Two samples on each of the three sites (pharynx, rectum, urine)|two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
41336670|NCT00300534|DEVICE|Abbott Laboratories Determine test for syphilis|
41336671|NCT00300534|DEVICE|Investigational syphilis immunochromatographic strip test|
41336672|NCT04260841|DEVICE|bed in 45 degrees for passive leg raising test|fluid responsiveness is tested by the passive leg raising test
41336673|NCT03616262|DRUG|Botox + Lidocaine|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
41336674|NCT03616262|DRUG|Lidocaine alone|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
41485354|NCT02218619|DRUG|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
41485355|NCT02218619|DRUG|Sugar Pill (placebo)|Placebo
41485356|NCT05228821|DRUG|Voxelotor Oral Tablet|During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment
41015685|NCT04988685|DEVICE|Sirolimus Eluting Balloon|PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon
41015686|NCT03894059|OTHER|Educational Intervention|Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
40818068|NCT05849935|DIAGNOSTIC_TEST|abioSCOPE|The abioSCOPE device with the PSP assay is intended to be indicated for ICU admitted patients at risk of developing sepsis. Results of abioSCOPE PSP assay may aid to identify sepsis in critically ill patients, together with all other clinical assessment and laboratory findings.
40818069|NCT06514664|OTHER|Using Probiotic Toothpaste|"Scaling and root planing (Phase 1 = non-surgical periodontal treatment) are performed in all patient groups.~Depending on the study groups, regular or probiotic toothpaste will be used. Toothpaste is instructed to be used twice a day"
40818070|NCT05175768|OTHER|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
40818071|NCT05175768|OTHER|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
40818072|NCT05175768|OTHER|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
40818073|NCT05952765|PROCEDURE|Immediate implant|"* Local anesthesia Septanest special® will be administered prior to the procedure.~* Teeth extraction will be initiated by intrasulcular incision via 15 C blade without flap elevation.~* The tooth to be extracted will be luxated atraumatically using periotomes and thin straight elevator and delivered using forceps.~* The socket will be inspected for integrity, using a UNC graduated periodontal probe.~grafting material either experimental or control will be used to graft jumping gap."
40818074|NCT04934709|DEVICE|Active PBMT-sMF|PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter. Six different sites of the knee extensor muscles (two medial, two lateral and two central points) were irradiated at the same time.
40818075|NCT04934709|DEVICE|Placebo PBMT-sMF|Placebo PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter, but without any emission of therapeutic dose. Placebo PBMT-sMF was applied at six different sites of the knee extensor muscles (two medial, two lateral and two central points).
40818076|NCT00348699|DRUG|AFP464|Given IV
40818077|NCT00348699|OTHER|pharmacological study|Correlative studies
40818078|NCT00348699|OTHER|laboratory biomarker analysis|Correlative studies
40818079|NCT03092830|GENETIC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
40818080|NCT05557552|RADIATION|standar thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with standard dose thoracic radiotherapy of 60 Gy/30Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
40818081|NCT05557552|RADIATION|decreased thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with decreased thoracic radiotherapy of 50Gy/25Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
41336675|NCT03512470|DEVICE|Sistema Prevena ™(TVAC)|The medications with a negative topical pressure system (Sistema Prevena ™) will be applied directly in the Operating Room. Thereafter medication will be checked in the inpatient ward after 48 h from the intervention, evaluating the possible absorption of exudate on the surface. If no absorption are detected within 48 hours, the medication won't be removed and renewed in the 7th day (± 2 days) post-operative; and to follow every 7 (± 2 days) until the points are removed. If the wound continues to progress towards recovery, the protocol will continue until discharge and / or rehabilitation and / or surgery.
41336676|NCT03512470|OTHER|Standard medication|standard medication in use (sterile gauze and TNT patch or medicated patches).
41336677|NCT00044655|DRUG|Risperidone|As prescribed by routine prescriber (not dictated by study protocol)
41336678|NCT00044655|DRUG|Olanzapine|As prescribed by routine prescriber (not dictated by study protocol)
41336679|NCT00044655|DRUG|Ziprasidone|As prescribed by routine prescriber (not dictated by study protocol)
41336680|NCT00044655|DRUG|Quetiapine|As prescribed by routine prescriber (not dictated by study protocol)
41336681|NCT00044655|DRUG|Aripiprazole|As prescribed by routine prescriber (not dictated by study protocol)
41336682|NCT06431412|OTHER|no intervention|no intervention
41336683|NCT05344612|RADIATION|CT Coronary Angiography|Upfront ct-coronary angiography
41336684|NCT05410899|OTHER|exercise|Women with urinary incontinence will done exercise including pelvic floor muscle and will taught pelvic floor muscle anatomy, physiology, disorders, treatment of disease
41336685|NCT03338036|DEVICE|Heart Rate Variability Biofeedback|HRV biofeedback constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes.
41336686|NCT03338036|DEVICE|Neurofeedback|LORETA Z-Score neurofeedback training will occur three times per week with a trained study investigator.
41336687|NCT05739240|PROCEDURE|Osteosynthesis|Osteosynthesis of distal radius fractures
41336688|NCT02422394|DRUG|Eltrombopag|
41336689|NCT03796884|DRUG|Linaclotide|Given PO
41336690|NCT03796884|OTHER|Placebo|Given PO
40818082|NCT02453165|PROCEDURE|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
40818083|NCT02453165|PROCEDURE|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
40818084|NCT05321758|BIOLOGICAL|Fecal Microbiota Transplantation|In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.
40818085|NCT05321758|DRUG|Immunosuppressive Agents|hormones, azathioprine, thalidomide
40818086|NCT02403817|BEHAVIORAL|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
40818087|NCT02403817|BEHAVIORAL|Eye Motor Training|Game play will be controlled by the player's eye movements (via an eye tracking device)
40818088|NCT02403817|BEHAVIORAL|Hand Motor Training|Game play will be controlled by the player's hand movements (via a joystick).
40818089|NCT01579565|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
40818090|NCT01579565|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
40818091|NCT05557539|BIOLOGICAL|blood samples, urine samples and nasopharyngeal swabs|The following samples will be collected: First time point : 6 blood sample tubes (5mL EDTA, 5mL heparinized and 7.5mL heparinized, 5mL citrate, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium). Second time point : 5 blood sample tubes (5mL EDTA,5mL heparinized and 7.5mL heparinized, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium).
40818092|NCT06596954|RADIATION|lymphocyte-sparing radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. While maintaining target coverage and traditional OAR (Organs At Risk) dose constraints, also address dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
40818093|NCT06596954|RADIATION|conventional radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. do not limit dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
40818094|NCT06607783|DIAGNOSTIC_TEST|MRI|TBC
40818095|NCT05239793|OTHER|NJOY e-cigarette|NJOY e-cigarette with Virginia Tobacco flavored 5% nicotine pods
40818096|NCT01478685|DRUG|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
40818097|NCT01478685|DRUG|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
40818098|NCT01478685|DRUG|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m\^2
40818099|NCT02101684|DRUG|Orteronel 300mg BID|
40818100|NCT06547021|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"A light electrical current with zero frequency (tDCS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
40818101|NCT06547021|DEVICE|Gamma Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with personalized gamma frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
40818102|NCT06547021|DEVICE|Theta Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with personalized theta frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
41336691|NCT04501757|BIOLOGICAL|Naxitamab/GM-CSF|naxitamab/GM-CSF for 5 Cycles
41336692|NCT01943188|RADIATION|stereotactic body radiation therapy|Undergo SBRT
41336693|NCT01943188|DRUG|cyclophosphamide|Given PO
41336694|NCT01943188|BIOLOGICAL|therapeutic autologous lymphocytes|Undergo autologous PBMC infusion
41336695|NCT01943188|OTHER|laboratory biomarker analysis|Correlative studies
41336696|NCT02980549|OTHER|children's sleep habits questionnaire|survey of children's sleep habits completed by parent
41336697|NCT00429572|DRUG|Fludarabine|30 mg/m\^2 intravenously Daily for 5 Days
41336698|NCT00429572|DRUG|Melphalan|70 mg/m\^2 intravenously Daily for 2 Days
41336699|NCT00429572|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion on Day 0.
41336700|NCT06099353|BEHAVIORAL|Heart Age|Heart Age is the phenotypic age based on the risk of the patient participant using a modified tool for CVD risk from the Framingham risk Score. The Heart Age is the age at which an individual would be expected to develop CVD in the next ten years relative to another individual of the same sex and age if all the current CVD risk factors were to be eliminated.
41336701|NCT06099353|BEHAVIORAL|Heart Age-HOPE-CVD App|Patient participants will use an online mobile, evidence-based behavioural change psychoeducation application for 24 weeks. New psychoeducational content is released every week. The first seven weeks of the programme seeks to resolve ambivalence about initiating a lifestyle change and increase the readiness and motivation to change. Between Weeks 8 and 15, the platform will support action planning and guide users to execute their preferred self-care behaviour safely and effectively. The remaining nine weeks will provide the user with the skills that will help them with coping and planning to manage relapses and temptations.
40818103|NCT06547021|DEVICE|Sham|"Sham stimulation (i.e. only slight stimulation at the beginning and at the end for a few seconds with majority of the time having no stimulation) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
40818104|NCT06320249|OTHER|High-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the high-frequency manipulation group, patients will undergo rotation-traction manipulation three times weekly. A total of 12 treatments for four weeks.
41336702|NCT06099353|BEHAVIORAL|Communication of Genetic Risk Score|General practitioners will draw 3ml of blood from each patient participant for analysis of the patient's genetic risk score of having cardiovascular disease. This genetic risk score will be communicated to the patient, and the communication will include informing patients what cardiovascular disease genetic risk is, what their genetic risk category compared to the population in Singapore is, and what their score means for the future.
41336703|NCT03091699|DRUG|Nicotine|Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
41336704|NCT03091699|BEHAVIORAL|Moderate Intensity Exercise|Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
40818105|NCT06320249|OTHER|Low-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the low-frequency manipulation group, patients will undergo rotation-traction manipulation once time weekly. A total of 4 treatments for four weeks.
40818106|NCT06320249|OTHER|Cervical traction|The procedure for cervical traction is as follows: The patient assumes a sitting position, and a cervical traction device with a chin strap is applied. The patient is instructed to slightly flex their head forward, approximately 10-15 degrees, based on their comfort level and symptom relief. Traction force starts at 3 kg and increases gradually in increments of 0.5 kg, with a maximum weight not exceeding 6 kg. The cervical traction group will be subjected to cervical traction three times a week. A total of 12 treatments for four weeks.
40818107|NCT06527248|DIETARY_SUPPLEMENT|Nitrate group|Daily consumption of 70 mL beetroot juice containing \~400 mg nitrate over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
40818108|NCT06527248|DIETARY_SUPPLEMENT|Placebo group|Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
40818109|NCT03744468|DRUG|BGB-A425|Humanized IgG1-variant monoclonal antibody against TIM-3
40818110|NCT03744468|DRUG|Tislelizumab|Humanized, IgG4-variant monoclonal antibody against PD-1
41336705|NCT02524067|BEHAVIORAL|Multifactorial circadian concept|Circadian light, systematic information, music, individual foreclosure
41485357|NCT03540771|OTHER|Palliative Care|"The intervention will comprise an approach to render palliative care, as taught to hepatologists through an on-line learning platform, and as delivered by PC providers as routine care. The elements of the intervention, which will be guided by a checklist and implemented over the course of interactions with the patient and caregivers at the initial, 1, 2, and 3 month visits, to include:~1. Patient/caregiver understanding of diagnosis, illness and prognosis~2. Symptom assessment and management~3. Psychosocial assessment and management~4. Distress screening and management~5. Discussion of goals of care~6. Advanced directives"
41485358|NCT02680431|OTHER|Blood sample|10 mL venous blood sample for analysis of plasma
40818111|NCT03744468|DRUG|LBL-007|Human anti LAG-3 IgG4-kappa antibody
40818112|NCT04732702|OTHER|no intervention|There will be no intervention.
40818113|NCT05156099|DEVICE|Ultrasound Scanning|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
40818114|NCT05156099|DEVICE|Ultrasound Scanning - 2 months later|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
41015687|NCT00793442|DIAGNOSTIC_TEST|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
41015688|NCT06499519|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
41156374|NCT06636149|OTHER|Circuit of maternal position changes during labor|"The intervention cohort will undergo the circuit of position changes every 2 hours. The circuit will be repeated up to 3 times or until the second stage of labor is achieved, delivery occurs, or labor arrest diagnosis is made. Participants will be considered as adherent to intervention arm if they undergo one complete circuit of maneuvers. Nurses will keep patients on continuous fetal monitoring during the circuit of position changes. Any persistent non-reassuring fetal status in one position of the circuit will prompt progression to the next position in the circuit. The planned circuit of maneuvers will be:~10-minutes of side-lying release on one side 10-minutes of side-lying release on other side 10-minutes of open-knee chest 10-minutes of shaking apples 20-minutes of flying cowgirl on one side 20-minutes of flying cowgirl on opposite side as position 5 20-minutes of running man on same side as position 5 20-minutes of running man on opposite side as position 5"
41156375|NCT05356195|BIOLOGICAL|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
41336706|NCT01822223|DEVICE|Dental implant-abutments|"At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a \& 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b \& 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration."
41156376|NCT02452125|DIETARY_SUPPLEMENT|Nicotine gum|Nicotine chewing gum
41156377|NCT00073788|PROCEDURE|PET Scans|PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
41156378|NCT05122793|BEHAVIORAL|Prevention offer|Improvement of outcomes through lifestyle changes and improved health literacy
41156379|NCT03925402|DRUG|Ertapenem|Ertapenem injection
40818115|NCT05696353|COMBINATION_PRODUCT|In-vehicle Device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smart phone app (downloaded on the teen's smart phone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data via the smart phone app and study website; and 3) A customized biweekly driving summary report via study website.
40818116|NCT05696353|BEHAVIORAL|Expert-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a traffic safety communication specialist to parents in the Feedback and Expert-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
40818117|NCT05696353|BEHAVIORAL|Peer-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a peer trainer who is a parent of teen with traffic citation and has participated in the Feedback and Peer-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
40818118|NCT04015284|PROCEDURE|Suprascapular Nerve Block + Posterior Cord Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
40818119|NCT04015284|PROCEDURE|Interscalene Brachial Plexus Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
40818120|NCT04873167|BEHAVIORAL|low fat|subjects subjected to a low-fat dietary regime
40818121|NCT04873167|BEHAVIORAL|mediterranean diet|subjects subjected to a mediterranean dietary regime
40818122|NCT04837209|DRUG|Niraparib|Capsule, taken by mouth
40818123|NCT04837209|DRUG|Dostarlimab|Intravenous infusion
41336707|NCT06332612|DRUG|Metformin Hydrochloride|Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.
40818124|NCT04837209|RADIATION|Radiation therapy|Radio Therapy
40818125|NCT06061276|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
41336708|NCT06332612|DRUG|betamethasone dipropionate|Group 1will recieve topical cream betamethasone thrice daily
41336709|NCT06332612|DRUG|Pentoxifylline|Group 1 will receive Pentoxifylline tablet 400 mg twice daily
41336710|NCT00400556|DRUG|ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination|
41485359|NCT05541991|DIETARY_SUPPLEMENT|single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a single dose of standardised rhubarb extract
40818126|NCT06061276|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
40818127|NCT06061276|DRUG|Camrelizumab|200mg intravenously every 2 weeks
41156380|NCT03925402|DRUG|Carbapenems|Other carbapenems injection
41336711|NCT02154334|DRUG|Esketamine|Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
41336712|NCT02154334|DRUG|Mometasone|Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
41485360|NCT05541991|DIETARY_SUPPLEMENT|placebo coated tablet|coated tablet without active principle
41485361|NCT05541991|DIETARY_SUPPLEMENT|double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a double dose of standardised rhubarb extract
41485362|NCT01429051|DRUG|Intranasal Fentanyl Spray (INFS)|Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.
40818128|NCT00509860|DRUG|Irinotecan|16 mg/m2 by vein Daily Over 1 Hour x 5 Days
40818129|NCT00778258|BIOLOGICAL|Baked Milk|At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
40818130|NCT00778258|BIOLOGICAL|Non-baked Milk|Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
40818131|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|Adequate dairy (\> 3 standard daily servings)
40818132|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|\< 1 standard dairy serving/day
40818133|NCT00574730|DRUG|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
40818134|NCT00574730|DRUG|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
40818135|NCT04092894|DRUG|Suvorexant 20 mg|Administration of oral Suvorexant 20 mg
41015708|NCT04548752|PROCEDURE|Biopsy|Undergo tumor biopsy
41015709|NCT04548752|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41015710|NCT04548752|PROCEDURE|Computed Tomography|Undergo CT scan
40818136|NCT04092894|DRUG|Placebo oral tablet|Administration of oral placebo (same non-identifiable form as active comparator)
40818137|NCT03831295|BIOLOGICAL|Anti-OX40 Antibody BMS 986178|Given IT or IV
41015711|NCT04548752|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41336713|NCT02154334|DRUG|Oxymetazoline|Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
40818138|NCT03831295|DRUG|TLR9 Agonist SD-101|Given IT
40818139|NCT05007496|BIOLOGICAL|AV-COVID-19|DCL previously loaded with varying quantity of S-protein
40818140|NCT06334081|PROCEDURE|undersized drilling technique|In group A The implant site preparation was made according to the protocol of the manufacturer except that the final drill was omitted. The drilling was done using a low speed reduction, high torque with coolant contra-angle hand piece with surgical motor unit. Speed of drilling was 800-1200 rpm.
40818141|NCT06334081|PROCEDURE|single drilling technique|In group B The implant bed was prepared using the new specially designed drills. First, the use of the guide drill of length 3.5mm with speed of 800 rpm and torque of 35 nm, then the use of the one drill of the same diameter of the selected implant size to the full length of the osteotomy site.
40818142|NCT03036683|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
40818143|NCT03036683|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
40818144|NCT00646763|DRUG|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
41015712|NCT04548752|DRUG|Olaparib|Given PO
41015713|NCT04548752|BIOLOGICAL|Pembrolizumab|Given IV
41015714|NCT06569069|OTHER|US guided PE|"The multifidus muscle near the posterior dorsal root (at L4-L5 or L5-S1) was targeted using a transverse ultrasound view, inserting the needle at an 80º short axis or a 45º long axis, based on vessel presence. For the tibial nerve in the popliteal region, the needle was inserted at an 80º angle after a transverse cut of the nerve.~Physio invasiva® needles (0.30 x 40-60 mm) were used in the lumbar region, and 0.30 x 30 mm needles in the popliteal region. Both areas received galvanic current (1.5 mA for three seconds and three impacts). Treatment included three US-guided PE sessions over a 1:7:14 schedule, though two participants skipped the third due to pain resolution."
41015715|NCT06569069|OTHER|Sham Acupuncture|"Participants in the control group were also treated in a prone position. Sham acupuncture treatment was applied at the superficial level of the posterior face of the thigh on the affected side, using five Agupunt® needles of 0.16 x 25 mm, inserted superficially in the lateral aspect of the lumbar area (L3-L4), lateral gluteal region, greater trochanter, lateral part of the distal third of the thigh, head of the fibula and lateral aspect of the leg in its middle third. The needles were left superficially subcutaneously for 15 minutes, performing this approach in three different sessions, again following a periodicity of 1:7:14 days."
41485363|NCT01429051|DRUG|Placebo|Matching intranasal placebo spray
40818145|NCT00646763|DRUG|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
40818146|NCT06265792|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
40818147|NCT06265792|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40818148|NCT06500780|BEHAVIORAL|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
40818149|NCT03418649|DRUG|Eplerenone 50 Mg Tab|50 mg PO per day for 10 days
40818150|NCT03418649|DRUG|Placebo Oral Tablet|PO once daily for 10 days
40818151|NCT04774536|DRUG|CRISPR_SCD001|CRISPR_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
40818152|NCT00330408|BEHAVIORAL|GP training|
40818153|NCT00096226|DRUG|Induction Carboplatin|
40818154|NCT00096226|DRUG|Induction Paclitaxel|
40818155|NCT00096226|PROCEDURE|Resection|
40818156|NCT00096226|DRUG|Consolidation Carboplatin|
40818157|NCT00096226|RADIATION|Radiation Therapy|
40818158|NCT00096226|DRUG|Consolidation Paclitaxel|
40818159|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)|Patients will be treated with a single eco-guided injection of Autologous LR-PRP in the elbow affected by epicondylitis.
40818160|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)|Patients will be treated with a single eco-guided injection of Autologous LP-PRP in the elbow affected by epicondylitis.
40818161|NCT06040203|DRUG|Placebo (saline solution)|Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
40818162|NCT06244082|DRUG|AOC 1044|AOC 1044 will be administered via intravenous (IV) infusion
40818163|NCT02959541|DRUG|Leucovorin|
41015739|NCT05933577|BIOLOGICAL|V940|IM injection
41015740|NCT05933577|BIOLOGICAL|Pembrolizumab|IV infusion
41015741|NCT05933577|OTHER|Placebo|IM injection
41015742|NCT06540586|PROCEDURE|anterior Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 25 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
41156381|NCT03816202|DEVICE|Sundt carotid shunt|The Integra Sundt™ carotid shunts are indicated for temporary carotid artery bypass during carotid endarterectomy procedures to help protect the cerebral hemispheres from ischemia during the period of carotid artery occlusion.
40818164|NCT01671293|BEHAVIORAL|Multicomponent remote care model|A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer \& waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.
40818165|NCT01671293|OTHER|Usual care|Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
40818166|NCT02130830|DRUG|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
40818167|NCT02130830|DRUG|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
40818168|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 5 mg, Single dose, 1 day
40818169|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 20 mg, Single dose, 1 day
40818170|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 60 mg, Single dose, 1 day
40818171|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 150 mg, Single dose, 1 day
40818172|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 300 mg, Single dose, 1 day
41015746|NCT03388606|BEHAVIORAL|Growth Mindset|30 Minute interactive video
41015748|NCT06100250|BEHAVIORAL|Motivational interviewing and specimen self-collection|Participants will be asked to attend a pre-test live AV conferencing session, collect and return a urine sample, a throat swab, a rectal swab, and a blood sample for bacterial STI testing, and attend a post-test live AV conferencing session.
41015751|NCT04524962|BIOLOGICAL|Descartes 30|Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
41015752|NCT06011213|BEHAVIORAL|Issuing health risk warning for a heat waves or cold spells|Whenever a health risk warning for a heat waves or cold spells is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.
41015753|NCT06011213|DEVICE|A digital heat or cold health risk early warning tool|A WeChat mini-program provides real-time updates on early warnings and health advisories.
41015754|NCT06011213|DEVICE|Self-monitoring blood pressure and ECG device|Devices for self-monitoring blood pressure and ECG
41015755|NCT06011213|BEHAVIORAL|Perform daily self-monitoring of their BP and ECG|Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
41015757|NCT05874258|OTHER|Real-PL training + Real-tES(tDCS)|PLtraining : around 40mins, tDCS: 20mins
41015758|NCT05874258|OTHER|Real-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
41015759|NCT05874258|OTHER|Placebo-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
41015760|NCT06527846|DRUG|JARDIANCE®|JARDIANCE®
41018029|NCT02954913|PROCEDURE|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
40818173|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 600 mg, Single Dose, 1 day
40818174|NCT01049165|DRUG|[14C] BMS-813160|Oral Solution, Oral, 150 mg, Single Dose, 1 day
40818175|NCT01049165|DRUG|Placebo|Oral Solution, Oral, 0 mg, Single Dose, 1 day
40818176|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 1200 mg, Single dose, 1 day
41018030|NCT04016324|DEVICE|InterStim Basic Evaluation lead and foramen needle|Commercial devices within their intended use as described in approved Instructions for Use.
41015762|NCT06040346|DRUG|Meplazumab for Injection|Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
41336714|NCT03633994|DRUG|Heparin|Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.
41015765|NCT06317285|DRUG|GSK3915393|GSK3915393 will be administered.
41015766|NCT06317285|DRUG|Placebo|Placebo will be administered.
41015767|NCT04777409|DRUG|Semaglutide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
41015768|NCT04777409|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
41336715|NCT03633994|DRUG|Normal saline|Normal saline bladder instillation
41336716|NCT06147778|DEVICE|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
41336717|NCT02939313|DEVICE|medial prefrontal cortex|a form of theta burst stimulation that noninvasively induces a depression in brain reactivity
40818177|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 2000 mg, Single Dose, 1 day
40818178|NCT06574269|DRUG|TLC590|Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590
41485364|NCT00209989|DRUG|Zarnestra|ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
41485365|NCT00209989|PROCEDURE|standard Radiation therapy|Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume
40818179|NCT06574269|DRUG|TLC590|TLC590 Dose 1
40818180|NCT06574269|DRUG|TLC590|TLC590 Dose 2
40818181|NCT06574269|DRUG|TLC590|The MTD of TLC590
40818182|NCT06574269|DRUG|TLC590|TLC590 Dose 3 (The SMC-suggested dose)
40818183|NCT06574269|DRUG|Ropivacaine|Ropivacaine
41018031|NCT00567788|DRUG|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
41018032|NCT00567788|DRUG|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
41018033|NCT05479175|DRUG|Ibuprofen|Ibuprofen
41018034|NCT05479175|DEVICE|Diode laser|Diode laser
41018035|NCT05479175|DEVICE|Nonactive Diode laser|Nonactive Diode laser
41485366|NCT01529398|OTHER|Sensorimotor training (SMT)|The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
40818184|NCT06574269|DRUG|TLC590|TLC590
40818185|NCT01940250|DRUG|Magnesium Sulphate|MgSO4 IV infusion
40818186|NCT01940250|DRUG|Sterile water|H2O IV infusion
40818187|NCT00052091|BEHAVIORAL|Problem Solving Therapy|A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
40818188|NCT00052091|BEHAVIORAL|Brief Supportive Therapy|A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
40818189|NCT06605118|DRUG|Azithromycin Injection|500mg azithromycin in 250 mL of normal saline
40818190|NCT06605118|DRUG|Placebo|250 mL of normal saline
40818191|NCT06605118|DRUG|Standard of Care Preoperative antibiotics|standard of care preoperative antibiotics (excluding azithromycin) prior to incision
40818192|NCT01967017|DRUG|Lidocaine|
40818193|NCT01967017|DRUG|Placebo|
41015774|NCT05906017|PROCEDURE|Open Hernia surgery|midline ventral hernia repair - open
41015775|NCT05906017|PROCEDURE|Robotic Hernia surgery|midline ventral hernia repair - robotic
41156382|NCT02625922|DRUG|Serelaxin|Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
41485367|NCT01529398|OTHER|Resistance training (RT)|The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
41485368|NCT01529398|OTHER|Control group (CG)|Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
41015781|NCT02690545|BIOLOGICAL|ATLCAR.CD30 cells|For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10\^8 cells/m\^2 and 2x10\^8 cells/m\^2. Phase II patients will receive the dose level decided upon in Phase I.
41485369|NCT04797520|DEVICE|Eko CORE Stethoscope|Eko CORE stethoscope will be used as a visual and auditory means of confirming placement of ETT
40818194|NCT05875753|DIAGNOSTIC_TEST|68Ga-FAPI-FS PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-FAPI-FS. The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-FAPI-FS administration."
40818195|NCT04219319|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
41485370|NCT04797520|DEVICE|Point of care ultrasound|"Point of care ultrasound will be used as a means of confirming placement of ETT. This is the gold standard used in standard of care"
40818196|NCT03172325|DRUG|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
40818197|NCT03172325|DRUG|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
41015788|NCT05403554|DRUG|Biological NI-1801|Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
41015789|NCT05403554|DRUG|NI-1801 in combination with anti-PD1 (Pembrolizumab)|In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.
41485371|NCT01527136|DRUG|entolimod|Given IM or SC
41015790|NCT05403554|DRUG|NI-1801 in combination with paclitaxel|The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.
41015791|NCT05403554|DRUG|Paclitaxel|The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
41015792|NCT00780962|DRUG|N-Acetylcysteine (NAC)|"Experimental:~* Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~* After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours."
41015793|NCT00780962|DRUG|0.9% Sodium-chloride|"Placebo:~* Before CT: 500 cc 0.9% Sodium-chloride~* After CT: NS at 67 cc/hour for up to 24 hours."
41485372|NCT01527136|OTHER|pharmacological study|Correlative studies
41485373|NCT01527136|OTHER|laboratory biomarker analysis|Correlative studies
40818198|NCT03172325|DRUG|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
40818199|NCT03172325|DRUG|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
40818200|NCT03503591|DEVICE|Hummingbird Tympanostomy Tube System|Insertion of a ventilation tube under sedation and local anesthetic
40818201|NCT05105750|DRUG|aspirin 100 mg/d|100mg aspirin for at least 3 days followed by aspirin 100 mg/d
40818202|NCT05105750|DRUG|indobufen 200 mg bid|100mg aspirin for at least 3 days followed by indobufen 200 mg bid
41156383|NCT02625922|DRUG|Placebo|Matching placebo i.v infusion
41156384|NCT06617832|DRUG|Active drug for acute migraine treatment|Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine
41336718|NCT02939313|DEVICE|dorsolateral prefrontal cortex|a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity
41336719|NCT02939313|DEVICE|sham|sham stimulation
41485374|NCT01597479|DRUG|Levobupivacaine|In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
41485375|NCT01295866|DEVICE|nasal nitric oxide|
41485376|NCT02149121|BIOLOGICAL|CT-P10|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
41156385|NCT06617832|DRUG|Placebo Oral Tablet|Inactive placebo pill (100 mg) looking like the active drug
41156386|NCT06646393|OTHER|Skin to skin contact|Father-baby skin-to-skin contact was applied within the first hour immediately after the cesarean delivery. During the Father-Baby Skin-to-Skin Contact stage, the newborns were laid face down on their father's bare chest and covered with a blanket.
41156387|NCT05741294|DRUG|Tirbanibulin 2.5 mg ointment|Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.
40818203|NCT06022965|OTHER|Best Practice|Receive SOC
40818204|NCT06022965|OTHER|Comprehensive Geriatric Assessment|Complete CARG-GA
40818205|NCT06022965|OTHER|Electronic Health Record Review|Ancillary studies
40818206|NCT06022965|OTHER|Questionnaire Administration|Ancillary studies
40818207|NCT06022965|OTHER|Supportive Care|Receive GA-based interventions
40818208|NCT06022965|OTHER|Telemedicine|Receive GA-based interventions via telemedicine
40818209|NCT01432340|BIOLOGICAL|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
41015806|NCT06566742|DRUG|Olutasidenib|Given by PO
41015807|NCT04858334|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41015808|NCT04858334|PROCEDURE|Computed Tomography|Undergo CT or CT/MRI
41015809|NCT04858334|PROCEDURE|Magnetic Resonance Imaging|Undergo CT/MRI
41015810|NCT04858334|DRUG|Olaparib|Given PO
41015811|NCT04858334|DRUG|Placebo Administration|Given PO
41156388|NCT05313815|RADIATION|Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)|External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes
41156389|NCT04794894|BEHAVIORAL|outpatient rehabilitation|Treatment provided after completion of inpatient, acute rehabilitation.
41156390|NCT06280716|DRUG|Placebo|Subcutaneous injection
41156391|NCT06280716|DRUG|Lebrikizumab|Subcutaneous injection
41156392|NCT06280716|DRUG|Topical Corticosteroid|Topical Corticosteroid
41336720|NCT04309357|DRUG|Alteplase|Alteplase in dose 0.9 mg/kg in acute ischemic patient with indications of thrombolytic therapy
41336721|NCT00481988|DEVICE|transcranial direct current stimulation|Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
41336722|NCT00481988|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
41015818|NCT01581580|PROCEDURE|Deep Brain Stimulation|standard of care DBS surgery for patients with Parkinson's Disease, dystonia, and essential tremor
41015819|NCT01581580|DEVICE|Medtronic Activa Tremor Control System|
41156393|NCT03836040|DRUG|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
41156394|NCT03836040|DRUG|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
41156395|NCT03836040|DRUG|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
41015843|NCT03755063|OTHER|Speech therapy apps|Speech therapy apps loaded on tablets
41015844|NCT05961215|DEVICE|Penguin Cold Cap|Penguin cold cap: administered 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.
41015848|NCT06104605|OTHER|Institutional interventions|Intervention will include, but not be limited to, the following: adding a referral option to chiropractic care in the electronic health record (EHR), optimizing referral option, e.g., creating a list of preferred providers. Additional strategies may be added depending on community health center staff engagement prior to implementation.
41336723|NCT00481988|DEVICE|transcranial direct current stimulation|one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
41015849|NCT06104605|OTHER|PCPs interventions|"Two one-hour interactive grand rounds/lunch seminars that allow for inter-professional learning for PCPs with optional continuing education credits for PCPs.~Short teaching cases involving clinical vignettes developed with local DCs, information about DCs (e.g., evidence-base for treatments), and logistics of the referral process (e.g., geographic location of community-based DCs who accept Medicaid) sent to participating providers unable to attend the seminars. Additional strategies may be added depending on primary care provider engagement prior to implementation."
41015850|NCT06104605|OTHER|Patient interventions|Printed and electronic educational materials (e.g., brochures) written at a sixth grade reading level in English and Spanish that present chiropractic as a safe and effective evidence-based treatment for LBP. These materials will be written, reviewed, and revised by the researchers with CHC patient input. Additional strategies may be added depending on patient engagement prior to implementation.
41015853|NCT03970109|DRUG|ANS-6637|200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
41015854|NCT03970109|DRUG|Placebo oral tablet|Placebo oral tablet
41015855|NCT06289413|OTHER|Development of AD/OI after BS|"OI is a type of AD that results in chronic supine-to-standing hypotension and disabling dizziness, lightheadedness, and even syncope. Whether arising from malabsorption, vagus nerve damage, or splanchnic vasodilation, the pathophysiology of OI in bariatric surgery is not clear and requires more investigation.~Treatment of OI usually consists of dietary and lifestyle changes, which may include compression stockings and abdominal binders. Medical options include peripheral vasoconstrictors and mineralocorticoids; some patients may be referred to Cardiology for further testing. Management is difficult and endurance and tilt training, inflatable abdominal bands, and beta-blockers have been proposed. One recent study demonstrated the treatment of refractory OI with Droxidopa. Yet, the success of treatment is individualized and necessitates more novel approaches."
41336724|NCT00481988|DEVICE|iomed phoresor transcranial direct current stimulation|for the sham group the current is turned off after 10 seconds
41015864|NCT04926675|BEHAVIORAL|Psychological Therapy|Participants will be receiving their one-to-one psychological therapy from IAPT as usual. They typically receive between 6 and 12 sessions with a psychological practitioner.
41336725|NCT03871465|DRUG|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
41015865|NCT04926675|BEHAVIORAL|Debt Advice|Participants will receive one-to-one support from a Citizen's Advice (CA) money advisor for as long as needed to resolve any money worries currently affecting their mental health.
41015871|NCT05540392|PROCEDURE|Acupuncture|10 treatments of acupuncture over the course of 10 weeks
41015872|NCT05540392|OTHER|Waitlist Control|The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
41015873|NCT05540392|OTHER|Questionnaires|Patients will complete Patient Reported Outcomes (PRO)
41015883|NCT06060665|DRUG|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for up to 52 weeks
41015884|NCT06060665|DRUG|Placebo|One capsule daily for up to 52 weeks
41015885|NCT05338775|DRUG|Talquetamab|Talquetamab will be administered as a subcutaneous (SC) injection.
41015886|NCT05338775|DRUG|Teclistamab|Teclistamab will be administered as a SC injection.
41015887|NCT05338775|DRUG|PD-1 Inhibitor|The PD-1 inhibitor will be administered as an intravenous injection.
41015893|NCT06151574|DRUG|zongertinib|zongertinib
41015894|NCT06151574|DRUG|pembrolizumab|pembrolizumab
41015895|NCT06151574|DRUG|cisplatin|platinum-pemetrexed chemotherapy
41015896|NCT06151574|DRUG|carboplatin|platinum-pemetrexed chemotherapy
41015897|NCT06151574|DRUG|pemetrexed|platinum-pemetrexed chemotherapy
41015899|NCT03223610|DRUG|Venetoclax|Administered orally, days 2-14, at varying doses of 200-800 mg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
41015900|NCT03223610|DRUG|Ibrutinib|Administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
41015901|NCT03223610|DRUG|Prednisone|Administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
41015902|NCT03223610|BIOLOGICAL|Obinutuzumab|Administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
41015903|NCT03223610|DRUG|Revlimid (lenalidomide)|Administered orally, days 1-15, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
40818210|NCT04477382|DIETARY_SUPPLEMENT|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.|Subjects suffering from house dust mite (HDM) allergic rhinoconjunctivitis who are reacting positively to chamber exposure with HDM are reevaluated in the exposure chamber 3 months after taking food supplements.
41485377|NCT02149121|DRUG|Rituxan|US-licensed reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
41485378|NCT02149121|DRUG|MabThera|EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
40818211|NCT01925495|OTHER|varied middle-ear pressure|
40818212|NCT01925495|DRUG|varied middle-ear gas composition|
40818213|NCT01925495|OTHER|varied ear-canal pressure|
41015904|NCT04452825|BEHAVIORAL|Cancer and Aging: Reflections for Elders (CARE) Intervention|For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
41485379|NCT00080938|DRUG|Temozolomide|Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
40818214|NCT02924194|DEVICE|stimulation ON|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
40818215|NCT02924194|DEVICE|stimulation OFF|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
40818216|NCT05972889|DEVICE|NexWave|Device subjects receive designated treatment mode twice daily for up to 8 weeks.
41156396|NCT03836040|OTHER|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
41336726|NCT03871465|PROCEDURE|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
41485380|NCT00080938|RADIATION|Radiation therapy|Standard whole brain radiation therapy 30 Gy in ten fractions.
41485381|NCT00669071|DRUG|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
41485382|NCT00669071|DRUG|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
41485383|NCT01742780|PROCEDURE|Proximal Humerus Intraosseous Vascular Access|EZ-IO Intraosseous Vascular Access System
41485384|NCT02212912|BEHAVIORAL|improvement intervention|"Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters."
41485385|NCT02212912|BEHAVIORAL|no intervention|No intervention indicated that the physicians among control hospital provide routine
40818217|NCT05972889|DEVICE|Sham|Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).
40818218|NCT04812093|DEVICE|Spectroscopic otoscope measurements|Spectroscopic otoscope measurements are taken with the investigational device. Each measurement consists of placing the device in the ear canal and illuminating the ear with multiple light sources in a short period of time. If wax is present in the ear canal, it is removed by the study physician and another measurement is taken.
40818219|NCT04992065|DRUG|NNC0385-0434 A 15 mg|15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
40818220|NCT04992065|DRUG|NNC0385-0434 A 40 mg|40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
40818221|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 15 mg)|Placebo administered as 1 tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces). placebo tablets are sized match to the active arm within dose level
40818222|NCT04992065|DRUG|NNC0385-0434 A 100 mg|"100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces)."
41336727|NCT03871465|DRUG|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
40818223|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 40 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
41015905|NCT04452825|BEHAVIORAL|Social Work and Supportive Counseling (SWSC) Intervention|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months). Training case participants will follow a slightly condensed schedule.
41015906|NCT00302146|DRUG|15-0 H20|
41015907|NCT06297291|DEVICE|Paradise Ultrasound Renal Denervation Treatment|"The Paradise Ultrasound Renal Denervation System (Paradise Ultrasound RDN) is an FDA-approved catheter-based system to treat hypertension by ablating the nerves around the renal arteries, disrupting the overactive sympathetic nerves that can cause high blood pressure. The Paradise procedure uses ultrasound energy to calm the nerves near the kidneys to help lower blood pressure.~Treatment is usually done in an outpatient setting and typically takes about an hour to perform. As a part of the treatment, a small flexible tube (catheter) is guided into the blood vessels near the kidneys and 7 seconds of ultrasound energy is applied 2-3 times. Both sides are treated and then the catheter is removed, leaving nothing behind. After the procedure, some people go home the same day or some stay overnight."
41336728|NCT02637804|DEVICE|stenfilcon A|contact lens
41485386|NCT00968760|PROCEDURE|Leukapheresis|"Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."
40818224|NCT04992065|OTHER|Placebo II A (for NNC0385-0434 A 100 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
40818225|NCT04992065|DRUG|Evolocumab 140 mg/mL, Repatha®|"Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL"
40818226|NCT01113008|PROCEDURE|Remote ischemic postconditioning|Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
41485387|NCT00968760|PROCEDURE|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
40818227|NCT01113008|PROCEDURE|Control group|In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
40818228|NCT06603220|DRUG|Oral EVO756|Oral EVO756, once daily
40818229|NCT01801748|DIETARY_SUPPLEMENT|oral wheat challenge|
40818230|NCT06415812|BEHAVIORAL|Evolutionary Systems Therapy|Evolutionary Systems Therapy is an individual form of psychotherapy (talk therapy) that has been previously tested trough a randomized controlled trial and a few cases series, confirming its feasibility and safety.
40818231|NCT05470101|DRUG|ITI-333|ITI-333 oral solution
40818232|NCT04184414|DRUG|CD19-CART|1-10x106 / kg CD19 CART cells
40818233|NCT06144827|DEVICE|Multiparametric MRI scans|Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software. We will also measure liver function using HepQuant SHUNT test in a subset of patients enrolled in this study.
40818234|NCT06144827|DEVICE|Multiparametric MRI scans + HepQuantShunt Test|Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials. Patients must not have any contraindications that would preclude MRI imaging or receipt of HepQuant SHUNT test for those agreeable to have HepQuant SHUNT test.
40818235|NCT02557100|DRUG|Abatacept|
40818236|NCT02557100|DRUG|Adalimumab|
40818237|NCT02557100|DRUG|Methotrexate|
41015917|NCT05676385|DIETARY_SUPPLEMENT|First concept product (containing 50 grams of carbohydrates)|Fasted intake of First concept product (randomised)
41015918|NCT05676385|DIETARY_SUPPLEMENT|Second concept product (containing 50 grams of carbohydrates)|Fasted intake Second concept product (randomised)
41485388|NCT00968760|PROCEDURE|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
41485389|NCT00968760|DRUG|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10\^6 U/m\^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
41485390|NCT00968760|DRUG|Carmustine|300 mg/m\^2 IV over 1 hour on Day -6
41485391|NCT00968760|DRUG|Etoposide|200 mg/m\^2 IV over 3 hours every 12 hours on Days -5 to -2
41485392|NCT00968760|DRUG|Cytarabine|200 mg/m\^2 by vein over 1 hour every 12 hours on Days -5 to -2.
41485393|NCT00968760|DRUG|Melphalan|140 mg/m\^2 IV over 30 minutes on Day -1
41485394|NCT01795274|RADIATION|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
41485395|NCT02989168|DRUG|GBT440|GBT440: Capsules which contain GBT440 drug substance in Swedish orange
40818238|NCT00369174|DRUG|rosiglitazone maleate|Given orally
40818239|NCT00369174|OTHER|laboratory biomarker analysis|Correlative studies
40818240|NCT06606158|OTHER|Exercises program|Strength, mobility, and balance exercises described within the standardized Physiotherapy plan. This plan includes early mobilization of the patient to a seated position (within the first 24 hours) and initiating walking within 48 hours, provided the patient's overall condition allows.
40818241|NCT00205517|PROCEDURE|Daily interruption of sedation versus sedation algorithm|
40818242|NCT06327074|BEHAVIORAL|Engaged Approach to Lung Cancer Screening|"Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.~Staff-facing materials include:~* Program website/manual/toolkit overview~* Implementation insights with experts video series~* Clinical placement placards~* Program and clinician communication tools~Candidate-facing materials include:~* Program welcome letter~* Maps and directions template~* Communication preferences~* Candidate letter templates (N=\~8)~* Program newsletter template and instructions~* Lung nodule size comparison chart"
41336729|NCT02637804|DEVICE|narafilcon A|contact lens
41336730|NCT02637804|DEVICE|delefilcon A|contact lens
41336731|NCT01195194|DRUG|PRE-TRANSPLANT (PRE=before)|"All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL)."
41336732|NCT00753623|DRUG|Ramelteon|ramelteon (8 mg)
41336733|NCT00753623|DRUG|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
41336734|NCT05934136|BEHAVIORAL|My Healthy Brain 1|My Healthy Brain 1 is an 8-week group program delivered via 90-minute Zoom meetings led by a clinical psychologist. It provides education on the link between dementia and lifestyle factors, including poor exercise, sleep, diet/nutrition, mental and social stimulation, alcohol, and smoking. My Healthy Brain 1 participants learn evidence-based mindfulness and behavior change skills to address common barriers to healthy habits, such as stress and setting achievable goals. My Healthy Brain 1 participants wear an activity watch to monitor lifestyle changes during the program.
41336735|NCT05934136|BEHAVIORAL|My Healthy Brain 2|My Healthy Brain 2 condition controls for the effect of time spent and support/feedback from the group and interventionist. Participants in My Healthy Brain 2 will receive education on lifestyle, brain health, and cognitive decline symptoms in addition to usual care as determined by their medical team. Each weekly session will focus on a different topic: 1) lifestyle and brain health, 2) physical activity, 3) sleep, 4) nutrition, 5) medical adherence, 6) cognitive health, 7) social support, and 8) a program overview. My Healthy Brain 2 is conducted in the same format as My Healthy Brain 1 (8 weekly Zoom sessions, 90 minutes each), but does not include behavior change strategies. My Healthy Brain 2 participants wear an activity watch to monitor lifestyle changes during the program.
41336736|NCT03892707|DRUG|Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum|"Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg."
40818243|NCT05757856|DRUG|NDX-3315 and NDX-3324|Oral solution
40818244|NCT05434065|DRUG|Celecoxib 200mg|Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
40818245|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule|Qing Re Huo Xue (QRHX) granule 10g bid for 24 weeks
41336737|NCT02142855|BEHAVIORAL|Concentric Exercise Training|8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
41336738|NCT02142855|BEHAVIORAL|Eccentric Exercise Training|8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
41336739|NCT04616092|DRUG|FEFINJECT|FEFINJECT injection
40818246|NCT04170504|DRUG|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
40818247|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule placebo|Qing Re Huo Xue (QRHX) granule placebo 10g bid for 24 weeks
40818248|NCT01948765|DRUG|Xenon and propofol|xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
41336740|NCT02958085|DRUG|NNC0174-0833|Doses of NNC0174-0833, dosed either once daily or once weekly
41336741|NCT02958085|DRUG|Placebo|Dosed either once daily or once weekly
41336742|NCT02653352|BEHAVIORAL|Lifestyle modification|The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
41485396|NCT01393457|DRUG|levodopa/carbidopa|800/200 mg/d
41485397|NCT01393457|DRUG|Ropinirole 2 mg/d|2 mg/d
41485398|NCT01393457|DRUG|Placebo|sugar pill
41485399|NCT01393457|DRUG|Ropinirole 4 mg/d|4 mg/d
40818249|NCT01948765|DRUG|propofol|propofol target controlled infusion (target 1.5-2.5µg/ml)
40818250|NCT03569176|DEVICE|Autism Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents or during ABA therapy.
40818251|NCT02668900|BEHAVIORAL|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
40818252|NCT06482853|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
40818253|NCT06482853|DRUG|Saline|Saline will be used as the placebo comparator.
40818254|NCT06446063|OTHER|Test product|Twice daily applications The product is applied to the entire face.
40818255|NCT06446063|OTHER|Control Product|Twice daily applications The product is applied to the entire face.
40818256|NCT00923975|DEVICE|DIDGET World Web Community Reports|During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
40818257|NCT05056922|BEHAVIORAL|Tele-PCIT|"Families randomized to Tele-PCIT will receive a time-limited version of PCIT via telehealth. The first 5 sessions focus on the child directed interaction (CDI) phase. The first session includes a teaching session where the parent will learn PRIDE/Do skills and Don't skills. The next 4 CDI sessions include coaching where the therapist coaches the parent on the these skills within the context of play. The first PDI session includes a teaching session where parents will be given instructions for providing commands and timeout procedures. During the 4 PDI coaching sessions, the therapist coaches the parent through timeout procedures. Handouts are emailed to families throughout therapy. The treatment period is 12 weeks to complete the 10 sessions to account for scheduling challenges. Families will be provided a Bluetooth headset for sessions. Families who do not have access to a computer, tablet, or smartphone with internet access will be provided with a tablet for therapy use."
41485400|NCT02785224|DRUG|Vasopressin Steroids Epinephrine|Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.
40818258|NCT05056922|BEHAVIORAL|Treatment as Usual|Families randomized to Treatment-as-Usual (TAU) will receive brief feedback and psychoeducation during the baseline visit and will be provided with community resources and referrals as needed. The TAU procedures will reflect the level of care families receive after an ASD assessment or professional consultation in our own clinic. For addressing behavioral concerns specifically, families will be provided handouts on behavior management tips, given access to a webinar workshop reviewing basic behavioral parenting principles, and instructed to engage with available services. The Vanderbilt Treatment \& Research Institute for ASD (TRIAD) Center offers a webinar series for managing challenging behaviors that parents will be directed to along with the Autism Speaks Challenging Behavior Toolkit handouts. The TAU period will be 12 weeks in length to match time specifications for the active treatment condition.
40818259|NCT03155919|DIETARY_SUPPLEMENT|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
40818260|NCT03155919|DIETARY_SUPPLEMENT|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
40818261|NCT00198861|OTHER|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
40818262|NCT02269176|DRUG|Low dose of telmisartan|
40818263|NCT02269176|DRUG|High dose of telmisartan|
40818264|NCT02269176|DRUG|Low dose of losartan|
40818265|NCT02269176|DRUG|High dose of losartan|
40818266|NCT02352272|OTHER|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
40818267|NCT03319953|DRUG|TAK-041|TAK-041 suspension
40818268|NCT03319953|DRUG|Placebo|TAK-041 placebo-matching suspension
41485401|NCT02995876|PROCEDURE|Glaze layer|A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
41485402|NCT02995876|PROCEDURE|E-max Press layer|A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
41485403|NCT00817076|DRUG|desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
41485404|NCT05600504|OTHER|no intervention|no intervention
41485405|NCT03463486|BEHAVIORAL|Physical activity|50min of endurance training combined with 50min of calisthenics; 1-3x/wekk; 6weeks up to 1year
41485406|NCT01775436|BEHAVIORAL|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care \& prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
41015919|NCT05676385|DIETARY_SUPPLEMENT|Reference product (containing 50 grams of carbohydrates)|Fasted intake of Reference product (randomised)
41015922|NCT05364554|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
41015925|NCT05795023|OTHER|NeuraLight|NeuraLight software-based platform
41015926|NCT06462690|OTHER|pre-mid-post test|(PIF) (DLQI) (GCS) Data Collection Forms Humidity measurement with DMM device
40818269|NCT03319953|DRUG|Second Generation Antipsychotics (SGA)|Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
40818270|NCT01097642|DRUG|Cetuximab|Cetuximab will be given at 400mg/m\^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m\^2 IV over 60 minutes.
40818271|NCT01097642|DRUG|Ixabepilone|Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
41336743|NCT01522768|DRUG|Afatinib and Paclitaxel|All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m\^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
40818272|NCT00664313|DRUG|Linezolid|600 mg po daily for 112 doses (16 weeks)
41336744|NCT05373316|RADIATION|Ultrahypofractionated MR-guided radiotherapy boost|External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MRI.
40818273|NCT00664313|DRUG|Placebo|Placebo given daily for 112 doses (16 weeks)
40818274|NCT05365568|PROCEDURE|Left Bundle Branch Area Pacing (LBBAP)|Left bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy
40818275|NCT05365568|PROCEDURE|Biventricular pacing (BiV)|Cardiac resynchronization therapy (CRT) using biventricular pacing (BiV)
40818276|NCT00519376|DRUG|GW642444M|drug
40818277|NCT00519376|DRUG|GW642444H|drug
40818278|NCT00519376|DRUG|placebo|
40818279|NCT04685005|DIETARY_SUPPLEMENT|"Wake Up"|The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up
41336745|NCT06434038|DRUG|Low Dose Regular insulin|Administered intranasally at 40 IU
41336746|NCT06434038|DRUG|High Dose Regular insulin|Administered Intranasally at 80 IU
41336747|NCT06434038|OTHER|0.9% Saline|Placebo control
40818280|NCT04685005|DIETARY_SUPPLEMENT|Caffeine|Caffeine
40818281|NCT04220242|OTHER|Video recordings with analysis thereafter applied|Recordings of surgical assessments in order to develop a model for Artificial Intelligence analysis
40818282|NCT04220242|OTHER|Examination of microsections of tissue excised for the purposes of cancer resection|Microscopic examination including by near-infrared examination of some of the tissue excised for the purposes of cancer resection to examine cellular mechanisms of fluorescence uptake and distribution
40818283|NCT04220242|OTHER|Cancer organoid development and testing|Some tissue will be taken from the specimens excised for the purposes of the cancer operation to develop experimental models of cancer tissue to allow examination of mechanisms of uptake and distribution of the fluorophores in cancer
40818284|NCT01932151|DRUG|Terlipressin and albumin|"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."
40818285|NCT05678205|DRUG|AB-201|NK Cell Therapy
40818286|NCT05678205|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
40818287|NCT05678205|DRUG|Fludarabine|Lymphodepleting chemotherapy
40818288|NCT03315793|DRUG|Duloxetine Hydrochloride|Administered orally
40818289|NCT03315793|DRUG|Placebo|Administered orally
40818290|NCT02645643|OTHER|Education of medical humanities|The medical students in the intervention group would gain education about the medical humanities, but not the control group.
40818291|NCT01065051|DRUG|Riociguat (Adempas, BAY63-2521)|1 mg single oral dose
40818292|NCT01065051|DRUG|Placebo|Single oral dose
40818293|NCT05585684|OTHER|Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection|Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.
40818294|NCT02387905|PROCEDURE|Management of Therapy Complications|Undergo vertebral body cement augmentation
40818295|NCT02387905|OTHER|Quality-of-Life Assessment|Ancillary studies
40818296|NCT02387905|OTHER|Questionnaire Administration|Ancillary studies
41018036|NCT06570018|PROCEDURE|Post operative enhanced recovery elements|According to the study group the researchers collaborated with surgeons, nurses, and anesthesiologists to implement post operative enhanced recovery protocol that defined clearly in the following elements Early nutrition, Early mobilization, Non-opioid analgesia. Early removal of abdominal drains and tubes throughout the patients' hospital stay up to their discharge.
40818297|NCT02387905|RADIATION|Stereotactic Radiosurgery|Undergo standard stereotactic spinal radiosurgery
41018037|NCT05286905|DEVICE|Osteosynthesis cephalomedullary nail|Osteosynthesis of reverse oblique peritrochanteric fractures with cephalomedullary nail
41018038|NCT05286905|DEVICE|Osteosynthesis proximal femur locking plate|Osteosynthesis of reverse oblique peritrochanteric fractures with proximal femur locking plate
41336748|NCT00910013|DRUG|Ropivacaine|0.5% intra-articular ropivacaïne (20cc)
41336749|NCT02676453|OTHER|Intervention|Dental hygienist support
41336750|NCT05347771|DRUG|Dupilumab|Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).
41336751|NCT05347771|DRUG|Placebo|The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
41336752|NCT03682055|DRUG|VK-2019|EBNA1 inhibitor
41336753|NCT02583997|PROCEDURE|Suturing of lower alveoli|After extraction of wisdom teeth, the lower alveoli are sutured closed.
41336754|NCT02583997|PROCEDURE|Non suturing of lower alveoli|After extraction of wisdom teeth, no alveoli are sutured closed.
41336755|NCT06236763|DEVICE|TOFscan foot|TOFscan will be applied on the foot and recovery from neuromuscular blockade will be observed over time. These will be compared with the control (TOFscan at the hand) on the same patient (gold standard monitor).
40818298|NCT05504304|PROCEDURE|open reduction and internal fixation plus primary subtalar arthrodesis|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
40818299|NCT05504304|PROCEDURE|conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
41018039|NCT00377676|DRUG|Cycloset|Usual diabetes therapy plus Cycloset
41018040|NCT00377676|DRUG|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
41018041|NCT01459406|DIETARY_SUPPLEMENT|Glucose|500 ml water drink containing 40g glucose
41018042|NCT01459406|DIETARY_SUPPLEMENT|Fructose|500 ml water drink containing 40g fructose
41018043|NCT01459406|DIETARY_SUPPLEMENT|Fructan|500 ml water drink containing 40g fructan
41018044|NCT01459406|DIETARY_SUPPLEMENT|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
41336756|NCT01983878|DRUG|Ramucirumab|Administered IV
41336757|NCT01187134|BEHAVIORAL|Change Management|Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
41336758|NCT03984812|DRUG|GSK3732394|It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL
41336759|NCT03984812|DRUG|Placebo|Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.
41336760|NCT04208217|BEHAVIORAL|Modeling to Learn (MTL)|Modeling to Learn is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
41018045|NCT00111644|DRUG|Ceftriaxone|1000mg iv daily
41018046|NCT00111644|DRUG|beta-lactam|750mg iv q 23h for 3-14 days
41018047|NCT00111644|DRUG|beta-lactam|1500mg iv q 12h for 3-14 days
40818300|NCT01796119|PROCEDURE|Ridge Splitting|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
40818301|NCT01796119|PROCEDURE|Implants placed using drilling technique|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
40818302|NCT05475665|DRUG|Irbesartan/Amlodipine|Irbesartan/Amlodipine once daily for 8 weeks
40818303|NCT05475665|DRUG|Irbesartan|Irbesartan once daily for 8 weeks
40818304|NCT05867433|BEHAVIORAL|STHS Intervention|"STHS program~The intervention group (10 schools) will participate in the STHS program. During the fall semester (September to December), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that provide education on civic engagement, healthy eating, and physical activity. During the spring semester (February to May), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that focus on implementing the school health environmental change project and receive support for maintaining individual-level healthy eating and physical activity behaviors."
40818305|NCT05867433|BEHAVIORAL|Usual Care|"No STHS program~The usual care group will be offered the same activities as the intervention group after the conclusion of the research study."
40818306|NCT06588530|BIOLOGICAL|TENIVAC|TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed) is an active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older.
40818307|NCT01344681|DRUG|Micafungin sodium|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~3. Administration Method:~   * Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever."
40818308|NCT01344681|DRUG|Itraconazole|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~3. Administration Method:~   * Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever."
40818309|NCT04331340|OTHER|Pharmacist review of LUTS|Pharmacist review and recommendations, including education, behaviour, lifestyle, or medications
40818310|NCT04331340|OTHER|Pharmacist Provision of healthy aging leaflets|Pharmacist will inquire about presence of LUTS and provide patient with healthy aging leaflets
40818311|NCT06277700|OTHER|Chiropractic Manipulation (HVLA - high velocity low amplitude)|Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.
41485407|NCT01775436|BEHAVIORAL|Healthy Living Control|"Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
41485408|NCT05980741|PROCEDURE|high-quality nursing|High-quality nursing
41485409|NCT05980741|PROCEDURE|Clinical Care Pathway|Clinical Care Pathway
41485410|NCT05980741|PROCEDURE|Roy Adaptation Model|Roy Adaptation Model
40818312|NCT06277700|OTHER|Dynamic Neuromuscular Stabilization|Participants in the groups receiving DNS exercise therapy will be given individualized exercises under the supervision of a physiotherapist. First, the participants were taught posterior diaphragm activation in the supine position and the ability to direct the intraabdominal pressure caudally, while preventing the cranial movement of the thorax, so that the chest and pelvis are in a neutral position and the thoracic diaphragm and pelvis are aligned in parallel. Participants will then be taught the ability to perform a chin tuck without disturbing the alignment of the rib cage. In this way, the cervical diaphragm, thoracic diaphragm and pelvic diaphragm will be aligned in parallel. Our aim in this alignment will be to activate the deep stabilizers as a reflex response to intra-abdominal pressure change with the correct diaphragm movement pattern. Participants will be asked to focus on and maintain this alignment throughout the entire DNS exercise pattern.
40818313|NCT01730326|DRUG|Paracetamol|1000 mg
40818314|NCT01730326|DRUG|Dexketoprofen|50 mg
40818315|NCT00728247|PROCEDURE|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
40818316|NCT05455918|DRUG|TIP treatment (paclitaxel/ifosfamide/cisplatin)|Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2\~5 (total 6g/m2) Cisplatin 25mg/m2/day D2\~5 (total 100mg/m2)
41015931|NCT06176027|DRUG|Azacytidine plus CAOLD regimen|Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1; pegaspargase 2500iu/m2 qd d2; dexamethasone 7.5mg/m2 qd d1-d5)
41336761|NCT04208217|BEHAVIORAL|Usual quality improvement (QI)|Usual quality improvement is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
40818317|NCT05475483|DRUG|SOM3355 capsules|Treatment will be blind for the whole duration of the study.
40818318|NCT05475483|DRUG|Placebo capsules|Treatment will be blind for the whole duration of the study.
41015935|NCT02203526|DRUG|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)
41485411|NCT01130636|DRUG|Oseltamivir|Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
41156397|NCT06401005|DRUG|Cadonilimab (AK104)|8Gy\*3 SBRT to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK104 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of albumin paclitaxel (260mg/m2, d1, Q3W) and carboplatin (AUC=6, d1, Q3W) were administered, followed by four cycles of sequential Doxorubicin 50mg/m2/d1 (Q3W) + Cyclophosphamide 600mg/m2/d1, Q3W for 4 cycles. Postoperative completion of 9 cycles of immunotherapy was continued ± the need for postoperative adjuvant radiotherapy was confirmed based on the patient's preoperative status.
41156398|NCT02389725|DEVICE|disposable elastic tourniquet|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
41156399|NCT02389725|DEVICE|blood pressure cuff|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
41156400|NCT02278133|DRUG|WNT974|
41156401|NCT02278133|DRUG|LGX818|
41336762|NCT01999712|PROCEDURE|Echocardiography|Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
41336763|NCT01952704|BEHAVIORAL|Aerobic exercise|
41336764|NCT01952704|BEHAVIORAL|Placebo control|Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
41336765|NCT01851525|DEVICE|ThermoCoolSmartTouch ablation catheter, Biosense Webster|
41336766|NCT05458362|BEHAVIORAL|Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST)|"Group BEAST consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.~Only the EMI group will receive EMI prompts and intervention."
41336767|NCT05458362|BEHAVIORAL|Control group Anxiety Sensitivity Treatment|Control group Anxiety Sensitivity Treatment consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.
41336768|NCT01428440|RADIATION|18FML10|apoptosis imaging radio ligand
41336769|NCT05243147|DEVICE|nasal stents|using nasal stents after septoplasty
41336770|NCT05243147|DEVICE|merocel|using merocel after septoplasty
41336771|NCT02156752|BEHAVIORAL|ACT|Treatment is based on Acceptance and Commitment Therapy
41336772|NCT02156752|BEHAVIORAL|SR|Treatment is based on Self-Regulation theory.
41336773|NCT02156752|BEHAVIORAL|WLO|Treatment is based on cooking tips and demonstrations.
41336774|NCT01985165|DRUG|Imrecoxib|
41336775|NCT00833807|DRUG|Nab-Paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
41336776|NCT00611767|DRUG|Thiopental|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
41336777|NCT00611767|DRUG|Placebo|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
41156402|NCT02278133|BIOLOGICAL|Cetuximab|
41336778|NCT02671760|DRUG|SM-1|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
41336779|NCT02671760|DRUG|Comparator|2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
41336780|NCT02671760|DRUG|Placebo|Placebo
41336781|NCT01482455|OTHER|Elevation of FFA during OGTT|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1"
41336782|NCT01482455|OTHER|Elevation of FFA during Clamp|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1."
41336783|NCT06409767|OTHER|Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.|The calculation of NEWS requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. Each parameter used to calculate the NEWS will be collected least three times a day by the attending nurse.
41336784|NCT00333424|BIOLOGICAL|pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine|6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
41336785|NCT03907969|DRUG|AZD7648|Core: AZD7648 will be administered orally
41336786|NCT03907969|DRUG|PLD|The starting dose of PLD is 40 mg/m\^2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles
41336787|NCT02560493|BEHAVIORAL|Exergaming Condition|Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
41336788|NCT01802515|DRUG|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
41336789|NCT01802515|DRUG|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
41336790|NCT01802515|DRUG|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
41336791|NCT04994522|DRUG|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
41336792|NCT03964506|DRUG|Hyperbaric oxygen|Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
41015936|NCT02203526|DRUG|TEDDI|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)
41015937|NCT02203526|BIOLOGICAL|Rituximab|Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)
41015938|NCT02203526|DRUG|Cytarabine|Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)
41015939|NCT02203526|DRUG|TEDD|Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle (Arm 1-A)
40818319|NCT04852042|BEHAVIORAL|mHealth|Participants will receive 2-3 text messages daily. The messages will include information to promote healthy eating and physical activity.
41015940|NCT02203526|DRUG|Ibrutinib (Arms 2, 3 and 4)|Ibrutinib given on day -3 to day -1 on cycle 1 (Arms 2, 3 and 4)
41015941|NCT02203526|DRUG|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-6 (Arm 4)
41015942|NCT02203526|DRUG|Ibrutinib (Arm 1 - Closed with Amendment G)|Ibrutinib given on day -14 to day -1 on cycle 1 (Arm 1)
41015943|NCT02203526|DRUG|Ibrutinib (Arm 4)|Ibrutinib given on days 1-10 for cycles 1-6 (Arm 4)
41336793|NCT00618904|DIETARY_SUPPLEMENT|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
41336794|NCT00618904|DIETARY_SUPPLEMENT|Placebo|Placebo administered bid for 6 weeks.
41336795|NCT03658317|DIAGNOSTIC_TEST|renal arterial resistive index|done by dupplex on renal arteries
41336796|NCT03658317|DIAGNOSTIC_TEST|uric acid level|serum sample for doing the test
41336797|NCT03658317|DIAGNOSTIC_TEST|serum urea and creatinine|serum samples for doing the test
41336798|NCT03658317|DIAGNOSTIC_TEST|24 hours urinary proteins|urine collected over 24 hours for doing the test
41336799|NCT03658317|DIAGNOSTIC_TEST|lipogram|serum sample for doing the test
41336800|NCT03658317|DIAGNOSTIC_TEST|HbA1c level|serum sample for doing the test
41336801|NCT03658317|DIAGNOSTIC_TEST|urine analysis|urine sample for doing the test
41336802|NCT03658317|DIAGNOSTIC_TEST|abdominal ultrasonography|done by the ultrasonography device
41336803|NCT04801641|DRUG|Placebo|Six placebo capsules taken orally twice daily
41336804|NCT04801641|DRUG|Nabilone|Titrated to two 0.5 mg capsules and four placebo capsules taken orally twice daily (Low-Dose) OR Titrated to six 0.5 mg capsules taken orally twice daily (High-Dose)
41336805|NCT01804842|DRUG|Met DR|metformin delayed-release tablets
41336806|NCT01368952|DEVICE|Pure prone positioning|Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
41336807|NCT01554189|DRUG|MK-8325|MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
41336808|NCT01554189|DRUG|Placebo|Placebo to match MK-8325 capsules, orally, once per day for 5 days
41336809|NCT02989480|RADIATION|PET CT|PET CT scans
41336810|NCT02989480|OTHER|Cardiac MRI|Cardiac MRI
40818320|NCT04852042|BEHAVIORAL|CHW support|The CHW will provide behavioral counseling to participants guided by a study website related to their healthy eating and physical activity goals.
40818321|NCT03118427|PROCEDURE|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
41015955|NCT04389632|DRUG|sigvotatug vedotin|Administered into the vein (IV; intravenously)
41015956|NCT04389632|DRUG|pembrolizumab|200mg every 3 weeks or 400mg every 6 weeks, given by IV
41015957|NCT04389632|DRUG|cisplatin|75 mg/m2 every 3 weeks, given by IV
41015958|NCT04389632|DRUG|carboplatin|AUC 5 mg/mL per min every 3 weeks, given by IV
41336811|NCT00550290|DRUG|Cefazolin PostOperatively|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
41336812|NCT00550290|DRUG|Cefazolin Preoperatively|Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
41336813|NCT05198427|OTHER|review of medical patient file|"The outcome measure is the evolution of HPV related lesions between :~* favourable evolution including partial or total regression~* unfavourable evolution including non-evolution or aggravation or recurrence."
41015964|NCT06013969|DRUG|Spesolimab|Spesolimab intravenous (i.v.) infusion
41015965|NCT02944071|DEVICE|Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter|
41015966|NCT04687774|DEVICE|ExaltTM Model D Single-Use Duodenoscope|The Exalt™ Model D Single-Use Duodenoscope is a sterile, single-use endoscope that facilitates access to the duodenum, delivery of accessories, and live video when connected to an Exalt™ Controller.
41015973|NCT02379416|DRUG|Nilotinib + Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
41336814|NCT05226767|DIETARY_SUPPLEMENT|NLC-V|NLC-V
41336815|NCT04657445|DIAGNOSTIC_TEST|visual analogue scale|A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
41336816|NCT03355768|DRUG|Romidepsin|Intravenous administration on a 28 day cycle
41336817|NCT03355768|DRUG|Pralatrexate|Intravenous administration on a 28 day cycle
41336818|NCT01033604|PROCEDURE|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
41336819|NCT01033604|PROCEDURE|Split skin graft alone.|Full thickness defects treated with split skin graft alone.
40818322|NCT03118427|PROCEDURE|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
41015976|NCT03964233|DRUG|BI 907828|Film-coated tablets
41015977|NCT03964233|DRUG|ezabenlimab|Solution for infusion
41015978|NCT03964233|DRUG|BI 754111|Solution for infusion
41015981|NCT06526884|OTHER|Next Day Clinic|A dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative.
41015993|NCT06383364|BEHAVIORAL|Medication Coordinator|The Medication Coordinator calls the patient app seven days after discharge in the transition of care from hospital to home
41336820|NCT00430885|DRUG|Octagam (IVIG)|Intravenous immunoglobulin 0.4 g/kg given as infusion
41336821|NCT01774292|PROCEDURE|Endotracheal intubation with injection of liquid in the cuff|
41336822|NCT01502670|DRUG|18F-FACBC Radiotracer|Test radiotracer uptake in lung nodule
41336823|NCT03991936|DRUG|Placebos|Normal saline intralesional injection
41336824|NCT03991936|DRUG|Triamcinolone Acetonide 2.5 mg/mL|2.5 mg/mL intralesional injection
41336825|NCT03991936|DRUG|Triamcinolone Acetonide 5.0 mg/mL|5.0 mg/mL intralesional injection
41336826|NCT03991936|DRUG|Triamcinolone Acetonide 7.5 mg/mL|7.5 mg/mL intralesional injection
41336827|NCT03991936|DRUG|Triamcinolone Acetonide 10 mg/mL|10 mg/mL intralesional injection
41015999|NCT02072850|DEVICE|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
41016000|NCT02072850|OTHER|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (\~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (\< 12 hours, days 2, 7-10 and at 6 months).
41016003|NCT06021353|DEVICE|UV fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
41016004|NCT06021353|DEVICE|IR fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
41016005|NCT06021353|PROCEDURE|LASIK|Laser-assisted in situ keratomileusis (LASIK) surgery
41016009|NCT06539026|OTHER|fluid therapy, 300 ml of crystalloid Ringer's solution.|"300 ml by dripping within 30 minutes, the fluid will be repeated by half the amount if needed to reach equal or less than 50% collapsibility.~the fluid that will be used is sterile Ringer's solution which is an isotonic intravenous solution with pH 5.0 - 7.5 and an osmolality of 308mOsmol/kg."
41016012|NCT03603795|DRUG|Eltrombopag|Eltrombopag concomitant with induction chemotherapy in patient with AML
41016013|NCT03603795|DRUG|Placebo|Placebo concomitant with induction chemotherapy patients with AML
41016020|NCT01174108|DEVICE|Miltenyi CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.
41016021|NCT01174108|OTHER|Donor derived G-CSF mobilized PBC|Cell Therapy
40818323|NCT02083705|PROCEDURE|CC+SI|Chest compression will be superimposed by sustained inflation during CPR
40818324|NCT02083705|PROCEDURE|3:1 CPR|CPR using 3:1 ratio (control group)
41156403|NCT05388864|BEHAVIORAL|Three-Tier Model|Families in the intervention will be counseled by a pediatric provider about ACEs, resilience, stress management, and healthy relationships. Families will also be referred to community health workers and parenting educators.
41156404|NCT04245878|OTHER|gastric ultrasound|gastric ultrasound for measurement of the antral area
40818325|NCT00064259|BIOLOGICAL|oblimersen sodium|Given IV
40818326|NCT00064259|DRUG|cisplatin|Given IV
41016032|NCT04421014|DIETARY_SUPPLEMENT|Ketone Ester drink|The main ingredient of the Ketone Ester drink \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)\] is regulated as GRAS (Generally Recognized as Safe) substance by the FDA (https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices\&amp;id=515). The Ketone Ester compound is already being sold in the market as a ketogenic supplement and is especially popular among athletes, such as cyclists (sold by the official website of the company TdeltaS(R) Global (https://www.deltagketones.com/products/g-ketone-performance). The dose and formulation (25 g of KE contained in 59 ml of a drink), daily scheme (3 times daily) and total duration (28 days) are identical to a previous safety human study. The Ketone Ester drink provided by DeltaG will be repackaged by the NIA Pharmacist into new bottles identical to the ones that will be used for the placebo to ensure the blinding of participants and researchers to the drink.
41016033|NCT04421014|DIETARY_SUPPLEMENT|Placebo: isocaloric dextrose drink|The main content of the Placebo will be an aqueous solution containing approximately 35 g of dextrose, a fruity flavor powder and stevia. We will also add Denatonium Benzoate (Bittrex) to match the bitterness of the Ketone Ester drink. The placebo will be prepared and dispensed by the NIA Pharmacist.
41016034|NCT00500994|DEVICE|MRI|The imaging study will use a block design to (i) optimize amygdala activation to emotionally valenced images, (ii) to optimize analysis of PPI and (iii) to optimize the go/no-task design. G. T2-sensitive functional images will be obtained on a MRI system with a 1.5 Tesla superconducting magnet and a standard head coil. An echo planar image sequence (TR=2500msec, TE=33 msec, 90 flip angle) with 30 contiguous 2mm thick coronal oblique slices with 1 mm interslice gap centered over the amygdala, tilted 30 to the anterior, to improve susceptibility artifact. Three-dimensional anatomical images will be taken for the co-registration of the functional images.
41016035|NCT05267171|OTHER|Web access|The intervention group will have access to the website where the information is provided. The control group will not have this access.
41336828|NCT05165706|BEHAVIORAL|Dietary Intervention Mediterranean Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
41485412|NCT05558995|OTHER|ketogenic diet|All the subjects will be instructed by a nutrition professional to have at least 3 meals per day consisting of 20 g to 30 g of carbohydrate in the form of green vegetables and salad, and 80 g to 100 g of protein in the form of meat, fish, fowl, eggs, shellfish and cheese for 12 weeks. Polyunsaturated and monounsaturated fats will also be included in the diet. Micronutrients (vitamins and minerals) will be given to each subject in the form of one capsule per day. The adherence to diet will be confirmed weekly through a food log and urinary ketones assessment using dipstick to ensure that all individuals remain in a ketotic state.
41485413|NCT05134896|DEVICE|Spatial light modulator|This device compensates for the eye's optical imperfections (aberrations) at the foveal and peripheral retina.
40818327|NCT00064259|DRUG|fluorouracil|Given IV
41485414|NCT00033904|DRUG|autologous human tumor-derived HSPPC-96|
41485415|NCT01062737|DRUG|ASU|
41485416|NCT00005965|DRUG|bryostatin 1|
41485417|NCT00005965|DRUG|cisplatin|
41485418|NCT05012865|DRUG|avelumab|as provided in real world practice
41485419|NCT05012865|DRUG|axitinib|as provided in real world practice
41485420|NCT01933464|DRUG|Cromolyn Sodium|
41485421|NCT01933464|DRUG|Normal Saline|
41485422|NCT05054322|DRUG|Fluticasone Propionate|Fluticasone propionate added to usual care, total dose 1000 mcg per day for 14 days
41485423|NCT03262506|OTHER|Computerized cognitive training|The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
41016036|NCT04846881|DRUG|Iclepertin|Iclepertin
41336829|NCT05165706|BEHAVIORAL|Dietary Intervention Standard Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
41336830|NCT05165706|BEHAVIORAL|Dietary Intervention Standard Low Fat Diet|Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
41485424|NCT05753670|DRUG|Tamsulosin|Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
41485425|NCT05753670|DRUG|Placebo|Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
41485426|NCT00211120|DRUG|Epoetin Alfa|
41016037|NCT04846881|DRUG|Placebo|Placebo
41016038|NCT05407714|DEVICE|SpaceOAR Treatment|"SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time."
41016039|NCT03519230|DRUG|Pamiparib capsule|60 mg twice daily (BID), orally (per os-PO)
41016040|NCT03519230|DRUG|Placebo capsule|60mg BID, PO
41016041|NCT02979873|DRUG|Sirolimus|Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).
41336831|NCT01155960|DRUG|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
41485427|NCT03511170|DRUG|XELIRI|Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle
41485428|NCT03511170|DRUG|XELOX|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
41485429|NCT04013230|BEHAVIORAL|Usual care|Visit doctor and nurse at the clinic.
41485430|NCT04013230|BEHAVIORAL|Web-COP|Usual care plus group sessions and a web-based treatment program for 12 weeks for the child and parents.
41485431|NCT01714375|DEVICE|QuietDose Device|"The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss."
41485432|NCT00857584|DRUG|Extended release quetiapine (quetiapine XR)|"Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.~Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study."
41485433|NCT00857584|DRUG|Sertraline|"Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.~Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study."
41016042|NCT06139328|DRUG|BI 765845|BI 765845
41016043|NCT06139328|DRUG|Placebo matching BI 765845|Placebo matching BI 765845
41016044|NCT06149637|PROCEDURE|Traditional neck dissection approach|.1. A transverse cervical incision is made with horizontal extension towards the affected side. 2. It is dissected through the subplatysmal plane, the posterior edge of the sternocleidomastoid muscle is dissected along its entire length. 3. Identification and dissection of the spinal nerve at Erb's point. 4. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it 5. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level 6. Identification and dissection of level III nodes 7. Identification and dissection of level IIA and IIB ganglia with identification and preservation of the accessory nerve.
41016045|NCT06149637|PROCEDURE|Anterior neck dissection approach|"1. A transverse cervical incision is made with horizontal extension towards the affected side.~2. It is dissected through the subplatysmal plane, the anterior edge of the sternocleidomastoid muscle is dissected along its entire length.~3. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it~4. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level~5. Identification and dissection of level III nodes~6. Identification and dissection of level IIA and IIB nodes with identification and preservation of the accessory nerve."
41016046|NCT04540861|DRUG|Siponimod|1 or 2 mg film-coated tablets. The tablets have to be taken orally once daily and swallowed whole with water, with or without food.
41016047|NCT06390865|PROCEDURE|Biopsy|Undergo biopsy
41016048|NCT06390865|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41016049|NCT06390865|PROCEDURE|Computed Tomography|Undergo CT scan
41016050|NCT06390865|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41016051|NCT06390865|DRUG|Sapanisertib|Given PO
41016052|NCT03097419|PROCEDURE|Remote post-ischemic conditioning|"A manual sphygmomanometer will be inflated over the brachial artery of the participants' arm that does not have an intravenous catheter actively infusing medications. If both arms are in use, then the participant's non-dominant arm will be used.~* The sphygmomanometer will be inflated to a pressure at least 20 mmHg greater than the participants' last recorded systolic blood pressure.~* The sphygmomanometer will be inflated for 5 minutes then rapidly deflated for 5 minutes, thereby concluding one iteration.~* Five (5) total iterations constitute the treatment.~* The left arm will be preferentially used instead of the right arm, unless the left arm is receiving medication administration."
41016053|NCT05762666|DEVICE|nociception level index monitor|The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
41016057|NCT05386108|DRUG|Elacestrant|300 mg, 400 mg
41016058|NCT05386108|DRUG|Abemaciclib|100 mg, 150 mg
41016059|NCT04277637|DRUG|BGB-11417|Film-coated tablets administered once daily at a dose as specified in the treatment arm
41016060|NCT04277637|DRUG|Zanubrutinib|320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)
41016061|NCT04277637|DRUG|obinutuzumab|Given as an intravenous infusion administered per label.
41336832|NCT04251819|DRUG|Placebos|Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
41336833|NCT04251819|DRUG|Baclofen 5 mg|Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
41336834|NCT04251819|DRUG|Baclofen 10mg|Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
41336835|NCT01352845|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
41336836|NCT01352845|OTHER|Placebo|0.5 mL dose, given at 0, 2 and 6 months
41016064|NCT03766763|DRUG|Venetoclax|"Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day.~* For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ).~* For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment)."
41016065|NCT01461590|OTHER|Whole blood|30mls/kg transfused over fours hours
41016066|NCT01461590|OTHER|Whole blood|20mls/kg transfused over four hours
41016067|NCT06046638|DRUG|Cyclopofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
41016068|NCT06046638|DRUG|Propofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
41016069|NCT03198611|DIAGNOSTIC_TEST|Echocardiography|Usual echocardiographic studies in patients suffering septic shock
41016070|NCT00059904|BIOLOGICAL|aldesleukin|
41016071|NCT00059904|BIOLOGICAL|rituximab|
41016072|NCT02505126|DEVICE|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
41016073|NCT02505126|DEVICE|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
41016080|NCT05599048|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
41016081|NCT05599048|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
41016082|NCT00732121|DRUG|Sitagliptin|100 mg daily for 4 weeks
41016083|NCT00732121|DRUG|Placebo|Placebo
41016084|NCT06075602|DEVICE|Impact of current PCI techniques/ devices in complex coronary artery lesions|To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions
41016085|NCT01117116|DRUG|fluticasone propionate and salmeterol|45/4.5 two puffs twice daily
41016086|NCT01117116|DRUG|budesonide and formoterol|80/4.5 two puffs twice daily
41016087|NCT05227651|DRUG|AK104|IV infusion,Specified dose on specified days
41016088|NCT00983814|DRUG|Droxidopa+Carbidopa|3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo
41016089|NCT05458349|DEVICE|acellular dermis|
41016090|NCT05848635|DRUG|Hydromorphone Hydrochloride|Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation
41016091|NCT05848635|DRUG|Morphine hydrochloride|Drug: Morphine Hydrochloride Morphine hydrochloride injection is used for perioperative lung tumor ablation
41016092|NCT03917381|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).
41156405|NCT02617667|DRUG|Cyclosporine A|topical ocular, eye drops
41336837|NCT04518020|PROCEDURE|40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA|40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).
41485434|NCT00857584|DRUG|adequate mood stabilizer|An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
41016093|NCT03917381|BIOLOGICAL|Acasunlimab in combination with docetaxel (in a single expansion cohort)|Acasunlimab and docetaxel will be administered intravenously once every 21 days.
41016094|NCT03917381|BIOLOGICAL|Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)|Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.
41016095|NCT03917381|BIOLOGICAL|Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)|Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.
41016096|NCT01110239|PROCEDURE|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
41016097|NCT06302764|DIAGNOSTIC_TEST|Qualitative & Quantitative Research|"1. Focused interviews - conducted by members of the appointed research team to recognize the issues faced by emergency medical staff in Poland, Ukraine, Portugal, and Spain with the aim of preparing the measurement framework.~2. Online questionnaire surveys - conducted using the Qualtrics platform (available in different, language versions - Polish, Ukrainian, Portuguese, and Spanish)."
41485435|NCT03734666|BEHAVIORAL|Mindfulness Based Relapse Prevention - Smoking and Alcohol|Mindfulness Based Relapse Prevention (MBRP) is a treatment for preventing relapse in addictive disorders that integrates mindfulness meditation with standard relapse prevention practices.
41485436|NCT03734666|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a form of therapy that aims to help individuals modify problematic emotions, behaviors, and thoughts.
41016098|NCT05305794|DRUG|Insulin + semaglutide treatment|Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)
41016099|NCT05305794|DRUG|Usual insulin treatment|Usual insulin treatment
41016100|NCT05305794|BIOLOGICAL|Biological check-up|at D0, D90 and D180
41016101|NCT05039905|DRUG|99mTc-MSA-ICG|Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
41016102|NCT03362515|DRUG|Furosemide|furosemide
41016103|NCT03362515|DRUG|Placebo|placebo
41016104|NCT06211049|DRUG|Vitex agnus-castus BNO 1095 (20 mg)|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
41016105|NCT06211049|DRUG|Placebo|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
41016106|NCT01879397|DEVICE|Research Ultrasound Exam|"Collection of backscattered ultrasound data during non-invasive ultrasound exam~* ARFI based images of the carotid artery and plaque~* Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam."
41156406|NCT02617667|DRUG|Placebo|topical ocular, eye drops
41485437|NCT05705817|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|The ASSET program is a 15-session training program that combines specific skill training, structured learning, social performance training and a social hour to practice skills through a manualized group intervention. Specific skills taught within the program include communication, enthusiasm and attitude, teamwork, networking, problem-solving and critical thinking, and professionalism.
41016107|NCT05877586|OTHER|CLARE app|"CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge."
41016108|NCT05451212|BIOLOGICAL|MuSK-CAART|Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.
41016112|NCT06008301|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.
41016113|NCT04261816|PROCEDURE|extubation in the operating room|Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation
41336838|NCT03373318|DRUG|Human albumin|Single dose as a primer for the CEC, in sufficient quantity to reach a concentration of 4% of the total volume of priming.
41016114|NCT04261816|PROCEDURE|extubation in the ICU|Patients who underwent liver transplantation extubation in the ICU following liver transplantation
41336839|NCT03373318|DRUG|Plasmalyte|The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
41336840|NCT04121572|DEVICE|Nasal cannula capnography|Capnography: a continuous wave form of the CO2 level with the digital reading of CO2 level at end of expiration
41336841|NCT00383877|DRUG|insulin detemir|
41016123|NCT06573021|DRUG|Near-infrared fluorescent cholangiography|For intra-operative fluorescent cholangiography, 2.5 mg indocyanine green (ICG, Pulsion Medical Inc., Irving, Tx) was administered intravenously 45-60 min prior to surgery, according to the recent guidelines from the International Society for Fluorescence Guided Surgery (ISFGS) and the latest consensus conference published in 2021.
41156407|NCT06646211|DRUG|Zanubrutinib , Thiotepa|"First 1-4 cycle~Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 1 for up to 4 cycle Drug: Zanubrutinib~* Zanubrutinib will be given at a dose of 160mg，bid，d1-d21"
41336842|NCT00383877|DRUG|insulin NPH|
41336843|NCT01385319|DEVICE|Bare metal stent implantation|"After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
41485438|NCT06337214|BEHAVIORAL|Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy|Comparing cancer patients who have participated in the program with those who have not, this study will examine differences in two types of quality of life questionnaires and constitution between the two groups.
41485439|NCT05662735|DEVICE|Mesh repair|Augmentation of hiatal hernia repair with TiMESH® reinforcement
41485440|NCT05662735|PROCEDURE|Suture repair|Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures
41485441|NCT02104336|DRUG|EPI-743|EPI-743 is the quinone oxidation product of alpha-tocotrienol
41485442|NCT01249365|BIOLOGICAL|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
41485443|NCT01913236|OTHER|Implementation intervention|Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
41485444|NCT00539357|DEVICE|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
41485445|NCT01458106|DRUG|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
41336844|NCT01385319|DEVICE|zotarolimus eluting stent|"After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
41336845|NCT05150795|DRUG|Pregabalin 150mg|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
41336846|NCT05150795|DRUG|Fentanyl 100 micrograms ampoule|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
41485446|NCT01458106|DRUG|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
41336847|NCT06168890|DIAGNOSTIC_TEST|PET/CT with choline in the restaging phase of prostate cancer.|PET/CT with choline in the restaging phase of prostate cancer in patients suffering from prostate cancer with biochemical recovery of the disease during hormonal therapy.
41336848|NCT05602376|BEHAVIORAL|U=U testing messaging scripts|On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health
41336849|NCT05602376|BEHAVIORAL|U=U adherence messaging scripts|After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.
41336850|NCT03880006|BEHAVIORAL|Case management|Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV. Individuals are assigned to a specific case manager who will provide support throughout the study. The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.
41336851|NCT05986240|DRUG|Danvatirsen|Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).
41485447|NCT03040323|DRUG|Lumason 60.7Mg Powder for Injection|Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
41485448|NCT03040323|DRUG|Placebos|Placebos injected prior to ultrasound-guided biopsy
41485449|NCT05339646|DRUG|SSD8432 dose 1~7 and Ritonavir|"Cohort 1 Period 1 single dose of SSD8432 dose 1 or placebo, on day 1. Period 2: single dose of SSD8432 dose 2 or placebo , on day 7. Period 3: single dose of SSD8432 dose 3 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 2:~Period 1 single dose of SSD8432 dose 4 or placebo, on day 1 Period 2: single doses of SSD8432 dose 5 or placebo , on day 7 Period 3: single dose of SSD8432 dose 6 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 3:~single dose of SSD8432 dose 7 or placebo on day1. ritonavir or placebo, before SSD8432 dose 7 and BID on SSD8432 dosing date."
41336852|NCT05986240|COMBINATION_PRODUCT|Danvatirsen + Venetoclax|"Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).~Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells."
41336853|NCT02478918|OTHER|Phone call|Automated phone call reminder
41336854|NCT00696098|OTHER|sodium butyrate|1 enema (60 ml) once daily containing 100mM
41336855|NCT00696098|OTHER|NaCl|1 enema (60 ml) once daily containing 0.9%NaCl
41336856|NCT01680939|DRUG|Morphine|0.2-0.5 mg/kg PO q4h
41336857|NCT01680939|DRUG|Ibuprofen|10mg/kg PO q6hrs
41336858|NCT02667028|PROCEDURE|PCI|percutaneous coronary intervention
41336859|NCT05007262|DRUG|Tangningtongluo tablets|Four pills each time and three times a day after meals.
41336860|NCT05007262|DRUG|Calcium dobesilate capsules|1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.
41336861|NCT01216345|DRUG|Cetuximab + Gemcitabine + Oxaliplatin|Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks
41336862|NCT05903378|OTHER|Relational touch practice|Relational touch practice during the first bedside session. Touch in care aims to improve the patient's perception of potentially painful or anxiety-provoking acts of care. It is based on techniques of skin contact, developing and deepening.
41336863|NCT00430898|DRUG|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
41336864|NCT00700063|DRUG|PEP005 Topical Gel|0.005%, two days treatment
41336865|NCT00700063|DRUG|PEP005 Topical Gel|0.01%, two days treatment
41336866|NCT00700063|DRUG|PEP005 Topical Gel|0.015%, two days treatment
41485450|NCT05339646|DRUG|SSD8432 dose 8~9|Cohort 4: SSD8432 dose 8 or placebo, on day 1 \~day6. Cohort 5: SSD8432 dose 9 or placebo, on day 1 \~day6.
41485451|NCT05339646|DRUG|SSD8432 dose 10~12 and ritonavir|Cohort 6: SSD8432 dose 10 or placebo, on day 1 \~day6. Cohort 7: SSD8432 dose 11 or placebo, on day 1 \~day6. Cohort 8: SSD8432 dose 12 or placebo, on day 1 \~day6 Cohort 9: to be decided
40818328|NCT04095663|PROCEDURE|Partial Colectomy|Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.
41336867|NCT00700063|DRUG|Vehicle gel|two days treatment
41336868|NCT00700063|DRUG|PEP005 Topical Gel|0.005%, three days treatment
41336869|NCT00700063|DRUG|PEP005 Topical Gel|0.01%, three days treatment
41336870|NCT00700063|DRUG|PEP005 Topical Gel|0.015%, three days treatment
41336871|NCT00700063|DRUG|Vehicle gel|three days treatment
41336872|NCT01041001|BIOLOGICAL|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
41336873|NCT01041001|PROCEDURE|Microfracture treatment|
41336874|NCT00066508|DRUG|bortezomib|
41336875|NCT04839406|BEHAVIORAL|Structured support of caregivers at the ICU|Structured support of caregivers at the ICU provided by a trained group of 10-15 ICU nurses
41336876|NCT04466813|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times."
41336877|NCT04466813|DEVICE|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
41336878|NCT00004467|DRUG|N-acetylcysteine (NAC)|Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.
41336879|NCT00004467|DRUG|Placebo|Infusion of 5% dextrose
41336880|NCT00029289|DRUG|Lutein (10 or 30 mg/day) capsules|
41336881|NCT04445688|DRUG|AD036|Oral administration before bed
41336882|NCT04445688|DRUG|Atomoxetine|Oral administration before bed
41336883|NCT04445688|DRUG|Placebo|Oral administration before bed
41336884|NCT01283867|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
41336885|NCT00303576|DRUG|dapivirine (TMC120) vaginal gel|
41336886|NCT05531513|BEHAVIORAL|Virtual Reality (VR) Meditation|"The VR-Meditation intervention comprises an evidence-based 360-degree high-definition video VR application incorporating elements of nature, mindfulness and compassion. The VR-Meditation intervention is 4 weeks long and includes includes 4 different themes during the course of the program. Each week will focus on a distinct theme and will consist of two 20-minute VR sessions starting with a 10-minute guided meditation related to the weekly theme (one new meditation per week), followed by 10 minutes of open exploration of the virtual environment, for a total of 8 distinct sessions. The weekly themes are as follows:~* Week 1 - Mindfulness of the Environment~* Week 2 - Embodied Mindfulness~* Week 3 - Embodied and Embedded Compassion~* Week 4 - Mindfulness, Compassion, and the External Environment~In addition to baseline measures, participants in the VR Meditation condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
41336887|NCT05531513|BEHAVIORAL|Psychoeducational Pamphlet|"The Psychoeducational Pamphlet intervention is 4 weeks long. Participants receive 1 pamphlet per week for a total of 4 different pamphlets. Handouts will provide information about managing stress and enhancing well-being, without referencing nature, mindfulness or compassion (e.g., eating habits, sleep hygiene, relaxation training, art exercises). The handouts will be based on empirical findings and will be written in accessible language with visual charts and specific practices to facilitate their implementation by participants. At the end of the study (i.e., after follow-up), Psychoeducation Pamphlet participants will receive access to the VR-Meditation program.~In addition to baseline measures, participants in the Psycho-educational Pamphlet condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
41336888|NCT06005272|OTHER|Questionnaire|Interviewer assisted completion of questionnaire.
41336889|NCT04251624|BEHAVIORAL|Goal Management Therapy|A cognitive training program aimed at improving cognitive deficits such as in memory, attention, learning, and executive functioning.
41336890|NCT04251624|BEHAVIORAL|Psychosocial Education|A group therapy program focusing on brain function, neuroplasticity, and lifestyle interventions.
41336891|NCT03556865|OTHER|A self administered questionnaire|"The questionnaire is in English language, it contains binary questions related to KAP on different preventive measures in pediatric dentistry and consists of 38 items divided into 4 sections as follows:~I) Socio-demographic data: (7 items). It includes gender, total years in practice, nature of primary practice, school of graduation, scientific degree and specialty II) Assessment of Knowledge towards preventive measures in pediatric dentistry. (16 items) III) Assessment of Attitude towards preventive measures in pediatric dentistry. (10 items) IV) Assessment of Practice towards preventive measures in pediatric dentistry. (5items) One score is given for each response to items."
41336892|NCT04356872|DRUG|Sintilimab|immune check point inhibitor, 200mg, iv, d1
41336893|NCT04356872|DRUG|Doxorubicin Hydrochloride|ADM, 60mg/m2, iv, d1
41336894|NCT04356872|DRUG|Ifosfamide|IFO, 1.8 g/m2/d, d1-5
41336895|NCT00474006|DRUG|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
41336896|NCT02253472|DEVICE|Deep Brain Stimulation|
41336897|NCT01089218|DRUG|oral amoxicillin/clavulanate 1g (875/125mg)|oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
41336898|NCT01089218|DRUG|control|no intervention with the same procedure of FB
41336899|NCT00656578|DRUG|4975|Single dose, solution
41336900|NCT00656578|DRUG|Placebo|Single dose, solution
41336901|NCT02232724|DEVICE|Choline PET/CT and Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
41336902|NCT03774368|OTHER|Emergency contraception website|Existing website with factual information about emergency contraception
41485452|NCT05339646|DRUG|SSD8432 dose 13 and Ritonavir|"Cohort 10:~Group A: SSD8432 dose 13, on day1 under fasting condition, on day 6 under fatty food condition, ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date.~Group B: SSD8432 dose 13, on day1 fatty food condition, on day 6 under fasting condition ,Ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date"
41485453|NCT05339646|DRUG|SSD8432 dose 14 and Ritonavir|Cohort 11: to be decided
41485454|NCT04736563|DEVICE|Joint and muscle gel Puressentiel|To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.
41485455|NCT00971958|PROCEDURE|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
41336903|NCT03774368|OTHER|Emergency contraception video|Existing video with factual information about emergency contraception
41336904|NCT04459494|PROCEDURE|Flapless implant surgery.|"Local anesthesia will be applied to the patients in the test group, and then the implant socket will be prepared without removing the flap and a dental implant will be placed.~Bite-wing film will be taken to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
41336905|NCT04459494|PROCEDURE|Conventional implant surgery.|"Local anesthesia will be applied to the patients in the control group, and then the implant socket will be prepared after reflecting the flap and a dental implant will be placed.~Patients in the control group will receive a full thickness flap elevation and an implant socket will be prepared afterwards the implant will be placed and then the flap will be closed with 4-0 silk suture.~Bite-wing film will be taken from both groups to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
41336906|NCT02944669|DEVICE|ReWalk Personal Device|
41336907|NCT01408134|OTHER|DE CT|Delayed scan (per VIVA protocol): The delayed scan will be performed 10 minutes after contrast second contrast bolus complete using axial acquisition at 100 kVp. Scan length will be limited to the cardiac structures.
41336908|NCT04273841|DIETARY_SUPPLEMENT|Military Energy Gum|Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.
41336909|NCT04273841|DIETARY_SUPPLEMENT|Placebo Gum|Pellet form placebo gum
41485456|NCT00971958|DEVICE|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
41485457|NCT00971958|DEVICE|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
41336910|NCT04622267|DEVICE|Barbed suture|to close a C-section incision
41336911|NCT04622267|PROCEDURE|Standard antimicrobial suture|to close a C-section incision
41336912|NCT03373344|BEHAVIORAL|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
41485458|NCT00971958|DEVICE|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
41485459|NCT00004421|DEVICE|implanted pulse generator|
41336913|NCT03373344|BEHAVIORAL|Placebo control exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
41336914|NCT05009238|OTHER|lumbar stabilization exercises|selected exercises will taught to participant and practiced 3 times per week for 6 weeks
41336915|NCT01761136|BIOLOGICAL|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
41336916|NCT01761136|BIOLOGICAL|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
41156408|NCT06646211|DRUG|Methotrexate , Thiotepa and Zanubrutinib|"Cycle 5 - 10 Drug: Methotrexate~* Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12 hours after the infusion of methotrexate (MTX) ends, administered every 6 hours until the MTX plasma concentration is ≤ 0.1 μmol·L-¹ at 48 hours; plasma concentration monitoring time points: 0, 6, 24, 48, 72 hours.】 Other Names: MTX Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 5 for up to 10 cycle Drug: Zanubrutinib Zanubrutinib will be given at a dose of 160mg，bid，d1-d21"
41336917|NCT06135389|BIOLOGICAL|Titration of paracetamol and its metabolites - scheme1|15 to 20 minutes and 1 to 2 hours after first perfusion and before second perfusion/administration of paracetamol
41336918|NCT06135389|BIOLOGICAL|Titration of paracetamol and its metabolites - scheme 2|30 to 40' after first perfusion and before second perfusion/administration of paracetamol (residual concentration)
41336919|NCT02021071|RADIATION|XperGuide|Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
41336920|NCT02021071|RADIATION|XperGuide with virtual path planning|Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
41336921|NCT01186367|BEHAVIORAL|Linear Aerobic Training|The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).
41336922|NCT01186367|BEHAVIORAL|Nonlinear Aerobic Training|The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).
41485460|NCT01148641|DIETARY_SUPPLEMENT|LNS|Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days (crossover design) and thereafter, 20 g per day for 14 days.
41485461|NCT01150890|BIOLOGICAL|Brodalumab|Administered as as an intravenous (IV) infusion over at least 30 minutes.
41485462|NCT01150890|DRUG|Placebo|Administered as as an intravenous (IV) infusion over at least 30 minutes.
41485463|NCT03034655|DEVICE|CDP|Vestibular rehabilitation using CDP
41485464|NCT03034655|DEVICE|Mobile posturography|Vestibular rehabilitation using mobile posturography
41485465|NCT03034655|OTHER|10 sessions|Vestibular rehabilitation, ten sessions
41485466|NCT03034655|OTHER|5 sessions|Vestibular rehabilitation, five sessions
41016149|NCT06572839|OTHER|Amnio-Maxx|Amnio-Maxx Dual Layer Amnion Patch is processed using aseptic techniques, treated with a saline solution and dehydrated.
41016152|NCT04471181|DEVICE|Endovascular repair of ruptured abdominal aortic aneurysm (EVAR) with Medtronic Endurant|Endovascular repair (EVAR) of ruptured abdominal aortic aneurysms with Medtronic Endurant II, and IIs device
41016153|NCT05650879|DRUG|ELVN-002|capsule
41016154|NCT05650879|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|intravenous
41016155|NCT05650879|DRUG|Trastuzumab emtansine|intravenous
41016166|NCT06079164|DRUG|KITE-197|A single infusion of CAR-transduced autologous T cells administered intravenously
41016167|NCT06079164|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
41336923|NCT01186367|BEHAVIORAL|Progressive Stretching|All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
41336924|NCT01186367|OTHER|Cardiopulmonary exercise test (CPET)|
41336925|NCT01186367|OTHER|Blood draws|Complete blood count
41336926|NCT02076334|OTHER|Far Infrared Fabric|
41336927|NCT02076334|OTHER|Spandex|
41336928|NCT04165304|DIETARY_SUPPLEMENT|sugar reduction|sugar reduction in the offered drinks
41336929|NCT04598841|DIETARY_SUPPLEMENT|supplement nutritional supporting|Special medical formula for the purpose of formula food
41336930|NCT01948349|OTHER|Tongue scraping|Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.
41336931|NCT01948349|OTHER|Bracket design|Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
41336932|NCT05425524|PROCEDURE|Care Bundle|Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
41336933|NCT00744640|DRUG|gemcitabine, oxaliplatin, capecitabine|gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
41485467|NCT05376670|DRUG|Intravesical aminoglycoside instillations|Overnight instillation of an aminoglycoside (CIC), varying treatment regimens
41485468|NCT05628519|BEHAVIORAL|Captain Sonar Exposition|Captain SonarTM is a naval battle game where two teams each composed of four participants clash. Each player has a well-defined role and it is imperative to communicate in a closed loop to advance in the game. This game also includes components similar to support for Trauma care: stress, speed of action, central communication and teamwork of four protagonists (Team Leader- Captain, intern-Second, nurse-Mechanic, Caregiver-Detector). This short video describes the rules and the Game progress: https://vimeo.com/173614346.
41485469|NCT05628519|BEHAVIORAL|Monopoly Exposition|Participant will be invited to play to Monopoly during 60 min
41485470|NCT05931666|OTHER|Gong Mobilization|"Patients are treated with Gong mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
41485471|NCT05931666|OTHER|Kaltenborn Mobilization|"Patients are treated with Kaltenborn mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
41485472|NCT04041349|DRUG|mouse nerve growth factor|mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
41336934|NCT01300767|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
41336935|NCT01300767|DEVICE|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
41336936|NCT01300767|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
41336937|NCT02283333|BEHAVIORAL|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
41485473|NCT00709436|DRUG|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
41016168|NCT06079164|DRUG|Fludarabine|Lymphodepleting chemotherapy administered intravenously
41485474|NCT00709436|DRUG|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
41485475|NCT03015727|DRUG|Docetaxel|3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.
41336938|NCT02283333|BEHAVIORAL|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
40818329|NCT04095663|OTHER|Medical Management|"Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
41336939|NCT04331925|BEHAVIORAL|Anxiety and depression screening|At the time of consent, the participant parent will be randomized into either the control or intervention groups. The control group will complete the Hospital Anxiety and Depression Scale (HADS) questionnaire at the start of the study. After two weeks or at the time of discharge, the control group will complete the HADS questionnaire again.
41336940|NCT04331925|BEHAVIORAL|Journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period
41336941|NCT04500067|DRUG|IVIG|Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
41336942|NCT02007252|DRUG|ACZ885|ACZ885 150 mg liquid pre-filled syringes were administered s.c..
41336943|NCT02007252|DRUG|Placebo|Matching placebo liquid pre-filled syringes were administered s.c..
41485476|NCT03015727|DRUG|Cisplatin|3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.
41485477|NCT03015727|RADIATION|IMRT/TOMO|intensity modulated radiation therapy or tomotherapy
41485478|NCT03015727|DRUG|Chemotherapy|2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
41485479|NCT01271751|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
41485480|NCT01271751|DRUG|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
41485481|NCT01254474|DEVICE|Cardiac chambers mapping with MAP 4|
41485482|NCT03880799|BEHAVIORAL|Mindfulness Session|one hour mindfulness session conducted by a certified mindfulness teacher with the breast cancer patient
41336944|NCT06450457|DEVICE|Polar H10 heart rate monitor|"Heart rate will be monitored utilizing a Polar H10 heart rate monitor, with the goal of reaching moderate to high intensity for 30 minutes during the one hour long therapy intervention"
41336945|NCT06450457|DEVICE|Therastride Treadmill System|Participants will be asked to walk on the Therastride Treadmill for 30 minutes.This treadmill can unweight patients so that the task of walking becomes easier. The treadmill's body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study.
41336946|NCT06450457|DEVICE|VECTOR Bioness|Participants will be asked to walk using the VECTOR Bioness on a track outside the gym with a harness attached to an overhead sling system. This system can unweight patients so that the task of walking becomes easier. The body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study. This system allows for overground walking on a small indoor track as opposed to walking on a treadmill.
41336947|NCT05702736|BEHAVIORAL|logotherapy-based intervention|Logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week.
41336948|NCT05218304|BIOLOGICAL|Blood sample|A questionnaire, physical measurements (height, weight, perimeter abdominal and blood pressure) for all arm will be done, approximately 5400 people carried out by investigators. Only 1800 will undergo blood samples carried out by nurses
41336949|NCT02529670|PROCEDURE|Laser|Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
41336950|NCT02529670|PROCEDURE|Drug: Lidocaine|1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
41336951|NCT02529670|PROCEDURE|Radiofrequency|Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
41336952|NCT00322387|DRUG|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
41336953|NCT02549521|DIETARY_SUPPLEMENT|Oral magnesium substitution|The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
41336954|NCT02549521|DIETARY_SUPPLEMENT|Placebo tablets without magnesium|The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
41336955|NCT04853277|BEHAVIORAL|Education|Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.
41336956|NCT00791804|DRUG|AeroLEF|"Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~* for nebulized administration as required by the patient.~* Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl."
41336957|NCT04734769|OTHER|Collect retrospectively clinical data on reproductive outcomes|Collect retrospectively clinical data on reproductive outcomes
41336958|NCT01668381|PROCEDURE|radiofrequency ablation|the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
41336959|NCT04134728|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
41336960|NCT04134728|BIOLOGICAL|Sarilumab|Sarilumab solution in PFS to be administered SC.
41336961|NCT04134728|DRUG|Placebo to GSK3196165/ Sarilumab|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.
40818330|NCT03550170|BEHAVIORAL|Teleconference|This intervention arm will be a 6-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-12 participants) to maximize participants' opportunities for interaction. A program manual divided into 6 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.
41016177|NCT05039619|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
41336962|NCT04134728|DRUG|csDMARDs|Stable dose of csDMARD(s) as SoC.
41016178|NCT05039619|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.
41016179|NCT05039619|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
41016180|NCT05039619|DRUG|Acetaminophen/paracetamol|Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
41016181|NCT05039619|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
40818331|NCT03550170|BEHAVIORAL|Internet|The internet course is similar to the teleconference format. It will occur in a 6-week period and be group based; i.e., 8-12 participants will begin the intervention at the same time and interact with each other during the 6-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions.
40818332|NCT03550170|BEHAVIORAL|1-to-1, in-person or videoconference|Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person or videoconference course will vary over the 6-week period. The OT will cover all 6 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session.
40818333|NCT01940575|DEVICE|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
40818334|NCT01940575|DEVICE|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
40818335|NCT06606184|PROCEDURE|Inspiratory muscle Training|Participants underwent a 12-week program consisting of inspiratory muscle training twice daily, incentive spirometry three times daily, and upper limb exercises along with marching in place for 30 minutes.
40818336|NCT06606184|PROCEDURE|Routine Care|Participants received routine care, which included encouragement to use incentive spirometry three times daily.
40818337|NCT06511674|OTHER|Cognitive-emotional and pain assessments|Data collection on cognitive-emotional and pain parameters using questionnaires.
40818338|NCT05105841|DRUG|Venetoclax|Oral Tablet
40818339|NCT05105841|DRUG|Ibrutinib|Oral Capsule
40818340|NCT05105841|DRUG|Obinutuzumab|Intravenous (IV) Infusion
40818341|NCT05487040|DRUG|PF-07321332 (nirmatrelvir)/ritonavir|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
40818342|NCT05080855|PROCEDURE|modified Millard technique vs Tennison-Randall technique|evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
40818343|NCT06157632|PROCEDURE|Thyriodectomy|Thyroidectomy
40818344|NCT01915121|BEHAVIORAL|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
40818345|NCT01915121|BEHAVIORAL|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
40818346|NCT04048707|DRUG|Angiotensin II|Intravenous
40818347|NCT04048707|DRUG|Midodrine|Pill
41016182|NCT05039619|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
41016183|NCT05039619|DRUG|Prednisone|Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
41016185|NCT06357975|PROCEDURE|Biopsy|Undergo biopsy
40818348|NCT04048707|DRUG|Octreotide|Subcutaneous
40818349|NCT04048707|DRUG|Albumin solution|Intravenous suspension
40818350|NCT06608134|BIOLOGICAL|Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection|Direct injection of biologic into the knee joint.
40818351|NCT01791049|DRUG|TD-1607|
40818352|NCT01791049|DRUG|Placebo|
40818353|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os until proven disease progression
40818354|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
41016186|NCT06357975|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41016187|NCT06357975|DRUG|Crizotinib|Given PO
41016188|NCT06357975|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
41336963|NCT05018169|BEHAVIORAL|BA-A|Session 1 focuses on the treatment rationale, structure, and expectations, and includes psychoeducation on depression. Session 2 focuses on working with parent(s) to help them support their teen through treatment. Session 3 focuses on the (situation)/behavior/feeling cycle and how teens individuals can get trapped in a cycle of depression and inactivity. Session 4 focuses on the assessment of values and choosing preferred activities to target. Session 5 focuses on teaching skills for in-person and electronic communication. Session 6 focuses on identifying barriers to treatment success. Session 7 focuses on teaching teens to handle disagreements. Session 8 focuses on the utilization of adaptive coping skills. Sessions 9-11 are meant to be used flexibly and should include review of any challenging concepts. Session 12 is the termination session and focuses on maintaining treatment gains. Between every session, teens will track their activity for homework.
41336964|NCT05029336|BIOLOGICAL|Depletion of CD3/CD19 in an autologous stem cell transplant|The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.
41336965|NCT00770224|BIOLOGICAL|rituximab|
41336966|NCT00770224|BIOLOGICAL|tositumomab|
41336967|NCT00770224|DRUG|cyclophosphamide|
41336968|NCT00770224|DRUG|doxorubicin|
41336969|NCT00770224|DRUG|prednisone|
41336970|NCT00770224|DRUG|vincristine|
40818355|NCT01131429|DRUG|Cisplatin|cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
41336971|NCT00770224|RADIATION|tositumomab|
41336972|NCT06034327|DEVICE|Single vision, impact-resistant spectacle lenses; Test Arm|Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia
41336973|NCT06034327|DEVICE|Single vision, impact-resistant spectacle lenses; Control Arm|Single vision, impact-resistant spectacle lenses
41336974|NCT00442182|DRUG|ITF2357|
40818356|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
40818357|NCT01131429|DRUG|Cisplatin|Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
40818358|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os as second-line treatment
40818359|NCT01083979|DRUG|Liposomes|Intravesical instillation
40818360|NCT03784599|DRUG|Trastuzumab emtansine|Infusion
40818361|NCT03784599|DRUG|Osimertinib|Tablet
40818362|NCT02330666|BEHAVIORAL|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
41016189|NCT06165705|DEVICE|CureSight|dichoptic therapy with anaglyph goggles and eye tracking
41016190|NCT05463224|DRUG|Lazertinib group|Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)
41016191|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
41016192|NCT04771130|DRUG|Azacitidine|Intravenous or subcutaneous administration for 7 days.
41016193|NCT04771130|DRUG|Posaconazole|Oral administration for 8 days on second cycle only.
41016194|NCT04771130|DRUG|BGB-11417|Oral administration for 28 days on a 28-day cycle.
41336975|NCT03504267|OTHER|Physical Activity Education and Resources|The intervention involves receiving evidence-based educational brochures as well as a list of local facilities where the participant can work out at no-cost to them,
41336976|NCT01400074|DRUG|Nilotinib, Imatinib|Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
41336977|NCT00878813|PROCEDURE|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
40818363|NCT02373436|OTHER|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
41016195|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 14 or 21 days on a 28-day
41336978|NCT00878813|PROCEDURE|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
41336979|NCT00194727|DRUG|Vinorelbine|20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
41336980|NCT00194727|DRUG|Capecitabine|825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
41336981|NCT02033850|BEHAVIORAL|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
41336982|NCT00069017|BIOLOGICAL|MEDI-522|MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
41336983|NCT00069017|OTHER|Placebo|Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D\&C Yellow #10.
40818364|NCT02373436|OTHER|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
40818365|NCT01447485|DRUG|Valsartan (VAL489)|
40818366|NCT04939597|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41016198|NCT05870176|BEHAVIORAL|Enhanced Referral|The enhanced referral uses an electronic referral and patient decision aid to provide choices to 3 different physical activity programs.
41016199|NCT05870176|BEHAVIORAL|Standard Referral|"The standard referral period will serve as the usual care comparator. Patients will receive a paper referral and Fitbit monitor."
41336984|NCT02284945|PROCEDURE|Open fixation|
41336985|NCT02284945|PROCEDURE|Keyhole surgery|
41336986|NCT05225506|BEHAVIORAL|Exercise|Exercise sessions will be one hour in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on movements specifically targeting common deficits seen in Parkinson's.
41336987|NCT02953067|PROCEDURE|Open reduction and internal fixation|Stratum 1: Conservative treatment versus open reduction and internal fixation Stratum 2: Open reduction and internal fixation versus arthrodesis
41336988|NCT02953067|PROCEDURE|Primary arthrodesis|Primary arthrodesis versus ORIF
40818367|NCT04939597|PROCEDURE|Cognitive Assessment|Complete cognitive testing
40818368|NCT04939597|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40818369|NCT04939597|DRUG|Memantine Hydrochloride|Given PO
40818370|NCT04939597|DRUG|Placebo Administration|Given PO
40818371|NCT04939597|OTHER|Questionnaire Administration|Ancillary studies
41016204|NCT00001721|DRUG|Cholesterol Suspension|
41016205|NCT00001721|DRUG|CRH|
41016206|NCT00001721|DRUG|Cholesterol|
41336989|NCT02953067|PROCEDURE|Conservative treatment|Conservative treatment versus open reduction and internal fixation
41336990|NCT02366793|OTHER|Accessory joint mobilization|Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.
41336991|NCT02366793|OTHER|Nerve mobilization|Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
41336992|NCT00255034|BIOLOGICAL|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
41336993|NCT00255034|BIOLOGICAL|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
41336994|NCT00255034|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
41336995|NCT00255034|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
41336996|NCT00888212|PROCEDURE|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
41336997|NCT04728451|BEHAVIORAL|Spectacle wear support|Parents of children in the full-time group are provided with encouragement, support, and counseling throughout the study in order to maximize their child's spectacle wear.
41485483|NCT00605865|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration."
41336998|NCT04728451|DEVICE|Spectacles|Children prescribed and provided spectacles with full correction of their refractive error, with the exception of prescriptions with ≥ +1.50D sphere (plus cylinder notation) in the least hyperopic eye, which will be symmetrically reduced by 1.00D
41336999|NCT02394990|BEHAVIORAL|Violence Brief Intervention|Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence
41337000|NCT02394990|BEHAVIORAL|ABI|
41337001|NCT04995614|DRUG|Radium-223|Prospective observational cohort study investigating patient-reported outcomes
41337002|NCT05752240|DEVICE|Transcranial direct current stimulation|Ten sessions of transcranial direct current stimulation over primary motor cortex to treat levodopa-induced dyskinesia
41337003|NCT06076005|OTHER|Advanced lung cancer patients' group|Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis
41337004|NCT01234519|DRUG|AEZS-108|128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
41337005|NCT01234519|DRUG|AEZS-108 at MTD|2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
40818372|NCT05577598|DEVICE|Implantation of a DBS therapy system|"The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula."
41016224|NCT04742595|BIOLOGICAL|SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes|Given IV
41016225|NCT04777357|DRUG|Cariprazine|Oral Capsule
41016226|NCT04777357|DRUG|Placebo|Oral Capsule
41016229|NCT03861000|DRUG|[C-11]T-1650|radio-labeled drug
41016230|NCT03861000|DRUG|BPN14770|selective compound
41018048|NCT04897581|BEHAVIORAL|Brief Behavioral Therapy for Insomnia, BBTI|BBTI includes sleep hygiene, stimulus control, and sleep restriction, and is administered in three 50-minute sessions over telehealth by psychologic team.
41337006|NCT04307901|DEVICE|Colon capsule endoscopy|Endoscopy performed using PillCam2 camera capsule for oral ingestion
41337007|NCT03716687|DEVICE|Prophylactic negative pressure wound dressing after laparotomy|Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
41485484|NCT06055036|BEHAVIORAL|Black Impact Intervention|The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
41485485|NCT06523387|BEHAVIORAL|Pivotal Response Treatment Online (PRT-O) Course|Pivotal Response Treatment - Parent Training
40818373|NCT04527991|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
40818374|NCT04527991|DRUG|Paclitaxel|Administered intravenously
40818375|NCT04527991|DRUG|Docetaxel|Administered intravenously
40818376|NCT04527991|DRUG|Vinflunine|Administered intravenously
40818377|NCT06528873|COMBINATION_PRODUCT|Concurrent optical and magnetic stimulation (COMS) treatment|"COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps:~Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1)~If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device."
40818378|NCT02887040|RADIATION|Radiation|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.
41018049|NCT04897581|BEHAVIORAL|Physical Self-Regulation, PSR|PSR is conducted over telehealth and consists of three 50-minute sessions focused on jaw relaxation exercises, proprioceptive awareness training, and diaphragmatic breathing entrainment.
40818379|NCT02887040|DRUG|Atengenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
41018050|NCT00971971|PROCEDURE|Dialysis|dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling
41485486|NCT06024083|BEHAVIORAL|Dialectical Behavior Therapy skills video intervention|A series of 14 animated videos (9 acceptance-oriented and 5 change-oriented skills videos) available in both English and Mandarin Chinese.
41485487|NCT00038649|DRUG|Gleevec|400 mg orally twice daily
41485488|NCT04004143|OTHER|No intervention|No intervention.
41485489|NCT03593811|DIAGNOSTIC_TEST|Questionnaires|Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.
41485490|NCT03593811|DIAGNOSTIC_TEST|4 channel electrogastrogram (EGG)|EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.
41485491|NCT03593811|DIAGNOSTIC_TEST|36 channel high resolution electrogastrogram (HR-EGG)|HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.
40818380|NCT02887040|DRUG|Astugenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
40818381|NCT01118520|DRUG|perindopril arginine|10mgs orally daily for the duration of the trial
40818382|NCT01118520|DRUG|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
40818383|NCT01118520|DRUG|placebo|one daily
41018051|NCT00971971|PROCEDURE|Standard SLED|
41018052|NCT03806452|DRUG|Hydroxycarbamide|Hydroxycarbamide tablets of 100 and 1000 mg
41018053|NCT03806452|DRUG|Placebo Oral Tablet|Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
41016231|NCT06249100|PROCEDURE|flexible mini percutaneous nephrolithotomy|In Group A (flexible mini-PCNL cases), a puncture will be done under fluoroscopic guidance medial to the posterior axillary line using an 18-gauge puncture needle. The puncture will be directed horizontally or with a slight upward inclination towards the lower or middle calyx. After a successful puncture, a 0.035 Fr Super Stiff guidewire will be inserted. Tract dilatation with amplatz dilator followed by access sheath insertion. Stone disintegration will be done with the flexible mini-nephroscopy (WiScope Digital Endoscope System by OTU Medical, California, USA) which has a shaft length of 38 cm, distal tip diameter is 15.3 F tapering to 10 F, working channel inner diameter is 6.6 F, and the angle of deflection of the distal tip is 210 degrees.
41016232|NCT06249100|PROCEDURE|Retrograde intrarenal surgery|n Group B, Flexible ureteroscopy will be used with a ureteral access sheath and laser fragmentation of renal stones will be done
41016235|NCT02219815|BEHAVIORAL|Prehab Intervention|Pre-operative, structured exercise intervention.
41016237|NCT05382364|DRUG|Tucatinib|Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.
41016238|NCT05321069|DRUG|BI 1015550|BI 1015550
41016239|NCT05321069|DRUG|Placebo|Placebo
41016242|NCT06462521|PROCEDURE|Cold Snare Piecemeal Resection (CSPR)|Qualifying polyps randomized to Cold Snare Piecemeal Resection (CSPR) will be removed using cold snare techniques (no electrocautery, no submucosal injection.)
41016243|NCT06462521|PROCEDURE|Cold Snare Endoscopic Mucosal Resection (Cold EMR)|Qualifying polyps randomized to Cold Snare Endoscopic Mucosal Resection (Cold EMR) will be removed using cold snare techniques (no electrocautery, with submucosal injection.)
41016249|NCT02133196|DRUG|Aldesleukin|Aldesleukin 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.
41016250|NCT02133196|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
41337008|NCT00196807|BEHAVIORAL|patient decision aid (print-based)|To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
41016251|NCT02133196|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
41016252|NCT02133196|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
41016253|NCT00775853|DRUG|6-[18F]Fluorodopamine|
41016254|NCT00775853|DRUG|6-[18F]Fluorodopa|
41016255|NCT00775853|DRUG|13N-Ammonia|
41485492|NCT03593811|DIAGNOSTIC_TEST|Magnetogastrogram (MGG)|MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
41337009|NCT03512119|DRUG|Lumacaftor-Ivacaftor treatment|Lumacaftor-Ivacaftor treatment during one year
41337010|NCT05051033|PROCEDURE|Mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery. Mitral surgery will be conducted using general anesthesia and cardiopulmonary bypass. Mitral surgery may be performed via a sternotomy or a right thoracotomy approach with or without robotic assistance. Standard techniques commonly include a ring or band annuloplasty to correct and prevent annular dilatation; leaflet prolapse and redundancy may be corrected by leaflet resection techniques and / or chordal reconstruction.
41337011|NCT05051033|DEVICE|Transcatheter edge-to-edge repair|Patients will be treated with a commercially-approved edge-to-edge mitral repair device. The steerable guide catheter (guide) is inserted into the femoral vein and advanced across the inter-atrial septum using image guided puncture. Fluoroscopic and echocardiographic guidance will be used to visualize the devices and assess the repair. The guide is positioned over the MV and the clip/clasp delivery system is inserted into the guide and positioned over the MV in accordance with the manufacturer's instructions. The delivery catheter is advanced until the clip/clasp emerges from the tip of the guide into the left atrium. The catheter is manipulated using the control handle until the clip/clasp is correctly oriented with respect to the line of coaptation of the mitral valve. The clip/clasp is opened, and advanced across the mitral valve into the left ventricle then pulled back to grasp the leaflets.
40818384|NCT02383654|PROCEDURE|Autologous Adipose-Tissue Derived Stem Cells|"1. Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~2. Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
40818385|NCT02182206|DRUG|BIBF 1120|
41016258|NCT06385496|PROCEDURE|Biopsy|Undergo biopsy
41016259|NCT06385496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41016260|NCT06385496|PROCEDURE|Computed Tomography|Undergo CT scan
41016261|NCT06385496|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41337012|NCT02152449|DIETARY_SUPPLEMENT|Oral nutritional supplementation|
41337013|NCT00355329|PROCEDURE|Tongue Acupuncture (Procedure)|
41337014|NCT04253470|OTHER|embryo transfer|Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy
41337015|NCT04812860|DRUG|HR18042|Tablet, Dosing frequency: once daily, Route of administration: oral
41337016|NCT04812860|DRUG|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
41485493|NCT03593811|DIAGNOSTIC_TEST|Electrocardiogram (EKG)|Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin
40818386|NCT00246181|PROCEDURE|radiation therapy|Patients will receive 3 fractions
40818387|NCT00835198|DRUG|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
40818388|NCT00835198|DRUG|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
41016262|NCT06385496|DRUG|Sapanisertib|Given PO
41016267|NCT05795699|DRUG|Ripasudil|K-321 ophthalmic solution
41016268|NCT05795699|DRUG|Placebo|Placebo ophthalmic solution
41337017|NCT04812860|DRUG|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
41337018|NCT04812860|DRUG|Tramadol hydrochloride ER|Tablet,Dosing frequency: once daily, Route of administration: oral
41485494|NCT03593811|DRUG|Ondansetron|Patients will be administered 4mg or 8 mg ondansetron dependent upon age in order to assess the effect of ondansetron on the symptoms of nausea and changes in slow wave dysrhythmias.
41485495|NCT03593811|DRUG|Cyproheptadine Oral Tablet|Patients will be prescribed a 5 day maintenance dose of cyproheptadine using dosing 4mg twice a day to examine the effects of pharmacological alteration of specific nausea pathways on gastric slow wave patterns in functional nausea patients
41337019|NCT04812860|DRUG|Placebo|Tablet,Dosing frequency: once daily, Route of administration: oral
41337020|NCT05483283|OTHER|Empowerment and Navigation|Empowerment and Navigation
41337021|NCT05483283|OTHER|SOC|SOC
41337022|NCT02353403|OTHER|Sugar|A 210g chocolate dairy dessert made with 35g of dextrose.
41337023|NCT02353403|OTHER|FOS|A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
40818389|NCT00676520|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
40818390|NCT00146419|BEHAVIORAL|Reduction in behaviors capable of sexually transmitting HIV|Clinic-level risk reduction counseling
41337024|NCT02024945|DRUG|Propiverine|Propiverine 15 mg tablets or 30 mg regulated release capsules
41337025|NCT01229956|GENETIC|DNA methylation analysis|
40818392|NCT06373653|DRUG|Manzanilla Sophia®|Matricaria recutita 0.025%, Ophthalmic solution.
40818393|NCT06373653|DRUG|Meticel Ofteno®|Hypromellose 0.5%, Ophthalmic solution.
40818394|NCT04974346|RADIATION|Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation|The para-aortic area, from left renal vein level to abdominal aorta bifurcation level，will be prophylactic irradiation. The other intervention is the same as control arm.
40818395|NCT04974346|RADIATION|Pelvic definitive concurrent chemoradiation|Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.
40818396|NCT05048836|OTHER|Food Subsidy, 6 months|Food subsidy for 6 months
40818397|NCT05048836|OTHER|Food Subsidy, 12 months|Food subsidy for 12 months
40818398|NCT05048836|BEHAVIORAL|Lifestyle Support, 6 months|lifestyle support intervention delivered by community health workers for 6 months
40818399|NCT05048836|BEHAVIORAL|Lifestyle Support, 12 months|lifestyle support intervention delivered by community health workers for 6 months
40818400|NCT05048836|OTHER|Food Delivery, 6 months|Twice monthly delivery of healthy food for 6 months
40818401|NCT05048836|OTHER|Food Delivery, 12 months|Twice monthly delivery of healthy food for 12 months
40818402|NCT02482662|PROCEDURE|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
41337026|NCT01229956|GENETIC|gene expression analysis|
40818403|NCT06606938|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4
41337027|NCT01229956|GENETIC|microarray analysis|
41337028|NCT01229956|GENETIC|reverse transcriptase-polymerase chain reaction|
41337029|NCT01229956|OTHER|laboratory biomarker analysis|
41337030|NCT05236660|DEVICE|Custom-made shoes: pressure-optimized|Pressure-optimized custom-made shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months.
41337031|NCT05236660|DEVICE|Custom-made indoor shoes: pressure optimized|Pressure-optimized custom-made indoor shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months. Specifically designed for indoor use.
41337032|NCT05236660|DEVICE|Foot temperature monitoring|Personalised at-home daily foot temperature monitoring at high-risk regions.
41337033|NCT05236660|BEHAVIORAL|Education|Personalised patient education consisting of quantitative feedback on in-shoe pressures, temperature measurements and footwear use and, in addition, motivational interviewing where indicated and needed to improve device use.
41337034|NCT04368104|DIAGNOSTIC_TEST|Darwish test (office hysteroscopic bubble suction and tubal peristalsis)|Testing Darwish test (office hysteroscopic bubble suction test and proximal tubal peristalsis) in women using minipills versus other cases not using hormones..
41337035|NCT01902173|PROCEDURE|Biopsy|Undergo a biopsy
41337036|NCT01902173|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41485496|NCT00626314|BIOLOGICAL|myoblast|autologous myoblast
41485497|NCT00626314|BIOLOGICAL|sham|sham injection procedure
41485498|NCT04585984|DIETARY_SUPPLEMENT|Experimental - Probiotic|Patients in the experimental group will take one compound (pill) a day for 21 days, containing a 50% combination of two probiotics: Lactobacillus rhamnosus and Bifidobacterium longum, at a dose of 10\^9 cfu/day. The carrier of lyophilized probiotics is maltodextrin and the mixture is encapsulated in hypromellose capsules.
41485499|NCT04585984|DIETARY_SUPPLEMENT|Placebo|Patients in the control group will take one unit of placebo a day for 21 days.
41337037|NCT01902173|PROCEDURE|Computed Tomography|Undergo a CT scan
41485500|NCT04294420|BEHAVIORAL|Patient education program|The education program provides information and guidance concerning aetiology, diagnostics and treatment of pain-predominant functional gastrointestinal disorders. The patient education program will be provided in a group setting and the children will participate along with one of their parents. The participants (n=20) will be divided into two groups consisting of ten child-parent pairs. Two lectures will be held, two weeks apart, two hours per lecture. Represented teachers are physician, psychologist and dietician.
41485501|NCT03443388|DEVICE|Hövding inflatable helmet|The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
41485502|NCT03325400|OTHER|Toothpaste non-fluoride and fluoride|"Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation."
41337038|NCT01902173|DRUG|Dabrafenib Mesylate|Given PO
40818404|NCT06606938|PROCEDURE|Normal Saline (Placebo)|Placebo at baseline, week 2, week 4
41337039|NCT01902173|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41016269|NCT05696717|DRUG|Ampreloxetine|Oral tablet, QD
41016270|NCT05696717|DRUG|Placebo|Oral tablet, QD
41337040|NCT01902173|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
41337041|NCT01902173|DRUG|Uprosertib|Given PO
41337042|NCT06048705|DRUG|GSK3901961|GSK3901961 was administered.
41337043|NCT06048705|DRUG|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
41337044|NCT06048705|DRUG|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
41337045|NCT00928512|DRUG|Secukinmab|Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
41337046|NCT00928512|DRUG|Placebo|Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
40818405|NCT06002854|DRUG|PRP( platelet rich plasma) and Insulin human|Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation
41485503|NCT04531995|DEVICE|CANKADO PRO-React Onco|CANKADO PRO-React Onco is approved as class I medical device within the European Union (registration number DE /CA59 /371/2020-R/Hd) and is compliant with the FDA classification for Mobile Medical Devices (2015) Appendix B. The purpose of CANKADO PRO-React Onco is to be an automated digital support for patients to help them decide how urgent it is to contact the attending physician based on the symptoms they independently record in the system. It supports patients with cancer under systemic, anti-tumor or anti-hormonal therapy in adjuvant, neoadjuvant, post-neoadjuvant or palliative situations. It is unsuitable for patients undergoing radiotherapy, cell and gene therapy, surgical procedures or alternative healing methods.
41485504|NCT02127775|DRUG|Lesinurad 400 mg (manufactured at Site 1)|
41485505|NCT02127775|DRUG|Lesinurad 400 mg (manufactured at Site 2)|
41485506|NCT00932230|OTHER|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
41485507|NCT04840966|DIAGNOSTIC_TEST|Flavor test|A simplified self-administrable flavor test has been proposted to all the enrolled subjects
41485508|NCT04840966|OTHER|Self-assesment questionnaire|"Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to no smell/flavor perception and 10 corresponding to excellent smell/flavor perception."
41485509|NCT04219683|PROCEDURE|Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap|Using Free Fibula Flap for reconstruction of mandibular segemental defect
41485510|NCT03873636|OTHER|Stimulation via noninvasive brain stimulation systems|Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the Soterix, Neuroelectrics, \& Halo devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
41485511|NCT01857765|BEHAVIORAL|Rehabilitation|Range of motion stretching exercises
41485512|NCT01857765|BEHAVIORAL|Follow-up|Follow-up with surgeon's clinic
41485513|NCT03138226|PROCEDURE|uterus transplantation|
40818406|NCT05103176|DEVICE|TMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
41485514|NCT03334721|DRUG|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
41485515|NCT03334721|DRUG|Placebo Oral Capsule|5 day trial of matched placebo
41485516|NCT04798118|PROCEDURE|toilet bronchoscope|Toilet bronchoscopy will be done by infuse normal saline or N-Acetylcysteine with a syringe, observing the flow of saline at the distal tip of the bronchoscope then suction intra bronchial visible secretions during the procedure and also suction of specific lobe guided by radiological finding in the patient A chest X-ray will be routinely performed prior and after the procedure, HRCT is mandatory when chest x-ray not clearly defining the collapse monitoring of heart rate, oxygen saturation, ventilator parameters, and arterial blood pressure will be done
41337047|NCT01412151|DRUG|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
41337048|NCT05172531|DRUG|Cisatracurium Besylate|Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。
41337049|NCT05172531|DRUG|saline 0.12ml/kg/hr|saline 0.12ml/kg/hr
41337050|NCT02068950|BEHAVIORAL|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
41337051|NCT01038089|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol
41485517|NCT00713999|DRUG|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
41485518|NCT02919241|BEHAVIORAL|Diagnostic interview|A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
41485519|NCT02919241|BEHAVIORAL|Combined interview and treatment.|Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
41485520|NCT03584984|PROCEDURE|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|Filling the socket with Mixing of autogenous bone graft and anorganic bovine bone in a 50:50 ratio
41485521|NCT03584984|PROCEDURE|Anorganic Bovine Bone (ABB)|Filling the socket with Anorganic bovine bone graft material only
41485522|NCT03584984|PROCEDURE|Absorbable gelatin sponge|Filling the socket with an absorbable gelatin sponge foam pack
41485523|NCT00564226|DRUG|SSR240600C|oral administration
41485524|NCT00564226|DRUG|tolterodine|oral administration
41485525|NCT00564226|DRUG|placebo|oral administration
41485526|NCT04472247|DIAGNOSTIC_TEST|Continuous EEG and EMG monitoring, with derived variables|All patients are monitored during their ICU stay by frontal EEG and EMG measuring devides, which are already in clinical use.
41485527|NCT05953766|DRUG|Ropivacaine injection|Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml
41485528|NCT05953766|DRUG|Normal saline injection|Sham block using 20 mL of normal saline
41485529|NCT02442583|OTHER|Brochure regarding sedentary behavior|This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
41485530|NCT00708786|DEVICE|ICD|Ventricular arrhythmia treatment
41485531|NCT00708786|DEVICE|CRT-D|Ventricular arrhythmia treatment
41485532|NCT03604107|GENETIC|Preimplantation Genetic Testing-Aneuploidy|trophectoderm biopsy samples will be analyzed for karyotype after clinical outcome is determined
41485533|NCT06225557|OTHER|ERAS community recommendation|Enhanced recovery techniques including opioid sparing anesthesia in elective cesarean section
41485534|NCT06225557|OTHER|Traditional postoperative care|Usual anesthesia and analgesia in elective cesarean section.
41485535|NCT02733315|BEHAVIORAL|Diabetes Conversation Map Program|"The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants."
41485536|NCT01708629|DRUG|210 mg brodalumab|210 mg brodalumab administered SC
40818407|NCT05103176|BEHAVIORAL|Object directed grasping|"Subjects will perform a precision grip with the right hand towards either a small or large target object positioned in front of them. The illumination of an LED (green or red) will instruct the subject to plan a precision grip towards either a small or large target object positioned in front of them. After \~1 second, the LED will extinguish and cue subjects to execute the intended object-directed hand action. The presentation of the visual stimuli will be synchronized with the iTBS stimulation, which will occur 800ms before the onset of every GO cue in order to modulate cortical activity during both the planning and execution phase of the action."
41485537|NCT01708629|DRUG|140 mg brodalumab|140 mg brodalumab administered SC
41485538|NCT01708629|DRUG|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
41485539|NCT01708629|DRUG|placebo|placebo administered SC
41485540|NCT06150456|PROCEDURE|extraction|extraction: in all groups, extraction will be performed
40818408|NCT01602029|DRUG|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
40818409|NCT01602029|DRUG|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
40818410|NCT01602029|DRUG|Placebo|Placebo added to TAU
40818411|NCT01602029|DRUG|Odansetron plus simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
41018054|NCT03565185|OTHER|robot-assisted gait training|Investigators will use robot-assisted gait training for rehabilitation of stroke
41018055|NCT03565185|OTHER|placebo|Investigators will use only conventional treatment without robot-assisted gait training
41337052|NCT00821782|DRUG|Levofloxacin; Azithromycin|
41485541|NCT06150456|RADIATION|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
41485542|NCT06150456|BIOLOGICAL|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
41485543|NCT00142233|DIETARY_SUPPLEMENT|ANTOX (vers.)1.2|"300 µg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine per day (for patients of 10 years and older)~150 µg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine per day (for patients aged between 5 and 9 years)"
41485544|NCT00142233|DRUG|Magnesium|"15 mmol per day (for patients of 10 years and older)~7,5 mmol per day (for patients aged between 5 and 9 years)"
41337053|NCT02445703|BIOLOGICAL|Inactivated Hepatitis A vaccine (HAV)|Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
41337054|NCT02445703|BIOLOGICAL|Combined hepatitis A and hepatitis B vaccine (HABV)|Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
41337055|NCT01736709|BIOLOGICAL|2012-2013 trivalent seasonal influenza vaccine|trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
41337056|NCT02608372|OTHER|LD|Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
41337057|NCT02608372|OTHER|UP|Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
41337058|NCT02608372|OTHER|CTR|Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
41337059|NCT04906824|DEVICE|great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing|VascuCel implantation in order to perform great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
41337060|NCT00301470|DEVICE|MR urography|undergoing both renal scintigraphy and MR within a month
41337061|NCT02090465|DRUG|Ingenol Mebutate|No intervention: observation of routine use of Picato®
41337062|NCT04035265|PROCEDURE|Blood test|Carpus and fingers of non-dominating hand MRI with gadolinium contrast
41337063|NCT02872324|OTHER|Procurement questionnaires|
41337064|NCT05152368|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41337065|NCT03681834|OTHER|Data collection|Data on the effectiveness and safety of the Cor-Knot® knotting device
41016278|NCT05789082|DRUG|Divarasib|Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.
41016279|NCT05789082|DRUG|Pembrolizumab|Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.
41016280|NCT05789082|DRUG|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles.
41016281|NCT05789082|DRUG|Cisplatin|Participants will receive IV cisplatin Q3W for four 21-day cycles.
41337066|NCT05287269|DIAGNOSTIC_TEST|Ocular Coherence Tomography|OCT images were recorded as a fast macular radial line scan with captured on either Heidelberg Spectralis (Heidelberg Engineering GmbH, Germany) or Topcon DRI Triton (Topcon Medical Systems inc. USA).
41337067|NCT03301233|DRUG|estradiol valerate and sildenafil|(45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
41337068|NCT01478061|DEVICE|Anastomosis (C-Port® )|creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
41337069|NCT03565991|DRUG|Avelumab|IV treatment
41337070|NCT03565991|DRUG|Talazoparib|Oral treatment
41337071|NCT01399840|DRUG|BMN 673|Oral capsule with multiple dosage forms given once daily
41337072|NCT02343419|OTHER|Methacholine Challenge Test|"Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.~In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes."
41337073|NCT04446767|RADIATION|polarized light|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks
41337074|NCT04446767|OTHER|Medical Care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
41337075|NCT05522296|DRUG|Mpox Vaccine|Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
41337076|NCT06373536|DIAGNOSTIC_TEST|Thermoacoustic imaging, MRI and Ultrasound imaging|This is a Thermoacoustic imaging exam that will last 10-15 minutes. Distinguishing; assessment of steatosis liver disease in obese and morbidly obese patients.
41337077|NCT00292812|DRUG|Nutritional supplementation (nucleotides)|
41016282|NCT05789082|DRUG|Pemetrexed|Participants will receive IV pemetrexed Q3W.
41337078|NCT00003519|DRUG|cyclophosphamide|
41337079|NCT00003519|DRUG|docetaxel|
41337080|NCT00003519|DRUG|doxorubicin hydrochloride|
41337081|NCT01646567|DRUG|SHP-141C|Topical Cream
41337082|NCT01646567|DRUG|Placebo to SHP-141C|Placebo Topical Cream
41337083|NCT01646567|DRUG|Betamethasone Valerate|Topical cream, 0.02%
41337084|NCT01646567|DRUG|Calcipotriol|Topical cream, 0.005%
41485545|NCT00142233|OTHER|Placebo ANTOX (vers)1.2|Placebo ANTOX (vers)1.2
41485546|NCT00142233|OTHER|Placebo Magnesiocard (2.5 mmol)|Placebo Magnesiocard (2.5 mmol)
41485547|NCT02548611|DRUG|Prasugrel|see arm description
40818412|NCT03428581|PROCEDURE|ALND with ARM +/- LVB|"Subjects will undergo removal of the lymph nodes in the underarm or axilla area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection."
41485548|NCT02548611|DRUG|Clopidogrel|see arm description
40818413|NCT03428581|PROCEDURE|ALND|Prospective and retrospective subjects undergoing an ALND.
40818414|NCT06608758|BEHAVIORAL|Electonic health record prompts with education|"1). A baseline audit will be conducted of uses of Current Procedural Technology (CPT) Evaluation and Management (E/M) codes and evaluate for differences in complexity of CPT E/M code use for patients with disabilities (PWD) aged 3-89 years old with specific disabilities versus patients aged 3-89 without the specific disabilities.~Using analyses of data, chart reviews, staff interviews and mock tracers, a frame of themes underlying CPT code differences will be co-produced to develop algorithms to identify patients with the specified disabilities at risk. Case studies for education on DO, and EHR prompts, alerts, and decision supports related to the algorithms will be co-produced along with education on the EHR materials. Evaluate for change in use of CPT E/M among PWD after implementation of algorithms and EHR prompts, alerts and decision support will be conducted post-intervention."
40818415|NCT06608758|OTHER|Standard of care|Patients without disabilities will receive standard care related to electronic health record prompts, alerts, and decision supports.
40818416|NCT06260631|DEVICE|high-intensity laser acupuncture and Exercise therapy program|"The experimental group will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program~The patients will perform an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
41485549|NCT00072020|DRUG|zoledronic acid|
41485550|NCT00072020|PROCEDURE|adjuvant therapy|
41485551|NCT00072020|PROCEDURE|neoadjuvant therapy|
41485552|NCT00025636|BIOLOGICAL|filgrastim|
41485553|NCT00025636|DRUG|carmustine|
41485554|NCT00025636|DRUG|cisplatin|
41485555|NCT00025636|DRUG|cyclophosphamide|
41485556|NCT00025636|DRUG|cytarabine|
41337085|NCT01291849|DRUG|Dixon up-and-down method|The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml-1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
41337086|NCT00715013|DRUG|Patupilone|Patupilone
41337087|NCT05299645|BEHAVIORAL|Interview|Pilot study with digital browsers
40818417|NCT06260631|OTHER|Sham laser acupuncture|"Sham laser acupuncture and exercise therapy program~The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
41337088|NCT00735761|DRUG|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
40818418|NCT06578559|DRUG|Cetuximab|500 mg/sqm intravenous infusion over 120-minute at cycle 1 (if well tolerated, it is administered over 90 minutes at second administration, and over 60 minutes by the third administration) every 14 days.
40818419|NCT06578559|DRUG|Encorafenib|300 mg once daily (four 75 mg oral capsules).
40818420|NCT02373956|DEVICE|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
40818421|NCT02373956|PROCEDURE|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
41337089|NCT00735761|DRUG|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
41337090|NCT01931150|DRUG|Topical Dapsone 5% Gel|
41337091|NCT01931150|OTHER|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
41337092|NCT01931150|DRUG|oral antibiotics|
40818422|NCT02795507|DEVICE|Rehabit-Tec System|Device with visual and kinesthetic feedback
40818423|NCT02795507|DEVICE|Rehabit-Tec System|Device without visual and kinesthetic feedback
40818424|NCT02795507|BEHAVIORAL|conventional exercises|
41337093|NCT04397926|DRUG|Individualized neoantigen peptides vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
41337094|NCT01802268|DRUG|Conversion from Tacrolimus to Sirolimus|
41337095|NCT01802268|DRUG|Maintenance on tacrolimus|
41337096|NCT00297128|DRUG|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
41337097|NCT00297128|DRUG|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
41337098|NCT02928666|OTHER|DSS for mitigating interactions between recommendations|DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
41337099|NCT05875389|OTHER|Virtual assessment|virtual assessment with a stroke neurologist/advanced practice nurse, with interdisciplinary support, to facilitate the care of patients admitted to primary stroke centres using existing tools for remote evaluation and review.
41016286|NCT05762107|DRUG|Placebo|Subject receives Placebo by subcutaneous injection daily for 28 days
41016287|NCT05762107|DRUG|ZT-01, 7 mg|Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days
41016288|NCT05762107|DRUG|ZT-01, 15 mg|Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days
41016289|NCT05762107|DRUG|ZT-01, 22 mg|Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
41016295|NCT03734198|DRUG|Ibrutinib|Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
41016296|NCT03734198|DRUG|Daratumumab|Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
41337100|NCT03119922|OTHER|No intervention|
41337101|NCT04774952|DRUG|RMC-5552|RMC-5552 for IV administration
41337102|NCT02503709|DRUG|CDK Inhibitor AT7519|Given IV
41485557|NCT00025636|DRUG|dexamethasone|
41337103|NCT02503709|OTHER|Laboratory Biomarker Analysis|Correlative studies
41337104|NCT02503709|DRUG|Onalespib|Given IV
40818425|NCT04291690|OTHER|Physical Component of the Intervention|We will encourage and assist patients to walk around the ward as tolerated and approved by their treating clinicians, to maximize the time spent out of bed, minimize the time spent in bed, and to encourage and assist them to perform chair rises to build lower extremity strength. For selected intervention patients with greater physical weakness, defined as SPPB ≤9, a Certified Exercise Physiologist will administer a supervised multicomponent exercise program combining strength, flexibility, balance and gait for the prevention of weakness and falls. The exercise program is adapted from the Vivifrail program which is an EU-funded initiative that provides a guide to prevent frailty, physical deconditioning, and incident disability in older persons. The program includes two daily sessions, one in the morning and one in the afternoon, for a duration of 20 minutes each. The morning session includes strength and flexibility exercises. The afternoon session targets balance and walking.
40818426|NCT04291690|OTHER|Cognitive Component of the Intervention|We will encourage and assist them to wear their hearing and visual aids (if they have these), orient them to time and place verbally and in writing on a clearly visible white-board in their hospital room - and also encourage their family members and caregivers to do so on a regular basis, and inquire about their sleep quality and communicate with the clinical team to reduce sleep disturbances. For selected intervention patients with greater cognitive impairments, defined as MMSE ≤26, we will provide cognitive simulation twice daily during the scheduled visits. Cognitive stimulation comprises of activities with the patient, including but not limited to current news, trivia, crossword puzzles, and memory games. These cognitive interventions are adapted from the Hospital Elder Life Program (HELP) that targets risk factors for delirium.
40818427|NCT04291690|OTHER|Nutritional Component of the Intervention|We will reinforce proper eating habits, encourage and assist patients to wear their dentures (if they have these), and inquire about their food preferences and eating barriers and communicate with the clinical dieticians to address these issues. For selected intervention patients with greater nutritional deficits, defined as a positive PONS, we will recommend to the treating clinicians to prescribe MedPass supplementation. PONS, developed as a preoperative screening tool but also used in nonoperative medical settings, reflects low body mass index, weight loss, low dietary intake, and albumin level. MedPass is a 60 mL calorically dense (2 kcal/mL) oral nutritional supplement consumed between meals 4 times per daily. If MedPass supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative supplementation strategies.
40818428|NCT04291690|OTHER|Iron-Deficiency Anemia (IDA) Component of the Intervention|We will verify their clinical blood test results for hemoglobin level and iron studies and apply the diagnostic criteria for iron deficiency as recommended by the Canadian Cardiovascular Society Guidelines for Heart Failure. These criteria are: (i) Hemoglobin \<130g/L in men or \<120g/L in women with (ii) a Ferritin \<100μg/L or a Ferritin \<300μg/L with a Saturation \<20%. For selected intervention patients with diagnosed iron deficiency anemia, according to these established criteria, we will recommend to the treating clinicians to prescribe Venofer intravenous iron replacement therapy. The use of intravenous iron replacement therapy is a Strong Recommendation in the Canadian Cardiovascular Society Guidelines. Venofer is prescribed at a dosage of 300 mg IV daily for a total of 3 doses. If Venofer supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative strategies.
40818429|NCT03761888|DIAGNOSTIC_TEST|optic nerve sheath measurement and transcranial doppler|evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value
40818430|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
40818431|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
40818432|NCT05980871|DRUG|Doxycycline|doxycycline (100 mg orally twice daily for 7 days)
40818433|NCT05980871|DRUG|Ceftriaxone|Ceftriaxone (1g intramuscularly once)
40818434|NCT05980871|DRUG|benzathine penicillin G|benzathine penicillin G (2.4 MU intramuscularly once)
40818435|NCT06306651|OTHER|High flow nasal cannula therapy group|Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC
40818436|NCT06306651|OTHER|Conventional oxygen therapy group|Patients who will be randomized to simple oxygen mask therapy. The simple face mask will be applied in a rate range between 6-10 L/min.
40818437|NCT01480414|BIOLOGICAL|4times injection|bone marrow derived mono nuclear stem cell
40818438|NCT01480414|BIOLOGICAL|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
40818439|NCT00635739|DIETARY_SUPPLEMENT|Whey protein|powdered, 46g supplement dissolved in fluids, twice daily
40818440|NCT00635739|DIETARY_SUPPLEMENT|Maltodextrin placebo|powdered, 46g supplement dissolved in fluids, twice daily
41337105|NCT02503709|OTHER|Pharmacological Study|Correlative studies
41337106|NCT00926666|DRUG|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
41337107|NCT02663180|BEHAVIORAL|Educational program|Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.
41337108|NCT02663180|BEHAVIORAL|Video contact|Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
41337109|NCT02708615|OTHER|Type of speculum vaginal insertion method|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
41337110|NCT00334204|DEVICE|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
41337111|NCT04119401|PROCEDURE|doppler-guided hemorrhoidal artery ligation|"Ligation: a lubricating gel is applied to the tip of the Transanal Hemorrhoidal Dearterialization device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. The terminal branches of the superior rectal artery are detected by the doppler signal 2-3 cm above the dentate line. The tip of the instrument is gently tilted and the arteries are ligated with a Z-shaped stitch using 2:0 braided polyglycolic acid suture inserted using a special needle-holder through an aperture in the operating proctoscope.~Mucopexy: after the haemorrhoid artery ligation, the suture is continued with three to five sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all detected artery ligations."
41337112|NCT04119401|PROCEDURE|Finger-guided hemorrhoidal artery ligation|"Ligation: the exact placement of all terminal branches of the superior rectal artery are found by intraoperative palpation at anal clock 2-3cm above the anorectal junction. Then arteries are ligated with Z-shaped suture using 2:0 braided polyglycolic suture.~Mucopexy is then performed in the same technique as in comparative group"
41337113|NCT04119388|OTHER|Adapted sports practices|Adapted sports practices for 30 minutes twice a week
41337114|NCT03700346|DEVICE|microdialysis|Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
41337115|NCT01039311|DEVICE|Optical Coherence Tomography|Obtain OCT images.
41337116|NCT04920032|DRUG|TAS-102|Given PO
41337117|NCT04920032|DRUG|Irinotecan|Given IV
41337118|NCT04920032|COMBINATION_PRODUCT|Standard Treatment|6 cycles for a 2-week regimen (infusional 5FU based) and up to 4 cycles for a 3-week regimen (oral capecitabine based) after randomization
41337119|NCT04920032|DIAGNOSTIC_TEST|Signatera MRD ctDNA Assay|To be performed within 6-8 weeks of Cycle 1 Day 1. A Mid-treatment ctDNA is to be completed within 6 - 8 weeks of starting treatment. ctDNA is to also be completed within four weeks after completion of study treatment (+/- two weeks)
41485558|NCT00025636|DRUG|etoposide|
41485559|NCT00025636|DRUG|melphalan|
41485560|NCT00025636|DRUG|methotrexate|
41156409|NCT06646211|DRUG|ASCT±Zanubrutinib|"Consolidation / maintenance treatment Patients who achieve a Complete Response (CR) or Partial Response (PR) after the ZT/ZMT treatment will enter consolidation/maintenance therapy.~Patients age ≤65 years old will undergo Autologous Stem Cell Transplantation (ASCT, with a recommended conditioning regimen that includes Thiotepa), followed by 6 months of maintenance treatment with zanubrutinib.~Patients age \> 65 will receive 6 months of maintenance treatment with zanubrutinib.~\*The study permits the prophylactic use of Granulocyte Colony-Stimulating Factor (G-CSF). For detailed usage, please refer to the guidelines from the National Comprehensive Cancer Network (NCCN) or the Chinese Society of Clinical Oncology (CSCO)"
41485561|NCT00025636|DRUG|vincristine sulfate|
41485562|NCT00025636|PROCEDURE|bone marrow ablation with stem cell support|
41485563|NCT00025636|PROCEDURE|peripheral blood stem cell transplantation|
41485564|NCT00290836|DRUG|Human fibrinogen/thrombin and bovine aprotinin (TachoComb H)|
41485565|NCT04091958|PROCEDURE|Pectoralis myo-glandular flap reconstruction.|Tumorectomy with surgical margin will be evaluated with frozen-section examination. Reconstruction starts with mobilization of skin flaps. The sternal head of the pectoralis major muscle will be disconnected from its insertion at the humerus. The muscle fibers will be mobilized off the chest wall. The pectoralis major receives dual blood supply. The pectoral branches of the thoraco-acromial artery enter the superior part of the muscle and the perforator branches of the internal mammary artery enter the medial part of the muscle. According to the location of the defect in the breast, the muscle will be mobilized based on one vascular pedicle. The muscle flap may consist of all or some segmental fibres of the sternal head of the pectoralis major muscle. In all cases, the muscle flap connection to the overlying breast parenchyma is kept intact and the clavicular head of the pectoralis major muscle is undisturbed. Closure of the cavity in layers over suction drain will follow.
41485566|NCT01692314|OTHER|Resistance training|
41485567|NCT00004153|GENETIC|reverse transcriptase-polymerase chain reaction|
41485568|NCT00004153|PROCEDURE|sentinel lymph node biopsy|
41016303|NCT02276495|OTHER|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
40818441|NCT06608615|OTHER|Kinesio Taping|"Facilitation (Functional) Technique for Tibialis Anterior Muscle: The patient sits with his leg extended. The ankle is placed in eversion and dorsi flexion. After one end of the I tape is adhered to the upper part of the Tibia, the other end is adhered to the dorsal surface of the foot with almost 100% tension. During the application, origin and insertion points are considered as the beginning and end. Then, plantar fexion is performed on the ankle and the remaining non-stick part is glued.~Functional Correction Technique: Correction technique is used to ensure full contact of the foot with the ground. The subtalar joint is positioned in eversion and taping is applied starting from under the medial malleolus, without tension until the lateral outer edge of the calceneus, and then with 100% tension, continuing until 10-15 cm below the head of the fibula. No tension is applied in the last 5 cm"
41016304|NCT02276495|DRUG|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
41016305|NCT02276495|DRUG|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|"100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)"
41156410|NCT06509906|DRUG|M9466|M9466 will be administered orally until progressive disease, unacceptable toxicity, death, or end of study.
41156411|NCT06509906|DRUG|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks (q2w) until progressive disease, unacceptable toxicity, death, or end of study.
41156412|NCT06509906|DRUG|Folinic acid|Folinic acid will be administered intravenously q2w as per standard of care.
41016308|NCT05993546|DEVICE|vacuum assisted sheath|allows for simultaneous suction with continuous irrigation throughout the case to enhance visibility and facilitate stone retrieval
41016309|NCT05993546|DEVICE|passive suction via conventional sheath|conventional access sheath for stone retrieval using current technique via passive suction
41485569|NCT04898491|OTHER|Pain assessment using a behavioral scale|"The pain of the subjects will be evaluated by two independent observers and with a blind result between them, coinciding with the application of two painful procedures used in routine practice: suction of tracheal secretions and the pressure in the nail bed by means of a pressure algometer. In addition, a painless procedure will also be performed to establish an element of control with the procedures painful. This will consist of the application of gentle friction with a cloth gauze, on a part of healthy skin tissue of the patient. The measurement will be performed twice for each patient and procedure depending on the level of sedation, so that the first measurement will be performed with a deeper sedation level and the second with a change in sedation level to moderate-mild.~In turn, the pain assessment will be carried out in three moments: first or baseline measurement, during the application of the painless and 15 minutes after finishing the procedures."
41485570|NCT01439230|DRUG|Donepezil|10 mg Tablet
41485571|NCT01439230|DRUG|Aricept®|10 mg Tablet
41485572|NCT04977661|DRUG|Vitamin E|Vitamin E is one of the body's most effective chain-breaking antioxidants that has shown to delay the pathogenesis of NASH.
41485573|NCT04977661|DRUG|Ursodeoxycholic acid|is a metabolic by-product of intestinal bacteria and has been proven to be useful in the non-surgical treatment of cholesterol gallstones and primary biliary cirrhosis (PBC)
41485574|NCT04977661|DRUG|Pentoxifylline|"it is a well-tolerated medication that improves blood~viscosity and erythrocyte rheological characteristics in individuals with peripheral vascular disease 20. In addition, PTX is a nonspecific phosphodiesterase inhibitor that increases cyclic adenosine monophosphate (cAMP) levels while decreasing TNF-a gene transcription"
41485575|NCT04583748|BEHAVIORAL|Sahaj Samadhi Meditation|Sahaj Samadhi Meditation (SSM) is a form of automatic self-transcending meditation that involves relaxed attention to a precise sound (mantra), to allow stress reduction and deep relaxation. This technique is easy to learn and offers the support of a group and facilitator.
41156413|NCT06509906|DRUG|Fluorouracil (5-FU)|Fluorouracil will be administered intravenously as per standard of care.
41156414|NCT06509906|DRUG|Bevacizumab|Bevacizumab will be administered intravenously, q2w until progressive disease, unacceptable toxicity, death, or end of study.
41156415|NCT06410625|DIAGNOSTIC_TEST|FLT PET imaging|Evaluation of response to chemotherapy with FLT PET imaging
41156416|NCT04581772|DRUG|DNL343|Multiple oral doses
41156417|NCT04581772|DRUG|Placebo|Single oral dose
41156418|NCT04581772|DRUG|DNL343|Single oral dose
41156419|NCT01846637|PROCEDURE|laparoscopic sleeve gastrectomy|
41156420|NCT00212290|DRUG|pioglitazone|
41156421|NCT00212290|DRUG|nateglinide|
41156422|NCT00212290|DRUG|placebo|
41156423|NCT00400257|BEHAVIORAL|Early detection of heart failure|Early detection of heart failure
41156424|NCT02898350|DEVICE|Pulsed dye laser treatment|Scar minimization with Pulsed dye laser treatment on suture removal day
41156425|NCT02898350|DEVICE|CO2 laser treatment|Scar minimization with CO2 laser treatment on suture removal day
41156426|NCT02898350|DEVICE|Combined PDL and CO2 laser treatment|Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
41485576|NCT04583748|BEHAVIORAL|Health Enhancement Program|The Health Enhancement Program (HEP) is a standardized program used to teach participants about health promotion, including the benefits of a lifestyle of healthy diet, music, recreation, and exercise. In HEP, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes.
41485577|NCT04622397|DRUG|Tranexamic acid injection|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
41485578|NCT04622397|DRUG|Saline|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
41337120|NCT02069704|DRUG|Bevacizumab biosimilar (BEVZ92)|"Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
41337121|NCT02069704|DRUG|Avastin® (bevacizumab, reference product)|"Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
41337122|NCT01525667|BIOLOGICAL|150M PLX-PAD|Single course, multiple IM injections
41337123|NCT01525667|BIOLOGICAL|300M PLX-PAD|Single course, multiple IM injections
41485579|NCT01769274|DRUG|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
41485580|NCT01769274|DRUG|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
41156427|NCT02898350|DEVICE|Split PDL and CO2 Laser treatment|Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
41156428|NCT01427231|DIETARY_SUPPLEMENT|glucose|The effect of a glucose solution on cognitive performance will be measured.
41156429|NCT01427231|DIETARY_SUPPLEMENT|sacharose|The effect of a sacharose solution on cognitive performance will be measured.
41337124|NCT01525667|BIOLOGICAL|Placebo|Single course, multiple IM injections
41485581|NCT05147038|DEVICE|Tele-coaching|"The participants are instructed to use a Fitbit fitness tracker to record the number of steps. This device is compatible with the m-PAC App, which was developed for this specific group of participants (individuals suffering from a chronic lung disease). The participants receive a feedback via the m-PAC App every day and they also receive a week report to be albe to adjust their step goal. They are asked to increase or keep their week goal every Sunday after reviewing a weekly report. The participants also receive tips for their PA improvement and they are asked for medication change specification (every Wednesday)."
41485582|NCT02546362|DEVICE|Cefaly|
41485583|NCT02667288|DRUG|A-101 Solution|
41485584|NCT02161822|DRUG|simvastatin|simvastatin 80mg qd for 5weeks
41016312|NCT03484819|DRUG|Copanlisib Hydrochloride|Given IV
41016313|NCT03484819|BIOLOGICAL|Nivolumab|Given IV
41016314|NCT05141682|DRUG|Oral Azacitidine|Given PO
41016319|NCT03376477|BIOLOGICAL|GM-CSF vaccine|Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.
41016320|NCT03376477|DRUG|Lenalidomide|Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
41016321|NCT03376477|DRUG|Prevnar13|Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
41016322|NCT03376477|OTHER|Placebo Prevnar13|Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.
41016323|NCT03376477|OTHER|Placebo GM-CSF Vaccine|Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.
41156430|NCT01427231|DIETARY_SUPPLEMENT|Placebo|The effect of a placebo drink with sweeteners on cognitive performance will be measured.
41156431|NCT00666835|DRUG|HX575 epoetin alfa Hexal AG|HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
41156432|NCT00666835|DRUG|ERYPO®, Janssen-Cilag|Solution for i.v. injection
41016331|NCT06653010|BIOLOGICAL|Universal CAR-T cells injection for treating mCRC|A novel universal CAR-T platform to treat cancer patients
41337125|NCT03590093|PROCEDURE|Periodontal surgery|After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
41337126|NCT03590093|PROCEDURE|EMD application|Application of Pref-Gel for 2 minutes and then the application on Enamel Matrix Derivatives on the surgically exposed root surface
41485585|NCT02610387|DEVICE|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
41485586|NCT02610387|DEVICE|Sham tDCS|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
41485587|NCT04686838|BEHAVIORAL|READyR II: A|Continuous monitoring for anomaly detection and contact phone call when a potential change in care needs is indicated by an anomaly.
40818442|NCT06608615|OTHER|Rigid Taping|"Talus Stabilization Taping: The affected ankle of the person to be taped was placed on a chair and asked to bring this foot to a neutral position by advancing the tibia over the foot through knee flexion while standing. Starting from the talus of the ankle, maximum tension was applied towards the medial and lateral malleolus.~Inversion Lock: This lock looks like an inverted 6 when viewed from the front and is used to restrict inversion movement. After the underwrap and anchor were applied, the tape was applied starting from the outer malleolus level. It was glued on itself by proceeding diagonally in front of the foot, passing it in front of the inner malleolus, passing under the foot and in front of the outer malleolus and closing the subtalar area, and the taping was completed by making an anchor on the upper side."
40818443|NCT02099344|DEVICE|Artegraft|Surgical placement of graft for hemodialysis access
40818444|NCT02099344|DEVICE|Propaten|Surgical placement of graft for hemodialysis access
40818445|NCT05587231|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The experimental group will have the Dextenza Insert implanted immediately after surgery
40818446|NCT05587231|DRUG|Topical Fluorometholone|Steroid drops will be administered by the subject according to the standard of care taper
41016332|NCT06653023|BIOLOGICAL|Universal CAR-T cells injection for treating HCC and NSCLC|A novel universal CAR-T platform to treat cancer patients
41485588|NCT04686838|BEHAVIORAL|READyR II: B|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content.
41485589|NCT01828944|DIETARY_SUPPLEMENT|olive oil|
41485590|NCT03537716|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
41337127|NCT03689972|DRUG|Natalizumab|Natalizumab 300 mg IV infusion.
41337128|NCT03689972|DRUG|Natalizumab|Natalizumab 300 mg SC injection or IV infusion.
41337129|NCT00626769|DIETARY_SUPPLEMENT|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
41337130|NCT00626769|DIETARY_SUPPLEMENT|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
41485591|NCT01121341|PROCEDURE|Vein harvesting|Endoscopic versus conventional vein harvesting
41485592|NCT01940497|DRUG|Doxorubicin|Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
41485593|NCT01940497|DRUG|Docetaxel|Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
41485594|NCT01940497|DRUG|Paclitaxel|Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
41485595|NCT01940497|DRUG|Trastuzumab|Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
40818447|NCT02567370|DRUG|AMG 581|Active drug
40818448|NCT02567370|DRUG|Placebo|Placebo
40818449|NCT01159171|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
40818450|NCT01159171|DRUG|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
40818451|NCT01159171|DRUG|oxaliplatin|40 mg/m2 iv weekly
41016343|NCT06653257|OTHER|Active surveillance|a non-operative management strategy aimed at avoiding unnecessary surgery in patients with thyroid nodules with a cytopathological diagnosis of Bethesda IV-VI, who do not present clinical or imaging characteristics suggesting malignancy and/or aggressiveness.
41016348|NCT06653647|BEHAVIORAL|Guided Imagery Therapy|Participants will be asked to listen to a pre-recorded, 10 to 15 minute guided imagery therapy (GIT) session via mobile application 5 out of 7 days per week for 8 weeks in addition to their usual care for their abdominal pain.
41016349|NCT05015218|DIAGNOSTIC_TEST|Vacular Ultrasound|To visualize the internal jugular veins ( IJVs) a linear transducer with a 5-10 MHz linear probe was placed over the neck, and the IJV was measured just below the bifurcation of the sternal and clavicular heads of the muscle. The IJV measurements were performed on the transverse axis over a single respiratory cycle. Patients with evidence of IJV thrombosis were excluded. IJV measurements included the antero-posterior maximum diameter at the end of expiration (IJVmax), the antero-posterior mimimum diameter/area at the end of inspiration (IJVmin), the IJV collapsibility index (IJV-CI) during spontaneous, quiet, breathing, \[(IJVmax - IJVmin area)/IJVmax\] and the ratio (R) of IJVmax-to-IJV-CI.
41016350|NCT01062685|DIAGNOSTIC_TEST|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
41156433|NCT06584643|DIAGNOSTIC_TEST|gasdermin d|evaluation of serum gasdermin d in vitligo patients and healthy controls
41156434|NCT03386305|DRUG|EnvarsusXR|Patients randomized to study drug will be converted to EnvarsusXR once daily.
41156435|NCT03386305|DRUG|Tacrolimus|Patients continue to take Tacrolimus BID, as a part of routine care.
41156436|NCT01812837|DEVICE|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
41156437|NCT01812837|DRUG|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
41156438|NCT01812837|RADIATION|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
40818452|NCT03456843|DRUG|Antiandrogen Therapy|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
40818453|NCT03456843|DRUG|Docetaxel|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
40818454|NCT03456843|OTHER|Laboratory Biomarker Analysis|Correlative studies
40818455|NCT03456843|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
40818456|NCT03456843|OTHER|Questionnaire Administration|Ancillary studies
40818457|NCT03456843|PROCEDURE|Radical Prostatectomy|Undergo cytoreductive radical prostatectomy
40818458|NCT04018976|DEVICE|AVACEN 100|The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm
40818459|NCT04018976|DEVICE|AVACEN 100 heat only|The AVACEN 100 applies heat (108 Fahrenheit) to the palm
40818460|NCT04018976|DEVICE|AVACEN 100 sham|The AVACEN 100 does not provide heat or vacuum
40818461|NCT01829633|PROCEDURE|Physiotherapy|Shoulder physiotherapy with exercises
40818462|NCT01117506|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
40818463|NCT01798173|BIOLOGICAL|Serum, plasma and DNA samples|
40818464|NCT01798173|PROCEDURE|Radiological exploration by CT scan or MRI|
40818465|NCT04807972|DRUG|ABBV-927|Intravenous (IV) Infusion
40818466|NCT04807972|DRUG|Budiglimab|Intravenous (IV) Infusion
40818467|NCT04807972|DRUG|modified FOLFIRINOX|Intravenous (IV) Infusion
41156439|NCT03990909|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
41156440|NCT03990909|DIETARY_SUPPLEMENT|Rice Protein|60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
40818468|NCT04283942|BEHAVIORAL|Intermittent calorie restriction (ICR)|"Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
40818469|NCT04283942|BEHAVIORAL|Continuous calorie restriction (CCR)|"Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × \[height (cm) - 100\] kg) every day by eating conventional food without time restriction.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
40818470|NCT00530829|DRUG|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
40818471|NCT06606509|DEVICE|Continuous Glucose Monitoring System (GX-01S)|Patients with Type 1 Diabetes Mellitus (T1DM) will receive Continuous Glucose Monitoring System (GX-01S) for seven days.
41337131|NCT02786836|DRUG|13C-Methacetin|"The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate."
41337132|NCT03997760|DRUG|TAK-755|Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
41337133|NCT03997760|OTHER|Placebo|Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
41337134|NCT00014586|DRUG|bicalutamide|
41156441|NCT03990909|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
41156442|NCT05746676|DRUG|Insulin|in treatment of periodontal defects
41156443|NCT05746676|DRUG|Hyaluronic acid|in treatment of periodontal defects
41156444|NCT03875599|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
41156445|NCT00551187|BIOLOGICAL|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
41156446|NCT00551187|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
41337135|NCT00014586|DRUG|goserelin acetate|
41337136|NCT00014586|PROCEDURE|orchiectomy|
41337137|NCT02701179|DRUG|Lignocaine 1% concentration solution|
41337138|NCT02701179|DRUG|Lignocaine 2% concentration solution|
41337139|NCT02473224|BIOLOGICAL|Norovirus GII.2 Challenge|GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10\^2 GEC or 1.2 x10\^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, or 1.2 x 10\^6 GEC, or 1.2 GEC x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3
41337140|NCT02473224|OTHER|Placebo|Placebo: 80 ml of sterile water for oral administration
41337141|NCT05013697|DRUG|Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib|TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14；Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
41337142|NCT05013697|DRUG|Paclitaxel + Cisplatin + TQB2450 injection|TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
41485596|NCT04054128|DRUG|Sodium Bicarbonate 7.5% Injection|Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
41485597|NCT04054128|DRUG|Heparin Sodium, 1000 Units/mL Injectable Solution 1|Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
41337143|NCT03250624|DRUG|CD5024 0.3% cream|Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.
41485598|NCT05006872|DEVICE|DIABE-TEXT|Participants will receive 170 text messages in their mobile phones during twelve months.
41156447|NCT00551187|BIOLOGICAL|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
41337144|NCT03250624|DRUG|Placebo|Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.
41337145|NCT03536650|DEVICE|DMR|"Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.~Other Names:~DMR Revita"
41337146|NCT05001776|PROCEDURE|Endovenous laser ablation|Laser ablation of the great saphenous vein close to sapheno-femoral junction
40818472|NCT03537365|DIETARY_SUPPLEMENT|Bovine Colostrum (BC) / intervention group|"Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first."
40818473|NCT03537365|DIETARY_SUPPLEMENT|FM85 / control group|"Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed."
40818474|NCT06125145|BEHAVIORAL|Geriatric Assessment and Promotora Coaching|In Visit 1 the community health worker/promotora will assess frailty, cognition, polypharmacy, depression, symptom burden, and social support. In Visits 2 and 3 the community health worker will deliver interpersonal communication techniques to deliver the problem solving coaching format, leverage cultural congruence with clients, and provide social support to assist in adopting healthy behaviors.
41016351|NCT04760275|DRUG|Fluoxetine|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT)."
41016352|NCT04760275|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of weekly CBT implemented with Coping Cat (CC). In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with CBT. All participants who do not remit will be randomized (1:1) to either (1) optimization of CBT (intensifying exposure practice and skills review), or (2) optimization of CBT and addition of the medication fluoxetine."
41016353|NCT05872035|DEVICE|Apple Software|Amplification settings established by algorithm and further adjusted by participants per their preference
41016354|NCT05872035|DEVICE|by Audiologist|Amplification settings established by clinical reference and further adjusted by an audiologist per current best practice
41016355|NCT04240002|DRUG|gilteritinib|Administered orally.
41016356|NCT04240002|DRUG|fludarabine|Administered by intravenous (IV) infusion
41016357|NCT04240002|DRUG|cytarabine|Administered by intravenous (IV) infusion
41016358|NCT04240002|DRUG|granulocyte colony-stimulating factor (G-CSF)|Administered by subcutaneous injection
41016361|NCT06569186|BEHAVIORAL|Cue-based feedings|Speech therapists will use cue-based protocols to guide feeds
41337147|NCT05001776|DRUG|Fondaparinux Sodium|Fondaparinux sodium for 7 days or 45 days
41337148|NCT00442260|DRUG|DOXIL|
41485599|NCT05631834|PROCEDURE|Thoracic epidurale|Epidurale Perioperative infusion of Ropivacaine
41337149|NCT00442260|DRUG|Abraxane|
41485600|NCT05631834|PROCEDURE|Erector spinae block|erector spinae interfascia Perioperative infusion of Ropivacaine
41485601|NCT05284461|DEVICE|dental implant with transepithelial abutments manufactured by Galimplant Dental System (Spain)|Dental implants with transepithelial abutments with distinct morphology
41337150|NCT02987244|DRUG|Chidamide|"Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose."
41337151|NCT02987244|DRUG|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1
40818475|NCT05588440|BIOLOGICAL|ONCT-808|"A single infusion of ONCT-808 autologous CAR-T cell infusion will be administered intravenously~Phase 1: Dose Escalation with bridging therapy as needed~Phase 2: Patients with LBCL or MCL will be enrolled into two separate dose expansion cohorts."
40818476|NCT05588440|DRUG|Bridging Therapy|Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines
40818477|NCT06386302|DRUG|Chidamide|30 mg/d orally twice-weekly
40818478|NCT06386302|DRUG|Venetoclax|100 mg d1 200 mg d 2 400 mg d3-d28 Orally
40818479|NCT06386302|DRUG|azacitidine|75 mg/m 2 /d subcutaneous injection or IV d1-d7
40818480|NCT04002284|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg p.o. d1-14, 21days/cycle
40818481|NCT03074292|PROCEDURE|phototherapy|estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
40818482|NCT00139295|DEVICE|Hylastan|
40818483|NCT02404870|DRUG|Placebo|Placebo
41337152|NCT02987244|DRUG|Epirubicin|epirubicin (70mg/m2)was administered intravenously on d1;
41337153|NCT02987244|DRUG|Vindesine|vindesine (4mg)was administered intravenously on d1;
41337154|NCT02987244|DRUG|Etoposide|etoposide (100mg) was administered intravenously on d1,2,3.
40818484|NCT02404870|DRUG|Canagliflozin|Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
40818485|NCT05901480|GENETIC|OTOV101N+OTOV101C Injections|The gene therapy of OTOV101N+OTOV101C injection via intracochlear injection.
40818486|NCT06035575|BEHAVIORAL|Educational video|Development of the original video used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script will typically be shown to the patient within 48-72 hours of the acute care visit, with a maximum window of 5 days post visit.
40818487|NCT04158726|BEHAVIORAL|modified Geriatric Assessment (mGA)|The mGA, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making.
40818488|NCT05480215|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
40818489|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for pregnant and lactating women
40818490|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for infant and young children
40818491|NCT01129089|DIETARY_SUPPLEMENT|Micronutrient powder|Micronutrient powder for infant and young children
40818492|NCT00532740|RADIATION|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
41016365|NCT06638996|DIETARY_SUPPLEMENT|CBG Intervention|50 mg CBG Administered
41337155|NCT02987244|DRUG|Prednisone|prednisone (60mg/m2)was administered intravenously by oral d1-5.
41485602|NCT04842136|OTHER|Scales and indexes|Patients with TMD regardless of diagnosis with sleep bruxism were assessed with the Jaw Function Limitations Scale (JFLS), Neck Disability Index (NDI), Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and Headache Impact Test-6 (HIT-6) scales.
41485603|NCT00321737|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
41485604|NCT00321737|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
41485605|NCT00321737|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
41485606|NCT04231942|DEVICE|Graduated Compression Stocking: continuous using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
41485607|NCT04231942|DEVICE|Graduated Compression Stocking: intermittent using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
41485608|NCT04125121|DRUG|Sevoflurane-propofol|General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
41337156|NCT04827810|DRUG|Gamitrinib|This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.
41485609|NCT05046639|DRUG|10 mL 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
41485610|NCT05046639|DRUG|10 mL preservative free saline|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.
41485611|NCT03318276|DRUG|SID142|SID142 is administrated to patients with PAD for 12 weeks
41485612|NCT03318276|DRUG|Rinexin® Tab|Rinexin® Tab is administrated to patients with PAD for 12 weeks
41485613|NCT03001752|DEVICE|Open flap immediate implant|Post-extraction implants will be inserted through open flap, without bone grafting
41485614|NCT03001752|DEVICE|Open flap immediate implant and bone grafting|Post-extraction implants will be inserted through open flap, adding bone grafting
41485615|NCT03001752|DEVICE|Flapless immediate implant|Post-extraction implants will be inserted without elevating flap or inserting bone grafting
41485616|NCT00537927|PROCEDURE|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
41016366|NCT06638996|OTHER|Placebo Intervention|Participants will be administered a placebo
41485617|NCT05211076|OTHER|Music Group|"The Introductory Information Form will be filled in by researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.On the 1st day of the post-op,mothers will be able to listen to Classical Turkish Music works in the forms of Saz Semaisi,Peşrev,Medhal in Rast,Uşşak,Kürdi,Muhayyer makams for 30 minutes via their phone at 11:00am.~While the mother continues to listen to the music,at the 16th minute,the researcher will manually milk the mother for at least 15 minutes until milk comes out.At the end of the milking process,the milk accumulated in the container will be measured by the researcher with injector,recorded in the Breast Milk Follow-up Form.At the end of the music session,it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~The same procedure will be applied to the mother atb05:00pm.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
41485618|NCT05211076|OTHER|Marmet Technique Group|"Consent will be obtained from those who agree to participate in the study. The Introductory Information Form will be filled by the researcher using face-to-face interview technique.~It will be ensured that the mother fills the State Anxiety Scale with her own statement.~The Marmet Technique will be applied to the mothers at 11:00am for 20-30 minutes by the researcher.~At the end of the milking process performed in accordance with the technique, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~At 05:00pm, the same procedure will be applied to the mother. At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
40818493|NCT04741958|DIAGNOSTIC_TEST|Ultrasound Guided Peripheral Thoracic Tumors|Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
41156448|NCT01383616|DEVICE|Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)|A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
40818494|NCT06597994|DEVICE|Amber UI system|Upgrade of Amber UI system recharge accessories and system firmware
41016367|NCT06440525|DRUG|RSLV-132|Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
40818495|NCT01691885|DRUG|Fluticasone Furoate|100mcg Once daily
41016368|NCT06440525|DRUG|Placebo|0.9% sodium chloride solution
41016369|NCT05629208|DRUG|Edecesertib|Tablets administered orally
41016370|NCT05629208|DRUG|Edecesertib Placebo|Tablets administered orally
41016371|NCT00092222|DRUG|Etoposide|Etoposide 50 mg/m2 /day continuous intravenous infusion (CIVI) over 24 hours x 4 days (days 1-4) of 21 day cycle. A maximum of 6 cycles of R-EPOCH-R will be administered except in exceptional circumstances.
41016372|NCT00092222|DRUG|Interferon-alpha|Ages 18 and over: Initial dose of 7.5 million units subcutaneous, three times weekly x 14 days; subsequent dosesincrease dose as tolerated each 14 days to a maximum of 45 million units subcutaneous three times weekly; Ages 12-17: Initial dose of 5 million units/m2 subcutaneous, three times weekly x 14 days Subsequent doses: Increase dose as tolerated each 14 days to a maximum of 30 million units/m2 subcutaneous, three times weekly
41016373|NCT00092222|DRUG|Rituximab|Rituximab 375 mg/m2 IV day 1, shall be administered prior to Doxil injection. When combined with EPOCH chemotherapy, Rituximab will be given on days 1 and 5.
41016374|NCT00092222|DRUG|Zidovudine|Cycle 1: Zidovudine 600 mg PO QID x 7-21 days in outpatient setting;600 mg PO q6hours x 7-21 (Intravenous zidovudine 300 mg q 6 hours may be substituted) days for inpatients; Cycle 2 and beyond: 600 mg PO QID x 7 days in outpatient setting; 600 mg PO q 6 hours x 7 days (300 mg q 6 hours may be substituted)
40818496|NCT01691885|DRUG|Vilanterol|25mcg Once daily
40818497|NCT01495130|PROCEDURE|ultrasound imaging|Undergo transrectal ultrasound
41016375|NCT00092222|DRUG|Liposomal Doxorubicin|21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
41016376|NCT00092222|DRUG|Bortezomib|1.3 mg/m2 IV days 1, 4, 8, and 11. Cycle length is 21 days.
40818498|NCT01495130|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
40818499|NCT03702920|BIOLOGICAL|SMT + PE-A 5%|Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
40818500|NCT03702920|OTHER|Standard Medical Treatment|Standard medical treatment according to the institution's standard practice
40818501|NCT03371407|OTHER|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
40818502|NCT06100744|DRUG|Adalimumab|SC Injection
40818503|NCT06100744|DRUG|Risankizumab|Subcutaneous (SC) Injection
41016377|NCT00092222|DRUG|Valganciclovir|Cycle 1: Valganciclovir 900 mg PO BID x 7-21 days in outpatient setting; 900 mg PO q 12 hours x 7-21 days for inpatients; Cycle 2 and beyond: 900 mg PO BID x 7 days for outpatients; 900 mg PO q 12 hours x 7 days (Intravenous ganciclovir 5 mg/kg may be substituted) for inpatients
41156449|NCT05026242|BEHAVIORAL|Almond intervention|Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
41485619|NCT05211076|OTHER|Control group|"The Introductory Information Form will be filled by the researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.The mothers will milk the mother manually by the researcher at 11:00am for at least 15 minutes until the milk does not come.~At the end of the milking process, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form in ml.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement. At 05:00pm, the same procedure will be applied to the mother.~At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
41337157|NCT05795868|DEVICE|Compression stocks|Pregnant women in the compression stockings group will wear the socks given for 3 weeks.
41485620|NCT01347658|DIETARY_SUPPLEMENT|Echinacea purpurea|Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
41485621|NCT01908790|DEVICE|Mespere Venous Oximeter|The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.
41337158|NCT05795868|OTHER|Knee socks|Pregnant women in the Knee socks group will wear the socks given for 3 weeks.
41485622|NCT01908790|DEVICE|Avoximeter 4000|The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
40818504|NCT04762043|DEVICE|Experimental System: MyoVoice|Person-centric augmentative and alternative communication (AAC) system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.
40818505|NCT04762043|DEVICE|Reference System: Electrolarynx|Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
40818506|NCT06145633|PROCEDURE|Biopsy|Undergo biopsy
40818507|NCT06145633|PROCEDURE|Biospecimen Collection|Undergo blood sample colleciton
40818508|NCT06145633|PROCEDURE|Bone Scan|Undergo bone scan
41485623|NCT03898921|RADIATION|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
40818509|NCT06145633|PROCEDURE|Computed Tomography|Undergo CT, SPECT/CT, PET/CT
40818510|NCT06145633|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
40818511|NCT06145633|OTHER|Gallium Ga 68 Gozetotide|Given IV
40818512|NCT06145633|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given 177Lu-PSMA-617
40818513|NCT06145633|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET
40818514|NCT06145633|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
40818515|NCT06145633|DRUG|Vorinostat|Given IV
40818516|NCT02969291|BEHAVIORAL|Reduced Sedentary Time Intervention (RSTI)|Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
40818517|NCT06607484|DRUG|SR-878|Intravenous infusion
40818518|NCT06607484|DRUG|Placebo|Intravenous infusion
40818519|NCT04081753|DEVICE|Remote monitoring of temperature|The patient will be set up with a remote monitoring device for temperature recording and the temperature will monitored remotely
40818520|NCT06606002|BEHAVIORAL|Group schema therapy|Group schema therapy based on the model by Farrell and Shaw, which is complemented with separate group sessions for the participants\&#39; parents
40818521|NCT06606002|BEHAVIORAL|Treatment as Usual (TAU)|TAU typically comprises visits at the outpatient clinic with variable frequency and content
40818522|NCT02511093|BEHAVIORAL|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~* BP measurements;~* an educational and counselling intervention on patient adherence;~* an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
40818523|NCT06587334|PROCEDURE|SRP|SRP alone
40818524|NCT06587334|PROCEDURE|Nd: YAG Laser Assisted SRP|the patients receive SRP combined with Nd: YAG laser
41156450|NCT05026242|BEHAVIORAL|Control|Participants will be provided with isocaloric snacks
41337159|NCT04066699|PROCEDURE|Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.|Transthoracic localization of suspicious lung lesion(s) in preparation for subsequent resection.
41337160|NCT03183960|BEHAVIORAL|Mentor|Traditional rehabilitation.
40818525|NCT03267043|BEHAVIORAL|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
40818526|NCT03267043|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
40818527|NCT06598449|DRUG|fenfluramine|Clear, cherry flavored oral solution
40818528|NCT01166373|BEHAVIORAL|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
41337161|NCT02288039|OTHER|Social Identity goal-based Intervention|Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
41337162|NCT04632745|OTHER|Wrist Rehabilitation|participants will undergo immobilization for the first 6 weeks of treatment
41337163|NCT03037567|BEHAVIORAL|Modified Weight Watchers plan|Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
41337164|NCT05255341|PROCEDURE|roll pedicle connective tissue graft with bovine bone|rotated pedicle connective tissue graft together with bovine bone applied for socket preservation after tooth extraction
41485624|NCT03898921|PROCEDURE|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 3 times.
41485625|NCT03632967|DEVICE|Tricinch Coil System Implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
41485626|NCT03110601|DEVICE|Control - Conventional SCS|Conventional SCS Parameters
40818529|NCT01166373|PROCEDURE|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
40818530|NCT01166373|PROCEDURE|ULS|uterosacral ligament suspension to suspend the vaginal apex
41485627|NCT03110601|DEVICE|Test - Stimgenics SCS|Stimgenics SCS Parameters
41016378|NCT00092222|DRUG|Doxorubicin|10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
41485628|NCT01832207|DEVICE|Transcutaneous electrical nerve stimulation|
41485629|NCT01832207|DEVICE|Placebo transcutaneous electrical nerve stimulation|
41485630|NCT01111019|DRUG|Recombinant human growth hormone (r-hGH)|Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
41485631|NCT01988506|DRUG|Interleukin 2|Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
41485632|NCT01293760|OTHER|Immediate insertion|Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
41485633|NCT01293760|OTHER|6 weeks interval insertion|Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
41485634|NCT06224322|OTHER|Assesment Scale|Caregiving burden will be assessed with Turkish validated scoring tools such as the Zarit scale and the Pediatric Quality of Life Inventory (PEDSQL) Family Impacts module before and after surgery.
40818531|NCT01166373|BEHAVIORAL|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
40818532|NCT01166373|OTHER|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
41016379|NCT00092222|DRUG|Vincristine|0.4 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
41016380|NCT00092222|DRUG|Cyclophosphamide|Cyclophosphamide: if CD4 \< 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 greater than or equal to 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.
41016381|NCT00092222|DRUG|Filgrastim (G-CSF)|Filgrastim 300 micrograms subcutaneous daily beginning day 6 until absolute neutrophil count recovery 5000 cells/mm3 (Pegfilgrastim may be substituted with PI approval, at the recommended dose of one 6mg syringe)
40818533|NCT02396771|PROCEDURE|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
40818534|NCT02396771|PROCEDURE|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
40818535|NCT06607614|OTHER|Colorectal Cancer Screening Fecal Immunochemical Test|Fecal Immunochemical Test
40818536|NCT05634746|DRUG|APT-1011|"APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate"
40818537|NCT05634746|DRUG|Placebo oral tablet|"Placebo orally disintegrating tablet.~Other Names:~PBO"
40818538|NCT05634746|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
40818539|NCT00904930|DEVICE|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
41016382|NCT00092222|DRUG|Prednisone|Prednisone 60 mg/m2/day PO x 5 days (days 1-5)of 21 day cycle.
41016383|NCT00092222|DRUG|Sirolimus|Maximum daily dose of 40 mg given as a single agent on 21 day cycle.
41016384|NCT00092222|OTHER|Observation Only|Observation of symptoms
41016385|NCT06654726|DRUG|aldafermin|aldafermin
41337165|NCT04511988|OTHER|Diagnostic Test|blood sample (20 ml) and biopsy
41337166|NCT00422357|DRUG|Urtica Dioica (Tea bag)|
41337167|NCT04479449|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
41337168|NCT04479449|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
41016386|NCT06654726|DRUG|Placebo|placebo
40818540|NCT00904930|DEVICE|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
40818541|NCT00559845|DRUG|5-fluorouracil|600 milligrams per meter squared (mg/m\^2) as an intravenous (i.v.) bolus over ≤15 minutes every 3 weeks for 4 cycles.
40818542|NCT00559845|DRUG|Epidoxorubicin|90 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
40818543|NCT00559845|DRUG|Cyclophosphamide|600 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
41485635|NCT05495984|BEHAVIORAL|ERPs with electroencephalography (EEG)|E-Prime 2.0 software will present visual and auditory stimuli in an experimental paradigm lasting approximately 30 minutes (ERPs). Visual stimuli will include photographs of color photographs of unfamiliar infants (aged 5- 10 months) balanced for ethnicity (Black/White) and gender (male/female) displaying happy neutral, and sad affective expressions. Auditory stimuli will include 2-second audio clips of high-distress and low-distress infant cries. Experimental procedure: Trials will consist of a central fixation cross (jittered 400-600ms), stimulus presentation (500ms faces, 2000ms cries), and blank screen (1000ms). Continuous electroencephalography (EEG) will be recorded using Net Station 4.2.1. A 128 Ag/Silver Chloride (AgCl) electrode net will be soaked in a warm potassium chloride solution, and net electrodes will be spaced evenly and symmetrically on each participant's head to cover the scalp.
41485636|NCT05495984|BEHAVIORAL|MIO|A 12-week, manualized, individual parenting psychotherapy developed specifically for mothers with addictions administered by the Principal Investigator. It is designed to foster a mother's capacity for mentalization or reflective functioning (RF). MIO is offered in conjunction with standard addiction treatment.
41485637|NCT02660528|DRUG|Tocilizumab|Subcutaneous tocilizumab
41485638|NCT00243464|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
41485639|NCT05037786|BEHAVIORAL|Infographic|Key themes related to pain and injury in elite players based on previous studies presented using an A3 infographic
41485640|NCT05037786|BEHAVIORAL|Powerpoint|Key themes related to pain and injury in elite players based on previous studies presented using a Powerpoint
41485641|NCT03731221|DRUG|Bupi HCI and lipo bupi|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
41485642|NCT03731221|DRUG|Bupi HCI|The LA used for the blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Control patients will have preservative free normal saline mixed with 0.5% bupivacaine HCL and all patients will have a total block solution volume of 60 ml.
40818544|NCT00559845|DRUG|Paclitaxel|Paclitaxel was administered at 80 mg/m\^2 i.v. over 1 hour weekly for 12 weeks.
40818545|NCT00559845|BIOLOGICAL|Bevacizumab|Bevacizumab was administered at 10 milligrams per kilogram (mg/kg) i.v. every 2 weeks for 6 cycles.
40818546|NCT05333172|OTHER|Dual task exercises|Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.
40818547|NCT04580758|COMBINATION_PRODUCT|Fractional laser with PRP fluid or PRP gel|20 participants divided into 2 groups of 10 10 participants will do Fractional laser with PRP fluid sessions and 10 participants will do Fractional laser with PRP gel
40818548|NCT03475706|DRUG|Solabegron immediate release tablets, low dose|twice daily for 12 weeks.
40818549|NCT03475706|DRUG|Solabegron immediate release tablets, high dose|twice daily for 12 weeks.
40818550|NCT03475706|DRUG|Matching Placebo|twice daily for 12 weeks.
40818551|NCT05193201|DRUG|recombinant human thrombopoietin injection|recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
41156451|NCT04458012|DIAGNOSTIC_TEST|Oculus Keratograph. Schirmer test. Tear fluid sample.|Objective measurements of the ocular surface using Oculus 5 keratograph. Slit lamp examination and tear fluid sample using Schirmer strips.
41156452|NCT05903118|BIOLOGICAL|RBMRNA-176|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection
41016388|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
41337169|NCT05616845|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
41337170|NCT01094808|DRUG|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
41337171|NCT01094808|DRUG|Placebo|Placebo capsules
41485643|NCT02917330|OTHER|Stretching and progressive strength training|Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
41485644|NCT00384176|DRUG|Cediranib|oral tablet once daily
41485645|NCT00384176|DRUG|Bevacizumab|intravenous infusion
41337172|NCT01094808|OTHER|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
41337173|NCT05227768|DRUG|VV116 25mg Group|4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.
41337174|NCT05227768|DRUG|VV116 200mg Group|6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.
41337175|NCT05227768|DRUG|VV116 400mg Group|6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.
41337176|NCT05227768|DRUG|VV116 800mg Group|6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.
41337177|NCT05227768|DRUG|VV116 1200mg Group|6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.
41016389|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
41337178|NCT00415545|BEHAVIORAL|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
41337179|NCT00415545|BEHAVIORAL|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
41337180|NCT02104323|DRUG|Endostatin|Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
41337181|NCT03382197|DEVICE|Nebulization|For inhalation of the radioaerosol a dose of DTPA-Tc99m (methionine-labeled diethylnitriaminepentaacetic acid) with 1mCi activity, associated with 10 drops of Fenoterol Bromide and 20 drops of Ipatropium Bromide diluted for a total of up to 3 ml of saline solution 0.9%. A MESH vibrating nebulizer (NIVO, Philips Respironics, Murrysville, Pennsylvania) will be used.
41485646|NCT00384176|DRUG|5-fluorouracil ( in FOLFOX)|intravenous infusion
41485647|NCT00384176|DRUG|Leucovorin (in FOLFOX)|intravenous infusion
41485648|NCT00384176|DRUG|Oxaliplatin (in FOLFOX)|intravenous infusion
41485649|NCT03941353|OTHER|Usual care|Benchmark study with retrospective patient analysis evaluating the actual care patients with a fragile hip fracture receive
41485650|NCT02435836|DRUG|Aripiprazole|
41485651|NCT01968694|DRUG|IV Lidocaine|
41485652|NCT01968694|DRUG|IV diphenhydramine|
41485653|NCT03118570|DRUG|setrusumab|Intravenous infusion
41485654|NCT03118570|DIETARY_SUPPLEMENT|Calcium|tablets
41485655|NCT03118570|DIETARY_SUPPLEMENT|Vitamin D|capsules
41337182|NCT03382197|DEVICE|Positive expiratory pressure valve|For nebulization associated with the EPAP valve will be used a non-invasive distribution system consisting of a non-toxic orofacial mask connected to a spring loaded EPAP valve. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
41337183|NCT03382197|DEVICE|Nonivasive ventilation|For nebulization associated with NIV, a noninvasive distribution system consisting of a non-toxic orofacial mask connected to the NIV circuit will be used, and the latter will be being fed by a radioaerosol flow generated by a nebulizer coupled to the circuit. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
41337184|NCT04503850|DRUG|Mirabegron 50 MG|Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
41337185|NCT04503850|DRUG|Alpha Blockers|Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
41337186|NCT02525406|OTHER|All surgeries performed from Jan 01, 2010 to Aug 31, 2020|
41337187|NCT05007340|OTHER|Blood draws|Blood draws will be performed by personnel that are both qualified and authorized by their employer/institution to perform the procedures. The procedures will be performed with standards expected in the context of clinical care. 40 mL (2-3 tbsp) of blood will be drawn in order to collect DNA, RNA, serum and PBMCs. Blood tubes will be sent to the Bank as per the SOP for patient blood sampling and processing. The blood will be processed, centrifuged and stored by a trained laboratory technician.
41337188|NCT05007340|OTHER|Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid)|If the patient's medical care or their participation in a research project involves a biopsy or surgery to remove tissue, the tissue not required for diagnosis (excess tissue) or hospital archives will be included in the biobank. This may include healthy tissue as well as tissue affected by the patient's health condition. The Investigators will not conduct extra procedures in order to obtain samples for the sole purpose of this study and will only operate on what's available. These may include blood samples, skin, lung and muscle biopsies, and bronchoalveolar lavage, all of which will be obtained from the pathology department.
41337189|NCT05007340|OTHER|Clinical data collection|Participant's relevant medical information from medical records, general health questionnaires and clinical assessments. The data includes gender, date of birth, race/ethnicity, habits, height, weight, vital signs, medical history, family history, pregnancy history, imaging data pertinent to ILDs and SARDs, results of routine blood tests, environmental exposures, medication and treatment exposures and adherence, function and quality of life, patient's assessment of their own health, clinical symptoms.
41337190|NCT05007340|OTHER|Genetic data/DNA/RNA|Results of the DNA or RNA sequencing, conducted for the Biobank and will be made available to future research; possible single nucleotide polymorphism (SNP) assays (including single SNP, low-plex or microarray-based assays).
41337191|NCT06438965|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|MSOT scans will be obtained from two muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patient with neuromuscular diseases.
41485656|NCT03118570|DRUG|zoledronic acid (optional)|Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
41485657|NCT06254963|OTHER|sand jump training|A series of progressive jumping activities on sand increasing in difficulty over the 6 week period
41485658|NCT06254963|OTHER|land jump training|A series of progressive jumping activities on land increasing in difficulty over the 6 week period
41485659|NCT04393766|DRUG|Normal Saline|normal saline(crystalloids)
41485660|NCT03235661|DEVICE|BiPAP|BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
41485661|NCT03235661|DEVICE|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
41485662|NCT03736213|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. I
41156453|NCT05903118|OTHER|Placebo|0.9% sodium chloride (normal saline) injection
40818552|NCT03517839|OTHER|Inspiratory muscle trainig|Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
40818553|NCT05332743|DIETARY_SUPPLEMENT|Nutrafol Vegan Women's Hair Supplement|Nutrafol's Vegan Women's Hair Supplement with patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, Curcumin, Saw Palmetto, 20% Tocotrienol/Tocopherol complex, and capsaicin in combination with other vegan nutrients used to support hair health such as Pea Sprout Extract, Bamboo, and a new innovative Maldavian Dragonhead flower extract.
41337192|NCT01136213|RADIATION|PET (Positron Emission Tomography) Study|5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
41337193|NCT01136213|OTHER|Brain MRI (magnetic resonance imaging)|A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.
41337194|NCT01136213|DRUG|Fluoxétine / Placebo|The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
41337195|NCT00333047|DRUG|Letrozole|
40818554|NCT04065074|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
40818555|NCT02782052|DRUG|Nebulized ipratropium bromide|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
40818556|NCT02782052|DRUG|Nebulized combination ipratropium bromide with salbutamol|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
40818557|NCT02782052|DRUG|Nebulized Placebo|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
40818558|NCT03142399|DIETARY_SUPPLEMENT|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
40818559|NCT06489821|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy in 5 fractions (body) or 2 or 4 fractions (spine) plus continuation of first line systemic therapy
40818560|NCT03894631|PROCEDURE|KDB/Phacoemulsification|50 eyes of 50 patients will receive combined KDB/phaco surgery
40818561|NCT03894631|PROCEDURE|Trabectome/Phacoemulsification|The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
40818562|NCT05941520|DRUG|Acolbifene Hydrochloride|Given PO
40818563|NCT05941520|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40818564|NCT05941520|PROCEDURE|Mammography|Undergo 3D mammography
41156454|NCT03149432|PROCEDURE|Mirror Therapy|by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
41156455|NCT03149432|DRUG|Gabapentin|titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
41337196|NCT01594346|DRUG|Alpha-Tocopherol|1,000 International Units, two times a day for 36 months
41337197|NCT01594346|DRUG|Sugar Pill|
41337198|NCT04140539|BIOLOGICAL|OTL-101|Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
41337199|NCT01770756|BEHAVIORAL|Self-Care Training|
41337200|NCT02715804|OTHER|Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
41156456|NCT03149432|PROCEDURE|Rehabilitation|Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
41337201|NCT02715804|DRUG|Placebo|Matching placebo for PEGPH20
41337202|NCT02715804|DRUG|nab-Paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
41156457|NCT03149432|OTHER|Local care|local care for directed healing of the stump.
41337203|NCT02715804|DRUG|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
41337204|NCT00049972|DRUG|paroxetine CR|
41337205|NCT05070325|OTHER|Cold application group|Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
41337206|NCT05070325|OTHER|Shotblocker group|Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
41337207|NCT05070325|OTHER|Control Group|Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
41337208|NCT03087708|DRUG|Naloxegol|Given PO
41337209|NCT03087708|OTHER|Placebo|Given PO
41337210|NCT03087708|OTHER|Laboratory Biomarker Analysis|Correlative studies
41337211|NCT03087708|OTHER|Quality-of-Life Assessment|Ancillary studies
41337212|NCT02957474|DRUG|GED-0301|
41337213|NCT02957474|DRUG|Omeprazole|
41337214|NCT04914819|BEHAVIORAL|Online Behavioral Weight Loss Program|Participants will be enrolled in a 16-week online behavioral weight loss program based on the Diabetes Prevention Program (DPP). The program involves weekly brief videos, a self-monitoring platform, automated feedback, and access to a health coach.
41337215|NCT04914819|BEHAVIORAL|Virtual weigh-in|Participants will be sent a digital scale and will be asked to complete a virtual weigh-in at home at the start of the study and again after 16 weeks.
40818565|NCT05941520|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
40818566|NCT05941520|DRUG|Tamoxifen|Given PO
40818567|NCT05304117|BEHAVIORAL|Advance Care Planning|Community Information Session and Private Sharing Session with trained social worker
41016392|NCT06192004|OTHER|None (Observational Study)|Not applicable since Observational Study
40818568|NCT00612417|DRUG|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
41016393|NCT06602596|BEHAVIORAL|Hoosier Sport|The Hoosier Sport intervention is an 8-week program designed for students in PE classes, focusing on enhancing physical activity and promoting health through sport. The curriculum includes unique sports activities, leadership exercises, and health education, aimed at improving students' physical and psychological well-being. The program also addresses the effects of screen time and social media on physical activity, encouraging healthier behaviors. Throughout the intervention, students wear AX3 accelerometers to track changes in their physical activity levels, helping to assess the program's impact.
41337216|NCT03790072|BIOLOGICAL|OmnImmune®|infusion of OmnImmune® (expanded gamma delta T lymphocytes)
41337217|NCT03507881|DEVICE|fusion|Internal fixation
40818569|NCT04819438|DRUG|Riluzole 50 mg Oral Film|Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.
41016394|NCT06594913|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
40818570|NCT04819438|DRUG|Rilutek 50Mg Tablet|One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
40818571|NCT06575933|DRUG|MK-1084|Oral administration
40818572|NCT06575933|DRUG|Midazolam|Oral administration
40818573|NCT06575933|DRUG|Digoxin|Oral administration
40818574|NCT03851120|DIETARY_SUPPLEMENT|Probiotics and LC-PUFA (480 mg DHA)|Probiotics and LC-PUFA (480 mg DHA)
40818575|NCT03851120|DIETARY_SUPPLEMENT|Placebo probiotics and control LC-PUFA (120 mg DHA)|Placebo probiotics and control LC-PUFA (120 mg DHA)
41337218|NCT06398951|DEVICE|Two nare high flow nasal cannula|Recently a new mode of high flow oxygen therapy has presented on the market where the prongs of high flow have different diameters .These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP.
41337219|NCT03523949|BEHAVIORAL|PNE|The PNE will be delivered by a physiotherapist in a single, group-based session.
40818576|NCT03851120|BEHAVIORAL|Psychosocial stimulation and healthy eating education|Psychosocial stimulation and healthy eating education
40818577|NCT01364558|DRUG|Diazepam|Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
40818578|NCT01364558|DRUG|Diazepam|IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
40818579|NCT02357082|RADIATION|MRI Scan|MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
41337220|NCT01511991|DRUG|Sevoflurane dosage titration|comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
41337221|NCT02311790|DIETARY_SUPPLEMENT|Trans-C16:1 supplement|Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
41337222|NCT02311790|DIETARY_SUPPLEMENT|Cis-C16:1 supplement|Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
41337223|NCT02766907|DEVICE|cryopreserved amniotic membrane|placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
41337224|NCT02593461|DEVICE|Daifert|
41337225|NCT02593461|OTHER|Control Group|
40818580|NCT04372147|PROCEDURE|MMA embolization|Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
40818581|NCT06605820|OTHER|None - Interview Only|None - Interview Only
40818582|NCT04804631|DEVICE|Enteral feeding tubes|Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
40818583|NCT03371134|BIOLOGICAL|Harvesting of muscular biopsies|Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
40818584|NCT01337843|OTHER|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
40818585|NCT01337843|OTHER|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
40818586|NCT00504517|OTHER|Evaluating Educational Models|Evaluating various forms of educational models for physicians.
40818587|NCT00090142|DRUG|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
40818588|NCT00090142|DRUG|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
40818589|NCT01186042|OTHER|Observational|No intervention
40818590|NCT04305184|DRUG|ASP0598|ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.
40818591|NCT04305184|OTHER|Placebo|Placebo matched to ASP0598 Otic solution was administered onto the TM through the external auditory canal via syringe.
40818592|NCT02592720|DRUG|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
41337226|NCT01316380|DRUG|placebo|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
41337227|NCT01316380|DRUG|tiotropium 2.5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
41337228|NCT01316380|DRUG|tiotropium 5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
41337229|NCT00150345|DRUG|voriconazole (Vfend)|voriconazole, early treatment
41337230|NCT00150345|DRUG|voriconazole (Vfend)|voriconazole, deferred treatment
41337231|NCT01335490|OTHER|Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel|The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
41337232|NCT00936793|DRUG|Darunavir|
41337233|NCT00936793|DRUG|Ritonavir|
41337234|NCT00936793|DRUG|Beclomethasone Dipropionate HFA|
41337235|NCT01054612|OTHER|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
41337236|NCT03770780|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
40818593|NCT02592720|DEVICE|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
40818594|NCT02592720|DEVICE|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
40818595|NCT04652206|DRUG|SCO-101|Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
40818596|NCT04652206|DRUG|Gemcitabine|Used according to marketing authorisation
40818597|NCT04652206|DRUG|Nab paclitaxel|Used according to marketing authorisation
41156458|NCT04260776|BEHAVIORAL|Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with a corresponding 1-way text messages
41337237|NCT03770780|DRUG|Placebo|Placebo in combination with Ketamine
41337238|NCT00816855|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
41337239|NCT00086294|DRUG|Intravenous Levodopa|
41337240|NCT00086294|DRUG|ACP-103|
41337241|NCT02019017|DRUG|Botulinum Toxin Type A 25 IU|
41337242|NCT02019017|DRUG|Botulinum Toxin Type A 50 IU|
41337243|NCT02452749|DIETARY_SUPPLEMENT|Cardiovascular health dietary supplement|Herbal/mineral dietary supplement
41337244|NCT05132595|DRUG|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
41337245|NCT05132595|DRUG|Esketamine at high dose|After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
41337246|NCT05132595|DRUG|Esketamine at low dose|After the induction of anesthesia, esketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h esketamine until starting skin suture.
41337247|NCT05132595|DRUG|Ketorolac at high dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h Ketorolac until starting skin suture.
41337248|NCT05132595|DRUG|Ketorolac at low dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h Ketorolac until starting skin suture.
41337249|NCT04421612|BEHAVIORAL|Co-mestring (co-coping)|8 modules with the aim to reduce stress, increase coping of social isolation and coping with the consequences of reduced positive experiences
41337250|NCT04348435|BIOLOGICAL|HB-adMSCs|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
41337251|NCT04348435|OTHER|Placebos|Saline
41337252|NCT06127511|OTHER|Food (peanut)|After the recruitment, the participants will follow a peanut-free diet for two weeks.
41337253|NCT06221956|BEHAVIORAL|relevis|Participants will receive access to the digital health intervention relevis in addition to TAU.
41337254|NCT02582931|DEVICE|MRI-guided SBRT|
41337255|NCT02582931|BEHAVIORAL|EORTC QLQ-C30 Questionnaire|30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
41337256|NCT02582931|BEHAVIORAL|EORTC QLQ-OV28 Questionnaire|28 questions having answers that range from 1 (not at all) to 4 (very much)
40818598|NCT02966964|DRUG|DWPUR001|
40818599|NCT02966964|DRUG|Placebo|
40818600|NCT01689870|DRUG|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
40818601|NCT01689870|DRUG|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
41156459|NCT04260776|BEHAVIORAL|Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with corresponding interactive, 2-way text messages
41337257|NCT04287439|BEHAVIORAL|Progressive muscle relaxation|Patients will receive a training session for progressive muscle relaxation exercise They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
40818602|NCT06404320|BEHAVIORAL|PA program - MoveU.HappyU|"Participants will meet with their program trainer once a week virtually for 4 weeks to engage in 30 minutes of behavioral change coaching and 30 minutes of a structured PA program that is tailored to their needs and goals. The intensity of the PA sessions will be self-selected. PA sessions will involve a warmup, a conditioning component consisting of individualized aerobic or resistance exercises, and a cool down/stretch.~Participants will also be instructed to independently engage in PA (outside of their session with the trainer) for 120 minutes at 50-65% of their maximum work capacity. This can be done by engaging in PA between 3-5 times per week."
41337258|NCT04287439|BEHAVIORAL|Mindfulness meditation|Patients will receive a training session for mindfulness meditation. They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
41337259|NCT04287439|OTHER|Attention matched control|Patients will receive a training session focusing on focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods
41337260|NCT03208049|BEHAVIORAL|Sleep Restriction Therapy|Sleep Restriction Therapy will regulate time spent in bed based on information collected from sleep diaries during evaluation and treatment. Sleep Restriction therapy is designed to improve sleep quality by matching opportunity for sleep to the amount of average total sleep calculated from sleep diaries. Once the quality of sleep has improved, sleep quantity is gradually increased by slowly increasing sleep opportunity. Stimulus control will strengthen the bed/sleep association by eliminating non-sleep activities from the bedroom.
41337261|NCT03208049|BEHAVIORAL|Cognitive Therapy|Cognitive Therapy is designed to identify maladaptive beliefs about sleep, challenge their validity, and replace them with more adaptive thinking patterns. This therapy aims to reduce sleep-related worry, anxiety, and fear. The treatment phase of the study lasts six weeks. During treatment, you will meet with a study therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
41337262|NCT00236405|DRUG|epoetin alfa|
41337263|NCT03898388|PROCEDURE|Bone Marrow Concentrate treatment|Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
41337264|NCT05753202|DEVICE|transcranial current direct stimulation|Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)
40818603|NCT02045381|PROCEDURE|MRI Group|A single research MRI
40818604|NCT04600076|BEHAVIORAL|BabyCenter site and the community group|Participants will be asked to sign on to the BabyCenter community group for people with pregnancy or infant loss at least 3 times weekly for 6 weeks. Participants may choose to post or comment on the site but are not required to do so.
40818605|NCT00907530|DRUG|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
40818606|NCT00907530|DRUG|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
41016400|NCT06592313|PROCEDURE|Intubation|Aiway management procedure involving the Insertion of an orotracheal cannula through the oropharynx.
41156460|NCT04260776|BEHAVIORAL|Phase 2: re-engagement text messages|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive interactive text messages designed to promote re-engagement
41156461|NCT04260776|BEHAVIORAL|Phase 2: re-engagement emails|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive a personalized email designed to promote re-engagement
40818607|NCT06606925|DIAGNOSTIC_TEST|fMRI with virtual reality flight simulator|During this scan, the subject will be wearing the stereogenic goggles called the Visual System HD (NordicNeuroLab) mounted in the scanner via a headcoil that can be adjusted to the subject\&#39;s comfort using the control arm and completely cover the eyes to prevent light exposure and to clearly visualize eye movement during the flight simulation. The subject will be using a visual response system with customized grips to simulate a stick and throttle in a jet cockpit while visualizing the flight simulation (PICT) in the goggles.
41016404|NCT05540886|BEHAVIORAL|TEACH CLEAN|"The intervention is primary a training facility cleaning champions to educate and supervise other existing facility cleaners with environmental hygiene responsibilities - training of trainers (ToT).~The training content includes as much as possible the seven contextualized modules of TEACH CLEAN training package (CLEAN BOX): i) Introduction to Infection Prevention and Control, ii) Personal hygiene and dress code, iii) Hand hygiene, iv) Personal protective equipment, v) Housekeeping/control of environment, vi) Waste handling, and vii) Linen handling.~Facility training will occur in three selected wards: i) maternity ward, including labour and post-natal rooms, ii) medicine ward, iii) and medicine ward.~There is also supervision stage that refers to ongoing mentorship of cleaning champions by the local partner while they educate and supervise existing facility cleaners with environmental hygiene responsibilities."
41337265|NCT02307604|GENETIC|Tumour markers testing|
41337266|NCT00760045|DRUG|Hydroxypropyl Guar Galactomannan|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
41337267|NCT00760045|DRUG|0.1% sodium hyaluronate ophthalmic solution|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
41016405|NCT04176796|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
40818608|NCT03136146|DRUG|Bortezomib|Given SC
41337268|NCT02892175|PROCEDURE|Advance Directives on End of Life|after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
40818609|NCT03136146|DRUG|Clofarabine|Given IV
40818610|NCT03136146|DRUG|Cyclophosphamide|Given IV
40818611|NCT03136146|DRUG|Dexamethasone|Given IV or PO
40818612|NCT03136146|DRUG|Etoposide|Given IV
40818613|NCT03136146|BIOLOGICAL|Ofatumumab|Given IV
40818614|NCT03136146|BIOLOGICAL|Pegfilgrastim|Given SC
40818615|NCT03136146|BIOLOGICAL|Rituximab|Given IV
40818616|NCT03136146|DRUG|Vincristine Sulfate Liposome|Given IV
40818617|NCT05015855|OTHER|NP-PC PrEP|All participating providers will be provided standard education around PrEP and HIV prevention, but half of the providers will be randomized to also partner with a nurse practitioner who will provide additional consultation to patients.
41016406|NCT06657274|DEVICE|RICORDO-DTx|"Tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities with an innovative digital solution for remote rehabilitation of cognitive difficulties according to digital therapeutics delivery model. Subjects assigned to the tele@cognitive group can access the app RICORDO-DTx through a tablet showing the prescribed rehabilitation activities to be performed.~Each cognitive exercise is structured into five levels of difficulty that adaptively increase (algorithm on both subject's performance and perceived difficulty). All data about patient progress and adherence will be collected with this digital solution and will be available to evaluate and monitor the results of rehabilitation."
41016407|NCT06657274|BEHAVIORAL|Home-based unstructured cognitive stimulation|Subjects assigned to the home-based unstructured cognitive stimulation will be requested to work on detailed activities for the same duration of the tele@cognitive intervention (3 sessions/week, 45 minutes/session). They will receive, from the therapist, an instructions booklet and a participant diary.
41337269|NCT05068076|DRUG|Perfluorobutane|Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI
41337270|NCT01107288|OTHER|Music-based multitask exercises program|Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.
40818618|NCT05015855|OTHER|OBGYN-PrEP|"OBGYN-PrEP is based on PC4PrEP (R01MH107297) that has four steps: announce the policy that PrEP counseling is the responsibility of OBGYN providers to address the purview paradox; train providers to manage patients on PrEP; use a screening tool to identify women appropriate for PrEP; and implementation coaching to monitor and encourage PrEP counseling"
40818619|NCT03575117|BEHAVIORAL|Common-Sense Model (CSM) Be Well|Theoretically informed text messages and images that cover how physical activity is linked to decreasing colorectal cancer risk.
40818620|NCT03575117|BEHAVIORAL|ACS usual messages|Information distributed by the American Cancer Society as information on the link between physical activity and cancer risk (source: www.cancer.org)
40818621|NCT03575117|BEHAVIORAL|NCI HealthyYouTXT--Get Active (HYT--GA)|Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
41337271|NCT01107288|OTHER|Music-based multitask exercises program|Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
41337272|NCT03948113|OTHER|Dialysis|
41337273|NCT04310865|DRUG|Yinhu Qingwen Granula|"Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days."
41485663|NCT03736213|BEHAVIORAL|Ultrasound biofeedback|In ultrasound biofeedback, the elements of traditional articulatory treatment are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
41016408|NCT06655935|PROCEDURE|Ordinary Transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO inside the left atrial cavity over stiff wire into the pulmonary veins
41485664|NCT04557306|BIOLOGICAL|CBT101 cells, every 2 weeks|CBT101 cells, every 4 weeks
41485665|NCT04557306|BIOLOGICAL|CBT101 cells, every 4 weeks|CBT101 cells, every 4 weeks
41485666|NCT02011750|DRUG|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
41485667|NCT02011750|DRUG|Placebo|Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
41485668|NCT04882423|OTHER|grilled hamburger (7 oz) with no vegetables|Test meal 1: grilled hamburger (7 oz) with no vegetables
41485669|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)|Test meal 2: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
41485670|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)|Test meal 3: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
41485671|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).|Test meal 4: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
40818622|NCT02553980|BEHAVIORAL|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
41016409|NCT06655935|PROCEDURE|modified transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO over the multipurpose catheter inside the left atrial cavity which might help in the shortage of the duration \& the cost of the procedure with less complication rate
41156462|NCT03474042|DRUG|GLPG2737|GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
41337274|NCT04310865|DRUG|Yin Hu Qing Wen Granula(low does)|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
41337275|NCT04310865|OTHER|standard medical treatment|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
40818623|NCT02553980|OTHER|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
40818624|NCT00948857|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|25 mg PO TID
41016410|NCT06657365|DEVICE|Radiofrequency (RF) Treatment with Volnewmer|Non-invasive radiofrequency-based skin tightening using the Volnewmer device.
41016411|NCT06657365|DEVICE|Radiofrequency (RF) Treatment with Thermage CPT|Non-invasive radiofrequency-based skin tightening using the Thermage CPT device.
41337276|NCT01142544|OTHER|Evaluation oxygenation under standard ventilator settings|Measure of PaO2 under standard FiO2-PEEP
41337277|NCT00895778|OTHER|Neuromuscular blockade with rocuronium and reversal with sugammadex|
41337278|NCT01937013|DRUG|Intranasal oxytocin|Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
41337279|NCT01937013|DRUG|Saline Nasal Mist|Participants will be randomized to receive placebo on either study visit 2 or 3.
41016412|NCT06652035|DIETARY_SUPPLEMENT|Quevir® (Quercetin Phytosome®)|500 mg Quevir® (Quercetin Phytosome®) tablet
41016413|NCT06652035|DIETARY_SUPPLEMENT|Bactoblis®|Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)
41156463|NCT03474042|DRUG|Placebo|Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
41337280|NCT04930952|DRUG|Ethanol-amine Oleate Sclerotherapy Injection|Intralesional Sclerotherapy Injection
41337281|NCT04649190|DEVICE|TAVI|Coronary access for PCI after TAVI
41337282|NCT03625804|GENETIC|PNS+AO+Training|Electrical stimulation was applied to the radial and ulnar nerve (PNS) of the paretic arm for 60 minutes. During the last 30 minutes of PNS, action observation (AO) was introduced in which subjects were required to watch a series of video clips. After one hour's PNS+AO, the subjects then proceeded to a 30-minute period of motor training of paretic hand.
40818625|NCT00948857|DIETARY_SUPPLEMENT|Placebo|Blinded placebo
40818626|NCT02315807|DEVICE|transcranial direct current stimulation|
41337283|NCT03625804|GENETIC|PNS+AOsham+Training|PNS was given as described before. During the last 30 minutes of the PNS, subjects were shown different photos illustrating a letter, a number or a hand as AOsham. The protocol of motor training was the same as described before.
41337284|NCT03625804|GENETIC|PNSsham+AOsham+Training|The 1-hour PNSsham was conducted with the electrical stimulation unit turned on but without current output. The protocols for AOsham and motor training were the same as those described before.
41337285|NCT04757376|BIOLOGICAL|CT-P41|60 mg/mL single dose, Solution for injection in PFS
41337286|NCT04757376|BIOLOGICAL|US-licensed Prolia|60 mg/mL single dose, Solution for injection in PFS
41337287|NCT00776698|DRUG|bevacizumab [Avastin]|7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
41337288|NCT00776698|DRUG|cisplatin|80mg/m2 iv every 3 weeks for 3 cycles
41337289|NCT00776698|DRUG|etoposide|100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
41337290|NCT06239324|DRUG|Latanoprost|Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.
41337291|NCT06507137|OTHER|Fractal|Walking in a treadmill while synchronizing their steps with fractal external visual cues
41337292|NCT06507137|OTHER|Isochronous|Walking in a treadmill while synchronizing their steps with isochronous external visual cues
41337293|NCT06507137|OTHER|Control|Walking in a treadmill
41337294|NCT00294684|DRUG|Corticosteroids|"Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop"
41337295|NCT00294684|DRUG|Placebo|"Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop"
40818627|NCT03504540|PROCEDURE|Blood test|Blood test for complement factors and genetic polymorphisms of AMD analysis
40818628|NCT01598558|DRUG|Cu-64 Rituximab|Up to 14 mCi, iv
40818629|NCT05049707|DRUG|IV magnesium sulfate|15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr
40818630|NCT05049707|OTHER|Placebo|500 cc normal saline delivered in equivalent rates as the treatment group
40818631|NCT01838330|DIETARY_SUPPLEMENT|psyllium|15 grams/day for 1 week, followed by 30 grams/day for 4 months
40818632|NCT02091531|DRUG|MLN0128|
40818633|NCT04294615|OTHER|FMT through a naso-jejunal tube|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
41337296|NCT01882192|BEHAVIORAL|Family physical activity planning|"This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting."
41337297|NCT02820688|DRUG|Bupivacaine 0.25%|
41337298|NCT02820688|DRUG|Prilocaine 1%|
41337299|NCT02820688|PROCEDURE|Infraclavicular Nerve Block|Ultrasound guided infraclavicular nerve block
41337300|NCT02820688|DRUG|Bupivacaine 0.167%|
41337301|NCT02820688|DRUG|Bupivacaine 0.125%|
41337302|NCT02820688|DRUG|Prilocaine 0.66%|
41337303|NCT02820688|DRUG|Prilocaine 0.5%|
40818634|NCT04294615|OTHER|FMT through TET|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
40818635|NCT03759886|DRUG|Paromomycin Sulfate Powder|The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
40818636|NCT04976673|DRUG|Triamcinolone Acetonide|The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
40818637|NCT04976673|PROCEDURE|Photodynamic Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
40818638|NCT04955483|DIAGNOSTIC_TEST|Virtual single energy combined with MAR reconstruction group|combined with MAR reconstruction group
41485672|NCT03814330|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement
41485673|NCT03814330|DIAGNOSTIC_TEST|Quality of Recovery Score|Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
41156464|NCT03868618|DEVICE|Genio™ system|The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.
41337304|NCT02820688|DEVICE|Ultrasound|All nerve blocks will be performed with ultrasound guidance
41485674|NCT03814330|OTHER|Sedation/Analgesia|Patients will be performed the procedure with sedation/analgesia under the condition of spontaneous breathing.
41016416|NCT06592248|DEVICE|Coc Knee|Implementation of a ceramic on ceramic knee prosthesis
41016417|NCT06589661|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under general anesthetic.
41016419|NCT06594926|DRUG|Testosterone Enanthate|Testosterone enanthate is a depot formulation used in Australia typically for androgen replacement in people with confirmed testosterone deficiency.
41016420|NCT06597734|DRUG|Azacitidine (AZA)|Given by SC or IV
41016421|NCT06597734|DRUG|Decitabine|Given by IV
41337305|NCT01695213|PROCEDURE|uncemented total hip arthroplasty|
41337306|NCT01082588|DRUG|Pravastatin|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
41016422|NCT06597734|DRUG|Olutasidenib|Given by PO
41016423|NCT06597734|DRUG|Cedazuridine|Given by PO
41016424|NCT06654999|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|"DERM variants + and DS"
41156465|NCT06108596|DRUG|Sintilimab with Interleukin-2+CAPOX|Sintilimab with Interleukin-2+CAPOX
41156466|NCT06096376|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Diaphragm ultrasound to assess respiratory muscle function and respiratory efficiency
41156467|NCT05167734|DRUG|Iron Dextran|1000 mg IV
40818641|NCT06053801|OTHER|Xolair|Prospective observational cohort study. There is no treatment allocation. Patients administered Xolair by prescription will be enrolled.
40818642|NCT01520701|DEVICE|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
40818643|NCT01520701|DRUG|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
40818644|NCT06587282|DEVICE|Bloom Micro Occluder System|Percutaneous transcatheter closure of PDA using Bloom Micro Occluder System
40818645|NCT00790647|BIOLOGICAL|filgrastim|16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
41016425|NCT06654310|BEHAVIORAL|Delivery of FCS Skills Curriculum|"The UW study team will conduct two 2-hour train-the-trainer sessions with all surgical attendings who have committed to participation as a trainer in the FCS curriculum. The designated trainer will deliver each 2-hour session during the existing formal educational time for residents. If existing protected educational time will not allow for a 2-hour training session, the sessions can be delivered in two 1-hour sessions. These sessions will be incorporated into the curriculum similar to all other formal training provided to residents with the same expectations to attend.~Each 2-hour FCS session starts with a 30-minute exercise in empathic communication. The remaining 90 minutes are devoted to skills that support decision making about surgery."
41016426|NCT04323553|DIAGNOSTIC_TEST|Pulsed-field gel electrophoresis and whole genome sequencing|Comparison of the two different techniques
41485675|NCT03814330|DEVICE|Laryngeal Mask Airway|Patients will be performed the procedure with Laryngeal Mask Airway during the procedure. Laryngeal Mask Airway is a supraglottic airway device to ventilate the patients during anesthetic procedure.
41156468|NCT05167734|DRUG|Erythropoietin (EPO)|40,000 units subcutaneous
41156469|NCT06646679|OTHER|Ultrasonic imaging|Ultrasonic imaging
41156470|NCT06275087|DRUG|Propofol|The experimental group will not receive volatile anesthetic, instead, they will receive propofol infusion
41156471|NCT06275087|DRUG|Sevoflurane|The control group will not receive TIVA, instead, they will receive sevoflurane via inhalation
41485676|NCT05981820|DIETARY_SUPPLEMENT|Creatine|To observe the effects of creatine in the study, 10 g of creatine supplementation was taken only on training days during the study period. Participants used 10 g of creatine monohydrate by dissolved in 200 ml of water. Creatine supplementation was taken in two doses of five grams, 30 minutes before and after training.
41485677|NCT05981820|OTHER|HIIT training|"In the first three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 4 sets of 12x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets~In the last three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 5 sets of 20x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets"
41485678|NCT03655236|DRUG|K0706|low dose, orally, once-daily
41485679|NCT03655236|DRUG|K0706|high dose, orally, once-daily
40818646|NCT00790647|DRUG|bortezomib|1.0 mg/m2/dose D -6, D-3, D +1, D + 4
40818647|NCT00790647|DRUG|melphalan|100 mg/m2/dose D -2, D -1
40818648|NCT00790647|PROCEDURE|Stem Cell Infusion|infusion of previously collected autologous stem cells
40818649|NCT01368692|PROCEDURE|position of shoulder retraction|position of shoulder retraction by placing a saline bag between the scapula
40818650|NCT01368692|PROCEDURE|position of neutral shoulder|neutral shoulder position during subclavian vein catheterization
40818651|NCT04817137|DEVICE|CareTaker PDA Device|Non-invasive blood pressure monitoring
40818652|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
40818653|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|5.0 grams of PGX
40818654|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|0 grams of PGX
40818655|NCT06582693|OTHER|Refer2Quit|The Refer2Quit intervention consists of automatic connection to the adult participant's choice of any or all of four evidence-based tobacco treatment options (varenicline, NRT, quitline, and/or smokefreeTXT), as well as motivational counseling provided by the study team. Supportive and motivational text messaging is also included in the intervention to connect or reconnect adult participants to treatments as needed. Text messaging and support would also focus on supporting appropriate use of NRT and/or varenicline if indicated.
40818656|NCT01120860|DEVICE|MRI|MRI - routine imaging sequences, designed for anatomical quantification
41156472|NCT00853203|BEHAVIORAL|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
41156473|NCT00853203|BEHAVIORAL|Questionnaires|Written survey taking about 1 hour.
41156474|NCT00853203|OTHER|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
40818657|NCT04125238|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
41156475|NCT00853203|BEHAVIORAL|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
41156476|NCT00853203|BEHAVIORAL|Written Materials|Written educational materials plus community resource information.
41337307|NCT01082588|DRUG|Placebo|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
41337308|NCT03834480|OTHER|Ultrasound guided Sacroiliac intra-articular injection|At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.
41337309|NCT01644981|OTHER|blood sampling|blood sampling
41337310|NCT06100107|OTHER|Mirror Therapy exercise|Mirror Therapy for the upper limb involves the use of a mirror to create a reflected image of the unaffected arm, making it appear as if both arms are moving symmetrically. During the therapy, the patient places their affected arm behind the mirror and their unaffected arm in front. While focusing on the mirror reflection, the patient performs various movements with the unaffected arm, giving the illusion that the affected arm is moving normally.
41337311|NCT06332183|GENETIC|Presence of polymorphisms|Statistical analysis of GWAS data, Genome-wide methylation pattern analysis, Integration of GWAS data and methylation data (meQTL analysis), Pathway enrichment analysis
40818658|NCT04125238|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive recent past events.
40818659|NCT02186379|BEHAVIORAL|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
40818660|NCT02186379|BEHAVIORAL|Usual Care Control|"Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters."
40818661|NCT06075329|BEHAVIORAL|Contemplative Practice|Contemplative practice included Maitribodh Sambodh Dhyaan (MSD), which was designed to increase feeling of love and connection by including most of components of different contemplative practices such as breath watch, mantra or vibrational sound chant, focused meditation, and visualization followed by loving-kindness or a gratitude exercise at the end.
40818662|NCT01672463|DRUG|OKN-007|"Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.~Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter."
40818663|NCT05528653|DRUG|Descovy|HIV infection pre-exposure prophylaxis
40818664|NCT05838027|BEHAVIORAL|Cash Transfer|Participants will receive $125 every 2 weeks for 8 payments via ClinCard, for a total of $1000.
41337312|NCT03651128|BIOLOGICAL|bb2121|bb2121
41337313|NCT03651128|DRUG|Daratumumab|Daratumumab
41337314|NCT03651128|DRUG|Pomalidomide|Pomalidomide
41337315|NCT03651128|DRUG|Dexamethasone|Dexamethasone
41337316|NCT03651128|DRUG|Bortezomib|Bortezomib
41337317|NCT03651128|DRUG|Ixazomib|Ixazomib
41337318|NCT03651128|DRUG|Lenalidomide|Lenalidomide
41337319|NCT03651128|DRUG|Carfilzomib|Carfilzomib
41337320|NCT03651128|DRUG|Elotuzumab|Elotuzumab
41337321|NCT00856817|DRUG|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
41337322|NCT00856817|DRUG|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
41337323|NCT04992299|BEHAVIORAL|Mindfulness-Based Intervention|6-week mindfulness-based intervention of 6 weekly 1 hour group sessions
41337324|NCT04992299|BEHAVIORAL|Cognitive-Behavioral Therapy|6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions
41337325|NCT04992299|BEHAVIORAL|Health Education|6-week health education didactic program of 6 weekly 1 hour group sessions
41337326|NCT06123741|BEHAVIORAL|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma) .
41337327|NCT06123741|BEHAVIORAL|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
41337328|NCT01841489|DRUG|Treatment A|1600 mg GS-9973 (Formulation 1)
41337329|NCT01841489|DRUG|Treatment B|1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
41337330|NCT01841489|DRUG|Treatment C|1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
41337331|NCT01841489|DRUG|Treatment D|1600 mg GS-9973 (Formulation 2)
41337332|NCT01841489|DRUG|Treatment E|1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
41337333|NCT01841489|DRUG|Treatment F|1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
41337334|NCT01841489|DRUG|Treatment G|1600 mg GS-9973 (Reference formulation)
41337335|NCT01841489|DRUG|Treatment H|1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
41485680|NCT03655236|OTHER|placebo|placebo, orally, once-daily
40818665|NCT04960930|DRUG|FMX101|topically once daily
40818666|NCT03116828|DRUG|Eslicarbazepine acetate|eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
40818667|NCT03116828|DRUG|Eslicarbazepine Acetate|eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
40818668|NCT03913026|BIOLOGICAL|Transplant with an expanded ECT-001 cord blood|"1. Patients will receive a conditioning regimen (such as: cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy).~2. The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~3. Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus). Tacrolimus will be discontinued on Day 100 post-transplant unless GVHD arises."
40818669|NCT02802423|DRUG|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
40818670|NCT03641768|DEVICE|MRI|You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
40818671|NCT03641768|DEVICE|PET|You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
40818672|NCT03641768|DEVICE|18F-Florbetapir|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
40818673|NCT03641768|DEVICE|Radioligand 18F-AV-1451|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
40818674|NCT03307603|RADIATION|yttrium-90 radioembolization|Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.
40818675|NCT03307603|DRUG|Phase Ib - nivolumab|240 mg intravenously
40818676|NCT03307603|DRUG|Phase II - nivolumab|nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
40818677|NCT05173948|OTHER|Kinesio taping|Kinesio taping: The tape is measured from the sacrum to the 12th thoracic vertebra with forwarding flexion of the trunk. The base is affixed to the insertion in the resting position. The muscle is elongated and the base anchored with skin displacement. The tape is then affixed with 10% stretch paravertebrally over the muscle bundles up to T12. The tape is rubbed with the muscle in the elongated state.
40818678|NCT05173948|DEVICE|Conventional physical therapy|Transcutaneous electrical nerve stimulation device settings, such as the frequency of 80 Hz, the pulse width of 100 µs, and symmetrical biphasic waveform. Four mediums sized (2 × 2 cm) carbon-impregnated rubber cutaneous electrodes were placed bilaterally in a standard dermatomal pattern over the most painful lumbar region. The current intensity was increased up to the patient's perception of paraesthesia. The supervised exercise therapy management consisted of stretching exercises for the back, iliopsoas, gluteal and hamstring muscles, and strengthening exercises for the abdominal and back muscles. Three sets of stretching exercises, each involving a 30-sec hold and 30-sec of rest repeated three times, were performed in three sessions per week over four weeks. One set of strengthening exercises, consisting of 10 repetitions with a 5-sec hold, was performed in three sessions per week over four weeks.
40818679|NCT06608082|DIAGNOSTIC_TEST|indocyanine green injected intravenously|During the procedure, after performing the hysterectomy, indocyanine green will be injected intravenously into the patient. A fluorescence video of the vaginal cuff will be recorded. The fluorescence of the recorded images will be analyzed by fluorescence analysis software to obtain an objective value of fluorescence.
40818680|NCT01611688|DRUG|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
40818681|NCT01611688|DRUG|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
41337336|NCT01841489|DRUG|Treatment I|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
41337337|NCT01841489|DRUG|Treatment J|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
41337338|NCT00505518|DRUG|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
41337339|NCT00505518|BEHAVIORAL|Collaborative psychiatric and primary medical care|Regular care visits from health workers
41485681|NCT00942695|OTHER|1.5PD|average American diet plus 1.5 oz per day pistachios
41485682|NCT00942695|OTHER|3.0PD|average American diet plus 3.0 oz per day pistachios
41485683|NCT00942695|OTHER|control|average American diet without pistachios
41485684|NCT00147602|DRUG|atorvastatin|
41485685|NCT05619055|OTHER|Routine treatment|Antibiotics, intravenous fluids and symptomatic supportive treatment.
40818682|NCT01611688|DRUG|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
40818683|NCT06584331|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days
41485686|NCT02581007|DRUG|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
40818684|NCT06584331|DIETARY_SUPPLEMENT|2 doses of Beetroot juice intake|This group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.
41485687|NCT02581007|DRUG|Melphalan|
40818685|NCT06584331|DIETARY_SUPPLEMENT|Placebo|In this group, the participants will receive 70ml of low-nitrate beetroot juice to consume in the morning.
40818686|NCT03195244|OTHER|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
40818687|NCT02928302|OTHER|TVU CL screening|Transvaginal ultrasound cervical length screening
41485688|NCT02581007|DRUG|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
41485689|NCT02581007|PROCEDURE|peripheral blood stem cell transplant|
41485690|NCT06248268|OTHER|(Neuro-)psychological assessment|The measurement, which takes place 1 week after the informed consent, aims to determine the distinct (neuro-) psychological patterns of suicidal behavior versus suicidal ideation, in comparison to two control groups.
40818688|NCT05745987|DRUG|Bavarian Nordic smallpox vaccine|A single dose of the Bavarian Nordic smallpox vaccine will be given at baseline.
40818689|NCT05745987|DRUG|Typhoid VI Polysaccharide Vaccine Injectable Solution|A single dose of the typhoid vaccine will be given at baseline.
40818690|NCT02958891|OTHER|Data collection|Collection epidemiological dental measures
40818691|NCT04603781|DIETARY_SUPPLEMENT|CBD Isolate|300 mg. daily dose of CBD Isolate Oil
40818692|NCT04603781|DIETARY_SUPPLEMENT|Full Spectrum CBD Oil|300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant
40818693|NCT04603781|DIETARY_SUPPLEMENT|Broad-Spectrum CBD Oil|300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant
40818694|NCT04603781|DIETARY_SUPPLEMENT|Placebo Oil|MCT Oil with mint flavoring
40818695|NCT02493257|DRUG|Capsaicin|
40818696|NCT02493257|DRUG|Placebo|
40818697|NCT05837247|OTHER|Game-based telerehabilitation exercises|online Game-based home exercises are physiotherapy programs that include exercises transformed into game activities to increase the child's participation in the rehabilitation process. The exercises were planned such as; the dwarf camel game as squat exercises; the flamingo balance game as single leg balance exercises and weight-bearing activities etc. The exercise program will be conducted for 6 weeks and 3 sessions in a week.
41485691|NCT06224621|PROCEDURE|Percutaneous Endocardial Septal Radiofrequency Ablation|Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
41485692|NCT03787576|DEVICE|Cataract surgery|Evaluation of patient satisfaction after bilateral cataract surgery with multifocal intraocular lens implantation
41337340|NCT05286268|DIAGNOSTIC_TEST|Ischemia Modified Albumin|"Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system."
41337341|NCT01048255|DRUG|VX-765|300mg Oral Tablet, 900mg TID
41337342|NCT00838383|DRUG|sitaxsentan (Thelin)|sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
40818698|NCT05295901|DEVICE|mKOAH application|mobile app installed group
41016427|NCT04323553|OTHER|Data collection|Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
41337343|NCT00838383|DRUG|sitaxsentan (Thelin)|Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
41337344|NCT00838383|DRUG|Placebo|Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
41016432|NCT06657547|OTHER|Normal conditions|Participants are administered salmeterol, after which they perform various performance tests in normal conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
41337345|NCT00444418|DRUG|Naltrexone|Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
41337346|NCT00444418|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
41337347|NCT00444418|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
41337348|NCT03346291|BEHAVIORAL|counseling|individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
41337349|NCT04212546|OTHER|Synbiotic test drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g inulin + Lactobacillus casei431 \[\>106cfu/mL\] per day for 21 days with their habitual diet.
41337350|NCT04212546|OTHER|Control drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g maltodextrin per day for 21 days with their habitual diet.
41337351|NCT05105529|BEHAVIORAL|Exercise|Cycling at 60% of VO2max on a cycle ergometer for 30 minutes
41337352|NCT05105529|OTHER|Ozone|Breathing 170ppb ozone
41016433|NCT06657547|OTHER|Heated conditions|Participants are administered salmeterol, after which they perform various performance tests in heated conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
41337353|NCT05105529|OTHER|Filtere Air|Breathing filtered air
41337354|NCT01462968|DEVICE|Activated clotting time versus blood-heparin concentration|Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
41337355|NCT06181227|DRUG|AVD-104|An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
41337356|NCT02733471|DRUG|Lidocaine|
41337357|NCT02733471|DRUG|Placebo|Placebo
40818699|NCT01177553|PROCEDURE|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
41337358|NCT04151446|DEVICE|Laser Scleral Microporation|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
41337359|NCT05317260|DRUG|Antiviral Agents|The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
41337360|NCT04199689|BIOLOGICAL|9vHPV Vaccine|9-valent human papillomavirus vaccine (9vHPV) is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles (VLPs) of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.
41337361|NCT04199689|OTHER|Placebo (Saline for Injection)|0.9% sodium chloride given as a 0.5-mL intramuscular injection
41337362|NCT01680991|DRUG|Obinutuzumab|Multiple doses of obinutuzumab.
41337363|NCT06228443|DRUG|Leflunomide 20 mg Film-coated Tablet|Leflunomide 20 mg Film-coated Tablet (Test Drug)
41337364|NCT06228443|DRUG|ARAVA® 20 mg Film-coated Tablet|ARAVA® 20 mg Tablets (Reference Drug)
41337365|NCT00049140|DRUG|EF5|
41337366|NCT00049140|OTHER|bioluminescence|
41337367|NCT00049140|OTHER|flow cytometry|
41337368|NCT00049140|OTHER|immunohistochemistry staining method|
41337369|NCT00049140|PROCEDURE|biopsy|
41337370|NCT01675206|DIETARY_SUPPLEMENT|Vitamin K2 supplementation|
41337371|NCT03049943|DEVICE|low level laser|
41337372|NCT03077711|DRUG|Trimethoprim|suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
41337373|NCT03077711|DRUG|Methenamine hippurate|antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
40818700|NCT01177553|DEVICE|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
40818701|NCT03782207|DRUG|Atezolizumab|Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
41337374|NCT04695236|DEVICE|ZOLL Intravascular Temperature Management system, Quattro catheter|ZOLL Intravascular Temperature Management system, Quattro catheter
40818702|NCT01734395|DRUG|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
40818703|NCT05893771|DRUG|Methylprednisolone Injection|Ultrasound-guided genicular nerve block comparing Methylprednisolone combined with Bupivacaine to bupivacaine alone. All patients will undergo TKA and will receive spinal anesthesia.
41337375|NCT04695236|OTHER|Standard Treatment|Standard Treatment for Ischemic Strokre
41337376|NCT05402904|DIAGNOSTIC_TEST|nerve conduction study|Routine nerve conduction study on both lower limbs as well as F- wave , Hoffman reflex and somatosensory evoked potential.
41337377|NCT04063865|DRUG|Tacrolimus|Tacrolimus (FK / Prograf) titrated to a goal trough of 6 - 8 ng/ml
41337378|NCT04063865|DRUG|Everolimus|Everolimus monotherapy - target trough levels 4 - 8 ng/ml as maintenance immunosuppression
40818704|NCT05893771|DRUG|Bupivacaine Hcl 0.5% Inj_#2|Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline
40818705|NCT05893771|DRUG|normal saline|Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
40818706|NCT06270836|DRUG|Tarcocimab|Intravitreal injection
41485693|NCT03096847|DRUG|ribociclib|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
40818707|NCT06270836|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
40818708|NCT03600636|PROCEDURE|Diffusion tensor imaging MRI|"1. axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~2. Fluid-attenuated inversion recovery~3. three-dimensional axial image weighted in T1~4. axial echo-planar image sequence~5. three-dimensional pulse sequence axial flight time"
41337379|NCT04134169|OTHER|Not applicable(observational study)|Not applicable(observational study)
41337380|NCT03038516|DRUG|Cholecalciferol|To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
41337381|NCT03038516|DEVICE|Placebo|To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
41337382|NCT02532413|DRUG|Poly IC|Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
41337383|NCT02532413|DRUG|Entecavir|Entecavir can inhibit the replication of HBV.
40818709|NCT04322305|DRUG|Pregabalin|Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
40818710|NCT04322305|OTHER|Placebo|Placebo capsules will be provided twice daily over 8 weeks and one week taper..
40818711|NCT00522314|DEVICE|NIV and ACBT|
40818712|NCT00522314|OTHER|Active Cycle of Breathing Techniques|
40818713|NCT00549263|DRUG|SB797620|
40818714|NCT04703608|DRUG|Ivermectin|Ivermectin 0.3-0.4mg/Kg daily for 3 days.
40818715|NCT04703608|DRUG|ASP|Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)
40818716|NCT04703608|DRUG|Placebo|Non-identical placebo
40818717|NCT06606496|DEVICE|Bispectral index (BIS)|The bispectral index (BIS) monitor is a quantitative electroencephalographic (EEG) device that is widely used to assess the hypnotic component of anaesthesia, especially when neuromuscular blocking drugs are used. If necessary, it may be necessary to increase or decrease MAC (minimum alveolar concentration) in the testosterone group according to the BIS monitoring value.
40818718|NCT00211393|DRUG|ketoconazole|600mg. /day for 6 weeks
40818719|NCT06599255|PROCEDURE|US-guided RSB and TAPB by one-puncture technique.|The probe will be positioned transversely in the midline of the abdomen, between the xiphoid process and the umbilicus, revealing the linea alba. It was then moved outward along the costal margin, demonstrating the rectus abdominis overlapping the transverse abdominis. A 22-gauge, 120-mm ultrasound-visible block needle will be inserted from the inner side . Under direct vision, we will reach the posterior rectus abdominis sheath and pierced the anterior layer of the posterior sheath. Saline was injected to adjust its position. After that, 15 mL of 0.25% bupivacaine will be administered (aspiration was performed for every 5 mL injection), and we will observe the local anesthetic spreading inward . Then, the needle will break through the posterior layer of the tendon, and saline will be injected to confirm the needle's placement in the transversus abdominis plane. After confirming the tip placement, 15 mL of 0.25% bupivacaine will be slowly injected. The needle tip will be advanced al
40818720|NCT06599255|PROCEDURE|multipont|", the probe will be moved outward along the costal margin until the external oblique muscle, internal oblique muscle, and transverse abdominis muscle will be visible \[9\]. The needle will be inserted in-plane until the tip was positioned in the plane between the internal oblique muscle and the transverse abdominis muscle. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution.~For the RSB, the same technique will be done as one puncture technique. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution."
41156477|NCT04757519|BEHAVIORAL|DPP-GLB Standard|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.
41337384|NCT03795636|OTHER|Garlic extract|A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water
40818721|NCT00793559|DRUG|terlipressin|1 mg of terlipressin one time only
40818722|NCT00793559|DRUG|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
41337385|NCT03795636|OTHER|NaOCl (COLTENE®)|Sodium hypochlorite
40818723|NCT00284557|BEHAVIORAL|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
40818724|NCT05752942|BEHAVIORAL|Student Intervention Matching System (SIMS)|"The Student Intervention Matching System (SIMS) is a pre-intervention matching assessment following the behavioral consultation model. The SIMS entails three steps to sequentially assess and then match students' individual characteristics to precise acquisition- or performance-based interventions. The 1st step corresponds to the problem identification stage in behavioral consultation. The 2nd step corresponds to the problem analysis stage of behavioral consultation.The 3rd step of SIMS corresponds to the implementation planning and evaluation stages of behavioral consultation."
40818725|NCT05752942|BEHAVIORAL|group-based social skills training|In the control condition, students received an unconditionally mismatched acquisition-based intervention (group-based social skills training). We selected group-based social skills training for four reasons: (a) participating schools had already been delivering it as their treatment-as-usual, (b) it is a common intervention in US schools, (c) it is only effective for students with acquisition needs, and (d) it represents a counterfactual contrast to the treatment condition because externalizing behaviors driven by performance needs will be reduced more by performance-based interventions than acquisition-based ones.
40818726|NCT02247011|OTHER|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
40818727|NCT02247011|RADIATION|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
40818728|NCT02247011|RADIATION|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
40818729|NCT02247011|OTHER|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
40818730|NCT02509052|OTHER|Laboratory Biomarker Analysis|Correlative studies
40818731|NCT02509052|DRUG|Leflunomide|Given PO
40818732|NCT02509052|OTHER|Pharmacological Study|Correlative studies
40818733|NCT03006172|DRUG|Inavolisib|Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).
40818734|NCT03006172|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
40818735|NCT03006172|DRUG|Letrozole|Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.
40818736|NCT03006172|DRUG|Palbociclib|Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
41485694|NCT03096847|DRUG|letrozole|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
41485695|NCT03096847|DRUG|goserelin|Premenopausal patients additionally received goserelin 3.6mg as monthly implant
40818737|NCT03006172|DRUG|Metformin|Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.
40818738|NCT03006172|DRUG|Trastuzumab|Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.
40818739|NCT03006172|DRUG|Pertuzumab|Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.
40818740|NCT03374267|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
40818741|NCT00004112|BIOLOGICAL|rituximab|
40818742|NCT00004112|DRUG|CHOP regimen|Cyclophosphamide, vincristine and doxorubicin as a drip into the bloodstream (intravenously) and prednisolone (steroid) as tablets taken with or after food.
40818743|NCT00004112|DRUG|cyclophosphamide|
41337386|NCT06507358|BEHAVIORAL|Parent-Child Interaction group|The intervention for the Parent-Child Interaction group consists of a 6-week program involving weekly 40-minute sessions of therapeutic horticulture in a group setting, with 4-6 participants per group. The sessions focus on sensory-motor activities aimed at helping children engage in daily tasks and activities. Various sensory stimuli are provided through different materials used in gardening activities, including visual, auditory, gustatory, tactile, and olfactory stimuli. The program encourages mutual support and sharing among group members, showcases different outcomes, and emphasizes a sense of responsibility for home care. With a family-centered approach, parental involvement serves as a mediator to promote children's overall development and abilities. Participants are required to complete homework assignments and maintain activity records, including documentation of the 6 sessions through photos and written records.
41337387|NCT01507571|OTHER|Dignity Therapy|"Dignity Therapy is a brief psychotherapeutic intervention consisting of:~1. a tape-recorded session with the patient using the DT question protocol~2. Transcription of the interview, which is then edited~3. A session where the edited transcript is returned to the patient who can give it to family members or friends.~If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by."
41337388|NCT02190630|DEVICE|Modified Clark Twin Block|The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
41485696|NCT05792124|PROCEDURE|Erector spina area block|After anesthesia and surgical intervention, bilateral ESP passage will be performed with ultrasonography from the T10 level 3 cm lateral to the midline. After cleaning the area with povidone iodine before the block, T10 transverse output will be determined using a linear ultrasound probe. Local anesthetic will be applied to the erector spina with the use of the needle used for peripheral block procedures and transverse access. With the serum treatment from the local anesthesia application, the location of the needle will be correct with the hydrodissection method. After the location of the needle is confirmed, a mixture containing 20 ml of LA and serum will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA is bupivacaine 0.5%, after 20 ml serum content.
40818744|NCT00004112|DRUG|doxorubicin hydrochloride|
40818745|NCT00004112|DRUG|prednisone|
40818746|NCT00004112|DRUG|vincristine sulfate|
40818747|NCT02039219|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
40818748|NCT02039219|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
40818749|NCT06116552|BEHAVIORAL|More Social Stories|Children listen to four stories while looking at accompanying images that contain more social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
41016434|NCT06657547|DRUG|Salmeterol inhalation and urine samples|After the experimental day under normal conditions, all participants are administered 200 µg of salmeterol daily (8 puffs from the MDI device) during a 6-day intervention period. Two hours after inhalation, the participants collect spot urine samples at home
41016435|NCT06656910|BEHAVIORAL|Self Compassion Group|"A 7-week self-compassion Programme:~Course 1:~Detective Warm-Up Game, Explaining the application of compassion/self-compassion.~Course 2:~Draw and Tell Warm-up Game, Breath Awareness Exercise, Mindful Eating Activity.~Course 3:~Walking Warm-Up, Body Scan Meditation, How Do You Treat Your Friend Activity.~Course 4:~Random Cards warm-up game, Compassion Meditation, Just Like Me Exercise.~Course 5:~Break, Self-compassionate letter writing.~Course 6:~Tree Drawing Warm-Up Game, Mountain Meditation, Recognize Your Inner Bully, Three Calming Breathing Exercises.~Course 7:~Considering the process with participants, Implementation of final tests, Tender farewell."
41016436|NCT06653894|PROCEDURE|patients undergoing hip replacement surgery|Hip surgery typically involves procedures aimed at repairing or replacing damaged hip joints to alleviate pain and restore mobility. Common types of hip surgery include total hip replacement, partial hip replacement, and hip arthroscopy. Total hip replacement involves removing the damaged joint and replacing it with an artificial implant, while partial hip replacement focuses on replacing only the damaged parts of the joint. Hip arthroscopy is a minimally invasive procedure used to diagnose and treat hip joint issues using small incisions and specialized instruments. Recovery from hip surgery can vary, but many patients experience significant improvement in pain levels and mobility with proper rehabilitation and physical therapy.
41016437|NCT06663579|OTHER|Fathers who practicing kangaroo care|The study group (n=28) It consists of fathers of babies practicing Kangaroo Care with both their mothers and fathers in the neonatal intensive care unit.
40818750|NCT06116552|BEHAVIORAL|Less Social Stories|Children listen to four stories while looking at accompanying images that contain less social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
40818751|NCT05552794|DIAGNOSTIC_TEST|Optic nerve Sheath Diameter (ONSD)|ONSD and rSO2 monitoring will perform when the patients arrived in ICU.
40818752|NCT06218251|DRUG|BOTOX|Intramuscular Injections
40818753|NCT02592616|BEHAVIORAL|CON|No exercise intervention.
40818754|NCT02592616|BEHAVIORAL|CW|One hour of continuous walking on a treadmill.
40818755|NCT02592616|BEHAVIORAL|IW|One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
40818756|NCT02734771|DRUG|Brentuximab vedotin|
40818757|NCT02734771|DRUG|Rituximab|
41016438|NCT06663579|OTHER|Fathers who not practicing kangaroo care|The control group (n=28) It consists of fathers of babies practicing Kangaroo Care with their mothers in the neonatal intensive care unit.
41337389|NCT06257134|OTHER|No systematic monitoring of symptoms|No systematic monitoring of symptoms will be carried out, and patients will receive the usual care. Data collection will be carried out with the assistance of a clinical research nurse up to 12 months, then under the direction of local healthcare teams at 18 months.
41337390|NCT06257134|OTHER|Systematic monitoring of symptoms|"once a month, individual patient scores will be sent to dialysis staff. Any score of 3 (severe symptoms) or 4 (overwhelming) on a scale of 0 to 4, on the IPOS-Renal instrument, will be permanently reported to the referrer to trigger the patient's usual symptom management.~Patients will complete 3 further HRQoL questionnaires at baseline, M6, M12 and M18: EQ-5D-5L, KDQoL-36, SONG Fatigue.~A clinical research nurse will be present in half of the participating dialysis units to help patients and dialysis teams to include and follow up patients, up to 12 months. Between 12 and 18 months, data will be collected in real life, under the guidance of local healthcare teams.~In the other half of the dialysis units, data will be collected under the direction of the local healthcare teams, who will have to organize themselves to ensure data collection. These units will also be asked to conduct semi-structured interviews as part of the qualitative phase."
41337391|NCT06153394|DRUG|Redesca (enoxaparin sodium for injection)|Redesca is low molecular weight heparin and a biosimilar biologic drug (biosimilar) to Lovenox. Indications have been granted on the basis of similarity between Redesca and the reference biologic drug Lovenox. As such, Redesca (enoxaparin sodium) is indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield.
41337392|NCT06153394|DRUG|Fragmin (dalteparin)|Fragmin is a low molecular weight heparin indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield. Our institution uses this drug for standard of care thromboprophylaxis (30 days) in this patient population.
40818758|NCT02734771|DRUG|Cyclophosphamide|
40818759|NCT02734771|DRUG|Doxorubicin|
40818760|NCT02734771|DRUG|Prednisone|
40818761|NCT02276352|DRUG|Treatment 1|
40818762|NCT02276352|DRUG|Treatment 2|
40818763|NCT02276352|DRUG|Treatment 3|
40818764|NCT00809991|RADIATION|hypofractionation|3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). T
40818765|NCT06164496|DEVICE|standart manual toothbrush|Device on plaque removal efficacy
40818766|NCT06164496|DEVICE|360 degree toothbrush|Device on plaque removal efficacy
40818767|NCT04552639|BEHAVIORAL|Newbridge Eating disorders Activity Treatment group|A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.
40818768|NCT04552639|BEHAVIORAL|Newbridge House treatment as usual|Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
40818769|NCT05513872|DRUG|Nicotine Replacement Therapy (NRT) Sampling|Participants randomized to this condition will receive a 4-week nicotine replacement therapy (NRT) starter kit containing both nicotine lozenges and patches in their original packaging.
40818770|NCT05513872|BEHAVIORAL|Practice Quitting (PQ) Counseling|Practice Quitting (PQ) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. The goals of the counseling sessions are 1) to gradually expose patients to nicotine withdrawal symptoms through practice quitting, and 2) to reduce fear and avoidance of the physical sensations associated with nicotine withdrawal.
40818771|NCT05513872|BEHAVIORAL|Motivational Interviewing (MI) Counseling|Motivational Interviewing (MI) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. Counseling content will incorporate MI-consistent principles, such as open questions, simple and complex reflections, and affirmations to facilitate participant statements in favor of behavior change. Discussion will focus on the motivational topics outlined in the USPHS guidelines for smokers not ready to quit: 1) relevance of smoking cessation or reduction to the individual, 2) risks of continued heavy smoking, 3) rewards of quitting and reduction, and 4) roadblocks to success, on a 5) repeated basis.
41016439|NCT06663644|OTHER|Muscle energy technique on iliotibial band|Post isometric relaxation involves the peripheral and central modulating mechanism by activating the muscles and joint mechanoreceptors. It can be effective for a variety of purposes including lengthening a shortened muscles, as a lymphatic or venous pump to aid the drainage of fluid or blood and increasing the range of motion. MET is a manual therapy intervention that can be used to stretch or lengthen muscles and fascia that lack flexibility.
41016440|NCT06663644|OTHER|Hamstring and abdominal muscle activation|The 90/90 exercises for abdominal and hamstring activation rotate the pelvis posteriorly in the sagittal and transverse plane, into a more neutral position. Hamstrings extend the hip, and therefore reciprocally inhibit hip flexors. Hamstrings and abdominals also aid in inhibiting paraspinal muscles via a posterior pelvic tilt / hip extension, a decrease in lumbar extension, and an increase in lumbar flexion.
41016441|NCT06663176|DRUG|RESP302|Nitric Oxide agent
41016442|NCT06663176|DRUG|RESP303|Nitric Oxide agent
41337393|NCT05015322|DRUG|bupivacaine and methylprednisolone|5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area
41337394|NCT05015322|DRUG|bupivacaine and methylprednisolone|5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection. In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint
41337395|NCT05015322|DRUG|bupivacaine and methylprednisolone|suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone
41337396|NCT01425645|OTHER|FDD program|FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
41337397|NCT04331028|DEVICE|Shockwave therapy|A shockwave therapy device will be applied in the alveolar socket area of a maxillary tooth, 2 weeks after tooth extraction was performed.
41337398|NCT00252876|DRUG|tesaglitazar|
41337399|NCT06252740|OTHER|No intervention|Comare the difference in batting mechanics, hip and thoracic spine mobility, and muscle stiffness in baseball players with and without a history of low back pain
41337400|NCT06313346|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules
41337401|NCT06313346|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
41337402|NCT01685203|DRUG|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
40818772|NCT05997095|OTHER|Neuromuscular electrical stimulation (NMES/0|NMES will be applied for 30 min and will be delivered using an approved, CE-marked device (Premier Combo Plus, Med-Fit Ltd, UK) using two large (7.5 × 13 cm) electrodes placed proximally and distally over the lateral quadriceps. The set protocols will be pre-programmed into to the device and the amplitude value will match the setting that was determined during a familiarisation visit
41016443|NCT06664021|DRUG|Tislelizumab combined with S-1|Tislelizumab：200mg q3w iv , lasts for one year. S-1：40mg, 50mg, or 60mg orally twice daily for 4 weeks, depending on body surface area, followed by 2 weeks of rest，lasts four cycles.
41156478|NCT04757519|BEHAVIORAL|DPP-GLB Enhanced|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.
41156479|NCT02187848|DRUG|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
41156480|NCT01368055|RADIATION|70 Gy/CGE|Low Risk
41156481|NCT01368055|RADIATION|72.5 Gy/CGE|Intermediate Risk
41337403|NCT01685203|DRUG|ABT-267|Tablet
41337404|NCT01685203|DRUG|Ribavirin (RBV)|Tablet
41337405|NCT04967911|OTHER|Rhythmic stabilization exercises|"PNF techniques and Conventional Treatment:~Experimental group received rhythmical Stabilization Technique on shoulder joint on all shoulder movements up to 1 minute in supine position For stability of joint ,re-establish dynamic rotator cuff stability and to enhance MS strength and decrease pain.~Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps).."
41337406|NCT04967911|OTHER|conventional treatment|Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
41337407|NCT00130468|DRUG|Hyalgan (sodium hyaluronate)|
41337408|NCT03649516|DEVICE|iCKD APP|Use iCKD APP to upload home bio-information data
41337409|NCT06508788|DEVICE|CO2 laser|Application of CO2 vulvo-vaginal laser according to standard therapy and moisturizing gels
41337410|NCT00259389|BEHAVIORAL|Directly observed therapy (DOT)|
41337411|NCT05328414|DRUG|Prednisolone|intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone
41337412|NCT04033380|DEVICE|Resin blocs (Grandio Blocs, VOCO)|composite-base bloc (Grandio Blocs, VOCO)
41337413|NCT04033380|DEVICE|Ceramic (Suprinity, VITA)|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
40818773|NCT06606379|DEVICE|I1 (Intervention)|Resin ring (DR- Resin ring, Egypt)
41337414|NCT00128752|BEHAVIORAL|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
41337415|NCT02657434|DRUG|Atezolizumab|Participants received IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
40818774|NCT06606379|DEVICE|I2 (Intervention)|Elliot separator (Pfingst \& Co, South Plainfield, NJ, USA)
40818775|NCT06606379|DEVICE|I3 (Intervention)|Stainless Steel Metal ring (TOR VM ring, Moscow, Russia)
40818776|NCT06606379|DEVICE|C (comparator)|Nickel titanium 3D-fusion ring (Garrison, USA)
40818777|NCT06608004|OTHER|test taking|Measurement of VAS for sensation of hunger, LFQP-France test, 24-hour semi-quantitative dietary recall, Assessment of energy expenditure linked to physical activity using the IPAQ (International Physical Activity Questionnaire) (only at inclusion), Screening for undernutrition risk factors using the SSQ (Social Support Questionnaire) (only at inclusion), Measurement of body composition by impedancemetry, Measurement of isometric grip strength by handgrip test, Measurement of quality of life (SF36), Study of olfacto-gustatory sensoriality (olfaction via the Sniffin\&#39; Sticks test, gustation via lingual application of impregnated strips and AHSP self-questionnaire) (carried out every other visit) and Measurement of gustatory evoked potentials in response to sugar.
40818778|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
40818779|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from CKD|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
40818780|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish CKD from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
40818781|NCT06606977|OTHER|Training|"During the detraining period, the athletes did not follow any external (personal) trainer-supported training program and their diet was not altered. Athletes have reported that they have stayed at home as a necessity of the Covid-19 pandemic process, and have done simple home exercises, walking and jogging exercises in a limited way during this time.~The training period included the standard wrestling trainings, which were determined by the national team coaches and realized at different intensities, during the 8 weeks when the training started. Following the period of detraining the level of training intensity was progressively increased throughout the initial 5 weeks. In the 6th and 7th week, training intensity peaked . In the 8th week prior to the competition, the training intensity was reduced in order to prepare and recover for the following competition. After the training period, the wrestlers participated in an international competition."
40818782|NCT06607575|OTHER|Control group|"1. The procedure for heel blood collection will be performed.~2. Pain assessment will be performed with the N-PASS scale during and after the procedure."
40818783|NCT06607575|OTHER|Warming|"1. The cotton sock will be warmed under the heater for 3 minutes. The sock will be put on the newborn and taken off after 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
40818784|NCT06607575|OTHER|Vibration|"1. A rechargeable toothbrush will be prepared for the newborn to whom vibration will be applied. The vibration process will be applied to the midline of the gastrocnemius muscle for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
40818785|NCT06607575|OTHER|Warming and vibration|"1. After the socks are warmed, they will be put on the newborn\&#39;s feet and both warming and vibration will be applied for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
40818786|NCT04018820|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
41016446|NCT06662708|DIAGNOSTIC_TEST|Accurate Prediction Artificial Intelligence Models|Diagnostic Test: Accurate Prediction Artificial Intelligence Models Post-operative pathology, precise pre-operative diagnosis (including benign and malignant, invasive, grading, subtypes) or 3D lesion modelling will be predicted based on the AI predictive model in response to the information provided
41016447|NCT06660550|PROCEDURE|laparoscopic inguinal hernia repair|traditional laparoscopic repair
41337416|NCT02657434|DRUG|Carboplatin|Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
41337417|NCT02657434|DRUG|Cisplatin|Participants received IV infusion of 75 mg/m\^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
41337418|NCT02657434|DRUG|Pemetrexed|Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
41337419|NCT00003413|BIOLOGICAL|filgrastim|
41337420|NCT00003413|DRUG|carmustine|
41337421|NCT00003413|DRUG|cisplatin|
41337422|NCT00003413|DRUG|melphalan|
41337423|NCT00003413|DRUG|paclitaxel|
41337424|NCT00003413|PROCEDURE|peripheral blood stem cell transplantation|
41337425|NCT00003413|PROCEDURE|surgical procedure|
41337426|NCT04250025|PROCEDURE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
41337427|NCT03796195|DRUG|.5% Bupivacaine|Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
41485697|NCT05792124|PROCEDURE|Retrolaminar block|The patient is in the prone position and the high-frequency linear ultrasound transducer is in parasagittal orientation, but the entry point is determined more medial than the ESP block. The needle entry point is 1-1.5 cm lateral to the targeted spinos process. The echogenic needle is advanced until it contacts the lamina in the craniocaudal plane and 0.5-1 for control. By giving cc 0.9 nacl solution, it is observed that the fluid is distributed between the erector spina muscle and the lamina. After the location of the needle is confirmed, a mixture of 20 ml of LA and saline will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA will consist of bupivacaine 0.5% and 20 ml physiological saline.
41485698|NCT01393184|DRUG|Nimotuzumab and Radiotherapy|Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
41485699|NCT04402775|OTHER|Tourniquet|A tourniquet will be used during surgery
41485700|NCT00974961|DRUG|bupivacaine, levobupivacaine|intrathecal injection 15\~20mg(for Levobupivacaine) or 10\~15mg(for Bupivacaine) once
41485701|NCT03915730|OTHER|Initial periodontal therapy|Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.
41485702|NCT04890951|PROCEDURE|Hysteropexy|Uterine preservation through suspension
41485703|NCT04890951|PROCEDURE|Hysterectomy and vaginal vault suspension|Uterine removal and sewing the vagina upwards
41485704|NCT01472328|PROCEDURE|HBO therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
41485705|NCT01472328|PROCEDURE|Hyperbaric room air|Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
41485706|NCT00468728|DRUG|PAR-101/OPT-80|capsules
41485707|NCT00468728|DRUG|Vancomycin|Capsules
41485708|NCT01224028|DRUG|Tacrolimus|oral
41337428|NCT00250497|BEHAVIORAL|New Moves|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
41337429|NCT02547519|DRUG|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
41337430|NCT02547519|DRUG|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
41337431|NCT05859906|OTHER|mechanical power measurement|"Mechanical power values of the patients;~* Before insufflation (baseline value),~* 0 min after insufflation,~* 15th min after insufflation,~* 30 minutes after insufflation,~* 45th minute after insufflation (if insufflation continues),~* 60th minute after insufflation (if insufflation continues),~* Intraoperative after insufflation It will be measured with the following formula in the specified periods. MP = 0.098 x minute ventilation x \[Peak inspiratory pressure - 0.5 x (Plateau pressure - Positive end-expiratory pressure)\]"
41337432|NCT01292525|DRUG|Tacrolimus|"A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®)."
41485709|NCT01224028|DRUG|Placebo|oral
41485710|NCT02126930|OTHER|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
41485711|NCT02126930|OTHER|Routine care|Patients randomized to this arm will receive care in the habitual manner.
41016448|NCT06660550|PROCEDURE|Needlescopic inguinal hernia repair|Needlescopic inguinal hernia repair
41156482|NCT02746081|DRUG|BAY1436032|The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
41485712|NCT02823652|OTHER|standard genetic education|Undergo usual care
41485713|NCT02823652|OTHER|Genetic Counseling|Complete remote counseling
41485714|NCT02823652|OTHER|Genetic Testing|Undergo germline testing
41485715|NCT02823652|OTHER|Internet-Based Intervention|Complete on-line genetic education
41485716|NCT02823652|OTHER|Survey Administration|Ancillary studies
41485717|NCT00531349|PROCEDURE|propofol general anesthesia|Regional analgesia combined with sedation or a propofol general anesthesia
41485718|NCT00531349|DRUG|Sevoflurane|General anesthesia
41485719|NCT01718470|PROCEDURE|Endotracheal tube|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
41337433|NCT01292525|DRUG|Placebo|"Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group."
41337434|NCT01353183|PROCEDURE|colonoscopy or rectosigmoidoscopy|Usual procedure
41337435|NCT01106391|DEVICE|"Cordis AAA stent graft system INCRAFT TM"|
41337436|NCT02401113|DIETARY_SUPPLEMENT|UA group|Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
41337437|NCT03904576|DRUG|BI 1358894|Film-coated tablet
41337438|NCT03904576|DRUG|Placebo|Film-coated tablet
41337439|NCT02062476|DIETARY_SUPPLEMENT|Lactobacillus GG|
41337440|NCT00778713|DRUG|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
41485720|NCT01718470|PROCEDURE|LMA|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
40818787|NCT06605859|DEVICE|GlucoTab|"Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal-insulin algorithm is to maintain blood glucose within acceptable targets according to the predefined health status.~For a limited time period after therapy start, three measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of the nursing homes/domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status.~Nurses and nursing assistants will be trained in the use of the GlucoTab."
40818788|NCT06605859|OTHER|Diabetes Treatment|Diabetes Standard Care
40818789|NCT00346281|DEVICE|32P BioSilicon|
40818790|NCT00570037|BIOLOGICAL|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
41337441|NCT03674541|DRUG|Pyridostigmine Bromide|Pyridostigmine Bromide 60 mg capsule by mouth as a one time dose
40818791|NCT01832129|DRUG|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
40818792|NCT01832129|DRUG|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
40818793|NCT02823054|DEVICE|EZ-Blocker|the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
40818794|NCT00737711|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
40818795|NCT02034682|DRUG|Volulyte 6%|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.
40818796|NCT02034682|DRUG|Geloplasma|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
41337442|NCT03674541|DRUG|Placebo|Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose
41337443|NCT05852730|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel
41337444|NCT05852730|DRUG|Other (e.g., promethazine, meclizine)|Subjects will self-administer other medications as available.
41337445|NCT00367341|DRUG|escitalopram|Participants will receive treatment with escitalopram for 12 weeks.
41337446|NCT00367341|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT will include 16 1 hour sessions provided over 12 weeks.
41337447|NCT04552626|BEHAVIORAL|Prolonged sitting (social breaks)|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a short social break. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
41485721|NCT01239446|OTHER|Not relevant (there is no intervention in the present study)|Not relevant (there is no intervention in the present study)
41485722|NCT04208074|OTHER|Exercise Intervention|Participants will exercise under the supervision of expert personal trainers and follow an optimized exercise program tailored to the strength and fitness level of each participant. Participants will exercise for 16 weeks; 2 days a week at the gym for an hour and 2 days of the week at home for 45 minutes.
41337448|NCT04552626|BEHAVIORAL|Prolonged sitting with step-up exercise break|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform a simple moderate-intensity step-up exercise for three minutes at a predetermined pace. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
41337449|NCT04552626|BEHAVIORAL|Prolonged sitting with simple resistance activity breaks|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
41337450|NCT05287724|DRUG|N-acetyl cysteine|1,500 mg twice daily for seven days
41485723|NCT04572126|BEHAVIORAL|Mindfulness Intervention|The mindfulness intervention includes strategies to cope with substance cravings based on previously published mindfulness techniques. Examples of strategies presented include paying close attention to sensations, acceptance of cravings, and self-kindness.
40818797|NCT06604988|BEHAVIORAL|Video-feedback intervention to promote positive parenting|"Each session will focus on three parental behaviours (that support child development) that have appeared clearly, frequently and consistently in the video (PICCOLO score of 2) in any of the 4 dimensions (affection, responsiveness, encouragement, teaching). Other aspects of parental behaviours that have scored 1 or 0 on the PICCOLO will also be considered, to increase their frequency or encourage their appearance. It is to be expected that all the behaviours collected in PICCOLO appear in one or more of the recordings, even if only occasionally. Behaviours that do not appear can be introduced through linking strategies with other behaviours in which parents show strength (for example, if a caregiver tends to name objects a lot, a link can be established between naming and asking the child the name of objects, if questions are behaviour that does not appear in the logs).~In each session, the caregiver is shown video clips that clearly show the positive parenting behaviours."
40818798|NCT02367274|DEVICE|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
40818799|NCT02543177|PROCEDURE|coronary angiography|
40818800|NCT02543177|PROCEDURE|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
40818801|NCT02543177|PROCEDURE|prior kidney irrigation|
41156483|NCT06249165|DRUG|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
41156484|NCT05302271|BIOLOGICAL|AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN|AAVrh.10hFXN will be administered intravenously.
41156485|NCT05302271|DRUG|Prednisone|All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.
41337451|NCT05287724|DRUG|Placebo|Placebo taken twice daily for seven days
41485724|NCT04572126|BEHAVIORAL|Control Intervention|The control intervention instructs participants to utilize their own, previously used strategies to cope with substance cravings.
41485725|NCT03762551|OTHER|skin biopsy|Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.
41485726|NCT04461119|DRUG|Evenamide|oral capsules for 4 weeks of treatment
41016449|NCT06662851|DIAGNOSTIC_TEST|UDFF|Ultrasound-Derived Fat Fraction (UDFF) is a quantitative ultrasound technique used to assess hepatic steatosis by measuring the amount of fat in the liver tissue. UDFF estimates fat content using specific ultrasound parameters, namely the attenuation coefficient (AC) and backscatter coefficient (BSC). The AC measures the rate at which ultrasound waves weaken as they pass through the liver, which correlates with fat content, while the BSC quantifies the amount of reflected ultrasound signal, providing additional insights into liver tissue characteristics.
41337452|NCT04011644|BEHAVIORAL|A-CHESS self-monitored|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a research team member. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
41337453|NCT04011644|BEHAVIORAL|A-CHESS peer-supported|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a counselor. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
41337454|NCT04011644|BEHAVIORAL|A-CHESS clinically-integrated|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a health coach. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
41337455|NCT04401410|BIOLOGICAL|Dose Finding Phase (MTD)|Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.
41337456|NCT04401410|BIOLOGICAL|Partially HLA-matched SARS-CoVSTs|Infusion of SARS-CoVSTs at the MTD level as determined in the Dose Finding Phase
41337457|NCT04401410|OTHER|Routine care (no SARS-CoVSTs)|Patients receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).
41337458|NCT06300892|OTHER|No intervention|samples from the incision site and GI tract collected
41337459|NCT02480998|BIOLOGICAL|IL-YANG Flu Vaccine QIV 0.5mL|
41337460|NCT02480998|BIOLOGICAL|IL-YANG Flu Vaccine TIV 0.5mL|
41156486|NCT05836987|DEVICE|AFSW Guided DOAC|The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
41337461|NCT05709314|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
41156487|NCT05836987|DRUG|Continuous DOAC therapy|DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.
41156488|NCT06646146|PROCEDURE|Fat grafting combine with hair transplantation|Patients enrolled in this experiment will be divided into two groups.The experimental group will have autologous fat tissue harvested during surgery for fat grafting in the patient's alopecia area, and a subsequent hair transplantation will be performed after three months when the transplanted fat has stabilized and survived.
41156489|NCT06646146|PROCEDURE|Hair transplantation|Patients enrolled in this experiment will be divided into two groups. The control group will undergo a simple hair transplantation surgery.
41337462|NCT01090674|OTHER|No intervention|We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
41337463|NCT01500863|DRUG|hCG|single shot of 6500 IU hCG s.c. at the time of triggering
41337464|NCT01500863|DRUG|triptorelin|single shot of 0.2mg triptorelin s.c. at the time of triggering
41337465|NCT01500863|DRUG|Triptorelin, estradiol valerate, micronized vaginal progesterone|4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
41337466|NCT01500863|DRUG|triptorelin, hCG|single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
41337467|NCT01500863|DRUG|triptorelin, hCG|Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
41337468|NCT01500863|DRUG|triptorelin, recombinant LH|300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
41337469|NCT04677049|DRUG|Niacin CRT|A controlled release technology (CRT) tablet of Niacin
41337470|NCT01983618|PROCEDURE|Interscalene nerve block and catheter|
41337471|NCT01983618|PROCEDURE|Interscalene catheter|
41337472|NCT00845507|DRUG|Exenatide|The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
41337473|NCT00845507|DRUG|Placebo|Placebo: Sterile solution in equivalent doses as Exenatide
41337474|NCT02150460|PROCEDURE|One-site peribulbar injection|injection into the inferior medial orbital compartment
41337475|NCT02150460|PROCEDURE|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
41337476|NCT04236219|DRUG|ALLN-346|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
41337477|NCT04236219|DRUG|Placebo|Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
41337478|NCT01531361|DRUG|Crizotinib|Given PO
41337479|NCT01531361|OTHER|Laboratory Biomarker Analysis|Correlative studies
41337480|NCT01531361|OTHER|Pharmacological Study|Correlative studies
41337481|NCT01531361|DRUG|Sorafenib Tosylate|Given PO
41337482|NCT01531361|DRUG|Vemurafenib|Given PO
41337483|NCT00610207|DEVICE|Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia
41337484|NCT04225390|DRUG|Dacarbazine (DTIC)|Dacarbazine powder for IV solution
41337485|NCT02217683|DRUG|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
41337486|NCT00033059|DRUG|Tolcapone|
40818802|NCT06243939|BEHAVIORAL|Motivational Interview to Increase Health Management Self-Efficacy and Quality of Life in Pregnant Women Diagnosed with Gestational Diabetes Mellitus|Motivational interviewing is a client-centered approach used to elicit behavioral change by helping clients explore and resolve their ambivalence.
40818803|NCT03541967|DEVICE|ADHEAR and PONTO 3 SUPER POWER on softband hearing aids|Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband
40818804|NCT04039750|DRUG|antibiotic rinse with suction|antibiotic rinse with suction
40818805|NCT04039750|PROCEDURE|suction only|no irrigation, suction only
40818806|NCT06605898|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
40818807|NCT06605898|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
41156490|NCT02933996|DEVICE|TEAS+GA group|The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
41337487|NCT03927911|DRUG|EXPAREL and Bupivacaine|Drug: EXPAREL and Bupivacaine HCl 0.5%
40818810|NCT00404755|DRUG|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
40818811|NCT00404755|DRUG|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
41337488|NCT03927911|DRUG|Standard of Care|Standard of Care
41337489|NCT05862298|DIAGNOSTIC_TEST|venous excess ultrasound score|Venous congestion is classified into 4 grades. If the Inferior vena cava is not plethoric, there is deemed to be no congestion (grade 0), and further Doppler examination is not performed. When the IVC is plethoric but there are no severely abnormal waveforms (defined as S-wave reversal on hepatic, \>50% pulsatility on portal, and a monophasic pattern on intrarenal Doppler), congestion is considered to be mild (grade 1). Plethoric IVC with at least 1 severely abnormal pattern is considered to be moderate congestion (grade 2), while 2 or more abnormal Doppler patterns constitute severe congestion (grade 3)
41337490|NCT04834752|OTHER|No intervention (Retrospective Cohort Observational)|History of PPI and H2RA prescription of the participants who were tested for COVID-19 will be reviewed.
40818812|NCT00404755|DRUG|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
40818813|NCT06416657|OTHER|Different anesthesia methods, namely local anesthesia and general anesthesia|"Patients in the local anesthesia group received only local anesthesia at the femoral artery puncture site without anesthesia drugs such as conscious sedation.~Patients in the general anesthesia group received not only local anesthesia at the femoral artery puncture site, but also fast-induction anesthesia with tracheal intubation or laryngeal mask insertion using isoproterenol, remifentanil, and muscle relaxants."
40818814|NCT06121141|DRUG|Full strength lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000
40818815|NCT06121141|DRUG|Dilute lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000 diluted with normal saline (09.% NaCl) in a 1:4 ratio
40818816|NCT01186926|DEVICE|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
41337491|NCT01993667|DRUG|Low Dose Acetazolamide|Administration of low dose acetazolamide
41337492|NCT01993667|DRUG|Normal Dose Acetazolamide|Administration of normal dose acetazolamide
41337493|NCT02596828|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
41337494|NCT02596828|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
41485727|NCT04461119|DRUG|Placebo|oral capsules for 4 weeks of treatment
40818817|NCT05396924|PROCEDURE|Rectal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
41337495|NCT02596828|DRUG|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
41337496|NCT02596828|DRUG|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
41337497|NCT05985395|BEHAVIORAL|HEART Camp Connect|Once eligible and enrolled, participants will complete 150 minutes of moderate-intensity exercise a week with help of a virtual exercise coach.
41337498|NCT01477073|DRUG|FSH-GEX™|
41337499|NCT01477073|DRUG|recombinant FSH|
41337500|NCT01477073|DRUG|urinary FSH|
41337501|NCT01477073|DRUG|Placebo|
41337502|NCT06507098|OTHER|Video-assisted training|Patients received a QR code and a link for access to a YouTube video recorded to this effect where the process of setting up the respiratory polygraph was explained. The contents of the video were the same as those in the face-to-face instructions. The visualization of the video was at home, and it could be viewed as many times as necessary.
41337503|NCT06507098|OTHER|Nurse training|A trained nurse with long experience in home sleep studies explained the setup of the respiratory polygraph. At the end of the intervention doubts about the procedure were addressed. Patients did not have access to the video.
41337504|NCT06269757|BEHAVIORAL|Individualized Exercise Program|"The individualized exercise program involves an initial 2D individual running evaluation designed for runners of all ages and abilities, to help improve performance and prevent injury. During the assessment patients receive a one-on-one evaluation with an exercise physiologist that includes:~* Running analysis;~* Training program review;~* Strength and flexibility assessment;~* Review of running video;~* Personalized final report."
41337505|NCT06269757|BEHAVIORAL|Standard Physical Therapy|Standard of care physical therapy for ITB band syndrome involves exercises designed to target structural weaknesses such as hip abductor weakness. Typical exercises include but are not limited to hip flexor stretches, side lying hip abduction, figure 4 bridges, lateral walks with exercise bands, and side planks.
41337506|NCT05141357|DRUG|HBI-8000 in combination with pembrolizumab|Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.
41337507|NCT06394076|DEVICE|Cross-linked sodium hyaluronate gel for injection containing lidocaine|Cross-linked sodium hyaluronate gel for injection containing lidocaine
41337508|NCT04287413|BEHAVIORAL|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination.~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
41337509|NCT04287413|BEHAVIORAL|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
41337510|NCT05031104|OTHER|Physical Exercise|The control group received a standard exercise program for 40 minutes, three times a week for three successive months. The program encompassed aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises.
41337511|NCT05031104|OTHER|Physical Exercise plus Low-energy Laser Therapy|The LLT group received the same program in addition to the application of LLT on both knees, each session before exercises.
41337512|NCT06322017|PROCEDURE|Rhythm control by Pulmonary Vein Isolation (PVI) procedure|"The PVI procedure involves the creation of a circumferential lesion around the ostium of the four pulmonary veins.~The choice of the type of energy to insure the lesion will be left to the discretion of the investigator, according to the center's habits and the patient's anatomy found on the scanner."
41156491|NCT02933996|DEVICE|Sham TEAS+GA group|No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.
41337513|NCT06322017|DRUG|Conventional care by antiarrhythmic drugs (flecainide, sotalol, amiodarone) or bradycardic drugs (all betablocker or calcium channel blocker therapy, digoxin)|"Ventricular rate control is carried out using negative chronotropic agents (e.g. beta-blockers, calcium channel blockers, digitalis, etc.) according to current recommendations. If this fails, ablation of the atrioventricular junction with placement of a permanent pacemaker can be carried out according to current recommendations. As part of this research, the choice of bradycardic drugs and interventions will be left to the discretion of the investigator according to the center's practices and current recommendations.~Rhythm control aims to reduce AF by cardioversion (if it persists) to restore sinus rhythm and subsequently maintain it by introducing anti-arrhythmic treatment. Several antiarrhythmic drugs (flecainide, sotalol or amiodarone) can be used in this setting. As part of this research, the choice of antiarrhythmic drugs will be left to the discretion of the investigator according to the center's practices and current recommendations."
40818818|NCT05396924|PROCEDURE|Temporal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
40818819|NCT03294174|DRUG|Ropivacaine injection|Ropivacaine administered to provide nerve block
40818820|NCT00544453|DRUG|[123I] MNI-308|Injection of \[123I\] MNI-308 and SPECT scanning
40818821|NCT00243451|OTHER|PET scan & fMRI|Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
40818822|NCT02124018|PROCEDURE|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
40818823|NCT02124018|DEVICE|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
40818824|NCT05433051|BIOLOGICAL|buccal miniscrew and TPA|intrusion of molars
40818825|NCT05433051|BIOLOGICAL|vertical holding appliance|intrusion of molars
40818826|NCT05978960|OTHER|Nutrition and resistance training exercise intervention|"3 month 2-3 times/week, 60 min exercise regimen utilizes compound movements to focus on body composition, strength, and mobility. Classes are run by certified strength and conditioning specialists and adjusted for linear progression and safety, progressing from compound to isolated movements to maximize safety.~The nutrition intervention focuses on dietary quality by following a healthy low-carbohydrate diet, focusing on nutrient dense foods high and avoiding processed foods and simple carbohydrates to keep totals under 100g/day. Participants will be advised to eat vegetables, avoid snacking, cook all meals with family and friends, avoid eating on the run, and focus on whole foods that require preparation. Calculations and quantification of calories will be avoided, while protein consumption goals are 1.3-1.8 g/kg per. Dietary strategy will be continuously discussed during exercise sessions and the PI will have twice monthly meetings with participants."
40818827|NCT06606470|BEHAVIORAL|All providers Better Communication Skills program' (ABCs) interprofessional provider education|The 'All providers: Better Communication Skills program' (ABCs) is a virtual, person-centred education curriculum for interprofessional health care providers. The ABCs program adopts a blended format (i.e., participants engage in both asynchronous online modules \[five\] and synchronous interactive workshops \[three\]) that has relevance to learners and clinicians at all levels of training and practice. The ABCs program focuses on four essential elements of being a skillful communicator: principles of effective communication, conversation structure, communication skills, and reflective practice. The program consists of virtual modules that provide any clinician with practical tools, tips, and strategies to implement when communicating with seriously ill patients and their families. Terminology is clarified and consistent, the complexities of conversations are simplified and the fundamental approach and structure can be applied to different contexts.
40818828|NCT05419128|BEHAVIORAL|PartnerCHESS|"The following ABCT services, from PartnerCHESS, will be available in the FamCHESS-C app but not in ACHESS-C:~ABCT tutorials. Interactive e-learning modules explaining key ABCT skills. Agreements between drinker and partner to follow key principles. Trigger identification and removal. Cravings discussion. Relapse plan. Reminders."
40818829|NCT05419128|BEHAVIORAL|ACHESS|ACHESS-C offers the following, which are also available in FamCHESS-C: Covid content, Instant Library, Discussion Groups, Personal Stories, Location Monitor, Surveys and Ecological Momentary Assessments, Guided Relaxation, Healthy Activities, Crisis Button, Skills Reminders
40818830|NCT04852705|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
41156492|NCT00549042|DRUG|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
41337514|NCT02025530|OTHER|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
41337515|NCT04989660|DRUG|6% aqueous phenol|1.5 mL of 6% aqueous phenol will be injected at each target genicular nerve under ultrasound guidance.
41337516|NCT04989660|DRUG|Isotonic saline|1.5 mL of isotonic saline will be injected at each target genicular nerve under ultrasound guidance.
41337517|NCT00264095|PROCEDURE|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
41337518|NCT05412667|DIETARY_SUPPLEMENT|TWK10|"1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection."
41337519|NCT05412667|OTHER|Placebo|"1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection."
41337520|NCT03503812|BEHAVIORAL|Intervention (1) for outdoor exposure reduction - Asthma in Children|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity"
41485728|NCT03452774|OTHER|Clinical Trial Matching|Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
40818831|NCT04852705|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
40818832|NCT06535347|BEHAVIORAL|Information about scheduling a follow-up appointment|Text message(s) will be sent following discharge from the emergency department, along with an after visit summary.
40818833|NCT02141698|DRUG|TAK-438|TAK-438 tablets
41337521|NCT03503812|BEHAVIORAL|Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' schools and houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners."
40818834|NCT02141698|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
40818835|NCT02141698|DRUG|Esomeprazole|Esomeprazole tablets
40818836|NCT03395691|PROCEDURE|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach
40818837|NCT03395691|PROCEDURE|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
40818838|NCT04465370|DEVICE|Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight|A Swan-Ganz catheter, FloTrac transducer, ClearSight finger cuff and ForeSight Elite sensors will be placed prior to the start of the catheterization procedure. Intermittent cardiac output and other hemodynamic parameters will be collected throughout the duration of the procedure and analyzed according to the Statistical Analysis Plan.
40818839|NCT03394066|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-eight TMS coil. An MRI compatible version of the figure-of-eight coil will be used inside the MRI scanner with an appropriate TMS coil holder.
40818840|NCT05410171|DEVICE|early warning platform|High risk inpatients will be evaluated by early warning platform
40818841|NCT02636244|DRUG|SHAPE Gel|
40818842|NCT06163183|DEVICE|Edi catheter|
40818843|NCT03193723|PROCEDURE|US guided five step field block|"Ultrasound will guide needle insertion in the following layers (except intradermic injection):~* Subdermic infiltration. Approximately 8 milliliters~* Intradermic injection (making of the skin wheal). of approximately 6 milliliters.~* Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose~* Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.~* Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac"
40818844|NCT03193723|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
40818845|NCT03359785|DRUG|Luvadaxistat|TAK-831 Tablets.
40818846|NCT03359785|DRUG|Matching Placebo|Matching Placebo Tablets.
40818847|NCT04418869|OTHER|Exercise bouts|Each subject performed three bouts with 45 minutes of exercise (continuous exercise, intermittent exercise and resistance exercise) in a randomized order. In addition a control session were performed where the subjects sat on a chair for 45 minutes.
40818848|NCT02694068|OTHER|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
41156493|NCT00549042|DRUG|Placebo|Placebo
41156494|NCT02033499|BEHAVIORAL|SMBG|Blood glucose levels are tested once daily.
41337522|NCT03503812|BEHAVIORAL|Intervention (1) for outdoor exposure reduction - Atrial Fibrillation|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity"
41485729|NCT04183647|DEVICE|whole body vibration / local vibration|Both the whole-body vibration application and the local vibration application will be applied to the patients in our cross-over study. Between the two applications will be given a washout period of one week. Patients will be evaluated both local and whole body vibration applications, 1 minute and 60 minutes after the end of the applications. After the evaluation, the patient will be rested in the sitting position until the evaluation at the 60th minute.
41485730|NCT03814941|OTHER|paper-based anesthesia record|to evaluate the incidence of artifacts in the AIMS database by paper-based anesthesia record
41337523|NCT03503812|BEHAVIORAL|Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners."
40818849|NCT02694068|OTHER|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
40818850|NCT04867187|OTHER|Repetitive transcranial magnetic stimulation (rTMS)|20 minutes of high frequency (20Hz) rTMS.
40818851|NCT04867187|OTHER|Mirror therapy using virtual reality|active mirror-based therapy
41485731|NCT03814941|OTHER|electronic documents|to evaluate the incidence of artifacts in the AIMS database by electronic documents anesthesia record
41485732|NCT02726919|DRUG|Clobazam|Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
40818852|NCT04867187|OTHER|Mirror therapy using sham mirror|20 minutes of sham mirror-based therapy
40818853|NCT00445211|DRUG|Heparin|Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
40818854|NCT00445211|OTHER|Without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin.
40818855|NCT01686425|PROCEDURE|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
40818856|NCT04213781|DEVICE|HappyMed Video Glasses|HappyMed allows the immersion of patients in films, cartoons or concerts.
40818857|NCT04213781|DRUG|Propofol|The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.
40818858|NCT04213781|DRUG|Sufentanil|0.1 µg/kg
41485733|NCT00838708|DRUG|SRD174 Cream|topical SRD174 Cream
41485734|NCT00838708|OTHER|vehicle cream|topical vehicle cream
41485735|NCT05276882|OTHER|Hypnosis|"It will be an individualized hypnosis session of Ericksonian type. It consists in going through 3 phases: induction, dissociation, suggestion.~The principle is to focus the patient's attention by talking to her or by surprising her, or by making her do an incongruous gesture which will make her focus on a restricted idea. She will reduce her field of consciousness and concentrate. This is where her work will begin, allowing her unconscious to function in order to find her solutions. At this moment, she is particularly receptive to suggestions and the hypnotherapist accompanies and guides her thoughts and her associations of ideas on therapeutic paths. He provokes a unique personal work which aims to promote healing."
41485736|NCT05276882|OTHER|pre-surgery consultation|"Dialogue with the patient to clarify her expectations.~* Answers to the patient's questions~* Precision on the organization of the hospitalization if necessary~* Information on the postoperative period with postural advice to facilitate the first getting up with less discomfort, and postures promoting rest in the postoperative period~* Information on relaxation techniques and their interest (abdominal breathing)"
41156495|NCT02186587|DEVICE|ConforMIS custom total knee|Total knee arthroplasty using ConforMIS custom total knee system with follow-up at 6 months
40818859|NCT06506188|BEHAVIORAL|LINK model|"The LINK model includes four elements:~(1) linking postpartum HIV testing and PrEP services to early infant vaccination, (2) screening for HIV risk among those who test negative for HIV at the early infant vaccination visit, (3) male partner engagement to support status awareness within couples and PrEP persistence, and (4) community-facility linkage (CFL) peer mom for ongoing support of breastfeeding women using PrEP and follow-up of breastfeeding women who disengage from PrEP care."
40818860|NCT00538967|DRUG|doxycycline|2 weeks once daily
40818861|NCT06608264|OTHER|stress ball intervention|Stress ball intervention; A medium hard, round, high quality stress ball of the same brand will be given to the patient\&amp;#39;s actively used hand 1-2 minutes before starting the continuous passive movement exercise by the researcher.The patient will be asked to squeeze and relax the stress ball for a count of 5 during continuous passive movement.After squeezing the stress ball, the patient should count to 5 and then relax it.The patient will be asked to continue this process until the continuous passive movement exercise is completed.
40818862|NCT06608264|OTHER|hand holding intervention|Hand holding intervention will be performed by the person the patient prefers. Before the continuous passive movement exercise, the person concerned will sit next to the patient\&#39;s bed and warm their hands at a level that will not disturb the patient.1-2 minutes before the continuous passive motion exercise, the patient will hold the patient\&#39;s hand with one hand, without using gloves, with moderate pressure, without rubbing or squeezing to an uncomfortable level.Hand holding intervention will continue until the continuous passive movement exercise is completed.
41156496|NCT01132378|PROCEDURE|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
41156497|NCT02517476|DIETARY_SUPPLEMENT|Nutritional therapy|Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
40818863|NCT02666651|DRUG|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
40818864|NCT02666651|OTHER|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
40818865|NCT06040008|GENETIC|blood collection|"* 3 blood collections over a period of 6 weeks~* V0 - Inclusion~* V1 - 3 weeks ± 14 days~* V2 - 3 weeks ± 14 days~* 1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit~* Clinical information obtained at each visit"
41337524|NCT03751969|DRUG|HSK3486|The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.
40818866|NCT03555981|OTHER|Early Kangaroo Mother Care|Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission
41337525|NCT01581996|DRUG|lanthanum carbonate|All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
40818867|NCT03555981|OTHER|Standard care|Incubator or radiant heater care until stable, off oxygen and \>24h of admission, at which point will start intermittent or continuous kangaroo mother care
40818868|NCT02421731|DEVICE|Robot-assisted gait training|Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
40818869|NCT02421731|OTHER|Conventional therapy|The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
40818870|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, TID
40818871|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, BID
41337526|NCT02734095|DEVICE|Ultrasound|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
41337527|NCT04442386|OTHER|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout
41337528|NCT04544124|BEHAVIORAL|Contingency management|Incentives will be provided for treatment attendance over a 12-week period.
41337529|NCT03823430|DIAGNOSTIC_TEST|Pupillometry|Pupillar diameter variation measurement
40818872|NCT01626118|DRUG|Indomethacin|capsules, 20 mg, TID
41156498|NCT03469258|DRUG|Pancrelipase|Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.
41156499|NCT04659278|DIETARY_SUPPLEMENT|Endourage 1200 mg OMD ™ Oral Mucosal Drops|The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
40818873|NCT01626118|DRUG|Placebo|capsules
40818874|NCT06608654|DEVICE|endoscope application|Intrauterine bronchoscopy application for fetal distress during labor
40818875|NCT06581614|DIAGNOSTIC_TEST|masticatory function test|During the test, participants will be given a piece of chewing gum to assess their masticatory function when the second molar implant-supported fixed denture is in place.
40818876|NCT04543266|PROCEDURE|Surgery|Resection of tumors
40818877|NCT03122678|DRUG|Thiamine|
40818878|NCT03122678|DRUG|Placebos|
40818879|NCT04671784|OTHER|EUS-E|EUS-E
41156500|NCT04659278|DIETARY_SUPPLEMENT|Isolate|The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
41337530|NCT03062267|OTHER|Mobile Interventionist|A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
41337531|NCT02690389|DRUG|Flumazenil|used alone or with acupuncture
41337532|NCT02690389|PROCEDURE|Acupuncture|used alone or with flumazenil
41337533|NCT05272657|OTHER|low-carbohydrate diet|subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet.
41337534|NCT05272657|OTHER|Mediterranean diet|subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
41337535|NCT02168712|OTHER|Moderate continuous exercise training|
41337536|NCT02168712|OTHER|Interval exercise training|
41337537|NCT03158090|PROCEDURE|Transnasal butterfly surgery|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
40818880|NCT05820152|DRUG|NFS-02 Injection|The starting dose is 1.5×108 vg, 0.05 mL eye/dose. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be escalated to 5.0×108 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the 5.0×108 vg, 0.05 mL eye/dose, the dose can be escalated to 1.5×109 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in ≥ 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be de-escalated to 5.0×107 vg, 0.05 mL eye/dose after the approval by SRC.
40818881|NCT00668382|BIOLOGICAL|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
40818882|NCT03509363|BEHAVIORAL|Stroke physiotherapy home exercise video|a set of exercise video with QR code provided in home exercise pamphlets
40818883|NCT00262236|DRUG|Aliskiren|
40818884|NCT03448666|COMBINATION_PRODUCT|Pembrolizumab|Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
40818885|NCT00394251|DRUG|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
40818886|NCT00394251|DRUG|ABI-007|260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
40818887|NCT00394251|DRUG|Taxol|175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
40818888|NCT00394251|DRUG|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
41485737|NCT00000607|DEVICE|Left ventricular assist device|A type of implantable heart pump
40818889|NCT00394251|DRUG|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
40818890|NCT06323941|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Isometric exercises (20 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
40818891|NCT06323941|BEHAVIORAL|Therapeutic exercises|Isometric exercises (20 minutes) to which will be added a placebo motor imagery intervention (imagining a blue sky).
40818892|NCT05800028|BEHAVIORAL|Learning new information|The purpose of this study is to test the effects of different social contexts when learning new information. Participants in the AD, SPPA, and HC experimental groups will be given tests to learn verbal information (location of drawings in a grid). The learning phases of these tests are presented in the form of a memory game in which participants are asked to make pairs of drawings by finding the second copy of the proposed pair by trial and error in a grid. After learning, a task of recognizing the position of the drawings in the grid is performed. Each participant will carry out this learning in three different conditions: 1) learning alone, 2) learning by observation of the reconstruction of the pairs of images by a partner, and 3) collaborative learning in which the two game partners discover and reconstruct the pairs together.
40818893|NCT04155918|DRUG|Group 1: AR882 Alone and in Combination with Febuxostat (FBX)|AR882 + Febuxostat, AR882 alone, Febuxostat alone
41485738|NCT00000607|DEVICE|Optimal medical therapy|(non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
40818894|NCT04155918|DRUG|Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)|AR882 + Allopurinol, AR882 alone, Allopurinol alone
40818895|NCT06437288|PROCEDURE|photodynamic therapy|Receive an intravenous infusion of hematoporphyrin injection
40818896|NCT06459089|BEHAVIORAL|Selection of the parent according to children preference|The children will select the parent who will accompany them during the anesthesia induction
41485739|NCT06418685|DEVICE|Treatment with Vibrating Capsule|"Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation."
41485740|NCT06319937|DIAGNOSTIC_TEST|Ultrasound|Ultrasound
40818897|NCT06459089|BEHAVIORAL|Bringing the favorite toy of the children that will accompany the child during their perioperative period|The children will bring tiheir favorite toy that will accompany them during their perioperative period
41016453|NCT06662721|DRUG|Baricitinib 4 MG|The patients received Baricitinib for 48 weeks. The method is to take Baricitinib 4mg every day for a period of 48 weeks. All the patients will be followed up prospectively for 48 weeks.
41016454|NCT06664190|DIAGNOSTIC_TEST|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)
41016455|NCT06664203|PROCEDURE|Selective turuncus block with 25 ml bupivacain|A high-frequency linear ultrasound (USG) probe will be used to locate the C7 transverse process, which will serve as a sonoanatomic landmark. Once the C5 ventral ramus is identified at the C7 transverse process level, the linear probe will be slightly caudally angled to visualize the C6 ventral ramus. The area where the superior trunk is formed by C5 and C6 will be examined with the USG probe until the superior trunk is visualized. Below the superior trunk, the middle trunk and the C8 ventral ramus will be visible. In Group 1, a total of 23 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used as the local anesthetic mixture, totaling 25ml. 7ml of the local anesthetic mixture will be injected into the superior trunk, the middle trunk for an additional 8 ml. The probe will then be directed caudally to obtain an optimal view of the lower trunk, where 10 ml of the same mixture will be injected close to the lower trunk.
41156501|NCT04659278|OTHER|Placebo|Total CBD = CBD + (CBD-A \* 0.877). Total THC = THCA-A \* 0.877 + Delta 9 THC, ND = \<LOQ, T-Caryophyllene = Trans-Caryophyllene, \<LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
41156502|NCT04659278|DIETARY_SUPPLEMENT|Peppermint Oil, masking flavor|Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
41156503|NCT06363877|DRUG|Povidone-Iodine|"Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of dilute aqueous povidone-iodine solution allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the povidone-iodine solution then wash-out with 2L of normal saline followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL povidone-iodine solution, suctioned, then washed-out with 500 mL normal saline."
41156504|NCT06363877|DRUG|Normal Saline|"Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of normal saline allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the solution, wash-out with 2L of normal saline, followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL normal saline solution, suctioned, then washed-out with 500 mL normal saline."
40818898|NCT05359874|DRUG|Bevacizumab-IRDye800CW|In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
41156505|NCT01976156|DIETARY_SUPPLEMENT|PhosphoLean|PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
41337538|NCT03158090|DRUG|sandostatin|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
40818899|NCT03907865|DRUG|Softacort|Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
40818900|NCT06236061|DRUG|LCZ|LCZ 200 mg
40818901|NCT06236061|DRUG|LCZ/AML 200 mg/2.5 mg|LCZ/AML 200 mg/2.5 mg
40818902|NCT06236061|DRUG|LCZ/AML 200 mg/5 mg|LCZ/AML 200 mg/5 mg
40818903|NCT06236061|DRUG|LCZ/AML 200 mg/10 mg|LCZ/AML 200 mg/10 mg
40818904|NCT04134117|BIOLOGICAL|Tisagenlecleucel|One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
41485741|NCT00754013|DRUG|Aricept (Donepezil hydrochloride)|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally."
41485742|NCT00754013|DRUG|Placebo|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally."
40818905|NCT01773551|OTHER|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
41156506|NCT01976156|DIETARY_SUPPLEMENT|Placebo|Placebo consists of rice flour
40818906|NCT05132361|DEVICE|SELUTION SLR™ 018 DEB|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
40818907|NCT05132361|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
40818908|NCT02760173|OTHER|perception of vertical after static roll-tilt over 5min|subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
41485743|NCT00356980|BIOLOGICAL|colloidal gold-bound tumor necrosis factor|
41485744|NCT00356980|OTHER|pharmacological study|
40818909|NCT03735628|DRUG|Copanlisib|Copanlisib: lyophilisate for reconstitution and further dilution for infusion
41156507|NCT04520685|DRUG|Oral cannabidiol 100mg/mL|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
41156508|NCT04520685|DRUG|Placebo|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
41337539|NCT03158090|RADIATION|radiotherapy|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
41485745|NCT01240213|DIETARY_SUPPLEMENT|Vitamin D|2000 IU per day of Vitamin D
41485746|NCT01240213|DIETARY_SUPPLEMENT|Placebo|1 Placebo per day
41485747|NCT04713098|DEVICE|Peripheral Nerve Stimulation|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
41485748|NCT04713098|DEVICE|Sham|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
41485749|NCT04857463|OTHER|Nutritional supplement drink|At the intervention period (0th to 12th week of the experiment), In addition to nutrition and health education, subjects were provided with 2 bottles of commercially available oral nutritional supplements (Meiji Mei Balance, Meiji Co., Ltd., Tokyo, Japan) every day, between lunch and dinner and before bedtime.
41156509|NCT02653066|OTHER|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
41485750|NCT04857463|OTHER|Nutritional education|At the intervention period (0th to 12th week of the experiment) , subjects will be given regular nutrition education by a qualified clinical dietitian to ensure the effectiveness of nutrition education, in order for the nutrition education group to benefit from participating in this trial, the subjects will also be provided with the same nutritional products after the trial
41485751|NCT05110807|DRUG|TQB3617|TQB3617 is a BET inhibitor.
41485752|NCT01485666|OTHER|Percutaneous Lead Management Kit|A kit of commercially available components to be used for HeartMate II driveline exit site cleaning, dressing and stabilization
41485753|NCT01181271|DRUG|Busulfan (conditioning for AUTO transplant)|0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
41156510|NCT02653066|OTHER|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
41337540|NCT04409626|OTHER|Plasma sodium level (continuous variables)|Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.
41337541|NCT04890561|DRUG|Lemborexant|Lemborexant oral tablets.
41337542|NCT04964557|DRUG|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
40818910|NCT03735628|DRUG|Nivolumab|Nivolumab: concentrate for solution for infusion
40818911|NCT04660201|BIOLOGICAL|AV7909|AV7909 (Liquid Formulation) is an investigational vaccine that is a preformulated, sterile, milky-white suspension for IM injection. It consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and CPG 7909 adjuvant
40818912|NCT04660201|BIOLOGICAL|AV7909|AV7909 (Lyophilized Formulation) is a thermostable, lyophilized version of the liquid AV7909 formulation. Sterile, milky-white suspension for intramuscular injection. It consists of polysorbate 80, CPG7909 adjuvant and AVA bulk drug substance
40818913|NCT02429492|DEVICE|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
40818914|NCT02027467|DIETARY_SUPPLEMENT|StemAlive®|
40818915|NCT02027467|DIETARY_SUPPLEMENT|Placebo (For StemAlive®)|
40818916|NCT03554057|DIAGNOSTIC_TEST|Coronary Computed Tomographic Angiography|All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
40818917|NCT02500927|DRUG|ASP8273 Capsules|oral
40818918|NCT02500927|DRUG|ASP8273 Capsules A|oral
40818919|NCT01661777|DRUG|Nasal steroid|
40818920|NCT01661777|PROCEDURE|Myringotomy tube placement|
40818921|NCT01661777|DRUG|Diuretic|
40818922|NCT01661777|DRUG|Antihistamine|
40818923|NCT01661777|BEHAVIORAL|Low salt diet|
40818924|NCT04309305|DEVICE|EksoGT™, Ekso Bionics, Berkley, CA, USA|The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking.
41485754|NCT01181271|DRUG|Etoposide (conditioning for AUTO transplant)|Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
40818925|NCT04309305|OTHER|Standard of Care|Standard gait therapy provided by licensed physical therapists post stroke.
41156511|NCT05074004|OTHER|Psychoeducation|Psychoeducation sessions were conducted by two psychiatric nurses (İK, SS) who are experts in their fields and have psychoeducation and group leadership certificates. Each session was held once a week in 30-45 minutes sessions. The training was carried out interactively; approximately the first 5 minutes were spent on warm-up, the basic information of that day's session was given for 25 minutes, and the last 10 minutes were in the form of questions and answers. Two separate groups were formed according to the day hospital program of the patients, and the psychoeducation program was carried out in two separate groups to conduct psychoeducation effectively.
41337543|NCT04964557|DRUG|Placebo|Placebo solution
41337544|NCT06013319|DRUG|Esmolol|The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
41485755|NCT01181271|DRUG|Cyclophosphamide (conditioning for AUTO transplant)|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
40818926|NCT04309305|OTHER|No Intervention|Testing Only
41016456|NCT06664203|PROCEDURE|Selective turuncus block with 15 ml bupivacain|In Group 2, 13 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used, totaling 15 ml. In Group 2, 5 ml of the local anesthetic mixture will be injected into the superior trunk, followed by 5 ml into the middle trunk and 5 ml into the lower trunk, as in Group II.
40818927|NCT05441683|PROCEDURE|horizontally extending incision|An intrasulcular incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Then horizontally extending incisions will be added to each side of the Intrasulcular incision, extending one to two teeth beyond the defected area, before a full-thickness flap is lifted.
41156512|NCT05311774|DRUG|Duloxetine 30 mg|tablet
41156513|NCT05311774|DRUG|Tramadol|tablet
41156514|NCT05311774|DRUG|Placebo|tablet
41156515|NCT06480396|DIAGNOSTIC_TEST|High-intensity radiological surveillance|The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.
41337545|NCT02915289|PROCEDURE|Povidone Iodine|Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
41337546|NCT02915289|PROCEDURE|Chlorhexidine gluconate|Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
41485756|NCT01181271|DRUG|Mesna (prior to AUTO transplant)|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
41485757|NCT01181271|OTHER|autologous (auto) peripheral blood stem cell transplantation|Infusion of autologous peripheral blood stem cells on Day 0.
40818928|NCT05441683|PROCEDURE|vertical releasing incision|An intrasulcular incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Vertical releasing incisions will be made on each side of the intrasulcular incision before a full-thickness flap is lifted.
40818929|NCT00416663|PROCEDURE|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
40818930|NCT02068846|DRUG|Ciprofloxacin|Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
40818931|NCT02068846|DRUG|Placebo|Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
41337547|NCT00797810|DRUG|Rituximab|
41337548|NCT05540210|DEVICE|measurement of PSP|one or two blood samples
41337549|NCT01728727|OTHER|UC-MSC transplantation|After enrolled, Participant will receive umbilical cord MSC transplantation of 1\*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
41337550|NCT01728727|OTHER|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
41337551|NCT06382961|DRUG|Dexmedetomidine injection|Combining with 3 μg.kg-1 sufentanil, 3 μg.kg-1 dexmedetomidine is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
41337552|NCT06382961|DRUG|Sufentanil injection|3 μg.kg-1 sufentanil is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
41337553|NCT04059471|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|Full dose and 500IU/dose
41337554|NCT02137707|DRUG|Gilenya|All patients will receive Gilenya
41337555|NCT05083949|DRUG|FDC 12.5mg empagliflozin/850mg metformin|empagliflozin/metformin
41337556|NCT05083949|DRUG|Empagliflozin|empagliflozin 10mg (R1)
41485758|NCT01181271|DRUG|Neupogen|Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
41156516|NCT06480396|DIAGNOSTIC_TEST|Lower-intensity radiological surveillance|The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.
41337557|NCT05083949|DRUG|Glifage®|Glifage® 850mg (R2)
41337558|NCT03630016|DIAGNOSTIC_TEST|Pulse oximetry with Owlet BabySat v1.0 sensor|A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
41337559|NCT01492166|DRUG|biphasic human insulin 30|Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
41337560|NCT01892241|DRUG|Pegasys(Roche)|180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
41485759|NCT01181271|DRUG|Fludarabine (conditioning for ALLO Transplant)|Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
41485760|NCT01181271|DRUG|Busulfan (conditioning for ALLO Transplant)|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
41156517|NCT02581371|DRUG|Cerebrolysin infusion|Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
41337561|NCT01892241|DRUG|Entecavir|continual entecavir therapy(0.5 mg orally once daily)
41337562|NCT00060151|DRUG|pazopanib hydrochloride|
41337563|NCT00324740|DRUG|vorinostat|Given orally
41337564|NCT00324740|DRUG|isotretinoin|Given orally
41337565|NCT01845519|BEHAVIORAL|Tailored Email|Participants will receive tailored emails.
41337566|NCT01845519|BEHAVIORAL|Targeted Email|Participants will receive targeted emails.
41337567|NCT01570452|PROCEDURE|colonic or colorectal resection|standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
41337568|NCT00836524|PROCEDURE|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
41337569|NCT06136455|DRUG|Listerine Clinical Solutions Teeth Strength|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
41337570|NCT06136455|DRUG|Listerine Total Care Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
41337571|NCT06136455|OTHER|Listerine Cool Mint Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash.
41337572|NCT06136455|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.
41337573|NCT01020968|BIOLOGICAL|Ixmyelocel-T|CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
41485761|NCT01181271|OTHER|non-myeloablative allogeneic (allo) transplant|Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10\^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10\^6/kg of recipient's actual body weight
41337574|NCT01020968|OTHER|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.
41337575|NCT05936593|DEVICE|Condylar Stabilizing (CS) insert|During TKA surgery a Condylar Stabilizing (CS) insert is implanted and tantalum beads are placed around the prosthesis.
41337576|NCT05936593|DEVICE|Cruciate Retaining (CR) insert|During TKA surgery a Cruciate Retaining (CR) insert is implanted and tantalum beads are placed around the prosthesis.
41337577|NCT03081572|DIAGNOSTIC_TEST|Platelet aggregation|Platelet aggregation
41337578|NCT00253799|DEVICE|Hylan GF-20|
41337579|NCT03642028|DRUG|Suvorexant|Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.
41337580|NCT03642028|OTHER|Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
41337581|NCT06075498|PROCEDURE|transversus abdominis plane block,|2 different plan blocks; 1. transversus plane block 2. quadratus lumborum plane block
41337582|NCT01966276|DRUG|Methyl-P plus Nutrient Formula|"* Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P (5mg)~ * Four tablets of CFS Nutrient Formula~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P (10mg)~ * Four tablets of CFS Nutrient Formula"
41337583|NCT01966276|DRUG|Methyl-P plus Nutrient matched placebos|"* Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo"
41337584|NCT01775800|OTHER|Treatment modification|
41485762|NCT01181271|DRUG|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
41485763|NCT01181271|DRUG|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
41485764|NCT01181271|DRUG|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
41485765|NCT04032158|DRUG|Evobrutinib|Participants received evobrutinib twice daily (BID).
40818932|NCT04040595|PROCEDURE|Abdominal fat biopsy|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
41156518|NCT02581371|OTHER|Placebo infusion|Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
41156519|NCT06493669|DIAGNOSTIC_TEST|Cognitive assessment|MoCA
41156520|NCT03377959|OTHER|Pilates Mat Classes|The intervention, the exercises, and their progressions were systematized based on protocol proposed by Siler (2008).
41337585|NCT04437680|DEVICE|Votiva device|A retrospective chart review of the medical records
41485766|NCT04032158|DRUG|Avonex®|Participants received avonex® IM injection once a week.
41485767|NCT04032158|DRUG|Avonex® matched Placebo|Participants received IM injection of placebo matched to Avonex® once a week.
41485768|NCT04032158|DRUG|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
40818933|NCT05319899|DRUG|ALXN1840|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
41337586|NCT04931212|PROCEDURE|FETO with Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
41337587|NCT05446922|OTHER|Diffusion MRI|All procedures will be performed during a single visit. Subjects will be invited to lie on the scanning bed that will be moved head first into the scanner such as the head lie under the scanner magnets. Hearing protection will be provided to each subject to muffle the noise produced by the MRI scanner. Subjects will also be provided with pillows and blankets to keep them comfortable. They will also be given a call button that they can push to stop the procedure at any time. MRI acquisition will be performed on 1.5T or 3.0T MRI scanners depending on centre's equipment. Acquisition protocol will include the following sequences with the best parameters chosen by local radiologist and technical BrainTale team.
41337588|NCT04101370|DRUG|Bosentan 125 mg|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
41337589|NCT04101370|DRUG|Tracleer 125Mg Tablet|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
40818934|NCT05319899|DRUG|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
40818935|NCT00897403|OTHER|biologic sample preservation procedure|
40818936|NCT00897403|PROCEDURE|diagnostic colonoscopy|
41485769|NCT01806038|OTHER|RPh Counseling + Outpatient Med Dispensing at Discharge|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist
41485770|NCT01806038|OTHER|Discharge Med Dispensing Plus Counseling - Current Practice|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
40818937|NCT05901051|DRUG|vonoprazan|Potassium competitive acid blocker
40818938|NCT05901051|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
41156521|NCT03377959|OTHER|Ballet Classes|The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.
41156522|NCT03714711|PROCEDURE|total hip arthroplasty|Total hip replacement
40818939|NCT05482620|PROCEDURE|Nordic walking program|Nordic walking program will consist of three training sessions per week, during eight weeks. Each session will last approximately 60 minutes, including warm-up, the intervention itself and cool-down. Intervention will consist in a 30 minutes Nordic walking, working at 70-85% of maximal heart rate, measured with a Polar pulsometer. Intervention will be delivered in groups (six patients per group as maximum), in designed circuits placed in A Coruña city.
40818940|NCT05482620|PROCEDURE|Educational sessions and usual care|Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
40818941|NCT05577377|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a structured attention training practice that you do with another person by following a predefined set of detailed instructions. One of the two people participating in the OM must have a clitoris. In this partnered practice, one person strokes the clitoris of another person with the tip of their left index finger for 15 minutes.
40818942|NCT05849714|OTHER|Peri-intervention Diabetes Management Algorithm (DIAPI)|Patients and healthcare workers will apply DIAPI's orders.
40818943|NCT05849714|OTHER|Usual Care|Patients and healthcare workers will apply the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's.
40818944|NCT00283803|DRUG|Exisulind|Oral antineoplastic agent that induces apoptosis in cancerous cells.
40818945|NCT00283803|DRUG|luteinizing hormone-releasing hormone (LHRH) agonist|Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
40818946|NCT00283803|DRUG|Antiandrogen|Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
40818947|NCT06537557|OTHER|the early in-hospital temperature management protocol for heat stroke patients|The early in-hospital temperature management protocol for heat stroke includes early identification, selection of cooling methods for rapid cooling, precise target temperature management, and dynamic monitoring. Effective temperature management will be implemented for heat stroke patients to improve their outcomes.
40818948|NCT05260073|DRUG|Tirbanibulin|Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.
41337590|NCT02020928|DEVICE|Low level laser therapy|Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.
41337591|NCT00502398|PROCEDURE|Blood test|
40818949|NCT06335524|BEHAVIORAL|Finger puppet|The intervention group will receive finger-puppets and additional training pertaining to infant parent interaction and developmentally appropriate infant communication training.
40818950|NCT06335524|BEHAVIORAL|Bookworm reading intervention training and routine EDI care.|Routine EDI care including Bookworm training.
40818951|NCT06600282|DRUG|Parecoxib|Pharmacokinetic study under fasting conditions
40818952|NCT05805371|BIOLOGICAL|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
40818953|NCT05805371|PROCEDURE|Biopsy|Undergo tumor biopsy
40818954|NCT05805371|PROCEDURE|Biospecimen Collection|Undergo blood, stool, and urine sample collection
40818955|NCT05805371|PROCEDURE|Bone Scan|Undergo bone scan
40818956|NCT05805371|PROCEDURE|Computed Tomography|Undergo CT scan
41337592|NCT00475072|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
40818957|NCT05805371|RADIATION|External Beam Radiation Therapy|Undergo radiation
40818958|NCT05805371|PROCEDURE|Leukapheresis|Undergo leukapheresis
40818959|NCT05805371|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion
40818960|NCT06254326|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|Participants will receive up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment
40818961|NCT06254326|BIOLOGICAL|Autologous Hematopoietic Stem cells (HSCs)|Participants will receive a single infusion of autologous CD34+ HSCs
40818962|NCT06254326|BIOLOGICAL|TTRNA-xALT|Participants will receive a single infusion of ex vivo expanded tumor-reactive T cells
40818963|NCT06254326|DRUG|Td vaccine|All patients will receive a full Td booster IM vaccine 4-24 hours prior to Vaccine #1 and vaccine site pretreatment with a one-fifth dose of Td intradermally, at the site of planned vaccine, 4-24 hours prior to vaccines #3, #5, #7 and #9.
40818964|NCT05071872|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
41337593|NCT00475072|DRUG|ribavirin|1000/1200mg po daily for 48 weeks
40818965|NCT03218072|DRUG|HLX01|a potential rituximab biosimilar
41156523|NCT03714711|PROCEDURE|total knee arthroplasty|Total knee replacement
41337594|NCT03799627|DRUG|Vadadustat|Vadadustat Tablets 150 mg
41337595|NCT03799627|DRUG|Epoetin Alfa|Epoetin Alfa
41337596|NCT03799627|DRUG|Vadadustat TIW|Oral Vadadustat
41337597|NCT01519336|DRUG|danoprevir|100 mg q12h
41337598|NCT01519336|DRUG|darunavir|600 mg q12h
41337599|NCT01519336|DRUG|ritonavir|100 mg q12h
41337600|NCT03504462|PROCEDURE|Specific block of medial and lateral plantar nerves|"Specific injection of long duration local anesthetic in contact with medial and lateral plantar nerves.~Local anesthetic : Ropivacaine : 0,375% - 5 ml per nerve."
40818966|NCT02308527|DRUG|Bevacizumab|10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
40818967|NCT02308527|DRUG|Temozolomide|200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
40818968|NCT02308527|DRUG|Temozolomide|100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
40818969|NCT02308527|DRUG|Irinotecan|50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
40818970|NCT02308527|DRUG|Bevacizumab|15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
40818971|NCT02308527|DRUG|Topotecan|0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
41156524|NCT03427606|PROCEDURE|Continuous Locked Suture vs Traditional 5-points suture for Laparoscopic Sacral Colpopexy|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using continuous locked suture vs traditional 5-points suture for mesh fixation
41156525|NCT04027673|BEHAVIORAL|TMW ECE Curriculum|The TMW-ECE program will constitute the treatment arm of the study (Cohort A) which will complete the multi-media online professional development course beginning Summer 2019.
41156526|NCT02754752|PROCEDURE|Electroacupuncture Therapy|Undergo electroacupuncture therapy
41156527|NCT02754752|PROCEDURE|Electroacupuncture Therapy|Undergo modified electroacupuncture therapy
41156528|NCT02754752|OTHER|Laboratory Biomarker Analysis|Correlative studies
41156529|NCT02754752|OTHER|Quality-of-Life Assessment|Ancillary studies
40818972|NCT02308527|DRUG|Temozolomide|150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
40818973|NCT02308527|DRUG|Dinutuximab Beta|10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression
40818974|NCT02308527|DRUG|Cyclophosphamide|250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
41156530|NCT02754752|OTHER|Questionnaire Administration|Ancillary studies
41156531|NCT04309006|PROCEDURE|CTG and customized healing abutment|screw- retained customized healing abutment
40818977|NCT04945850|PROCEDURE|routine care intraocular sx|Fluid was collected during routine intraocular surgery
40818978|NCT06274801|DRUG|Seralutinib|Capsule containing seralutinib
40818979|NCT06274801|DEVICE|Gereic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib delivery
40818980|NCT03454399|PROCEDURE|Suction orogastric tube which is attached to TEE probe|Suction orogastric tube which is attached to TEE probe
41156532|NCT04309006|PROCEDURE|CTG and conventional healing abutment|conventional healing abutment
41156533|NCT00721708|DIETARY_SUPPLEMENT|pure carnosine|one time dose of pure carnosine (450 mg)
41156534|NCT00721708|OTHER|Beef|one time dose, 150 g of beef
41156535|NCT00721708|OTHER|Chicken|One time dose, 150g of chicken breast
41156536|NCT00721708|OTHER|Chicken broth|one time dose of chicken broth obtained from 150g of chicken breast
41156537|NCT00011778|DRUG|bortezomib|
40818981|NCT02098499|DRUG|Haloperidol|5mg IV
40818982|NCT02098499|DRUG|Metoclopramide 10mg|10mg IV
40818983|NCT02098499|DRUG|Diphenhydramine|25mg IV
40818984|NCT01165112|DRUG|Bendamustine Hydrochloride|Given IV
40818985|NCT01165112|DRUG|Carboplatin|Given IV
40818986|NCT01165112|BIOLOGICAL|Rituximab|Given IV
40818987|NCT01165112|DRUG|Etoposide|Given IV
41156538|NCT00011778|RADIATION|radiation therapy|
41156539|NCT06501885|BEHAVIORAL|Ethnodrama Intervention|The intervention is six drama performances that are designed to transform community member beliefs about and foster support of young women's PrEP use, reduce PrEP-related enacted stigma toward young women, and reduce PrEP-related anticipated and internalized stigma among young women.
41156540|NCT04175834|DRUG|cetrizine|prophylaxis
41156541|NCT04175834|DRUG|diphenhydramine|prophylaxis
41156542|NCT05463835|DIETARY_SUPPLEMENT|RubusElite|Each 500ml serving of this beverage will contain approximately 30g of milk protein alongside 750mg of polyphenols derived from blackberry puree. The study participant will consume 2 x 500ml per day which will contribute 60g protein and 1500mg polyphenols. No adverse effects associated with the consumption of dairy protein or berry fruits at the proposed intake levels have been reported to date.
41156543|NCT05463835|DIETARY_SUPPLEMENT|'Protein rich' dairy beverage|This dairy beverage will contain approximately 30g of milk protein /500ml serving and will not contain polyphenols.
41156544|NCT05463835|DIETARY_SUPPLEMENT|'Low Protein' dairy beverage|This product also contains no polyphenols and negligible protein.
41156545|NCT01394263|DRUG|Histrelin hydrogel implant|50 mg histrelin acetate in hyrogel implant
41156546|NCT01394263|DRUG|Zoladex goserelin implant|goserelin implant injection.
40818988|NCT01165112|OTHER|Laboratory Biomarker Analysis|Correlative studies
40818989|NCT03677466|DRUG|Pharmaco-invasive strategy|"Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography."
40818990|NCT03677466|PROCEDURE|Primary PCI|After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
40818991|NCT06142396|COMBINATION_PRODUCT|Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone|"This intervention is Daratumumab-hyaluronidase in combination with the chemotherapy regimen CyBord (cyclophosphamide, bortezomib, and dexamethasone) and then with lenalidomide maintenance in patients with newly diagnosed multiple myeloma who have new onset renal failure."
40818992|NCT00473967|BIOLOGICAL|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
40818993|NCT05120973|PROCEDURE|multispectral imaging|Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein
40818994|NCT05120973|PROCEDURE|fluorescence for lymphatic mapping|Indocyanine green injected in abdominal wall
40818995|NCT04049253|DRUG|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
40818996|NCT04330833|OTHER|Novel Communication Intervention|The intervention is a series of 3 guided discussions (using visual aids) between the child's primary oncology physician/nurse team and the child's parent(s) with the purpose of improving parental comprehension of the options for goals of treatment, along with the benefits and burdens of each option.
40818997|NCT04330833|OTHER|Enhanced Usual Care Parent Education|The Enhanced Usual Care Parent Education is a series of 3 discussions between the child's primary oncology nurse and the child's parent(s) designed to control for time and attention. These discussions are focused on answering parents' questions and reviewing routine disease and treatment related information. Parents will receive a 1-hour face-to-face session every 3-4 months for a total of 3 sessions. At each session, parents choose 2-3 topics to review with the nurse.
40818998|NCT03667807|DEVICE|Repetitive transcranial magnetic stimulation|Non invasive brain stimulation
40818999|NCT05091281|DEVICE|Intubation of the double lumen tube by Macintoch laryngoscope|After induction of anesthesia insertion of the double lumen tube was done by Macintosh laryngoscope
40819000|NCT05091281|DEVICE|Intubation of the double lumen tube by Glidescope videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by GlideScope® videolaryngoscope
40819001|NCT05091281|DEVICE|Intubation of the double lumen tube by C-MAC®(D) videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by C-MAC®(D) videolaryngoscope
40819002|NCT03741946|PROCEDURE|Triangle of Sedillot identification using ultrasonography|Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
40819003|NCT00839449|DRUG|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
40819004|NCT05354466|DRUG|Sugammadex injection|sugammadex as reversal agent
40819005|NCT05354466|DRUG|Neostigmine|neostigmine as a reversal agent
40819006|NCT06543849|PROCEDURE|Target Temperature Management Treatment|Target Temperature Management Treatment
41016457|NCT06662643|PROCEDURE|Delayed transanal pull-through anastomosis|Laparoscopic surgery is recommended. A standard 5-port method is used to create pneumoperitoneum after placing the trocar. The sigmoid colon and upper rectal mesentery are dissected along Toldt's fascia. Autonomic nerves should be preserved, and high ligation of the inferior mesenteric vessels with lymph node dissection is recommended. TME: Using a posterior-to-anterior approach, the mesorectal plane is dissected down to the pelvic floor, cutting the Waldeyer's fascia to enter the intersphincteric space, where sharp dissection is carried out toward the levator ani muscle hiatus. The dissection endpoint is the dentate line, where the proximal colon is exteriorized by at least 2 cm and sutured to the anal canal with 6-8 stitches, without a protective ileostomy.Two to four weeks after the first surgery, after the colon has adhered well to the surrounding tissue, the exteriorized colon is excised (under epidural or spinal anesthesia, trimming the exteriorized colon to form the anus).
41156547|NCT05946447|DEVICE|Ultrasound|The gastric antrum will be scanned using ultrasound.
40819007|NCT01708265|OTHER|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
40819008|NCT01708265|PROCEDURE|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
40819009|NCT03571802|DRUG|Simvastatin|"* The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~* There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery."
41156548|NCT06212765|DRUG|L-citrulline|to take 1 pod a day for 45 days
41156549|NCT01562821|DRUG|activated recombinant human factor VII|An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
41156550|NCT01562821|DRUG|activated recombinant human factor VII|An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
41156551|NCT01562821|DRUG|placebo|An initial placebo bolus dose followed by placebo every second hour until completion of surgery
41156552|NCT00312364|DRUG|MRE0094|
40819010|NCT06223789|DEVICE|Pulsed Field Ablation|Pulsed field ablation using the Volt PFA System
40819011|NCT05023473|PROCEDURE|Pericapsular nerve group block|patients will receive pericapsular nerve group block
40819012|NCT05023473|DRUG|Morphine Sulfate|morphine will be given to both groups as patient-controlled analgesia PCA
40819013|NCT04025502|DEVICE|Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System|The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
40819014|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Enhanced Parent Involvement|
40819015|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Minimal Parent Involvement|
40819016|NCT04748068|DEVICE|7-Fr Glidesheath Slender|The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market
40819017|NCT04748068|DEVICE|Cordis 7-Fr radial sheath|Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
40819018|NCT01394757|DRUG|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
40819019|NCT00422149|DRUG|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
40819020|NCT00422149|DRUG|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
40819021|NCT00422149|DRUG|Placebo treatment|Placebo treatment
41156553|NCT03786783|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
41156554|NCT03786783|DRUG|Carboplatin|Given IV
41156555|NCT03786783|DRUG|Cisplatin|Given IV
40819022|NCT06607510|OTHER|Experimental HIIT|Subjects belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. This program is designed in a standardized warm-up: joint mobility exercises and neuromuscular activation (5 minutes). Main part os the training is design in treadmill walking exercise (28 minutes). Participants must complete four four-minute blocks at an intensity of 85-95% of peak heart rate.The initial starting speed is 5 km/h and adjust the intensity with incline increments of 2%. Between sets, a prescribed active rest period lasts three minutes, during which patients walk on the treadmill at an intensity of 60-70% of peak heart. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
40819023|NCT06607510|OTHER|Experimental HIFT|Subject belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. AMRAP will consist of a circuit of six global, functional exercises with external loads \[i) squat; ii) rowing; iii) dead weight; iv) chest press; v) step up; vi) farmer walk\]. Patients will perform 10 repetitions of each exercise and complete as many rounds as possible within the specified time. Between blocks, there will be a prescribed active rest period lasting three minutes, during which patients will walk on the treadmill at an intensity of 60-70% of peak heart rate. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
40819024|NCT01174537|BIOLOGICAL|New Castle Disease Virus|Patients will receive IV 1\*10\^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
40819025|NCT01416103|OTHER|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
40819026|NCT01416103|OTHER|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
40819027|NCT02569372|BIOLOGICAL|GC1102|GC1102(Recombinant Hepatitis B Human Immunoglobulin)
40819028|NCT04828577|BEHAVIORAL|Real Time Neurofeedback|Participants receive feedback from own brain activity.
40819029|NCT04828577|BEHAVIORAL|"Idealized/Sham Neurofeedback"|Participants receive idealized feedback not related to their own brain activity.
40819030|NCT06606223|DIAGNOSTIC_TEST|serum ammonia test|precaution of withdrawal serum ammonia
41156556|NCT03786783|DRUG|Cyclophosphamide|Given IV
41156557|NCT03786783|DRUG|Dexrazoxane|Given IV
41156558|NCT03786783|BIOLOGICAL|Dinutuximab|Given IV
41156559|NCT03786783|DRUG|Doxorubicin|Given IV
41156560|NCT03786783|DRUG|Etoposide|Given IV
41156561|NCT03786783|RADIATION|External Beam Radiation Therapy|Undergo EBRT
41156562|NCT03786783|DRUG|Isotretinoin|Given PO
41156563|NCT03786783|DRUG|Melphalan|Given IV
41156564|NCT03786783|BIOLOGICAL|Sargramostim|Given SC
41156565|NCT03786783|DRUG|Thiotepa|Given IV
41156566|NCT03786783|DRUG|Topotecan|Given IV
41156567|NCT03786783|DRUG|Vincristine|Given IV
41156568|NCT06430671|DRUG|CLS12311 low|Peptide-coupled Red Blood Cells (RBCs)
41156569|NCT06430671|DRUG|CLS12311 medium|Peptide-coupled Red Blood Cells (RBCs)
41156570|NCT06430671|DRUG|CLS12311 high|Peptide-coupled Red Blood Cells (RBCs)
41156571|NCT06430671|DRUG|uncoupled RBCs|autologous Red Blood Cells (RBCs)
41156572|NCT05065164|DRUG|Denosumab Only Product|denosumab subcutaneous injection /6 months, twice a year
41156573|NCT04092699|DEVICE|semiautomatic software|semiautomatic segmentation is as accurate as the direct volume of maxillary sinus and as well as the manual segmentation.
40819031|NCT02047591|OTHER|Relaxing-touch method|
40819032|NCT03757650|DRUG|Bismuth Subsalicylate|omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1
40819033|NCT01588340|PROCEDURE|MRI (Magnetic resonance imaging)|Subject will complete a 15 minute scan in the MRI
40819034|NCT01588340|PROCEDURE|Ultrasound exam|The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
40819035|NCT03299881|DEVICE|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
40819036|NCT03299881|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
40819037|NCT02784119|PROCEDURE|temporary porto-caval shunt|temporary porto-caval shunt
40819038|NCT01345591|PROCEDURE|Fat Grafting|
40819039|NCT06229431|OTHER|The Carer Support Needs Assessment Tool Intervention (CSNAT-I)|"The CSNAT tool The tool includes 16 questions about the need for more support.~The five-stage person-centered approach~In the present study, the CSNAT-I consist of at least two meetings between the older spousal caregiver and the district nurse,1-4 weeks apart, following 5 stages:~1. Introduction of the CSNAT tool as a conversation starter.~2. Time for the spousal caregiver to consider the questions in which more support is needed.~3. An assessment conversation takes place.~4. A shared action plan is formed based on the assessment conversation.~5. Continuous shared review of the action plan."
40819040|NCT06130774|OTHER|Retro walking and conventional|Patient will start retro walking with first he/she will raise his/her one foot with toe off first then heel will be off from ground. swing phase of same leg would be done in backward direction with flexion on knee and extension will be performed on hip. Then patient will place the same foot on ground behind the other foot, with toe touch first on ground, and so this way patient would continue his retro-walk for 20 minutes
40819041|NCT06130774|OTHER|conventional therapy|Hot pack in supine lying (10min) TENS (10min ) Tibiofemoral mobilization (grade 1,2 ,3) (10rep) Static quadriceps exercise in supine (10rep x 3sec x2set) hip abduction in side lying(10repx 2set) knee bending exercise in prone lying ( 10rep x 2set) Hamstring stretch in supine ( 10 rep x 2 set)
41337601|NCT06148350|OTHER|Stroke Rehabilitation|Both the groups received interventions three days/week for 30-60 minutes for four weeks
41337602|NCT01929707|DRUG|LY3050258|
41337603|NCT01929707|DRUG|Placebo|
40819042|NCT06333522|DRUG|Losartan|Patients will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively.
40819043|NCT03040011|DRUG|Dexamethasone|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
40819044|NCT03040011|DRUG|Bupivacaine|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
40819045|NCT03040011|PROCEDURE|Bilateral Pudendal Nerve Block|Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
41156574|NCT06269796|DIAGNOSTIC_TEST|Little Developmental Coordination Disorder Questionnaire (LDCDQ)|"The Little Developmental Coordination Disorder Questionnaire (LDCDQ) is a parent questionnaire consisting of 15 items designed to screen for motor coordination difficulties in 3- and 4-year-old children. It comprises 15 items grouped into two distinct factors: gross motor skills and fine motor skills. A Likert scale is used, ranging from one to five, where one (1) indicates Not at all like your child and five (5) indicates Very much like your child. The total of the 15 items is added up to obtain a total score of 75."
41337604|NCT02000219|BIOLOGICAL|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
41337605|NCT03788616|DRUG|Fuji IX EXTRA|High-viscosity glass ionomer (Fuji IX EXTRA)
41337606|NCT03788616|DRUG|ACTIVA KIDS bioactive restorative material|Modified composite (ACTIVA KIDS)
41337607|NCT03437993|OTHER|Recollect, the game|"Recollect is a working memory training game"
41337608|NCT03437993|OTHER|Tetris|App-based video game where shapes are rotated and placed to fit a grid
41337609|NCT06265467|PROCEDURE|Closed Sinus Elevation|using a unique design of osteotomes to crestally elevate the Schneiderian membrane of the maxillary sinus floor
41337610|NCT06265467|PROCEDURE|Open Sinus Elevation|using a unique design of sinus elevators to laterally elevate the Schneiderian membrane of the maxillary sinus floor
41337611|NCT00748865|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
41337612|NCT00748865|OTHER|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye one time
40819046|NCT03040011|PROCEDURE|Bilateral Levator Ani Muscle Injection|Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
40819047|NCT03040011|DRUG|Saline|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
41337613|NCT00329784|BIOLOGICAL|Peanut Consumption Group|Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
40819048|NCT05720858|OTHER|Aerobic exercise|Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.
40819049|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
40819050|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|"Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task)."
40819051|NCT05733611|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus
40819052|NCT05733611|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
40819053|NCT05733611|BIOLOGICAL|atezolizumab|anti-PD-L1 monoclonal antibody
40819054|NCT05733611|BIOLOGICAL|bevacizumab|anti-VEGF therapy
40819055|NCT02671903|DEVICE|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
40819056|NCT06012448|DRUG|Dupilumab|"Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24.~In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks."
40819057|NCT00996515|DRUG|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
40819058|NCT00996515|DRUG|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
40819059|NCT05555797|DEVICE|308nm Excimer laser|Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)
40819060|NCT05555797|DRUG|Tazarotene Topical Gel|Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks
41156575|NCT06269796|DIAGNOSTIC_TEST|Bruininks- Oseretsky Test of Motor Proficiency 2nd Edition (BOT-2)|The BOT-2 is standardized for children and adolescents aged 4 to 21 years and 11 months, and the full test takes 45 to 60 minutes to perform. The BOT-2 test was used to detect deviation from the norm and the likelihood of a diagnosis for DCD. The BOT-2 measures fine and gross motor proficiency, with subtests focusing on stability, mobility, strength, coordination, and object manipulation.
41156576|NCT00847223|DRUG|ZARNESTRA (Tipifarnib)|
41156577|NCT06047379|DRUG|NEO212 Oral Capsule|NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
41337614|NCT04269941|OTHER|total or subtotal gastrectomy|resection of the gastric tumor
41337615|NCT03148795|DRUG|Talazoparib|1 mg daily
40819061|NCT05555797|DRUG|Betamethasone Valerate|.Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.
40819062|NCT03165240|DRUG|BI 690517|Film-coated tablet
40819063|NCT03165240|DRUG|Eplerenone|Film-coated tablet
40819064|NCT03165240|DRUG|Placebo|Film-coated tablet
40819065|NCT05211401|DRUG|Active arm 200 mg|Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
40819066|NCT05211401|DRUG|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera® or biosimilar ) in 400 ml of NaCl 0.9%.
41156578|NCT06047379|DRUG|Ipilimumab|Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
41156579|NCT06047379|DRUG|Pembrolizumab|Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
41156580|NCT06047379|DRUG|Nivolumab|Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
41337616|NCT04285372|PROCEDURE|Side branch protection/ballooning|Side branch protection in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
40819067|NCT05211401|DRUG|Placebo arm|Placebo arm: 1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
40819068|NCT03172962|BEHAVIORAL|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
40819069|NCT03172962|BEHAVIORAL|Usual care (control)|Will receive the usual care at the hospital
40819070|NCT02349607|DRUG|PF-05089771 300mg|PF-05089771 300 mg
40819071|NCT02349607|DRUG|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
40819072|NCT02349607|DRUG|Placebo|Placeco
40819073|NCT02349607|DRUG|pregabalin 300 mg|pregabalin 300 mg
41337617|NCT04285372|PROCEDURE|No side branch protection/ballooning|No intervention on the side branch
40819074|NCT02349607|DRUG|ibuprofen 600 mg|ibuprofen 600 mg
40819075|NCT03085628|DRUG|Oxytocin|40IU
40819076|NCT03085628|DRUG|Placebo|40IU
40819077|NCT00142168|DRUG|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
40819078|NCT00142168|DRUG|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
40819079|NCT03440723|DEVICE|DilaCheck|Measuring device for the measurement of cervical dilation
40819080|NCT03440723|DIAGNOSTIC_TEST|Cervical dilation examination|Sterile vaginal examination using subjective methods for measurement of cervical dilation
40819081|NCT01921218|DRUG|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
40819082|NCT01921218|DRUG|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
40819083|NCT01921218|DRUG|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
40819084|NCT01921218|DRUG|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
40819085|NCT06521515|DIAGNOSTIC_TEST|Lung Ultrasound Morphology Patterns|Two blinded investigators conducted daily lung ultrasound examinations. Each lung was scanned in six regions, categorizing ultrasound findings into four aeration patterns: normal (N-score 0), moderate (B1-lines score 1), severe (B2-lines score 2), and consolidation (C-score 3). The global LUS score ranged from 0 to 36. Patients were grouped into TLP if they exhibited a tissue-like pattern in any region or DBP if they displayed diffuse B-lines and shred signs in most regions. Localized TLPs indicated concentrated areas of non-aeration.
40819086|NCT04173260|DRUG|Deutetrabenazine 6 MG|Increasing doses of Deutetrabenazine
40819087|NCT03664791|PROCEDURE|Vanguard Rocc|Patient operated with the Vanguard Rocc knee prosthesis
41156581|NCT06047379|DRUG|Regorafenib|Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
40819088|NCT00218816|BEHAVIORAL|Nebulizer Education Intervention|Asthma Education
40819089|NCT00218816|BEHAVIORAL|Standard Asthma Education Groups|Asthma Education
40819090|NCT06048718|DRUG|Trastuzumab-Deruxtecan (T-DXd)|Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
40819091|NCT05148442|DRUG|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody
40819092|NCT00222430|PROCEDURE|Fluoroscopy|Use of fluoroscopy during arterial insertion of coronary catheter
41156582|NCT06047379|DRUG|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
41337618|NCT04259034|OTHER|diagnosis of periodontitis in oral lichen planus patients|diagnosis of periodontitis in oral lichen planus patients
41337619|NCT04259034|OTHER|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
40819093|NCT00222430|PROCEDURE|Active Comparator|Standard coronary angiography technique; no fluoroscopic assistance
40819094|NCT06607627|COMBINATION_PRODUCT|Gefurulimab|Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.
40819095|NCT04185402|DRUG|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
40819096|NCT00500058|DRUG|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
40819097|NCT00500058|DRUG|Rituximab|Rituximab 375 mg/m\^2 will be administered by IV infusion.
40819098|NCT05386550|DRUG|Xevinapant (Debio 1143)|Participants will receive 3 cycles of oral solution of Xevinapant (Debio 1143) at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of Xevinapant (Debio 1143) at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
40819099|NCT05386550|RADIATION|IMRT|Participants will receive 66 Gy of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week.
40819100|NCT05386550|DRUG|Placebo|Participants will receive 3 cycles of oral solution of placebo matched to Xevinapant (Debio 1143) once daily from Day 1 to 14 per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of placebo matched to Xevinapant (Debio 1143) from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
40819101|NCT01576419|DRUG|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
40819102|NCT01576419|DRUG|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
40819103|NCT00123279|DRUG|Microplasmin|25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
40819104|NCT01636063|DRUG|Mifepristone|Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
40819105|NCT01636063|DRUG|Misoprostol|Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
40819106|NCT05868733|DRUG|Day 1 Lower Dose (2×106 pfu)|rVSV∆G-LASV-GPC
40819107|NCT05868733|DRUG|Day 1 Higher Dose (1×107 pfu)|rVSV∆G-LASV-GPC
40819108|NCT05868733|DRUG|Placebo|Placebo
40819109|NCT04022239|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
40819110|NCT04022239|DRUG|Bendamustine|Given IV
40819111|NCT04022239|DRUG|Cyclophosphamide|Given IV
40819112|NCT04022239|BIOLOGICAL|Filgrastim-sndz|Given SC
40819113|NCT04022239|DRUG|Fludarabine|Given IV
40819114|NCT04022239|DRUG|Melphalan|Given IV
40819115|NCT04022239|DRUG|Mycophenolate Mofetil|Given PO
40819116|NCT04022239|BIOLOGICAL|Rituximab|Given IV
40819117|NCT04022239|DRUG|Tacrolimus|Given IV and PO
40819118|NCT04022239|RADIATION|Total-Body Irradiation|Undergo TBI
40819119|NCT00888524|PROCEDURE|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
40819120|NCT00888524|PROCEDURE|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
40819121|NCT05427448|DIAGNOSTIC_TEST|Measurement of amyloid and pTau blood biomarkers|Detection of plasma Amyloid beta 1-40 and 1-42 peptide and phosphorylated tau isoforms.
40819122|NCT01163357|DRUG|bortezomib|Given IV
41156583|NCT06047379|DRUG|Paclitaxel|Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
41337620|NCT02137304|DEVICE|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
40819123|NCT01163357|DRUG|fludarabine phosphate|Given IV
40819124|NCT01163357|OTHER|melphalan|Given IV
40819125|NCT01163357|RADIATION|total marrow irradiation|Undergo TMI
40819126|NCT01163357|DRUG|tacrolimus|Given IV and orally
40819127|NCT01163357|DRUG|sirolimus|Given orally
40819128|NCT01163357|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
40819129|NCT01163357|OTHER|laboratory biomarker analysis|Correlative studies
40819130|NCT06497777|GENETIC|MicroRNA (mir-642b-3p)|A circulating microRNA in the blood of pancreatic cancer patients.
40819131|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + deep sea water|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a supplementation composed by deep sea water
40819132|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + Placebo|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
40819133|NCT06600243|DIETARY_SUPPLEMENT|Control + deep sea water|A group that will maintain their usual live and at the same time will receive a supplementation composed by deep sea water
40819134|NCT06600243|DIETARY_SUPPLEMENT|Control + Placebo|A group that will maintain their usual live and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
40819135|NCT03156686|PROCEDURE|HOME-based hospitalization|patients in Home care treatment (HC) group will be treated at home
40819136|NCT03997968|DRUG|CYT-0851|Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
40819137|NCT03997968|DRUG|CYT-0851 in combination with gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
40819138|NCT03997968|DRUG|CYT-0851 in combination with capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
40819139|NCT03997968|DRUG|CYT-0851 in combination with rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
40819140|NCT05897190|BIOLOGICAL|SARS-CoV-2 mRNA vaccine (RBMRNA-405)|Dose A
40819141|NCT05897190|BIOLOGICAL|CoronaVac®|Dose B
41156584|NCT06047379|DRUG|FOLFIRI Protocol|"FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating."
40819142|NCT01025349|DRUG|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
40819143|NCT02507180|OTHER|LEFt clinical decision rule|"The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: \> 1 point"
40819144|NCT01714037|DRUG|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
40819145|NCT01714037|DRUG|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
40819146|NCT01714037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
41337621|NCT03472768|DIAGNOSTIC_TEST|Plasma Haptoglobin Concentration|N/A, comparison of haptoglobin concentration between groups
41337622|NCT03459157|DRUG|HIV prevention package including PrEP|All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
41337623|NCT04971369|DIAGNOSTIC_TEST|89Zr-NY001|89Zr-NY001 injection followed by 89Zr-NY001 PET scan
41337624|NCT03757260|DEVICE|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is methylene blue. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is illuminated for 60 seconds to activate the agent using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
41337625|NCT03757260|DEVICE|Placebo of photodynamic therapy|The placebo of the antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is saline solution. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is not illuminated (falsely activated) for 60 seconds using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
41337626|NCT05264636|OTHER|Sucrose|Sucrose Beverage
41337627|NCT05264636|OTHER|Steviol Glycosides|Steviol Glycoside Beverage
41337628|NCT05074862|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
41337629|NCT05074862|DIETARY_SUPPLEMENT|Maltodextrin and fat-based placebo|Dosis isocaloric to the KetoneAid Arm
41337630|NCT04006704|DRUG|D/C/F/TAF FDC placebo|Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
41337631|NCT02757404|DRUG|Ultrasonography guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.
41337632|NCT02757404|DRUG|Electrical stimulation guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.
41337633|NCT02757404|DRUG|Manual needle placement injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
41337634|NCT01270724|DRUG|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).|Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
41337635|NCT02844140|PROCEDURE|DE-CT's and SE-CT|Patients included in the trial will receive 3 extra DE-CT's and 3 extra SE-CT's
41337636|NCT04477525|PROCEDURE|Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block|The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score \>5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.
41337637|NCT04477525|DRUG|Bupivacaine Injection|20 cc of 0.25% bupivacaine will be injected
41337638|NCT03582969|OTHER|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
41337639|NCT03582969|OTHER|Placebo|Placebo capsules
41337640|NCT03619850|DRUG|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
40819147|NCT01714037|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
40819148|NCT01714037|DRUG|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
40819149|NCT02202512|DRUG|Placebo|tablets
40819150|NCT02202512|DRUG|Cimetidine|
40819151|NCT02202512|DRUG|Placebo|tablets
40819152|NCT02202512|DRUG|Placebo|tablets
40819153|NCT02202512|DRUG|BI 1060469 high dose|tablets
40819154|NCT02202512|DRUG|BI 1060469 low dose|tablets
40819155|NCT02202512|DRUG|Naproxen|
40819156|NCT02202512|DRUG|BI 1021958|tablets
40819157|NCT03979014|BIOLOGICAL|Gardasill 9™ vaccine|3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
40819158|NCT06443710|DRUG|Technetium [99mTc]-H7ND injection|Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
40819159|NCT03840304|OTHER|Yoga@work|Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
40819160|NCT05371080|BIOLOGICAL|HZ/su vaccine|No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)
40819161|NCT03811925|PROCEDURE|Angioplasty and drug coated balloon of the superficial femoral artery (SFA)|In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
41156585|NCT06047379|DRUG|Bevacizumab|Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
41337641|NCT03619850|DRUG|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
41337642|NCT05975372|DEVICE|Blossom tissue expander|Mentor spectrum adjustable saline breast implant for expansion is placed with the Blossom tissue expander above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
41485771|NCT04416620|OTHER|The PCOS pharmaceutical care service|"The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects."
41337643|NCT05975372|DEVICE|Standard tissue expansion|Mentor spectrum adjustable saline breast implant for expansion is placed with (without the Blossom tissue expander) above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
41337644|NCT01318668|BIOLOGICAL|vaccination with Nicvax|5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
41485772|NCT00249691|DRUG|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
41337645|NCT06307977|BEHAVIORAL|Couples Health Project|A 3-session, couples motivational Interviewing drug use and HIV risk reduction intervention
41337646|NCT02918539|DRUG|florbetapir F 18 PET scan|For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
41337647|NCT03372447|DRUG|Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg|Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
41337648|NCT01755338|DRUG|Methylprednisolone|Methylprednisolone 15mg/kg
41337649|NCT01755338|DRUG|Placebo|Placebo
41337650|NCT01451866|OTHER|resistance training|hypertrophic resistance training
41485773|NCT00249691|DRUG|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
41485774|NCT02991170|PROCEDURE|unipolar or bipolar radiofrequency ablation+CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
41485775|NCT02991170|PROCEDURE|CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
41485776|NCT06285968|BEHAVIORAL|Multidimensional Sleep Health Promotion Intervention|Multi-component multidimensional sleep health promotion intervention that includes sleep health and sleep hygiene education, behavioral coaching, personalized feedback, goal setting and establishment of a sleep health plan, self-monitoring, supportive accountability, and addressing light and noise in the sleep environment.
41485777|NCT00644449|OTHER|placebo|placebo
41485778|NCT00644449|DRUG|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
40819162|NCT03811925|PROCEDURE|Angioplasty and stenting of the superficial femoral artery (SFA)|In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
40819163|NCT01824199|DRUG|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
40819164|NCT03259503|DRUG|Busulfan|Given IV
40819165|NCT03259503|DRUG|Gemcitabine|Given IV
40819166|NCT03259503|DRUG|Melphalan|Given IV
40819167|NCT03259503|DRUG|Olaparib|Given PO
41156586|NCT00587899|PROCEDURE|Pulmonary Vein Isolation|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
41337651|NCT01451866|OTHER|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
41485779|NCT00644449|OTHER|placebo|placebo
40819168|NCT03259503|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
40819169|NCT03259503|OTHER|Pharmacokinetic Study|Correlative studies
40819170|NCT03259503|BIOLOGICAL|Rituximab|Given IV
40819171|NCT03259503|DRUG|Vorinostat|Given PO
40819172|NCT03596047|DEVICE|Radial wave therapy|6 radial waves' sessions. A weekly session of radio waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar (depending on patient tolerance), with a frequency of 12Hz, the frequency should increase to 17HZ the first 500 impulses to create mild anesthesia in the area; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area, specifically in the ischiocavernosus and bilateral bulbo-sponge muscles. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
41485780|NCT00644449|DRUG|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
41485781|NCT05318209|OTHER|Exercise|Closed-chain Shoulder Girdle Scapular Depression Exercise
40819173|NCT03596047|DEVICE|Placebo therapy|"There will be a weekly session of placebo wave therapy, using the respective device to prevent the patient from receiving the radial wave. The same parameters of the real therapy will be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation."
41485782|NCT02545855|DEVICE|High-flow nasal cannula therapy|All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
41485783|NCT02545855|DEVICE|Home oxygen therapy (HOT)|All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
41485784|NCT03347552|BEHAVIORAL|HOME|"Prior to discharge from the inpatient unit, the HOME program provider or another member of the research team, will meet individually with the Veteran to provide further information regarding the HOME program intervention. Efforts are made to schedule the initial phone call and home visit that occur during the first week after discharge. Following the home visit, the HOME provider may continue to have weekly contact with the Veteran via the telephone or in person until he or she is disenrolled following engagement in outpatient care. Engaged in care is defined as attendance at two individual outpatient mental health appointments or engagement in equivalent or elevated care as determined by the PI. All clinical contacts with the Veteran may include the following: suicide risk assessment, review and modification of the Veteran's safety plan, review and modification of the discharge plan, involvement of the Veteran's support system, and facilitation of engagement in outpatient care."
41485785|NCT04673513|OTHER|Psychotherapy|In light of COVID-19 considerations, interventions are currently being provided via telehealth technology.
41485786|NCT01296659|DRUG|ridaforolimus|Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
41485787|NCT04731402|OTHER|Acupressure, laughter yoga and mindfulness stress reduction program|Initiatives will be applied to the experimental group. only measurement tools will be applied to the control group
41485788|NCT02302313|DEVICE|CO2 laser and ANI monitor|Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
41485789|NCT06290518|DIETARY_SUPPLEMENT|Ligilactobacillus salivarius CECT5713|Oral administration of a capsule containing 9.5 log10 cfu of the strain.
41485790|NCT06290518|DIETARY_SUPPLEMENT|Placebo|Oral administration of a capsule containing maltodextrin.
41485791|NCT00238875|PROCEDURE|stereotactic body radiation therapy|Procedure/Surgery: stereotactic body radiation therapy
40819174|NCT02732795|OTHER|Morphine pharmacokinetic evaluation|Each group received morphine and blood drawn to evaluate morphine PK
40819175|NCT06608745|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty performed with conventional technique
41016458|NCT06662643|PROCEDURE|Direct Anastomosis Plus Prophylactic Ileostomy|ISR is categorized into partial ISR (PISR), subtotal ISR, and total ISR (TISR). Correspondingly, the anastomosis site after coloanal anastomosis is located below the levator ani hiatus (PISR, near the dentate line; subtotal-ISR and TISR, below the dentate line).The dissection steps are the same as in the first stage of the Staged Turnbull-Cutait Pull-through Anastomosis group (TME and intersphincteric space dissection).The bowel is transected at least 1 cm below the tumor, leaving a larger segment of healthy tissue on the non-tumor side while ensuring that no more than 1/3 of the dentate line is resected to avoid impairing fecal control.Anastomosis is performed using absorbable sutures under direct visualization. A protective ileostomy is created 25-30 cm from the ileocecal valve.3 to 6 months after surgery, the ileostomy is reversed. Prior to closure, digital rectal examination, defecography, MRI, colonoscopy, and other evaluation must perform.
41016459|NCT06663943|DRUG|CM313 (SC)|CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies
41016460|NCT06663943|DRUG|Glucocorticoids|Patients in the control group receive azathioprine in combination with steroid therapy.
40819176|NCT06608745|PROCEDURE|computer-assisted total knee arthroplasty|total knee arthroplasty performed with imageless computer-assisted surgery
40819177|NCT03389555|DRUG|vitamin C, vitamin B1, hydrocortisone|Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
40819178|NCT03389555|DRUG|Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
40819179|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 12
40819180|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 6
40819181|NCT01637636|DRUG|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
40819182|NCT01637636|DRUG|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
40819183|NCT01118104|OTHER|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
40819184|NCT03245736|DRUG|Tisotumab Vedotin|All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
40819185|NCT01434394|DRUG|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"
40819186|NCT06157177|DRUG|Metaxalone 640 mg Oral Tablet|Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.
41016461|NCT06659523|DIETARY_SUPPLEMENT|EPS supplement intervention|31 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the intervention group, and were given for 12 weeks of one daily dose of 1.5 g powdered capsules of EPS.
41016462|NCT06659523|DIETARY_SUPPLEMENT|Placebo|29 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the placebo group, and were given for 12 weeks of one daily dose of placebo.
40819187|NCT00643786|DRUG|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
40819188|NCT00643786|DRUG|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
41156587|NCT03570606|DEVICE|bone graft substitute|orthopaedic or spine bony defects
41156588|NCT05390697|OTHER|Educational videos|Educational videos include (1) danger and prevention of VPD; (2) rationales of completing immunization; (3) immunization amid the COVID-19 pandemic; (4) vaccine misconception; and (5) adverse events following immunization and how to treat it. Each video was less than 2 minutes with clear and straightforward messages according to the National Institute of Health guideline for health education. Materials were distributed through WhatsApp and viewed for five weeks.
41156589|NCT02756299|OTHER|Educational Support|General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
41156590|NCT02756299|OTHER|Standard Support|General information about OSA and PAP treatment at baseline
41016463|NCT06664723|DEVICE|high tone external muscle stimulation|Device HiToP®: Parameters of (HTEMS), Voltage: 230-V Pulse widths: ≤350 mA. Electrical Frequency: Frequencies continuously scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 m W. Intensity: the electrical stimulation will be adjusted to a pleasant level that will not produce any pain or discomfortable paraesthesia, Duration 30 minutes per session. Electrodes will be placed around ulcer. It will be introduced 3 times per week, for 8 weeks Prior to intervention, skin sensation will be assessed using warm water in a test-tube (temperature), pin prick (pain) and cotton wool (light touch) to ascertain the skin sensitivity
41016464|NCT06664723|OTHER|Standard medical treatment (SMT)|The Standard care of diabetic foot ulcers includes good glycemic control, adequate nutrition, off-loading (via bed rest or casts), local care (moist dressings and topical management), lessening of edema, surgical debridement of devitalized wound tissue and antibiotic therapy.
41016465|NCT06662747|DIAGNOSTIC_TEST|None - observational study only|No interventions, diagnostics tests for HIV, pregnancy, STIs and BV only
41016466|NCT06664177|PROCEDURE|Transversalis Fascia Plane Block|In the Transversalis Fascia Block group, the same procedure will be followed as in the Quadratus Lumborum block group, with the ultrasound probe being placed in the same location, and the same in-plane technique will be applied with a 22G 100 mm peripheral block needle. After hydrodissection, 20 mL of 0.5% bupivacaine will be injected slowly in the same manner.
41156591|NCT03558750|BIOLOGICAL|Nivolumab|Given by IV
41156592|NCT03558750|BIOLOGICAL|Rituximab|Given by IV
41156593|NCT03558750|DRUG|Lenalidomide|Given by mouth
41156594|NCT03942861|DRUG|Solu-Medrol|Standard treatment according to Danish Guidelines for acute severe ulcerative colitis.
41156595|NCT01785797|DEVICE|Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma|
41156596|NCT00447239|PROCEDURE|glucontrol (insulin therapy)|
41156597|NCT05168696|OTHER|Virtual Reality Glasses|Virtual Reality Glasses
41156598|NCT00128908|DRUG|Standard Continuous Highly Active Antiretroviral Therapy (HAART)|
41156599|NCT00128908|DRUG|Rapidly Cycled HAART|
41156600|NCT01537900|DRUG|Grazoprevir|GZR 100 mg tablet by mouth q.d. for 7 days.
41337652|NCT04499638|DEVICE|Peripheral vascular catheters|Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
40819189|NCT04669938|OTHER|oropharyngeal and intestinal microbiota|analysis of oropharyngeal and intestinal microbiota
40819190|NCT04669938|OTHER|host genotype|analysis of a part of host genotype
40819191|NCT04669938|OTHER|host immune factors|analysis of host immune factors
40819192|NCT04669938|OTHER|viral sequence|analysis of viral sequence
40819193|NCT02815046|DRUG|Botulinum toxin type A|Intravesical injections of Botulinum toxin A (Botox) into the bladder wall.
40819194|NCT02815046|DEVICE|Polyacrylamide hydrogel|Midurethral injections of the bulking Agent Bulkamid into the submucosal tissues of the urethra.
40819195|NCT01126658|OTHER|drainage of cerebrospinal fluid (CSF)|Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
40819196|NCT02685748|DRUG|Aspirin|1000 mg pd in two doses
41156601|NCT04124016|DIETARY_SUPPLEMENT|Inulin|Powder of inulin fractions dissolved into 250 ml of water
41156602|NCT04124016|DIETARY_SUPPLEMENT|green tea extract|Powder of green tea extract dissolved into 200 ml of water
41156603|NCT04124016|DIETARY_SUPPLEMENT|grape seed|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol monomers) dissolved into 200 ml of water
41156604|NCT04124016|DIETARY_SUPPLEMENT|grape seed extract|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol oligomers) dissolved into 200 ml of water
41016467|NCT06664177|PROCEDURE|Quadratus Lumborum Block (QLB)|In the Quadratus Lumborum block group, in the lateral decubitus position, a convex ultrasound probe will be sterilely placed in the subcostal area and above the iliac crest. The quadratus lumborum and psoas major muscles, as well as the L4 vertebra's transverse process, will be visualized. Using the in-plane technique and a 22G 100 mm peripheral block needle, the placement will first be identified through hydrodissection in the subfascial area between the quadratus lumborum and psoas major muscles. After localization, 20 mL of 0.5% bupivacaine will be injected slowly, aspirating every 5 cc, while visualizing the local anesthetic pushing the fascia in the ultrasound image.
41016468|NCT06663254|DRUG|Hydroxyethyl starch 130/0.4|Individualized goal-directed administration of 6% Hydroxyethyl starch (HES) 130/0.4: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min. If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. If the use of HES exceeds 30 ml/kg, sodium acetate Ringer will be replaced. In addition, patients will have a background infusion of sodium acetate Ringer's solution at 4 ml/kg/h to satisfy the maintenance fluid requirements during surgery.
41156605|NCT04859218|PROCEDURE|RBC transfusion|two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
41337653|NCT01427114|DRUG|rituximab, cyclophosphamide, vincristine, and prednisolone|6 cycles of R-CVP followed by 2 cycles of rituximab
41337654|NCT00618865|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
41485792|NCT04016337|DIETARY_SUPPLEMENT|Beverages|The beverages were all made with lemon and maqui extracts, and different sweeteners
40819197|NCT02685748|DRUG|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
41156606|NCT05577663|OTHER|Routine treatment of the extraction socket|Suturing of the extraction socket with resorbable suture PGA 5/0 in order to protect the blood clot
41485793|NCT04049617|DRUG|Evixapodlin|Tablets administered orally.
41485794|NCT03298295|DEVICE|Continous Subcutaneous Insulin Infusion Catheter|Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
41485795|NCT05142371|OTHER|Best Practice|Continue current activities of daily living
41485796|NCT05142371|OTHER|Exercise Intervention|Participate in exercise intervention
40819198|NCT02685748|DRUG|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
40819199|NCT00252694|DRUG|candesartan|32 mg oral tablet
40819200|NCT01540630|DRUG|CNV1014802|CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
40819201|NCT01540630|DRUG|Placebo|Double-blind placebo comparator for 28 days.
41156607|NCT05577663|PROCEDURE|Socket seal technique by a free gingival graft|Placement of a free gingival graft in the socket opening in order to protect and stabilize the blood clot followed by suturing
41156608|NCT05577663|PROCEDURE|Socket seal technique using a synthetic resorbable membrane|Placement of a synthetic barrier in the socket opening in order to protect and stabilize the blood clot followed by suturing
41156609|NCT04848116|DRUG|Nivolumab|Nivolumab is an investigational drug in this study.
41337655|NCT05212376|OTHER|Foot massage|"Foot massage is applied in the form of pressure, rubbing and stimulation with special hand and finger techniques to reflex - warning points corresponding to all regions, organs and systems in the body. It is applied by applying pressure to all reflex points in the area from the toes to the ankles.~In the study, a quiet and comfortable environment will be prepared at a room temperature of approximately 23-26 0C, and techniques that reveal the relaxing and calming effect of the massage will be selected. Thumb compression, slapping, patting, rubbing and squeezing movements are planned to be applied for a total of 20 minutes, 10 minutes on each foot, at the same time every day for 7 days."
41337656|NCT05843591|BEHAVIORAL|aerobic exercise or Tai Chi Chuan interventions|8-week aerobic exercise (AE group), 8-week Tai Chi Chuan training (TCC group)
40819202|NCT02563535|DEVICE|DEB|angioplasty with Litos drug eluting balloon
40819203|NCT02563535|DEVICE|PTA|angioplasty with conventional balloon
41337657|NCT00001827|BIOLOGICAL|aldesleukin|
41337658|NCT00001827|BIOLOGICAL|incomplete Freund's adjuvant|
41337659|NCT00001827|BIOLOGICAL|p53 peptide vaccine|
41337660|NCT00001827|BIOLOGICAL|sargramostim|
41337661|NCT00001827|BIOLOGICAL|therapeutic autologous dendritic cells|
41485797|NCT05142371|OTHER|Quality-of-Life Assessment|Ancillary studies
41485798|NCT05142371|OTHER|Questionnaire Administration|Complete questionnaires
40819204|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet before Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 6 days. 2 x 24 hour urines will be collected on days 3 and 4.
40819205|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose before Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 5 of the 6-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
41337662|NCT00001827|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
40819206|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Program|Subjects will go on a 10-week Intestive level Optifast VLCD weight loss program
40819207|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Transition Phase|After completion of the 10-week Optifast VLCD Program, subjects will be weaned off the Optifast products for 4 weeks.
40819208|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet after Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 11 days and collect 2 x 24 hour urines on days 8 and 9
40819209|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose after Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 10 of the 11-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
40819210|NCT00571246|DRUG|Topiramate|Participants are randomized to take Topiramate (250mg/day) 2 times a day
40819211|NCT00571246|DRUG|lamotrigine|Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day
41156610|NCT04848116|DRUG|HuMax-IL8|HuMax-IL8 is an investigational drug in this study.
41156611|NCT03353155|BEHAVIORAL|Usual Care|
41156612|NCT03353155|BEHAVIORAL|CareHub|
41156613|NCT01510314|BIOLOGICAL|C-reactive protein and procalcitonin dosages|
41156614|NCT00459433|PROCEDURE|Biopsychosocial intervention|Psychosocial versus usual care
40819212|NCT00571246|OTHER|Placebo|Participants are randomized to take placebo
41337663|NCT00445341|DRUG|Flavopiridol|Flavopiridol 30 mg/m\^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
41337664|NCT03713424|DRUG|Clavulanic Acid|Beta lactamase inhibitor for smoking cessation
41337665|NCT03713424|DRUG|Placebo oral capsule|placebo
40819213|NCT06607757|DRUG|Capivasertib|find arm A description
40819214|NCT06607757|DRUG|Fulvestrant injection|find arm B description
40819215|NCT02760771|OTHER|with BAV|balloon dilation of the aortic valve prior to implantation of the THV
40819216|NCT02760771|OTHER|without BAV|no balloon dilation of the aortic valve prior to implantation of the THV
40819217|NCT04694521|PROCEDURE|openSide to end colorectal anastomosis .|open Side to end colorectal anastomosis
40819218|NCT04694521|PROCEDURE|open end end to end stapler anastomosis|open end to end stapler anastomosis
40819219|NCT06424158|OTHER|Massage Therapy|Massage therapy (MT) has been proven as an alternative non-opioid pain management intervention, particularly towards reducing pain, diminishing depression, improving immune function, and increasing alertness in the adult population. MT raises the temperature of local tissues, dilates capillaries, accelerates the circulation of blood and lymph, promotes the absorption of local tissue metabolism and mass inflammation, improves the nutritional supply of surrounding muscle groups, promotes their growth and development, and relieves pain.
41156615|NCT02040532|DRUG|Gabapentin|The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
41337666|NCT03643016|OTHER|Surgical strategy based on a software|Surgical strategy décision based on a software
41337667|NCT03304652|DRUG|Zaleplon|Sleep Aid; 10mg; Oral; Single Use
41337668|NCT03304652|OTHER|Natural Sleep|Natural Sleep without medication
41337669|NCT04039789|BEHAVIORAL|Project active legs|Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).
41337670|NCT04039789|PROCEDURE|Usual care|Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
41337671|NCT00865046|OTHER|Periosteal stimulation|Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
41337672|NCT00865046|OTHER|Control-Periosteal Stimulation|Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
41337673|NCT04377789|DIETARY_SUPPLEMENT|Quercetin Prophylaxis|a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1
40819220|NCT06441071|PROCEDURE|position|Patients undergoing Video-assisted Thoracoscopic Surgery were selected for the study, and nerve block was performed before surgery, followed by holding different positions for 30 min, after which the effect of the block was measured.
40819221|NCT00634257|BEHAVIORAL|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
41016469|NCT06663254|DRUG|Sodium acetate Ringer|"Individualized goal-directed administration of crystalloid alone: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min.~If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. In addition, patients will have a background infusion of sodium acetate, the maintenance fluid requirement during surgery."
41016470|NCT06663995|DRUG|Study Group|"It will include 16 patients with periodontitis stage II, grade B, at least 2 sites with pocket PD = 4-5 mm and CAL = 3-4 mm each will receive non-surgical periodontal therapy followed by application of propolis gel.~After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy"
41016471|NCT06663995|DRUG|Control (placebo) group|"After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing)."
41016472|NCT06662695|DIETARY_SUPPLEMENT|Ginger-based supplement|Ginger-based supplement in a dosage of 1500 mg
41016473|NCT06662695|DIETARY_SUPPLEMENT|Placebo|Capsules containing corn flour
41016474|NCT06663410|DEVICE|SPG block with the use of the Tx360 device|A SPG block was performed using the Tx360 nasal applicator according to the manufacturer's instructions bilaterally, injecting 0.3cc of lidocaine 2% into each nostril.
41016475|NCT06663046|BIOLOGICAL|Single dose injection of certain dose of UWD-00B|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-00B cells
41016476|NCT06664268|BIOLOGICAL|Plasma rich in growth factors (PRGF-Endoret)|Plasma Rich Fibrin (PRF) is a newer modality in regenerative medicine derived from the patient's own blood. PRF does not use anticoagulants during processing, leading to a natural fibrin matrix that supports prolonged release of growth factors and cytokines .This matrix has been shown to enhance wound healing and improve scar texture and appearance .
41016477|NCT06664268|DEVICE|Fractional CO2 laser assisted PDT|Fractional CO2 laser therapy is a well-established technique for scar treatment, including postburn scars. This technology utilizes laser energy to create microthermal zones in the skin, which stimulates collagen production and skin remodeling while minimizing damage to surrounding tissues .
41156616|NCT04648111|DIAGNOSTIC_TEST|Vital sign measurement|Vital signs measurement will be obtained by the research staff using hospital standard medical devices and the Anura Research App will also be used to measure vital signs. Measurement will take place before surgery and post surgery (1 ±2hrs and 2 ±4hrs after surgery).
41337674|NCT04377789|DIETARY_SUPPLEMENT|Quercetin Treatment|a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
41337675|NCT00662727|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
40819222|NCT01551576|DEVICE|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe. PAI is a non-ionizing imaging technique
40819223|NCT04893629|BIOLOGICAL|mono nuclear cells injection|trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group
40819224|NCT04893629|DRUG|Digoxin+furosemide+captopril|classical heart failure medical treatment
40819225|NCT01751906|DEVICE|Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
41337676|NCT00662727|DEVICE|Placebo|Placebo
41337677|NCT01902693|OTHER|No intervention for this study|No intervention
41337678|NCT02515188|DRUG|Propacetamol|Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
41337679|NCT02515188|DRUG|Placebo|Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
41337680|NCT05516940|OTHER||
41337681|NCT03460470|DRUG|Sildenafil|PDE5 Inhibitor
41337682|NCT03460470|DRUG|Placebo oral capsule|Placebo for Sildenafil
41337683|NCT03655080|RADIATION|Radiation therapy|Using the View Ray System
40819226|NCT01751906|DEVICE|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
40819227|NCT04929002|OTHER|No intervention|No intervention
40819228|NCT06455111|OTHER|Keenoa|Keenoa is an artificial intelligence-enhanced, image-assisted tool, is a newly designed mobile application that may facilitate collection of dietary data. Serving as a visual food diary, individuals can upload a picture of their meal, choose the food items eaten using a preselected food list available by the app, and confirm the portion size with the presented visual aids.
40819229|NCT06455111|OTHER|ASA24|The Automated Self-Administered 24-Hour (ASA24) dietary recall or record is a free, web-based tool that enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries.
40819230|NCT05087927|BEHAVIORAL|Gain framing plus demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
40819231|NCT05087927|BEHAVIORAL|Loss framing plus demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
40819232|NCT05087927|BEHAVIORAL|Gain framing plus not demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
40819233|NCT05087927|BEHAVIORAL|Loss framing plus not demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
40819234|NCT06349083|DRUG|Psilocybin|One 25 mg capsule and one 5 mg capsule (30 mg total) administered once orally
40819235|NCT06349083|OTHER|Inactive Placebo|Two matching placebo capsules administered once orally
40819236|NCT06349083|BEHAVIORAL|Supportive therapy sessions|Participants will receive three supportive therapy sessions of manual-based treatment from a Center for Psychedelic Medicine (CPM) clinician, accompanied by a Silver Hill Hospital (SHH) therapist who has an ongoing therapeutic relationship with the participant. The CPM clinician will be a licensed physician, clinical psychologist, or nurse practitioner who will be solely responsible for the content of the intervention. The SHH therapist will provide additional support and continuity with clinical treatment.
40819237|NCT00800319|DRUG|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
40819238|NCT00800319|DRUG|Placebo|Volume matched placebo; oral solution; single dose
40819239|NCT01892436|DRUG|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
40819240|NCT01892436|DRUG|Placebo|Placebo
40819241|NCT00790166|DEVICE|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
40819242|NCT00790166|DEVICE|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
41016478|NCT06663150|BEHAVIORAL|health intervention with a socio-community approach|"The intervention consists of five components, including education, cognitive stimulation, physical activity, nutrition, and socio-community aspects. The duration of the intervention will be 6 months and will be conducted in either in-person or virtual format, individually or in groups, depending on the nature of each component. Mode of Delivery:~The intervention will be offered in both in-person and synchronous virtual formats. Participants who are unable to attend in person or who face difficulties doing so on any occasion will have the option to join the sessions through a real-time videoconferencing platform. In both modalities, the professionals in charge will supervise and guide the activities, ensuring proper execution and adherence to the study's objectives. The research team will maintain a detailed record of attendance and participation using the RedCap platform for appropriate tracking."
41016479|NCT06663514|OTHER|SupporTive Care At Home|"Home-based medical care is based on a specialized home-based medical team approach, including following:~Specialized Home-Based Medical Team Approach Initial Assessment and Education Initial Home Visits and Education Multidisciplinary Team Meeting Regular Assessment After the Initial Visit"
41016480|NCT06664281|BEHAVIORAL|SIT|sprint interval training
41156617|NCT04454671|OTHER|Ultrasound-guided percutaneous neuromodulation (NMPE)|It is a technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor site. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
41156618|NCT04454671|OTHER|Ultrasound-guided dry needling|Dry needling technique under ultrasound imaging in order to ensure accurate placement of the needle for optimum results.
41485799|NCT00270348|DRUG|ciclesonide|
41156619|NCT04565392|DRUG|Famotidine 20 milligram tablet|1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
41485800|NCT04404946|OTHER|phenylephrine infusion|in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated
41485801|NCT04404946|OTHER|norepinephrine infusion|in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated
40819243|NCT00790166|DEVICE|CPAP + No added humidity|ambient humidity
40819244|NCT04308434|OTHER|CSD190601-11|Flavor variant CSD190601-11 of a 1.5% nicotine ENDS product
40819245|NCT04308434|OTHER|CSD190601-12|Flavor variant CSD190601-12 of a 1.5% nicotine ENDS product
40819246|NCT04308434|OTHER|CSD190601-13|Flavor variant CSD190601-13 of a 1.5% nicotine ENDS product
40819247|NCT04308434|OTHER|CSD190601-14|Flavor variant CSD190601-14 of a 1.5% nicotine ENDS product
40819248|NCT04308434|OTHER|CSD190601-15|Flavor variant CSD190601-15 of a 1.5% nicotine ENDS product
40819249|NCT04308434|OTHER|CSD190601-16|Flavor variant CSD190601-16 of a 1.5% nicotine ENDS product
41337684|NCT03655080|DRUG|nab-Paclitaxel|"* Dose 15 mg/m\^2~* Should be administered by IV over 30 minutes"
40819250|NCT04308434|OTHER|CSD190601-17|Flavor variant CSD190601-17 of a 1.5% nicotine ENDS product
40819251|NCT04308434|OTHER|CSD190601-21|Flavor variant CSD190601-21 of a 3.0% nicotine ENDS product
40819252|NCT04308434|OTHER|CSD190601-22|Flavor variant CSD190601-22 of a 3.0% nicotine ENDS product
40819253|NCT04308434|OTHER|CSD190601-23|Flavor variant CSD190601-23 of a 3.0% nicotine ENDS product
40819254|NCT04308434|OTHER|CSD190601-24|Flavor variant CSD190601-24 of a 3.0% nicotine ENDS product
40819255|NCT04308434|OTHER|CSD190601-25|Flavor variant CSD190601-25 of a 3.0% nicotine ENDS product
40819256|NCT04308434|OTHER|CSD190601-26|Flavor variant CSD190601-26 of a 3.0% nicotine ENDS product
41016481|NCT06664281|BEHAVIORAL|SIT combined RIPC|sprint interval training combined with remote ischemic preconditioning
41337685|NCT01804647|OTHER|No study treatments administered - blood draws only|
41337686|NCT02395289|BEHAVIORAL|Cognitive-Based Compassion Training (CBCT)|"Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week."
41485802|NCT04404946|OTHER|placebo infusion|in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
41485803|NCT06446466|DEVICE|PEMF ON-OFF|"In the experimental condition PEMF ON-OFF, the participants will start the exercise session with PEMF in ON modality. The PEMF device will be kept ON for 17 minutes. Then, it will be turned OFF while the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect on PEMF at the onset of the exercise. Data acquired in the first 17 minutes (PEMF ON) will be compared with those recorded in the last 17 minutes (PEMF OFF) of the exercise session."
41485804|NCT06446466|DEVICE|PEMF OFF-ON|"In the experimental condition PEMF OFF-ON, the participants will start the exercise session with PEMF in OFF modality. The PEMF device will be kept OFF for 17 minutes. Then, it will be turned ON and the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect of PEMF during the exercise, when the muscle will have worked for 17 minutes. Data acquired in the first 17 minutes (PEMF OFF) will be compared with those recorded in the last 17 minutes (PEMF ON) of the exercise session."
41485805|NCT03254030|OTHER|Colonic inspection|Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
41485806|NCT01923623|DRUG|Ropivacaine block|
41016482|NCT06664346|BEHAVIORAL|Immersive virtual reality mindfulness|Immersive virtual reality mindfulness
41016483|NCT06662604|BIOLOGICAL|Bone marrow stem cells concentrate , platelet rich fibrin , bone graft|All participants will be treated with Bone marrow stem cells concentrate , platelet rich fibrin , bone graft.
41016484|NCT06662604|BIOLOGICAL|platelet rich fibrin and bone graft|All participants will treated with platelet rich fibrin PRF , bone graft.
40819257|NCT04308434|OTHER|CSD190601-27|Flavor variant CSD190601-27 of a 3.0% nicotine ENDS product
40819258|NCT01949025|OTHER|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
40819259|NCT05258214|OTHER|Mulligan Bent Leg Raise|Mulligan's bent leg raise, as well as the extreme Straight Leg Raise, can be used to relieve Low Back Pain. It can be used to treat leg discomfort that is above the knee. Bent Leg Raise methods are used where there is a restricted range of motion in the hip flexion joint, as well as low back pressure with or without referred leg pain.
40819260|NCT05258214|OTHER|Mulligan Traction Straight Leg Raise|Mulligan traction leg raise exercises are a non-invasive treatment that has been shown to help people with low back pain and reduced hip flexion range. Conservative sciatica therapy focuses on pain relief, but increasing Straight Leg Raise range will help restore normal mobility and reduce the severity of low back disability.
40819261|NCT05258214|OTHER|Neural Mobilization|These techniques are designed to mobilize a nerve with as little pressure down, resulting in a larger longitudinal excursion than techniques that actually lengthen the nerve bed, such as tensioning procedures.
40819262|NCT00283426|DRUG|Soluble beta-1,3/1,6-glucan|
40819263|NCT05791409|DRUG|Epcoritamab|Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
41016485|NCT06658340|BEHAVIORAL|Positivity in Post-COVID|A training to support well-being and self-management in patients with post-COVID-19 syndrome
41337687|NCT02395289|BEHAVIORAL|Health discussion|Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
41337688|NCT04568811|BIOLOGICAL|Adenovirus Type-5 Vectored COVID-19 Vaccine|Low dose adenovirus type-5 vectored COVID-19 vaccine (5E10 vp)
41337689|NCT04154397|DEVICE|cerebellar transcranial stimulation|Feedforward-based training benefits from a dynamic postural task by application of cerebellum transcranial electrical stimulation (ctDCS) of different modes (direct current vs. noise vs. sham) were administered using a one-channel direct current stimulator (NeuroConn DC-Stimulator PlusTM) with study mode enabled for single blinding. Following the baseline trial of posture tracking, participants of three groups were seated in a chair for 20 min to receive either active or sham cerebellar tDCS prior to the posture tracking and transfer test phases.
41337690|NCT00587444|DRUG|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is \< 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is\>480 seconds
41337691|NCT00587444|DRUG|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is \<600 seconds anytime during CPB
41337692|NCT00587444|DRUG|heparin concentration HC|"will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%"
41337693|NCT01665768|DRUG|Everolimus|The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL.
41337694|NCT01665768|BIOLOGICAL|Rituximab|375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
41337695|NCT05899894|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA mode will be titrated as per protocol alongside titration of PEEP levels. Peep will be titrated for all NAVA levels in a descending order 10,5,0 NAVA level will be titrated in an ascending order 0.5, 1.0, 1.5, 2.0 at each PEEP level
41337696|NCT02508519|PROCEDURE|Acupuncture|An acupuncture needle insertion according to zonal or balance method.
41337697|NCT04897646|OTHER|SFRMS/SPLF CPAP-telemonitoring diagnosis/therapeutic algorithm.|"In 2020, a working group from the Société Française de Recherche et de Médecine du Sommeil (SFRMS) and the Société de Pneumologie de Langue Française (SPLF) have proposed a CPAP-telemonitoring diagnosis/therapeutic algorithm for newly treated patients with obstructive sleep apnea.~The algorithm is exhasutively described in the following published article: Prigent, A., Gentina, T., Launois, S., et al. \[Telemonitoring in continuous positive airway pressure-treated patients with obstructive sleep apnoea syndrome: An algorithm proposal\]. Rev. Mal. Respir., 2020, 37: 550-560."
41337698|NCT03232138|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
41337699|NCT03232138|DRUG|Placebo|Inactive ingredients
41337700|NCT00169806|OTHER|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
41337701|NCT05534152|OTHER|sumac|1% iranian brown sumac
41337702|NCT05956262|DEVICE|AR-toothbrush machine|Student in AR group received a two-time repeated AR-based training for 30 minutes at two-week intervals. The AR-based training system (PVIX Oral, EPED) digitized the steps of the toothbrushing technique applying optical tracking technology to enable the participants to obtain immediate scoring after the completion of practice. The scoring depends on the level of removing simulated dental plaque. The AR system was equipped with an optical tracking unit, a 3D training head model, and a wireless toothbrush. The toothbrushing practice time for the upper and lower jaw is 3 minutes, respectively. A tooth-brushing song played while the students implemented.
41337703|NCT05956262|BEHAVIORAL|Teach proper brushing skills|Students in the traditional group received a two-time repeated 10-minute lesson regarding proper toothbrushing skills in the classroom at two-week intervals. The students were taught by a well-trained dental hygienist using teaching aids (such as dental models, and toothbrushes).
41337704|NCT00813267|BIOLOGICAL|mesenchymal stem cell infusion|
41337705|NCT00813267|BIOLOGICAL|bone marrow mononuclear cell infusion|
41337706|NCT02955771|COMBINATION_PRODUCT|PDT-Deuteporfin（6 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
41016489|NCT06664229|BEHAVIORAL|Fall and dementia prevention exercise|"The fall and dementia prevention exercise is designed as a combination of balancing and cognitive exercise and games that is conducted as a group activity. The session will be provided three times per week for six weeks for a pilot test and three times per week for 12 weeks for a main comparison study.~The fall prevention exercise involves the pressure mat based balancing exercise such as side stepping, heel or toe standing, and quarter squat. The safety bar will be placed around the mat, so that older adults with instability can hold while they follow the movements.~The cognitive exercise will concise of multiple types of cognitive tasks to train memory, numeric processing, spatial perception, and logical thinking. For example, memory task such as memorizing the series of positions on the screen and use the mat to point the positions in the right order.~At the end, older adults play games in which they use balancing movements and cognitive tasks to gain scores for their team."
41016490|NCT06662929|RADIATION|Radiation|Radiotherapy for the Head \& Neck Cancer
40819264|NCT05791409|DRUG|Venetoclax|All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
40819265|NCT06604546|DRUG|hyaluronidase|150 IU group D1:150 IU hyaluronidase+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:150 IU hyaluronidase+250 ml Lactated Ringe's (LR)(Subject's left or right arm)； D3:150 IU hyaluronidase+500 ml Normal Saline (NS)(subject's left or right leg)； D4:150 IU hyaluronidase+1000 ml Lactated Ringer's (LR)(Subject's back)； 385 IU group D1:385 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:1500 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm).
40819266|NCT06604546|DRUG|Placebo|150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg)； 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).
40819267|NCT02495246|BIOLOGICAL|ChAd3-EBO-Z|
41016491|NCT06664580|OTHER|Metabolic Bariatric Surgery Procedures|Observational analysis of various metabolic bariatric surgeries, including LSG, RYGB, and OAGB, focusing on long-term outcomes related to weight maintenance, nutritional health, and patient satisfaction.
41016494|NCT06664060|DRUG|osteoimplant|30 lower third molars will be selected and prescribed preoperative treatment with two units of Osteoimplant Complex® 5 days prior to surgery and postoperative treatment with one unit of Osteoimplant® for 8 weeks from the time of surgery. Both nutritional supplements will be administered every 24 hours.
41016495|NCT06664060|DRUG|Placebo|30 lower wisdom teeth will be selected and prescribed placebo, both preoperatively 5 days prior to surgery and postoperatively for 8 weeks from the time of surgery.
41016496|NCT06664476|BEHAVIORAL|PortCare Professional Training Program|The intervention is a targeted educational program to enhance oncology nurses' skills in managing Port-A-Catheters for chemotherapy patients. It includes a preparatory phase to assess baseline knowledge and practices, followed by an implementation phase with theoretical and practical training. Theoretical sessions cover device basics and care guidelines, while practical sessions provide hands-on training on procedures like catheter insertion, flushing, and removal. This program aims to improve patient safety, reduce complications, and boost nurses' confidence in Port-A-Catheter care.
40819268|NCT02495246|BIOLOGICAL|Ad26.ZEBOV|
40819269|NCT02626234|DRUG|INC280|
40819270|NCT02626234|DRUG|digoxin|
40819271|NCT02626234|DRUG|rosuvastatin|
41156620|NCT03594786|DEVICE|endovascular aneurysm repair (EVAR)|Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
41156621|NCT05267249|PROCEDURE|Autotransplantation and Apicoectomy|Autotransplantation of a mature teeth with simultaneous extra-oral root-end resectoin
41337707|NCT02955771|COMBINATION_PRODUCT|PDT-Deuteporfin（9 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
41156622|NCT05048407|DEVICE|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
41156623|NCT06138132|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
41156624|NCT06138132|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
41156625|NCT06362265|DRUG|LY3209590|Administered SC.
41156626|NCT06646952|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
41337708|NCT02955771|DEVICE|stenting|The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
41337709|NCT00455936|DRUG|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
41485807|NCT05241717|BEHAVIORAL|Web-based Management of Adolescent Pain (WebMAP)|Participants will be asked to complete one module per week, which are approximately 20 minutes in length. Survivors and parents will be asked to spend approximately 4.5 hours each over the course of the intervention on WebMAP including 4 hours to complete the modules and 30 minutes total corresponding with a coach. Each week, patients log into WebMAP to learn a new skill and practice that skill for 1 week to allow time for skills acquisition. WebMAP consists of two separate, password-protected programs including one for adolescents and one for parents (http://webmap2.com).
41485808|NCT02711683|DRUG|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
41485809|NCT02711683|DRUG|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
41485810|NCT01751035|BEHAVIORAL|Risk Reduction through Family Therapy|RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
41485811|NCT01751035|BEHAVIORAL|Treatment as Usual|Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
41485812|NCT02859948|DRUG|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
41485813|NCT03721536|DIAGNOSTIC_TEST|hemodynamic parameters|vital signs on the monitor including heart rate, mean arterial pressure, peripheral oxygen saturation and End-tidal Carbon Dioxide
40819272|NCT05925530|DRUG|Durvalumab|Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
41337710|NCT00455936|PROCEDURE|chemotherapy|gemcitabine(1250mg/m2 iv on D1 \& 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
40819273|NCT00303771|DRUG|fluorouracil|
41156627|NCT06336707|DRUG|HS-20089|Intravenous infusion
41156628|NCT06336707|DRUG|Adebrelimab|Intravenous infusion
41337711|NCT01784614|DRUG|LY2624803 - Solution|Administered orally as reconstituted solution
41337712|NCT01784614|DRUG|LY2624803 - Capsule|Administered orally as a capsule
41337713|NCT01784614|DRUG|Placebo - Solution|Administered orally as solution
41337714|NCT01784614|DRUG|Placebo - Capsule|Administered orally as a capsule
41485814|NCT03721536|DIAGNOSTIC_TEST|arterial blood gase|Arterial blood gas including partial oxygen pressure and partial carbon dioxide pressure is an important routine investigation to monitor the acid-base balance of patients, effectiveness of gas exchange, and the state of their voluntary respiratory control.
40819274|NCT00303771|DRUG|irinotecan hydrochloride|
41337715|NCT06185868|OTHER|No intervention measures|No intervention measures
40819275|NCT00303771|DRUG|leucovorin calcium|
40819276|NCT01330628|DEVICE|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
41337716|NCT05427175|RADIATION|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
41337717|NCT05427175|DRUG|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
40819277|NCT01330628|PROCEDURE|Balloon angioplasty|standard balloon catheters for PTA
40819278|NCT06230016|OTHER|questionnaires|"human and social science questionnaire (specifically designed by the expert lab of Grenoble) on motivation and restraint perceived by patient and parents, elaborated especially for this study.~Questionnaire administred before the start of current care APA programm and after 4 to 6 months."
41156629|NCT06336707|DRUG|Bevacizumab|Intravenous infusion
41156630|NCT06336707|DRUG|Cisplatin / carboplatin|Intravenous infusion
41337718|NCT02314871|OTHER|Epidural analgesia|see Arm/group description
41337719|NCT02314871|DRUG|Piritramide|see Arm/group description
41337720|NCT02314871|DRUG|Morphine|see Arm/group description
41337721|NCT05103995|OTHER|no intervention|no intervention, just observation
41337722|NCT00353990|DRUG|Insulin Aspart|
41337723|NCT03591913|DRUG|Misoprostol|Oral tablets
41485815|NCT04093635|DEVICE|Negative Pressure Wound Therapy|VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at -125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs
41485816|NCT02350374|OTHER|carbohydrate counting|"patients must fill their logbook with the following data:~* cho amount at breakfast, lunch, snack and dinner~* insulin amount at breakfast, lunch, snack and dinner"
41485817|NCT04887246|BIOLOGICAL|COVID-19 vaccines|COVID-19 vaccines available at Colombia
41485818|NCT06406946|DIETARY_SUPPLEMENT|Lion's mane blend|1.8 gram per day of lions mane, consisting of 3 x 600mg capsules
41485819|NCT06406946|DIETARY_SUPPLEMENT|Lion's mane and reishi blend|1.8 gram per day of lions mane and reishi blend, consisting of 3 x 600mg capsules
41485820|NCT06406946|DIETARY_SUPPLEMENT|Placebo|1.8-gram microcrystalline cellulose placebo powder, 3x600mg capsules
41485821|NCT02512536|DRUG|Botulinum Toxin Type A|Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
41485822|NCT01649271|DRUG|Herceptin|3-weekly
41337724|NCT04296604|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
41485823|NCT01649271|DRUG|afatinib|at MTD level
41485824|NCT01649271|DRUG|trastuzumab|3-weekly
41485825|NCT01649271|DRUG|Herceptin|weekly
41337725|NCT02302755|DRUG|TP10|All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
41485826|NCT01649271|DRUG|afatinib|at MTD level
40819279|NCT06230016|OTHER|PedsQL quality of life questionnaires|validated PedsQL (The Pediatric Quality of Life Inventory) questionnaires administred to children (if adequate) and parents before the start of current care APA programm and after 4 to 6 months
40819280|NCT01669252|DRUG|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
41337726|NCT04614467|BIOLOGICAL|CLBS16|GCSF-mobilized autologous CD34+ cells
41337727|NCT04614467|BIOLOGICAL|Placebo|isotonic solution (no CD34+ cells)
41337728|NCT03037307|OTHER|Test Product|Five strips of test adhesive cream for upper denture, as per application instructions.
41337729|NCT03037307|OTHER|Positive Contol|Three dabs of positive control adhesive cream for upper denture, as per application instructions.
41337730|NCT03037307|OTHER|Negative Control|No adhesive
41337731|NCT05298228|DRUG|Remimazolam bolus does administration|The beginning dose of remimazolam is 0.3 mg/kg, and when LMA insertion is successful, the dose will be decreased by 0.05 mg/kg in the next patient. When LMA insertion is unsuccessful (failed), the dose will be increased by 0.05 mg/kg in the next patient.
41485827|NCT01649271|DRUG|afatinib|escalating dose
41485828|NCT00506649|OTHER|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
40819281|NCT03362502|GENETIC|PF-06939926|"Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels."
41485829|NCT01687348|DRUG|lidocaine aguettant|
41485830|NCT02756936|DRUG|Daclatasvir Zeta|1 tablet contains 60 mg Daclatasvir
41485831|NCT02756936|DRUG|Clatazev|1 tablet contains 60 mg Daclatasvir
41485832|NCT00541970|BIOLOGICAL|Cervarix|Intramuscular injection, different dosing /schedule
41485833|NCT00541970|DRUG|Placebo|Intramuscular injection, different dosing /schedule
41485834|NCT04063488|DRUG|Metreleptin|This is an observational study in which the subjects will serve as their own controls. Study testing will be conducted at baseline (pre-treatment) and for 2 years, post-treatment with metreleptin.
41485835|NCT04658836|DRUG|Triamcinolone Acetonide 40mg/mL|Intratympanic application of triamcinolone acetonide
41485836|NCT01069991|BEHAVIORAL|Patient education group|Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.
41485837|NCT01069991|BEHAVIORAL|Wait list control group|No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
41485838|NCT02550730|BEHAVIORAL|Birth Sisters Best Beginnings for Babies|Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
41485839|NCT02550730|OTHER|Usual maternity care|Usual prenatal, intrapartum and postpartum maternity care
41485840|NCT02290275|DIETARY_SUPPLEMENT|Creatine|Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
41485841|NCT02290275|OTHER|Walking Exercise|Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
41485842|NCT02290275|DIETARY_SUPPLEMENT|placebo (maltodextrin)|Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
41485843|NCT05089474|DEVICE|Streamline Surgical System|The Streamline System is a device that delivers viscoelastic into Schlemm's Canal.
41485844|NCT00240942|DRUG|Letrozole|
41016498|NCT06661980|DRUG|Dexmedetomidine Injectable Solution|Dexmedetomidine 200 mcg/ 2 mL IV.
41016499|NCT06661980|OTHER|Placebo|Normal Saline IV.
41156631|NCT04990128|COMBINATION_PRODUCT|Aspire Needle + Emcyte PureBMC|The Aspire Needle will be utilized to extract the bone marrow and the Emcyte PureBMC will be used to concentrate bone marrow aspirate. The final concentrate will be injected into the hip.
41156632|NCT04990128|DRUG|Triamcinolone|40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip.
41156633|NCT03936309|OTHER|Scar Deactivation Surface Release Technique protocol|▪ Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
41156634|NCT03936309|OTHER|Scar Infiltration with 0.25-1% Lidocaine|▪ Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
41156635|NCT03936309|OTHER|Physical therapy|▪ Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
41156636|NCT06047041|BEHAVIORAL|EIS Only|"The EIS Only Condition includes middle schools who have elected to implement the EIS. The EIS:~* Is an online tool to that enables schools to identify students in need of additional mental or behavioral health support and provides recommendations for evidence-based practices.~* Asks teachers and students to report on 7 areas of student social-emotional functioning~* Facilitates schools' understanding of social-emotional student needs and recommended evidence-based practices at a variety of levels (e.g., school-, grade-, and individual-level).~EIS Only Condition supports include:~* Technical assistance professional development sessions to support the implementation of EIS and schoolwide practices related to identifying and supporting student mental health needs.~* Individualized technical assistance for schools to support EIS implementation."
41337732|NCT01604096|OTHER|Multifaceted information campaign|"Following is the description of the multifaceted intervention:~* brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~* posters (same distribution as brochures)~* short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~* radio-spots transmitted in local radio stations~* advertisements in local newspapers~* banners on websites of local newspapers~* newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~* training courses in counselling strategies, directed to a subgroup of GPs and paediatricians"
40819282|NCT06606821|DRUG|Tirzepatide|Investigational drug will be administered as a sc. injection once-weekly.
40819283|NCT06606821|DRUG|Placebo|Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
41337733|NCT01690988|DRUG|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
41485845|NCT04899193|DRUG|Pergoveris FD|Participants will be administered with 900 IU of recombinant human follicle-stimulating hormone (r-hFSH) and 450 IU of recombinant human luteinizing hormone (r-hLH) freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
41485846|NCT04899193|DRUG|Pergoveris Liquid|Participants will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Pergoveris Liquid) as subcutaneous injection using disposable pen-injector on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
40819284|NCT00756184|DEVICE|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
40819285|NCT00756184|DEVICE|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
40819286|NCT04649359|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
40819287|NCT05155618|PROCEDURE|INTERVENTION GROUP|Personalized advice to prevent side effect according to their health status will be provided by a dietitian and a physiotherapist.
40819288|NCT02608775|DEVICE|Metrodoloris Medical System|Application of a skin electrode
40819289|NCT02608775|DEVICE|Aisys® care station, Acertys|Standard photoplethysmography
40819290|NCT00938821|PROCEDURE|Caudal block|Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
40819291|NCT06537128|BEHAVIORAL|LUNA-Adolescent|Learning to Understand and Navigate Anxiety-Adolescent (LUNA-Adolescent) includes parent-led, internet-based cognitive behavioral therapy (CBT) for anxiety among autistic youth.
41337734|NCT01690988|DRUG|Normal Saline (placebo)|Normal saline IV following induction of anesthesia or administration of sedative medications
41337735|NCT01690988|DRUG|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
41337736|NCT01170949|DRUG|Miltefosine|50 or 100 or 150mg per day
41337737|NCT01170949|DRUG|Placebo|Placebo
41337738|NCT03879629|DRUG|Carvedilol|oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day
41156637|NCT06047041|BEHAVIORAL|EIS + ECHO|"EIS + ECHO supports include supports from the EIS Only condition plus:~* Monthly ECHO sessions for student support teams (SSTs; e.g., interdisciplinary groups of staff tasked to support student mental health). The ECHO experience involves:~  * Didactic training to support EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Case-based learning and collaborative problem-solving related to EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Collaboration with colleagues in schools that are also implementing the EIS.~ * Opportunities to consult with university faculty and content experts in school mental health.~* Individualized SST coaching supports to facilitate the implementation of mental and behavioral health practices and strategies discussed during ECHO sessions."
41337739|NCT06460831|DEVICE|Microcatheter|The microcatheter group undergoes alcohol ablation using a microcatheter.
41485847|NCT04899193|DRUG|Gonal-f|Participants will be administered with 900 IU of folitropin alfa (Gonal-f) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
41485848|NCT04899193|DRUG|Luveris|Participants will be administered with 450 IU of lutropin alfa (Luveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
41156638|NCT05768321|DRUG|GEC255 tablets|"Part 1: Dose escalation After initial starting dose cohort, daily dosages in subsequent cohorts are determined by cohort review committee.~Part 2: Dose expansion Daily oral dosage RP2D based on data from Part 1"
41156639|NCT04925245|OTHER|Clinical Reminder|Clinical reminder in the electronic medical record
41156640|NCT06492057|DEVICE|Electromyostimulation (EMS)|EasymotionSkin body suit for digitally controlled electric impulses via Easymotion-2 software on crew iPad (frequency, impulse rate, duration) are transferred from integrated dry electrodes of the EMS- stimulation suit to activate surface muscle groups of the body (trunk), arms and legs
41156641|NCT06492057|DEVICE|Myoton|The non-invasive Myoton technology collects data from passive muscle properties (tone and stiffness) obtained from selected anatomical surface muscle groups
41485849|NCT06428435|DIAGNOSTIC_TEST|Vision Test|Remote vision testing via digital screen
41485850|NCT03524183|BEHAVIORAL|Virtual Fitness Buddy Ecosystem|The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
41485851|NCT04821531|OTHER|PT Pal|Patients will be guided through individualized exercises that will be selected by their primary physical therapists. The exercises aim to improve lung function, maintain joint flexibility, muscle strength balance and mobility
41485852|NCT04821531|OTHER|Exercise Manual|Patients will be guided through individualized exercises that will be selected by their primary physical therapists. The exercises aim to improve lung function, maintain joint flexibility, muscle strength, balance and mobility
41485853|NCT05761873|OTHER|Provision of audit and feedback via email and paper|Provision of A\&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
41485854|NCT05761873|OTHER|Provision of audit and feedback via paper only|Provision of A\&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
41337740|NCT06460831|DEVICE|OTW|The OTW group undergoes alcohol ablation using an OTW balloon.
41337741|NCT03192176|DRUG|Fezolinetant|Oral Capsule
41337742|NCT03192176|DRUG|Placebo|Oral Capsule
41337743|NCT02296294|DRUG|Elo-mel® (Fresenius Kabi Austria)|an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
41337744|NCT02296294|DEVICE|Body Composition Monitoring|BCM measurements every 10 minutes for 6 hours.
41337745|NCT05615038|PROCEDURE|Contact aspiration Thrombectomy|Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.
41337746|NCT05615038|PROCEDURE|Stent retriever thrombectomy|Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.
41337747|NCT02866604|PROCEDURE|Sterofundin|
41337748|NCT02866604|PROCEDURE|0.9% saline|
41485855|NCT05965531|DRUG|Trifluridine/Tipiracil|TAS-102 is given in a dose of 35 mg/m2, twice daily on the 1st to 5th and 8th to 12th days of the period of neoadjuvant radiotherapy.
41485856|NCT05965531|RADIATION|intensity-modulated radiotherapy|intensity-modulated radiotherapy
41485857|NCT01330420|BEHAVIORAL|Relaxation Response Resiliency Program for Depression|"The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:~* Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.~* Examination and reversal of negative thought patterns.~* Physical movement, including stretching and yoga.~* Healthy eating and other positive lifestyle behaviors.~* Goal setting."
41485858|NCT00450983|BIOLOGICAL|muromonab-CD3|
41485859|NCT00450983|BIOLOGICAL|natural killer cell therapy|
41485860|NCT00450983|DRUG|fludarabine phosphate|
41485861|NCT00450983|DRUG|methotrexate|
41485862|NCT00450983|DRUG|thiotepa|
41485863|NCT00450983|GENETIC|gene expression analysis|
41485864|NCT00450983|OTHER|flow cytometry|
41485865|NCT00450983|OTHER|immunologic technique|
41485866|NCT00450983|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41485867|NCT00450983|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
41485868|NCT00450983|RADIATION|total-body irradiation|
41485869|NCT05876455|PROCEDURE|Conventional Subgingival Instrumentation|On the conventional non-surgical periodontal therapy side, a power-driven piezo-electric ultrasonic scaling device with scaling tips will be used the majority of the time to debride subgingival biofilm and calculus, and manual standard Gracey curette instruments (Gracey curettes Hu-Friedy, Chicago, IL, USA) will be used to remove residual deposits from the root surface.
41485870|NCT05876455|PROCEDURE|minimally invasive non-surgical periodontal therapy|minimally invasive non-surgical periodontal therapy will undergo careful scaling and root planing under magnification (use of 3.5 X magnification loupes) with mini curettes and using an ultrasonic device with specific thin and delicate tips. These instruments will be carefully inserted through the periodontal pocket of the affected tooth to reach the root surface for debridement. Caution will be taken to preserve the stability of soft tissues.
41485871|NCT02914236|DEVICE|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
41485872|NCT02327741|DRUG|plavix|taking plavix more than 12 months
41485873|NCT02327741|DRUG|plavix|taking plavix less than 12 months
41485874|NCT06309446|DEVICE|Zoralan Wound|Topical application of approximately 0.2 g per test field (approx. 1.2 cm in diameter each) once daily during a 12-day treatment period (11 treatments).
41485875|NCT05223257|OTHER|AOT|Observation of video sequences showing unimanual and bimanual goal-directed actions followed by the execution of the observed actions with upper limbs for unimanual and bimanual actions.
41485876|NCT02961166|DRUG|IgM enriched Immunoglobulins|Treatment for 3 days
41485877|NCT04874636|DRUG|LY3556050|Administered orally
41485878|NCT04874636|DRUG|Placebo|Administered orally
41485879|NCT04701515|OTHER|Chart review|Chart review
41485880|NCT05033366|DIAGNOSTIC_TEST|Proov Test|Rapid response urine PdG, FSH, E1G and LH test strips, Proov
41485881|NCT02075671|DRUG|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
41337749|NCT00588523|DRUG|temozolomide followed by high dose busulfan and thiotepa|Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
41337750|NCT03039790|BIOLOGICAL|NoV Vaccine|NoV vaccine injection administered.
41337751|NCT02353338|PROCEDURE|Surgical intervention|Surgical management of radial fracture
41485882|NCT02075671|DEVICE|Blu-U Light Therapy|Intervention used in experimental and sham arms
41485883|NCT02075671|OTHER|Placebo vehicle only|Intervention only includes the placebo vehicle solution
41485884|NCT04094376|OTHER|receiving operation during the day or at night|eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)
41485885|NCT03582761|BIOLOGICAL|EV71 vaccine|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
41337752|NCT02353338|PROCEDURE|Conservative management|Immobilized/cast for 6 weeks
41337753|NCT02353338|DEVICE|cast|
41485886|NCT00459121|DRUG|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
41485887|NCT00459121|DRUG|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
41485888|NCT00459121|DRUG|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
41485889|NCT00459121|PROCEDURE|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
41485890|NCT00725114|BIOLOGICAL|Tetrodotoxin|30 µg twice daily for 4 days
41485891|NCT00725114|BIOLOGICAL|Placebo|2 mL subcutaneous injection twice daily for 4 days
41485892|NCT00929331|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
41337754|NCT02417675|OTHER|Community-based Adherence Clubs|"Women in the AC arm are prescribed 2 months of their current ART medication (compared to 1 month in the SOC) and will be advised to go to the AC office immediately, where they will be scheduled for their first session. Women will attend AC meetings every two months. At these meetings, women will receive a 2 month supply of medication, health education and peer-support. A trained Community Health Worker (CHW) will also collect blood samples, weight, and current signs/symptoms from women.~Each participant has 5 working days after their AC session to come and collect her medication. Those who have defaulted will be followed up by the CHW via phone calls and, possibly, home visits. If reached, women will be told to return immediately to the main ART facility for receipt of ART care."
41156642|NCT06492057|DIAGNOSTIC_TEST|Electromyography (EMG)|As a standard method, surface EMG collects data from nerve impulse-triggered active muscle contractions, pre/postflight only
41485893|NCT03561441|DRUG|Tailored aggressive hydration|"1. Hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg for 1 hour after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the upper normal limit (UNL), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
41485894|NCT03561441|DRUG|Tailored standard hydration|"1. Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
41485895|NCT01806506|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
41485896|NCT01806506|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
41156643|NCT06492057|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI is a clinically standard (non-radiation) imaging method to study structural changes of the human body (organs, muscle, bones, tendons) at the macroscopic level, pre/postflight only
41485897|NCT02671227|DRUG|intrathecal Mg sulfate.|intrathecal Mg sulfate 50 mg.
41485898|NCT02671227|DRUG|intrathecal bupivacaine 15 mg.|intrathecal bupivacaine 15 mg.
41016501|NCT06663891|OTHER|Functional MRI with EEG per MRI|"2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent.~Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,"
41016502|NCT06663527|COMBINATION_PRODUCT|Fumigating-washing Therapy With CPD|All patients underwent anal fistulectomy based on the Parks classification. For postoperative infection prophylaxis, cefuroxime was used at a dosage of 2g per dose, twice daily. Commencing the day following surgery, a fumigating-washing therapy was conducted once daily either after defecation or two hours prior to intravenous infusion. In the study group, a medical solution used for fumigating-washing therapy was prepared by blending 200 ml of CPD with 2 liters of water at 40 °C. This medicinal solution was then transferred into the reservoir of an ultrasonic atomizing fumigating-washing device (Model:TM50-C, Xuzhou Tianma Medical Equipment Factory, China) that was classified by the FDA as Class II (special controls).
41016503|NCT06663527|COMBINATION_PRODUCT|fumigating-washing therapy with a placebo|fumigating-washing therapy with a placebo
41156644|NCT06492057|DIAGNOSTIC_TEST|Dynamometry|Dynamometry is a standard functional and diagnostic method to test muscle strength in sports and rehabilitation. pre/postflight only
41156645|NCT02519270|BIOLOGICAL|IGN002|IGN002 is a monoclonal antibody fusion protein.
41156646|NCT06538818|DEVICE|Ultra Phonophoresis|"Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of a hyaluronic acid-containing gel will be applied gel pad over the wrist and along the course of median nerve at the carpal tunnel.~The following parameters will be used: intensity of 1.0 W/em2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the hyaluronic acid-containing gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.~The following parameters will be used:~* intensity of 1.0 W/cm2~* 1MHz frequency~* pulsed (25%)~* 5 min/session, 5 d/wk, for 3 weeks."
41016504|NCT06662773|DRUG|TQB3616 capsule + itraconazole|C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors
41016505|NCT06662773|DRUG|TQB3616 capsule + rifampicin|C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer
40819292|NCT06537128|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes 12 weekly sessions of transdiagnostic cognitive behavioral therapy (CBT) for anxiety in autistic youth.
40819293|NCT03736993|OTHER|Additional blood sampling|Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
41156647|NCT03395873|DRUG|Avelumab|"* Decitabine 20mg/m2 IV day 1-5, every 28 days~* Avelumab 10mg/kg IV, day 1, every 14 days"
41485899|NCT05199766|DRUG|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease|This is an open-label, single-arm, single-stage phase II trial of voxelotor in patients with sickle-cell disease. Voxelotor 500mg tablets. Voxelotor will be administered as 500mg tablets orally once daily. The participant should always take all 3 tablets in a row at the same time each day, unless the study doctor has instructed them to adjust the dose.
41156648|NCT03771209|DIAGNOSTIC_TEST|ultrasound examination|ultrasound assessment
41016506|NCT06663631|DRUG|Hibernation drug|Chlorpromazine promethazine therapy are performed at the same time as mechanical thrombectomy. Intravenously pumped at a rate of 4ml/l until 50ml is completely pumped. The subject is closely monitored after the start of the drug to assess the safety of the drug.
41156649|NCT05618626|OTHER|Physical exercise and dietary intervention for NAFLD|Investigators will assess the efficiency of the intervention by measuring adherence to physical exercise and nutritional diet.
41016507|NCT06663631|DRUG|Placebo group|50ml of normal saline was used as placebo control and 4ml/l was injected intravenously at the beginning of mechanical thrombectomy until complete pumping.
40819294|NCT06247111|OTHER|Remote Blood Pressure Monitoring + Telehealth|Remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
40819295|NCT06247111|OTHER|Usual care|Participants receive usual care, no intervention.
40819296|NCT06594042|DIAGNOSTIC_TEST|serum preptin|serum preptin level in chronic kidney disease
41156650|NCT03340818|OTHER|Bone Marrow Concentrate|Bone marrow concentrate is bone marrow harvested from the iliac crest and minimally processed in a centrifuge. It is then injected into the suspected painful disc (s) using fluoroscopic guidance
41156651|NCT03340818|OTHER|Placebo|Injection of normal saline dorsal to the transverse process after sham bone marrow aspiration
41156652|NCT06447298|OTHER|Satisfaction questionnaires|Use of a post-laparoscopy satisfaction questionnaire designed to be adapted to the context of laparoscopic surgery. This post-laparoscopy questionnaire was inspired by the PedsQL generic care satisfaction questionnaire, a standardised and validated questionnaire.
41156653|NCT04066400|OTHER|Nutritional Intervention|Dietary Counselling
41156654|NCT06570434|DRUG|budoprutug|monoclonal antibody
41156655|NCT03948815|OTHER|interventional birthing room|The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.
40819301|NCT06065319|DEVICE|Wearable Sensors|Participants will wear smartwatches and smartrings and this data will be used to design algorithms which seek to find associations between device data and recovery.
40819302|NCT04399473|BEHAVIORAL|Pain Neuroscience Education (PNE)|Participates in the experimental group will receive 15mins X 4 sessions of pain education by the eligible trained physical therapist in addition to usual care PT treatment.
41156656|NCT01601639|DEVICE|Endoscopic Band Ligation|Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
41156657|NCT01601639|DEVICE|Argon plasma Coagulation (APC) for GAVE|APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
41156658|NCT04384692|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
41156659|NCT04384692|DRUG|Busulfan|Given IV
41156660|NCT04384692|DRUG|Cyclophosphamide|Given IV
41156661|NCT04384692|DRUG|Fludarabine|Given IV
41156662|NCT04384692|DRUG|Melphalan|Given IV
41156663|NCT04384692|DRUG|Methotrexate|Given IV
41156664|NCT04384692|DRUG|Mycophenolate Mofetil|Given IV or PO
41156665|NCT04384692|DRUG|Ruxolitinib|Given PO
41156666|NCT04384692|DRUG|Tacrolimus|Given IV and PO
41156667|NCT04384692|RADIATION|Total-Body Irradiation|Undergo TBI
41156668|NCT04384692|PROCEDURE|Computed Tomography|Undergo CT scan
40819303|NCT01338480|OTHER|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
40819304|NCT04796103|PROCEDURE|Dextrose Prolotherapy|In the patients in the prolotherapy injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of 5% dextrose, 1 ml each, will be applied periarticularly. In addition, home exercise program will be given to this group.
41337755|NCT02417675|OTHER|Standard of Care for Mothers|Women will be referred immediately from the maternity ART clinic to their nearest adult ART clinic at their first postpartum clinic visit. At referral, they receive an initial 1-month supply of their current ART medication. At the first appointment after transfer into the general ART service, patients undergo clinical history and examination by a doctor or clinical nurse practitioner. Laboratory investigations are ordered according to standard protocols or based on clinician discretion. For the 1st 4 months in the new service, stable patients are dispensed 1 month of ART; subsequent visits are 2-monthly for medication refill, with clinician review 6-monthly; patients with particular clinical or psychosocial concerns may be reviewed more regularly, or referred to higher levels of care.
41337756|NCT02417675|OTHER|Standard of Care for Infants|All infants will receive care at their nearest primary care clinic. Following national protocols, all HIV-infected mothers are issued a 6-week supply of nevirapine syrup after delivery and counselled on daily nevirapine prophylaxis. Infant follow-up takes place within 1 week postpartum with the mother (at the MOU) and then at 6 weeks postpartum (at the nearest primary care clinic) when HIV PCR testing of the infant is carried out. Following national protocols, infants who are breastfed beyond 6 weeks receive HIV PCR testing 2-4 weeks after the cessation of breastfeeding, again conducted at the nearest City of Cape Town primary care clinic.
41156669|NCT04384692|PROCEDURE|Echocardiography|Undergo echocardiography
41156670|NCT04384692|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
40819305|NCT04796103|PROCEDURE|Serum Physiological Group (placebo control group)|In the patients in serum physiological injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of saline will be applied periarticularly. In addition, home exercise program will be given to this group.
41156671|NCT04384692|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40819306|NCT00504855|OTHER|Casting using Gortex (waterproof) cast padding materials|
40819307|NCT00504855|OTHER|Casting using cotton/cotton-poly cast padding materials|
40819308|NCT01972308|BEHAVIORAL|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
40819309|NCT01972308|BEHAVIORAL|Usual Care|Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
41337757|NCT03383614|DRUG|LSF emodepside (BAY 44-4400) or matching placebo|Emodepside administered as an LSF oral solution (1mg/mL)
41337758|NCT01131078|DRUG|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
40819310|NCT00365105|DIETARY_SUPPLEMENT|Calcium|At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
40819311|NCT00365105|DIETARY_SUPPLEMENT|Vitamin D|400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
41156672|NCT04384692|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
41156673|NCT05179408|BEHAVIORAL|Telerehabilitation|Telerehabilitation intervention consisting of exercise training, education, and behavioral support
40819312|NCT00365105|DRUG|zoledronic acid|4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
40819313|NCT00365105|DRUG|Sm-153|Single dose intravenously 1 mCi/kg body weight.
40819314|NCT00365105|RADIATION|Sr-89|Single dose intravenously 4 mCi.
40819315|NCT04588012|BEHAVIORAL|The online self-help Program OurRelationship developed by prof. Brian Doss and prof. Andrew Christensen.|The OurRelationship program is developed by prof. Brian Doss and prof. Andrew Christensen.
41016514|NCT06663774|DIAGNOSTIC_TEST|Physical Fitness Tests|Ippon Reactive Agility Test (IRAT), Y-Balance Test, Upper-Quarter Y Balance Test, Flamingo Balance Test, Flamingo Balance Test, Standing Long Jump Test, 20m Sprint Test, Hand Grip Test, T-Agility Test, Nelson Hand Reaction Test, Judo Specific Fitness Test
41016515|NCT06662630|DEVICE|High-Frequency Oscillatory Ventilation|Administer 10 minutes of high-frequency oscillatory ventilation in mechanically ventilated patients.
41156674|NCT00006006|BIOLOGICAL|recombinant interferon alfa|
40819316|NCT04588012|BEHAVIORAL|"The off line self-help course Pas på Parforholdet."|"The book Pas på parforholdet is written by Mattias Stølen Due."
40819317|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, intraoperative stage|Trocar layout is recorded by photo or diagram. The video of conventional or robot-assisted laparoscopy and intraoperative laparoscopic ultrasound images (where applicable) are recorded by the surgeon and anonymized. Depth measurements of internal structures (tumors, cysts, vascular network, anatomical landmarks) are taken using identifiable points on the surface of the liver for tumour resection.
40819318|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, postoperative stage|The registration of imaging data in conventional or robot-assisted laparoscopy is performed by the scientific team using the developed registration algorithm. The data obtained from the clinical intervention will help improve the registration algorithm.
41156675|NCT00006006|DRUG|thalidomide|
41156676|NCT00866502|DRUG|sNN0031|Continuous ICV infusion for two weeks
41156677|NCT00866502|DRUG|Placebo|Continous ICV infusion
41156678|NCT04128514|DEVICE|Panoptix Toric|Cataract surgery and IOL implantation
41156679|NCT06647290|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
41156680|NCT05376787|DEVICE|Medline NE Grounding Pad|Split Universal Grounding Pads
41156681|NCT05517265|DRUG|Calquence|acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
41156682|NCT05517265|DRUG|Calquence|acalabrutinib according to Calquence® SmPC.
41485900|NCT05763706|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
41485901|NCT01962181|DRUG|Ritalin|Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
41485902|NCT01962181|DRUG|Placebo|
41485903|NCT03343613|DRUG|LY3381916|IDO-1 inhibitor administered orally
41485904|NCT03343613|DRUG|LY3300054|PD-L1 inhibitor administered IV
41485905|NCT01295294|DRUG|Tranexamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
41485906|NCT01295294|DRUG|Mefenamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
41485907|NCT01295294|DRUG|Placebo|3 times daily per oral during bleeding/spotting episodes
40819319|NCT06044909|OTHER|Preoperative data collection|Patient code (anonymised) + inclusion number, repeated on each page. Anonymised CT or MRI scan and date of scan. Type of cancer, planned surgery and approach (robotic or laparoscopic). Patient's age. Patient's surgical history. Toxic habits: tobacco, alcohol. Healthy liver, liver disease, cirrhosis. Anticoagulant and antiaggregant treatment.
40819320|NCT06044909|OTHER|Intraoperative data collection|Endoscope calibration. Intraoperative surgical and ultrasound images. Measurements for tumor's size and tumor's distances from liver surface and vascular vascular structures.
41337759|NCT01131078|DRUG|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.
41337760|NCT01131078|DRUG|Irinotecan|Irinotecan was administered as a 240 mg/m\^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
41337761|NCT00220259|DRUG|Fluticasone or placebo|
41337762|NCT05481970|DRUG|dexmedetomidine,ketamine,lidocaine,propofol|Group (A): Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.
41337763|NCT05481970|DRUG|fentanyl,propofol|In group (B) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
41337764|NCT03105661|DRUG|Labetalol Hydrochloride 200 mg|Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
41337765|NCT03105661|DRUG|NIFEdipine 60 mg|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
41337766|NCT03105661|DRUG|Atenolol 25 mg|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
41337767|NCT05258513|DIETARY_SUPPLEMENT|Placebo Supplementation|8 weeks of placebo supplementation
41337768|NCT05258513|DIETARY_SUPPLEMENT|GG sourced from Annatto|8-weeks of Geranylgeraniol supplementation
41337769|NCT03976518|DRUG|Atezolizumab|Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).
41337770|NCT00305734|DRUG|bortezomib|Given IV
41337771|NCT00305734|DRUG|gemcitabine hydrochloride|Given IV
41337772|NCT00305734|OTHER|laboratory biomarker analysis|Correlative studies
41337773|NCT02304419|DRUG|Galunisertib|Administered orally.
41337774|NCT04939532|BEHAVIORAL|Text-Messaging (TM)|"Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes."
41337775|NCT04939532|BEHAVIORAL|Patient Navigation (PN)|"Patients in the PN condition, who respond yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. In addition they will receive a notice via text message that a Community Health Worker will contact them for patient navigation. At this time, patients will will have the option to opt-out of the phone call from the patient navigator. The Patient Navigation includes advice from navigators to address practical barriers to COVID testing such as logistics, transportation, and expenses as well as behavioral barriers such as hesitancy, fear, and uncertainty."
41485908|NCT01295294|DRUG|Mirena (Levonorgestrel IUS, BAY86-5028)|In vitro release rate 20 microgram/24 hours. Intrauterine system
41485909|NCT04963595|DRUG|Pyrotinib|400 mg once daily
41485910|NCT04963595|DRUG|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsules on day 1 to be taken at the hospital, and on day 8 at home.
41485911|NCT04963595|DRUG|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
41485912|NCT03113513|PROCEDURE|fixation of the vaginal apex|In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
41485913|NCT04323241|OTHER|Controlled cord traction|In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.
40819321|NCT06044909|OTHER|Postoperative data collection|Definitive anatomical pathology with the measurement of resection margins.
41485914|NCT00629265|DEVICE|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
41485915|NCT00611481|BEHAVIORAL|Tai Chi|a set of pre-designed Tai Chi Movements
41485916|NCT00611481|BEHAVIORAL|Strength training|Lower-extremity strength training exercises
41485917|NCT00611481|BEHAVIORAL|Low-Impact Exercise Control|a set of chair-based low-impact exercises
40819322|NCT02794844|DRUG|Genotype Guided PPI Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
41485918|NCT06011629|DEVICE|Aquacel dressing|Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
41485919|NCT03165877|OTHER|Low-glycemic index|Subjects ate low-glycemic index lunches and dinners (\<55%),consisting of salad, main course and dessert, respectively.
41337776|NCT06075368|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
40819323|NCT04865731|DRUG|Dermaprazole|Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.
40819324|NCT04865731|DRUG|Aquaphor|Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.
40819325|NCT06377696|OTHER|Best Practice|Receive SOC
41337777|NCT01574261|DRUG|Placebo|Placebo for four months
41337778|NCT01574261|DRUG|Inositol|Inositol 4g/die for four months
41337779|NCT02778373|DIETARY_SUPPLEMENT|Vitargo ®, Swecarb AB, Karlskrona, Sweden|
41337780|NCT02778373|DIETARY_SUPPLEMENT|DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA|
41337781|NCT02778373|OTHER|Placebo: Water|
41337782|NCT01856855|RADIATION|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
41485920|NCT03165877|OTHER|Control|Subjects ate standard lunches and dinners (\>60%),consisting of salad, main course and dessert, respectively.
41485921|NCT01077466|DRUG|Natalizumab|300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
41337783|NCT05798819|DRUG|GLS-010|IV infusion
41337784|NCT05798819|DRUG|Placebo|IV infusion
41337785|NCT05798819|DRUG|paclitaxel|IV infusion
41337786|NCT05798819|DRUG|cisplatin|IV infusion
41337787|NCT05798819|DRUG|carboplatin|IV infusion
41337788|NCT05798819|DRUG|bevacizumab|IV infusion
41485922|NCT02897986|DRUG|administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination|
41337789|NCT01505114|DRUG|Maraviroc|300-mg tablet, once daily, from Week 0 through Week 48
41485923|NCT03594695|DIAGNOSTIC_TEST|HSCRP and NLR|hs-CRP levels and NLR values will be studied from routine blood samples.
41485924|NCT01533766|DRUG|CombiflexOmega|intravenously over 5 days infusion
41485925|NCT01533766|DRUG|SmofKabiven|intravenously over 5 days infusion
41337790|NCT01505114|DRUG|Emtricitabine|200-mg capsule, once daily, from Week 0 through Week 48
41337791|NCT01505114|DRUG|Tenofovir disoproxil fumarate|300-mg tablet, once daily, from Week 0 through Week 48
41337792|NCT01505114|OTHER|Maraviroc placebo|Once daily from Week 0 through Week 48
41337793|NCT01505114|OTHER|Emtricitabine placebo|Once daily from Week 0 through Week 48
41337794|NCT01505114|OTHER|Tenofovir disoproxil fumarate placebo|Once daily from Week 0 through Week 48
41337795|NCT03696004|DRUG|FEC-100|Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
41337796|NCT05126134|DIAGNOSTIC_TEST|KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)|completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h
41337797|NCT05633797|DEVICE|FibriCheck|During the patient's intensive care unit (ICU) stay, they will be monitored constantly to detect atrial fibrillation (standard care). After ICU dismissal, patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative. Patients need to use the FibriCheck application for a minimum of 3x/day and can perform extra measurements when symptoms are present.
41337798|NCT03702855|DRUG|Tetrabenazine Tablets 25 mg|
41337799|NCT02238782|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
41337800|NCT02238782|OTHER|[14C] selumetinib IV solution|single, radiolabeled, IV (infused), microdose (80 μg) of \[14C\] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
41337801|NCT05884268|DRUG|Venlafaxine|Patients scheduled for elective LC will receive 150 mg venlafaxine before surgery
41337802|NCT05884268|DRUG|Placebo|Patients scheduled for elective LC will receive placebo venlafaxine before surgery
41485926|NCT04943484|PROCEDURE|imaging fluorescence NIR/ICG|"Preoperative upper GI endoscopy (UGE) UGE with submucosal injection of 2ml of ICG 0.125mg/ml solution to four peritumoral sites 15-20 hours before surgery Surgery D2 Distal gastrectomy with dissection of 1, 3, 4sb, 4sd, 5, 6, 7, 8a, 9, 11p, 12a lymph node stations (LNS) D2 Total gastrectomy with dissection of 1, 2, 3, 4sa, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 11d, 12a LNS Intraoperative NIR/ICG technology, change of surgical conduct (CSC) A visualization of the operative field (OF) with NIR/ICG technology is performed at the beginning of surgery and before to dissect each LNS. Subsequently, surgery is performed with the naked eye.~At the end, a visualization of the OF is performed using NIR/ICG technology to verify whether residual lymph nodes in each D2 nodal station exist. CSC is defined as the occurring of the following situation: in case of persistence of nodal fluorescence in D2 nodal stations, the completion of the dissection of the residual nodal fluorescent structures."
41485927|NCT05125380|DIAGNOSTIC_TEST|VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine)|A triage test that involved a gynaecological exam that applies acetic acid and then Lugol's iodine on the surface of the external os of the cervix.
41485928|NCT05125380|DIAGNOSTIC_TEST|VIA (Visual Inspection with Acetic acid)|A triage test that involved a gynaecological exam that applies acetic acid on the surface of the external os of the cervix.
41485929|NCT03407521|DRUG|Misoprostol|induction of abortion using misoprostol
41485930|NCT03407521|DRUG|isosorbide mononitrate|isosorbide mononitrate
41485931|NCT03407521|DRUG|Placebo|Placebo
41337803|NCT05821036|BEHAVIORAL|Activitiy Management|"Activity Management training will be applied for 5 weeks, 2 sessions per week, and the 1st and 10th sessions will be pre and post-training evaluation, a total of 10 individual, internet-based sessions.~Week 1:Awareness training and ergonomics training including spine anatomy, correct posture use, ergonomic strategies were planned to increase awareness about FMS. Week 2:Focusing on the challenging activities stated by the individuals, it is aimed to change the behavior by arranging the activity resting cycle in daily life. In addition, the management, adaptation and modification of the activities will be provided within the scope of time management training. Week 3: Joint and energy conservation principles training will be given and it is aimed to create body mechanics and proper posture suitable for activities.Week 4: Relaxation training will be provided as a method of coping with pain.Week 5: Re-evaluation/review of the targets set to reduce pain during activities will be provided."
41337804|NCT06109129|DEVICE|EXOPULSE Mollii Suit|EXOPULSE Mollii Suit is a personal assistive medical device which is used for low energy whole body transcutaneous electrical stimulation - 20 Volt and 20 Hz. It is composed of a control unit, a jacket and pants with 58 embedded electrodes in direct contact with the skin. EXOPULSE Mollii Suit is used for activation of muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle may subsequently relax.
41337805|NCT02929368|DEVICE|PICC implantation under fluoroscopy|PICC Catheter implantation
41337806|NCT02929368|DEVICE|PICC Implantation under Sherlock System|PICC Catheter implantation
41485932|NCT05993715|DIETARY_SUPPLEMENT|Nitrate supplementation|Participants ingested 2 × 70 mL/day shots of concentrate nitrate-rich (\~12.8 mmol/day nitrate) or nitrate-depleted (\~0.08 mmol/day nitrite) beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK). Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
41016518|NCT06662539|DRUG|Petrelintide|Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
41016519|NCT06662539|DRUG|Placebo|Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
41016520|NCT06662916|BEHAVIORAL|Microbiota-Diversity Enhancing Diet on children with Autism Spectrum Disorder|Microbiota-Diversity Enhancing Diet on Children with ASD (MIND-DASE) suggested that increasing microbiota diversity through dietary interventions can have significant benefits on the neurodevelopmental outcomes of children with ASD
41016521|NCT06663319|DRUG|JNJ-89402638|JNJ-89402638 will be administered.
41016522|NCT06663618|DRUG|prednison|Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.
41337807|NCT01963780|DEVICE|OCS Lung Preservation|
41337808|NCT00866060|DRUG|Memantine|20mg memantine
41337809|NCT00866060|DRUG|Donepezil|10mg donepezil
41337810|NCT00866060|DRUG|Placebo donepezil|Placebo donepezil
41016523|NCT06663618|DRUG|Mycophenolate mofetil|Oral Mycophenolate mofetil 0.75g bid for 6 months.
41337811|NCT00866060|DRUG|Placebo memantine|Placebo memantine
40819326|NCT06377696|OTHER|Medical Device Usage and Evaluation|Wear wearable device
40819327|NCT06377696|DRUG|Metformin|Given PO
40819328|NCT06377696|OTHER|Neurocognitive Assessment|Undergo neurocognitive test
41337812|NCT02992873|DEVICE|Layperson allocated to start CPR and fetch nearest AED|Dispatching laypersons to fetch an AED and start CPR in out-of-hospital cardiac arrest
41337813|NCT02992873|DEVICE|Layperson allocated to start CPR|Dispatching laypersons to start CPR out-of-hospital cardiac arrest
40819329|NCT06377696|OTHER|Questionnaire Administration|Ancillary studies
41337814|NCT04368000|BEHAVIORAL|Intermittent prone positioning instructions|Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.
41337815|NCT04368000|BEHAVIORAL|Usual care positioning with no instructions|Participants will not be given instructions to lie in the prone position for any duration.
41337816|NCT02167724|OTHER|Bucco-dental examination|
41337817|NCT02167724|OTHER|Blood sample|
41337818|NCT02167724|OTHER|Clinical and social questionnaire|
41337819|NCT01886755|DIETARY_SUPPLEMENT|ORS rehydration solution|
41337820|NCT01886755|DIETARY_SUPPLEMENT|placebo|
41337821|NCT00735527|DRUG|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
41337822|NCT00735527|DRUG|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
41337823|NCT04220710|DIAGNOSTIC_TEST|DNA extraction and methylation detection|DNA extraction and methylation detection
41337824|NCT01048047|DRUG|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
41337825|NCT04480346|BEHAVIORAL|Challenging Horizons Program|Intervention delivered in high schools provided by school mental health professional over the course of an academic year with twice-weekly meetings with students and 10 evening group meetings with students and 10 group sessions with parents.
40819330|NCT04746235|DRUG|Decitabine and Cedazuridine|Given PO
41337826|NCT00971542|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
41485933|NCT05993715|DIETARY_SUPPLEMENT|Placebo supplementtaion|2 × 70 mL/day shots of concentrate nitrate-depleted (\~0.08 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
41485934|NCT03012672|DRUG|Cladribine|Given IV
41485935|NCT03012672|DRUG|Cytarabine|Given IV
41485936|NCT03012672|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|Given SC
41016525|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (150 cm from Duodenojejunal Junction)|This intervention involves performing a One Anastomosis Gastric Bypass surgery with the bypassed length of the small intestine set at 150 centimeters from the duodenojejunal junction. This shorter limb length is designed to achieve weight loss while potentially reducing the risk of nutritional deficiencies. The procedure is performed laparoscopically, with the stomach divided to create a gastric tube attached to a loop of the small intestine. Postoperative outcomes will include assessments of weight loss, total weight loss percentage, excess weight loss percentage, and nutritional markers such as albumin, calcium, and iron.
41016526|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (170 cm from Duodenojejunal Junction)|This intervention involves performing a One Anastomosis Gastric Bypass surgery with a bypassed length of 170 centimeters from the duodenojejunal junction, offering an intermediate limb length. This distance is intended to balance weight loss effectiveness with moderate risks of nutritional deficiencies. The laparoscopic procedure involves creating a gastric tube attached to a segment of the small intestine, bypassing the proximal portion. Outcomes monitored postoperatively include weight loss, percentage of total and excess weight loss, and nutritional parameters such as albumin, calcium, and iron levels.
41337827|NCT05121961|PROCEDURE|Sacroiliac intra-articular injection|CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
41485937|NCT03012672|DRUG|Mitoxantrone Hydrochloride|Given IV
41485938|NCT03012672|OTHER|Quality-of-Life Assessment|Ancillary studies
40819331|NCT04746235|DRUG|Venetoclax|Given PO
41485939|NCT03012672|OTHER|Questionnaire Administration|Ancillary studies
40819332|NCT02436668|DRUG|Ibrutinib|
40819333|NCT02436668|DRUG|Gemcitabine|
40819334|NCT02436668|DRUG|Nab-paclitaxel|
40819335|NCT01549886|DRUG|Y-90-Zevalin|Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
41485940|NCT04014855|DRUG|Iron Supplement|in iron deficiency anemia
41485941|NCT05738759|DRUG|Epidural Anesthetic Cocktail|The anesthetic cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.
41485942|NCT05738759|DRUG|Placebo|The placebo is soaked with NSS in the gelfoam size 1x2 cm as well and applied on the epidura before removal of the endoscope.
41485943|NCT01584453|DRUG|Sodium Nitrite|A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
41485944|NCT01584453|DRUG|Sodium Chloride Placebo|The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
41485945|NCT04974866|DRUG|EGFR-TK Inhibitor|epidermal growth factor receptor tyrosine kinase inhibitors
41485946|NCT03044041|DRUG|Tranexamic Acid|IA (intra-articular) tranexamic acid after capsule closure
41485947|NCT02387593|DEVICE|ENDOCUFF|One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
41485948|NCT02816866|OTHER|empowered primary care model|mode of survivorship care
41485949|NCT02816866|OTHER|specialty survivor clinic|mode of survivorship care
41016527|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (200 cm from Duodenojejunal Junction)|This intervention consists of performing a One Anastomosis Gastric Bypass with the bypass length set at 200 centimeters from the duodenojejunal junction. This longer bypass length is designed to maximize weight loss outcomes but may carry a higher risk of nutritional deficiencies. The procedure is done laparoscopically, where the stomach is divided, creating a tube that is joined to the small intestine at the specified length. Postoperative assessments will focus on weight loss effectiveness, total and excess weight loss percentages, and the risk of nutritional deficiencies by measuring markers such as albumin, calcium, and iron.
41016528|NCT06663865|DIETARY_SUPPLEMENT|Active|"40g bio-active whey protein concentrate powder containing dairy phospholipids~Other Names:~Active Treatment"
41337828|NCT01689324|BIOLOGICAL|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
41016529|NCT06663865|DIETARY_SUPPLEMENT|Placebo|"Around 40g pea protein powder not containing dairy phospholipids~Other Names:~Placebo Treatment"
41337829|NCT02244229|DRUG|Tamsulosin|
41337830|NCT02244229|DRUG|Finasteride|
41016530|NCT06663657|OTHER|Cognitive Sensorimotor Exercises|Patients in group A will receive cognitive sensorimotor exercises for 30 minutes, sessions for 5 days per week for 8 weeks.
41016531|NCT06663657|OTHER|Task Oriented Training group|Patients in group B will receive task oriented training for 30 minutes, sessions for 5 days per week for 8 weeks.
41016532|NCT06663748|DRUG|ARX788|2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
41016533|NCT06664125|DRUG|JMKX003002 will be administered orally|tablets for oral administration.
41016534|NCT06664125|DRUG|Sevelamer carbonate|tablets for oral administration.
41016535|NCT06663163|OTHER|Observation|This study was an observational study without intervention
41337831|NCT02244229|DRUG|Placebo|
41337832|NCT04447911|DRUG|Empagliflozin 25 MG|Empagliflozin 25mg per os once daily for 30 days
41337833|NCT04447911|DRUG|Placebo|Placebo per os once daily for 30 days
41337834|NCT02177812|DRUG|GSK2879552|GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
41337835|NCT02177812|DRUG|ATRA|ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing
41337836|NCT00809055|DRUG|Caffeine citrate|Caffeine to be administered as outlined to compare efficacy of different dosages.
41485950|NCT00004997|DRUG|Leucovorin|
40819336|NCT01549886|DRUG|Moxtezafin Gadolinium|"Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m\^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily"
41337837|NCT00688623|DRUG|Everolimus|Everolimus 5 mg tablets were supplied in blister packs
41337838|NCT04306757|DEVICE|Evone|Airway ventilation device
41337839|NCT04306757|DEVICE|Primus|Airway ventilation device
41337840|NCT06304857|DRUG|Dapagliflozin|10 mg tablet q.d
41337841|NCT06304857|DRUG|Placebo|tablet matching dapagliflozin 10 mg q.d
41337842|NCT05885568|BIOLOGICAL|blood sampling|Blood sampling from healthy volunteers
41337843|NCT05885568|OTHER|drone transportation|drone transportation
41485951|NCT03754374|OTHER|access to healthcare|use or non-use of dedicated health facilities
40819337|NCT01549886|DRUG|Rituximab|Day 1 and Day 8: Rituximab 250 mg/m\^2 intravenous infusion
40819338|NCT05437562|OTHER|Ewing Amputation|All patients will receive Ewing Amputation to test feasibility.
41337844|NCT05885568|OTHER|car transportation|car transportation
41337845|NCT05059847|OTHER|Training|Training routine assigned by randomized chart
41337846|NCT04259060|DRUG|Hydroxocobalamin with Butyrate|"In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2."
41337847|NCT04259060|DRUG|Placebo with Butyrate|"In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day."
41337848|NCT00001890|DRUG|Estrogen therapy|
41337849|NCT03125161|DRUG|HAI|HAI
41337850|NCT03125161|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
41337851|NCT04276779|OTHER|Alcohol administration|Participants in the alcoholic beverage group will be provided a dose of 95% alcohol (0.99g/kg for males and 0.90 g/kg for females body weight) distributed in two equally spaced beverages (mixed with orange juice 1:5 ratio). This dose will produce a breath alcohol content ranging between .08-.10.
41337852|NCT04276779|OTHER|Placebo administration|Individuals in the placebo condition will receive orange juice with 4 ml of alcohol layered on top of the juice. Ethanol will be sprayed on the rims of the glasses.
41337853|NCT04276779|BEHAVIORAL|Positive mood induction|Participants will be randomized to either positive mood induction procedure. Both conditions involve listening to music that reliably induces positive mood, while simultaneously reading self-referent statements that also induce either positive mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
41337854|NCT04276779|BEHAVIORAL|Negative mood induction|Participants will be randomized to either negative mood induction procedure. Both conditions involve listening to music that reliably induces sad mood, while simultaneously reading self-referent statements that also induce either sad mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
40819339|NCT06604910|DIETARY_SUPPLEMENT|branched chained amino acid|patients undergoing branched chained amino acid
40819340|NCT01888536|DRUG|Limaprost|
40819341|NCT01888536|DRUG|Pregabalin|
40819342|NCT01888536|DRUG|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
40819343|NCT01888536|DRUG|Placebo(for Limaprost)|mimic Limaprost tablet
40819344|NCT01783314|PROCEDURE|MRI of liver|MRI of liver with intravenous gadoxetate disodium
41485952|NCT03976583|DRUG|Cpp-Acp|Remineralising agent
41485953|NCT03976583|OTHER|Pearl powder|Natural product
41485954|NCT04597294|COMBINATION_PRODUCT|FLOT + HIPEC + Surgery|HIPEC with irinotecan after 4 doses of preoperative FLOT chemotherapy
41485955|NCT04597294|COMBINATION_PRODUCT|FLOT + Surgery|Perioperative FLOT chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery
41485956|NCT02160275|DEVICE|Artificial Pancreas (Inreda Diabetic BV)|Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype
41485957|NCT02160275|DEVICE|Insulin pump therapy|Patients' own insulin pump with fast-acting insulin analog
41485958|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
41337855|NCT03788967|DRUG|TBPM-PI-HBr|TBPM-PI-HBr tablets administered orally.
40819345|NCT00688324|DRUG|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
40819346|NCT04251767|OTHER|washed microbiota transplantation|"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.~Dose and frequency: 5u, once."
41337856|NCT03788967|DRUG|Ertapenem|Antibiotic Therapy for cUTI.
41337857|NCT03788967|DRUG|Dummy Infusion|Dummy intravenous infusion.
41337858|NCT03788967|DRUG|Dummy tablets|Dummy tablets orally.
41337859|NCT01598207|DRUG|Marinol|5mg BID, orally for 1 month
41485959|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
41485960|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
41485961|NCT04498741|DRUG|Tacrolimus|Subjects will receive tacrolimus once daily on Day 1 and Day 24
41485962|NCT04498741|DRUG|Dabigatran|Subjects will receive dabigatran once daily on Day 1 and Day 13
41485963|NCT04498741|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Day 1 and Day 13
41485964|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
41485965|NCT04498741|DRUG|Midazolam|Subjects will receive midazolam once daily on Day 1 and Day 16
41485966|NCT04476719|DRUG|ATAFENOVIR 200 MG KAPSUL|A 200 mg capsule 0ral administration with 240 ml water
41485967|NCT04476719|DRUG|ARBIDOL 100 MG KAPSUL|Two 100 mg capsules will be administrated with 240 ml water orally.
41485968|NCT00601666|DRUG|Zolpidem|
41485969|NCT01103622|DRUG|AZD1656|Oral tablet bd, step-wise increased dosage
41485970|NCT01103622|DRUG|Digoxin|Oral tablet od on Day 4
41156683|NCT06646939|BEHAVIORAL|PT and OT with a simulated environment|Upon admission to the inpatient rehabilitation unit, participants will undergo a physical and occupational therapy evaluation. The evaluations will include the outcome measures chosen to track for this study (10-meter walk test and Quality Indicators). If a patient meets inclusion/exclusion criteria, informed written consent will be obtained. Throughout the patient's stay, therapists will have the opportunity to perform community integration treatments using the simulated environment. This could include activities such as negotiating a curb, crossing a street, or shopping at a marketplace. The therapist will document the amount of time (units billed) spent performing these interventions. The research investigators will not act as a patient's therapist throughout their admission.
41485971|NCT01103622|DRUG|Placebo|Oral tablet bd, step-wise increased dosage
41485972|NCT01631175|BEHAVIORAL|psychosocial treatment|psychosocial treatment, verbal therapy, relaxation exercises
41156684|NCT06608368|DRUG|Test Dentifrice (Sensodyne Repair and Protect Original Mint)|Dentifrice containing 5% w/w NovaMin (Calcium Sodium Phosphosilicate) and 1040 ppm fluoride as sodium fluoride.
41156685|NCT06608368|DRUG|Positive Control Dentifrice (Sensodyne Fresh Mint)|Dentifrice containing 5% w/w KNO3 and 1150 ppm fluoride as sodium fluoride.
41156686|NCT06608368|DRUG|Reference Dentifrice (Crest Cavity Protection Regular)|Dentifrice containing 1100 ppm fluoride as sodium fluoride.
41156687|NCT03425461|BIOLOGICAL|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
41156688|NCT03425461|BIOLOGICAL|Ipilimumab|Given IV
41156689|NCT03425461|OTHER|Laboratory Biomarker Analysis|Correlative studies
41156690|NCT03425461|BIOLOGICAL|Nivolumab|Given IV
41485973|NCT01140490|PROCEDURE|Sub-total Parathyroidectomy|Sub-total Parathyroidectomy
41485974|NCT05556070|OTHER|Arm 1|: Local retailer produce vouchers ($25 value) will be distributed to the families biweekly over a 32-week period for a total of 16 vouchers. The vouchers can be redeemed for fresh produce at the grocery store that issued the vouchers.
41485975|NCT05556070|OTHER|Arm 2|Boxes of fresh fruits and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks.
41485976|NCT05556070|OTHER|Arm 3|subjects in this arm will receive the usual standard of care at the clinic for the study period
41485977|NCT05556070|OTHER|Brighter Bites app|"Participants in Arms 1 and 2 will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
41485978|NCT00891748|GENETIC|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
41485979|NCT03872401|DRUG|Evolocumab|Administered subcutaneously using an autoinjector pen.
41485980|NCT03872401|DRUG|Placebo|Administered subcutaneously using an autoinjector pen.
41485981|NCT00633516|DEVICE|Optical Spectroscopy|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
41156691|NCT03425461|OTHER|Pharmacological Study|Correlative studies
41156692|NCT02962063|BIOLOGICAL|durvalumab|Durvalumab can be given irrespective of CBC, at the discretion of the treating physician.
41156693|NCT02962063|DRUG|carboplatin AUC 2/paclitaxel|
41337860|NCT01598207|DRUG|Placebo|5mg BID, orally for 1 month
41337861|NCT01085604|OTHER|Core Stabilization|"The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.~Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
41337862|NCT03636880|BEHAVIORAL|Brief treatment for Insomnia|This behavioral intervention provides participants with an individualized plan to modify sleep patterns contributing to insomnia, as well as education about sleep hygiene and habits that help and hurt sleep.
41337863|NCT03636880|BEHAVIORAL|Sleep Monitoring|This intervention involves using sleep diaries to track daily aspects of sleep, including bed time, wake time, hours of sleep, nighttime awakenings, daytime naps, and sleep quality.
41337864|NCT02877316|OTHER|MYPLAN-safety plan as an application for smart phones|MYPLAN app as a integral part of the standard treatment
41337865|NCT02877316|OTHER|safety plan on paper|Standard treatment with safety plan on paper
41337866|NCT01759628|DRUG|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
41337867|NCT03945201|OTHER|Virtual walking trails|During time on the treadmill, participants walk in front of Bionautica Trails, the virtual walking trails created by Plas.md. Participants can select between seven trails including various nature themed trails and a space setting. While walking, participants wear wireless headphones that provide audio of cardiac rehabilitation education at random intervals. These education pieces cover six categories of information: Understanding Your Heart Condition, Diet, Exercise, Medication, Managing Risk Factors, and Emotional Health.
41485982|NCT05314114|PROCEDURE|No axillary surgery|No axillary surgery
41485983|NCT02757976|DEVICE|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave \> 7 mV, pacing threshold \< 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
41485984|NCT02757976|DEVICE|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
41485985|NCT05280132|PROCEDURE|Personalized antibiotic treatment|Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.
41485986|NCT05280132|OTHER|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
41485987|NCT01939925|OTHER|New plain language summary format|New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
41485988|NCT01939925|OTHER|Current plain language summary format|Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
41485989|NCT05841446|DRUG|test apixaban tablets|specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China
41485990|NCT05841446|DRUG|reference apixaban tablets|specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA
41485991|NCT02444793|DRUG|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
41485992|NCT02444793|DRUG|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
41156694|NCT02962063|RADIATION|External beam radiation (EBRT)|Radiation will be delivered starting on a Monday or Tuesday between Days 29-30, based on the first induction durvalumab dose administered on Day 1. Patients will be treated 5 days/week at 1.80 Gy/day, to a total planned dose of 41Gy in 23 fractions. Induction Day 15 has a -1/+2 day window, and Day 29 has a -1/+1 day window.
41156695|NCT02962063|PROCEDURE|esophagogastrectomy|Patients undergo surgical resection 6-10 weeks after the completion of chemoradiation.
41156696|NCT02962063|DRUG|Tremelimumab|Tremelimumab will be administered once at 300 mg on Day 29 prior to chemoradiation only.
41485993|NCT04205370|DEVICE|Deactivated Pregnancy Coach|Naturalistic monitoring of their typical sleep patterns and behaviors
41156697|NCT06435624|DEVICE|intelligent rehabilitation robot training system|"Using an intelligent rehabilitation robot training system to simulate a real work environment, providing functional oriented treatment for stroke patients and improving upper limb motor function.~The instrument used is the Burt upper limb robot training system produced by Estun Medical Co., Ltd."
41485994|NCT04205370|DEVICE|Active Pregnancy Coach|The Pregnancy Coach will begin to deliver alerts when supine sleep is detected. Sleep metrics will be visible on the smartphone app.
41485995|NCT04442490|DRUG|SAGE-217|SAGE-217 oral capsules.
41485996|NCT04442490|DRUG|Placebo|SAGE-217 matched-placebo oral capsules.
41485997|NCT01182558|OTHER|Hypothenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
41485998|NCT01182558|OTHER|Thenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
40819347|NCT04251767|OTHER|placebo|"Placebo (edible suspension of the same color as the washed microbiota suspension，5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.~Dose and frequency: 5u, once."
41485999|NCT01182558|OTHER|EDB muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
41486000|NCT01182558|OTHER|Relaxation of muscle|The muscle on the opposite side will be maintained at rest.
40819348|NCT04404036|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
40819349|NCT00798070|DRUG|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
40819350|NCT00798070|DRUG|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
41337868|NCT03945201|OTHER|Standard of care|"Participants receive normal standard of care cardiac rehabilitation, completing multiple pieces of exercise equipment at increasing intervals according to the Jefferson Methodist Cardiac Rehabilitation program's protocols. Participants are given the option to use the treadmill for up to 15 minutes."
41337869|NCT00962468|OTHER|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
41486001|NCT05418166|DRUG|Evolocumab|evolocumab 140mg subcutaneous injection after regular take Ticagrelor and Aspirin for 5 days.
41486002|NCT04053465|OTHER|Heat acclimation|14 days of aerobic exercise in a hot environment
41486003|NCT04053465|OTHER|Exercise in a cool environment|14 days of aerobic exercise in a cool environment
40819351|NCT03972345|DRUG|Norditropin® FlexPro®|Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
41156698|NCT06435624|OTHER|repetitive facilitative exercise|Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
41156699|NCT06435624|OTHER|conventional therapy|Basic training, including passive joint movement and activities of daily living exercise.
41156700|NCT03703856|DRUG|Memantine|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of early auditory information processing memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
41156701|NCT03703856|DRUG|Placebo|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
41156702|NCT06645938|DRUG|single dose of vepdegestrant as tablet formulation (Treatment A)|Single 200 mg dose of vepdegestrant registrational (200 mg strength) tablet.
41486004|NCT00770536|DRUG|A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
41486005|NCT00770536|DRUG|A3: AMG 386 15mg/kg + Liposomal doxorubicin|A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
41337870|NCT03597503|DRUG|SPN-810|Flexible dose
41337871|NCT03597503|DRUG|Placebo|Placebo
41337872|NCT06086457|RADIATION|Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 50Gy in 25 fractions to planning gross tumor volume (PGTV) with involved site included.
41337873|NCT06086457|DRUG|TP or PF regimen depended on investigator's choice.|A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.
41486006|NCT00770536|DRUG|B1: AMG 386 10 mg/kg + Topotecan|B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
41486007|NCT00770536|DRUG|B3: AMG 386 15mg/kg + Topotecan|AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
41486008|NCT00324649|DRUG|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
41486009|NCT00324649|DRUG|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
40819352|NCT05614908|OTHER|11 week restrictive regime|"As part of standard care at AUH (until May 2024), patients are immobilized in scotch cast with the foot in plantarflexion during week 0-4. Next, the scotch cast is replaced by a ROM-WALKER in plantarflexion for the next 7 weeks (week 5-11 after injury). The ROM-WALKER is gradually corrected from 30 degrees plantarflexion to 0 degrees. No weight bearing or exercises is allowed and they are not allowed to remove the ROM-WALKER during week 0-10. At week 11, the patients are allowed weight bearing up to 30 kg, after which there is no longer weight bearing restrictions.~From week 12 they are allowed full weight bearing with a 1 cm heel lift i their shoes."
40819353|NCT05614908|OTHER|8 week liberal regime|"The patients are treated with a walker orthosis with 3 wedges in plantarflexion, during week 1-2 with no weight bearing and no exercises. After 2 weeks, the tendon will be examined, and if no defect in the tendon is detected by palpation, the patients will start partially weight bearing in week 3-5, and full weight-bearing week 6-8. They are instructed in unloaded exercises for the calf and anklejoint after 2 weeks, and loaded exercises (elastic) after 5 weeks, with a maximum position til 0 degrees in the anklejoint. Balancetraining and stationary bike training after 7 weeks. The wedges are removed one by one after 3, 5 and 7 weeks, respectively.~If there is a palpable defect in the tendon after 2 weeks, the patient must wait 1 week with partially weight bearing and exercises, and remove the wedges at 4, 5 and 7 weeks after the initiation of treatment.~From week 9, walking i their shoes with a 1 cm heel lift."
41016536|NCT06662435|BEHAVIORAL|GYNCOG|"Participants in the GYNCOG arm will be asked to participate in a home-based cognitive training program utilizing BrainHQ. Participants will be instructed to use the Brain HQ app for approximately 2.5 hours per week. Patients will be provided with a calendar to help keep track of daily BrainHQ use, including the number of exercises completed and the amount of time spent on the app per day.~Patients will be asked to undergo the exercises that target the speed and accuracy of information processing. Examples of the exercises include:~Double Decision: This exercise tests your ability to quickly identify and choose between two options.~Eye for Detail: It challenges participants to spot small differences between two similar images.~Participants will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week (i.e., 2.5 hours per week) for 10 weeks, for a total of approximately 25 hours."
41016537|NCT06663358|DRUG|Pegunigalsidase-alfa|Administered via intravenous (IV) infusion under conditions of routine clinical care
41156703|NCT06645938|DRUG|single dose of vepdegestrant as tablet formulation (Treatment B)|Single 200 mg dose of vepdegestrant variant (200 mg strength) tablet.
41337874|NCT06086457|BIOLOGICAL|PD-1 inhibitor|Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or discontinuation for administrative reasons (up to 35 cycles).
41337875|NCT02685111|DRUG|Filgrastim|Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.
41337876|NCT02685111|DRUG|Peg-filgrastim|Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
41337877|NCT04510402|DRUG|Povidine iodine nasal swabs|Daily versus twice daily nasal application
41337878|NCT01721629|PROCEDURE|Sudden wean of nasal CPAP|
41337879|NCT01721629|PROCEDURE|Gradual wean of nasal CPAP|
41337880|NCT01934868|DRUG|prolotherapy solution of 20% dextrose|After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
41337881|NCT01934868|DRUG|Epidural Steroid Injection|Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
41337882|NCT06349343|BIOLOGICAL|CD19/BCMA Hi-TCR-T cell therapy|CD19/BCMA Hi-TCR-T cell will be infused intravenously at the dose of 1×10\^6 cells/kg.
41486010|NCT06493149|OTHER|Massage therapy|Participants receive a Swedish massage based on the tensegrity principle.
40819354|NCT05499455|DEVICE|Positional Sleep Belt|Rematee Positional Sleep Belt
41156704|NCT01954758|OTHER|personalized Embryo Transfer (pET)|
40819355|NCT05499455|DEVICE|Control|Control Device
40819356|NCT03687593|DEVICE|Legion™ CR Oxinium and CoCr Femoral Implants combined with Legion™/Genesis™ II XLPE High Flex Tibial Inserts|Single arm study, all subjects received the Legion™ CR Femoral Oxinium and CoCr Implant with Legion™/Genesis™ II XLPE Hi-flex Tibial Insert
41156705|NCT01954758|OTHER|Frozen Embryo Transfer (FET)|
41156706|NCT01954758|OTHER|Fresh Embryo Transfer (ET)|
41337883|NCT01376388|DRUG|GSK573719/GW642444 Inhalation Powder|GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
41337884|NCT06110104|OTHER|routine physiotherapy program for knee osteoarthritis|The Routine physiotherapy program comprises a combination of closed kinetic chain and open kinetic chain exercises, including straight leg raising, isometric quadriceps, isometric hip adduction, terminal knee extension, semi-squat, and leg press for 6 weeks.
41486011|NCT06461481|DEVICE|Withings Scanwatch|Data captured by the used smartwatches (Withings Scanwatch) includes activity-related data (step count, minutes in certain intensity levels), basic cardiovascular measurements such as heart rate, and sleep-related data (total time asleep, sleep efficiency and quality etc.).
41016538|NCT06664216|BEHAVIORAL|incorrect trocar placement marks.|Participants in the experimental group will perform trocar placements on laparoscopic models that have been pre-marked with incorrect insertion sites by previous participants. These marks simulate procedural steps or anatomical landmarks that are intentionally incorrect.
41016539|NCT06662617|OTHER|modified thoracoabdominal nerve block through perichondrial approach|After the patient fell asleep, surgery was not yet started. Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
41016540|NCT06662617|OTHER|Transversus Abdominal Plane block|After the patient fell asleep, surgery was not yet started. Following sterile conditions for bilateral TAP block application, USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline . After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
41486012|NCT03858738|DEVICE|Thermographic breast examination performed by Braster device|Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.
41486013|NCT01401049|DRUG|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
41016545|NCT06662513|OTHER|No Intervention: Observational Cohort|No intervention - retrospective observational study
41016546|NCT06663306|DRUG|Pemetrexed|Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks
41016547|NCT06663306|DRUG|Bevacizumab|Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.
41016548|NCT06664242|DEVICE|Placebo|these patients will be subjected to the same usual routine of pharmacological analgesia, consisting of the administration of 1g of dipyrone at the discretion, with escalation to tramal (dose) and physiotherapy in the hospital ICU, in addition to an application of TENS, with the device turned on, with programming on channels that are not connected to the patients, so as to generate visual and auditory feedback.
41016549|NCT06664242|DEVICE|TENS low frequence group|Patients in this group will undergo the hospital usual analgesia and physiotherapy routine, in addition to conventional TENS with a low frequency of 5 Hz and a pulse width of 250 µs.
41016550|NCT06664242|DEVICE|Conventional TENS|In this group, patients will undergo the usual routine of analgesia and hospital physiotherapy, in addition to TENS with a frequency of 140 Hz, pulse width of 50 µs.
41156707|NCT04615715|BEHAVIORAL|CMV Risk-Reduction Intervention|CMV Risk-Reduction Intervention
41156708|NCT04615715|BEHAVIORAL|Stress Reduction Messaging|Stress Reduction Messaging
41486014|NCT01401049|DRUG|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
41486015|NCT02900963|OTHER|weekly assessment of patient's weight|Biological assessment to determine biological and inflammatory status Quality of life questionary
41486016|NCT04230694|DEVICE|Dexcom Generation 6 CGM (Dexcom Gen6) device|Standing orders for blood sugars less than 100 will allow for administration of glucose replacement in the intervention group based on Dexcom Gen6 readings.
41486017|NCT00640679|DRUG|Abrupt Clopidogrel Interruption|Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
41016551|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 2 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
41156709|NCT06137144|DRUG|AZD3470|AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
41156710|NCT05589584|DRUG|N acetyl cysteine with weight reduction|high dose 2400mg/day
41156711|NCT06644222|BEHAVIORAL|AIRROSTI exercises|Group A will receive AIRROSTI exercises for 45 minutes / one session daily for five days per week
41156712|NCT06644222|BEHAVIORAL|Thera band exercises|Group B will receive Thera band exercises for 45 minutes/one session per day for five days per week.
41156713|NCT00187135|DRUG|Fentanyl|"1. Fentanyl - 1 mcg/kg in 3 ml normal saline~2. Fentanyl - 0.5 mcg/kg in 3 ml normal saline"
41337885|NCT06110104|OTHER|Retro-walking program|Retro-walking program is about 10 min of supervised retro walking training 3 days a week for 6 weeks at their comfortable walking speed . The participants will be instructed to gradually increase their walking time up to 30 min over the 6-week period.
41486018|NCT00640679|DRUG|Clopidogrel Tapering|Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
41486019|NCT02119117|DIETARY_SUPPLEMENT|CoQ10|This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF
41486020|NCT02119117|DIETARY_SUPPLEMENT|Placebo|This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
41486021|NCT01995266|DRUG|Asunaprevir|
41486022|NCT01995266|DRUG|Daclatasvir|
41486023|NCT02899832|DEVICE|NIRS|Near Infra Red Spectroscopy
40819357|NCT04266964|PROCEDURE|Manual examination|"With the patient in a supine position, squeeze the skinfold between your thumb and pointfinger on the inner aspect of the middle third of the thigh and on the inner aspect of the middle third of the calf.~Place your hand under the proximal calf and the heel and move the leg into maximum flexion at the hip and knee joints. After the response, if any, is completed, move the limb back into full extension. Each of these movements lasts for one second."
40819358|NCT04675658|BEHAVIORAL|CBPA + family support|Classroom Based Physical Activity + family support as described in the Arm
41486024|NCT02637375|DRUG|Ganetespib|
41486025|NCT02637375|DRUG|Paclitaxel|
41486026|NCT02637375|DRUG|Doxorubicin|
41486027|NCT02637375|DRUG|Cyclophosphamide|
41486028|NCT06002971|DEVICE|Blood pressure measurement|Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.
41486029|NCT01246622|DRUG|cytarabine|Given IV
41486030|NCT01246622|DRUG|lenalidomide|Given PO
41486031|NCT06358755|DEVICE|Defocus Incorporated Multiple Segments lenses|Defocus Incorporated Multiple Segments lenses that provide optical defocus for myopia control will be given to this group of participants.
41486032|NCT06358755|DEVICE|single vision spectacle lenses|Single vision spectacle lenses will be given to this group of participants.
41486033|NCT06358755|DRUG|Low dose atropine|0.01% atropine administrated twice per day (1 drop in the morning and 1 drop at night before bedtime) will be given as intervention.
41486034|NCT03596931|DRUG|Statins (Cardiovascular Agents)|Prescribed with statins
41486035|NCT03356028|BEHAVIORAL|Child and adolescent psychiatry and Epidemiology|psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
41486036|NCT03356028|OTHER|salivary biological collection|Saliva sampling will be done using a specific kit
41486037|NCT03356028|BEHAVIORAL|qualitative analysis of the discourse|two semi-structured interviews, the first with the teenager alone, the second with the lone parents
41486038|NCT03356028|BEHAVIORAL|Parenthood|Parenting Sense of Competence (PSOC) questionnaires completed online.Two visits will be realized: a first in the month preceding the start of the trial and a second in the month following the end of the trial
41486039|NCT03356028|BEHAVIORAL|Cognitive alterations|Episodic memory will be assessed using Grober and Buschke. The evaluation of the cognitive alterations will include two stages: a first in the month preceding the start of the trial and a second in the month following the end of the trial. For child and parents
41486040|NCT03356028|BEHAVIORAL|Impact on schooling|collect of several data about the number of absences of the child, the number of exclusions and hours of detention of the child, as well as the school reports of the child
41486041|NCT03356028|BEHAVIORAL|Sleep disorders and associated somatizations|Evaluation of sleep disorders and associated somatizations by connected watche and sleep questionnaire
40819359|NCT04675658|BEHAVIORAL|CBPA|Classroom Based Physical Activity
40819360|NCT02813096|DRUG|folfox4 chemotherapy regimen|"Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
40819361|NCT02813096|OTHER|Placebo|"Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
41486042|NCT03605654|BIOLOGICAL|MDR-102|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
41486043|NCT03605654|DRUG|Immunosuppressive Agents|Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study
40819362|NCT05137197|DEVICE|Predictix Genetics Antidepressant|Predictix Genetics Antidepressant (PGA) is a software tool that is intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with MDD.
41486044|NCT00474851|DRUG|Norethindrone acetate + estrogens|Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
41486045|NCT00474851|DRUG|norethindrone acetate + placebo|norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
41486046|NCT01792219|OTHER|Interprofessional collaboration in health care module|An educational module
41486047|NCT04156620|DRUG|Secukinumab|The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)
41486048|NCT04156620|DRUG|Placebo|The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
41486049|NCT01828710|DIETARY_SUPPLEMENT|Myo-inositol normospermic|4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.
41486050|NCT01828710|DIETARY_SUPPLEMENT|Myo-inositol OAT|B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months
41486051|NCT01828710|DIETARY_SUPPLEMENT|Folic Acid normospermic|Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.
41486052|NCT02017548|BEHAVIORAL|Life-extension default advance directive|
41486053|NCT02017548|BEHAVIORAL|Comfort default advance directive|
41486054|NCT00359242|BEHAVIORAL|Infant Sleeping and Soothing|Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.
41486055|NCT00359242|BEHAVIORAL|Repeated Food Exposure|Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
41486056|NCT03728218|DEVICE|Contact lenses (Orthokeratology)|Contact lenses
41486057|NCT03728218|DEVICE|Contact lenses (Soft Multifocal)|Contact lenses
41486058|NCT03737565|DEVICE|Optimax stent®|Percutaneous coronary intervention with Optimax stent®
41016552|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 4 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
41016553|NCT06662500|DEVICE|Intravascular Lithotripsy|The Shockwave Intravascular Lithotripsy (IVL) System with the Shockwave Javelin Coronary Catheter is intended to treat calcified stenosis, including calcified stenoses that are anticipated to exhibit resistance to balloon crossing, full dilatation or subsequent uniform coronary stent expansion.
41016554|NCT06663332|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
41016555|NCT06663137|DRUG|NDV01 intravesical controlled release formulation of gemcitabine and docetaxel|NDV01 is administered intravesically using a catheter.
41016556|NCT06664515|PROCEDURE|Ciro Costagliola|invert flap tecnique
41337886|NCT06110104|OTHER|whole body vibration training|whole body vibration is 3 days per week for 6 weeks. During the training, the participants will perform static squat training barefoot on the platform with bent knees (30° and 60°). The distance between the feet was consistent with the shoulders. the duration time, sets and total time will be increased progressively over the 6-week.
41486059|NCT01974336|DRUG|ursodeoxycholic acid|
41486060|NCT03569150|OTHER|Cultural adaptation/implementation COMFORT CC|The COMFORT Communication Curriculum (CC) will be culturally-adapted for 2 Native American reservation communities. The investigators will then implement the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities by training interdisciplinary healthcare professionals to conduct culturally-respectful and relevant Advance Care Planning. The investigators will then conduct a cluster-assigned pilot, wait-list controlled trial of the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 Native Americans completing Advance Care Planning with a trained healthcare professional and 30 Native Americans receiving usual care.
41486061|NCT00667810|DRUG|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
41486062|NCT00667810|DRUG|bapineuzumab|Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
41486063|NCT00667810|DRUG|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
41486064|NCT02637921|OTHER|Hypoxia|21 days confinement in normobaric hypoxic (FiO2 = 14%)
41486065|NCT02637921|OTHER|Ambulatory|Participants hava a standardized activity level throughout the intervention
40819363|NCT03236259|DIETARY_SUPPLEMENT|Brainport high dose|berry extract, high dose. Daily ingestion of capsule
40819364|NCT03236259|DIETARY_SUPPLEMENT|Brainport low dose|Berry extract, low dose. Daily ingestion of capsule
40819365|NCT03236259|DIETARY_SUPPLEMENT|Placebo|Maltodextrin. Daily ingestion of capsule
40819366|NCT03384563|DRUG|Dexmedetomidine|Dexmedetomidine 9 arms
40819367|NCT00562497|DRUG|Prochymal®|Prochymal® intravenous infusion.
40819368|NCT00562497|OTHER|Placebo|Placebo-matching Prochymal® intravenous infusion.
40819369|NCT00562497|OTHER|Corticosteroid|Administration will be intravenously as prescribed by the caregiver.
41486066|NCT02637921|OTHER|Normoxia|21 days confinement in normobaric normoxic (FiO2 = 21%) environment
41486067|NCT02637921|OTHER|Bed Rest|Participants remain on supine bed rest throughout the intervention
41486068|NCT02637921|OTHER|Standardised nutritional intake|Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
41486069|NCT03649412|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.
40819370|NCT05925452|DRUG|GenaKumab|GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w
40819371|NCT02108717|DEVICE|Remote CT reading using the iPhone|
40819372|NCT02108717|DEVICE|CT reading using LCD monitor|
40819373|NCT05921695|DRUG|Normal Saline infusion and Ringer lactate infusion|The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.
41156714|NCT00187135|DRUG|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
41337887|NCT03838380|OTHER|Smartphone application|Mobile management group participants were given monitoring system devices including a glucometer with Bluetooth connectivity and an accelerometer to detect physical activity level. The mobile phone application specifically designed for this study was installed at enrollment for the mobile management group to collect clinical data and messages from the patients. The application consisted of four sections: clinical data, nutrition and diet, medication, and messaging system and information. Patients allocated to the mobile management group recorded their blood glucose level and diet via the smartphone application, and health care providers regularly scanned clinical data and messages from patients and sent return messages with tailored medical and nutritional guidance.
41156715|NCT00187135|DRUG|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
41486070|NCT03649412|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
40819374|NCT04801238|PROCEDURE|LCBDE + LC|"Experimental group: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC) is performed under full anaesthesia. Once the dissection has exposed the cystic a clip or ligature is placed peripherally on the cystic duct. Through an incision in the duct central to the clip or ligature a cholangiogram catheter is introduced into the cystic duct and the cholangiogram is completed.~After identification of the bile duct stones and anatomy, a cholangioscope is introduced through the duct incision into common bile duct. The stones are identified visually and removed by Dormia basket. If the stones are very large, they may be partitioned mechanically or by electrohydraulic lithotripsy. In the presence of CBDS wedged in the papilla these stones will be removed and a secondary cholangiogram will be performed. Subsequently, the cholangioscope is taken out. Then the cystic duct is divided and the gallbladder is dissected out from the liver by hook cautery and removed."
40819375|NCT04801238|PROCEDURE|ERC + LC|Control intervention: (First step) Endoscopic retrograde cholangiography (ERC) is routinely performed in sedation but or in full anaesthesia. ERC is performed with the patient in the supine position. The endoscope is passed down to the second part of the duodenum where the papilla is identified. Cannulation of the papilla and the common bile duct is performed with a papillotome and a guidewire. A cholangiography will confirm the presence, location and size of the CBDS and aims in further choice of extraction method. Stones can be extracted by papillotomy and by either balloon or by a basket. Additional balloon dilation of the papilla, or lithotripsy may be required. If stone extraction is incomplete or if the conditions are unclear a temporary common bile duct stent is placed which has to be removed with additional ERC after 1-2 months (Second step) laparoscopic cholecystectomy is performed after 2-14 days
40819376|NCT00628472|DRUG|botulinum type a|12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort
40819377|NCT06146751|DRUG|Superparamagnetic Iron Oxide Nanoparticles|Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
40819378|NCT01817699|OTHER|High Hb target|"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."
40819379|NCT01817699|DIETARY_SUPPLEMENT|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
40819380|NCT04323137|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
40819381|NCT04323137|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
40819382|NCT04323137|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
40819383|NCT00301600|DRUG|Mycophenolate mofetil|MMF,1.0g/d
40819384|NCT00798629|BIOLOGICAL|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
40819385|NCT02901587|DRUG|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
40819386|NCT02901587|DRUG|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
40819387|NCT02901587|DRUG|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
40819388|NCT06292754|PROCEDURE|magnesium pin in additional to the suture anchor|magnesium pin in additional to the suture anchor used routinely in clinical practice
40819389|NCT06292754|PROCEDURE|routine suture anchor|routine suture anchor for the treatment-as-usual
40819390|NCT03828422|DIAGNOSTIC_TEST|imaging|
40819391|NCT01426919|OTHER|Head CT scan and blood draw within 12 hours of injury|
40819392|NCT05783310|BEHAVIORAL|Psychoeducation Intervention|The participants in the intervention group will receive six sessions of psychoeducation intervention, lasting 60 minutes per session for six weeks. The intervention will be provided face-to-face using lectures and discussions. There will also be sharing of experience by the caregivers of children with cancer and a sharing by a caregiver of a childhood cancer survivor. The group format has been chosen to enable caregivers to offer emotional support to each other. The intervention has four components: cancer education, coping skills training, stress management techniques training, and psychological support. The intervention group will also receive the usual care.
41016559|NCT06664411|DRUG|Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy|Patients were treated by Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg/m2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy
41016560|NCT06663228|DIAGNOSTIC_TEST|MMS|miniature mass spectrometry with AI assistance
41016561|NCT06663475|BEHAVIORAL|a video-based health education about smoking cessation for expectant fathers|Tailored for expectant fathers, this smoking cessation health education information will be developed based on transtheoretical model to motivate a quit attempt and maintain abstinence by using videos.
41016562|NCT06663475|BEHAVIORAL|Usual Care|general health education about hazards of smoking for expectant fathers in obstetric clinic
41016563|NCT06664632|BEHAVIORAL|Exp|"Participants in this group will receive treatment using the Knee Sync Partner, a novel portable device designed to provide electrical traction and stimulation specifically for the knee joint.~controlled mechanical traction to the knee joint to reduce joint contact pressure, enhance synovial fluid flow, and increase joint space. This is expected to alleviate pain and improve mobility."
41156716|NCT00187135|DRUG|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
40819394|NCT03471338|BEHAVIORAL|Cognitive rehabilitation|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): The patient performs the program (PRESCO software) on his computer autonomously at home at a rate of 3 sessions per week. A neuropsychologist performs at-home visits and weekly phone meetings to train the patient to the software, to encourage him to do exercises and to answer any software use-related questions.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
41156717|NCT06612424|DRUG|ANTERİOR QUADRATUS LUMBORUM BLOCK|In the Quadratus Lumborum block group, Participants will be placed in the lateral decubitus position. A convex ultrasound probe will be placed in sterile conditions along the midaxillary line, in the subcostal area above the iliac crest, to visualize the quadratus lumborum and psoas major muscles, as well as the L4 vertebral transverse process. Using an in-plane technique, a 22G, 100 mm peripheral block needle will be advanced anterior to the quadratus lumborum muscle and into the subfascial space between the quadratus lumborum and psoas major muscles. After confirming the correct location with hydrodissection, 25 mL of 0.25% bupivacaine will be injected slowly, observing the fascial displacement on ultrasound. The same procedure will be repeated on the contralateral side.
41337888|NCT02792660|DEVICE|Injeq IQ-Needle|Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
41337889|NCT04118062|BEHAVIORAL|Questionnaires|Questionnaires
41337890|NCT04118062|BEHAVIORAL|Semi-structured individual interviews|Semi-structured individual interviews
41337891|NCT04118062|OTHER|Focus Group|Focus Group
41337892|NCT04118062|OTHER|DELPHI Consensus Method|DELPHI Consensus Method
41337893|NCT02565277|BIOLOGICAL|Influenza Vaccine|
41337894|NCT02565277|DRUG|Placebo|
41337895|NCT03383068|DRUG|Acarbose 100 MG|for metformin uneffective subjects, using acarbose for 3 months
41337896|NCT03383068|DRUG|Exenatide|for metformin uneffective subjects, using Exenatide for 3 months
41337897|NCT03383068|DRUG|Orlistat|for metformin uneffective subjects, using Orlistatfor 3 months
41337898|NCT03383068|DRUG|Metformin|metformin effective subjects,act as control group
41337899|NCT00633048|DRUG|NSA-789|
41337900|NCT00633048|DRUG|placebo|
41337901|NCT05255536|PROCEDURE|Serratus Anterior Plan Block with 20 ml|Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.
41337902|NCT05255536|PROCEDURE|Serratus Anterior Plan Block with 30 ml|Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.
41337903|NCT04655924|DEVICE|Clinical Decision Support System|Clinical Decision Support System using Measurement-Based Care and Digital Decision Support Platform
41337904|NCT04107636|PROCEDURE|Vacuum assisted biopsy|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (\<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location.
41337905|NCT04107636|PROCEDURE|conventional lumpectomy|After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
41337906|NCT01985386|DIETARY_SUPPLEMENT|GDS capsule with meal|GDS capsule with meal
41337907|NCT01985386|DIETARY_SUPPLEMENT|Ferrous sulfate with meal|Ferrous sulfate with meal
41337908|NCT01688999|DRUG|Cabozantinib|60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.
41337909|NCT02971293|DRUG|AZD8871 100 µg|The subjects will receive one dose of AZD8871 100 µg single dose DPI.
41337910|NCT02971293|DRUG|AZD8871 600 µg|The subjects will receive AZD8871, 600 µg single dose DPI.
41156718|NCT06612424|DRUG|İNTRATECHAL MORPHİNE GROUP|In the intrathecal morphine group, 100 micrograms of morphine (0.1 mL) will be added to the 12 mg of intrathecally administered bupivacaine.
41156719|NCT06295237|DEVICE|Intellisync+|mechanical ventilator software automatically detecting and adjusting ventilator parameters to control or reduce the number of events.
41156720|NCT05335005|DRUG|MK-2060|MK-2060 administered via IV infusion
41156721|NCT01267058|BIOLOGICAL|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine|Intramuscular, single dose
41337911|NCT02971293|DRUG|Placebo|The subject will receive Placebo single dose DPI.
41337912|NCT03381911|OTHER|Embodied Conversational Agent|The Embodied Conversational Agent (ECA) is a computer generated character that can interact with study subjects through a touch screen computer. The ECA is programmed to respond with relevant speech and body language to a subject's responses.
41337913|NCT06391567|OTHER|There was no intervention in this study.|There was no intervention in this study.
41337914|NCT05059704|OTHER|Circuit Class Training|Station 1 will include tasks for warm-up specific for upper extremity, station 2 will include shoulder exercises, station 3 will include elbow exercises, station 4 will include wrist exercises and station 5 will include hand activities and functional training. Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
41337915|NCT05059704|OTHER|Individual Task specific training|Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
40819395|NCT03471338|BEHAVIORAL|Standard Psychological care|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): A neuropsychologist performs at-home visits and weekly phone meetings consisting in discussion of the patient's cognitive disorders.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
40819396|NCT06429397|DRUG|Anlotinib and Penpulimab|Enrolled patients received a treatment cycle every 21 days: 200mg of piamprizumab was given intravenously on the first day of treatment, and 12mg of anrotinib hydrochloride capsule was given continuously for 14 days and suspended for 7 days.
41156722|NCT01267058|BIOLOGICAL|GSK Biologicals' acellular pertussis vaccine|Intramuscular, single dose
41156723|NCT01267058|BIOLOGICAL|Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine|Intramuscular, single dose
41156724|NCT05060237|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|"Photodynamic therapy (PDT) using BF-RhodoLED® XL (ALA-PDT, Ameluz®-PDT):~Topical application of 3 tubes BF-200 ALA on the expanded treatment field (60 cm²), followed by red light illumination with BF-RhodoLED® XL after 3 h incubation of study medication under light-tight, occlusive dressing."
41156725|NCT02892006|BEHAVIORAL|Improvisational Comedy|6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
41156726|NCT05364541|DEVICE|MyoVista wavECG|A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.
40819397|NCT03785249|DRUG|MRTX849|MRTX849 will be administered orally once or twice daily in a continuous regimen
40819398|NCT03785249|DRUG|Pembrolizumab|Pembrolizumab is administered as an intravenous infusion once every 3 weeks
40819399|NCT03785249|DRUG|Cetuximab|Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
40819400|NCT03785249|DRUG|Afatinib|Afatinib will be administered orally once a day in a continuous regimen
40819401|NCT02007057|PROCEDURE|Suprascapular nerve block|
40819402|NCT02007057|PROCEDURE|Interscalene nerve block|
40819403|NCT01328834|DRUG|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
40819404|NCT00420004|DRUG|LY2216684|3-mg and 6-mg tablets
40819405|NCT00420004|DRUG|Placebo|
40819406|NCT00420004|DRUG|Escitalopram|10-mg capsules
40819407|NCT04609358|OTHER|intervention group|When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.
40819408|NCT00374569|PROCEDURE|Gymnastic Routine|A combination of gymnastic movements are performed
41016564|NCT06664632|DIAGNOSTIC_TEST|control|This will include a combination of isometric and isotonic exercises aimed at strengthening the knee musculature, enhancing joint stability, and reducing pain. The exercise regimen will focus on major muscle groups supporting the knee, such as the quadriceps, hamstrings, and calf muscles.
41016565|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.
40819409|NCT01415648|OTHER|cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation|continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
40819410|NCT01415648|OTHER|standard cerebral monitoring and hemodynamic optimisation|the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
41156727|NCT01763346|DRUG|Metformin|metformin 1000 mg bid
41156728|NCT01763346|DEVICE|gastric banding|LAP-BAND
41156729|NCT03525483|DIAGNOSTIC_TEST|Ultrasound for renal resistivity index measurement|"Collection of urine over 3 hours for creatinine clearance measurement, with serum creatinine in parallel with urine collection to calculate measured creatinine clearance and estimate glomerular filtration rate Evaluation of the renal vascular resistance index in Doppler ultrasound by a resuscitator trained in the technique at the time of inclusion.~Collection of demographic, clinical and biological data for inclusion of the patient such as weight, age, sex, arterial lactatemia, arterial pH, volume status, use of diuretics, use of vasopressors, use of nephrotoxic drugs ..."
41156730|NCT02722759|OTHER|hemoglobin measurement|
41156731|NCT00797186|OTHER|Intensive risk factor management|Aggressive medical and lifestyle therapy.
41156732|NCT04553029|OTHER|No intervention|This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).
41156733|NCT04237623|DRUG|Sargramostim|250mcg/m2/day IV starting Day +5
41156734|NCT04237623|OTHER|Control Arm|Standard G-CSF given to those who decline to receive GM-CSF
41156735|NCT00385697|BIOLOGICAL|Teplizumab|Daily IV dosing for 14 days, repeated at Week 26
41156736|NCT00385697|DRUG|Placebo|Daily IV dosing for 14 days, repeated at Week 26
41486071|NCT05863884|BEHAVIORAL|Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake|CHWs will conduct home visits to provide diabetes and COVID-19 health education based on the participant's needs, interests, and clinical health assessment results. All adults in the household will be invited to participate in the health education discussions. At each visit, the CHW will use diabetes management and COVID-19 educational materials to facilitate and inform discussions. CHWs will also make available at-home COVID-19 testing kits with instructions for the patient and their household family members. The discussion of COVID-19 beliefs, perceptions, and related behaviors will be raised during a later visit, i.e., after rapport and trust has been established and if it has not been raised by the participants during the earlier visits. In addition, CHWs will help schedule vaccination and healthcare appointments upon participant's interest.
41486072|NCT03077035|OTHER|glass ionomer sealants|
41486073|NCT03077035|OTHER|resin-based sealant|
41486074|NCT05180552|DEVICE|HEALiX is an alternative restraint patient safety device|The HEALiX is a rigid, spiral, exoskeleton-like device made of lightweight stainless steel (Austenitic SAE 316 or equivalent) that comes in various sizes to fit different arm lengths circumference of the patient's bicep. After appropriate measuring and following the fit guide, the HEALiX is placed on the patient's arm so that the hand rests on a soft, padded hand cradle. The trajectory of the end hand cradle is at a 30-degree upward angle to prevent peripheral dependent edema. This hand cradle is surrounded by foam to provide increased support for the patient and also to protect the medical team from any injury. A wrist bracelet (wrist assist) goes around the patient's wrist and prevents the patient from removing the device. The spiral exoskeleton holds the arm in a neutral position with contact points with the patient's skin at the upper deltoid region only.
41486075|NCT05180552|DEVICE|soft wrist restraints|Soft wrist restraints are padded cloth restraints that are worn by patients on wrist and secured to bed frame.
41486076|NCT00008151|DRUG|cyclosporine|
41486077|NCT00008151|DRUG|fludarabine phosphate|
41486078|NCT00008151|DRUG|gemtuzumab ozogamicin|
41486079|NCT00008151|DRUG|methotrexate|
41486080|NCT00008151|DRUG|mycophenolate mofetil|
40819411|NCT05837403|PROCEDURE|Platelet rich plasma injection|venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.
41156737|NCT06646107|DEVICE|MInimed 780G|Minimed 780G HCL system (Metronic, Northridge, Ca, USA) is ConformitèEuropëenne(CE)-marked and includes additional functionality aiming to provide further protections from high glucose levels. When the system is used in Auto Mode automatically calculate the insulin dose based on information received from CGM. Signals are converted by the transmitter to sensor glucose values. Sensor values are then transmitted to the insulin pump. Sensor glucose and insulin delivery data are stored by the pump and may be uploaded. The HCL system can be programmed to automatically calculate insulin doses (both basal insulin and correction boluses) based on information received from CGM780G and the adherence to MD.
41156738|NCT06504446|DRUG|NOC-110|Inhalation powder
41486081|NCT00008151|PROCEDURE|allogeneic bone marrow transplantation|
40819412|NCT05837403|DRUG|Nitroglycerin ointment|application of the ointment twice daily
41486082|NCT00008151|PROCEDURE|peripheral blood stem cell transplantation|
41486083|NCT00008151|RADIATION|radiation therapy|
41486084|NCT05070871|DIETARY_SUPPLEMENT|Hydrolyzed Collagen|Hydrolyzed collagen type II derived from the bone powder of Norwegian Atlantic salmon.
40819413|NCT03478475|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|
40819414|NCT03478475|OTHER|Placebo|Placebo pill (microcrystalline cellulose 66.3%, starch 33.2%, magnesium stearate 0.5%)
40819415|NCT02752958|DRUG|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
41486085|NCT05070871|OTHER|Placebo|Pure maltodextrin.
41156739|NCT06504446|OTHER|Placebo|Inhalation powder
41156740|NCT05330325|DRUG|Somapacitan|Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.
41486086|NCT05070871|DIETARY_SUPPLEMENT|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and collagen type 2.
41486087|NCT03570086|DIAGNOSTIC_TEST|diagnostic|using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
41486088|NCT04781387|DRUG|CRS3123|Study drug dosed at 200 mg PO BID (treatment arm A) or 400 mg PO BID (treatment arm B) for total of 10 days
41486089|NCT04781387|DRUG|Active Comparator|Active comparator is administered 125 mg PO QID
41486090|NCT01418482|DEVICE|Mepilex Border Ag|a silver dressing
41486091|NCT00755859|DRUG|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
41486092|NCT00755859|DRUG|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
41486093|NCT03155386|OTHER|Angiommamography|"A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~* The intensity of lesion enhancement~* The presence and type of artefacts on the recombined images.~* The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions"
41486094|NCT01349582|PROCEDURE|flow diversion|endovascular treatment with flow diversion including standard management of thrombo-embolic risk
41486095|NCT01349582|OTHER|conservative management|conservative management is watchful observation of the aneurysm until indication for intervention arises
41486096|NCT01349582|PROCEDURE|endovascular coiling|standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
41486097|NCT01349582|PROCEDURE|balloon parent vessel occlusion|sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
41486098|NCT01349582|PROCEDURE|surgical clipping|clipping of the aneurysm following invasive brain surgery
41486099|NCT04236570|DEVICE|Thermode(hot plate) and cold water bath|Standardized protocol will consisted of stimulus test (TS) generated by thermode and conditioning stimulus (CS) using cold water bath.
41486100|NCT04236570|DEVICE|TENS(transcutaneous electrical nerve stimulation)|TENS protocol will consisted of test stimulus (TS) and conditioning stimulus (CS) both generated by TENS
41016566|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients also in this group remained in supine lying position. Median nerve mobilization was performed by placing the scapula in a depressed position with one hand while placing the elbow in 90° flexion, forearm in supination, and wrist and fingers in extension with the other hand. Then, the therapist passively abducted the shoulder into 90- 100° and available external rotation ROM of the arm. Then from this position, the therapist extended the elbow with or without contra lateral side bending of the neck (tensioner or slider technique, respectively). Patients performed 30 repetitions of slider median nerve mobilization by performing elbow extension and wrist extension, with the neck placed in ipsilateral side bending or performing elbow flexion and wrist flexion with the neck placed in contralateral side bending. \[35\]. Tensioner technique was performed by applying simultaneous elbow extension with contralateral side bending of the neck and hold for 15 sec and relax for 10 sec .
41486101|NCT04365114|DIAGNOSTIC_TEST|Breast Screening Mammography with single reader|One clinician examined each woman's mammograms for signs of cancer
41156741|NCT05330325|DRUG|Norditropin®|Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
41156742|NCT00762723|DEVICE|Trinica Anterior Lumbar Plate System|Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
41156743|NCT03920761|DEVICE|EarlySense Insight system|a small piezoelectric sensor pad that can be placed under the mattress and provide contact-free monitoring by measuring and recording a patient's vital signs and motion parameters
41486102|NCT04365114|DIAGNOSTIC_TEST|Breast screening mammography with two readers|Two clinicians seperately examined each woman's mammograms for signs of cancer
40819416|NCT01833910|OTHER|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
40819417|NCT01833910|OTHER|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
40819418|NCT01419613|BEHAVIORAL|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
40819419|NCT01419613|BEHAVIORAL|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
41016568|NCT06661109|OTHER|Intervention (Kinesio Taping) group|No randomized study was found investigating the effect of kinesio taping on comfort levels in women having a cesarean delivery.
41016569|NCT06663488|PROCEDURE|Thoracic epidural anesthesia|The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered .
41016570|NCT06663488|PROCEDURE|Thoracic spinal anesthesia|Thoracic spinal anesthesia: At T5-T6 or T6-T7, a 27G needle was inserted. The needle's stylet will be removed and the hub observed for free flow of CSF; once flow of clear CSF, 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected
41016571|NCT06664671|OTHER|Experimental|Patients will inhale thyme oil via inhaler sticks with instructions on proper usage, supervised by the researcher. Each patient will complete the Patient Introduction Form, Asthma Control Test, and pre-test sections of the Asthma Symptom and Respiratory Parameters Form. Measurements of FEV1 and FEV1/FVC will be recorded. On the fourth day of hospitalization, post-test data will be collected.
41016572|NCT06664671|OTHER|Placebo|Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
41016573|NCT06664671|OTHER|Control (Standard treatment)|Patients will complete pre- and post-test forms without any intervention.
41016574|NCT06661993|OTHER|Placebo|placebo film-coated tablet orally or via a nasogastric tube for seven days .
41016575|NCT06661993|DIETARY_SUPPLEMENT|Alpha-lipoic acid|Alpha-lipoic acid 1800 mg orally or via a nasogastric tube for seven days .
41016576|NCT06664684|OTHER|Energy-restricted dietary intervention|The diets were planned based on current guidelines, manuals, systematic reviews, and meta-analyses published in recent years on MAFLD \[5-6, 27-28\]. In this diet, carbohydrates constituted 50%-55% of total energy intake, proteins constituted 10%-20%, and fats constituted 25%-35%. The content of the diets was tailored to each patient, considering various factors such as sex, age, and physical activity status.
41156744|NCT03920761|DEVICE|Advanced Neonatal Epidermal System|a system of neonatal non-invasive adhesive sensors. Sensors are attached directly on the patient's body and are capable of continuously measuring and recording heart rate, respiratory rate, oxygen saturation, and skin temperature.
41016577|NCT06664684|OTHER|Energy + time-restricted dietary intervention|Patients in the energy + time-restricted diet group followed the same dietary intervention and a 16:8 eating pattern where they were instructed to restrict their energy intake to an 8-h time window and not to consume energy-containing foods or drinks during the remaining 16 h. Participants were allowed to consume energy-free beverages such as water, coffee, and tea during fasting. The timing of the eating window during the day varied according to participants' lifestyles and habits. However, considering the importance of nocturnal fasting, the eating window in all patients started at 10:00-12:00 in the day and ended at 18:00-20:00 in the evening. The energy-restricted diet group did not follow any time restriction in the planning of main meals and snacks.
41486103|NCT04365114|DIAGNOSTIC_TEST|Test threshold|Threshold used by readers examining the breast screening mammograms, defined using their previous proportion of cases recalled
41486104|NCT02981303|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
41016578|NCT06662890|OTHER|Supersaturated oxygen|"Supersaturated O2 (SSO2) therapy immediately following primary percutaneous coronary intervention (PCI) using radial artery access in the cardiac catheter laboratory.~https://www.zoll.com/products/supersaturated-oxygen-therapy"
41016579|NCT06662890|OTHER|Sham (No Treatment)|Control (sham) procedure involving wrist manipulation in addition to standard care.
41016580|NCT06662903|PROCEDURE|Cranioplasty with Titanium mesh|Cranioplasty using titanium mesh
41016581|NCT06662903|PROCEDURE|Cranioplasty with bone cement|Cranioplasty using bone cement
41016582|NCT06663761|BEHAVIORAL|Stimuli|"Stimuli (the order of stimuli 1-4 will be electronically randomized), with a break time between stimuli of 5-10 minutes:~1. Non-invasive blood pressure measurement~2. Heat~3. Mechanical stimulation~4. Visual stimulation~5. Cold pressor test~6. Spicy taste"
41016583|NCT06664645|PROCEDURE|LHB tendon reinforcement|complete repair with LHB tendon reinforcement
41016584|NCT06664645|PROCEDURE|complete repair without reinforcement|conventional rotator cuff complete repair without reinforcement
41156745|NCT03930238|BEHAVIORAL|VA MapTrek|The objective is to report activity levels in our virtual environment to Veterans, thereby encouraging them to walk more.
41156746|NCT03930238|BEHAVIORAL|Fitbit Only|Fitbit Only
41337916|NCT01499797|OTHER|The CareWell programme|"The CareWell programme contains the following components:~* multidisciplinary primary care teams~* working with proactive care plans integrating cure, care and welfare~* advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)~* medication review~* case-management~* guidelines for consultation of in-hospital geriatric experts~* guidelines for transfers from primary care to home-based facilities and hospital and back~* practice guidelines for management of common geriatric conditions"
41337917|NCT02533856|OTHER|ETOC|Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
41337918|NCT00881699|BEHAVIORAL|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
41337919|NCT00881699|BEHAVIORAL|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
41337920|NCT05911945|PROCEDURE|Flexible Ureterorenoscopy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, a 26 cm, 4.8 Fr JJ stent was placed under fluoroscopy and the procedure was terminated. Patients underwent a second f-URS session, 4 - 6 weeks later. After the JJ stent was removed, an 11 - 13 Fr UAS was placed in the ureter. Digital flexible ureterorenoscope was used as the flexible ureteroscope. Stone fragmentation was performed in dusting mode using a Ho:YAG laser with a 272 µ probe. After fragmentation, a 26 cm 4.8 Fr JJ stent was inserted into the ureter. The JJ stent was removed at 4 - 6 weeks postoperatively.
41337921|NCT05911945|PROCEDURE|Mini Percutaneous Nephrolithotomy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, patients were positioned in prone position and access was performed to the appropriate calyx with an 18-gauge percutaneous access needle using the triangulation technique accompanied by fluoroscopy, in the same session. After the guidewire was introduced into the pelvicalyceal system, sequential dilatation was applied with Amplatz dilatators, and a 21 Fr metallic sheath was placed. Stones were fragmented with a yttrium-aluminum-garnet (Ho:YAG) Laser lithotripter. At the end of the procedure, a 14 Fr nephrostomy catheter was placed in according to the residual stone, hemorrhage, and perforation status. In other cases, the procedure was concluded as totally tubeless.
41337922|NCT05210621|DRUG|Ocrelizumab|ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
41486105|NCT02981303|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
41486106|NCT04173299|PROCEDURE|early tips|patients with early tips
41486107|NCT04846517|DEVICE|Transcranial Magnetic Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC~LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
41486108|NCT02606175|OTHER|Taking questionnaires and tests|"At predefined timepoints:~* 2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)~* 1 test for medication adherence: BAASIS~* 1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)~* 1 test about medication knowledge"
41486109|NCT00449826|PROCEDURE|Computed Tomographic Angiography|CT scan
41486110|NCT01922167|DIETARY_SUPPLEMENT|Leucine|
41486111|NCT01922167|DIETARY_SUPPLEMENT|Alanine|
41486112|NCT05861466|DRUG|intra-vitreal injection of Ranibizumab|The intravitreal injection will be performed with ranibizumab (0.5 mg/0.05 mL through a 27-gauge needle that will be inserted into the sclera 3.5 mm from the corneal limbus in pseudophakic patients, and 4 mm in phakic patients.
41486113|NCT05861466|PROCEDURE|anterior chamber paracentesis|A 27-gauge needle on a 1-mL syringe will be inserted into the anterior chamber of the eye, and approximately 0.05 mL of aqueous humor will be withdrawn.
41486114|NCT00574925|DRUG|Esomeprazole|
41486115|NCT01527617|OTHER|Cranberry|beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
41486116|NCT01527617|OTHER|Non-Cranberry beverage|Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
41486117|NCT00172536|BEHAVIORAL|Exercise training|Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
41486118|NCT00172536|OTHER|Control|Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
41016588|NCT06663033|PROCEDURE|colorectal surgery|surgery for colorectal cancer
41486119|NCT00283790|DRUG|zolpidem tartrate|
41486120|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 1|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10\^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL."
41486121|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 2|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
41486122|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 3|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
41486123|NCT03858166|DRUG|PEG-rhG-CSF|6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
40819420|NCT06410261|BEHAVIORAL|Exercise rehabilitation program|"* The sessions will consist of a customized low-impact, resistance-base rehabilitation regime to increase muscle strength and functionality by focusing on isolating each targeted muscle, without increasing the participant's fatigue or pain level.~* The goal of phase one will be to start muscle activation without increasing fatigue or pain. Low intensity, single set of 30-35 repetitions for each of the targeted muscles will be performed by the participants, followed by stretching; the goal of phase two will be to progressively develop muscle strength, without increasing pain or fatigue. A single set of 20-25 repetitions for each muscle will be prescribed, followed by stretching; during phase three, the emphasis will be on further development of muscle strength, function, and endurance."
41016589|NCT06664333|OTHER|Semi-structured interviews|"The study consists of conducting two semi-structured interviews, with an estimated duration of 15 to 30 minutes, with siblings of children hospitalized in pediatric intensive care at Necker-Enfants Malades Hospital and Robert Debré Hospital.~The first interview will take place during the stay in intensive care, the second 1 month after discharge from pediatric intensive care."
41486124|NCT03014180|DEVICE|"In-Clinic LVAT"|Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
41486125|NCT02667171|BEHAVIORAL|Supervised COPD Rehabilitation (control group)|"The control group receives standardized conventional supervised COPD rehabilitation (CCR) in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks. The CCR will last 60-120 minutes each session (50% exercise and 50% education).~Physical Exercises in CCR consist endurance based at Borg dyspnea 4-7 for 20-30 minutes and resistance training for upper and lower limb at 50-80% of one repetition maximum of 2-3 sets. Educations sessions consist information a dialogue regarding, life with COPD, participants topics, Medication, daily activity, Nutrition, Smoking cessation, Respiratory and relaxation exercises."
41337923|NCT04116190|BEHAVIORAL|Telerehabilitation|Short inpatient multidisciplinary rehabilitation followed by home-based telerehabilitation and a short evaluation period at the end of it.
41486126|NCT02667171|BEHAVIORAL|Online COPD rehabilitation (experimental)|"Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks. Each session lasts for 60minutes (60% exercise 40% education). Physical exercises consist high repetitive time-based muscle endurance training, including 5-7 upper and lower limb exercises, performed with a volume of four sets per exercise equivalent to 50-80% of one repetition. Self-rated Borg CR-10 score equivalent from moderate to very strong shortness of breath in active phases.~Educations consists same information as for the control group."
41486127|NCT05777161|BEHAVIORAL|Parent Coached Exposure Therapy - Individualized|Subject and parent begin by working with a therapist to create an individualized fear hierarchy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
41486128|NCT05777161|BEHAVIORAL|Cognitive Behavior Therapy|Subjects will work with a therapist using anxiety management strategies to address thoughts, feelings, and behaviors.
41486129|NCT05777161|BEHAVIORAL|Parent Coached Exposure Therapy - Group (removed from study)|Subjects and parents will work in a group setting to receive exposure therapy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
41486130|NCT03429517|DIAGNOSTIC_TEST|Lipogram|liporgram samples
41486131|NCT02075827|BEHAVIORAL|Competitive video game|1 hour playing video game
41486132|NCT02075827|BEHAVIORAL|Little Big Planet|1 hour playing video game
41486133|NCT02123212|OTHER|Mailer|Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
41486134|NCT02123212|OTHER|In-person recruitment|UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.
41486135|NCT02123212|OTHER|EHR Alert|EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
41486136|NCT00860366|DRUG|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
41486137|NCT00860366|OTHER|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
41486138|NCT05414032|BIOLOGICAL|AZD2936|AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.
41486139|NCT03537274|BIOLOGICAL|PEG-Intron|PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.
41486140|NCT03537274|BIOLOGICAL|Interferon Alfa-2B|Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
41486141|NCT00121316|DRUG|Pimecrolimus|Pimecrolimus Cream 1 %
41016591|NCT06663384|OTHER|Evaluation of Augmented Reality technology in TKA compared to standard TKA|Evaluation of effectiveness of AR system used to perform bone cuts when compared to traditional jigs in primary TKA
41156747|NCT06399003|BIOLOGICAL|SIBP MMR Vaccine|This is a live attenuated measles, mumps, and rubella combined vaccine (Shanghai MMR) in a freeze-dried powder form, developed and manufactured by Shanghai Institute of Biological Products. A single dose of 0.5 mL, containing not less than 3.0 log CCID50 of both live measles virus and rubella virus and 4.3 log CCID50 of live mumps virus. 0.5ml per dose.
41337924|NCT04116190|BEHAVIORAL|Conventional inpatient rehabilitation|Multidisciplinary inpatient rehabilitation, no adjustments due to the study.
41486142|NCT00121316|DRUG|Placebo|Vehicle cream (placebo cream)
41486143|NCT05364060|OTHER|Questionnaires|Different questionnaires detailed in the objectives part
40819421|NCT05470842|DEVICE|Continuous glucose monitoring (Dexcom G6)|"All participants will be issued with the Dexcom G6 device. The trial team will buy the readers or smartphones and sensors and provide the participants with all the necessary equipment. Participants will be shown how to wear the Dexcom G6 device, which they will be asked to wear for up to 10 days (=the lifespan of one sensor).~There will be no change in the standard care of the participants' diabetes management, during the study period."
41486144|NCT06085092|BEHAVIORAL|Open weighing|The open-weighing intervention aims to challenge beliefs about weight gain. The study coordinator (SC) will explain open weighing, discuss any concerns you have about your weight, and construct a weight graph with the number of weeks on the x-axis and weight in pounds on the y-axis. The SC will help identify beliefs about gaining weight, which will be written on a Feared Outcomes Form. The SC will ask you to predict your weight, mark the weight prediction on the graph, weigh you on a standing scale, record your weight, and discuss your responses to seeing your weight, including any reasons for a difference between your predicted and actual weight. Each week, the SC will graph your actual and predicted weights over time and discuss anything that you are learning from this process. The SC will ask you to complete the Feared Outcomes Form once per day over the next week, review it each week, and talk to you about what you are learning from this process.
41486145|NCT06085092|BEHAVIORAL|Blind weighing|The blind weighing intervention aims to help you see self-weighing as an eating disorder symptom that you should stop, and that weight is not important to your identity or self-esteem. To do this, the study coordinator will explain why blind weighing might be helpful. You will then be asked to step backwards on a standing scale. The study coordinator will record your weight but will not share your weight information with you. The study coordinator will discourage you from thinking or talking about your weight.
41486146|NCT01390285|DEVICE|Transcutaneous electric nerve stimulation|The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
41486147|NCT01390285|DEVICE|sham transcutaneous electrical nerve stimulation|The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
41486148|NCT02819141|DRUG|Dexmedetomidine|Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
41486149|NCT06034561|DRUG|Bortezomib|Patients should receive one or two courses of this regimen, aiming to achieve complete remission as a bridge to proceed with allogeneic HSCT.
41486150|NCT00937378|DRUG|SER120|Nasal Spray, once a day
41486151|NCT00937378|DRUG|Placebo|Nasal Spray
41486152|NCT02993315|BIOLOGICAL|nDC vaccination|
41486153|NCT02993315|BIOLOGICAL|placebo injection|
41486154|NCT02276014|DIETARY_SUPPLEMENT|Beta-carotene|
41486155|NCT02746471|DEVICE|Reveal LINQ|
41486156|NCT01736436|DRUG|Treatment with APG101|Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
41486157|NCT01736436|PROCEDURE|Bone marrow collection|During the study, bone marrow will be collected 4 times to assess study objectives
41486158|NCT01736436|PROCEDURE|Blood drawings|During the study, blood will be drawn at different time points to assess study objectives
41486159|NCT02684708|DRUG|cyclophosphamide, vincristine, prednisone, dacarbazine|28-day chemotherapy cycle
40819422|NCT02627547|BEHAVIORAL|Normal training|5-10 hours of endurance training each week
41486160|NCT02684708|DRUG|cyclo, vcr, pred, dacarb,etop and doxo|21-day chemotherapy cycle
41486161|NCT01366378|DRUG|methylnaltrexone|
41486162|NCT00378404|DRUG|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
41486163|NCT00378404|RADIATION|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
41486164|NCT01294475|BEHAVIORAL|Planned Activities Training|Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
41486165|NCT02903719|DRUG|Ropivacaine|All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
41486166|NCT05585476|DEVICE|C02 microablative laser|The C02 microablative laser was the first to be used in the treatment of menopausal genitourinary syndrome. Its mechanism of action is based on the emission of light at a wavelength of 10600nm that is absorbed by the water molecules contained in the vaginal mucosa, leading to local remodeling of connective tissue and neoformation of collagen, elastic fibers and other components of the extracellular matrix.
41486167|NCT05585476|COMBINATION_PRODUCT|Regenerative topical treatment|It is a moisturizing and regenerating gel whose active ingredients are olive oil, trimethylglycine and xylitol.
41486168|NCT00062010|BIOLOGICAL|interferon alpha|Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
41486169|NCT00062010|DRUG|13-cis-retinoic acid|13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
40819423|NCT02627547|BEHAVIORAL|De-training|No training
41486170|NCT00062010|DRUG|paclitaxel|paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
41486171|NCT00393965|DRUG|MPC-6827|2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.
41486172|NCT02865252|OTHER|MWM Treatment|
41486173|NCT02865252|OTHER|MWM Sham|
40819424|NCT05008575|BIOLOGICAL|anti-CD33 CAR NK cells|6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion
40819425|NCT05008575|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
41486174|NCT01765582|DRUG|5-fluorouracil|Participants in Arm A will receive 3200 milligrams per square meter (mg/m\^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
41486175|NCT01765582|DRUG|bevacizumab|Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
40819426|NCT05008575|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
40819427|NCT04895293|DRUG|RBM-007 Injectable Solution|Sterile solution
40819428|NCT02937077|DEVICE|Medtronic Reveal LINQ|
40819429|NCT03100240|PROCEDURE|Modified Supper Long Protocol|In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes
40819430|NCT01380535|DRUG|ECP Methoxsalen|Methoxsalen delivered by ECP
40819431|NCT01380535|DRUG|Standard of Care|Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
40819432|NCT06110858|BEHAVIORAL|Tinkering Activities|Tinkering activities encompass elements of science, art and technology. They emphasize that learning is not simply about teachers imparting knowledge to students, but rather about students actively constructing knowledge themselves. Tinkering activities are characterized by three key elements: active engagement, open-ended exploration and problem-solving. In such activities, participants are provided with products without telling the steps. They are then encouraged to attempt creating it on their own. During this hands-on learning process, participants need to flexibly change their mindset, think outside the box and tackle emerging problems, which challenge their executive functions.
41156748|NCT06399003|BIOLOGICAL|GSK MMR Vaccine (PRIORIX)|PRIORIX (combined measles, mumps and rubella vaccine, live, attenuated) is a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain) and Wistar RA 27/3 rubella strains of viruses, separately obtained by propagation either in chick embryo tissue cultures (mumps and measles) or MRC5 human diploid cells (rubella). 0.5ml per dose.
41156749|NCT06399003|BIOLOGICAL|Yellow Fever Vaccine (Stamaril)|This is a live, attenuated, lyophilized yellow fever vaccine manufactured by Sanofi Pasteur Europe, Lyon, France. A single dose of 0.5 mL contains with not less than 1000 IU of yellow fever virus 17D-204 strain. 0.5ml per dose.
41156750|NCT06401096|PROCEDURE|Preoperative respiratory exercises|The Triflo Exerciser
41156751|NCT05432583|BIOLOGICAL|BNT163|Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection
41486176|NCT01765582|DRUG|capecitabine|Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
41486177|NCT01765582|DRUG|irinotecan|Participants will receive IV infusion of 165 mg/m\^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m\^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
41486178|NCT01765582|DRUG|folinic acid|Participants will receive IV infusion of 200 mg/m\^² (Arm A) or 400 mg/m\^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m\^2 in the maintenance therapy.
41486179|NCT01765582|DRUG|oxaliplatin|Participants will receive 85 mg/m\^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
40819433|NCT01004731|DRUG|Cetuximab in combination with Carboplatin/Gemcitabine|A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
41156752|NCT05432583|OTHER|Placebo|Placebo
41156753|NCT02631616|DRUG|Somatostatin|Monthly injections of Somatostatin
41156754|NCT04448821|DRUG|Metformin|Single administration of metformin
41156755|NCT04448821|DRUG|Metformin + Nilotinib|Coadministration of metformin and nilotinib
41486180|NCT01799863|DRUG|Ketorolac trometamol 0.45% with carboxymethylcellulose|
41486181|NCT01799863|DRUG|Preservative free artificial tear|
41337925|NCT01149772|BEHAVIORAL|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
41337926|NCT05514925|DRUG|Bevacizumab Injection [Avastin]|Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
41486182|NCT03507257|DRUG|Flortaucipir|All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
41486183|NCT03507257|DRUG|Florbetaben|All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
41486184|NCT03507257|DRUG|Fluorodeoxyglucose|All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
41486185|NCT01884662|BEHAVIORAL|Virtual walking|"As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs walking; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking."
41486186|NCT01884662|BEHAVIORAL|Wheeling tape|This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
41486187|NCT05827081|DRUG|Ribociclib|Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
41337927|NCT05514925|PROCEDURE|Peripheral Retinal Cryoapplication|In the operating room under peribulbar anesthesia, four focal conjunctival incisions are made on each quadrant between the muscles insertions. The Tenon capsule is opened with scissors to expose the sclera. Four to six cryo-applications are made per quadrant, at the edge of muscle insertion and a line behind. The exposure time is 4 to 5 seconds. 7-0 resorbable sutures are then put on each quadrant to close the conjunctiva.
41337928|NCT04389268|DIAGNOSTIC_TEST|Visual Event-Related Potentials|Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).
41337929|NCT00202345|DRUG|Iron sucrose|
41337930|NCT03168841|DRUG|Efinaconazole Topical|Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
41337931|NCT05932381|OTHER|Complete decongestive therapy|the patients will receive Complete decongestive therapy in the form of intermittent pneumatic compression, Exercising, bandaging, and manual lymphatic drainage with Pressures of 50, 80, and 120 mmHg and timing 5, 20, and 50 secs
41337932|NCT05932381|OTHER|Medical treatment|the patients will receive routine medical treatment
41337933|NCT05750485|OTHER|Pupilometric evaluation|Pupilometric evaluation under procedural sedation with propofol
40819434|NCT00534287|DRUG|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
41486188|NCT05827081|DRUG|Letrozole|Letrozole 2.5 mg orally once daily continuously
41486189|NCT05827081|DRUG|Ansastrozole|Anastrozole 1 mg orally once daily continuously.
41486190|NCT05827081|DRUG|Goserelin|Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
41486191|NCT05827081|DRUG|Leuprolide|Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
41486192|NCT05827081|DRUG|Exemestane|Exemestane 25 mg once daily continuously
41337934|NCT05351190|DEVICE|Dexcom G6 CGM|rtCGM to be worn by user continuously for the duration of the 12 month study
41337935|NCT03647748|DEVICE|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment.
41337936|NCT01251822|DRUG|PEG 3350 plus electrolytes|Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
41486193|NCT02468492|BIOLOGICAL|Platelet Rich Plasma|Platelet rich plasma injection into knee versus placebo (saline) injection.
41486194|NCT02468492|OTHER|Normal Saline|Platelet rich plasma injection into knee versus placebo (saline) injection.
41486195|NCT00334061|DEVICE|Penumbra System|
41486196|NCT05717504|DEVICE|Implantable Loop Recorder|Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)
41486197|NCT05717504|OTHER|Quality of life survey|A quality of life survey will be performed at the end of the follow-up period. The survey will be done over the phone or in person if the follow-up visit is in person.
41486198|NCT05177874|DEVICE|Traumacel FAM Trium|Absorbable Hemostat (oxidized non-regenerated cellulose)
40819435|NCT00534287|DRUG|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
41486199|NCT05177874|DEVICE|Surgicel Fibrillar|Absorbable Hemostat (oxidized regenerated cellulose)
41486200|NCT01371266|DIETARY_SUPPLEMENT|Honey|60.7 grams orally daily times 14 days
40819436|NCT03988699|DEVICE|Tinnitus Implant System|Device will deliver stimulation below hearing thresholds continuously or intermittently.
41156756|NCT06646523|OTHER|High-speed bodyweight resistance training|"The participants of the experimental group (high-speed bodyweight resistance training) will receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The experimental intervention will be performed at maximum speed. During the initial home visit, the speed at which the participant can perform one set of each exercise at maximum speed will be timed. Speed-based progression will be determined every four weeks by increasing the number of repetitions in each set of exercises performed during subsequent home visits."
41337937|NCT01251822|DRUG|Prucalopride|"Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.~Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days."
41337938|NCT00493480|DRUG|carvedilol|6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
41337939|NCT00493480|DRUG|propranolol|80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
41337940|NCT01131845|DRUG|UT-15C SR (treprostinil diethanolamine)|Single dose, 1 mg UT-15C SR
41486201|NCT01371266|DIETARY_SUPPLEMENT|High Fructose Corn Syrup 55 (HFCS 55)|65.7 gram daily orally times 14 days
41486202|NCT01371266|DIETARY_SUPPLEMENT|CHO (sugar)|50 grams daily orally times 14 days
41486203|NCT05594303|BIOLOGICAL|Autologuos transplantation of bronchial basal cells|Autologuos transplantation of bronchial basal cells
41486204|NCT06412588|DRUG|Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days|Group A:The patient was treated with oral Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth for 14 days.
41486205|NCT06412588|DRUG|Vonoprazan+Amoxicillin|Group B: Patients were treated with oral Vonoprazan 20mg, bid + amoxicillin 1.0g, bid for 14 days.
41486206|NCT06412588|DRUG|Vonoprazan+doxycycline|Group C: Patients were treated with oral Vonoprazan 20 mg, bid + doxycycline 0.1 g, bid for 14 days.
41486207|NCT01074762|BEHAVIORAL|Structured personal care|General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
40819437|NCT04099797|GENETIC|C7R-GD2.CART cells (ICV infusion)|"Dose levels in the current phase of study are ICV infusion followed by IV infusion (DL 1b, 2b, 3b, 4b)~a. Dose level 1b ICV: 5 x 10\^6 cells/dose (followed by standard IV dose) b. Dose level 2b ICV: 1 x 10\^7 cells/dose (followed by standard IV dose) c. Dose level 3b ICV: 2 x 10\^7 cells/dose (followed by standard IV dose) d. Dose level 4b ICV: 5 x 10\^7 cells/dose (followed by standard IV dose)"
40819438|NCT04099797|GENETIC|C7R-GD2.CART cells (IV infusion)|Standard IV dose: 30 million cells/m2 divided into two doses given at least 5 days and no greater than 10 days apart.
41337941|NCT06244719|DEVICE|Vibrotactile Stimulation|Shirts contain embedded vibration motors that stimulate the impaired upper-extremity at 18 different locations. The gloves stimulates the fingertips.
41486208|NCT00002241|DRUG|Indinavir sulfate|
41486209|NCT00002241|DRUG|Ritonavir|
41486210|NCT00002241|DRUG|Lamivudine|
41486211|NCT00002241|DRUG|Stavudine|
41337942|NCT02882165|OTHER|Medical review|"A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified"
41337943|NCT01341236|OTHER|different nutrional regimen|compare bolus versus intermittent nutrition
41337944|NCT01341236|OTHER|comparison of different feeding regimens|compare intermittent versus bolus nutrition
41337945|NCT06089655|DEVICE|CGMS|The Intervention group is to use CGMS to estimate the effect on blood glucose (HbA1C).
41486212|NCT05525793|OTHER|Transitional care model|The patients who were assigned to this group with the transitional care model, 6 weeks of counseling and intervention training provided continuity of care and a safe transition, and patients were encouraged about symptom management and a healthy lifestyle.
41486213|NCT01298401|BIOLOGICAL|ganitumab|
41486214|NCT01298401|DRUG|capecitabine|
41486215|NCT01298401|DRUG|gemcitabine hydrochloride|
41016593|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected.
41486216|NCT01298401|RADIATION|3-dimensional conformal radiation therapy|
41486217|NCT01918540|PROCEDURE|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
41486218|NCT01918540|PROCEDURE|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
41337946|NCT06089655|BEHAVIORAL|AI diet application|The Intervention group is to use an AI diet application to estimate the effect on blood glucose (HbA1C).
41486219|NCT01918540|DEVICE|MS-30 femoral stem|This is the stem used in the study.
41337947|NCT04644055|DIAGNOSTIC_TEST|EUS- share wave of the liver|Evaluation of the right and left hepatic lobe with EUS-guided share wave
40819439|NCT05963412|OTHER|Meaning Centered Coping Program|"Meaning Centered Coping Program is a psychological intervention program developed for women diagnosed with breast cancer, based on the Meaning Making Model (Park, 2010; Park and Folkman, 1997) and Wong's (2010) principles of Meaning Therapy. Each weekly session had specific topics. These are:~Session 1: Guiding patients to tell the story of their breast cancer and psycho-education; Session 2: Encouraging patients to talk about the effects of breast cancer on their lives and learning to accept their difficult emotions; Session 3: Focusing on cognition through the meaning attributed to breast cancer; Session 4: Learning to take alternative perspectives and defusing their negative thoughts; Session 5: Exploring personal strengths; Session 6: İdentifying important life values and moving toward value-based actions; Session 7: Finding meaning in breast cancer and life; Session 8: Focusing on Future plans and hopes"
40819440|NCT04132830|OTHER|In Utero HIV Exposure|Born to mother who had HIV infection during pregnancy.
40819441|NCT04132830|OTHER|No In Utero HIV Exposure|Born to mother who did not have HIV infection during pregnancy.
40819442|NCT03075488|DEVICE|Accuro|spinal anesthesia injection based on identification of entry site with pre-procedural ultrasound scan with Accuro device
40819443|NCT03075488|PROCEDURE|cutaneous landmarks|spinal anesthesia injection based on identification of entry site with palpation of cutaneous landmarks
40819444|NCT00693823|PROCEDURE|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
41016594|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK WİTH ADJUVANT|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 8 mg de-xamethasone are injected.
41016595|NCT06662955|BEHAVIORAL|audible cues|Terminal knee extension exercise with audible cues
41016596|NCT06662955|BEHAVIORAL|Exercise|Terminal knee extension exercise
41337948|NCT04611061|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
41337949|NCT04611061|DRUG|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
41486220|NCT04178161|DEVICE|Laser treatment|Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
41486221|NCT04601298|OTHER||
40819445|NCT00693823|DEVICE|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
40819446|NCT06605144|OTHER|1- Vasopressors - Mean arterial pressure 55-59|Vasopressors will be titrated according to 55-59 range.
40819447|NCT06605144|OTHER|2- Vasopressors - Mean arterial pressure 60-65|Vasopressors will be titrated according to 60-65 range.
41337950|NCT03940014|OTHER|Data collection from standard follow up|"Annual clinical consultation with an Hereditary Haemorrhagic Telangiectasia (HHT) specialist and/or pneumologist and organ specialists when necessary (such as hepatologists, cardiologists and neurologists).~Explorations (contrast echography, chest Computed Tomography and treatments performed according to international guidelines.~TransCatheter Embolotherapy for each treatable Pulmonary Arteriovenous Malformations (PAVMs) and follow-up every 3 years.~Chest Computed Tomography (CT) every 6-12 months."
41016599|NCT06663605|DRUG|PALI-2108|Oral dose
41016600|NCT06663605|DRUG|PALI-2108 Placebo|Oral dose
41016601|NCT06664398|BEHAVIORAL|one HIIT|one HIIT high intensity interval training
41016602|NCT06664398|BEHAVIORAL|four HIIT|four HIIT high intensity interval training
41337951|NCT05097170|PROCEDURE|NIRS during ventricular tachycardia ablation|"NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia."
41337952|NCT02905110|DRUG|Methotrexate|Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
41016603|NCT06659445|DRUG|ONL1204 Opthalmic solution|Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
41337953|NCT02905110|DRUG|Etoposide|Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.
41337954|NCT02905110|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
41337955|NCT04556201|DEVICE|SOLTIVE™ Premium SuperPulsed Laser Fiber System|SOLTIVE™ SuperPulsed Laser Fiber System and SOLTIVE™ Laser Fibers for single-use only
41337956|NCT01794546|BEHAVIORAL|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
41337957|NCT00736593|DRUG|Nexagon™ or Nexagon™ vehicle|
41337958|NCT05984511|PROCEDURE|I-125 Seeds Brachytherapy in PVTT|Iodine125 seed implantation into the PVTT was conducted 3-7 days after TACE when the results of the liver function tests were comparable to those obtained before TACE. Pre-procedural planning was conducted using a three-dimensional conformal radiation therapy treatment planning system (TPS) to determine the number of Iodine125 seeds required, the target location for implantation, the best percutaneous puncture site and the access route. The targeted zone for implantation was the tumour thrombosis in the segmental portal vein, left/right portal vein. Implantation was guided by CT, and the Iodine125 seeds were implanted into the PVTT using 18 G needles and the implantation gun that housed the Iodine125 seeds in the cartridge chamber.
40819448|NCT06605144|OTHER|3- Vasopressors - Mean arterial pressure 66-69|Vasopressors will be titrated according to 66-69 range.
40819449|NCT06605144|OTHER|4- Vasopressors - Mean arterial pressure 70-75|Vasopressors will be titrated according to 70-75 range.
40819450|NCT01032291|DRUG|cetuximab|Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
41016604|NCT06659445|DRUG|Avacincaptad Pegol intravitreal solution|Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection
41016605|NCT06659445|OTHER|Sham|Sham injection
41016606|NCT06662877|DRUG|Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib|Albumin-bound Paclitaxel, 125mg/m2,iv.drip,d1,d8,Q3W +Tegafur Gimeracil Oteracil (S-1) 40-60mg,p.o,bid,d1-d14,Q3W+Anlotinib 10mg,p.o,d1-d14,Q3W
41016607|NCT06662877|DRUG|Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)|Oxaliplatin 85 mg/m2,d1,iv.drip,Q2W + Leucovorin 400mg/m2,d1,iv.drip,Q2W+ Fluorouracil 2400 mg/m2 civ46h, Q2W
41016608|NCT06663553|PROCEDURE|TU-LESS|patients in TU-LESS group will receive transumbilical laparoendoscopic single-site surgery (TU-LESS) for hysterectomy
41016609|NCT06663553|PROCEDURE|vNOTES|patients in vNOTES group will receive transvaginal natural orifice transluminal endoscopic surgery (TU-LESS) for hysterectomy
41016610|NCT06664151|BIOLOGICAL|Fluzone Trivalent|Inactivated influenza vaccine, 0.5mL single-dose, pre-filled syringe, via intratumoral (into a tumor) injection per protocol.
41016611|NCT06660433|DEVICE|Point-of-care respiratory test platform|A point-of-care respiratory multiplex testing platform situated within a long-term care facility to provide rapid test results
40819451|NCT01032291|DRUG|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
40819452|NCT02345772|DRUG|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
41337959|NCT05984511|PROCEDURE|Transcatheter arterial chemoembolization|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE).
40819453|NCT02345772|DRUG|Docetaxel|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
41337960|NCT05984511|DRUG|Atezolizumab plus Bevacizumab|Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .
41337961|NCT04572685|DRUG|Paliperidone Palmitate|A long acting extended release injectable suspension intended for monthly intramuscular administration
41337962|NCT00281567|DRUG|Tiotropium|
41337963|NCT00281567|DEVICE|Respimat SMI|
41337964|NCT00281567|DEVICE|HandiHaler|
41337965|NCT03245710|OTHER|Placebos|starch
41337966|NCT03245710|DIETARY_SUPPLEMENT|Zhibai Dihuang powder|the Traditional Chinese Medicine Formula Powder Product
41337967|NCT06043245|PROCEDURE|Duodenal Switch|Classic Duodenal Switch
41337968|NCT06043245|PROCEDURE|SADI-S|SADI-S with a 300cm common channel
40819454|NCT02345772|DRUG|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
40819455|NCT02345772|DRUG|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
41337969|NCT06043245|PROCEDURE|Minigastric Bypass|Classic minigastric bypass
41337970|NCT04148768|DEVICE|Inferential therapy|Interferential therapy(IFT) utilises two of these medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross \& they literally interfere with each other - hence another term that has been used in the past but appears to be out of favour at the moment - Interference Current Therapy. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation.
41337971|NCT04148768|DEVICE|short wave diathermy|SWD: Technical specification of Generator frequency: 27.12 MHz, ± 0.6% Output power: continuous High-Frequency max. 400 W, pulsed High-Frequency max. 1000 W (peak) Pulse duration: ca. 400 µs Pulse repetition frequency: 15-200 Hz adjustable in 10 steps Mains supply: 230-240 V / 50 Hz Mains voltage variation: approx. ± 10% Current consumption: approx. 6 Ampere (at 230 V)
41337972|NCT01914939|DRUG|Oxytocin|
41337973|NCT01914939|BEHAVIORAL|Social Skills focused CBT|
41337974|NCT01914939|BEHAVIORAL|Stress management/relaxation training|
40819456|NCT00027365|BIOLOGICAL|Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A|
40819457|NCT00027365|BIOLOGICAL|NefTat|
40819458|NCT00027365|DRUG|AS02A Adjuvant|
40819459|NCT00027365|BIOLOGICAL|gp120W61D|
40819460|NCT03232242|DIAGNOSTIC_TEST|Next-generation sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
40819461|NCT04469920|DRUG|Saroglitazar Magnesium 2 mg|1 tablet, single dose at Day 1
40819462|NCT04469920|DRUG|Saroglitazar Magnesium 4 mg|1 tablet, single dose at Day 1
40819463|NCT04449952|OTHER|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing
40819464|NCT04449952|OTHER|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.
41337975|NCT01914939|DRUG|placebo drug|
41337976|NCT02522078|DRUG|dry misoprostol|400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
41337977|NCT02522078|DRUG|wet misoprostol|400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
41337978|NCT03321370|DIAGNOSTIC_TEST|Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention|Continuous electrocorticography via subdural electrode strips for 1 to 3 weeks in the neuro intensive care unit following traumatic brain injury
41337979|NCT05026645|PROCEDURE|Clinical interventions performed in acute settings (contaminated environment)|Any clinical intervention performed on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic).
41337980|NCT05026645|PROCEDURE|Protection (clinician and patient)|As interrelated competence of the clinical intervention, any protection procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with.
41486222|NCT03403166|BEHAVIORAL|DASH diet|Diet intervention
40819465|NCT04449952|OTHER|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
40819466|NCT04449952|OTHER|Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula|Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.
40819467|NCT04449952|DEVICE|Concept Curve Winter Series Toothbrush|Participants will brush teeth at least one minute with provided bristled toothbrush.
40819468|NCT04449952|DEVICE|Listerine Cool Mint Floss|Participants will use marketed fluoride-containing dentifrice, floss.
40819469|NCT05864950|DEVICE|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
40819470|NCT05350930|OTHER|Assessment of patient satisfaction regarding tele-consultation|Questionnaire completed following the teleconsultation, if applicable.
40819471|NCT05350930|OTHER|Literacy questionnaire|Questionnaire completed during hospitalization for the first chemotherapy cycle
40819472|NCT05350930|OTHER|Collection of socio-demographic characteristics|Questionnaire completed during patient hospitalization for the first chemotherapy cycle
41016612|NCT06660433|OTHER|Existing respiratory virus testing platform|Currently used respiratory virus testing platforms
41016613|NCT06663787|DRUG|Trastuzumab (Herceptin)|Continuing anti-HER2 treatment
41016614|NCT06663787|DIAGNOSTIC_TEST|SIgnatera|A personalized, tumor-informed test.
41016616|NCT06662669|DRUG|YL-13027|YL-13027 is a small molecule inhibitor of the TGF-βRI target.
41337981|NCT05026645|PROCEDURE|Decontamination (clinician and patient)|As interrelated competence of the clinical intervention and protection, any decontamination procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with. This crucial step is usually expected prior the patient's transfer into a clean zone like the emergency room or its equivalent.
40819473|NCT05350930|OTHER|Assessment of patient knowledge on chemotherapy side effects and support medications|Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
40819474|NCT05350930|OTHER|Assessment of patient satisfaction on pharmaceutical follow-up|Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
40819475|NCT05996055|DEVICE|improved version_support device|designed the NTUH version_support device based on the clinical suggestion.
40819476|NCT05996055|DEVICE|the NTUH version_support device|original designed by NTUH
40819477|NCT05166278|BEHAVIORAL|De-escalation training|The intervention will include training on verbal and nonverbal de-escalation techniques. The training will be prepared according to the recommendations of the Beta Project of the American Association for Emergency Psychiatry, the World Health Organization Quality Rights training to act, unite and empower for mental health and a handbook for the use of de-escalation skills in a hospital setting by Amdur E. The first part of the education is based on theoretical backgrounds: aggressive behavior in a psychiatric patient, risk factors, focusing on factors that can be modified, communication, de-escalation. The second part is a practical workshop. The training will be 16 hour duration in total. A short handbook and a list of verbal and non-verbal approaches will be prepared for all staff members involved in the training.
40819478|NCT01261442|PROCEDURE|Nerve Conduction Study (NCS)|An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
41016617|NCT06662669|DRUG|HY-0102|HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.
41016618|NCT06662669|DRUG|Gemcitabine|Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.
41016619|NCT06662669|DRUG|Nab-paclitaxel|Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis
40819479|NCT03563677|OTHER|dual expert guidance structure|Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together
40819480|NCT02540330|DRUG|Fulvestrant|
41016620|NCT06663072|DRUG|Fulvestrant|"Safety-Run In: Starting Dose: 500 mg IM on Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.~Dose Expansion: 500 mg IM: Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses."
41337982|NCT02685618|DRUG|Iloprost|
41337983|NCT02685618|DRUG|Saline|
41016621|NCT06663072|DRUG|177Lu-DOTATATE|"Safety-Run In: Starting Dose: 7.4 GBq (200 mCi) IV every 8 weeks for a total of 4 Cycles~Dose Expansion:177Lu-DOTATATE7.4 GBq (200 mCi) IV or 3.7 GBq (100 mCi) IV: IV dose every 8 weeks for a total of 4 Cycles."
41016622|NCT06663267|OTHER|NOT|This retrospective cohort study involves no new interventions. It analyzes existing health data collected from subjects exposed to varying atmospheric conditions to assess impacts on health outcomes.
41337984|NCT02685618|DEVICE|Phillips M1006B, offset by -10mmHg|Administration of blood pressure module M1006B: offset by -10 mmHg
41337985|NCT02685618|DEVICE|Philips M1006B, No offset|Administration of blood pressure module M1006B: No offset
41337986|NCT01770145|DRUG|APOKYN|"Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes)."
41337987|NCT01770145|DRUG|L-dopa|Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
41337988|NCT01770145|DRUG|Trimethobenzamide|Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
41337989|NCT06284759|OTHER|post-discharge telenursing intervention|Tele-nursing based on Orem's Self-Care Theory was applied to patients with lower extremity fracture surgery. Phone/video calls 24-48 after discharge. hours, 7-10. day,18-21. day, 28-30th day and 40-45th day. day was made. Telephone or video conference interviews were held on the day and time convenient for the patient. After each meeting, the date and time of the next meeting was planned. The video conferencing method (zoom, skype, whatsapp, etc.) was presented to the patient's preference and the decision was made together. In phone/video conference calls, patients were informed about their current problems. Additionally, patients' questions were answered. Prior to tele-nursing monitoring, the researchers identified emergent or urgent situations; Patients were informed that they should consult their doctor if this occurs. The interview with each patient lasted an average of 30 minutes.
41337990|NCT02320214|DEVICE|Miami w/ frag Personal lubricant|
41337991|NCT01055457|DEVICE|Vistakon Investigational Multi-Purpose Solution II|contact lens care solution
41337992|NCT01055457|DEVICE|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
41337993|NCT04295707|DEVICE|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
41337994|NCT04295707|DEVICE|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
41486223|NCT03403166|BEHAVIORAL|Fruits and vegetables diet|Diet intervention
40819481|NCT06607588|OTHER|Not applicable- observational study|Not applicable- observational study
41016623|NCT06663189|DRUG|treatment withdrawal|Patients will STOP their DMT
41486224|NCT03403166|BEHAVIORAL|Control diet|Diet intervention
41016624|NCT06663189|DRUG|Usual DMT continuation|Patients will continue their DMT during the trial as usual : Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate
41016625|NCT06663189|OTHER|MRI|Cerebral+spinal cord enhanced MRI (M0) Cerebral enhanced MRI (M6, Relapse early visit) Unenhanced cerebral MRI (M12, M18, M24, Relapse distant visit
41016626|NCT06663189|BEHAVIORAL|Quality of Life questionnaires|EQ-5D5L: EuroQol-5-Dimension 5 levels Burden of Treatment Questionnaire (BTQ self-administered questionnaires) Hospital Anxiety and Depression (HAD) questionnaire
41016627|NCT06663189|OTHER|Disability evaluation tests|EDSS: Expanded Disability Status Scale 25Foot/Walk 9-HPT:Nine Hole Peg Test
41016628|NCT06664008|DRUG|PPI (proton pump inhibitor)|It reduces stomach acid production and manage GERD symptoms
41016629|NCT06664008|DRUG|Probiotic|Live microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate.
41016630|NCT06664008|DRUG|Zinc|Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.
41016631|NCT06662981|BEHAVIORAL|preoparative information and education|The intervention will include oral and written education about the operation, nursing and active participation in self-care. The intervention will take place in 3 phases: One week before THA, one day before THA after patient admission and postoperatively, before patient discharge. After a rough description of the operation, the anatomy and functionality of the joint will be presented, underlining the necessity of the operation. Instructions for recognizing and managing potential complications will be given. Patients will be informed about the appropriate post-operative walking aids, walking style, sitting up techniques, standing-up techniques, lying down techniques and getting in and out of the car. There will be a demonstration of muscle strengthening exercises, isometric quadriceps and gluteal exercises, Patients will also be informed about the necessity of prophylactic postoperative antithrombotic and antibiotic treatment.
41016632|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM|Experimental subjects will receive the iotaSOFT Insertion System with AIM using robotic controlled stop
41016633|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM Control|iotaSOFT Insertion System with AIM using standard of care insertion techniques
41337995|NCT04407624|OTHER|Intermittent Exercise|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. During the loading period, taking into consideration the heart rate, fatigue and shortness of breath, exercises such as walking, squat, limb movements with weights, stepping on the steps, walking on different floors are shown. Stretching exercises are done during the cooling period. Intermittent loading workouts will consist of 3-minute loads and 1-minute rest intervals. Participants are contacted every two weeks via communication methods such as e-mail, message and telephone conversation. Exercise diary is given to all patients and is taken from them at the end of the study.
41337996|NCT04407624|OTHER|Control|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In loading period, moderate aerobic exercise is consist of brisk walking to reach 60-85% of the person's maximum heart rate. Stretching exercises are done during the cooling period.
41337997|NCT01496404|PROCEDURE|Electrocautery|Electrocautery using cutting mode of epidermis and dermis of skin.
41337998|NCT01496404|PROCEDURE|Scalpel|Incising skin (epidermis and dermis) with scalpel.
41337999|NCT04917250|DRUG|Gemcitabine|1000mg/㎡，d1,4 ivdrip
41016634|NCT06664112|DEVICE|AIDA Analysis|The women will be followed until and after the birth, under intrapartum ultrasound monitoring, with all clinical, ultrasonographic and obstetric parameters, analyzed by AIDA method.
41016635|NCT06663969|OTHER|Temporal Interference|Researchers applied temporal interference (TI) stimulation to the deep brain nuclei of patients who had undergone SEEG monitoring, recording changes in electrical activity detected by SEEG.
41338000|NCT04917250|DRUG|Pegaspargase|2500IU/㎡, maximum dose less than 3750IU
41338001|NCT04917250|DRUG|Etoposide|100mg/㎡，d1-3 ivdrip
41486225|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block using bupivacaine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
41016636|NCT06662968|OTHER|Lollipop group|In the Lollipop group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were given lollipops for sucking without chewing after waking up.Throughout the entire sucking process, we continuously monitor vital signs.
41016637|NCT06662968|OTHER|Control group|In the Control group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were received routine nursing treatment.
41016638|NCT06664372|PROCEDURE|Trans fontanelle US Guided VP Shunt|Insertion of proximal VP shunt catheter by trans fontanelle US
41016639|NCT06663501|DEVICE|Assisted Motion with Enhanced Sensation training|During the AMES intervention, the AMES device will flex or extend the wrist/hand joint, and the participant's task will be to assist this motion. As the wrist/hand joint moves, the machine will be delivering a vibratory mechanical stimulus on the opposite side to the direction of movement. The activity of the muscles during the movement of the wrist/hand joint will be recorded by the device and it will be shown on a screen to be used as feedback during the training
41016640|NCT06664567|BEHAVIORAL|Colorectal cancer screening test|delivery of colorectal cancer screening test by GP
41486226|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block with bupivacaine and Dexmetonidine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
41016641|NCT06658067|DEVICE|Continuous Glucose Monitor (CGM)|The first CGM sensor will be applied as directed during the first visit with a brief training by staff. Participant will be instructed to remove and replace the device every 14 days for the remainder of the 3-month trial period. Participant will also be instructed to scan the sensor three times daily. Compliance may be tracked via remote accessing of the blood glucose log on the online FreeStyle portal. CGM models used will include the Abbott FreeStyle Libre 2 and 3 and Dexcom G5, G6 and G7.
41338002|NCT04917250|DRUG|Dexamethasone|20mg/d d1-4 ivdrip
41016642|NCT06662760|DRUG|TQB3002 Tablets|TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular phosphorylation process by competitively binding to Adenosine triphosphate (ATP) site of intracellular tyrosine kinase binding domain, thereby inhibiting EGFR downstream signaling, ultimately achieving the purpose of inhibiting tumor growth.
41338003|NCT05166603|OTHER|TeleGRACE|Patients receive a virtual home visit and care from the GRACE team
41486227|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block with bupivacaine and magnesium slphate for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
41486228|NCT00354341|DRUG|Epoetin beta|
40819482|NCT06399510|OTHER|Sterofundin fluid therapy|Sterofundin is known as balanced solution which has similar electrolytes content as per human plasma.
40819483|NCT00963716|DEVICE|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
40819484|NCT00963716|DEVICE|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
41016643|NCT06663982|PROCEDURE|Connective tissue graft + L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket. Following papilla incisions, an intra-sulcular incision on the vestibular side of the extraction socket will be extended with a #15c scalpel, creating a socket to insert the connective tissue graft (CTG). The CTG will be harvested from the palatal area following a specific incision technique to obtain a graft around 1.5 mm thick, which will be fixed with a mattress suture.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
41486229|NCT03501914|BEHAVIORAL|Mindfulness|A mindfulness program based on mindfulness-based principles developed by colleagues in Manchester will be adapted to be accessible for people with intellectual disabilities (ID) in Pakistan. This intervention will be translated into Urdu afterwards focus group will be conducted to get the views from people with ID, thei care takers and other stake holders to adapt and culturally modify the program. It will include some mindfulness based exercises i.e.welcome \& introduction, exploring senses, its all in the mind, Mindful eating, breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking.
40819485|NCT01157325|PROCEDURE|Neuraxial analgesia|Neuraxial analgesia will be given at any time if the parturient requested analgesia
41486230|NCT03518892|DIAGNOSTIC_TEST|Resting Metabolic Rate|30 minute test to determine daily caloric needs
41486231|NCT03518892|DIAGNOSTIC_TEST|Body Composition|Total Body DXA scan to determine fat mass, fat-free mass, and percent body fat
40819486|NCT01157325|PROCEDURE|Non-neuraxial analgesia|No neuraxial analgesia will be given to those who will not want to an analgesia
40819487|NCT05472675|PROCEDURE|Botulinum toxin and bupivacain|Botulinum toxin A AND bupivacain( local anesthetic)
41016644|NCT06663982|PROCEDURE|L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
41016645|NCT06662994|DRUG|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Identify patients that have had a previous vitrectomy and have DME that requires anti-VEGF therapy. Then using a treat-extend-stop protocol6,7 that I previously published, treat patients with DME using high dose aflibercept, until the fluid has resolved and then extend the time interval in between treatments for those patients, while maintaining a fluid-free macula.
41486232|NCT03518892|BEHAVIORAL|Dietary Assessment|Self administered dietary logs
41486233|NCT05534308|PROCEDURE|Transoperative taping|The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, on intraoperative period associated with compression with elastic stockings.
40819488|NCT01854892|OTHER|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
40819489|NCT01854892|OTHER|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
40819490|NCT01854892|OTHER|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
40819491|NCT05122260|DRUG|Q-Griffithsin|intranasal spray administered as a single dose
40819492|NCT05122260|OTHER|Placebo|intranasal spray administered as a single dose
41486234|NCT05534308|OTHER|No trasoperative taping|Patients will received only compression stockings after surgery
40819493|NCT02094027|BEHAVIORAL|Guided Self Help|A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
41486235|NCT05590871|DEVICE|FlashPoint renal denervation system|Radio-frequency ablation of renal arterial sympathetic nerves
41486236|NCT02791893|DEVICE|VNS device|Hand held device to use for self administration of vagus nerve stimulation.
40819494|NCT02094027|OTHER|Treatment As Usual|Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
40819495|NCT06477146|DRUG|Milk thistle (MT)|MT capsules will contain 300 mg of MT with 80% content of Silymarin, standardized to 240mg Silymarin content. Dosing will be based on body weight with maximum dose of 600 mg/day. Dosing will be either 1 or 2 capsules per day based on weight.
41486237|NCT02791893|DEVICE|Inactive device|Hand held device to use for self administration of simulated vagus nerve stimulation.
41486238|NCT00729274|DRUG|normal saline solution|Two 4ml nebulizations with 30 minute interval
41486239|NCT02468622|OTHER|Blood samples|There is no intervention, but we will take blood samples during a spontaneous migraine attack
41486240|NCT04413864|OTHER|Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration|"Assigned Interventions:~* Blood samples collection at inclusion (D0) and follow-up visits (D2, D7 and M6)~* CAM-ICU scores during ICU hospitalisation, neurological questionnaires at M6 (GOAT, GOSE, MOCA, Barthel Index, PTSD, GDS, Rankin score, HADS)"
41486241|NCT00304226|DRUG|valsartan|
41486242|NCT00304226|DRUG|amlodipine|
41486243|NCT03367325|DEVICE|CDS-NVAF|The CDS-NVAF is intended for patients diagnosed with NVAF and treated with VKA. This tool calculates the time in the therapeutic range (TTR) using the Rosendaal method considering the last International Normalized Ratio (INR) data. The INR data are found in the clinical history of NVAF patients. The CDS-NVAF will be activated when the physician introduces the last INR value. At this time the TTR will be calculated automatically. If the TTR value is \< 65%, a pop up screen with a warning text will open suggesting a change to DOAC therapy. The physician can decide whether to change or not the previous prescription. If the TTR value in \> 65% the pop up screen will not appear. The TTR value will remain registered on the screen of the follow up of oral anticoagulant use and can be consulted in future queries. The diffusion of the CDS-NVAF will be made by an announcement on the first day of the intervention when the health care professional opens the electronic clinical history.
40819496|NCT06477146|DRUG|Placebo|The placebo is consistent of Psyllium husk fiber, in 500mg per capsule composition.
40819497|NCT06477146|BEHAVIORAL|Lifestyle Modification|"The primary instructions for lifestyle modification are:~1. Physical activity goal- 20-30 minutes per day 5 to 7 days per week. The aim is 150 minutes a week and more than 300 calories burnt for each workout.~2. Adequate hydration- 4-5 bottles of water a day.~3. Limitation of sugar-free beverages- once daily and 1-2 (8 oz) cups of skim/1% milk (or dairy alternative) daily.~4. Avoidance of beverages with added sugar such as soda, Kool-Aid, juice, and Gatorade.~5. Ideal consumption- three meals daily(breakfast, lunch, dinner)and one snack.~6. Snack Goal \<200 calories. If a 2nd, 3rd, etc. snack is desired it will only be a vegetable.~7. Five servings of fruits/vegetables per day.~8. Each food we recommend eating should have dietary fiber \>3 grams/serving. Ideally \>5 grams/serving.~9. The given survival guide will have all information regarding serving size and portion allotment.~10. MyPlate.gov handout given which will guide participants in relation to portion control."
41016647|NCT06662682|OTHER|Whole-Body Vibration|The intervention (IC) will be specified as a five-minute Whole-Body Vibration session. The WBV take place on a side alternating vibration plate (Wellengang, Germany). The patients stand barefoot on the vibration plate on a prescribed position. In this position the amplitude will be 6-7mm. The WBV protocol contains mobilizing sequences with lower frequencies and activating sequences with higher frequencies
41016648|NCT06662682|OTHER|Control Condition|Non-intervention control condition
41016649|NCT06663566|OTHER|Diagnose the patients right heart function as well as right heart fibrosis|Diagnose the patients right heart function as well as right heart fibrosis
41016650|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
41016651|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
41486244|NCT04969718|OTHER|LEADS Plus educational posters|This intervention covers depression and its symptoms, the link between depression and suicide, the risk and protective factors associated with suicide, the warning signs of suicide, seeking help and overcoming barriers to seeking help, and school and community suicide prevention resources. Six educational posters will also be displayed in class rooms
41486245|NCT04969718|OTHER|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers, originally developed in the USA which to train teachers/school staff to identify the suicide risk in students and encourage students at risk of suicide to seek professional help. Six educational posters will also be displayed in classrooms.
41338004|NCT04363944|DEVICE|mRehab|mRehab (mobile Rehab) was created to better support in-home upper limb rehabilitation programs. It incorporates a task-oriented approach and immediate performance-based feedback. mRehab consists of 3D-printed household items (a mug, bowl, key, and doorknob) integrated with a smartphone and an app. The app guides participants through practice of activities of daily living (ADL), for example, sipping from a mug. It can also consistently measure time to complete an activity and quality of movement (smoothness/accuracy) during the performance of ADLs. In each session of exercise participants receive feedback on the number of repetitions they complete for each activity, the average time to complete the activity and the average smoothness to perform the activity. Participants were trained in use of mRehab in lab visits and then took mRehab home to use the system. mRehab recorded longitudinal data.
41338005|NCT03182153|DEVICE|Extended Cardiac Monitoring|Extended External Cardiac Monitoring
41338006|NCT03080051|DRUG|[18F]MNI-952|Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.
41016652|NCT06663826|DIAGNOSTIC_TEST|oculomotor and pupillary function assessment|This is an exploratory open-label single-centre research project intended to collect data of PD patients in order to develop machine learning models for helping in the diagnosis and monitoring of PD. Each patient will have an initial visit and then a second visit after two weeks. The estimated duration of the study visit 1 is 3 hours, not taking into account the time for patient information and informed consent. The estimated duration of the study visit 2 is 2 hours. During these two visits, patients will undergo an MDS-UPDRS assessment, a neos examination, a standard manual ocular motor and pupil function examination, and gait assessment simultaneously with GaitQ senti and an IMU sensor placed on their back. In the two weeks separating the two visits, patient's gait will be monitored daily at home with GaitQ senti, where they will perform a daily TUG test comprising of 15 m walk, 5 sit to stand, and 5-minute walk. Healthy individuals data will be included from a previous study.
41338007|NCT03080051|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-952.
41016656|NCT06662565|BEHAVIORAL|Behavioral modification|"It includes:~.- Reducing or eliminating smoking and carbonated drinks.~* Weight loss in overweight or obese individuals.~* Caffeine Reduction: Limiting caffeine intake, especially for those consuming at least 400 mg per day.~* Consume Adequate Water: 6 to 8 glasses of water per day.~* Refrain from consuming fluids 2 to 3 hours before bedtime.~* Identify Bladder Irritants: such as sugar substitutes, citrus fruits, and tomato.~* Increasing fiber intake like fruits, and vegetables to reduce constipation with adequate hydration to make stools softer and easier to pass"
41338008|NCT00971230|DRUG|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
41338009|NCT00971230|DRUG|Placebo|Placebo
41338010|NCT04865445|DRUG|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
41338011|NCT04865445|DRUG|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
41338012|NCT00431223|BEHAVIORAL|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
41338013|NCT05310760|DRUG|Vit C|Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
41338014|NCT02049788|BEHAVIORAL|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
41486246|NCT04969718|OTHER|Screening by Professionals programme plus educational posters|This is an indicated or selective intervention which is based on students' responses to the baseline questionnaires. Participating health professionals review students' responses to the questionnaires used in the study and students whose scores meet pre-established cutoff points will be invited to participate in a professional mental health clinical assessment and if needed, referred to clinical services. Six educational posters will also be displayed in classrooms.
41486247|NCT04969718|OTHER|educational posters|Six educational posters will be displayed in all schools in this cluster.
41486248|NCT04969718|OTHER|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents), originally developed in the USA which to train parents to support the young people at risk of suicide. Six educational posters will also be displayed in classrooms.
41486249|NCT05861336|DRUG|Losartan|Losartan will be administered at the dose of 25 mg PO qd starting on Cycle 1 Day 1. If this dose will be tolerated during week 1, escalation to 50 mg PO qd at Cycle 1 Day 8
41486250|NCT05861336|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 28 days
41486251|NCT05861336|DRUG|Nab paclitaxel|nab-paclitaxel 125 mg/m2 on days 1, 8, and 15
41486252|NCT05861336|RADIATION|Stereotactic Body Radiation Therapy|7 consecutive fractions for a total dose of 35-42 Gy
41486253|NCT04771663|OTHER|Breathing a mixture of O2, N2 and CO2 and monitoring SpO2 on each finger|The experiment consists of two separate phases. In one phase, the volunteers inhale one of the mixtures for five minutes. After enough time of recovery, the volunteers undergo the other phase in which they inhale the other mixture of gases. Both phases of the measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of both volunteer hands throughout the experiment.
41486254|NCT02743234|OTHER|Fecal microbiota transplantation|FMT follows 4-10 days of vancomycin 125 mg x 4 daily
41486255|NCT02743234|DRUG|Fidaxomicin|Fidaxomicin 200 mg x 2 daily for 10 days
41486256|NCT02743234|DRUG|Vancomycin|Vancomycin 125 mg x 4 daily for 10 days
41486257|NCT05480592|DRUG|HS-10380|Administered orally as a tablet
41338015|NCT02049788|BEHAVIORAL|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
41338016|NCT04534049|OTHER|Intensive Strength Training (IST)|
41338017|NCT04534049|OTHER|Strength Endurance Training (SET)|
41338018|NCT04534049|OTHER|Flexibility Training (FT)|
41338019|NCT04059874|DRUG|donafenib tablets|donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group
41338020|NCT02484950|BIOLOGICAL|Mesenchymal stem cell augmentation in rotator cuff repair|Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.
41486258|NCT05480592|DRUG|Placebo|Administered orally as a tablet
41486259|NCT03074253|DIAGNOSTIC_TEST|Echocardiography|Patients are undergoing echocardiography
41486260|NCT03074253|DIAGNOSTIC_TEST|magnetic resonance imaging|Patients are undergoing magnetic resonance imaging
41486261|NCT03074253|DIAGNOSTIC_TEST|computed tomography|Patients are undergoing computed tomography
41486262|NCT03074253|DIAGNOSTIC_TEST|blood withdrawl|Peripheral blood samples are being collected from all patients
41486263|NCT05115591|DIAGNOSTIC_TEST|Spinal Ultrasound|Spinal Ultrasound is performed by an observer who records ultrasound characteristics of the intervertebral space chosen by the anesthetist who will practice spinal anesthesia
41486264|NCT05115591|PROCEDURE|Spinal Anesthesia|Spinal anesthesia is performed by an anesthetist after the observer recorded ultrasound characteristics of the intervertebral space chosen by the anesthetist, who is blinded to the ultrasound evaluation.
41486265|NCT03236415|DEVICE|Xience Drug Eluting Stent|Patients will undergo insertion of a drug eluting stent with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
41486266|NCT03236415|DEVICE|ABSORB Bioresorbable Vascular Scaffold|Patients will undergo insertion of a bioresorbable vascular scaffold with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
41486267|NCT00415194|DRUG|pemetrexed|500 mg/m\^2, IV, every 21 days, six 21 day cycles
41486268|NCT00415194|DRUG|cisplatin|75 mg/m\^2, administered IV, every 21 days, six 21 day cycles
41486269|NCT00415194|DRUG|placebo|Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
41486270|NCT01475084|DEVICE|cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps|"The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.~Forceps biopsy will be performed on usual way."
41486271|NCT06213714|DEVICE|5G Tele-Robotic-Assisted PCI|The 5G Tele-Robotic-Assisted VRS100 system is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
41486272|NCT04223531|DRUG|Normal Saline 0.9% Infusion Solution Bag|Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
41486273|NCT03340064|DRUG|Levetiracetam|levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)
41486274|NCT04941339|DRUG|MRG002|Administrated intravenously
41486275|NCT03373136|DEVICE|Polypectomy|Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
41486276|NCT04188314|DRUG|Desflurane|The intervention group will receive desflurane for maintenance of anaesthesia, and the quality of recovery score will be compared post-operatively with the control group who received isoflurane.
41486277|NCT04188314|DRUG|Isoflurane|The control group will receive Isoflurane for maintenance of anesthesia. The quality of recovery score will be compared post-operatively with patients in the intervention group who received desflurane.
41486278|NCT00679926|DRUG|Once daily|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
41016657|NCT06662565|OTHER|Pelvic floor down-training|"Pelvic floor down training exercises aimed at promoting relaxation and deconditioning of the pelvic floor muscles (PFM). It will be practiced three sessions per week for 8 weeks.~Biofeedback-Assisted pelvic floor down-training:~Procedure:~* Rectal biofeedback will be inserted.~* The therapist asks the woman to focus on consciously relaxing and releasing the PFM after each contraction or exercise while watching biofeedback screen.~* Then, breathe deeply and fully into her abdomen, allowing her pelvic floor to naturally relax and lengthen.~* And to incorporate relaxation techniques such as visualization, or progressive muscle relaxation to promote overall muscle relaxation and reduce PFM tension.~* Exercises are typically repeated around 10-20 times per session. This number can vary depending on the patient's condition and tolerance, as well as the therapist's assessment and treatment plan."
41156757|NCT06646523|OTHER|Control group (Bodyweight intervention, usual speed)|"The participants of the control group (Bodyweight intervention, usual speed) will also receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The control intervention will be performed at the usual speed. The same procedures that will be carried out to determine the maximum speed in the experimental group will be used to determine the usual speed in the control group. There will be no progression in the speed of performing the exercises. However, participants in the control group will also receive a home visit from the main researcher every four weeks to avoid bias related to the amount of attention given to participants in the experimental group."
41486279|NCT00444093|DRUG|Opii normata treatment|"After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day."
41486280|NCT00444093|DRUG|Loperamid Treatment|"All patients who receive as a result of randomisation loperamide~After beginning of diarrhea grade 1:~Initial 4mg and 2mg after any unformed stool. The maximum dose amounts to16mg per day.~After beginning of diarrhea grade 2:~Intensive therapy with 2mg loperamide every 2 h. The maximum dose amounts to 16mg per day."
41486281|NCT00004800|BIOLOGICAL|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
41486282|NCT00004800|BIOLOGICAL|diphtheria-tetanus vaccine|
41486283|NCT00477295|DRUG|Zonisamide|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
41486284|NCT00477295|DRUG|Carbamazepine|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
41486285|NCT01507155|DEVICE|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
41486286|NCT04599127|OTHER|Mobilization with movement|The physical therapist will adjust the active movement of the shoulder joint during the arm elevation or abduction and shoulder external rotation
41486287|NCT04599127|OTHER|Conventional physical therapy|The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
41486288|NCT03359577|DIETARY_SUPPLEMENT|Psorax35|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
40819498|NCT06477146|DEVICE|Fibroscan|FibroScan will be completed to measure Elastography. Elastography works by emitting small pulse of energy which may be perceived as a vibration which quickly calculated the stiffness of the liver, which correlates to fat deposition and fibrosis.
41016660|NCT06664086|BEHAVIORAL|economic and psychological burden|measuring the economic and psychological burden of infertility
41486289|NCT03359577|DIETARY_SUPPLEMENT|MCT oil|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
41486290|NCT01333891|DRUG|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
41486291|NCT01333891|DRUG|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
41486292|NCT01333891|DEVICE|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
41486293|NCT01333891|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
41486294|NCT01333891|DEVICE|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
41486295|NCT03903926|BIOLOGICAL|5000 volunteers (6-35 months)-EV71 vaccine|two doses EV71 vaccines will be administrated on day 0, 30 respectively
40819499|NCT03293433|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
41156758|NCT05835466|DRUG|reparixin|reparixin at 1200mg TID three times per day.
41338021|NCT02484950|PROCEDURE|Standard arthroscopic rotator cuff repair|All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
40819500|NCT06607172|DEVICE|oral irrigator|water flosser device
40819501|NCT06607172|DEVICE|oral irrigator|water flosser and 0.075% CPC
40819502|NCT06607172|DRUG|Cetylpyridinium Chloride (CPC)|Cetylpyridinium 0.075%
41016661|NCT06664463|OTHER|Arousal enhancment protocol|"Auditory stimulation: Playing familiar music or personalized playlists tailored to the patient's preferences evokes emotional responses and promotes arousal.~Olfactory stimulation: Using essential oils or fragrances associated with calming or invigorating properties fosters emotional connections and evokes nostalgia through scents linked to positive memories.~Visual stimulation: Displaying photographs of family members or significant events provides comforting visual stimulation and stimulates visual awareness.~Tactile stimulation: Gentle touch or therapeutic massage engages the patient through tactile input, promoting physiological and emotional responses.~Besid thsi protocl also the will recivce routine care throughout study period The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive s"
41016662|NCT06664463|OTHER|Routine Care|The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive supportive care, including pain management, hydration, and nutrition, as well as physical, occupational, or speech therapy as needed based on their recovery progress
41016663|NCT06664658|PROCEDURE|peep 5|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
41338022|NCT02259946|DRUG|BI 1744 CL|
41338023|NCT02259946|DRUG|Placebo|
41338024|NCT02259946|DRUG|Tiotropium bromide|
41338025|NCT05693649|BEHAVIORAL|No Direct Patient Outreach|Patient will not receive direct outreach prompting them to schedule and/or complete colorectal cancer screening.
41338026|NCT05693649|BEHAVIORAL|Direct Patient Outreach: Colonoscopy Only|Patient will receive direct outreach including an order to schedule and complete colonoscopy.
40819503|NCT04243018|BEHAVIORAL|Acceptance and Commitment Therapy Group Treatment|The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.
40819504|NCT04243018|BEHAVIORAL|Peer Support Group|The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
40819505|NCT03416920|OTHER|Wellframe|Wellframe mobile phone app
41338027|NCT05693649|BEHAVIORAL|Direct Patient Outreach: Sequential Choice|Patient will receive direct outreach including an order to schedule and complete colonoscopy then an at-home fecal immunochemical test (FIT) if colonoscopy is not completed.
41338028|NCT05693649|BEHAVIORAL|Visit-Based Nudge/Text|Patient's clinician will receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will also receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
41338029|NCT05693649|BEHAVIORAL|No Nudge/Text|Patient's clinician will not receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will not receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
41338030|NCT02636738|DEVICE|Vela XL thulium laser, laser fiber and accessories.|The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
41338031|NCT01399255|BIOLOGICAL|Insulin lispro|Dosage form- Subcutaneous Injection
41338032|NCT03030391|OTHER|PET|
41338033|NCT03030391|OTHER|MRI|
41338034|NCT00348491|DRUG|Lumiracoxib|
41338035|NCT00656760|OTHER|PET/CT|PET/CT is being performed on all patients in the study.
41338036|NCT02623491|DRUG|JNJ-55375515|Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
41016664|NCT06664658|PROCEDURE|peep 10|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
41486296|NCT03627507|BIOLOGICAL|Hepa-B|Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine. This bulk is formulated to prepare finished dosage to manufacture large scale in fully GMP compliant plant. Incepta has conducted preclinical study at Bioneed, India. After successful completion of preclinical study, this non inferiority clinical trial with innovator product is needed for Licensure in Bangladesh.
41486297|NCT03627507|BIOLOGICAL|Engerix B|.'Engerix B' is a recombinant DNA hepatitis B vaccine. It is sterile suspension of purified surface antigen of hepatitis B virus obtained by culturing genetically yeast cells (Saccharomyces cerevisiae cells), which carry the gene that codes for HBsAg
41016665|NCT06663917|OTHER|Experimental frequency allocation table (FAT) - 438 Hz|"The modified cochlear implant program (experimental FAT) changes which frequencies are presented to the cochlear implant. The experimental FAT frequency of 438 Hz will be loaded onto the subjects processor via the CI Select Mobile App. Subjects will use the experimental FAT for one month."
41016666|NCT06663917|OTHER|Standard FAT - 188 Hz|All subjects will retain one program with the standard 188 Hz FAT. Subjects will use the standard FAT for one month.
41016667|NCT06663839|DRUG|Biological NILK-2301|Treatments will be administered every two weeks in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Should evidence emerge showing that treatment beyond one year may prolong benefit in responding patients, the protocol will be amended to ensure that these responding patients may continue with the study treatment beyond 12 months until disease progression.
41016668|NCT06662786|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
41016669|NCT06662786|BIOLOGICAL|Cetuximab|Cetuximab will be administered.
41016670|NCT06662786|DRUG|5-fluorouracil|5-fluorouracil will be administered as chemotherapy regimen.
41486298|NCT00614926|DRUG|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
41016671|NCT06662786|DRUG|Leucovorin calcium/Levoleucovorin|Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
41016672|NCT06662786|DRUG|Oxaliplatin|Oxaliplatin will be administered as chemotherapy regimen.
41016673|NCT06662786|DRUG|Irinotecan Hydrochloride|Irinotecan hydrochloride will be administered as chemotherapy regimen.
41338037|NCT02623491|DRUG|Placebo|Participants will receive matching placebo.
41486299|NCT00614926|DRUG|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
41338038|NCT00004125|DRUG|cyclophosphamide|
41338039|NCT00004125|DRUG|docetaxel|
41338040|NCT00004125|DRUG|doxorubicin hydrochloride|
41338041|NCT00004125|DRUG|paclitaxel|
41338042|NCT00004125|DRUG|tamoxifen citrate|
41338043|NCT00004125|RADIATION|radiation therapy|
41338044|NCT06268509|DIAGNOSTIC_TEST|Nutritional panel laboratory examination|As stated in group description
41338045|NCT06268509|DIETARY_SUPPLEMENT|Pregnancy supplements (other than provided by Ministry of Health)|As stated in group description
41338046|NCT06268509|DIAGNOSTIC_TEST|Fetomaternal ultrasound|As stated in group description
41338047|NCT06434025|DRUG|Iron Carboxymaltose|Iron Carboxymaltose 500 mg. 2 vials administered IV.
41338048|NCT06434025|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg Tab, PO, onde a day.
41338049|NCT06434025|DRUG|Placebo of Iron Carboxymaltose|Solution Sodium Chloride 0,9% 100 ml, IV, once.
41338050|NCT06434025|DRUG|Placebo of Dapagliflozin|Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg
41338051|NCT03793283|DEVICE|CSII|Currently receiving CSII therapy during 6 or more months.
41338052|NCT03793283|DRUG|Multiple dose insulin injections|Currently receiving MDI therapy during 6 or more months.
41338053|NCT02899260|DEVICE|Peanut Exercise Ball|A Peanut shaped exercise ball.
41338054|NCT02826876|DRUG|Topical use|Topical use of Ropivacaine in laparoscopic surgery
41338055|NCT02826876|OTHER|laparoscopic repair of inguinal hernia|intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia
41338056|NCT02826876|OTHER|laparoscopic bariatric surgery|intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
41016674|NCT06663696|DEVICE|Supraflex Cruz Sirolimus-eluting Coronary Stent System|Biodegradable polymer-coated, cobalt-chromium sirolimus-eluting coronary stent
41016675|NCT06663124|DEVICE|EC-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are extreme capsule.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
41486300|NCT01957566|PROCEDURE|APS|
41016676|NCT06664034|BEHAVIORAL|Multi-component reproductive health care intervention|"The multi-component reproductive health care intervention includes:~1. Young cancer patients presenting to oncology visits will complete a clinic-based reproductive health needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future and ii) need for contraception.~2. Reproductive health patient navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's reproductive health needs, ii) provide individualized patient education and counseling on a) infertility risk related to cancer type and treatment and b) screening and management strategies for reproductive health needs, iii) provide support with the goal of engaging in goal-concordant reproductive health care.~3. Telehealth reproductive health consultation will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
41016677|NCT06663813|BEHAVIORAL|Educational Intervention|Utilizing the Health Belief model, educational materials detailing diabetes risk factors to address perceived susceptibility, diabetes severity and complications to address perceived severity, and PCP follow-up information and medication assistance programs to address perceived barriers will be provided.
41016678|NCT06664736|BEHAVIORAL|Exercise|The exercise group performed a home-based exercise program consisting of aerobics 3 days a week with videos and strengthening and stretching exercises 2 days a week with infographics, for 8 weeks.
41016679|NCT06664736|BEHAVIORAL|Physical activity|The control group was advised to increase physical activity
41338057|NCT03611036|OTHER|Strength training|Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
41486301|NCT03672305|BIOLOGICAL|c-Met/PD-L1 CAR-T cell injection|injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes
41486302|NCT04222374|PROCEDURE|Intervention in the UroCCR sites|"1. Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent)~2. DNA extraction:~   * For the patients of Bordeaux University Hospital, 2 aliquots will be constituted:~  * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA,~  * 1 aliquot for the UroCCR biobank.~  * For patients from other UroCCR centers, only 1 aliquot will be constituted:~  * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA.~3. Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux."
41016680|NCT06664749|OTHER|Three stair position pillow group|Preterm infants were monitored with three stair position pillows.
41016681|NCT06664749|OTHER|Positioning material group|Preterm infants were monitored with positioning material pillows.
41338058|NCT03611036|OTHER|Endurance training|Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
41338059|NCT04949425|DRUG|Adavosertib|Patients will receive Adavosertib orally.
41338060|NCT01498536|BEHAVIORAL|aerobic exercise|3 times per week for 12-weeks
41338061|NCT01176890|DRUG|GLP-1|"1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
41338062|NCT01176890|OTHER|Saline|"Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
41486303|NCT04222374|PROCEDURE|Intervention in the CRB of Bordeaux University Hospital|"1. Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank.~2. Overall packing of GWAS samples for shipment to the NCI.~3. Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study."
41486304|NCT04222374|PROCEDURE|Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital|Transfer of the data associated with the samples to the NCI.
41486305|NCT04222374|PROCEDURE|Subsequent intervention at the NCI (for information)|"1. Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network.~2. GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples."
41016682|NCT06663670|OTHER|Intraneural Facilitation Therapy|"* The initial hold, known as the facilitation hold, involves placing the contralateral joint in a maximal loose-pack position that will be comfortable for the patient. An illustration of this would be positioning the ankle joint on the contralateral side in full plantar flexion and inversion. Throughout the entire session, this position will be maintained using a stretch strap. It is crucial to emphasize that there is no muscle engagement in the joint where the facilitation takes place, only a slight stretch.~* Once the pressure elevation occurs, the subsequent phase known as the secondary hold will be initiated to direct the augmented flow of epineurial blood toward the transperineurial vessels connecting the epiperineum and the endoneurial capillaries of the target area.~* The final maneuver, the sub hold, leverages Bernoulli's principle to augment blood flow through the ischemic endoneurial capillaries experiencing heightened transmural pressure."
41486306|NCT02267668|BEHAVIORAL|STEP|Physical therapists guide participants through novel set of assigned exercises
41486307|NCT02267668|BEHAVIORAL|Control|Participants self-guide through standard exercises
41486308|NCT05234372|BEHAVIORAL|mivacunaLA|Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (\<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites \& resources.
41016683|NCT06663670|OTHER|Nerve Flossing Technique|"Tibial Nerve:~1. Passively flex the hip while dorsiflexing and everting the ankle to create tension; flex the knee to unload, then extend and plantarflex to reload.~2. Flex the hip, extend the knee, and dorsiflex and evert the ankle to induce tension; flex the hip to unload, then extend and plantarflex to reload.~3. Lift the leg, flex the hip, and extend the knee; dorsiflex and evert the ankle to induce tension, then plantarflex to unload.~Common Peroneal Nerve:~1. Passively flex the hip and plantarflex and invert the ankle to induce tension; flex the knee to unload, then extend and dorsiflex to reload.~2. Flex the hip, extend the knee, and plantarflex and invert the ankle to induce tension; flex the hip to unload, then extend and dorsiflex to reload.~3. Lift the leg, flex the hip, and extend the knee; plantarflex and invert the ankle to induce tension, then dorsiflex to unload."
41486309|NCT03370874|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
41016684|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose A|altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169
41016685|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose B|altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169
41016686|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose C|altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169
41338063|NCT00006968|BIOLOGICAL|filgrastim|
41486310|NCT03370874|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to diabetic foot ulcer
41016687|NCT06663436|BIOLOGICAL|TYPHIBEV|TYPHIBEV administered intramuscularly on Day 1
41016688|NCT06663436|COMBINATION_PRODUCT|Infanrix hexa|Infanrix hexa administered intramuscularly on Day 169
41016689|NCT06663436|BIOLOGICAL|MR-VAC|MR-VAC co-administered subcutaneously on Day 1 and Day 169
41338064|NCT00006968|DRUG|cyclosporine|
41338065|NCT00006968|DRUG|pentostatin|
41338066|NCT00006968|PROCEDURE|allogeneic bone marrow transplantation|
41338067|NCT00006968|PROCEDURE|peripheral blood stem cell transplantation|
41338068|NCT06396988|OTHER|Novamin application|Teeth from this group will be treated with the application of Sensodyne Repair\&Protect Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
41338069|NCT06396988|OTHER|Parodontax application|Teeth from this group will be treated with the application of Parodontax Complete Protection Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
41486311|NCT01527084|PROCEDURE|surgical intervention after percutaneous catheter drainage|Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
41486312|NCT05124561|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
41486313|NCT05124561|BIOLOGICAL|Placebo|Nebulized inhalation through the mouth
41486314|NCT02958423|DEVICE|Transcranial DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers
41486315|NCT02958423|DEVICE|Transspinal DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers
41486316|NCT02958423|DEVICE|Transcranial DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients
41486317|NCT02958423|DEVICE|Transspinal DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients
41486318|NCT04941482|BEHAVIORAL|Periodic health check program for post-stroke|The stroke survivors will be assessed their physical and mental health, recurrence risks, and harmful behaviors at 0, 1, 3, and 6 months by specific scales.
41486319|NCT04941482|BEHAVIORAL|Guiding the appropriate rehabilitation exercises|The appropriate rehabilitation exercises will be designed and guided for each patient and they will be followed up by the daily online report.
41486320|NCT04941482|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will carry out on post-stroke patients in the first three months (one time per week in the first month and one time per the second and third month). This intervention method aims to discover and resolve patient's conflicts by a standardized communication skill to improve their mental health and change negative behaviors.
41016690|NCT06663449|PROCEDURE|subcostal transversus abdominis plane block|subcostal transversus abdominis plane block will be performed using 20 mL of 0.25 bupivacaine
41486321|NCT04941482|DEVICE|Functional near-infrared spectroscopy|The fNIRS devices as an effective monitoring and therapeutic tool, evaluating the evolution of neural activity and stroke rehabilitation and recovery. Moreover, the cortex hemodynamic measure by fNIRS may detect early various mental disorders such as depression, anxiety, schizophrenia... through cognitive tasks.
41486322|NCT03722095|DEVICE|active tDCS|A current of 2 milliampère (mA) through electrodes of 5x5cm.
41486323|NCT03722095|DEVICE|sham tDCS|Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.
41486324|NCT03722095|DEVICE|iTBS|54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
41016691|NCT06663449|PROCEDURE|erector spinae plane block|erector spinae plane block will be performed using 20 mL of 0.25 bupivacaine
41016692|NCT06662942|DRUG|StrataMGT|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
41016693|NCT06662942|DRUG|Placebo|The placebo is a silicone-based product that does not contain StrataMGT. It will be applied topically to the vulvar skin.
41338070|NCT03822546|OTHER|Conventional cigarette|Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals
41338071|NCT03822546|OTHER|myblu 25 mg freebase|E-cigarette used for 10 inhalations every 30 seconds
41338072|NCT03822546|OTHER|myblu 16 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
41486325|NCT04289506|DIAGNOSTIC_TEST|mRNA expression|The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).
41338073|NCT03822546|OTHER|myblu 25 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
41338074|NCT03822546|OTHER|myblu 40 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
41338075|NCT03822546|OTHER|blu PRO 48 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
41338076|NCT02719457|OTHER|6 minute walk test (6 MWT)|6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity
41486326|NCT02140307|BEHAVIORAL|Relaxation Response-based Mental Health Promotion (RR-MHP)|"The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship)."
41016694|NCT06658132|DRUG|0.5~1ug/kg/min remifentanil combined with 0.2~0.5mg/kg/h esketamine for the physiological testing phase of DBS surgery.|Throughout the first and third stages of surgery, all patients receive a traditional induction of anesthesia. Fifteen minutes before the second stage of surgery (MER and clinical assessment), when the burr hole is ready, the propofol and sevoflurane infusion is discontinued, and patients receive 0.5\~1ug/kg/min remifentanil combined with 0.2\~0.5mg/kg/h esketamine. On completion of the second stage of surgery, the interventional drug is discontinued and propofol combined with sevoflurane is resumed until the end of the third stage.
41486327|NCT02254161|DRUG|Matching placebo|Tablet
41486328|NCT02254161|DRUG|BI 1181181 healthy elderly|Tablet
41486329|NCT02254161|DRUG|BI 1181181 Healthy young|Tablet
41486330|NCT00862238|BEHAVIORAL|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, \& C
41486331|NCT00862238|OTHER|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, \& C
41486332|NCT03835221|DEVICE|methafilcon A toric contact lenses|Bilateral daily wear of methafilcon A toric contact lenses
41486333|NCT03835221|DEVICE|fanfilcon A toric contact lenses|Bilateral daily wear of fanfilcon A toric contact lenses
41486334|NCT02480218|OTHER|Neuropsychological test battery|Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
41486335|NCT00505375|DRUG|CTLA-4 Ig|Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses
41486336|NCT00505375|OTHER|Placebo|Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
41486337|NCT01988961|BIOLOGICAL|Golimumab|SC injections
41486338|NCT03589521|BEHAVIORAL|ABCT_Military|15 Weekly Couple Therapy Sessions
41486339|NCT06072365|OTHER|nutritional intake questionnaire|patients completed a nutritional intake questionnaire before to start the treatment, 3mounths after and twelve months after
41486340|NCT02124941|DRUG|N-acetyl cysteine|Upon completion of baseline (abstinence) 1H-MRS scanning, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
41486341|NCT02124941|DIAGNOSTIC_TEST|[18F]FDG PET scan|All subjects will undergo \[18F\]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
41486342|NCT02124941|DIAGNOSTIC_TEST|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans at 7T, including before and after two-weeks of placebo and NAC administration.
41486343|NCT02124941|DIAGNOSTIC_TEST|[11C]APP311 PET scan|All subjects will undergo \[11C\]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
41486344|NCT00110162|DRUG|antiandrogen therapy|
41486345|NCT00110162|DRUG|releasing hormone agonist therapy|
41486346|NCT00110162|PROCEDURE|orchiectomy|
41486347|NCT04312269|OTHER|Targeted Memory Reactivation (TMR)|Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
41486348|NCT05745792|OTHER|Description of clinical, immunological and tumor features of patients harboring Hu Abs|This observationnal study involves clinical data and bio. samples (DNA and tumors block). Demographic and clinical data already in French Reference Center on PNS database will be reviewed. Additional data will be obtained from the referral physicians. The results of diagnostic tests performed to detect Hu-Abs in the patients are already in this database and will be retrospectively analyzed. In addition, the 4 available techniques (immunofluorescence, commercial immunodot, Western blot, and CBA) will be performed from Jan. 2022 to Dec. 2022.Tumor samples from 2 cohorts will be analyzed: (i) tumors of patients with Hu-Abs and PNS, and (ii) tumors of patients without PNS (mostly SCLC). After selecting patients, the study will involve 3 steps: (i) pathological confirmation; (ii) DNA sequencing and CNV analysis (panel of genes involved in anti-Hu autoimmunity; mainly ELAVL1 to 4, encoding for HuA to HuD, the 4 main proteins of the Hu family); and (iii) whole-genome RNA sequencing.
41486349|NCT00879892|DRUG|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
41486350|NCT00879892|OTHER|Hypothermia|24 hour, target core temperature 33
41486351|NCT03417193|DRUG|opioid free Anesthesia vs Opioid based Anesthesia|Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
41016695|NCT06661837|OTHER|Clinical examination and mobile photo|Children were both clinically examined and a mobile photo was taken for assessment
41016696|NCT06659315|BEHAVIORAL|Couples Problem Solving Therapy|A couples-based problem solving program to deal with depression, PMTCT adherence, and couple communication.
41016697|NCT06662578|OTHER|Traditional memory workshop|The participants received 8 weekly sessions of 60 minutes of neurocognitive stimulation, based on French memory workshops.
41016698|NCT06662578|OTHER|Equine assisted therapy memory workshops|The participants received 8 weekly sessions of 60 minutes, based on traditional memory workshops (French type of neurocognitive stimulation) with the mediation of a horse (example : working on associative memory by selecting which object is used for the horse between 2 presented objects).
41016699|NCT06663371|BEHAVIORAL|Basic Physical Fitness|The single module training paradigm followed a circuit-style format, with each training module consisting of 6 to 8 distinct exercise movements. Taking the INT training intervention on Mondays as an example, the training protocol involved completing one major module (e.g., plyometric exercises) before transitioning to another module (e.g., core stability exercises). Specific exercise methods, such as box jumps, were performed until all sets were completed before moving on to the next exercise (e.g., continuous depth jumps).
41338077|NCT02719457|OTHER|Spot marching test (SMT)|Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
41338078|NCT06451276|DEVICE|Nasoalveolar molding in unilateral cleft lip and palate|compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate
41338079|NCT02058641|DRUG|Darapladib|EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
41338080|NCT00493441|DRUG|AVN944|150, 200, 250, 300, or 400 mg q12h
41338081|NCT04629976|DRUG|NCO-48 Fumarate 4 mg|2 x 2mg NCO-48 Fumarate over 28 days of therapy
41338082|NCT04629976|DRUG|NCO-48 Fumarate 20 mg|2 x 10 mg NCO-48 Fumarate over 28 days of therapy
41338083|NCT04629976|DRUG|Tenofovir Alafenamide 25 mg|25 mg over 28 days of therapy
41338084|NCT02740712|DRUG|Caffeine|200 mg (4 x 50mg) Tablet
41338085|NCT02740712|DRUG|Warfarin|10 mg (2 x 5mg) Tablet
41338086|NCT02740712|DRUG|Omeprazole|40 mg Tablet
41338087|NCT02740712|DRUG|Midazolam|5 mg/mL
41338088|NCT02740712|DRUG|digoxin|.25 mg Tablet
41338089|NCT02740712|DRUG|Vitamin K|10 mg Tablet
41338090|NCT02740712|DRUG|Rucaparib|200 \& 300 mg tablet
41338091|NCT01188460|BEHAVIORAL|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
41338092|NCT01188460|BEHAVIORAL|Sleep diary|
41486352|NCT04235452|DIAGNOSTIC_TEST|Somatosensory evoked potential|"Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out."
40819506|NCT04686851|OTHER|Comprehensive Geriatric Assessment and follow-up|"All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA.~Follow-up on initial treatment plan is scheduled to one month after baseline CGA."
41016700|NCT06663371|BEHAVIORAL|Traditional Physical Training|In the fundamental strength training, a circuit training modality is employed, with each training segment comprising 5 to 7 exercise movements. For instance, a series of squat exercises is performed initially, followed by upper body strength training such as bench presses; each movement must be completed with the specified number of sets and repetitions before proceeding to the next exercise. Explosiveness training enhances the rapid contraction capabilities of the muscles through a series of jumping and throwing movements, while flexibility exercises improve the range of motion of muscles and joints through a combination of static and dynamic stretching.
41338093|NCT02853149|BEHAVIORAL|Spinal Cord Injury (SCI)|"The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
41486353|NCT01633411|DEVICE|Focal Cryoballoon Ablation System - 6 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
41486354|NCT01633411|DEVICE|Focal Cryoballoon Ablation System - 8 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
41486355|NCT01633411|DEVICE|CryoBalloon Focal Ablation System - 10 seconds|"Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
41486356|NCT04919863|DRUG|NTP42:KVA4|Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
41486357|NCT04919863|DRUG|Placebo|Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
41016701|NCT06663293|OTHER|Conventional Nasal Cannula|The initial flow rate for nasal cannula oxygen was set at 3 L/min. In cases of hypoxia, the oxygen concentration was adjusted by increasing the flow rate by 1 to 2 L/min.
41016702|NCT06663293|OTHER|High-flow nasal cannula|The high-flow nasal oxygenation device was set to a temperature of 36°C and an FiO2 of 0.4. The initial oxygen flow rate for the high flow group was determined according to the age and weight of the patients, based on our pediatric intensive care team's guidelines and the reference from the Slain study. When SpO2 fell below 94%, it was considered hypoxia, and the flow rate was increased by 2 to 4 L/min.
41016703|NCT06664528|DIAGNOSTIC_TEST|ECHOCARDIOGRAPHY|A complete echocardiographic exam will be perfomed during each cardio-oncologic evaluation.
41338094|NCT02853149|BEHAVIORAL|Caregiver Intervention(CCC)|"The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
41338095|NCT02853149|BEHAVIORAL|Caregiver Control (CC)|The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
41338096|NCT02283541|BEHAVIORAL|Automatic self-transcending meditation|ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
41338097|NCT00661167|DRUG|ABI-007|ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
41338098|NCT04955301|BEHAVIORAL|Priming intervention|The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.
41338099|NCT05178290|BEHAVIORAL|CHILD back-to-ECE COVID-19 saliva testing|Preschool children and their parent will complete saliva COVID-19 tests at the start of the school year and after winter break as part of a back-to-ECE safely intervention. Tests may be completed during pick up, at drop off, or during school, depending on local on-campus regulations.
41486358|NCT04120090|DRUG|low dose ruxolitinib|The dose for adult patients(Age\>=14 years) is generally 10 mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 5mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 2.5mg twice daily.
41486359|NCT04120090|DRUG|high dose ruxolitinib|The dose for adult patients(Age\>=14 years) is generally 20mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 10mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 5mg twice daily
41486360|NCT00103311|DRUG|ispinesib|Given IV
41486361|NCT00103311|OTHER|laboratory biomarker analysis|Correlative studies
41016704|NCT06664528|DIAGNOSTIC_TEST|ELETTROCARDIOGRAPHY (ECG)|An ECG tracing will be obtained during each cardio-oncologic evaluation.
41338100|NCT05178290|BEHAVIORAL|ECE personnel back-to-ECE COVID-19 saliva screening|ECE personnel will complete saliva COVID-19 tests biweekly through the school year as part of a back-to-ECE safely intervention. Tests may be completed on the ECE campus or in the parking lot, depending on local on-campus regulations
41338101|NCT05178290|BEHAVIORAL|SAGE garden programming|The SAGE garden programming includes installation of a garden; teacher training via Zoom and/or short videos, a binder and website support along with other accompanying materials and teacher technical support (email, text, phone); gardening supplies and gear (e.g., hats, watering cans, gloves); and delivers active songs, games, science experiments and other outdoor learning opportunities.
41486362|NCT06492486|RADIATION|Adaptive radiotherapy|Volumetric and biological adaptive radiotherapy will be delivered based on interval imaging with MRI and PET scan during treatment.
41486363|NCT02165865|PROCEDURE|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
41016705|NCT06664528|DIAGNOSTIC_TEST|LABORATORY TESTS|The cardiac biomarkers high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) will be dosed according to the current recommendations of Cardio-Oncology Guidelines.
41338102|NCT01392768|DRUG|Levetiracetam|Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
41338103|NCT01392768|DRUG|Placebo|Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
41338104|NCT04599972|DRUG|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
41338105|NCT04599972|DRUG|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
41338106|NCT00545467|DRUG|Aripiprazole|Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
41338107|NCT04060849|DRUG|Nozin|Given via nasal single-use popswabs or single-use cotton tipped applicators
41486364|NCT03021694|DIETARY_SUPPLEMENT|Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men|
41486365|NCT05501366|DIETARY_SUPPLEMENT|Ketone Supplement|Four different exogenous ketone products at two serving sizes or a non-ketogenic placebo (one study product per test day). 1) Monoester of BHB (R)-1,3 butanediol (BHB Mono-ester), 2) diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) 3) diester of AcAc and (R,S)-1,3 butanediol (AcAc Di-ester) \& 4) (R) -1,3 butanediol only (BDO). All products will be delivered in 2 different dosages 180mg/kg and 360mg/kg on separate testing days.
41486366|NCT05501366|BEHAVIORAL|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
41486367|NCT05501366|BIOLOGICAL|Blood Draw|IV cannula will be inserted at the start of each Test Day, and removed at the end of each Test Day, Blood samples will be collected according to the schedule in Figure 1. Cannula will be flushed with a small volume of saline after each sample to maintain patency. We will draw 504 mL of blood, which is about 2.1 cups throughout the 4-week intervention
41486368|NCT05501366|OTHER|Breath Reading|Participants will breathe into a commercially available handheld breath acetone analyzer according to the schedule. Participants will wear a fitted face mask attached to a metabolic cart for a 10-minute period every 60 minutes
40819507|NCT04582435|DRUG|Insulin Icodec|Participants will receive 1 dose from a prefilled pen, administered subcutaneously (under the skin), once a week by designated study staff, for a total of at least 8 and a maximum of 16 doses which equals 8-16 weeks of treatment.
40819508|NCT02099162|DEVICE|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
41486369|NCT05501366|OTHER|Heart Rate Variability|Participants will wear a Bluetooth heart rate monitor chest strap throughout the test day.
41486370|NCT05501366|OTHER|CGM/CKM|Continuous Ketone Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day
41486371|NCT05501366|RADIATION|DXA|Lean Body Mass will be assessed once via DXA
41486372|NCT05501366|OTHER|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
41486373|NCT01401621|BEHAVIORAL|Scratchoff Prompt: Name of Test|A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
40819509|NCT03117790|DRUG|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
40819510|NCT03117790|DRUG|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
40819511|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Perception Training: Visual Sweeps; Mind's Eye; Hawk Eye; and Divided Attention. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
40819512|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Cognitive Control Training: Mind Bender; Divided Attention; Card Shark; and Freeze Frame. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
41338108|NCT04060849|OTHER|Best Practice|Receive standard of care
41338109|NCT04541095|OTHER|EX_IMF|Infant formula with large amounts of beta-palmitate (about 60%).
41338110|NCT04541095|OTHER|ST_IMF|Infant formula with low amounts beta-palmitate (about 10%).
41338111|NCT04176536|DRUG|BI 764198|Capsules
41338112|NCT03622216|DRUG|Bradanicline|Three different doses over the course of the study
41338113|NCT03622216|DRUG|Placebo|Matching placebo for Bradanicline
41338114|NCT04246424|BEHAVIORAL|Fibit + Coaching|This intervention is a combination of the coaching and fitbit interventions
41338115|NCT04246424|BEHAVIORAL|Coaching|"Coaching Participants who are assigned coaching group will receive telephone coaching. Coaches follow a guide developed by Kelly Glazer Baron, Jennifer Duffecy, Kathryn Reid, and Lauren Caccamo. The first session is an approximately 30 minute engagement session, with the purpose of getting to know the participant to increase likelihood for participation. The end goal is to have participants express Desire, Ability, Reason, Need, Can (DARN-C) to make changes in sleep). The remainder calls (week 2-6) are follow-up calls lasting about 5 minutes. The goal of these calls is to keep participants motivated and address any issues with the Fitbit hard or software.~Participants will also receive weekly email lessons to their personal email address for 1-6 weeks."
41338116|NCT04246424|BEHAVIORAL|Fitbit|Fitbit Participants in the fitbit group will receive a Fitbit Charge 3 black, and asked to wear it for 1-6 weeks. Participants will monitor their sleep through the sleep section in the Fitbit app on the smartphone. Participants will be provided login information so that researchers can access this data and asked to keep Bluetooth on. After week 6, participants can choose to continue to wear the device for the duration of the study (12 weeks). Though wear at weeks 7-12 is not required, researchers will still use any data that was collected from the fitbit during that time. At the completion of their participation, researchers retain the login information and the device is switched to a personal login of the participants choice.
41338117|NCT00056550|BIOLOGICAL|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
41338118|NCT04450342|DEVICE|Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue. The REGENETEN Bioinductive Implant is a bioabsorbable implant device that provides a layer of collagen over injured tendons. The implant is designed to provide a layer of collagen between a flat tendon and the surrounding tissue. After hydration, the implant is an easy-to-handle, pliable, nonfriable, porous collagen sheet.
41338119|NCT04450342|PROCEDURE|Arthroscopic rotator cuff repair|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear without supplement.
41338120|NCT04450342|DEVICE|Arthroscopic rotator cuff repair for revision surgery|The Arthroscopic rotator cuff repair can also occur in recurrent tears. The REGENETEN Bioinductive Implant will be applied during the ARCR procedure.
41338121|NCT00310063|PROCEDURE|acupressure therapy|Acupressure wristband
41486374|NCT01401621|BEHAVIORAL|Scratchoff Prompt: Call to Action|A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
41486375|NCT01401621|BEHAVIORAL|Control|No scratch-off element
41486376|NCT05632211|BIOLOGICAL|AVT05|Pre filled syringes filled with AVT05
41486377|NCT05632211|BIOLOGICAL|Simponi|Pre filled syringes filled with Simponi
41486378|NCT05556759|PROCEDURE|control|patient will be operated under general anesthesia
41486379|NCT05556759|PROCEDURE|IPS|patients will receive ultrasound-guided anterior IPS block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
41338122|NCT00310063|PROCEDURE|sham intervention|Sham wristband
41338123|NCT00111436|DRUG|Etanercept|Enbrel 50 mg once weekly or 50 mg twice weekly
41338124|NCT02913833|OTHER|Pain evaluation|Pain will be assessed four times per day on a visual analogic scale.
41338125|NCT04526704|DRUG|Pexidartinib|200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
40819513|NCT06608394|OTHER|no intervention|no intervention
41486380|NCT05556759|PROCEDURE|Supra-iliac QL|patients will receive ultrasound-guided supra-iliac anterior QL block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
41486381|NCT01536158|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
41486382|NCT01536158|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
41486383|NCT05495828|DRUG|Orelabrutinib|Orelabrutinib, 150mg, po, qd
41486384|NCT06227156|DRUG|Disitamab Vedotin Injection|2.0 mg/kg, intravenous infusion，D1, every 2 weeks is a treatment cycle
41486385|NCT05286723|OTHER|Multicomponent Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
41486386|NCT02450708|GENETIC|KIR genotyping|
41486387|NCT02450708|GENETIC|HLA genotyping|
41486388|NCT03074747|DIAGNOSTIC_TEST|questionnaires|After filled the questionnaires, the patients will receive the PSG monitoring
41486389|NCT02551666|OTHER|Balance recovery training|Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
41486390|NCT02551666|OTHER|Tai Chi exercise|Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
41486391|NCT01176214|PROCEDURE|Early tracheostomy|"Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset."
41486392|NCT01176214|PROCEDURE|Late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
41338126|NCT05587608|PROCEDURE|combined thoracic segmental spinal epidural anesthesia|ultrasound guided thoracic segmental spinal anesthesia at the level of T10 interlaminar space , patients will be in sitting position, spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the Dura matter. 2cc of heavy Marcaine plus 25 ug fentanyl are injected through the spinal needle.
41338127|NCT02071641|DRUG|Sunitinib|
41338128|NCT02457299|PROCEDURE|Two Stage Esophagectomy|Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction
41338129|NCT02457299|PROCEDURE|One Stage Esophagectomy|Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
41338130|NCT00524667|DRUG|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until \>1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
41338131|NCT04748913|DEVICE|Radiographic examination|Standardized bitewing radiographs will be performed by the principal investigator
41338132|NCT04748913|DEVICE|Scanning with DIAGNOcam|The surface of the selected teeth will be examined under near infrared light using the DIAGNOcam device
41338133|NCT04748913|DEVICE|Scan with DIAGNOcam and Indocyanine|One the dye has been applied, a new series of images will be taken with Diagnocam
41338134|NCT04748913|DIAGNOSTIC_TEST|Visual-tactile exploration with separation|The point of contact will be open in the corresponding proximal area of the lesion using an elastic orthodontic separator
41338135|NCT05384795|OTHER|Lung ultrasound|Lung atelectasis score
41338136|NCT00132158|DRUG|Irinotecan (Camptosar), Gefitinib (Iressa)|See Detailed Description for treatment plan.
41338137|NCT04709874|OTHER|Paravertebral block|Paravertebral block using nerve stimulator guidance will be done at C7-T1
41338138|NCT04709874|OTHER|Suprascapular block|Paravertebral block using nerve stimulator guidance will be done
41338139|NCT05305976|OTHER|Telerehabilitation|The 8 week exercise program with telerehabilitation
41338140|NCT01458795|PROCEDURE|Endovenous laser ablation|
41338141|NCT06092086|DRUG|Loratinib|Continuous daily PO dosing of lorlatinib 100mg QD.
41338142|NCT01909219|DRUG|Sodium picosulphate/magnesium Citrate|Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
41486393|NCT04973553|OTHER|upper limb rehabilitation|the intervention consisting of two components: a) Upper limb training protocol; b) Technology-assist training.
41486394|NCT04539886|DEVICE|CellFX System|CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
41486395|NCT04539886|DEVICE|Intralesional Electrodesiccation|Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode
41338143|NCT00263315|DRUG|nebulised liposomal amphotericin B|
41338144|NCT01785498|BEHAVIORAL|Supplementary resources|Clinical and educational resources for patients, their families and the professionals who care for them.
41338145|NCT01394211|DRUG|anastrozole|Given PO
41338146|NCT01394211|DRUG|pazopanib hydrochloride|Given PO
41338147|NCT01394211|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
41338148|NCT00961558|PROCEDURE|Varicocelectomy|Varicocelectomy
41338149|NCT02215616|DRUG|Laquinimod|Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
41338150|NCT02215616|DRUG|Placebo|Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
41338151|NCT03955497|OTHER|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
41338152|NCT03955497|DRUG|Sodium Hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
41338153|NCT03955497|PROCEDURE|Extraction of abdominal fat|In the experimental group, abdominal fat was extracted before operation to prepare Autologous Adipose-derived Mesenchymal Stem Cell Gel.
41338154|NCT01698177|BIOLOGICAL|Influenza vaccine|Seasonal inactivated trivalent vaccine
41338155|NCT01698177|BIOLOGICAL|Influenza vaccine|Seasonal inactivated trivalent vaccine
41338156|NCT04288297|PROCEDURE|distal minimally invasive chevron osteotomy|With an electric motor-driven machine the resection of the medial eminence as well as a V-shaped osteotomy was performed in hallux valgus patients. Intraoperative fluoroscopy was used to identify the ideal osteotomy site and to control the Intervention. Fixation of the metatarsal head was achieved with a screw or with a K wire. Residual bone ridges were reamed and bone debris washed out.
41338157|NCT02225925|RADIATION|Brachytherapy|
41486396|NCT00334100|BEHAVIORAL|Exercise|Treadmill exercise
41486397|NCT05567120|OTHER|PATH-Care|Individuals will receive the 8-session PATH-Care intervention, delivered virtually (via videoconference or phone) to mitigate negative emotions and stress experienced by informal caregivers of individuals with ADRD. The therapist in the first session will also guide the participant in the tablet-based exercises (WELLPath).
41486398|NCT01458821|BEHAVIORAL|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
41486399|NCT01200264|DRUG|apremilast|apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
41016706|NCT06663683|OTHER|Hip thrust|The subjects in Hip Thrust (HT) group will be instructed to perform low-load gluteus activation exercises, which included single-leg bridges, clamshells and quadruped hip extensions. One set of ten repetitions or steps will perform for each exercise. In this training program three stages which focused on enhancing hypertrophy and strength of the hip extensors in sequence. During the training period, the subjects will be instructed to maintain their usual daily activities and diet. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between the sessions. Hip thrust training 3 sets with 10 repetitions in each set and 2 minutes rest between each set.
41338158|NCT01842646|DRUG|PF-04449913|Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
41338159|NCT03683043|DRUG|Long GnRH agonist protocol|"8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used."
41338160|NCT03683043|PROCEDURE|Embryo transfer|Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
41338161|NCT03362489|PROCEDURE|IVF / IVF-ICSI|"In the IVF arm, oocyte retrieval is performed 36 hours after the HCG injection, in the operating room, under transvaginal ultrasound guidance, under local or general anesthesia. The procedure lasts about 20 minutes and the patients are discharged on the same day. The oocytes retrieved from the follicles are transported immediately to the lab for fertilization with the partner's sperm. Fertilization is done either via conventional IVF, or via ICSI, depending on the indication. Embryos are later transferred into the uterus on day 3 or day 5, under ultrasound guidance, in the outpatient department."
41338162|NCT03362489|PROCEDURE|IUI|"In the conversion to IUI arm, IUI is performed 24 to 36 hours after ovulation trigger. The partner provides the sperm on site on the morning of the insemination, which is performed in the outpatient department."
41338163|NCT04470011|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
41338164|NCT04470011|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
41338165|NCT00647907|DRUG|Voriconazole|Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
41338166|NCT00352066|DRUG|apricitabine|
41338167|NCT00767299|DRUG|arzoxifene|20 mg, QD, PO,24 weeks
41338168|NCT00767299|DRUG|Placebo|QD, PO, 24 weeks
41338169|NCT02244008|OTHER|joint mobilization|The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
41338170|NCT02244008|OTHER|manual contact|The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
41338171|NCT06152692|DEVICE|SHAM Continuous positive airway pressure|Placebo treatment
41338172|NCT06152692|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group
41338173|NCT02542813|DRUG|IM oxytocin 10 IU|IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
41338174|NCT02542813|DRUG|IH oxytocin 50 mcg|IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
41338175|NCT02542813|DRUG|IH oxytocin 200 mcg|IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
41338176|NCT02542813|DRUG|IH oxytocin 400 mcg|IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
41338177|NCT02542813|DRUG|IH oxytocin 600 mcg|IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
41338178|NCT02542813|DRUG|Placebo|Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
41338179|NCT01024660|DRUG|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
41338180|NCT01024660|DRUG|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
41338181|NCT01024660|DRUG|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
41338182|NCT06266871|DRUG|SOX+Tislelizumab+LDRT|"All patients will start with one cycle of neoadjuvant therapy of SOX plus tislelizumab regimen: S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; tislelizumab: 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another two cycles of SOX plus tislelizumab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of SOX plus tislelizumab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with SOX regimen for up to 5 cycles."
41338183|NCT00004852|DRUG|Efavirenz|
41338184|NCT00004852|DRUG|Lamivudine|
41338185|NCT00004852|DRUG|Zidovudine|
41338186|NCT04904315|OTHER|Mindera Kit|The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.
40819514|NCT00569244|DRUG|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
40819515|NCT00569244|DRUG|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
41338187|NCT00260572|BEHAVIORAL|Questionnaires to evaluate QOL|Questionnaire to evaluate QOL administered preoperatively and postoperatively at set intervals.
41338188|NCT00260572|BEHAVIORAL|Questionnaires to evaluate heartburn and quality of life|Questionnaires to evaluate heartburn and quality of life administered preoperatively and at set intervals postoperatively.
41338189|NCT00260572|BEHAVIORAL|Questionnaire to evaluate satisfaction with treatment|Questionnaire administered postoperatively at set intervals.
41338190|NCT00260572|BEHAVIORAL|Questionnaire to evaluate presence or absence of pain|Questionnaire administered preoperatively and at set intervals postoperatively.
41338191|NCT03505424|OTHER|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
41338192|NCT03505424|OTHER|Group 2: NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
41338193|NCT03505424|OTHER|Group 3: SMART NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 3 parents will be asked to download the SMART NICU2HOME app.
41338194|NCT04583345|BEHAVIORAL|Questionnaires|Questionnaires: Physical therapists ask questions these assess quality of life, anxiety and depression, physical activity level.
41338195|NCT02726334|DRUG|BNC101 Solution for Infusion|Administration: Administered via IV infusion once a week over 60 minutes (1 hour).
41338196|NCT02726334|DRUG|BNC101 in combination with FOLFIRI|"BNC101 - Starting dose as determined by Arm A portion (one dose level below recommended Phase 2 dose).~BNC101 Administration: Administered via IV Infusion once a week over 60 minutes (1 hour).~FOLFIRI components:~Irinotecan (IRI) - Starting dose 180 mg/m2 (over 90 minutes on Day 1) Leucovorin (LV) - Starting dose 400 mg/m2 (administered over 120 minutes on Day 1 concurrently with IRI) 5-FU bolus - Starting dose 400 mg/m2 (administered after LV on Day 1, then) 5-FU infusion - Starting dose 2400 mg/m2 (administered over 48 hours starting on Day 1)~FOLFIRI Cycles are repeated every 14 days."
40819516|NCT02442310|DRUG|Deferiprone delayed release tablet formulation|Deferiprone 600 mg delayed release tablet formulation
40819517|NCT02442310|DRUG|Deferiprone oral solution|Deferiprone 100 mg/mL oral solution
40819518|NCT02632279|DIETARY_SUPPLEMENT|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
41486400|NCT01839630|DRUG|Sorafenib (Nexavar, BAY43-9006)|sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
40819519|NCT02632279|DIETARY_SUPPLEMENT|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
40819520|NCT02632279|DEVICE|Stimulator ON|Participants will be tested while their stimulator is turned ON
40819521|NCT02632279|DEVICE|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
40819522|NCT00043108|DRUG|carboplatin|
40819523|NCT00043108|DRUG|paclitaxel|
40819524|NCT00043108|PROCEDURE|conventional surgery|
40819525|NCT00043108|RADIATION|radiation therapy|
41338197|NCT04894357|OTHER|Phenotypic resistance measure|SDM experiments: Reverse transcriptase mutants of HIV-1 will be obtained by site-directed mutagenesis using specific primers introducing the expected mutations into plasmids pNL4.3 and CRF02_AG. HIV-1 stocks will be obtained by transfecting 293-T cells with the various HIV-1 molecular clones. 48 hours after transfection, the viral supernatants will be recovered, quantified for HIV-1p24gag antigen (Vidas BioMérieux) and frozen at -80°C.The single-cycle virus titers will be determined on HeLa-P4 cells in which the expression of b-galactosidase is inducible by the HIV Tat protein. Phenotypic analysis: creation of replication competent chimeric viruses through homologous recombination between patient or laboratory virus-derived PCR fragments and the corresponding NL4-3 vector where the whole Gag-PR, RT-RNaseH or IN coding regions have been deleted through inverse PCR. The susceptibility to Doravirine will be calculated through a single round infection assay in TZM-bl cells.
41338198|NCT05474989|DRUG|LSD|Moderate to high dose LSD
41338199|NCT05474989|DRUG|Active placebo|Low dose LSD
41338200|NCT04238689|BIOLOGICAL|TB31F|Monoclonal antibody
41338201|NCT05115825|BEHAVIORAL|Behavioral Intervention|Attend Mobile Pain Coping Skills Training
41338202|NCT05115825|OTHER|Quality-of-Life Assessment|Ancillary studies
41338203|NCT05115825|OTHER|Questionnaire Administration|Ancillary studies
41338204|NCT05045105|OTHER|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.
41338205|NCT01628393|DRUG|Ozanimod|Oral capsule taken once a day
40819526|NCT05285618|DEVICE|Argus II|In response to the stimulation/image on the monitor subjects will be asked to make perceptual judgments and complete simple behavioral tasks. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, reporting shape by selecting a tactile object of similar shape, or locating a target by moving around, rotating the head, and pointing. Sighted control subjects will perform similar tasks in virtual reality.
41338206|NCT01628393|DRUG|Placebo|Oral capsule taken once a day
41338207|NCT02348294|OTHER|Shear- force 19 newton and 3,9 kpa pressure for half an hour|
41338208|NCT04490304|OTHER|durability of posterior soft tissue repair|how durable is the posterior soft tissue repair after total hip arthroplasty in primary osteoarthiritis patients?
41338209|NCT01213914|DEVICE|An FDA approved continuous renal replacement device|"70ml/kg/hr for treatment group for 48 hours with the following requirements:~* double lumen dialysis catheter should be placed in the internal jugular or femoral vein~* Anticoagulation will be determined by prescribing physician~* Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours~* Blood flow rate will be set to ensure a filtration fraction of no more than 25%~* Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours~* Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized~* All antibiotics will be dose adjusted for renal replacement therapy"
41338210|NCT01213914|OTHER|Control Group|Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population
41338211|NCT04031157|DEVICE|Predictix Antidepressant|Predictix Antidepressant guided treatment
41338212|NCT00117728|DRUG|nevirapine|
41486401|NCT05980286|BEHAVIORAL|Piano Improvisation|Piano Improvisation taught by a professional instructor for 16 weeks.
41486402|NCT05980286|BEHAVIORAL|Music Listening|Music Listening facilitated by a professional instructor for 16 weeks.
41486403|NCT01270737|DIETARY_SUPPLEMENT|Whole soy (soy flour)|40g soy flour per day for six months
40819527|NCT03054350|DRUG|Vadadustat|Daily oral dose
40819528|NCT03054350|DRUG|Placebo|Daily oral dose
40819529|NCT05027126|DRUG|Dexketoprofen 25 MG|Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral
40819530|NCT05027126|DRUG|Fixed dose Dexketoprofen-Vitamin B Complex|Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
40819531|NCT02909985|OTHER|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
40819532|NCT02909985|OTHER|ERG|Participants will undergo electroretinography using both normal settings and infrared as the stimuli.
40819533|NCT02909985|OTHER|VEP|Participants will undergo visual evoke potential tests using both normal settings and infrared as the stimuli.
40819534|NCT05980091|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle
40819535|NCT05980091|DIAGNOSTIC_TEST|Serum LH, E2, P4|In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels
41338213|NCT01027572|DEVICE|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
41338214|NCT06450223|DRUG|Perampanel 12 MG|1 tablet of Perampanel Tablets 12 mg
41338215|NCT06450223|DRUG|Fycompa 12 mg film-coated tablets|1 tablet of Perampanel Tablets 12 mg
41338216|NCT04509557|DRUG|[177Lu]Ludotadipep|Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.
41338217|NCT06165016|DEVICE|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
41338218|NCT06165016|DEVICE|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
41338219|NCT01311739|DRUG|Cyanocobalamin|
41338220|NCT05913518|DEVICE|Neurofeedback active|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Active neurofeedback group aims at enhancing the sensorimotor rhythm (12-15 Hz).
41338221|NCT05913518|DEVICE|Neurofeedback placebo|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Placebo feedback group (PFT) : patients enhance random frequency bands
41338222|NCT03650036|DRUG|Pulp Therapy CTZ Paste|CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
41338223|NCT03650036|DRUG|Pulp Therapy ZOE Paste|The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
41338224|NCT05007093|DRUG|Anlotinib hydrochloride|If intolerance occurs, the dose can be downregulated
41338225|NCT00003838|PROCEDURE|T-cell replete PBPC allograft|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver \>5x10\^6 CD34+ cells/kg.
41338226|NCT00003838|DRUG|Methotrexate|IV MTX on days +1, +3, and +6 will be given
41338227|NCT00003838|DRUG|Cyclosporine|CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade \> II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade \> II GVHD will have CSA discontinued regardless of chimerism results.
41338228|NCT00003838|DRUG|G-CSF|G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
41338229|NCT05490381|OTHER|Iodixanol|Given via injection
41338230|NCT05490381|PROCEDURE|Angiogram|Undergo diagnostic cerebral angiogram
41338231|NCT05490381|PROCEDURE|Arterial Embolization|Undergo tumor vessel embolization
41338232|NCT05490381|DRUG|Polyvinyl Alcohol|Given via catheter
41338233|NCT05490381|DRUG|Ethiodized Oil|Given via catheter
41338234|NCT05490381|PROCEDURE|Computed Tomography|Undergo head and neck CT scans
41338235|NCT05490381|OTHER|Chart Abstraction|Ancillary studies
41338236|NCT00322751|DRUG|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
41338237|NCT05829811|DEVICE|Lifestyle APP and Artificial Intelligence solutions validation|The lifestyle APP will take into account all the psychological aspect linked to the disease, including the social isolation. Lifestyle APP is not a measurement technology but it is a preventive measures against diabetes evolution that provide insights and advices daily, by the collection of structured data of parameters, essential to feed the AI for Risk analysis module. The involvement of Physicians expert in this discipline will evaluate the effectiveness of the psychosocial education.
41338238|NCT04322682|DRUG|Colchicine|Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
41338239|NCT04322682|DRUG|Placebo oral tablet|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
41338240|NCT03490019|DRUG|Metformin|500, 850 or 1000 mg depending on body weight once daily for 24 weeks
41486404|NCT01270737|DIETARY_SUPPLEMENT|daidzein|66mg daidzein per day for six months
41486405|NCT01270737|DIETARY_SUPPLEMENT|milk powder|40g low-fat dry milk per day for six months
41338241|NCT00959894|DRUG|Etravirine (Intelence)|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
41338242|NCT00959894|DRUG|Truvada|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
41338243|NCT03217318|DEVICE|ureteral stenting with standard or modified ureteral stent|Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
41338244|NCT00422669|DEVICE|Medtronic Dual-Chamber Pacemaker|A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
41338245|NCT00422669|DEVICE|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
41338246|NCT00093470|PROCEDURE|Clinical Observation|Undergo observation
41338247|NCT00093470|DRUG|Tipifarnib|Given PO
41338248|NCT02200068|OTHER|SANOIA Website|
41338249|NCT03620604|DEVICE|Stress urinary incontinence surgery|All patients were treated according to the Urology protocols of our unit. They were patients with stress urinary incontinence refractory to pelvic floor exercises so they underwent surgery
41338250|NCT02731976|OTHER|Dietary intervention|
41338251|NCT06156449|OTHER|Thyme oil|The composition of NV-2016 Coded Thyme Essential oil (Origanum vulgare) (GC-201900528) was obtained with Nature\&Nurture (10 µL) macra (Barcode No: 8697742121135, Registration No: 381751). Content of origanum vulgare oil used: 1.3% y-Terpinene, 2.7% p-Cymene, 5.6% linalool, 1.2% terpinen-4-ol, 1.2 borneol, 1.2% β-Bisabolene Contains 3.2% tymol and 75.7% carvacrol.
41338252|NCT04493463|DRUG|Methylprednisolone 40 mg + Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the treatment group will consist of a total of 30 ml study solution, containing 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
41338253|NCT04493463|DRUG|Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the control group will consist of a total of 30 ml study solution, containing 15 ml of 1% ropivacaine and 15ml saline.
41338254|NCT00369746|DRUG|citalopram|tablets, 60 mg maximum, daily, 12 weeks
41338255|NCT04115345|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
41338256|NCT01674946|OTHER|saline|intraduodenal perfusion
41156759|NCT05240664|BEHAVIORAL|Have A Say Programme|Each dyad of participants will receive a 4-session ACP programme, which consists of 2 group-based sessions and 2 dyadic sessions, one hour for each session. The group-based sessions are led by nurse which include didactic educational components, guided reflection, videos, and group sharing. Dyads of participants will be provided with information about ACP, the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are facilitated by trained ACP facilitators and guided by an ACP booklet. Dyads of participants will be supported to have an individualized ACP discussion guided by an ACP booklet. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
41338257|NCT01674946|OTHER|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
41338258|NCT01674946|OTHER|oleanolic acid|intraduodenal perfusion
41338259|NCT01674946|DIETARY_SUPPLEMENT|oleic acid|intraduodenal perfusion
41338260|NCT05774613|DIETARY_SUPPLEMENT|Effect of a Hibiscus sabdariffa beverage|Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion
41338261|NCT05463172|OTHER|abdominal strengthening exercises|abdominal strengthening exercises
41338262|NCT05463172|OTHER|pelvic floor muscles strengthening exercises|to strengthen pelvic floor muscles
41338263|NCT04673344|DEVICE|Regeneten Collagen Patch|Partial rotator cuff repair surgery with the addition of the Regeneten scaffold
41338264|NCT04010812|OTHER|Questionnaire|RHDS- Readiness For Hospital Discharge Scale, Patient Self-Assessment Form
41338265|NCT04511338|DEVICE|Dialyzer with Endexo|"Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)"
41016707|NCT06663683|OTHER|Back squat|In Back Squat (BS) resistance training the subjects starts with the standing position with the feet flat on the floor, the knees and hips in a neutral, extended anatomical position, and the spine in an upright position with preservation of its natural curves. The squat movement will begin with the descent phase as the hips, knee and ankles flex. A common instruction will be given to the subjects to descend until the top of the thigh is at least parallel with ground and the hip joint is at least level with or slightly below the knee joint. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between sessions. Back squat training 3 sets with 10 repetitions in each set \& 2 minutes rest between each set.
41156760|NCT05240664|BEHAVIORAL|Attention-control health talks|Dyads of participants in the control group will receive 4-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health, and healthy diet.
41156761|NCT06141694|DEVICE|The LIBERTY® Robotic System|"The LIBERTY® Robotic System is intended for use in the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters, to facilitate navigation to anatomical targets in the peripheral vasculature.~The LIBERTY® Robotic System is not intended for coronary or neurointerventional procedures."
41156762|NCT06647056|DRUG|Psilocybin|Administration of psilocybin 25 mg
41156763|NCT06647056|OTHER|MRI|Two standard MRI + fMRI scans before (D-3) and after (D5) treatment
41156764|NCT06643377|DRUG|Enlicitide|Oral tablet
41156765|NCT00002855|DRUG|Bicalutamide|
41156766|NCT00002855|DRUG|Doxorubicin hydrochloride|
41156767|NCT00002855|DRUG|Estramustine Phosphate Sodium|
40819536|NCT05980091|DRUG|Estradiol Valerate 2 MG|"Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)"
41156768|NCT00002855|DRUG|Flutamide|
40819537|NCT05980091|DRUG|Progesterone 100 Mg Vaginal Insert|The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily
41156769|NCT00002855|DRUG|Ketoconazole|
41156770|NCT00002855|DRUG|Nilutamide|
41156771|NCT00002855|DRUG|Therapeutic Hydrocortisone|
41338266|NCT02912962|BEHAVIORAL|Self-Regulation Intervention adapted from the Alert Program ®|
41338267|NCT04573192|DRUG|L19TNF|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
41338268|NCT04573192|DRUG|Lomustine|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
41486406|NCT01201941|OTHER|e-Chasqui|"The laboratory component of the PIH-EMR, termed e-Chasqui, permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests."
41486407|NCT05889468|DRUG|Aspirin 81Mg Ec Tab|Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.
41486408|NCT05889468|DRUG|Placebo|Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.
41486409|NCT03914950|DIAGNOSTIC_TEST|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen with parenteral contrast medium (Visipaque=Iodixanol) if creatinine, GFR, and TSH levels are within the normal range and oral (water) contrast medium within TOF-18F-FDG PET/CT. In the case of elevated creatine or decreased GFR or TSH levels a diagnostic CT of the abdomen or upper abdomen without contrast medium is performed.~Biopsy or FNA or operation of the pancreas."
41486410|NCT00712205|DRUG|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
41486411|NCT00712205|DRUG|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
41486412|NCT05279365|BIOLOGICAL|Pfizer/BioNTech (BNT162b2)|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
41486413|NCT05279365|BIOLOGICAL|Moderna|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
41486414|NCT05614557|DEVICE|Stratacel|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
41338269|NCT02125630|PROCEDURE|Surgery|Surgery to primary tumor
41338270|NCT02125630|DRUG|Systemic therapy|Systemic therapy based on tumor phenotype
41338271|NCT00625040|OTHER|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test."
41486415|NCT05614557|DEVICE|Stratamed|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
40819538|NCT05980091|DIAGNOSTIC_TEST|Serum P4 day of ET|On the day of embryo transfer (ET), a blood test is taken to measure serum P4
41338272|NCT02868099|DRUG|Romiplostim|
41338273|NCT02868099|DRUG|Placebo|
41486416|NCT05322499|DRUG|Camrelizumab|200mg/dose intravenous infusion, D1, once every 3 weeks (q3w);
41486417|NCT05322499|DRUG|Irinotecan|100-125mg/m2，d1，d8；q21d
41486418|NCT05322499|DRUG|Paclitaxel|135-175mg/m2，d1，Q3W
41486419|NCT05322499|DRUG|Paclitaxel-albumin|100-135mg/m2, d1、d8，Q3W
41486420|NCT05322499|DRUG|Docetaxel|60-75mg/m2，d1，Q3W
41486421|NCT05322499|DRUG|Anlotinib|12mg，qd，d1-d14，q3w
41486422|NCT02304458|BIOLOGICAL|Ipilimumab|Given IV
41486423|NCT02304458|OTHER|Laboratory Biomarker Analysis|Correlative studies
41486424|NCT02304458|BIOLOGICAL|Nivolumab|Given IV
41486425|NCT02304458|OTHER|Pharmacological Study|Correlative studies
41486426|NCT01563419|DEVICE|Indicator magnifying window (Izumi Planning Co.)|"IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens"
41486427|NCT00589030|RADIATION|brachytherapy|The target dose of TheraSphere® is 80-150Gy
41486428|NCT00589030|RADIATION|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150Gy
41486429|NCT04167176|PROCEDURE|Erector spinae plane block|Patients will be placed on their right side. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10-cm needle will be inserted using an in-plane approach in a cranial to caudal direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
41486430|NCT04167176|PROCEDURE|Port site infiltration|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of the LA mixture. The volume will be divided equally between port sites. A total of four ports-supraumbilical, subxiphoid and two ports in the right subcostal area at mid-clavicular and anterior axillary line will be made.
41486431|NCT04167176|DEVICE|Ultrasound machine (Mindray DP 9900 plus; Mindray Bio-Medical Electronics, Shenzhen, China)|Ultrasound will be used to identify the erector spinae muscles and to guide the LA mixture injection.
41486432|NCT04167176|DRUG|Bupivacaine 0.5%|Bupivacaine 0.5% will be included in the injected LA mixture.
41486433|NCT04167176|DRUG|Lidocaine 2%|Lidocaine 2% will be included in the injected LA mixture.
41486434|NCT00601809|OTHER|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
41156772|NCT00002855|DRUG|Vinblastine|
40819539|NCT05980091|PROCEDURE|Embryo transfer|Procedure in which embryo is transferred into the uterus
41156773|NCT00002855|PROCEDURE|Conventional Surgery|Surgical castration
41486435|NCT00601809|DRUG|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
41486436|NCT06141824|DEVICE|Lucira COVID-19 & Flu Test|The Lucira COVID-19 \& Flu Test is a rapid, single-use, molecular test for the qualitative detection and discrimination of SARS-CoV-2, Influenza A, and Influenza B viral RNA in nasal swab samples.
41486437|NCT04978116|DIAGNOSTIC_TEST|Chest X-Ray (CXR)|"The 3 following imagings will be performed in the emergency room: chest X-Ray (CXR), low-dose CT scan (LDCT) and lung ultrasonography (LUS) will be performed for all included patients, but only one will be available to the clinician in charge of the patient according to the allocation arm.~The blinding will be maintained during the first 5 days, and hence will not influence the diagnosis and the treatment of the patient.~The clinician in charge will be asked to assess on a 3-level Likert scale the probability of pneumonia (high, intermediate, low level) while considering all available clinical and biological data, plus the imaging modality according to the randomization arm."
41486438|NCT04978116|DIAGNOSTIC_TEST|Low-dose CT scan (LDCT)|See above in CXR paragraph
41486439|NCT04978116|DIAGNOSTIC_TEST|Lung ultrasonography (LUS)|See above in CXR paragraph. LUS will be performed by another clinician than the one in charge of the patient
41338274|NCT02791867|DRUG|AphoelineBrake|The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
41486440|NCT01618136|DRUG|E7449 alone|Will be administered as single agent orally, once daily (QD) continuously in 28-day cycles to determine the MTD. In these subjects, a food-effect component will be conducted under fed/fasted conditions to determine the effect of food on the bioavailability of E7449 administered orally QD.
41338275|NCT02891252|PROCEDURE|outpatient procedure|
41338276|NCT04472013|OTHER|Data collection from lumbar puncture|Cerebro spinal fluid (CSF) will be acquired by lumbar puncture and sent for routine analysis including CSF chemistry, cytology and microbiology. Targeted CSF proteomics using OLINK Proximity Extension Assay (PEA) technology to assess a potential CNS-contribution of the disease will be performed.
40819540|NCT05575492|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
40819541|NCT05575492|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
40819542|NCT03213782|OTHER|Nature based sounds|Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
40819543|NCT06539052|DIAGNOSTIC_TEST|anti-HDV positive with the reflex testing methodology|Rate of screening for HBsAg in all migrants attending to one of the center participating to the project rate of screening for anti-Delta in all HBsAg patients identified rate of anti-Delta-positivity in HBsAg-positive subjects rate of linkage-to-care at one of the infectious disease center participating to the project rate of HDV-RNA testing in all anti-Delta positive subjects rate of treatment for HDV in all HDV-RNA-positive subjects Rate of screening for HIV Ab in all migrants attending to one of the center participating to the project Rate of screening for HCV Ab in all migrants attending to one of the center participating to the project.
40819544|NCT03746600|BEHAVIORAL|Project TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
40819545|NCT00945529|DRUG|inhaled nitric oxide (iNO)|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
40819546|NCT00845039|BIOLOGICAL|Cetuximab|Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
40819547|NCT00845039|DRUG|Irinotecan|180 mg/m² every 14 days until disease progression or participant intolerance
41486441|NCT01618136|DRUG|E7449 plus TMZ|Dose escalation,will be administered orally, once daily for 7 consecutive days along with 150 mg/m2/d TMZ administered orally, once daily for 5 consecutive days in 28-day cycles to determine the MTD of E7449 in combination with TMZ.
40819548|NCT00845039|BIOLOGICAL|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
41338277|NCT04472013|OTHER|Data collection from blood draw|Plasma samples will be acquired for plasma cytokine proteomics using CyTOF (mass cytometry analysis) technology.
40819549|NCT01846663|DRUG|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
40819550|NCT01846663|DRUG|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months treatment
40819551|NCT06102135|DIETARY_SUPPLEMENT|Peptamen 1.3 PHGG|The amount of tube feed will be assess by the health Care Professional.
40819552|NCT05519501|DEVICE|SyntrFuge System|Microsized Adipose Tissue
40819553|NCT05519501|PROCEDURE|Standard of Care|Offloading
40819554|NCT04239222|DEVICE|Revo-M|Investigational energy storage and return prosthetic foot with using novel elastic elements.
40819555|NCT04239222|DEVICE|Taleo|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transfemoral amputee subjects
40819556|NCT04239222|DEVICE|Proflex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects
40819557|NCT02913430|DRUG|Fulvestrant|500mg IM Q28 days
40819558|NCT02913430|DRUG|Tamoxifen|20mg PO Qdaily
40819559|NCT02913430|DRUG|Palbociclib|Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
40819560|NCT04193761|DIAGNOSTIC_TEST|taurine level|Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.
40819561|NCT06446856|DEVICE|VR application|"The VR application consists of a software (Tree) developed as part of a research project at MIT and legally acquired via the HTC store Viveport. Duration of the VR application: approx. 5 min."
40819562|NCT02845622|DIETARY_SUPPLEMENT|Hazelnut|This dietary supplement contains 30 g of hazelnut.
40819563|NCT02845622|DIETARY_SUPPLEMENT|Cocoa|This dietary supplement contains 2.5 g of cocoa powder.
40819564|NCT02845622|DIETARY_SUPPLEMENT|No hazelnuts / No cocoa|This dietary supplement does not contain hazelnut nor cocoa powder.
40819565|NCT02845622|DIETARY_SUPPLEMENT|Cream|This dietary supplement is just a cream obtained by grinding hazelnuts.
40819566|NCT02845622|DIETARY_SUPPLEMENT|Snack|This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
40819567|NCT05082454|DEVICE|Open repair|Open repair of the aortic heart valve and ascending thoracic aorta
40819568|NCT03837665|BIOLOGICAL|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
40819569|NCT05986968|DRUG|Ticagrelor|Ticagrelor monotherapy for 12 months
40819570|NCT05986968|DRUG|Aspirin|Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months
40819571|NCT04547907|DRUG|Nab-paclitaxel+ trastuzumab+ patuzumab|Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
40819572|NCT04547907|DRUG|Docetaxel+ carboplatin+ trastuzumab + patuzumab|Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
40819573|NCT02480491|OTHER|measuring cell freeDNA|measuring cell free DNA using PCR
40819574|NCT06511700|PROCEDURE|It is a implementation a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology following the usual technique|Internationally, some experiences demonstrate that the administration of intravitreal injections, especially by nurses trained in aseptic techniques, is feasible without compromising patient safety. Although there is already some experience in Spain, it is a new procedure within the nursing field of the Ophthalmology service for which no results have been reported.
40819575|NCT01316757|BIOLOGICAL|cetuximab|Given IV
40819576|NCT01316757|DRUG|paclitaxel|Given IV
41338278|NCT04472013|OTHER|CNS magnetic resonance imaging (MRI) imaging|3Tesla magnetic resonance imaging (MRI) will be performed to document early/manifest encephalitic changes in COVID-19 patients.
41486442|NCT01618136|DRUG|E7449 plus carboplatin and paclitaxel|Dose escalation, E7449 will be administered orally, once daily continuously in 21-day cycles along with carboplatin and paclitaxel, which will be administered via i.v. infusion on Day 1 of the cycle only, to determine the MTD of E7449 in combination with carboplatin and paclitaxel.
40819577|NCT01316757|DRUG|carboplatin|Given IV
40819578|NCT01316757|DRUG|erlotinib hydrochloride|Given PO
40819579|NCT01316757|OTHER|laboratory biomarker analysis|Correlative studies
40819580|NCT06603402|RADIATION|low-dose involved-field radiotherapy combined with immunochemotherapy|low-dose involved-field radiotherapy combined with immunochemotherapy
40819581|NCT00091338|BIOLOGICAL|MART-1 antigen|
40819582|NCT00091338|BIOLOGICAL|gp100 antigen|
40819583|NCT00091338|BIOLOGICAL|incomplete Freund's adjuvant|
40819584|NCT00091338|BIOLOGICAL|recombinant interleukin-7|
40819585|NCT03960580|DRUG|OPN-375|OPN-375, BID
40819586|NCT06301828|DRUG|Envafolimab Injection|Endostar+SBRT+Envafolimab Injection
40819587|NCT06301828|DRUG|Endostar|Endostar+SBRT+Envafolimab Injection
40819588|NCT03047395|BIOLOGICAL|risankizumab|Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
40819589|NCT06535230|DRUG|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
40819590|NCT06535230|DRUG|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
40819591|NCT06535230|DEVICE|Hemodynamic monitoring with pressure recording analytical method (PRAM)|The pulse contour device MostCare (Vytech, Vygon, Padova, Italy) provides functional hemodynamic monitoring using the pressure recording analytical method.
41016713|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to sit on a chair with their back facing the examiner, placing their arms in a relaxed position with their head supported on a surface in front of them. The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
41486443|NCT05072197|DEVICE|Mobile device as a support tool for the treatment of women with breast cancer undergoing chemotherapy|This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers.
41486444|NCT05686083|DIETARY_SUPPLEMENT|C6 ketone di-ester|C6 ketone di-ester
41486445|NCT05686083|DIETARY_SUPPLEMENT|Novel ketone di-ester|Novel ketone di-ester
40819593|NCT03106844|DRUG|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
40819594|NCT05917990|BEHAVIORAL|Dyadic Text-Messaging Micro-Intervention|Participants receive text-messages consisting of information and skills relevant to improving couples' communication and relationship functioning.
40819595|NCT06313008|DRUG|Empagliflozin 10 MG|eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
40819596|NCT06313008|DRUG|Vildagliptin 50 MG|eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).
41486446|NCT04761705|DRUG|JV-GL1|Experimental Treatment
41486447|NCT04761705|DRUG|Latanoprost 0.005% Ophthalmic Solution|Active Control
40819597|NCT04981366|DIETARY_SUPPLEMENT|Protein supplement|40g of whey protein in the breakfast;
40819598|NCT04981366|DIETARY_SUPPLEMENT|isocaloric supplement|42g of isocaloric supplement in the breakfast;
40819599|NCT05950516|DRUG|Semaglutide|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
40819600|NCT05950516|DRUG|Semaglutide Pen Injector [Ozempic]|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
40819601|NCT04022785|DRUG|Azacitidine|Given IV or SC
40819602|NCT04022785|DRUG|BRD4 Inhibitor PLX51107|Given PO
40819603|NCT05426031|DRUG|Protamine fixed dose|250 mg of protamine intravenously (IV), one time use
40819604|NCT05426031|DRUG|Protamine ratio dose|1mg of protamine per 100 units of heparin given intravenously (IV), one time use
40819605|NCT00408655|DRUG|paclitaxel|Given IV
40819606|NCT00408655|DRUG|carboplatin|Given IV
40819607|NCT00408655|DRUG|temsirolimus|Given IV
40819608|NCT01426984|DRUG|methylphenidate|a capsule containing 20 mg
40819609|NCT01144975|DRUG|XOMA 052|Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
40819610|NCT01144975|DRUG|Placebo|Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
40819611|NCT04621240|BEHAVIORAL|Online SMART & Stress Solutions|1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
40819612|NCT01441908|DRUG|Pravastatin|40mg or 80mg dose 28 days for 6 month period
40819613|NCT06599567|OTHER|Traditional therapy|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises
40819614|NCT06599567|OTHER|Graded motor imagery|Cold-Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, graded motor imagery training (body right-left discrimination exercise, imagining the movement and exercising the opposite limb in front of the mirror).
40819615|NCT06599567|OTHER|Nintendo Wİİ|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, games involving your relevant shoulder such as boxing and bowling on the Nintendo Wii game console.
40819616|NCT05381441|BEHAVIORAL|Safety Action Feedback and Engagement (SAFE) Loop|Nursing units randomized to the intervention arm will undergo the SAFE Loop intervention, which involves five Key Attributes: (1) obtaining input from nurses on which problems to address; (2) focusing on selected high-priority events, (3) prompting nurses to report the high-priority events for a designated period and write more informative reports; (4) following standardized investigative procedures to integrate information from sources internal and external to CSMC, and (5) providing feedback to nurses about safety problems and mitigation plans. During all phases, the SAFE Loop Team collaborates with frontline nurses and Unit Managers.
40819617|NCT03366558|DIAGNOSTIC_TEST|UPDRS questionnaires|UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.
40819618|NCT03366558|DIAGNOSTIC_TEST|20-step walking test|20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
40819619|NCT03504982|DRUG|Vericiguat (BAY1021189)|A : 2.5 mg vericiguat A\*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C\*: 10 mg vericiguat
41486448|NCT00222352|DIAGNOSTIC_TEST|Point of Care cTnL testing|"The study design will be a phase IV prospective, randomized (1:1), parallel-group trial utilizing concurrent controls. The experimental group of interest will be patients receiving the POC cTnI test, and the control group will be patients receiving the central laboratory cTnI test.~The treating physician will be blinded to the randomization and will receive only the POC results from half the study patients and only the laboratory results for the remaining half."
41486449|NCT00512382|DEVICE|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
41486450|NCT05294939|DIETARY_SUPPLEMENT|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
40819620|NCT03504982|DRUG|Moxifloxacin|D: 400 mg moxifloxacin
40819621|NCT03504982|DRUG|Placebo|A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
40819622|NCT01606683|OTHER|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
40819623|NCT01606683|OTHER|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
40819624|NCT01606683|OTHER|No intervention|
41156774|NCT05345197|DRUG|emicizumab|This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
40819625|NCT04112797|BIOLOGICAL|Allergovac himenoptera|Treatment with allergy vaccine againts Apis mellifera, Vespula spp or Polistes dominula
40819626|NCT01183052|OTHER|Training|20 sessions of training
41156775|NCT05664126|DRUG|VST infusion|single intravenous (IV) infusion.
41156776|NCT05664126|DEVICE|CliniMACS|Cells infusions are prepared using the ClinMACS
41156777|NCT04585737|DRUG|Dolutegravir / Lamivudine Pill|Experimental
41156778|NCT04585737|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill|Active comparator
41486451|NCT05294939|DIETARY_SUPPLEMENT|Control product consumption|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, 90g of carbohydrates should be consumed every hour.
41486452|NCT04463303|OTHER|lung ultrasound|patient with or without weaning induced pulmonary adema
41486453|NCT06300671|OTHER|Foot Posture Index-6|Foot Posture Index 6 (API-6) is a clinical diagnostic tool that broadly measures whether a foot is in neutral, supination or pronation posture. During the evaluation, individuals' static standing postures in a comfortable position are observed and scored. When using API-6, researchers visually evaluate the foot according to 6 criteria, each rated on a 5-point (-2 to +2) Likert scale. Each item is scored between -2 (supination) and +2 (pronation) and 0 (for neutral position), with the total score being between -12 (high degree of supination) and +12 (high degree of pronation). The grouping of reference values showing foot posture can be summarized as follows; Neutral position from 0 to +5, pronation position from +6 to +9, hyperpronation position from +10 to +12, supination position from -1 to -5, and supination position from -6. It shows a high degree of supination position up to -12. Higher scores represent a more pronated foot posture.
40819627|NCT02690428|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
40819628|NCT06115486|OTHER|Control Arm ACSM Guidelines|The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.
40819629|NCT06115486|OTHER|Experimental Arm 6-12-25 repetitions per set|The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.
40819630|NCT03289663|DRUG|synergistic combination of insecticides|third generation insecticide -treated bednets
40819631|NCT03289663|DRUG|Pyrethroids|Conventional insecticide
40819632|NCT06605339|BEHAVIORAL|Virtual Reality|Virtual Reality Distraction
40819633|NCT06607497|OTHER|Intervention using an AI enabled risk communication tool (PERDICT.AI)|Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.
40819634|NCT06607497|OTHER|Telemonitoring with Primary Tech Enhanced Care (PTEC-DM)|The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.
40819635|NCT06607666|DRUG|Lanreotide autogel|Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs
41338279|NCT04472013|OTHER|Microscopy of defined brain regions on autopsy specimens|High dimensional, microglia-centric CODEX fluorescent microscopy of defined brain regions on autopsy specimens will be acquired from medulla oblongata, cortex, cerebellum, and olfactory bulb. A brain-specific CODEX panel for the assessment of the immune microenvironment was implemented, with inclusion of a wide array of myeloid/microglia markers, T-cell markers, and a few neuronal markers. All the antibodies have been validated and tested in formalin-fixed tissues of different zones of glioblastoma tumors including invading tumor periphery. The Panel will be modified to include the viral entry receptors, CD147, ACE2 and TMPRSS2. Presence of SARS-CoV-2 virus particles will be assessed by qPCR, andMultiplexed Ion Beam Imaging (MIBI) technology will be used to visualize tropism of virus to specific cellular brain compartments.
41338280|NCT04319770|DEVICE|enamel matrix derivative (EMD)|periodontal regenerative surgery with enamel matrix derivative (EMD) (control)
40819636|NCT06189703|DEVICE|tRNS|transcranial random noise stimulation applied to the right IFG and the left DLPFC
41338281|NCT04319770|DEVICE|hyaluronic acid (HA)|periodontal regenerative surgery with hyaluronic acid (HA) (test)
41338282|NCT04472468|DEVICE|Percutaneous Balloon Pericardiotomy|"* Subxiphoid approach under fluoroscopic guidance is used.~* An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is advanced into the pericardial space.~* Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections."
41486454|NCT04340921|BIOLOGICAL|COVID-19 exposure|Observation only
40819637|NCT03679078|DIETARY_SUPPLEMENT|IDDSI nutritional supplement drink|ready-to-use nutritional supplement drink to be taken daily for 28 days
40819638|NCT05799612|DRUG|Paclitaxel|Given by IV (vein)
40819639|NCT05799612|BIOLOGICAL|mRNA plus Lysate-loaded Dendritic Cell Vaccine|Given by IV (vein)
40819640|NCT05799612|DRUG|PEGYLATED-INTERFERON ALPHA-2A|Given by IV (vein)
41486455|NCT06197958|OTHER|eccentric exercises|eccentric exercises like walking down stairs, lowering a weight during shoulder press, the downward motion of squatting, the downward motion of a push-up, lowering the body during a crunch, lowering the body during a pull-up 3 sets with 10 RM (repetition maximum) for six week training.
40819641|NCT05799612|DRUG|Filgrastim|Given by IV (vein)
40819642|NCT00132691|DRUG|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
40819643|NCT00132691|DRUG|oral corticosteroid with immunosuppressive agents as needed|Prednisone
40819644|NCT00372372|DRUG|risedronate|
41486456|NCT06197958|OTHER|concentric exercises|concentric exercises like walking upstairs, pushing up in a bench press, the beginning portion of a deadlift when you lift the barbell off the ground, sitting up in a sit up, pushing up from a lowered push-up and standing up in a back squat 3 sets with 10 RM.
40819645|NCT06606652|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
40819646|NCT06606652|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
40819647|NCT03629665|BEHAVIORAL|Intensive Language-Action Therapy (ILAT)|ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
40819648|NCT03629665|DEVICE|Repetitive navigated Transcranial Magnetic Stimulation during naming training|Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
40819649|NCT05349227|BEHAVIORAL|Digital Health Coaching Program|Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
40819650|NCT05349227|DEVICE|Fitbit|Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
40819651|NCT01789060|OTHER|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
40819652|NCT06037096|OTHER|Attend-PE model|A pulmonary embolism follow-up care model consisting of structured elements for follow-up after discharge from hospital.
40819653|NCT01349361|PROCEDURE|Daylight mediated photodynamic therapy|
40819654|NCT06012500|DRUG|Xenon-129|Inhaled contrast for MRI
40819655|NCT04809818|DRUG|LT3001 drug product|Multiple doses of LT3001 drug product administered by intravenous infusion
41486457|NCT05748613|BEHAVIORAL|Computerized Anxiety Sensitivity Treatment|Brief computerized treatment for anxiety sensitivity
41486458|NCT05748613|BEHAVIORAL|Health Education Control|Brief computerized presentation on healthy behaviors
40819656|NCT04809818|DRUG|Placebo|Multiple doses of Placebo administered by intravenous infusion
40819657|NCT04809818|DRUG|Aspirin|Loading and maintenance doses of Aspirin administered by oral
40819658|NCT04809818|DRUG|Clopidogrel|Loading and maintenance doses of Clopidogrel administered by oral
40819659|NCT04809818|DRUG|Apixaban|Multiple doses of Apixaban administered by oral
40819660|NCT04809818|DRUG|Dabigatran|Multiple doses of Dabigatran administered by oral
40819661|NCT06604819|DRUG|Ozone gel placed after closed sinus lifting then implant placed simultaneously.|The patient received closed sinus lifting using osteotomes then ozone gel is prepared. Pure olive oil was blasted with 25 μ/ml O3 gas for two days, or until the oil changed from a greenish-colored liquid to a whitish gel. The longevity Ext 120 ozone generator executed out this process then implants were placed.
40819662|NCT06604819|PROCEDURE|closed sinus lifting using osteotomes with simultaneous implant placement|The patient received closed sinus lifting using osteotomes with implant placed simultaneously.
40819663|NCT06225739|OTHER|Electronic pregnancy register|Electronic pregnancy register will be created based on local ANC register to monitor pregnancy outcomes across all sites. Pregnant women of all ages attending antenatal care (ANC) facility will be registered
40819664|NCT06225739|OTHER|In-depth interviews and focus group discussions|In-depth interviews (IDIs) and focus group discussions (FGDs) will be used to assess the user experience and the perceptions of pregnant women and health workers on the feasibility, usability, and acceptability of open-source mobile applications for tracking pregnancy outcomes
40819665|NCT01973387|DRUG|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
40819666|NCT01973387|DRUG|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
40819667|NCT06608732|BIOLOGICAL|Inaticabtagene autoleucel|CNCT19 combined with autologous hematopoietic stem cell transplantation，Dose: （0.5 -2）x 10\^6/kg CNCT19 Cell Injection via intravenous infusion.
40819668|NCT05010122|DRUG|Decitabine and Cedazuridine|Given PO
40819669|NCT05010122|DRUG|Gilteritinib|Given PO
40819670|NCT05010122|DRUG|Venetoclax|Given PO
40819671|NCT02959827|DRUG|Iodinated contrast agents|Use of iodine contrast agents and doses following the decision of the treating physician.
40819672|NCT03158623|BIOLOGICAL|Platelet Rich Plasma|
40819673|NCT03158623|BIOLOGICAL|Cellerate|
41486459|NCT04043130|BEHAVIORAL|Pulse|The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
40819674|NCT06186128|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
40819675|NCT05100940|PROCEDURE|Cardiac Catheterization|Cardiac Catheterization
40819676|NCT06608784|DIAGNOSTIC_TEST|Electrocardiography|12-lead electrocardiography
40819677|NCT00642174|DRUG|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
40819678|NCT00642174|DRUG|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
40819679|NCT03835754|DEVICE|OCS Heart System|The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
40819680|NCT06052826|OTHER|Best Practice|Undergo standard of care
40819681|NCT06052826|OTHER|Cognitive Intervention|Receive delirium prevention education
40819682|NCT06052826|OTHER|Comprehensive Geriatric Assessment|Undergo geriatric assessment
40819683|NCT06052826|OTHER|Nutritional Intervention|Undergo nutritional optimization
40819684|NCT06052826|PROCEDURE|Physical Therapy|Undergo physical function optimization
40819685|NCT06052826|OTHER|Questionnaire Administration|Ancillary studies
40819686|NCT04231058|DEVICE|TENS and pulmonary rehabilitation|Three treatments with TENS per week for 3 weeks each , lasting 45 minutes
40819687|NCT05462834|OTHER|Compressed Air|Participants will be instructed to use compressed air during sleep as a placebo control.
40819688|NCT05462834|OTHER|Supplemental Oxygen|Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.
40819689|NCT01730833|BIOLOGICAL|pertuzumab|Given IV
40819690|NCT01730833|BIOLOGICAL|trastuzumab|Given IV
41156779|NCT06543407|BEHAVIORAL|SWITCH IT|"Behavioral support for switching, 7-10 sessions with SWITCH IT coach delivered during the first 8 weeks of the study. SWITCH IT participants will also have the opportunity to receive supported field trips to explore e-cigarette options based on availability, cost, and preferences during week 4 and week 6."
41486460|NCT06444932|PROCEDURE|Joint Mobilization|Patellofemoral and tibiofemoral joint mobilization
40819691|NCT01730833|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
40819692|NCT01730833|OTHER|laboratory biomarker analysis|Optional correlative studies
40819693|NCT00992381|DRUG|PN400|500mg Naproxen and 20mg esomeprazole
40819694|NCT00992381|DRUG|Naprosyn|500mg Naproxen
40819695|NCT04303078|OTHER|Varying levels of harness support during walking|Participants will complete a standard gait and motion analysis at varying levels of harness support and stabilization (low, moderate, and high levels).
40819696|NCT00002211|DRUG|Nelfinavir mesylate|
40819697|NCT00002211|DRUG|Delavirdine mesylate|
40819698|NCT00002211|DRUG|Stavudine|
40819699|NCT00002211|DRUG|Didanosine|
40819700|NCT05190029|DIAGNOSTIC_TEST|Series of questions to parents of children in a virtual form.|A questionnaire of 5 questions was provided in an online format addressed to the parents or legal representatives of each child. These questions were related to the child's own aspects (behavioral, psychomotor and cognitive parameters), as well as parameters oriented to the mother (pregnancy and childbirth).
40819701|NCT05190029|OTHER|Intervention by teachers|"The school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which assesses five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-50%), normal (50-80%) and high (80-100%). Low and high values are considered impairments in one or more of the evaluated areas."
40819702|NCT05190029|PROCEDURE|Physiotherapeutic evaluation|"A physiotherapeutic evaluation of the state of the RP and craniosacral system was performed according to the method of Andrzej Pilat and John E. Upledger.~The 14 primitive reflexes explored were: Moro reflex, cervical asymmetric, supine labyrinthine tonic, prone labyrinthine tonic, palmar grasp, plantar grasp, lateral trunk propulsion, parachute, Galant, search, cervical symmetric, Babinski, cochleo-palpebral and acoustic. These reflexes were considered as: inactive (0), or active (1).~In the evaluation of the craniosacral system, the following parameters were explored: dura mater sway, frontal bone, parietal bones, temporal bones, temporomandibular joint and sphenoid bone. These parameters were considered as: normal (0), or blockage (1)."
40819703|NCT04160247|PROCEDURE|Immediate implant placement|Implants are placed in fresh socket
40819704|NCT04160247|PROCEDURE|Angulated screw-retained crowns placement|To insert the restorations by angulated screw systems
40819705|NCT04160247|PROCEDURE|Cemented crowns placement|To cement the restorations onto the implant abutment
41156780|NCT06543407|OTHER|E-cig Provision Only|Provision of e-cigarettes (NJOY) based on combusible use for the first 8 weeks of the study.
41156781|NCT00752999|DRUG|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
41338283|NCT00646438|DRUG|Strict Glycemic Control for one year post-op CABG|"The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control."
41338284|NCT03961893|DEVICE|G-EYE first and standard colonoscope|Patients undergo two successive colonoscopies, first balloon-assisted colonoscopy (G-EYE device) and then standard colonoscopy
41338285|NCT03961893|DEVICE|standard colonoscope first and G-EYE|Patients undergo two successive colonoscopies, first standard colonoscopy and then balloon-assisted colonoscopy (G-EYE device)
41338286|NCT04403698|DRUG|Alendronate Effervescent Oral Tablet|At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
40819706|NCT00831740|OTHER|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
41486461|NCT06444932|PROCEDURE|Resistance Exercise Training|Lower limb resistance exercise training
41486462|NCT06444932|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS)|Transcutaneous Electric Nerve Stimulation (TENS)
41486463|NCT06444932|DEVICE|Heating Pad|Heating pad for heat therapy
41486464|NCT04708639|DRUG|Alectinib|Use of ctDNA to establish response and resistance to alectinib.
41486465|NCT05623943|PROCEDURE|Endovascular treatment|Patients treated with endovascular treatment, including balloon angioplasty alone and balloon angioplasty plus stenting.
41486466|NCT00002679|BIOLOGICAL|filgrastim|
41486467|NCT00002679|DRUG|cyclophosphamide|
41486468|NCT00002679|DRUG|doxorubicin hydrochloride|
41486469|NCT00002679|DRUG|paclitaxel|
41486470|NCT00002679|DRUG|tamoxifen citrate|
40819707|NCT00831740|OTHER|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
40819708|NCT00579241|PROCEDURE|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
40819709|NCT02193386|OTHER|No intervention, no follow-up, only registration|Usual Care
40819710|NCT02193386|OTHER|Intervention period|Predefined intervention program
41486471|NCT00002679|RADIATION|radiation therapy|
41486472|NCT00256984|PROCEDURE|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
41486473|NCT03627520|DRUG|[14C]Sulfatinib|300 mg Sulfatinib with 100 µCi \[14C\]
41486474|NCT01452711|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
41486475|NCT01452711|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
40819711|NCT06607133|PROCEDURE|surgery|patients undergo conventional/open thyroidectomy or endoscopic thyroidectomy for large benign thyroid nodules
41486476|NCT01452711|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
41486477|NCT01452711|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
41486478|NCT04825574|DRUG|Avapritinib|avapritinib tablet
41486479|NCT04779541|OTHER|observation|observation of the mechanisms of acceptance or rejection of the vaccine
41338287|NCT03357770|DRUG|mesenchymal stem cells|we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature \[5\]. The low-dose is 1 × 10\^7cells / 3mL, the medium-dose is 5 × 10\^7cells / 3mL and the high dose is 1 × 10\^8cells / 3mL
41486480|NCT05495035|DRUG|Olverembatinib, APG-2575, Dexamethasone|"* Period 1: Subjects will orally take olverembatinib 40mg adult equivalent dose alone QOD from Day 1 to Day 14 (D1 - D14) =. The investigator may start the combination therapy in advance based on medical conditions of the subjects, but not earlier than Day 5/the third dose (D5).~* Period 2: 1) Subjects will orally take olverembatinib 40mg adult equivalent dose QOD from Day 15 to Day 42 (D15 - D42)).~  2) Subjects will orally take APG-2575 at a ramp up 200mg/400mg/600mg adult equivalent dos QD from D13 to D42 at a dose . In addition, a 3-day dose escalation from D13 to D15 will be needed, and the designated reference dose will be reached on D15.~  3) Subjects will orally take dexamethasone 6 mg/m2/day, QD from D15 to D42 at 6 mg/m2/day."
41486481|NCT01233648|OTHER|rate control via CRT-D and AVN ablation|rate control
41486482|NCT01233648|OTHER|rhythm control via pharmacologic, electrical or ablative therapies|rhythm control
41486483|NCT01438528|DEVICE|easypod ™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
41486484|NCT06484634|DRUG|Low molecular weight heparin|A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
40819712|NCT06607133|PROCEDURE|staged thermal ablation|patients undergo multiple sessions of thermal ablation for large benign thyroid nodules
40819713|NCT05616819|OTHER|Active light exposure|Active light at the wave length of 470nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a method to regulated circadian rhythm.
41486485|NCT02524717|DRUG|JNJ-56021927|Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
41486486|NCT04278898|DRUG|N-Acetylcysteine|N-acetylcysteine Single Dose 2700 mg taken orally
41486487|NCT00848107|DRUG|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
41486488|NCT03421808|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS
41486489|NCT00000963|DRUG|Didanosine|
41486490|NCT00368901|DRUG|Darbepoetin alfa|Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
41486491|NCT00000660|DRUG|Etoposide|
41486492|NCT03858192|PROCEDURE|Colorectal surgery procedure|Elective admission for colorectal surgery
40819714|NCT05616819|OTHER|Placebo light exposure|Placebo light at the wave length of 578nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a control to investigate the regulation of circadian rhythm.
40819715|NCT00770042|DRUG|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
41338288|NCT06009068|OTHER|Surgimap soft ware|20 healthy subjects will be recruited in the study, the q angle will be measured using goniometer and surgimap soft ware, 3 examiners will measure the q angles for the same individuals to check the inter rater reliability, and the test will be repeated after 2 days by the same examiners to check the intra rater reliability
41486493|NCT03858192|PROCEDURE|Emergency abdominal surgery|Emergency admission necessitating emergency surgery
41486494|NCT03858192|DRUG|Antibiotics|Treatment for infection and reason for admission
41486495|NCT04390542|BEHAVIORAL|Psychoeducation|"6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:~Session 1: Communication, Support, Self Care, Symptom Management~Sessions 2-4: Communication, Symptom Management, Support~Sessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning"
41486496|NCT00208806|OTHER|congestive heart failure patients|observational echo data on congestive heart failure patients
41486497|NCT02839148|DIETARY_SUPPLEMENT|Food supplementation|"Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS."
41486498|NCT00106236|BEHAVIORAL|exercise|
41486499|NCT02683265|DRUG|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
41486500|NCT02683265|DRUG|Placebo|Placebo capsules
41486501|NCT02229539|DRUG|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
40819716|NCT00770042|DRUG|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
40819717|NCT00770042|DRUG|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
40819718|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 8
40819719|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 6
40819720|NCT00770042|DRUG|Avanafil|Avanafil 200mg Days 1 and 6
40819721|NCT01689714|DRUG|Tc 99m EC20|
41156782|NCT00752999|DRUG|Placebo|Placebo tablet, oral, twice-a-day
41486502|NCT02229539|DRUG|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
41486503|NCT02229539|OTHER|Placebo|2.5 mL placebo and 2.5 mL water administered orally
41486504|NCT02242565|DEVICE|ShangRing|ShangRing device for male circumcision
41486505|NCT04310839|PROCEDURE|Colectomy|colectomy due to neoplastic (stage 1) or diverticulosis
41486506|NCT01929031|DRUG|ibuprofen + caffeine|FDC tablet
41338289|NCT05467605|DIETARY_SUPPLEMENT|probiotics( Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),|therapeutic intervention, Children will be randomized into two groups using sealed envelopes on admission after meeting inclusion criteria, group ONE will receive multi strain probiotic product which contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
41338290|NCT05467605|OTHER|maltose dissolved in distilled water|the other group placebo (GROUP TWO ) will receive maltose dissolved in 10 ml distilled water .
41338291|NCT06157580|DRUG|Compound 21|differences in vasodilation to compound 21 in the skin between groups
41486507|NCT01929031|DRUG|ibuprofen|tablet.
41486508|NCT01929031|DRUG|ibuprofen|tablet
40819722|NCT00764387|DRUG|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
40819723|NCT00764387|DRUG|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
40819724|NCT06606340|DRUG|Eteplirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
40819725|NCT06606340|DRUG|Golodirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
40819726|NCT06606340|DRUG|Casimersen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
41156783|NCT03924193|DRUG|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
41486509|NCT01929031|DRUG|caffeine|tablet
41486510|NCT01929031|DRUG|ibuprofen + caffeine|Fixed Dose Combination (FDC) tablet
41486511|NCT01929031|DRUG|placebo|tablet
41486512|NCT01929031|DRUG|placebo|tablet
41486513|NCT01929031|DRUG|caffeine|tablet
40819727|NCT01498575|BEHAVIORAL|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
40819728|NCT05897840|DEVICE|Fiber-optic probe CeVOX|Installation of the fiber-optic probe within the existing central venous catheter for continuous monitoring of SvcO2
40819729|NCT06606236|OTHER|H2O2 at 35% for 8 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
40819730|NCT06606236|OTHER|H2O2 at 40% for 20 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
41156784|NCT03924193|BEHAVIORAL|Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy
41156785|NCT03924193|OTHER|Combination LDX and Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy
41338292|NCT06157580|DRUG|Angiotensin II|differences in vasoconstriction to angiotensin II in the skin between groups
41338293|NCT00963313|DRUG|Adalimumab (HUMIRA®)|Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
41486514|NCT01929031|DRUG|ibuprofen|tablet
41486515|NCT01929031|DRUG|ibuprofen + caffeine|FDC tablet
41486516|NCT00003436|DRUG|amsacrine|
41486517|NCT00003436|DRUG|asparaginase|
41486518|NCT00003436|DRUG|cytarabine|
41486519|NCT00003436|DRUG|daunorubicin hydrochloride|
41486520|NCT00003436|DRUG|etoposide|
41486521|NCT00003436|DRUG|methotrexate|
41486522|NCT00003436|DRUG|mitoxantrone hydrochloride|
41486523|NCT00003436|DRUG|therapeutic hydrocortisone|
41486524|NCT00003436|PROCEDURE|allogeneic bone marrow transplantation|
41486525|NCT05227612|DRUG|Psilocybin|Participants will receive two doses of psilocybin (10mg, 25mg) as well as 12 sessions of CBT.
41486526|NCT01870245|DRUG|ACHN-975|Intravenous multiple dose
41486527|NCT01870245|DRUG|placebo|Intravenous multiple dose
41486528|NCT01752543|DRUG|Conivaptan|Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
41486529|NCT01752543|DRUG|Placebo (Dextrose)|Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
41486530|NCT01045174|DEVICE|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
41486531|NCT00431275|DRUG|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
41486532|NCT00431275|DRUG|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
40819731|NCT06606236|OTHER|H2O2 at 25% plus cold blue light for 15 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
40819732|NCT06491563|BIOLOGICAL|BRII-179|BRII-179 will be given via intramuscular injection
40819733|NCT06491563|DRUG|BRII-835 (VIR-2218)|BRII-835 will be given via subcutaneous injection
40819734|NCT06491563|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
40819735|NCT01996267|DRUG|PTC+Pertuzumab|Cycle repeated every 21 days
41338294|NCT04501172|BEHAVIORAL|Questionnaire completion|"Participants are contacted through social networks (Facebook) which provide a link to website that contains the questionnaire. Then, they complete the questionnaire which consists of the following 2 parts:~1. participant's demographic characteristics with questions regarding age, visual acuity - refractive error, spectacles and contact lenses use, and compliance to mask-wearing directives.~2. 20 items that construct 5 subscales: a) near vision (5 items), b) distance vision (3 items), c) ocular discomfort (3 items), d) driving (2 items), e) limitations (3 items), need for help (2 items), work collaboration (1 item), and emotional impact (1 item).~The impact of spectacles on the compliance of Greek people to mask-wearing directives will be assessed via this questionnaire."
41338295|NCT02797769|DRUG|Other Biologics|Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
41338296|NCT02797769|DRUG|Tocilizumab|Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
40819736|NCT01996267|DRUG|FEC-T+Pertuzumab|Cycle is repeated every 21 days
40819737|NCT06093178|BEHAVIORAL|Human coach-led digital health platform|This is an existing commercial digital platform developed by our technology partners (Empeal). The platform comes in the form of a smartphone app available via Android and Apple devices. Participants will communicate with their coach through the app via video, audio or text. Surveys are conducted on the app. Support content is also available through this app.
40819738|NCT02427568|DRUG|MDMA (125 mg)|Two sessions of MDMA (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
40819739|NCT02427568|DRUG|Placebo|Two sessions of placebo (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
40819740|NCT02427568|BEHAVIORAL|Therapy|Non-directive therapy
41156786|NCT02160834|BEHAVIORAL|B-MOBILE Smartphone-Based Intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
41156787|NCT02160834|BEHAVIORAL|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
41338297|NCT03174561|DIETARY_SUPPLEMENT|Inuline, Choline and Silymarin|Combination of one sachet: Inuline (5000 mg), Silybum marianum seed extract (50 mg), Choline (37 mg) The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days. Diet restriction is consider together with dietary supplement intake.
41338298|NCT03174561|OTHER|diet restriction|diet restriction for 28 days
40819741|NCT01741142|DRUG|ABT-436|Subjects receiving ABT-436
40819742|NCT01741142|DRUG|Escitalopram|Subjects receiving escitalopram
40819743|NCT01741142|DRUG|Placebo|Subject receiving placebo
40819744|NCT04698785|DRUG|Treatment by regorafenib and best supportive care|"Treatment for 13 cycles (12 months) maximum.~During each cycle :~* patients ≥ 16 years old and patients \<16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~* patients \< 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment"
40819745|NCT01342354|RADIATION|Stereotactic Radiation|Escalating Doses of SBRT in periods of three doses over 10 days
40819746|NCT02831738|DIETARY_SUPPLEMENT|Polydextrose|Polydextrose 12 g
40819747|NCT02831738|DIETARY_SUPPLEMENT|Control Treatment|no polydextrose
40819748|NCT00460486|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
41156788|NCT05216029|OTHER|Best Practice|Receive standard of care
41156789|NCT05216029|OTHER|Informational Intervention|View oncology dashboard
41156790|NCT05216029|OTHER|Questionnaire Administration|Ancillary studies
40819749|NCT05813652|OTHER|Pre-pandemic time period (Jun 22, 2018 to March 12, 2020)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
40819750|NCT05813652|OTHER|Peri-pandemic time period (March 13, 2020 to December 3, 2021)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
40819751|NCT00005574|DRUG|Gentamicin|
40819752|NCT06607263|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
40819753|NCT06607263|DRUG|Essential oils mouthrinse|Essential oils mouthrinse
41338299|NCT01999348|DRUG|Fixed Combination Bimatoprost and Timolol|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
40819754|NCT06607263|DEVICE|Dental floss|Dental floss
40819755|NCT06607263|DRUG|Toothpaste|A commercially available fluoride toothpaste
40819756|NCT06607263|DEVICE|Toothbrush|A commercially available adult toothbrush
40819757|NCT03580642|DEVICE|eHealth Technologies|The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
40819758|NCT06256666|DEVICE|BIS Quantitative EEG|Pain assessment will be conducted before and in the postoperative period using the objective PANAID scale and, when possible, the NRS. Simultaneously, EEG recordings using the BIS (Bispectral Index) will be performed. Cognitive status will be assessed before surgery using the Pfeiffer scale
40819759|NCT04595682|DRUG|Placebo|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
40819760|NCT04595682|DRUG|Alcohol|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
40819761|NCT05526976|OTHER|PERISCOPE-care|Patients with planned elective surgery will be asked to complete the PERISCOP3E-Care questionnaire (modified-Althaus \& Kalkman, DN4, HADS, Stait-trait, NRS, MPI, EQ-5D-5L) preoperative. One month and three months post op the patients will be contacted to check if they developed persistend postoperative pain and they will also complete questionnaires (DN4, HADS, Stait-trait, NRS, MPI and EQ-5D-5L).
40819762|NCT01466660|DRUG|Afatinib|afatinib once daily
40819763|NCT01466660|DRUG|gefitinib|Gefitinib once daily
41338300|NCT03790540|DEVICE|DentalVibe|It is a vibrotactile device that aids in reducing pain during local anesthesia injection in pediatric patients
40819764|NCT05014464|DRUG|Crizotinib|Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
40819765|NCT03374800|DRUG|Placebo (0.9% saline)|normal saline
40819766|NCT03374800|DRUG|Pantoprazole|40 mg powder for injection reconstituted with 0.9% saline
40819767|NCT06608706|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) for psychosis|EMDR aims to treat and process trauma by safely retrieving the trauma memories while taxing the working memory. EMDR targets trauma symptoms through memory reprocessing of traumatic memories, and consists of eight flexible phases: history taking/case conceptualization; preparation for memory reprocessing; assessment/identification of a target memory; desensitization/reprocessing; installation of positive cognition; body scan; closure; and re-evaluation. EMDR in the current trial has psychosis-specific adaptations including focus on psychoeducation, preparation for reprocessing and patient safety. Techniques targeting dissociation, psychotic symptoms and psychosis-related challenges are included.
40819768|NCT05413785|BEHAVIORAL|Telehealth in Parole/Probation Office|Onsite (telehealth) linkage toHep C treatment in a Probation and Parole office setting via an onsite nurse navigator. The navigator will provide Hep C education, draw labs, and facilitate a telemed visit with a UK GI provider.
40819769|NCT01842932|DRUG|Phloroglucin|Premedication of colonoscopy
40819770|NCT01842932|DRUG|Cimetropium bromide|Premedication of colonoscopy
40819771|NCT01842932|PROCEDURE|Colonoscopy|Diagnostic examination of colon
40819772|NCT01842932|DRUG|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
40819773|NCT03100539|OTHER|Therapist treated massage|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
41338301|NCT03790540|DRUG|Topical Benzocaine 20%|Topical benzocaine 20% gel on the mucosal injection site prior to injection
40819774|NCT03100539|OTHER|Care ally assisted massage|CA-M consisted of in-person training for veteran/care-ally dyads to learn a standardized 30-minue massage routine, instructional DVD, and printed treatment manual. Participants were to complete three care ally-assisted massage sessions weekly for 12-weeks.
40819775|NCT03816176|DRUG|Isavuconazonium sulfate|Intravenous (IV) infusion
40819776|NCT03816176|DRUG|Isavuconazonium sulfate|Oral capsule
40819777|NCT06163495|BEHAVIORAL|Screen Free Time with Friends intervention|School-based extracurricular intervention focusing on time spent with friends and screen media use
40819778|NCT05187624|DRUG|RO7428731|Participants will receive RO7428731 as described.
40819779|NCT03730961|DRUG|BMS-986231|Intravenous administration
41486533|NCT03602443|BEHAVIORAL|LSVT®BIG Intervention|Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.
41486534|NCT03602443|BEHAVIORAL|Waitlist Control|Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.
41486535|NCT03657212|DRUG|Zolpidem|The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
41486536|NCT04583449|BEHAVIORAL|Mental imagery|"Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery)."
40819780|NCT03730961|DRUG|Furosemide|Intravenous administration
40819781|NCT03730961|DRUG|Placebo|Intravenous administration
40819782|NCT05472623|DRUG|Adagrasib|Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery.
40819783|NCT05472623|COMBINATION_PRODUCT|Adagrasib/Nivolumab|Oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240mg every 2 weeks for 3 doses prior to surgery.
40819784|NCT04527237|OTHER|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total. The session duration of an individual will be approximately 25 minutes.~Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application."
40819785|NCT04527237|OTHER|Placebo|Unlike acupressure, it will only be in contact with gloves, to reduce the electrical effect of touch, away from the actual acupressure points.
40819786|NCT04619797|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
40819787|NCT04619797|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
40819788|NCT04619797|DRUG|Pemetrexed|Pemetrexed 500 milligrams per square meter (mg/m\^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
40819789|NCT04619797|DRUG|Carboplatin|Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
40819790|NCT04619797|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
40819791|NCT04619797|DRUG|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
40819792|NCT04619797|DRUG|Pembrolizumab|Pembrolizumab at a fixed dose of 200 mg, administered by IV infusion, Q3W, on Day 1 of each 21-day cycle.
40819793|NCT04488159|DRUG|Capecitabine|Tablet
40819794|NCT04488159|DRUG|Oxaliplatin|Infusion
40819795|NCT04488159|DRUG|Fluorouracil|Infusion
40819796|NCT04488159|DRUG|Leucovorin|Infusion
40819797|NCT04488159|DEVICE|Immunoscore® assay|Whole-slide tissue analysis of CD3+ and cytotoxic CD8+ T cells in the tumor and in the invasive margin
40819798|NCT04488159|OTHER|Physical exercise|Increasing stair walking exercise twice a week over 12 weeks total.
40819799|NCT06439888|DRUG|all-trans retinoic acid|per os treatment, started from the same day as SBRT, during 3 successive days, every 3 weeks, for a maximum of 4 cycles
40819800|NCT06439888|RADIATION|Stereotactic Body Radiation Therapy|Standard of Care, planned over 1 or 2 weeks, every lesions must be irradiated
40819801|NCT05011305|DRUG|Saroglitazar Magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
40819802|NCT05011305|DRUG|Saroglitazar Magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
40819803|NCT05011305|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
40819804|NCT05025098|DRUG|Standard therapy|"For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle."
40819805|NCT05025098|DRUG|Precision therapy|Precision therapy for both AML and MDS patients is standard therapy + tumor board determined precision therapy. The tumor board determined precision therapy can be all available drugs with a marketing authorization in Norway.
40819806|NCT04903873|DRUG|EU101|EU101 will be administered via intravenous infusion.
40819807|NCT06083324|OTHER|Dose escalated resistance training|All individuals will be engaging in resistance training during and/or after their cancer treatment
40819808|NCT06000111|BEHAVIORAL|3 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 3-days and nights of face-down positioning post-operatively.
40819809|NCT06000111|BEHAVIORAL|7 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 7-days and nights of face-down positioning post-operatively.
40819810|NCT06445153|OTHER|Intervention with clinical decision support system|To this phase, patient data is automated and systematically analyzed in order to derive decision support based on current evidence and make it available to Digi-POD users (patients, relatives, nursing staff, doctors, other healthcare professionals).
40819811|NCT04315792|DRUG|Endoxifen|Administration of Endoxifen for 3 weeks
40819812|NCT04315792|DRUG|Placebo oral tablet|Administration of Placebo for 3 weeks
40819813|NCT04927156|DEVICE|BALT medical devices|"Includes, but is not limited to, the following:~* Access devices~* Aneurysm treatment devices~* Ischemic Stroke and peripheral occlusive diseases treatment devices~* Arterio-Venous Malformations/fistulas treatment devices"
40819814|NCT00994201|OTHER|DCE-MRI, DW-MRI and MRS|"Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.~Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS."
40819815|NCT01382303|DRUG|Pentoxifylline|Pentoxifylline 400mg three times a day
41338302|NCT02738580|DRUG|COS with GnRH antagonists and rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
40819816|NCT01382303|DRUG|Placebo|placebo tablet three times a day
41338303|NCT02738580|DRUG|COS with GnRH antagonists and HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
41338304|NCT06068647|DIAGNOSTIC_TEST|Lung ultrasound, computed tomographic scan and patch-based cardio-respiratory evaluations|"Ultrasonographic findings will be obtained with machines supplied with clinical Units. Additionally, US scans as acquired with open research platform will also be gathered. For both scanners, ultrasonographic scans will be performed and videos will be recorded and stored in each landmark. Metal cutaneous landmarks will be positioned and left during computed tomographic (CT) scans, indicating the areas of ultrasonographic assessment.~Finally, on the same day of enrolment, a wearable system for measuring physiological signals, will be applied. Within the scope of this study, sensors will be applied to the upper chest. The following information will be collected by each sensor: electrocardiography, respiratory effort, respiratory flow, activity, position, and sound pressure level."
41338305|NCT05367713|OTHER|patients having had an osteitis of the cranial flap after craniectomy|description of management and failure of cranial flap after craniectomy
41338306|NCT05813613|OTHER|Squatting with the aid of Kynapsis Virtual Training apparatus.|Squatting exercise was performed using a virtual reality (VR) machine (kynapsis) for guidance in both groups. Squats were performed while the hands were kept in front of the bodies and the knees flexed to 90 degrees following a rhythm of two seconds for descent, two second ascent mimicking the movement done on the VR machine.
40819817|NCT05124652|DEVICE|Auto Adjusting Prosthesis|Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
40819818|NCT05131399|DEVICE|Phase A1|Plastic standard ankle foot orthosis
40819819|NCT05131399|DEVICE|Phase B1|carbon medical device ankle foot orthosis
41338307|NCT00619606|DEVICE|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
40819820|NCT05131399|DEVICE|Phase A2|Plastic standard ankle foot orthosis
40819821|NCT05131399|DEVICE|Phase B2|carbon medical device ankle foot orthosis
40819822|NCT03987802|DRUG|Faster-acting insulin aspart|Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
40819823|NCT06608238|DRUG|D-MNA 200 mcg|D-MNA , (doxorubicin) patch, 200 mcg
40819824|NCT06608238|DRUG|D-MNA 100 mcg|D-MNA (doxorubicin) patch, 100 mcg
40819825|NCT06608238|OTHER|Placebo|P-MNA patch, placebo
40819826|NCT05682287|DEVICE|448kHz capacitive resistive monopolar radiofrequency|Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.
40819827|NCT05682287|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
40819828|NCT06034951|DIETARY_SUPPLEMENT|Compleat 1.5 HP|Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.
40819829|NCT00003044|DRUG|cisplatin-e therapeutic implant|
40819830|NCT01587261|DRUG|Vitamin C|Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
41016714|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to lay prone position.The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
41156791|NCT06454071|OTHER|Blood test|Immunologic tests including Interleukin 6 were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The IL-6 tests and NK cells were carried out in our hospital.
41338308|NCT00619606|DEVICE|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
41156792|NCT03313583|PROCEDURE|Transfusion of blood products|
41338309|NCT00619606|DEVICE|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
41338310|NCT00619606|DEVICE|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
40819831|NCT01587261|DRUG|Placebo|Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
40819832|NCT04363697|DRUG|Dapagliflozin|Dapagliflozin
40819833|NCT04363697|DRUG|Placebo|Matched placebo
40819834|NCT04484896|OTHER|Gain-framed SMS message|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
40819835|NCT04484896|OTHER|Loss-framed SMS message|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
40819836|NCT04484896|OTHER|Information SMS message|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
40819837|NCT06135896|DRUG|Tripegfilgrastim|Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers
40819838|NCT00110630|BEHAVIORAL|10-week smoking cessation group therapy combined with NicoDerm CQ|
40819839|NCT06607055|DIAGNOSTIC_TEST|Blood collection|HLA-DR dosage, at the time of inclusion and once a week then
40819840|NCT04845659|DRUG|Doptelet Pill|40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
40819841|NCT06608524|BEHAVIORAL|Self-regulated learning strategy|The experimental group uses self-regulated strategy.This program selects classroom performance , homework quality , experimental operation, and test score as academic performance (score) evaluation variables.
40819842|NCT06608524|BEHAVIORAL|Standard learming method|The control group uses standard learming method. The program selects classroom performance, homework quality, experimental operation, and test score evaluation form as academic performance (score) evaluation variables.
40819843|NCT01187368|DEVICE|EVAHEART Left Ventricular Assist System (LVAS)|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
41016715|NCT06663800|OTHER|Ujjayi Paranayama|Inhale or breathe in slowly while taking a deep, prolonged breath through both nostrils. As you inhale, attempt to tighten your throat and feel the air in your throat. Air should not come into contact with the interior of the nose. When air enters the throat, an odd sound is made. Allow the breath to be loose and easy while you slightly tighten the back of your throat and hiss lightly as you breathe in and out. The sound isn't forced, but it should be loud enough for someone to hear you if they were close. Now close your right nostril and release the breath through your left. As you exhale, try making the sound HHHHHAAAA
41016716|NCT06663800|OTHER|Standard Protocol|Control Group will perform Deep Breathing Adhering to a FITT model protocol, with a frequency of 5 days. Intensity set at 8 repetitions, duration range from 10 to 15 minutes
41338311|NCT03101527|DRUG|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
41338312|NCT00931294|BEHAVIORAL|Choir singing|"Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material To Live with IBS for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months."
41338313|NCT00931294|BEHAVIORAL|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
41338314|NCT00071214|BIOLOGICAL|S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine|
41338315|NCT02737176|OTHER|Tobacco cessation intervention|"The nicotine dependence status is evaluated by the Fagerstrom Test for Nicotine Dependence test; those who 3 or more score are eligible for the intervention.~During the study, attending doctors implement a tobacco cessation intervention with standard treatments for above oral diseases.~Even if the subjects failed to abstain from smoking, the treatment is continued.~In case of the use of the nicotine replacement therapy, The investigators supply NRTs (nicotine patch or gum) for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy."
40819844|NCT01187368|DEVICE|HeartMate 3|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
40819845|NCT03832855|BIOLOGICAL|pING-hHER3FL|Plasmid vaccine containing HER3
40819846|NCT06535022|DIETARY_SUPPLEMENT|Cyclic enteral daytime feeding with ketogenic nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|Nighttime fasting and ß-hydroxybutyrate supplementation
41338316|NCT04776889|DRUG|Rosuvastatin 20mg|Rosuvastatin 20mg/day for 6 months added to bilateral subcapsular orchiectomy
41338317|NCT04776889|PROCEDURE|surgical castration|bilateral subcapsular orchiectomy
41338318|NCT05076331|DIAGNOSTIC_TEST|PI-2620 tracer for Tau PET scan|Tau PET scans are obtained using PI-2620 tracer provided by Life Medical Imaging.
41338319|NCT01328769|DRUG|Febuxostat|
41338320|NCT01328769|DRUG|Placebo|
41338321|NCT01852630|DRUG|cefepime + Albumin|cefepime + Albumin will be given for 2 days
41338322|NCT01852630|DRUG|Imipenem + Albumin|Imipenem + Albumin will be given for 2 days.
40819847|NCT01448785|DEVICE|abiliti system implant|Subjects will receive implanted abiliti System.
41338323|NCT05468580|PROCEDURE|Endoscopic Coeliac Artery Release (eCAR)|Endoscopic Coeliac Artery Release (eCAR); The Median Arcuate Ligament will be cleaved via an endoscopic retroperitoneal approach using a 4 trocar technique described in detail by van Petersen (12). To rule out learning curves and procedural variation all the procedures will be performed by two experienced eCAR surgeons in the MST-Dutch Expert Centre of Gastrointestinal Ischemia. All procedures will be videotaped. Both eCAR surgeons will not be involved in the follow up procedures.
41338324|NCT05468580|PROCEDURE|Sham Operation|The sham operation consists of making 4 incisions up to the fascia similar to endoscopic AC release (eCAR). After 60 to 75 minutes of general anesthesia, in accordance with the average operating time of eCAR, the sham operation is ended. This study design allows for patient and observer blinding and for the sham group the eCAR approach is still feasible if the CARoSO outcome support this without applying additional scar tissue.
40819848|NCT01448785|DEVICE|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
40819849|NCT06039436|DRUG|Anti-Thymocyte Globulin (Rabbit)|Indications for trial stopping: subjects occur pregnancy events, severe organ function impairments, or emergency events related or unrelated to treatment; or subjects are unwilling to continue participating in the clinical trial.
40819850|NCT00118352|BIOLOGICAL|alemtuzumab|Given IV
40819851|NCT00118352|RADIATION|total-body irradiation|Undergo low-dose TBI
40819852|NCT00118352|DRUG|fludarabine phosphate|Given IV
41016717|NCT06663215|OTHER|School Based Bullying Prevention Program|Three forms were administered to the adolescents: Personal Information Form, Bullying and Cyberbullying Scale for Adolescents (BCE-A) and Adolescent Future Expectations Scale. Adolescents were included in a school-based bullying prevention program the next day. One month later, the forms were administered again.
41016718|NCT06663085|DIETARY_SUPPLEMENT|Enteral feeding|intervention group received enteral feeding breastmilk during transfusion
41486537|NCT05550883|OTHER|Aerobic exercise|The patients in this group participated in aerobic exercise training for 45 minutes, three sessions per week for 6 weeks. They underwent the proper warm up to minimize the risk of musculoskeletal injury .The training session started by a proper warm up for 5 min in the form of mild stretching for the involved muscle group to prepare the exercised muscles and improve blood supply for skeletal muscle to prevent fatigue or injury. Patients in this study group performed aerobic exercise (in the form of treadmill training) All sessions were supervised to ensure correct technique and monitor the appropriate amount of exercise. The training session ended by a proper cooling down for 5 min to prevent fatigue or injury.
41156793|NCT05416879|DEVICE|Actigraph GT3X+BT|7 day monitoring of physical activity, sedentary behaviour and sleep using the Actigraph GT3X+BT
40819853|NCT00118352|DRUG|cyclosporine|Given PO or IV
40819854|NCT00118352|DRUG|mycophenolate mofetil|Given PO
40819855|NCT00118352|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
40819856|NCT00118352|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
40819857|NCT00118352|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
40819858|NCT00118352|OTHER|laboratory biomarker analysis|Correlative studies
40819859|NCT00792662|DRUG|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
40819860|NCT00792662|DRUG|Placebo|Standard inactive pill.
40819861|NCT00596245|DRUG|MT400|MT 400, naproxen sodium 550mg
40819862|NCT02845479|OTHER|Integrative Care|Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
41156794|NCT04449133|DRUG|AD128|Oral administration of two capsules before sleep for 7 days.
41156795|NCT04449133|DRUG|Placebo|Oral administration of two capsules before sleep for 7 days.
41156796|NCT05996497|BEHAVIORAL|behavioral measures|behavioral measures
40819863|NCT02842515|OTHER|teeth avulsion|
40819864|NCT06585904|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteer will ingest 1 dose of beetroot juice containing 400mg of inorganic nitrate for 10 days.
40819865|NCT06585904|OTHER|Exercise|The volunteer will perform moderate aerobic exercise for 10 consultative days on a cyclergometer.
41338325|NCT01983449|DRUG|Dexamethasone Sodium Phosphate Injection, USP|Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
41338326|NCT04597515|PROCEDURE|Robot Breast reduction surgery|Breast reduction surgery, using a robot by removing a breast disc at the base
41338327|NCT03578380|PROCEDURE|Surgery|Lymphovenous anastomosis
41338328|NCT03578380|OTHER|Compression and drainage therapy|Treatment with compression stockings and manual drainage (massage therapy)
41338329|NCT03436147|OTHER|POP-Q|Pelvic Organ Prolapse Quantification
40819866|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for 120 days
40819867|NCT05308472|DRUG|DISC-1459|Oral dose level 2, once a day for 120 days
40819868|NCT05308472|DRUG|Placebo|Oral dose, once a day for 120 days
40819869|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for up to 8 months
40819870|NCT06599554|OTHER|follow up scores|"The radiological reports will be read, analyzing when the bony consolidation of the fracture is reported in relation to the time elapsed since the operation.~The questionnaires will be submitted to all patients who have completed the course at 1 year.~All patients who sign the informed consent will be asked to complete the questionnaires either at the time of the follow-up visit by common clinical practice or by telephone, in the event that the patients have exceeded the 1-year follow-up"
40819871|NCT00075725|DRUG|Cyclophosphamide|Given IV
40819872|NCT00075725|DRUG|Cytarabine|Given IT, SC, or IV
41156797|NCT05996497|OTHER|Electrophysiological measures|Electrophysiological measures
41338330|NCT03520205|PROCEDURE|Quadratus Lumborum Block|Bilateral block using ultrasound will be performed before surgery and after surgery on patient using Stimuplex 100mm needle with Bupivacaine 0.25% 0.4 mL/kg, maximum dose 25 mL each side under general anaesthesia
41338331|NCT03520205|PROCEDURE|Continuous Epidural|Patient will be given 6 mL/hour of Bupivacaine 0.25% for intraoperative analgesia and continued epidural 6 mL/hour Bupivacaine 0,125% as postoperative analgesia in 24 hours.
41338332|NCT00252317|DRUG|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
40819873|NCT00075725|DRUG|Daunorubicin Hydrochloride|Given IV
40819874|NCT00075725|DRUG|Dexamethasone|Given PO or IV
40819875|NCT00075725|DRUG|Doxorubicin Hydrochloride|Given IV
40819876|NCT00075725|DRUG|Leucovorin Calcium|Given IV
40819877|NCT00075725|DRUG|Mercaptopurine|Given PO
40819878|NCT00075725|DRUG|Methotrexate|Given IT or IV
40819879|NCT00075725|DRUG|Pegaspargase|Given IM
40819880|NCT00075725|DRUG|Prednisone|Given PO or IV
40819881|NCT00075725|RADIATION|Radiation Therapy|Undergo radiation therapy
40819882|NCT00075725|DRUG|Thioguanine|Given PO
40819883|NCT00075725|DRUG|Vincristine Sulfate|Given IV
41338333|NCT00252317|DRUG|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
40819884|NCT03447314|DRUG|GSK1795091|GSK1795091 will be available as solution for injection
40819885|NCT03447314|DRUG|GSK3174998|GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
40819886|NCT03447314|DRUG|GSK3359609|GSK3359609 will be available as solution for infusion.
40819887|NCT03447314|DRUG|Pembrolizumab|Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
40819888|NCT00283270|BEHAVIORAL|Brief counselling|
41486538|NCT05550883|DRUG|Fibromyalgia Agents|tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
41486539|NCT02161250|DIETARY_SUPPLEMENT|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
41486540|NCT02161250|DIETARY_SUPPLEMENT|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
41486541|NCT00399971|PROCEDURE|Ex Vivo Immunotherapy|Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
41486542|NCT00399971|DRUG|Ex vivo immunotherapy|i.v. infusions, once a week, at least 6 to 12 months
41486543|NCT04244669|DEVICE|IPG with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% in that area. It can be reprogrammed as many times as necessary during the 14-21 days of margin.
41486544|NCT04244669|DEVICE|IPG with SCS DTM|In this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms
41016719|NCT06663709|OTHER|BRACE|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 0-3 : Balance: Romberg, tandem standing, single leg stance TUG test Resistance: chair rise, Stair climbing Aerobic exercises: 6mint walk, count reverse from 30, push wall and reverse count from 20 Cognitive: count reverse from 50. Week 4-6: Balance: Sit to stand, functional reach, Tug Test, Perturbation, Kick a ball Resistance: stair climbing Aerobic Exercises: Marching in space, Cycling Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Combination of all Resistance: Combination of all Aerobic Exercises: Cycling , Marching, 6 min Walk Cognitive: Combination of all
41016720|NCT06663709|OTHER|TASK-oriented|Study will be conducted after the approval of Ethical review board. Task oriented training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 1-3 Warm Up (sit to stand,5 reps)(cycling 3-5 min) , Single leg stand with eye open 15 sec, with eye close 10sec, forward, backward, and side stepping (5 reps) reaching, Transition from sit to stand, Walk then back to sit (3 min),Walk with even steps(3min) Walk with carrying objects. (3min) Week 4-6 Warm up Period, Task oriented training (7 Reps of each task) Week 7-9 Warm up Period, Task oriented training (9Reps of each task)
41338334|NCT02262013|BEHAVIORAL|Parents as Coaches|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.
41486545|NCT04787393|DEVICE|Heartfelt device|The Heartfelt device uses a system of scanner in a compact device to generate depth images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit, For the measurements to take place, the participant walks in the field of view of the device, measurments are only taken when the patients has bare feet and no slippers/shoes, so the location of the device in the home is choosen to match this requirement. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.
41156798|NCT05996497|OTHER|Training 1|Training 1
41338335|NCT02262013|BEHAVIORAL|Parent Weight Loss|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
40819889|NCT00283270|BEHAVIORAL|Behavior|
40819890|NCT04818502|DEVICE|Tendyne™ Mitral Valve System|Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.
40819891|NCT04193085|OTHER|Observational|Observational
41338336|NCT02984891|PROCEDURE|Optical Coherence Tomography (OCT)|Procedure will be performed using the OCT Dragonfly catheter is a hydrophilic-coated catheter that uses infrared light with a central wavelength between 1,250 and 1,350 nm. Axial resolution with OCT is 10-20 microns, and maximum tissue penetration with OCT is approximately 1.5 mm-3 mm.
41338337|NCT02984891|PROCEDURE|Intravascular Ultrasound (IVUS)|Procedure will be performed using the IVUS Kodama catheter is a hydrophilic-coated catheter that used high-fidelity ultrasound transmission to capture high-definition images of coronary artery anatomy. It uses ultrasound waves with a frequency of 40 or 60 MHz, as opposed to 20 MHz in conventional IVUS, to improve resolution while optimizing tissue penetration. It provides axial resolution of \< 40 microns and tissue penetration of 10 mm.
40819892|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
40819893|NCT02052726|BIOLOGICAL|Placebo|Placebo administered at Month 0, 1, and 3.
40819894|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
40819895|NCT02052726|BIOLOGICAL|placebo|Placebo administered at Day 1, 8, and 30.
40819896|NCT01391572|RADIATION|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
40819897|NCT01391572|RADIATION|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
40819898|NCT01391572|DRUG|cisplatin|
40819899|NCT01391572|DRUG|fluorouracil|
40819900|NCT00102544|DEVICE|EM Tracking|Utilizing electromagnetic tracking technology as a fusion and navigation tool for minimally invasive interventional procedures.
40819901|NCT06489990|COMBINATION_PRODUCT|combination intervention strategy of [Comorbidity-Co-causes-Joint-prevention]|combination intervention strategy of \[Comorbidity-Co-causes-Joint-prevention\]
40819902|NCT06489990|COMBINATION_PRODUCT|routine health education and mental health knowledge|routine health education and mental health knowledge
40819903|NCT00634712|DRUG|Candesartan|
40819904|NCT00634712|DRUG|Placebo|
40819905|NCT03965884|OTHER|Physical therapy and rehabilitation|Physical therapy and rehabilitation
40819906|NCT00096148|DRUG|idarubicin|Given IV
40819907|NCT00096148|DRUG|cytarabine|Given IV
41338338|NCT02491827|OTHER|Cellvizio mini laser probe|Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
41338339|NCT00949845|DRUG|Endotoxin|
41338340|NCT05498025|OTHER|Deterra activated charcoal pouch|drug disposal pouch
41338341|NCT04356924|BEHAVIORAL|Psychological treatment|The treatment is an adjusted (to the cognitively impaired individual) combination of CBT, ACT, validation strategies, and psychoeducation. One focus is to increase motivation to lifestyle changes, and to a larger degree live life in correspondence with internal goals.
41338342|NCT04356924|BEHAVIORAL|Cognitive training|Computer based training tasks implemented with adaptive intensity. The cognitive training method that will be used is mainly related to executive control (i.e., ability to coordinate thoughts and actions in accordance with internal goals).
41338343|NCT03534791|OTHER|Reminders|Personalized email which will aim for reminding of the translator about the PLSs on hold.
40819908|NCT00096148|BIOLOGICAL|bevacizumab|Given IV
40819909|NCT00096148|OTHER|laboratory biomarker analysis|Correlative studies
40819910|NCT03082183|DRUG|Rifampicin|once daily
40819911|NCT03082183|DRUG|BI 425809|once daily
40819912|NCT01271010|DRUG|Cyclophosphamide|Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.
41016721|NCT06663007|DRUG|RC48|During the patient treatment phase, the subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.
41156799|NCT05996497|OTHER|Training 2|Training 2
41486546|NCT04787393|DEVICE|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records if they wish to do so.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.~The data from the scales will be reviewed retrospectively, as the comparison in this study is with standard care, not with enhanced provision of care, which would be the case if we were using automatic reporting of weights."
40819913|NCT01271010|DRUG|Fludarabine|Participants received fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle.
40819914|NCT01271010|DRUG|Rituximab|Participants received 375 mg/m\^2 IV on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle.
40819918|NCT04214483|OTHER|No intervention|There is no intervention for this study.
40819919|NCT05522244|DIAGNOSTIC_TEST|extended CTA|Extending the standard CTA 6 cm below the carina.
40819920|NCT05055297|DEVICE|SELUTION SLR™ DEB 014|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
40819921|NCT05055297|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
40819922|NCT05627258|BIOLOGICAL|VRC-HIVMAB0115-00-AB|VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
40819923|NCT02927925|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
40819925|NCT05202574|DRUG|Intravenous drug|intravenous drug injection
40819926|NCT01663701|OTHER|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
40819927|NCT01663701|OTHER|Usual care|Patients are managed according to admitting doctors' orders
40819928|NCT06537297|DRUG|Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab|"* Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly;~* Furmonertinib(160mg QD);~* bevacizumab(5mg/kg，once monthly) until progressive disease."
40819929|NCT03014310|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
41338344|NCT06338852|OTHER|Socio demographic and evaluation questionnaires|Socio demographic and evaluation questionnaires Used to measure the awareness of gynaecologists about role of physical therapy in genital prolapse
41338345|NCT01160861|DRUG|MEMP1972A|Repeating ascending dose
41338346|NCT01160861|DRUG|placebo|Repeating ascending dose
41338347|NCT00723268|DRUG|Prednisolone|5MG Prednisolone per day for 3 months
41338348|NCT00723268|DRUG|Colchicine|0.5 MG Colchicine per day for 3 months
40819930|NCT03014310|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
40819931|NCT03014310|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
40819932|NCT05774054|DRUG|Crystalloid|received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)\> 65 mmHg despite adequate fluid resuscitation
40819933|NCT05774054|DRUG|noradrenaline|received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
40819934|NCT04751409|PROCEDURE|Chest Radiography|Undergo CXR
40819935|NCT04751409|PROCEDURE|Computed Tomography|Undergo CT-chest
40819936|NCT04751409|PROCEDURE|Follow-Up|Undergo intense follow-up
40819937|NCT04751409|PROCEDURE|Follow-Up|Undergo limited follow-up
40819938|NCT04751409|PROCEDURE|Imaging Technique|Undergo imaging
40819939|NCT04751409|OTHER|Questionnaire Administration|Ancillary studies
40819940|NCT00585221|DRUG|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
40819941|NCT00585221|DRUG|Imatinib|Continue imatinib until progression.
40819942|NCT05497349|OTHER|Leukocyte Rich- PRP injection|Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
41338349|NCT03438760|BEHAVIORAL|Science + Phonological Awareness|The goal is to facilitate phonological awareness during science lessons. Because phonological awareness does not relate to science learning, this is a placebo.
41486547|NCT03375294|DRUG|Nitrous Oxide|One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
40819943|NCT05497349|OTHER|Leukocyte Poor- PRP injection|Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
40819944|NCT02949986|BEHAVIORAL|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
40819945|NCT04376684|BIOLOGICAL|Otilimab|Otilimab will be administered once via IV route.
41016722|NCT06663007|DRUG|Envafolimab|During the treatment phase of the patient, the subjects received subcutaneous injections of Envafolimab (400 mg) every 3 weeks until the patient experienced disease progression or death.
41486548|NCT01412372|DRUG|Mesalamine|2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo
40819946|NCT04376684|BIOLOGICAL|Placebo 1|Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
40819947|NCT04376684|BIOLOGICAL|Placebo 2|Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
40819948|NCT04376684|DRUG|Standard of care|All participants will receive standard of care as per institutional protocol.
40819949|NCT02482194|BIOLOGICAL|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
41156800|NCT02243605|DRUG|Cabozantinib S-malate|Given PO
41338350|NCT03438760|BEHAVIORAL|Science + Grammar Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with grammatical structures related to science processes.
41486549|NCT01412372|DRUG|Placebo|This is an inactive pill
41486550|NCT01777620|BIOLOGICAL|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
40819950|NCT06606795|OTHER|Spinal Manipulation|For the treatment to be applied in the SMT group, segmental dysfunctions will be determined using static and dynamic palpation techniques and the applications will be applied with a chiropractic method, high-speed, low-amplitude spinal manipulation method, at the level of the dysfunctional spine.
40819951|NCT03479268|DRUG|Ibrutinib|Given PO
40819952|NCT03479268|OTHER|Laboratory Biomarker Analysis|Correlative studies
41016723|NCT06663878|GENETIC|MWAV201|Nonreplicating, recombinant gene transfer vector
40819953|NCT03479268|DRUG|Pevonedistat|Given IV
40819954|NCT03479268|OTHER|Pharmacokinetic Study|Correlative studies
40819955|NCT03479268|OTHER|Pharmacological Study|Correlative studies
40819956|NCT03525184|OTHER|Additional protein and multi-nutrient beverage|During SR+, participants will consume a multi-nutrient beverage and additional protein (\~1.5 grams·kg-1 body weight·day-1 versus the lower end of MDRI of \~0.9 grams·kg-1 body weight·day-1) during and after the period of sleep restriction. The multi-nutrient beverage contains arginine, glutamine, vits C \& D, zinc and omega-3 fatty acids (DHA and EPA).
40819957|NCT03525184|OTHER|Placebo beverage|The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).
40819958|NCT04114643|BIOLOGICAL|Prothrombin Complex Concentrate|Octaplex will be administered when the blood bank receives an order for coagulation factor replacement
40819959|NCT04114643|BIOLOGICAL|Frozen Plasma|Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
40819960|NCT03311139|DRUG|Antithrombotic agents|Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
41016724|NCT06664593|OTHER|integrated perinatal mental health pathway|This observational study examines whether assessing psychosocial risk factors and screening for depression and anxiety at different time points during the perinatal period, using a stepped protocol, helps to more quickly detect women with depressive and anxiety symptoms.
41338351|NCT03438760|BEHAVIORAL|Science + Vocabulary Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with vocabulary related to science processes.
41486551|NCT01777620|DRUG|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
40819961|NCT04728477|DEVICE|OPti BP measurements|measurement of blood pressure with the new smartphone App ( OPTIBP)
40819962|NCT01044212|DRUG|Docusate|Docusate 100mg BID
40819963|NCT01044212|DRUG|Bowel medications|Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
40819964|NCT05055323|DRUG|Pyrvinium Pamoate|Given PO
40819965|NCT04206254|BIOLOGICAL|gp96|heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
40819966|NCT04885322|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
41338352|NCT01763112|DEVICE|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
40819967|NCT06153420|DRUG|CIN-103|CIN-103 BID
40819968|NCT06153420|DRUG|Placebo|Placebo for CIN-103 BID
40819969|NCT06607224|DEVICE|Experimental (Decision making guided by CGM)|Patients use FSL2 and a smartphone. Libreview app will be used to assess interstitial glucose, alarms, and trend arrows, and LibreLinkUp app for research team. Concurrently, CG will be performed using the FreeStyle Optium Neo glucometer from Abbott. The nursing staff will be trained to manage and respond to alarms and trend arrows according to established protocols. The basal insulin adjustment protocol establishes with fasting and premeal targets between 140-180 mg/dL. For prandial insulin, corrective guidelines set according to each patient sensitivity factor, with additional adjustments for the intervention group based on trend arrows. The hypoglycemia alarm sets below 85 mg/dL. If activated, nursing staff will confirm the value via CG. If values are below 70 mg/dL, follow hypoglycemia protocol and if below 100 mg/dL with a descending trend arrow, 15 grams of slow-acting carbs. The hyperglycemia alarm will be set above 300 mg/dL and nurse inform investigators to make decisions.
40819970|NCT05552261|DRUG|Cenegemin in the DEFENDO Study|"Cenegemin as administered in the DEFENDO Study. Long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered in Stage 1 Neurotrophic Keratitis (NK) patients enrolled in the DEFENDO Study (NCT number NCT04485546).~No intervention was performed in this follow-up / extension trial."
40819971|NCT05802706|OTHER|No intervention.|No intervention.
41486552|NCT01747720|DIETARY_SUPPLEMENT|Vitamin D3|Given orally
40819972|NCT03956277|DEVICE|PUG|This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
40819973|NCT02154620|PROCEDURE|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
40819974|NCT02154620|DEVICE|Synthes TCP volar plate|
40819975|NCT06495229|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
40819976|NCT06601647|PROCEDURE|adjuvant type|ropivacaine combined with adjuvant
40819977|NCT04188418|DRUG|Fentanyl Citrate Buccal Tablet|Given transmucosally
40819978|NCT04188418|DRUG|Morphine|Given PO
40819979|NCT04188418|OTHER|Physical Performance Testing|Complete shuttle walk test
40819980|NCT04188418|OTHER|Placebo Administration|Given PO
40819981|NCT04188418|OTHER|Quality-of-Life Assessment|Ancillary studies
40819982|NCT04188418|OTHER|Questionnaire Administration|Ancillary studies
40819983|NCT02913001|OTHER|Low Glycemic Load Diet|Participants received a diet education on a low glycemic load diet.
40819984|NCT02913001|OTHER|Usual Eating Plan|Participants received a diet education to continue with their usual eating plan.
40819985|NCT02927704|OTHER|Gingival crevicular fluid (GCF) sample|Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
41486553|NCT01747720|DIETARY_SUPPLEMENT|Placebo|
41486554|NCT02497118|DRUG|Endostatin|Endostatin,7.5mg/m\^2,intravenous, d1-14;
40819986|NCT01372072|DEVICE|non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)|Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
40819987|NCT05718271|OTHER|Explicit instructions before extinction|"Shocks will no longer be administered during the next phase."
40819988|NCT05718271|OTHER|Explicit instructions after extinction|"Tomorrow no shocks will be administered."
41156801|NCT02243605|OTHER|Laboratory Biomarker Analysis|Correlative studies
41156802|NCT04165070|BIOLOGICAL|Pembrolizumab|IV infusion
41338353|NCT00365768|DRUG|Glutamine|Administered orally twice daily for 21 days
41338354|NCT00365768|OTHER|Placebo|Administered orally twice daily for 21 days
41486555|NCT02497118|DRUG|Vinorelbine|vinorelbine,25mg/m\^2,intravenous, d1, d8;
41486556|NCT02497118|DRUG|Cisplatin|Cisplatin，75mg/m\^2 intravenous,divide into d1-3
41486557|NCT04386174|OTHER|Neurofeedback|Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.
41486558|NCT01398943|DRUG|Tetrahydrobiopterin (BH4)|single dose = 5 mg/kg
41486559|NCT01398943|DIETARY_SUPPLEMENT|Antioxidant Cocktail|1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
40819989|NCT06118541|BEHAVIORAL|Vestibular Rehabilitation therapy|"Vestibular rehabilitation exercises of 30 to 60 minutes twice a week for eight weeks~Vestibular rehabilitation exercise program:~1. Eye-Head Coordination exercise~2. Sitting balance exercises~3. Standing Static balance exercises~4. Standing Dynamic balance exercises~5. Ambulation exercises"
40819990|NCT03886337|DEVICE|Germicidal lighting|Germicidal ambient lighting
40819991|NCT00709293|DRUG|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
40819992|NCT00709293|DRUG|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
40819993|NCT04177485|BEHAVIORAL|SMS text reminders|SMS reminders (in English and the local language) for the 2nd dose of Pentavalent vaccine were sent 28, 30 and 32 days after the 1st dose. SMS reminders for the 3rd dose of Pentavalent vaccine were sent 61, 66, and 68 days after the 1st dose. SMS reminders for the measles-containing vaccine were sent 274, 279, and 281 days after the child's date of birth.
41338355|NCT04892680|BEHAVIORAL|Online Diabetes Self-Management Education and Support (DSMES) Program|Digital delivery of a DSMES program designed to build self-management skills and support diabetes management. Recipients have access to online curriculum, a live CDCES, group-based communication forums, and connected technology to track weight, food intake, physical activity and glucose levels.
41338356|NCT02635529|PROCEDURE|OFD+ DFDBA|After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
41338357|NCT02635529|PROCEDURE|OFD+ DFDBA+ AM|After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
41338358|NCT05046236|OTHER|Interactive POWER rehabilitation|Interactive POWER rehabilitation training for twice a week, total 12 weeks, that consisted of 6 types of equipment for strength training.
41338359|NCT05046236|OTHER|Conventical physical training|Conventional physical training models in current clinical use for twice a week, total 12 weeks, that consisted of strength training, balance training, stretching, gait training, and etc.
41338360|NCT03058263|DRUG|Dose of Neostigmine|Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
41338361|NCT01386892|OTHER|No intervention|There is no intervention for this study
41338362|NCT01915095|DEVICE|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
41486560|NCT04146311|DRUG|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) into the left infrapatellar fat pad.
40819994|NCT04693104|DEVICE|PVA Hydrogel|PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.
40819995|NCT04693104|DEVICE|Synvisk-One®|Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.
40819996|NCT05124509|BIOLOGICAL|Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)|Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
40819997|NCT05124509|BIOLOGICAL|Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)|Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
40819998|NCT05676151|BEHAVIORAL|Music Therapy|20-minute music-therapy-informed interventions (musical bingo, songwriting, lyric scramble) guided by a music therapist
40819999|NCT06137378|BIOLOGICAL|KEYTRUDA®|200 mg KEYTRUDA® i. v. in 3-week cycle (q3w)
41016725|NCT06663397|OTHER|Laughter Yoga|Laughter Yoga sessions lasting 45 minutes each week for a total of 4 sessions. These sessions will include 30 minutes of laughter and breathing exercises, followed by 15 minutes of laughter meditation and relaxation
41016726|NCT06663397|OTHER|Standard Childbirth Preparation Training|the sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions
41156803|NCT04165070|DRUG|Carboplatin|IV infusion
41338363|NCT01915095|DEVICE|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
41338364|NCT01915095|OTHER|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
41338365|NCT01915095|OTHER|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
41338366|NCT04430699|DRUG|Cisplatin|Participants will be given Cisplatin by intravenous infusion at a predetermined dose 1x weekly up to 8 weeks.
41486561|NCT04146311|DRUG|isotonic saline|A bolus injection (0.25 ml) of isotonic saline (5%) into the left infrapatellar fat pad.
41156804|NCT04165070|DRUG|Paclitaxel|IV infusion
41156805|NCT04165070|DRUG|Pemetrexed|IV infusion
41338367|NCT04430699|DRUG|Pembrolizumab|Participants will be given Pembrolizumab by intravenous infusion at a predetermined dose 1x every 3 weeks up to 36 weeks.
41338368|NCT04430699|RADIATION|Radiation Therapy|Standard of care radiation therapy 1x daily up to 8 weeks.
41338369|NCT03654560|DEVICE|HemoStyp|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.
40820000|NCT00561158|BEHAVIORAL|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~* Rate Your Plate: determining high fat foods~* Label Reading: reading food labels~* Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~* Recipe Modification: preparing old recipes in new ways to reduce fat~* Eating Out: order healthier fast foods~* Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~* Substituting fat-modified foods for high fat foods~* Avoiding fat as a seasoning or flavoring~* Avoiding fried foods~* Modifying meat~* Replacing high fat foods with fruits, vegetables, grains and breads"
40820001|NCT05775159|DRUG|Volrustomig|CTLA-4/Anti-PD-1 Bispecific Antibody
40820002|NCT05775159|DRUG|Bevacizumab|15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
40820003|NCT05775159|DRUG|Lenvatinib|Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
40820004|NCT05775159|DRUG|Rilvegostomig|anti- PD-1 and TIGIT bispecific antibody
40820005|NCT05775159|DRUG|Gemcitabine|1000 mg/m2, IV infusion
40820006|NCT05775159|DRUG|Cisplatin|25 mg/m2, IV infusion
40820007|NCT00350870|DRUG|disulfiram|250mg per day of Disulfiram plus CBT
40820008|NCT00350870|DRUG|Placebo|Placebo plus CBT
40820009|NCT00350870|BEHAVIORAL|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
40820010|NCT00350870|DRUG|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
40820011|NCT06193200|DRUG|Dexamethasone sodium phosphate|Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion
40820012|NCT06193200|OTHER|Placebo|Placebo encapsulated in autologous erythrocytes and administered via IV infusion
40820013|NCT02142517|PROCEDURE|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
40820014|NCT02142517|PROCEDURE|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
40820015|NCT01317537|OTHER|Electronic personal health record|
40820016|NCT05043519|DRUG|FAM-NP41|The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.
40820017|NCT05652231|DIAGNOSTIC_TEST|caries assessment|the child will examined for dental caries, caries prevalence, caries indices (def and DMF, or DMF)
40820018|NCT00001399|DRUG|Transduced CD34+ Cells|
40820019|NCT06315283|DRUG|TV-44749|Administered subcutaneously (sc)
40820020|NCT06315283|DRUG|Oral olanzapine|Administered orally
40820021|NCT05550038|DIAGNOSTIC_TEST|Compression ultrasound|Patients receive a 3-point compression ultrasound performed by the general practitioner to look for proximal deep vein thrombosis.
40820022|NCT04265508|OTHER|Assessment of hemostatic profile|To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)
40820023|NCT02379026|DIETARY_SUPPLEMENT|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
40820024|NCT02379026|BEHAVIORAL|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
40820025|NCT02379026|DIETARY_SUPPLEMENT|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
41016729|NCT06663098|DRUG|Atezolizumab|1200 mg IV on day 1 of every 21 days, during induction phase and maintenance phase
41156806|NCT04165070|BIOLOGICAL|Vibostolimab|IV infusion
41156807|NCT04165070|BIOLOGICAL|Boserolimab|IV infusion
41156808|NCT04165070|BIOLOGICAL|MK-4830|IV infusion
41156809|NCT04165070|BIOLOGICAL|MK-0482|IV Infusion
41156810|NCT04165070|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
41156811|NCT04165070|BIOLOGICAL|HER3-DXd|IV Infusion
41486562|NCT04146311|OTHER|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
40820026|NCT06605391|BEHAVIORAL|Caregiving While Black-LIVE|Caregiving while Black-LIVE is a psychoeducation program that aims to intensify the development of caregiver mastery by integrating the online learning assets of the fully asynchronous Caregiving while Black program with synchronous, group-based opportunities for interactivity and active learning. The Caregiving while Black course includes topics of navigating the healthcare system, managing home life, and caregiver self-care. Once enrolled in the course, participants will be provided instructions for accessing the weekly sessions and course online, and supplemental course materials will be mailed to them. The Canvas platform enables the research team to monitor each individual's movement in the cohort through the asynchronous part of the course. Nudges and reminders to view these materials are sent twice a week via text or email with participant's consent. Synchronous sessions are conducted on a videoconferencing platform.
40820027|NCT06602219|DRUG|LY4100511|Administered orally
40820028|NCT06602219|DRUG|Placebo|Administered orally
41486563|NCT00683267|DRUG|4975, highly purified capsaicin|One dose administered by direct instillation into the surgical site
40820029|NCT04037631|DIAGNOSTIC_TEST|Diagnostic device|Diagnostic test
41016730|NCT06663098|DRUG|Carboplatin|AUC 4 or 5, depending on patient's characteristics, on day 1 every 21 days during induction phase
41016731|NCT06663098|DRUG|Etoposide|80 mg/sqm or 100 mg/sqm, depending on patient's characteristics, on days 1-2-3 of every 21 days
41156812|NCT06088355|BEHAVIORAL|HV-PDAE: High Volume Partnered Dance Aerobic Exercise|HV-PDAE classes will meet 5 times a week for 90 minute sessions for 3 weeks at onset of trial and then every 4 weeks for a year. All participants will receive 112.5h of training. PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
41156813|NCT06088355|BEHAVIORAL|MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise|MV-PDAE: MV classes will meet biweekly for 52 weeks for 65-minute sessions. All participants will receive 112.5h of training. . PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
41156814|NCT06088355|BEHAVIORAL|MV-WALK: Moderate Volume Walking|MV-WALK (65-minute sessions): WALK will control for the walking that participants in PDAE do and will also take place in groups to control social effects of intervention. Walking for
41156815|NCT05018728|DRUG|Voxelotor|Voxelotor is taken orally once a day. Participants 12 years or older will take 1500 mg/day. Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
41486564|NCT00683267|DRUG|Placebo|One dose administered by direct instillation into the surgical site
41486565|NCT01389466|BIOLOGICAL|Step 1|Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
41486566|NCT01389466|BIOLOGICAL|Step 2|Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
41486567|NCT02420418|DIETARY_SUPPLEMENT|N-acetyl-cysteine (NAC)|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.
41338370|NCT03654560|DEVICE|Surgicel|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.
41338371|NCT00433667|DRUG|RWJ-333369|
41338372|NCT03613818|BEHAVIORAL|eCHECKUP TO GO|eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
41338373|NCT04594304|BEHAVIORAL|Behavioral: Usual care plus eToolkit|A baseline e-survey will be sent to participants prior to their scheduled appointment to collect baseline alcohol/tobacco use levels as well as a series of questions evaluating precursors to behaviour change. If randomized into the intervention group, patients will be sent a link to a tailored toolkit based on their behaviours, motivation to change and other pertinent factors. Patients who identify as non-smokers and meet the low-risk drinking guideline, will complete a third screening survey for physical activity. The cumulative patient profile (CPP) status for the patient for alcohol/smoking will be automatically updated post-baseline survey, and the PCP will receive a notification via EMR about the status update. For patients identifying with risky behaviours, the PCP will receive a prompt to update the CPP for the patient and will receive a link, embedded in the EMR, to a PCP-facing toolkit that facilitates evidence-based intervention.
41338374|NCT05027113|BEHAVIORAL|Mindfulness meditation|Participants use the meditation app 10% Happier to practice mindfulness meditation (see detailed description in arm/group section)
41338375|NCT04444492|DRUG|Ranibizumab Injection|initial three injections of Ranibizumab - afterwards pro re nata monthly
41338376|NCT04444492|DEVICE|Laser photocoagulation|Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times
41338377|NCT05987475|PROCEDURE|Breast reconstruction|Breast reconstruction and breast augmentation based on the indications as listed out in the instructions for use of the medical device under investigation
41338378|NCT04623255|DRUG|OCTAPLAS|plasma exchange
40820030|NCT06606405|DIAGNOSTIC_TEST|scapular dyskinesis test|Scapular dyskinesia in athletes will be visually evaluated. It will be considered present if, during 3 out of 5 arm elevation attempts, any of the following are observed: prominence of the medial or upper scapular border, lower scapular angle, excessive clavicular elevation, or rapid downward rotation of the scapula. After the tester demonstrates the required movements, the athletes will practice the movement. The test will begin with the arms at the sides of the body, elbows straight, and shoulders in neutral rotation. Two testers will observe from behind and video record the movements. Participants will be instructed to raise their arms as high as possible simultaneously, using the \&amp;#39;thumbs up\&amp;#39; position, and to maintain this position for 3 seconds before lowering their arms for another 3 seconds. Athletes will perform the arm elevation with a dumbbell weight calculated as 1.4% of their body weight (Kamonseki, Haik, Ribeiro, Almeida, \&amp;amp; Camargo, 2023).
40820031|NCT04200443|DRUG|Cabozantinib|Given PO
40820032|NCT04200443|OTHER|Quality-of-Life Assessment|Ancillary studies
41338379|NCT03933124|DEVICE|Virtual Reality|The Virtual Reality intervention is used for 10 minutes minimal 3 times a day on postoperative day 2-4.
40820033|NCT04200443|OTHER|Questionnaire Administration|Ancillary studies
40820034|NCT04200443|DRUG|Temozolomide|Given PO
41338380|NCT05391620|OTHER|Cardiac rehabilitation with 3/7 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3/7 method 3 rep (15 sec of rest), 4 rep (15 sec), 5 rep (15 sec), 6 rep (15 sec), 7 rep. (total volume : 25 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned."
41338381|NCT05391620|OTHER|Cardiac rehabilitation with 3X9 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3X9 method 9 rep 1 minute of rest, 9 rep (1 min) and 9 rep (total volume : 27 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned"
41338382|NCT04481945|DRUG|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
41338383|NCT05432024|DEVICE|Catheter ablation|An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.
40820035|NCT00793429|DRUG|Prucalopride|
40820036|NCT00793429|OTHER|Placebo|
40820037|NCT01367418|DRUG|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
40820038|NCT01367418|DRUG|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
40820039|NCT04193345|OTHER|Documentation of Maternal blood loss and neonatal outcome|Comparing and monitoring the maternal blood loss and neonatal effect of delayed umbilical cord clamping and early umbilical cord clamping after delivery of the baby durin cesarean delivery in severe preeclampsia
40820040|NCT03846726|PROCEDURE|standard TME surgery|radical resection for rectal cancer
40820041|NCT03241823|DIAGNOSTIC_TEST|Abdominal ultrasound .|Abdominal ultrasound for each patient before and after treatment.
40820042|NCT03241823|DIAGNOSTIC_TEST|Model for End-Stage Liver Disease|Model for End-Stage Liver Disease before and after treatment.
40820043|NCT03241823|DIAGNOSTIC_TEST|Fibro Scan.|Liver stiffness by Fibro scan before and after treatment.
40820044|NCT03241823|DIAGNOSTIC_TEST|Child-Turcotte-Pugh score.|Child-Turcotte-Pugh score before and after treatment
40820045|NCT05220319|DRUG|Methylprednisolone|250 mg Methylprednisolone made up with 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional dose in 100 ml will be given.
40820046|NCT05220319|DRUG|NaCl 0.9%|100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
40820047|NCT04717336|OTHER|SODIUM CHLORIDE|It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
41338384|NCT03538990|OTHER|DASH Eating Pattern|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets.
40820048|NCT04717336|OTHER|placebo|placebo capsules
41338385|NCT06506292|DRUG|Adebrelimab|Adebrelimab:1200 mg, iv, d1
41338386|NCT06506292|DRUG|XELOX|oxaliplatin: 130 mg/m2,iv,d1; capecitabine: 1000 mg/m2,po,pid,d1-d14
41338387|NCT05211245|DEVICE|therapeutic ultrasound|Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain \& muscle spasm by altering nerve conduction velocity \& changes in cell membrane permeability along with increased rate of tissue repair \& wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons \& joint capsules, thus leading to decrease in the pain \& muscle spasm, stiffness of the joint \& temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central \& peripheral sensitization.
41338388|NCT05718453|COMBINATION_PRODUCT|Laboratory Tests|Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
41338389|NCT05851092|DRUG|HRS-2189 Tablets|HRS-2189 Tablets
41338390|NCT01769482|DRUG|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
41338391|NCT01769482|DRUG|placebo|
41338392|NCT00896350|DRUG|Standard Care Chemoradiation|"External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician."
41338393|NCT06401252|BEHAVIORAL|Mindfulness-based intervention|"• The mindful mediators are asked to act as neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each 19 stimuli. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction... how interesting)"
40820049|NCT06434766|DEVICE|sham stimulation|sham theta-burst transcranial magnetic stimulation
40820050|NCT06434766|DEVICE|intermittent theta-burst stimulation (iTBS)|intermittent theta-burst transcranial magnetic stimulation
40820051|NCT04326413|PROCEDURE|Oral hygiene instruction and simple scaling|Monitor the changes of gum condition
40820052|NCT06608342|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19-CART|Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation
40820053|NCT05263986|DRUG|MRTX849|"Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1."
41338394|NCT00241449|DRUG|Fulvestrant|intramuscular injection 250 mg
41338395|NCT00241449|DRUG|Tamoxifen|20 mg oral tablet
41338396|NCT02763241|DRUG|Cleanoze®|Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
41486568|NCT02420418|OTHER|Placebo|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
41486569|NCT00630019|DRUG|1.5% levofloxacin ophthalmic solution|Topical application
41486570|NCT00630019|DRUG|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
40820054|NCT06607536|OTHER|calcium chloride surface treatment in mini implant|0.1M of Calcium Chloride were used to immersed the orthodontic mini implant
40820055|NCT06607536|OTHER|Acid Etched|Mini implant etched in Hydrochloric acid
40820056|NCT05099055|DRUG|Dexmedetomidine 0.004 MG/ML [Precedex]|Injection of 3 mcg of dexmedetomidine and 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
40820057|NCT05099055|DRUG|Opioids|Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
40820058|NCT06606132|OTHER|Exercise|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person\&#39;s condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
41338397|NCT02763241|DRUG|Saline (Syringe irrigation)|Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
40820059|NCT02242435|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
40820060|NCT02242435|DRUG|4 mL Injection of Placebo|
41338398|NCT00643448|DRUG|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
41338399|NCT00643448|DRUG|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
40820061|NCT05726565|OTHER|multidisciplinary cardiac rehabilitation|A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
40820062|NCT00555763|DEVICE|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
40820063|NCT05771636|BEHAVIORAL|Mental Imagery|"Mental Imagery consists of imagining a situation in the most vivid way possible, including all sensory modalities (visual image, sensations, smells, sounds, emotions). It can be used to act as a motivational amplifier, by pre-experimenting a situation in imagination.~The best possible self imagery consists of imagining the best version possible of one's self , after accomplishing all their major life goals, in a future where everything turned out the best way possible. What does this best version of you do, in terms of actions, on an everyday basis ? The planned imagery exercise consists of rehearsing an activity in a mental way, before actually doing it. It can help to visualize the outcome of this activity and benefits it can provide to the participant before actually getting it done."
40820064|NCT05771636|BEHAVIORAL|Control condition (activity planification)|The participant identifies 4 activities that he plans to do in the course of the next 2 weeks.
41338400|NCT00643448|DRUG|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
41338401|NCT04054739|DEVICE|Robot-assisted gait training|intervention with robot-assisted gait training
41338402|NCT04054739|DEVICE|Treadmill gait training|intervention with treadmill gait training
41338403|NCT05248529|OTHER|Education booklet|Hip/Knee Replacement Adaptation Booklet explains preoperative preparation, post-operative care practices, how to walk with walker, what needs to be done at home after discharge
41338404|NCT04930172|DEVICE|Steerable introducers|endografts via total transfemoral approach for visceral vessels cannulation
41338405|NCT05642065|OTHER|Hip muscle activation home exercise program|Participants will perform a home exercise program consisting of five hip muscle activation exercises with the use of a resistance band. The program will be eight weeks in duration, and participants will perform the exercises twice weekly.
41338406|NCT02584023|DEVICE|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
40820065|NCT05014126|BEHAVIORAL|Pain, Stress and Emotions|2-hour, zoom-delivered, group intervention focused on teaching patients how pain is processed in their brain and learning about the role of psychosocial factors in their pain conditions.
41338407|NCT05459480|OTHER|the jigsaw technique in web-based distance education|The online training for the intervention group continued for a total of 6 weeks according to the jigsaw technique.
40820066|NCT03473106|DEVICE|Pneumatic tourniquet use|Surgery requiring a pneumatic tourniquet on the thigh
40820067|NCT03312920|DEVICE|active anodal tDCS|active anodal tDCS with memory task
40820068|NCT03312920|DEVICE|sham tDCS|sham tDCS with memory task
40820069|NCT03312920|DEVICE|active cathodal tDCS|active cathodal tDCS with memory task
40820070|NCT05347225|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD.
40820071|NCT06329401|DRUG|AP01|Oral inhalation solution
41338408|NCT04673240|DRUG|Botulinum toxin type A injection|"Adult patients with spasticity due to traumatic brain injury, spinal cord injury, or MS, treated with Botulinum Toxin type A.~As this is a non-interventional study, no diagnostic, therapeutic, or experimental intervention is involved. Subjects will receive clinical assessments, medications, and treatments solely as determined by their study physician."
41338409|NCT02437968|BEHAVIORAL|Camp Cope-A-Lot (Computer-assisted CBT program)|Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
41338410|NCT05721755|DRUG|Carboplatin|Given IV
41338411|NCT05721755|DRUG|Cisplatin|Given IV
41338412|NCT05721755|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
41338413|NCT05721755|DRUG|Fluorouracil|Given IV
41338414|NCT05721755|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41338415|NCT05721755|DRUG|Paclitaxel|Given IV
41338416|NCT05721755|BIOLOGICAL|Pembrolizumab|Given IV
41338417|NCT05721755|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41338418|NCT05721755|OTHER|Quality-of-Life Assessment|Ancillary studies
40820072|NCT06329401|OTHER|Placebo|Placebo oral inhalation solution
41338419|NCT05721755|RADIATION|Radiation Therapy|Undergo radiation therapy
41486571|NCT02987101|PROCEDURE|Liposuction|Adipose tissue is harvested by liposuction from either abdomen or thighs.
41338420|NCT03073213|DRUG|Ixekizumab|Administered as subcutaneous (SC) injection
41338421|NCT04928157|DEVICE|Positive Airway Pressure (PAP)|A device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
41338422|NCT00832689|DRUG|Irinotecan and Gemcitabine|
41338423|NCT04901104|DRUG|Thymosin Alpha1|Drug interventions have been done in previous clinical studies
41338424|NCT01697904|PROCEDURE|Titration of oxygen during newborn resuscitation in delivery room|
41338425|NCT06396260|OTHER|Diffusion Kurtosis Imaging (DKI)|Non-invasive MRI sequence which extracts information of diffusion signals from complex brain tissue
41338426|NCT06396260|OTHER|Resting State Magnetoencephalography|Non-invasive method of measuring resting state brain activity through magnetoencephalography (MEG)
41338427|NCT02338167|PROCEDURE|Blood sampling|A blood sample will be taken during a routine blood draw
41338428|NCT04628611|DEVICE|Video laryngoscopy|Endotracheal intubation using video laryngoscopy
41486572|NCT02987101|OTHER|Standard wound care|Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
41338429|NCT04628611|DEVICE|Flexible intubating laryngoscopy|Endotracheal intubation using flexible intubating laryngoscope
41338430|NCT05437913|OTHER|Psychological intervention (self-compassion based)|4 weeks intervention for both primary caregivers and adolescents with T1D will be done online through videoconferencing and will be based on three validated protocols that use self-compassion (MSC and MSC Teens).
41486573|NCT02987101|DRUG|Adipose-Derived Regenerative Cells|Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
41486574|NCT02749292|DRUG|Rituximab|re-dosing dependent on interventional arm parameter.
41338431|NCT02959970|DRUG|dapsone gel|Dapsone (ACZONE) 7.5% gel topically once daily.
41338432|NCT02211950|DRUG|BI 44847|
41338433|NCT02211950|DRUG|Acarbose|
41338434|NCT02211950|OTHER|Japanese diet|
41338435|NCT00035152|DRUG|Paclitaxel and carboplatin|
41338436|NCT02732249|DRUG|Esomeprazole|Given 30 min before morning and evening meals
41338437|NCT02732249|DRUG|Bismuth Potassium Citrate|Given 30 min before morning and evening meals
41338438|NCT02732249|DRUG|Clarithromycin|Given 30 min after morning and evening meals
41338439|NCT02732249|DRUG|Metronidazole|Given 30 min after meals or at bedtime
41338440|NCT03066297|PROCEDURE|Extent of pulmonary resection|Extent of pulmonary resection selected based on the institutional decision-making algorithm
41338441|NCT01201967|OTHER|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
41338442|NCT01201967|OTHER|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
41338443|NCT00876486|DRUG|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
41486575|NCT03460769|OTHER|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).
41486576|NCT00275938|DRUG|interferon alpha 2b plus ribavirin|
41486577|NCT00275938|DRUG|interferon alpha 2b plus placebo|
41486578|NCT03621059|BEHAVIORAL|habit reversal training (HRT)|"The intervention group received 4 sessions during 3months of behavior intervention and then, were reassessed at 3 and 6 months following treatment.~Pyridoxine(50mg)"
41338444|NCT00876486|DRUG|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
41338445|NCT05396807|DEVICE|AI|The aim of using AI software to support physicians in choosing the most effective treatment.
41338446|NCT05203003|OTHER|Assessment of MRD|"Bone marrow aspirate for assessment of MRD will be performed at 2 years (+/- 3 month) after randomization in patients still under treatment and in complete response.~Thereafter, bone marrow aspirate for assessment of MRD will be repeated at 3 and 4 years in patients that maintain complete response, irrespective of the randomization arm and therefore of treatment administration."
41338447|NCT04955496|PROCEDURE|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
40820073|NCT06607653|DEVICE|Olfactory training|Olfactory training used repeated stimulation of different olfactory substances at high concentrations, combined with odor association and odor identification training, twice in the morning and evening, each time for 5 minutes, for 15 weeks.
40820074|NCT04667520|BEHAVIORAL|Lifestyle Physical Activity (LPA)|This intervention has 3 components: (1) an orientation session to LPA and using the Fitbit; (2) Six telephone physical activity counseling sessions; and (3) monitoring activity with the Fitbit, which is provided to them during their study participation.
41338448|NCT00034151|DRUG|S-8184 Paclitaxel Injectable Emulsion|
41338449|NCT00005640|PROCEDURE|Preoperative Endoscopy|
41338450|NCT00005640|RADIATION|Technetium Tc 99m Sulfur Colloid|
41338451|NCT00005640|PROCEDURE|Gamma Probe|
41338452|NCT00005640|PROCEDURE|Biopsy of Sentinel Lymph Nodes|
41338453|NCT03336060|DIAGNOSTIC_TEST|Cortical Correlates of Jump Landing Task|The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).
41338454|NCT02994095|BEHAVIORAL|Pilot Study|Trained community health agents used Motivational Interviewing-based counseling and action planning in monthly home visits with adults with diabetes
41338455|NCT03294772|OTHER|hand sanitizer|DCCs received alcohol-based hand sanitizer and a program educational.
41338456|NCT03294772|OTHER|liquid soap|DCCs received liquid soap and a program educational.
41338457|NCT02817750|DRUG|zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
41486579|NCT01335997|DRUG|ER niacin/laropiprant (ERN/LRPT)|ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
41486580|NCT01335997|DRUG|ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)|ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
41486581|NCT01335997|DRUG|Simvastatin (SIM)|Simvastatin 10 mg oral tablet taken once daily
41486582|NCT01335997|DRUG|Placebo Run-In|Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
41486583|NCT01335997|DRUG|SIM-matching placebo|Placebo for simvastatin 10 mg oral tablet taken once daily
41486584|NCT04560348|OTHER|adventure-based cognitive behavioral intervention|The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
41338458|NCT02817750|DRUG|zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
41338459|NCT02353676|DRUG|Bupivacaine|1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
41338460|NCT02353676|OTHER|SALINE|1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
41338461|NCT03013959|DRUG|Pranoprofen|it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
41338462|NCT02106572|DRUG|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900 13 times during treatment period
41338463|NCT02106572|DRUG|Mitomycin C|intravesical instillation of Mitomycin C 10 times during treatment period
41338464|NCT04764968|DRUG|Dasiglucagon|Abdominal s.c. administration using a multi-dose reusable pen injector
41338465|NCT04569760|DRUG|50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)|Oral cannabinoid oil preparation dosed in 1ml increments
41338466|NCT04569760|DRUG|Placebo Oil|Oral MCT Oil Preparation - No cannabinoids- titrated as tolerated up to a maximum of 8mls twice daily (equivalent to 200 mg- 800 mg total dose of the active product)
41338467|NCT01379729|OTHER|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
41338468|NCT01379729|OTHER|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
41338469|NCT06260072|DRUG|magnesium and riboflavin supplement|Five capsules considered one dose of the intervention (one 400 mg magnesium capsule and four 100 mg riboflavin capsules)
41338470|NCT00005675|DRUG|Oral bovine type I collagen|500 mcg of CI daily for 15 months
41338471|NCT00005675|DRUG|Placebo|CI placebo daily for 15 months
41486585|NCT00427713|DRUG|capecitabine|
41486586|NCT00427713|DRUG|oxaliplatin|
41486587|NCT00427713|PROCEDURE|adjuvant therapy|
41486588|NCT00427713|PROCEDURE|standard follow-up care|
41486589|NCT01618188|DRUG|Faster-acting insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
41486590|NCT01618188|DRUG|insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
40820075|NCT04667520|BEHAVIORAL|Fitbit Only|Participants are provided with a Fitbit during their study participation.
40820076|NCT04315688|DRUG|insulin degludec|Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
40820077|NCT06607419|DRUG|Blinatumomab|Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.
41338472|NCT06269575|BEHAVIORAL|SAFE NUTRITION PROGRAM|"Safe nutrition program:~patient education, caregiver training, behavioral swallowing intervention, position, oral care, swallowing exercises, swallowing assessment"
41338473|NCT02773472|DEVICE|electroacupuncture|The acupoints that will be stimulated are: daheng, tianshu, zhongwan, xiawan, qihai, guanuian, hegu, guchi, zusanli, sanyinjiao, gongsun. An alternating fast-slow frequency of 20Hz/6Hz will be used with an interval of 250msec. The intensity (mA) will be adjusted to a level tolerated by each individual patient.
40820078|NCT00529230|BEHAVIORAL|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
40820079|NCT00529230|OTHER|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
40820080|NCT03179254|DRUG|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
40820081|NCT03179254|DRUG|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
40820082|NCT04234789|DIAGNOSTIC_TEST|cardiopulmonary exercise testing with dynamic hyperinflation maneuver|test performed as recommended by ATS guidelines
41338474|NCT02773472|DRUG|morphine|Patient will not receive electroacupuncture. Patient will use morphine for analgesia.
41338475|NCT01480232|DRUG|EVP-6124|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
41338476|NCT01480232|DRUG|Placebo Capsule|One placebo capsule ingested orally daily for 12 weeks (84 days)
41338477|NCT01480232|DRUG|NicoDerm Patch (Active)|One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
41338478|NCT01480232|DRUG|NRT Patch (Placebo)|One NRT patch (Placebo) daily for first 6 weeks (42 days).
40820083|NCT04234789|DIAGNOSTIC_TEST|spirometry|test performed as recommended by ATS guidelines
40820084|NCT04234789|DIAGNOSTIC_TEST|pletysmography|test performed as recommended by ATS guidelines
40820085|NCT04234789|DIAGNOSTIC_TEST|forced oscillometry technique|test performed as recommended by ATS guidelines
40820086|NCT06563466|OTHER|The experimental intervention PEGASUS|See arm description.
40820087|NCT06563466|OTHER|Treatment as usual|See arm description
40820088|NCT05326191|DIAGNOSTIC_TEST|Ultrasound|All study interventions/procedures will happen during the participants routine clinic visit in which they will receive their routine Ultrasound scan, followed by an additional research scan, which will take approximately 2-3 minutes. A blood sample will also be taken from participants as part of their routine pregnancy care. Residual blood from the same sample will be used to conduct an additional test to quantify Placental Growth Factor (PlGF). Participants will also be asked questions about their relevant medical history and demographic data which is also routinely collected as part of their pregnancy record.
40820089|NCT04451564|BEHAVIORAL|Mindfulness oriented recovery enhancement|8- week psychological program based on mindfulness techniques
40820090|NCT05838053|PROCEDURE|Lobectomy with systemic lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
41016745|NCT06662838|OTHER|Ergonomics Awareness and First Aid Training Program|The ergonomic awareness and first aid training program includes training on possible situations that children of seasonal agricultural worker families may encounter in the field.
41338479|NCT01480232|BEHAVIORAL|Brief Supportive and Behavioral Treatment|Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
41338480|NCT05148117|DIAGNOSTIC_TEST|Suspected Sepsis Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
41338481|NCT05148117|DIAGNOSTIC_TEST|Control Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
41338482|NCT02201667|DRUG|Ticagrelor|180-mg loading dose followed by 90mg twice daily for 30 days
41338483|NCT02201667|DRUG|clopidogrel|300-mg loading dose followed by 75mg once daily for 30 days.
41338484|NCT02201667|DRUG|Aspirin|300mg loading dose aspirin and followed by 100mg once daily
41338485|NCT02201667|PROCEDURE|PCI|PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
41338486|NCT01010269|DEVICE|Vanguard Complete Knee|Vanguard Knee is a metal and polyethylene system indicated for cemented tibial and femoral use.
41338487|NCT01010269|DEVICE|Vanguard High Flex RP|Vanguard High Flex RP is an extension to the existing Vanguard Knee and has been specifically designed to facilitate greater than 135 degrees of knee flexion.
41338488|NCT00965549|DRUG|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
41338489|NCT00965549|DRUG|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
41338490|NCT00965549|DRUG|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
41338491|NCT02839811|PROCEDURE|Immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
41338492|NCT06057649|OTHER|Effleurage Abdominal Massage|perform the effleurage massage by following these steps: Lie in supine position with knee slightly flexed. Start from the right lower quadrant, using gentle pressure, rub in tiny clockwise circular motions using any non-analgesic cream, towards right rib cage then towards upper left side, moving down the left side to hip bone. Keep up the circular massage while moving inward, toward your belly button for three minutes. After three minutes, use a little more pressure, continuing the circular movements for 10 minutes. Massage for 10 minutes a day for two months during the first 3 days of the menstrual cycle.
41338493|NCT00618813|OTHER|radiation therapy|Undergo radiation therapy
41338494|NCT00618813|OTHER|therapeutic conventional surgery|Undergo surgery
41338495|NCT00618813|DRUG|etoposide|Given IV
40820091|NCT05838053|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
40820092|NCT06254703|DIAGNOSTIC_TEST|VexLUS (venous excess lung ultrasound)|IVC, hepatic veins (HVs), portal veins (PVs) and intrarenal veins (IRVs), and lung ultrasound
41338496|NCT00618813|DRUG|ifosfamide|Given IV
41338497|NCT00618813|DRUG|doxorubicin hydrochloride|Given IV
41338498|NCT00618813|DRUG|cyclophosphamide|Given IV
41338499|NCT00618813|DRUG|vincristine sulfate|Given IV
41338500|NCT00618813|DRUG|topotecan hydrochloride|Given IV
41338501|NCT00618813|BIOLOGICAL|filgrastim|Given SC
41338502|NCT05905770|DRUG|Alemtuzumab Injection [Campath]|Alemtuzumab 1mg/kg
41338503|NCT02435394|BEHAVIORAL|Remote Coach plus Asthma Module|The intervention is for a remote coach to assist patients with asthma for practices which will use Asthma module for guidance for asthma care.
41338504|NCT02435394|BEHAVIORAL|Asthma Module- No Coach|The intervention is for practices to use the Asthma module for guidance for asthma care without assistance by a remote coach.
41338505|NCT02435394|BEHAVIORAL|CHADIS- no Asthma Module|The practices will use the general CHADIS tool without access to the Asthma Module add-on to assist in asthma care.
40820093|NCT05807464|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
40820094|NCT02087618|OTHER|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
40820095|NCT02087618|OTHER|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
40820096|NCT04549805|DIAGNOSTIC_TEST|Computed Tomography Coronary Angiography|In order to optimise the quality of the Computed Tomography Coronary Angiography scan images, participants might be given tablets or an injection (e.g. beta-blockers, calcium channel antagonist, ivabradine) to slow their heart rate and glyceryl trinitrate (GTN) following local protocol guidance.
40820097|NCT05184101|DRUG|Unfractionated Heparin|Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
40820098|NCT04975126|OTHER|CatInfo tool|Presentation about cataract surgery
40820099|NCT02584231|DRUG|desmopressin|One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: \>6 months and \< 2years: 60µg; ≥2 years and \<4 years: 120µg PO and ≥4 years and \<8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
40820100|NCT02938832|BEHAVIORAL|Advice on what food to choose and eat|Dietary advice
40820101|NCT01690546|DRUG|very low dose naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
41156816|NCT06647186|PROCEDURE|Non Incised Papillae Surgical Approach|Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. A single horizontal or oblique incision was made in the mucosa located on the cortical bone tissue, apical to the intrabony defect. The mesiodistal extension of the incision was sufficient to allow access to the defect. Tissue coronal to the incision was raised to full thickness from the incision line to expose the bone peaks delimiting the intrabony defect. The granulation tissue was removed from the bone walls of the defect. Dental plaque and calculus deposits were removed from the root surface with ultrasonic scaler tips and micro-minicurettes. A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with horizontal internal mattress sutures then simple interrupted sutures.
41338506|NCT02237898|BEHAVIORAL|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application \& Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
40820102|NCT01690546|DRUG|extended release naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
40820103|NCT01690546|DRUG|buprenorphine/naloxone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
40820104|NCT05698017|DRUG|hOMSC300|Human Oral Mucosa Stem Cells
40820105|NCT05698017|OTHER|Sham Procedure|Lumbar Puncture Only
40820106|NCT00842946|BEHAVIORAL|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
40820107|NCT00842946|BEHAVIORAL|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
40820108|NCT06607432|DEVICE|Transcranial Interference Stimulation (tIS)|Field strength dose of 0.30 - 0.40 V/m
40820109|NCT06607432|OTHER|Sham tIS|Sham transcranial interferential stimulation. Sham comparator to be administered to all groups.
40820110|NCT01529983|PROCEDURE|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
40820111|NCT03581539|PROCEDURE|Transverses Abdominis Plane (TAP) block|TAP block - Participants will get an injection of bupivacaine and exparel (numbing medicine) in the four different locations of your stomach. To be more specific, the injection placed between your oblique muscles in four different locations right after you are asleep and just before the start of surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
40820112|NCT03581539|PROCEDURE|Quadratus Lumborum (QL) block|QL block - Participants will get an injection of bupivacaine with exparel (numbing medicine) in two locations in your lower stomach. To be more specific, an injection will take place inside your quadratus lumborum muscle which is slightly deeper than your oblique muscles right after you are asleep and right before surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
41338507|NCT02237898|BEHAVIORAL|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.
41338508|NCT02237898|DEVICE|Sensordrone™ carbon-monoxide sensor|A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.
41338509|NCT02237898|DEVICE|MoMba Live Long Smartphone application|The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.
41338510|NCT04826029|OTHER|Standard strategy|In the standard arm, patients will complete CA 125 (+/- HE4) at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days), complete the HAD and EQ5D self-questionnaires, and be managed according to INCa 2018 recommendations. If clinical symptoms, marker elevation, and/or imaging workup occur, the patient will be referred to the multidisciplinary consultation meeting (MDC) for management according to INCa 2018.
41338511|NCT04826029|OTHER|Follow-up strategy|In the interventional arm, patients will perform at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days) a CA125 assay (+/- HE4 assay), a thoracoabdominal CT scan after contrast injection and a whole body MRI (T2, DW and T1 sequences after fat saturation before and after gadolinium injection) with a maximum delay of 15 days between the two examinations, and will complete the HAD and EQ5D self-questionnaires. A senior radiologist from each center will perform a prospective reading of each of the images. For any suspicious anomaly identified, the following criteria will be analyzed: Size, location, number, evolution, contrast after injection, MRI signal (T2, Diffusion, Dynamic Enhancement Curve). The RECIST criteria (version 1.1) will be applied.
41338512|NCT02802072|DEVICE|Enterprise stent implantation|Enterprise stent system (Johnson \& Johnson (Shanghai) Medical Equipment Co.,Ltd., China) is a closed loop self-expanding stent system that is made of Ni-Ti alloy. It consists of a self-expanding stent and a delivery system.
41338513|NCT02802072|DRUG|Only aspirin medication|Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
41338514|NCT02451488|DRUG|GM-CSF|14 days in a dose of 125 µg/m\^2
41338515|NCT02451488|OTHER|Standard of Care|No neo-adjuvant therapy prior to surgical intervention
41338516|NCT04709913|DRUG|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
41338517|NCT01329341|OTHER|Service Dogs|Service dogs will be trained to help Veterans with PTSD
41338518|NCT04741646|DRUG|Ferric Citrate|Auryxia® 210 mg ferric iron tablets equivalent to 1 g of FC and matching placebo will be supplied as 200 tablets in 400cc high-density polyethylene bottles.
41338519|NCT04741646|DRUG|Placebo|Placebo to match Ferric Citrate tablets
41338520|NCT04279652|OTHER|Combined exercise|Combined exercise program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
41338521|NCT01024062|DRUG|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
41338522|NCT00017628|DRUG|cyclophosphamide|
41338523|NCT00017628|DRUG|filgrastim|
40820113|NCT03581539|PROCEDURE|Surgeon Infiltration using Exparel|SI group - at the end of the surgery and just prior to you waking up, the surgeon will use a needle to inject the surgical incision site with bupivacaine and exparel (numbing medicine) spreading the medicine evenly as the needle is slowly withdrawn to make sure all layers are evenly filled with the medicine that will numb the area.
40820114|NCT04424628|RADIATION|Low dose radiotherapy A|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again
41338524|NCT00017628|DRUG|methylprednisolone|
41338525|NCT00017628|PROCEDURE|Autologous Stem Cell Transplantation|
41338526|NCT02341404|DRUG|2-hydroxyflutamide (2-HOF)|Two components are mixed, transferred to a syringe and administered with injection into the prostate
41338527|NCT03933280|DRUG|Nalbuphine|i.v. nalbuphine bolus of 50 μg/kg.
41338528|NCT03933280|DRUG|Propofol|A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min
41486591|NCT03716245|PROCEDURE|supraclavicular lymph node dissection|people with supraclavicular lymph node metastasis before surgery should receive dissection of supraclavicular lymph node and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
41486592|NCT03716245|RADIATION|supraclavicular area radiotherapy|people with supraclavicular lymph node metastasis before surgery should receive radiotherapy of supraclavicular area and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
41486593|NCT04796779|DEVICE|Tandem t:slim X2 with Control-IQ Technology Pro|"The Tandem t:slim X2 with Control-IQ Technology Pro is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is very similar to the commercially available t:sli X2 with Control-IQ but modified to accept the lower weight and Total Daily Insulin of the studied population."
41486594|NCT04796779|DEVICE|Standard Care (SC)|Standard of Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study Dexcom G6 CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump without hybrid closed-loop control capabilities (low-glucose suspend or predictive low-glucose suspend functionality is permitted).
41486595|NCT04796779|DEVICE|Tandem t:slim X2 with Control-IQ Technology V1.5|"The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features."
41486596|NCT00017823|PROCEDURE|Acupressure|
40820115|NCT04424628|RADIATION|Low dose radiotherapy B|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
41338529|NCT03933280|DRUG|Dexmedetomidine|i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.
41338530|NCT03933280|DRUG|Benoxinate Hydrochloride 0.4% Eye Drops|Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
41338531|NCT01619605|PROCEDURE|shrimp challenge|Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
41338532|NCT05743257|BEHAVIORAL|Questionnaire|Each participant completes a questionnaire (online or paper version) about socio-demographic characteristics, health outcomes (general health, respiratory health, and weight status), physical activity and sedentary behaviors, perception of neighborhood characteristics, air quality, and noise exposure.
41338533|NCT05743257|BEHAVIORAL|Food diary supply|Sample of participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops. For each food purchase, participants provided details of date, place of purchase and foods purchased (name, quantity and expense incurred). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary.
41486597|NCT05636826|DRUG|atherolive-drug|placebo
41486598|NCT01272362|DRUG|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
41486599|NCT00039962|DRUG|thymalfasin (thymosin alpha 1)|
41486600|NCT00039962|DRUG|PEGinterferon alfa-2a|
41486601|NCT00567047|DRUG|vildagliptin|
41486602|NCT00233506|DRUG|CpG 7909|
41486603|NCT01790035|DRUG|LGG|
41338534|NCT05743257|BEHAVIORAL|Interviews (semi-structured)|Sample of participants was interviewed about their food provisioning practice and living conditions.
41338535|NCT05743257|BEHAVIORAL|air and noise|Sample of participant were instructed to wear air and noise sensors to record their daily environmental exposure for 7 consecutive days, except for sleeping, bathing and performing activities in the water. Particulate matter concentrations, the temperature, and the relative humidity were measured - the nitrogen dioxide (NO2) and ozone (O3) concentrations were determined with data loggers that integrate reliable electrochemical gas sensors. Noise levels was measured using noise dosimeters. Sensors were accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
41486604|NCT01790035|DRUG|Placebo|
41486605|NCT05709977|OTHER|Acupuncture|Fixed set of acupuncture points
41486606|NCT05709977|DRUG|Antihistamine nasal spray|Carelastin® (1 mg/ml) azelastine nasal spray
41486607|NCT03207841|OTHER|LC/HP|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include \~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio \<1.5 and fat intake set at \~30% of the total energy intake.
41486608|NCT04792775|BEHAVIORAL|PE+ER|PE includes the following components: a) psychoeducation about the common reactions to traumatic events and presentation of the treatment rationale b) repeated in vivo exposure to traumatic stimuli, c) repeated, prolonged, imaginal exposure to traumatic memories, and d) relapse prevention strategies and further treatment planning (session 12). DBT Emotion Regulation Skills is integrated as part of this intervention. DBT training provides skills to understand, name, experience and tolerate emotions, as well as skills to change negative emotional responses and to reduce vulnerability to emotion dysregulation (Linehan et al., 2015). The current project includes an adapted 3- session individual emotion regulation skills training intervention to be implemented concurrently with PE which consists of initial teaching/instruction and brief skills review for the remainder of PE treatment.
41338536|NCT01944488|DRUG|GnRH agonist|100 µg/m2 body surface max 100 µg i.v.
40820116|NCT03319563|DRUG|Local anesthetic-epinephrine|"* Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~* Lidocaine 5 mg/Kg.~* Epinephrine 5 mcg/ml of the total volume.~* Add normal saline to a total volume of 100 ml/10 cm of the wound length."
41338537|NCT05660512|PROCEDURE|Intracept Procedure|Radiofrequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
41338538|NCT03542149|DRUG|480 mg Piperaquine phosphate|480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
41338539|NCT03542149|DRUG|640 mg Piperaquine phosphate|640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
40820117|NCT03319563|DRUG|Saline|normal saline 100 ml/10 cm of the wound length
40820118|NCT03231917|PROCEDURE|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
40820119|NCT03231917|PROCEDURE|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
41338540|NCT03542149|DRUG|200 mg OZ 439|200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
40820120|NCT04225052|DRUG|YHP1903|YHP1903 Tab. 1mg
40820121|NCT04225052|DRUG|Champix|Comparator Champix Tab. 1mg
41338541|NCT03542149|DRUG|400 mg OZ 439|400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
41338542|NCT03542149|DRUG|800 mg OZ 439|800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
40820122|NCT06493357|BEHAVIORAL|PAC-Man|"PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach high risk MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings."
40820123|NCT06493357|BEHAVIORAL|Standard of Care|Routine care as provided by Ministry of Health.
41338543|NCT03542149|DRUG|960 mg PQP|960 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
41338544|NCT03542149|DRUG|320 mg PQP|320 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
41338545|NCT06067724|OTHER|Pelvic and trunk control exercises|Patients in this group will be treated by the traditional physical therapy program in addition to a 18 sessions of pelvic and trunk control exercises for 40 min included abdominal drawing in maneuver for contraction of transversus abdominis pelvic tilting exercises and pelvic stabilization exercises from different positions. Pelvic tilting exercises included; anterior, posterior, lateral pelvic tilting and pelvic rotation on a therapeutic ball. Pelvic stabilization exercises include bridging, half bridging, clamshell from supine and side lying, quadribed exercises, weight shifting on the affected limb from standing by forward and diagonal reach out, ball bridging and rhythmic stabilization exercises
41338546|NCT02533401|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
41338547|NCT02533401|DRUG|Fludarabine|Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
41338548|NCT02533401|DRUG|Rituximab|Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
40820124|NCT00559429|DRUG|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
40820125|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
40820126|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
40820127|NCT00559429|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
41338549|NCT01507623|DEVICE|Capnography (Phillips MP20 monitor)|"In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation\* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.~\*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures"
41338550|NCT04759222|DIAGNOSTIC_TEST|vascular occlusion test|The VOT was performed five times in each patient, before the induction of general anesthesia (baseline, T0), 30 min after the induction of general anesthesia (T1), 30 min after applying CPB (T2), 10 min after injection of protamine (T3), and after sternal closure (T4). Before induction of anesthesia, an NIRS sensor was placed on the thenar eminence and an automated tourniquet was placed around the upper arm. The arterial catheter was placed in the contralateral radial artery and the baseline blood pressure was measured. When the baseline tissue oxygen saturation (StO2) was stabilized, the automatic tourniquet was inflated to 50 mmHg over the patient's baseline systolic blood pressure and maintained for 5 min. After the 5-min ischemic period, the tourniquet rapidly deflated to 0 mmHg. StO2 data were continuously recorded during the VOT procedure.
41338551|NCT05070741|BEHAVIORAL|Heat Therapy|Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (\~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged \~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted \~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.
41486609|NCT05689593|OTHER|Low-intensity ESWT Group|ESWT; With the MODUS ESWT system, the patient's shoulder will be in 80° passive abduction, the elbow will be in 90° flexion, and the forearm will be applied to 2 separate parts of the shoulder. The first application will be applied from front to back in the anterior shoulder joint and the upper limit of the treatment will be approximately 1 finger lateral to the coracoid process, the second application will be applied from the lateral scapula to the posterior shoulder joint (0.06 mJ/mm2, 1500 impulses, 1.5 bar).( Modus ESWT® RadialShockwaveTherapy)
40820128|NCT00813605|OTHER|FOLFIRI|"Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion"
40820129|NCT00813605|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
40820130|NCT00813605|OTHER|Placebo|Inactive dummy agent (to maintain blind)
41486610|NCT05689593|OTHER|Low-intensity laser Group|The laser will be made parallel to the joint line with the patient's arm, the arm will be in internal rotation at the posterior of the shoulder and the arm will be in external rotation at the anterior of the shoulder. The wavelength of 850 nm will be applied for 5 minutes in total 30 Joules.
40820131|NCT00813605|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
40820132|NCT06044935|OTHER|Standard Diet|Consisting of 15% protein, 35% fat, and 50% carbohydrate, matching the macronutrient composition of a typical American diet
40820133|NCT06044935|OTHER|Ketogenic Diet|Consisting of a macronutrient composition of 15% protein, 80% fat, and 5% carbohydrate
41486611|NCT05689593|OTHER|Conventional Control Group|Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.
41486612|NCT04766736|PROCEDURE|Quantification of netrin-1 signals by antibody-based approaches|Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
40820134|NCT06044935|DIETARY_SUPPLEMENT|Placebo|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
40820135|NCT06044935|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
40820136|NCT03466099|DRUG|KVD001 Injection|Intravitreal KVD001 Injection
40820137|NCT03466099|OTHER|Sham Procedure|Sham Procedure
40820138|NCT03260894|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered intravenously every 3 weeks.
40820139|NCT03260894|DRUG|Epacadostat|Epacadostat 100 mg administered orally twice daily.
40820140|NCT03260894|DRUG|Sunitinib|Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.
40820141|NCT03260894|DRUG|Pazopanib|Pazopanib 800 mg administered orally once daily.
40820142|NCT05495841|DEVICE|Pre-oxygenation|Process of administrating oxygen prior to intubation
40820143|NCT05878327|OTHER|Thrombophilia screening|No intervention. Blood is drawn for analysis.
40820144|NCT02227953|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
40820145|NCT02227953|DEVICE|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
41338552|NCT02972281|BIOLOGICAL|Immunological diagnosis tests|(Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...
41338553|NCT04163367|BEHAVIORAL|Safer Kids|A behaviorally based parent training program with the purpose to reduce or prevent child abuse.
41338554|NCT04163367|OTHER|Intervention as usual (IAU)|Everything that's included in the social service units' regular handling of cases; such as the formal investigation and family treatment. The units cannot offer Safer Kids as a part of IAU.
41338555|NCT01607073|DRUG|Verapamil|"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."
41338556|NCT03349593|DIAGNOSTIC_TEST|Echocardiography|Preoperative transthoracic echocardiography
41338557|NCT05326568|OTHER|Complementary treatment practice|Applying sesame oil to the patients assigned to the intervention group by applying 10 drops to the 10 cm circumference of the cannula for 10 minutes
41338558|NCT04909294|RADIATION|Stereotactic Radiotherapy with Linac MRI|"38 Gy in 4 fractions of 9.5 Gy over the entire prostate,~+/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI."
41338559|NCT00422240|DRUG|Adapalene/Benzoyl Peroxide|Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
41338560|NCT00422240|DRUG|Adapalene Gel, 0.1%|0.1% of adapalene gel topically daily in the evening for 12 Weeks.
41338561|NCT00422240|DRUG|Benzoyl Peroxide Gel 2.5%|2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
41338562|NCT00422240|DRUG|Gel Vehicle|Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
41338563|NCT04062799|OTHER|no intervention|It is an observationa study. There is no intervention.
40822982|NCT05643183|OTHER|Astmakompas|The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
41338564|NCT00675662|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention with Trim Tots pre-school programme.
41338565|NCT00675662|BEHAVIORAL|waiting list control|waiting list control
41338566|NCT06391840|OTHER|Airway ultrasound|Pre-operative airway ultrasound
41338567|NCT01905904|DRUG|sevorane|Sevorane 4% Sevorane 7%
41338568|NCT03370913|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
41338569|NCT05316519|OTHER|Transcutaneous Vagus Nerve Stimulation|Visuomotor task training with transcutaneous stimulation targeting landmark that activates biomarker
41338570|NCT02845999|BIOLOGICAL|allogenic immunotherapy based on Natural Killer cells adoptive transfer|day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10\^6 ; 8.10\^6 and 12.10\^6 cells/kg of recipient body weight
41338571|NCT02845999|BIOLOGICAL|cetuximab|day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
41338572|NCT02845999|DRUG|Cyclophosphamide|day -6 : cyclophosphamide 60 mg/Kg
41338573|NCT02845999|DRUG|fludarabine|day -6 to day -2 : fludarabine 25 mg/m2
41486613|NCT05676086|BEHAVIORAL|indoor light intervention|"Persons allocated to the indoor light intervention arm will be given a lamp to be placed at home with specific instructions to install it in a room where they spend most of their time, in order to supplement the existing indoor lighting. Thus, all people of the intervention arm will be equipped with the LUMIE Halo lamp. Utilizing both warm-white and cool-white LEDs, Lumie Halo delivers 10,000 lux at 20 cm at maximum brightness in Day Mode. The touch slider allows the user to adjust the brightness while mixing the color temperature of the light."
40820146|NCT03326557|PROCEDURE|Membrane Sweeping versus Transcervical Foley Catheter for Induction of Labour in Women with Previous Caesarean Delivery|Subjects undergoing induction of labour (IOL) will be randomly assigned to two interventional arms (Group 1: membrane sweeping or Group 2: transcervical Foley catheter insertion). Before IOL, modified Bishop score will be assessed for cervical favourability. After 24 hours of IOL, improvement of modified Bishop score will be reassessed. If the cervix is favourable, amniotomy will be performed followed by augmentation with intravenous oxytocin. If the cervix is still unfavourable and amniotomy is impossible, membrane sweeping will be continued for one more day in Group 1 whereas conservative management will be undertaken for one day in Group 2. Suitability for amniotomy will be reassessed on the next day. After amniotomy, subsequent intrapartum management will be based on the hospital protocol. If amniotomy is still impossible after 2 days of IOL, the ward Obstetrician will discuss with women regarding option of Caesarean section.
40820147|NCT05341895|OTHER|Kinesiotape|Taping
40820148|NCT06433583|DEVICE|transcutaneous auricular vagal nerve stimulation|"The use of TENS ECO PLUS and the vagus nerve ear electrode medical devices for transcutaneous auricular vagal nerve stimulation (taVNS) everyday for 10 minutes twice a day or 20 minutes for 8 successive weeks. Patients are included at week 0, use taVNS between week 2 and 10, and are followed up until week 22.~Patient adherence: percentage of patients performing 20 minutes of daily stimulation on at least 5 days a week for at least 6 cumulative weeks."
40820149|NCT06608953|DEVICE|Enhanced external counterpulsation|A device applying external pneumatic cuff pressure to the lower limbs, thighs, and buttock sequentially in the diastolic phase synchronouslty with electrocardiography to assist the cardiac function via diastolic augmentation mechanism.
40820150|NCT01476189|DRUG|Experimental paracetamol formulation|experimental
40820151|NCT01476189|DRUG|Marketed paracetamol|Marketed paracetamol
40820152|NCT01476189|DRUG|Higher dose marketed paracetamol|Higher dose marketed paracetamol
41338574|NCT02845999|DRUG|interleukin-2|day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
40820153|NCT00248118|DRUG|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
40820154|NCT01792817|DEVICE|GammaCore|Treatment with active gammacore vagus nerve stimulator
40820155|NCT01792817|DEVICE|Sham GammaCore device|Treatment with sham stimulator
40820156|NCT02925078|DEVICE|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with \<2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
40820157|NCT06608901|DRUG|REGN7544|Administered per the protocol
40820158|NCT06608901|DRUG|PB|Administered per the protocol
40820159|NCT02031835|PROCEDURE|BWSTT (3 days a week for maximum of 20 minutes session)|
40820160|NCT05807100|DIAGNOSTIC_TEST|Baseline Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
40820161|NCT05807100|DIAGNOSTIC_TEST|6th month Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
40820162|NCT06300125|PROCEDURE|Cryoablation|Percutaneous Cryoablation of Breast Cancer
41338575|NCT01375738|PROCEDURE|Roux-en Y gastrojejunostomy|After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25\~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30\~40cm from the new gastric-jejunal junction.
41486614|NCT05676086|BEHAVIORAL|no indoor light|Persons allocated to the control group will receive no indoor light supplementation and will undergo assessment procedures only. Exposure to the outdoor intervention will be taken into account in the analysis in three ways, (1) by locating the distance between people's home and the modified outdoor light, (2) by a question about the awareness of the change in outdoor light, timing, and duration of exposure and what they think of it, and (3) by recording the amount of light exposure over the 24 hours during two weeks at baseline and after the 1-year light interventions
41486615|NCT04514965|OTHER|Blood sampling|Blood sampling
41486616|NCT04514965|DEVICE|Fibroscan|Measurement of liver stiffness
41156817|NCT06647186|PROCEDURE|Conventional flap design|"Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. Intrasulcular incision was made splitting the buccal papilla from the palatal papilla. All defects were approached by elevating a flap only on the buccal side and leaving the oral portion of the interdental supracrestal soft tissues undetached. The full-thickness elevation of the marginal portion of the flap was performed with a microsurgical periosteal elevator.~After removal of granulation tissue from the bone walls of the defect, root and defect debridement was performed with manual and mechanical (ultrasonic) instruments with tips for subgingival instrumentation.~A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with simple interrupted sutures."
41156818|NCT05286775|OTHER|Clinical treatment and Knee educational program|"Three weekly medical interventions, according to the patient's need as observed at baseline.~1. 3ml paraspinal infusion of 1% Lidocaine (segmental spinal level);~2. 5,000 impulses of Radial Shockwave Therapy (pneumatic generator, 0.16mJ/mm² of energy and 20Hz of frequency) at the most painful spot of the knees;~3. \*6,000 pulses of Focused Shockwave Therapy (electromagnetic generator) at four sites of the painful knee.~   For those with knee pain of 7 or above in Visual Analogue Scale after the treatments above, the interventions below will be delivered in the order they appear:~4. Ultrasound guided genicular nerve block: infusion of up to 10ml 0.50% Levobupivacaine without vasoconstrictor;~5. Hydrodissection of superficial and deep plane nerves: infusion of 10ml 5% dextrose diluted in water (D5W);~6. Intra-articular Infusion of Hyaluronic Acid: ultrasound guided infusion of 2.5ml of sodium hyaluronate at the knee joint.~   * Four weekly applications."
41486617|NCT04514965|OTHER|Question|Question about pruritus
41486618|NCT02158611|OTHER|Lifestyle counseling|
41486619|NCT02776579|OTHER|Girls-only resistance training|
41486620|NCT04559971|DRUG|SLN124|SLN124 for subcutaneous (s.c.) injection
40822983|NCT00387738|BIOLOGICAL|Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate|Escalating doses, 6 weekly subcutaneous (under the skin) injections
41486621|NCT04559971|DRUG|Placebo|Sodium chloride for s.c. injection
41486622|NCT05387707|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablets administered twice daily
41486623|NCT05387707|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablets administered twice daily
40820163|NCT05190354|DEVICE|Xtremity Polymer Prosthetic Socket|Subjects with transtibial unilateral or bilateral amputation who have experience using a standard carbon fiber or high temperature thermoplastic prosthetic socket will be evaluated and fitted with a below knee prosthesis socket
40820164|NCT05540249|DIETARY_SUPPLEMENT|carbohydrates|Patients will orally consume 355mL CHO after 20:00 the evening before surgery.
40820165|NCT02241057|DEVICE|Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|
41156819|NCT05286775|OTHER|Knee educational program|"Three weekly 60-minute educational program sessions with the following services:~Stretching and strengthening exercises for specific muscle groups (hip flexors, extensors, and abductors; knee flexors and extensors; plantar flexors; and abdominal muscles), using one's own body and gravity resistance. Patients will be encouraged to practice them at home at least twice a week after the end of the sessions.~Nutritional guidance: Instructions on the importance of adequate weight management, healthy food consumption, and the adequate intake of nutrients.~Physical activities: Counseling on home-based physical activities, according to their physical capacities, to protect knee joints.~General health: psychology counseling, encouraging participants to apply strategies and self help conduct to improve their general health; Occupational Therapy: Activities of Daily Living strategies to protect knee joints; Nursing: Counseling on strategies for improving healthy sleeping habits."
40820166|NCT02241057|OTHER|Temperature Probe|
40820167|NCT05449379|OTHER|Respiratory training with the use of resistance set on respiratory muscle trainer|Performing respiratory training with resistance set on respiratory trainer.
40820168|NCT05449379|OTHER|Respiratory training without resistance set on respiratory muscle trainer|Performing respiratory training with no resistance set on respiratory trainer
40820169|NCT00481715|BEHAVIORAL|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
41156820|NCT06553625|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation used in the central nervous system (CNS) in functional neurosurgery
41156821|NCT06038929|DEVICE|Vagal nerve stimulant|Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses. The implanted electrodes transmit electrical impulses travel to areas of the brain to treat conditions (intractable epilepsy, depression) and also send electrical impulses to the stomach.
40820170|NCT00481715|BEHAVIORAL|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
40820171|NCT04526353|DRUG|Oxybutynin 1 mg/ml Syrup|"The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.). It will be administered at the dose of 0.1 mg/kg/twice a day to patients randomized to the study treatment group. The dose will be adapted to the child's weight to the nearest kilogram.~The recommended dosage for older children with neurologic bladder is 0.3 to 0.4mg/kg/day, whilst the dosage we will be using is effectively 0.2mg/kg/day. This is because we are taking into account the absence or pharmacological studies of oxybutynin use in children \<1 year of age, as well as their specific liver metabolism. Furthermore, the dose of 0.1mg/kg twice daily is the dose used in children within the same age group in the study by Casey et al, 2012"
40820172|NCT04270942|BIOLOGICAL|teplizumab|anti-CD3 humanized monoclonal antibody
40820173|NCT06595823|DRUG|Betadine|To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.
40820174|NCT00599391|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
41486624|NCT05387707|DRUG|TCS Cream|TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
40820175|NCT05921682|OTHER|observation|This study is an observational study. Patients will receive conventional cooling measures and organ function support.
40820176|NCT05668819|DEVICE|TH-001|TH001 is a software program intended to treat adults with prediabetes.
40820177|NCT01932320|DRUG|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
40820178|NCT01932320|DRUG|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
40820179|NCT01932320|DRUG|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
40820180|NCT01932320|DRUG|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
41338576|NCT01375738|PROCEDURE|Gastroduodenostomy|After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
41338577|NCT00302770|DRUG|quetiapine|
41338578|NCT03099798|OTHER|Questionnaires|"All patients will complete a number of questionnaires at different time points.~* SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~* 1 week, 1 month, 3, 6 and 12 months after treatment"
41338579|NCT03099798|DIAGNOSTIC_TEST|MRI abdomen|Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
41486625|NCT05387707|DRUG|Placebo|Oral Placebo tablets administered twice daily
41486626|NCT05387707|DRUG|Vehicle Cream|Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
41486627|NCT02304991|DRUG|Liquid Peanut Extract|5000mcg/ml peanut protein
41338580|NCT01620008|PROCEDURE|Delayed Cord Clamping|At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
41486628|NCT02304991|DRUG|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
41486629|NCT04650503|OTHER|No intervention|No intervention
41486630|NCT05850988|OTHER|%80 Oxygen concentration|Patients will be administered %80 Oxygen for 3 minutes during preoxygenation.
41486631|NCT05850988|OTHER|%100 Oxygen concentration|Patients will be administered %100 Oxygen for 3 minutes during preoxygenation.
41486632|NCT01470612|DRUG|CP-690,550|5 mg tablets, BID, for at least 12 months
41486633|NCT01470612|DRUG|CP-690,550|10 mg tablets, BID, for at least 12 months
41486634|NCT04831372|PROCEDURE|Off Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a standard operating room table
41486635|NCT04831372|PROCEDURE|On Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a traction table
41486636|NCT00548951|OTHER|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
41486637|NCT00548951|OTHER|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
41486638|NCT00548951|OTHER|Control|Receive no sessions in a Snoezelen Room.
41486639|NCT04177563|OTHER|whole body cryostimulation|Whole-body cryotherapy
41486640|NCT00073242|DRUG|Leptin|leptin administration
41486641|NCT00073242|BEHAVIORAL|Dietary modification|Subjects lose 10% of body weight via dietary restriction
41486642|NCT00073242|DRUG|T3 repletion|administer T3
40820181|NCT01375868|BIOLOGICAL|Silgard|vaccination with tetravalent antiviral vaccine
40820182|NCT01774253|DRUG|Vismodegib|
41486643|NCT03762486|OTHER|TENS|4 electrodes were placed 2-3 cm lateral to the incision of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
40820183|NCT05064293|BEHAVIORAL|Navigation Arm|Families will be offered a formal assessment to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to the navigator for connection to care or study-provided tele-video visits. Navigators will outreach families monthly during the 6-month study period. The navigator will inquire about the child's status and re-evaluate barriers to access. When barriers exist, the navigator will help in facilitating specialty treatment initiation and assess appropriateness of tele-video therapy sessions until ongoing MH services can be arranged. Families/patients reporting that index symptoms have resolved will be offered a 'watchful waiting' approach. Subjects accepting 'watchful waiting' will be outreached quarterly, but not beyond the end of the 6-month follow-up period.
40820184|NCT05064293|BEHAVIORAL|Control Arm|Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders (e.g., substance use). After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider. Control arm participants do not receive navigation.
41486644|NCT03762486|OTHER|TAES|4 electrodes were placed at the ST25, P6, ST36, and LI4 acupuncture points of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
40820185|NCT01094314|OTHER|embryo culture medium|comparison between two types of embryo culture medium
40820186|NCT00063895|DRUG|erlotinib hydrochloride|Given PO
40820187|NCT00063895|OTHER|pharmacological study|Correlative studies
40820188|NCT00063895|OTHER|pharmacogenomic studies|Correlative studies
40820189|NCT00063895|OTHER|laboratory biomarker analysis|Correlative studies
40820190|NCT05934526|DRUG|Placebo|Matching capsule containing placebo
40820191|NCT05934526|DRUG|Seralutinib|Capsule containing seralutinib
40820192|NCT05934526|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib or placebo delivery
40820193|NCT06485973|OTHER|Modified Dental Anxiety Scale (MDAS)|The MDAS is described as a scale to provide a more comprehensive assessment of dental anxiety. The MDAS has shown favorable psychometric properties with acceptable reliability and validity.
40820194|NCT00998751|DRUG|oral masitinib|7.5 mg/kg/day
40820195|NCT06135636|BEHAVIORAL|Education|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
41486645|NCT06043518|DIAGNOSTIC_TEST|MRI|We will examine patients with congenital upper-limb amputations using functional and structural MRI in both the brain and the spinal cord as well as questionnaires and clinical measures of motor function
41486646|NCT06043518|DIAGNOSTIC_TEST|MRI|We will examine healthy patients using functional and structural MRI in both the brain and the spinal cord and questionnaires.
40820196|NCT06135636|BIOLOGICAL|Vaccine administration|Option to receive Tdap at their convenience at the WIH obstetric care clinic provided to participant
40820197|NCT02478840|DRUG|Lamazym|recombinant human alpha-mannosidase
41486647|NCT02261844|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 1 gm po x 10 days prior to liver resection
41486648|NCT02261844|DRUG|Placebo|Placebo 1 pill daily X 10 days
41486649|NCT03028740|DRUG|Placebo|Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
41486650|NCT03028740|DRUG|Cenicriviroc|Cenicriviroc, 150 mg, tablet, orally, once daily for up to approximately 40 months.
40820198|NCT04911244|DIAGNOSTIC_TEST|bronchoalveolar lavage|endobronchial sampling through bronchoscopy
40820199|NCT04924530|DIETARY_SUPPLEMENT|Maltodextrin|Co-ingestion of maltodextrin with a high fat meal
40820200|NCT04924530|DIETARY_SUPPLEMENT|Sucrose|Co-ingestion of sucrose with a high fat meal
40820201|NCT04924530|DIETARY_SUPPLEMENT|Lactose|Co-ingestion of lactose with a high fat meal
40820202|NCT01962636|DRUG|Fludarabine|25 mg/m\^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
40820203|NCT01962636|DRUG|Cyclophosphamide|60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
40820204|NCT01962636|RADIATION|Total Body Irradiation|165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
40822984|NCT00387738|BIOLOGICAL|Histamine base|Escalating doses, 6 weekly subcutaneous (under the skin) injections
40822985|NCT03378427|DRUG|Tedizolid Phosphate 200 MG [Sivextro]|Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.
40820205|NCT01962636|DRUG|Cyclosporine A|Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
40820206|NCT01962636|DRUG|Mycophenylate mofetil|Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
41486651|NCT02299817|DRUG|Denosumab|"Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.~Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.~Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast."
41338581|NCT06449989|DIAGNOSTIC_TEST|Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI|"For molecular genetic research, archival formalin-fixed and paraffin-embedded tumor blocks will be used. Research method - HRM-PCR sequencing to determine mutation status of KRAS, NRAS and BRAF (RotorGene 6000, ABI Prism 3500) and fragmentation analysis to determine MSI (ABI Prism 3500) Subject to study: mutations in the KRAS, NRAS, BRAF genes, as well as MSI status and HER2neu expression (± amplification) Somatic mutations in the RAS family genes are planned to be studied in exons 2 (codons 12 and 13), exon 3 (codon 61) and exon 4 (codon 146). In the case of the BRAF gene - exon 15 (codons 597-601). Determination of microsatellite instability is planned using five markers: BAT25, BAT26, NR21, NR24, NR27, associated with structural and functional disorders of the DNA unpaired base repair system.~Assessment of HER2 gene status is planned by immunohistochemical (IHC) screening of HER2neu expression. IHC-screening of HER2-status will be performed using an antibody clone 4B5 (Ventana)."
41338582|NCT02656862|OTHER|No intervention|
41338583|NCT00003760|DRUG|irofulven|Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
41338584|NCT02829775|DRUG|Pegylated Interferon Alfa-2a|Participants will maintain the same dose they were receiving in the parent protocol.
41338585|NCT02829775|DRUG|Recombinant Interferon Alfa 2a|Participants will maintain the same dose they were receiving in the parent protocol.
41338586|NCT04085042|DEVICE|PIVC pack|The PIVC pack is a sterile container that includes inside all the need devices to perform peripheral catheterization. The pack is color-coded to inform healthcare professionals about the catheter caliber inside.
41486652|NCT02299817|DRUG|Placebo|Placebo
41486653|NCT02512926|DRUG|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
41486654|NCT02512926|DRUG|Cyclophosphamide|
40820207|NCT01962636|BIOLOGICAL|Umbilical cord blood|Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
40820208|NCT03764631|DRUG|Empagliflozin|Drug
40820209|NCT03764631|DRUG|Dipeptidyl-peptidase 4 (DPP-4) inhibitors|Dipeptidyl-peptidase 4 - Drug
40820210|NCT06606197|OTHER|Having sex with other men|Having sex with other men
40820211|NCT03540537|OTHER|Patient-controlled intravenous analgesia|PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
40822986|NCT05864365|DRUG|ATH434|ATH434 taken by mouth two times per day
41156822|NCT02292641|PROCEDURE|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
41156823|NCT06646770|PROCEDURE|Segmentectomy|Pulmonary anatomic segmentectomy with mediastinal nodal dissection via VATS, RATS or open approach.
41156824|NCT06646770|PROCEDURE|Lobectomy|Pulmonary lobectomy with mediastinal nodal dissection via VATS, RATS or open approach.
41156825|NCT06191133|DRUG|Fenofibrate|Fenofibrate is an FDA approved drug for cardiovascular indications and have decades of data supporting a favorable safety profile event with chronic use.
41338587|NCT02620046|DRUG|Vedolizumab SC|Vedolizumab SC 108 mg injection
41338588|NCT05477017|DRUG|SGLT2 inhibitor|Selective inhibitors of the sodium and glucose co-transporter 2 (SGLT2) originated as antidiabetic drugs thanks to their hypoglycemic and glycosuric effect.
41338589|NCT04301011|BIOLOGICAL|TBio-6517|Engineered Oncolytic Vaccinia Virus
41338590|NCT04301011|BIOLOGICAL|Pembrolizumab|Immune checkpoint inhibitor.
41338591|NCT04499846|OTHER|Therapeutic education|Patients will follow a therapeutic education in order to inform them about the mechanism of action of statins. After this intervention a questionnaire will use to measure compliance.
41338592|NCT05287204|DIAGNOSTIC_TEST|Musculoskeletal ultrasound|Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
41338593|NCT05287204|DIAGNOSTIC_TEST|Assessments of muscle strength and physical function|A battery of tests of physical function and muscle strength (see outcomes section for details).
41338594|NCT05287204|DIAGNOSTIC_TEST|Metabolomics|Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
41338595|NCT06187285|DRUG|Empagliflozin 25 MG|Patient will get Empagliflozin 25
41338596|NCT06187285|DRUG|Sitagliptin 100mg|Patient will get Sitagliptin 100 mg
41338597|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
41338598|NCT01225276|DRUG|Placebo|Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
41338599|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
41338600|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
41338601|NCT04363463|OTHER|prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
41486655|NCT02512926|DRUG|Etoposide|
41486656|NCT00643565|DRUG|Standard chemotherapy|As prescribed
41156826|NCT06191133|PROCEDURE|Cervical Conization|Cold knife conization or loop electrosurgical excision to remove cells and tissue in the cervix
41486657|NCT00643565|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
41486658|NCT00774696|DRUG|clarithromycin 500mg tablets|
41486659|NCT05477498|DRUG|Ferric carboxymaltose|Application of FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection.
41486660|NCT05477498|DRUG|Placebo|Application of placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
40820212|NCT03540537|OTHER|Quadratus Lumborum Block|Ultrasound-guided Quadratus lumborum block: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 20 ml of 0.375 % ropivacaine will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
40820213|NCT03540537|OTHER|Thoracic Paravertebral Block|Ultrasound-guided Thoracic paravertebral block: The patient is placed in the lateral position, the spinous processes of T6 and T8 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. Then 15 ml 0.375% ropivacaine is injected into the paravertebral space of T6 and T8.
40820214|NCT02313727|DRUG|Pamidronate|intravenous infusion of pamidronate 60 mg
40820215|NCT02313727|OTHER|Placebo (NaCl 0.9%)|intravenous infusion of NaCl 0.9% 500 ml
41338602|NCT04742036|DRUG|Capivasertib|Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.
41338603|NCT04742036|DRUG|Paclitaxel|"Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression."
40820216|NCT05201430|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
40820217|NCT05201430|DRUG|CapeOX|oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
40820218|NCT01813552|DRUG|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
40820219|NCT01813552|DRUG|Omeprazole|40 mg delayed-release oral capsules, once daily
40820220|NCT01813552|DRUG|Ritonavir|100 mg oral tablets, once daily
40820221|NCT06474520|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
40820222|NCT05098574|DRUG|Yaz|Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
40820223|NCT05098574|DRUG|Placebo|Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
40820224|NCT01461265|PROCEDURE|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
40820225|NCT06361251|DEVICE|CRYONOVE (EC14_4osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
40820226|NCT06361251|DEVICE|CRYONOVE (EC05osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
40820227|NCT06444555|DIETARY_SUPPLEMENT|BEP supplement|The BEP supplement used in Burkina Faso is a fortified medium-quantity lipid-based nutrient supplement called Plumpy'Doz. The product is a peanut and milk-based ready-to-use nutritional formulation produced by Nutriset. A peanut-based BEP formulation with a trademark Plumpy'Sup produced by Hilina Enriched Foods PLC will be used in Ethiopia.
40820228|NCT06444555|DIETARY_SUPPLEMENT|Multiple Micronutrient supplement|The MMN formulation is based on the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP). The formulation contains 15 minerals and vitamins and is administered as a tablet.
40820229|NCT02994953|DRUG|Avelumab|Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
40820230|NCT02994953|DRUG|M9241|Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
40820231|NCT02994953|DRUG|Avelumab (Once weekly)|Participants received avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
40820232|NCT02994953|DRUG|M9241 (MTD)|Participants received M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
40820233|NCT02994953|DRUG|Avelumab (Expansion cohort)|Participants in the expansion cohorts received Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
40820234|NCT05707351|BIOLOGICAL|Adynovate|Adynovate will be injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (\<=) 5 minutes (maximum infusion rate, 10 milliliters per minute \[mL/min\]).
40820235|NCT00769925|BEHAVIORAL|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
41486661|NCT01544738|OTHER|Aponeurotic stimulation (the diacutaneous fibrolysis method)|Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
40820236|NCT00769925|BEHAVIORAL|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
40820237|NCT02030080|BEHAVIORAL|Financial incentives|
40820238|NCT02030080|BEHAVIORAL|Teams|
40820239|NCT02030080|BEHAVIORAL|Framing of feedback|
40820240|NCT02030080|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
41486662|NCT01544738|OTHER|Placebo stimulation|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
41486663|NCT06103565|OTHER|Clinical Decision Support Tool|Clinical decision support tool to enable pharmacists to monitor adherence to guideline-directed medical therapy for patients with heart failure with reduced ejection fraction
41486664|NCT03055702|OTHER|Mobile phone text message reminder|an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
41486665|NCT05187702|OTHER|Functional exersize|Participants will be given balance and strengthening exercises covering the balance exercise protocol.
41486666|NCT05187702|OTHER|Aerobic exersize|60% of the maximum heart rate is given 3 walking eccentricity per week
41486667|NCT02800213|DEVICE|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
41486668|NCT02800213|DEVICE|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
41486669|NCT00319982|DRUG|Diltiazem|Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
41486670|NCT00319982|DRUG|Placebo|Placebo comparator (double-blind allocation of study medication)
41486671|NCT01664221|DRUG|Epoetin Alfa|Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
40820241|NCT06350487|DRUG|SGLT2 inhibitor|Enavogliflozin (0.3mg oral tablet once daily) will be administrated.
41486672|NCT02018926|DRUG|Mocetinostat|Mocetinostat (a histone deacetylase \[HDAC\] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle
40820242|NCT03783000|DRUG|BI 425809|Treatment T
40820243|NCT03783000|DRUG|BI 425809 mixed with [C-14]-BI 425809|Treatment R
40820244|NCT03484156|DEVICE|Installation of 3PEGASE Sensor|Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss
40820245|NCT00123370|DRUG|Modafinil|
40820246|NCT00027378|DRUG|fluoxetine (Prozac)|fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
40820247|NCT00027378|DRUG|Placebo plus Treatment As Usual|placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
40820248|NCT04801433|OTHER|Boleda Supramolecular Active Zinc Conditioner|Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
41486673|NCT02018926|DRUG|Azacitidine|Azacitidine (a hypomethylating agent \[HMA\]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
40820249|NCT04801433|DRUG|Capotetriol scalp solution|Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
40820250|NCT04801433|OTHER|Supramolecular Hydrogel|Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
40820251|NCT00592228|DEVICE|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,~1. FFR group: if FFR\<0.75~2. Routine DES group"
40820252|NCT01478230|DRUG|Nicotine|Nicotine 5 mg Inhaler
40820253|NCT01478230|DRUG|Nicotine|Nicotine 10 mg Inhaler
40820254|NCT06539858|OTHER|massage|General back massage from the base of the neck to the sacrum. Classical massage techniques such as stroking and kneeding will be applied. To be performed by a specialist physiotherapist.
40820255|NCT05609877|DRUG|Isotonic saline|Isotonic saline will be administered intravenously instead of pre-procedure analgesia.
40820256|NCT05609877|PROCEDURE|Less Invasive Surfactant Administration (LISA)|All infants will be treated with the Less Invasive Surfactant Administration (LISA) procedure
40820257|NCT05609877|DRUG|Fentanyl|Fentanyl 0.5-1.0 mcg/kg will be administered intravenously as pre-procedure analgesia
40820258|NCT05609877|BEHAVIORAL|Non-pharmacological standard operating procedure|All infants will receive the same non-pharmacological standard operating procedure.
40820259|NCT00649766|BEHAVIORAL|tailored newsletter|Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease
40820260|NCT00649766|BEHAVIORAL|targeted newsletter|Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
40820261|NCT05082051|DRUG|Part A|"Randomized, double-blind, placebo-controlled dose escalation part to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after single oral dose administration in healthy adult subjects.~Single-dose administration of CDX-7108 at the following anticipated dose levels. 10 000, 50 000, 150 000, 250 000, and 500 000 lipase units will be evaluated in 5 sequential cohorts of 6 subjects each."
41338604|NCT03430336|OTHER|CDSS provides drug-therapy relevant information|External computerized decision support system (CDSS: RpDoc® eMMa Software, RpDoc® Solutions GmbH, Saarbruecken) provides drug-therapy relevant information about participating patients with polypharmacy on demand to the general practitioners (GPs) such as data about diagnoses and treatments. The information is based on claims data gathered from all health care professionals involved in the care of the patient (e.g. specialized physicians, other GPs, psychotherapists as well as data about hospital stays and prescription data from pharmacies).
41338605|NCT03430336|OTHER|Modification of medication|GPs can add and modify patient's data within the CDSS (e.g. remove drugs which are not taken by the patient anymore, add most recent laboratory findings about kidney function etc.) to enrich and update claims data based information.
41338606|NCT03430336|OTHER|Assessment of medication appropriateness|GPs systematically assess the appropriateness of the medication supported by the CDSS, which will alert in case of drug-drug, drug-disease, and drug-age interactions as well as other inappropriateness, such as prescriptions with regard to incorrect dosage or Dear Doctor letters.
41338607|NCT03430336|OTHER|Medication plan|GPs print out the updated medication plan including also recommendations for medication use and reasons for prescription in lay language (also available in foreign languages for patients with migration background) as well as recommendations on drugs to use / to avoid including over-the-counter drugs (OTC) (optional) and hand it out to the patient.
41338608|NCT03430336|OTHER|Guidance in medication process|GPs receive guidance via the CDSS (e.g. recommendations addressing certain types of medication errors and high risk prescribing, developed by the German Society for Internal Medicine in collaboration with other scientific medical societies).
41338609|NCT03749213|DRUG|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
41338610|NCT03043261|BEHAVIORAL|Williams LifeSkills|Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
41338611|NCT03950960|DRUG|BMS-986256|Specified dose on specified days
41338612|NCT03950960|DRUG|Itraconazole|Specified dose on specified days
41338613|NCT00004916|DRUG|ifosfamide|
41338614|NCT00004916|DRUG|paclitaxel|
41338615|NCT00004916|DRUG|teniposide|
41338616|NCT00004916|PROCEDURE|peripheral blood stem cell transplantation|
41486674|NCT01956617|OTHER|lumbar plexus block|
41486675|NCT01216852|DRUG|Losartan Potassium|100 mg tablet
41486676|NCT05555368|OTHER|Quality of Recovery Score|Descriptive
41486677|NCT00405613|DRUG|Aspirin|
41486678|NCT06233084|DRUG|Desogestrel-Test product|Desogestrel Tablets 0.075 mg Manufactured by: POND'S CHEMICAL THAILAND R.O.P., Thailand
41486679|NCT06233084|DRUG|Desogestrel-Reference product|Desogestrel Tablets 0.075 mg Manufactured by: N.V. Organon, The Netherlands
41486680|NCT01339663|DRUG|cyclophosphamide|Given IV
41486681|NCT01339663|BIOLOGICAL|aldesleukin|Given SC
41486682|NCT01339663|BIOLOGICAL|autologous tumor cell vaccine|Receive T-APC via IV
41486683|NCT01339663|OTHER|laboratory biomarker analysis|Correlative studies
41486684|NCT01339663|OTHER|immunologic technique|Correlative studies
41486685|NCT01339663|OTHER|immunohistochemistry staining method|Correlative studies
41486686|NCT01339663|GENETIC|polymerase chain reaction|Correlative studies
41486687|NCT01339663|BIOLOGICAL|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
41486688|NCT02777112|OTHER|e-mental health program|This program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking.
41486689|NCT02777112|OTHER|e-mental health program and job coaching|This combines the e-mental health program and interactive job coaching delivered through telephone. The e-mental health program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking. The job coaching can be accessed by appointment.
41486690|NCT02777112|OTHER|No intervention|Receiving generic information about men's depression from the Movember Foundation website: https://ca.movember.com/programs/mental-health
40820262|NCT05082051|DRUG|Part B|"Randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after multiple oral dose administration in healthy adult subjects.~It will evaluate multiple dose administration of CDX-7108 at an appropriate low (50 000 lipase units), mid (150 000 lipase units), and high dose (250 000 lipase units) 4 times a day (QID) for 6 consecutive days in 3 sequential cohorts of 6 subjects each."
41486691|NCT00345657|DRUG|Niacin Extended Release/Lovastatin|
40820263|NCT05082051|DRUG|Part C|"Randomized, double-blind, placebo-controlled, single-dose, 2-way crossover part to assess POC of CDX-7108 in terms of PD as well as its safety, tolerability, and immunogenicity in subjects with EPI.~Approximately 10 subjects with severe EPI from partial/total pancreatectomy or chronic pancreatitis will be enrolled. It is anticipated that Part C (POC study) will commence after completion of the third single-dose cohort from Part A (SAD study) and following SRC review of the data from this cohort."
40820264|NCT06495840|OTHER|no intervention|no intervention
40822987|NCT04942015|DRUG|Honghuaruyi Wan|Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
41156827|NCT06191133|PROCEDURE|Hysterectomy|In a hysterectomy, the uterus, cervix, both ovaries, both fallopian tubes, and nearby tissue are removed.
41486692|NCT03851926|RADIATION|Hypofractionated volumetric radiotherapy in 20 fractions|Hypofractionated radiotherapy at 3 Gy per fraction for localized prostate cancer.
41486693|NCT00894738|PROCEDURE|Testing (MRS, US, DEXA, blood tests)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
41486694|NCT04700163|BIOLOGICAL|C144-LS and C-135-LS|A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
41486695|NCT04503395|DEVICE|ESAR treatment: Endograft + Heli-FX Endoanchor|ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
41486696|NCT04503395|DEVICE|FEVAR treatment : Fenestrated endograft|Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
41486697|NCT02436993|DRUG|Carboplatin|Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
41486698|NCT02436993|DRUG|Paclitaxel|80 mg/m\^2 IV over 1-3 hours weekly for 12 doses
41486699|NCT02436993|DRUG|Bevacizumab|10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
41486700|NCT02436993|DRUG|Trastuzumab|4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
41486701|NCT02436993|DRUG|Pertuzumab|840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
41486702|NCT06295328|DRUG|Terbinafine|terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
40820265|NCT06354907|BEHAVIORAL|The Kids' Empowerment Program|The 12-session KEP provides support and information while teaching children self-management skills based on techniques derived from a combination of best, evidence-based practices (e.g., using elements of cognitive behavioral therapy, behavioral activation, brief behavioral activation, and interpersonal therapy. Adjustment is enhanced with a comprehensive approach that strengthens cognition (how to think about things), changes behavior (problem solving or planning actions), and focuses on emotions (identifying and expressing feelings), social relationships (peers, parents, siblings), and physical health (de-stressing, exercise). Group leaders follow a training manual with developmentally appropriate scripts, instructions for behavioral applications in (e.g., craft or game activities) and practice plans.
41486703|NCT06295328|DRUG|Placebo|Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
41486704|NCT06295328|DRUG|Tenofovir|Tenofovir 245mg standard of care
40820266|NCT05783245|OTHER|Polarcare Machine|Use of Polar Care ice machine as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
40820267|NCT05783245|OTHER|Standard of care ice therapy|Use of commercial reusable ice packs as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
40820268|NCT04683081|DEVICE|mechanical cervical ripening|mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
40820269|NCT03297073|DRUG|paracetamol|"Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form"
40820270|NCT03297073|PROCEDURE|hepatic surgery|
40820271|NCT06358729|BEHAVIORAL|Typical Nipple|Infants are fed their typical milk/formula by their caregiver when hungry, one feeding with their typical nipple.
40820272|NCT06358729|BEHAVIORAL|Challenging Nipple|Infants are fed with a smaller sized nipple (i.e. with a smaller aperture, slowing the rate of milk delivery).
40820273|NCT02346331|OTHER|WHO algorithm of fluid boluses guided by physical examination|
40820274|NCT02346331|OTHER|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
40820275|NCT02346331|OTHER|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
40820276|NCT02346331|OTHER|Oxygen delivery|
40820277|NCT02346331|OTHER|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
41486705|NCT04793048|DEVICE|a noninvasive intraoral electrotherapy device|a noninvasive intraoral electrotherapy device to treat periodontal disease at-home for 20 minutes a day
41486706|NCT04793048|DEVICE|a sham device|a sham device to be used at-home for 20 minutes a day
41486707|NCT01593241|DRUG|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
41486708|NCT01593241|RADIATION|Involved node RT|Involved node RT
41486709|NCT04823962|DRUG|rhGM-CSF + hydrogel|The active substance: molgramostim (rhGM-CSF)
41486710|NCT04823962|DRUG|Placebo hydrogel|Placebo hydrogel
41486711|NCT04823962|OTHER|Standard care|Compression therapy and neutral dressings
41486712|NCT03754465|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer
40820278|NCT02346331|OTHER|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
40820279|NCT05192499|PROCEDURE|Stool test|At inclusion (day 0), stools will be collected with a kit for to remove to 5 mg for each patient.
40820280|NCT05192499|PROCEDURE|Blood test|Blood sample taken during inclusion (day 0) will be collected. There is between 19 and 26 mL for each patient.
41486713|NCT03754465|PROCEDURE|Hydrogel SHEET(Vehicle control)|Application of Hydrogel SHEET to diabetic foot ulcer
41486714|NCT04619719|DEVICE|Hyperbaric Oxygen Therapy (HBOT)|Patients assigned to the treatment arm will receive up to 5 treatments of hyperbaric oxygen therapy administered daily at 2.0 atmospheres for 90 minutes per session.
41486715|NCT01599130|DRUG|Entecavir|entecavir 0.5mg per day
41486716|NCT01599130|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug per week
41486717|NCT01168206|DIETARY_SUPPLEMENT|TK3|Tritofano 160mg / Timina140mg and starch 150 mg
41486718|NCT01168206|DIETARY_SUPPLEMENT|1 capsule, 3 times per day|Placebo
41486719|NCT03344861|DRUG|Porfimer Sodium|Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
40820281|NCT05192499|PROCEDURE|Induced sputum|At inclusion (day 0), bronchial aspiration after inhalation induction of 4 mL of 6% salt serum administered (after 200 μg of salbutamol via an inhalation chamber during a bronchial drainage session).
40820282|NCT05192499|PROCEDURE|nasale virology|At inclusion (Day 0), patients will be taken nasal swab for virology with swab adapted for nasal swab or with suction trap when blowing the child's nose (depending on center practice)and multiplex PCR.
40820283|NCT03222830|PROCEDURE|personal embryo transfer|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
40820284|NCT04417595|DRUG|Fish Oil (Containing Omega-3 Acids)|Fish Oil Supplement
40820285|NCT04417595|DRUG|Olive Oil|Olive Oil Supplement
40820286|NCT04808947|PROCEDURE|Local infiltration analgesia|Procedure: Local infiltration analgesia performed by surgeons.
40820287|NCT04808947|PROCEDURE|Ultrasound-guided adductor canal block|Procedure: Ultrasound-guided adductor canal and iPACK blocks performed by anesthesiologists preoperatively.
40820288|NCT05024175|DIAGNOSTIC_TEST|Disease assessments|CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
40820289|NCT05024175|PROCEDURE|Tumor Biopsy|Tumor Biopsy per protocol
40820290|NCT05024175|DIAGNOSTIC_TEST|Blood test|Blood Test per protocol
40820291|NCT02251561|DEVICE|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
40820292|NCT02251561|DEVICE|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
41338617|NCT03115125|OTHER|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 of hospitalization in medical reanimation.|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 (or on leaving the service if before D14) of hospitalization in medical reanimation.
41486720|NCT03344861|DEVICE|Fiber optic|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
41486721|NCT00567866|DRUG|Quetiapine|50 or 100 mg of quetiapine orally
40820293|NCT02251561|DEVICE|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
41156828|NCT06191133|RADIATION|Chemoradiation|Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in the bloodstream. Radiotherapy uses high energy waves similar to x-rays to kill cancer cells.
41338618|NCT02509676|OTHER|stretching exercise|dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
40820294|NCT04734522|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
40820295|NCT02032693|DIETARY_SUPPLEMENT|Everycell™|
40820296|NCT02032693|OTHER|Placebo|
40820297|NCT06607549|DRUG|Loncastuximab tesirine and rituximab (Lonca-R)|Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 4 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).
40820298|NCT05767346|DRUG|Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)|Aficamten (CK-3773274) tablets administered orally
40820299|NCT05767346|DRUG|Placebo to match aficamten|Placebo for aficamten (CK-3773274) administered orally
40820300|NCT05767346|DRUG|Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)|Metoprolol succinate tablets administered orally
40820301|NCT05767346|DRUG|Placebo to match metoprolol succinate|Placebo for metoprolol succinate administered orally
40820302|NCT03526237|BEHAVIORAL|24 week community based DPP Group Lifestyle Balance Program|a) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
40820303|NCT03526237|BEHAVIORAL|Wait-List Control community based DPP Group Lifestyle Balance Program|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
40820304|NCT05287841|PROCEDURE|Batten batten graft|The batten grafts are autologous grafts from the patients' own tissue, produced from nasal septal quadrangular cartilage. This will be obtained during the septoplasty portion of the procedure. The batten graft will be used to stabilize the internal nasal valve and prevent nasal valve collapse on inspiration.
40820305|NCT05287841|PROCEDURE|Septoplasty|A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.
40820306|NCT05287841|PROCEDURE|Inferior Turbinate Reduction|The bilateral inferior turbinates will be surgically ablated.
40820307|NCT03047356|BEHAVIORAL|"If-then plans"|"If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)"
40820308|NCT03047356|OTHER|Control|Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
40820309|NCT05405491|OTHER|PCR based strategy|Early adjustment of antimicrobial therapy according to the results of a multiplex PCR-based testing, used in addition to standard microbiological culture of the tracheal aspirate, in immunocompromised patients with suspected VAP or HAP requiring MV
40820310|NCT05405491|OTHER|Standard care|Broad-spectrum antimicrobial therapy adjustment after results of standard microbiological culture of the tracheal aspirate in immunocompromised patients with suspected VAP or HAP requiring MV
40820311|NCT01693341|OTHER|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
41486722|NCT02353052|OTHER|follow up|The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
40820312|NCT06012019|OTHER|Biological sampling in Periodontitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction : gingival explant sampling~J+15 : Healing control"
40820313|NCT06012019|OTHER|Biological sampling in Gingivitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
40820314|NCT06012019|OTHER|Biological sampling in Control Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
41486723|NCT00466908|DEVICE|Pentacam and IOL Master|Pentacam and IOL Master
40820315|NCT05763186|OTHER|Sampling|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
40820316|NCT05763186|OTHER|Sampling and rinsing|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
40820317|NCT06606990|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
40820318|NCT06606990|PROCEDURE|Computed Tomography|Undergo CT
40820319|NCT06606990|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40820320|NCT06606990|BIOLOGICAL|Pidnarulex|Given IV
40820321|NCT05379712|OTHER|Resource® Support Plus|Nestlé Resource Support Plus® is a high energy- and protein-density Medical Food enriched with omega 3 polyunsaturated fatty acids. This is a nutritionally complete formula, in an easy to swallow, palatable, concentrated low volume, available in 2 flavours optimized for cancer patients undergoing chemotherapy and/or radiation in taste tests. It provides in a 125 mL serving: 250 kcal, 11.5 g protein and 0.95g of omega-3 fatty acid (eicosapentaenoic acid, EPA).
40820322|NCT06174688|DRUG|BOTOX|Intramuscular Injections
40820323|NCT06174688|DRUG|Placebo|Intramuscular Injections
40820324|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
40820325|NCT03587701|DRUG|Placebo injection (Period 1)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
40820326|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
41338619|NCT03108300|DRUG|Propranolol Hydrochloride|propranolol hydrochloride is a beta-adrenergic receptor blocker
41486724|NCT00039520|DRUG|docetaxel|
41486725|NCT00039520|DRUG|sulindac|
41486726|NCT01376817|DRUG|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
41338620|NCT03108300|DRUG|Doxorubicin|Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
41486727|NCT01376817|DRUG|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
41156829|NCT05904171|BEHAVIORAL|Tangotherapy|"Learning and practicing a series of moves - both individual and with a partner - taken from Argentine Tango, according to the Riabilitango (R) approach. The training is aimed at improving both physical (e.g., balance, change of direction, coordination, endurance) and cognitive (i.e., learning, divided attention, inhibition, planning) domains, in a pleasant, enjoyable, and inclusive environment.~This group-based training will take place twice a week (1h each session), for 6 weeks."
40820327|NCT03587701|DRUG|Placebo injection (Period 2)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
40820328|NCT05791695|OTHER|Non Applicable|No study-specific interventions for this observational study.
40820329|NCT03804021|GENETIC|No Intervention|Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)
40820330|NCT01707433|OTHER|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
40820331|NCT00004248|BIOLOGICAL|aldesleukin|
40820332|NCT00004248|DRUG|doxorubicin hydrochloride|
40820333|NCT05868863|OTHER|datas of medical record.|"Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~* Analgesic intake before and after the procedure~* Functional criteria: early rising, walking"
40820334|NCT05384418|RADIATION|HDP-Tc99m bone scintigraphy|HDP-Tc99m bone scintigraphy
41486728|NCT00386126|DRUG|Iron Sucrose IV 200mg, once a week, for 5 weeks|
41016833|NCT06662552|DEVICE|whole body vibration using crazy fit machine|It will be applied on the whole body All subjects will be asked to stand in a squat position on the vibration platform with the knees bent 90 this position will be chosen because the vertical sinusoidal accelerations of the vibration platform had to be damped by the different muscles around the joints of the lower extremity) ,at a frequency of 30 Hz, 5 - 30 minutes per day, 3 times per week, for 6 weeks, and the physiotherapist will be standing beside the patient
41016834|NCT06662552|DEVICE|Pulsed electromagnetic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology. It consists of an appliance, motorized bed and solenoids. The appliance will be connected to electrical mains supplying230Vat frequency of 50 or 60 Hz with earth connection, Intensity 0-100. It will be used in the treatment of patient in group B. Subjects will be positioned in a supine position, and the treatment will be performed by placing the applicator centered over their thigh region (quadriceps muscle's area), for 15 minutes per day, 3 times per week for 6 weeks, the physiotherapist will be sitting beside the patient"
41016835|NCT06662552|OTHER|traditional physical therapy program|In the form of splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises on quadriceps muscle 15 minutes per day, 3 times per week for 6 weeks.
41156830|NCT05904171|BEHAVIORAL|Physical activity|Walking and stretching in group twice a week (1h each session), for 6 weeks.
41156831|NCT01193283|DRUG|Cyclophosphamide|30 my/kg for 4 days
41486729|NCT00386126|DRUG|Ferrous sulfate 200mg PO TID, for 8 weeks|
41156832|NCT01193283|DRUG|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
41156833|NCT04685018|DEVICE|fMRI acquisition|Participants from the two groups will perform an avoidance-relief task inside an MRI scanner
41338621|NCT02795455|BEHAVIORAL|Interoceptive Exposure (IE)|Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
41338622|NCT02795455|BEHAVIORAL|Family Based Therapy-Weight Gain Control (FBT-WG)|Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
41338623|NCT02795455|DIETARY_SUPPLEMENT|meal replacement shake|
41338624|NCT01268904|DRUG|Valproate|Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
41338625|NCT02855645|DRUG|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
41338626|NCT02855645|DRUG|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
41338627|NCT03530202|DRUG|Creatine monohydrate|Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
41338628|NCT03530202|DRUG|Maltodextrin Powder|Participants will consume Maltodextrin Powder (Globe Plus 10 DE Maltodextrin Powder, Univar Canada) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water. On non-training days, supplements will be consumed at the participant's leisure.
41338629|NCT05337345|DRUG|Cendakimab|Specified Dose on Specified Days
41338630|NCT00517218|DRUG|Genasense® (, oblimersen sodium G3139)|
41338631|NCT01455233|DRUG|besivance|topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery
41486730|NCT00231257|DEVICE|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
41156834|NCT00199992|PROCEDURE|application of autologous platelet gel|
41338632|NCT01455233|DRUG|vigamox|topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
41338633|NCT04214041|OTHER|Autologous fat grafting|A fat graft will be aspirated from the abdomen under local anaesthesia and processed using the Microfat grafting technique. Afterwards the fat graft will be injected in the previously created pouch at the recipient site. Then the pouch will be closed using interrupted sutures 5-0 vicryl.
41486731|NCT00231257|PROCEDURE|Brachytherapy|Brachytherapy
41486732|NCT01043120|DRUG|Barusiban|IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
41486733|NCT01043120|DRUG|Placebo|IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
41486734|NCT00123955|DRUG|Spironolactone|25mg tablet daily for 9 months
41486735|NCT00123955|DRUG|Placebo|Placebo tablet daily for 9 months
41486736|NCT03918109|DRUG|OTO-313|single intratympanic injection of gacyclidine
41486737|NCT03918109|DRUG|Placebo|single intratympanic injection of placebo
41486738|NCT00418821|BIOLOGICAL|Laronidase|dose of 0.58mg/kg body weight intravenously (IV) every week
41486739|NCT03677791|OTHER|Virtual tour in coronary computed tomography - 360° counselling environment|Virtual tour in coronary computed tomography - 360° counselling environment for CCTA patients
41486740|NCT03677791|OTHER|Current practice|counselling in accordance with current practice: written patient information letter and verbal counselling at the hospital during the CT-examination
41486741|NCT03798665|DRUG|Pegfilgrastim（PEG-rhG-CSF）|From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency
41338634|NCT04214041|OTHER|Sub-epithelial connective tissue graft|A subepithelial connective tissue graft of a size that corresponds to that of the defect will be harvested from the palate using the trap door technique. The donor site will be closed using cross horizontal sling sutures and interrupted sutures 4-0 vicryl. Subsequently, the graft will be inserted in the previously created pouch at the recipient site and secured to the flap using vicryl sutures 5-0. Then the pouch will be closed using interrupted sutures.
41486742|NCT01878487|DEVICE|Thrombus aspiration (Intravascular Ultrasound catheter (Boston))|"There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.~All patients will have an Intravascular Ultrasound three times:~1. At baseline~2. After thrombus aspiration with a thrombus extraction catheter~3. After stent deployment~We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such."
41486743|NCT01763684|DEVICE|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
41486744|NCT01763684|PROCEDURE|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
41486745|NCT01239875|BIOLOGICAL|dendritic cell vaccine therapy|Given intratumorally
41486746|NCT01239875|PROCEDURE|cryotherapy|Undergo cryoablation
41486747|NCT01239875|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
41486748|NCT01239875|OTHER|laboratory biomarker analysis|Correlative studies
41486749|NCT01239875|OTHER|immunoenzyme technique|Correlative studies
40820335|NCT01546441|BEHAVIORAL|interprofessional assessment|assessment by interprofessional team
40820336|NCT01546441|BEHAVIORAL|usual care|usual care in primary care clinic
41338635|NCT00862394|DRUG|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
41338636|NCT00862394|DRUG|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
41338637|NCT00862394|DRUG|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
41486750|NCT01239875|OTHER|immunohistochemistry staining method|Correlative studies
41486751|NCT01239875|BIOLOGICAL|autologous dendritic cell-tumor fusion vaccine|Given intradermally
41486752|NCT00392236|DEVICE|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
41486753|NCT00392236|BEHAVIORAL|Treatment as usual|Participants will receive treatment as usual.
40820337|NCT02518958|DRUG|RRx-001|
40820338|NCT02518958|DRUG|Nivolumab|
40820339|NCT04959617|DEVICE|Quantitative Fecal Immunochemical Test (qFIT)|The study only included quantitative FIT examination in the general physical examination population over 30 years old.
40820340|NCT06605833|DIAGNOSTIC_TEST|Lead ECG|"Participants will undergo a standard 12 lead ECG in order to record the electrical activity of the heart. This typically takes a few minutes and the ECG is read by a cardiologist~This is a Standard of Care test being performed at a non Standard of Care timepoint"
41486754|NCT06157762|PROCEDURE|Erector spinae plane block|ultrasound guided lumbar erector spinae plane block
41486755|NCT06157762|PROCEDURE|Erector spinae plane block performed by surgeon|Erector spinae plane block performed by surgeon
40820341|NCT06605833|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|"A transthoracic echocardiogram will be performed in accordance to standard British Society of Echocardiography guidelines. This will involve undertaking an ultrasound scan of the participant's heart with ultrasound jelly to obtain information including left ventricular function and valvular function.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
40820342|NCT06605833|DIAGNOSTIC_TEST|Cardiac MRI|"A cardiac MRI scan will be performed in order to assess the morphology and function of the heart in accordance with international guidelines. Data that will be derived includes biventricular volumes and function and myocardial strain data.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
40820343|NCT06605833|DIAGNOSTIC_TEST|Cardiac Biomarker Screening|"* Cardiac Troponin I,~* NTproBNP\],~* lipid profile,~* HbA1c~* ferritin~These are Standard of Care tests being performed at a non Standard of Care timepoint"
41338638|NCT00862394|DRUG|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
41338639|NCT01455506|DRUG|Decitabine plus Fludarabine and Busulfan|"* Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient \>20% above ideal body weight~* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.~* Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.~Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.~Hematopoietic cells will be infused on day 0."
41338640|NCT04308954|DRUG|[18F]flumazenil|\[18F\]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
41486756|NCT05641974|BEHAVIORAL|Helpers Stay Quit Training|"The Helpers Stay Quit training emphasizes a tobacco-user centered, non-confrontational approach to encouraging others to quit smoking. Helpers Stay Quit trainees learn how to offer a 4-step helping conversation. The four steps of a helping conversation parallel the 4 core training modules of Helpers Stay Quit (Awareness, Understanding, Helping, Relating). A key learning objective of Helpers Stay Quit, is for Helpers to learn how to manage their own expectations for the process and outcome of a helping conversation (e.g. Helpers are taught that they cannot make anyone quit, but they can offer non-judgmental support, and information about effective cessation aids). Consequently, Helpers are taught to manage their own behavior when helping others (e.g. avoiding nagging or pushing a tobacco-user to quit). The helping conversation focuses on encouraging behavior change that is aligned with the tobacco user's current willingness/readiness to take any action toward quitting."
41338641|NCT03379441|DRUG|Pembrolizumab Injectable Product|Pembrolizumab Injectable Product 200 mg Q3W Intravenous
41338642|NCT04494477|BEHAVIORAL|The IN•clued program|The INclued program as previously described.
41338643|NCT03487315|DIAGNOSTIC_TEST|immunoblot|immunoblot
41338644|NCT03049072|RADIATION|Protons and Carbon Ions|
41338645|NCT01421069|DRUG|etanercept|"Subjects aged \<18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).~Subjects aged greater than or equal to 18 years or \>62 kg will receive etanercept SC at a dose of 50 mg QW."
41338646|NCT03780413|BEHAVIORAL|PR-ESSENCE treatment|
41338647|NCT03780413|BEHAVIORAL|Control (TAU)|
41338648|NCT01515488|OTHER|Nurse-initiated triage|Nurse-assisted triage for obtaining medical history and presenting problem(s)
41338649|NCT01515488|OTHER|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
41338650|NCT01791790|DEVICE|Stimulation|
41338651|NCT01791790|DEVICE|SHAM|no stimulation
41338652|NCT01562197|DRUG|axitinib|The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.
41338653|NCT01562197|DRUG|Axitinib plus Lomustine|Lomustine 90mg/m²
41338654|NCT01126294|DIETARY_SUPPLEMENT|5 mg melatonin|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
41338655|NCT01126294|DIETARY_SUPPLEMENT|10 mg melatonin|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
41338656|NCT01126294|DIETARY_SUPPLEMENT|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
41486757|NCT01592305|DRUG|atazanavir|multiple oral doses
41338657|NCT05940350|BEHAVIORAL|Telerehabilitation Stroke Coaching of Program (TeleSCoP) group|"The sampling criteria will be assigned to the intervention (TeleSCoP) and control groups by stratified randomization (1:1) in patients with acute ischemic stroke. A three-month telerehabilitation-based coaching intervention will be applied to stroke patients in the intervention group. Within the scope of telerehabilitation-based coaching initiative, coaching initiatives will be planned for the management of symptoms and complications for modifiable risk factors. Patients in the intervention group will receive discharge education with the education booklet prepared on the 4th or 5th day in the hospital, and informative videos prepared in cooperation with the multidisciplinary team will be shared with the patients. Patients will be called by phone at weeks 1, 2, 3, 4, 6, 8, and 10. The patients in the control group will be given the Stroke Education Brochure of the Ministry of Health and they will benefit from routine hospital services for three months."
41486758|NCT01592305|DRUG|danoprevir|multiple oral doses
41486759|NCT01592305|DRUG|ritonavir|multiple oral doses
41486760|NCT01592305|DRUG|tenofovir disoproxil fumarate|single oral doses
41486761|NCT04940949|DRUG|Lu AF90103|Lu AF90103 - powder for solution for infusion
41486762|NCT04940949|DRUG|Placebo|Placebo - powder for solution for infusion
41486763|NCT00523224|PROCEDURE|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
41338658|NCT02820441|DRUG|Zopiclone|
41338659|NCT02820441|DRUG|Placebo|
41338660|NCT00735098|OTHER|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
41338661|NCT00735098|OTHER|strength training exercise|strength training exercise, 3 times per week for 8 weeks
41338662|NCT00735098|OTHER|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
41338663|NCT00735098|OTHER|Control group|8 week control group
41486764|NCT00523224|BIOLOGICAL|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
41486765|NCT02731417|OTHER|acupuncture|Acupuncture for women with post partum urinary retention
41486766|NCT02731417|DEVICE|Foley catheter|Foley catheter insertion for women with post partum urinary retention.
41486767|NCT04993300|DEVICE|transcranial magnetic stimulation (TMS)|The methamphetamine user will undergo a one-month TMS intervention. In Week 1, subjects will attend continuously 5 daily TMS sessions. From Week 2 to Week 4, subjects are treated once a week. Each session will have 40 repeats of 4-second train and 15-sec train interval.
40820344|NCT06605833|OTHER|Basic Observations|"* Heart rate~* Blood pressure~* Oxygen SAT~* Respiratory rate~These are Standard of Care observations being performed at a non Standard of Care timepoint"
41486768|NCT02128217|DRUG|Sofosbuvir|Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
41338664|NCT05258526|OTHER|Home based exercise training|The intervention will be based on a remote approach, lasting 12 weeks. The training routine will consist of aerobic (walking), muscle strengthening and stretching exercises, with a frequency of three days per week. The contents related to the exercise prescription will be made available by phone call, text messages and short videos for exercise demonstration.
41338665|NCT00704392|DRUG|XL647|Tablets supplied at 50-mg strength administered orally daily
41338666|NCT00704392|DRUG|XL147|Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
41338667|NCT00285649|OTHER|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
41338668|NCT00285649|OTHER|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
41338669|NCT00285649|OTHER|Usual Medical Care|Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
41338670|NCT00334698|DRUG|Cetirizine|
41486769|NCT02128217|DRUG|Ribavirin|Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
41486770|NCT02128217|DRUG|Ledipasvir/Sofosbuvir|Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
41486771|NCT04957836|OTHER|reversal with sugammadex|reversal with sugammadex for immediate extubation in the operating room
41486772|NCT00856830|DRUG|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.~* All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.~* At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks."
41486773|NCT03760250|DRUG|Imiquimod 5% cream|Imiquimod 5% Cream application to keloid skin area 5-times per week for 6 weeks, starting 1-week before keloid excision
41486774|NCT03607526|OTHER|Barriers|NGT sessions identifying barriers to vegetable intake.
41486775|NCT03607526|OTHER|Facilitators|NGT sessions identifying facilitators to vegetable intake.
41486776|NCT00005765|DRUG|nicotine|
41486777|NCT00005765|DRUG|alcohol|
40820345|NCT00673023|OTHER|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
41338671|NCT00334698|DRUG|Pseudoephedrine|
41338672|NCT00334698|DRUG|Cetirizine with Pseudoephedrine|
41486778|NCT03340870|DRUG|Sonazoid™|Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
41486779|NCT02802631|DRUG|Minocin (minocycline) for Injection|Intravenous formulation of minocycline, a derivative of tetracycline
40820346|NCT03962257|OTHER|EngagedMD online learning platform|The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
40820347|NCT06280950|DRUG|Everolimus|"* The first step is the addition of everolimus to participants in this group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization."
41338673|NCT03053401|PROCEDURE|Adductor Canal Block|Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
41338674|NCT03053401|PROCEDURE|Femoral Nerve Block|Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
40820348|NCT06280950|DRUG|Tacrolimus (continued reduction)|"* Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization.~* They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks.~* Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction"
40820349|NCT06280950|DRUG|Tacrolimus (maintain 50% reduction)|- Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
41338675|NCT03053401|DEVICE|Ultrasound|Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
41338676|NCT03053401|DEVICE|Stimuplex A needle|22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
41486780|NCT02802631|OTHER|Placebo|Placebo - Normal Saline
41486781|NCT04312295|BEHAVIORAL|ACP-SCT program|The ACP-SCT program was designed to improve nurses' knowledge and competence in discussing ACP with Chronic Kidney Disease patients.
40820350|NCT06280950|DRUG|Everolimus|"* The first step is the addition of everolimus to participants in the interventional group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is to continue on the reduced tacrolimus and everolimus regimen."
40820351|NCT00657839|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
41338677|NCT03053401|DRUG|local anaesthetic injection|Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
41338678|NCT03053401|DRUG|Steroid Drug|Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
41338679|NCT00817037|DRUG|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
41338680|NCT00817037|DRUG|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
41338681|NCT00817037|DRUG|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
41338682|NCT00510367|DRUG|5-Fluorouracil|500 mg/m\^2 By Vein Daily x 2 Days
40820352|NCT00657839|DRUG|Placebo|Matching placebo
40820353|NCT01101971|OTHER|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
41338683|NCT00510367|DRUG|Cyclophosphamide|500 mg/m\^2 By Vein On Day 1
41338684|NCT00510367|DRUG|Doxorubicin|50 mg/m\^2 By Vein Over 72 Hours
41338685|NCT01431469|DIETARY_SUPPLEMENT|Cow's milk|Powdered Whole Cow's Milk
41338686|NCT01431469|DIETARY_SUPPLEMENT|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
41486782|NCT05682846|DRUG|Sodium glycerophosphate pentahydrate solution|Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml
41486783|NCT02489019|DRUG|Sodium chloride|Sodium chloride will be used as a placebo comparator in this trial
41486784|NCT02489019|DRUG|Fentanyl|Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
41486785|NCT05532059|DRUG|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Lenvatinib, tislelizumab, gemcitabine and cisplatin
41486786|NCT05532059|DRUG|gemcitabine and cisplatin|gemcitabine and cisplatin
41486787|NCT05215080|DIETARY_SUPPLEMENT|Organic Formula Milk|Organic formula milk is given to the infants three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
41486788|NCT03250494|DRUG|Dulox capsule (60mg)|each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
40820354|NCT06575647|DRUG|Tafenoquine|"Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia).~Tafenoquine will be given as follows,~\>10 kg to ≤ 20 kg - 150 mg (1 tab), \>20 kg to ≤ 35 kg - 300 mg (2 tabs), \> 35 kg - 450 mg (3 tabs)"
40820355|NCT05945602|OTHER|Neurophysiologic Biomarker Assessments|Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.
40822988|NCT04942015|DRUG|Placebo of Honghuaruyi Wan|Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
41338687|NCT01787851|DRUG|Triheptanoin oil|
41486789|NCT03250494|DRUG|combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI|each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
41486790|NCT03250494|DRUG|a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone|each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
41486791|NCT03625518|DRUG|prostaglandins E2|insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction
41486792|NCT03625518|DEVICE|intracervical balloon catheter combined with pitocin|insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol
41338688|NCT04013165|BEHAVIORAL|Active control|Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.
41486793|NCT04998019|BEHAVIORAL|PositiveLinks|"The PositiveLinks (PL) patient mobile app delivers appointment reminders, daily queries (check-ins) of mood, stress and medication adherence, tailored educational resources, access to the PL team for individualized assistance, and the opportunity to interact with other users on a secure, anonymous community message board (CMB)."
41486794|NCT05148962|BIOLOGICAL|GRT-R910 10 mcg Dose (after AZ)|10 mcg vaccine by intramuscular (IM) injection on Day 1 (required) and on Day 113 (optional)
41486795|NCT05148962|BIOLOGICAL|GRT-R910 30 mcg Dose (after AZ)|30 mcg vaccine by intramuscular (IM) injection on Day 1 (required) and on Day 113 (optional)
41338689|NCT04013165|BEHAVIORAL|Village-based intervention|"1. Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~2. Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults."
41338690|NCT03870906|BEHAVIORAL|Occupational-specific health talk|Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
41338691|NCT03870906|BEHAVIORAL|WhatsApp interaction|Individual WhatsApp interactions last 3-month and consist of 2 parts. First part is regular WhatsApp message. The schedule will be adjusted according to the participants' quitting status. Second part is real-time discussion intervention based on participants' socio-demographic characteristics, smoking habit at baseline and updated smoking status obtained during online conversation. At 3-month follow-up, participants who are still smoking are encouraged to join an additional 1-month online group chat moderated by a smoking cessation counselor.
41338692|NCT03870906|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
41338693|NCT03870906|BIOLOGICAL|Text message|Participants will receive regular text messages with similar frequency to those in the intervention group.
41338694|NCT03662555|DEVICE|Neuromuscular electrical stimulation|"Neuromuscular electrical simulation (NMES) Two self-adhesive electrodes (2 mm thick) will be placed over the rectus femoris, vastus medialis and vastus lateralis muscles. The electrodes will be placed on the motor points of each muscle. The stimulator discharges biphasic rectangular pulses. The stimulation frequency and duty cycle will be 50 Hz and 5 s of stimulation followed by a 5 s pause for each rep. The intensity of electrical flow will be at each subject's maximum that they can tolerate. The stimulation will be for 5 x 5 min sets with 1 min rest between sets.~Blood flow restriction~A handheld Doppler probe (Hi-Dop) will detect their auscultatory and visual pulse using the doppler's screen. The cuff will be inflated initially up to their systolic blood pressure and then incrementally by 10 mmHg until no auscultatory or visual pulse is detected. A percentage of 40% or 80% of each subject's LOP will then be used during the BFR conditions."
41338695|NCT05660889|OTHER|Blood sampling.|Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.
41486796|NCT05148962|BIOLOGICAL|GRT-R910 10 mcg Dose (After Adenovirus based vaccine)|GRT-R910 10 mcg vaccine by intramuscular (IM) injection on Day 1 and on Day 29
41486797|NCT05148962|BIOLOGICAL|GRT-R910 10 mcg Dose (after mRNA based vaccine)|GRT-R910 10 mcg vaccine by intramuscular (IM) injection on Day 1 and on Day 29
41486798|NCT04134923|DRUG|[11C] Pittsburgh Compound-B (PIB)|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] PIB. Participants will then undergo a \[11C\] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.
41486799|NCT04699526|OTHER|Universal Prevention Curriculum Training for Schools|School administrators and teachers participated in UPC training and formed prevention leadership action teams
41486800|NCT00472836|DRUG|CP-945,598|Administration of CP-945,598 in subjects with normal renal function.
41486801|NCT00472836|DRUG|CP-945,598|Administration of CP-945,598 in subjects with severe renal impairment.
41486802|NCT03664518|DRUG|Eltrombopag|subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50\~150×109/L，the eltrombopag dose Maintain. platelet count between 150\~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
40820356|NCT05491941|OTHER|Sepsis Bundle|Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.
40820357|NCT00274235|DRUG|sulfadoxine-pyrimethamine / mefloquine|
40820358|NCT00192049|DRUG|Gemcitabine|
40820359|NCT00192049|DRUG|mitomycin C|
40820360|NCT04497857|OTHER|Coordinated Specialty Care (CSC)|CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders
40820361|NCT03258658|BIOLOGICAL|Autologous Engineered Urethral Construct|urethral construct
40820362|NCT04750473|PROCEDURE|Computed Tomography|Undergo PET/CT scan
40820363|NCT04750473|DRUG|Fluciclovine F18|Given IV
40820364|NCT04750473|DRUG|Gallium Ga 68 Gozetotide|Given IV
40820365|NCT04750473|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
40820366|NCT00883870|DRUG|mesenchymal stem cells|Intramuscular injection
40820367|NCT00883870|DRUG|Plasmalyte A|Intramuscular injection
40820368|NCT04565444|DIETARY_SUPPLEMENT|Ketone|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* Isocaloric carbohydrate control: dextrose + vanilla flavouring"
40820369|NCT04565444|DIETARY_SUPPLEMENT|Ketone + Protein|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
40820370|NCT04565444|DIETARY_SUPPLEMENT|Protein|"* Isocaloric carbohydrate control: dextrose + stevia~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
40820371|NCT01748474|PROCEDURE|Supplemental oxygen via a mask|
40820372|NCT06059872|OTHER|High Intensity Interval Training (HIIT)|HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.
40820373|NCT06184464|OTHER|ACETATE LEUPRELINE|USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION
40820374|NCT06464185|DRUG|Bispecific antibody-based combined with CAR-T cell therapy|"lymphocytes collection, and bispecific antibody-based therapy will be performed after successful Lymphocytes collection: Obinutuzumab:1000mg, cycle 1 day 1(C1D1) ,IV.~Glofitamab: 2.5 mg, C1D8; 10 mg,C1D15 ; 30 mg,C2D1 and C3D1, IV. It can be combined with other Immunization therapy during the use of bispecific antibodies according to the patient's condition.~On C4D1, the patient will be pretreated with fludarabine and cyclophosphamide (FC) regimen, and then infused with CART cells at a specific dose of 4 \* 1000000/Kg. Bispecific antibody maintenance therapy will be initiated on month 1/2/3 after CART infusion. In Phase1 bispecific maintenance therapy will be divided into three dose groups, using a 3 + 3 dose escalation design. In Phase 2, bispecific maintenance therapy will be used at the MTD dose of Phase 1."
41486803|NCT01507974|DRUG|Preventive antibiotic treatment- NITROFURANTOIN|P.O NITROFURANTOIN 100 mg per day for 6 weeks
41486804|NCT01507974|DRUG|Preventive antibiotic treatment- CEPHALEXIN|P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
41338696|NCT01136746|DRUG|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
41338697|NCT01136746|DRUG|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
41338698|NCT01136746|DRUG|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
41338699|NCT05635279|OTHER||
41338700|NCT04716010|OTHER|Control|Participants will complete a shopping task in the online grocery store, and the products that contain red meat will not have warning labels or a 30% increase in price.
41338701|NCT04716010|OTHER|Warning Labels|While completing the shopping task in the online grocery store, the health and environmental warning labels will appear next to the image of every product that contains red meat.
41338702|NCT04716010|OTHER|Tax|While completing the shopping task in the online grocery store, all products containing red meat will have a 30% increase in price.
41338703|NCT04716010|OTHER|Combined Warning Labels and Tax|While completing the shopping task in the online grocery store, all products containing red meat will have the health and environmental warning labels appear next to the product image and a 30% increase in price.
41338704|NCT01820494|OTHER|Experimental Infant Formula|Infant formula to be fed ad libitum
41338705|NCT02702492|DRUG|KPT-9274|
41338706|NCT02702492|DRUG|Niacin ER|
41338707|NCT02702492|DRUG|Nivolumab|
41338708|NCT05843305|DRUG|BPI-452080|Subjects will receive BPI-452080 until disease progression
41338709|NCT02920229|DRUG|68Ga- PSMA|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
41486805|NCT01507974|DRUG|PREVENTIVE TREATMENT- AMOXICILLIN|P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
41486806|NCT01507974|DRUG|PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
41486807|NCT01507974|DRUG|PREVENTIVE TREATMENT- CEFUROXIME|P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
41486808|NCT01507974|DRUG|PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM|P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
41486809|NCT03826498|BIOLOGICAL|CP CB-MNC injection|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
40820375|NCT05512247|BEHAVIORAL|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company + brief weekly behavioral support with study staff
40820376|NCT01783574|DRUG|Testosterone|
41338710|NCT05912348|BEHAVIORAL|Low Physical Activity and Added Carbohydrate Group|Young men and women will transition into a low physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group. One of the control groups will undergo a low physical activity intervention.
41338711|NCT05912348|BEHAVIORAL|Low physical Activity Control|Young men and women will transition into a low physically active lifestyle for 10 days.
41338712|NCT05912348|BEHAVIORAL|High Physical Activity and Added Carbohydrate Group|Young men and women will transition into a high physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group.
41338713|NCT04443894|OTHER|PECS block|PECS block is performed at the side of surgery (II) before incision with ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
41338714|NCT04443894|OTHER|local infiltration|local infiltration of the surgical wound before incision with πwith ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
41338715|NCT02677623|DRUG|Pyridium|
41486810|NCT03826498|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training etc.
40820377|NCT01783574|DRUG|Placebo|
40820378|NCT06207799|DRUG|Elranatamab|Given by SC
41338716|NCT02677623|DRUG|Sodium Fluorescein|
41338717|NCT02677623|DRUG|Mannitol|
41338718|NCT02677623|OTHER|Normal Saline|
41338719|NCT06263244|DRUG|Ziltivekimab|Monoclonal antibody targeting IL-6
41338720|NCT06263244|DRUG|Placebo|Placebo
41338721|NCT04944927|OTHER|Recording of clinical parameters and electrocardiogram parameters|Retrospective recording of demographic information (age, sex, age at diagnosis), genetic information, cardiological information, pharmacological treatments, electrocardiogram data. All above data will be deidentified.
41338722|NCT00045591|DRUG|celecoxib|100 mg PO bid
41338723|NCT00045591|DRUG|Celecoxib|400 mg PO bid
41486811|NCT01626521|OTHER|CT pulmonary angio, blood tests|CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
41486812|NCT02858492|DRUG|GSK2982772 60 mg|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
41486813|NCT02858492|DRUG|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
41486814|NCT00771381|DRUG|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
41486815|NCT00771381|DRUG|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
40820379|NCT06207799|DRUG|Lenalidomide|Given by PO
40820380|NCT06207799|DRUG|Plerixafor|Given by SC
40820381|NCT06207799|DRUG|Melphalan|Given by IV
40820382|NCT06207799|DRUG|Busulfan|Given by PO
41338724|NCT02744560|DIETARY_SUPPLEMENT|spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
41486816|NCT03962582|DEVICE|Matrix back|The Matrix back will replace the individual's back and the measures will be taken.
41486817|NCT02122406|OTHER|Hospital Anxiety and Depression Scale (HADS) questionnaire|Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
40820383|NCT06207799|DRUG|G-CSF|Given by IV
40820384|NCT06207799|PROCEDURE|Stem cell transplant|Given by IV
40820385|NCT02430896|DRUG|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
40820386|NCT02430896|DRUG|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
40820387|NCT05746650|PROCEDURE|Electrical stimulation|Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
40820388|NCT05746650|DRUG|Growth hormone (somatropin)|Daily injection of growth hormone
40820389|NCT05746650|OTHER|Control (No electrical stimulation, nor growth hormone)|No electrical stimulation, nor growth hormone
41338725|NCT03655769|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
41338726|NCT03655769|DEVICE|sham transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
41338727|NCT05316493|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|dietary guidance, exercise guidance, lifestyle intervention
41338728|NCT05316493|DRUG|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
41486818|NCT04810403|BEHAVIORAL|SOMEBODY Eating Disorder Prevention Program|Participants will receive daily activities to complete on their most frequently used social media platform for 14 consecutive days. Daily activities have been adapted from the Body Project - an intervention that has been demonstrated to reduce internalization of the thin ideal and reduce risk for eating disorders. Examples of activities to be piloted include unfollowing social media accounts the participant perceives as reinforcing the thin-ideal and posting a selfie without makeup or editing. Based on feedback from participants, the intervention may be altered to improve acceptability, feasibility, and preliminary evidence of potential efficacy.
41486819|NCT01432418|OTHER|Wheelchair skills training program|A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
41486820|NCT00361335|DRUG|Golimumab|2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
41486821|NCT00361335|DRUG|Methotrexate|Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
41486822|NCT00361335|DRUG|Placebo|Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
41486823|NCT00361062|BEHAVIORAL|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
41486824|NCT00406042|DRUG|prednisolone acetate 1%|
41486825|NCT03898895|COMBINATION_PRODUCT|Radiotherapy+anti-PD-1 antibody|The total radiation dose is over 45Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
41486826|NCT02721836|BEHAVIORAL|Yoga|Yoga intervention 12 weeks, twice weekly 75-minute intervention Yoga postures, breathing, relaxation, and meditation
41486827|NCT02721836|BEHAVIORAL|Nutrition Counselling|Evidence-based Nutrition Counselling, 3 appointments within 12 weeks
41486828|NCT01026155|OTHER|Respiratory muscle training|Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
41486829|NCT04979286|OTHER|Kinesiotaping|"Y strip kinesiotaping will be applied to both the gastrocnemius muscles while keeping the participant's ankle in full dorsiflexion. The tape will start from the plantar surface of the toe and continue proximally. The medial Y tail will be applied along the medial border of the gastrocnemius and the lateral Y tail along the lateral border of the gastrocnemius, at approximately 20% tension from the resting length. End points will end just below the popliteal crease."
41486830|NCT04979286|OTHER|Placebo Kinesiotaping|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
41486831|NCT01780987|DRUG|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
41486832|NCT01780987|DRUG|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
40820390|NCT00134654|DRUG|Premarin|Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
41338729|NCT05316493|DRUG|Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg|enrolled patients will be treated with LNG-IUS.
41338730|NCT04824222|DRUG|Human fecal microbiota, MBiotix HBI|The FMT will be administered orally in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).
41338731|NCT04824222|DRUG|Placebo|Double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules)
41486833|NCT01780987|DRUG|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
41486834|NCT02027675|OTHER|High fat poor micronutrient meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.
40820391|NCT01478802|DEVICE|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
41338732|NCT04824222|DRUG|SOC|The standard COVID 19 pharmacological treatment
41338733|NCT03820908|DRUG|Bisantrene|The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
41338734|NCT04541732|OTHER|Thoracic epidural block|Patients who will be subjected to epidural block will be placed in the lateral position then, after sterilization of the skin, 21 G spinal needle will be inserted at T9-T11 intervertebral spaces. The epidural space will be located using the loss of resistance to air technique and a mixture of bupivacaine 0.25% + 50 μ fentanyl targeting T6 level will be injected following induction of general anaesthesia.
40820392|NCT01478802|DEVICE|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
41338735|NCT04541732|OTHER|Ultrasound-guided bilateral quadratus lumborum block|Patients who will be subjected to major abdominal surgeries will be placed in a supine position with a pillow under their side to obtain an appropriate view of quadratus lumborum muscle. After sterilization of the skin and ultrasound-guided identification of the quadratus lumborum muscle, 20 ml bupivacaine 0.25% + 25μ fentanyl will be injected on each side following induction of general anaesthesia
41338736|NCT04541732|DRUG|Induction of general anaesthesia with propofol|propofol: 1.5-2.5mg/Kg
41338737|NCT04541732|DRUG|Muscle Relaxant|Atracurium : 0.5mg/Kg.
41338738|NCT04541732|DRUG|Maintenance of general anaesthesia|Sevoflurane 0.7-1.5 MAC in 40% oxygen
41486835|NCT02027675|OTHER|Mediterranean meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
41486836|NCT02654171|DRUG|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
41486837|NCT02654171|DRUG|Placebo|The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
41338739|NCT02546310|DRUG|HTL0009936|
41338740|NCT02546310|DRUG|HTL0009936 matching placebo|
41486838|NCT05526326|DEVICE|Transplant with normothermic machine perfused (NMP) donor liver|The enrolled recipient will receive a DBD or DCD donor liver that underwent normothermic machine perfusion with the OrganOx metra®
40820393|NCT06607952|OTHER|scenario-based case videos teaching protocol|"Students in the experimental group will receive a new teaching method of scenario-based case video interventions. These videos cover five key scenarios: Triage, SDH and ETTC, AMI and D2B, COPD AE and TOCC, and Sepsis and the CVC Procedure.~This teaching method is grounded in experiential learning theory and critical thinking strategies, designed to guide students in learning emergency nursing through video experiences. In each class, the instructor will first introduce the foundational concepts of emergency nursing for each system. Students will then watch a 15-minute scenario-based case video. Afterward, the instructor will facilitate a 15-minute discussion using reflection sheets to promote experiential learning and critical"
41338741|NCT05779800|DEVICE|Flowble resin composite stent|Flowble resin composite is a filling material used in operative dentistry and characterized by being flow and easily adapting the surfaces.
41338742|NCT05779800|DEVICE|periodontal pack|Non eugenol containing dressing supplied in two tubes
41338743|NCT02152072|OTHER|Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination|
40820394|NCT06607952|OTHER|traditional lecture-based teaching method|Students in the control group will receive traditional lecture-based instruction on the five topics: Triage, SDH and ETTC , AMI and D2B , COPD AE and TOCC , and Sepsis and the CVC Procedure. During the lectures, the instructor will encourage students to ask questions and engage in discussions to enhance understanding.
41338744|NCT03627000|OTHER|failure after reimplantation|description of cinical and microbiological failure
41338745|NCT02679781|DRUG|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
41338746|NCT02679781|DRUG|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
41338747|NCT01308294|BIOLOGICAL|2 vaccine injections in 1 limb|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
41338748|NCT01308294|BIOLOGICAL|2 vaccine injections in distinct limbs|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
41338749|NCT01308294|BIOLOGICAL|"2 vaccine injections in distinct limbs"|
41338750|NCT00761358|DRUG|Z-338|Oral
41338751|NCT00761358|DRUG|Placebo|Oral
41338752|NCT06227806|PROCEDURE|Tibial Tubercle Transfer|Patients will receive the TTT surgery followed by a home exercise program.
41338753|NCT06227806|PROCEDURE|Home Exercise Program|Patients will receive an extensive home exercise program.
41338754|NCT06078891|BIOLOGICAL|BCG vaccine|Three intra-dermal vaccinations over a period of one year.
41486839|NCT02866045|PROCEDURE|EUS-guided fine needle biopsy|EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
41338755|NCT05145673|OTHER|Placebo (OGTT)|The control group was given an glucose solution to oral glucose tolerance test (OGTT) The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
41338756|NCT05145673|OTHER|Cinnamon (OGTT plus aqueous cinnamon extract)|The intervention group was given an glucose solution to OGTT followed by a cinnamon aqueous extract. The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
41338757|NCT00368472|DRUG|Perampanel|Perampanel 2 mg to 12 mg, once daily during the OLE study
41338758|NCT05033678|DEVICE|Diagnostic algorithms|Assessors of teledermoscopy will be randomly assigned to use the results of artificial intelligence when the assess a teledermoscopic case.
41486840|NCT02866045|PROCEDURE|Single incision needle knife biopsy|For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
41486841|NCT03936673|PROCEDURE|Percutaneous nephrostomy|
41486842|NCT00073619|BEHAVIORAL|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
41486843|NCT01934738|DRUG|PF-06273340|Tablets, 100 mg TID, 14 days
41486844|NCT01934738|DRUG|Placebo|Tablets, TID, 14 days
41486845|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
41486846|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
41486847|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
41486848|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
41486849|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
41486850|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
41486851|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
41338759|NCT03269136|DRUG|PF-06863135 monotherapy IV or SC|PF-06863135 will be administered intravenously or subcutaneously.
41338760|NCT03269136|DRUG|PF-06863135 + dexamethasone|PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.
41338761|NCT03269136|DRUG|PF-06863135 + lenalidomide|PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally
41338762|NCT03269136|DRUG|PF-06863135 + pomalidomide|PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally
41338763|NCT03639987|DRUG|Aducanumab|Administered as specified in the treatment arm.
41338764|NCT03639987|DRUG|Placebo|Administered as specified in the treatment arm.
41486852|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
41486853|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
41486854|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
41338765|NCT03521401|BEHAVIORAL|Exercise|Participants assigned to the exercise group will undergo structured, progressive resistance and aerobic exercise for 8 weeks. Resistance training and aerobic training will each be completed twice weekly for a total of 16 resistance and 16 aerobic exercise training sessions.
41338766|NCT05589740|BEHAVIORAL|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
41338767|NCT05589740|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations from USDA My Plate
41486855|NCT03938714|PROCEDURE|Hemorrhoidectomy|Excision of third and fourth degree hemorrhoids
41486856|NCT05922475|DIETARY_SUPPLEMENT|Protein|"Post-exercise protein group consumed protein immediately after exercise sessions.~Pre-sleep protein group consumed protein 30 minutes before sleep."
41486857|NCT05922475|OTHER|Placebo|Resistance exercise training only group did not consume supplemental protein.
40820395|NCT06088953|DIAGNOSTIC_TEST|VRB test|"V1 (inclusion) : VRB test for detecting speech comprehension disorders in noise.~V2 (3 months) : all patients ( independent of the result of the VRB test) will be invited to attend a hearing test within 3 months in order to confirm the diagnosis of deafness by means of a tone audiometry and an ENT medical consultation."
41338768|NCT03258944|OTHER|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
41338769|NCT01755104|DIETARY_SUPPLEMENT|Stablor|
41338770|NCT01755104|DIETARY_SUPPLEMENT|Placebo|
41338771|NCT00379886|DRUG|Propofol Thiopental|
41338772|NCT01413867|PROCEDURE|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the EEA stapler Covidien
41338773|NCT01413867|PROCEDURE|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery
41338774|NCT02030860|DRUG|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
41338775|NCT02030860|DRUG|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
41338776|NCT02030860|DRUG|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
41338777|NCT02365805|DRUG|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
41338778|NCT02365805|DRUG|Epirubicin + Cisplatin + Fluorouracil|Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
41338779|NCT02365805|DRUG|Docetaxel + Ciclofosfamide|Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
41338780|NCT01611298|BIOLOGICAL|Tetanus|"Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection."
41338781|NCT05676827|DIAGNOSTIC_TEST|Diagnostic Criteria for Temporomandibular Disorders Clinical Examination|Clinical examination made by experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the DC/TMD.
41338782|NCT05676827|DIAGNOSTIC_TEST|Blood test|Blood samples will be tested to investigate two polymorphisms of genes encoding proteins for serotonin receptors HTR2A - rs4941573 in intron 3 and dopamine DRD3 - rs6280 (Ser9Gly) and levels of serotonin, dopamine, C-reactive protein, cortisol, sodium, potassium, and calcium.
41486858|NCT02190474|BEHAVIORAL|Mindfulness Group|Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
40820396|NCT01359241|PROCEDURE|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
40820397|NCT01359241|DRUG|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
40820398|NCT05209802|OTHER|Group A: High intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
40820399|NCT05209802|OTHER|Group B: moderate intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
41338783|NCT00628225|BEHAVIORAL|Counseling and Nicotine replacement (CN)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement."
41338784|NCT00628225|BEHAVIORAL|Counseling, Nicotine replacement and Bupropion (CNB)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR."
41338785|NCT02469727|BEHAVIORAL|Fitbit|Participants will use the FitBit device to track their physical activity
41338786|NCT02469727|BEHAVIORAL|Facebook group|Participants will receive and post messages and receive badges on the Facebook group
41338787|NCT04695418|DIETARY_SUPPLEMENT|Rice Germ|The rice germ was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
41338788|NCT04695418|COMBINATION_PRODUCT|Placebo|An isocaloric wheat germ-based supplement was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
41338789|NCT00493155|DRUG|RG1530|Administered po at escalating doses (10 cohorts)
41338790|NCT06427148|OTHER|"The biofeedback-assisted VR game Golden Breath"|"The biofeedback-assisted VR game Golden Breath that we presented in this study was designed to meet children's healthcare needs quickly and efficiently while reducing pain and fear during medical procedures in the pediatric population. Golden Breath u"
41338791|NCT00558233|BEHAVIORAL|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
41338792|NCT00558233|BEHAVIORAL|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
41338793|NCT05666570|DEVICE|Avelle NPWT|wound management therapy
41338794|NCT05339204|PROCEDURE|allo-HSCT|allo-HSCT from any type of donor
41338795|NCT04479007|DEVICE|Probe based optical techniques|During the intervention of inspecting the airways, different segments of the alveolar compartment will be imaged by two different probe based (CLE and OCT).
41338796|NCT01318525|DRUG|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
41338797|NCT01318525|DRUG|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
41338798|NCT03771001|OTHER|Motivational Interviewing coaching and habit-building app|Coaches will use a manualized motivational interviewing approach and participants' wellness promoting changes will be supported via a habit building app that also delivers a micro-mindfulness program
41338799|NCT05438706|DRUG|chidamide|Chidamide, an HDAC inhibitor
41338800|NCT05438706|DRUG|camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
41338801|NCT05438706|DRUG|carboplatin|Carboplatin \[diammine(1,1-cyclobutanedicarboxylato)platinum(II)\] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.
41338802|NCT05438706|DRUG|capecitabine|Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
41338803|NCT06260891|DRUG|25 mg/day zinc|25 mg of zinc as zinc gluconate taken orally once a day
41338804|NCT06260891|DRUG|40 mg/day zinc|40 mg of zinc as zinc gluconate taken orally once a day
41338805|NCT00080184|PROCEDURE|Low Energy Neurofeedback System|
41338806|NCT01499212|PROCEDURE|I:E ratio|I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
41338807|NCT05134636|OTHER|Text triage|The e-triage will consist of 16 questions, modified from the validated NCI Pro-CTCAETM, which will be sent to patients via WaytoHealth©'s two-way texting system 96 hours prior to their scheduled immunotherapy infusion. Questions will pertain to common or emergent immune related adverse events as defined by the NCCN guidelines and two senior disease experts. Patients will be prompted via text to measure the presence and severity of symptoms over the week prior. A final question will be included to capture any additional symptoms patients wish to disclose.
41338808|NCT05247983|PROCEDURE|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"|"patient undergoing Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
41338809|NCT02485613|DRUG|bortezominb and dexamethasone|The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
41338810|NCT05135429|OTHER|Bathing|The data of the study were obtained from premature newborns born at 34 weeks and above, who were hospitalized.
41338811|NCT06444594|DRUG|TRPM8 Agonist|menthol gel 4-10%
41338812|NCT06444594|DRUG|TRPV1 Agonist|camphor gel 5-20%
41338813|NCT06444594|DRUG|TRPV4 Agonist|capsaicin gel 0.05-1%%
41338814|NCT06444594|DRUG|TRPM8, TRPV4, TRPV1 Agonists|menthol (4-10%), capsaicin (0.05-1%), camphor (5-20%)
41338815|NCT06444594|OTHER|Vehicle gel|Inactive vehicle gel
41338816|NCT03688945|PROCEDURE|Art Therapy|Attend art viewing sessions
41338817|NCT03688945|OTHER|Best Practice|Receive standard of care
41338818|NCT03688945|OTHER|Questionnaire Administration|Ancillary studies
41338819|NCT05557097|DIAGNOSTIC_TEST|Intrapartum sonography|Intrapartum ultrasound performed as an adjunct to clinical examination to assess fetal occiput position prior to performing vacuum delivery
41338820|NCT06248242|DRUG|Edaravone dexborneol|edaravone 10 mg and dexborneol 2.5 mg twice daily
41486859|NCT01364181|DRUG|Udenafil|Udenafil 50mg qd po
41338821|NCT03157336|OTHER|Non Inferiority WTM Interventional Trial|The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be \< 10 ppm as per the recommendations of the World Health Organization.
41338822|NCT04703062|BEHAVIORAL|Experimental group 1|It is planned to do exercises for 50 minutes a day, 2 days a week during 8 weeks with physiotherapist. It will be planned individually according to the needs of the patients. Exercises will progress in the following weeks by changing the number of repetitions, the amount of resistance and the amount of time. Counseling about physical activity and the suggested sports activity will be provided. In daily living activities ergonomics and joint protection principles will be taught. Informing Family.
41338823|NCT04703062|BEHAVIORAL|Experimental group 2|Counseling about physical activity and the suggested sports activity will be provided.Patients make aerobic and strengthening exercises by himself based on physiotherapist's suggestions. Informing Family about; Why are the exercises necessary To what extent the families should be protective The harmful effects of inactivity There will be information about the resting-activity cycle when there is bleeding.
41338824|NCT01650441|DRUG|Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg|In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
41338825|NCT01650441|RADIATION|CT thorax|"CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.~The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose."
41338826|NCT00756093|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops one drop each eye one time
41338827|NCT00756093|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops one drop each eye one time
41338828|NCT00756093|OTHER|Blink Tears|Blink Tears one drop each eye one time
41338829|NCT00756093|OTHER|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops one drop each eye one time
41338830|NCT03197350|DIAGNOSTIC_TEST|cMR|cardiac MRI done to complete the diagnosis
41338831|NCT03197350|BIOLOGICAL|biomarker|Biomarker correlation with cMR parameters Prognostic information
41338832|NCT03869216|BEHAVIORAL|Educational Shared Decision-Making Intervention|The intervention includes a web-based patients' decision aid about PSA-based prostate cancer screening, risks and preferences. The providers receive a summary of the USPSTF 2018 guidelines and main components of the Agency for Healthcare Research and Quality (AHRQ) SHARE curriculum, a link to a video of a prototypical shared decision making conversation, and a laminated shared decision making reminder card.
40820400|NCT06605482|OTHER|Patient Reported Outcome Measures|Participants will complete the following outcome measures American Shoulder and Elbow Surgeons Evaluation Questionnaire - upper limb function score 12-Item Short Form Survey - general health questionnaire
41338833|NCT05229588|DRUG|Lurbinectedin 4 MG Injection [Zepzelca]|"Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride).~Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate."
41338834|NCT04520867|OTHER|STRENGTH|Patients with esophageal (EC) and gastroesophageal junction (GEJC) cancers who are seen in the Esophageal and Gastric Multidisciplinary Clinic (EGMDC) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at UCCC Metro will be offered enrollment into the study. Patients will complete the patient reported assessments focused on QOL and physical activity on provided tablet computers during UCCC visits at specified time points. If unable to complete assessments in person they will be e-mailed to the patient via REDCap to complete. Additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.
41338835|NCT04415190|OTHER|early palliative care|early palliative care
40820401|NCT06605482|OTHER|Range of Motion|Shoulder and Elbow Range of Motion collected at the time of radiographic union
41338836|NCT06265610|PROCEDURE|TIVA/TCI|: The aim of this study was to evaluate the effects of total intravenous anesthesia with target-controlled infusion (TCI/TIVA) on intraoperative hemodynamic parameters and postoperative awakening criteria in pediatric endovascular intervention patients
41338837|NCT02001688|DRUG|Kamada-AAT for Inhalation, 80mg|
40820402|NCT05599451|OTHER|THS Blade device|Tobacco Heating System (THS) device with Blade technology for Blade tobacco stick use
40820403|NCT05599451|OTHER|THS Induction Mono device|Tobacco Heating System (THS) device with Induction technology (combined Charger-Holder device for Induction tobacco stick use).
41338838|NCT02001688|DRUG|Placebo|
41338839|NCT02001688|DRUG|Kamada-AAT for Inhalation, 160mg|
41338840|NCT00076856|DRUG|Temozolomide|
41338841|NCT01039428|DIETARY_SUPPLEMENT|HS219|Chewing for 30 min three time a day far after meal
41338842|NCT01039428|DIETARY_SUPPLEMENT|Placebo|Chewing for 30 min three times a day far after meal
41338843|NCT03749668|OTHER|non applicable|no intervention in this observational study
40820404|NCT05599451|OTHER|THS Induction Mid device|Tobacco Heating System (THS) device with Induction technology (device with Induction stick Holder for Induction tobacco stick use and separate Charger).
41338844|NCT06120933|DIETARY_SUPPLEMENT|Hair Nutra Growth Supplement & Hair Nutra Boost Supplement|"Study Initiation (Week 0) to Week 8:~Each participant will take both the Hair Nutra Growth capsules and the Hair Nutra Boost capsules.~Participants should take 2 capsules of Hair Nutra Growth daily, one in the morning and one in the afternoon, with food or after a meal. The capsules should be taken with water.~Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
41338845|NCT06120933|DIETARY_SUPPLEMENT|Hair Nutra Growth|"From Week 9 to Week 12:~Participants should ONLY take the Hair Nutra Growth. Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
41338846|NCT06122753|PROCEDURE|preemptive TIPS|The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
41338847|NCT06122753|PROCEDURE|standard second prophylaxis|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic band ligation will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
41338848|NCT04771481|DRUG|Metoclopramide|Metoclopramide 10 mg + NSS 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
41156835|NCT06645834|DEVICE|Smart MDI System|"The Smart MDI system consists of the InPen™ system and Simplera™ system.~The InPen™ system includes a reusable smart bolus insulin pen injector with Bluetooth combined with the InPen™ app to help users take insulin doses.~And InPen™ app which communicates with the InPen™ injector and compatible continuous glucose monitoring (CGM) devices to collect and display information on insulin delivered by the injector as well as current and past glucose values.~The Simplera™ system consists of a disposable integrated sensor-transmitter platform (Simplera™ Sensor) and the Simplera™ app which receives data from the Simplera™ sensor via Bluetooth Low Energy (BLE) radio signal"
41338849|NCT04771481|DRUG|Normal Saline 10 mL Injection|Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
41338850|NCT01197794|DRUG|AZD1981|AZD1981 twice daily
41338851|NCT01197794|DRUG|AZD1981|AZD1981 once daily
41338852|NCT01197794|DRUG|Placebo|Placebo to match AZD1981
41338853|NCT01706991|DEVICE|Pediatric Vision Scanner eye scan|Subject is scanned with a 2.5 second pediatric vision scanner device test.
41156836|NCT05836571|PROCEDURE|Biopsy|Undergo biopsy
41338854|NCT06169995|DRUG|Remimazolam Tosilate|bolus dose: 5mg，IV supplemental dose: 2.5mg，IV
41338855|NCT03136913|DEVICE|Cytoplast® TXT-200|Non-resorbable membrane
41338856|NCT03136913|DEVICE|MinerOss® Cortical and Cancellous Chips (FDBA)|Mixture of allograft mineralized cortical and cancellous chips
41338857|NCT03136913|PROCEDURE|Open Flap Technique|After extraction, the socket wound is left open to heal by secondary intention
41338858|NCT03136913|PROCEDURE|Closed Flap Technique|After extraction, the socket wound is closed by primary closure
41338859|NCT05030597|DRUG|68Ga-DOTA-FAPI|Intravenous access is pre-established. Quality control is carried out to confirm the radiochemical purity of 68Ga-DOTA-FAPI by HPLC. Intravenous administration of 68Ga-DOTA-FAPI according to 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
41338860|NCT05030597|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 20-30 minutes after injection.
41338861|NCT01750840|DEVICE|Biomet® EBI Bone Healing System|A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.
41338862|NCT01750840|DEVICE|Biomet Orthopak® Non-Invasive Bone Growth Stimulator System|A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.
41338863|NCT01750840|DEVICE|Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator|A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
41338864|NCT06234085|OTHER|VCA feedback report available|Access to feedback report described in the intervention
41156837|NCT05836571|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41156838|NCT05836571|DRUG|Cabozantinib|Given PO
41156839|NCT05836571|PROCEDURE|Computed Tomography|Undergo CT
41156840|NCT05836571|BIOLOGICAL|Ipilimumab|Given IV
41156841|NCT05836571|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41156842|NCT05836571|BIOLOGICAL|Nivolumab|Given IV
41156843|NCT04483791|COMBINATION_PRODUCT|DynamX Novolimus Eluting Coronary Bioadaptor System|up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and\<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System
41338865|NCT05906576|DRUG|Infliximab|Infliximab in the treatment of Crohn's disease in children
41338866|NCT05620173|DEVICE|Vedea Amblyopia Therapy (VAT)|Children will use the VAT for 5 days per week, 30 minutes per day. They play VR-games using a VR-headset, which content is optimized for dichoptic training.
41338867|NCT05620173|DEVICE|Occlusion therapy|Children are given an eye patch to occlude their dominant eye with for a prescribed number of hours per day. This may typically range anywhere between 2-8 hours per day, depending on the severity of the amblyopia.
41338868|NCT03777397|OTHER|Questionnaire|Questionnaire on the level of awareness of this risk among health sector employees, and more specifically the Lyon Civilian Hospices, and on participation in breast cancer screening for HCL employees, particularly among night shift staff.
41338869|NCT03529890|DRUG|Nivolumab|"Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1"
41338870|NCT03529890|RADIATION|Radiation therapy of the pelvis|Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)
41338871|NCT03529890|PROCEDURE|Radical cystectomy with standardized pelvic lymphadenectomy|Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)
41338872|NCT05394207|DIETARY_SUPPLEMENT|L. casei DG® (Lactobacillus paracasei CNCM I-1572)|L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
41338873|NCT05394207|OTHER|placebo|The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
41338874|NCT00533299|DRUG|Hydralazine and magnesium valproate|Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
41338875|NCT00533299|DRUG|Placebo|Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
41338876|NCT03272971|DEVICE|Radio-frequency Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radiofrequency.
41338877|NCT04228445|DRUG|3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
41338878|NCT04228445|DRUG|Saline spray|Placebo
41338879|NCT00719524|DRUG|OMBRABULIN (AVE8062)|Dose escalation study with combination chemotherapy
41338880|NCT06337994|DRUG|Memantine Hydrochloride|Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day (once daily). The dosage was then increased to 10 mg/day after a week and maintained till the end of the study. In the case of intolerance to this increase, the dosage was flexibly adjusted according to the condition of the patient.
41338881|NCT01807611|RADIATION|Total Lymphoid Irradiation|Participants receive total lymphoid irradiation over four doses.
41338882|NCT01807611|DRUG|Fludarabine|Given IV.
41338883|NCT01807611|DRUG|Cyclophosphamide|Given IV.
41338884|NCT01807611|DRUG|Thiotepa|Given IV.
41338885|NCT01807611|DRUG|Melphalan|Given IV.
41338886|NCT01807611|BIOLOGICAL|HPC,A Infusion|Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
41338887|NCT01807611|BIOLOGICAL|TC-NK Infusion|Participants receive infusions of TC-NK.
41338888|NCT01807611|BIOLOGICAL|G-CSF|"Participants receive G-CSF subcutaneously or intravenously.~Donors receive G-CSF subcutaneously during cell mobilization."
41338889|NCT01807611|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
41338890|NCT01807611|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
41338891|NCT01807611|DRUG|Mycophenolate mofetil|Given intravenously or orally.
41338892|NCT03491280|GENETIC|NGS Diagnostic|Blood take for genetic diagnostic.
41338893|NCT00871676|BEHAVIORAL|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
41338894|NCT00871676|BEHAVIORAL|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
41338895|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Cream preparation|Apply medication twice a day to affected areas of atopic dermatitis
41338896|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Ointment preparation|Apply medication twice a day to affected areas of atopic dermatitis
41338897|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Lipocream preparation|Apply medication twice a day to affected areas of atopic dermatitis
41338898|NCT05592158|PROCEDURE|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and covered with an amnion-chorion membrane.
41338899|NCT06156462|DEVICE|ResAppDx v.20|Software device measuring cough sounds to aid diagnosis of respiratory diseases
40820405|NCT05599451|OTHER|CIG|Subject's preferred brand of commercially available regular (non-mentholated) cigarettes. (Cigarettes are not provided by the study sponsor.)
40820406|NCT00977275|RADIATION|Interstitial Implant Brachytherapy|Via tubes placed at the time of wide local excision delivered over 5 days
41338900|NCT04631367|BEHAVIORAL|Kukaa Salama: mHealth intervention|Kukaa Salama is a 8-week social group program of COVID-19 prevention messaging, which includes sending informational SMS once per week and holding secure group discussions on COVID-19 prevention. Weekly SMS messages will focus on COVID-19 knowledge, including information about transmission, hand washing, respiratory hygiene (coughing and sneezing in ways that won't spread germs), face masks, and physical distancing. Participants can also respond to the SMS with any questions about COVID-19, and the study team will respond with further information and/or additional resources. Weekly group chats will be administered using the customized WelTel platform, and will focus on discussions of how participants can apply and practice the information on COVID-19 prevention in their daily lives. Each group chat will be composed of 15-20 participants, and will be facilitated by a research assistant in Kampala as well as a peer navigator.
41338901|NCT04631367|DEVICE|Face Mask + Soap|Participants will be offered the opportunity to pick up a parcel that contains a face mask, bar of soap, and a small parcel of food from the partner agency YARID.
41338902|NCT04974268|OTHER|Specific supervised exercise and weight loss program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal, manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
41338903|NCT01154907|DRUG|Praziquantel|One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
41338904|NCT03403855|DEVICE|Rocket® IPC- Long External Length|Rocket® IPC- Long External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
41338905|NCT03403855|DEVICE|Rocket® IPC- Short External Length|Rocket® IPC- Short External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
41338906|NCT02715050|DEVICE|Active or Placebo Phototherapy (MR4)|
41338907|NCT02985684|DEVICE|GORE® CARDIOFORM ASD Occluder|Percutaneous Atrial Septal Defect Closure
41338908|NCT05021380|OTHER|GROUP|Non-invasive diagnosis of dental pain, dental root canal treatment, salivary specimen collection from the first visit to next and the last during 4 weeks of dental care
40820407|NCT01461928|DRUG|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
40820408|NCT01461928|DRUG|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
40820409|NCT05759338|DEVICE|Revian Red All LED cap|"The cap is a dual-band LED light therapy wireless smart cap. It has been shown to be effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women."
40820410|NCT02279771|PROCEDURE|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
40820411|NCT02279771|PROCEDURE|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
40820412|NCT02279771|DEVICE|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
41338909|NCT03458988|DEVICE|Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)|Data will be acquired for 10 minutes with a reusable off the shelf adult SpO2 sensor. The Nellcor™ Adult SpO2 Sensor, model DS-100A, is indicated for use when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are required for patients weighing greater than 40 kg.
41338910|NCT04445051|DEVICE|SpeediCath® Standard male or female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male or female.
41338911|NCT04445051|DEVICE|New intermittent Variant 1 catheter for male or female|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 for male or female.
41338912|NCT04445051|DEVICE|New intermittent Variant 2 catheter for male or female|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 for male or female.
41338913|NCT02280525|DRUG|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
41338914|NCT02280525|DRUG|Rituximab|375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
41338915|NCT02280525|DRUG|Fludarabine|"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
41156844|NCT05262920|BEHAVIORAL|The BSM Intervention|The BSM intervention entailed a daily electronic journal for monitoring BF and BNP with feedings, bi-weekly texting for 6 weeks from a research nurse for informational support and to promote personalized goal-setting and problem-solving, and hyperlinks to eight uniform BNP educational modules (knowledge and skills) and online resources. 1. Fundamentals of BF (FBF), 2. Deep breathing (DB), 3. BNP non-pharmacological strategies (BNPS), 4. Guided imagery (GI), 5. Pain neurophysiology specifically related to BF (PN-BF), 6. Catastrophizing, 7. Stress reactivity, and 8. Common pumping issues and interventions (CPI).
40820413|NCT03094364|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
41338916|NCT02280525|DRUG|Cyclophosphamide|"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
40820414|NCT05567419|DIAGNOSTIC_TEST|Biological assays|PCR and NGS-WGS on stools and respiratory samples
40820415|NCT05032690|DRUG|Bosutinib capsule|Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast
40820416|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast
41338917|NCT02280525|PROCEDURE|NK Cells|"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10\^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
41338918|NCT02280525|DRUG|Cytarabine|Cytarabine 2 mg/m2 by vein on Days -6 to -2.
41338919|NCT06361420|PROCEDURE|Driving pressure-guided positive end expiratory pressure|The positive end expiratory pressure setting rules are as follows: a 10-cycle experimental ventilation will be carried out at each level of positive end expiratory pressure after intubation, and the driving pressure of the last cycle will be recorded. The positive end expiratory pressure value corresponding to the lowest driving pressure is recognised as the optimal ventilation parameter. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
40820417|NCT05032690|DRUG|Bosutinib|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours
40820418|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast
40820419|NCT06420219|OTHER|Non-Interventional Study|Non-interventional study
40820420|NCT06437626|DRUG|Mexidol|50 mg/ml IV solution, 250 mg tablets
40820421|NCT06437626|DRUG|Placebo|Placebo IV solution, Placebo tablets
40820422|NCT04158141|DRUG|Carboplatin|Given IV
40820423|NCT04158141|DRUG|Cisplatin|Given IV
40820424|NCT04158141|PROCEDURE|Decortication|Undergo decortication
40820425|NCT04158141|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
40820426|NCT04158141|DRUG|Pemetrexed|Given IV
40820427|NCT04158141|DRUG|Pemetrexed Disodium|Given IV
40820428|NCT04158141|RADIATION|Pencil Beam Scanning|Undergo PBS
40820429|NCT04158141|PROCEDURE|Pleurectomy|Undergo pleurectomy
40820430|NCT04158141|OTHER|Quality-of-Life Assessment|Ancillary studies
40820431|NCT04158141|OTHER|Questionnaire Administration|Ancillary studies
40820432|NCT01318278|DRUG|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
40820433|NCT01318278|DRUG|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
40820434|NCT05908071|DRUG|SHEN26 capsule|Capsule administered orally after meals.
40820435|NCT05908071|DRUG|SHEN26 placebo|Capsule administered orally after meals.
40820436|NCT00000554|PROCEDURE|Angiography, MRI, Dobutamine-Stress Echocardiography, PET,|
40820437|NCT00000554|PROCEDURE|Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing|
40820438|NCT00633373|DRUG|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
40820440|NCT05621759|DRUG|Cyclophosphamide|Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.
40820441|NCT05621759|DRUG|Abatacept|Calcineurin-inhibitor produced by Astellas.
40820442|NCT05621759|DRUG|Tacrolimus|Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.
41156845|NCT05262920|BEHAVIORAL|Attention Control|The Attention Control and Intervention groups both receive fourth-trimester care videos. The educational modules are the following: Urgent maternal warning signs, caring for the maternal body after birth; infant care; COVID-19 and infant health prevention; maternal and infant immunization; infant safety in the home; maternal and infant dietary recommendations; and national and health resources to support BF in the workplace
40820443|NCT01980303|DRUG|Esketamine|Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
40820444|NCT06489158|DIAGNOSTIC_TEST|Detect VOCs in exhaled gas|The exhaled gas of the patients should be collected within one week before surgery and be tested within 24 hours after enrollment. Then receive treatment according to the existing diagnosis and treatment process.
40820445|NCT05818917|DRUG|FHND5071|"The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks.~FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards.~Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data."
41156846|NCT06468280|PROCEDURE|Radical surgery|Radical gastrectomy with standard D2 lymphadenectomy will be performed, along with radical surgery for resectable metastatic lesions.
41156847|NCT06468280|DRUG|PD-1 Monoclonal Antibody|PD-1 monoclonal antibody will be administered at a dosage of 20 mg/kg via intravenous infusion, once every cycle, each cycle spanning three weeks. The investigators will select the specific PD-1 antibody utilized based on clinical considerations, which may include sintilimab, toripalimab, or nivolumab.
41156848|NCT06468280|DRUG|XELOX Chemotherapy Regimen|"Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle."
40820446|NCT06106009|DRUG|PF-07976016|Oral solution, oral suspension or solid oral formulation(s)
40820447|NCT06106009|DRUG|Placebo|Oral solution, oral suspension or solid oral formulation(s)
40820448|NCT06106009|DRUG|Midazolam|Midazolam oral solution
40820449|NCT05864521|DIETARY_SUPPLEMENT|Active Beetroot Juice Supplement (aBRJ)|aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol inorganic nitrate (range for inter-batch variability) taken orally.
40820450|NCT05864521|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Supplement (pBRJ)|pBRJ will consist of 70ml concentrated beetroot juice and will be chemically devoid of inorganic nitrate taken orally.
40820451|NCT04730869|OTHER|Standard Treatment Plus Metabolic Therapy Program|"See description under Arms."
41156849|NCT06468280|PROCEDURE|Local Treatment|"Additional local treatment for unresected metastatic lesions during phase 2 systemic therapy is permitted, including:~* Bone metastasis, distant lymph nodes, adrenal metastasis: Radiation therapy.~* Lung and liver metastasis: Radiofrequency ablation, interventional embolization, or radiation therapy.~* Peritoneal metastasis: Hyperthermic intraperitoneal chemotherapy (HIPEC).~* Other metastatic lesions: Non-surgical treatment options discussed by the multidisciplinary team."
41156850|NCT03293329|OTHER|Diaphragm manual therapy techniques|3 diaphragm manual therapy techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position.
40820452|NCT05079698|DRUG|177Lu-PSMA-617|Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.
40820453|NCT05079698|PROCEDURE|Stereotactic Body Radiotherapy (SBRT)|No later than 5 weeks (+/- 7 days) after the 2nd cycle of 177Lu-PSMA-617, patients will then undergo SBRT (900 cGy x 3 fractions).
40820454|NCT02976636|BEHAVIORAL|Family-based behavioral therapy|Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
41156851|NCT03293329|OTHER|Diaphragm mobilization through active hipopressive gymnastic exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures: standing and standing bending forward.
41156852|NCT03293329|OTHER|Ischemic compression techniques in shoulder myofascial trigger points|Ischemic compression techniques in infraespinatus and supraespinatus myofascial trigger points during one minute each muscle. The pressure increases gradually until the individual feels a tolerable pain.
41338920|NCT06361420|PROCEDURE|Optimal oxygenation-guided positive end expiratory pressure|Positive end expiratory pressure will be maintained at the level facilitating optimal oxygenation during the off-pump period. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
41338921|NCT06361420|PROCEDURE|Ventilation strategy|A Pressure regulated volume control mode is used in the patients before extubation. The ventilation target are: (1) a pulse oximetry ≥ 90% or a partial pressure of arterial oxygen ≥ 60mm Hg; (2) a partial pressure of arterial carbon dioxide: 35 \~ 50 mm Hg and (3) a pondus hydrogenii (pH) value \> 7.20. The ventilation parameters are: (1) tidal volume: 6 \~ 8 mL/Kg predictive body weight; (2) respiratory rate 10 \~ 15 cycles per minute; (3) inspiratory/expiratory ratio: 1:1.5 (1:2.5 - 1:3 in the patients with chronic obstructive pulmonary disease); positive end expiratory pressure: 0 \~ 8 cm centimeter water column. On-pump ventilation parameters are: (1) tidal volume: 4 mL/Kg predictive body weight; (2) respiratory rate: 4 circles per minute; (3) positive end-expiratory pressure: 4 cm centimeter water column; (4) inspiratory oxygen fraction: 21%.
41338922|NCT06361420|PROCEDURE|Management of hypoxemia|Management of hypoxemia will be initiated immediately through the following steps: (1) carefully checking anaesthesia apparatus malfunction, airway normality, and monitoring accuracy; (2) improving cardiac function, correcting fluid overload, and alleviating systemic inflammation; (3) performing alveolar recruitment manoeuvres as described above; (4) increasing the tidal volume and positive end expiratory pressure within the upper limits; (5) increasing the respiratory rate while addressing concurrent hypercapnia; (6) titrating the fraction of inspiratory oxygen until the pulse oximetry reaches or exceeds 90%; and (7) considering the use of extracorporeal membrane oxygenation if any following situations occurred 14: (a) a partial pressure of arterial oxygen \< 50 mm Hg for more than 3 hours; (b) a partial pressure of arterial oxygen to inspiratory oxygen fraction ratio \< 80 mm Hg for more than 6 hours; or (c) a critical respiratory acidosis for more than 6 hours.
41338923|NCT02033655|DIETARY_SUPPLEMENT|Protein supplementation|\> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
41338924|NCT02033655|BEHAVIORAL|Diet counseling and group education lessons|Participants meet once a week for 6 months to participate in group lessons and counseling.
41338925|NCT01620593|DRUG|Placebo|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of placebo after castration, blinded to the patient and the study team.
41338926|NCT01620593|DRUG|Metformin|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of metformin after castration, blinded to the patient and the study team.
41486860|NCT06205017|DIETARY_SUPPLEMENT|Foods for Special Medical Purposes|"In order to facilitate patient weaning and to improve the enjoyment of foods used in this semi-liquid phase, our Center intends to test Foods for Special Medical Purposes (AFMS) to ensure better nutritional intake, including vitamin D3 and calcium, good palatability, and thus better adherence to the recommended nutritional indications in the immediate postoperative period than the homogenized foods used in the standard diet."
41486861|NCT03466359|BEHAVIORAL|DEF-EI : Energy restriction induced energy deficit|DEF-EI : Energy restriction induced energy deficit The content of their energy intake will be decreased by 10% daily compared with the phase one of the protocol (stabilization of intake). This decrease will be allowed by the internship nature of the clinical program; all the meals are prepared and served by the personal of the clinical centre.
41486862|NCT03466359|BEHAVIORAL|DEF-EX : Exercise induced energy deficit|DEF-EX : Exercise induced energy deficit While their intake will remain the same as phase 1, they will increase their physical activity energy expenditure by 10% thanks to an increase of their prescribed exercise intensities or durations.
41486863|NCT04069871|DEVICE|trans-cutaneous electrical nerve stimulation.|• Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.
41486864|NCT04069871|DEVICE|Sham TENS|Patients in the control group will receive sham TENS.
41486865|NCT01270165|DRUG|telbivudine|600mg, oral daily over 12 months
41486866|NCT04335318|DEVICE|AI-assisted colonoscopy|Colonoscopies performed with assistance of an AI tool that highlights the areas that are susceptible to be a polyp.
41486867|NCT00327288|DRUG|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
40820455|NCT02976636|BEHAVIORAL|Parenting training|Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
40820456|NCT01574157|DRUG|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
41156853|NCT03323983|OTHER|data collection|data collection
40820457|NCT01574157|DRUG|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
41156854|NCT04461938|OTHER|Fasting|The study intervention consists of one fasting cycle of 72 hours prior to biopsy/resection. Depending on clinical condition, patients can be hospitalized during the course of the study (e.g. need for medical assistance due to immobilization). Patients in good clinical condition will be admitted on day 3.
41156855|NCT05150002|DEVICE|Spinal cord stimulation|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
41156856|NCT03816332|BIOLOGICAL|Ipilimumab|Given IV
41156857|NCT03816332|BIOLOGICAL|Nivolumab|Given IV
41156858|NCT03816332|DRUG|Prednisone|Given PO
41156859|NCT03816332|DRUG|Tacrolimus|Given PO
41338927|NCT03571113|OTHER|Survival / not survival|Outcome with good neurological status vs. bad neurological status at hospital discharge
41338928|NCT02865928|DRUG|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivicaine
41338929|NCT02865928|DRUG|Normal Saline|Same injection technique as intervention arm with normal saline
41338930|NCT05064540|DEVICE|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
41338931|NCT05064540|DEVICE|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
41338932|NCT00978133|PROCEDURE|Dermabond ProPen (2-octylcyanoacrylate)|Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers
41338933|NCT00978133|PROCEDURE|Skin closure with skin staples|Skin closure with skin staples
41338934|NCT05324956|OTHER|No intervention|Individuals will not receive any interventions
41338935|NCT00415753|BEHAVIORAL|No antibiotics if se-procalcitonin is below stated limit|
41338936|NCT04818489|DRUG|Colchicine 0.5 MG|colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the standard protocol
41338937|NCT04818489|OTHER|the standard protocol only|the local standard protocol for COVID19
40820458|NCT05741840|BEHAVIORAL|PBT-A|PBT-A provides all the elements of family based treatment for children with obesity, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
40820459|NCT05741840|BEHAVIORAL|Health Education (HE)|The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
40820460|NCT03362099|DRUG|Varenicline Tartrate or bupropion|the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
40820461|NCT04410666|OTHER|Green Tea mouthwash|"an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C, in sterile glass containers.~Each application was 10 ml. applied for 1 minute."
41338938|NCT03209011|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
41338939|NCT04255368|OTHER|Water-soluble choline|600 mg choline as choline bitartrate
41338940|NCT04255368|OTHER|Fat-soluble choline|600 mg choline as phosphatidylcholine
41338941|NCT04255368|OTHER|No choline control|No choline
41338942|NCT04440462|OTHER|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
41338943|NCT04440462|OTHER|Sterile water|2 ml of sterile water
41338944|NCT03383055|BIOLOGICAL|CMV-MVA Triplex Vaccine|"* CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~* TDap administered on Day 56"
41338945|NCT02778425|PROCEDURE|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
41338946|NCT02778425|PROCEDURE|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
40820462|NCT04410666|OTHER|Placebo Mouthwash|distilled water
40820463|NCT04066192|DRUG|Brexpiprazole|Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.
40820464|NCT04066192|DRUG|Placebo|A medically inert placebo medication will be used as described in the study arms.
40820465|NCT01505673|DRUG|Liraglutide|Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months
40820466|NCT01505673|DRUG|Saline|Placebo injection of 1.8mg saline once daily for 6-months
40820467|NCT01080066|OTHER|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m\^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m\^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
41156860|NCT05166512|BEHAVIORAL|DPP Cooks|6 'food agency' based cooking skills classes during the first 4 months of the DPP
41338947|NCT02778425|PROCEDURE|beta blockers|A standard dose of NSBB (propranolol) was applied to the primary prevention patients according to the Baveno VI recommendations if there were no contraindications.
41338948|NCT02778425|PROCEDURE|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
41338949|NCT02778425|PROCEDURE|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
41338950|NCT02778425|PROCEDURE|Somatostatin+Endoscopic therapy|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
41338951|NCT02778425|PROCEDURE|Somatostatin+Endoscopic therapy+PSE|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
41486868|NCT00327288|DRUG|docetaxel|IV once every 21 days for duration of study
41338952|NCT05698004|OTHER|prone positioning|The target duration of prone positioning is 8 h/d to 10 h/d with 2 to 3 breaks (1-2 hours each), if needed. Daily prone positioning sessions will be protocolized to continue until 1 of the following stopping criteria is met: a relative improvement in the FIO2 requirement by 40% from the baseline value that sustained for 24 hours; endotracheal intubation; or discharge from the ICU.
41338953|NCT02688725|DEVICE|post mastectomy ultrasound|post mastectomy ultrasound
41338954|NCT00476398|PROCEDURE|Capsule endoscopy|Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
41338955|NCT00002968|BIOLOGICAL|edrecolomab|Given IV
41338956|NCT00002968|OTHER|laboratory biomarker analysis|Correlative studies
41338957|NCT06180733|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery. Patients will be monitored for response and possible progression using MRI and pipelle biopsies.
41338958|NCT01861613|BIOLOGICAL|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)|
41338959|NCT01660997|DRUG|MLN9708|
41338960|NCT01660997|DRUG|Dexamethasone|
41486869|NCT02122120|DIETARY_SUPPLEMENT|HEN|Patients with tube feeding with FSMP for at least twelve months
41486870|NCT03123536|DEVICE|Point-of-care Ultrasound|Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
41486871|NCT04058574|DEVICE|Proprioception measurement on isokinetic dynamometer|Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
41486872|NCT02954926|DRUG|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
41486873|NCT04006314|OTHER|Autologous platelet rich plasma and dextrose solution.|"Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.~Dextrose solutions are injected to the genicular nerves."
41486874|NCT01708590|DRUG|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
41486875|NCT01708590|DRUG|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
41486876|NCT01708590|DRUG|placebo|Placebo administered subcutaneous (SC)
40820468|NCT05430191|OTHER|Cascade Screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
40820469|NCT06607211|DIAGNOSTIC_TEST|Transcranial Color-Coded Doppler (TCCD)|As part of the clinical practice, the examination will be performed with ultrasound machines that have presets for TCCD, using a low-frequency sector probe (2-25 MHz) with a transtemporal approach to obtain a scan through the midbrain plane. Through the use of Color Doppler and Pulsed-Wave Doppler, a spectral doppler waveform of the M1 segment of the middle cerebral artery velocity is obtained bilaterally. If hypoperfusion signs are discovered, TCCD will be repeated to assess the effects of each intervention.
41156861|NCT05166512|BEHAVIORAL|DPP|Standard DPP
41338961|NCT01256320|OTHER|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
41338962|NCT01256320|OTHER|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
41338963|NCT01980225|PROCEDURE|Collapse|inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
41338964|NCT05991895|DRUG|Iruplinalkib|Iruplinalkib is administered orally with approximately fixed dosing times each day. The recommended dosage is once daily, on an empty stomach or with food, at 60 mg per dose for the first 1 to 7 days. If tolerated, the dosage is increased to 180 mg per dose starting from the 8th day.
41338965|NCT03491904|DRUG|Fasinumab AI|Self-administered with auto injector
41338966|NCT03491904|DRUG|Fasinumab PFS|Prefilled syringe administered by study staff
41486877|NCT04205396|BEHAVIORAL|Written emotional disclosure|Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
41486878|NCT04205396|BEHAVIORAL|Resilience training|Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
41486879|NCT04205396|OTHER|No treatment|Participants will complete baseline and outcome assessments and no intervention will be conducted.
41486880|NCT03117036|DRUG|Chemotherapy|Systemic chemotherapy with curative intent
41486881|NCT03166683|OTHER|Hemopatch|Liver resection surgery with collagen and polyethylene glycol haemostatic/sealant patch placement
41486882|NCT03166683|OTHER|Standard of care|Standard of care include other sealant / hemostatic devices as patches or liquid/gels
41486883|NCT06030141|OTHER|sesame oil application|sesame oil application
41486884|NCT06030141|OTHER|nigella sativa oil application|nigella sativa oil application
41156862|NCT02367742|BEHAVIORAL|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
41338967|NCT02278224|BEHAVIORAL|Group based rumination focused CBT|The RFCBT is a group trans-diagnostic manual based psychotherapy for depression and anxiety. RFCBT focuses on increasing effective behaviour - i.e., not stopping rumination but making it functional. It's grounded within the core principles and techniques of CBT for depression with two adaptations: (1) a functional-analytical perspective using Behavioural Activation (BA) approaches, (2) an explicit focus on shifting processing style via imagery and experiential approaches.
41338968|NCT02278224|BEHAVIORAL|Group based CBT|The control group is gold standard group based CBT based on Becks manual for CBT for depression.
41338969|NCT00654420|DRUG|Dalotuzumab|Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
41338970|NCT00654420|DRUG|Erlotinib|Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
40822989|NCT06606834|DIAGNOSTIC_TEST|sonoelastography|Elasticity is defined as the ability of an organ or tissue to return to its original shape after being deformed by an applied force or stress. Based on this principle, sonoelastography is a technique used to assess the elasticity of tissues and organs during ultrasonography. This assessment allows measurement of changes in stiffness of soft tissues following physiological or pathological processes.
41486885|NCT01199679|PROCEDURE|Mucosectomy|Endoscopic mucosal resection in the upper GI tract.
41486886|NCT01199679|PROCEDURE|Rubber Band Ligation|Endoscopically ligate esophageal varices at or above the gastroesophageal junction or to ligate internal hemorrhoids.
41338971|NCT01599572|OTHER|zinc supplementation|30mg/day of zinc in the form of zinc gluconate
41338972|NCT02198560|DEVICE|RS-3000 Lite|
41338973|NCT00430547|DRUG|Carbimazole, radio-active iodine (I131)|
41486887|NCT01752647|PROCEDURE|Low dose computed tomography|Low dose computed tomography scan
41338974|NCT02919917|DRUG|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
41486888|NCT00014625|DRUG|indisulam|
41338975|NCT02919917|DRUG|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
41486889|NCT00930371|OTHER|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
41486890|NCT00930371|OTHER|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
41486891|NCT05649241|DRUG|Nicotine patch|Nicotine replacement therapy patch
41486892|NCT05649241|DRUG|Nicotine gum|Nicotine replacement therapy gum
41486893|NCT05649241|BEHAVIORAL|Medication Therapy Management|Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.
41486894|NCT03440541|COMBINATION_PRODUCT|REGE pro|REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
41486895|NCT01113944|BEHAVIORAL|Program 1|
41486896|NCT01113944|BEHAVIORAL|Program 2|
41486897|NCT02938403|BEHAVIORAL|In vivo counseling|Participants in the intervention group will receive 4 in session nicotine replacement therapy and counseling focused on their experience of using NRT, including positive experiences, side effects and smoking cessation expectancies. They will also received nicotine replacement therapy (nicotine lozenge and patch) to use for smoking cessation.
41486898|NCT02938403|BEHAVIORAL|Standard Smoking Cessation Counseling|Participants will receive 4 sessions of standard behavioral counseling to address their smoking. In addition, participants will received nicotine replacement therapy (Nicotine lozenge and patch) to use for smoking cessation.
41486899|NCT00054912|BIOLOGICAL|EP2101|
41338976|NCT06009198|DRUG|Iron folate tablets|Iron folate tablets will be administered to the underweight school going adolescents girls and boys to see the affect on BMI and micronutrients
40820470|NCT02924207|OTHER|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
41338977|NCT05352867|BIOLOGICAL|SARS-CoV-2 (LVRNA009) 50μg group|50μg/person
41338978|NCT05352867|BIOLOGICAL|SARS-CoV-2 (LVRNA009) 100μg group|100μg/person
41338979|NCT05352867|OTHER|Placebo|0.5ml/person
41338980|NCT03398252|DRUG|Doxazosin XL|Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).
41338981|NCT03398252|DRUG|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
41338982|NCT01496274|BIOLOGICAL|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
41338983|NCT03552289|DEVICE|Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
41338984|NCT03552289|DEVICE|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
41338985|NCT03272880|BEHAVIORAL|Arts-Based Programming|This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
41486900|NCT03543241|DIAGNOSTIC_TEST|MyoStrain|Prior to cardiac catheterization, patients will be stress testing with low dose Dobutamine to evaluate wall motion, segmental, and global myocardial strain at rest and under stress to determine the accuracy of detecting ischemia and viability of myocardial tissue.
41486901|NCT04408599|DRUG|NC410|NC410 is an experimental antibody drug that may make the immune response more active against cancer
41016850|NCT06663111|OTHER|Blood samples for PK|Blood sampled for pharmacokinetic study
41338986|NCT00706758|BEHAVIORAL|IBS school|Structured patient group education
41338987|NCT00706758|BEHAVIORAL|IBS-guidebook|Written information - IBS-guidebook
41338988|NCT04128605|PROCEDURE|Suprascapular nerve block (SSNB)|"SSNB is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. Then, a mixture of 5 mls of Bupivacaine, 5 mls Lidocaine 1% and 10 mls of saline are injected at posterior shoulder towards suprascapular notch surrounding suprascapular nerve."
41486902|NCT04602910|DEVICE|a web-based shared decision-making tool|Five major parts were developed with the use of the action research approach. The Introduction and Options (parts 1 and 2) describe the severity of the cancer treatment and infertility and the knowledge of fertility preservation, respectively. The SDM tool was designed as a step by step process (part 3) that involves the comparison of options, patient's values and preferences, their knowledge regarding infertility and options, and reaching a collective decision. The Resources (part 4) provide information on the hospitals that provide such services, and the References (part 5) list all the literature cited in the website. The results show the web-based SDM meets both the patients' and health providers' needs and helps reproductive-age patients with breast cancer make decisions on fertility preservation.
41486903|NCT06070974|DIAGNOSTIC_TEST|CMR and blood collection|All patients enrolled will undergo 2 CMR examination (within 3-5 days post PCI and after six months), and blood collection at third day after PCI (T0). Patients recruited at Centro Cardiologico Monzino will be subjected to a blood withdrawal also at different time points: 1- 3- 6 months after STEMI (T1, T2, and T3 respectively).
40820471|NCT00701142|BIOLOGICAL|Haemocomplettan® P|Single intravenous infusion
41338989|NCT04128605|PROCEDURE|Intraarticular shoulder steroid injection (IAS)|"IAS is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. IAS is performed by injecting 40 mg of Triamcenolone Acetonide along with 2 ml of Lidocaine 1% into glenohumeral articular space"
41338990|NCT00662285|DIETARY_SUPPLEMENT|Iron supplement: Niferex 100 mg|A: 100 mg pr day in 8 days
41338991|NCT02597985|OTHER|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
41338992|NCT02597985|OTHER|Usual Care|
41338993|NCT03234270|DEVICE|Core temperature measurements|Core temperature measurements with coretemp pill
41338994|NCT01391468|DIETARY_SUPPLEMENT|Probiotics|intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations
41338995|NCT01391468|DIETARY_SUPPLEMENT|Cornstarch|placebo will be given in 6 months
41338996|NCT04057040|DRUG|PTG-300|Active
41338997|NCT04057040|DRUG|Placebo|Placebo
41338998|NCT03736551|BEHAVIORAL|5:2 diet|very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet)
41338999|NCT03736551|BEHAVIORAL|Renal Weight Management Programme|Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
41339000|NCT00572728|PROCEDURE|CT|Undergo 18F-FLT PET/CT
41339001|NCT00572728|DRUG|18F-FLT|Undergo 18F-FLT PET/CT
41339002|NCT00572728|PROCEDURE|PET|Undergo 18F-FLT PET/CT
41339003|NCT05719077|BEHAVIORAL|EDITH-HC|This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.
41339004|NCT05406245|DIETARY_SUPPLEMENT|Carbohydrate drinking|Administration of carbohydrate fluid
41339005|NCT05001568|DEVICE|Immediate in-brace correction: Conventional Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
41339006|NCT05001568|DEVICE|Immediate in-brace correction: Optimized Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
41339007|NCT05001568|DEVICE|Long-term bracing: Conventional Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
41339008|NCT05001568|DEVICE|Long-term bracing: Optimized Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
41339009|NCT00047853|DEVICE|Shock device|A participant could receive a shock or not receive as shock
40820472|NCT00701142|BIOLOGICAL|Saline solution|Single intravenous infusion
41016851|NCT06663111|OTHER|Blood samples for PK|Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.
41339010|NCT00047853|DEVICE|Acoustic startle|Acoustic startle for MEG only
40820473|NCT06379958|DRUG|leramistat 40mg|Oral capsule
40820474|NCT06379958|DRUG|Itraconazole 200 mg|Oral capsule
41339011|NCT04707924|DEVICE|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
41339012|NCT04347616|BIOLOGICAL|UCB-NK cells|Natural killer cells generated from CD34+ hematopoietic progenitor cells derived from an allogeneic umbilical cord blood
41339013|NCT04347616|DRUG|IL-2|In vivo cytokine support
41339014|NCT04123431|DEVICE|Total Hip Replacement|Primary elective total hip replacement
41339015|NCT05619003|DEVICE|Biatain Silicone Sacral dressing|Biatain Silicone Sacral will be applied over the bony prominence of the sacral area
41339016|NCT03249701|DEVICE|Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
41339017|NCT03249701|DEVICE|Electroacupuncture|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
41339018|NCT03249701|DEVICE|sham Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by transcutaneous electrical acupoint machine, even no truly actualized.
41339019|NCT01456520|DRUG|Vycavert|single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
41339020|NCT01456520|DRUG|Norco|single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
41339021|NCT01091142|DRUG|NP001|Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
41339022|NCT01091142|DRUG|Placebo|Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
41339023|NCT04616794|BEHAVIORAL|Cognitive Engagement Group|Participants in this group will be encouraged to lead a cognitively stimulating lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase cognitively stimulating activities and by assisting participants outlining goals to progressively adopt a more cognitively active lifestyle.
41339024|NCT04616794|BEHAVIORAL|Physical Activity Group|Participants in this group will be encouraged to lead a physically active lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase physical activities and by assisting participants outlining goals to progressively adopt a more physically active lifestyle.
41339025|NCT04616794|BEHAVIORAL|Diet Group|Participants in this group will be encouraged to adopt a healthy diet, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to change their diet and by assisting participants outlining goals to progressively adopt a Mediterranean-like diet.
41339026|NCT04616794|BEHAVIORAL|Multimodal group|Participants assigned to this group will select which domain they wish to tackle first. Interventions are as described for the single-domain interventions.
41339027|NCT04111653|OTHER|Mud therapy|Application of sludge poultice
41339028|NCT05907772|OTHER|No intervention|No intervention
41339029|NCT03907813|DRUG|Exparel|liposomal bupivacaine wound infiltration
41339030|NCT03907813|OTHER|Saline infiltration|saline wound infiltration
40820475|NCT06379958|DRUG|Phenytoin 100 Mg Oral Capsule|Oral capsule
40820476|NCT06379958|DRUG|Simvastatin 40mg|Oral capsule
41339031|NCT02667236|DRUG|A-101 Solution|Active Drug
41339032|NCT02667236|OTHER|Vehicle Solution|Placebo
41339033|NCT02871518|DRUG|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT
41339034|NCT02871518|DRUG|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT
41339035|NCT00568620|PROCEDURE|Placement of nasogastric feeding tube|"Glucose tolerance test via nasogastric feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
40820477|NCT06379958|DRUG|Upadacitinib 15 MG|Oral Capsule
40822990|NCT06045182|PROCEDURE|Maitland mobilization|Participants in this group will be first given hot pack and TENS for 10 min. Then they will be given Maitland Mobilizations (10 oscillations total of 3 sets )with 10 sec rest in between. Mobilization will be Unilateral or central based on the patient condition and Intensity of Mobilizations increases as per patient tolerance in 2nd and 3rd session.
41339036|NCT00568620|PROCEDURE|Nasojejunal feeding tube|"Glucose tolerance test via nasojejunal feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
41339037|NCT01463124|BEHAVIORAL|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
41339038|NCT01463124|BEHAVIORAL|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
41339039|NCT00533169|DRUG|ZD6474|Part A = Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m\^2 by mouth daily on days 2-28.
41339040|NCT00533169|DRUG|Retinoic Acid|Part B, C = 80 mg/m\^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
41339041|NCT03006900|OTHER|Pilates|Pilates
41339042|NCT03006900|OTHER|Massage|Massage
41486904|NCT02358343|BEHAVIORAL|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
41486905|NCT02358343|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
41486906|NCT02358343|DRUG|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
41486907|NCT00494039|PROCEDURE|Radioactive seed implant to prostate|
40820478|NCT05978336|BEHAVIORAL|Health Coaching Program|"The HC program will be delivered over 26-weeks. Participants will have an initial hour-long HC session where the BAP coach will conduct a brief physical assessment and work with the participant to establish their physical activity goals and develop a plan. After the initial consult, coaches will conduct 8 x 20-minute phone calls with participants over the 26-week trial decreasing from bi-weekly phone calls in weeks 1-12 to monthly phone calls in weeks 13-26.~Participants in the HC group will have an overall goal of increasing their weekly participation in moderate to vigorous physical activity by 50 minutes, via 5-, 7-, or 10-minute bouts of progressive exercises, at a rate of perceived exertion range of 13-14 (somewhat hard) by week 16. Participants will have access to specific exercise sessions made available by YouTube and/or hardcopy manuals created by the research team."
40820479|NCT05978336|BEHAVIORAL|Health Education Program|Participants will begin with a one-hour, group-based, interactive education session on falls prevention delivered either in-person or by Zoom. Following the initial education session, ED participants will receive additional group education sessions (in-person or by Zoom) with the same duration and schedule as the HC program covering a variety of healthy aging topics.
40822991|NCT06045182|PROCEDURE|Piriformis stretch|Piriformis stretch will be given to this group. In first session piriformis stretch will be given for 10 sec with 10-second resting time in between with, 7 rep total of 1 set. For the 2nd and 3rd session repetitions will be increase to 8 and 10 respectively.
41339043|NCT02398721|OTHER|Fine Needle Aspiration Cytology|
41339044|NCT01431521|DRUG|MK-4074 200 mg|2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
40822992|NCT06045182|PROCEDURE|Electrotherapy|Hot pack and TENS for 10 min
41339045|NCT01431521|DRUG|Placebo for MK-4074|2 x 100-mg capsules, orally, BID for 4 weeks.
41339046|NCT01431521|DRUG|Pioglitazone hydrochloride 30 mg|1 x 30-mg tablet, orally, once daily for 4 weeks
41339047|NCT01431521|DRUG|Placebo for pioglitazone hydrochloride|1 x 30-mg tablet, orally, once daily for 4 weeks
41339048|NCT00644124|DRUG|aflibercept|in combination with standard treatment R-CHOP
41339049|NCT05295940|DRUG|LY3841136|Administered SC.
41339050|NCT05295940|DRUG|Placebo|Administered SC.
41339051|NCT01885949|DRUG|Tivozanib|Oral
41339052|NCT01885949|DRUG|Enzalutamide|oral
41339053|NCT02076243|DRUG|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
41339054|NCT02456571|DEVICE|CTC biomarker expression prevalence|
41339055|NCT01128166|DEVICE|COGNIS CRT-D|"Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion."
41339056|NCT01333098|DRUG|Mifepristone|300mg per day, by mouth, for 21-28 days
41339057|NCT04123171|DIAGNOSTIC_TEST|Neuroimaging studies|Complementary exams are not invasive and will be performed in enrolled individuals who sign a comprehensive informed consent form
41339058|NCT02866461|OTHER|No treatment|Observation
41339059|NCT04140682|DEVICE|PAV+ mode|PAV+ mode by using Puritan-Bennett 840 ventilator
41339060|NCT04140682|DEVICE|PSV mode|PSV mode by using Puritan-Bennett 840 ventilator
41339061|NCT02688153|DEVICE|EDWARDS INTUITY|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR \& CABG.
41339062|NCT02688153|DEVICE|Stented aortic bioprostheses|In comparison to control valves available on the market.
41339063|NCT04078191|DRUG|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
41339064|NCT06417008|DRUG|HS-20117|Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)
41339065|NCT06417008|DRUG|Aumolertinib|110 mg orally once daily.
41339066|NCT02135549|DIETARY_SUPPLEMENT|SugarDown|4 or 8 gram dose in tablet form, before meals, daily for one week
41339067|NCT02135549|DRUG|Placebo Oral Tablet|Placebo comparator
41339068|NCT03510910|DRUG|Acetaminophen|acetaminophen 600 mg to be taken every 8 hours (TID)
41339069|NCT03510910|DRUG|Percocet|"Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN"
41339070|NCT05193604|DRUG|TQB2858 injection|TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.
41339071|NCT05193604|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
40822993|NCT05061108|BEHAVIORAL|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education
41339072|NCT05193604|DRUG|Gemcitabine hydrochloride for injection|Chemotherapy medicine for metastatic pancreatic cancer
41339073|NCT05193604|DRUG|Paclitaxel for injection (albumin bound)|Chemotherapy medicine for metastatic pancreatic cancer
41339074|NCT00396422|DRUG|RWJ-445380|
41339075|NCT02569333|OTHER|Educational video|iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
41339076|NCT04567420|DRUG|Palbociclib|4 week cycles
41339077|NCT04567420|DRUG|Fulvestrant|4 week cycles
41339078|NCT04567420|DRUG|Adjuvant Therapy|Standard of Care
41339079|NCT02707601|DRUG|E/C/F/TAF|150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
41339080|NCT02707601|DRUG|F/R/TAF|200/25/25 mg FDC tablet administered orally once daily
41339081|NCT02707601|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
41339082|NCT02702167|DEVICE|High-frequency rTMS|10 Hz active stimulation, once daily
41339083|NCT02702167|DEVICE|Low-frequency rTMS|1 Hz active stimulation, once daily
41339084|NCT02702167|DEVICE|Sham rTMS|Sham stimulation, once daily
41339085|NCT04471168|DEVICE|Cryo-Auriculotherapy|3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
41339086|NCT04471168|DEVICE|Sham comparator|3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
41339087|NCT02044315|DEVICE|ICD programming|
41339088|NCT06047860|RADIATION|Radiotherapy|hypofractionated radiotherapy/SBRT
41339089|NCT06047860|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor within one week of radiotherapy
41339090|NCT06047860|DRUG|Granulocyte-macrophage colony-stimulating factor subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
41339091|NCT06047860|DRUG|Interleukin 2 subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
41339092|NCT06047860|DRUG|Endostatin|Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
41339093|NCT01597440|DRUG|N-carbamylglutamate|"Active NCG \& Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner)."
41339094|NCT01597440|OTHER|Standard of Care|Standard of Care
41339095|NCT02451189|DIETARY_SUPPLEMENT|Inulin acetate ester|Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
41339096|NCT02451189|DIETARY_SUPPLEMENT|Inulin propionate ester|Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
41339097|NCT02451189|DIETARY_SUPPLEMENT|Inulin butyrate ester|Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
41339098|NCT03638336|DEVICE|ILY robotic flexible ureteroscopy|fragmentation of nephrolithiasis
41339099|NCT00938093|BEHAVIORAL|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
41339100|NCT00938093|BEHAVIORAL|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
41339101|NCT00800475|DRUG|Gemfibrozil Tablets|
41339102|NCT03128307|DEVICE|Zyppah Anti-snoring Appliance|Use of an OTC mouth guard at night to prevent snoring
41339103|NCT03417505|DEVICE|Scleral lenses treated with Tangible Hydra-PEG|Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
41339104|NCT03417505|DEVICE|Untreated scleral lenses|Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
41339105|NCT00397553|DRUG|Insulin glulisine|
41486908|NCT03795896|DIAGNOSTIC_TEST|Optic nerve sheath diameter|The intracranial pressure will be measured by the optic nerve sheath diameter and after giving the mannitol osmotherapy the intracranial pressure will be monitored by the optic nerve sheath diameter
41486909|NCT00261963|DEVICE|ultraviolet light|
41486910|NCT03666559|DRUG|Azacitidine|Chemotherapy
41339108|NCT02327078|DRUG|Nivolumab|specified dose and dosing schedule
41339109|NCT02327078|DRUG|Epacadostat|oral twice daily continuous at the protocol-defined dose
41339110|NCT02327078|DRUG|Chemotherapy|Specified dose on specified days
41339111|NCT04106180|DRUG|GM-CSF|Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.
41339112|NCT04106180|DRUG|Sintilimab|Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.
41339113|NCT04106180|RADIATION|SBRT|Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.
41339114|NCT05376956|DIAGNOSTIC_TEST|Muscle Energy Technique|Using Muscle Energy Technique in Individuals With Hamstring Shortness
41339115|NCT05376956|DIAGNOSTIC_TEST|Proprioception neuromuscular facilitation (PNF)|Using proprioception neuromuscular facilitation (PNF) in Individuals With Hamstring Shortness
41339116|NCT04090697|DRUG|Oxandrolone|Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.
41339117|NCT03580525|DRUG|Nicotine saline infusion 0.00mcg/kg/s|saline 0.00mcg/kg/s
41486911|NCT01403974|DRUG|BI 836845|Intravenous infusion once every week
41486912|NCT01520532|OTHER|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
41339118|NCT03580525|DRUG|Nicotine infusion 0.24mcg/kg/s|nicotine 0.24mcg/kg/s
41339119|NCT03580525|DRUG|Nicotine infusion 0.096mcg/kg/s|nicotine 0.096mcg/kg/s
41339120|NCT03580525|DRUG|Nicotine infusion 0.048 mcg/kg/s|nicotine 0.048mcg/kg/s
41339121|NCT03580525|DRUG|Nicotine infusion 0.024mcg/kg/s|nicotine 0.024mcg/kg/s
41339122|NCT05724381|DIAGNOSTIC_TEST|auramine phenol staining|The samples will be divided into 2 parts. The 1st part will be subjected to a direct wet saline smear, iodine smear, and concentration techniques. The 2nd part will be used to perform thin smears of the fecal concentrates and air-dried on 2 different slides. The first slide will be stained with Kinyoun's acid-fast stain and examined with the conventional light microscope and the second will be stained with auramine-phenol stain and examined with the fluorescent microscope.
41339123|NCT04460365|DIETARY_SUPPLEMENT|10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin|"This is a lutein (10mg), zeaxanthin (2mg) and meso-zeaxanthin (10mg) one-a-day food supplement which combines all three macular carotenoids.~These three nutrients are found at the back of the eye, at the macula, where they form the macular pigment (yellow colour). Meso-zeaxanthin is particularly concentrated at the centre of this pigment.~Lutein and zeaxanthin can be found in fruits and dark green leafy vegetables and meso-zeaxanthin is present in some species of fish and seafood."
41339124|NCT04460365|OTHER|Placebo|Softgel capsule containing sunflower oil (no active ingredients)
41339125|NCT00323427|BEHAVIORAL|The Living Well with Hearing Loss Workshop|Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
41339126|NCT00323427|DEVICE|hearing aid services|Standard VA audiological hearing aid dispensing services
41339127|NCT00054418|DIETARY_SUPPLEMENT|calcium carbonate|calcium 600 mg daily administered orally for one year
41339128|NCT00054418|DIETARY_SUPPLEMENT|vitamin D|vitamin D 400 U daily administered orally for one year
41339129|NCT00054418|DRUG|risedronate sodium|risedronate 35 mg weekly administered orally
41339130|NCT00054418|OTHER|placebo|placebo tablet weekly administered orally for one year
41339131|NCT05260125|DRUG|Ultrasound-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. A linear probe with a frequency of 7-8 MHz on the SonoScape A8 ultrasound device will be used for suprascapular block under ultrasound guidance. the ultrasound probe was placed in the coronal plane over the suprascapular fossa. Suprascapular fossa was scanned from medial to lateral side to identify suprascapular nerve. After identification, solution of suprascapular nerve block will be injected into the area around the nerve under the scanning with in-plane technique with a 22 gauge 90 mm spinal needle."
41339132|NCT05260125|DRUG|Anatomical Landmark-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. The suprascapular notch projection will be determined using the anatomical landmark technique defined by Dangoisse et al., and then suprascapular nerve block will be applied with a 22 gauge 90 mm spinal needle to the patients"
41339133|NCT01519349|BIOLOGICAL|rAAV1.CMV.huFollistatin344|"* First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)"
41339134|NCT04563572|DEVICE|PPG Smartwatch|Participants will then receive a PPG sensor in form of a smartwatch) model and will be instructed to wear them continuously for 48 hours. Simultaneously, a 48-hour Holter ECG will be performed. Start time on the PPG-sensor and the Holter ECG will be matched and continuous heart rhythm and -rate monitoring will be initiated. Patients will wear the devices over a 48-hour period of time.
41486913|NCT04884867|BEHAVIORAL|CBT-based supportive skills delivered by phone by lay coaches|8-10 weekly coaching sessions delivered by telephone
41486914|NCT03296384|OTHER|Clinical and environmental evaluation|For schizophrenic's patients, specific assessment will be perform
41486915|NCT06457399|DRUG|Heliox|Treatment for 30 minutes with Heliox from a commercial tank (Oxhelⓒ, Air Liquideⓒ) with a fixed mixture of 70% helium and 30% oxygen with non-rebreather mask or reservoir bag at a flow of 12-15 lpm.
41486916|NCT06457399|DRUG|Oxygen|Treatment for 30 minutes with oxygen at FiO2 of 31% with Venturi mask.
41486917|NCT03712982|BEHAVIORAL|Attention to Variability - Patient Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
41486918|NCT03712982|BEHAVIORAL|Attention to Variability - Partner Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology in their partner that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
41486919|NCT03712982|BEHAVIORAL|Attention to Variability - Patient & Partner|Same as patient and partner only conditions, just that in this condition both the patient and partner do their corresponding intervention rather than only one of them.
41156863|NCT02367742|BEHAVIORAL|EA + Resistance Training (RT)|"Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:~* Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.~* Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%."
41486920|NCT03712982|OTHER|Infertility Stories - Reading|Reading Stories About Others' Infertility Experiences
41486921|NCT00030043|DEVICE|Penetrating auditory brainstem implant|
41486922|NCT04346420|OTHER|Standard interface|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
41486923|NCT04346420|DEVICE|Double-Trunk Mask|The standard nasal cannula interface accompanied with the DTM is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
41486924|NCT00503711|DRUG|Vandetanib|100 mg every other day, 100mg once daily
41486925|NCT00503711|DRUG|Vandetanib 300 mg|300mg once daily
41486926|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus|0.5 mL, Subcutaneous
41486927|NCT01064141|BIOLOGICAL|OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines|0.5 mL, Subcutaneous and 0.5 mL, Intravascular
41486928|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines|0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous
41486929|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)|0.5 mL Subcutaneous and 0.5 mL Subcutaneous
41339135|NCT01921283|DEVICE|BIS sensor attachment|For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
41339136|NCT01921283|DRUG|no- BIS sensor attachment|
41339137|NCT05757479|PROCEDURE|Steroid-eluting stent implantation|The sinus cavity with inflammation receives one bioabsorbable steroid-eluting sinus stent.
41339138|NCT05757479|DRUG|Steroid nasal spray|1 spray into each nostril once a day.
41339139|NCT05757479|PROCEDURE|nasal saline rinses|The saltwater runs through nasal passages and drains out of the nostril.
41339140|NCT00826384|PROCEDURE|balloon catheter|transcatheter arterial chemoembolization therapy with balloon catheter
41339141|NCT01216904|DRUG|nicotine patch|7 mg patches to be worn for 16 hours per day
41339142|NCT01216904|DRUG|placebo|placebo patch to be worn 16 hours per day
41339143|NCT05263726|BEHAVIORAL|DSMP through a Mobile Applications|This interventional divided the disease self-management program manual for patients with hypertension into 4 units, including: Unit 1: hypertension brief introduction and complications. Unit 2: dietary precautions for patients with hypertension. Unit 3: medication treatments for patients with hypertension. Unit 4: the content included stress management (emotional control, spiritual support) of patients with hypertension. The experimental group received the mobile apps educational program for at least 30 minutes each session and at least once every two days. After two weeks and six weeks, a follow-up telephone interview helped to strengthen the health self-management self-confidence. The researcher used the back office administration at the computer end to observe how the experimental group operated and used the mobile devices. The effect of interventions was then evaluated after three months when the patients returned.
41339144|NCT04248686|BEHAVIORAL|CoED Online Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity
41339145|NCT04117594|DIAGNOSTIC_TEST|WB-MRI|Whole body MRI with diffusion-weighted imaging (DWI)
41339146|NCT06240624|OTHER|No intervention|No intervention will be given.
41339147|NCT03225560|OTHER|Bowel Preparation|Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
41339148|NCT05369533|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
41339149|NCT05369533|DRUG|Sinemet Pill|Sinemet 25/100 will be taken 1 hour prior to TR, for the first 18 sessions.
41339150|NCT05369533|DRUG|Placebo|Placebo will be taken 1 hour prior to TR, for the first 18 sessions.
41339151|NCT05386849|DEVICE|FUSION closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
41339152|NCT03299452|DRUG|Non Chemotherapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
41339153|NCT03299452|DRUG|Chemotherapy and target therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
41339154|NCT03299452|DRUG|Chinese herb medicine|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
41339155|NCT03507192|DEVICE|Muscle relaxation using full body massage machine|Receiving muscle relaxation machine massage every morning and evening for 30 minutes during a year
41339156|NCT05778929|DIAGNOSTIC_TEST|Radiomics Model|"A total of 694 consecutive eligible patients with first episode of acute pancreatitis that recommended for iopromide 370 mgI/ml enhanced pancreatic CT scan within 14 days after onset of symptoms (the sample size ratio of training set: test set: validation set is 5:2:3) will be sequentially enrolled at 10 sites (This study is observational in nature. The routine enhanced pancreatic CT protocol at all selected sites is similar or equivalent to that used in the PI site in the study).~Relevant clinical information of the enrolled subjects is collected. Radiomics features are extracted from the selected regions of interest on pancreatic CT images and classified. The subjects are followed up for 12 months and divided into recurrent group and non-recurrent group according to the first recurrence status."
41339157|NCT06233838|DEVICE|KHA80 hemoperfusion treatment|On the basis of hemodialysis or hemodiafiltration treatment, Jianfan KHA80 hemoperfusion treatment was given, and the frequency of hemoperfusion treatment was ≥2 times/month.
41339158|NCT01468038|DRUG|Trazodone|active trazodone and sentra pm-like placebo
41339159|NCT01468038|OTHER|Sentra PM|Active Sentra PM and trazodone-like placebo
41339160|NCT01468038|DRUG|Sentra PM and Trazodone (CoPack Kit Trazamine)|A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
41339161|NCT01468038|DRUG|Placebo trazodone and placebo Sentra PM|Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
41339162|NCT03661372|OTHER|Robot|Use of a telesimulation robot using contextual interview format.
41339163|NCT03661372|OTHER|Face-to-face|Use of face-to-face patient interview using contextual interview format.
41339164|NCT05243004|OTHER|Phone Nurse consultation|"A phone call will be made by the nurse 72 hours before the surgery. During this phone call, the nurse :~* underlines the preoperative preparation instructions (skin preparation, fasting period, specific medical instructions given by the anesthesiologist, administrative instructions)~* ensures that the reason for hospitalization is understood~* answers the patient's questions."
41339165|NCT01870791|DRUG|Omegaven|Weekly omegaven infusion in combination with EOX chemotherapy
41339166|NCT02697058|BIOLOGICAL|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
41339167|NCT02697058|DRUG|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
41339168|NCT03199144|DRUG|Chemotherapy|3 cycles of Gemzar-Abraxane
41339169|NCT03199144|RADIATION|Stereotactic radiotherapy|Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
41339170|NCT03199144|PROCEDURE|Surgery|Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
41339171|NCT01191957|DRUG|Busulphan plus Cyclophosphamide|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg"
41486930|NCT03917017|DEVICE|Radiomics and Watson artificial intelligence|"The artificial intelligence platform developed by IBM Watson can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.~The imaging histology can be used to conduct intraoperative navigation surgical resection and treatment monitoring, and established a prognosis model to predict the prognosis of patients by grading the results of postoperative follow-up and microvascular invasion of pathological liver cancer, so as to better achieve accurate diagnosis and treatment of the disease."
41486931|NCT00497952|BIOLOGICAL|hematopoetic stem cell infusion|Enriched hematopoietic stem cell infusion
41486932|NCT02093221|BIOLOGICAL|180 mg/kg Alpha1-PI|
41486933|NCT02093221|BIOLOGICAL|90 mg/kg Alpha1-PI|
41486934|NCT02093221|BIOLOGICAL|Placebo|
41486935|NCT03195777|DEVICE|PET/CT|PET/CT imaging will be performed (with fluorodeoxyglucose, \[FDG\] as a tracer). Thereafter, subjects will be monitored for development of PTS. We will then assess the ability of PET/CT top predict the subsequent development of PTS.
41486936|NCT06436040|OTHER|Pathological response assessment|The pathological response classification in our study was based on the histopathologic examination of the surgically resected specimens reviewed by two experienced pathologists.
41486937|NCT05808075|OTHER|NovaProTM Fill Universal Dental Composite|NovaProTM Fill Universal ,Nanova product
41486938|NCT04749836|PROCEDURE|His bundle pacing implantation, Left bundle branch area pacing implantation, Bachmann bundle pacing|"Different active fixation leads and the dedicated delivery sheaths are introduced via standard transvenous approach under fluoroscopic guidance. His bundle potential mapping is performed in a unipolar setting with the use of the electrophysiological system for His bundle pacing. After localizing the His bundle potential, the pacing is attempted before the lead fixation to confirm HB capture. The lead is then screwed into position. Acute HBP threshold ≤ 2.5V at 1ms is considered acceptable. On the other hand, the initial site for LBBP is approximately 1-1.5 cm distal to the HBP lead position in the RV septum along the line between the HBP site and RV apex in the right anterior oblique (30°) fluoroscopic view. Bachmann bundle pacing (upper atrial septum) will be performed with the J-stylet modification technique or with specialized catheter method using the SelectSecure active fixation lead.~Stepwise approach for conduction pacing will also be tested."
41486939|NCT06049836|OTHER|Holograms|Clinical decision making based on visualising liver 3D holographic augmented reality liver models
41156864|NCT01568112|DRUG|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
41156865|NCT01568112|DRUG|BG00012 placebo|Placebo matching BG00012
41156866|NCT01568112|DRUG|ASA|325 mg microcoated aspirin (ASA)
41486940|NCT06049836|OTHER|PDF|Clinical decision making based on visualisation of 3D liver rendering on computer monitors on a PDF file
41486941|NCT04605263|DEVICE|STN-PPN DBS Surgery|Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets
41486942|NCT04605263|PROCEDURE|Deep Brain Stimulation Surgery (DBS)|DBS lead implantation of bilateral STN
41486943|NCT00169819|DRUG|Abciximab|
41486944|NCT02400671|BEHAVIORAL|SMS messaging|
41156867|NCT01568112|DRUG|ASA placebo|Placebo matching aspirin
41486945|NCT03293784|COMBINATION_PRODUCT|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks."
41339172|NCT01191957|DRUG|Busulphan plus Fludarabine|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²"
41339173|NCT01791465|DRUG|extended-release exenatide|Single arm study - 2mg Bydureon every 7 days x 16 weeks
41486946|NCT03293784|COMBINATION_PRODUCT|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks."
41486947|NCT04068844|BEHAVIORAL|Exercise training|Exercise training, either whole body or isolated single leg
41486948|NCT06095141|DRUG|Cisplatin|Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8. The administration of other chemotherapeutic agents including gemcitabine, nab-paclitaxel, fluorouracil, irinotecan, capecitabine is applied according to the National Comprehensive Cancer Network (NCCN) guideline. PARP inhibitor will be recommended to patients with platinum-sensitive metastatic PDAC after six months of cisplatin based regimen.
41486949|NCT02876783|OTHER|Observational - No intervention|
41486950|NCT00751907|DRUG|atorvastatin|40mg daily for 4 months
41486951|NCT00751907|DRUG|Placebo|Matching placebo daily for 4 months
41486952|NCT04648566|PROCEDURE|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
41486953|NCT04648566|PROCEDURE|Intrauterine administration of sperm washing medium|Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
41486954|NCT00986180|DRUG|NUCYNTA|50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
41486955|NCT00986180|DRUG|Oxycodone IR|5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
41486956|NCT03957330|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
41486957|NCT03940794|OTHER|Verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. A transabdominal Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
41486958|NCT03997214|DEVICE|inspiratory muscle strength training|The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
41486959|NCT01915693|RADIATION|Radiotherapy|External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
41339174|NCT02305550|DEVICE|electrical pulsed plasma discharge synthesis of nitric oxide|An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
41339175|NCT01616069|DRUG|epinephrine and levosimendan|epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
41486960|NCT00521027|DEVICE|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
41486961|NCT00521027|PROCEDURE|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
41486962|NCT00349557|DRUG|bevacizumab, bicalutamide and goserelin|
41486963|NCT00349557|PROCEDURE|intensity modulated radiation therapy (IMRT)|
41339176|NCT00948285|PROCEDURE|MRI|magnetic resonance imaging (MRI)
41339177|NCT02485067|DRUG|THVD-201|Combination of Tolterodine 2mg and Pilocarpine 9mg
41339178|NCT02485067|DRUG|Placebo(For THVD-201)|
41339179|NCT02485067|DRUG|Detrusitol 2mg tablet|Tolterodine 2mg
41339180|NCT02485067|DRUG|Placebo(For Detrusitol 2mg tablet)|
41339181|NCT06412276|BEHAVIORAL|Control|Food menu will be provided as is typical for the out of home outlet
41339182|NCT06412276|BEHAVIORAL|Product price promotions removed|Food menus with no price reductions to products
41339183|NCT06412276|BEHAVIORAL|Bulk buy reductions removed|Food menus with bundles provided but not at reduced prices
41339184|NCT06412276|BEHAVIORAL|Volume value pricing removed|Food menus with proportionate pricing for multi-size products
41486964|NCT05637320|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems|The intervention arm will consist of a transdiagnostic psychotherapy program: The Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC). MATCH draws from various domains of evidence-based treatment and consists of 33 treatment modules. There are several core module sequences for problem areas such as depression, anxiety, trauma, and disruptive behavior, and a clinician can utilize these sequences based on the primary concern of the presenting child. If an individual reports additional stressors or comorbid conditions, the clinician can modify the sequence of the modules to address these comorbidities. MATCH treatment is flexible and is tailored for each individual client.
41339185|NCT06412276|BEHAVIORAL|No price-based incentives|Food menus with no price-based incentives offered
41339186|NCT01793090|DRUG|Epi-743|EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
41339187|NCT01793090|OTHER|Placebo supplementation|Placebo will be administered in the same formulation as the active comparator
41339188|NCT01725295|OTHER|NST|A form of physical therapy
41339189|NCT01725295|OTHER|Hydrotherapy|
41339190|NCT01332695|DRUG|ST101|tablets for oral administration
41339191|NCT01332695|DRUG|Placebo|placebo to match
41339192|NCT03692312|DRUG|Tideglusib|Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
41339193|NCT03692312|DRUG|Placebo|Matching placebo formulation
41339194|NCT00920946|DRUG|Dimebon|20 mg Dimebon orally TID
41339195|NCT00920946|OTHER|Placebo|Orally TID
41339196|NCT03893851|BEHAVIORAL|Interactions Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
41339197|NCT05116891|DRUG|CAN04 (nadunolimab)|FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
41339198|NCT05116891|DRUG|mFOLFOX|mFOLFOX/CAN04
41339199|NCT05116891|DRUG|DTX|DTX/CAN04
41339200|NCT05116891|DRUG|G/C|G/C/CAN04
41339201|NCT05068427|DRUG|Chidamide|20mg or 30mg orally twice per week(BIW)
41339202|NCT05068427|DRUG|Envafolimab|400mg subcutaneous infusions every 4 weeks
41486965|NCT01519986|DIETARY_SUPPLEMENT|Vitamin D3|Supplement of vitamin D3
41339203|NCT03022513|OTHER|Gluten free diet|The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
41339204|NCT01543113|OTHER|sequencing|sequencing
41339205|NCT01209572|DEVICE|calorimetric chamber|Participants stayed 26h in a calorimetric chamber. They performed a series of physical activities such as walking on a treadmill at different speeds, writing, standing, standing-sitting, stepper , rest , sleeping and eating. They also performed a power test on an ergocycle at different speeds.
41339206|NCT01209572|DEVICE|Free living conditions|Volunteers followed the protocol of doubly labeled water to evaluate their energy expenditure during 10 days in free living conditions. For this period, their heart rate, parameters of actimetry and other parameters were recorded.
41339207|NCT02724111|DRUG|sufficient dose of rocuronium|
41339208|NCT02724111|DRUG|sugammadex 10 min after position change|
41339209|NCT02310360|RADIATION|Fallypride|
41339210|NCT00549406|PROCEDURE|computerized visual training|two one-hour training sessions per week, for five consecutive weeks
41339211|NCT00549406|PROCEDURE|computerized word puzzles|two one-hour sessions per week, for five consecutive weeks
41339212|NCT00549406|PROCEDURE|video-game based visual training|two one-hour training sessions per week, for five consecutive weeks
41339213|NCT00991367|OTHER|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
41339214|NCT00991367|OTHER|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
41339215|NCT05883839|OTHER|Student Group|"Sexual Healthcare Questionnaire will be applied to nursing students to adapt it to Turkish."
41339216|NCT04528004|DRUG|Nicotinamide riboside|Nicotinamide riboside 250mg capsules
41339217|NCT04528004|OTHER|Placebo|Matching placebo 250mg capsules
41339218|NCT01047436|DRUG|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
41339219|NCT01047436|DRUG|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
41339220|NCT06440265|OTHER|AM-PAC inpatient short form (low function)|"The Activity Measure for Post-Acute Care(AM-PAC) 6-clicks instruments have advantages in that they are simple and quick to complete, easy to use within usual care and has been validated in the entire hospital population. It has gained broad adoption in acute care hospital and, although it includes items for people at lower levels of function, there is a concern of a floor effect in ICU measurement. So, new AM-PAC items are developed to measure physical function at the lowest level and added 2 new items to AM-PAC inpatient mobility short form. It lowered the floor effect and increased statistical power, measurement breath, and sensitivity.~2 new items~* Turning head~* Following simple instructions"
41339221|NCT04176718|DRUG|Daratumumab|predetermined dose, intravenously, at predetermined times per cycle
41339222|NCT04176718|DRUG|Carfilzomib|predetermined dose, intravenously, give 3 times per cycle
41339223|NCT04176718|DRUG|Pomalidomide|predetermined dose, orally, daily per cycle
41339224|NCT04176718|DRUG|Dexamethasone|predetermined dose, orally, given 8 times per cycle
41339225|NCT02027272|DRUG|Dexamethasone|Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
41339226|NCT02482740|DRUG|Letrozole|letrozole 2.5 mg qd was given for 12 months or till disease progress
41339227|NCT02482740|DRUG|tamoxifen|tamoxifen was given 20 mg qd for 12 months or till disease progress
41339228|NCT05354973|DEVICE|Consilium CareTM|This is an observational study using the Consilium CareTM smartphone ePRO application.
41339229|NCT04516824|PROCEDURE|Orthopaedic Surgical Procedures|Intramedullary nails, Dynamic Compression Plate, Dynamic Hip Screw, Manipulation Under Anaesthesia POP, Ilizarov, Cannulated Screw Fixators, Bipolar Hemiarthroplasty, Locking Compression Plate, AO External fixators, Tension Band Wiring Patella, Pelvis and Acetabulum Fixations, Elbow Reconstructions, K wiring, Disc Excision, Spine Fracture i-e TPSF, Posterior Cervical Decompression and LMS, Dura repair, AD cage,Bilateral Total Hip Replacement, Unilateral Total Hip Replacement, Bilateral Total Knee Replacement, Unilateral Total Knee Replacement, Knee Arthroscopy for Mensicectomy, Arthroscopic Anterior Cruciate Ligament reconstruction,Removal of Implant, Amputations, VAC dressings,Wound wash, Arthrotomy for Septic Arthritis, Biopsy
41339230|NCT02500472|DIETARY_SUPPLEMENT|Kava|3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
41339231|NCT05488925|DRUG|Vitamin E|Evion, 400 mg
41339232|NCT05488925|DRUG|Diclofenac Sodium|Voltral SR100, 100 mg
41339233|NCT05488925|DRUG|Piroxicam|Feldene, 20 mg
41339234|NCT05488925|DRUG|Tramadol|Tramal, 50 mg
41339235|NCT05369780|DIETARY_SUPPLEMENT|Hydrolyzed Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
41339236|NCT01759355|PROCEDURE|FDG PET/MR|Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
41486966|NCT01519986|DIETARY_SUPPLEMENT|Placebo|Placebo
41486967|NCT03055663|OTHER|Sedation by watching virtual reality sedative program|Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
41486968|NCT03055663|PROCEDURE|Sedation by using intravenous sedative|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
41486969|NCT03055663|DRUG|Midazolam|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
41486970|NCT01072474|PROCEDURE|Capnography|Capnographic monitoring
41486971|NCT01072474|PROCEDURE|Standard monitoring|Standard monitoring
41486972|NCT03597360|RADIATION|CT scan|Participants will receive the first LDIR treatment in one session on the same day, i.e., two CT scans of the brain that delivers a total X-ray dose (CTDIvol)10 of about 80 mGy. Participants will then be transported back to Baycrest Health Sciences. Participants will receive another LDIR treatment, i.e. a single CT scan of the brain (40 mGy), 2 weeks after the first session. They will receive a third LDIR treatment, i.e., a single CT scan of the brain (40 mGy), 2 weeks after the second session. Date, time and X-ray dose will be recorded for each participant and sent to their family physician for entry into in their health record.
41486973|NCT05759936|DIETARY_SUPPLEMENT|500mg seaweed|4 week supplementation of 1 capsule per day of seaweed
41486974|NCT05759936|OTHER|Placebo|4 week placebo supplement of 1 capsule per day
41486975|NCT02570113|DEVICE|Peregrine System Infusion Catheter|The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
41486976|NCT05173038|BEHAVIORAL|second ejaculate|group patients received IUI for pregnancy assistance 1 hour after the first sperm extraction. The two semen were mixed and treated.
41486977|NCT06214533|DRUG|Ropivacaine 0.5%|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.
41486978|NCT06214533|DRUG|Normal Saline|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.
41486979|NCT03187366|OTHER|Bottom-up intervention|Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.
41486980|NCT01971970|BIOLOGICAL|Infliximab|Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.
41486981|NCT01971970|BIOLOGICAL|Adalimumab|ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
41486982|NCT06158074|PROCEDURE|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 60 minutes targeted the pudendal nerve, thrice weekly for a total of 4 weeks.
41486983|NCT06158074|PROCEDURE|sacral neuromodulation|In the prone position, patients undergo sacral nerve root localization through MRI and CT fusion analysis. A 3D-printed sacral foramen puncture template is crafted for precision. Using local anesthesia, a 20G needle at a 60° angle enters the S3 sacral foramen along the template. A temporary stimulator, delivering square waves (14-35 Hz, 210-360 μs), tests motor and sensory responses to confirm accuracy. Self-fixating electrodes are then implanted, validated, and tunneled subcutaneously. External connection to a temporary stimulator provides a 4-week therapeutic experiential stimulation.
41486984|NCT03457155|OTHER|VS-I dosing in plasma samples|"VS-I dosing in plasma samples using ELISA protocol :~* At intensive care admission time~* 24h after admission time~* In case of FA occurrence~* In case of sinusal rhythm recovery (in patients with new onset FA)"
41486985|NCT04542265|COMBINATION_PRODUCT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
41339237|NCT05469100|DRUG|Selpercatinib|Administered orally
41339238|NCT00159380|DRUG|Aminoguanidine|500mg
41156868|NCT05168826|DEVICE|SAPIEN 3 Transcatheter Heart Valve|Implantation of the SAPIEN 3 valve
41339239|NCT00159380|DRUG|Placebos|2ml
41339240|NCT00369044|DRUG|prednisone|
41339241|NCT06198218|OTHER|Scapular mobilization|Group A: will be treated with manual scapular mobilization in upward rotation and downward rotation, adduction and abduction of scapula.Sets of 10 repetitions were applied with a rest interval of 30 seconds between set for 20 minutes, activity based scapular mobilization(Codman pendulum exercises, scapular pushups, band wall apart ,wall ball circles and advance study wall pushups) along with conventional physical therapy program(heating,EMS,stretching for tight muscles , strengthening exercises and graduated active exercises) for 25 min
41339242|NCT06198218|OTHER|Conventional physical therapy program|Group B:will receive conventional physical therapy program including (heating to improve circulation and release muscle tension,EMS,stretching for stiff muscle,weight bearing, strengthening exercises \& graduated active exercises)for 20 min along with activity based scapular mobilization (Codman pendulum exercises,band wall apart,wall ball circles, scapular pushups and advance study wall pushups)for 20 min with 5 min resting interval.
41486986|NCT01700049|DRUG|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
41486987|NCT03480126|OTHER|Herbal Teas|Steeped tea ingested 3 times a day for 3 mos
41486988|NCT01145430|OTHER|Laboratory Biomarker Analysis|Correlative studies
41486989|NCT01145430|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
41486990|NCT01145430|OTHER|Pharmacological Study|Correlative studies
41486991|NCT01145430|DRUG|Veliparib|Given PO
41486992|NCT00128414|DRUG|Colchicine (for 6 months)|colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.
41486993|NCT00128414|DRUG|Placebo|Tablets identical in colour, shape, and taste were provided in blister packs.
41486994|NCT02775474|DRUG|Use of Intraoperative Intravenous Methadone|The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
41486995|NCT02775474|DRUG|Use of Intraoperative Intravenous Fentanyl|The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
41339243|NCT04391153|PROCEDURE|ERCP with tissue sampling|Patients with biliary strictures undergo ERCP o EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
41486996|NCT06004219|BEHAVIORAL|Peer counseling group|A community advisory board (CAB) will be set up for need assessment and to design the peer support program. Virtual meetings will be held quarterly for year 1 and 2. The group will consist of (up to 12 members) and will include at least 2 patient partners (patients with a recently diagnosed ulcer), 2 peer pals (patients with a healed DFU), family members or caregivers (limited to only 1 person per family represented on the CAB), healthcare workers (podiatrist, nurse, or case manager), medical equipment company representatives, and others. We will ask them about potential barriers at the first meeting, have flexible meeting times, and intentionally limit the number of healthcare providers. At the last meeting, we will seek feedback and input from the CAB. In addition, this group will have the opportunity to participate in a focus group which will be moderated with a trained, bilingual assistant and will last 40-60 minutes.
41486997|NCT02814435|OTHER|Questionnaire|The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
41486998|NCT02814435|OTHER|Computerised contrast sensitivity function test|This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
41486999|NCT05709483|DRUG|Aspirin|Platelet assays including VerifyNow Aspirin assay, VerifyNow Base assay, platelet aggregometry, Thromboxana A2 levels- will be measured at baseline and 1 hour after administration of single-dose enteric-coated 81 mg aspirin
41487000|NCT00712738|DRUG|Nifedipine|
40822994|NCT02966093|DRUG|Lenvatinib|Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
41339244|NCT00020449|BIOLOGICAL|recombinant interleukin-12|
41339245|NCT00020449|DRUG|paclitaxel|
41487001|NCT00712738|PROCEDURE|Phlebotomy|
41487002|NCT00712738|PROCEDURE|Urinalysis|
41487003|NCT00712738|PROCEDURE|Echocardiogram|
41487004|NCT00712738|PROCEDURE|Electrocardiogram|
41487005|NCT05583136|DEVICE|Parietal tACS combined with visuo-attentional training|Parietal tACS combined with visuo-attentional training
41487006|NCT05583136|DEVICE|Sham (placebo) tACS combined with visuo-attentional training|Sham (placebo) tACS combined with visuo-attentional training
41487007|NCT05583136|DEVICE|Sham (placebo) tACS combined with phonics training|Sham (placebo) tACS combined with phonics training
41487008|NCT04302259|DEVICE|Intelligent Spine Interface|"ISI-C is a bi-directional, two anatomical location Epidural Electrical Stimulation (EES) system to bridge the lesion core in patients with chronic complete and incomplete spinal cord injury (SCI). This Intelligent Spine Interface, or ISI will interpret recorded neural information from above a spinal cord lesion and transfer that information, via deep neural network-based interpreters (i.e. models), to stimulation sites (electrodes) below the lesion with the aim of restoring volitional control of the lower limb."
41487009|NCT04525638|DRUG|177Lu-Dotatate|7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
41487010|NCT04525638|DRUG|Nivolumab|240 mg flat dose of nivolumab intravenously as a 30-minutes infusion
41487011|NCT06258759|BIOLOGICAL|autologous platelet-rich plasma supplement|the semen of the additional autologous platelet-rich plasma supplement group will be added by 5% PRP and mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
41487012|NCT06258759|BIOLOGICAL|no autologous platelet-rich plasma supplement|the semen mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
41487013|NCT00203970|BEHAVIORAL|Observation|Using a data abstraction form, we wish to gather the following information: 1) Patient demographics 2) identity of the attending, residents, and interns caring for the patient 3)whether the patient had any absolute or relative contraindications for receiving LMWH 4) how the patient was treated for his/her condition
41487014|NCT06148571|DEVICE|left bundle branch area pacing|left bundle branch area pacing locates ventricular lead into the interventricular septum to capture left bundle branch areas.
41487015|NCT04674397|RADIATION|Radioisotope GFR test|
41487016|NCT00903448|DRUG|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
41487017|NCT00903448|DRUG|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
41487018|NCT02372071|DEVICE|BiliCare|Two measurements with the BiliCare device
41487019|NCT05178433|COMBINATION_PRODUCT|Use baby moisturizers by NeoChine|During continuous phototherapy, use skin basic care and protection in combination with baby moisturizing products, use the whole body twice a day, and the amount of each time is not less than 5 grams.
41339246|NCT00020449|DRUG|pegylated liposomal doxorubicin hydrochloride|
41339247|NCT00126425|DRUG|123I-mIBG (meta-iodobenzylguanidine)|Single dose
41339248|NCT04126460|DRUG|Toripalimab|Toripalimab is a type of PD-1 antibody
41339249|NCT02177214|PROCEDURE|MRI scan|Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
41339250|NCT03743298|DRUG|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
41487020|NCT01718548|DIETARY_SUPPLEMENT|Cordyceps Sinensis (CS) and Lingzhi|
41487021|NCT01718548|DIETARY_SUPPLEMENT|Tea and Flour|Placebo
41487022|NCT01087671|DRUG|tafluprost|prostaglandin analogue
41487023|NCT00609466|DRUG|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
41487024|NCT00609466|DRUG|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
41487025|NCT00609466|DRUG|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
41487026|NCT04489758|DIAGNOSTIC_TEST|X-ray velocimetry analyzed by 4Dx XV Ventilation Analysis|Fluoroscopy will be performed for a complete tidal breath and full exhalation at 5 angles (AP, +/- 36 degrees from AP, and +/- 72 degrees from AP) while the patient's arms are raised overhead. 4Dx XV Ventilation Analysis software will be used to analyze these images. Both groups will also undergo pulmonary function testing and take a questionnaire regarding respiratory symptoms.
41339251|NCT01426724|DRUG|Contrast Enhanced Ultrasonography|Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
41339252|NCT05845411|BEHAVIORAL|Mindful Eating|Nutritional advice through expository content, group discussion, and exchange of experiences on self-knowledge, food awareness, and relationship with food and the body.
41339253|NCT05845411|OTHER|Standard dietary treatment|Hypocaloric dietary prescription and nutritional education.
41339254|NCT02450500|BEHAVIORAL|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
41339255|NCT04753723|COMBINATION_PRODUCT|Gentamycin with Platform Wound Device|Treatment of wounds with gentamycin and covered with platform wound device.
41339256|NCT03449706|DRUG|Early combination anti-retroviral treatment|Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
41339257|NCT00595868|DRUG|Varenicline|0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
41339258|NCT00595868|DRUG|Placebo|same as Varenicline arm
41339259|NCT01453933|DRUG|raltegravir|Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
41339260|NCT00722098|BIOLOGICAL|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
41339261|NCT00722098|BIOLOGICAL|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
41339262|NCT05375825|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery: minimally invasive (VATS/robotic) or open (thoracotomy)
41339263|NCT05375825|DRUG|LMB-100|1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery
41339264|NCT05375825|DIAGNOSTIC_TEST|Immunohistochemical Assay for Mesothelin|Performed at screening to determine mesothelin expression; separate testing of tumor mesothelin expression will be assessed retrospectively in resected tumor tissues. The device is not diagnostic; protocol assessment of mesothelin expression status will only be used to help to increase the possibility that all persons enrolling on the study might derive benefit from therapy.
41339265|NCT04639505|DIAGNOSTIC_TEST|ELISA|ELISA kit detecting the serum AMH level
41487027|NCT05919121|OTHER|Therapeutic exercise|"1. Stretching exercise of posterior shoulder capsule~2. Strengthening exercises: consists of 6 strengthening exercises all of which have been recommended as essential for any shoulder rehabilitation program.~3. The remaining 2 exercises are the seated press-up and the elbow push up. Both will be performed to fatigue or for a maximum of 25 repetitions. The quality of all repetitions of each exercise will continuously monitored by the investigator of the study"
41339266|NCT04639505|DIAGNOSTIC_TEST|Chemiluminescence|CLIA method detecting the serum AMH level
41487028|NCT05919121|OTHER|hydrocortisone phonophoresis|In this study, the effective area of radiation (ERA) in the mode continuous (100 percent) is 5 cm2, in 1 MHz and 0.7 W/cm2, with four ERA treated areas. Therapy lasted five minutes (three minutes in the insertion of the supraspinatus and 37 two minutes in the infraspinatus insertion) three times weekly over 6 weeks in addition to therapeutic exercises
41487029|NCT05919121|OTHER|hydrocortisone iontophoresis|A direct current electrical stimulation unit will be used to apply iontophoresis. The unit has two electrodes; one electrode is for the negative current, and one is for the positive current. The Active (Negative) electrode will be placed on the anterolateral aspect of the shoulder joint. The passive electrode: will be placed on the upper arm region. Intensity of the current: Between the range of 3-5 mA at the point of sensation of patient was set. Treatment duration: Calculated accordingly with intensity of current. Method of application: hydrocortisone gel 10% will be administered by applying on the active rubber electrode for each session three times weekly over 6 weeks in addition to therapeutic exercises.
41487030|NCT05566548|DIAGNOSTIC_TEST|Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species|It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.
41487031|NCT05259878|OTHER|Adverse Childhood Events|"• The Adverse Childhood Events (ACE) scale is a validated 10-item binary questionnaire (yes or no) that retrospectively measures domains of physical, emotional, and sexual abuse in the first 18 years of life. Scores range from 0 to 10 with higher scores indicating more adverse experiences during patients' childhood."
41487032|NCT00004218|DRUG|chlorambucil|
41487033|NCT00004218|DRUG|cyclophosphamide|
41487034|NCT00004218|DRUG|doxorubicin hydrochloride|
41487035|NCT00004218|DRUG|fludarabine phosphate|
41487036|NCT00004218|DRUG|prednisolone|
41487037|NCT00004218|DRUG|vincristine sulfate|
41487038|NCT04614623|DEVICE|AHCL pump|Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia
41487039|NCT04614623|OTHER|Video conferencing Application|Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control
41487040|NCT04149795|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
41339267|NCT04803890|PROCEDURE|"No-Touch Radiofrequency Ablation"|"No-Touch Radiofrequency Ablation Using Octopus Electrodes and Combined RF Energy Delivery Mode"
41339268|NCT06167772|DIETARY_SUPPLEMENT|BCAA|"branched-chain amino acid (bcaa) (ratio valine:leucine:isoleucine = 1.2:2:1) 40 g/day (leucine 19 g/day) form: powdered bcaa sealed in 8 g sachet package or bcaa parenteral 250 mL per bag.~frequency: 1 sachet bcaa dissolved in oral nutrition supplement (standard nutrition) 5 times per day, or bcaa parenteral, or combination of bcaa enteral \& parenteral.~duration: 10 days"
41339269|NCT06167772|OTHER|Standard nutrition|Target energy of 20 kcal/kg BW/day Target protein ratio protein:non-protein calorie 1:70
41487041|NCT00415844|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
41487042|NCT00658645|DRUG|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
41487043|NCT00658645|DRUG|Placebo|Encapsulated tablets, orally, 12 weeks
41487044|NCT00658645|DRUG|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
41487045|NCT03358745|OTHER|Standard meal, bread/butter as starter|Reference lunch. Bread and butter are eaten during the first 15 min. Soup, cheese and salad are eaten within the following 15 min.
41487046|NCT03358745|OTHER|Standard meal with soup as starter|Lunch meal in which soup is eaten during the first 15 min. Bread, butter, cheese and salad are eaten within the following 15 min.
41339270|NCT06167772|OTHER|Standard physiotherapy|A symmetric biphasic rectangular pulse was employed, with a frequency of 100 Hz, pulse width of 500 µs, Ton 5 s, Toff 25 s, ramp up of 1 s and ramp down of 1 s.
41339271|NCT01856803|DRUG|anti thymoglobulin|
41339272|NCT05326074|OTHER|Animal assisted therapy cohort|A therapy dog will be present in the room during the routine outpatient psychiatric visit.
41339273|NCT03307018|PROCEDURE|Postoperative systematic bronchial aspiration.|Postoperative flexible bronchoscopy and systematic bronchial aspiration.
41339274|NCT00373906|DRUG|Bortezomib (Velcade)|
41339275|NCT06417268|PROCEDURE|Caudal epidural analgesia|"patient will be placed in the left lateral position with flexed hips.After palpating the landmarks (the upper posterior iliac spine and sacral hiatus from the edges of an equilateral triangle), an epidural puncture is performed in the most proximal region of the sacral hiatus with the needle inclined 45-60° to the skin. While palpating with the index finger of the left hand, the needle is inserted immediately below the spinous process S4.~After perforating the membrane, the needle will be advanced no more than 1-3 mm to avoid a bloody puncture or an intrathecal injection, The confirmation of the correct position of the caudal needle before injection by performing the modified 'swoosh' test performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of saline. Bupivacaine 0.25% at a dose of 1 ml/kg will be injected, with care taken not to exceed the maximum recommended dose (2 mg/kg)."
41339276|NCT06417268|PROCEDURE|Ultrasound-guided Combined Pericapsular Nerve Group Block|"With supine position, the probe will be put in a transverse plane along the anterior inferior iliac spine (AIIS) to identify the iliopsoas muscle, femoral nerve, and femoral artery (FA).~Then the probe will be rotated counter clockwise to align with the pubic ramus to visualize the AIIS, iliopsoas prominence (IPE), FA, iliopsoas, and iliopsoas notch.~Under direct vision, a 22-gauge, 50-mm echo needle will be advanced in the lateral-medial plane between the psoas tendon and the pubic ramus until the needle tip touches the IPE. The needle will be withdrawn, and after negative aspiration, 1 ml/kg (Bupivacaine 0.25%) is injected"
41339277|NCT06417268|PROCEDURE|Ultrasound-guided Lateral Femoral Cutaneous Nerve Block|patient remains supine, and the transducer is parallel to the inguinal ligament. With the femoral artery and vein as guidance, the lateral part of the sartorius muscle and fascia lata is visualized. Approximately 3 cm inferior from this point, the branches of the lateral femoral cutaneous nerve are visualized in the hypoechoic fat-filled subfascial space between the sartorius muscle medially and the tensor fascia lata muscle laterally. A 22-gauge, 50-mm needle is inserted with in plane approach at a shallow angle to reach the area of the nerve and after negative aspiration, 0.1 ml/kg (Bupivacaine 0.25%) is injected.
41339278|NCT06417268|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
41339279|NCT06417268|DRUG|Morphine|If a FLACC pain Score is ≥ 4/10, the patient in the PACU will receive morphine (intravenous, 0.03 mg/kg), and the maximum allowed dose is 0.1mg/kg every 4 hours.
41339280|NCT06417268|DRUG|Acetaminophen|P atients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
41487047|NCT03358745|OTHER|Standard meal with cheese as starter|Lunch meal in which cheese is eaten during the first 15 min. Bread, butter, soup and salad are eaten within the following 15 min.
41487048|NCT03358745|OTHER|Standard meal with salad as starter|Lunch meal in which salad is eaten during the first 15 min. Bread, butter, soup and cheese are eaten within the following 15 min.
41487049|NCT06352229|BEHAVIORAL|Playful Learning in Infancy Program|Research-based knowledge on play with babies delivered to the parents systematically by public health visitors based on a manual, activity cards, and video clips at four time points from 0 to 12 months postpartum.
41487050|NCT06352229|BEHAVIORAL|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
41487051|NCT05615688|PROCEDURE|Pain Intensity following Placement of Orthodontic Separators|Elastomeric separators will be placed on the mesial and distal of lower first permanent molars for a total of four separators per subject. Subjects will wear receive an activity monitor prior to placement of elastic separators and instructed to wear it 24/7 unless showering or swimming. Subjects will complete a recurrent Pain Scale Questionnaire 2-4 hrs after placement of elastics and every 24 hrs from day 2- 7.
41487052|NCT05351554|DRUG|Namilumab|Namilumab administered subcutaneously
41487053|NCT05351554|DRUG|Placebo|Placebo administered subcutaneously to match namilumab dosing
41487054|NCT05351554|DRUG|Open label Namilumab|Namilumab administered subcutaneously
40820480|NCT04043234|DEVICE|RESCU|Retrospectively Supervised Classification Updating (RESCU) is founded on two innovations that promise significant improvement in performance and outcome. The first is a highly robust machine intelligence algorithm, an Extreme Learning Machine with Adaptive Sparse Representation (EASRC), and the second is a novel adaptive learning algorithm and communication interface we call Nessa. We contend that these two technologies allow the prosthetic device to adapt to its user from the initial fitting through continuing, long-term use in the activities of daily living, shifting the paradigm of training from the current prospective data gathering methods to a more dynamic retrospective application.
41487055|NCT05351554|DRUG|Prednisone|Prednisone or equivalent
41487056|NCT04832321|OTHER|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan man with different profiles of illness severity, treatment, and treatment response.
41487057|NCT02316249|DRUG|Estradiol|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
41487058|NCT02316249|OTHER|placebo|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
41487059|NCT00204165|PROCEDURE|MRI of the small bowel|
41487060|NCT03247517|DRUG|Placebo|Placebo was administered once daily
41487061|NCT03247517|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
41487062|NCT03247517|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
41487063|NCT05727371|COMBINATION_PRODUCT|Regen Matrix-PRP-XLHA|Single intra-articular injection at Day 0
41339281|NCT00432562|DRUG|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
41339282|NCT05824767|DRUG|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring peptide hormone of the same name which is a component of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II (Giapreza) was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
41339283|NCT06096389|OTHER|100 Drop Jumps|100 drop jumps from 60 cm height. Divided into 5 sets of 20 reps
41339284|NCT06096389|DIETARY_SUPPLEMENT|Whey supplementation|Consume whey protein isolate based on subjects' daily protein intake
41339285|NCT06096389|DIETARY_SUPPLEMENT|Carbohydrate supplementation|Consume carbohydrate (isocaloric to whey)
41339286|NCT06096389|DIETARY_SUPPLEMENT|House cricket supplementation|Consume defatted house cricket powder based on subjects' daily protein intake
41339287|NCT03771989|BIOLOGICAL|autologous, micro-fragmented adipose tissue|"The active treatment is an intra-articular injection with autologous, microfragmented adipose tissue prepared using the Lipogems system.~Implantation of the graft is performed with the patient supine using two injections sites in order to reduce the risk of extra-articular injection."
41339288|NCT03771989|OTHER|Saline|The placebo is an injection with saline
41339289|NCT02443155|DRUG|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
41339290|NCT02443155|DRUG|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
41339291|NCT02443155|DRUG|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
41339292|NCT04913571|DRUG|Eribulin|Eribulin
41339293|NCT04913571|DRUG|Tislelizumab|Tislelizumab
41339294|NCT06168474|OTHER|Simplified layered consent form|The simplified consent form includes all essential elements of trial consent including an explanation of the trial procedures, data and sample collection, and follow-up information. The form also outlines important ethical considerations for patients, such as confidentiality, regulatory and safety requirements, the ability to drop out, and the necessary process and contact numbers for grievances or feedback. In addition to the text, the form includes links to additional written information and videos that can be accessed on top of the simplified informed consent form (i.e., the additional layers in the layered consent process). These materials are hosted on the main SNAP trial website (https://www.snaptrial.com.au/patients) and are available in English and French. Participants will be able to access these directly through embedded hyperlinks using provided electronic tablets.
41339295|NCT06168474|OTHER|Full-length consent form|The full-length informed consent form contains all information upfront. Links to additional information will not be provided on the form but are freely available on the Internet should the participant wish to access them.
41339296|NCT04880460|DIETARY_SUPPLEMENT|Magnesium Glycinate tablet 200mg|Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs
41339297|NCT04880460|DIETARY_SUPPLEMENT|Placebo tablet 200mg|Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs
41339298|NCT03054740|DRUG|Gebauer Ethyl Chloride|Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
41339299|NCT03054740|DRUG|Nature's Tears|Sterile water mist will be administered 1-2 sprays prior to intravenous access
41487064|NCT05727371|DEVICE|Hylan G-F 20|Single intra-articular injection at Day 0
41487065|NCT05727371|DRUG|Placebo|Single intra-articular injection at Day 0
41487066|NCT04029441|OTHER|the eradication Hp|the eradication of Hp based on antimicrobial susceptibility test
40820481|NCT04043234|DEVICE|Pattern Recognition|Pattern recognition prostheses associate the patterns of activity of multiple EMG sites to the action of a prosthesis. Such strategies have historically required prospective calibration of the EMG activation patterns.
40820482|NCT05947565|DIAGNOSTIC_TEST|Invasive Urodynamic Study|"Invasive Urodynamic Study (Filling cystometry and pressure-flow study) Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped.~While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded."
40820483|NCT05313321|DEVICE|Primary total hip arthroplasty receiving the Insignia Stem|Patients receiving the Insignia Stem and associated Stryker Acetabular Component for total hip arthroplasty
41339300|NCT04691557|OTHER|Mobile Health Application|YoungAsthma is a web-based mobile health app has been developing user-focused for adolescents with asthma and evidence-based by the research team. It is the integrated version of the knowledge content to software that enables effective management of asthma by strengthening the interaction between adolescents and healthcare professionals.
41339301|NCT04691557|OTHER|Usual Care|Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by specialist training nurse for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this nursing intervention that is only one-off and consist face-to-face training with adolescents video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
41339302|NCT02597192|OTHER|probiotic oral hygiene products with Bacillus (PIP, Chrisal)|products with Bacillus probiotics
41339303|NCT02597192|OTHER|oral hygiene products without Bacillus|products without Bacillus
41339304|NCT02257125|BEHAVIORAL|high incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
41339305|NCT02257125|BEHAVIORAL|low incentive|"Subjects are required to use their arms in order to control a virtual hand on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards."
41487067|NCT02116959|DRUG|Melphalan|
41487068|NCT02116959|DRUG|Carboplatin|
41487069|NCT02116959|DRUG|Etoposide|
41487070|NCT02116959|DRUG|Vincristine|
41339306|NCT04888728|DRUG|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
41339307|NCT04888728|DRUG|Nebivolol|Nebivolol
41339308|NCT04888728|DRUG|Paroxetine|Paroxetine
41339309|NCT02122055|DRUG|Fentanyl|Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
41339310|NCT02122055|PROCEDURE|Sedation assessment|Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.
41339311|NCT02122055|PROCEDURE|Screen of weaning|1. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，
41339312|NCT02122055|DRUG|Propofol|Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
41339313|NCT02122055|DRUG|Midazolam|Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
41339314|NCT02122055|DRUG|Dexmedetomidine|After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
41339315|NCT05169736|BEHAVIORAL|Cognitive Behavioural Therapy|Intervention based on cognitive behavioural therapy principles and adapted to mental health problems related to the climate crisis. Intervention's main purpose is to increase management of mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
41339316|NCT04229069|DIETARY_SUPPLEMENT|alkaline salt mixture|blood and tissue alkalinisation
41339317|NCT04229069|DIETARY_SUPPLEMENT|placebo|no blood and tissue alkalinisation
41339318|NCT05254587|DEVICE|IOLMASTER 700 TK|4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett True K Classic K, Barrett True K TK) will be performed using the preoperative biometry and post operative refraction data.
41487071|NCT02195466|DRUG|Tipranavir (TPV)|500 mg bid on days 7-14
41487072|NCT02195466|DRUG|Ritonavir (RTV)|200 mg bid on days 7-14
41487073|NCT02195466|DRUG|Fluconazole (FCZ)|200 mg loading dose on day 1, followed by 100 mg qd until day 13
41487074|NCT02668926|DRUG|Lisdexamfetamine, d-amphetamine, Placebo|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
40820484|NCT02357966|BIOLOGICAL|514G3|True Human Monoclonal Antibody
40820485|NCT02357966|DRUG|Placebo|Buffered saline solution
40820486|NCT02357966|DRUG|Standard IV antibiotic therapy|standard antibiotic therapy will be determined by the attending physician and will be guided by the results of cultures with sensitivities.
40820487|NCT03848208|DRUG|cytisine|cytisine film-coated oral tablet
40820488|NCT03848208|DRUG|placebo|matching placebo oral tablet
40820489|NCT00840047|DRUG|Methionine|Intravenous injection
40820490|NCT01787396|DRUG|Gemigliptin 50mg|
40820491|NCT01787396|DRUG|Placebo(Metformin)|
40820492|NCT01787396|DRUG|Metformin|
40820493|NCT01787396|DRUG|Placebo(Gemigliptin)|
41339319|NCT00162708|PROCEDURE|Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)|
41339320|NCT00162708|PROCEDURE|Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)|
41339321|NCT00162708|DRUG|CDDP, 5 Fu|
41339322|NCT01297023|DIETARY_SUPPLEMENT|calcium phosphate|20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\]
41339323|NCT01297023|DIETARY_SUPPLEMENT|vitamin d|20 subjects consume for 8 weeks a bread with vitamin d3 \[10µg/d\]
41339324|NCT01297023|DIETARY_SUPPLEMENT|calcium phosphate and vitamin d|20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\] and vitamin d3 (10µg/d\]
41487075|NCT02668926|DRUG|d-amphetamine, Placebo, Lisdexamfetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
41487076|NCT02668926|DRUG|Placebo, Lisdexamfetamine, d-amphetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
41339325|NCT01297023|OTHER|placebo|All participants consume two weeks before intervention a bread without calcium an vitamin d.
41487077|NCT00955136|DEVICE|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
41339326|NCT03275805|OTHER|Duration of Pavlik Harness treatment|The only intervention that varies from standard of care (12 weeks of treatment) will be the duration of bracing (for the treatment to normalization arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
41339327|NCT03275805|OTHER|12 week standard of care|The intervention for this arm will be standard treatment for this pathology.
41487078|NCT00672165|BIOLOGICAL|ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195|A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
41487079|NCT06182904|DEVICE|Dynamic compression plate|Fixation of fibula in some cases with dynamic compression plate
41487080|NCT04941521|DRUG|Exenatide 2 mg [Bydureon]|Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
41339328|NCT05218538|DIAGNOSTIC_TEST|Fibroscan (non interventional)|An elastography test that includes an ultrasound wave imaging of the liver to estimate liver fatness, in combination with a proprioty examination of the liver stiffness.
41339329|NCT06074718|OTHER|pricking therapy and wheat grain moxibustion|pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points
41339330|NCT02176980|BEHAVIORAL|Brief alcohol counseling|Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
41339331|NCT02176980|BEHAVIORAL|Group and Individual Therapy Sessions|Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
41339332|NCT01686347|DRUG|ropivacaine|
40820494|NCT00396006|BIOLOGICAL|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
41339333|NCT04927351|BEHAVIORAL|Electronic Medical Record Based Discharge Medication Order Set|New medication discharge order set including recommended opioid quantities, adjunct pain medication
41339334|NCT05355818|DRUG|Delgocitinib|Cream for topical application
41339335|NCT05355818|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.
41339336|NCT01922986|DEVICE|active rTMS|10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
41339337|NCT01922986|DEVICE|sham rTMS|20 minutes of sham rTMS stimulation
41339338|NCT01922986|BEHAVIORAL|conventional stroke therapy|conventional stroke therapy consisting of exercises and physical training
41339339|NCT02020291|DRUG|Foxy-5|
41339340|NCT04410081|DRUG|14C-lazertinib|A single oral dose of 14C-lazertinib will be administered.
41339341|NCT05844774|DEVICE|HPI (using HemoSphere) - guided algorithm|Treatment of hypotension guided by the hypotension prediction index. Patients will receive treatment following the predetermined HPI-algorithm when the HPI exceeds 85%.
41339342|NCT05844774|DEVICE|Treatment of hypotension following standard of care|Patients receive standard of care treatment for hypotension, with a goal-mean arterial pressure (MAP) of 65mmHg.
41339343|NCT04553978|DRUG|WD-1603|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
40820495|NCT06607887|DRUG|IV antibiotic|Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.
40820496|NCT06607887|DRUG|Oral antibiotic|Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.
41339344|NCT03396640|PROCEDURE|Unicondylar Knee Arthroplasty|"Incision will be midline incision, as with a TKA, for maximum security of blinding.~Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not."
41339345|NCT03396640|PROCEDURE|Total Knee Arthroplasty|Incision will be midline incision, as standard. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.
41339346|NCT01966653|DRUG|nitrofurantoin|nitrofurantoin 100 mg po tid for 5 days
41339347|NCT01966653|DRUG|fosfomycin|fosfomycin 3g po single dose
41339348|NCT03787095|BIOLOGICAL|Cemiplimab|Administered as an intravenous (IV) infusion
41339349|NCT03787095|BIOLOGICAL|Placebo|Diluent for REGN2810, administered as an IV infusion
41339350|NCT04386473|DEVICE|pacemaker|electrode is implanted in left bundle branch in LBBP; electrode is implanted in right ventricular outflow tract septal in RVOP
41339351|NCT02785666|DRUG|grazoprevir/elbasvir, ribavirin|To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
41339352|NCT02785666|BEHAVIORAL|Behavioural Intervention|To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
41339353|NCT05935475|PROCEDURE|Anatomical landmark guided dialysis catheter insertion|.: Before insertion, the catheter depth was calculated from the insertion point to the catheter tip point (midway the vertical line from the clavicular head of sternocleidomastoid to inter nipple line.
41339354|NCT05935475|PROCEDURE|ECG guided dialysis catheter insertion|after inserting the dialysis catheter into right IJV, the guidewire will be then withdrawn until the tip to be exactly positioned at the entry of the Superior Vena Cava in the right atrium. This will be ECG guided: the p wave appears as biphasic wave in the RA then the catheter will be withdrawn at 0.5 cm intervals until the P-wave returned to a normal configuration. (At that point, the catheter will be secured at the skin with suture and dressed with a transparent dressing
41339355|NCT01924195|DRUG|Anlotinib|Anlotinib QD po.
41339356|NCT01924195|DRUG|Placebo capsule|Placebo QD po.
41339357|NCT04741295|DRUG|Low molecular weight heparin|Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
41339358|NCT04976478|DRUG|Nimotuzumab|Patients receive Nimotuzumab: 200mg, intravenous infusion, weekly for 6 weeks.
41339359|NCT04976478|RADIATION|EBRT combined with brachytherapy|"IMRT/VMAT are adopted. A total dose of 45-50.4 Gy, 1.8\~2.0Gy/f, 25\~ 28F in pelvic and/or extension filed. For patients with metastasis in pelvic lymph node and abdominal para-aortic lymph node, the dose of radiation in local lesion will be increased to 60\~66Gy. For patients at stage IIIB, concurrent radiation will be given in parametrial extension or in the late course the dose will be increased to 60Gy.~Brachytherapy: Three dimensional high dose rate brachytherapy is used with HR-CTV D90 cumulative dose of 80\~85Gy (EQD2); If the tumor diameter is ≥4cm, HR-CTV D90 cumulative dose is ≥87Gy (EQD2). Brachytherapy combined with external beam radiotherapy will be completed within 8 weeks."
41339360|NCT05841641|DEVICE|Laser Bandage|The Diode Laser will create a biological bandage at a wavelength of 810 nm, set at 5W in continuous-wave mode, applied via a 400-µm optical fibre.
41339361|NCT05841641|PROCEDURE|Hemostatic agent with surgical stent|Following graft harvesting, the donor site was secured with a hemostatic agent and protected with a palatal stent
41339362|NCT05788029|PROCEDURE|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy
41339363|NCT05788029|PROCEDURE|open pancreaticoduodenectomy|open pancreaticoduodenectomy
41339364|NCT02611518|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
41339365|NCT02611518|DRUG|JNJ-54861911|JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
41339366|NCT02611518|DRUG|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
41339367|NCT02848313|DRUG|Elamipretide|40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
41339368|NCT00625014|DRUG|Haloperidol|Haloperidol 3 mg/day for 8 days
41339369|NCT01083225|BEHAVIORAL|Client feedback|Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
41339370|NCT01083225|BEHAVIORAL|Treatment as usual|Treatment as usual, consultations
41339371|NCT02388672|DIETARY_SUPPLEMENT|decaffeinated coffee|Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
41339372|NCT02388672|DIETARY_SUPPLEMENT|chlorogenic acid|Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
41339373|NCT02388672|DIETARY_SUPPLEMENT|green coffee bean extract supplement|Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)
41339374|NCT02388672|DIETARY_SUPPLEMENT|placebo|Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)
41339375|NCT05018468|DEVICE|Ventilation|Patients in group 1 undergo ventilation with an anatomical facial mask and 100% oxygen for three minutes. Patients in group 2 undergo ventilation with a nasal mask and 100% oxygen for three minutes. In both groups, ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
41339376|NCT00829062|DEVICE|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
41339377|NCT00148525|BEHAVIORAL|Social Cognitive Theory|6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.
41487081|NCT04941521|BEHAVIORAL|Drug Counseling|Once weekly drug counseling sessions for cocaine use with trained masters-level therapists.
41487082|NCT04273581|DRUG|placebo|100mg/d，qn，for 14 days.
41156869|NCT06395961|PROCEDURE|high ankle block|"The block position is in the middle and lower third of the calf, about 15cm above the inner or outer ankles. 0.375% ropivacaine is used for the block and the total dose is 35ml. The ultrasound probe is placed vertical to the longitudinal axis of the body. On the lateral of tibia and fibula, 5ml of local anesthetic was injected to block the superficial peroneal nerve and 10ml for the deep peroneal nerve. On the posterior of the calf, 10ml of local anesthetic was injected to block the tibial nerve and 5ml for the sural nerve. On the inner side of the calf, 5ml of local anesthetic was injected to block the saphenous nerve. The water separation technique is used and 2ml of physiological saline is injected before blocking to clarify the position of the needle tip and avoid nerve damage. 20 minutes after, the effect was measured using acupuncture by visual analogue scale (VAS) score. If the VAS score is less than 3, the block is considered successful and surgery is immediately performed."
40820497|NCT02079831|BEHAVIORAL|Energy Restriction|"Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity."
41339378|NCT00148525|BEHAVIORAL|goal system theory|This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.
40820498|NCT02079831|BEHAVIORAL|Higher protein|The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
41339379|NCT03458403|PROCEDURE|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for. The endoscope is removed halfway up the esophagus and inserted into the pylorus to the descending duodenum. The gesture is repeated three times.
41339380|NCT00798473|DRUG|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
40820499|NCT02079831|BEHAVIORAL|Lower Protein|The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
40820500|NCT03945721|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring."
40820501|NCT03945721|RADIATION|Radiation Therapy|radiation therapy
40820502|NCT02338895|DEVICE|Ultrasound|Ultrasound of inferior vena cava and kidneys
40820503|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
41339381|NCT00798473|OTHER|IV saline infusion|
41339382|NCT05267483|OTHER|No intervention|No intervention
41339383|NCT06393413|DRUG|Jiedu Yizhi Formula|Observation after 24 weeks of drug treatment
41339384|NCT06393413|DRUG|Donepezil Hydrochloride Tablets|Donepezil Hydrochloride Tablets
41339385|NCT01730001|PROCEDURE|Early Intubation|
41339386|NCT01730001|PROCEDURE|Late intubation|
41339387|NCT05117268|PROCEDURE|SDF Application for caries arrest|Intervention will be performed by trained consultants following the recommended protocol for SDF application: (A) Gross debris will be removed from cavity to allow better contact with SDF; (B) Protective coating of petroleum jelly will be applied to surrounding facial skin and lips to prevent chances of temporary tattoo formation; (C) Area to be treated shall be isolated using cotton rolls and saliva ejectors to prevent gingival irritation; (D) Extra caution will be exercised when applying SDF on primary teeth adjacent to permanent teeth to avoid inadvertent black staining; (E) One drop will be used used for the whole appointment. Bent micro-brush is to be used for application time of 1 min is to be used to reduce systemic absorption; (F) Compressed air shall be applied with gentle flow for up to 3 minutes. Entire dentition will be treated with sodium fluoride varnish to prevent caries
41339388|NCT05117268|PROCEDURE|Glass ionomer restoration|The lesions of control group glass ionomer restoration group will be treated according to following clinical protocol: (A) Isolation of treatment area using cotton rolls and saliva ejectors; (B) Carious lesion excavation using high speed handpiece; (C) High viscosity glass ionomer cement mixed following manufacturer's instructions; (D) Cavity will be slightly overfilled using a flat plastic instrument, the occlusal surface will be protected with Vaseline and gloved finger will be used to apply slight pressure for 30s. Postoperative instructions will be clearly explained to each patient caregiver.
41339389|NCT05117268|PROCEDURE|Hall technique|In Hall technique, correct size preformed metal crown will be selected and shall be placed without caries excavation. The crown will be filled with glass ionomer cement and seated with finger pressure. Local anesthesia was not used finger pressure was maintained on the crown until the glass ionomer cement was set.
41487083|NCT04273581|DRUG|Thalidomide|100mg/d，qn，for 14 days.
41487084|NCT01036490|OTHER|Exercise|Exercise training for 12 weeks followed by home exercise for 40 weeks
41487085|NCT05367726|OTHER|patients having had skin coverage of the knee|the cutaneous cover is not always optimal to protect the prosthesis, an act of reconstructive plastic surgery is then necessary
41487086|NCT02704780|DRUG|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
41339390|NCT03238079|BIOLOGICAL|10% IGIV|300-900 mg/kg
41487087|NCT00219583|DRUG|UK-390,957|
41487088|NCT03386565|DRUG|sodium chloride solution|intraoperative IV infusion
41487089|NCT03386565|DRUG|Lidocaine|intraoperative IV infusion
40820504|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
41339391|NCT02758912|DRUG|оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg|
41339392|NCT06145217|DRUG|SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg|To evaluate the drug-drug interaction between SPRYCEL® 100 mg and Omeprazole under fasted conditions in healthy, adult, human subjects.
41339393|NCT01956994|DIETARY_SUPPLEMENT|Whey protein supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
41339394|NCT01956994|DIETARY_SUPPLEMENT|Carbohydrate supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
41339395|NCT01287767|BEHAVIORAL|A multidimensional support program|Counseling, education and problem-solving in support group, ad hoc counseling
41339396|NCT06119555|DIETARY_SUPPLEMENT|Cinnamon Capsules|The intervention consists of four cinnamon capsules (each 1.5 grams, totaling 3 grams) a day, with two with breakfast and two with dinner for 60 days
41487090|NCT02929446|PROCEDURE|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
41487091|NCT02929446|PROCEDURE|Mobilisation and breathing exercises|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
41487092|NCT00793780|DRUG|Naltrexone 25mg|Naltrexone 25mg caplets taken orally once a day for 8 weeks
41487093|NCT00793780|OTHER|Placebo|Placebo caplet (inactive substance) taken orally once a day for 8 weeks
40820505|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 10 g/ day for 14 days
40820506|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 20 g/ day for 7 days
41339397|NCT01665976|DRUG|RO4917838|film coated tablet, single dose
41339398|NCT01665976|DRUG|RO4917838|oral suspension, single dose
41487094|NCT03055442|OTHER|Dosage of myo-inositol|Quantitative analysis of myo-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
41487095|NCT03055442|OTHER|Dosage of D-chiro-inositol|Quantitative analysis of D-chiro-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
41487096|NCT04171271|BEHAVIORAL|Activating kinesthetic motor imagery training|Participants in the activating kinesthetic motor imagery training group will imagine high effort exercises (e.g. planking, boxing, jumping, squats, push-ups) in the sessions in home using the study audio-video motor imagery script for 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
40820507|NCT06518317|DRUG|Aspirin|Short duration of aspirin (3 months) is compared to long duration of aspirin (12 months)
41339399|NCT01665976|DRUG|RO4927838|hard gelatin capsule, single dose
41339400|NCT00151541|DRUG|Dapsone Topical Gel + adapalene gel 0.1%|
40820508|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
40820509|NCT04015609|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
41339401|NCT00151541|DRUG|Dapsone Topical Gel + benzoyl peroxide gel 4%|
41339402|NCT00151541|DRUG|Dapsone Topical Gel + vehicle control|
41339403|NCT04755283|BIOLOGICAL|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
41339404|NCT04755283|DRUG|Rivaroxaban|Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
41339405|NCT00691977|RADIATION|Radiation Therapy followed by prostatectomy|Radiation Therapy
41339406|NCT01638169|DEVICE|adding a heel|walking with and without heels on the gaitrite system
41339407|NCT00428376|DEVICE|Building Blocks|
41339408|NCT04251741|DIAGNOSTIC_TEST|Adalimumab trough concentration|In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration
41339409|NCT04251741|OTHER|Usual care|In the usual care group, switch to subsequent biological is based on secondary randomisation
41487097|NCT04171271|BEHAVIORAL|Relaxing kinesthetic motor imagery training|Participants in the relaxing kinesthetic motor imagery training group will imagine relaxing (low effort) exercises (e.g. breathing exercises, stretching, body awareness exercises) in home using the study audio-video motor imagery script 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
41487098|NCT02699684|DEVICE|Lotrafilcon B contact lenses with EOBO-41|Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41
41487099|NCT02699684|DEVICE|Lotrafilcon B contact lenses|Lotrafilcon B contact lenses packaged with copolymer 845
41487100|NCT02699684|DEVICE|Hydrogen peroxide-based lens care solution|Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses
41487101|NCT02699684|DEVICE|Saline solution for rinsing contact lenses|Commercially-available saline solution used as needed
41487102|NCT02699684|DEVICE|Saline solution for rinsing contact lens case|Commercially-available solution used as needed
41487103|NCT02239341|OTHER|Music Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.
41487104|NCT02239341|OTHER|Muscle Conditioning Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
41487105|NCT04361903|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours
41487106|NCT03421158|BEHAVIORAL|breastfeeding|Newborns were breastfed during the procedure
41487107|NCT03421158|DIETARY_SUPPLEMENT|oral sucrose|Newborns were given oral sucrose during the procedure
40820510|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
41339410|NCT02996500|DRUG|PF-06650833|Investigational
41339411|NCT02996500|DRUG|Placebo|Placebo
41487108|NCT03421158|BEHAVIORAL|Skin-to-Skin contact|Newborns were placed in direct contact with their mothers during the procedure
41487109|NCT03421158|BEHAVIORAL|Non-nutritive sucking|newborns were given a pacifier to suck on during the procedure
41339412|NCT02996500|DRUG|Tofacitinib|Investigational
41339413|NCT00530491|PROCEDURE|Fast track lung surgery|fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
41339414|NCT00923962|DRUG|Glucagon like peptide-1|0,1 pmol/kg/min
41339415|NCT00923962|DRUG|Adenosine|20-40 microgram/minute
41487110|NCT00920517|BIOLOGICAL|rDEN2/4delta30(ME) vaccine|10\^3 PFU dose
41487111|NCT00920517|BIOLOGICAL|Placebo|placebo for rDEN2/4delta30(ME) vaccine
41487112|NCT01058720|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU orally once daily for 12 weeks
41487113|NCT03582826|BEHAVIORAL|Nutritional counselling|Behavioral nutritional counselling delivered via the Internet.
41487114|NCT03582826|BEHAVIORAL|Stress-reduction counseling|The psycho-behavioral intervention includes administering questionnaires and monthly maintenance psychological support delivered via the Internet.
41487115|NCT02603302|RADIATION|Dose Escalation Radiotherapy|RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU
41487116|NCT02603302|PROCEDURE|Delayed surgery|Surgery after 8 weeks with TME (total mesorectal excision)
41487117|NCT06495515|DRUG|Dalpiciclib，Toremifen|"1. Dalpiciclib : 150mg orally, once a day, taken for 3 weeks, stopped for 1 week, with a cycle of 4 weeks. It is recommended to take medication at the same time every day, with warm water for delivery. It is recommended to do so on an empty stomach and fast for at least 1 hour before and after taking the medication.~2. Toremifen: 60mg orally, once a day If it is a premenopausal or perimenopausal patient, it is necessary to combine with OFS (OFS includes bilateral ovariectomy or GnRHa drugs)."
41487118|NCT04319159|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|Combination Product: Photodynamic therapy (PDT) using BF-RhodoLED® (ALA-PDT, Ameluz®-PDT).
41487119|NCT05690087|DRUG|Lidocaine|intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation
41487120|NCT05690087|DRUG|sodium chloride 0.9% solution|intravenous sodium chloride 0.9% solution volume matched bolus and infusion.
41487121|NCT01989962|OTHER|E4E intervention|The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
41487122|NCT05502692|BEHAVIORAL|CHARACTERISE|Cohort 1 Cohort 2
41339416|NCT03781388|DRUG|Bupivacaine|Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) \<0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
41339417|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
41339418|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
41339419|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
41339420|NCT02106104|DRUG|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
41339421|NCT02106104|DRUG|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
41339422|NCT00437203|DRUG|PF-00477736|"* Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~* If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."
41339423|NCT00437203|DRUG|gemcitabine|gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
41339424|NCT01455155|OTHER|Creative therapy (art and music therapy)|Creative therapy composed of groups of activities relating to music and art sciences 8 sessions (2 sessions per week for 4 weeks) These activities emphasized on stimulating of cognition, physical, emotion, communication, social relationship, and spiritual domains.
41339425|NCT01455155|OTHER|Physical therapy|Physical therapy composed of a series of physical therapy program including types of exercises and gait training if possible (5 times/week).
41339426|NCT01707095|OTHER|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
41339427|NCT01707095|OTHER|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
41339428|NCT01456728|DIETARY_SUPPLEMENT|Progastria|"All subjects will receive 2 x 20 mg omeprazole per day for 28 days.~L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days."
41339429|NCT01456728|DIETARY_SUPPLEMENT|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
41339430|NCT05076994|OTHER|Exercise therapy|A series of home exercise videos to improve patient adherence to exercise prescription
41487123|NCT03838861|BEHAVIORAL|NEMO: NEw MOdel of follow-up|The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
40820511|NCT04015609|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
40820512|NCT05474781|DRUG|Epclusa|HCV treatment
40822995|NCT02966093|DRUG|Placebo|Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
41339431|NCT05076994|OTHER|Standard Care|An exercise prescription and verbal instructions in clinic
41339432|NCT02031627|DEVICE|pneumatic compression - 1 hour per day|Pneumatic compression treatment once per day (1 hour)
41339433|NCT02031627|DEVICE|pneumatic compression - 2 hours per day|pneumatic compression treatment twice per day in the AM \& PM (2 hours)
41339434|NCT02031627|DEVICE|pneumatic compression - 4 hours per day|pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM \& PM (4 hours)
41339435|NCT05549414|DEVICE|Proton Radiation|Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios
41339436|NCT00630708|DRUG|Benazepril|20 mg per day
41339437|NCT00630708|DRUG|Losartan|100 mg per day
41339438|NCT00630708|DRUG|Benazepril+Losartan|combination treatment of 10 mg benazepril and 50 mg losartan per day
41487124|NCT06363786|OTHER|Test patches|Patches (incontinence product cut outs) with a low pH formula or control patches without formula.
41487125|NCT04405895|OTHER|Breakfast Diet|Breakfast Diet (3Mdiet) consist on high-energy breakfast and reduced in energy and carbohydrate (CH) dinner. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 3Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 3Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
41339439|NCT03869164|DEVICE|ValveClamp|ValveClamp is an easy-to-operate transcatheter edge-to-edge mitral valve repair system with larger coaptation width
41339440|NCT02511275|PROCEDURE|Renal microdialysis|Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
41339441|NCT03766113|OTHER|Neurofeedback coupling electroencephalogram and functional MRI in time actual|One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual
41487126|NCT04405895|OTHER|Allday Diet|Allday Diet (6Mdiet) consist in 6 small meals: breakfast, lunch and dinner and 3 snacks, with calories and carbohydrates (CH) evenly distributed throughout the day. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 6Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 6Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
41339442|NCT03766113|OTHER|Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference."
41339443|NCT03766113|OTHER|Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program"
41339444|NCT05130268|DRUG|Dronedarone|Dronedarone 400 mg twice daily in addition to usual care
41487127|NCT00960830|DRUG|mirtazapine|mirtazapine 15 mg daily tablets
41487128|NCT00960830|DRUG|mirtazapine|15 mg daily
40822996|NCT01035437|DRUG|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
41339445|NCT04306666|OTHER|Regional anesthesia|Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.
41339446|NCT02531503|OTHER|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
41339447|NCT02092168|DRUG|BIA 9-1067|
41339448|NCT05855213|DEVICE|High Velocity Nasal Insufflation|A relatively new respiratory support modality which delivers very high velocity flows. This improves ventilatory efficiency via washing out carbon dioxide occupying the anatomical dead space of the upper airways.
41339449|NCT05855213|DEVICE|Non-invasive positive pressure ventilation|An established non-invasive ventilation method via delivery of an expiratory positive airway pressure and inspiratory positive airway pressure.
41487129|NCT01098864|DEVICE|transcranial magnetic stimulation|low frequency (1 Hz) repeated transcranial magnetic stimulation will be delivered to the dorsal lateral prefrontal cortex (DLPFC) area for a period of 15 minutes to test for effect on executive function (e.g., decision choice and subjective value). Four sessions will be conducted per subject; 2 active stimulations,(1 left DLPFC, 1 right DLPFC) and 2 sham stimulations (1 left DLPFC, 1 right DLPFC) with a minimum of 48 hours between every stimulation. Pre and post stimulations measures of cognitive and executive function will be collected and analyzed for significant differences.
41487130|NCT05164666|BIOLOGICAL|TAK-103|TAK-103 intravenous infusion
41487131|NCT01951885|DRUG|tacrolimus|Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
41487132|NCT01951885|DRUG|methotrexate|MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient \< 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
41487133|NCT01951885|DRUG|Mycophenolate mofetil|Patients will receive Mycophenolate beginning on day +1. Patients \>40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients \< 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol
41487134|NCT01951885|DRUG|Methotrexate (low dose)|MTX 5mg/m2 IV on day +1, +3, +6. If patient\<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
41487135|NCT00006055|DRUG|anti-thymocyte globulin|
41487136|NCT00006055|DRUG|cyclophosphamide|
41487137|NCT00006055|DRUG|cyclosporine|
41487138|NCT00006055|DRUG|filgrastim|
41487139|NCT00006055|DRUG|methylprednisolone|
41487140|NCT00006055|DRUG|prednisone|
41487141|NCT00006055|PROCEDURE|Autologous Peripheral Blood Stem Cell Transplantation|
41487142|NCT00456430|DRUG|Escitalopram|10 mg a day of escitalopram by mouth per day for 4 weeks. Dose may be increased to 20 mg a day after the 4th week depending on tolerance and treatment response.
41487143|NCT00018811|BEHAVIORAL|Relaxation training & thermal biofeedback|
41487144|NCT00018811|BEHAVIORAL|Surface EMG biofeedback|
41487145|NCT01268605|PROCEDURE|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
41487146|NCT01268605|PROCEDURE|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
41487147|NCT06426108|DRUG|Fluoride Varnishes|the investigators will utilize a fluoride varnish with a concentration of 22,600 ppm F. The application will be facilitated using a microbrush, ensuring thorough coverage over the entire length of the lesion for a duration of 30 seconds. Following application, the varnish will be finished with water to create a film on the tooth surface. After completing the interventions, patients will receive instructions to refrain from consuming hard foods and to postpone tooth brushing for at least four hours, adhering to the manufacturer's recommendations.
41487148|NCT06426108|DRUG|Varnishes placebo|the investigators will apply a placebo varnish without the active ingredient (fluoride), ensuring that it is packaged identically to the fluoride varnish and has the same taste and texture, thus maintaining consistency in application. The varnish will be applied using a microbrush, spreading it evenly over the entire length of the lesion for a duration of 30 seconds. Following the interventions, patients will receive instructions to avoid consuming hard foods and to delay tooth brushing for at least four hours after applying the varnish.
41339450|NCT04777123|OTHER|sitting position|patients will be left seated for 2 minutes after subarachnoid injection
41339451|NCT01372813|DRUG|vandetanib|Daily dose 300mg/day by mouth, 28 day cycle
41339452|NCT04289194|DRUG|HCR040 (Phase 1)|(Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)
41339453|NCT04289194|DRUG|Placebo (Phase 2)|(Phase 2) Intravenous administration of vehicle solution
41339454|NCT04289194|DRUG|HCR040 (Phase 2)|(Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)
41339455|NCT04625088|OTHER|Standardized liquid test meal|During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.
41339456|NCT04625088|DRUG|Atropine + Standardized liquid test meal|During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
41339457|NCT04907812|DRUG|Tranexamic acid|Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery
41339458|NCT04907812|PROCEDURE|Surgery|This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints \<50 contracture ii. PIP joints \<40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints \>50 degree contracture ii. PIP Joints \>40 degrees contracture b. \>2 fingers involved
41339459|NCT00887068|DRUG|Azacitidine|32 mg/m\^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
41487149|NCT06426108|RADIATION|Low-Intensity Laser 1J|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 1 Joule, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the buccal surface (both mesial and distal aspects), as well as the center of the lesion.
41487150|NCT06426108|RADIATION|Low-Intensity Laser 2J|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 2 Joules, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the buccal surface (both mesial and distal aspects), as well as the center of the lesion.
41339460|NCT04897594|DRUG|TERN-201|Investigational drug
41339461|NCT04897594|OTHER|Placebo|Matching placebo
41339462|NCT05822960|DEVICE|far-infrared radiation|far-infrared radiation on foot acupoints (Yinlingquan and Sanyinjiao acupoints) during dialysis
41339463|NCT00107822|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
41487151|NCT05769933|DEVICE|Simultaneous EEG-fMRI at 7 Tesla|Scalp electroencephalography (EEG) and functional magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
41487152|NCT05769933|DEVICE|Structural MRI at 7 Tesla|Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
41487153|NCT00123474|DRUG|dasatinib|Tablets, Oral, 50 mg BID, indefinitely, survival study
41487154|NCT00123474|DRUG|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
41487155|NCT00123474|DRUG|dasatinib|Tablets, Oral, 100 mg QD, indefinitely, survival study
41339464|NCT04494529|DRUG|12 mg betamethasone + placebo|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
41339465|NCT04494529|DRUG|24 mg betamethasone|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Active Comparator group will receive the standard 2nd intramuscular injection of 12 mg of betamethasone."
41339466|NCT02776306|OTHER|Mirror Box therapy|In mirror box therapy the patient uses the reflection of their good arm to trick to brain into thinking that the effected arm is working.
41339467|NCT03341234|DRUG|Bupivacaine|30 ml %0,25 bupivacaine
41487156|NCT00123474|DRUG|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
41487157|NCT02923882|OTHER|'$100Kitchen and improved cookstove'|
41339468|NCT03341234|DRUG|Saline|2 ml saline subcutaneously
41487158|NCT00888459|DRUG|nicotine replacement therapy|4 mg nicotine lozenges, ad lib, for 12 weeks.
41487159|NCT00888459|DRUG|placebo NRT|Placebo nicotine lozenges
41487160|NCT02349971|DEVICE|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
41487161|NCT02148861|DRUG|Insulin icodec|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
41487162|NCT02148861|DRUG|insulin degludec|Administered once-daily subcutaneously (s.c., under the skin) for 35 days
41487163|NCT02148861|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once-daily for 35 days
41339469|NCT03341234|DEVICE|Ultrasound|Ultrasound guided block
41339470|NCT05469880|OTHER|moisturizing cream and 5% benzoyl peroxide gel|"Group A: Eclaran 5% every evening and formula 609567 49 every morning, for 3 months.~Then the group is divided: Group A1/ formula 609613 37 and Group A2/ formula 609567 49 every morning, for the next 3 months"
41339471|NCT05469880|OTHER|anti-acne face cream and 5% benzoyl peroxide gel|"Group B: Eclaran 5% every other night and 609613 37 every morning, for 3 months.~Then the group is divided: Group B1/ 609613 37 and Group B2/ formula 609567 49 every morning, for the next 3 months"
41487164|NCT00384878|DRUG|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
41487165|NCT04102813|BEHAVIORAL|Functional Therapy|It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
41487166|NCT01892657|DRUG|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
41487167|NCT04650152|DRUG|Tricor (fenofibrate), 145 mg, film-coated tablet|Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
41487168|NCT00444457|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
41487169|NCT00444457|BIOLOGICAL|7vPnC|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
41487170|NCT05777460|DEVICE|Thoracic endovascular aortic repair (TEVAR)|The TEVAR procedure involves the placement of a covered stent (a metal mesh tube with a layer of fabric) into the weakened area of the artery.
41487171|NCT00121134|DRUG|Bevacizumab|Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
41487172|NCT00121134|DRUG|Cyclophosphamide|Once a day for 6 months
41487173|NCT00121134|DRUG|Methotrexate|Twice daily for the first two days of every week for 6 months
41487174|NCT00121134|DRUG|Capecitabine|"Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)"
41487175|NCT04860063|DRUG|Berberine|Participants randomly assigned to the intervention group will be provided with Berberine 500 mg administrated per os three times a day for six months
41487176|NCT04860063|DRUG|Placebo|Participants randomly assigned to the Placebo group will be provided with placebo administrated per os three times a day for six months
41487177|NCT02534844|DRUG|Parts A/B: Adrabetadex|900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion
41487178|NCT02534844|OTHER|Parts A/B: Sham Control|No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick
41339472|NCT05302102|OTHER|Unilateral plyometric training|The paretic-limb-only plyometric training group received a plyometric exercise program performed unilaterally through the paretic leg only for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
41339473|NCT05302102|OTHER|Bilateral plyometric training|The double-limb plyometric training group received a plyometric exercise program performed bilaterally through the paretic and non-paretic legs for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
41339474|NCT05302102|OTHER|Standard physical therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
41339475|NCT05914740|PROCEDURE|Ultrasound guided functional remodeling of lower extremity superficial vein valve|Preoperative ultrasound was used to re-evaluate and confirm the valve function, disinfect the tissue, inject hyaluronic acid around the great saphenous vein valve to reshape the valve about 1-2ml, monitor the whole process under ultrasound, pump back for protection during injection, and inject multiple times at different points.
41339476|NCT04483752|OTHER|CHEST CT SCAN|Chest CTscan at 3 and 12 months
41339477|NCT04426292|DIAGNOSTIC_TEST|Serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
41339478|NCT01761942|DIETARY_SUPPLEMENT|fatty acids preparation- eye-q|3x2 tablets daily by 70 days
41339479|NCT06419790|DEVICE|EIT electrode belt, spirometry|Placing electrode belt for EIT monitoring and measuring tidal volume with spirometer
41339480|NCT03297944|DRUG|Alprazolam 2mg (2ALP/PLC)|2mg alprazolam administered at night, placebo administered in the morning.
41339481|NCT03297944|DRUG|Alprazolam 1mg (1ALP/PLC)|1mg alprazolam administered at night, placebo administered in the morning.
41339482|NCT03297944|DRUG|Alprazolam 0.5mg (0.5ALP/PLC)|0.5mg alprazolam administered at night, placebo administered in the morning.
41339483|NCT03297944|DRUG|Zolpidem 10mg (ZOL/PLC)|10mg alprazolam administered at night, placebo administered in the morning.
41339484|NCT03297944|DRUG|Placebo (PLC/PLC)|Placebo administered at night, placebo administered in the morning.
41339485|NCT03297944|DRUG|Alprazolam 1mg (PLC/ALC)|Placebo administered at night, 1mg alprazolam administered in the morning.
41339486|NCT04504019|DEVICE|USCTR|Ultrasound guided CTR via a single \< 1 cm wrist or palmar incision. The procedure will be performed using the SX-One MicroKnife®, also known as UltraGuideCTR
41339487|NCT04504019|PROCEDURE|mOCTR|Mini-open CTR via a single 1-3cm palmar incision
41339488|NCT01973972|BEHAVIORAL|Weight management|Weight management group visits using low-carbohydrate diet followed for weight management.
41339489|NCT01973972|BEHAVIORAL|Shared medical appointments (SMA)|Diabetes management group visits for diabetes management.
41339490|NCT04917731|DRUG|Botulinum toxin type A|Botox injected at digital artery
41339491|NCT05243719|BIOLOGICAL|ADP101|Active dry powder formulation at various volumes.
41487179|NCT02423356|PROCEDURE|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
40822997|NCT02833753|DRUG|Oxaliplatin|"Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy . Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 4: Oxaliplatin 55 mg/m2 IP every 2 weeks on day #1 of chemotherapy (due to DLTs found)"
41339492|NCT04606368|DEVICE|Thermage FLX|Monopolar radiofrequency will be applied through the Thermage FLX machine to the subject's right lower jaw and submentum area.
41339493|NCT00923624|OTHER|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
41339494|NCT00923624|BEHAVIORAL|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
41339495|NCT03051269|DRUG|Calcium chloride|Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
41339496|NCT03051269|DEVICE|Electroporation|"Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY."
41339497|NCT05639829|BEHAVIORAL|Time-restricted eating|Restriction of calorie intake to an 8-hour window, with water only fasting in the remaining 16 hours of the 24-hour period
41339498|NCT00365742|DRUG|simvastatin|
41339499|NCT00365742|DRUG|red yeast rice|
41339500|NCT00365742|DRUG|pharmaceutical grade fish oil|
41339501|NCT00365742|BEHAVIORAL|therapeutic lifestyle changes|
41339502|NCT01722357|BEHAVIORAL|Pedometer|Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.
41339503|NCT01722357|BEHAVIORAL|Exercise Counseling|Manualized cognitive behavioral treatment program including goal setting, adding exercise throughout the day, physical limitations/injuries, maintaining motivation, benefits of exercise, FITT principles, exercise as recreation, and restructuring thoughts related to activity.
41339504|NCT05171855|DRUG|Lonapegsomatropin|Study participants are individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks
41487180|NCT03340142|DEVICE|VIVO™|Diagnose the area of a PVC or VT onset
41487181|NCT04340349|DRUG|Hydroxychloroquine Sulfate|A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.
41487182|NCT04340349|DRUG|Bromhexine 8 MG|TMPRSS2 blocker
41487183|NCT01194336|DRUG|Huperzine A|dosage form: tablet dose frequency: once only
41487184|NCT01194336|DRUG|Donepezil|dosage form: tablet dosage frequency: once only
41487185|NCT01194336|DRUG|Galantamine|dosage form: tablet dosage frequency: once only
41339505|NCT05385926|RADIATION|Radiotherapy|Patients who had complete response or partial response after at least 3 cycles (no more than 6 cycles) of chemotherapy combined with immunotherapy receive local radiotherapy 21 days. For those non-CR oligo-metastatic disease or symptomatic lesion, SBRT or conventional RT delivered. Maintenance therapy of immunotherapy for 2 years.
41339506|NCT02635685|OTHER|Clinical Decision Support tool|Automatized support tool for identification of patients with a diagnosis of atrial fibrillation without appropriate anticoagulant therapy for stroke prevention.
41487186|NCT01194336|OTHER|Placebo|dosage form: tablet dosage frequency: once only
41487187|NCT03641521|BEHAVIORAL|Parent-led behavioral strategies|Intervention parents participated in an additional 20-25-min segment led by the nutrition educator during which the week's behavioral strategy was introduced. The following six behavioral strategies were introduced (one each week) as a segment of each cooking skills session: 1) have your child help prepare vegetables for meals (Child Help), 2) use a plate that shows the amount of vegetables to include for a meal (My Plate), 3) make vegetables visible and accessible by removing other foods from the dining area during the meal and leaving the vegetables (Make Avail/Visible), 4) serve at least 2 vegetables with the meal (Serve 2), 5) serve vegetables before the meal (Serve First), and 6) use a bigger spoon to serve the vegetables (Big Spoon).
41487188|NCT04883970|OTHER|124I-18B10(10L) PET/CT|Study participants will undergo 124I-18B10(10L) PET/CT scans
41487189|NCT04873375|DRUG|Cemiplimab|After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks
41487190|NCT02185651|DRUG|Zavesca® Prescription|"Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
41487191|NCT03476525|DRUG|Fluoxetine|Patients are tested for their normal prescription fluoxetine medication
41487192|NCT05829213|PROCEDURE|"arch-bridge-type esophagogastric reconstruction after proximal gastrectomy"|"1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. Creating the seromuscular flap (arch-bridge)~4. The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis."
41339507|NCT00621010|DRUG|CTS21166 (ZPQ-21166)|"Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion"
40820513|NCT04127357|PROCEDURE|1450 ppm fluoride toothpaste brushing x Resin sealing (FluroShield, Dentsply, Brazil).|"After randomization of the children, the selected molars were allocated through a randomized sequence list in 2 groups: A. Brushing with 1450 ppm fluoride toothpaste, donated by the researcher; B. Resin Sealing (FluroShield, Dentsply, Brazil).~The teeth included in the second group (group B) underwent a second randomization: B1. With absolute isolation; B2. With relative isolation. For the group with absolute isolation, topical anesthesia and local papillary infiltration were performed for subsequent staple placement. Relative isolation was performed with cotton rollers and moisture control suction. The sealant selected was the opaque fluroshield to facilitate visualization upon visual examination during reevaluations and was applied following the manufacturer's standards. The teeth were clinically and radiographically followed at 6 and 12 months and two sessions of motivation reinforcement were performed through video and brush change at 3 and 9 months."
41156870|NCT06395961|PROCEDURE|general anesthesia|intravenous injection of midazolam 0.03-0.05 mg/kg, etomidate 0.15-0.20 mg/kg, cisatracurium 0.15-0.20 mg/kg, and sufentanil 0.3-0.5 μg/kg. Intraoperative anesthesia maintenance using intravenous infusion of remifentanil 0.1-0.3 μg/kg·min, propofol 4-6 mg/kg·h, maintain bispectral index (BIS) value of 40-60, maintain intraoperative blood pressure and heart rate fluctuations within ± 20% of the baseline value, intermittently inject cisatracurium intravenously as needed. After the surgery, the patient was transferred to post-anaesthesia care unit (PACU). After regaining consciousness and regaining autonomous breathing, the tracheal catheter was removed and transferred to the ward when the indications for transfer were met.
41156871|NCT05899673|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
41156872|NCT05325658|OTHER|FEES, treatment with modified diet, electrical swallowing muscle stimulation.|Endoscopic swallowing assessment (FEES) consists of three parts:1) assessment of mouth, throat anatomy and more; 2) the patient is given to swallow a certain amount and consistency of liquids and solid food. 3) evaluated: preparation of the bolus for swallowing, aspiration. An 8-point Penetration-Aspiration scale is described.Swallowing exercises. Swallowing exercises are also used in practice, which can help coordinate the swallowing muscles or stimulate the nerves involved in the swallowing reflex.Transcutaneous electrical stimulation is a method of treating dysphagia in which weak electrical impulses stimulate the muscles in the neck area associated with swallowing. In patients with oropharyngeal dysphagia, patients have great difficulty swallowing water of normal consistency or other non-thick liquids, so they should be thickened with special thickeners to such an extent that the patient does not experience discomfort and be able to swallow.
41339508|NCT05810389|COMBINATION_PRODUCT|Fluoride|Application methods of delivery of topical fluoride
41339509|NCT02758041|DEVICE|Sebacia Microparticles|
41339510|NCT01826448|DRUG|PLX3397|
41339511|NCT01826448|DRUG|vemurafenib|
41339512|NCT01425320|DRUG|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
40820514|NCT04758884|OTHER|Telemedicine|Visits by videoconference in months 0, 1, 2, 3, 4 and 6.
40820515|NCT06606275|DRUG|Apixaban|Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa, playing a crucial role in preventing blood clot formation. It is commonly prescribed for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) and for treating and preventing venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
40822998|NCT04590313|PROCEDURE|Arthrodesis|MTPJ I arthrodesis
41339513|NCT01425320|DRUG|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
41339514|NCT01425320|DRUG|dapsone 5% gel|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
41339515|NCT01425320|DRUG|adapalene 0.3% gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
41339516|NCT02323308|OTHER|blood sampling|
41339517|NCT03595449|DRUG|Lidocaine jelly|lidocaine 2% jelly applied during Mohs surgery
41339518|NCT03595449|DRUG|Surgilube|surgilube (placebo) applied during Mohs surgery
41339519|NCT05589623|OTHER|Copenhagen adduction exercise|The CAE is a progressive eccentric training program that enhances hip adduction. The fact that exercises are done with a partner and do not require special equipment makes them more useful in a team setting. The MPCA program, adapted from the original CAE, included six progressive levels for eight weeks, beginning with an assisted isometric adduction hold (level 1) and progressing incrementally to a complete CAE as the original exercise (level 6). The progression in levels will depend on a pain score ≤ 4/10 numeric rating scale (NRS) in the adductor squeeze test and post-session DOMS score ≤ 4/10 NRS.
41339520|NCT05589623|OTHER|Usual rehabilitation program|The usual rehabilitation program will include leg swings extension/flexion, leg swings abduction/adduction, standing hip circles, isometric standing hip adduction using elastic bands, stretching exercises, balance training on a wobble board, and single leg coordination exercises. Difficulty and volume are progressing incrementally.
41339521|NCT04728815|BEHAVIORAL|TAU - Phase 1|4-8 weeks of TAU treatment
41339522|NCT04728815|BEHAVIORAL|CAMS - Phase 1|4-8 weeks of CAMS treatment
41339523|NCT04728815|BEHAVIORAL|DBT - Phase 1 and 2|up to 16 weeks of DBT treatment
41339524|NCT04728815|BEHAVIORAL|CAMS - Phase 2|Up to 8 weeks of CAMS treatment
40822999|NCT05838508|BEHAVIORAL|Exercise intervention|Research participants will be assigned to two exercise conditions.
41487193|NCT05935436|DEVICE|Cardiac Shock Wave Therapy|When operating CSWT, it is necessary to determine the target myocardium for treatment, adjust the height of the water bladder, set the energy that the patient can tolerate, and then start the treatment. During the treatment, the vital signs of the subjects should be detected.
41487194|NCT05821088|PROCEDURE|Biopsy|Undergo tissue biopsy
41156873|NCT05788406|OTHER|Short foot exercises, Dynamic balance exercises and insole|Short foot exercises is used to improve muscle strenght, Dynamic balance exercises is used to improve balance and insole is used to improve MLA
41156874|NCT05063292|PROCEDURE|Patients in Group II will receive active prewarming with an air forced blanket (full body blanket) 30 minutes prior to the operation|Core temperature and 4-points skin temperatures measurements will be recorded all over the operation. Patients will be delivered 2 Litre/minute oxygen with a nasal cannula.Iv hydration will be continued by room temperatured balanced electrolyte solution with an infusion rate of 2mL/kg/hr. Spinal anesthesia will be applied at the level of L3-L4 by a 25 Gauge Quincke needle with a dose of 12.5-15 mg hyperbaric bupivacaine in the sitting position.
41487195|NCT05821088|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41487196|NCT05821088|DRUG|Carboplatin|Given IV
41487197|NCT05821088|PROCEDURE|Computed Tomography|Undergo CT
41487198|NCT05821088|DRUG|Etoposide|Given IV
41487199|NCT05821088|DRUG|Ifosfamide|Given IV
41487200|NCT05821088|DRUG|Lenalidomide|Given PO
40820516|NCT06606275|DRUG|Warfarin|Warfarin is a vitamin K antagonist widely used as an anticoagulant to prevent thromboembolic events, particularly in conditions like atrial fibrillation, venous thromboembolism, and in patients with mechanical heart valves. It inhibits the enzyme vitamin K epoxide reductase, thereby reducing the activation of vitamin K-dependent clotting factors (II, VII, IX, X) and regulatory proteins C and S. Due to its narrow therapeutic index, warfarin requires regular monitoring of the International Normalized Ratio (INR) to optimize anticoagulation while minimizing the risk of bleeding. Warfarin's pharmacokinetics and pharmacodynamics can be influenced by genetic polymorphisms, diet, and drug interactions, necessitating individualized dosing strategies.
40820517|NCT05008731|DRUG|Botulinum toxin|100 units (0.5ml) in 1 injection
41487201|NCT05821088|PROCEDURE|Positron Emission Tomography|Undergo PET
41487202|NCT05821088|BIOLOGICAL|Tafasitamab|Given IV
40820518|NCT05008731|OTHER|Placebo|Placebo 0.5 ml in 1 injection
40820519|NCT02465788|DEVICE|GentleTouch|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
40820520|NCT01988532|OTHER|No treatment given|Subject will only fill out a questionnaire
41339525|NCT04728815|BEHAVIORAL|DBT - Phase 2|Up to 8 weeks of DBT treatment
41339526|NCT06362395|RADIATION|Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)|Precise radiation therapy delivered in a single session using magnetic resonance imaging for guidance.
41487203|NCT06284577|DIETARY_SUPPLEMENT|Multistrain Probiotic|Participants will recieve a multi-strain probiotic daily for 6 months
41487204|NCT06284577|DIETARY_SUPPLEMENT|Placebo - maltodextrin|Participants will recieve placebo/ maltodextri daily for 6 months
41487205|NCT01782508|DRUG|imatinib|a selectively inhibits the KIT protein tyrosine
41487206|NCT01782508|DRUG|Interferon|Interferon belongs to the large class of glycoproteins known as cytokines.
41487207|NCT04763694|DEVICE|Multifocal soft contact lenses|Myopic subjects wore multifocal soft contact lenses for 12 months
41487208|NCT04993677|DRUG|SEA-CD40|Given into the vein (IV; intravenously); schedule is cohort-specific
41487209|NCT04993677|DRUG|pembrolizumab (KEYTRUDA®)|Given by IV; schedule is cohort-specific.
41487210|NCT04993677|DRUG|pemetrexed|Given by IV on Day 1 of each 21-day cycle.
41487211|NCT04993677|DRUG|carboplatin|Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.
41339527|NCT03023605|BEHAVIORAL|Training Intervention for PE Diagnosis|"Focused on the Emergency Department staff and the rotating residents during the months 4 and 5 of 2015, and consisted of:~1. Clinical Update Sessions for staff ED (20 physicians)~2. training sessions for residents that rotate in ED (60 physicians )~3. Development of a triptych, including clinical prediction scales, combination algorithm of scales and D-Dimmer value~4. Development of posters, with brief information~5. Dissemination by e-mail of scientific information~6. Direct reminder during the working day"
41487212|NCT03063762|DRUG|Atezolizumab|"Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule"
41487213|NCT03063762|DRUG|Bevacizumab|"Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle."
41487214|NCT03063762|DRUG|RO6874281|"Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part"
40820521|NCT06606548|BEHAVIORAL|comprehensive oral care|including cleaning, facial massage, oral muscle massage and stretching, and oral moisturizing.
40820522|NCT06080464|OTHER|VERABAND information|The device, VERABAND™, activity data reports (including a summary broken down by week) will be provided to treating clinicians prior to each patient's follow-up clinic visit.
40820523|NCT01846676|BEHAVIORAL|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
40820524|NCT01846676|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
40820525|NCT06318806|OTHER|Psychotherapy|Psychotherapy is a type of treatment that can help individuals experiencing mental health conditions and emotional challenges.
40820526|NCT04274049|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
41156875|NCT06646588|DRUG|Fruquintinib|Fruquintinib: Oral, once daily, 2 weeks on and 1 week off. The product can be taken with food or orally on an empty stomach, and needs to be swallowed whole. It is recommended that the dose be taken at the same time each day; if the patient vomits after taking the dose, no refill is needed; a missed dose should not be added the next day, but the next prescribed dose should be taken as usual.
41156876|NCT06646588|DRUG|Tislelizumab|Tislelizumab: intravenous drip 200mg，day1，once every three weeks.
40820527|NCT04274049|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
40820528|NCT02342457|DEVICE|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
40820529|NCT05807087|PROCEDURE|Conventional osteotomy|The nasal skeleton was accessed using a closed approach or an open approach is done via a transcolumellar and infracartilaginous incision. Osteotomy was made using osteotomes.
41339528|NCT00810043|DEVICE|Kyphon® Curette|The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
41339529|NCT05248646|DRUG|Sibeprenlimab 400 mg|Sibeprenlimab 400 mg s.c. q 4 weeks
41339530|NCT05248646|DRUG|Placebo|Placebo s.c. q 4 weeks
41339531|NCT02361489|DEVICE|V-Go|Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
41339532|NCT02858713|DRUG|Calcipotriene + Betamethasone Dipropionate|Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
41339533|NCT02858713|DEVICE|App|App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
40820530|NCT05807087|PROCEDURE|Piezosurgery osteotomy|full exposure of the nasal bony pyramid is needed.
40820531|NCT00230061|BIOLOGICAL|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
40820532|NCT02985892|OTHER|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
40820533|NCT02985892|OTHER|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
40820534|NCT06445166|DRUG|Propranolol Hydrochloride|"Dosing is as follows:~* Patients who weigh 40 to 59 kg:~  * 40 mg BID (target)~ * 20 mg BID (half the target)~* Patients who weigh ≥ 60 kg:~  * 60 mg BID (target)~ * 30 mg BID (half the target)"
41339534|NCT01977807|DEVICE|Proscan, Zyoptix and Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
41339535|NCT04842877|DRUG|Valemetostat tosylate|200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
41339536|NCT00187044|BIOLOGICAL|PolyEnv1 vaccine|administered subcutaneously as 10\*7 pfu in 0.8 mL
41339537|NCT05210413|DRUG|Spartalizumab in Pediatric cohort|Infusion of spartalizumab at four dose escalation levels: 2, 3, 4 and 6 mg/kg in successive cohorts of 3 patients, depending on the number of patients with dose-limiting toxicity (DLT) to maximum tolerated dose (MTD).
41339538|NCT05210413|DRUG|Low-dose Pazopanib in Pediatric Cohort|Oral pazopanib treatment at a fixed dose of 225mg/m²/day
40820535|NCT01289353|DRUG|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
41339539|NCT05210413|DRUG|Spartalizumab in Adult cohort|Infusion of 400 mg of spartalizumab on Day1 of each cycle.
41339540|NCT05210413|DRUG|Low-dose Pazopanib in Adult Cohort|Oral pazopanib treatment with a fixed dose of 400 mg/day
41339541|NCT00185172|OTHER|placebo|Placebo oral tablets for 2 weeks
41339542|NCT00185172|DRUG|olmesartan medoxomil|olmesartan medoxomil oral tablets for 8 weeks
41339543|NCT00185172|DRUG|olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets|olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
41339544|NCT00626834|DRUG|Vigabatrin|Dose 1 BID
40820536|NCT01289353|RADIATION|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
41339545|NCT00626834|DRUG|Vigabatrin|Dose 2 BID
41339546|NCT00626834|DRUG|Vigabatrin|Dose 3 BID
41339547|NCT00626834|DRUG|Matching placebo|Matching placebo BID
41339548|NCT04681365|OTHER|Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)|Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)
41339549|NCT03706040|BIOLOGICAL|Placebo|subcutaneous (SC) injection
41339550|NCT03706040|BIOLOGICAL|Risankizumab|subcutaneous (SC) injection
41487215|NCT00767065|RADIATION|Cardiac Computed Tomography|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate \<70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
41487216|NCT00767065|OTHER|Standard care|Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
41487217|NCT02257463|DRUG|theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations|
41487218|NCT02257463|OTHER|peripheral muscles exercise training|
41487219|NCT02257463|DEVICE|inspiratory muscle training|Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
41487220|NCT04236726|OTHER|Questionnaire|HRQoL questionnaires
40820537|NCT04256668|DIAGNOSTIC_TEST|Obtaining one or semen samples|Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
41487221|NCT04404452|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart and lung sounds using electronic stethoscopes
40820538|NCT06597266|DEVICE|Smart template - designed prosthetic check socket|Evidence-generated trial prosthetic sockets are designed automatically by performing machine learning analysis of past socket designs that were produced by expert clinicians, the participant's residual limb size and shape descriptors and patient descriptors
40820539|NCT06597266|DEVICE|Clinician-designed prosthetic check socket|Active comparator prosthetic sockets are designed by expert prosthetists, bespoke to the participant, in a computer aided design environment (CAD)
40820540|NCT05705128|DRUG|Dexmedetomidine|Dexmedetomidine will be given with bupivaciane for postoperative pain control
40820541|NCT05190315|DRUG|Chlorpromazine|"Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide."
40820542|NCT05190315|DRUG|Temozolomide|"Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events \> grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle."
40820543|NCT05190315|RADIATION|Radiation Therapy|Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
41156877|NCT06646588|RADIATION|Radiotherapy|Radiotherapy synchronised with drugs.
41156878|NCT06632834|DRUG|simvastatin therapy|Simvastatin should be administered initially with the dose of 10 mg once daily for adult and 0.25 mg/Kg once daily for children. Dose of simvastatin will be increased to the dose of 20 mg once daily for adult and 0.5 mg/Kg once daily for children after the check at 3 months without adverse effects.
41156879|NCT03904888|PROCEDURE|r-TAPP|Robot-assisted repair
41339551|NCT01590667|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
41339552|NCT01590667|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
41339553|NCT00788918|DRUG|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
41339554|NCT01080625|DRUG|phenylephrine|100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
41339555|NCT01080625|DRUG|epinephrine|10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
41339556|NCT01080625|DRUG|placebo control|10ml of normal saline is administered at the time of reperfusion
41339557|NCT05060198|DRUG|Artemether-lumefantrine (AL)|AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.
41339558|NCT05060198|DRUG|Dihydroartemisinin-piperaquine (DP)|DP is the current second-line antimalarial in Kenya, per Kenya Ministry of Health.
41339559|NCT03082807|DIETARY_SUPPLEMENT|NCDsport|Negative Calorie Diet supplemented with exercise
41339560|NCT03082807|DIETARY_SUPPLEMENT|LCDsport|Low-Calorie diet with exercise
41339561|NCT03648606|OTHER|mesure of skin temperature|"The infants are placed in a closed incubator to study the variability of the heart and respiratory frequencies according to the regulation of the incubator and to quantify the time spent outside. Data will be collected during the first 10 days of life of the preterm infant. Skin temperatures at six body sites (the abdomen, pectoral region, eye, hand, thigh and foot) were measured (using infrared thermography) during nocturnal polysomnography in 29 9-day-old preterm neonates (postmenstrual age:~209 9 days). The investigators then determined whether the duration of the W episode depended upon the local skin temperatures measured at the start, during and end of the episode."
40820544|NCT04260763|BEHAVIORAL|Social Cognition Group|Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.
40820545|NCT04260763|DEVICE|Novel Mobile App|"The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking."
41339562|NCT04105322|OTHER|Kinesio Taping|The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.
40820546|NCT00909545|DRUG|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
40820547|NCT00909545|DRUG|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
40820548|NCT00909545|DRUG|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
40820549|NCT00909545|DRUG|Placebo|4 Placebo to Match (PTM) tablets once daily
40820550|NCT00082706|DRUG|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
41339563|NCT05872698|DRUG|Carvedilol|Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure, and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment. It is taken by mouth.
41339564|NCT05872698|DRUG|Placebo|Placebo
41339565|NCT01337518|DRUG|EZN-4176|EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
40820551|NCT00082706|DRUG|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
40820552|NCT00082706|DRUG|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
40820553|NCT00082706|DRUG|Gemcitabine|Day: 1 \& 5 Dose: 200 mg/m2 (Two doses only)
40820554|NCT02697227|BEHAVIORAL|Behavioral Intervention|Receive BATS counseling
40820555|NCT02697227|OTHER|Laboratory Biomarker Analysis|Correlative studies
41339566|NCT03656666|DRUG|Apremilast|Apremilast oral tablets
41339567|NCT03656666|DRUG|Placebo|Placebo oral tablets
40820556|NCT02697227|DRUG|Nicotine Patch|Receive nicotine patch
40820557|NCT02697227|OTHER|Questionnaire Administration|Ancillary studies
40820558|NCT02697227|BEHAVIORAL|Smoking Cessation Intervention|Receive standard smoking cessation counseling
40820559|NCT05049213|DRUG|Carrageenan nasal spray and 1% PVP- mouthwash and gargle|"Day1 to Day7~1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time~2. Oral gargling 3 times/day, 15cc/per time"
40820560|NCT05475210|DRUG|177Lu-DOTA-EB-TATE|Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.
41156880|NCT03904888|PROCEDURE|l-TAPP|Laporoscopic repair
41156881|NCT03904888|PROCEDURE|local anesthetics|local anesthetics will be administred
41487222|NCT02023736|OTHER|Systemic Therapy Inventory of Change (STIC)|The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.
41487223|NCT02023736|OTHER|Treatment as Usual|Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
41487224|NCT04213352|OTHER|Wrist Splint|Neutral position and volar supported wrist orthosis which limits the flexion and deviation while allowing pronation, supination, and extension of the wrist.
41487225|NCT04213352|OTHER|Rigid Taping|Rigid taping in the neutral position will be performed to allow pronation, supination, and extension of the wrist while limiting the flexion and deviation.
40820561|NCT05475210|OTHER|Amino Acid Solution|The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
40820562|NCT04911400|OTHER|Upper-lower clear plastic retainers + Class III elastics|Addition of Class III elastics to clear plastic retainers
40820563|NCT04911400|OTHER|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
40820564|NCT05838755|DRUG|GSK3858279|GSK3858279 will be administered
40820565|NCT05838755|DRUG|Placebo|Placebo will be administered
40820566|NCT00712725|DRUG|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
40820567|NCT00712725|DRUG|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
40820568|NCT00712725|DRUG|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
40820569|NCT00712725|DRUG|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
40820570|NCT00712725|DRUG|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
40820571|NCT00712725|DRUG|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
40820572|NCT00712725|DRUG|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
40820573|NCT02238431|DRUG|Lucrin depot|scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
40820574|NCT02238431|DRUG|OCP|to schedule the start of the artificial cycle
40820575|NCT02238431|OTHER|Natural|to use the normal menstrual period to schedule treatment start
40820576|NCT05408507|BEHAVIORAL|ABC123 Framework|This care planning framework aims to implement existing tools in geriatric medicine, palliative medicine, and medical oncology to aid in cancer care planning for older adults with newly diagnosed incurable advanced cancer and to test the delivery of goal-concordant care. This patient-centered intervention is the ABC123 care planning framework in parallel with usual care that includes a physical function assessment, chemotherapy toxicity estimate calculation, and a guided goals of care discussion.
41339568|NCT04882904|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
41339569|NCT05194605|OTHER|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
41339570|NCT04745390|RADIATION|Radiation therapy|Patients will be randomized between standard of care palliative irradiation of 2000cGy in 5 fractions (Arm 1) versus radiobiologically guided dose selection also in 5 fractions (Arm 2). For all patients randomized, radiation is to be delivered in 5 fractions delivered over 5 to 15 days.
41339571|NCT03896906|DEVICE|High-flow nasal cannula|Apply high ﬂow heated (34 °C) and humidified nasal oxygen with the OptiFlow System (Thrive, Fisher \& Paykel®, Aukland New Zealand) using a ﬂow of 30 liter/minute and an inspiratory oxygen fraction (FiO2) of 1.0. Increase the oxygen flow to 60 liter/minute over the course of the first minute. Ask the patients not to speak during anesthesia induction and keep the mouth closed.
41339572|NCT03896906|DEVICE|simple mask|Perform standard preoxygenation by oxygen insufflation via a face mask using the standard anesthesia ventilators (semicircular system) with 100% oxygen ﬂow of 12 liter/minute. The patients breathe with tidal volume.
41339573|NCT05016440|DRUG|Lisinopril|10mg Lisinopril daily for 6-8 weeks postpartum
40820577|NCT04448314|DIAGNOSTIC_TEST|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
40820578|NCT05708638|OTHER|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
40820579|NCT05708638|OTHER|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
41339574|NCT03879460|DRUG|Naltrexone Hydrochloride|50 mg per os naltrexone hydrochloride
40820580|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo|Low Repeat Dose
40820581|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13)|High Repeat Dose/High Repeat Multiple Dose
40820582|NCT04681833|DRUG|Placebo|Liquid diluent/Lyophilised Powder
40820583|NCT01549808|OTHER|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
40820584|NCT01549808|OTHER|mobilization|sitting, standing and walking
41339575|NCT01978392|BEHAVIORAL|Self-management group workshops|This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
41339576|NCT06507215|DIAGNOSTIC_TEST|Protein analysis|The investigator enrolled 149 healthy volunteers and collected peripheral blood samples for protein analysis. While 18 of these individuals with protein levels in the range of 40%-64% were predicted to be carriers by the monocyte assay, subsequent DYSF sequencing analysis in 14 of 18 detected missense variants in only four. Analysis of DNA methylation patterns at the DYSF locus showed no changes in methylation levels at CpG islands and shores between samples.
41339577|NCT04912661|DIETARY_SUPPLEMENT|Ferinject|intravenous iron carboxymaltose
41339578|NCT04021576|OTHER|preventative training program|complementary training of leg-, hip- and core-strength/stability
41339579|NCT05728749|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
41339580|NCT03694067|OTHER|Punch skin biopsy|One 1 mm punch biopsy will be taken from the patients from balding scalp. Another 1 mm punch biopsy will be taken from an area of occipital non-balding scalp of the same individual. Local anesthesia will be injected around the biopsy site beforehand.
41339581|NCT00044525|DRUG|BAY59-8862 (Cytotoxic Taxane)|1 h intravenous infusion every 3 weeks
41339582|NCT00002097|DRUG|Nystatin|
41487226|NCT03713775|OTHER|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.
41339583|NCT03185923|DRUG|TCM plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical \& Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days."
41339584|NCT03185923|DRUG|TCM placebo plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days."
41339585|NCT00171613|DRUG|Octreotide|
41339586|NCT04207008|OTHER|iBDecide Decision Support Application|The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.
41339587|NCT06239285|DEVICE|Brief Violence Intervention VR (BVI-VR)|BVI-VR is being developed as a hospital-based brief gun violence intervention program founded on the principles of positive psychology, motivational goal setting (via gameplay), psychoeducation, cognitive-behavioral therapy, and dialectical behavioral therapy. All steps of the BVI-VR emphasize being in control of making positive choices, and how to locate and leverage opportunities within their communities to improve their well-being. BVI-VR empowers patients to be the driver of their well-being
41339588|NCT06239285|OTHER|Treatment as Usual (TAU)|group will receive a community resource brochure (the same one that is provided at the end of BVI-VR). This brochure provides contact detail for services in the local area. These include organizations that provide mental health counseling, mentorship services, career development programs, organized community activities and sports, educational support, financial support, substance abuse programs, and resource assistance (e.g., food, housing, etc.).
41339589|NCT00122070|DRUG|Quetiapine Fumarate|Dosage can vary from 50 to 150 mg at PI's discretion
40820585|NCT06601868|DIETARY_SUPPLEMENT|R-Support Prepare & After nutritional supplement|R-Support is a nutritional supplement containing proteins, Vitamine A, Vitamine B6, Vitamine B11, Vitamine B12, Vitamine C, Vitamine D3, Vitamine E, IJzer, Koper, Selenium, Zink, Magnesium, Omega-3 and Beta-glucanen.
41156882|NCT04293341|BEHAVIORAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
40820586|NCT05617053|DEVICE|DAART|
41339590|NCT06424041|OTHER|Fecal Microbiome Transplantation|Healthy donor fecal microbiome transplantation, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
41339591|NCT06424041|OTHER|Sham Fecal Microbiome Transplantation|Capsules containing preservative solution only, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
40820587|NCT05617053|DEVICE|ATP/Supera stenting|
40820588|NCT05640479|DRUG|Pregabalin|patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
40820589|NCT05640479|DRUG|Dexmedetomidine|patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
41487227|NCT03713775|OTHER|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (\~15 min), together with supporting written information.
40820590|NCT05372731|OTHER|Recruitment Maneuver|RM after BAL
40820591|NCT04580368|DRUG|CFTR Modulators|Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
40820592|NCT01588314|DRUG|Gabapentin|gabapentin 100 mg capsules
41156883|NCT04293341|BEHAVIORAL|Cognitive Processing Therapy for PTSD|CPT is a well established evidence-based psychotherapy for PTSD. CPT focuses on teaching patients to evaluate and change the upsetting thoughts that they have had since their trauma.
41487228|NCT00462059|BEHAVIORAL|Treatment|
40820593|NCT01588314|DRUG|placebo|compounded placebo capsules
40820594|NCT00721760|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
40820595|NCT00721760|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
41156884|NCT04293341|BEHAVIORAL|Cognitive Behavioral Therapy for MDD|CBT for MDD is a well established evidence-based psychotherapy for depression. CBT for MDD focuses teaching patients how to change their behaviors and challenge their negative thoughts to improve their mood.
40820596|NCT00721760|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
40820597|NCT05384106|DIETARY_SUPPLEMENT|(R)-1,3-butanediol|Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels
41156885|NCT04293341|BEHAVIORAL|Cognitive Behavioral Therapy for Panic Disorder|CBT for Panic Disorder is a well established evidence-based psychotherapy. CBT for Panic Disorder focuses teaching patients how to change their behaviors through exposure practices and challenge their anxious thoughts to reduce their experience of panic attacks and avoidance.
40820598|NCT04883294|DIAGNOSTIC_TEST|Electronic Nose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. Failed breath tests were excluded from analysis; the reason for failure was documented.
40820599|NCT02687685|OTHER|Skin to skin contact immediate|Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.
41339592|NCT04689217|DRUG|intrathecal drug injection|"All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height"
41339593|NCT03395860|DRUG|ATG|group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
41339594|NCT06391476|OTHER|Study of the evolution of a cohort of children born between 22 and 25 weeks gestational age|"* Study of mortality in a cohort of children born between 22 and 25 weeks gestational age~* Study of neonatal morbidity~* Description of postnatal growth~* Description of nutrition and breastfeeding at discharge~* Study of the neurological, respiratory and growth outcome at 2 years."
41339595|NCT05551910|DRUG|Esketamine|The patients in the test group were given esmketamine (50mg / 2ml \* branch, Jiangsu Hengrui Pharmaceutical Co., Ltd.) 0.15-0.5mg/kg H was pumped intravenously. Two minutes after the administration, the pain was scored with the cpot pain observation scale. The target cpot was \< 3 points. The dose of esketamine was adjusted according to the cpot score.
41339596|NCT05551910|DRUG|Remifentanil|Patients in the control group were given remifentanil (1mg / branch, Yichang humanwell Pharmaceutical Co., Ltd.) 0.05-2ug/kg Minutes after administration, the analgesic score was measured with cpot pain observation scale. The target cpot was less than 3 points, and the dose of remifentanil was adjusted according to the cpot score.
41339597|NCT05551910|DRUG|propofol|propofol
41339598|NCT04921657|DRUG|Rosuvastatin 10mg|
41339599|NCT03606655|DRUG|Kava|Kava: 75 mg three times daily (3 capsules)
41156886|NCT06647368|OTHER|PET with 18-FDG|The intervention is a 1,5 hour PET scan, which will be performed in three steps (heart scan, brain scan and heart scan) and administration of radioactively labelled glucose (18-FDG) in two doses.
41339600|NCT04738604|OTHER|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany|The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.
41339601|NCT04738604|OTHER|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
41339602|NCT00321360|DRUG|Propofol|
41339603|NCT00321360|DEVICE|Patient maintained sedation|
41339604|NCT04563104|DIAGNOSTIC_TEST|Lung Ultrasound|We will evaluate the role of lung ultrasound on the duration of antibiotics, we hypothesize that ultrasound imaging may have a role, will be correlated with, procalcitonin (PCT). The created database will help in establishing conclusion and recommendations that will help to improve the antibiotics duration and decrease the resistance.
41339605|NCT04144049|DRUG|MT921|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
41339606|NCT04144049|DRUG|Placebo|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
40820600|NCT02687685|OTHER|skin to skin contact early|Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
41339607|NCT02978170|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
40820601|NCT06370572|OTHER|PAINAD EHR Prompt|Implementation of PAINAD EHR prompt in the ED workflow for PLWD presenting to the ED with hip pain
41339608|NCT06133985|OTHER|Costovertebral mobilizations + Conventional PT|"Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 10 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness."
41339609|NCT06133985|OTHER|Conventional treatment|diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
41487229|NCT06534528|DRUG|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
41487230|NCT05346783|DRUG|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
41487231|NCT05346783|OTHER|Placebo (vehicle)|1 drop 6 times a day
41487232|NCT05346783|DRUG|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
40820602|NCT05142254|DRUG|Tadalafil|2.5-5 mg/day
40820603|NCT05142254|DRUG|Hydroxyurea|20 mg/kg/day
40820604|NCT05142254|DRUG|Placebo|identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
40820605|NCT06230510|BEHAVIORAL|Introduction of Milk Type|Beginning at approximately age 2, milk (equivalent to 2 cups/day) will be provided at no cost to the family for one year.
41487233|NCT03905564|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).
40820606|NCT06230510|BEHAVIORAL|Child Nutrition Counseling|Parent/caregivers will receive quarterly phone-based counseling by a Registered Dietitian (RD) on how to introduce the toddler to the assigned milk and the importance of continuing to drink the assigned milk for the one year.
40820607|NCT01402076|DRUG|Tasimelteon|20mg daily dosing, Days 4-20
40820608|NCT01402076|DRUG|Rosiglitazone|4mg, single dose, Days 3 and 20
40820609|NCT01402076|DRUG|Midazolam|10mg, single dose, Days 1 and 18
40820610|NCT04379245|OTHER|Data research, database analysis|"Extraction of virological data at the virology laboratory (date, SARS-COV2 PCR result, identification number, sex, date of birth) (Excel file)~* Extraction of demographic and viro-immunological data from patients infected with HIV and on PrEP followed at the Hospices Civils de Lyon, France, over the period concerned (Access extraction)~* Data crossing (Excel / Access) and statistical analysis~* Calculation of the positivity rate per calendar period (= number of diagnosed cases / number of patients tested) and the attack rate per calendar period (number of diagnosed cases / number of people exposed (= active file of patients followed reduced by the number already known to be positive))."
40820611|NCT01384500|OTHER|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
40823000|NCT06607159|OTHER|Implementation of healthy habits teaching protocol|Protocol for teaching healthy lifestyle habits, aimed at school-age children (initially between 1st and 4th grade of primary school), to be implemented transversally in schools. This protocol takes into account three levels of action: school, family and pupils. It includes materials in paper format and digital materials, that can be used both at school and at home.
41487234|NCT03905564|DRUG|Diclegis (Registered Trademark)|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Duchesnay Inc.).
41487235|NCT01630681|BEHAVIORAL|Internet-based stepped care|Interactive support and Cognitive Behavioral Therapy
41487236|NCT03856684|BEHAVIORAL|Self-sampling kit sent at home|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
41339610|NCT00802724|BEHAVIORAL|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
41487237|NCT03856684|BEHAVIORAL|Self-sampling kit sent at home + SMS reminder|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~After 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
40820612|NCT04352764|DIAGNOSTIC_TEST|CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test|The tests are being distributed under section IV.D of the current United States Food and Drug Administration (FDA) policies for diagnostic tests for coronavirus disease 2019. The test is available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19
40820613|NCT02022215|DRUG|ME1111 Solution, Low strength|ME1111 Solution, Low strength, applied once daily for 48 weeks
40820614|NCT02022215|DRUG|ME1111 Solution, High strength|ME1111 Solution, High strength, applied once daily for 48 weeks
40820615|NCT02022215|DRUG|Matching Vehicle Solution|Matching Vehicle Solution, applied once daily for 48 weeks
40820616|NCT04752566|BIOLOGICAL|Eculizumab|Eculizumab will be administered via IV infusion once a week for 4 weeks.
40820617|NCT04752566|DRUG|Placebo|Placebo will be administered via IV infusion once a week for 4 weeks.
40820618|NCT01809145|OTHER|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
40820619|NCT03147612|BIOLOGICAL|Blinatumomab|Given via central catheter
40820620|NCT03147612|DRUG|Cyclophosphamide|Given IV
40820621|NCT03147612|DRUG|Cytarabine|Given intrathecally or IV
40820622|NCT03147612|BIOLOGICAL|Filgrastim|Given SC
40820623|NCT03147612|DRUG|Methotrexate|Given intrathecally or IV
40820624|NCT03147612|BIOLOGICAL|Pegfilgrastim|Given SC
40820625|NCT03147612|DRUG|Ponatinib|Given PO
40820626|NCT03147612|BIOLOGICAL|Rituximab|Given IV
40820627|NCT03147612|DRUG|Vincristine|Given IV
40820628|NCT02429557|OTHER|Abdominal compression|Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
40820629|NCT02429557|OTHER|Sham abdominal compression|Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
40820630|NCT02429557|DRUG|Placebo pill|Placebo pill given 1 hour before the second heat up tilt
40820631|NCT02429557|DRUG|midodrine|Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
40820632|NCT06352892|DRUG|Maridebart Cafraglutide|Solution for SC injection.
40820633|NCT06607874|OTHER|Non-Interventional Study|Non-Interventional study
40820634|NCT01865812|DRUG|Obeticholic Acid|All participants were treated with OCA (oral administration, 10 mg, once daily \[QD\]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
40820635|NCT01059682|DRUG|Dalcetrapib|Dalcetrapib 600 mg orally once daily
40820636|NCT01059682|DRUG|Placebo|Placebo orally once daily
40820637|NCT00978055|DRUG|1: Liothyronine Sodium Tablets|"Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
40820638|NCT00978055|DRUG|2: Cytomel® Tablets|"Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
40820639|NCT06561880|DRUG|Gilteritinib|"Induction therapy regimen(2 courses):~triple regimen therapy: Azacitidine 75mg/m2/d d1-7; Venetoclax 100mg d1,200mg d2,400mg d3-28; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~dose-adjusted triple regimen therapy: Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~Patients with no remission after the first induction course will receive another course with triple regimen therapy; Patients with complete remission after the first induction course will receive another course of dose-adjusted triple regimen therapy."
40820640|NCT06561880|DRUG|Cytarabine|"Consolidation therapy (3 courses):~intermediate-dose cytarabine regimen :2g/m2 q12h d1-3, age \< 60 years;1g/m2 q12h d1-3, age ≥60 years.~If NGS detected FLT3 mutation before consolidation chemotherapy, gilteritinib will be added during the consolidation course at d4-17."
40820641|NCT06561880|DRUG|Gilteritinib|"Maintenance treatment (6 courses):~dose-adjusted triple regimen therapy:Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28."
40820642|NCT02138409|DRUG|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
40820643|NCT02138409|DRUG|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
40820644|NCT04930549|DRUG|Dapagliflozin 10Mg Tab|Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
40820645|NCT04930549|DRUG|Placebo|Patients receive placebo tablets once a day during 12 weeks
40820646|NCT04930549|PROCEDURE|impedance cardiography|impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
40820647|NCT04930549|PROCEDURE|Applanation tonometry|Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
40820648|NCT04930549|PROCEDURE|post-ischemic hyperemia of forearm|An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
40820649|NCT04930549|PROCEDURE|haemodynamics parameters|haemodynamics parameters will be evaluated using automatic oscillometric recorder
40820650|NCT04316611|DRUG|Potassium chloride|Direct intravenous injection (IVD) 20 mmol potassium chloride
40820651|NCT05205538|OTHER|Sprint interval exercise training|A 10-minute sprint interval exercise training protocol that is performed three times per week for a total of 12 weeks.
40820652|NCT05564650|BIOLOGICAL|Navitoclax|Given PO
40820653|NCT05564650|DRUG|Venetoclax|Given PO
40820654|NCT05564650|DRUG|Decitabine|Given IV
40820655|NCT05564650|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41156887|NCT06159114|DRUG|Ningmitai capsule|Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
40820656|NCT05564650|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41156888|NCT06159114|DRUG|Celecoxib capsule|Celecoxib is one of NSAIDs recommended by the CUA Prostatitis Guidelines for alleviating pain symptoms in CP/CPPS patients. The instruction of Celecoxib capsule is 1 capsule at a time, 1 time a day.
41156889|NCT06159114|DRUG|Ningmitai placebo|Ningmitai placebo, a look-alike substance that contains no active drug, similar to Ningmitai capsule in color, smell, taste, shape, texture and other characteristics, 0.38g/ capsule.
40820657|NCT05564650|OTHER|Laboratory Biomarker Analysis|Correlative studies
40820658|NCT05564650|OTHER|Quality-of-Life Assessment|Ancillary studies
40820659|NCT00433160|DRUG|Teriparatide|daily, subcutaneous
40820660|NCT00433160|DRUG|Placebo|daily, subcutaneous
40820661|NCT02460354|DRUG|Metformin|Metformin 500 mg pill dispensed once orally
40820662|NCT06238141|OTHER|Expressive writing|"According to the writing prompts, online expressive writing focuses on stressful events and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.~Writing prompts are developed based on Emotional Processing Theory (EPT) and Cognitive Adaptation Theory (CAT)."
40820663|NCT06238141|OTHER|Neutral writing|According to the writing prompts, online neutral writing focuses on immediate surroundings and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.
40820664|NCT05362773|DRUG|MGD024|MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
40820665|NCT06011798|DRUG|Aflibercept|Anti-VEGF control
40820666|NCT06011798|DRUG|foselutoclax|Experimental drug
40820667|NCT05899595|OTHER|Exercise protocol|"Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~* Subjective fatigue (Rate of Fatigue scale)~* Heart rate variability with a holter ECG~* Muscle pain with a visual analogue scale~* Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises."
40820668|NCT04095351|DIAGNOSTIC_TEST|Pulmonary function test|Spirometry or plethysmography, measurement of diffusion capacity
40820669|NCT04095351|DIAGNOSTIC_TEST|Imaging|Thoracic ultrasound, HRCT as scheduled within routine clinical examinations, echocardiography
40820670|NCT04095351|BIOLOGICAL|Blood sampling|Standard laboratory test for CTDs as part of routine clinical examination
40820671|NCT02199951|DRUG|Dihydroartemisinin and piperaquine|Antimalarial
40823001|NCT01791881|DRUG|Hugeltox|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
40823002|NCT01791881|DRUG|Botulinum Toxin Type A(Botox®)|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
40823003|NCT03429673|PROCEDURE|Surgeries|Lobectomy or segment/wedge dissection
41156890|NCT06159114|DRUG|Celecoxib placebo|Celecoxib placebo, a look-alike substance that contains no active drug, similar to Celecoxib capsule in color, smell, taste, shape, texture and other characteristics, 0.2g/ capsule.
41156891|NCT06646731|DEVICE|cryoneurolysis|Peripheral nerve cryoneurolysis of the foot
40823004|NCT06338514|OTHER|Real dry needling|dry needling into the muscle under ultrasound guidance.
41156892|NCT06646731|DEVICE|sham cryoneurolysis|a sham probe will be placed percutaneously proximal to target nerves. No cryoneurolysis will be given.
41339611|NCT00802724|BEHAVIORAL|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
41339612|NCT00878306|DRUG|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
41156893|NCT05842915|BEHAVIORAL|Questionnaire|Baseline and 3 month questionnaire
41156894|NCT00023621|DRUG|celecoxib|
41339613|NCT00878306|DRUG|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
41339614|NCT00878306|DRUG|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
41339615|NCT00878306|DRUG|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
41339616|NCT03961295|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
41339617|NCT03534713|DRUG|Carboplatin|carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
41339618|NCT03534713|DRUG|Paclitaxel|paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
41339619|NCT03534713|DRUG|Cisplatin|Cisplatin 40mg/m² given once a week during 5 weeks
40820672|NCT04033887|DIAGNOSTIC_TEST|13 Rapid Diagnostic Tests and reference tests|"Rapid diagnostic tests:~1. HCV antibody test (under development); bioLytical Laboratories~2. DPP® HCV (under development); Chembio Diagnostic Systems~3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~4. Rapid Anti-HCV Test; InTec~5. First Response HCV Card Test; Premire Medical Corporation~6. Signal HCV Ver 3.0; Arkray healthcare~7. TRI DOT HCV; J. Mitra \& Co~8. Triplex HIV, HCV, HBsAg; Biosynex SA~9. Standard Q HCV Ab; SD Biosensor~10. HCV Hepatitis Virus Antibody Test; Artron Laboratories~11. SD Bioline HCV; Abbott Diagnostics~12. OraQuick HCV; OraSure~13. Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0"
40820673|NCT05249933|DRUG|Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8|Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
41339620|NCT03534713|RADIATION|Radiotherapy|45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines
40820675|NCT06495723|DRUG|LIS1|The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.
40820676|NCT06607341|BEHAVIORAL|Multi-level, community-digital health promotion intervention|"Community level activities:~1. Capacity building for community-based organizations, and~2. Community health workers will facilitate linkage to community resources, including health/social service access referrals and client social support.~Individual level activities:~1. Goal setting and self-monitoring,~2. Tailored feedback,~3. Personalized lifestyle coaching, health and social service referral support, and~4. Digital access and digital health literacy skills building~Social network:~1. Social network-based activities, and~2. Digital health literacy skills building"
40820677|NCT00379782|OTHER|Navigation|Navigation and escourt
41339621|NCT03557736|BEHAVIORAL|Training mode|type of exercise training completed for 12 weeks
41339622|NCT06336681|DEVICE|PrO2Fit Device|The flow-resistive protocol using the device requires participants to maximally inhale as hard as they can and as long as they can against a small leak (2mm diameter hole) until task failure. This records maximum inspiratory pressure (MIP) and sustained maximal inspiratory pressure (SMIP) values which will be recorded and the best is chosen for the software template by the participant to continue their training session (previously described in arm/group description). The use of the device occurs three times a week, and used for 6-8 weeks.
40820678|NCT05582850|DRUG|DT-9081 - dose escalation|Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.
40820679|NCT05582850|DRUG|DT-9081 - expansion|A homogeneous patient population will receive DT-9081 at up to 3 dose levels.
40820680|NCT03109093|DRUG|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab."
41339623|NCT03064269|BIOLOGICAL|CD19 CAR-T cells|CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
41339624|NCT02062372|DEVICE|7 T MRI|Overview Technical DetailsField strength: 7 Tesla Bore size: 60 cm System length: 317,5 cm RF power: 7,5 kW / 8x1 kW Gradient strength: SC 72 Gradients (max. 70 mT/m @ 200 T/m/s) Helium Consumption: Zero Helium boil-off technology
41339625|NCT02062372|PROCEDURE|Biopsy|During surgery patients will receive standard biopsies plus one study biopsy from a region of interest. The neuro-surgeon will determine the feasibility of the extra biopsy and the optimal biopsy tract. A screen capture from the neuronavigation system will be saved for each biopsy to relate the findings on 3T and 7T MRI to histopathology.
41339626|NCT02139267|BIOLOGICAL|GX-188E|DNA vaccine administered via IM route using TDS-IM electroporation device
41339627|NCT02813863|DRUG|SP2086|
41339628|NCT02813863|DRUG|Metformin|
41339629|NCT04587895|BEHAVIORAL|VITAAL Exergame|12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.
41487238|NCT03856684|BEHAVIORAL|"Letter offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear.~Women are invited to ask the kit online, on our website.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
41487239|NCT03856684|BEHAVIORAL|"SMS offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request).~Women are invited to ask the kit by answering 1 by SMS.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
40820681|NCT01333969|PROCEDURE|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
40820682|NCT01327053|DRUG|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
40820683|NCT06606600|OTHER|Intensive Kebbi robot interventions|The intensive Kebbi robot interventions will receive 30 minutes, 3 times per week for 12 weeks.
41156895|NCT06550297|BEHAVIORAL|Medically Tailored Meals and Nutritional Counseling|God's Love We Deliver's current MTM program, which consists of weekly home-delivered MTMs and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. The Food is Medicine Coalition Clinical Committee establishes and regularly updates the MTM Nutrition Standards, which catalogue the nutrition quality of this evidence-based intervention. Arms 1-3 will receive 10 MTMs per week for 8 months. Arm 4 will receive a distinct dosing down approach as follows: 10 MTMs/week in months 1-3, 9 MTMs/week in month 4, 8 MTMs/week in month 5, 7 MTMs/week in month 6, 6 MTMs/week in month 7, and 5 MTMs/week in month 8.
41487240|NCT00076804|BEHAVIORAL|Directly Observed Therapy|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
41487241|NCT03535675|DRUG|Muscadine Plus|Ellagic acid inhibits DNA Methyltransferase. DNA Methyltransferases (DNMTs) are a family of enzymes that regulate chromatin methylation and use S-adenosyl methionine (SAM) as the methyl donor. Ellagic acid's metabolite, urolithin-A inhibits the protein complex nuclear factor kappa-light-enhancer of activated B-cells (NFkB), potentially leading to increased rates of apoptosis and decreases in cancer cell proliferation. Extracts from Vitis rotundifolia have shown inhibition of the phosphatidylinositol 3-kinase-Akt pathway.
41487242|NCT03535675|DRUG|Placebos|The placebo capsules are rice flour that will be placed in white opaque capsules identical to the ones used for MPX.
41487243|NCT03322618|BIOLOGICAL|blood samples|7 tubes of 6 ml (42 ml of blood )
41487244|NCT00115297|DRUG|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
41487245|NCT00115297|DRUG|Placebo|Participants who were 2 to 3 years old received placebo montelukast tablets and participants who were 12 months to 2 years old received placebo montelukast granules.
41487246|NCT06180317|OTHER|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI and VAS just before the endometrial biopsy procedure, VAS during the procedure and again with STAI and VAS after the procedure.
41487247|NCT02593435|GENETIC|NGS test|"To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.~To know mutation characteristic spectrum of BRCA1/2."
41487248|NCT05778552|DEVICE|Home-based pelvic muscle training devices or traditional PFMT at hospital|Performed home-based pelvic muscle training devices at home or traditional PFMT at hospital
41487249|NCT01601366|DEVICE|LNG-IUS|"The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them"
41487250|NCT01601366|DRUG|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
41487251|NCT05497193|DRUG|perampanel|China's state food and drug administration approved indications for adults and children aged 4 or more focal epileptic hair company or not with secondary comprehensive seizures of epilepsy, adding treatment, in July 2020 to monotherapy without clinical approval, the current domestic perampanel monotherapy clinical effectiveness and safety of focal epilepsy in children have not been reported.
41487252|NCT04336514|DEVICE|Semi-compressed felt pad (SCF)|Participants with forefoot callus will receive routine treatment of debridement of callus. Along with the debridement, a Plantar Metatarsal Pad (PMP) made of Semi-Compressed Felt (SCF) with appropriate cut outs will be placed in their shoes. The thickness of the SCF would be selected based on the patient weight, and appropriateness of the thickness would be confirmed by the Medilogic pressure measurement. A 50% pressure reduction is the desired outcome.
41487253|NCT03446911|RADIATION|SABR|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy.
41487254|NCT03446911|COMBINATION_PRODUCT|SABR + pembrolizumab|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy + 2 rounds of pembrolizumab
41487255|NCT01066091|OTHER|Mashed potatoes|Mashed potatoes: Potatoes + Skim milk powder
41487256|NCT01066091|OTHER|Mashed potatoes + Oleic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid
40820684|NCT02388035|DRUG|Cefotaxime|
40820685|NCT04053400|DRUG|Ketamine|
40820686|NCT06196463|PROCEDURE|Erector spinale block (ESP block)|The Study has the Objective to analyze the efficacy of the ESP block in spine Surgery (juvenile idiopathic scoliosis) to control perioperative pain
40820687|NCT06196463|PROCEDURE|AG + sham block|General anesthesia
40820688|NCT04434625|DRUG|Polyethylene glycol|Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score\<3 in IM group and those in the control group underwent colonoscopy directly
40820689|NCT01598337|DRUG|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
40820690|NCT01598337|DRUG|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
40820691|NCT01598337|DRUG|Clopidogrel|75 mg orally started 6-8hours before surgery
40820692|NCT01598337|DRUG|Prasugrel|10 mg daily as per instructions of investigators
40820693|NCT06389331|OTHER|closed the defect with barbed suture|In direct hernia, content was reduced, and the fascia transversalis (pseudo sac) was pulled and incorporated into closure with a non-absorbable polypropylene barbed monofilament size-0 suture
40820694|NCT06580119|BEHAVIORAL|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
40820695|NCT01165788|PROCEDURE|Semi structured personal interview|A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
40820696|NCT00842153|DRUG|Clobetasol propionate foam|Topical Clobetasol propionate foam
40820697|NCT00842153|DRUG|Vehicle foam|Vehicle foam does not include the active drug.
40820698|NCT05382468|OTHER|Intradialytic exercise|Intradialytic exercise comprised of a set warm up, aerobic, active,passive \& cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month \& supervised by principle investigator.
40820699|NCT01275612|BIOLOGICAL|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
40820700|NCT01895231|DRUG|Iron isomaltoside 1000 (Monofer®)|
40820701|NCT01895231|DRUG|Placebo|
40820702|NCT06204861|OTHER|Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode.
40820703|NCT06204861|OTHER|Balance Training|The training program consists of five exercises: single-limb stance, single-limb stance with ball toss, single-limb stance with kicking, step-down with a single-limb stance, and wobble board. The program is conducted three times a week, and the difficulty level is increased every two weeks. Before and following the training, a physiotherapist will lead a warm-up and stretching session.
40820704|NCT06204861|OTHER|Balance Training Combined with Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode. However, the B+CRET group received balance training along with CRET treatment.
40820705|NCT02607917|OTHER|Mass Media plus clinic intervention.|
40820706|NCT02607917|OTHER|Media|
40820707|NCT03120260|OTHER|Diet|Intervention 'Diet+ short sleep versus normal sleep
40820708|NCT05186103|OTHER|observation|The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).
40820709|NCT02435407|BEHAVIORAL|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
40820710|NCT02435407|OTHER|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
40820711|NCT04915989|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
40820712|NCT00534118|BIOLOGICAL|donor lymphocytes|Given IV
40820713|NCT03620552|DRUG|18F-S16|A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans
40820714|NCT03193814|DRUG|Chemotherapy + Apatinib|chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
41339630|NCT04587895|BEHAVIORAL|Conventional Training UI|12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The PFM training booklet is based on exercises that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises.
41487257|NCT01066091|OTHER|mashed potatoes + Palmitic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
41156896|NCT06550297|BEHAVIORAL|Cardiovascular Health Promotion Educational Program|Culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.
41487258|NCT01739920|OTHER|Povidone-iodine|Povidone iodine 5% drop will be instilled into conjunctival sac.
41487259|NCT01739920|OTHER|Saline Solution|1 drop of saline solution 0.9% will be instilled into conjunctival sac.
41487260|NCT06417736|DRUG|Megestrol Acetate 40 MG|160mg/one time/day
41487261|NCT06035471|DIAGNOSTIC_TEST|MeD-seq|MeD-seq analyse: DNA treatment bisulfite --\> unmethylated C-nucleotide trabsformed in uracil.--\> PCR --\> next generation sequencing (NGS) --\> localization methylated nucleotides (enzym LpnPI).
41487262|NCT05154032|OTHER|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions three times a week for 3 weeks.
41487263|NCT00320567|DRUG|norgestimate/ethinyl estradiol|
40820715|NCT03200275|DIAGNOSTIC_TEST|Immunocatch™ Legionella Urine Antigen Test|A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
40820716|NCT05721937|DRUG|Abrocitinib|taken by mouth
40820717|NCT00000146|DRUG|Methylprednisolone|
40820718|NCT00000146|DRUG|Prednisone|
40820719|NCT04960384|DRUG|FGF-2|The FGF-2 method of use comprises a pledget of gelatin sponge, with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of fibrin glue used for applications in ear surgery. The concentration of the FGF-2 solution will be 100μg of FGF-2 per 1 mL with an estimated dose of about 20 μg in 0.2ml. Fibrin glue will be applied to secure gelatin sponge after placement according to the size of the membrane perforation. Application of the study treatment will occur at Visit 1 and may be repeated at each follow up visit as needed for a maximum of three treatments in the Randomized Treatment Phase (Visit 1, Visit 2, and Visit 3).
41156897|NCT03761407|DRUG|100 mg GRT0151Y|100 mg capsule (1 x 100 mg capsule)
41156898|NCT03761407|DRUG|125 mg GRT0151Y|125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)
41487264|NCT01996943|DRUG|Ethanol|6% volume/volume ethanol in 0.45% saline solution.
41487265|NCT01996943|DRUG|Placebo|"The placebo with be 0.45% saline solution (half normal saline)."
41487266|NCT03308266|DIAGNOSTIC_TEST|electromyography|
41487267|NCT01019863|DRUG|oxaliplatin|oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
41487268|NCT03449836|COMBINATION_PRODUCT|Streptococcus salivarius 24SMBc + Strept. oralis 89a|nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a
41487269|NCT03449836|COMBINATION_PRODUCT|fluticasone + mometasone|nasal spray based on fluticasone + mometasone
41487270|NCT03449836|OTHER|placebo|nasal spray based on isotonic solution
41487271|NCT05407025|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and tissue samples
41487272|NCT05407025|OTHER|Questionnaire Administration|Complete risk factor questionnaire
41156899|NCT03761407|DRUG|150 mg GRT0151Y|150 mg (1 x 100 mg capsule and 1 x 50 mg capsule)
41156900|NCT03761407|DRUG|225 mg GRT0151Y|Day 1: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule) Day 2 - 5: 225 mg (2 x 100 mg capsules and 1 x 25 mg capsule)
41156901|NCT03761407|DRUG|Matching placebo|Matching placebo capsules using the same dosing regimen as defined in the treatment groups.
40820720|NCT04960384|DRUG|Placebo|FGF-2 will be replaced with sterile water to saturate a pledget of gelatin sponge. The method will be otherwise identical to the FGF-2 intervention.
40820721|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
40820722|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
41487273|NCT01668693|OTHER|ERA (Endometrial Receptivity Array)|"The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction."
40820723|NCT02746601|BEHAVIORAL|Risk Assessment, Counselling & Resources|A risk assessment tool is completed on a tablet. The results are scanned into the patient's electronic medical record. A healthcare provider gives behavioural counselling on identified risk factors. The patient is given a customized handout that includes health recommendations and resources based on the participant's identified risk factors.
40820724|NCT02027818|DRUG|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
40820725|NCT06519175|OTHER|Conservative treatment|Patients are provided with physiotherapy support and the provision of prostheses with the goal of ensuring as much walking functionality as possible.
40823005|NCT06338514|OTHER|Sham dry needling|dry needling into the subcutaneous fatty tissue under ultrasound guidance.
41487274|NCT01668693|OTHER|Personalized Embryo Transfer|When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
41487275|NCT01668693|OTHER|Second ERA|A second ERA will be performed to confirm receptivity after further administration of Progesterone.
40820726|NCT06519175|PROCEDURE|Single or multi-stage surgery|Correction of the deformity is pursued by one or more surgical procedures with the timing and the techniques (growth modulation, acute correction, gradual correction, soft tissues procedures, combined techniques) chosen according to the surgeon's preference to achieve the maximum possible walking functionality without orthopedic aids.
40820727|NCT06519175|PROCEDURE|Amputation|Limb surgery, whether or not associated with realignment or soft-tissue surgery, is performed, aimed at providing the maximum possible walking function through a prosthesis.
40820728|NCT00050531|DRUG|Gleevec|400 mg orally twice daily.
40820729|NCT00050531|DRUG|Peg-alpha interferon (Peg-Intron)|PEG-IFN 0.5 mcg/kg each week subcutaneously.
40820730|NCT00050531|DRUG|Sargramostim (GM-CSF)|125 mcg/m\^2 three times per week subcutaneously.
40820731|NCT05268393|BEHAVIORAL|BREATHE-T1D|BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.
40820732|NCT06608680|BEHAVIORAL|iTBS|Excitatory stimulation of supramarginal gyrus
40820733|NCT06608680|BEHAVIORAL|cTBS|Inhibitory stimulation to supramarginal gyrus
40820734|NCT06608680|BEHAVIORAL|Sham Stimulation|Sham stimulation of supramarginal gyrus
40820735|NCT05775549|OTHER|None (Observational Study)|Not Applicable since observational study
40820736|NCT05045820|DEVICE|needling acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis. Needling acupuncture treatment will last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of treatment which contains 10 treatment sessions."
40820737|NCT05045820|DEVICE|laser acupuncture|Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin. Laser acupuncture treatment will also last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of laser acupuncture treatment which contains 10 treatment sessions.
40820738|NCT04484649|BEHAVIORAL|Sleeping Healthy/Living Healthy|Sleeping Healthy/Living Healthy will be a school based health center (SBHC)-based intervention integrating mind-body integrative health (MBIH) and sleep hygiene strategies to improve sleep quality in urban adolescents. The Sleeping Healthy/Living Healthy intervention content and format will be determined in a Development Phase 1. The investigator anticipates the intervention will consist of two group and two one-on-one sessions. The intervention will be grounded in social-cognitive theory and use motivational interviewing to support MBIH and sleep hygiene strategies. Sessions will be delivered once per week by SBHC providers and health educators.
40823006|NCT06605976|BEHAVIORAL|DAX CoPilot Group|Participants in this group were given a license for DAX CoPilot and asked to use it for clinical documentation.
41339631|NCT04587895|BEHAVIORAL|Conventional Training MI|"12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu)."
41339632|NCT05148559|BEHAVIORAL|Reminder Sent Via Preferred Method of Communication|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a vaccine reminder notice every other month via their preferred method of communication (text message, email, mailed letter) until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
40823007|NCT06607107|DRUG|mFOLFOX7 combined with Camrelizumab and apatinib|mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.
40823008|NCT03407495|DRUG|IOP Injection (MPB-1523)|one dose, once IV injection at Day 1
41156902|NCT06647394|PROCEDURE|Matrix Dressing|extracellular matrix dressing soaked in 4% topical lidocaine to the skin graft donor site
41339633|NCT05148559|BEHAVIORAL|Reminder Sent Via Mailed Letter|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a mailed vaccine reminder letter every other month until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
41339634|NCT04955509|OTHER|MRI|conventional MRI and diffusion MRI
41339635|NCT03942549|DEVICE|Retropubic midurethral sling|Midurethral sling
41339636|NCT00048490|DEVICE|transcranial magnetic stimulation (TMS)|
41339637|NCT01873807|DRUG|IDA|Idarubicin: 15mg/m2/d: -8-\>-6d
41339638|NCT01873807|RADIATION|TBI|TBI: 4.5 Gy/d, -5d, -4d
41339639|NCT01873807|DRUG|CTX|CY:60mg/kg/d, -3d, -2d
41339640|NCT01873807|DRUG|VP-16|VP-16: 15mg/kg, -2d, -1d
41339641|NCT04569617|OTHER|Resistance Training - UL endurance protocol|UL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
41339642|NCT04569617|OTHER|Resistance Training - UL strength protocol|UL strength protocol - 2 series of 8 repetitions, elbow flexion at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
41487276|NCT00197496|PROCEDURE|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
40820739|NCT04484649|BEHAVIORAL|Attention Control|"The Attention Control Intervention condition will meet the requirements for a comparison treatment for testing behavioral interventions - equivalent in contact time, credible and interesting, and exert limited treatment effects.~In the same number of sessions and format as the Sleeping Healthy/Living Healthy intervention (anticipated to be two group and two one-on-one sessions delivered once per week by SBHC providers and health educators), the study will teach participants about sleep and other health topics relevant to adolescents (e.g., nutrition, injury prevention) devoid of the MBIH elements in our integrated intervention."
41487277|NCT02568566|OTHER|Laboratory Biomarker Analysis|Correlative studies
41487278|NCT02568566|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
40820740|NCT04420572|DRUG|ozone injection|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
40820741|NCT04420572|DRUG|betamethasone|1ml betamethasone will be used for steroid injection.
40820742|NCT05210517|DRUG|Empagliflozin 25 MG|25 once daily one week treatment
41156903|NCT05164133|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab
41339643|NCT04569617|OTHER|Resistance Training - LL endurance protocol|LL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test strength of 1 maximum repetition, (recovery 1 minutes between sets).
41487279|NCT03966248|OTHER|Chinese Tuina therapy|"1. The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle;~2. The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb;~3. Massage the spleen and stomach meridians of the affected lower extremes;~4. Roll the soft tissues around the affected knee;~5. Relax the gastrocnalis muscle~6. The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time;~7. Push the patella and do the passive movement of the affected knee;~8. Strength training of the affected knee.~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
41487280|NCT03966248|OTHER|Physical Manual therapy|"1. Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa.~2. Activity training: Mainly about the knee joint flexion and extension movement training.~3. Strength training: Mainly about quadriceps muscle resistance exercises~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
40820743|NCT05210517|DRUG|Benzbromaron|100 mg once daily 1 one week treatment
40820744|NCT05210517|DRUG|Empagliflozin 25 MG + benzbromarone 100 mg|combined treatment once daily for one week
40820745|NCT02356419|DRUG|Recombinant erythropoietin stimulating protein|Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
40820746|NCT02218086|DEVICE|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
40820747|NCT02218086|DEVICE|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
40820748|NCT02218086|DEVICE|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
40820749|NCT02218086|DEVICE|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
40820750|NCT02218086|DEVICE|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
40820751|NCT02218086|DEVICE|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
40820752|NCT02218086|DEVICE|Slackline vs. standing-on-1-leg vs. control|beginners have to train 9 times \~15minutes within y few weeks.
40820753|NCT01023555|OTHER|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
40823009|NCT03986580|DEVICE|Annular closure device|Annular closure, following limited discectomy procedure at a single LS level between L4 and S1
40823010|NCT02816593|DRUG|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
41339644|NCT04569617|OTHER|Resistance Training - LL strength protocol|LL strength protocol - 2 series of 8 repetitions, knee extension at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
41339645|NCT04963634|OTHER|Biobanking|For patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).
41339646|NCT02465489|DRUG|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
41339647|NCT02465489|DRUG|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
40820754|NCT05768438|OTHER|Mulligan with upper limb movement|Group A subjects will receive mulligan mobilizations with upper limb movement of the involved side. The patient will be in a sitting position and the therapist will stand beside the patient. The therapist will place one thumb overlapped by the other on one of the selected cervical and then the therapist will push down the spinous process of that specific vertebrae, the pressure will be sustained and the patient will actively abduct his/her arm, assistance will be provided if needed. Initially it will start from 10 repetitions and 1 set which will further progress up to 2 or 3 sets as per patient's tolerance with 60 seconds rest in between each set.
41339648|NCT02868164|DRUG|Fecal Microbiota Transplantation|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 6 month.
41339649|NCT02868164|DRUG|Standard Treatment|Standard Treatment
41339650|NCT02868164|OTHER|Weight Reduction|routine exercise for weight reduction
41339651|NCT01624467|BIOLOGICAL|Necitumumab|800 mg necitumumab, administered once per week IV
41339652|NCT04036513|PROCEDURE|MINST|"For reducing the need of surgical treatment in patients with chronic periodontal disease, we will use specifically designed Hu-Friedy curettes mini five, micro mini five and after five together with piezoelectric device with thin and delicate tips that produce less periodontal trauma than usual Gracey curettes."
40823011|NCT02816593|DRUG|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
41339653|NCT04036513|PROCEDURE|Conventional SRP|Scaling and root planing with conventional instruments.
41339654|NCT04682249|DRUG|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
41339655|NCT04682249|DRUG|Sintilimab|Sintilimab
41339656|NCT04682249|DRUG|Apatinib|Apatinib
41339657|NCT01068613|DRUG|QAX028|QAX028 60 mcg via inhalation device
41339658|NCT01068613|DRUG|QAX028|QAX028 20 mcg via inhalation device
41339659|NCT01068613|DRUG|Tiotropium|Tiotropium via inhalation device
41339660|NCT01068613|DRUG|Placebo|Placebo to QAX028 via inhalation device
41339661|NCT01235507|DRUG|methotrexate|stable dose as prescribed
41339662|NCT01235507|DRUG|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
41339663|NCT04835441|DRUG|ALPN-101|Blinded ALPN-101 will be administered
41339664|NCT04835441|DRUG|Placebo|Blinded placebo matching ALPN-101 will be administered.
41339665|NCT06405685|DRUG|Nimotuzumab|Nimotuzumab 400 mg will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
40820755|NCT05768438|OTHER|McKenzie exercises with neural mobilizations|The subjects of Group B will receive McKenzie exercises. Initially, it will start with retraction exercises. The frequency of exercises will be 10 to 15 repetitions followed by three to four sets with one second hold. On the second or third day, the cervical extension will be added. While in the second week the same set of exercises will be administered with the patient in a sitting position combined with application of over pressure at the end range by therapist. In the third week, extension and retraction exercises will be performed along with traction which will be applied by the therapist. Finally, in the fourth week all retraction and lateral flexion then neck rotation and the last one retraction with neck flexion will be added. Neural mobilizations will be given to patients in group B in supine lying. From proximal to distal, 20 oscillations (1 oscillation/ 1 second)
40820756|NCT02152059|DRUG|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
40820757|NCT05979220|DRUG|Dalpiciclib combined with Letrozole|A multicenter, single arm, prospective Phase II clinical study
40820758|NCT01762956|OTHER|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
40820759|NCT03586323|DRUG|superior laryngeal nerve block with lidocaine|SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
40820760|NCT05956665|BEHAVIORAL|Shed-MEDS deprescribing intervention|See single arm description
40820761|NCT03163693|DRUG|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
40820762|NCT03163693|OTHER|normal saline|receive equal volume of normal saline
40820763|NCT02419196|OTHER|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
40820764|NCT01452230|BEHAVIORAL|Supervised physical activity|Supervised physical activity
40820765|NCT03785860|OTHER|Dietary Fiber|Dietary fiber will be given in a powder form to mix with a beverage of one's choice.
40820766|NCT03785860|OTHER|Placebo|Placebo will be given in a powder form to mix with a beverage of one's choice.
40820767|NCT06607458|DRUG|Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab|Trifluridine-tipiracil plus Bevacizumab Alone
40820768|NCT06607458|DRUG|Trifluridine-tipiracil plus Bevacizumab Alone|Trifluridine-tipiracil plus Bevacizumab Alone
40820769|NCT02076308|OTHER|Electroacupuncture and physical therapy|real electroacupuncture
41339666|NCT06405685|DRUG|AG|Patients will receive AG as conversion therapy up to 6 months. Gemcitabine 1000 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle. nab-Paclitaxel 125 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
41339667|NCT00712270|DRUG|Aripiprazole|Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
41487281|NCT02446327|OTHER|Blood sampling for biomarker assessment|
40820770|NCT02076308|OTHER|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
40820771|NCT04613765|BEHAVIORAL|Measure adherence behaviors|"Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings."
41339668|NCT00712270|DRUG|Risperidone|Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
41339669|NCT02230839|BEHAVIORAL|Exercise|Participants will complete a progressive 6-month exercise training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include stationary cycling, elliptical and rowing machines, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55). Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using resistance machines (total days of exercise will still be 4 to 5).
41339670|NCT02230839|BEHAVIORAL|Energy Restriction-Induced Weight Loss|The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (\<30% of calories from fat) diet will be used as part of the weight loss intervention.
41339671|NCT03022604|DIETARY_SUPPLEMENT|C4/Generation 4|12 grams of C4/Generation 4
41339672|NCT03022604|DIETARY_SUPPLEMENT|C450X|12 grams of C450X
41339673|NCT03022604|DIETARY_SUPPLEMENT|Placebo|12 grams of flavored dextrose
40820772|NCT03523793|BEHAVIORAL|Clinical Practice Guideline Implementation|The Study team will use several methods from the implementation strategy taxonomy of the Effective Practice and Organization of Care (EPOC) classification system to improve our likelihood for successful neck and low back pain implementation consisting of: 1) educational materials, workshops and outreach visits from trainers; 2) external consultant testimonials; 3) iterative quality improvement processes (including ongoing analysis of clinician feedback to improve process); 4) routine collection of patient reported outcomes to engage discussion among clinician groups and outpatient division leaders) and 5) local organization consensus process (including feedback from key outpatient division stakeholders).
41339674|NCT02143141|DRUG|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
40820773|NCT03523793|OTHER|Standard Care|Considering the stepped wedge design with a 12-week washout phase, clinics will be providing standard physical therapy prior to receiving clinical practice guideline training.
40820774|NCT03195660|DEVICE|ASV Therapy|AirCurve 10 ASV device set up in AutoSet mode
40820775|NCT01684709|BEHAVIORAL|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
40820776|NCT04419740|BEHAVIORAL|Mindfulness based psychological intervention|Women in the intervention group will have to use an application during 1 month. They will do meditation during 15 minutes each day.
40823012|NCT02816593|DRUG|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
40823013|NCT01396265|DRUG|Afatinib|single dose
40823014|NCT01396265|DRUG|Afatinib|single dose
40823015|NCT01396265|DRUG|Rifampicin|multiple doses
40820777|NCT00338832|BEHAVIORAL|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
40820778|NCT00338832|BEHAVIORAL|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
40820779|NCT05209451|BEHAVIORAL|Digital, evidence-based behavioral health program for smoking cessation|Remotely delivered, 12-week smoking cessation program delivered through the patient portal. The program will deliver a smoking cessation intervention that links study participants to tailored, interactive and effective evidence-based smoking cessation resources.
40820780|NCT05209451|OTHER|Bluetooth enabled iPad|Bluetooth enabled iPad with data plan coverage that provides a personal Wi-Fi (Internet) hot spot for all home devices and allows for up to 64 GB of cellular data.
40820781|NCT05209451|BEHAVIORAL|Coaching Support|Six coaching calls, 15-20 minutes each in duration. The research coach will use motivational interviewing and goal setting to enhance the participant's technology access and use and digital literacy.
40820782|NCT06605729|OTHER|e-learning|The content of this e-learning is based on most recent scientific knowledge and guidelines about the management of chronic pain and physical activity and on behavioral change. Four themes are presented: chronic pain, physical activity and chronic pain, specific populations and behavior change.
40820783|NCT03691818|DRUG|X0002 Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
40820784|NCT03691818|DRUG|Ibuprofen Tablet|Ibuprofen Tab 400mg, tid.
40820785|NCT03691818|DRUG|Ibuprofen Placebo Tab|Ibuprofen Placebo Tab 400mg, tid.
40820786|NCT03691818|DRUG|X0002 Placebo Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
40820787|NCT05892770|DRUG|Zinc gluconate supplement|Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
40820788|NCT05892770|DRUG|Botulinum toxin type A|This is the current standard of care for treatment of spasmodic dysphonia. Botox injection goes into the vocal cord muscle, and will be occur in both the control and experimental arms of the study.
40820789|NCT03425006|DRUG|Itacitinib|a JAK 1 selective small molecule inhibitor
40820790|NCT03425006|BIOLOGICAL|Pembrolizumab|a highly selective humanized monoclonal antibody (mAb)
40820791|NCT00702533|DEVICE|Pentagastrin Injection BP|
40820792|NCT00702533|DRUG|Pentagastrin|
40820793|NCT05894096|DEVICE|Cold Atmospheric Plasma Jet Treatment|Application of Colf Atmospheric Plasma Jet on the wound
40820794|NCT05894096|DEVICE|Alginate Patch|Application of Alginate Patches on the wound
40820795|NCT04073784|DRUG|Gemcitabine combined with Aptinib and Toripalimab|"Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance."
40820796|NCT03839485|DRUG|Endodontic treatment using Guedes-Pinto Paste|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
40820797|NCT03839485|DRUG|Endodontic using Guedes-Pinto Paste without antibiotic|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
40820798|NCT06609070|DRUG|CHG0521 Oral Coating|The subjects will receive an oral coating of CHG0521 in the form of drops, in addition to the clinician\&#39;s standard treatment regimen, for a duration of 6 months or until confirmed progression, unacceptable toxicity, or any criteria for withdrawal from the trial.
40820799|NCT04485611|BEHAVIORAL|Supervised aerobic + resistance training and nutritional support|The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements\]\]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
40820800|NCT03659903|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy
40820801|NCT05608395|DRUG|11C-Methionine PET/CT|11C-Methionine PET/CT will be applied in patients in 11C-Methionine PET/CT Arm, based on planning MRI, prior chemo/radiotherapy (2 weeks prior C1D1)
40820802|NCT05467761|DRUG|Oral Psilocybin|25mg orally
40820803|NCT05467761|DRUG|IV Psilocybin|5mg intravenously
40820804|NCT06608056|DRUG|Pain management after surgery|Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.
40820805|NCT05764304|DRUG|Sinomenine|Participants will receive one intra-articular injection every 4 months
40820806|NCT05764304|DRUG|Glucocorticoid|Participants will receive one intra-articular injection every 4 months
40820807|NCT05118464|OTHER|Dual-task training|Dual-task training includes simultaneous execution of motor and cognitive tasks. The motor tasks in this study will be walking, going up and downstairs, turning, throwing, and holding a ball. Cognitive tasks will be an n-back test, verbal fluency, remembering sequences of numbers, and performing simple summing.
40820808|NCT03690492|OTHER|The Box 2.0|Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
41487282|NCT02327416|DRUG|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
40820809|NCT06344052|DRUG|SP-002|SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration
40820810|NCT06344052|DRUG|Vismodegib|The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
40820811|NCT02041975|DIETARY_SUPPLEMENT|Nutriose FB06|Wheat dextrin soluble fibre
40820812|NCT02041975|DIETARY_SUPPLEMENT|Placebo|
40820813|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention|The BAI contained components of effective interventions developed for young adult drinkers both in health care and educational settings and was specifically tailored to the unique needs and risk factors of Airmen. The 1-hour group intervention was administered using the principles of motivational interviewing (MI) in an interactive Socratic style to generate feedback and discussion. Open-ended questions, reflections, as well as the decisional balance scale were used to increase Airmen's motivation to remain alcohol free.
40823016|NCT06608979|BEHAVIORAL|Screening/Referral and Prevention|Session 1: One hour PTSD Screening/referral and Psychoeducation on interpersonal violence (consent, drug-and-alcohol-facilitated assault, intimate partner violence); Session 2: One hour sessions on Protective Behavioral Strategies for interpersonal violence (skills training)
40823017|NCT04862949|DRUG|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
40820814|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention Booster|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
41339675|NCT02143141|DRUG|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
41339676|NCT06348758|OTHER|questionnaire|E-Questionnaire will be sent to the students
41339677|NCT04884997|DRUG|toripalimab|toripalimab 3mg/kg, Q2w;
41339678|NCT04884997|DRUG|Temozolomide Injection|Temozolomide 150mg/m2,d1-5,Q4w
41487283|NCT02327416|DRUG|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
41487284|NCT02327416|DRUG|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
41487285|NCT01853930|BEHAVIORAL|Platform for Administering Eye-movement Control Training|The Platform for Administering Eye-movement Control Training (PAECT) meta program will incorporate all of the exercises that the investigators have developed and validated over the course of our previous Merit Review grants (Seiple, Szlyk et al., 2005, 2011). The PAECT platform will be designed to allow patients to easily run the training exercises in their homes and to practice at their convenience. The PAECT will employ an executive component that will keep track of the exercises that are practiced and record performance. Each time a subject opens the platform, it will choose the exercise for that subject based upon previous training and performance.
41487286|NCT05093036|OTHER|Variations in PrEP care delivery at public health services|Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring
41487287|NCT01565850|DRUG|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
41487288|NCT01565850|DRUG|DRV|DRV 800 mg (2 × 400 mg tablets) administered orally once daily
41487289|NCT01565850|DRUG|COBI|COBI 150 mg tablet administered orally once daily
41487290|NCT01565850|DRUG|FTC/TDF|FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
41487291|NCT01565850|DRUG|D/C/F/TAF Placebo|D/C/F/TAF placebo tablet administered orally once daily
41487292|NCT01565850|DRUG|DRV Placebo|DRV placebo tablet administered orally once daily
41487293|NCT01565850|DRUG|COBI Placebo|COBI placebo tablet administered orally once daily
41487294|NCT01565850|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
41487295|NCT03098914|OTHER|Cohort Study； pathogen； clinical features|Cohort Study； pathogen； clinical features
41487296|NCT00555035|DRUG|GSK1349572|
41487297|NCT03365167|RADIATION|LANAP (Laser Assisted New Attachment Procedure)|radiation of Nd:YAG laser in periodontal pocket
40820815|NCT01398319|BEHAVIORAL|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence (Coker et al., 2011). While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
40820816|NCT04939181|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents:~pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
40820817|NCT04939181|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
40820818|NCT05469789|OTHER|No Intervention|As it is an observational study, no intervention is administered in this study.
40820819|NCT05785741|DRUG|DB-1310|Administered I.V.
41487298|NCT03365167|RADIATION|LANAP off|radiation of Nd:YAG laser in off mode in periodontal pocket
41487299|NCT01064323|DEVICE|Intermittent pneumatic compression of the lower extremities|IPC will be done for 3 divided hours daily for 4 weeks
41487300|NCT05425693|OTHER|Hybrid Warm-up|Dynamic + stretching exercises
41487301|NCT05425693|OTHER|Dynamic Warm-up|Dynamic exercises
41487302|NCT05425693|OTHER|Stretching Warm-up|Stretching exercises
40820820|NCT05785741|DRUG|Trastuzumab|Administered I.V.
40820821|NCT05785741|DRUG|Osimertinib|Administered I.V.
40820822|NCT05452954|BEHAVIORAL|Brief behavioral parent training|In the newly developed intervention, both stimulus control and contingency management techniques will be offered in a brief behavioral parent training consisting of two intervention sessions and one booster session.
41487303|NCT00558909|DRUG|BI 44847|
41487304|NCT00558909|DRUG|placebo for BI 44847|
41487305|NCT04769687|BIOLOGICAL|probiotic Vivomixx®|Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
41487306|NCT04769687|BIOLOGICAL|prebiotic Orafti®Synergy1|Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
41487307|NCT04769687|OTHER|Placebo|Placebo
41487308|NCT03757273|PROCEDURE|FFF with CAD/CAM customized cutting guide|This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton and lower legs. the CT scan will be sent to the modeling company for producing autoclavable 3D models and cutting guides of the mandible and fibula to be used during the workflow as well as a model of the final reconstructed mandible. Surgery will be performed by two surgical teams, one for cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, osteotomy guides secured; cuts then accomplished as planned virtually. fibular flap is harvested and cutting guides secured to replicate osteotomies and reshaping as planned to conform with remaining mandible. fixation and pedicle anastomosis is performed. Finally, the operation completed with soft tissue reconstruction.
40820823|NCT02657681|DEVICE|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
41339679|NCT00509938|DRUG|human lactoferrin peptide 1-11|Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
41487309|NCT03757273|PROCEDURE|FFF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton. the C.T scan will be sent to the modeling company for planning three-dimensional model of the mandible. autoclavable model will be prepared for mandible to be used during the workflow for plate reshaping and positioning to conform with the remaining mandible.~Surgery will be performed by two surgical teams, one in charge of cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, and resection/ reconstruction then performed in conventional surgical manner with microvascular anastomosis. Finally, the operation will be completed with soft tissue reconstruction."
41487310|NCT03479463|BIOLOGICAL|Dehydrated human amnion/chorion membrane|Laryngectomy/pharyngectomy patched with dehydrated human amnion chorion allograft
41487311|NCT00266071|BEHAVIORAL|Cutaneous response|
41487312|NCT02159170|BIOLOGICAL|NGF injection|single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
41487313|NCT01252719|DRUG|Single-Dose IV Oritavancin Diphosphate|Oritavancin was administered as a single IV dose.
41487314|NCT01252719|DRUG|IV Vancomycin|Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
41487315|NCT01252719|DRUG|Placebo|Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
41487316|NCT05320341|PROCEDURE|TIVA|During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.
41487317|NCT05320341|PROCEDURE|SEVO|During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
41487318|NCT00910091|DRUG|BN83495|BN83495 will be administered as a 40 mg tablet once a day orally
41487319|NCT00910091|DRUG|Megestrol Acetate (MA)|MA will be administered orally as 160mg daily
40820824|NCT02657681|DEVICE|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
41487320|NCT04724044|DRUG|Tablets|Oral tablets of similar appearance to active study drug
41487321|NCT04724044|DRUG|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
40820825|NCT04161443|OTHER|physiotherapy|"* Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~* The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention)."
40820826|NCT03904953|OTHER|Pilates Training|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
41339680|NCT01043783|OTHER|Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.
41339681|NCT02005510|BEHAVIORAL|Mailed in-home high-risk HPV testing kit|
41339682|NCT02005510|OTHER|Usual care|
41339683|NCT05666206|PROCEDURE|fibrin sealant in hypospadias|fibrin sealant will be used over the suture line
41487322|NCT01816919|OTHER|collecting breath samples|
41487323|NCT00289874|DRUG|montelukast sodium|montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
41487324|NCT00289874|DRUG|Comparator: Placebo|Placebo. Up to 3 weeks of treatment
41487325|NCT02674061|BIOLOGICAL|Pembrolizumab|Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle
41487326|NCT01389583|DRUG|AUY922|70 mg/m2 60-min i.v. infusion weekly
41487327|NCT02583893|DRUG|Sirolimus|Given PO
41487328|NCT02583893|DRUG|Mitoxantrone|Given IV
41487329|NCT02583893|DRUG|Etoposide|Given IV
41487330|NCT02583893|DRUG|Cytarabine|Given IV
40820827|NCT03904953|OTHER|Conventional exercise programme|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
40820828|NCT05723965|OTHER|As training material for deep learning model.|Using labeled images as training materials for artificial intelligence to develop object detecting model.
41339685|NCT02428933|DRUG|Bromocriptine|The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
41339686|NCT01909986|DRUG|[14C]ONO-4053|Single dose \[14C\]ONO-4053
41339687|NCT01506219|PROCEDURE|Geriatrician-performed CGC|Individual disease management and coping was provided using the holistic approach during the face-to-face counselling, where the actual problems, expectations and aims were defined in dialogue with the patient and/or relatives. Afterwards, targeted problem solving with focus on the potentially reversible causes of functional deterioration was established. Finally, medication adjustment was carried out with particular attention to drugs which may lead to iatrogenic functional deterioration, delirium, falls, and malnutrition. Furthermore, the intervention included intravenous antibiotics or blood transfusions (if indicated) conducted by the geriatrician at the rehabilitation units.
41339688|NCT01695460|DRUG|D3 Vitamin ®|"Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast."
41339689|NCT01695460|DRUG|Placebo|
41339690|NCT05229640|DEVICE|Fibroscan|Subjects will fast for at least three hours, then have at least 10 fibroscan readings of their liver.
41339691|NCT04177875|DRUG|Teripalimab|Teripalimab Injection 240mg/6ml fixed dose (3mg/kg for patients weighing less than 40kg) ,injection on day 1, each infusion for 30min (no less than 60 minutes for the first injection); every 3 weeks. docetaxel dose was 75mg/m2, injection on day 1;Albumin-bound Paclitaxel (no anti-allergic treatment required), 260mg/m2, injection on day 1; Cisplatin was 75mg/m2, injected on day 1.A total of two treatment cycles.
41339692|NCT01553591|DRUG|Eluxadoline|Oral tablets twice daily
41339693|NCT01553591|DRUG|Placebo|Oral tablets twice daily
40820829|NCT05723965|OTHER|As materials for external validation for the buildup model.|Using the external validation set to evaluate prediction rate and survival outcome.
40820830|NCT00837265|BIOLOGICAL|Balugrastim|Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.
40820831|NCT00837265|DRUG|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
40820832|NCT00837265|DRUG|Chemotherapy Regimen|The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
40820833|NCT01683006|DRUG|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering."
40820834|NCT01683006|DRUG|Placebo|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
40823018|NCT06380686|OTHER|data collection|Demography, Social history, Riskfactors, Relevant medical history, Oncological family history, Disease \& treatment history, Molecular Pathology and Results, Treatment data, Response data, progession free survial, overall survival.
41487331|NCT05132036|OTHER|lung ultrasound|"Subjects are enrolled during their usual session in the hemodialysis unit of the Amiens University Hospital. Before starting the hemodialysis, lung ultrasound according to the 8 sites score and a measure of bioimpedance will be performed in dorsal decubitus. In a 2nd time, an echocardiography is realized. During haemodialysis session, biological analysis and clinical score will be assessed"
41487332|NCT05120323|BEHAVIORAL|vDOT Intervention Group|The vDOT intervention group will submit video clips of doses of inhaled controller asthma medication via the Emocha® smartphone application with each prescribed dose of inhaled controller medication. Each video will include a date and time stamp of the medication dose. Participant videos will be evaluated by trained personnel using an inhaler technique checklist to score each dose and create a report detailing the steps that were taken to complete the medication dose.
40820835|NCT00795548|DRUG|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
41339694|NCT00674375|OTHER|Electronic risk alerts|Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
41339695|NCT03889990|DEVICE|IQOS|"Smoke IQOS"
41339696|NCT05104086|DEVICE|ultrasound elastography|strain ratio and resistivity index
41487333|NCT03050008|OTHER|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
41487334|NCT03050008|OTHER|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound.
41339697|NCT05369624|OTHER|Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)|"The strength training program included upper and lower limb exercises, initially with no weights but progressively adding weights once a week depending on symptoms, in 2 sets with 6-8 repetitions, for at least 5 days a week. The exercises recommended were the 'hanger' (which exercises the latissimus dorsi muscle), 'butterfly' (pectoralis major muscle), 'neck press' (triceps brachii and deltoids), leg flexion (biceps femoris and gastrocnemius) and leg extension (quadriceps femoris).~As resistance training, patients could choose between walking or cycling 3 to 5 days per week, for at least 20 minutes, increasing the duration of the exercise weekly, depending on their symptoms"
41339698|NCT00366418|DRUG|Rituximab|
41339699|NCT04741087|DRUG|AMT-101 (oral)-Dose A|AMT-101 is an orally administered biologic therapeutic, taken once daily.
41487335|NCT04333472|DRUG|Piclidenoson|Piclidenoson 2 mg orally every 12 hours for up to 28 days
41487336|NCT04333472|DRUG|Placebo|Placebo orally every 12 hours for up to 28 days
41487337|NCT01059539|DRUG|Cariprazine|Cariprazine was supplied in capsules.
41487338|NCT04310618|OTHER|No intervention|No intervention
41339700|NCT04741087|DRUG|AMT-101 (oral)-Dose B|AMT-101 is an orally administered biologic therapeutic, taken once daily.
41339701|NCT03739710|DRUG|Docetaxel|Docetaxel will be administered.
41339702|NCT03739710|DRUG|Feladilimab|Feladilimab will be administered.
41339703|NCT03739710|DRUG|Ipilimumab|Ipilimumab will be administered.
41339704|NCT03739710|DRUG|GSK4428859A|GSK4428859A/EOS884448 will be administered.
41339705|NCT03739710|DRUG|Dostarlimab|Dostarlimab will be administered.
41339706|NCT03739710|DRUG|GSK6097608|GSK6097608 will be administered.
41339707|NCT02192619|OTHER|observational|
41339708|NCT00067626|DIETARY_SUPPLEMENT|Chromium|500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)
41339709|NCT05462912|DEVICE|custom foot orthotic|The goal of this study is to find out whether the use of software generated custom-made orthopedic foot orthoses improves pain in the long term.
41339710|NCT02544698|BIOLOGICAL|One dose of PCV13a vaccine|
41339711|NCT02544698|BIOLOGICAL|One dose of PCV13a vaccine|
40820836|NCT06587919|DEVICE|Neurofeedback|EEG-based neurofeedback, administered with the Neuroguide software.
41339712|NCT02544698|BIOLOGICAL|three doses of PCV13a vaccine|
41339713|NCT02544698|BIOLOGICAL|three doses of PCV13a vaccine|
41339714|NCT04961476|DIETARY_SUPPLEMENT|1-MNA|1-MNA supplementation
41339715|NCT04745247|PROCEDURE|RSS|"Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours~Sham Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours : the number of stimuli is reduced compared to the effective RSS"
41339716|NCT02903368|DRUG|Apalutamide|
41339717|NCT02903368|DRUG|Leuprolide|
41339718|NCT02903368|DRUG|Prednisone|
41339719|NCT02903368|DRUG|Abiraterone Acetate|
41339720|NCT00484367|BEHAVIORAL|Adolescent group therapy|Adolescent group therapy
41339721|NCT00484367|BEHAVIORAL|Transitional family therapy|Transitional family therapy
41339722|NCT05539924|DRUG|Pregabalin 150mg gabapentin 400mg|oral administration
41339723|NCT04044313|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
41339724|NCT04044313|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
41339725|NCT04044313|DRUG|Toripalimab|240mg intravenously every 3 weeks
41339726|NCT02748525|OTHER|Milk|Milk, in the form of 8 oz. half and half, administered after CCK scan, and patient is rescanned and ejection fraction measured to determine if ejection fraction is low.
41339727|NCT02748525|BIOLOGICAL|CCK|CCK is standard of care, used in HIDA scans for gallbladder function evaluation. It is given intravenously to cause the gallbladder to contract. The usual dose of CCK is 0.02mg/kg slowly over 3 minutes as per standard.
41339728|NCT00918346|DRUG|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
41487339|NCT02442674|DRUG|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.~Dosage: Depending on age, weight and serum sodium response:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days"
41339729|NCT00519610|OTHER|Chart Review|Patients' charts will be reviewed for relevant medical information.
41487340|NCT02442674|OTHER|Placebo|Placebo tablet matching active drug
41487341|NCT05993117|DEVICE|G114R VNS system|All patients treated with Rechargeable Implantable Vagus Nerve Stimulation System (G114R)
41487342|NCT00749736|DIETARY_SUPPLEMENT|cholecalciferol|"4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm."
41487343|NCT00749736|DIETARY_SUPPLEMENT|doxercalciferol|1 mcg of doxercalciferol per day
41487344|NCT00749736|DIETARY_SUPPLEMENT|placebo|"placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm."
41487345|NCT04646486|BEHAVIORAL|Video debriefing|Obstetric teams will review their own performance on video in a debriefing session to improve future performance.
41487346|NCT02691793|DRUG|Sunitinib|sunitinib 37.5mg QD
41487347|NCT02719847|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
41487348|NCT01233921|BIOLOGICAL|palifermin|Given IV
41487349|NCT01233921|OTHER|flow cytometry|Correlative studies
41487350|NCT01233921|OTHER|laboratory biomarker analysis|Correlative studies
41487351|NCT01233921|OTHER|pharmacological study|Correlative studies
41339730|NCT01883219|DRUG|TKIs|Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily. If the patients had T315I mutations, ponatinib will be given. If the BCR/ABL levels increased or did not decrease after one month's use of TKI, donor lymphocyte infusion will be given and the TKI drugs will be modulated. If the patients experienced hematologic relapse, they will withdraw from the study.
41339731|NCT04773704|DIAGNOSTIC_TEST|FILMARRAY® Pneumonia Plus Panel technique|FILMARRAY® Pneumonia Plus Panel technique (multiplex PCR) on a respiratory sample
41339732|NCT02708472|DEVICE|synchronized Transcranial Magnetic Stimulation (sTMS)|"Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.~The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes."
41487352|NCT02356003|DEVICE|Low frequency repetitive transcranial magnetic stimulation|Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
41487353|NCT06429839|COMBINATION_PRODUCT|Nimotuzumab with chemoradiotherapy|Radiotherapy,40-50.4Gy/20-28f. Nimotuzumab 400mg,ivgtt,W2d. Chemotherapy, S-1,40-60mg/m2, on BSA, orally twice daily on radiotherapy days.
41339733|NCT02995473|DRUG|NP000888|270 µg/g topical (BID) for 24 weeks
41339734|NCT02995473|DRUG|Vehicle|Topical (BID) for 24 weeks
41339735|NCT04064372|BEHAVIORAL|Mindful response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of mindfulness, equanimity, and non-judgment, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
41339736|NCT04064372|BEHAVIORAL|Strengths-based response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of strengths-based, narrative self-analysis, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
41339737|NCT05904314|BEHAVIORAL|Simulation training in electronic fetal monitor management|Simulation training in electronic fetal monitor management
41487354|NCT03053219|DRUG|AC0010|Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
41487355|NCT04006223|DIAGNOSTIC_TEST|11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
41487356|NCT04006223|DIAGNOSTIC_TEST|11C-PIB or 18F-florbetapir PET/MR after treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
41487357|NCT00342836|PROCEDURE|Akt levels|
41487358|NCT00933517|DRUG|vectibix|9mg/kg at D1 of each 21-days cycle
41487359|NCT00933517|DRUG|fluorouracile|500 mg/m2 at D1 of each 21-days cycle
41487360|NCT00933517|DRUG|Epirubicine|100 mg/m2 at D1 of each 21-days cycle
41487361|NCT00933517|DRUG|cyclophosphamide|500 mg/m2 at D1 of each 21 dyas cycle
41487362|NCT00933517|DRUG|docetaxel|100 mg/m2 at D1 of each 21 days cycle
41487363|NCT00010192|BIOLOGICAL|rituximab|Given IV
40820837|NCT05488548|DRUG|EP31670|EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
40820838|NCT06425939|OTHER|Force plate assessment|On Day 1, Day 45 and Day 90: 3x drop jumps, 2 min rest, 3x counter movement jumps, 2 min rest, 3x dynamic push-ups
40820839|NCT06425939|DEVICE|Whoop wrist band|Whoop wrist worn activity tracker (not a medical device) collects continuous data via smartphone app. This is a marketed device. This is not a device study.
40820840|NCT05827549|DRUG|Blincyto|Vincristine 1.5mg/m2, L-asparaginase 6,000 IU/m2 Idarubicin 10mg/m2 will be administered for induction therapy. Ifosfamide 1.8g/m2 Etoposide 100mg/m2 will be administered for consolidation therapy, then patients will be sorted into groups depend on their potential risk and Blinatumomab IV will be administered over 28 days. Intensification course will be administered 4 times repeated. 1. etoposide 100mg/m2 Ifosfamide 3.4g/m2 with MESNA / 2.oral 6-mercaptopurine 50mg/m2, methotrexate 25mg/m2 / 3.Ara-C 1.0g/m2, Idarubicin 5mg/m2 / 4.vincristine 2mg/m2 are the courses for repetition.
40820841|NCT00385944|DRUG|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
40820842|NCT00385944|DRUG|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
40820843|NCT01242696|PROCEDURE|Coronary artery stenting|Coronary artery stenting with drug eluting stents
40820844|NCT00675818|DEVICE|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
40820845|NCT00675818|DEVICE|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
40820846|NCT00926731|DRUG|AZD1152|Variable dose via a 7-day continuous infusion
40820847|NCT00926731|DRUG|LDAC (low dose cytosine arabinoside)|20 mg subcutaneous injection given twice daily
40820848|NCT02358031|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 35 cycles (up to \~2 years).
40820849|NCT02358031|DRUG|Cisplatin|Cisplatin 100 mg/m\^2 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
40820850|NCT02358031|DRUG|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
40820851|NCT02358031|DRUG|5-FU|5-FU 1000 mg/m\^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
40820852|NCT02358031|BIOLOGICAL|Cetuximab|Cetuximab on Day 1 at a dose of 400 mg/m\^2 IV, and then 250 mg/m\^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity
40820853|NCT00697866|BIOLOGICAL|HBV-MPL vaccine 208129|3 consecutive lots; 3-dose intramuscular injection
40820854|NCT00697866|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
40820855|NCT04576039|DIAGNOSTIC_TEST|saline infusion sonography|Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.
40820856|NCT04894305|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection.
41339738|NCT00059319|PROCEDURE|single aorta clamp with retrograde cardioplegia|
41339739|NCT00059319|PROCEDURE|multiple aorta clamps with antegrade cardioplegia|
40820857|NCT02750345|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
40820858|NCT02750345|DRUG|Nitisinone Baked Tablet|A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
40820859|NCT02750345|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered.
40820860|NCT02234713|BEHAVIORAL|Motivational Interview|
40820861|NCT02234713|OTHER|Video Attention Control|
40820862|NCT04526951|DRUG|Intravenous injection of Tenecteplase and one dose of placebo tablet|Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)
40820863|NCT04526951|DRUG|One tablet of Acetylsalicylic Acid and one dose of IV placebo|300 mg Acetylsalisylic acid
40820864|NCT03537248|DEVICE|ASP-57|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
41339740|NCT00391248|DRUG|Erlotinib|150 mg in a single daily dose, starting Day 1 through Day 22
41339741|NCT02758925|DRUG|Rituximab|375mg/m2 IV day 1
40820865|NCT03537248|DEVICE|ReNu® Multiplus|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
40820866|NCT05270330|OTHER|This is an observational study, we don't have any interventions.|No intervention
40820867|NCT02463747|DRUG|Piperacillin/tazobactam|Initial treatment will be with Piperacillin + Tazobactam
40820868|NCT02463747|DRUG|Ceftazidim|Patient with sensitivity to penicillin will receive Ceftazidim
40820869|NCT02463747|DRUG|Meropenem|In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem
40820870|NCT02463747|DRUG|Vancomycin|Supplementation of Vancomycin will be at the discretion of the treating physician
40820871|NCT02864186|DEVICE|control|Women wont use support bra 24 hours a days for six months
40820872|NCT02864186|DEVICE|surgical support bra|Women will use surgical support bra 24 hours a day for six months
41487364|NCT00010192|BIOLOGICAL|aldesleukin|Given SC
40820873|NCT02864186|DEVICE|common support bra|Women will use common support bra 24 hours a day for six months
40820874|NCT05636410|DIAGNOSTIC_TEST|Larynx and trachea ultrasound|After meeting enrolment criteria the larynx and trachea ultrasound will be performed at 32 and 42 weeks of gestation.
40820875|NCT04098432|DRUG|Nivolumab|Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
40820876|NCT04098432|RADIATION|Stereotactic radiotherapy|The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
40820877|NCT00629746|DEVICE|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~1. The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~2. A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~3. The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~4. The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
40820878|NCT05808946|DRUG|Alpha-Lipoic Acid|1200 mg of ALA daily (given as two 600 mg capsules once daily)
40820879|NCT05808946|DRUG|Sepsis Supportive Care|Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
40820880|NCT06606626|BEHAVIORAL|Sleep deprivation|Partial (4h) or total (0h) sleep deprivation
40820881|NCT06606626|BEHAVIORAL|Sleep place|8h sleep at home or in the laboratory
40820882|NCT05993312|OTHER|quality of life|To describe the relationship between distant sequelae of trauma assessed by the GOSE scale and quality of life
40820883|NCT00812006|DRUG|rizatriptan benzoate|rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
40820884|NCT00812006|DRUG|Comparator: placebo|Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
40823019|NCT03738995|BIOLOGICAL|Red cell or whole blood transfusion during pregnancy and up to 6 weeks postpartum|Administration of red cell or whole blood transfusion to parturients during pregnancy and up to 6 weeks postpartum
40823020|NCT00218582|BEHAVIORAL|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
41339742|NCT02758925|DRUG|Bendamustine|90mg/m2 IV day 1-2
41487365|NCT00010192|OTHER|laboratory biomarker analysis|Correlative studies
41487366|NCT00010192|OTHER|pharmacological study|Correlative studies
41339743|NCT02758925|DRUG|Cytarabine|1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4
41487367|NCT06306235|OTHER|Questionnaire|Part A: 30 patients will be interviewed. Part B: 300 patients will complete written questionnaire on tablet.
40820885|NCT01062841|BEHAVIORAL|Targeted Infection Control|"Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers."
40823021|NCT00218582|BEHAVIORAL|Standard psychiatric day treatment|Individual counseling, groups, medication
41016994|NCT05099770|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Participants will have a kidney biopsy followed 14 weeks later with a REACT injection into the biopsied kidney, then, another 12 weeks (+28 days) later a REACT injection into their contralateral kidney.
41156906|NCT05310344|COMBINATION_PRODUCT|Albumin-bound paclitaxel and bevacizumab|Patients will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles.
41016995|NCT05099770|PROCEDURE|Sham Comparator|Participants will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 12 weeks (+28 days) after the first sham procedure.
41339744|NCT04673955|DRUG|Encorafenib|Observation of real-life treatment with encorafenib and cetuximab
41339745|NCT04673955|DRUG|Cetuximab|Observation of real-life treatment with encorafenib and cetuximab
41339746|NCT06097325|DIAGNOSTIC_TEST|Clance impostor phenomenon scale|"The CIPS will be used as diagnostic test in the online survey."
41339747|NCT06097325|DIAGNOSTIC_TEST|Maslach Burnout Inventory for Medical Professional|"The MBI-HSS-MP will be used as diagnostic test in the online survey."
41487368|NCT00225121|DRUG|PF-00299804|investigational drug by oral route (escalating doses depending on safety) administered until progression
41156907|NCT06646445|DRUG|Pembrolizumab 200mg IV q3w day 1 of 21-day cycle|Pembrolizumab 200 mg via a 30-minute IV infusion q3w on Day 1 of each 21-day cycle; 8 cycles ± 9 additional cycles (17 cycles in total).
41156908|NCT06646445|PROCEDURE|Watch-and-wait approach|"Watch-and-wait strategy:~* TAP-CT scan every 3 months (± 7 days) for 2 years from inclusion.~* Colonoscopy with biopsies at months 3, 6, 12, 24."
41156909|NCT06646445|PROCEDURE|Surgery|Standard of care surgery performed with a maximal delay of 21 days (3 weeks) from inclusion.
41339748|NCT02539914|OTHER|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
41339749|NCT02539914|OTHER|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
41339750|NCT04809025|DEVICE|endoscopy|gastroscope
41339751|NCT04809025|PROCEDURE|Surgery|radical gastrectomy
41487369|NCT02293330|DRUG|continuous infusion of levobupivacaine|continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h
41487370|NCT02293330|DRUG|Intermittent bolus infusion of levobupivacaine|Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
40823022|NCT02762955|BIOLOGICAL|BCD-057|BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
41339752|NCT03365336|DRUG|polyherbal formulation|Each Flu Care consist of 350 mg of polyherbal component
41339753|NCT03365336|DRUG|Oseltamivir 75mg|All the participant has to take 75 mg of oseltamivir for five days.
41339754|NCT04926792|DEVICE|Leadless Pacemaker|Leadless pacemaker implantation
41339755|NCT00108836|DRUG|XBD173|
41339756|NCT00837239|DRUG|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
41339757|NCT00837239|DRUG|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
41339758|NCT00837239|DRUG|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
41339759|NCT02533076|OTHER|Challenge agent: capsaicin|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging."
41487371|NCT01478165|DRUG|Total intravenous anesthesia|Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
41487372|NCT01478165|DRUG|Total intravenous anesthesia plus palonosetron|Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
41487373|NCT04145583|DRUG|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
40823023|NCT02762955|BIOLOGICAL|Humira®|Humira is the original adalimumab (produced by F. Hoffman-La Roche)
40823024|NCT01672658|DEVICE|Sensory Kinetics Balance System|Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
40823025|NCT01672658|OTHER|Traditional Vestibular Rehabilitation|Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
40823026|NCT05353712|OTHER|SUCROSE|50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
40823027|NCT05353712|OTHER|CONTROL|35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
40823028|NCT05353712|OTHER|ARA20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
40823029|NCT05353712|OTHER|ARA40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
41339760|NCT02533076|OTHER|Challenge agent: placebo|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging."
41339761|NCT02533076|DEVICE|Mechanical stimulation with Von Frey filaments|Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
41339762|NCT02533076|DEVICE|Temperature sensitivity measurement with Advanced Thermal Stimulation|Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
40823030|NCT05353712|OTHER|TAG20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
40823031|NCT05353712|OTHER|TAG40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
40823032|NCT00654836|BIOLOGICAL|bevacizumab|Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
41017000|NCT06602232|DRUG|DR-01|DR-01 will be administered via IV infusion.
41017006|NCT05591417|PROCEDURE|Bilevel Erector spinae plane block|Patients will receive bilevel erector spinae plane block with bupivacaine
41017007|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexamethasone|Patients will receive bilevel erector spinae plane block with bupivacaine and dexamethasone
41017008|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexmedetomidine|Patients will receive bilevel erector spinae plane block with bupivacaine and dexmedetomidine
41339763|NCT01117181|DRUG|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
41017009|NCT05591417|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
41487374|NCT04145583|DRUG|voriconazole +HSK3486|Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
41487375|NCT01679587|DRUG|Molidustat (BAY85-3934)|20 mg molidustat as a single tablet
41487376|NCT01679587|DRUG|Placebo|Single oral dose of matching placebo will be given in each treatment arm
41487377|NCT03776253|BEHAVIORAL|Psychosocial Care Conquer Fear Support intervention (psychoeducation, attention training, worry management, and detached mindfulness components)|Attend CFS
40820886|NCT02313870|DRUG|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
41017013|NCT06603246|DRUG|GDC-6988|GDC-6988 will be administered using a dry powder inhalation
41017014|NCT06602921|DIETARY_SUPPLEMENT|TruBeet inorganic beetroot juice|400 mg nitrate-rich beetroot powder, mixed with 300 mL water.
41017015|NCT06602921|DIETARY_SUPPLEMENT|Caffeine|6 mg/kg caffeine powder in capsule form.
41017016|NCT06602921|OTHER|Cold pressor test|3 min cold pressor test using the left foot in cold water (0-2 degree).
41017017|NCT06601270|OTHER|There are no interventions as the study is purely observational.|There are no interventions as the study is purely observational.
41487378|NCT03776253|OTHER|Questionnaire Administration|Ancillary studies
41487379|NCT04729192|OTHER|ObsQoR-10T Questionnaire|The ObsQoR-10T questionnaire consists of 10 items assessing physical comfort and pain, physical independence, and emotional status. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
40823033|NCT00654836|DRUG|Carboplatin|Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
40820887|NCT02313870|DRUG|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
40820888|NCT02300558|DRUG|Eleclazine|Tablets administered orally
40820889|NCT02300558|DRUG|Eleclazine placebo|Tablets administered orally
40820890|NCT06598033|DRUG|VC plus herbal medicine|Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
40820891|NCT06606964|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI examinations were conducted using a 1.5 Tesla closed MRI system with a body coil and spine coil. The participants\&#39; knees were positioned in full extension and their feet were in a neutral position during imaging. The scan was performed from the anterior superior iliac spine to the tip of the toes, and both legs were included in the field of view
40823034|NCT00654836|DRUG|ABI-007|Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
41339764|NCT01117181|DRUG|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
41339765|NCT01117181|OTHER|Psychosocial intervention|"The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem solving of specific issues that the caregiver brings to the sessions~* Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day"
41339766|NCT04249284|DRUG|BMS-986165|Specified dose on specified days
41339767|NCT04249284|DRUG|BMS-986165 prototype 1|Specified dose on specified days
41339768|NCT04249284|DRUG|BMS-986165 prototype 2|Specified dose on specified days
41339769|NCT03499340|BEHAVIORAL|text-only PWL|control condition (no image)
41339770|NCT03499340|BEHAVIORAL|low arousal graphic PWL|pictorial warning
41339771|NCT03499340|BEHAVIORAL|high arousal graphic PWL|pictorial warning
41339772|NCT03499340|BEHAVIORAL|absolute risk|Percentage risk information for smoking-related diseases for smokers
41339773|NCT03499340|BEHAVIORAL|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
41339774|NCT01782404|DEVICE|Chlorhexidine|Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
41339775|NCT06183268|RADIATION|Spot Delete|"The treatments plans will utilize the scripted spot delete method to remove spots from the skin rind. To ensure all relevant skin spots are removed, the SkinSpots structure will be a 0.5 cm rind extending inward from the skin contour within 5 cm of the CTV. Spots will be removed from this structure and optimization will continue. Optimization objectives will be utilized to spare the skin rind structure during treatment planning, in addition to deleting spots."
41339776|NCT03513289|OTHER|Patient, Carer, and Clinician Interviews|Post-ICU follow-up interviews conducted over the phone, lasting between 30-60 minutes.
41487380|NCT00000396|BEHAVIORAL|Patient self-care education|
41487381|NCT00220987|OTHER|Intensive Insulin Therapy|Maintain blood glucose 4.5 - 6.o mmol/L
41487382|NCT00220987|OTHER|Conventional Insulin therapy|Maintain blood glucose 8-10mmol/L
41339777|NCT02979561|DRUG|Dabigatran Etexilate|All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
41339778|NCT02979561|DRUG|Warfarin|all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
41339779|NCT01464814|DIETARY_SUPPLEMENT|probiotic plus fish oil capsule|Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.
41339780|NCT01464814|DIETARY_SUPPLEMENT|Fish oil capsule|Fish oil capsule, T.I.D., for seven (7) days
41339781|NCT01107704|BEHAVIORAL|Family Support Intervention|Multifaceted family support intervention
41339782|NCT00871936|DRUG|SLx-4090|SLx-4090
41339783|NCT00871936|OTHER|Placebo|matching tablets
41339784|NCT00871936|DRUG|Metformin|
41339785|NCT05090124|DRUG|Adalimumab|Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.
41339786|NCT05090124|DRUG|Placebo|Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.
41339787|NCT04718402|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
41339788|NCT05810298|OTHER|Asana Practice|Yogasana training will be comprised of active movements when standing. Spine and limbs stretches eccentrically respecting the movement patterns of body without pushing limits. Transition in between poses will be synchronized with breathing pattern in zero resistance flow. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of standing poses training will last for 4 weeks.
41339789|NCT05810298|OTHER|Pranayam Practice (Rhythmic regulated breathing)|Breathing exercises will be comprised of diaphragmatic breathing, holding the breath after inhaling deeply and exhaling passively or exhaling actively by contracting abdominal muscles and inhaling passively. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of breathing exercises will last for 4 weeks.
41339790|NCT05810298|BEHAVIORAL|Smoking Education Program|The aim of the education is to increase awareness of subjects who are chronical smokers. The subject education will be performed at least once via face to face interview. Education topics will be covered basic information about harmful effects of habitual smoking and how to reduce the side effects of nicotine withdrawal.
41339791|NCT03366974|DRUG|Midazolam|Midazolam 5 mg PO, Midazolam 1 mg IV
41339792|NCT03366974|DRUG|Clarithromycin|Clarithromycin 500 mg bid
41339793|NCT03366974|DIETARY_SUPPLEMENT|Grapefruit juice|Grapefruit juice 500 mL
41339794|NCT01237301|DEVICE|CGM Group|Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
41339795|NCT01237301|DEVICE|SMBG Group|Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.
40820892|NCT06606964|OTHER|Isokinetic Strength|The strength of the concentric knee extensor-flexor and concentric hip abductor-adductor muscles was measured using an isokinetic dynamometer at two different angular velocities: 60˚/sec and 180˚/sec. Three repetitions were performed at 60˚/sec, and five repetitions were performed at 180˚/sec. To calculate the H/Q ratio, we divided the peak concentric torque of the hamstrings by that of the quadriceps during the same contraction velocity. Similarly, to determine the Add/Abd ratio, we divided the peak concentric torque of the adductors by that of the abductors during the same contraction velocity
41339796|NCT04046601|DEVICE|impedance|After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
41339797|NCT06224868|OTHER|insufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.
41339798|NCT06224868|OTHER|desufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.
41339799|NCT00588380|DRUG|GLP-1|GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
41339800|NCT05826041|BEHAVIORAL|(INSPIRE) INtervention Support groups: Peers Inspiring Resilience and Empowerment.|The support group contains both structured components, which are psychoeducational and focused on skill-building, and an unstructured component where discussion is open and determined by the needs and interests of the clients present (e.g., support and process-oriented.)
41339801|NCT05826041|BEHAVIORAL|Traditional Domestic Violence Support Group|The activities of the group are determined by agency staff from week to week and may be open group discussion, psychoeducation, or a combination of both.
40820893|NCT05841004|DEVICE|Investigational device|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
41487383|NCT03670264|BEHAVIORAL|Quitline Incentive|The incentive structure emphasizes engaging with the quitline, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the quitline, for maintaining involvement in the quitline program (compensation per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
41487384|NCT03670264|BEHAVIORAL|Tobacco Cessation Incentive|The incentive payment structure emphasizes quitting regardless of engagement with the quitline (though the quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
41487385|NCT03670264|BEHAVIORAL|Way to Health (WTH) Platform|The WTH platform is a web-based platform that sends reminder text messages to participants regarding study procedures and has has secure financial tracking and processing systems to manage participant payments, including the ability to track earnings and pay participants via a non-integrated payment system.
41487386|NCT03670264|BEHAVIORAL|Quitline Delivered Treatment|The quitline provides tobacco cessation treatment to individuals who enroll in treatment. This treatment includes 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between proactive calls.
41487387|NCT04243434|DRUG|Vincristine Sulfate Liposome|Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.
41487388|NCT04243434|COMBINATION_PRODUCT|CHOP|CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
41487389|NCT04243434|COMBINATION_PRODUCT|R-CHOP|R-CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
41487390|NCT06332001|OTHER|Experimental Group|Listening of music of patient's choice during WB-MRI
41487391|NCT06332001|OTHER|Control Group|Standard care condition during WB-MRI
40820894|NCT05841004|DEVICE|Comparator device|Hollister Infyna Chic, single-use compact catheter.
40820895|NCT01792375|PROCEDURE|Concurrent membrane sweeping with Dinoprostone|"Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix."
41339802|NCT03994276|DIETARY_SUPPLEMENT|Chickpea powder|Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
41339803|NCT01105949|DEVICE|Marketed nasal strip|Marketed nasal strip
41339804|NCT01105949|DEVICE|NexGen AB 2R11|Nasal strip prototype
41339805|NCT01105949|DEVICE|NexGen JB Organic PET/PE|Nasal strip
41339806|NCT00964249|DRUG|GW642444|Long acting Beta 2 agonist
41339807|NCT00964249|DRUG|Placebo|Matching placebo
41339808|NCT04076618|DEVICE|Vest|Weighted Vest worn \> or = 8 hours per day
41339809|NCT04076618|BEHAVIORAL|Resistance Exercise Training|Structured exercise training 3 days a week
41339810|NCT04076618|BEHAVIORAL|weight loss program|a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
40820896|NCT01792375|DRUG|10mg Dinoprostone vaginal insert|"For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening"
40820897|NCT00617071|OTHER|medical chart review|
40820898|NCT00617071|OTHER|survey administration|
40820899|NCT00617071|PROCEDURE|fecal occult blood test|
40820900|NCT00617071|PROCEDURE|screening colonoscopy|
40820901|NCT01457014|DEVICE|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
40820902|NCT01457014|DEVICE|Continuous positive airway pressure|continuous positive airway pressure
40820903|NCT01457014|DEVICE|servo ventilation manual|servo ventilation titrated in manual mode
40820904|NCT02683486|DEVICE|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
40820905|NCT02683486|DEVICE|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
40820906|NCT02979509|OTHER|Endoscopic ultrasound- (EUS) guided tissue sampling|EUS- guided tissue sampling of solid and/or cystic pancreatic and non-pancreatic lesions as part of their medical care.
40820907|NCT03424954|BEHAVIORAL|EpxOstomy|A 30-day post-operative automated text-messaging intervention for home monitoring of ileostomy output
40820908|NCT05339750|DEVICE|AI-based smartphone application|AI-based smartphone application to record and interpret the patch test results
40820909|NCT05339750|DIAGNOSTIC_TEST|Allergen patch|Allergens applied to a patch which is placed on the skin on the forearm region. The patch contains 10 dime-sized disks which contain a different allergen.
40820910|NCT01145352|DRUG|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
40820911|NCT04379479|DRUG|Dialyzable Leukocyte Extract|Experimental Intervention. Dialyzable Leukocyte Extract
40820912|NCT04379479|DRUG|Placebo oral|Placebo
40820913|NCT05842954|DRUG|KLU156|Oral use. KLU156 (400/480 mg) is the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg will take a fraction of the dose according to weight group as defined in the protocol.
40820914|NCT05842954|DRUG|Coartem|Oral use. Dosing will be selected based on patient's body weight as per product's label.
40820915|NCT02509039|DRUG|CC-122|5 continuous days out of 7 days per week intermittent dosing
40820916|NCT04983875|BEHAVIORAL|BAC-Enhanced Letter|The BAC-Enhanced Letter intervention includes enhancing the standard mammography results letter with a few additional lines of text informing patients of their personal BAC status.
40823035|NCT03892083|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, including children with cerebral palsy.
41487392|NCT05581290|DEVICE|AI-Flex|A flexible multi-modal bio-sensing device with integrated AI capability used to measure ECG (heart's electrical activity), body temperature, and PPG (blood volume in tissue); primarly mounted on the wrist and chest.
41487393|NCT03258853|DEVICE|Bionic Pancreas|Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
40820917|NCT04983875|BEHAVIORAL|Waitlist Control|Patients randomized to this group will receive a standard post-mammography results letter which does not include any information about their personal BAC status. However, participants randomized to this group will be informed of their personal BAC findings at the end of their study participation (approximately 6 months after mammography).
40820918|NCT03568253|OTHER|Caries treatment|Treatment by Bulk fil composite after randomization of the tooth
40820919|NCT03568253|OTHER|Caries treatment|Treatment by High viscosity glass ionomer after randomization of the tooth
40820920|NCT05974475|RADIATION|SBRT|State-of-art SBRT will be delivered in 3-5 fractions; prescription doses and fractionation schedules will be defined according to patient- and tumor-related characteristics (e.g. pulmonary comorbidities, tumor location: peripheral vs central vs ultra-central).
41487394|NCT03258853|OTHER|Usual Care|Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
40820921|NCT05974475|PROCEDURE|Surgery|State-of-art surgery will be consist in pulmonary anatomical resection (i.e. segmentectomy or lobectomy) and systematic lymph node dissection.
40820922|NCT00503581|PROCEDURE|Biopsy|Undergo biopsy
40820923|NCT00503581|OTHER|Laboratory Biomarker Analysis|Correlative studies
40820924|NCT00503581|DRUG|Megestrol Acetate|given orally
40820925|NCT00503581|OTHER|Pharmacological Study|Correlative studies
40820926|NCT00503581|OTHER|Quality-of-Life Assessment|Ancillary studies
41487395|NCT00173537|PROCEDURE|for BMPR II study|
41487396|NCT00173537|GENETIC|BMPRII|
40820927|NCT00503581|PROCEDURE|Therapeutic Conventional Surgery|undergo hysterectomy
40820928|NCT05098938|DRUG|Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773|Oral (upper gum area), 50mg, 1 tablet.
40820929|NCT05098938|DRUG|Placebo|Oral (upper gum area), 1 table.
41487397|NCT02309775|OTHER|Auriculotherapy|First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
41487398|NCT06216743|DIAGNOSTIC_TEST|MRI and CT|Patients will undergo an additional MRI, cineMRI and CineCT cscan.
41487399|NCT05380076|OTHER|Mindfulness meditation|6 minutes of watching a video tape made for the study that inspire mindfulness like meditation just before entering the examination circuit.
41487400|NCT05380076|OTHER|Mobilization of inner resources|6 minutes of watching a video tape made for the study that provide psychological stimulation just before entering the examination circuit
41487401|NCT05380076|OTHER|Biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.
41487402|NCT06354855|OTHER|Group is doing breathing exercises while watching videos|Group is doing breathing exercises while watching videos: A video consisting of 30-minute exercises will be shot for these patients. And each patient will be asked to do the breathing exercise for 30 minutes by watching this video.
41339811|NCT06508151|PROCEDURE|neovaginoplasty and vaginal mold spreaded with photoinduced-imine-crosslink hydrogel|Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
41339812|NCT06508151|PROCEDURE|neovaginoplasty and vaginal mold|Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
41339813|NCT00010803|DRUG|Ginkgo biloba|120mg twice a day
41339814|NCT00010803|DRUG|Placebo|One pill twice daily
41339815|NCT03807778|DRUG|Mobocertinib|Mobocertinib capsule.
41339816|NCT06021847|OTHER|Ozonated water|ozonated water was prepared with a concentration of (2-4 mg/l) ozone for 1 min. in a 25 mg of double distilled water 37o C employing an Ozone generator (Ozone generator type N 1888A, China.)
41339817|NCT06021847|OTHER|Chlorhexidine mouthwash|Commercial available chlorhexidine mouthwash in the market was used.
41339818|NCT02680561|DRUG|Fluticasone Propionate MDPI|
41339819|NCT02680561|DRUG|Fluticasone Propionate/Salmeterol MDPI|
41339820|NCT02680561|DRUG|Fluticasone propionate/salmeterol|
41339821|NCT03348813|BEHAVIORAL|HIV/STI Prevention Intervention|The targeted HIV/STI risk reduction intervention was delivered with groups of up to 8 participants through 8, 45-minute modules equally divided over 2 days (4 modules per session). It was designed to enhance participants' knowledge and ability to reduce their risk of HIV/STIs. Grounded in both social/behavioral and cognitive theories, the intervention includes psychoeducation, and was intended to enhance participants' HIV/STI prevention knowledge, attitudes, beliefs and skills in a manner relevant to Black adolescents.
41339822|NCT03348813|BEHAVIORAL|General Health Control Intervention|"The original Promoting Health among Teens (PHAT) Project was designed to increase knowledge and motivation regarding healthful dietary practices, aerobic exercise, and breast and testicular self-examination, and to discourage cigarette smoking. The 8-hour, 2-session PHAT intervention was shortened to mirror the Project GOLD HIV/STI risk reduction curriculum. This was done to control for the Hawthorne effect and reduce the likelihood that effects of the HIV/STI risk reduction intervention can be attributed to its nonspecific features, including special attention. From an ethical standpoint, adolescents in both conditions received a valuable and engaging health-risk-reduction intervention as opposed to usual care."
41339823|NCT03208075|OTHER|normal diet|Diet containing 1500mg of phosphorus
41017026|NCT03202316|DRUG|Atezolizumab|Given IV
41017027|NCT03202316|DRUG|Cobimetinib|Given PO
41017028|NCT03202316|DRUG|Eribulin|Given IV
41017029|NCT03202316|OTHER|Laboratory Biomarker Analysis|Correlative studies
41017030|NCT03202316|OTHER|Pharmacological Study|Correlative studies
41339824|NCT03208075|OTHER|low-phosphorus diet|Diet containing 500mg of phosphorus
41339825|NCT03208075|OTHER|high-phosphorus diet|Diet containing 2300mg of phosphorus
41339826|NCT02226419|DIETARY_SUPPLEMENT|Break in L-carnitine treatment|Levocarnitine oral tablet supplement at individual doses
41487403|NCT06354855|OTHER|Medium pace walking group|Medium pace walking group: 30 minutes daily. Walking at a moderate pace is required. Physical activity levels will be monitored with the ActiGraph GT3X+ Accelerometer.
40823036|NCT00004552|DRUG|acamprosate (Campral)|
41487404|NCT03330912|DEVICE|Neutral seat height|Seat height set relative to participant's leg length with neutral set at the measured lower leg length
41487405|NCT03330912|DEVICE|Very low seat height|"Seat height set relative to participant's leg length, 2 below the measured lower leg length"
41017041|NCT05867927|DEVICE|Robotic-assisted surgery (da Vinci)|Robotic-assisted surgery (da Vinci)
41017042|NCT05867927|DEVICE|Non-da Vinci Surgery|Non-da Vinci Surgery
41017045|NCT06610526|DRUG|Dapagliflozin|Dapagliflozin by oral administration
41339827|NCT00664157|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decisiontest
41339828|NCT00664157|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
41487406|NCT03330912|DEVICE|Low seat height|"Seat height set relative to participant's leg length, 1 below the measured lower leg length"
41487407|NCT03330912|DEVICE|Very high seat height|"Seat height set relative to participant's leg length, 2 above the measured lower leg length"
41487408|NCT03330912|DEVICE|High seat height|"Seat height set relative to participant's leg length, 1 above the measured lower leg length"
41487409|NCT03484117|BEHAVIORAL|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.
41339829|NCT02342613|BIOLOGICAL|Activated PTCy-MILs|The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
41487410|NCT04064619|DRUG|Solifenacin Succinate 5 MG|gradual weaning of drug vs. stopping
40820930|NCT01646645|BIOLOGICAL|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
40820931|NCT04796324|DRUG|Ixabepilone Injection|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
40820932|NCT06311136|BEHAVIORAL|Valence-Specific Ecological Momentary Intervention|The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.
41487411|NCT04451603|PROCEDURE|Surgery|Surgical resection of the liver
41487412|NCT04451603|RADIATION|Radiation therapy|Y-90 radioembolization therapy is the main treatment
41487413|NCT04451603|DRUG|Drug treatment|Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors
40820933|NCT04301076|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
40820934|NCT04301076|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40820935|NCT04301076|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
40820936|NCT04301076|DRUG|Cyclophosphamide|Given IV
40820937|NCT04301076|DRUG|Doxorubicin Hydrochloride|Given IV
40820938|NCT04301076|DRUG|Etoposide|Given IV
40820939|NCT04301076|DRUG|Lenalidomide|Given PO
40820940|NCT04301076|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40820941|NCT04301076|DRUG|Prednisone|Given PO
40820942|NCT04301076|DRUG|Vincristine Sulfate|Given IV
40820943|NCT05917379|BIOLOGICAL|fecal microbiota|FMT utilizes stool from a healthy donor and puts them into capsules after processing
40820944|NCT05917379|OTHER|Placebo|Starch into the same outlook capsule with fecal microbiota
40820945|NCT05917379|DIETARY_SUPPLEMENT|synbiotics|Lactobacillus Helveticas+ Bifidobacterial longum + inulin(3g/day)
40820946|NCT06331364|OTHER|electronic clinical decision support tool (eCDST) diagnostic plan|Participants will be followed for 30 days from enrollment to record clinical outcomes and any antimicrobials used. Analyses will compare clinical outcomes and antimicrobial use between the intervention arm and usual care.
41017046|NCT06493513|DEVICE|40Hz stimulation|Exogenous 40Hz stimulation is a physical intervention that induces gamma oscillations, oscillations and pulsations at the corresponding frequency, and may lead to a significant reduction in β-amyloid, reversal of tau protein hyperphosphorylation, and consequently improvement of cognitive function in patients.
41156910|NCT06646445|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy (5-fluorouracil/capecitabine ± oxaliplatin 3 months to 6 months) will be prescribed according to the current guidelines, at the investigator's discretion.
41487414|NCT04971798|BIOLOGICAL|Cell-free Stem Cell-derived Extract Formulation (CCM)|Intraarticular injection
41487415|NCT05402774|DIAGNOSTIC_TEST|point-of-care ultrasound|point-of-care ultrasound
41487416|NCT05935566|OTHER|health questionnaire|Telephone interview with patient to verify medical history, including tonsillectomy and adenoidectomy.
41487417|NCT03861403|DRUG|TRX518|Administered by IV infusion
41487418|NCT03861403|DRUG|Cyclophosphamide|Administered by IV infusion
41487419|NCT03861403|DRUG|Avelumab|Administered by IV infusion
41487420|NCT02833545|DEVICE|Ozone gas|Injection of ozone gas intra articularly
41487421|NCT02833545|DRUG|Steroid injection|Injection of steroids (diprospan) intra articularly
41487422|NCT04059224|DRUG|Trametinib|Trametinib 2 mg once a day by mouth.
41487423|NCT04059224|DRUG|Dabrafenib|Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.
41487424|NCT01030341|DEVICE|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
41487425|NCT04499365|DRUG|68Ga-DOTA/NOTA-FAPI-04|Each patient receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT scan within specified time.
41487426|NCT04499365|DIAGNOSTIC_TEST|PET/CT scan|PET/CT scan
41487427|NCT06305130|OTHER|No intervention|No intervention
41487428|NCT00031083|GENETIC|Interferon-beta|
41487429|NCT06168565|DEVICE|Intermittent pneumatic compression (AirRelax)|Moderate pressure (around 80mmHg); high pressure (around 200mmHg), both applied on the lower-limbs
41487430|NCT03983252|DRUG|[F-18]PBR06|PET radiopharmaceutical
41487431|NCT01984203|OTHER|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
41017047|NCT06075628|OTHER|Left Atrial Appendage Occlusion|Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.
41339830|NCT03928444|PROCEDURE|intradermal injection of adipose derived stem cells to one side of the face|"Lipoaspiration for preparation of ADSC will be done according to the following technique:~Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of (50 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe.~* Autologous adipose tissue derived stem cells (At-ADSCs) will be separated from the lipo-aspirate using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~* Viability of collected cells will be checked using trypan blue stain. Characterization of the isolated ADSCs population will be performed by flow cytometry."
41339831|NCT03928444|PROCEDURE|intradermal injection of saline to one side of the face|intradermal injection of saline to one side of the face
41017051|NCT06156215|BEHAVIORAL|Vaccine Messaging|"1. Video clips - short (approximately 3-minute) Public Service Announcement type videos to be viewed by participant using a QR code on their smartphone. If no smartphone is available, the video will be shown to the participant on an iPad.~2. Printed materials - one page information sheets handed to subjects by CRCs.~3. Face to face messaging - short (\< 1 minute), scripted message from the patient's providers in the ED (nurse or provider)~Each site will maintain a library of~A. 5 versions of the videos - the version used in any participant will be tailored to that participant's stated race/ethnicity.~B. 5 versions of printed flyers - likewise, the version will be tailored to the participant's stated race/ethnicity.~C. 1 version of scripted message to be delivered in English or Spanish."
41339832|NCT01269177|DEVICE|Non invasive ventilation|"Indications for the use of NIV are at least one of the following:~* Respiratory Rate ≥ 30 bpm~* PaO2/FiO2 \< 200~* pH \< 7.35 and PaCO2 \> 45 mmH~Contraindications for the use of NIV are at least one of the following:~* Coma~* Hemodynamic instability / shock~* Lack of compliance~Indications for endotracheal intubation (ETI) are at least one of the following:~* Respiratory or cardiac arrest~* Coma~* Hemodynamic instability"
41339833|NCT01072240|DRUG|rituximab [Mabthera/Rituxan]|As prescribed by physician
41339834|NCT02781415|PROCEDURE|Traditional Acupuncture Session|"Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49)."
41339835|NCT02781415|DRUG|Morphine Titration|"Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal."
41339836|NCT00074620|DRUG|PEG-hirudin|
41339837|NCT01002495|BIOLOGICAL|VM202|Endocardial injections on Day 0.
41339838|NCT00382655|PROCEDURE|Education and referral|
40820947|NCT06145165|OTHER|Nerve block with ropivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
41017052|NCT06156215|BEHAVIORAL|Vaccine Acceptance Question|"The last question in the Vaccine Acceptance Survey in both the Intervention M and Intervention Q arms of the study is Would you accept the COVID-19 booster vaccine in the emergency department today if your doctor asked you?"
41017053|NCT06612086|DRUG|Dapagliflozin (Forxiga)|we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient
41017054|NCT05923060|DRUG|Topical Aminolevulinate|Topical Levulan Kerastick is applied to actinic keratoses.
41017055|NCT05923060|PROCEDURE|Photodynamic therapy (PDT)|PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells.
41017056|NCT05923060|PROCEDURE|Red light illumination|To occur post-PTD; used for activation of ALA during photodynamic therapy.
41487432|NCT01984203|OTHER|Progressive Heavy Strength Exercises|"All scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The rotator cuff exercises are performed with 4 sets of gradually progressive loading and decreasing the repetitions performed in each set.~Week 1: 15reps (70% 1RM) Week 2-3: 12 reps (75% 1RM) Week 4-5: 10 reps (80% 1RM) Week 6-8: 8 reps (85% 1RM) Week 9-12: 6 reps (90% 1RM)~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
41017057|NCT06223672|OTHER|Walnuts|56g of walnuts consumed each day for 7 days
41339839|NCT01494025|BEHAVIORAL|Diet and Exercise|Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
41017058|NCT06223672|OTHER|Simply White Diary-free chocolate bar|68g of the white chocolate style-bar each day for 7 days
41339840|NCT02475629|BIOLOGICAL|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
41339841|NCT02475629|DRUG|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
41339842|NCT02580591|DRUG|Empagliflozin|
41339843|NCT02580591|DRUG|Placebo|For blinding purposes
41339844|NCT03975049|RADIATION|Chemoradiation|Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.
41339845|NCT03975049|DRUG|FOLFOXIRI Protocol|Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
41339846|NCT03975049|DRUG|Folfox Protocol|Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
41339847|NCT01451567|BEHAVIORAL|Ergonomic plan|participants in the intervention group were evaluated by the REBA and received an overall coaching that stretched over four meetings Each session paid special attention to, and included explanations about, the anatomy and physiology of body regions
41339848|NCT04333992|DRUG|propofol and remifentanil|intravenous propofol and remifentanil using target-controlled infusion (TCI) devices
41487433|NCT02893137|DEVICE|Optune|For further information see www.optune.com
41487434|NCT02893137|PROCEDURE|Craniectomy|A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
41017059|NCT06606106|DRUG|LY3537031|Administered SC
41017060|NCT06606106|DRUG|Placebo|Administered SC
41017061|NCT04763772|DIAGNOSTIC_TEST|Body Fat Distribution Imaging Report|Those randomized to body fat distribution imaging will be scanned on a 1.5 Tesla Siemens Aera MRI scanner (Siemens, Erlangen, Germany), located in the Center for Advanced Heart and Vascular Care using a 6-minute dual-echo Dixon Vibe protocol providing a water and fat separated volumetric data set covering neck to knees, and a multiecho Dixon acquisition for proton density fat fraction assessment in the liver. Images of the liver will be acquired using a 16-channel SENSE extra large Torso coil and images from the rest of the body will be acquired using the body coil. Volumetric imaging datasets of the body derived by MRI will be generated and adipose tissue/fat depots will be quantified: abdominal subcutaneous compartment (ASAT), visceral compartment (VAT), and hips and buttocks (lower body fat); proton density fat fraction of the liver (i.e. hepatic steatosis) as well as the quality of lean (skeletal muscle) including muscle volume and degree of fat infiltration.
41017062|NCT04763772|DIAGNOSTIC_TEST|Basic Weight Information|Body weight and body mass index
41017063|NCT04763772|BEHAVIORAL|Patient Provided|Body weight/fat distribution information will be provided directly to the patient
41339849|NCT04333992|DRUG|sevoflurane and remifentanil|inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
41339850|NCT02793804|DEVICE|Oraquick (made in Thailand)|
41339851|NCT01249157|DEVICE|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
41339852|NCT04838041|DRUG|Asciminib 40 MG|40 mg by mouth (PO) when used with imatinib.
41339853|NCT04838041|DRUG|Asciminib 40 MG Twice Daily|40 mg twice daily when used with nilotinib.
41339854|NCT04838041|DRUG|Asciminib 80 MG daily|80 mg daily when used with dasatinib.
41339855|NCT04838041|DRUG|Imatinib|Maximum dose of 400 mg PO once daily.
41339856|NCT04838041|DRUG|Nilotinib|Maximum dose of 300 mg twice daily.
41339857|NCT04838041|DRUG|Dasatinib|Maximum dose of 100 mg PO once daily.
41339858|NCT02990481|BIOLOGICAL|TRK-950|Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle
41339859|NCT02990481|BIOLOGICAL|TRK-950|"Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle~High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle"
41487435|NCT00727727|DRUG|Piribedil|
41017064|NCT04763772|BEHAVIORAL|Physician Provided|Body weight/fat distribution information will be provided directly to the physician
41017067|NCT05572515|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
41017068|NCT05572515|DRUG|Pomalidomide|Pomalidomide will be administered orally.
41017069|NCT05572515|DRUG|Bortezomib|Bortezomib will be administered subcutaneously.
41017070|NCT05572515|DRUG|Dexamethasone|Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.
41017071|NCT05572515|DRUG|Carfilzomib|Carfilzomib will be administered intravenously.
40820948|NCT06145165|COMBINATION_PRODUCT|Nerve block with liposomal bupivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
40820949|NCT06145165|OTHER|Intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
40820950|NCT03224507|DRUG|KRdD followed by auto-HCT|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
40820951|NCT03224507|DRUG|KRdD only|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
41017072|NCT06587347|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy, or use a loading dose, 25 μg/kg, administrated within 3 minutes, then 0.15μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy.
41017073|NCT06587347|DRUG|Standard medical treatment (SMT)|Patients will receive standard antiplatelet therapy.
41017074|NCT06599632|BEHAVIORAL|Values-based Cognitive Behavioral Therapy (V-CBT)|The intervention offers a 10-session treatment for spinal cord injury (SCI). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
41017075|NCT03120624|PROCEDURE|Biopsy|Undergo image-guided biopsy
41017076|NCT03120624|PROCEDURE|Computed Tomography|Undergo CT
41017077|NCT03120624|OTHER|Fluorine F 18 Tetrafluoroborate|Given IV
41017078|NCT03120624|OTHER|Pharmacological Study|Correlative studies
41017079|NCT03120624|PROCEDURE|Positron Emission Tomography|Undergo TFB-PET
41017080|NCT03120624|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
41017081|NCT03120624|DRUG|Ruxolitinib Phosphate|Given PO
41017082|NCT03120624|DRUG|Technetium Tc-99m Sodium Pertechnetate|Given IV
41017083|NCT03120624|PROCEDURE|Biospecimen Collection|Undergo mouth rinse, buccal swab, urine, and blood sample collection
41017084|NCT05166005|DRUG|vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).
41487436|NCT06047392|DIAGNOSTIC_TEST|CT coronary angiography|Patients will undergo a CTCA according to local, standard protocol.
40820952|NCT04210362|BEHAVIORAL|Workshops on responsive caregiving|Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.
41339860|NCT02990481|BIOLOGICAL|TRK-950|Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle
41339861|NCT00236613|DRUG|topiramate|
41339862|NCT01713257|DIETARY_SUPPLEMENT|Immunoenhancing diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
41339863|NCT01713257|DIETARY_SUPPLEMENT|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
41339864|NCT02839473|DEVICE|Castalie water spray|
41339865|NCT02839473|DEVICE|Hydrogel Hydrosorb®|
41339866|NCT00171002|DRUG|valsartan/amlodipine|
41339867|NCT06395740|OTHER|Enteral nutrtion|enteral nutrition via nasogastric tube.
41339868|NCT06395740|OTHER|TPN|of NPO strategy except for medications to be given via nasogastric tube till 14 days from day of stroke with fulfilment of nutrition requirement by parenteral route
41339869|NCT02832817|DEVICE|Pulse oximeter|For each monitoring of Arterial Oxygen Saturation, measures of Arterial Pulsed Oxygen Saturation will be made for each pulse oximeter.
41339870|NCT02714023|PROCEDURE|Normal Saline|Intra-operative irrigation with normal saline
41339871|NCT02714023|PROCEDURE|Sterile Water|Intra-operative irrigation with sterile water
41339872|NCT00890669|OTHER|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~* treadmill training with additional body load (A1),~* control condition (conventional physical therapy group) (B). and~* treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
41339873|NCT04701749|DEVICE|Percutaneous left atrial closure|Percutaneous left atrial closure was performed under general anesthesia with angiographic control and transesophageal echocardiography. The procedure takes between 15 and 20 minutes. This begins with a right femoral venipuncture, progression of the guide in the right atrium allowing atrial trans-septal puncture to catheterize the left atrium. A nitinol prosthesis is implanted (Boston Watchman) at the ostium of the left auricle between the left superior pulmonary vein and the circumflex artery. After a tensile test verifying the stability of the prosthesis, the absence of peri-prosthetic leakage is verified by ETO and angiographic control. The patient is monitored 48 hours before discharge to eliminate the appearance of pericardial effusion and prosthetic embolization. Aspirin 75 mg monotherapy is started the same day with stopping anticoagulation.
41339874|NCT04701749|OTHER|No Percutaneous left atrial closure|No Percutaneous left atrial closure
41339875|NCT01444183|BEHAVIORAL|Progressive muscle relaxation|"Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
41339876|NCT01444183|BEHAVIORAL|Sham exercise|"The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
41339877|NCT03420157|OTHER|Focus Group|Focus Group of 2 hours. Women will be asked to give their opinion about the communication media of the vaginal self-sampling kit.
41339878|NCT00663104|BEHAVIORAL|exercise|exercise: 3 joint sessions/week for 12 months
41339879|NCT00663104|BEHAVIORAL|exercise + cimicifuga racemosa|exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)
41339880|NCT00663104|BEHAVIORAL|wellness control, placebo|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
41339881|NCT02159768|DEVICE|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
41339882|NCT02108223|DRUG|fix dose r-FSH (Gonal-f)|recombinant follicle stimulation
41339883|NCT02108223|DRUG|r-LH supplementation|recombinant luteinizing hormone
41339884|NCT02108223|DRUG|r-FSH (Gonal-f)|recombinant follicle stimulation hormone
41339885|NCT01301404|DIETARY_SUPPLEMENT|10% carbohydrate drink|In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
41339886|NCT01201304|BEHAVIORAL|Standard exposure|Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.
41339887|NCT01201304|BEHAVIORAL|Enhanced exposure|Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.
41339888|NCT01201304|BEHAVIORAL|Intensive exposure|Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.
41339889|NCT01201304|BEHAVIORAL|Expressive writing|Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
41339890|NCT00001753|PROCEDURE|Magnetic resonance imaging|
41339891|NCT01498497|DRUG|EUR-1100|
41339892|NCT01498497|DRUG|Placebo|
41339893|NCT00381589|DRUG|ipratropium bromide 0.03% spray|
41339894|NCT02971007|DRUG|Oral Encochleated Amphotericin B (CAMB)|lipid-crystal nano-particle formulation amphotericin B
41339895|NCT02971007|DRUG|Fluconazole|
41017100|NCT06617364|PROCEDURE|gastrointestinal transit time measurement using MSOT and ICG contrast agent|The subject arrives at the clinic in the morning, fasting according to the preparation instructions from the Childrens Hospital Erlangen for the H2 breath test. Before taking the liquid containing lactose and ICG, the first measurement is performed using MSOT, followed by the H2 breath test. After the liquid to be detected is fully consumed, the second H2 breath test measurement, which only takes a few minutes, is conducted. According to the official guidelines of the Childrens Hospital Erlangen, the hydrogen concentration in the breath is measured at 30-minute intervals. During the 30-minute breaks, further MSOT measurements are carried out, also at 30-minute intervals. Each of these only takes about 10 minutes, they do not interfere with the H2 breath test measurement routine. After the ninth and final H2 breath test measurement a final MSOT examination is conducted. Afterwards participants are offered an optional MRI examination, which can be used to measure intestinal motility.
40820953|NCT06428058|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing the effects on sexual health knowledge, attitudes, and sexual history and counseling skills at medium (6-) and long-term (12 and 24 months) follow-up. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, lesbian, gay, bisexual, and transgender (LGBT) and sexual violence, clinical skills training, ethics, and community resources and cultural considerations."
40820954|NCT04240457|COMBINATION_PRODUCT|Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.
40820955|NCT01562522|OTHER|Psychological counseling|Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
41339896|NCT04254445|OTHER|Personalized training video|Using a few demographic and medical details of the patients, provided by the medical staff, the video generator will create a 2-minute personalized custom video, suitable to the age, gender, language, and medical condition of the patients. No identifying information will be used, to protect patient's privacy.
41017102|NCT03843788|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (\>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.
41339897|NCT02506491|OTHER|Pilates exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
41339898|NCT02506491|OTHER|Muscular exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
41339899|NCT02506491|OTHER|Control Group|No exercise
41339900|NCT00591162|DRUG|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
41339901|NCT00591162|RADIATION|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
41339902|NCT00591162|PROCEDURE|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
41339903|NCT01238952|DRUG|NK012 and carboplatin|NK012 and carboplatin via infusion once every 28 days
41339904|NCT06311253|OTHER|Emoform Glic Toothpaste|Daily use of Emoform Glic toothpaste twice a day during home oral hygiene
41339905|NCT06311253|OTHER|Emoform Glic Mouthwash|Daily use of Emoform Glic mouthwash twice a day during home oral hygiene
41339906|NCT00259519|PROCEDURE|Induction of delivery|Induction of delivery
41339907|NCT03162094|DRUG|AVX012 Ophthalmic Solution Low dose|Ocular topical administration of AVX Ophthalmic Solution Low dose
41339908|NCT03162094|DRUG|AVX012 Ophthalmic Solution High dose|Ocular topical administration of AVX Ophthalmic Solution High dose
41339909|NCT03162094|DRUG|Placebo (vehicle)|Ocular topical administration of placebo (vehicle Ophthalmic Solution)
41339910|NCT04159701|DRUG|LY3454738|Administered IV
41339911|NCT04159701|DRUG|Placebo|Administered IV
41339912|NCT00110591|DRUG|PRO 140|Monoclonal antibody to CCR5
41339913|NCT00068484|DRUG|topotecan hydrochloride|Given IV
41339914|NCT00068484|DRUG|bortezomib|Given IV
41339915|NCT00068484|OTHER|pharmacological study|Correlative studies
41339916|NCT00068484|OTHER|laboratory biomarker analysis|Correlative studies
41339917|NCT00858676|DRUG|acarbose|50mg acarbose 3 times a day PO. duration: one year
41487437|NCT05944120|COMBINATION_PRODUCT|Aromatherapy patches|This study anticipates that Staff-reported stress levels will decrease when nurses use strategies from the Crisis Intervention Cart while at work.
41487438|NCT00789763|DRUG|Gemcitabine|300 mg/m2/one per week, i.v., during 5 weeks.
40820956|NCT04816656|OTHER|ePROMs assessment|"At inclusion the patient received a unique login code which he/she used to start the care path. After signing the informed consent on the digital pathway, the patient needed to fill in the questionnaires that were presented at fixed time points throughout this study.~Based on the data collected from the questionnaires the patient received customized information and advice. In case of COVID-19, the information and advice was based on the guidelines from Sciensano and the Belgian government. If the patient suffered from side effects from the cancer therapy, they received tips and tricks how to manage these complications. The collected data was forwarded to the patient medical file. As such health care workers were be able to use this information in the patients' follow up consultations."
41339918|NCT05154357|OTHER|Elastic Sac|Half an hour before the feeding time, the infant will be placed in the elastic sac, be laid in the right lateral position within the nest with an angle of 45 degrees and will be allowed to take a rest within the elastic sac for half an hour. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
41339919|NCT05154357|OTHER|Control|Half an hour before the feeding time, the infant will be laid in the right lateral position within the nest with an angle of 45 degrees without performing any different application and will be allowed to take a rest. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
41339920|NCT06060704|DRUG|Envafolimab|150mg Qw, delivered as a single 1.5ml subcutaneous injection in under 30s , every 4 weeks for one cycle(Q4w).
41339921|NCT06060704|DRUG|Trifluridine/Tipiracil|35 mg/m2 (maximum single dose of 80 mg), po, on days 1-5 and 8-12 of each treatment cycle, twice daily for 28 days, within 1 hour after breakfast or dinner take medicine.
41487439|NCT00789763|RADIATION|Radiotherapy|1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
40820957|NCT06162663|DRUG|Suvorexant Tablets|Suvorexant initially with 10-20 mg for 28 days
40820958|NCT06162663|OTHER|Placebo Control|Matched Placebo Control for 28 days
40820959|NCT06607848|DEVICE|Low-Add EDOF IOL|Acunex Vario AN6V
40820960|NCT06607848|DEVICE|EDOF IOL|PureSee EDOF IOL
40820961|NCT05674929|DRUG|BPL-003|A single dose administered intranasally
40820962|NCT03549676|BIOLOGICAL|Fecal Microbiota Transplantation|For patients who do not respond or partial respond for first time FMT treatment, a second time FMT treatment using different donor should be considered.
40820963|NCT05275010|DRUG|Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)|A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the anterior thigh, using either a handheld syringe with hypodermic needle (Arm 1) or the on-body delivery system (Arm 2).
40820964|NCT05275010|DEVICE|Handheld Syringe with Hypodermic Needle|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using a handheld manual syringe.
40820965|NCT05275010|DEVICE|On-Body Delivery System|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using the on-body delivery system (OBDS).
41339922|NCT06060704|DRUG|Bevacizumab|ivgtt, 5mg/kg, d1, d15, every 4 weeks for one cycle (Q4w). The subjects will receive Trifluridine/Tipiracil plus Bevacizumab and Envafolimab until disease progression, intolerable toxicity, initiation of other anti-tumor therapy, death, withdrawal of informed consent, or loss of follow-up.
41339923|NCT03815760|DEVICE|Blood Flow Restriction|Subjects will perform sidelying external rotation exercise
41339924|NCT04419662|DRUG|Phenylephrine|"Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect."
41487440|NCT00789763|DRUG|Sorafenib|200-800 mg/day p.o. during 5 weeks
41487441|NCT00199771|DRUG|7.5% NaCl in 6% dextran 70 solution|
41487442|NCT00289757|BIOLOGICAL|Havrix™|2 doses at 6 months interval
40820966|NCT05763719|BEHAVIORAL|Rabbits for Resilience (RFR) + HIKA|Economic empowerment program using animal husbandry for young adolescents and healthy relationship program for parents/couples in same household
40820967|NCT05763719|BEHAVIORAL|Rabbits for Resilience (RFR) only|Economic empowerment program using animal husbandry with young adolescents
40820968|NCT05763719|BEHAVIORAL|HIKA Healthy Relationship Program|Healthy relationship program for parents/couples
40820969|NCT05460273|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
40820970|NCT00004664|DRUG|megestrol|
40820971|NCT00004664|BEHAVIORAL|Exercise|
40820972|NCT02817113|DRUG|NC-6004|One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks
40820973|NCT02817113|DRUG|Cetuximab|One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.
40820974|NCT02817113|DRUG|5-FU|One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
40820975|NCT06606678|OTHER|Exercise|supervised exercise training; twice a week for 12 months
40820976|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Face-to-face)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week."
40820977|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Internet-based)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system."
40820978|NCT06606249|BEHAVIORAL|Self-Help Plus (SH+)|"Self-Help Plus is a novel, brief, low-intensity intervention, recently developed by the World Health Organization (WHO) and intended to help people with and without mental disorders cope with distress stemming from diverse types of adversity.The key components of the program are based on acceptance and commitment therapy (ACT), a distinct form of cognitive-behavioural therapy. SH+ draws on ACT techniques of coping with stress, compassion and acceptance toward oneself and others, and living following one's values.~An online version called Doing what matters in times of stress is available as an illustrated guide and pre-recorded audio."
40820979|NCT06606249|BEHAVIORAL|Psychological First Aid (PFA)|Psychological First Aid (PFA) is also developed by the WHO and is a general supportive intervention, aimed at listening and understanding the needs and concerns of people, providing support without pressuring them to talk.
40820980|NCT03062553|BEHAVIORAL|Metacognitive Training (MCT)|MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
40820981|NCT03062553|BEHAVIORAL|Sham/MCT|"The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.~MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions."
41339925|NCT04419662|OTHER|Combination of PEEP and positioning|"Six time points based on combinations of the following:~Three different levels of PEEP (as set on the ventilator): 0, 6 and 12 mmHg. Two different positions: 1) torso elevated 30 degrees, legs horizontal and 2) torso horizontal, legs elevated 30 degrees."
41339926|NCT04847141|BIOLOGICAL|C19-IG 20%|Anti-COVID-19 Immune Globulin (Human) 20%
41339927|NCT04847141|DRUG|0.9% Sodium chloride|C19-IG 20% matching placebo
41339928|NCT00415623|DRUG|Amlodipine|Amlodipine 5mg/ day
41339929|NCT00415623|DRUG|Amlodipine|Amlodipine 10mg/ day
41339930|NCT01614340|BEHAVIORAL|Cognitive-Behavioral Pain Self-management Program|The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
41339931|NCT01144091|DRUG|pentoxyphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
41339932|NCT01144091|DRUG|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
41339933|NCT01144091|DRUG|pentoxiphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
41339934|NCT01144091|DRUG|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
41339935|NCT02772224|DEVICE|Drug eluting balloon angioplasty|In the DEB group, the guide wire will be passed through the occluded or stenosed lumen and the predilatation of the target lesion with standard balloon(s) will be performed before dilatation with a paclitaxel-eluting balloon of the diameter, at least about that of the pre-dilatation balloon (Arteryguard, Rientech, Dezhou, China). The drug eluting balloons will then be inflated according to the manufacturer recommendations. The patients will then be followed every six months for a year to compare its treatment efficacy and safety with that of conventional balloon angioplasty group.
41339936|NCT02772224|DEVICE|Conventional balloon angioplasty|The guide wire will be passed through the occluded or stenosed lumen and the conventional balloons will be inflated as recommended by the manufacturer. The primary and secondary outcome will then be assessed and compared with DEB group, on follow up at six and 12 months.
41339937|NCT03150810|DRUG|Pamiparib|60 mg (20 mg capsules) administered orally twice a day
41339938|NCT03150810|DRUG|Temozolomide|Doses of up to 120 mg (as 20 mg capsules) administered orally once daily (QD) as specified in the treatment arm
41339939|NCT00741104|DRUG|Infliximab|Treatment of RA with Infliximab according to and under normal routine clinical practice.
41339940|NCT04053218|COMBINATION_PRODUCT|Exercise plus omega-3 supplement|Supervised aerobic exercise and omega-3 supplement
41339941|NCT04053218|DIETARY_SUPPLEMENT|Placebo|Olive oil placebo
41339942|NCT02831283|DRUG|11C-PBR28|11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
41339943|NCT02831283|DRUG|18F-Florbetaben|18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
41017106|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 1
41017107|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 2
41017108|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 3
41156911|NCT00802334|DRUG|generic lopinavir/ritonavir|"1. Screening visit~   • Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~2. Baseline visit~   • (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~3. Week 4~   * Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment"
40820982|NCT03062553|DEVICE|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
40820983|NCT03584997|PROCEDURE|ABB And Autogenous Particulate|Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
40820984|NCT03584997|PROCEDURE|PRF, ABB & Autogenous Particulate|adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
41156912|NCT04332367|DRUG|Carboplatin|Carboplatin IV
41156913|NCT04332367|DRUG|Paclitaxel|Paclitaxel IV
41339944|NCT02831283|PROCEDURE|Lumbar puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
40820985|NCT05687812|DIETARY_SUPPLEMENT|Cephalaria Syriaca flour-added bread|100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH).
40820986|NCT02408003|DRUG|Levosimendan|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
40820987|NCT02408003|DRUG|Milrinone|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
40820988|NCT00782171|DEVICE|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
40820989|NCT00918164|DRUG|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
40820990|NCT05469243|DRUG|Psychedelic|retrospective survey of previous use
40820991|NCT05781334|OTHER|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
40820992|NCT04147897|DEVICE|FOCUS|FOCUS is a self management mHealth application for people with serious mental illness.
40820993|NCT05179603|DRUG|THOR-707|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
40820994|NCT05179603|DRUG|Pembrolizumab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
41339945|NCT05764811|DRUG|Canagliflozin 100mg|100 mg daily for a month
40820995|NCT05862012|DRUG|ISB 2001|Participants will receive escalating doses of ISB 2001
40820996|NCT05862012|DRUG|ISB 2001|Participants will receive injection of ISB 2001 as determined in Part 1.
40820997|NCT01384448|PROCEDURE|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
40820998|NCT01384448|PROCEDURE|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
40820999|NCT02154100|DIETARY_SUPPLEMENT|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
40821000|NCT02154100|DIETARY_SUPPLEMENT|Placebo|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
40821001|NCT01969383|OTHER|Heated pool training|
41017109|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation
41017112|NCT04981119|OTHER|Apheresis|Apheresis procedure performed for collection of PBMCs.
41339946|NCT04570982|BIOLOGICAL|Convalescent Plasma|The objective of this protocol is to provide a coordinated approach for distribution and guidance for safe and effective administration of convalescent serum with antibodies against SAR CoV-2 for treatment of patients with COVID-19 infection who are most likely to benefit from this investigational treatment and monitor them.
40821002|NCT03006029|DRUG|TAB08|The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
40821003|NCT06608914|DRUG|Nandrolone decanoate|Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
40821004|NCT06608914|DRUG|Saline|Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
40821005|NCT05770934|OTHER|Blood flow restricted low-load resistance exercise|Blood flow restricted low-load resistance exercise
40821006|NCT05058690|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|"* Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~* Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~* If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~* Collect a further blood sample at 120 minutes.~* Send samples all together to laboratory for glucose measurement."
41017113|NCT04981119|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
41017114|NCT04981119|DIAGNOSTIC_TEST|Long Range NGS HLA typing|Long range NGS on whole blood to determine germline HLA type.
41017115|NCT05535166|PROCEDURE|Surgical resection|"All participants enrolled will undergo surgical resection prior to treatment. The maximal resection that can be achieved without undue risk to the patient will be attempted, with decisions about feasibility and extent of resection left to the discretion of the neurosurgeon. In instances where an STR is the best extent of resection achieved prior to start of therapy, a second-look surgery may be performed between cycles of chemotherapy after discussion with the principal investigator."
41017116|NCT05535166|PROCEDURE|Ommaya/VPS|All participants enrolled on S-1 will undergo
41017117|NCT05535166|DRUG|Methotrexate|Route of administration: Intravenously (IV)
41017118|NCT05535166|DRUG|Cisplatin|Route of administration: Intravenously (IV)
41017119|NCT05535166|DRUG|Vincristine|Route of administration: Intravenously (IV)
41017120|NCT05535166|DRUG|Cyclophosphamide|Route of administration: Intravenously (IV)
41017121|NCT05535166|DRUG|Carboplatin|Route of administration: Intravenously (IV)
41017122|NCT05535166|DRUG|Topotecan|Route of administration: Intravenously (IV)
40821007|NCT02153424|DRUG|Apixaban|
40821008|NCT00349323|BEHAVIORAL|Community directed treatment|
40821009|NCT05335187|DEVICE|micro-macro electrode implantation|One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
40821010|NCT04096820|BIOLOGICAL|Uromune|2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.
40821011|NCT05155332|DRUG|BI 1831169|BI 1831169
40821012|NCT05155332|DRUG|anti-PD-1 antibody|anti-PD-1 antibody
40821013|NCT01728506|BEHAVIORAL|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
40821014|NCT02684812|DRUG|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
40821015|NCT05573750|BEHAVIORAL|Singing group|Intervention involves singing groups with person with dementia and carer. Please see earlier descriptions.
40821016|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
41017123|NCT05535166|DRUG|Etoposide|Route of administration: Intravenously (IV)
41017124|NCT05535166|DRUG|Pegfilgrastim|Route of administration: subcutaneous (SQ)
41017125|NCT05535166|DRUG|Filgrastim|Route of administration: subcutaneous (SQ) or Intravenously (IV)
41017126|NCT05535166|RADIATION|Irradiation|All participants in stratum N will undergo craniospinal irradiation (CSI) with boost to the primary tumor site once they reach 36 months of age. The dose given is based on the molecular risk group and disease response to chemotherapy as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
41017127|NCT05535166|OTHER|Educational and Media Intervention|Participants watch a 75-minute caregiver education video program and receive access to interactive games on a smartphone or tablet throughout the optional cognitive study.
41017128|NCT05535166|OTHER|SOC, Educational and Media Intervention|Standard-of-care (SOC) treatment during main cognitive study. After the one-year serial cognitive evaluation, participants will be offered participation in the cognitive study group I intervention.
41017130|NCT06318299|DIETARY_SUPPLEMENT|Ketone Ester|Commercially available ketone ester drink (KetoneAid, Virginia, USA)
41017131|NCT06318299|OTHER|Placebo|Taste and appearance matched noncaloric placebo drink
41017132|NCT05020743|OTHER|No intervention|Not applicable for a Natural History Study
41017136|NCT06586957|DRUG|NKT3964|Oral CDK2 Degrader
41156914|NCT04332367|DRUG|Ramucirumab|Ramucirumab IV
40821017|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
40821018|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
40821019|NCT04723641|OTHER|functional training exercises|progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
41339947|NCT01830244|DRUG|Nab-Paclitaxel|Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
40821020|NCT00215566|DRUG|DDP733|
40821021|NCT00256815|DRUG|chemotherapy|
40821022|NCT00256815|PROCEDURE|Radiation|
40821023|NCT04333186|OTHER|Data from ultrasound measurements|Data from ultrasound measurements and from the electronic patient record will be obtained / analyzed. One additional blood sample will be obtained within 24 hours after inclusion, during planned blood collection (from arterial line or venous puncture).
40821024|NCT05710211|BIOLOGICAL|Clonal architecture determination|"Biological:~* Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing~* Secondary outcome: transcriptomic study by RNA-sequencing"
40821025|NCT05923931|DEVICE|cooling blanket|On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
40821026|NCT05923931|DEVICE|non-cooling blanket|Patients do not receive cooling blanket according to randomization. Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, convection,etc.
40821027|NCT04882644|BEHAVIORAL|Aerobic Exercise|The subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption three times per week for 60 min/session (including 5 min warm-up and 5 min cool down) with treadmills, ellipticals, and rowing machine. The subjects attend health education sessions (eg, general health knowledge of NAFLD and metabolic diseases, and elements of a healthy lifestyle) monthly in the 12 months.
40821028|NCT06607601|DRUG|Palbociclib|Treatment information in the electronic health record indicates initiation of palbociclib after metastatic diagnosis
40821029|NCT06607601|DRUG|Letrozole|Treatment information in the electronic health record indicates initiation of letrozole after metastatic diagnosis
40821030|NCT01673815|OTHER|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
40821031|NCT05915416|BEHAVIORAL|Child Abuse and Neglect Prevention Program|The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
40821032|NCT05014815|DRUG|Ociperlimab|Ociperlimab intravenous injection
40821033|NCT05014815|DRUG|Tislelizumab|Tislelizumab intravenous injection
40821034|NCT05014815|DRUG|histology-based chemotherapy|Administered intravenously
40821035|NCT05014815|DRUG|Placebo|Administered as an intravenous injection
41339948|NCT05097157|DEVICE|Potenza|Subjects are treated with the Potenza™ device if they present with conditions such as, but not limited to: wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks, or loose skin on the face, neck and/or body.
40821036|NCT01415479|BEHAVIORAL|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
41339949|NCT01233570|DRUG|Tacrolimus|Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
40821037|NCT01415479|BEHAVIORAL|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
40821038|NCT01415479|BEHAVIORAL|Default|"Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT."
41339950|NCT05240963|PROCEDURE|Temporal PEEK implant|Temporal PEEK implant to reconstruct temporal fossa after temporalis muscle transfer
41339951|NCT04146038|DRUG|Azacitidine|Given IV
40821039|NCT06157996|DRUG|lenvatinib and tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w + Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
40821040|NCT06157996|DRUG|tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab is entered, and the specific dosage is the same as the treatment period.
40821041|NCT00005631|BIOLOGICAL|filgrastim|
40821042|NCT00005631|BIOLOGICAL|rituximab|
40821043|NCT00005631|DRUG|carboplatin|
40821044|NCT00005631|DRUG|etoposide|
40821045|NCT00005631|DRUG|ifosfamide|
40821046|NCT01398332|DEVICE|Stent graft (EXCLUDER)|Endovascular repair
40821047|NCT05316233|DEVICE|VOLITE XC|Intradermal Injection
40821048|NCT05316233|DEVICE|VOLITE XC|Subdermal Injection
40821049|NCT05519436|OTHER|Assessment|"Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System."
40821050|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
41339952|NCT04146038|DRUG|Decitabine|Given IV
40821051|NCT05153811|BEHAVIORAL|mHealth|Participants will engage with an application designed to gamify drinking reduction.
40821052|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
40821053|NCT00615589|DRUG|Fludarabine/Busulfan x 4 days|"* Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.~* Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.~The Fludarabine shall be administered prior to the Busulfan each day."
40821054|NCT00615589|PROCEDURE|stem cell transplant|Allogeneic, peripheral blood stem cell transplant
40821055|NCT06602388|OTHER|Biological sampling|Collection of biological samples from healthy volunteers: Stool, urine, saliva, buccal swab, nasal swab, superficial skin swab, hair
40821056|NCT02294838|DEVICE|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
40821057|NCT02294838|OTHER|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
40821058|NCT02294838|OTHER|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
40821059|NCT00884039|DRUG|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
40821060|NCT00884039|DRUG|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
40821061|NCT04363255|DRUG|Etoposide Injection|Etoposide(100mg/m2, d1-3, q3w) combined with platinum was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
40821062|NCT04363255|DRUG|Carboplatin Injection|Carboplatin(AUC 5, d1, q3w) or Cisplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
40821063|NCT04363255|DRUG|Cisplatin injection|Cisplatin(75mg/m2, d1, q3w) or carboplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
40821064|NCT04363255|DRUG|Toripalimab|After 4-6 cycles of chemotherapy, JS001(240mg, d1, q3w) combined with anlotinib were followed and continued until disease progression.
40821065|NCT04363255|DRUG|Anlotinib hydrochloride|After 4-6 cycles of chemotherapy, anlotinib(12mg qd, d1-14, q3w) combined with JS001 were followed and continued until disease progression.
40821066|NCT06605209|DEVICE|Peripheral Balloon-Expandable Covered Stent System|The intervention in this clinical trial involves the Peripheral Balloon-Expandable Covered Stent System. This stent system is specifically designed for the treatment of stenosis and/or occlusion in the common and external iliac arteries.
40821067|NCT00321958|DEVICE|CSA System (CryoSpray AblationTM System)|10 second spray times
41339953|NCT04146038|DRUG|Salsalate|Given PO
40821068|NCT00321958|DEVICE|CryoSpray Ablation|10 second spray times
41339954|NCT04146038|DRUG|Venetoclax|Given PO
41339955|NCT04616924|DRUG|RHB-204|RHB-204
41339956|NCT04616924|DRUG|Placebo|Matching placebo to RHB-204
40821069|NCT00096174|BIOLOGICAL|cetuximab C225|400 mg/m\^2 IV over 120 minutes on Day 1, 250 mg/m\^2 IV over 60 minutes on Day 8, then weekly
40821070|NCT00096174|DRUG|cisplatin|75 mg/m\^2 IV over 30-60 minutes starting day 15 every 3 weeks \* 3 (Days 1, 22, and 43 of radiation therapy (RT))
40821071|NCT00096174|RADIATION|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d \* 7 weeks (35 fractions)
41017138|NCT05199948|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
41017139|NCT05199948|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
41017140|NCT00024622|DRUG|18F-Fluoro-L-dopa|
41017141|NCT00024622|DRUG|O-15 Water|
41339957|NCT04155125|DRUG|efepoetin alfa|The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.
41339958|NCT04155125|DRUG|Mircera|The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.
41487443|NCT01131793|DEVICE|PowerAssert RF wire in crossing coronary in-stent chronic total occlusions|Radio frequency ablation of chronic total occlusions within a stent of a coronary artery using Niobe Magnetic Navigation System (MNS) and the PowerAssert Radiofrequency Guidewire
41487444|NCT05181332|OTHER|Prediction model|Clinical models were developed and validated to predict liver-related complications and survival outcomes in pediatric patients with biopsy-proven with cirrhosis.
41487445|NCT00026364|DRUG|fluorouracil|
41487446|NCT00026364|DRUG|gefitinib|
41487447|NCT00026364|DRUG|irinotecan hydrochloride|
41487448|NCT00026364|DRUG|leucovorin calcium|
40821072|NCT03317093|DRUG|Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
40821073|NCT03317093|OTHER|Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
40821074|NCT04871412|DIETARY_SUPPLEMENT|Vitamin D3 Drops|1,000 - 10,000 units daily based on serum levels for the duration of the study
40821075|NCT04871412|DIETARY_SUPPLEMENT|Coriolus Versicolor|1.5g twice daily for the duration of the study
41017142|NCT05865886|DRUG|BI 1291583|BI 1291583
41487449|NCT00211991|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|
40821076|NCT04871412|DIETARY_SUPPLEMENT|Trident SAP 66:33 Lemon|3g once daily for the duration of the study
40821077|NCT04871412|DIETARY_SUPPLEMENT|Probiotic Pro12|12 billion colony forming units daily during the peri-operative period (approximately 1 month pre and post-surgery)
41017143|NCT05865886|DRUG|Placebo|Placebo matching BI 1291583
41017144|NCT04634227|DRUG|Ascorbate|Following 15g test dose, 75g administered 75g dose on days 1 and 2. Further doses of ascorbate will be determined by serum ascorbate levels measured by the end of the week to reach a target serum concentration between 20 -30 mM. Ascorbate doses will continue to be escalated until either the target serum concentration or maximum dose of 125 g is administered.
41017145|NCT06608069|BEHAVIORAL|Educational counselling|Enrolled participants will be counselled and educated by pharmacist on the therapy and benefits of adherence.
41017146|NCT06602414|PROCEDURE|Conservative treatment|Conservative treatment instead of surgical repair
41156915|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 1)|"* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)"
41156916|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 2)|"* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™(D168)"
41339959|NCT02910089|BEHAVIORAL|Shared Decision Making|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
41339960|NCT05856279|PROCEDURE|mulligan SNAG and mulligan lion position|manual therapy techniques for lumbar spine
41339961|NCT03472963|DRUG|Single dose of Genvoya® and a single 800 mg dose of Darunavir®|Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral
41487450|NCT04427644|PROCEDURE|Laparascopic Sleeve Gastrectomy|Operations performed for complciation of laparascopic sleeve gastrectomy
41487451|NCT04427644|PROCEDURE|İnterventional radiologic drainage|İnterventional radiologic drainage of gastric leakage
41487452|NCT04427644|DIAGNOSTIC_TEST|Complte Blood Count and Biochemical evaluation|blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
41487453|NCT04427644|DIAGNOSTIC_TEST|Computed tomography|Admitted to observe leakage
41487454|NCT04530240|PROCEDURE|Liver Transplantation|Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.
41487455|NCT01699386|OTHER|Control Study Formula|feed as lib
41487456|NCT01699386|OTHER|Experimental Study Formula|feed as lib
40821078|NCT04871412|DIETARY_SUPPLEMENT|Provitalix Pure Whey Protein|1 scoop (22g) once daily during the peri-operative period (approximately 1 month pre and post-surgery) and during any adjuvant chemotherapy and radiation treatments
40821079|NCT04871412|DIETARY_SUPPLEMENT|Theracurmin 2X|1.2g twice daily after the peri-operative period. including during adjuvant chemotherapy and radiation
40821080|NCT04871412|DIETARY_SUPPLEMENT|Green Tea Extract|700 mg twice daily after the peri-operative period. Will not be given during adjuvant radiation or chemotherapy treatments.
40821081|NCT04871412|OTHER|Nutrition Recommendations|Based on the Mediterranean diet and lower glycemic index foods
40821082|NCT04871412|OTHER|Physical Activity Recommendations|150 minutes moderate intensity aerobic exercise per week plus the addition of a resistance exercise program on 2 of those days
40821083|NCT04871412|BEHAVIORAL|Psychological Recommendations|Activities with the intention of actively improving the participant's mental and emotional health
40821084|NCT02788773|DRUG|Durvalumab|
40821085|NCT02788773|DRUG|Tremelimumab|
41156917|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 3)|"* 10 mcg R21 in 50 mcg Matrix-M™ (D0)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)"
41339962|NCT01561040|DIETARY_SUPPLEMENT|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
41339963|NCT03362203|OTHER|Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
41487457|NCT04791878|DRUG|Mesenchymal stem cells|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed
40821086|NCT05385081|OTHER|genomic profiling|next generation sequencing
40821087|NCT03964246|BEHAVIORAL|Compassion Meditation (CM) intervention|"10 weekly 90-minute sessions. Sessions 1-3 assist participants in basic mindfulness breathing practices; sessions 4-8 focus on personal analysis of factors underlying difficulties with compassion for self or others; sessions 9 and 10 review content and assist with relapse prevention.~\[These were planned as in-person groups but due to the COVID-19 social distancing requirements that started after initiation of cohort 1, the investigators had to retool the intervention for telehealth delivery.\]"
40821088|NCT03964246|OTHER|Healthy Aging Psychoeducation|"The investigators planned to administer a 10-week psychoeducational in-person group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent randomized controlled trial. This would include use of an existing library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity.~\[Unfortunately, with the switch to telehealth format necessitated by the COVID-19 social distancing requirements, the consensus of the investigators and staff was that these proved too be too dry/dull/academic to be a credible attention control in a telehealth format for the target population.\]"
41156918|NCT06320535|PROCEDURE|Fine needle aspiration (FNA)|Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.
41339964|NCT03362203|OTHER|Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
41339965|NCT02352649|DRUG|Neovasculgen|
41339966|NCT03968081|BEHAVIORAL|Cyberball|a ball tossing playing game in which the experimentor can control the number of throws received by the participants
41017152|NCT06621472|OTHER|Retrolaminar block technique|patients will be placed in a sitting position. The transducer will be positioned vertically 3 cm lateral to the midline at the level of the 7th thoracic transverse process. The muscles of the back, the transverse process, and the pleura between two transverse processes will be visualized. The needle will be introduced in a cranial-caudal direction toward the lamina using the in-plane method until the tip lay in the lamina 1 mL of normal saline will be injected to confirm the correct needle tip position by visualizing the spread. After negative aspiration, 20 mL of 0.25% isobaric bupivacaine. The procedure will be repeated on the opposite side.
41156919|NCT04949464|PROCEDURE|Computed Tomography|Undergo LDCT
41487458|NCT02916043|PROCEDURE|Cardiovascular surgery with cardiopulmonary bypass|Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
41487459|NCT04407611|BEHAVIORAL|Online modality|Return of BRCA results directly online or return of printed BRCA results if participant cannot access online or chooses not to
41156920|NCT04949464|BEHAVIORAL|Smoking Cessation Intervention|Use Positively Smoke Free - Mobile
41156921|NCT05179096|BEHAVIORAL|Mindfulness-based intervention|The program consists of a series of awareness practices: the exercises are presented in progression, starting from the awareness of the external environment, then the self-awareness in the environment, the awareness of the body and the five senses, the awareness of the interconnection among the various forms of life and, eventually, meditation exercises that characterize the awareness of the cognitive processes
41487460|NCT04407611|BEHAVIORAL|Genetic counselor follow-up|Optional genetic counselor follow-up over the telephone
41487461|NCT01347866|DRUG|PF-05212384|PF-05212384 intravenous infusion weekly starting at 110 mg.
41339967|NCT04333875|DEVICE|TAVR or SAVR|Patients with critical aortic stenosis as defined by an AVA \<0.6 cm2 or a transvalvular mean gradient of \>60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to TAVR or SAVR.
41487462|NCT01347866|DRUG|PD-0325901|PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
41487463|NCT01347866|DRUG|PF-05212384|PF-05212384 intravenous infusion weekly starting at 95 mg.
40821089|NCT04695119|OTHER|Exposure is septic shock (defined according to Sepsis-III) and standard treatment according to departmental protocols.|Collection of data, biomarker and echocardiography analysis will be centralized and blinded. Assessment of endpoints will be blinded.
40821090|NCT01635673|OTHER|Exercise intervention|Whole body vibration exercise 3 times per week
40821091|NCT05578638|COMBINATION_PRODUCT|Aloe Vera rosemary tropical application|10 ml of the Aloe Vera rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
40821092|NCT05578638|COMBINATION_PRODUCT|aloevera tropical application|10 ml of the Aloe Vera spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
40821093|NCT05578638|COMBINATION_PRODUCT|rosemary tropicalapplication|10 ml of the rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
40821094|NCT06598072|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
40821095|NCT06598072|DRUG|Essential oils mouthwash|Essential oils mouthwash
40821096|NCT06598072|DEVICE|Dental floss|Dental Floss
40821097|NCT05460364|DRUG|BR1018-1|"Treatment group A : One tablet of BR1018-1 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
40821098|NCT05460364|DRUG|BR1018-2|"Treatment group B : One tablet of BR1018-2 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
40821099|NCT04717297|BEHAVIORAL|Medication Management Remote Intervention|First, the study pharmacist reviews the older adult's medication for potentially inappropriate medications. The pharmacist collaborates with the prescribing physician(s) to deprescribe as indicated. The pharmacist educates the older adult and OT on any changes that were made. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT provides training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered remotely.
40821100|NCT04717297|BEHAVIORAL|Waitlist Control|A trained research assistant will complete two attention control visits in the homes of participants. Visit will consist of semi-structured interview exploring the participant's life history.
41156922|NCT02657018|DEVICE|MOBIGAME|Mobile phone based game-like software application and platform (MOBIGAME) that includes individualized and structured exercise regimens (endurance, strength, balance and flexibility) that are based on the user's individual fitness evaluation (through established fitness tests) and incorporated into the story line of a gardening simulation game.
40821101|NCT04717297|BEHAVIORAL|Medication Management In-Person Intervention|Participants in the waitlist control will be offered the medication management intervention to be completed in person. If they consent, the study pharmacist will review their medication for potentially inappropriate medications. The pharmacist will collaborate with the prescribing physician(s) to deprescribe any inappropriate medication as indicated. The pharmacist will educate the older adult and OT on any changes. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants will receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT will provide training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered in person.
41339968|NCT03778580|DIETARY_SUPPLEMENT|Pyridoxamine Dihydrochloride|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid
41339969|NCT03778580|DRUG|placebo|placebo
40821102|NCT06605768|DIETARY_SUPPLEMENT|Complex with Biotin, Collagen, Keratin, Hyaluronic Acid.|"Biotin, Collagen \&amp;amp; Keratin Beauty Complex 25,000 mcg, 60 capsules, oral route of administration."
41339970|NCT02947490|OTHER|Self BP measurement|BP home measurement by patient, results to GP and GP alters treatment as per usual practice
40821103|NCT06605768|DIETARY_SUPPLEMENT|Placebo product|Placebo, 60 capsules, oral route of administration
41339971|NCT02947490|OTHER|Standard Care|Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
41339972|NCT02947490|OTHER|Standard BP management|GP to measure BP and manage BP control
41339973|NCT02947490|OTHER|Treatment|Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
41339974|NCT00126672|DRUG|Rapamycin|
41339975|NCT00988377|OTHER|dietary intervention|whey protein 10-40 g
41339976|NCT00988377|OTHER|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
41487464|NCT01347866|DRUG|irinotecan|Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
41487465|NCT01914055|DEVICE|angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
41156923|NCT02657018|OTHER|Control|One-time standard lifestyle counseling including the promotion of baseline activities of daily life as well as a structured exercise plan including strength and endurance exercises with moderately increasing intensity and duration that is to be implemented autonomously.
41156924|NCT06615726|BEHAVIORAL|Regular physical activity|Best medical treatment plus regular physical activity. Each subject is equipped with an exercise guidance expert to regularly guide and adjust the exercise plan according to the subject's personal conditions throughout the trial period. After randomization, the exercise guidance expert formulated an individualized aerobic exercise plan based on the subject's preferences and their own exercise abilities. After each exercise, subjects filled out the exercise diary , and reported back to the exercise guidance expert.
41339977|NCT03930667|PROCEDURE|clips|
41156925|NCT06615726|OTHER|Control group|Best medical treatment
41339978|NCT03930667|PROCEDURE|knotting|
41339979|NCT00755391|BEHAVIORAL|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
41339980|NCT00755391|BEHAVIORAL|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
41339981|NCT01576666|DRUG|LDE225|
41339982|NCT01576666|DRUG|BKM120|
41487466|NCT01914055|DEVICE|OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
41487467|NCT00292487|DRUG|Iopamidol 370 mgI/mL|
41339983|NCT04774913|PROCEDURE|Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)|CTO PCI completed as a two step procedure with an initial planned CTO modification and a completion procedure after 8-12 weeks
41339984|NCT03632668|DRUG|AD-2071 10/20mg|AD-2071 10/20 mg tablet
41339985|NCT03632668|DRUG|AD-2072 80/5mg|AD-2072 80/5mg tablet
41339986|NCT03632668|DRUG|AD-2071 10/20mg + AD2072 80/5mg|AD-2071 10/20 mg + AD-2072 80/5mg tablet
41487468|NCT04666415|OTHER|Osteopathic treatment|Targeted osteopathic protocol for AN : 5 sessions of osteopathic treatment that are spaced around one week between 2 sessions. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized during the session of 25 minutes.
41487469|NCT06091852|DIETARY_SUPPLEMENT|Intrinsically labelled milk protein|20 grams of protein dissolved in 500 mL of water
41487470|NCT00380692|DRUG|Atomoxetine|
41487471|NCT00380692|DRUG|Placebo|
41339987|NCT00981682|DRUG|SER120|once a day treatment of nocturia
41339988|NCT02454894|DRUG|lidocaine|surface anesthesia with lidocaine
41339989|NCT02454894|PROCEDURE|postoperative management|lying without the pillow for half an hour after lumbar puncture
41339990|NCT02621645|PROCEDURE|Early selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
41339991|NCT02621645|PROCEDURE|Late selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
41339992|NCT02621645|DEVICE|Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle|
41339993|NCT02621645|DEVICE|Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle|
41487472|NCT02348723|DRUG|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR)between 2.0 - 3.0
40821104|NCT03989427|OTHER|Brushing first and Flossing later (BF)|Participants will follow Brushing first and flossing later (BF) sequence for 2 weeks, and after 1 week wash out period, Flossing first and Brushing later (FB) sequence for another 2 weeks.
40821105|NCT03989427|OTHER|Flossing first and Brushing later (FB)|Participants will follow Flossing first and Brushing later (FB) sequence for 2 weeks, and after 1 week wash out period, Brushing first and flossing later (BF) sequence for another 2 weeks.
40821106|NCT06605716|PROCEDURE|Enucleation of cysts|Surgical removal of cystic structures larger than 1 cm in patients included in the study arms. Patients were monitored for TCR during the procedure.
40821107|NCT06332560|BEHAVIORAL|Anti-inflammatory diet (DI)|12-week personalized dietary advice based on the Dutch Dietary Guidelines under the guidance of a dietician.
40821108|NCT06332560|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Seven individual sessions led by a psychotherapist. The content of the CBT will be psycho-education regarding pain mechanisms and DI.
40821109|NCT03222973|DRUG|BIIB033 (opicinumab)|Administered as specified in the treatment arm
40821110|NCT03222973|DRUG|Placebo|Administered as specified in the treatment arm
40821111|NCT01591421|DRUG|BKM120|PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
40821112|NCT01591421|DRUG|Panitumumab|IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
40821113|NCT00406705|BEHAVIORAL|Helium-Hyperoxia|
40821114|NCT01376063|DRUG|FG-4592|"FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9"
40821115|NCT04253106|GENETIC|Liquid biopsies (blood, gastric fluid).|Next generation sequencing of a panel of diffuse gastric cancer genes, methylation analysis. Samples collected during routine screening endoscopy.
40821116|NCT02105493|DRUG|500 microgram of Nitroglycerin|500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
40821117|NCT02105493|DRUG|Saline 5 mL|Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
40821118|NCT01098604|DEVICE|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
41017153|NCT06621472|OTHER|subcostal TAP technique|The transducer will be placed obliquely along the subcostal margin near the xiphisternum in the midline of the abdomen. The rectus abdominis muscle and underlying transversus abdominis muscle will be identified. The position of the transversus abdominis muscle will be confirmed by sliding the transducer laterally until the aponeuroses of the external and internal oblique muscle will be visualized. The transversus abdominis muscle will be then identified, being posterior to the internal oblique muscle and will be followed back medially to confirm its position beneath the rectus muscle. the needle will be introduced through the rectus muscle in a superomedial-to-inferolateral direction towards the transversus abdominis muscle using the in-plane method, and 20 mL of 0.25% isobaric bupivacaine will be injected
41017154|NCT06621472|OTHER|Epidural|By loss of resistant technique and insertion of epidural catheter at the level of thoracic vertebrae 10
40821119|NCT01098604|DEVICE|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
41017155|NCT06621121|OTHER|Tenecteplase|The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg/kg, up to a maximum of 25 mg, based on their clinical condition and the preferences expressed by the patients and their families.
41487473|NCT02348723|DRUG|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
40821120|NCT05979636|OTHER|Novamin containing toothpaste|children's teeth will be brushed using Novamin containing toothpaste.
40821121|NCT05979636|OTHER|Fluoride containing toothpaste|children's teeth will be brushed using Fluoride containing toothpaste.
41017156|NCT06621121|OTHER|Alteplase|The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg/kg, up to a maximum of 90 mg, based on their clinical condition and the preferences expressed by the patients and their families.
40821122|NCT00336011|DEVICE|Magnetic resonance imaging|
41017159|NCT06618118|DRUG|Fosigotifator|Oral Use
41017160|NCT06618118|DRUG|Placebo|Oral Use
41017161|NCT06620237|DEVICE|Implantation of the Solia CSP S pacing lead for LBBAP|Left bundle branch area pacing using a Solia CSP S lead
40821123|NCT05417269|DRUG|IMCY-0141|"The investigational medicinal product (IMP) consists in a small synthetic peptide (23 amino acids - IMCY-0141) combining a known human epitope of MOG flanked with a thioredox motif, presented in the form of a freeze-dried sterile powder and diluent for subcutaneous (SC) administration. The diluent includes the adjuvant aluminium hydroxide (alum) at a concentration of 900 μg/mL. Treatment will be injected within 4h of resuspension of the powder with the diluent.~Treatment will consist of 6 immunizations (separated by 14 days) of the IMP by SC injection in the upper arm, in the region of the triceps (lateral part of the arm, midway between the elbow and the shoulder). Half of the dose to be administered will be injected concomitantly in both arms."
40821124|NCT05417269|DRUG|Placebo|"The placebo will be administered by subcutaneous route, once every two weeks for 6 times. Placebo will be administered to patients randomized in the placebo group during Phase II only."
40821125|NCT05417269|DRUG|Dimethyl Fumarate|"Dimethyl Fumarate (DMF) will be given orally, according to its SmPC for the whole duration of the study.~Dimethyl Fumarate (DMF) will be administered to patients randomized in the active control group during Phase II only."
40821126|NCT02991794|DEVICE|EinsteinVision 3D visualization system|Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.
40821127|NCT04147390|DRUG|prescribe topical 0.03 % tacrolimus|prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
41487474|NCT01431352|DRUG|Letrozole|2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
41487475|NCT01431352|DRUG|Chinese herbal medicine granules or Chinese herbal medicine granules placebo|twice a day for 6 month
40821128|NCT04147390|DRUG|prescribe mycophenolate mofetil(MMF)|MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
40821129|NCT06606561|DRUG|NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)|A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF
40821130|NCT06606561|DRUG|0.9% Sodium Chloride Injection, USP|In lieu of AF, the saline for injection will be used as a placebo. Vials acquired from the manufacturer is pipetted into glass vials, stoppered, capped, placed in labeled header foil pouches, and sealed. These are transferred to a quarantine freezer to await post-production testing.
41339994|NCT02621645|DEVICE|Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber|
41487476|NCT03706170|BEHAVIORAL|Physiological recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
41017165|NCT06615570|DRUG|VX-973|Suspension for oral administration.
41017166|NCT06615570|DRUG|Placebo|Suspension for oral administration.
41017172|NCT05987332|DRUG|IDE196|Dosed orally, twice daily
41017173|NCT05987332|DRUG|Crizotinib|Dosed orally, twice daily
41017174|NCT05987332|DRUG|Pembrolizumab|IV administration every 3 weeks
41156926|NCT06646484|DIAGNOSTIC_TEST|Impedancemetry evaluation|Each patient eligible for the study will, additionally to the standard care, have repeated measure of impedancemetry along their hospital stay ; Theses measure will be compared to the usual measure of hydration and natremia and agreement between clinical status of interest will be discussed.
41156927|NCT06438120|BEHAVIORAL|Chatbot-based positive psychology intervention|Eight positive psychology exercises will be delivered, including positive introduction, personal strengths, using strengths, three good things, gratitude, hope and optimism, active/constructive responding, and savoring.
41339995|NCT05720962|PROCEDURE|uninterrupted accompanying support|"When the participants in the experimental group are taken to the delivery unit, when the neck dilation is 4 cm, a person they want will be taken with them to support them.~Afterwards, the pain status and satisfaction of the participants will be questioned when it is 4 cm, 6 cm, 8 cm and 10 cm."
40821131|NCT06592495|DRUG|Period 1|DWJ1589 or DWC202315
40821132|NCT06592495|DRUG|Period 2|DWJ1589 or DWC202315
41487477|NCT03706170|BEHAVIORAL|EEG recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
41339996|NCT02959190|DRUG|Galcanezumab|Administered SC
40821133|NCT06592495|DRUG|Period 3|DWJ1589 or DWC202315
40821134|NCT06592495|DRUG|Period 4|DWJ1589 or DWC202315
40821135|NCT03497546|OTHER|Exercise|Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
41017175|NCT05987332|DRUG|Ipilimumab|IV administration every 3 weeks for 4 Cycles
41017176|NCT05987332|DRUG|Nivolumab|IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance
41017177|NCT05987332|DRUG|Dacarbazine|IV administration every 3 Weeks
41017178|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
41487478|NCT02426853|BEHAVIORAL|Questionnaires|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
41017179|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
41017180|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
41017181|NCT05875441|DRUG|Placebo|16 placebo capsules will be administered as a single dose.
40821136|NCT01598883|DRUG|Heparin|150 U/kg
40821137|NCT01598883|DRUG|ATryn|1000 IU
40821138|NCT03843385|DRUG|encapsulated faecal microbiota filtrate|Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
40821139|NCT03843385|DRUG|encapsulated faecal microbiota|Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
40821140|NCT03843385|DRUG|Placebo|Sterile saline encapsulated in hypromellose capsules and frozen.
41017185|NCT06618599|PROCEDURE|Mid-transverse process to pleura block combined with erector spinae block|The probe will be placed vertically 3 cm lateral to the T5 spinous process and the transverse process will be identified. The needle will be introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. One milliliter of normal saline will be injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. 20 mL of 0.25% bupivacaine will be injected .The needle will be directed aiming for the midpoint between the transverse process and pleura from cephalad to caudad. One milliliter of normal saline will be given to confirm the position of the needle tip, then a total of 20 ml of 0.25% ropivacaine will be injected
41156928|NCT04939324|BIOLOGICAL|Blood samples at 2 sites: peripheral vein and tumor-draining vein|"D0: surgery (inclusion): oncological lung resection~* Blood samples at 2 sites: peripheral vein and tumor-draining vein~* Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)"
41156929|NCT05872620|DRUG|Orforglipron|Administered orally
40821141|NCT01528891|DRUG|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
40821142|NCT01528891|OTHER|Placebo|
41156930|NCT05872620|DRUG|Placebo|Administered orally
41487479|NCT02426853|OTHER|Photos|At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
41487480|NCT02426853|BEHAVIORAL|Pamphlets|At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
41487481|NCT05755152|OTHER|polyphenol-lecithin precipitate (PLP)|Chewing gum made with material produced from patented technology to rapidly isolate polyphenols from fruit juice (PLP).
41487482|NCT05755152|OTHER|control formulation|Chewing gum made with material produced from conventional technology (e.g cranberry extract).
40821143|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine|Combination therapy
40821144|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule|Single agent
40821145|NCT05081349|DRUG|L-Carnitine, 250 Mg Oral Capsule|single agent
40821146|NCT06446752|BIOLOGICAL|Bexsero|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
40821147|NCT06446752|BIOLOGICAL|Placebo|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
40821148|NCT01975662|DRUG|Daptomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
40821149|NCT01975662|DRUG|Vancomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
40821150|NCT03381365|DEVICE|CuraSeal Percutaneous Intraluminal Closure System|
40821151|NCT06511557|DEVICE|Non immersive virtual reality ( xbox kinetic)|"Treatment starts with a gentle warm-up i.e. hot pack for 10 minutes and gentle stretching of Quadriceps, hamstrings and calves. Each game was performed for 10 minutes with 1 minute rest between games. 3 sessions Per Weeks for 8 weeks (45 Min per Session) were given. All the exergames target muscles like Hamstring, Quadriceps and calves to improve function of knee joint and reduce pain.~Baseline assessment was done at the start of the session and proper cool down and stretching will be performed at the end of each session to promote flexibility and reduce muscle soreness"
40821152|NCT06511557|OTHER|Kinetic chain exercises|Session starts with a gentle warm-up i.e. Hot pack for 10 minutes and gentle stretching. Each exercise is performed in 2 sets, each set of 10 repetitions with 1min rest between sets. 3 sessions Per Weeks for 8 weeks (45 Min Per Session) were given .Kinetic chain exercises involve integrated movements that engage multiple joints and muscle groups \& focus on strengthening muscles like quadriceps, hamstrings, glutes, and calf muscles, improving joint stability, function, and reducing pain. Baseline assessment was done at the start of the session and proper cool down and stretching was performed at the end of each session to promote flexibility and reduce muscle soreness
40821153|NCT02165956|DIETARY_SUPPLEMENT|New Infant Cereal|New Infant Cereal
41017186|NCT06618599|PROCEDURE|paravertebral block|the transducer will be positioned laterally 3 cm to the midline at T5 spinous process, defining the spinous process, pleura, transverse process, the paravertebral (PV) space, and superior costotransverse ligament. The trapezius, rhomboid major, and erector spinae muscles will be recognized as superficial to the hyperechoic transverse process shadow. However, when the rhomboid major muscle disappeared, this indicated that we will be at the 7th thoracic vertebra's level. Local infiltration using 2-3 mL of 2.0% lignocaine will be done. A spinal 22-gauge needle will be injected at the cephalic side of the transducer using an in-plane technique, and the needle directed towards the costotransverse ligament (CTL). The passage of the needle through the CTL will be associated with a pop, informing that the superior costotransverse ligament will be passed. Following a 3 mL testing dose of normal saline containing epinephrine (1:200,000), 30 mL bupivacaine 0.25% injected.
41017187|NCT06623721|DEVICE|Movement-evoked transcutaneous auricular Vagus nerve stimulation|"Intervention requires wearing of an inertial measurement unit (IMU) sensor on an affected upper limb together with a transcutaneous auricular Vagus nerve (taVNS) stimulator on an outer ear on the contralateral side.~Intervention involves IMU measurement-evoked initiation of taVNS during conventional neurorehabilitation therapy that is defined by the patient\&amp;#39;s doctor and therapist. Typically this is around 60 minutes/day of 50-300 repetitive upper limb movements targeting specific deficits such as flexor synergies and/or wrist, triceps or shoulder activation.~taVNS intensity is calibrated at the start of every neurorehabilitation session by the patient to the maximal comfortable level with instructions to avoid pain or any serious discomfort. Patient is always accompanied by a therapist trained in the use of taVNS and the device is easy to immediately remove should any discomfort occur."
40821154|NCT02165956|DIETARY_SUPPLEMENT|Standard Infant Cereal|Standard Infant Cereal
40821155|NCT04804657|DIETARY_SUPPLEMENT|Sage extracts Cognivia|Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).
40821156|NCT04804657|DIETARY_SUPPLEMENT|Placebo|Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
40821157|NCT03241771|BEHAVIORAL|Naloxone Navigator 1.0|Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
41339997|NCT02335034|BEHAVIORAL|Study Group Educational courses, DVD, print material of lectures|2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
41339998|NCT02335034|BEHAVIORAL|Control Group only make evaluations / consultations with all professional teams|"Evaluations and consultations with all professional teams without classes for 2 years.~At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years."
41339999|NCT02931747|DIETARY_SUPPLEMENT|Placebo|Subjects are received Placebo once daily for 16 weeks.
41340000|NCT02931747|DIETARY_SUPPLEMENT|Bacopa Monnieri 300 mg/day|Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
41340001|NCT02931747|DIETARY_SUPPLEMENT|Bacopa Monnieri 600 mg/day|Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
41340002|NCT05476380|DRUG|camrelizumab|Camrelizumab:200 mg, IV., d1, q3w; Paclitaxel:175 mg/m2,continuous IV., d1, 24h q3w; Cisplatin:75 mg/m2, iv., d1,q3w
41340003|NCT06234072|DRUG|Astragalus + Gemcitabine|Participants will receive Astragalus combined with Gemcitabine. Astragalus, a traditional Chinese medicine, exhibits promising potential in cancer treatment. Studies suggest its role in regulating immune responses, suppressing tumors, and improving overall treatment outcomes in cancer patients. Astragalus combined with chemotherapeutic drug such as Gemcitabine is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effects and decrease side effects. This synergistic approach holds potential for more effective and targeted therapeutic outcomes in pancreatic cancer patients.
41340004|NCT06234072|DRUG|Gemcitabine alone|Gemcitabine is a potent chemotherapy drug widely employed in treating various cancers, including pancreatic cancer. As a nucleoside analog, it disrupts DNA synthesis, impeding cancer cell proliferation. Gemcitabine is administered intravenously and has shown efficacy in alleviating symptoms, improving survival rates, and enhancing the quality of life for patients undergoing cancer treatment.
41340005|NCT04410913|DRUG|Psilocybin plus Visual Healing Set and Setting|Psychedelic session (psilocybin 25 mg) with a therapist who will guide and accompany participants before, during, and after the psychedelic session. In addition, participants will have the chance to view nature-themed videos before and after the psychedelic sessions. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
41340006|NCT04410913|DRUG|Psilocybin plus Standard Set and Setting|Psychedelic session (psilocybin 25 mg) with a therapist will guide and accompany participants before, during, and after the psychedelic session. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
41340007|NCT03402360|OTHER|Virtual Reality rehabilitation group|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: virtual reality upper extremity motor rehabilitation~1 hour: virtual reality neurocognitive training"
41340008|NCT03402360|OTHER|Control group rehabilitation|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: upper extremity motor rehabilitation~1 hour: neurocognitive training"
41340009|NCT00917137|PROCEDURE|TBNA + transbronchial lung biopsy + bronchial washing|
41340010|NCT01352013|DIETARY_SUPPLEMENT|Omega-3 (oil)|5ml daily with breakfast for 56 days.
41340011|NCT01352013|DIETARY_SUPPLEMENT|Fatty Acids (placebo)|5ml daily with breakfast for 56 days.
41340012|NCT04826120|PROCEDURE|PCEA Infusion|Patients of this group Had PCEA during the second stage of labor
41340013|NCT04826120|PROCEDURE|Continuous epidural infusion|Patients of this group Had continuous epidural infusion during the second stage of labor
41340014|NCT02705755|DRUG|TD-9855|Administered orally.
41340015|NCT02705755|DRUG|Placebo|Administered orally.
41340016|NCT01962389|DEVICE|Winsor Laser Catheter|
41340017|NCT03644381|OTHER|Oral Immunotherapy|Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing
41340018|NCT01670708|BEHAVIORAL|HOPE|HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
41340019|NCT01670708|BEHAVIORAL|Probation as Usual|Probation officer supervises following standard protocols.
40821158|NCT00489424|DRUG|Placebo|
40821159|NCT00489424|DRUG|Acetaminophen|
40821160|NCT00489424|DRUG|Fluvastatin|
40821161|NCT01022957|GENETIC|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
40821162|NCT05176197|OTHER|Almond|Participants will consume almonds every day for 16 weeks.
40821163|NCT05176197|OTHER|Control|Participants will consume pretzels every day for 16 weeks.
40821164|NCT00135928|DRUG|Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)|
40821165|NCT05305833|BIOLOGICAL|Stem Cells|ATMP
41017188|NCT06370208|DIETARY_SUPPLEMENT|Probiotic Bactoblis® EVOL (Streptococcus salivarius eK12)|Bactoblis® EVOL: containing one billion CFU of probiotic Streptococcus salivarius eK12
41340020|NCT04247321|DEVICE|Licox® Brain Tissue Oxygen Monitoring System|Invasive brain tissue oxygenation monitoring
41340021|NCT04247321|DEVICE|Near-infrared spectroscopy (NIRS)|Non-invasive approach to monitoring brain tissue oxygenation which uses two wavelengths of near infrared light and takes measurements of the ratio of oxyhemoglobin to total hemoglobin
41340022|NCT00768768|OTHER|Electrokinetic Transungual System (ETS) - Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min"
41487483|NCT01454908|DEVICE|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
41487484|NCT06048666|BIOLOGICAL|Intra ovarian by platelet rich plasma|On the day of PRP infusion (within 10 days after completion of menstrual bleeding) we will take 20 cc of venous blood from each participant of group A to prepare PRP. The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages, respectively. Then, by discarding part of the plasma, PRP will be prepared with a final concentration of one million platelets per microliter. The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide.
41487485|NCT02241421|DRUG|Amoxicillin|
41487486|NCT02241421|DRUG|Vancomycin|
41487487|NCT02241421|OTHER|Placebo|
41487488|NCT03277209|DRUG|Plerixafor|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
41487489|NCT01324635|DRUG|Panobinostat|Given PO
41487490|NCT01324635|RADIATION|Stereotactic body radiation therapy|Undergo SBRT
41487491|NCT01324635|PROCEDURE|Quality-of-life assessment|Ancillary studies
41487492|NCT01324635|RADIATION|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
41487493|NCT03185442|DEVICE|Pulsed Radiofrequency|Pulsed Radiofrequency is performed if the sensory threshold is below 0.5 volts, the PRF consists of 380 pulses
41487494|NCT01946191|BEHAVIORAL|24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts.|Participants were assigned to a specific coach, who contacted the participants via the EHR weekly for 1 month, biweekly in months 2 to 6, monthly in months 7 to 12, and quarterly in months 13 to 24, for a total of 24 scheduled contacts. Coaching group participants received brief questionnaires relevant to weight management, including a text field where they could discuss questions or barriers. On the basis of participant responses and self-monitoring data in the EHR flow sheets, coaches wrote a brief personalized note with advice on questionnaire topics and responses to any queries or barriers mentioned by the participant. Coaching participants who did not complete questionnaires or log information into the flow sheet for 2 weeks were considered inactive and were contacted by telephone or e-mail and invited to reengage at any time. Coaching participants were able to send secure messages to the coach.
41487495|NCT01946191|BEHAVIORAL|Online self-monitoring|Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.
41487496|NCT01946191|BEHAVIORAL|Real-time updates to Primary Care physicians|Referring PCPs of coaching group participants received regular support, including real-time progress reports with counseling tips delivered via the EHR, notification of weight change in increments of at least 10 pounds, and annual progress reports at 12 and 24 months.
41017189|NCT05247190|BEHAVIORAL|Treating self-criticism|A psychological treatment given i a group format targeting self-criticism. The treatment is based on treatment principles from Cognitive behavior therapy, Self-compassion, Acceptance and Commitment Therapy and also contains psychoeducation. The group treatment consists of 8 sessions delivered once a week for 2 hrs during 8 weeks in a child- and adolescent psychiatric outpatient setting.
41340023|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min"
41487497|NCT05508464|RADIATION|Arm 2: SABR|SABR to all tumors 6 Gy x 5 over three weeks
41487498|NCT05508464|RADIATION|Arm 1: Standard of Care|Standard of care palliative radiotherapy
40821166|NCT00785421|DRUG|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS \< 80 % and increased creatinin plasma levels (\>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
41340024|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min"
41487499|NCT04874675|DRUG|diclofenac / acetaminophen /codeine|routine pain medication used post extraction of third molars
41487500|NCT04874675|DRUG|ibuprofen/acetaminophen/codeine|routine pain medication used post extraction of third molars
41487501|NCT03036319|DEVICE|Active tDCS|Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.
41487502|NCT03036319|DEVICE|Sham tDCS|Participants will receive sham tDCS for up to 260 sessions
41487503|NCT03036319|BEHAVIORAL|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
41487504|NCT03036319|DEVICE|Active tACS|Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
41487505|NCT03036319|DEVICE|Sham tACS|Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
41017190|NCT04219085|DEVICE|Continuous Glucose Monitor|Wearing of a continuous glucose monitor to monitor blood glucose levels in women with gestational diabetes
41340025|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min"
41487506|NCT03036319|DEVICE|Active tRNS|Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
40821167|NCT00785421|DRUG|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
40821168|NCT00785421|DRUG|only chemotherapy|observation, no treatment with LMWH
41017191|NCT04219085|OTHER|Routine Care|Use of a glucometer to monitor blood glucose levels in women with gestational diabetes
41017192|NCT06626087|DIAGNOSTIC_TEST|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
41017193|NCT06626087|DIAGNOSTIC_TEST|LI-RADS|The Liver Imaging Reporting and Data System (LIRADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
41487507|NCT03036319|DEVICE|Sham tRNS|Participants will receive sham transcranial random noise stimulation for up to 260 sessions
41487508|NCT00229736|GENETIC|AAV-hAADC-2|9 x 10\^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
40821169|NCT06306963|DIAGNOSTIC_TEST|Gastric Emptying|"Measured by radioscintigraphy after overnight fast using a radiolabeled meal consisting of two 99mTc - labeled scrambled eggs, one slice of whole wheat bread and one glass of 111In DTPA skim milk (320kcal, 30% fat). A variable region of interest program will be used to quantitate counts in the stomach. Data will be summarized as GE T1/2 and GE % emptied at 1, 2 and 4 hours.~To assess gastric emptying, the protocol meal as described above will be given. Anterior and posterior scans of the abdomen, each of two minutes duration, will be obtained right after the meal is ingested to ensure adequate acquisition of counts. Scans will then be done at time 0 subsequently in 15-minute intervals to 90 minutes, then in 30-minute intervals thereafter to 240 minutes supine."
40821170|NCT04915170|DEVICE|Inspiratory muscle training|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O)
40821171|NCT03438955|DRUG|Omacor|Omacor soft capsule 4000mg for 16days
40821172|NCT03438955|DRUG|Pritor|Pritor tablet 40mg for 7days
40821173|NCT03438955|DRUG|Omacor + Pritor|Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
40821174|NCT03438955|DRUG|Pritor + Omacor|Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
40821175|NCT06607562|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
40821176|NCT06607562|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
40821177|NCT06523621|DRUG|Nivolumab|2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle
40821178|NCT05763615|OTHER|Tractography MRI|"Addition to the sequences usually done for the care of these patients (CubeT2, Diffusion, CubeT1, CubeT2 fiesta, ASL, T1 injected with gadolinium), of a so-called research tractography sequence benefiting from CE marking and not requiring specific injection.~Search sequence acquisition time: 10 minutes."
41017199|NCT06620926|OTHER|IDH mutant-type|The first arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
41017200|NCT06620926|OTHER|IDH wild-type|The second arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
41017201|NCT06619860|DRUG|VX-993|Tablets for oral administration.
41017202|NCT06619860|DRUG|Pregabalin|Capsules for oral administration.
41156931|NCT05971147|DIETARY_SUPPLEMENT|Fish oil|Participants in this group will receive 5g fish oil with high EPA and DHA content per day
41156932|NCT00025545|DRUG|cyclophosphamide|
41156933|NCT00025545|DRUG|methotrexate|
41156934|NCT00025545|PROCEDURE|peripheral blood stem cell transplantation|
41156935|NCT00025545|RADIATION|radiation therapy|
41156936|NCT04073849|DRUG|EPOGEN® (epoetin alfa)|Active drug
41340026|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min"
41340027|NCT01025232|DRUG|Ranibizumab|Intravitreal Injection of 2.0mg formulation
41340028|NCT01863901|DEVICE|Treatment with Cryo-Touch III device|
41156937|NCT04073849|OTHER|Normal Saline|Placebo
41340029|NCT03358004|DRUG|Vinorelbine Tartrate|Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A
40821179|NCT01438801|DRUG|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS \<0).
40821180|NCT02310230|DEVICE|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
40821181|NCT00919750|OTHER|Cytology Specimen Collection Procedure|Correlative studies
40821182|NCT03005301|DEVICE|intelligent electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25\~40mm in length and 0.30\~0,38mm in diameter.Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes."
40821183|NCT03005301|DEVICE|Hwato electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.~Treatment time: each treatment time is 30 minutes."
40821184|NCT02745782|OTHER|Observational Study|Observational Study
40821185|NCT01413620|DRUG|dl-alpha-tocopheryl acetate|Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
40821186|NCT02220855|DRUG|BKM120|
40821187|NCT01282307|BEHAVIORAL|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
40821188|NCT00434083|DRUG|sumatriptan|
40821189|NCT00434083|DRUG|naproxen sodium|
40821190|NCT03069170|BIOLOGICAL|Stem Cell Transplantation|Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
40821191|NCT02997553|DRUG|Indocyanine green|Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
40821192|NCT02997553|DRUG|Technetium99|"Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node"
40821193|NCT02997553|DEVICE|Optonuclear probe|The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
41017203|NCT06619860|DRUG|Placebo (matched to pregabalin)|Placebo matched to pregabalin for oral administration.
41017204|NCT06619860|DRUG|Placebo (matched to VX-993)|Placebo matched to VX-993 for oral administration.
41340030|NCT03358004|DRUG|Capecitabine 500 MG|Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
41340031|NCT05899829|DRUG|Camlipixant + Rifampin|Camlipixant will be administered alone as well as in co-administration with rifampin
40821194|NCT02997553|DEVICE|Quest Camera|The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
40821195|NCT06602180|OTHER|Scapular PNF technique, (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT).|"Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments.~Scapular PNF:~Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~TAPA involves an intervention protocol composed of:~10-min neuro dynamics oriented to the activity 10-min proprioceptive neuromuscular facilitation activities. 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,"
40821196|NCT06602180|OTHER|Scapular PNF technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT))|"Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
41340032|NCT05899829|DRUG|Camlipixant + Rabeprazole|Camlipixant will be administered alone as well as in co-administration with rabeprazole
41340033|NCT02253628|OTHER|Cold espresso|Volunteers consumed cold espresso with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
41340034|NCT02253628|OTHER|Hot instant coffee|Volunteers consumed hot instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
41340035|NCT02253628|OTHER|Cold instant coffee|Volunteers consumed cold instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
41340036|NCT02253628|OTHER|Hot filter coffee|Volunteers consumed hot filter coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
41340037|NCT03237429|DIAGNOSTIC_TEST|bioimpedance spectroscopy|"Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.~Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery."
41340038|NCT02480803|DRUG|Continuous intrajejunal infusion of levodopa-carbidopa|Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
41340039|NCT02480803|DEVICE|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
41340040|NCT05459766|BEHAVIORAL|Action observation and motor imagery|Observation and imagination of functional tasks that will be performed during the postoperative rehabilitation program.
41340041|NCT05459766|BEHAVIORAL|Usual care|Participants will be educated about the postoperative rehabilitation program
41340042|NCT04362189|BIOLOGICAL|HB-adMSC|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
41340043|NCT04362189|OTHER|Placebo|Saline
41340044|NCT00442949|PROCEDURE|Catheterization immediate PCI|Catheterization immediate PCI
41340045|NCT00442949|PROCEDURE|delayed PCI|delayed PCI
41340046|NCT00320190|DRUG|Imatinib|Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
41340047|NCT00320190|DRUG|Dasatinib|Dasatinib tablets administered orally at a dose of 100 mg once daily.
41340048|NCT02637167|DRUG|Rifaximin|Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
41487509|NCT00229736|GENETIC|AAV-hAADC-2|3 x 10\^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
41340049|NCT02637167|DRUG|Saccharomyces boulardii|The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
41487510|NCT03820934|DIAGNOSTIC_TEST|Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these tests. Fibroscan uses vibrations sent through the liver to measure its stiffness and the fibrosure uses laboratory and demographic parameters to create a score associated with a certain level of fibrosis. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
40821197|NCT06602180|OTHER|Activity-Oriented Antiedema Proprioceptive Therapy (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT)|"Activity-Oriented Proprioceptive Antiedema Therapy TAPA:~TAPA involves an intervention protocol composed of:~* 10-min neuro dynamics oriented to the activity~* 10-min proprioceptive neuromuscular facilitation activities.~* 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
40821198|NCT00006042|BIOLOGICAL|filgrastim|
40821199|NCT00006042|DRUG|cyclophosphamide|
40821200|NCT00006042|DRUG|fludarabine phosphate|
40821201|NCT00006042|DRUG|mycophenolate mofetil|
40821202|NCT00006042|DRUG|tacrolimus|
40821203|NCT00006042|PROCEDURE|allogeneic bone marrow transplantation|
40821204|NCT00006042|RADIATION|radiation therapy|
40821205|NCT03036345|DEVICE|Dual-monitoring|Monitored using both INVOS and FORE-SIGHT monitors.
41487511|NCT06360315|OTHER|Incentive letter for pneumococcal vaccination to the patient and to the GP|Incentive letter for pneumococcal vaccination to the patient and to the GP
41487512|NCT05667350|OTHER|Blood drawing|Blood drawing before anti-cancer therapy
40821206|NCT03029195|DEVICE|Nasoalveolar molding therapy|Presurgical infant orthopedics
40821207|NCT02513290|DRUG|Bilastine|
40821208|NCT02513290|DRUG|Loratadine|
40821209|NCT06608667|DEVICE|The study was retrospective and did not involve the application of interventions|The study was retrospective and did not involve the application of interventions
40821210|NCT05019742|DRUG|SPH3127|SPH3127 - selective renin inhibitor
40821211|NCT05019742|DRUG|Placebo|Placebo
40821212|NCT06606912|OTHER|Skeletal muscle, subcutaneous fat and visceral fat area|CT-based measurement of skeletal muscle, subcutaneous fat and visceral fat areas at L1, L2, L3, L4 and L5 levels.
40821213|NCT01468207|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
40821214|NCT01468207|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
40821215|NCT06598189|DEVICE|Ear-SD|The Ear-SD is a purely EEG recording device Continuous Electroencephalogram (cEEG), Electromyogram (EMG), Electrooculogram (EOG), Photoplethysmogram (PPG), Electrodermoactivity (EDA), and Inertial Measurement Unit (IMU). The Ear-SD device rests on the ears and connects to the scalp by two sticker electrodes.
40821216|NCT06598189|DIAGNOSTIC_TEST|Electroencephalogram|Standard 21-channel scalp-continuous electroencephalogram (cEEG) with video recording and electrocardiogram (ECG)
40821217|NCT06345794|DRUG|LY4100511 (DC-853)|Administered orally.
40821218|NCT06345794|DRUG|Itraconazole|Administered orally.
41487513|NCT05667350|OTHER|Blood drawing|Blood drawing before radical treatment
41487514|NCT04060719|DRUG|BI 894416|tablet
41487515|NCT04060719|DRUG|Rifampicin|tablet
40821219|NCT06345794|DRUG|Fluconazole|Administered orally.
40821220|NCT06345794|DRUG|Carbamazepine|Administered orally.
41487516|NCT05879198|BEHAVIORAL|Computer-based Intervention|The current project proposes to pilot a computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
41487517|NCT02381951|DEVICE|spinal cord stimulation (St Jude Medical)|implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
41487518|NCT00517179|DRUG|Vardenafil 10mg|
40821221|NCT06605248|BEHAVIORAL|App-based self-management tool plus usual care|The app-based self-management tool will be delivered after patients receive usual care from their general practitioners. The 8-week mobile app intervention will involve daily sessions on pain education and clinical hypnosis for back pain management (5 minutes, 15 minutes of listening to hypnotherapy audio and engaging in physical/social activities for 5 minutes.
41017210|NCT05100862|DRUG|Zanubrutinib|Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.
41017211|NCT05100862|DRUG|Rituximab|Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
41017212|NCT05100862|DRUG|Lenalidomide|Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
41017213|NCT05100862|DRUG|Obinutuzumab|Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
41156938|NCT03443752|OTHER|Shotokan-Karate|The Shotokan-Karate training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
41156939|NCT03443752|OTHER|Tai-Chi|The Tai-Chi training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
41487519|NCT00001045|DRUG|Nevirapine|
41487520|NCT00001045|DRUG|Zidovudine|
41487521|NCT00001045|DRUG|Didanosine|
41487522|NCT03660358|DEVICE|kinesiotape application|kinesiotape application to diaphragm, chest wall and abdomen in preterm infants.
41487523|NCT01775865|DRUG|Salsalate|4 weeks of daily salsalate
41487524|NCT01775865|DRUG|Placebo (for salsalate)|4 week of daily placebo
41487525|NCT01046266|DRUG|RO5083945|700mg iv weekly
41487526|NCT01046266|DRUG|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
41487527|NCT04053413|OTHER|Decision Aid|The decision aid is a series of web pages that includes videos, questions, and evidence-based information. The decision aid is designed to help women think about what matters to them and what questions they may have for their doctor or midwife. At the end, they receive a summary of which way they are leaning and what matters most to them.
41487528|NCT06253819|OTHER|survey and physical test|6 min. walking test respiratory function test 30 second sit-stand test respiratory muscle test tıme up and go corbin posture analysis Waist/Hip Circumference Ratio Glucose and Cholesterol values Lanss Neuropathic Pain Scale
41487529|NCT03961022|DIETARY_SUPPLEMENT|Polyherbal supplement: ReWin(d) vs Placebo|Supplementation during 4 weeks + 72 hours post acute exercice
40821222|NCT06605248|BEHAVIORAL|Patient information digital fact-sheet plus usual care|The face-sheet will be delivered after patients receive usual care from their general practitioners.This digital intervention will contain educational material for chronic back pain that includes details about diagnosis, prognosis and treatment options.
41487530|NCT01484613|DEVICE|quadripolar LV lead (Quartet)|All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
41487531|NCT05985733|OTHER|Biochemical analysis|Oxidative stress and inflammation markers were analyzed in serum and saliva of TMD and healthy subjects.
40821223|NCT03082534|DRUG|Pembrolizumab, Cetuximab|"Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR."
40821224|NCT05798780|BEHAVIORAL|ENHANCE Intervention - Exercise and Nutrition|During radiation, participants will attend in-person supervised resistance training sessions once a week for 7 weeks, followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks, after radiation. Sessions will last approximately 30 minutes. During radiation, participants will be provided 15 meals each week for 7 weeks, 105 meals total. Participants will be asked to participate in 1 weekly dietary coaching session (in-person during radiation and video conference following radiation), create weekly SMART goals, follow an alternative Mediterranean diet pattern, and log all meals, snacks, and supplements consumed for the 12-week intervention.
40821225|NCT05798780|BEHAVIORAL|ENHANCE Intervention - Nutrition Only|During chemoradiotherapy, participants will be provided 15 meals each week for 7 weeks (105 meals total) that will accommodate common NIS concerns (ex. dysphagia and difficulty chewing) following an aMED dietary pattern (5 breakfast, 5 lunch, and 5 dinner), will be taught proper portion size, and will be asked to record percentages of each meal consumed in a provided food journal, in addition to any outside meals, snacks, or nutritional supplements. They will be provided with dietary coaching weekly to discuss NIS, aMED diet compliance, and set weekly SMART goals (approximately 30 min). Following completion of chemoradiotherapy (5 weeks), participants will be provided dietary coaching weekly (in-person or via videoconference), discuss NIS, aMED diet compliance at home, and set weekly SMART goals (30 min). Trainers will monitor participants' Fitbit active minutes in real time throughout the intervention period and provide aerobic exercise encouragement accordingly.
40821226|NCT04000308|DRUG|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
40821227|NCT04000308|DRUG|Wound Infiltration|Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
40821228|NCT05062304|DRUG|Fluticasone Furoate-Vilanterol Trifenatate|Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.
41156940|NCT06461650|BEHAVIORAL|Nicotine cessation program|Participants will complete up to 4 sessions of a nicotine cessation program over either 12-24 weeks if receiving neoadjuvant chemotherapy prior to surgery or over 4-6 weeks if not receiving neoadjuvant chemotherapy prior to surgery. Each session will be 30-60 minutes long. Participants receiving neoadjuvant chemotherapy will also be eligible for nicotine replacement therapy; however, it must be stopped 6 weeks before surgery.
41487532|NCT00285948|DEVICE|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
41487533|NCT05690126|DIETARY_SUPPLEMENT|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
41340050|NCT03154294|DRUG|paclitaxel|Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
41340051|NCT03154294|DRUG|TAK-228|TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
41340052|NCT03154294|DRUG|TAK-117|TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
41340053|NCT02713945|DRUG|Simvastatin|Experimental drug administrated orally
41340054|NCT02713945|DRUG|Placebo|Treatment for the control group
41340055|NCT04682106|DRUG|LY3493269|Administered orally.
41340056|NCT04682106|DRUG|Placebo|Administered orally.
41340057|NCT02985489|DIETARY_SUPPLEMENT|Olimel Parenteral Nutrition|Olimel 5.7% with electrolytes
41340058|NCT04758741|BEHAVIORAL|Acceptance and Commitment Therapy|Investigating the impact of Acceptance and Commitment Therapy on Resiliency in women affected by domestic violence
41340059|NCT04758741|OTHER|placebo|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience
41340060|NCT04306302|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V.
41340061|NCT04306302|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo.
41340062|NCT03466671|DRUG|TTA-121|A nove intranasal spray of oxytocin and placebo
41340063|NCT04341584|DRUG|Anakinra|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level \> 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
41340064|NCT03561246|OTHER|Incline treadmill walking|Those with a Pp \<0.47 or \>0.53 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
41340065|NCT03561246|OTHER|Decline treadmill walking|Those with a Pp \<0.47 or \>0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
41340066|NCT03561246|OTHER|Level Treadmill (Control)|Those with a Pp \<0.47 or \>0.53 will undergo LEVEL training during which individuals will walk for 15 minutes at a 0-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
41340067|NCT03012360|DRUG|ceftriaxone|2 g iv every 24h
41340068|NCT03012360|DRUG|ciprofloxacin|400 mg iv every 8h
41340069|NCT03012360|DRUG|imipenem|1 g iv every 8h
41340070|NCT03012360|DRUG|linezolid|600 mg iv every 12h
41340071|NCT03012360|DRUG|placebo|The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
41340072|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 75 milligrams (mg) orally, twice daily (BID) up to Week 48
41340073|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 25 mg orally, once daily (QD) up to Week 48
40821229|NCT05062304|DRUG|Furoate-umeclidinium-vilanterol|Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.
40821230|NCT06605586|DRUG|Tasquinimod|treatment with tasquinimod capsules once daily
40821231|NCT00328653|DRUG|Cyclosporine NOVA22007 0.05%|
40821232|NCT00328653|DRUG|Cyclosporine NOVA22007 0.1%|
40821233|NCT00328653|DRUG|Vehicle|
40821234|NCT01804582|OTHER|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
40821235|NCT00567671|PROCEDURE|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
41017226|NCT06632028|OTHER|artificial intelligence assisted spinal rehabilitation|In artificial intelligence-based rehabilitation, it is more advantageous compared to other treatment methods in terms of the fact that technology applications can be designed according to the level and abilities of the individual and that the parameters such as duration, intensity, difficulty and speed of the treatment can be flexibly configured for the therapist and the patient.
41340074|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 75 mg orally, QD up to Week 48
40821236|NCT00567671|PROCEDURE|Sham comparator|Sham treatment
40821237|NCT00998673|DEVICE|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
40821238|NCT00998673|DEVICE|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
40821239|NCT04611958|DRUG|ERCP with Bupivacaine infusion|"Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom."
40821240|NCT04644796|DRUG|saline 0.9%|Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
40821241|NCT04644796|DRUG|Liposomal bupivacaine|Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
41017227|NCT06632028|OTHER|conventional therapy|In cervical disc herniation, non-invasive physical therapy applications such as laser treatment, hot-cold treatment methods, Transcutaneous Electrical Nerve Stimulation (TENS), interferential currents, manual therapy applications, kinesiological taping and exercise therapy, as well as painkillers and nonsteroidal anti-inflammatory drugs and antidepressive drugs are among the most preferred methods in treatment.(6)
41340075|NCT02975349|DRUG|Placebo|Placebo were administered for 24 weeks
41340076|NCT02975349|DRUG|Tecfidera|Tecfidera; 120 mg hard capsule BID for 7 days then 240 mg hard capsule BID for duration of treatment (48 weeks).
41340077|NCT02975349|DRUG|Evobrutinib|Following Placebo for 24 weeks, participants received Evobrutinib 25 milligram (mg) orally, once daily (QD) from Week 24 to 48 weeks.
41340078|NCT00232050|DRUG|Omalizumab|
41340079|NCT04829461|DEVICE|Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal|Procedure using a single-use cystoscope for stent removal
41487534|NCT05690126|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are taken during 6 weeks by healthy volunteers
41340080|NCT04829461|DEVICE|Standard of care reusable cystoscope used for stent removal|Procedure using a reusable cystoscope for stent removal
41340081|NCT00003551|DRUG|aminocamptothecin colloidal dispersion|
41340082|NCT01938560|OTHER|Survey Responses|Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
41340083|NCT00001036|DRUG|Thymalfasin|
40821242|NCT05484531|DEVICE|CLEAR|Reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude
40821243|NCT04042142|OTHER|glucagon|Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
41340084|NCT00001036|DRUG|Interleukin-2, Polyethylene Glycolated|
41340085|NCT00001036|DRUG|Zidovudine|
41340086|NCT01619488|DEVICE|Adjustable Gastric Band|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
41340087|NCT05106036|OTHER|Clinical Support Decision Tool|Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
41340088|NCT02244619|DRUG|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
41340089|NCT02244619|DRUG|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
41340090|NCT03431792|DEVICE|Long Tail Balloon|s. description of experimental Arm
41340091|NCT02164604|DRUG|intravitreal injection of 0.03ml ranibizumab|
40821244|NCT01793337|OTHER|Exposure to cold environmental temperature (-20°C)|
40821245|NCT04236908|DRUG|NSAIDS|Naproxen 500mg by mouth twice a day as needed.
40821246|NCT04236908|DEVICE|Battlefield Acupuncture|"Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men).~Battlefield acupuncture utilizes up to 10 ASP acupuncture needles (5 in each ear). The Battlefield Acupuncture points include: cingulate gyrus, thalamus, omega-2, point zero, and shen men. The semi-permanent needles are left in place and typically stay in place for 2-7 days. Needles will usually fall out on their own, can be removed by the patient or the patient can call study staff and come in for removal if desired."
41017231|NCT04805814|DIAGNOSTIC_TEST|CMR results disclosed|The results of the CMR are disclosed, and used to guide management
41017232|NCT04805814|DIAGNOSTIC_TEST|CMR performed but results not disclosed|The results of the CMR are not disclosed, and management is angiography-guided
41340092|NCT01301417|DEVICE|ColonRing™|Creation of a circular Compression Anastomosis
41017233|NCT06395753|DRUG|Debio 4228|Administered as IM injection.
41017234|NCT05506982|DRUG|Psilocybin|Given PO
41340093|NCT05526092|OTHER|Dietary intervention|Changes in metabolism, microbiota, vitality and comprehensive health after 6 week consumption of oat / rice.
41340094|NCT02741310|DRUG|Placebo|Administered by intravenous infusion
41340095|NCT02741310|DRUG|Sumatriptan|Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5
41340096|NCT02741310|DRUG|Erenumab|Administered by intravenous infusion
41340097|NCT05427864|DIAGNOSTIC_TEST|Multiparametric Prostate MRI|Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer
41340098|NCT03766542|DEVICE|Bi-level positive airway pressure with ventilatory support|Positive airway pressure will be applied in the experimental group through a oronasal interface, in ventilatory support mode (Bi-level) with a fixed backup rate.
41340099|NCT03766542|DEVICE|continuous positive airway pressure without ventilatory support|Continuous positive airway pressure (CPAP) will be applied in the active comparator group through a oronasal interface.
41017235|NCT05506982|BEHAVIORAL|Psychotherapy|supportive care
41017236|NCT05506982|OTHER|Quality-of-Life Assessment|Ancillary studies
41017237|NCT05506982|OTHER|Questionnaire Administration|Ancillary studies
41340100|NCT02336880|BEHAVIORAL|Internet-delivered cognitive behavioural therapy|
41340101|NCT05318040|DRUG|CMS121|CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease
41340102|NCT05318040|DRUG|Placebo|Placebo will be provided as visually matching placebo capsules.
41340103|NCT00702936|DRUG|TELMISARTAN|80 mg daily
41340104|NCT00702936|DRUG|RAMIPRIL|5 mg daily
41340105|NCT04073641|OTHER|No intervention|No intervention
41340106|NCT04561284|DIETARY_SUPPLEMENT|Indigestible fiber (classified)|Participants will be asked to ingest 12 grams of indigestible fiber powder per day for a period of 8 weeks. Three times daily, they will take 4 grams of powder with their meal.
40821247|NCT04236908|DEVICE|GV26 with manual tonification|"Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle).~The protocol for using GV26 is as follows: With the patient in a seated position the acupuncturist places a 40mm needle in the acupuncture point GV26 (located on the philtrum, on the anterior midline, at the junction of the upper 1/3 and lower 2/3 of the distance from the nose to the margin of the upper lip). The acupuncturist then rapidly rotates the needle at the handle clockwise and counterclockwise (known as manual tonification) for 20-40 seconds at a time. The patient then stands up and assesses their pain. This will be performed up to 6 cycles. If a patient is unable to sit or stand, this may also be performed in a supine position with the patient attempting to sit or stand every 20-40 seconds."
41017238|NCT06460311|OTHER|PEDAL and EMS|"Group A will receive EMS with Stationary cycle. EMS will be given at quadricep muscles. The pads will placed vertically in the midline along the knee and the pelvis. EMS will be given at frequency = 35 to 70 Hz, pulse duration = 100 μs, pulse period = 50 ms, Intervention will be will be performed for 60 minutes for 3 times or week for 4 weeks.~Conversely, the endurance training phase will involve securing the cycle seat while children cycle at their maximum capacity, aiming for a heart rate between 70% to 80% of their maximum. Prior to and following each session, stretching exercises targeting the calf, quadricep, and hamstring muscles will be administered, with a 10-second hold during both the warm-up and cool-down sessions. Pre and post measurements will be conducted to evaluate mobility and gait"
41017239|NCT06460311|OTHER|PEDAL|"In Group B, participants will exclusively receive the Pediatric Endurance and Limb Strengthening program without EMS. Similar to Group A, this program will incorporate the use of a stationary cycle. The warm-up and cool-down periods will also include a 10-second hold for each targeted muscle group. The intervention will consist of 60-minute sessions conducted three times per week over a span of four weeks.~Pre and post-assessments of gait and mobility will be conducted using the Gait Outcomes Assessment List (GOALTM) Questionnaire and the time up and go test."
41340107|NCT04561284|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to ingest 6 grams of placebo powder per day for a period of 8 weeks. Three times daily, they will take 2 grams of powder with their meal.
41487535|NCT02860065|DRUG|CPC-201|solifenacin and donepezil
41340108|NCT05637957|DEVICE|active transcranial direct current stimulation|Device: 20 minutes of up to 2.0 mA active anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
41340109|NCT05637957|DEVICE|sham transcranial direct current stimulation|Device: 1 minute of 1.0 mA anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) and 19 minutes with unit turned off and electrodes remaining in place Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
41340110|NCT03065725|PROCEDURE|late FDG|In addition to regular FDG-PET/CT 60 minutes post injection, an extra scan 180 minutes post injection is made.
40821248|NCT06109051|DEVICE|EndeavorOTC|EndeavorOTC™ is an over-the-counter digital therapeutic designed to improve attention function, ADHD symptoms, and quality of life in users 18 years of age and older with primarily inattentive or combined-type ADHD, who have been identified as having a significant attentional impairment. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is not intended to be a replacement for any form of ongoing treatment. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
40821249|NCT05824923|PROCEDURE|Pulmonary arterial denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 ℃ for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA.~For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician."
41340111|NCT03577951|PROCEDURE|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
41340112|NCT03577951|PROCEDURE|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
41340113|NCT05133206|OTHER|Advice on fasting before the procedure|Patients are allowed to eat and drink freely up to the point of transfer to the Catheter Laboratory.
41017248|NCT05932290|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
41340114|NCT06438744|PROCEDURE|Thread embedding acupuncture (TEA) + standard therapy|"* TEA : one-time TEA using 30 gauge TEA needle with 30 mm polydioxanone thread at CV3 through CV4, SP6 and ST36 bilaterally~* Standard therapy : 2 mg dienogest daily for 8 weeks after TEA"
41340115|NCT03167125|OTHER|Automated Prompts|This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
41340116|NCT03167125|OTHER|Automated Plus Live Prompts|This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
41017249|NCT05932290|DRUG|Standard of care|Standard of care
41340117|NCT01673490|DRUG|Dutasteride/Tamsulosin|0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
41340118|NCT00488059|DRUG|enfuvirtide [Fuzeon]|90 mg SC twice daily
41340119|NCT00488059|DRUG|Optimized background ARV|As prescribed
41340120|NCT00488059|DRUG|Integrase inhibitor|As prescribed
41340121|NCT00488059|DRUG|enfuvirtide [Fuzeon]|180 mg SC once daily
41340122|NCT04523467|DRUG|Anti-angiogenic Targeted Drugs|A tyrosine kinase inhibitor inhibits vascular endothelial growth factor (VEGF) receptors 1-3, showed efficacy in hepatocellular carcinoma
41340123|NCT04523467|DRUG|Ginsenoside Rg3|An active ingredient extracted from ginseng leachate, which can restrain angiogenesis and reduce the expression of programmed cell death ligand 1 (PD-L1) on the tumor cell surface and block the binding of programmed cell death 1 (PD-1) and PD-L1
41340124|NCT04523467|PROCEDURE|TACE|A specific type of chemoembolization that blocks the hepatic artery to treat liver cancer
40821250|NCT05824923|DRUG|Guideline-directed medical therapy (GDMT) for heart failure|"GDMT medication recommendation including:~* Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~* Beta-receptor blocker (BB)~* Mineralocorticoid receptor antagonist (MRA)~* Sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2023 ESC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 12-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion."
40821251|NCT04587843|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day)."
40821252|NCT04587843|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day for 1 year (2 tablets, taken twice a day).
40821253|NCT05420714|DEVICE|Dexcom Professional Continuous Glucose Monitoring|Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
40821254|NCT00411827|PROCEDURE|PRK with conjunctival impression cytology before and after surgery|
40821255|NCT00411827|PROCEDURE|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
40821256|NCT00801489|DRUG|Cytarabine|Given IV
40821257|NCT00801489|DRUG|Decitabine|Given IV
40821258|NCT00801489|BIOLOGICAL|Filgrastim-sndz|Given SC
40821259|NCT00801489|DRUG|Fludarabine Phosphate|Given IV
40821260|NCT00801489|DRUG|Gemtuzumab Ozogamicin|Given IV
40821261|NCT00801489|DRUG|Idarubicin|Given IV
40821262|NCT00801489|OTHER|Laboratory Biomarker Analysis|Correlative studies
41340125|NCT01782885|PROCEDURE|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
41340126|NCT01782885|DRUG|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
41340127|NCT01833806|DEVICE|ExAblate MRgFUS|Focused Ultrasound Ablation
41340128|NCT00546936|DRUG|ranibizumab|0.5mg ranibizumab
41340129|NCT00546936|DRUG|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
40821263|NCT00308893|GENETIC|Genetic analysis|Compare BDNF polymorphism among responders and non-responders
41340130|NCT02155504|DRUG|ASP3700|oral
41340131|NCT02155504|DRUG|itraconazole|oral
41340132|NCT02155504|DRUG|Placebo|oral
40821264|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with the sodium nitrate and nitrite as an additive.
40821265|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate plus vegetables|"The same intervention as of intervention meat with added nitrate consumed together with mixed vegetables."
41340133|NCT04691531|DEVICE|The use of classical Gauge 22 needle|After induction of general anesthesia, patients will undergo caudal block by using classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
41340134|NCT04691531|DEVICE|The use of classical Gauge 27 needle|After induction of general anesthesia, patients will undergo caudal block by using Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
40821266|NCT06608602|OTHER|tidal volume adjustment during surgery|tidal volume adjustment during surgery according to body weight or FVC
41340135|NCT04737967|DRUG|Venlafaxine|Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)
41340136|NCT04737967|DRUG|Memantine|Patients will receive memantine (10 mg) once daily (Morel et al., 2016)
41340137|NCT05557136|DEVICE|Multistranded stainless steel fixed retainer|Multistranded stainless steel fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
41340138|NCT05557136|DEVICE|Polyether-Ether-Ketone (PEEK) fixed retainer|Polyether-Ether-Ketone (PEEK) fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
41340139|NCT02479386|OTHER|No intervention|No intervention was administered in this study.
41340140|NCT03748420|OTHER|Adherence Intervention|The adherence enhanced intervention consists of clinical decision support related to cardiovascular risk factors enhanced with external medication adherence information and is delivered at the point of care to the healthcare provider and patient.
41340141|NCT03812783|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
41487536|NCT02860065|OTHER|Positron emission tomography (PET)|measure activity of cerebral acetylcholinesterase
41487537|NCT04002336|BEHAVIORAL|Traditional Voice therapy|Traditional method of voice therapy
41340142|NCT03812783|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
41340143|NCT03812783|DRUG|Sorafenib|administration of Sorafenib
41340144|NCT03812783|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Irinotecan, Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
41340145|NCT03812783|DRUG|FOLFIRINOX|Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
41340146|NCT00367705|DIETARY_SUPPLEMENT|VSL#3®|1-2 sachets/day per os, 6 months
41340147|NCT00367705|DIETARY_SUPPLEMENT|Placebo|1-2 sachets/day per os, 6 months
41340148|NCT05505149|OTHER|physiotherapy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
41487538|NCT04002336|BEHAVIORAL|Voice Therapy App|Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
41487539|NCT05270200|DRUG|Azacitidine|Patients will recieve six courses of azacitidine 100mg through a needle under skin on Days 1-5.Each course is 28 days long.
41487540|NCT05270200|DRUG|Chidamide|Patients will recieve oral chidamide 5mg per day for no more than 2 years.
41487541|NCT04191655|DEVICE|High Definition Colonoscopy|A colonoscopy that used high definition (HD) camera
41487542|NCT04191655|DEVICE|Dye Spraying Chromocolonoscopy|A colonoscopy that used high definition camera in addition to dye spraying on the interior colon surface.
41487543|NCT01684137|DIETARY_SUPPLEMENT|Joalis Bambi Analerg|
41487544|NCT01684137|DIETARY_SUPPLEMENT|Joalis Bambi Bronchi|
41487545|NCT01684137|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
41487546|NCT01684137|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
41487547|NCT03876977|PROCEDURE|Robotic laparoscopic decompression of pudendal nerve entrapment|"Robotic laparoscopic decompression of pudendal nerve entrapment.~Transperitoneal Laparoscopic Robotic assistance"
41340149|NCT03672669|GENETIC|Advanced Platelet Rich Fibrin (A-PRF)|blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF
41340150|NCT03672669|GENETIC|Leukocyte- and platelet-rich fibrin (L-PRF)|blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
41340151|NCT02158455|PROCEDURE|NT SVG grafts|
41340152|NCT00369278|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Tablets for oral administration
41340153|NCT06189066|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
41340154|NCT00937508|BEHAVIORAL|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
41487548|NCT03952611|PROCEDURE|Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
41340155|NCT00937508|DRUG|varenicline|varenicline (an approved medication for smoking cessation)
41487549|NCT03952611|DEVICE|distal Cap|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
41487550|NCT03952611|DEVICE|Endocuff|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
41340156|NCT00937508|DRUG|placebo|sugar pill without any active medication
41340157|NCT05687253|DRUG|BX1000|IV BX1000
41340158|NCT05687253|DRUG|Rocuronium Bromide|IV Rocuronium
41340159|NCT04399057|DIAGNOSTIC_TEST|shear Wave Elastosonography|both the left cavernous body and the right cavernous body are ideally divided longitudinally into three sections: proximal, middle and distal. subsequently for each section of the corpora cavernosa the stiffness of the tissue is calculated by means of a specific Region Of Interest (ROI). the result is expressed in Kilopascals and in a color scale. when registering the stiffness the patient is asked to hold their breath.
41340160|NCT02801006|DEVICE|stenfilcon A|contact lens
41487551|NCT00331071|DRUG|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
41487552|NCT00331071|DRUG|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
41487553|NCT02856880|OTHER|Test zinc-IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride and 0.1% w/w IPMP and 1426ppm fluoride as sodium fluoride.
41340161|NCT02801006|DEVICE|etafilcon A|contact lens
40821267|NCT05763901|DIAGNOSTIC_TEST|Clinical tests and motor control evaluation using Inertial Measurement Units|Each patient is evaluated using clinical tests (Movement ABC2, Test of Motor Competence), a screening questionnaire (DCD-Q), and wearable Inertial Measurement Units to assess balance and motor control during a Natural Walking and Tandem Walking test.
40821268|NCT03661788|DRUG|Atomoxetine|14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
41340162|NCT05690906|DEVICE|ReSpace™|The experimental group subjects will be injected with ReSpace™ hydrogel.
40821269|NCT03661788|DRUG|Placebos|14-day treatment interval: first week one placebo pill, second week two placebo pills
40821270|NCT06042725|PROCEDURE|Biospecimen Collection|Undergo optional collection of blood samples
41340163|NCT05690906|DEVICE|gauze packing|The subjects of both groups will be given gauze packing
41340164|NCT02520713|GENETIC|Genetic testing and GAIN report|All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.
41340165|NCT01313468|BEHAVIORAL|1 x 4 minute interval|1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
41487554|NCT02856880|OTHER|Test zinc non- IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride, 0% w/w IPMP and 1426ppm fluoride as sodium fluoride.
41487555|NCT02856880|OTHER|Positive control|Positive control toothpaste containing 0.454% w/w stannous fluoride (Fluoride Toothpaste (1100ppm Fluoride as stannous fluoride)).
41487556|NCT02856880|OTHER|SLS negative control|Negative control toothpaste containing 2.0% SLS, 0.65% Tegobetain and 1150 ppm fluoride as sodium fluoride
40821271|NCT06042725|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
40821272|NCT06042725|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40821273|NCT06042725|PROCEDURE|Chest Radiography|Undergo chest x-ray
40821274|NCT06042725|PROCEDURE|Computed Tomography|Undergo PET/CT
41340166|NCT01313468|BEHAVIORAL|4 x 4 minutes Intervals|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
41487557|NCT02856880|OTHER|non-SLS negative control|Negative control toothpaste containing 1426 ppm fluoride as sodium fluoride
40821275|NCT06042725|BIOLOGICAL|Daratumumab|Given SC
40821276|NCT06042725|DRUG|Dexamethasone|Given PO
40821277|NCT06042725|DRUG|Lenalidomide|Given PO
41156941|NCT06646783|DRUG|[68Ga]Ga-NODAGA-SNA014|Perform whole-body PET/CT scans on the subjects at 30 minutes (± 5 minutes), 60 minutes (± 10 minutes), 120 minutes (± 20 minutes), and 240 minutes (± 30 minutes) after administration. Among them, PET scanning can be performed on 1-2 subjects in a certain dose group or each dose group for 30-60 minutes. Among the four CT scans, one CT scan is a conventional low-dose CT scan (120mA), and the remaining three are extremely low-dose CT scans (10-20mA). The main researchers and nuclear medicine physicians can decide whether to change the subsequent image acquisition time and duration of the subjects based on the image information obtained from the enrolled subjects.
41340167|NCT01313468|BEHAVIORAL|Moderate continuous Training|47 minutes of Moderate continuous Training
41340168|NCT02019758|DRUG|Oral Viscous Budesonide|Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
41340169|NCT02019758|DRUG|Fluticasone MDI|Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
41487558|NCT04738682|OTHER|Digital dietary registration|"The purpose of the intervention is to test whether digital dietary registration can yield more precise and consistent data, than conventional pen and paper based registration.~Furthermore a subjective evaluation of the use of digital registration will be conducted by the staff upon completion of the intervention. The format will be individual interviews held by the investigators."
41487559|NCT04738682|OTHER|Conventional dietary registration|The conventional way of doing dietary registration. This is done by a paper form, with the dietary options listed. The form is then filled in and logged by staff working in the afternoon.
41487560|NCT03474250|DIAGNOSTIC_TEST|Magnetic Resonance test for kidney|Magnetic Resonance test for kidney
41487561|NCT00004890|BIOLOGICAL|aldesleukin|
40821278|NCT06042725|PROCEDURE|Low Dose Computed Tomography of the Whole Body|Undergo WBLDCT
40821279|NCT06042725|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40821280|NCT06042725|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40821281|NCT06042725|DRUG|Venetoclax|Given PO
40821282|NCT06042725|PROCEDURE|X-Ray Imaging|Undergo x-rays
40821283|NCT06042725|OTHER|Questionnaire Administration|Ancillary studies
40821284|NCT02185014|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
41340170|NCT02019758|DRUG|Placebo slurry|Slurry of sucralose - 4 mL twice daily
41340171|NCT02019758|DRUG|Placebo inhaler|Placebo inhaler - 4 puffs twice daily
41487562|NCT00004890|DRUG|Biomed 101|
41487563|NCT04404530|DRUG|Palynziq|Participants will take Palynziq as prescribed by their genetics doctor. In accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, patients will have their first injection of Palynziq at the Emory Genetics Clinic under the supervision of a physician. After initiating therapy, patients will continue to mail in blood spot filter papers and 3-day dietary records to their clinic providers as standard components of clinical care.
40821285|NCT03854526|OTHER|Evaluation of the quality of direct and indirect partial dental coronal restorations in adults|"The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning."
40821286|NCT03164317|OTHER|Intervention|A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
40821287|NCT03164317|OTHER|Control|No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
40821288|NCT01823783|OTHER|Muscle biopsy|Muscle biopsy
40821289|NCT03449693|DIETARY_SUPPLEMENT|Magnesium Oxide Supplement|Magnesium Oxide tablet
40821290|NCT06547112|DRUG|Motixafortide|Dose = 1.25 mg/kg via subcutaneous injection
40821291|NCT06547112|DRUG|G-CSF|Dose = \~10 µg/kg (and maximum of 15 µg/kg) via subcutaneous injection
40821292|NCT05130216|OTHER|Genicular Nerve Radiofrequency Ablation|Radiofrequency Ablation (RFA)
41487564|NCT01066689|DRUG|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
41487565|NCT01066689|DRUG|Physiological serum (Sodium Chloride, sodium citrate)|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
40821293|NCT04809558|BEHAVIORAL|Tongue resistance exercise|Participant will complete tongue resistance exercises.
40821294|NCT01373684|DRUG|Peginterferon alfa-2a|180 μg per week s.c. for a total duration of 48 weeks.
40821295|NCT01373684|DRUG|Nucleos(t)ide analogue|All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
40821296|NCT06040918|DRUG|N-803|fixed dose of 1 mg by subcutaneous (SC) injection
40821297|NCT06609018|DEVICE|Test Lenses (stenfilcon A)|Daily disposable, soft contact lenses worn for one week
41487566|NCT03528629|DRUG|Zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion.
41340172|NCT06444568|OTHER|Dietary Intervention|The intervention includes the application and follow-up of different diet therapies to individuals (Ketogenic diet and MIND).
41340173|NCT05154565|BEHAVIORAL|Guided meditation|App-based guided meditation intervention through Headspace. This can be accessed through various mobile devices.
41340174|NCT05182541|OTHER|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
41340175|NCT05182541|OTHER|Problem solving therapy|Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks
41340176|NCT05182541|OTHER|Face to face PST course|Face to face interviews with nurses with psychological counselors, combined with auxiliary tools, identify patients' problems, set goals for patients, provide different solutions, and let patients choose appropriate ways according to their preferences. Once a week, 1 hour for the first time and 45 min for the rest for 5 weeks.
41340177|NCT05182541|OTHER|Professional psychological intervention|The mental health physicians and (or) psychological counselors strengthened the intervention and carried out specialized nursing
41340178|NCT01178723|DIETARY_SUPPLEMENT|breakfast size|"The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.~(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.~Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).~The instructions will be adapted to each patient individually"
41340179|NCT03304262|DEVICE|rTMS|Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
41340180|NCT02340572|DRUG|PRS-080#022-DP|hepcidin antagonist
41340181|NCT02340572|DRUG|PRS-080-Placebo#001|Placebo treatment
41340182|NCT01117025|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
41340183|NCT01117025|PROCEDURE|Circumferential PVI+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
41340184|NCT03623022|DRUG|Clinical Center Reference Endotoxin (CCRE)|subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
41340185|NCT03623022|DRUG|Normal saline|subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
41340186|NCT00829660|DRUG|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
41340187|NCT00829660|DRUG|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
41340188|NCT05999812|DRUG|all trans Retinoic Acid|ATRA orally 45 mg/m2 QD in 2 divided doses days 1-7, repeat every 14 days
41340189|NCT05999812|DRUG|Atezolizumab|Atezolizumab IV D1, 840 mg every 14 days
41340190|NCT05999812|DRUG|Bevacizumab|Bevacizumab IV D1, 10 mg/kg every 14 days
41340191|NCT04713670|DRUG|(A) T-V14|vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)
41340192|NCT04713670|DRUG|(B) T-V7|vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)
41017255|NCT06546800|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
41340193|NCT04713670|DRUG|(C) D-V14|vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)
41340194|NCT04713670|DRUG|(D) HD-V14|vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)
41487567|NCT02925806|OTHER|Non-interventional study - retrospective database review|
40821298|NCT06609018|DEVICE|Control Lenses (omafilcon A)|Daily disposable, soft contact lenses worn for one week
40821299|NCT02739529|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
40821300|NCT05425446|DRUG|DONQ52|Subcutaneous (SC) injection
40821301|NCT05425446|DRUG|Placebo|Subcutaneous (SC) injection
41340195|NCT04713670|DRUG|(E) BQ-V14|vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)
41340196|NCT04713670|DRUG|(F) RH-V14|vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)
41340197|NCT04713670|DRUG|(G) BQ-L14|lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)
41340198|NCT04713670|DRUG|(H) T-L14|lansoprazole(takepron)-based triple therapy for 14 days (T-L14)
41340199|NCT05917899|BEHAVIORAL|Virtual Family-Centered Rounds|The care team will use a computer with a speaker camera, mounted on a stand with wheels to launch telehealth visits using the application ExtendedCare. This platform meets HIPAA security rules and launches from the patient's electronic health record. From within this telehealth visit, a care team member will send a message (via text or email) to the parent(s) that includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. Parent do not need to download or use an application. The care team will invite the video interpreter to join the visit if a parent is present. Family-centered rounds will then proceed in usual fashion with the care team and \[if in attendance\] parent(s). Parents can participate in virtual family-centered rounds as much, or as little, as they choose.
41340200|NCT03515239|PROCEDURE|lumbopelvic fixation for spinopelvic dissociation|unilateral and bilateral lumbopelvic fixation for spinopelvic dissociation
41340201|NCT04775394|OTHER|Bronchoscopy|Bronchoalveolar lavage, mucosal biopsy and bronchial brushes during bronchoscopy
41340202|NCT01329068|BEHAVIORAL|individual consult|regular individual consultations
41340203|NCT01329068|BEHAVIORAL|group medical consult|group medical consult
41340204|NCT00952601|DIETARY_SUPPLEMENT|Modified Atkins diet|Low carbohydrate diet
41340205|NCT02866929|PROCEDURE|Decortication|Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.
41340206|NCT02866929|DEVICE|Orthodontics|Self-ligation brackets in upper and lower teeth
41340207|NCT02866929|DRUG|Mucograft|Porcine naturally cross-linked collagen matrix
41340208|NCT00253929|DRUG|Intra-arterial infusion of adenosine|
41340209|NCT00253929|DRUG|intra-arterial infusion of caffeine|
41487568|NCT04464993|BEHAVIORAL|Device-based feedback, self-monitoring, and education: CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app on an android tablet and a Fitbit to use throughout the 16-week intervention.t. SST feedback will be provided within the smartphone application. Self-monitoring will provide passive and objective feedback regarding SST behaviors. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
40821302|NCT04821674|BIOLOGICAL|DS-5670a|DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
40821303|NCT04821674|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
40823037|NCT03321903|DEVICE|Carlo Erba Ink Injection|Carlo Erba India ink is used in this study as a paramagnetic oxygen sensor that is injected into tissue, and which, when measured using EPR Oximetry, can provide sensitive, repeated, and direct measurements of tissue oxygen. Each study participant will receive at least one ink injection of 20-50µL of Carlo Erba India Ink. The ink injection will occur within 5mm of the body surface (i.e., skin or mucosa), and may be injected into tumor, postsurgical field of radiation, and/or adjacent normal tissue. Carlo Erba Ink is an aqueous suspension composed of charcoal powder, water for injection, and a suspending agent. Carlo Erba is the name of the manufacturer that supplies the charcoal.
41017257|NCT05309382|DIAGNOSTIC_TEST|Prospera|Monthly testing and results provided
41017258|NCT05377489|DRUG|RTX-GRT7039|RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.
41340210|NCT00253929|DRUG|intra-arterial infusion of acetylcholine|
41340211|NCT00253929|DRUG|intra-arterial infusion of sodium nitroprusside|
41340212|NCT00253929|PROCEDURE|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
41340213|NCT06066190|OTHER|Web-Based Training on ERAS Protocols Applied in Gynecological and Obstetric Surgery|Web-Based Training will be given to Midwives and Nurses on ERAS Protocols Applied in Gynecological and Obstetric Surgery. The training will last 6 weeks and they will be asked to watch a training video every week.
41340214|NCT04986111|PROCEDURE|Linear skin closure with wound drain|"An oval incision is made around the ileostomy and the continuity of the intestinal tract is restored after adhesion division.~Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. A Jackson-Pratt drainage tube is placed in the subcutaneous tissue and vertical mattress suture is performed with a non-absorbable thread."
41340215|NCT04986111|PROCEDURE|Purse-string skin closure with negative pressure wound therapy|"Recover the intestinal continuity after adhesion division by making a circular incision along the ileostomy Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. Negative pressure wound therapy is performed after suturing the subcutaneous tissue using absorbable thread."
41340216|NCT02392468|DRUG|Placebo matching BI 409306 25 mg|Film-coated tablet
41340217|NCT02392468|DRUG|Placebo matching BI 409306 50 mg|Film-coated tablet
41340218|NCT02392468|DRUG|BI 409306 25 mg|Film-coated tablet
41340219|NCT02392468|DRUG|BI 409306 50 mg|Film-coated tablet
41340220|NCT02027064|DRUG|Interferon-alpha|
41340221|NCT00926991|OTHER|No intervention|No intervention; observation only
41340222|NCT01489228|DRUG|E1224|100 mg tablets
41340223|NCT01489228|DRUG|Benznidazole|100mg tablets
41340224|NCT01489228|DRUG|Placebo|tablets
41340225|NCT03554304|DRUG|WCK 5222|FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)
41340226|NCT03554304|DRUG|IV placebo matched to WCK 5222 / Moxifloxacin IV solution|"Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet"
41340227|NCT03554304|DRUG|Moxifloxacin 400-mg|Moxifloxacin 400-mg positive control (overencapsulated tablet)
41340228|NCT05047016|OTHER|Virtual investigational product|The virtual investigational product is a predefined text (e.g. AB123F). By entering the code into the application, the virtual 'administration' of the IP is conducted.
41340229|NCT03398824|DRUG|metformin HCl|Receive metformin HCl
41340230|NCT03612544|OTHER|ENDS (Vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
41340231|NCT03612544|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
41340232|NCT03286881|OTHER|Brief individual psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
41340233|NCT03286881|OTHER|Brief group psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
41340234|NCT03286881|OTHER|Combined intervention|Traditional psychotherapy and medication provided by a clinical psychologist and a psychiatrist in secondary care.
41340235|NCT03286881|OTHER|Minimum psychological intervention|Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.
41340236|NCT03286881|OTHER|Usual treatment|Medication provided by a general practitioner.
41340237|NCT02030093|BEHAVIORAL|Telephone-based counseling|Telephone-based continuing care wil be provided to patients in different frequency
41340238|NCT05333640|DEVICE|Sirolimus Drug Coated Balloon|AVFs treated with SDCB
41340239|NCT05333640|DEVICE|Paclitaxel Drug Coated Balloon|AVFs treated with PDCB
41340240|NCT04342416|BEHAVIORAL|Visiospatial Interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
41340241|NCT06367972|PROCEDURE|Local Consolidation Therapy|Participants may receive radiation therapy. The choice of LCT and radiation therapy regimen will be determined by a multidisciplinary team including the study doctor.
41487569|NCT04464993|BEHAVIORAL|Sedentary Screen Time lockout: LOCKOUT|Sedentary Screen Time lockout: LOCKOUT Sedentary Screen Time lockout: LOCKOUT The investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits feature to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be prompted to plan for their screen time and provided modest allowances for exceeding their screen time in a given week.
41340242|NCT06367972|PROCEDURE|Next-line Systemic Therapy|The specific next-line systemic therapy will be determined by your doctor.
41340243|NCT02402881|BEHAVIORAL|Patient-centered education bundle|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
41340244|NCT00003549|DRUG|CMF regimen|
41340245|NCT00003549|DRUG|cyclophosphamide|
41340246|NCT00003549|DRUG|fluorouracil|
41340247|NCT00003549|DRUG|methotrexate|
41340248|NCT03624790|BIOLOGICAL|rRSV A/Maryland/001/11|10\^5 PFU; delivered intranasally
41340249|NCT00534560|DRUG|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
41340250|NCT00534560|DRUG|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
41340251|NCT00534560|DRUG|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
41340252|NCT06295146|OTHER|Intervention A: 1-on-1 wheelchair skills training by a peer coach|"Trainees will engage in 1:1 virtual zoom meetings facilitated by the study team scheduled weekly for 6 sessions with the opportunity for 2 makeup sessions. Sessions will last approximately 30 minutes and may include goal setting, review of progress, instruction, and homework of prescribed content for trainees to review. Participants may upload videos of themselves completing skills through Qualtrics to get feedback."
41340253|NCT06295146|OTHER|Intervention B: Training via educational videos|Intervention B will be a series of educational videos that participants review and then are encouraged to the practice the skills. Participants will have access to the materials for 8 weeks. Group 3 will have access to approximately 3 hours of wheelchair skills video training content. Actual viewing time will depend upon the individual's training goal. While they will receive a weekly reminder about practicing, there is no prescribed frequency for how often they should be practicing the skills in the videos.
41340254|NCT02055170|DRUG|finasteride 5mg oral daily|
41340255|NCT02228772|DRUG|MLN 9708|Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
40821304|NCT05868005|OTHER|Clinical decision support system for screening of migrants using the ISMiHealth software tool.|"The implementation of the screening programme will be facilitated using a simple and user-friendly software tool (ISMiHealth).~When an individual attends the PCC for any reason, the tool will generate an alert for health professionals in the EPR system, with recommendations on the conditions that should be considered for screening, based on this patient's characteristics (country of birth, age and sex). Health professionals will decide what diseases/conditions should be screened for, supported by the recommendations of the digital software (intervention centres) or based on their knowledge on the epidemiological background of the diseases (control centres). In any case, health professionals will be responsible for requesting serology tests, chest radiographies and/or referrals to specialists."
40821305|NCT06512051|DRUG|SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin|"Drug: SHR-A2102~Drug: Adebrelimab~Drug: Cisplatin/ Carboplatin"
41340256|NCT02228772|DRUG|Vincristine|Standard chemotherapy dosage and duration
41340257|NCT02228772|DRUG|Cytarabine|Standard chemotherapy dosage and duration
41340258|NCT02228772|DRUG|Doxorubicin|Standard chemotherapy dosage and duration
41340259|NCT02228772|DRUG|Mercaptopurine|Standard chemotherapy dosage and duration
41340260|NCT02228772|DRUG|Cyclophosphamide|Standard chemotherapy dosage and duration
41340261|NCT02228772|DRUG|Methotrexate|Standard chemotherapy dosage and duration
41340262|NCT06430814|OTHER|No intervention|No intervention
41340263|NCT06350357|OTHER|punching closure|The hole clamping and the grooves hold the metal clips better
41340264|NCT06350357|OTHER|Conventional clipping|Metal lip closure is one of the most commonly used closure methods
41340265|NCT05412836|DEVICE|AqueousJoint|AqueousJoint is a liposomal boundary lubricant, which coats the cartilage surface and protects it from further damage and degradation.
41340266|NCT01186094|DEVICE|Cypher|Sirolimus-eluting stent
41340267|NCT01186094|DEVICE|Endeavor Resolute|Zotarolimus-eluting Stent
41340268|NCT01339208|OTHER|Telemedicine diabetes intervention|3 month duration telemedicine consultation and diabetes education
41340269|NCT01605201|BIOLOGICAL|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
41340270|NCT04429074|PROCEDURE|Minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy
41340271|NCT01474889|DEVICE|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
41340272|NCT00493467|DRUG|Ibritumomab Tiuxetan (Zevalin)|"111In Zevalin (5 mCi of \^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."
41340273|NCT00493467|DRUG|Rituximab|250 mg/m\^2 Intravenously Over 4-6 Hours On Days 1 and 8.
41340274|NCT03537183|OTHER|Exercise training|12 weeks, 3 hours a week, moderate intensity exercise training
41017268|NCT06230367|BEHAVIORAL|Sexual health advocacy for guys|5 month HIV prevention program delivered via text messaging
41017269|NCT06230367|BEHAVIORAL|Healthy lifestyle control|5 month control group program delivered via text messaging
41017271|NCT06369740|OTHER|Case scenarios - questionnaire|Participants fill in a questionnaire on the current care of hemophilia A and envisioned use scenarios of a point-of-care diagnostic device for hemophilia A.
41017272|NCT06369740|OTHER|Case scenarios - Focus groups|Participants partake in focus groups on the current care for hemophilia A, the envisioned use scenarios of point-of-care diagnostic device for hemophilia A and desired features of such a diagnostic device.
41017273|NCT06369740|OTHER|Use scenarios - Usability test|Participants are asked to perform basic tasks with the mock-ups with minimal instructions, they will also be given a graphic of the user interface (GUI).
41017274|NCT06369740|OTHER|Use scenarios - interview|The participants will be interviewed and asked for their opinions and experiences with the mock-ups.
41017275|NCT03856216|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given IV
40821306|NCT01296633|BEHAVIORAL|Medtable|Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
41017276|NCT03856216|DRUG|Bendamustine|Given IV
40821307|NCT06110715|OTHER|theta tACS stimulation|The low intensity transcranial electrical stimulation will be administered with a battery-powered, current-controlled, multi-channel stimulator from Neuroelectrics® Starstim 8. This device comes with a neoprene headcap to hold the electrodes in place. TACS will be delivered concurrently with the task. The multichannel, current-driven stimulator (Neuroelectrics StarStim 8) will be used to control independent stimulation electrodes on the scalp of the volunteer. The stimulation intensity will be up to 2 mA.
40821308|NCT06110715|OTHER|sham tACS stimulation|A placebo control stimulation will use an identical montage to the stimulation montage. However, polarities of the electrodes will be such that only a minimal amount of current reaches the brain, which is achieved through controlled current shunting between neighboring electrodes. This so-called ActiSham protocol is a verified method to imitate the sensations of actual tACS, with minimal stimulation of the brain .
40821309|NCT03758079|DRUG|Doxepin|10 mg Doxepin for 4 weeks
41017277|NCT03856216|BIOLOGICAL|Filgrastim-sndz|Given IV
41017278|NCT03856216|DRUG|Fludarabine|Given IV
41017279|NCT03856216|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
41017280|NCT03856216|DRUG|Melphalan|Given IV
41017281|NCT03856216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Given IV
41017282|NCT03856216|BIOLOGICAL|Rituximab|Given IV
41017283|NCT03856216|DRUG|Tacrolimus|Given IV and PO
41156943|NCT05914155|DRUG|Rituximab (genetical recombination)|Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
41156944|NCT05914155|DRUG|Placebo|Administer placebo IV infusion every two weeks for two doses in double-blind phase.
41017289|NCT03691220|BEHAVIORAL|Telemetric Intervention|Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.
41340275|NCT00880100|DRUG|Ultrase® MT12|Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
41340276|NCT03967847|DRUG|Ketorolac|Oral Ketorolac
41340277|NCT01921452|DEVICE|Quantitative POC TSH Kit|A drop (approximately 30 microliter \[mcL\]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
41340278|NCT01921452|DEVICE|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
41017292|NCT01950390|BIOLOGICAL|Bevacizumab|Given IV
41017293|NCT01950390|BIOLOGICAL|Ipilimumab|Given IV
40821310|NCT03758079|DRUG|Gabapentin|dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks
41017298|NCT04133831|OTHER|Total Survival|"The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: \[(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)\] / \[number of patients alive on waitlist at start of year\]."
41156945|NCT05914155|DRUG|Rituximab (genetical recombination)|Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.
41156946|NCT06102005|DRUG|Lunsekimig|Pharmaceutical form: solution for injection Route of administration: subcutaneous
41156947|NCT06102005|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
41340279|NCT01921452|DEVICE|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
41340280|NCT05581355|BEHAVIORAL|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
40821311|NCT02118766|DRUG|AN2728 Topical Ointment, 2%|
40821312|NCT02118766|DRUG|Matching vehicle control|
40821313|NCT02808195|OTHER|Constraint-induced therapy|
40821314|NCT02808195|OTHER|kinect-based constraint-induced therapy|
40821315|NCT03941457|BIOLOGICAL|BiCAR-NK cells (ROBO1 CAR-NK cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
40821316|NCT04101539|DEVICE|OPTIMA-guided catheter ablation|Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.
40821317|NCT04101539|DEVICE|Standard PVI|Standard PVI for AF.
41340281|NCT04746313|BIOLOGICAL|blood test|"* to analysis prolactin in healthy subjects and scleroderma patients~* then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin"
41340282|NCT00232414|DRUG|Quetiapine|
41340283|NCT01037751|BEHAVIORAL|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
41340284|NCT01037751|BEHAVIORAL|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
41017299|NCT04133831|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
41340285|NCT02027974|DEVICE|Iconacy Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
41340286|NCT02027974|DEVICE|Stryker Accolade Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
41340287|NCT03764462|DRUG|AD-101 45mg|Raloxifene 45mg tablet
41340288|NCT03764462|DRUG|Raloxifene 60mg|Raloxifene 60mg tablet
41340289|NCT03147573|DIAGNOSTIC_TEST|1-hour blood pressure monitoring (1BPM)|This method consists of performing blood pressure measurements programmed at 5-min intervals over 1 hour. Two extra recordings taken at the start and end of this period are discarded. Blood pressure is measured in a quiet room at the same health centre.
41487570|NCT04464993|BEHAVIORAL|Context-based prompts: TEXT|The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV, not text message based) that will provide simple adaptive content. Content of the prompts will be educational (i.e., based on risks of sedentary screen time) and motivational (i.e., advice to reduce sedentary screen time).
40821318|NCT02182440|BIOLOGICAL|recAP|One hour infusions once daily for three days
40821319|NCT02182440|OTHER|Placebo|1 hour IV infusion once daily for 3 days
41487571|NCT04464993|BEHAVIORAL|Earn sedentary screen time through moderate-vigorous physical activity: EARN|Earn sedentary screen time through moderate-vigorous physical activity: EARN Participants assigned to the EARN component will earn SST by engaging in a \>5 min continuous bout of exercise (as defined by Fitbit minutes \>4 metabolic equivalents). They will earn SST on a 3:1 ratio up until they reach their baseline level of MVPA (5 mins of exercise earns 15 mins of SST). They will receive behavioral strategies to reduce screen time within the app (e.g., self-efficacy, barriers, exercising safely) and a planning tool for scheduling MVPA.
40821320|NCT04966494|DIETARY_SUPPLEMENT|BOSB|BOSB consisted on a oats (26 %), common beans (30 %), water and emulsifier-based snack bar, administered daily (50 g/day) during 8 weeks.
40821321|NCT03234855|DEVICE|LMD|Physician uses LMD to measure defect during procedure.
40821322|NCT06264817|DEVICE|MOBIDERM Autofit Armsleeve|"In the intervention group, during the intensive phase, patients wear day and night MOBIDERM AUTOFIT during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and MOBIDERM Autofit Armsleeve at night during 5 weeks"
40821323|NCT06264817|DEVICE|Compressive bandaging|"In the control group, during the intensive phase, patients wear compressive bandaging day and night-time, according to the usual practice during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and self bandages at night during 5 weeks"
40821324|NCT06607068|OTHER|None (Observational study)|None (Observational study)
40821325|NCT06142513|OTHER|Assessment|Between December 2023 and June 204, 46 volunteer participants aged 18 years and older who met the inclusion criteria and were followed up at Istanbul University, Istanbul Faculty of Medicine, Department of Chest Diseases and Istanbul Faculty of Medicine, Department of Internal Medicine were included in the project. Participants' body composition, comorbidities, exercise capacity, peripheral muscle strength, sleep quality and quality of life were assessed.
41017300|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined
41017301|NCT06515470|DRUG|Fulvestrant|500 mg intramuscular injections on Day 15 and then every 28 days
41487572|NCT00602277|OTHER|Laboratory Biomarker Analysis|Correlative studies
41487573|NCT00602277|BIOLOGICAL|Wild-type Reovirus|
41487574|NCT05713552|DEVICE|Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock|CONTROL
41487575|NCT05713552|DEVICE|Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock|TEST
41487576|NCT03514641|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
41487577|NCT03514641|DRUG|Placebo|Placebo (inactive) tablet to match the active drug
41340290|NCT03147573|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring (ABPM)|The device is programmed to record the participant's BP every 20 min and 30 min during the day and night, respectively. Participants are advised to carry on with their normal daily activities, avoiding any intense physical exertion, and to remain at rest when their BP is being measured.
41340291|NCT03147573|DIAGNOSTIC_TEST|Office blood pressure measurement (OBPM)|Two readings were made one minute apart with a validated automatic sphygmomanometer in a sitting position after five minutes of rest. The average of two readings is calculated. The procedure is repeated during 3 office visits at least a week apart.
41340292|NCT03147573|DIAGNOSTIC_TEST|Home blood pressure monitoring (HBPM)|For each blood pressure recording, at least two consecutive measurements should be taken, at least one minute apart. Blood pressure should be recorded twice daily, ideally in the morning and evening. Blood pressure recording should continue for at least four consecutive days, ideally seven. The average of the above readings should be calculated, ignoring the first day.
40821326|NCT03484507|DRUG|Chlorhexidine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
41017302|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles using dose determined in Part A
41340293|NCT03577522|DEVICE|Avenir cementless hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
41340294|NCT03577522|DEVICE|Corail HA-coated hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
41340295|NCT03140124|BEHAVIORAL|Exercise|Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).
40821327|NCT03484507|DRUG|Povidone-Iodine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
41017320|NCT04560504|OTHER|Control Group|Leisure activities
41017321|NCT04560504|OTHER|Oculomotor Training Group|Eye movement training
40821328|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
40821329|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
41156948|NCT01018576|OTHER|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
41340296|NCT03140124|BEHAVIORAL|Worry Stone|For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.
41340297|NCT05601050|OTHER|There is no intervention|There is no intervention
41340298|NCT04456595|BIOLOGICAL|Adsorbed COVID-19 (inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
41340299|NCT04456595|BIOLOGICAL|Placebo|Placebo of Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
41340300|NCT02490839|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
41340301|NCT02490839|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
41340302|NCT04634019|BEHAVIORAL|Financially incentivized knowledge assessments|We will conduct quarterly provider knowledge assessments at selected health facilities and will pay facilities a financial bonus if providers perform well on these tests. For the intervention, 12 clinical vignettes were created. These vignettes cover typical patient cases such as malaria, diarrhea and respiratory infections, and assess providers' ability to correctly diagnose and treat hypothetical questions. All medical staff members will be informed hat every 3 month there will be a knowledge assessment based on these vignettes and that the results will determine the total bonus payment made to the facility.
41340303|NCT03783013|OTHER|High Lycopene Tomato Juice With Soy Germ Extract|Tomato juice made from high lycopene tomatoes with soy germ extract added
41340304|NCT03783013|OTHER|Low Lycopene Tomato Juice|Tomato juice made from low lycopene tomatoes with no soy germ extract added
41340305|NCT00420342|DRUG|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 A -Active study medication encapsulated tablet
41340306|NCT00420342|DRUG|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 B - Active study medication encapsulated tablet
40821330|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
40821331|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-5
40821332|NCT02455661|DEVICE|TR Band (TM)|
40821333|NCT02455661|DEVICE|AngioSeal|
40821334|NCT02455661|DEVICE|StarClose|
40821335|NCT00006441|DRUG|Lamivudine/Zidovudine|300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
40821336|NCT00006441|DRUG|Nelfinavir mesylate|1250 mg twice daily for 104 weeks.
40821337|NCT00006441|DRUG|Aldesleukin|7.5 million units twice daily. Treatment will last until conclusion of study.
40821338|NCT06272838|OTHER|Biodex balance system|In addition to the conventional exercise program, it will be applied on a platform with the Biodex balance system for 4 weeks, 5 days a week, in a total of 20 sessions.
40821339|NCT06272838|OTHER|The conventional balance exercise program|The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.
41017326|NCT05652205|DRUG|Linaclotide|Capsule; oral
41017327|NCT05652205|DRUG|Placebo for Linaclotide|Capsule; oral
41017328|NCT04172532|PROCEDURE|Biopsy|Undergo tissue collection
41017329|NCT04172532|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41017330|NCT04172532|PROCEDURE|Computed Tomography|Undergo CT
41156949|NCT06446531|DRUG|Placebo|Oral tablet administered once daily
41156950|NCT06446531|DRUG|Rybelsus Tablet|Oral tablet started at a 3mg dose once daily and increased to 7mg once daily or maximum tolerable dose.
41156951|NCT06446531|DRUG|Jardiance 25Mg Tablet|Oral 25 mg Sodium-Glucose Co-Transporter (SGLT2) inhibitor administered once daily
41156952|NCT06446531|DRUG|Metformin|Oral tablet started at a dose of 500mg with an increase of 500mg weekly up to a maximum dose of 2000mg (4 tablets)
41156953|NCT06446531|DRUG|Actos|Oral tablet dosed at 15mg once daily
41340307|NCT00420342|DRUG|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)|Active control encapsulated tablet
41340308|NCT00650897|DRUG|Escitalopram|10-20 mg once daily
40821340|NCT00907803|DRUG|ST-246 400 mg|Capsules, 400 mg daily for 14 days
40821341|NCT00907803|DRUG|ST-246 600 mg|Capsules, 600 mg daily for 14 days
40821342|NCT00907803|DRUG|Placebo|Capsules, once daily for 14 days
41340309|NCT03039049|DRUG|Triptorelin 0.1 mg|a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
40821343|NCT03315104|BIOLOGICAL|FLU-IGIV|Single dose, sterile liquid formulation for IV administration.
40821344|NCT03315104|OTHER|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration.
40821345|NCT03648489|DRUG|Paclitaxel|Please refer to arm/group description
41340310|NCT05784870|DRUG|Shengxuening Tablet|Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
41340311|NCT05784870|DRUG|Ferrous succinate|Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
41340312|NCT02372110|DRUG|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
41340313|NCT02372110|DRUG|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
41340314|NCT03169114|DRUG|Amikacin Injection|Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
41340315|NCT03169114|PROCEDURE|Appendicectomy|Patients allocated to Surgery Management Strategy will undergo appendicectomy
41340316|NCT06501040|OTHER|Web-based Educational Intervention|View web-based educational video
41340317|NCT06501040|OTHER|Questionnaire Administration|Pre video baseline survey and a post video educational survey
41340318|NCT01351857|OTHER|Transition Coordinator|The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
41340319|NCT05041062|DRUG|Nivolumab|Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.
41340320|NCT05041062|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
40821346|NCT03648489|DRUG|TAK228|Please refer to arm/group description
40821347|NCT05723835|DRUG|Somapacitan|Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
40821348|NCT04670458|OTHER|no intervention|no intervention
40821349|NCT03582865|DRUG|Tamoxifen 20 mg|Tamoxifen 20 mg is a selective estrogen receptor modulator
40821350|NCT04533217|PROCEDURE|Vertebroplasty|Injection of cement into vertebral lesion(s)
41340321|NCT01061645|DRUG|MOC31-PE|Immunotoxines
41340322|NCT01786850|PROCEDURE|Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)|High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
41340323|NCT06087094|DRUG|HRS-7450 ；Placebo|HRS-7450 or Placebo
41340324|NCT06231004|PROCEDURE|glucocorticosteroid and surgery|Take glucocorticosteroid at once in the morning and use the following course of treatment: 6 tablets/day for 7 days-- 5 tablets/day for 2 days-- 4 tablets/day for 2 days-- 3 tablets/day for 2 days-- 2 tablets/day for 2 days-- 1 tablets/day for 2 days--surgery
41340325|NCT01674985|BIOLOGICAL|Microtransplantation|Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
41340326|NCT04480749|DIAGNOSTIC_TEST|Access to Facility based Syphilis Testing|List of facilities where syphilis testing can be accessed
40821351|NCT00825058|DRUG|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
41340327|NCT04480749|DIAGNOSTIC_TEST|Syphilis Self-Test|Rapid Treponemal Test kit
41017331|NCT04172532|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
40821352|NCT00825058|DRUG|placebo|oral administration 12 hours intervals
40821353|NCT00825058|DRUG|paroxetine|oral 20 mg/day
40821354|NCT03127774|DRUG|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
40821355|NCT03127774|DRUG|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
40821356|NCT03127774|PROCEDURE|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
40821357|NCT01926171|DRUG|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
40821358|NCT01357135|DRUG|Metformin|
40821359|NCT01357135|DRUG|Sitagliptin|
40821360|NCT01357135|DRUG|Sulfonylurea|
40821361|NCT01357135|DRUG|Antihyperglycemic Medication|
41017332|NCT04172532|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41017333|NCT04172532|DRUG|Peposertib|Given PO
41017334|NCT04172532|OTHER|Placebo Administration|Given PO
40821362|NCT03280303|OTHER|non-interventional|
40821363|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
40821364|NCT04499248|OTHER|Lumigan|Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost
41340328|NCT03797690|PROCEDURE|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure
41340329|NCT03797690|PROCEDURE|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
41340330|NCT00351806|DRUG|Erigeron breviscapus injection|
41340331|NCT00351806|DRUG|hua tuo zai zao wan (a herbal medicine pill)|
41340332|NCT00351806|DRUG|Compound stroke herbal medicine (8 herbal)|
41340333|NCT02557334|DIETARY_SUPPLEMENT|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
41340334|NCT02557334|DIETARY_SUPPLEMENT|High Dose Strawberry Powder|40 g freeze dried strawberry powder
40821365|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.
40821366|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.
40821367|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.
40821368|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.
40821369|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
40821370|NCT02253563|BEHAVIORAL|Resistance Training|
40821371|NCT02253563|BEHAVIORAL|Balance Training|
40821372|NCT00121524|DRUG|Epinephrine|Epinephrine 1 mg is given iv. every 3 min during CPR
40821373|NCT00121524|DEVICE|Intravenous needle|An intravenous needle in placed as soon as possible during CPR
40821374|NCT00121524|DRUG|Atropine|Atropine 3 mg iv in initial systole
40821375|NCT00121524|DRUG|Amiodarone|amiodarone 300 mg iv after repeated failed defibrillation attempts
41340335|NCT02557334|DIETARY_SUPPLEMENT|Placebo Powder|40 g color and taste matched placebo powder
41340336|NCT01304472|DRUG|Prasugrel|Prasugrel 10mg per day
41340337|NCT01304472|DRUG|Clopidogrel|Clopidogrel 150mg per day
41340338|NCT05703113|BEHAVIORAL|Web 2.0 tools|Education with Web 2.0 tools
41340339|NCT02963766|DRUG|Dulaglutide|Administered SC
41340340|NCT02963766|DRUG|Placebo|Administered SC
40821376|NCT02029183|DEVICE|Bi level positive pressure ventilation|Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
41340341|NCT02977507|OTHER|Lytera 2.0|Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
41340342|NCT02977507|DRUG|4% Hydroquinone Topical Cream|4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
41340343|NCT02977507|OTHER|SkinMedica Facial Cleanser|SkinMedica facial cleanser applied to the face as directed.
41340344|NCT02977507|OTHER|SkinMedica Rejuvenative Moisturizer|SkinMedica rejuvenative moisturizer applied to the face as directed.
41340345|NCT02977507|OTHER|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
41340346|NCT05410808|OTHER|Questionnaires and physical examination|Patients will be examined and demographic data, disease characteristics will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
41340347|NCT05410808|OTHER|Questionnaire|Demographic data will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
41340348|NCT04083794|OTHER|Laboratory based assessments|physical maneuvers to assess physiological responses in bone blood flow
41487578|NCT02452541|OTHER|Prognostic tests|"* Brain CT-Scan on day 1, 3 and 7~* Brain MRI on day 7~* SomatoSensory Evoked Potentials on day 7~* Electroencephalogram on day 7~* Serum biomarkers on day 1, 3 and 7~* Daily clinical exams"
41487579|NCT05552170|OTHER|day-case surgery|Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.
41487580|NCT06007547|DRUG|Poractant Alfa|Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
41487581|NCT00457899|DRUG|Quetiapine IR (Immediate Release)|oral
40821377|NCT02029183|DEVICE|bi-level positive airway pressure|
40821378|NCT04051385|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
40821379|NCT04051385|OTHER|Gingival crevicular fluid and serum collection|GCF with filter paper using the intracrevicular method and serum collection
41487582|NCT06394843|OTHER|Ultrafiltration|Patients are selected depending on need of ultrafiltration
40821380|NCT01854632|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
40821381|NCT01854632|BIOLOGICAL|Matched placebo|Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
41340349|NCT01121952|OTHER|Chiropractic (HVLA) manipulation|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
41340350|NCT00744692|BIOLOGICAL|Unrelated Umbilical Cord Blood Transplant|Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
41487583|NCT04891965|BIOLOGICAL|ART24|Each ART24 capsule will contain lyophilized ART24 and inactive excipients. ART24 will be supplied in a dose strength of 5×10\^9 CFU/capsule. Subjects will receive 1 capsule daily.
41487584|NCT04891965|DRUG|Placebo|Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
41487585|NCT01019473|DRUG|AFQ056|
41487586|NCT01019473|DRUG|Placebo|
41487587|NCT04811365|OTHER|Screening|After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms
41487588|NCT00836017|OTHER|No Intervention|No intervention was administered as part of the study.
41340351|NCT00744692|DRUG|Reduced Intensity Conditioning|
41340352|NCT00671970|DRUG|Bevacizumab and Erlotinib|"Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs \& 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent."
41487589|NCT06092385|OTHER|Data collection|"Clinical assessment and blood sampling at day of inclusion and in 6- monthly intervals for stable cirrhotic patients; at day of inclusion and on days 3, 7, 14 and 28 for acute decompensation or acute-on-chronic liver failure patients; assessment of clinical, psychosocial/behavioural and patient-reported data in parallel with blood sampling;~* Biobanking of PBMCs and serum/plasma samples~* Biobanking of other biological material if sampled for clinical reasons (liver biopsies, ascites, urine, gut mucosa, lymph nodes)"
41487590|NCT04603170|OTHER|DRUG|taking drug medication prescribed by psychiatrists for at least one month
41487591|NCT00005918|DRUG|Efavirenz|
41487592|NCT00005918|DRUG|Lamivudine|
41487593|NCT00005918|DRUG|Stavudine|
40821382|NCT05245786|BIOLOGICAL|Copper Cu 64 Anti-CEA Monoclonal Antibody M5A|Given IV
40821383|NCT05245786|PROCEDURE|Imaging Technique|Undergo imaging
40821384|NCT05306561|PROCEDURE|Systane iLux thermal pulsation treatment|Systane iLux thermal pulsation uses light emitting diode (LED) technology to emit light that is absorbed by pigments (melanin and hemoglobin) in the eyelid. The pigments convert the light energy to heat, which is then transferred to the surrounding tissues, including the meibomian glands. The device heats the eyelid to 40-42°C and maintains it above 40°C during the heating period, which can be 40 seconds or more. This helps melt the meibum. After the heating phase, the meibomian glands are expressed with the built in expression system.
40821385|NCT03824158|BEHAVIORAL|Facilitated advance care planning (in-person or telephonic)|The facilitator will contact the patient to schedule the ACP discussion. ACP discussions will be led by a nurse or social worker with supportive oncology experience who has been trained as a Respecting Choices facilitator, include the patient's caregiver when available, last 45-60 minutes, and be held in a private location at or near the patient's oncology clinic, or telephonically. Facilitators will use a structured interview tool as a discussion roadmap and provide guidance in choosing a medical decision maker, exploring serious illness understanding and experiences, identifying goals and values, and making future treatment decisions. Facilitators will provide a copy of a written advance directive, assist with completion when appropriate, and make recommendations for communicating goals and sharing written preferences.
41340353|NCT05942170|DRUG|ICG/ blue dye|The SLN mapping procedure was performed as previously described by using IGC or blue dye. The injection technique of the tracers was the same for both cervical and endometrial cancer. The cervical injection was done by insulin syringe(one ml) inserting full needle length (1 cm) and complete injection at 3, 9 o'clock, or 2,4,8,10 o'clock.
41340354|NCT03882853|OTHER|Conservative exercise group|The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
40821386|NCT03824158|BEHAVIORAL|Web-based advance care planning|Instructions for accessing and using the PREPARE website will be shared with participants upon randomization. Patients and their caregivers review the 5 steps of PREPARE (approximately 10 minutes per step) and create an action plan for each step. The PREPARE website includes a link to a written advance directive that participants are able to complete. The PREPARE website can be reviewed on a home computer or on a tablet in the oncology practice.
40821387|NCT02780635|BEHAVIORAL|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
41340355|NCT03882853|OTHER|Tree pose added exercise group|"The group will be thought exercise series which will be based on recommendations which is published on October 2016 by UK national osteoporosis foundation, also be taught tree pose of yoga. Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed."
41340356|NCT03704389|BEHAVIORAL|Clinical decision support|Clinical decision support nudges within the electronic health record
41340357|NCT02723019|BEHAVIORAL|Volunteer Peer Mentor+Behavioral Health Nurse|Intervention group participants receive intervention services from a Volunteer Peer Mentor and a Behavioral Health Nurse
41340358|NCT00852761|DRUG|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
41340359|NCT00852761|DRUG|Clobex lotion|Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
41340360|NCT02052323|DRUG|Artesunate/mefloquine (AS/MQ)|"* artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours~* mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours~* primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours"
41487594|NCT03474432|DEVICE|Optical Coherence Tomography|OCT will be performed with the St. Jude OCT system. Detection of metallic stent struts will be performed automatically with manual adjustments made as necessary. Stent area tracings will be automatically performed by interpolated contours connecting the center point of the luminal surface of each detected metallic strut. Stent expansion will be determined as the minimum stent area divided by the average reference lumen area and presented as a percentage. Neo-intimal hyperplasia (NIH) area will be determined in follow-up examinations as the area between the stent and lumen contours. Incomplete stent apposition (ISA) area will be determined as the area between the stent contour and the lumen contour at the site of malapposed struts, in a region not overlying a side branch ostium.
41487595|NCT01764230|DRUG|triptorelin|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
40821388|NCT02780635|BEHAVIORAL|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
40821389|NCT04007237|DRUG|shampoo with different composition|To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
40821390|NCT06481228|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
40821391|NCT06481228|DRUG|Venetoclax|BCL2 inhibitor
40821392|NCT06481228|DRUG|Olverembatinib|TKI
40821393|NCT00457821|DRUG|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
41340361|NCT02550093|PROCEDURE|Intervention 1|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 1 (Day 1).
41340362|NCT02550093|BEHAVIORAL|Washout Period|The wash-out period will be between intervention 1 and intervention 2. 13 days in length.
40821394|NCT00457821|DRUG|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
41340363|NCT02550093|PROCEDURE|Intervention 2|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 2 (Day 14).
41340364|NCT00797706|DRUG|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
41487596|NCT01787539|DRUG|Postoperative Chemotherapy|"Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery."
40821395|NCT00457821|DRUG|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
41487597|NCT02898753|DRUG|VAL-1221|VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
41017338|NCT05687136|PROCEDURE|Biopsy|Undergo tissue biopsy
41340365|NCT00784706|OTHER|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
41340366|NCT00784706|OTHER|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
41340367|NCT00784706|OTHER|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
41340368|NCT05579223|DRUG|Intrathecal Hydromorphone Mono Injection|Experimental Drug: Hydromorphone Hydrochloride Injection. Administration: subarachnoid space mono bolus inject, + 5% glucose injection diluted to 75 μg:1.5ml, Speed ≤ 0.5 ml/s
41017339|NCT05687136|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41017340|NCT05687136|PROCEDURE|Computed Tomography|Undergo CT
41340369|NCT05579223|DRUG|Intrathecal Placebo Mono Injection|Placebo: 5% glucose injection. Administration: subarachnoid space mono bolus inject, 1.5ml, Speed ≤ 0.5 ml/s
41487598|NCT02898753|DRUG|RhGAA|Active comparator
41487599|NCT00548938|DRUG|Gliadel wafer|Implanted at surgery
41487600|NCT00548938|DRUG|Temozolomide|During External Beam Radiation
41487601|NCT00548938|RADIATION|External Beam Radiation Therapy|60 Gy
41487602|NCT01059266|DRUG|PURETHAL Grasses, 20.000 AUM/ml|subcutaneous injections of increasing doses according to the described regimen
41487603|NCT02098538|DRUG|Regorafenib|All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
40821396|NCT00457821|DRUG|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
41017341|NCT05687136|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41017342|NCT05687136|DRUG|Peposertib|Given PO
41017343|NCT05687136|PROCEDURE|Positron Emission Tomography|Undergo PET
41017344|NCT05687136|DRUG|Tuvusertib|Given PO
41340370|NCT05423704|OTHER|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
41340371|NCT02082665|DRUG|Rosuvastatin10 mg tablet|Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
41340372|NCT02082665|DRUG|Midazolam 3 mg syrup|Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
41340373|NCT02082665|DRUG|Dabrafenib 75 mg capsule|Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
41340374|NCT04739241|DRUG|premixed insulin therapy|Premixed insulin treatment: 30% of the calculated dose was administered before breakfast and before lunch (biphasic insulin lispro 50% or biphasic insulin aspart 50%) and the remaining 40% of the dose before dinner (biphasic insulin lispro 25% or biphasic insulin aspart insulin 30%).
41340375|NCT04739241|DRUG|basal bolus insulin therapy|Basal-bolus insulin treatment: 50% dose in insulin glargine and 50% dose in insulin lispro or aspartic, distributed in equal parts in the 3 main meals
41340376|NCT01673425|DRUG|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
40821397|NCT02995083|DRUG|40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine|Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
41340377|NCT03288441|DRUG|Hold|Hold antithrombotic therapy
41487604|NCT01546935|DRUG|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
41487605|NCT03161964|DRUG|Propranolol 80 Mg Oral Capsule, Extended Release|Propranolol capsule over-encapsulated to match placebo for blinding
40821398|NCT02995083|DRUG|Normal Saline 10 ml|Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
40821399|NCT02995083|DRUG|Air 10 ml|Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
40821400|NCT01358812|DRUG|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL\* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
41340378|NCT03288441|DRUG|Prophylactic dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type)
41340379|NCT03288441|DRUG|Change antithrombotic Drug|Change in type of antithrombotic therapy
41340380|NCT03288441|BIOLOGICAL|Change platelet transfusion threshold|Increase or reduce platelet transfusion threshold
41487606|NCT03161964|DRUG|Placebo oral capsule|Placebo capsule over-encapsulated to match propranolol for blinding
41487607|NCT01573169|DRUG|Enoxaparin|enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
40821401|NCT00814697|DEVICE|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
40821402|NCT02073838|DRUG|Ribavirin|
40821403|NCT02073838|DRUG|Vismodegib|
40821404|NCT02073838|DRUG|Decitabine|
41156954|NCT06646198|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Perform transjugular intrahepatic portosystemic shunt under the guidance of DSA
41156955|NCT06646198|DRUG|Donafenib|Half-dose donafenib, 100mg BID P.O. unless any evidence of disease progression or unacceptable side effects.
40821407|NCT05133622|OTHER|Physical Activity Level|IPAQ-SF assesses the physical activity levels of the individuals. The short form of the questionnaire consists of seven questions and provides information about the time spent sitting, walking, moderately vigorous, and vigorous activities. In scoring, below 600 MET-min/week indicates individuals who are not physically active, 600-3000 MET-min/week values indicate low physical activity levels, and 3000 MET-min/week and above values indicate individuals with high physical activity levels. In our study, sedentary individuals who receive 600-3000 MET-min/week from the questionnaire will be included
41017353|NCT03728985|DEVICE|GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis|Endovascular Aortic Stent-Graft
41156956|NCT05051683|PROCEDURE|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer|endoscopic management using stent , clipping and sewing combined with radiologic interventional drainage was used. For duodenal ulcer only metallic stent was used due to narrow space while for gastric ulcer either stent , clipping and sewing were used due to capacious space.
41156957|NCT01388088|DRUG|Spironolactone|25 mg twice a day
41340381|NCT03288441|DRUG|Full dose antithrombotics|Continue full dose antithrombotic therapy
41340382|NCT03288441|DEVICE|Mechanical measures|Mechanical measures to reduce thrombotic risk including: IVC filter insertion, Intermittent Pneumatic Compression (IPC), Removal of Central venous catheter
41340383|NCT03288441|DRUG|Intermediate dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type). Intermediate dose in between prophylactic and full dose
41340384|NCT01503619|OTHER|laboratory biomarker analysis|Correlative studies
41340385|NCT01835314|DRUG|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
41340386|NCT01578590|DIETARY_SUPPLEMENT|Lean minced meat (beef)|A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
41340387|NCT03647462|DEVICE|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
41487608|NCT01573169|OTHER|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization|placebo standard therapy
41487609|NCT00236067|DRUG|Gabitril|
41487610|NCT05579574|DRUG|BMS-986322|Specified dose on specified days
41156958|NCT01388088|DRUG|Amiloride|5 mg twice a day
41487611|NCT05579574|DRUG|Loestrin|Specified dose on specified days
41487612|NCT01176110|DEVICE|LMA Perfect Temp|The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
41487613|NCT05572970|DRUG|Balstilimab|An anti-programmed death 1 (PD-1) monoclonal antibody.
41487614|NCT05572970|DRUG|Zalifrelimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
41487615|NCT04331444|DEVICE|CGM|Using the CGM during the entire study period of 12 months.
41487616|NCT04331444|BEHAVIORAL|training course|The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.
41487617|NCT04331444|BEHAVIORAL|Peer-support|The peer-support will be facilitator-led by the primary investigator with peer exchange in group sessions (3 sessions over the study period, 3 hours per session) with 6-8 participants in every group.
41487618|NCT06226155|BEHAVIORAL|TENDAI4PrEP|An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.
41487619|NCT06226155|OTHER|Enhanced treatment as usual|"Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy.~safety during pregnancy/postpartum, and PrEP availability at the ANC."
41487620|NCT00678041|DRUG|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
40821408|NCT05133622|OTHER|Evaluation of knee extension and elbow flexion muscle strength|"To measure the knee extension strength, the individual brings the knee from 90 degrees flexion to full extension in sitting. To standardize the test, the lower extremities will be fixed of the chair with a belt, allowing full extension of the knee. Three measurements will be performed from the distal tibia with a dynamometer, and the score will be recorded in Newtons.~Elbow flexion will also be measured in a sitting position in a chair. To standardize the given resistance, the upper extremity of the individual will be fixed to the arm support of the chair, allowing elbow flexion with a belt. During the measurement, the individual will try to flex the forearm in supination. Meanwhile, three measurements will be taken from the distal forearm with a dynamometer. The average score will be recorded in Newtons."
40821409|NCT05133622|OTHER|Evaluation of functional strength of trunk muscles|"Sit-ups test: The sit-ups test is a measure the endurance of the abdominal and hip-flexor muscles. The physiotherapist will fix the feet and ask the individuals to do trunk flexion in the knee flexion position. The number of movements performed for 30 seconds will be recorded.~Push-ups test: The test will be in the prone position, with the hands at shoulder level and the elbows flexed, positioned near to the body. Individuals will raise the head, shoulders, and trunk from the ground with their elbows in full extension. The test is performed with the knees in full extension for men and modified knees in flexion for women. The number of movements performed for 30 seconds will be recorded."
41340388|NCT00278551|BIOLOGICAL|Immune ablation and hematopoietic stem cell transplant|Autologous Hematopoietic Stem Cell Transplant
41156959|NCT01388088|DRUG|Placebo|twice a day
41156960|NCT02635711|BEHAVIORAL|Adapted Taekwondo training|Adapted Taekwondo training for beginners
41156961|NCT02635711|BEHAVIORAL|Control|Daily jogging
41156962|NCT06645652|BEHAVIORAL|Training in observational drawing|"* 6 weeks of online gallery browsing based on different topics~* Daily practice drawing from observation with training adding up to 1 hour a week~* Documenting progress and reflection writing"
41340389|NCT05160662|PROCEDURE|New guidlines|New guidelines for this group are being developed using NICE guidelines (evidence-based recommendations for health and care in England) as a model and will be tested in clinical practice
41340390|NCT00839436|DRUG|CYT107|
41340391|NCT04066010|OTHER|Mobile application (BP-n-Me)|"The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys."
41340392|NCT02359136|PROCEDURE|local infiltration anesthesia using Ropivacaine and Epinephrine|150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
41340393|NCT02359136|PROCEDURE|local infiltration anesthesia using saline|150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
41340394|NCT02359136|PROCEDURE|Multimodal analgesic regimen|All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
41340395|NCT00026975|PROCEDURE|Hyperbaric Oxygen|
41487621|NCT00678041|DRUG|Placebo|Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
41487622|NCT02928718|PROCEDURE|ERCP|Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
41487623|NCT02533375|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
41487624|NCT00982449|OTHER|FIAU-PET-CT-2|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
41487625|NCT00982449|OTHER|FIAU-PET-CT-4|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
41487626|NCT00351598|RADIATION|Definitive Radiotherapy|60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
41487627|NCT05684471|PROCEDURE|Ultrasound Guided Suprainguinal Fascia iliaca Block|Patients in this group will be administered SFIB with 50 mL of local anesthetic solution (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
41487628|NCT05684471|PROCEDURE|Ultrasound Guided Anterior Quadratus Lumborum Block|Patients in this group will be administered anterior QLB with 40 mL of local anesthetic (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
41487629|NCT05905263|OTHER|Application group with virtual reality|Each student will be introduced to the materials to be used for virtual reality and will be informed about the application. After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and students will be asked to wear them on their heads. Students will then be required to wear gloves. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. If the student experiences symptoms such as dizziness and nausea during the application, the application will be terminated. If the student wants to continue the practice after listening, it will be continued. While the students are inside the application, the interface will be introduced through the images projected to the computer simultaneously.
41487630|NCT05036395|OTHER|The routine assessment protocol and AI-assisted cEEG Diagnostic tool|The AI-assisted cEEG diagnostic tool is an automated seizure reporting system, including a quantitively EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction. The tool can report electrographic seizures in real time during cEEG monitoring. The neonatologists will evaluate the neonates by AI-assisted cEEG diagnostic tool, clinical conditions, real-time cEEG and amplitude-integrated EEG traces. The investigators will make a decision after review the neonates clinical conditions, AI-assisted cEEG diagnostic report, the cEEG and amplitude-integrated EEG.
41487631|NCT05036395|OTHER|The routine assessment protocol|The routine assessment protocol is that the neonatologists will evaluate the neonates by clinical conditions, real-time cEEG and amplitude-integrated EEG traces.
41487632|NCT05484843|BEHAVIORAL|telenursing training based on self-care theory|"* A training guide based on the self-care theory specific to individuals diagnosed with stroke was prepared.~* Identification of the study/control group (randomization)~* Patients were informed and consents were obtained.~* Sample suitability was evaluated in line with the cognitive levels and inclusion criteria of patients diagnosed with stroke.~* All patients included in the sample group were pre-tested before discharge.~* Training was offered for the study group patients in line with the guide prepared based on self-care theory.~* Tele-nursing training was applied to the study group patients.~* Control group patients were followed up~* Post-tests were administered at the end of the 12-week period~* The training of the control group patients was completed~* Your data has been evaluated"
41487633|NCT05484843|BEHAVIORAL|just observation|For 3 months, patients were observed without intervention. The standard discharge training of the clinic was given.
41487634|NCT05384717|OTHER|Fidget Device|Fidget spinner, stress ball, pop-it, or fidget cube
41487635|NCT05384717|OTHER|Control group|No intervention
40821410|NCT05133622|OTHER|Muscle Endurance|"Lateral bridge test: Lateral bridge test involves static, isometric contractions of the lateral muscles on each side of the trunk that stabilizes the spine.~Modified Biering-Sorensen test: The test measuring how many seconds the individual can keep the unsupported upper body horizontal, while placed prone with the buttocks and legs fixed to the couch by three wide canvas straps and the arms folded across the chest.~Trunk flexors endurance test: Trunk flexion test involving a static, isometric contraction of the anterior muscles, stabilizing the spine until the individual exhibits fatigue. The researcher stops the test when the individual cannot hold the assumed position.~Prone bridge test: The prone bridge test measures the muscular endurance of the abdominal muscles."
40821411|NCT05133622|OTHER|Flexibility|"Back scratch test The back-scratch test evaluates upper extremity flexibility. The individual will externally rotate one arm over her/his shoulder to reach the lowest point on the back with the palm facing the back. The other extremity reaches the highest point on the back with the palm facing forward by internal rotation of the other arm. The distance between the middle fingers of both hands will be measured with a tape measure.~Sit and reach test Sit and reach test evaluates lower extremity flexibility. In the test, a sit and reach board is used. The 0 reference point is taken as the 25 cm inner part where the feet are placed on the sit and reach the board. The part closer to the individual from the reference point shows negative values, and the part towards the far side shows positive values. Individuals will reach as far as with their fingertips by placing their feet on a sit-and-reach board."
41156963|NCT06645652|BEHAVIORAL|Arts engagement through digital galleries|"* 6 weeks of online gallery browsing based on different topics~* 2 hours of weekly activities consist of reading and navigating technology~* Reflection writing"
41156964|NCT06207084|BEHAVIORAL|asynchronous content only|Receives asynchronous exercise content and no live training
41487636|NCT02982031|PROCEDURE|shamrock|This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.
41487637|NCT02982031|PROCEDURE|paramedian transverse scan|The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
41487638|NCT00776165|BIOLOGICAL|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
41487639|NCT00776165|BIOLOGICAL|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
41487640|NCT03533257|DRUG|AMX0035|Combination Therapy of TUDCA and Sodium Phenylbutyrate
41340396|NCT01853852|DRUG|GR181413A/AT1001 solution|Powder for reconstitution
41340397|NCT01853852|DRUG|GR181413A/AT1001 capsule|Size 2, hard gelatin capsule, white opaque / blue opaque
41340398|NCT01853852|OTHER|Potable water|Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
41340399|NCT01853852|DRUG|Placebo capsule|Solution matched
41340400|NCT03825497|OTHER|Promotion of activity during and after hospitalization|1) a welcome folder encouraging physical activity; 2) encouragement to use a walk path established in the ward; 3) encouragement to use posters containing exercise suggestions;4) prescription of a walk-plan for in-hospital use; 5) encouragement to pick up clothes and beverages by oneself; 6) prescription of a walk-plan at discharge for at home use 7) follow-up on walk plan after discharge by municipality
40821412|NCT05133622|OTHER|Balance|"Single leg stance test Individuals bend one knee and place the sole on the other thigh and maintain their balance in this position. The test will be performed separately for the right and left extremities with eyes open and closed. The single-leg stance balance time was recorded as seconds (Linda,2013).~Functional reach test The functional reach test evaluates dynamic balance and limit of stability. This test measures the distance between the length of an outstretched arm in a maximal forward reach from standing while maintaining a fixed base of support. The scoring record is centimeter. Higher scores indicate a good level of balance (Lin,2012)."
41340401|NCT03634176|DIAGNOSTIC_TEST|optical nerve sheet diameter|The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
41340402|NCT01209806|DRUG|simethicone|400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
41340403|NCT00493610|DRUG|N-acetylcysteine(Mucomyst)|
41340404|NCT05942677|PROCEDURE|proportion of colorectal lesions|Evaluation of the proportion of colorectal lesions detected by a computer-aided detection system (CADe) compared with experienced endoscopists.
41340405|NCT03935490|PROCEDURE|emergency transrectus sheath pre-peritoneal mesh repair (e-TREPP)|"The Trans REctussheath PrePeritoneal mesh repair (TREPP) was developed in 2006 as an open preperitoneal technique to reduce CPIP. In short: a 4-5 centimeters (cm) transverse incision is made about 1 cm above the localization of the deep inguinal ring. The anterior rectus sheath is opened. After retracting the rectus muscle medially, the preperitoneal space (PPS) is bluntly dissected and a complete overview can be achieved. All possible hernia orifices can be visualized such as: a direct, indirect, pantaloon, and/or femoral hernia. A self-expandable mesh is then positioned in the PPS. Due to the upstream principle no mesh fixation is necessary."
41340406|NCT00903994|DRUG|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
41340407|NCT00741260|DRUG|Neratinib|Neratinib orally once daily continually
41340408|NCT00741260|DRUG|Capecitabine|Capecitabine orally on days 1-14 of each 21 day cycle
40821413|NCT05133622|OTHER|Fatigue|"Individuals will score perceived fatigue during walking and running activities with the Modified Borg Scale. According to the scale, 0 indicates no fatigue, and a score of 10 indicates unbearable fatigue (Borg,1987)."
41156965|NCT06207084|BEHAVIORAL|Asynchronous content and health coaching and no live training|Receives asynchronous content, health coaching and no live training.
41156966|NCT06207084|BEHAVIORAL|asynchronous content only and 1 on 1 live training|receives asynchronous content and live 1 on 1 training
41340409|NCT02498327|OTHER|Gelatine Capsule|Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
41340410|NCT02498327|OTHER|Venavine Intensive®|Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
41487641|NCT03533257|DRUG|Placebo|Placebo
41156967|NCT06207084|BEHAVIORAL|asynchronous content and health coaching and 1 on 1 training|receives asynchronous content, health coaching, and live training
41156968|NCT06207084|BEHAVIORAL|asynchronous content and group training|receives asynchronous content and live group training
41156969|NCT06207084|BEHAVIORAL|Asynchronous content and health coaching and group training|receives asynchronous content, health coaching, and live group training
41156970|NCT05558098|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once per day for 14 days or until intensive care unit discharge or death
41340411|NCT00826488|DEVICE|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
41156971|NCT05558098|OTHER|Standard of Care|Current standard of care for management of critically ill patients
41340412|NCT05270967|DIAGNOSTIC_TEST|F-18 FDG PET/CT imaging|Oncological imaging
41340413|NCT05270967|BIOLOGICAL|Pfizer/biontech mRNA vaccine|COVID-19 vaccine
41340414|NCT04261777|DRUG|Ferrotran® (Ferumoxtran-10)|"Ferrotran® in a dose of 0.13 mL/kg body weight of the reconstituted freeze-dried preparation (i.e. 2.6 mgFe/kg body weight). The recommended dose should be diluted in 100 mL of NaCl 9 mg/mL (0.9%) solution for injection/infusion prior to administration via the infusion filter as a slow intravenous infusion over 30 minutes (at a maximum rate of 4 mL/min).~Ferrotran® will be administered once to each patient. Histologically confirmed diagnosis and pre-operative staging are performed prior to the study as part of standard care. Surgery (RP with ePLND) and sampling of tissue specimens is performed after the Ferrotran®-enhanced MRI as part of standard care."
41340415|NCT05722977|DRUG|Surufatinib + envafolimab|Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks
41340416|NCT04880993|DRUG|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd
41340417|NCT04880993|DRUG|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
41340418|NCT05181748|BIOLOGICAL|Autologous platelet rich plasma|Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.
41340419|NCT00466661|DRUG|Acamprosate|666 mg po TID
41340420|NCT00466661|DRUG|Placebo|2 tabs po TID
41340421|NCT01505244|BEHAVIORAL|Before-School Physical Activity|3 days/week of before-school moderate to vigorous physical activity
41340422|NCT05561634|RADIATION|Radiotherapy|Irradiation of the tumoral bed.
41340423|NCT05561634|OTHER|Observation|Patients will be followed up in consultation every 3 months.
41340424|NCT05561634|DRUG|Vismodegib|Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,
41340425|NCT03955120|BEHAVIORAL|Dayzz mobile sleep training|"1. The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~2. Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~3. Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study."
41340426|NCT03955120|OTHER|Treatment as usual|Standard medical care for specific sleep condition
41340427|NCT05882604|DRUG|Mesna Injection|1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.
41340428|NCT05882604|DRUG|Arthrocentesis with ringer solution|Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid
41340429|NCT03246711|BEHAVIORAL|Fasting|Totally or partially fasting the holy month of ramadan for muslims
41340430|NCT05106439|BEHAVIORAL|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
41340431|NCT05106439|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
41340432|NCT05106439|BEHAVIORAL|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
41340433|NCT04903886|OTHER|observational|observational
41340434|NCT05880160|OTHER|Phased withdrawal of heart failure medications|As per arm/group description
41340435|NCT04672902|PROCEDURE|Single-operator cholangioscopy guided electrohydraulic lithotripsy|Single-operator cholangioscopy guided electrohydraulic lithotripsy has the advantage of providing direct visualization of the bile ducts, enabling a single physician to diagnose and perform the therapeutic intervention in a single procedure.
41156972|NCT00475787|PROCEDURE|Spinal Manipulation|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
41156973|NCT00475787|PROCEDURE|Detuned Ultrasound|"US machine is turned on and set at 0 w/cm2"
41340436|NCT06445569|DIETARY_SUPPLEMENT|KH-1|3 capsules and one stick packet consumed daily around the same time
41340437|NCT06445569|OTHER|Placebo|3 capsules and one stick packet consumed daily around the same time
41340438|NCT03810053|BEHAVIORAL|Mobile App/Online Module|Short didactic explainer video that will provide information about cancers and benefits of uptake of cancer prevention and early detection measures.
41340439|NCT04732572|BEHAVIORAL|Sleep and healthy lifestyle education|Participants in both groups will receive age-appropriate standardized educational material for both Optimal Sleep Hygiene and Healthy Habits. Educational play will also be encouraged by providing take-home materials. Participant and parent/legal guardian (s) will be given verbal and written directions on the use of these materials at the time of the visit. Research Coordinators will encourage and track utilization of the sleep hygiene educational tools during the trial.
41487642|NCT02876575|DEVICE|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
41340440|NCT04732572|OTHER|Other supportive care|Throughout the course of the trial participants identified by the principal investigator as having suboptimal asthma or rhinitis will be referred to their primary care physician for management and further treatment of these problems. All participants will receive a generic brand of an over-the-counter saline nasal spray to use as needed for nasal dryness and crusting. Proper use of the spray will be reviewed and demonstrated by the research coordinator at the baseline visit.
41340441|NCT04732572|PROCEDURE|Adenotonsillectomy|Surgery will be performed by board-certified otolaryngologists with or without the assistance of resident physicians in accredited otolaryngology training programs. Prior to the surgical procedure, tonsillar size will be graded using a standardized scale of 0-4. Extent of adenoid tissue will also be graded as mild (0-33%), moderate (34-66%) or severely (67-100%) obstructing the posterior choanae. Complete bilateral tonsillectomy and removal of obstructing adenoid tissue will be performed by cold dissection, monopolar electrocautery or plasma knife-assisted surgical technique under general anesthesia. All procedures will be performed using inpatient facility for 3-4 days.
41340442|NCT02756845|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
41340443|NCT05255627|OTHER|Control|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
41340444|NCT05255627|OTHER|Mobile application group (Experimental Group)|"A mobile application program was installed on the phones of the experimental group students for their benefit. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
41340445|NCT04180917|OTHER|Survey|survey
41340446|NCT01059890|DRUG|cefotaxime|
41340447|NCT01059890|DRUG|Metronidazole|
41340448|NCT01059890|DRUG|Ciprofloxacin|
41340449|NCT01059890|DRUG|Fosfocine|
41340450|NCT02001506|DRUG|FEC3-D3|"Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
41340451|NCT02180568|PROCEDURE|Lipiodol|Lipiodol-guided lung localization technique
41340452|NCT02180568|PROCEDURE|Hookwire|Hookwire-guided lung localization technique
41340453|NCT02180568|DRUG|Lipiodol|
41340454|NCT02157584|DRUG|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
41340455|NCT02157584|DRUG|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
41340456|NCT03551184|BIOLOGICAL|Endotoxin|Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
41340457|NCT03551184|BIOLOGICAL|Placebo|Saline administered intravenously
41340458|NCT02480062|OTHER|mWELLCARE|mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
41340459|NCT02480062|OTHER|Usual Care|Usual care at the community health centers
41487643|NCT00846521|DRUG|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
41340460|NCT00107172|PROCEDURE|surgery|
41340461|NCT00107172|RADIATION|brachytherapy|
41340462|NCT03058302|BEHAVIORAL|CETA (Common Elements Treatment Approach)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
41340463|NCT02157168|BEHAVIORAL|Community health worker|"Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey."
41340464|NCT00043004|BIOLOGICAL|bevacizumab|
41340465|NCT00043004|DRUG|FOLFOX regimen|
41340466|NCT00043004|DRUG|fluorouracil|
41340467|NCT00043004|DRUG|leucovorin calcium|
41340468|NCT00043004|DRUG|oxaliplatin|
41340469|NCT00043004|PROCEDURE|conventional surgery|
41340470|NCT00043004|PROCEDURE|radiofrequency ablation|
41340471|NCT02152540|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
41340472|NCT02152540|DEVICE|Sham rTMS|Placebo Device that simulates active rTMS treatment
41340473|NCT01229410|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
41340474|NCT01229410|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
41340475|NCT02796079|BIOLOGICAL|mesenchymal stem cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell
41340476|NCT02796079|BIOLOGICAL|saline|saline injections
40821414|NCT00496483|DRUG|LCP Tacro (tacrolimus)|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
40821415|NCT00496483|DRUG|Prograf|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
41340477|NCT01896414|DIETARY_SUPPLEMENT|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
41340478|NCT01896414|DIETARY_SUPPLEMENT|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
41340479|NCT03801798|DRUG|GC1102|NAs antivirals+GC1102 180,000 IU
41340480|NCT03801798|OTHER|GC1102 Placebo|NAs antivirals+GC1102 Placebo
41340481|NCT05128604|DEVICE|Gastroenterostomy|Endoscopic ultrasound guided gastroenterostomy
41340482|NCT06321276|DEVICE|extracorporeal shockwave therapy|Extracorporeal shock wave therapy (ESWT) is a non-invasive procedure that uses single-pulse acoustic waves generated outside the body and focused on a specific area of the body. Shock waves promote axonal regeneration of peripheral nerves through various molecular reactions. Although the anti-nociceptive mechanisms of ESWT have not yet been elucidated, ESWT may produce analgesia through biochemical changes in the nerve fiber itself and reduce inflammation of soft tissues.
41340483|NCT00443625|DRUG|SK3530|
41340484|NCT05759390|DIAGNOSTIC_TEST|Ultrasound elastography|Using an ultrasound scanner for chest ultrasound examinations. If patients has multiple sub pleural lung lesions, the largest and most approachable lesion to perform 2 Dimensions- shear wave elastography (2D-SWE) will be chosen.
41340485|NCT05432895|DEVICE|Dynamic splint|Device treats plantar fasciitis and replacing boot immobilization which is quite benign
41340486|NCT00815776|DEVICE|Clayton Intra-aural Device (CID)|"The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID)."
41340487|NCT00815776|DEVICE|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
41487644|NCT04616339|DRUG|PF-06882961 100 mg|"PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)"
40821416|NCT06037941|DIAGNOSTIC_TEST|E-Nose testing|At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.
40821417|NCT06037941|DIAGNOSTIC_TEST|Research blood|Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.
40821418|NCT04666831|BEHAVIORAL|Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)|The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
40821419|NCT00309712|DRUG|fenofibrate 160 mg and placebo|
40821420|NCT00309712|DRUG|simvastatin 20 mg and placebo|
40821421|NCT00309712|DRUG|fenofibrate 160 mg and simvastatin 20 mg|
40821422|NCT06067048|DRUG|Zanubrutinib Oral Capsule|36 cycles (1 cycle is 28 days)
40821423|NCT02578680|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
40821424|NCT02578680|DRUG|Cisplatin|IV infusion
40821425|NCT02578680|DRUG|Carboplatin|IV infusion
40821426|NCT02578680|DRUG|Pemetrexed|IV infusion
40821427|NCT02578680|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
40821428|NCT02578680|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
40821429|NCT02578680|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
40821430|NCT02578680|DRUG|Saline solution|IV infusion
40821431|NCT04862234|DRUG|Dulaglutide|A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.
40821432|NCT04862234|DRUG|Placebo|A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
40821433|NCT04862234|DEVICE|Continuous glucose monitor (CGM), blinded|Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
40821434|NCT05440006|DRUG|Fuzuloparib|Fuzuloparib Capsules; 150mg; single dose per cycle.
40821435|NCT01329796|DRUG|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
40821436|NCT01329796|DRUG|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
40821437|NCT06605404|DIAGNOSTIC_TEST|blood and tissue samples|routine standard of care
40821438|NCT06605404|OTHER|blood and tissue samples|Routine standard of care
40821439|NCT06605560|OTHER|Platelet Rich Plasma|PRP contains a high concentration of platelets obtained by centrifugation of autologous blood. After degranulation of platelets, various growth factors and cytokines are released and accelerate cartilage matrix synthesis, restrain synovial membrane inflammation and promote cartilage healing.
40821440|NCT06148311|DRUG|Matching placebo|One matching placebo will be given under the tongue on a thin dissolvable film.
40821441|NCT06148311|DRUG|Dexmedetomidine|Dexmedetomidine 120 mcg will be given under the tongue on a thin dissolvable film.
40821442|NCT05232968|OTHER|Long-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
40821443|NCT05232968|OTHER|Short-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
40821444|NCT01223885|DIETARY_SUPPLEMENT|Camel's milk|Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
40821445|NCT02370537|DRUG|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
40821446|NCT02370537|DRUG|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
41340488|NCT00815776|OTHER|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
41340489|NCT05118711|DIAGNOSTIC_TEST|Cardiorespiratory fitness|Cardiopulmonary exercise testing
40821447|NCT04508751|OTHER|"3T Free-Breathing Fetal Magnetic Resonance Imaging"|Subject will have a one time MRI scan.
41340490|NCT05118711|DIAGNOSTIC_TEST|Lung function|Body plethysmography
41340491|NCT05118711|DIAGNOSTIC_TEST|Muscular strength and balance tests|Handgrip strength test, mid-thigh pull test and standing balance test in static tandem stance
40821448|NCT06534229|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine-needle aspiration|Endoscopic ultrasound-guided fine-needle aspiration for biopsy
41487645|NCT01948466|BEHAVIORAL|Commercials|These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
41487646|NCT00300625|PROCEDURE|Application of the San Francisco Syncope Rule|
40821449|NCT02662153|OTHER|Observation only|No intervention.
40821450|NCT03608137|OTHER|Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships|To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
40821451|NCT02704923|DRUG|Atropine|Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
40821452|NCT02704923|DRUG|Placebo|Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
40821453|NCT04677660|BIOLOGICAL|TAK-919|TAK-919 intramuscular injection
41340492|NCT05118711|DIAGNOSTIC_TEST|Micro- and macrovascular endothelial function and cardiac function|Measurement of flow-mediated dilation, static and dynamic retinal vessel analysis, echocardiography
41340493|NCT05118711|DIAGNOSTIC_TEST|Blood sampling and analysis|Blood sampling by venepuncture
40821454|NCT04677660|BIOLOGICAL|Placebo|Placebo intramuscular injection
41340494|NCT05118711|DIAGNOSTIC_TEST|Physical activity|Physical activity surveillance using accelerometers
41340495|NCT05118711|DIAGNOSTIC_TEST|Questionnaires|Global physical activity questionnaire (GPAQ), short-form 8 health survey (SF-8), barriers to physical activity, fatigue assessment scale (FAS), modified medical research council dyspnea scale (mMRC), depression, anxiety, and stress scale (DASS21), post-COVID-19 syndrome symptoms
41340496|NCT05118711|DIAGNOSTIC_TEST|Body composition|Dual-energy x-ray absorptiometry (DXA)
41487647|NCT04600466|OTHER|Molecular testing for all participants.|Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.
40821455|NCT03088748|DEVICE|Journey II posterior cruciate retaining total knee arthroplasty|
40821456|NCT03088748|DEVICE|Journey II posterior bi-cruciate retaining total knee arthroplasty|
40821457|NCT01909180|DEVICE|Revolution CT Scanner|"These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational."
40821458|NCT06284993|PROCEDURE|electroacupuncture(more frequent)|With the patient in a prone position, the local skin will be routinely sterilized, Ashi points will be perpendicularly inserted into the plantar fascia layer with a depth of approximately 15-20 mm depending on the location. BL57, KI3, and BL60 will be punched perpendicularly 10-15 mm deep into the skin. All needles except the Ashi points will be manually stimulated with small, equal manipulations of lifting, thrusting, twirling, and rotating to achieve De qi (a sensation including soreness, numbness, distention, and heaviness), and the practitioner has a feeling of needle sinking and tightness. The electroacupuncture instrument is connected to the needle handle of BL57 and BL60 respectively. During the needle retention period, except for BL57 and BL60, which are connected to the electroacupuncture instrument, Ashi points and KI3 perform a small and uniform twisting technique three times every 10 min, and a total of 3 times within 30min.
41487648|NCT04600466|OTHER|Germline Testing|Germline testing will be done on prospectively identified patients and in retrospectively identified patients who are still alive.
41487649|NCT04600466|OTHER|Survey|Survey will be administered on prospectively identified patients and in retrospectively identified patients who are still alive. Survey will be administered in person or via telephone. The survey in the language of the participants choice (English or Spanish) on sociodemographic information, current and/or prior PPI (proton pump inhibitor), H2 blocker, antibiotic, tobacco, alcohol, and recreational drug use. Questionnaire will include other risk factors for gastric adenocarcinoma such as certain dietary constituents (high salt diet, high consumption of processed meat, etc.) and occupational exposures.
41487650|NCT04943978|OTHER||just observational blood and liver sampling
41340497|NCT01375439|OTHER|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
41340498|NCT04571736|OTHER|access to the internet information platform|This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.
41340499|NCT02287662|OTHER|Vancouver 3M Clinical Pathway|
41340500|NCT00141401|DRUG|Pregabalin|
41340501|NCT00515099|DRUG|Antithymocyte globulin|Daily 4-day escalating dose
41340502|NCT00515099|DRUG|Placebo|Daily 4-day saline solution
41340503|NCT06020768|OTHER|the bed-head was raised to an angle of 0, 20, 30 and 45 degrees|With each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes.
41340504|NCT03080532|OTHER|dietary habits|
41487651|NCT02955017|BEHAVIORAL|traditional follow_up|"* Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.~* Two days of a complete medical check at 9 and 15 months"
41487652|NCT02955017|BEHAVIORAL|"distance follow-up new technologies"|"* Multidisciplinary support with long distance monitoring Mobile apps.~* Two days of a complete medical check at 9 and 15 months"
41487653|NCT04636359|BEHAVIORAL|Acupuncture stimulation|The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).
40821459|NCT06284993|PROCEDURE|electroacupuncture(less frequent)|"The intervention is the same as Group M except that the frequency of acupuncture will be once per week acupuncture. During the treatment period, in addition to acupuncture, patients will be visited twice a week for a total of 8 visits by telephone or in person. If the content of the visit aligns with the established efficacy evaluation visit in the program, it will be carried out as planned. If not, the patient will be inquired about the progress of their condition since the previous treatment, any rescue medication taken, and other relevant information. Visits that do not involve improvement in relevant indicators of study concern do not need to be recorded.~The electroacupuncture will last for 30 min and will be performed three sessions per week or one session per week for a total of 12 or 4 sessions in four consecutive weeks. Participants in both groups will be treated and (or) evaluated separately."
40821460|NCT06035393|DRUG|HRG2005 inhalation|Drug 1: dose 1; dose 2; dose 3
40821461|NCT06035393|DRUG|Placebo to match HRG2005 inhalation|Drug 2
41340505|NCT02541500|DRUG|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
41487654|NCT00561704|DRUG|losartan|losartan, 100mg daily,
41487655|NCT05389683|BEHAVIORAL|Elimination Diet|An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.
41487656|NCT02944370|BEHAVIORAL|PlayFit - modified exercise games|Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
41487657|NCT00996775|BEHAVIORAL|brief alcohol intervention|this intervention consists of brief assessment and feedback
41487658|NCT00996775|BEHAVIORAL|standard care|education about harmful effects of alcohol use and NIAAA recommended drinking limits
41340506|NCT01402024|DRUG|Aprepitant|"The patient on study group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and~The patient with weight category of 41-65 kg in study group will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg"
41487659|NCT06276036|OTHER|Identification of specific markers|Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.
41487660|NCT03050203|OTHER|custom pack|Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
41487661|NCT03050203|OTHER|standard care|The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
41340507|NCT01402024|DRUG|Placebo|"Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule)."
41340508|NCT02530099|PROCEDURE|CN-group|Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.
41340509|NCT02530099|PROCEDURE|Procedure-group|Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
41340510|NCT01600105|DRUG|Perfusion MRI|1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
41340511|NCT04574869|DRUG|RLS-0071 10 mg/kg|Single dose IV infusion of 10 mg/kg RLS-0071
41340512|NCT04574869|DRUG|RLS-0071 40 mg/kg|Single dose IV infusion of 40 mg/kg RLS-0071
41340513|NCT04574869|DRUG|Placebo|The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia \[USP\]).
41340514|NCT04574869|DRUG|RLS-0071 10 mg/kg|Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
41340515|NCT04574869|DRUG|RLS-0071 40 mg/kg|Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
41340516|NCT03687476|DRUG|VTS-270|VTS-270 200 mg/mL administered as described in the arm group description.
41340517|NCT04528394|RADIATION|Photon|Photon combined with Carbon ion in Arm 1
41340518|NCT04528394|RADIATION|Proton|Proton combined with Carbon ion in Arm 2
41340519|NCT04528394|RADIATION|Carbon ion|Same dose and fractionation will be used in both arms.
41340520|NCT03122652|DRUG|Teriflunomide 14 MG Oral Tablet [Aubagio]|1 tablet once a day
41340521|NCT03122652|DRUG|Placebo Oral Tablet|1 tablet once a day
41340522|NCT03121482|DEVICE|HFNC|Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
41340523|NCT03121482|DEVICE|NIV|Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
41487662|NCT04218500|OTHER|Niacinamide 4%|cream moisturizer
41487663|NCT04218500|OTHER|Virgin Coconut oil 30%|cream moisturizer
41487664|NCT04659252|OTHER|n/a - samples collected along routine care samples only|This is a non-interventional study.
41487665|NCT00130455|DRUG|escitalopram|
41487666|NCT01656538|DRUG|Paclitaxel|
41487667|NCT01656538|DRUG|Reolysin|
41487668|NCT00124995|DRUG|terbutaline|
41487669|NCT00362479|DRUG|DR-1021|1 tablet daily
41340524|NCT06437639|DRUG|Mexidol|Neurocytoprotector
41340525|NCT02972593|BIOLOGICAL|Blood and blood products for transfusion|Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb \>7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.
41340526|NCT06508398|DIAGNOSTIC_TEST|Microbiological Diagnostic Testing|"This study involves microbiological diagnostic testing of clinical samples collected from ICU patients diagnosed with healthcare-associated infections (HAIs). The intervention includes:~Sample Collection: Blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs.~Pathogen Identification: Using biochemical tests, MALDI-TOF mass spectrometry, and 16S rRNA sequencing to identify bacterial and fungal pathogens.~Antimicrobial Susceptibility Testing: Determining the resistance profiles of the identified pathogens to various antimicrobial agents.~Evaluation of New Compounds: Testing the antimicrobial efficacy of new 4-thiazolidinone derivatives against isolated pathogens.~This comprehensive approach aims to enhance the understanding of pathogen distribution and resistance patterns in HAIs."
41340527|NCT06346704|OTHER|Digital HealthTechnology|Subject will wear the Syde® for 1 month every 6 months
41340528|NCT06189625|OTHER|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
41487670|NCT01587937|OTHER|Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics|See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
41487671|NCT05174494|DIAGNOSTIC_TEST|Evaluation of serum CRP and NT-proBNP|All patients were evaluated to 6-months post-treatment reduction of serum CRP and NT-proBNP
41340529|NCT06189625|PROCEDURE|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended."
41340530|NCT01998113|DRUG|Glyburide vs Insulin trials|Affecting groups 1 and 2
41340531|NCT01998113|DRUG|Metformin vs Insulin trials|Affecting groups 3 and 4
41340532|NCT01998113|DRUG|Metformin vs Glyburide trials|Affecting groups 5 and 6
41340533|NCT04304404|BEHAVIORAL|Breast Cancer Risk Reduction Program (BrCaRRP)|Women in the intervention group will complete the pre-tests electronically, and a 12-week intervention program will be implemented. The first meeting will be face-to-face individual training. In this training session, the risk of developing breast cancer will be calculated with each participant using breast cancer risk assessment tools. Modifiable and non-modifiable factors that increase breast cancer risk will be explained. With the participant, it will be decided which of the modifiable risk factors will be improved. Guidance will be given on topics such as genetic counseling, breast cancer screenings, increasing physical activity, healthy nutrition, weight control, smoking and alcohol use. The interventions will continue with phone calls and the 12-week program will be completed.
41487672|NCT05285670|BEHAVIORAL|Digital counseling plus interactive two-way SMS dialogue|We will utilize a digital counseling tool on a tablet to provide initial reproductive life planning counseling while waiting for an HIV care provider. We will then use Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women following enrollment and for up to 2 years. Women will receive automated theoretically grounded SMS messages targeting the appropriate reproductive health needs and will have the capability to respond and spontaneously message a nurse based at the clinic. . Automated SMS will be delivered at times and in languages based on patient preferences, weekly the first 3 months, every other week in months 4-12, and monthly during the last year of the trial. If there is a change in the reproductive health needs, more frequent messaging will be re-initiated at the same frequency as enrollment.
41487673|NCT03984123|DEVICE|Brachial cuff, in order to achieve ischemic stimuli|Standard treatment with no brachial cuff inflation
40821462|NCT06035393|DRUG|Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 3
40821463|NCT06035393|DRUG|Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 4
40821464|NCT04972708|GENETIC|Cross-sectional genetics study|Cross-sectional genetics study
41487674|NCT03996642|BEHAVIORAL|Avatar Life Review|VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
41340534|NCT02371018|DIETARY_SUPPLEMENT|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
41340535|NCT00427375|PROCEDURE|local rectal excision|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
41340536|NCT00427375|PROCEDURE|total mesorectal excision|standard surgery
41340537|NCT02967640|DRUG|Ketalar|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection
41487675|NCT06065774|PROCEDURE|The Laterally Closed Tunnel Technique with SCTG|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
41487676|NCT06065774|DRUG|The Laterally Closed Tunnel Technique with collagen matrix mucograft|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
40821468|NCT00975104|DRUG|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
40821469|NCT00975104|DRUG|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
41340538|NCT02967640|DRUG|NaCl 9%|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
41340539|NCT01553760|PROCEDURE|Phacoemulsification using an ACM as the sole fluid source|A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
41340540|NCT01553760|PROCEDURE|Conventional Phaco|a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
41340541|NCT02647372|PROCEDURE|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
40821470|NCT00975104|DRUG|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
40821471|NCT00975104|DRUG|Placebo|Placebo IV QW
40821472|NCT05340387|OTHER|Balance Resistance Aerobic Cognitive exercises (BRACE)|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. Week 1-3 : Balance: Romberg, tandom standing, single leg stance Resistance: chair rise Aerobic exercises: 6mint walk Cognitive: count reverse from 50 Week 4-6: Balance: Sit to stand, functional reach, Tug Test Resistance: stair climbing Aerobic Exercises: Marching in space Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Perturbation, throwing a ball, kicking a ball Resistance: Floor transfer, squatting Aerobic Exercises: Cycling Cognitive: Count even number from 1-50, calculation, addition, subtraction, multiplication division Week 10-12: Balance: Combination of All Resistance: Combination of All Aerobic Exercises: 6 minutes' walk test, marching steps, cycling Cognitive: Combination of all
41340542|NCT02647372|PROCEDURE|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
41340543|NCT05433974|BIOLOGICAL|Blood sample collection|Blood sample collection : 2 X 6 mL
41340544|NCT06507228|DIAGNOSTIC_TEST|NWL PEBBLE STT|At home testing for OSA with AcuPebble.
41340545|NCT00118404|BEHAVIORAL|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
41340546|NCT00118404|DRUG|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
41340547|NCT00118404|OTHER|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
41340548|NCT00118404|BEHAVIORAL|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
41487677|NCT06065774|PROCEDURE|Modified Coronally Advanced Tunnel Technique with SCTG.|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
41487678|NCT06065774|DRUG|Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
41487679|NCT02987959|DRUG|TAK-228|TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
41487680|NCT01193036|BEHAVIORAL|Part 1: Interview + Questionnaires|Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.
41156974|NCT05306730|DEVICE|ECHOcardiography, Point-of-Care UZ|Emergent echocardiography is reproducible method providing clinically significant information during primary survey of acute cardiovascular diseases. Possible benefit is the risk stratification of acute non-stemi coronary syndromes and differentiation from other serious conditions, such as pulmonary embolism or aortic dissection. The aim of interest is to consider riscs and benefits of the ultrasound of heart done by non-cardiologist after standardized course.
41340549|NCT02558972|DRUG|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
41487681|NCT01193036|BEHAVIORAL|Part 2: Multiple Questionnaires|Questionnaires to be repeated about every 2 weeks for 1 year.
41487682|NCT00977730|DIETARY_SUPPLEMENT|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
41487683|NCT00977730|DIETARY_SUPPLEMENT|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
41017354|NCT05667298|DRUG|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
41017355|NCT05667298|DRUG|Adjuvant chemoradiotherapy|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
41017356|NCT03984188|DRUG|Theophylline ER|200 mg extended release (ER) low-dose theophylline taken orally daily
41017357|NCT03984188|DRUG|Placebo oral tablet|Manufactured methylcellulose placebo tablet taken orally daily
41017358|NCT03984188|OTHER|Standard of Care Treatment|Per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment
41017363|NCT06295549|BIOLOGICAL|LUCAR-G39P cells product|LUCAR-G39P cells product Prior to infusion of the LUCAR-G39P, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
41017364|NCT05988892|BEHAVIORAL|Physical Activity|Use Exercise to increase physical activity (PA), as measured by cardiovascular endurance, muscular strength, and balance in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address and to increase quality of life (QOL), as measured by physical functioning and fatigue, in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address.
41017366|NCT04134325|BIOLOGICAL|Nivolumab|Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells
41017367|NCT04134325|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells
41487684|NCT02013479|DIETARY_SUPPLEMENT|SelenoPRECISE|Produced by Pharma Nord ApS, Vejle, Denmark
41487685|NCT02013479|DIETARY_SUPPLEMENT|Placebo|Produced by Pharma Nord ApS, Vejle, Denmark
41487686|NCT05476107|DRUG|AMT-126|Single or daily dosing at doses A, B, C, D, E, F; G, H, and I
41017368|NCT03609060|DRUG|Dexamethasone|Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
41487687|NCT05476107|DRUG|Placebo|Single or daily dosing at doses A, B, C, D, E, F; G,H, and I
41487688|NCT05476107|OTHER|Radioactive Tablet (Part 2 Only)|Single dose in two periods in Part 2 (optional)
41487689|NCT03717194|DRUG|Ertugliflozin|Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
41340550|NCT02558972|DRUG|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
41487690|NCT03717194|DRUG|Placebo|Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
41487691|NCT03290365|DRUG|platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
41487692|NCT03290365|DRUG|platelet rich plasma + normal saline|The normal salin as the placebo intervention was injection control group.
41487693|NCT03272464|DRUG|Trametinib|Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
41340551|NCT02558972|DRUG|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
41340552|NCT02558972|DRUG|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
41340553|NCT01042054|OTHER|Standard optimised recovery protocol.|"* Epidural analgesia for the first 48 hours postoperatively.~* Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout."
41340554|NCT01042054|OTHER|Wound catheter plus patient-controlled analgesia.|"* Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~* Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~* Sham epidural catheter applied to the patient's back for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout."
41340555|NCT01779804|PROCEDURE|OFAR|OFAR
41340556|NCT02315417|DRUG|gevokizumab|
41340557|NCT02315417|DRUG|Placebo|
41340558|NCT02315417|DRUG|gevokizumab open-label|
41340559|NCT00565357|DEVICE|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
41340560|NCT00565357|OTHER|Control|Standard care in the neonatal intensive care unit
41340561|NCT04517110|DRUG|Pregabalin 300 mg|Pregabalin 300 mg, capsule
41340562|NCT04517110|DRUG|Pregabalin 75 mg|Pregabalin 75 mg twice daily, capsules
41340563|NCT04517110|DRUG|Pregabalin 300 mg Placebo|Placebo, matching Pregabalin 300 mg capsule
41340564|NCT04517110|DRUG|Pregabalin 75 mg Placebo|Placebo, matching Pregabalin 75 mg capsules
41340565|NCT04517110|OTHER|Usual Care|Usual Care
41340566|NCT02790684|DRUG|DS-8500a|
41340567|NCT05746000|BEHAVIORAL|Intervention Group (IG)|Three individual diet counselling that includes sugar calculation (sugar exchange) (60 minutes per session) at baseline, week-4 and week-8.
41340568|NCT05746000|BEHAVIORAL|Control Group (CG)|Three individual diet counselling (60 minutes per session) at baseline, week-4 and week-8.
41340569|NCT00620737|BIOLOGICAL|Autologous Human Fibroblasts (Isolagen TherapyTM)|"1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits"
41340570|NCT00620737|BIOLOGICAL|Placebo|"1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits"
41487694|NCT03272464|DRUG|Dabrafenib|Dabrafenib may work by stopping your cancer cells from duplicating.
41340571|NCT00074867|DRUG|CP-547,632|
41340572|NCT02950441|DIETARY_SUPPLEMENT|Nicotinamide Riboside|
41340573|NCT02950441|OTHER|Placebo|
41340574|NCT01670825|PROCEDURE|Pulsed radiofrequency|Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
41340575|NCT01670825|DRUG|Corticosteroid injection|Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
41340576|NCT01670825|DRUG|Local anethestic injection|
41340577|NCT02945839|DRUG|Preventative Medication (PM)|Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
41340578|NCT02945839|BEHAVIORAL|Enhanced Usual Care|General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
41340579|NCT02945839|BEHAVIORAL|PMR (progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension
41340580|NCT03099304|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
41487695|NCT03272464|DRUG|INCB039110|Itacitinib may work by stopping your tumor cells from living and growing.
41487696|NCT01415765|DRUG|MLN4924|Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
41340581|NCT03099304|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
41340582|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
41340583|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
41340584|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
40821473|NCT05340387|OTHER|Otago's Protocol|"Study will be conducted after the approval of Ethical review board. The Otago's exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. WEEK 1-3: Warm up: March, head movement, neck movement, back extension, trunk movement, ankle movements Strength: Front knee strengthening, Back knee strengthening, Side hip strengthening, Calf raises, Toe raises (10 repetitions each) Balance: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel toe stand), Tandem walk (heel toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backwards, Sit to stand, Stair walking. (10 repetitions each) Flexibility: calf stretch, back of thigh stretch Hold for 10 to 15 seconds and repeat on other leg.~Walk: 5 or 10 minutes' walk~This protocol will be followed for 12 weeks with increased repetitions after every 3 week."
41340585|NCT00679380|PROCEDURE|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
41340586|NCT00679380|DRUG|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
41340587|NCT00679380|DRUG|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
41340588|NCT00679380|DRUG|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
41340589|NCT00679380|DRUG|Placebo|Placebo
41340590|NCT02940028|BEHAVIORAL|Expressive writing|Brief expressive writing intervention
41340591|NCT02940028|BEHAVIORAL|Control writing|Brief fact-based writing exercise.
41340592|NCT03397550|OTHER|salt restriction education|Salt intake target：\<5g/d Method：the standard salt restriction education will be lasting for 10-15 minutes by oral explanation at baseline.
41340593|NCT01044056|DRUG|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
40821474|NCT01023087|DRUG|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
40821475|NCT01023087|DRUG|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
40821476|NCT05984277|DRUG|Volrustomig|Volrustomig
40821477|NCT05984277|DRUG|Pembrolizumab|Pembrolizumab
40821478|NCT05984277|DRUG|Carboplatin|Carboplatin
40821479|NCT05984277|DRUG|Paclitaxel|Paclitaxel
40821480|NCT05984277|DRUG|Pemetrexed|Pemetrexed
40821481|NCT01146652|DRUG|SAR153191 (REGN88)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
40821482|NCT01491386|DEVICE|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
40821483|NCT01491386|DEVICE|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
40821484|NCT04673370|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines techniques regulating body, breath and spirit. According to traditional Chinese theory, every movement of Ba Duan Jin has unique effect to different Zang-fu organs.
40821485|NCT04673370|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
40821486|NCT00024661|DRUG|LErafAON|
40821487|NCT06606054|OTHER|Educational and implementation Neurocardiology tool|Sites in this arm will be provided with an educational and implementation Neurocardiology tool aiming to improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1.
40821488|NCT06606054|OTHER|No educational or implementation tool will be provided|Participants will be followed for up to 12 months. No educational or interventional tool will be provided to sites in this arm until the follow-up period has ended.
40821489|NCT03549871|DRUG|Fitusiran|Pharmaceutical form: solution for injection Route of administration: subcutaneous
40821490|NCT03549871|DRUG|BPA prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
41340594|NCT01044056|DRUG|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
40821491|NCT03549871|DRUG|Factor (FVIII or FIX) prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
40821492|NCT06110897|BEHAVIORAL|High Dose Resistance Exercise Training|Progressive resistance exercise training
40821493|NCT06110897|BEHAVIORAL|Low Dose Resistance Exercise Training Group|Progressive resistance exercise training
40821494|NCT06606015|DRUG|I.V Paracetamol.|Pharmacological thereby for hsPDA closure in the preterm neonates.
40821495|NCT06606015|DEVICE|Echocardiography.|It is routinely performed in neonates for PDA screening and detection of any other cardiac anomalies.
40821496|NCT06606015|DEVICE|Electrical Cardiometry|Non invasive hemodynamics monitoring
40821497|NCT00383643|DRUG|zolpidem tartrate|
40821498|NCT00383643|DRUG|sodium oxybate|
40821499|NCT00383643|DRUG|Matching Placebos|
40821500|NCT00986401|DRUG|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
41340595|NCT01044056|DRUG|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
41340596|NCT01787045|OTHER|Early and Active Physical Therapy|"Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.~Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc."
41487697|NCT01415765|DRUG|Etoposide|CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
41487698|NCT01415765|DRUG|Prednisone|PO (by mouth) twice daily on days 1-5 of every 21 day cycle
40821501|NCT00986401|DRUG|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
40821502|NCT03666507|PROCEDURE|Intraoperative Monitoring during resection of brain tumor|Intraoperative Monitoring during resection of brain tumor
41340597|NCT01787045|OTHER|Passive Range of Motion|Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
41487699|NCT01415765|DRUG|Vincristine|CIV on days 1-4 of every 21 day cycle
40821503|NCT01878617|RADIATION|Craniospinal Irradiation with boost to the primary tumor site|All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
40821504|NCT01878617|DRUG|Cyclophosphamide|Route of Administration (ROA): Intravenously (IV)
40821505|NCT01878617|DRUG|Cisplatin|ROA: IV
40821506|NCT01878617|DRUG|Vincristine|ROA: IV
40821507|NCT01878617|DRUG|Vismodegib|ROA: Orally (PO)
41487700|NCT01415765|DRUG|Cyclophosphamide|IV on day 5 of each 21 day cycle
40821508|NCT01878617|DRUG|Pemetrexed|ROA: IV
40821509|NCT01878617|DRUG|Gemcitabine|ROA: IV
40821510|NCT01878617|OTHER|Aerobic Training|
40821511|NCT01878617|OTHER|Neurocognitive Remediation|
40821512|NCT05105282|PROCEDURE|Two different blocks with same local anesthetic volume|Deep serratus anterior block and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
40821513|NCT05540769|PROCEDURE|catheter guided ASD closure|transcatheter secundum ASD device closure
40821514|NCT01267331|PROCEDURE|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
40821515|NCT01267331|PROCEDURE|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
40821516|NCT01367223|DIETARY_SUPPLEMENT|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
40821517|NCT01367223|DIETARY_SUPPLEMENT|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
40821518|NCT03822312|DEVICE|DBT-TOBI|The DBT-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through
40821519|NCT03822312|DEVICE|MRI-TOBI|The MRI-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through. The MRI scan is completed at the same time as the TOBI scan. Participation in this part of the intervention is optional.
41340598|NCT01729676|DRUG|Degarelix or GnRH agonist|Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
41340599|NCT02425436|DRUG|Ginkgo Biloba Extract|
41487701|NCT01415765|DRUG|Doxorubicin|CIV on days 1-4 of each 21 day cycle
41487702|NCT01415765|DRUG|Rituximab|IV on day 1 of each 21 day cycle
41487703|NCT01415765|DRUG|Filgrastim|Subcutaneously beginning Day 6 of each 21 day cycle
41487704|NCT01070459|BEHAVIORAL|Aerobic exercise group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
41340600|NCT02425436|OTHER|Placebo|
41487705|NCT01070459|BEHAVIORAL|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
41487706|NCT01070459|BEHAVIORAL|Follow-up first aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
41487707|NCT01070459|BEHAVIORAL|Follow-up control group|No intervention will be offered in a period of 9 months after the passive mobilisation programme
41487708|NCT01070459|BEHAVIORAL|Follow-up second aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
40821520|NCT06607367|DRUG|Ruxolitinib (JAKAVI®)|Initial starting dose will be 10mg BD
40821521|NCT06607367|DRUG|Eltrombopag (Revolade®)|Initial starting dose will be 50mg daily
41340601|NCT02371694|OTHER|Test drink|"The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour."
40821522|NCT05293444|DIETARY_SUPPLEMENT|Maltodextrine|400 ml at 10PM night before surgery(12.5g/100ml) 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery.
40821523|NCT05293444|OTHER|overnight fasting|no intervention
41340602|NCT01318421|DRUG|ELND002|
41340603|NCT00668850|DRUG|Generex Oral-lyn™|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
41340604|NCT00668850|DRUG|Regular human insulin|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
41340605|NCT03556982|BIOLOGICAL|CART-123 cells|CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
41340606|NCT02273414|DRUG|BIIL 284 BS - rising dose|
41340607|NCT02273414|DRUG|Placebo|
41340608|NCT00937001|PROCEDURE|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
41340609|NCT02400060|BEHAVIORAL|Telephone-Based Intervention|Receive text messaging
41340610|NCT02400060|OTHER|Survey Administration|Ancillary studies
41340611|NCT02400060|OTHER|Laboratory Biomarker Analysis|Correlative studies
41340612|NCT01231828|DRUG|L-carnitine|L-carnitine 4g per day (4 bottles of 10ml).
41340613|NCT01231828|DRUG|Lactulose|Lactulose (30-60 ml per day)
41340614|NCT00774956|PROCEDURE|Exercise training program|A 6 week shoulder exercise training program
41340615|NCT00774956|PROCEDURE|Exercise training program|A 6 week shoulder exercise training program
41340616|NCT01824836|DRUG|anastrozole|Given PO
41340617|NCT01824836|OTHER|questionnaire administration|Ancillary studies
41340618|NCT01824836|OTHER|laboratory biomarker analysis|Correlative studies
41340619|NCT01824836|OTHER|pharmacogenomic studies|Correlative studies
41340620|NCT00256646|DRUG|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
41340621|NCT01496144|PROCEDURE|Manual therapy and active exercises|"Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.~Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises"
41340622|NCT01496144|PROCEDURE|Detuned ultrasound and active exercises|Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
41340623|NCT02348840|DEVICE|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
41340624|NCT04738240|DIAGNOSTIC_TEST|Intra-operative endoscopy|Intra-operative endoscopy to assess rectal anastomosis
41340625|NCT05447260|DRUG|Ruxolitinib|Dosage based on platelet count
41340626|NCT01844791|DRUG|OCZ103-OS|OCZ103-OS is given in combination with chemotherapy each cycle
41340627|NCT01844791|DRUG|Platinum|Platinum is given as standard chemotherapy each cycle
41340628|NCT01844791|DRUG|Gemcitabine|Gemcitabine is given as standard chemotherapy each cycle
41340629|NCT04006067|OTHER|changing surgical gloves|All the surgical team including surgeons, surgical assists and scrub technicians replaced their outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure.
41487709|NCT04031781|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 100% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
41487710|NCT04031781|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 50% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
41487711|NCT04875611|DRUG|Opdivo|Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).
41487712|NCT01345175|DRUG|Rifaximin|Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
41487713|NCT01345175|DRUG|Placebo|Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
41487714|NCT06455436|DEVICE|Standard healing abutment|Participants will undergo a surgery to place an immediate klockner dental implant and will be receive a standard healing abutment
41487715|NCT06455436|DEVICE|Individualized healing abutment|Participants will undergo a surgery to place an immediate klockner dental implant and will be receive an individualized healing abutment
41487716|NCT06037226|BEHAVIORAL|Postpartum pelvic floor rehabilitation|biofeedback with Pelvic floor muscle training (PFMT)
40821524|NCT06126952|DRUG|Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)|"2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day"
40821525|NCT06126952|DRUG|Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray|2 sprays per nostril of Placebo twice daily.
41340630|NCT02377908|OTHER|Online Survey|Online questionaire submitted to experts in geriatrics in different European countries. 12-item survey.
41487717|NCT04361149|DRUG|Capsaicin Topical Cream (0.075%)|Capsaicin cream will be administered as a topical skin cream
41340631|NCT01493934|DRUG|injection of 6-DIG|Unique injection dose of 92.5 MBq
41340632|NCT01678313|DRUG|Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)|Study group
41340633|NCT01678313|DRUG|Doxazosin 4 mg every day (QD)|Control group
41340634|NCT05265104|DRUG|SDF with stainless steel crown|Silver Diamine Fluoride (38%) applied to the carious lesion in the primary molars with a brush and the tooth is sealed with a stainless steel crown
41340635|NCT05265104|DEVICE|Diode laser application with stainless steel crown|Diode laser will be applied to the carious lesions primary molars to eradicate the bacteria and then the tooth will be sealed with stainless steel crown
41340636|NCT05265104|OTHER|stainless steel crown only|the primary molars with carious lesions will be sealed with stainless steel crowns following the concept of hall technique
41340637|NCT05664555|DRUG|Fluorescein Sodium|Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
41487718|NCT04361149|DEVICE|Delsys Trigno Galileo System|A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.
41487719|NCT04361149|DEVICE|Excaliber, Natus Medical|Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.
40821526|NCT06126952|DRUG|Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray|"2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day"
40821527|NCT00619424|DRUG|pazopanib|Oral tablet administered daily in dosages of 400 - 800 mg.
40821528|NCT00619424|DRUG|erlotinib|oral tablet taken daily in dosages of 100-150 mg.
40821529|NCT00619424|DRUG|pemetrexed|IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
40821530|NCT00006164|DRUG|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight \<75 kg, \>75 kg) daily in two divided doses for 24 weeks
40821531|NCT00006164|DRUG|Peginterferon alfa-2a|90 mcg/week injection, for 3.5 years
41340638|NCT04974190|DEVICE|Nasal Spray Device|A Nasal Spray apparatus containing a liquid
41340639|NCT04462978|OTHER|Non IgE-mediated food allergy|
41340640|NCT05936346|DIETARY_SUPPLEMENT|Salvia haenkei 175mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
41340641|NCT05936346|DIETARY_SUPPLEMENT|Salvia haenkei 350mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
41340642|NCT04308408|BEHAVIORAL|Guideline Daily Amounts|All food items displayed the corresponding GDA label in the lower left corner of the front of the package.
41340643|NCT04308408|BEHAVIORAL|Multiple Traffic Light|All food items displayed the corresponding MTL label in the lower left corner of the front of the package.
41340644|NCT04308408|BEHAVIORAL|Warning Labels|"Food products were labeled with High in labels In the lower left corner of the front of the package. In total, 37 of the 60 food products in the shopping site did not display a WL."
41340645|NCT04308408|BEHAVIORAL|Video|Participants viewed a short (less than 1 min) video explaining how to interpret the label.
41340646|NCT05941910|DRUG|Q10|240mg of Q10 orally, every day
41340647|NCT04872504|DEVICE|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen record the incidence of intraoperative hypotension
40821532|NCT00171925|DRUG|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance \> 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).
41340648|NCT01301755|PROCEDURE|Lung aspiration|direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
41487720|NCT04361149|OTHER|Placebo Cream|Placebo cream will be administered as a topical skin cream
41487721|NCT02516527|DRUG|Ipilimumab|
41487722|NCT04764656|DRUG|Brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
41487723|NCT05953974|OTHER|Clinical score of Granillo and al.|Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
40821533|NCT00171925|DIETARY_SUPPLEMENT|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
40821534|NCT06398431|DEVICE|Walking analysis sensor|Participant gait analysis with the inertial sensor
41340649|NCT02544204|BIOLOGICAL|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
41340650|NCT02544204|BIOLOGICAL|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
41487724|NCT03605511|DIAGNOSTIC_TEST|ADAMTS 13, complement and angiogenic biomarkers|ADAMTS 13, complement and angiogenic biomarkers
41487725|NCT02796937|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
41487726|NCT00466830|OTHER|questionnaire administration|
41487727|NCT00466830|PROCEDURE|management of therapy complications|
41487728|NCT00466830|PROCEDURE|psychosocial assessment and care|
41487729|NCT00466830|PROCEDURE|quality-of-life assessment|
41487730|NCT01517659|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
40821535|NCT02337283|DRUG|BI 425809|Tablets
40821536|NCT02337283|DRUG|Placebo|Tablets
41340651|NCT04645004|DRUG|Aspirin 81Mg Non-enteric coated Tab|one tab daily
41340652|NCT02562976|OTHER|gastric atrophy and intestinal metaplasia|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
41340653|NCT03389269|OTHER|Meal test|240 min mixed meal test with aspiration using AspireAssist.
41340654|NCT03345173|DRUG|CI-581-a|Two infusions in the context of naltrexone induction protocol.
41340655|NCT03345173|DRUG|CI-581-b|Two infusions in the context of naltrexone induction protocol.
41487731|NCT02902536|OTHER|No interventions|
41487732|NCT02733952|DRUG|Tranexamic Acid|
40821537|NCT02761187|OTHER|No Intervention|
40821538|NCT02186652|DRUG|Pantoprazole|
40821539|NCT03307161|OTHER|osteopathic manual therapy|Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
40821540|NCT04746482|PROCEDURE|single visit root canal retreatment|cases that were subject to root canal retreatment performed in single visit
41340656|NCT02779530|DRUG|Diclofenac|50 mg po, b.i.d for 6 days
41340657|NCT02779530|OTHER|Placebo|Placebo po, b.i.d. for 6 days
41340658|NCT02737605|DRUG|Intranasal Esketamine|Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.
41487733|NCT02733952|PROCEDURE|Pericervical Tourniquet|
41487734|NCT04511221|DIETARY_SUPPLEMENT|Bifidobacterium animals subsp. lactis BL04+PreforPro|One 15mg capsule taken orally each day
41487735|NCT04511221|DIETARY_SUPPLEMENT|Bifidobacterium animals subsp. lactis BL04|One 15mg capsule taken orally each day
41487736|NCT04511221|OTHER|Placebo|One 15mg capsule taken orally each day
41487737|NCT03056261|PROCEDURE|Combined general and epidural|Combined general and epidural anaesthesia
41487738|NCT03056261|PROCEDURE|General anaesthesia|General anaesthesia
41487739|NCT02496936|OTHER|SFA|High saturated fatty acid/SFA oil source
41487740|NCT02496936|OTHER|MUFA|High monounsaturated fatty acid/MUFA oil source
40821541|NCT05121454|DEVICE|Serenno Sentinel, model Alpha 2.0, software version: 8.0|intra-abdominal pressure measurements compared to a Foley Manometer at different insufflation pressures between 5 and 25 cmH20 at 30seconds intervals.
40821542|NCT03591614|BIOLOGICAL|DKK1|The investigational agent is a DKK1 peptide-loaded autologous dendritic cell vaccine dispensed at a dose of 5-10x106 in 0.5 mL Plasma-Lyte A + 5% HSA.
40821543|NCT06598514|DRUG|Chlorhexidine|Participants will use a 2% chlorhexidine perineal lavage following defecation
40821544|NCT06598514|DRUG|Sterile Water|Participants will use a sterile water perineal lavage following defecation
40821545|NCT02546440|DRUG|Dimethyl fumarate|dose escalation from 30 mg/d to maximally 720 mg/d over 9 weeks, then continuing with the highest tolerated dose following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until either progression or unacceptable side effects occur
40821546|NCT01170065|DRUG|BIBF 1120|Intermediate dose BIBF 1120 twice daily
40821547|NCT01170065|DRUG|BIBF 1120|High dose BIBF 1120 twice daily
40821548|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 twice daily
40821549|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 once daily
40821550|NCT05970133|PROCEDURE|Colectomy with NOSE procedure|The specimen will be extract from the anus.
40821551|NCT05160519|RADIATION|Class IV Laser|"30 participants will be irradiated with Class IV laser therapy over the left parasternal area to examine the efficacy of class IV laser on ejection fraction, Cardiac Biomarker and functional outcomes.~Device: Litecure LCT-1000C Class IV laser will be used in contact method over the left parasternal area in 2nd, 3rd intercostal space and apex. Dosage and Parameters for the irradiation will be calculated. Parameters: 1. Wavelength: 980nm, 2. Power/ Energy density: 6W/6J/cm2 3. Frequency: CW 4. Energy delivered at each spot: 360J 5. irradiation spots: 3 6. Irradiation time: 60 sec at each spot.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
41487741|NCT02496936|OTHER|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
40821552|NCT05160519|RADIATION|Sham Class IV Laser|"30 participants in sham control group will be suppose to irradiate with Class IV laser therapy over the left parasternal area, but the radiation will not be delivered.~Device: Litecure LCT-1000C Class IV laser will be placed over the left parasternal area in 2nd, 3rd intercostal space and apex without switching on the instrument.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
40821553|NCT00563069|DRUG|Midazolam|
40821554|NCT03344107|OTHER|USSQ questionnaire administration after RIRS.|USSQ symptoms questionnaire administration after RIRS
40821555|NCT04172415|OTHER|Retrospective cohort|Chart Review
41017380|NCT04699994|DRUG|FLOT therapy|Preoperative FLOT therapy
41017381|NCT04589585|DEVICE|DiVeRt|DiVeRt - Vascular Reconstruction Device and Delivery System
40821556|NCT05628506|DRUG|Potassium iodide|Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
40821557|NCT00896363|DRUG|GSK163090 1 mg|Developed for the treatment of Major Depressive Disorder
40821558|NCT00896363|DRUG|GSK163090 Placebo|Developed for the treatment of Major Depressive Disorder
40821559|NCT00896363|DRUG|GSK163090 3 mg|Developed for the treatment of Major Depressive Disorder
40821560|NCT03179111|PROCEDURE|Pneumoperitoneum Pressure|There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
41017382|NCT02698501|DRUG|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
41017383|NCT02698501|DRUG|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
41017384|NCT04086472|BIOLOGICAL|Clesrovimab|Single dose of clesrovimab administered via IV infusion.
41340659|NCT02737605|DRUG|Intravenous Esketamine|Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.
41017385|NCT04086472|OTHER|Placebo|Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.
41017386|NCT04086472|BIOLOGICAL|RSV-A Memphis 37b|Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.
41017387|NCT06034821|DRUG|Subanesthetic dose intravenous ketamine (KET)|This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant. Treatments will be given two times a week for a maximum of 8 treatments during the acute arm of the study. The investigators will be able to modify dose and number of treatments as indicated clinically per pragmatic clinical trials procedures. Patients will be clinically assessed prior to each treatment to evaluate response and appropriateness of continuation of treatment. Per FDA guidelines a maximum 60mg/dose will be given regardless of body weight.
41340660|NCT02737605|DRUG|Moxifloxacin|Participants will receive 400 mg Moxifloxacin orally.
41340661|NCT02737605|DRUG|Oral Placebo|Participants will receive matching placebo orally.
41340662|NCT02737605|DRUG|Intravenous Placebo|Participants will receive placebo 40 minutes, intravenous infusion.
41340663|NCT02737605|DRUG|Intranasal Placebo|Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
41340664|NCT01801189|DRUG|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
41340665|NCT01801189|DRUG|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
41340666|NCT00246376|BEHAVIORAL|Diet|ATP-III diet
41340667|NCT00246376|BEHAVIORAL|Exercise|Supervised exercise in study gym
41340668|NCT00246376|DRUG|Niacin|Niaspan, titrated up to 2 grams per day
40821561|NCT03740542|PROCEDURE|Esophagectomy|Surgical removal of part of esophagus
40821562|NCT03740542|PROCEDURE|Pyloroplasty|pyloric drainage procedure
40821563|NCT04080479|DIAGNOSTIC_TEST|Quadriceps Muscle Layer Fitness|The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
40821564|NCT04080479|DIAGNOSTIC_TEST|Muscle Strength|All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.
40821565|NCT04080479|DIAGNOSTIC_TEST|Acute Physiology and Chronic Health Evaluation|All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
40821566|NCT04080479|DIAGNOSTIC_TEST|Sequential Organ Failure Assessment|All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
40821567|NCT04080479|DIAGNOSTIC_TEST|Nutritional Risk Screening|All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
41340669|NCT00246376|DRUG|Fenofibrate|Tricor, 120 mg per day
41340670|NCT00246376|OTHER|Placebos|Placebos for Niaspan and Tricor
41340671|NCT02412527|OTHER|Patch III heart rate sensor|
41340672|NCT05658419|PROCEDURE|socket sheild|the socket shield technique, in which a partial root fragment was retained around an immediately placed implant with the aim of avoiding tissue alterations after tooth extraction. Histologic evaluation in a beagle dog showed no resorption of the root fragment and new cementum formed on the implant surface.
41487742|NCT02496936|OTHER|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
41487743|NCT02496936|OTHER|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
40821568|NCT04080479|DIAGNOSTIC_TEST|Energy and Protein Intake|The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
40821569|NCT01571050|DRUG|Purified water|Ingestion of 30 mL of purified water
40821570|NCT01571050|DRUG|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
41156975|NCT04783519|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
41340673|NCT00723853|BEHAVIORAL|Reach-Out Program, nutritional and exercise program|"This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise."
41340674|NCT00723853|BEHAVIORAL|Reach-In Program, standard of care|This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
41340675|NCT04723004|COMBINATION_PRODUCT|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Bevacizumab 15mg/kg, IV infusion, every 3 weeks (q3w), Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
41340676|NCT04723004|DRUG|Sorafenib|"Control group:~Sorafenib 400mg, po, Bid, continuous administration, until occurrence of termination event specified in the protocol."
41340677|NCT04143425|DIAGNOSTIC_TEST|3-Tesla conventional magnetic resonance imaging|T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
41340678|NCT04143425|DIAGNOSTIC_TEST|Advanced imaging without contrast use|Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
41340679|NCT04143425|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-weighted imaging|Cerebral blood volume and vessel architectural imaging parameters
41340680|NCT03527186|DRUG|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
41487744|NCT06195696|BEHAVIORAL|employs questionnaires|The first phase is a quantitative study that employs a questionnaire to investigate the current state of illness perception and the distribution of coping styles in kidney transplant recipients, and to explore the differences in illness perception between positive coping and negative coping patients after kidney transplantation; The second phase involves a descriptive qualitative study that utilizes face-to-face, semi-structured, in-depth interviews to investigate the causes of differences in illness perceptions of different coping styles in kidney transplant recipients who experience idiosyncrasies.
41487745|NCT03626506|DRUG|Spironolactone|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.
41487746|NCT03626506|DRUG|Indapamide|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.
41487747|NCT03626506|DRUG|Amlodipine|After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.
41487748|NCT02884349|PROCEDURE|RoM assessment|This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
41340681|NCT03456180|DEVICE|Haemoadsorption with Cytosorb cartridge|microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
41487749|NCT04710966|PROCEDURE|arthroscopic debridement|For the arthroscopic debridement, only stump refreshing and surrounding soft tissue cleaning were performed.
41340682|NCT00395616|DRUG|Botox (drug)|
41487750|NCT04710966|PROCEDURE|arthroscopic repair|For the arthroscopic repair, we converted partial tears into full-thickness tears and sutured them.
41487751|NCT00792870|BEHAVIORAL|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
40821571|NCT01571050|DRUG|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
40821572|NCT01571050|DRUG|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
40821573|NCT01571050|DRUG|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
40821574|NCT05290987|DEVICE|nasal spray|2 sprays in each nostril, 6 times a day
41340683|NCT04142944|DEVICE|Dexcom G6 with alert|Dexcom G6 CGM device with the predictive hypoglycaemia alert function
41340684|NCT04142944|DEVICE|Dexcom G6 without alert|Dexcom G6 CGM device without the predictive hypoglycaemia alert function
41340685|NCT00247273|DRUG|risedronate|tablet, 5 mg risedronate, once a day for 2 years
41340686|NCT00247273|DRUG|risedronate|oral, 150 mg risedronate, once a month for 2 years
41340687|NCT05286567|DRUG|RGRN-305|Heat shock protein 90 inhibitor
41340688|NCT05286567|DRUG|Placebo|Placebo (blinded)
41340689|NCT01821885|BEHAVIORAL|Spirometry and a brief advice to quit smoking|During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
41340690|NCT01821885|BEHAVIORAL|Brief advice to quit smoking|During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
41340691|NCT06263725|OTHER|Restricted dietary protein|Participants will be allocated to 5 week isocaloric restricted protein intake
41340692|NCT06263725|OTHER|Habitual diet|Participants will be follow their habitual, high protein intake
41340693|NCT01040728|DRUG|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
41340694|NCT01040728|DRUG|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
41487752|NCT03335293|DRUG|100 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
41487753|NCT03335293|OTHER|normal saline|placebo comparator
40821575|NCT02413736|DRUG|Imatinib|Imatinib 400 mg/day
41487754|NCT03335293|DRUG|200 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
40821576|NCT03995680|DRUG|Mebendazole|Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
40821577|NCT03717792|OTHER|no intervention|no intervention
40821578|NCT02780856|DEVICE|Imaging with the Calcivis System|Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black \& white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
40821579|NCT05413265|BEHAVIORAL|Phases 1 and 2|Phase 1 participants will help inform the cultural adaptation of the study design and materials. Phase 2 will enroll 10 dyads (20 individuals) of AN/AI people who smoke and a family member. Dyad participants will help beta-test the feasibility and acceptability of the financial incentives intervention.
40821580|NCT04086368|DEVICE|Adolescent Lateral Entry Femoral Nail|The use of an less invasive implant that has the same accuracy.
40821581|NCT04086368|DEVICE|Pediatric LCP Hip Plate System|Open approach to the femur where the osteotomy and osteofixation with plate and screws are preformed
40821582|NCT01080768|DRUG|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
40821583|NCT01080768|DRUG|Amlodipine|Amlodipine 5 mg/day.
41340695|NCT01040728|DRUG|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
41340696|NCT01040728|DRUG|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
41340697|NCT01040728|DRUG|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
41340698|NCT01069809|BIOLOGICAL|AGS-004|HIV-1 Immune Therapy
41340699|NCT01069809|BIOLOGICAL|Placebo|Inactive Placebo Injection
41340700|NCT01838304|DEVICE|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
41340701|NCT01838304|DEVICE|Monitoring|Manual recording of drug doses determined by CRNA
41340702|NCT02816476|DRUG|Daratumumab|
41340703|NCT05380908|OTHER|None of any intervention|The patients did not have any intervention.
41340704|NCT00417833|DRUG|Intravitreal Bevacizumab|
41340705|NCT02940860|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
40821584|NCT01080768|DRUG|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
40821585|NCT01080768|DRUG|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
40821586|NCT00621556|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
40821587|NCT04507451|PROCEDURE|inspiratory and expiratory muscle training|inspiratory muscle training using threshold IMT device expiratory muscle training using a bottle filled of water
40821588|NCT04507451|PROCEDURE|inspiratory and expiratory exercises|inspiratory exercise using fractionated inspirations expiratory exercise using a bottle filled with water at a minimum level
40821589|NCT06606145|PROCEDURE|Lymphovenous Anastomosis|LVA involves connecting functional lymphatic vessels to nearby veins, allowing for the rerouting of lymphatic fluid into the venous system, thus improving lymphatic drainage.
41340706|NCT02940860|DRUG|Iron sucrose|Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
40821590|NCT06606145|PROCEDURE|Vascularized Lymph Node Transfer|VLNT involves transferring healthy lymph nodes along with their blood supply to the affected lymphoedematous area, aiding in lymphatic fluid transport and potentially promoting lymphangiogenesis.
41340707|NCT03401476|DRUG|Morphine Sulfate|Morphine Sulfate Tablets
41340708|NCT06229210|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
41340709|NCT03352869|DRUG|Exenatide|Use Exenatide for 3 months to treat PCOS
41340710|NCT03352869|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
41340711|NCT04816292|PROCEDURE|Active Comparator: Hot Snare Polypectomy|Hot Snare Polypectomy with the use of electrocautery for the resection of polyps.
40821591|NCT06606145|PROCEDURE|Combined Lymphovenous Anastomosis and Vascularized Lymph Node Transfer|Combined simultaneous surgical intervention during which both VLNT and LVA are performed on the operated limb.
40821592|NCT06606145|PROCEDURE|Complex Decongestive Therapy|The current standard of care for most BRCL patients includes conservative measures known as Complex Decongestive Therapy (CDT), consisting of compression therapy with low-stretch bandages, manual lymphatic drainage, exercise, and skincare.
40821593|NCT02871713|OTHER|Bilateral Quadratus lumborum block with 0.5% ropivacaine|Bilateral Quadratus lumborum block with 0.5% ropivacaine
40821594|NCT02871713|OTHER|Intrathecal Morphine with 100 mcg morphine|Intrathecal Morphine with 100 mcg morphine
40821595|NCT00727142|PROCEDURE|Surgical treatment|Insertion of a functioning shunt
40821596|NCT04601428|BIOLOGICAL|IA therapy of HCC with CSR02-Fab-TF|Intra-Arterial Infusion of CSR02-Fab-TF
40821597|NCT04899258|PROCEDURE|Femtosecond laser assisted LASIK|Refractive surgery
41340712|NCT04816292|PROCEDURE|Experimental: Cold Snare Polypectomy|Cold Snare Polypectomy without the use of electrocautery for the resection of polyps.
41340713|NCT03369210|DRUG|red blood cell transfusion trigger|patients receive a RBC unit with different target ranges for the post-transfusion Hb levels
40821598|NCT05785533|OTHER|Smartphone App|App that provides recovery guidance based on pain and functional outcomes
40821599|NCT05785533|OTHER|Standard of Care|Paper based discharge instruction that provide information on pain management
41340714|NCT05795257|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
41340715|NCT04572698|DRUG|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
41340716|NCT04572698|DRUG|Eylea|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
41340717|NCT00633893|DRUG|Apixaban|Tablets, Oral, twice daily, 12 months
41340718|NCT00633893|DRUG|Placebo|Tablets, Oral, twice daily, 12 months
41487755|NCT03483168|BEHAVIORAL|Culturally sensitive pain education|The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.
41340719|NCT01961102|PROCEDURE|hysteroscopy/curettage in case of suspicious aspect will be done a rapid section|
41340720|NCT00628342|DRUG|Esomeprazole|20mg Oral tablet once daily
41340721|NCT00628342|DRUG|Esomeprazole|40mg Oral tablet once daily
41487756|NCT03483168|BEHAVIORAL|Standard pain education program|"For the standard translated PNE, The English translation of Pain Neuroscience Education: slides for supporting and illustrating your explanation at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators."
41487757|NCT01099527|DRUG|Everolimus (RAD001)|dose escalation of capecitabine, everolimus
41340722|NCT00628342|DRUG|Placebo|Oral once daily
41340723|NCT02032186|DRUG|Magnesium citrate|Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
41340724|NCT02151799|PROCEDURE|Abdominoplasty and liposuction|
41340725|NCT06032572|PROCEDURE|VRS100 robotic-assisted PCI|The VRS100 is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
41340726|NCT06032572|PROCEDURE|Manual PCI|Use the traditional technique of manually advancing intracoronary guidewires, balloons, and stents at the patient's tableside.
41487758|NCT01099527|DRUG|Capecitabine|dose escalation of capecitabine, everolimus
41487759|NCT01509742|DRUG|liraglutide|Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
41487760|NCT01509742|DRUG|placebo|Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
41487761|NCT03817801|DEVICE|NSE balloon|NSE (Goodman®) predilation + DCB (Sequent® Please) treatment
41340727|NCT05153564|DRUG|Semaglutide 1.34 mg/mL|Semaglutide will be administered at a dose of 0.25, 0.50 or 1.0 mg as indicated on scale drum once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
41487762|NCT03817801|DEVICE|NC balloon|NC balloon predilation + DCB (Sequent® Please) treatment
41487763|NCT03573505|DRUG|BG00011|Administered as specified in the treatment arm.
41487764|NCT03573505|DRUG|Placebo|Administered as specified in the treatment arm.
41340728|NCT05153564|DRUG|Semaglutide 3.0 mg/mL|Semaglutide will be administered at a dose of 2.0 mg corresponding to the increment of 67 (pen injector units) as indicated on scale drum. once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
41340729|NCT05153564|DRUG|NNC0480-0389 10 mg/mL|NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.
41340730|NCT05153564|DRUG|NNC0480-0389 30 mg/mL|NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.
41340731|NCT05153564|DRUG|Microgynon®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
41340732|NCT02663947|DEVICE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
41340733|NCT00821899|BIOLOGICAL|administration of autologous bone marrow blood|administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
41340734|NCT02233582|DRUG|Ibuprofen|We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
41340735|NCT02233582|DRUG|Sugar pill|
41487765|NCT00700609|BEHAVIORAL|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
41487766|NCT04430855|DRUG|Upadacitinib|Tablet; Oral
41487767|NCT04430855|DRUG|Placebo|Tablet; Oral
40821600|NCT03201042|DIAGNOSTIC_TEST|PCR based assay|"Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined.~In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen)."
40821601|NCT03201042|DIAGNOSTIC_TEST|Serology based assay|"1. The Imugen Lyme Antibody Analysis which includes immunoglobulin M (IgM),immunoglobulin G (IgG), and immunoglobulin A (IgA) antibody capture immunoassay and IgG and IgM based Western blots. In Cohort 1a and 1b.~2. The Immunetics C6 Lyme ELISA assay.~3. A 2-tier Lyme test performed and interpreted according to Centers for Disease Control (CDC) Guidelines~4. A Rickettsia antibody test will be used to identify Spotted Fever and Typhus fever groups infections.~Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared."
40821602|NCT03201042|DIAGNOSTIC_TEST|Tcell based assay|A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis.
40821603|NCT01432145|DRUG|6-Mercaptopurine|6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.
40821604|NCT01432145|DRUG|Methotrexate|Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
40821605|NCT04696367|PROCEDURE|Emergency laparotomy|Midline laparotomy for acute intra-abdominal pathology
40821606|NCT03865108|PROCEDURE|Ultrasound imaging|This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
40821607|NCT03865108|PROCEDURE|Cervical speculum examination|This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
40821608|NCT04929925|DIAGNOSTIC_TEST|serum procalcitonin in acute bacterial meningitis|Serum Procalcitonin estimation will be done by Cobas e411Roch diagnostic,Switzerland apparatus by immunoassay method (electrochemiluminescence immunoassay) by using sample serum or plasma heparin or EDTA with reference range less than 0.5ng/ml ( no sepsis) but 0.5-2ng/ml)follow up is recommended) and more than 2 (sepsis)
40821609|NCT06604975|PROCEDURE|Measure of Basal Copeptin level|"Copeptin test is performed after solid fasting since midnight without water restriction. After blood collection on heparin tube used for biological inclusion criteria, heparinized plasma is transferred to Timone University hospital (transport temperature +4°C) for screening copeptin assay.~The basal copeptin level determines the next step:~1. copeptin ≥ 30 pmol/L defines the diagnosis of NDI and results in a specific care;~2. copeptin \&lt; 30 pmol/L defines the group of eligible patients for arginine stimulation"
40821610|NCT06604975|PROCEDURE|Measure of arginine-stimulated copeptin|The arginine-stimulated copeptin test start at 8 am, after solid fasting since midnight without water restriction, and 30 min of rest in decubitus position. A dose of 0.5 g/kg of arginine (maximum 40g) diluted in 0.9% NaCl is infused over 30 min through a peripheral venous line. Copeptin is measured at T0 (before infusion), T45, T60, T90, and T120 min after infusion.
40821611|NCT06604975|PROCEDURE|IRM|"Based on our previous study, patients with basal copeptin value over 3.53 pmol/L are considered as positive diagnosis of PP (Se 100%, Sp 87.4%) and cerebral MRI is not performed for this group of patients (PP group).~A cerebral and pituitary MRI performed according to reference procedures (without and with contrast medium used in routine care) for patients considered as an uncertain diagnosis (UD) based on basal copeptin value (\&amp;lt; 3.53 pmol/L). MRI interpretation is performed by two independent neuroradiologists (one from the recruiting center and one from the pilot center). In case of discrepancies, a third independent interpretation will be performed by a neuroradiologist from the coordinating center. Abnormal pituitary MRI (thickened pituitary stalk pituitary tumor, ectopic neurohypophysis, septo-optic dysplasia, empty sellar, Rathke pouch) allows a diagnosis of CDI leading to etiological investigations and AVP treatment."
41156976|NCT04783519|BEHAVIORAL|Brief Alcohol Screening and Intervention for College Students (BASICS)|Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.
41156977|NCT02145195|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
41340736|NCT00446225|DRUG|Erlotinib|"150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib"
41487768|NCT05033574|DIAGNOSTIC_TEST|Biochemical study of hormone levels|Biochemical study of the level of follicle-stimulating hormone, luteinizing hormone, estradiol, total testosterone, prolactin, 17-hydroxyprogesterone, dehydroepiandrosterone sulfate, cortisol, insulin, thyroid-stimulating hormone, tetraiodothyronine, thyr
41487769|NCT05033574|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys
40821612|NCT06604975|BEHAVIORAL|Water reduction at home|Patients with basal copeptin ≥ 3.53 pmol/l (PP group), and UD patients with normal MRI have gradual reduction of water intake at home without AVP treatment : gradual reduction with 20% in the first week, 30% in the second, 40% in the third, reaching 50% of daily fluid in the last week including restriction overnight, deletion drink before sleep. Some recommendations will be provided to help physicians. For all these latest patients, a clinical reassessment (weight, height, heart rate, blood pressure, input/output 24 hours balance) is performed one month later.
40821613|NCT02992951|DEVICE|DACC-Coated Post Operative Dressing|Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.
41487770|NCT05033574|RADIATION|Radiography of the hands|Determination of bone age using radiography of the hands
41340737|NCT00446225|DRUG|Carboplatin|"Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given."
41340738|NCT00446225|DRUG|Gemcitabin|Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
41340739|NCT00446225|DRUG|Docetaxel|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
41487771|NCT05033574|BEHAVIORAL|Consultation of a medical psychologist|Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence
41487772|NCT05607641|DRUG|Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets|"These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day."
41487773|NCT05607641|DRUG|Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets|"These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day."
41487774|NCT05607641|DRUG|Neospastil, solution for injection then Neospastil, film-coated tablets|"These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).~Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day."
40821614|NCT06404372|DEVICE|Demetech Barbed PDO Suture|The Demetech Barbed PDO Suture will be used for the correction of midface wrinkles in all patients enrolled in this study.
40821615|NCT02648997|DRUG|Nivolumab - 240 mg|240 mg every 2 weeks
40821616|NCT02648997|DRUG|Ipilimumab - 1 mg/kg|1 mg/kg every 3 weeks
40821617|NCT02648997|DRUG|Nivolumab - 480 mg|480 mg once every 4 weeks
41156978|NCT00207298|PROCEDURE|Positron Emission Tomography|Each patient will receive an 18F-FDG PET/CT scan
41340740|NCT00446225|DRUG|Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
41340741|NCT04536493|DRUG|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)|1 application of LET topical anesthetic gel
41340742|NCT04536493|DRUG|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)|3 applications of LET topical anesthetic gel
41340743|NCT02394262|RADIATION|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
41340744|NCT02394262|OTHER|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
41340745|NCT04071808|DIAGNOSTIC_TEST|ELISA Test|The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.
41340746|NCT03526692|BEHAVIORAL|Neurofeedback|Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.
40821618|NCT02648997|DRUG|Nivolumab - 3 mg/kg|3 mg/kg every 3 weeks
40821619|NCT02648997|RADIATION|External Beam RT|IMRT, 3D-CRT, or proton-beam radiation therapy
40821620|NCT04765423|DEVICE|[F-18] NaF PET/CT|Radiotracer F-18 NaF used on the PET/CT imaging
40821621|NCT04765423|DEVICE|[F-18] fluciclovine PET/CT|F-18 fluciclovine (Axumin ®) used on the PET/CT camera
41340747|NCT04904536|DRUG|Atorvastatin|40mg atorvastatin + standard care daily for 12 months.Atorvastatin 40mg has TGA approval for general marketing for the treatment of hypercholesterolaemia and cardiovascular prevention under a number of manufacturer names.The study medication selected will be the atorvastatin 40mg (Apotex) which is scored, and allows down-titration to 20mg should a participant develop symptoms.The study medication will be packaged, labelled and dispensed directly to particpants by the Syntro Health pharmacy in Australia. A comparable atorvastatin 40mg is being sourced in Chile, and will be dispensed from the pharmacy of the Clínica Alemana de Santiago. Similarly, a comparable atorvastatin 40mg is being sourced in Hong Kong, and will be dispensed from the site's pharmacy.
41340748|NCT04904536|OTHER|Standard Care|Standard care for neurological symptoms as a result of COVID-19 infection.
41340749|NCT00453661|BEHAVIORAL|Questionnaire|"Intervention Group:~Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.~Comparison Group:~Exit Questionnaire only."
41340750|NCT00453661|BEHAVIORAL|Patient Navigator (PN)|Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
41340751|NCT05939193|PROCEDURE|Urine-guided hydration|The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of surgery, with a cumulative dose not exceeding 250 mg. Intravenous rehydration is performed to balance urine output and to maintain the SVV ≤10%.
41340752|NCT05939193|PROCEDURE|Routine hydration|The target is to maintain urine output at 0.5 ml/kg/h or higher according to routine practice. That is, furosemide is only administered when clinically necessary or at discretion of responsible anesthesiologists; intravenous rehydration is performed to maintain the SVV ≤10%.
41340753|NCT05939193|DRUG|Forced administration of furosemide|Forced administration of furosemide
41340754|NCT05939193|DRUG|Routine administration of furosemide|Routine administration of furosemide
41340755|NCT00215189|BEHAVIORAL|In SHAPE (Pilot Health Promotion Intervention)|
41340756|NCT00881140|DRUG|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
41487775|NCT00968292|DEVICE|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
41487776|NCT05808153|RADIATION|radiotracer injection|MRI with radiotracer injection
41340757|NCT04280484|OTHER|Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
40821622|NCT01018472|DIETARY_SUPPLEMENT|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
40821623|NCT01018472|OTHER|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
40821624|NCT03483038|DRUG|Liposomal Irinotecan|Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.
41487777|NCT01781741|COMBINATION_PRODUCT|therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Undergo TEMLA and SBRT
41487778|NCT01781741|OTHER|quality-of-life assessment|Ancillary studies
40821625|NCT03483038|DRUG|FOLFOX regimen|Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
40821626|NCT01077999|DRUG|Carboplatin|Carboplatin AUC = 2 , weekly.
40821627|NCT01077999|DRUG|Paclitaxel|Paclitaxel 50 mg/m2, weekly
41487779|NCT02629913|DEVICE|mementor somnium|
40821628|NCT01077999|DRUG|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
40821629|NCT01077999|RADIATION|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
40821630|NCT05271032|DIAGNOSTIC_TEST|use of Trasnpulmonary termodiluetion technique|All the patients underwent to invasive hemodynamic monitoring through the transpulmonary thermodilution technique (PiCCO, PULSION medical system. Gettinge; Solna, Sweden). Briefly, the technique consists in the administration of a cold saline bolus in superior vena cava while monitoring the corresponding temperature variation through a femoral arterial catheter equipped with a tip thermistor. Accordingly, a 5 French catheter equipped with a tip thermistor was inserted into the femoral artery.
40821631|NCT01637363|BEHAVIORAL|Psychoeducation|6 x 2 hours of psychoeducation
41340758|NCT04280484|OTHER|Sham Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
41340759|NCT00653406|DRUG|Risperidone long acting injectable|
41340760|NCT01120821|DRUG|Gleevec|400 mg once daily for 12 months
41487780|NCT02629913|OTHER|wait list|delayed access to mementor somnium
41487781|NCT01197430|OTHER|exercise training|
40821632|NCT02577770|DEVICE|acupuncture|therapeutic acupuncture treatment with actual needles
40821633|NCT02577770|DIETARY_SUPPLEMENT|200mg caffeine|8g coffee, po
40821634|NCT02577770|DIETARY_SUPPLEMENT|400mg caffeine|16g coffee, po
40821635|NCT02577770|DIETARY_SUPPLEMENT|Decaffeinated|decaffeinated coffee, po
40821636|NCT00998855|BEHAVIORAL|Exercise|12 wk aerobic or/ resistance exercise program
41340761|NCT01100762|DEVICE|Cranial Electric Stimulation (CES)|We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
41340762|NCT01100762|DEVICE|Treadmill|The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
41487782|NCT02571166|BIOLOGICAL|HSV529|Live, Replication-defective HSV-2 virus
40821637|NCT02715024|DRUG|Tamsulosin|Oral
40821638|NCT02715024|DRUG|Solifenacin|Oral
41340763|NCT01100762|DEVICE|CES and Treadmill|Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
41340764|NCT01723176|PROCEDURE|Echocardiography|
41340765|NCT02373566|DEVICE|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
41340766|NCT00095810|DRUG|aripiprazole|Tablets, Oral, 1-10mg, Once daily, 6 weeks.
41340767|NCT05093569|DEVICE|K'watch|Patients
41340768|NCT04915105|DIAGNOSTIC_TEST|Markers data from PBMCs|Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.
41340769|NCT00757367|DRUG|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
41340770|NCT00404638|DRUG|Desmopresin|
41340771|NCT00404638|BEHAVIORAL|Paula Method of Circular Muscle Exercise|
41340772|NCT03692195|DEVICE|WHOOP Strap 2.0|The WHOOP Strap 2.0 is worn on the wrist, continuously throughout the 7-day period of which participants will be assigned. It measures heart rate, sleep, strain, and recovery.
41340773|NCT03692195|OTHER|No Device|The WHOOP Strap 2.0 is not worn on the wrist for a seven day period.
41340774|NCT05291741|DIETARY_SUPPLEMENT|VLCD|Advice regarding VLCD
41487783|NCT02571166|DRUG|Valacyclovir|500 mg orally, once daily for 4 weeks
41487784|NCT03108092|OTHER|STRIP intervention|The STRIP intervention consists of 9 steps: 1. structured history taking of medication 2. recording medication and diagnoses in STRIPA 3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria 4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation 5. shared decision-making with the patient with possible adaptation of the recommendation 6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions) 7. generation of general practioner (GP) report 8. delivery of the report to the patient and to the GP (optional additional direct communication) 9. follow-up
41487785|NCT03108092|OTHER|Control|Standard care in the department where the trial is conducted
41487786|NCT02235038|BEHAVIORAL|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
41487787|NCT02235038|BEHAVIORAL|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
41487788|NCT02235038|BEHAVIORAL|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
41487789|NCT00425334|DRUG|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
41487790|NCT00425334|DRUG|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
40821639|NCT05884112|DEVICE|"MAGSTIM reprtitive Transcranial Magnetic Stimulator (rTMS) System"|iTBS is a new treatment method for depression. It uses the principle of magnetoelectricity to intermittently stimulate local brain nerves. In recent years, domestic and foreign studies have confirmed its efficacy and safety for depression. In addition, research has also It shows that iTBS has better therapeutic effect and efficiency than the previous regular rTMS.
41487791|NCT00001026|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
41487792|NCT00001026|BIOLOGICAL|rgp120/HIV-1IIIB|
41487793|NCT00001026|BIOLOGICAL|rgp120/HIV-1MN|
41487794|NCT00001026|BIOLOGICAL|rgp120/HIV-1 SF-2|
41487795|NCT00001026|BIOLOGICAL|HIVAC-1e|
41487796|NCT00218166|DRUG|GABA Agonists|GABA drugs administered acutely by mouth
41487797|NCT03929549|DEVICE|RCMP titration|An overnight titration polysomnogram with gradual mandibular protrusion and assessment of polysomnographic parameters (i.e. AHI, oxygen saturation, etc.) at various magnitudes of protrusion.
40821640|NCT05884112|DEVICE|sham control|sham control
40821641|NCT01169415|DRUG|Dexamethasone acetate|Participants will receive a protracted (30 days) course of dexamethasone after surgery.
40821642|NCT01169415|DRUG|Dexamethasone|Participants will receive a protracted (14 days) course of dexamethasone after surgery.
40821643|NCT04395638|DIETARY_SUPPLEMENT|3200IU Vitamin D3 per day for 8 weeks|3200IU Vitamin D3 per day for 8 weeks
40821644|NCT04395638|DIETARY_SUPPLEMENT|20,000IU Vitamin D3 per week for 8 weeks|20,000IU Vitamin D3 per week for 8 weeks
41340775|NCT05291741|DIETARY_SUPPLEMENT|Standard care|Standard dietary advice for weight loss before bariatric surgery
41487798|NCT05028049|DRUG|Sufentanil injection|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
41487799|NCT05028049|DRUG|Remifentanil Hydrochloride|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
41487800|NCT05028049|OTHER|plain areas|Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
41487801|NCT05028049|OTHER|plateau areas|Patients should be long staying residents in plateau areas (altitude level\>3000 meters above sea level)
40821645|NCT04801368|DRUG|Randomization of two local anesthetics.|Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
40821646|NCT02448953|PROCEDURE|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
40821647|NCT02448953|PROCEDURE|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
40821648|NCT00003406|DRUG|carboplatin|
40821649|NCT00003406|DRUG|docetaxel|
40821650|NCT00003406|DRUG|ifosfamide|
41340776|NCT06000761|PROCEDURE|Standardized oral Care|One sponge-tipped swab, saturated with sterile water or human milk, will used clean the oral cavity with 15 seconds each area. Surfaces include all 4 quadrants of the gum surface and upper posterior part of the oropharynx. A second swab, with sterile water or milk will be used on the ventral and posterior surfaces of the tongue. A third swab, saturated with sterile water or human milk, will be used to clean the outer surface of any dwelling oral tubes (endotracheal tube, NAVA or feeding tube). Lips will be cleaned with a sterile gauze saturated with sterile water or human milk. Oral cavity will be suctioned as needed with an oral suction devise to remove secretions.
40821651|NCT00003406|PROCEDURE|autologous bone marrow transplantation|
40821652|NCT00003406|PROCEDURE|bone marrow ablation with stem cell support|
40821653|NCT00003406|PROCEDURE|peripheral blood stem cell transplantation|
40821654|NCT03867565|OTHER|Nutritional intervention|Indirect calorimetry Weight development Nitrogen balance Food records Physical activity Nutritional risk screening and assessment Inflammatory response Wound healing as number of days from burn to no more need of dressing changes via health care facility Frequency of infections as the number, sort, dose, and length of antibiotic treatment(s) from burn to no more need of dressing changes via health care facility
40821655|NCT05565573|DRUG|Medroxyprogesterone Acetate 500 MG Oral Tablet|500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate At a dosage of 500 mg/day
41017388|NCT06034821|DEVICE|Electroconvulsive therapy (ECT)|ECT will be given in a standard manner 3 times a week for 4 weeks. The Initial ECT treatment will be Right Unilateral (RUL) ultra-brief pulse at 6x seizure threshold determined during titration at first visit. If there is not satisfactory improvement with RUL the investigator may change to Bilateral (BL) utilizing brief pulse using 0.5 modified half-age method to determine stimulus intensity. The seizure threshold may increase during the course of treatment and the dose of the electric stimulus may need to be increased incrementally. It is suggested to change to bilateral after three to five RUL treatments if response to treatment is not satisfactory. Treatments will be given three times a week for up to 4 weeks.
41156979|NCT06353841|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week in four weeks.
41340777|NCT06048380|DRUG|Ripasudil|"Glanatec Ophthalmic Solution 0.4% W/V with ripasudil hydrochloride hydrate as active ingredient is currently being used by patients with ocular hypertension or open-angle glaucoma.~Inhibition of Rho kinase to facilitate aqueous outflow from the conventional outflow pathway via the trabecular meshwork and Schlemm's canal has been suggested as the IOP-lowering mechanism of action by ripasudil."
41340778|NCT06048380|OTHER|Placebo|Saline eye drops
41487802|NCT06476392|DRUG|Melatonin 10 MG|2 Melatonin tablets (each 5 mg) once daily (egual 10 mg/day) in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 5 mg/day.
41487803|NCT06476392|DRUG|Placebo|2 placebo tablets once daily in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 1 tablet.
41487804|NCT05136118|PROCEDURE|TAPB|TAPB will be given to parturients whether by the modified surgeon assisted approach or by the ultra-sound guided approach.
41487805|NCT03795714|DIAGNOSTIC_TEST|IVUS or OCT and Invasive physiologic indices|IVUS or OCT measurement in order to evaluate the lesion morphology and stent optimization, and invasive physiologic measurement in order to functional significance of epicardial stenosis
41487806|NCT03377764|PROCEDURE|Landmark Technique Control group|Spinal Anesthetic
40821656|NCT05565573|DEVICE|Levonorgestrel-Releasing Intrauterine System|Uterine cavity insertion
40821657|NCT03010891|BEHAVIORAL|The bundle of supportive interventions|usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC \> 45 minutes
41487807|NCT03377764|PROCEDURE|Neuroaxial block using Ultrasound Guidance|Ultrasound guided Spinal Anesthetic
41487808|NCT01124344|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once Daily, 14 days
40821658|NCT03010891|BEHAVIORAL|Usual NICU care|usual NICU care + positioning + gentle touch +routine KMC \< 20 minutes
40821659|NCT04538235|PROCEDURE|Thoracic Regional Analgesia|In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
40821660|NCT01212497|BEHAVIORAL|Mindfulness meditation coaching|Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
40821661|NCT00803257|OTHER|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
40821662|NCT05181774|DIAGNOSTIC_TEST|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
41156982|NCT04611724|DRUG|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
41156983|NCT03714997|PROCEDURE|Walking training|Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
41340779|NCT01952613|DEVICE|FES|In phase 1, five subjects (randomly chosen) will be provided the FES device and instructed to use it for ambulation for the 6 months. At the baseline visit, gait data will be collected from this group. On the 6 month follow up visit, same data collection procedure will be performed and the devices will be collected back from the subjects. After performing quality check on these devices, phase 2 of the data collection will start by providing the devices to the other five subjects and their baseline data will be collected.
40821663|NCT05181774|DIAGNOSTIC_TEST|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
40821664|NCT03867786|BEHAVIORAL|Exercise|Participants will complete an acute exercise visit.
40821665|NCT03867786|BEHAVIORAL|Video Control|Participants will complete a video control visit.
40821666|NCT03760757|DIETARY_SUPPLEMENT|ESPO-572®|ESPO-572® is the same as PCSO-524®, except it has krill oil added to it.
40821667|NCT03760757|DIETARY_SUPPLEMENT|PCSO-524®|PCSO-524® (Lyprinol®/Omega XL®) is a nutritional supplement containing a patented extract of highly condensed form of stabilized marine lipids from the New Zealand green lipped mussel (Perna canaliculus) that is combined with olive oil and vitamin E. This marine oil lipid and omega-3 polyunsaturated fatty acid (PUFA) blend is a diverse mixture of sterol esters, sterols, polar lipids, triglycerides, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (split between the triacylglycerol and polar lipid classes), and free fatty acids.
40821668|NCT03373890|BEHAVIORAL|Short Burst Interval Locomotor Treadmill Training (SBLTT)|SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
40821669|NCT05544292|OTHER|Antiinflammatory/DMARDs|Antiinflammatory/DMARDs
40821670|NCT06345482|DRUG|MHB039A|a bispecific antibody
41017389|NCT06311994|DEVICE|Virtual reality|"Factors that may affect patient compliance with the VR-based intervention method to be applied to patients undergoing knee surgery and the factors that may affect the measurements to be performed were evaluated through a literature review and inclusion and exclusion criteria were created."
41340780|NCT00116194|BEHAVIORAL|Physical Activity|
40821671|NCT00156988|DRUG|cerium nitrate-silver sulfadiazine (cerium-flamazine)|
40821672|NCT03650101|PROCEDURE|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.
40821673|NCT06578416|DIAGNOSTIC_TEST|Standardized assessments of speech and language abilities|Standardized and observational assessment of speech and language abilities
41156984|NCT05102760|PROCEDURE|Nerve Block using FIC Proceedure|Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure
41156985|NCT05102760|PROCEDURE|Nerve Block using PENG Proceedure|Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure
41156986|NCT00027963|DRUG|gabapentin|
41156987|NCT00027963|OTHER|placebo|
40821674|NCT06193408|DRUG|VR-AD-1005|oral capsule
40821675|NCT06193408|DRUG|Placebo|oral capsule
40821676|NCT00969761|DRUG|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
40821677|NCT00969761|DRUG|BI 6727|low to high dose
40821678|NCT00195520|DRUG|Totelle®|
41156988|NCT06575998|OTHER|Training|A 4-hour training for PCPs consisting of an onsite training, an e-learning and a webinar on the treatment of insomnia.
41340781|NCT05400369|DRUG|Sitafloxacin|Oral administration, 50 mg tablets
41340782|NCT05400369|DRUG|Moxifloxacin Hydrochloride|Oral administration, 400 mg tablets
40821679|NCT05566431|OTHER|ICP|The intervention is a management protocol that includes ICP monitoring for children with severe traumatic brain injury
40821680|NCT05566431|OTHER|CREVICE|The intervention is a management protocol that is based on imaging and clinical examinations without ICP monitoring for children with severe traumatic brain injury
40821681|NCT00631150|DRUG|Levetiracetam (Keppra)|
41017390|NCT04596852|DEVICE|Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch|"Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability."
41017391|NCT02028299|PROCEDURE|2D doppler echo with Definity solution|Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
41017392|NCT01258205|DRUG|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
41156989|NCT06575998|OTHER|Pro-active identification|Pro-active identification of patients with clinical insomnia symptoms. Patients receiving care from the participating practices will be asked to fill-out the Insomnia Severity Index (ISI).The ISI is used to identify patients with clinical insomnia symptoms in the general practice. Trained practices will receive feedback on the ISI for half of the patients with clinical symptoms according to the ISI.
41156990|NCT06623240|BIOLOGICAL|allogeneic Hope Biosciences adipose-derived mesenchymal stem cells|"Product: Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)~Dose determined by body weight:~* 50 million cells in 50mL saline: \&gt; 10 kg to \&lt; 22 kg~* 100 million cells in 100mL saline: \&gt; 22 kg to \&lt; 45 kg~* 200 million cells in 250mL saline: \&gt; 45 kg Route: Intravenous Regimen: Weeks 0, 4, and 8 (Group AB) or Weeks 20, 24, and 28 (Group BA)"
41156991|NCT06623240|OTHER|Normal Saline Solution 0.9%|Product: Normal Saline Solution 0.9% Route: Intravenous Regimen: Weeks 0, 4, and 8 (Group BA) or Weeks 20, 24, and 28 (Group AB)
41156992|NCT05079958|BEHAVIORAL|cognitive-behavioral education|four-week cognitive-behavioral education course
41156993|NCT05079958|BEHAVIORAL|12-week brisk walking|12-week brisk walking
41340783|NCT06283134|BIOLOGICAL|BioTTT001 hepatic artery infusion|"BioTTT001 monotherapy period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, administered every 2 weeks, for a total of two doses after enrollment.~BioTTT001 in combination with toripalimab and regorafenib period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, D2 and D16, 4 weeks per cycle， and the dose of BioTTT001 will be determined according to the safety observation results in the monotherapy phase."
40821682|NCT06599710|DIETARY_SUPPLEMENT|AndoSanTM|Fermented water-based exctract of Agaricus subrufesence, Hericum erinacus, and Grifola frondosa
40821683|NCT01778335|PROCEDURE|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
41340784|NCT06283134|DRUG|toripalimab|BioTTT001 in combination with toripalimab and regorafenib period: toripalimab 80mg intravenous D1 and D15, 4 weeks per cycle.
40821684|NCT06606860|DRUG|Oxantel Pamoate|Oxantel Pamoate tablet, 250mg
41340785|NCT06283134|DRUG|regorafenib|BioTTT001 in combination with toripalimab and regorafenib period: regorafenib 80 mg oral administration, D1-D21, 4 weeks per cycle.
41340786|NCT03285893|OTHER|oral cell DNA adducts|oral cells will be collected, DNA isolated, and analyzed for adducts
41340787|NCT02826655|DEVICE|WF-AO-OCT|WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
41340788|NCT00289614|DRUG|Iopamidol 370 mgI/dL|
40821685|NCT06606860|DRUG|Placebo|Placebo tablet
40821686|NCT05045742|OTHER|Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2|We will retrospectively compare the alarms produced from traditional vital sign alarms (thresholds set by clinicians) versus the BioVitals Index vs the National Early Warning Score 2
40821687|NCT00908869|DRUG|Vinorelbine, Cyclophosphamide and Interferon alpha 2b|"Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week ."
40821688|NCT05840770|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41017393|NCT03804229|DRUG|Butylphthalide soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills(100mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
41487809|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 3 mg, Once Daily, 14 days
41017394|NCT03804229|DRUG|Placebo soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
41017395|NCT01469676|DEVICE|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
41156994|NCT04286893|DIAGNOSTIC_TEST|Flow mediated vasodilatation|Measurement of brachial artery diameter change before and after limb ischaemia.
41156995|NCT04286893|DIAGNOSTIC_TEST|High resolution ECG|Measurement HRV using high resolution ECG
41156996|NCT04286893|DIAGNOSTIC_TEST|Blood withdrawal|Measurement of endothelial inflammation markers
41156997|NCT06127966|PROCEDURE|Erector Spinae Plane Block|The patient assumes a prone position, and the appropriate lumbar vertebral level is identified using ultrasound, based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is placed in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process and the overlying erector spinae and latissimus dorsi muscles. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process and there is no blood or gas upon aspiration, 2-3 mL of isotonic saline solution is injected to confirm the correct needle position. Local anesthetic is then injected between the erector spinae muscle and the transverse process. The spread of the local anesthetic in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
41340789|NCT01712776|DEVICE|Vapocoolant (Pain Ease)|Topical stream 4-10 seconds duration to skin.
41340790|NCT01712776|DEVICE|Nature's Tears Sterile Water|Topical stream 4-10 seconds duration to skin
41340791|NCT02861118|OTHER|No Intervention|
41487810|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 10 mg, Once Daily, 14 days
40821689|NCT05840770|BIOLOGICAL|Cemiplimab|Given IV
40821690|NCT05840770|PROCEDURE|Computed Tomography|Undergo CT scan
40821691|NCT05840770|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
40821692|NCT05840770|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40821693|NCT06353256|BEHAVIORAL|usual postpartum care|Usual clinical and educational postpartum care
41340792|NCT01229280|DRUG|Darifenacin|Single dose 7.5 mg tablets of darifenacin
41340793|NCT01229280|DRUG|Darifenacin|Single dose 7.5 mg tablets of Darifenacin
41487811|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 30 mg, Once Daily, 14 days
41487812|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 45 mg, Once Daily, 14 days
41487813|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 60 mg, Once Daily, 14 days
41487814|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 90 mg, Once Daily, 14 days
41487815|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
41487816|NCT05887895|DRUG|INS062 injection、INS068 injection、HR20014 injection|"INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects."
40821694|NCT06353256|BEHAVIORAL|usual postpartum care + community health worker intervention|participants will receive routine care and also community health worker support and visits.
41340794|NCT04258293|DIAGNOSTIC_TEST|Blood sampling|fasting venous glycemia, venous glycemia after sugar loading, glycated hemoglobin and platelet count
41340795|NCT02225236|BEHAVIORAL|Classroom Intervention|
41340796|NCT02253394|DRUG|Ambrisentan plus Spironolactone|Cardiopulmonary fitness
41340797|NCT02253394|DRUG|Ambrisentan plus Placebo|Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
41340798|NCT05445336|BEHAVIORAL|PREVENT Program|PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.
41340799|NCT02187224|DRUG|Progesterone|
41340800|NCT02187224|DRUG|Placebo (for Progesterone)|
41340801|NCT05267938|DRUG|Topical Anesthetic|The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa
41340802|NCT05267938|DRUG|Local anesthetic|After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
41340803|NCT01819194|DEVICE|senofilcon A|
41340804|NCT02970539|DRUG|Oraxol|Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.
41340805|NCT02970539|DRUG|Ramucirumab|Ramucirumab will be administered by iv infusion and supplied as a solution at a concentration of 10 mg/mL
41340806|NCT02650167|BIOLOGICAL|Colostrum feeding|
41340807|NCT02650167|BIOLOGICAL|formula for preterm infants|
41340808|NCT03822780|DRUG|Hydroxychloroquin|Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg\*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg\*d to 10mg/kg\*d, p.o., bid ; the maximum daily dose is 400mg.
41340809|NCT01319045|DRUG|Iloprost|Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
41340810|NCT00111891|DRUG|niacin (+) laropiprant|
41340811|NCT00111891|DRUG|Comparator: placebo (unspecified)|
41487817|NCT04736043|OTHER|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as adjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate adjuvant chemotherapy after surgery, thus developing a platform to predict the outcomes of each patient.
41340812|NCT01340404|PROCEDURE|Stem cell transplantation|Stem cell transplantation
41340813|NCT01340404|PROCEDURE|Transfusion program|Transfusion program
41340814|NCT03587467|OTHER|collect fecal specimens|collect fresh fecal specimens of participants
41340815|NCT00002146|DRUG|Magnesium sulfate|
41340816|NCT00002146|DRUG|Foscarnet sodium|
41340817|NCT04371185|DRUG|BAT2206|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
41340818|NCT04371185|DRUG|Stelara(US-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
41340819|NCT04371185|DRUG|Stelara(EU-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
41340820|NCT00067444|DRUG|Paroxetine CR|
41340821|NCT00863941|DRUG|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
41340822|NCT00863941|DRUG|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
41340823|NCT05320536|DRUG|Guilingji Capsule|This medicine is capsule medicine, take method is oral.
41340824|NCT05320536|DRUG|Placebo|This medicine is capsule medicine（Placebo）, take method is oral.
41340825|NCT06370949|DRUG|Bupivacain|Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain
41340826|NCT06370949|DRUG|bupivacain+dexmedetomidine|Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
41340827|NCT05136040|DRUG|Bupivacaine|Two Different Low-Doses Of Isobaric Bupivacaine ( Group İzobarik bupivakain (5 mg) + fentanil and Group İzobarik bupivakain (7 mg)+ fentanyl ) were administered to the subarachnoid space
41340828|NCT04883697|OTHER|vitrectomy with ILM peeling and ILM flap technique|outcomes after vitrectomy with ILM peeling and ILM flap technique for macukar hole repair are assessed
41340829|NCT02275910|DRUG|E7090|
41487818|NCT02583386|BEHAVIORAL|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
41340830|NCT03444467|DRUG|NNC9204-1513|"Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
41340831|NCT03444467|DRUG|Glucagon|Participants will receive single dose of 1 mg glucagon s.c. injection.
41340832|NCT03444467|DRUG|Placebo|Participants will receive single dose of placebo (for double dummy injections).
41340833|NCT02855086|BIOLOGICAL|Cetuximab|Administered intravenously (IV)
41340834|NCT02855086|DRUG|Cetuximab-IRDye 800CW|Administered intravenously (IV)
41340835|NCT02855086|PROCEDURE|Tumor resection|Standard of care treatment
41340836|NCT01813968|PROCEDURE|Ischemic postconditioning|
41340837|NCT00460525|BIOLOGICAL|FMP2.1/AS02A|3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
41340838|NCT00460525|BIOLOGICAL|Rabies Vaccine|White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
41340839|NCT00479167|DRUG|Bortezomib and Tositumomab I-131|
41340840|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered orally once on Day 1 and Day 9, respectively
41340841|NCT05063968|DRUG|Placebo|Tablet is administered orally once on Day 1 and Day 9, respectively
41487819|NCT02583386|OTHER|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
41487820|NCT01247246|DRUG|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
41487821|NCT01247246|DRUG|Placebo|Placebo
41487822|NCT00798876|DIETARY_SUPPLEMENT|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
41487823|NCT00798876|DIETARY_SUPPLEMENT|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
41340842|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered fasted orally once on Day 1
41340843|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered after a high-fat meal orally once on Day 9
41340844|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered orally once daily for 14 Days continuously
41340845|NCT05063968|DRUG|Placebo|Tablet is administered orally once daily for 14 Days continuously
41340846|NCT02320240|DRUG|Duloxetine|Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
41340847|NCT02320240|DRUG|Venlafaxine|Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
41340848|NCT02320240|DRUG|Desvenlafaxine|Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
41340849|NCT02320240|DRUG|Citalopram|Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
41340850|NCT02320240|DRUG|Escitalopram|Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
41340851|NCT02320240|DRUG|Fluoxetine|Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
41340852|NCT02320240|DRUG|Fluvoxamine|Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
41340853|NCT02320240|DRUG|Paroxetine|Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
41340854|NCT02320240|DRUG|Sertraline|Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
41487824|NCT00798876|DIETARY_SUPPLEMENT|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
41340855|NCT00725829|DRUG|simvastatin|Simvastatin 40mg/d
41340856|NCT00725829|DRUG|ezetimibe|ezetimibe 10mg/d
41487825|NCT00798876|DIETARY_SUPPLEMENT|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
41487826|NCT00798876|OTHER|Medical Examination|Subjects will have a routine medical exam.
41487827|NCT00798876|OTHER|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
41487828|NCT00798876|OTHER|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
41487829|NCT00798876|PROCEDURE|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
41487830|NCT02603393|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
41487831|NCT02603393|DRUG|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
41487832|NCT02603393|DRUG|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
41487833|NCT00033124|BEHAVIORAL|Behavior Therapy|
41487834|NCT02072148|PROCEDURE|PET/CT|PET scan or CT scan q 4 months for 5 years
41487835|NCT02072148|RADIATION|Radiotherapy|Postoperative XRT 5000 cGy
41487836|NCT02072148|RADIATION|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5000 cGy"
41487837|NCT02072148|RADIATION|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5600 cGy"
41487838|NCT01222286|DRUG|IPH2101|0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
41487839|NCT02431182|BEHAVIORAL|Memory Training Workshop|"1. Presentation of the workshop: Objectives and Methodology~2. Explanation of the different types of memory and its implication in normal life~3. Strategies for gathering and codification of the information~4. Strategies for selection and storage the information~5. Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory~6. Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences~7. Strategies for recuperation according to the individual profile. Improving self-esteem~8. Strategies for recuperation Social skills.~9. Personal and social skills~10. New contexts and opportunities~11. Evaluation of the workshop"
41340857|NCT00725829|DRUG|placebo|placebo
41340858|NCT00516958|DRUG|Topical Dermacyn|Topical Dermacyn once a day for 10 Days
41340859|NCT00516958|DRUG|Topical Dermacyn and Levofloxacin|Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
41340860|NCT00516958|DRUG|Topical Saline and Levofloxacin|Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
41340861|NCT03395067|BEHAVIORAL|Intervention group|Lifestyle counseling coupled with psychotherapeutical intervention
41340862|NCT00552344|BIOLOGICAL|Cimzia|"* Active substance: Certolizumab Pegol~* Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous use"
41340863|NCT00776191|DRUG|Physioneal 35|Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
41340864|NCT00776191|DRUG|Physioneal 40|Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
41340865|NCT00255606|DRUG|docetaxel|Given in 3- or 4- week courses
41340866|NCT00255606|DRUG|prednisone|Given in 3- or 4- week courses
40821695|NCT04465032|OTHER|Gut microbiome transplantation|Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
40821696|NCT03130387|DEVICE|Office Hysteroscope|Diagnosis of C.S niche in patients wit AUB by office hysteroscope
40821697|NCT05904028|DRUG|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
40821698|NCT05904028|DEVICE|Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule|Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule
41340867|NCT01744041|BEHAVIORAL|Dyadic Interpersonal Psychotherapy|This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
41340868|NCT01744041|OTHER|Enhanced Treatment as Usual|This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
41340869|NCT04894227|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell）|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
41340870|NCT05683418|DRUG|TOS-358|Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor
41340871|NCT06353204|BEHAVIORAL|Halt-intervention|The Halt-intervention is a Dutch extrajudicial, or diversion, measure for minors (aged 12-17) who committed a minor offence. The intervention can consist of conversations with the Halt-employee, working or learning assignments to learn from the mistakes made or to work on certain skills, such as social skills, and/or apologizing to the victim.
41340872|NCT01525108|BEHAVIORAL|Self monitoring of blood pressure|Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
41340873|NCT01525108|OTHER|Usual Care|Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
41340874|NCT00427167|BIOLOGICAL|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
41340875|NCT00427167|BIOLOGICAL|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
41340876|NCT00427167|DRUG|AMA1-C1/Alhydrogel + CPG 7909|
41340877|NCT04480515|OTHER|in-hospital mortality rate|In-hospital mortality rate during pandemic of 2020 will be compared with the in-hospital mortality rate of the last year's same time period
41487840|NCT03816514|PROCEDURE|SpHb monitoring|Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring
40821699|NCT06605300|DRUG|Intranasal Oxytocin (IN-OXT)|Subject assigned to receive intranasal administration of oxytocin (24 IU).
40821700|NCT06605300|DRUG|Intranasal Vasopressin (AVP)|Subjects assigned to receive intranasal administration of AVP (20 IU).
41340878|NCT03238352|DEVICE|Potassium oxalate|Oral rinse containing 1.5 percent (%) KOX and 0 ppm fluoride
41340879|NCT03238352|DRUG|Sodium fluoride|Oral rinse containing 0.02% weight by weight (w/w) sodium fluoride (NaF)
41340880|NCT03238352|OTHER|Placebo|Oral rinse containing 0% KOX and 0 ppm fluoride
41487841|NCT03816514|PROCEDURE|Conventional management|Conventional management without SpHb monitoring
41487842|NCT03427502|DRUG|Bupivacaine-epinephrine|10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline
40821701|NCT06605300|DRUG|Intranasal Placebo|Subjects assigned to receive intranasal administration of placebo.
40821702|NCT05266872|OTHER|Observational study with sample and data collection|Observational study with sample and data collection
40821703|NCT05055258|DRUG|KVD824|KVD824 300 mg Modified-Release Tablets
41487843|NCT03427502|DRUG|normal saline|normal saline
41487844|NCT00682682|OTHER|Virtual Reality video distraction|"Virtual Reality involves wearing a helmet and playing a game called Snow world. This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are in the game."
41487845|NCT00682682|OTHER|Virtual Reality video game|"Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being in the game. The game used for this study is Snow World"
40821704|NCT05055258|DRUG|Placebo to KVD824|Placebo to KVD824 300 mg Modified-Release Tablets
40821705|NCT03158012|BIOLOGICAL|Autologous Microbial Transplant|Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
40821706|NCT02785458|BEHAVIORAL|EMC2 Strategy|The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
40821707|NCT06272084|DEVICE|Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO|Retrospective Data Analysis of TPE treatments with multiFiltratePRO
40821708|NCT02200328|DRUG|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
40821709|NCT02200328|DRUG|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
40821710|NCT06078202|DRUG|ABBV-903|Tablet; oral
40821711|NCT05058612|DRUG|Midodrine|10 mg PO/NG q8h
40821712|NCT05058612|DRUG|Placebo|Microcrystalline cellulose PO/NG 18h
40821713|NCT05463952|DRUG|vepdegestrant|ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.
40821714|NCT00744978|DRUG|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
40821715|NCT00744978|DRUG|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
40821716|NCT06607523|DIETARY_SUPPLEMENT|Inulin|Inulin, 4g twice daily for 42 days
40821717|NCT05923294|PROCEDURE|Coronally advanced flap with connective tissue graft|In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area.
41340881|NCT05894772|BEHAVIORAL|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the Power over Pain Portal for 4 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference. The overall objective is to determine the implementation (guided by Proctor's implementation conceptual framework) and clinical effectiveness of the PoP Portal in a sample of youth (12-18 years of age) who are on the waitlist for tertiary care consultation at any pediatric CP clinic in Canada.
41340882|NCT03839940|DRUG|Dexamethasone|Given as mouthwash
41340883|NCT03839940|OTHER|Placebo|Given as mouthwash
41340884|NCT03839940|OTHER|Questionnaire|Ancillary studies
41340885|NCT03839940|OTHER|Quality-of-Life Assessment|Ancillary studies
41340886|NCT03839940|DRUG|Everolimus|Standard of care
41340887|NCT04336111|PROCEDURE|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
41340888|NCT05589012|BIOLOGICAL|Cell line and virus|C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
41487846|NCT00968799|PROCEDURE|Hyperthermic intraoperative intraperitoneal chemotherapy|Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.
41487847|NCT00968799|PROCEDURE|Cytoreduction|"Surgical removal of tumor nodules~including resection of organs infested with tumor"
41487848|NCT00968799|DRUG|Cisplatin|Cisplatin is applied as chemotherapy during surgery
40821718|NCT06606743|BEHAVIORAL|High-Intensity Interval Training|Participants will receive a total of 20 in-person sessions of 45 minutes duration. Subjects perform high-speed movements with minimal recovery between movements. Hand weight will be used to increase intensity as training progresses.
40821719|NCT06606743|BEHAVIORAL|High-Velocity Circuit Resistance Training|Participants in this group will perform a total of 20 in-person training sessions using 12 resistance exercises performed in 3 circuits with minimal recovery between exercises.
40821720|NCT05077995|DEVICE|Polar M200|Participants will have to wear the activity monitors (AP and Polar M200) for at least 7 days. Minutes spent in each activity type will be summed to a total day score. Participants will be instructed to do their regular daily life activities without limitation, but to note their main activity categories in an activity diary, with a main focus on cycling and participation in structured exercise.
40821721|NCT06607250|RADIATION|MRI|All enrolled patients underwent multiparametric magnetic resonance imaging, encompassing T2-weighted imaging (T2WI) and magnetic resonance diffusion-weighted imaging (DWI), in the coronal, sagittal, and axial planes.
40821722|NCT01771848|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
40821723|NCT01961284|DEVICE|Zygomatic implant placement|
41487849|NCT01587586|BIOLOGICAL|PEGASYS 180 µg Q1W|48 doses, solution, 48 weeks
41487850|NCT01587586|BIOLOGICAL|P1101 180 µg Q1W, 48 doses|48 doses, solution, 48 weeks
41487851|NCT01587586|BIOLOGICAL|P1101 270µg Q1W, 48 doses|48 doses, solution, 48 weeks
41487852|NCT01587586|BIOLOGICAL|P1101 450µg Q2W, 24 doses|24 doses, solution, 48 weeks
41487853|NCT04648124|DEVICE|IRMf-r (séquence resting state)|Functional MRI of functional brain networks
41487854|NCT00719849|BIOLOGICAL|anti-thymocyte globulin|30mg/Kg Days -6 to -4
41487855|NCT00719849|DRUG|cyclophosphamide|50 mg/Kg Day -6
40821724|NCT01961284|DEVICE|conventional implants and augmentation of maxilla|
40821725|NCT04527874|BEHAVIORAL|VITAL model|"The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening."
41487856|NCT00719849|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
41487857|NCT00719849|DRUG|fludarabine phosphate|40mg/m2 Days -6 to -2
41487858|NCT00719849|DRUG|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
40821726|NCT01480804|OTHER|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
40821727|NCT01862471|DEVICE|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
40821728|NCT01862471|DEVICE|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
40821729|NCT06264219|BIOLOGICAL|Microbiome restoration - FMT|Pathogen-free microbiota from maternal stool sample is transferred from mother to infant.
41487859|NCT00719849|PROCEDURE|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
41487860|NCT00719849|RADIATION|total body irradiation|200 cGy Day -1
40821730|NCT06264219|BIOLOGICAL|Microbiome restoration - FVT|Sterile-filtered and ultracentrifuged FMT, containing only viruses, is transferred from mother to infant.
40821731|NCT06264219|BIOLOGICAL|Placebo|Inactive solution buffer
40821732|NCT06264219|OTHER|Vaginal birth, untreated control|No intervention. This group is for secondary outcomes comparisons.
40821733|NCT06608628|OTHER|Experimental Group|The experimental group students will play a patient safety escape room game. Control group students will be given traditional education. The knowledge level and team cooperation of the two groups will be compared.
40821734|NCT01888731|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
40821735|NCT00551915|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
40821736|NCT00551915|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
40821737|NCT00551915|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
40821738|NCT00551915|BIOLOGICAL|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
40821739|NCT00551915|BIOLOGICAL|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
40821740|NCT02306863|DEVICE|vibrating chair|vibration provided via physioacoustic method
40821741|NCT02306863|DEVICE|sham treatment|simulated whole-body vibration
40821742|NCT06489795|PROCEDURE|Laparoscopic or robot-assisted radical/simple hysterectomy|In the experimental arm, patients with early-stage cervical cancer will be treated by using laparoscopic or robot-assisted radical, or in the case of SHAPE criteria, simple hysterectomy.
40821743|NCT06489795|PROCEDURE|Abdominal radical/simple hysterectomy|In the control arm, patients with early-stage cervical cancer will be treated by using abdominal radical, or in the case of SHAPE criteria, simple hysterectomy as standard therapy.
41487861|NCT06051565|DRUG|Polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.
41487862|NCT02754908|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation.
41487863|NCT02754908|BEHAVIORAL|tutoring classes|They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks).
40821744|NCT03661424|DRUG|HER2 BATs|A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.
40821745|NCT03786302|DRUG|TAMP bioglass|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
40821746|NCT03786302|DRUG|Biodentine|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
41487864|NCT01521039|PROCEDURE|Blood samples|2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
41340889|NCT05589012|BIOLOGICAL|Infection of human placental culture explants|"Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.~Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air."
41340890|NCT05589012|BIOLOGICAL|Determination of viral load in tissues by qRT-PCR|"The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.~Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV."
41487865|NCT03687658|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
41487866|NCT02331368|PROCEDURE|Autologous Stem Cell Transplant|
41487867|NCT02331368|DRUG|Melphalan|140-200 mg/m\^2
40821747|NCT01279629|DRUG|Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).|Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
40821748|NCT02193035|OTHER|Microparticle levels|Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
40821749|NCT01904149|DRUG|Placebo|Placebo single oral dose (first 8 hours)
40821750|NCT01904149|DRUG|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
40821751|NCT01904149|DRUG|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
40821752|NCT01904149|DRUG|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
40821753|NCT01904149|DRUG|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
40821754|NCT01904149|DRUG|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
40821755|NCT01904149|DRUG|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
40821756|NCT06009887|BEHAVIORAL|Motivational Interview|Motivational interviewing is a collaborative speaking style to strengthen one's own motivation and commitment to change. Motivational interviewing is not a technique but a fundamental therapeutic style that does not try to make people change their behavior against their will. Proven to be effective in many areas of healthcare, motivational interviewing is widely used to help people resolve their indecision about change, explore their concerns, and set their own goals. The purpose of the motivational interviews conducted in the study is to increase the belief in normal and natural birth by enabling pregnant women to understand the factors that affect their low belief in normal birth, to take action for change and to believe in change, and to minimize the practices that cause medicalization of birth such as cesarean section by reducing medical birth beliefs.
40821757|NCT06606353|BEHAVIORAL|Talk-To-Jo|"Participation begins with the completion of a socio-demographic questionnaire. Next, participants test the Talk-to-Jo intelligent digital health companion on a tablet: first, a member of the research team explains the tool to the dyad (person with a neurocognitive disorder and their caregiver). The person with the disorder then interacts with Talk-to-Jo, possibly with the help of their caregiver. An observer is present, but does not intervene unless there are questions or technical problems. At the end of the test, health recommendations are given. Questions focus on the participant's memory and depression.~Next, a 30-minute interview is conducted with a member of the research team to gather impressions of the tool, digital skills, barriers and facilitators to using AI, as well as your expectations of Talk-to-Jo.~An additional individual interview can be arranged if required."
40821758|NCT02987907|DRUG|Dexamethasone|use dexamethasone 10mg (2ml) I.A. during TACE
40821759|NCT02987907|DRUG|Normal Saline|use normal saline 2ml I.A. during TACE
40821760|NCT06411977|DIETARY_SUPPLEMENT|Vegetable juice|Vegetable juice (Fa. Fitrabbit, Voglsam)
41340891|NCT01799161|BIOLOGICAL|gp96-Ig Vaccine|
41340892|NCT01799161|DRUG|Theophylline|300 mg capsule daily of Theophylline during 1st course, then adjusted dose
41340893|NCT01799161|OTHER|Oxygen|24-hr oxygen delivered via nasal cannula or oxygen mask during 1st course, then adjusted dose.
41487868|NCT02331368|DRUG|Lenalidomide|5-15 mg/day starting 45-90 days post-transplant
40821761|NCT00903136|OTHER|questionnaire administration|
40821762|NCT00903136|PROCEDURE|comparison of screening methods|
41487869|NCT02331368|DRUG|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
40821763|NCT00903136|PROCEDURE|diagnostic endoscopic procedure|
41487870|NCT06227013|BEHAVIORAL|Whistleblowing intervention|the participated nurses will receive session about Whistleblowing
40821764|NCT00903136|PROCEDURE|esophagogastroduodenoscopy|
40821765|NCT00903136|PROCEDURE|tethered capsule endoscopy|
40821766|NCT04428190|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
40821767|NCT04428190|OTHER|Placebo|Sachet manufactured to mimic 10g of HMO
40821768|NCT06279104|DRUG|physician's choice of chemotherapy|physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
40821769|NCT06279104|DRUG|immune checkpoint inhibitor based therapy|immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
40821770|NCT01000922|DRUG|Regular Human Insulin|Individual dose of RHI administered subcutaneously
40821771|NCT01000922|DRUG|Lispro|Individual dose of lispro administered subcutaneously
40821772|NCT01000922|DRUG|VIAject|Individual dose of VIAject administered subcutaneously
40821773|NCT01000922|DRUG|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
41017396|NCT05121116|BEHAVIORAL|Online Mindfulness-Based Stress Reduction (MBSR)|Participation in an 8-week MBSR program consisting of pre-recorded mindfulness practices, including a guided body scan in week 1, guided sitting meditation in week 2, mindful yoga practices in week 3 and 4, meditation on difficult emotions in week 5, visualization meditation in week 6, lovingkindness meditation in week 7, and a silent meditation in week 8. Most practices last approximately 30 minutes and participants were encouraged to engage in a mindfulness practice daily or as often as possible. In weeks 2 - 8 participants could choose to alternate the practice introduced each week with practices from previous weeks. Participants had immediate access to all practices but were asked to complete them sequentially and in the order described above over a period of eight weeks. The MBSR program also encourages participants to employ mindfulness in their daily lives, and gives access to educative readings and videos related to the weekly mindfulness practices.
40821774|NCT01000922|DRUG|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
40821775|NCT01000922|DRUG|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
40821776|NCT00731653|DRUG|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
40821777|NCT01824823|DRUG|afatinib|Given PO
41017397|NCT00042328|DRUG|Valacyclovir|
40821778|NCT01824823|OTHER|placebo|Given PO
40821779|NCT00672087|GENETIC|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
40821780|NCT01513603|DRUG|CLAG-M|IV times 5 days
40821781|NCT01513603|DRUG|CLAG-M|Chemotherapy
40821782|NCT02703012|OTHER|Adjustment of ventilator settings by EIT|Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
40821783|NCT06605443|DEVICE|Breath analyzer|The study subject will be advised to sit quietly for minimum 10 minutes prior the sampling to avoid temporal changes in levels of volatile organic compunds (VOCs) related to body movement or try to avoid abrupt changes in body posture. Then, he/she will be asked to blow in the breath analyzer in order to obtain the exhaled VOCs profile.
40821784|NCT06605443|DEVICE|Skin patch|A skin patch will be placed in the anterior part of the patient\&#39;s arm for the obtention of the skin VOCs profile (estimated sampling time of around 1 h). These profiles will be recorded with a dedicated software and analyzed using standard statistical methods.
40821785|NCT06605443|GENETIC|Liquid biopsy|Circulating free tumor DNA (cfDNA) will be extracted from patient\&#39;s blood and analyzed to detect mutations in BRAF and other prognostic genes.
41340894|NCT01799161|PROCEDURE|Immunologic Evaluation|Frequency of IFN-y,CD8 cells in response to vaccine in available tumor samples Blood draw to assess immunological response \[frequency of CD4+, FoxP3 (Treg), et al\] in treated patients.
41340895|NCT02881671|GENETIC|genetic blood analysis|patients will undergo a blood sample (15 ml) to analyse their genetic profile
41340896|NCT02022592|DRUG|Lormetazepam|
41340897|NCT02022592|DRUG|Midazolam|
41340898|NCT01619813|DRUG|Docetaxel, Reolysin and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
41340899|NCT01619813|DRUG|Docetaxel and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
41340900|NCT00000703|DRUG|Bleomycin sulfate|
41340901|NCT00000703|DRUG|Vincristine sulfate|
41340902|NCT00000703|DRUG|Doxorubicin hydrochloride|
41340903|NCT00000703|DRUG|Cyclophosphamide|
41340904|NCT00000703|DRUG|Allopurinol|
41340905|NCT00000703|DRUG|Methotrexate|
41340906|NCT00000703|DRUG|Cytarabine|
41340907|NCT00000703|DRUG|Leucovorin calcium|
41340908|NCT00000703|DRUG|Zidovudine|
41340909|NCT00000703|DRUG|Dexamethasone|
41340910|NCT00809510|DRUG|ABT-089|20 mg ABT-089 taken once-daily for 6 months
40821786|NCT06608446|OTHER|Telerehabilitation|"The telerehabilitation intervention will begin from 10 days post-surgery, the operation will be carried out at home from Monday to Friday via the TeleHab device (Vald Performance) up to 2 months after the surgery.~Exercises for ROM recovery and strength recovery will be carried out three days a week and only exercises for ROM recovery will be carried out two days a week. The progression of the exercises will be carried out taking into account the pain and fatigue recorded by the patient at the end of each exercise session."
40821787|NCT06608446|OTHER|Standard Care|Standard care intervention follow the usual treatment according to current clinical practice, no structured physiotherapeutic interventions will be carried out. It consists of the delivery of two booklets, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid its possible onset through the demonstration of exercises to be carried out at home, self-massage techniques for the scar, behaviors and lifestyle to be adopted immediately after surgery.
40821788|NCT01896076|OTHER|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
41017398|NCT00040404|DRUG|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
41017399|NCT00040404|DRUG|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
41017400|NCT00040404|DRUG|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
41017401|NCT00040404|OTHER|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
41340911|NCT02505802|DRUG|BoNT-A injection|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
41340912|NCT00345514|BEHAVIORAL|Behavioral Intervention Arm|The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)
41340913|NCT00345514|BEHAVIORAL|Organizational Interventions Arm|Leadership, team building, benchmarking at the clinic and program level
41340914|NCT04189640|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
41340915|NCT04213118|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg QD PO d1-14, 21 days per cycle.
41340916|NCT04213118|PROCEDURE|TACE|TACE first, followed by anlotinib within day4（+/-1days）
41340917|NCT05765214|BEHAVIORAL|Intervention Group (IG)|"In general, the education will cover:~(i) Colorectal cancer - knowledge, perceptions, self-care, and social norms (CRC-KPSS): Knowledge; Perceptions (perceived susceptibility, perceived severity, perceived benefits, perceived barriers); Self-care; and Social norms; and information on colorectal cancer screening (ii) Healthy nutrition colorectal for cancer risk reduction and complementary to diabetes guideline (increasing consumption of fiber, fruits, vegetables, whole grains, and calcium; reducing red and processed meat, fat, added sugars and alcohol)"
41340918|NCT01716949|RADIATION|Radiotherapy|45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks
41340919|NCT01716949|PROCEDURE|Hyperthermia|10 sessions, therapeutic time 60 min
41340920|NCT01716949|DRUG|5-Fluorouracil|250 mg/m\^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
41340921|NCT01716949|DRUG|Capecitabine|1650 mg/m\^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
41340922|NCT01716949|DRUG|Oxaliplatin|50 mg/m\^2/d as 2-hour bolus infusion on d2, 9, 23, 30
41340923|NCT03342404|DRUG|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.
41340924|NCT03342404|OTHER|Placebo|Placebo, Subcutaneous, every 21 days
41340925|NCT03342404|OTHER|Best Supportive Care (BSC)|Best Supportive Care (BSC)
41340926|NCT02954861|OTHER|No intervention|No intervention
41340927|NCT02621372|OTHER|platelet count|Correlation of esophageal varices with platelet count
41340928|NCT00498368|DRUG|Intravenous Rituximab|"Rituximab Therapy \[27 Patients\]~* Rituximab 1 gm IV on Treatment Day 1~* Rituximab 1 gm IV on Treatment Day 15~* Rituximab 1 gm IV on Treatment Day 168~* Rituximab 1 gm IV on Treatment Day 182"
40821789|NCT05642234|PROCEDURE|Epidural Ultrasonography|In this study, we measured the intervertebral distance and skin-epidural distance with the help of ultrasonography in the thoracic and lumbar regions in sitting and rider positions.
40821790|NCT03921619|DEVICE|Shoulder Sling|soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
41340929|NCT00498368|DRUG|ACE/ARB|ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
41340930|NCT00498368|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Fish Oil Supplement|Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
41340931|NCT02572804|DEVICE|Epidural|Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
41340932|NCT02572804|DEVICE|Rectus Sheath Catheters|Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
41340933|NCT02321397|DRUG|Oxycodone|
41340934|NCT02321397|DRUG|Naloxone|Prolonged Release Tablets
41340935|NCT02762760|BIOLOGICAL|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
41340936|NCT02762760|BIOLOGICAL|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
41340937|NCT04063644|DEVICE|Vis Glyc Neo|1 drop in each eye, three times a day.
41340938|NCT04063644|DEVICE|Physiological saline solution|1 drop in each eye, three times a day.
41340939|NCT02732223|DIETARY_SUPPLEMENT|Functional treatment|Omega 3 fatty acids, plant sterols and polyphenols
41340940|NCT02732223|DIETARY_SUPPLEMENT|Control treatment|placebo supplements
41340941|NCT03885609|DEVICE|ToothWave|RF-utilizing powered toothbrush for teeth whitening
41487871|NCT03111914|DIAGNOSTIC_TEST|Dual Energy Computed Tomography|"The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care."
40821791|NCT01133405|DRUG|LY2886721|Oral capsules
40821792|NCT01133405|DRUG|Placebo|Oral capsules
41340942|NCT03885609|DEVICE|powered toothbrush|regular powered toothbrush with no RF
40821793|NCT03446053|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
41017402|NCT00132769|DRUG|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
41340943|NCT03482336|OTHER|Four FOP label designs|"Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a healthy level while the second unhealthy. Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables."
41487872|NCT02593773|DRUG|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after Week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
41487873|NCT05872893|DRUG|Ondansetron|Patients will receive age-adjusted doses of ondansetron 5mg/m2
41487874|NCT05872893|DRUG|Dexamethasone|Patients will receive dexamethasone 4mg/m2
41487875|NCT01822574|PROCEDURE|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
41487876|NCT01822574|PROCEDURE|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
41487877|NCT01822574|PROCEDURE|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
41487878|NCT02547155|PROCEDURE|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
41487879|NCT02547155|PROCEDURE|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
41487880|NCT04746911|DRUG|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
40821794|NCT03446053|OTHER|INT200-Placebo|Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
40821795|NCT02094742|PROCEDURE|biopsy|
40821796|NCT05208086|DIAGNOSTIC_TEST|Detection of monoclonal component|Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
40821797|NCT02179736|DEVICE|Restylane|
40821798|NCT02607241|DEVICE|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
40821799|NCT02607241|DEVICE|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR \> 0.8, residual diameter stenosis \< 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis \> 40% or FFR \< 0.8).
40821800|NCT06188650|DRUG|Anlotinib|After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
41340944|NCT01766245|DRUG|semaglutide|For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
41017403|NCT00132769|DRUG|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
41017404|NCT02565797|DEVICE|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
41340945|NCT01336257|OTHER|SEBASTIAN Clinical Decision Support System (CDSS)|SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
41340946|NCT05326204|OTHER|Home blood glucose monitoring|Self monitoring of capillary blood glucose
41487881|NCT06259136|PROCEDURE|A transitional palliative care intervention|The Pal-Cycles intervention starts just before the care transition from curative oncology care to palliative care with a goals of care conversation between a hospital care provider and the patient. The conversation will be recorded in a summary of treatment and care form which will be completed by a hospital based clinician based on the key elements of the conversation with the patient and the treatment and care plan. Afterwards a (digital) copy of the form is given to the patient and another copy is sent to the general practitioner in combination with the discharge letter.
41487882|NCT03039660|BEHAVIORAL|RefreshMD|Online Sleep Improvement Course
41017405|NCT01000246|BIOLOGICAL|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
41340947|NCT03105375|DRUG|Single ascending dose of X842|Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.
41340948|NCT03105375|DRUG|Multiple ascending dose of X842|Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.
40821801|NCT05392855|OTHER|Symptom driven performance of airway clearance|Perform symptom driven/intermittent airway clearance therapy with frequency based off of patient's daily symptoms including mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
40821802|NCT05392855|OTHER|Continuous daily performance of airway clearance|Continue run-in protocol of twice daily airway clearance using twice daily mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
41340949|NCT03105375|DRUG|Losec|Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.
40821803|NCT01874275|DEVICE|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
40821804|NCT01238835|DEVICE|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
40821805|NCT00362583|DRUG|Fentanyl|
40821806|NCT04171596|BEHAVIORAL|Primary care coordination|"A registered nurse currently employed at Duke Integrative Medicine, who is also trained as an integrative health coach, will serve in the PCC role. The intervention will flow as follows:~The PCC will call study participants every 2 months during the 6 months (more frequently as needed) for a semi-structured phone check-in, and will track the intervention through the REDCap database. The PCC will use guiding questions to frame the call, but will also:~Respond Ask follow-up questions Provide suggestions that are guided by the patient response and appropriateness to the individual situation and needs and scope of practice.~Prior to the call, the PCC will review the patient chart to see if any outstanding orders, medical visits due, and review the patient health goals (known as the pre-work).~The PCC will call the patient to provide intervention. If patient is not available, the PCC will leave a message, or contact via MyChart to see about scheduling a time to talk."
40821807|NCT05653050|DEVICE|CamAPS HX|Fully automated closed-loop system (CamAPS HX) with ultra-rapid insulin aspart.
40821808|NCT05653050|DEVICE|Standard insulin pump therapy with CGM|Participants usual insulin pump therapy with Freestyle Libre 3 CGM
40821809|NCT05319483|OTHER|No intervention|No intervention.
41340950|NCT04506281|DRUG|neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
41340951|NCT03119441|DEVICE|Dental Water Jet|Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.
41340952|NCT03119441|DEVICE|Dental Floss|Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
41340953|NCT01190020|DRUG|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
40821810|NCT06086444|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
40821811|NCT06086444|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
40821812|NCT04860895|DIAGNOSTIC_TEST|AP-23|AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
40821813|NCT04577716|DIAGNOSTIC_TEST|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
40821814|NCT04577716|DIAGNOSTIC_TEST|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
41340954|NCT01190020|DRUG|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
41340955|NCT05519124|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
41340956|NCT02491216|OTHER|Acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
41340957|NCT03594461|DRUG|Aflibercept Injection|Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy
41340958|NCT06025084|DRUG|Egg Shell nanoparticles|Evaluate the effects of egg shell nanoparticles combined with Titanium dioxide nanoparticles in the treatment of dentin hypersensitivity at different time intervals.
40821815|NCT04577716|DIAGNOSTIC_TEST|12-month CT Aortic Angiogram|CT scan to assess aortic morphology and the stent graft
40821816|NCT04577716|OTHER|24-month review|This will consist of a telephone consultation with the study participant and review of electronic clinical records
40821817|NCT00182780|DIETARY_SUPPLEMENT|American ginseng|
40821818|NCT00182780|OTHER|Placebo|
40821819|NCT00395291|DRUG|MK-0677|The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
40821820|NCT00395291|DRUG|Placebo|Placebo
40821821|NCT01882049|DEVICE|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
40821822|NCT04051710|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
41340959|NCT02100410|DEVICE|Delefilcon A toric contact lens T1|Iteration 2-87-1 with embossed mark
41340960|NCT02100410|DEVICE|Delefilcon A toric contact lens T2|Iteration 2-87-1 without embossed mark
41340961|NCT02100410|DEVICE|Delefilcon A toric contact lens T3|Iteration 2-87-2 with embossed mark
41340962|NCT02100410|DEVICE|Delefilcon A toric contact lens T4|Iteration 2-87-2 without embossed mark
41487883|NCT03039660|BEHAVIORAL|Bond Between Us|Online Educational Course
40821823|NCT04051710|DRUG|Reference Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
40821824|NCT04051710|DRUG|Placebo|Placebo Product
40821825|NCT00064766|DRUG|doxycycline|
40821826|NCT03028480|DRUG|NUCALA Injection|Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
40821827|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
40821828|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
40821829|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
40821830|NCT03893240|DIAGNOSTIC_TEST|Neutralizing Antibody to SPK-3006 capsid|Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
41340963|NCT02100410|DEVICE|Delefilcon A toric contact lens T5|Iteration 2-87-3 with embossed mark
41487884|NCT00003079|DRUG|bryostatin 1|
41487885|NCT00003079|DRUG|cytarabine|
40821831|NCT02947165|DRUG|NIS793|Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.
41017406|NCT01743092|BEHAVIORAL|Webinar|Some clients will receive a webinar as part of their treatment.
41340964|NCT02100410|DEVICE|Delefilcon A toric contact lens T6|Iteration 2-87-3 without embossed mark
41340965|NCT02665468|BEHAVIORAL|Supported adoption intervention|An intervention where a healthcare system implements quality improvement by sending patients proactive reminders, motivational messages, and educational support to encourage use of a new service (i.e., secure messaging)
40821832|NCT02947165|DRUG|PDR001|Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
40821833|NCT04098237|DRUG|Pancrelipase|Pancrelipase delayed-release capsules
41017407|NCT01743092|BEHAVIORAL|Tutuorial workbook|A work book about their addiciton
41017408|NCT05960682|OTHER|Questionnaire|Patients will complete the French version of the Brief Index of Sexual Functioning for Men (BISFM) paper questionnaire. The BISFM is a self-administered questionnaire. It has 22 questions, grouped into 7 domains allowing a qualitative and quantitative evaluation of the sexual experience: D1 (desire), D2 (excitement), D3 (frequency of activity), D4 (receptivity), D5 (pleasure, orgasm ), D6 (relationship satisfaction), D7 (problems affecting sexuality).
40821834|NCT05337514|BEHAVIORAL|Enhanced Engagement|EngAGE will allow care partners send older adults encouragement which will be read aloud to the older adult through the EngAGE app.
41017409|NCT02138318|OTHER|High definition (HD) endoscopy|
41017410|NCT02138318|OTHER|chromoendoscopy|
41340966|NCT02665468|BEHAVIORAL|Active comparator control|The investigators will use an attention control (a control intended to balance the attention Veterans receive from the facility mailings and to enhance masking of intervention versus control). As an attention control must not have information about the intended intervention, the investigators will mail out general wellness information available on the VHA National Center for Prevention
41487886|NCT03216070|DRUG|Dasatinib 50 MG|50mg of dasatinib orally daily
40821835|NCT05337514|BEHAVIORAL|Standard Engagement|Care partners can encourage their older adult partner using traditional / existing communication mechanisms.
40821836|NCT02649218|BIOLOGICAL|Ligelizumab|QGE031 240 mg s.c. q4w
40821837|NCT01370837|OTHER|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
41017411|NCT04616144|DEVICE|Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser|Fresh Corneal Lenticule Implantation using ReLex-Smile
41017412|NCT00626977|DRUG|ropivacaine|15 ml of ropivacaine 0.125% peridural once
41487887|NCT04063436|DEVICE|New nasal pillows mask with PAP therapy|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
41487888|NCT04714320|DRUG|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
41487889|NCT04714320|DRUG|Placebo|IONIS-AGT-LRx-matching placebo will be administered by SC injection.
40821838|NCT01370837|OTHER|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
40821839|NCT05607082|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
40821840|NCT00266214|DRUG|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
40821841|NCT00112411|DRUG|Bronchodilator|
40821842|NCT01430507|DRUG|Revamilast|Tablet, Low dose, Once daily for 12 weeks
40821843|NCT01430507|DRUG|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
40821844|NCT01430507|DRUG|Revamilast|Tablet, High dose, Once daily for 12 weeks
41017413|NCT00626977|DRUG|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
41487890|NCT00557076|BEHAVIORAL|Familiar Auditory Sensory Training|Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.
41487891|NCT00557076|BEHAVIORAL|Sham Auditory Sensory Training|The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
41487892|NCT05114837|DRUG|allogeneic CAR19 regulatory T cells (CAR19-tTreg)|A single dose administration of CAR19-tTreg
41487893|NCT05114837|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)
41487894|NCT05114837|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
41487895|NCT01211418|BEHAVIORAL|Integrative Meditation|"Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.~Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB \& IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.~Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study."
41487896|NCT01211418|BEHAVIORAL|Supportive Counseling|"NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.~The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion."
41487897|NCT00605735|DRUG|BMS-582949|Tablets, Oral, 300 mg, once daily, 12 weeks
41487898|NCT00605735|DRUG|Placebo|Tablets, Oral, placebo, once daily, 12 weeks
41487899|NCT04671186|DIETARY_SUPPLEMENT|Culturelle (Lactobacillus rhamnosus strain GG)|Culturelle probiotics are typically sold over the counter as dietary supplements Probiotics group will take 1 capsule of probiotics orally once daily
41487900|NCT04671186|OTHER|Placebo|Placebo group will take 1 capsule of placebo orally once daily
41487901|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
41487902|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
41487903|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
41487904|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
41487905|NCT01008852|DRUG|Placebo|Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
41487906|NCT03083236|OTHER|Standard PBI|Standard Parent Based Intervention (PBI)
40821845|NCT01430507|DRUG|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
40821846|NCT03350087|DEVICE|intermittent theta burst stimulation|"In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total)~Other Names:~intermittent theta burst stimulation"
40821847|NCT03350087|DEVICE|continuous theta burst stimulation|"In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total).~Other Names:~continuous burst stimulation"
40821848|NCT03350087|DEVICE|iTBS+cTBS group|In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total)
41487907|NCT03083236|OTHER|Enhanced|Enhanced Parent Based Intervention (EPBI)
41487908|NCT03433144|DRUG|Tranexamic Acid Injectable Solution|the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia
41487909|NCT03433144|OTHER|Placebo (normal saline 0.9%)|An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
41487910|NCT03203135|BEHAVIORAL|Nutritional prevention programme|The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
40821849|NCT03350087|DEVICE|sham theta burst stimulation|"In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total).~Other Names:~sham theta burst stimulation"
40821850|NCT03350087|DEVICE|VCT|"The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.~Other Names:~The upper extremity programs virtual cycling training program"
40821851|NCT03350087|DEVICE|VCT+optimal rTMS group|In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1.
40821852|NCT01676753|DRUG|Dinaciclib|Given IV
40821853|NCT01676753|DRUG|Pembrolizumab|Given IV
40821854|NCT00570791|DEVICE|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
40821855|NCT06285747|OTHER|Non-Interventional Study|Non-Interventional Study
40821856|NCT04599270|OTHER|PREVENTURE Program|Adolescents will be follow PREVENTURE program (2 session of 90 min).
40821857|NCT04599270|OTHER|Routine care|Adolescents will be follow routine care
40821858|NCT06605417|GENETIC|Methylomics|Methylomics analysis of FFPE blocks and frozen tissues
40821859|NCT06605417|GENETIC|RNA sequencing|RNA sequencing of FFPE blocks and frozen tissues
40821860|NCT06605417|GENETIC|Spatial transcriptomics|Spatial transcriptomics of FFPE blocks and frozen tissues
40821861|NCT06605417|GENETIC|Liquid biopsy|cfDNA characterization extracted from blood/saliva
40821862|NCT06607926|DRUG|Thymosin Alpha 1|4.8 mg subcutaneous injection twice weekly over 12 weeks
40821863|NCT06607926|DRUG|Tislelizumab|200mg, IV, d1 of each 21-d cycle, four cycles
40821864|NCT06607926|DRUG|Platinum-doublet chemotherapy|Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.
40821865|NCT05778084|DRUG|Empagliflozin 10 MG|Blood samples will be collected as a baseline to test for N-terminal Pro-B-type Natriuretic Peptide, followed by administration of empagliflozin for 6 months, and then another blood samples will be collected after 6 months.
40821866|NCT00395135|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
41487911|NCT01644110|DRUG|INCB018424/CC-4047|"Cohort 1: For patients (1-41) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.~Cohort 2: For patients (42-90) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; the starting dose of pomalidomide is 0.5 mg po once daily."
41487912|NCT00661141|DRUG|Antizol|
41487913|NCT00661141|DRUG|Placebo|
41487914|NCT00661141|OTHER|Ethanol|oral dose of ethanol (0.5 g/kg)
41487915|NCT02273336|OTHER|cytology specimen collection procedure|Undergo tissue and blood sample collection
41487916|NCT02273336|OTHER|laboratory biomarker analysis|Correlative studies
41487917|NCT02743910|OTHER|ptDNA|Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.
41487918|NCT02743910|OTHER|Tissue sample|Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available)
41487919|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given intravenously only once at dose of 10 mg
41487920|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
41487921|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
41487922|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
41487923|NCT03071094|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4
41487924|NCT03071094|DRUG|Nivolumab|Nivolumab will be administered intravenously every 2 weeks (from week 2)
40821867|NCT00395135|DRUG|Matching Placebo BID|Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
40821868|NCT05882864|DRUG|6-Gingerol|6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
40821869|NCT05882864|DRUG|Triamcinolone Acetonide 0.1% Oromucosal Paste|Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
40821870|NCT00937404|BIOLOGICAL|Poliorix|All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
40821871|NCT04907149|DRUG|GLPG3970 film-coated tablet|Participants will receive a single oral dose of GLPG3970.
40821872|NCT04907149|DRUG|[14C]GLPG3970 solution for infusion|Participants will receive an i.v. microtracer microdose.
40821873|NCT04907149|DRUG|[14]GLPG3970 oral solution|Participants will receive a single oral dose \[14C\]GLPG3970.
41487925|NCT02702713|DIETARY_SUPPLEMENT|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
41487926|NCT02702713|DIETARY_SUPPLEMENT|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
41487927|NCT02702713|DIETARY_SUPPLEMENT|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
41487928|NCT02702713|DIETARY_SUPPLEMENT|Bakery placebo|Bakery placebo: Biscuits without enrichment
41487929|NCT02702713|DIETARY_SUPPLEMENT|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
41487930|NCT02702713|DIETARY_SUPPLEMENT|Egg placebo|Egg placebo: Frozen pancakes without enrichment
41487931|NCT06007066|DRUG|HSK16149 capsule|Subjects will be given 40mg or 60mg of HSK16149 orally.
41487932|NCT06007066|DRUG|Placebo|Subjects will be given HSK16149 placebo orally.
40821874|NCT03294096|DIETARY_SUPPLEMENT|Routine care + Nutritional product|Routine post-op care + Nutritional supplement by specific product
40821875|NCT03294096|OTHER|Routine care|Routine post-op care
41340967|NCT04786730|DRUG|Centanafadine|Doses of centanafadine will be taken once daily in the morning on Days 1 through 14. The fixed dose strengths will be administered according to body weight. Up to 12 subjects will be enrolled in the 9 to 12 years age cohorts (Cohorts 1 and 6), up to 8 subjects will be enrolled in each of the 6 to 8 years age cohorts (Cohorts 2 and 3), and up to 5 subjects will be enrolled in each of the 4 to 5 years age cohorts (Cohorts 4 and 5).
41340968|NCT05290051|GENETIC|Optical Genome Mapping (Bionano®)|Search for chromosome abnormalities through alteration of the optical map of the genome compared to reference genome using the Bionano® 's pipeline.
41340969|NCT05290051|GENETIC|Longread sequencing (Nanopore®)|Search for chromosome abnormalities from the sequencing data obtain from high molecular weight DNA molecules using dedicated analysis pipeline.
41487933|NCT00726154|BEHAVIORAL|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
41487934|NCT00726154|BEHAVIORAL|Collaborative Care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
41487935|NCT04265339|OTHER|Smoking cessation|Participants are required to quit smoking
41487936|NCT06398821|DIETARY_SUPPLEMENT|G3P-01|Nutritional supplement to promote healthy aging
41487937|NCT06398821|DIETARY_SUPPLEMENT|Placebo|Placebo
41487938|NCT00885014|BEHAVIORAL|CBT|Telephone cognitive-behavioral therapy
40821876|NCT06024837|OTHER|CT Images|Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer
41487939|NCT00885014|BEHAVIORAL|EAP|Employees Assistance Program
41487940|NCT02573090|PROCEDURE|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
41487941|NCT02573090|PROCEDURE|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
41487942|NCT02881840|DRUG|14C-APD421|
41487943|NCT00999648|OTHER|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
40821877|NCT06327633|OTHER|Olfactory Training|The subjects repeatedly sniffed pleasant scents of rose, lemon, clove, eucalyptus, coffee and cinnamon twice a day, 5-min per time, with focus, until the completion of the study.
40821878|NCT00161577|DRUG|Ketorolac|Intravenous ketorolac every 6 hours for 24 hours
40821879|NCT00161577|OTHER|Placebo|Placebo Comparator
41340970|NCT03216668|DRUG|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks.
41340971|NCT03216668|DRUG|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
41340972|NCT02947334|BIOLOGICAL|Bococizumab|Bococizumab PFS
41340973|NCT02947334|DRUG|Placebo|Placebo
41340974|NCT05735236|DEVICE|BFR Cuff|The BFR cuff will be applied to the proximal thigh of the surgical leg while the patient completes specified physical therapy exercises.80% occlusion pressure will be determined by PT's in clinic through the use of a Delphi unit. Subjects will then be able to use the Saga Fitness app to adjust this pressure if it differs from the automatic calibrated pressure.
41340975|NCT01057862|DRUG|Naltrexone|Targeted dosage of 50mg PO daily
40821880|NCT00068250|DRUG|rituximab|375 mg/m2, intravenously three days prior to the first cycle of methotrexate
41340976|NCT01057862|OTHER|Placebo|Sugar pills daily PO
41487944|NCT00999648|OTHER|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
41487945|NCT00927693|OTHER|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
41340977|NCT01255293|PROCEDURE|1000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
41017414|NCT06280313|COMBINATION_PRODUCT|Splenectomy+Targeted therapy+ Immunotherapy|Eligible patients with unresectable hepatocellular carcinoma accompanied by cirrhotic portal hypertension were enrolled in the trial, and all participants underwent either open or laparoscopic splenectomy, with or without devascularization around the cardia. Starting two weeks post-surgery, patients began intravenous infusion of PD-1 monoclonal antibody, Tislelizumab, at a dosage of 200mg every three weeks. Three weeks post-surgery, patients commenced oral administration of the targeted therapy, Lenvatinib, with a dosage based on body weight: 8mg (≤60kg) or 12mg (\>60kg), once daily.
41487946|NCT03321162|DIAGNOSTIC_TEST|scan protocol|Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
41487947|NCT02756026|DIETARY_SUPPLEMENT|Multiple micronutrient supplement (Nutri-Fem)|Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
41487948|NCT06492200|OTHER|Psyllium husks|Patients in the intervention group will receive nutritional counseling and will be asked to take 10g (one tablespoon) of ground psyllium husks daily to significantly increase the fiber content of their diet.
41487949|NCT00450619|RADIATION|Samarium Sm 153 lexidronam pentasodium|1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
41017415|NCT01837316|DRUG|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
41017416|NCT01837316|DRUG|Placebo|First strip: Inhalation powder of lactose
41017417|NCT00068055|DRUG|Omr-lgG-am|Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
41017418|NCT00068055|DRUG|Polygam® S/D|Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
41017419|NCT00068055|DRUG|Placebo|Normal Saline.
41017420|NCT00396734|DRUG|Provigil (Modafinil)|Increase from 100mg to 400mg during 1 month of treatment
41017421|NCT00396734|DRUG|Topamax (Topiramate)|Increase from 25mg to 200mg in one month (double every week)
41487950|NCT00450619|BIOLOGICAL|Sargramostim|100 mcg/injection x 4 days given subcutaneously
41017422|NCT00965900|PROCEDURE|Endoscopic band ligation|"* Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
41017423|NCT00965900|DRUG|Propranolol|"* start with 20 mg of propranolol b.i.d~* Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
41487951|NCT00450619|BIOLOGICAL|Recombinant vaccinia-TRICOM vaccine|2 x 10\^8 PFU given subcutaneously on day 1.
41487952|NCT00450619|BIOLOGICAL|Recombinant fowlpox-TRICOM vaccine|1 x 10\^9 PFU given subcutaneously on days 15 and 29
41487953|NCT01097941|BIOLOGICAL|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
41487954|NCT01097941|BIOLOGICAL|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
41487955|NCT01097941|BIOLOGICAL|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
41487956|NCT05417503|OTHER|Non-invasive ventilation bi-level|For the NIV intervention, two levels of positive airway pressure (bi-level) were used: the positive inspiratory airway pressure (IPAP) was fixed at 6 cmH2O (centimeters of water), which could be gradually increased up to 14 cmH2O (2 cmH2O every minute), depending on the patient's comfort. and gradually increased to 14 cmH2O (2 cmH2O every minute), While the expiratory airway pressure (EPAP) was set at 3 cmH2O, it could be gradually increased up to 7 cmH2O (1 cmH2O every minute), depending on the patient's comfort.while expiratory airway pressure (EPAP) was fixed at 3 cmH2O and gradually increased to 7 cmH2O (1 cmH2O every minute).
41487957|NCT05417503|OTHER|Non-invasive ventilation placebo|The same pressure chosen by the subject during adaptation was used in the placebo intervention; however, a T tube was connected between the equipment and the circuit, creating a leak and leaving the circuit open. The tube characteristics were: 22 x 18 x 22 mm nebulizer T-connector.
41487958|NCT00486564|DRUG|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
41487959|NCT03150849|DIAGNOSTIC_TEST|C-X-C Chemokine Receptor 4|marker assessed by flowcytometry in a blood sample
41487960|NCT01011244|BIOLOGICAL|ADIPOPLUS|"autologous cultured adipose-derived stem cells~1x10e7 cells/1cm2 depending on surface area of fistula"
41487961|NCT02385253|BEHAVIORAL|Educational training program|"The educational training program (intervention) consists of four sequential phases:~1. Knowledge Acquisition~2. Skills Assessment~3. Deliberate Practice~4. Clinical Proficiency"
41340978|NCT01255293|PROCEDURE|5000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
41340979|NCT00424034|DRUG|GSK1325760A|
41340980|NCT02270489|BIOLOGICAL|AFFITOPE® PD01A + Adjuvant|s.c. injection
41340981|NCT02270489|BIOLOGICAL|AFFITOPE® PD03A + Adjuvant|s.c. injection
41340982|NCT02270489|BIOLOGICAL|Adjuvant without active component|s.c. injection
41487962|NCT02737332|DRUG|Zytiga® (Abiraterone Acetate)|Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
41487963|NCT02737332|DRUG|SoluMatrix™ (Abiraterone Acetate)|SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
41487964|NCT00709839|DRUG|Hydrocortisone|0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
41340983|NCT04884906|BIOLOGICAL|Camrelizumab|200mg/m2, iv, d1, Q3W, a total of 6 cycles
41340984|NCT04884906|RADIATION|radiotherapy|1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.
40821881|NCT00068250|DRUG|methotrexate|Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
41340985|NCT04884906|DRUG|Albumin Paclitaxel|260mg/m2, iv, d1, Q3W, a total of 6 cycles
41340986|NCT04884906|DRUG|Cisplatin|80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles
41340987|NCT03247010|OTHER|Blood sampling|Blood samples are taken before each cycle of Radium 223
41340988|NCT01151176|DRUG|Regular Insulin|1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
41340989|NCT01151176|DRUG|Regular Insulin|"Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose \>141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; \> 400=16U"
41487965|NCT00709839|DRUG|Glucose 33%|1ml/kg body weight, intravenous bolus given at time-point 0'
41487966|NCT04175444|DIAGNOSTIC_TEST|VisuALL Field Analyzer|Each participant will conduct a visual field test with the visuaALL headset.
41487967|NCT04175444|DIAGNOSTIC_TEST|Humphrey Field Analyzer|Each participant will conduct a standard of care Humphrey Visual Field.
41487968|NCT05542979|DRUG|HH-003 injection|HH-003 injection is administrated via I.V. infusion
41487969|NCT05542979|DRUG|Placebo|Placebo is administrated via I.V. infusion
41487970|NCT00270257|DRUG|Buprenorphine/Naloxone|Oral tablet
41487971|NCT02034058|DEVICE|Wingspan Stent System|The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
41487972|NCT06053775|DEVICE|Transcranial Direct Current Stimulation|tDCS+OCT
41487973|NCT06053775|DEVICE|Transcranial Alternating Current Stimulation|tACS+OCT
41487974|NCT06053775|DEVICE|tES sham|tES sham + OCT
41487975|NCT06053775|DEVICE|Online Cognitive Training|OCT
41487976|NCT00044980|PROCEDURE|nutritional support|
41340990|NCT05663476|OTHER|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
41340991|NCT03156725|DRUG|Ferrous Sulfate|
41487977|NCT00044980|PROCEDURE|quality-of-life assessment|
41487978|NCT00297856|BIOLOGICAL|Boostrix®|Single dose
41487979|NCT00297856|BIOLOGICAL|Td (Tetanus diphtheria) vaccine|Single dose
41340992|NCT03156725|DIETARY_SUPPLEMENT|Aspiron|
41340993|NCT01555736|DRUG|grass (80%) and rye (20%) pollens allergoids|comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
41487980|NCT00727948|DRUG|Aspirin|325 mg tablets, once daily for 45 days
41487981|NCT04606836|DRUG|Bupivacaine Hydrochloride|See group descriptions
41487982|NCT01323751|DRUG|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
40821882|NCT00068250|DRUG|temozolomide 100 mg/m^2|Temozolomide 100 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
41340994|NCT04693806|OTHER|Continuous CO2 Level|Embryos will be cultured in a single, continuous CO2 setting
41340995|NCT01438359|DRUG|PA21 and Furosemide with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
41340996|NCT01438359|DRUG|No PA21; Furosemide with food|The maximum dosage of Furosemide will be 40 mg/day
41340997|NCT01438359|DRUG|PA21 with food and Furosemide 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
41340998|NCT05001581|PROCEDURE|Arthroscopic partial repair of massive rotator cuff tear|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons
41487983|NCT05050890|OTHER|ctDNA level during neoadjuvant chemotherapy|ctDNA samples will be collected from patients at baseline, during neoadjuvant therapy (every 15 days) and before the surgical procedure
41487984|NCT03214874|DRUG|Demadex 20mg Tablet|Immediate Release (IR) Torsemide
41487985|NCT03214874|DRUG|ER Torsemide 20mg Tablet|Extended Release Torsemide 20 mg tablet given once daily
41487986|NCT02006628|DRUG|Placebo|Placebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
40821883|NCT00068250|DRUG|temozolomide 150 mg/m^2|Temozolomide 150 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
40821884|NCT00068250|DRUG|temozolomide 200 mg/m^2|Temozolomide 200 mg/m\^2 per day by mouth for five days on weeks 4 and 8.
41487987|NCT02006628|DRUG|GWP42003|GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
41487988|NCT01965470|OTHER|Combination Prevention|
41487989|NCT01965470|OTHER|Enhanced Care|
41487990|NCT02979236|DEVICE|STENTYS Xposition S|
41487991|NCT02833701|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
41487992|NCT02833701|BIOLOGICAL|Bevacizumab|Given intravenously (IV)
41487993|NCT02833701|OTHER|Laboratory Biomarker Analysis|Correlative studies
41487994|NCT02833701|OTHER|Quality-of-Life Assessment|Ancillary studies
41487995|NCT00374426|DRUG|sertraline|
41487996|NCT04492826|PROCEDURE|Postoperative infections rate|Assess the postoperative infection rate after otolaryngology bone flap surgery.
40821885|NCT00068250|RADIATION|radiation therapy|Whole brain irradiation (WBRT) during weeks 11, 12, and 13, five days per week (excluding weekends). A daily dose of 2.4 Gy delivered in two fractions of 1.2 Gy each with a minimum inter-fraction interval of 6 hours, with a total dose to brain and meninges of 36 Gy.
40821886|NCT00068250|DRUG|post-radiation therapy temozolomide|Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
40821887|NCT04086537|DIAGNOSTIC_TEST|hepcidin levels and BMPR2 expression|Samples will be collected in the three groups. Hepcidin levels will be measured in serum using ELISA and BMPR2 expression will be assessed as previously described using real time-qPCR
40821888|NCT03167970|DEVICE|Pill cam|Patient is asked to swallow the esophageal capsule.
40821889|NCT03167970|OTHER|EGD|Patient will undergo standard EGD
40821890|NCT03640052|DRUG|Placebo oral capsule|Placebo capsule before sleep
40821891|NCT03640052|DRUG|LTM1201L|LTM1201L capsule before sleep
40821892|NCT03640052|DRUG|LTM1201LN|LTM1201LN capsule before sleep
40821893|NCT03640052|DRUG|LTM1201LB|LTM1201LB capsule before sleep
40821894|NCT03640052|DRUG|LTM1201LD|LTM1201LD capsule before sleep
40821895|NCT04886544|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
40821896|NCT03872427|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40821897|NCT03872427|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40821898|NCT03872427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40821899|NCT03872427|OTHER|Pharmacodynamic Study|Correlative studies
40821900|NCT03872427|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40821901|NCT03872427|DRUG|Telaglenastat Hydrochloride|Given PO
40821902|NCT02059551|PROCEDURE|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
40821903|NCT06599840|BEHAVIORAL|Parent intervention|This is a novel intervention based on established CBT-based parenting strategies that are regularly used to strengthen parent-child cooperation and reduce conflicts. Here, the strategies are adapted to address typical challenges of T1D family life. The program structure consists of six weekly modules and a seventh booster module. Each of the first six modules has a theme with information on a parental strategy associated with the theme, self-reflective questions, and an assignment where parents plan to implement the strategy during the upcoming week. One month later, a seventh session is held to summarize the program and make plans for future progress.
40821904|NCT03634566|DRUG|N-Acetylecysteine|N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
40821905|NCT03634566|DRUG|Placebo|Ringer acetate continuous infusion at the same rate for 2 days.
40821906|NCT06519123|OTHER|Ambient Digital Scribes|AI technology used to populate clinical notes.
40821907|NCT00596154|OTHER|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
40821908|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #1|Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
40821909|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #2|Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
40821910|NCT04707989|OTHER|Ketone Free Placebo|Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
40821911|NCT01011491|OTHER|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 \& 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
40821912|NCT01011491|OTHER|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 \& 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
40821913|NCT03517514|OTHER|Physical Therapy service|routine physical therapy care
40821914|NCT01953549|PROCEDURE|physical fitness training|
40821915|NCT01953549|PROCEDURE|relaxation|
40821916|NCT01690559|DRUG|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
40821917|NCT03298984|DRUG|Alvocidib|IV bolus followed by IV infusion
41340999|NCT05001581|PROCEDURE|Arthroscopic partial repair of rotator cuff with biceps augmentation|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons and because of good quality of the long head of the biceps tendon, its uses as biological reinforcement of the reconstruction to achieve better clinical and radiological outcome
41341000|NCT02047968|BEHAVIORAL|wake therapy|
41341001|NCT05656118|DEVICE|Genoss® DCB|Paclitaxel coated balloon with a shellac plus vitamin E excipient
40821918|NCT03298984|DRUG|Cytarabine|continuous infusion
41341002|NCT03135639|OTHER|NeuroConn Plus Stimulator tACS|Transcranial alternating current stimulation (tACS) is a novel, noninvasive brain stimulation approach in which weak electric currents are applied to the scalp. The electric currents that are applied to the scalp are in a sine-wave pattern.
40821919|NCT03298984|DRUG|Daunorubicin|IV bolus
41341003|NCT03135639|OTHER|NeuroConn Plus Stimulator Sham|For sham stimulation, the participant receives up to 1 minute of tACS stimulation until the stimulation fades. This mimics the same skin sensations that a participant would experience during a tACS session.
41341004|NCT01153568|DIETARY_SUPPLEMENT|Vitamin D 3|Patients will bew given a single capsule to take once daily
41341005|NCT01153568|OTHER|placebo|placebo tablets
41341006|NCT01652222|OTHER|CONEM-BETA + socio-educational training|4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
41341007|NCT01652222|OTHER|Socio-educational training only|4 socio-educative training sessions during 8 weeks
41341008|NCT05058118|DRUG|FL058|50mg、250mg、500mg、1000mg、1500mg、2000mg
41341009|NCT05058118|DRUG|Placebo|empty bottle
40821920|NCT05231577|PROCEDURE|7.5fr ultra-fine ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 1 patients used 7.5fr ultra-fine ureteroscopy
40821921|NCT05231577|PROCEDURE|9.2fr Ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 2 patients used 9.2fr Ureteroscopy
41341010|NCT00081744|DRUG|Tigecycline|
41341011|NCT05919953|DEVICE|Virtual reality|Immersive virtual reality neck exercises targeting relaxation, mobility, control, and speed of movement, using the Pico G2 4K headset.
41487997|NCT05953753|BEHAVIORAL|Food system and demand generation|The project is focused on improving egg consumption through enhanced availability, accessibility, and improved demand. To achieve this goal, the project intervention mix will work through three pathways: access, enabling environment, and demand. The access pathway aims to sustain availability and consumption of eggs by school children (age 6-9 years) from BoP households through interventions targeted at the Poultry Association of Nigeria (PAN) and state lead egg aggregators for the HGSFP. The enabling environment pathway focuses on the broader institutional, governance, and political factors to support accessibility, availability, improved consumption, and increased consumer demand for eggs. The demand pathway will be addressed by mass media and interpersonal communication to increase the willingness and motivation of parents/caregivers in BoP households to support and sustain egg consumption by pre-school children in Kaduna State.
40821922|NCT06605274|OTHER|Web-Based Education Program|"Before being discharged from the clinic, the women who experienced perinatal loss filled out the Personal Information Form, Perinatal Grief Scale, Edinburgh Postnatal Depression Scale, Beck Hopelessness Scale, and Stress Coping Styles Scale individually. The women were informed about the use of the website. The discharged women were contacted by phone, given the passwords of the birliktegücleniyoruz.com website, and invited to use the website for the five-week education program. Each week, only one session determined for that week was uploaded to the site. Participants who wished to do so were able to watch the uploaded sessions more than once. Retrospective sessions also remained accessible on the site. Each session lasted an average of 20-30 minutes. Women who completed five sessions were contacted by phone in the sixth week. Women filled out the PGS, EPDS, BHS, and SCSS online a second time"
40821923|NCT06605274|OTHER|Control|Before being discharged from the perinatology clinic, the women filled out the Personal Information Form, PGS, EPDS, BHS, and SCSS individually. Six weeks after discharge, the participants filled out the same measurement tools online again. During this process, the hospital's routine monitoring continued for the control group. The website was opened to the use of participants who wanted to use the site after the completion of the final tests.
40821924|NCT04941807|DEVICE|Platelet-rich plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
40821925|NCT04941807|DEVICE|Platelet-poor plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
40821926|NCT04479475|BEHAVIORAL|Supportive care through community support persons|The adapted B-SBNT involves families and the wider social networks of people receiving MMT to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members, e.g., income-generating activities. MMT client participants attend seven sessions over the course of six weeks: (1) Introduction, (2) Working in a social network-based setting, (3) Setting drinking and drug use goals, (4) Coping skills 1, (5), Coping Skills 2, (6) Making lifestyle changes, (7) Generating income. Social support persons attend up to five sessions over the course of six weeks.
41017424|NCT00965900|PROCEDURE|EBL+Propranolol|"1. EBL~   * Perform EBL within 7 days after randomization~  * Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~  * Acid suppression using proton pump inhibitor until eradicated.~  * After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~2. Propranolol~   * start with 20 mg b.i.d~  * Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~  * After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
41017425|NCT04113759|BEHAVIORAL|Blood Flow Restriction Rehabilitative Therapy|"BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain \<2/10 on VAS and RPE \<5 on 0-10 scale. (Heerey et al), and no break down in form."
41017426|NCT04113759|BEHAVIORAL|Sham BFR Rehabilitative Therapy|The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
41017427|NCT02566551|PROCEDURE|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
40821927|NCT05550870|DIETARY_SUPPLEMENT|Raw fenugreek seed powder|It will be given to group 1
40821928|NCT05550870|DIETARY_SUPPLEMENT|Roasted fenugreek seed powder|It will be given to group 2
41487998|NCT00532818|DRUG|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
41341012|NCT05919953|BEHAVIORAL|Therapeutic education|"Several brochures will be given to participants. These brochures will cover the general principles of pain, the persistence of pain, tips for managing chronic non-specific pain, and the use of immersive virtual reality in the rehabilitation of chronic non-specific neck pain.~The information provided in the brochures will be discussed with the physiotherapist during the teleconsultations in order to individualize the therapeutic education."
40821929|NCT05547633|OTHER|sinusitis screening consultation|"Questioning to look for suspicious anamnestic elements such as rhinorrhea, nasal obstruction, smell disorders, facial pain and clinical examination including nasofibroscopy.~Patients with signs of sinusitis will be managed according to current recommendations (diagnostic imaging tests, medical treatment or even surgery if necessary)."
40821930|NCT06475209|DRUG|Adebrelimab combined with Apatinib|Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Atezolizumab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Apatinib is given orally at a dosage of 250mg daily from day 1 to day 14, every 3 weeks, with a one-week hiatus following two weeks of continuous intake. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
40821931|NCT02386891|OTHER|Thermal Environment|
41341013|NCT05421546|DIETARY_SUPPLEMENT|Spermidine or Placebo|The supplement, Spermidine, is made mainly from wheatgerm and can be bought in health food shops. It is a powder that can be easily dissolved in water and taken as a drink. The 'placebo' is a sugar powder that can be similarly dissolved in water and taken as a drink.
41487999|NCT00532818|DRUG|Placebo|Cisplatin + Topotecan plus placebo
40821932|NCT01086956|DRUG|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
41488000|NCT01167257|DRUG|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
41017428|NCT02566551|DEVICE|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
41017429|NCT02566551|PROCEDURE|TURP|Bipolar transurethral resection of the prostate
41017430|NCT02566551|DEVICE|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
41341014|NCT05597904|GENETIC|Genetic predisposition|Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
41488001|NCT01167257|DRUG|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
41017431|NCT02078739|BEHAVIORAL|Yoga Program at home using internet technology|
41488002|NCT01558336|DRUG|praziquantel|praziquantel 40 mg/kg oral tablets
41341015|NCT03185468|GENETIC|4SCAR-PSMA|PSMA-specific 4th Generation CART
41017432|NCT05433558|OTHER|Neuropsychological Rehabilitation|Neuropsychological Rehabilitation
41341016|NCT03185468|GENETIC|4SCAR-FRa|FRa-specific 4th Generation CART
41341017|NCT00592072|DIETARY_SUPPLEMENT|Medium chain fatty acid (Octanoic and Decanoic acid)|Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
41341018|NCT00592072|OTHER|Splenda (Placebo Control)|Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
41341019|NCT03839056|DEVICE|IC+PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~This intervention is included in the clinical practice routine"
41488003|NCT03476863|PROCEDURE|Alveolar Recruitment Maneuver|Patients in the Experimental Group will be submitted to ARM, immediately after abdominal desinflation of the pneumoperitoneum (PNP). The ARM will be performed with PEEP of 15 cmH2O for thirty seconds, 20 cmH2O for thirty seconds, 25 cmH2O for thirty seconds, 30 cmH2O for one minute and a inspiratory plateau pressure of 15 cmH2O above PEEP, totaling two minutes and thirty seconds.The data of the TIE will be continuously recorded and the hemodynamic and respiratory function variables such as heart rate (HR), respiratory rate (RF), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2) and final gas expiratory pressure carbon dioxide (PETCO2) will be recorded in several moments: immediately after the monitoring, and the patient is still on spontaneous ventilation, 5min after orotracheal intubation, after the installation of the pneumoperitoneum, before and after the execution of the MRA and in the Post-OP, in the first 24h, along with new lung function tests.
41488004|NCT03476863|PROCEDURE|Conventional mechanical ventilation|Immediately after intubation, patients will undergo mechanical ventilation with the ventilator (Dixtal DX 5020) in volume controlled mode with an ideal tidal volume of 7 ml / kg body weight, a set frequency to maintain a carbon dioxide of 35-42 mmHg, and an inspiratory / expiratory ratio of 1: 2. The inspiratory oxygen fraction (FIO2) will be 0.5.
41341020|NCT03839056|DEVICE|PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
41341021|NCT03839056|DEVICE|PIEB+PCEA standar flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
41341022|NCT05838794|OTHER|Mckenzie exercise for neck|The McKenzie protocol will be used to manage extension, rotation, and lateral flexion dysfunctions in patients with non-specific neck pain. An experienced physical therapist will perform the protocol 3 times a week for 6 weeks, tailoring exercises to each patient's individual needs based on limited and painful directions of movement. Exercises include retraction, extension, rotation, lateral flexion, and overpressure techniques. Patients will receive education on posture and body mechanics, and exercises will be progressed over time as the patient improves.
41488005|NCT00423475|DRUG|goserelin acetate|
41488006|NCT00423475|PROCEDURE|adjuvant therapy|
41488007|NCT00423475|RADIATION|radiation therapy|
41488008|NCT06361979|DRUG|SHR-A1811|SHR-A1811: intravenous
40821933|NCT04269577|BEHAVIORAL|SSP training|Participants will practice the Swipe Slide Pattern (SSP) task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
40821934|NCT01242410|DEVICE|Silicon ring (Arabin Cervical Pessary)|Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
40821935|NCT04272866|OTHER|Clinpro sealant|Resin based sealant
40821936|NCT04272866|OTHER|Embrace wetbond sealant|Moisture tolerant hydrophilic resin based sealant
41488009|NCT06361979|DRUG|Bevacizumab|Bevacizumab:intravenous
41488010|NCT02641197|DEVICE|AngioDefender|"Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.~Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators."
41488011|NCT00400621|DRUG|acetaminophen|
40821937|NCT04272866|OTHER|Triage sealant|Glass ionomer sealant
40821938|NCT02049190|DRUG|onapristone|
40821939|NCT02049190|DRUG|abiraterone|
41017433|NCT05600218|DRUG|No intervention - Observational study|Real life drug evaluation
41017434|NCT02968199|BEHAVIORAL|A brief intervention|The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
41017435|NCT05225181|BEHAVIORAL|perform physical exercise|one 60-min session of physical training
41017436|NCT05225181|BEHAVIORAL|cognitive training|one 60-min session of cognitive training
41017437|NCT05225181|BEHAVIORAL|control group|perform body stretching(15min) and health education courses(90min)
41341023|NCT05838794|OTHER|Stabilization exercise|Cervical and scapulothoracic stabilization exercises will be performed by an experienced physical therapist 3 times a week for 6 weeks, with each session including a warm-up, stabilization exercises, and cool-down and stretching exercises. Postural education will be provided using mirrors to find a neutral balanced position, and the cervical bracing technique with deep neck flexor activation will be used to stabilize the cervical spine. Upper extremity range of motion exercises and cervical dynamic isometric exercises with elastic resistive bands will also be performed. Scapulothoracic stabilization exercises will include specific exercises for muscles affecting scapular orientation related to neck pain, using latex bands with mild or medium tension.
41017438|NCT05173467|PROCEDURE|Robot-assisted Invasion-controlled Surgery|The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.
41017439|NCT05173467|PROCEDURE|Traditional-open Surgery|This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
41017440|NCT03162861|DRUG|sevoflurane inhalation for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
41017441|NCT03162861|DRUG|propofol for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
41341024|NCT01067313|DEVICE|Dialyzer Ultraflux EMiC2|Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
40821940|NCT06513377|OTHER|Performance test|The participant will be asked to execute a protocol in the movement lab that induces progressive feelings of fatigue. This protocol includes a sequence of relevant functional activities, such as stair walking, slope walking, crouching, walking different path shapes. During this execution the Ratings of Perceived Exertion will be questioned, and simultaneously physiological and movement data will be collected.
40821941|NCT03094650|DEVICE|MindMotion PRO|Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises.
40821942|NCT05480436|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28
41017442|NCT04731441|BEHAVIORAL|Home-based Exercise Program Prior to CRS-HIPEC|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
41017443|NCT04731441|BEHAVIORAL|Exercise Education|Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
41017444|NCT01430130|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
40821943|NCT05480436|BIOLOGICAL|COVID-19 vaccine|received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)
41488012|NCT05988749|OTHER|Biofourmis Digital Platform|The intervention is a combination of the American Heart Association's Digital Heart Failure CarePlans and Education Content, delivered through and combined with the Biofourmis Platform. Patients enrolled in this arm will wear the device for 90 days and provide data to the participant's care team.
40821944|NCT05480436|BIOLOGICAL|IIV4+PPV23|received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
41017445|NCT00648297|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fed
41017446|NCT00648297|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fed
41017447|NCT03840785|OTHER|Argentine tango|"Argentine tango sessions will consist of:~* Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~* Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling"
41017448|NCT01648777|DEVICE|L bupivacaine|"L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
41017449|NCT01648777|DRUG|placebo|"* Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~* Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
41341025|NCT01067313|DEVICE|Dialyzer Ultraflux AV1000S|Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
41017450|NCT01856140|BIOLOGICAL|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
41341026|NCT01060124|DRUG|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
41341027|NCT04127461|DEVICE|Medtronic endoscope|The endoscope is a minimally invasive tool used to remove veins from the leg traditionally used for CABG.
41341028|NCT00236210|BEHAVIORAL|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
41341029|NCT00236210|BEHAVIORAL|VIP program|Risk assessment, lifestyle counselling, exercise program
41341030|NCT03260283|DRUG|Pethidine hydrochloride|In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations
41341031|NCT03260283|DRUG|Ropivacaine HCl Inj 7.5 MG/ML|In Group II patients will be administered with 2 ml of ropivacaine (0.75%)
41341032|NCT03260283|DRUG|Fentanyl|15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
41341033|NCT04208880|BEHAVIORAL|TBH Brain Workout 1.0|TBH Brain Workout program with easy challenge activities.
41341034|NCT04208880|BEHAVIORAL|Brain Health Book Club|Each week a new chapter will be read that contains new information to enhance brain health.
41341035|NCT04208880|BEHAVIORAL|TBH Brain Workout 2.0|TBH Brain Workout program with moderately difficult challenge activities.
41341036|NCT04208880|BEHAVIORAL|TBH Memory 1.0|TBH Memory program with easy challenge activities.
41341037|NCT04208880|BEHAVIORAL|TBH Memory 2.0|TBH Memory program with moderately difficult challenge activities
41017451|NCT05458479|DRUG|Fluoxetine|All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
41017452|NCT03969342|DEVICE|Point of care ultrasound training|Five-day in-person training on point of care ultrasound using portable ultrasound devices followed by remote monitoring of practice scanning
41341038|NCT02804373|DRUG|Oxytocin (OXT) continuous|Administration of 24 IU of oxytocin daily during 28 days
41341039|NCT02804373|DRUG|Placebo|Placebo daily during 28 days
41341040|NCT02804373|DRUG|Placebo continuous|Placebo administration the following 2 days after each OXT administration, during 28 days.
41488013|NCT05941689|DEVICE|AI-assisted colonoscopy|AI can not only detect suspicious lesions timely, and label them in the field of view of the colonoscopy, but also monitor withdrawal speed and calculate the clean withdrawal time automatically.
40821945|NCT06477783|DRUG|Teclistamab|Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.
40821946|NCT04971785|DRUG|Semaglutide (SEMA)|Administered as subcutaneous (SC) injection
40821947|NCT04971785|DRUG|Cilofexor (CILO)/Firsocostat (FIR)|Tablets administered orally
40821948|NCT04971785|DRUG|PTM SEMA|Administered as SC injection
40821949|NCT04971785|DRUG|PTM CILO/FIR|Tablets administered orally
41017453|NCT04683055|PROCEDURE|Phacoemulsification combined with trabeculectomy|Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
41017454|NCT04683055|PROCEDURE|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
41017455|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists.
41017456|NCT05534282|BEHAVIORAL|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
41017457|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
41017458|NCT04898218|OTHER|Exercise|The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.
41341041|NCT02804373|DRUG|Oxytocin|Administration of 24 IU of oxytocin every 3 days during 28 days.
41341042|NCT01098032|DEVICE|RenalGuard system|The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate \>300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
41488014|NCT02253836|DRUG|Tipranavir|TPV
41488015|NCT02253836|DRUG|Ritonavir|RTV
41488016|NCT02253836|DRUG|Atazanavir|TAZ
41488017|NCT04997941|DRUG|Tamoxifen Oral Product|Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.
41488018|NCT04997941|DIAGNOSTIC_TEST|Assessment of Ki-67|Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.
41488019|NCT04997941|PROCEDURE|Surgery|The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
41488020|NCT04768166|DRUG|Miglustat 100 MG|100mg/TID in 4w then 200mg/TID in 8 w
40821950|NCT03819556|OTHER|Milk protein in fresh milk|Milk protein in increasing doses.
40821951|NCT00446953|DRUG|betamethasone|2x12 mg betamethazone c-section at 38 weeks
40821952|NCT00446953|OTHER|placebo|c-section at 39 weeks
41341043|NCT01098032|DRUG|Systemic alone therapy|Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
40821953|NCT06605573|DIAGNOSTIC_TEST|Panbio™ HCV Self Test|Rapid diagnostic test (self-test and professional) plus laboratory reference tests
41341044|NCT04864327|BEHAVIORAL|Brief smoking cessation advise|The tobacco cessation protocol consisted of performing a routine assessment (asking) of cigarette use; providing advice on the importance of quitting; performing an assessment of the tobacco user's readiness to quit; assisting in setting a quit date; and making arrangements for follow-up visits. This protocol is popularly known as the 5A's strategy (The first 3A's should be delivered to all smokers regardless of their willingness to quit). Tobacco users were identified by staff nurses. Clinicians provided brief advice on quitting, and the researcher assessed the patient's dependence and readiness to quit. Patients who were not ready to quit were motivated to consider quitting, whereas those who were ready to quit were referred to practitioners who could assist them and follow them in the tobacco cessation clinic
41341045|NCT03156413|DEVICE|F&P nasal mask|Investigative Nasal Mask to be used for OSA therapy
41341046|NCT03026205|DRUG|ARMS-I|
41017459|NCT01603550|OTHER|Sleep Deprivation|Sleep Deprivation
41341047|NCT01942408|PROCEDURE|Repeat PVI|Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
41488021|NCT03123861|DRUG|Gabapentin|Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
40821954|NCT03630198|DRUG|Corticosteroid with lidocaine|Intralesional corticosteroid injection
40821955|NCT03630198|DRUG|Corticosteroid with normal saline|Intralesional corticosteroid injection
40821956|NCT05636384|OTHER|Home-based care|"Home-based medical care is based on a specialized home-based medical team approach, including following:~1. Specialized Home-Based Medical Team Approach~2. Initial Assessment and Education~3. Initial Home Visits and Education~4. Multidisciplinary Team Meeting~5. Regular Assessment After the Initial Visit"
41017460|NCT01603550|OTHER|Energy Restriction|Energy Restriction
41017461|NCT03074734|OTHER|Exposure to secondhand tobacco smoke|The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
41017462|NCT02287415|DRUG|BIA 2-093|
41017463|NCT02287415|DRUG|Warfarin|
41017464|NCT05078723|DIETARY_SUPPLEMENT|Limonene|The investigators will ask the participants to swish 5 times and swallow 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract). The participant will be monitored for a total of 2 hours. Breath samples will be acquired at a total of 11 time points throughout the study. Measurements include 2 baseline measurements followed by the orange peel extract consumption.
41017465|NCT00826501|PROCEDURE|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
41017466|NCT00826501|PROCEDURE|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
41017467|NCT01241734|DRUG|Revlimid|"Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage II:~RICE + Lenalidomide at the MTD days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days"
40821957|NCT06608576|OTHER|Face-to-face standard treatment|Individualized early intervention treatment on physical therapy area as usual in the early intervention facilities once a month for two months. Instructions will be given to the parents for follow-up at home to stimulate the baby's motor development until next face-to-face session.
41017468|NCT03086798|PROCEDURE|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
41017469|NCT03086798|PROCEDURE|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
41017470|NCT00237952|DRUG|EDTA chelating agents|
41017471|NCT04072965|OTHER|balance training|Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
41017472|NCT05163912|BEHAVIORAL|Virtual home intervention|Group classes with active videogames and discussions
41017473|NCT01462903|BIOLOGICAL|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
41017474|NCT03448367|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
41017475|NCT02320019|DRUG|Placebo|Placebo matching YH14618
41017476|NCT02320019|DRUG|YH14618|
41017477|NCT04545242|DRUG|Dexamethasone|Intravenous dexamethasone (low vs. moderate doses) during 10 days
41017478|NCT05937035|PROCEDURE|Customized allogenic bone block surgery|After studying the CBCT to regenerate the posterior sites of the mandible, the investigators will design CAD/CAM freeze- dried bone allograft to fit exactly on the defect morphology that the patients present. A full thickness flap will be released to have a correct access of the defects. Releasing incisions will be performed to achieve the correct closure of the flap. The sterile blocks have to fit perfectly on the defect and fixed by screws. Covered with resorbable membranes fixed with pines and suture. 4 months later, photographs, periapical xrays digital impressions and 2nd CBCTwill be performed. During the implant surgery, a bone trephine will be removed and sent into a Laboratory to make a histological study of the bone block for histomorphometry. After 3 months, second-stage surgery and healing caps will be placed if needed. Impressions will be taken 2 weeks after to perform the final crowns.
41488022|NCT03123861|DRUG|Placebo oral capsule|Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
41017479|NCT02233231|DRUG|Varenicline|Varenicline 2 mg x 1 day 7 to week 12
41488023|NCT03230799|PROCEDURE|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
41488024|NCT03230799|PROCEDURE|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
40821958|NCT06608576|OTHER|Telematic Support|The physiotherapist in charge of the telematic sessions will review and guide in real time through WhatsApp platform, the performance and active participation of the parents in the therapeutic activities being asked to follow-up at home in the face-to-face appointment, correcting, as necessary.
40821959|NCT02694913|OTHER|Non Interventional|This is a non therapeutic, pilot study.
40821960|NCT02947854|DRUG|Fimaporfin (Photosensitizer)|
40821961|NCT02947854|BIOLOGICAL|Hiltonol (Poly-ICLC)|
40821962|NCT02947854|BIOLOGICAL|HPV E7 (Human Papilloma Virus E7) peptides|
40821963|NCT02947854|BIOLOGICAL|KLH (Keyhole Limpet Hemocyanin)|
40821964|NCT06241001|OTHER|eccentric streching|The player will lift up one leg from starting position so he stands on his to-be-trained leg. For performing eccentric exercises of the gastrocnemius muscles, the player will lower his heel until he will feel a slight stretch, while keeping his knee extended
40821965|NCT06241001|OTHER|IASTM|Specially designed tools are used to apply longitudinal pressure along muscle fibers, and treatment usually includes applying to more than the tissues in the isolated location of the pain
40821966|NCT05215860|BEHAVIORAL|Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders|WHO toolkit for Tobacco cessation (5A's and 5R's model)
40821967|NCT05215860|OTHER|visual exposure to personal intraoral photographs of oral lesions at baseline and review|Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
40821968|NCT01968291|BEHAVIORAL|Teach-back|Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
40821969|NCT04730778|DIAGNOSTIC_TEST|serum creatinine and estimated glomerular filtration rate, on daily basis|Assess establishing criteria of CIN through a week after primary PCI
40821970|NCT02911740|OTHER|Urine LAM Ag test|TB diagnostic assay
40821971|NCT06385392|DEVICE|Haptic module and insole device|System for use in daily in-community use that detects the occurrence of freezing of gait (FOG) and triggers external cueing stimuli to unfreeze the individual.
40821972|NCT05423340|OTHER|E-cigarette Flavor|Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
40821973|NCT05423340|OTHER|Tobacco Free Nicotine Pouch|participants will use tobacco free oral nicotine pouches
40821974|NCT04384601|DRUG|Chemotherapy|Perioperative chemotherapy will be administered according to description in two arms.
40821975|NCT06268886|DRUG|BMS-986446|Specified dose on specified days
40821976|NCT06268886|OTHER|Placebo|Specified dose on specified days
40821977|NCT03387995|DEVICE|LVIS stent|The paitents treated by LVIS stent implantation.
40821978|NCT03387995|DEVICE|Solitaire stent|The paitents treated by Solitaire stent implantation.
40821979|NCT03387995|DEVICE|Enterprise stent|The paitents treated by Enterprise stent implantation.
40821980|NCT03387995|DEVICE|Neuroform stent|The paitents treated by Neuroform stent implantation.
40821981|NCT03387995|DEVICE|Flow diverter (FD) stent|The paitents treated by Enterprise FD implantation.
40821982|NCT01894880|PROCEDURE|early SSC|bonding straight after birth
40821983|NCT01894880|PROCEDURE|late SSC|bonding after termination of operation
40821984|NCT04259788|OTHER|AHEI diet|Main intervention is the consumption of an AHEI diet for 12 weeks.
40821985|NCT00165750|DRUG|DONEPEZIL HYDROCHLORIDE|One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
41017480|NCT02233231|DRUG|Placebo|similar tabl
41488025|NCT01088802|RADIATION|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
41488026|NCT01088802|DRUG|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
41017481|NCT03750396|PROCEDURE|Surgical resection|Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.
41017482|NCT03750396|RADIATION|Stereotactic body radiotherapy|Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57\~97.5Gy/6\~10 Fraction).
41341048|NCT01163695|BEHAVIORAL|Children's development account|Children in the experimental condition (the SUUBI program) received, in addition to the usual care, an economic empowerment intervention aimed at promoting asset accumulation for families-and consisting of three major components: 1) workshops focused on asset-building and future planning; 2) a monthly mentorship program for adolescents with peer mentors on life options; and 3) a Child Development Account (CDA), dedicated to paying for secondary schooling, vocational training and/or a family small business. The CDAs were matched savings accounts, with a match rate of 2:1 as an incentive for participants to save, but with a limit on the maximum savings that could be matched (the match cap, in this case, was equivalent to $10 a month).
40821986|NCT03692494|OTHER|Standard of care voice therapy|Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder
40821987|NCT03692494|OTHER|Expiratory muscle strength training (EMST)|EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
40821988|NCT01989780|DRUG|Paclitaxel|
40821989|NCT01989780|DRUG|Bevacizumab|
40821990|NCT01989780|DRUG|Letrozole|
40821991|NCT01989780|DRUG|Anastrozole|
40821992|NCT01989780|DRUG|Exemestane|
41017483|NCT03750396|PROCEDURE|Radiofrequency ablation|RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.
41341049|NCT02389530|DRUG|Fluorescein|Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
40821993|NCT01989780|DRUG|Fulvestrant|
40821994|NCT01989780|DRUG|Goserelin|
40821995|NCT01989780|DRUG|leuprorelin|
40821996|NCT01255813|DEVICE|Stimulation (Sub-perception)|Stimulation applied below the perception threshold
40821997|NCT01255813|DEVICE|Stimulation (Full)|Stimulation applied above the perception threshold
40821998|NCT01255813|OTHER|Control|No stimulation applied
40821999|NCT05755256|DIETARY_SUPPLEMENT|Probiotic|After randomization, participants will consume the probiotic for 12 weeks.
40822000|NCT05755256|DIETARY_SUPPLEMENT|Placebo|After randomization, participants will consume the placebo for 12 weeks.
40822001|NCT05135195|OTHER|In-House Developed VR Platform - AMD, DR, Glaucoma|Participants will conduct experiments using commercial VR headsets and controllers. Visual impairments will be systematically simulated in VR. There are three visual impairment simulations (AMD, DR, and glaucoma) at three levels of severity (mild, moderate, or severe). Symptoms' simulation tools include a gaussian blur shader, distortion shader, and a culling mask with a gray spot in the middle.
40822002|NCT05135195|OTHER|In-House Developed VR Platform - Glaucoma|In the second set of experiments, a multidimensional visual impairment simulation of a single pathology (glaucoma) will be used at three levels of severity (mild, moderate, or severe). The post-processing package to simulate includes glare, difficulty in light, change adaptation, ambient occlusion, visual clutter, and overall blurred effect. The shader graph package will be used to create a distortion localized on assets surfaces only.
40822003|NCT00446472|DRUG|Regranex®|Regranex gel will be used for a total of 16 weeks
41341050|NCT05632913|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
41488027|NCT01088802|DRUG|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
41488028|NCT01663935|DRUG|Levodopa/carbidopa|This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
41488029|NCT03952234|DRUG|L-Citrulline|To determine the safest maximum dose of L-Citrulline which could be used as a potential treatment for adults with disorder of energy metabolism called MELAS
41488030|NCT06156735|OTHER|Passive Music Therapy (P)|Music Therapy Intervention
41488031|NCT06156735|OTHER|Active Music Therapy (A)|Music Therapy Intervention
41488032|NCT06156735|OTHER|Standard Care Control Condition (C)|Without any intervention
41488033|NCT04629859|PROCEDURE|mandibular setback and maxillary advancement|12 patients will undergo mandibular setback and maxillary advancement
40822004|NCT00446472|DRUG|Hydrogel|Placebo hydrogel will be applied for 16 weeks
40822005|NCT02867943|OTHER|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
40822006|NCT04563728|BEHAVIORAL|Surveillance camera(s)|the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)
40822007|NCT05818956|DRUG|TAK-227|TAK-227 capsules.
40822008|NCT03654170|DRUG|BI 425809 mixed with [C-14] BI425809|Oral Solution
40822009|NCT06468527|DRUG|Diponecaftor|"Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains:~* DIR 300 mg/day~* POS 600 mg/day~* NES 10 mg/day"
40822010|NCT06468527|DRUG|Placebo|Placebo once daily for 8 weeks. Oral administration.
40822011|NCT00068913|DRUG|Dichloroacetate|
41488034|NCT04629859|PROCEDURE|mandibular setback|12 patients will undergo mandibular setback
40822012|NCT03464357|RADIATION|fMRI|"The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately."
40822013|NCT01628679|BEHAVIORAL|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
41488035|NCT02812979|DEVICE|Airvo2 with Aerogen Solo|Nebulization of salbutamol with Airvo 2 and Aerogen solo
40822014|NCT00895752|DRUG|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
40822015|NCT04854967|OTHER|Rescind home oxygen order|A note will be entered in the medical record describing the participants randomization into the intervention group. The note will be signed by study staff and will accompany the discontinuation of the patient's home oxygen by a study clinician.
40822016|NCT04854967|BEHAVIORAL|Provider Education|A note will be entered in the medical record informing the patient's individual medical providers (i.e. primary care provider, pulmonologist) of their randomization into the intervention group. The note will include the evidence-base for oxygen use among patients with COPD.
40822017|NCT04854967|BEHAVIORAL|Patient Education|"The patient will receive a patient education page about discontinuation of home oxygen after recovery from a hospitalization that was developed by Consumer Reports in conjunction with the Choosing Wisely Campaign."
40822018|NCT04854967|BEHAVIORAL|Teach-to-goal inhaler training|Teach-to-goal (TTG) inhaler training is a patient-centered education strategy that has been shown to decrease inhaler misuse and decrease acute care utilization. The training is tailored to the patient and meets guideline recommendations for assessment and instruction of inhaler technique. The rounds of assessment and demonstration can be completed until acceptable skill level is attained and tailored to the specific medication prescribed.
41488036|NCT02812979|DEVICE|Mask|Usual nebulization of salbutamol with mask
41341051|NCT01259921|BEHAVIORAL|neurofeedback|Operant conditioning of the EEG provided by computer reinforcement.
41341052|NCT05148689|DRUG|Oxymetazoline hydrochloride Cream, 1%|Cream
41341053|NCT05148689|DRUG|Rhofade™ (oxymetazoline) cream, 1%|cream
41341054|NCT05148689|DRUG|Placebo|cream
41341055|NCT00381719|DRUG|AGN 203818|3 mg Capsule twice daily for 4 weeks
41341056|NCT00381719|DRUG|AGN 203818|20 mg Capsule twice daily for 4 weeks
41341057|NCT00381719|DRUG|AGN 203818|60 mg Capsule twice daily for 4 weeks
41341058|NCT00381719|DRUG|placebo capsule|Capsule twice daily for 4 weeks
41341059|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
41341060|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
41341061|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
40822019|NCT04854967|BEHAVIORAL|Pursed lip breathing|Pursed lip-breathing will be taught to the participants randomized to the intervention arm. This simple technique relieves breathlessness and has been shown to improve functional capacity in patients with COPD. Participants will be given an instructional handout to refer to after the visit.
40822020|NCT05714618|DIAGNOSTIC_TEST|Gadolinium-enhanced cardiac MRI|Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis.
40822021|NCT05714618|DIAGNOSTIC_TEST|B Natriuretic Peptide|Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days.
40822022|NCT05714618|DIAGNOSTIC_TEST|Systemic inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days.
41341062|NCT00728195|DRUG|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
41488037|NCT02812979|DEVICE|arm control Airvo2 without nebulization of salbutamol|Airvo2 with Aerogen Solo. No nebulization of salbutamol
40822023|NCT01702090|DRUG|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
40822024|NCT05143723|DRUG|Gonadotropin-releasing hormone agonist|luteal phase support with gonadotropin-releasing hormone agonist
40822025|NCT03546595|OTHER|Auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
41341063|NCT00728195|DRUG|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
40822026|NCT03546595|OTHER|Sham auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
40822027|NCT06560346|OTHER|Geneticlly confirmed disease causing FXN mutatuion|No intervention in this observational Natural History Study
40822028|NCT06560346|OTHER|Healthy Control|No intervention in this observational Natural History Study
40822029|NCT00001250|DRUG|preoperative dose intense chemotherapy (FLAC/G-CSF)|
41488038|NCT04068649|RADIATION|Palliative Radiation Therapy|Undergo palliative RT
41488039|NCT04068649|OTHER|Quality-of-Life Assessment|Ancillary studies
41488040|NCT04068649|OTHER|Questionnaire Administration|Ancillary studies
41488041|NCT04068649|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41488042|NCT00971841|DRUG|Paclitaxel|
41488043|NCT00988065|DRUG|Placebo run-in dose|Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
41488044|NCT00988065|DRUG|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
40822030|NCT06607393|DRUG|Pembrolizumab|
41017484|NCT00784446|DRUG|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."
40822031|NCT06607393|DRUG|Pemetrexed|
40822032|NCT06607393|DRUG|Cisplatin|
40822033|NCT06607393|DRUG|Carboplatin|
41017485|NCT05528094|DIETARY_SUPPLEMENT|GeniusDrops|"The active ingredients listed below are safe and the study sponsor has noted there are no known side effects of the supplement. The main ingredients are:~Hibiscus flower- Has been shown to boost oxygenation to the brain and vital organs. Has also demonstrated efficacy for boosting the immune system.~Gingko leaf- Has been shown to stimulate memory by increasing mental sharpness and clarity.~Rhodiola- Helps regulate energy and stress level. Gotu kola- Has been shown to have impacts on reducing anxiety. Licorice Root- Helps boost the key brain neurotransmitter called Brain Derived Neurotrophic factor which can help with cognitive development Peppermint Leaf- Reduces fatigue while helping improve cognitive abilities. Has also been shown to promote immune system function."
40822034|NCT04913181|DIAGNOSTIC_TEST|Artificial intelligence sepsis prediction model|The main purpose of this paper is to evaluate the accuracy of the sepsis prediction model established in the early stage. The occurrence of sepsis is determined by the daily clinical judgment of doctors, and the results of sepsis prediction model are matched and corrected.
40822035|NCT04016558|BEHAVIORAL|StreamLine|"StreamLine is an education/disease management program that focuses on systematic methods to identify and resolve specific blood glucose problems, primarily through changes in carbohydrate consumption, and use of basal and bolus insulin. Participants will attend a brief, four-hour meeting with a Certified Diabetes Educator (CDE) and, using standardized blood glucose data, will learn how to employ a five-point blood glucose management system to identify and resolve blood glucose problems (e.g., excursions, lows) that have the greatest HbA1c or hypoglycemic impacts.~Participants will then meet individually (30 minutes) with their CDE to review their blood glucose data, identify a specific blood glucose problem, and use the five-point program to create a plan to address the problem. Four additional individual meetings (30 minutes) will occur at approximately two to three-week intervals to best support individualized and participant-tailored management-change efforts."
40822036|NCT04016558|BEHAVIORAL|TunedIn|"TunedIn utilizes emotion regulation-based strategies to help participants observe that how they feel affects what they do regarding diabetes management. Participants will attend two highly interactive group workshops (6 hours followed by 2 hours) facilitated by a psychologist or social worker experienced in diabetes. Each will identify and discuss common emotional responses related to blood glucose management (e.g., over-reacting, avoiding, and lack of mindfulness).~Between the two workshops (two weeks), participants will complete a feeling log to document feelings, situation/context, and resolution around specific management events. Two individual meetings with the interventionist (30 minutes) will allow participants to identify and address a specific diabetes distress-related problem. Four web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
41341064|NCT02120469|DRUG|everolimus|Given PO
41341065|NCT02120469|DRUG|eribulin mesylate|Given IV
41341066|NCT02120469|OTHER|pharmacological study|Correlative studies
41017486|NCT05571501|DEVICE|Gait assessment using the GAITRIte walkway|10-20 walking assessment using the GAITRite walkway
41341067|NCT02120469|OTHER|laboratory biomarker analysis|Optional correlative studies
41341068|NCT05825989|BEHAVIORAL|Healthy Beat Acupunch Regimen|The Healthy Beat Acupunch (HBA) regimen, developed by Chen et al. (2017), is based on the Meridian Theory or Jing-Luo Theory. The HBA regimen focuses on body movement with hands swinging, resulting in the natural swinging of fists that hit on acupoints. There are three phases: phase 1 is activating qi and blood; phase 2 is punching meridians; phase 3 is relaxing body and mind.
41341069|NCT01222897|DRUG|Valacyclovir hydrochloride|
41341070|NCT06318260|DRUG|Dobutrex|Dobutamine (Dobutrex®) infusion. will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug/kg/min in participants with eGFR below 30 mL/min/1,73 m2. Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped.
41488045|NCT00988065|DRUG|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
41488046|NCT00988065|DRUG|Placebo|Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
41488047|NCT05946954|PROCEDURE|Immediate Dentoalveolar Restoration|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
41488048|NCT05946954|PROCEDURE|Ice cream cone technique|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
40822037|NCT04016558|BEHAVIORAL|FixIt|"FixIt combines components of StreamLine and TunedIn to allow participants to explore feelings and expectations alongside the identification of problematic blood glucose patterns. StreamLine will be co-facilitated by a psychologist/social worker experienced in diabetes and a CDE. Participants will attend two group workshops (six hours followed by four hours), separated by two weeks.~Between the two workshops, participants will record their blood glucose data and keep a parallel feeling log to provide context. Four individual meetings with an interventionist (30 minutes) will allow participants to identify and address a specific blood glucose problem and create a plan to address it. Full discussion of diabetes distress-related aspects of the plan will take place to enhance mindfulness and identify typical emotion regulation strategies to ease problem resolution. Three web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
41017487|NCT01786408|DEVICE|TAP20-C|
41017488|NCT01786408|DEVICE|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
41017489|NCT04641923|OTHER|Adhesion barrier|Adhesion barrier application at the time of first surgery
41017490|NCT01435668|BEHAVIORAL|Brief Motivational Intervention (BMI)|Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.
41017491|NCT01435668|BEHAVIORAL|Simple written advice|Patients receive an information leaflet.
41488049|NCT03416244|DRUG|Nivolumab|Nivolumab 240 mg IV fixed dose every two weeks
41017492|NCT05647512|DRUG|LM-305|Administered intravenously
41017493|NCT05647512|DRUG|Dexamethasone|Administered orally
41017494|NCT04315285|BEHAVIORAL|Treadmill gait training with verbal instruction|Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
41341071|NCT05388734|OTHER|alternative medicine education consultation|The intervention will consist in a 1h30 individual consultation with a GP physician. Patients will be able to ask any questions they have regarding treatments for their breast cancer delivered outside of the hospital. Topics such as benefit-risk ratios, placebo effects and expectancies from CAM will be discussed with the patients. This consultation will promote a shared-decision model to help patients better discuss these matters with their healthcare providers.
41341072|NCT02295436|DRUG|minodronic acid|comparison of different doses, ages and medication conditions
41017495|NCT02059928|DEVICE|Intraosseous Device|
41017496|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Lower Dose|Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight \< 60 kg and Age \< 65 years and ASAI and II)
41017497|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Approved Dose|(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight \<60 kg and Age \<65 years and ASAI and II)
41017498|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Lower Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight \< 60 kg and Age \>/=65 years and ASA 3 or 4
41341073|NCT02789072|OTHER|central aortic pressure (measured in mmHg).|"Blood pressure will only be measured during the 0g (microgravity) phase. Seven 5 ml blood sample will be drawn in the aircraft: before the first parabola (1) and after each block of 5 parabola (6).~On ground after flight, a 9th 5 ml blood sample will be drawn and then the mobil-o-graph, the SOMNOtouch NIBP and the intravenous cannula will be removed."
41341074|NCT03140657|DRUG|Nanocurcumin|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
41341075|NCT03140657|DRUG|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
41341076|NCT03779906|DRUG|Isovue|Isovue will be given to all subjects per the standard of clinical care.
41488050|NCT03416244|DRUG|Ipilimumab|Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
41488051|NCT02387983|DRUG|Posaconazole|Posaconazole 300 mg solid oral tablet
41488052|NCT00712426|DRUG|Creatine Monohydrate|Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration
41488053|NCT00712426|DRUG|Placebo|Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
41017499|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Approved Dose|(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight \<60 kg and Age \>/=65 years and ASA 3 or 4
40822038|NCT03262350|BEHAVIORAL|Yoga|The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
40822039|NCT01991223|DRUG|Dex infusion|Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
41017500|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Lower Dose|(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
40822040|NCT01991223|DRUG|NS infusion|Normal saline will be infused during surgery
41017501|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Approved Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
41017502|NCT02010424|OTHER|control group|standard IVF protocol
41017503|NCT02010424|DEVICE|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
41341077|NCT00682760|DRUG|Korean Botulinum toxin type A (KbtxA) and Botox injection|Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
41017504|NCT01618539|DRUG|propofol|varying intravenous dosages
41341078|NCT01427660|BEHAVIORAL|Community Health Worker Diabetes Education: Print media|Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
41341079|NCT01427660|BEHAVIORAL|CHW Diabetes Education: tailored web site|Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
41017505|NCT06301165|DRUG|TPC induction chemotherapy|TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).
41017506|NCT06301165|DRUG|GP induction chemotherapy|GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)
41017507|NCT03770468|PROCEDURE|Blood drawl|
41017508|NCT05728892|DRUG|Melatonin 3 MG|Preopertive melatonin adminstration oral 0.2 mg /kg 45 min before general anaethesia.
41017509|NCT05728892|OTHER|Placebo|Placebo medication will be given to control group
41341080|NCT02668055|BIOLOGICAL|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
41341081|NCT02403960|DIETARY_SUPPLEMENT|probiotic|the patients used probiotic tablets in addition to scaling and root planning
41488054|NCT01268332|DRUG|Non-medicated Intravaginal Ring|Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
41488055|NCT00278889|DRUG|AZD2171|oral tablet
41488056|NCT00278889|DRUG|5-fluorouracil|intravenous infusion
41488057|NCT00278889|DRUG|Leucovorin|intravenous infusion
41488058|NCT00278889|DRUG|Oxaliplatin|intravenous infusion
41488059|NCT00278889|DRUG|Bevacizumab|intravenous infusion
40822041|NCT04359290|DRUG|Ruxolitinib administration|Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.
40822042|NCT04319380|BIOLOGICAL|Tetanus/diphtheria toxoids|One dose of tetanus/diphtheria toxoids vaccine (June) in year 1 and year 2.
40822043|NCT04319380|DRUG|SMC with SP+AQ|Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
40822044|NCT04319380|BIOLOGICAL|RTS,S/AS01|One booster dose of RTSS/AS01 (June) in year 1 and 2.
40822045|NCT04319380|DRUG|SMC placebo|Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
40822046|NCT06029673|DRUG|Cabergoline 1 MG|Dopamine agonist
40822047|NCT06029673|DRUG|Placebo|Placebo
40822048|NCT02596958|DRUG|Bevacizumab|Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
40822049|NCT01824329|PROCEDURE|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
41341082|NCT02403960|DIETARY_SUPPLEMENT|placebo|the patients used placebo tablets in addition to scaling and root planning
41341083|NCT00922038|BEHAVIORAL|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
41341084|NCT02267902|DRUG|DA-1229|
41341085|NCT03243955|DEVICE|Verum TEAS|TENS unit with electrodes applied to acupuncture point locations
41341086|NCT03243955|DEVICE|Sham TEAS|TENS unit with electrodes applied to non-acupuncture point locations
41341087|NCT02189304|DRUG|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
41341088|NCT02189304|DRUG|PT009|PT009 administered as 2 inhalations
41341089|NCT02189304|DRUG|Symbicort Turbohaler|Symbicort Turbohaler taken as 2 inhalations
41341090|NCT03965546|COMBINATION_PRODUCT|Sorafenib combined with ET140202-T cell|"1. Sorafenib starting dose of 400mg b.i.d. a.c.~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion"
41341091|NCT03965546|COMBINATION_PRODUCT|TAE combined with ET140202-T cell|"1. Transarterial embolization(TAE) treatment~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)"
41341092|NCT03965546|BIOLOGICAL|ET140202-T cell|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)
41341093|NCT01711580|OTHER|EORTC QLQ-C30|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
41341094|NCT01711580|OTHER|EORTC QLQ-BN20|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
41341095|NCT01711580|OTHER|Hopkins Verbal Learning Test-Revised (HVLT-R)|The HVLT-R is a cognitive test to assess verbal learning and memory.
41341096|NCT01711580|OTHER|Stroop color-word test|The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
41341097|NCT01711580|OTHER|Controlled oral word association test (COWA)|The COWA is a measure of verbal fluency that requires expressive language and executive functions.
41341098|NCT01711580|OTHER|Jamar hand dynamometer|The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
41341099|NCT01711580|OTHER|EORTC QLQ- FA13|The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
41341100|NCT01711580|OTHER|Trail Making Test (TMT)|The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
41341101|NCT01908049|DIETARY_SUPPLEMENT|Probiotic.|
41341102|NCT01908049|DIETARY_SUPPLEMENT|Placebo|
41488060|NCT04190719|OTHER|multimodal prehabilitation|"Paprika prehabilitation program content: patients will have choices for each activity. Messages and motivation will be reinforced by using a mobile app or leaflet advices, according to patient's preferences.~* Physical activity promotion by discovering ebike, personalised gymnastics and encouragement to increase the number of daily steps of patients, measured by a wristband and a mobile App~* An individualized nutritional optimization plan with dietary advices and protein supplementation (if necessary).~* Psychological support will be proposed through auto-hypnosis sensibilisation or management of stress with Cognitive Behavior Stress Management technics"
41488061|NCT01878162|OTHER|Exercise|
40822050|NCT01824329|PROCEDURE|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
40822051|NCT05068063|DRUG|Bupivacaine Injection|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of Bupivacaine 0.25%
40822052|NCT05068063|DRUG|normal Saline|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
40822055|NCT00022685|BIOLOGICAL|epratuzumab|
40822056|NCT04442256|DRUG|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
41488062|NCT05966675|DEVICE|conduction system pacing|Implantation of cardiac implantable electronic device (CIED) with conduction system pacing (left bundle branch area pacing or his bundle pacing).
41488063|NCT05966675|DEVICE|right ventricular or biventricular pacing|Implantation of cardiac implantable electronic device with right ventricular or biventricular pacing according to left ventricular ejection fraction and current ESC guidelines.
41488064|NCT02519335|DRUG|Dexrazoxane|Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
40822057|NCT03911323|OTHER|diabetic retinopathy|Patients with diabetes enrolled will undergo nonmydriatic fundus imaging and seven-field stereoscopic photography. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the AI algorithm will be compared to the diagnosis of seven-field stereoscopic photography by ophthalmologist. Sensitivity and specificity will be calculated to evaluate the performance of AI algorithm.
40822058|NCT03354546|DIAGNOSTIC_TEST|Frailty index|A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
40822059|NCT05131776|DEVICE|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
40822060|NCT03920293|BIOLOGICAL|Ravulizumab|Concentrated sterile, preservative-free aqueous solution (10 milligrams \[mg\]/milliliter \[mL\]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
40822061|NCT03920293|DRUG|Placebo|Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
41017510|NCT03518320|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
40822062|NCT04744389|DEVICE|Hypothermic Machine Perfusion|The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.
41341103|NCT01574417|DIETARY_SUPPLEMENT|control margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
41341104|NCT01574417|DIETARY_SUPPLEMENT|plant stanol-enriched margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
41341105|NCT00197340|DRUG|Epidural ropivacaine|
41341106|NCT04635345|OTHER|External Vibrator - patient-administered.|Patient provided with external vibrator for self-use, as well as vaginal dilators.
41341107|NCT04635345|OTHER|Standard care|Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.
41341108|NCT03641794|DRUG|DN1406131|IDO1 and TDO2 inhibitor
41341109|NCT03641794|DRUG|Placebo|Placebo
41341110|NCT00106249|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
41488065|NCT05968560|BEHAVIORAL|CBT Skills Group for CHR Youth|"CBT skills group is designed to boost peer support, reduce isolation, normalize psychotic-like experiences to lessen distress, reduce cognitive biases, facilitate positive beliefs, and enhance reasoning and decision-making. CBT skills group uses CBT to Prevent Paranoia manual to teach individuals to make adaptive appraisals of their experiences (e.g. voices and other cognitive intrusions) to prevent the perception of such events as threatening."
41488066|NCT05968560|BEHAVIORAL|Individual CBT sessions|CBT skills learned in group are personalized in individual sessions focused on: a) facilitating learning of CBT skills; b) tailoring CBT skills to personal goals; c) facilitating successful interaction with peers in the group; and d) providing academic and vocational support. Youth may opt to invite family members to join individual sessions as needed.
40822063|NCT04744389|DEVICE|Normothermic Machine Perfusion|Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
40822064|NCT06032234|OTHER|This is an observational study|This is an observational study
40822065|NCT02501720|PROCEDURE|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
40822066|NCT02501720|PROCEDURE|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
41017511|NCT03518320|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
41017512|NCT03985553|BEHAVIORAL|Parenting Self-Management Program|
41017513|NCT06209112|DRUG|Sevoflurane|The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
41341111|NCT00106249|DEVICE|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
41341112|NCT01425307|DRUG|Hydroxyurea|Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
41341113|NCT04841213|PROCEDURE|Dental implantation|Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue
41341114|NCT06031181|PROCEDURE|Sublobar Resection|Sublobar Resection includes segmentectomy and wedge resection
41341115|NCT00407641|DRUG|Tinzaparin administration|Patients will receive tinzaparin during the HD session
41341116|NCT00407641|DRUG|Heparin administration|Patients will receive Heparin as an anticoagulant during the HD session.
41341117|NCT05795400|DRUG|Dapagliflozin 10mg Tab|10 mg tablets given once daily, per oral use
41341118|NCT05795400|DRUG|Placebo|tablet of placebo drug dosed once daily
41341119|NCT06066853|DRUG|MDMA|MDMA-assisted psychotherapy
41017514|NCT06571786|DRUG|Perflutren lipid microsphere|Definity (Lantheus Medical Imaging, N Billerica, MA) in 25 mL of saline infused for up to 6 minutes
41017515|NCT01527916|DRUG|placebo|Placebo Comparator
41017516|NCT01527916|DRUG|donepezil|Active Comparator
41017517|NCT01527916|DRUG|ABT-126|low dose, middle dose, high dose
41017518|NCT01663272|DRUG|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
41341120|NCT03218189|OTHER|Country characteristics|Observational study of country characteristics
40822067|NCT02501720|PROCEDURE|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
40822068|NCT05539560|OTHER|Olfactory training with essential oils|Olfactory training twice daily with essential oils from Urtegaarden Aps with scents of orange, lavender, clove and peppermint. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
40822069|NCT05539560|OTHER|Olfactory training with fragrance-free oils|Olfactory training twice daily with fragrance-free oils from Urtegaarden Aps in the same four containers as the intervention group. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
40822070|NCT02852395|DRUG|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
40822071|NCT02852395|DRUG|Placebo|Oral dose; appearance matched to JNJ-48816274
40822072|NCT00055354|PROCEDURE|Acupuncture|
40822073|NCT00055354|BEHAVIORAL|Cognitive Behavioral Therapy|
40822074|NCT05529316|DRUG|Botensilimab|An anti-CTLA-4 monoclonal antibody
40822075|NCT05529316|DRUG|Balstilimab|An anti-PD-1 monoclonal antibody
40822076|NCT00118313|BIOLOGICAL|incomplete Freund's adjuvant|
41017519|NCT01663272|DRUG|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
41017520|NCT01144104|BEHAVIORAL|Public Service Announcement|
41488067|NCT05968560|BEHAVIORAL|CBT Skills Group for Families|"Family members are taught the same CBT skills that are taught to CHR youth to facilitate use of CBT skills at home. Family members also learn how to prompt CHR youth to use CBT skills through effective communication, such as empathic listening and encouraging alternative explanations. CBT skills group for family members uses a combination of didactic learning (skills are described in CBT Skills for Families manual and demonstrated via video examples) and practice (skills are role-played). Youth attend one group session and one individual session per week, and family members attend one group session per week."
41488068|NCT04677881|OTHER|Intervention group|intervention group: bread with sourdough control group: bread with yeast
40822077|NCT00118313|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
40822078|NCT00118313|BIOLOGICAL|sargramostim|
40822079|NCT00118313|BIOLOGICAL|tetanus toxoid helper peptide|
41017521|NCT01144104|BEHAVIORAL|Interactive Multi-Media Computer Program|
40822080|NCT00118313|DRUG|dimethyl sulfoxide|
41341121|NCT04720560|DIAGNOSTIC_TEST|regulatory B cell by flow cytometry|"4-Evaluation of the Frequency of regulatory B cells (Bregs) by Flow Cytometry Using flow cytometry, circulating Bregs will be detected using FITC-conjugated-CD38, PE-conjugated-CD24 (Bioscience, USA), and PerCP-conjugated CD19 (BD Bioscience, USA). Briefly, 100 µl of blood sample will be incubated with 10 µL of CD24, CD38 and CD19 for 20 minutes at 4 °C in the dark. Following incubation, RBCs will be lysed and washed. Cells will be fixed and permeabilized then stained with APC-conjugated IL-10 (BD Bioscience, San Jose, CA, USA) and analysis will be done by FACS Calibur flow cytometry with CellQuest software (Becton Dickinson Biosciences, San Jose, CA, USA).~An isotype-matched negative control will be used for each sample. Forward and side scatter histograms will be used to define the lymphocytes population. CD19+ IL-10+ B cells will be gated, then the expression of CD38 and CD24 on the CD19+B cells will be detected. Bregs will be identified as CD19+ IL-10+CD24+hiCD38+hi cells."
40822081|NCT00118313|DRUG|imiquimod|
40822082|NCT00118313|PROCEDURE|adjuvant therapy|
40822083|NCT02374814|DRUG|Rabies vaccine|Compare dose schedule and route of administration
40822084|NCT02374814|DRUG|Placebo|Placebo
40822085|NCT03326921|BIOLOGICAL|CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|Given IV
40822086|NCT03326921|DRUG|Fludarabine|Given IV
40822087|NCT03326921|OTHER|Laboratory Biomarker Analysis|Correlative studies
40822088|NCT06605040|OTHER|Dissemination via Social Media|"Participants in the experimental group will follow a scientific Instagram profile where content will be shared. The profile will remain open, allowing permanent access to all posts. To optimize Instagram\&amp;amp;#39;s algorithm, we will use an existing active profile. Any control group participants already following the profile will be removed upon allocation.~For each selected article, we will create three presentations using Instagram features like carousel images and short videos, shared as posts, stories, and reels. This strategy will provide content for 30 weeks of daily posts. Each post will feature visually appealing graphics to convey scientific information and support evidence-based practice (EBP) competencies."
40822089|NCT06605040|OTHER|Dissemination via Email|The participant allocated to the control group will receive a different summary each day, along with a link to the full article. This strategy was chosen to replicate the approach used by scientific journals to disseminate new issues.
40822090|NCT06502691|OTHER|Best Practice|Receive of standard care
40822091|NCT06502691|PROCEDURE|Biopsy of Breast|Undergo breast biopsy
41017522|NCT01144104|BEHAVIORAL|Sleep Hygiene Video|
41341122|NCT04921410|DEVICE|Biofeedback Knee Sleeve|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. A 'bad' knee motion will provide a haptic output to the wearer (biofeedback) so that they can take note of what the previous motion was that caused the device to signal a warning.
41341123|NCT04921410|DEVICE|Sham Biofeedback|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. This intervention will provide sham biofeedback during training sessions.
40822092|NCT06502691|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
40822093|NCT06502691|OTHER|Electronic Health Record Review|Ancillary studies
40822094|NCT06502691|OTHER|Fludeoxyglucose F-18|Given FDG
40822095|NCT06502691|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
40822096|NCT06502691|DRUG|Immune Checkpoint Inhibitor|Receive ICI treatment
41017523|NCT03626129|PROCEDURE|Oximetry guided deflation|"At the cath.lab. (Step 1) a hemostasis test is performed: oxymetry device on the thumb, compress a.ulnaris, evaluate if curve on device (=Patent hemostasis). If patent no further action. If not patent, air is deflated until a.radialis is patent (curve on device and no bleeding). If bleeding occurs before patency then re-inflate 1-2 ml. air until hemostasis (=no patent hemostasis). In patients with Patent hemostasis no action is taken in sixty minutes whereafter the TR-band is fully deflated (Step 2), and if bleeding then air is re-inflated until hemostasis and step 2 is repeated every 20 minutes until the TR-band is fully deflated with hemostasis. If no patent hemostasis at cath.lab. a hemostasis test is performed after 20 min. If patent hemostasis is achieved no action is taken in sixy minutes (as above). If still not patent then further action as in group A."
41017524|NCT01068327|DRUG|gemcitabine hydrochloride|Given IV
41017525|NCT01068327|DRUG|leucovorin calcium|Given IV
41341124|NCT04012333|DRUG|OLIMEL 7,6%E / PeriOLIMEL 2,5%E|OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
41488069|NCT06125574|OTHER|Osteopathic Manipulative Medicine|Individuals in the experimental cohort will undergo a systematic osteopathic manipulative treatment protocol encompassing paraspinal inhibition, rib raising, and condylar decompression techniques.
41017526|NCT01068327|DRUG|fluorouracil|Given IV
41017527|NCT01068327|DRUG|nelfinavir mesylate|Given PO
41488070|NCT04335526|DRUG|Cholestyramine Resin|Change bile acid pool by cholestyramine treatment
41488071|NCT04275765|BEHAVIORAL|Arm 2:Behavioral Intervention with nudges & Facebook interaction|Participants will receive nudges and be enrolled to Facebook group for self-learning.
41017528|NCT01068327|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
41017529|NCT01068327|RADIATION|hypofractionated radiation therapy|Undergo radiotherapy
41341125|NCT03375762|OTHER|Remote ischemic perconditioning|Five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
41341126|NCT03375762|OTHER|Sham remote perconditioning|Sham five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
41341127|NCT02437721|OTHER|infant formula containing folic acid|
41341128|NCT02437721|OTHER|infant formula containing MTHF|
41488072|NCT04275765|OTHER|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
41488073|NCT05704036|DRUG|Transdermal estrogen|Transdermal estradiol 0.1 mg/day, applied once weekly
41488074|NCT05704036|DRUG|Progesterone|Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
40822097|NCT06502691|DRUG|Poly (ADP-Ribose) Polymerase Inhibitor|Receive PARP inhibitor treatment
40822098|NCT06502691|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FTT PET
41017530|NCT01068327|PROCEDURE|therapeutic conventional surgery|Undergo surgery
41017531|NCT01119261|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
41017532|NCT01119261|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
41017533|NCT03844451|DRUG|Liposomal Bupivacaine|At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.
41017534|NCT03844451|DRUG|Bupivacaine and Epinephrine|At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
41017535|NCT04745143|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of schizophrenia
41017536|NCT04745143|DRUG|Placebo Cap|Use of placebo as a comparator
41017537|NCT01130740|BEHAVIORAL|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
41017538|NCT05404516|DRUG|Sorafenib|"Induction cycle(s): 400 mg BID on days 8-21.~Consolidation cycles 1-4: 400 mg BID on days 1-21.~Maintenance therapy: 400 mg BID for one year."
41017539|NCT05404516|DRUG|Idarubicin|"Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3."
41017540|NCT05404516|DRUG|Cytarabine|"Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3."
41017541|NCT05004727|DRUG|Guselkumab|Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
41017542|NCT05004727|DRUG|Placebo|• Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
41017543|NCT03646344|DRUG|Heme Arginate 25 MG/ML|IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
41017544|NCT03646344|DRUG|0.9% Sodium-chloride|Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
41488075|NCT06275191|BEHAVIORAL|Multicomponent intervention|The multicomponent intervention consists of (1) a single 45-60-minute academic detailing session with provider participants, plus (2) provision of patient post-extraction instruction materials and (3) provision of blister-packaged acetaminophen and ibuprofen for distribution to adolescent/young adult patients after tooth extraction in the course of clinical practice
41488076|NCT06275191|OTHER|Usual care|No intervention.
41488077|NCT06131749|OTHER|No intervention|No intervention, observational cohort study
40822099|NCT06502691|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
40822100|NCT05397587|BIOLOGICAL|Experimental Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
41017545|NCT02996721|BIOLOGICAL|Vitamin D3|Vitamin D3 (cholecalciferol) will be provided to participants of the study.
41017546|NCT06302387|PROCEDURE|Acellular Dermal Matrix|The ADM arm involved vertical soft tissue augmentation using an acellular dermal matrix. This process included the placement of a porcine dermal collagen graft (Mucoderm®, Institut Straumann AG, Switzerland) atop the dental implant site. The graft, measuring 15x20 mm, was hydrated in a 0.5% Metronidazole solution for 20 minutes before application, then trimmed and placed to extend 10 by 5 mm beyond the implant margins in both buccal and lingual directions. The primary wound closure was achieved using double mattress suturing with 6-0 Prolene (Ethicon, USA).
41341129|NCT04746157|OTHER|Nurse intervention|Patients will undergo an individualized patient care plan conducted by a lead nurse. According to their results on the Stroke Riskometer and their cardiovascular risk factors, the nurse will prepare a phone call for the next two weeks with information and support adapted to each patient and their necessities. Phone calls will be repeated monthly until the sixth month, then, one more the ninth month and one last previous to the end of the treatment. Patients will be able to contact the reference nurse whenever they would need to.
41017547|NCT06302387|PROCEDURE|Soft Tissue Expansion using Tenting Technique|The Tenting Technique arm involved soft tissue expansion using a submerged healing abutment to promote soft tissue growth. After implant placement, 2 mm healing abutments were set on the implants. Flaps were mobilized using vertical releasing incisions, and tension-free wound closure was achieved with horizontal mattress sutures followed by suturing the incision line with interrupted sutures for primary and submerged healing. This method aimed to create a subepithelial healing space for soft tissue expansion and augmentation.
41017548|NCT01915368|BEHAVIORAL|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
41341130|NCT02293590|DRUG|Certolizumab Pegol|
41341131|NCT00852098|PROCEDURE|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
41341132|NCT00852098|PROCEDURE|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
41341133|NCT01386229|DRUG|Ketamine|During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
41341134|NCT01386229|DRUG|Etomidate|During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
41341135|NCT04566757|BIOLOGICAL|Umbilical Cord Blood Plasma|Intravenous Infusion of Umbilical Cord Blood Plasma
41341136|NCT00588757|DEVICE|Optease IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
41017549|NCT01915368|BEHAVIORAL|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
41017550|NCT01915368|BEHAVIORAL|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
41266258|NCT06100575|BEHAVIORAL|Website (www.mee-leven.be)|"The tool is a website aimed siblings and children of someone who has suicidal thoughts and/or behaviors. The intended objectives of the tool are 1) to contribute to knowledge about suicide and health care options, 2) to increase perceived competences in dealing with suicidality of a family member, 3) to reduce perceived pressure and negative feelings such as hopelessness and 4) to be accessible and user-friendly.~These objectives are achieved by providing the following content: 1) concerning the sibling/child themselves (primary objective) : information about the potential impact of having a suicidal family member, own needs, informal and formal (self) care, dealing with the suicidal family member, dealing with other family members 2) concerning the suicidal family member (Secondary objective): information about the suicidal process, signal recognition, how to provide support/create a safe environment for suicidal loved ones , help available for suicidal relatives"
41341137|NCT00588757|DEVICE|Gunter-Tulip IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
41341138|NCT00877760|DRUG|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
41341139|NCT00877760|DRUG|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
41341140|NCT00233181|BEHAVIORAL|Home-based adherence monitoring|
40822101|NCT05397587|BIOLOGICAL|Control Vaccine|The EV71 vaccine was manufactured by Institute of Medical Biology,Chinese Academy of Medical Sciences ,and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
41341141|NCT03924427|DRUG|BMS-986165|Oral tablet administration
41341142|NCT00442130|BIOLOGICAL|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
41341143|NCT00442130|PROCEDURE|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
41341144|NCT01174836|OTHER|Educational session|Physicians will have a brief education session provided in powerpoint about the risks of CT
41341145|NCT01481766|DIETARY_SUPPLEMENT|Ferrous Sulfate|6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
41341146|NCT01481766|DIETARY_SUPPLEMENT|Placebo|0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
41341147|NCT01481766|BEHAVIORAL|Dietary counseling|Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
41341148|NCT01518309|DRUG|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
41341149|NCT00453323|DRUG|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
41341150|NCT00453323|DRUG|Capecitabine|capecitabine 900mg/m2 bid po on day 1\~14, 1 weeks rest, until disease progression
41341151|NCT04459104|OTHER|Low glycemic load|Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
41341152|NCT04459104|OTHER|High glycemic load|Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
40822102|NCT05843903|BEHAVIORAL|#BabyLetsMove|The #BabyLetsMove digital health intervention uses a multi-level, systems-change approach. At the systems-level, racially concordant young adult WIC moms will be trained as health coaches. At the person level, adolescent WIC clients will be given empirically supported behavior goals, self-monitoring text messages with automated feedback, tailored skills training materials, a FitBit device, and tailored peer coaching support. The #BabyLetsMove intervention design is based on formative Teen Mom Study findings to build social cognition, affect, and skills to modify 3 concrete, achievable, and easily monitored behavioral targets: (1) Limit television viewing time to less than 2 hours per day; (2) Walk at least 10,000 steps per day; and (3) Do 20 minutes or more of exercise per day.
40822103|NCT04728152|OTHER|Blood and salivar test|"Saliva samples will be taken (concomitant with a visit carried out as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks).~Blood samples will be taken at two stages (concomitant with a blood test performed as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks)."
41266259|NCT04447885|DEVICE|weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
41341153|NCT00096551|DRUG|Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)|
41341154|NCT00096551|DRUG|Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)|
41488078|NCT01515930|BEHAVIORAL|Parent Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding monitoring diabetes care.
40822104|NCT00539383|DRUG|ANG1005|IV infusion once every 21 days
40822105|NCT00062023|DRUG|Acetylsalicylic acid (Aspirin)|Patients receive oral aspirin once daily for 12 months.
40822106|NCT00062023|DRUG|Sulindac|Patients receive oral sulindac twice daily for 12 months.
40822107|NCT00062023|DRUG|Ursodiol|Patients receive oral ursodiol three times daily for 12 months.
40822108|NCT00062023|OTHER|Sulindac Placebo|Oral sulindac placebo twice daily.
40822109|NCT05272137|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
40822110|NCT04807088|PROCEDURE|Tactile-kinesthetic Stimulation|
40822111|NCT04807088|OTHER|Placebo|
40822112|NCT04914923|DEVICE|Muse|Muse is an EEG headset device created by Interaxxon to track brain waves during mindfulness sessions.
40822113|NCT04914923|BEHAVIORAL|Cognitive Behaviour Therapy (CBT)|Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard treatment for OCD. The efficacy of CBT has been well established, with numerous studies demonstrating that it leads to significant and lasting reduction in OCD symptoms for the majority of completers.
40822114|NCT04914923|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-based interventions (MBIs) including MBCT, are interventions that incorporate formal and informal mindfulness practice in order to treat mental health concerns.
40822115|NCT00000419|DRUG|Premarin and Provera|
40822116|NCT02286934|DRUG|Carvedilol|"* Day 1 to 3 : Carvedilol 12.5 mg qd~* Day 4 to 8 : Carvedilol 25 mg qd~* Day 9 to 11 : Carvedilol 12.5 mg qd"
40822117|NCT02286934|OTHER|Isoproterenol Sensitivity Test|Day 0, 1, 8 : Isoproterenol Sensitivity Test
41341155|NCT00096551|DRUG|Recombinant Fowlpox-GM-CSF|
40822118|NCT06598228|OTHER|No Intervention: Observational Cohort|no intervention
41266260|NCT06545344|OTHER|Best Practice|Receive usual care
40822119|NCT05659719|OTHER|Recifercept|Patients received recifercept intervention in the phase 2 clinical trial
40822120|NCT06401031|DEVICE|Press Needle|Press needle is patch-type acupuncture needle which has a very small needle. This is placed onto acupuncture point and give a simultaneous stimulation, which is held in place with a small, sterile surgical adhesive patch.
40822121|NCT06401031|DEVICE|Sham Press Needle|Sham press needle is a surgical adhesive patch without needle, that is placed onto acupuncture point
40822122|NCT06363890|DIAGNOSTIC_TEST|TAQMan Array Card|Real time PCR test to detect diarrheal pathogens.
40822123|NCT02368912|DRUG|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
40822124|NCT02368912|DRUG|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
40822125|NCT02368912|DRUG|ASP1707 single dose fasted|Oral, healthy young male
40822126|NCT02368912|DRUG|ASP1707 single dose fed|Oral, healthy young male
41266261|NCT06545344|PROCEDURE|Palliative Care Consultation|Attend a palliative care visit
41266262|NCT06545344|OTHER|Survey Administration|Ancillary studies
41266263|NCT06545344|OTHER|Tumor Board Review|Undergo evaluation by tumor board
41266264|NCT05768373|DEVICE|3M™ Clinpro™ Fluoride Aqueous Solution|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
41017551|NCT06085417|DRUG|Bupivacaine + dexamethasone|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
41266265|NCT05768373|DEVICE|3M™ Vanish™|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
41266266|NCT01852084|DEVICE|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
40822127|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
40822128|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
41266267|NCT01852084|DEVICE|enVista control lens|Spherical Control lens
40822129|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
40822130|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
41266268|NCT05939297|OTHER|Heart Health Self-efficacy and Self-Management Scale|In order to measure the self-management and self-efficacy levels of the individuals, patients will be administered the Heart Health Self-efficacy and Self-Management Scale.
41266269|NCT05939297|OTHER|Self-Care Management Scale in chronic diseases|For the external construct validity statistical method, the self-management level of the individuals will also be determined with the Self-Care Management in Chronic Diseases Scale, which has been previously validated and reliable in Turkish.
41266270|NCT05939297|OTHER|general self-efficacy scale|For the external construct validity statistical method, the self-efficacy level of the individuals will also be determined with the general self-efficacy scale, which has been previously validated and reliable in Turkish.
41266271|NCT05785195|DEVICE|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
41266272|NCT01393977|PROCEDURE|rehabilitation of limb function|only receive rehabilitation of limb function
41266273|NCT01393977|PROCEDURE|Stem Cells Transplantation|mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
41266274|NCT03393026|DRUG|Lurasidone|Lurasidone 40-160 mg/day for 6 weeks
41266275|NCT00962026|DRUG|Rilonacept|Rilonacept given subcutaneously, dose per package labeling, once weekly.
41266276|NCT01041248|DRUG|Tocilizumab|8mg/kg every 2 weeks i.v.
41266277|NCT01618760|DRUG|Risperidone Tablet 1 mg|1 mg tablet once a day
41266278|NCT01618760|DRUG|Risperidone|1 mg tablet once a day
41266279|NCT05631912|BIOLOGICAL|Autologous CD19-STAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1×10\^6 cells/kg) ,dose 2 (3×10\^6 cells/kg) ,dose 3 (1×10\^7 cells/kg); Phase 2 : Appropriate dose
41266280|NCT05631912|DRUG|Fludarabine|Intravenous fludarabine 25-30 mg/m\^2/day on days -5, -4, and -3.
41266281|NCT05631912|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
41266282|NCT03863314|DEVICE|Virtual Simulation|Virtual simulation of workplace-related scenarios of pre-recorded videos using the same actors
41266283|NCT03863314|OTHER|In-person Simulation|In-person simulation of workplace-related scenarios with live actors
41266284|NCT00789633|DRUG|Masitinib|Masitinib at 9 mg/kg/day given orally twice daily
41266285|NCT00789633|DRUG|Placebo|Matching placebo given orally twice daily
41266286|NCT00789633|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m2 by intravenous infusion
41266287|NCT02804763|DRUG|Placebo|Solution for infusion, 0,9% saline
41266288|NCT02804763|DRUG|Dapirolizumab pegol (DZP)|Solution for infusion
41266289|NCT02487108|DRUG|TV-46763|TV-46763 will be administered per dose and schedule specified in the arm description.
41266290|NCT02487108|DRUG|Placebo|Placebo matching to TV-46763 will be administered per schedule specified in the arm description.
41266291|NCT01289496|DRUG|Peg-interferon alpha-2a, Ribavirin|"* 4 weeks RBV priming;~* 24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);~* 24 weeks Follow-Up~Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.~Ribavirin 200 mg tablets"
41266292|NCT05430620|DRUG|Oxygen|Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
41266293|NCT06484894|DEVICE|Pentacam and IOL master|Device used for measurement of central corneal thickness
41266294|NCT02876978|GENETIC|CAR-GPC3 T Cells|Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
41266295|NCT02876978|DRUG|Fludarabine|30 mg/m\^2/day x 4 days
41266296|NCT02876978|DRUG|Cyclophosphamide|500 mg/m\^2/day x 2 days
40822131|NCT02368912|DRUG|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
40822132|NCT02368912|DRUG|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
40822133|NCT00651495|BEHAVIORAL|Patient decision aids for chronic conditions|Videos providing comprehensive information about chronic disease management
40822134|NCT00470093|BIOLOGICAL|recombinant interferon-α|
40822135|NCT00470093|BIOLOGICAL|recombinant interleukin-6|
40822136|NCT06516614|BEHAVIORAL|Sleep Coach|Sleep-promoting intervention consisting of 4 phone sessions to improve sleep duration and consistency.
40822137|NCT06516614|BEHAVIORAL|Diabetes Education|Participants will receive a a binder with educational information about diabetes and educational messages from the study team.
40822138|NCT06605313|DEVICE|SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System|Transcathether Edge-to-Edge repair for tricuspid regurgitation with SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System.
41488079|NCT01515930|BEHAVIORAL|Parent & Child Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding diabetes care.
41488080|NCT01515930|BEHAVIORAL|Computer-Delivered Information|Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
40822139|NCT06415981|DEVICE|Hypoglossal nerve and/or Ansa Cervicalis stimulation|Device stimulation of the hypoglossal nerve and/or Ansa Cervicalis
40822140|NCT04446260|DRUG|SHR-A1811|be administered via intravenous (IV) infusion
40822141|NCT05438602|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
40822142|NCT05438602|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
40822143|NCT05438602|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
40822144|NCT05438602|DRUG|Placebo for ritonavir|Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
40822145|NCT04899375|DEVICE|Floss band|Tissue-flossing, is the use of an elastic band to provide compression on soft-tissue and joints whilst performing active and, or passive range of motion.
40822146|NCT04899375|DEVICE|ACE bandage|An ACE bandage is a cloth wrap used to provide compression
40822147|NCT02850861|DEVICE|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
40822148|NCT05514938|DRUG|Polypill|Polypill formulation consisting of rosuvastatin, aspirin, and prasugrel or consisting of rosuvastatin, aspirin, and clopidogrel.
40822149|NCT05514938|DRUG|Usual Care (individual medications prescribed by primary cardiologist)|Typical prescriptions for post-acute coronary syndrome care including statin, aspirin, and prasugrel or clopidogrel.
40822150|NCT00756795|BEHAVIORAL|Intervention group|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis."
41266297|NCT00519870|DRUG|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
41266298|NCT00519870|DRUG|losartan|II: losartan
41266299|NCT00519870|DRUG|Nifedipine, losartan|I: nifedipine II: losartan
41266300|NCT04217265|DRUG|Letrozole then misoprostol|total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
41266301|NCT04217265|DRUG|placebo then misoprostol|placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
41266302|NCT00372892|DRUG|Rituximab|375mg/m2 per week for 4 consecutive weeks
41266303|NCT00372892|DRUG|Placebo|Saline IV placebo once per week for 4 consecutive weeks
41266304|NCT00977470|DRUG|Erlotinib|150 mg taken orally once daily
41266305|NCT00977470|DRUG|Hydroxychloroquine|1000 mg taken orally once daily after erlotinib
41341156|NCT01159457|BIOLOGICAL|Hepatitis B vaccination (Sci-B-Vac)|A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
41341157|NCT01159457|BIOLOGICAL|Hepatitis B vaccination (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
41341158|NCT00911222|OTHER|non-interventional|non-interventional
40822151|NCT05024929|PROCEDURE|Whole body scan|"Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).~During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor."
40822152|NCT03225989|DRUG|LOAd703|Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
40822153|NCT03885232|BEHAVIORAL|Experimental: PIVOT with MI|Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
41341159|NCT01858597|DIAGNOSTIC_TEST|biachemical detection|"Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.~Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed."
41341160|NCT00549653|DRUG|GW856553|
41341161|NCT02901080|DEVICE|Alpha Stim AID cranial electrotherapy stimulation|- 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
41341162|NCT02901080|BEHAVIORAL|Pregnancy test|- Pregnancy test x 1 (day 1)
41341163|NCT02901080|OTHER|Anxiety questionnaire|- GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
41488081|NCT03780231|OTHER|non-ischemic scar|"non-ischemic LGE with no underlying labelled cardiomyopathy is detected on CMR"
41488082|NCT04161014|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150mg twice daily for 3 years
40822154|NCT03885232|OTHER|Active Comparator: Control|Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
41488083|NCT00298779|DRUG|omeprazole and bortezomib|
41488084|NCT00112866|DRUG|cilengitide|Given IV
41488085|NCT00112866|PROCEDURE|therapeutic conventional surgery|Undergo tumor resection
41488086|NCT00112866|OTHER|pharmacological study|Correlative studies
41488087|NCT00112866|OTHER|laboratory biomarker analysis|Correlative studies
41488088|NCT06367855|DRUG|Dexamethasone|long-acting corticosteroid IV route
40822155|NCT04857437|DRUG|PF-07202954 Repeat Dose|10, 30, 100, 300, 600, 1200 milligrams (mg)
41488089|NCT06367855|DRUG|Normal saline|normal saline
40822156|NCT04857437|DRUG|PF-07202954 Single Dose|10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
40822157|NCT04857437|DRUG|Placebo|Matching Placebo
41488090|NCT03276221|BEHAVIORAL|Abstinence|Cannabis users randomized to this condition will be enrolled in a contingency management intervention for 30 days of cannabis abstinence.
40822158|NCT00003103|BIOLOGICAL|oblimersen sodium|
40822159|NCT00003103|DRUG|docetaxel|
40822160|NCT03472664|OTHER|low carbohydrate/high fat diet|Modified Mediterranean-Ketogenic Diet is a low carbohydrate/high fat diet.
40822161|NCT03472664|OTHER|low fat/high carbohydrate diet|American Heart Association Diet is a low fat/high carbohydrate diet.
40822162|NCT05961332|DEVICE|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
41341164|NCT02901080|OTHER|Quality of life questionnaire|- EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
41341165|NCT02901080|OTHER|Work and social questionnaire|- WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
41341166|NCT02901080|OTHER|Sleep questionnaire|- Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
41341167|NCT02901080|OTHER|Depression questionnaire|- PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
41341168|NCT02901080|OTHER|Quality of life and financial questionnaire|- CSRI questionnaire x 3 (day 1, week 12 and week 24)
41488091|NCT03891966|PROCEDURE|Rigid Splint|50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.
41488092|NCT03891966|PROCEDURE|Soft Dressing|50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
41488093|NCT01287039|DRUG|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
41488094|NCT01287039|DRUG|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
41488095|NCT03956836|DIAGNOSTIC_TEST|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in 40 patients undergoing CRC
41488096|NCT04360044|DRUG|THC ~5%|4 puffs of vaporized flower containing THC \~5%
41488097|NCT04360044|DRUG|CBD ~12%|4 puffs of vaporized flower containing CBD \~12%
41488098|NCT04360044|DRUG|THC ~5% and CBD ~12%|4 puffs of vaporized flower containing THC \~5% and CBD \~12%
41488099|NCT04360044|DRUG|Sham Cannabis|4 puffs of vaporized flower from which the THC and CBD have been extracted
41488100|NCT03544996|COMBINATION_PRODUCT|TD Insulin|Human Insulin USP formulated in a solution capable of transdermal delivery.
41488101|NCT03230500|PROCEDURE|Computer guided implant placement|Implant will be placed immediately using computer aided surgical guide
41488102|NCT01150617|DRUG|Insulin glargine plus insulin analogues|"* Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c\<6.5% at the end of the follow-up.~* Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of \< 7.0% at the end of the follow-up."
41488103|NCT06356363|OTHER|Data collection|data collection
41488104|NCT00192244|BIOLOGICAL|CAIV-T, Liquid|
41488105|NCT01108406|DEVICE|Sonitus SoundBite System|Non Surgical Bone Conduction Device
41341169|NCT04885127|OTHER|Palliative Care + Digital Symptom Monitoring|Previously described in Arm description
41341170|NCT03423615|BEHAVIORAL|Comprehensive Health & Hygiene Improvement Program (CHHIP)|CHHIP is an intense, multi-component holistic school health program based on the WHO Health Promoting School framework and designed for implementation by lay fieldworkers.
41341171|NCT00608491|DRUG|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
41341172|NCT00608491|DEVICE|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
41341173|NCT05094570|DRUG|Dupilumab Prefilled Syringe|Dupilumab 300 mg
41488106|NCT01108406|DEVICE|SoundBite Hearing System|
41488107|NCT03895723|PROCEDURE|laparoscopic and robotic liver resection|laparoscopic and robotic procedure for liver resection
41488108|NCT03895723|PROCEDURE|open surgery|using open surgery procedure for liver resection
41341174|NCT00050336|DRUG|Lonafarnib (SARASAR)|
41341175|NCT04734626|DIAGNOSTIC_TEST|Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence|CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise
41341176|NCT00645203|DRUG|cefdinir|cefdinir oral suspension, 25 mg/kg once daily for 10 days
41341177|NCT02456454|DRUG|Risperidone|Liquid risperidone
41488109|NCT00050232|DRUG|AVP-923|
41488110|NCT02010788|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
41488111|NCT02520752|DRUG|INC280|
41488112|NCT02520752|DRUG|Midazolam|
41488113|NCT02520752|DRUG|Caffeine|
41488114|NCT04029896|BIOLOGICAL|HB-adMSCs|intravenous infusion of Hope Biosciences autologous adipose-derived stem cells
40822163|NCT05961332|DEVICE|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
41341178|NCT02456454|DRUG|Valproic Acid|Liquid valproic acid
41341179|NCT02456454|DRUG|Placebo|
41341180|NCT00982748|BEHAVIORAL|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
41488115|NCT00658827|OTHER|No intervention|This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
41488116|NCT00324766|DRUG|levosimendan|1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
41488117|NCT00324766|DRUG|placebo,|24 h, infusion
41488118|NCT05222503|DEVICE|Knee Brace + OPUM Digital Knee|Knee Brace + OPUM Digital Knee
41488119|NCT05222503|DEVICE|Knee Brace|Knee Brace without OPUM Digital Knee
41488120|NCT03565458|DRUG|Gemigliptin|zemiglo 50mg,LG Chem
41488121|NCT03565458|DRUG|Dapagliflozin|forxiga, dapagliflozin 10mg
41488122|NCT03565458|DRUG|Empagliflozin|jardiance 25mg, empagliflozin
41488123|NCT00105976|DRUG|MM-093|
41488124|NCT02338193|DRUG|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
41488125|NCT02338193|DRUG|DAPA|10 mg dapagliflozin QD for 20-24 weeks
41488126|NCT02338193|DRUG|MET XR|1000 mg Metformin XR BID for 20-24 weeks
41488127|NCT00808964|DRUG|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
41488128|NCT02390609|DRUG|Ibrutinib (Treatment A) [Reference]|Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
41488129|NCT02390609|DRUG|Ibrutinib (Treatment B)|Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
41488130|NCT02390609|DRUG|Ibrutinib (Treatment C)|Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
41017552|NCT06085417|DRUG|Bupivacaine + magnesium sulphate|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
41488131|NCT02390609|DRUG|Ibrutinib (Treatment D)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.
41017553|NCT06085417|DRUG|bupivacaine|bupivacaine
41017554|NCT02275897|PROCEDURE|Slow Speed of spinal injection|Speed of injection over 60 seconds
41017555|NCT02275897|PROCEDURE|Fast Speed of spinal injection|Speed of injection over 15 seconds
41341181|NCT01100294|BIOLOGICAL|Vaccination with FLUVAL P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml (total 3 μg HA), single dose."
41341182|NCT05326906|DRUG|PD-1/PD-L1 inhibitors|PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)
41341183|NCT02114060|BIOLOGICAL|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
41341184|NCT02114060|BIOLOGICAL|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
41341185|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
41341186|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
41341187|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
41341188|NCT02114060|BIOLOGICAL|Placebo|0.9% Normal Saline (NaCl)
41488132|NCT02390609|DRUG|Ibrutinib (Treatment E)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.
41017556|NCT01575561|DRUG|Lurasidone|Lurasidone 20-80 mg taken orally once daily
41488133|NCT02390609|DRUG|Ibrutinib (Treatment F)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
41488134|NCT03134443|DRUG|Andrographolide sulfonate|Routine treatment for acute tonsillitis + Xiyanping injection
41488135|NCT03134443|DRUG|Andrographolide sulfonate simulation|Routine treatment for acute tonsillitis + Xiyanping injection simulation
41017557|NCT00722644|BEHAVIORAL|Cognitive Behavioral Stress Management|
41017558|NCT04963504|DIAGNOSTIC_TEST|Rest-to-exercise|Pulmonary diffusing capacity is assessed at rest and during exercise (70% of VO2max on a bicycle ergometer)
41017559|NCT04963504|DIAGNOSTIC_TEST|Sitting-to-supine|Pulmonary diffusing capacity is assessed in the sitting and supine position
41017560|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years."
41341189|NCT03202368|DRUG|Tocilizumab|162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first
41341190|NCT04603274|PROCEDURE|8 sessions of electroacupuncture to the upper limb with carpal tunnel syndrome|All participants will accept 8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians. Acupuncture sterile disposable needles 0,25x 0,25 mm will be inserted for 20 minutes at specific acupuncture points to all patients. Electrical stimulation will be applied at specific acupuncture points for 20 minutes.
41488136|NCT02582866|DRUG|Lacosamide|"* Pharmaceutical Form: Oral tablets~* Concentration: 50 mg~* Route of Administration: Oral administration"
41488137|NCT00405886|DRUG|Neramexane|Oral tablets, duration: 16 weeks
41488138|NCT00405886|DRUG|Placebo|Oral tablets, duration: 16 weeks
41488139|NCT00486018|DRUG|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
41488140|NCT00486018|DRUG|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
41488141|NCT00486018|DRUG|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
41488142|NCT00232271|DRUG|Clexane|
41488143|NCT03596736|PROCEDURE|Elbow Hemiarthroplasty|
41488144|NCT03596736|PROCEDURE|Total Elbow Arthroplasty|
41341191|NCT00047593|DRUG|IOP Lowering Medications|
41488145|NCT06132763|BEHAVIORAL|Hydration Intervention|"Teacher \& student ambassadors: serve as hydration role models, identify Hydration Heroes, monitor filter lights on hydration stations, \& update the water meter visual.~Kick-off event: event to kick off the hydration intervention to include water bottles distribution with a station to personalize, experiential activities, and information about the intervention.~Social marketing: student-developed marketing campaign Make water your superpower will be placed in high-traffic areas of the school. Hydration Headquarters will be located in the lunchroom displaying a water meter illustrating bottle refills from the school's hydration stations.~Behavioral reinforcement: on random days, students drinking water and/or with a water bottle will receive small incentives.~Education and outreach: Hydration Tip Sheets, hydration signage in classrooms, and hydration trivia on hydration stations. Teachers will deliver 1 hydration lesson per month that align with Standards of Learning."
41488146|NCT06132763|OTHER|Control - Assessments Only|Assessments only
41341192|NCT00320294|DRUG|irinotecan|
41341193|NCT00320294|DRUG|cisplatin|
41341194|NCT02123394|OTHER|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
41341195|NCT02123394|OTHER|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
41488147|NCT00437632|DRUG|GSK598809|GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
41488148|NCT00437632|DRUG|Placebo|Subjects will receive matching placebo capsules to GSK598809 orally with water.
41488149|NCT00437632|DRUG|Caffeine|Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.
41488150|NCT00048204|DRUG|GW597599B|
41488151|NCT00048204|DRUG|paroxetine|
41488152|NCT02274844|BEHAVIORAL|Living Well with Diabetes Program|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
41488153|NCT05989724|DRUG|SON-DP|Solution for IV administration
41341196|NCT05538429|PROCEDURE|erector spinal plane combined with serratus anterior plane block|The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.
41488154|NCT03533023|BEHAVIORAL|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.
41488155|NCT03533023|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.
41488156|NCT03531398|OTHER|Metabolic test meal challenge|Metabolic test meal challenge
41488157|NCT05430126|DRUG|Protein Kinase Inhibitor|This retrospective pharmacovigilance study will include protein kinase inhibitor and exclude those drugs known to cause hepatotoxicities
41488158|NCT02622451|BEHAVIORAL|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
41488159|NCT02622451|BEHAVIORAL|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
41488160|NCT05027243|PROCEDURE|bilateral temporomandibular joint arthroscopy|The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.
41488161|NCT05027243|DRUG|Xeomin® (Merz)|For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
41488162|NCT01173471|DRUG|AZD4017|tablet, oral, one tablet once daily, 28 days
41488163|NCT01173471|DRUG|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
41488164|NCT01173471|DRUG|AZD4017|tablet, oral 2 tablets twice daily, 28 days
41488165|NCT01173471|DRUG|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
41488166|NCT00482651|RADIATION|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
41488167|NCT00482651|PROCEDURE|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
41488168|NCT00482651|PROCEDURE|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
40822164|NCT05961332|DEVICE|Zeiss Clarus 700 imaging|Zeiss Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
40822165|NCT06606392|DEVICE|Biodex balance system|The Biodex Balance System has a wide range of clinical applications and provides objective measures from testing that can be used to establish progressions and discharge criteria, as well as be part of a comprehensive Fall Risk Assessment or Fall Screening Program. Balance ability can be assessed either statically or dynamically, as well as bilaterally and unilaterally. It also allows for bilateral comparisons between involved and uninvolved limbs.
40822166|NCT06606392|OTHER|Short Foot Exercise|Short foot exercise is used as a therapeutic exercise to strengthen intrinsic foot muscles and used as training to create an MLA. It helps improve the balance in functional movement of FF subjects, decreases navicular drop (ND) through intrinsic muscle activation, supports navicular stability, and improves balance
40822167|NCT05010369|DIAGNOSTIC_TEST|spectroscopic measurement|measurement of the tissue with spectroscopy
40822168|NCT05010369|DIAGNOSTIC_TEST|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
40822169|NCT05010369|DIAGNOSTIC_TEST|histopathology and cytology|Histopathology and cytology will be performed on the samples
41341197|NCT05932394|BEHAVIORAL|Projection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery|"Patients are randomized into two groups (control group and intervention group). Initially, all patients are administered the Mini-Mental State Examination scale (MMSE) to assess their initial cognitive state and their sociodemographic and anthropometric data.~In the intervention group, patients and/or companions are asked to provide visual material, which could consist of photographs of loved ones and/or places known to the patient. 30 minutes after the extubation of the patients, the CAM-ICU scale is administered.~In the control group, after the surgical intervention and 30 minutes after the patient's extubation the CAM-ICU scale is administered."
40822170|NCT04902404|OTHER|First Pathways Game|The First Pathways Game is a free, online parenting education program. Parents watch short videos (approximately 30 seconds) on the First Pathways Game website to receive neuroscience knowledge and ideas for age-appropriate game ideas to play with their child. The game ideas employ common household items, such as measuring cups and paper.
40822171|NCT00018330|BEHAVIORAL|Weight Loss|
40822172|NCT00611442|DRUG|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
41266306|NCT03950973|BEHAVIORAL|CareAvenue|CareAvenue is an e-health tool providing information about diabetes management and low-cost resources. Participants in this group have access to CareAvenue and receive a weekly automated phone call and text messages related to CareAvenue and its resources as well as diabetes management.
41341198|NCT05932394|BEHAVIORAL|the usual unit treatment|CAM-ICU scale is administered to the Control group. No visual material is used.
41488169|NCT00482651|PROCEDURE|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
40822173|NCT00611442|DRUG|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
40822174|NCT06341712|DRUG|Cabozantinib|Participants will receive cabozantinib orally Once daily (QD) on a continuous dosing schedule for cycles of 28 days.
40822175|NCT06341712|OTHER|Best Supportive Care (BSC)|Participants will receive BSC. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
40822176|NCT06341712|OTHER|Best Supportive Care (BSC)|Participants will receive BSC alone. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
41266307|NCT03950973|BEHAVIORAL|Guest Assistance Program|The Guest Assistance Program (GAP) is a resource, which provides assistance with medical and non-medical needs and resources to patients receiving medical care at University of Michigan health system. Participants in this group are provided with GAP information and receive text messages related to diabetes management.
41488170|NCT04852900|OTHER|Decompression with 30%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
41488171|NCT04852900|OTHER|Decompression with 40%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
41488172|NCT04852900|OTHER|Decompression with 50%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
40822177|NCT00996281|DRUG|Azilsartan medoxomil and chlorthalidone|Combination tablet.
41488173|NCT05391841|DRUG|NOVOCART Inject|Autologous Chondrocyte Implantation
41488174|NCT03912441|BIOLOGICAL|BCD-147|Bispecific anti-HER2 monoclonal antibody
41488175|NCT02319395|GENETIC|Blood Sampling and DNA collection|"One blood sampling during the study. A small number (1 to 5) of markers type tag SNPs or coding SNP  (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate."
41017561|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years."
40822178|NCT00996281|DRUG|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
40822179|NCT01817673|DIETARY_SUPPLEMENT|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
40822180|NCT01817673|DIETARY_SUPPLEMENT|placebo|
40822181|NCT04597021|DEVICE|use of a wiresless US transducer|to (evaluate the practicability of applying a wireless US transducer for central venous catheter-placement in these patients.
40822182|NCT00000273|DRUG|opiates|prescription opioids
41017562|NCT00513422|DIETARY_SUPPLEMENT|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years."
41017563|NCT00513422|DIETARY_SUPPLEMENT|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years."
41017564|NCT04112693|PROCEDURE|Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020.~The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse."
40822183|NCT04677400|OTHER|More than Body Appearance (MBA) Intervention|"The MBA is an online psychological intervention designed to improve body image. The intervention lasts 15 days, and it comprises two types of activity (1st and 2nd week).~During the first week of the MBA intervention, participants sill read three blocks of psychoeducational material including information about: 1) body image; 2) positive body image and healthy lifestyles; and 3) body functionality.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important. Each assignment focused on two areas of body functionality: 1) body's senses and physical capacities; 2) health and creative skills; 3) self-care/daily routine and communication with others. For each writing assignment, participants were asked to reflect, describe, and specify why these aspects of body functionality were personally important and meaningful to them."
40822184|NCT03836430|BEHAVIORAL|Newborn Behavioral Observation-Family Wellness (NBO-FW)|The intervention has been described in the arm description.
41488176|NCT03557424|DRUG|Polyglucosamine Glucomannan normal dose (Verum)|Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
40822185|NCT00307840|DRUG|paricalcitol|
40822186|NCT02574650|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
40822187|NCT06608641|DRUG|Endoxifen enteric-coated tablet (8 mg)|Patients will continue treatment with their initial randomized medication for 3 weeks
41017565|NCT01897311|DEVICE|transcutaneous electrical nerve stimulation|
41488177|NCT03557424|DRUG|Polyglucosamine Glucomannan high dose (Verum)|Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
41488178|NCT03557424|DRUG|Placebo Comparator: Placebo|Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
41488179|NCT01829841|DRUG|Famitinib|Famitinib 25 mg p.o. qd
41488180|NCT01829841|DRUG|Sunitinib|Sunitinib 50 mg p.o. qd
40822188|NCT06608641|DRUG|Placebo Tablets|Patients will be treated with Endoxifen Placebo Tablets for 21 days
40822189|NCT05788783|BEHAVIORAL|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
40822190|NCT05788783|OTHER|Canine Education & Bonding|Active control intervention. An 6-week session of semi-structured activities. Sessions are 45 minutes in length. Youth in this condition engage in an educational component, passive observation of dog-training skills, and an active free-play session with the dog-handler teams.
40822191|NCT05592366|BEHAVIORAL|Care Partner Hospital Assessment Tool|Complete the adjusted CHAT as well as demographic and caregiving questionnaires during and after loved one's hospitalization.
41017566|NCT04502771|DRUG|Antifungal treatment|Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit
41017567|NCT03481946|DRUG|BAY1093884|0.3 mg/kg given intravenously
41017568|NCT03481946|DRUG|BAY1093884|1 mg/kg given intravenously
41017569|NCT05319418|BEHAVIORAL|Daily Blood Pressure Monitoring|Patients are provided standard off-the-shelf blood pressure monitors and take their BP vitals daily. Patients report their daily BP through phone or online. BP data is viewed online by physicians who use their independent medical judgement for any changes in medical management.
41017570|NCT02716844|OTHER|Exercise|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
41341199|NCT03257618|DRUG|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
40822192|NCT05340621|DRUG|OKI-179 + binimetinib|"Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously.~Phase 2: Patients will be treated with the RP2D."
41488181|NCT04432103|BIOLOGICAL|Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.
41488182|NCT04432103|BIOLOGICAL|Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.
41488183|NCT00267943|DRUG|telmisartan 80 mg + hydrochlorothiazide 25 mg|
41488184|NCT02590835|PROCEDURE|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
41488185|NCT02590835|PROCEDURE|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
41488186|NCT05031689|BIOLOGICAL|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
41488187|NCT05031689|BIOLOGICAL|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract|Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.
41488188|NCT02935166|OTHER|Respiratory muscle training|General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
41488189|NCT01455363|PROCEDURE|BCC surgery|This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
41341200|NCT03257618|OTHER|QoL, neurocognitive and psycholpathological assessment|This assessment will be performed at baseline, at 6 months, 12 months, 18 months, at the end of the treatment with TMZ, 6 months after the end of TMZ
41488190|NCT01455363|OTHER|Tourniquet ischemia|In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
40822193|NCT02631174|DRUG|Antithrombin III|We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
41341201|NCT00616772|DRUG|ABT-335|Capsule
41488191|NCT01455363|OTHER|Laser speckle imaging|During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
41488192|NCT02912845|DRUG|KamRAB - HRIG|wound infiltration or IM injection
41488193|NCT05344430|PROCEDURE|cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy|We will be conducting cone beam computer tomography for percutaneous transthoracic needle biopsies.
41341202|NCT00616772|DRUG|Placebo|Capsule
41341203|NCT00616772|OTHER|Atorvastatin|Capsule
41341204|NCT03138291|DEVICE|Somnodent|Each pregnant women will be treat with a Somnodent
41341205|NCT02868255|PROCEDURE|Collection of human samples|Several types of samples will be used to test the effect of the drug candidate
41341206|NCT05255705|OTHER|Observation only|Observation only
41341207|NCT04409730|OTHER|Photographic Posture Analysis|Postural evaluation was done using the photographic method. All measurements were made by two researchers experienced in postural analysis evaluation. Canon camera and national geographic tripod with double spirit level were used for evaluation. The camera was placed on a 115 cm high tripod, 1.5 m away from the subjects. Spirit levels have been adjusted so that the tripod is completely flat on the ground. The tripod was taped to the floor to maintain the same distance between the camera and the participants. Six photographs of each child whose feet on the ground, in a free-sitting position, 3 from the front and 3 sides were taken by the researchers.
41341208|NCT01690819|PROCEDURE|Conventional Ventilatory Strategy|The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
41488194|NCT02158286|OTHER|Measuring emptying rate from the gastric tube|
40822194|NCT01382121|BEHAVIORAL|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
41488195|NCT04099173|BEHAVIORAL|Brief Mindfulness Based Intervention|This intervention will consist of four, 45 minute individual mindfulness training sessions (one session per day, over a range of 12 subsequent days) provided by a trained mindfulness facilitator.
41488196|NCT01826786|DRUG|JNJ-42165279 (100 mg)|JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
41488197|NCT01826786|DRUG|Placebo|Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
41488198|NCT02802618|OTHER|Interactive 3D visualization technique|The pulmonary rehabilitation consists of exercise training during two times/week for 10 weeks and a theoretic part presented with 3D visualization technique.
41488199|NCT03971266|DEVICE|Activity Monitor|Wear a Fitbit
41488200|NCT03971266|OTHER|Media Intervention|Complete smartphone based PRO diary
41488201|NCT05592392|DEVICE|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
41488202|NCT04116853|BEHAVIORAL|ADAPTIVE Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
41488203|NCT04116853|BEHAVIORAL|STATIC Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
41488204|NCT04276844|DIAGNOSTIC_TEST|Ultrasonography using the two-dimensional (2D) mode|Diaphragmatic amplitude assessed by ultrasonography during quiet breathing and after sniff test, before the surgery and at day 7 post-surgery in all patients.
41488205|NCT04276844|DIAGNOSTIC_TEST|Respiratory Functional Explorations|Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV) and total lung capacity (TLC) measured at day 7
40822195|NCT01382121|BEHAVIORAL|Control|watching a video unrelated to the fitness test and self-efficacy
40822196|NCT05108025|DRUG|Topical Powder|Topical Powder mixed with diluent
41266308|NCT00331435|PROCEDURE|Ocular photodynamic therapy with verteporfin|Ocular photodynamic therapy with 6 mg per meter squar of body sarface of verteporfin with PDT lazer application for 83 seconds
41266309|NCT05695326|BEHAVIORAL|3D printing technology learning program|The study is aimed to evaluate a 3D printing technology learning program for rehabilitation professionals
41488206|NCT05190653|OTHER|Early palliative and supportive care|The intervention itself will be predominantly the provision of education and information. It is possible that patients in the intervention arm may receive treatment recommendations to help manage symptoms.
41488207|NCT06204211|DIAGNOSTIC_TEST|ophthalmologic examinations|All the included personnel underwent routine ophthalmologic examinations on binoculus, including slit lamp microscope observation, intraocular pressure, diopters of refractive error, best corrected visual acuity, AL measurement, fundus photography and optical coherence tomography, adhering to the established and normalized principles.
40822197|NCT05108025|DRUG|Placebo Topical Powder|Placebo Topical Powder mixed with diluent
40822198|NCT03533439|DIAGNOSTIC_TEST|Near infrared spectroscopy|Four channel measurement of regional haemoglobin oxygen saturation (SO2) in the blood of the bowel, kidney and brain of neonates with gastroschisis during reduction within a silo and after surgery will be performed.• Routine surgical procedure will be followed (clinically indicated silo placement and closure as is currently practised). There will be no change in the clinical practice in place during this pilot study. Clinical management will be as already practiced with the supervision of the consultant with clinical responsibility dictating management
40822199|NCT00162747|DRUG|Aquaphor|
41266310|NCT06044493|DRUG|Myreptic-N Tablet|Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit
41266311|NCT06044493|DRUG|Mycophenolate mofetil Tablet/Capsule|Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit
41266312|NCT01938287|DEVICE|SENSIMED Triggerfish|
41266313|NCT04965740|DRUG|Cannabis|Recreational Cannabis
40822200|NCT00162747|DRUG|Sunflower Seed Oil|
40822201|NCT05928117|OTHER|Education|Pregnant women will be given training to cope with the fear of childbirth.
40822202|NCT04749758|BIOLOGICAL|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.
41341209|NCT01690819|PROCEDURE|Protective Ventilatory Strategy|The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
41341210|NCT04771104|DIETARY_SUPPLEMENT|Amino Acid Challenge (AAC)|The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.
40822203|NCT02818374|DEVICE|oral accessibility spatula (SAB)|
41341211|NCT04679714|DEVICE|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed on the mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
41341212|NCT00005883|DRUG|phenethyl isothiocyanate|
41341213|NCT02353689|DIETARY_SUPPLEMENT|low FODMAP|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
41341214|NCT02353689|DIETARY_SUPPLEMENT|moderate FODMAP|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
41341215|NCT02353689|DIETARY_SUPPLEMENT|high FODMAP|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
41341216|NCT05475444|DEVICE|Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels|antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.
41341217|NCT05475444|DEVICE|Ciprofloxacin paste and solution|Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection
41341218|NCT04058158|DRUG|SB12 (proposed eculizumab biosimilar)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
41341219|NCT04058158|DRUG|Soliris (eculizumab)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
41341220|NCT00289393|BEHAVIORAL|Perceived outcome by both patient and physician|
41341221|NCT02163772|PROCEDURE|Intracordal hyaluronate injection|
41488208|NCT00704093|DEVICE|Right ventricular pacing|Right ventricular pacing vs. sinus rhythm or atrial pacing at the same rate
41488209|NCT04765774|OTHER|Ekspressive touch|Patients will be divided into three groups. The expressive touch group will touch the patient's hand.
41488210|NCT04765774|OTHER|Music|The music chosen by the patient will be played in the music group.
41488211|NCT06287606|DRUG|CTP0302-A|Subjects randomized into group CTP0302-A will take a bowel preparation from the evening until the following morning.
41488212|NCT06287606|DRUG|CTP0302-B|Subjects randomized into group CTP0302-B will take a bowel preparation on the Colonoscopy day
41488213|NCT06287606|DRUG|Conventional OST|Subjects randomized into group Conventional OST will take a bowel preparation from the evening until the following morning.
41488214|NCT02384941|DRUG|Placebo|Placebo once daily, before first meal of the day.
41488215|NCT02384941|DRUG|Sotagliflozin|Sotagliflozin once daily, before first meal of the day.
41488216|NCT04848311|PROCEDURE|lymph nodes dissection at 253 station assisted by ICG|In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.
41488217|NCT02035839|DEVICE|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
41488218|NCT02035839|DEVICE|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
41488219|NCT02035839|DEVICE|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
41488220|NCT04269564|DEVICE|stepwise PEEP|"* a PEEP of 4 cmH2O will be used after intubation till 5 minutes after pneumoperitonium, and adjusted in a step wise approach after lung ultrasound by adding 2 cmH2O, repeating ultrasound 5 minutes after every change in peep till no lung collapse is detected by lung ultrasound with a maximal peep of 10 cmH2O, or if hemodynamic instability occurs.~* Lung ultrasound examination will be performed at a minimum three times in each patient; the first will be performed 1 min after starting mechanical ventilation of the lungs, 5 minutes after pneumoperitonium, 5 min after every peep increase in stepwise peep group and the last time at the end of the surgery.~We define anaesthesia-induced atelectasis to be significant if any region has a consolidation score of ≥ 2."
41488221|NCT01305174|DEVICE|PROTEGE GPS stent vs. VISI-PRO stent|Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease
41488222|NCT01411865|OTHER|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
41017571|NCT06449573|OTHER|Exercise capacity|cardiopulmonary exercise test used assessment of exercise capacity
41488223|NCT01411865|OTHER|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
41488224|NCT06278740|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|Upper extremity pathologies of participants with ultrasound
41488225|NCT02802774|OTHER|Plaster Splint|The custom plaster splint is the historical standard. The surgical incision is dressed with non-stick gauze, 4x4 gauze pads, cotton padding, a plaster splint applied to the palmar surface of the palm and forearm, and then a cloth wrap to keep it all in place. Patients will wear the plaster splint for 2 weeks post-op.
41488226|NCT02802774|OTHER|Velcro Brace|The Velcro wrist brace is a commercially available over-the-counter splint which will initially be fitted over a thin layer of non-stick gauze, 4x4 gauze, and cotton padding. Patients will be asked to wear the brace as much as possible for the first 2 weeks post-op.
40822204|NCT04971538|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
40822205|NCT06605261|OTHER|Yoga (intervention) group|The yoga (intervention) group comprises 64 women with breast cancer who have been randomly assigned and are undergoing endocrine therapy. To alleviate arthralgia and vasomotor symptoms (hot flashes, night sweats), a structured yoga program will be administered during the initial months of endocrine therapy, consisting of 60-minute sessions, 4 days per week, for a duration of one month.
40822206|NCT03798730|BEHAVIORAL|Solid Model|"Cake and biscuit will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods of rating drying and discrimination tests which is the stronger in drying)"
41266314|NCT02334150|DRUG|CSEA (ropivocaine and sufentanil)|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
41488227|NCT02802774|OTHER|Soft Dressing|Patients in the soft dressing group will have non-stick gauze, 4X4 gauze, cotton padding, and a cloth wrap. It will be the same dressing as the custom splint without the plaster slab. Patients wear the soft dressing for the first three days post-op.
40822207|NCT03798730|BEHAVIORAL|Liquid Model|"Intervention Description: To study the effect of protein denaturation on perception of whey protein beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying). Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein beverages."
41266315|NCT03594968|DIAGNOSTIC_TEST|polycystic ovary syndrome|3 to 5th day of the women's normal cycle, we will perform a routine gynecological examination, a basic vaginal ultrasound, a basal hormone profile evaluation
41266316|NCT02109081|DRUG|Dexamethasone|
41266317|NCT02109081|DRUG|Placebo|
41266318|NCT00127751|BEHAVIORAL|Enhance health lifestyle changes and medication compliance|
41488228|NCT06248541|DEVICE|treatment with low-level laser therapy|low-level laser therapy (wavelength of 620 - 640nm)
41488229|NCT06248541|DEVICE|treatment with conventional light diodes|conventional light diodes
41488230|NCT03355014|DRUG|Combination of gemigliptin/metformin HCl sustained release 50/1000mg|Gemigliptin/Metformin HCl extended release 25/500mg 2tablets
41488231|NCT03355014|DRUG|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg|Zemiglo 50mg 1 tablet Glucophage XR 2 tablets
41017572|NCT01642394|BEHAVIORAL|Diabetes Self-Management Program|"The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.~Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader."
41017573|NCT05306067|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
41488232|NCT03713879|DEVICE|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
41017574|NCT05306067|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests
41488233|NCT03713879|DRUG|Indomethacin|rectally administered indomethacin before or after ERCP
41488234|NCT05717192|DEVICE|InterVapor®-System|"The InterVapor System uses heated water vapor to ablate the airways and parenchyma within targeted regions of the lung. Lung remodeling occurs after an initial localized inflammatory response and a subsequent healing and repair. The remodeling of the tissue results in reductions in tissue and air volume in the targeted regions of the lung. The remodeled lung tissue does not re-inflate as a result of collateral ventilation.~The lung volume reduction of diseased hyper-inflated lung segments after InterVapor treatment is expected to increase elastic recoil by reducing the most compliant segments of the lung, decompressing segments of healthier lung allowing for alveolar recruitment, and improving the mechanical efficiency of the respiratory muscles. These mechanical changes are anticipated to improve pulmonary function, exercise capacity and quality of life."
41488235|NCT00453427|DRUG|Alemtuzumab (Campath-1H)|The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (\> 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.
41488236|NCT00228423|DRUG|Clopidogrel 75 mg daily|Daily dose of 75 mg Clopidogrel
41488237|NCT00228423|DRUG|water pill daily|Daily dose of water pill (placebo)
41488238|NCT03743740|OTHER|Spinal stabilization exercise|The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.
41017575|NCT06339827|BEHAVIORAL|Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List|Participants are randomized and will receive the ASQ-GYO prompt list within 2 weeks prior to their new patient appointment with the gynecology oncology physician.
41266319|NCT02070861|OTHER|Ventricular pacing and passive leg raise|Ventricular pacing and passive leg raise
41488239|NCT02945670|BEHAVIORAL|Focus Group|We had recruited 64 women and completed 7 focus group sessions
41488240|NCT01055132|DEVICE|Etafilcon A toric contact lens|contact lens to correct astigmatism
41017576|NCT05089734|BIOLOGICAL|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
41266320|NCT06249750|DRUG|Immunotherapy|Immunotherapy is currently a hot spot in the field of tumor research. Immune Checkpoint Inhibitor (ICI) is a monoclonal antibody designed to target the negative immunoregulatory pathway overexpressed in tumor cells, which can release the anti-tumor immunosuppressive signals and restore the killing of tumors by the immune cells, and thus exert anti-tumor effects. ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d.
41266321|NCT06249750|DRUG|Targeted therapy|Recent studies have found that the combination of RTK inhibitors and ICIs can exert synergistic effects on different mechanisms, which can compensate for the deficiencies of single-agent RTK inhibitors and single-agent ICIs in the treatment of CRPC and become a potential novel therapeutic strategy for solid malignant tumors. RTK inhibitor regimen: Anlotinib, 12mg, po., d2\~15, q21d.
41488241|NCT01055132|DEVICE|Nelfilcon A toric contact lens|contact lens to correct astigmatism
41488242|NCT02310711|OTHER|Standard of Care|"Standard of care for early stage breast cancer is breast conserving therapy at this center.~Other concomitant standard of care treatment • Radiation therapy to the whole breast~o 45-50 Gy delivered over 25-28 fractions with a boost to the tumor bed of 10-16 Gy delivered over 5-8 fractions"
41488243|NCT03525730|DRUG|Valproic Acid|Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.
41488244|NCT03525730|DRUG|Pyrimethamine|Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.
41488245|NCT05607719|DRUG|Bevespi|Two puffs twice a day
41488246|NCT05607719|DRUG|Bretzri|Two puffs twice a day
41266322|NCT06249750|DEVICE|Hyperthermia|"Thermal stimulation is a rapidly developing physiotherapeutic tool, which is playing an increasingly important role in the field of comprehensive tumor therapy due to its unique low adverse effects and high compatibility. A large number of clinical studies have shown that the addition of heat stress to multimodal tumor therapy does not significantly increase toxicity and side effects, and the combination of heat stress with other therapies can have the effect of 1+1\>2. ET-SPACE near-infrared irradiation whole-body hyperthermia: d1, d8, q21d, rectal temperature reaches 38.5\~39 ℃ and then maintain 1h."
41266323|NCT02310048|DRUG|MT-1303-FormA|
41266324|NCT02310048|DRUG|MT-1303-FormB|
41266325|NCT00544921|DRUG|GLY-230|
41266326|NCT00544921|OTHER|Placebo|No drug administered
41266327|NCT03496753|DEVICE|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
41266328|NCT01989221|DRUG|Sancuso®|Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
41488247|NCT00306150|DRUG|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
40822208|NCT06232564|COMBINATION_PRODUCT|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
41488248|NCT00306150|DRUG|Placebo|Placebo is used according to the description of Arm 1
41488249|NCT01880125|DRUG|Tramadol HCI/Acetaminophen|Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
41488250|NCT03939325|RADIATION|ESWL|The impact of different frequencies on pattern of disintegration of renal stones
41488251|NCT02969941|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
41488252|NCT05266820|DRUG|Thalidomide|For the experimental group, the intervention was thalidomide（100mg PO Bid)
40822209|NCT05867836|DIETARY_SUPPLEMENT|IFA vs. MMS during pregnancy|Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
41488253|NCT05266820|DRUG|TAS-102|TAS-102
41488254|NCT04408430|DEVICE|Transseptal ViMAC|Transseptal TMVR using balloon-expandable aortic transcatheter valves.
40822210|NCT06604533|PROCEDURE|Intervention: MRI-Linac SABR|The treatment planning protocol follows the UK SABR Consortium Guidelines. Patients will be prescribed the maximum isotoxic dose achievable while meeting normal organ tolerances (normal liver, kidney, spinal cord, stomach, duodenum, small and large bowel, heart, lungs, chest wall). The lowest acceptable SABR doses are indicated in the dose range Table within the protocol. The maximum dose/fraction also indicates the maximum the dose can be escalated to for each adaptive session on the MRI-Linac.
40822211|NCT02973542|DRUG|Ethosuximide|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
40822212|NCT02973542|OTHER|Placebo|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
40822213|NCT05839600|DRUG|BI 1821736|Solution for infusion
40822214|NCT00835640|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
40822215|NCT00835640|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
40822216|NCT01527513|DRUG|Eslicarbazepine acetate (BIA 2-093)|Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
40822217|NCT01527513|DRUG|Placebo|Treatments will be administered by oral route, once-daily, in the evening.
40822218|NCT01025076|DEVICE|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
40822219|NCT00223808|OTHER|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
40822220|NCT00223808|OTHER|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
40822221|NCT00223808|OTHER|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
40822222|NCT05653882|BIOLOGICAL|AB248|Intravenous infusion of AB248: CD8+ T cell selective interleukin-2 investigational drug
40822223|NCT05653882|BIOLOGICAL|pembrolizumab|Intravenous infusion of pembrolizumab
41488255|NCT04798612|DRUG|Pegasys|45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between
41488256|NCT04798612|DRUG|Saline|0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between
41488257|NCT02472223|DRUG|Betadine 5%|"One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."
41488258|NCT02472223|DRUG|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
41488259|NCT05126355|BEHAVIORAL|On the Move group exercise|The OTM exercise program is a group-based program led by a certified OTM instructor. The frequency and duration of OTM is 50 minutes, twice weekly for 12 weeks for a total of 24 classes. The OTM exercise program is based on principles of motor learning that enhance smooth and automatic movement control. The program contains a warm-up (5 minutes), stepping patterns (15 minutes), walking patterns (15 minutes), strengthening exercises (10 minutes), and cool-down exercises (5 minutes). The warm-up and cool down contain gentle range of motion exercises and stretches for the lower extremities and trunk. Considered essential components, the stepping and walking patterns are progressively more difficult, goal-oriented patterns that promote the timing and coordination of stepping integrated with the phases of the gait cycle.
41488260|NCT01179698|PROCEDURE|Navigation surgery|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
41488261|NCT01179698|PROCEDURE|Navigation system|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
41488262|NCT05726461|DEVICE|AndroidAPS-rt-CGM;|Insulin therapy (aspart, lispro or glulisine) with AndroidAPS-rt-CGM.AndroidAPS-rt-CGM consists of three components:1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone.
41017577|NCT05089734|DRUG|Docetaxel|Administered intravenously
41017578|NCT02466308|DEVICE|SAM Ultrasound Diathermy Device|
41017579|NCT00341224|BEHAVIORAL|Group-mentoring intervention|Group mentoring used to teach social skills to middle school students
40822224|NCT03217084|DRUG|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
41488263|NCT05726461|DEVICE|sensor augmented pump(SAP);|Insulin therapy (aspart, lispro or glulisine) with sensor augmented pump(SAP).SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
41488264|NCT05237518|DEVICE|EarlySense Noomi system|The EarlySense device is intended for continuous contact-free monitoring of heart rate and respiration rate at home, or in professional healthcare settings. The system is intended for remote monitoring of patients by healthcare professionals and is indicated mainly for elderly population monitoring.
41488265|NCT04098900|DIAGNOSTIC_TEST|Click Sexual Health Test|The Click Device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
41488266|NCT03590392|BIOLOGICAL|ChAdOx1 Chik|ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
40822225|NCT03217084|DRUG|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
40822226|NCT06548074|BEHAVIORAL|H-PACE Behavioral Intervention|Participate in the H-PACE program
40822227|NCT06548074|OTHER|Accelerometer|Wear an accelerometer
40822228|NCT06548074|OTHER|Questionnaire Administration|Ancillary studies
40822229|NCT06548074|OTHER|Supportive Care|Parents may participate in an optional virtual peer support group
40822230|NCT03783468|OTHER|decrease of sedation doses and switch of ventilator settings|tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
40822231|NCT02916888|OTHER|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
40822232|NCT02916888|OTHER|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
40822233|NCT02999477|DRUG|Pembrolizumab|Pembrolizumab will be administered in clinic every three weeks.
40822234|NCT02999477|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered in clinic every week.
40822235|NCT02999477|PROCEDURE|Biopsy|Biopsies for research purposes will be performed at three separate timepoints during treatment.
40822236|NCT00002849|BIOLOGICAL|recombinant interferon alfa|first 2 years
40822237|NCT00002849|DRUG|dexamethasone|40 mg\*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles\*
40822238|NCT02944357|DRUG|Cisplatin|Given IV
40822239|NCT02944357|DRUG|Gemcitabine Hydrochloride|Given IV
40822240|NCT02944357|PROCEDURE|Radical Cystectomy|Undergo cystectomy
40822241|NCT02944357|BIOLOGICAL|Tumor Cell-Derived Vaccine Therapy|Given AGS-003-BLD ID
40822242|NCT04790812|DRUG|Celecoxib|Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
40822243|NCT04790812|DRUG|Acetaminophen|Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
41488267|NCT03287336|DRUG|Tranexamic Acid|Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.
40822244|NCT04790812|DRUG|Placebo|A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
40822245|NCT03145792|BEHAVIORAL|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
40822246|NCT03145792|BEHAVIORAL|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
40822247|NCT04697186|DRUG|Berberine|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
40822248|NCT04697186|DRUG|Amoxicillin|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
40822249|NCT04697186|DRUG|Rabeprazole|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
40822250|NCT04697186|DRUG|Amoxicillin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
40822251|NCT04697186|DRUG|Clarithromycin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
40822252|NCT04697186|DRUG|Rabeprazole|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
40822253|NCT04697186|DRUG|Bismuth|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
40822254|NCT06605196|BEHAVIORAL|Resources and guided facilitation|Participants in the intervention arm will participate in a planning period at the beginning of the intervention period to establish the goals for the partnership. The investigators will use the prioritized list of AHD partnership features developed in prior research to guide the initial planning period and then assist the partnership members to plan to implement the corresponding strategies focused on their areas of interest (e.g., developing collaborative projects, hiring faculty, staff, or students to conduct data analysis). The investigators will use telephone, email communication, and video conferencing to communicate with AHD partnerships, regularly assess progress towards goals, and adjust goals and strategies based on the progress. One additional in person visit to each AHD partnership in the intervention arm will be made in year 2 of implementation to review goals and progress and provide additional guidance and tailored support as needed.
40822255|NCT06605196|BEHAVIORAL|Existing resources|Individuals will be referred to existing resources in the Learning Community.
41488268|NCT01180439|DEVICE|Adjustment of ventilator settings (device)|Decrease in pressure support, increase in respiratory back-up rate, increase in expiratory positive airway pressure (EPAP) to counteract effect of PEEPi, and adjustment of cycling (at higher percentage of peak inspiratory flow)
41488269|NCT05437367|OTHER|Scapular Stabilization exercises|Therapeutic exercises
40822256|NCT00182052|DRUG|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
40822257|NCT00182052|OTHER|Placebo|Given orally twice daily.
41488270|NCT05437367|OTHER|Postural correction exercises|Therapeutic exercises
41488271|NCT03039179|DEVICE|polyurethane foam dress|Application of the polyurethane foam dress at the heel in the immediate postoperative period before applied the Walker
40822258|NCT00515294|DRUG|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
41488272|NCT04680234|PROCEDURE|DMEP kit|Superficial Cryotherapy using dimethyl ether and propane (DMEP) at -57C
41488273|NCT04680234|DEVICE|Dermapen|Under aseptic precautions, the dermapen was moved on the alopecic patches diagonally, vertically and horizontally 4 to 5 times in each direction Pin point bleeding was taken as an end point
40822259|NCT00515294|OTHER|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
40822260|NCT00515294|DRUG|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
40822261|NCT00515294|OTHER|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
40822262|NCT03345654|OTHER|Hearing Aids|The signal processing of newly fit hearing aids will be evaluated for acceptability based on the toolset, which takes additional patient information beyond hearing threshold (like cognition) to determine the optimal hearing aid signal processing strategies.
40822263|NCT06607861|DRUG|saline group|nebulization of 4 mL 0.9% saline twice daily
41488274|NCT02706782|DRUG|TAI-meso-CART|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
40822264|NCT06607861|DRUG|dexmedetomidine group|nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily
40822265|NCT06607861|DRUG|lidocaine group|bilateral nebulization (60 mg) using a mucosal atomization device twice daily
40822266|NCT03176472|DRUG|ricolinostat|120 mg per dose in 12 mL liquid formulation
40822267|NCT03176472|DRUG|Placebo|12 mL liquid formulation placebo
41488275|NCT02361294|OTHER|Blood samples|
40822268|NCT03871101|PROCEDURE|Scalpel|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with scalpel for placing the healing abutment.
40822269|NCT03871101|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
41017580|NCT05684679|OTHER|Incentive spirometer plus Chest physiotherapy|Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.
41017581|NCT05684679|OTHER|Diaphragmatic breathing exercise plus Chest physiotherapy|Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
41017582|NCT03841643|DEVICE|patient-specific implant|solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect
41017583|NCT03841643|DEVICE|cement|norian cement for reconstruction of the cranial defect
41017584|NCT01451294|DRUG|Administration of phenylephrine|Phenylephrine: 50-100µg
41017585|NCT01451294|DRUG|Administration of ephedrine|Ephedrine: 5- 10 mg
41017586|NCT04417491|DEVICE|Dry Needling|Real dry needling will be conducted according to the fast-in and fast-out principle. The intervention will be applied until a total of four local twitch responses will be elicited
41488276|NCT01041066|DRUG|labetalol|0.4 mg/kg labetalol intravenously 4 min before intubation
41488277|NCT01041066|DRUG|nicardipine|20 ㎍/kg nicardipine intravenously 4 min before intubation
41488278|NCT02563821|PROCEDURE|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
41488279|NCT02563821|DRUG|Levobupivacaine|
41488280|NCT02563821|DRUG|sufentanil|
41488281|NCT02563821|DRUG|clonidine|
41488282|NCT02563821|DEVICE|epidural catheter|
41488283|NCT03246126|DEVICE|Valiant™Thoracoabdominal Stent Graft System|The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
41488284|NCT00469768|DRUG|dapivirine reservoir intravaginal ring|a silicone elastomer reservoir ring containing 25mg of dapivirine
41488285|NCT00469768|DRUG|dapivirine matrix intravaginal ring|a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine
41488286|NCT00469768|OTHER|placebo intravaginal ring|a silicone elastomer intravaginal ring containing no dapivirine
41488287|NCT02636192|DRUG|No Intervention|This is an observational study and participants did not receive any intervention in this study.
40822270|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.~Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.~Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.~Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours."
40822271|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.~Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects."
40822272|NCT01986309|DRUG|Lidocaine|Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
40822273|NCT01986309|DRUG|Normal saline|Sodium Chloride 0.9% infusion
40822274|NCT02666495|OTHER|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement \& stabilisation; phase 2 - developing trust \& understanding; phase 3 - developing awareness \& acceptance; phase 4 - testing change \& strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
40822275|NCT02241876|DRUG|N-acetylcysteine|
40822276|NCT00012129|DRUG|liposomal annamycin|
40822277|NCT05820698|OTHER|The Mediterranean style diet|"Participants in the Mediterranean style diet group will be provided with recommendations to include a minimum of 5 servings of fruits and vegetables (combined) per day, 2 servings of whole grains per meal per day, at least two servings of extra virgin olive oil per day, a maximum two servings of dairy products per day (excluding milk in coffee/tea), a minimum of 3 servings of fish per week (of which two should be oily fish), less than 2 servings of red meat or processed meat per week. Confectionary and sugar sweetened beverages should be limited to less than 2 servings per week.~Participants randomised to the Mediterranean style intervention will be provided with support documents including a dietary guideline booklet, recipes, meal plans, shopping and product swap lists, as well as eating-out and budget-eating advice sheets. Food deliveries containing key food items of the diet intervention will be scheduled for week 1, week 4, and week 8 of the study."
40822278|NCT05820698|OTHER|The UK diet|"Participants in the UK diet with time-restricted eating group will be provided with recommendations of a nutritionally balanced diet, corresponding to the average intakes of the UK population. Participants will be advised to consume no more than 4 portions of fruits and vegetables combined per day, to have at least two servings of dairy per day, to limit the consumption of white fish to less than 1 serving per week, with ≤1 serving of oily fish per month. Nuts and seeds consumption should also be limited to ≤1 serving per week and at least 3 servings of white and red meat should be consumed per week.~Participants randomised to the UK diet will be provided with support documents including a dietary guideline booklet, recipes, and meal plans. A £30 reimbursement will be provided to participants for their grocery shopping on week 1, week 4, and week 8 of the study."
40822279|NCT05820698|OTHER|Time-restricted eating|Participants randomised to the time-restricted eating interventions will be advised to limit food intake to a 10-hour eating window and to abstain from food intake for a 14-hour fasting window. Hydration is to be maintained during the fasting window with water and/or plain teas/coffees
40822280|NCT04956731|OTHER|Pharmacist Provision of Medication Abortion|Pharmacists providing start to finish medication abortions
40822281|NCT05139381|DRUG|Mepolizumab|Treatment with Mepoluzimab
40822282|NCT03342573|DRUG|Cosentyx|Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
40822283|NCT01313845|DRUG|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
40822284|NCT01313845|DRUG|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
40822285|NCT06608199|BIOLOGICAL|pneumococcal disease prevention|2P+1 programme of PCV13
40822286|NCT01956630|BIOLOGICAL|Genetically modified DCs plus CIK cells|
40822287|NCT01956630|BIOLOGICAL|Donor leukocyte infusions (DLI)|
40822288|NCT04050696|DEVICE|BQ 1.2|BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen
40822289|NCT05890170|OTHER|Patient Reported Outcomes Measures|Questionnaires and information extracted from the medical records would be collected.
40822290|NCT05671575|OTHER|Questionnaire about Epilepsy|After obtaining informed consent, a structured questionnaire will be administered to the accompanying relative. The questionnaire consists of 5 sections: participants socio-demographic characteristics, patient demographic and clinical characteristics, participants knowledge about epilepsy including sources of knowledge and management of an acute seizure, general attitudes, and behaviors towards the People with epilepsy, Stigma scale of epilepsy.\[14\], and Quality of life in epilepsy-10 inventory (QOLIE-10) as the main data collection tool as regard quality of life of patients with epilepsy.
40822291|NCT03202355|DEVICE|Fixed Appliance Orthodontic Treatment|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
40822292|NCT03202355|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
41341222|NCT04403841|OTHER|patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control|The intervention consisted group education on type 2 diabetes, including, in addition to usual diabetes care: information on diet, exercise, drug therapy, and adherence
41341223|NCT04403841|OTHER|Usual diabetes care alone|Usual diabetes care was consistent with the ADA guidelines (15) and comprised standard dietary and exercise advice in addition to antidiabetes treatment
41341224|NCT04960462|PROCEDURE|nerve root sleeve reinforcement|treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement
41341225|NCT02774668|OTHER|"Grab-and-Go meal plan"|"The Grab-and-Go meal plan will provide Atkins shakes and bars for breakfast, lunch, and snacks. For dinner, the participant will receive a freshly-prepared meal. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan.~The amount of weight loss caused by these two meal plans is not expected to differ."
40822293|NCT06608810|DRUG|nerve block with 0.5% ropivacaine|General anesthesia tracheal intubation was used. Induction was performed with midazolam 0.05ml/kg, etomidate 0.3-0.4mg/kg, sufentanil 0.3μg/kg-0.4μg/kg, and rocuronium bromide 0.8mg/kg, and after sufficient oxygen and denitration, the tracheal tube was placed by visual laryngoscopy, and the position of the tube was determined by auscultation of the lungs to determine the position of the catheter, and the respiratory sounds of the sides were symmetrically clear, so that the catheter was fixed and mechanical ventilation was performed. Anesthesia was maintained with remifentanil 0.1～0.3μg/(kg-min), propofol 2\~4mg/(kg-h) rate microinfusion pump for continuous infusion. BIS was kept between 40\~60. Intraoperative rocuronium bromide was given intermittently to maintain muscle relaxation. Perioperative fluid replacement followed the (4:2:1) rule in all patients. For maintenance of hemodynamic stability, ephedrine or atropine was administered, at the anesthesiologist's discretion, if verified a
40822294|NCT04753658|DRUG|lorlatinib|Oral
40822295|NCT06605456|OTHER|Proprioceptive neuromuscular facilitation with postural education|"Phase 1: Active Rhythmic Initiation The exercise was demonstrated to the students in a seated position, as sitting is considered the functional position for neck motion and stability. Then, the exercises was passively practiced on the students using tactile input. After passive demonstration, students were asked to perform the same exercise actively and verbal commands were used to guide and correct them.~Phase 2: Self-Resisted Rhythmic Initiation Modified The investigators applied resistance by placing the palm of one hand on the right side of the chin to strengthen the muscles.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration."
40822296|NCT06605456|OTHER|Active neck muscle stretching and strengthening exercises|"Phase 1: Active Muscle Stretching In this phase, participants were instructed on performing active muscle stretching exercises for all cervical muscles, including neck flexors, extensors, lateral flexors and neck rotators. Each stretch was held for a period of 25-30 seconds and repeated three times.~Phase 2: Self-Isometric Strengthening Participants were provided with a demonstration of self-isometric strengthening exercise for the neck muscles. The exercises involved six movement patterns: cervical flexion, cervical extension, right/left lateral flexion and right/left rotation. For each exercise the participants were required to apply resistance against the direction of movement using their hand without allowing any motion in the neck.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration."
40822297|NCT04829305|DRUG|SHR2285|SHR2285 is a selective inhibition of human FXIa small molecule compound.
40822298|NCT01328535|DRUG|temozolomide|Given PO
41341226|NCT02774668|OTHER|"Jump-Start meal plan"|"The Jump-Start plan will provide Atkins frozen meals at breakfast, lunch and dinner and these meals will be supplemented with fresh salads and vegetables. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan. The amount of weight loss caused by these two meal plans is not expected to differ."
40822299|NCT01328535|OTHER|flow cytometry|Correlative studies
40822300|NCT01328535|OTHER|staining method|Correlative studies
40822301|NCT01328535|PROCEDURE|biopsy|Optional correlative studies
41341227|NCT04201834|DRUG|Risperidone|capsule or tablet, 0.5 mg
41341228|NCT04201834|DEVICE|BioStamp nPoint device|MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.
41341229|NCT05572541|DIAGNOSTIC_TEST|Fonseca questionnaire|Fonseca questionnaire for the evaluation of temporomandibular dysfunction
41341230|NCT00469872|PROCEDURE|Context-focused compared to child-focused interventions|
41488288|NCT01090830|DRUG|Belinostat, carboplatin, paclitaxel and bevacizumab|"Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles."
40822302|NCT01328535|OTHER|laboratory biomarker analysis|Correlative studies
41341231|NCT00854061|DRUG|T-Pred|sterile ophthalmic solution
41341232|NCT00854061|DRUG|Pred Forte|sterile ophthalmic solution
41341233|NCT02927184|DRUG|VK2809|
41341234|NCT02927184|DRUG|Placebo|
41341235|NCT02360449|BEHAVIORAL|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
41341236|NCT05944445|DRUG|Linezolid 600 mg|Linezolid 600mg injection
41341237|NCT06104891|DIETARY_SUPPLEMENT|Recharge Placebo Control 1|Participants will use their Radicle Recharge Placebo Control 1 as directed for a period of 5 hours.
41341238|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 1|Participants will use their Radicle Recharge Active Study Product 1 as directed for a period of 5 hours.
40822303|NCT02227173|DRUG|BMS-986020|
40822304|NCT02227173|DRUG|Montelukast|
40822305|NCT02227173|DRUG|Flurbiprofen|
40822306|NCT02227173|DRUG|Digoxin|
41341239|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 2|Participants will use their Radicle Recharge Active Study Product 2 as directed for a period of 5 hours.
40822307|NCT04773782|DRUG|avapritinib|oral administration
40822308|NCT00613925|DEVICE|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
40822309|NCT00613925|DEVICE|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
40822310|NCT01311115|BEHAVIORAL|Group commitment contract|"1. Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.~2. The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.~3. Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
40822311|NCT01311115|BEHAVIORAL|Smoking cessation education and counseling|Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
40822312|NCT00096499|DRUG|ispinesib|Given IV
40822313|NCT00096499|OTHER|pharmacological study|Correlative studies
40822314|NCT00096499|OTHER|laboratory biomarker analysis|Correlative studies
40822315|NCT05797532|OTHER|breastfeeding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
40822316|NCT05797532|OTHER|skin to skin contact|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
40822317|NCT05797532|OTHER|swaddling and holding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
40822318|NCT06607094|DEVICE|Rezum|The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
40822319|NCT04134130|DRUG|Degarelix 120 MG [Firmagon]|Two doses of degarelix, 240 mg, subcutaneously once, at study start.
40822320|NCT04134130|DRUG|Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector|Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
40822321|NCT04134130|DRUG|Testosterone Undecanoate|One dose 1000 mg testosterone once, after 3 weeks.
40822322|NCT04275271|BEHAVIORAL|Educational intervention|Skill centered Protocol Training based on IMB model
40822323|NCT01500603|DEVICE|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
41341240|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 3|Participants will use their Radicle Recharge Active Study Product 3 as directed for a period of 5 hours.
41341241|NCT02347462|DEVICE|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
40822324|NCT01500603|DEVICE|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
40822325|NCT06607406|RADIATION|Accelerated radiotherapy|6 fractions per week, BID fractions one day per week
41341242|NCT02347462|OTHER|Standard care|Standard care according to the hospital severe asthma protocol
41341243|NCT02657876|BIOLOGICAL|ExpressGraft-C9T1 Skin Tissue|ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
41488289|NCT05393843|DIETARY_SUPPLEMENT|omega-3 fatty acids, anthocyanins and alpha-cyclodextrins|administration for 12 weeks
40822326|NCT06607406|RADIATION|Conventional radiotherapy|5 fractions per week, daily M-F
40822327|NCT04480190|DRUG|Gemcitabine|IV Gemcitabine 1000mg/m2 to be given on Days 1, Day 8 (Before Cisplatin); 3 week cycles
40822328|NCT04480190|DRUG|Cisplatin|IV Cisplatin 25mg/m2 to be given on Days 1, Day 8
40822329|NCT04480190|DRUG|Fluorouracil|Infusional 5-FU 225 mg/m2/d via Continuous IV infusion, to be given Days 1-5 and 8-12 during RT
40822330|NCT04480190|RADIATION|Short course ChemoRT|"Radiation Therapy:~Sim: All patients will undergo 4D-CT simulation with 3 hours fasting with or without IV contrast. Compression may be used depending on the tumor motion.~Radiation Target Volume: The gross tumor volume (GTV) will be defined on all relevant imaging datasets including diagnostic CT, MRI, MRCP and/or ERCP data. An iGTV will be generated using the 4D datasets. The clinical target volume (CTV) will include the entire iGTV as well as portal lymphatic and celiac nodal space for all patients with selective treatment of the SMA and pancreaticoduodenal depending on the tumor location. A 5 mm margin will be added to the CTV to generate the planning target volume (PTV).~Radiation Dose: The dose will be 30 Gy in 10 fractions (3 Gy per fraction) for all patients using either 3D Conformal or Intensity Modulated Radiation Therapy techniques."
40822331|NCT05093907|DRUG|BEY1107|Administer once daily, PO, 3-week continuous dose.
40822332|NCT05093907|COMBINATION_PRODUCT|Capecitabine|Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.
41488290|NCT05393843|BEHAVIORAL|diet|12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women
41488291|NCT05393843|OTHER|placebo|sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins; administration for 12 weeks
40822333|NCT04082390|DIETARY_SUPPLEMENT|RELEASE|Dietary supplement
41488292|NCT06172166|BEHAVIORAL|Transdisciplinary Care for Transition|Young adults with T1D will participate in three visits during which they will see a diabetes nurse educator, psychologist, and transition navigator/social worker who will co-deliver care. TCT Visits 1 and 2 will be before the first adult diabetes healthcare visit, during trial months 1 and 2 respectively. These visits will focus on improving transition readiness, establishing care with an adult T1D specialist, and navigating psychosocial barriers to successful transition. TCT Visit 3 will occur after the first adult T1D healthcare visit, within one month of the first adult T1D care visit or during trial month 7 if the visit has not yet occurred. TCT Visit 3 will focus on overcoming barriers to satisfactory adult T1D healthcare.
40822334|NCT04082390|DIETARY_SUPPLEMENT|Placebo|Placebo
40822335|NCT06606587|DEVICE|Comfort-in Jet Injection Method|Application of Comfort-in Jet Injection Method: Comfort-in jet injection method was used for palatal anesthesia of the permanent 1st molar.
40822336|NCT06606587|OTHER|Traditional Dental Injection|Application of Traditional Dental Injection Method: Traditional Dental Injection method was used for palatal anesthesia of the permanent 1st molar.
40822337|NCT05802082|OTHER|The Modified Yale Preoperative Anxiety Scale (m-YPAS) of children|Postoperative 0,5,10,15,30,45,60.and 120 minutes , PAED and WBYAS values
40822338|NCT05401812|DRUG|Intravenous glucocorticoid therapy|Betamethasone, dexamethasone, or methylprednisolone
40822339|NCT04058756|DRUG|PDR001|PDR001
40822340|NCT01568151|BEHAVIORAL|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
40822341|NCT01568151|BEHAVIORAL|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
40822342|NCT05186831|BEHAVIORAL|Texting|Patients will be asked to text their BP. They will receive an automated response to their texts.
40822343|NCT05186831|BEHAVIORAL|Online patient portal|Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.
40822344|NCT00851578|DEVICE|WATCHMAN|WATCHMAN LAA Closure Device
40822345|NCT05908526|BEHAVIORAL|Baseline surveys, Cognitive testing and EMAs|Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.
40822346|NCT05908526|DEVICE|Actiwatch|Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.
40822347|NCT05908526|DRUG|suvorexant (or placebo)|FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
40822348|NCT05908526|OTHER|Placebo|An inactive substance that looks like the drug or treatment being tested.
40822349|NCT04562402|PROCEDURE|Phacoemulsification|cataract surgery via phacoemulsification
40822350|NCT04562402|PROCEDURE|Endoscopic cyclophotocoagulation|Endoscopic ablation of the ciliary body
40822351|NCT04083313|DEVICE|Technique used for closing the appendiceal stump|In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump
40822352|NCT05118789|DRUG|NVL-520|Oral tablet of NVL-520
40822353|NCT02088073|DRUG|Sodium zirconium cyclosilicate|Sodium zirconium cyclosilicate
40822354|NCT02088073|DRUG|Placebo|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
40822355|NCT00497549|PROCEDURE|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
40822356|NCT00497549|PROCEDURE|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
40822357|NCT03905031|DEVICE|InfraScanner 2000|The InfraScanner is a portable screening device that measures lateralized differences in optical density (OD) to determine the presence of intracranial hematoma. A difference in OD\>0.2 is abnormal and suggestive of intracranial hematoma.
40822358|NCT05785715|DRUG|NX-13 250mg|NX-13 250mg tablet, plus 2 placebo tablets
40822359|NCT05785715|DRUG|NX-13 750mg|NX-13 250mg tablets times 3 to equal 750mg
40822360|NCT05785715|DRUG|NX-13 Placebo|NX-13 Placebo tablets times 3 for blinding purposes
40822361|NCT04171791|DRUG|ABT-199 (venetoclax)|Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
41341244|NCT01632176|BEHAVIORAL|Brief, motivational interview and one booster session|This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There is one booster call 10 days after the intervention/
41341245|NCT04513405|DIAGNOSTIC_TEST|Blood sampling|"a peripheral venous blood sample will be analyzed to measure the levels of estrone and estradiol.~The sample of the blood sample will be deposited in the red cap tube with a polymeric gel."
41341246|NCT04513405|PROCEDURE|Shave Biopsy|in the tissues, of the related estrogenic receptors, estrogen α receptors, estrogen β receptors (ER- α, ER-β) and G protein-coupled estrogen receptor 1 (GPER) correlates with the functional status of these receptors
41341247|NCT00675311|BEHAVIORAL|DM-Standard|Device/t+ Medical Diabetes Management System
41341248|NCT00675311|BEHAVIORAL|Disease Management Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
41341249|NCT03966352|OTHER|Questionnaire|Enrolled subjects will complete a questionnaire to ascertain information on treatment considerations, obstacles, motivations, and outcomes encountered on their pathway to fatherhood.
41341250|NCT03518463|COMBINATION_PRODUCT|Enhanced recovery after surgery (ERAS)|The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
41341251|NCT05628129|OTHER|smartphone application service and phone reminder|smartphone application service and phone reminder for appointments of parents of congenital ectopia lentis patients
41341252|NCT01300949|DIAGNOSTIC_TEST|Spaeth/Richman Contrast Sensitivity Test|internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes that decrease in contrast by fading to a white background.
41341253|NCT01300949|DIAGNOSTIC_TEST|Pelli-Robson Contrast Sensitivity Chart|wall chart contrast sensitivity test measuring central vision using black letters that decrease in contrast by fading to a white background.
41341254|NCT04584944|RADIATION|Dual energy X-ray absorptiometry|"Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups."
41341255|NCT04559997|OTHER|Exercise+FU|6 years intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
41341256|NCT04559997|OTHER|Active Comparator group Exercise|After 3 weeks of intensive therapy, we withdrew treatment and monitored their condition for 6 years and received only hospital base treatment
41341257|NCT01160224|DRUG|GW766944|Drug: GW766944 (Active Drug Treatment)
41341258|NCT01160224|OTHER|Placebo|This is placebo to match.
41341259|NCT00707486|DEVICE|Hemcon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
41341260|NCT00707486|DEVICE|Gauze with Pressure and/or Gelfoam|Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
41488293|NCT06207214|OTHER|Self-help book for university students.|"The intervention being tested, is a self-help book for university students based on Acceptance and Commitment Therapy. The book was published in 2021 and is called The Unbreakable Student: 6 Rules for Staying Sane at University. The book is by Dr Nic Hooper.~The self-help book will be posted in paper form to all participants. There are 8 chapters in the book and participants will be given eight weeks to read the book at home (with a suggestion of reading one chapter per week)."
40822362|NCT02728544|OTHER|exercise and blood tests|At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
41341261|NCT04705428|OTHER|FLUORINE VARNISH|"Participants in all groups will receive written oral hygiene and oral prophylaxis instructions. All groups will receive the application of fluorine varnish every 3 months.~The application of fluoride in the three groups will be done as follows:~-Drying of the teeth, placement of the fluorine varnish on the teeth by quadrants. The varnish will be left to dry for a few seconds according to the manufacturer's instructions. Children in all groups will be asked to avoid brushing and flossing for one day after applying fluoride. They will be instructed to avoid hard food and hot drinks for 4 hours. Children and parents will be instructed on how to care for their teeth at home: brush teeth with conventional toothpaste containing 1000 ppm sodium fluoride, for 3 minutes without rinsing.~In the following reviews (3 and 6 months) the effectiveness of the treatments will be evaluated by visual examination, tactile examination, fluorescence and photography."
41341262|NCT02658968|DRUG|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
41341263|NCT00641459|OTHER|Observational BPSD treatment study|Observational BPSD treatment study
41341264|NCT01957085|OTHER|observation only|This is an observational only, nonintervention study. There will be no patient contact. This was a de-identified point prevalence study of hepatitis C infection in hospitalized patients in an inner city hospital.
41341265|NCT01204424|DEVICE|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)
41341266|NCT01204424|DEVICE|minimal invasive crestal sinus lift with the JEDER Systh.|"The mucous membrane is opened from the toothless part of the maxillary crest up to the bone and the bone is scraped by a cylindrical cutter in the shape of a tunnel up to slightly underneath the maxillary sinus membrane and hydraulic pressure is being built up within the DKK. A centrally placed drill within the DKK slowly moves in the direction of the membrane. At the moment of the first minimal perforation of the remaining bone the pressurized fluid pushes the membrane back and ensures that the membrane is not perforated by the drill.~The SVP is used to generate hydraulic vibrations, which help to further raise the membrane from the bone (principle of the percussion drill). After the maxillary sinus membrane has successfully been elevated, the working fluid is extracted and bone replacement material is introduced via the bore."
41341267|NCT01637090|DRUG|Everolimus|"The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.~Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.~If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded."
41341268|NCT00432640|PROCEDURE|Endoscopic ultrasound staging|Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA
41341269|NCT00432640|PROCEDURE|Surgical staging|Surgical staging
41341270|NCT05560295|PROCEDURE|Naser Al-Husban|uterine surgery
40822363|NCT03989414|DRUG|CC-92480|Specified dose on specified days
40822364|NCT03989414|DRUG|Bortezomib|Specified dose on specified days
40822365|NCT03989414|DRUG|Dexamethasone|Specified dose on specified days
41341271|NCT02318069|BIOLOGICAL|FSME-immune|0.5 ml im as scheduled in the 5 arms
41341272|NCT00938197|DRUG|Fimasartan|Fimasartan (1d\~7d) Amlodipine (12d\~14d) Fimasartan + Amlodipine(15d\~21d)
41341273|NCT00938197|DRUG|Amlodipine|Amlodipine (1d\~10d) Amlodipine (25d\~27d) Fimasartan + Amlodipine(28d\~34d)
40822366|NCT03989414|DRUG|Daratumumab|Specified dose on specified days
40822367|NCT03989414|DRUG|Carfilzomib|Specified dose on specified days
40822368|NCT03989414|DRUG|Elotuzumab|Specified dose on specified days
40822369|NCT03989414|DRUG|Isatuximab|Specified dose on specified days
41488294|NCT03469336|DRUG|PF-06763809|Three different concentrations will be administered to three different treatment fields: 2.3%, 0.8% and 0.23%
40822370|NCT03989414|DRUG|Carfilzomib|Specified dose on specified days
41488295|NCT03469336|OTHER|Vehicle|Vehicle matching PF-06763809.
41488296|NCT03469336|DRUG|Calcipotriene/calcipotriol|Calcipotriene/calcipotriol 50 ug/mL solution
40822371|NCT06095882|OTHER|acupuncture|"Study group: Acupuncture treatment was performed from day 3 to day 14 after surgery. Points include: Zhongwan, Tianshu, Watercourse, Taichong, Sanyinjiao, Zusanli, Yin Lingquan.~Control group: No intervention, the urinary tube was removed until the 14th day after surgery. Patients with urinary retention may receive further acupuncture treatment."
40822372|NCT00905762|DRUG|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
40822373|NCT00905762|DRUG|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
40822374|NCT00905762|DRUG|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
41017587|NCT04417491|DEVICE|Sham Needling|Sham dry needling with be conducted with a sham needle device. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient
41341274|NCT00467012|DRUG|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
41341275|NCT00467012|DRUG|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
41341276|NCT02863861|DRUG|Dexmedetomidine-ketamine|
41341277|NCT02863861|DRUG|propofol-ketamine|
41341278|NCT04669509|DIAGNOSTIC_TEST|Liver function tests|Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, hemoglobin, platelet count), coagulation parameters (prothrombin time, activated partial thromboplastin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. It will also be recorded whether mortality develops on day 7 and day 28.
41341279|NCT01706120|DRUG|Bevacizumab|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
41488297|NCT03469336|DRUG|Betamethasone|Betamethasone 1 mg/g solution
41488298|NCT05506410|DRUG|Rituximab|Young patients (\< 65 years of age) were treated with R-BAP for 6 cycles (efficacy was assessed every 2 cycles, and adverse events were recorded), together with oral ibrutinib, followed by oral ibrutinib for 1 year after chemotherapy (efficacy was assessed every 3 months). Elderly patients (≥65 years of age) received 4 cycles of R-BAP (efficacy assessed every 2 cycles, and adverse reactions recorded), followed by 4 cycles of rituximab consolidation (efficacy assessed every 2 cycles) and 1 year of oral zanubrutinib (efficacy assessed every 3 months).
41488299|NCT02996045|OTHER|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-6, and scans scored 7-8 for which an alternative scan scored 8-9 exists.~This screen will show the appropriateness score of the original scan order, and will display up to 7 alternative scans that are scored \>4 and greater than or equal to the original score for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication."
41488300|NCT01745211|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser with array handpiece
40822375|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Placebo Product (PP)|1 spray (0 mg melatonin)
40822376|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Active Control (AC)|1 spray (1 mg melatonin)
40822377|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Test Product (TP)|1 spray (0.3 mg melatonin)
40822378|NCT01921374|BIOLOGICAL|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
40822379|NCT01921374|BIOLOGICAL|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
40822380|NCT01921374|BIOLOGICAL|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
40822381|NCT01921374|BIOLOGICAL|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
41341280|NCT01706120|DRUG|Paclitaxel|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
41341281|NCT01706120|DRUG|Carboplatin|• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
41341282|NCT01986517|BEHAVIORAL|No feedback|Therapists will receive no feedback.
41341283|NCT01986517|BEHAVIORAL|Feedback after every fourth session|
41341284|NCT05829564|OTHER|virtual reality|The individuals participating in the study will experience virtual reality.
41341285|NCT05829564|OTHER|cervical mobilization|The individuals participating in the study will be applied cervical mobilization techniques.
41341286|NCT05829564|OTHER|exercise|The individuals participating in the study will performed neck-specific exercises.
41341287|NCT01781624|OTHER|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
40822382|NCT01921374|BIOLOGICAL|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
41017588|NCT06192602|BEHAVIORAL|AIM_AT|The program consists of 10 weekly/biweekly, 2-hour sessions (4-months), based on the modified Kemp's model/manual of Adherence therapy and mindfulness-based psychoeducation program developed by the research team.
41017589|NCT06192602|BEHAVIORAL|CPG|Psychoeducation group program (12-18 members/group) consists of 10 two-hour sessions, weekly/biweekly (similarly, 4-month duration) and is guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psychoeducation programs for psychosis.
41017590|NCT06192602|BEHAVIORAL|TAU|Routine/Usual care only (control) group participants (and the two treatment groups) will receive usual community mental healthcare services.
41017591|NCT00781326|DRUG|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
41017592|NCT00781326|DRUG|Placebo|Placebo will be given in doses matching those of nimodipine.
41017593|NCT04055194|DRUG|Tranexamic acid tablets|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
41017594|NCT04055194|DRUG|Placebo oral tablet|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
41017595|NCT05904600|DEVICE|Respiratory muscle training|The training of the intervention group will have an initial workload of 30% of maximal inspiratory and expiratory pressures, which will be increased weekly by 10% according to tolerance, if not tolerated by 5%. In addition, patients will be instructed to maintain a normal respiratory rate (12-16 breaths per minute). Moreover, they will continue their usual treatment.
41017596|NCT05904600|DEVICE|Control group|In the control group, the respiratory muscle training will be simulated by using the device without load throughout the study period using an opaque adhesive tape surrounding the device to mask the valve position.
41017597|NCT01297218|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
41017598|NCT05384847|DRUG|Thyroid hormone T3|Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.
41341288|NCT02724280|DEVICE|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
41341289|NCT02724280|DEVICE|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
41341290|NCT00848289|BEHAVIORAL|Interviews|Data collected by personal interview for Epidemiology and Nutrition Questionnaires, with personal and follow-up telephone interviews.
41341291|NCT01715090|DEVICE|Web-based insulin titration|
41341292|NCT00487994|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
41488301|NCT06164314|DRUG|Dexmedetomidine|In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation
41488302|NCT05234957|PROCEDURE|Bilateral Lateral Rectus Recession|Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.
41341293|NCT00487994|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
41341294|NCT00487994|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
41341295|NCT02813590|OTHER|Ascitic fluid puncture|
41341296|NCT02813590|OTHER|Skin swaps from puncture side|
41341297|NCT02813590|OTHER|Stool samples|
41341298|NCT02495090|GENETIC|Exome sequencing|Plain DNA sequencing
41341299|NCT01045551|DRUG|Apremilast|20mg taken orally twice per day for 12 weeks
41341300|NCT00944957|DRUG|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
41341301|NCT00944957|DRUG|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
41488303|NCT05340348|OTHER|Blood samples (36 mL) + fecal samples + hair sample|Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion
41488304|NCT02493777|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
41488305|NCT02493777|DRUG|Placebo|
41488306|NCT05436717|BEHAVIORAL|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
41488307|NCT04067336|DRUG|Ziftomenib|Oral administration
40822383|NCT00845260|BEHAVIORAL|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
40822384|NCT00845260|BEHAVIORAL|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
40822385|NCT00834470|DRUG|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
41341302|NCT00944957|DRUG|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
40822386|NCT03003221|BEHAVIORAL|AIR-P Dental Toolkit|The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
40822387|NCT03003221|BEHAVIORAL|Parent Training|The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
41341303|NCT00944957|DRUG|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
41341304|NCT02733146|OTHER|cardiac arrest|
41341305|NCT06201403|DIAGNOSTIC_TEST|Determination of biomechanical properties of muscles|All evaluations will be performed with a MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. The data of the cases to be evaluated and the patterns related to the measurements will be transferred to the device by establishing a computer connection. Measurements will be performed unilaterally. The measurement point of the subjects' unilateral muscles will first be marked with a pencil. The physiotherapist will hold the device vertically and apply downward pressure (18N) to the muscle body. When the red light on the plexiglass frame of the device probe turns green, the pressure application will be stopped and will remain constant until 5 strokes are made. In every 5 beats, the duration of 1 beat is 15 ms and the time between beats is 8 ms. The SENIAM sensor location guide will be considered as a reference for the estimated motor point determination in the MyotonPRO measurement.
41341306|NCT03648411|GENETIC|Drug resistance molecular markers|Proportion of the drug resistance molecular markers will be found-out and compared.
41341307|NCT05526781|DEVICE|Clareon monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
41341308|NCT06506851|OTHER|AR-based Training with Microsoft HoloLens 2®|Practical nurses in this group receive AR-based training using Microsoft HoloLens 2®. This training method incorporates augmented reality technology to provide immersive and interactive learning experiences, enhancing their proficiency in device utilization.
40822390|NCT00693641|OTHER|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
40822391|NCT00693641|OTHER|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
40822392|NCT00031655|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
40822393|NCT00031655|BIOLOGICAL|donor lymphocytes|Given IV
40822394|NCT00031655|DRUG|cyclosporine|Given PO
40822395|NCT00031655|RADIATION|total-body irradiation|Undergo TBI
41341309|NCT06506851|OTHER|Traditional Guideline-based Self-Learning|Practical nurses in this group follow traditional guideline-based self-learning methods without augmented reality technology. They rely on conventional educational materials and guidelines for learning device utilization skills.
41488308|NCT00666783|DRUG|palonosetron|receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
41488309|NCT00666783|DRUG|Granisetron|receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
40822396|NCT00031655|DRUG|fludarabine phosphate|Given IV
40822397|NCT00031655|DRUG|mycophenolate mofetil|Given PO
40822398|NCT00031655|OTHER|laboratory biomarker analysis|Correlative studies
40822399|NCT00031655|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
40822400|NCT06050668|COMBINATION_PRODUCT|Essential Amino Acid Supplementation|Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)
40822401|NCT06605924|OTHER|Tobacco-free|Ad contains baseline language + language that product is tobacco-free
40822402|NCT06605924|OTHER|Discrete|Ad contains baseline language + language that product is discrete
40822403|NCT06605924|OTHER|Convenient|Ad contains baseline language + language that product is convenient
40822404|NCT04360512|PROCEDURE|Posteriorization of the talus|Three sets of a 30-s grade IV mobilization
40822405|NCT06608836|OTHER|an ice massage|an ice massage
40822406|NCT06608836|OTHER|the cold spray|the cold spray
40822407|NCT06607380|BIOLOGICAL|TNM002|A single intramuscular (IM) gluteal injection
41341310|NCT00493714|BEHAVIORAL|Questionnaire|Surveys lasting 30 minutes or more.
40822408|NCT06607380|BIOLOGICAL|Adsorbed tetanus vaccine|A single IM deltoid injection
40822409|NCT06607380|BIOLOGICAL|TNM002 + adsorbed tetanus vaccine|A single IM gluteal injection+ a single IM deltoid injection
40822410|NCT00746265|BEHAVIORAL|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
40822411|NCT04347473|DRUG|Ilumya Injectable Product|IL-23 injection
40822412|NCT02887053|DEVICE|MRI|
40822413|NCT02019446|DEVICE|Laser Treatment YAG laser|YAG Laser / FOX Laser
40822414|NCT02019446|DRUG|Standard Treatment (control group) terbinafine hydrochloride tablets|Terbinafine hydrochloride tablets tablets
40822415|NCT02402894|OTHER|no intervention|
40822416|NCT06072300|BEHAVIORAL|Physical activity calorie equivalent labelling|Physical activity calorie equivalent labelling on beverage vending machines
40822417|NCT02647541|DIETARY_SUPPLEMENT|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
40822418|NCT03548506|DEVICE|Omnidirectional Deep Brain Stimulation of STN|Deep Brain Stimulation
40822419|NCT03548506|DEVICE|Directional Deep Brain Stimulation of STN|Deep Brain Stimulation
40822420|NCT05734053|OTHER|Nilotinib|There was no treatment allocation. Patients administered Nilotinib by prescription could be enrolled.
41017599|NCT05384847|OTHER|Control Group|The control group will have testing and study procedures as per protocol but will not be admitted to the General Clinical Research Center (GCRC) and will not receive the study medication. After completion of phase I, participants will be permitted to enroll in Phase II.
41341311|NCT00796224|DRUG|60 mg/kg azithromycin ER|subjects taken 60 mg/kg azithromycin ER
41341312|NCT00796224|DRUG|30 mg/kg azithromycin IR|subjects taken 30 mg/kg azithromycin IR (Immediate Release)
41341313|NCT04282369|DEVICE|HHHFNC|noninvasive ventilation modality
41341314|NCT04282369|DEVICE|NCPAP|noninvasive ventilation modality
41341315|NCT04282369|DEVICE|NIPPV|noninvasive ventilation modality
41341316|NCT04282369|DEVICE|NHFO|noninvasive ventilation modality
40822421|NCT02471274|DRUG|sotagliflozin|single 400 mg dose
40822422|NCT06512896|OTHER|FOLactis|Evaluate the safety,tolerability, efficacy of intraluminal injection of FOLactis combined with chemotherapy, target therapy, and immunotherapy
40822423|NCT03104972|DEVICE|tDCS|Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
41341317|NCT00179998|DRUG|Recombinant Human DNase (Pulmozyme)|2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
40822424|NCT03104972|DEVICE|tRNS|Children in the active tRNS group will received 0.75mA of tRNS (100-640Hz) to their left dorsolateral prefrontal cortex (dlPFC) and the right inferior frontal gyrus (IFG) via semi-dry 5cm X 5cm electrodes, attached under designated electrode positions (F3, F8) of a tES cap that followed the International 10-20 system (InnoSphere Inc., Haifa). The left dlPFC and right IFG were chosen, based on their contribution in executive control and inhibition. tRNS will be applied for 20 minutes per session during an iPad cognitive training. Similar duration has also been used in paediatrics using tDCS29. Similar to a previous tRNS study in children, and the rational provided for tDCS we will apply 0.75mA.
40822425|NCT03104972|DEVICE|sham|For sham-tRNS we will use the same montage as in active tRNS. For sham-tDCS we will use the same montage as in active tDCS. The only difference between active and sham tES would be that in the case of the sham tES the 30 sec of ramp up of the current from 0 to 0.75mA would not be followed by 19 min of stimulation at 0.75mA as in active tES, but would immediately be followed by 30 sec ramp down period to 0mA. Such method has been shown to provide effective blindness of the stimulation condition as both active and sham tES would lead to slight itching sensation that would disappear due scalp habitation. No further stimulation would be provided in the sham group during the daily session.
40822426|NCT04293510|PROCEDURE|renal biopsy and blood sampling|renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
40822427|NCT00137137|PROCEDURE|Placement of the mini-screw|
41017600|NCT06573359|OTHER|questionnaire|Turkish translation of the scale will be made by a native English speaker and the back translation will be made into English, and the consistency of the original and Turkish translation will be evaluated by a three-person expert committee. The psychometric properties of the scale will be investigated according to the methods used for the validity of the original scale. The validity of the scale was validated by analyzing the correlations between the rcs-e-tr score obtained at admission (both for each partial item and the total score) and other suitability indicators used in Turkey (FIM Motor and Barthel) using Spearman's rank correlation coefficient r (rho). will be evaluated. Additionally, to check the ability of rcs-e-tr to capture case complexity, it will be correlated with other scores usually recorded in our rehabilitation services on admission, using Spearman's rank correlation coefficient r(rho).
41017601|NCT05922904|DRUG|Brentuximab vedotin|Given by IV (vein)
41156998|NCT06127966|PROCEDURE|0.9% physiological saline (20ml) injection under ultrasound-guided Erector Spinae Plane Block (ESPB).|The patient is placed in a prone position, and the appropriate lumbar vertebral level is determined using ultrasound based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is positioned in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process, erector spinae, and latissimus dorsi muscles above it. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process, and there is no blood or gas upon aspiration, 2-3 milliliters of isotonic saline solution are injected to confirm the correct needle position. Subsequently, 20 milliliters of 0.9% physiological saline is injected between the erector spinae muscle and the transverse process. The diffusion of the physiological saline in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
41017602|NCT05922904|DRUG|Doxorubicin Hydrochloride|Given by IV (vein)
41341318|NCT00179998|DRUG|Placebos|2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject
41341319|NCT02977533|DRUG|GZ402668|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41341320|NCT02977533|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41341321|NCT02977533|DRUG|Acyclovir|"Pharmaceutical form: tablet~Route of administration: oral"
41017603|NCT05922904|DRUG|Pembrolizumab|Given by IV (vein)
41017604|NCT05922904|DRUG|Dacarbazine|Given by IV (vein)
41017605|NCT06572956|BIOLOGICAL|CAR-T/CAR-NK cell injection|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
41341322|NCT04737759|BEHAVIORAL|Taking Care of Us|A social-behavioral intervention that is targeted at the couple living with heart failure and delivered via Zoom.
41341323|NCT04737759|OTHER|SUPPORT|SUPPORT is an educational counseling intervention that is targeted at the couple living with heart failure and delivered by Zoom.
41341324|NCT05264480|PROCEDURE|Bone augmentation with minimally invasive corticotomy (piezotomy)|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Trough the vertical releasing incisions a piezosurgical device is used to perform corticotomy. 1 week after surgery OTM is initiated."
41341325|NCT05264480|PROCEDURE|Bone augmentation without corticotomy|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Corticotomy is not performed in this group. 1 week after surgery OTM is initiated."
41341326|NCT03938025|PROCEDURE|Gastric volume resected in sleeve gastrectomy|Misure of resected gastric volume and outcome
40822428|NCT05801757|DRUG|Remimazolam|Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
40822429|NCT05801757|DRUG|Propofol|propofol 2-3mg/kg/h
40822430|NCT02748434|OTHER|Lipohypertrophy|
40822431|NCT02748434|OTHER|Normal Subcutaneous Tissue|
41341327|NCT00186472|BEHAVIORAL|Brief Cognitive Behavioral Treatment|
40822432|NCT05156840|BEHAVIORAL|Telehealth follow-up|A telehealth follow-up visit will be conducted via the Epic electronic medical record with a pediatric hospitalist following hospital discharge.
41017606|NCT04894045|OTHER|Personalized management|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
41017607|NCT06473558|DEVICE|Biometrics (or AI Biomaker)|Patients will be asked to read a story and their facial expressions and audio cues will be recorded.
41341328|NCT03321890|DRUG|Chidamide|Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
41341329|NCT03321890|DRUG|prednisone|oral, 20mg / day,after breakfast
41341330|NCT03321890|DRUG|Cyclophosphamide|oral, 50mg / day,after lunch
41341331|NCT03321890|DRUG|etoposide|oral, 50mg / day,after dinner
41341332|NCT03321890|DRUG|Methotrexate|oral, 10mg / times, once a week,after breakfast
41341333|NCT00554255|DRUG|SB751689|
41341334|NCT02374073|OTHER|Functional Massage|The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.
41341335|NCT02374073|OTHER|Protocolized physiotherapy|therapeutic exercises, analgesic electrotherapy and cryotherapy
41341336|NCT00622570|DRUG|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
41341337|NCT00622570|DRUG|thiopental|"2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.~Maintenance: 3 mg/kg/h in perfusion"
41341338|NCT05108441|OTHER|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris|In sedated critically ill children, quadriceps femoris thickness and cross sectional area will be measured with thigh bedside ultrasound, performed by two trained operators consecutively. These two measurements will also be made at the exact same location on a magnetic resonance imaging transverse view of the thigh, to allow comparing them to ultrasound measurements.
41341339|NCT01175590|DRUG|Besivance|Ocular administration to affected eye for 7 days
41341340|NCT01175590|DRUG|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
41341341|NCT00504192|DRUG|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
41341342|NCT06446804|OTHER|None, pure observationnal study|Pure observatonnal study
41341343|NCT05695404|PROCEDURE|Segmentectomy|Lung resection
41341344|NCT05462691|PROCEDURE|tuberosity suture|to suture or not suture the tuberosities in reverse shoulder arthroplasty because of a proximal humeral fracture
40822433|NCT03579472|DRUG|Bintrafusp Alfa|Given IV
41017608|NCT01583725|PROCEDURE|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
41017609|NCT01583725|BEHAVIORAL|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
41017610|NCT04777461|OTHER|Survey on patient's perspectives on the development of an structured education programme for PCOS|The outcome of this survey will help with developing curriculum for the structured education programme.
41017611|NCT04777461|OTHER|Pre-pilot questionnaire|The questionnaire is aimed to capture the knowledge and expectations of the participants from taking part in the educational sessions.
41017612|NCT04777461|OTHER|Piloting the structured education programme for PCOS|Piloting the education program through 2 educational group sessions
41341345|NCT04827719|DRUG|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
41341346|NCT04816370|DIAGNOSTIC_TEST|FSFI|2 group and 2 subgroup
41341347|NCT04889755|BEHAVIORAL|SibACCESS|The primary goal of the SibACCESS program is to increase siblings' exposure to and opportunity to process cancer-related cues to decrease onset or intensification of posttraumatic stress. The program is focused on siblings, with a brief parent education component. Parents will receive psychoeducation and brief skills training to support siblings enrolled in the program. Siblings will participate in 7 group sessions and one individual session in which they will learn skills and strategies to confront information about cancer and tolerate uncomfortable thoughts and feelings related to cancer, and thereby reduce avoidance of cancer-related emotions.
41341348|NCT04624672|DRUG|Semaglutide (1 Mg Dose)|Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery
41341349|NCT04624672|DRUG|Placebo|Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery
41341350|NCT01751360|DRUG|SYR-472|
41341351|NCT02103595|DEVICE|Accu-Chek FlexLink|Insulin pump device used for 4-weeks under real life conditions
40822434|NCT03579472|DRUG|Eribulin Mesylate|Given IV
40822435|NCT06394661|DRUG|Serplulimab|Serplulimab plus neoadjuvant nab-PE. Specific medication measures: Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serulizumab 4.5mg/Kg ivgtt on Day 3）every 3 weeks for 6 cycles.
40822436|NCT05056688|DIAGNOSTIC_TEST|Testicular Model BSE/TSE Training Set|The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.
41017613|NCT04777461|OTHER|Post-pilot questionnaire|The questionnaire aimed to capture participant's satisfactions and knowledge gained by taking part in the pilot study
41017614|NCT04777461|OTHER|cognitive outcomes outcome evaluation form|This aimed to capture skills developed, knowledge gained and changes in participants behaviour and perceptions by taking part in the pilot study.
41341352|NCT02103595|DEVICE|Accu-Chek FlexLink Plus|Insulin pump device used for 4-weeks under real life conditions
41341353|NCT04107428|DRUG|Somatostatin|A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.
41341354|NCT04107428|DRUG|Placebo|A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
40822437|NCT04288453|BEHAVIORAL|Engagement in a 8-week community-based activity program|"Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.~Other Names:~• Pathways and Resources for Engagement and Participation"
40822438|NCT02701777|OTHER|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
40822439|NCT02701777|BEHAVIORAL|Training|The participant will be asked to perform exercises using their hands and arms.
41341355|NCT06309498|PROCEDURE|blood test|11 DOC levels will be measured in enrolled patients
41341356|NCT04343391|BEHAVIORAL|Brief transdiagnostic cognitive-behavioral therapy|Time-limited transdiagnostic evidence-based psychological treatment
41341357|NCT04343391|DRUG|Pharmacological treatment|Treatment as usual in PC
41341358|NCT00028795|DRUG|temozolomide|
41341359|NCT00028795|PROCEDURE|adjuvant therapy|
41341360|NCT00028795|RADIATION|radiation therapy|
41341361|NCT02597972|PROCEDURE|Fracture repair|
41341362|NCT02597972|PROCEDURE|Fracture repair with joint replacement|
41341363|NCT00959699|DRUG|PegIFN-2b|PegIFN-2b (1.5 μg/kg/week subcutaneously)
41341364|NCT00959699|DRUG|RBV|Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
41341365|NCT00959699|DRUG|Placebo to Boceprevir|Placebo to boceprevir (orally, three times per day)
41341366|NCT00959699|DRUG|Boceprevir|Boceprevir (800 mg, orally, three times per day)
41341367|NCT02283372|DRUG|nab-Paclitaxel|
41341368|NCT02283372|DRUG|Gemcitabine|
41341369|NCT02283372|RADIATION|Intensity modulated radiation|
41341370|NCT04205110|DIAGNOSTIC_TEST|PET-CT|PET-CT compared to intravascular imaging for assessment of atherosclerotic plaques in stable angina patients
41341371|NCT00641706|DRUG|vorinostat|Given orally
40822440|NCT02701777|OTHER|Sham STDP|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.
40822441|NCT02701777|OTHER|Multisite-STDP|Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
41341372|NCT00641706|PROCEDURE|therapeutic conventional surgery|Patient undergoes surgery
41341373|NCT00641706|DRUG|bortezomib|Given IV
41341374|NCT02762708|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
41341375|NCT02762708|BEHAVIORAL|Caloric Restriction|Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
41341376|NCT02762708|DRUG|Exendin-9,39|"A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
41341377|NCT02762708|DRUG|Normal Saline|"subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
40822442|NCT03894969|BIOLOGICAL|GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
41017615|NCT02154815|OTHER|Questionnaires : Patient-Reported Outcomes|Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, 24, 36, 48, 72 months
41017616|NCT04619316|DRUG|Trametinib 2 MG [Mekinist]|Monotherapy with Trametinib is given in patients with BRAF wildtype.
41017617|NCT04619316|DRUG|Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]|Combination therapy is given in patients with BRAF V600E mutation.
41017618|NCT03996928|OTHER|Exercise|
41017619|NCT02845271|DRUG|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
41017620|NCT02845271|DRUG|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
41017621|NCT02845271|DRUG|acetaminophen or paracetamol|"Pharmaceutical form: tablet~Route of administration: oral"
41341378|NCT05392166|DIAGNOSTIC_TEST|blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides , abdominal ultrasound|blood samples will be collected at admission for assessment of blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides will be assessed within the first 24 hours after hospital admission. For the control group, the blood samples will be collected during the pediatric diabetes clinic follow-up visits. Abdominal ultrasound will be done to all the study participants.
41341379|NCT00508469|DRUG|Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
41341380|NCT00508469|DRUG|Travoprost 0.004% eye drops|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
41341381|NCT00508469|DRUG|Timolol 0.05% eye drops|One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
40822443|NCT03894969|BIOLOGICAL|Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)|2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
40822444|NCT05173688|DRUG|Propofol|The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
40822445|NCT06372522|DRUG|Pitocin Injectable Product|The primary dose of oxytocin is 1.0 mU/min, with an incremental increase by 2.5 mU/min every 30 minutes, until 20.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation \> 6 cm).
40822446|NCT04419051|OTHER|Owlet Band|The Owlet Band is a wearable fabric band pregnancy tracker made up of small sensors that are able to detect natural low-level electrical signals normally produced by the mother's heart and baby's (fetal) heart.
40822447|NCT06605105|DRUG|CYB003|CYB003 is a synthetic psilocybin analog
40822448|NCT03817320|DRUG|Ixazomib|"Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D"
40822449|NCT03817320|DRUG|Vincristine|"IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and \< 1 year: 1.2mg/m2/dose~\< 6 months: 1mg/m2/dose"
40822450|NCT03817320|DRUG|Dexamethasone|"Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and \< 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~\< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)"
40822451|NCT03817320|DRUG|Asparaginase|"Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose"
40822452|NCT03817320|DRUG|Doxorubicin|"Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose"
40822453|NCT03817320|DRUG|Methotrexate (IT)|For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
40822454|NCT03817320|DRUG|Triple IT (Methotrexate, Hydrocortisone, Cytarabine)|For patients with CNS 3, on Days 1, 8, 15, 22, and 29
40822455|NCT03817320|DRUG|Leucovorin|For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
40822456|NCT06440889|DEVICE|Bio-Ray Knee Guard|Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)
40822457|NCT00391469|OTHER|Rapid infusion of 2 liters of 4oC normal saline|Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
40822458|NCT00391469|DRUG|Rapid infusion of cold normal saline|
40822459|NCT02307097|PROCEDURE|Cognitive-Behavioural Bibliotherapy|
40822460|NCT02307097|PROCEDURE|Cognitive-Behavioural Therapy|
40822461|NCT02307097|OTHER|WAIT|
40822462|NCT01559922|DRUG|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
40822463|NCT01559922|DEVICE|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
40822464|NCT00928278|DRUG|Treatment A|Inhaled, 300/150, single dose
40822465|NCT00928278|DRUG|Treatment B|Inhaled, 300/150, single dose
40822466|NCT00928278|DRUG|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
40822467|NCT00928278|DRUG|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
40822468|NCT01900106|DRUG|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
40822469|NCT01900106|DRUG|abacavir/lamivudine + darunavir/ritonavir|abacavir/lamivudine + darunavir/ritonavir
40822470|NCT06432192|DIAGNOSTIC_TEST|APO-Easy|Testing for the APOE genotype using the APO-Easy Genotyping test
40822471|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
40822472|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
40822473|NCT06060132|DRUG|Sodium arsenite chloride injection|Patient use of arsenite sodium chloride injection
40822474|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
40822475|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
40822476|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
41488310|NCT04081766|BEHAVIORAL|SUGAR Handshake|"An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics.~Components of the SUGAR Handshake intervention will be covered under five main domains:~1. Signs and symptoms of hypoglycemia.~2. Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications.~3. Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications.~4. Acknowledgement by the patient~5. Recap and summary~The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit."
41341382|NCT00508469|DEVICE|Travalert Dosing Aid|Approved device used with study medication to record time of instillation and quantify dosing
41017622|NCT02845271|DRUG|fixed combination of paracetamol + codeine|"Pharmaceutical form: capsule~Route of administration: oral"
40822477|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
40822478|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
40822479|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
40822480|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
40822481|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
41017623|NCT02845271|DRUG|fixed combination of paracetamol + tramadol hydrochloride|"Pharmaceutical form: tablet~Route of administration: oral"
41017624|NCT02061462|PROCEDURE|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
41017625|NCT00079547|BEHAVIORAL|Low-calorie diet|low-calorie diet
41017626|NCT00079547|BEHAVIORAL|low-carbohydrate diet|low-carbohydrate diet
41017627|NCT02383758|DRUG|Glycerin Suppository|Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
40822482|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
40822483|NCT02298179|DRUG|Placebo|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
40822484|NCT03253172|DIETARY_SUPPLEMENT|Potassium Chloride|Two potassium supplements with varying anions.
40822485|NCT03253172|DIETARY_SUPPLEMENT|Potassium Citrate|Potassium Citrate
41341383|NCT02347254|DEVICE|Transcranial ExAblate|Transcranial ExAblate MRgFUS
41341384|NCT02603172|DRUG|GSK3039294|GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
41341385|NCT02095990|DRUG|Hydroquinone|
41341386|NCT02095990|DRUG|Placebo|
41341387|NCT00421590|DRUG|SMC021|
41341388|NCT04379960|OTHER|Peptides|Peptides will be added to PBMCs in in vitro cell culture.
41341389|NCT04882358|DEVICE|ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
41341390|NCT04882358|DRUG|SGLT2 inhibitor|treatment with a standard dose of SGLT-2 inhibitor
40822486|NCT03253172|DIETARY_SUPPLEMENT|Placebo|Placebo
40822487|NCT06280872|OTHER|Physiological Based Cord Clamping|see Arm Description
40822488|NCT06280872|OTHER|Differed Cord Clamping|see Arm Description
40822489|NCT06606288|DEVICE|Conduction system pacing|Implant with a Medtronic dual-chamber transvenous pacemaker on or after the study data with lead type and placement data indicating conduction system pacing
40822490|NCT06606288|DEVICE|Bi-ventricular pacing|Implant with a Medtronic bi-ventricular pacemaker (CRT-P) on or after the study date
40822491|NCT02163967|DEVICE|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
40822492|NCT06505018|DEVICE|Cureety techcare|"Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: correct (green), compromised (yellow), state to be monitored (orange), or critical state (red). (Note: the color code is not visible to the patient).~The medical team uses the dashboard for daily patient monitoring and manages alerts related to the clinical classification of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device."
40822493|NCT01952444|BIOLOGICAL|ETI-204|A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
40822494|NCT01952444|DRUG|Ciprofloxacin|A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.
40822495|NCT02072460|OTHER|electromyography|
40822496|NCT02072460|OTHER|electroencephalography|
40822497|NCT02072460|OTHER|approaches from psychophysics|
40822498|NCT03490422|PROCEDURE|Pulpotomy|Pulpotomy in mature carious permanent teeth
40822499|NCT05362227|DRUG|Low volume macrogol|Clensia 2 lt
40822500|NCT05362227|DRUG|High volume macrogol|Selg 4 lt
40822501|NCT05134285|OTHER|blood pressure,BMI, blood sample|Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
40822502|NCT01524432|DRUG|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
40822503|NCT01524432|DRUG|Placebo|No drug loaded microcapsules socks
41017628|NCT02383758|DRUG|Bisacodyl suppository|If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
41017629|NCT02383758|DRUG|Senna|If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
41341391|NCT00475371|DRUG|MKC253 Inhalation Powder|Inhalation powder
40822504|NCT05627531|BEHAVIORAL|Narrative Medicine|Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
40822505|NCT03891004|PROCEDURE|Subcuticular Skin Closure|We will only close the subcuticular layer with suture
40822506|NCT03891004|DEVICE|Tissue Adhesives|No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
40822507|NCT04084548|DRUG|Lidocaine and ketamine|Perioperative lidocaine and ketamine infusion (see below for dosages and timings)
40822508|NCT04084548|DRUG|Lidocaine|Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
40822509|NCT04084548|DRUG|Ketamine|Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
40822510|NCT04084548|DRUG|Placebo|Perioperative placebo infusion (normal saline)
40822511|NCT01671501|BEHAVIORAL|Motivational Interviewing|
40822512|NCT01671501|BEHAVIORAL|Email Feedback|
40822513|NCT01671501|OTHER|Usual Care|
41341392|NCT05887089|OTHER|drone transport|additional transport of samples at room temperature by drone (departure from the CHU Amiens-Picardie, 1 hour flight in the CHU Amiens-Picardie air perimeter, return to the CHU Amiens-Picardie)
41341393|NCT00374036|DRUG|ECC|capecitabine
41341394|NCT00374036|DRUG|FOLFIRI|Irinotecan
41341395|NCT01489761|DEVICE|percutaneous coronary intervention|drug eluting stent implantation
41341396|NCT04259346|DRUG|Ixekizumab|Administered SC.
41341397|NCT00781404|DRUG|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
41341398|NCT02568852|PROCEDURE|Combined anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
41341399|NCT02568852|PROCEDURE|General anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
41488311|NCT01763814|PROCEDURE|Femoral nerve block|A visible or palpable cephalad movement of the patella will confirm needle placement.
41488312|NCT01763814|PROCEDURE|Femoral nerve block non stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
41488313|NCT01763814|PROCEDURE|Femoral nerve block stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
41488314|NCT00058721|DRUG|I-123-5-IA85380|
40822514|NCT04092907|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
40822515|NCT04092907|DRUG|placebo|Ophthalmic Solution
40822516|NCT01437098|DEVICE|MDT-2111 CoreValve for TAVI|CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
40822517|NCT02403635|DRUG|Midazolam|
40822518|NCT02403635|DRUG|ASP2151|
40822519|NCT03262025|PROCEDURE|Operated|Patients were either managed conservatively or underwent emergency laparotomy
41017630|NCT03679260|OTHER|Carbohydrate restricted diet|20 grams total carbs/day
41017631|NCT03679260|OTHER|Non-restricted diet|Subject follows normal diet
40822520|NCT00201448|BIOLOGICAL|Hepatitis A Vaccine|Single dose give IM
40822521|NCT00201448|BIOLOGICAL|Towne CMV Vaccine|Single dose given subcutaneously
40822522|NCT01575938|BEHAVIORAL|HIV prevention intervention|"The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention."
40822523|NCT01575938|BEHAVIORAL|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
40822524|NCT06602050|OTHER|HG and NIF|In mechanically ventilated patients, handgrip strength, the Negative Inspiratory Force (NIF) value obtained via the ventilator, and physical function through various tests will be assessed.
41017632|NCT03679260|OTHER|Phone counseling with dietitian|Weekly calls with dietitian
41341400|NCT02382614|DEVICE|Spiration Valve System|
41341401|NCT00540527|DRUG|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
41341402|NCT00540527|DRUG|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
41341403|NCT02332798|DRUG|PF-04958242|Administered as specified in the treatment arm
41341404|NCT02332798|DRUG|Placebo|Administered as specified in the treatment arm
41341405|NCT01681290|DRUG|CBX129801|
41341406|NCT03166657|PROCEDURE|office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure
41341407|NCT00992914|PROCEDURE|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
41341408|NCT00992914|PROCEDURE|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
41341409|NCT01291706|DEVICE|Transcranial Doppler|Negative predictive value of transcranial doppler in patients with mild to moderate traumatic brain injury
41341410|NCT03104829|BEHAVIORAL|Motivational interviewing|
41341411|NCT03104829|DRUG|DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later|
41488315|NCT05304286|BEHAVIORAL|Acceptance and Commitment Therapy|The aim of ACT is to address avoidance behaviors by increasing openness to difficult experiences, such as pain, and to develop an awareness of behavioral options that will aid to facilitate behavior change processes that are in accord with living a values-based life.
41488316|NCT02960061|DRUG|Neoadjuvant chemotherapy|Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
40822525|NCT01789138|BEHAVIORAL|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
40822526|NCT03284333|DEVICE|other|no arm
40822527|NCT04644978|OTHER|anonymous online survey|An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary and it can be terminated at any time without having to give any reasons.
40822528|NCT05709717|PROCEDURE|Regenerative therapy with SVF-PRP to supplement perianal surgery|Regenerative therapy with autologous stromal vascular fraction derived mesenchymal stem cells and platelet-rich plasma to supplement perianal surgery
41341412|NCT03645915|OTHER|Immunohistochemistry|Immunohistochemistry of Glut1 expression was performed in these 36 cases of neuroendocrine tumor.
41341413|NCT03021590|DRUG|Clarithromycin 500Mg Oral Tablet|"Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth"
41341414|NCT03021590|DRUG|Levofloxacin 500Mg Oral Tablet|Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
41341415|NCT03821480|DRUG|Test drug|Fluconazole capsule 50 mg Manufacturer: West Ryde
41341416|NCT03821480|DRUG|Reference drug|Fluconazole capsule 50 mg Manufacturer: Amboise
41341417|NCT00576368|DRUG|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
41341418|NCT01769612|OTHER|No Intervention|
41341419|NCT06247449|DIAGNOSTIC_TEST|Brain imaging|Brain Magnetic resonance (or computed tomography if magnetic resonance is contraindicated)
41341420|NCT06247449|DIAGNOSTIC_TEST|Analysis of circulating tumor DNA|One single blood draw for analysis of circulating tumor DNA
41341421|NCT06247449|BEHAVIORAL|Testing Morbidities Index|Questionnaire regarding the participant's perception of brain imaging.
41341422|NCT01720472|GENETIC|Biomarker studies|
41341423|NCT05944913|DEVICE|Prevena|PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.
41341424|NCT04520308|DRUG|Dupilumab Only Product|SC injections of 300 mg dupilumab every 2 weeks for 24 weeks following a loading dose of 600 mg on day 1
41341425|NCT03887975|PROCEDURE|Monoplane Occlusion|Monoplane and lingualized occlusion effect on force distribution
41341426|NCT03887975|PROCEDURE|Lingualized occlusion|Monoplane and lingualized occlusion effect on force distribution
40822529|NCT05877027|OTHER|Exercise|The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.
40822530|NCT05877027|OTHER|Topical Diclofenac|They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.
40822531|NCT05877027|OTHER|Platelet-Rich-Plasma (PRP)|8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.
40822532|NCT03895086|OTHER|Specific Physical Activity|An individual one hour face-to-face session conducted by adaptated physical activities teachers followed by eight telephone sessions by physical therapists and adaptated physical activities teachers (4 sessions each)
40822533|NCT03895086|BEHAVIORAL|Classic Physical Activity|"One session per week in groups conducted by adaptated physical activities teachers of Siel Bleu association"
41341427|NCT00481689|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
41341428|NCT02252068|BEHAVIORAL|I-CBT|New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
41341429|NCT02252068|BEHAVIORAL|IDC|Individual Drug Counseling manual that has demonstrated efficacy for the treatment of drug dependence.
41341430|NCT05292573|DRUG|Metformin|During the intervention period, metformin is given 500 mg tablet b.i.d. Those who stopped taking metformin will remain in the study not counting as protocol violation.
41341431|NCT00638690|DRUG|Placebo|Four tablets once daily until disease progression
41341432|NCT00638690|DRUG|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
41341433|NCT00638690|DRUG|Prednisone/prednisolone|5 mg twice daily until disease progression
41341434|NCT00272480|DRUG|Zidovudine/lamivudine|
41341435|NCT00272480|DRUG|Placebos|
41341436|NCT03996889|DEVICE|Endovascular treatment of aneurysms of the popliteal artery by GORE VIABAHN® stent in elective surgery|"The intervention can be performed under local anesthesia (LA), regional locus (ALR) or general anesthesia (AG) (data collected) by first approach: percutaneous or conventional.~The data collected are:~* Number of GORE VIABAHN® stent used (length and diameter of each)~* Embolization of collaterals and other related actions~* Operative complications~* Intraoperative fibrinolysis~* Collar cover\> 2 cm~* Lack of overlap in the overlap zone (nb: between 4 and 8 cm above the joint spacing)~* Arteriography in profile, kink"
41341437|NCT05460390|OTHER|Therapeutic drug monitoring (TDM)|Serum trough level of adalimumab and anti-adalimumab antibody will be obtained at time of enrollment and every 3 months until the end of the study. Adalimumab dose optimization goal will be to achieve trough drug level in the range of 5 -8 μg/mL.
41488317|NCT02960061|PROCEDURE|D2 radical resection|Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
41488318|NCT02960061|DRUG|Hyperthermic intraperitoneal perfusion chemotherapy|Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
40822534|NCT05699993|DRUG|Itraconazole|Itraconazole was administered orally
40822535|NCT05699993|DRUG|IBI351|IBI351 was administered orally
40822536|NCT05699993|DRUG|Dextromethorphan|Dextromethorphan was administered orally
40822537|NCT03434431|OTHER|Reverse dieting|
40822538|NCT02183480|DRUG|Linagliptin, low dose|
40822539|NCT02183480|DRUG|Linagliptin, medium dose|
41341438|NCT05116683|DRUG|ATX-101|Patients will be given ATX-101 at 60 mg/m2 IV weekly in continuous 21 day cycles.
41488319|NCT02960061|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
41488320|NCT04121754|DEVICE|MR-001|Participants will walk using the investigational device (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 3 times a week for 5 weeks.
41488321|NCT04121754|OTHER|Active Walking|Participants will walk for thirty (30) minutes at a time, 3 times a week for 5 weeks. No mobile devices, music players or headphones will be allowed. They will wear foot sensors during their active walking sessions to measure gait biomechanics.
40822540|NCT02183480|DRUG|Linagliptin, high dose|
40822541|NCT06127264|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's
40822542|NCT03698786|BEHAVIORAL|Exercise|Participants will be required to complete two, 8-hours trials (exercise \& control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
40822543|NCT01529580|BEHAVIORAL|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|"The intervention has 3 components:~1. One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~2. Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~3. Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training."
41488322|NCT02958982|DRUG|RP3128|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
40822544|NCT04606199|BEHAVIORAL|Mindfulness-based intervention, up to 5 minutes 0-3 times/day|The intervention consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3 minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
40822545|NCT02567682|DRUG|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
40822546|NCT06225895|PROCEDURE|general anesthesia|patients will receive general anesthesia.
40822547|NCT06225895|PROCEDURE|Erector spinae plane block|patients will receive Erector spinae plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
40822548|NCT06225895|PROCEDURE|a rhomboid intercostal nerve block|patients will receive a rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
40822549|NCT06225895|DRUG|Bupivacaine|20 ml of bupivacaine 0.25%
41341439|NCT02094625|DRUG|N-Acetylcysteine|"NAC will be administered intravenously over \~60 minutes starting 4 hours following completion of cisplatin chemotherapy.~Three dose levels have been pre-determined:~Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg~Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.~As of August 2018: Dose escalation completed with MTD not reached. Dose level 3 (450mg/kg) selected for expansion with NAC."
41488323|NCT02958982|DRUG|Placebo|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
40822550|NCT06474091|OTHER|Non-Interventional Study|Non-Interventional Study
40822551|NCT06607016|DRUG|KJ103 for Injection|Subjects will administered KJ103 intravenously on D1 and adjunctively on D8
40822552|NCT06607016|DRUG|Cyclophosphamide|Hence treatment prevents formation of new anti-GBM antibodies.
40822553|NCT06607016|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
40822554|NCT06607016|PROCEDURE|Plasma exchange (PE)|PLEX removes the patient\&#39;s pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
40822555|NCT01284478|DRUG|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
40822556|NCT04495556|DIAGNOSTIC_TEST|MRI|The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
40822557|NCT04709016|BEHAVIORAL|self-questionnaire|self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months
41341440|NCT02606396|PROCEDURE|Cryotherapy|Cryotherapy employs thermal ablation to treat esophageal cancer and BE. Ablation is achieved by intracellular disruption and ischemia that is produced by freeze-thaw cycles using liquid nitrogen or carbon dioxide
41341441|NCT02606396|PROCEDURE|Esophagogastroduodenoscopy (EGD)|EGD is a diagnostic procedure that allows the physician to diagnose and treat problems in the upper gastrointestinal (UGI) tract. The doctor uses a long, flexible, lighted tube called an endoscope.
40822558|NCT05257148|DRUG|Zofenopril 30 mg|Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
40822559|NCT05257148|DRUG|Nebivolol 5 mg|Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
40822560|NCT05257148|DRUG|Zofenopril 30 mg + Nebivolol 5 mg|Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake
40822561|NCT06209593|DIETARY_SUPPLEMENT|Compleat plant protein tube feed|Patients on a tube feed will act as their own control and switch to new tube feed.
40822562|NCT01323270|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
40822563|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
40822564|NCT01323270|BIOLOGICAL|Saline|0.5 mL dose, given at 0, 2 and 6 months.
40822565|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
40822566|NCT05587569|DEVICE|Treatment of metatarsus adductus and hallux valgus with the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure|Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated study duration will be 5 years post index procedure.
40822567|NCT03762616|DIAGNOSTIC_TEST|Micro-ultrasound targeted biopsy|Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system
40822568|NCT03762616|DIAGNOSTIC_TEST|mpMRI targeted biopsy|Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
40822569|NCT05835232|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
40822570|NCT03088631|DRUG|Metformin|will receive metformin (1500 mg/day) starting with the commencement of oral contraceptive pills in the preceding cycle until the day of human chorionic gonadotropin triggering.
40822571|NCT03088631|OTHER|Placebo|will receive corn-flour placebo tablets (three tablets daily).
40822572|NCT05124587|OTHER|No intervention group|No intervention group
40822573|NCT05544175|PROCEDURE|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation: Spinal cord stimulation affects nerve tissues with a defined electrical current. We will use low-voltage electrical stimulation of the posterior roots of the spinal cord in the MRI region of the localized conus medullaris. Electrodes are inserted epidurally from a laminotomy in the lumbosacral region.~Physiotherapy will be based on recommendations for spinal patients."
41017633|NCT03909776|DRUG|Cisplatin|Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
40822574|NCT05518773|OTHER|Observational|Observational
41341442|NCT02606396|PROCEDURE|Endoscopic ultrasound (EUS)|EUS is a procedure that allows a doctor to obtain images and information about the digestive tract and the surrounding tissue and organs, including the lungs. Ultrasound testing uses sound waves to make a picture of internal organs.
41341443|NCT01720693|PROCEDURE|Hypoperfusion of renal artery|The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
41341444|NCT00952952|DRUG|Mesalamine|
41341445|NCT00944580|BIOLOGICAL|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
40822575|NCT05973981|BEHAVIORAL|Package standardization|Conditions vary in terms of amount of cigarette packages that are subject to standardization
40822576|NCT06608329|DRUG|HDM1002|Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.
40822577|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
40822578|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
41341446|NCT01440504|OTHER|culture ex vivo with exposure to different therapeutic agents alone or in combination.|When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.
41341447|NCT00636155|DRUG|cenersen sodium|2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4
41341448|NCT00636155|DRUG|Rituximab|375 mg/m2 on day 2
41341449|NCT00636155|DRUG|Cyclophosphamide|250 mg/m2 on days 2, 3, and 4
41341450|NCT00636155|DRUG|Fludarabine|25 mg/m2 on days 2, 3, and 4
41341451|NCT01339780|RADIATION|BS, SPECT/CT, PET/CT, MRI|Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
41341452|NCT02716662|DIETARY_SUPPLEMENT|Axona|medical powder, supplement food
40822579|NCT00246025|DRUG|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
40822580|NCT00246025|DRUG|placebo|matching placebo capsule, once a day, oral administration
40822581|NCT02754141|BIOLOGICAL|BMS-986179|Specified dose on specified days
40822582|NCT02754141|BIOLOGICAL|Nivolumab|Specified dose on specified days
40822583|NCT02754141|BIOLOGICAL|rHuPH20|Specified dose on specified days
40822584|NCT03172065|DRUG|Normal saline|intravenous flluid
40822585|NCT03172065|DRUG|Dexmedetomidine|anaesthetic adjuvants and pain killer medication.
40822586|NCT02526524|DRUG|Met DR|metformin delayed-release tablets
40822587|NCT02526524|DRUG|Met IR|metformin immediate-release tablets
40822588|NCT02526524|DRUG|Placebo|
40822589|NCT01598753|DRUG|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day"
40822590|NCT01598753|DRUG|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
41017634|NCT05597020|DRUG|Daridorexant|Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
41341453|NCT03554785|BEHAVIORAL|Clinician and Non-clinician staff training|"An optimized training program for non-clinical staff, clinicians and administrators developed by TFI's National LGBT Health Education Center that will include content-specific webinars and Office Hours for specific CHC consultations to optimize the provision of SGM health services at each CHC and to foster the development of in-house expertise to sustain ongoing training and quality improvement in the provision of care for LGBT patients."
41488324|NCT04604743|BEHAVIORAL|Intervention, TBN|The intervention will target adolescents aged 15-17 years who have not received at least one dose of the HPV vaccine. The intervention has yet to be named; this will occur through the conduct of Aim 1. Our intervention, when developed, will improve knowledge of HPV, COVID-19, the HPV vaccine, and the COVID-19 vaccine (Information), reduce stigma and distrust improving motivation (Motivation), leading to improved vaccine confidence and higher vaccination rates and lower vaccine hesitancy (Behavioral Skills). Each one of these three change objectives will be encapsulated in its own Zoom-based session with the near peer interventionist. We anticipate that each modular session will be no longer than seven minutes; thus, the entire three module intervention will be no longer than twenty-one minutes long.
41488325|NCT04132583|DRUG|Deflox®|Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.
40822591|NCT01598753|BEHAVIORAL|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
40822592|NCT01598753|BEHAVIORAL|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
40822593|NCT01485900|DRUG|SAR407899A|"Pharmaceutical form:capsule~Route of administration: oral"
40822594|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
40822595|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
40822596|NCT01258153|DRUG|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
41488326|NCT04132583|DRUG|Cataflam DD®|Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
41017635|NCT05597020|DRUG|Placebo|Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
41017636|NCT03376204|OTHER|No intervention|No intervention
41341454|NCT03972605|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
41341455|NCT00628134|DRUG|calfactant|single inhaled dose by nebulizer
41341456|NCT00628134|DRUG|isotonic saline|single inhaled dose by nebulizer
41488327|NCT03021109|DEVICE|Measurement of inferior vena cava diameters with ultrasound|The patient is placed in the supine position. Curvilinear probe is used. Subxiphoid view is obtained. The IVC is visualized in the longitudinal plane as it enters the right atrium. The diameter of the IVC for calculation of the caval index is measured 2 cm from where it enters the right atrium
41488328|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
41488329|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
41488330|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
41488331|NCT00430495|DRUG|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
40822597|NCT04920630|BEHAVIORAL|Cognitive Behavioral Therapy - Insomnia (CBT-I)|CBT-I will be delivered via 5 weekly virtual group therapy sessions. Session content is manualized and adapted from existing CBT-I protocols to be relevant to a virtual adolescent group and will include: Session 1 - Introduction of group members, group rules, psychoeducation regarding sleep, and instructions on completion of sleep log. Session 2 - Review sleep log, sleep hygiene, relaxation training, and stimulus control. Session 3 - Review sleep log, sleep restriction, and cognitive strategies (positive self-statements, worry management). Session 4 - Review sleep log and sleep restriction, and problem-solving barriers. Session 5 - Maintenance and relapse prevention.
41156999|NCT04472442|PROCEDURE|Intermittent hypoxia|"Acute intermittent treatment (AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. AIH (using 9% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
41341457|NCT05069389|OTHER|Data collection|"Some data will be collected for all patients included :~* specific treatment administered in COVID unit~* dosages of treatment~* inclusion in clinical trials~Evolution of French recommendations and the publication of scientific articles"
41341458|NCT00608881|DRUG|coenzyme Q10|4 - 300 mg CoQ chewable wafers taken orally twice a day
41341459|NCT00608881|OTHER|placebo|an inactive substance
41341460|NCT00127816|PROCEDURE|Permanent prostate implant|
41341461|NCT01595308|DIETARY_SUPPLEMENT|Pomegranate juice|Pomegranate juice
41341462|NCT01124513|PROCEDURE|Induced Erythema|Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm\^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
41341463|NCT02579863|BIOLOGICAL|Pembrolizumab|IV infusion
41488332|NCT01400386|OTHER|Coffee bioavailability trial|Coffee bioavailability trial
41488333|NCT01307839|DRUG|5% lidocaine patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.
41488334|NCT01307839|DRUG|placebo patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
40822598|NCT02476084|OTHER|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
40822599|NCT02476084|OTHER|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
40822600|NCT02476084|OTHER|Biological samples collection|Draw of research blood samples.
41341464|NCT02579863|DRUG|Lenalidomide|oral capsules
41341465|NCT02579863|DRUG|Dexamethasone|oral tablets
41341466|NCT06278155|OTHER|Social relation training with social robot|"The protocol is divided in two sections: basic and advanced social relations.~The basic social relationssection consists of 4 stages:~Stage 1 focuses on spontaneous eye contact between the child and the robot Strage 2 introduces the goal of spontaneously looking at a peer Stage 3 focuses on respecting the turn between children Stage 4 aims to encourage peer cooperation Nao social robot helps children to develop specific social skills.~The advanced social relation section consists of 5 stages:~Stage 1: The goal is to initiate physical interaction with a peer during a game Stage 2 is focused on mand (verbal requests) directed to peers Stage 3: The goal is to respond spontaneously to questions or statements from peers In the Stage 4 the child should to play with peers for at least 5 minutes Stage 5: the goal is to conduct at least 4 verbal exchanges on a given topic with peers At each stage, Nao provides verbal prompts to guide the child toward the appropriate response"
41341467|NCT06278155|OTHER|Traditional social relations training|Traditional social relations training is the same as the experimental one, however in this context the entire protocol is conducted without the aid of social robot NAO.
41488335|NCT04241991|RADIATION|Active laser|Participants will receive laser irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the irradiation on eight points distributed over the muscle belly, using a gallium arsenide aluminum (Ga-As-Al) laser (λ: 808 nm) equipment. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
41488336|NCT04241991|RADIATION|Placebo laser|Participants will receive placebo irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the placebo irradiation on eight points distributed over the muscle belly. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
41488337|NCT03422367|BEHAVIORAL|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
41488338|NCT00673387|DRUG|pramlintide acetate|subcutaneous injection, twice a day
41488339|NCT00673387|DRUG|metreleptin|subcutaneous injection, twice a day
41488340|NCT00673387|DRUG|placebo-P|subcutaneous injection, twice a day
41488341|NCT00673387|DRUG|placebo-M|subcutaneous injection, twice a day
41488342|NCT05530148|BEHAVIORAL|Martial Arts Training Group|Participants in the experimental intervention group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, they will be instructed in the three exercises practiced in the experimental group, known as hubud, chi sau and padwork. Hubud is a turn-based, partnered, coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Chi Sau is a simultaneous contact drill from Chinese Kung Fu, specifically the Wing Chun school. Padwork is an amalgam of punching and kicking combinations used against focus pads or padded sticks to improve coordination, most commonly seen in kickboxing and Muay Thai. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of these exercises by the end of their participation in this intervention.
41488343|NCT05530148|BEHAVIORAL|Flexing, Toning and Balance|Participants in the active comparator group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, participants will start with a 5-minute warmup of basic joint mobilization exercises and dynamic stretching techniques. After this, participants will engage in a mild intensity circuit of exercises using resistance bands, bodyweight exercises and stability/balance exercises for approximately 50 minutes. The last 5 minutes of the session will be left for cooldown exercises and light stretching. Heartrate will be monitored regularly in order to prevent these exercises exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
41488344|NCT05162365|BIOLOGICAL|IBI314|Low/medium/high dose, intravenously, once, on Day 1
41488345|NCT05162365|OTHER|Placebo|Placebo, intravenously, once, on Day 1
41488346|NCT02416414|DEVICE|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
41488347|NCT02416414|DEVICE|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
41017637|NCT02984397|DRUG|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
41488348|NCT00784186|DRUG|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
41488349|NCT00784186|DRUG|misoprostol|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
41017638|NCT02984397|DRUG|Placebo|
41017639|NCT02984397|OTHER|Standard of Care|
41017640|NCT02742103|BIOLOGICAL|CSL_112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
41488350|NCT00784186|DRUG|placebo|placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
41488351|NCT00569530|DRUG|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
41488352|NCT00569530|DRUG|Sham|Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
41017641|NCT02742103|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
41017642|NCT06047197|BIOLOGICAL|RC19D2 cell injection|The functional component of RC19D2 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
41017643|NCT03311074|GENETIC|Strimvelis|Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
41017644|NCT03670589|RADIATION|Radiosurgery gammaknife|This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor
41341468|NCT03588104|DEVICE|POWER2DM system|This system consists of two components: 1) the web-based Shared Decision Making Dashboard, used to set self-management goals together with a health care professional with the use of both short- and long-term predictive computer simulation models, and 2) the POWER2DM Self-Management Support System as a mobile application and webpage, used to support behavioural change in DM self-management. The system is fed with data from an activity tracker, a glucose monitor and manual data entry. Power2DM support will be provided as an adjunct to usual care
41341469|NCT03588104|OTHER|Usual care|Usual care as given to diabetes patients by the patient's diabetes care team.
41341470|NCT00235053|DRUG|fluticasone/salmeterol DISKUS 250/50|
41341471|NCT02948504|PROCEDURE|Coiling or Clipping|All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
41341472|NCT01462591|DIETARY_SUPPLEMENT|L-citrulline|2 weeks of L-citrulline supplementation (100mg/kg of body weight).
41488353|NCT01727466|BEHAVIORAL|Facing Your Fears|FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
41488354|NCT02920918|DRUG|Canagliflozin|
41488355|NCT02920918|DRUG|Sitagliptin|
41341473|NCT05154071|OTHER|Collection of medical data|Collection of adverse events, of mortality, length of hospitalization
41488356|NCT05142566|DEVICE|MANTA Vascular Closure Device|Evaluate the safety of ultrasound guided deployment of MANTA VCD.
41488357|NCT05998941|DRUG|TQB2868 injection|TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.
41488358|NCT05998941|DRUG|Paclitaxel injection|Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.
41488359|NCT05998941|DRUG|Cisplatin injection|Cisplatin injection can inhibit the DNA replication process of cancer cells
41341474|NCT06384300|OTHER|Financial Incentives|In the financial incentive group, participants will receive reimbursement for transportation, accommodation, and food costs, along with RMB 200 (about 30 US dollar) to compensate for potential income loss due to endoscopy, provided they undergo the endoscopy.
40822601|NCT02476084|OTHER|Questionnaires|Administration of validated patients' questionnaires.
41017645|NCT03670589|PROCEDURE|Microsurgery resection|Classical surgical approach with oto-neurosurgery procedures
41017646|NCT00807092|DRUG|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
41017647|NCT00807092|DRUG|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
41341475|NCT06384300|OTHER|Motivational Intervention|For the motivational intervention group, researchers will provide detailed information about the social norms surrounding endoscopy screening, including the prevalence of screening participation, the potential risks of gastric cancer, and the health benefits of screening.
41341476|NCT06384300|OTHER|Mixed Intervention|Participants in the mixed intervention group will receive both financial incentives and motivational intervention.
41341477|NCT00054860|BIOLOGICAL|EP HIV-1090|
41341478|NCT00633360|DRUG|Drospirenone and ethinyl estradiol|Once daily by mouth
41017648|NCT00807092|DRUG|metformin|Metformin dose must remain the same as that used prior to the trial.
41341479|NCT00633360|DRUG|Placebo|Once daily by mouth
41341480|NCT00510770|DEVICE|CPAP application|
41488360|NCT05998941|DRUG|Carboplatin injection|Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.
41488361|NCT05998941|DRUG|Bevacizumab injection|Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).
41488362|NCT01340105|PROCEDURE|Microwave ablation|Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
40822602|NCT04851210|OTHER|No intervention|No intervention
40822603|NCT04312360|DRUG|therapeutic endoscopy with metronidazole and fosfomycin disodium|therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
40822604|NCT02295215|OTHER|Exercise|Exercise Training for 4 months
40822605|NCT05264441|DEVICE|In-Check DIAL G16|Patients will inspire into an In-Check DIAL G16 device.
40822606|NCT02337530|DRUG|Selumetinib|
40822607|NCT02337530|DRUG|Pemetrexed|
40822608|NCT02337530|DRUG|Cisplatin|
40822609|NCT02337530|DRUG|Carboplatin|
40822610|NCT01088165|DRUG|Adalimumab treatment arm|Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals
40822611|NCT01088165|DRUG|Fumaric acid esters treatment group|"First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).~Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period."
40822612|NCT01088165|OTHER|Narrow band UVB radiation|"No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.~Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation"
40822613|NCT06197191|DEVICE|Fukuda Denshi Cardimax ECG device model FCP-7101|ecg and holter will be done one day before and one day after then after 1,6,12 month after transcatheter closure of ASD
40822614|NCT04853693|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
40822615|NCT04853693|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
40822616|NCT02125903|DRUG|Ropivacaine|Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
40822617|NCT03402971|DIAGNOSTIC_TEST|echocardiography|echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
40822618|NCT00882596|DEVICE|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
40822619|NCT04140695|DRUG|Tradipitant|BID
40822620|NCT04140695|DRUG|Placebo|BID
40822621|NCT01349322|RADIATION|Standard fractionation whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 25 fractions of 2.0 Gy for a total dose of 50.0 Gy or 16 fractions of 2.67 Gy for a total dose of 42.7 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
40822622|NCT01349322|RADIATION|Hypofractionated whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 15 fractions of 2.67 Gy for a total dose of 40.0 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
40822623|NCT01349322|RADIATION|Concurrent boost|15 fractions of 3.2 Gy for a total dose of 48 Gy to the lumpectomy cavity. Given concurrently with treatment to the entire breast. May be given by either electron beam or photon beams using either 3D-CRT or IMRT.
40822624|NCT01349322|RADIATION|Sequential boost|6 fractions of 2.0 Gy per fraction for a total dose of 12 Gy or 7 fractions of 2.0 Gy for a total dose of 14 Gy to the lumpectomy cavity. May be given by either electron beam or photon beams using either 3D-CRT or IMRT. Begins without a treatment break after completion of the treatment to the entire breast.
40822625|NCT05056220|DRUG|Human albumin|20% Human Albumin infusions (every 10th day +/- 4 days) with dosing according to the participants bodyweight (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
40822626|NCT05056220|DRUG|sodium chloride|0.9% NaCl infusions (every 10th day +/- 4 days) with dosing according to the corresponding volume used of 20% Human Albumin (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
41341481|NCT06076239|OTHER|ESWT Group|EG were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment. 1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks at 10 Hz, medium energy level (\<0.28 mJ/mm2).
40822627|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
41488363|NCT01340105|PROCEDURE|Radiofrequency ablation|Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
41488364|NCT00432302|DRUG|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg \[14C\]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
41488365|NCT02987023|PROCEDURE|uterus transplantation|Uterus transplantation from live donor
41488366|NCT05038579|PROCEDURE|Musiquence|The participants performed a customized cognitive stimulation program, that was implemented in an augmented reality format, using Musiquence.
41488367|NCT04635293|PROCEDURE|preoperative infusion of levosimendan|the study group will consist of patients who have received a continuous infusion of levosimendan 0.1 μg/kg/min for 24 hours before cardiac surgery
41488368|NCT04635293|PROCEDURE|no preoperative infusion of levosimendan|the control group will consist of patients who proceeded to the cardiac operation without any infusion for 24 hours preoperatively
40822628|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
41341482|NCT06076239|OTHER|Control Group|Both EG and CG were given conventional treatment.Conventional treatment is consist of Ultrasound therapy (Gymna Pulson200) (1 mHz. treatment dose average 1.5 w/cm², intermittent with a small head (50%), 5 minutes (45)) around the glenohumeral joint of the cases in both groups participating in the study; TENS applied at an intensity that the patient can tolerate, covering the painful area (modified biphasic asymmetric pulse, and it was set to a pulse width of 100 μs and a frequency of 100 Hz, 20 min,) (Hometech ht 66b); hotpack and exercises (posterior capsule stretching, wand exercises, mobilization approximately 60 minutes of conventional treatment consisting of exercises and shoulder isometric exercises) was applied once a day, 5 times a week in both groups.
41341483|NCT04928313|DRUG|Glatiramer Acetate|Cinnomer® was injected subcutaneously 3 times per week at least 48 hours apart.
41341484|NCT04662645|OTHER|Palliative Therapy|Undergo embedded palliative care
41341485|NCT04662645|OTHER|Questionnaire Administration|Ancillary studies
41341486|NCT01154322|DEVICE|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
41341487|NCT05338658|DRUG|Peptide Alarm Therapy (PAT)|PAT is given on Day 1 by IT injection after the 1st anti PD-1/PD-L1 infusion and again 36-48 hours later on Day 3.
40822629|NCT02362516|DRUG|BI 425809|
40822630|NCT05076916|BEHAVIORAL|The effectiveness of the web-based education programme among cancer patients|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
40822631|NCT02383745|OTHER|Acute EEG with fast EEG electrode|
40822632|NCT02502669|DRUG|Finasteride 23.5 mg tablets|
41341488|NCT06382740|PROCEDURE|Liver transplantation|Liver transplantation
41488369|NCT04350320|DRUG|Colchicine Tablets|standard therapy for COVID-19 according to the stablished hospital protocols.
41488370|NCT04350320|DRUG|Standard therapy for COVID-19 according to the stablished hospital protocols.|standard therapy for COVID-19 according to the stablished hospital protocols.
40822633|NCT02502669|DRUG|Finasteride 33.5 mg tablets|
40822634|NCT02502669|DRUG|Placebo tablets|
41017649|NCT05345483|DEVICE|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter
41017650|NCT01085175|DRUG|LMI 1195|Single bolus intravenous injection of LMI 1195
41017651|NCT06325462|DEVICE|sensors of regional cerebral oxygen saturation (O3 regional oximeter, Masimo Corp, Irvine, CA) FDA Reg No. 3011353843|O3 regional oximetry monitors the regional hemoglobin oxygen saturation of the blood (rSO2) in adult patients, placed on the forehead by noninvasive and continuous combining arterial and venous oxygen saturation signals from near-infrared spectroscopy (NIRS)
41017652|NCT00099775|DRUG|Caspofungin|
41488371|NCT06187493|DRUG|lisinopril, enalapril|"1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
40822635|NCT00322023|DRUG|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
40822636|NCT00322023|DRUG|D-serine|
40822637|NCT00322023|DRUG|D-serine|
40822638|NCT00322023|DRUG|D-serine|
41017653|NCT04452344|DRUG|opioid-containing analgesic|hydrocodone/ acetaminophen combination product
41017654|NCT04452344|DRUG|two over-the-counter analgesics|combination of over-the-counter analgesics (ibuprofen/acetaminophen)
41017655|NCT00298038|DRUG|Rifaximin|Oral
41017656|NCT00298038|DRUG|Placebo|Oral
41017657|NCT04332172|OTHER|General information|General information related to pregnancy is provided electronically.
41017658|NCT04332172|BEHAVIORAL|Baseline brief intervention|Interactive brief motivational intervention is delivered electronically. Provides an introduction, describing the purpose and duration, emphasizing the non-judgmental nature of the brief intervention (BI). Uses a high-quality video featuring gain-framed messaging, quit recommendation, and testimonial from a race-matched woman; tailored on race-ethnicity, efficacy, binge frequency, and level of concern regarding her own alcohol use. The e-BI poses a question regarding the participant's willingness to avoid alcohol throughout her pregnancy. Responses to this question will sort participants into one of three major branches, each using motivational principles to promote alcohol abstinence during pregnancy.
41341489|NCT02288442|OTHER|exercise|Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
40822639|NCT02128815|OTHER|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
40822640|NCT04123912|BEHAVIORAL|Kinesio Taping - Functional Movement Power Training|Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.
40822641|NCT04123912|BEHAVIORAL|Jogging with placebo taping|Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
40822642|NCT06191978|DRUG|ASTX727|Given by PO
40822643|NCT06191978|DRUG|Venetoclax|Given by PO
41017659|NCT04332172|BEHAVIORAL|Remote online booster sessions|Two \< 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.
41017660|NCT04332172|BEHAVIORAL|SMS|Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.
41017661|NCT00464724|PROCEDURE|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
41017662|NCT03826329|OTHER|observational study|this is an observational study, there is no intervention in this study
41017663|NCT02312310|DIETARY_SUPPLEMENT|Cocoa Flavanol|12 weeks administration of cocoa flavanol
40822644|NCT06069141|DRUG|Benzathine Penicillin G|Benzathine Penicillin G (2.4 MU intramuscularly once)
40822645|NCT06069141|DRUG|Doxycycline Capsule|doxycycline (100 mg orally twice daily for 7 days)
41017664|NCT05750693|GENETIC|PIK3CA analysis|"PIK3CA will be investigated together with HER2 in pre-NAD tissue samples, in order to evaluate the correlation with response to NAD chemotherapy, with a 16-gene MYRIAPOD kit. This evaluation will be performed on all 58 patients in the study for group (responders and not responders).~Moreover 10 patient samples (5 responders and 5 non-responders) will be subjected to gene expression profile analysis. Specifically, a transcriptomic analysis will be performed on total RNA from one inch of cells (10-50 cells isolated by LCM from FFPE biopsy, RNA seq) which will allow to have the transcriptional profile for each patient of protein-coding transcripts (coding RNAs) and long non-coding RNAs.~In addition, an NGS analysis by TSO500 will be performed in parallel, on the slide following the previous one, to have the genome sequence (523 genes) on the same 10-50 cells isolated by LCM from FFPE biopsy for the identification of any mutations."
41266329|NCT04173741|OTHER|USG measurement|IVC was visualized in the subxiphoid long axis by using convex probe (5-1 MHz). Diameters of IVC was measured 2 cm caudally to the junction of hepatic vein in M-mode. IJV diameter was measured in the short axis by using linear probe (12-5 MHz) and M-mode. IJV visualized in the junction of cricothyroid membrane level and midclavicular line. Maximum and minimum diameter values were measured in the M mode. Distensibility (maximum diameter - minimum diameter / minimum diameter) and collapsibility (maximum diameter - minimum diameter / maximum diameter) indices were calculated after USG measurements were done.
41488372|NCT06187493|DRUG|dapagliflozin, empagliflozin|"1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
41488373|NCT04191798|BEHAVIORAL|Telerehabilitation using the KinexConnect system for rehabilitation after TKA.|KinexConnect subjects are asked to Perform CPM therapy for 4 weeks. Perform a KCK home exercise program (HEP) for 6 weeks.
41488374|NCT04191798|BEHAVIORAL|Traditional outpatient PT for rehabilitation after TKA.|Control subjects are asked to undergo standard outpatient physical therapy (PT) with a licensed physical therapist plus supplemental home exercises as directed. Nominally patients are expected to have 3 PT sessions per week for 4 weeks.
41488375|NCT03242460|DRUG|Pomalidomide 4 MG|Pomalidomide 4mg Days 1-21
41488376|NCT03242460|DRUG|Dexamethasone 20mg|Dexamethasone 20mg Days 1, 8, 15, 22
41266330|NCT05651971|BEHAVIORAL|measurement group|Measurement of the distance between the origin of LCA (left colonic artery，LCA) and IMA (inferior mesenteric artery，IMA) root and the distance between IMA and IMV (inferior mesenteric vein，IMV) at the origin of LCA in rectal cancer patients
41266331|NCT04568850|DIAGNOSTIC_TEST|Plasma IgG levels|Plasma IgG levels of subjects who tested reactive for IgG SARS CoV-2 antibodies will be monitored every month for 4 months for IgG levels
41266332|NCT02749214|OTHER|Blood Sample Collection|Participants will have two to three tablespoons (30 cc) of peripheral blood drawn to test for inflammatory markers.
41266333|NCT02749214|OTHER|Breath Sample Collection|Participants will be asked to breathe into the Breath Sampler containing a rapid passive volatile organic compounds (VOC) sampling device. A disposable mouthpiece is placed over a portion of the sampler where the participant placed his/her mouth. The mouthpiece will be disposed of after each use and a new one will be used for each participant. Prior to sample collection, the participant will be asked to rinse his/her mouth with water. Then the participant will breathe deeply into the sampler five times with breaths being five minutes apart to collect the alveolar breath.
41266334|NCT01255774|DRUG|ranibizumab|An open-label, study of intravitreally administered ranibizumab
41266335|NCT02130414|DRUG|Sandimmun® IV|2 mg/kg IV
41266336|NCT02130414|DRUG|CyCol® capsules|37.5 mg CyCol® capsules
41266337|NCT06353776|PROCEDURE|conjunctival biopsy after micropulse transscleral laser therapy|"During MicroPulse TLT, all patients received periocular anesthesia, with an injection of 5 to 10 ml of Lidocaine (Xylocaine 5mg/ml ®) to achieve complete anesthesia.~The investigators employed the 810 nm Cyclo G6® Laser in its MicroPulse® mode (Iridex Corporation, Mountain View, CA, USA) and delivered laser energy to the eye using the second-generation MicroPulse P3® probe (Iridex Corporation, Mountain View, CA, USA). The laser was calibrated to generate a power output of 2500 mW, and a MicroPulse duty cycle of 31.3%. The curved end of the probe's footplate (bunny ears) was positioned 0.5 to 1 mm away from the corneoscleral limbus, maintaining a perpendicular orientation to the eyeball.~Following the laser therapy, an immediate conjunctival biopsy measuring 2 \* 2 mm and avoiding the laser-treated region was performed."
41266338|NCT05831982|OTHER|Person-centered strength training and nutrition intervention|Focus on high intensity strength training and nutrition intervention with focus on energy and protein intake. Focus on social relations
41266339|NCT05831982|OTHER|Standard training|Training as usual when discharged with a rehabilitation plan.
41266340|NCT05728788|DRUG|Antitumor drugs|Anthracyclines, immune checkpoint inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors
41266341|NCT05468970|OTHER|NO Intervention|NO Intervention
41266342|NCT04426305|OTHER|community health worker support|usual care by professional primary care providers + emotional support by trained community health worker
41266343|NCT04426305|OTHER|care as usual|care as usual is provided by professional primary care provider
41266344|NCT03448640|DRUG|Drug used in the examination of premature infants.|to investigate side effects of eye drops used
41266345|NCT02550158|PROCEDURE|Educational program EDU-MICI|
41488377|NCT03242460|DRUG|Cyclophosphamide 400mg|Cyclophosphamide 400mg Days 1, 8, 15
41488378|NCT03041649|OTHER|GT button change - Mic-Key|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
40822646|NCT01388439|DRUG|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants \< 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants \> 38 weeks PMA. Dosing in infants \< 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants \> 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants \> 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
41266346|NCT05449704|DRUG|DA-5218|single dose administration (DA-5218 one tablet once a day)
41341490|NCT05823649|DIETARY_SUPPLEMENT|Early feeding/intervention group|The patients will be given orally 5 to 10 ml of warm water as first feeding. If there will be no problem of swallowing and other clinical complication, they will be further provided 20 ml of water after 10 minutes. If further patients do not suffer from nausea, vomiting and other discomfort, 100 ml clear fluid or less than it will be provided as based on the protocol followed by the study. We will use oral rehydration solution (ORS) as clear fluid.
41266347|NCT05449704|DRUG|DA-5218-R1 + DA-5218-R2 + DA-5218-R3|single dose administration (DA-5218-R1 one tablet once a day + DA-5218-R2 one tablet once a day + DA-5218-R3 one tablet once a day)
41341491|NCT01929018|BEHAVIORAL|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
41341492|NCT01929018|BEHAVIORAL|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
41341493|NCT01929018|BEHAVIORAL|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
41341494|NCT04068038|OTHER|Ventilation protocol|An evidence based ventilation protocol will be implemented at participating sites. This will include limits on peak inspiratory pressure (28cmH2O), driving pressure (16cmH2O), tidal volume (mild 8ml/kg, mod/severe 6ml/kg), positive end expiratory pressure to fraction of inspired oxygen table, permissive hypercarbia (mild allow pH 7.30, mod/severe allow pH 7.20) and permissive hypoxia (mild SpO2 92-97%, mod/severe SpO2 88-92%).
41341495|NCT01113788|DEVICE|tricuspid isthmus imaging with Cartosound|tricuspid isthmus imaging with Cartosound
41341496|NCT02481791|DRUG|Remifentanil and/or propofol|Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
41266348|NCT03185546|OTHER|NNC Spectrum Cigarette|Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.
41266349|NCT03185546|OTHER|VLNC Spectrum Cigarette|Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks
41266350|NCT03185546|OTHER|Moderate nicotine level e-liquid|Participants are provided with moderate nicotine level e-liquid for 13 weeks
41266351|NCT03185546|OTHER|Low nicotine level e-liquid|Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks
41488379|NCT03041649|OTHER|GT button change - Mini One|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
41488380|NCT00115713|BEHAVIORAL|Aerobic Exercise Training|
41488381|NCT00115713|BEHAVIORAL|Resistance Exercise Training|
41488382|NCT05569603|BEHAVIORAL|Chronobiology-guided lifestyle interventions|1) timed bright light exposure using blue-enriched white light glasses, 2) recommendations for meal timing, and 3) sleep hygiene education
41488383|NCT03162536|DRUG|Nemtabrutinib|Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
41488384|NCT01403064|BIOLOGICAL|ALD518|IV
41488385|NCT01403064|DRUG|0.9% saline|IV Infusion
41488386|NCT03317665|DEVICE|Mesh for hernia repair|Permacol, Parietex, Progrip, Strattice Perforated, and Surgimend.
41488387|NCT02770885|DRUG|Dulaglutide|Treatment with dulaglutide for 3 weeks.
41488388|NCT02770885|DRUG|Placebo|Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
41488389|NCT00231218|DRUG|dietary supplement--echinacea, propolis, and vitamin c|
41488390|NCT05129436|DRUG|Vaxigrip Tetra 2020/2021|vaccine against seasonal influenza
41488391|NCT04639713|DEVICE|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
41341497|NCT02481791|DRUG|Remifentanil and/or propofol|Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
40822647|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval recess group,we injected 20 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into into the Rotator cuff interval/anterior capsule.
41341498|NCT02481791|DRUG|propofol|Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
41341499|NCT06078696|DRUG|Siplizumab|Premedication with diphenhydramine 50 mg PO is to be given 1 hour prior to siplizumab infusion. Premedication with hydrocortisone succinate 100 mg IV infused over 30 minutes and acetaminophen 650 mg PO are to be given at least 30 minutes prior to siplizumab infusion. Siplizumab 4.8 mg/kg total is given on Day -14 and 0.6mg/kg is given on days -6, -1, 0, and +1. It will be given as an IV infusion over 1 hour.
41341500|NCT06078696|PROCEDURE|Exchange Transfusion|Patient will undergo a red blood cell exchange transfusion to achieve a Hemoglobin S (HgbS) level \< 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).
41488392|NCT04565613|DIETARY_SUPPLEMENT|Enteral protein supplementation|"The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.~Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue."
41341501|NCT06078696|PROCEDURE|Total Body Irradiation|Radiation dose is 2Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
41341502|NCT06078696|PROCEDURE|Stem Cell Infusion|Standard institutional procedures should be followed for the processing and administration of stem cell products for infusion. The infused graft under no circumstances is to be irradiated. No in-line leukocyte filter should be used and no medications or fluids should be given piggyback through the catheter lumen used for infusion of stem cells. Vital signs should be monitored before beginning the infusion and periodically during administration and in accordance with institutional guidelines. Pre-medications prior to the graft infusion will be according to the institutions standard practice. Benadryl, epinephrine, hydrocortisone, and oxygen be available at the bedside, as well as an emergency medical code cart available in the vicinity of the patient, for emergency use in case of an infusion reaction.
41488393|NCT01742520|DRUG|multiple doses of sucrose|unlimited number of doses par day- current status in our NICU
40822648|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval and posterior glenohumeral recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval and posterior glenohumeral recess group,we injected 10 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the Rotator cuff interval/anterior capsule and 10 mL mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the posterior glenohumeral.
40822649|NCT06009237|DRUG|ABBV-903|Tablet; oral
40822650|NCT06009237|DRUG|Placebo for ABBV-903|Tablet; oral
40822651|NCT00849615|DRUG|Docetaxel|50mg/m2 qd15
40822652|NCT00849615|DRUG|5-Fluorouracil|2600mg/m2 qd15
40822653|NCT00849615|DRUG|Oxaliplatin|85mg/m2 qd15
40822654|NCT00849615|DRUG|folinic acid|200mg/m2 qd15
40822655|NCT03734653|DRUG|Transdermal Testosterone|Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
40822656|NCT03734653|DRUG|Standard of Care, Enzalutamide|Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.
40822657|NCT04830904|DEVICE|personalized Lycra garments|the subjects wear lycra garments during the assessment time and for some days after the assessment
40822658|NCT03334851|DRUG|PF-06835375|Intravenous (IV) or subcutaneous (SC) administration. Subjects will receive one or two doses. Doses will be ascending and determined by emerging data.
40822659|NCT03334851|DRUG|Placebo|Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
40822660|NCT00593853|DRUG|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
40822661|NCT00593853|DRUG|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
41488394|NCT01742520|DRUG|Formula or breast milk|1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
41488395|NCT02068521|DRUG|somavaratan|Subcutaneous injection
40822662|NCT03500172|BEHAVIORAL|DTP|Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
40822663|NCT03500172|BEHAVIORAL|ICM|Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
40822664|NCT00043017|PROCEDURE|MRI/MRS|Serial MRI studies evaluated for prognostic properties related to therapeutic response.
40822665|NCT00043017|RADIATION|gadopentetate dimeglumine|Imaging agent used for contrast enhancement in each of the MRIs.
40822666|NCT06026371|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
40822667|NCT06026371|DRUG|Placebo|Given PO
41341503|NCT06078696|DRUG|Cyclophosphamide 50mg|Cyclophosphamide will be given on days +3 and +4 at a dose of 50 mg/kg. Hydration prior to cyclophosphamide should be given according to standard institutional practice. Day +3 dose should occur between 60 and 72 hours after graft infusion and day +4 post-transplant should occur approximately 24 hours after prior dose. Cyclophosphamide will be given as an IV infusion over 1-2 hours depending on volume or as per institutional standard practice. Cyclophosphamide will be dosed according to adjusted ideal body weight (AIBW) in patients weighing \> 125% ideal body weight (IBW).
41341504|NCT06078696|DRUG|Mesna|Mesna is to be given starting 1 hour prior to cyclophosphamide at the same dose (50 mg/kg) as a continuous infusion over 24 hours.
40822668|NCT03018418|RADIATION|Proton therapy|Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions
41488396|NCT02045992|DIETARY_SUPPLEMENT|caffeine|Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
41488397|NCT00724490|PROCEDURE|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
41488398|NCT04275206|OTHER|Harkány medicinal water|The aim is to prove the effectiveness of Harkány medicinal water on patients suffering from psoriasis and rheumatoid arthritis. The control group is treated with tap water.
40822669|NCT03018418|DRUG|Chemotherapy|5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
40822670|NCT00297895|PROCEDURE|Completion Lymphadenectomy|complete lymph node dissection of lymph node basin with positive node
40822671|NCT00297895|PROCEDURE|Monitoring with nodal ultrasound|serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
41341505|NCT06078696|DRUG|Sirolimus Oral Tablet|Sirolimus will be given orally with a loading dose of 12 mg, then followed by 4 mg orally daily. Dosage will be adjusted to a therapeutic target of 10 - 15ng/ml in first 3 months post transplant and 3-10 after 3 months. Sirolimus should be started on day +5. It will be continued until at least day 180. Sirolimus can be tapered or continued according to the treating physician discretion and the presence of absence of GVHD and/or degree of donor chimerism. Sirolimus should be continued if donor chimerism is less than 50% to prevent graft loss.
41488399|NCT04275206|OTHER|Tap water (placebo control)|The control group is treated with tap water.
41488400|NCT05620602|OTHER|Remedial treatment within 3 months|"The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
41488401|NCT05620602|OTHER|Remedial treatment within 3 to 6 months|"The interval between the time of this treatment and the last day of the last therapy is 3-6 months.~Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
41488402|NCT05620602|OTHER|Remedial treatment within 6 to 12 months|"The interval between the time of this treatment and the last day of the last therapy is 6-12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
41488403|NCT05620602|OTHER|Remedial treatment after 12 months|"The interval between the time of this treatment and the last day of the last therapy is more than 12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
40822672|NCT01076062|PROCEDURE|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
40822673|NCT00177567|DRUG|lithium carbonate|
40822674|NCT00177567|DRUG|Depakote-ER|
41488404|NCT03275636|BIOLOGICAL|Peripheral blood stem cells|Hematopoietic stem cell transplantation with PBSC
41488405|NCT01461564|PROCEDURE|Colonoscopy|Screening colonoscopy
41488406|NCT04751292|OTHER|Exposure to high altitude|permanence at high (\>2500 m) altitude; permanence is defined as being born and living at high altitude with the total time spent at lower altitudes not exceeding 2 years in the past 10 years
41488407|NCT00003521|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41488408|NCT06088849|PROCEDURE|Venipuncture|The lactating mother will be asked to collect milk samples and donate 2 blood samples, which is not a part of their normal follow-up/treatment. We will also aks the parents if we can collect a blood sample fo the infant (0-6 months).
40822675|NCT00177567|DRUG|risperidone|
41341506|NCT06078696|DRUG|Rituximab or Biosimilar|Rituximab (375 mg/m2/dose) will be administered on Days -14 and -6. In those subjects receiving ongoing renal replacement therapy, rituximab should be administered several hours after hemodialysis. The first rituximab solution for infusion should be administered intravenously at an initial rate of 50 milligrams/hour (mg/hr). The rate may be escalated by 50mg/hr every 30 minutes to a maximum of 400 mg/hr. Subsequent infusions may be started at 100 milligrams/hour (mg/hr) and titrated by 100 mg/hr every 30 minutes to a maximum of 400mg/hr if the subject tolerated the first infusion.
41341507|NCT05345938|DRUG|Mitoxantrone Hydrochloride Liposome|Intravenous injection (IV), on day 1 of each 28-day cycle (q4w)
41341508|NCT06262204|PROCEDURE|Hallux Valgus Treatment with Shark Screw®|This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
41341509|NCT06262204|PROCEDURE|Hallux Valgus Treatment with metal screw|This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
41488409|NCT03306953|PROCEDURE|Rectus muscle approximation|The surgeon will take sutures to approximate rectus muscles at the end of cesarean delivery.
41488410|NCT01501136|OTHER|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
41488411|NCT01501136|OTHER|VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
41488412|NCT01501136|OTHER|gemcitabine,pegaspargase,cisplatin,dexamethasone|Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
41488413|NCT01501136|OTHER|cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
41488414|NCT01501136|RADIATION|Radiotherapy|Suitable type intensity-modulated radiation therapy(IMRT)50Gy
40822676|NCT00177567|DRUG|olanzapine|
40822677|NCT00177567|DRUG|paroxetine|
40822678|NCT00177567|DRUG|bupropion|
40822679|NCT00177567|DRUG|lamotrigine|
40822680|NCT00177567|DRUG|venlafaxine|
41341510|NCT02980991|DRUG|Pemetrexed|Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
41341511|NCT02980991|DRUG|Cisplatin|Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
41341512|NCT04831593|OTHER|Group El|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
40822681|NCT00177567|DRUG|tranylcypromine|
41341513|NCT04831593|OTHER|Group Em|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
41488415|NCT01884922|DRUG|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
41488416|NCT01884922|DRUG|Vinblastine|"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
40822682|NCT00177567|DRUG|mirtazapine|
40822683|NCT06487507|BEHAVIORAL|Low fat diet|Prior to surgery, participants complete diet records for 7 days. After, they will receive one shipment containing prepared meals (refrigerated, frozen and fresh) low fat Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track their food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
40822684|NCT06487507|BEHAVIORAL|Lower carbohydrate diet|Prior to surgery, participants complete diet records for 7 days. After, they will receive one shipment containing prepared meals (refrigerated, frozen and fresh) lower carbohydrate Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track their food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
40822685|NCT03752190|DRUG|Cosyntropin|intramuscular and intravenous administration
40822686|NCT01780714|OTHER|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
40822687|NCT01780714|OTHER|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
40822688|NCT04350671|DRUG|Interferon Beta-1A|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Interferon-β 1a in COVID-19 patients.
40822689|NCT04350671|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
41341514|NCT05080504|DEVICE|Eko DUO|"Each subject will take an Eko DUO device home and take DUO recordings immediately before or after their prescribed CardioMEMS measurements.~The DUO recordings will be taken at 3 predefined chest locations: the right upper sternal border, left upper sternal border, and right anterolateral. Each DUO recording lasts about 15 seconds. The total time per recording session is expected to be 2-4 minutes, which allows for time between recordings and any potential repeat recordings. Study participation will last for 90 days."
41341515|NCT03027869|DEVICE|transcranial direct current stimulation|15 minute anodal stimulation 1.5mA
41341516|NCT04113278|GENETIC|FGL2 immunohisyochemistry|Correlation between FLG2 expression and progression free survival and overall surviv
41341517|NCT04055025|OTHER|Placebo|Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.
41341518|NCT04055025|OTHER|Ghrelin|Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.
41341519|NCT03498976|PROCEDURE|pulsed radiofrequency|Echoguided technic
41488417|NCT00858962|DRUG|Raltegravir|400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
41488418|NCT05120206|PROCEDURE|Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA;and American Eagle Instruments,Missoula, MT,USA).|Non-surgical and surgical periodontal therapy in cigarette smokers and non-smokers
41488419|NCT03438214|DRUG|Vancomycin Continuous infusion|Will be administered a loading dose of 25mg/kg followed of 2g infused in 24h. Serum levels will be measured after the end of the loading dose (peak) and after 24 hours (steady state). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and area under curve (AUC) /MIC≥400mg.h/L
41488420|NCT03438214|DRUG|Vancomycin Intermittent infusion|Will be administered a loading dose of 25mg/kg followed of 1g every 12h. Serum levels will be measured after the end of the loading dose (peak) and one hour before the next dose (trough). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and AUC/MIC≥400mg.h/L.
41017665|NCT02266381|PROCEDURE|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
41488421|NCT01855074|DRUG|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
41488422|NCT02963064|BIOLOGICAL|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
41017666|NCT02266381|PROCEDURE|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
41341520|NCT03938636|DRUG|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
41341521|NCT04716049|OTHER|Powerade©, CHP, CJ, FR, CWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL during the game~Carbohydrate and protein (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the game.~Tart cherry concentrate (CJ): players will drink 30 mL of CJ within 30 minutes after the end of the game.~Foam roller (FR): players will follow FR protocol using a polyvinylchloride pipe roller. They will begin with the FR at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth at a cadence of 1 second superior and 1 second inferior for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.~Cold Water Immersion (CWI): will be the last strategy used. Players will immerse their lower body to the level of hips for 10 minutes in cold water (13-14°C)."
41341522|NCT04716049|OTHER|Powerade©, CHP, STR, ICWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL of Powerade© during the game~Carbohydrate and protein intake (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the competition.~Stretching (STR): players will perform 10-min of static stretching, involving 2 unilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.~Intermittent Cold-Water Immersion (ICWI): will be the last strategy used. It will consist of five 2 min intermittent immersions of the lower limb (up to the iliac crest) in a cold-water bath (13-14ºC), separated by 2 min rest in ambient air. Ice will be added to the bath at regular intervals to maintain water temperature at 13-14ºC. Players will be instructed to stand in the bath, with as little movement as possible."
41341523|NCT01518140|DEVICE|Oxygen Delivery Devices|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
41488423|NCT01327144|DRUG|Famciclovir|Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
41488424|NCT01327144|DRUG|Aciclovir|Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
41488425|NCT03277235|BEHAVIORAL|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
41488426|NCT02039466|PROCEDURE|volume controlled ventilation|
41488427|NCT02039466|PROCEDURE|pressure controlled ventilation|
41488428|NCT04948580|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
41017667|NCT02266381|PROCEDURE|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
41017668|NCT01679899|DRUG|Vildagliptin|Vildagliptin 50mg bid orally for 12 months
41017669|NCT01679899|DRUG|Gliclazide MR|Gliclazide MR 60 or 120mg orally for 12 months
41017670|NCT04765059|DRUG|Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
41017671|NCT04765059|DRUG|Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
41488429|NCT02245061|OTHER|paired pulses cortical electrical stimulation|
41488430|NCT01624441|DRUG|Dinaciclib|Given IV
41488431|NCT01624441|DRUG|Epirubicin Hydrochloride|Given IV
41488432|NCT01624441|OTHER|Laboratory Biomarker Analysis|Correlative studies
41488433|NCT06179927|OTHER|QT voice|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes made via tablet. In the scenario, the depictions will be presented in color. They, guided by QT Robot's narrator voice, will have to choose from two or three alternatives the one that represents the appropriate mental state by selecting it on the tablet. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
41488434|NCT06179927|OTHER|Image stimuli|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the control group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes on paper. They, guided by the narrator's voice of the operator will have to choose from two or three alternatives the one that represents the appropriate mental state by indicating it on the paper. Consequently, feedback will be provided by the operator to return information to the subject on the accuracy of the response.
41488435|NCT02060474|DRUG|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
41488436|NCT03250676|DRUG|H3B-6545|Oral capsules by mouth once daily
41488437|NCT01584206|DRUG|Ezetimibe|10mg ezetimibe/day, at least 4 months
41488438|NCT01832935|DRUG|insulin glargine|The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
41488439|NCT01832935|DRUG|Insulin NPH|The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
41488440|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 13 mCi radiation dose|13 mCi 18F-FDG dose
41341524|NCT01518140|BEHAVIORAL|Questionnaires|2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
41341525|NCT00032006|RADIATION|brachytherapy|
41341526|NCT00032006|RADIATION|radiation therapy|
41341527|NCT04341311|DRUG|Marizomib|- Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.
41341528|NCT04341311|DRUG|Panobinostat|- Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course
41341529|NCT02792283|BIOLOGICAL|whole blood collection|
41341530|NCT00539318|PROCEDURE|Blood drawing|Once when enroll in study
41488441|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 5 mCi radiation dose|5 mCi 18F-FDG dose
41488442|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 2.5 mCi radiation dose|2.5 mCi 18F-FDG dose
41488443|NCT03519659|DIAGNOSTIC_TEST|PET/CT Scan with 6.5 mCi radiation dose|6.5 mCi 18F-FDG dose
41488444|NCT03519659|DIAGNOSTIC_TEST|PET/CT Scan with not yet determined radiation dose|We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
40822690|NCT04350671|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
40822691|NCT00612014|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
41017672|NCT04961333|BEHAVIORAL|Multidisciplinary Rehabilitation|Body therapies to improve breathing, normalise dysfunction in the autonomic nervous system, relaxation, mindfulness, in some part Acceptance and Commitment Therapy given preferably through body therapies.
41017673|NCT06556680|DEVICE|Optical coherence tomography|In the OCT-guided biopsy arm, n=100 study subjects will be enrolled. The investigators will conduct biopsies and imaging using our newly developed OCT catheters and real-time image processing and display algorithms.
41017674|NCT01542112|OTHER|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
41017675|NCT01542112|OTHER|No treatment|Patients in this arm receive the usual routine in the department.
41017676|NCT00949013|OTHER|immunohistochemistry staining method|
41017677|NCT00949013|OTHER|laboratory biomarker analysis|
41017678|NCT05873387|DEVICE|Use of Eko DUO stethoscope (paired ECG/PCG)|Auscultation of heart sounds using electronic stethoscope
41017679|NCT03698773|OTHER|Access to routine information|Access to routine pain-control information
41341531|NCT00748306|DRUG|GSK2190915 - 100mcg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
41341532|NCT00748306|DRUG|Placebo|Matching Intervention Drug
41341533|NCT04350372|DEVICE|MitraClip Procedure|MitraClip procedure with MitraClip NT System
40822692|NCT00612014|DRUG|TZP-101|"40 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
41488445|NCT04100174|RADIATION|focal brachytherapy boost to SBRT|As above
41488446|NCT05369286|DRUG|"MAX-40279-01 and Toripalimab"|"MAX-40279-01combined with Toripalimab"
41341534|NCT00940849|DIETARY_SUPPLEMENT|Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
41488447|NCT05974436|OTHER|Blood and dialysate sampling|"Blood is sampled from the inlet and outlet dialyzer bloodline at 5min after dialysis start.~Spent dialysate is sampled from the outlet dialysate line at 5, 30, 90 and 240min after dialysis start.~Blood and dialysate samples are analysed for different uremic toxins. Dialysis efficiency is calculated from the analysed toxin concentrations."
41488448|NCT01553279|BIOLOGICAL|V419|Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate \[meningococcal outer membrane protein complex\], and Hepatitis B \[recombinant\] vaccine administered via 0.5 mL intramuscular injection.
41488449|NCT01553279|BIOLOGICAL|PREVNAR 13®|Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).
41341535|NCT00940849|DIETARY_SUPPLEMENT|Standard macaroni meal|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
41341536|NCT04225312|DRUG|Personalized extended interval dosing of natalizumab|Personalized extended interval dosing of natalizumab with a schedule from every 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.
41341537|NCT04225312|DRUG|Standard interval dosing|Standard interval dosing in control group and historic group
41341538|NCT02911051|DEVICE|Actreen Hydrolite Cath|Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
41341539|NCT00678236|OTHER|Refobacin Bone Cement R|Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
41341540|NCT00678236|OTHER|Refobacin Plus Bone Cement|Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
41341541|NCT00763607|GENETIC|Protein expression by immunohistochemistry and immunofluorescence|Protein expression by immunohistochemistry and immunofluorescence
41341542|NCT02282488|OTHER|Low protein formula|
41341543|NCT02282488|OTHER|High protein formula|
41341544|NCT01184339|DEVICE|MicroPhage S. aureus/MSSA/MRSA Blood Culture Test|"In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.~Approximately 5 hour rapid test."
41341545|NCT00561340|DIETARY_SUPPLEMENT|Pediasure|50% will be randomized to pediasure with nutritional counseling
41341546|NCT00561340|BEHAVIORAL|Nutritional counseling|50% randomized to nutritional counseling only
41341547|NCT03667794|DIAGNOSTIC_TEST|body plethysmography|measurement of conventional lung function parameters
41488450|NCT01553279|BIOLOGICAL|MCC-TT|Meningococcal Group C polysaccharide conjugate vaccine to tetanus toxoid adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
41488451|NCT01553279|BIOLOGICAL|MCC-CRM|Meningococcal Group C conjugate vaccine to CRM-197 adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
41488452|NCT01553279|BIOLOGICAL|Hib-MCC|Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.
41488453|NCT01553279|BIOLOGICAL|MMR Vaccine|Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).
41488454|NCT03525418|BIOLOGICAL|Longeveron Mesenchymal Stem Cells|Allogeneic bone marrow-derived mesenchymal stem cell
41488455|NCT05484453|DIAGNOSTIC_TEST|Complete Eye Examination by Ophthalmologist|complete eye examination (gold standard) including cover test, biomicroscopy and cycloplegic refraction with retinoscopy, performed by an ophthalmologist.
41488456|NCT01732874|DRUG|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
41488457|NCT01732874|DRUG|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
40822693|NCT00612014|DRUG|TZP-101|"80 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
40822694|NCT00612014|DRUG|TZP-101|"160 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
40822695|NCT00612014|DRUG|TZP-101|"320 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
41341548|NCT03667794|DIAGNOSTIC_TEST|impulse oscillometry|measurement of central and peripheral airway resistance
41341549|NCT03667794|DIAGNOSTIC_TEST|multiple breath washout|measurement of ventilation heterogeneity
41341550|NCT01224106|DRUG|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
41341551|NCT01224106|DRUG|Placebo|Participants received Placebo SC injection Q4W.
41341552|NCT02745041|DRUG|Fibrinogen Concentrate|"Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm \[FIBTEM ≤ A5 10mm\]~FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC"
40822696|NCT00612014|DRUG|TZP-101|"600 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
40822699|NCT04224636|COMBINATION_PRODUCT|Atezolizumab Injection, Bevacizumab Injection|Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE
40822700|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
40822701|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
40822702|NCT01741324|DIETARY_SUPPLEMENT|No extra vitamin D|Milk drink with no extra vitamin D (placebo)
41017680|NCT03698773|OTHER|Access to website|Access to informational website: thepainlesspush.com
40822703|NCT06581731|DRUG|remimazolam combined with remifentanil|Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.
40822704|NCT06581731|DRUG|dexmedetomidine combined with remifentanil|Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.
40822705|NCT02076269|OTHER|No Intervention|Patients are receiving no treatment in this study and there is no investigational product involved
40822706|NCT05824039|DIETARY_SUPPLEMENT|Tea infusion|Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
40822707|NCT02432560|DRUG|Sirolimus|Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
41017681|NCT01993264|OTHER|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
41017682|NCT06293417|DRUG|Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin|Treatment group
41017683|NCT06293417|DRUG|Dose escalation of moderate-intensity statin|Control group
41017684|NCT04893889|DIAGNOSTIC_TEST|Shear-wave elastography|Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
40822708|NCT02432560|DRUG|Everolimus|Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
40822709|NCT02511834|DEVICE|VEST External Support|
40822710|NCT02511834|PROCEDURE|Coronary Artery Bypass Surgery|
40822711|NCT03354481|BEHAVIORAL|Arithmetic facts solving|The experiment will contain several tasks. The main one will be a computerized task on arithmetic facts where participants will have to solve simple additions. There will also be three additional tasks: a processing speed task where the participant will have to tell the orientation of an arrow as fast as possible, a visuo-spatial task where the participant will have to reproduce a tapping block sequence and an arithmetic task where the participant will try to solve a maximum of operations in a limited time.
40822712|NCT01018134|DRUG|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
40822713|NCT01018134|DRUG|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
41341553|NCT02745041|OTHER|Cryoprecipitate|"Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm \[FIBTEM A5 ≤ 10mm\]~FIBTEM A5 0mm (Flat Line) = 20 Units Cryo FIBTEM A5 1- 4mm = 16 Units Cryo FIBTEM A5 5 - 6mm = 14 Units Cryo FIBTEM A5 7 - 8mm = 10 Units Cryo FIBTEM A5 9 - 10mm = 8 Units Cryo"
40822714|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
40822715|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
40822716|NCT01018134|DRUG|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
40822717|NCT01018134|DRUG|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
40822718|NCT01971749|PROCEDURE|Coronary stent procedure (CSP)|
40822719|NCT01971749|PROCEDURE|Coronary-artery bypass grafting (CABG)|
41341554|NCT02392676|DRUG|OLAPARIB|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
41341555|NCT02392676|DRUG|PLACEBO|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
40822720|NCT03751358|PROCEDURE|Unilateral Erector spinae plane block|Magnetic résonance imaging
40822721|NCT04750694|BEHAVIORAL|Resistance training|A full-training programme with high intensity followed by back squat exercise with blood flow restriction. Inflatable cuffs will be placed proximally on both thighs. The cuff pressure will be 50% of individual arterial occlusion pressure and will be maintained during the rest intervals. Participants will perform 30, 15, 15 and 15 repetitions of 30% of 1 Repetition Maximum. Totally 75 repetitions will be performed. 45 seconds rest interval between sets will be given.
40822722|NCT01474772|DRUG|Pregabalin|150-300 mg/day given in 3 divided doses as capsules
41017685|NCT04600960|DRUG|Eltrombopag|The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L，the eltrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.
41017686|NCT02762669|DRUG|Oxytocin|Oxytocin, 10-7mol/L to 10-5mol/L
40822723|NCT01474772|OTHER|placebo|matching placebo capsules given in 3 divided doses
40822724|NCT06605755|PROCEDURE|Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine|"The test vaccine in this study was Pentaxim®, a pentavalent vaccine produced by Sanofi Pasteur, France.This vaccine is a combination vaccine consisting of adsorbed acellular DTP and inactivated polio vaccine (DTaP-IPV) and Haemophilus influenzae type b conjugate vaccine (Hib).~1. Intervention group: 1 dose of experimental vaccine at 2, 4 and 6 months of age, and 1 dose of enhanced vaccine at 18 months of age.~2. Control group: 1 dose of experimental vaccine at 2, 3 and 4 months of age, and 1 dose of enhanced vaccine at 18 months of age."
40822725|NCT04443517|PROCEDURE|Alpha Optimization|Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of desflurane and opioid.
40822726|NCT04443517|BEHAVIORAL|Emergence from anesthesia with propofol|Infusion of 400 mg/h of propofol during the final 10-20 minutes of surgery. Total doses of propofol administered are likely to be in the range of 1-3 mg/kg.
40822727|NCT02924714|OTHER|Discontinuation of imatinib|
40822728|NCT02196116|OTHER|PET|PET Scan with \[18F\]-Flutemetamol
40822729|NCT02196116|OTHER|MRI|
40822730|NCT02196116|OTHER|neuropsychological tests|
41017687|NCT04285190|DRUG|T89|The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.
41488458|NCT04514536|DEVICE|Health monitors|"* The connected scale (iHealth HS2) measures weight from 5 to 180kg and BMI.~* The connected actimeter (iHealth AM4) monitors activity (number of steps, distance, calories), sleep (automatic sleep recognition, effective sleep time, number of awakenings) and swimming (automatic activity recognition, session duration, swim type recognition and number of laps).~* The connected blood pressure monitor (iHealth Track KN-550BT)is a medical device that measures blood pressure and pulse rate.~* The activity monitor (manufactured by RF Track) consists of a housing that can be positioned as a pendant or at the hip. It includes an accelerometer, gyroscope, magnetometer, barometer, radio transceiver, and led. The sensor records the raw signals.~* The touchpad allows the subject to connect to the Calliope app. This app allows the data recovery, storage, analysis, visualization, and all the required settings for the platform to work together."
41488459|NCT01315132|DEVICE|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
41017688|NCT06573190|DIAGNOSTIC_TEST|Transient elastography|Liver Stiffness Measurement, Controlled Attenuation Parameter
41017689|NCT06573190|DRUG|Tenofovir Disoproxil Fumarate|Guided Therapy
41017690|NCT02414087|DEVICE|ICB Medical insoles|"Study group:~Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.~Control group:~Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months"
41017691|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (immediate group)|Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.
41017692|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (waitlist group, intervention administered following 4-week waitlist period)|"Four week waitlist period during which participants receive treatment as usual. Following the waitlist period, participants will receive the telemedicine pain management intervention:~Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management."
41017693|NCT00491790|DRUG|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
41017694|NCT00491790|OTHER|Sterile water|Sterile water
41017695|NCT02247310|DRUG|Interferon beta-1b (Betaferon®, BAY 86-5046)|Patients will be treated with Betaferon
41017696|NCT02247310|DEVICE|BETACONNECT|Auto-injector device to support the injection of Betaferon
41341556|NCT02324868|DEVICE|Shower patch IV catheter protection|Shower patch will be available for the patient for bathing activities
41017697|NCT04286347|PROCEDURE|HCV, HBV, HIV tests|HCV, HBV, HIV testing during consultation with Anesthesiologist before a planned surgery
41017698|NCT00024518|DRUG|30,000 units hrINF-alpha|
41017699|NCT00024518|DRUG|5,000 hrINF-alpha|
41341557|NCT02324868|DEVICE|Conventional IV catheter protection|No Shower patch will be provided during study period
41017700|NCT00024518|OTHER|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA).
41017701|NCT03842475|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Bariatric surgery
41017702|NCT01764607|DRUG|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
41017703|NCT02708745|BEHAVIORAL|Intervention Survey|
41017704|NCT02708745|BEHAVIORAL|Placebo Survey|
41017705|NCT01242904|DRUG|bimodal solution|200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
41341558|NCT01510028|BIOLOGICAL|Recombinant human arylsulfatase A|6 patients treated with HGT-1110 EOW by IT injection
41341559|NCT00019214|BIOLOGICAL|MART-1 antigen|
41341560|NCT00019214|BIOLOGICAL|aldesleukin|
40822731|NCT04463199|OTHER|Craniocervical flexion training|"PBU airbag was clipped together and folded in, fastened, and placed suboccipital. Uninflated pressure sensor was kept below the neck, so that it touched the occiput then inflated to a stable baseline pressure of 20 mmHg to just fill the space below the neck but not to push it into lordosis. Subjects were demonstrated the correct action of the deep cervical flexors that is gentle nodding of head as if saying yes."
41488460|NCT04808466|DRUG|Paclitaxel|Paclitaxel is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
41488461|NCT04808466|DRUG|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
40822732|NCT06602583|DIAGNOSTIC_TEST|Standard Dose Coronary angiography|The radiation exposure of this group would be collected from database of already done studies in the months prior to the initiation of the study (so as to prevent observer bias which may happen once the interventional cardiologist knows his inclusion in study, and may use a shorter or longer cine runs, thus influencing the outcomes). This would best represent the real-world data set, according to the routinely followed standard dose/ older low dose protocol.
40822733|NCT06602583|DIAGNOSTIC_TEST|New low dose angiography|a comparative arm where the patients being once eligible for the study; would undergo angiography using the new low dose protocol.
41488462|NCT03582280|DRUG|Amorphous Calcium Carbonate (ACC) - Amor|Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
41488463|NCT06221553|BIOLOGICAL|B7H3 specific CAR T cell with IL-7Ra signaling domain|Autologous T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) with additional of IL-7 receptor alpha signalingdomain given via indwelling central nervous system (CNS) catheter
40822734|NCT04362371|DEVICE|Ainara|1 g at each administration
40822735|NCT05854576|PROCEDURE|vascular acess|AVF
40822736|NCT01510145|DRUG|Travoprost 0.004% BAK-free|Containing Polyquad (PQ) preservative
40822737|NCT02235675|DEVICE|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
40822738|NCT03885570|PROCEDURE|Mitral valve replacement|Blood transfusion
40822739|NCT05369520|DEVICE|TESCoN device - Thoracic stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the thoracic spinal cord (T7-T12, Group 1).
40822740|NCT05369520|DEVICE|TESCoN device - Lumbosacral stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the lumbosacral spinal cord (L1 - L3, Group 2).
40822741|NCT06145516|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Hybrid CBT-I (self-guided digital format focusing on sleep restriction therapy and stimulus control + telehealth video-consultations with psychologist)
40822742|NCT06145516|BEHAVIORAL|Sleep education therapy (SET)|Self-guided digital sleep education (sleep hygiene, sleep physiology, sleep disturbances etc) + telehealth video-consultations with research nurse
40822743|NCT04960878|DIETARY_SUPPLEMENT|Synbiotic|Synbiotics sachet mainly contained Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, and fructooligosaccharides.
40822744|NCT04960878|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
40822745|NCT00162500|BIOLOGICAL|Peptide Vaccine (MUC-1)|
41341561|NCT00019214|BIOLOGICAL|gp100 antigen|
41488464|NCT00472121|DEVICE|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
40822746|NCT00683917|DRUG|Proellex 25 mg|Proellex 25 mg, 1 capsule daily for 4 months
40822747|NCT00683917|DRUG|Proellex 50 mg|Proellex 50 mg, 2 capsules daily for 4 months
40822748|NCT00683917|DRUG|Lupron Depot|Lupron 3.75 mg monthly intramuscular injections for 4 months
40822749|NCT01746121|GENETIC|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
40822750|NCT05256420|DEVICE|Kinesiotape|Application of a kinesiotape bandage on the knee.
40822751|NCT05256420|DEVICE|Sham Bandage|Application of a sham bandage on the knee.
40822752|NCT05451290|DRUG|Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur|Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).
40822753|NCT03153644|BEHAVIORAL|Interview|1 hour semi-structured
40822754|NCT03153644|BEHAVIORAL|Observation|Field Observation
40822755|NCT00612547|DRUG|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
40822756|NCT06343870|DRUG|testosterone pellet (100 mg)|Intervention arm: Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)
40822757|NCT06343870|DRUG|Placebo|Pellet of cholesterol (placebo)
41341562|NCT01326390|DEVICE|dTA/dBA C-arm fluoroscopy system with Dyna CT|C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry
41341563|NCT01326390|PROCEDURE|DSA arteriogram- hepatic arteries|Standard of care
41341564|NCT01326390|PROCEDURE|CO2 aortogram|Standard of care
41488465|NCT02335736|DRUG|Gonadotropins releasing hormone antagonist|
41488466|NCT05691686|OTHER|Finely milled whole wheat-legume bread|The intervention examines the effect of finely milled wheat-legume bread in subjects with normal body weight.
41341565|NCT03739736|OTHER|Combination of TB/HIV prevention activities (arm A)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In arm A ART was initiated regardless of CD4 count. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
41341566|NCT03739736|OTHER|Combination of TB/HIV prevention activities (arm B)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In this arm B ART was initiated according to national guidelines. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
41341567|NCT03739736|OTHER|Standard of care (arm C)|"The standard of care arm C communities have access to HIV testing services (usually at the health facility), HIV care and ART provision according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility. TB diagnostics are as per national guidelines including Xpert®TB/RIF for those who are HIV positive. All diagnosed cases of TB are treated as in the intervention arm. TB screening and prevention at HIV care clinics are as is in the intervention arm."
41341568|NCT04078074|DEVICE|Maxillary OSS|Maxillary OSS will be a night guard for the top teeth. Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo cone beam computed tomography (CBCT) airway imaging with and without splint.
41341569|NCT04078074|DEVICE|Mandibular OSS|Mandibular OSS will be a night guard for the bottom teeth.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
41488467|NCT05691686|OTHER|Less processed whole wheat-legume bread|The intervention examines the effect of less processed whole wheat-legume bread in subjects with normal body weight.
41488468|NCT05691686|OTHER|Less processed whole wheat bread|The intervention examines the effect of less processed whole wheat bread in subjects with normal body weight.
41488469|NCT05691686|OTHER|White wheat bread|The intervention examines the reference food product in subjects with normal body weight.
41488470|NCT00004755|DRUG|allopurinol|
41488471|NCT00004755|DRUG|glucantime|
41488472|NCT02908737|DEVICE|Bass and Treble|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
41488473|NCT02784353|BEHAVIORAL|Perioperative rehabilitation program|"Perioperative rehabilitation program~* preoperative rehabilitation : 2 weeks prior to operation~* postoperative rehabilitation : 3 months after operation"
41488474|NCT02784353|BEHAVIORAL|Conventional|conventional perioperative management without rehabilitation program
41488475|NCT00548171|BIOLOGICAL|Boostrix™|Intramuscular injection, 1 dose
41488476|NCT01342536|BEHAVIORAL|Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)|"The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)"
41488477|NCT05555563|OTHER|MTAD irrigation|Final irrigation protocol was performed using 5 ml MTAD (n=50).
41488478|NCT02528123|PROCEDURE|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
41488479|NCT02528123|DRUG|Tobramycin and dexamethasone|Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure
41488480|NCT02528123|DRUG|Ofloxacin|Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
40823038|NCT03321903|OTHER|EPR Oximetry Measurement|An oximetry measurement visit consists of \~ 30 minutes of continuous scans of tissue oxygen in vivo, using an oxygen sensor (i.e., India ink) injected into the tumor that is noninvasively scanned using EPR oximetry. Scans, converted into measurements of pO2, characterize the current tumor oxygen level at: (1) 'steady state' (while breathing room air), 2) response to hyperoxygenation therapy (inhaling oxygen-enriched air for 10 min), and 3) response to resuming inhaling room air. EPR measurements are repeated noninvasively throughout radiation or chemotherapy, to examine changes. The minimum number of visits depends on the patient's cohort; all may have additional measurements. If the ink injection is not surgically removed, EPR oximetry measurements can be repeated indefinitely.
40823039|NCT02030717|DRUG|klonidin|spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
41341570|NCT04078074|DEVICE|Modified farrar splint|Modified farrar splint will be a night guard for the top teeth that positions and maintains the lower jaw in a more forward position.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep. This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
41341571|NCT05428540|DIETARY_SUPPLEMENT|Polyphenol-rich supplement|Polyphenol-rich capsules containing 1,200 mg of a combination of plant extracts rich in polyphenols. Frequency: 3 capsules a day. Duration: 12 weeks.
41341572|NCT05428540|OTHER|Placebo|Placebo
41341573|NCT04720313|DRUG|NXC-201 (formerly HBI0101)|NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.
41488481|NCT02528123|DRUG|Proxymetacaine 0.5%|Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
41488482|NCT02528123|DRUG|Oxybuprocaine 0.4%|Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
41488483|NCT00097396|BIOLOGICAL|rF1V vaccine|
40822758|NCT03398265|BEHAVIORAL|Treatment Navigation (Intervention)|Subjects in the intervention arm will begin a discussion with the interventionist about whether they are interested in treatment and medication choices for opioid use disorder. The interventionist will use a decision tool informed by the Substance Abuse and Mental Health Services Administration (SAMSHA) guide to medication assisted treatment in order to help make an informed decision about treatment choices. Once a decision is reached, the Treatment Navigator will communicate with the subject periodically to assist with entering treatment and help with locating other social services as needed within the community. The Treatment Navigator will emphasize getting into treatment as quickly as possible once a decision is made. The Treatment Navigator and the subject will continue communicating throughout the 6 month study period. Subjects will also receive overdose education and be offered take-home naloxone.
40822759|NCT03398265|OTHER|Control|Subjects in the control arm will receive referrals from Department of Corrections (DOC) staff for treatment per DOC protocols. Subjects will not receive any treatment navigation or treatment decision making. Subjects will also receive overdose education and be offered take-home naloxone.
40823040|NCT02030717|DRUG|epidural anesthesia|epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
40823041|NCT02418208|DIAGNOSTIC_TEST|Performint EEG tests and BNA analysis|
41017706|NCT01242904|DRUG|icodextrin|200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
41341574|NCT01459887|DRUG|CHOP combined with CMAB304|Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
41341575|NCT01459887|DRUG|CHOP, CMAB304|First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
41341576|NCT01614795|BIOLOGICAL|Cixutumumab|Given IV
41341577|NCT01614795|OTHER|Laboratory Biomarker Analysis|Correlative studies
41341578|NCT01614795|DRUG|Temsirolimus|Given IV
41341579|NCT01210976|DRUG|levosimendan|12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min
41341580|NCT01210976|DRUG|placebo|nacl 0.9% coloured with thiamin in same volume and time than levosimendan
41341581|NCT03395327|OTHER|quality of life questionnaire|QLQ-C30 and BR23 (Quality of Life Questionnaire and Breast 23) Questionnaire FSFI (Female Sexual Function Index)
41488484|NCT03077906|OTHER|Medical Files data extraction|Medical Files data extraction
41488485|NCT06123923|OTHER|no intervention|no intervention, just retrospective observation
41488486|NCT05388240|OTHER|Education via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources."
41017707|NCT00191061|DRUG|duloxetine hydrochloride|
41341582|NCT03870672|DEVICE|Contralaterally Controlled Functional Electrical Stimulation|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.
41341583|NCT03870672|DEVICE|New rTMS approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
41017708|NCT03652103|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block Catheterisation|After receiving general anesthesia, patients will positioned prone. Before operation begins, ESP block catheter will be applied with ultrasound guidance to the same level as surgeon's incision.
40823042|NCT02858986|PROCEDURE|3D laparoscopy|
41341584|NCT03870672|DEVICE|Conventional rTMS approach|Facilitation of M1 will be achieved using 5Hz rTMS. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
41341585|NCT03870672|DEVICE|Sham rTMS approach|In the sham rTMS group, ipsilesional motor hotspot will be targeted in half the patients and cHMC location will be targeted in the other half (based on random assignment). Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
41341586|NCT03905525|DRUG|CFZ533|Biological
40823043|NCT02858986|PROCEDURE|4K laparoscopy|
41017709|NCT03652103|DRUG|Bupivacaine 0.25% Injectable Solution|Perineural Injection
41017710|NCT02379949|BEHAVIORAL|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
41017711|NCT02379949|BEHAVIORAL|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
41341587|NCT03905525|OTHER|Placebo|liquid placebo for injections
41341588|NCT01011088|OTHER||Not any artificial interventions were given
41488487|NCT05388240|OTHER|Education and Exercise via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources. The app will also be used to help guide participants through an eight-week shoulder exercise program, together with physical therapy remote support."
41341589|NCT04675697|DRUG|Platinum-etoposide+Anlotinib|Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1\~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5\~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4\~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
41341590|NCT00899600|DRUG|Ketamine|Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
41488488|NCT04059458|DEVICE|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.
41488489|NCT04059458|DRUG|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.
41488490|NCT00857792|DRUG|regadenoson|Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
41488491|NCT01732484|PROCEDURE|intraocular lens implantation|
41488492|NCT04739150|DRUG|nintedanib|nintedanib
41488493|NCT02078336|DRUG|Midazolam Mylan|
41488494|NCT02078336|DRUG|Lorazepam Mylan|
40823044|NCT04606589|DEVICE|neoGuard vital signs monitor|The neoGuardTM device is a 4-in-1 wearable vital signs monitor designed to continuously measure temperature, pulse rate, respiratory rate and blood oxygen saturation in newborns.
41341591|NCT00899600|OTHER|Normal saline|Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
41341592|NCT00560794|BIOLOGICAL|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
41341593|NCT06092762|DRUG|AK120|subcutaneous injection every 2 weeks
41488495|NCT02078336|DRUG|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
41488496|NCT00003708|DRUG|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
41488497|NCT04162132|DEVICE|Smartphone app|Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.
41488498|NCT03599830|OTHER|Cognitive test passations|"Tests :~MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences"
41488499|NCT02700711|DRUG|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
41488500|NCT02700711|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
40823045|NCT03271073|DRUG|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
41488501|NCT02700711|DRUG|Duloxetine|The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
41488502|NCT05370820|DRUG|Tranexamic acid|IV 2 minutes, IV 10 minutes, IM
40823046|NCT05061719|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
41488503|NCT00540683|DEVICE|Diffuse Optical Spectroscopy|Muscle properties
40822760|NCT04401306|OTHER|Home-based self-regulated simulation training (SRST)|Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
41488504|NCT05530343|DIAGNOSTIC_TEST|Seattle protocol|Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.
41488505|NCT05530343|DIAGNOSTIC_TEST|WATS3D brushings|Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.
41488506|NCT03776721|PROCEDURE|Liposuction|Liposuction is performed on the abdomen or thighs.
41488507|NCT03776721|PROCEDURE|Fat graft|30mL harvested lipoaspirate is injected at the affected axillary site.
41488508|NCT03776721|PROCEDURE|Sham graf (Saline injection)|30mL saline is injected at the affected axillary site.
41488509|NCT03776721|BIOLOGICAL|Stem cell injection|4mL stem cell suspension injected at the affected axillary site.
41488510|NCT03776721|PROCEDURE|Saline injection|4mL saline injected at the affected axillary site.
40822761|NCT04401306|OTHER|Centralized instructor-regulated simulation training (IRST)|Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
40822762|NCT04126564|BEHAVIORAL|Inner Engineering Online|Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations \& yoga.
41266352|NCT03185546|OTHER|Tobacco Flavors|Participants can choose e-liquid flavors from a selection of tobacco flavors
41266353|NCT03185546|OTHER|Tobacco and non-tobacco e-liquid flavors|Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices
41488511|NCT04399928|DEVICE|Total Hip Arthroplasty|Total hip arthroplasty with the R3 Acetabular Hip system.
41488512|NCT00188487|DEVICE|magnetic resonance imaging (MRI) of the thorax|
41488513|NCT04199013|DRUG|Ropivacaine 0.75% Injectable Solution|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
41488514|NCT04199013|DRUG|Fentanyl Citrate|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
41488515|NCT01072955|BIOLOGICAL|Bovine Heparin|5.000UI/mL bottle with 5mL
41488516|NCT01072955|BIOLOGICAL|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
41488517|NCT01725321|OTHER|Narrow band imaging|Colonoscopy with new narrow band imaging
41488518|NCT01948986|DRUG|Ertugliflozin|Single oral administration of 3 X 5 mg tablets.
41266354|NCT01256216|DEVICE|Total Knee Replacement with Vanguard Total Knee|Patients indicated for a total knee replacement utilizing the Vanguard Total Knee System.
41266355|NCT00936988|DRUG|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
41266356|NCT04410874|BIOLOGICAL|Imvamune|Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10\^7, 1x10\^8, or 4x10\^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)
41266357|NCT04957459|OTHER|No intervention|No intervention
41266358|NCT04216173|OTHER|Acupuncture|Acupuncture weekly for 12 consecutive weeks. Acupuncture protocol consists of both scalp and body acupuncture points.
41266359|NCT05032950|DRUG|Midazolam|Midazolam administered as a single dose on Day 1
41266360|NCT05032950|DRUG|PF-07321332/ritonavir + Midazolam|"PF-07321332/ritonavir:~Administered orally every 12 hours for a total of 9 doses on Days 1-5~Midazolam:~Administered orally as a single dose on Day 5"
41266361|NCT05032950|DRUG|Ritonavir + Midazolam|"Ritonavir:~Administered orally every 12 hours for a total of 9 doses on Day1-5.~Midazolam:~Administered orally as a single dose on Day 5"
41266362|NCT04992702|BEHAVIORAL|Animated Video|Animated video to improve learning and motivation
41266363|NCT04901572|DIAGNOSTIC_TEST|QISI device|QISI device will simulate its use in ICSI procedures and evaluate sperm cells according to WHO guidelines.
41266364|NCT04459845|BEHAVIORAL|Parent Child Interaction Therapy|Parent-child Interaction therapy (PCIT; Eyberg and Robinson, 1982) s a manualized evidence-based behavioral parent training program that integrates social learning and attachment theories. Parents proceed through two distinct phases: Child-Directed Interaction (CDI) resembles traditional play therapy, and Parent-Directed Interaction (PDI) resembles clinical behavior therapy. During all sessions, the therapist coaches each parent in vivo in their use of the CDI and PDI skills with their child.
41341594|NCT05379192|OTHER|Group 1, Group 2, Group 3, Group 4|The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm
41341595|NCT04987424|DIAGNOSTIC_TEST|Development and validation of Lymphedema levels diagnostic|A single intervention was carried out in which the patients were summoned for an interview and anthropometric measurements of the upper limbs, thus calculating the arm volume for a lymphedema primary diagnosis .
41341596|NCT04432168|PROCEDURE|Fetoscopic Laser Surgery|Fetoscopic Photocoagulation of the connecting vascular anastomoses on the surface of the placenta.
41341597|NCT04432168|OTHER|Standard Treatment|"In the control group, the choices of treatment include expectant management, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)) or preterm delivery, depending on the judgment of the fetal surgeon with regard to the gestational age and state of the disease.~* Expectant management will consist of close monitoring with ultrasound including Doppler measurements of the middle cerebral artery peak systolic velocity (MCA-PSV), at least every week.~* IUT: the intrauterine infusion of red blood cells into the circulation of the donor twin treat anemia.~* PET: the intrauterine infusion of saline into the circulation of the recipient twin to treat polycythemia.~* Preterm delivery: Induction of labor or cesarean section before 36 weeks of gestation."
41341598|NCT04836091|BEHAVIORAL|Waitlist|From day 31 to day 60 (ie., during month 2) of the trial, participants in the waitlist arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
41341599|NCT04836091|BEHAVIORAL|Intervention|From day 1 to day 60 (ie., entire 2 month duration) of the trial, participants in the intervention arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
41341600|NCT03494023|DIAGNOSTIC_TEST|Endoscopic ultrasound|Measurement of the common bile duct diameter
41341601|NCT00141310|DRUG|Sildenafil citrate|
41341602|NCT04045691|DRUG|Encorafenib|Observation of real-life treatment with encorafenib and binimetinib
41341603|NCT04045691|DRUG|Binimetinib|Observation of real-life treatment with encorafenib and binimetinib
41341604|NCT01401101|OTHER|PCM|Care Manager (CM) intervention
41341605|NCT01401101|OTHER|MEU|The MEU condition consists of only the clinician education and patient screening without written feedback.
41488519|NCT04493866|OTHER|Messages to departmental employees to improve quality of consent form completion|All interventions directed to members of the plastic surgery department: Intervention 1: Poster illustration common mistakes on consent forms. Intervention 2: Group message explaining Quality Improvement Project to the department. Intervention 3: Email from Consultant lead in support of project. Intervention 4: Further group message illustrating gains and ongoing goals of the project.
41488520|NCT03907384|BEHAVIORAL|Mat Pilates training|This group completed 12-weeks of training
41488521|NCT04532359|DEVICE|Implant placement|Implant placement
41488522|NCT04227236|OTHER|E-based virtual facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using an e-based virtual trainer on a computer. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
41488523|NCT04227236|OTHER|In-person facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using the standard in-person training method. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
41488524|NCT04498403|DRUG|Crisaborole 2%|Crisaborole 2% ointment
41017712|NCT04740606|DEVICE|Augmented Reality Navigation System|Investigators will assess the nodules based on the CT images of subjects before procedure. And then, the appropriate intra-airway path planned by the Augmented Reality Navigation System will be selected. The bronchoscopy with intra-airway navigation under the guidance of the Augmented Reality Navigation System will be performed and the following surgical information will be record.
41488525|NCT00486317|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
41488526|NCT05808192|DRUG|Immunosuppressive|compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
41017713|NCT01160965|DRUG|0.5% levobupivacaine|15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
41017714|NCT01160965|DRUG|0.75% Ropivacaine|15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
41341606|NCT05132101|DRUG|Patients who received Palbociclib as first line therapy in MBC setting|Patients who received Palbociclib as first line therapy in MBC setting
41488527|NCT06187558|PROCEDURE|Pelvic and abdominal organ suspension technique|The intervention involves a unique organ suspension technique tailored for minimally invasive gynecologic surgeries. A fragment of a Foley catheter (2 cm of a 1 Fr/Ch) is tied at the end of an absorbable 2-0 Polyglactin suture with a straight needle to create the suspension device. This suture is introduced into the pelvic cavity via an ancillary port. It's designed to penetrate organs such as the ovary, posterior peritoneum, vesico-uterine peritoneum, or bowel. Once the suture is retrieved by passing it through the abdominal wall and pulled so that the Foley segment faces the organ's surface, it's secured using a Kelly clamp. This setup eliminates the need for a knot and offers the surgeon the flexibility to adjust the suspension tension as required.
41488528|NCT03530176|RADIATION|18Fluoride-Sodium Fluoride radio-isotope|The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.
41488529|NCT05656521|DRUG|101-PGC-005|'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.
41488530|NCT05656521|DRUG|Dexamethasone|Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.
40822763|NCT04126564|BEHAVIORAL|Reading a book/ journal|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
41488531|NCT04319185|OTHER|Assistance to perform Peritoneal Dialysis (PD) at home|The patient receives assistance of up to one visit per day for three months depending on the patient's needs, as assessed by the interdisciplinary team, the nephrologist, and the primary investigator or delegate.
41488532|NCT01980966|DRUG|MHAA549A|IV dose
41488533|NCT01980966|DRUG|Placebo|IV dose
41488534|NCT01980966|DRUG|oseltamivir [Tamiflu]|Orally b.i.d, 5 days
41488535|NCT06152952|PROCEDURE|The rhomboid flap approach|"The rhomboid flap Approach :~The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers~The deep suturing approach :~A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. T then the deep fascia will be approximated and the wound will be closed"
41488536|NCT05531318|OTHER|Qualitative Interview|Participants will be interviewed about their experiences of substance use, post-traumatic stress and the way they regulate their emotions.
40822764|NCT05366491|DIAGNOSTIC_TEST|Il-38 serum level|measurement of serum levels of IL-38
40822765|NCT02198482|DRUG|Volasertib|
40822766|NCT02198482|DRUG|Cytarabine|
40822767|NCT02198482|DRUG|Daunorubicin|
40822768|NCT02198482|DRUG|Mitoxantrone|
40822769|NCT03787810|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for assessment of left ventricular dysfunction
41488537|NCT05030558|BEHAVIORAL|Web-assisted patient education intervention designed according to the common-sense model|Implementation of patient education with the website created about fibromyalgia disease in 4 weeks according to the disease perception themes reached as a result of the qualitative research.
41488538|NCT05030558|BEHAVIORAL|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.
40822770|NCT03732326|PROCEDURE|bariatric surgery|Bariatric surgery for enrolled patients who fulfill the including criteria
40822771|NCT02249299|DRUG|Sativex Oromucosal Spray|Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
41488539|NCT06073210|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
40822772|NCT02249299|DRUG|Placebo|
40822773|NCT02708849|DRUG|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
40822774|NCT02708849|DRUG|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
40822775|NCT02708849|DRUG|Placebo|oral dose placebo
40822776|NCT06236542|DEVICE|NextGen automated tracheostomy suctioning device|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctionings using an automated robotic suctioning device.
40822777|NCT06236542|DEVICE|NextGen mixed-reality tracheostomy tube change system|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy tube changes using the mixed reality tracheostomy tube change system.
40822778|NCT06236542|DEVICE|NextGen Tracheostomy Toolkit|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctioning using the robotic suctioning device; and tracheostomy tube changes using the mixed reality tracheostomy tube change system.
40822779|NCT01980277|DRUG|LY2780301 + paclitaxel|Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
40822780|NCT00481325|DRUG|pexacerfont|Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
40822781|NCT00481325|DRUG|escitalopram|Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
40822782|NCT00481325|DRUG|placebo|Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
40822783|NCT04618042|DRUG|FX06|FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
40822784|NCT04618042|DRUG|Placebo of FX06|Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
40822785|NCT00017589|BIOLOGICAL|oblimersen sodium|
40822786|NCT00017589|DRUG|gemtuzumab ozogamicin|
40822787|NCT04503668|DRUG|Ondansetron|8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
40822788|NCT04503668|DRUG|Dexamethasone|20 mg IV on day 1 pre-chemotherapy
41017715|NCT05166434|PROCEDURE|trans-crestal sinus lifting|this study will be divided in to three different groups, each group will receive a same technique of Crestal maxillary sinus lifting and implant placement at 2,4,6 mm heights.
41017716|NCT04950335|PROCEDURE|AOPT|The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.
41488540|NCT06073210|BEHAVIORAL|Action observation plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a action observation intervention (observing movements without actually doing them).
40822789|NCT04503668|DRUG|Neurokinin-1 Receptor Antagonist (NK1-RA)|150 mg IV on day 1 pre-chemotherapy
40822790|NCT04503668|DRUG|Olanzapine|5 mg by mouth on days 1-4 of chemotherapy (taken at night)
40822791|NCT04503668|DRUG|Compazine|5-10 mg by mouth, available as needed, every 6 hours, days 1-5
41341607|NCT00261794|BEHAVIORAL|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
41341608|NCT00261794|BEHAVIORAL|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
41488541|NCT06073210|BEHAVIORAL|Sham action observation plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a sham action observation intervention (observing space planets).
41488542|NCT00110136|DRUG|St. John's Wort|St. John's Wort 300mg tablet three times per day
41488543|NCT00782574|DRUG|AZD2281|Tablets Oral BID
41488544|NCT00782574|DRUG|Cisplatin|IV every 3 weeks
41488545|NCT02475941|OTHER|Non Weight bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
41488546|NCT02475941|OTHER|Early Weight Bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
41488547|NCT00005595|DRUG|arsenic trioxide|
41488548|NCT00696579|DRUG|BCG|6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
40822792|NCT02520258|OTHER|Oral glucose tolerance test (OGTT)|OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
40822793|NCT02520258|OTHER|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
40822794|NCT03040414|DEVICE|MedtronicMinimed 670G 3.0 hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID).
40822795|NCT03040414|DEVICE|Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.|The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
40822796|NCT03073018|DRUG|Fosinopril|oral administration, capsules
41017717|NCT04950335|PROCEDURE|AOCT|Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.
41017718|NCT01049919|DEVICE|Bone marrow concentration device|Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb
41017719|NCT01049919|PROCEDURE|Placebo procedure (sham)|Sham bone marrow aspiration, sham delivery to affected limb
41017720|NCT00188526|DEVICE|lung biopsy|
41017721|NCT06325774|RADIATION|Hypofractionated radiation therapy|54 Gy in 15 daily fractions of 3.6 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
41017722|NCT01040871|DRUG|VELCADE|VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
41341609|NCT00584779|DRUG|Gabapentin|CLcr:14-5 mL/min
41341610|NCT00584779|DRUG|Gabapentin|CLcr: 29-15 mL/min
41341611|NCT00584779|DRUG|Gabapentin|Hemodialysis
41341612|NCT00584779|DRUG|Gabapentin|CLcr: 29-30 mL/min
41341613|NCT02363855|DRUG|BAY 1841788(ODM-201)|Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
41341614|NCT00291746|DRUG|Esomeprazole|
41341615|NCT00291746|PROCEDURE|Bravo technique|
41488549|NCT00696579|DRUG|gemcitabine|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
41488550|NCT03047837|DRUG|ASA|Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
41488551|NCT03047837|DRUG|MET|Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
41488552|NCT03047837|OTHER|Placebo|Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
41488553|NCT04260867|OTHER|Essential Oil|Those randomized to the treatment group will have containers filled with the essential oil of their choice.
41488554|NCT04260867|OTHER|No Essential Oil|Those randomized to the control group will then be given empty single-use handheld aromatherapy containers containing no essential oil.
41488555|NCT05941455|DEVICE|Venus-Neo Surgical Aortic Valve|Implant of a Venus-Neo Surgical Aortic Valve
40822797|NCT03073018|DRUG|Pravastatin|oral administration, capsules
40822798|NCT03073018|DRUG|Fosinopril Placebo|oral administration, capsules
40822799|NCT03073018|DRUG|Pravastatin Placebo|oral administration, capsules
40822800|NCT05497050|BEHAVIORAL|Family education|By calling the families in the experimental group by phone; Nursing interventions for family empowerment will last for 10 weeks, they will be invited to the Family Health Center (FHC) or child metabolism polyclinic twice in this process, they will be called once a week (with 2 phone calls) for two weeks after the face-to-face training initiative in the first stage, In the second stage, at the end of the face-to-face training, they will be informed that they will be called once a week for two weeks (4 phone calls in total). The families in the experimental group will be informed that 4 weeks after the completion of the training and phone calls (at the 10th week), they will call the FHC or the pediatric metabolism polyclinic again for the application of the post-tests and that the nursing training for family empowerment will be completed.
41488556|NCT00242619|DRUG|rosiglitazone|Rosiglitazone was administered at two different doses over the 12-week period.
40822801|NCT03691844|DRUG|AMZ001|diclofenac gel
41017723|NCT01040871|DRUG|Rituximab|Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
41017724|NCT01040871|DRUG|Cyclophosphamide|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
41341616|NCT04212936|PROCEDURE|Intraabdominal pressure|Limited intraabdominal pressure during laparoscopic cholecystectomy between 8 and 10 mmHg.
41488557|NCT02796118|DRUG|ASP2151|Oral
40822802|NCT03691844|DRUG|Placebo|Placebo
40822803|NCT03691844|DRUG|Comparator|diclofenac gel
40822804|NCT03571373|OTHER|No intervention|No intervention due to the observational set-up of this study.
40822805|NCT02103725|DRUG|pimecrolimus 10 mg/g cream|
40822806|NCT02103725|DRUG|Vehicle cream|
40822807|NCT01430923|DRUG|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
40822808|NCT01430923|DRUG|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
40823047|NCT03088436|DEVICE|preoperative prone MRI and supine second-look ultrasound data|Patients were examined using a standard clinical MRI protocol in the prone position with both arms placed above the head. Second-look ultrasonographies were performed. Patients were instructed to lie supine, with their hands behind their heads.
40823048|NCT02080039|DEVICE|Electrical Stimulation|
40823049|NCT00958464|PROCEDURE|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[Gd-DTPA2-\] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
40823050|NCT04902924|BEHAVIORAL|repeated cold water therapy|This information can be found the description of the experimental arm.
41017725|NCT01040871|DRUG|Doxorubicin|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
41017726|NCT01040871|DRUG|Prednisone|Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
41017727|NCT01040871|DRUG|Vincristine|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
41017728|NCT05551364|DEVICE|ATLAS 2030 exoskeleton|"Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases:~1. Telephone contact phase (1 session)~2. Inclusion Phase (1 session)~3. Signing of informed consent (1 session)~4. Initial Evaluation Phase (1 session)~5. Treatment Phase (1st part) (7 sessions)~6. Monthly Evaluation Phase (1 session)~7. Treatment Phase (2nd part) (7 sessions)~8. Monthly Evaluation Phase (1 session)~9. Treatment Phase (3rd part) (7 sessions)~10. Final Evaluation Phase and results (2 sessions)"
41017729|NCT01649856|DRUG|CHOP|CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
41017730|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
41017731|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
41017732|NCT00306592|BIOLOGICAL|BG00002 (natalizumab)|
41017733|NCT04376996|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design - only a diagnostic testing|Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood
41017734|NCT00821691|DRUG|Amantadin|Amantadin caps
41341617|NCT05739331|DEVICE|machine learning algorithm|Machine learning algorithm run on EBUS images for real-time labelling of mediastinal lymph nodes and lymph node level
41341618|NCT02903966|DRUG|GSK2982772|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
41341619|NCT02903966|DRUG|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
41488558|NCT02796118|DRUG|Placebo|Oral
41488559|NCT05496660|OTHER|NHE+KT|the Nodic hamstring exercise plus the kinesio taping with tension during 4-week consisting 12 sessions
41488560|NCT05496660|OTHER|NHE|the Nodic hamstring exercise plus the kinesio taping without tension during 4-week consisting 12 sessions
40822809|NCT06606457|BEHAVIORAL|Pain Acknowledgment Coping and Empowerment in CF (PACE CF)|The Pain Acknowledgment Coping and Empowerment in CF (PACE CF) program is a newly developed 3-session mind-body pain management intervention for adults with cystic fibrosis (CF), developed with CF community input. The sessions are delivered by the the CF care team psychologist. Each session will teach mind-body strategies to increase comfort and reduce the impact of pain on the participant\&#39;s life. These strategies include understanding pain in CF from a mind-body perspective, learning relaxation and mindfulness-based skills, identifying and practicing individualized cognitive and behavioral strategies that improve comfort and well-being, and discussing communication skills that empower people living with CF and pain. Participants will receive a workbook that will provide related education and resources and reinforce skill practice.
40822810|NCT01892787|DRUG|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
41488561|NCT01717586|DRUG|Pravastatin|Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into three cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg or 40mg.
41341620|NCT03865849|DEVICE|Cooled radiofrequent treatment|In the cooled radiofrequency group a treatment of 60°C measured at the tip and on average 80°C in the targeted tissue is applied during 150 seconds using the Coolief system.
41341621|NCT03865849|DEVICE|Conventional radiofrequent treatment|In the conventional radiofrequency group a treatment of 80°C at the tip is applied during 90 seconds at each nerve.
41341622|NCT00703430|DRUG|Memantine|Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
41341623|NCT03336203|DRUG|Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet|treatment either with allopurinol or febuxostat
41341624|NCT03477669|DIETARY_SUPPLEMENT|chamomile/probiotic arm|Caregivers will administer 5 drops of the study product once a day with a feeding at mid-day.
41341625|NCT03477669|DIETARY_SUPPLEMENT|Placebo of chamomile/probiotic arm|Caregivers will administer 5 drops of the placebo study product once a day with a feeding at mid-day.
41341626|NCT04247789|OTHER|Self-reported questionairres|the fatigue will be determined through self reported questionnairres
41341627|NCT00456924|DRUG|VA2914|
41341628|NCT04905810|DRUG|Azacitidine|Given IV
41341629|NCT04905810|DRUG|Decitabine|Given IV
41341630|NCT04905810|DRUG|Venetoclax|Given PO
41341631|NCT04958525|PROCEDURE|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal in basal ganglia region:According to the brain CT scan and reconstruct the operation plan, choose a side by 2 cm before the coronal suture line 4 cm and 3 cm center longitudinal incision formation of 2 cm bone drilling the hole, ultrasonic measurement and the size of hematoma puncture depth, and guide the puncture direction, the transparent channel under endoscopic direct placement hematoma backend, after entering the hematoma cavity, under the neural endoscopic removal of hematoma,Wash the hematoma cavity with warm salt water.Bipolar electrocoagulation hemostasis for active bleeding.An indwelling drainage tube was placed in the hematoma cavity, and ultrasonography determined that the hematoma was cleared satisfily without active bleeding.
41341632|NCT04958525|PROCEDURE|Small bone window craniotomy for hematoma removal under microscope|Small bone window craniotomy for hematoma removal under microscope:Small bone window craniotomy in frontotemporal region, no blood vessels and non-functional areas of the hematoma nearest to the cortex was cut open, the hematoma was removed under the microscope and the cavity of the hematoma was washed with warm saline, and bipolar electrocoagulation hemostasis was performed for active bleeding.An indwelling drainage tube was placed in the hematoma cavity and the operation was completed without active bleeding.
40822811|NCT01892787|DRUG|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
40822812|NCT01613989|PROCEDURE|Prosthetic hip surgery, operated under manual control|: Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
40823051|NCT04902924|BEHAVIORAL|repeated warm water therapy|This information can be found the description of the experimental arm.
40823052|NCT04902924|OTHER|control|This information can be found the description of the experimental arm.
41341633|NCT03023319|DRUG|Bosutinib|100mg daily for 4 cycles (21 days per cycle)
41341634|NCT03023319|DRUG|Pemetrexed|500 mg/m2 every 21 days for 4 cycles
41341635|NCT02224274|DRUG|Clopidogrel|
41341636|NCT02224274|DRUG|Ticagrelor|
41341637|NCT03756870|PROCEDURE|Percutaneous coronary intervention (PCI)|A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
41341638|NCT00058188|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
41341639|NCT00058188|DRUG|calcium gluconate|Given orally
41341640|NCT00058188|DRUG|zoledronic acid|Given IV
41341641|NCT04463238|COMBINATION_PRODUCT|Guided cartilage regeneration membrane|On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.
41341642|NCT04463238|PROCEDURE|Microfracture|Operate in accordance with the clinical microfracture surgery method.
41341643|NCT00862498|OTHER|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
41341644|NCT02283840|DRUG|BIA 2-093|
40822813|NCT01613989|PROCEDURE|Prosthetic hip surgery operated under navigation based on EOS imaging|The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
40822814|NCT05545995|OTHER|embryo selection|The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A
41488562|NCT01717586|DRUG|Placebo|Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
41488563|NCT05250466|PROCEDURE|Radiofrequency technology|The vulva and vagina were routinely disinfected with iodophor, the negative plate was placed on the patient's waist and abdomen, and the vulva module was selected for treatment for 10 minutes per side, for a total of 20 minutes. Parameters: power 10-20W, temperature 38-42C°, once every 10 days, 5 times in total
41488564|NCT05250466|PROCEDURE|Electrical stimulation|Routine vulvovaginal disinfection with iodophor, vaginal probes are placed in channel A, electrode pads are placed in channels B\\C\\D respectively, the frequency of electrical stimulation (the most comfortable amount) is adjusted, 10 times is a course of treatment, and mild lesions are treated for 1-2 courses of treatment , 2 to 3 courses of treatment for moderate to severe lesions.
41488565|NCT00699062|DRUG|singular|The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
41488566|NCT00699062|DRUG|placebo|The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
41488567|NCT01020136|DRUG|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
40822815|NCT01269359|PROCEDURE|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
40822816|NCT03784846|BEHAVIORAL|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
40822817|NCT03784846|BEHAVIORAL|Stress Management Education|SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
40822818|NCT04396769|BEHAVIORAL|FLOW-PA|Classes were designed to provide the opportunity to be physically activity at a moderate-vigorous level. Each station included exercise options to accommodate varying fitness levels and offer students choice. Heart rate monitors provided consistent biofeedback to students throughout the intervention. Participants were evaluated based on the number of minutes they spent each class between 60-80% of their maximal heart rate. Games were intermixed either as a station or as a break in the circuit (e.g. short game of tag half-way through the workout) to make physical activity enjoyable and engaging.
41488568|NCT01020136|DRUG|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
41488569|NCT01775969|OTHER|Text Message|A text message with instructions is sent to the patient
40822819|NCT04396769|BEHAVIORAL|PE class as usual|PE teachers were instructed to teach class as usual. Research staff were not involved in class activities or instruction. In this school district PE class as usual includes sports-based instruction in which students learn the rules to games and then practice playing.
40822820|NCT02100163|BEHAVIORAL|Virtual Reality Hypnosis|The patient receives virtual reality hypnosis daily.
40822821|NCT02100163|BEHAVIORAL|Audio Hypnosis|Patient will listen to an Audio Hypnosis recording daily.
40822822|NCT02100163|OTHER|Standard treatment|
40822823|NCT06556238|OTHER|Nicotine Metabolite Ratio|Blood specimens will be drawn, in clinic, by clinical staff trained in blood collection (e.g., certified medical assistant, nurse). Through regular clinic procedures, lab staff will ship for processing to Quest. Quest uses liquid chromatography tandem mass spectrometry with a limit of detection of 2ng/ml for all analytes and will quantify NMR within 3-6 days of sample arrival. Samples will be consumed during testing. Results of NMR will be returned to primary care providers, and NMR-informed medication recommendations will be made to participants.
40822824|NCT03876015|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
40822825|NCT04767178|DRUG|Ibuprofen (Sanofi, Istanbul, Turkey)|Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
40822826|NCT04767178|DRUG|Paracetamol (GlaxoSmithKline, Istanbul, Turkey)|Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
40822827|NCT03831880|DRUG|Genotropin|Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily
40822828|NCT03831880|DRUG|somatrogon|0.66 mg/kg/week given subcutaneously once weekly
40822829|NCT03424369|PROCEDURE|Tympanoplasty|Tympanoplasty
40822830|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZFR00|IOL replaces the natural lens removed during cataract surgery.
41017735|NCT00821691|DRUG|Placebo|Placebo caps
41488570|NCT01775969|OTHER|Voicemail|A voicemail with instructions is sent to the patient
41488571|NCT06309134|BEHAVIORAL|Healthy Families Bright Futures Program|Seven weekly online group sessions with separate sessions for teens and caregivers. Sessions focus on increasing knowledge and acceptance of LGBTQ+ identities, alcohol use and dating violence social norms correction, bystander intervention, assertive communication skills, social emotional skills, family problem solving, and parenting behaviors.
41488572|NCT01193127|DRUG|OMS302 Solution|
41341645|NCT02558452|DRUG|Tacrolimus once daily (Advagraf)|Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory
40822831|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZYR00|IOL replaces the natural lens removed during cataract surgery.
40822832|NCT03372434|DEVICE|TECNIS Multifocal Intraocular Lens: Model ZLB00|IOL replaces the natural lens removed during cataract surgery.
41488573|NCT01193127|DRUG|OMS302 Mydriatic Solution|
41488574|NCT01193127|DRUG|OMS302 Anti-inflammatory Solution|
41488575|NCT01193127|DRUG|Balanced Salt Solution (BSS) Solution|
41488576|NCT03465826|BEHAVIORAL|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
41488577|NCT03465826|BEHAVIORAL|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
41488578|NCT03769883|BEHAVIORAL|Exercise and diet|The participants will undergo diet or combined diet and exercise. The exercise will be provided at different volumes
40822833|NCT01352741|DRUG|Tapentadol Prolonged Release|100 - 500 mg per day orally twice daily for a maximum of 12 weeks
40822834|NCT01352741|DRUG|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
41488579|NCT03769883|BEHAVIORAL|Diet|Dietary intervention
41488580|NCT02077439|DEVICE|Hand Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
41488581|NCT02077439|DEVICE|Hand and Arm Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
41488582|NCT02077439|OTHER|Conventional therapy|Training for 20 sessions for one hour, 3-5 times per week.
40822835|NCT01352741|DRUG|Tapentadol Prolonged Release open label maintenance|100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
40822836|NCT03078790|DEVICE|iPad|a 10 minute electronic guided deep breathing module offered via an iPad
41341646|NCT00446641|DRUG|Cilostazol|cilostazol 100mg twice a day for 4 weeks
41017736|NCT02690246|OTHER|questionnaire|a questionnaire based study
41341647|NCT00446641|DRUG|placebo|placebo 1 tablet twice a day matching for cilostazol
41341648|NCT05187572|BEHAVIORAL|Group intervention|This intervention was developed during 14 sessions, held twice a week, with a duration of 45 to 60 minutes each. The sessions were developed as group-based interventions, facilitated by a leader and a co-leader from each community institution.
41341649|NCT05489133|BEHAVIORAL|Modified prolonged exposure|Imaginary and in vivo expo, in addition to psychoeducation
41341650|NCT02915692|DEVICE|ERASE Silver Coated Foley Catheter|Foley catheter from ERASE CAUTI Kit will be administered as required.
41341651|NCT02915692|DEVICE|Comparator Silver Coated Catheter|Foley catheter coated with silver
41341652|NCT03350802|DIAGNOSTIC_TEST|procalcitonin test|All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
41341653|NCT03745404|DRUG|Lidocaine 5% medicated Plaster|
41488583|NCT00554775|DRUG|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
41488584|NCT00554775|DRUG|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
40822837|NCT06605352|DIAGNOSTIC_TEST|The BIOFIRE®FILMARRAY® Pneumonia Panel|"The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes.~Using rapid diagnostic test to improve the proportion of antibiotics change, including escalation, de-escalation, discontinuation, or addition of antimicrobial medications in 24 hours within sample collection."
40822838|NCT05227560|OTHER|Complementary Therapies|The emotional freedom technique was applied to the experimental group.
40822839|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
40822840|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
40822841|NCT01310400|BIOLOGICAL|Agrippal|"Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
41341654|NCT03745404|DRUG|Placebo Plaster|
41488585|NCT03749629|OTHER|GeneSight Psychotropic test|GeneSight® Psychotropic powered by CPGx® technology, the only test for depression reimbursable by Medicaid and Medicare. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
40822842|NCT04151628|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent
40822843|NCT06464900|BEHAVIORAL|Routine Care|Provide patients with regular medication guidance, dietary guidance, exercise guidance and knowledge about diabetes mellitus and hypoglycaemia; test and record blood glucose regularly every day; answer patients' clinical questions and provide psychological support in a timely manner.
40822844|NCT06464900|BEHAVIORAL|Based on BCW Theory of Health Education|BCW theory was applied to analyse behaviour and develop interventions in terms of capability, motivation and opportunity. Capability: Intensive daily management of diabetes through intervention functions (education, training, persuasion, modelling) to change attitudes and habits, understand the negative consequences of fear of hypoglycaemia, improve hypoglycaemia awareness and self-regulation skills. Opportunity: Through the intervention function (education, training, realization) to improve the awareness of hypoglycemia awareness, timely detection of hypoglycemia. In the event of a hypoglycaemic event patients know how to deal with it. Motivation: Through intervention functions (environmental reconstruction, realisation) that take full account of external factors and their own opportunities. Glucose management through microsoft platforms, on-site teaching and coaching by specialist nurses to create opportunities for patients who can change excessive/avoidant behaviours.
41341655|NCT03338881|DRUG|[14C]-TAK-659|\[14C\]-TAK-659 solution.
41341656|NCT03338881|DRUG|TAK-659|TAK-659 tablets.
41341657|NCT00739960|DRUG|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
41488586|NCT03749629|OTHER|Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines|Guidelines for treatment
41488587|NCT05757323|OTHER|infant formula based on hydrolyzed protein|infant formula based on hydrolysed protein
40822845|NCT05951075|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm
40822846|NCT04038892|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
40822847|NCT04038892|OTHER|Nintendo Wii Fit Based Exercise Training|Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
40822848|NCT04038892|OTHER|BreathingLabs Breathing Games Based Exercise Training|BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
40822849|NCT05389475|PROCEDURE|anoplasty in treatment of post hemorroidectomy anal stenosis|Diamond flap versus V-Y flap
40822850|NCT05660902|OTHER|ROM Exercises|The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
40822851|NCT02023801|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
40822852|NCT04174989|OTHER|Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)|ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.
40822853|NCT04174989|OTHER|Regular fresh-frozen plasma (not treated)|Regular fresh-frozen plasma (not treated)
40822854|NCT04465435|OTHER|Web-based self-report questionnaires|Web-based self-report questionnaires based on well established instruments.
41341658|NCT02564068|DRUG|Oxytocin|"To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment."
41341659|NCT03676205|BIOLOGICAL|PRP|Platelet-Rich Plasma
40822855|NCT04465435|OTHER|Focus Group Interviews|Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
40822856|NCT02180256|PROCEDURE|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
40822857|NCT02524015|OTHER|Novel physical therapy|
40822858|NCT02524015|OTHER|Standard physical therapy|
40822859|NCT05151640|DRUG|Nintedanib|Nintedanib
40822860|NCT01686750|BEHAVIORAL|Integrated care centers|
41341660|NCT03676205|OTHER|Traumeel|Homeophatic Treatment
41341661|NCT06352437|DRUG|BI 3034701|BI 3034701
41341662|NCT06352437|DRUG|Placebo matching BI 3034701|Placebo matching BI 3034701
41341816|NCT04085692|BEHAVIORAL|Low-Dose, High-Frequency Simulation-Based Training|"Twelve weeks of LDHF training~The simulation-based training sessions take place at the EMDC, at extra workstations set-up as ordinary EMD workstations in an out-of-the-way area. Before each session, the EMD is informed about the simulation call and receives instructions concerning technical differences from a regular call. The instructor acts as a standardised caller, guided by a computer program. This program, the Danish version of Resuscitation Quality Improvement for Telecommunicators (Laerdal Medical AS, Stavanger, Norway), is a training program for DA-CPR based on the simulation platform Laerdal Learning Application. This modified version of the RQI-T program has, one test scenario, one data collection scenario and six different cardiac arrests scenarios as well as a feedback checklist based on the Danish dispatcher protocol Danish Index for Emergency Care.~Each simulation session takes approximately 20 minutes, including introduction and feedback"
41341817|NCT01537289|DEVICE|Pigtail catheter insertion (Cook)|insertion of pigtail catheter to decompress pneumothorax
41341818|NCT01537289|DEVICE|chest tube (28-French)|inserting chest tube to decompress pneumothorax
41341819|NCT00195624|BIOLOGICAL|Alemtuzumab (Campath )|Campath administered at a dose of 10/mg/day for 10 days
41341820|NCT00195624|DRUG|Cyclosporine|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
40823076|NCT04679922|PROCEDURE|Soft Tissue Enhancement around dental implant|Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants \*. Group II (Experimental Group): FLA \*\*+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
40823077|NCT05906758|PROCEDURE|Angiography|Coronary angiography with less than 20cc of contrast materials
41341821|NCT03891615|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells through deadly DNA damage."
41341822|NCT03891615|DRUG|Osimertinib|Osimertinib blocks mutated EGFR, which may cause tumor regression (when the tumor starts to shrink) and prevent the spread of the cancer.
41341823|NCT03723408|DEVICE|ClearLine IV (formerly, AirPurge)|Patient safety device that automatically and continuously detects and actively removes air from IV lines - protecting patients from dangerous air burden, air embolism, air infusions.
41341824|NCT03111589|BIOLOGICAL|Inactivated influenza A (H1N1) virus vaccine|All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
41341825|NCT03111589|DIAGNOSTIC_TEST|Blood sampling|Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
41341826|NCT05528562|OTHER|PrEP Rapid Access|'Rapid PrEP Access' is a low-threshold intervention designed to provide on-site access to HIV self-testing at the Victory Program for persons who use opioids.
41341827|NCT05528562|OTHER|HIV self-testing|After enrollment the research assistant (RA) will provide the participant with a HIV self-test and provide instructions on how to obtain a proper sample for the test. It uses an oral fluid test and yields results within 20 minutes.
41341828|NCT05528562|OTHER|Dried blood spot testing|HIV Dried blood spot (DBS) testing provides an accurate method of measuring the HIV viral load in comparison to plasma viral load.
40823078|NCT02417116|OTHER|Tear supplement|Application as required to improve comfort
40823079|NCT02417116|OTHER|Tear supplement 2|Application as required to improve comfort
40823080|NCT02417116|DIETARY_SUPPLEMENT|Omega 3 nutrition supplement|Taken each day
40823081|NCT02417116|DEVICE|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
41341829|NCT00486889|BIOLOGICAL|alglucosidase alfa|Dose: 20 mg/kg every 2 weeks; Route of administration: Intravenous infusion
41341830|NCT03134469|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement
41341831|NCT03134469|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement
41341832|NCT03526341|DEVICE|ReliaTack™ Articulating Reloadable Fixation Device|ReliaTack™ Articulating Reloadable Fixation Device with Deep Purchase Tacks
41341833|NCT01603979|BIOLOGICAL|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
41341834|NCT02282891|DRUG|Propofol|Induction of general anesthesia using propofol 2mg/kg
41341835|NCT02282891|DRUG|Propofol-Ketamine|Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
41341836|NCT05228080|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay(ELISA)|Peripheral blood samples will be drawn from each patient at study entry (before reperfusion therapy) and at 12,24 hours after reperfusion therapy.Serum will be immediately separated by centrifugation at 3000 rpm for 15 minutes and stored at -80°C. Endocan,ICAM-1,VCAM-1,MMP-9 levels will be determined in duplicate by commercially available enzyme-linked immunosorbent assay (ELISA).
41341837|NCT04319640|BEHAVIORAL|Cognitive behaviour therapy for insomnia|CBT-I for children with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 5 weekly modules.
41341838|NCT04319640|BEHAVIORAL|psychoeducation for ASD|psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
41341839|NCT06350149|OTHER|Sugar Sweetened Beverages (SSB)|The following are considered SSBs: non-diet soft drinks/sodas, flavored juice drinks, sweetened tea, energy drinks, and electrolyte replacement drinks.
41341840|NCT06350149|OTHER|Hi GI|The Glycemic Index of the high-GI meals will be at least 75
41341841|NCT06350149|OTHER|Lo GI|The Glycemic Index of the low- -GI meals will not be higher than 55.
41341842|NCT01492816|BEHAVIORAL|Community Mobilization|The proposed study seeks to continue C2P community mobilization efforts that have developed coalitions that plan for and bring about structural changes for purposes of reducing Human Immunodeficiency Virus (HIV) incidence and prevalence among youth in targeted communities at nine sites. Earlier phases of C2P have been outlined in ATN Protocols 016a, 016b, 040/040b. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action (accomplished in an earlier phase of C2P); coalitions establishing a shared vision and mission; development of a strategic plan focused on structural changes to reduce risks associated with HIV; process documentation; and feedback as technical assistance to the coalitions.
41341843|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1|"25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.~The dose decisions are at the discretion of the investigator."
41341844|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2|"12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.~\>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.~The dose decisions are at the discretion of the investigator."
41341845|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3|"15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.~The dose decisions are at the discretion of the investigator."
41341846|NCT04761952|DRUG|azathioprine|daily orally
41341847|NCT04761952|DRUG|infliximab|intravenously, at 0, 2,6 weeks with every 8-week-interval later
41341848|NCT04761952|DRUG|N-3 Polyunsaturated Fatty Acids|Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E\&DHA-E; per capsule one at a time, Three times a day.
41341849|NCT01063504|DRUG|teriparatide|
40823082|NCT02417116|OTHER|Saline|Application as required to improve comfort
41341850|NCT05330624|BIOLOGICAL|plague vaccine(F1+rV)|plague vaccine(F1+rV) (Lanzhou Institute of Biological Products Co.,Ltd) of 1.0ml, three doses
41341851|NCT03531606|DRUG|Mechnicov probiotics|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
41508981|NCT03277066|DRUG|Diclofenac Sodium Active Topical Patch 1|HP-5000 Active Topical Patch 1 were applied on subjects with Osteoarthritis of the knee(s)
40823083|NCT05402176|OTHER|Whole Lung Lavage|Whole Lung Lavage (WLL) is performed as standard of care. Outcome following WLL is observed.
41341852|NCT03531606|DRUG|Placebo|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
41341853|NCT03015623|BIOLOGICAL|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
41341854|NCT03015623|DEVICE|Sham|The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
41341855|NCT01405027|PROCEDURE|Educational Intervention|Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
41341856|NCT01405027|OTHER|Patient education and management skills training|Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
41341857|NCT03903913|DRUG|S-1226|The drug product S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) nebulized with a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8% or 12% CO2.
41341858|NCT02111070|BIOLOGICAL|IL-YANG FLU Vaccine|0.5mL
41341859|NCT04746781|BEHAVIORAL|Mobile 360° Video intervention|Using 360° Videos to educate participants about the effect of diabetes.
41341860|NCT04746781|BEHAVIORAL|Motivation and Problem Solving (MAPS)|Using Motivation and Problem Solving to help people enroll in the Diabetes Prevention Program.
41341861|NCT04746781|BEHAVIORAL|Risk notification/education|Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.
41341862|NCT01712490|DRUG|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
41341863|NCT01712490|DRUG|doxorubicin|Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
41341864|NCT01712490|DRUG|bleomycin|Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
40823084|NCT00461864|PROCEDURE|ultrasound examination of the hip|
41341865|NCT01712490|DRUG|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
41341866|NCT01712490|DRUG|dacarbazine|Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
41341867|NCT05462899|OTHER|Purpose in life, goals, and expectations|There is no intervention. This is a cross-sectional study.
40823085|NCT06266949|DIAGNOSTIC_TEST|SONDA|Perimetry based visualfield analysis
40823086|NCT00881998|PROCEDURE|Minimally Invasive Total Hip Arthroplasty|
40823087|NCT00881998|PROCEDURE|Conventional Total Hip Arthroplasty|
40823088|NCT03788018|DRUG|lidocaine and dexmedetomidine IV|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
40823089|NCT03788018|DRUG|saline IV|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
41341868|NCT04677023|OTHER|GrandioSO x-tra® bulk|The prepared cavities will be restored with GrandioSO X-tra (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using using Elipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
41341869|NCT04677023|OTHER|Admira fusion X--tra® bulk|he prepared cavities will be restored with Admira fusion X-tra®️ bulk (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using usingElipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
41341870|NCT02762123|DRUG|BMS-986142 200mg|
41341871|NCT02762123|DRUG|BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)|
41341872|NCT02762123|DRUG|BMS-986142 350mg|
41341873|NCT04173403|DRUG|450mg AK102|AK102 Q4W
41341874|NCT04173403|DRUG|300mg AK102|AK102 Q4W
41341875|NCT04173403|DRUG|150mg AK102|AK102 Q2W
41341876|NCT04173403|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
41508982|NCT03277066|DRUG|Diclofenac Sodium Active Topical Patch 2|HP-5000 Active Topical Patch 2 were applied on subjects with Osteoarthritis of the knee(s)
41341877|NCT01173822|OTHER|Ultrafiltration of residual blood|The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
41341878|NCT02616536|OTHER|Teaching methods|the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
41341879|NCT00673218|DRUG|Placebo|Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
41341880|NCT00673218|DRUG|Xolair|150 to 375 mg is administered SC every 2 or 4 weeks
41341881|NCT03017833|OTHER|Laboratory Biomarker Analysis|Correlative studies
41341882|NCT03017833|DRUG|Metformin|Given PO
41341883|NCT03017833|OTHER|Pharmacological Study|Ancillary studies
41341884|NCT03017833|DRUG|Sapanisertib|Given PO
41341885|NCT02428075|BEHAVIORAL|FCHV visit|Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
41341886|NCT03923504|OTHER|Physical Activity Intervention (PAI)|Those who opt-in to attend in-person study visits and to undergo COVID testing will also complete an MRI exam and CPET testing. Participants unwilling to have COVID testing done will only complete an MRI exam and home-based testing. All testing will take place either within 6 weeks of initiating systemic treatments or within 8 weeks of completing radiation then at 3 \& 6 months. Patients may participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training,15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down. Participants will have the ability to participate in training sessions facilitated via online channels at home.
41341887|NCT03923504|OTHER|Healthy Living Control|Patients randomized to the control arm will either attend online sessions via secure video conferencing (e.g. Zoom) or telephone or to come to a centralized meeting location (if safety allows) to participate in organized health workshops. Session attendance will be required 2 times/month (over the 6 months). Make up sessions will be offered for those participants who have to miss a group session. Each session lasts 60 minutes and matches the number of visits made by the PAI group as much as possible.
41341888|NCT03842501|DIETARY_SUPPLEMENT|Release Supplement|Calorie reduced diet plus Release supplement
41341889|NCT03842501|DIETARY_SUPPLEMENT|Placebo|Calorie reduced diet plus Placebo
41341890|NCT03024229|DEVICE|LifePort® perfusion machine|Renal perfusion on LifePort® machine
41341891|NCT00033449|DRUG|gefitinib|Given orally
40823090|NCT06321419|BEHAVIORAL|Advanced Trauma Life Support training|Advanced Trauma Life Support (ATLS) is a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. The programme was developed by the Committee of Trauma of the American College of Surgeons. The course includes intial treatment and resuscitation, triage and interfacility transfers. Leaning is based on practical scenario-driven skill stations, lectures and includes a final performance proficiency evaluation. Physicians will be trained in an accredited ATLS training facility in India.
41341892|NCT00033449|RADIATION|radiation therapy|Undergo radiation therapy
41341893|NCT00033449|DRUG|cisplatin|Given IV
41341894|NCT00033449|OTHER|laboratory biomarker analysis|Correlative studies
41341895|NCT01894334|DRUG|Ulinastatin|
41341896|NCT01894334|DRUG|Tranexamic acid|
41341897|NCT01894334|DRUG|Edaravone|
41341898|NCT05392049|OTHER|Bowen's therapy|Bowens technique will be apply on patients of TMJ for 2 repetitions in 1 set, 4 sets in each session for 4 weeks.
41341899|NCT05392049|OTHER|Post isometric relaxation|post isometric relaxation technique and jaw exercises (strengthen the weakened muscles, stretch the shortened muscles) with dosage 5 times/session, 5 sec rest and 2times/week for 4 weeks will apply on patients.
41341900|NCT03616249|OTHER|Sleep|Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
41508983|NCT03277066|DRUG|Placebo patch|Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
41508984|NCT04143243|BEHAVIORAL|ACT on Life|1 day group workshop of ACT plus ERS
41508985|NCT04143243|BEHAVIORAL|Education, Resources, and Support|1 day group workshop of Education, Resources, and Support
41341901|NCT03616249|OTHER|Resistance Exercise|After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.
41341902|NCT01822249|DRUG|EPI-743|
41341903|NCT01822249|DRUG|Placebo|
41341904|NCT04737161|BIOLOGICAL|T regulatory cells|T regulatory cells isolated by immunomagnetic selection; donor cells collected through large volume apheresis.
41341905|NCT05748236|DRUG|Lamotrigine tablet|Lamotrigine: Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day).
41341906|NCT05748236|DRUG|Carbamazepine-Containing Product in Oral Dose Form|Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day).
40853020|NCT06003153|OTHER|Mixed Meal Tolerance Test (MMTT)|The MMTT is developed by the Metabolism and Nutrition Metabolic Kitchen at the MGH TCRC. The meal is a high-calorie, high-carbohydrate and moderate-to-high glycemic index challenge composed of commonly consumed breakfast food items. It provides nearly 90 grams of carbohydrates and mimics an oral glucose challenge. The participants will undergo a MMTT at Visit 1 and Visit 2.
40853021|NCT01161537|DRUG|VX-770|Tablet.
41341907|NCT02622048|BEHAVIORAL|Triple P Positive Parenting Programme|10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
41341908|NCT04223206|DIETARY_SUPPLEMENT|NATURLENS|Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
41341909|NCT01424319|DRUG|Atrasentan low dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
41341910|NCT01424319|DRUG|Atrasentan high dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
41341911|NCT01424319|DRUG|Atrasentan placebo group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
41341912|NCT01611311|DRUG|BI 409306|Film-coated tablet
41341913|NCT01611311|DRUG|Placebo|Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
41341914|NCT04929691|DEVICE|CPAP helmet|helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation
41341915|NCT04929691|OTHER|Standard of care non-helmet based CPAP ventilation|Standard of care ventilation without helmet-based CPAP
41341916|NCT03139435|PROCEDURE|Biopsy|Undergo skin biopsy
41341917|NCT03139435|OTHER|Questionnaire Administration|Ancillary studies
41341918|NCT03139435|DIAGNOSTIC_TEST|Ultrasound Tomography|Undergo peripheral nerve ultrasound
41341919|NCT00223652|BEHAVIORAL|Telephone cognitive behavioral therapy|An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
40853022|NCT01161537|DRUG|Placebo|Tablet.
41341920|NCT05778357|OTHER|Group1|75 healthy infants were included. Neuromotor development was evaluated with the Denver II Developmental Screening Test and Alberta Infant motor scale.
41341921|NCT00498641|PROCEDURE|computer program and patching|
40823091|NCT04979897|OTHER|Intensive care unit stay during the COVID-19 pandemic|Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open \[close\] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
40823092|NCT05777122|DRUG|lignocaine gel|pharmacological ,topical anesthetic gel
40823093|NCT05777122|OTHER|sugar free chewing gum|non pharmacological
40823094|NCT06606067|DRUG|Duloxetine|30 mg daily 2 weeks before surgery and 1 week after surgery
40823095|NCT06606067|DRUG|Placebo|Placebo tablet daily
40853023|NCT01441323|BEHAVIORAL|Nutrition|Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
41341922|NCT05241288|COMBINATION_PRODUCT|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices:~Device 1: Albuterol eMDPI Device 2: Albuterol eMDPI Patient-facing smart device application (App) Device 3: Digital Health Platform (DHP, Cloud solution)"
41341923|NCT00724646|OTHER|Survey|3 individual surveys
41341924|NCT00724646|OTHER|Focus group|Focus group discussions facilitated by a psychologist
41341925|NCT02470429|DEVICE|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
41341926|NCT02470429|DEVICE|Hyabak 0.15% eye drops|Preservative-free
41341927|NCT02470429|DRUG|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
41341928|NCT02482649|BEHAVIORAL|EAA/T|bi-weekly for 12weeks
41341929|NCT02482649|DRUG|Methylphenidate|dosage adjustment according to clinical effectiveness, QD for 12weeks
41341930|NCT02482649|DRUG|Atomoxetine|dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
41341931|NCT05440344|DRUG|Imlunestrant|Administered orally.
41341932|NCT04568876|DIETARY_SUPPLEMENT|Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
41341933|NCT04568876|COMBINATION_PRODUCT|Standard Therapy|Standard therapy established for individual patients
41341934|NCT05342142|BEHAVIORAL|Aerobic and ResistanceExercise|Exercise program consisting of 12 weeks of aerobic and resistance exercises
41488682|NCT04040153|BEHAVIORAL|Guiding Good Choices|Guiding Good Choices is a 5-session group-based prevention program for parents of early adolescents. Weekly 2.5 hour sessions will be held at participants' primary care clinics and led by two trained interventionists. Through didactic material, video segments, interactive activities, and home practice, the curriculum teaches parents to understand the progression from individual and environmental risk and protective factors to substance use and problem behavior, enhances parenting behaviors and skills, teaches effective family management skills, strengthens parent-adolescent interactions and bonding, broadens opportunities for family involvement, teaches conflict reduction and anger management skills, and teaches adolescents skills to resist peer influences to engage in risky behavior. Parents who opt not to attend groups will be offered a self-guided intervention manual containing the same core content and video access, plus supportive coaching to motivate use and address questions.
40823096|NCT06240741|DRUG|[68Ga]Ga-DOTA-TATE|Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1).
41341935|NCT04781049|PROCEDURE|Trans-Perineal Laser Ablation of Prostate|"TPLA treatment will be performed using the EchoLaser EVO system (Elesta SpA - Calenzano, FI, Italy). EchoLaser EVO consists of four echolasers, a multi-source laser system with a wavelength of 1064nm and Echolaser Smart Interface (ESI), a treatment planning device for safely inserting introductor needles and optical fibers into prostate tissue. EchoLaser therapy is a micro-invasive percutaneous procedure that uses laser light transmitted through applicators (optical fibers) for a few minutes, causing a heating of the affected tissue to its irreversible damage in situ, without the need to remove it. EchoLaser therapy, through flat-tip fibers, produces an ellipsoidal clotting area (area where the tissue has irreversible damage). EchoLaser therapy will be performed under ultrasound guidance."
41341936|NCT04781049|PROCEDURE|Trans-Urethral Resection of Prostate|TURP is the gold standard for the treatment of benign prostatic obstruction. It will be performed by using a bipolar energy resectoscope. The procedure will be carried out with patient in a lithotomic position.
40823097|NCT06240741|DRUG|68Ge/68Ga Generator|Radionuclide generator
41341937|NCT05179057|DRUG|Posoleucel|Administered as 2-4 milliliter infusion, visually identical to placebo
41341938|NCT05179057|DRUG|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel
41341939|NCT01407406|DRUG|BIIB023 - low dose IV Dose|
41341940|NCT01407406|DRUG|BIIB023 - high dose IV Dose|
41341941|NCT05882123|OTHER|cerebral microbleeds|Whether patients with acute ischemic stroke are complicated by cerebral microbleeds
41341942|NCT06086236|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.
41341943|NCT00533351|DRUG|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
41341944|NCT00533351|DRUG|placebo|placebo 50 mg capsules three-times daily for 2 weeks
41341945|NCT00250068|DRUG|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
41341946|NCT01603706|PROCEDURE|Echo guided implantation group|Lead placement according echo strain imaging result
41341947|NCT03480646|DRUG|CPI-1205|Administered orally
41341948|NCT03480646|DRUG|Enzalutamide|Administered orally
40823098|NCT04060381|DRUG|Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine|Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
40823099|NCT01748136|DEVICE|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
40823100|NCT02181478|DRUG|cyclophosphamide|All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
40823101|NCT02181478|DRUG|fludarabine phosphate|Given by IV during prep at 40mg/m2 for 5 days
40823102|NCT02181478|RADIATION|total-body irradiation|Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
40823103|NCT02181478|DRUG|cyclosporine|Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
40823104|NCT02181478|DRUG|mycophenolate mofetil|Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
40823105|NCT02181478|PROCEDURE|umbilical cord blood transplantation|Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
40823106|NCT02181478|PROCEDURE|mesenchymal stem cell transplantation|The total dosage of hMSC will be 2x10\^6cells/kg (+/-20%).
40823107|NCT04088435|RADIATION|Intraoperative radiotherapy|The IORT component of this treatment is being delivered as per standard clinical practice. 20 Gy in one fraction will be delivered at the time of lumpectomy.
40823108|NCT01727648|BEHAVIORAL|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
40823109|NCT01727648|BEHAVIORAL|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
40823110|NCT01727648|BEHAVIORAL|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
40823111|NCT01727648|BEHAVIORAL|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
40823112|NCT02721121|PROCEDURE|circumferential pulmonary vein isolation|
41157213|NCT00788879|BEHAVIORAL|TSSC Randomized Behavioral Intervention for weight loss|"We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).~Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes."
40823113|NCT02721121|PROCEDURE|Linear ablation in addiction to circumferential pulmonary vein isolation|
40823114|NCT03511508|BEHAVIORAL|ChroPreg + standard care|"* Ongoing update of individual maternity care plan.~* Extra consultation with the specialized midwife at 20-24 weeks of pregnancy about psychological well-being during pregnancy.~* Extra consultation with the specialized midwife at 30-33 weeks of pregnancy about individual birth preparation, breastfeeding and post-partum care.~* Possibility for psychologist consultation.~* Post-partum: Telephone follow-up by the specialized midwife 1 and 2 weeks after discharge.~* Postnatal follow-up: 4-6 weeks after delivery: conversation with specialized midwife about the pregnancy and birth."
41341949|NCT03480646|DRUG|Abiraterone/Prednisone|Administered orally
41488683|NCT03595085|PROCEDURE|catheter directed fragmentation and thrombolysis|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery. After ensuring initial flow, Initial bolus dose of streptokinase (250.000 international unit) will be given over 10 min followed by continuous infusion of (100.000 international unit per hour)for 24 hours
41488684|NCT03595085|DRUG|Streptokinase|intravenous streptokinase at a dose of 250 000 international unit as a loading dose over 30 minutes, followed by 100 000 international unit per hour over 12-24 hours
41488685|NCT05444686|DIAGNOSTIC_TEST|99mTc-FAPI|inject the tracer to subjects and perform SPECT/CT scans
41488686|NCT04009538|OTHER|Rehabilitation program|exercise program twice a week
41488687|NCT02575911|DEVICE|Femtosecond Laser System|Used for the creation of a corneal flap in patients undergoing LASIK surgery
40823115|NCT01167010|DRUG|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
40823116|NCT01167010|DRUG|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
40823117|NCT01167010|DRUG|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
41341950|NCT01763632|DEVICE|Transcutaneous bilirubinometry|Device: JM-103 (Minolta, Osaka, Japan, jaundice assessment) Procedure: Transcutaneous bilirubinometry (TcB)
41488688|NCT02575911|PROCEDURE|LASIK surgery|
40823118|NCT05132998|OTHER|Cardiac Rehabilitation Program|In addition to standard medical care, for an 8-week period, patients will have access to the core components of a CRP, delivered by a multidisciplinary rehabilitation team
41488689|NCT02721693|DEVICE|Treadmill exercise test|Patients are subjected to an incremental exercise test to exhaustion on a treadmill
40823119|NCT05132998|OTHER|Community exercise intervention|In addition to standard medical care, for an 8-week period, patients will have access to a community exercise intervention oriented by a sports professional
41488690|NCT01262742|DRUG|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
41488691|NCT01262742|DRUG|Carbetocin|90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
41488692|NCT01262742|DRUG|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
41488693|NCT01262742|DRUG|Carbetocin|110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
41341951|NCT00108615|DRUG|Metformin|
41488694|NCT01262742|DRUG|Carbetocin|120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
40823120|NCT05149040|OTHER|"survey Intensive care of very elderly: What do they wish for themselves?"|self-administered mailed survey
40823121|NCT01510015|DRUG|Risperidone|variable dose
40823122|NCT06105216|OTHER|Crossword and word search puzzles|Students in the intervention group received hard copies of the puzzles at the end of the laboratory practice.
41488695|NCT04942158|PROCEDURE|Non-instrumentation technique with use of CTZ paste|After local anesthesia and rubber dam isolation, the pulp chamber will be accessed. After the location of root canals entrance, an initial irrigation will be conducted using 1% sodium hypochlorite. Then, a paste containing two antibiotics (chloramphenicol and tetracycline) and zinc oxide and eugenol (CTZ paste) will be placed in the pulp chamber floor, into the root canal entrances. Then, a layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
41488696|NCT04942158|PROCEDURE|Instrumentation technique and filling with Zinc Oxide and Eugenol paste|After anesthesia and rubber dam isolation, pulp chamber will be accessed with burs, and the root canals entrance will be prepared using a Gates Glidden bur. The root canal length determination will be done subtracting 1 mm from the radiographic measurements performed on the different roots. The instrumentation will be performed with 21mm stainless steel endodontic hand K-files, with International Organization for Standardization (ISO) tip ranging from #08 to #35. Irrigation will be performed using 1% sodium hypochlorite. After the last file, a final irrigation will be conducted with ethylenediaminetetraacetic acid and tegentol (EDTA-T) and 0.9% sodium chloride solution, and the root canals will be dried with paper points. Then, the root canals will be filled with a Zinc Oxide and Eugenol paste (ZOE paste), inserted into the root canals with a lentulo spiral. A layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
40823123|NCT04374591|DRUG|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
40823124|NCT06606730|DRUG|Pembrolizumab|Administration of pembrolizumab for 6 months
40823125|NCT06606730|OTHER|Deescalation|Patients will be followed up according to standard practice for 4 years
40823126|NCT00130143|DRUG|Ethyol (Amifostine)|
40823127|NCT02839226|DRUG|AR/101|
41488697|NCT01713049|DRUG|18F-FLT|0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
41488698|NCT00605761|DRUG|SB656933|50 mg treatment
40823128|NCT02839226|DRUG|Placebo|
40823129|NCT02049827|OTHER|participation in the study|
40823130|NCT05192018|PROCEDURE|Early reversal of a defunctiong ileostomy|Early reversal of a defunctiong ileostomy after 3 weeks of its creation
40823131|NCT05720364|DRUG|TP-05 (lotilaner oral), fasted group|TP-05 (lotilaner oral), fasted group
41341952|NCT00108615|DRUG|Pioglitazone|
41341953|NCT00108615|DRUG|Metformin|
41341954|NCT00108615|DRUG|Pioglitazone|
41341955|NCT00108615|RADIATION|CT scans|To measure changes in adipose tissue volumes
41341956|NCT00108615|PROCEDURE|Oral glucose tolerance test|To detect a change in glucose tolerance
41341957|NCT00398125|DRUG|GSK364735|
41341958|NCT04594668|DRUG|Senicapoc|The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
41341959|NCT05480241|DRUG|Pancreatic Enzyme Replacement Therapy|Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
40823132|NCT05720364|DRUG|TP-05 (lotilaner oral), high-fat group|TP-05 (lotilaner oral), high-fat group
40823133|NCT05720364|DRUG|TP-05 (lotilaner oral), low-fat group|TP-05 (lotilaner oral), low-fat group
40823134|NCT03834506|BIOLOGICAL|Pembrolizumab|IV infusion
40823135|NCT03834506|DRUG|Docetaxel|IV infusion
40823136|NCT03834506|DRUG|Prednisone|Oral tablets
40823137|NCT03834506|DRUG|Placebo|IV infusion
41341960|NCT05480241|DRUG|Placebo|Placebo + Omeprazole 20mg once daily on fasting
41488699|NCT00605761|DRUG|SB656933|150 mg treatment
40823138|NCT03834506|DRUG|Dexamethasone|Oral tablets
40823139|NCT05894538|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
40823140|NCT05894538|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
40823141|NCT01084278|DRUG|Colchicine|Colchicine tablets
40823142|NCT00883012|BIOLOGICAL|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:~Active substance:~Split Influenza virus\*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms\*\*, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms\*\*, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms\*\* Two doses, one month apart"
40823143|NCT00883012|BIOLOGICAL|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
40823144|NCT02240823|OTHER|adipose derived stem cells|
40823145|NCT00976378|DRUG|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
40823146|NCT00976378|DRUG|NOX-A12|single IV dose, at efficacious dose level
40823147|NCT04301479|DRUG|hydrocortisone sodium succinate|Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
40823148|NCT04301479|DRUG|Saline|Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
40823149|NCT05596487|OTHER|repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students. In data collection, an end-of-life care nursing questionnaire, Frommelt attitude scale, positive-negative affect scale, and modified simulation effectiveness tool were used.
41341961|NCT05634876|BIOLOGICAL|UB-312 Injection|UB-312, provided by Vaxxinity, contains 300 μg of p4573kb Drug Substance (synthetic peptide immunogen) formulated with CpG1 and Adju-Phos as a white, opaque, liquid suspension. The biological will be injected intramuscularly. The injection site will be the deltoid muscle.
41341962|NCT05634876|BIOLOGICAL|Placebo Injection|Placebo will be injected intramuscularly. The injection site will be the deltoid muscle.
41341963|NCT01736163|DRUG|Thyrogen|0.9 mg IM, administrated for 2 consecutive days
41341964|NCT01736163|DRUG|131I|28 mCi or ≥ 1.036 GBq.
41341965|NCT01736163|OTHER|Thyroid Hormone Withdrawal|Stop taking hormone therapy
41488700|NCT04333108|DRUG|Masitinib|Masitinib 6 mg/kg/day
41488701|NCT04333108|OTHER|Placebo|Matching placebo
41341966|NCT03035422|DRUG|Sequential Packaging (SET)|"Sequential chemotherapy:~* Thiotepa 5 mg / kg / day for 1 day (D-13)~* Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)~* Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)~* Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)~* Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)~* Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)"
41341967|NCT03035422|DRUG|Transfusion graft|Graft of peripheral stem cells is preferred at D0
41341968|NCT03035422|DRUG|Prevention of GVHD|"* Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5~* Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)~* Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)"
41488702|NCT04333108|OTHER|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.
41488703|NCT05865080|DRUG|Ketamine|0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution before spinal anesthesia
40823150|NCT06536205|BEHAVIORAL|psychoeducation|Psychoeducation, psychological difficulties or physical diseases; These are structured educational interventions aimed at teaching people about their illness and their emotional responses to the illness, developing coping skills, ensuring compliance with the illness and cooperation with treatment.
40823151|NCT05618886|OTHER|Education|The education about urinary incontinence, PFM and PFMT together with lifestyle behavior modifications such as using the knack, maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure will be provided along with the PFMT instruction.
40853024|NCT01441323|BEHAVIORAL|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
40853025|NCT05482841|DIAGNOSTIC_TEST|Lung ultrasound score|To evaluate the incidence of pulmonary atelectasis in the post-anesthesia care unit (PACU) using lung ultrasound.
41341969|NCT03035422|DRUG|Care supports|According to the protocols of each center
41341970|NCT03035422|DRUG|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II"
41488704|NCT05865080|DRUG|Placebo|Normal saline
41488705|NCT02963870|OTHER|Security Plan|This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
41488706|NCT02138292|DRUG|Trametinib (2mg)/Digoxin (.25mg)|"1. Trametinib (2mg) will be administered orally on a daily basis.~2. Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks."
41488707|NCT04842565|DRUG|Sintilimab|Sintilimab (200mg ivdrip D1 Q3W)
41488708|NCT04842565|DEVICE|TACE|TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.
40853026|NCT02227199|DRUG|Brentuximab Vedotin|Given IV
41341971|NCT04453605|OTHER|standard treatments|patients were treated according to the good clinical practice recommended by the international guidelines, and followed a six-month or an yearly calendar of follow-up visits
41341972|NCT06039150|PROCEDURE|M-TAPA Block|M-TAPA Block; The block will be done by the same experienced anesthesiologist by using ultrasound(USG) after the surgical intervention is completed.The external oblique, internal oblique, and transversus abdominis muscles were shown on the costochondral angle in the sagittal plane at the 10th costal margin by using a high-frequency linear probe. Bilaterally in the midclavicular line at the level of the 10th rib (arcus costarum),0,5 ml/kg 0.25% Bupivacaine (maximum dose 2mg/kg) was administered to between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue.
41341973|NCT06039150|PROCEDURE|Local anesthetic infltration to port sites|Local anesthetic infiltration to port sites; The surgeon infiltrated 0.5 ml/kg of 0.25% Bupivacaine (maximum dose of 2mg/kg) in the skin, subcutaneous tissue, and muscle fascia at each of the three laparoscopic port areas at the end of the surgery.
41036498|NCT05300308|OTHER|usual care|The information about lymphoedema and its prevention is given during the hospital stay by the physical therapist of the department of urology. Skincare consists of daily skin moisturizer of feet and legs and prevention and care of wounds. Active exercises are performed to gain endurance and muscle strength after surgery and to stimulate the blood and lymph circulation. The exercises are supervised by the home physical therapist. Frequency of the supervised exercises is gradually decreased. If a patient develops lymphoedema, he/she receives compression stockings.
41341974|NCT01023373|DRUG|Medical treatment|hypotensive drugs, statins and anti-platelets
41341975|NCT01023373|PROCEDURE|PTRS|Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS
41488709|NCT01763749|DRUG|Closone|Closone 75mg/100mg, 4weeks, PO
41488710|NCT01763749|DRUG|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
40823152|NCT05618886|OTHER|Education and PFMT|Along with education twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant's will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participant's will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary.
40823153|NCT02072135|DRUG|Exparel|
40823154|NCT04416529|BEHAVIORAL|Tele-MBCT|Please see arm/group description.
40823155|NCT05735366|DRUG|SAIL66|SAIL66 as a IV infusion
40823156|NCT05679544|BIOLOGICAL|Characterization of early biological effects following exposure to PAHs|Biological samples collected in period of exposure and after holidays
40823157|NCT05662904|BIOLOGICAL|Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion|CD33-deleted CD34+ hematopoietic stem cells derived from the initially matched family donor
40823158|NCT05662904|DRUG|Gemtuzumab Ozogamicin|Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
40823159|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
41341976|NCT01023373|DEVICE|renal artery stent|Non-drug intervention, percutaneous transluminal renal artery stent angioplasty
41341977|NCT01023373|DEVICE|renal artery stent|Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
41341978|NCT02924272|DRUG|Ixazomib|Ixazomib Capsules
41341979|NCT04414488|PROCEDURE|Thoracic paravertebral block (ThPVB)|Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process. A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura. An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA). The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification). Plain bupivacaine (0.3 ml\*kg-1) was then injected after a negative aspiration test for air or blood. The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer. Testing was symmetrical on both sides of thorax. A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
41488711|NCT03058419|DRUG|JNJ-54175446 150 mg|Subjects will receive JNJ-54175446 150 mg capsules orally (1\*100 mg + 1\*50 mg) under fasted conditions on Day 7, 9, 10 and 11.
41488712|NCT03058419|DRUG|JNJ-54175446 600 mg|Subjects will receive JNJ-54175446 600 mg (6\*100 mg capsules) orally on Day 8.
41488713|NCT03058419|DRUG|Midazolam 2 mg|Subjects will receive midazolam 2 mg oral emulsion \[2 (milligram per milliliter (mg/mL)\] as a drug cocktail on Day 1, 7 and 11.
41488714|NCT03058419|DRUG|Warfarin 10 mg|Subjects will receive warfarin 10 mg tablets (2\*5 mg) orally as a drug cocktail on Day 1, 7 and 11.
41488715|NCT03058419|DRUG|Caffeine 50 mg|Subjects will receive caffeine 50 mg tablet (1\*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
41488716|NCT03058419|DRUG|Dextromethorphan 30 mg|Subjects will receive dextromethorphan 30 mg capsule (1\*30 mg) orally as a drug cocktail on Day 1, 7 and 11.
41488717|NCT03058419|DRUG|Bupropion 150 mg|Subjects will receive Bupropion 150 mg tablet (1\*150 mg) orally as a drug cocktail on Day 1, 7 and 11.
40823160|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
41341980|NCT04321278|DRUG|Hydroxychloroquine + azithromycin|Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
41341981|NCT04321278|DRUG|Hydroxychloroquine|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
41341982|NCT02351739|DRUG|pembrolizumab|
41341983|NCT02351739|DRUG|ACP-196 in combination with pembrolizumab|
41341984|NCT05006391|OTHER|Tele-Coaching (Online) Community-Based Exercise|"PHASE 1-Intervention Phase (6 months): Participants will engage in an individual tailored home-based exercise program involving aerobic, resistance, balance and flexibility training \~60min, 3 times per week for 24 weeks. Intervention will include: Component 1) biweekly 60 min personal online coaching with a certified trainer from the YMCA (13 sessions) who will monitor and progress exercise intensity; Component 2) weekly online group-based exercise classes \~60 min each led by a trainer at YMCA; Component 3) monthly online evidence-based self-management education sessions focused on topics related to self-management and health, and physical activity living with HIV; and Component 4) a wireless physical activity monitor (WPAM) to self-monitor steps, distance, calories burned, and active minutes.~PHASE 2: Post-Intervention (6 months): Participants will be encouraged to continue with unsupervised home / outdoor-based exercise 3 times per week and to continue using their WPAM throughout."
41341985|NCT05816954|DIAGNOSTIC_TEST|Chest Computed Tomography Scan per normal clinical practice|Normal Clinical practice
41341986|NCT05022641|DEVICE|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console (see Figure 1), as per device functionality requirements.
41341987|NCT05312268|DRUG|Rasburicase|Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.
41341988|NCT03743376|BIOLOGICAL|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
41488718|NCT03058419|DRUG|Omeprazole 20 mg|Subjects will receive omeprazole 20 mg capsule (1\*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
41488719|NCT03806374|DRUG|Ketamine|ketamine
41488720|NCT03806374|DRUG|Propofol|propofol
40823161|NCT03354884|DRUG|cabozantinib|cabozantinib 60 mg orally once daily
40823162|NCT02029716|DRUG|RTA 408 Lotion 0.5%, 1%, 3%|
40823163|NCT02029716|DRUG|Lotion vehicle/placebo|
40823164|NCT01546025|BEHAVIORAL|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
40823165|NCT01546025|BEHAVIORAL|Relaxation training|One hour training in relaxation techniques
41488721|NCT03806374|DRUG|Fentanyl|fentanyl
41488722|NCT03806374|DRUG|Cisatracurium|cisatracurium
41488723|NCT03806374|DRUG|Lidocaine|lidocaine
41488724|NCT03886987|DEVICE|Blue Non Sterile Powder Free Nitrile Examination Gloves|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
41488725|NCT00376194|DRUG|DMSA|
40823166|NCT03454269|DIAGNOSTIC_TEST|Optical Coherence Tomography|The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
41157214|NCT02764788|OTHER|Specific auriculotherapy|Specific auriculotherapy with needles
41488726|NCT02674906|DRUG|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
40823167|NCT04837729|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
40853027|NCT02227199|DRUG|Carboplatin|Given IV
40853028|NCT02227199|DRUG|Etoposide|Given IV
40853029|NCT02227199|DRUG|Ifosfamide|Given IV
40853030|NCT02227199|OTHER|Laboratory Biomarker Analysis|Correlative studies
40853031|NCT03803683|DEVICE|mLab App|The mLab App is a web application that uses an image processing algorithm to interpret the results of the OraQuick® In-Home HIV Test.
41488727|NCT02674906|DRUG|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
41488728|NCT04267107|OTHER|Individual Managing Fatigue Program|The Individual Managing Fatigue Program includes six weekly sessions that focus on sleep, communication and body mechanics, activity stations, priorities and standards, and balancing daily schedule. Each session includes three parts: 1) a pre-session activity 2) in-session activities/information and 3) homework. Prior to coming to each session, participants will be asked to complete activities that will help them prepare for the in-session discussions. During each session participants will discuss and practice the topics most important to them. Based on their discussions, participants and therapists will decide on activities to complete during each session and as homework. The therapist will help the participant begin the homework at the end of each session, and the participant will finish it outside of the session at home. At the beginning of the following session, the therapist and participant will review the homework.
40823168|NCT02813655|DRUG|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
40823169|NCT02813655|DRUG|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
40823170|NCT06178536|PROCEDURE|Bone Consumption|The surgery will be done using a bone consumption protocol
40823171|NCT06178536|PROCEDURE|Bone expansion|implants will be placed after a bone expansion protocol
41488729|NCT00891917|DIETARY_SUPPLEMENT|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
41488730|NCT00891917|DIETARY_SUPPLEMENT|syrup (placebo)|syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
40823172|NCT01638052|DRUG|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
40823173|NCT01719029|OTHER|Low-Carbohydrate/Higher Fat Diet|
40823174|NCT01719029|OTHER|High Carbohydrate/Low fat diet|
40823175|NCT00620425|DRUG|Sumatriptan|injection
40823176|NCT02334683|DEVICE|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
40823177|NCT02334683|DEVICE|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
40823178|NCT06082596|DRUG|BEBT-908 for injection|"Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle."
40823179|NCT04302701|OTHER|Dichoptic treatment using virtual reality|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
40823180|NCT04302701|OTHER|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near.
40823181|NCT03745443|PROCEDURE|increase and decrease positive end-expiratory pressure|20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11. Ventilation with PEEP 11 was maintained for 2 minutes. Then, PEEP was reduced by 2 on every 5 breaths to 5 cmH2O
40823182|NCT05385887|DRUG|Ciprofloxacin 500 mg|One tablet of 500mg Ciprifloxacine, twice a day
40823183|NCT05385887|DRUG|Metronidazole 500 mg|One tablet of 500mg Metronidazole, three times a day
41488731|NCT00000569|DRUG|triamcinolone|1200 micrograms of triamcinolone in daily divided doses
41488732|NCT00000569|OTHER|Placebo|Placebo
40823184|NCT05385887|DRUG|Placebo|Placebo tablets
41488733|NCT02951442|BIOLOGICAL|Biological sample|
40823185|NCT04365543|BEHAVIORAL|Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia|Please see arm/group descriptions
40823186|NCT04365543|BEHAVIORAL|Psychoeducation and Relaxation Therapy (PRT)|Please see arm/group descriptions
40823187|NCT05749003|OTHER|sensorimotor training exercise|Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.
40823188|NCT05749003|OTHER|conventional physical therapy program of exercise.|stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
40823189|NCT04537299|DRUG|Fisetin|\~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 \& 1 and Days 8 \& 9)
40823190|NCT04537299|DRUG|Placebo|Placebo looks exactly like the treatment drug, but it contains no active ingredient
41488734|NCT02951442|PROCEDURE|Non invasive Arterial investigations|
41488735|NCT02951442|PROCEDURE|Abdominal tomodensitometry|
41488736|NCT01335373|DRUG|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
41488737|NCT05188053|DRUG|HTX-011|Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution
40823191|NCT01778049|DRUG|BI 10773|Empagliflozin active
41341989|NCT03743376|BIOLOGICAL|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
40823192|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
40823193|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
40823194|NCT01778049|DRUG|BI 10773|Empagliflozin active
40823195|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
40823196|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
40823197|NCT01778049|DRUG|BI 10773|Empagliflozin active
40823198|NCT01778049|DRUG|BI 10773|Empagliflozin active
40823199|NCT01778049|DRUG|BI 10773|Empagliflozin active
40823200|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
40823201|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
40823202|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
40823203|NCT01778049|DRUG|BI 10773|Empagliflozin active
40823204|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
40823205|NCT00349180|DRUG|Enoxaparin sodium|
40823206|NCT02157441|PROCEDURE|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
40823207|NCT02098369|BEHAVIORAL|Written education material (basic)|Education material on COPD distributed to all participants.
40823208|NCT02098369|BEHAVIORAL|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
41341990|NCT02126241|OTHER|NICaS guided CRT optimization|"1. Baseline CO measurement by NICaS~2. AV delay optimization:~   1. AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS~  2. The AV delay yielding the maximal CO, will be considered the optimal AV delay~  3. The device will be programmed using the optimal AV delay~3. VV delay optimization:~   1. After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS~  2. The VV delay yielding the maximal CO, will be considered the optimal VV delay~  3. The device will be programmed using the optimal VV delay"
41488738|NCT05188053|DRUG|ropivacaine , epinephrine , ketorolac diluted in sodium chloride|Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride
40823209|NCT02098369|BEHAVIORAL|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
40823210|NCT02098369|BEHAVIORAL|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
40853032|NCT03803683|BEHAVIORAL|HIV Prevention Information|Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.
41341991|NCT03825445|DRUG|GnRHa (Fertipeptil 0.1mg)|Two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial) for ovulation trigger after ovarian stimulation for IUI.
41341992|NCT03825445|DRUG|hCG (Pregnyl 5000IU)|hCG (Pregnyl 5000IU) for ovulation trigger after ovarian stimulation for IUI.
40823211|NCT04254159|OTHER|Superimposed Neuromuscular Electrical Stimulation|NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.
40823212|NCT04254159|OTHER|Quadriceps Strengthening|Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.
40823213|NCT04254159|BEHAVIORAL|Patient Education Program|The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
40823214|NCT04254159|OTHER|Aerobic Exercise Training|Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
40823215|NCT00075387|DRUG|Carboplatin|Given IA
40823216|NCT00075387|DRUG|Cyclophosphamide|Given IV
40823217|NCT00075387|DRUG|Etoposide Phosphate|Given IV
40823218|NCT00075387|OTHER|Quality-of-Life Assessment|Ancillary studies
40823219|NCT00075387|DRUG|Sodium Thiosulfate|Given IV
40823220|NCT03134365|OTHER|Mixed meal|Mixed meal with identical composition and physical characteristics (colour, texture, consistency, temperature) but distinctively different palatability.
40823221|NCT03134365|OTHER|Combined meal|Combined meal.
40823222|NCT01812200|DRUG|Dabigatran, Ticagrelor, ASA|
41488739|NCT06181799|DIAGNOSTIC_TEST|Mass spectrometry using the PTR TOF-1000 (IONICON PTR-TOF-MS - Trace VOC Analyzer, Eduard-Bodem-Gasse 3, 6020 Innsbruck, Austria (Europe).|"Once enrolled in the study, all participants are scheduled to undergo the following tests:~The analysis of volatile organic compounds obtained from exhaled air will be carried out by a combination of real-time analytical methods, the use of a real-time mass spectrometer with ionization by the proton transfer method. Machine learning models will be employed to analyze the patterns identified in the exhaled air volatilome data.~Before and immediately after the exercise test, all patients are scheduled to record a single-lead ECG and pulse wave, using a portable single-lead recorder (Cardio-Qvark) (Russia, Moscow). Single lead-ECG and pulse wave parameters will be interpreted using machine learning models."
40823223|NCT01812200|DRUG|Rivaroxaban, Ticagrelor, ASA|
40823224|NCT01812200|DRUG|Phenprocoumon, Ticagrelor, ASA|
40823225|NCT04574856|RADIATION|Dose-Intensified Radiotherapy|Adaptive, dose-intensified radiotherapy targeting an advanced imaging signature, with a target, nominal radiotherapy dose of 80 Gy.
40823226|NCT04574856|DRUG|Temozolomide|Temozolomide chemotherapy (75 mg/m2 daily for 6 weeks)
40823227|NCT04574856|DRUG|Adjuvant temozolomide|Adjuvant temozolomide will be delivered at 150-200 mg/m2 days 1-5 every 28 days for 6 cycles, with additional cycles delivered at the discretion of the investigator.
41341993|NCT03914651|DRUG|300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
41341994|NCT03914651|DRUG|150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
41341995|NCT01895634|DEVICE|Rev-01|Treatment arm patients have used Rev-01 at least once
41341996|NCT00906906|DEVICE|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
41341997|NCT02212080|DRUG|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
41488740|NCT06160570|RADIATION|Intensive Modulated Radiation Therapy|Radiotherapy technique: IMRT
41488741|NCT06160570|RADIATION|3-Dimension Conformal Radiation Therapy|Radiotherapy technique: 3DCRT
41488742|NCT04328571|DIETARY_SUPPLEMENT|OLE enzymatically treated|OLE (Olive leaf extract ) enzymatically treated + maltodextrin
40823228|NCT05387980|DRUG|CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
41341998|NCT02212080|DRUG|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
41341999|NCT04062370|DRUG|Ranibizumab|Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
41342000|NCT04062370|DEVICE|laser photocoagulation|After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
41342001|NCT05057468|DRUG|Cyclosporine|2.5-5 mg orally for 3 months
40823229|NCT03873181|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in laparoscopic abdominal, gynecological, or urological surgeries.
40823230|NCT03641248|DRUG|Enteric coated Devil's Claw|Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
40823231|NCT03641248|DRUG|Non-enteric coated Devil's Claw|Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
40823232|NCT05550623|DEVICE|Tourniquet|Tourniquet use in transfemoral amputation.
40823233|NCT04733170|DIAGNOSTIC_TEST|KnowNow SARS-CoV-2 Rapid Antigen Test|KnowNow SARS-CoV-2 Rapid Antigen Test for the detection of Covid-19 in saliva, as compared to high sensitivity reverse transcription polymerase chain reaction (RT-PCR) of nasopharyngeal swabs as the reference test method
40823234|NCT03099941|OTHER|Biofeedback|The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
40823235|NCT02136680|OTHER|CASA Education|Basic palliative care competencies for outpatient use.
40823236|NCT02614807|DIETARY_SUPPLEMENT|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
40823237|NCT02928003|PROCEDURE|Lung surgery|Genetic analysis and questionnaires
40823238|NCT00529126|DRUG|SKY0402|SKY0402
41342002|NCT05057468|DRUG|Rituximab|375 mg/ m2 weekly dose for a maximum of 4 weeks
41342003|NCT02869685|RADIATION|radiotherapy|radiotherapy
41342004|NCT00899678|DRUG|Certolizumab Pegol|"400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg"
41488743|NCT04328571|DIETARY_SUPPLEMENT|OLE + probiotic|OLE (Olive leaf extract) co-administered with probiotic
41488744|NCT04328571|DIETARY_SUPPLEMENT|OLE|OLE (Olive leaf extract) + maltodextrin
41488745|NCT05153421|DEVICE|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
41488746|NCT02279693|OTHER|CBCT|10 participants will receive a cone beam computed tomography (CBCT) repositioning
40823239|NCT00529126|DRUG|Bupivacaine HCl|Bupivacaine HCl
40823240|NCT00369005|PROCEDURE|Red blood cell transfusion guidelines|
40823241|NCT01385111|PROCEDURE|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
40823242|NCT01385111|PROCEDURE|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
41488747|NCT02279693|OTHER|fiducial marker (kV imaging)|10 participants will receive a kV imaging of fiducial marker repositioning.
41488748|NCT02279693|RADIATION|IGRT Associated With IMRT|
41488749|NCT06411587|DIAGNOSTIC_TEST|Ultrasound imaging and functional assessment|Participants in this study will undergo two types of assessments: capturing muscle images using ultrasound and evaluating their function through clinical scales.
41488750|NCT03514654|PROCEDURE|Mastectomy|Removal of the whole breast.
40823243|NCT01263392|DEVICE|Intermittent catheterization|Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria \& leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
41342005|NCT00899678|DRUG|Certolizumab Pegol|"200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg"
41488751|NCT03514654|PROCEDURE|Therapeutic Mammoplasty|Excision via lumpectomy of multifocal or multicentric cancers with breast volume displacement techniques to maximise cosmetic outcomes.
41488752|NCT01653561|DRUG|Apatinib|The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
41488753|NCT03346486|OTHER|Control diet|Regular diet
41488754|NCT03346486|OTHER|Intervention diet|Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.
41342006|NCT05839236|COMBINATION_PRODUCT|Atorvastatin Calcium Tablets|The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
41342007|NCT05786534|DIETARY_SUPPLEMENT|Green Seaweed|400 mg per day
41342008|NCT04617106|PROCEDURE|Radial artery cannulation|cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)
41342009|NCT03582267|DIETARY_SUPPLEMENT|Docosahexaenoic Acid (DHA)|Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
41342010|NCT00943410|RADIATION|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
41342011|NCT00943410|DRUG|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
40823244|NCT01891799|OTHER|Option B+|"* Using one low toxicity triple ARV regimen \[(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)\] for all women, rather than adapting regimens by CD4+~* Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART~* Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women"
40823245|NCT03208907|DRUG|CQ coadministered with PQ|113 subjects in a 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
41342012|NCT00136357|BEHAVIORAL|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
41342013|NCT03802240|DRUG|Sintilimab|200mg IV Q3W
40823246|NCT03208907|DRUG|DHA-PQP coadministered with PQ|In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
40823247|NCT03208907|DRUG|CQ and PQ starting on Day 42|98 subjects in a 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
41342014|NCT03802240|DRUG|IBI305|15mg/kg IV Q3W
41342015|NCT03802240|DRUG|Pemetrexed|500mg/m2 IV Q3W
41342016|NCT03802240|DRUG|Cisplatin|75mg/m2 IV Q3W
41342017|NCT03802240|DRUG|Placebo1|Placebo1 IV Q3W
41342018|NCT03802240|DRUG|Placebo2|Placebo2 IV Q3W
41488755|NCT02357563|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
41488756|NCT02357563|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
40823248|NCT03208907|DRUG|DHA-PQP and PQ starting on Day 42|95 subjects in a 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
40853033|NCT03803683|DEVICE|HIV Home Tests|Youth randomized into this arm will receive OraQuick® In-Home HIV Test.
41157215|NCT02764788|OTHER|non-specific auriculotherapy|non-specific auriculotherapy with needles
41342019|NCT02814136|PROCEDURE|Ablation|
41342020|NCT03598660|GENETIC|Sorcin gene expression|Sorcin gene expression Will be measured by real time PCR
41342021|NCT03598660|OTHER|Annexin A3 serum mesurement|serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)
41342022|NCT05309369|BEHAVIORAL|Preferred Music|Participants will listen to selected music using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
41342023|NCT05309369|BEHAVIORAL|Nature Sounds|Participants will listen to nature sounds using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
41342024|NCT02607462|BIOLOGICAL|PRP|
41342025|NCT02607462|OTHER|Placebo|
41342026|NCT02683460|PROCEDURE|Patella resurfacing|
41342027|NCT02683460|PROCEDURE|Patella retention|
41342028|NCT00777257|BIOLOGICAL|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
41342029|NCT00777257|BIOLOGICAL|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
41342030|NCT00777257|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
40823249|NCT04202510|PROCEDURE|Glaucoma and Cataract Surgery|Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
40823250|NCT03610945|DRUG|Fluconazole|Subjects will receive fluconazole once daily from Day 5 to Day 18
40823251|NCT03610945|DRUG|Quinidine|Subjects will receive quinidine twice daily from Day 5 to Day 12
40823252|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 14
40823253|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 8
40823254|NCT04617418|BEHAVIORAL|Change in touchscreen interactions|The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions
40823255|NCT02686151|DRUG|Letrozole|used after oocyte retrieval
40823256|NCT02686151|DRUG|Polygeline|used after oocyte retrieval
40823257|NCT02686151|DRUG|Sodium Chloride|used after oocyte retrieval
40823258|NCT02686151|DRUG|dexamethasone|used after oocyte retrieval
40823259|NCT05322577|DRUG|Bemarituzumab|Intravenous (IV) infusion
40823260|NCT05322577|DRUG|CAPOX|CAPOX administered as a combination of oxaliplatin as an IV infusion and capecitabine orally as tablets.
40823261|NCT05322577|DRUG|SOX|SOX administered as a combination of oxaliplatin as an IV infusion and S-1 orally.
40823262|NCT05322577|DRUG|Nivolumab|IV infusion.
40823263|NCT04706273|DEVICE|GORE® VIABAHN® Endoprosthesis|Participants receiving the GORE® VIABAHN® Endoprosthesis
40823264|NCT00746239|DRUG|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
41488757|NCT06406517|DRUG|Gadopiclenol|Gadopiclenol is an FDA-approved gadolinium-based contrast agent (GBCA) for neurological and abdominal contrast-enhanced MRI. Participants will receive this contrast agent at one of three different doses prior to undergoing a congenital heart cardiac MRI/MRA. This contrast agent will be compared to gadobenate dimeglumine, the standard-of-care.
40823265|NCT00746239|DRUG|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
40823266|NCT02593422|BEHAVIORAL|Expressive Writing|Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
40823267|NCT02593422|BEHAVIORAL|Fact Writing (Control)|Participants will be asked to write about the facts of their experience with ovarian cancer
40823268|NCT02614170|OTHER|Prospective Blood Draw|This is prospective collection blood and urine study. This is not a treatment trial or device trial.
40823269|NCT05753566|DRUG|Rezvilutamide|Specifications of 80 mg; orally, once a day
40823270|NCT05753566|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
40823271|NCT05753566|RADIATION|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
40823272|NCT06608797|BEHAVIORAL|Learning and memory training|The experimental group will receive memory retraining exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 training sessions).
40823273|NCT06608797|BEHAVIORAL|Sham Comparator|The sham comparator group will receive sham memory exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 placebo control sessions).
40823274|NCT02145104|DRUG|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
40823275|NCT05254275|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
41488758|NCT06406517|DRUG|Gadobenate dimeglumine|Gadobenate dimeglumine is an FDA-approved GBCA that is used in standard clinical practice at UCSD for contrast-enhanced MRI/MRA studies, including cardiac MRI/MRA. This contrast agent is the standard of care to which gadopiclenol will be compared.
40823276|NCT05254275|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
40823277|NCT01730339|DRUG|PF-06473871|Single dose administered by injection four different times
40823278|NCT01730339|DRUG|PF-06473871|Single dose administered by injection three different times
40823279|NCT03345160|DRUG|Peanut Flour|open label oral immunotherapy
40823280|NCT03887260|DRUG|Morphine PCA pump|Morphine given postoperatively.
40823281|NCT03887260|PROCEDURE|ESP block|Regional anaesthesia technique performed under ultrasound guidance before surgery
40823282|NCT03887260|DRUG|Fentanyl|Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
40823283|NCT01133275|DRUG|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
41036499|NCT01142557|DRUG|Interferon beta-1a (Rebif)|A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.
40823284|NCT01133275|DRUG|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
40823285|NCT00985907|DRUG|Doxil, melphalan, bortezomib|"Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2"
40823286|NCT00856089|DRUG|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
40823287|NCT02912130|DIETARY_SUPPLEMENT|Protein Supplementation|1.2-1.5g/kg/body weight per day
40823288|NCT02912130|OTHER|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
40823289|NCT02912130|OTHER|Resistance Exercise|60 minutes per week of progressive resistance training
40823290|NCT03038607|DRUG|Aspirin|This group were subjected to aspirin 75 mg once daily for 6 weeks.
41018056|NCT05244525|DRUG|Bupivacaine with Epinephrine|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
41342031|NCT03868670|DEVICE|responsive neurostimulation|The RNS® System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to continuously monitor brain electrical activity, detect abnormal electrical activity and respond by delivering imperceptible levels of electrical stimulation to normalize that activity before an individual experiences seizures. This is an Early Feasibility Study determining the safety and efficacy of NAc-RNS in the treatment of LOC eating in treatment-refractory obesity.
41342032|NCT03007628|DEVICE|Magpro X100|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
41342033|NCT03007628|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
41342034|NCT03007628|OTHER|Treatment as usual (TAU)|Participants will engage in their intpatient treatment program as-usual.
41342035|NCT05711719|DRUG|Vericiguat|Up-titration will be performed as guided by the evaluation of blood pressure and clinical symptoms
41342036|NCT05711719|DRUG|Placebo|Administered the same way
41342037|NCT04339725|OTHER|DNA extraction|Extraction fecal DNA and compare disease group to normal group
41342038|NCT00732706|PROCEDURE|Sartorius Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.
41342039|NCT00732706|PROCEDURE|Quadriceps Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
41342040|NCT03975530|BEHAVIORAL|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it.
41342041|NCT03975530|BEHAVIORAL|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit.Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
41342042|NCT05889169|OTHER|Neurorehabilitation|Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)
41342043|NCT03003130|DEVICE|Restylane Defyne|Intradermal injection
41342044|NCT03003130|DEVICE|Restylane|Intradermal injection
41342045|NCT00928304|DRUG|Florbetaben (BAY94-9172)|300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
41342046|NCT06056401|BEHAVIORAL|record Hemodynamic variables, respiratory variables and arterial blood gas at specific times|Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .
41036500|NCT00443248|DEVICE|Vaginal Heat Wash-Out Device|No drug administered. Device tested twice with each subject.
41342047|NCT02708004|DRUG|Aprocitentan|Formulated in capsules in 2 different strengths; 2 capsules per day
41342048|NCT02708004|OTHER|Placebo|Matching active drug
41488759|NCT06410170|DEVICE|MIRA Device|At home diagnostic testing
40853034|NCT04566432|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
41036501|NCT04094506|DRUG|ASP1948|Intravenous
41342049|NCT03672552|OTHER|FFWP and Improved Oral Care|The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
41342050|NCT05157776|DRUG|PD-1 and chemotherapy|Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP
41342051|NCT05058404|DRUG|Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles); Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
40823291|NCT06465303|DRUG|RTP-026|Intervention is for each subject administered as three 30-minutes infusions of either A: 25μg/kg RTP-026; or B: ≥ 26μg/kg and ≤75μg/kg RTP-026; or C: A maximum of 3 x treatment dose RTP-026 as given in B;
40823292|NCT06465303|DRUG|Placebo|Intervention is for each subject administered as three 30-minutes infusions of placebo
40823293|NCT00822705|DRUG|Placebo tablet|Control arm
40823294|NCT05344339|PROCEDURE|Distal gastrectomy|Reconstruction after Distal Gastrectomy
41036502|NCT01895166|PROCEDURE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
41342052|NCT05058404|DRUG|Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles);~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
41342053|NCT05058404|DRUG|Immunochemotherapy regimen: R-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-CHOP Q21 + 2 cycles Q21 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis planned by the study."
40823295|NCT02660450|OTHER|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
40823296|NCT02660450|OTHER|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
40823297|NCT02660450|OTHER|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
40823298|NCT02112682|PROCEDURE|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
40823299|NCT03122353|DRUG|Calcipotriene and betamethasone suspension|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
40823300|NCT03122353|DRUG|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
41036503|NCT01895166|PROCEDURE|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
40823301|NCT03122353|DRUG|Placebo|vehicle used as placebo
40823302|NCT06606171|BEHAVIORAL|Chair Sitting (30 minutes)|This intervention involves a single session of chair sitting for 30 minutes, where participants will sit in a standardized non-swivel chair and perform desk-based activities like computer use.
40823303|NCT06606171|BEHAVIORAL|Floor Sitting (30 minutes)|This intervention entails a single session of floor sitting for 30 minutes, with participants seated on a cushioned mat performing similar desk activities as in the chair sitting session.
41342054|NCT05058404|DRUG|Immunochemotherapy regimen: R-CHOP (Arm B)|"Arm B (Experimental arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging: induction therapy shall be completed based on the response achieved and on the treatment chosen:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-CHOP Q21+ 2 cycles Q21of rituximab~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis."
40823304|NCT06606171|BEHAVIORAL|Daily Floor Sitting Practice (1 month)|Participants will be instructed to incorporate at least one hour of floor sitting into their daily routine for a duration of one month.
40823305|NCT06327555|BEHAVIORAL|the traditional rehabilitation group|The traditional rehabilitation group takes a face-to-face approach, with therapists providing outpatient rehabilitation instruction twice a week for six weeks.
40823306|NCT06327555|DEVICE|the remote rehabilitation group|The telerehabilitation group uses smart wearables and mobile apps worn around the knee joint to perform remote rehabilitation at home. At least twice a week, both sets of training sessions are identical.
40823307|NCT01971463|OTHER|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
40823308|NCT04709484|DRUG|USG-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
40823309|NCT04709484|DRUG|Palpation-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
40823310|NCT06089213|OTHER|real-time intervention|An individual exercise program will be carried out at home, supervised remotely via videoconference.
40823311|NCT00637637|DRUG|indinavir sulfate|
40823312|NCT00637637|DRUG|ritonavir|
40823313|NCT00637637|RADIATION|radiation therapy|
40823314|NCT01390779|DEVICE|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
40823315|NCT04490980|DRUG|butorphanol|Observed group:Intravenous drip of Butorphanol in patients after cesarean section;control group: intravenous drip of saline in patients after cesarean section
40823316|NCT04400084|OTHER|Placenta perfusion|Placenta perfusion in double closed circuit, during 3 hours
40823317|NCT01103154|DRUG|carvedilol|6.25mg per day, increase to 6.25mg bid
40823318|NCT01103154|DRUG|nadolol + ISMN|nadolol 40-80mg ISMN 10-20mg
40823319|NCT02956044|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
40823320|NCT02956044|DRUG|Metformin|1000 mg metformin
40823321|NCT02956044|DRUG|Glimepiride|4 mg glimepiride
40823322|NCT02956044|DRUG|Sitagliptin|100 mg sitagliptin
40823323|NCT05801393|RADIATION|CT, MRI|"HRCT with no IV contrast administration and bone algorithm. Intra thecal injection of contrast, then CT in prone position to obtain direct coronal cuts.~MR cisternography using a three dimensional constructive interference in steady state (3D-CISS) sequence."
41157216|NCT02764788|OTHER|seed auriculotherapy|non-specific auriculotherapy with seeds
40823324|NCT00713921|DRUG|Fesoterodine Oral Product|After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
40823325|NCT02826434|BIOLOGICAL|PVX-410|This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
40823326|NCT02826434|BIOLOGICAL|Durvalumab|This is an intravenous infusion of a monoclonal antibody.
40823327|NCT02826434|DRUG|Hiltonol|This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
40823328|NCT03895398|OTHER|nutrition and psychosocial intervention with community participatory|community participation to ensure the intervention is given to the study subject (underfive children)
40823329|NCT06604793|DIETARY_SUPPLEMENT|Creatine|Creatine monohydrate
40823330|NCT06604793|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
40823331|NCT01704729|PROCEDURE|group1|Non-cycloplegic self-refraction +conventional glasses
40823332|NCT01704729|PROCEDURE|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
41165743|NCT02710097|DRUG|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
40823333|NCT01704729|PROCEDURE|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
40823334|NCT01704729|PROCEDURE|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
40823335|NCT03865667|DEVICE|PROFEMUR® Preserve Femoral Stem|Total Hip Total Hip Arthroscopy
40823336|NCT00006046|BIOLOGICAL|monoclonal antibody hu3S193|
40823337|NCT04548648|DRUG|Acalabrutinib|Acalabrutinib at 100 mg is taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
40823338|NCT04548648|DRUG|Isavuconazole|Prophylactic treatment with isavuconazole includes loading dose of 372 mg (2 capsules) administered orally every 8 hours for 6 doses (48 hours), followed by maintenance administration of 372 mg (2 capsules) once daily as long as the subject is on study treatment.
40823339|NCT06159881|PROCEDURE|Corneal Cross Linking|Total fluence adapted to thinnest point pachymetry
40823340|NCT02521233|DRUG|Candesartan + Chlorthalidone (8mg+12,5mg)|
40823341|NCT02521233|DRUG|Candesartan + Chlorthalidone (8 mg + 25 mg)|
40823342|NCT02521233|DRUG|losartan+hydrochlorothiazide|
40823343|NCT03826836|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
40823344|NCT06355947|OTHER|Cognitive cycling training|Cycling training conducted with cognitive tasks
40823345|NCT06355947|OTHER|Cognitive treadmill training|Treadmill training conducted with cognitive tasks
40823346|NCT06162546|OTHER|Registry|Registry Participation, providing data and clinical specimen
40823347|NCT05226780|DRUG|NBI-921352|Administered orally
40823348|NCT04881929|DRUG|KN026|KN026 in Combination With Docetaxel
40823349|NCT00348907|DRUG|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
41488760|NCT03629379|DRUG|Ustekinumab|Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
41488761|NCT03629379|DRUG|Vedolizumab|Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
40823350|NCT00348907|DRUG|late thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
40823351|NCT05941338|DRUG|Tirelizumab ,+Carboplatin+albumin-bound paclitaxel|Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab , Carboplatin, albumin-bound paclitaxel
40823352|NCT02736266|DRUG|Pembrolizumab (MK-3475)|Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
40823353|NCT03070860|RADIATION|PET scan 18-FDG and 18-NAF|"Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.~PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG)."
40823354|NCT06179628|DRUG|Low bolus concentration and volume|Compare Low and Standard concentrations and volumes of bupivacaine boluses for continuous adductor block
40823355|NCT03294239|PROCEDURE|Transurethral extraction of bladder stone(s)|Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
40823356|NCT03294239|PROCEDURE|percutaneous extraction of bladder stone(s)|Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
40823357|NCT02046226|DEVICE|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
40823358|NCT05646355|BEHAVIORAL|Proactive CRC Screening Outreach|Proactive approach that incorporates a mailed outreach invitation to screen with fecal immunochemical testing (FIT), followed by active assistance to colonoscopy completion if preferred or indicated by FIT test result.
40823359|NCT05646355|BEHAVIORAL|Usual Care|Participants will not receive additional outreach from the study team regarding CRC screening.
40823360|NCT01933230|DEVICE|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period"
40853035|NCT01023724|DRUG|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
41165744|NCT02710097|DRUG|Placebo|No active cannabinoids. Administered over 20 minutes via a vaporizer.
41488762|NCT00134043|DRUG|vorinostat|Given orally
41488763|NCT01725776|DRUG|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg (as for the injectable solution)
41488764|NCT03161548|DRUG|Induction chemotherapy|"All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14"
41488765|NCT03161548|PROCEDURE|Tongue conservation surgery|Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
40823361|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-active|Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
40823362|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-sham|Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
40823363|NCT03256903|DRUG|Methoxyflurane|Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.
40823364|NCT03256903|DRUG|Standard of care|Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
40853036|NCT01023724|DRUG|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
40853037|NCT00528801|BEHAVIORAL|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
41165745|NCT01319175|OTHER|Hip flexion strength training|
41165746|NCT01321983|OTHER|Inspiratory muscular training - IMT|
41342055|NCT05058404|DRUG|Immunochemotherapy regimen: G-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-bendamustine Q28 (28-days cycles);~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in Stable Disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
41488766|NCT03161548|RADIATION|postoperative CCRT|"Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy"
41488767|NCT04178265|OTHER|Electroacupuncture|needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints.
40823365|NCT05379062|BEHAVIORAL|Active Singing Group|The participants of the Active Singing Group take part in a weekly 45-minute singing activity in a group over a period of 3 months. In total the investigators expect 12 choir rehearsals. The rehearsals will take place between 2pm and 3.30pm in the church of the Wehrle-Diakonissen Private Clinic in Salzburg. The group will be led by a professional and experienced choir director.
40823366|NCT05379062|BEHAVIORAL|Receptive Music Group|The participants of the Receptive Music Group will individually listen to the already researched CD for Parkinson's patients (Bernatzky, Wendtner, Volc, 2012) at home at the same time on one weekday.
40823367|NCT01071200|DRUG|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
40823368|NCT01071200|DRUG|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
40823369|NCT06484257|BEHAVIORAL|Myopia|Participants in this arm would receive progressive addition lenses specifically designed to correct myopia. These lenses would typically have a prescription for correcting nearsightedness (myopia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
40823370|NCT06484257|OTHER|Hypermetropia|Participants in this arm would receive progressive addition lenses specifically designed to correct hypermetropia. These lenses would typically have a prescription for correcting farsightedness (hypermetropia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
40823371|NCT06238843|DRUG|irinotecan|Subjects in the contral arm will receive irinotecan 125mg/m2 IV D1, D8, Q3W in 3-weeks cycles or 150mg/m2 IV D1, Q2W in 2-week cycles
40823372|NCT06238843|DRUG|IBI343|IBI343: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles
40823373|NCT06238843|DRUG|paclitaxel|Subjects in the contral arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles.
40823374|NCT03833271|BIOLOGICAL|Influenza vaccine, Immune function|Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
40823375|NCT03456791|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
40823376|NCT02980146|OTHER|Non interventional study|
40823377|NCT02545660|OTHER|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
40823378|NCT02545660|OTHER|White Light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
40823379|NCT00537667|DRUG|anakinra|anakinra
40823380|NCT00537667|DRUG|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
40823381|NCT04710641|DRUG|MTL-CEBPA|Administered once every 3 weeks on Day 1 of each 3 week cycle.
40823382|NCT04710641|DRUG|Sorafenib|Oral adminstration twice a day
40823383|NCT01013155|DRUG|perindopril erbumine|8 mg tablet
40823384|NCT06555302|BEHAVIORAL|Cognitive Rehabilitation|Cognitive rehabilitation will be OT-led, one-on-one sessions focused on teaching cognitive strategies and their application to a broad set of activities/settings. The goal is to facilitate cognitive skill learning and generalization, by applying the new cognitive strategies to the participant's performance of home-based and community-based activities (taught through the subsequent OT portion of the intervention).
40823385|NCT06555302|BEHAVIORAL|Occupational Therapy|OT upper extremity rehabilitation will have 2 components: task-practice and metacognitive strategy training. The task-practice involves a patient repetitively practicing stroke-impaired movement skills within the context of a functional task to promote recovery of the impaired skills. THE task practice sessions will be coached/guided by the therapist through a metacognitive strategy training process which is based on the Cognitive Orientation to Occupational Performance (CO-OP) approach aimed at enhancing self-management during home and community living tasks.
40823386|NCT00994734|DRUG|Mifepristone|home administration of mifepristone
40823387|NCT00391677|BEHAVIORAL|Social skills training with attention shaping procedures|Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
41342056|NCT05058404|DRUG|Immunochemotherapy regimen: G-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case 2 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-bendamustine Q28;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
41488768|NCT02056392|DRUG|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
41488769|NCT02056392|DRUG|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
41488770|NCT02056392|DRUG|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
41488771|NCT04694183|DRUG|Camrelizumab|200mg, intravenous drip administration, d1, every 3 weeks.
41488772|NCT04694183|DRUG|S-1|Oral, d1-14, every 3 weeks.
40823388|NCT00391677|BEHAVIORAL|Social skills training without attention shaping|Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
40823389|NCT06608043|BEHAVIORAL|Reborn lifestyle adjustment program|"The sessions are based on the 'Do Live Well' model, Kolb's Experiential Learning Theory, and CBT-based problem-solving skills.~Introduction to the Reborn Lifestyle: Core principles of the Reborn Program for building a healthy lifestyle during and after breast cancer.~Physical Activity: The role of physical activity during treatment and exercises to boost energy levels.~Fatigue Management: Scientific methods for managing fatigue during and after treatment.~Pain Management: Effective techniques to reduce pain and improve quality of life.~Mental Health Burden: Strategies to alleviate mental health burdens and cope with stress.~Quality Sleep: Practical methods to improve sleep patterns and achieve quality rest.~Preventive Rehabilitation Approaches: Essential rehabilitation strategies to protect health and reduce recurrence risk.~The study will be conducted online, with evaluations and sessions via Zoom before and after the 12-week modules."
40823390|NCT06608043|PROCEDURE|Conventional Physiotherapy and Occupational Therapy|Patients in the control group will continue conventional medical treatments, occupational therapy and physiotherapy sessions.
40823391|NCT04875507|BEHAVIORAL|Positive Psychology|This intervention aim to examine the effectiveness of PPI in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese children who are living in poverty. Participants in the experimental group will receive a 1.5 hour workshop on 4 positive psychology techniques, including (1) gratitude visit/letters, (2) 3 good things, (3) you at your best, and (4) using signature strengths. A booster intervention will be given at 1-week follow-up.
40823392|NCT02514694|DRUG|LEO32731|
40823393|NCT02514694|OTHER|Placebo|
40823394|NCT00945061|RADIATION|intracavitary balloon brachytherapy|Patients undergo brachytherapy
40823395|NCT00945061|RADIATION|intraoperative radiation therapy|Patients undergo radiotherapy
40823396|NCT06605872|DEVICE|GlucoTab|Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. Insulin therapy prescription for the next 24 hours is suggested once daily by the GlucoTab system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the algorithm is to maintain fasting and premeal glucose concentrations between 100-140 mg/dl, (5.6 to 7.8 mmol/l).
40823397|NCT06605872|OTHER|Diabetes Treatment|Diabetes Standard Care
40823398|NCT00531076|BIOLOGICAL|bevacizumab|"Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.~In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles"
40823399|NCT05034315|OTHER|Whole egg consumption|The participants in the whole egg group consumed two whole eggs immediately after exercise.
40823400|NCT03754582|DRUG|Perampanel|Oral tablets.
40823401|NCT03754582|DRUG|Perampanel|Intravenous infusion.
40823402|NCT00136240|BEHAVIORAL|Computer Assisted Education for Behavior Change|
40823403|NCT04545164|DIAGNOSTIC_TEST|CAD4TB|CAD4TB is a Computer Aided Diagnosis (CAD) image processing algorithm that can aid interpretation of Chest X-ray images to accurately detect tuberculosis.
40823404|NCT04545164|DIAGNOSTIC_TEST|FujiLAM|Fujifilm SILVAMP TB LAM is a high sensitivity test for mycobacterial lipoarabinomannan (LAM) in urine samples.
40823405|NCT04815122|RADIATION|SPECT TRODAT-1|The Single-photon Emission Tomography (SPECT) TRODAT-1 will be performed after the voluntary rest in a dark and silent room for 30 minutes, to eliminate possible influences from external stimuli; the radiopharmaceutical \[99mTC\] -TRODAT-1 will be injected through the venous access previously established, 4 hours after the injection of the radiopharmaceutical, the acquisition of cerebral SPECT will be performed in the two groups of obese women, with and without COMT Val158Met polymorphism. The images will be acquired on Philips BrightView XCT equipment, equipped with a double detector.
40823406|NCT04793230|DIAGNOSTIC_TEST|biopsying|The procedure was carried out under general or local anesthesia. An otolaryngologist conducts the endoscopic intranasal operation, while an eye surgeon removes tissue from the sac and lacrimal tubes using lacrimal probes passed through the canaliculi.
40823407|NCT05974657|OTHER|Probiotic Lactobacillus acidophilus LA85|Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.
40823408|NCT03584191|OTHER|No treatment given|Completion of a survey
40823409|NCT04077866|DRUG|Temozolomide|Temozolomide is an FDA-approved drug that is given to patients
41018057|NCT05244525|DRUG|Bupivacaine alone|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Control patients will receive an injection containing 20mL of 0.5% bupivacaine alone.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale.Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
41018058|NCT05751135|DEVICE|Focal muscle vibration|Focal muscle vibration will be provided by a longitudinal muscle vibrator on muscles of lower limb; hamstrings, quadriceps, illiopsoas, calf, gluteus maximus and medius. Each muscle will be targeted 3 times with 30 seconds time period and keeping 10 second interval.
40823410|NCT04077866|BIOLOGICAL|B7-H3 CAR-T|B7-H3-targeting CAR-T cells derived from patient own peripheral blood mononuclear cells will be given to patients via intracerebral injection though an Ommaya catheter
40823411|NCT05611229|DRUG|Nivolumab|Nivolumab
40823412|NCT05611229|DRUG|Pembrolizumab|Pembrolizumab
40823413|NCT05611229|COMBINATION_PRODUCT|Dabrafenib+Trametinib|Dabrafenib+Trametinib
40823414|NCT05611229|COMBINATION_PRODUCT|Ipilimumab+Nivolumab|Ipilimumab+Nivolumab
40823415|NCT05611229|COMBINATION_PRODUCT|Vemurafenib+Cobimetinib|Vemurafenib+Cobimetinib
40823416|NCT05611229|COMBINATION_PRODUCT|Encorafenib+Binimetinib|Encorafenib+Binimetinib
40823417|NCT01338077|DRUG|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
41018059|NCT05751135|PROCEDURE|Stretching|Stretching of shortened lower extremity muscle
41018060|NCT05751135|PROCEDURE|Strengthening|Strengthening exercises for weak lower extremity muscles
40823418|NCT01338077|DRUG|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
40823419|NCT03062618|DRUG|PRCL-02|Oral tablet(s) administered with water
40823420|NCT03062618|DRUG|Placebo Oral Tablet|Administered with water
40823421|NCT00025428|DRUG|carboplatin|
40823422|NCT00025428|DRUG|cyclophosphamide|
40823423|NCT00025428|DRUG|doxorubicin hydrochloride|
40823424|NCT00025428|DRUG|etoposide|
40823425|NCT00025428|DRUG|vincristine sulfate|
40823426|NCT00025428|PROCEDURE|adjuvant therapy|
40823427|NCT00025428|PROCEDURE|conventional surgery|
40823428|NCT00025428|PROCEDURE|neoadjuvant therapy|
40823429|NCT02933073|BIOLOGICAL|OncoImmunome|The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
40823430|NCT02180880|DRUG|Pregabalin and Oxcarbazepine|"Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice."
40823431|NCT03292939|DIAGNOSTIC_TEST|A complete Doppler ﬂow assessment of the maternal and fetal circulation|A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
40823432|NCT01767077|DIETARY_SUPPLEMENT|Butter oil|Daily intake of 40 g butter oil
40823433|NCT01767077|DIETARY_SUPPLEMENT|Cream|Daily intake of 100 g cream (40%)
40823434|NCT01212211|OTHER|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
40823435|NCT06319469|DRUG|silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
41342057|NCT05058404|DRUG|Immunochemotherapy regimen: G-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
41383596|NCT05926739|DEVICE|Electrical stimulation and biofeedback with Phenix Liberty medical device|"12 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.~The patient will undergo 12 therapeutic functional reeducation sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used. The patients will complete questionnaires at the end of the care.~Overall, the functional rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 12 sessions between 6 and 8 weeks~* 1 end visit, within the week after the 12th session"
40823436|NCT06319469|DRUG|silodosin 8 mg capsule|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
40823437|NCT02223611|DRUG|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)\<1.25 m2 40mg twice a day, 1.25 m2≤BSA\<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
40823438|NCT02223611|DRUG|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
40823439|NCT00212199|DRUG|orlistat|
40823440|NCT00212199|BEHAVIORAL|Brief cognitive behavioral counseling|
40823441|NCT00728520|DRUG|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
40823442|NCT05853055|PROCEDURE|Respiratory training|Respiratory training will be included in the rehabilitation program of a subgroup of post-COVID-19 patients. The intervention group will train twice daily for the length of their rehabilitation stay using an incentive spirometer (Voldyne 5000 R, Sherwood Medical, St. Louis, USA). Subjects will be instructed to first completely exhale slowly. Then inspire slowly up to 70% of their vital capacity, producing a constant flow controlled via feedback from the device. This procedure will be repeated every 30 s (paced by a metronome) for 15 min. The training will be conducted twice a day, resulting in a total of 60 inspirations per day.
40823443|NCT05151432|DEVICE|Pulsed Ultrasound|Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W
40823444|NCT05151432|DEVICE|Pulsed Electromagnetic field|The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.
40823445|NCT05151432|OTHER|Traditional exercise program|Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening
41018061|NCT05751135|PROCEDURE|Positioning|Positioning of participant to maintain a good body posture
40823446|NCT05151432|DEVICE|Sham Pulsed US & Electromagnetic field|The patients will receive Sham Pulsed US \& Electromagnetic field.
40823447|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Physics Forceps|Extraction of mandibular molars using physics forceps
40823448|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Conventional Forceps|Extraction of mandibular molars using conventional forceps
40823449|NCT04215939|BEHAVIORAL|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
40823450|NCT04215939|BEHAVIORAL|Thermoneutral environment participants with spinal cord injury|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
40823451|NCT04215939|BEHAVIORAL|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
40823452|NCT04215939|BEHAVIORAL|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
40823453|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy male participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
40823454|NCT04215939|BEHAVIORAL|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
40823455|NCT04215939|BEHAVIORAL|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
40823456|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy female participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
40823457|NCT04215939|BEHAVIORAL|Warm environment healthy female participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
40823458|NCT04359732|OTHER|hybrid PET/MRI|An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
40823459|NCT00993512|DRUG|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
40823460|NCT00993512|DRUG|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
40823461|NCT00993512|OTHER|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
41018062|NCT00238927|DRUG|inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)|
41165747|NCT00535093|DEVICE|rapid streptococcal testing|Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
41165748|NCT03500666|DEVICE|Robot|Robot lateral neck lymph node dissection
41488773|NCT04694183|DRUG|Oxaliplatin|130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).
41488774|NCT04694183|DRUG|Paclitaxel|Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).
40823462|NCT02583230|BEHAVIORAL|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
40823463|NCT03506451|OTHER|Demographics questionnaires and the FACT HN questionnaire|Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
40823464|NCT04850976|DEVICE|Endotracheal intubation|Every eligible patient was intubated using either SAM-VL or McGrath MAC® according to their randomization allocation
40823465|NCT06605742|OTHER|Consultancy|In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them.The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects
40823466|NCT02609750|OTHER|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
40823467|NCT02609750|OTHER|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
40823468|NCT00693017|DRUG|Zonisamide|"50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
40823469|NCT00693017|DRUG|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
40823470|NCT02943824|OTHER|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
40823471|NCT02943824|OTHER|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
40823472|NCT04074018|OTHER|Self-rehabilitation program|facial self-rehabilitation for a duration of 6 months
40823473|NCT04074018|OTHER|Conventional rehabilitation program|Conventional facial rehabilitation for a duration of 6 months
40823474|NCT03587831|PROCEDURE|Vertical Sleeve Gastrectomy|Surgical Procedure: Vertical Sleeve Gastrectomy
40823475|NCT03587831|BEHAVIORAL|Lifestyle Modification Counseling|Behavioral Intervention: Lifestyle Modification Counseling
40823476|NCT05714072|DRUG|Ruxolitinib|10mg BID or 15mg BID
40823477|NCT05714072|DRUG|Abemaciclib|50, 100 and 150 mg
41342058|NCT05058404|DRUG|Immunochemotherapy regimen: G-CHOP (Arm B)|"4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion."
40823478|NCT05327634|OTHER|self-questionnaire|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
40823479|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
41383597|NCT04337359|DRUG|Ruxolitinib|5 mg. Tablet
41383598|NCT05311215|DRUG|SL-1002|SL-1002 injectable solution
41383599|NCT05311215|DRUG|Placebo|Matching placebo injectable solution
40823480|NCT05383443|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training (group) or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
40823481|NCT05383443|BEHAVIORAL|Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
40823482|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|This component will be based on in-person 60-minute group sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
40853038|NCT00528801|PROCEDURE|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
41165749|NCT03500666|DEVICE|Total endoscopic|Total endoscopic lateral cervical lymph node dissection
40823483|NCT05383443|OTHER|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
40823484|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (once a week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
40823485|NCT05383443|BEHAVIORAL|Physical exercise|In-person group training (monthly): 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher.
40823486|NCT05383443|BEHAVIORAL|Nutrition education|In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants. The participants will have the opportunity to consume the prepared meals at home.
40823487|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|In-person group 60-minute sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
40823488|NCT05383443|BEHAVIORAL|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
40823489|NCT06607328|OTHER|Assessment of participants in terms of different aspects.|This group was composed of individuals who have the prehypertensive stage.
40823490|NCT03431818|OTHER|Nasal cannula flow rate|This is a crossover study where observations will be obtained at five nasal cannula flow rates: 0.5, 1, 2, 4 and 6 liters per minute.
40823491|NCT05492799|DRUG|AX 250|biweekly infusion by intracerebroventricular (ICV) infusion
40823492|NCT04171180|DRUG|budesonide/formoterol|apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
40823493|NCT05346991|OTHER|Tobacco Free Teachers, Tobacco Free Society program|"The Tobacco Free Teachers, Tobacco Free Society (TFT-TFS) program provides teachers with the knowledge and skills to quit tobacco use, or to help someone else quit; it also helps schools comply with national tobacco control policies. School principals implement four TFT-TFS program components with teachers in their schools during school hours across an academic year (August-April):~* Adopting a school tobacco control policy~* Providing cessation support (e.g. distribution of self-help quit booklets and referrals to government cessation resources)~* Conducting monthly group discussions with teachers about tobacco~* Hanging six thematic posters in the school~With the goal of establishing a tobacco-free school environment, the program incorporates six program themes: 1. Teachers as Role Models; 2. Health Effects of Tobacco; 3. Motivation to Quit-or Help Others to Quit; 4. Skills to Quit; 5. Dealing with Withdrawal; and 6. Maintenance and Celebration."
40823494|NCT00906451|DRUG|Simvastatin|Simvastatin
40823495|NCT05346965|BEHAVIORAL|Musical training|The musical training intervention comprised songs, rhythm and visual creativity to encourage the children to experience music-making as fun.
40823496|NCT04946409|OTHER|no intervention|no intervention
40823497|NCT05709067|DIETARY_SUPPLEMENT|Probiotic|6 Billion CFU per day
40823498|NCT05709067|DIETARY_SUPPLEMENT|Placebo|0 CFU per day
40823499|NCT04777994|DRUG|ABBV-CLS-484|Oral Capsule
40823500|NCT04777994|DRUG|Programmed Cell Death-1 (PD-1) Inhibitor|Intravenous (IV) infusion
40823501|NCT04777994|DRUG|Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)|Oral Tablet
40823502|NCT01766492|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
40853039|NCT05720299|DRUG|Treatment with Akkermansia muciniphila|120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
41157217|NCT03453177|DRUG|Standard of Care + Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
41342059|NCT05058404|DRUG|Immunochemotherapy regimen: G-CVP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 4 cycles of G-CVP Q21;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
41342060|NCT05058404|DRUG|Immunochemotherapy regimen: G-CVP (Arm B)|"Arm B (Experimental arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 4 cycles of G-CVP Q21~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
41488775|NCT02969993|OTHER|Questionnaires|evaluating the voice outcome by the fullfilment of the voice handicap index
40853040|NCT05720299|OTHER|Treatment with placebo|120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
40823503|NCT04752137|DRUG|Indocyanine green|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
40823504|NCT04752137|DEVICE|SPY-PHI|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
40823505|NCT00338273|DRUG|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
41342061|NCT03573804|OTHER|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
40823506|NCT00338273|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
40823507|NCT02615860|OTHER|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
40823508|NCT02615860|PROCEDURE|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
40823509|NCT00607711|DRUG|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
40823510|NCT06608355|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen of brain.
41342062|NCT01170468|DRUG|Vitamin D3|Vitamin D3 5000 IU orally, daily for 2 years
40823511|NCT06606665|OTHER|Cognitive skills test|Cognitive skills; It will be evaluated with the Montreal Cognitive Assessment Scale.
40823512|NCT06606665|OTHER|Reaction time test|Reaction time; It will be evaluated with the 12-Red Square Test on the App-coo test application via tablet.
40823513|NCT06606665|OTHER|Quality of life assessment|Quality of life assessment; It will be evaluated with the Nottingham Health Profile.
40823514|NCT06606665|OTHER|Lower extremity muscle strength assessment|Lower extremity muscle strength assessment; It will be evaluated with a 30-second sit-and-stand test.
40823515|NCT06606665|OTHER|Hand grip strength measurement test|Hand grip strength measurement test; It will be evaluated with a dynamometer.
40823516|NCT06606665|OTHER|Pulmonary function assessment|Pulmonary function assessment; It will be evaluated by spirometry.
40823517|NCT06606665|OTHER|Balance assessment|Balance assessment will be done with the Wii Fit Balance Board.
40823518|NCT05421897|DRUG|Dinutuximab with Chemotherapy|Rapid infusion of dinutuximab in 4 hours or less
40823519|NCT05517213|DRUG|Etoposide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
40823520|NCT05517213|DRUG|Cyclophosphamide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
40823521|NCT06608108|OTHER|Non-intervention|Non-intervention
40823522|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
41157218|NCT03453177|PROCEDURE|PK|Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.
41157219|NCT03453177|PROCEDURE|Analysis of Bacterial Isolates|For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.
41488776|NCT06041841|DRUG|LB54640|LB54640 QD Oral
40823523|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
40823524|NCT00119912|PROCEDURE|A 1 Intervention arm Flex Sig|Screening by flexible sigmoidoscopy
40823525|NCT00119912|PROCEDURE|A 2 Intervention arm Flex Sig + iFOBT|In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
41342063|NCT01170468|DRUG|Placebo|Placebo orally, daily for 2 years
41342064|NCT00225212|DRUG|Rituximab 375 mg/m2|
40823526|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 5|(Serving 1: 5 grams of creatine + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
41018063|NCT05063097|OTHER|urine test|The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol \[THC\]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
41342065|NCT05861557|DRUG|Toripalimab|240mg, Q3W，I.V., D1, 2 cycles (1cycle of toripalimab before and after the SBRT radiotherapy, respectively), followed by the maintenance of toripalimab for 6 months after the surgery.
41018064|NCT05063097|OTHER|Fagerström questionnaire|Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.
41508986|NCT03579342|BEHAVIORAL|App-technology and active coaching to improve lifestyles behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
40823527|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 3|(Serving 1: 3 grams of creatine + 5 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
40823528|NCT06606704|DIETARY_SUPPLEMENT|Creatine Intermittent 5|(Serving 1: 2.5 grams of creatine + 5.5 grams of placebo in the morning, Serving 2: 2.5 grams of creatine + 5.5 grams of placebo at least 6 hours after Serving 1).
40823529|NCT06606704|DIETARY_SUPPLEMENT|Placebo|(Serving: 8 grams of placebo in the morning; Servings 2: 8 grams of placebo at least 6 hours after Serving 1).
40823530|NCT00183378|BEHAVIORAL|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
40823531|NCT00183378|BEHAVIORAL|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
40823532|NCT00183378|BEHAVIORAL|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
40823533|NCT00183378|BEHAVIORAL|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
41018065|NCT05063097|OTHER|Exhaled carbon monoxide (CO) measurement|Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of \> 3 parts per million (ppm) signifying active smoking.
41018066|NCT01190540|BEHAVIORAL|Training and supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.
41342066|NCT05861557|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Subjects were treated with SBRT radiotherapy (8Gy\*5Fx), after 1 cycle of immunotherapy
41342067|NCT05402722|DRUG|Eribulin|Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
41342068|NCT05402722|DRUG|anti-PD-1 antibody|Sintilimab Injection，Intravenous infusion，200mg，3-week cycle
41342069|NCT00552994|DEVICE|Cypher Select plus|Drug eluting stent
41342070|NCT00552994|DEVICE|Xience V stent|Drug eluting stent
41342071|NCT02668172|DRUG|Pasireotide LAR 60 mg|as mono-therapy or in combination with pegvisomant
41342072|NCT02668172|DRUG|Pegvisomant|only in combination with pasireotide LAR
40823534|NCT04072601|DRUG|Placebo oral tablet|Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
41342073|NCT01309373|OTHER|Patient assessment|2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
40823535|NCT04072601|DRUG|Atorvastatin 10mg|Tablet, can be adjusted to 2 tablets if tolerated
40823536|NCT04018560|BEHAVIORAL|Al-Anon Intensive Referral (AIR)|AIR is intended to facilitate Al-Anon participation.
40823537|NCT00221715|DEVICE|femoropopliteal artery bypass|Bypass by autologous saphenous vein
40823538|NCT00221715|DEVICE|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
40823539|NCT06275984|OTHER|online CPR-AED training|"The online CPR-AED training consists of successfully completing the online training course. To access the course, interested persons must register on a Moodle environment platform, with free and open access, through the following link: https://register.magnore.com/registre-curs-de-reanimacio -cardiopulmonary-dea/~Online training takes 3-4h and the participant will have access for 1 month (7x24h)."
40823540|NCT04253899|PROCEDURE|Appendectomy|Interval Appendectomy
40823541|NCT04253899|OTHER|Observation|observation and follow up
40823542|NCT00086801|DRUG|doxorubicin hydrochloride|given IV
40823543|NCT00086801|DRUG|gemcitabine hydrochloride|given IV
40823544|NCT00086801|DRUG|vinblastine|given IV
40823545|NCT00086801|PROCEDURE|fludeoxyglucose F 18 positron-emission tomography (PET) scan|
40823546|NCT00086801|PROCEDURE|CT scan|
40823547|NCT05697289|OTHER|satisfaction survey|Non-comparative longitudinal observational study over 12 months conducted during usual follow-up of patients living with HIV-1 and having changed treatment for an injectable dual therapy with prolonged release cabotegravir-rilpivirine. Decision to change treatment and follow-up of patients are part of routine care. Study is proposed after the doctor has taken the decision to modify treatment, the patient has accepted and injectable dual therapy is prescribed. It is based on self-questionnaires to collect patient perceptions (Patient-Reported Outcomes) and clinical and biological data collected routinely at inclusion and during follow-up visits.
40823548|NCT06232460|DIETARY_SUPPLEMENT|H80|5g, 10g \& 20g
40823549|NCT01070693|PROCEDURE|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
41018067|NCT01190540|BEHAVIORAL|Training and Supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.
41018068|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
41157220|NCT04117906|BEHAVIORAL|STAGE training for anxiety|STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.
40823550|NCT01070693|DEVICE|Prolene Hernia System|Prolene Hernia System
40823551|NCT01070693|PROCEDURE|Lichtenstein technique|Lichtenstein technique
40823552|NCT05693740|PROCEDURE|Accelerated crosslinking (ACXL)|Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.
40823553|NCT00091130|BIOLOGICAL|HspE7|Given SC
40823554|NCT00091130|OTHER|placebo|Given SC
41342074|NCT00168168|DRUG|G-CSF/Filgrastim|
41342075|NCT00617617|DIETARY_SUPPLEMENT|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
40823555|NCT00091130|OTHER|laboratory biomarker analysis|Correlative studies
41342076|NCT00617617|OTHER|Placebo|Control Group - Control Group participants will receive an identical placebo.
40823556|NCT06245057|OTHER|Maternity care home model (MCHM)|The maternity care home model is defined as office based prenatal care integrated with comprehensive social services.
40823557|NCT02830347|DRUG|Amoxicillin|Extraction
40823558|NCT02830347|PROCEDURE|Extraction|Extraction of third molars
40823559|NCT02378012|OTHER|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
40823560|NCT02378012|OTHER|Computer-Assisted Intervention|Receive iPad and instruction manuals.
40823561|NCT02378012|OTHER|Questionnaire Administration|Ancillary studies
40823562|NCT03380546|DRUG|Acarbose|Women will receive acarbose at an initial dose of 50 mg once daily in the beginning of the meal for which the postprandial glucose value is the highest, with progressive increase every 2 days or more: adding a pill before another meal, and then increasing dose of acarbose to 100 mg if post-prandial glucose goals are not obtained, with a maximal dose of 3 x 100 mg / day.
40823563|NCT03380546|DRUG|Prandial insulin|Women will receive prandial fast-acting insulin according to usual practice (routine care according to French recommendations), i.e. one injection before each meal usually.
40823564|NCT00190138|DEVICE|Bi-ventricular pacing|
40823565|NCT02562508|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
40823566|NCT02562508|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
40853041|NCT03578328|PROCEDURE|targeted temperature management|Temperature control to targeted temperature (32-36C) after return of spontaneous circulation after cardiac arrest and resuscitation
40853042|NCT01890564|OTHER|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
40823567|NCT04203069|DEVICE|Control group : Day-time compression sleeve|"In the control group, patients wear only day-time compression garment : lymphatrex during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
40823568|NCT04203069|DEVICE|Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit|"In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
40823569|NCT06605651|BIOLOGICAL|Anti-Staphylococcus aureus Bacteriophages (PP1493 and PP1815) intra-articular injection with 0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
40823570|NCT06605651|DRUG|0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
40823571|NCT05680480|BIOLOGICAL|Telitacicept 240 mg|Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.
40823572|NCT05680480|BIOLOGICAL|Telitacicept 160 mg|Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.
40823573|NCT05680480|DRUG|Placebo|Participants will receive placebo weekly in addition to SOC for 48 weeks.
41018069|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
41018070|NCT01997775|DRUG|METFORMIN|Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 \> 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
41018071|NCT00062426|BIOLOGICAL|bevacizumab|
41018072|NCT00062426|DRUG|capecitabine|
41018073|NCT00062426|DRUG|fluorouracil|
41018074|NCT00062426|DRUG|leucovorin calcium|
41018075|NCT00062426|DRUG|oxaliplatin|
41018076|NCT05078736|OTHER|Moderate intensity intermittent training|In group A participants will receive moderate intensity intermittent training including running of 5 km with 1-min at 70% of maximal aerobic speed with interval of 1-min passive recovery, exercises will be performed by gym trainer for 5 weeks including 3 days/week
41018077|NCT05078736|OTHER|Moderate intensity continuous training|In group B participants will receive moderate intensity continuous training ran continuously the same 5 km at 70% of maximal aerobic speed, exercises will be performed by gym trainer for 5 weeks including 3 days/week.
41157221|NCT01585805|PROCEDURE|Biopsy|Undergo biopsy
40823574|NCT05718752|DIAGNOSTIC_TEST|Maximal incremental exercise test|Gas exchange are measured during all the test on ergocycle until oxygen consumption reach its maximum value
40823575|NCT05718752|DIAGNOSTIC_TEST|30-min submaximal exercise test|A 30-min submaximal test on ergocycle. Gas exchange are measured during all the test. Blood samples are collected before, at the end of exercise and after 3 hours of recovery
40853043|NCT01890564|OTHER|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
41157222|NCT01585805|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample collection
40853044|NCT01890564|OTHER|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
40853045|NCT02021630|OTHER|Outcomes|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
40853046|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
41157223|NCT01585805|DRUG|Cisplatin|Given IV
41157224|NCT01585805|PROCEDURE|Computed Tomography|Undergo CT
41157225|NCT01585805|DRUG|Gemcitabine|Given IV
40823576|NCT05581082|OTHER|Pragmatic, exploratory study of Precision Medicine|This pragmatic, exploratory study consists of individuals with frailty who are referred from routine care to a physical therapy-based strengthening intervention. This specific study will collect ancillary measures to evaluate our outcomes. The study staff will not be conducting any interventions themselves - the physical therapy program is as per usual care.
40823577|NCT06607276|DRUG|Adebrelimab and capecitabine|Adebrelimab：1200mg, iv, q3w capecitabine:1250mg/m2, po, bid,treat for 2 weeks and rest for 1 week
41342077|NCT04705168|DIAGNOSTIC_TEST|Nevisense electrical impedance spectroscopy|Each participants will undergo Nevisense electrical impedance spectroscopy in order to characterize the electrical impedance spectroscopy scores of nevi in patients with ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) \> 5 mm in diameter
41342078|NCT03699904|DRUG|Valaciclovir|Participants will self-administer Valaciclovir 1 gram three times daily for 8 weeks.
40823578|NCT06607276|DRUG|capecitabine|capecitabine:1250mg/m2, po, bid,treat for 2 weeks and rest for 1 week
40823579|NCT02273076|DEVICE|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
40823580|NCT04699812|DEVICE|ELECTROCARDIOGRAM (ECG) PATCH WEAR|ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
40823581|NCT00873379|DIETARY_SUPPLEMENT|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
40823582|NCT00873379|DIETARY_SUPPLEMENT|placebo|half a white placebo tablet
40823583|NCT06608381|PROCEDURE|Arm I (Total omentectomy),|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
40823584|NCT06608381|PROCEDURE|Arm II (Partial omentectomy)|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
40823585|NCT03216304|DRUG|100 mg safinamide|"Safinamide will be administered as follows:~* Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~* Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~* Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
40823586|NCT03216304|DRUG|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
40823587|NCT03216304|DRUG|20 mg rosuvastatin calcium period 2|- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
40823588|NCT00387179|DRUG|Melatonin|5mg, pill, once
40823589|NCT00387179|DRUG|Methylxanthine|2.9 mg/kg, pill, once
40823590|NCT00387179|PROCEDURE|Light Therapy|Bright light exposure
41342079|NCT03699904|DRUG|Placebo capsules (containing Avicel blend)|Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
40853047|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
40853048|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
40853049|NCT01481454|BIOLOGICAL|2011 to 2012 Trivalent Influenza Vaccine|0.5 mL, Intramuscular
41018078|NCT01607034|DRUG|Dexpramipexole|150 mg single dose
41018079|NCT01498926|DRUG|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
41018080|NCT01498926|DRUG|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
41018081|NCT01231763|OTHER|No intervention (not applicable)|No intervention (not applicable)
41157226|NCT01585805|DRUG|Gemcitabine Hydrochloride|Given IV
41342080|NCT05605704|DRUG|atherolive|In each study population(Diabetic), the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
40823591|NCT03897127|DRUG|Cytarabine|"Induction therapy: 200 mg/m2 i.v. (continuously) d1-7~Consolidation therapy:~* Patients age 18-60 years~  o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3~* Patients age \>60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3"
40823592|NCT03897127|DRUG|Daunorubicin|Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3
40823593|NCT03897127|DRUG|CPX-351|"Induction 1:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3,5~Induction 2:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3~Consolidation therapy:~o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine \[65 U/m²\] i.v. (90 min) d1,3"
40823594|NCT05639153|DRUG|DR30303|DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
40823595|NCT04003480|DEVICE|FRAME|External support for vein grafts in peripheral bypass surgery
40823596|NCT02445677|DEVICE|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
40823597|NCT02445677|DEVICE|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
41018082|NCT00991302|BEHAVIORAL|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
41018083|NCT03541733|OTHER|mid-gut tubing|mid-gut tubing at different time
41018084|NCT05134376|OTHER|During Episiotomy Repair, Women Will Be Watching Virtual Reality Glasses Accompanied by Music|Unlike the experimental group, only video and music application will not be applied to the pregnant women included in the control group. Other applications will be done exactly.
41018085|NCT05298852|DIAGNOSTIC_TEST|High resolution computed tomography of the chest|All participants were subjected to High resolution computed tomography of the chest.
41018086|NCT04603924|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
41157227|NCT01585805|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41157228|NCT01585805|DRUG|Veliparib|Given PO
41157229|NCT05418868|DRUG|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be administered.
41157230|NCT05418868|DRUG|Cabotegravir >=400 mg/mL|CAB \>=400 mg/mL will be administered by IM or SC injection.
41157231|NCT05418868|DRUG|Cabotegravir Formulation I|CAB Formulation I will be administered by IM injection.
41157232|NCT05418868|DRUG|rHuPH20|rHuPH20 will be administered.
41157233|NCT05418868|DRUG|RPV|RPV will be administered by IM injection.
41342081|NCT03954704|DRUG|Dalutrafusp alfa|Administered intravenously
41342082|NCT03954704|DRUG|mFOLFOX6 Regimen|Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin
40823598|NCT05432388|DRUG|remibrutinib|oral tablets
41018087|NCT04603924|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
41157234|NCT04239157|BIOLOGICAL|Canakinumab|Given SC
41157235|NCT04160000|DEVICE|Catheter ablation|Delivery of physical energy from external energy source via percutaneously inserted electrophysiologic catheter to destroy heart tissue in the human atrium and adjoining vasculature
41157236|NCT04160000|DRUG|Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation|Administration of antiarrhythmic drug to achieve either rate control or restoration of sinus rhythm for management of atrial fibrillation
41157237|NCT04160000|DEVICE|Insertion of CardioMems Hemodynamic monitor|Insertion of wireless hemodynamic monitor to provide hemodynamic data to guide heart failure therapy to achieve heart failure improvement.
41342083|NCT03954704|DRUG|Dalutrafusp alfa|Administered intravenously
40823599|NCT05432388|DRUG|placebo|oral tablets
40853050|NCT00856544|DRUG|CP-690,550|Film coated tablet, 5 mg PO BID, 1 year
40853051|NCT00856544|DRUG|CP-690,550|Film coated tablet, 10 mg PO BID, 1 year
40853052|NCT00856544|DRUG|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
40853053|NCT00856544|DRUG|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
40853054|NCT01169935|DRUG|Administration of intra-dermal Endorem|single dose, intradermal
40853055|NCT01169935|BIOLOGICAL|Mantoux test|single dose, intradermal
40853056|NCT01169935|BIOLOGICAL|Autologous Endorem-labelled mononuclear cells|single dose, intravenous
40853057|NCT01169935|DRUG|Administration of Endorem|single dose, intravenous
40853058|NCT01510743|PROCEDURE|Catheterization of subclavian vein|Catheterization of subclavian vein
40853059|NCT01510743|PROCEDURE|Catheterization of internal jugular vein|Catheterization of internal jugular vein
40853060|NCT00777361|DRUG|AZD3480|Iv single dose, 4-hour infusion of 25 mg
40823600|NCT05037448|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
40823601|NCT01168791|DRUG|doxorubicin in combination with palifosfamide-tris|"palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles."
40823602|NCT01168791|DRUG|doxorubicin in combination with placebo|"doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles."
40823603|NCT05976503|DRUG|Tunodafil Hydrochloride Tablets|100mg Tunodafil Hydrochloride Tablets
40823604|NCT05976503|DRUG|Placebo|Placebo
40823605|NCT05976503|OTHER|Alcohol|0.5 g/kg alcohol
40823606|NCT06484621|BEHAVIORAL|Acceptance and Commitment Therapy-Based Physical Activity Intervention|Provides experiential training in values-clarification and acceptance strategies to increase autonomous motivation for achieving self-determined physical activity goal via group-based workshops, email feedback, and brief support telephone calls.
40823607|NCT06484621|BEHAVIORAL|Physical Activity Education Control|Provides didactic instruction on physical activity and behavioral strategies for achieving prescribed physical activity goals via group-based workshops, email feedback, and brief support telephone calls.
40823608|NCT02345668|BEHAVIORAL|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
40823609|NCT02345668|DRUG|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
40823610|NCT02345668|BEHAVIORAL|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
40823611|NCT00777400|DRUG|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
40823612|NCT05969548|DEVICE|active 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
40823613|NCT05969548|DEVICE|active 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
40823614|NCT05969548|DEVICE|active 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
40823615|NCT05969548|DEVICE|sham 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
40823616|NCT05969548|DEVICE|sham 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
40823617|NCT05969548|DEVICE|sham 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
40823618|NCT05551013|DRUG|APG-157|"APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~* Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~* Progression post TMZ (will receive APG-157 only)~* Ongoing Optune (will receive concurrent Optune + APG-157)~* Progression post Optune (will receive APG-157 only)"
41157238|NCT04160000|DRUG|Empiric heart failure drug therapy|Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.
41157239|NCT01837719|DRUG|Atazanavir|300-mg capsule
41157240|NCT01837719|DRUG|Cobicistat|150-mg tablet
41157241|NCT01837719|DRUG|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
41488777|NCT02202863|DIETARY_SUPPLEMENT|Red wine grape pomace flour (WGPF)|Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
41488778|NCT05610592|PROCEDURE|total mesorectal exicision|
40823619|NCT00435162|DRUG|Valsartan 0.25 mg/kg|once daily
40823620|NCT00435162|DRUG|Valsartan 1.0 mg/kg|once daily
40823621|NCT00435162|DRUG|Valsartan 4.0 mg/kg|once daily
40853061|NCT00777361|DRUG|AZD3480|Oral solution single dose of 50 mg
40853062|NCT02376972|DRUG|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
41157242|NCT03283878|DRUG|Cefazolin|"Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2."
41488779|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 24 weeks
41488780|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.0 mcg/kg QW SC for 24 weeks
41488781|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 16 weeks
41488782|NCT00302081|DRUG|ribavirin (SCH 18908)|800-1200 mg daily for 24 weeks
41488783|NCT00302081|DRUG|ribavirin (SCH 18908)|800-1200 mg daily for 16 weeks
41488784|NCT01152866|DRUG|Choriogonadotropin alpha (r-hCG)|Choriogonadotropin alpha 250 μg was administered subcutaneously on the day following the last dose of follitropin alpha (Gonal-F).
41488785|NCT01941940|DRUG|Tocilizumab|Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
41488786|NCT01941940|DRUG|DMARDs|Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
40823622|NCT00962169|OTHER|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
40823623|NCT00962169|OTHER|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
41488787|NCT04120584|DEVICE|Forma Eye Applicator|"Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.~The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment."
41488788|NCT03008239|DEVICE|FiberSense sensor|The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
41488789|NCT03008239|DEVICE|Dexcom Sensor|Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.
40823624|NCT02172495|DRUG|Tiotropium bromide|Tiotropium bromide 18 micrograms
40823625|NCT00067847|BEHAVIORAL|State-directed nutrition policy change|
40823626|NCT02120170|PROCEDURE|Colon polypectomy|
40823627|NCT01713660|DEVICE|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
40823628|NCT03285087|DRUG|DEX 0.2 μg/kg/h.|DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
40823629|NCT00416156|BEHAVIORAL|Lifestyle modification|
41342084|NCT02763267|OTHER|Oral glucose tolerance test|75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant \[4-14 weeks gestation\] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at 6-12 weeks postpartum)
41342085|NCT01731275|DRUG|E6011|A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
41488790|NCT05084703|OTHER|Functional tests|"* Symmetry indices between the two limbs obtained thanks to the scores of the functional tests : Y balance test~* Muscle endurance index obtained from functional test scores : Closed Kinetic Chain Upper Extremitie Stability test"
41488791|NCT01860911|DRUG|Insulin|
40823630|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
40823631|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
40823632|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
40823633|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
40823634|NCT06517251|OTHER|Arm-hand BOOST|"Aha BOOST consists of 20 one-hour BOOST sessions (spread over 4 weeks, 5 days a week) and one hour of individual technology-supported therapy per week (divided in two times 30 minutes), with the aim to provide intensive, goal-oriented upper limb therapy. The sessions will be executed with a maximum of two participants, under supervision of a trained therapist.~The group sessions are focused on four key aspects: neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. The different exercises are tailored to the individual patient, based upon ongoing assessment, discussion within the group of therapists, and individual treatment goals of the patient. Additionally, patients exercise two times 30 minutes per week with the AMADEO® (Tyromotion, Austria), an upper limb robotic device, focusing on finger and hand rehabilitation."
41157243|NCT06598631|DRUG|Volenrelaxin|Administered SC
41157244|NCT06598631|DRUG|Placebo|Administered SC
41157245|NCT06125639|BEHAVIORAL|Sauna Bathing|Participants will take part in 9 evening sauna bathing session over the course of 3 weeks
41488792|NCT01860911|DRUG|NG-monomethyl-L-arginine|
41488793|NCT06095336|OTHER|telerehabilitation|The individuals included in the research will be divided into three groups. Group 1 (experiment): This is the exercise group followed by the telerehabilitation method. Group 2 (experiment): This is the group where traditional physical therapy methods will be applied. The 3rd group will be taken as the control group, there will be no intervention and they will be asked to continue their daily lives.
40823635|NCT06517251|OTHER|Lower limb BOOST|L-BOOST consists of 20 one-hour sessions and a personalized two times 30 minutes self-exercise program per week and focused on strengthening exercises for the lower limbs and general reconditioning. During the group sessions, circuit-class training is performed according to a standardized written protocol: 20 minutes of cycling on a sitting bike, 20 minutes of strengthening exercises for muscles around hip and knee (e.g. sit-to-stand training), 10 minutes of knee exercises using quadriceps bench in free swing mode and 10 minutes of leg press exercises. Again, a gradual increase in levels of difficulty is provided. Additionally, each patient receives a self-exercise program (balance; strengthening of foot, knee, and hip muscles; walking exercises), which is executed two times 30 minutes per week under minimal supervision of a therapist. None of the exercises involve the use of the upper limb.
40823636|NCT00241631|DRUG|Fluticasone Propionate|500 u
40823637|NCT00241631|DRUG|placebo|
41488794|NCT01300052|DRUG|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
41488795|NCT01300052|DRUG|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
41488796|NCT01728402|PROCEDURE|blood draw, bone marrow procedure, or tissue biopsy|
41488797|NCT04450576|DIAGNOSTIC_TEST|Glycosylated hemoglobin|Glycosylated hemoglobin levels associated with correlative measures of diastolic cardiac function
41488798|NCT04469621|DRUG|SAR443122|Pharmaceutical form:capsule Route of administration: oral
41488799|NCT04469621|DRUG|Placebo|Pharmaceutical form:capsule Route of administration: oral
41488800|NCT03511443|DIAGNOSTIC_TEST|hsRDT|Testing highly sensitive RDT detection for low parasitemia
41488801|NCT02287129|DRUG|Oxaliplatin|130 mg/m2
41488802|NCT02287129|DRUG|Epirubicin|50 mg/m2
41488803|NCT02287129|DRUG|Capecitabine|625 mg/m2
41488804|NCT02287129|DRUG|5-FU|200 mg/m2
41488805|NCT02287129|DRUG|Carboplatin|2 mg/ml min
40823638|NCT00241631|DRUG|Theophylline|Theophylline placebo capcule
40823639|NCT06077994|BEHAVIORAL|digital Remote Patient Monitoring+BEPR+ (dRPM+)|In addition to the BEPR+ program as described, patients will use the Cloud Dx Connect Health System to take daily physiological readings (Blood pressure, heart rate, oximetry, body temperature and body weight). These data will be transmitted to a secured server supported by the provincial health care system. Participants and therapists will interact with these data in their respective dashboards and in conjunction with participants' determined medical action plan, engage in or make changes to participants current self-management regimens.
41488806|NCT02287129|DRUG|Paclitaxel|50 mg/m2
41488807|NCT02287129|RADIATION|radiation|total dosage 41,4 Gy
41488808|NCT02287129|PROCEDURE|Biopsy|translational analysis
41488809|NCT03949244|DRUG|Latanoprost 0.005%|Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
41488810|NCT03949244|DRUG|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
41488811|NCT03949244|DRUG|Normal saline 0.9%|Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
41488812|NCT03949244|DIAGNOSTIC_TEST|Nailfold capillaroscopy|An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
41488813|NCT01736241|DRUG|LY3053102|
41488814|NCT01736241|DRUG|Placebo|
41488815|NCT02768714|DRUG|Eurofarma's pegfilgrastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
41488816|NCT02768714|DRUG|Neulastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
41488817|NCT02362555|OTHER|no intervention was used in this observational study|
41488818|NCT00115557|OTHER|Practice intervention|Performance feedback, academic detailing, practice facilitation, IT support
41488819|NCT00115557|OTHER|Practice intervention 2|Performance feedback only.
41488820|NCT00063414|DRUG|Alicaforsen|
41488821|NCT03178526|DRUG|Lovastatin gel|Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
41488822|NCT03178526|DRUG|Placebo|placebo gel
41508987|NCT03579342|BEHAVIORAL|App-technology to improve lifestyle behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
41342086|NCT01731275|DRUG|E6011 Matching Placebo|A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
40823640|NCT06077994|BEHAVIORAL|Enhanced Breathe Easy Pulmonary Rehabilitation Program (BEPR+)|Patients will attend the BEPR+ program 3 days per week for 6 weeks or 2 days per week for 8 weeks (total of 16 sessions). Patients will receive 90 minutes of personalized and supervised exercise training (aerobic and resistance) and 60 minutes of education designed to promote self-management. Patients will also received one-on-one sessions with a therapist to review their medical action plan for exacerbation management, program and lifestyle goals (including physical activity), determine referral needs for other health services (i.e. smoking cessation, weight management, and psychological support). Patients will use an activity monitor for feedback and motivation for physical activity.
40823641|NCT00996294|PROCEDURE|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
40823642|NCT04529369|PROCEDURE|Middle lobe only Photoselective vaporization of the prostate (PVP)|Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes
40823643|NCT04529369|PROCEDURE|Complete PVP|Traditional Photoselective vaporization of the prostate PVP
40823644|NCT01209455|DRUG|Chlorphenamine and Ranitidine|We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
40823645|NCT01209455|DRUG|Paracetamol|Therapeutic IV administration of 1g paracetamol results in a plasma concentration of \~12 mg/l. To achieve a desired concentration of \~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
40823646|NCT01209455|DRUG|Paracetamol|To achieve a local paracetamol concentration of \~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
40823647|NCT03286946|PROCEDURE|block with Blunt-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
40823648|NCT03286946|PROCEDURE|block with sharp-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
40823649|NCT05849441|BEHAVIORAL|Aware Program|The program includes interactive, multimedia lessons for adolescent participants to learn, practice, and apply different mindfulness skills. Parent-adolescent pairs will have the option to subscribe to a mobile messaging service that includes progress reminders, encouragement, and practice content. Parent participants also have access to online resources to support and monitor their teen's use of the program.
40823650|NCT05423574|PROCEDURE|robotic Trans Abdomino Pre Peritoneal prothesis repair|The treatment of primary and incisional ventral hernia using the robotic assisted laparoscopy technique
41018088|NCT06567639|PROCEDURE|Catheter ablation|"Hybrid epicardial right ventricular (RVOT-EPI) mapping and Brugada syndrome substrate ablation technique.~The procedure is performed in the hybrid operating room. The Advisor™ HD-Grid Mapping Catheter is delivered inside the chest through a working port and positioned under thoracoscopic view over the pulmonary artery that is consequently labeled on EAM. As a standard protocol the mapping catheter is positioned over the pulmonary artery and moved down progressively over the RVOT-EPI under continuous thoracoscopic view and at least three consecutive beats are required for each recording location point with a stable catheter position."
41018089|NCT03154697|OTHER|Data collection of sleep disturbances in individuals with SMS|Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey
41342087|NCT04099836|DRUG|Atezolizumab|1200 mg IV every 3 weeks
41342088|NCT04099836|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks
40823651|NCT05041595|DIAGNOSTIC_TEST|Lyme diagnostic assay|Serological and immunoresponse assay
40853063|NCT02376972|DRUG|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
40853064|NCT02376972|DRUG|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
40853065|NCT02376972|DRUG|METROGEL VAGINAL|METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
40853066|NCT02233023|DRUG|Pramipexole|
40853067|NCT02233023|DRUG|Bromocriptine and other dopamine agonists|
41018090|NCT06066515|DRUG|survodutide|once weekly subcutaneous injection
41018091|NCT06066515|DRUG|Placebo|once weekly subcutaneous injection
41018092|NCT00452335|DRUG|Lubiprostone|12 mcg capsule once daily (QD)
41018093|NCT00452335|DRUG|Lubiprostone|12 mcg capsule twice daily (BID)
41018094|NCT00452335|DRUG|Lubiprostone|24 mcg capsule twice daily (BID)
41342089|NCT04601844|DRUG|Pozelimab|Single dose administered subcutaneously
41342090|NCT04601844|DRUG|Cemdisiran|Single dose administered SC
41342091|NCT02945943|OTHER|High Velocity Low Amplitude mobilization|Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
41342092|NCT02945943|OTHER|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
41342093|NCT02159989|DRUG|Sapanisertib|Given PO
41342094|NCT02159989|BIOLOGICAL|Ziv-Aflibercept|Given IV
40823652|NCT06378749|BEHAVIORAL|PreCharge|PreCharge is an intervention for Hereditary Cancer Syndrome Previvors that administers brief assessments and uses multivariate algorithms and tailoring technology to provide timely, individualized, bi-directional text messages to improve resilience and coping. The program uses proven approaches to behavior change tailoring to increase resilience by promoting a positive mindset, strong social connections, and a deep sense of meaning and purpose. It will also proactively provide access to online tools prior to medical appointments to address scanxiety (e.g., management of emotion tips; mindfulness meditation; communication scripts; breathing exercises). At any time, users will be able to text a trigger word to indicate that they need extra support and will receive just-in-time assistance via text message.
40823653|NCT02182661|DRUG|Ba253BINEB|
40823654|NCT05747482|OTHER|Surgery procedure|Omentectomy vs omental preservations during gastric surgery
40823655|NCT04835909|BEHAVIORAL|Modern board and card games group|Modern board and card games group
40823656|NCT04835909|BEHAVIORAL|Paper and pencil tasks group|Paper and pencil tasks group
40823657|NCT02511483|DRUG|Propranolol PO|20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
40823658|NCT02511483|DRUG|IV-PCA morphine|Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
40823659|NCT02511483|DRUG|Placebo PO|Placebo tablets administered with the same schedule of Propranolol tablets
40823660|NCT02511483|PROCEDURE|Quantitative Sensory Testing (QST)|Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
40823661|NCT02511483|OTHER|Psychometric assessment|Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
40823662|NCT02511483|GENETIC|COMT-haplotypes|Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
40823663|NCT06225024|DEVICE|ESWT|Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects
40823664|NCT06225024|DRUG|BoNT A|BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
40823665|NCT01610440|BIOLOGICAL|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
40823666|NCT01472783|DRUG|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
40823667|NCT01990430|BEHAVIORAL|Exercise Intervention|"Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.~The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer."
40823668|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
40823669|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
40823670|NCT05859373|COMBINATION_PRODUCT|TQB2450 injection, sequential or concurrent chemoradiation|TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
40823671|NCT00898300|OTHER|biologic sample preservation procedure|
40823672|NCT00898300|PROCEDURE|biopsy|
40823673|NCT03488888|DRUG|Normal Saline 0,9%|Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
40823674|NCT03488888|DRUG|Bupivacaine|Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
40823675|NCT03403231|BEHAVIORAL|INVENT Secure Messaging Intervention|We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
40823676|NCT00150358|DRUG|Sildenafil Citrate|
41157246|NCT04270656|PROCEDURE|Insulin pump therapy|5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)
41157247|NCT04270656|PROCEDURE|Multi-injection treatment ( MDI ).|Corresponds to an outpatient visit if the patient is randomized into the multi-injection group
41342095|NCT06225804|DRUG|ABSK112|In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
41342096|NCT00909818|RADIATION|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
41342097|NCT00909818|RADIATION|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
41342098|NCT02502955|PROCEDURE|Comparison autopsy methods|Comparison of post-mortem angiography/virtual autopsy and medical autopsy
41342099|NCT05998824|BEHAVIORAL|SCD-specific COVID-19 vaccination information (SCVI) video|SCD-specific COVID-19 vaccination information (SCVI) video developed by health care providers with input from a community advisory board of people with sickle cel disease and their caregivers.
41342100|NCT05118750|DRUG|ALTO-300 oral (PO) tablet|One tablet daily
41342101|NCT02943668|DRUG|Deferasirox|Given PO
41342102|NCT02943668|OTHER|Laboratory Biomarker Analysis|Correlative studies
40823677|NCT00324428|PROCEDURE|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
40823678|NCT02715882|DRUG|CBLB502|
40823679|NCT02715882|DRUG|Placebo|
40823680|NCT00113646|DRUG|MEDI-507|MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
41342103|NCT02758561|BEHAVIORAL|Workshop|"The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist."
40823681|NCT00113646|PROCEDURE|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6
40823682|NCT05059821|BIOLOGICAL|Peptide cancer vaccine|Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
40823683|NCT02811913|OTHER|repetitive transcranial magnetic stimulation (rTMS)|"3 types of interventions on different sessions~* session 1 - High frequency rTMS targeting contralesional sensory cortex~* session 2 - Low frequency rTMS~* session 3 - sham rTMS"
41342104|NCT00558740|OTHER|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
41342105|NCT03084432|DIAGNOSTIC_TEST|Dual Energy X-ray Absorptiometry|Dual Energy X-ray Absorptiometry done for both studied groups
40823684|NCT02811913|OTHER|peripheral sensory stimulation|peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS
40823685|NCT01389401|DRUG|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
40823686|NCT02200419|OTHER|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
40823687|NCT02230761|DRUG|XOPH5 Ointment|
40823688|NCT02230761|DRUG|Placebo|
40823689|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with carbohydrate counting|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the total grams of carbohydrates counted. This is the same as commercial hybrid closed-loop insulin therapy (standard treatment).
40823690|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with meal size estimation|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the qualitative amount of carbohydrates estimated (e.g., low-carb meal).
40823691|NCT06021158|COMBINATION_PRODUCT|Fully automated Lyumjev delivery system with meal detection|In this system, the patient does not initiate a Lyumjev insulin bolus at mealtime. An algorithm is used to detect a meal and administer a subsequent bolus, rather than requiring a carbohydrate count.
40823692|NCT04926207|BEHAVIORAL|Physical Activity Breaks Intervention|Participants will be asked to walk on a treadmill for 3 min at a moderate intensity (55% of heart rate reserve) at an increasing speed and incline to reach and maintain their target heart rate.
41018095|NCT00315094|BEHAVIORAL|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
41018096|NCT03525834|DRUG|Everolimus|Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.
41018097|NCT02097134|DRUG|Melphalan|Given IA
41157248|NCT06315751|DRUG|Gemlapodect|Gemlapodect is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of tics associated with TS. Administered in the form of oral capsules.
41508988|NCT03035578|DRUG|Morphine|Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
41018098|NCT00677339|DRUG|L-arginine|L-arginine 6g orally daily
41018099|NCT00677339|DRUG|Vitamin D|Cholecalciferol 50000 IU once monthly orally
41018100|NCT00677339|DRUG|Placebo L-arginine|placebo L-arginine once daily
41018101|NCT00677339|DRUG|Placebo Vitamin D|placebo vitamin D orally once monthly
41157249|NCT06315751|DRUG|Placebo|Administered in the form of oral capsules with inert ingredients.
41157250|NCT03277586|DRUG|Probio'Stick|Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
40823693|NCT04926207|BEHAVIORAL|Talking Breaks Control|Every 30 min a researcher will start a brief conversation with a participant based on a pre-selected topic, which will change with each break. Topics are standardized across participants and include, for example, pollution, smart clothes, and hydration. A presentation will be followed by questions and answers. The break will last 3 min.
40823694|NCT00048815|DRUG|Citalopram|Established Selective Serotonin Reuptake Inhibitor antidepressant
40823695|NCT00048815|DRUG|St. John's Wort|Natural extract from the St. John's Wort plant.
40823696|NCT00048815|DRUG|Placebos|Placebo pill
40823697|NCT03289832|DIETARY_SUPPLEMENT|Crucera-SGS|Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
40823698|NCT03289832|DIETARY_SUPPLEMENT|Meriva 500-SF|Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
40823699|NCT05357664|DEVICE|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
40823700|NCT05357664|DEVICE|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
40823701|NCT02460783|OTHER|Boost (R) 5-2 diet|Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.
40823702|NCT02460783|OTHER|Healthy Living Diet|Counseling and educational material on diet portion, consistency
41157251|NCT03277586|DRUG|Placebo|Identically formulated and packaged inactive substance
41342106|NCT04179760|BIOLOGICAL|SCM-AGH|SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
40823703|NCT05345769|BIOLOGICAL|AM712(ASKG712)|AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
40823704|NCT03263923|BEHAVIORAL|Cognitive behavioral intervention and journaling|Cognitive behavioral skills training and 4 weeks of online journaling
40823705|NCT03263923|BEHAVIORAL|Reflective journaling|"Reflective journaling training and 4 weeks of online journaling~Training in reflective journaling and 4 weeks of online journaling"
40823706|NCT02082457|DRUG|YKP10811 5mg|
40823707|NCT02082457|DRUG|YKP10811 20mg|
40823708|NCT02082457|DRUG|YKP10811 placebo|
40823709|NCT02953457|BIOLOGICAL|Durvalumab|Given IV
40823710|NCT02953457|OTHER|Laboratory Biomarker Analysis|Correlative studies
40823711|NCT02953457|DRUG|Olaparib|Given PO
40823712|NCT02953457|BIOLOGICAL|Tremelimumab|Given IV
40823713|NCT02170363|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
40823714|NCT04546295|OTHER|Brushlink application|Brushlink application + Interproximal brush
40823715|NCT04546295|OTHER|Water-flosser|Water-flosser
40823716|NCT04546295|OTHER|Interproximal brush|Interproximal brush alone
40823717|NCT05211804|DRUG|Ophthalmic Drugs|Patients will receive the same treatment as if not a part of the project
40823718|NCT04657380|BEHAVIORAL|PLAN-e-PSY mobile application|"The full version of the application to be evaluated will result from the process of co-design phase of the intervention based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers, to define the content and form of the smartphone application during co-building workshops"
40823719|NCT04657380|BEHAVIORAL|Control Group|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network
40823720|NCT01459640|DRUG|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
40823721|NCT01459640|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells|"Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)"
40823722|NCT01539343|DRUG|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
40823723|NCT01252550|DIETARY_SUPPLEMENT|Activia® (125g/pot)|Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
40823724|NCT01252550|DIETARY_SUPPLEMENT|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
40823725|NCT00444704|DRUG|PRA-027|
40823726|NCT01963013|DEVICE|Non-returning catheter valve|
40823727|NCT01963013|DEVICE|Conventional urine bag|
40823728|NCT03351114|DRUG|Crisaborole|Apply Crisaborole 2% ointment to affected skin twice per day.
40823729|NCT05433038|DEVICE|skeletally anchored maxillary expander|used from day one and activated two times per day for two weeks
40823730|NCT04533542|OTHER|Measurement|Undergo sensory measurements
40823731|NCT04533542|OTHER|Questionnaire Administration|Ancillary studies
40823732|NCT06276582|DEVICE|Screening for neonatal jaundice with a mobile health device|Picterus Jaundice Pro will be used to screen for neonatal jaundice by taking 6 photos of the newborns skin, where the Picterus calibration card is place.
40823733|NCT02442453|DRUG|Topical application of curenext gel|Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
40823734|NCT02442453|DRUG|Placebo|Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
40823735|NCT04919226|DRUG|177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
40823736|NCT04919226|DRUG|CAPTEM (Capecitabine and Temozolomide)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
40823737|NCT04919226|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
40823738|NCT04919226|DRUG|Everolimus|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
40823739|NCT04919226|DRUG|FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
40823740|NCT00842439|BEHAVIORAL|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
40823741|NCT00842439|DIETARY_SUPPLEMENT|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
40823742|NCT01187446|RADIATION|Total skin electron beam therapy (TSEBT)|TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
41508989|NCT03035578|DRUG|Morphine|Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
40823743|NCT01187446|DRUG|Vorinostat|Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
40823744|NCT00501592|DRUG|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
40823745|NCT00501592|DRUG|Placebo|Placebo
40823746|NCT05239455|DEVICE|Reveos® Automated Blood Processing System|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.
40823747|NCT00668018|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg orally on demand prior to intercourse
40823748|NCT03197974|BEHAVIORAL|Mindfulness for Bipolar|Brief online self-management program with email coaching support
40823749|NCT03197974|BEHAVIORAL|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
40823750|NCT01322399|PROCEDURE|Structural Integration|"Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement."
40823751|NCT01322399|PROCEDURE|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
40823752|NCT00445848|BIOLOGICAL|bevacizumab|
40823753|NCT00445848|DRUG|erlotinib hydrochloride|
41157252|NCT05904288|DEVICE|Smartwatch Garmin Vivosmart [wearable sensor]|Garmin Vivo Smart is a fitness tracker, which is aimed at collecting patient's motor activity and heart rate data from embedded Inertial Movement Unit (IMU) and Photoplethismograph (PPG) sensors.
40823754|NCT02523131|DEVICE|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:~* Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
41342107|NCT04179760|OTHER|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
41342108|NCT03050307|DRUG|TAK-438|TAK-438 tablets
41508990|NCT00659958|DRUG|Zonisamide|300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
40823755|NCT02523131|DEVICE|Medtronic insulin pump 640G|Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
40823756|NCT05544045|DEVICE|Surpass Streamline Flow Diverter System|The Surpass Streamline FDS is indicated for use in the endovascular treatment of adults (age 18 years or older) with unruptured large (≥ 10 mm) saccular, wide-neck (neck width ≥ 4 mm or dome/neck ratio \< 2 mm) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm to ≤ 5.3 mm.
40823757|NCT04841759|OTHER|Exercise|8 week exercise program, nutritional \& psychological consultation
40823758|NCT00723866|OTHER|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
41018102|NCT06338475|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
41018103|NCT06338475|BEHAVIORAL|Individual Supportive Listening (ISL)|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
40823759|NCT00723866|OTHER|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
40823760|NCT00420615|DRUG|Patupilone and Omeprazole|
40823761|NCT00420615|DRUG|Patupilone + Midalzolam|
40823762|NCT00413829|DRUG|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
40823763|NCT04006210|COMBINATION_PRODUCT|ND0612 Solution for SC infusion|Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump
40823764|NCT04006210|COMBINATION_PRODUCT|Placebo for SC infusion|Placebo solution administered SC via infusion pump
40823765|NCT04006210|DRUG|Oral IR-LD/CD|Encapsulated LD/CD 100mg/25mg
41018104|NCT01159067|DRUG|deferasirox|Given orally
41157253|NCT05904288|DEVICE|Soturi™ [digital mobile app]|Soturi software is a proprietary mobile application, for people with Parkinson's Disease (PD) designed to record symptoms, by means of self-report diary, set reminders for medication intake. Soturi™ Physical Exercise Program and Speech Exercise Program.
41157254|NCT05904288|OTHER|Clinical Assessment|Outpatient repeated-measures clinical evaluations, which include assessment of motor symptoms through MDS-UPDRS and ecological motor tasks, to observe changes with respect to medication intake, and changes over a 6 month period time.
40823766|NCT04006210|DRUG|Placebo for Oral IR-LD/CD|Encapsulated Placebo for LD/CD 100mg/25mg
40823767|NCT00588172|DRUG|Metformin|1000mg bid for 1 week
40823768|NCT02692040|DRUG|G3215|Gut hormone analogue
40823769|NCT02692040|DRUG|Placebo|0.9% saline
40823770|NCT03372460|DEVICE|Active stimulation|For active tDCS, the investigators will use a 1x1 configuration with the anode placed over EEG coordinates AF7/Fp1/AF3 (using the 10-20 EEG convention) and the cathode between EEG coordinate OZ and the contralateral mastoid (covering approximately PO8/P8). The investigators will use 3x3 cm sponge covered electrodes and a 2mA current for 25 minutes per session.
40823771|NCT03372460|DEVICE|Sham stimulation|For sham tDCS, the investigators will use the same electrode and sponge configuration as active tDCS, but using the device study mode (10 µA over 15 ms current pulse applied every 550 ms, 3ms peak current).
40823772|NCT03372460|OTHER|Virtual Reality (VR)|Participants will undergo VR exposure to trauma-related context.
40823773|NCT04913987|DEVICE|Stryker Triathlon total knee replacement|Knee arthroplasty using a standard care total knee.
40823774|NCT04913987|DEVICE|Zimmer Biomet Persona Partial Knee unicondylar knee replacement|Knee arthroplasty using the Zimmer Biomet Persona Partial Knee (PPK).
40823775|NCT01882517|DIETARY_SUPPLEMENT|Yogurt that contains plant stanol esters|
40823776|NCT01882517|DIETARY_SUPPLEMENT|Placebo yogurt|
40823777|NCT00355537|DRUG|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
40823778|NCT00355537|DRUG|0.9% saline|Saline injection intramuscular every 2 weeks
40823779|NCT00524953|DEVICE|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last \~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
40823780|NCT03824405|DRUG|BTX 1204|BTX 1204 liquid formulation
40823781|NCT03824405|DRUG|Vehicle|Vehicle liquid formulation
40823782|NCT00269269|DRUG|antihypertensive drug|
40823783|NCT00269269|BEHAVIORAL|placebo|
40823784|NCT00881153|DRUG|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
40823785|NCT00881153|DRUG|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
40823786|NCT05234424|OTHER|THRIVE|During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.
41018105|NCT05634265|BEHAVIORAL|Vijana-SMART|The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
41342109|NCT03050307|DRUG|Lansoprazole|Lansoprazole capsules
40823787|NCT05599139|BEHAVIORAL|Low iodine diet|Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake \< 50 mcg per day and thereby depleting the overall iodine store in the body.
40823788|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-1|Section 1: Deep breathing exercises: A deep breath is taken as far as possible by raising the arms up to the sky. Breathing is held for 4-5 seconds after deep inspiration. Breathing is performed rhythmically and slowly, while the arms are placed in a normal position. After deep inspiration, one can exhale either by forming the lips in the whistling position or by laughing. In each deep breathing exercise technique, the expiration time of the exhalation process should be longer than the inspiration time.
40823789|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-2|Section 2: Warm-up exercises (10 minutes): Hands are clapped by holding parallel to each other. The fingertips and the palms touch each other, stimulating the acupuncture points on both hands, and the individual's energy level rises. In order to further raise the energy level and synchronize the movements of the group, a rhythm is added in the form of 1-2, 1-2-3. After several rhythmic hand-clapping movements, one more movement is added. Hands are clapped by swinging left and right. Then, an audible rhythm in the form of ho, ho, ha-ha-ha is also added to the hand-clapping movement. People in the group look at each other, and smile.
40823790|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-3|"Section 3: Childish games (10 minutes): Childish games are used that will help to laugh for no reason, just like a child. Imagining these games and plays, the arms are raised upwards in the form of a Y with palms facing the sky, motivating the group by saying very good (clap), very good (clap), yes. The leader of laughter yoga speaks out very good (clap), very good (clap), hey (arms to the right and left) to keep the group's energy high and generate enthusiasm in the deep breathing exercises and laughter exercises sections. According to the energy and desire of the group, this section is completed after about 10 minutes."
41342110|NCT03050307|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
41342111|NCT03050307|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
40823791|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-4|"Section 4: Laughter exercises (15 minutes): This section contains a variety of laughter exercises that will laugh, such as greetings, laughter cream, exploding balloon laughter, preparing and drinking strawberry milk, bonuses, hot soup, lion, aloha, bird, appreciation, elevator, and cream pie. A laugh is raised by doing only laughter exercises for no reason at all. At the end of this section, relaxation is achieved for about three minutes using deep breathing exercises. The group is given verbal guidance Put your hand on your heart, feel your heartbeat, let's exhale with a smile, make a wish or pray, smile as if we had achieved our wish, and the laughter yoga session is terminated."
40823792|NCT03294954|GENETIC|GINAKIT Cells|"Six dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~* Dose Level 5 = 3 x 10\^8~* Dose Level 6 = 1 x 10\^9"
41342112|NCT03050307|DRUG|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
41342113|NCT00772811|DRUG|Flu-Mel|"* Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.~* Melphalan will be administered following the completion of Fludarabine infusion at day -2."
41342114|NCT03674307|OTHER|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
41342115|NCT03674307|OTHER|Regular Screening|Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry
41342116|NCT01086449|BIOLOGICAL|Herpes Zoster Vaccine GSK 1437173A|Investigational vaccine (GSK 1437173A) administered intramuscularly.
41342117|NCT01908855|BEHAVIORAL|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
41342118|NCT01908855|BEHAVIORAL|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
41342119|NCT03858569|PROCEDURE|active management of third stage of labor|Active management of the third stage of the labor will be done administering oxytocin and cord traction.
41342120|NCT03245294|PROCEDURE|lumbar epidural injection|the pattern of pressure decrease from ligamentum flavum to epidural space
41342121|NCT00874224|PROCEDURE|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
41342122|NCT00874224|PROCEDURE|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
41342123|NCT01878240|PROCEDURE|EVAR without coils embolization/ Coils embolization during EVAR|
41342124|NCT05205928|DRUG|Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy|The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.
41342125|NCT00174889|DRUG|Pregnenolone|
41342126|NCT00648492|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
41342127|NCT00648492|DRUG|Glucophage® XR 500 mg|500mg, single dose fed
41342128|NCT00083304|DRUG|Efaproxiral|"75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).~Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days."
41342129|NCT00083304|RADIATION|Whole Brain Radiation Therapy (WBRT)|3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
41342130|NCT00083304|OTHER|Supplemental Oxygen|"4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days."
41342131|NCT00096304|DRUG|docetaxel|
41342132|NCT00096304|DRUG|epirubicin hydrochloride|
41342133|NCT04190446|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41342134|NCT04190446|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
41342135|NCT04190446|OTHER|Quality-of-Life Assessment|Ancillary studies
41342136|NCT04190446|OTHER|Questionnaire Administration|Ancillary studies
41342137|NCT04190446|PROCEDURE|Computed Tomography|Undergo CT scan
41342138|NCT04190446|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41342139|NCT04190446|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41508991|NCT00586534|BEHAVIORAL|I/GDC + VR/CER|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
40823793|NCT05039671|BEHAVIORAL|Measurement-based care (MBC)|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
40823794|NCT04216368|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
40823795|NCT04216368|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
41342140|NCT05740267|PROCEDURE|Natural Orifice Specimen Extraction|After bowel resection, all bowel anastomoses are created via side-to-side intracorporeal anastomosis, either isoperistaltic or antiperistaltic. The surgical steps of NOSE with the transrectal method are illustrated in Figure 1. First, the rectosigmoid colonic lumen is blocked with a bowel clamp. After rectal irrigation with povidone-iodine water, a transanal endoscopic microsurgery (TEM) scope or Alexis wound protector is inserted through the anus, reaching the upper rectum. Enterotomy is performed at the upper rectum, and a suction device is used to clean any fecal spillage. The TEM scope is pushed forward beyond the rectal opening, and the specimen is extracted with the TEM scope. The rectal opening is closed with a barbed suture, and an air leak test is performed to identify anastomotic leakage.
41342141|NCT05551260|OTHER|Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition|"Day 0: sending of the information notice~Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)~Between day 1 and day 21 : second part of the Day 1 tests"
41342142|NCT05590104|PROCEDURE|Hysteroscopic CS scar defect repair|Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis.
41342143|NCT03581799|OTHER|Oral dispersible tablet|Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
41342144|NCT04687436|DEVICE|mechanical cervical ripening|mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon
41342145|NCT04970433|PROCEDURE|Electroacupuncture (EA)|Acupuncture at Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation with a pair of electrodes connecting on LI4/PC6 and ST36/SP6.
41342146|NCT04970433|PROCEDURE|Laser acupuncture (LA)|The laser applies to each point for 40 seconds, which delivers 3 J of energy at each of the acupoints as those in electroacupuncture group.
41342147|NCT04970433|PROCEDURE|Sham laser acupuncture (SLA)|The laser device without any laser output applies on the acupoints the same as those in the LA group.
41342148|NCT02864706|DRUG|Everolimus|"All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used."
41342149|NCT02864706|DRUG|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
41342150|NCT02864706|DRUG|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
41342151|NCT02864706|DRUG|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
40823796|NCT02226562|DRUG|Potassium nitrate and sodium fluoride|3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride
40823797|NCT02226562|DRUG|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
40823798|NCT05486000|DEVICE|Atrial shunt implant system|"Patients with chronic left heart failure who meet the conditions of the clinical trial undergo interventional surgery with the Atrial Shunt Implant System"
40823799|NCT05642143|DIAGNOSTIC_TEST|Dual Energy X-ray Absorbtiometry scan|Evaluation of body composition and bone mass density
40823800|NCT05642143|DIAGNOSTIC_TEST|High-resolution peripheral quantitative computed tomography|High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.
40823801|NCT05642143|DIAGNOSTIC_TEST|Microindentation|Measures Bone Material Strength Index (BMSi) of cortical bone.
40823802|NCT05642143|DIAGNOSTIC_TEST|Thermal perception thresholds|Heat and cold perception thresholds
41488823|NCT04971265|BEHAVIORAL|Low SES/High Supports|Participant will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
41488824|NCT04971265|BEHAVIORAL|Low SES/ Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
41488825|NCT04971265|BEHAVIORAL|High SES/High Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
41488826|NCT04971265|BEHAVIORAL|High SES/Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
41488827|NCT01992523|DRUG|Ticagrelor mashed pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
41488828|NCT01992523|DRUG|Ticagrelor integral pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
41488829|NCT05043623|DEVICE|Rhinoswab Junior|Rhinoswab Junior is a single use self-administered nasal swab intended to collect clinical specimens from the patient's nasal passages
41342152|NCT02244658|DRUG|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7\~14 consecutive days
41157255|NCT05859009|PROCEDURE|EUS-Guided Therapy of Glue and Coil|This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.
41342153|NCT06315686|DRUG|pemetrexed|The efficacy of Furmonertinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was evaluated once a week during the treatment phase. After the brain lesions were evaluated as CR, the drug holiday study phase was added. During the study period, the patients were followed up once a week until the investigators deemed the subjects unfit to continue to participate in the study or the efficacy was evaluated as disease progression (PD).
41342154|NCT03011775|DRUG|Pioglitazone 15 mg Tablet|Pioglar (Ranbaxy India):1 tablet per day in the morning for 6 months
41488830|NCT05043623|DEVICE|Combined nose and throat swab|Combined nose and throat swab (standard of care)
41342155|NCT03011775|DRUG|Isosorbide Dinitrate 10Mg Tablet|1-2 tablets 2 times a day
41488831|NCT05043623|DEVICE|Saliva swab|Saliva swab
41488832|NCT05043623|DIAGNOSTIC_TEST|Abbott Panbio™ COVID-19 antigen self-test kit|COVID-19 antigen self-test kit for the screening of active COVID-19 infection. It is a single-use, in vitro, visually read rapid immunoassay that uses a human nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen. It is intended to be used manually by untrained lay users (self testing) in a private setting.
41488833|NCT01943721|DRUG|VISION5 Product|
40823803|NCT05642143|DIAGNOSTIC_TEST|Nerve conduction studies|Nerve conduction and amplitude of sural nerve
40823804|NCT05642143|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score 31|A validated self-assessment questionnaire quantifying the severity and distribution of autonomic symptoms across six domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor functions) by scoring 31 clinically selected questions
40823805|NCT05642143|DIAGNOSTIC_TEST|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
40823806|NCT05642143|DIAGNOSTIC_TEST|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
40823807|NCT05642143|DIAGNOSTIC_TEST|Assessment of cardiovascular autonomic neuropathy|Electrocardiographic recordings at rest and during cardiovascular autonomic reflex tests.
41488834|NCT02196519|DEVICE|Sylys Surgical Sealant|
41488835|NCT04415736|OTHER|No intervention, observational study|
40823808|NCT05642143|DIAGNOSTIC_TEST|Handgrip strength|Evaluation of muscle strength
40823809|NCT05642143|DIAGNOSTIC_TEST|Force plate platform|Evaluation of balance while standing still
41342156|NCT03011775|DRUG|Acetylsalicylic Acid 75Mg Tablet|1 tablet per a day
41342157|NCT03011775|DRUG|Bisoprolol Fumarate 2.5 MG Oral Tablet|1 tablet per a day
41342158|NCT03011775|DRUG|Rosuvastatin Calcium 20 MG Oral Tablet|1 tablet per a day
41342159|NCT03011775|DRUG|Ramipril 5 MG|1 tablet per a day
41342160|NCT01226472|BIOLOGICAL|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
41342161|NCT01604434|PROCEDURE|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
41342162|NCT01604434|PROCEDURE|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
41342163|NCT04319445|BEHAVIORAL|Mindfulness session(s)|The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).
41342164|NCT01581905|PROCEDURE|Conventional Laparoscopic Hysterectomy (LH)|Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
41342165|NCT01581905|PROCEDURE|Robot Assisted Hysterectomy|Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
41342166|NCT02015104|BIOLOGICAL|BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))|TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
40823810|NCT05642143|DIAGNOSTIC_TEST|Biospecimen collection|Biochemistry including bone turnover markers, glycemic status, inflammation markers i.e
40823811|NCT05642143|DIAGNOSTIC_TEST|Isometric leg extension strength|Evaluation of muscle strength
40823812|NCT05642143|DIAGNOSTIC_TEST|Michigan Neuropathy Screening Instrument|MNSI is used to assess status of peripheral neuropathy. It includes two separate assessments: a 15-item self-administered questionnaire and a lower extremity examination that includes inspection and assessment of vibratory sensation and ankle reflexes.
40823813|NCT00236496|DRUG|topiramate|
40823814|NCT03009708|OTHER|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
41157256|NCT05859009|DRUG|Non-Selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
41157257|NCT00377312|DRUG|Parathyroid Hormone (1-34)|PTH(1-34) IV given over a one week period
41342167|NCT02015104|BIOLOGICAL|PANVAC|A recombinant virus vector vaccine containing genes for human carcinoembryonic antigen (CEA), mucin-1 (MUC-1) and three co-stimulatory molecules (designated Triad of costimulatory molecules (TRICOM): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3).
41342168|NCT05537506|DEVICE|Bracket slot 0.018|That includes12 patients who will be treated using the bracket slot 0.018×0.025-inch system.
41342169|NCT05537506|DEVICE|Bracket slot 0.022|Includes12 patients who will be treated using the bracket slot 0.022×0.028-inch system
41342170|NCT04954391|PROCEDURE|Pulsed radiofrequency neuromodulation of the suprascapular nerve only|"PRF stimulation of the suprascapular nerve under ultrasound navigation in the notch of the scapula using the Cosman G4 apparatus with the introduction of stimulation: sensory: 50 Hz; 1 ms; up to 0.5 V; motor: 2 Hz; 1 ms; voltage - twice the sensory threshold, but not less than 1V; after introduction of 1 ml of 0.75% ropivacaine, PRF is performed: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec. Before removing the cannula, local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg.~Under the US navigation, an RF cannula will be placed sequentially at the axillary nerve in the quadrilateral foramen and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation and local administration of 0.75% ropivacaine 1 ml PRF session imitation lasting 480 sec will be carried out. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg"
41488836|NCT04046796|GENETIC|NGS Diagnostic|Blood take for genetic diagnostic.
41488837|NCT01850095|DRUG|treatment azelaic acid (azelan)|treatment for 6 months
41488838|NCT01850095|DRUG|dorspirenone/ethynil estradiol|
41488839|NCT05466006|PROCEDURE|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), SCTG will be harvested from the palate and sutured to the flap. Simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
41508992|NCT00586534|BEHAVIORAL|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
40823815|NCT01304212|DRUG|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
40823816|NCT01304212|DRUG|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
40823817|NCT01304212|DRUG|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
40823818|NCT01304212|DRUG|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
40823819|NCT03521713|DRUG|EPORON|"* Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~* Formulation : Solution in PFS"
41018106|NCT02501889|BEHAVIORAL|Walnut-rich weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
41342171|NCT04954391|PROCEDURE|Pulsed radiofrequency neuromodulation of the suprascapular, axillary, and articular branch of the lateral pectoral nerves|Under ultrasound navigation an RF cannula will be placed sequentially at the suprascapular nerve, at the axillary nerve and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation from RF generator and local administration of 0.75% ropivacaine 1 ml to each nerve, PRF neuromodulation session will be carried out: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec to each nerve. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow to each nerve. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg
41342172|NCT00284336|DRUG|Caelyx|
41342173|NCT00284336|DRUG|endoxan|
41342174|NCT01786434|DRUG|Routine medication arm|50 micrograms of fentanyl given before the procedure
41342175|NCT01786434|DRUG|Fentanyl on-demand arm|Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
41342176|NCT01828567|BEHAVIORAL|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.
41488840|NCT05466006|PROCEDURE|Soft tissue augmentation with xenogenic volume stable collagen matrix (VCXM)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), VCMX will be sutured to the flap and simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
41488841|NCT05292963|OTHER|Intervention #1: Fatherhood Works Program Delivered to Participants|Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
41488842|NCT05492253|OTHER|Infant fruit|Infants will be fed prune puree
40823820|NCT03521713|DRUG|EPREX|"* Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~* Formulation : Solution in PFS"
40823821|NCT03569748|DEVICE|IQOS|IQOS USE FOR 12 WEEKS
41488843|NCT05492253|OTHER|Infant vegetable|Infants will be fed carrot puree
41488844|NCT05492253|OTHER|Infant meat|Infants will be fed beef puree
40823822|NCT03569748|DEVICE|E-CIG|ELECTRONIC CIGARETTE FOR 12 WEEKS
40823823|NCT01901523|BEHAVIORAL|Reporting of discrepancy to journal|
40823824|NCT05170750|OTHER|Foams|Every subject will perform 24 randomized trials on force platform.
40823825|NCT05170750|OTHER|Foam / Orthopedic insole|3/5 of the initial population will perform static and locomotion task, with randomized conditions.
40823826|NCT03773133|DRUG|Satoreotide tetraxetan|Radioactivity delivered in 2 administrations (cycles): one loading dose followed by a lower maintenance dose, 6 weeks apart until progression or unacceptable toxicity (up to 4 additional cycles could be administered depending on efficacy and tolerability).
41342177|NCT04313504|DRUG|Niraparib|Niraparib \& Dostarlimab combination
41342178|NCT04313504|DRUG|Dostarlimab|Niraparib \& Dostarlimab combination
41342179|NCT00092391|BIOLOGICAL|Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live|0.5 mL subcutaneous injection of one of three sub-lots on Day 0
40823827|NCT03773133|DRUG|Satoreotide trizoxetan|Imaging companion: 1 administration at screening and one administration at End of core Trial cycle.
41342180|NCT00092391|BIOLOGICAL|Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)|0.5 mL subcutaneous injection on Day 0
41488845|NCT05492253|OTHER|Infant grain|Infants will be fed oatmeal cereal
41488846|NCT00417404|DRUG|Aquasol A|IM Aquasol A 10,000IU three times weekly
41488847|NCT00417404|DRUG|aquasol A|10,000 IU three times weeks, by intramuscular injection
41488848|NCT00417404|OTHER|sham injection|sham injection
41488849|NCT03188666|DRUG|REGN2477|Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
41488850|NCT03188666|DRUG|Matching placebo|Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
41342181|NCT05097976|DRUG|Methylprednisolone|21 x 4mg tablets beginning on POD 1
40823828|NCT05326581|DEVICE|mri|The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
40823829|NCT00902993|DRUG|AZD1446|Solution, oral single and multiple dose
40823830|NCT00902993|DRUG|Placebo|Placebo
40823831|NCT02502227|BEHAVIORAL|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
41488851|NCT02379286|OTHER|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
41488852|NCT03915353|OTHER|No Intervention|No Intervention
40823832|NCT05365880|DRUG|Liquid Lidocaine|The investigational treatment is 2 mL of aqueous 2% lidocaine.
41488853|NCT01776463|DRUG|Z-360|
41488854|NCT01776463|DRUG|placebo|
41488855|NCT02751970|PROCEDURE|Dental restoration|Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
41488856|NCT02751970|PROCEDURE|3 step ER|Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
41488857|NCT02751970|PROCEDURE|2 step ER|Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
41488858|NCT02751970|PROCEDURE|2 step SE|Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
40823833|NCT05365880|DRUG|Placebo|The active placebo comparator will be provided to participant.
41488859|NCT02751970|PROCEDURE|1 step SE|Enamel and dentin will be conditioning with acidic primer/adhesive resin.
41488860|NCT03729076|OTHER|Crystalloid|Patients will receive the rapid co-loading with plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
41488861|NCT03729076|OTHER|Colloid|Patients will receive the rapid co-loading with 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
41488862|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
41488863|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
41488864|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
41488865|NCT01471119|BIOLOGICAL|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
40823834|NCT02264665|DRUG|sunitinib|sunitinib 37.5mg/d orally
41157258|NCT00240097|DRUG|Intervention A: Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
41157259|NCT00240097|DRUG|Intervention B: Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
41342182|NCT05097976|DRUG|Placebo|21 sugar tablets beginning on POD 1 with standard management
41342183|NCT05166486|OTHER|Calisthenic exercise|"Exercises involving major muscle groups will be given. Before starting the calisthenic exercises, they will be asked to perform 10 repetitive warm-ups and breathing exercises. The intensity of the calisthenic exercises will be adjusted on a weekly basis.~Calisthenic exercises are repeated 10-15 times in the first and second weeks; third and fourth weeks 15-20 repetitive; In the five, six, seven and eight weeks, it will be done with 25-30 repetitions.~Patients will be asked to keep an exercise diary and weekly follow-ups will be made over the phone.~Within eight weeks, each patient will come for control twice a month and will be asked to perform the exercises individually under the supervision of a physiotherapist. Patients will be asked to do the exercises three times a week for 8 weeks."
41342184|NCT02382965|DEVICE|transcranial focused ultrasound|
40823835|NCT02264665|DRUG|everolimus|everolimus 10mg/d orally
40823836|NCT02264665|DRUG|chemotherapies recommended in france|depends on the chemotherapy prescribed (IV)
40823837|NCT04088084|DIETARY_SUPPLEMENT|palmitoylethanolamide (PEA) 600 mg|PEA 600 mg was added to topical therapy
40823838|NCT05980364|OTHER|Technology-based training structured according to the Health Promotion Model|Experimental group: A video recording was created with a total of 6 zoom applications to be shared with the patients. The content of the video recordings consists of a presentation accompanied by a slide show with open-ended questions prepared by considering the basic concepts of the trainings and the Health Promotion Model. Video recordings, each of which lasted approximately 15-25 minutes, were shared with patients once a week for a total of 6 weeks via WhatsApp. After each video, patients were given three days to watch the video recordings and create their own responses. After this three-day period, the researcher called the patients with whom he shared the content and gave counseling for 10-15 minutes and received feedback. Follow-up was done in the second 6-week period. During the monitoring process, two reminder interviews were made over the phone, with an interval of 2 weeks, for reminder and counseling, and the post-test data were collected at the end of the monitoring period.
40823839|NCT04140955|PROCEDURE|Tapering plan and telephone counselling|Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
40823840|NCT06105736|BEHAVIORAL|Behavioral Intervention in a small group platform|RT is small-group-based, intensive behavioral intervention session delivered twice weekly over a secure remote platform for 60-minutes over 5 weeks. Each session is led by a psychologist trained and certified in RT. Caregiver groups meet at the same frequency and duration but at different times. Each session has a specific focus for teaching participants to identify emotions and incorporation of cognitive behavioral therapy (CBT) and mindfulness skills that are reinforced through repeated practice. Each session will include a review, relaxation, new material didactic, activities to reinforce material, mindfulness, and homework.
40823841|NCT03272828|DEVICE|Nobel Biocare titanium dental implants|
40823842|NCT06026345|DEVICE|Affera Platform|A cardiac ablation will be performed using the Affera Platform
40823843|NCT04805203|OTHER|blood sample analyses|maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
40823844|NCT04454216|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
40823845|NCT04369118|PROCEDURE|Conventional follow-up|Patients in this group benefit from conventional post-operative follow-up
40823846|NCT04369118|DEVICE|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up. The patient wear the selective chest wall restriction belt from Day 2 (after surgery) until he ceases to need it.
40823847|NCT02801279|OTHER|Conventional bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
40823848|NCT02801279|OTHER|Kinect-based bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
40823849|NCT00387413|DRUG|Duloxetine|Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
40823850|NCT00387413|DRUG|GSK189254|Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
40823851|NCT00387413|DRUG|GSK189254 Placebo|Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
41342185|NCT04500223|OTHER|Cervical Cranioflexion exercise plus cardiopulmonary exercise|Intervention:Cervical Cranioflexion exercise plus cardiopulmonary exercise
41342186|NCT04500223|OTHER|Cervical stretch exercise plus cardiopulmonary rehabilitation|control:Cervical stretch exercise plus cardiopulmonary rehabilitation
40823852|NCT00387413|DRUG|Duloxetine Placebo|Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
40823853|NCT01121627|OTHER|Computerized cognitive training|A 12 week computerized cognitive training at home with the Attengo™ software program.
40823854|NCT00774839|BEHAVIORAL|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
40823855|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
41342187|NCT00273299|DRUG|valsartan plus hydrochlorothiazide|
41342188|NCT01366534|BIOLOGICAL|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
41342189|NCT01366534|BIOLOGICAL|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
41342190|NCT01366534|BIOLOGICAL|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
41342191|NCT01366534|OTHER|Sporozoite challenge|Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
41488866|NCT05227300|DRUG|Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
41488867|NCT05227300|DRUG|2% lidocaine with 1:100,000 epinephrine|Septodont's standard formulation of 2% lidocaine with epinephrine
40823856|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin and Sunlight exposure
40823857|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
40823858|NCT04371822|DRUG|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
40823859|NCT04371822|OTHER|placebo|No Intervention
40823860|NCT05238142|DEVICE|MiniMed™ 780G Insulin Pump system|MiniMed 780G insulin pump with Guardian 4 sensor (phase 1) MiniMed™ 780G BLE 2.0 insulin pump used in combination with Disposable Sensor 5 (phase 2)
40823861|NCT04059523|DRUG|S6G5T-3|once daily
40823862|NCT04059523|DRUG|Retin-A® 0.1% Cream|once daily
40823863|NCT04159987|OTHER|Spinraza intrathecal injection|The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
40823864|NCT04206553|DRUG|dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.
41342192|NCT03718273|DRUG|Ivabradine|"Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good"
41342193|NCT03718273|DRUG|Digoxin|The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance \<60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
41342194|NCT03334656|BIOLOGICAL|biological dressing|to test a biological dressing on the wound healing of the split-thickness skin graft donor site
40823865|NCT04206553|DRUG|Matching Placebo|Matching dupilumab without active substance
40823866|NCT04206553|DRUG|Oral corticosteroids (OCS)|Prednisone or prednisolone per standard of care to obtain control of disease activity.
40823867|NCT00367718|DRUG|Velcade|velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
40823868|NCT01872039|DRUG|Perdipine injection|IV
40823869|NCT05517369|PROCEDURE|Hybrid ESD+|Injection of the Lift Up solution, followed by circumcision of the lesion using a snare tip or ESD knife. Using an additional working channel (AWC), the lesion is resected using a grasper and snare.
41342195|NCT03334656|OTHER|Paraffin gauze dressing|standard intervention : Paraffin gauze dressing on the wound healing
40823870|NCT00453115|DRUG|Oxaliplatin|oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
40823871|NCT00453115|DRUG|Gemcitabine|gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
40823872|NCT05106712|DRUG|Vitamin D3|4000IU per day for around 12 weeks.
40823873|NCT05106712|DRUG|Clomiphene Citrate|"oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively."
40823874|NCT05106712|DRUG|Letrozole|"oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively."
41342196|NCT04430790|DRUG|Doxapram|Loading dose and continuous doxapram infusion.
41342197|NCT04430790|DRUG|Placebo|Loading dose and continuous placebo infusion.
41342198|NCT03592173|DIAGNOSTIC_TEST|Paired TMS & Peripheral Nerve Stimulation|Method of assessing neurophysiology and activity of the spinal cord
41342199|NCT03614702|BIOLOGICAL|1-dose cIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
40823875|NCT05106712|OTHER|placebo|participants in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration
40823876|NCT05925283|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
40823877|NCT05925283|DRUG|Esketamine|intranasal esketamine 1mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
40823878|NCT05925283|DRUG|midazolam and esketamine|oral midazolam 0.3mg/kg and intranasal esketamine 0.6mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
40823879|NCT01370200|PROCEDURE|plasma exchange treatment|the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
40823880|NCT05069714|DRUG|MTX-hold|Temporary discontinuation of methotrexate for 1 or 2 weeks
40823881|NCT03790774|BEHAVIORAL|Neurofeedback|Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
40823882|NCT04639960|DRUG|Risperdal|Twelve weeks of treatment with a gradual increase of dosage over one week and a gradual decrease over two weeks.
40823883|NCT04639960|DRUG|Placebo|Twelve weeks of placebo treatment.
40823884|NCT01745523|PROCEDURE|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
40823885|NCT01745523|PROCEDURE|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
40823886|NCT03625830|DEVICE|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
40823887|NCT03625830|DEVICE|rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
40823888|NCT05076760|BIOLOGICAL|MEM-288 Intratumoral Injection|Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).
40823889|NCT05076760|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
40823890|NCT05073003|DRUG|altSonflex Placebo|2 doses of altSonflex Placebo, administered intramuscularly, in the non-dominant arm, either at Day 1 and Day 85 or at Day 1 and Day 169 (depending on the vaccination schedule) to adults in the ST1_Adults_Placebo_GR1 and ST1_Adults_Placebo_GR2 groups in Stage 1 (Europe).
40823891|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose C|2 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to adults in the ST1_Adults_Dose C_GR1 and ST2_Adults_Dose C groups in Stage 1 and 2 (Europe and Africa) and children in the ST2_Children_Dose C group in Stage 2 (Africa), and at Day 1 and Day 169 to adults in the ST1_Adults_Dose C_GR2 group in Stage 1 (Europe); 3 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose C_Safety and ST2_Infants_Dose C_Dose find groups in Stage 2 (Africa).
40823892|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose B|2 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to children in the ST2_Children_Dose B group in Stage 2 (Africa); 3 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose B_Safety and ST2_Infants_Dose B_Dose find groups in Stage 2 (Africa).
40823893|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose A|3 doses of altSonflex1-2-3 Dose A administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose A_Safety and ST2_Infants_Dose A_Dose find groups in Stage 2 (Africa).
40823894|NCT05073003|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 to adults in the ST2_Adults_Control C group and children in the ST2_Children_Control B and ST2_Children_Control C groups in Stage 2 (Africa); 2 doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to infants in the ST2_Infants_Control A_Safety, ST2_Infants_Control B_Safety, ST2_Infants_Control C_Safety and ST2_Infants_Control_Dose find groups in Stage 2 (Africa).
40823895|NCT05073003|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to adults in the ST2_Adults_Control C group in Stage 2 (Africa).
40823896|NCT05073003|COMBINATION_PRODUCT|GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine|1 dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine administered intramuscularly, in the non-dominant arm, at Day 253 to infants in the ST2_Infants_Control A_Safety, ST2_Infants_Control B_Safety, ST2_Infants_Control C_Safety and ST2_Infants_Control_Dose find groups in Stage 2 (Africa).
40823897|NCT05073003|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to children in the ST2_Children_Control B and ST2_Children_Control C groups in Stage 2 (Africa).
40823898|NCT05073003|BIOLOGICAL|Serum Institute of India's Measles and rubella vaccine|2 doses of Serum Institute of India's Measles and rubella vaccine administered subcutaneously, in the non-dominant arm, at Day 29 and Day 281 to infants in the safety groups, and at Day 1 and Day 253 to infants in the dose-finding groups, in Stage 2 (Africa).
40823899|NCT05325216|PROCEDURE|POPRC+OIN|Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
41342200|NCT03614702|BIOLOGICAL|1-dose sIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
41342201|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
41342202|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
41342203|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
40823900|NCT05325216|PROCEDURE|SRC+OIN|Standard radical cystectomy with orthotopic ileal neobladder
40823901|NCT02629848|DRUG|Motesanib|Motesanib (AMG 706) 5 x 25 mg tablets
40823902|NCT02629848|DRUG|Placebo|Motesanib placebo-matching tablets
41342204|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
41157260|NCT04051190|DIETARY_SUPPLEMENT|VLED group|10-week weight loss period with total meal replacement, consisting of 750 kcal/day. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and at 1 year.
41488868|NCT03292536|DRUG|Merestinib|"\*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\*~Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks"
41488869|NCT03934320|OTHER|FAMCAT|The intervention is a computer-based software algorithm (FAMCAT) for use in general practice with a family history questionnaire.
41342205|NCT03614702|BIOLOGICAL|1-dose cIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
41342206|NCT03614702|BIOLOGICAL|1-dose sIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
41342207|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
41488870|NCT06289803|DEVICE|probe confocal laser endomicroscopy|probe confocal laser endomicroscopy will be used to identify the tumor behavior
41488871|NCT06044532|OTHER|Experimental|At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated. At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.
41488872|NCT03775720|BEHAVIORAL|Dietary advice|Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.
41488873|NCT00402454|DRUG|isoniazid, rifampin + isoniazid or rifampin + pyrazinamide|
41488874|NCT02074592|BEHAVIORAL|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
41488875|NCT02074592|BEHAVIORAL|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
41488876|NCT03752944|PROCEDURE|lefort I osteotomy for maxillary advancement|fixation of lefort I osteotomy in patients with retruded maxilla with two prebent plates versus four miniplates.
41488877|NCT02515149|DEVICE|Point of care CD4 device (Alere PIMA)|for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
41488878|NCT02291770|BIOLOGICAL|Mesenchymal Stromal Cells|Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
41488879|NCT03709459|DRUG|Doxycycline|Participants will be asked to take Doxycycline 100mg/day for 12months duration
41488880|NCT02789397|DRUG|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
40823903|NCT02629848|DRUG|Paclitaxel|Paclitaxel IV
40823904|NCT02629848|DRUG|Carboplatin|Carboplatin IV
40823905|NCT04577755|PROCEDURE|Biopsy|Undergo tissue biopsy
40823906|NCT04577755|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40823907|NCT04577755|PROCEDURE|Computed Tomography|Undergo CT
40823908|NCT04577755|DRUG|Pomalidomide|Given PO
40823909|NCT04577755|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
40823910|NCT00648674|DEVICE|Apligraf|Applied at Day 0, possible re-application at Week 6
40823911|NCT03198455|DIETARY_SUPPLEMENT|Agaricus blazei Murill-based mushroom extract, Andosan™|Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
40823912|NCT03198455|OTHER|Placebo|Drinking water with food coloring and salt
40823913|NCT01420874|DRUG|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
40823914|NCT01420874|BIOLOGICAL|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
40823915|NCT00075946|BIOLOGICAL|rituximab|Given IV
40823916|NCT04373408|PROCEDURE|ACL repair without anterolateral repair|Surgical repair of the ACL using semitendinous autograft
40823917|NCT04373408|PROCEDURE|ACL repair with anterolateral repair|Surgical repair of the ACL using semitendinous autograft, and surgical repair of the ALL using an allograft (Arthrex, Extra-Articular Augmentation device)
40823918|NCT01229072|BIOLOGICAL|Heparin sodic|Heparin sodic 150UI/kg
40823919|NCT01229072|BIOLOGICAL|heparin liquemine|Heparin sodic 150UI/kg
40823920|NCT03888404|OTHER|Pregnancy preferences (Aim 1)|The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
40823921|NCT03888404|OTHER|Sociocultural environment (Aim 2)|For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
40823922|NCT03888404|OTHER|Pregnancy preferences (Aim 3a)|The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
40823923|NCT03888404|OTHER|Pregnancy (Aim 3b)|The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
40823924|NCT02093429|DRUG|INCB047986|INCB047986 will be supplied as tablets.
40823925|NCT06607081|COMBINATION_PRODUCT|Multidisciplinary Preoperative Risk Evaluation and the Corresponded Pre ERAS intervention|The operative risk factors are multidisciplinary evaluated and the corresponded multimodal measures are used to optimize the whole condition of the elderly patient undergo spinal fusion surgery for his/her safty, early and fully recovery.
40823926|NCT05304767|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
41342208|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
40823927|NCT00002454|BIOLOGICAL|autologous tumor cell vaccine|
40823928|NCT02408354|DRUG|Triheptanoin|"Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.~Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose."
40823929|NCT02408354|DRUG|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
41342209|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
41342210|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
41342211|NCT04951180|OTHER|Demographic data and MRI images extraction|The data were retrospectively extracted pre- and postoperatively after hip arthroscopy. The prognosis of the surgery was evaluated through MRI images.
41342212|NCT05346861|DRUG|Trastuzumab plus chemotherapy|Trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy Experimental: Pyrotinib +Trastuzumab + chemotherapy
40823930|NCT05851872|PROCEDURE|Coronary angiogram|Being done per standard of care
41342213|NCT05346861|DRUG|Trastuzumab in combination with pyrotinib plus chemotherapy|Pyrotinib: 400 mg po QD, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy
41342214|NCT05732597|PROCEDURE|Coronary angiography|A coronary angiogram is a procedure that uses X-ray imaging to see the patient's blood vessels of the heart. The test is generally done to see if there's a restriction in blood flow going to the heart.
41342215|NCT03537937|OTHER|Lower SpO2 Target|SpO2 target 90% (range 88-92%)
41342216|NCT03537937|OTHER|Intermediate SpO2 Target|SpO2 target 94% (range 92-96%)
41342217|NCT03537937|OTHER|Higher SpO2 Target|SpO2 target 98% (range 96-100%)
40823931|NCT05851872|PROCEDURE|Right heart catheterization|Being done per standard of care
40823932|NCT03042377|OTHER|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
41342218|NCT01251991|DRUG|Psyllium husks|Oral suspension, oral use, two daily dosages consisting of 5 grams each
41488881|NCT02789397|DRUG|Placebos|IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
40823933|NCT03042377|DRUG|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
41342219|NCT01251991|DIETARY_SUPPLEMENT|Isolated soy protein|Oral suspension, oral use, 30 grams once per day
41342220|NCT01251991|DIETARY_SUPPLEMENT|Isolated whey protein|Oral suspension, oral use, 30 grams once per day
41342221|NCT01251991|OTHER|Microcrystalline cellulose|Oral suspension, oral use, two daily dosages consisting of 5 grams each
41342222|NCT04685655|OTHER|Therapeutic plasma exchange|Treatment with therapeutic plasma exchange. Plasma from healthy donors is used.
41488882|NCT02188511|OTHER|Group A|90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to \< 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.
41342223|NCT00360672|DRUG|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
41342224|NCT02447068|DEVICE|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
41342225|NCT02447068|DEVICE|Luma Light|NBUVB light
41342226|NCT02447068|DEVICE|Occlusive Dressing|Off-the-shelf occlusive dressing
40823934|NCT03042377|DRUG|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid \& antibiotic paste and the cavity was filled with temporary restorative material.
40823935|NCT03042377|DRUG|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
40823936|NCT06607146|BEHAVIORAL|Sound Success|Subjects will be instructed to perform auditory training with the Sound Success computer-based auditory training program. This is a free program that requires a brief account registration. Subjects will be instructed to perform auditory training on a personal device and will be recommended a target usage of at least 30 minutes 5 times per week.
40823937|NCT06607146|BEHAVIORAL|Standard of Care|Subjects will be provided a list of common exercises for auditory training. This is the current standard of care at our institution.
40823938|NCT02150057|DEVICE|Breg Fusion Unloading Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
40823939|NCT00874458|PROCEDURE|magnetic resonance imaging|
40823940|NCT00874458|PROCEDURE|radiomammography|
40823941|NCT00874458|PROCEDURE|ultrasound imaging|
40823942|NCT05289193|DIAGNOSTIC_TEST|PET Scan|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
40823943|NCT05289193|DRUG|Nivolumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
40823944|NCT05289193|DRUG|Ipilimumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
40823945|NCT05289193|PROCEDURE|Surgical Resection of Melanoma|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
40823946|NCT05563883|OTHER|event occurence|occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...
40823947|NCT05910047|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing molecular hydrogen and pyrroloquinoline quinone
40823948|NCT05910047|DIETARY_SUPPLEMENT|Placebo|Inert substance
40823949|NCT05238012|DRUG|Xuezhikang Capsule|Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
40823950|NCT05238012|DRUG|Atorvastatin Calcium Tablets|Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;
40823951|NCT01703689|BEHAVIORAL|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
40823952|NCT01703689|BEHAVIORAL|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
40823953|NCT06438445|DIETARY_SUPPLEMENT|Real Jelly|Participants will receive 500mg of royal jelly capsules per day for two months.
40823954|NCT06438445|DIETARY_SUPPLEMENT|Placebo|Participants will receive 500mg of placebo capsules per day for two months.
41488883|NCT02188511|OTHER|Group B|On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
41488884|NCT02188511|OTHER|Group C|On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
41488885|NCT02188511|OTHER|Group D|On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
41488886|NCT02188511|OTHER|Group E|"On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).~Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine."
40823955|NCT03232814|BEHAVIORAL|Group-based walking|The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
41342227|NCT00003687|DRUG|dextromethorphan hydrobromide|
41342228|NCT00003687|DRUG|morphine sulfate|
41488887|NCT00515541|DRUG|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
41488888|NCT02685202|DEVICE|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
40823956|NCT00309140|DRUG|enzastaurin|500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
41342229|NCT04856215|DRUG|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The Investigational Medicinal Product (IMP) consist of 1) 111Indium- and 2) 90Yttrium-labelled anti-CD66 (BW250/183) monoclonal antibody.~The anti-CD66 is a murine IgG1 monoclonal antibody originally developed as an in vivo leucocyte and bone marrow imaging agent (Boßlet 1985, Thomsen 1991). BW 250/183 anti-CD66 is a murine IgG1 kappa monoclonal antibody, originally produced as an anti-CEA antibody.~The batch of antibodies required for treatment will be radiolabelled by Royal Free Hospital radiology team with Indium 111 and Y90 for patient."
41342230|NCT02702284|BEHAVIORAL|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
40823957|NCT05988294|OTHER|Pilates exercises|One-hour Pilates exercise program was given by a certified trainer to patients three times per week for 12 weeks. The exercise program followed the basic principles of the Pilates method. Our protocol comprised the following components of Pilates-based exercises: strength and stabilization, flexibility and range of motion, proper body alignment, balance, coordination, and body awareness. Resistance bands and 26 cm Pilates balls were used as supportive equipment. The exercise sections consisted of 5 minutes breathing, 10 minutes warm-up, 35 minutes conditioning phase and 10 minutes cool-down.
40823958|NCT05988294|OTHER|Conventional physical therapy exercise program|Diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs for 45 minutes, 3 days/ week for 12 weeks.
40823959|NCT05888961|BIOLOGICAL|Blood samples|"Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up"
40823960|NCT05888961|OTHER|Interviewing the subject and scales|"Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session"
40823961|NCT05888961|OTHER|Neurocognitive evaluation|cognitive complaint questionnaire (CCQ), taste, smell, MoCA and MMSE (if not performed in the previous 6 months) Carried out at the 1st session. Repeated at 6 and 12 months for follow-up.
40823962|NCT05888961|OTHER|Taste tests|"Sweet and salty flavors at the 1st session and acid and umami flavors at the 2nd session. Repeated at 6 and 12 months for follow-up.~Placement of electrodes on the scalp, recording of gustatory evoked potentials, subjective gustatory evaluation by means of visual analogue scales rated from 0 to 10, identification and naming of each of the primary flavors"
40823963|NCT05888961|OTHER|Computerized food preference questionnaires|Performed at the 1st session on a tactile tablet. Repeated at 6 and 12 months for follow-up.
40823964|NCT05888961|OTHER|Nutritional status - body composition|Measurement of anthropometric data, bioelectrical impedancemetry (measurement of fat mass, lean mass, water mass and bone mass in kg), measurement of blood pressure and heart rate Performed at the 2nd session Repeated at 6 and 12 months for follow-up.
41342231|NCT02702284|BEHAVIORAL|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
41342232|NCT05155839|DRUG|MRG001|Administrated intravenously
41488889|NCT04016961|OTHER|AAT - Dog|therapy dog added to inpatient PT and OT session
41488890|NCT04016961|OTHER|TAU - No Dog|PT and OT as usual without the addition of therapy dog
41488891|NCT03829137|DEVICE|Verum laser acupuncture|The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.
41488892|NCT03829137|DEVICE|Sham laser acupuncture|The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.
40823965|NCT02183337|DRUG|BI 1356|
40823966|NCT02183337|DRUG|BI 1356 + Pioglitazone|
40823967|NCT02183337|DRUG|Pioglitazone|
41488893|NCT03986736|DIAGNOSTIC_TEST|Laboratory analysis - upon admission|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL
41488894|NCT03986736|DIAGNOSTIC_TEST|Laboratory analysis - 24 hours after injury|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
40823968|NCT05302206|DIETARY_SUPPLEMENT|colonic infusion|colonic glucose or colonic saline infusion
40823969|NCT03521232|DRUG|Niclosamide|enema given twice daily for 6 weeks
40823970|NCT03741023|PROCEDURE|Blood draw (venipuncture or fingerstick)|Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.
40823971|NCT03103672|PROCEDURE|Percutaneous transhepatic cholangiography|Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
41157261|NCT04051190|PROCEDURE|Sleeve Gastrectomy group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (sleeve gastrectomy)
41342233|NCT00169013|DRUG|Gabapentin|
41342234|NCT00005065|DRUG|paclitaxel|Given IV
41342235|NCT00005065|DRUG|carboplatin|Given IV
41342236|NCT00005065|DRUG|motexafin gadolinium|Given IV
41342237|NCT00005065|PROCEDURE|conventional surgery|Undergo complete surgical resection
40823972|NCT03733028|BEHAVIORAL|Mobile Intervention for Reducing Anger (MIRA)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
40823973|NCT03733028|BEHAVIORAL|Mindfulness Intervention|"This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance."
40823974|NCT06279793|DRUG|Long-chain n-3 fatty acids|"Omegaven® is a 10% fish oil emulsion supplement with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It is a lipid emulsion supplement that optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids.~Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose.~Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL).~Timeframe:~Day -1: 0.20 g fish oil/kg BW/d; the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion.~Intraoperative Day: No dose~Post OP (Day 0): 0.20 g fish oil/kg BW/d~Post OP ( Day 1 to max Day 7): 0.20 g fish oil/kg BW/d"
40823975|NCT06279793|DRUG|Intravenous 0.9% Sodium Chloride|Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d)
40823976|NCT02614040|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
40823977|NCT02614040|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
40823978|NCT03926000|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
40823979|NCT03926000|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
40823980|NCT00350272|DRUG|Elvucitabine|Elvucitabine 10 mg orally daily
40823981|NCT00350272|DRUG|Lamivudine|Lamivudine 300 mg orally daily
40823982|NCT00350272|DRUG|Tenofovir|Tenofovir open-label 300 mg orally daily
40823983|NCT00350272|DRUG|Efavirenz|Efavirenze open-label 600 mg orally daily
40823984|NCT06276881|BEHAVIORAL|Visual Stimulation|AI-guided visual stimuli presented on an electronic screen
40823985|NCT04883710|OTHER|Gene therapy|This is a prospective patient registry.
40823986|NCT02763475|DRUG|cyclophosphamide|60mg/kg by vein on day -6
40823987|NCT02763475|DRUG|Fludarabine|25mg/m2 iv daily on day -5 to -1
40823988|NCT02763475|PROCEDURE|NK cell infusion|"* First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~* Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
41342238|NCT00005065|RADIATION|radiation therapy|Undergo radiation therapy
40823989|NCT02763475|DRUG|IL-2|1x10\^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
40823990|NCT00460759|DRUG|Moxifloxacin|
40823991|NCT00460759|DRUG|Rifapentine|
40823992|NCT05975008|BEHAVIORAL|RECLAIM - Reconnecting to Civilian Life using Activities that Improve Mindfulness|Brief virtual mindfulness-based intervention
40823993|NCT04381637|DEVICE|NIPE monitor|NIPE monitor connected to the anesthetic station. No part of the device in contact with the patient. No action on patient or anesthesia. Automatic recording of Heart rate and NIPE index during the study period.
40823994|NCT04381637|PROCEDURE|Tetanic stimulations|"Three tetanic stimulations will be performed (10-30 and 60 milliamps) under general anesthesia, before surgical incision.~Stims performed via the muscle relaxation monitor (used in standard practice in this population) Each stim lasts for 5 seconds. Interval between two stims : 3-5 minutes Order on intensities randomized by a latin square of order 3."
40823995|NCT06281665|DRUG|Low-dose aspirin|The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
40823996|NCT06281665|DRUG|Placebo|The control group will receive similar appearing placebo daily for 6 months.
40823997|NCT04829799|DRUG|1% preservative-free lidocaine|Instillation of intracameral lidocaine after initial paracentesis incision.
40823998|NCT04829799|DRUG|Phenylephrine 1.0%/ Ketorolac 0.3%|Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
40823999|NCT00562276|PROCEDURE|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
40824000|NCT05670548|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks. Placenta and umbilical cord blood are collected during delivery.
41342239|NCT04488549|OTHER|Survey|International E-survey
41342240|NCT02617329|OTHER|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
40824001|NCT02106624|OTHER|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
40824002|NCT01371253|OTHER|Nintendo wii balance training|
40824003|NCT01371253|OTHER|EVA-soles|
41157262|NCT04051190|PROCEDURE|Gastric Bypass group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (gastric bypass)
41342241|NCT02617329|OTHER|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
41342242|NCT03649815|COMBINATION_PRODUCT|App4Independence|"The mobile, app-based platform was designed to:~* Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement~* Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises)~* Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness~* Provide basic health/safety functionality and track level of wellness~* Provide an anonymous peer-peer online network for strategy sharing~* Provide an ambient sound detector to assist with identifying hallucinations"
41342243|NCT03631394|OTHER|beetroot and anthocyanin|Beetroot and anthocyanin will be taken for 7 days during the study two hours prior to eating.
41488895|NCT03022058|DEVICE|Ear-EEG system|Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
40824004|NCT03640858|DEVICE|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
40824005|NCT00269503|PROCEDURE|Prone Distraction|
40824006|NCT00269503|PROCEDURE|Side-Posture Manipulation|
41157263|NCT01212484|DRUG|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
41342244|NCT03631394|OTHER|beetroot and placebo|Beetroot and placebo will be taken for 7 days during the study two hours prior to eating.
41342245|NCT02203942|OTHER|NAAT testing|comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
41342246|NCT01315340|PROCEDURE|Ocular rigidity, outflow facility and intraocular pressure measurement|The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
41508993|NCT00286026|DRUG|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
40824007|NCT00269503|PROCEDURE|Side-Posture Manipulation & Prone Distraction|
40824008|NCT00269503|PROCEDURE|Usual Care (Control Group)|
40824009|NCT00597363|DEVICE|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH \& Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
41342247|NCT05714670|DRUG|Curcumin Oral Capsule|Curcumin 1000 mg Oral Capsule beside the standard of care
40824010|NCT00597363|OTHER|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
40824011|NCT03610581|BIOLOGICAL|Ad26.HPV16|Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
41488896|NCT02083237|BEHAVIORAL|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
41342248|NCT03175250|BEHAVIORAL|Health Education|Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing
41488897|NCT01912274|DRUG|Pracinostat|Elderly newly diagnosed patients will all receive pracinostat
41488898|NCT01912274|DRUG|Azacitidine|Elderly newly diagnosed patients will all receive azacitadine
41488899|NCT03239886|OTHER|imatinib discontinuation|imatinib discontinuation
41488900|NCT00516009|DRUG|DEXAMETHASONE|
41488901|NCT00516009|OTHER|PLACEBO|
40824012|NCT03610581|BIOLOGICAL|Ad26.HPV18|Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
40824013|NCT03610581|BIOLOGICAL|MVA.HPV16/18|Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
41342249|NCT03175250|BEHAVIORAL|Action Plan|Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.
41488902|NCT04213976|PROCEDURE|Ileostomy|Use of an ileostomy to decompress the proximal bowel, perfored either as a conventional loop ileostomy or as described by Santulli et al. or by Bishop and Koop.
41488903|NCT04557202|DRUG|Tamsulosin Oral Capsule|To assess the efficacy of peri-operative alpha1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.
41488904|NCT04557202|DRUG|Placebo|Placebo - control group
41488905|NCT01851018|RADIATION|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
41488906|NCT01851018|RADIATION|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
40824014|NCT03610581|BIOLOGICAL|Placebo|Participants will receive matched placebo as a solution for intramuscular injection.
41157264|NCT01212484|DRUG|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
41342250|NCT03175250|BEHAVIORAL|Memory Practice|Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
41342251|NCT01071941|BIOLOGICAL|administration of rRp450 into the hepatic artery|Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
40824015|NCT05911451|PROCEDURE|Arteriovenous fistula creation|It is recommended to create the arteriovenous fistula 3 to 6 months before the expected start of hemodialysis treatment using locoregional anesthesia. It is recommended to use minimal venous and arterial diameters of 2mm for radiocephalic fistulas and 3mm for brachiocephalic and brachiobasilic fistulas. It is recommended to avoid creating an arteriovenous fistula at the same side as a pacemaker, central venous catheter, or arterial stenosis. It is recommended to use the following order of preference for arteriovenous fistula creation: radiocephalic fistula as first choice, brachiocephalic fistula as second choice, and brachiobasilic fistula as third choice.
40824016|NCT05911451|PROCEDURE|Arteriovenous graft placement|It is recommended to implant the arteriovenous graft 2 weeks before the expected start of hemodialysis treatment under antibiotic prophylaxis. Implantation of an early-cannulation graft is recommended for patients who require more urgent start of hemodialysis to avoid the use of a temporary central venous catheter. It is recommended to use minimal arterial and venous diameters of 3mm and 4mm, respectively. It is recommended to avoid placing an arteriovenous graft at the same side as a pacemaker, central venous catheter, or arterial stenosis.
40824017|NCT05911451|PROCEDURE|Central venous catheter placement|It is recommended to place a tunneled central venous catheter just before the start of hemodialysis treatment under local anesthesia, with conscious sedation if preferred by the patient. The catheter should preferably be placed in the right internal jugular vein with ultrasound-guided puncture and fluoroscopy control under sterile conditions. According to usual practice at the trial center, catheters may be implanted by surgeons, interventional radiologists, or nephrologists.
40824018|NCT03466138|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
40824019|NCT00004564|DRUG|Clopidogrel|
40824020|NCT00004564|DRUG|Atorvastatin|
40824021|NCT06605001|OTHER|Delay of Gratification|Children will complete a delay of gratification task with 1 of 2 rewards
41342252|NCT03882866|PROCEDURE|3D-printed non-coplanar template|3D-printed non-coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed non-coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed non-coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
41488907|NCT00365937|BIOLOGICAL|Immunological peptides and immunological adjuvants|
40824022|NCT02204605|BEHAVIORAL|Video-based Consensus Opinion|
40824023|NCT06444360|BEHAVIORAL|IMPACT|The IMPACT intervention consists of 10 sessions: 2 sessions focused on HIV acquisition/transmission risk reduction (RR), 1 session focused on orienting and rationale to behavioral activation (BA), 6 sessions integrating BA and HIV RR counseling (including PrEP or ART and HIV care), and 1 final session on strategies for slip-ups and recurrence management.
40824024|NCT06444360|BEHAVIORAL|eSOC|The eSOC group consists of 2 sessions focused on HIV acquisition/transmission risk reduction (RR).
40824025|NCT03660228|OTHER|Peri-Transfusion QOL Assessment|Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
40824026|NCT02783040|DRUG|Midazolam|
40824027|NCT02783040|DRUG|Warfarin|
40824028|NCT02783040|DRUG|Omeprazole|
40824029|NCT02783040|DRUG|Midazolam|
40824030|NCT02783040|DRUG|Digoxin|
41488908|NCT00365937|BIOLOGICAL|HLA-A2 peptides|Tyrosinase.A2: lyophilized powder, 326 mcg, 5 injections every 3 weeks MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks MAGE-4.A2: lyophilized powder, 299 mcg, 5 injections every 3 weeks MAGE-3.A2: lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-1.A2: lyophilized powder, 298 mcg, 5 injections every 3 weeks NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-10.A2: lyophilized powder, 309 mcg, 5 injections every 3 weeks
40824031|NCT02783040|DRUG|BI 425809|
40824032|NCT05344352|DIETARY_SUPPLEMENT|Multistrain Probiotic|8-week daily administration
40824033|NCT05344352|OTHER|Placebo|8-week daily administration
40824034|NCT03206632|DRUG|BI 690517|single dose
40824035|NCT03206632|DRUG|Placebo|single dose
40824036|NCT04859985|DEVICE|SELUTION SLR|Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis \> 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).
40824037|NCT04859985|DEVICE|DES|For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
40824038|NCT00758264|BIOLOGICAL|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
40824039|NCT00758264|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
41488909|NCT00365937|BIOLOGICAL|Montanide ISA51|Oil emulsion (W/O: droplet test S57 IN 001), conductivity less than 10mcs.cm-1, viscosity: 1500 mPas (brookfield DVI - spindle 2- Speed 30). For human applications. Injected 5 times every 3 weeks.
40824040|NCT04900337|DRUG|AMOR 18 Powder & Inhalation|AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
40824041|NCT04900337|DRUG|Placebo|Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
40824042|NCT05664295|DIAGNOSTIC_TEST|Jenkins Sleep Disorders scale and Epworth Sleepiness scale|Jenkins Sleep Disorders scale and Epworth Sleepiness scale
40824043|NCT04218838|DEVICE|CornerLoc SI Joint Stabilization Procedure|CornerLoc minimally invasive SI Joint Stabilization System
40824044|NCT04218838|DRUG|Intra-articular Sacroiliac Joint Steroid Injection|Standard of Care - Steroid injection into the sacroiliac joint
40824045|NCT04209114|BIOLOGICAL|Nivolumab|Specified dose on specified days
40824046|NCT04209114|PROCEDURE|Radical cystectomy (RC)|Surgical removal of the bladder
40824047|NCT04209114|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
40824048|NCT05063188|OTHER|Connective Tissue Massage|Connective tissue massage was started from lumbosacral region and continued lower thoracic, scapular, interscapular, and cervical regions, respectively.
40824049|NCT05063188|OTHER|clinical pilates exercises|Exercises were applied 3 times for 6 weeks, a total of 18 sessions. One session consisted of 10 minutes of warm-up, 40 minutes of Clinical Pilates exercises and 10 minutes of cooling down (60 minutes in total).
40824050|NCT03673787|DRUG|ipatasertib|Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
41488910|NCT00365937|BIOLOGICAL|IMP321|"Official name of the LAG-3 molecule is CD223. Chemical structure: hLAG-3Ig is a soluble human recombinant LAG-3 protein comprising the extra-cellular Ig-like domains.~The IMP321 drug product is composed of a soluble recombinant protein at a 1.18 mg/ml concentration, in PBS (Na2HPO4 2H2O 8.1mM, KH2PO4 1.47mM, NaCl 137mM, KCl 2.68mM, PH 7.2). Batch number: S017/LC1/041011.IMP321 will be provided in 250mcl aliquots in brosilicate siliconized vials."
40824051|NCT03673787|DRUG|Atezolizumab|Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
40824052|NCT04734821|PROCEDURE|Near Infra-Red Fluorescence Guided Surgery|ICG injection around tumor each four direction by endoscopy followed by NIR fluorescence guidance laparoscopic or robotic esophagectomy or gastrectomy
40824053|NCT05236465|BEHAVIORAL|A 3-day course|The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
40824054|NCT05236465|BEHAVIORAL|Waiting list|Treatment as usual (TAU) in the first 10 weeks. After 10 weeks: Behavioural: A 3-day course. The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
40824055|NCT02186054|DEVICE|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
40824056|NCT03657563|OTHER|Positive psychological intervention|"Participants in the intervention group are required to record three good things every night before sleeping for five days a week using WeChat. Such things could be ordinary, minor or important.~WeChat is a common communication tool used in China, just like Facebook, basic messages could be sent individually and posting pictures or texts is also available."
40824057|NCT03670277|DEVICE|etafilcon A|Test Soft Contact Lens
40824058|NCT03670277|DEVICE|Habitual Orthokeratology Lenses|CONTROL
40824059|NCT06605937|OTHER|Eustachian milking maneuver with routine postoperative treatment protocol|Eustachian milking maneuver will be applied by the patients parents 3 times a day for 7 days in the post-operative period.
40824060|NCT06605937|OTHER|Routine postoperative treatment protocol|The children adenoidectomy and/or adenotonsillectomy whose parents will not apply eustachian healing maneuvers in the post-operative period.
40824061|NCT01128348|BEHAVIORAL|patient advocate|patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
40824062|NCT06606691|DEVICE|Xiaomi Mi Smart Band 8|The wearable device, Xiaomi Mi Smart Band 8, will be used solely for observational purposes to assess its accuracy in measuring sleep parameters, oxygen saturation, and heart rate in comparison to nocturnal polygraphy. Participants are receiving routine care as prescribed by their clinicians, and the wearable device is not part of their medical treatment but is being observed alongside standard polygraphy tests.
41342253|NCT03882866|PROCEDURE|3D-printed coplanar template|3D-printed coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
41342254|NCT00854867|DRUG|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
41342255|NCT00854867|DRUG|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
41342256|NCT02411877|PROCEDURE|Normothermia|Device: Trevo Pro Retriever (Stryker Corp.)
41342257|NCT02411877|PROCEDURE|Mild hypothermia|Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)
41488911|NCT03438825|PROCEDURE|Mitral valve replacement/repair|Mitral valve replacement/repair: standard of care operation of the mitral valve due to severe insufficiency
41488912|NCT03915366|DRUG|Valganciclovir Oral Solution [Valcyte]|Treatment for CMV
40824063|NCT02117895|PROCEDURE|Celiac plexus resection|Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
41488913|NCT03915366|DRUG|Tuberculostatic Agents|Treatment for tuberculosis
41488914|NCT02882243|DEVICE|FLXfit Cage for fusion|Evaluating patient outcomes and radiographic outcomes
41488915|NCT00210873|DRUG|topiramate|
41488916|NCT01772264|DRUG|PF-05089771|titration from 150mg BID to 450mg BID
41488917|NCT01772264|DRUG|Placebo|matched placebo
41488918|NCT03093389|DRUG|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
41488919|NCT03093389|DRUG|Placebo|Matching placebo capsules
41488920|NCT02118090|DRUG|Chloroquine sulfate|Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
41488921|NCT02118090|DRUG|DHA-PP|DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
41488922|NCT01836406|DRUG|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
41488923|NCT00206830|DEVICE|Triage Profiler S.O.B. Panel|
41488924|NCT02896582|DRUG|Obinutuzumab|1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+
41488925|NCT02896582|DRUG|Dexamethasone|40 mg D1 to D4 in GA-DHAP
41488926|NCT02896582|DRUG|Aracytine|2g/m² D1 \& D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM
41488927|NCT02896582|DRUG|Cisplatinum|100 mg/m² D1 in GA-DHAP
41488928|NCT02896582|DRUG|Etoposide|400 mg/m² D-6 to D-3 in GA-BEAM
41488929|NCT02896582|DRUG|Melphalan|140 mg/m² D-2 in GA-BEAM
40824064|NCT02117895|PROCEDURE|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
40824065|NCT02281474|DRUG|Nilotinib|
41488930|NCT02896582|DRUG|Carmustine|300 mg/m² D-7 in GA-BEAM
41488931|NCT04338217|DEVICE|Bionator|This is a functional appliance that is used to overcome the functional problems and to correct the open bite deformity
41488932|NCT04338217|DEVICE|Removable Appliance with Posterior Bite Planes|This is a one-jaw appliance that is used in conjunction with a tongue crib to control the faulty positions of the tongue and to help in closing the open bite through the use of posterior bite planes.
41488933|NCT04573764|DIETARY_SUPPLEMENT|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|"The intervention is D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester and will be bought commercially. As an example: One bottle of KetoneAid KE4 PRO with 60 ml contains 30 g D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester. For more information please refer to: https://shop.ketoneaid.com/collections/all/products/ke4-pro. Placebo will be a taste-matched water solution provided by the company. The placebo solution and the active solution will be prepared in identic bottles and investigators will be blinded."
41488934|NCT04573764|DIETARY_SUPPLEMENT|Placebo|Taste-matched water
41488935|NCT01090921|DRUG|Bortezomib|"Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone."
41488936|NCT04725448|DRUG|Toripalimab|240mg, ivgtt, d1, every 3 weeks until disease progress or intolerable toxicity, up to 2 years of administration
41488937|NCT04725448|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, every 3 weeks, up to 2 years of administration
40824066|NCT02434354|DRUG|pembrolizumab|200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
40824067|NCT05623254|OTHER|no comparator - TAU (Treatment-as-usual)|"Learning the ability in mindfulness practice by specific measure (FFMQ) changes in FIVE FACET MINDFULNESS QUESTIONNAIRE (FFMQ) compared to baseline): this questionnaire measures the mindfulness ability of patients before and after the APP application (minimum score 113.7-low mindfulness ability=worse outcome ; maximum score 144.3-high mindfulness ability=better outcome) \[Time Frame: At Three-six months\]~Introduction of the mindfulness program during a preliminary face-to-face session to patients and caregivers~TAU Weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)"
40824068|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 subcutaneous (SC) injection
41488938|NCT04725448|DRUG|Nab-paclitaxel|260mg/m2,d1 or 130mg/m2,d1,8, ivgtt, every 3 weeks, up to 6 cycles
41488939|NCT04725448|DRUG|Carboplatin|AUC=4～5, d1, ivgtt, every 3 weeks, up to 6 cycles
41488940|NCT04111406|DRUG|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
41488941|NCT04111406|DRUG|Protocol based|"Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~1. insertion at mid-level of surgical insertion~2. insertion depth is 3-5 cm in space, not more than 5 cm~3. using benzoin tincture and transparent dressing to fix catheter~4. test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~5. After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage"
41342258|NCT02411877|DEVICE|Trevo Pro Retriever (Stryker Corp.)|Device: Trevo Pro Retriever (Stryker Corp.)
41342259|NCT02411877|DEVICE|Zoll Thermogard XP technology with the Quattro catheter|Device: Zoll Thermogard XP technology with the Quattro catheter
41342260|NCT02331654|OTHER|Experimental treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes
41342261|NCT02331654|OTHER|Placebo treatment|Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
41342262|NCT00330239|DRUG|Paroxetine CR|
41342263|NCT05931068|OTHER|Pre- and postoperative assessment|Pre- and postoperative assessment will consist of measurement of energy expenditure (direct and indirect calorimetry), aerobic capacity (cardiopulmonary exercise test), and physical activity (accelerometry).
41488942|NCT00604136|BIOLOGICAL|tumor infiltrating lymphocytes|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro. Tumor infiltrating lymphocytes from these cultures will be assessed for tumor reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x2 days IV)and fludarabine (25 mg/mE2/day IV x5days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 10E9 tumor-reactive lymphocytes followed by high dose IL-2 (720,000 IU/kg/dose IV every 8 hours for up to 15 doses).
41488943|NCT06445634|OTHER|Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis|Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis in Glaucoma Patients with Secondary Synechial Angle Closure
41488944|NCT01006564|OTHER|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
41488945|NCT01006564|OTHER|Other|Insertion of gold seeds into prostate for image registration.
41488946|NCT00307606|DRUG|Solu-medrol 125 mg|
41488947|NCT04553861|DEVICE|Ambulatory blood pressure monitoring|Every 30 minutes from 7 AM to 10 PM and every 1 hour from 10 PM to 7 AM
41488948|NCT04553861|DEVICE|Galaxy Watch Active2|Every 1 hour by subject (on-demand) from 7 AM to 10 PM and every 5 minutes (automatic) from 10 PM to 7 AM
41488949|NCT04722601|DRUG|Venetoclax|A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.
41488950|NCT04722601|DRUG|Obinutuzumab|Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.
40824069|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
40824070|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
40824071|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
40824072|NCT05685732|DRUG|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
40824073|NCT05685732|OTHER|placebo|matching placebo
41488951|NCT04722601|DRUG|CC-486|An oral form of azacitidine (a standard chemotherapy drug).
40824074|NCT06258486|DRUG|ICG injection|Patient will have a green dye (ICG) injected into the lymph node to better visualize non-sealed leaks in order to pre-emptively seal any lymphatic leaks.
41342264|NCT04940741|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
41342265|NCT04940741|OTHER|Placebo|comparator without active ingredient
41342266|NCT04402385|DRUG|Aspirin 81 mg|Participants randomized to 81 mg of Aspirin daily
41342267|NCT04402385|DRUG|Placebo|Participants randomized to placebo daily
41488952|NCT04173624|DIAGNOSTIC_TEST|Endosonography|Endosonography (EUS) is endoscopic method for evaluated pancreatic and biliary pathology.
41488953|NCT04173624|DIAGNOSTIC_TEST|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for evaluating pancreatic and biliary pathology
41488954|NCT01598441|DRUG|iloprost nebuliser solution|Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
40824075|NCT06258486|OTHER|Non-Injection/Control|No ICG injection
40824076|NCT06258486|PROCEDURE|Prostatectomy with pelvic lymph node dissection|Robotic assisted prostatectomy with pelvic lymph node dissection
41342268|NCT01855867|DRUG|Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
41342269|NCT01722214|BIOLOGICAL|Adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
41342270|NCT01722214|OTHER|Placebo|Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
41342271|NCT02467660|BEHAVIORAL|Mindfulness Meditation|Using study-provided iPod device to listen to guided meditations daily
41342272|NCT02467660|BEHAVIORAL|Health & Wellness Education|Using study-provided iPod device to listen to educational podcasts daily
41342273|NCT00333970|BEHAVIORAL|cognitive remediation|individual cognitive training
41342274|NCT00513370|BIOLOGICAL|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
41342275|NCT04464473|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
41488955|NCT01598441|DRUG|distilled water|1-2 ml aerosolized distilled water inhalation per session
40824077|NCT04690907|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy and 2 virtual dietary counseling sessions.
40824078|NCT06380439|PROCEDURE|wrist ankle acupuncture|wrist ankle acupuncture: wrist ankle acupuncture using 0.25 x 25mm filiform needle on lower 1, lower 4, lower 5 area ipsilateral to the surgical side, then covered with 5cm long micropore, retention for 4 hours
40824079|NCT05145361|DRUG|B001 injection|B001 injection 50mg/5mL Intravenous solution
40824080|NCT05145361|BIOLOGICAL|Placebo|Placebo 5mL Intravenous solution
40824081|NCT02340182|DRUG|Vancomycin|250mg 3dd2
40824082|NCT02340182|DRUG|Ciprofloxacin|500mg 2dd1
40824083|NCT02340182|DRUG|Metronidazole|500mg 3dd1
40824084|NCT05764473|OTHER|The impact of MedDiet on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
40824085|NCT05764473|OTHER|The impact of UCLP on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
40824086|NCT00001155|DRUG|cyclophosphamide|
40824087|NCT02512601|DRUG|Sulodexide|Sulodexide (two capsules of Sulodexide 15 mg twice daily).
40824088|NCT02512601|OTHER|Compression therapy|"Compression:~* With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.~* With a bandage: 7-10 m long and 10 cm wide.~* Both strategies (orthosis vs bandage) are equally applicable."
40824089|NCT01418131|DRUG|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
40824090|NCT01418131|DRUG|Placebo|Placebo
40824091|NCT04285307|BEHAVIORAL|Sleep Hygiene tips|Students receive a packet of information on how to improve their sleep habits and hygiene.
40824092|NCT03649529|BIOLOGICAL|GPA-TriMAR-T|Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
40824093|NCT04372654|DEVICE|Electroducer Sleeve|The device's safety will be assessed at the radial and femoral puncture site
40824094|NCT06605092|OTHER|Emotional stimulation|Presentation of the paintings by distinguishing 3 conditions: (1) contemplating each painting (visual stimulation), (2) listening to the original music composed from each painting (auditory stimulation), (3) contemplating and listening to the association of each painting with each specific music (bimodal stimulation)
40824095|NCT02291757|DIETARY_SUPPLEMENT|NEM brand eggshell membrane|NEM 500 mg, once daily, p.o.
40824096|NCT02291757|DIETARY_SUPPLEMENT|Placebo|Placebo, 500 mg, once daily, p.o.
40824097|NCT05370963|DRUG|Hylase versus dexmedtemodine|fluroscopic guided lumber epidural injection
40824098|NCT02144506|OTHER|T&E|
40824099|NCT02144506|OTHER|OTAGO|
40824100|NCT01069159|DRUG|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
40824101|NCT01069159|DRUG|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
40824102|NCT04820257|BEHAVIORAL|Home based exercise|Exercise at home and behavioural change to increase daily exercise
40824103|NCT03975127|OTHER|SMS text|A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
40824104|NCT04522154|DIAGNOSTIC_TEST|Magnet resonance imaging|Patients will receive a cardiac magnet resonance tomography before and 3-month after the procedure
40824105|NCT00002839|DRUG|cisplatin|
40824106|NCT00002839|DRUG|fluorouracil|
40824107|NCT00002839|PROCEDURE|conventional surgery|
40824108|NCT00002839|PROCEDURE|neoadjuvant therapy|
40824109|NCT00002839|RADIATION|radiation therapy|
40824110|NCT02970006|DEVICE|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
40824111|NCT01122342|DRUG|Testosterone propionate|Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
40824112|NCT03037099|BEHAVIORAL|Enhanced GI Concept Education|
40824113|NCT01618383|OTHER|colonoscopy or rectosigmoidoscopy|Usual procedure
40824114|NCT06605911|DRUG|topical triamcinolone acetonide|ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks
41342280|NCT00290303|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
41342281|NCT01144741|OTHER|PTSD Checklist-Civilian (PCL-C)|Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
41342282|NCT01144741|OTHER|Modified Flanagan Quality of Life Scale|Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.
41018107|NCT02501889|BEHAVIORAL|Standard weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
41018108|NCT04622254|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
41342283|NCT01144741|OTHER|Center for Epidemiologic Studies Depression Scale (CES-D)|Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
41342284|NCT01144741|OTHER|Functional Enquiry (or Review of Systems) Form|Completed during the interview; it is a checklist of medical problems.
41342285|NCT01144741|OTHER|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire|The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
41342286|NCT01144741|OTHER|FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)|Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.
41342287|NCT01144741|OTHER|Medical Records Review|Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
41342288|NCT03414268|OTHER|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
41342289|NCT03414268|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
41342290|NCT03405974|DRUG|Aspirin|Aspirin (acetylsalicylic acid)
41342291|NCT03405974|DRUG|Placebo|Placebo
41342292|NCT00166621|DRUG|Buspirone|
41342293|NCT04346277|BIOLOGICAL|IC14, a monoclonal antibody against CD14|IC14 is a recombinant chimeric anti-human monoclonal antibody directed against human CD14. It recognizes both membrane-bound CD14 and soluble CD14.
41342294|NCT00223613|DRUG|daily intranasal administration of insulin|
41342295|NCT01476553|PROCEDURE|Extensive Intraperitoneal Lavage (EIPL)|"EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.~Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius)."
41342296|NCT05566327|BEHAVIORAL|De-implementation Bundle|"A multicomponent intervention directed at the drivers of low value preoperative testing.~An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing scheduled surgery will be ordered at the discretion of a consulting anaesthesiologist only. Workshops will be delivered to surgical, internal medicine, and anaesthesia divisions. The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies.The clinical departments will commit to supporting the change in policy. Nurses will be coached to feel comfortable calling the anesthesiologist about any preoperative tests ordered, and the PAC nurses will have the authority to cancel tests. Check boxes will be removed from surgeons' and family physicians' order forms to reduce to ease of ordering the tests."
41342297|NCT03130504|DRUG|17α hydroxy progesterone caproate|where patients will have a 17α hydroxy progesterone caproate intramuscular injection every week starting from 24 weeks of gestation till completed 37 weeks
41342298|NCT01402323|OTHER|time point of tooth extraction|
41342299|NCT00290680|DRUG|bortezomib|
41342300|NCT00290680|DRUG|celecoxib|
41342301|NCT04145193|DRUG|Standard of Care - mFOLFOX6|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
41342302|NCT04145193|DRUG|E1 - mFOLFOX and durvalumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)"
41342303|NCT04145193|DRUG|E2 - mFOLFOX6, durvalumab and oleclumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)"
41342304|NCT04145193|DRUG|E3 - mFOLFOX6, durvalumab and monalizumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)"
41342305|NCT04313673|DIAGNOSTIC_TEST|second trimester ultrasonography|Patients undergoing routine antenatal screening between 18-24 weeks and measuring cervical length with transabdominal ultrasonography in the same session
41342306|NCT01105468|DEVICE|Breath Collecting Unit|Collect two breath gas samples per patient on one day before surgery
41342307|NCT01105468|DEVICE|Breath Collecting Unit|Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
41342308|NCT01498770|DRUG|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
41342309|NCT01498770|DRUG|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
41018109|NCT04622254|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
41342310|NCT01498770|DRUG|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
41342311|NCT01498770|DRUG|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
41342312|NCT01498770|DRUG|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
41342313|NCT01498770|DRUG|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
41342314|NCT01498770|DRUG|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
41342315|NCT01498770|DRUG|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
41342316|NCT01498770|DRUG|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
41342317|NCT01498770|DRUG|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
41342318|NCT01498770|DRUG|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
41342319|NCT01498770|DRUG|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
41342320|NCT01498770|DRUG|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
41342321|NCT05935813|OTHER|Study characteristics of adolescents affected by dental caries|Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).
41342322|NCT06106685|DRUG|High-dose washed microbiota suspension|The high-dose group will be administered a high dose of washed microbiota suspension。
41342323|NCT06106685|DRUG|Low-dose washed microbiota suspension|The low-dose group will be administered a low dose of washed microbiota suspension.
40824115|NCT06605911|DRUG|Topical Curcumin|Ten patients with OLP received topical curcumin four times per day for six weeks.
40824116|NCT06605911|DRUG|topical triamcinolone acetonide combiend with topical curcumin|Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.
40824117|NCT05787132|OTHER|Balance Board therapy|Balance board therapy will be performed. balance board therapy has been shown to improve the sitting balance in children with cerebral palsy
41018110|NCT05077254|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
41018111|NCT05077254|BIOLOGICAL|Moderna COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
41018112|NCT05077254|DRUG|SOC IS Regimen|Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.
41342324|NCT06106685|DRUG|Placebo|The control group will be given equal volume placebo (120ml carrier solution matching the volume of WMT-001), which contains 10% sterile glycerol and saline injection. The drug was administered once a day for 4 days.
41342325|NCT04540575|BEHAVIORAL|NICU Acquires MOM|Mother receives 1) hospital-grade electric smart breast pump for home use at no charge to the mother while the infant is in the NICU and the mother continues to pump; 2) free pickup of expressed MOM from home to transport to NICU 2-3 times per week during weekdays as needed; 3) receives payment for opportunity costs of pumping and handling milk at $24.00/day for each day that the mother pumps during her infant's NICU stay
41342326|NCT04540575|BEHAVIORAL|Mother Provides MOM|Mother receives standard Rush NICU lactation care
41342327|NCT01960192|DRUG|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
41342328|NCT01960192|DRUG|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
41342329|NCT00520650|DRUG|Aripiprazole|
41342330|NCT05501457|DEVICE|Muscle strengthening with neuromuscular electrical stimulation|The effect of peripheral muscle strengthening training in addition to pulmonary rehabilitation in COPD patients on the patient's performance will be examined.
41342331|NCT01231672|BIOLOGICAL|Routine biological analyses|Bilirubinemia (total and conjugated), hematology, hemogram, SOFA score
41342332|NCT03878160|OTHER|Individual Interview|Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.
41342333|NCT00740818|OTHER|No Intervention|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
41342334|NCT00740818|PROCEDURE|Sham Logan Basic Adjustment|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
41342335|NCT00740818|PROCEDURE|Logan Basic adjustment|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
41342336|NCT03606707|DRUG|Steroids|intra-articular steroid injection for atlantoaxial joint
41488956|NCT03647683|OTHER|Self-Compassion|"Participants are introduced to the concept of self-compassion. Treating oneself with kindness, while being mindfully aware of the present moment as well as the fact that suffering is part of human life - a shared human experience.~Participants are instructed to use this strategy to cope with the following heat stimulus."
41488957|NCT03647683|OTHER|Acceptance|"Participants are introduced to the concept of acceptance. Thoughts, Emotions and Reactions do not need to be related. Being aware of the present moment helps with accepting the present state and reacting contradictory to the thoughts and feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
41488958|NCT03647683|OTHER|Distraction|"Participants are introduced to the concept of distraction. Distracting oneself from the present situation helps with not perceiving pain, painful thoughts or feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
41488959|NCT03647683|OTHER|Heat pain|Participants receive heat pain stimuli using the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
40824118|NCT05787132|OTHER|Perceptual Motor therapy|Perceptual motor therapy will be performed, it has been shown to improve dynamic sitting in children with cerebral palsy.
40824119|NCT00733772|DIETARY_SUPPLEMENT|flaxseed|30 grams/day of flaxseed for 12 weeks
41342337|NCT04629586|OTHER|No intervention|Observational research study
41342338|NCT01507441|GENETIC|gene mapping|
41342339|NCT01507441|GENETIC|microarray analysis|
41342340|NCT01507441|GENETIC|mutation analysis|
41342341|NCT01507441|GENETIC|nucleic acid sequencing|
41342342|NCT01507441|OTHER|laboratory biomarker analysis|
41342343|NCT05760924|DEVICE|Cardiac Resynchronization Therapy Devices with Defibrillator Function (CRT-D) or CRT-D Leads Replacement|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The new CRT-D will be connected with leads and placed back into the pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture.
41342344|NCT05760924|DEVICE|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right and Left Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. RV and LV pacing will be inactivated and only LBB pacing will be switched on.
41342345|NCT05760924|DEVICE|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. LBB and LV pacing will be switched on.
41342346|NCT03529734|OTHER|12 min running|This was already explained in the description of arm
41342347|NCT03529734|OTHER|Local strengthening exercises|This was already explained in the description of arm
41342348|NCT04737954|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
41342349|NCT04737954|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
41342350|NCT01525745|RADIATION|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
41342351|NCT01525745|RADIATION|External Beam Radiation Therapy|10 consecutive days of standard radiation
41488960|NCT03660293|DRUG|Atorvastatin|cardio-protective agents
41488961|NCT03660293|DRUG|Captopril|cardio-protective agents
41488962|NCT03660293|DRUG|L-carnitine|cardio-protective agents
41488963|NCT03279497|BEHAVIORAL|Health game|Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
41488964|NCT03279497|BEHAVIORAL|Sport and fitness application|Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
41488965|NCT00316147|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|
40824120|NCT00733772|BEHAVIORAL|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
40824121|NCT02034175|DEVICE|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
41488966|NCT06285630|OTHER|Observational, no intervation will be made|No intervention will be made, only longitudinal sample collection.
41488967|NCT00168597|DRUG|Vitamin A|
40824122|NCT02034175|DEVICE|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
40824123|NCT03130660|DEVICE|Ultrasonography|Ultrasound guidance for central line
40824124|NCT02654288|OTHER|gemcitabine-based chemotherapy|
40824125|NCT03946124|DRUG|Fesoterodine|Fesoterodine, the drug used in this study, is an appropriate medication for routine and standard care of overactive bladder.
41342352|NCT00951119|DEVICE|Resperate|device-guided breathing exercises
41342353|NCT00951119|DEVICE|Resperate|breathing device without slowing of breathing frequency
41342354|NCT03795545|PROCEDURE|SWL|Shock wave lithotripsy
41342355|NCT01000818|DRUG|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
41342356|NCT01000818|DRUG|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
41342357|NCT01000818|DRUG|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
41342358|NCT00651768|DRUG|budesonide/formoterol|
41342359|NCT00651768|DRUG|Symbicort pMDI + budesonide HFA pMDI|Symbicort 2 X 160/4.5mcg \& budesonide HFA pMDI 4 X 160mcg
41342360|NCT00820313|BEHAVIORAL|Dr. Dean Ornish Program for Reversing Heart Disease|"Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program."
41342361|NCT01339676|DRUG|Colecalciferol|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
41342362|NCT01339676|DRUG|Placebo capsules|Identically appearing once weekly peroral placebo capsules
41342363|NCT02766972|PROCEDURE|Rapid Ventricular Pacing|Use of Rapid Ventricular Pacing to improve surgical clipping of intracranial aneurysms
41342364|NCT01113190|BEHAVIORAL|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a decisional balance exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed."
41342365|NCT01113190|BEHAVIORAL|Intervener-delivered Brief Intervention (IBI)|"IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller \& Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions."
41488968|NCT06050473|PROCEDURE|Nerve-sacrificing procedure|Surgical fixation of the clavicle fracture will be performed through a horizontal incision over the clavicle. During the incision and soft tissue dissection, the surgeon will not attempt to identify the supraclavicular nerve branches. Instead, the surgeon will cut the nerve branches during the dissection.
41488969|NCT06050473|PROCEDURE|Nerve preserving procedure|Surgical fixation of the clavicle fracture will be performed through the same horizontal incision over the clavicle. The surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
41488970|NCT03487783|DRUG|Aripiprazole Oral Solution|Aripiprazole 2-20 mg/day (2-20 mL/day)
41488971|NCT03487783|DRUG|Placebo Oral Solution|Placebo 2-20 mg/day (2-20 mL/day)
40824126|NCT01945216|DRUG|Alogliptin|Alogliptin tablets
41488972|NCT02249312|DRUG|BIIL 284 BS|
41488973|NCT02249312|DRUG|Placebo|
40824127|NCT00831610|PROCEDURE|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
40824128|NCT00831610|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
40824129|NCT05211921|DEVICE|Multi-Gyn ActiGel Plus|vaginal gel
40824130|NCT03705780|OTHER|the short OSAS scale|Parents fill in the short OSAS screening scale in preoperative interview，calculate score of the scale.
40824131|NCT03705780|DIAGNOSTIC_TEST|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
40824132|NCT02581956|BEHAVIORAL|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
40824133|NCT02581956|BEHAVIORAL|No walking exercise|no exercise
40824134|NCT03537742|BIOLOGICAL|alirocumab|alirocumab 150mg Subcutaneous
40824135|NCT03537742|BIOLOGICAL|placebo|placebo to match alirocumab
40824136|NCT03698045|DRUG|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
40824137|NCT00931723|DRUG|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
41342366|NCT01113190|BEHAVIORAL|Adapted Motivational Enhancement Therapy (AMET)|This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (\~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
40824138|NCT00931723|DRUG|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
40824139|NCT00931723|DRUG|Placebo|Oral treatment twice daily.
40824140|NCT01593995|DRUG|Epidermal growth factor (EGF) ointment|"EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect"
40824141|NCT06217523|OTHER|Pharmacogenomics-directed Hyperlipidaemia Management|Pharmacogenomics-directed Hyperlipidaemia Management
40824142|NCT04248920|BEHAVIORAL|Clinic to Community Education Program|The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
40824143|NCT05945771|DIETARY_SUPPLEMENT|Grape seed extract|Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.
41342367|NCT01113190|BEHAVIORAL|Enhanced Usual Care (EUC)|The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
40824144|NCT03933410|DRUG|KB195|KB195 is a novel glycan
40824145|NCT04429581|OTHER|Anthropometry|
40824146|NCT01381003|GENETIC|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
40824147|NCT03172806|DIAGNOSTIC_TEST|Polysomnography|To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
40824148|NCT00167102|DRUG|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
40824149|NCT05872997|DIAGNOSTIC_TEST|Sensory Motor Training|Mobilization With Movement Along With Sensory Motor Training
40824150|NCT00869804|BEHAVIORAL|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
40824151|NCT00869804|BEHAVIORAL|Attention control|
41018113|NCT05077254|DRUG|SOC IS Reduction|Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.
41488974|NCT05056610|OTHER|food antigens on duodenal mucosa|Administration of food antigens on duodenal mucosa and determining the response through confocal laser endomicroscopy
41488975|NCT06320808|OTHER|FDA template PMI|Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.
40824152|NCT03644914|BEHAVIORAL|10-week Reading Program|Intervention sessions will be carried out during the school day in a private school room. In each session, the investigator will work with the child individually to help him or her read better. Intervention will incorporate word recognition and phonetic decoding of words established as meeting 1st grade essential literacy standards. Learning techniques will involve games, play, movement, music, and breaks (i.e., the child is able to move about and associate words with color, video, and music. Three 5-minute breaks will be integrated into each 1-hour session to allow the child time to rest and process learned material). Intervention will also use each child's personal interests as a context around which sight words will be learned.
40824153|NCT02854488|DRUG|Yervoy|
40824154|NCT06015750|DRUG|methotrexate|Methotrexate will be administered SC or orally weekly for 104 weeks.
40824155|NCT06015750|DRUG|rituximab|Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
40824156|NCT06015750|DRUG|bortezomib|Bortezomib will be administered via IV bolus or SC, as needed.
40824157|NCT06015750|DRUG|IVIg|IVIg will be administered via IV monthly through initial 74 weeks.
40824158|NCT06015750|DRUG|Folic Acid|Folic acid will be given orally as long as methotrexate is being dosed.
40824159|NCT04685707|DEVICE|Visual feedback monitoring system (HFFS)|Participants will follow the exercise monitoring system's instructions displayed on a TV. Treadmill walking speed will be set at a comfortable walking speed.
40824160|NCT04685707|OTHER|Control|Participants will monitor the intensity of exercise independently using a standard heart rate monitor and control it by adjusting the treadmill speed (walking speed).
40824161|NCT00394602|BEHAVIORAL|Interview|Interview regarding perceptions of side effects that are related to chemoradiation treatment.
41488976|NCT06320808|OTHER|Decision Critical PMI|Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template and modified, according to decision science principles, to include benefit information, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.
40824162|NCT00394602|OTHER|Questionnaire|3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
40824163|NCT03142724|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
40824164|NCT01714206|DRUG|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
40824165|NCT01714206|DRUG|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
40824166|NCT01714206|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
40824167|NCT04636177|BEHAVIORAL|Pain Rehabilitation Virtual Reality (PRVR)|Participants will receive approximately 8, 1-hour physiotherapy sessions delivered over the course of 6-12 weeks. Adequate dose: 75% (6 of 8 sessions).
40824168|NCT00097474|DRUG|Hydrocortisone|Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated
41342368|NCT03817749|DIETARY_SUPPLEMENT|Exogenous ketone monoester|Participants will consume 20g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
40824169|NCT00097474|DRUG|Melatonin|Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated
40824170|NCT00097474|DRUG|Placebo|Placebo
40824171|NCT04994782|BEHAVIORAL|GAME-EOL|The GAME-EOL involves Hello game booklets as well as meetings with an interventionist. Players (ICD recipient and their family member or friend dyad) take turns asking the questions in their booklet and providing their answers to the question. The gameplay continues until all questions are answered or the dyad wishes to stop. Following the completion of the game play, participants will be offered the opportunity to complete advance directives using the conversation guide and advance directive form included in the conversation guide that accompanies the questionnaire booklet.
40824172|NCT00504504|DRUG|Rituximab|375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
40824173|NCT00504504|DRUG|Adriamycin|25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
40824174|NCT00504504|DRUG|Bleomycin|10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
40824175|NCT00504504|DRUG|Vinblastine|6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
40824176|NCT00504504|DRUG|Dacarbazine (DTIC)|375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
41342369|NCT05448508|DEVICE|Automatic lancet|An automatic lancet, which can reach a depth of 2.4 mm-3 mm, was used for safe piercing in babies.
41342370|NCT02821988|DEVICE|External fetal monitor for Nonstress test|
41342371|NCT02821988|DEVICE|Ultrasonography for Biophysical profile|
41342372|NCT04426240|DRUG|Cyclosporine microemulsion|Intervention group receives topical cyclosporine dry eye treatment before cataract surgery
40824177|NCT02763904|DIETARY_SUPPLEMENT|Intensive nutritional counseling|Dietary counseling + energy-dense oral nutritional supplements since admission
40824178|NCT02763904|OTHER|Dietary counseling|Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
40824179|NCT06605963|DRUG|PPV-06|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
41342373|NCT06009575|DIETARY_SUPPLEMENT|Iron Supplement Tablets|The intervention group received IST and local culture-based nutrition education
41342374|NCT04092504|OTHER|gero-erat|"The intervention is a standardize Care Plan which will be developed based on the evidence of caring for eldery patients in a trauma setting. The Care Plan will have its base in, the concept of ERAS and CGA. Also, patient experience will be taken in consideration and complement the care pathway.~Patients admitted to the trauma unit will be given the care and asked to be a part of the study witch include to fill out surveys at baseline, six months and 1 year."
41488977|NCT06320808|OTHER|Standard Information|The intervention is an information format viewed by participants. This patient medication information format is the current standard of care patient medication information that is included with the drug. No drug or device is included as part of this intervention.
41488978|NCT00436904|DRUG|Alemtuzumab|30 mg Monday, Wednesday, and Friday x 5 weeks
41488979|NCT00436904|DRUG|Rituximab|375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
41488980|NCT02397005|DRUG|ZL-2102|A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
41488981|NCT02397005|DRUG|Placebo matching ZL-2102|
41488982|NCT05589519|DEVICE|Partial rehabilitation using PEEK|A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis for partial rehabilitation of edentulous jaws.
41488983|NCT00415441|PROCEDURE|Physiotherapy program|
41488984|NCT00415441|PROCEDURE|Placebo physiotherapy treatment|
41488985|NCT05714839|DRUG|Bela|Bela will be administered.
41488986|NCT05714839|DRUG|Belamaf|Belamaf will be administered.
41488987|NCT05714839|DRUG|Lenalidomide|Lenalidomide will be administered.
41488988|NCT05714839|DRUG|Dexamethasone|Dexamethasone will be administered.
41342375|NCT02387073|OTHER|Electrical version patient reported outcome questionnaire|"Assess satisfaction of patients with electrical version patient reported outcome questionnaire."
41342376|NCT04551560|OTHER|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
41342377|NCT05909462|DRUG|2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine|ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection
41342378|NCT03882736|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two different well-known flaps for gluteal augmentation
41342379|NCT02262676|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients treated by Physicians under approved local prescriptions
41342380|NCT04246268|DEVICE|INVOcell|Female participants undergoing in vitro fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproduction will be asked to participate.
41342381|NCT01770886|DRUG|UE2343|Oral capsule
41488989|NCT05714839|DRUG|Standard of Care|Either standard of care (SoC) or an emerging treatment for Multiple Myeloma will be administered
41488990|NCT03899311|OTHER|protein-sparing modified fast diet|a PSMF diet follow the usual care format in the Center
41488991|NCT06434077|BIOLOGICAL|GcMAF injections (100 ng)|The GcMAF 100 ng (Gc protein macrophage-activating factor) will be injected subcutaneously.
41488992|NCT06434077|OTHER|placebo|the placebo solution will be injected subcutaneously 100 ng.
41488993|NCT02139124|DRUG|Placebo|Oral placebo capsule
41488994|NCT02139124|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
41488995|NCT02139124|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
41488996|NCT02139124|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
41488997|NCT02139124|DRUG|PRC-063 100 mg|Oral 100 mg capsule - active
41488998|NCT06018974|DEVICE|Yetitablet gaming|Playing digital games like bowling, memory games, coordination games ect. with the Yetitablet.
41488999|NCT05102292|DRUG|HLX208|HLX208 450mg bid po
40824180|NCT06605963|DRUG|Placebo|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
40824181|NCT05030519|DRUG|Pyrotinib|Pyrotinib 400 mg once daily(monotherapy or combined Trastuzumab/Inetetamab and chemotherapy)
40824182|NCT02929901|DIETARY_SUPPLEMENT|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
40824183|NCT02929901|DIETARY_SUPPLEMENT|caffeine|caffeine plus placebo
40824184|NCT02929901|DIETARY_SUPPLEMENT|chlorogenic acid|chlorogenic acid plus placebo
40824185|NCT02929901|DIETARY_SUPPLEMENT|placebo|placebo plus placebo
41342382|NCT01770886|DRUG|Placebo|Oral capsule
41342383|NCT06249880|OTHER|Observation|This project seeks to recruit 20 male and 20 female typically developing individuals, between the ages of 3 and 25 years of age. Non-invasive measurements of movement patterns (motion analysis and force plate data) will be collected during bipedal gait.
41489000|NCT02434432|BEHAVIORAL|music therapy selected by mothers|mothers' choice of music
41489001|NCT02434432|BEHAVIORAL|Music therapy recorded lullaby|recorded lullaby
41489002|NCT06452875|PROCEDURE|Primary Needle Knike Fistulotomy|"After verifying the eligibility of the papillary morphology (excluding flat or diverticular papillae according to Viana's classification), access to the bile duct will be initiated using the primary needle knife fistulotomy technique. After the first contact of the needle knife with the papilla, the endoscopist will have a total of 8 minutes, after which he can change to other cannulation techniques (eg standard cannulation methods through the papillary orifice) or even stop the procedure.~During ERCP all patients will be submitted to PEP prophylaxis with indomethacin. Also as a prophylactic PEP measure a pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct. For the purpose of this study, a dedicated form (attached) will be created with the various variables to be analyzed."
41342384|NCT00559013|DEVICE|Staple line reinforcement|Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
41342385|NCT03922711|DRUG|Pridopidine|Oral capsule
41342386|NCT03922711|DRUG|Placebo|Oral capsule
41342387|NCT03502941|DIETARY_SUPPLEMENT|6.3 g of EAAs mixture and whey protein isolate|A single dose of the mixture of EAAs/whey
41342388|NCT03502941|DIETARY_SUPPLEMENT|12.6 g of EAAs mixture and whey protein isolate|A double dose of the mixture of EAAs/whey
41342389|NCT03502941|DIETARY_SUPPLEMENT|12.6 g of whey protein isolate|Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey
41342390|NCT01680146|DIETARY_SUPPLEMENT|PRO+FAT|
41342391|NCT01680146|DIETARY_SUPPLEMENT|PRO|
41342392|NCT02324712|DEVICE|Acupuncture|Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
41342393|NCT02324712|DEVICE|Sham Acupuncture|Acupuncture using non-penetrating Park Sham Needles for 20 minutes
41342394|NCT01364142|PROCEDURE|endobronchial blocker|After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
41342395|NCT05826002|BEHAVIORAL|Digital self-guided psychological intervention for insomnia|A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.
41342396|NCT05570357|DIETARY_SUPPLEMENT|Berberine+Cinnamon (TDS)|The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract
41342397|NCT05570357|OTHER|Placebo (TDS)|Placebo contains Maltodexterin
41342398|NCT04527666|DRUG|Anticoagulation Agents|Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
41342399|NCT04124406|DEVICE|Cologuard|multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
41342400|NCT02497053|DRUG|pemetrexed/platinum chemotherapy|Four cycles of pemetrexed/platinum chemotherapy
41342401|NCT02497053|DRUG|Pemetrexed/platinum chemotherapy|Six cycles of pemetrexed/platinum chemotherapy
41342402|NCT02628704|DRUG|Selinexor|The fixed dose of selinexor is 60 mg (three 20 mg tablets)
41342403|NCT02628704|DRUG|Placebo (for selinexor)|sugar tablet manufactured to mimic selinexor tablet
41342404|NCT02628704|DRUG|carfilzomib|Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
41342405|NCT02628704|DRUG|Dexamethasone|Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
41342406|NCT02239367|BEHAVIORAL|Depression Decision Aid|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
41342407|NCT02253940|DRUG|BILR 355 - Treatment A (current tablet formulation)|
41342408|NCT02253940|DRUG|BILR 355 - Treatment B (new tablet formulation)|
41342409|NCT02253940|DRUG|BILR 355 - Treatment C (new capsule formulation)|
41342410|NCT02253940|DRUG|BILR 355 - Treatment D (current tablet formulation)|
41342411|NCT02253940|DRUG|BILR 355 - Treatment E (new capsule formulation)|
41342412|NCT02253940|DRUG|Ritonavir|
41342413|NCT01056419|PROCEDURE|Total Thyroidectomy|Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
41342414|NCT01056419|DRUG|Propylthiouracil|150-600 mg in two-three divided doses
41342415|NCT03931980|PROCEDURE|Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection|we perform robotic surgery using the da Vinci Robot System Si version and laparoscopic surgery to treat rectal cancer
41342416|NCT00373464|DRUG|etoricoxib|
41342417|NCT03838601|DRUG|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
40824186|NCT06297850|DEVICE|Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)|A CGM device placed on the posterior aspect of the upper arm in which a sensor placed in the skin registers glucose values. Via Bluetooth, these readings are sent to a receiver near the patient every 5 minutes. The CGM system can alert when deviating glucose levels, but will for this observational study be blinding to patients and clinical staff. Thus, the patients' diabetic care will rely on standard practice.
40824187|NCT04326244|DIAGNOSTIC_TEST|blood test|High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin
41342418|NCT04973085|DEVICE|Cold circulated water|Cold water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
41342419|NCT04973085|DEVICE|Body-temperature circulated water|Body-temperature water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
40824188|NCT04326244|DIAGNOSTIC_TEST|genetic test|FTO、MC4R、BDNF、PPARG、ADRB3、UCP1
40824189|NCT04326244|DIAGNOSTIC_TEST|Constitution in Chinese Medicine Questionnaire|Constitution in Chinese Medicine Questionnaire
41342420|NCT00001685|BIOLOGICAL|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
41342421|NCT02049229|DEVICE|percutaneous coronary intervention|Optimax-stent implantation
41342422|NCT02049229|DEVICE|percutaneous coronary intervention|Synergy stent implantation
41342423|NCT03472040|DRUG|BCX7353|BCX7353 mg oral capsules administered once daily
40824190|NCT04326244|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale
40824191|NCT04326244|DIAGNOSTIC_TEST|cephalometry|Evaluation of craniofacial morphology in OSA patients
40824192|NCT04326244|DIAGNOSTIC_TEST|polysomnography|to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
40824193|NCT04083261|OTHER|DNA Genotek Oragene 600|Saliva-based DNA sample collection kit
40824194|NCT00101816|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
40824195|NCT00773786|DRUG|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
40824196|NCT00773786|DRUG|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
41342424|NCT01464294|DEVICE|Milled ceramic restorations|Restoration of back teeth with milled ceramic crowns or onlays
41342425|NCT01464294|DEVICE|Milled nano-composite restorations|Restoration of back teeth with milled crowns or onlays
40824197|NCT03304054|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
40824198|NCT03304054|DRUG|Placebo Oral Tablet|tablets matching amifampridine phosphate, 3 to 4 times a day
40824199|NCT00387374|BIOLOGICAL|bevacizumab|Given IV
40824200|NCT00387374|DRUG|paclitaxel|Given IV
40824201|NCT00387374|DRUG|carboplatin|Given IV
40824202|NCT00387374|RADIATION|radiation therapy|Undergo radiotherapy
40824203|NCT06607237|DEVICE|DM-28|1 drop in each eye, 4 to 6 times per day
41342426|NCT05832060|DEVICE|Active tDCS|Active tDCS will be delivered over TPC for a stimulation session. The anodal electrode will be placed on the left TPC, T7/TP7 position according to the 10-20 International EEG 10-20 System for electrode placement. The cathodal electrode will be placed on the right TPC, T8/TP8 position. Intensity will be set at 1 mA, the duration of stimulation will be 20 min.
41342427|NCT05832060|DEVICE|Active tRNS|Active tRNS will be delivered to bilateral TPC for a stimulation session. The electrodes will be placed on the left and right TPC, respectively T7/TP7 and T8/TP8 position, at 0.75 mA (100-500 Hz) for 20 min.
41342428|NCT05832060|DEVICE|Sham tRNS or tDCS|Sham tRNS or tDCS will be delivered over bilateral TPC for a stimulation session. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down without the participants awareness.
41342429|NCT03325010|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
41342430|NCT03325010|DRUG|Placebo oral capsule|non-active dosage form
40824204|NCT02921555|DRUG|Methylprednisolone|Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
41342431|NCT02587104|OTHER|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
41342432|NCT01525420|BEHAVIORAL|Acceptance Therapy (ACT)|ACT
41342433|NCT01525420|OTHER|Cognitive Behavioral Therapy (CBT)|CBT
41489003|NCT04857983|DRUG|Memantine|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
40824205|NCT02921555|DRUG|Prednisone|Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
40824206|NCT06064877|BIOLOGICAL|Ficlatuzumab|Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
41342434|NCT01397513|DRUG|Aspirin|Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
41489004|NCT04857983|DRUG|Placebo|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
41489005|NCT01870882|BEHAVIORAL|Attentional retraining|
40824207|NCT06064877|BIOLOGICAL|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
41342435|NCT03418376|DIETARY_SUPPLEMENT|Beta-alanine supplementation|The supplementation protocol of β-alanine (Etixx® Omega Pharma Belgium NV) involves oral intake of 4 x 800mg (3.2g/day29, 43) daily with at least 2h apart of slow-release β-alanine during the first 12 weeks. After this loading period, subjects will receive a maintenance dose of 2 x 800mg (1.6g/day) β-alanine for the remaining study duration.
41489006|NCT01870882|BEHAVIORAL|Control condition|
41489007|NCT03852173|BEHAVIORAL|Wasserschulen|"Schools receive following materials and trainings:~* one training sessions for teachers (at the beginning of the intervention)~* refillable water bottles for each school student~* drying rack for water bottles for each classroom~* educational material for each class and for school events~* informational material for parents"
41489008|NCT02518919|OTHER|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
41489009|NCT02518919|OTHER|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
40824208|NCT06064877|OTHER|Placebo|Placebo for this study will be normal saline
40824209|NCT03756363|PROCEDURE|Non-solvent|Root canal filling removal using ProTaper retreatment instruments. Single session retreatment procedures.
40824210|NCT03756363|PROCEDURE|Solvent|Root canal filling removal using ProTaper retreatment instruments in combination with a gutta percha solvent. Single session retreatment procedures.
40824211|NCT02231411|PROCEDURE|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
40824212|NCT02231411|PROCEDURE|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
40824213|NCT02231411|PROCEDURE|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
40824214|NCT03041675|DEVICE|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
40824215|NCT03041675|DEVICE|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
40824216|NCT04265729|DIETARY_SUPPLEMENT|Neocate Infant and Junior marketed products|use of Neocate Infant and Junior marketed products
40824217|NCT02763254|BIOLOGICAL|baltaleucel-T|Autologous EBV-specific T cells
40824218|NCT05961969|PROCEDURE|Robotic surgery|"1. Patients with rectal cancer.~2. Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis"
40824219|NCT06384274|OTHER|Emotional Freedom Technique|All people have an energy body. If the energy flow is interrupted, emotions such as stress and fear arise. By clicking on energy points to improve energy flow, the individual gets rid of energy blockages.
40824220|NCT06384274|OTHER|Virtual Reality Glasses|It is aimed to reduce the patient's anxiety by making her feel like she7 he is there by watching and listening to relaxing content of the beach and nature.
40824221|NCT02518594|DRUG|Vaginal progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to \< 35 wks
40824222|NCT02518594|DRUG|Placebo|placebo softgel capsule, daily from randomization to \< 35 wks
40824223|NCT02518594|DEVICE|Arabin Pessary|Placement management from randomization to \< 35 wks
41383600|NCT04188860|DRUG|A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel|"A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for all patients:~* Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months~* Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses"
40824224|NCT05520333|BEHAVIORAL|BIPAS Alcohol|Weekly text messages for three months.
40824225|NCT05753930|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
40824226|NCT04195256|DRUG|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
40824227|NCT04195256|DRUG|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
40824228|NCT04195256|DRUG|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
40824229|NCT04195256|DRUG|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
40824230|NCT01203436|PROCEDURE|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
40824231|NCT01203436|PROCEDURE|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
40824232|NCT05164601|OTHER|No Intervention - Observational Only|Clinical Follow-Up
40824233|NCT00944814|DIETARY_SUPPLEMENT|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
41489010|NCT05900557|DIAGNOSTIC_TEST|ECoG monitoring|Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.
40824234|NCT00944814|DIETARY_SUPPLEMENT|LNS without zinc|LNS containing no zinc
40824235|NCT02593812|BEHAVIORAL|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
40824236|NCT02826421|DEVICE|UltraSert Preloaded Delivery System|Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
40824237|NCT02826421|DEVICE|iTec Preloaded Delivery System|Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
40824238|NCT02826421|DEVICE|iSert Preloaded Delivery System|Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
41383601|NCT06567184|BEHAVIORAL|Strong Hearts Urban|A 12-week multi-level intervention targeting behavior modification, nutrition education, strength training, aerobic exercise, and stress reduction activities
40824239|NCT02826421|DEVICE|Monarch III D Manual IOL Delivery System|Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
41342436|NCT03418376|OTHER|Exercise intervention|The exercise training program (6 months) involves 3 week cycles (week I-III). During week I, subjects will perform high volume moderate intensity cardiovascular cycle training (3x/week). Twice a week, subjects perform 3h training sessions (70-80% HRmax\*) and once a week a 1.5h session will be executed (80-90% HRmax). During week II, subjects will perform low volume maximum intensity interval cycle training (3/w). High intensity interval cycle training (HIIT) will consist of 3x maximal sprints (90-100% HRmax) of 1.5min, interspersed with 3min rest intervals. A 5min standardized warming up and 5min cooling down will be performed. Week III involves a recovery week where subjects will perform one training session of 1.5h at an exercise intensity of 70-80% HRmax and one session of HIIT.
40824240|NCT04676308|OTHER|Artificial Intelligence|Artificial intelligence
40824241|NCT01867957|BIOLOGICAL|Low-dose GC1109|50ug/dose
40824242|NCT01867957|BIOLOGICAL|High-dose GC1109|100ug/dose
40824243|NCT01867957|BIOLOGICAL|Low-dose Placebo|0.9% Saline 0.5 mL
40824244|NCT01867957|BIOLOGICAL|High-dose Placebo|0.9% Saline 1.0 mL
41342437|NCT02257112|DEVICE|Multistage low-energy stimulation|The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
41342438|NCT01894867|DIETARY_SUPPLEMENT|magnesium|supply magnesium oxide for 6 weeks
41342439|NCT01894867|DIETARY_SUPPLEMENT|Placebo|
41342440|NCT05418725|DEVICE|PVI and Linear lesion using PEF|PVI and Linear lesion using PEF
41342441|NCT05418725|DEVICE|PVI and Linear lesion using CFRF|PVI and Linear lesion using CFRF
41342442|NCT05104788|DRUG|Icotinib|Oral
40824245|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental|40 Gy / 15 Fractions EBRT + HDR-Brachytherapy
40824246|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of Care|45 Gy / 25 Fractions EBRT + HDR-Brachytherapy
41342443|NCT05104788|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
41342444|NCT05104788|DRUG|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles
41342445|NCT05104788|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles
41489011|NCT05355649|DEVICE|PREGNOLIA SYSTEM|"The Pregnolia System is composed of two products: an active device (Pregnolia Control Unit) and a single-use sterile probe (Pregnolia Probe).~The intended use of the Pregnolia System is to provide information about the mechanical properties of the uterine cervix by assessing the tissue stiffness through a proxy parameter (the closing pressure, denominated CSI, or Cervical Stiffness Index, in mbar). The Pregnolia System is intended to be used in conjunction with the information obtained from the clinical evaluation of the patient and in addition to other standard examinations."
41489012|NCT00553592|DRUG|Bicifadine|600mg/day
40824247|NCT04583254|DRUG|Concurrent Chemotherapy|Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
40824248|NCT06037785|BEHAVIORAL|Self-Paced Self-Management (SPSM)|(SPSM) consists of two components: 1) HR Self-monitoring, and 2) online Shock Management modules (N=4) with weekly telephone coaching, completed over 1 month.
40824249|NCT02502604|BEHAVIORAL|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
40824250|NCT04267731|DIETARY_SUPPLEMENT|VMK223|Heat killed and purified Bifidobacterium breve polysaccharide-based extract
41342446|NCT01283893|PROCEDURE|Laparoscopic distal gastrectomy with D2 lymphadenectomy|The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
41489013|NCT00553592|DRUG|Bicifadine|placebo tablet
41489014|NCT00553592|DRUG|Bicifadine|1200 mg
41489015|NCT00343343|DEVICE|NovoFine® needle 6 mm|
41489016|NCT00343343|DEVICE|NovoFine® needle 4 mm|
40824251|NCT04267731|DIETARY_SUPPLEMENT|Cellulose|Bulking agent in food production without probiotic properties
40824252|NCT03603535|DEVICE|sensiTVT|The study is designed as a prospective single arm study. All women with an indication for suburethral tape placement for therapy of SUI and meeting the inclusion criteria will be offered study participation to record the objective outcome after one year.
40824253|NCT01693874|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction
40824254|NCT01693874|BEHAVIORAL|control (health education)|health education
40824255|NCT04446130|DRUG|Decitabine combined with HAAG Regimen|Decitabine :20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine :1mg/d,d3\~16,intravenous infusion; Aclarubicin :10mg/d, d3\~d10, intravenous infusion; Cytarabine :10mg/m2,q12h,d3-16, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection
40824256|NCT04969965|DRUG|aumolertinib|EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
40824257|NCT03455868|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
40824258|NCT03090386|OTHER|Cognitive Surveys|Complete the Cognitive Communication Survey, standardized cognitive and language assessments, and the Follow-up Cognitive Communication Survey after treatment
40824259|NCT02599649|DRUG|Lirilumab|3 mg/kg by vein every 4 weeks.
41342447|NCT00169767|OTHER|Comparison study between KTP and HoLAP for BPH|Comparison study between KTP and HoLAp for BPH
41489017|NCT05637346|PROCEDURE|Intra-operative ultrasound measurement|A patient-specific 3D model will be created using an available pre-operative CT scan. Anatomical target points are selected on this virtual model before the start of the surgery. Prior to surgery, a patient-reference electromagnetic (EM) sensor will be placed between the patient and the matrass on the operating table to account for patient movement during acquisition. Intra-operatively, an initial point registration of the 3D model with the electromagnetic tracking system (EMTS) will be performed based on ultrasound (US) imaging of the arterial bifurcations by the surgeon. Then, the surgeon will acquire multiple US sweeps of the pelvic arteries (abdominal aorta and left and right iliac arteries). For validation purposes, the pre-operatively defined anatomical target points will be visualized on US imaging and by pinpointing the EM tracked pointer. All tracking and US data will be recorded and stored for post-operative analysis.
41489018|NCT02287493|OTHER|Pharmacokinetic Analysis|
40824260|NCT02599649|DRUG|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
40824261|NCT02599649|DRUG|Azacitidine|75 mg/m\^2 by vein for 7 days of a 28 day cycle.
41342448|NCT04671095|DEVICE|ERCP procedure with single use duodenoscope|ERCP is an endoscopic procedure done to relieve bile duct obstruction. It is done either under conscious sedation or deep sedation. The endoscope is inserted thorough the mouth and is taken to the second part of duodenum (small bowel). The ampulla is identified and the bile duct is cannulated. Biliary obstruction is relieved either by placing a stent or removing the stone/s
40824262|NCT06607822|DEVICE|A patient-centered assistant system based on Large-Language Model (LLM)|Participants will engage in a 10-minute medical consultation using LLM model interface embedded in a tablet device before their regular face-to-face consulation with physicians. During the trials, participants could engage in free conversations covering aspects including risk factors, symptoms, diagnosis, examinations, treatment, advice and caution, etc. Participants who have completed the ophthalmic imaging examination will be asked to input results into the assistant model to generate structured reports.
40824263|NCT01571908|DRUG|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
40824264|NCT01571908|DRUG|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
40824265|NCT01571908|DRUG|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
40824266|NCT01571908|DRUG|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
40824267|NCT03510468|DRUG|Tenofovir alafenamide|Each tablet contains 25 mg of tenofovir alafenamide.
40824268|NCT03510468|DRUG|Rifapentine|Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to \< 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
41342449|NCT04358913|DEVICE|MR scan with the Alberta linac-MR P3 system|Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
41342450|NCT02238236|DRUG|Alesion®|Dry Syrup
41342451|NCT02287805|OTHER|qualitative survey|
41342452|NCT02287805|OTHER|quantitative survey|
41342453|NCT00544466|DRUG|fludarabine phosphate|25 mg/m2 day -7 through day -3 prior to transplant
41342454|NCT00544466|DRUG|melphalan|140 mg/m2 day -2 prior to transplant
41342455|NCT00544466|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Cells infused on Day 0 of transplant regimen
41342456|NCT00544466|RADIATION|intensity-modulated radiation therapy|Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
41342457|NCT00946023|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
40824269|NCT03510468|DRUG|Isoniazid (INH)|Each tablet is formulated as 100 or 300 mg of isoniazid.
40824270|NCT03510468|DIETARY_SUPPLEMENT|Pyridoxine|Each tablet contains 50 mg of pyridoxine
40824271|NCT00441649|DRUG|Methylphenidate|
40824272|NCT00076336|DRUG|Telbivudine|600mg/day oral tablet for 104 weeks
40824273|NCT00076336|DRUG|Lamivudine|100mg/day oral tablet for 104 weeks
40824274|NCT00076336|DRUG|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
41342458|NCT00946023|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily; Days 3 and 4: 50 mg/kg IV daily
41342459|NCT00946023|RADIATION|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
41342460|NCT00946023|DRUG|Tacrolimus|Start on Day 5 through Day 180
41342461|NCT00946023|DRUG|Mycophenolate Mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
41342462|NCT00946023|DRUG|Rituximab|Day 30 and every week after for 8 total doses: 375 mg/m\^2 IV
41342463|NCT00946023|BIOLOGICAL|Allogeneic Bone Marrow Transplant (BMT)|Day 0: Donor bone marrow infusion
41342464|NCT05031806|DRUG|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.randomized 7:3 for each active concentration to Vehicle.
41342465|NCT05031806|DRUG|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
41383602|NCT00991211|DRUG|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
41342466|NCT05031806|DRUG|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
41342467|NCT05031806|DRUG|Vehicle (eye drop formulation without aCT1)|"36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.~During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2)."
41342468|NCT01055470|DRUG|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
41489019|NCT05622292|DEVICE|HARKIT I-Care Application|HARKIT I-Care Application is an application available in the google play store. The application is specifically developed for the secondary prevention of cardiovascular disease. The features included in the application are (1) Health information logging, (2) Health information education, and (3) Teleconsultation with a cardiologist. Information that can be logged includes smoking behavior, medications, weight, blood sugar level, blood pressure, cholesterol level, physical activity, and Quality of life. Educational content can be accessed by patients in the form of articles and short videos.
41489020|NCT01196078|DRUG|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
41489021|NCT01196078|DRUG|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
41489022|NCT05476653|OTHER|MRI procedure|Pulmonary MRI based on a 1.5 T machine (Siemens VIDA) or a 3T machine (Siemens SOLA) without the use of contrast product according to a protocol based on a 3D-UTE sequence acquired in free breathing but with a respiratory synchronization system in association with weightings in T1 and T2.
41489023|NCT05611450|OTHER|disease self-management application|The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.
41489024|NCT05701137|OTHER|EMDR-RTE|The experimental group will have EMDR recent traumatic event.
41489025|NCT05701137|OTHER|TAU|The comparator group will have usual psychological intervention.
41489026|NCT04078126|COMBINATION_PRODUCT|BFF|Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)
41489027|NCT04078126|COMBINATION_PRODUCT|Symbicort Turbuhaler|Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)
41489028|NCT05913466|DRUG|Tranexamic Acid group|Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
41489029|NCT05913466|DRUG|Distilled water group|This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
41489030|NCT04822233|DEVICE|Hall Technique (HT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swap and dispensed in a transport medium for microbial analyses.The preformed metal crown (PMC) will placed without local anesthetic and without crimping or trimming. When the contact points are tight, an orthodontic elastic separator will be placed for 2 hours prior to PMC placement. The PMCs will be cemented with glass ionomer Ketac cem.
41489031|NCT04822233|DEVICE|Modified Hall Technique (MHT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses.This group will in addition to all the procedures for the Hall will have the Caries lesions treated with 30% Silver Diamine Fluoride (SDF) before cementation of the stainless-steel crowns.
41489032|NCT04822233|DEVICE|Conventional Technique (CT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses. Conventional occlusal, proximal slicing and when necessary buccal and lingual surfaces will be carried out under local anesthesia and dental dam isolation local anesthesia.The PMC will be trimmed and crimped at the gingival margin to improve the fit, and cemented with Ketac cem.
41489033|NCT03911518|PROCEDURE|Loop drainage|Loop drainage will occur via 2 small incisions, approximately 2 cm, with the cuff from the base of a sterile glove pulled through and then tied off.
41489034|NCT03911518|PROCEDURE|Incision and drainage|The wound will be incised with a #11 blade scalpel along the point of maximal fluctuance, approximately 2-3 cm, and then all loculations bluntly dissected with a set of Kelly clamps. After drainage of pus, the wound will be loosely packed with gauze.
41489035|NCT02747862|OTHER|Chart Review|"Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP \[i.e. identifiable APC mutation\], and/or a compatible family history or personal adenoma burden of \> 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016."
41489036|NCT02935205|DRUG|Enzalutamide|Given PO
41342469|NCT01055470|DRUG|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
41489037|NCT02935205|DRUG|Indomethacin|Given PO
40824275|NCT05971030|DEVICE|Cortical brain stimulation of mPFC and dlPFC|Left medial prefrontal cortex combined with dorsolateral prefrontal cortex electrical stimulation
40824276|NCT01832623|OTHER|Exploration of Vitamin D roles|"* Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound~* Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside"
40824277|NCT01880749|DRUG|RAD001|
40824278|NCT04405128|DIAGNOSTIC_TEST|Transcranial Tissue Doppler (TCTD)|"Doppler ultrasound technique called Brain Tissue Velocimetry (Brain TV), to investigate brain tissue motion over the cardiac cycle."
41342470|NCT06384625|OTHER|AIRWISE|AIRWISE (Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education) utilizes personal air cleaners (PACs) to filter indoor air, while enhanced aspects focus on improving compliance to PAC use. Key components include low-cost sensors (PurpleAir, Inc, USA) that change color according to air quality index (AQI) and behavioral recommendations that correspond to varying AQI levels.
41342471|NCT02550860|DRUG|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
41489038|NCT02252718|OTHER|Stool Assessment|"After passing a stool by the child participating in the study, within a short-time interval (\<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition."
41489039|NCT04834843|OTHER|Observational study, no intervention|Observational study, no intervention
40824279|NCT04405128|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging|Brain MRI for investigation of brain tissue motion in the presence of suspected stroke.
40824280|NCT03394599|DEVICE|TheraTrainer + Motiview|TheraTrainer will be used in conjunction with Motiview.
40824281|NCT03394599|DEVICE|TheraTrainer Only|TheraTrainer will be used.
40824282|NCT01460355|DRUG|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
40824283|NCT01460355|DRUG|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
40824284|NCT04861467|DRUG|Camrelizumab|IV
40824285|NCT06428942|OTHER|low-potassium vegetables|low-potassium vegetables 3 to 5 serving according to their daily suggested requirement
40824286|NCT01641146|BEHAVIORAL|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
40824287|NCT01641146|BEHAVIORAL|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
41489040|NCT05880836|DEVICE|nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen|nebulized delivery of bronchodilator via in-line drug delivery maintaining high-flow nasal cannula oxygen
41489041|NCT05880836|DEVICE|standard jet nebulization (SJN) with face mask|standard jet nebulization delivery of bronchodilator
41489042|NCT05731791|RADIATION|Radiation Therapy to partial breast|Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment (Arm 1) and patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment (Arm 2).
40824288|NCT05816642|DRUG|sunitinib or pazopanib|Single targeted therapy
40824289|NCT05816642|DRUG|PD-1 inhibitor combined with axitinib|targeted therapy combined with immunotherapy
40824290|NCT05275543|DEVICE|Paro Robot|Device: PARO therapy seal PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
40824291|NCT02962271|DEVICE|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
40824292|NCT02020876|OTHER|DECIPHER Questionnaire|Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
40824293|NCT06511739|DRUG|SYHX1901|SYHX1901 tablet
41342472|NCT02550860|DRUG|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
41342473|NCT03775603|DEVICE|TOFscan|comparison of TOFscan over TOF-Watch SX
41342474|NCT04731688|BEHAVIORAL|Weight Maintenance Group|The behavioral program is rooted in social learning theory and based on our existing prenatal intervention but with full food provision to ensure gestational fat mass loss is steady and closely supervised. Brief counseling sessions are designed to review self-monitoring records, reinforce adherence to the structured food provision program, problem-solve barriers, and provide additional support. Individuals will be provided with a structured meal plan designed to promote 25% calorie restriction during the second trimester followed by eucaloric intake during the 3rd trimester. Participants will be provided three meals and two snacks on 7 days at no cost.
41342475|NCT04055844|DRUG|Decitabine|10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.
41342476|NCT04055844|DRUG|Ruxolitinib|Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to \>100 x 10\^9/L.
41342477|NCT04055844|DRUG|Donor Lymphocyte Infusion (DLI)|DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.
41342478|NCT01679704|DIETARY_SUPPLEMENT|Food products|
41342479|NCT05424952|OTHER|Conversational AI Service (Chatbot)|WhatsApp or Messenger Chatbot for COVID-19 vaccines
41342480|NCT01678560|DEVICE|Monitoring every 3 months by face-to-face visits|These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
41342481|NCT01678560|DEVICE|Frequent remote monitoring|These patients will be monitored using wireless modems as the method to obtain adherence and efficacy and follow-up phone calls
41342482|NCT03288727|OTHER|interviews with a psychologist|an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported.
41342483|NCT03104959|DIETARY_SUPPLEMENT|N-acetyl cysteine|
41342484|NCT03104959|OTHER|placebo|
41342485|NCT05759104|DRUG|Infliximab|Drug
41342486|NCT05759104|PROCEDURE|Stomy|Surgery
41342487|NCT04250610|OTHER|Survey|On-line survey.
41342488|NCT02094729|DRUG|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
41342489|NCT02094729|DRUG|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
41489043|NCT03757351|DRUG|DNL747|Repeating oral dose
41489044|NCT03757351|DRUG|Placebo|Repeating oral dose
41489045|NCT04689919|DRUG|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
41489046|NCT02065700|DRUG|Filgotinib|Administered as Oral Tablets
41489047|NCT00290160|BEHAVIORAL|Protein supplementation|
41489048|NCT02216318|OTHER|blue light|
41489049|NCT04969159|OTHER|no intervention|standard treatment in the clinical routine
40824294|NCT06511739|DRUG|placebo|Oral tablet
41342490|NCT02094729|DRUG|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
41342491|NCT02094729|DRUG|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
41342492|NCT02180490|DRUG|UHAC 62 XX tablet|
41342493|NCT02180490|DRUG|UHAC 62 XX capsule|
41489050|NCT00969631|DRUG|metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
41489051|NCT00969631|PROCEDURE|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
40824295|NCT00037817|DRUG|Decitabine|assigned dose level on day 4 and day 10 of each 34 day cycle
40824296|NCT00037817|BIOLOGICAL|Depsipeptide|assigned dose level on day 4 and day 10 of each 34 day cycle
41342494|NCT06404229|DIAGNOSTIC_TEST|CardioPulmonary Exercise Testing|CardioPulmonary Exercise Testing using an arm ergometer prior to surgery
41342495|NCT00336661|DEVICE|PerioWave|
41342496|NCT05562700|OTHER|On-line questionnaire|"It is a self-administered questionnaire (20 minutes) with several subparts:~* Socio-demographic questions: age, height, weight, smoking status, etc.~* Care: date of accident, initial treatment, duration of symptoms, complications, return to work, return to sport, recovery of skills, etc.~* Functional results"
41342497|NCT01585168|DRUG|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
41342498|NCT01585168|DRUG|Placebo|Identically appearing sugar pill, given orally
41342499|NCT03016039|DIETARY_SUPPLEMENT|Curcumin supplementation|use of curcumin supplementation as an additive treatment to the conventional treatment
41342500|NCT01502761|DRUG|Magnesium Sulfate|Intra-arterial
41342501|NCT00271791|DRUG|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
41342502|NCT00271791|DRUG|Prednisone|PO, Placebo, 17 days
41342503|NCT00663338|DRUG|Rotigotine|Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
41489052|NCT03054259|DRUG|Rituximab|1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
41489053|NCT03054259|DRUG|Methylprednisolone|100mg infusion on days 1 and 15
41489054|NCT03054259|DRUG|Normal Saline|250ml infusion on days 1 and 15
41508994|NCT04431765|OTHER|Eye Movement Desensitization Reprocessing therapy|The Eye Movement Desensitization Reprocessing therapy uses bi-alternating (right-left) sensory stimulation through eye movements. The patient follows the therapist's fingers from right to left in front of his eyes and also by auditory stimuli. The patient wears a helmet that alternately makes him hear a sound to the right, then to the left or touch the patient holds in his hands buzzers that alternately vibrate from right to left, or alternatively the therapist taps the patient's knees or the back of his hands.
41342504|NCT00809575|OTHER|questionnaire administration|
41342505|NCT00809575|OTHER|fatigue assessment and management|
41342506|NCT00809575|OTHER|observation|
41342507|NCT00809575|OTHER|quality-of-life assessment|
41342508|NCT00780104|DRUG|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
41342509|NCT00780104|DRUG|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
41342510|NCT06183736|DRUG|CVL237 tablets|CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
41342511|NCT04914195|DRUG|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.
41342512|NCT01677676|BIOLOGICAL|FP-01.1|IM injection
41342513|NCT01677676|BIOLOGICAL|FP-01.1-Adjuvant|IM injection
41342514|NCT00832091|DRUG|Thymosin Beta 4|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
41342515|NCT00832091|DRUG|Placebo|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
41342516|NCT02552667|DRUG|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
41342517|NCT02552667|DRUG|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
41342518|NCT01191424|DRUG|CHF1535 NEXT DPI|FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER
41342519|NCT01191424|DRUG|BDP DPI and formoterol DPI|FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
41342520|NCT00130494|DRUG|Zoledronic acid|
41342521|NCT02705352|DRUG|5-Fluorouracil|Treatment medication
41342522|NCT02705352|OTHER|Normal saline|Placebo
41342523|NCT00155467|PROCEDURE|CT|
41342524|NCT03051217|OTHER|Placebo|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use Q2W"
40824297|NCT00037817|DRUG|Celecoxib|400mg PO BID on days 4 through 34 of each cycle
41157265|NCT04290156|OTHER|joint visits|The intervention is the implementation of joint transition visits with the participation of both the pediatric and the adult gastroenterologist. One-year intervention period was chosen. In total, there are four joint visits every third months for the adolescents aged 17-18. Each joint visit lasts for at least for 20 minutes, although in case of complex medical history, there is no restriction with respect to the length of the visit. Joint transition visits 1, 2 and 3 (V1-3) are led by the pediatric gastroenterologist, and visit 4 (V4) is led by the adult gastroenterologist.
41342525|NCT03051217|DRUG|Certolizumab Pegol|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
41342526|NCT04870255|DEVICE|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
41342527|NCT04870255|DEVICE|Dorsomedial Prefrontal Cortex (DMPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
41342528|NCT04870255|DEVICE|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
41342529|NCT00000440|DRUG|naltrexone (Revia)|
41342530|NCT00000440|DRUG|sertraline (Zoloft)|
41342531|NCT03320486|DRUG|Dapaconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
41342532|NCT03320486|DRUG|Ketoconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
41342533|NCT05455255|OTHER|Experimental|FL was applied by Jonathan Bergmann and Aaron Sams in 2007 for high school students who had to be absent from chemistry class. Bergmann and Sams published all the learning activities they used during the lesson as videos. Bergmann and Sams (2012) stated that in this model, which they developed over time, it is not compulsory for the trainer to explain the entire course content in the videos, and the important thing is to allocate time to active learning methods during the course. In the FL model, the summary of the course content is presented to the individuals outside the classroom with tools such as video and power point presentations. In the lesson, activities are carried out for the active participation of the student. The student performs the course content outside of the classroom, and the homework and learning the course in the classroom.
41342534|NCT04481880|DIAGNOSTIC_TEST|measuring IAP and respiratory parameters|Effect of IAP on respiratory parameters Correlation between IAP and Gastric and urinary bladder pressures
41342535|NCT04946760|OTHER|Sham Manipulation|The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention.
41342536|NCT03993301|OTHER|Probiotic A formula|Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
40824298|NCT05074888|DRUG|Prospekta|Oral administration.
40824299|NCT05074888|DRUG|Placebo|Oral administration.
41342537|NCT03993301|OTHER|Probiotic B formula|Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
41342538|NCT03993301|OTHER|Regular formula|Feeding baby two meals a day with regular formula at least.
41018114|NCT02481687|OTHER|Confocal laser endomicroscopy|Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
41018115|NCT05415098|DRUG|APG-5918|"The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.~The dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study."
41342539|NCT04548479|DEVICE|PEP bottle|PEP bottle: it will be performed with a bottle of distilled water and a plastic tube, where the patient breathes against a resistance during expiration.
41342540|NCT06220188|DRUG|[177Lu]Lu-PSMA I&T|2 cycles (3 GBq in first cycle and 6 GBq in the second cycle) of \[177Lu\]Lu-PSMAI\&T radioligand therapy at 6-week intervals
41342541|NCT04756349|OTHER|composite resin restoration|All patients will receive adhesive composite resin restorations. There will be 3 groups (different adhesives): Clearfil SE, Optibond All-in-One and Prime \& Bond Universal.
41342542|NCT03029767|OTHER|Aerobic exercise .|The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
41342543|NCT03029767|OTHER|Resistance exercise|"The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.~Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed."
41018116|NCT05694559|BEHAVIORAL|Genetic Testing and Counseling|Participants will complete testing
41342544|NCT03029767|OTHER|Aerobic and resistance exercise|The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.
41342545|NCT05784103|DEVICE|Clarifi Modulum|During consenting period, the Modulim equipment will be calibrated and setup ready for scanning. Subject's volar aspect of the thumb along with the palm surface will be ready to target the optical camera head. Actual scanning takes less than 60 seconds. The images will be processed offline. During processing 3-5 different regions of interest will be taken to measure the oxygen parameters such as tissue oxygen saturation, oxy-hemoglobin, deoxy-hemoglobin, superficial hemoglobin, and sub-surface hemoglobin.
41342546|NCT05784103|DEVICE|Perimed PeriFlux 5000|Transcutaneous oxygen monitoring (TCOM or TcpO2) is a noninvasive, clinically-approved method to obtain skin oxygen levels. The method is quantitative, and measures oxygen delivery to the skin from underlying tissue. Before positioning the electrode, an adhesive fixation ring will be placed on the dry skin on the volar aspect of the thumb and an electrolyte as a contact liquid will be filled half and the probe is aligned into it by rotating clock-wise to fasten it. Recording will be started and waited for the oxygen level to stabilize and a fixed value will be recorded. The probe will be heated to about 45oC. Although this device has other options, only the measurement of O2 will be performed using this device.
41489055|NCT06414070|BEHAVIORAL|Jenga Dada|Jenga Dada aims to empower women participating in community-based economic groups by training them to recognize inequality, challenge it, and work toward positive changes in their lives related to finances, health, and relationships and increase social support on these issues within the groups. Jenga Dada is expected to include eight modules: 1) overview of the intervention, 2) gender roles, 3) economic control and abuse, 4) intimate partner violence (IPV), 5) reproductive coercion (RC), 6) family planning (FP), 7) financial literacy, and 8) life goals. The Jenga Dada intervention is group discussion-based and draws on two effective interventions: ARCHES (a facility-based contraceptive counseling intervention providing support for RC and IPV) and Girls Invest (a mobile health application with integrated modules on gender, IPV, and financial literacy). The intervention will be facilitated by a local NGO in partnership with group leaders.
41489056|NCT00045175|DRUG|7-hydroxystaurosporine|
41018117|NCT05694559|BEHAVIORAL|Screening Form|Participants will complete forms with demographics and history
41018118|NCT02787356|DRUG|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic
41018119|NCT02787356|DRUG|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD
41018120|NCT06034158|DRUG|single-dose madopar, single-dose propranolol, and single-dose placebo by order|Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
41018121|NCT06034158|DRUG|single-dose madopar, single-dose placebo, and single-dose propranolol by order|Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
41018122|NCT06034158|DRUG|single-dose propranolol, single-dose madopar, and single-dose placebo by order|Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
41342547|NCT05784103|DEVICE|Apple Watch Oxygen Sensor|The apple watch is equipped with green, red, and infrared LEDs that shine light onto the blood vessels in the wrist, with photodiodes measuring the amount of light reflected back. Apple's algorithms use this information to calculate the color of the blood, which is an indication of how much oxygen is in the blood. Bright red blood is well oxygenated, while darker blood has less oxygen. This can measure blood oxygen levels between 70 and 100 percent. Most healthy people have blood oxygen levels that range from 95 to 100 percent. The apple watch sensor will be positioned on the user's preferred wrist.
41342548|NCT05784103|DEVICE|Innovo iP 900AP|The pulse oximeter enables transcutaneous monitoring of the oxygen saturation of hemoglobin in arterial blood. In this study, volar aspect of thumb and index finder of the subject will be used to measure blood oxygen saturation.
41342549|NCT04530968|OTHER|No intervention|No intervention
41489057|NCT00045175|DRUG|topotecan hydrochloride|
41489058|NCT03842813|DEVICE|DES-CRE8|Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.
41489059|NCT03738020|DEVICE|HA IDF (YVOIRE classic)|Treatment with HA IDF
41489060|NCT03738020|DEVICE|Restylane|Treatment with Restylane
41489061|NCT04257552|BEHAVIORAL|Healthy Beyond Pregnancy|Web-based application grounded in tenants of behavioral economics.
41489062|NCT04257552|BEHAVIORAL|Pre-Scheduled Postpartum Visit|Participants will have their postpartum visit scheduled while they are still in the hospital after delivery.
41489063|NCT04257552|OTHER|Attention Control|Participants will receive texts related to infant care to mirror the attention participants receive in the Healthy Beyond Pregnancy intervention.
41489064|NCT00127036|DRUG|XELOX|XELOX: Oxaliplatin 130 mg/m\^2 intravenously (IV); Capecitabine 825 mg/m\^2 by mouth (po)
41489065|NCT00127036|DRUG|XELIRI|XELIRI: Irinotecan 240 mg/m\^2 IV; Capecitabine 825 mg/m\^2 by mouth (po)
41489066|NCT00127036|DRUG|Bevacizumab|7.5 mg/kg intravenously (IV)
41489067|NCT05496335|DRUG|AGN-151586|Intramuscular Injection
41489068|NCT05496335|DRUG|BOTOX|Intramuscular Injection
41489069|NCT05496335|DRUG|Placebo|Intramuscular Injection
41489070|NCT01166906|DEVICE|pain blocking|pain blocking
41489071|NCT05949671|OTHER|mediterranean, gluten-free and mediterranean gluten-free diet intervention|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients in the control group (n=10) did not receive any special dietary intervention. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
41489072|NCT01458730|DRUG|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
41489073|NCT02121275|DEVICE|Ultrasound of the lungs|Ultrasound examination of the lungs
41489074|NCT02121275|DEVICE|Electric impedance tomography|Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
40824300|NCT05477537|OTHER|Adapted physical activity program|subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.
41489075|NCT03145402|BIOLOGICAL|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
40824301|NCT05477537|OTHER|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual)
41342550|NCT00227968|BEHAVIORAL|Interpersonal Social Rhythm Therapy (IPSRT)|
41342551|NCT00227968|BEHAVIORAL|Clinical Status and Symptom Response Therapy (CSSRT)|
41342552|NCT05298163|DRUG|Calcitriol capsules|Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
41342553|NCT05298163|DRUG|Placebo|One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
41342554|NCT04725604|DEVICE|pH probe|"Patients who agree to take part will have a pH probe inserted into their injured limb. The pH probe will be attached to a pH monitor which will record pH data for up to a maximum of 72 hours (24 hours per probe). The surgical team will not have access to the pH data. During the time they are considered at risk for ACS, patients will be monitored in the routine way (using regular clinical assessment and pressure monitoring). If ACS is diagnosed in the routine way, then treatment (fasciotomy) will be offered as appropriate."
41342555|NCT00906334|DRUG|ON 01910.Na|The original dosing regimen was 800 mg/m\^2 ON 01910.Na.
41489076|NCT03145402|BIOLOGICAL|Placebo|Injection of Placebo in patients with Heart failure via coronary arteries
41489077|NCT03119506|BEHAVIORAL|Recess|Recess timing and duration effects on lunch intake
41342556|NCT00906334|DRUG|ON 01910.Na|Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
41342557|NCT01974440|DRUG|Bendamustine|90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
41342558|NCT01974440|DRUG|Rituximab|375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
41342559|NCT01974440|DRUG|Cyclophosphamide|750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
41342560|NCT01974440|DRUG|Doxorubicin|50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
41489078|NCT02788682|GENETIC|WT+ Diplotype|3 or 4 vitamin D binding protein major alleles
41489079|NCT02613741|OTHER|Lifestyle-based physical activity|Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
41489080|NCT05502965|OTHER|dietary pattern|Reprocessed and intolerant foods were removed from the dietary pattern, and the food were cooked at home for experimental subjects.
41489081|NCT05502965|OTHER|EEN|All energy and nutrients are obtained from exclusive enteral nutrition.
41018123|NCT06034158|DRUG|single-dose propranolol, single-dose placebo, and single-dose madopar by order|Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
41489082|NCT01024686|BIOLOGICAL|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
41018124|NCT06034158|DRUG|single-dose placebo, single-dose propranolol, and single-dose madopar by order|Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
41018125|NCT06034158|DRUG|single-dose placebo, single-dose madopar, and single-dose propranolol by order|Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
41018126|NCT06461104|BEHAVIORAL|Structured Physical Activity Programme|A somatic examination will also be conducted by a sports physician, which will include the assessment of muscle strength, cardiorespiratory fitness, walking gait, blood pressure, and body mass index (BMI). Based on this evaluation, the sports physician will design a personalised physical activity programme for the participants in the intervention group.
41157266|NCT06218914|BIOLOGICAL|NT-112: Autologous, engineered T Cells targeting KRAS G12D|"* Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion of T cell receptor (TCR) T cells~* Post-infusion recombinant interleukin-2 (rIL-2)"
41342561|NCT01974440|DRUG|Vincristine|1.4 mg/m\^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
41489083|NCT01024686|BIOLOGICAL|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
41342562|NCT01974440|DRUG|Prednisone|100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
41342563|NCT01974440|DRUG|PCI-32765 (Ibrutinib)|560 mg (4\*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
41342564|NCT01974440|DRUG|Placebo|Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
41342565|NCT00864123|BEHAVIORAL|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks that is based on the protocol used in POTS (2004). Sessions 1-4 will be held twice weekly; thereafter sessions will be held on a weekly basis. This evidence-based E/RP intervention (POTS, 2004) includes psychoeducation, cognitive training, and exposure and response prevention. By design, this manual provides sufficient flexibility to accommodate the child's developmental needs and address maladaptive parent-child interactions (e.g., accommodation).
41489084|NCT01024686|BIOLOGICAL|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
41489085|NCT02227147|DRUG|rhNGF 20µg/ml|
41489086|NCT02227147|OTHER|Placebo|Formulation containing antioxidant
41489087|NCT03382730|OTHER|Chlorhexidine Mouth Rinse|Oral chlorhexidine gluconate oral rinse
41489088|NCT03382730|OTHER|Chlorhexidine Mouth Rinse De-Adoption|Multifaceted education and audit/feedback.
41489089|NCT02874209|OTHER|sodium MRI|
41489090|NCT00523536|BEHAVIORAL|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
41489091|NCT05030766|DRUG|Nicotine Replacement Therapy|6 weeks of Nicotine replacement patches
41489092|NCT05030766|BEHAVIORAL|Mindfulness Training Smoking Cessation Intervention|Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.
41342566|NCT00864123|DRUG|D-cycloserine|D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.
41342567|NCT00864123|DRUG|Placebo pill|This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
41342568|NCT03520426|DEVICE|Votiva RF|The Votiva system is approved by the U.S. Food and Drug Administration for treatment of sexual dysfunction as well as in combination with Kegel exercises for tightening of the muscles of the pelvic floor to increase muscle tone. One part of the system, the fractora handpiece, is approved for tissue coagulation for the purpose of skin rejuvenation. The Votiva has two hand pieces, Forma and Fractora, which have been cleared by the United States Food and Drug Administration (FDA) and are used during dermatological procedures.
41342569|NCT04461613|OTHER|Original IPAQ followed by a revised one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
41342570|NCT04461613|OTHER|Revised IPAQ followed by an original one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
41489093|NCT05030766|BEHAVIORAL|Contingency Management Smoking Cessation Intervention|Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.
41157267|NCT05383651|DEVICE|bellavista 1000|observational use of Bellavista 1000 ventilator in adult ventilated patients
41342571|NCT00653068|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
41342572|NCT00653068|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC rescue
41342573|NCT00653068|DRUG|Carboplatin|Given IV
41342574|NCT00653068|DRUG|Cisplatin|Given IV
41342575|NCT00653068|DRUG|Cyclophosphamide|Given IV
41342576|NCT00653068|DRUG|Etoposide|Given IV
41342577|NCT00653068|BIOLOGICAL|Filgrastim|Given IV or SC
41342578|NCT00653068|OTHER|Laboratory Biomarker Analysis|Correlative studies
41342579|NCT00653068|DRUG|Leucovorin Calcium|Given IV or PO
41157268|NCT05383651|DEVICE|bellavista 1000 neo|observational use of Bellavista 1000 ventilator in neonatal ventilated patients
41157269|NCT01931683|DRUG|remifentanil|The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
41342580|NCT00653068|DRUG|Methotrexate|Given IV
41342581|NCT00653068|DRUG|Thiotepa|Given IV
41489094|NCT05145582|BEHAVIORAL|The Self-Guided PSP Wellbeing Course|An unguided version of a transdiagnostic ICBT program that has shown promising initial outcomes in prior research (https://doi.org/10.2196/27610).
41342582|NCT00653068|DRUG|Vincristine Sulfate|Given IV
41342583|NCT05458869|PROCEDURE|HPV Self-Collection|Use HPV self-collection kit
41342584|NCT05458869|OTHER|Interview|Attend interview
41342585|NCT05458869|OTHER|Survey Administration|Complete surveys
41342586|NCT01560104|DRUG|Veliparib|
41342587|NCT01560104|DRUG|Carboplatin|
41342588|NCT01560104|DRUG|paclitaxel|
41342589|NCT01560104|DRUG|placebo|
41342590|NCT04431804|OTHER|silver nanoparticle|fungicidal effect of silver nanoparticles on aspergillus isolates
41342591|NCT06063525|OTHER|Structural anatomy|images acquired with 3T MRI system with 32 channel head coil
41342592|NCT03684525|PROCEDURE|Extraction of primary canines|"At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~* If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~* If Canine is emerged to oral cavity: No further CBCT scan will be taken~* If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
41342593|NCT00152789|PROCEDURE|Oxygen measurement - Eppendorf machine|
41342594|NCT03365440|DEVICE|esoECG-3D catheter|Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.
41342595|NCT05385913|OTHER|Multivitamin-no intervention|No intervention. All participants will be given a multi-vitamin to take for the duration of the study
41342596|NCT03230357|DEVICE|PICC guided by EDUG|ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
41489095|NCT05145582|BEHAVIORAL|Online Discussion Forum|An online discussion forum designed to provide an opportunity for participants to support one another in their use of the ICBT program.
41342597|NCT01012804|GENETIC|western blotting|
41342598|NCT01012804|OTHER|immunohistochemistry staining method|
41342599|NCT01012804|OTHER|laboratory biomarker analysis|
41342600|NCT05840523|OTHER|Proprioceptive Neuromuscular Facilitation exercises|The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
41342601|NCT05840523|OTHER|The Range Of Motion exercises|The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
41342602|NCT04324268|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
41018127|NCT06461104|BEHAVIORAL|Psychoeducational Programme|The control group undergoes a 12-week psychoeducational programme on nutrition and PA, consisting of 8 sessions. Led by a dietitian and psychologist, topics include PA benefits, healthy eating, and sedentary lifestyle risks. The experimental group receives 3 sessions on dietary habits before starting PA intervention, ensuring differentiation. It's expected the experimental group directly benefits from exercise, while the control group benefits from PA education. At the trial's end, control group members can join the PA programme for free.
41018128|NCT04839081|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
41018129|NCT00951210|BIOLOGICAL|PLX-PAD|IM injection
41018130|NCT02057757|DRUG|Nitazoxanide|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
41018131|NCT02057757|DRUG|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
41018132|NCT01940705|OTHER|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
41018133|NCT01940705|OTHER|Hearing-Aid DVD|Take-home DVD about hearing aids
41018134|NCT01940705|BEHAVIORAL|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
41342603|NCT04324268|OTHER|Placebo|Placebo
41342604|NCT05654662|DRUG|Corsodyl Original Dentifrice|It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million \[ppm\] Fluoride ion \[F\])
41018135|NCT01940705|OTHER|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
41018136|NCT03711123|BEHAVIORAL|Group metacognitive therapy|10 weekly Group session of 90 minutes duration
41018137|NCT03711123|BEHAVIORAL|Clinical management|10 weekly individual sessions With clinical management including guided self-help
41018138|NCT01743937|PROCEDURE|Coronary occlusion with balloon inflation|
41018139|NCT02350959|DRUG|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
41018140|NCT02350959|DRUG|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
41018141|NCT05986929|OTHER|focus group|Two semi-structured group interviews, lasting 30-60 minutes, on facilitators and barriers to poster use by staff members (N=6-8).
41018142|NCT05986929|OTHER|electronic survey|An electronic survey of 15 closed questions on the acceptability of the magnetic posters (N=100).
41018143|NCT05281367|PROCEDURE|Breast milk odor group|The researcher applied the breast milk that dripped on the pad for 3 minutes before the heel stick for 36 premature newborns in the breast milk odor group. About three cc breast milk dripped onto a sterile pad and placed at a distance of 10 cm from the nose of the newborn. It continued until 3 minutes after the invasive procedure. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
41157270|NCT01931683|DEVICE|laryngeal mask airway (LMA)|LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
41342605|NCT05654662|DRUG|Colgate Cavity Protection Dentifrice|It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
41157271|NCT01906645|OTHER|Care Transitions Innovation (C-TraIn)|Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
41342606|NCT02425969|PROCEDURE|PCI|Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
41342607|NCT02425969|DRUG|Optimal Medical Therapy|Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
41342608|NCT05231421|BEHAVIORAL|Focus Group|Each focus group will consist of 5-10 participants. They will first introduce to each other and be asked to keep information shared during the session private. The moderator will initiate some questions for the group to discuss. Prompt and follow-up questions will be asked. There is no right or wrong answer for each question and no sensitive questions will be asked. The conversations during the focus group discussion will be recorded. The group will be debriefed about the purpose of the study and have a chance to ask any questions about the study if they have. The focus group discussion for each session will last about 60-90 minutes.
41342609|NCT04869189|DEVICE|JJVC Marketed Contact Lens|Acuvue Oasys® 1-Day
41342610|NCT00862524|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
41342611|NCT00862524|DRUG|Gemcitabine, nucleoside analogue; intravenous|multiple dose, single schedule
41342612|NCT03625960|DRUG|Cantharidin|A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.
41342613|NCT03625960|DRUG|Trichloroacetic Acid|Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
41342614|NCT03170492|OTHER|RehaCom Computerized Cognitive Training for 480 minutes|Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
41342615|NCT03170492|OTHER|Pencil-and-Paper Cognitive Training for 480 minutes|Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
41489096|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 1|Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
41489097|NCT00686075|OTHER|Placebo, Cohort 1|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
41489098|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 2|Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
41489099|NCT00686075|OTHER|Placebo, Cohort 2|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
41489100|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
41489101|NCT00686075|OTHER|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
41489102|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
41489103|NCT00686075|OTHER|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
41489104|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
41489105|NCT00686075|OTHER|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
41489106|NCT05055895|DRUG|Anticholinergic burden|"The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1."
41489107|NCT03994718|OTHER|Music intervention|The music therapist will work with subjects for up to 60 minutes each session.
41489108|NCT03994718|OTHER|Visual arts intervention|The visual artist will work with subjects for up to 60 minutes each session.
41157272|NCT00733551|DRUG|GSK962040|GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
41342616|NCT04027036|BIOLOGICAL|Inactivated poliovirus vaccine in reduced doses|"contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age"
41342617|NCT02014545|DRUG|Lucanthone|The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.
41342618|NCT02014545|OTHER|Placebo|Only standard treatment of whole brain radiation therapy is done.
41342619|NCT00389805|DRUG|bortezomib|
41342620|NCT00389805|DRUG|pemetrexed disodium|
41342621|NCT00389805|GENETIC|gene expression analysis|
41342622|NCT00389805|GENETIC|mutation analysis|
41342623|NCT00389805|GENETIC|protein expression analysis|
41342624|NCT00389805|GENETIC|reverse transcriptase-polymerase chain reaction|
41342625|NCT00389805|OTHER|flow cytometry|
41489109|NCT03994718|OTHER|Creative writing intervention|The creative writer will work with subjects for up to 60 minutes each session.
41489110|NCT02637635|PROCEDURE|Autologous fat transplantation|100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
41018144|NCT05281367|PROCEDURE|Facilitated tucking group|The Facilitated tucking position was given to 36 premature newborns in the Facilitated tucking group, from 3 minutes before to 3 minutes after the heel stick procedure. Premature newborns were kept in the facilitated tucking position by the investigator using the incubator windows without opening the incubator cover to prevent heat loss of the newborn. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
41157273|NCT00733551|DRUG|Placebo|Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
41342626|NCT00389805|OTHER|immunoenzyme technique|
41342627|NCT00389805|OTHER|immunohistochemistry staining method|
41342628|NCT00184067|BIOLOGICAL|Montanide ISA 51|
41342629|NCT00419835|DRUG|enalapril|
41342630|NCT00419835|DRUG|losartan|
41342631|NCT01438775|DRUG|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
41342632|NCT05017168|DRUG|CT-P63|CT-P63 will be administered
41342633|NCT05017168|DRUG|Placebo|Placebo-matching CT-P63
41342634|NCT04673812|DRUG|Bupivacaine-fentanyl|"Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL."
41489111|NCT02637635|PROCEDURE|Expander prosthesis|breast reconstruction with expander prosthesis.
41489112|NCT05420974|PROCEDURE|NIR fluorescence imaging of the vascular perfusion of the meniscus using ICG|NIR fluorescence imaging of vascular perfusion using the Arthrex NIR fluorescence scope and Indocyanin Green
41489113|NCT02088190|PROCEDURE|Sleeve gastrectomy|Type of bariatric surgery
41489114|NCT00878514|DRUG|Alprazolam|Alprazolam 1 mg tablet
41489115|NCT00878514|DRUG|Xanax|Xanax 1 mg tablet
41489116|NCT02232490|BIOLOGICAL|hepcortespenlisimut-L|hepcortespenlisimut-L (V5) is given in experimental arm
41489117|NCT02232490|BIOLOGICAL|Placebo|
41489118|NCT04155307|DEVICE|Anal EndoFLIP®|Anal EndoFLIP® measure to evaluate anal compliance
41489119|NCT04155307|DIAGNOSTIC_TEST|Anal Manometry|Anal Manometry done in standard care
41342635|NCT05848336|BEHAVIORAL|Gluten Free Casein Free Diet|Thirty children with autism were evaluated before the diet (Pre-Test) and after 8 weeks of dietary intervention (Post-Test).
41342636|NCT03447067|PROCEDURE|computer guided surgical|has three cutting guided plane for identify the position of place of the third molar, it have beveled cut for stability after remove the teeth and placing the bony window
41342637|NCT03447067|PROCEDURE|Conventional surgery|Low speed motor with surgiacl round burs and surgical fissure for removal a covering bone with decapitation and guttering formation
41342638|NCT03447067|DEVICE|CBCT|For measuring the bone removeal
41342639|NCT03447067|DEVICE|CBCT|for identifed the nerve
41342640|NCT05100004|DEVICE|Accelerated Theta Burst Stimulation|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
41342641|NCT05100004|DEVICE|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
41489120|NCT04155307|DIAGNOSTIC_TEST|Defecography|Defecographydone in standard care
41489121|NCT04155307|DIAGNOSTIC_TEST|Electromyogram|Electromyogram done in standard care
41342642|NCT03144830|DEVICE|Exoskeleton|This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
41342643|NCT06350604|BEHAVIORAL|Project WHADE: A Partner-Based Physical Activity Program for Women|Combination of behavioral, cognitive, social, and acceptance-based skills training to increase physical activity
41342644|NCT06435962|DEVICE|sonography|measurement of optic nerve in RRMS by sonography and visual evoked potential( VEP) as correlation of axonal affection in RRMS patient
41342645|NCT00626340|DRUG|MDD diagnosis and Estrogen treatment|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
41342646|NCT00626340|DRUG|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
41342647|NCT00626340|DRUG|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
41489122|NCT04105426|DIETARY_SUPPLEMENT|Antioxidants|one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
41018145|NCT05281367|PROCEDURE|Non-nutritive sucking group|36 premature newborns who were in the non-nutritive sucking group were given a silicone pacifier suitable for the week of the baby's mouth from 3 minutes before to 3 minutes after the heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
41157274|NCT00310024|DRUG|bortezomib|Given IV
41157275|NCT00310024|DRUG|vorinostat|Given orally
41342648|NCT00626340|DRUG|No depression and estrogen treatment|Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
41342649|NCT00669591|DRUG|Bavituximab|Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
41342650|NCT02236650|BEHAVIORAL|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
41342651|NCT02236650|OTHER|Treatment as Usual|Treatment as Usual for 4 weeks
41342652|NCT05573568|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen
41342653|NCT00576147|DEVICE|Infrascanner|The main Near-Infrared spectroscopy (NIRS) head measurement
41342654|NCT03327363|DEVICE|Feedback using ICT based monitoring system|In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
41489123|NCT04105426|DIETARY_SUPPLEMENT|Placebo|one placebo tablet three times per day for 3 months.
41489124|NCT04226573|OTHER|Preoperative anxiety levels|"Serums were separated from blood samples taken from all patients in the study, Using the anti-human TNF-α and IL-6 enzyme-linked immunosorbent assay (ELISA) kits in the Elisa device, the TNF-α and IL-6 cytokines will be measured to determine their concentration.~No routine blood will be drawn during the procedures. Preoperative anxiety levels will be evaluated with STAI-Continuity and STAI-Statefulness scale."
41489125|NCT05137470|OTHER|This is an observational study|This is an observational study
40824302|NCT06140381|PROCEDURE|Eccentric training|The eccentric program will last for 16 weeks, with a frequency of 2 sessions per week, totalling 32 sessions. At least 1 day of rest will be required between two training sessions. The participants will be placed in the similar position of the neuromuscular assessments (reference position). The Biodex System 4 dynamometer settings for the exercise sessions were also like the settings used for the assessments. The training program will be divided into two phases: a familiarization phase and a progression phase
40824303|NCT06140381|PROCEDURE|Conventional therapy|3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation
40824304|NCT02705014|DRUG|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
40824305|NCT00000224|DRUG|Buprenorphine|
40824306|NCT02510365|BIOLOGICAL|Functional collagen scaffold|Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
40824307|NCT05903131|BEHAVIORAL|Telemedicine behavioral weight intervention|Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (12 months total). Each telephone session will be 30 minutes long.
40824308|NCT05903131|DRUG|Progestin|Released via the levonorgestrel-releasing IUD.
40824309|NCT05903131|BEHAVIORAL|Enhanced usual care|1-3 page handouts
40824310|NCT05903131|DRUG|Levonorgestrel-releasing IUD.|Standard of care
40824311|NCT04385641|OTHER|Cell infusion for Dose-finding (Group A)|Group A：HLA-I and HLA-II molecular typing were performed at the serological and molecular levels, and the HLA-I and HLA-II molecular antigens of donor and subjects match on 3, 4, 5 or 6 / 6. After the successful matching, the non myeloablative immunosuppressive pretreatment with cyclophosphamide (900 mg / m＾2 / day) and fludarabine (30 mg / m＾2 / day) will be performed 6, 5, 4 and 3 days before the infusion of UCB-NK cells. After the pretreatment, the cell infusion was started on day 0, and the cell infusion could be divided into 50% and 50% for two consecutive days or every other day. To ensure clinical safety, if treatment-related adverse events reach DLT after the first infusion, the cell infusion will stop.
41342655|NCT05394181|OTHER|Notification|Notification of patient and primary care clinician of presence of at least moderate coronary artery calcium on a prior non-gated chest CT
41342656|NCT02565862|DRUG|Daclatasvir|
41342657|NCT02565862|DRUG|Metformin|
41342658|NCT03395041|DIAGNOSTIC_TEST|cardiac imaging tests|cardiac computed tomography, echocardiography, intravascular ultrasound, optical coherence tomography
41342659|NCT04461145|BEHAVIORAL|command|The participant was asked to walk along the walkway while backward counting numbers with increment of seven starting from a randomly given number.
41342660|NCT02752425|DEVICE|Visual feedback|Use of ultrasound echography for tongue articulatory visual feedback
41342661|NCT06231914|DEVICE|StarWalker® PQX|Third-generation ASP-powered technology for ultra performance: Highest pico power \& energy, shortest pico pulse width, wide range of laser wavelengths, exceptional spot size capabilities, largest fluence spectrum for flat-top handpieces
41342662|NCT01013090|DRUG|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
41342663|NCT01013090|DRUG|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
41342664|NCT05535270|DIAGNOSTIC_TEST|Oxford Depression Questionnaire (ODQ)|"The Oxford Depression Questionnaire (ODQ)is a patient-centered questionnaire. The scale contains three sections: i) the patient's experience in the past week; ii) the patient's experience before the illness worsened, and iii) the patient's emotional feelings about receiving antidepressant treatment. The 26-item questionnaire contains four dimensions of emotional blunting: not caring (NC), emotional detachment from others (ED), reduction in positive emotions (RP), and general reduction in emotions (GR). Patients not taking antidepressants were only required to rate the first two sections ."
41342665|NCT04336007|DEVICE|Resistive Diathermy (INDIBA® Activ Ct9)|Intervention is conducted using a 65-mm diameter Resistive (RES) electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity is administered in the following manner: cream was applied to the upper limbs existent area, and the electrical output is marked at 75% by moving the movable electrode and if not tolerated by the patient lowered until 35%, Therapy is conducted for 20 minutes, prior swimming time trials.
41342666|NCT04336007|DEVICE|Resistive Diathermy OFF (INDIBA® Activ Ct9)|Placebo is conducted using a 65-mm diameter RES electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity IS NOT administered, the cream was applied to the upper limbs existent area and moving the movable electrode, intervention is conducted for 20 minutes, prior to swimming time trials.
41342667|NCT04336007|OTHER|Control|This group will warm-up as they usually do in competitions, for later time trial measuring.
41342668|NCT05181241|DRUG|Dimolegin|"Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia"
41342669|NCT05933772|DEVICE|Lens A (comfilcon A toric lens)|One month wear
41342670|NCT05933772|DEVICE|Lens B (lehfilcon A toric lens)|One month wear
41342671|NCT01465451|PROCEDURE|curative resection for colorectal cancer|right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
41342672|NCT01465451|DRUG|intra-operative 5-FU chemotherapy|"5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.~5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A."
41342673|NCT05233423|DEVICE|compressed cold therapy bandage|Compressed cold therapy bandage was applied by wrapping the operated knee of the patients. The patients in the intervention group received 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
41342674|NCT01235338|DRUG|LDX + Venlafaxine XR|"* Day 1-5 LDX 30mg~* Day 6-10 LDX 50mg~* Day 11-15 LDX 70mg~* Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~* Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~* Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~* Day 31-34 Venlafaxine XR 150mg daily~* Day 35-38 Venlafaxine XR 75mg daily."
40824312|NCT04385641|OTHER|Cell infusion for Extended research (Group B)|Group B：Non myeloablative immunosuppressive pretreatment and cell transfusion were the same as group A.
41342675|NCT01235338|DRUG|Venlafaxine XR + LDX|"* Day 1-5 Venlafaxine XR 75mg~* Day 6-10 Venlafaxine XR 150mg~* Day 11-15 Venlafaxine XR 225mg~* Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~* Day 21-25 Venlafaxine XR and LDX 50mg daily~* Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~* Day 31-34 Venlafaxine XR 150mg~* Day 35-38 Venlafaxine XR 75mg."
41342676|NCT05920070|PROCEDURE|therapeutic mammoplasty|therapeutic oncoplastic surgeries in cases of breast cancer
41342677|NCT02876484|DRUG|Colesevelam|
41342678|NCT02876484|DRUG|Chenodeoxycholic Acid|
41342679|NCT02876484|OTHER|Water|
40824313|NCT01119833|DRUG|GMI-1070|Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
40824314|NCT01119833|DRUG|Placebo|Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
40824315|NCT03465462|DIETARY_SUPPLEMENT|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
40824316|NCT03465462|DIETARY_SUPPLEMENT|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
41157276|NCT00310024|OTHER|laboratory biomarker analysis|Correlative studies
41157277|NCT00310024|OTHER|pharmacological study|Correlative studies
41018146|NCT05281367|PROCEDURE|Control group|"The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study.~Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP)."
41018147|NCT03068299|OTHER|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
41342680|NCT02062970|BIOLOGICAL|blood draw|
41342681|NCT06070727|OTHER|Obturator|Evaluation of patient satisfaction and oral healthy related quality of life of Polyetherketoneketone(PEKK) and metal framework for management of maxillectomy cases.
41342682|NCT04552067|DRUG|Lovenox|patients given curative dose of Lovenox
41342683|NCT04552067|DRUG|Enoxaparin|patients given curative dose of Enoxa
41342684|NCT04702204|DRUG|Denosumab 60 MG/ML|"Denosumab, another antiresorptive agent, is a fully human monoclonal IgG2 antibody that binds to the receptor activator of the nuclear factor-kB ligand (RANKL) with high specificity and affinity. Denosumab inhibits bone resorption by affecting the development, activation, and survival of osteoclasts.~Denosumab 60 mg subcutaneously was administered to the patients whose consent forms were obtained, once every 6 months."
41489126|NCT04310813|DIAGNOSTIC_TEST|Multimodal spectroscopic analysis|During time of bladder or prostate resection, freshly excised cold cup biopsies of both bladder cancer or healthy bladder mucosa were taken and sent for inspection through label-free multimodal fiber optic spectroscopy (MFOS) within 30 minutes
41342685|NCT03103776|OTHER|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
41157278|NCT05255276|DRUG|Sitravatinib 50 mg|50 mg Sitravatinib on Day 1 (Group 1A)
41157279|NCT05255276|DRUG|Sitravatinib 100 mg|100 mg Sitravatinib on Day 1 (Group 2A)
41342686|NCT04171063|DEVICE|Thoracic compressor|The intervention is the use of the thoracic compressor for the conservative treatment of pectus carinatum
41342687|NCT03193944|DRUG|D-vitin, soft gelatin capsule (vitamin D3,50000 IU)|Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.
41342688|NCT03193944|DRUG|Placebo vitamin D3|vitamin D as a placebo
41342689|NCT01996436|DRUG|Nicardipine|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
41342690|NCT01996436|DRUG|Verapamil|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
41342691|NCT01996436|DRUG|Nicardipine + Verapamil + Nitroglycerin|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
41342692|NCT03536273|OTHER|Pilates Group Exercises|For 12 weeks, 3 repetitions per week
41342693|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
41342694|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
40824317|NCT03465462|DIETARY_SUPPLEMENT|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
41342695|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 3|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
41342696|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 4|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
41342697|NCT04144179|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
41342698|NCT03685929|PROCEDURE|Punch skin biopsy|Two punch biopsies will be performed in each patient, one at the border of the skin lesion, and one at the adjacent healthy skin. A disposable biopsy punch of 4 mm will be used. A biopsy punch is a small circular blade (like an apple corer) which is rotated into the skin to obtain a cylindrical specimen. Local anaesthesia will be applied and the circular wound will be closed by a single suture. Sutures will be removed after one week.
41489127|NCT06218264|DIETARY_SUPPLEMENT|Ingestion of an amino acid supplement|Oral intake of a supplement containing amino acids
41489128|NCT04997226|DEVICE|tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 1 and 3.
41489129|NCT04997226|DEVICE|Sham tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 2 and 4.
41489130|NCT00354250|DRUG|ispinesib|Given IV
41342699|NCT05934890|BIOLOGICAL|Walvax PCV13-TT|"PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually.~The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added."
41342700|NCT05934890|BIOLOGICAL|Pfizer PCV13|PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.
41342701|NCT06001892|BEHAVIORAL|Tennessee Youth Prepared for Success|both 5 day classroom interventions.
41342702|NCT03239262|PROCEDURE|Concomitant Mapping and Radiofrequency Ablation|"Mapping of GP around the orifice of pulmonary veins was performed, together with their radiofrequency ablation. In the area of right-side pulmonary veins, the procedure was performed prior to initiation of extracorporeal circulation. In case of the left-side PVs; the procedure was performed after initiation of extracorporeal circulation. Part of this procedure was also a decision and ablation of the ligament of Marshall.~GP mapping was performed using high-frequency stimulation (1000 beats min-¹, potential 18V, pulse width 1.5ms). The indication for GP ablation was a doubling in the R-R interval in the sinus rhythm, or ventricular rate slowing of more that 50% associated with a decrease of blood pressure\>20mmHg in patients with AF. In case of a positive response, radiofrequency ablation of the ganglia was performed following switching of the pen at the console. This procedure was repeated until the activity of the ganglia has disappeared."
41342703|NCT03239262|PROCEDURE|No intervention|No intervention was performed in patients without ganglionated plexi.
41342704|NCT04540783|DEVICE|Transcranial direct current stimulation (tDCS)|10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.
41342705|NCT00655304|DEVICE|Prometheus (R) liver support dialysis|6-8 hours of dialysis
41342706|NCT00655304|DEVICE|CVVHDF (Continuously Veno-Venous Hemodiafiltration)|6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
41342707|NCT05778162|DIAGNOSTIC_TEST|Synovasure® RISC™ Panel|The Synovasure® RISC™ Panel is a laboratory-developed test (LDT) panel (CD Laboratories, Clinical Laboratory Improvement Amendments \[CLIA\] Registration No.: 21D0216863) intended to provide indications for diagnosing different types of arthritis that may correspond to higher risk levels for postoperative complications in patients experiencing knee pain and/or inflammation prior to primary knee arthroplasty.
41342708|NCT02090673|DRUG|Exenatide|
41342709|NCT06204289|BEHAVIORAL|Nurse-led Supportive Care Programme|Nurse-led supportive care programme was applied to family caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 40 minutes to interview with family caregivers at the clinic.
41342710|NCT02257060|PROCEDURE|Endocardial Ablation|
41342711|NCT00398138|BIOLOGICAL|WT-1 analog peptide vaccine|
41342712|NCT00398138|BIOLOGICAL|incomplete Freund's adjuvant|
41342713|NCT00398138|BIOLOGICAL|sargramostim|
41342714|NCT00398138|GENETIC|polymerase chain reaction|
41342715|NCT00398138|OTHER|flow cytometry|
41342716|NCT00398138|OTHER|immunoenzyme technique|
41489131|NCT02926820|BEHAVIORAL|Cogmed QM|The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
41489132|NCT03920176|DIAGNOSTIC_TEST|Computed tomography coronary angiography|CTCA \>64 detector row scanner
41489133|NCT03920176|OTHER|ASSIGN Score|ASSIGN Cardiovascular Risk Score
40824318|NCT04152551|DRUG|Risedronate Oral Tablet|Oral bisphosphonate
40824319|NCT04814368|BIOLOGICAL|canakinumab|intra-articular injection (into the knee)
41018148|NCT03068299|OTHER|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
41157280|NCT05255276|DRUG|Itraconazole|Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)
40824320|NCT04814368|BIOLOGICAL|LNA043|intra-articular injection (into the knee)
40824321|NCT04814368|OTHER|Placebo to canakinumab|intra-articular injection (into the knee)
41489134|NCT05863143|BEHAVIORAL|Nutritional and Exercise|Provide Nutritional Education Program and Falls Module Exercise (FME) to the intervention group
41489135|NCT04008966|DRUG|combined oral contaraceptive pills|1 tablet daily between days 5 and 25 of the cycle before stimulation
41489136|NCT04008966|DRUG|recombinant FSH|300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
41489137|NCT04008966|DRUG|Urinaru gonadotropin|150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
41489138|NCT04008966|DRUG|GnRH antagonist|0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
41489139|NCT04008966|DRUG|Human chorionic gonadotropin|10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
40824322|NCT02312219|DRUG|Folic Acid|1 mg folic acid once daily
40824323|NCT02312219|DRUG|Placebo|placebo once weekly
41489140|NCT04008966|DRUG|GnRH agonist|0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
41489141|NCT04008966|PROCEDURE|Ovum pick up|34 hours after triggering under the guidance of transvaginal ultrasound
41489142|NCT04008966|PROCEDURE|Embryo transfer|Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
41489143|NCT04008966|DRUG|natural Progesterone|400 mg twice daily per vagina
41489144|NCT01727986|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
41489145|NCT00276822|OTHER|communication intervention|Patient Education Programs to include surveys, questionnaires, interviews, and videos.
41489146|NCT03517696|PROCEDURE|Membrane sweeping|Participants assigned to membrane sweeping will have an additional exam during their initial evaluation in which the membranes will be separated from the cervix and lower part of the uterus with a finger inserted into the cervical os. This would be done with at least one rotation counterclockwise and one rotation clockwise.
41489147|NCT02923674|BEHAVIORAL|Weight loss|All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.
41489148|NCT02923674|BEHAVIORAL|Exercise|Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.
41489149|NCT02923674|BEHAVIORAL|Sitless|Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level \<3).
41489150|NCT03297671|DRUG|RhIg prophylaxis|Two RhIg prophylaxis injections for Rh negative women
41489151|NCT03297671|DEVICE|ELDONCARD|ELDONCARD point-of-care test.
40824324|NCT02312219|DRUG|Low Dose Methotrexate|An anti-inflammatory drug
40824325|NCT06606041|PROCEDURE|Dry Needling|This. minimally invasive technique is based on the insertion of a sterile, low-caliber, monofilament needle, without the injection or extraction of any additional substances, into hyperirritable muscle nodules. There are two categories within this technique, based on the depth at which the needle is inserted: superficial needling (or the Baldry technique), in which the needle is inserted up to the subcutaneous cellular tissue overlying the myofascial trigger point (up to 10 mm); and deep needling, where the needle is inserted into the muscle with the intention of reaching the myofascial trigger point. Reaching the trigger point was the investigators goal. Regardless of the technique selected, the aim is to generate controlled micro spasms in the affected muscle area, alternating with periods of muscle relaxation.
41018149|NCT06574217|BEHAVIORAL|Stepping Stones (StSt)|StSt is an individual-level intervention designed to help youth make healthy decisions. StSt is delivered in-person by an adult guide during four \~30-50 minute sessions over a period of up to 8 weeks. The adult guide leads the youth through health-focused discussions related to identifying personal values, making a social network map, and then creating and refining individualized plans.
41018150|NCT06574217|BEHAVIORAL|Like|Like is an hour-long film that discusses the impact of social media on the brain. Study staff will organize for each individual participant to watch the film in-person. The film does not include information related to the outcomes of interest for the study.
41018151|NCT00820339|PROCEDURE|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
41018152|NCT00820339|PROCEDURE|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
41018153|NCT06023095|DRUG|LY3502970|Administered orally.
41018154|NCT06023095|DRUG|Placebo|Administered orally.
41018155|NCT02522897|DRUG|Ranibizumab|
41018156|NCT02522897|DEVICE|Laser|
41018157|NCT00585754|DRUG|Guanfacine|1.5mg BID
41018158|NCT00585754|DRUG|Placebo|placebo
41018159|NCT04516161|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC
41489152|NCT03297671|DIAGNOSTIC_TEST|ELDONCARD Test|LHVs will perform ELDONCARD test.
41018160|NCT03799458|DEVICE|Active High-definition transcranial direct current stimulation (HD-tDCS)|Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
41489153|NCT05968443|DEVICE|ophthalmic surgery|any ophthalmic surgery using Dafilon® suture
41489154|NCT06166238|PROCEDURE|Millard and Tension Randal Technique|Millard recognized that the majority of Cupid's bow, one philtral column, and the philtral dimple were intact on the medial aspect of a unilateral cleft lip but required rotation to shift the tissue into a normal anatomic position (Millard, 1964b) The Tennison-Randall technique involves a back-cut that extends from the cleft Cupid's bow peak toward the center of the philtrum that is filled by a laterally based triangular flap whose width is the measured deficiency in lip height.
41489155|NCT02243267|OTHER|sample collection|
41489156|NCT02927977|OTHER|control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
40824326|NCT06606041|PROCEDURE|Ischemic Compression|Ischemic compression is a conservative, manual technique used on myofascial trigger points, in which pressure should be exerted between 30 and 90 seconds on these same areas. It is suggested that it leads to the normalization of the biomechanical properties of muscle fibers, restoring the muscle\&#39;s functional condition and probably reducing the risk of injury. Thus, the therapeutic effects include the stimulation of mechanoreceptors, with pain attenuation mainly due to the depletion of specific neurotransmitters and temporary obstruction of local blood flow (local ischemia), followed by a rapid influx of oxygenated blood to the area under pressure relief,(37) which will cause an increase in muscle metabolism.
41489157|NCT02927977|OTHER|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks.
41489158|NCT03332238|DEVICE|Autologous Stomal Vascular Fraction Material|Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™
41489159|NCT03332238|DEVICE|Ringer's solution|Ringer's solution
41489160|NCT06014918|DEVICE|A new smart device application (Smart APS)|The application sends alarms to patients to enter their pain intensity and opioid-related side effects at the times set by the researcher. Additional entries for severe pain or opioid side effects are also available at any other time. Researchers can monitor the results in real-time via an integrated web program. If a red flag sign is observed during regular office hours, an anesthesiologist participating in the research will visit the patient for assessment and intervention. In addition, patients can watch pre-made perioperative pain-related educational videos through the smart APS.
41489161|NCT00005614|DRUG|Gemcitabine hydrochloride|Gemcitabine via IV
40824327|NCT06606041|PROCEDURE|Cross Tapes|Cross tapes, as the name implies, based on an equidistant intersection of three or four polyester tapes with a non-elastic adhesive acrylic coating, with the 3 lines oriented in a latero-medial direction. It is recommended that it be applied to the muscle area where the myofascial trigger point has been detected, at a 45º angle to the muscle fibers. Its application may have several purposes, such as muscle support, improving the stability of the fibers; pain relief, especially in areas where muscle tension and/or inflammation are present; aiding lymphatic drainage; promoting blood circulation. Before it is applied, the skin should be clean (disinfecting the area with alcohol) and dry, without any lotion or other ointments and the maximum period of use should not exceed 24 hours due to the risk of changes in position, either due to sweating or direct intervention by the patient himself.
41489162|NCT01038440|DIETARY_SUPPLEMENT|Safflower Oil|One softgel consumed daily with food
41489163|NCT01038440|DIETARY_SUPPLEMENT|EPA|Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
40824328|NCT02024269|BIOLOGICAL|Adipose Derived Stem Cells|
40824329|NCT02545114|DRUG|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
41018161|NCT03799458|DEVICE|Sham High-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
41018162|NCT04188535|DIAGNOSTIC_TEST|MRI IMAGING|Imaging with MRI will be performed as per disease site standards.
41018163|NCT05229224|OTHER|Osteo fluidic Sensitive méthod|Manual therapy, without manipulative treatment, based on rebalancing of the body with manual pressures on specific body areas.
41018164|NCT05229224|OTHER|Placebo method|Soft Manual pressures at specific points that are defined as non-effective and non-deleterious for patients.
41489164|NCT01038440|DIETARY_SUPPLEMENT|SDA|Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
41489165|NCT06067321|OTHER|abdominal ultrasound, insertion of naso-gastric tube|measurement antral cross sectional area, volume and pH of residual stomach contents
41018165|NCT04901117|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
41018166|NCT04901117|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
41489166|NCT00560430|DRUG|telmisartan|80 mg per day, orally, weeks 1-14
41489167|NCT00560430|DRUG|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
41489168|NCT00560430|DRUG|placebo|placebo; orally weeks 1-14
41489169|NCT05992818|DIAGNOSTIC_TEST|comparing DRS-R-98 (The Delirium Rating Scale--Revised-98) and 3D-CAM (3-minute diagnostic assessment for CAM-Confusion Assessment Method-defined delirium) tests to assess postoperative delirium|determine the test that is more effective and practical in the assessment of POD
41489170|NCT00006472|DRUG|carboplatin|Carboplatin AUC 6 days 1 and 22
41489171|NCT00006472|DRUG|fluorouracil|5FU 225mg/m2 continuous infusion on days 1-42 during radiation
41489172|NCT00006472|DRUG|paclitaxel|taxol
41489173|NCT00006472|PROCEDURE|conventional surgery|
41489174|NCT00006472|RADIATION|radiation therapy|The initial fields should be treated AP:PA when possible to a dose of 4500 cGy in 180 cGy fractions
41489175|NCT04527653|DEVICE|Tixel|Non-invasive thermo-mechanical treatment
41489176|NCT02833766|DRUG|anti-EGFR-IL-dox|First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days
41342717|NCT05303025|OTHER|Survey|Survey to acquire baseline demographic information as well as information regarding professional experience, working environment and attitudes towards artificial intelligence.
41342718|NCT05303025|OTHER|Semi-structured group discussion|Semi-structured group discussion.
41342719|NCT04868162|DRUG|MRG003|Administered intravenously
41342720|NCT03562520|BEHAVIORAL|Behavior change counseling|"Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers."
41342721|NCT03562624|DRUG|BAY98-7443|"Active ingredient content (in mg IND/LNG):~low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5"
41342722|NCT03562624|DRUG|Levonogestrel (Skyla, BAY86-5028)|Comparative LNG dose
41342723|NCT00189436|DRUG|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
41342724|NCT00189436|DRUG|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
41342725|NCT03304093|DRUG|Nivolumab Injection|Nivolumab 3mg/kg every 2 weeks
41342726|NCT02590640|DEVICE|Repetitive transcranial magnetic stimulation, MagStim Rapid2|"This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain."
41342727|NCT02590640|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
41342728|NCT04748822|OTHER|questionnaires|The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
41342729|NCT00224692|DRUG|Low dose ketamine|
41342730|NCT04485936|DEVICE|Epitomee Device|medical Device designed to enhance the feeling of early satiation and prolonged satiety
41342731|NCT01964027|DRUG|second line chemoregime for advanced gastric cancer|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment \* 6 cycles as the second line chemoregime for advanced gastric cancer
41342732|NCT05411224|OTHER|Custom made orthosis|In patients with Morton Neuroma, stride length, stance phase percentage, swing phase percentage, cadence and speed parameters, and fore, mid and hind foot pressure distribution will be recorded with the Zebris FDM-THM-S treadmill system in the analysis of barefoot walking after the physical examination evaluation of the cases.While the treadmil is in a static state, pressure distribution measurement will be taken by baropedography, and personalized insoles will be produced according to the baropedographic pressure map. Patients will be delivered to the patient for indoor and outdoor use for 4 weeks. After a 4-week usage period, measurements related to pressure and walking parameters will be repeated.
41342733|NCT03127852|DEVICE|Medly|
41342734|NCT01046968|DIETARY_SUPPLEMENT|Lepticore|300 mg twice daily
41342735|NCT01816373|DEVICE|Vacuum Bell|Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
41342736|NCT06482255|OTHER|manual therapy and therapeutic exercise|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise"
41342737|NCT06482255|OTHER|manual therapy and therapeutic exercise and virtual reality|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise~* virtual reality"
41342738|NCT04104204|DRUG|Intrathecal morphine|0.5% Iso/Hyperbaric bupivacaine 2-3 ml add morphine 0.1 mg for spinal anesthesia
41342739|NCT04104204|DRUG|Ultrasound guided supra-inguinal fascia iliaca block|Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia
41342740|NCT04226144|DEVICE|Breath Stacking Group|Lung recruitment technique using manual bag resuscitation with oronasal mask interface
41342741|NCT04226144|DEVICE|Breath stacking and EMT|Lung recruitment technique with one way valve with counter resistance during all expiratory phase
41489177|NCT00631449|DRUG|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.
41489178|NCT00631449|DRUG|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
41018167|NCT04901117|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
41018168|NCT04901117|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
41018169|NCT04901117|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
41489179|NCT05034341|OTHER|Multimodal Prehabilitation|"In addition to Standard Clinical Care~Behavioral - An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to home exercise program. They will also participate in a single session of Cognitive-Behavioral Therapy and will receive an educational pamphlet about Pain and Neuroscience Education.~Dietary Supplement - Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar free."
41489180|NCT05034341|OTHER|Standard Pre-Surgical Clinical Care|"* Education related to preoperative activity and home-based exercise program.~* Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment."
40824330|NCT04991727|BEHAVIORAL|recruitment maneuvers|"Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery"
41489181|NCT04068636|PROCEDURE|Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.|Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
41489182|NCT04561375|DRUG|Sufentanil|30 µg tablet of sublingual sufentanil
41489183|NCT04561375|DRUG|Fentanyl|50 µg fentanyl
41157281|NCT05255276|DRUG|Rifampin|Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)
41342742|NCT03175952|DIAGNOSTIC_TEST|virtual histology intravascular ultrasound|Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.
41489184|NCT04532801|DRUG|Kisspeptin-10|kisspeptin-10 IV infusion
41489185|NCT04532801|OTHER|mixed meal tolerance test|mixed meal tolerance test
41489186|NCT03052322|DRUG|MSB11022|Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
41489187|NCT03052322|DRUG|EU-Humira|Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
41489188|NCT03274674|OTHER|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
41489189|NCT00153608|BIOLOGICAL|WT1 126-134 peptide|
41489190|NCT04774887|BIOLOGICAL|HPV vaccine, Merck|Vaccination against HPV will be offered to 900 children/grandchildren aged 9 through 18 of women attending the Community Meetings.
41342743|NCT00135525|DRUG|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
41342744|NCT00135525|DRUG|Placebo|Placebo
41489191|NCT05154812|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
41489192|NCT05154812|DRUG|Routine medical care|Routine medical care
41489193|NCT04614246|DRUG|BAY1817080|Tablet, oral administration
41489194|NCT04614246|DRUG|Elagolix|Tablet, oral administration
41489195|NCT04614246|DRUG|Placebo|Tablet, oral administration
41489196|NCT03757975|PROCEDURE|urethral length measure|measure of urethral length, distribution of questionnaires before and after operation
41489197|NCT01321008|RADIATION|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
40824331|NCT03777917|DEVICE|Belotero Balance®|Belotero® Balance for infraorbital hollows. Mode of application: subdermal injection.
40824332|NCT03414255|BIOLOGICAL|Micronized DHACM|1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
41342745|NCT00721357|BEHAVIORAL|Treadmill walking|Subjects will perform treadmill walking at a self-selected velocity
41489198|NCT01321008|DRUG|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
41489199|NCT01321008|DRUG|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
41489200|NCT01321008|DRUG|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
41489201|NCT01321008|DRUG|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
41018170|NCT04901117|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
41018171|NCT04901117|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
41018172|NCT03588169|DIETARY_SUPPLEMENT|semi-structured interviews|"About 30 minutes and touching on the following subjects:~* perception of hospital meals~* patient representation of ONS~* taking ONS and feelings about it"
41018173|NCT03992105|OTHER|prospective cohort|"topics included openly in the Respite Site, made up of the first 50 subjects followed prospectively"
41018174|NCT04844229|PROCEDURE|Bilateral transnasal sphenopalatine ganglion block.|SPG block will be performed with the patient in supine position using cotton-tipped plastic hollow applicator inserted in the nose with the swab soaked in 1.5 ml 10%lignocaine. The applicator will be inserted parallel to the floor of the nose until resistance encountered. The swab will be rested in the pterygopalatine fossa superior to the middle turbinate and removed after 10 min. This procedure will be repeated in the other nostril too.
41018175|NCT04844229|PROCEDURE|Bilateral ultrasound guided greater occipital nerve block.|GONB will be performed with the patients lying in prone position using high frequency (6-13 MHz) probe of Siemens Acuson X300 machine placed in transverse orientation lateral to external occipital protuberance parallel to the superior nuchal line to detect occipital artery where the nerve is located medial to it 1.5inch; then 20 gauge needle will be inserted out of plane to avoid vascular injury. 4 ml of treatment solution containing 2.5 mg/ml bupivacaine and 1 mg/ml dexamethasone (prepared by adding 2 ml bupivacaine 0.5% + 1 ml dexamethasone + 1 ml saline) will be injected on each side.
41018176|NCT05336500|OTHER|Pilates method exercises|Participants will be randomised into two groups that will be treated with Pilates exercises for 12 weeks (twice a week for 60 minutes). The control group will receive guidance on the specific activation of the center of strength (the powerhouse), while the experimental group will receive guidance to perform the exercises in a relaxed and smooth way.
41018177|NCT05105503|DEVICE|Eko CORE Digital Stethoscope|The digital stethoscope will be used to take 9 recordings around each subject's maturing AVF once per week until study participation is over
41018178|NCT03237923|DEVICE|EasySense device|Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.
41018179|NCT06562036|DRUG|Sildenafil|Patients were given oral sildenafil as 2 mg per kg per day, 6-hourly with an increment of 0.5 mg per kg per dose and a target maintenance dose of 2 mg per kg per dose every 6 hour by nasogastric tube.
41018180|NCT06562036|DRUG|Milrinone|In this group, Milrinone was initiated at 0.5 ug per kg per minute using intravenous infusion through a syringe pump, and sildenafil was given in the same protocol mentioned for the Sildenafil Group.
41018181|NCT05391217|OTHER|Remote assessment of patient reported outcomes and daily activity|Electronic patient-reported outcomes (NIH PROMIS) will be collected and combined with remotely monitored physical activity, heart rate, and sleep, as measured with a Fitbit (Sense).
41018182|NCT02541240|OTHER|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
41018183|NCT01437514|RADIATION|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
41018184|NCT02783404|DRUG|Amoxicillin|Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
41018185|NCT02783404|DRUG|Amoxicillin-Potassium Clavulanate|"Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
41018186|NCT03946761|DEVICE|Cancer goggle system|-The cancer goggle system is being used as a non-significant risk device
41018187|NCT01327781|DRUG|Endoxifen Hydrochloride|Given PO
41018188|NCT01327781|OTHER|Laboratory Biomarker Analysis|Correlative studies
41018189|NCT01327781|OTHER|Pharmacological Study|Correlative studies
40824333|NCT03414255|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
41018190|NCT01327781|OTHER|Questionnaire Administration|Ancillary studies
41018191|NCT04391010|OTHER|Surgical masks|Surgical masks will be applied in health care providers
41018192|NCT04391010|OTHER|Filtering respirators|Filtering respirators will be applied in health care providers
41018193|NCT03323905|DEVICE|Symphony MRI guided High Intensity Focused Ultrasound (HIFU)|The use of the MRI-HIFU for the ablation of leiomyomas
41018194|NCT06379841|PROCEDURE|Green Draping Procedure|The green draping will include only an under-buttock. After normal hand hygiene and scrub, the green draping procedure will have the surgeons don only a single pair of sterile gloves.
41018195|NCT06379841|PROCEDURE|Full Draping Procedure|The full draping will include under-buttocks, two-leg drapes, blue towels, and a top drape. After normal hand hygiene and scrub, the draping procedure will have the surgeon don a surgical gown and two sets of sterile gloves for the surgeon.
41157282|NCT05424094|BEHAVIORAL|multi-professional group programme 'kinderleicht'|12-16 children/adolescents who participate in the multi-professional group programme 'kinderleicht' receive coaching in the areas of behaviour, exercise, nutrition and medicine from qualified professionals on fridays during 11 months.
41157283|NCT01024036|DRUG|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
41157284|NCT01024036|DRUG|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
40824334|NCT01010568|DRUG|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
40824335|NCT00074529|DRUG|MK0677|
41018196|NCT06304337|DEVICE|New oropharyngeal airway group|Oropharyngeal airwayIt is composed of nasal plug, bite mouth, oropharyngeal passage, oxygen supply tube, rope and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.For patients undergoing endoscopic surgery/examination to prevent airway obstruction caused by backtongue fall, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time, JK model can monitor oropharyngeal end-expiratory carbon dioxide collection.
41018197|NCT05910762|BEHAVIORAL|Associative inference|Participants will engage in an associative inference paradigm. Memory will be assessed behaviorally and neural representations will be assessed using functional magnetic resonance imaging.
41018198|NCT05910762|BEHAVIORAL|Category learning|Participants will engage in a category learning paradigm. Memory will be assessed behaviorally (Arms 2 and 3), and neural representations will be assessed using functional magnetic resonance imaging (Arm 2).
41018199|NCT05910762|BEHAVIORAL|Sleep|Participants will sleep after engaging in a category learning paradigm while electroencephalography data are collected, and memory will be assessed behaviorally after sleep.
41018200|NCT01350206|PROCEDURE|hepatic resection|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
41157285|NCT01024036|DRUG|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
41342746|NCT00721357|OTHER|Magnetic resonance spectroscopy|Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
41489202|NCT02771795|DRUG|Herceptin (trastuzumab)|Intravenous administration
41489203|NCT02771795|DRUG|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
41018201|NCT01350206|PROCEDURE|TACE|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
41342747|NCT02802956|OTHER|Daily Life Promotion Program|Daily Life Promotion Program
41342748|NCT02802956|OTHER|general rehabilitation treatment|general rehabilitation treatment
41342749|NCT01429155|GENETIC|Interleukin 28B genotype|Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
41342750|NCT01245231|GENETIC|protein expression analysis|
41342751|NCT01245231|GENETIC|western blotting|
41342752|NCT01245231|OTHER|flow cytometry|
41342753|NCT01245231|OTHER|laboratory biomarker analysis|
41342754|NCT01245231|OTHER|medical chart review|
41342755|NCT02966236|DRUG|Tranexamic Acid|
41342756|NCT02966236|DRUG|Placebos|
41342757|NCT02098928|BEHAVIORAL|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
41342758|NCT02098928|DEVICE|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
41018202|NCT00563797|DRUG|Mecamylamine|mecamylamine 10mg/day for 12 weeks
41342759|NCT03850171|OTHER|Exercise Training|Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
41342760|NCT04898868|PROCEDURE|cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recored.
41342761|NCT04898868|PROCEDURE|Umbilical cord miking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
41342762|NCT04110444|DRUG|Sildenafil|oral sildenafil t.d.s for high-risk pregnancies
41342763|NCT00698776|DRUG|Lenalidomide|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
41342764|NCT00698776|BIOLOGICAL|Monocyte derived DCs loaded with KRN7000|10 million DCs injected intravenously
41342765|NCT01168375|DRUG|conventional therapy plus umbilical cord serum eye drop|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
41342766|NCT01168375|DRUG|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
41018203|NCT00563797|DRUG|Placebo|Placebo pill
41342767|NCT03068052|BEHAVIORAL|No incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment.
41342768|NCT03068052|BEHAVIORAL|Incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment, for which they will received a loss-framed incentive. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment and will receive an additional unconditional pro-social incentive.
41342769|NCT01951911|DRUG|Ketamine|Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.
41342770|NCT01951911|DRUG|Placebo|
41018204|NCT03576001|DRUG|Testosterone Undecanoate|administered through injections by study staff
41342771|NCT03252262|OTHER|Vitalize 360|A comprehensive geriatric assessment system and wellness coaching program.
41342772|NCT00962481|DRUG|Bimosiamose|
41342773|NCT00962481|DRUG|Placebo|
41018205|NCT03576001|BEHAVIORAL|hybrid exercise|hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based
41342774|NCT01641224|DRUG|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
41342775|NCT01641224|DEVICE|Atractylodes|Atractylodes (\~10-15g)
41342776|NCT01641224|DEVICE|Paeonia Lactiflora|Paeonia Lactiflora (\~15-30g)
41342777|NCT01641224|DEVICE|Tangerine Peel|Tangerine Peel (\~10g)
41342778|NCT01641224|DRUG|Ledebouriella Root|Ledebouriella Root (\~10g)
41342779|NCT01641224|DRUG|Radix codonopsitis|Radix codonopsitis (\~10-15g)
41342780|NCT01641224|DRUG|Radix curcumae|Radix curcumae (\~10g)
41342781|NCT01641224|DRUG|Fingered citron|Fingered citron (\~10g)
41342782|NCT01641224|DRUG|Tuckahoe|Tuckahoe (15g)
41342783|NCT01641224|DRUG|Placebo|Placebo is blindly given to patients.
41018206|NCT00906646|DIETARY_SUPPLEMENT|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
41018207|NCT00906646|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
41342784|NCT02852291|BEHAVIORAL|Parents Make the Difference|10 parent training sessions delivered to groups of caregivers
41342785|NCT02852291|BEHAVIORAL|Parents Make the Difference Plus|10 parent training sessions delivered to groups of caregivers, with 3 home visits
41018208|NCT02165722|BEHAVIORAL|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit \[chronic and acute\] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
41342786|NCT00987636|DRUG|Zoledronic acid|"intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients \< 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients \>= 18 years will receive a bodyweight-dependent dose:~Patients \>40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h"
41342787|NCT00987636|DRUG|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: \<9 kg= 1mg/kg BW 9 - \<16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW \>23 - 34 kg= 0.95 mg/kg BW \>34 kg = 0.8 mg/kg BW
41342788|NCT00987636|DRUG|Treosulfan|12 g/m² d-5 to d-3
41342789|NCT02866318|DEVICE|Echocardiography|
41342790|NCT02071329|DRUG|Vaccine FP-01.1|
41342791|NCT02071329|DRUG|Placebo|
41342792|NCT02071329|OTHER|Virus Challenge|
41342793|NCT05219006|DIETARY_SUPPLEMENT|ketogenic dieting|Atkins modified diet: 1.2-1.5 g/kg/day of protein with a ratio 1:1 (fat: carbohydrate + protein)
41018209|NCT03358576|DRUG|Ertapenem|Antibiotic for complicated intra-abdominal infection
41018210|NCT03358576|DRUG|Sulopenem-Etzadroxil/Probenecid|Antibiotic for complicated intra-abdominal infection
41018211|NCT03358576|DRUG|Ciprofloxacin|Antibiotic for complicated intra-abdominal infection
41018212|NCT03358576|DRUG|Metronidazole|Antibiotic for complicated intra-abdominal infection
41018213|NCT03358576|DRUG|Amoxicillin-Clavulanate|Antibiotic for complicated intra-abdominal infection
41018214|NCT03358576|DRUG|Sulopenem|Antibiotic for complicated intra-abdominal infection
41018215|NCT05855200|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
41018216|NCT05855200|DRUG|CAPEOX|CAPEOX will be administered.
41018217|NCT05855200|DRUG|FOLFOX|FOLFOX will be administered.
41018218|NCT01131481|DEVICE|Intraocular lens|
41342794|NCT05219006|DIETARY_SUPPLEMENT|healthy dieting|Normocaloric diet established by a nutritionist. 1.2-1.5 g/kg/day of protein with a maximum contribution of 50 % carbohydrates of the total calorie intake eliminating industrialized food.
41342795|NCT03275519|OTHER|Randomization to not receive prophylactic antibiotics after surgery.|No antibiotics were ordered after surgery.
41342796|NCT03275519|OTHER|Randomization to receive prophylactic antibiotics after surgery|In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
41489204|NCT01513564|DRUG|Postoperative epidural morphine|The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
41018219|NCT06018740|DIETARY_SUPPLEMENT|Daily Balance Gummy|Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.
41342797|NCT00004056|BIOLOGICAL|filgrastim|
41342798|NCT00004056|DRUG|asparaginase|
41342799|NCT00004056|DRUG|cytarabine|
41342800|NCT00004056|DRUG|daunorubicin hydrochloride|
41342801|NCT00004056|DRUG|melphalan|
41342802|NCT00004056|DRUG|thioguanine|
41342803|NCT00004056|PROCEDURE|peripheral blood stem cell transplantation|
41342804|NCT03677544|OTHER|laparoscopic approach with an extended pelvic lymph|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
41342805|NCT04820036|DIAGNOSTIC_TEST|Insulin Resistance|Insulin resistance: Fasting glucose and insulin will also be measured to calculate Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), as a surrogate of IR
41342806|NCT04820036|BEHAVIORAL|Quality of Life Assessment|Quality of life will be assessed using the Chronic Liver Disease Questionnaire.
41342807|NCT04820036|DIAGNOSTIC_TEST|Liver Function Test|EUS-guided liver biopsy and portal pressure gradient measurement
41342808|NCT04820036|DIAGNOSTIC_TEST|Radiologic features of NASH|Controlled attenuation parameter (CAP) and liver stiffness scores assessed by transient elastography (TE)
41342809|NCT04820036|DIAGNOSTIC_TEST|Serologic features of NASH|Laboratory value assessment of alanine aminotransferase (ALT), liver chemistries, platelet counts, albumin and calculated NAFLD Fibrosis Score (NFS).
41342810|NCT00149890|DRUG|Basiliximab|Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.
41342811|NCT00149890|DRUG|Cyclosporine/cyclosporine microemulsion|Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
41342812|NCT00149890|DRUG|Steroid|Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
41342813|NCT02136316|DRUG|ASP7962|Oral
41342814|NCT02136316|DRUG|Placebo|Oral
41342815|NCT04859504|DEVICE|transcranial alternating current stimulation (NE Starstim)|dual-channel theta-tACS over right DLPFC and cerebellum simultaneously
41342816|NCT04430868|BEHAVIORAL|lifestyle redesign program|In this group, it starts with health education, the participants then change their opinions and experience health activities, and it ends with discussion and sharing their experience.
41342817|NCT05769907|BEHAVIORAL|Intervention Group|The study will consist of one session per week for 8 weeks, during which the participant will receive MI for 30-45 minutes. All participants will receive the MI intervention according to their readiness to lose weight measured by means the P-weight and S-weight at the beginning of each session.
41342818|NCT00593775|PROCEDURE|assisted hatching|assisted hatching with laser
41342819|NCT04692818|DIAGNOSTIC_TEST|GE Logiq E10 clinical ultrasound scanner|2D B-mode, Doppler, and shear wave elastography images of the lesion
41342820|NCT04692818|DIAGNOSTIC_TEST|Verasonics research scanner|3D B-mode imaging, microvessel imaging, and shear wave elastography
41342821|NCT02469584|PROCEDURE|small stitch anterior colporrhaphy|A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
41342822|NCT05915117|DIETARY_SUPPLEMENT|Polyphenols of pomegranate fruit peel extract (PoPex)|PoPex in form of capsule will be orally administered in total daily dose of 500/mg in subjects with metabolic syndrome and obesity over 8 weeks.
41342823|NCT05915117|DRUG|Placebo|Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
41342824|NCT02327728|PROCEDURE|Botulinum toxin A injection (5 sites: 12.5U)|
40824336|NCT04802239|OTHER|Medical hypnosis group|"Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~* State of calm at rest of 3 minutes.~* Hypnotic induction by catalepsy of the eyes guided by breathing.~* The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques."
40824337|NCT04802239|OTHER|calm wake group|healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
41342825|NCT02327728|PROCEDURE|Botulinum toxin A injection (4 sites: 10U)|
41342826|NCT02327728|DRUG|Botulinum toxin A 12.5U|
41342827|NCT02327728|DRUG|Botulinum toxin A 10U|
41342828|NCT02466204|DRUG|corifollitropin alfa|Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
41342829|NCT02466204|DRUG|Follitropin Beta|Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
41342830|NCT01701856|DRUG|Interferon beta-1b|250 mcg, s.c., each other day for 12 months
41342831|NCT02499575|DRUG|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
41342832|NCT02499575|DRUG|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
41342833|NCT01381224|OTHER|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
41342834|NCT02673528|PROCEDURE|Laparoscopic appendectomy|Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
41342835|NCT05477251|PROCEDURE|microwave ablation|MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the guide needle lumen. Once the target was reached, ablation was performed at a power of 40 watts. Once the lesion was covered by the ablation zone, the ablation completed.
41342836|NCT05477251|PROCEDURE|lobectomy|lobectomy for GGOs located in hilar regions
41342837|NCT00022893|DRUG|Iodine-131 Anti-B1 Antibody|
41342838|NCT04016090|DIETARY_SUPPLEMENT|Folic Acid|Folic acid (5 mg)
41342839|NCT04016090|OTHER|Placebo|Placebo capsule
41342840|NCT02769013|OTHER|Pre-treatment follow up|No active intervention; medical support provided if needed
41342841|NCT02769013|OTHER|S. haematobium treatment|Praziquantel-treatment for S. haematobium positive volunteers
41342842|NCT02769013|OTHER|Post treatment follow up|No active intervention; medical support provided if needed.
41342843|NCT02769013|OTHER|Olfactometer experiment|No active intervention; medical support provided if needed.
40824338|NCT06300918|OTHER|Time|Time point of injecting anti-VEGF drugs
41342844|NCT06098586|BEHAVIORAL|Self-managed exercise therapy program|Exercise program focusing on functional re-learning and strengthening of the musculoskeletal system with the aim to create a stable wrist that can be used in a pain-free manner in activities of daily living.
41342845|NCT06098586|PROCEDURE|Partial wrist denervation|AIN and PIN neurectomy through a dorsal approach as described by Berger (Berger, 1998).
41342846|NCT04878276|DEVICE|Dimet 5|The application is carried out according to the enclosed instructions for use.
41342847|NCT02364661|BEHAVIORAL|Over night starvation (fasting)|HBV viral load will be analyzed after over-night starvation versus following a morning meal
41342848|NCT04974957|DRUG|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion"
41342849|NCT06259604|OTHER|PIOMI|Babies in this group will be administered PIOMI once a day, 30-45 minutes before feeding, for 14 days.
41342850|NCT06259604|OTHER|PIOMI+kangaroo care|Babies in this group will start using PIOMI once a day, 30-45 minutes before feeding, and kangaroo care for at least 30 minutes during the last 2 minutes of non-nutritive sucking phase of PIOMI, for 14 days.
41342851|NCT02587975|DRUG|Evogliptin|10 mg
41342852|NCT03001414|BIOLOGICAL|Placebo followed by Autologous EPCs transfected with human eNOS|4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months
40824339|NCT02789670|OTHER|Blood sample collection|Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
41018220|NCT01177072|OTHER|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
41342853|NCT03001414|BIOLOGICAL|Autologous EPCs transfected with human eNOS followed by Placebo|4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months
41342854|NCT03001414|BIOLOGICAL|Autologous EPCs transfected with human eNOS|4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
41342855|NCT01641081|DRUG|Formoterol Fumarate in the Pressair DPI, Low Dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
41342856|NCT01641081|DRUG|Formoterol Fumarate in the Pressair DPI, High Dose|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
41342857|NCT01641081|DRUG|Foradil Aerolizer, Low Dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
41342858|NCT01641081|DRUG|Foradil Aerolizer, High Dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
41342859|NCT01641081|DRUG|Placebo|Placebo in the Pressair for 14 days
41342860|NCT01171742|PROCEDURE|Intermittent hepatic inflow occlusion (IHIO)|Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
41342861|NCT05668806|DEVICE|Cerviron|Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21 (devices composed of substances or of combinations of substances to be introduced into the human body via a body orifice or applied to the skin and absorbed by or locally dispersed in the human body). Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
41018221|NCT01177072|OTHER|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
41018222|NCT02067403|OTHER|Pressure-support Eadi optimization|
41018223|NCT04327284|DEVICE|Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
41018224|NCT04327284|DEVICE|Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
41018225|NCT05459129|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
41018226|NCT05459129|DRUG|Tiragolumab|Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
41018227|NCT05459129|DRUG|Carboplatin|Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.
41018228|NCT05459129|DRUG|Paclitaxel|Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.
41342862|NCT00031135|DRUG|Choline Chloride|
41342863|NCT06379880|DEVICE|CONTINUUM+ CONNECT remote monitoring|"CONTINUUM+ CONNECT is a web platform, accessible via the internet, which contains the digital medical device (DMN) Continuum+ alert module. This is a medical software intended for the interpretation of clinical constants, symptoms, adverse events and pain, generating alerts with a view to improving the monitoring of patients undergoing anticancer treatment. The Continuum+ Alert Module version 1.0.0 dated 30 April 2021 is CE-marked and will be used in accordance with the manufacturer's instructions for use by patients in the experimental group."
41342864|NCT01086267|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
41342865|NCT01086267|DRUG|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
41342866|NCT01086267|DRUG|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
41157286|NCT06025877|OTHER|PrecivityAD2(TM) blood test|The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.
41157287|NCT03124550|BEHAVIORAL|Exergame Experience|Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
41342867|NCT02100813|DRUG|LEO 43204|
41342868|NCT02100813|DRUG|Placebo|
41342869|NCT02128204|DEVICE|lidocaine contained hyaluronate facial dermal filler|HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.
41342870|NCT02128204|DEVICE|hyaluronate facial dermal filler|Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
41342871|NCT05874336|DRUG|Aramchol|Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid) is a synthetic small molecule, produced by conjugation of cholic acid (bile acid) and arachidic acid (saturated fatty acid) linked by a stable amide bond.
41342872|NCT01432704|DRUG|colecalciferol|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
41342873|NCT02837861|DRUG|Routine Nutritional Support plus supplemental IV amino acids|Enteral nutrition as tolerated Plus supplemental IV AA infusion to meet the target of approximately 1.5-2.0gm protein/kg/day total starting within 24 hours of injury for 5 days.
41342874|NCT02837861|OTHER|Routine Nutritional Support|Enteral nutrition as tolerated.
41342875|NCT03962634|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
41342876|NCT03962634|DRUG|Articaine Injection|Local anesthetic
41383603|NCT00991211|DRUG|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
40824340|NCT06605183|BEHAVIORAL|Community walking program using Nordic walking poles|This is a group, community walking program at local parks using Nordic walking poles. Participants will be encouraged to walk briskly but safely for 60 minutes one time per week with the ultimate goal of using this community walking program to build up their step count to 10,000 steps per day. We do not anticipate that the weekly walk will get them to 10,000 steps but we will use that as a weekly event to drive behavioral change throughout the week.
40824341|NCT00147862|DRUG|Tranexamic Acid|
41018229|NCT06572943|OTHER|Moderate intensity physical activity|Moderate intensity exercise of 30 minutes for at least 4-5 times per week (if not daily).
41018230|NCT02353312|DRUG|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
41018231|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #1|two most popular varieties of cowpea currently consumed in the selected geographic area
41342877|NCT04261283|OTHER|Experimental|"The Circuit Training will be consisting of:~1. Habituation Exercises~2. Exercises for the gaze stability (The two exercises are specifically for the patients who reported a high score on oscillopsia severity questionnaire~3. Exercises to improve Saccade Latency.~4. Adaptation Exercises~5. Substitution Exercises~6. Postural Control Exercises~7. General Conditioning Activities~8. Cawthorne-Cooksey Exercises~9. Ocular Motor Exercises~10. Gait Exercises~11. Treatment to Decrease Sensitivity to Motion in the Environment"
41018232|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #2|two most popular varieties of cowpea currently consumed in the selected geographic area
41342878|NCT04261283|OTHER|Active Comparator|Medicines as prescribed by the ear, nose, and throat (ENT) specialist and Home-based exercise Programme (Simple and general vestibular rehabilitation exercises) will be recommended to the patients to perform. ( Not under the supervision of neuro-therapist)
41342879|NCT06126406|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion Subjects will receive conditioning therapy by ludarabine and Cyclophosphamide before cell infusion.
41342880|NCT06126406|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
41342881|NCT01611662|DRUG|gemcitabine hydrochloride|Given IV
41342882|NCT01611662|DRUG|cisplatin|Given IV
40824342|NCT06605794|DEVICE|FreeFlow percutaneous atrial septal shunt|The trial devices included a percutaneous atrial septal shunt and an atrial septal shunt delivery system. The specifications of the atrial septal shunt device were -φ5, φ7, φ9, φ11, and the specifications of the atrial septal shunt delivery system-FFISS-B were 9F and 10F.
40824343|NCT01429428|OTHER|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
40824344|NCT01429428|OTHER|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
41018233|NCT03586895|BEHAVIORAL|e-Connect|e-Connect
41018234|NCT01142245|DRUG|Oral esomeprazole|• Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
41018235|NCT01142245|DRUG|Intravenous Esomeprazole|"Esomeprazole IV 80mg loading bolus~* Esomeprazole intravenous infusion 8mg/hr for 72 hours"
41018236|NCT03700359|DRUG|Anlotinib Hydrochloride|Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
41018237|NCT03700359|DRUG|Lobaplatin|Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
41018238|NCT03700359|DRUG|Etoposide|Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
41342883|NCT01611662|PROCEDURE|therapeutic conventional surgery|Undergo radical cystectomy
41342884|NCT01611662|OTHER|laboratory biomarker analysis|Correlative studies
41342885|NCT02465762|DEVICE|ultrashape Fat reduction|Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
41342886|NCT03623906|PROCEDURE|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
40824345|NCT04569136|OTHER|Education|The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.
41018239|NCT02356835|DEVICE|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
41018240|NCT02356835|DEVICE|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
41018241|NCT03090399|DEVICE|FloTrac|For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
41018242|NCT00453765|DRUG|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
41018243|NCT00453765|DRUG|placebo|placebo
41018244|NCT05560867|DEVICE|robot-assisted training|These training platforms use gamified training tasks to improve motor control in the hemiparetic arm
41018245|NCT04922801|DIAGNOSTIC_TEST|Nuclear Medicine whole-body|Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).
41018246|NCT04922801|DIAGNOSTIC_TEST|SPECT/CT imaging.|SPECT/CT scan at 24-48 hr post MRT
41342887|NCT03623906|PROCEDURE|Air insufflation colonoscopy|Room air insufflation colonoscopy
41342888|NCT04247529|OTHER|Exposure to conflicting health information|At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.
41018247|NCT04922801|DIAGNOSTIC_TEST|PET/CT imaging.|3-6 months Pre and post-therapy PET/CT imaging
41342889|NCT04247529|OTHER|No exposure to conflicting health information|At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
41342890|NCT01226589|PROCEDURE|MRS|
41342891|NCT00529412|OTHER|Seprafilm|two sheets per body
41342892|NCT03157999|BEHAVIORAL|Intervention group (CAST)|"Intervention duration is expected to be 6 months. A full-time registered nurse (RN) will function as a Care Transitions Coordinator (CTC) who works collaboratively with one local hospital and other health and non-health representatives to deliver the intervention, which includes:~* care coordination and system navigation (including facilitating timely primary care follow-up);~* medication management;~* assessing the needs and risk of the participants (including in-depth assessment of depressive symptoms);~* evidence-based management of depressive symptoms and other chronic conditions to prevent the onset and worsening of other chronic conditions;~* patient and caregiver education; and goal setting and problem-solving therapy."
41342893|NCT06353867|OTHER|Group Exercise|The children with special needs included in the study were included in group exercises for 45 minutes 2 days a week in groups of 10 children each. Group exercises were planned as balance and coordination exercises including warm-up and cool-down periods. In the warm-up and cool-down periods, counting in place and balance exercises were performed. The exercises included tasks such as side walking, tandem walking, walking on a balance board, walking in a figure 8, walking over obstacles, throwing a ball to the person next to him/her while passing through cones, and throwing a ball by jumping while passing through cones.The exercises were made more difficult by following a progressive method every 2 weeks. The exercises were performed in 3 sets of 5 repetitions under the supervision of a physiotherapist.
41018248|NCT04922801|DEVICE|Patient-led radiation monitor (SELFIE)|"Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire."
41018249|NCT04922801|DIAGNOSTIC_TEST|LAB TEST|Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.
41018250|NCT04453852|BIOLOGICAL|COVID19 vaccine|COVID19 recombinant spike protein with Advax-SM adjuvant
41342894|NCT02353325|DIETARY_SUPPLEMENT|non-encapsulated FeSO4|
41342895|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4, before cooking|
41342896|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4, after cooking|
41342897|NCT02353325|DIETARY_SUPPLEMENT|non-encapsulated FeSO4 + ascorbic acid|
41342898|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4 + ascorbic acid, before cooking|
41342899|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4 + ascorbic acid, after cooking|
41342900|NCT04685369|OTHER|Medical Data extraction|Medical Data extraction
41342901|NCT05431738|DEVICE|Gastroesophageal stent placement|A gastroesophageal stent is placed during a digestive endoscopy performed under general anesthesia, under endoscopic and fluoroscopic control
41018251|NCT04453852|BIOLOGICAL|Saline|Saline control
41018252|NCT00129519|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
41342902|NCT06087731|DRUG|Tocilizumab|Tocilizumab (8mg/kg) every 4 wekks
41342903|NCT00164567|BEHAVIORAL|Onsite IPV specialist|
41342904|NCT00164567|BEHAVIORAL|Empowerment focused intervention|
41342905|NCT06115824|DRUG|Orelabrutinib|Combination of orelabrutinib on a methotrexate-based chemotherapy regimen with a starting dose of 150 mg/d
41342906|NCT01086904|BIOLOGICAL|inactivated non adjuvanted pandemic H1N1 vaccine|two administrations at D and D21 (15 µg HA)
41342907|NCT00505544|BEHAVIORAL|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
41342908|NCT00505544|DEVICE|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
41342909|NCT04260529|DRUG|CyPep-1|Intratumoral injection
41342910|NCT04260529|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
41342911|NCT00853190|DRUG|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
41018253|NCT06475131|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
41018254|NCT06117462|OTHER|Assesment of CFS|Assesment of CFS
41342912|NCT00853190|DRUG|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
41342913|NCT00369408|DRUG|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
41342914|NCT00369408|DRUG|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
41342915|NCT03144089|DEVICE|Articulated Oral Airway|The AOA is a novel device which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. The AOA will be evaluated for efficacy of mask ventilation.
41018255|NCT02077517|PROCEDURE|Roux en Y Gastric Bypass|
41018256|NCT04140149|BEHAVIORAL|Living with Hope|12-week, CBT-based, psychoeducational skills class
41018257|NCT02496884|DRUG|DS-5565|DS-5565 7.5 mg tablet for oral use
41018258|NCT02496884|DRUG|Placebo|Placebo tablet for oral use to match DS-5565 7.5 mg tablet
41018259|NCT03643822|DRUG|Dexamethasone 4mg|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
41018260|NCT03643822|DRUG|Dexmedetomidine|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
41018261|NCT03643822|OTHER|Saline|Control/Placebo intervention
40824346|NCT04569136|OTHER|Therapeutic ultrasound|Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.
40824347|NCT04569136|OTHER|Sham ultrasound|Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.
40824348|NCT04569136|OTHER|Breast massage|Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.
40824349|NCT04569136|OTHER|Usual obstetric care|Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.
40824350|NCT02055534|OTHER|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
40824351|NCT02055534|OTHER|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
40824352|NCT06607042|BEHAVIORAL|Psychotherapy|Psychotherapy according to the Berlin Dissexuality Therapy (BEDIT)
40824353|NCT01084980|DRUG|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
41018262|NCT01298284|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
41018263|NCT05467670|DRUG|Pembrolizumab|A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
41018264|NCT05467670|DRUG|ALX148|A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
41018265|NCT05467670|DRUG|Doxorubicin|An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
40824354|NCT05568459|OTHER|Non-Interventional|No study treatment will be administered in this study.
40824355|NCT02779907|OTHER|No Intervention|No interventions planned for this observational study
40824356|NCT05111106|DEVICE|Symfony IOL|Implantation of Intraocular lens with extended depth of focus.
40824357|NCT02919280|OTHER|Observational Study|The Dallas 2K is a 10-year natural history, longitudinal, prospective study of a cohort of 2,000 participants. There is no medication or non-medication treatment or intervention provided by this study.
40824358|NCT06357871|OTHER|No intervention|No intervention
41489205|NCT01513564|DRUG|Local anaesthesia|Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
40824359|NCT01686659|DEVICE|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin \[SpHb\] and Pleth Variability Index \[PVI\]) to the clinicians in the operating room
40824360|NCT02425605|RADIATION|CCRT|The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
41018266|NCT03250663|BEHAVIORAL|Online Treatment response|Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.
41018267|NCT03250663|DRUG|EUCRISA|Participants are given EUCRISA (crisaborole) ointment 2%.
41018268|NCT02047604|DRUG|SAN-300 0.5 mg/kg QW|
41018269|NCT02047604|DRUG|SAN-300 1.0 mg/kg QW|
41342916|NCT03144089|DEVICE|Guedel oral airway (active comparator)|The Guedel oral airway is a standard oral airway commonly used to facilitate mask ventilation. The Guedel oral airway will be evaluated for efficacy of mask ventilation.
41018270|NCT02047604|DRUG|SAN-300 2.0 mg/kg QOW|
41018271|NCT02047604|DRUG|SAN-300 4.0 mg/kg QOW|
41018272|NCT02047604|DRUG|SAN-300 4.0 mg/kg QW|
41489206|NCT02647736|OTHER|Hypertonic saline infusion|
41018273|NCT02047604|DRUG|Placebo|
41018274|NCT02734485|DEVICE|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
41489207|NCT00263991|DEVICE|EEC-techniques|
41018275|NCT02734485|DEVICE|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
41018276|NCT02886533|OTHER|Antithrombotic|Collection of clinical, biological data
40824361|NCT02425605|DRUG|sorafenib|Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
41018277|NCT00794872|OTHER|blood sampling|
41018278|NCT03260816|BEHAVIORAL|Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
41018279|NCT03260816|OTHER|Referrals as Usual (RAU)|Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
41018280|NCT03397511|BEHAVIORAL|Financial Incentives|Baseline Interview, 2 Counseling Sessions at baseline and 2 weeks post baseline, and one follow up survey at one month
41018281|NCT03285646|DRUG|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
41018282|NCT03285646|DRUG|Placebo|Subcutaneous (SC) every 4 weeks (Q4W)
41342917|NCT05248009|DEVICE|Semi-Permanent Tattoo Ink|Subjects will receive semi-permanent tattoo ink in place of the permanent ink utilized in the standard of care. Subjects will be monitored during their treatment course and for 15 months following treatment completion.
41342918|NCT01099761|BIOLOGICAL|ACE-031 0.5 mg/kg q4wk|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
41342919|NCT01099761|BIOLOGICAL|ACE-031 1.0 mg/kg q2wk|ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
41018283|NCT05166122|DIAGNOSTIC_TEST|Artificial Intelligence|Introduction of digitized system with an AI tool to detect and intrepret the severity of diabetic retinopathy and presence of diabetic macular edema in screening for diabetes patients
41018284|NCT04213794|DRUG|Cisplatin|Undergo HIPEC with doxorubicin and cisplatin
41342920|NCT01099761|OTHER|Placebo|Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
41489208|NCT00343239|DRUG|Docetaxel|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
41018285|NCT04213794|PROCEDURE|Cytoreductive Surgery|Undergo cytoreduction
41018286|NCT04213794|DRUG|Doxorubicin|Undergo HIPEC with doxorubicin and cisplatin
41018287|NCT04213794|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with doxorubicin and cisplatin
41018288|NCT04213794|DRUG|Sodium Thiosulfate|Given IV
41018289|NCT04213794|PROCEDURE|Computed Tomography|Undergo CT scan
41018290|NCT04213794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41018291|NCT04213794|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41342921|NCT02885272|PROCEDURE|Computed Tomography|Undergo PET/CT scans
41342922|NCT02885272|RADIATION|Fludeoxyglucose F-18|Given IV
41342923|NCT02885272|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
41018292|NCT04213794|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41018293|NCT01070004|OTHER|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
41342924|NCT02885272|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
41489209|NCT00343239|DRUG|Cisplatin|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
41489210|NCT00343239|DRUG|Fluorouracil|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days"
41342925|NCT04861636|BEHAVIORAL|HealthTRAC|Behavioral weight management intervention targeting emotion regulation skill building. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
41157288|NCT04486833|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
41489211|NCT05753761|BEHAVIORAL|Behaviour- & Imaging-Guided Stepping Training Early Post-Stroke (BIG STEPS) intervention|Using baseline accelerometry data, personalized goals of replacing sedentary time with stepping time will be developed.
41489212|NCT00949611|BEHAVIORAL|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
41489213|NCT00949611|BEHAVIORAL|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
41489214|NCT03668236|DRUG|Isotonic crystalloids|"Types of fluid to be used in both intervention groups:~* IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~* Fluids used for dehydration: Water or isotonic glucose should be used~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy"
41489215|NCT04072016|DEVICE|Beacon Aqueous Microshunt|The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.
41489216|NCT01632761|DIETARY_SUPPLEMENT|Vitamin D3 .|
40824362|NCT02676336|DIETARY_SUPPLEMENT|Violet™ Molecular Iodine (I2)|
41342926|NCT04861636|BEHAVIORAL|SBWC|Behavioral intervention focused on behavioral weight control. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
41342927|NCT03096886|BEHAVIORAL|Computer-Augmented Cognitive Behavioral Therapy|"The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy."
41489217|NCT01632761|DRUG|omega-3 fatty acids (fish oil)|
41489218|NCT01632761|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
41489219|NCT01632761|DIETARY_SUPPLEMENT|Fish oil placebo|
41489220|NCT05969379|GENETIC|Analysis of biomarkers and their correlation with clinical characteristics and outcome|"This is a non-interventional study involving clinical data, neuroimaging analysis, and biological samples. Demographics and clinical data are collected in the database of the French Reference Centre. Additional or missing data will be obtained by contacting the referral physicians. All the neuroimages available will be analysed by dedicated software. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids). Additional samples for genetic testing will be collected upon explicit written consent."
41489221|NCT02807168|OTHER|NT-proBNP (Cardiac Biomarkers)|
41342928|NCT04888182|DIETARY_SUPPLEMENT|intervention|a protein intake of ≥25 E%. An oral nutritional supplement (containing 1570 kJ/100 g and 92 g protein/100 g. Atpro 200) was used as supplement to the patients' habitual diet.
41342929|NCT01473355|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
41342930|NCT04697108|OTHER|Shoulder reproduction teste assisted by laser pointer|In the step (1) of Familiarization in which the SRTLP was applied through a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability
41342931|NCT05146934|RADIATION|high resolution CT|Ground glass，honeycomb，reticulation, consolidation
41489222|NCT06228573|PROCEDURE|Yoga|Yoga program: In weeks 2-9, participants will attend twice weekly 1-hour sessions of yoga led by a certified yoga instructor trained in the intervention by collaborator Pearson. Videos will be provided for completion of home sessions. The yoga program is based on the Pain Care Aware certification program.38 Details of the program as well as the training of instructors are provided in the appendices. Briefly, classes will consist of 3 parts: centring and warming up aimed at regulating physiology prior to beginning the yoga postures; yoga postures and guided relaxation.
41489223|NCT03547700|DRUG|Romidepsin|Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
40824363|NCT02676336|OTHER|Placebo|
40824364|NCT01844011|OTHER|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
41018294|NCT01070004|OTHER|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
41018295|NCT05226962|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid supplement ingested in a dose intended to provide \~0.35 g of ketone monoester per kg body mass of the participant
41018296|NCT05226962|OTHER|Placebo|A liquid placebo that is volume- and taste-matched to the ketone monoester supplement
41489224|NCT03547700|DRUG|Ixazomib|Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
41018297|NCT05592886|OTHER|SMT04 formula|The SMT04 formula is a synbiotic containing probiotics and prebiotics
41342932|NCT04245657|OTHER|Tissue Dielectric Constant Measurement|Sub-tissue fluid proportion will be evaluated via Moisture Meter D (Delfin Technologies, Kuopio, Finland) on both upper extremity (right and left) in predefined reference points on volar side (6 cm distal and 8 cm proximal points from cubital crease, 10 cm inferior side point from axilla and dorsal point of web space in the hand) by using four different probes which can assess 0.5 mm, 1.5 mm, 2.5 mm and 5.0 mm depth. Values taken by 2.5 mm depth probe will be used to calculate the ratio (affected side TDC value/Unaffected side TDC value) to stage lymphedema severity along with the International Society of Lymphology staging system. This device mainly aims to assess the dielectric constant of tissues which is related to the amount of tissue water. In the case of pre-lymphedema or lymphedema, one can assess objectively regarding sub-tissue fluid changes via this device. Triplicate measurements will be taken for each reference point.
41018298|NCT05592886|OTHER|Active placebo|The active placebo is 2 mg Vitamin C with an inert substance made of starch filler. The flavor, coloring and appearance are unidentifiable to the study product.
41018299|NCT06005259|DRUG|Spironolactone|Spironolactone 25 mg capsule
41018300|NCT06005259|DRUG|Placebo|Placebo capsule
41018301|NCT02186964|PROCEDURE|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
41018302|NCT02186964|PROCEDURE|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
41018303|NCT02186964|PROCEDURE|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
41018304|NCT06449339|DRUG|Carvedilol|Patients in the NSBB arm will receive generic carvedilol. The starting dose of oral carvedilol is 6.25mg daily (to be taken once or twice per day) and can be adjusted at each scheduled visit (either by increasing the dosage or frequency of dose administration) according to patients' tolerance, as well as the blood pressure and pulse rate that the systolic blood pressure should be not lower than 90 mmHg and pulse rate not lower than 55 beats per minute. The dosage of carvedilol can also be titrated or discontinued at unscheduled visit according to patient's condition. In case carvedilol is discontinued, it can be resumed from the starting dose at next scheduled visit if there is no contraindication for carvedilol. The dose of carvedilol will be kept at 6.25-12.5mg per day unless there are additional non-hepatic indications such as arterial hypertension or cardiac disease warranting higher carvedilol dosage. The maximum allowed dose of carvedilol is 50mg daily as per drug instruction.
41018305|NCT00797615|BEHAVIORAL|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
41342933|NCT04245657|OTHER|Muscle strength measurement|Participants' muscle strength of shoulder flexion, abduction, and elbow flexion will be assessed via Handheld digital dynamometer (Lafayette Manual Muscle Tester, Model 01165, LaFayette Instruments, NY, USA). Both upper extremities will be assessed three times and the average value will be recorded.
40824365|NCT05671224|OTHER|Visual aid|Handout and video describing different types of induction of labor
41018306|NCT00797615|BEHAVIORAL|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
41018307|NCT05769673|PROCEDURE|Placement of dental implant|Placement of a dental implant on the edentulous ridge
41018308|NCT05769673|PROCEDURE|Placement of stock healing abutment|Placement of stock healing abutment after implant has been placed on the edentulous ridge
41018309|NCT05769673|PROCEDURE|Placement of customized CAD/CAM healing abutment|Placement of customized CAD/CAM healing abutment after implant has been placed on the edentulous ridge
41018310|NCT02605590|DRUG|AIR DNase|
41489225|NCT05038332|RADIATION|Ultra-hypofractionated radiation therapy|34 Gy in 5 fractions to prostate bed, every other day, M-F, \~2 weeks (25 Gy in 5 fractions to pelvic lymph nodes if included)
41489226|NCT05038332|RADIATION|Moderately Hypo-fractionated Radiation Therapy|55 Gy in 20 fractions to prostate bed, daily, M-F, 4 weeks (42 Gy in 20 fractions to pelvic lymph nodes if included)
41018311|NCT02605590|DRUG|Placebo|
41018312|NCT05437679|OTHER|Blood collection|Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.
41157289|NCT04486833|DRUG|osimertinib|Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
41489227|NCT03659526|DIAGNOSTIC_TEST|Deformation imaging|Deformation parameters derived using myocardial velocity imaging or speckle tracking
41018313|NCT03608800|BEHAVIORAL|Intermittent fasting|The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks
41018314|NCT02220010|DEVICE|Pancreatic stent|The plastic stent is introduced in the pancreatic duct by a duodenoscope
41018315|NCT02139163|OTHER|Cohort Study|
41018316|NCT05050188|DRUG|H008|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water.
41018317|NCT05050188|DRUG|H008 placebo|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
41342934|NCT04245657|OTHER|Hand-Grip Strength Measurement|Handgrip strength will be assessed with LaFayette Professional Hand Dynamometer, Model 5030L1, LaFayette Instruments, NY, USA). The standard position which can be achieved by 90-degree elbow flexion, shoulder abducted, and hand mid-prone positioned; 90-degree shoulder abduction and 90-degree shoulder abduction positions will be used to assess hang-grip strength. Three measurements will be requested and the maximum value of them will be recorded. 1 minute resting period will be provided between the positions at which handgrip is assessed.
41342935|NCT04245657|OTHER|Pain Threshold Measurement|The sensitive pain threshold and normal pain threshold will be evaluated by a digital algometer (Wagner FDIX, Greenwich, USA) on reference points as follows: C5-C6 zygapophyseal joints' lateral points, upper trapezius (proximal, middle and distal lateral points, length measured by a tape from C7 Processus spinosus to acromion and this length will be divided equally into three parts for proximal, middle and distal lateral point), deltoid muscle (crista deltoidea), dorsum of the webspace.
41342936|NCT04245657|OTHER|International Physical Activity Questionnaire-Short Form (IPAQ-SF)|This scale was intended to be filled to assess participants' physical activity levels within the last seven days. Then, MET calculations will be done via a basic Excel Spreadsheet which is pre-defined MET values formulated inside. Scale data then obtained according to the participants' answers and recorded.
41342937|NCT04245657|OTHER|Fatigue Impact Scale|"This scale has 9 items that can be answered as Strongly Disagree through Strongly Agree by numbered as 1 and 7, respectively. Then total points will be calculated and divided into 9 to achieve the Fatigue Impact Scale score. The higher points will be indicated more perceived fatigue, while lower points indicate less."
41342938|NCT04245657|OTHER|Disabilities of Arm, Shoulder and Hand Scale (DASH)|"DASH has 30 items related to upper extremity function. Participants will be requested to grade some expressions related to the function within a 5-point Likert scale as follows: No difficulty: 1, Mild Difficulty:2, Moderate Difficulty: 3, Severe Difficulty: 4 and Unable to perform: 5). The symptom score of the DASH will be calculated as dividing filled items total score to filled items' number and minus one from this data then multiplying with 25. The higher points indicate a deteriorated shoulder and hand function while lower points indicate a better upper extremity function."
41342939|NCT04245657|OTHER|Exercise Benefits/ Barriers Scale|Exercise Benefits/Barriers Scale has 43 items each can be graded within a four-point Likert type scale. Barrier items are reverse coded. 43 items are all related to exercise and exercise beliefs in both in the aspect of health and general. Strongly disagree, disagree, agree, strongly agree will be scored as 1,2,3,4 or vice versa whether the item should de reversely coded, respectively. Total scores ranged between 29 and 172. The barrier scale score is ranged between 14 and 56. The benefits scale is also ranged between 29 and 116. The higher the score of Barriers scale, the greater the perception of barriers to exercise.
41342940|NCT04245657|OTHER|Beck Depression Scale|Beck Depression Scale has 21 items each can be scored within 0 to 3. All items are related to the depressive mood of a participant. The higher the score of the Beck Depression Scale, the higher the depression level.
41342941|NCT03814460|DIAGNOSTIC_TEST|Assessment of Tone, Pain and Thickness|Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles
41489228|NCT04304365|OTHER|Follow-up clinic visit|Participants will be scheduled for a visit with a provider in 1-2 weeks that will include an ultrasound examination.
41018318|NCT05050188|DRUG|Lansoprazole|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
41018319|NCT04124549|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 HD hours.
41018320|NCT04124549|OTHER|Intradialytic Combined Exercise|Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Patients were asked to perform aerobic exercise 20-min and resistance exercise 10-min in the first stage. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE. In the following stages, aerobic exercise was continued 15-min for the second stage, 10-min for the third and the forth stage, 15-min for the fifth stage and 20-min for the last stage. And the time for resistance exercise was adjusted for the total exercise time. The resistance of exercise also progressive increased in order to adapt the target RPE. It was accessible to patients of different ages, gender, cultures and ethnicities.
41157290|NCT04486833|DRUG|Platinum-Based Chemotherapy|Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
40824366|NCT03866785|DIAGNOSTIC_TEST|interview|The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.
40824367|NCT03866785|DIAGNOSTIC_TEST|Adult Physical Activity Questionnaire (APAQ)|The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.
40824368|NCT03866785|DEVICE|Activity actigraph|An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.
40824369|NCT03866785|OTHER|Peer training|"The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~* Skills in physical activity advice~* Knowledge of functional signs (symptoms)~* Knowledge to examine heart rate and perceived effort rate"
40824370|NCT03866785|OTHER|Physical Activity Program|"During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months."
40824371|NCT00467545|DRUG|telbivudine|
40824372|NCT04518852|COMBINATION_PRODUCT|TACE combined with sorafenib and PD-1 mAb|the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
40824373|NCT02233738|BEHAVIORAL|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
40824374|NCT02233738|BEHAVIORAL|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
40824375|NCT03649373|PROCEDURE|Noergaard technique|The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
40824376|NCT00099242|DRUG|rivastigmine transdermal patch|
40824377|NCT06079060|DEVICE|Synthetic Nitrile Condom (61mm)|61mm width Synthetic Nitrile Condoms
41018321|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Ozone Injection|All procedures were performed under light sedation in a sterile operating room. Ozone was created by an ozone generator (Dr. J. Hänsler Ozonosan, Iffezheim, Germany). Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid plus ozone injection received additionally 5ml of ozone at a concentration of 28 g/ml for each transforaminal epidural injection level.
40824378|NCT06079060|DEVICE|Control Latex Condom|61mm width Natural Rubber Latex Condom
41018322|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|All procedures were performed under light sedation in a sterile operating room.Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid injection received two mL of dexamethasone (8 mg) and 3 mL of saline for each transforaminal epidural injection level
41157291|NCT06501989|DRUG|Biweekly 5-FLUOROURACIL (5-FU)|5-FU 2400 mg/m². Infusion for 46 hours. Leucovorin 200 mg/m². Either a vascular endothelial growth factor (VEGF) inhibitor or epidermal growth factor (EGFR) inhibitor or may be added to the regimen at the discretion of the treating physician. Repeat every 2 weeks.
40824379|NCT00592540|PROCEDURE|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
41018323|NCT06392555|DEVICE|Device-Aided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, aided by the device
41018324|NCT06392555|OTHER|Device-Unaided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, unaided by the device
41018325|NCT00005758|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
41018326|NCT00005758|BIOLOGICAL|HIV-1 Immunogen|
41018327|NCT03616418|DRUG|antiplatelet drugs;statins;antihypertensive drugs|
41018328|NCT01175824|DRUG|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
41018329|NCT01175824|DRUG|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
41018330|NCT01175824|DRUG|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
41018331|NCT02618330|DEVICE|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
41018332|NCT04908813|DRUG|HLX22|IV Q3W D1
41018333|NCT04908813|DRUG|Placebo|IV Q3W D1
41018334|NCT04908813|DRUG|Trastuzumab|IV Q3W D1
41018335|NCT04908813|DRUG|Oxaliplatin|IV Q3W D1
41018336|NCT04908813|DRUG|Capecitabine|PO Q3W D1-D14
41342942|NCT04493944|BEHAVIORAL|Culinary workshop|A 3-hour culinary workshop will be led by a chef. The aim of this workshop will be to develop participants' culinary skills related to the preparation and consumption of recipes based on seaweeds, through various practical activities in the kitchen (starter, main course, dessert). An evaluation questionnaire will be completed at the end of the workshop.
41342943|NCT01902836|BIOLOGICAL|Conventional treatment plus DLE|"Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:~Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month"
41018337|NCT06395168|OTHER|Combined Newborn and Lactation Visit|See Arm/Group Description
41342944|NCT01902836|BIOLOGICAL|Conventional treatment plus placebo|Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
41489229|NCT04304365|OTHER|Text message|Participants will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. They will receive a survey link through text message at this time.
41018338|NCT03904979|OTHER|Writing exercises|Participants will be given journals with writing prompts to be completed throughout their pregnancy.
41018339|NCT01162005|DRUG|Tacrolimus|dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
41018340|NCT01412840|OTHER|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
41018341|NCT01412840|OTHER|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
41018342|NCT06364826|DRUG|Sintilimab, bevacizumab, gemcitabine|This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
41018343|NCT06364826|RADIATION|IMRT|IMRT
41018344|NCT05573516|PROCEDURE|Open reduction and internal fixation|unicortical fully threaded 4mm screws will be used as positional screws after completely reducing the fracture
41018345|NCT03328689|OTHER|Physical activity program|This arm will begin with PT assessment. Following this, participants will meet with a specialist who will design an individualized physical activity program. Classes will include warm up, 40 minutes of individualized exercises and a cool down that will include back pain specific exercises including core strengthening. The first 4 weeks of exercise will include a 30-minute education program. Education comprise information on back pain, efficient use of the back during daily activities, self-management, self-efficacy and pain neurophysiology. Classes will run for a 12-week period. Participants will be encouraged to attend the exercise facility at least 3 times a week. An activity monitor will be provided to all participants. We will use group classes to facilitate the development of social support.
41018346|NCT03328689|OTHER|Control group standard care|"Participants from the control group will receive usual care which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.~Participants in the control group will also receive and activity monitor for collection of physical activity data. This activity monitor may also be used for positive feedback and activity reinforcement"
41018347|NCT06562140|OTHER|No intervention - cross-sectional observational study|No intervention - cross-sectional observational study
41018348|NCT06572618|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41018349|NCT06572618|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41018350|NCT06572618|DRUG|Nemtabrutinib|Given PO
41342945|NCT01698073|BEHAVIORAL|mCOL|
41342946|NCT01698073|OTHER|AS+|
41018351|NCT06572618|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
41018352|NCT06572618|BIOLOGICAL|Rituximab|Given IV
41018353|NCT02138851|DIETARY_SUPPLEMENT|Ficus Carica (300g/day)|Ficus Carica (300g/day), parallel design
41018354|NCT02138851|DIETARY_SUPPLEMENT|Placebo (300g/day)|Placebo (300g/day), parallel design
41018355|NCT01332149|DRUG|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
40824380|NCT04509245|BEHAVIORAL|Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone|During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
40824381|NCT04274530|BEHAVIORAL|Cognitive Behavioural Therapy|Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.
41018356|NCT01332149|DRUG|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
41018357|NCT00902616|DIETARY_SUPPLEMENT|L-arginine|3gm TDS for three months
41018358|NCT00902616|DIETARY_SUPPLEMENT|Placebo Lactose powder|3gm TDS for 3 months
41018359|NCT03275727|BEHAVIORAL|iACT-BC|A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
41157292|NCT06501989|DRUG|Biweekly Modified FOLFOX6|Oxaliplatin 85 mg/m². 5-FU 400 mg/m² on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m² Infusion for 46 hours. Leucovorin 200 mg/m2. Repeat every 2 weeks
41342947|NCT01665898|PROCEDURE|Cold Biopsy forceps|removal of polyps using cold biopsy forceps
41342948|NCT01665898|PROCEDURE|Cold snare biopsy|Removal of colon polyps using cold snare biopsy
41342949|NCT03418220|OTHER|blood and aqueous humor sampling|The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).
41018360|NCT03325413|BEHAVIORAL|Systematic inclusion of family members|Systematic inclusion of family members/ reference person in the perioperative process
41342950|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
41342951|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 3mcg
41342952|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 15mcg
41342953|NCT00902057|DRUG|placebo|saline subcutaneous
41342954|NCT05394428|OTHER|No intervention|No intervention
41342955|NCT04708340|DRUG|Rejuveinix (RJX) Active Comparator|Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and sodium bicarbonate.
41018361|NCT03325413|BEHAVIORAL|Preoperative information|Detailed preoperative information about delirium prevention and procedures
41018362|NCT03325413|BEHAVIORAL|Physical and breathing exercises|Preoperative execution of physical and breathing exercises if necessary
41018363|NCT03325413|DIETARY_SUPPLEMENT|Dietary supplements|Dietary supplements if necessary
41018364|NCT03325413|OTHER|Evaluation of long-term medication|Avoidance of unsuitable drugs for elderly if possible
41018365|NCT03325413|PROCEDURE|Regional anesthesia|Regional anesthesia whenever possible
41018366|NCT03325413|OTHER|Personal aids|Personal orientation aids until anesthesia induction
41018367|NCT03325413|DEVICE|Temperature management|Perioperative warming
41018368|NCT03325413|DEVICE|Neurmonitoring|Using Bispectral index (BIS) to measure the depth of anesthesia
41018369|NCT03325413|PROCEDURE|Pain catheter|A pain catheter will be used as postoperative pain therapy if possible
41018370|NCT01587326|DRUG|Escitalopram|escitalopram 10 mg/d to 20 mg/d
41018371|NCT03219333|DRUG|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
41018372|NCT02588040|BIOLOGICAL|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
41342956|NCT04708340|DRUG|Placebo Comparator|0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection
41342957|NCT03527303|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
41342958|NCT03826693|DRUG|Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
41489230|NCT04304365|OTHER|Low Sensitivity Pregnancy Test (LSPT)|Participants will be instructed on how to test their urine 14 days after the medication abortion for continued pregnancy. LSPT can detect hCG levels as low as 2000 mIU/ml.
41018373|NCT03969771|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program was developed by the University of Massachusetts Medical School.
40824382|NCT06465953|DRUG|Ivosidenib|Two 250 mg tablets, totaling 500 mg, administered orally once daily until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
40824383|NCT06465953|DRUG|Azacitidine|Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
40824384|NCT01453946|DRUG|Entocort|Entocort capsules, taken orally, 6 mg daily.
41018374|NCT01961830|DRUG|ME1100 inhalation solution|
40824385|NCT01632228|DRUG|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
41018375|NCT00612313|DRUG|Fluoxetine|Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
41018376|NCT00612313|BEHAVIORAL|Relapse prevention cognitive behavioral therapy (CBT)|After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
41018377|NCT03963518|DRUG|Immune checkpoint inhibitor|Immune checkpoint inhibitor
41018378|NCT06127134|PROCEDURE|peripheral angioplasty for tibial vessels|repair tibials blood vessels throughout two concepts using angioplasty ballooning
41157293|NCT06501989|DRUG|Biweekly FOLFIRI|"Irinotecan 180 mg/m2. 5-FU 400 mg/m2 on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m2 Infusion for 46 hours. Leucovorin 200 mg/m2.~Repeat every 2 weeks."
41342959|NCT03826693|DRUG|Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
41342960|NCT00713284|DRUG|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
41342961|NCT01074840|OTHER|Peanut flour|Peanut-allergic subjects will be given peanut flour in increasing amounts.
41342962|NCT03828565|PROCEDURE|ScvO2 Perioperative continue monitoring|"ScvO2 Perioperative continue monitoring with PreSep® system. If SvcO2 is less than 65% or decreases by more than 10% of its base value, the other parameters affecting ScvO2 (BIS (40-60% objective), Hb (objective\> 8g / dL), SaO2 (objective\> 94%)) are evaluated. If, after correcting for these parameters, the ScvO2 is not corrected, the preload-dependence parameters are evaluated (variation of the pulsed pressure) to guide the vascular filling: VF of 250 mL of crystalloids if PPV\> 13%, norepinephrine if PPV\<9%, reassess if PPV between 9 and 13%.~If VF or norepinephrine does not correct ScvO2 (\> 65%), a measurement of arterial lactate is performed. If lactatemia is\> 2 mmol / L, a positive inotrop is introduced after ETO if possible. If lactatemia is \<2 mmol / L, a return to the evaluation phase of the parameters influencing ScvO2 is necessary."
41489231|NCT00097877|DRUG|biphasic insulin aspart|
41489232|NCT00097877|DRUG|insulin glargine|
41489233|NCT01749917|OTHER|Exercise program|Exercise program An brief exercise session including proprioceptive and dexterity activities
41489234|NCT01749917|OTHER|Control intervention|Active upper limb range of movement exercises for 15 minutes.
40824386|NCT01632228|DRUG|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
41018379|NCT02304094|DRUG|methylprednisolone|the steroid group shall receive a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
41018380|NCT02304094|OTHER|Manual manipulation|the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
41018381|NCT05596669|DRUG|Ketamine|to examine the pain-relieving effects of ketamine vs ketamine magnesium infusion, as well as their influence on postoperative morphine consumption following nephrectomy; the secondary goal is to assess hemodynamic effects and pain severity
41036504|NCT05210192|DRUG|Lidocaine Hydrochloride 1% Solution for Injection_#2|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
41342963|NCT00846352|PROCEDURE|Variation in the time for performing bronchoscopy|The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
41342964|NCT02539524|OTHER|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
40824387|NCT01632228|DRUG|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
41342965|NCT02539524|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
40824388|NCT05783921|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"TQB2618 injection is an Anti TIM-3 (T-cell immunoglobulin and mucin domain-3) monoclonal antibody.~Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
41342966|NCT03456414|OTHER|Virtual reality exercise during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
41342967|NCT01039038|RADIATION|curietherapy and radiotherapy|boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)
41342968|NCT00564200|DRUG|Bortezomib|"PREACONDICIONAMIENTO:~* 2 cycles of 21 days : Velcade days: 1, 4, 8 and 11~* 1 cycle of 13 days : Velcade days 1, 4, 8 and 11~ACONDICIONAMIENTO:~- Day -2: Velcade~POSTRANSPLANTATION:~* 2 cycles of 21 days : Velcade days 1, 8 and 15~* 5 cycles of 56 days : Velcade days 1, 8 and 15"
41342969|NCT00564200|DRUG|dexamethasone|"PREACONDICIONAMIENTO:~- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"
41342970|NCT00564200|DRUG|Fludarabine|"ACONDICIONAMIENTO:~- Days -9 al -5: Fludarabine"
41342971|NCT00564200|DRUG|Melphalan|"ACONDICIONAMIENTO:~- Days -4 and -3: Melphalan."
41342972|NCT05934708|BEHAVIORAL|Eccentric leg extension|Participants will complete a 10 x 10 eccentric leg extension on a Cybex Norm dynamometer. Upon arrival, participants will be asked their perceived readiness to perform on a 11 point numeric rating scale. Before the running protocol a baseline blood sample will be collected, as well as passive and active delayed onset muscle soreness (DOMS), a countermovement jump. Half way through each set (i.e., after the 5th repetition) participants will be asked to rank their level of difficulty on a 11 point OMNI Res scale. This will occur during each set. Participants will have follow up blood draws, measures of muscle function (i.e, jump height) and soreness measured immediately after and 24 and 48 hours post-exercise.
41342973|NCT03073382|OTHER|Chart review|This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.
41342974|NCT00402285|DIETARY_SUPPLEMENT|lycopene supplement|
41342975|NCT00402285|DIETARY_SUPPLEMENT|fish oil supplement|
41342976|NCT00402285|OTHER|Placebo|placebos for lycopene and fish oil.
41342977|NCT05825586|DEVICE|Distilled waters based eye drops|Distilled Waters (DW)-based eyedrops
41342978|NCT01994278|DEVICE|Peri Clean|
41342979|NCT03258450|BEHAVIORAL|Psycho-behavioural intervention arm (PBI)|The first session introduces the rationale of the intervention and is designed to encourage participants to recognize the autonomous role they can play in their health and well-being. Patients will be trained on breathing as a relaxation technique. The second session focuses on building behavioural skills to manage common symptoms for colorectal cancer patients. The third session focuses on cognitive strategies to address worries and existential distress. The last session focuses on maximizing social support and applying skills learned so far in dealing with loved ones. Participants will be provided an MP3 player that contains the relaxation exercise recording and a folder with summaries of the session content.
41342980|NCT06398093|BEHAVIORAL|Self-Compassion Tool Kit|Participants will mediate, journal their reactions, exercise, and apply sleep hygiene measures over the course of four weeks.
41342981|NCT02269982|DEVICE|AR-v7 assays|
41342982|NCT05831514|OTHER|Mobile Application Supported Education Program (G-MUEP)|Parents who meet the inclusion criteria will use the Mobile Application Supported Education Program (G-MUEP).
41342983|NCT01193049|DRUG|Prednisone|Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period
41342984|NCT01193049|DRUG|Placebo|Matching placebo tablets as a single oral dose on Day 1 of each study period
41342985|NCT04642378|DRUG|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
41342986|NCT04642378|DRUG|routine insulin treatment regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
41342987|NCT02022644|DRUG|nanoliposomal irinotecan|The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
41342988|NCT00108277|BEHAVIORAL|Breathing Training-Raise CO2|while breathing 9 breaths per minute, patients are instructed to raise CO2
41342989|NCT00108277|BEHAVIORAL|Breathing Training- Lower CO2|while breathing 9 breaths per minute, patients are instructed to lower CO2
41342990|NCT02171156|DRUG|nintedanib|soft gelatin capsule
41342991|NCT00804128|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
40824389|NCT05783921|DRUG|Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
41018382|NCT04412941|BEHAVIORAL|Myofunctional exercises|"Myofunctional exercises: Respiratory rehabilitation exercises with diaphragmatic breathing, thoracic mobilization exercises and manual pompage techniques, followed by manual trigger point therapy techniques, that were identified by palpation following the guidelines provided by Travell and Simons trigger point manual, the accessory inspiratory muscles like pectoralis minor muscle, scapula elevator muscle, Sternocleidomastoid muscle.~Home oropharyngeal exercises: at every patient will be taught oropharyngeal exercises to perform at home twice a day (the duration of 15 minutes each session) involving in particular exercises for soft palate, tongue, facial and genio-glosso muscle.~The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep."
41018383|NCT04412941|BEHAVIORAL|The rules of sleep hygiene|The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep.
41018384|NCT06292143|OTHER|Advance Care Planning Toolkit|Participants or their caregivers will access the digital platform for advance care planning
41018385|NCT01221441|BIOLOGICAL|TissueGene-C|Single intraarticular injection at 3 x 10e7 cells
41018386|NCT01221441|DRUG|Normal Saline|Single intraarticular injection of normal saline as a placebo control
41018387|NCT03623958|DEVICE|Image guided Video-Assisted Thoracic Surgery (VATS) resection|Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
41018388|NCT03623958|PROCEDURE|Video-Assisted Thoracic Surgery|Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
41342992|NCT00804128|DRUG|Gadavist|Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging
41342993|NCT06043934|OTHER|Neural Mobilization with Intermittent Cervical Traction|This group will receive Neural Mobilization with Intermittent Cervical Traction along with routine physical therapy. The patient will be positioned in a supine position with 10 to 15 degrees of flexion on a comfortable treatment table. A suitable pillow will be arranged to support their head. The cervical traction device's integrity and readiness will be confirmed by the therapist. The starting weight will be about 10% of the patient's body weight, and this will slowly increase up to an appropriate level. The on-and-off times will be decided based on the patient's comfort and specific condition. Generally, a ratio of 3:1 or 4:1 (hold: rest) is used. For instance, 60 seconds of traction followed by 20 seconds of rest. The total treatment time will generally range between 15-20 minutes for 3 to 4 times per week. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).
41342994|NCT06043934|OTHER|Neural Mobilization|"This Group will receive Neural Mobilization with routine physical therapy. Each nerve glide exercise will be performed ideally around 2-3 times, depending on the patient's comfort and tolerance levels. The intensity of the exercise is governed by the degree of stretch applied to the nerve. This should be within the patient's comfort level, causing a mild stretching sensation rather than pain. Each nerve glide will be performed in a set of 10-15 repetitions. Rest periods should be provided between each repetition and set, ensuring the patient's comfort.~In median nerve glide the patient will be seated comfortably. Their arm will be guided into shoulder depression, elbow extension, forearm supination, and wrist and finger extension. The patient will then be instructed to slowly flex and extend their wrist while maintaining the other positions. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session)."
41018389|NCT06103370|BEHAVIORAL|Peer-educator-based network|The intervention is a social network-based method of dispersing HIV knowledge, HIV self-testing (HIVST) kits, and naloxone in social networks of people who inject drugs (PWID). It targets index participants (peers) to receive training on HIVST, peer education, and linkage to syringe service programs (SSPs) for HIV services.
41018390|NCT02419716|DEVICE|Cologuard|Prescription of Cologuard for at-home stool collection
41018391|NCT00461526|DRUG|crofelemer|125 mg crofelemer vs. placebo
41018392|NCT06347354|DRUG|Indocyanine green|Subdermal injection of 2,5 mg (1 cc) of ICG
41342995|NCT01976585|DRUG|rhuFlt3L/CDX-301|"rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.~RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7."
41342996|NCT01976585|DRUG|Poly-ICLC|Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
41342997|NCT01430949|PROCEDURE|Catheter Ablation of Paroxysmal Atrial Fibrillation|Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
41342998|NCT05685394|DRUG|Dapagliflozin|Dapagliflozin 10mg P.O. daily
41018393|NCT05027217|OTHER|No intervention|No intervention. Arms are subdivided based on patients' diagnostic status on admission to ICU.
41018394|NCT03282084|DIAGNOSTIC_TEST|EGD with biopsy|Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
41018395|NCT03282084|DIAGNOSTIC_TEST|EGD and impedance-pH study on PPI|Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
41157294|NCT06501989|DRUG|mFOLFOXIRI|Irinotecan 165 mg/m2. Oxaliplatin 85 mg/m2. 5-FU 2400 mg/m2 Infusion for 46 hours. Repeat every 2 weeks.
41342999|NCT02373891|DRUG|Surfolase CR|T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
41343000|NCT02373891|DRUG|Surfolase CR|T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
41343001|NCT04151719|DRUG|Methylnaltrexone bromide (MNTX)|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
40824390|NCT01294943|DEVICE|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
41489235|NCT05340777|DEVICE|Training Obstetric staff on Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to ensure staff are trained on the newly registered and provided medical device. We will gather feedback on how to improve the training curriculum from participants. We will also gather information from the healthcare workers immediately post-use of an Ellavi UBT device following their management of a refractory PPH case. These surveys will help us to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of PPH care.
40824391|NCT01779869|DRUG|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (\<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
40824392|NCT02370004|PROCEDURE|Resistive Flexibility and Strength Training|"RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions."
40824393|NCT03094078|OTHER|News item with spin|Interpretation of news item with spin
40824394|NCT03094078|OTHER|News item without spin|Interpretation of news item without spin
40824395|NCT02538419|BEHAVIORAL|CPAP + Peer Support|
41157295|NCT05534802|DRUG|Ulinastatin|On the basis of conventional treatment, according to the instructions or previous research doses (general anesthesia and tracheal intubation, after cardiopulmonary bypass transfer starts): 10,000 U/kg Ulinastatin (National Medicine Approval No. H19990134, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour and pumped through the central vein.
41343002|NCT02029391|OTHER|Manual pressure release|Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
41343003|NCT02029391|OTHER|Kinesio tape|Kinesio tape was adhered from insertion to origin of the upper trapezius muscle
41343004|NCT03278444|OTHER|Basic drugs therapy of HCC|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
40824396|NCT02538419|BEHAVIORAL|CPAP + Individual Education|
40824397|NCT03328169|BEHAVIORAL|Mindfulness-Based Therapy|Participants are taught relaxation and mindfulness techniques to practice. They also learn about various alternative medicine modalities to which they can apply mindfulness with the target of reducing insomnia. The group meets weekly for 2 hours for a duration of 9 weeks.
40824398|NCT03328169|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A licensed psychologist is delivering Cognitive Behavioral Therapy for Insomnia to women for 90-120 minutes weekly for nine weeks. The Cognitive Behavioral Therapy for Insomnia protocol is well documented in published literature.
40824399|NCT00002522|DRUG|cisplatin|
40824400|NCT00002522|DRUG|cyclophosphamide|
40824401|NCT00002522|DRUG|etoposide|
40824402|NCT00002522|PROCEDURE|autologous bone marrow transplantation|
41157296|NCT05534802|OTHER|saline|On the basis of conventional treatment, 50 ml of normal saline for 1 hour and pumped through the central vein.
41157297|NCT05008224|BIOLOGICAL|Pembrolizumab|"200 mg IV administered on Day 1 of each 3-week cycle for 3 cycles during pembrolizumab monotherapy.~400 mg IV administered on Day 1 of each 6-week cycle for 4 cycles as pembrolizumab consolidation."
41343005|NCT03278444|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
41018396|NCT03560219|DIAGNOSTIC_TEST|Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis|"Key variables that will be recorded include the following:~* Clinical~  * Age~ * Gender~ * BMI~ * Diabetes Mellitus~ * Hypertension~ * Heart Failure~ * Ischemic Stroke / TIA~ * Thromboembolism~ * Coronary Artery Disease~ * Peripheral Arterial Disease~ * Glomerular Filtration Rate~* Contrast-enhanced MRI~  o Presence and extent of atrial fibrosis~* Biomarkers~  * IL-6~ * CRP~ * D-dimer~ * Fibrinogen~* Transthoracic Echocardiography~  * LA Volume Index (LAVI)~ * LA Strain, Global~ * LA Strain rate, Positive peak, Global~ * LA Strain rate, early negative peak, Global~ * LA Strain rate, late negative peak, Global~ * LA Emptying Fraction (LAEF)~ * LVH~ * LVEF~* Endothelial function o FMD"
41018397|NCT06098820|OTHER|Vitamin D status|Four different groups will be compared with each other in terms of vitamin D effect.
41018398|NCT00399438|DRUG|Placebo|Tablets, Oral, once daily, 2 weeks
41018399|NCT00399438|DRUG|BMS-562086|Tablets, Oral, once daily, 2 weeks
41018400|NCT05277467|OTHER|no intervention|no intervention
41018401|NCT05081739|DIAGNOSTIC_TEST|Prospera Transplant Assessment|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of dd-cfDNA in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available LDT developed by Natera, Inc. Natera is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA)."
41018402|NCT05081739|PROCEDURE|Endomyocardial biopsy|Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week in months 2 and 3, then monthly through month 6, then every 1-3 months through the end of month 12.
41018403|NCT02752048|DRUG|TAS-205|2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
41018404|NCT02752048|DRUG|Placebo|1 group: Placebo group. Oral administration for 24 weeks, BID after meal
41018405|NCT01975389|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
41018406|NCT01975389|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
41343006|NCT03278444|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
41343007|NCT06272357|OTHER|Antiarrhythmic drugs|Antiarrhythmic drugs in pediatrics
41343008|NCT01936597|OTHER|Therapeutic and preventive strategies|Single set (control Arm)
41018407|NCT05513638|DIAGNOSTIC_TEST|the clinical use of artificial intelligence in the diagnosis of prostate cancer|Each study site will enroll consecutive eligible patients and randomize them to either (a) a group with human-based interpretation or (b) a group with human-artificial intelligence interactive interpretation, both of which are utilized as standards of care.
41018408|NCT01573624|DRUG|FF/GSK573719|100/15.6
41018409|NCT01573624|DRUG|FF/GSK573719|100/31.25
41018410|NCT01573624|DRUG|FF/GSK573719|100/62.5
41018411|NCT01573624|DRUG|FF/GSK573719|100/125
41018412|NCT01573624|DRUG|FF/GSK573719|100/250
41018413|NCT01573624|DRUG|FF|100
41018414|NCT01573624|DRUG|FF/VI|100/25
41018415|NCT05540223|DEVICE|DREAMS 3G RMS|Subject undergoes implantation of DREAMS 3G RMS
41018416|NCT05540223|DEVICE|Xience DES|Subject undergoes implantation of Xience DES
41018417|NCT03018353|DRUG|Patients receiving Sof/Vel (Epclusa) and Navigation services|Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
41018418|NCT05095480|DRUG|Red Yeast Rice Pill|Taking Lesstat
41343009|NCT01936597|OTHER|Therapeutic and preventive strategies|Controller
41343010|NCT01936597|OTHER|Therapeutic and preventive strategies|Audio
41343011|NCT03928340|DRUG|Metformin|"40 patients will be treated with metformin~(1 gm twice daily (with the 2 main meals)), combined with insulin therapy"
41343012|NCT03928340|DRUG|Insulin|40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)
40824403|NCT00002522|PROCEDURE|bone marrow ablation with stem cell support|
41018419|NCT05095480|DRUG|Placebo|Placebo receiving group
41018420|NCT05983653|PROCEDURE|arthrocentesis without PRP|150 ml arthrocentesis without PRP
41018421|NCT05983653|PROCEDURE|arthrocentesis with PRP|150 ml arthrocentesis with PRP
41018422|NCT05543746|DRUG|Brexanolone|Enrolled subjects will receive a 60-hour infusion of Brexanolone (BRX) according to FDA approved protocol for administration. A programmable peristaltic infusion pump will be used to ensure accurate delivery.
41018423|NCT00927017|OTHER|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
41018424|NCT00927017|OTHER|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
41018425|NCT01374113|DRUG|50mg safinamide|50 mg safinamide on Day 1
41343013|NCT03749850|DRUG|LTLD|"Patients will receive up to six cycles at three-weeks intervals of:~* Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~* 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~* Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol."
41343014|NCT03749850|PROCEDURE|MR-HIFU induced hyperthermia|"Patients will receive up to six cycles at three-weeks intervals of:~- 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour.~In case of toxicity, hyperthermia dosages will be adjusted as specified in the study protocol."
41343015|NCT03749850|DRUG|Cyclophosphamide|"Patients will receive up to six cycles at three-weeks intervals of:~- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol."
41343016|NCT00655239|BEHAVIORAL|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
41343017|NCT00655239|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
41343018|NCT06376435|DRUG|Herombopag Olamine Tablets|Herombopag Olamine；combined rhTPO;combined IL-11
41343019|NCT01831011|DRUG|mildronate injection|
41343020|NCT01831011|DRUG|cinepazide maleate injection|
41489236|NCT06447337|DIAGNOSTIC_TEST|Continous body temperature monitoring|The investigational product will be placed on the participants' body in axilar joint and connected to the mobile phone. The values of the current temperature will apear on the monitor and it will be recorded in the database with date and time for each record. In parallel, study staff will occasionally measure the temperature using standard hospital thermometer.
41489237|NCT00418301|OTHER|Precision Spinal Cord Stimulation and PET Scan|Imaging procedure to assess spinal Cord Stimulation.
41489238|NCT01714349|PROCEDURE|Nerve Transfer|A nerve transfer procedure will be individualized to each patient's functional deficit.
41489239|NCT04213872|BEHAVIORAL|Meditative Movement|The Meditative Movement program is a blend of meditation and exercise based on Tai Chi and Qigong.
41489240|NCT06337253|DRUG|Sulfadoxine/pyrimethamine plus amodiaquine|Seasonal Malaria Chemoprevention with SPAQ has not been trialed or introduced in Malawi yet. This intervention trial is different from others because of the location and because, traditionally, a full round of SMC with SPAQ that involves between 3-5 cycles is administered. Our trial is the first one that will only distribute one cycle of SMC with SPAQ. The data collected during the 42 days after SMC distribution will be used to estimate the medicines chemoprevention effectiveness at preventing malaria in children aged 3-59 months. This data, together with the resistance markers data will then be fed into a dynamical model that collaborators at Imperial College London have developed that will predic the potential impact of upscaling SMC in similar geographies.
40824404|NCT00002522|PROCEDURE|peripheral blood stem cell transplantation|
40824405|NCT00002522|PROCEDURE|syngeneic bone marrow transplantation|
40824406|NCT00002522|RADIATION|radiation therapy|
40824407|NCT04942340|DRUG|Atipamezole & Caffeine|In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
40824408|NCT04942340|DRUG|Dexmedetomidine Hydrochloride & Saline|In this arm, subjects will be infused with Precedex \& Saline at 15 mg/kg across 5 minutes
41343021|NCT01831011|DRUG|aspirin|
41343022|NCT01335594|PROCEDURE|clinical, endoscopical and manometric evaluation|clinical evaluation: questionnaire endoscopical analysis manometry
41343023|NCT06127472|OTHER|Training in detection and diagnosis of ASD|To improve detection and diagnosis of ASD the participating mental health institutes will be trained by the research group on how to detect and diagnose autism in older adults. The basis of the ASD training involves two separate training sessions. Part one focuses on recognition and detection of ASD, specifically in older adults, and will be offered to the entire teams of the participating centres. The second part of the training focuses on the diagnosis of ASD and as such is offered primarily to diagnosticians. Follow up will consist of monthly recurring options for online consultation during the entire project to discuss clinical cases by experts in ASD in older adults from PersonaCura, clinical centre of excellence for personality and developmental disorders in older adults (dr. A. Videler and R. Wilting).
41489241|NCT04430257|OTHER|HIV and PrEP education|Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.
41489242|NCT04430257|BEHAVIORAL|Motivational interviewing|Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.
41489243|NCT04430257|BEHAVIORAL|Problem-solving and planning|Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.
41489244|NCT04430257|BEHAVIORAL|Patient navigation|Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites
41489245|NCT04430257|OTHER|PrEP information|A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.
40824409|NCT02198599|PROCEDURE|Mobility-enhancing-nursing intervention|Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
40824410|NCT02376101|PROCEDURE|Surgery less than 60 minutes|
40824411|NCT02982317|PROCEDURE|Manual palpation identification lumbar spine|
40824412|NCT02982317|PROCEDURE|Automated ultrasound technology identification|This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
40824413|NCT02982317|PROCEDURE|Lumbar level identification gold standard ultrasound|
40824414|NCT06176872|DIAGNOSTIC_TEST|Cardiac Computed Tomography Angiography|Non-invasive imaging of the heart, the greater vessels and the coronary arteries using computed tomography.
40824415|NCT01757223|BIOLOGICAL|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
40824416|NCT01757223|BIOLOGICAL|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
40824417|NCT04043754|PROCEDURE|Procedure/Surgery: Periodontal surgery with Membrane|Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
41343024|NCT06127472|OTHER|PE program|An adapted PE program for older adults with a recent diagnosis of ASD. The PE program consists of seven, two-hour group meetings on a weekly basis.
41343025|NCT03083106|DEVICE|Elevoplasty|The Elevo™ Kit Snoring Intervention Device is designed to facilitate deployment of the Elevo™ suture implant into the submucosal tissue of the soft palate via a minimally invasive, outpatient procedure performed by an otolaryngologist in a medical office setting.
41343026|NCT03906591|PROCEDURE|allogenic bone ring|allogenic bone ring with simultaneous dental implant placement
41343027|NCT03906591|PROCEDURE|autogenous bone ring|autogenous bone ring with simultaneous dental implant placement
41343028|NCT00430027|DRUG|Capecitabine|Given 650 mg/m\^2 BID on days of ration therapy, 825 mg/m\^2 day 1-14, day 15-20 off x 4
41343029|NCT00430027|DRUG|Oxaliplatin|Oxaliplatin 30 mg/m\^2, 130mg/m2 IV Q 21 days x 4
41343030|NCT00430027|DRUG|Cetuximab|Initial Cetuximab 400 mg/m\^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
41343031|NCT05455840|DEVICE|Da Vinci SP surgical platform|using Da Vinci SP platform in thymothymectomy or extended thymectomy
41343032|NCT01976624|DRUG|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
41343033|NCT05153863|DEVICE|C Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
41343034|NCT02545972|DRUG|tacrolimus extended release|daily dosing of tacrolimus
41343035|NCT03518034|DRUG|AndroGel®|testosterone administered topically
41343036|NCT03518034|DRUG|Placebo|placebo administered topically
41343037|NCT06325540|PROCEDURE|indirect pulp capping with theracal pt|indirect pulp capping using the theracal pt material
41343038|NCT06325540|PROCEDURE|indirect pulp capping with therabase|indirect pulp capping using the therabase material
41343039|NCT06325540|PROCEDURE|indirect pulp capping with biodentine|indirect pulp capping using the biodentine material
41343040|NCT05119972|DRUG|ZSP1603|ZSP1603 administered orally
41343041|NCT05119972|DRUG|Placebo|Placebo administered orally
41343042|NCT02387450|DRUG|Sildenafil|100 mg per day
41343043|NCT02387450|DRUG|Placebo|Placebo with same presentation as the active drug
40824418|NCT04043754|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
40824419|NCT01760330|DRUG|IV acetaminophen|
40824420|NCT01760330|DRUG|Placebo|
41343044|NCT02918721|DEVICE|Restylane Lidocaine|Intradermal injection
41343045|NCT02918721|DEVICE|Restylane|Intradermal injection
41343046|NCT03813199|DRUG|ABX464 50mg|ABX464 is a new anti-inflammatory drug
41343047|NCT03813199|DRUG|Matching Placebo|placebo matching with ABX464
41343048|NCT03813199|DRUG|ABX464 100mg|ABX464 is a new anti-inflammatory drug
41343049|NCT03813199|DRUG|Methotrexate|MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
41343050|NCT02561676|OTHER|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
41343051|NCT02561676|OTHER|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
41343052|NCT01657227|BEHAVIORAL|Intervention to patients|"Multifaceted intervention consisting of:~* Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.~* Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.~* Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change."
41018426|NCT03663075|BEHAVIORAL|Group information (GI)|The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.
41018427|NCT03663075|BEHAVIORAL|Structured person-centered support (PCS)|The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
41343053|NCT01657227|BEHAVIORAL|Intervention to professionals|"Multifaceted intervention consisting of:~* Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.~* Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.~* Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional."
41018428|NCT05357391|DEVICE|The Pressure Injury Prediction and Education model using a mobile application system|Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
41343054|NCT01657227|OTHER|Usual care|Usual care for T2DM received in primary health care
41343055|NCT04093206|DIETARY_SUPPLEMENT|EpiCor and Vitamin C|One daily dose
41343056|NCT04093206|DIETARY_SUPPLEMENT|Vitamin C|One daily dose
41343057|NCT02415504|BEHAVIORAL|Enhanced care transition|Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
41343058|NCT02415504|BEHAVIORAL|Standard care transition|Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
40824421|NCT00004480|DRUG|botulinum toxin type A|
41343059|NCT00041704|DRUG|Anidulafungin, VER002|
41489246|NCT04430257|OTHER|Referrals|Study staff will provide basic information about PrEP and referrals to PrEP clinicians.
41489247|NCT01325727|OTHER|Brief computerized feedback|Brief computerized feedback
41489248|NCT01325727|OTHER|Resources only (control)|Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
40824422|NCT05728151|DRUG|Articaine and Epinephrine Only Product|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
40824423|NCT05728151|DRUG|levobupivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
41343060|NCT03505957|DEVICE|SafeBreak Vascular|SafeBreak Vascular will be installed in all the IV lines of consenting participants for up to 7 days.
41343061|NCT01855204|RADIATION|Computed tomographic urography|Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
41018432|NCT03709550|DRUG|Decitabine|Given IV
41018433|NCT03709550|DRUG|Enzalutamide|Given PO
41343062|NCT04348136|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
40824424|NCT05728151|DRUG|mepivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and in peribulbar block on postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
40824425|NCT04453085|DRUG|JR-171 (lepunafusp alfa)|IV infusion
40824426|NCT00608023|DRUG|Tesamorelin|
41343063|NCT02880735|DEVICE|Non Invasive Ventilation.|Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
41343064|NCT01704976|DEVICE|SR-WBV|Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
40824427|NCT00608023|DRUG|Placebo for Tesamorelin|
41343065|NCT01704976|DEVICE|SR-WBV|Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
40824428|NCT05291975|DEVICE|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
40824429|NCT05291975|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
41018434|NCT05750524|OTHER|reflexology hand massage|Reflexology massage methods applied randomly to both trial groups.
41018435|NCT05750524|OTHER|classical hand massage|Classical hand massage methods applied randomly to both trial groups.
41343066|NCT04709094|DRUG|Danicopan|Danicopan was dosed as 2 x 100 milligram (mg) tablets.
41343067|NCT04709094|DRUG|Warfarin|Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).
41018436|NCT01099124|DRUG|M2ES|polyethylene glycol rh recombinant endostatin
41018437|NCT04448561|DRUG|ASP8082|oral
41018438|NCT04448561|DRUG|morphine|oral
41018439|NCT04448561|DRUG|Placebo|oral
41018440|NCT06440707|DEVICE|High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)|The active study treatment involves delivering a weak form of electrical stimulation via 5 small electrodes to the brain tissue at risk of infarction.
41018441|NCT06440707|DEVICE|Sham tDCS|Sham patients will have cap and electrodes in place, but no stimulation will be delivered.
41018442|NCT00903838|DRUG|pardoprunox|1.5 to 12 mg/day
41343068|NCT04709094|DRUG|Bupropion|Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.
41343069|NCT04709094|DRUG|Ethinyl Estradiol/Norethindrone|EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
41343070|NCT00537771|DRUG|Anastrozole|1 mg once daily oral dose
41343071|NCT00537771|DRUG|Tamoxifen|20 mg once daily oral dose
41343072|NCT00411840|PROCEDURE|intraarterial and intramuscular injection of BMCs|
41343073|NCT01666353|RADIATION|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)|PET/CT imaging with \[18F\] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
41343074|NCT06450808|DIETARY_SUPPLEMENT|Dried Microalgae biomass|The products to be tested are pestos enriched with different amounts of the microalgae Phaeodactylum tricornutum (3, 4 and 5%). After drying, the microalgae Phaeodactylum, which has already been used in two previous applications (application german ethic F-2020-001), is added to the pesto. Three different pestos will be produced and enriched with different amounts of the microalgae Phaeodactylum.
41343075|NCT00572312|DRUG|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
41343076|NCT02805894|DRUG|NBTXR3 activated by IMRT only|Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
41343077|NCT02805894|DRUG|NBTXR3 activated by Brachytherapy & IMRT|Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy \& IMRT treatment
40824430|NCT05788588|DRUG|HR19006|An emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume, administered via a central venous line over a time period of approximately 15 hours per day.
41343078|NCT00024674|DRUG|SS1(dsFv)-PE38|
41018443|NCT00903838|DRUG|pramipexole|0.75-4.5 mg/day
41343079|NCT01866813|BEHAVIORAL|Cognitive training intervention group|The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
41343080|NCT01962467|DRUG|FF/LEV FDC|Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
40824431|NCT05788588|DRUG|All-in-one parenteral nutrition|Trial participants are prescribed TPN by the attending physician, which will be administered via a central venous line over a time period of approximately 15 hours per day. The formulation is an emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume (nitrogen content, heat and liquid quantity as equal as HR19006).
40824432|NCT03292419|PROCEDURE|Topography-guided LASIK|LASIK surgery
40824433|NCT04061954|BEHAVIORAL|Comprehensive family intervention including individual sessions of FORNET|"Families in the intervention group received:~1. Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~2. Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~3. Trauma-focused therapies (FORNET), which aim also at reducing violent behaviour~4. Parents receive training regarding agriculture and micro credit projects, and financial assistance~5. One child per family receives a social skill training group preparing them for returning to school~6. Access to schools and school material~7. If needed medical assistance is provided~8. If needed legal assistance is provided"
41018444|NCT05379829|DRUG|Ziltivekimab|Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).
41343081|NCT01962467|DRUG|FF|Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
41343082|NCT01962467|DRUG|LEV|Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
41343083|NCT04251195|BEHAVIORAL|Cognitive Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
41343084|NCT04251195|BEHAVIORAL|Active Control Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
41343085|NCT04931550|DEVICE|Pacemaker implantation|Different pacing sites will be chosen according to the patients condition.
41018445|NCT05379829|DRUG|Placebo|Participants will be administered 3 doses s.c. Q4W.
41018446|NCT05369221|DEVICE|ReSpace™|All of the subjects will be injected with ReSpace™ hydrogel.
40824434|NCT03905369|OTHER|Decision aid and SDM booster|The investigators develop the decision aid and SDM booster. The scope of the investigators of decision making combines the clinical and patient perspective. The decision aids are developed for patients with TC either newly diagnosed or patients with advanced disease, presently in the follow-up at the participating centers, covering the whole treatment trajectory of these patients (Figure 4). Three treatment decisions are considered: 1) the extent of thyroid resection, 2) the use of RAI, and 3) the initiation of TKIs.The SDM-booster is developed alongside the decision aids, as the SDM-booster (or values clarification exercise) is often a component developed together with a decision aid. The SDM-booster aims to shape patients' values regarding aspects of the decision and ensuing treatment preferences.
40824435|NCT03905369|OTHER|Deliberation training|The investigators develop the deliberation training. It makes physicians more aware and responsive to patients' values. The communication training for physicians will consist of 1) an e-learning SDM-training lasting 40 minutes and, 2) an individual values deliberation training lasting 2 hours.
40824436|NCT05664347|BEHAVIORAL|Verbal teach to goal education|Participants were showed how to use correctly their inhalers and then asked again to show the technique. For each incorrect step, the patients were corrected and asked to repeat the steps until they mastered the technique. This process was repeated a maximum of three times.
40824437|NCT05664347|BEHAVIORAL|Video based teach to goal education|Participants were educated by the a video-based teach to goal method. using a smartphone, an educational video illustrating the correct technique for each of the inhalers used by the patient was displayed. After watching the video, the patients were asked to show again how to use their inhaler and for each wrong step the video was displayed again until mastering the correct technique a maximum of three times. At the end of the interview participants in the intervention group received a copy of the video via WhatsApp and were all invited to watch the video whenever needed.
40824438|NCT06036160|OTHER|Integrated care|Psychiatric follow-up, cognitive behavioral therapy, physical exercise, psychoeducation
40824439|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
40824440|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
41018447|NCT06102876|OTHER|Physical activity (PA) program|The PA program is specific for each patient according to their mobility profile assessed using a decision tree comprising 3 tests: 1) the number of repetitions in the 30-second sit-to-stand test, 2) the score in the Short Physical Performance Battery (SPPB) test and 3) grip strength. The PA program has to be performed once daily.
41018448|NCT05508334|DRUG|RC88|Every 2 weeks for a maximum of 2 years
40824441|NCT03114436|OTHER|Observational Data Collection|All aspects of deceased donor care in the ICU.
41018449|NCT05841017|BEHAVIORAL|Psychotherapy with Immersive Virtual Reality support.|Psychoeducational group intervention and cognitive behavioural therapy individual intervention.
41018450|NCT00304070|DRUG|Cisplatin|Given IV
41018451|NCT00304070|PROCEDURE|Conventional Surgery|Patients undergo surgery
41018452|NCT00304070|DRUG|Doxorubicin Hydrochloride|Given IV
41018453|NCT00304070|DRUG|Etoposide|Given IV
41018454|NCT00304070|BIOLOGICAL|Filgrastim|Given subcutaneously
41018455|NCT00304070|DRUG|Mitotane|Given orally
41018456|NCT00304070|BIOLOGICAL|Pegfilgrastim|Given subcutaneously
41018457|NCT00051116|DRUG|CC-5013|
41018458|NCT01974050|BEHAVIORAL|Text message surveillance|
41018459|NCT04025814|DEVICE|CaregiverAssist|CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.
41343086|NCT02314286|DRUG|Rosuvastatin|Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
41343087|NCT02314286|DRUG|Placebo|
41018460|NCT04025814|BEHAVIORAL|Behavioral Parent Training (CLS Parent Group)|Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff
41018461|NCT02634294|DRUG|Peg interferon alfa-2b|Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1\~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
41018462|NCT00666367|DRUG|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
41018463|NCT00666367|DRUG|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
41018464|NCT00760279|DRUG|Azithromycin|
41343088|NCT01066650|DEVICE|Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)|Drug eluting Stent
41018465|NCT00936026|DRUG|Neramexane|Drug-Drug Interaction Study
41018466|NCT06521346|PROCEDURE|Active cycle breathing technique|The ACBT was included if it was described as containing three essential components: 1) breathing control, 2) FET and 3) thoracic expansion exercises. The technique may also include postural drainage (PD) or percussion/shaking.
41018467|NCT06521346|PROCEDURE|Routine care|Routine care delivers after extubating such as percussion or chest physiotherapy
41343089|NCT01066650|DEVICE|Xience V (Everolimus-eluting stent)|Drug eluting stent
41343090|NCT05796349|DIAGNOSTIC_TEST|multifrequency EIT-based for detecting intracranial abnormalities|For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps.MFEIT image sequences were obtained according to certain imaging algorithms.
41343091|NCT06005038|BEHAVIORAL|pSOPT|computerized cognitive training practicing speed of processing, the difficulty will be adjusted based on real-time monitored RMSSD (parasympathetic nervous system signals)
41343092|NCT06005038|BEHAVIORAL|MLA|computerized mental leisure activities on cross-word puzzle, Sudoku, and solitaire; ECG will also be applied.
41343093|NCT00744731|DRUG|placebo|placebo for 1 week
41343094|NCT00744731|DRUG|carisbamate|400 mg/day to 1,200 mg per day
41343095|NCT04369872|PROCEDURE|Microwave ablation|Microwave ablation of lung lesion using Solero Microwave Tissue Ablation system.
40824442|NCT03030495|DEVICE|Comprehensive physiologic evaluation|Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
41343096|NCT01253967|PROCEDURE|Collection of stool samples|Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.
40824443|NCT03030495|DEVICE|Intravascular imaging devices|Intravascular ultrasound or optical coherence tomography
40824444|NCT00521430|BIOLOGICAL|anti-thymocyte globulin|
40824445|NCT00521430|DRUG|busulfan|
40824446|NCT00521430|DRUG|cyclosporine|
40824447|NCT00521430|DRUG|fludarabine phosphate|
40824448|NCT00521430|DRUG|methotrexate|
40824449|NCT00521430|DRUG|methylprednisolone|
41343097|NCT01253967|OTHER|Health economics questionnaire|For a subset of subjects, additional economic data will be gathered by completing a questionnaire
40824450|NCT00521430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40824451|NCT00521430|PROCEDURE|peripheral blood stem cell transplantation|
40824452|NCT01297361|OTHER|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
41343098|NCT02484040|RADIATION|Two-week course of radiation|33 Gy in 10 fractions for 2 weeks
41343099|NCT02484040|DRUG|Two-week course of radiation|oral capecitabine, 825mg/m2, bid
41343100|NCT04130100|BIOLOGICAL|Low Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
41343101|NCT04130100|BIOLOGICAL|High Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
41343102|NCT04130100|DRUG|Sodium Hyaluronate|Sodium Hyaluronate injection
40824453|NCT00929188|DRUG|JNJ-42160443|Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
40824454|NCT00929188|DRUG|Placebo|Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
41018468|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
41018469|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg|Amlodipine 10mg+Valsartan 160mg
41157298|NCT05008224|DRUG|Doxorubicin|"25 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET scan 2 and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).~35 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive, \<60 years of age)."
41157299|NCT05008224|DRUG|Vinblastine|6 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
41343103|NCT06321640|GENETIC|Cohort A: primarily operable disease, candidate to adjuvant|This cohort includes any patient with nonmetastatic disease, candidate to surgery as primary treatment, for whom adjuvant therapy with targeted or immune therapy is recommended based on prior information obtained on the diagnostic biopsy. This cohort represents a control group, for whom high-throughput DNA/RNA sequencing is considered feasible in the vast majority of cases, and will not be considered in the computation of the primary endpoint
41018470|NCT03639480|DRUG|Valsartan 160mg+Atorvastatin 40mg|Valsartan 160mg+Atorvastatin 40mg
41018471|NCT05434897|DRUG|AK3280 Cream|Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
41018472|NCT05434897|DRUG|Placebo cream|Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
41343104|NCT06321640|GENETIC|Cohort B: locally advanced disease|Patients in this cohort are eligible if diagnosed with or highly suspected of locally advanced (nonmetastatic) neoplasm and candidate to a diagnostic/confirmatory biopsy and subsequent treatment with targeted therapy, immune therapy or radiotherapy, where the treatment is administered with potentially curative intent. Patients in this cohort may be considered for enrolment prior to a formal diagnosis, so the study should be offered on the basis of a high suspicion of invasive cancer upon radiological evidence.
41343105|NCT06321640|GENETIC|Cohort C: metastatic disease|In this cohort, patients are eligible if diagnosed with invasive cancer with radiologically proven metastatic localization and candidate to treatment with targeted or immune therapy.
41343106|NCT06321640|GENETIC|Cohort D: Progressive disease|In this cohort, patients are eligible if a tumor biopsy is considered indicated by the referring physician upon disease progression to prior treatment in the metastatic setting or for hematological neoplasms. Definition of progression is based on the investigator's judgement and does not strictly require RECIST 1.1 definition, although all relevant radiological data will be collected whenever possible. Tumor biopsy must be collected no more than 6 months after the documented date of progression.
41343107|NCT06321640|GENETIC|Cohort E: Hematological neoplasms|Any patient that is expected to be treated with targeted agents. Special consideration will be given to patients affected by chronic lymphoid leukemia and follicular lymphoma treated with BTKi, PI3Ki, BCL-2i +/- monoclonal antibodies. Any patient that is expected to be treated with immunotherapy. Special consideration will be given to patients affected by Hodgkin lymphoma and Diffuse Large B-cell lymphoma treated with ICIs, Tafasitamab/Lenalidomide, immunoconjugates.
41343108|NCT06321640|GENETIC|Cohort F: Toxicity|In this cohort, patients are enrolled upon experiencing an adverse event of grade 3/4 as per CTCAE v 5.0 that, in the opinion of the investigator, is unequivocally caused by a targeted or immune therapeutic. The event may occur at any time after the last dose of the drug. Events may be of any nature but particular attention will be given to those events for which pathophysiology is currently poorly understood (severe myocardial or neurologic Immune-related events or DS-8201-induced pneumonitis)
41343109|NCT00000768|DRUG|Glutamic acid hydrochloride|
41343110|NCT00000768|DRUG|Ganciclovir|
41343111|NCT01723202|DRUG|dabrafenib|150 mg orally twice daily given orally
41343112|NCT01723202|DRUG|trametinib|150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally
41343113|NCT01723202|OTHER|Correlative Studies|"1. Signaling inhibition studies in tumor biopsies (10 pts in each arm; 5 pts per center)~2. BRAF mutation studies in circulating plasma DNA (all study patients)~3. Mechanisms of drug resistance in tumor biopsies or tumor blocks (5 pts in each arm)~4. Assess predictors of response (Archival tumor block/unstained slides in all study patients)~5. Pharmacokinetic studies (First 10 pts enrolled on each arm)~6. Pharmacogenomics studies (All study patients)"
41343114|NCT05596474|DIETARY_SUPPLEMENT|Beet-root juice|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.
41157300|NCT05008224|DRUG|Dacarbazine|375 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
41489249|NCT05134506|BEHAVIORAL|Dance for PD® classes|The intervention consisted of 16 60-min classes, performed twice weekly over a period of 8 weeks and instructed by a single researcher who had the approval to use it for research reasons.
41489250|NCT02418143|DEVICE|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
41343115|NCT05596474|RADIATION|red-light therapy|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.
41343116|NCT05596474|DIETARY_SUPPLEMENT|Placebo|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.
41343117|NCT05596474|RADIATION|sham light|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.
41343118|NCT02011672|OTHER|nutrient-enriched milk|
41343119|NCT02011672|OTHER|regular milk|
41343120|NCT04572893|DRUG|danicamtiv|Myosin activator
41343121|NCT03597789|BEHAVIORAL|Helping the Noncompliant Child (HNC)|HNC is a mastery-based, family-focused, clinic-based treatment for young children aged 3-8 years with problem behavior.
41343122|NCT02329860|DRUG|Apatinib|
41343123|NCT02329860|DRUG|Placebo|
41343124|NCT04324476|DRUG|Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine|Drug: Bevacizumab 5mg/kg, iv, 30min, d1, 2w; Drug: Oxaliplatin 85mg/㎡, iv, 120min, d1, 4W; Drug: Irinotecan 150mg/㎡, iv, 90min, d15, 4w; Drug: Capecitabine 1000mg/㎡, bid, d2-8, 2w.
41343125|NCT04915872|PROCEDURE|Blood sampling (T0, inclusion)|Blood sample (5 ml) at 30 minutes after the loading dose of 4g/0.5g over 30 minutes for therapeutic drug monitoring at peak concentration (Cmax)
41343126|NCT04915872|PROCEDURE|other samplings (T1)|"- T1 : Day of the first surgical revision, under PTZ administered by continuous infusion : Blood sample (5 ml) for therapeutic drug monitoring at steady state concentration (Css).~Urinary sample and collection of urinary volume between T0 and T1 (Urinary Clearance) NPT fluid sample and collection of NPT volume between T0 and T1 (Peritoneal Clearance) Peritoneal sampling for therapeutic drug monitoring at the site of infection (CPt)"
41489251|NCT00044421|DRUG|Ruboxistaurin mesylate|
41489252|NCT04815330|OTHER|increment sweep gas flow|If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.
41489253|NCT04815330|OTHER|non-invasive ventilation|In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved.
41489254|NCT06111274|DRUG|Pimicotinib (ABSK021)|The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.
41343127|NCT04072536|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
41343128|NCT04072536|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
41343129|NCT05756205|DEVICE|Immersive Virtual Reality (IVR)|"The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation. It consists of three modules that can be chosen completely or separately.~The aspects that conform this intervention will be: information about, the most common perinatal mental health problems, exercises based on attention to breathing (mindfulness-relaxation), 6 weeks of duration, for 14 minutes a day, knowledge from involved personnel of the number of times the woman has connected and the time she has done the exercise, satisfaction questions to pregnant women after pregnancy, alerts to notify the principal investigator if there is a problem with e-health, and, finally, an email address to contact the principal investigator."
41018473|NCT00125827|DRUG|clofarabine (oral formulation)|Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
41343130|NCT02429349|PROCEDURE|surgery|Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
41018474|NCT00078390|DRUG|S-3304|S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
41018475|NCT00078390|OTHER|Chemo-irradiation|Standard of care chemo-irradiation
41018476|NCT01867684|OTHER|Psychotherapy|
41018477|NCT06222255|PROCEDURE|Transanal Irrigation (TAI)|The combination of transanal irrigation (TAI) and Loperamide (Lopmin®) involves administering Loperamide orally, with a daily dosage of 2 mg for males (2 tablets once daily) and 1 tablet for females (1 tablet once daily). This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate symptoms associated with LARS (Low Anterior Resection Syndrome).
41018478|NCT04201288|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|Acceptance-Based Behavior Therapy (ABBT) In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified barriers to retention in care. Interventionists will help participants identify potential challenges to acceptance, including disclosure concerns. At the second session, participants will practice acceptance-based coping skills and a behavioral plan will be developed to target barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage their HIV.
41018479|NCT04201288|BEHAVIORAL|Enhanced-Treatment-as-Usual (ETAU)|ETAU will consist of two brief sessions lead by study interventionists, performed at the same times and by same methods as ABBT. Topics of education include safe sex practices, review of treatment options, and review of HIV-related indices of health.
41157301|NCT05008224|DRUG|Bleomycin|10 units/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
41157302|NCT05008224|DRUG|Etoposide|200 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Days 1-3 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
41343131|NCT05180604|BEHAVIORAL|experience learning programs of eHealth care|The experience learning programs of eHealth care was included six sections of activities. Six activities were conducted based on eHealth literacy framework and experience learning theory to improve patients' abilities to engage in eHealth care service. The outcome indicators were eHealth literacy, patient health engagement, the acceptance of eHealth care, eHealth usage status, and their learning experience
41343132|NCT02433691|OTHER|simultaneous aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
41343133|NCT02433691|OTHER|sequential aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
41343134|NCT02433691|OTHER|stretching and toning|anaerobic stretching and toning followed by memory training.
41343135|NCT01880203|PROCEDURE|aspiration in thyroid node for Molecular Cytogenetic Analysis.|
41343136|NCT01779895|DIETARY_SUPPLEMENT|Lactobacillus paracasei probiotic strain|
41343137|NCT01779895|DIETARY_SUPPLEMENT|Placebo|maltodextrin
41343138|NCT01631292|DIETARY_SUPPLEMENT|600 IU Vitamin D3|Once daily
41343139|NCT01631292|DIETARY_SUPPLEMENT|2000 IU Vitamin D3|Once daily
41343140|NCT01631292|DIETARY_SUPPLEMENT|4000 IU Vitamin D3|Once daily
41343141|NCT03455634|DEVICE|Twin Block|functional appliances for the stimulation of the mandibular growth
40824457|NCT00810485|DRUG|ADX10059|oral administration
41018480|NCT06329154|DEVICE|Extracorporeal shock wave therapy|The experimental group received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. The control group was only given conventional rehabilitation therapy. According to the patient's tolerance and the specific condition, extracorporeal shock wave therapy was performed twice a week, 2000-3000 times each time, energy parameters of 2.5-3.5Bar, 8-15Hz, treatment interval \> 1 day, consecutive 4 weeks. Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser and wax therapy. Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
41018481|NCT06329154|OTHER|conventional rehabilitation therapy|Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser, and wax therapy (same as the control group). Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
40824458|NCT00810485|DRUG|ADX10059|oral administration
40824459|NCT00810485|DRUG|ADX10059|oral administration
40824460|NCT00810485|DRUG|ADX10059 Matching Placebo|oral administration
40824461|NCT06445764|OTHER|e-learning|Participants will complete an e-learning course over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This course prepares participants for an in-person assessment.
40824462|NCT06445764|OTHER|Virtual reality training|Participants will complete a virtual reality training over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This training prepares participants for an in-person assessment.
40824463|NCT06606119|OTHER|Data and tissue collection|Collection of bone marrow, blood, feces, medical record data, and patient response surveys.
40824464|NCT03409211|DIETARY_SUPPLEMENT|PEVCO|All subjects will receive PEVCO for 6 more weeks.
40824465|NCT03409211|DIETARY_SUPPLEMENT|Dietary Supplement Capsules without Coconut Oil|All subjects will receive placebo (PBO) for 3 weeks
40824466|NCT04194736|OTHER|Ultrasound scan|"First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan."
40824467|NCT05180318|DRUG|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
40824468|NCT05180318|DRUG|0.9% saline|0.9% saline
41018482|NCT04122001|DEVICE|Active HD-tDCS|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (angular gyrus). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
41018483|NCT04122001|DEVICE|Sham|Current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.
41343142|NCT03455634|DEVICE|Sander bite jumping appliance|functional appliances for the stimulation of the mandibular growth
41343143|NCT01710904|DRUG|Targinact® (oxycodone/naloxone)|
41489255|NCT01404715|DRUG|Metformin|Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
40824469|NCT01110837|OTHER|Allergen|Allergen nasal challenge
40824470|NCT01110837|OTHER|Placebo challenge|Placebo nasal challenge
40824471|NCT03112525|DIAGNOSTIC_TEST|CYP3A4/5 and P-gp phenotyping|Phenotyping using a simplified version of the Geneva cocktail
40824472|NCT03112525|GENETIC|CYP3A4/5 and P-gp genotyping|Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
40824473|NCT02682589|PROCEDURE|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
41343144|NCT00366938|DRUG|Lumiracoxib|
41343145|NCT04576416|OTHER|AI augmented training and clinical feedback|"The educational platform has two modules:~The training module includes AI enhanced case training on a library of 10,000+ benign and malignant skin lesion cases each coupled to written learning modules. Participants will be able to track their progression through automatically generated performance statistics and discuss difficult cases with peers within the application.~Clinical feedback is defined as diagnostic feedback on all cases registered in the registration module. Feedback during the trial will be based on either histopathology or the consensus agreement of domain experts (if no biopsy is taken). Feedback on referred or dismissed skin lesions will be provided by independent experts in skin cancer diagnostics ( \>10 years of experience) through a web-based review system developed by our group."
41343146|NCT02490904|DRUG|Eplerenone|Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
41343147|NCT02490904|DRUG|Placebo|Double-blinded Placebo administered for 4 days at 25mg every 12 hours
40824474|NCT02682589|PROCEDURE|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
40824475|NCT06086860|OTHER|Mulligan mobilization with dry needling.|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
40824476|NCT06086860|OTHER|Mulligan mobilization without dry needling|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
41343148|NCT06347965|BEHAVIORAL|Low load blood flow restriction training|Low load blood flow restriction training will be conducted on the subjects three times a week. Each training session includes upper and lower limb training, with 4 groups trained and repeated 30, 15, 15, and 15 times for each group. Train for a total of 12 weeks.The resistance strength will remain at 30% RM for weeks 1-12.
41489256|NCT01404715|DRUG|Imatinib|A single oral dose of 600 mg of imatinib
40824477|NCT06420362|OTHER|Blood Flow Restriction|"Before BFR training, a repetition maximal (1-RM) test will be determined by selecting a weight with which athletes can perform a maximum of 10 repetitions. The number of repetitions obtained here and the weight lifted will be written into the Brzycki formula, whose validity and reliability has been proven, and 1-TM will be calculated.~Brzycki formula; 1-TM = \[100 x (Weight Lifted) / \[(102.78 - 2.78 x (Number of Reps)\] The arterial occlusion pressure of the participants will be measured with a Doppler Ultrasound device by increasing the cuff to the point where the auscultatory pulse of the brachial artery ceases until occlusion occurs in the brachial artery. Then, 60% of this value will be calculated and BFR will be performed during the exercises."
40824478|NCT03390478|OTHER|Combined Intervention Group|Experimental: Combined Intervention Program is composed by a Cognitive Stimulation Program (CSP), a Physical Activity Program (PAP) and Animal Assisted Therapy (AAT). During the PAP participants that use rolling-walkers, will do PAP using the Auto-Blocking kit mechanism for rolling walkers (ABMRW).
40824479|NCT00502723|PROCEDURE|Radical retropubic prostatectomy|Radical retropubic prostatectomy
40824480|NCT00502723|PROCEDURE|Radical laparoscopy prostatectomy|Radical laparoscopy prostatectomy
40824481|NCT03994887|DEVICE|Experimental group|EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
40824482|NCT03468816|DEVICE|Sensor activation (on DryMax Extra Soft)|Study profile of sensor activation
40824483|NCT06036017|OTHER|Earplugs|There are numerous studies that suggest using earplugs can regulate a patient's sleep and may reduce the risk of delirium (Locihova 2017) (Van Rompaey 2012). However, there is no hard and fast rule concerning the duration, timing, and preference of earplug use. The duration of earplug use may vary and will be determined based on the needs of the patient, and it will be ensured that they are used throughout the night (Rompaey 2012).
40824484|NCT06036017|OTHER|Music Therapy|Music therapy will be applied to help the patient relax and fall asleep. Moreover, the choice of music genre will be suitable for the patient's preferences, and it will be ensured that it is played at a low volume. Specific guidelines will be applied regarding the frequency and duration of music therapy, it will be performed twice a day after surgery at a low volume and via headphones, each session lasting 30 minutes (Sibenda A et al. 2019).
41018484|NCT04122001|OTHER|Word List Learning Intervention (WordLLI)|Participants will receive a word list learning intervention (WordLLI) of semantically related and unrelated word lists. Word lists are presented across 10 trials, with an additional trial after a 10-minute delay to assess delayed recall. Immediately following verbal presentation of word lists during each trial, participants will be instructed to recall as many of the words from the list as possible. Participants may use the written modality as a strategy during recall. Word lists include 12 words matched based on psycholinguistics attributes (e.g., imageability, frequency). This task is designed to help participants improve memory via enhancing list learning capabilities.
41489257|NCT04580121|DRUG|RO7283420|RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
41018485|NCT04466514|DRUG|ASTX029|Form: tablet; Route of Administration: oral
41018486|NCT06573775|DEVICE|pulsed ultrasound|treatment of myofacial trigger points with therapeutic ultrasound
41018487|NCT06573775|OTHER|myofascial release|manual massage and range of motion exercises
41018488|NCT06573775|DEVICE|lidocaine phonophoresis|transdermal tranmission of lidocaine molecules via ultrasound
41489258|NCT04580121|DRUG|RO7283420|RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.
41018489|NCT00228449|DRUG|peginesatide|
41018490|NCT01470027|DRUG|N-acetylcysteine|900mg NAC effervescent tablets
41018491|NCT01470027|DRUG|Placebo|effervescent tablets
41489259|NCT04580121|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion 8 mg/kg (for participants with a weight of 30 kg and above) and 12 mg/kg (for participants with a weight of less than 30 kg). Tocilizumab will be given as rescue medication.
41343149|NCT06347965|BEHAVIORAL|Progressive resistance training group|The subjects will undergo progressive resistance training three days a week, three groups per day, with each group repeating 10 times. Training includes upper and lower limbs. The resistance load increases over time, with a resistance load of 30% RM for weeks 1-4, 50% RM for weeks 5-8, and 70% RM for weeks 9-12.
41343150|NCT01407289|DRUG|Insulin Aspart, Insulin Glargine|The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
41343151|NCT03931889|DIETARY_SUPPLEMENT|Vitamin D3|Cap. Cholecalciferol 40,000 IU
41343152|NCT03216980|DIETARY_SUPPLEMENT|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
41343153|NCT03216980|DIETARY_SUPPLEMENT|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
41343154|NCT03216980|DIETARY_SUPPLEMENT|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
40824485|NCT06036017|OTHER|Presence of Family After Extubation:|According to the guidelines titled 'Family presence and visit in Adult ICU' published by the American Association of Critical Care Nurses (AACN) in 2012; it is recommended that a family member or friend chosen by the patient be present to provide 24-hour uninterrupted emotional and social support for patients in intensive care. Allowing the patient's family to visit helps maintain the patient's social connections and contributes to the psychological well-being of the patient with family support. In addition to routine visits, patients' families can spend longer periods with the patient during their intensive care process and information about the patient is conveyed to close family members. Research shows that family presence in the intensive care unit reduces the incidence of delirium (Eghbali-Babadi, 2017) (Rosa 2017).
41157303|NCT05008224|DRUG|Cyclophosphamide|1250 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
41343155|NCT03216980|DIETARY_SUPPLEMENT|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
41343156|NCT02932319|DEVICE|Foley catheter|The Foley cathter will be inserted at term + 4 days for 24 hours.
41343157|NCT02932319|OTHER|expectative|expectative until the next day befor starting the induction
41343158|NCT05023460|DEVICE|Paresthesia-free (burst) ONS|Stimulation intensity target of 60% of paresthesia threshold.
41343159|NCT05023460|DEVICE|Placebo|ONS system deactivated
41343160|NCT05486065|DRUG|Semaglutide|Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
41343161|NCT05486065|DRUG|Placebo|Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
41489260|NCT04580121|DRUG|Dasatinib|Dasatinib 100 mg film-coated tablets will be administered daily until symptom resolution (up to 100 mg twice daily \[BID\] for a maximum 3 days); orally. Dasatinib will be given as rescue medication.
41489261|NCT04580121|DRUG|Dexamethasone|20 mg IV of dexamethasone will be administered as pre-medication at least 60 minutes prior to the all RO7283420 infusions or injections during cycle 1.
41343162|NCT00794469|OTHER|Water|Children will drink 10 cc/kg of cold water(4 degrees centigrade)
41489262|NCT04580121|DRUG|Paracetamol/acetaminophen|500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
41489263|NCT04580121|DRUG|Diphenhydramine|25 mg or 50 mg of diphenhydramine will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
41489264|NCT05249530|OTHER|Chiropractic spinal adjustment|Chiropractic spinal adjustment
41489265|NCT05249530|OTHER|Non-force simulation|Non-force simulation
41489266|NCT02438852|OTHER|Placebo|Given IV
40824486|NCT00060814|OTHER|Combined intervention|300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
41343163|NCT05892536|PROCEDURE|dental regenerative endodontics|regenerative procedures performed in necrotic mature permanent teeth
41343164|NCT04938089|OTHER|Maintenance|Regular compliant individual is defined in the study as a subject attending 100% of his/her recall visits with a maximum interval of 6 months. Irregular compliant individual is defined as a subject who missed at least one of the recall visits but continued to appear on an irregular basis with a maximum interval of 18 months, non-smoker individual is defined as a subject who never smoked, and lastly, smoker individual is defined as a subject who is smoking \> 9 cigarettes per day.
41343165|NCT04001660|PROCEDURE|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
41343166|NCT02224937|DRUG|Melatonin|
41343167|NCT02224937|DRUG|Placebo|
41489267|NCT02438852|OTHER|Questionnaire Administration|Ancillary studies
41489268|NCT02438852|DRUG|Ropivacaine Hydrochloride|Given IV
41489269|NCT00899470|DRUG|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
41489270|NCT00899470|DRUG|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
41343168|NCT02644694|DRUG|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
41343169|NCT00922519|OTHER|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 6 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
41343170|NCT02774291|BIOLOGICAL|Aldesleukin|Given IV
40824487|NCT03135444|BEHAVIORAL|PSA TOOL|Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.
40824488|NCT03135444|BEHAVIORAL|Revised PSA TOOL|Patients will be given the revised PSA TOOL, after providers have given their initial feedback.
41343171|NCT02774291|BIOLOGICAL|Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Given IV
41343172|NCT02774291|DRUG|Cyclophosphamide|Given IV
41343173|NCT02774291|BIOLOGICAL|Filgrastim|Given SC
41343174|NCT02774291|DRUG|Fludarabine Phosphate|Given IVPB
41343175|NCT02774291|OTHER|Laboratory Biomarker Analysis|Correlative studies
41343176|NCT04134377|OTHER|Protein Food Snack|The intervention is 6-months using a food snack with control being three months prior to and three months after-study invention whereby serum albumin levels will be collected monthly. If patients are participating in a supplement program, they will be maintained throughout all ten months of the study so long as the criteria for the supplement program (enrollment and discontinuation) is still being met.
41343177|NCT05770739|BEHAVIORAL|Perioperative accelerated rehabilitation surgical measures|To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period
41343178|NCT05770739|BEHAVIORAL|Traditional treatment|To provide traditional perioperative treatment for children with cholangiectasia
41343179|NCT05578313|DRUG|Medical Cannabis|Patients will be observed throughout their treatment with medical cannabis, prescribed to them by for clinically treating their disease (treatment is not an intervention of the study).
41343180|NCT00493844|OTHER|Exercise testing|Exercise testing
41343181|NCT00493844|OTHER|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
41343182|NCT06229808|DEVICE|Multifunctional Birthing ball|"In order to reduce low back pain in labor, massages will be applied to the experimental group in the first stage of labor for 30 minutes each at the end of the latent, active and transition phases (cervical dilatation 3-4 cm, 5-7 cm, 8-10 cm), respectively.~Perineal heating application is planned to be performed at least twice until the delivery occurs as 20 minutes of application and 20 minutes of tissue rest periods when the second stage of labor begins (the duration of this stage may reach 2 hours in primiparous women)."
41343183|NCT04819867|DRUG|Propolis|propolis is an extract derived from bee hives
41343184|NCT04819867|DRUG|Gluma Desensitizer|Gluma is a desensitizer agent
41489271|NCT00899470|DRUG|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
40824489|NCT03135444|BEHAVIORAL|Informal Interview|Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
40824490|NCT03336372|DRUG|Picato|Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
40824491|NCT04965948|OTHER|Novel food snack|Consumption of snack enriched with camelina sativa oil, twice a day for 12 weeks
40824492|NCT04965948|OTHER|Placebo snack|Consumption of placebo snack (no enriched with camelina sativa oil), twice a day for 12 weeks
40824493|NCT02981407|BIOLOGICAL|Red Blood Cell Transfusion|Transfusion of packed red blood cell units
40824494|NCT05606536|DRUG|Crystalloid Solutions|Locally approved crystalloid solution will be given at the predefined infusion rate
40824495|NCT03651518|DRUG|Kineret|100 mg, once/day sc 6 months
40824496|NCT03651518|DRUG|Humira|40 mg/15 days sc 6 months
40824497|NCT03651518|DRUG|Stelara|45 mg/12 weeks sc, 6 months
40824498|NCT03651518|DRUG|Cosentyx|300mg sc every week for 1 month, then 300 mg/month sc for 5 months
40824499|NCT03651518|DRUG|Roactemra|480 mg/perf/4 weeks 6 months
40824500|NCT03651518|DRUG|Rituximab|2 sessions of 1000 mg at inclusion and 15 days after inclusion
41018492|NCT04426058|DRUG|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
41018493|NCT04426058|DRUG|Fascia Illica|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
41343185|NCT03863184|DRUG|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
41343186|NCT03863184|DRUG|Lenalidomide|Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles
41343187|NCT03863184|DRUG|Rituximab|Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
41343188|NCT01012037|DRUG|linagliptin low dose|patient to receive tablets containing low dose linagliptin twice daily
41343189|NCT01012037|DRUG|placebo|patient to receive placebo tablet(s) matching linagliptin
41343190|NCT01012037|DRUG|linagliptin medium dose|patient to receive a tablet containing medium dose linagliptin once daily
41343191|NCT06392178|DEVICE|SugarVita|Serious digital game (application) that can be played on mobile phone, tablet or personal computer. Self-developed game.
41343192|NCT01905306|PROCEDURE|computer guided implant planning|
41343193|NCT01905306|PROCEDURE|free hand implants placement|
41343194|NCT04819191|BEHAVIORAL|SHARING Choices|SHARING Choices is a multicomponent communication intervention to proactively engage family members or friends and to support advance care planning in primary care
41343195|NCT00257322|DRUG|GM-CSF|250ug/m\^2 SQ QD with a cap of 500mcg SQ QD
41343196|NCT05565794|DRUG|Pemigatinib|Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
41343197|NCT00497159|OTHER|Placebo|Placebo TID x 90 days
41343198|NCT00497159|DRUG|Dimebon|Dimebon 20 mg TID x 90 days
41343199|NCT01838655|DRUG|Nitisinone|Oral dose of 2mg daily for 12 months.
41343200|NCT02977039|OTHER|NDPR diet|nutrient rich plant based diert
41343201|NCT02977039|OTHER|USDA healthy eating diet|DASH diet
41343202|NCT01467089|OTHER|Two way video assessment|Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
41343203|NCT05526625|OTHER|Ultrasound-based measurements of IVC & IJV.|Ultrasound-based measurements of IVC \& IJV.
41343204|NCT00003804|BIOLOGICAL|dactinomycin|
41343205|NCT00003804|DRUG|vincristine sulfate|
41343206|NCT00003804|PROCEDURE|conventional surgery|
41343207|NCT00159614|DRUG|KW-3902IV|
40824501|NCT04284124|OTHER|Erector Spinae block|Patient in the prone position 20 min before induction of general anesthesia. Skin is sterilized by 10% povidone iodine. An US multifrequency convex probe (1-8 MHz) will be used for block. A 22G, 50-mm in length needle will be used and block will be performed at the T4 level of the spine using in-plane approach where a convex probe is placed 2-3 cm lateral to the spine using sagittal approach. Erector spinae muscle and the transverse processes are located and the needle will be inserted deep into the muscle. The needle is directed craniotomy-caudally. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic to monitor spread then 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic is monitored in both cranial and caudal directions
40824502|NCT01048307|DEVICE|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
40824503|NCT04113174|OTHER|Decision Analytic Modelling|Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
41489272|NCT00899470|DRUG|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
41489273|NCT00515931|RADIATION|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
40824504|NCT05086757|BEHAVIORAL|TRRP|Receive TRRP services
41343208|NCT05177224|OTHER|Ultrasound acquisitions to define liner position during movements|"Ultrasound acquisition of the dual mobility cup will be performed before and after movement. Acquisitions will be performed on the groin area.~Movement will be performed 3 times and are:~* Walking~* Knee-bending~* Standing up~* Stair climbing Movement acquisition of the lower limb will be performed using reflective markers placed on the skin. The movements will be recorded using motion capture system (infrared cameras). The load applied by the patients on the ground when doing these movements will be recorded with a force plate."
40824505|NCT05086757|BEHAVIORAL|Enhanced Usual Care|Participants will receive an educational flyer with service referrals
40824506|NCT04398173|DIAGNOSTIC_TEST|multiparametric MRI|T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging
40824507|NCT02781025|OTHER|Blood draw|A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
40824508|NCT04844658|DIETARY_SUPPLEMENT|NASAFYTOL®|Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.
40824509|NCT04844658|DIETARY_SUPPLEMENT|FULTIUM® -D3 800|Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).
40824510|NCT04844658|DRUG|Strandard of care treatment|Strandard of care treatment for Covid-19 infection
41018494|NCT03447327|PROCEDURE|single burr hole|patients with CSDH operated by single burr hole craniostomy under local anaesthesia
41343209|NCT00036231|DRUG|RG1068 (Synthetic Human Secretin)|
41343210|NCT05137275|BIOLOGICAL|Anti-5T4 CAR-raNK Cells|In the 3+3 dose escalation study, the minimum initial dose is 3.0×10\^9 cells and then escalate to 6.0× 10\^9 and 9.0× 10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 3\\8 of each cycle. In dose extension study, the initial dose will be determined by RP2D determined by the results of dose escalation study, and the other intervention methods are consistent.
41343211|NCT02940197|BEHAVIORAL|MediterrAsian diet|no other description
41489274|NCT05348980|DRUG|Phenylephrine Hydrochloride 4 mg|Intramuscular Phenylephrine HCL 04 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
41489275|NCT05348980|DRUG|Phenylephrine Hydrochloride 8 mg|Intramuscular Phenylephrine HCL 08 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
41489276|NCT03822065|DRUG|LY03005|80 mg oral tablet single dose
41343212|NCT00287846|DRUG|imatinib mesylate|
41489277|NCT05335291|OTHER|Questionnaire study|The Turkish validity and reliability of the questionnaire will be examined.
40824511|NCT00922155|DEVICE|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
41018495|NCT05146128|OTHER|Strengthening exercises|The participants had to perform specific exercices 3 times a week during 8 weeks
41018496|NCT01376011|DIETARY_SUPPLEMENT|quercetin/placebo|Quercetin 500mg once per day versus placebo
41489278|NCT05304611|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection|Administered one time via subcutaneous route.
41489279|NCT05304611|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB) intravenous injection|Administered one time via intravenous route.
41489280|NCT05304611|OTHER|Placebo|Normal saline administered one time via subcutaneous route.
41489281|NCT00074737|DRUG|cenersen|cenersen with standard of care
41489282|NCT00074737|DRUG|Idarubicin|standard of care for AML
41489283|NCT00074737|DRUG|Cytarabine|standard of care Ara-C and High dose Ara-C
41489284|NCT00521417|BEHAVIORAL|short-term dynamic therapy|
41489285|NCT00521417|BEHAVIORAL|long-term dynamic therapy|
41489286|NCT02151812|DEVICE|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
41489287|NCT02151812|DEVICE|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
41489288|NCT00939120|DRUG|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
41343213|NCT01149525|DRUG|L-Carnitine|2g oral solution , twice per day (morning/evening), during 3 months
41489289|NCT00939120|DRUG|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
41489290|NCT00939120|DRUG|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
41489291|NCT05041621|DEVICE|Sensor augmented MDI therapy plus mobile application|"Participants will use the mobile application to calculate their basal dose and to calculate their meal bolus dose by entering their glucose value, carbs (if applicable), fat composition (high fat or not), and type and timing of postprandial exercises. Participants will receive their dosing parameters weekly upon adjustments made by the reinforcement learning algorithm. Participants will be contacted by telephone on Weeks 1, 3, 5, and 7 in case of any technical difficulties or questions.~All participants will be asked to complete the:~(i) Diabetes treatment satisfaction questionnaire (DTSQ) and hypoglycemia fear survey-II (HFS-II) at baseline, halfway through the intervention, and post-intervention.~(ii) mHealth usability questionnaire (MAUQ) at post-intervention."
40824512|NCT05325749|GENETIC|Screening|Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
40824513|NCT05325749|GENETIC|Family history record|Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
40824514|NCT05325749|OTHER|Questionnaire survey|Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
41018497|NCT04303260|BEHAVIORAL|Physical exercises|The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation.
41018498|NCT06295133|BEHAVIORAL|Stress|The stress management intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators of stress will be recorded to assess the progress of each student.
41157304|NCT05008224|DRUG|Vincristine|1.4 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
41157305|NCT05008224|DRUG|Procarbazine|100 mg/m\^2 orally (PO) administered as part of escBEACOPP chemotherapy on Days 1-7 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
41157306|NCT05008224|DRUG|Prednisone|40 mg/m\^2 PO administered as part of escBEACOPP chemotherapy on Days 1-14 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
41157307|NCT01774461|OTHER|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
41157308|NCT00661466|DRUG|Bupivacaine Collagen Sponge|
41157309|NCT00661466|DRUG|Placebo|placebo
41489292|NCT01703884|DRUG|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (\> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
41489293|NCT05758480|BIOLOGICAL|Blood sample (at inclusion and 6 months later)|(56ml of blood, 8 tubes) 3 heparin, 1 EDTA , 2 SST, 2 CPT
41489294|NCT05758480|OTHER|Patient questionnaires (at inclusion and 6 months later)|(4 questionnaires) Symptoms in the last week, Fatigue Impact Scale (FIS), Short-Form 36 (SF-36) and Nijmegen.
41489295|NCT05045352|DEVICE|echogenic needles for intravenous access|echogenic needles for intravenous access (subclavian vein) ultrasound guided procedure
41489296|NCT06304025|BIOLOGICAL|Wharton's jelly mesenchymal stem cells (WJ-MSCs)|Four doses of 1x10 6 of thawed allogeneic WJ-MSCs or expanding allogeneic WJ-MSCs / kg at 1, 4, 11, and 18 days
40824515|NCT05325749|GENETIC|Diagnostic|The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
41157310|NCT01110161|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
41343214|NCT01149525|DRUG|Placebo|oral solution, twice per day (morning/evening), during 3 months
41343215|NCT00314054|DRUG|HCV-796|HCV-796 1000mg single dose
40824516|NCT05325749|GENETIC|Selective screening|The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
40824517|NCT00858741|RADIATION|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
41343216|NCT03486249|OTHER|Repetition of medical examinations performed as part of the care|Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.
41343217|NCT02047708|DRUG|Zibotentan|Selective endothelin-A antagonist
41343218|NCT00482365|OTHER|biologic sample preservation procedure|biologic sample preservation procedure
41343219|NCT00482365|OTHER|medical chart review|review of patients' medical records at study entry and every 6 months
41343220|NCT00482365|OTHER|Patient interview|Elicit demographic data as well as information about personal habits such as drinking and smoking.
41343221|NCT03904004|PROCEDURE|Peroral endoscopic myotomy|Endoscopic myotomy after performing a tunnel to reach the muscular layer through a mucosal incision
41343222|NCT03904004|PROCEDURE|Neumatic dilatation|Inflation of a ballon of specific diameter in the gastro-oesophageal junction
41343223|NCT03904004|PROCEDURE|Botulinum toxin injection|Injection of botulinic toxin to inhibit the contraction of the gastro-oesophageal junction muscular layer
41343224|NCT03904004|PROCEDURE|Laparoscopic Heller Myotomy|Five or six small incisions are made in the abdominal wall and laparoscopic instruments are inserted. The myotomy is a lengthwise cut along the oesophagus, starting above the lower oesophageal sphincter (LOS) and extending down onto the stomach a little way. The oesophagus is made of several layers, and the myotomy only cuts through the outside muscle layers which are squeezing it shut, leaving the inner mucosal layer intact.
40824518|NCT00858741|RADIATION|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
40824519|NCT04368091|DEVICE|Xtreme Touch - Neo sirolimus coated PTA balloon catheter|The Xtreme Touch (Magic Touch PTA) - Neo Sirolimus PTA Balloon Catheter is the world's first sirolimus coated PTA balloon. The purpose of the X-TOSI all-comers registry is to collect short and long-term clinical performance data on the Xtreme Touch (Magic Touch PTA) -Neo sirolimus PTA balloon catheter in the treatment of atherosclerotic disease in the infrainguinal arteries in an all-comers patient population in real world daily clinical practice.
40824520|NCT02885454|DRUG|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
41343225|NCT04330989|BEHAVIORAL|iNSC and Adherence supporter training|"Integrated next step counseling: iNSC is a structured, patient-centered approach informed by motivational interviewing techniques, which aims to foster an environment for joint-problem solving in order that the participant may identify their individual needs to increase or sustain sexual health through biomedical and non-biomedical approaches. iNSC frames the counselling sessions as a non-judgmental discussion to explore the facilitators and challenges to sexual health and medication adherence.~Adherence supporter training: Participants will be asked to identify a partner, family member, or friend to whom they are willing to disclose their HIV status (for HIV-positive women) or their intent to initiate PrEP (for HIV-negative women). Participants may also select a clinic-based peer to serve this adherence supporter role. Trainings will emphasize basic HIV knowledge, importance of antiretroviral adherence, potential drug side effects, and practical strategies for supporting adherence."
41343226|NCT03415672|BIOLOGICAL|HBVaxPro|Three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
41343227|NCT03415672|BIOLOGICAL|HBAI20|Three doses of HBAI20 at 0, 1, and 2 months. The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
41343228|NCT00074542|DRUG|Epanova™ (Omega-3 Free Fatty Acids)|
40824521|NCT02885454|DRUG|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
40824522|NCT02885454|DRUG|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
40824523|NCT02885454|DRUG|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
41343229|NCT06398665|DEVICE|Intermittent Theta-Burst Stimulation|Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting motor threshold (MT)
41343230|NCT04312789|DRUG|Avatrombopag|Given PO
41343231|NCT00053014|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40824527|NCT04986046|OTHER|Home Plate Lite|Home Plate Lite comprises electronic educational content (e.g. recipes, instructional videos) disbursed at least weekly.
40824528|NCT04986046|OTHER|Virtual Home Plate|Virtual Home Plate comprises two, 45-minute weekly sessions where parents work together with a study staff member to discuss the themes and prepare the components of a meal, including entrees, side dishes, and desserts.
40824529|NCT04986046|OTHER|Fruit and Vegetable prescription|All families will receive FVRx over two months; FVRx can be redeemed for fresh, frozen, or canned produce at participating retailers in Philadelphia
40824531|NCT04899440|DEVICE|Water Flosser|A pressurized stream of water to reduce gingivitis and remove adherent plaque
41343232|NCT00053014|DRUG|cyclosporine|
40824532|NCT04899440|OTHER|Control|No Oral Irrigator Control
41018499|NCT04410926|OTHER|Corrective exercises|The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes
41018500|NCT04410926|OTHER|Neuromuscular electrical stimulation|The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles for 30 minutes. The surface electrodes were placed over the abductor halluces. The control group received placebo NMES with no current stimulation.
41018501|NCT02665481|BEHAVIORAL|MBSR|
41018502|NCT02665481|BEHAVIORAL|Exercise|
41018503|NCT02665481|BEHAVIORAL|Health Education|
41018504|NCT04928742|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
40824533|NCT03872830|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
41489297|NCT05845931|DIETARY_SUPPLEMENT|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).
40824534|NCT03872830|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
40824535|NCT05600816|DEVICE|Pounce Venous Thrombectomy System|The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.
40824536|NCT03482284|OTHER|Dietary Intervention|Participants receive different monosaccharides for a defined number of days.
40824537|NCT05363293|DRUG|AL 001|a crystal engineered lithium-salicylate-proline lithium delivery product
40824538|NCT05363293|DRUG|Placebo|matching placebo formulation
40824539|NCT01280539|DEVICE|Transcutaneous electrical nerve stimulation|3 weeks, 5 times a week, 60 minutes a day.
40824540|NCT06079073|BEHAVIORAL|Orofacial myofunctional therapy with autofeedback|Participants opening a code unlocking the OMTa treatment module of the application will be given a direct communication link to the PhD students, Diana Hansen (Norway) and Andres Koster (Estonia) and two research co-ordinators. Dr. Hansen and Andres Köster has obtained an Academy of Orofacial Myofunctional Therapy (AOMT) certification diploma. One physical start up session will be scheduled at Ahus and at North Estonia Medical Center. This 60 minute session will be used to instruct participants in OMT exercises and use of the app. All participants will receive a disposable toothbrush and standardized balloons. After that, biweekly video sessions (time 20-30 min) will be scheduled.
40824541|NCT01338610|BIOLOGICAL|ESBA105 ophthalmic solution|
40824542|NCT01338610|OTHER|ESBA105 vehicle|Inactive ingredients used as Run-In and placebo comparator
41489298|NCT05989113|OTHER|Administration of the IPAQ-SF questionnaire|Administration of the IPAQ-SF questionnaire at the patient's consultation and upon return home
40824543|NCT00413920|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
40824544|NCT00413920|DRUG|Prednisone|Oral tablets
40824545|NCT02502058|DEVICE|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
40824546|NCT01978249|PROCEDURE|Systemic chemotherapy|
40824547|NCT01978249|PROCEDURE|primary tumor resection (PTR)|primary tumor resection (PTR) using open or laparoscopy or robotic surgery
40824548|NCT04782245|DRUG|Dapagliflozin 10mg|The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.
40824549|NCT04782245|DRUG|Placebo|Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
40824550|NCT02573246|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
40824551|NCT02573246|DEVICE|rTMS|rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
40824552|NCT02573246|DEVICE|Sham rTMS|Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
40824553|NCT05602675|DRUG|LY3871801|Administered orally.
40824554|NCT05602675|DRUG|Methotrexate|Administered orally.
40824555|NCT05602675|DRUG|Warfarin|Administered orally.
40824556|NCT05602675|DRUG|Dextromethorphan|Administered orally.
40824557|NCT05602675|DRUG|Midazolam|Administered orally.
40824558|NCT05602675|DRUG|Repaglinide|Administered orally.
40824559|NCT01054937|DRUG|4SC-203|i.v. administration
40824560|NCT01054937|DRUG|Placebo|i.v. administration
40824561|NCT04385238|OTHER|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
40824562|NCT01325090|DRUG|BOTOX|A syringe of 1 ml contain 25 Allergan units.
40824563|NCT01325090|OTHER|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
40824564|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 0.8 mg/kg|Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa
40824565|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 3.2 mg/kg|Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
41489299|NCT04791423|BIOLOGICAL|GRAd-COV2|GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues
41343233|NCT00053014|DRUG|fludarabine|
41343234|NCT00053014|DRUG|mycophenolate mofetil|
41489300|NCT04791423|OTHER|Placebo|Saline solution
41343235|NCT00053014|PROCEDURE|peripheral blood stem cell transplantation|
41018505|NCT06216951|PROCEDURE|Vital Pulpotomy|Vital pulpotomy involves the removal of the coronal pulp, while MTA is used to seal the root orifices. It is clear that vital pulp treatments for symptomatic pulpitis are a more reliable, cost-effective, and generally easier option than root canal treatment (RCT) once the mineral trioxide aggregate (MTA) is introduced in dentistry. In vital pulpotomy, as opposed to RCT, tooth healing and symptoms are diminished while the vitality of the tooth is maintained. Furthermore, vital pulpotomy is a significantly more practical and economical treatment alternative than RCT.
41018506|NCT03837691|DEVICE|Placement of Snowshoe Suture Anchors|Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device
41489301|NCT00378183|DRUG|risperidone|
41157311|NCT06538142|PROCEDURE|Photobiomodulation + Restoration with Self-cure Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Application of photobiomodulation;~4. Relative isolation (lip bumper, cotton roll and aspirator);~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Cleaning with cotton and water;~7. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~8. Application of mild compressed air on adhesive for 3 seconds;~9. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~10. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~11. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
41343236|NCT00053014|RADIATION|radiation therapy|
41343237|NCT03152188|DRUG|FMT|Fifteen FMT Openbiome capsules administered at the same time
41343238|NCT03152188|OTHER|Placebo|Fifteen placebo capsules administered at the same time
41343239|NCT04573491|GENETIC|Pharmacogenetic test|genotyping for genes that affect drug metabolism
41343240|NCT04573491|OTHER|Medication review|systematic and interdisciplinary method aiming to increase quality of medication treatment
40824566|NCT01238770|DRUG|Pazopanib|"Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I."
40824567|NCT04493684|DRUG|GSK3739937 (PIB)|GSK3739937 will be administered as oral suspension.
40824568|NCT04493684|DRUG|Placebo|Placebo will be given orally during each dosing day.
40824569|NCT04493684|DRUG|GSK3739937 (Tablet)|GSK3739937 Tablet will be administered via oral route.
40824570|NCT01991080|BEHAVIORAL|biofeedback|Patients will go through biofeedback sessions
41343241|NCT02740036|DEVICE|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
41343242|NCT02482792|OTHER|Norwegian Psychomotor Physiotherapy|The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
41343243|NCT02482792|OTHER|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
41489302|NCT02681744|BEHAVIORAL|Resistance Training|24-weeks of progressive strength training
41489303|NCT04400331|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
40824571|NCT01991080|DRUG|Wheatgerm juice|Patient will drink wheatgerm juice
40824572|NCT06600763|OTHER|Ice pack|The temperature of the area where the ice pack is applied will be measured at one minute intervals, and when the relevant area reaches a temperature of 13.6 0C, the physician will be informed and the drain removal procedure will be initiated.
41343244|NCT01755260|OTHER|Jejunostomy tube feeding|The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
41343245|NCT04123444|DRUG|Iloprost|Continuously infusion for 72 hours. treatment dose 1 ng/kg/min
41343246|NCT04123444|DRUG|Isotonic saline|Continuously infusion for 72 hours.
41489304|NCT04258475|DRUG|Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.|Raltegravir will be dosed in a fasted state in all periods. Participants will take Raltegravir along with other ART medication.
41489305|NCT04258475|DRUG|Calcium carbonate antacid tablet|PK analysis of different doses of calcium carbonate antacid in patients undergoing ART treatment for HIV using Raltegravir.
41508995|NCT04431765|BEHAVIORAL|Trauma-Centred Cognitive and Behavioural Therapy|A CBT is a short, scientifically validated therapy that focuses on the interactions between thoughts, emotions and behaviours. These therapies focus on the current problems of the person, while taking into account their historical causes. They help gradually overcome disabling symptoms and aim to strengthen adaptive behaviours. A CBT relies on different techniques that help the patient to identify the mechanisms at the origin of his difficulties, to experiment with new behaviors and thus to gradually come out of vicious circles that perpetuate and aggravate the psychic suffering.
41343247|NCT00646750|DRUG|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|"Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1."
41343248|NCT05936372|BEHAVIORAL|Acute intense aerobic exercise|The acute intense aerobic exercise bout (iE) will consist of a 13-minute 20-meter shuttle run. During this exercise bout two speeds, based on a percentage of the estimated maximal oxygen consumption (VO2max), will be combined: a fast-paced speed (fast: 85% of VO2max) and a slow-paced speed (slow: 60% VO2max). A total of 3 series of 3 min of the fast-paced speed will be carried interspersed with 2 series of 2 min of the slow-paced speed. Prior to the iE start, a warm-up protocol consisting of 2 min slow and 1 min fast will be done with the objective to familiarize participants with the iE speeds. A 5-minute rest period will be guaranteed before starting the iE. Transition time between iE and the rotational visuomotor adaptation task (rVMA) will be 4 min.
41489306|NCT03296436|BIOLOGICAL|NEOX® CORD 1K®|NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
41489307|NCT01685073|DRUG|Zolpidem extended-release|nightly administration of zolpidem extended-release
40824573|NCT06600763|OTHER|warm gel pad|Gel pads kept at room temperature will be applied to the drain area of the pediatric patient whose surgical drain indication is decided to end, in a sheath designed to wrap around the drain. After waiting for 10 minutes in the application area, the drainage system will be removed by the physician.
40824574|NCT06326619|PROCEDURE|Primary tumor resection|In addition to systemic therapy a primary tumor resection was performed.
40824575|NCT06326619|PROCEDURE|Systemic Therapy|chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis
41489308|NCT01685073|BEHAVIORAL|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
41489309|NCT03809988|DRUG|Palbociclib|Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
41489310|NCT03809988|DRUG|Endocrine therapy|Endocrine therapy alone (letrozole or fulvestrant)
41489311|NCT04853992|DRUG|LEO 152020|LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.
41508996|NCT01620294|PROCEDURE|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
40824576|NCT03233763|PROCEDURE|Bone Marrow Aspirate|Diagnostic Bone Marrow aspirate
40824577|NCT01866423|DRUG|orteronel|Given PO
40824578|NCT01866423|OTHER|laboratory biomarker analysis|Correlative studies
40824579|NCT02116647|BEHAVIORAL|Psychoanalytic therapy|
40824580|NCT01129037|OTHER|Goal directed fluid management based on continuous monitoring of stroke volume|Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased \< 10% in response to receding VL: SV is optimized, no further VL required.
40824585|NCT06358781|OTHER|Whole grain wheat flour|Group A: whole grain flour: 0 g Group B: Whole grain flour: 25 g Group C: Whole grain flour: 50 g Group D: whole grain flour: 100g
40824586|NCT03155334|OTHER|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~* individual reading of the text;~* individual questionnaire for a quantitative and qualitative evaluation;~* a brief semi-structured interview to each participant;~* a text revision to address any problems identified from participant feedback."
40824587|NCT00795834|DIETARY_SUPPLEMENT|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
40824588|NCT00795834|DIETARY_SUPPLEMENT|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
40824589|NCT03645525|DRUG|Human Umbilical Cord-derived Mesenchymal stem cell|The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10\^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube
40824590|NCT03645525|DRUG|placebo|saline
40824591|NCT05679167|BEHAVIORAL|Supervised digital training with focus on core stability|After randomization, Group 1 will be digitally supervised by experienced physiotherapist.
40824592|NCT05679167|BEHAVIORAL|Supervised digital training with focus on aerobic exercise|After randomization Group 2 will be digitally supervised by experienced physiotherapist.
40824593|NCT05679167|BEHAVIORAL|Non-supervised daily physical activity|After randomization Group 3 will receive training instruction regarding daily physical activity.
40824594|NCT00790868|DRUG|d-cycloserine|50mg
40824595|NCT00790868|DRUG|placebo|50mg
41343249|NCT01685372|BIOLOGICAL|Fluzone High Dose|A single-dose of high-dose influenza vaccine will be administered to subjects randomized to this arm
41343250|NCT01685372|BIOLOGICAL|Fluzone|A single-dose of standard-dose influenza vaccine will be administered to subjects randomized to this arm
41343251|NCT02551913|BEHAVIORAL|Control|the adolescents will not receive any specific intervention
41343252|NCT02551913|BEHAVIORAL|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
41343253|NCT06245824|DRUG|Trastuzumab deruxtecan (T-DXd) with pyrotinib|T-DXd, 5.4mg/kg IV day 1 of a 21-day cycle. Pyrotinib, 400mg or 320mg, orally once a day, daily of a 21-day cycle.
41343254|NCT06151418|DRUG|Novel hormonal therapy|As provided in real-world setting
41343255|NCT05401604|DIETARY_SUPPLEMENT|Moderate probiotic beer consumption|Consumption of one can of probiotic beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
41343256|NCT05401604|DIETARY_SUPPLEMENT|Moderate normal beer consumption|Consumption of one can of normal beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
41343257|NCT02614261|DRUG|Galcanezumab|Administered SC
41343258|NCT02614261|DRUG|Placebo|Administered SC
41343259|NCT02654041|DRUG|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
41343260|NCT02406339|DEVICE|NMES|Neuromuscular Electrical Stimulation
41343261|NCT02406339|DEVICE|Vascular Occlusion|Restriction of sanguine flow to the lower limbs
41343262|NCT05653336|DEVICE|PerQseal® Closure Device System|Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
41343263|NCT00176878|PROCEDURE|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10\^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10\^9/kg.
41343264|NCT00176878|DRUG|Fludarabine monophosphate|fludarabine 175 mg/m\^2 (total) on Days -6 through -3.
41343265|NCT00176878|PROCEDURE|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
41343266|NCT00176878|DRUG|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
41343267|NCT00176878|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
41343268|NCT01237223|DRUG|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
41343269|NCT01237223|DRUG|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
41343270|NCT01237223|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet
41343271|NCT01237223|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
41343272|NCT01237223|DRUG|Placebo of Aliskiren|Aliskiren placebo tablet
41343273|NCT01237223|DRUG|Placebo of Amlodipine|Amlodipine placebo capsule
41343274|NCT01237223|DRUG|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
41343275|NCT01237223|DRUG|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
40824596|NCT02214225|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
41343276|NCT02822352|OTHER|Chromoendoscopy|High definition virtual chromoendoscopy
41343277|NCT04412772|DRUG|Tocilizumab|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen.
41343278|NCT04412772|DRUG|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
41343279|NCT06141499|BEHAVIORAL|Provider educational materials|Dialysis providers will receive educational material about the kidney transplantation and waitlisting process.
41343280|NCT06141499|BEHAVIORAL|Patient letters|Dialysis patients will receive letters with information about their status within the kidney transplantation and waitlisting process. Letters will describe kidney waitlist status, living donor transplantation, Hepatitis C positive kidney transplants, and high Kidney Donor Profile Index (KDPI) transplants.
41343281|NCT01900405|DRUG|Dexmedetomidine|
41343282|NCT00810251|DEVICE|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
41343283|NCT06022224|BIOLOGICAL|hAd5-S-Fusion+N-ETSD|Clear and colorless liquid. Each vaccine is supplied in a 2-mL vial containing 1.0 mL of extractable vaccine at a concentration of 1 × 10\^11 viral particles/mL.
41343284|NCT06022224|BIOLOGICAL|Placebo (0.9% (w/v) saline)|Clear and colorless liquid.
41343285|NCT00729560|DRUG|Flutamide|250 mg twice daily for 4 weeks
41343286|NCT00729560|DRUG|Placebo|Placebo twice daily for 4 weeks
41343287|NCT00004695|DRUG|PEG-interleukin-2|
41343288|NCT05674643|DIAGNOSTIC_TEST|Gastric Ultrasound Baseline Scans|The patient's abdomen will be scanned using the ultrasound device by an expert scanner and novice scanner for baseline assessment of the antral CSA and gastric volume using Perlas US qualitative grading assessment.
41343289|NCT05674643|DIAGNOSTIC_TEST|Acetaminophen Absorption Test (AAT)|"Prior to starting the AAT, a baseline plasma acetaminophen level (250 microliters) will be obtained from the intravenous catheter. The subject will then be given 12.5 mg/kg or max 650mg of single batch 32mg/mL acetaminophen followed by 6oz of water PO. Up to 3 additional small volume blood samples will be drawn for acetaminophen levels.~These additional blood samples (250 microliters each) will be obtained to measure acetaminophen plasma levels at the following goal intervals after acetaminophen administration.T1:10-20 mins, T2:35-45 mins, T3: 60mins. At the time of each lab draw gastric ultrasound will be assessed by the expert scanner to correlate gastric ultrasound with the acetaminophen absorption test as a gold-standard of gastric emptying."
41508997|NCT01620294|PROCEDURE|surgical site infection|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
41343290|NCT05674643|DIAGNOSTIC_TEST|Gastric Ultrasound Serial Scans|Cohort 1 will have multiple scans as part of assessing gastric emptying. These sequential scans after the baseline assessment will be done in line with the Acetaminophen Absorption Test timeline (T1:10-20 mins, T2:35-45 mins, T3: 60mins) and will be performed by an expert scanner only.
41489312|NCT04853992|DRUG|LEO 152020 placebo|LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.
41489313|NCT03863093|DEVICE|Electro Medical Systems AIRFLOW®|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
41489314|NCT03863093|DEVICE|Electro Medical Systems Piezo|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
41489315|NCT03203486|OTHER|Mediterranean Diet|Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
40824597|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
40824598|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
40824599|NCT04247191|BEHAVIORAL|P-Chat|The P-Chat is a brief individually delivered intervention based on the principles of Motivational Interviewing (MI) and focuses on increasing parents' motivation to reduce permissiveness toward underage alcohol use while reducing defensiveness and barriers to implementing these rules with their teen.
40824600|NCT04247191|BEHAVIORAL|PBI|"The PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of the two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third, is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
40824601|NCT04247191|BEHAVIORAL|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above. Parents in this arm of the study will receive both interventions.
40824602|NCT05946785|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
40824603|NCT05946785|DRUG|insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
40824604|NCT05971225|OTHER|remote monitoring only|remote monitoring only can replace in-office device monitoring
40824605|NCT02465749|DRUG|Continuous oxygen|Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;
40824606|NCT02465749|DEVICE|blue light-absorbing sunglasses|Wearing blue light-absorbing sunglasses at daily time;
40824607|NCT02465749|DRUG|Compound thrombosis capsule sig: 1.5g/tid|Compound thrombosis capsule sig: 1.5g/tid
41343291|NCT02219672|DRUG|Triplitode|"Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir ."
41343292|NCT02219672|DRUG|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
41489316|NCT03244943|PROCEDURE|Non surgical periodontal Treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia. On average, the treatment of the entire oral cavity was completed within four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with multilaminated drills.
41489317|NCT03751956|DRUG|HSK3486|The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of \[14C\]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
41489318|NCT03576183|BIOLOGICAL|VLA1701|VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)
41489319|NCT03576183|BIOLOGICAL|Placebo|buffer component of VLA1701
41489320|NCT03576183|OTHER|Challenge Strain|LSN03-016011/A
41489321|NCT04247152|OTHER|Intraoperative Aberrometry vs preoperative biometry|Hypothesis: Intraoperative aberrometry measures lower levels of astigmatism more accurately than preoperative biometry in patients undergoing cataract surgery.
41018507|NCT03837691|BEHAVIORAL|Moderate Intensity Diet & Exercise Program|After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
41343293|NCT01997138|DRUG|Anakinra 100 mg in 2 ml saline IA|
40824608|NCT02465749|DRUG|Ginkgo biloba pills sig: 300mg/tid;|Ginkgo biloba pills sig: 300mg/tid;
40824609|NCT02465749|DRUG|Vitamin B sig: 10mg/tid|Vitamin B sig: 10mg/tid
40824610|NCT02465749|DRUG|Vitamin AD sig: 1 tablet/tid|Vitamin AD sig: 1 tablet/tid
40824611|NCT04832906|DRUG|Ulipristal Oral Tablet|A selective progesterone receptor modulator (SPRM), as a medical line of treatment for uterine fibroids. Due to its selective anti-proliferative and pro-apoptotic action, Ulipristal Acetate (UA) is assumed to be effective in reducing abnormal uterine bleeding (AUB) and fibroid size.
41018508|NCT01983800|DRUG|Isoflurane|
41489322|NCT01109563|BEHAVIORAL|Marijuana Check-Ins|The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
41489323|NCT01346774|DRUG|Cranberry powder capsules|2 cranberry powder capsules twice a day
41489324|NCT01346774|DRUG|Placebo powder capsules|2 placebo capsules twice a day
41489325|NCT05707143|OTHER|home based stabilization exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
40824612|NCT04832906|PROCEDURE|Uterine artery embolization|Selective embolization of uterine arteries bilaterally, using polyvinyl alcohol (PVA) particles administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected.
40824613|NCT02163720|DRUG|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
40824614|NCT02310854|PROCEDURE|ACL Repair|augmented suture of acute ACL rupture (\<3 weeks after injury)
40824615|NCT02310854|PROCEDURE|ACL reconstruction|reconstruction hamstring autograft
40824616|NCT05331209|OTHER|Acupuncture|Weekly acupuncture treatments, for 8 weeks (8 treatments)
40824617|NCT05331209|OTHER|Acupuncture-Acupressure|Weekly acupuncture, for 8 weeks, with daily self-acupressure by the patient at home.
40824618|NCT01394224|DRUG|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
41343294|NCT00003761|BIOLOGICAL|rV-DF3/MUC1|"- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~* Level 1 4.76 x 106 PFU~* Level 2 4.76 x 107 PFU~* Level 3 4.76 x 108 PFU"
40824619|NCT01394224|DRUG|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
41343295|NCT02827487|DRUG|Tramadol|Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.
41343296|NCT02827487|DRUG|Celecoxib|Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
41489326|NCT05707143|OTHER|kegel exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
41489327|NCT01483469|DRUG|RO4917523|orally daily, 14 days
40824620|NCT03908372|DRUG|Docetaxel|Induction CT: Docetaxel 75mg/m2 IV on d1, every 21 days for two cycles
40824621|NCT03908372|DRUG|Cisplatin|Induction chemotherapy:cisplatin 75mg/m2 IV on d1,every 21 days for two cycles.Concurrent chemoradiotherapy:cisplatin 100mg/m2 IV on d1 of each 21 days for at least two cycles during 70 Gy radiotherapy
41489328|NCT01483469|DRUG|RO5011232|\[11C\]-RO5011232 intravenously
40824622|NCT03908372|RADIATION|IMRT|IC+IMRT arm:the patients with complete response will receive 60Gy to the gross target volume of nasopharynx, partial response 64Gy, and the absence of response or stable will receive 70Gy. CCRT arm: 70Gy to the gross target volume of nasopharynx.
41018509|NCT01983800|DRUG|Propofol/midazolam|
41018510|NCT03168347|BEHAVIORAL|Anecdotal Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.
41018511|NCT03168347|BEHAVIORAL|Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only research study evidence.
41343297|NCT02827487|DRUG|Placebo 1|Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
41343298|NCT02827487|DRUG|Placebo 2|Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
41343299|NCT02827487|PROCEDURE|IUD|IUD insertion
41343300|NCT02390960|DRUG|Sildenafil Cream|Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
41489329|NCT02288182|DEVICE|Straumann VivOss|Patients will receive Straumann VivOss for sinus augmentation.
41489330|NCT02288182|DEVICE|Geistlich Bio-Oss|Patients will receive Geistlich Bio-Oss for sinus augmentation.
41343301|NCT02390960|DRUG|Placebo Cream|Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
41343302|NCT02390960|DEVICE|Penile Plethysmography (RigiScan)|During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
41343303|NCT03394118|DRUG|Osimertinib|A cycle of study treatment is defined as 28 days. Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
41343304|NCT01898962|PROCEDURE|Complete Surgical Removal|
41343305|NCT01898962|RADIATION|Stereotactic Radiosurgery|
41343306|NCT01898962|RADIATION|Ablative external beam radiation dose|
41343307|NCT01898962|PROCEDURE|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
41343308|NCT01898962|RADIATION|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
41343309|NCT00700349|OTHER|Small loan|Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
41343310|NCT05108961|PROCEDURE|Acupuncture|one session with precise acupunture points
40824623|NCT05401695|DEVICE|HA330 hemoadsorption technique|Hemoadsorption (HA) treatment An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in the intervention group. We will select a blood circuit for each machine according to the patient's body weight. Vascular access will be established with ultrasound-guided insertion of a double-lumen venous catheter into the right internal jugular or femoral vein. HA will be performed for a maximum of 4 hours, and the second session will be started approximately 24 hours after the end of the first session. The blood flow rate will be started low and be gradually increased while monitoring real-time blood pressure and vital signs with an arterial-line monitor. After the end of the HA session, CRRT will be continued if required.
40824624|NCT02793596|OTHER|Obstetrical patients|Epidural waveform analysis as a confirmation of loss of Resistance
40824625|NCT05525429|BEHAVIORAL|Nutrition Education|Multidimensional nutrition education will be provided.
40824626|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
40824627|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
40824628|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
41018512|NCT03168347|BEHAVIORAL|Anecdotal + Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.
41018513|NCT03168347|BEHAVIORAL|No Evidence|Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
41165750|NCT01932983|DEVICE|Train of four test|TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
41165751|NCT01828385|DRUG|Magnesium Sulfate|Magnesium sulfate + rocuronium + sugammadex
40824629|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
40824630|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
40824631|NCT03693963|DEVICE|Serranator|The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
40824632|NCT03633630|DRUG|Amla|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
40824633|NCT03633630|DRUG|Placebo|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
40824634|NCT03332719|BIOLOGICAL|Etanercept|
40824635|NCT03332719|DRUG|Methotrexate|
41018514|NCT01221259|DRUG|E2212|single ascending doses ranging from 10mg to 250mg
41018515|NCT01221259|DRUG|placebo|a single dose of matching placebo
41343311|NCT05108961|BEHAVIORAL|A digital stress scale|The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)
41343312|NCT05108961|BEHAVIORAL|a relaxation questionnaire|The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale
41343313|NCT05108961|DIAGNOSTIC_TEST|Bispectral Index|BIS is based on an EEG analysis algorithm
41343314|NCT00004194|DRUG|fludarabine phosphate|
41343315|NCT00873704|OTHER|supplemental postoperative oxygen|
41343316|NCT05609383|OTHER|assessment|An exit evaluation was initiated immediately upon recovery from anesthesia
41343317|NCT03278925|PROCEDURE|Biopsy|Undergo biopsy
41343318|NCT03278925|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41343319|NCT03278925|PROCEDURE|Computed Tomography|Undergo CT
41343320|NCT03278925|DRUG|Defined Green Tea Catechin Extract|Given PO
41343321|NCT03278925|OTHER|Laboratory Biomarker Analysis|Correlative studies
41343322|NCT03278925|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41343323|NCT03278925|OTHER|Pharmacological Study|Correlative studies
41343324|NCT03278925|OTHER|Questionnaire Administration|Ancillary studies
41343325|NCT03278925|PROCEDURE|Ultrasound|Undergo ultrasound
40824636|NCT02185430|DRUG|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
40824637|NCT02185430|DRUG|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
40824638|NCT06453330|BIOLOGICAL|Horizontal platelet-rich fibrin (H-PRF)|Most commercially available centrifuges used for PRF production are fixed-angle systems designed primarily for pelleting samples to the bottom of tubes and are not particularly efficient at separating the cell layers effectively. Research has demonstrated that PRF produced using horizontal centrifugation (H-PRF) can lead to a higher concentration of platelets and leukocytes compared to PRF produced from fixed-angle centrifugation (LPRF). The resulting PRF from horizontal centrifugation is termed 'horizontal platelet-rich fibrin' (H-PRF). The H-PRF clot will be produced using a Bio-PRF horizontal centrifuge machine. This machine is CE marked and regularly used in the Dublin Dental University Hospital.
40824639|NCT00292838|DRUG|fluticasone 25, 50, 100, 200 mcg|
40824640|NCT02937298|DIETARY_SUPPLEMENT|Control Meal|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
40824641|NCT02937298|DIETARY_SUPPLEMENT|Berry Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
40824642|NCT02937298|DIETARY_SUPPLEMENT|Sea Buckthorn Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
40824643|NCT02937298|DIETARY_SUPPLEMENT|Wild Garlic Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
41343326|NCT05553262|BEHAVIORAL|Behavioral support|Behavioral support as described under 'Arm description'.
41343327|NCT02762045|BIOLOGICAL|Ad5-gag|Ad5-gag is used as vaccine in all arms.
41343328|NCT02762045|BIOLOGICAL|Placebo|Preservation Solution is used as control in all arms.
41343329|NCT01894555|DRUG|Aspirin|81 mg daily for 4 weeks
41343330|NCT05597241|DRUG|apimostinel|N-methyl-D-aspartate (NMDA) receptor modulator
41343331|NCT05597241|DRUG|Placebo|Placebo
41343332|NCT04270565|BEHAVIORAL|In-Field Gait-Training|The intervention will deliver a series of vibrations on the participants' wrists through the Garmin when the sensors indicate that their contact time in milliseconds exceeds a threshold. The runners will be asked to reduce the amount of time their foot is in contact with the ground by picking their feet up more quickly. Participants will also receive a series of exercises based on noted impairments at baseline. The feedback during running will be completed twice per week for four weeks.
41018516|NCT01101841|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
41343333|NCT04270565|BEHAVIORAL|Home Exercise|Participants will receive a series of exercises based on noted impairments at baseline. Exercises will be completed twice per week for four weeks.
41343334|NCT00052832|DIETARY_SUPPLEMENT|doxercalciferol|
41343335|NCT03774706|DRUG|Misoprostol|two tablets misoprostol 400 μg sublingual
41343336|NCT03774706|DRUG|Tranexamic Acid|two ampoules of tranexamic acid (1gm in 10 ml) in 100ml saline
41343337|NCT03774706|DRUG|placebo to tranexamic acid|placebo to tranexamic acid (110 ml saline)
41343338|NCT00125892|DRUG|duloxetine|
41343339|NCT05386875|DIAGNOSTIC_TEST|rK28|"rK28 RDT (Index): The Leishmania Ab Rapid Test is a rapid immunochromatographic test that uses the recombinant antigen rK28 to detect antibodies against Leishmania species in human serum, plasma, or whole blood samples intended for primary VL diagnosis. It is a Research Use Only product commercialized by CTK Biotech, Inc. (USA).~IT-Leish rK39 RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by Bio-Rad (France). This is currently the recommended RDT for VL diagnosis in Kenya.~Kalazar Detect rK39, RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by InBios (United States)."
41018517|NCT01101841|DRUG|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
41018518|NCT03100825|DRUG|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
41343340|NCT00444834|DRUG|Carvedilol|50 mg
41343341|NCT03964493|DRUG|TNP-2092|TNP-2092 100mg/vial
41343342|NCT03964493|DRUG|Vancomycin|Vancomycin 1g/vial
41343343|NCT02795065|DRUG|Enoxaparin|Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
41343344|NCT02795065|DRUG|Bemiparin|Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
41343345|NCT06343454|OTHER|Digital Interocclusal Record In Different Head Positions|Recording the position of the upper and lower teeth in the bite position in different head positions with an intraoral scanner
41343346|NCT03688893|DEVICE|Laser Application for Dental Bleaching|The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
41018519|NCT00428610|DRUG|LY573636-sodium|LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
41018520|NCT04745949|DRUG|Brentuximab Vedotin|Given IV
41018521|NCT04745949|DRUG|Cyclophosphamide|Given IV
41018522|NCT04745949|DRUG|Doxorubicin|Given IV
41343347|NCT05681897|PROCEDURE|Platelet-Rich Plasma Injections (PRP) on the Scalp|each subject will be treated with 3x PRP injections on the scalp with 2 weeks interval in addition to daily minoxidil administration.
41343348|NCT04185662|DIETARY_SUPPLEMENT|sucralose|daily intake different dose of artificial sweeteners sucralose or placebo
41343349|NCT02772991|OTHER|troponin measurement|Cardiac catheterization (for patients with \>50% lesions) or discharge or in patients with intermediate risk.
41343350|NCT00035412|DRUG|St. John's Wort|
41343351|NCT03408886|DRUG|Vancomycin|Oral vancomycin is administered to reduce pathogenic bacteria.
41343352|NCT03408886|DRUG|MoviPrep|MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
41343353|NCT03408886|BIOLOGICAL|Full Spectrum Microbiota|Gut bacteria from healthy human donors are administered orally in a pill form
41343354|NCT02603406|DRUG|erythropoietin|
41343355|NCT02034864|OTHER|Osteopathic manipulative treatment|A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.
41018523|NCT04745949|BIOLOGICAL|Nivolumab|Given IV
41018524|NCT04745949|DRUG|Prednisone|Given PO
41018525|NCT04745949|OTHER|Quality-of-Life Assessment|Ancillary studies
41343356|NCT02034864|OTHER|Placebo of osteopathic manipulative treatment|"A standardized placebo of manipulative treatment consisting in light touch and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment."
41343357|NCT01751789|BEHAVIORAL|Linkage|
41343358|NCT01751789|OTHER|Treatment as Usual|
41343359|NCT01111721|BEHAVIORAL|Project POWER HIV Risk-reduction Intervention|Nine session group-based behavioral intervention for incarcerated female adults.
41343360|NCT01111721|BEHAVIORAL|NC DOC Standard of Care for STIs|Standard North Carolina Department of Correction intake STI testing and counseling.
41343361|NCT01898000|BEHAVIORAL|Triphala mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
41343362|NCT01898000|BEHAVIORAL|Chlorhexidine mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
41343363|NCT04831268|OTHER|Glucose as reference food|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
41018526|NCT04745949|BIOLOGICAL|Rituximab|Given IV
41018527|NCT02438241|PROCEDURE|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
41343364|NCT04831268|OTHER|Lentils and lupins mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from lentils and lupins mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
41343365|NCT04831268|OTHER|Trahanas with tomato sauce mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
41489331|NCT02790853|PROCEDURE|Biopsy|Undergo brush biopsy and incisional biopsy
41489332|NCT02790853|PROCEDURE|Fluorescence Imaging|Undergo PS2.1/PS3 imaging
41489333|NCT02790853|PROCEDURE|High-Resolution Microendoscopy|Undergo HRME imaging
41489334|NCT02790853|DRUG|Proflavine Hemisulfate|Applied on mucosa
41489335|NCT05553899|RADIATION|PET-MRI|magnetic resonance imaging with positron emission tomography scanning using the tracer 18F-FDG
41489336|NCT02906241|BEHAVIORAL|Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams|This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
41489337|NCT02906241|BEHAVIORAL|Physicians: Educational Module|Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
41489338|NCT04174976|PROCEDURE|wall hernia repair|Wall hernia repair with mesh
41489339|NCT04502823|PROCEDURE|Management based on sFlt-1/PlGF values|"In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF:~* Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~* Fetuses with sFlt-1/PlGF \<38 weekly follow up will be recommended and delivery at ≥40 weeks."
41489340|NCT04804865|OTHER|prognostic assessment|determination of a prognostic score with 3 clinical and 5 biological parameters.
41489341|NCT00452517|PROCEDURE|Percutaneous Coronary Intervention|
41489342|NCT06236451|DRUG|Aripiprazole|Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.
41489343|NCT06236451|DRUG|Risperidone|Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.
41343366|NCT04831268|OTHER|Halva with currants mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
41489344|NCT06110728|BEHAVIORAL|Habit Change|Participants assigned to the Habit Change arm will be asked to track behaviors related to their specific goals on a daily basis through the app and will be allowed to engage with the app freely. Goals can include things like reaching a step goal, sleeping for a certain number of hours, or making healthy food choices.
41489345|NCT02433054|DEVICE|CE-certified dedicated venous stents|Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
41489346|NCT02737748|DRUG|TWB-103 Group|Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
41489347|NCT02737748|DRUG|Placebo Group|Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
41489348|NCT03192865|PROCEDURE|diaphragmatic assessment using ultrasounds.|A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
41489349|NCT04191837|OTHER|Self-administered acupressure treatment group|Subjects in the self-administered acupressure exercise group will receive two training sessions (2 hours each, 1-week apart). The self-administered acupressure treatment protocol was developed based on Chinese medicine meridian theory by previous studies and modified. The acupoints are indicated for knee pain and have been commonly used and tested for feasibility in pilot study. The training will be conducted in a group format with 4-6 subjects per group. Each subject will then receive a handout and an acupressure log. They will be told to perform the self-acupressure twice per day for 12 weeks.The capability of participants for self-administered acupressure will be inspected by the instructor with a competency checklist in each session. And a demonstration video will be sent to the participants via WhatsApp for their reference at home.
41489350|NCT04191837|OTHER|Knee health education control group|Subjects in the health education control group will receive knowledge related to knee OA symptom management. The health education will be conducted in a talk format for 2 hours for two sessions. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR and reviewed. Subjects in knee health education group will be told to follow the knee health instruction for 12 weeks.
41489351|NCT05640219|DEVICE|laparoscopic trocar 12mm|long laparoscopic trocar 12mm (36 french) with central hole from its tip till its handle with transparent sheath
41165752|NCT01828385|DRUG|Saline|Saline + rocuronium + sugammadex
41165753|NCT02450123|DRUG|sunitinib|
41165754|NCT01504009|OTHER|Muscle training|12 weeks of strength training 2-3 times/week
41489352|NCT05134246|PROCEDURE|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
41489353|NCT05134246|PROCEDURE|Carotid artery stenting (CAS)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, local anaesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is mandatory for all patients who undergo CAS.
41489354|NCT06250049|OTHER|Diabetic foot care protocol|Introduction of the diabetic foot care protocol in Primary Care in Salamanca, sensitization, and training of nursing professionals in Health Centers (HC).
41489355|NCT06250049|OTHER|Group education sessions for patients and/or caregivers|Conducting group education sessions for patients and/or caregivers on Diabetic Foot Care at the Health Centers.
41489356|NCT02775708|DEVICE|Pillcam endoscopy system|
41489357|NCT02466230|DEVICE|Repetitive transcranial magnetic stimulation|Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
40824644|NCT01175434|OTHER|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
40824645|NCT06053203|OTHER|Exposure of interest - Moderate or High-risk Preeclampsia|No intervention
41018528|NCT02438241|PROCEDURE|TENS Group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
41018529|NCT02438241|PROCEDURE|Placebo TENS group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
41343367|NCT05087563|DEVICE|Neurolens spectacle lens|spectacle lens
41343368|NCT05087563|DEVICE|Placebo spectacle lens|spectacle lens for refractive correction
41343369|NCT01381809|DRUG|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
41343370|NCT01381809|DRUG|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
41343371|NCT05242809|BEHAVIORAL|Group-based PFMT group|The intervention group receives PFMT supervision in groups of about 6-8 women
41343372|NCT02227290|DRUG|Naftin Cream|
41343373|NCT02227290|DRUG|Placebo Cream|
41489358|NCT03823495|OTHER|12-week PAP|It is a non-drug intervention, using exercises to reduce elderlies chronic pain.
41489359|NCT03174951|DRUG|IVIg|Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.
41489360|NCT01267721|PROCEDURE|Blood sampling|Blood sampling at various time points. Additional 92 mL blood.
41489361|NCT01608386|PROCEDURE|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
41489362|NCT01321619|DRUG|Daflon|Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
41489363|NCT01321619|DRUG|Varicell placebo|Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
41489364|NCT02005887|DRUG|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
41018530|NCT03662750|DIAGNOSTIC_TEST|Brain Imaging|"The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo:~1. Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain),~2. Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium),~3. Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning),~4. Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker).~Venous cannula will be inserted into the forearm for the duration of the scans."
41018531|NCT03850886|DIETARY_SUPPLEMENT|Niacinamide Oral Tablet|Nature's Life Niacinamide 1000 mg
41018532|NCT03850886|DRUG|Antidiabetic|Metformin or Sulphonylurea
41018533|NCT06309199|DIETARY_SUPPLEMENT|Biogaia|Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
41018534|NCT06309199|OTHER|Placebo|Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
41018535|NCT02242877|DRUG|Telmisartan|
41018536|NCT02242877|DRUG|Telmisartan combined with hydrochlorothiazide|
41489365|NCT02005887|DRUG|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
40824646|NCT04848714|DRUG|ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL|Antivenin latrodectus (black widow) equine immune F(ab)2\] lyophilized powder for solution 10 mL for intravenous use \[parenteral formulation\]; hence, a single-dose fasting pharmacokinetic study is planned.
40824647|NCT02435680|DRUG|MCS110|taken by I.V
40824648|NCT02435680|DRUG|carboplatin|taken by I.V
41489366|NCT02005887|DRUG|letrozole|Letrozole 2.5 mg orally every day for 6 cycles
41489367|NCT05473962|DIAGNOSTIC_TEST|assessment and quantification of symptoms related to post-traumatic stress.|Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
41489368|NCT03476369|DRUG|Fentanyl|Premedicated with Fentanyl (at least 25mcg by IV)
41489369|NCT03476369|DRUG|Ticagrelor 90Mg Tablet|Ticagrelor administered crushed vs non-crushed
41489370|NCT04249544|DRUG|Pramipexole|1mg of pramipexole
41489371|NCT04249544|DRUG|Placebo|1mg equivalent of placebo
41489372|NCT01797835|BEHAVIORAL|CHAT brief MI intervention|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
40824649|NCT02435680|DRUG|gemcitabine|taken by I.V
40824650|NCT04691141|DRUG|ATG-016|59 patients enrolled will be treated with ATG-016, orally, each 4 week (28-day) a cycle
40824651|NCT05282576|OTHER|NPF Group|Participants allocated to the experimental group completed until discharged, neurophysiological facilitation(NPF) techniques in addition to conventional physiotherapy.
40824652|NCT05282576|OTHER|Control Group|Critical ill patients was applied their conventional physiotherapy which includes chest physiotherapy and mobilization until discharged
40824653|NCT00174681|DRUG|Insulin Glargine|
40824654|NCT01057225|DRUG|carfilzomib|Given IV
40824655|NCT01057225|DRUG|cyclophosphamide|Given orally
40824656|NCT01057225|DRUG|thalidomide|Given orally
40824657|NCT01057225|DRUG|dexamethasone|Given orally
41018537|NCT02879097|BIOLOGICAL|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
41018538|NCT02879097|BIOLOGICAL|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
41018539|NCT02879097|DRUG|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
41018540|NCT02879097|DRUG|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
40824658|NCT02868034|BEHAVIORAL|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
41018541|NCT06312826|PROCEDURE|Abdominal US|The acquired images included B-mode images of the left hepatic lobe through transverse and longitudinal scans including images of the umbilical portion of the left portal vein, and images of the right hepatic lobe through subcostal and intercostal scans including images of the right hepatic dome, right portal vein, and right hepatic vein with additional images of the confluence of both portal vein and three hepatic veins. When a liver observation was seen, additional images were taken, and its diameter was measured on both transverse and longitudinal planes.
41343374|NCT03929406|DEVICE|Brain Tissue Imprint|"Brain Tissue Imprint procedure (BTI) is performed during DBS surgery. Before the implantation of the electrode, the surgeon uses a dilator. It is a rigid stylet with a blunt end, intended to prepare the way for the final electrode. This dilator is lowered gently through the cerebral parenchyma up to the target then removed to be replaced by the electrode.~In our BTI study, the standard dilator used in DBS surgery will be replaced by a CE marked Medical Device. This brain imprint kit will be used for each hemisphere. The procedure is the following:~* The guide tube with the first stylet is set up to the target~* Withdrawal of the first stylet and insertion of the second stylet for one minute to have a spontaneous and adequate tissue adhesion~* Withdrawal of the guide tube containing the stylet. This last step will prevent contamination of the harvested material on the stylet during the removal."
41343375|NCT03309241|DRUG|PF-06882961|Single Ascending Doses of PF-06882961 from 3mg to TBD mg.
41343376|NCT03309241|OTHER|Placebo|Placebo Single Dose
41489373|NCT01797835|BEHAVIORAL|usual care|Youth receive a brochure with information on AOD use.
41489374|NCT03682458|GENETIC|Study of Neurodegenerative Diseases Induced Stem Cells|The aim of this study is to generate iPS-induced stem cell lines from patients with neurological and neurodegenerative diseases to differentiate into neurons and glial cells to study the pathological cellular and molecular processes of these diseases. These in vitro cultures will also be used to validate molecules or experimental therapeutic approaches. IPS cells will be generated by the reprogramming of isolated 10-mL cells of peripheral venous blood.
41489375|NCT05633108|OTHER|No Intervention|No intervention will be administered.
41489376|NCT03140852|BEHAVIORAL|Mind Over Matter; Healthy Bowels, Healthy Bladder|This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
41343377|NCT04416269|DRUG|Oral Anti-diabetes Drugs alone|OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
41343378|NCT04416269|DRUG|Basal bolus insulin|Basal insulin with glargine or detemir will be used as per the hospital formulary.
41343379|NCT04416269|DRUG|Supplemental insulin|Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG \>140 mg/dl.
41343380|NCT04416269|DEVICE|Continuous glucose monitoring (CGM)|"A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes."
41343381|NCT02982642|DRUG|1612 capsule|Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
41343382|NCT02982642|DRUG|Placebos|Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
41343383|NCT01432938|BIOLOGICAL|dulaglutide|Administered subcutaneously
41343384|NCT01432938|DRUG|Warfarin|Administered orally
41489377|NCT03249337|DRUG|Ripasudil hydrochloride hydrate 0.4% ophthalmic solution|"the ophthalmic solution will be administered three or six per times per day in the eye designated as the Study Eye upon study enrollment"
41489378|NCT00057213|DRUG|Radafaxine|
41489379|NCT00807677|DRUG|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
41489380|NCT01386151|DRUG|Keratinocyte Growth factor|KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
41489381|NCT01386151|DRUG|Saline placebo|Normal (0.9%) saline will be used as a placebo.
41489382|NCT03145077|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
41018542|NCT06312826|PROCEDURE|AMRI|The study subjects receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination is conducted using a 3T MRI machine, and the MRI protocol consists of T2-weighted imaging, diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
40824659|NCT02868034|BEHAVIORAL|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
41018543|NCT04875104|DEVICE|Orthodontic treatment with Invisalign system|Patients are going to receive an orthodontic treatment with Invisalign aligners.
41018544|NCT04875104|DEVICE|Orthodontic treatment with Spark system|Patients are going to receive an orthodontic treatment with Spark aligners.
41018545|NCT04875104|DEVICE|Orthodontic treatment with Quicksmile system|Patients are going to receive an orthodontic treatment with Quicksmile aligners.
41343385|NCT03221660|DEVICE|F-Composite 2 system|Procedures will be done using local anesthesia (if the patients wants that). The cavity is prepared according to the principles of the adhesive technique. First the adhesive will be applied and polymerized, afterwards the flowable resin-based restorative material will be applied and polymerized and then the sculptable resin-based restorative material will be applied and polymerized; all materials will be light-cured within short time with an experimental curing light.
41343386|NCT02623699|DRUG|Tofersen|Administered as specified in the treatment arm.
41343387|NCT02623699|DRUG|Placebo|Administered as specified in the treatment arm.
41343388|NCT02333136|DEVICE|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
41343389|NCT00209092|DRUG|Docetaxel|"Sequential Therapy: Docetaxel will be given at 100 mg/m\^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m\^2 IV Day 1."
41343390|NCT00209092|DRUG|Capecitabine|Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
41343391|NCT04849195|OTHER|No intervention|No intervention
41343392|NCT05081089|DRUG|Artemether-lumefantrine|Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.
41489383|NCT03145077|OTHER|Questionnaire Administration|Ancillary studies
40824660|NCT02868034|BEHAVIORAL|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
40824661|NCT02868034|BEHAVIORAL|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
40824662|NCT01596335|DRUG|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
40824663|NCT01596335|DRUG|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
40824664|NCT02319161|DRUG|Calcium channel blocker and beta blocker|The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
41018546|NCT04875104|DEVICE|Orthodontic treatment with ClearCorrect system|Patients are going to receive an orthodontic treatment with ClearCorrect aligners.
41018547|NCT03808896|PROCEDURE|stylet-assisted epiglottic lifting|use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
41018548|NCT03808896|DEVICE|bougie-assisted intubation|use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
41018549|NCT03623828|DRUG|Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe|Product administered using an external continuous subcutaneous infusion pump.
41018550|NCT05641194|DEVICE|Legacy Alerting System|Description: Standard alerting system in place at the fire station.
41018551|NCT05641194|DEVICE|Intervention 2: EaseAlert Standalone|Description: EaseAlert will activate and alert the subject of an emergency call without the legacy alerting system. EaseAlert (standalone) replaces the legacy alerting system.
41018552|NCT04973488|OTHER|Therapeutic plasma exchange|The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
41165755|NCT05926505|DRUG|Placebo|Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
41165756|NCT05926505|DRUG|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks. After the first period the patients will be randomized 1:1 to continue receiving subcutaneous treatment with 100mg anakinra once daily for 4 weeks or placebo once daily for 4 weeks.
41489384|NCT04016792|DRUG|Placebo|Placebo will be administered once daily
41489385|NCT04016792|DRUG|200 mg SPN-812|200 mg SPN-812 will be administered once daily and compared to Placebo
41489386|NCT01229735|DRUG|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
41489387|NCT01229735|DRUG|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
41489388|NCT02398630|RADIATION|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
41018553|NCT06204393|OTHER|Thyroid metabolic index|"The following indicators were collected from these patients: hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication.~Psychological evaluations (using the 7-item Generalized Anxiety Disorder Questionnaire, GAD-7, and the Patient Health Questionnaire 9, PHQ-9) and interventions."
41018554|NCT00949780|DRUG|Chloral Hydrate|
41018555|NCT03552159|BEHAVIORAL|Behavioral activation|Activity scheduling, monitoring, review and re-scheduling
41489389|NCT02398630|OTHER|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
41489390|NCT02398630|OTHER|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
40824665|NCT06479265|OTHER|Phyical/Cognitve Exercise|Participants will report to the CERC and review informed consent with a study investigator. Eligibility assessments (PAR-Q, WCST64, Medical History) will be done post-consent. Data collected will include age, body composition, gender, aerobic capacity, chronic medication use, and treated pathologies. All measurements will occur during one visit. Participants will lay supine for 5 minutes to measure resting heart rate (HR) using an HR monitor. This resting HR, with age-predicted HR max, will determine HR reserve (HRR). Participants will master the WCST64 and identify walking pace on the Blue Goji treadmill. They will complete a baseline 10 Meter Walk Test, followed by the digital WCST64 under 7 conditions, ending with a post-intervention 10 Meter Walk Test.
40824666|NCT01949623|OTHER|Anterior Chamber (AC) tap|Aqueous Samples will be collected for measurement of biomarkers
40824667|NCT06178016|OTHER|Bystander Intervention Program for Dating Violence|"The Bystander Intervention Program for Dating Violence includes the following topics: Dating violence and its types (Session 1), risk factors and consequences of dating violence (Session 2), bystander intervention in dating violence and barriers to intervention (Session 3), bystander intervention strategies for dating violence (Session 4), self-care for bystanders witnessing dating violence (Session 5).~Each session is planned to last 60-90 minutes. Materials will be used in the Bystander Intervention Program for Dating Violence are PPT (PowerPoint Presentations) slides, videos, interactive scenarios, and group discussions. The Bystander Intervention Program for Dating Violence is planned to be applied face-to-face in 4 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group."
40824668|NCT03362931|DEVICE|XEN45|XEN45 unilaterally implanted in the study eye
40824669|NCT05496686|DRUG|4.7 microCi 225Ac-MTI-201|4.7 microCi intravenous solution
40824670|NCT05496686|DRUG|9.5 microCi of 225Ac-MTI-201|9.5 microCi intravenous solution
40824671|NCT05496686|DRUG|19 microCi of 225Ac-MTI-201|19 microCi intravenous solution
40824672|NCT05496686|DRUG|38 microCi of 225Ac-MTI-201|38 microCi intravenous solution
40824673|NCT05496686|DRUG|76 microCi of 225Ac-MTI-201|76 microCi intravenous solution
40824674|NCT05496686|DRUG|152 microCi of 225Ac-MTI-201|152 microCi intravenous solution
40824675|NCT05496686|DRUG|254 microCi of 225Ac-MTI-201|254 microCi intravenous solution
40824676|NCT05496686|DRUG|424 microCi of 225Ac-MTI-201|424 microCi intravenous solution
40824677|NCT05496686|DRUG|564 microCi of 225Ac-MTI-201|564 microCi intravenous solution
40824678|NCT05496686|DRUG|750 microCi of 225Ac-MTI-201|750 microCi intravenous solution
40824679|NCT05496686|DRUG|998 microCi of 225Ac-MTI-201|998 microCi intravenous solution
40824680|NCT05496686|DRUG|1327 microCi of 225Ac-MTI-201|1327 microCi intravenous solution
40824681|NCT00000344|DRUG|Buprenorphine/naloxone|
41018556|NCT03552159|OTHER|Psychoeducation|Education on dementia, caregiving stress, event scheduling and communication skills
41489391|NCT02398630|OTHER|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
41489392|NCT00915928|DRUG|Perindopril|2,5 mg daily for 3 months
41489393|NCT00915928|DRUG|Placebo|Placebo dayli for 3 months
41489394|NCT01714232|DEVICE|Contour® PLUS BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
41489395|NCT01714232|DEVICE|OneTouch® SelectSimple™ BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
41489396|NCT01714232|DEVICE|Accu-Chek® Performa BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
40824682|NCT02218073|DRUG|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
41018557|NCT05668793|DIAGNOSTIC_TEST|GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in the group were collected and methylation tests were performed according to the kit instructions.
41018558|NCT05314153|DRUG|Brexanolone|Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
41018559|NCT06531707|DRUG|Ibuprofen + Loratadine fixed dose|Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day
41508998|NCT05477108|DRUG|Treatment A (BGF MDI HFO with oral activated charcoal)|Subject will receive 4 inhalations as a single dose with oral activated charcoal - test formulation; administered during 1 Treatment Period.
41343393|NCT05081089|DRUG|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
41489397|NCT01714232|DEVICE|Accu-Chek® Active BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
40824683|NCT02218073|DRUG|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
40824684|NCT02218073|DRUG|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
40824685|NCT03661905|OTHER|Cognitive therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
40824686|NCT03661905|BEHAVIORAL|Exposure and Response Prevention|Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
40824687|NCT06225648|OTHER|threonine|There are 7 different threonine test levels ranging from 5 to 45 mg of threonine per kilogram body weight per day.
40824688|NCT01757561|PROCEDURE|propofol|use total intravenous anesthesia with propofol
40824689|NCT01757561|PROCEDURE|sevoflurane|use inhalation anesthesia with sevoflurane
40824690|NCT02181361|DRUG|hirudin plus aspirin|natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily
41489398|NCT01714232|DEVICE|Freestyle Freedom® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
40824691|NCT02181361|DRUG|Warfarin|an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
40824692|NCT04131205|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
40824693|NCT06464744|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|Intermittent Theta burst stimulation will be delivered on the on the primary motor cortex using a figure-of-eight coil, supported by neuronavigation. The stimulation intensity will be set to 90% of the motor threshold
40824694|NCT06464744|PROCEDURE|Placebo stimulation using a placebo coil|The placebo coil looks identical to the active coil but it only delivers skin tingling and no active brain stimulation.
40824695|NCT01259076|PROCEDURE|magnetic resonance imaging|Undergo MRI at baseline and 1 year later.
40824696|NCT01259076|PROCEDURE|digital mammography|Undergo digital mammography at baseline and 1 year later.
40824697|NCT01259076|PROCEDURE|conventional surgery|Undergo gastric bypass surgery
40824698|NCT02952963|DRUG|Chenodeoxycholic Acid|
40824699|NCT02952963|DRUG|Colesevelam|
41018560|NCT06531707|DRUG|Ibuprofen|Suspension 2,000 mg / 100 mL, 20 mL twice a day
40824700|NCT04199273|PROCEDURE|Magnetic stimulation|Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.
40824701|NCT04199273|PROCEDURE|Electric stimulation|Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
40824702|NCT00315107|DRUG|Alesse|
40824703|NCT05989087|DIAGNOSTIC_TEST|CSF|Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.
40824704|NCT04277117|BEHAVIORAL|Waitlist|"Phase 1 (6 months)~• Educational materials on such topics as healthy eating for diabetes."
40824705|NCT04277117|BEHAVIORAL|Medically tailored meals - Daily delivery with human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 MTM a week: mix of hot and frozen, and 5-10 snacks per week. Meals and snacks offer approx. 1200 kcal per day.~* Delivery: 3 to 5x per week. Each delivery day, one meal is warm, the other is frozen. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (at minimum in-person hand-off \& visual check) with the participant."
41018561|NCT06531707|DRUG|Loratadine|Suspension 1 mg / 1 mL, 5 mL twice a day
41343394|NCT05081089|DRUG|Sulphadoxine-pyrimethamine with amodiaquine|Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.
41343395|NCT05081089|DRUG|Tafenoquine|100mg tafenoquine tablets are prepared into a 1mg/mL solution in water. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
41018563|NCT05036187|BEHAVIORAL|Behavioral Weight Loss Intervention|Rx Weight Loss: PRIDE is a fully automated online behavioral obesity treatment that is tailored for sexual minority women and involves viewing 12 online video lessons delivered each week, self-monitoring body weight, calorie intake, and physical activity levels, and receiving personalized automated weekly feedback on progress toward goals.
41018564|NCT05036187|BEHAVIORAL|Minority Stress Intervention|The Minority Stress Intervention is designed to help sexual minority women cope with stress and stigma (e.g., due to weight, sexual orientation, gender). In this program, participants watch online video lessons that teach cognitive and behavioral strategies for coping with minority stress so that it may have less of an influence on participants' weight and well-being.
41343396|NCT05575089|DEVICE|Inspiratory muscle training - Powerbreath|"The device Powerbreath is an inspiratory muscle training used to train respiratory muscles. Currently, it is one of the most used devices for the TMI, a linear load model with continuous application of inspiratory pressure throughout inspiration, in which the inspiratory regulating valve remains open while allowing an unrestricted expiration that generates resistance through a spring or of an electronic valve system, ability to offer greater load during training."
40824706|NCT04277117|BEHAVIORAL|Medically tailored meals - Weekly delivery with no human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 frozen MTM and 5-10 healthy snacks (with the goal of providing 2 meals and 1-2 snacks for 5 days of the week). Meals and snacks offer approx. 1200 kcal per day. Nutritionally similar and frequently the same meal as that delivered in the daily delivery arm.~* Delivery: 1x per week shipment.~* Engagement: Meals are shipped to the participant's home. No human engagement."
40824707|NCT04277117|BEHAVIORAL|Medically tailored meals - Standard MOWCTX delivery with human interaction|"Phase 2 (6 months)~* Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~* Delivery: 2 to 4x a week (depending on participant availability), including daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day or more (depending on the 2 to 4x a week delivery schedule participant is on) also including 1 frozen MTM to total 5 meals per week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~* MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care)."
40824708|NCT03217370|OTHER|education of guidelines|"* Guidelines will be updated and education will be given to haematologists in several ways.~* ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components"
40824709|NCT05899231|BEHAVIORAL|Prehabilitation Programming|"12-weeks of online prehabilitation programming including:~1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.~2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).~3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence."
40824710|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000|
40824711|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000|
40824712|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000|
40824713|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000|
40824714|NCT01213186|DRUG|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5\*10E6/kg for 48 weeks.
40824715|NCT01213186|DRUG|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5\*10E6/kg for 48 weeks.
40824716|NCT03568552|BEHAVIORAL|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
40824717|NCT03897725|OTHER|Telehealth Coaching|Telehealth coaching to promote adherence
41018565|NCT05036187|BEHAVIORAL|Negative Body Image Intervention|The Negative Body Image Intervention is designed to help participants improve their body image. In this program, participants will watch online video lessons that provide education on queer women's body image and teach cognitive and behavioral strategies for improving your body image (regardless of your weight) to reduce its influence on your health.
41343397|NCT05575089|OTHER|Aerobic exercise in cycle ergometer|10 face-to-face non consecutive sessions with 30 minutes in a cycle ergometer(divided into three steps: heat 5 minutes; 20 minutes with a comfortable and supportable speed or load ( individually prescribed) and 5 minutes recovery
41343398|NCT05575089|OTHER|Deep breathing exercises|Diaphragmatic exercises ( deep inspirations) associated to raise upper limbs ( 3 times - 10 repetitions each)
41343399|NCT04773847|PROCEDURE|Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.|Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.
40824718|NCT04287569|DEVICE|Record during endoscopy of video-endoscopy sequences and reflectance|Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
40824719|NCT03697499|COMBINATION_PRODUCT|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
40824720|NCT03697499|COMBINATION_PRODUCT|fish oil and sham exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
40824721|NCT03697499|COMBINATION_PRODUCT|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
41018566|NCT05036187|BEHAVIORAL|Social Support Intervention|The Social Support Intervention provides online opportunities for participants to receive more social support as they work toward their weight loss goals. Participants receive education on the importance of social support for weight management, they can earn badges for completing program milestones, and they gain access to a private online forum to get support and advice from other participants.
41018567|NCT04993352|DRUG|recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
41018568|NCT04530175|OTHER|blood sampling|2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.
41018569|NCT02560636|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
41018570|NCT02560636|RADIATION|Radiotherapy|Radiotherapy
41018571|NCT05458193|DRUG|Daridorexant|Film-coated tablet for oral use
41343400|NCT03484689|BEHAVIORAL|Mindfulness-based cognitive therapy MBCT|8-week mindfulness-based cognitive therapy
41018572|NCT05458193|DRUG|Placebo|Film-coated tablet for oral use
41018573|NCT00575744|PROCEDURE|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
41018574|NCT05734092|DEVICE|Traditional orthodontic treatment|As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.
41343401|NCT00864344|DRUG|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
41489399|NCT03048253|BIOLOGICAL|OrienX010|Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.
41489400|NCT05854017|DIETARY_SUPPLEMENT|Theanine for stress relief formulation|Theanine for stress relief formulation tablet
40824722|NCT03697499|COMBINATION_PRODUCT|soy oil and sham exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
41165757|NCT01044901|PROCEDURE|MRI, Transthoracic Echocardiography, tonometry, EKG|Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
41165758|NCT04760197|OTHER|no intervention|no intervention
41165759|NCT02460536|BEHAVIORAL|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
41343402|NCT00864344|DRUG|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
41343403|NCT01964729|DEVICE|rTMS|The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.
40824723|NCT04384445|BIOLOGICAL|Zofin|Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10\^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.
41343404|NCT01964729|DEVICE|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
40824724|NCT04384445|OTHER|Placebo|Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
40824725|NCT01819129|DRUG|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
40824726|NCT01819129|DRUG|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
40824727|NCT01819129|DRUG|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
41343405|NCT06188260|DRUG|Systane COMPLETE Lubricant Eye Drops|Active Ingredients: Propylene Glycol 0.6% Purpose: Lubricant
41343406|NCT01836367|DRUG|Ingenol Mebutate 0.015%|Picato
41343407|NCT02446860|DRUG|nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit.
40824728|NCT04782050|DEVICE|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
40824729|NCT06136286|DEVICE|Blood Flow Restriction (BFR) Cuff|The intervention group will receive therapy with a blood flow restriction cuff that restricts blood flow at their individual limb occlusion pressure during specific exercises.
40824730|NCT05108090|PROCEDURE|sentinel lymph node biopsy (SLNB)|"Preoperative Lymphoscintigraphy: A standard injection of 2 mCi of 99m-Technetium sulfur colloid. Sequential immediate and delayed images will be obtained using SPECT/CT using a gamma probe. Ten-second counts will be done in areas of high activity to identify location of sentinel lymph node (SLN). After removal of the lymph node, a 10-second count will be done of the lymph node ex-vivo followed by 10-second count of the lymph node resection bed to ensure removal of SLN (less than 10% activity of LN).~Surgical resection: Mohs micrographic surgery followed by SLNB. Intraoperative margins around the tumor will be confirmed through frozen section analysis. Patients with planned free flap reconstruction, will undergo SLNB with intraoperative, frozen section analysis. If lymph node is positive, immediate completion neck dissection will occur."
40824731|NCT06390696|BIOLOGICAL|Microbial intervention|Children in microbial intervention arm receive an indoor sandbox containing play sand enriched with organic leaf compost, moss and humus substances. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and microbe rich growing medium containing organic leaf compost, moss, biochar and humus substances.
41165760|NCT02460536|BEHAVIORAL|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
40824732|NCT06390696|OTHER|Placebo|Children in placebo arm receive an indoor sandbox containing visually similar play sand modified with peat with low microbial diversity. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and growing medium containing peat, inorganic fertilizers, and potting gravel with low microbial diversity.
41343408|NCT04427228|RADIATION|Radiosurgery Single Treatment|Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) \< 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.
41343409|NCT04427228|RADIATION|Radiosurgery Three Treatments|Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group
41343410|NCT03152110|OTHER|HIIT|"A handcycle or tabletop ergometer will be used for HIIT. Exercise sessions will be scheduled 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.~Supervised exercise sessions: Measures include HR, BP, RPEs, Feeling Scale, and PPO. After warming up, individualized work/rest phases will be prescribed based on their PPO from their maximal aerobic test. Participants will be held at 90% PPO as a constant target intensity to start, shortening the work phase, and if necessary, lengthening the recovery phase. These parameters will be progressed each session. The trainer will determine when to change their work/rest parameters based off of HR and RPEs.~Unsupervised exercise sessions: Participants will repeat the same HIIT protocol they performed during the previous supervised session. The bike computer automatically stores HR and PPO."
41343411|NCT02040298|DRUG|Clemastine|4mg tablet twice daily
41343412|NCT02040298|DRUG|Placebo|Placebo tablet twice daily
41165761|NCT02460536|BEHAVIORAL|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
41165762|NCT02460536|BEHAVIORAL|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
41343413|NCT02397967|OTHER|Neuropsychological assessments|"Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
41489401|NCT05854017|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
41489402|NCT01365117|DRUG|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder \[one 20 U, two 20 U and one 40 U cartridges)
41343414|NCT02509611|OTHER|Hatha yoga|Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
41489403|NCT01365117|DRUG|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder \[one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)\])
41489404|NCT02027181|DEVICE|Device FreeO2 v2.0|"* Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
41489405|NCT02027181|DEVICE|Device FreeO2 v2.0|"* Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
40824733|NCT00429117|BEHAVIORAL|Survey|Internet survey lasting 30 to 40 minutes.
41489406|NCT02838810|DRUG|peginterferon alfa|peginterferon alfa-2b or peginterferon alfa-2a
40824734|NCT02082223|BEHAVIORAL|Interventions to improve preop QOL/resilience deficits|Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
40824735|NCT01607333|DRUG|Lamotrigine use|Lamotrigine prescription during the study period
40824736|NCT01567202|PROCEDURE|Surgery|Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
40824737|NCT01567202|DRUG|Chemotherapy|Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
40824738|NCT01567202|RADIATION|Radiotherapy|Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
40824739|NCT01567202|BIOLOGICAL|DC vaccination|Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
40824740|NCT01567202|DRUG|blank placebo|Saline that has the same appearance with DC vaccine.
40824741|NCT06216782|OTHER|Non-intervention|Non-intervention
40824742|NCT01698450|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
41489407|NCT02838810|DRUG|Nucleoside analogues|Nucleoside analogues
41489408|NCT00552383|PROCEDURE|NIDCAP based developmental care|"Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff \[this includes 3 of the investigators\], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided baby -friendly care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU."
41489409|NCT03900065|PROCEDURE|Preconditioning|Foam-mediated intermittent negative pressure will be applied to the skin of the planned flap for 5 days before surgery.
41489410|NCT03989622|OTHER|evaluation of the visual field on the ground|evaluation of the visual field on the ground
41489411|NCT06390644|DIAGNOSTIC_TEST|Periorbital Massage Therapy|Participants in this arm will receive periorbital massage therapy administered by a trained practitioner. The massage technique will involve gentle circular motions around the eye sockets and brow bone area, aiming to improve eyelid and tear gland function.
41489412|NCT06390644|OTHER|Control Group (Standard Care)|"Participants in this arm will receive standard care for dry eye disease, which include artificial tears. They will not receive periorbital massage therapy."
41489413|NCT00002639|DRUG|chemotherapy|
41489414|NCT00002639|DRUG|suramin|
41489415|NCT00045903|BEHAVIORAL|Exposure and Ritual Prevention (Cognitive Behavioral Therapy)|
41489416|NCT00045903|BEHAVIORAL|Stress Management Therapy (Cognitive Behavior Therapy)|
41489417|NCT02649985|DRUG|[F-18]PBR06|PET radiopharmaceutical
41489418|NCT02649985|DRUG|[C-11]PBR28|PET radiopharmaceutical
41489419|NCT01167959|PROCEDURE|Roux en Y gastric bypass and lap. gastric banding|Standard RYGB and LAGB procedures
40824743|NCT03522038|PROCEDURE|percutaneous coronary intervention|PCI was performed using standard techniques. Antiplatelet and antithrombotic agents were prescribed according to current PCI guidelines. A procedure was considered successful when achieving TIMI flow grade 3 with \<30% angiographic residual stenosis in the CTO vessel. All patients received drug-eluting stents and were discharged on dual antiplatelet therapy with duration of at least on year.
40824744|NCT01608217|DRUG|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
40824745|NCT01608217|DRUG|Placebo|placebo (tablet) three times daily for a period of three weeks.
40824746|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
40824747|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
40824748|NCT04690803|DRUG|air cooling|intervention is adding air-cooling to treatment
41343415|NCT01207674|OTHER|Summons of patients and filling questionnaire|The study is conducted at the same time by 7 French specialised centres. The recruitment period is comprised between April 2009 and September 2011.For the first stage of the study, an initial evaluation will be performed at the time of recruitment. It consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and half hour, and focused mainly on gambling trajectory and severity, and on psychiatric and addictive comorbidities. The evaluation is completed by a set of self-administered questionnaires focused on cognitive distortions, temperament and character, ADHD, etc.For the second stage of the study, the cohort will be re-evaluated each year, based on the same questionnaires that for initial evaluation. Each participant will be followed-up during 5 years. The study will thus end up in September 2016.
41489420|NCT01167959|BEHAVIORAL|Prodimed dietary intervention|3 months of using the prodimed diet
40824749|NCT04521998|DEVICE|electroacupuncture|Electroacupuncture used to reduce the inflammation was proved previously.
40824750|NCT04521998|DEVICE|TENS|Patients who unlike needles would like to choose TENS as treatment for pain relief.
40824751|NCT02791191|DRUG|LY3202626|Administered orally
40824752|NCT02791191|DRUG|Placebo|Administered orally
40824753|NCT00302276|DRUG|Metobes-compound|
40824754|NCT00499382|PROCEDURE|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
40824755|NCT00499382|PROCEDURE|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
40824756|NCT06413420|DRUG|Sunosi (solriamfetol)|Exposure to at least 1 dose of solriamfetol at any time during pregnancy.
41343416|NCT05376189|DIETARY_SUPPLEMENT|400 IU|An Oral Vitamin D3 400 IU will be given once daily for a total of 8 weeks
41343417|NCT05376189|DIETARY_SUPPLEMENT|5000 IU|An Oral Vitamin D3 5000 IU will be given once daily for a total of 8 weeks
41489421|NCT01103466|DEVICE|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
41489422|NCT01103466|DEVICE|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
41489423|NCT01103466|DEVICE|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
41508999|NCT05477108|DRUG|Treatment B (BGF MDI HFA with oral activated charcoal)|Subject will received 4 inhalations as a single dose with oral activated charcoal - reference formulation; administered during 2 Treatment Periods.
41509000|NCT04610333|BEHAVIORAL|Modified MBSR programme|1 hour group session once a week in 10 weeks
41509001|NCT05698433|OTHER|No intervention|No intervention
40824757|NCT06413420|DRUG|Other prescription wake-promoting medications or stimulants|Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.
40824758|NCT06413420|OTHER|No treatment|No treatment
40824759|NCT03440918|OTHER|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
40824760|NCT03440918|OTHER|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
40824761|NCT04839978|BEHAVIORAL|Connect Program|The Connect program includes school-based screening, brief intervention and referral, and will be treated as part of the participating schools' prevention programs. A computer-based screening and brief intervention will be supported by Cherokee Nation Behavioral Health (CNBH) supervised Connect coaches universally, to reduce potential stigma associated with speaking to a Connect coach and to reinforce drugfree norms among all students. Follow-up of moderate to high-risk youth will be conducted by a Connect Coach through Zoom, other electronic communication, or in-person visits, with referral to Cherokee Nation or community services if deemed necessary.
41343418|NCT05376189|DIETARY_SUPPLEMENT|10000 IU|An Oral Vitamin D3 10000 IU will be given once daily for a total of 8 weeks
41343419|NCT05376189|DRUG|Fixed Drug Combination|Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
41343420|NCT04154995|DIAGNOSTIC_TEST|Venipuncture|Blood testing at 3, 6 and 12 months
41343421|NCT04154995|DIAGNOSTIC_TEST|Ultrasound Quadriceps Muscles|Ultrasound measurement of quadriceps muscle mass and health
40824762|NCT04839978|BEHAVIORAL|Communities Mobilizing for Change and Action (CMCA)|The community-level intervention Communities Mobilizing for Change and Action (CMCA) will involve educating and organizing of adult volunteers and consent will be assumed by their participation. We will provide trainings and tools, including Family Action Kits, to support local families, community organizations and citizens, including information on national and local opioid and other drug use, evidence-based policies, programs and practices, and how to motivate and create family and local action for drug prevention.
41343422|NCT02108522|BIOLOGICAL|Multivirus Specific T cells|
41343423|NCT01156363|PROCEDURE|Dialysis|regular haemodialysis or peritoneal dialysis
40824763|NCT05819021|DEVICE|SAINT® Neuromodulation System (NMS)|The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.
41343424|NCT01156363|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
41343425|NCT02410590|DRUG|Rocuronium|
41489424|NCT03294486|DRUG|Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)|"Phase 1, TG6002 administered in a total volume of 250mL of saline solution (0.9 %) as three intravenous infusions at the following doses:~* Dose 1 : 5.0 log10 pfu •Dose 2 : 6.0 log10 pfu •Dose 3 : 7.0 log10 pfu •Dose 4 : 7.5 log10 pfu~* Dose 5 : 8.0 log10 pfu •Dose 6 : 8.5 log10 pfu Additional dose levels •Dose 2-1 : 5.5 log10 pfu •Dose 3-2 : 6.5 log10 pfu Phase 2a, treatment IV at the recommended Phase 2 dose 5-Flucytosine (5-FC) is provided in its commercial packaging with brand name ANCOTIL 500 mg, tablet (Ancotil®) marketed by MEDA Pharma: polypropylene tube containing 100 tablets.~  5-FC administered orally as 500 mg tablets taken 4 times per day (qid). Daily starting dose is 200 mg/kg. The daily dose will be adjusted at Day 19 following the measurement of 5-FC plasma concentration at steady state (Day 7), which should be kept below 100 mg/L."
40824764|NCT02114125|BEHAVIORAL|Physical Activity|group-based physical activity
40824765|NCT02114125|BEHAVIORAL|Cognitive Training|individual-based, multi-domains cognitive training
41036505|NCT05210192|DRUG|Placebo|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
41036506|NCT00489606|DRUG|SK3530|
41343426|NCT02410590|DRUG|Sugammadex|
41343427|NCT02410590|DRUG|Cisatracurium|
41343428|NCT02410590|DRUG|Neostigmine/Atropine|
41343429|NCT02410590|DRUG|Succinylcholine|
41489425|NCT04596228|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
41489426|NCT00537420|DRUG|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
41489427|NCT00537420|DRUG|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
41489428|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
41343430|NCT06213415|DRUG|Corticosteroid|Oral steroids plus intratympanic injection
41343431|NCT01876472|BEHAVIORAL|Assessment of music perception skills|A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
41343432|NCT04619381|BEHAVIORAL|CORONARY ARTERY DISEASE AND CLOPIDOGREL: PATIENT SURVEY|Survey is a non-standardized assessment of demographics, medication compliance and reasons for non- compliance.
41343433|NCT04144062|OTHER|CAD/CAM crowns|CAD/CAM crowns
41343434|NCT02002065|BIOLOGICAL|Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
41343435|NCT02002065|BIOLOGICAL|Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
41489429|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
41489430|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
41489431|NCT00537420|DRUG|Sibutramine|Sibutramine will be taken once daily with or without food
41489432|NCT01211080|DRUG|Propranolol|Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
40824766|NCT01952665|DEVICE|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
41343436|NCT00666536|DRUG|valsartan and amlodipine|
41018575|NCT05734092|DEVICE|Low-Level Laser|"The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage."
41343437|NCT00666536|DRUG|valsartan and amlodipine|
41343438|NCT04233840|DRUG|P1101 (Ropeginterferon alfa-2b)|solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks
41343439|NCT04233840|DRUG|Nivolumab|"Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101"
41343440|NCT03860844|DRUG|Isatuximab|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
41343441|NCT03860844|DRUG|Dexamethasone or equivalent|Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
41343442|NCT03860844|DRUG|Fludarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41343443|NCT03860844|DRUG|Cytarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41343444|NCT03860844|DRUG|Liposomal daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41489433|NCT06137690|DEVICE|other antifungal agents,breathing machine|If treatment failure for patients in group A and group B，change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
41489434|NCT01254266|BEHAVIORAL|inpatient hospitalization and follow up|An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.
41489435|NCT01254266|BEHAVIORAL|inpatient treatment and follow up|one month inpatient treatment followed by a year-long follow up on the inpatient unit.
41489436|NCT01254266|PROCEDURE|bariatric surgery|bariatric surgery.
41489437|NCT01254266|BEHAVIORAL|inpatient treatment with follow up|1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
41489438|NCT04192279|DIAGNOSTIC_TEST|lactate clearance|Lactate clearance rate was monitored within 6 hours after admission
41489439|NCT02459496|BEHAVIORAL|dietary consulting and advise|first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
41489440|NCT03199430|DIETARY_SUPPLEMENT|Epigallocatechin gallate|
41343445|NCT03860844|DRUG|Daunorubicin (nonliposomal)|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
41343446|NCT03860844|DRUG|Idarubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41489441|NCT03199430|DIETARY_SUPPLEMENT|Placebo|1450mg Corn Flour
40824767|NCT01952665|DEVICE|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
40824768|NCT01728077|DRUG|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
40824769|NCT00361699|DRUG|Statin|
41489442|NCT06176066|PROCEDURE|CEST PH MRI based resection of glioblastoma|Using pre-operative amine chemical exchange saturation transfer pH weighted MRI, regions of interest that correspond to infiltrating glioblastoma will be identified and via intraoperative neuronavigation, guide resection of glioblastoma
41489443|NCT02991027|DEVICE|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical short cavity tunable laser
41343447|NCT03860844|DRUG|Filgrastim or equivalent|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41343448|NCT03860844|DRUG|Mitoxantrone|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41343449|NCT03860844|DRUG|Doxorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41343450|NCT03860844|DRUG|Vincristine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41489444|NCT02991027|DEVICE|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical tunable vertical cavity surface emitting laser
41489445|NCT03168971|BEHAVIORAL|Managing Anxiety from Cancer (MAC)|The intervention consists of seven telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques, problem-solving strategies, and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
41489446|NCT01401257|DRUG|PXT3003 Low dose|Liquid,5 ml, twice a day, 12-month treatment
41489447|NCT01401257|DRUG|PXT3003 Intermediate Dose|Liquid,5 ml, twice a day, 12-month treatment
41489448|NCT01401257|DRUG|PXT3003 High Dose|Liquid,5 ml, twice a day, 12-month treatment
41489449|NCT01401257|OTHER|Placebo|Liquid,5 ml, twice a day, 12-month treatment
41343451|NCT03860844|DRUG|Pegaspargase (PEG) Asparaginase|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
40824770|NCT01310179|GENETIC|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
40824771|NCT04486482|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
41343452|NCT03860844|DRUG|Cyclophosphamide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41489450|NCT06039384|DRUG|INCB099280|Administered as specified in the treatment arm description
41489451|NCT06039384|DRUG|adagrasib|Administered as specified in the treatment arm description
41489452|NCT00102518|DRUG|Aripiprazole|2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
40824772|NCT04486482|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
40824773|NCT01882010|DRUG|sargramostim|"lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days"
41343453|NCT03860844|DRUG|Etoposide|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
41489453|NCT03889366|DRUG|Aprepitant 125 mg|Single dose in the fasted state during treatment period 1,2 or 3
41489454|NCT05367518|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable tablet (lozenge) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
40824774|NCT01882010|DRUG|placebo|saline solution daily subcutaneous injection 56 days
41489455|NCT05367518|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable table (lozenges) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
40824775|NCT01882010|DIAGNOSTIC_TEST|Sham Comparator: Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
40824776|NCT02275390|BEHAVIORAL|Nurse-led Psycho-education (or SPBB: self-learning program)|"The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).~\[Note: SPBB consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5: Dealing with \[physical and mental health\] effects of the illness).\]"
41489456|NCT01642914|DRUG|Linaclotide 290 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
40824777|NCT02275390|BEHAVIORAL|Usual Psychiatric Outpatient Care|These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
41343454|NCT03860844|DRUG|Methotrexate|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
41343455|NCT03860844|DRUG|L - Asparginase|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
41343456|NCT03860844|DRUG|Hydroxyurea|Pharmaceutical form: Solution for injection Route of administration: PO
41343457|NCT03860844|DRUG|L - Asparaginase (Erwinase)|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
41489457|NCT01642914|DRUG|Linaclotide 145 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
41489458|NCT01642914|DRUG|Matching placebo|oral capsule, taken once daily each morning at least 30 minutes before breakfast
41489459|NCT04001101|COMBINATION_PRODUCT|RT and Anti-PD-1|limited metastatic site radiation
41489460|NCT04001101|DRUG|Anti-PD-1|anti-PD-1 therapy alone
40824778|NCT01184833|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
40824779|NCT01571284|DRUG|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
40824780|NCT01571284|DRUG|FOLFIRI|irinotecan, 5-FU and leucovorin
41343458|NCT02315105|PROCEDURE|Laparoscopic Greater Curvature Plication|LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
41343459|NCT04901390|DIETARY_SUPPLEMENT|Yogurt with B. lactis and added cane sugar|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with cane sugar twice daily for 14 days.
41343460|NCT01752075|DRUG|Revlimid|The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
41343461|NCT00949806|DRUG|BNT (intradermal injection)|"Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient."
41343462|NCT04574674|BEHAVIORAL|Flexibility exercise programme|Static passive flexibility exercises.
40824781|NCT03600766|DRUG|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks.
41343463|NCT04574674|BEHAVIORAL|Resistance exercise programme|Body weight and resistance bands exercises.
40824782|NCT03600766|DRUG|placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
41343464|NCT04235088|OTHER|Somatosensory intensive intervention|The intensive somato-sensory intervention will take place during 3 weeks, 5 days per week, for 2 hours per day (30 hours of practice). During the week-ends, some somato-sensory written activities will be explained and handed to each family (6 hours of practice) Therapy sessions will be carried out in groups and each child will have his or her own therapist in charge of his or her treatment along the whole intervention. A daily check-list, design for that purpose, will be used by the therapist in order to register the gradually increased complexity of the activities and individual progression. The principal investigator will supervise all the interventions in order to assure their uniformity, adjusting the somato-sensory training protocol to the individual needs of each subject.
40824783|NCT04006613|OTHER|Circuit Training|20 minutes of High Intensity Aerobic Training (HI) on treadmill: 2 minutes warm up + 4x 4 minutes HI+ 2 minutes of active recovery; 10 minutes of dynamic balance training; 10 minutes of functional strength training.
40824784|NCT04006613|OTHER|Usual Care|Exercises aimed at improving mobility and balance
41343465|NCT03426761|DRUG|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
40824785|NCT06490653|DRUG|Blood Stopper (Ankaferd)|5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
41343466|NCT03426761|DRUG|Vancomycin|Examples of standard of care arm; infusions one to three times per day depending on the antibiotic for a total of three to eight weeks
41343467|NCT02737371|DRUG|F901318 Dose level A oral|Adverse events days 1-10
41343468|NCT02737371|DRUG|Placebo dose level A oral|Placebo adverse events days 1-10
41343469|NCT02737371|DRUG|F901318 Dose level B oral|F901318 adverse events days 1-10
41343470|NCT02737371|DRUG|Placebo dose level B oral|Placebo adverse events days 1-10
41343471|NCT02737371|DRUG|F901318 Dose level C oral|F901318 adverse events days 1-10
40824786|NCT05530395|DIAGNOSTIC_TEST|Testosterone levels|Blood sample to determine testosterone levels
40824787|NCT02638389|DRUG|Sirolimus|evaluate the efficacy and safety of sirolimus in these patients
40824788|NCT03060512|DRUG|Polyethylene Glycol 3350|"Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
40824789|NCT03060512|DRUG|Movantik|"Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
41018576|NCT06068816|DIETARY_SUPPLEMENT|Nutrient-dense drink|a nutrient-dense drink developed by FrieslandCampina in line with the European Society for Clinical Nutrition and Metabolism guidelines for the dietary management of older malnourished patients
41018577|NCT04442737|DRUG|D/C/F/TAF FDC|A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
41018578|NCT04442737|DRUG|TAF/FTC FDC|TAF/FTC ARV regimen will be administered once daily.
41018579|NCT04442737|DRUG|INI Based Regimen|The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
40824790|NCT04352985|DEVICE|Toraymyxin PMX-20R (PMX Cartridge)|The intervention is two (2) treatment sessions of PMX cartridge administration within approximately 24 hours of each other. Each treatment session will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute). In cases where the clinical status of the subject is improving, or if the subject suffers from a relapse and the treating physician believes an additional PMX treatment may improve the clinical outcome of the subject, they may administer an additional PMX treatment session (for a total of 3 treatment sessions) at their discretion. All subjects will continue to receive standard medical care for COVID 19 and septic shock.
41343472|NCT02737371|DRUG|Placebo Dose level C oral|Placebo adverse events days 1-10
40824791|NCT01389154|PROCEDURE|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
40824792|NCT01524003|PROCEDURE|cryotherapy|cryotherapy treatment of the uterine cervix
40824793|NCT01524003|PROCEDURE|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
40824794|NCT00875238|BIOLOGICAL|trastuzumab|
40824795|NCT00875238|DRUG|doxorubicin hydrochloride|
40824796|NCT00875238|GENETIC|polymorphism analysis|
40824797|NCT00875238|OTHER|laboratory biomarker analysis|
41343473|NCT06434090|DRUG|Liposomal irinotecan|Liposomal irinotecan will be given biweekly at a dose from 70mg/m2 to 90mg/m2.
40824798|NCT00875238|OTHER|questionnaire administration|
40824799|NCT00875238|PROCEDURE|assessment of therapy complications|
40824800|NCT00875238|PROCEDURE|magnetic resonance imaging|
40824801|NCT04904796|OTHER|CIMT|CIMT : Constraint-Induced Movement Therapy (CIMT) is a deviation from traditional treatments, used to treat hemiplegia. Its aim is to stimulate the functional use of the affected limb and reverse the process developmental is disregard. In this method, the unaffected or less affected limb is restrained, so the person has to use the affected limb.
40824802|NCT04904796|OTHER|H-HABIT|H-HABIT : Hand-Arm Bimanual Intensive Therapy (HABIT) in children with hemiplegia is a new intervention developed at Columbia University. HABIT aims to improve the use and coordination of both arms in daily function. Unlike CIMT, HABIT focuses on improving the ability to perform bimanual activities. Participants will be monitored via webcam-based software (i.e. ZOOM) while they performed the activities in their own home.
40824803|NCT05783076|DRUG|Stereotactic body radiation therapy|Details have been shown in arm descriptions.
40824804|NCT05783076|DRUG|adoptive cell therapy with vNKT cells|Details have been shown in arm descriptions.
41343474|NCT06434090|DRUG|Bevacizumab|bevacizumab will be given biweekly at a dose of 5mg/m2
41343475|NCT03442595|OTHER|Intensive diabetes education and medication management|Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
41489461|NCT03547336|DEVICE|Theranova 400 Dialyzer|Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
41036507|NCT01574300|OTHER|therapeutic interventions|All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
41036508|NCT00054353|DRUG|fludarabine phosphate|Given IV
41509002|NCT00461253|DEVICE|Levonorgestrel-releasing IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
41343476|NCT04381533|BEHAVIORAL|Internet-delivered Adolescent Community Reinforcement Approach (I-A-CRA)|The intervention is a behavioral internet-based intervention based on the Adolescent Community Reinforcement Approach. The program encompasses text, pictures, videos, and written as well as practical assignments (skills training). The main components of the treatment for the young adult with problematic alcohol use consist of psychoeducation and functional analysis, goal formulation, increasing prosocial behaviors, relapse prevention, problem solving, and communication training. The accompanying significant other receives modules containing information focusing on gaining an understanding of the treatment components aimed at the young adult, as well as communication training to improve communication between the young adult and the significant other.
41343477|NCT04381533|BEHAVIORAL|Psychoeducation, information on use of alcohol and its effects|The intervention is a behavioural internet-based intervention including psychoeducation focusing on providing information on alcohol, alcohol use, and its effects. The psychoeducation is provided via texts and pictures, and there is a possibility of asking questions to a therapist if needed however no therapist contact is mandatory. There are separate programs directed towards the young adult and the accompanying significant other. The programmes give brief self-help tips at the end. The intervention approximately corresponds to the information given in a primary care setting for someone with problematic alcohol use.
41343478|NCT03116841|DRUG|Vonoprazan|Vonoprazan 20 mg
41343479|NCT00826709|DEVICE|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
41343480|NCT03903276|OTHER|rehabilitation|Tens
41343481|NCT06407336|DIAGNOSTIC_TEST|Contrast sensitivity|Contrast sensitivity will be assessed by using two different techniques of refraction on is Cylinderical lens and other is Spherical equivalent
41343482|NCT06407336|OTHER|Refraction|Refraction will be performed and contrast sensitivity will be assessed to assess patient comfort level and compliance.
41343483|NCT03859804|PROCEDURE|Standard transrectal 12 core biopsy|TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
41343484|NCT03859804|PROCEDURE|MRI- US fusion prostate biopsy (FPB)|FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
41343485|NCT03535090|DRUG|Methylprednisolone|
41343486|NCT01314144|DRUG|Bupivacaine|intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
41489462|NCT03547336|DEVICE|FX800 Dialyzer|Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
41036509|NCT00054353|DRUG|melphalan|Given IV
41036510|NCT00054353|RADIATION|total-body irradiation|Undergo TBI
41036511|NCT00054353|DRUG|mycophenolate mofetil|Given PO
41036512|NCT00054353|DRUG|cyclosporine|Given PO
41036513|NCT00054353|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
41036514|NCT00054353|PROCEDURE|peripheral blood stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
40824805|NCT02590822|DIETARY_SUPPLEMENT|Cambridge Weight Plan|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
41343487|NCT02774044|DRUG|Cadisurf|Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
41343488|NCT02774044|DRUG|Survanta|
41343489|NCT06507332|DRUG|Letrozole 2.5mg|to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)
41343490|NCT04762264|DEVICE|ProFlor inguinal hernia device|Device follow up after inguinal hernia repair with ProFlor
41343491|NCT04712669|DRUG|rodatristat ethyl 300 mg tablet BID|rodatristat ethyl 300 mg tablet + matching placebo tablet twice daily on top of standard of care
41343492|NCT04712669|DRUG|rodatristat ethyl 600 mg BID|2 rodatristat ethyl 300 mg tablets twice daily on top of standard of care
41343493|NCT04712669|DRUG|Placebo|2 matching placebo tablets on top of standard of care
40824806|NCT02590822|OTHER|Supervised Exercise Sessions|"The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
40824807|NCT04577300|DRUG|NT-501|Implant of Neurotech NT-501 device(s)
40824808|NCT04577300|OTHER|Sham comparator|Sham implantation
40824809|NCT06160856|DIAGNOSTIC_TEST|Abdominal ultrasound|Measurement of venous congestion in abdominal target-organs (liver, kidneys) by calculating VExUS score
41036515|NCT00054353|OTHER|laboratory biomarker analysis|Correlative studies
41343494|NCT02681640|OTHER|68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
41489463|NCT02245022|DRUG|Dolutegravir 50mg od|Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od
41343495|NCT02681640|DEVICE|Positron Emission Tomography PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT
41343496|NCT00767793|DRUG|Placebo|One drop in each eye every 12 hours for seven days
41343497|NCT00767793|DRUG|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
41343498|NCT00767793|DRUG|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
41343499|NCT00767793|DRUG|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
41343500|NCT01228149|DRUG|Trabeculectomy with preoperative Diamox/DexaEDO treatment|Filtrating glaucoma surgery, preoperative treatment with Diamox (acetazolamide) 28 day prior surgery. DexaEDO (dexamethasone) 7 days prior surgery
41343501|NCT01228149|DRUG|Trabeculectomy with preoperative Cosopt S treatment|Filtrating glaucoma surgery, preoperative treatment with Cosopt S (dorzolamide/timolol) 28 day prior surgery.
41343502|NCT01823757|OTHER|Pharmaceutical care|pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
41343503|NCT06245681|DRUG|gender affirming hormone therapy|both groups are receiving gender-affirming hormone therapy; we do not compare the groups, but look at whether hormone therapy with testosterone or estrogen might have an effect on myocardial function, organ lipid content and subcutaneous to visceral fat ratio
41343504|NCT06004193|BEHAVIORAL|Exercise|At least 150 minutes of exercise in a week
41489464|NCT02245022|DRUG|Standard of Care|Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
41489465|NCT03791710|PROCEDURE|autologous fat grafting|regular liposuction procedure at which sufficient amount of fat is extracted from the patient and then the fat is processed then grafted underneath the burn wound
41343505|NCT05203744|DRUG|Tafenoquine prophylaxis|"The study will be conducted in three parts with 200 participants invited to participate in the study.~* Part 1 consist of 200 participants to be administered a loading dose of 600 mg tafenoquine (200 mg daily for 3 days) followed by 200 mg weekly for two weeks.~* Part 2: The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose.~* Part 3: The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose."
41343506|NCT00314041|BIOLOGICAL|Meningococcal C|
41343507|NCT00314041|BIOLOGICAL|DTP/Hib|
41343508|NCT00193128|DRUG|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
41343509|NCT00193128|DRUG|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
41343510|NCT00193128|DRUG|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
41343511|NCT00193128|RADIATION|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
41343512|NCT00466024|BEHAVIORAL|Health Coach and HEPA Air cleaners|Health Coach for ETS reduction in home and 2 HEPA air cleaners
41343513|NCT00466024|BEHAVIORAL|Health Coach and HEPA air cleaners|Behavioral training and 2 HEPA air cleaners
41343514|NCT05316350|DEVICE|Electrocardiogram recording|ECG recording with investigational device
41343515|NCT05316350|DEVICE|Electrocardiogram recording|ECG recording with reference device
41343516|NCT02725736|DRUG|Atosiban|"After random allocation to a treatment group, women will receive Atosiban as follows:~Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling."
41343517|NCT02725736|DRUG|Nifedipine|"After random allocation to a treatment group, women will receive Nifedipine as follows:~Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours."
41343518|NCT03250130|BEHAVIORAL|hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
41343519|NCT00024206|DRUG|orantinib|Given orally
41343520|NCT00024206|OTHER|laboratory biomarker analysis|Correlative studies
41343521|NCT00024206|OTHER|pharmacological study|Correlative studies
41343522|NCT00141622|DRUG|Slow sodium|
41343523|NCT01899768|DRUG|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
41489466|NCT03791710|DRUG|Topical Cream|serial dressing with topical agents e.g Silver Sulphadiazine
41343524|NCT01899768|DRUG|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
41343525|NCT05284656|DRUG|combination of Pentoxifylline 400 MG and Folic Acid|drugs used to delay progression of chronic kidney disease
41343526|NCT05284656|DRUG|folic acid|drugs used to delay progression of chronic kidney disease
41343527|NCT05284656|DRUG|Pentoxifylline 400 MG|drugs used to delay progression of chronic kidney disease
41343528|NCT00433927|DRUG|5-FU|5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2
41489467|NCT03791710|PROCEDURE|split thickness skin grafting|depridment and split thickness skin grafting
41343529|NCT00433927|DRUG|folinic acid|Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1
41489468|NCT01175811|DRUG|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
41489469|NCT01175811|DRUG|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
41489470|NCT01175811|DRUG|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
41489471|NCT00545675|DRUG|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
41489472|NCT00545675|DRUG|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
41343530|NCT00433927|DRUG|irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min day 1
41343531|NCT00433927|DRUG|cetuximab|Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8
41343532|NCT00433927|DRUG|bevacizumab|Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1
41343533|NCT01651234|DRUG|GCC-4401|"* Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg GCC-4401C~ * Cohort 2: 5.0-mg GCC-4401C~ * Cohort 3: 10-mg GCC-4401C~ * Cohort 4: 20-mg GCC-4401C~ * Cohort 5: 40-mg GCC-4401C~ * Cohort 6: 80-mg GCC-4401C"
41343534|NCT01651234|DRUG|GCC-4401C|"* Capsule, identical in appearance to GCC-4401C, for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg matching placebo~ * Cohort 2: 5.0-mg matching placebo~ * Cohort 3: 10-mg matching placebo~ * Cohort 4: 20-mg matching placebo~ * Cohort 5: 40-mg matching placebo~ * Cohort 6: 80-mg matching placebo"
41343535|NCT02253160|DEVICE|Spectra Optia CMNC|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
41489473|NCT04469010|DIETARY_SUPPLEMENT|Iron Bis-Glycinate Chelate and Vitamin C|28 mg iron 240 mg vitamin C
41489474|NCT04469010|DIETARY_SUPPLEMENT|Iron Bis-Glycinate Chelate|28 mg iron
41489475|NCT04469010|DIETARY_SUPPLEMENT|Placebo|Matched placebo
40824810|NCT05571007|OTHER|True acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
40824811|NCT05571007|OTHER|Sham acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
40824812|NCT04650412|OTHER|Bundle of comorbidities care|Pulmonary function tests, blood gas analysis, transthoracic echocardiography, sleep study after stabilization of patient's index clinical condition, thus 1 month after hospital discharge
40824813|NCT01244581|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
40824814|NCT01244581|DRUG|Placebo|Placebo mixture in two daily doses for 7 days
40824815|NCT03281330|BEHAVIORAL|auditory cues and music during walking|the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
41036516|NCT04514315|PROCEDURE|Minimally invasive cardiac valvular surgery|Minimally invasive valve surgery via right mini-thoracotomy.
41036517|NCT04514315|PROCEDURE|Conventional cardiac valvular surgery|Conventional valve surgery via full median sternotomy
41343536|NCT02253160|DEVICE|COBE Spectra MNC|It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
41343537|NCT02253160|DRUG|Granulocyte-colony stimulating factor (G-CSF)|Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
41343538|NCT01899040|DEVICE|neuromodulation for episodic migraine headache|
41343539|NCT01846208|DRUG|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
41343540|NCT01846208|DRUG|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
41489476|NCT05518084|OTHER|Liponovo tissue product|Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.
40824816|NCT06132399|DEVICE|META QUEST 3 virtual reality glasses|The RESET virtual reality software will be integrated into META QUEST 3 glasses (Meta Platforms, San Francisco, CA, US) by DYNAMICS.
40824817|NCT06132399|DEVICE|Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan)|This group will use the Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan) gaming system with the Sports package games.
40824818|NCT06132399|OTHER|Usual care|The UC intervention consists of 3 sessions/week of 90' of physical therapy and occupational therapy conducted by a physiotherapist and an occupational therapist.
40824819|NCT06381414|BEHAVIORAL|Observation|"Identify the prevalence of early wear in primary dentition, using Childhood Early Oral Aging Syndrome (CEOAS) index.~The CEOAS index involves scores of 0 to 3 for the assessment of tooth wear and dental management, whereas scores of I, II and III are used concomitantly in cases of the presence of enamel defects."
40824820|NCT04998539|OTHER|Wheelchair forward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
40824821|NCT04998539|OTHER|Wheelchair backward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the backward direction. Participants will pull the wheelchair when moving backwards.
40824822|NCT04998539|OTHER|Upright technique|Participants will move the wheelchair across the 5 m soft surface using the upright technique. The upright technique involves the wheelchair being moved with all 4 wheels on the ground.
41343541|NCT02171039|DRUG|Dabigatran|
41343542|NCT02171039|DRUG|Atorvastatin|
41343543|NCT05151562|BEHAVIORAL|Virtual Music Therapy|Each study participant will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be delivered by a board-certified music therapist (using Zoom as a primary platform). These individualized therapeutic encounters will use music that is personally meaningful and familiar to the participant and the participant's loved ones to facilitate reminiscence. Decision-making processes made by the music therapist will reflect a flexible session structure and series of intervention choices contingent on each participant's cultural identity, expressive and receptive communication, fine and gross motor ability, affect, orientation to time and place, and personal preferences on any given day.
41489477|NCT02838121|DRUG|Aclasta|Aclasta once annually for 2 years
40824823|NCT04998539|OTHER|Wheelie technique|Participants will move the wheelchair across the 5 m soft surface using the wheelie technique. The wheelie technique involves the wheelchair being tipped backward and balanced on the rear wheels. Participant wheelchair occupants will always be upright when being moved using the wheelie technique.
40824824|NCT04998539|OTHER|Wheelchair occupant upright body position|The participant occupying the wheelchair (wheelchair occupant) will be seated with a body position that is upright (back is leaning against the wheelchair back rest and arms on wheelchair arm rests) while the wheelchair is being moved.
40824825|NCT01789983|BEHAVIORAL|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
40824826|NCT01789983|OTHER|Collect Blood, GA and Other Survey Tools|"* Geriatric Assessment (GA) (Version 5)~* Functional Assessment of Cancer Therapy-General (FACT)~* Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~* Outcome Expectations for Exercise (OEE) scale29~* Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~* Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~* Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
40824827|NCT03481803|DRUG|MS1819-SD|Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.
40824828|NCT01201616|OTHER|High Fat Low Carbohydrate Diet|55% total energy intake from fats, 17% from protein and 28% from carbohydrate
40824829|NCT01201616|OTHER|Low fat High Carbohydrate Diet|20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
41036518|NCT03539562|DRUG|Morphine Sulfate and Promethazine|Morphine sulfate and promethazine
41343544|NCT05838820|DIAGNOSTIC_TEST|Nine-Hole Peg Test|The Nine-Hole Peg Test is a standardized test that measures manual dexterity and finger movement speed in individuals with hand impairments. The test involves the placement of nine pegs in a pegboard, one at a time, and then removal of each peg as quickly as possible using one hand. The test is timed, and the time required to complete the test provides an indication of manual dexterity and finger movement speed. The Nine-Hole Peg Test has been previously validated and is commonly used in clinical practice.
41343545|NCT05838820|DIAGNOSTIC_TEST|Jebsen-Taylor Hand Function Test|is a standardized test that assesses fine motor skills and functional abilities of the hand. The test involves the completion of seven subtests, including writing, simulated page turning, picking up small objects, stacking checkers, lifting large objects, simulated feeding, and stacking cans. Each subtest is timed, and the time required to complete each subtest provides an indication of hand function. The Jebsen-Taylor Hand Function Test has been previously validated and is commonly used in clinical practice.
40824830|NCT03982264|PROCEDURE|ESD procedure|ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.
41343546|NCT02561104|PROCEDURE|Laser-assisted cataract surgery.|
41343547|NCT02561104|PROCEDURE|Traditional manual phacoemulsification|
41489478|NCT02838121|DRUG|Placebo|No IV aclasta
41489479|NCT05392335|OTHER|Myofascial stretch|Myofascial stretch will be applied at hip adductors, hamstrings and calf muscles for 10 -15 repetitions on each muscle. 2-3 sessions will be performed in a week for 8 weeks.
41489480|NCT05392335|OTHER|Functional massage along with myofacial stretch|In this group during the first 20 minutes, ten minutes FM will be applied to each lower extremity of the subject. The muscle groups to which FM would be applied were hip adductors, hamstrings and calf muscles. During the remaining period traditional physiotherapy involving myofascial strecth will be given. 2-3 session will be performed in a week for 8 weeks.
41489481|NCT03683524|DRUG|Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
41489482|NCT03683524|DRUG|Current ART|To continue with their current ART
40824831|NCT03982264|PROCEDURE|EMR-C procedure|A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
40824832|NCT00706329|DEVICE|Deflux|Patients undergo surgery using Deflux to correct umbilical hernia
40824833|NCT06151951|OTHER|Cervical Stabilization|Isometric stretching and strengthening exercises of Neck flexor muscle including suboccipitalis, levator scapulae,scalnae anterior and upper trapezius. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.
41165763|NCT02125318|DRUG|Anagrelide CR|Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
41343548|NCT00774969|DRUG|Metronidazole|Metronidazole 10% ointment three times a day 7 days
41343549|NCT06145204|OTHER|questionnaire|anamnesis, OMSPQ, DN4, Brief Pain Inventory-short form, lymph-ICF-LL
41343550|NCT04816786|OTHER|no intervention will be administered, this is a retrospective observational study.|no intervention will be administered, this is a retrospective observational study.
41343551|NCT01041391|PROCEDURE|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
41343552|NCT06267716|PROCEDURE|PENG block|preoperative ultrasound-guided pericapsular nerve group block
41343553|NCT06267716|PROCEDURE|IPB|preoperative ultrasound-guided iliopsoas plane block
41489483|NCT00654966|DRUG|Urotensine II|A few drops of the drug will be administered to the skin by iontophoresis.
41489484|NCT00654966|DRUG|Soluble epoxide hydrolase|A few drops of the drug will be administered to the skin by iontophoresis.
41343554|NCT02177786|DRUG|Selonsertib|Tablets administered orally once daily
41509003|NCT00461253|DEVICE|Copper IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
41509004|NCT01078870|DRUG|Lexapro|10mg/cap 1\~2# QD
41343555|NCT02177786|DRUG|Placebo to match selonsertib|Tablets administered orally once daily
41343556|NCT02111629|DRUG|Fluconazole and Secnidazole|
41343557|NCT04400227|OTHER|Family Talk|"Family Talk is an evidence-based, parent-youth dyadic approach that uses psychoeducation and skills building to help families make meaning of a parent's adversity, increase resilience, and improve family functioning.~The Family Talk model comprises two components: the first involves a series of cognitive-behavioral techniques to bolster problem solving and communication skills among family members; the second involves a facilitated family meeting to develop a shared narrative for discussing each family member's experience of the parent's illness."
41343558|NCT03832816|DRUG|Placebo|Placebo vapor (distilled water)
41509005|NCT01078870|DRUG|Cymbalta|30mg/cap 30\~60mg/QD
41509006|NCT01078870|DRUG|Placebo|1\~2#/cap QD
41343559|NCT03832816|DRUG|Vaporized THC alone|Acute exposure to vaporized THC
41343560|NCT03832816|DRUG|Vaporized CBD alone|Acute exposure to vaporized CBD
41343561|NCT03832816|DRUG|Vaporized CBD with THC|Acute exposure to vaporized CBD with THC
41343562|NCT03753386|OTHER|Oxygen therapy simulation|"The intervention consists of reproducing oxygen therapy situations in healthy individuals by replacing oxygen bottles with bottles of air. A TeleOx® device will be placed on the circuit between the source and the nasal cannula for respiratory signals recording.~The intervention will last 30 minutes, containing the following activities in the given order:~* rest (9 minutes);~* drinking water (1 minute);~* rest (1 minute);~* coughing (1 minute);~* rest (1 minute);~* reading aloud (1 minute);~* rest (1 minute);~* breathing by the mouth (1 minute);~* rest (1 minute);~* exercising (running) (3 minutes) and~* rest (10 minutes)~Recordings will be retrieved after each test."
41343563|NCT05588713|PROCEDURE|Brief assessment protocol|The intervention constitutes of a brief assessment protocol for assessing ADHD.
41343564|NCT05588713|PROCEDURE|Comprehensive assessment protocol|The intervention constitutes of a comprehensive assessment protocol for assessing ADHD.
41343565|NCT05615155|OTHER|Platelets Rich Fibrin (i-PRF / C-PRF)|one site of the mouth will be injected with i-PRF and the other site will be injected with C-PRF
41343566|NCT02091193|DIETARY_SUPPLEMENT|Krill Oil (Supplement A)|
41343567|NCT02091193|DIETARY_SUPPLEMENT|Placebo (Supplement B)|
41343568|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
41343569|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
41343570|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
41343571|NCT01347073|DRUG|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (\~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
41343572|NCT00408291|PROCEDURE|Winsta PH osteosynthesis device|The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
41343573|NCT00528008|OTHER|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
41343574|NCT00528008|OTHER|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
41343575|NCT01977157|DEVICE|bioimpedance mesurements|Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
41343576|NCT00063986|PROCEDURE|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
41343577|NCT04645576|DEVICE|Face correction with injectable fillers|Injection of hyaluronic acid-based fillers
41343578|NCT05274009|OTHER|No cooling (control)|Participants are exposed to 35°C, 60% relative humidity for 8 hours.
41489485|NCT02477163|OTHER|Ayurveda treatment|"1. Gokshuradi Guggulu (compound Ayurvedic preparation: Gokshura + Guggulu + Triphala + Trikatu + Musta) - 1 g, 3 times in a day after food with warm water.~2. Varunadi kvath (ingredients: Varuna tvak + Bilva moola + Apamarga + Chitrak moola + Arani + Shigru + Bruhati + Kirattikta + Karanja + Shatavari) - 40 ml 2 times in a day after food.~3. Rasayan Churna (powder of Gokshura + Amalaki + Guduchi in equal quantities ) - 3 g, 3 times a day with water.~4. Bhumyamalaki (Tamalaki Rasayan) tablet - 1 g, 2 times in a day after food with water.~5. Uricare (of Punarvasu Pharmacy, Petlad road, Nadiad) tablet - 1 g, 3 times in a day after food with warm water.~6. Niruha Basti (procto-colonic administration of ayurvedic medicine) with Punarnavadi kvath (decoction) - in the morning, before one hour of the lunch."
41489486|NCT02693093|DRUG|NI-03|
41165764|NCT06003023|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to participants in both arms.
41489487|NCT02693093|DRUG|Placebo|
41489488|NCT05854823|RADIATION|dose-reduced radiotherapy|Patients receive 50Gy/25F, 2Gy/F QD, five days a week for 5 weeks
41489489|NCT00070538|DRUG|cytarabine|
41489490|NCT00070538|DRUG|laromustine|
41489491|NCT05559775|DRUG|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
41489492|NCT03862066|OTHER|Blood collection|5 milliliters (mL) of blood will be collected at the time of surgery
41489493|NCT03862066|OTHER|Tissue collection|Left over tissue will be collected at the time of surgery
41489494|NCT02767895|BEHAVIORAL|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
41489495|NCT00251719|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
41489496|NCT00251719|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
41343579|NCT05274009|OTHER|Recommended cooling|Participants are exposed to 35°C, 60% relative humidity for 3 hours, are then moved to an air-conditioned room for 2 hours (\~23°C, \~50% relative humidity), and then return to the heat for a final 3 hours.
41343580|NCT05274009|OTHER|Hybrid cooling|Participants are exposed to 35°C, 60% relative humidity for 2 hours, are moved to an air-conditioned room for 1 hour (\~23°C, \~50% relative humidity), return to the heat for 2 hours, move back to the air-conditioned room for 1 hour, and then return to the heat for a final 2 hours
41343581|NCT02128919|DEVICE|tDCS|Transcranial Direct Current Stimulation
41343582|NCT01712191|DEVICE|NUsurface Meniscus Implant|
41343583|NCT03932890|DEVICE|Patient controlled fluid device administering high volume thirst guided fluid bolus|The administration of a 200ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
41343584|NCT03932890|DEVICE|Patient controlled fluid device administering low volume thirst guided fluid bolus|The administration of a 50ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
41343585|NCT06418152|BEHAVIORAL|Multi-modal treatment|Multi-modal treatment was designed to target PD-specific declines in the areas of cognitive function and gait and posture impairments. MMT consists of simultaneously training a motor and cognitive task.
41489497|NCT00251719|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
41489498|NCT01558180|BEHAVIORAL|Telephone Care Management|series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
41489499|NCT01558180|BEHAVIORAL|Usual Care|educational handouts on pediatric insomnia
41489500|NCT01549106|DRUG|IPI-145|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
41489501|NCT01549106|DRUG|Placebo|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
41489502|NCT03073395|DRUG|[68Ga]P16-093|Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093
41489503|NCT02717897|OTHER|No intervention|This study is not interventional
41489504|NCT02541162|BEHAVIORAL|Oral information and interviews|interviews about sexuality and self experience during the disease
40824834|NCT06151951|DEVICE|Pressure Biofeedback|"In this method patients in supine position. Sphygmomanometer is used and 100 mmHg pressure will be maintained before the treatment start then cuff will be placed under the occiopit of spine and patient will be asked to press the cuff against the occiopit until gauze show target pressure then hold this position for 6 second and release. Repeated this pressure to 10 times, 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
41036519|NCT03652311|DEVICE|ThermoNeuroModulation TNM Device|Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
41165765|NCT06003023|BEHAVIORAL|Tailored Exercise Prescription|Participants in both arms will receive the results of their exercise stress test, which includes information on the duration, frequency, and intensity of their physical activity.
41343586|NCT04019236|OTHER|visual analogue scale (VAS),Respiratory distress observational scale (RDOS) and other Nursing care|Distressed patient will be assessed by visual analogue scale(VAS) or respiratory distress observational scale.Nursing interventions will be done according to its causes as giving supplemental O2 therapy, pharmacologic therapy ,initiating positive pressure ventilation or change Ventilator settings (TV, PEEP, Inspiratory pressure ), Improve inspiratory muscle function by Nutrition, positioning or by minimizing use of steroids , clearing airway by Suctioning, Check O2 saturation level frequently and maintain O2 saturation between 95-100%, ,Raising the HOB (Head of the Bed), high Fowler's ,Give pain medications as prescribed or diuretics as ordered and If thick secretions increase oral fluids intake
41343587|NCT01160042|DRUG|Metformin|Metformin Tablets 1000 mg
41343588|NCT01160042|DRUG|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
41489505|NCT05816057|BIOLOGICAL|semaglutide injection|The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.
41489506|NCT01350843|DIETARY_SUPPLEMENT|Orange Juice|250ml of orange juice or a sugars matched orange drink daily
41489507|NCT04452253|DIETARY_SUPPLEMENT|PS128|PS128 belongs to Lactobacillus plantarum subsp. plantarumand. Probiotic capsules contain 10 billion CFU (colony forming units) of PS128
41489508|NCT04452253|DIETARY_SUPPLEMENT|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
41489509|NCT04452253|DIETARY_SUPPLEMENT|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 10 billion of PS23 cells.
41489510|NCT04452253|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose.
41489511|NCT01483859|OTHER|preoperative liver stiffness measurement|Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
41489512|NCT01506544|DRUG|Hydroxyurea|20mg/kg of Hydroxyurea or the patient's standard daily dose
41489513|NCT03847103|OTHER|Robotic-assisted Therapy with Bilateral Practice|40-minute robotic-assisted therapy with bilateral practice program for wrist and forearm repetitive movement training was performed during each session.
41489514|NCT03847103|OTHER|Unilateral Task-specific Training|40 -minute unilateral task-specific training using various tasks: picks up beans with spoon, pouring water from one glass to another glass, opening and closing a drawer, drinking from a mug, and wiping the table were chosen for facilitating multitude of upper extremity functions. Three tasks per session were chosen for various specific components of hand-arm function training.
41489515|NCT03847103|OTHER|Sensorimotor Stimulation Program|10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach
41489516|NCT00367549|DIETARY_SUPPLEMENT|Energy-containing soft drink|Commercial energy/sports drink
41343589|NCT02619006|OTHER|Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
41343590|NCT04998292|DEVICE|Piezo-surgery with low level laser therapy|Low level laser therapy
41343591|NCT04998292|DEVICE|Piezo-surgery only|Piezo-surgery only
41343592|NCT04655846|BEHAVIORAL|Nursing intervention outcome: Breastfeeding Counseling (5244)|"Educational sessions: The nursing professional will carry out 1 educational session per week, for 4 weeks; each lasting between 45 and 60 minutes. The topics that make up each of the activities are:~1. Educational Session: Awareness towards the process of breastfeeding. Inform about the psychological and physiological benefits of breastfeeding.~2. Educational session: Teach the composition of breast milk. Teach the baby's correct alignment, latch, and areolar understanding of the breast. Instruct on breastfeeding positions.~3. Educational Session: Explain the extraction and conservation of breast milk.~4. Educational session: Explain the signs, symptoms, and management strategies for duct obstruction, mastitis, and nipple trauma. Talk about your needs for rest, hydration, and diet during breastfeeding."
41343593|NCT04655846|BEHAVIORAL|Nursing education about maternal care and usual education in maternity preparation course|Educational intervention by a nursing professional on the provision of adequate care at the level of growth and development in infants under one year of age, activities not related to the breastfeeding process
41343594|NCT06350877|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will be a 6-week supervised program. Participation will involve engaging in a weekly 1-h session provided in-person at the campus athletics and recreation centre. Each 1-h session will include: (1) 30 min of behaviour change coaching; and (2) 30 min of supervised and structured physical activity training. The intervention materials will include a behaviour change workbook for facilitating the 30 min of behaviour change coaching. Each week participants will complete the behaviour change workbook in session with the program trainer, whereby the overarching goal is to introduce and reinforce engagement in behaviour change techniques and to facilitate the learning objectives and experiences for each weekly session.
41343595|NCT03649139|DRUG|sublingual immunotherapy drops|artemisia annua (sweet sagewort) allergen extract drops
40824835|NCT06151951|DEVICE|Visual Biofeedback|"In this method Led Head Band light will be used as a visual feedback. Patients in sitting or standing position with neck straight with the alignment of front wall marking followed by control movement training. Patient will be asked to follow the marking through head band light while performing motion control training. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
40824836|NCT00072891|BEHAVIORAL|telephone counseling|
41343596|NCT03649139|DRUG|Placebo drops|sublingual placebo drops
41489517|NCT01075841|DRUG|Cetuximab|Subjects who are eligible for Erbitux treatment according to the indication in the national label of Erbitux (i.e. where Erbitux is used in combination with platinum-based therapy for the treatment of subjects with recurrent and/or metastatic SCCHN) according to the approved national label as in routine clinical practice under the supervision of an investigator experienced in the use of antineoplastic medicinal products.
40824837|NCT03838991|OTHER|Blood sample|A study specific blood sample will be collected.
40824838|NCT03838991|OTHER|Waste bone tissue|For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.
40824839|NCT01759563|DEVICE|nasopharyngeal targeted brain cooling|
40824840|NCT02931604|DEVICE|SinuSafe Medical Device for Maxillary Sinus|Sinus lavage via the natural sinus ostium, without ostial dilation.
40824841|NCT01982006|PROCEDURE|Cataract surgery with Phacoemulsification|"Each patients randomized in the phaco arm will undergo a conventional cataract surgery.~Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.~Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center."
41343597|NCT01848795|DEVICE|EndoBarrier Gastrointestinal Liner|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
41343598|NCT01848795|DEVICE|Easy life balloon|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
41489518|NCT01781000|BEHAVIORAL|Brain Fitness & Brain Training- Posit Science|Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
41489519|NCT01781000|BEHAVIORAL|Facial Affect Training- FAT|Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
41489520|NCT01781000|BEHAVIORAL|Treatment as usual|standard treatment protocol of schizophrenia ward
41343599|NCT03547349|DEVICE|Digital Incentive Spirometer|This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer
41343600|NCT03547349|DEVICE|Jamboxx Respiratory Therapy Device|THe Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx Respiratory Therapy Device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
40824842|NCT01982006|DEVICE|Femtosecond laser-assisted cataract surgery|"Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.~Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.~Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm"
40824843|NCT02323841|PROCEDURE|conservative treatment|we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
41343601|NCT04646226|DEVICE|AV graft|The purpose of the surgery is to connect a large vein in the arm to a nearby artery indirectly by inserting a graft material (graft surgery)
41343602|NCT04646226|PROCEDURE|surgical intervention for creation of a fistula|The purpose of the surgery is to connect a large vein in the arm to a nearby artery directly (fistula surgery)
40824844|NCT04994873|BEHAVIORAL|STEP|Behavioral intervention to increase positive affect
40824845|NCT04994873|BEHAVIORAL|Enhanced TAU|Standard care plus a phone app with a personalized safety plan
40824846|NCT02085096|BEHAVIORAL|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
40824847|NCT03770728|DRUG|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
41343603|NCT02182999|DEVICE|Wound infiltration catheter|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
40824848|NCT03770728|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
40824849|NCT03770728|DRUG|Background therapy: Metformin alone or in combination with SU|Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.
40824850|NCT04046315|DIAGNOSTIC_TEST|CMR|GLS measurement with CMR
41165766|NCT06003023|BEHAVIORAL|Healthy Lifestyle Education|Participants in both arms will receive information on healthy living, including topics such as physical activity, sleep, stress management, and diet.
41343604|NCT02182999|DRUG|NaCl 0.9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
41343605|NCT02182999|DRUG|Ropivacaine 0.2%|The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
41343606|NCT06343129|BEHAVIORAL|Dietary education program|"Jumpstart educational program:~https://www.rochesterlifestylemedicine.com/about-community-jumpstart/"
41343607|NCT01759693|PROCEDURE|Blood sampling|Blood sampling
41343608|NCT00296166|PROCEDURE|Catheter ablation|
41343609|NCT00296166|PROCEDURE|Thoracoscopic epicardial ablation|
41343610|NCT02454452|PROCEDURE|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
40824851|NCT04332939|OTHER|transcranial direct current stimulation|real tDCS sessions
40824852|NCT04332939|OTHER|Physical exercise|Aerobic exercise and physical training combined with sham tDCS
40824853|NCT03009838|DRUG|Letrozole|oral tablets 2.5 mg
40824854|NCT03009838|PROCEDURE|ovarian drilling|laparoscopic electrocauterization
40824855|NCT04610489|DIAGNOSTIC_TEST|Quidel Sofia SARS Antigen FIA|Obtained via bilateral mid-turbinate swab.
40824856|NCT02069730|DRUG|Selinexor|"If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE)."
40824857|NCT02069730|DRUG|EGFR or HER2 Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor"
40824858|NCT02069730|DRUG|FGFR Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor"
41343611|NCT02454452|PROCEDURE|Saphenous vein stripping|Saphenous vein stripping
41343612|NCT02454452|PROCEDURE|CHIVA|conservative hemodynamic treatment venous insufficiency
41343613|NCT04828850|PROCEDURE|Endobronchial ultrasound transbronchial needle aspiration lymph node staging|EBUS-TBNA in clinical N0 NSCLC patients
41489521|NCT03195153|DRUG|Atorvastatin 80mg|30 DAYS OF atorvastatin 80 mg
41489522|NCT03195153|DRUG|ALLOPURINOL 300 MG|30 DAYS OF ALLOPURINOL 300 MG
40824859|NCT02069730|DRUG|C-KIT Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor"
40824860|NCT02069730|DRUG|Anti-androgen|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens"
41343614|NCT05265390|OTHER|Adolescents watching an informational video|In the information video; The materials used during the PCR test, how long the process will take, how the sample will be taken, why healthcare professionals wear personal protective equipment, and what adolescents should do are included.
41343615|NCT02077036|DEVICE|Kinetic Oscillation Stimulation Device|
41343616|NCT02077036|DEVICE|Kinetic Oscillation Stimulation Device in placebo mode|
41343617|NCT01283178|RADIATION|intensity-modulated radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
41343618|NCT01283178|DRUG|cisplatin|Given IV
41343619|NCT01283178|RADIATION|image-guided adaptive radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
41343620|NCT01283178|OTHER|3'-deoxy-3'-[18F]fluorothymidine|Undergo FLT-PET scans for IMRT/IGART
41343621|NCT01283178|PROCEDURE|positron emission tomography/computed tomography|Undergo FDG/FLT-PET scans for IMRT/IGARTT
41343622|NCT01283178|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET scans for IMRT/IGART
41343623|NCT04770025|DEVICE|High-density transcranial alternating current stimulation|High-density electrode configuration with transcranial alternating current stimulation in the beta (15-40Hz) frequency range
41343624|NCT04770025|DEVICE|Sham stimulation|High-density electrode configuration with sham stimulation
41343625|NCT04770025|BEHAVIORAL|Motivational interviewing|Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
41343626|NCT00225667|DRUG|Irbesartan|
41343627|NCT04787263|BIOLOGICAL|CD19-CAR_Lenti T cell|Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain. The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10\^6 CAR+ cells/kg.
41157312|NCT06538142|PROCEDURE|Restoration with Self-cure Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Relative isolation (lip bumper, cotton roll and aspirator);~4. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~5. Cleaning with cotton and water;~6. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~7. Application of mild compressed air on adhesive for 3 seconds;~8. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~9. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~10. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
41343628|NCT02277236|RADIATION|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
41489523|NCT03195153|DRUG|Atorvastatin 80mg AND allopurinol 300 mg|30 days of atorvastatin and allopurinol 300 mg
40824861|NCT02069730|DRUG|NOTCH Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor"
40824862|NCT02069730|DRUG|MEK or PI3K Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor"
41343629|NCT02277236|RADIATION|CT imaging|Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
41343630|NCT04322240|DRUG|Alpha lipoic acid|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
41343631|NCT02966899|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
41343632|NCT04838795|BIOLOGICAL|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) as compared to the general unvaccinated population in South Africa
41343633|NCT04672031|OTHER|Glycemic Targets|The intervention is glycemic targets that are lower than those currently recommended by ADA and ACOG: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL instead of fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL.
41343634|NCT02280096|DRUG|4-aminopyridine|Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
41343635|NCT02280096|DRUG|Placebo|The placebo arm will include Microcrystalline Cellulose placebo
41343636|NCT03978572|BEHAVIORAL|Resistance Training|Exercise intervention designed to improve muscular strength and power
41343637|NCT03978572|BEHAVIORAL|Moderate-Intensity Continuous Cycling|Exercise intervention designed to improve cardiorespiratory fitness and muscular endurance
41343638|NCT03978572|BEHAVIORAL|High-Intensity Interval Cycling|Exercise intervention designed to improve cardiorespiratory fitness, muscular endurance, and muscular strength and power
41343639|NCT01003340|BEHAVIORAL|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
41343640|NCT02764086|RADIATION|Radiation|Escalated dose of minimum 65Gy to the iGTV, with 60 Gy to PTV.
41343641|NCT00995189|DEVICE|Opti-Free RepleniSH|Contact lens care solution containing polyquaternium-1 (PQT)
41343642|NCT00995189|DEVICE|ReNu MultiPlus|Contact lens care solution containing polyhexamethylene biguanide (PHMB)
41343643|NCT00995189|DEVICE|Contact lenses|Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
41343644|NCT03850704|DRUG|Selinexor|
41343645|NCT03638518|OTHER|Acupuncture|Acupuncture 5 weeks treatment. 2 sessions a week (30 minutes each session)
41343646|NCT03638518|OTHER|Physiotherapy|Core stability exercises programme. 2 sessions a week (30 minutes each session) during 5 weeks
41343647|NCT03731910|DIAGNOSTIC_TEST|MRI|liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.
41343648|NCT00137293|DRUG|GAP-486 (ZP-123)|
41489524|NCT00321828|BIOLOGICAL|bevacizumab|bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
41489525|NCT00321828|DRUG|fluorouracil|5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
41489526|NCT00321828|DRUG|leucovorin|leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
41489527|NCT00321828|DRUG|oxaliplatin|Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
41489528|NCT03744871|OTHER|N95 Respirator|SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).
41489529|NCT03272061|OTHER|Aerobic-based exercise program|Aerobic-based exercise will be carried out on a cycling ergometer three times a week for 30 minutes at 70% of the maximal workload. Every two weeks, the maximal workload will be reassessed, and training loads will be readjusted accordingly. Fully supervised training sessions will be performed with three-to-four study participants at a time. Subjects should maintain their body weight during the intervention period.
41343649|NCT00137293|DRUG|0.9% Sodium Chloride, USP|
41343650|NCT05265936|PROCEDURE|Passing a guidewire through a double j stent|The previously placed double J stent is removed up to the urethral meatus with a cystoscope and forceps and kept fixed at the meatal level without further pulling. Then, after reaching the kidney by passing a guidewire through it, the double j stent is removed. Followed by the routine lithotripsy procedure.
41343651|NCT05265936|PROCEDURE|Double J stent removal and guidewire insertion|The double j stent is completely removed with the cystoscope and forceps, and the guidwire is inserted into the ureter by visualizing it with the cystoscope. Followed by the routine lithotripsy procedure.
41489530|NCT00495547|DRUG|Azacitidine|Azacitidine
41343652|NCT04533516|OTHER|Manual therapy technics|Manual therapy technics
41343653|NCT04533516|OTHER|Inspiratory Muscle Training|Inspiratory Muscle Training
41343654|NCT01840436|DEVICE|MUCIPLIQ|MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
41343655|NCT01840436|DEVICE|Placebo|Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
41343656|NCT00969488|OTHER|High protein diet|"INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats)."
41343657|NCT00644813|OTHER|Scapular with glenoid neck fractures|
41343658|NCT03607149|DRUG|Pemetrexed|"standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)"
41343659|NCT01855490|DRUG|Exenatide|
41343660|NCT06433024|DIAGNOSTIC_TEST|PPG Diagnostic|The study investigates venous competence through three distinct exercises using photoplethysmography (PPG) technology to record blood flow in the leg veins of 20 subjects, split into two groups: those with chronic venous disease (CVD) and those without. The null hypothesis is that there will be no significant difference in venous filling times (VFT) and PPG trace variations between subjects with CVD and those without under different physical conditions. The alternative hypothesis suggests that individuals with CVD will show distinct PPG patterns, particularly shorter VFT and varied pressure changes, indicative of venous reflux or obstruction. This hypothesis is chosen based on prior evidence suggesting observable differences in venous function between affected and non-affected individuals.
41343661|NCT05258981|DIAGNOSTIC_TEST|MRI|Brain MRI
41343662|NCT05522543|OTHER|Conventional treatment with Passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
41343663|NCT05522543|OTHER|Conventional treatment with manual segmental lumbar traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
41343664|NCT00789724|DRUG|Anakinra|100 mg daily subcutaneous injection for 14 days
41343665|NCT00789724|DRUG|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
41343666|NCT04168151|OTHER|lung recruitment protocol|lung recruitment protocol applied to postcardiac surgery hypoxic adult patients with measurement of trans alveolar pressure as an index for lung recruitment
41343667|NCT01770119|BIOLOGICAL|MMR vaccination|Unprotected children will be vaccinated with two MMR vaccines
41343668|NCT02237365|DRUG|81mg aspirin|1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
41343669|NCT02237365|DRUG|1000mg aspirin|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
41343670|NCT02237365|DRUG|Placebo|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
41343671|NCT03529175|DRUG|Abraxane (nab-paclitaxel)|
41343672|NCT03529175|DRUG|Gemcitabine|
41343673|NCT04878289|BEHAVIORAL|TOTAL with Motivational Telemedicine Sessions|Teaching Obesity Treatment Options to Adult Learners Educational Video with 3, 30 minute motivational sessions at 1 week, 6 months, and 12 months after viewing video
41343674|NCT05799547|OTHER|cold group|Application will be made in the form of 10 minutes of application to the cesarean section incision, 20 minutes of break and 10 minutes of application.
41343675|NCT03137056|DEVICE|Hemodialysis with Theranova|"Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
41343676|NCT03137056|DEVICE|Hemodialysis with FX1000|"FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min"
41343677|NCT03137056|DEVICE|Hemodiafiltration with FX1000|FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
41343678|NCT02078089|DRUG|Morphine|Morphine will be given to patients as part of their standard care
41343679|NCT02078089|DRUG|Oxcarbazepine|Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
41343680|NCT00085644|BIOLOGICAL|adalimumab (D2E7)|Adalimumab 40 mg every other week, subcutaneous
41343681|NCT00085644|BIOLOGICAL|placebo|Placebo every other week, subcutaneous
41343682|NCT04743401|OTHER|Tele-exergaming Tablet|"The Tele-Exergame platform virtually supervises exercise tasks and coaches patients to perform evidence-based foot and ankle exercises that have been designed to improve balance, cognition, and lower extremity vascular health.~The exergame program uses a game-based approach, similar to playing a video game, which helps to increase patient motivation and engagement in the cognitively demanding exercise program."
41343683|NCT01171313|DRUG|XP21279 and carbidopa (experimental)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
41343684|NCT01171313|DRUG|Sinemet (comparator)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
41343685|NCT01171313|DRUG|Placebo for XP21279 and carbidopa|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
41343686|NCT01171313|DRUG|Placebo for Sinemet|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
41489531|NCT00495547|DRUG|Beta Erythropoietin|Beta Erythropoietin
41489532|NCT05967052|DRUG|Pregabalin|Pregabalin pharmacotherapy
41489533|NCT05967052|BEHAVIORAL|Independent walking training|Independent walking training
41489534|NCT05967052|DRUG|Placebo|Placebo
41489535|NCT05967052|BEHAVIORAL|Gradual movement therapy in the ward|Gradual movement therapy in the ward
40824863|NCT04695002|BEHAVIORAL|MIRA|Based on the initial assessment, the citizen and professional agree what outcomes the citizen should report in MIRA. This could be pain, mood, sleep quality, energy level, dependent on the priorities of the citizen. Similarly, different activities are reported, e.g. exercise, social activities, prolonged sitting or work-related tasks. The citizen and the professional agree how often the citizen reports the outcomes and tasks, and the citizen is notified by the MIRA-app when it's time for reporting. The data will be visualized in a graph for the professional in the back-end of the system, making it possible for the citizen and the professional to view the same, real-time reported data. This provides the base for discussing and adjusting the course of rehabilitation as symptoms change over time. At the same time, this increases the citizen's knowledge of how symptoms, mood, sleep and activities all interact, thereby giving them the tools better cope with their health condition.
40824864|NCT04695002|BEHAVIORAL|Control|Citizens in the control group participate in the standard course of vocational rehabilitation, without the use of MIRA app. Citizens are referred from the jobcenter if the case manager assesses that a health condition limits the citizen's ability to resume work. The typical course of rehabilitation lasts 4-12 weeks, and is managed by a physiotherapist, a psychologist and a physician. Depending on the condition of the citizen, the rehabilitation may be managed by only two of the three professionals. During the course of rehabilitation, the citizen may consult the team with varying frequency. If physical rehabilitation is part of the prescribed rehabilitation, the citizen shows up twice per week for several weeks of supervised exercise, whereas rehabilitation courses where self-management is in focus, only biweekly consultations may be provided. The decisions and planning of contents and duration of the rehabilitation programme is done in collaboration with the citizen.
41489536|NCT05967052|BEHAVIORAL|Telerehabilitation|Telerehabilitation
40824865|NCT06269198|DEVICE|WARD-CSS|"Patients' continuously monitored vital signs will be recorded via a bedside tablet device (data not visible).~The clinical staff will have access to the continuously monitored vital signs through a mobile device (smart phone) with a purpose-built app-based GUI displaying vital sign status and summaries, alarms, and device connectivity. The GUI will alert the clinical staff (acoustic and visual signals) when any of the predefined thresholds for deviating vital signs are exceeded."
40824866|NCT01981200|OTHER|Resistance training in AECOPD|The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
40824867|NCT02109874|BIOLOGICAL|AERAS-404 (mcg H4/nmol IC31)|Dose escalation
40824868|NCT02109874|BIOLOGICAL|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|
41489537|NCT05967052|BEHAVIORAL|Psychotherapy|Psychotherapy
41489538|NCT00845806|OTHER|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
41489539|NCT00267449|DEVICE|SoftScan Optical Breast Imaging System|
41489540|NCT03681327|OTHER|Sensory stimulation during sleep|Sensory stimulation during sleep
41489541|NCT02701166|DRUG|Bezafibrate|bezafibrate 400mg per day
41489542|NCT02701166|DRUG|Placebo|placebo 400mg per day
41489543|NCT03951896|BIOLOGICAL|PRP|A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects.All of the injections were done every two weeks, for a total of 3 times using 21 G injection needles with injection technique of posterior approach.
40824869|NCT05794230|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Liquid solution - intramuscular
41343687|NCT00492895|DRUG|Discontinuation of Azathioprin|Discontinuation of Azathioprin
41343688|NCT00610077|DRUG|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
41343689|NCT00610077|DRUG|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
41343690|NCT05118568|DEVICE|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
41343691|NCT06358976|OTHER|Vibration plus anti-spastic hand splint|vibration stimulation will be applied to the spastic hand antagonistic muscles using a volar anti-spastic hand splint and the Myovolt Arm vibrator.
41489544|NCT03951896|OTHER|Saline injection|2 ml's of NaCl solution with 0,9% concentration was applied to the shoulders of the participants.
41489545|NCT02508753|DRUG|CXA-101/tazobactam|1000/500 mg single IV dose administered over 60 minutes
41489546|NCT02508753|DRUG|CXA-101/tazobactam|3000/1500 mg single IV dose administered over 60 minutes
41489547|NCT02508753|DRUG|Moxifloxacin|400 mg tablet
41489548|NCT02508753|DRUG|placebo|single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
41489549|NCT03453801|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
41489550|NCT03453801|BIOLOGICAL|FluMist®|FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
41489551|NCT04086836|DEVICE|TAVR|Patient recieving a TAVR
41489552|NCT05298319|DEVICE|high flow nasal cannula|The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.
41489553|NCT03750435|PROCEDURE|AF ablation or left-sided AT ablation|According to the type of AF/AT, single or double transseptal and subsequent catheter ablation in the left atrium using radiofrequency will be performed.
40824870|NCT05794230|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Liquid solution - intramuscular
40824871|NCT05794230|BIOLOGICAL|Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)|Oral suspension - oral
40824872|NCT05794230|BIOLOGICAL|Pneumoccocal Vaccine|Suspension for injection - intramuscular
40824873|NCT05794230|BIOLOGICAL|Measles, Mumps, and Rubella Vaccine live (MMR) - TRESIVAC®|Lyophilized powder for injection - subcutaneous
40824874|NCT05794230|BIOLOGICAL|DTwP-HepB-Hib-IPV vaccine|Suspension - intramuscular
40824875|NCT05794230|BIOLOGICAL|DTaP-IPV-Hib-HepB vaccine|Liquid solution - intramuscular
40824876|NCT05794230|BIOLOGICAL|Hepatitis A vaccine - HAPIBEV™|Suspension for injection - intramuscular
40824877|NCT05794230|BIOLOGICAL|Rotavirus vaccine|Oral solution - oral
40824878|NCT05794230|BIOLOGICAL|Typhoid conjugate vaccine (TCV)|Suspension for injection - intramuscular
40824879|NCT05794230|BIOLOGICAL|Measles vaccine - MeasBio®|Freeze-dried powder for reconstitution and injection - subcutaneous
40824880|NCT05794230|BIOLOGICAL|Varicella vaccine live - VARIPED®|Sterile powder and diluent for injection - subcutaneous
40824881|NCT05794230|BIOLOGICAL|Varicella vaccine live - Onvara|Lyophilized powder for injection - subcutaneous
40824882|NCT05794230|BIOLOGICAL|Measles, Mumps, and Rubella Vaccine live (MMR) - OMZYTA®|Lyophilized powder for injection - subcutaneous
40824883|NCT05794230|BIOLOGICAL|Hepatitis A vaccine - Avaxim 80 U|Suspension for injection - intramuscular
40824884|NCT03795207|COMBINATION_PRODUCT|SBRT + Durvalumab|"Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy"
40824885|NCT03795207|RADIATION|SBRT|SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
40824886|NCT00359333|DRUG|Gemcitabine , Docetaxel|Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
40824887|NCT06343038|DRUG|Injection, 161Tb-SibuDAB,1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline
40824888|NCT06343038|DRUG|Injection, 177Lu-PSMA-I&T, 1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline
40824889|NCT06343038|DRUG|Injection, 161Tb-SibuDAB, Dose Escalation|"Intravenous injection via peripheral venous catheter of 161Tb-SibuDAB in saline. The intervention comprises 4 cycles at 6-week intervals.~The 161Tb-SibuDAB entry activity will be calculated based on dosimetry and toxicity data from the first 3 patients in Phase Ia of the study.~The escalated or de-escalated 161Tb-SibuDAB activity for the subsequent 3-patient cohorts will be determined based on the clinical and biochemical safety information and on organ dosimetry results of the entry/previous cohort. Up to 4 escalation or de-escalation steps will be performed."
40824890|NCT02825966|DEVICE|AUDICOR then LifeVest then AUDICOR|Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
41489554|NCT02745886|DRUG|metformin 0.85 twice daily for 6 months|
40824891|NCT04401618|OTHER|Retrospective evaluation of RMGI and GIC Class V Restorations|Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
40824892|NCT03664674|DRUG|OTO-104|Single intratympanic injection of 12 mg dexamethasone
41343692|NCT06358976|OTHER|Anti-spastic hand splint|the use of anti-spastic hand splint alone.
40824893|NCT03664674|DRUG|Placebo|Single intratympanic injection of placebo
40824894|NCT05102617|DEVICE|PicoSure Pro Device|This device will be used for up to 4 treatments over the designated areas.
40824895|NCT05102617|DEVICE|PicoSure Device|This device will be used for up to 4 treatments over the designated areas.
40824896|NCT05102617|DRUG|Topical Cosmeceuticals|Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.
40824897|NCT05081947|BEHAVIORAL|COMPASS|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
40824898|NCT02731222|OTHER|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
40824899|NCT04963140|OTHER|Optimized self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device
40824900|NCT04963140|OTHER|Conventional self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms
40824901|NCT00280800|DEVICE|constant CPAP devices|different CPAP mode
40824902|NCT00280800|DEVICE|automatic CPAP devices|different CPAP mode
40824903|NCT01566695|DRUG|Oral Azacitidine|300 mg daily, days 1 to 21 of each 28-day treatment cycle
40824904|NCT01566695|DRUG|Placebo|Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
41343693|NCT06358976|OTHER|Vibration|The use of hand vibrator alone
41489555|NCT02745886|BEHAVIORAL|Calorie restriction|
41509007|NCT01138787|DIETARY_SUPPLEMENT|Reference spread|Single dose (30 gr) of spread, containing 2250 mg PS
41509008|NCT01138787|DIETARY_SUPPLEMENT|Placebo spread|Single dose (30 gr) of regular light margarine
40824905|NCT01566695|OTHER|Best Supportiv Care (BSC)|BSC included and was not limited to packed RBC (packed red blood cell \[pRBC\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
40824906|NCT05126264|DRUG|Ibuprofen 400 mg|morning and afternoon
41036520|NCT00490646|DRUG|ixabepilone|"Ixabepilone 40 mg/m\^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.~For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated."
41165767|NCT06003023|BEHAVIORAL|Physical Activity Lifestyle Intervention Informed by the Theory of Planned Behavior|Participants randomized to the CHD-PAL arm will receive coaching to: 1) change attitudes towards physical activity; 2) increase perceptions of other people's approval of physical activity; 3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance and will be accompanied by goal-setting.
41165768|NCT04527783|OTHER|experimental group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
41165769|NCT04527783|OTHER|control group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
41343694|NCT02201472|DEVICE|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
41343695|NCT06250504|DRUG|APRETUDE (cabotegravir) 600 mg\3 mL|choice of 2-monthly injectable long acting cabotegravir. The initial visit will be followed by planned visit for the first injection, one month visit for second injection, and then 2-monthly CAB LA injections with repeat HIV testing and pregnancy testing, and referral to peer navigators for adherence and retention support. We will conduct HIV testing, STI testing, Hep B, Hep C, and safety bloods (Full Blood Count, Creatinine, Liver Function Tests) at baseline, HIV testing two monthly, and annual safety bloods, alongside annual STI testing.
41343696|NCT06250504|DRUG|DAPIRING (Dapivirine) 25mg Vaginal Ring|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
41343697|NCT06250504|DRUG|tenofovir disoproxil and emtricitabine|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
41343698|NCT06250504|DRUG|Tenofovir Disoproxil, Lamuvidine and Dolutegravir|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
41343699|NCT04329325|BIOLOGICAL|Blinatumomab|Please see detailed summary.
41343700|NCT04329325|DRUG|dasatinib|Please see detailed summary.
41343701|NCT04329325|DRUG|dexamethasone|Please see detailed summary.
41343702|NCT04329325|DRUG|methotrexate|Please see detailed summary.
41343703|NCT03066310|DIAGNOSTIC_TEST|Next generation sequencing|The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
41343704|NCT02897076|DRUG|betamethasone 24 mg|
41343705|NCT02897076|DRUG|12mg betamethasone +placebo|
41509009|NCT01138787|DIETARY_SUPPLEMENT|Test spread|Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
41165770|NCT01226485|DRUG|Taladegib|Administered IV
41165771|NCT05233761|DRUG|Defined CBD|300 mg CBD and 8 mg Terpenes administered as two small capsules.
40824907|NCT05126264|DRUG|Ibuprofen 400 mg|morning, afternoon and night
40824908|NCT00402714|PROCEDURE|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
40824909|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
40824910|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
40824911|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
40824912|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
40824913|NCT02192762|BEHAVIORAL|Withdrawal regulation training|Withdrawal coping skills
40824914|NCT02192762|BEHAVIORAL|Relaxation training|Relaxation skills instruction
40824915|NCT01117844|RADIATION|Proton Radiation|Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
41036521|NCT00490646|DRUG|docetaxel|Docetaxel 100 mg/m\^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
41343706|NCT03170908|BEHAVIORAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression
41343707|NCT04866641|DRUG|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.
40824916|NCT05639101|OTHER|Clinical Decission support system management & mobile App Intervention Group|"The clinicians treating the patients will use a clinical decision support system that includes predictive models associated with the level of risk of exacerbation. This models have been obtained in asthmatic patients by applying data mining techniques and multilevel analysis in the study of the influence of clinical characteristics and the environment of each subject.~The patients will use a mobile app to help manage their symptoms."
40824917|NCT01799239|DEVICE|Test product|The test product consists of an adhesive with a new top film
40824918|NCT01799239|DEVICE|SenSura|SenSura is the CE-marked and commercially available comparator product
40824919|NCT04844203|DIAGNOSTIC_TEST|Polygraphy with surface electrodes|Patients referred for ENMG to the Clinical Physiology Department and complaining of postural unsteadiness will undergo a polygraphy recording using surface electrodes (Natus Medical Incorporated), performed at the end of ENMG
40824920|NCT03978962|DEVICE|Guided Tissue Regeneration|"Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction."
40824921|NCT05102097|BEHAVIORAL|Warm-up|Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week
40824922|NCT05102097|BEHAVIORAL|Main exercise|Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks
40824923|NCT05102097|BEHAVIORAL|Cool down|Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week
40824924|NCT05102097|BEHAVIORAL|Standard of care|Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
40824925|NCT03985410|DRUG|ETX2514|intravenous infusion
40824926|NCT03985410|DRUG|Placebo|intravenous infusion
40824927|NCT03985410|DRUG|moxifloxacin|oral tablet
40824928|NCT05210114|DEVICE|Skin Hydration Sensor|The device is a skin hydration sensor. The sensor is placed on the skin at the inner arm. It is non-invasive and measures in seconds the percent water content of the dermis by quantifying its dielectric constant.
40824929|NCT00990145|DRUG|EDP-322|
40824930|NCT01636505|DRUG|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
40824931|NCT01636505|DRUG|gnrh agonist (suprefact)|suprefact 5.5 ml
40824932|NCT00990327|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
40824933|NCT00990327|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
40824934|NCT04757688|RADIATION|Cardiac radioablation (CRA)|CRA to 25 Gy in 1 fraction
40824935|NCT04740840|DRUG|Levamlodipine|According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
41165772|NCT05233761|DRUG|Placebo|Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.
41343708|NCT04557007|DRUG|Pembrolizumab|Drug trough-level will be measured in patients on Pembrolizumab with or without additional chemotherapy in routine care.
41343709|NCT00030160|BEHAVIORAL|Strength Training|
41343710|NCT01355497|DRUG|GTx-024|subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.
41343711|NCT01355497|DRUG|placebo|subject will receive matching placebo for the duration of the trial
40824936|NCT04740840|DRUG|Amlodipine|According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
40824937|NCT02387801|DRUG|Ixekizumab|Administered SC
40824938|NCT02655523|DRUG|Triamcinolone|1 mL of 40 mg of Triamcinolone
40824939|NCT02655523|DRUG|Dexamethasone|1 mL of 4mg of Dexamethasone
40824940|NCT02655523|DRUG|Normal Saline|1 mL of preservative free normal saline
40824941|NCT02655523|DRUG|Bupivacaine|2 mL of 0.5% bupivacaine
41036522|NCT00490646|DRUG|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
40824942|NCT03392883|BEHAVIORAL|Laddr|Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
40824943|NCT00864669|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
40824944|NCT00864669|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
40824945|NCT00006799|DRUG|megestrol acetate|
40824946|NCT00006799|PROCEDURE|quality-of-life assessment|
40824947|NCT02969096|PROCEDURE|Targeted Cryoablation Therapy|A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
40824948|NCT04380103|DRUG|XELOXIRI/Bevacizumab|bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
41343712|NCT03726541|OTHER|physiotherapy|Physiotherapy program includes breathing exercises, incisive spirometer study, grade ambulation. Oxygen saturation, heart rate and blood pressure values will be recorded before and after the session. Changes in the follow-up parameters will be discussed.
41343713|NCT04889612|PROCEDURE|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
41343714|NCT04889612|PROCEDURE|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and hand free). After putting the Hand Tutor glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
41343715|NCT00230295|PROCEDURE|IMR LAG|
41343716|NCT04827940|OTHER|Progressive relaxation exercise with music|"The progressive relaxation technique includes exercises for the muscles in the body to consciously contract and relax together with deep breathing exercises while sitting comfortably or lying down accompanied by music.~Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients did the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients were taught to do the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music."
41343717|NCT03125655|DIAGNOSTIC_TEST|Inflammatory markers|
41343718|NCT02920879|PROCEDURE|PEEP-level, driving pressure|Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
41343719|NCT02849184|DRUG|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
41343720|NCT02849184|OTHER|Placebo|Placebo once daily before bedtime.
41343721|NCT04823741|GENETIC|PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
41343722|NCT01600391|BEHAVIORAL|Usual care|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.
41489556|NCT04996563|OTHER|Video|A brief educational video, approximately 9 minutes in duration, on pelvic organ prolapse is sent electronically to patients to view prior to their initial visit in order to provide early access to information. The video was created to educate patients on the following key components of prolapse: the clinical condition, associated symptoms, common risk factors, evaluation and diagnosis, non-surgical treatment options, and surgical treatment options. Simple drawings and animations are included as visual aids to enhance the ability to conceptualize prolapse and its management options.
40824949|NCT01468610|DRUG|desvenlafaxine|50-100 mg daily for 8 weeks
40824950|NCT00866047|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
40824951|NCT04965974|DEVICE|Digital blue light blocking filter|digital blue light blocking filter will be given to 80 dry eye subjects in mobile phones and laptops and 80 individuals will be without filters digital devices users
40824952|NCT00934947|DRUG|Propranolol|40 mg
40824953|NCT00934947|DRUG|Placebo|sugar pill
40824954|NCT00934947|DRUG|Propanolol|120 mg twice per day
40824955|NCT02323204|BEHAVIORAL|Link for Injured Kids|Psychological First Aid
40824956|NCT02323204|OTHER|So you've been in an accident|Educational materials
40824957|NCT04333511|DEVICE|TPS (NEUROLITH)|6 treatments of TPS over 2 weeks
40824958|NCT04333511|DEVICE|Sham-TPS (NEUROLITH)|6 treatments of Sham-TPS over 2 weeks
40824959|NCT05615987|DRUG|Onabotulinumtoxina for Injection|200iu/2ml in both groups
40824960|NCT04790825|PROCEDURE|Full mouth scaling and root planing (FMSRP)|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
40824961|NCT02138474|OTHER|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
40824962|NCT02138474|OTHER|Placebo|Unmedicated sucrose pillules
41343723|NCT01600391|BEHAVIORAL|Overground visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.
41343724|NCT01600391|BEHAVIORAL|Treadmill visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
41343725|NCT04668547|DEVICE|Hysteroscopic Embryolysis|Hysteroscopic removal of the products of conception for induced abortion using a hysteroscopic morcellator. If this method of induced abortion fails, a traditional Dilation and Curettage procedure is performed
41343726|NCT05609136|OTHER|Bobath+Scapular Stabilization Exercises|Scapular stabilization exercises will be given to patients in addition to Bobath therapy. It will be applied with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
41343727|NCT03771781|DRUG|Empagliflozin Tablets|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.
41343728|NCT03771781|DRUG|Empagliflozin Tab 25 MG|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.
41489557|NCT04915482|DRUG|Combined use of TPO-RAs with low-dose anti-CD20 antibody|Experimental: Combined use of TPO-RAs with low-dose anti-CD20 antibody The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.
41489558|NCT04915482|DRUG|The best available therapy|The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
41489559|NCT02307266|BEHAVIORAL|Standard of care + supplementary education|
40824963|NCT05352698|DIAGNOSTIC_TEST|NT ProBNP (Roche)|This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
41018580|NCT04402827|DIAGNOSTIC_TEST|Susceptibility to infection|"ACE2 and CD26 receptor study: After genomic DNA extraction and quantification using a NanoDrop-1000, 14 ACE2 SNPs (rs1978124, rs2048683, rs2074192, rs2106809, rs2285666, rs233575, rs4240157, rs4646142, rs4646155, rs4646156, rs4646188, rs4830542, rs6632677, and rs879922) will be studied. In addition, one CD26 (DPP4) SNP (rs7608798) will be analysed (qualitative measure).~SARS-CoV-2 CD4/CD8 T cell response: SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).~KIR characterization: Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed."
40824964|NCT01994239|DRUG|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
41018581|NCT05010109|PROCEDURE|6 Minute Walk Functional Test|Participate in 6 MWT
40824965|NCT01994239|RADIATION|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
41018582|NCT05010109|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
41018583|NCT05010109|PROCEDURE|Computed Tomography|Undergo SPECT/CT
41343729|NCT04769336|DEVICE|Central Lab based CBC|lab samples will be sent to the central lab for CBC analysis
41018584|NCT05010109|PROCEDURE|Echocardiography|Undergo echocardiogram
41343730|NCT04769336|DEVICE|Point of Care CBC|lab samples will be analyzed at point of care
41343731|NCT01488188|BIOLOGICAL|Influenza vaccine|Administration of 1 dose (0.2 ml) by nasal route
41343732|NCT01488188|BIOLOGICAL|Influenza vaccine|Administration of 1 dose (0.2 ml) by sublingual route
41343733|NCT03741140|DIAGNOSTIC_TEST|Motivation tests|Motivation tests will characterize elementary deficits of motivation
41343734|NCT04976309|DRUG|Lu AG09222|Single dose
41343735|NCT04976309|DRUG|Placebo|Single dose
41343736|NCT01963962|DRUG|Copper IUD|
41343737|NCT01963962|DRUG|Levonorgestrel IUD|
41018585|NCT05010109|PROCEDURE|Exercise Cardiac Stress Test|Undergo stress test
41018586|NCT05010109|OTHER|Questionnaire Administration|Complete questionnaires
41343738|NCT05078671|DRUG|Olaparib|olaparib treatment
41343739|NCT05078671|DRUG|Cobicistat|Pharmacokinetic booster
41343740|NCT03300427|DRUG|sacubitril/valsatran|sacubitril/valsatran 100 or 200 mg BID
41343741|NCT03300427|DRUG|valsartan|Valsartan 80 or 160 mg BID
41018587|NCT05010109|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
41018588|NCT02337829|DRUG|Acalabrutinib (Arm A)|"* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z"
41489560|NCT02307266|BEHAVIORAL|Standard of care + additional visits|
41018589|NCT02337829|DRUG|Acalabrutinib (Arm B)|"B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y."
41018590|NCT00003545|DRUG|nelarabine|
41018591|NCT00573963|DRUG|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
41018592|NCT00573963|DRUG|saline solution|2 injections of 20mL plain saline solution - one on each side.
41018593|NCT02872415|BIOLOGICAL|Blood puncture site|Blood puncture site
41018594|NCT06572605|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41018595|NCT06572605|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41018596|NCT06572605|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41018597|NCT06572605|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
41018598|NCT06572605|OTHER|Electronic Health Record Review|Ancillary studies
41018599|NCT06572605|RADIATION|External Beam Radiation Therapy|Undergo EMD-EBRT
41018600|NCT06572605|PROCEDURE|Image Guided Biopsy|Undergo image-guided EMD biopsy
41343742|NCT03300427|DRUG|placebo to valsartan|placebo to valsartan 80 or 160 BID
41343743|NCT03300427|DRUG|placebo to sacubitril/valsartan|placebo to sacubitril/valsartan 100 or 200 mg BID
41343744|NCT01199497|DRUG|Group 1|fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
41343745|NCT01199497|DRUG|Group 2|placebo
41343746|NCT00029341|BEHAVIORAL|Treatment Interruption|
41343747|NCT04707027|DRUG|Aflibercept Injection (2 mg/0.05 ml)|Intravitreal aflibercept injections (treat and extend regimen)
41343748|NCT04707027|OTHER|Defer treatment|Follow up with fundus photo and OCT every 4 weeks
41343749|NCT02072694|OTHER|75 grams of glucose plus water solution|"A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
41489561|NCT02307266|BEHAVIORAL|Standard of care|
41489562|NCT01367665|DRUG|vismodegib|150 mg once daily until disease progression or unacceptable toxicity
41489563|NCT01434186|DRUG|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
41489564|NCT01434186|DRUG|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
41489565|NCT01434186|DRUG|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
41489566|NCT01434186|DRUG|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
41489567|NCT06483542|OTHER|bioenergetic balance|Bioenergetic balance is calculated for all patients who had a resting energy expenditure measurement with indirect calorimetry.
41489568|NCT03964064|RADIATION|Stereotactic Radiotherapy|"GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).~Normal Tissue Limit: Reference to TG101 Report"
41489569|NCT03964064|RADIATION|3D-printing Template-assisted CT-guided I125 Seed Implantation|CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.
41489570|NCT00874003|DRUG|mirtazapine|oral tablet, 30 mg daily
41489571|NCT00874003|DRUG|placebo|oral tablet, 1 daily
41343750|NCT02072694|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
41489572|NCT01939496|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
41489573|NCT01939496|DRUG|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
41489574|NCT02998970|DRUG|Empagliflozin|single oral tablet once daily.
41489575|NCT02998970|DRUG|Placebo|single oral tablet once daily.
41489576|NCT05759143|BEHAVIORAL|Nest Platform|Patient- and clinician-facing portal via secure link
41489577|NCT00242736|DRUG|Esomeprazole|
41489578|NCT06156189|DIETARY_SUPPLEMENT|Enteral Feeding|Feeding via Nasogastric tube in intubated and ventilated patients
41018601|NCT06572605|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41018602|NCT06572605|BIOLOGICAL|Talquetamab|Given SC
41018603|NCT02528292|PROCEDURE|Synovial biopsy|Ultrasound guided synovial biopsy of inflamed joint
41343751|NCT01756833|DRUG|Doxycycline|100 mg po bid
41343752|NCT01756833|DRUG|Placebo|capsule identical to the doxycycline capsule
41343753|NCT06400693|OTHER|Endotracheal Intubation|Preparation of all necessary equipment for endotracheal intubation
41489579|NCT05813288|DRUG|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
41489580|NCT05813288|DRUG|Placebo|Oral administration of placebo tablet
41489581|NCT02119819|DRUG|LY2944876|Administered SC
41489582|NCT02119819|DRUG|Exenatide extended-release|Administered SC
41489583|NCT02119819|DRUG|Placebo|Administered SC
41343754|NCT06400693|OTHER|Supraglottic Airway|Preparation of all necessary equipment for laryngeal mask
41489584|NCT02119819|DRUG|Metformin|Oral
41489585|NCT02831647|DIETARY_SUPPLEMENT|AYMES PRAGUE|AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
41489586|NCT00003748|DRUG|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
41489587|NCT01550744|DRUG|Ustekinumab 45 mg|Form = Injection, route = subcutaneous
41489588|NCT01550744|DRUG|Ustekinumab 90 mg|Form = Injection, route = subcutaneous
41489589|NCT01550744|DRUG|Placebo|Form = Injection, route = subcutaneous
41509010|NCT02641158|OTHER|Control Group|"After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward."
41343755|NCT01116804|PROCEDURE|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
41343756|NCT01116804|PROCEDURE|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
41343757|NCT01116804|PROCEDURE|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
41343758|NCT01116804|PROCEDURE|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
41343759|NCT03642275|BEHAVIORAL|iCardia4HF|Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
41343760|NCT00591175|BEHAVIORAL|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
41343761|NCT00591175|BEHAVIORAL|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
41343762|NCT00591175|BEHAVIORAL|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
41343763|NCT04996277|PROCEDURE|angiography|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
41343764|NCT04996277|PROCEDURE|Thrombus suction|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
41343765|NCT04996277|PROCEDURE|Fibrinolytic therapy|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
41489590|NCT04995705|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention. ACT encourages individuals to remain open to internal experiences (positive, negative and neutral), rather than attempting to control or ameliorate them (which may only serve to increase pain and suffering). It also encourages individuals to focus on committing to a life that is congruent with their core values, regardless of the experiences that show up for them. The premise of this model is to learn to modify the relationship one has with their internal experiences (thoughts, feelings, physical sensations etc.), rather than change the experiences per se. This is achieved through different processes including mindfulness, acceptance, defusion and exploration of values. These core tenets of ACT help to cultivate psychological flexibility.~This ACT intervention is delivered as a 5-week group for stroke survivors and adults with brain injury. It comprises of experiential and didactic components."
41018604|NCT02528292|DRUG|Anti-TNF therapy|Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
41018605|NCT04913493|PROCEDURE|Cytocam-IDF|Patients receive an extra medical imaging test perioperatively with the Cytocam-IDF
41489591|NCT05927272|PROCEDURE|SKIN SAMPLES|"At baseline: one 4 mm Ø skin biopsies: on forearms (excluding skin folds): fresh At month 3 and month 6: Two 4 mm Ø skin biopsies will be performed on the same lesion selected at baseline (one on a repigmented area, one on a non-responded area): fresh~Fresh Skin biopsies will be analyzed the same day using Single-cell RNA sequencing (scRNAseq)."
41489592|NCT05927272|PROCEDURE|BLOOD SAMPLES|Blood samples will be taken (30 mL) at week 0, week 12, week 24 for the measurement of pro-inflammatory cytokines and chemokines ligands in blood sera.
40824966|NCT00203112|DRUG|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
40824967|NCT00203112|DRUG|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
40824968|NCT05585229|DRUG|Psilocybin-assisted Psychotherapy|Participants will complete a 8-week structured psychotherapeutic intervention involving administration of 25mg and 37.5mg PEX010 on two separate occasions.
40824969|NCT02796872|DIETARY_SUPPLEMENT|GOS|GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)
40824970|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 3%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
40824971|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 2%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
40824972|NCT02796872|DIETARY_SUPPLEMENT|Mother's breast milk|exclusively breastfed infants for at least 7 days prior to enrollment
41018606|NCT04865094|OTHER|cyclic merocyanine|long-UVA absorber
41018607|NCT04865094|OTHER|placebo|placebo
40824973|NCT03279913|DEVICE|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
41018608|NCT05345691|BIOLOGICAL|Bmab 1000|60 mg administered as a single SC (subcutaneous) injection once every 6 months.
41018609|NCT05345691|BIOLOGICAL|Prolia®|60 mg administered as a single SC injection once every 6 months
41018610|NCT06315257|DRUG|PVX7|PVX7 Immunotherapy
41018611|NCT06532201|OTHER|Su jok seed therapy|Su Jok will be applied to the reflection points on the hand based on the painful area of the individual. The painful areas will be determined with the applicator and black pepper seeds will be placed on these areas. Circular massage will be applied to the areas where the seeds are located for 30 minutes.
41165773|NCT02895243|OTHER|Prehabilitation|The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
41343766|NCT04996277|BEHAVIORAL|Medication stabilized the condition|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
41343767|NCT04835688|PROCEDURE|Transmyringeal ventilation tube insertion|"In both groups, the tympanic membrane will be anesthetized by local application of topical prilocaine (EMLA) or phenol or by infiltration anaesthesia of the outer ear canal. The choice of method is left to the discretion of the surgeon.~For the experimental group, insertion of a ventilation tube will be performed. An incision is performed, usually in the lower, anterior quadrant of the tympanic membrane and the transmyringeal tube is inserted."
41489593|NCT05927272|DEVICE|narrowband UVB|narrowband UVB (Nb-UVB) 2 times a week
41489594|NCT05927272|DRUG|Systemic Steroids|Oral minipuls of systemic steroids (Medrol 16mg twice a week) for 24 weeks
40824974|NCT00393302|PROCEDURE|HIV screening in pregnancy|
40824975|NCT03876691|OTHER|Patients|Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a do-not-resuscitate.
40824976|NCT03876691|OTHER|Physician|The current emergency medical department departments within the preparation of the attending physician
40824977|NCT06086652|DIAGNOSTIC_TEST|PET/CT|detection of possible primary tumor
40824978|NCT05936502|OTHER|Extranodal extension|Extranodal extension presence or absence on radiology and pathology assessment
40824979|NCT06214052|DRUG|VH4524184|VH4524184 will be administered.
40824980|NCT06214052|DRUG|Placebo|Placebo will be administered.
40824981|NCT03993990|BEHAVIORAL|individual empowerment-based intervention|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.
40824982|NCT01056003|OTHER|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
40824983|NCT04460924|DRUG|Integrase strand transfer inhibitors|Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
40824984|NCT06038526|PROCEDURE|Biospecimen Collection|Undergo buccal, nasal, and blood sample collection
40824985|NCT06038526|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
40824986|NCT06038526|BIOLOGICAL|Canakinumab|Given SC
40824987|NCT06038526|PROCEDURE|Carbon Monoxide Measurement|Undergo CO testing
40824988|NCT06038526|OTHER|Survey Administration|Ancillary studies
41018612|NCT05130567|DRUG|LP-128 capsules|Oral dosing with LP-128 capsules
41018613|NCT05130567|OTHER|Matching Placebo|Oral dosing with placebo capsules to match LP-128 capsules.
41018614|NCT01558700|DRUG|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
41018615|NCT01558700|DRUG|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
41018616|NCT03747081|DRUG|Rivaroxaban|Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.
41018617|NCT03747081|DRUG|Warfarin|Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.
41018618|NCT00907894|DRUG|LDT600 (Telbivudine)|LDT600 (Telbivudine)
41343768|NCT04835688|PROCEDURE|Sham-treatment|For the control group, the ENT-specialist will touch the tympanic membrane with an alligator ear forceps to simulate getting a paracentesis. In the same procedure, without having made a paracentesis, a ventilation tube is placed on the tympanic membrane and removed again afterwards. The reason for the above-mentioned is to simulate getting a paracentesis and insertion of a ventilation tube.
41343769|NCT03858686|DRUG|FP-025 capsules|FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
41343770|NCT03858686|DRUG|Placebo FP-025 capsules|Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
41343771|NCT02074761|DEVICE|SImmetry|"The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
41343772|NCT06442176|DIAGNOSTIC_TEST|OCT|Enhanced depth imaging optical coherence tomography (EDI-OCT) using the Heidelberg Spectralis HRA + OCT (Heidelberg Engineering, Inc., Franklin, MA, USA)
41343773|NCT05479136|DRUG|PET imaging with 18F fluciclovine|PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
41343774|NCT04990102|DRUG|CPX-351|Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2
41343775|NCT00005792|DRUG|etoposide phosphate|Etoposide phosphate 1363 mg/m\^2/day IV over 4 hours (total dose 2726 mg/m\^2, or 2400 mg/m\^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
41343776|NCT00005792|DRUG|melphalan|Melphalan 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2), followed immediately by topotecan. Days -7, -6, -5
41343777|NCT00005792|DRUG|topotecan|Topotecan 3.3 mg/m\^2/day (starting total dose = 10 mg/m\^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
40824989|NCT02938078|DEVICE|Avenova Lid Cleanser|Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
41343778|NCT00005792|PROCEDURE|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
41343779|NCT02089867|OTHER|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
41343780|NCT02089867|DRUG|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
40824990|NCT06289127|BEHAVIORAL|Lower Quarter Y Balance Test|The LQYBT is a widely used test for assessing lower extremity dynamic balance and neuromuscular control. Participants' lower limb balance was performed using The Y Balance Test Kit™ (Move2Perform, Evansville, IN).
41343781|NCT02089867|DIETARY_SUPPLEMENT|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
41343782|NCT05891470|DEVICE|MonaLisa Touch device|sessions with intra-vaginal CO2 laster system
41343783|NCT05891470|DEVICE|Vaginal dilatators|Home use of vaginal dilatators (at least twice a week for minimum 5 minutes)
41343784|NCT03229304|OTHER||
41383604|NCT02564172|DEVICE|CMS group|"Conus medullaris stimulation with pentapolar surgical lead includes:~* Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~* Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~* If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~* If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect)."
40824991|NCT00334997|PROCEDURE|endoscopic surgery|
40824992|NCT00334997|PROCEDURE|laser surgery|
40824993|NCT00334997|RADIATION|radiation therapy|
40824994|NCT03937648|DRUG|COL-144 50mg|COL-144 50mg
40824995|NCT03937648|DRUG|COL-144 100mg|COL-144 100mg
40824996|NCT03937648|DRUG|COL-144 200mg|COL-144 200mg
40824997|NCT03937648|DRUG|COL-144 400mg|COL-144 400mg
40824998|NCT03937648|DRUG|Placebo|Placebo
41343785|NCT06387277|OTHER|RV1551P GB3224|"RV1551P GB3224 Approximately 2 mg/cm² of product is applied to the Z1 or Z3 study areas (randomization).~From D1 to D2, a single product application is done at the study center by the subject in the presence of the clinical research technician (CRT) after epidermal ablation with an erbium YAG laser. After application, a dressing is placed on the measurement area and removed the following day at the center on D2 and D3 by the CRT before measurements.~From D3 to D18, two product applications are done with a minimum 4-hour interval:~* On visit days (D3, D5, D8, D10, D12, D15): an application is done at the study center by the subject in the presence of the CRT after measurements. A second application is done at home in the evening.~* On non-visit days (D4, D6, D7, D9, D11, D13, D14, D16, D17, D18): the subject applies 2 product applications at home (morning and evening).~Subjects receive the product at the end of visit 3 and return it at the last visit (visit 9)."
41343786|NCT03140488|DRUG|Oxytocin|Patients will be randomized to low dose or high dose oxytocin for induction of labor.
41343787|NCT00914719|BEHAVIORAL|Information only|
41343788|NCT00914719|BEHAVIORAL|Sexual risk reduction intervention|
41343789|NCT00914719|BEHAVIORAL|sexual risk reduction + alcohol risk reduction component|
41343790|NCT06396130|DEVICE|Photobiomodulation by low level diode laser|Diode laser exposure (Lite Medics 1.00-Watt serial number 148 Ver. SwvM. 150VS108VT.100) will be carried out using a continuous mode with 10 Hz frequency, 980 nm wavelength, and max power 15 WCW. The tip will be applied both at the buccal and the lingual side for 30 s each.
41343791|NCT06396130|OTHER|Mock Laser Application|Placebo for control group
41343792|NCT02736929|BEHAVIORAL|Cognitive Processing Therapy - Cognitive|CPT-C is a brief cognitive behavioral treatment for PTSD. It consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
41343793|NCT00993980|PROCEDURE|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
40824999|NCT04177420|DEVICE|FIR-C mattress|infrared-C irradiation by hot mattress with a powered heating compress
40825000|NCT04177420|DEVICE|FIR-C abdominal pad|infrared-C irradiation by hot abdominal pad with a powered heating compress
40825001|NCT04177420|DEVICE|fake FIR-C mattress|normal mattress with fake controller, custom make for placebo group
40825002|NCT04177420|DEVICE|fake FIR-C abdominal pad|normal abdominal pad with fake controller, custom make for placebo group
40825003|NCT01127555|DRUG|5-fluorouracil, leucovorin, oxaliplatin|D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
40825004|NCT01108432|OTHER|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
40825005|NCT01839240|DRUG|azacitidine|Given IV or SC
40825006|NCT01839240|DRUG|cytarabine|Given IV
41343794|NCT00993980|PROCEDURE|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
41343795|NCT02324413|DRUG|Clonidine|Comparison between placebo and 2 different concentrations of clonidine
41343796|NCT02324413|DRUG|Placebo|
41343797|NCT06217640|DIAGNOSTIC_TEST|Dual X Ray Absorptiometry|"* Dual X Ray Absorptiometry in the combination with functional tests~* Near-infrared spectroscopy in combination with hand grip strength"
41343798|NCT02385591|BEHAVIORAL|Telephone Support|telephone-based physical activity advice and support delivered by a trained professional facilitator.
41343799|NCT02385591|BEHAVIORAL|SMS Support|Telephone-based physical activity advice and support delivered by SMS.
40825007|NCT01839240|DRUG|mitoxantrone hydrochloride|Given IV
40825008|NCT01839240|OTHER|laboratory biomarker analysis|Correlative studies
41018619|NCT06572215|DRUG|Dapagliflozin|On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
41018620|NCT06387784|DIETARY_SUPPLEMENT|Beetroot juice|In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate. Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.
41343800|NCT06111404|PROCEDURE|central urinary bladder dissection|A metal catheter was then inserted in the bladder. The catheter was rotated so the tip was pointing upward, to stretch the bladder pillars. The bladder was dissected with monopolar scissors with the catheter in place. Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014). Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
40825009|NCT05814198|DIAGNOSTIC_TEST|HALP score|we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
40825010|NCT04612842|BEHAVIORAL|Motivational Interviewing|The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
41018621|NCT06387784|DIETARY_SUPPLEMENT|Placebo juice|In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice. The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice. Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.
41018622|NCT04590391|DEVICE|Visual and Auditory Breathing-swallowing Coordinated Training device|This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
41489595|NCT03801265|PROCEDURE|Lumbar plexus block|Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
41489596|NCT03801265|PROCEDURE|Quadratus lumborum type 3 block|Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
40825011|NCT06233864|DRUG|Disitamab Vedotin|Disitamab Vedotin
40825012|NCT06233864|DRUG|Gemcitabine|Gemcitabine
40825013|NCT05082220|PROCEDURE|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
40825014|NCT00823992|DRUG|placebo|sc once weekly
40825015|NCT00823992|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, then 20mg sc once weekly
40825016|NCT00492479|DRUG|Kinerase Pro+Therapy Line day repair, serum, night repair|
40825017|NCT00492479|DRUG|Kinerase Pro+Therapy Line Ultra rich day repair|
41343801|NCT06111404|PROCEDURE|Lateral urinary bladder dissection|The broad ligament is dissected down till the uterine bundle is identified. Once the uterine vascular bundle is identified the space can be dissected just above these vessels to reach the lateral margins of cervix. Any fatty tissue should be moved with the bladder. Uterine vessels are then tackled by desiccation or ligation. Similar procedure is done on the opposite side. Once the bladder is completely dissected and lifted off from the cervix below, midline adhesions of the bladder and pillars can be gradually separated using sharp dissection or Ligasure staying near to cervix (Chen et al., 2007).
41343802|NCT06111404|DEVICE|Wolf laparoscopy tower|set of instruments used for laparoscopic surgery
41343803|NCT02043509|BEHAVIORAL|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
41343804|NCT02077972|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
41343805|NCT05409118|DEVICE|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
41343806|NCT05409118|DEVICE|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
40825018|NCT00492479|DRUG|LubriDerm|
40825019|NCT06100289|DRUG|Vedolizumab IV|Vedolizumab IV injection.
40825020|NCT06100289|DRUG|Vedolizumab SC|Vedolizumab SC injection.
41343807|NCT03506113|DRUG|Gram stain-guided antibiotic choice|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics.
40825021|NCT03483805|DIETARY_SUPPLEMENT|Protalsafe|mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water
40825022|NCT03483805|DIETARY_SUPPLEMENT|Placebo|maize maltodextrin in powder form, to be diluted in water
40825023|NCT01081301|BEHAVIORAL|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
40825024|NCT05427539|DEVICE|TEST LENS|AO1DfA manufactured with PG hydration
40825025|NCT05427539|DEVICE|CONTROL LENS|AO1DfA manufactured with IPA hydration
40825026|NCT00591968|DEVICE|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
40825027|NCT03397888|DRUG|Betrixaban|80 mg capsule
40853068|NCT01526395|DRUG|Propofol|"The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be amnestic, meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week."
40853069|NCT05795153|DRUG|LOU064|LOU064 (Open-Label) taken orally for 12 weeks
41343808|NCT03506113|DRUG|Guidelines-based antibiotics choice|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
41343809|NCT05071911|PROCEDURE|TAD (Targeted Axillary Dissection)|Dual agent SLNB + resection of proven lymph nodes metastasis marked with clip at diagnosis
41343810|NCT03045640|OTHER|FSI ECD|The FSI ECD intervention was delivered in a structured curriculum format, covering a range of topics from health, water and sanitation, good hygiene, early stimulation, conflict resolution, to good communication. It was designed to improve vulnerable households home environment and engagement with their children in order to improve child development outcomes. The curriculum was delivered by bachelor-level trained staff with beneficiaries on an individual, one on one basis, using active coaching to promote child well being and behaviors with caregivers.
41343811|NCT04095962|OTHER|Exercise|The MT program will be conducted for 6 months, twice a week in 60 minutes sessions. Sessions will be divided in warm-up (10 minutes, including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (35-45 minutes, including balance/coordination training, strength and aerobic exercises) and cool down (5 minutes with breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine \[18\] and the WHO \[19\].
41343812|NCT01518634|DRUG|Imipramine treatment|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
41489597|NCT03801265|DRUG|Ropivacaine injection|0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
41489598|NCT00045669|DRUG|imatinib mesylate|
41489599|NCT06074081|OTHER|motor relearning program|MRP is a therapy to regain particular motor function and neglecting accessory movements by engaging cognitive behavior .
41489600|NCT06074081|OTHER|mirror therapy|Mirror therapy enhance functional activities in patient with hemiplegic stroke. For betterment of result high quality methodological studies and larger sample size is required.
40825028|NCT05173610|RADIATION|Radiation: Stereotactic body radiotherapy (SBRT)|"Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma.~1. Target delineation The GTV is set using diagnostic CT, MRI, PET-CT, etc. CTV is delineated including the microscopic range in GTV and internal margin using 4D-CT. The PTV is expanded by considering the uncertainty of the daily patient posture setting and placement.~2. Radiotherapy All patients are treated using 3D-CRT, IMRT, or VMAT. Total dose and fractionations will be determined depending on the location and character of the metastasized tumor. Detailed radiation prescriptions is summarized in the following paragraph.~   i. Liver: 48-60 Gy in 4 fractions ii. Lung: 45-60 Gy in 3-4 fractions iii. Brain: 27-30 Gy in 3-5 fractions iv. bone: 24-40 Gy in 3-5 fractions v. adrenal gland: 30-60 Gy in 3-8 fractions vi. other organ: depending on the clinicians' decision"
40825029|NCT00681564|PROCEDURE|One-Stage Full-Mouth Disinfection|"* Scaling and root planing, four quadrants in one session~* Tongue brushing with a 1% chlorhexidine gel (1 minute)~* Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~* Subgingival chlorhexidine (1%) irrigation in all pockets~* Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~* Basic oral hygiene instructions~* Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
40825030|NCT00681564|PROCEDURE|Periodontal care|"* Basic oral hygiene instructions~* Supragingival plaque removal"
40825031|NCT00384319|DEVICE|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
40825032|NCT01710943|BEHAVIORAL|Web-based Cognitive Behavioral Treatment|"Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week."
40825033|NCT04075422|DRUG|Bezlotoxumab Injection [Zinplava]|Treatment with bezlotoxumad according to the routine clinical practices
41018623|NCT06456294|BEHAVIORAL|MHC Outreach Intervention|Adult PC clinics are randomized to receive the MHC Outreach Intervention early (n=7 clinics) vs. delayed (n=7 clinics). In early intervention clinics, patients prescribed chronic opioid therapy, on a chronic opioid registry, and receiving their medication from the intervention clinic are sent emails and letters inviting them to schedule an MHC appointment. Clinical staff at the early intervention clinic are educated to encourage attendance. During MHC visits, MHC staff assess patients prescribed Chronic Opioid Therapy (COT), educate them about overdose, prescribe naloxone, and order guideline-concordant opioid monitoring.
41018624|NCT03821571|DIAGNOSTIC_TEST|Brain MRI|Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
41343813|NCT01518634|DRUG|Placebo|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
41343814|NCT00128362|PROCEDURE|Radio-guided sentinel node biopsy|
41343815|NCT00128362|PROCEDURE|Axillary sampling|
41343816|NCT03351062|DRUG|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day.
41343817|NCT03351062|DRUG|Toremifene|Patients will be given 60mg Toremifene once a day.
41489601|NCT04047524|OTHER|Monitoring using a FitBit|Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
41489602|NCT00384644|DEVICE|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
41489603|NCT03568279|PROCEDURE|Two-handed jaw thrust|The assistant applied two-handed jaw thrust for intubation.
41489604|NCT03568279|PROCEDURE|Control|The intubation was done without two-handed jaw thrust.
41489605|NCT04743141|DRUG|Rimegepant / BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
41489606|NCT02774096|DRUG|xenon|
41489607|NCT05668338|DEVICE|Implantable or non-implantable MED-EL hearing solution|Receipt of an implantable or non-implantable MED-EL hearing solution
40825034|NCT05423938|DIETARY_SUPPLEMENT|Diabetic|It is a hypercaloric and hyperproteic dietary supplement formulated to contribute to control the glycemia with: a specific mix of carbohydrate with a low GI, fiber, EVOO and EPA\&DHA
40825035|NCT05423938|DIETARY_SUPPLEMENT|Control|It is a hypercaloric and hyperproteic dietary supplement formulated without the ingredients to contribute in the glycemia control
40825036|NCT00785551|DRUG|quinine sulfate|2 x 324mg given in one dose to healthy subjects
40825037|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
40825038|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
40825039|NCT03880383|BEHAVIORAL|Coaching|Parents will interact and communicate regularly with a coach in person or by telephone. Coaches will be responsible for: identifying developmental concerns, proactive health promotion, guidance and training for developmental stimulation, parent support and education about child development, navigation of the health care system and self-management techniques. The frequency of coaching will be: once a month (minimum), for 18 months, at an average of 2.5 hours per month.
41018625|NCT05245812|DEVICE|da Vinci SP Surgical System|This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
41018626|NCT04485533|DEVICE|VisuXL® Gel|"VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day."
41018627|NCT04485533|DEVICE|HYLO®|"HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day"
41018628|NCT00120042|DRUG|Misoprostol|600 mcg misoprostol swallowed after delivery of fetus
41018629|NCT00120042|DRUG|Oxytocin|10 units oxytocin administered intramuscularly after delivery fetus
41018630|NCT05639088|BEHAVIORAL|Transition preparation program|"AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management.~Caregivers will attend a virtual or in-person session with a transition coach."
41489608|NCT06112392|DIAGNOSTIC_TEST|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）
41489609|NCT06112392|DIAGNOSTIC_TEST|Treatment （Oral standard anti-Parkinson's drugs）|Treatment （Oral standard anti-Parkinson's drugs）
40825040|NCT03880383|BEHAVIORAL|Online parent education|Parents will be provided access to an online platform which will provide educational resources and access to parent-parent support. Online resources on child development are curated by researchers and representative of parent groups, and linked to this online platform. The themes covered in the online tool include resources on child development, accessing health care services and managing emotions and family dynamics. These topics range from: practical tips for managing day-to-day challenges, strategies to cope and support the child's transitions from one stage to another, practical tips when looking for developmental services for the child: knowing where and how to access services.
41018631|NCT05639088|OTHER|Educational materials|AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months
41489610|NCT01468805|PROCEDURE|Cockroach mitigation/extermination|
41489611|NCT03277638|DRUG|Pembrolizumab at 7 days prior|Pembrolizumab injections 7 days before surgery
41489612|NCT03277638|DRUG|Pembrolizumab at 14 days post|Pembrolizumab injections 14 days after surgery
41489613|NCT03277638|DRUG|Pembrolizumab at 35 days post|Pembrolizumab injections 35 days after surgery
40853070|NCT03955991|BEHAVIORAL|R-CBSM|10 weekly educational modules via an electronic tablet. A participant workbook is also provided that contains a summary of the rationale for each module, outline of each technique, and homework exercises.
40853071|NCT03955991|BIOLOGICAL|Influenza vaccine|Standard of care Influenza vaccine for that given year.
40853072|NCT06482450|OTHER|LetsTalkShots (patient-facing CDS)|LetsTalkShots is a website which provides patients/parents with tailored videos addressing vaccine concerns.
41018632|NCT05196412|DEVICE|PulseOn Arrhythmia Monitor device|Wearing of the wrist device for a period of two weeks
41018633|NCT02566759|DRUG|TAK-831 Oral Suspension|TAK-831 oral suspension.
41018634|NCT02566759|DRUG|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
41018635|NCT02566759|DRUG|TAK-831 Tablet|TAK-831 tablet.
41489614|NCT03277638|PROCEDURE|Laser Interstitial Thermotherapy|surgical procedure to heat hard to reach tumors with a laser beam
41489615|NCT02375139|DRUG|DA-1229_01|complex single administration
41489616|NCT02375139|DRUG|E+M|co-administration of 2 drugs
41489617|NCT00424775|DRUG|MK0683, vorinostat|vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
41489618|NCT02932514|DEVICE|Eversense (Senseonics) Continuous Glucose Monitoring System|"* Evaluate accuracy of Eversense CGM System to SMBG Meter.~* Compare performance between abdomen and arm insertion sites.~* Determine the usability of the Eversense System in a home-use setting for 180 days."
41489619|NCT06444945|DEVICE|Heating pad|Heating pad will be used for heating purpose.
41489620|NCT06444945|DEVICE|Transcutaneous electrical nerve stimulation(TENS)|TENS is used for symptomatic pain relief
40853073|NCT06482450|OTHER|LetsTalkShots (provider-facing CDS)|The provider-facing CDS component will propagate patient concerns obtained from LetsTalkShots (and the appropriate talking points to address the talking points) into the electronic health record (EHR) for the provider at the point of care.
41018636|NCT06002763|OTHER|PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)|PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
41018637|NCT06002763|OTHER|WHOQoLBREF (World Health Organization Quality of Life Brief Version)|The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
41018638|NCT06002763|OTHER|EQ-5D-3L1 (not an acronym)|The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
41018639|NCT04535596|OTHER|Exercise|12 week long strength training exercises for knee
41018640|NCT05273567|DRUG|guanfacine-ER|guanfacine-er dispensed daily, starting at 1mg and increasing to 4mg/day or the maximum tolerated dose.
41018641|NCT05273567|OTHER|Placebo|placebo will be dispensed similar to the active arm.
41018642|NCT00882011|OTHER|Latest generation chemotherapies for T-LBL + transplant|"1. Standard doses of one of the following chemotherapies:~   * Holzer~  * LSA2-L2 modified~  * Stanford regimen~  * Hyper CVAD~  * Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~  * Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~2. Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
41018643|NCT03511521|DRUG|NPH Insulin|Intermediate acting insulin
41343818|NCT00952419|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
41343819|NCT00952419|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
41489621|NCT06444945|PROCEDURE|Mulligan mobilization with movement (MWM)|It provides short term pain relief and to restore pain-free, functional movements by achieving full range at the joint
41489622|NCT06444945|PROCEDURE|Kaltenborn joint mobilization|The purpose of joint mobilization is to restore normal, painless joint function. In restricted joints, this involves the restoration of joint play to normalize the roll-gliding that is essential to active movement.
41489623|NCT06444945|PROCEDURE|Resistance Training exercise|Resistance training increases muscle strength by making your muscles work against a weight or force.
41489624|NCT05154435|DRUG|mostcare hemodynamic monitor|mostcare hemodynamic monitoring integrated into the radial artery catheter. According to the data obtained, intraoperative fluid management was arranged with certain algorithms.
41489625|NCT00044668|DRUG|AC2993|Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
41489626|NCT00653952|DRUG|CAELYX|Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
41489627|NCT00653952|DRUG|Paclitaxel HCl|Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
41489628|NCT01953939|OTHER|Prosthetic Limb Users|There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
41489629|NCT06456736|OTHER|None, non-interventional study|Not applicable, non-interventional study
41489630|NCT05419830|BEHAVIORAL|BBTI|Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
41018644|NCT03511521|DRUG|glargine|basal insulin
41018645|NCT03511521|DRUG|Insulin Aspart|prandial insulin
41018646|NCT03377348|PROCEDURE|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
41018647|NCT02520024|BEHAVIORAL|self-directed care|
41343820|NCT00952419|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
41343821|NCT03797885|OTHER|No treatment given|No treatment is administered to the participants for this study
41343822|NCT00464620|DRUG|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
41343823|NCT02300844|DRUG|NNC0174-0833|"Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated."
40853074|NCT06482450|OTHER|Appointment Reminder Message|"The regular text message and e-mail appointment reminder includes a vaccine primer (e.g. Vaccines are due and reserved for the participant's child), but no patient- or provider-facing CDS."
41343824|NCT02300844|DRUG|placebo|Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
41343825|NCT05457400|DRUG|ENSO 16|30 g ENSO 16 dissolved in Water
41489631|NCT05419830|OTHER|PM antihypertensive dosing or Chronotherapy|participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
41489632|NCT05419830|OTHER|AM antihypertensive dosing|participants will be asked to continue taking their antihypertensive medication within an hour of awakening
41489633|NCT06180265|DIAGNOSTIC_TEST|presepsin, procalciton, endotoxin|measurement of presepsin, procalciton, endotoxin plasmatic levels
41489634|NCT06380868|PROCEDURE|Intravascular imaging-guided PCI|Intravascular imaging including intravascular ultrasound or optical coherence tomography.
41343826|NCT05457400|DRUG|Glucose Powder|30 g Glucose Powder dissolved in Water
41343827|NCT00859573|DRUG|Modafinil|400 mg/day
41343828|NCT00859573|DRUG|Placebo|inactive substance
41343829|NCT00809614|BIOLOGICAL|AIN457|The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
41343830|NCT00809614|BIOLOGICAL|Placebo|Matching placebo to AIN457
41343831|NCT00987727|DRUG|carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|One drop in each eye three to six times daily, as needed
41343832|NCT00987727|DRUG|sodium hyaluronate 0.18% (VISMED® Multi)|One drop in each eye three to six times daily, as needed
41343833|NCT02168660|DRUG|Vitamin D3|Vitamin D3, liquid formulation, 5000 IU/mL.
41343834|NCT00509028|DRUG|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
41343835|NCT00509028|DRUG|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
41343836|NCT04486391|DRUG|Tislelizumab|200 mg administered via intravenous (IV) infusion once every 3 weeks
41343837|NCT04486391|DRUG|Salvage Chemotherapy|Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
41343838|NCT03790267|OTHER|Questionnaire administration|One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.
41343839|NCT03408288|OTHER|Hemapoche|Use of Hemapoche scale to assess hematuria in reference samples
41343840|NCT03408288|OTHER|Hemastick|Use of Hemastick scale to assess hematuria in reference samples
41343841|NCT03408288|OTHER|Color description|Describe color of reference sample
41343842|NCT06287658|BEHAVIORAL|Training on Kegel exercise and Ba Duan Jin applications online|Kegel exercises and Ba Duan Jin applications online
41343843|NCT06287658|BEHAVIORAL|training on Kegel exercises and Ba Duan Jin applications after the research is completed|Women in the control group will be given training on Kegel exercises and Ba Duan Jin applications after the research is completed.
41343844|NCT04905836|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
41343845|NCT04905836|DRUG|Placebo|Excipient solution
41343846|NCT04691011|OTHER|Muscular MRI|MRI (1.5T)
41343847|NCT04691011|OTHER|Electrophysiological exam|MUNIX
41343848|NCT04691011|OTHER|Brain MRI|MRI (7T)
41343849|NCT04691011|OTHER|Spinal cord MRI|7T and 3T MRI
41343850|NCT05984628|PROCEDURE|human umbilical cord mesenchymal stem cells|After the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings.
41343851|NCT05984628|PROCEDURE|blank solvent|After the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings.
41343852|NCT03884556|DRUG|TTX-030|Variable dose and schedule
41343853|NCT03884556|DRUG|Pembrolizumab|Dose and schedule per standard of care
41343854|NCT03884556|DRUG|Gemcitabine|Dose and schedule per standard of care
41343855|NCT03884556|DRUG|nab paclitaxel|Dose and schedule per standard of care
41489635|NCT06380868|PROCEDURE|Angiography-guided PCI group|Deployment of a drug-eluting stent under angiography.
41489636|NCT01772758|DRUG|BH4 5mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 5 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
41489637|NCT01772758|DRUG|BH4 20mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
41489638|NCT01772758|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
41489639|NCT05648786|BEHAVIORAL|Laddr® plus Behavioral- Group and individual counseling|"Smartphone application utilizing the Community Reinforcement Approach (CRA) to facilitate social support in substance use treatment.~Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services."
41343856|NCT04471532|BEHAVIORAL|Behavior change intervention|"It is a 3-month, multimodal, minimal contact, pedometer-driven, behavior change intervention to promote and support physical activity, that is initiated 3 months after THA. There is one initial, physiotherapist-led, face-to-face, physical activity counselling including 1) a brief motivational interviewing regarding physical activity, 2) patient education regarding physical activity after THA including recommendations and safety based on an orthopedic surgeon guided video and leaflet, 3) handling out pedometer and educational material i.e. a practice-oriented leaflet with advice on how to use a pedometer, a step-calendar and goal setting as well as strategies to incorporate physical activity into daily life. This initial counselling is followed by two, physiotherapist-led, telephone-assisted counselling after respectively three and seven weeks."
41343857|NCT06138392|DEVICE|Dental implant (ELEMENT RC INICELL, Thommen Medical)|Dental implant
41343858|NCT02766049|BIOLOGICAL|DC|Autologous dendritic cells (3x10e7)
41343859|NCT02766049|BIOLOGICAL|DC10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
41343860|NCT02766049|BIOLOGICAL|DC10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
41343861|NCT03595189|DRUG|Cilastatin|Dose escalation 3-hour single intravenous administration
41343862|NCT03595189|DRUG|Placebo|3-hour single intravenous administration
41343863|NCT00290355|BIOLOGICAL|GSK 249553 vaccine|Intramuscular injection, 13 doses
41343864|NCT00290355|BIOLOGICAL|Placebo|Intramuscular administration, 13 doses
41343865|NCT06340776|OTHER|Acupressure|For the acupressure application, planning was made to adjust the temperature, light and silence of the environment and to pay attention to privacy. 5 points that positively affect gastrointestinal functions and pain were selected (SP6, ST36, PC6, HT7 AND LI4). The duration of the session was determined to be approximately 18-20 minutes, depending on the preparation and pressure time to be applied on the 5 selected points (a total of 10 points were applied since each point will also be applied to its counterpart in the other extremity). Acupressure application was applied to each point for 1.5 minutes (1.5\*10=15 minutes).
41343866|NCT03987867|BIOLOGICAL|CIK cell|CIK cell injection
41343867|NCT03987867|BIOLOGICAL|Sintilimab Injection|IBI308 injection
41343868|NCT03987867|DRUG|Pemetrexed|Pemetrexed injection
41343869|NCT03987867|DRUG|Liposome paclitaxel|Liposome paclitaxel injection
41343870|NCT03987867|DRUG|Carboplatin|Carboplatin injection
41343871|NCT01586962|DRUG|IFF flavor 316 282, Paracetamol, Pseudoephedrine|Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
41343872|NCT01386190|OTHER|Exercise/Social Behavioral|Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
41343873|NCT04135664|PROCEDURE|esophagectomy|esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy
41343874|NCT04135664|COMBINATION_PRODUCT|chemoradiation|concurrent chemotherapy and radiotherapy
41343875|NCT04135664|OTHER|active surveillance|No further adjuvant therapy
41343876|NCT04516941|DRUG|Edoxaban Tablets|Treatment
41343877|NCT04516941|DRUG|Colchicine Tablets|Treatment
41343878|NCT00063388|BIOLOGICAL|Cetuximab|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
41383605|NCT02564172|OTHER|OMM group|"Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~* at effective dose, and minimal effective dose on the basis of adverse events and contraindications~* as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches...) will not be forbidden or contra-indicated."
41383606|NCT06282185|OTHER|Physiotherapy|supervised training program for twelve weeks + usual care + advice about exercise
41489640|NCT05648786|BEHAVIORAL|Behavioral- Group and individual counseling|The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.
41489641|NCT00895947|DRUG|interferon-alpha|a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
41489642|NCT00895947|OTHER|placebo|placebo lozenges for oral dissolution taken once daily for 16 weeks
41343879|NCT05908929|PROCEDURE|SRP and concomitant insertion of PRF membrane|The pockets were treated with scaling and root planing (SRP) along with the simultaneous insertion of a Platelet Rich Fibrin (PRF) membrane. Blood samples were drawn without anticoagulants in 10 mL tubes, which were immediately centrifuged at 4000 rpm for 8 minutes. Upon centrifugation, the blood showed three distinct layers: the uppermost layer contained platelet poor plasma, the middle layer consisted of a fibrin clot, and the lowermost band appeared bright red due to the presence of red blood cells. The fibrin clot polymerized in a diffuse manner within the tube, which was then cut with sharp scissors and squeezed between two glass slides to obtain a thick membrane. The PRF membrane was carefully handled using a carrier and isolated with a periodontal pack dressing (Coe-Pak). All patients were followed up at one week and six weeks after the treatment.
41343880|NCT05908929|PROCEDURE|SRP|The pockets were treated using the conventional procedure of scaling and root planing (SRP) utilizing curettes and an ultrasonic device. All patients were followed up at one week and six weeks after the treatment.
41343881|NCT02743975|DRUG|Bevacizumab-800CW|dose finding: 4.5mg; 10mg; 25mg; 50mg
41343882|NCT05648123|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
41343883|NCT06147336|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, fixated within the inter-atrial septum.
41343884|NCT01085162|DRUG|BMS747158|BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
41343885|NCT02300506|OTHER|No intervention|
41343886|NCT06049251|OTHER|ELDOA exercises|"The patients will be asked to sit down on a floor in upright position and keep their legs apart and knees semi-flexed, feet in outward and upward position, knees constantly pushing downwards, straight lower back, raise arms with palms facing upward, and chin should be pulled back.~ELDOA stretch for L5-S1 level Patients will be asked to lay on floor and flatten and bring their legs up and straight with the support of wall, straight knees and keep distance between them, connect their toes, raise arm and externally rotate with wrist extension than press their heels and palms out.~ELDOA exercises will be performed with 2 sets of 5 repetitions with 45 second hold and15 sec rest between each set once a day."
41343887|NCT06049251|OTHER|Lumbar SNAGS and motor control exercises|"The patient will be seated and his pelvis will be stabilized with belt at the level of the anterior superior iliac spine while the SNAGs are administered. The ulnar aspect of the therapist's hand will be placed over the spinous processes of the affected segment's superior vertebrae, for flexion glide and inferior vertebrae for extension glide respectively. A passive glide will be applied and kept up until the patient finished a full movement arc. The glides will be given for six repetitions for three sets every session. Glide can be given unilateral for other movements.~Motor Control Exercises:~Exercise training with 7sec Hold and 10 reps"
41343888|NCT06417190|DRUG|Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)|Single-arm, open-label
41343889|NCT00216229|BIOLOGICAL|Combined vaccine against hepatitis A and B (Twinrix)|
41343890|NCT01547962|DEVICE|Gintuit|"Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture."
41343891|NCT01547962|OTHER|autologous Free Gingival Graft (FGG)|Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
41343892|NCT04062006|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
41343893|NCT05495191|DIAGNOSTIC_TEST|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
41343894|NCT00895908|BEHAVIORAL|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
41343895|NCT00895908|BEHAVIORAL|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
41343896|NCT04146129|DRUG|CDX-0159|Single dose of one of four dosages of CDX-0159
41343897|NCT04146129|DRUG|Normal saline|Single infusion of normal saline
41343898|NCT02809118|DRUG|AM-111 0.4 mg/ml|AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
41343899|NCT02809118|DRUG|AM-111 0.8 mg/ml|AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
41343900|NCT02809118|OTHER|Placebo|Placebo gel is administered with a single dose into the affected ear after topical anesthesia
41489643|NCT03373734|DEVICE|Enjoy Your Bump|Online life skills course based on Cognitive Behavioural Therapy Principles.
41489644|NCT02546336|DEVICE|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
41489645|NCT03715075|PROCEDURE|Caesarean Section|Caesarean Section
41489646|NCT05783518|DRUG|desflurane|Intraoperative anesthesia maintenance
41343901|NCT03966092|PROCEDURE|Quadratus lumborum block|"* Bilateral Quatratus lumborum block is performed with ultra sound guidance. The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen). Laterally, these three are merging to from fascia transversalis. Under fascia transversalis, we can see quadratus lumborum muscle. Punction point in lateral, 1cm in the plan separating quadratus lumborum block and fascia transversalis~* 20 ml of ropivacaïne 3.75mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
41489647|NCT05783518|DRUG|propofol|Intraoperative anesthesia maintenance
41489648|NCT02503020|DIETARY_SUPPLEMENT|Preterm infants formula A|Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
41489649|NCT02503020|DIETARY_SUPPLEMENT|Preterm infants formula B|"Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.~At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age."
41489650|NCT02145026|DRUG|Epoetin beta|Epoetin beta 30,000 or 60,000 IU per week SC injection
41489651|NCT05373173|BEHAVIORAL|Tele-assessment + In-person assessment|All consented families will complete an initial home-based tele-assessment visit via Zoom that includes the TAP-Preschool and a brief symptom-focused developmental interview with a consented clinician. The initial tele-assessment session includes interviewing and developmental assessment to mimic real-world use of TAP-Preschool. After the session, the examiner will record the clinical diagnosis issued (ASD, other developmental concerns, or typical development) and complete two diagnostic certainty ratings. All initial TAP-Preschool administrations will be recorded via Zoom, and 50% of administrations (randomly selected) will be co-scored by a blinded examiner, unaware of prior assessment results and diagnostic decision, to evaluate inter-rater reliability. Within 7 days of the remote assessment, families will participate in an in-person diagnostic assessment including common comprehensive measures of ASD, cognitive skills, and adaptive behavior.
41489652|NCT01094418|OTHER|Nerve conduction studies ( NCS) of the peripheral nerves|"Standard NCS of the sural, superficial peroneal sensory nerves, peroneal, tibial motor nerves, radial and median sensory nerves, median motor nerves, F-wave studies of the Tibial and median nerves.~NCS of the distal sensory nerves; dorsal sural Medial dorsal cutaneous and medial plantar nerves."
41489653|NCT05214963|DEVICE|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode
41489654|NCT05214963|DEVICE|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode
41489655|NCT02815449|OTHER|Meals prepared with iron fortified cube with Low stabilizer level|Meals prepared with iron fortified cube with Low stabilizer level
41489656|NCT02815449|OTHER|Meals prepared with iron fortified cube with Medium stabilizer level|Meals prepared with iron fortified cube with Medium stabilizer level
41343902|NCT01071291|DRUG|Niaspan|Niaspan™
41343903|NCT01071291|DRUG|Comparator: Placebo|Placebo
41343904|NCT02510274|DRUG|ASP3325|oral
41343905|NCT03463213|BEHAVIORAL|SHE Tribe|Social network-based peer-facilitated intervention to promote adoption of health behavior
41343906|NCT03131011|OTHER|UV fluorescent ink|"The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light. Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy dot tattoos. Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up."
41343907|NCT00354952|DRUG|Macrolides (azithromycin or clarithromycin)|
41343908|NCT04227119|DEVICE|Irrigated ablation catheter|After completion of ablation, the ablation catheter will be serially positioned in the cardiac chambers (either the left or right side of the heart). The stop cock will be turned to the pressure transducer and waveforms will be stored corresponding to each chamber.
41343909|NCT04227119|DEVICE|Balloon tipped PA catheter|After removal of the irrigated ablation catheter, a 5F balloon tipped PA catheter which will be positioned under fluoroscopic guidance in each previously evaluated chamber and the chambers will be measured again.
41343910|NCT00150150|PROCEDURE|Interstitial laser photocoagulation|
41489657|NCT02815449|OTHER|Meals prepared with iron fortified cube with High stabilizer level|Meals prepared with iron fortified cube with High stabilizer level
41489658|NCT00596037|DRUG|Growth hormone - LB03002|
41489659|NCT03506984|DEVICE|Threshold Inspiration Muscle Training Device|Threshold based trainer is a small handled device.It includes a mouthpiece and a calibrated spring loaded valve. The valve control a constant inspiratory pressure training load and the patient must generate a suffient inspiratory pressure in order for the inspiratory valve to be opened and allow the air to be inhaled. The amount of resistance can be adjusted by varying the compression of the spring-loaded valve. Adjustment from 9cmH2o to 41cmH2o.
41489660|NCT03506984|DEVICE|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be used in High interval intensity training.
41489661|NCT00266357|DRUG|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
41489662|NCT00266357|DRUG|Placebo / Duration of Treatment: 2 days for screening period|
41343911|NCT00964769|BIOLOGICAL|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
41343912|NCT02039089|DRUG|E2006 2.5 mg|
41343913|NCT02039089|DRUG|E2006 10 mg|
41343914|NCT02039089|DRUG|E2006 25 mg|
41343915|NCT02039089|DRUG|Placebo|
41343916|NCT02691468|DEVICE|PVC DLT|PVC DLT is type of double lumen tube that is composed of PVC
41343917|NCT02691468|DEVICE|silicon DLT|silicon DLT is type of double lumen tube that is composed of silicon
41343918|NCT02672644|DEVICE|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
41343919|NCT02672644|DEVICE|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
41343920|NCT02689544|OTHER|intervention with static stretching|Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.
41343921|NCT02689544|OTHER|intervention with Dynamic Stretching|Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.
41343922|NCT02689544|OTHER|Control|The control group volunteers no received intervention
41489663|NCT03686449|PROCEDURE|Non-cultured Autologous Keratinocyte Suspension|New method for treatment of post-burn raw area
41489664|NCT03686449|PROCEDURE|Adipose-Derived Stem cell-Keratinocyte Suspension|New method for treatment of post-burn raw area
41489665|NCT03686449|PROCEDURE|Split skin graft|Traditional method for treatment of post-burn raw area
41343923|NCT03607240|PROCEDURE|lung ultrasound-guided alveolar recruitment|Alveolar recruitment maneuver will be performed under lung ultrasound-guidance. Positive pressure will be not exceed 40cmH2O and duration of positive pressure inflation will not exceed 10 seconds.
41343924|NCT03607240|PROCEDURE|conventional alveolar recruitment|Alveolar recruitment will be provided with positive pressure of 30cmH2O for 10 seconds
41343925|NCT04709250|PROCEDURE|interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine will be injected
41489666|NCT04896814|PROCEDURE|Transcutaneous tibial nerve stimulation|The participant will be placed in the supine position with the soles of the feet together and the knees flexed and abducted at 90º. Two adhesive electrodes will be used for each leg. First one: 32 mm of diameter that will be placed in the posterior tibial nerve, that is, 4-5 cm cranial to the internal malleolus, between the posterior edge of the medial border of the tibia and the soleus tendon. Second one: 50x50 mm to be placed in the ipsilateral calcaneus. The electrodes will be connected to the NeuroTracTM PelviTone stimulation device. The stimulation range will be selected according to the tolerable pain limit for the patient, between 0.5 and 20 mA (adjustable in 1 mA levels).The intensity elevation will be allowed each time the patient perceives the fading of the previous sensation due to accommodation. Under no circumstances should the stimulation cause a painful feeling.
41343926|NCT04709250|PROCEDURE|selective nerve block|"the patient will be put in the sitting position, linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to view of the suprascapular nerve. 5-8 mL of 0.25% bupivacaine is injected to block the SSN.~The ultrasound probe put on the posterior aspect of the shoulder to view the circumflex artery, 10 mL of 0.25% bupivacaine this will lead to loss of sensation over the deltoid.lateral pectoral nerve block (LPNB) will be done by injecting a volume of 8 ml of a 0.25% bupivacaine The probe will be moved towards the biceps muscle until the musculocutaneous nerve is seen and 8 ml of 0.25% bupivacaine will be injected."
41343927|NCT04709250|DRUG|bupivacaine|bupivacaine
41383607|NCT03763539|PROCEDURE|SWL|Shock wave lithotripsy
41383608|NCT02861534|DRUG|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
41383609|NCT02861534|DRUG|Placebo for vericiguat|2.5, 5.0, or 10.0 mg orally once daily
40825041|NCT03880383|BEHAVIORAL|Online peer support|Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge. This will put each family at the centre of each network (family, friends, health providers), allowing family networks to link with one another. Families will be able to find resources, create connections with the coach, health providers and other families, thus creating a network to support one another.
41343928|NCT00998036|DRUG|Temsirolimus|"Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg"
41343929|NCT00998036|DRUG|Cisplatin|Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
41343930|NCT00998036|DRUG|Erlotinib|"Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg"
41343931|NCT02812108|DEVICE|intracranial stent, flow diverter and coils|
41383610|NCT00209235|BEHAVIORAL|Neurocognitive and psychosocial testing|Neurocognitive and psychosocial testing
41509011|NCT02641158|BEHAVIORAL|Care Facilitation Group|"The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services."
40825042|NCT05999175|DEVICE|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.
40825043|NCT05999175|DEVICE|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."
40825044|NCT05999175|DEVICE|subjects of this group will use their routine oral hygiene products.|subjects of this group will use their routine oral hygiene products.
40825045|NCT06496867|PROCEDURE|Early Internal Fixation|Early internal fixation of the LC1 fragility fracture of the pelvis will be defined as percutaneous anterior and/or posterior pelvic internal fixation with cannulated screw(s), medullary implant(s), or sacroiliac joint fusion device(s). The implant number, design, diameter, thread type (fully-threaded or partially-threaded), sacral segment (S1, S2, S3, or any combination there of), length, trajectory including sacroiliac or transsacral-transiliac, application with or without a washer, and ingrowth or ongrowth surface designs will be at the discretion of the treating surgeon.
40825046|NCT06496867|OTHER|Nonoperative Care with Early Rehabilitation|Nonoperative care with early rehabilitation will consist of nonoperative treatment of the pelvis fracture, including early consultation of the physical therapist, physiotherapist, or local equivalent rehabilitation provider at the time of randomization for a first attempt at mobilization of the patient within 24 hours of randomization. Patients who are unable to ambulate with assistance after five or more days of attempted mobilization by rehabilitation providers may be considered for delayed internal fixation treatment at the discretion of the patient and the treating surgeon. Delayed internal fixation after five or more days of attempted mobilization by rehabilitation providers will not be considered a treatment crossover event.
40825047|NCT05059223|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
40825048|NCT05059223|DRUG|Placebo|Placebo tablets, taken twice daily
40825049|NCT04982406|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
40825050|NCT05648864|DEVICE|Viamigo|Mobile application with the aim to enhance the independent outdoor mobility of the user while a coach (informal caregiver) can monitor the route from a distance.
40825051|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666) IV|intravenous infusion
40825052|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666)|exposed via pregnancy and lactation
40825053|NCT02729610|DEVICE|double-lumen endotracheal tube (DLT group)|In this arm, after anesthesia induction, a double lumen endotracheal tube will be intubated for one-lung ventilation
40825054|NCT02729610|DEVICE|endobronchial blocker (BB group)|In this arm, after anesthesia induction, an endobronchial blocker will be intubated for one-lung ventilation
40825055|NCT06139653|DEVICE|Moment 1: IMT. Moment 2 CardioBreath.|"Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
40853075|NCT05998564|DEVICE|Connecting patients to both non-invasive monitors to observe and compare the monitor's capabilities.|All patients will be connected to the NOL monitor and the SCA monitor during general anesthesia.
40825056|NCT06139653|DEVICE|Moment 1: CardioBreath and moment 2: IMT.|"CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act.~Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks."
40825057|NCT00237068|DRUG|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
40825058|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-6 months|Modification of behaviours achieved with reframing thoughts and impulses
40825059|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-12 months|Modification of behaviours achieved with reframing thoughts and impulses
40825060|NCT06061289|DIETARY_SUPPLEMENT|SP Detox Program|The production use and disposal of toxic chemicals and synthetic materials have increased the risk of exposure to health-threatening toxins. Causal relationships between toxic chemicals and diseases have been well established. However, many patients endure chronic symptoms that are associated with exposure to toxins before advanced stages of specific diseases are realized. Thus, there is a great demand for noninvasive laboratory tests that can provide timely assessment of chemical exposure and the capability of hepatic detoxification
40825061|NCT03602313|DEVICE|Body Weight Support Gait Training|
40825062|NCT03602313|OTHER|Traditional Gait Training|
40853076|NCT00317382|DEVICE|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
41343932|NCT00478530|PROCEDURE|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
41343933|NCT03025516|DEVICE|Rapid Biosensor Systems (RBS) TB Breathalyser|Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
41343934|NCT03025516|DEVICE|eNose AeonoseTM|The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
41343935|NCT05320640|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
41489667|NCT04896814|PROCEDURE|Placebo|The participant will be placed in the same position. Two 50 x 50 mm adhesive electrodes will be placed on the external face of the thigh, on a single leg. This area is outside the territory of the posterior tibial nerve. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied. This simulated current being considered to be insufficient to achieve therapeutic effects in the body and to be outside of the usual ranges described in electrotherapy manuals regarding pain management. The intensity will be selected according to the paint limit level of the patient, between 0.5 and 60 mA (adjustable in 0.1 mA levels), where a low or moderate sensation of the patient will be sought, without muscle contraction.
41343936|NCT05320640|DRUG|Decitabine|Low-dose decitabine inhibits the activity of DNA methyltransferase, which can increase tumor antigens and HLA expression, enhance antigen processing, promote T cell infiltration, and boost effector T cell function.
41343937|NCT05320640|DRUG|Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）|Immune checkpoint inhibitors (ICIs) have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.
41343938|NCT05541250|BIOLOGICAL|Autologous Human Schwann Cell|A one-time dose of 1000 μl\* or 80 to 100 million ahSC prepared from segments of the sural nerve from the leg recovered from the participant.
41343939|NCT05478967|PROCEDURE|IVA injection before vitrectomy|Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
41343940|NCT02058706|DRUG|enzalutamide|Given PO
41343941|NCT02058706|DRUG|bicalutamide|Given PO
41343942|NCT02058706|PROCEDURE|orchiectomy|Undergo orchiectomy or receive LHRH analogue therapy
41343943|NCT02058706|DRUG|leuprolide acetate|Undergo orchiectomy or receive LHRH analogue therapy
41343944|NCT02058706|DRUG|goserelin acetate|Undergo orchiectomy or receive LHRH analogue therapy
41343945|NCT02058706|OTHER|laboratory biomarker analysis|Correlative studies
41489668|NCT06344936|DRUG|HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules|Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice
41489669|NCT02257541|DRUG|BGJ398|
41489670|NCT02257541|DRUG|Imatinib Mesylate|
41489671|NCT02109510|DRUG|nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration|
41489672|NCT02109510|DRUG|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|
41018648|NCT04772092|BIOLOGICAL|Blood samples|"during the routine blood test, collection of additional blood samples:~* 1 x 5 mL heparinized tube for plasma collection and storage~* 1 heparinized 5 mL tube for immunophenotyping~* 4 x 10 mL EDTA tubes for white blood cell (WBC) collection and cryopreservation"
41018649|NCT04772092|OTHER|Data collection|"* clinical examination data~* test results to measure the degree of geriatric fatigability~* Frailty screening questionnaire for neoplasia patients (G8 score)"
41343946|NCT00357786|DRUG|Replagal agalsidase alfa|
41343947|NCT00357786|DRUG|Replagal|
41343948|NCT03637894|DIETARY_SUPPLEMENT|Feeding infants with fermented formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
41343949|NCT03637894|OTHER|Feeding infants with standard formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
41343950|NCT03637894|OTHER|Breastfeeding infants|Reference group
41343951|NCT02907281|OTHER|Observational|Observational
41343952|NCT02966106|DEVICE|Right prefrontal low frequency rTMS|A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
41343953|NCT02966106|OTHER|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
41343954|NCT01183481|DRUG|Aprepitant|Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
41343955|NCT01183481|RADIATION|Palliative radiation therapy|Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
41343956|NCT01183481|DRUG|Granisetron|Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
41343957|NCT05981755|OTHER|Breathing tasks|Breathing tasks include normal breathing through nose or mouth, breathing while resting wakefully, increase and decrease in breathing rate, and breath counting.
41343958|NCT05981755|DEVICE|Brain mapping with stimulation|Electrical stimulation will be used to find specific areas of the brain involved in breathing function. Stimulation will be applied using a Nihon Kohden MEE-1000A neural function measuring system with the MS-120BK extension unit for brain stimulation.
41343959|NCT01451957|OTHER|Exercise - caloric balance|90 min exercise on Day 1 with meals afterward resulting in caloric balance for the day (i.e.; extra kcals provided to account for energy expended during exercise)\]
41343960|NCT01451957|OTHER|No Exercise - hyper-caloric diet|Subjects remain sedentary on Day 1 and they ingest meals that are identical to those ingested on the day they performed exercise (i.e.; more calories ingested than expended because no exercise performed).
41343961|NCT01451957|OTHER|No exercise - caloric balance|Subjects remain sedentary on Day 1 and they ingest a similar proportion of macronutrients however, the total calories ingested will be lower than the other two trials, resulting in caloric balance for the day.
41343962|NCT02450240|BEHAVIORAL|standardized diagnostic assessment|
41343963|NCT02450240|BEHAVIORAL|self-report questionnaires|
41343964|NCT02450240|BEHAVIORAL|behavioral tasks|
41343965|NCT02450240|OTHER|physiological measurements|
41489673|NCT02109510|PROCEDURE|single port thoracoscopic bullectomy|Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
41489674|NCT04461366|DEVICE|Monopolar radiofrequency|The RF electrode was moved randomly for 30 seconds over each scar. The total duration of the treatment session is only 5 minutes for each cheek. It takes 15 minutes if the forehead and 2 cheeks are affected.
41489675|NCT04461366|DEVICE|Pulsed dye laser|PDL was applied for the affected areas with no pre-treatment regimens or topical anaesthetics. There was no requirement for skin cooling.
41489676|NCT04842838|DEVICE|paclitaxel DCB|Drug-coated balloon is a new kind of coronary interventional device. The balloon coated with anti-cell proliferation drugs (paclitaxel, etc.) is sent to the stenosis site. The balloon is closely adhered to the vascular wall during the expansion, and the drug is rapidly and evenly coated on the disaffected vessels.In recent years, DCB has gradually become an alternative for the treatment of in-stent restenosis (ISR), small vessel disease (SVD) and bifurcation disease.
41489677|NCT04842838|DEVICE|DES|Provisional T technique is the preferred method for the treatment of bifurcation lesions with the existing stent.According to the 2018 European Guidelines on revascularization and the consensus group of the European Bifurcation Club (EBC), Provisional T technique is still the first choice for the treatment of Bifurcation, despite the problems related to side branches.
41489678|NCT05870137|DEVICE|HoloLens2TM|Participants assigned to Mixed Reality-supported care used the HoloLens2 device, which provided support using technology that was permitted by the device. This support included remote assistance and holographic versions of patient-specific investigation results, such as radiological findings, biochemistry, and guidelines for completing the procedure (insertion of chest drain).
41343966|NCT02450240|OTHER|structural and functional magnetic resonance imaging and EEG|
41343967|NCT02450240|OTHER|biomarker and microbiome assessments|
41343968|NCT02450240|OTHER|blood to derive induced pluripotent stem cells|
41343969|NCT02450240|OTHER|genetic and epigenetic assessments|
41343970|NCT04969458|OTHER|survey application|"Data collection tools used in the study;~* Clinic and Demographic Evaluation Form~* Oswestry Low Back Pain Disability Index (ODI)~* Patterns of Activity Measure Pain (POAM-P)~* Roland-Morris Disability Questionnaire (RMDQ)~* Hospital Anxiety and Depression Scale (HADS)~* Graded Chronic Pain Scale Version 2.0 (GCPS 2.0)"
41343971|NCT04765176|DEVICE|Endovascular Repair|Endovascular repair of the infrarenal aorta using a AAA stent graft.
41343972|NCT04774224|DRUG|Baricitinib|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.
41343973|NCT04774224|DRUG|Placebo|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
41343974|NCT03064165|DRUG|Bupivacaine-epinephrine|Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
41343975|NCT03064165|PROCEDURE|Sham block|Injection as for obturator nerve block, but with placebo
40825063|NCT06390540|OTHER|Exercise|During the training, verbal information will be given about the importance of exercise, exercise barriers, and the potential benefits of exercise on the mother and baby in the postpartum period. In the training, the points that the mother should pay attention to before exercise will also be discussed. In the following process, videos containing deep breathing and relaxation exercises will be sent to women. The videos will be recorded by the researchers at Ankara University Physiotherapy application laboratory. Recording videos will be delivered to women through social networks. Women will be allowed to do these exercises for a total of 8 weeks.
40825064|NCT03085511|BEHAVIORAL|Egg breakfast (EB)|Breakfast is considered as high quality protein diet, but has similar weight, energy, and macronutrients as the active comparator. The details are as follows: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.6%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
41343976|NCT03064165|PROCEDURE|Obturator nerve block|Postoperative obturator nerve block
41343977|NCT03064165|DRUG|Sodium Chloride 9mg/mL|Placebo
41343978|NCT01011595|PROCEDURE|Cervical Mediastinoscopy|Surgical Meciastinal Lymph Node Staging
41343979|NCT01011595|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
41343980|NCT01011595|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
41343981|NCT05299502|BEHAVIORAL|Nutritional Intervention|4 individual 1-hour in person (or virtual, according to potential public health restrictions and patients' preference) motivational interviews (12, 18, 24 and 30 weeks) with a registered dietitian will be conducted to elaborate S.M.A.R.T. (Specific,Measurable, Attainable, Relevant, Timely) goals regarding diet, based on the 2019 Canada's Food Guide. Between those individual follow-ups, 4 phone calls with the registered dietitian will be provided (15, 21, 27, 33 weeks). Throughout the study, 10 informative nutritional video clips will also be provided. Participants receiving the intervention will have access to an online Facebook private community to discuss and share experiences, thus maintaining motivation and providing social support.
41343982|NCT04063540|DRUG|Amiloride|Treatment by Amiloride vs placebo in crossover
41343983|NCT04063540|DRUG|Placebos|Treatment by Amiloride vs placebo in crossover
41343984|NCT01965028|DEVICE|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4 Arms: tRNS
41018650|NCT05585333|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
41343985|NCT01547806|DRUG|Filgrastim|Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
41343986|NCT01547806|DRUG|Plerixafor|Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
41383611|NCT01302288|PROCEDURE|Per oral endolumenal myotomy|patient cohort having flexible endoscopic submucosal esophageal partial myotomy
41343987|NCT01547806|PROCEDURE|Apheresis|The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
41343988|NCT04921969|DRUG|Ruxolitinib|The study cream will be applied topically twice a day for up to 52 weeks.
41343989|NCT04921969|DRUG|Vehicle Cream|Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
41343990|NCT00802880|DRUG|Dacarbazine|
41343991|NCT01511640|DRUG|Pregabalin|pregabalin 2x daily for duration of study
40825065|NCT03085511|BEHAVIORAL|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
40825066|NCT03085511|BEHAVIORAL|Weight Loss Diet|Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.
40825067|NCT03085511|BEHAVIORAL|Cereal Breakfast (CB)|Breakfast is considered as low quality protein diet, but has similar weight, energy, and macronutrients as that in experimental group. The details are as follows: weight 293 g, energy 398 kcal, energy density 1.36 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
40825068|NCT01107600|PROCEDURE|Immediate implant and socket preservation|Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.
40825069|NCT02865889|PROCEDURE|Laparoscopy in Gynecologic Oncologic Indications|
41343992|NCT01511640|DRUG|Placebo|placebo 2x daily for duration of study
41343993|NCT02640755|DRUG|[14C]AZD2014|Radiolabelled dual TORC1/TORC2 inhibitor
41343994|NCT02640755|DRUG|Multiple dose AZD2014|Dual TORC1/TORC2 inhibitor
41343995|NCT02640755|DRUG|Fulvestrant|Hormonal Agent
41343996|NCT02640755|DRUG|Paclitaxel|Taxane
41343997|NCT03953040|DIAGNOSTIC_TEST|intracoronary imaging (IVUS, OCT)|Patients presenting with non STE-ACS will be subjected after performing PCI of the culprit lesion to intracoronary imaging with the help of IVUS and OCT of the non-culprit lesions to detect and image the so-called vulnerable plaques
41343998|NCT04925830|BEHAVIORAL|Heart rate variability biofeedback; haemoncephalography biofeedback|Ten 25-minute weekly heart rate variability biofeedback and 30 minute haemoencephalogrphy biofeedback sessions
41343999|NCT04248556|OTHER|Health care product|Health care product (gel) - to be applied on the participant's skin
41344000|NCT02828995|OTHER|Comprehensive Diabetes Stigma Survey|"The surveys to be administered in the ENDSTIGMA study are as follows:~1. The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~2. The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~3. Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence."
41344001|NCT02943044|DEVICE|No intervention, this is an observational study|Non interventional, non-invasive measurements of tissue samples suspected of squamous cell carcinoma using an optical probe.
41344002|NCT04026646|PROCEDURE|Proprioceptive Neuromuscular Facilitation stretching exercise|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.It will be applied 3 days in a week for 8 week.
41344003|NCT04026646|PROCEDURE|Static stretching exercise|Static stretching exercises will be applied 2 repetition. Totally 30 seconds stretching for hamstring muscle group will be performed. It will be applied 3 days in a week for 8 week.
40825070|NCT02865889|PROCEDURE|Conventional surgery (abdominal radical surgery)|
41344004|NCT00382551|BEHAVIORAL|Moderate daily consumption of Red wine|
41344005|NCT00382551|BEHAVIORAL|Moderate daily consumption of beer|
41344006|NCT00382551|BEHAVIORAL|Moderate consumption of fruit juice rich in polyphenolics|
41344007|NCT06446050|BIOLOGICAL|MSC-L|Human umbilical cord-derived mesenchymal stem cells (MSCs) genetically modified to express antitumor chemokine and co-stimulatory molecule will be administered intravenously at a dose of 1/2/3 x 10\^6 cells/kg, every 21 days for at least 6 cycles of treatment.
41344008|NCT00934713|DRUG|montelukast|montelukast 4mg once per day for 8 weeks period
41344009|NCT00002675|BIOLOGICAL|filgrastim|
41344010|NCT00002675|DRUG|carboplatin|
41489679|NCT05870137|OTHER|Standard care|The standard care for the intervention involved participants performing the invasive technical procedure to treat a tension pneumothorax using their standard clinical skills and knowledge, without the aid of the HoloLens2 device. The participants in the standard care group did not receive any additional support or guidance beyond what is typically available in a clinical setting. The goal of the study was to compare the effectiveness of the standard care approach with the use of Mixed Reality-supported care using the HoloLens2 device.
41344011|NCT00002675|DRUG|cisplatin|
41344012|NCT00002675|DRUG|cyclophosphamide|
41344013|NCT00002675|DRUG|etoposide|
41344014|NCT00002675|DRUG|mesna|
40825071|NCT01651832|BEHAVIORAL|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
41018651|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Randomized participants were assigned 1:1 to E-PST or HLM.
41344015|NCT00002675|DRUG|vincristine sulfate|
41344016|NCT02719210|BIOLOGICAL|High Volume Plasma Exchange|
41344017|NCT02719210|DRUG|Hypertonic 3% saline|
41344018|NCT02719210|DRUG|Mannitol|
41344019|NCT02719210|DEVICE|Elective positive pressure ventilation|
41344020|NCT04524091|OTHER|Positive end expiratory pressure|Initially, the patients will be ventilated using pressure support ventilation with an inspiratory pressure adjusted to achieve 6 - 8 ml/kg of PBW with a minimal esophageal pressure swing of 5 cmH2O and a PEEP of 5 cmH2O. After 5 minutes, we will measure five IPSexp and five IPSinsp in random order and considering a resting period between each occlusion in order to avoid learning effect and disconfort. The IR will be calculated using the average of the measured IPSexp and the average of the IPSinsp. Besides, we will register the average of esophageal pressure and transpulmonary pressure swings continuously. The same procedure will be carried out with 10 and 15 cmH2O of PEEP. Inspiratory pressure will be kept constant throughout the protocol.
41344021|NCT04539262|DRUG|Remdesivir (RDV)|Administered as an aerosolized solution
41344022|NCT04539262|DRUG|Placebo|Administered as an aerosolized solution
41344023|NCT02578095|DRUG|VK5211|Capsule
41344024|NCT02578095|DRUG|Placebo|Capsule
41344025|NCT05708729|DEVICE|MCS surgery for CPSP|The investigational devices that will be used for the MCS surgeries are the following: the Vanta with AdaptiveStim Technology Primary cell neurostimulator or the Intellis Implantable Neurostimulator with AdaptiveStim Technology from Medtronic, Inc. (MN, USA). These implantable neurostimulators are intended to generate electrical pulses and to deliver stimulation trough one or more leads as part of a neurostimulation system for pain therapy in adults.
41344026|NCT05708729|DEVICE|Vc-DBS surgery for CPSP|For the deep brain stimulation procedure, we will use Vercise stimulators from Boston Scientific together with the Cartesia Directional Leads or the Percept PC stimulator from Medtronic.
41489680|NCT02715206|BEHAVIORAL|keepin' it REAL classic|keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training
41489681|NCT02715206|BEHAVIORAL|keepin' it REAL rural|keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.
41344027|NCT05408091|DRUG|TRL345, a human monoclonal antibody|Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody
41344028|NCT02332876|BEHAVIORAL|Exercise|
41344029|NCT02332876|BEHAVIORAL|Control|
41344030|NCT02625389|DRUG|Lipiodol® Ultra Fluid with surgical glues|Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
41344031|NCT05622968|DEVICE|Foley catheter|Insertion of 18G Foley catheter into the cervical canal and inflating the balloon to 60 mls using sterile water
41344032|NCT05622968|DRUG|Intravaginal prostaglandin E2|Insertion of intravaginal Dinoprostone
41344033|NCT03876704|DRUG|High dose of fat-Soluble Vitamin|Supplementation of 5 times current dose of fat-soluble vitamins by intravenous perfusion
41344034|NCT03876704|DRUG|Conventional dose of fat-Soluble Vitamin|Supplementation of the current dose of fat-soluble vitamins by intravenous perfusion
41344035|NCT06356415|DRUG|Bupivacaine injection|Group one will receive infraclavicular block using bupivacaine
41344036|NCT06356415|DRUG|Bupivacaine+ Dexamethasone+ Dexmedetomidine|Group two will receive infraclavicular block using dexamethasone and dexmedetomidine added to the bupivacaine
41489682|NCT02715206|BEHAVIORAL|control|control group continues to teach whatever prevention curriculum they were using prior to study
41489683|NCT05589961|DRUG|TMZ|After enrollment, temozolomide 50mg/m2 was given orally for QD until progression, and radiotherapy and PF 0.2g/ time for TID were started one week later until progression. Pembrolizumab 200mg once every 3 weeks until progression; The radiotherapy regimen depends on the patient's recurrence and initial treatment.
41489684|NCT01321463|DRUG|PH-797804|6 mg oral tablet once daily for 12 weeks
41489685|NCT01321463|DRUG|Placebo|Placebo oral tablet once daily for 12 weeks
41489686|NCT00276861|DRUG|gemcitabine hydrochloride|
41489687|NCT00276861|DRUG|oxaliplatin|
41489688|NCT01009671|DRUG|ART 44|
41344037|NCT05299151|OTHER|Vestibular exercises|The vestibular exercise program basically consists of 3 groups of exercises: adaptation, substitution, and habituation exercises. It is aimed to provide vestibular adaptation with adaptation exercises. Exercises that include visual and somatosensory cues to improve gaze and postural stability constitute substitution exercises. Balance exercises can be performed with eyes open and closed, or somatosensory cues can be changed by performing them on soft ground. Removing or reducing clues allows the patient to use other systems as well. The basis of habituation exercises is the reduction of the pathological response as a result of repeated exposure to the provocative stimulus. Habituation is specific to the type, intensity, and direction of stimuli. In most cases, the movement that stimulates the pathological response is less frequently performed during daily activities and promotes compensation for the initially abnormal signal of treatment.
41344038|NCT05299151|OTHER|Standard neurorehabilitation exercises|A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises (standing on one leg, tandem, balance board, etc.) will be applied.
41344039|NCT04137055|DRUG|ZSP0678-10mg|ZSP0678 tablet administered orally under fasted condition
41489689|NCT01009671|DRUG|ART 50|
41489690|NCT00146341|DRUG|Telmisartan/HCTZ|
41489691|NCT00146341|DRUG|Telmisartan|
41489692|NCT05480163|OTHER|Measurement records|Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.
41489693|NCT06113926|OTHER|Bystander Acknowledgment|"The experimenter said That is so messed up that they excluded you in the task. And honestly, I would say it was racist... acknowledgment of the participants experience, ...this shouldn't have happened, and I'm really sorry it did... an apology, and ...I'm going to talk to the primary investigators of the study to figure out how we can make sure that this won't happen to other people a plan of action."
41489694|NCT02218970|BEHAVIORAL|strength training|
41489695|NCT02218970|BEHAVIORAL|no training (control)|
41489696|NCT00259168|DRUG|Nateglinide|
41489697|NCT01950234|DRUG|ACTH|Acthar gel
41344040|NCT04137055|DRUG|ZSP0678-30mg|ZSP0678 tablets administered orally under fasted condition
41344041|NCT04137055|DRUG|ZSP0678-60mg|ZSP0678 tablets administered orally under fasted condition
41489698|NCT01950234|DRUG|Placebo|Placebo
41489699|NCT04905030|BEHAVIORAL|Information T1|A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in non-scientific, non-statistical terms and is emotionally charged: the consequences of cervical cancers are portrayed by testimonies of cancer survivors from Sweden.
41489700|NCT04905030|BEHAVIORAL|Information T2|A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in scientific terms and incidence and mortality statistics are reported. The information is not emotionally charged but rather aseptic.
41344042|NCT04137055|DRUG|ZSP0678-120mg|ZSP0678 tablets administered orally under fasted condition
41344043|NCT04137055|DRUG|ZSP0678-180mg|ZSP0678 tablets administered orally under fasted condition
41489701|NCT04905030|BEHAVIORAL|Information C|A4 information sheet containing a reminder of the upcoming HPV vaccination, and information on the history and characteristics of the Swedish national vaccination program.
41489702|NCT00943267|DRUG|Drotrecogin alpha|Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
41489703|NCT00943267|DRUG|Saline (NaCl 0.9%)|Normal saline is given intrabronchially by bronchoscopy at t=0
41489704|NCT00943267|DRUG|Endotoxin|Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
41489705|NCT00943267|PROCEDURE|Bronchoscopy|Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
40825072|NCT04066569|OTHER|Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam|"After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions"
40825073|NCT04066569|OTHER|Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)|"After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo."
40825074|NCT01742910|PROCEDURE|intraocular lens implantation|
41344044|NCT04137055|DRUG|ZSP0678-240mg|ZSP0678 tablets administered orally under fasted condition
41344045|NCT04137055|DRUG|ZSP0678-320mg|ZSP0678 tablets administered orally under fasted condition
40825075|NCT01224821|BIOLOGICAL|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
41489706|NCT00943267|PROCEDURE|Blood sampling|Blood sampling is done by venapuncture at t=0 and t=6
40825076|NCT03690453|DRUG|Ivermectin|single dose of Ivermectin
40825077|NCT00874406|DRUG|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
40825078|NCT00874406|DRUG|folfox4|folfox4 will be done within 28 days after liver resection
40825079|NCT05883332|DRUG|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-50%)
41344046|NCT04137055|DRUG|ZSP0678|ZSP0678 tablets administered orally under fasted or fed condition
41344047|NCT04137055|DRUG|ZSP0678-Dose 1|ZSP0678 tablets administered orally once daily for 14 Days
41344048|NCT04137055|DRUG|ZSP0678-Dose 2|ZSP0678 tablets administered orally once daily for 14 Days
41344049|NCT04137055|DRUG|ZSP0678-Dose 3|ZSP0678 tablets administered orally once daily for 14 Days
41489707|NCT03206463|DRUG|4 mg Delta-9-THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
41489708|NCT03206463|DRUG|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
41489709|NCT03206463|DRUG|2 mg Delta-9-THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
40825080|NCT05883332|OTHER|Oxygen|100% oxygen at 10 Liters/minute
41018652|NCT03759223|BEHAVIORAL|Healthy Living Messages (HLM)|Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care. Randomized participants were assigned 1:1 to E-PST or HLM.
41489710|NCT02646930|PROCEDURE|Endometrial biopsy|Endometrial biopsy in women undergoing first IVF cycle
41489711|NCT00074776|DRUG|Lithium|Participants will receive lithium.
41489712|NCT00074776|DRUG|Lamotrigine|Participants will receive lamotrigine.
41344050|NCT04137055|DRUG|ZSP0678 Placebo|Participants will receive placebo matching to ZSP0678 orally.
41344051|NCT00002749|DRUG|carboplatin|
41344052|NCT05137210|OTHER|Male Counseling and Facility Navigation|At enrollment, study staff distribute pamphlet with male-specific messaging and contact information for nearest facility. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling. Meeting at location of participants choice. Follow-up male-specific counseling is offered every 14 days thereafter until 90 days is reached OR 4-week follow-up ART refill visit is completed. Participants who choose to initiate ART are escorted to nearest health facility and provided facility navigation assistance.
41344053|NCT05137210|OTHER|Home-Based ART Initiation and Facility Navigation|"At enrollment, study staff distribute two pamphlets on: 1) male-specific messaging and 2) details about home-based ART initiation. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling, and a detailed description of home-based ART initiation with a nurse. Meeting at the location of participants choice. Follow-up male-specific counseling and information about home-based initiation is offered every 14 days thereafter until 90 days OR 4-week ART follow-up refill visit is complete. Participants who choose to initiate ART at home or in the community will meet with a nurse at a place of the participants choosing. Those who choose to initiate at the facility will receive facility navigation and initiation. All clients will receive a warm handover for their 4-week ART follow-up visit."
41344054|NCT05137210|OTHER|Stepped Intervention|"Day 0-14 Arm 1 (Male-specific counseling and facility navigation arm) implemented. Day 14-30, if not yet initiated, a psychosocial counsellor will trace the participant to provide advanced counselling and motivational interviewing. Psychosocial counsellors will act as 'Male Mentors' and meet with men as frequently as needed. Day 30-89 if not yet initiated, nurse-led home-based ART initiation will be offered, following the same steps as listed in the Home-Based ART Initiation Arm."
41344055|NCT04224987|DRUG|Azithromycin|"Azithromycin will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight or age-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
41344056|NCT04224987|OTHER|Placebo|"Placebo will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
41344057|NCT06138704|PROCEDURE|Retrograde Intrarenal Surgery|All RIRS procedures were performed under general anesthesia with direct videoscopic and fluoroscopic guidance. The decision to use a flexible or semirigid ureteroscope depended on the location of the Stones. If this was not enough to pass the ureteroscope, we placed a JJ catheter for passive dilatation. Stones were fragmented using a holmium-YAG laser and grasped by a stone basket when applicable. Contrast injection was performed at the end of the procedures to confirm the absence of extravasation and stone-free status. Ultrasonography (USG) was performed three months, six months, and one year after the procedures to evaluate stone recurrence and hydronephrosis.
41344058|NCT04437810|BIOLOGICAL|Albumin|- Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)
41344059|NCT04437810|OTHER|Standard Medical Treatment|standard medical therapy
41344060|NCT01634100|DRUG|Probenecid|Probenecid
41344061|NCT01634100|DRUG|Rifampicin|Rifampicin
41344062|NCT01634100|DRUG|Empagliflozin|BI Drug
41344063|NCT01634100|DRUG|Empagliflozin|BI Drug
41344064|NCT01634100|DRUG|Rifampicin|Rifampicin
41344065|NCT01634100|DRUG|Probenecid|Probenecid
41344066|NCT01634100|DRUG|Empagliflozin (BI 10773)|BI Drug
41344067|NCT02749786|OTHER|Skin Biopsy|Skin biopsies will be performed via the Keys punch technique from normal facial skin.
41344068|NCT02045225|BEHAVIORAL|Reduction of social anxiety & substance use in gay/bi men|The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
41344069|NCT05399836|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants.
41489713|NCT00157079|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|
41489714|NCT00476632|BEHAVIORAL|Questionnaire|50 Minute Interview
41489715|NCT05579275|BIOLOGICAL|JCXH-212 Injection|Based on the development principle of NCV, a community-type tumor neoantigen mRNA vaccine, JCXH-212 injection, has been developed that can be applied to patients with malignant solid tumors. NCVs activate tumor-specific CD4+ T cells and CD8+ T cells through active immunity, and these T cells can inhibit and kill tumor cells in cancer patients, thus prolonging the survival of cancer patients.
41489716|NCT03835143|PROCEDURE|subinguinal varicocelectomy|varicocele ligation done at the level of subinguinal region
41489717|NCT02452996|DRUG|GNbAC1|Single dose of IMP, IV infusion
41489718|NCT02686645|BIOLOGICAL|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
41018653|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST) (non-randomized)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Non-randomized participants were assigned to E-PST only.
41344070|NCT05078086|OTHER|No intervention|No intervention
41344071|NCT02867384|DRUG|Obinutuzumab|B cell depletion
41344072|NCT02867384|DRUG|Placebo|Placebo
41344073|NCT03914872|BIOLOGICAL|Neoantigen DNA Vaccine|The schedule for vaccination will be weeks 1, 5, 9, 13, 17, and 21. All vaccines will occur within +/- 1 week with at least 3 weeks between vaccines.
41344074|NCT03914872|DEVICE|Integrated electroporation device|"* Ichor Medical Systems~* All study injections will be given intramuscularly using an integrated electroporation device"
41344075|NCT02728206|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
41344076|NCT03903536|PROCEDURE|Thrombectomy|A small procedure where surgeons make a cut in the hemorrhoid and drain the blood.
41344077|NCT03903536|PROCEDURE|Hemorrhoidectomy|A surgery to remove the hemorrhoid, including the blood vessels and clot.
41344078|NCT06409104|DRUG|Propofol|will receive 1-2 mgkg-1 propofol injection over 30s followed by of propofol a 0.05 to 0.1 mg /kg/min infusion
41344079|NCT06409104|DRUG|Dexmedetomidine|will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.
41489719|NCT02686645|DRUG|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
41489720|NCT02686645|DRUG|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
41489721|NCT02686645|DRUG|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
41489722|NCT04567914|DIAGNOSTIC_TEST|Bilaterally abdominal muscle thickness with ultrasonography|AIS group was evaluated for localization of curvature and degree of curvature. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness in the supine and standing positions in both groups. Spirometry evaluation was performed in both groups
40825081|NCT00794365|DRUG|Varenicline|"There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water."
40825083|NCT03719404|PROCEDURE|sodium hypochlorite|sodium hypochlorite is used as primary irrigant and edta is used as secondary irrigant in endodontic retreatment cases
40825084|NCT03719404|PROCEDURE|chlorhexidine|Chlorhexidine is used as primary irrigant and citric acid is used as secondary irrigant in endodontic retreatment cases
40825085|NCT01519050|BEHAVIORAL|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
40825086|NCT00286195|DEVICE|Multi-Link Frontier Coronary Stent System|Bare metal stent
40825087|NCT00226408|DRUG|Interferon-alpha-2b|
40825088|NCT03350139|DEVICE|gamma knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice
40825089|NCT00665756|PROCEDURE|second Trabeculectomy|second trabeculectomy with mitomycin-c
40825090|NCT00665756|PROCEDURE|Ahmed Implant|Ahmed silicone drainage device
40825091|NCT03494517|DRUG|Magnesium Sulfate|Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
40825092|NCT03989973|DIAGNOSTIC_TEST|Gastroscopy|Gastroscopy
40825093|NCT02840643|BEHAVIORAL|Bimanual hand therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
40825094|NCT02840643|BEHAVIORAL|Constraint therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
41344080|NCT04527536|DIAGNOSTIC_TEST|Neonatal hyperbilirubinemia|Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
41344081|NCT05336019|BEHAVIORAL|Diabetes self-management Coaching|A 12-week Diabetes self-management coaching program
41344082|NCT05336019|OTHER|Usual care|Assigned to 12 weeks of usual care which includes a physical examination, history taking,, medication refill, lab investigation, and health education
40825095|NCT02699008|DRUG|Clopidogrel|Antiplatelet agent
40825096|NCT02699008|DRUG|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
40825097|NCT04509518|OTHER|Exercise therapy program plus TENS therapy|All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
40825098|NCT02501317|BEHAVIORAL|Active Perineal Rehabilitation protocol|Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/
40825099|NCT02501317|BEHAVIORAL|Kari Bo protocol|Group exercises to pelvic floor rehabilitation
40825100|NCT05997849|BEHAVIORAL|Mobile application|A mobile application for the management of anxiety and depressive symptoms through self-applied emotional regulation tools.
40825101|NCT01688921|BIOLOGICAL|AFLURIA vaccine (2012-2013 formulation)|Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
40825102|NCT01688921|DEVICE|Needle-Syringe|
41489723|NCT03456154|DRUG|Botox Injectable Product|60u will be used at 3 sites of masseter muscle, on each side of the face
41489724|NCT03456154|DEVICE|Occlusal splint|In this group patients will receive an occlusal splint which will be worn everyday for 6 months at night.
41344083|NCT05129683|OTHER|Anodal tDCS cerebellar stimulation group|Single-session atDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given
41344084|NCT05129683|OTHER|Anodal tDCS cerebral (M1) stimulation group|single session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
41344085|NCT05129683|OTHER|sham group|single session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
41344086|NCT02325440|DRUG|Fingolimod|Fingolimod: 0.5 mg p.o. (o.i.d)
41344087|NCT02325440|DRUG|Natalizumab|Natalizumab: 300 mg i.v. (once at baseline);
41165774|NCT05895630|BEHAVIORAL|Interactive physical exercise|Interactive remote sessions of physical exercise in groups of 10 patients. The sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The intervention will last 12 weeks. The sessions will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
41344088|NCT05312099|OTHER|Case control|Case control study
41344089|NCT01550614|GENETIC|Alferminogene tadenovec|One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
41344090|NCT03904862|DRUG|CX 4945|CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
41489725|NCT00054600|DRUG|Methoxsalen|
41344091|NCT05305053|OTHER|preoperative MDT discussion|high-risk patients are subjected to an MDT discussion among care providers
41344092|NCT02183610|DRUG|[14C] BI 1356 as oral (p.o.) solution|
41489726|NCT00054600|PROCEDURE|Extracorporeal Photopheresis|
41489727|NCT02543619|OTHER|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
41489728|NCT00573781|DIETARY_SUPPLEMENT|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
41489729|NCT00573781|DIETARY_SUPPLEMENT|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
41489730|NCT00573781|DIETARY_SUPPLEMENT|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
41489731|NCT01163630|DRUG|esomeprazole/ASA Fixed Dose Combination (FDC)|esomeprazole 20 mg/ASA 81 mg oral capsule
41489732|NCT03000218|DRUG|Ursodeoxycholic acid|Ursodeoxycholic acid 300mg bid for 8 weeks
41489733|NCT03000218|DRUG|Metformin|Day 29 to 56: Metformin 500mg bid
40825103|NCT01688921|DEVICE|Stratis needle-free injection device|
40825104|NCT06521775|PROCEDURE|Computed Tomography|Undergo PET/CT
40825105|NCT06521775|OTHER|Electronic Health Record Review|Ancillary studies
41344093|NCT02183610|DRUG|[14C] BI 1356 solution for i.v. infusion|
41344094|NCT01700595|PROCEDURE|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
40825106|NCT06521775|DRUG|Ga-68 PSMA-11|Given IV
40825107|NCT06521775|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41344095|NCT00805818|DRUG|NNZ-2566|"Solution for intravenous infusion.~20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours."
41344096|NCT00805818|DRUG|Placebo|Sodium Chloride 0.9% Injection
41344097|NCT03632551|OTHER|Specific binaural hearing evaluations|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
41344098|NCT00004889|BIOLOGICAL|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
41344099|NCT02545452|DRUG|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
41344100|NCT02545452|DRUG|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
41344101|NCT02545452|DRUG|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
41344102|NCT02545452|DRUG|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
41344103|NCT02545452|OTHER|Tampon|
41344104|NCT02793206|DEVICE|Imaging|
41344105|NCT03872336|DRUG|Experimental labetalol dose|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
41489734|NCT03000218|DRUG|Placebo|Day 1 to 56: Placebo bid
41489735|NCT03792087|DRUG|SmofKabiven Peripheral|Total Parenteral Nutrition
41489736|NCT03792087|DRUG|Hospital compounded emulsion|Total Parenteral Nutrition
41489737|NCT03493516|DIAGNOSTIC_TEST|PET scan quantifying sympathetic denervation using [18F]-LMI1195|A cardiac PET scan will be obtained to quantify the percentage of the left ventricle that is denervated and has reduced uptake of the sympathetic nerve tracer \[18F\]-LMI1195
41489738|NCT03868462|DEVICE|Optos P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
41489739|NCT03868462|DEVICE|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
41489740|NCT06015243|DRUG|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
41344106|NCT03872336|OTHER|Current standard of care|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the standard dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
41344107|NCT03353441|DIETARY_SUPPLEMENT|Microencapsulated Sublingual Glycine (MSG)|Glycine (MSG) tablet
41344108|NCT03353441|DIETARY_SUPPLEMENT|Placebo|Lactose tablet manufactured to mimic Glycine (MSG) tablet
41344109|NCT04583267|DRUG|tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration|Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
41344110|NCT03908086|OTHER|Risk factors in RA cohort|
41344111|NCT03908086|OTHER|Risk factors in general population|
41344112|NCT06004440|DEVICE|Ion Endoluminal System|Subjects will under a planned procedure with the Ion Endoluminal System
41344113|NCT04179604|DRUG|Levosimendan|Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
41344114|NCT04179604|DRUG|Placebos|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
41344115|NCT00861094|DRUG|cisplatin|
41344116|NCT00861094|DRUG|5-FU|
41344117|NCT00861094|DRUG|oxaliplatin|
41344118|NCT00861094|RADIATION|radiation therapy|
41344119|NCT00861094|DRUG|Folinic Acid|
41344120|NCT05983016|DEVICE|Philips EPIQ-7, Philips Healthcare, Bothell, WA, USA|"All patients had their abdominal aortic aneurysm maximum anterior-posterior diameter estimated with two-dimensional ultrasound using a 5 MHz curved array transducer (Philips® C5-1 transducer, Philips Healthcare, Bothell, WA, USA).~After the acquisition, a three-dimensional ultrasound acquisition was performed with a 3D-matrix transducer (Philips® X6-1 transducers, Philips Healthcare, Bothell, WA, USA)."
41344121|NCT06357962|OTHER|Semi-permanent acupuncture|These are sessions that last approximately one hour. The selection of points will be based on the energy diagnosis made during the first visit. In some cases, a point may be changed depending on progress. During the session, an interrogation will be conducted to assess symptoms and signs of the condition, and to evaluate if there have been any adverse reactions to the previous session. At the end of the visit, semi-permanent acupuncture will be applied to the selected points.
41344122|NCT06357962|OTHER|Sham of semi-permanent acupuncture|A simulated semi-permanent acupuncture session will be conducted, consisting of specific placebo materials without needles and without stimulation for a few minutes. These points will not correspond to any acupuncture point and will be located on the hands, feet, and back. Stickers without pins will be applied, but never in critical points related to contraction stimulation or cervical ripening.
41344123|NCT00782106|BIOLOGICAL|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
41344124|NCT00782106|BIOLOGICAL|Recombinant human hyaluronidase + immune globulin intravenous|"1. IV infusion of IGIV, 10% to determine pharmacokinetics~2. Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered"
41344125|NCT03774836|DRUG|Tramadol|IV Tramadol 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
41344126|NCT03774836|DRUG|Morphine|Morphine 4 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
41344127|NCT03774836|OTHER|Placebo|Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
40825108|NCT02581462|DRUG|FLOT alone|"Pre-operative therapy:~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43"
41344128|NCT00877734|DRUG|baclofen|10 mg Baclofen administered tid for 11 weeks
41344129|NCT00877734|DRUG|placebo|Placebo administered tid for 11 weeks
41344130|NCT00877734|BEHAVIORAL|BRENDA counseling|
41344131|NCT01161927|DRUG|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
41344132|NCT01161927|DRUG|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
41489741|NCT04104854|DEVICE|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds
41344133|NCT06139445|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage (MLD), one of the components of complex decongestive physiotherapy, is a gentle massage technique with proven positive effects on lymphatic circulation. MLD can be applied to different parts of the body (e.g., arms, legs, neck, abdomen, and trunk), with a different technique for each region (stationary circle, scoop, pump, and rotary)
41344134|NCT06139445|OTHER|Plasebo Group|random superficial touches not involved in any manual technique
41344135|NCT01352767|DEVICE|InsuPad|Heating pad
41489742|NCT02984618|PROCEDURE|Sphenopalatine ganglion block|Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
41489743|NCT02984618|PROCEDURE|Epidural blood patch|Autologous sterile blood (20ml) will be infused in the lombar epidural space.
41344136|NCT05637073|DRUG|Dienogest|Some women in the cohort will be treated with dienogest for one year after consensus with the physician
41344137|NCT05637073|PROCEDURE|Laparoscopic cystectomy|Some women in the cohort will be treated with laparoscopic cystectomy after consensus with the physician
41344138|NCT05637073|OTHER|Control with ultrasound without other type of intervention|Some women in the cohort will be followed with ultrasound control, without other intervention, after consensus with the physician
40825109|NCT02581462|BIOLOGICAL|FLOT + Herceptin/Pertuzumab|"Pre-operative therapy:~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43."
40825110|NCT04553653|OTHER|checklist|The checklist will be implemented and healthcare providers use the checklist to manage the patients.
40825111|NCT01797848|DRUG|Peginterferon alfa 2a|
40825112|NCT01797848|DRUG|Ribavirin|
40825113|NCT01797848|DRUG|Placebo matching Daclatasvir|
41344139|NCT03864627|DRUG|MOR106|MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
41489744|NCT02163486|DEVICE|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
41489745|NCT02163486|DEVICE|I-GEL|"Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc"
41344140|NCT03864627|DRUG|Placebo|Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
41344141|NCT00005015|DRUG|Fluoxetine|
41344142|NCT04407286|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3 capsules
41489746|NCT01150318|DRUG|Administration of 131 iodine|100 mCi 131 iodine irradiation
41489747|NCT04364425|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide
40825114|NCT01797848|DRUG|Daclatasvir|
40825115|NCT06339502|BEHAVIORAL|Jigsaw Technique|The jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
40825116|NCT03352583|DIETARY_SUPPLEMENT|Protein|40g calcium caseinate
41165775|NCT05895630|BEHAVIORAL|Video physical exercise|Individual remote sessions of physical exercise based on pre-recorded videos. The video sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The videos will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
41344143|NCT04280081|DRUG|Selpercatinib|Administered orally
41344144|NCT05549089|DEVICE|Insignia™ twin brackets|it is metal orthodontic twin brackets with customized base and individual arch-wires for each patient
41344145|NCT05549089|DEVICE|Maestro® 3D Ortho Studio software (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and 3D printing indirect bonding tray
41344146|NCT05549089|DEVICE|Ray set® device (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and double-layer vacuum-formed thermoplastic indirect bonding tray
41344147|NCT01017692|PROCEDURE|MRI|MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
41344148|NCT00221663|DEVICE|surgery techniques (sternotomy for aortic valve replacement)|
41344149|NCT04118673|BEHAVIORAL|Lifestyle Prescription (LRx)|Standard care during consultations with the addition of a physical lifestyle prescription
41489748|NCT04364425|DRUG|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
41489749|NCT04364425|DRUG|Normal saline|Ultrasound guided injection using 15ml or 12 ml of normal saline
41489750|NCT02116426|BIOLOGICAL|Blood work in the ambulance|Blood sample for copeptin and troponin HS testing is taken during ambulance care.
41489751|NCT02116426|BIOLOGICAL|Blood work upon arrival in the emergency room|Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.
40825117|NCT03122821|OTHER|Real Transcranial direct stimulation+Mental Imagery|"The subject will be practicing mental imagery along with mental imagery. A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
40825118|NCT03122821|OTHER|Sham Transcranial Direct Stimulation +Mental Imagery|"The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
41344150|NCT06206772|DIAGNOSTIC_TEST|Resting state HD-EEG recording|All subjects will be recorded with a resting state HD-EEG recording. 12 minutes in the eyes closed and 12 minutes in the eyes open condition.
40825119|NCT04393467|DEVICE|tSMS|tSMS delivered on bilateral motor cortex
40825120|NCT04393467|DEVICE|sham tSMS|sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS
41344151|NCT05528328|DEVICE|CACIPLIQ20®|CACIPLIQ20®
40825121|NCT03836326|OTHER|Sensorimotor intervention|Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.
40825122|NCT03836326|OTHER|Control|Routine care provided by health professionals in the NICU
40825123|NCT03836326|OTHER|Story telling attention refocusing intervention|A contact-free intervention where parents share stories with their infant for 10 minutes 3 times per week.
40825124|NCT04615975|DIETARY_SUPPLEMENT|Ketogenic diet with phytoextracts|Patients were provided with an individualized nutritional ketogenic plan during hospitalization
40825125|NCT01149486|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
41344152|NCT05528328|DRUG|Placebo (saline solution)|Placebo (saline solution) administered in identic al vials
41344153|NCT05454241|DRUG|Anti-CD7 CAR-T|Universal CAR-T cells targeting CD7
41344154|NCT03135262|DRUG|Idasanutlin|Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams \[mg\], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
41383612|NCT01502267|DRUG|High dose IVIG and B cell depleting agents|"1. IVIG(2g/kg two times on day 1, 30)~2. Rituximab(375mg/m2 on day 3)~3. Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)"
41489752|NCT02116426|BIOLOGICAL|Blood work at 3 hours post-arrival in the emergency room|Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
41489753|NCT04131543|DRUG|Cabozantinib 20 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
41489754|NCT04131543|DRUG|Cabozantinib 40 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
40825126|NCT01149486|DRUG|Hyzaar®|100/25 mg Tablets
40825127|NCT00384423|DRUG|PRX-03140|
40825128|NCT01063491|PROCEDURE|bypass graft angiography|
40825129|NCT01903551|DEVICE|Loco-regional catheter|it is an intra-fascial catheter for realing of the drug locally
40825130|NCT00132795|BEHAVIORAL|Daily monitoring of alcohol & drug use, & therapy skills|Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
40825131|NCT00132795|BEHAVIORAL|control group|standard care (no added treatment)
40825132|NCT02804698|BEHAVIORAL|Education intervention|13-week educational and physical activity intervention
40825133|NCT01952990|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
40825134|NCT00723346|BIOLOGICAL|GRASPA|50 UI/Kg
40825135|NCT00723346|BIOLOGICAL|GRASPA|100 UI/Kg
40825136|NCT00723346|BIOLOGICAL|GRASPA|150 UI/Kg
40825137|NCT00723346|DRUG|native L asparaginase|10000UI/m2, 14 infusions during 4 chemotherapy cycle
41165776|NCT04039555|DEVICE|CO2 intimate|Two sessions with CO2 intimate laser for vaginal symptoms treatment
41344155|NCT03135262|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).
41489755|NCT04131543|DRUG|Cabozantinib 60 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
40825138|NCT03310008|BIOLOGICAL|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
41489756|NCT01739621|DRUG|Proellex 12 mg|
41489757|NCT01739621|DRUG|Proellex 24 mg|
41489758|NCT00923000|DRUG|Nalbuphine|Nalbuphine 10mg with oral administration
40825139|NCT01655043|DRUG|Regadenoson|Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
40825140|NCT01655043|DRUG|gadofoveset trisodium|All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
41489759|NCT00923000|DRUG|Morphine|Morphine 10mg with oral administration
41489760|NCT00923000|DRUG|Morphine with Long dan xie gan tang|Morphine 10mg with oral administration
40825141|NCT03426358|DEVICE|LSM assessed by Elastographic Techniques|Performing Transient Elastography, ARFI or 2D-SWE on patients at baseline (within 1 month before HSCT) and after HSCT on days +9/10, +15/17, +22/24
40825142|NCT02089464|DEVICE|NBS-guided rTMS|
41344156|NCT03135262|DRUG|Venetoclax|Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
41344157|NCT03135262|DRUG|Rituximab|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment.
41344158|NCT03878043|OTHER|Follow-up Care|Follow up care provided upon readmission to patients who were diagnosed with a TSDH upon initial visit.
41018654|NCT03465696|BEHAVIORAL|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
41344159|NCT01801774|DRUG|Subtenon 20-mg triamcinolone injection|Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
41344160|NCT01801774|DRUG|Placebo|
41489761|NCT00923000|DRUG|Nalbuphine with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
41489762|NCT00923000|DRUG|Nubian with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
41489763|NCT02903992|RADIATION|Dual-energy X-ray absorptiometry (DXA)|Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
40825143|NCT02089464|DEVICE|Sham rTMS|
41165777|NCT04039555|DEVICE|Erbium-yag|Two sessions with Erbium-yag laser for vaginal symptoms treatment
41489764|NCT00466453|BEHAVIORAL|knowledge-adaptive Web-based instruction|
41344161|NCT00604357|DRUG|anti-CD 25 mAb, Sirolimus, MMF|"Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter)."
41344162|NCT01387074|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
41344163|NCT06175104|BEHAVIORAL|HeartGPS|"HeartGPS includes three key components:~1. Sessions with a psychologist trained to deliver the intervention using attachment-based and trauma-informed therapy techniques, coupled with mind-body skills. The intervention can be delivered in-person or via telehealth, in accordance with participants' preferences.~2. Educational resources, including a series of modules to complement the sessions and evidence-based tools to support psychological adjustment and coping, parent-infant bonding and attachment, and parent-clinician communication.~3. A personalized care plan, charting mental health care needs, goals, and preferences, with evidence-based strategies to support longer-term wellbeing."
41344164|NCT00833612|DEVICE|Counterpulsation with IAB|IABC pre-reperfusion PCI
41344165|NCT05338944|BEHAVIORAL|Dialectical behavioral therapy|Working with psychologists through DBT skills training.
41344166|NCT05338944|BEHAVIORAL|Lifestyle|Working with kinesiologist and registered dietician to improve lifestyle habits.
41344167|NCT01789749|OTHER|Snare Tip Soft Coagulation|
41344168|NCT01789749|OTHER|No Snare Tip Soft Coagulation|
41344169|NCT00657930|DRUG|insulin detemir|observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
41344170|NCT00728728|DRUG|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
41344171|NCT00728728|DIETARY_SUPPLEMENT|Placebo|Placebo
41344172|NCT00623766|DRUG|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
41344173|NCT00623766|DRUG|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
40825144|NCT02089464|PROCEDURE|Task oriented rehabilitation|
40825145|NCT05396170|PROCEDURE|phlebotomy|500ml of blood phlebotomized per standard of care to reduce symptoms from polycythemia
40825146|NCT05448313|BEHAVIORAL|Dyadic intervention|Dyads comprising a Veteran and cohabitating support person will participate in the 16-week VA MOVE! weight loss program delivered by video platform. They will then participate in 6 group sessions focused on weight maintenance skills. Communication skills will be taught throughout the intervention.
40825147|NCT05448313|BEHAVIORAL|Veteran-only intervention|Veterans will participate in a 72-week weight management program delivered by video platform. 16 sessions will address weight loss, with 6 additional ones addressing weight loss maintenance.
40825148|NCT00367744|DRUG|Rosiglitazone|Rosiglitazone 4mg BID
41344174|NCT00623766|DRUG|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
41344175|NCT00623766|DRUG|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
41344176|NCT00623766|DRUG|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
41489765|NCT02667015|BEHAVIORAL|Psychotherapy (Anxiety Sensitivity Intervention)|3 week, 6-session psychotherapy targeting anxiety sensitivity
40825149|NCT00367744|DRUG|Placebo|Placebo for rosiglitazone
41489766|NCT00228514|DRUG|Rosuvastatin|
41489767|NCT00228514|PROCEDURE|Positron emission tomography|
41489768|NCT01633736|OTHER|Usual care plus progresive resistance training|Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
41489769|NCT06324318|BEHAVIORAL|Parenting in 2 Worlds (P2W)|P2W is a culturally-adapted parenting intervention designed specifically for urban American Indian families. It is a 10-week, 10-lesson manualized curriculum with accompanying videos, designed to be facilitated by American Indians from the local communities. The workshop lessons cover topics like the identification of family values, culturally influenced child rearing values and traditions, sources of support for parents, and ways to improve parenting skills to communicate with, monitor, and guide adolescents to avoid substance use, unprotected sex and other risk behaviors
41489770|NCT06324318|BEHAVIORAL|Healthy Families in 2 Worlds (HF2W)|HF2W is a 10-week informational family health program. The workshop lessons cover topics such as oral health, CPR and first aid, dating safety, and teen mental health.
41489771|NCT03535779|BIOLOGICAL|Hepatitis B|The Hepatitis B virus, is a double stranded DNA virus that prevents Hepatitis B in the population
41489772|NCT03535779|BIOLOGICAL|Tetanus Toxoid|The Tetanus vaccine, also known as tetanus toxoid (Td/IVP), is an inactive vaccine used to prevent tetanus in the population
41489773|NCT02976324|DEVICE|external diaphragmatic pacemaker group|9 counts per minute, with stimulate frequency 40 Hz
41489774|NCT06358170|BEHAVIORAL|Circuit Training Combine with Square-Stepping Exercise|Circuit Training Combine with Square-Stepping Exercise
41489775|NCT02808949|DRUG|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
40825150|NCT03165214|DEVICE|coil|microcoils
40825151|NCT03165214|DEVICE|hystoacryl glue|hystoacryl mixed with lipidol
41165778|NCT04039555|DEVICE|CO2 intimate or Erbium-yag|Two sessions of one of the two lasers with no therapeuthical energy
40825152|NCT04788797|DRUG|Prolyl Endopeptidase|Two capsules three times a day.
40825153|NCT04788797|OTHER|Placebo|Two capsules three times a day
40825154|NCT00521599|DRUG|Mometasone furoate dry powder inhaler|
40825155|NCT00521599|DRUG|Placebo|
40825156|NCT05554978|DRUG|Landiolol|patient receives landiolol in addition to standard-of-care
40825157|NCT05554978|DRUG|Sodium Chloride (NaCl) 0.9%|Placebo
40825158|NCT00293709|DRUG|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
40825159|NCT01556048|BEHAVIORAL|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, \& Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
41344177|NCT00623766|DRUG|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
41489776|NCT04007770|OTHER|Acupuncture|10 treatments of acupuncture over the course of 10 weeks with a +/- 7 day window
40825160|NCT04940897|OTHER|Use of CareSens ketone meter|Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA
40825161|NCT06179160|DRUG|INCB161734|INCB161734 will be administered at protocol defined dose.
40825162|NCT06179160|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
40825163|NCT06179160|DRUG|Retifanlimab|Retifanlimab will be administered at protocol defined dose.
40825164|NCT05067920|DIAGNOSTIC_TEST|Levels of SARS-COV-2 antibodies|Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)
40825165|NCT05067920|DIAGNOSTIC_TEST|rRT-PCR SARS-Cov-2|Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th
40825166|NCT05067920|DIAGNOSTIC_TEST|Hematological and immunological biomarkers|Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.
41165779|NCT00874497|DRUG|tetomilast|Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
41165780|NCT00874497|DRUG|placebo|Placebo for 104 weeks (2 years)
41344178|NCT00623766|DRUG|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
41344179|NCT00623766|DRUG|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
41344180|NCT00623766|DRUG|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
41489777|NCT04007770|OTHER|Sham Acupuncture|10 treatments of sham acupuncture over the course of 10 weeks with a +/- 7 day window. After the 16-week study concludes patients in this group will have the option of receiving up to 10 sessions of real acupuncture; however, these sessions must be completed within 6 months of study conclusion.
41489778|NCT04007770|OTHER|16 week waiting period + optional Acupuncture|Optional real acupuncture after 16 weeks waiting period. This arm is Closed to accrual.
41489779|NCT01425333|PROCEDURE|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
41344181|NCT00623766|DRUG|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
41344182|NCT04334044|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib 5 mg twice a day
41344183|NCT00182013|DRUG|Risperidone|Open treatment with Risperidone
41489780|NCT01425333|PROCEDURE|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
41489781|NCT04792190|DRUG|dapagliflozin|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.
41489782|NCT04792190|DRUG|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
41489783|NCT03945669|PROCEDURE|Intramedullary Nailing|fracture fixation of the tibial shaft fracture with an intramedullary nail.
41489784|NCT03945669|PROCEDURE|External Ring fixation|fracture fixation of the tibial shaft fracture with an external ring fixator.
41489785|NCT01305148|DEVICE|Warfarin GenoSTAT Test|Use of genetic information from the GenoSTAT test to determine the warfarin dose
41489786|NCT05805735|OTHER|Face care product (Eye cream)|The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects
41489787|NCT03311100|OTHER|immunohistochemistry assay|biomarkers expression
41489788|NCT05062902|DEVICE|High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device|A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.
41489789|NCT05062902|DRUG|Botulinum Neurotoxin|Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
41489790|NCT00925080|DEVICE|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
41489791|NCT05771675|DRUG|Simvastatin|40Mg Oral Tablet
41489792|NCT05771675|DRUG|Placebo|Matching Simvastatin Placebo tablet
41489793|NCT04658017|DEVICE|GARNET device|Use of new filter in conjunction with standard of care dialysis.
41489794|NCT04359576|DIAGNOSTIC_TEST|Primary and secondary hemostasis|Focus on platelet aggregation, primary and secondary hemostasis parameters
41489795|NCT03710993|DEVICE|oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding transfer standard and reference devices to assess oximeter calibration and accuracy.
41344184|NCT00182013|DRUG|Olanzapine|Open treatment with Olanzapine
41344185|NCT00182013|DRUG|Quetiapine|Open treatment with Quetiapine
41344186|NCT01551485|DRUG|Zolpidem|The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG
41344187|NCT01551485|DRUG|Placebo|Pacebo tablet, blinded given on the first night after surgery
41489796|NCT00674557|DRUG|SOD1 inhibitor ATN-224|
41489797|NCT00674557|DRUG|exemestane|
41489798|NCT00674557|GENETIC|protein expression analysis|
41489799|NCT00674557|GENETIC|proteomic profiling|
41489800|NCT00674557|OTHER|laboratory biomarker analysis|
41489801|NCT00674557|OTHER|pharmacological study|
41489802|NCT06185335|GENETIC|ANB-010, dose 1|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 1.
41489803|NCT06185335|GENETIC|ANB-010, dose 2|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 2.
41489804|NCT06185335|GENETIC|ANB-010, dose 3|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 3.
41489805|NCT00006466|DRUG|beta alethine|
41344188|NCT00644241|BIOLOGICAL|stem cell harvest|stem cells will be harvested from the iliac crest of the patients
41344189|NCT00644241|PROCEDURE|angiographic transplantation of stem cells|autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
41344190|NCT05060081|OTHER|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
41344191|NCT05060081|OTHER|Traditional plank exercise program group|Traditional plank exercise program group will do a warm-up for 10 minutes and then perform five exercises includes prone bridge, side bridge, supine bridge on exercise ball, prone bridge on exercise ball, superman on exercise ball. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
41344192|NCT06501794|DEVICE|Quantitative measurement of eye movements|Saccadometer © - diagnostic device: non-invasive quantitative assessment of eye movement
41344193|NCT06019390|DEVICE|Presage care|A screening questionnaire completed by the family caregiver focused on functional and clinical autonomy of the patient (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with relative or their surroundings.
40825167|NCT05067920|DIAGNOSTIC_TEST|Mitochondrial DNA|One time quantification mitochondrial DNA haplogroup.
41165781|NCT03807453|OTHER|Microbiota|The scalp microbiota
41344194|NCT00064623|DRUG|Capsaicin Dermal Patch|
41344195|NCT03945656|DRUG|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks
41344196|NCT03945656|DRUG|Insulin glargine|Participants will receive daily s.c. injections of insulin glargine U100 for 12 days
41344197|NCT03285490|DRUG|KX2-391 Ointment 1%|Dose: 1% (250 mg single-use packets); Dosage form: Ointment; Route of administration: Topical
41165782|NCT02762539|DRUG|omega-3 enriched SMOF lipid emusion|
41344198|NCT03285490|DRUG|Placebo|Dosage form: Ointment; Route of administration: Topical
40825168|NCT05067920|DIAGNOSTIC_TEST|SARS-CoV-2 Viral Culturing|Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.
40825169|NCT05067920|DIAGNOSTIC_TEST|Sequencing COVID-19|Sequencing viral protein spike (S) COVID-19 related to CT value below 15.
40825170|NCT05297279|BEHAVIORAL|Home delivery Omega-3 rich Food|The active treatment arm will receive voucher (with a specified amount) weekly home delivery omega-3 rich food for the 12-weeks (3 months) intervention. Participants will be limited to purchasing foods rich in omega-3 only.
40825171|NCT05297279|BEHAVIORAL|Dietary Motivational Coaching|The active treatment arm will receive weekly personalize dietary couching by a dietary coach on omega-3 rich food for the 12-weeks intervention. Participant will also receive educational materials and guidance about what kind of food to order, how to cook, prepare (recipes) and store omega-3 rich foods.
40825172|NCT05297279|BEHAVIORAL|Home delivery Food|The control treatment arm will receive voucher (with a specified amount) weekly home delivery food (any kind of food) for the 12-weeks (3 months) intervention. Participant will not receive dietary coaching on food choices and will not be limited to purchasing foods rich in omega-3.
41344199|NCT04587973|PROCEDURE|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group
41344200|NCT04587973|PROCEDURE|Group Ropivacaine|Plain ropivacaine group
41344201|NCT04587973|PROCEDURE|Group Control|Control group
41344202|NCT03583112|DRUG|Dapoxetine Hydrochloride Tablet|oral one dapoxetine hydrochloride tablet before MRI scan
41344203|NCT03583112|DRUG|Placebo Tablet|oral one placebo tablet before MRI scan.
41344204|NCT03478462|DRUG|CLR 131|IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
41344205|NCT02117791|DRUG|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
41344206|NCT05373940|DEVICE|ICD implantation|"This group will undergo an ICD implantation (type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.~Patients of the HFOT+ICD group will be scheduled for ICD implantation."
41489806|NCT06429319|DEVICE|"hydrous biopolymer with silver ions Argiform"|Patients will receive an injection of MD NOLTREX™ into the target knee joint. MD will be administered in accordance with the instructions for use of MD NOLTREX™: 4.0 ml per injection (2.5 + 1.5 ml, or 2.0 + 2.0 ml from two syringes through one needle \[one puncture\]) at intervals of one week. The course within this open study is a maximum of 2 injections. The number of injections is determined by the doctor depending on the stage of gonarthrosis and the clinical response
41489807|NCT04602065|DRUG|IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)|IBI318, 300mg, Q2W, Intravenous influsion.
41489808|NCT01904617|OTHER|Dextrose|
40825173|NCT06140797|COMBINATION_PRODUCT|Multimodal prehabilitation combined with perioperative ERAS care（PREERAS）|Pre-admission risk assessment and targeted intervention provided by multidisciplinary team
40825174|NCT02802241|DRUG|placebo|
40825175|NCT02802241|DIETARY_SUPPLEMENT|peppermint oil|
40825176|NCT00929773|DEVICE|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
41344207|NCT05373940|DEVICE|No ICD implantation|"Patients of the HFOT alone group will not undergo ICD implantation (except if they develop sustained ventricular arrhythmias and fulfil for secondary prevention ICD implantation), and continue with medical therapy optimization only."
41344208|NCT05682768|PROCEDURE|Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures|Adding suporting sutures between th posterior gastric wall and ancreatic stump in whipple procedure, the sutures are Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures.
41344209|NCT04841850|OTHER|Clinical and biological characteristics|"* Age at beginning of IOT~* Sex~* Atopic and non atopic Comorbidities~* Sensitization to aero-allergens~* Sensitization to trophallergens~* Stage of severity of the elicited reaction~* Hazelnut Specific IgE + Cor a 1,8,9,14 before IOT and during follow up~* Hazelnut skin prick test before IOT and during follow up~* Adverse effects of IOT and their stage (in hospital and at home)~* Use of adrenaline auto-injector (in hospital and at home)~* Maintenance dose"
41344210|NCT06240793|PROCEDURE|unilateral transforaminal epidural steroid block|unilateral transforaminal epidural steroid block
41157313|NCT06538142|PROCEDURE|Photobiomodulation + Restoration with Photopolymerizable Bulk-fill Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment;~3. Relative isolation;~4. Application of photobiomodulation;~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Selective etching of enamel adjacent to demarcated opacities with 35% phosphoric acid for 20s;~7. Active application of universal adhesive (Ambar) on dentin and enamel for 20 seconds (repeat procedure);~8. Application of mild compressed air on adhesive for 5 seconds;~9. Photoactivation for 10s;~10. Restoration with Tetric N Ceram bulk-fill composite resin; with increments up to 4 mm, extending to demarcated opacities;~11. Photoactivation for 10 seconds;~12. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~13. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
41344211|NCT06240793|PROCEDURE|bilateral transforaminal epidural steroid block|bilateral transforaminal epidural steroid block
41344212|NCT00102804|DRUG|Pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV) administration, every (q) 21 days, until disease progression
41344213|NCT00102804|DRUG|Placebo|IV administration, q 21 days
41344214|NCT00102804|OTHER|Best Supportive Care|Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
41344215|NCT04063228|OTHER|Simple Skill Group|will practice the following skills as needed: bed mobility, transfer, walking, and stairs.
41344216|NCT04063228|OTHER|Complex Skill Group|The program will consist of interventions at the impairments level with an emphasis on core strengthening, functional lower extremity strengthening, balance and endurance training, and at the skill acquisition level. Participants will learn pre-running skills (walking, stairs with handrail, walking backward, walking over obstacles, walking on toes, stairs without handrail, bounding), running skills (force generation in vertical plane: hopping, alternate hopping, running in place in gravity minimized position and against gravity; force generation in horizontal plane: bounding, alternate bounding, open chain movement for swing phase, running) and post running skills (running forward, backward, sideways, skipping, hopping).
41344217|NCT00760890|DIETARY_SUPPLEMENT|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
41344218|NCT00760890|DIETARY_SUPPLEMENT|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
40825177|NCT00929773|DEVICE|Placebo laser|Inactive laser light.
41344219|NCT05865756|OTHER|Acoustic cough features analysis|Acoustic cough features analysis
41344220|NCT05165004|BEHAVIORAL|Kangaroo Mother Care|the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation
41489809|NCT01904617|OTHER|Normal Saline|
41489810|NCT00742066|DRUG|Irbesartan|Single dose 600mg orally
41489811|NCT00742066|DRUG|Felodipine|single dose 10mg Felodipine ER
41489812|NCT00742066|DRUG|Placebo|Single dose tablet orally
41489813|NCT00813566|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.
40853077|NCT02315534|DRUG|BBI608|"In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide."
41344221|NCT05165004|BEHAVIORAL|Hammock Positioning|After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed
41344222|NCT05165004|BEHAVIORAL|Routine Care of NICU|; encircling the neonate in a fetal position using rolled towel inside the incubator.
41344223|NCT06046586|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
41344224|NCT06046586|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
41344225|NCT06046586|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
41344226|NCT06046586|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
41344227|NCT04556929|DIAGNOSTIC_TEST|Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera|An ultra-high sensitivity camera attached to the side arm of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
41344228|NCT04556929|DIAGNOSTIC_TEST|Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera|In-built camera of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
41344229|NCT04556929|DIAGNOSTIC_TEST|Biopsies|Following image capture, biopsies (approx 5x5x5mm size) will be taken from regions of the anterior, posterior, lateral and inferior walls of the resection cavity corresponding to the imaged areas.
41344230|NCT01701349|DRUG|Fosbretabulin + paclitaxel + carboplatin|Fosbretabulin 200 mg/m2 IV infusion
41344231|NCT01701349|DRUG|Placebo + paclitaxel + carboplatin|Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
41344232|NCT02048657|DEVICE|Foley Airway Stylet Tool|
41489814|NCT00813566|DRUG|3'-deoxy-3'-[18F]fluorothymidine (FLT)|Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
41489815|NCT00813566|DRUG|[15O]-H2O|Brain scan with imaging agent to determine tumor blood flow
41344233|NCT02048657|DEVICE|introducer-tool|
41344234|NCT00117572|DRUG|docetaxel|75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)
41344235|NCT00117572|DRUG|cisplatin|75 mg/m2 on day 1
41344236|NCT00117572|DRUG|hydroxyurea|Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
41489816|NCT00813566|DRUG|[11C]Acetate|Brain scan with imaging agent to determine growth activity of tumor
41489817|NCT00000386|BEHAVIORAL|Exposure and Response Prevention|
41489818|NCT00000386|BEHAVIORAL|Family Treatment Program|
41489819|NCT00000386|BEHAVIORAL|Relaxation Training|
41489820|NCT00000386|BEHAVIORAL|Behavior therapy|
41489821|NCT00000386|BEHAVIORAL|Family Counseling|
41489822|NCT02887300|BEHAVIORAL|Mantra Meditation|"Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review."
41344237|NCT00117572|DRUG|fluorouracil|750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
41489823|NCT00532038|DRUG|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Patients will apply ThermoProfen daily for approximately 12 hours for up to 12 months for treatment of the pain associated with osteoarthritis of the knee.
41489824|NCT01620619|OTHER|Arthroscopic Bankart Repair alone|Usual arthroscopic Bankart repair
41489825|NCT01620619|PROCEDURE|Closure of rotator interval|Usual arthroscopic Bankart repair plus rotator cuff interval closure
41489826|NCT03453567|PROCEDURE|Valve Replacement|Aortic valve replacement
41489827|NCT00727766|DRUG|Clofarabine|
41489828|NCT01985074|BEHAVIORAL|Case-management intervention|The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
41489829|NCT00486616|DEVICE|electrical impedance tomography|
41489830|NCT00486616|PROCEDURE|double-lumen tube placement|
41157314|NCT05272787|OTHER|TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
41344238|NCT00117572|PROCEDURE|chemotherapy|See protocol for details
41344239|NCT00117572|PROCEDURE|radiotherapy|See protocol for details
41489831|NCT01910389|DRUG|Tadalafil|
41344240|NCT02147106|OTHER|Videoconsultation|
41344241|NCT04103203|DIAGNOSTIC_TEST|PathoRobot/ Patho-Doc Test result|Test results of the new diagnostics will be available to the treating physician.
41344242|NCT03016832|DRUG|Placebo drug that simulates Irbesartan tablets|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing
41344243|NCT03016832|DRUG|irbesartan tablets|irbesartan tablets 150mg /qd, oral dosing
41344244|NCT03016832|DRUG|Placebo drug that simulates HuangKui capsule|Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
41344245|NCT03016832|DRUG|HuangKui Capsule|HuangKui Capsule 2.5g/tid, oral dosing.
41344246|NCT04396327|DRUG|SM-1|diphenhydramine, zolpidem and lorazepam
41489832|NCT01910389|DRUG|Placebo for tadalafil|
41489833|NCT02774135|OTHER|direct occupational therapy intervention|Short term direct individual occupational therapy (9-12 weeks).Participants will receive occupational therapy intervention according to health law. The study will document the therapeutic intervention implemented in practice using the Documentation of Occupational Therapy Session during Intervention (DOTSI).
41489834|NCT00469157|DRUG|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
41489835|NCT00794976|DRUG|Dexamethasone Iontophoretic Patch (low dose)|
40825178|NCT06346366|DEVICE|Bihormonal artificial pancreas (BIHAP) / closed loop|"The investigational device is a dual-hormonal fully closed loop system (BIHAP; industrial name AP® 5, Inreda Diabetic B.V.) which aims at optimally controlling plasma glucose levels. This BIHAP contains of two pumps for subcutaneous infusion of either insulin (Humalog, 3 ml pre-fill cartridge, Eli Lilly) or glucagon (GlucaGen, Novo Nordisk; 3.15 ml cartridge Accu-Chek Spirit, Roche) via an infusion set (Accu-Chek Insight Flex or AccuChek Flex Link, Roche), two subcutaneously placed glucose-sensors (Guardian, Medtronic) and an algorithm driving pump infusion rates based on the sensor input. Daily self-measurements of blood glucose (SMBGs; Accu-Chek Instant, Roche) are needed for calibration of the glucose sensors.~The BIHAP-system has to be worn continuously, except while showering."
40825179|NCT03871348|DRUG|SAR441000|"Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral"
40825180|NCT03871348|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
40825181|NCT02088593|DEVICE|Simulated Dawn Light Box|per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.
40825182|NCT02088593|BEHAVIORAL|Sleep Hygiene instructions|Sleep Hygiene instructions read aloud
40825183|NCT02737553|PROCEDURE|Enclosed morcellation|After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
41344247|NCT04396327|DRUG|Active Comparator|diphenhydramine and lorazepam
41344248|NCT02974660|DRUG|Protamine sulfate|
41344249|NCT02974660|DRUG|0.9% NaCl|
41344250|NCT03419507|DEVICE|Endotracheal tube introducer|The doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by the adult size, endotracheal tube introducer with using No. 3 Macintosh blade
41344251|NCT03419507|DEVICE|Macintosh laryngoscopy|The doctors who drawed envelope number 1 will asked to intubate with using No. 3 Macintosh blade
41344252|NCT01117805|BEHAVIORAL|Telephone counseling intervention|self-regulation telephone counseling program for African American women with asthma
41344253|NCT03276260|DEVICE|PMD-200|Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.
41344254|NCT04376424|DIAGNOSTIC_TEST|Hand Held Ultrasound|Guideline directed medical therapy for heart failure with the addition of hand held ultrasound
41344255|NCT03369704|DRUG|Omalizumab|Omalizumab were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
41344256|NCT03369704|DRUG|Placebo|Placebo were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
41344257|NCT05751252|DRUG|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.0625 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
41344258|NCT05751252|DRUG|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.025 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
41344259|NCT01681836|DRUG|15Nitrogen(15N)-labeled sodium nitrite|15Nitrogen(15N)-labeled sodium nitrite 20 mg once
41344260|NCT01681836|DRUG|15Nitrogen(15N)-labeled sodium nitrate|15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
41344261|NCT04459923|PROCEDURE|ultrasound-guided erector spinae plane block catheter|for postoperative pain management ultrasound-guided erector spine plane block catheter placement
41344262|NCT04459923|PROCEDURE|thoracic epidural catheter|for postoperative pain management thoracic epidural catheter placement
41344263|NCT00732238|OTHER|Shortened course of antibiotic therapy|By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
41344264|NCT00732238|OTHER|Standard Therapy|Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
41344265|NCT03216395|DEVICE|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.
41344266|NCT03216395|DEVICE|Hemo-clipping|Hemo-clipping \<=20 clips
41344267|NCT03216395|DEVICE|thermo-coagulation|contact thermo-coagulation \< = 8 pulses
41344268|NCT03216395|DRUG|Epinephrine|epinephrine injection (diluted 1:1000) beneath peptic ulcer \<20 mls
41344269|NCT05322083|DRUG|Doravirine|Doravirine will be given to patients after failure on the first NNRTI regimen.
41344270|NCT04472819|DRUG|SHR2285 tablet|single dose or multi-dose
41344271|NCT04472819|DRUG|Placebo|single dose or multi-dose
41344272|NCT02525952|PROCEDURE|Hepatectomy|Surgical removal of all lesions
41344273|NCT02525952|PROCEDURE|TACE|Transarterial chemoembolization with lipiodol and pirarubicin
41344274|NCT04432181|OTHER|ophthalmic examination|ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation
41489836|NCT00794976|DRUG|Dexamethasone Iontophoretic Patch (high dose)|
41489837|NCT00794976|DRUG|Dexamethasone Passive Patch|
40825184|NCT02737553|PROCEDURE|vaginal morcellation|After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
41344275|NCT02825940|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
41344276|NCT02825940|DRUG|Gemcitabine|Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m\^2 on Days 1 and 8.
41344277|NCT02825940|DRUG|Cisplatin|Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m\^2 on Day 1.
41344278|NCT04427410|DIAGNOSTIC_TEST|Salivary test|Salivary test for measured of oxytocin levels
41344279|NCT02324036|DEVICE|EMPATHy Toolkit|Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
41344280|NCT02324036|BEHAVIORAL|Coached Care|Community health worker provides participation training to patient
40825185|NCT02508740|DRUG|bevenopran|Single oral dose
41344281|NCT01462045|BEHAVIORAL|Mindfulness-based exercise|8-week program of mindfulness-based stretching and breathing exercises
41344282|NCT00952770|PROCEDURE|transradial coronary intervention|percutaneous coronary intervention with transradial approach
41344283|NCT02805062|PROCEDURE|Digital Pleural Manometry|Measurement of intra-pleural pressure and the removal of pleural fluid.
41489838|NCT00794976|DRUG|Placebo Patch|
41489839|NCT01333280|BEHAVIORAL|Double Trouble in Recovery|DTR is a 12 Step-based fellowship for individuals with co-occurring problems of substance abuse and mental illness
41489840|NCT01333280|BEHAVIORAL|Treatment as usual|Receive usual treatment at the programs
41489841|NCT03970928|DEVICE|PVI|A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data. The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
41489842|NCT00706511|DEVICE|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
40825186|NCT05273021|DIAGNOSTIC_TEST|TAPS|all participants are investigated by the Dutch TAPS tool (Tobacco, Alcohol, Prescription medication and other Substances-tool). A screener and short assessment of possible substance use problems
40825187|NCT01884558|DRUG|isavuconazole|oral
40825188|NCT01884558|DRUG|metformin|oral
40825189|NCT05940545|DRUG|Favipiravir|Small molecule antiviral
40825190|NCT05940545|DRUG|Ribavirin|Small molecule antiviral
41157315|NCT05272787|OTHER|TH Lip Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
41489843|NCT00274820|DIETARY_SUPPLEMENT|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
41489844|NCT00274820|DRUG|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
40825191|NCT00899717|PROCEDURE|Occlusal adjustment|modification of occlusal surfaces
41344284|NCT02805062|PROCEDURE|Magnetic Resonance Imaging|Subject lies a long tunnel shaped scanner and images are recorded.
41344285|NCT03986567|BEHAVIORAL|gamification for partner notification among youngsters|"Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification"
41344286|NCT00364468|DRUG|pegfilgrastim|
41344287|NCT02483065|OTHER|mortality at discharge and 3-months after the admission in patients with and without dementia|Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
41344288|NCT06095206|DRUG|GenSci094|On the morning of day 1 pre-meal, a single SC injection of 150 μg GenSci094 was administered in the abdominal wall.
41344289|NCT04525560|OTHER|PEG-ELS-S|2/3 dose of PEG-ELS was taken orally from the evening on the day before colonoscopy, and the remaining 1/3 dose of PEG-ELS was orally administered in the morning of the next day.
41489845|NCT00274820|DRUG|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
40825192|NCT00899717|PROCEDURE|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
40825193|NCT00750529|DRUG|Galantamine and Donepezil|the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
40825194|NCT02370641|DIETARY_SUPPLEMENT|PomX|1000 mg POMx daily for 4 weeks
40825195|NCT02496845|DRUG|VL#FIA3-30|Vasoactive dual treatment (MH30-01 \& IS045-01)
40825196|NCT06422858|DRUG|Serplulimab|Serplulimab will be administered as a fixed dose of 300 mg via intravenous infusion every three weeks, continuing for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
41157316|NCT05272787|OTHER|Facial Moisturizer B (Control)|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
41157317|NCT05272787|OTHER|Sunscreen|Auxiliary product
41344290|NCT04525560|OTHER|PEG-ELS-L|PEG-ELS is given orally on the day before colonoscopy, which is divided into 10-12 portions and taken one portion every hour. If half of the total amount is not completed at afternoon ward round the day before colonoscopy, nasogastric feeding is recommended.
41344291|NCT03615989|BEHAVIORAL|Resistance and Plyometric Exercise|A single resistance and plyometric exercise bout per trial.
41344292|NCT03615989|DIETARY_SUPPLEMENT|Carbohydrate (Maltodextrin powder mixed with water)|50 grams immediately after exercise bout. 50 grams 1 hour after exercise bout.
41344293|NCT03615989|DIETARY_SUPPLEMENT|Skim Milk|500 ml immediately after exercise bout. 500 ml 1 hour after exercise bout.
41344294|NCT01934608|BEHAVIORAL|Refill synch|
41344295|NCT03975517|BEHAVIORAL|PrEP|Define the behavioral characteristics of the active file of patients using PrEP in Strasbourg in 2019.
41344296|NCT03422016|DIAGNOSTIC_TEST|electroretinogram (ERG)|an ERG is a measure of the eyes response to a flash of light
41344297|NCT01751204|DIETARY_SUPPLEMENT|Calcium tablet|
41344298|NCT01751204|DIETARY_SUPPLEMENT|Calcium ion water (250mg)|
41344299|NCT01751204|DIETARY_SUPPLEMENT|Calcium ion water (125mg)|
41344300|NCT02373306|PROCEDURE|Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation|
41344301|NCT06213636|BIOLOGICAL|CD19/CD22-CAR T cells|"The intervention in this clinical trial involves a novel approach using CD19/CD22-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/CD22-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/CD22-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/CD22-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
41344302|NCT03190681|DRUG|Ritalin 10Mg Tablet|ingestion of an oral single-dose
41344303|NCT01461798|DIETARY_SUPPLEMENT|assessment of efficacy of Benecol yogurt|Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
41489846|NCT00274820|DRUG|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience \< grade 1 thalidomide-attributed toxicity using CTC criteria.
40825197|NCT06422858|DRUG|Tegafur-gimeracil-oteracil potassium capsule(S1)|S1 will be administered at a dose of 60 mg/m2 per day, taken orally in two divided doses on day 1 concurrent with radiotherapy, repeated every 28 days; and from day 1 to day 14 of each 21-day cycle, for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
40825198|NCT06422858|RADIATION|Radiotherapy|Radiotherapy will be delivered as a total dose of 50.4 Gy in 28 fractions over six weeks using techniques such as IGRT, IMRT, VMAT, or TOMO, targeting the primary tumor and associated lymph nodes
41344304|NCT01461798|DIETARY_SUPPLEMENT|Placebo Yogurt|Yogurt without the active principle
41344305|NCT01461798|DIETARY_SUPPLEMENT|yogurt|yogurt without plant stanols
41344306|NCT01058057|DRUG|atorvastatin|atorvastatin 80mg p.o. daily seven days before PCI
41489847|NCT02275130|PROCEDURE|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
41489848|NCT02275130|DEVICE|Radiesse Voice (Calcium Hydroxyapatite)|
41489849|NCT02613013|DEVICE|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
41489850|NCT02613013|DEVICE|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
41489851|NCT02613013|DRUG|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
40825199|NCT06422858|DRUG|Cisplatin|Cisplatin will be administered at a dose of 75 mg/m\^2 on day 1 concurrent with radiotherapy, repeated every 28 days
41157318|NCT05272787|OTHER|Facial wash|Auxiliary product.
41344307|NCT00102336|BIOLOGICAL|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
41344308|NCT00102336|DRUG|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
41344309|NCT03566498|DIETARY_SUPPLEMENT|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements
41344310|NCT03566498|DIETARY_SUPPLEMENT|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
41344311|NCT03860168|OTHER|PICU Up!|The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
40825200|NCT05440669|BEHAVIORAL|white noise|white noise will reduce pain and stress in nasal cpap application
41344312|NCT05969262|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
41344313|NCT03803449|DRUG|50-200mg propofol|participants in both groups are given standard regimen including 50-200mg propofol.
41344314|NCT03803449|DRUG|50ug fentanyl|participants in fentanyl group are given intervention regimen: 50ug fentanyl.
41344315|NCT03803449|DRUG|1 mg midazolam|participants in both groups are given standard regimen including 1 mg midazolam.
41344316|NCT00976261|DRUG|GSK1614235|Glucose lowering in Type 2 Diabetes Mellitus
41344317|NCT00976261|DRUG|Sitagliptin|Glucose lowering in Type 2 Diabetes Mellitus
41344318|NCT00976261|OTHER|Placebo|Comparator
41344319|NCT04368741|DIETARY_SUPPLEMENT|SANZ®KINGWILL|20g nutrition product (SANZ®KINGWILL) was used as extra meal at 10:00am and 15:00pm, respectively.
41344320|NCT04368741|DIETARY_SUPPLEMENT|GLUCERNA SR®|17.5g nutrition product (GLUCERNA SR®) was used as extra meal at 10:00am and 15:00pm, respectively.
41344321|NCT05147597|OTHER|Questionnaire|"Cases diagnosed with Idiopathic pulmonary fibrosis (IPF) in the chest diseases outpatient clinic will be informed about the study, and the informed consent form will be signed by the specialist physician and demographic information will be obtained from the cases who accepted to be included in the study.~The surveys will be contacted by the patient at 1-week intervals and answered by the patient by the responsible researcher and chest diseases physician."
41344322|NCT06417398|BIOLOGICAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
41344323|NCT06455358|DRUG|61Cu-NODAGA-LM3|Single intravenous administration of 61Cu-NODAGA-LM3 at an amount of 20 -40 μg (or 13 - 26 nmol) and an activity range of 150 MBq (±25%) followed by up to three PET/CT acquisitions.
41344324|NCT06455358|OTHER|Comparator|Single intravenous administration of 68Ga-DOTA-TOC and PET/CT acquisitions as part of standard clinical care.
41344325|NCT03201484|OTHER|FACE-Q questionnaire, 3D photography|FACE-Q questionnaire, 3D photography
41489852|NCT02613013|PROCEDURE|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
41489853|NCT02613013|DRUG|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
40825201|NCT01806025|OTHER|no intervention|
40825202|NCT04739618|DRUG|Keytruda Injectable Product|PD-1 inhibitor antibody
40825203|NCT04739618|DRUG|Yervoy Injectable Product|Anti-CTLA-4 antibody
40825204|NCT04739618|DRUG|GM-CSF|1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
40825205|NCT04739618|PROCEDURE|Non-ablative Cryosurgical freezing|To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
40825206|NCT00346502|DRUG|20% betulinic acid ointment|
40825207|NCT00346502|DRUG|BA|20% Betulinic Acid Ointment
41344326|NCT00835276|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
41344327|NCT00835276|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
41344328|NCT04732780|OTHER|No intervention|No intervention
41344329|NCT01505140|OTHER|Whole walnuts|75 gm whole walnuts per day will be consumed with usual Western style diet
41344330|NCT05964205|OTHER|Electronic clinical decision support tool|Electronic clinical decision support tool
41344331|NCT06015841|BIOLOGICAL|Placebo|The placebo is a solution matching the study vaccine formulation.
40825208|NCT06154941|PROCEDURE|Giomer Varnish|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession
40825209|NCT06154941|PROCEDURE|CPP-ACP varnish|CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. CPP-ACP Varnish delivers bioavailable calcium and phosphate ions to occlude dentinal tubules treating dentin hypersensitivity
41344332|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose A|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
41344333|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose B (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
41344334|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose C (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
41344335|NCT00205946|DRUG|Bupropion|150 mg of bupropion administered 5 hours before fMRI scanning
41344336|NCT00205946|DRUG|Placebo|Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
41383613|NCT04540315|BEHAVIORAL|MobiMD|MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.
40825210|NCT04189653|OTHER|Continuous Monitoring|Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
40825211|NCT05797038|DRUG|Tacrolimus for the treatment of IMN|Remission after tacrolimus treatment of IMN
40825212|NCT02430948|OTHER|Color-coded materials|A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
41344337|NCT05816590|OTHER|Med@HOME Mobile App|Meds@HOME is a software application designed for use on a personal mobile device. The app allows primary caregiver to create routines where they can detail how to perform the routine, start date and time, and frequency (daily, weekly, monthly). Optional push notifications can be set so that users are alerted to an upcoming routine. Only primary caregivers can create, edit, and delete routines. All caregivers can check off on routines and receive notifications. Caregivers can also post notes related to routines or events. App enables an inventory of caregiver troubleshooting strategies and inventory reminders.
40825213|NCT02430948|OTHER|Academic detailing|Educational outreach to address the rationale and data supporting recommendations for and against screening
40825214|NCT02430948|OTHER|Standard support|Screening recommendations presented in standard format
40825215|NCT02430948|OTHER|No academic detailing|Physician receives study orientation for not the academic detailing curriculum
40825216|NCT00932620|DRUG|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
41344338|NCT00269295|BIOLOGICAL|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10\^7 cfu, 5 X 10\^8 cfu, and 5 X 10\^9 cfu.
41344339|NCT00269295|DRUG|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
40825217|NCT00932620|DRUG|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
40825218|NCT05827562|DIAGNOSTIC_TEST|flow cytometry|"Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~1. CD3+CD4-CD8αα+~2. CD3+CD4-CD8α+CD8βlow~3. CD3+CD4-CD8α+CD8βhigh~4. CD3+CD4+CD8αβhigh~5. CD3+CD4+CD8αα+"
40825219|NCT06159205|OTHER|standard exercises|Standard exercises for TKA patients.
40825220|NCT06159205|OTHER|core stability exercises|Core stability exercises for TKA patients.
41157319|NCT04093466|DRUG|CX1003|Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
40825221|NCT01211353|BEHAVIORAL|Personalized Drinking Feedback|Personalized feedback about one's drinking habits
40825222|NCT01211353|BEHAVIORAL|Education-Only|Educational information about alcohol use
40825223|NCT01567592|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
40825224|NCT01467115|RADIATION|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
40825225|NCT01467115|DRUG|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
41344340|NCT06212388|BIOLOGICAL|Ex-vivo expanded allogeneic γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
41344341|NCT06212388|DRUG|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
41383614|NCT03683719|DRUG|Delgocitinib cream|Cream for topical application.
40825226|NCT01467115|BIOLOGICAL|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
40825227|NCT01467115|DRUG|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
40825228|NCT01467115|DRUG|Erythropoetin|Subcutaneous or intravenous
40825229|NCT01467115|DRUG|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
40825230|NCT01467115|DRUG|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
41344342|NCT06212388|DRUG|Pembrolizumab|Pembrolizumab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
41344343|NCT03148184|DIAGNOSTIC_TEST|shoulder x-ray|post operative shoulder x-ray at minimum 2 year post op
41344344|NCT05315024|DRUG|Fluarix Tetra|Fluarix Tetra
41344345|NCT05315024|DRUG|Imiquimod cream|Imiquimod cream
41344346|NCT03344874|DEVICE|Stethee®|Stethee® is a new wireless digital stethoscope.
41344347|NCT03344874|DEVICE|3MTM Littmann® Classic IIITM|3MTM Littmann® Classic IIITM is the conventional stethoscope.
41344348|NCT00287755|DRUG|S-1|S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
41344349|NCT01780207|DEVICE|PFO Closure|
41344350|NCT05442125|OTHER|Using DNA methylome to select embryos|DNA methylation level Embryo with methylation level closest to the optimal level (from one couple patients) is the one for embryonic transfer to uterus
41344351|NCT05442125|OTHER|Using morphologic score to select embryos|blastocyst will transferred according to morphologic score or blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
41344352|NCT02256345|DRUG|KNO3|Active Comparator
41344353|NCT02256345|DRUG|KCl|Placebo Comparator
41344354|NCT01167088|DRUG|Mitoquinone mesylate|2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.
41344355|NCT01167088|DRUG|Placebo|Placebo
41344356|NCT01052831|DRUG|Naltrexone|50-100 mg qd for 8 weeks
41344357|NCT01052831|DRUG|Placebo|50-100 mg qd for 8 weeks
41344358|NCT05211973|DEVICE|Wrist Actigraphy Device|a watch like wearable sensor
41344359|NCT05211973|DEVICE|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
41344360|NCT05211973|DEVICE|Chair Scale|a wheel-chair compatible scale to measure body weight
41344361|NCT05211973|DEVICE|Handheld Body Fat Percentage Device|a handheld device that measures body fat percentage
41344362|NCT05211973|DEVICE|Bioelectric Impedance Analysis Scale|a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
41344363|NCT02900599|OTHER|Observationnal (no intervention)|
41344364|NCT04011306|DEVICE|Lumina24 BLU|Lumina24 BLU is the technology used to deliver continuous low-irradiance phototherapy for the treatment of acute burns
41344365|NCT02443051|BEHAVIORAL|Attention Bias Modification|Computer delivered modification in 80% of trials
41344366|NCT00251849|DRUG|Rifalazil|
41344367|NCT05498792|DRUG|CBL0137|Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
41344368|NCT05498792|DRUG|Ipilimumab|Patient will be on Ipilimumab (1 mg/kg)
41344369|NCT05498792|DRUG|Nivolumab|Patient will be on Nivolumab (3 mg/kg)
41344370|NCT05135468|DRUG|CU-40102 Spray|topical application, 1\~4 sprays each time, once daily
41344371|NCT04290767|DIAGNOSTIC_TEST|Sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy)|Enhanced-contrast brain ultrasound with intravenously sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy) injection and using the time-intensity curve profile to evaluate brain microcirculation.
41344372|NCT06198894|PROCEDURE|steroid-eluting sinus stent implant|In-office bilateral placement of the steroid-eluting sinus stent in the ethmoid sinuses under local anesthesia
41344373|NCT06198894|DRUG|Systemic glucocorticoids|Groups were given oral methylprednisolone (32 mg/d on days 1-5; 16 mg/d on days 6-10; and 8 mg/d on days 11-20),
41344374|NCT06198894|DRUG|saline irrigations|Patients were routinely treated with saline irrigations (250ml) twice daily
41344375|NCT06198894|DRUG|Placebo|Groups were given systemic glucocorticoid placebo
40825231|NCT01467115|DRUG|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
40825232|NCT06408675|OTHER|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
41344376|NCT06198894|PROCEDURE|sham procedure|The sham procedure was performed in-office under local anesthesia
40825233|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
41344377|NCT02727504|DEVICE|Electrocardiogram|ECG at inclusion and M12
40825234|NCT00983515|DRUG|Ritonavir|One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
40825235|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
40825236|NCT02387164|DRUG|Alum-GAD|Two doses à 20 microgram 30 days apart subcutaneously administrated
40825237|NCT02387164|DRUG|Vitamin D3|2000 Units (IE) (50 microgram) vitamin D3 daily
40825238|NCT06081413|PROCEDURE|bariatric surgery|bariatric surgeries - sleeve gastrectomy, roux-en-Y gastric bypass, one anastomosis gastric bypass, adjustable gastric band
40825239|NCT02393846|DRUG|Ketoprofen gel|Topical ketoprofen as used in gel form.
40825240|NCT02393846|DRUG|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
40825241|NCT03226756|DRUG|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
40825242|NCT04299919|PROCEDURE|Minimally invasive treatment|All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
40825243|NCT04299919|PROCEDURE|Hepatectomy|All hepatocellular carcinoma (HCC) patients received hepatectomy.
40825244|NCT02891681|DEVICE|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
40825245|NCT00310284|BEHAVIORAL|Computerized delivery of cognitive-behavioral treatment of insomnia|
40825246|NCT00310284|BEHAVIORAL|Self-help manual to improve insomnia symptoms|
40825247|NCT03220581|BEHAVIORAL|Referral for care|referral for addictions support
41344378|NCT02727504|DEVICE|2D and 3D echocardiography|2D and 3D echocardiography at inclusion and M12
41344379|NCT02727504|DEVICE|Dobutamine stress echocardiography|dobutamine stress echocardiography at inclusion
41489854|NCT02613013|PROCEDURE|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris \>0.1mm. and patency was determined by direct visualization of the posterior chamber.
41489855|NCT02037035|DRUG|Ketamine|
41489856|NCT05765630|BIOLOGICAL|BLOOD SAMPLES|BLOOD SAMPLES
41489857|NCT04385966|PROCEDURE|Interscalene brachial plexus block|Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.
40825248|NCT03220581|BEHAVIORAL|Behavioral therapy|therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
40825249|NCT04333953|OTHER|No intervention|No intervention, observational study
40825250|NCT03796143|BEHAVIORAL|The Mindfulness and Acceptance Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
40825251|NCT03796143|BEHAVIORAL|The Cognitive Behavioral Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
40825252|NCT02670707|DRUG|Cytarabine|Cytarabine 100 mg/m\^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
40853078|NCT02315534|DRUG|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m\^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m\^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m\^2.
40853079|NCT00895310|DRUG|Ketoconazole|Ketoconazole is taken three times a day by mouth.
41344380|NCT02727504|BIOLOGICAL|Blood tests|Blood test electrolytes, creatinine, hemoglobin, NT-proBNP, CRP, ST-2 at inclusion and M12
41344381|NCT02727504|DEVICE|Cardiac MRI|Cardiac MRI at inclusion
41344382|NCT02727504|DEVICE|Cardiac scanner|Cardiac scanner at inclusion
41344383|NCT02727504|OTHER|6-minutes walking test|6-minutes walking test at inclusion and M12
41344384|NCT02727504|OTHER|Duke Activity Score|Duke Activity Score at inclusion and M12
41344385|NCT03900663|DEVICE|Anthropometric measures|Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference
41344386|NCT01063946|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion"
40825253|NCT02670707|DRUG|Vinblastine/prednisone|"Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m\^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m\^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m\^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
41344387|NCT04018105|OTHER|Oral glucose tolerance test (OGTT) with or without metformin|Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
41344388|NCT01589692|PROCEDURE|Open Reduction and Internal Fixation|Internal fixation with a volar locking plating system
41344389|NCT01589692|PROCEDURE|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
41344390|NCT01589692|PROCEDURE|Percutaneous Pinning|Pinning with any number of Kirschner wires
40825254|NCT02100020|OTHER|Direct Referral to physical activity|Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
40825255|NCT02307292|DEVICE|POLARIS Peripheral Vascular Self Expanding Stent System|
41344391|NCT01589692|PROCEDURE|Closed Reduction and casting|Closed reduction and immobilization with a cast and/or splint
41344392|NCT04459078|DRUG|Camrelizumab|Intravenous administration of (200mg/3weeks)
41344393|NCT04459078|DRUG|Albumin Paclitacxel|intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)
40825256|NCT05223881|DEVICE|13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)|After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.
41344394|NCT04459078|DRUG|Apatinib|Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)
41344395|NCT06139198|BEHAVIORAL|Self-MAnagement intervention for Reducing The epilepsy burden among Ugandans|SMART-U sessions are operationalized in written curricula, including an intervention manual, participant manual, slides, and handouts typically delivered over a period of 10-12 weeks.
40825257|NCT00270660|BEHAVIORAL|biopsy, audiometry, ET function test, ear swab culture, DNE|
41344396|NCT03270618|DEVICE|CAD/CAM Surgical Template|The templates were designed based on virtual planning and manufactured using three-dimensional printing technique. The template is designed to assist the surgeon to perform the osteotomy and predrill the screw holes to guide the distractor position.
41489858|NCT04385966|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|"Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999)."
41489859|NCT00613535|DEVICE|Mechanical debridement|Mechanical shaver will be used to remove large chondral flaps and loose fragments
41489860|NCT00613535|DEVICE|Paragon T2|Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.
41489861|NCT00613535|PROCEDURE|Lavage debridement|Remove loose chondral fragments
40825258|NCT02280824|PROCEDURE|CA-TAVR|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
40825259|NCT02280824|DEVICE|Amplatzer Duct Occluder|
40825260|NCT00760461|DRUG|Domperidone|10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
40825261|NCT03711929|DRUG|DE-109 Intravitreal Injections|440 ug of DE-109 Injectable Solution
40825262|NCT03711929|OTHER|Sham Procedure|The sham procedure mimics an intravitreal injection without penetrating the eye.
40825263|NCT03711929|DRUG|DE-109 Intravitreal Injections|Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
40825264|NCT03711929|DRUG|DE-109 Intravitreal Injections (Open Label)|After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)
40825265|NCT04535713|DRUG|Gemcitabine|600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+
40825266|NCT04535713|DRUG|Doxorubicin|18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+
40825267|NCT04535713|DRUG|Docetaxel|25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+
41344397|NCT05849545|DEVICE|Garston tool|GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. Using the Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes were given over the painful area. Baseline values were recorded for demographics evaluation and episodes of pain onsets. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.
41344398|NCT05849545|PROCEDURE|Neuromuscular Re-education|General stretching and strengthening exercises for the neck muscles. The protocol of treatment for the NMR group included the use of the Neuromuscular re-education soft tissue mobilization technique (NMR) followed by active movements of the patient.
41344399|NCT02022891|BEHAVIORAL|systematic psychological care|Prevention treatment plan that provides systematic medical and psychological care at routine pediatric consultations for SCD. Bio-psychosocial paradigm applied at pediatric consultations.
41489862|NCT00613535|DEVICE|Mechanical Debridement|Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments
41489863|NCT00613535|DEVICE|RF- based Debridement|Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
41489864|NCT04757038|DEVICE|Intradiscal injection|The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided.
41344400|NCT02606344|OTHER|Mico-finance based intervention|
41344401|NCT00383266|DRUG|Pemetrexed|
41344402|NCT00383266|DRUG|Carboplatin|
41344403|NCT02382289|PROCEDURE|radiofrequency ablation for sacroiliac joint arthropathy|comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
41344404|NCT05837000|DRUG|Dexmedetomidine|Patient will receive 0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
41489865|NCT05213143|DRUG|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening. The maintenance dose of olanzapine from Day 0 to Day 6, than tapered until discontinuation from Day 7 to Day 27. Lurasidone initiated with 40mg/d on Day 0, maintained until Day 13, with a flexible dose (40-80mg/d, qd) from Day 28 to Day 111.
41489866|NCT00759135|DRUG|2.5 mg NX-1207|Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
41489867|NCT00759135|DRUG|0.125 mg NX-1207|Low dose; single intraprostatic injection of 0.125 mg NX-1207
41344405|NCT05837000|DRUG|Ketamine|Patient will receive 0.5ml/kg bupivacaine 0.25% + 0.5mg/kg ketamine caudally
40825268|NCT04535713|DRUG|Nivolumab|240 mg i.v. on Day 1 beginnning Cycle 2+
41344406|NCT05837000|DRUG|Magnesium sulphate|Patient will receive 0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.
41344407|NCT05906914|DRUG|cladribine + homoharringtonine + cytarabine|CHA Protocol: cladribine (5mg/m2, d1-3) + homoharringtonine (2mg/m2, d1-5) + cytarabine (100mg/m2 d1-7).
41344408|NCT01465373|DRUG|Endometrin|100 mg per vagina TID
41344409|NCT01465373|DRUG|Progesterone in Oil|50 mg IM injection daily
41344410|NCT06262672|OTHER|Evaluation form|This form is a form of demographic information, questions that question the habits of COVİD-19 era, and evaluation scales.
41344411|NCT02868151|DRUG|Ascorbic Acid|Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
41344412|NCT02868151|DRUG|Zinc acetate|Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
41344413|NCT06097741|DEVICE|MRI sequences|Ultra short / zero TE sequence on MRI being tested on healthy patients and improved by manually fine tuning the sequence
41489868|NCT00759135|DRUG|finasteride|Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
41489869|NCT00760565|DRUG|RO4905417|3mg/kg iv every 28 days for 3 infusions
41489870|NCT00760565|DRUG|RO4905417|20mg/kg iv every 28 days for 3 infusions
41489871|NCT00760565|DRUG|RO4905417|7mg/kg iv every 28 days for 3 infusions
41489872|NCT00760565|DRUG|placebo|3mg/kg iv every 28 days for 3 infusions
41489873|NCT00760565|DRUG|placebo|7mg/kg iv every 28 days for 3 infusions
41489874|NCT00760565|DRUG|placebo|20mg/kg iv every 28 days for 3 infusions
41489875|NCT01782235|DRUG|Tocilizumab|
41489876|NCT01782235|DRUG|Placebo|
41489877|NCT00639847|BEHAVIORAL|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
41344414|NCT02823236|DRUG|Topical Pirfenidone|Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
41344415|NCT02823236|DRUG|Triamcinolone + Pirfenidone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
41344416|NCT02823236|DRUG|Intralesional Triamcinolone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.
41344417|NCT06107790|DRUG|HS022|"8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg"
41344418|NCT06107790|DRUG|Trastuzumab|"8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg"
41383615|NCT03683719|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
41383616|NCT03969979|DIAGNOSTIC_TEST|Shear wave elastography|shear wave elastogrophy will be performed
41489878|NCT00639847|BEHAVIORAL|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
41489879|NCT02253030|DEVICE|Optical Coherence Tomography|
41489880|NCT03654469|OTHER|questionnaires and electronic mini-spirometry|prospective screening study based on questionnaires and electronic mini-spirometry (Néo-6(®)) that includes a representative sample of dairy farmers from the departments of Morbihan and Île-et-Vilaine in Brittany
40825269|NCT04167215|PROCEDURE|superior gluteal artery flap and lumbar artery falp|Doppler ultrasound will be used to confirm location of the superior gluteal artery perforators or lumbar perforators . Flaps will be designed to allow deepithelialization and dissection . After complete sketolization of the flap it will be analyzed for viability and trimmed to achieve the desired bulk.
41383617|NCT02723786|BIOLOGICAL|GSK1070806|Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.
41036523|NCT06201338|PROCEDURE|Screening of preoperative frailty|"The day before the surgery, a multimodal evaluation is performed regarding :~Cognitive assessment: Mini mental State evaluation (MMSE) test Physical functional assessment: Chair raising Addiction assessment: Fagerstrom Assessment of the social environment: environmental assessment Nutritional assessment: Grip test Quality of life: completion of SF 36 scale and QOR15 scale"
41344419|NCT06107790|DRUG|Vinorelbine Bitartrate|"Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~Second section:9 treatment cycles, 3 weeks/cycle, 27 weeks. Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). The investigator may decide whether to continue treatment with vinorelbine at his discretion.~3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first."
41489881|NCT01163448|RADIATION|High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy|A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
41489882|NCT06026020|OTHER|Biological samples collection|Samples of blood, faeces, saliva are collected for analysis.
41489883|NCT05803928|DRUG|lenvatinib + anti-PD-1 antibodies|A ablation treatment group B ablation+ lenvatinib + anti-PD-1 antibodies treatment group
41489884|NCT05803928|PROCEDURE|ablation|radiofrequency ablation or microwave ablation
41489885|NCT04791475|PROCEDURE|adding Dexmedetomidine and dexamethasone to bupivacaine in USG guided supraclavicular brachial plexus block.|The linear transducer probe (frequency 4 -12 Hz) of USG machine will be used. A superficial skin wheal will be made by 2ml of 1% lignocaine subcutaneously at the point of needle insertion. USG guided Brachial plexus block will be performed by supraclavicular route via the subclavian perivascular approach in in-plane technique from lateral to medial using 22 gauge spinal needle. Study Drug will be administered via Pressure Monitoring line connected to syringe according to the allocated group with repeated aspiration and incremental dosing. • Intercostobrachial nerve block will be performed to alleviate the tourniquet pain. A 25 G needle will be inserted at the level of axillary fossa. The entire width of the medial aspect of arm, starting at the deltoid prominence and proceeding inferiorly, will be infiltrated with 5ml of 1% Lignocaine with Epinephrine (1:4,00,000) to raise a subcutaneous wheal. •
41489886|NCT00476554|DRUG|Sapacitabine|Sapacitabine
41489887|NCT04590066|BEHAVIORAL|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
41489888|NCT05438498|DRUG|Evusheld (tixagevimab+cilgavimab) IM or IV|Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
41489889|NCT03967951|OTHER|CT radiomic feature evaluation|"Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated.~In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be.~Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated."
41489890|NCT05201196|OTHER|Conventional physical therapy|Targeted muscle stretching and Strengthening (flexors, Extensors, abductors, internal and external rotators, of Shoulder, Elbow, forearm (supination \& pronation) and hand 10 repetitions×1 set, 4 days/ week. Transcutaneous Electrical nerve Stimulation for 10-20 min, 4 days/ week. Total of 16 sessions were given each consisting of 45 mins.
41489891|NCT05201196|OTHER|Task Oriented Training|"Experimental group was given Task oriented protocol including activities such as Table-top polishing, Arm cradling, Reach forward and pick-up or touch an object, Reached sideway to pick-up an object and transferring it to a table in front, Pouring~½ cup of water from a measuring pot into wide mouth glass held in opposite hand, Picking up pen from thumb and first two fingers, lifting a basket and placing it on the table 10 repetitions×1 set for each activity, 4-5days/week. Total of 16 sessions were given each consisting of 45 mins"
41489892|NCT02588950|DRUG|U-500R|
41344420|NCT03327246|DEVICE|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
41383618|NCT02723786|DRUG|1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids|This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
41383619|NCT03126682|DRUG|Wellbutrin SR 300Mg Extended-Release Tablet|Wellbutrin SR 300Mg Extended-Release Tablet
41036524|NCT03905200|DIAGNOSTIC_TEST|3D-speckle tracking imaging|The strain peak value and strain peaking time of each segment (including 16 segments) of the left ventricular myocardium can be obtained by 3d-sti technology.
41036525|NCT00232804|DEVICE|Bx Cypher stent|
41036526|NCT01600300|DEVICE|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
40825270|NCT04167215|PROCEDURE|The gluteal pocket|pocket will be created by undermining in a plane just superficial to the gluteal muscle from the lower body lift line inferiorly extending to within 5 cm of the inferior gluteal crease. should extend only over the medial half of the buttock.
41344421|NCT04694157|DEVICE|cardiac shock wave therapy|Two target segments of left ventricle will be chosen for all participants. In each target segment, 9 sties will be administered with 200 shots at each site. Low-intensity SW (200 impulses/spot; energy flux 0.09 mJ/mm2), will be administered under electrocardiographic R-wave gating. The entire treatment period will last 3 months with 9 sessions. CSWT will be administered in the first week, followed by a 3-week non-treatment interval.
41344422|NCT06214923|DEVICE|RelieVRx|Participants will use RelieVRx daily for 20min/day for 3 weeks
41489893|NCT01565616|DRUG|Conditioning Regimen with Bone Marrow Transplant|"The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV"
41489894|NCT00057083|OTHER|Telemedicine Care|
41489895|NCT05567484|DRUG|Itraconazole|100 mg two capsules of itraconazole were given twice daily to 30 patient group A for one week per month.baseline LFTs were also monitered
41489896|NCT05969613|PROCEDURE|Regional block|regional block with 0.25% Bupivacaine at a dose of 2ml/kg with adrenaline
40825271|NCT04167215|PROCEDURE|infragluteal dermal lifiting flap|dermal flap will be performed for lifting the ptotic buttocks with ill-defined infragluteal fold. This deepithelialized dermal flap allows for the creation of a well-defined stable infragluteal fold through an incision of the infragluteal fold and exposure of ischial tuberosity and anchor it to the ischial tuberosity.
40825272|NCT04755166|PROCEDURE|Lateral ridge augmentation|
40825273|NCT03789695|DRUG|Dabigatran Etexilate|Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
40825274|NCT05022199|DEVICE|SPY fluorescent angiography|This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
40825275|NCT01572363|DRUG|Sildenafil|50 mg once
40825276|NCT04346108|BIOLOGICAL|Immune Globulin Intravenous (IGIV)|Participants will receive IGIV infusion.
40825277|NCT04346108|BIOLOGICAL|Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)|Participants will receive IGSC, 20% SC infusion.
40825278|NCT06524557|DIAGNOSTIC_TEST|with chronic liver disease|patients with hepatitis B virus，hepatitis C virus, or other chronic liver disease
40825279|NCT05186701|OTHER|Kinesio Tape|"Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis."
40825280|NCT05186701|OTHER|Conventional Physical Therapy|Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
41344423|NCT06214923|DEVICE|Sham-VR|"Participants will use Sham-VR, consisting of video, images, and sound in a head-mounted display but lack the sense of presence and immersive features of Active-VR (for example, scene changes with head movement). Participants will use the Sham-VR daily for 20min/day for 3 weeks"
41344424|NCT06214923|OTHER|No-VR (natural history control)|Participants will continue regular/usual care without any VR devices (goggles or audiovisual input)
41489897|NCT05969613|PROCEDURE|Wound infiltration|Infiltration of surgical site with 0.25% Bupivacaine at 0.5ml/kg dose
41489898|NCT05969613|PROCEDURE|Caudal block|Infiltration of caudal epidural space with 0.25% Bupivacaine at 1ml/kg dose
40825281|NCT01007071|DRUG|Human Growth Hormone (1-134)|Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
41489899|NCT02390349|OTHER|Placebo|
40825282|NCT01007071|DRUG|Placebo|Subjects randomized to placebo
40853080|NCT00895310|DRUG|Hydrocortisone|Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
41344425|NCT01948518|DRUG|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
41344426|NCT03011528|DRUG|VDC-IE x2|"Week 1, 5, 9 and week 13:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, 7, 11 and week 15:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"
41344427|NCT03011528|DRUG|VDC-IE|"Week 1 and week 5:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"
41489900|NCT02390349|DIETARY_SUPPLEMENT|Curamin|
41489901|NCT02390349|DIETARY_SUPPLEMENT|CuraMed|
41489902|NCT01169532|DRUG|ridaforolimus|Given PO
41489903|NCT01169532|DRUG|vorinostat|Given PO
41489904|NCT01169532|PROCEDURE|biopsy|Optional correlative studies
41489905|NCT01169532|OTHER|pharmacological study|Correlative studies
41036527|NCT01600300|DEVICE|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
41344428|NCT03011528|DRUG|TEMIRI|"Week 9, 12, 15 and week 18:~* Temozolomide, PO, D1 to D5, 150mg/m²/d~* Irinotecan, IV, D1 to D5, 50mg/m²/d"
40825283|NCT03274427|DEVICE|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
41344429|NCT03011528|DRUG|Consolidation BuMel|"After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~* Busulfan, IV, D-5 to D-2, dosa according to the weight~* Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~- PBSC infusion, D0, at least 3.10\^6 CD34/kg"
41344430|NCT03011528|DRUG|Maintenance|"\* 1st year : VC~* Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~* Cyclophosphamide, PO, 25mg/m² continuously"
41344431|NCT03011528|PROCEDURE|Local treatment by surgery|Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added
41344432|NCT03011528|RADIATION|Local treatment by radiotherapy|Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy
41344433|NCT06302868|BEHAVIORAL|Telemedicine Exposure Therapy Using Photos and Videos|Participants will complete 12 60-minute exposure therapy sessions using photos/videos and progress to in vivo exposures.
41344434|NCT06302868|BEHAVIORAL|Telemedicine-Based Virtual Reality Exposure Therapy|Participants will complete 12 60-minute exposure therapy sessions in a Virtual Reality Clinic using Virtual Reality stimuli and progress to in vivo exposures.
41344435|NCT02415595|DRUG|BMS-955176|HIV Maturation Inhibitor
41344436|NCT02415595|DRUG|EFV|EFV
41489906|NCT01169532|OTHER|laboratory biomarker analysis|Correlative studies
41489907|NCT02731326|DEVICE|AliveCor|"The AliveCor Heart Monitor, an FDA-approved smartphone technology, snaps on to the patient's study smartphone similar to a protective case and works through a free application, AliveECG. It captures a highly sensitive (98%), specific (97%), and accurate (97%) single-lead ECG recording through two electrodes on the back of the patient's smartphone. When the application is opened, recording begins automatically when both electrodes make contact with skin. Transmissions are automatically uploaded to the study patient portal within the AliveCor cloud."
41489908|NCT02731326|BEHAVIORAL|Behavioral Altering Messaging|Behavioral altering messages relating to the participant's AF and underlying cardiac risk factors will be systematically selected from a bank of text messages developed through collaboration by the study team and an expert interdisciplinary panel from the American Heart Association. The content of the text messages will not include PHI. The final text message bank will be housed internally and maintained by the Data Manager and text messages will be pushed automatically from this database. The only identifying link to participants included in this database will be their study-provided phone number
41036528|NCT03298139|OTHER|3 levels of gravity (1G, 1.8G, 0G).|healthy volunteers will experience 3 levels of gravity (1G, 1.8G, 0G).
41036529|NCT04250272|PROCEDURE|Thoracoscopic lobectomy|Thoracoscopic lobectomy was performed for lung cancer
41344437|NCT02415595|DRUG|TDF/FTC|TDF/FTC
41344438|NCT04873843|BEHAVIORAL|Functional digital game training group|Functional digital game training group is divided in 16 participants. In one session, participants in the functional digital game training group completed 40 minutes of intervention using various functional digital game such as working memory, memory, and attention. (Total 10 session)
41344439|NCT04873843|BEHAVIORAL|Individual cognitive training|Functional digital game training group is divided in 16 participants. In one session, participants in the individual cognitive training group completed 40 minutes of intervention using various cognitive training such as working memory, memory, and attention. (Total 10 session)
41344440|NCT05399602|DIAGNOSTIC_TEST|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and CSF sampling (sample 1 in NfL level measurement)
41489909|NCT06299124|DRUG|RGT-419B|RGT-419B will be administered orally
41489910|NCT04982874|DRUG|Furosemide 40 mg|Administered with 240 mL of water
41489911|NCT04982874|DRUG|Lasix® 40 mg Tablet|Administered with 240 mL of water
41489912|NCT01712737|OTHER|Dietary intervention|
41489913|NCT06076850|DEVICE|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Active|"Treatment protocol:~* EFD 0.096 mJ/mm2~* 2 sessions / week; 5000 shocks / session~* 6 weeks treatment~* total: 12 sessions~* Li-ESWT to start after removal of indwelling catheter"
41489914|NCT06076850|DEVICE|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Sham|"Treatment protocol:~* EFD 0 mJ/mm2~* 2 sessions / week; 5000 shocks / session~* 6 weeks treatment~* total: 12 sessions~* Li-ESWT to start after removal of indwelling catheter"
41489915|NCT03320421|RADIATION|Radiation therapy|"Radiation to the whole breast: 43.5 Gy in 15 fractions in 3 weeks. Simultaneous radiation to the surgical cavity: 49.5 Gy in 15 fractions in 3 weeks.~Intensity modulated radiation treatment is used."
41489916|NCT03426566|OTHER|retrospective observational study with no intervention|no intervention
41489917|NCT00105300|DRUG|Adalimumab|
41489918|NCT00003093|BIOLOGICAL|filgrastim|
41489919|NCT00003093|BIOLOGICAL|sargramostim|
41489920|NCT00003093|DRUG|carboplatin|
41489921|NCT00003093|DRUG|cyclophosphamide|
41489922|NCT00003093|DRUG|doxorubicin hydrochloride|
41489923|NCT00003093|DRUG|etoposide|
41489924|NCT00003093|PROCEDURE|conventional surgery|
41489925|NCT00003093|PROCEDURE|neoadjuvant therapy|
41489926|NCT01625130|DIETARY_SUPPLEMENT|Broccoli sprout homogenate|Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
41344441|NCT05399602|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of CSF. It is test of responsivity to ventriculo-peritoneal shunt placement
41344442|NCT05399602|DIAGNOSTIC_TEST|Lumbar infusion test|Diagnostic test accompanying the first lumbar puncture made as i diagnostic test of hydrocephalus. Based on infusion of saline by 90 mL per hour with measurement of CSF pressure each 1 minute and then count of so-called Rout (index).
40825284|NCT03274427|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
40825285|NCT03274427|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
40825286|NCT04510883|BEHAVIORAL|PACO|The intervention is a fully-automated web-based eHealth application in which two embodied conversational agents engage in dialogue with older adults in order to motivate them towards dietary behavior change and decrease loneliness. The application consists of five different modules, each one applying different behavior change techniques.
40825287|NCT04510883|BEHAVIORAL|Waiting list + PACO|Waiting list + PACO
40825288|NCT01456195|DRUG|Placebo|Fasiglifam placebo-matching tablets
40825289|NCT01456195|DRUG|Fasiglifam|Fasiglifam tablets
40825290|NCT04341545|OTHER|Placebos|Placebo 4 tablets a day for one week.
40825291|NCT04341545|DRUG|Letrozole tablets|Letrozole 10mg daily for one week.
40825292|NCT05192629|DRUG|Dexmedetomidine|Premedication by intranasal dexmedetomidine
41036530|NCT04450615|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions, with a total duration of 5 weeks and a frequency of 3 sessions per week.~Dynamic exercises: 2 sets of 10 to 15 repetitions (each side) Isometric exercises: 2 sets of 5 to 15 seconds (each side) Week 1- As mentioned above Week 2- Add 1 set Week 3 - Add 5 seconds and 5 repetitions Week 4 - Add 1 set Week 5- Add 5 seconds and 5 repetitions"
41344443|NCT05399602|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
41344444|NCT05399602|PROCEDURE|General Anesthesia|Standardized combinated general anesthesia with combination of i.v. and inhalated drugs according the protocol. Given by anesthesiologist.
41344445|NCT05399602|PROCEDURE|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of CSF (5 days, 1 month a 2 months after surgery)
40825293|NCT05192629|DRUG|Midazolam|Premedication by intranasal midazolam
40825294|NCT03040869|OTHER||
40825295|NCT05154136|DRUG|Etrumadenant|Capsule
40825296|NCT05154136|DRUG|Itraconazole|Capsule
40825297|NCT04796688|DRUG|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
40825298|NCT03694743|DEVICE|2Shape rotary system|root canal preparation
40825299|NCT02667223|BIOLOGICAL|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
40825300|NCT02667223|BIOLOGICAL|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
40825301|NCT02667223|BIOLOGICAL|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
40825302|NCT02667223|BIOLOGICAL|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
40825303|NCT02667223|BIOLOGICAL|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
40825304|NCT02279849|OTHER|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
40825305|NCT02279849|OTHER|Pricing|The pricing incentives were used to help promote sales of healthier food items.
40825306|NCT02279849|OTHER|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
40825307|NCT01620151|PROCEDURE|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
40825308|NCT05027490|OTHER|CANUT support|CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
40825309|NCT05027490|OTHER|Anthropometric measures|These measures include weight, waist size, hip size and brachial circumference
41344446|NCT05399602|PROCEDURE|Blood sampling #1|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours prior surgery
41344447|NCT05399602|PROCEDURE|Blood sampling #2|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours after surgery
41344448|NCT05399602|PROCEDURE|Blood sampling #3|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 5 days after surgery
41344449|NCT05399602|PROCEDURE|Blood sampling #4 and #5|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
41489927|NCT01625130|DIETARY_SUPPLEMENT|alfalfa sprout homogenate|200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
41489928|NCT01374295|OTHER|video|watch a 3 minute video
41489929|NCT01374295|OTHER|standard education|Receives standard verbal education from healthcare provider
41489930|NCT04136691|OTHER|simulation training|Burn patient scenario was performed with the intervention group.
41489931|NCT03710720|BEHAVIORAL|TIPS app|Psycho-educational electronic application
41489932|NCT03710720|BEHAVIORAL|Trauma Focused-Cognitive Behavioral Therapy|Effective form of trauma therapy for adolescents
41489933|NCT03205930|BIOLOGICAL|Neo-MASCT|The end product of Neo - MASCT technology is DC and CTL cells.DC injection,in each treatment cycle day 8, axillary, inguinal lymph node with subcutaneous injection. CTL cells， in every treatment cycle 21-28 days.
41489934|NCT04625426|DEVICE|3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant|Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant
41489935|NCT04625426|DEVICE|Conveen EasiCleanse and Conveen Critic Barrier|Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream
41489936|NCT04625426|DEVICE|Standard cleansing and Conveen Critic Barrier|Hospital's standard care for IAD management
40825310|NCT05027490|OTHER|Prehension strength measurement|Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
40825311|NCT05027490|BEHAVIORAL|QVA Questionnaire|Food quality of life questionnaire
40825312|NCT05027490|BEHAVIORAL|QLQ C30 Questionnaire|Quality of Life questionnaire Core 30
40853081|NCT01839812|DRUG|Cosyntropin|A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
41344450|NCT02698852|DEVICE|BuMA Supreme|Stent platform: cobalt-chromium alloy
41489937|NCT04540354|DRUG|Optimal Medical Therapy (OMT)|Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.
41489938|NCT04540354|DEVICE|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
41344451|NCT00658866|PROCEDURE|Microdialysis|PK measurements with microdialysis
41344452|NCT03436745|DRUG|Zolpidem|In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach \<50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.
41344453|NCT01886495|OTHER|nutrition intervention|
41344454|NCT06220240|OTHER|Modified Training Programme|Eccentric muscle contractions and 3-minute rest breaks will be used.
41344455|NCT06220240|OTHER|Routine Training Programme|A routine training program will be used.
41489939|NCT05813366|OTHER|Acupuncture|Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.
41489940|NCT05813366|OTHER|Tryptophan-Rich Diet|"All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc.~Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed."
41489941|NCT05813366|OTHER|Vitamin B6 Supplementation|All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.
41344456|NCT00002413|DRUG|Emivirine|
41344457|NCT06507371|RADIATION|node-sparing modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
41344458|NCT06507371|DRUG|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
40825313|NCT05027490|BEHAVIORAL|Scratch & Snif Test|The Scratch \& Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
41344459|NCT06507371|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
41344460|NCT06507371|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
41344461|NCT06507371|RADIATION|standard short-course radiotherapy|radiation targeting the tumor bed and surrounding tumor-draining lymph nodes: 25Gy/5Fx
40825314|NCT05027490|BEHAVIORAL|Taste Strip Test|The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
40825315|NCT05027490|BEHAVIORAL|24 H feed back questionnaire|This questionnaire describes patient's food and drink intakes during the last 24 ours
41344462|NCT03073200|DRUG|Ixekizumab|Administered SC
40825316|NCT05027490|BEHAVIORAL|Condiment questionnaire|This questionnaire used to assess condiments consumption
40825317|NCT05027490|BEHAVIORAL|Tobacco questionnaire|This questionnaire used to assess tobacco consumption
40825318|NCT05027490|OTHER|Nutrition interview|This interview will be conducted by a dietician
40825319|NCT00747669|DRUG|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
40825320|NCT05489653|BEHAVIORAL|mixed music|Learn about the effects of listening to music and doing activities with it on sleep.
40825321|NCT04833153|BEHAVIORAL|Person-First - Please (PFP)|PFP takes 10 weeks and consist of four modules: Information, Person, Autonomy and Dignity. Information module takes 1 hour contact on first week. The other modules will follow every third weeks, starting from week 2. So that on week 2, 5 and 8 researcher meet nurses in 4 hours education session. Between the modules, nurses can take contact online to the researcher.
41344463|NCT03073200|DRUG|Placebo|Administered SC
41344464|NCT03073200|DRUG|Etanercept|Administered SC
41344465|NCT01935674|DRUG|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
41344466|NCT01935674|DRUG|Continue Ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
41344467|NCT02663245|OTHER|Intervention 1|"* Diabetes specific consultation~* Basic training in clinical guidelines~* Platform of communication for professionals~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.~* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
41489942|NCT02212002|DRUG|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
41489943|NCT05975736|BEHAVIORAL|Search only for masses|Participants search the simulated mammogram for simulated masses.
41489944|NCT05975736|BEHAVIORAL|Search only for calcifications|Participants search the simulated mammogram for simulated calcifications.
41489945|NCT05975736|BEHAVIORAL|Search for both together|Search the simulated mammogram for both simulated masses and simulated calcifications at the same time.
41489946|NCT05975736|BEHAVIORAL|Search for one after the other|Search the simulated mammogram for first for simulated masses and then for simulated calcifications sequentially (or vice versa).
41489947|NCT06309927|PROCEDURE|Operative hysteroscopy (by tissue removal device)|Surgical evacuation of the uterine cavity using the Truclear Mini-Elite hysteroscopic tissue removal device
41489948|NCT06309927|PROCEDURE|Suction curettage|Surgical evacuation of the uterine cavity with electrical vacuum suction curette
41489949|NCT00482183|DRUG|Pioglitazone|
40825322|NCT03739645|BEHAVIORAL|Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety|After fear conditioning the cue induces autonomic responses like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after cueing or conditioning. Activity across blocks in the conditioning stage shows that the skin conductance can be described by levels, and slopes which might be related to state anxiety and trait anxiety (Spielberger trait and state anxiety inventory or questionnaire). These skin conductance measures may be concrete metrics for psychological processes in healthy subjects. We will carry out a partial correlation analysis of levels, state anxiety and trait anxiety, and then a similar analysis of slopes, state anxiety and trait anxiety. These results may show that concrete skin conductance levels and slopes are related to metrics of subjective self report measures of state and trait anxiety.
40825323|NCT01820403|OTHER|portion size kcal of box lunch|
40825324|NCT04958044|DRUG|Calcium Gluconate|Calcium electroporation
40825325|NCT00741195|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
40825326|NCT00741195|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
40825327|NCT06606639|DIETARY_SUPPLEMENT|Caffeine|acute caffeine intake (3 mg/kg)
41344468|NCT02663245|OTHER|Intervention 2|"* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.~* Basic training in clinical guidelines.~* Platform of communication for professionals.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
41344469|NCT03367611|DIAGNOSTIC_TEST|Immunochemical faecal occult blood test (iFOBT)|All participants in the study will collect a single faecal sample for haemoglobin measurement.
41489950|NCT02643017|DRUG|Dexmedetomidine|Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
40825328|NCT06606639|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
40825329|NCT00900679|BEHAVIORAL|telephone-based intervention|
40825330|NCT00900679|OTHER|counseling intervention|
40825331|NCT00900679|OTHER|educational intervention|
40825332|NCT00900679|OTHER|medical chart review|
40825333|NCT00900679|OTHER|questionnaire administration|
40825334|NCT00900679|PROCEDURE|psychosocial assessment and care|
40825335|NCT00900679|PROCEDURE|quality-of-life assessment|
40825336|NCT01897753|DRUG|growth hormone|36 months
40853082|NCT01712425|BIOLOGICAL|0-24 week prime/boost regimen|ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
40853083|NCT01712425|BIOLOGICAL|0-8 week prime/boost regimen|ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
41489951|NCT02643017|DRUG|normal saline|Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
41489952|NCT02440568|DRUG|Cytarabine|Cytarabine (100mg/m\^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
41489953|NCT02440568|DRUG|Idarubicin|Idarubicin (12 mg/m\^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.
40825337|NCT04270162|DEVICE|Respiratory muscle training 1|"For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups."
40825338|NCT04270162|OTHER|Respiratory muscle training 2|"Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups."
40825339|NCT04270162|OTHER|Respiratory muscle training 3|The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
40825340|NCT05570994|DRUG|177Lu HTK03170|Subjects will receive 177Lu HTK03170 treatment over 5 cycles, each cycle occurs every 8 weeks.
40825341|NCT05570994|DRUG|68Ga-HTK03149|68Ga-HTK03149 PET/CT imaging; intravenous during screening
40825342|NCT00849706|OTHER|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
40825343|NCT02104271|PROCEDURE|Argon Plasma Coagulation|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
40825344|NCT02104271|PROCEDURE|Historical control|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
41489954|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 0.625mg/m\^2
41489955|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 1.25mg/m\^2
41489956|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 2.0mg/m\^2
41489957|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 3.0mg/m\^2
41489958|NCT03362918|BEHAVIORAL|High Intensity Interval Training|"The exercise prescription is as follows:~Type: High-Intensity Interval Training on a treadmill, elliptical trainer or cycle ergometer.~Intensity: 30 seconds of high-intensity alternating with 90 seconds of low intensity for a total of 10 cycles~* High intensity for most individuals will occur at approximately 90% of maximum heart rate. Using the rating of perceived exertion scale, participants should be exercising at a 9/10, which is very difficult to maintain the intensity and results in only being able to speak a few words at a time.~* Low intensity is defined as light activity and rated as 2-3/10 on the rating of perceived exertion scale. Participants should be able to carry on a conversation and maintain the pace for hours.~Duration: 30 minutes Frequency: 3 times per week"
40825345|NCT04237038|PROCEDURE|laparoscopic Nissen fundoplication short gastric vessel division|Randomized clinical trial conducted in forty patients submitted to SGVD and forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life. A randomized clinical trial was conducted with 87 patients submitted to laparoscopic Nissen fundoplication between February 2013 to december 2014 according to the guidelines established by the Mexican Consensus for the study of Gastroesophageal reflux disease (GERD
40825346|NCT03359057|DRUG|ethinyl estradiol + levonorgestrel + folic acid|One coated tablet of ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days in 3 cycles (12 weeks).
40825347|NCT03359057|DRUG|Folic Acid|One coated tablet of folic acid 0.4 mg for 7 days in 3 cycles (12 weeks).
41344470|NCT03409575|OTHER|5 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 5 minutes of NMES will be made in 4 sets. Fifteen contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
41344471|NCT03409575|OTHER|10 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 10 minutes of NMES will be made in 2 sets. Thirty contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
41344472|NCT01203124|DRUG|AZD8848|The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
41344473|NCT01203124|DRUG|Placebo|Placebo
41344474|NCT01961999|PROCEDURE|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output \<0,5ml/Kg/h for \> 6 hours"
41344475|NCT01961999|PROCEDURE|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (\<0,5ml/Kg/h \>12h), despite therapy refractory extravascular fluid overload azotemia \>40mmol/L or 240mg/dL metabolic acidosis (pH\<7,2) hyperkaliemia (k+\>6mmol/L)"
41344476|NCT04120480|DIAGNOSTIC_TEST|Pharmacogenomic test|The RightMed test is an end-to-end solution which includes sample collection, PGx testing services, data analysis, and clinical interpretation that helps prescribers select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on FDA medication labels. The RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1) Green - use as directed; 2) Yellow - use with caution; and 3) Red - adjust dose or choose alternative mediation.
41344477|NCT00600249|DRUG|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
40825348|NCT00869245|OTHER|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
40825349|NCT00869245|OTHER|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
40825350|NCT03690739|DRUG|Carboplatin|Administration according to investigator's discretion
41489959|NCT03362918|BEHAVIORAL|Continuous Aerobic Exercise Training|"The exercise prescription for the continuous aerobic exercise group is as follows:~Type: Aerobic exercise including walking, running, cycling or using the elliptical trainer.~Intensity: Moderate intensity, defined as 50-60% of the participant's maximum heart rate. On the rating of perceived exertion scale, this corresponds with a 4-6/10, which allows participants to hold a conversation while breathing heavily.~Duration: 50 minutes Frequency: 3 times per week"
41489960|NCT04238832|OTHER|Salt Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home salt base nicotine
40825351|NCT03690739|DRUG|Gemcitabine|Administration according to investigator's discretion
41489961|NCT04238832|OTHER|Free Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home free base nicotine
40825352|NCT03690739|DRUG|Bevacizumab|Administration according to investigator's discretion
40825353|NCT03690739|DRUG|PLD|Administration according to investigator's discretion
41344478|NCT00600249|DRUG|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
41489962|NCT00041249|DRUG|brostallicin|
40825354|NCT03690739|DRUG|Paclitaxel|Administration according to investigator's discretion
40825355|NCT03690739|DRUG|PLD|Administration 30 mg/m² q21
40825356|NCT03690739|DRUG|Trabectedin|Administration 1.1 mg/m² q21
40825357|NCT03690739|DRUG|Cisplatin|Administration according to investigator's discretion
40825358|NCT06605521|PROCEDURE|Subclavian lymph node dissection+radiotherapy|The patient grouping is determined jointly by the researchers and participants, and patients in Group A are selected for supraclavicular lymph node dissection and radiotherapy.
40825359|NCT06605521|PROCEDURE|Simple clavicular region radiotherapy|If the patient chooses Group B treatment plan, they will receive simple clavicle area radiotherapy.
41344479|NCT06446895|DIAGNOSTIC_TEST|Coronariography|Patients were classified as MICAD or MINOCA by the presence or absence of an epicardial vessel with ≥50% stenosis after performing a coronariography.
41344480|NCT03856749|OTHER|Remote wheelchair skills training|"Prior to the first training session, the trainer will be provided with the results from the assessment immediately preceding training to provide him/her time to individualize the training session. Trainer will provide self-study materials (the Caregiver Handbook and caregiver-training video-recording) and an explanation on how these materials should be used.~The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual using remote technology. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last up to 60 minutes at intervals a minimum of 3 days."
41344481|NCT02109744|DRUG|Decitabine|
41344482|NCT05810376|BEHAVIORAL|Digital-based physical activity intervention|The digital behavioral program comprises goal planning, motivational messages and video calls, social support, and routine follow-up of weekly goals.
41344483|NCT05810376|OTHER|Patient education and exercise|Patient education will include information on osteoarthritis, prognosis, pain management, importance of physical activity and exercise. The exercise program will include warm up, stretching and strengthening.
41344484|NCT04197206|OTHER|costotransverse block|patient controlled analgesia devices with tramadol
41344485|NCT00658450|BEHAVIORAL|Cognitive rehabilitation training|"A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.~Children will complete these tasks in 16 session for 8 weeks."
41344486|NCT04067011|DRUG|Ciprofloxacin 500Mg Tablet|Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.
41344487|NCT04067011|DRUG|Doxycycline 100Mg Tablet|Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
41344488|NCT04067011|BIOLOGICAL|AV7909|0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.
40825360|NCT01758224|OTHER|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
40825361|NCT01758224|OTHER|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
40825362|NCT04829474|OTHER|Survey|It is a survey that the patient and doctor must complete.
40825363|NCT03676543|PROCEDURE|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
40825364|NCT04075968|OTHER|Cognitive exercise|Cognitive exercise will be applied
41157320|NCT06646497|BIOLOGICAL|Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow|"1. Conditioning regimen Thymoglobulin (0.5/mg/kg à D-9, 2 mg /kg at D-8 and 2.5 mg/kg à D-7), Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant, Cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day -1).~2. Stem cell source Bone Marrow only. Target of 4 × 10\^8 nucleated cells/kg recipient body weight. Granulocyte colony stimulating factor is given subcutaneously starting on day +5 at 5 mg/ kg/day until the absolute neutrophil count is greater than 1.5 × 10\^9/L for 3 days.~3. GVHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4. Tacrolimus (0,2 à 0,3 mg/kg/day per os divided into 2 doses or 0.05 to 0.1 mg/kg/d IVSE) and mycophenolate (MMF) will begin from D+5. In absence of GvHD, MMF will be stopped between D35 and D45 and Tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT (except patients and their donor with EBV serology and EBV PCR negative)."
41489963|NCT00238706|DEVICE|Radiofrequency ablation|
41489964|NCT05000086|DRUG|99Tc methylene diphosphonate|22mg qd，Once a day for 7 consecutive days
41489965|NCT01138865|DEVICE|AutoSet Spirit--Wash--Modified-AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
41489966|NCT01138865|DEVICE|Modified-AutoSet Spirit--Wash-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
41489967|NCT00050323|DRUG|Allogeneic DCs and Autologous RCC Tumor Derived Cells|
41489968|NCT05226598|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations
41489969|NCT05226598|DRUG|Carboplatin|Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
41489970|NCT05226598|DRUG|Cisplatin|Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
41489971|NCT05226598|DRUG|Paclitaxel|Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
41489972|NCT05226598|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
41489973|NCT05226598|DRUG|Pemetrexed|Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
41489974|NCT05226598|BIOLOGICAL|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations
41489975|NCT01303705|DRUG|Anti-OX40|Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
40825365|NCT04075968|OTHER|Home exercise|Home exercise will be applied
41489976|NCT01303705|RADIATION|Radiation|8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment. Imaging such as bone scan, MRI, CT scan, or radiograph must identify the target lesion as consistent with metastatic disease. Any bone lesion that is inducing pain or where there may be a clinical concern for potential pathological fracture will be selected over asymptomatic lesions.
40825366|NCT05922072|PROCEDURE|Nasogastric aspiration for measurement of Residual Gastric Volume|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.
40825367|NCT05922072|PROCEDURE|Nasogastric Aspiration for Measurement of Gastric pH|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
41489977|NCT01303705|DRUG|Cyclophosphamide|CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.
41489978|NCT01157559|DRUG|Ziprasidone|8 week prospective study
41489979|NCT02001831|DIETARY_SUPPLEMENT|Supplement|
41489980|NCT02001831|DIETARY_SUPPLEMENT|Placebo|
40825368|NCT04358705|OTHER|Aim 1: Online survey|"This survey will evaluate perceptions of flavors on appeal, purchasing and risk perceptions of cigarillo products among young adult and adolescent cigarillo users. This survey will be used to inform survey design for further aims.~As a proxy for biological verification of tobacco use status, data on brand, frequency, and pricing will be collected to confirm user status~Participants will rate the role of flavor and report perceptions of product appeal, health risk, advertising exposure and use intentions. Participants will also complete purchase and substitution tasks."
40825369|NCT04358705|BEHAVIORAL|Eye Tracking Activity|The eye tracking activity consists of a single in-person eye tracking activity that will take place in a private office in Columbus, Ohio where the participant will be seated in a chair within a typical viewing distance from a computer monitor equipped with an infrared camera on the monitor to capture precise eye movements. Participants will have their gaze monitored continuously by the camera on the computer monitor while a randomized set of stimuli (e.g., tobacco product images) are viewed (n=30) for 10 seconds per image. Following each image, an on-screen closed response question will re-center the participant's gaze for standardization prior to the next image.
41344489|NCT01528436|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
40825370|NCT04358705|OTHER|Eye tracking survey|Other Names: Participants will complete a survey using Qualtrics immediately after the eye tracking activity and one week following completion of the activity via email to measure recall of brand name, product flavors, perceptions of cigarillo harm, and tobacco use behaviors and intentions.
40825371|NCT04358705|BEHAVIORAL|Online Experimental Marketplace (ETM)|"Administered online via Qualtrics~Participants are given an account balance for use during their assigned ETM based on their average weekly tobacco use calculated from previous interview. Participants will view all four price conditions and all four flavor conditions in random order for a total of 16 rounds~Cigarillo price conditions: 1) market price 2) ½ market price 3) 2X market price 4) 4X market price~Flavor condition: 1) flavored cigarillos and fruit-flavored disposable-cigarettes available 2) unflavored cigarillos and fruit-flavored ecigarettes available 3) flavored cigarillos and tobacco-flavored e-cigarettes available 4) unflavored cigarillos and tobacco-flavored e-cigarettes available.~Participants will purchase cigarillos with their account balance. During all ETM conditions, constant-priced alternative tobacco products (smokeless tobacco, nicotine lozenges, nicotine gum, and the nicotine patch) will be available in addition to the cigarillos and e-cigarettes."
40825372|NCT04358705|OTHER|Aim 3 survey|"Consists of:~* A screener and demographic data collection.~* A tobacco product withdrawal scale~* Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~* The tobacco product withdrawal scale again~* Measurements of nicotine dependence and flavor preferences"
40825373|NCT04358705|OTHER|Cognitive Interviews|Cognitive Interviews will be done in-person, using Zoom, or over the phone. Interviews will be video or audio recorded. . The participant will be given a select section of the survey questions from Aim 1. The survey will be uploaded to Qualtrics to reflect the way that survey would be conducted in Aim 1. With the survey questions in front of the participant on the computer screen, research personnel will ask probing questions about each one of the survey questions. If the participant is not able to participate in person or via Zoom, they will be allowed to be interview over the phone with access to the Qualtrics survey or a paper form. If the participant is unable to access the internet, the participant will be read the questions by research personnel. The participant will provide feedback about the questions and walk the research personnel through their thought process for approaching each survey question.
40825374|NCT04358705|OTHER|Supplemental Aim 1 Interviews|Participants from the preceding online survey (who identify as women from Aim 1/supplemental aim 1 survey) who agreed to be contacted for future study will be emailed an invitation to the eligibility screener. Individuals interested will complete a screener to ensure participants identify as women and to verify that they have ever used cigarillos. Eligible participants will be contacted to schedule a 60- to 90-minute Zoom interview about their tobacco, nicotine, and cannabis product use experiences, with particular focus on flavored cigarillo usage initiation, current use, and responses to potential flavor restrictions.
41157321|NCT01022671|DRUG|Belotecan|3.0 mg/m2, Day 1, 8, 15 every 4 weeks
41344490|NCT01528436|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
41344491|NCT01528436|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
41344492|NCT03710694|DEVICE|DAV132|"DAV132:~* Dosage: 15 g/day activated charcoal (22.5 g/day DAV132)~* Route: Oral~* Duration: duration of fluoroquinolone treatment + 2 days~DAV132 is regulated as a medical device in Europe and as a drug in the United States of America."
41344493|NCT00868361|DRUG|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
41344494|NCT00307814|DRUG|Epoetin Alfa|
41344495|NCT00801710|DEVICE|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|"Revascularization of coronary artery chronic total occlusion.~Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant"
41344496|NCT02635867|PROCEDURE|Indirect Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
41344497|NCT02635867|PROCEDURE|Indirect Pulp capping-Calcium hydroxide - Dycal|Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
41344498|NCT02635867|PROCEDURE|Indirect Pulp capping-Resin-based dentin bonding agent|Use of a dental restorative protocol using resin-based dentin bonding system only
41344499|NCT02635867|PROCEDURE|Direct Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
40825375|NCT04726033|DRUG|64Cu-DOTA-TLX592|TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)
40825376|NCT04860934|BEHAVIORAL|Dual Task Training Program Group|Fifteen patients will receive Dual Task Training Program. Total Period: 8 Weeks.
40825377|NCT04860934|BEHAVIORAL|Control Group|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
41344500|NCT02635867|PROCEDURE|Direct Pulp capping-Calcium hydroxide - Dycal|\\Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
41489981|NCT06464432|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR); Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD) consisting of 4 therapeutic modules: 1. Emotion Regulation, 2, Self-concept, 3. Relationship Patterns, 4. Prolonged Exposure.
40825378|NCT02001415|OTHER|Spectacles|Normal spectacle lenses were used to correct myopia as the control group.
40825379|NCT02001415|OTHER|Myovision|Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
40825380|NCT02001415|OTHER|Orthokeratology|Orthokeratology lenses.
41489982|NCT03281863|DIAGNOSTIC_TEST|C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate|Throat culture to detect the causative organism
41344501|NCT03949127|OTHER|Exercise Group|The group who will meet a physiotherapist who will show them strengthening and stretching muscles associated with pelvic tilt.
41344502|NCT02996110|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
41344503|NCT02996110|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
41344504|NCT02996110|BIOLOGICAL|Relatlimab|Specified Dose on Specified Days
41489983|NCT00940797|DRUG|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
41489984|NCT00940797|DRUG|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
41489985|NCT03727659|BEHAVIORAL|SHADE therapy + CONNECT FaceBook support|"See study arms description."
41489986|NCT04289597|DIAGNOSTIC_TEST|Distance between hyoid bone-skin (DSHB)|Distance between hyoid bone-skin
41489987|NCT04289597|DIAGNOSTIC_TEST|Vocal cord anterior commissura-skin distance (DSAC)|Vocal cord anterior commissura-skin distance
41489988|NCT04289597|DIAGNOSTIC_TEST|minimum distance of the trachea to the skin at the level of suprasternal notch|Distance of the trachea to the skin at the level of suprasternal notch
41489989|NCT04289597|DIAGNOSTIC_TEST|Thyroid isthmus-skin distance (DSI)|Thyroid isthmus-skin distance
41489990|NCT04289597|DIAGNOSTIC_TEST|Skin-epiglottic distance (DSE)|Skin-epiglottic distance
41489991|NCT03804502|DEVICE|TearCare|The TearCare System warms the eyelids to melt the meibum by applying heat to the external surface of the eyelids for 15 minutes. Following completion of the thermal portion of the procedure, the clinician performs manual expression of each of the eyelids.
41489992|NCT02715934|OTHER|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
41489993|NCT02715934|OTHER|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
41489994|NCT05940753|OTHER|Survey about travel willingness regarding cancer treatment and follow-up|No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.
41489995|NCT03420664|DEVICE|Orthosis VACOped|Orthosis for lower limb immobilisation
41489996|NCT03420664|DEVICE|Below knee cast|Below knee cast for lower limb immobilisation
41036531|NCT05289804|DEVICE|NITESGON|"NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain."
41157322|NCT01399684|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m\^2) intravenous (IV) bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
41344505|NCT02996110|DRUG|BMS-986205|Specified Dose on Specified Days
41344506|NCT02996110|DRUG|BMS-813160|Specified Dose on Specified Days
41344507|NCT03712995|PROCEDURE|'Cutler-Beard modified with graft'|A tarsoconjunctival graft was harvested from the contralateral upper eyelid, with an extra 3 mm of conjunctiva from the superior edge of tarsus and was attached to the upper eyelid defect, differently than previously described.
41344508|NCT02289521|DEVICE|Transcranial Direct Current Stimulation|"We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~* Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~* Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation)."
41344509|NCT06237673|DIAGNOSTIC_TEST|CT|CT-directed clinical management strategy
41344510|NCT06237673|DIAGNOSTIC_TEST|invasive coronary angiography (ICA)|Standard clinical management directed by conventional invasive coronary angiography (ICA).
41489997|NCT03035721|DIETARY_SUPPLEMENT|Low protein formula|Infants were enrolled to receive low protein formula (energy: 65 kcal/100 mL, protein: 1.2 g/100 mL, protein-to-energy ratio:1.9 g/100 kcal, carbohydrates: 8 g/100 mL, fat: 3.1 g/100 mL) for the firsts 4 months of life.
41489998|NCT03035721|DIETARY_SUPPLEMENT|Standard protein formula|Infants were enrolled to receive standard protein formula (energy: 68 kcal/100 mL, protein: 1.7 g/100 mL, protein-to-energy ratio:2.5 g/100 kcal, carbohydrates: 7.1 g/100 mL, fat: 3.5 g/100 mL) for the firsts 4 months of life.
41489999|NCT04967963|PROCEDURE|HAM|Transplantation of HAM
41018655|NCT03465696|BEHAVIORAL|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~1. Stelara® acts in an almost all-natural way to help control psoriasis.~2. Stelara® blocks one of the genetic causes of psoriasis.~3. Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~4. Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
41490000|NCT03564444|BIOLOGICAL|Bivalent influenza vaccine|A single dose of bivalent vaccine (10\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.
41490001|NCT03564444|OTHER|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
41490002|NCT00212121|RADIATION|high dose boost|high dose boost
41490003|NCT00212121|PROCEDURE|boost|low dose versus high dose
41490004|NCT03531190|DIETARY_SUPPLEMENT|Nutritional supplement (Protein + MIX)|Protein supplement as needed + 750 mg vitamin C, 15 g. arginine, 35 mg. zinc and two multivitamin tablets, by mouth every day for 35 days.
41490005|NCT03531190|DIETARY_SUPPLEMENT|Nutritional supplement (Protein)|Protein supplement as needed
41490006|NCT04915014|PROCEDURE|sleeve gastrectomy with transit bipartition (SG +TB)|In case of a first intention procedure, a typical sleeve gastrectomy is performed, calibrated on a 36 French bougie, stapling starting 4 to 6 cm from the pylorus. Antecolic gastroileal anastomosis is performed 250 cm from the ileocecal transition, on the antrum using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 120 cm from the ileocecal junction. Thus, alimentary limb is 130cm and common limb 120cm.
41490007|NCT04915014|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|A small gastric pouch (30 cc) is performed. Antecolic gastroileal anastomosis is performed 200 cm from the Treitz junction, using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 50 cm from the Treitz junction. Thus, alimentary limb is 150cm and biliary limb 50cm.
41490008|NCT00093600|DRUG|cytarabine|
41490009|NCT00093600|DRUG|daunorubicin hydrochloride|
41490010|NCT00093600|DRUG|midostaurin|
41490011|NCT05472662|DRUG|Placebo 152a|Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant
41490012|NCT05472662|DRUG|Placebo 134a|Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant
41490013|NCT05504590|DEVICE|Tuohy needle group|Ultrasound-guided caudal epidural block with Touhy needle
41490014|NCT05504590|DEVICE|Quincke needle group|Ultrasound-guided caudal epidural block with Quincke needle
41490015|NCT05061576|BEHAVIORAL|Standard of Care advice on physical activity|Oral advice on exercise from a physician.
41344511|NCT04124224|OTHER|Unidos|The investigators will collaborate with our community partners to implement and evaluate a Community-Clinical Linkage (CCL) model in which Community Health Workers (CHWs) connect individuals to social determinant and community health services and build sociocultural resilience through CHW-facilitated individual and group support. As a public health practice-based study that incorporates evidence-based strategies, the investigators seek to establish Unidos effectiveness in Arizona counties with the highest percentage of Latinos of Mexican origin (Yuma, Pima, Santa Cruz, and Maricopa). Unidos CHWs, based in local health departments, will use evidence-based strategies to address three elements that are important in addressing chronic disease risk: 1) health promotion resources and programs; 2) individual and group-based social support; and 3) leveraging community resources to address social determinants of health.
40825381|NCT03627559|PROCEDURE|Pancreaticoduodenectomy microdialysis catheter analyses|A thin microdialysis catheter is implanted before skin closure after pancreaticoduodenectomy. Analyses of the microdialysate are done at certain timepoints postoperatively. No intervention is done based on the results. The patients are following standard of care.
40825382|NCT00097162|PROCEDURE|Anodal stimulation|
40825383|NCT06389734|BEHAVIORAL|Manual soft tissue release|"The manual soft tissue release includes muscle energy techniques and passive stretching, targeting the anterior scalene, upper trapezius, pectoralis major, pectoralis minor, and diaphragm.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
40825384|NCT06389734|BEHAVIORAL|Myofascial release|"The myofascial release includes suboccipital muscle, anterior chest wall myofascial, and anterior neck myofascial.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
40825385|NCT06389734|BEHAVIORAL|Exercise training|The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.
40825386|NCT05477173|BEHAVIORAL|The Strengths and Difficulties Questionnaire (SDQ) Parent Version Parent : It consists of 25 questionnaires used to screen for behavioral problems in children aged 4-17 years.|screen by using psychometric scales
40825387|NCT01633203|DRUG|epirubicin + cisplatin + capecitabine polychemotherapy|"EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~* Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~* Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~* Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea."
40825388|NCT03887520|DIAGNOSTIC_TEST|Blood draw for Lp(a)|Collect sample for Lipoprotein(a) testing
40825389|NCT01463930|BEHAVIORAL|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
40825390|NCT01463930|BEHAVIORAL|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
40825391|NCT06604416|OTHER|Forward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate forward walking.
40825392|NCT06604416|OTHER|Backward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate backward walking.
40825393|NCT06149117|DRUG|"test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®"|Take one capsule orally every cycle(T or R)
40825394|NCT05479435|BEHAVIORAL|Blue Prescription Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. It will be followed up with the blue prescription program once a week for 12 weeks and will be re-evaluated at the end of the 12th week. Motivation and support will be provided according to the blue prescription philosophy, home exercise program, physical activity selection, obstacles to the activity are discussed, the participant will be asked to determine the appropriate program and keep an activity diary. Throughout the study, the participant will be able to communicate with the physiotherapist by any method (phone, SMS, email).
40825395|NCT05479435|BEHAVIORAL|Video Based Home Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.
40825396|NCT05479435|BEHAVIORAL|Supervised Group Exercise Program|DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Exercises will be done with a physiotherapist for 12 weeks 3 days a week and will be evaluated again at the end of the 12th week.
40825397|NCT02635139|BEHAVIORAL|Breakfast skipping|18h fasting period in the morning
40825398|NCT02635139|BEHAVIORAL|Dinner skipping|18h fasting period in the evening
40825399|NCT03442257|BEHAVIORAL|SMS|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. Participants will receive four semi-personalized messages per week in addition to their usual care. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
41018656|NCT01164046|DRUG|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
41344512|NCT05844657|OTHER|Case report form|Sociodemographic information (age, gender, height, body mass index, marital status, occupation, education level, contact information), frequency of smoking and alcohol use, frequency of caffeine consumption, frequency of salt consumption, dominant side, background, family history, medical and audiological information were recorded.
41344513|NCT05844657|OTHER|Tinnitus disability scale|Tinnitus disability scale was used to evaluate the tinnitus severity of Meniere's patients. It consists of 25 items in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Tinnitus level or severity is determined by calculating the total score of the answers given.
41344514|NCT05844657|OTHER|A feeling of fullness and/or pressure in the ear|The feeling of fullness or pressure in the ear was evaluated verbally by receiving yes/no responses from the participants.
41344515|NCT05844657|OTHER|Dizziness intensity and frequency|In order to determine the frequency and severity of dizziness, the participants were asked to mark the appropriate score between 1-10 points.
41344516|NCT05844657|OTHER|Dizziness disability inventory|The dizziness disability inventory was used to determine the disability level of the individuals participating in our study. It consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'.
41344517|NCT05844657|OTHER|Vertigo symptom scale-short form|The short form of the vertigo symptom scale was used to determine the frequency and duration of vertigo in the individuals participating in our study. The vertigo symptom scale consisting of 8 questions consists of vertigo (VSS-V), and the vertigo symptom scale consisting of 7 questions consists of two subsections consisting of a total of 15 questions: anxiety (VSS-A). Each item; Never (0), Very rarely (1 point), Often (2 points), Often - every week (3 points), Very often - On average, at least twice a week (4 points). The total score ranges from 0 to 60.
41344518|NCT05844657|OTHER|Hearing Impairment Scale|The Adult Hearing Impairment Scale was used to determine the effect of the current hearing impairment levels of the individuals participating in our study on their daily living activities. The scale consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Participants mark the most appropriate expression for them.
40825400|NCT01245881|DEVICE|Non-ablative fractional photothermolysis laser|"* Wavelength: 1,550 nm;~* Energy: 15 mJ/MTZ;~* Total coverage: 20%;~* Total density: 1,048 MTZs/cm2;~* Density per pass: 131 MTZ/cm2;~* Number of passes: 8."
40825401|NCT01245881|OTHER|broad-spectrum sunblock (SPF 50+)|
40825402|NCT03535662|DRUG|Orvepitant|Single oral dose
40825403|NCT03535662|DRUG|Itraconazole|Once daily dosing for 10 days
40825404|NCT06411886|DIAGNOSTIC_TEST|Allergen challenge|Inhaled allergen
40825405|NCT06411886|DIAGNOSTIC_TEST|Saline challenge|Inhaled saline
41018657|NCT01164046|DRUG|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
41344519|NCT05844657|OTHER|Cervical Range of Motion (CROM 3) device|"Cervical Range of Motion (CROM) device was used to evaluate the sense of proprioception and range of motion (ROM) in the cervical region muscles. A total of six positions were performed: right cervical rotation, left cervical rotation, right cervical lateral flexion, left cervical lateral flexion, cervical extension and cervical flexion."
41344520|NCT05844657|OTHER|Temporomandibular joint range of motion assessment|In our study, the temporamandibular joint range of motion (ROM) was evaluated with a ruler specific to each participant in four positions, including mandibular depression, protraction, and right and left lateral deviation.
41344521|NCT05844657|OTHER|Posture evaluation with New York posture analysis|The New York Posture Evaluation method was used to obtain information about the general posture correctness of the participants. Posture changes that may occur in 13 different parts of the body, 7 from the side and 6 from the back, including the head, neck, shoulder, back, waist, hip and ankle, were examined in the anatomical position of the individuals. As a result of the observation, the posture of the individual was scored according to whether it was severely bad (1 point), moderately bad (3 points), and straight (5 points). The total score obtained varies between 13-65.
41490016|NCT05061576|BEHAVIORAL|Structured advice on physical activity|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
41490017|NCT01031459|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|Telephone survey of all patients.
40825406|NCT06305936|OTHER|Intervention with 100% plant-based diet|The intervention consists of three key components: 1) Educational materials (videos), 2) Participation in a cooking workshop introducing plant-based meals, complete with recipes, and 3) Daily delivery of plant-based dinner meals over a four-week period. The remaining meals during the period are modified by the participant to also adhere to a 100% plant-based composition.
40825407|NCT03252093|DRUG|Angiotensin-(1-7)|Subcutaneous injection of 200 mcg/kg/day
40825408|NCT03252093|DRUG|Placebo for Angiotensin-(1-7)|Subcutaneous injection of Placebo
40825409|NCT06287593|OTHER|ctDNA monitoring|Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.
40825410|NCT02208453|DEVICE|InSpace Implantation|InSpace device Implantation
40825411|NCT00378625|DRUG|Artesunate|
40825412|NCT05343130|DEVICE|Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation activated by the brain-computer interface based on hand movement intention.
40825413|NCT05343130|DEVICE|Sham Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation which activation will be independent of the brain-computer interface based on hand movement intention.
40825414|NCT03095027|DEVICE|FID122819 contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
40825415|NCT03095027|DEVICE|Stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
41018658|NCT06419049|DEVICE|Altimate Medical EasyStand Bantam|Child will stand in stander 5 days per week for 60 min during each 8 wks intervention
41018659|NCT01313234|BEHAVIORAL|Education|Theory based education and systematic daily assessment
41344522|NCT05844657|OTHER|Evaluation of the anterior tilt angle of the head|Anterior tilt angles of the head of the participants were evaluated with photographs taken from the lateral (lateral) side. The anterior tilt angle was calculated as the angle between the line drawn between the C7 cervical spinous process and the tragus and the straight line drawn vertically from C7.
40825416|NCT01654159|PROCEDURE|Monofocal IOL|Monofocal Intraocular lens will be implanted
40825417|NCT01654159|PROCEDURE|Multifocal IOL|Multifocal IOL will be implanted
41344523|NCT05844657|OTHER|Evaluation of postural balance with the Freemed pressure platform|Postural sway and lower extremity weight transfer were evaluated with the Freemed baropodometric pressure platform (Rome, Italy) system, which has been shown to be valid and reliable.
41344524|NCT05844657|OTHER|Static balance assessment with tandem stance test|In our study, the tandem stance test was used for static evaluation. A total of four assessments were made on the participants, first with their right foot in front, eyes open and eyes closed, then left foot in front with eyes open and eyes closed.
41344525|NCT05844657|OTHER|Dynamic balance assessment with tandem gait test|In our study, the tandem gait test was used for dynamic evaluation. A straight line was created with a white tape attached to the floor, almost 2 feet away from the 10-foot-long wall. The participant was asked to walk along the line created by taping the heel of the forward foot to touch the toe of the back foot, at a comfortable pace in daily life and with eyes open.
41344526|NCT05844657|OTHER|Headache, Temporomandibular pain and Craniocervical pain presence and severity assessment|Headache, temporomandibular pain and craniocervical pain were asked to mark the person from the photographs taken from the front, back and side in the form of a human figure. Pain severity was evaluated with the numerical rating scale (NRS).
41344527|NCT05844657|OTHER|Pain sensitivity assessment in the head, neck, shoulder girdle and upper back region|In our study, muscle tenderness was evaluated by manual pressure algometry and palpation. Muscle tenderness was assessed in the upper and lower regions of the masseter, temporalis, sternocleidomastoid, and upper trapezius muscles on both right and left sides.
41490018|NCT02176408|BEHAVIORAL|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
40825418|NCT01654159|PROCEDURE|Toric IOL|Toric IOLS will be implanted
40825419|NCT05411523|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
41018660|NCT04513600|DIAGNOSTIC_TEST|Cardiac MRI|Lab work: Hs- Troponin, Serum N-terminal-proBNP CMR: Native T1, Native T2, extracellular volume, strain and strain rate.
41018661|NCT02791633|OTHER|Questionnaire|Quality of recovery and quality of recovery follow up questionnaires
41344528|NCT05844657|OTHER|International physical activity questionnaire-measurement of physical activity level with short|The short form of the international physical activity questionnaire was used to determine the physical activity level of the individuals participating in our study. The short form of the international physical activity questionnaire evaluates the last week and consists of a total of 4 sections and 7 questions. Duration of physical activity that requires intense physical effort, such as heavy lifting, soccer, or fast cycling; times of doing moderate physical activities that cause breathing slightly more often than usual; The total duration of walks at work, home, for sports, exercise and hobby, and the total sitting time spent in a day at work, at home or while resting are calculated.
41344529|NCT05844657|OTHER|Evaluation of sleep quality with the Pittsburgh sleep quality index|The Pittsburgh Sleep Quality Index (PUKI) was used to evaluate the sleep quality and disturbance of the individuals participating in our study in the last month. It consists of a total of 24 questions. The participant responds to each item according to the frequency between 0-3 points. The total score (0-21 points) from these components indicates whether the sleep quality is good or not.
41490019|NCT02176408|BEHAVIORAL|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
41490020|NCT02176408|BEHAVIORAL|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
41490021|NCT02834650|OTHER|Cardiac MRI with contrast|Cardiac MRI
40825420|NCT05411523|OTHER|Questionnaire Administration|Complete questionnaires
40825421|NCT05411523|PROCEDURE|Spinal Cord Stimulation|Receive spinal cord stimulation therapy
40825422|NCT04634539|DRUG|Gemcitabine|Gemcitabine will be administered at 600, 800, or 1000 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Gemcitabine will be administered immediately after the infusion of nab-paclitaxel. Pre-medication with may be administered per institutional standard practice at the investigator's discretion with gemcitabine.
40825423|NCT04634539|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 75, 100, or 125 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Nab-paclitaxel will be given first, before infusion of gemcitabine. Pre-medication for nab-paclitaxel may be administered per institutional standard practice at investigator's discretion.
41036532|NCT05289804|DRUG|Lidocaine / Prilocaine Topical Cream|A topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential.
41036533|NCT05289804|DEVICE|C5/C6 stimulation|The electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location.
40825424|NCT04634539|DRUG|L-glutamine|The dose levels of L-glutamine in this study will be 0.1, 0.2, and 0.3 g/kg oral twice daily (rounded to nearest 5 g with an upper limit of 15 g twice daily (30 g/day) for any dose level) taken at the same time each day during the treatment period. L-glutamine will be administered for 1 week (+/-1 day) prior to addition of gemcitabine/nab-paclitaxel. Each dose of L-glutamine should be mixed immediately before ingestion with 8 oz. (240 mL) of a cold or room temperature beverage, such as water, milk or apple juice, or 4 oz. (120 mL) to 6 oz. (177 mL) of food such as applesauce or yogurt. L-glutamine is formulated in 5 gram packets as a white crystalline powder in paper-foil-plastic laminate. Complete dissolution is not required prior to administration.
40825425|NCT05199376|DEVICE|Cryotherapy|The cryotherapy treatment lasts approximately 30 minutes during which two 10-minute freezing cycles are performed, separated by a reheating phase. During the freezing phases, the temperature is lowered below -40°C in the ablation zone, a temperature that is lethal for the cells.
40825426|NCT04963530|PROCEDURE|Treatment with monolithic zirconia restorations|Treatment with monolithic zirconia restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
40825427|NCT04963530|PROCEDURE|Treatment with lithium disilicate restorations|Treatment with lithium disilicate restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
40825428|NCT04963530|PROCEDURE|Treatment with metal ceramic restorations|Treatment with metal ceramic restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
41018662|NCT05322317|OTHER|ADVANCE-PC training via ECHO|To assess the feasibility of using a technology-based platform to deliver the ADVANCE-PC program to multiple primary care clinics. This model will be based on the ECHO program, a tele-mentoring program which uses communications technology to provide facilitated education, case review, and peer-to-peer problem solving remotely. Our working hypothesis is that the use of ECHO will be efficient (allowing several clinicians and teams to be supported simultaneously while creating a community of practice), feasible (that clinicians will enroll and share experiences via mentoring, guidance, feedback, and didactic education), and have the potential to impact patients as clinicians perceptions shift to favor ACP, their skills increase, and they are able to integrate ACP for patients with dementia into their clinic.
41018663|NCT02841644|PROCEDURE|Operatively treated traumatic arthrotomy|operatively treated traumatic arthrotomy.
41490022|NCT02834650|OTHER|Cardiac MRI without contrast|Cardiac MRI
41490023|NCT02834650|OTHER|Blood Test|Hematocrit, Creatinine, Troponin, BNP
41490024|NCT02834650|OTHER|Heart Rate|Holter Monitor
41490025|NCT02834650|OTHER|Pulmonary Function Test|Pulmonary Function Test
41490026|NCT02834650|OTHER|Genetic Testing|Genetic Testing
41490027|NCT02834650|OTHER|Repeat MRI scan|Repeat MRI scan
41490028|NCT05494645|DRUG|Exparel|Liposomal bupivicaine
41490029|NCT05494645|DRUG|Peripheral Nerve Block|Peripheral nerve block without Exparel
41490030|NCT03516214|DRUG|EGF816|Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
41490031|NCT03516214|DRUG|Trametinib|Continuous oral treatment (once daily) with the MEK inhibitor trametinib.
41490032|NCT05430984|PROCEDURE|Laparoscopic TAPP inguinal hernia repair|"Isolation of preperitoneal space will be accomplished to guarantee the mesh flattening with the medial border at the pubic symphysis, the lateral border at the psoas major and anterior superior iliac spine, superior border at least 3 cm above the conjoined tendon, medial inferior border 3 cm below the pectineal ligament, and lateral inferior border to permit perietalization of the spermatic cord (6-8 cm isolation of the hernia sac and spermatic cord).~For the mesh fixation group, the mesh will be fixed to the abdominal wall using suture, spiral tacks, whereas for the non-fixation group it will be left as it is and the operation will be concluded. A mesh measuring 15x10cm is placed in the preperitoneal space and fixed using limited numbers of tacks or suture. In some cases, based on body habitus, a slightly smaller mesh could be used. The peritoneum will be closed over the mesh."
41490033|NCT05215769|BEHAVIORAL|Health Education|Participate in a video intervention
41490034|NCT05215769|OTHER|Questionnaire Administration|Complete questionnaires
41490035|NCT06353711|BEHAVIORAL|CA-LINC Intervention|Participants received the CA-LINC intervention.
41490036|NCT06353711|BEHAVIORAL|Treatment as Usual|Participants received Treatment as Usual
41490037|NCT01190943|OTHER|Laboratory Biomarker Analysis|Correlative studies
41490038|NCT03324932|DRUG|Denosumab Injection|AI intake + denosumab injection per 6 months VS only AI intake
41490039|NCT03778658|BEHAVIORAL|Physical Activity Intervention|Participants will engage in a multimodal aerobic and strength training intervention.
41490040|NCT05145686|DIAGNOSTIC_TEST|Matris metalloproteinase -2, -8, -9 expressions|. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.
41490041|NCT06032962|PROCEDURE|salpingectomy|surgical removal of the fallopian tubes
41490042|NCT00485628|DRUG|Atomoxetine Hydrochloride|
41490043|NCT03802253|BEHAVIORAL|Time Restricted Feeding(TRF)|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm) in the first 6 months. 6 months later, Participants will receive a diet of 1200-1500kcal/d without a restriction of feeding time.
41490044|NCT03802253|BEHAVIORAL|Reduced Calorie Diet (RCD)|Participants will receive a diet of 1200-1500kcal/d and keep their usual eating pattern.
41490045|NCT05754307|PROCEDURE|Access Flap|Intrasulcular incisions at the teeth adjacent to the defect, using the simplified papilla preservation technique (SPPT) or modified papilla preservation technique (MPPT). Granulation tissue is excised and debridement via hand and power-driven instruments follows. Flaps are repositioned and papilla are sutured with horizontal internal mattress doubled by a single interrupted interdental suture.
40825429|NCT04963530|PROCEDURE|No intervention|No intervention.
40825430|NCT03651856|DRUG|ATM FOG in PD|open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
40825431|NCT02976480|PROCEDURE|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
41490046|NCT05754307|PROCEDURE|Closed Surgical Technique|"Strictly intrasulcular incisions are performed at the teeth adjacent to the defect (mid-buccal to mid-lingual) without incising the interdental papilla. Full thickness gingival flaps, at the base of the papilla, which is retained intact, are elevated in a closed-tunneling manner, granting access to the interdental osseous defect. Debridement is performed via power-driven tips and mini curettes, without intentionally excising the granulation tissue that lines the osseous defect. Flaps are repositioned by gentle pressure and suturing is not required."
40825432|NCT02976480|PROCEDURE|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
40825433|NCT03171246|DIETARY_SUPPLEMENT|Solid food-based intervention|Individually tailored energy content according to age/activity
40825434|NCT03764917|OTHER|Time|Different detecting time
40825435|NCT04943458|OTHER|Monitoring of cerebral autoregulation|Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.
40825436|NCT02088502|DRUG|N-acetylcysteine|
40825437|NCT02088502|DRUG|Theophylline|
41036534|NCT05289804|DEVICE|Sham NITESGON|Sham NITESGON
41490047|NCT02196701|DRUG|Adalimumab|Administered by subcutaneous injection every other week.
41036535|NCT04647851|OTHER|Remote exercise intervention Down syndrome|See arm description
41036536|NCT02040402|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|Pneumococcal vaccine 3+1 and 2+1 schedule comparison
41036537|NCT02040402|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|3+1 doses vs 2+1 doses
41344530|NCT05844657|OTHER|Evaluation of fatigue with the fatigue severity scale|The Fatigue severity scale was used to evaluate the fatigue status of the individuals participating in our study. The scale uses a scoring system ranging from 1-7, which starts as I do not agree (1 point) and increases gradually towards I agree (7 point). It consists of 9 items in total and people mark the option that suits them.
41344531|NCT05844657|OTHER|Evaluation of anxiety-depression status with hospital anxiety and depression scale|The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the anxiety and depression status of the individuals participating in our study. For each item, the participant answers with a four-point (0-3 points) response option. Therefore, the possible score probabilities in line with the answers given are minimum '0' and maximum '21'. The cut-off point for the anxiety subscale is 10 points, while the cut-off point for the depression subscale is 7 points.
41344532|NCT05844657|OTHER|Evaluation of quality of life with short form-12 (SF-12)|The Short form SF-12 Questionnaire was used to evaluate the quality of life of the individuals participating in our study. The summary score of the physical and mental components varies between 0-100, and the higher the score in the components, the better the quality of life.
41344533|NCT05844657|OTHER|the International Fall Efficiency Scale|The International Fall Activity Scale (UDES) was used to evaluate both the attack and the general fear of falling of the individuals participating in our study. It consists of 16 questions in total. The answer to each question is marked on a scale between 1 and 4 points. Expressions such as I never worry (1 point), I worry a little (2 point), I am very worried (3 point), I am very worried (4 point) are used as the level of anxiety increases as the score increases. The total score obtained ranges from 16 (no worries) to 64 (extremely worried).
41344534|NCT05844657|OTHER|assessment of muscle performance|In our study, the strength of cervical flexors, anterior and oblique trunk flexors, cervical extensor muscles, back extensor muscles, trapezius muscle, and rhomboid major-minor muscles were evaluated. In addition, the endurance of the deep cervical flexor muscles, cervical flexors and cervical extensor muscles were also evaluated.
41344535|NCT00995605|DRUG|AMAP102|AMAP102 or Placebo
41344536|NCT04023344|DRUG|Humalog Mix25|Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
41344537|NCT04023344|DRUG|Insulin Lispro Biphasic 25|"Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses"
41344538|NCT04985513|PROCEDURE|Ventilation during cardiopulmonary bypass|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
41344539|NCT03634228|DRUG|Cytarabine|Given SC
41344540|NCT03634228|DRUG|Milademetan Tosylate|Given PO
41344541|NCT03634228|DRUG|Venetoclax|Given PO
41344542|NCT01542294|DRUG|s1|60-90mg/m2/d P.O. day 1-14, repeated every 21 days
41344543|NCT01542294|DRUG|Oxaliplatin|130mg/m2 d1 repeated every 21 days
41344544|NCT02279160|DRUG|APD811|
41344545|NCT02279160|DRUG|Placebo|Placebo
41344546|NCT00242710|DRUG|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
41344547|NCT00242710|DRUG|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
41344548|NCT00242710|DRUG|CE 0.45 mg/MPA 1.5mg|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
41344549|NCT00242710|OTHER|Placebo|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
41344550|NCT01155791|DRUG|Docetaxel|IV 75 mg/m2
41344551|NCT01155791|DRUG|Biosyn|IV dosage varies
41344552|NCT01155791|DRUG|Prednisone|5mg, orally
41344553|NCT00268476|DRUG|Celecoxib|
41344554|NCT00268476|DRUG|Docetaxel|
41344555|NCT00268476|DRUG|Prednisolone|
41344556|NCT00268476|DRUG|ADT|
41344557|NCT00268476|DRUG|Zoledronic Acid|
41344558|NCT00268476|DRUG|Abiraterone|
41344559|NCT00268476|RADIATION|Radiotherapy to the prostate|
40825438|NCT02088502|DRUG|0.9% sodium chloride|All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
40825439|NCT00940095|DRUG|Clazosentan 5 m/h|Continuous intravenous infusion of clazosentan (5 mg/h)
41018664|NCT02841644|OTHER|Non-operatively treated traumatic arthrotomy|non-operatively treated traumatic arthrotomy.
41036538|NCT03259633|DRUG|Selumetinib|open-label, single-arm, multicenter intermediate access protocol
41344560|NCT00268476|DRUG|Enzalutamide|
41344561|NCT00268476|DRUG|Metformin|
41344562|NCT00268476|DRUG|Transdermal Oestradiol|
41344563|NCT02422563|PROCEDURE|hysterectomy|radical hysterectomy
41344564|NCT02422563|RADIATION|Radiation|
41344565|NCT02422563|DRUG|Cisplatin|
41344566|NCT02422563|DRUG|Paclitaxel|
41344567|NCT02422563|DRUG|Carboplatin|
41344568|NCT02422563|DRUG|Ifosfamide|
41344569|NCT00713557|DEVICE|drug-eluting stent|drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
41344570|NCT00713557|DRUG|Tirofiban|upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
41344571|NCT02382770|PROCEDURE|Open abdomen procedure|Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
41344572|NCT04847739|PROCEDURE|Seton Placement|This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.
41344573|NCT04847739|DRUG|AVB-114|AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.
41344574|NCT03411434|DRUG|Methylphenidate Oral Tablet|cf arm group description
41344575|NCT01300000|OTHER|Human Milk|ad lib
41344576|NCT01300000|OTHER|Investigational infant formula|ad lib
41344577|NCT01300000|OTHER|Milk based standard infant formula|ad lib
40825440|NCT00940095|DRUG|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)
40825441|NCT00940095|DRUG|Placebo|Continuous intravenous infusion of placebo-matching clazosentan
40825442|NCT00912080|GENETIC|genomic signature|genomic signature analysis
40825443|NCT04052438|DIAGNOSTIC_TEST|HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.|
41344578|NCT05734014|BEHAVIORAL|Healthy Relationship|The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.
41344579|NCT06195046|DEVICE|Baroreflex Activation Therapy (BAT)|activation of BAROSTIM NEO system that affects autonomic modulation with BAT therapy.
40825444|NCT00741494|DEVICE|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
40825445|NCT01299857|DRUG|Rituximab|375mg/m2
40825446|NCT03553498|DRUG|IV acetaminophen|acetaminophen given intravenously
41344580|NCT05928624|DEVICE|Withings Home Blood Pressure Device and Scale|The intervention will be whether the data generated from home monitoring devices are shared with the clinical providers. The investigators are not testing the efficacy of these approved devices.
41490048|NCT02196701|DRUG|Methotrexate|Methotrexate was provided as 2.5 mg tablets for oral administration.
40825447|NCT03553498|DRUG|IV placebo|given intravenously
40825448|NCT03553498|DRUG|hydromorphone|hydromorphone given intravenously
40825449|NCT05743075|DRUG|Ensifentrine|A dual PDE3/PDE 4 inhibitor
40825450|NCT05743075|DRUG|Placebo|Placebo solution
40825451|NCT05144880|OTHER|electroacupuncture|A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
41018665|NCT06086535|PROCEDURE|Intercostal nerve cryoanalgesia vs BRILMA blockade|For BRILMA block, 0.4 ml/kg of 0.3% ropivacaine will be injected and a catheter will be placed on the 4th intercostal space after surgery. For intercostal nerve cryoanalgesia an external cryogenizer system will be used during surgery
41018666|NCT01723891|DRUG|Surfolase capsule|
41018667|NCT01723891|DRUG|HT-002-01|
41344581|NCT05928624|OTHER|Standard of Care|Standard of Care
41344582|NCT01637857|DIETARY_SUPPLEMENT|sham oligoantigenic diet associated to lifestyle instruction|sham oligoantigenic diet associated to lifestyle instruction
41344583|NCT01637857|DIETARY_SUPPLEMENT|oligoantigenic diet|oligoantigenic diet associated to life style counseling
41490049|NCT03216018|BEHAVIORAL|"Prevention program: In Favor of Resilient Self"|"Prevention program: In Favor of Resilient Self"
41018668|NCT00273364|PROCEDURE|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
41157323|NCT01399684|DRUG|Bevacizumab|Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
41018669|NCT00273364|DRUG|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
41018670|NCT02002897|DEVICE|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
41018671|NCT02002897|DEVICE|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
41018672|NCT02070159|DRUG|Clopidogrel 600 mg|Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
41157324|NCT01399684|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
41344584|NCT03512275|DRUG|Bermekimab Monoclonal Antibody 400 mg|subcutaneous injection
41344585|NCT01983683|DRUG|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
41490050|NCT06311162|BEHAVIORAL|Life-Style app|The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
41018673|NCT02070159|DRUG|Prasugrel 30 mg|Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.
40825452|NCT06605131|DRUG|GP+Toripalimab+CCRT|"1. Induction Chemotherapy (GP Regimen combined with Toripalimab):~1. GP Regimen Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Toripalimab: For patients weighing ≥ 40 kg: 240 mg on Day 1; For patients weighing less than 40 kg: 3 mg/kg; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
40825453|NCT06605131|DRUG|GP+CCRT|"1. Induction Chemotherapy (GP Regimen ): Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
40825454|NCT02969590|DRUG|Leuprolide acetate|Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.
40825455|NCT02969590|DRUG|Estrogen and Progesterone Replacement|Replace hormones exogenously to create an artificial cycle
40825456|NCT02969590|DRUG|Progestin|Synthetic progestin to assess effects on cervical mucus.
40825457|NCT01727115|OTHER|Infant Formula Feeding|"Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~* If the challenge is positive: The children continue the assigned formula~* If the challenge is negative: A Follow up formula is given~  * (Nan pro2) if child \> 6 months~ * (Nan pro1) if child \< 6 months"
41018674|NCT02070159|DRUG|Prasugrel 60 mg|Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
40825458|NCT04607941|OTHER|Questionnaires|Self-administered questionnaires
41490051|NCT06311162|OTHER|Sham Comparator|The parents get a flyer with information on second-hand smoke exposure and references to smoking cessation programs, and do not have an active app during the main intervention period.
40825459|NCT04607941|OTHER|Phone interviews|A small amount of subjects will be selected at random for phone interviews.
40825460|NCT05939856|OTHER|Lymph node dissection before bladder resection|Lymph node dissection before bladder resection
40825461|NCT05939856|OTHER|Lymph node dissection after bladder resection|Lymph node dissection after bladder resection
40825462|NCT00599404|DRUG|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
40825463|NCT02928029|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
40825464|NCT02928029|DRUG|Placebo|Matching placebo
40825465|NCT02928029|DRUG|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
41018675|NCT06527287|OTHER|Neurocognitive Ankle Training for Instablity to Optimize Neuromusculoskeletal outcomes (NATION)|The NATION rehabilitation protocol will serve as the true intervention group. NATION is a 6-week evidence-based chronic ankle instability (CAI) rehabilitation protocol that incorporates neurocognitive exercises. Participants will complete up to 18 unsupervised home sessions and up to 12 supervised sessions. Treatment volume and exercises may vary based on participant progress and study team member guidance.
41157325|NCT01399684|DRUG|MEGF0444A|Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
41157326|NCT01399684|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.
40825466|NCT02928029|DRUG|Dexamethasone|Dexamethasone is administered orally at 40 mg
40825467|NCT01579825|OTHER|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
41157327|NCT01399684|DRUG|Placebo|Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
41344586|NCT01983683|DRUG|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily
41490052|NCT02910674|DEVICE|Dario Blood Glucose Monitoring System|Accuracy with usability assessment
41490053|NCT00587600|PROCEDURE|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
40825468|NCT03065101|DEVICE|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
41157328|NCT05852496|DRUG|Vitamin D|vitamin D supplement in cancer patients which receive taxane drugs with vit D deficiency and complaining from Peripheral neuropathy.
41157329|NCT01425541|DRUG|estrace|0.5-1 mg once a day PO for 7 days
41490054|NCT00587600|PROCEDURE|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
41490055|NCT04336124|DRUG|CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)|"Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles.~Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing.~A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day.~If 2 or more patients experience a DLT, no further dose escalation will occur."
41490056|NCT05760586|DRUG|Tovorafenib|Oral RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL)
41157330|NCT01425541|DRUG|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
41157331|NCT04868981|DRUG|GST-HG141 tablets|Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
41490057|NCT04302558|BEHAVIORAL|Exercise Blood Flow Restriction training|While exercising, an Inflatable cuff, similar to a blood pressure cuff, is applied to the proximal aspect of the femur of the affected lower extremity inflated to occlude blood flow
41490058|NCT04302558|BEHAVIORAL|SHAM Exercise Blood Flow Restriction training|While exercising Inflatable cuff, similar to a blood pressure cuff, applied to the proximal aspect of the femur of the affected lower extremity with limited inflation pressure to not occlude blood flow
41344587|NCT01983683|DRUG|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
41344588|NCT01983683|DRUG|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
41490059|NCT00376311|DRUG|oral salmon calcitonin|
41490060|NCT03073785|DRUG|Capecitabine|Given PO
41490061|NCT03073785|DRUG|Fluorouracil|Given IV
41490062|NCT03073785|OTHER|Laboratory Biomarker Analysis|Correlative studies
41490063|NCT03073785|OTHER|Pharmacological Study|Correlative studies
41490064|NCT03073785|RADIATION|Stereotactic Body Radiation Therapy|Undergo hypofractionated stereotactic radiotherapy
41490065|NCT03073785|DRUG|Zoledronic Acid|Given IV
41490066|NCT01078337|PROCEDURE|bone marrow aspiration|
41490067|NCT01078337|PROCEDURE|peripheral blood sampling|
40825469|NCT03065101|OTHER|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
40825470|NCT03065101|DEVICE|Sliding Hip Screw|Sliding Hip Screw
40825471|NCT02635347|PROCEDURE|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
40825472|NCT02635347|DEVICE|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
40825473|NCT03305419|DRUG|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
40825474|NCT03305419|DRUG|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
41157332|NCT04868981|DRUG|Matching Placebos for GST-HG141 tablets|Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
40825475|NCT01868620|DEVICE|Iontophoretic CXL|
40825476|NCT01868620|DEVICE|Standard CXL|
40825477|NCT03264105|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
40825478|NCT03264105|OTHER|conventional resin-based flowable composite|retention rate evaluation of conventional resin-based flowable composite
41344589|NCT05859867|OTHER|Promotion of Healthy Nutrition and Physical Activity|Through scheduled and specific activities, enrolled subjects receive information for the promotion of the Mediterranean diet and Mediterranean lifestyle habits, according to the pyramid of the Mediterranean diet. In addition, subjects receive general recommendations about the promotion of regular recreational motor activity, the pyramid of physical activity for pediatric age, and free games appropriate to age. These activities are conducted by professionals in the food (nutritionists) and sports sectors and are aimed in the preparation of simple recipes repeatable at home, and in motor play activities to encourage physical activity. Information regarding clinical, and socio-demographic parameters and family habits will be collected through validated questionnaires.
40825479|NCT04294316|DIAGNOSTIC_TEST|Sonovue|Twice dose of 2.4ml of Sulphur hexafluoride microbubbles contrast Sonovue administration to evaluate brain microcirculation
40825480|NCT06389682|DRUG|68Ga-NYM005 injection|he radiation dose is about 2-7 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM005 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
40825481|NCT00463983|DRUG|octreotide|
40825482|NCT00195000|DRUG|Mylotarg|6 mg/m2 on day 1
40825483|NCT00195000|DRUG|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
40825484|NCT01342965|DRUG|Erlotinib|Erlotinib was supplied as tablets.
40825485|NCT01342965|DRUG|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
40825486|NCT01488292|BEHAVIORAL|RECAP social skills and reading program|weekly individual and group sessions
41344590|NCT01833390|DRUG|HXe MRI lung ventilation|MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
41344591|NCT04851327|BEHAVIORAL|High Energy preload|Tests the extent to which participants reduce their intake at a meal following ingestion of a high energy preload drink
41344592|NCT04851327|BEHAVIORAL|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
41344593|NCT04851327|BEHAVIORAL|Test meal|Test meal to follow low or high energy preload
41344594|NCT05195424|DIAGNOSTIC_TEST|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care
41344595|NCT06435494|OTHER|Systematic use of patient reported outcome measures in clinical work with the patients|Se description of the arms
41344596|NCT02338856|DRUG|MB12066 200mg|100mg bid (multiple dose, day 8)
40825487|NCT00378911|DRUG|sunitinib malate|Given orally
40825488|NCT04863248|DRUG|Trilaciclib|Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
41344597|NCT02338856|DRUG|Placebo|100mg bid (multiple dose, day 8)
40825489|NCT04863248|DRUG|Placebo|Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
40825490|NCT04863248|DRUG|Docetaxel|Docetaxel administered IV on Day 1 of each 21-day cycle.
40825491|NCT00858260|GENETIC|blood sample|Searching for Klotho variants in DNA
40825492|NCT02362945|DRUG|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
40825493|NCT00527683|DRUG|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
40825494|NCT00527683|DRUG|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
40825495|NCT00527683|BEHAVIORAL|Group therapy|Participants attend group sessions once a week
40825496|NCT05568914|DEVICE|Indirect Calorimetry|Indirect Calorimetry (Q-NRG Metabolic Monitor, COSMED) is performed to determine the Resting Energy Expenditure before hemodialysis.
41344598|NCT00255008|BIOLOGICAL|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
41344599|NCT00255008|DRUG|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
41344600|NCT00255008|BIOLOGICAL|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
41344601|NCT00255008|DRUG|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
41344602|NCT05723874|DRUG|BI 425809|BI 425809
41344603|NCT05723874|DRUG|bosentan|bosentan
41344604|NCT06149741|PROCEDURE|Defunctioning left-sided loop colostomy|Descending or left transverse double-barrelled loop colostomy in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision, and anastomosis.
41344605|NCT06254846|OTHER|Urine sample, 1st stream|Use of the Colli-Pee® device for collecting the first urine stream
41344606|NCT06254846|OTHER|Cervico-vaginal swab|"Use of a gold standard reference method = HPV PCR using the Anyplex® II HPV HR kit (Seegene) carried out on a cervico-vaginal swab in ThinPrep® medium (liquid medium medium into which the cervico-vaginal swab is discharged)."
41344607|NCT05354869|DEVICE|Urostym|electric pelvic floor muscle stimulator
41344608|NCT05354869|BEHAVIORAL|Standard care|patient education on home exercises and stretching
41344609|NCT01528618|DRUG|gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
40825497|NCT05568914|DEVICE|Bio-electrical Impedance Analysis (BIA)|Bio-electrical Impedance Analysis (BIA101/BIVA, Akern) is used to analyse the body composition (Fat Mass, Fat Free Mass, Phase Angle).
40825498|NCT05568914|OTHER|Nutritional assessments|The Nutritional assessments consist of a dietary anamnesis and a 3-day nutritional diary to determine the nutritional (caloric and protein) intake of the participants.
40825499|NCT01125969|BEHAVIORAL|Incentives|Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).
40825500|NCT01125969|BEHAVIORAL|Education|Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
40825501|NCT01125969|BEHAVIORAL|Peer mentoring|Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
41344610|NCT01528618|DRUG|5-Fluorouracil and cisplatin|The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
41344611|NCT01329172|OTHER|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 1 gram per day during two months
41344612|NCT01329172|OTHER|placebo|sun flower oil with Poly Unsaturated Fatty Acid 1g/day
41344613|NCT01661725|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|60 subjects were divided into three groups (20 subjects each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
41344614|NCT04112745|OTHER|Static magnet|Static magnet with 2,000 Gauss
41344615|NCT04112745|OTHER|Placebo|Polyvinyl chloride resin material black jewelry
41344616|NCT06030076|DRUG|Tildrakizumab|As provided in real-world clinical practice.
41344617|NCT01318928|DRUG|Metronidazol|metronidazol. 400mg x 3 per day for 10 days
41344618|NCT06168968|BEHAVIORAL|Life and Medication Recommendations|Based on obtained subjective and objective data from patient-filled questionnaire and laboratory testing respectively, lifestyle and medication recommendations will be provided for secondary prevention of cardiovascular and cerebrovascular diseases
40825502|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
40825503|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
40825504|NCT02880514|DEVICE|PROPEL Mini Sinus Implant|Sinus implant with 370 mcg of mometasone furoate released over 30 days
41018676|NCT06527287|OTHER|Evidence-Based|The Evidence-Based rehabilitation protocol will serve as the active comparator group. The Evidence-Based protocol will be similar to the intervention (i.e., NATION protocol), but the exercises will exclude the neurocognitive tasks. Participants assigned to the Evidence-Based protocol will complete up to 18 unsupervised home sessions and up to 12 supervised sessions over the course of 6-weeks. Treatment volume and exercises may vary based on participant progress.
41018677|NCT05004922|OTHER|Embryo transfer into upper cavity|Transfer of embryos in upper cavity
41018678|NCT05004922|OTHER|Embryo transfer into midcavity|Transfer of embryos in mid cavity
40825505|NCT02880514|PROCEDURE|Balloon Sinus Dilation Alone|
41018679|NCT04327934|DRUG|GnRH antagonist|GnRH antagonist up to 16 days.
41018680|NCT04327934|DRUG|GnRH antagonist + MethylTESTOSTERone 5 MG|GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
41018681|NCT02270060|OTHER|Music Therapy|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
41018682|NCT02270060|OTHER|Music Listening|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
41018683|NCT01767792|DRUG|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
41165783|NCT05422339|DEVICE|The MapHabit system|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
41490068|NCT05197218|DIETARY_SUPPLEMENT|Prebiotic|Combination of a polyphenol rich extract of chokeberry (Aronia melanocarpa) and a polyphenol rich extract of cranberry (Vaccinium macrocarpon Aiton) will be administered for 18 days.
41490069|NCT02180126|OTHER|Follow-up|Follow-up of of patients with borderline positive ANCA test results
40825506|NCT05154617|DIAGNOSTIC_TEST|Standard surgical monitoring, along with the Flo Trac® system monitoring.|Under standard thoracic anesthesia protocol, extra monitoring will be done by FloTrac® System using a minimally invasive sensor in combination with an advanced monitoring device to derive cardiac output (CO) and cardiac index (CI) parameters through arterial pulse pressure waveform analysis. Intraoperative blood gases collection will be at different intraoperative times. From this data, calculations will be performed to obtain DO2, DO2i, O2ER, and O2ERi.
40825507|NCT04006990|BEHAVIORAL|Provision of recliner chairs and encouragement to get out of bed|Provision of recliner chairs and encouragement to get out of bed
40825508|NCT00314717|BEHAVIORAL|Control diet|
41344619|NCT01666015|OTHER|EXERCISE (EX)|"This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.~The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games)."
41344620|NCT01666015|OTHER|Standard Care|This group will be under standard care without any EX intervention.
41344621|NCT05888532|DRUG|Copper-64 labeled Granzyme B (64Cu-GRIP B)|Given IV prior to imaging
41344622|NCT05888532|PROCEDURE|Positron Emission Tomography (PET)|Imaging procedure
41344623|NCT03868475|PROCEDURE|Vacuum-assisted percutaneous excision|The intervention group will undergo the vacuum assisted percutaneous excision (VAPE). All VAPE procedures will be performed on a digital supine table using the ATEC© Breast Biopsy System hand piece (Hologic) with a 9-gauge needle and a 10 or 20 mm aperture providing 6-mmHg of suction strength to completely excise the breast lesion.
40825509|NCT00314717|BEHAVIORAL|Low GI diet|
41344624|NCT03868475|PROCEDURE|Open surgical excision|The control group will undergo standard open surgical excision of the breast lesion. This will be done in the operating room using preoperative image-guided localization with radioactive seed (I-125) or in the procedure room of the Breast Care Centre if appropriate (i.e. lesion is palpable and localization is not required).
41344625|NCT00392951|DRUG|sirolimus|Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
41490070|NCT03291353|DRUG|pembrolizumab|200 mg IV given every three weeks
40825510|NCT03776773|OTHER|Pollution exposure|Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
40825511|NCT03419377|OTHER|Standard care and sexological counseling|6-8 sexological consultants in a period of six months
40825512|NCT00273754|DRUG|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
40825513|NCT00273754|DRUG|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
41036539|NCT05997043|DRUG|oral anti-Parkinson drugs and injection of botulinum toxin|The experimental group was treated with oral anti-Parkinson drugs and injection of botulinum toxin
41036540|NCT05997043|DRUG|oral anti-Parkinson's drugs|The control group only took oral anti-Parkinson's drugs.
41036541|NCT06507293|PROCEDURE|Paravertebral block|Before the general anesthesia induction, paravertebral block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
41344626|NCT01576224|DEVICE|"Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark"|To be removed during training exercises three to five times a day
41490071|NCT03606876|DRUG|BAT1806 injection|Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
41490072|NCT04870138|DRUG|Azithromycin|Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.
41490073|NCT04870138|DRUG|Ceftriaxone|Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.
40825514|NCT05699252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention will be used to help participants learn about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.
40825515|NCT05699252|BEHAVIORAL|Hypnotic Cognitive Therapy (HYP-CT)|The HYP-CT intervention will be used to help participants learn about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.
40825516|NCT05699252|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will be used to help participants learn about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.
40825517|NCT06235762|BEHAVIORAL|Nutritional Intervention|This clinical trial evaluate the effects of nutritional intervention (individualized and personalized for each patient) on anthropometric, biochemical and cardiovascular parameters in participants with type 2 diabetes mellitus
40825518|NCT03829943|DIAGNOSTIC_TEST|Vitamin D|Blood will be drawn for Vitamin D level
41344627|NCT02625467|PROCEDURE|Penetrating keratoplasty|Conventional Penetrating keratoplasty technique
41344628|NCT02625467|PROCEDURE|Pachymetry and Excimer laser assisted lamellar keratoplasty|Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
41344629|NCT02625467|DRUG|Treatment posterior to surgery|Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
41344630|NCT06423001|DIETARY_SUPPLEMENT|PostbiotiX Slowing 4 g sachets PostbiotiX Slowing is a food supplement based on Fermented FOS from Lactobacillus paracasei CNCM I-5220.|Each patient will be supplied with the investigational product at Visit 0, PostibiotiX Slowing and at visit 3, based on the outcome of the randomization at V0 (Sequence AB, PostbiotiX Slowing/Placebo; Sequence BA, Placebo/PostbiotiX Slowing).
41344631|NCT05405569|OTHER|CPR Arms Angle 90º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.
41344632|NCT05405569|OTHER|CPR Arms Angle 60º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.
41344633|NCT03304912|BEHAVIORAL|PrEP Education and option to accept a PrEP prescription|Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
41344634|NCT05263011|OTHER|Avocado|1 avocado as evening snack
41344635|NCT05263011|OTHER|low fat yogurt|1 serving of low fat yogurt matching calories of 1 avocado
41344636|NCT05263011|OTHER|low fat yogurt + fiber +fat|low fat yogurt mixed with ultra processed olive oil + fiber supplement, equivalent to fat and fiber content in 1 avocado
41344637|NCT04348188|BEHAVIORAL|Education program on healthy habits|6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
41344638|NCT02650440|PROCEDURE|Novel Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
41344639|NCT02650440|PROCEDURE|Standard Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
41344640|NCT04944758|DEVICE|Light therapy|Light therapy
41344641|NCT04922710|BEHAVIORAL|Home-based aerobic exercise|Guidelines for exercise programming (ACSM, 2018) will be followed including a warmup and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise for 60 minutes per day, three times a week, for 12 weeks. Participants who are unable to do a 60-minute session would instead complete it in two 30-minute sessions. The prescribed intensity will be based on estimated heart rate reserve, calculated using resting heart rate and age-adjusted heart rate maximum (220-age in years). Participants will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
41344642|NCT02419586|OTHER|bubble gum|Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
41344643|NCT05759481|DRUG|Propofol|Propofol is administered starting at surgery induction and ending at skin closure
40825519|NCT04657640|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) for 3 months intermittently
40825520|NCT04657640|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements (MMS) and loading dose of Iron and Folic Acid (IFA)|"Daily regimen of MMS for 3 months intermittently. MMS is the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) tablet containing fifteen micronutrients including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg).~For the first 5 weeks of the study, participants will also receive weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) as a loading dose, in addition to daily MMS."
41344644|NCT05759481|OTHER|Placebo|Placebo is administered starting at surgery induction and ending at skin closure
41344645|NCT04722380|PROCEDURE|periodontal regenerative surgery|Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract
40825521|NCT02075047|DRUG|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
41036542|NCT06507293|PROCEDURE|Erector spiane plane block|Before the general anesthesia induction, erector spinae plane block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
41036543|NCT01748929|DRUG|Albendazole|
41036544|NCT01748929|DRUG|Placebo|
41036545|NCT00074035|DRUG|pentostatin|4 mg/sq m IV infusion over 20-30 min q 2 weeks
41036546|NCT04654338|RADIATION|SABR + HDR|One SABR treatment + one HDR brachytherapy treatment
41490074|NCT04870138|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.
41036547|NCT04029922|DRUG|MT-5111 (experimental study drug)|Experimental treatment with MT-5111
41018684|NCT04372615|DRUG|Inebilizumab|"RCP: Blinded treatment on Day 1, Day 15,~* Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~* Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care)."
41018685|NCT04372615|DRUG|Placebo|The placebo group will receive IV matching placebo on Day 1 and Day 15,
41018686|NCT03499652|DIAGNOSTIC_TEST|neonatal bacterial meningitis risk score|In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision
40825522|NCT02075047|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
41490075|NCT04870138|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of wild-type (WT) Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
40825523|NCT00847665|OTHER|repositioning|Turning every 4 or 2 hours
40825524|NCT01367704|BEHAVIORAL|"Coaching Boys Into Men program"|Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
40825525|NCT00589056|DRUG|cisplatin|
40825526|NCT00589056|DRUG|etoposide|
40825527|NCT00589056|DRUG|nelfinavir mesylate|
40825528|NCT00589056|GENETIC|protein expression analysis|
40825529|NCT00589056|OTHER|immunohistochemistry staining method|
40825530|NCT00589056|OTHER|laboratory biomarker analysis|
41018687|NCT01565993|DEVICE|Hemoclip|"A rotatable clip-fixing device Quickclip 2 standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm"
41018688|NCT01565993|DEVICE|Conventional Polipectomy|Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
41018689|NCT05661292|DIAGNOSTIC_TEST|Fecal inmunochemical test|A fecal inmunochemical test will be performed prior to colonoscopy.
41018690|NCT05661292|DIAGNOSTIC_TEST|Colonoscopy|A colonoscopy will be performed. Any polyp identified will be resected (polypectomy) and analyzed histologically. NOTE: The subject and colonoscopist will be blinded to FIT test results and risk category.
41036548|NCT02080026|BIOLOGICAL|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
41165784|NCT03618810|DRUG|PEGCSF first level prophylactic use|6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy
40825531|NCT00589056|PROCEDURE|biopsy|
40825532|NCT00589056|RADIATION|radiation therapy|
40825533|NCT06054516|DIAGNOSTIC_TEST|13C-enriched pyruvate|Before starting the hyperpolarization injection procedure, the patient will be scanned using the standard MR imaging defined in the clinical protocol and 13C prescriptions and a pre-scan will be completed. The clinical investigator will mount the administration syringe in the MR compatible power-injector with pre-adjusted injection volume calculated according to body weight (0.43 ml /kg bw). This setting is checked by the scanning operator and clinical investigator. The injection valve is set for agent delivery, and agent injected at a rate of 5 ml/s. The timings are monitored using a stopwatch on the SPINLAB. Following injection of hyperpolarized \[1-13C\]-Pyruvate , 20 ml of sterile saline in a separate syringe, already attached to the patient line, will be used to flush the IV line at the same injection rate (5 ml/s).
41165785|NCT03618810|DRUG|PEGCSF second level prophylactic use|6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
41490076|NCT04870138|BIOLOGICAL|Neisseria gonorrhoeae strain FA7527|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of isogenic LptA mutant Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
41490077|NCT04016220|DRUG|Budesonide|first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.
41344646|NCT05749874|DRUG|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
41344647|NCT05749874|BEHAVIORAL|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
41344648|NCT06050577|DRUG|oral Semaglutide/Rybelsus|Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.
41344649|NCT06050577|DRUG|Placebo|Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.
41344650|NCT01894776|DRUG|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
41344651|NCT01894776|DRUG|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
41344652|NCT01789710|DRUG|Bupropion|All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
41344653|NCT01789710|DRUG|Nicotine replacement therapy|All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
41344654|NCT01789710|BEHAVIORAL|Contingency Management|All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
41344655|NCT02597686|BEHAVIORAL|SD-PB training|
41344656|NCT03382327|PROCEDURE|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review. Both will be compared to the actual surgery performed in the operating room.
40825534|NCT04938999|BEHAVIORAL|Music-visual guided physical activity (MVgPA)|"The MVgPA adopts the information-motivation-strategy model to address the personal and environmental challenges in PA initiation and maintenance of adults with intellectual disability.~To support the staff of residential care facilities in implementing 24 sessions of MVgPA in 12 weeks, the first six sessions will be led by the RA1 and co-facilitated by the staff, while the subsequent sessions will be conducted by the staff only. At week 6, another set of MVgPA will be implemented to increase the participant's interest; two sessions will be co-facilitated by RA1. At weeks 6 and 9, the RN and RA1 will hold a meeting with the staff of the residential care facilities to acknowledge the achievement of the staff and adults with ID, as well as to address any of their concerns related to the implementation of MVgPA, and to identify the facilitators and tackle barriers to the implementation of the MVgPA."
40825535|NCT04938999|BEHAVIORAL|Usual care|As control group, residential care facilities will conduct their usual activities during the study period. A trained RA will record the activities conducted by the residential care facilities during the study period.
40825536|NCT03024333|OTHER||Investigators will use the blender to prepare different viscous foods and liquids. Then, a sound detection device will be attached on the participant's neck. The device will record three times of swallowing sounds at three placements (Apleft, Apright, B) separately with participants' head-trunk in neutral position and also record sounds in the neck such as breathing sound, throat clearing and cough sounds. Participants will use 5 ml spoon to intake different viscous foods or liquids. The conversation will also be recorded using a Sony recorder (ICD-SX713) in each data collection session. The voice recording will not be analyzed, which only provides the additional information about which foods or liquids subjects swallow or at which placement sensor records swallowing sounds.
40825537|NCT00511433|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles."
40825538|NCT00511433|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
40825539|NCT02616497|DRUG|Aspirin|COX-1 inhibitor
40825540|NCT02616497|DRUG|Triflusal|COX-1 inhibitor
41036549|NCT02080026|BIOLOGICAL|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
41344657|NCT02583464|DRUG|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
41344658|NCT00565240|DRUG|Marvelon|oral contraceptive
41344659|NCT00565240|DRUG|Nuvaring|contraceptive vaginal ring
41344660|NCT00565240|DRUG|Letrozole|Aromatase Inhibitors
41344661|NCT06242106|DEVICE|Glucometer|A glucometer, which is a portable device used to measure blood glucose levels, was used in this study to collect data. It is a dependable and widely used tool for assessing glycemic control in people with diabetes, including gestational diabetes
41344662|NCT04324086|DEVICE|Calcium hydroxide with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of calcium hydroxide
41344663|NCT04324086|DEVICE|Calcium hydroxide with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in reemoval of calcium hydroxide
41344664|NCT04324086|DEVICE|Calcium hydroxide with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of calcium hydroxide
41344665|NCT03077789|PROCEDURE|TRABECULOTOMY|Evaluation of the prognosis of different surgery in congenital glaucoma
41344666|NCT01269827|DRUG|Pentoxifylline|Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
41344667|NCT01269827|DRUG|starch tablets|Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
41344668|NCT01236768|DRUG|AG200-15|"Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period."
41344669|NCT01236768|DRUG|Levora|One tablet of Levora will be taken each day for a 28 day cycle.
41344670|NCT02929381|DEVICE|Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
41344671|NCT02929381|DEVICE|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
41344672|NCT06326164|PROCEDURE|kinesio-taping.|A therapeutic tape that's applied strategically to the body to provide support, reduce pain, swelling and improve performance. Kinesio taping will be applied on both lower limbs. Taping will be applied for 4 days, 24 hours a day, on the lower limbs, and it will be removed for only one day per week.
41344673|NCT06326164|PROCEDURE|A designed physiotherapy program.|The designed physiotherapy program included passive stretching, weight bearing, muscle strengthening, functional exercises, neurodevelopmental treatment, splinting, balance training, and gait training. The treatment protocol will be repeated each session per weeks for twelve weeks.
41344674|NCT03875833|DEVICE|Collagen Nerve Wrap Conduit|The collagen nerve wrap conduit will be placed on all exposed radial and ulnar nerves at the time of free flap harvest.
41344675|NCT02652572|DRUG|Granexin|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
41344676|NCT02308904|OTHER|Blood Draw/Semen Exam|"Females:~1. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.~1. Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.~2. Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older)."
18249528|NCT06566963|DRUG|MK-1708|MK-1708 oral suspension
18249529|NCT06566963|DRUG|Placebo|Placebo oral suspension
40825541|NCT06416176|OTHER|Mindfulness-Based Stress Reduction (MBSR) Program|Participants in the experimental group received an 8-week MBSR program by an MBSR instructor. Each meeting were planned as a 3-hour session that completes the mindfulness training procedures by doing an opening meditation of 30- 45 minutes about that week, after the information about the meeting topic of the week is discussed. Experiences after meditation were shared with the group. Each week, the meeting topic and meditation continued with different contents, and practice meditations on the subject were held every week and home exercises were given. Home practice meditations were performed by listening to the guide audio recording with headphones. All home exercises in the training content were followed up on a daily basis and recorded.
40825542|NCT04634513|BIOLOGICAL|strain CVD 1208S-122|Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli
40825543|NCT04634513|OTHER|Placebo|Sodium bicarbonate buffer
41036550|NCT02080026|DRUG|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
40825544|NCT03000543|BIOLOGICAL|Vaccine|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
41490078|NCT04016220|DRUG|normal saline|first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
41490079|NCT01700036|DRUG|Alpha-1-Antitrypsin (AAT)|AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
41490080|NCT04780841|DRUG|RDX013|RDX013 is an experimental drug that is a potassium secretagogue
41490081|NCT04780841|DRUG|Placebo|Placebo treatment that looks identical to experimental treatment
40825545|NCT04663061|BEHAVIORAL|Medical weight loss|Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight
40825546|NCT04663061|BEHAVIORAL|Diabetes education|Participants will receive standard of care diabetes education
41490082|NCT02694471|BEHAVIORAL|physical inactivity or bed rest with supervised recovery|All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
41036551|NCT02080026|DRUG|atovaquone/proguanil|"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"
41344677|NCT02308904|OTHER|Retrospective data/Chart Review/Relevant Clinical Results|"1. 1. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2\* MRI. 4. Ferritin levels.~2. NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.~3. 1. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.~4. 1. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).~5. Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement."
40825547|NCT04663061|BEHAVIORAL|Continuous glucose monitoring|Participants will use CGM devices to track blood glucose levels in near real time
40825548|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
40825549|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
40825550|NCT01887821|DRUG|Chloroquine|
40825551|NCT01887821|DRUG|Dihydroartemisinin/Piperaquine|
40825552|NCT03407053|DIETARY_SUPPLEMENT|Ultra-processed diet|Consuming ultra-processed diet over a 2-week period
40825553|NCT03407053|DIETARY_SUPPLEMENT|Unprocessed diet|Consuming unprocessed diet over a 2-week period
40825554|NCT03760159|DEVICE|Kinocardiography unintrusive recording|"The Kinocardiography (Kino) is a device which records the electric and mechanic function of the heart. The device comprises a combination of ECG recording, (6 degrees of freedom), accelerometer and gyroscope sensors. The Kino device consists of a back and a chest housing in contact with the patient. The back housing is placed in the middle of the lower back of the patient, and the chest housing is placed on the chest (either on the sternum or on the costal grill at the apex of the heart). The housings are connected by two cables. Data obtained from the device are visualized on a digital application via a Bluetooth connection.~For the group A, the KCG records the cardiac signals while the patient performs specific respiratory manoevres, as describe above.~For group B, C, D, the KCG records the cardiac contraction during sleep along with the PSG recording."
41344678|NCT02308904|OTHER|Pituitary MRI|"MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.~MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted."
41344679|NCT03425851|OTHER|Diapers|Receive 600 diapers.
41344680|NCT03425851|OTHER|Resources of diaper banks|Caregivers will receive resources of diaper banks.
40825555|NCT01218100|DRUG|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
40825556|NCT01218100|DRUG|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
40825557|NCT01218100|DRUG|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
40825558|NCT01218100|DRUG|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
40825559|NCT01089023|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
40825560|NCT01135914|DRUG|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
40825561|NCT01135914|PROCEDURE|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
40825562|NCT02451683|OTHER|Electrophysiology Assessment of Time Domain|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
41344681|NCT00518336|PROCEDURE|Blood sampling|Blood sampling at Visit 3, 5 and 7.
41344682|NCT00518336|PROCEDURE|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
41344683|NCT00518336|BIOLOGICAL|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
41344684|NCT02030249|BEHAVIORAL|Low calorie diet administered from 0 to 2 months|The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
41344685|NCT02030249|BEHAVIORAL|High Protein / Low Glycaemic Index|Please see description of the Arm by the same name.
41344686|NCT02030249|BEHAVIORAL|Moderate Protein / High Glycaemic Index|Please see description of the Arm by the same name.
40825563|NCT02451683|OTHER|Electrophysiology Assessment of Location|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
40825564|NCT02451683|OTHER|Training with some stimulation|motor task combined with real or sham stimulation
41490083|NCT00260169|BEHAVIORAL|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
40825565|NCT04994730|BEHAVIORAL|Quality of life according to the reconstruction technique|"For this retrospective analysis, 118 patients could be included, 17 of whom had undergone ante-brachial free flap reconstruction, 16 of whom had undergone this reconstruction within the last 2 years.~The primary endpoint: Analysis of the quality of life score according to the reconstruction technique (free ante-brachial flap versus others) will be performed by a Wilcoxon-Mann-Whitney test."
40825566|NCT03622112|DRUG|AZD7594 DPI 55μg/50μg.|A non-steroidal and selective modulator of the GR.
40825567|NCT03622112|DRUG|AZD7594 DPI 99 µg/90 µg|A non-steroidal and selective modulator of the GR.
41036552|NCT04587440|OTHER|Pelvic inclination measurement|Ultra-sound based measurements of the pelvic inclination lying, standing and seating position. EOX X-ray in seating position.
41344689|NCT02245880|DEVICE|Glidescope|videolaryngoscope
40825568|NCT03622112|DRUG|AZD7594 DPI 198 µg/180 µg|A non-steroidal and selective modulator of the GR.
40825569|NCT03622112|DRUG|AZD7594 DPI 396 µg/360 µg once daily.|A non-steroidal and selective modulator of the GR.
40825570|NCT03622112|DRUG|AZD7594 DPI 792 µg/720 µg|A non-steroidal and selective modulator of the GR.
41344690|NCT02245880|DEVICE|ILMA|handling of the device till the optimal ventilation achieved
40825571|NCT03622112|DRUG|Placebo for AZD7594 once daily.|Placebo for AZD7594
40825572|NCT03622112|DRUG|FF 100 µg once daily (open-label)|Fluticasone furoate
40825573|NCT04152330|OTHER|Early stimulation protocol on neuropsychomotor development of children with congenital heart disease|A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
41344691|NCT01875068|BEHAVIORAL|Consultations between NPs and PAs and their supervising physicians|Required discussion with physician prior to referral by a nurse practitioner or physician assistant
41344692|NCT01875068|BEHAVIORAL|versus NPs and PAs who are not required to discuss patient referrals (control group).|
41344693|NCT01240967|DRUG|TC-5214|Oral tablets, single dose
40825574|NCT02764723|DRUG|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
41344694|NCT00174928|DRUG|Lansoprazole|Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
41344695|NCT00174928|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
41344696|NCT02979483|PROCEDURE|Integrative supportive care|"At the inclusion, the investigator determine a personalized program of supportive care procedures for each patient (for instance : treatment of pain and nutritional support,stenting of bile duct and/or duodenum, tumor biopsy for pathologic diagnosis ,..)~At the end on the integrative supportive care, according to the ECOG-PS of patients , they will be classified into two groups:~* Group 1 :Good prognosis - ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~- Group 2 : Poor prognosis - ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patients will be treated by: FOLFOX7lightened"
40825575|NCT02764723|DRUG|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
41490084|NCT00260169|BEHAVIORAL|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
41490085|NCT06048432|OTHER|Conventional Physiotherapy + telephysiotherapty|Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.
41490086|NCT03492827|DRUG|chlorhexidine acetate gargle|observe whether it can achieve the effect of preventing postoperative infection
40825576|NCT01766895|OTHER|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
41036553|NCT01021969|OTHER|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
40825577|NCT01886690|DRUG|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
40825578|NCT01886690|DRUG|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
40825579|NCT01983722|DRUG|Stiripentol|
40825580|NCT04217967|DRUG|Ixazomib|the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
40825581|NCT04217967|DRUG|Lenalidomide|the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
40825582|NCT06167005|PROCEDURE|Primary bariatric-metabolic surgery|Primary bariatric-metabolic surgery
40825583|NCT05842863|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a treatment program that helps teens reduce suicidal and self-harm behaviors by teaching them coping skills for managing negative emotions. DBT includes weekly individual therapy, weekly multifamily skills group, and 24/7 telephone-based skills coaching from the therapist.
40825584|NCT05842863|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBTI) is a type of counseling that helps people improve sleep by changing their sleep behaviors and thinking about sleep. In CBTI, people learn about sleep regulation, factors that influence quantity and quality of sleep, and specific techniques to optimize sleep. In this study, CBTI will be delivered using a self-guided online program called Firefly.
40825585|NCT01241344|DRUG|Brincidofovir|"* Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
40825586|NCT01241344|OTHER|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
40825587|NCT03121677|BIOLOGICAL|Personalized tumor vaccine|"* Cycle 12 vaccine administration is optional~* The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D) . At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection."
40825588|NCT03121677|DRUG|Poly ICLC|-The personalized tumor vaccine will be co-administered with poly-ICLC.
40825589|NCT03121677|BIOLOGICAL|Nivolumab|-Nivolumab will be administered at a dose of 240 mg intravenously
40825590|NCT03121677|PROCEDURE|Peripheral blood draws|-Time of biopsy, during the pre-treatment check (any time before cycle 1 day 1), Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse
40825591|NCT03121677|PROCEDURE|Leukapheresis|"* Prior to the initiation of treatment and up to five days prior to treatment on cycle 6 day 1, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.~* Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations."
40825592|NCT03121677|BIOLOGICAL|Rituximab|-Other anti-CD20 mAb treatment can be used
40825593|NCT03121677|PROCEDURE|Biopsy|-Biopsies on lymph node or extranodal site(s) are to be obtained at: screening (only after the patient is deemed eligible; during cycle 2 (after treatment on C2D15 and prior to treatment on C3D1); disease relapse or progression (if this occurs)
40825594|NCT00977938|DRUG|Placebo & Aspirin|
40825595|NCT00977938|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|
40825596|NCT04561323|DIAGNOSTIC_TEST|Dual-energy CT|"Patients suspected of acute bowel ischemia will be scanned in the dual-energy CT scanner.~The abdominal imaging protocols are predetermined by the Department of Diagnostic Radiology, Righospitalet, Denmark."
40825597|NCT00123097|COMBINATION_PRODUCT|Chlorinated polyethylene elastomer|Chlorinated polyethylene
40825598|NCT03938220|DEVICE|Electrical Cardiometry|Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
40825599|NCT03234556|PROCEDURE|Biopsy of Prostate|Undergo SR-Bx
40825600|NCT03234556|OTHER|Laboratory Biomarker Analysis|Correlative studies
41344697|NCT04545411|DRUG|Dapagliflozin 10 MG [Farxiga]|4-Week, double-blind, once daily oral 10mg dapagliflozin
40825601|NCT03234556|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Undergo MRI
40825602|NCT03234556|DIAGNOSTIC_TEST|MRI Ultrasound Fusion Guided Biopsy|Undergo MRUS-Bx
41344698|NCT04545411|DRUG|REMD-477|4-Week, double-blind, once weekly subcutaneous injection with 35mg REMD-477 in 1mL solution.
41344699|NCT04545411|DRUG|Placebo|4-Week, double-blind, once weekly subcutaneous injection with placebo in 1mL solution.
40825603|NCT03626272|OTHER|educational intervention|The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
40825604|NCT05908409|DRUG|IDP-121|IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
41036554|NCT06388525|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|
41490087|NCT04660890|DRUG|ALXN2050|ALXN2050 will be administered orally twice daily as powder-in-capsule.
41344700|NCT02112461|BEHAVIORAL|SCP-Hospice Alert|The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
41344701|NCT02748785|DRUG|Methotrexate|Methotrexate will be continued
41490088|NCT04660890|DRUG|ALXN2050-matching Placebo|ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.
41490089|NCT04660890|DRUG|Moxifloxacin|Moxifloxacin will be administered as a single oral dose.
41490090|NCT04660890|DRUG|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo will be administered as a single oral dose.
41490091|NCT04775186|PROCEDURE|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
41490092|NCT03617757|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Patients will be invited to have oral glucose tolerance test. 2mL blood will be taken for analysis at 0 minute and 120 minutes.
41344702|NCT02748785|BIOLOGICAL|Seasonal Influenza vaccine|all subjects will be vaccinated with a seasonal influenza vaccine
41344703|NCT05843617|DIETARY_SUPPLEMENT|Liposomal Vitamin C|1000 mg of ascorbic acid in liposomal formulation
41490093|NCT03617757|DIAGNOSTIC_TEST|HbA1c|2mL blood will be taken for analysis of HbA1c.
41490094|NCT04426279|OTHER|questionnaire assesment|15-minute face-to-face questionnaire
41490095|NCT05135052|DEVICE|Rhenium-SCT|Rhenium-SCT irradiation device
41490096|NCT00005634|DRUG|vorinostat|
40825605|NCT05280106|PROCEDURE|Pre-dilution online hemodiafiltration with citrate dialysate|After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. Phase 1 used CD with 50% of the heparin dose of the baseline. Phases 2 and 3 used 25% heparin and no heparin, respectively. New dialyzers were introduced at the beginning of each phase and the heparin dose was resumed during the washout phase. The calcium concentration in the dialysis fluid was kept constant (1.5 mmol/L) to allow evaluation of the effect of CD on calcium balance
41344704|NCT05843617|DIETARY_SUPPLEMENT|Traditional Vitamin C|1000 mg of ascorbic acid in traditional formulation
41344705|NCT05186363|DRUG|Chemopreventive Agent - SPAQ|Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children 3-59 months.
40825606|NCT05280106|PROCEDURE|Post-dilution hemodiafiltration with citrate dialysate|same protocol with post-dilution Ol-HDF in these same patients for the later 12 weeks.
40825607|NCT02845947|BEHAVIORAL|Music Therapy|The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
40825608|NCT05594069|OTHER|triple pre-rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
40825609|NCT05594069|OTHER|triple rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
40825610|NCT05857033|OTHER|Buccal and direct palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and direct palatal injection
40825611|NCT05857033|OTHER|Buccal and indirect palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and indirect palatal injection
40825612|NCT05857033|OTHER|Buccal and direct palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and direct palatal injection
40825613|NCT05857033|OTHER|Buccal and indirect palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and indirect palatal injection
40825614|NCT04644744|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
40825615|NCT04644744|DEVICE|Normothermic machine perfusion (NMP)|End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
40825616|NCT01763320|PROCEDURE|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
41344706|NCT05186363|DRUG|Control Test - no drugs given|This is where children aged 3-59 months do not receive any chemoprevention drugs but do receive health promotion messages and visit from health workers similar to the chemoprevention SPAQ arm.
41344707|NCT03250819|OTHER|SNP analysis|The collected blood samples will be used to investigate the occurrence of SNPs (single nucleotide polymorphisms) in both study groups
41344708|NCT01199198|DRUG|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
41344709|NCT01199198|DRUG|Placebo|Placebo by mouth once a day for 14 days.
41344710|NCT02583360|DIAGNOSTIC_TEST|Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy|Addition of research HRM along with diagnostic VFSS with parental choice of therapy
41344711|NCT05090098|OTHER|None intervention|None intervention
41344712|NCT00544505|DRUG|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
41490097|NCT04977063|DEVICE|Atmo gas capsule|The Atmo Gas Capsule measures the capsules location and motility/transit times through gas sensing capabilities
40825617|NCT01763320|DRUG|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
40825618|NCT03221608|PROCEDURE|Surgery and HIPEC with Lobaplatin|The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
40825619|NCT03221608|PROCEDURE|Surgery without HIPEC|The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
40825620|NCT02497378|DRUG|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
40825621|NCT02497378|DRUG|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m\^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
41344713|NCT00373880|DRUG|Aripiprazole + Cocaine|Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
41344714|NCT00373880|DRUG|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
41490098|NCT04977063|DEVICE|SmartPill|The SmartPill measures the capsules location and motility/transit times through pH sensing
41490099|NCT02277678|DRUG|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
41490100|NCT02277678|DRUG|Opioid administration morphine|
41490101|NCT00002149|DRUG|Clavulanate potassium|
41490102|NCT00002149|DRUG|Pseudoephedrine hydrochloride|
41490103|NCT00002149|DRUG|Amoxicillin trihydrate|
41490104|NCT00446537|PROCEDURE|Methylphenidate|
41490105|NCT02938754|BEHAVIORAL|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
40825622|NCT02497378|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
40825623|NCT03855631|GENETIC|Intervention on primary cultured cells|The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
40825624|NCT03780478|DRUG|Nerve block|0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
40825625|NCT03780478|DRUG|Placebo Saline Injection|Saline injection, total volume 2ml
41344715|NCT05868460|DEVICE|High intensity laser|patients will receive Nd: YAG with wavelength 1064 nm, peak power 3KW, energy density 360-1780 mJ/cm2, a short duration 120-150 micro sec, a mean power 10.5 W, a low frequency 10-40 HZ, a duty cycle of 0.1%, a probe diameter of 0.5 cm and spot size of 0.2 cm2. The treatment will be applied into 3 phases in each session. In addition to the traditional physical therapy exercise program (passive and active ROM exercises, stretching and strengthening exercises) for 20 minutes, total session time is 35 minutes, 3 days/ week for 4 weeks.
41344716|NCT05868460|OTHER|traditional physical therapy exercise program|passive and active ROM exercises, stretching and strengthening exercises for 35 minutes, 3 days/ week for 4 weeks.
41344717|NCT05868460|DEVICE|placebo High intensity laser|patients will receive placebo HILT including the same treatment as in group A but the laser device will be turned off.
41490106|NCT02938754|BEHAVIORAL|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
41490107|NCT00630097|DRUG|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
41490108|NCT01004094|BEHAVIORAL|simple goal setting|This group will set goals only
41490109|NCT01004094|BEHAVIORAL|goal setting plus action intentions|This group will set goals and form action intentions (plans)
41490110|NCT01004094|BEHAVIORAL|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
41490111|NCT01004094|BEHAVIORAL|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
41490112|NCT04072380|DRUG|SUVN-G3031|SUVN-G3031 Tablets
41490113|NCT04072380|DRUG|Placebo|Placebo Tablets
41490114|NCT02828241|DRUG|DFD-04 Ointment|
41490115|NCT02828241|OTHER|Placebo Ointment|
41490116|NCT02753491|BEHAVIORAL|Motivational short interview|New designed motivational short interview model
41490117|NCT01475006|DRUG|AMG 595|AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
41344718|NCT00605358|BEHAVIORAL|Open Door intervention|"Open Door intervention subjects will:~1. receive an evaluation~2. receive a referral to a local mental health provider~3. identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources."
41344719|NCT04640753|PROCEDURE|Endoscopic procedure for achalasia|POEM procedure will have a high technical feasibility, with effective clinical resolution of symptoms both in the short and long term.
41344720|NCT06204510|OTHER|complex decongestive therapy|This application consists of manual lymph drainage, skin care, compression bandage and exercises. This phase will continue for 3 weeks, 5 days a week.
41344721|NCT00410345|DRUG|Mifepristone|
41344722|NCT04212403|DRUG|Levofloxacin|The control group receives AMP.
41344723|NCT02056756|DRUG|Carfilzomib|
40825626|NCT04408417|DEVICE|Prototype child safety seat with tension indicator lights|The prototype child safety seat is a convertible rear-facing seat with a harness system that includes tension indicator lights.
40825627|NCT04408417|DEVICE|Control child safety seat|The control child safety seat is a convertible rear-facing seat without tension indicator lights.
40825628|NCT03172091|DEVICE|eNose (electronic nose)|Collection of exhaled breath for an immediate analysis by electronic nose
40825629|NCT03172091|DEVICE|Spectrometry|Collection of exhaled breath for an immediate analysis by mass spectrometry
40825630|NCT04881500|OTHER|Motivational interview|Patients will follow motivational interview (2 individual sessions by phone)
40825631|NCT04881500|OTHER|Routine Care|Patients will follow routine care
40825632|NCT04918953|DRUG|methylprednisolone|The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
40825633|NCT04918953|DRUG|budesonide atomization suspension|(3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
40825634|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
40825635|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Radiofrequency Ablation|Ultrasound-guided Percutaneous Radiofrequency Ablation
40825636|NCT01833260|BEHAVIORAL|Music|
40825637|NCT01340937|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
41344724|NCT05131100|DRUG|Somavert|As provided in real world practice
41344725|NCT04100291|OTHER|Faecal microbiota transplantation|FMT by daily enema with donor faeces
41344726|NCT04100291|OTHER|Placebo|Placebo by daily enema with placebo mixture
40825638|NCT01340937|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
40825639|NCT01340937|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
40825640|NCT01340937|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
40825641|NCT01340937|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
40825642|NCT03809091|DIAGNOSTIC_TEST|Whole genome sequencing|Whole genome sequencing of patients and their family will be performed. Among the variants detected by WGS, disease-causing variants will be analyzed by using segregation analysis.
40825643|NCT01058512|DRUG|NOV-205|"There will be 4 treatment Groups with 10 patients in each group:~* Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~* Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~* Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~* Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days"
40825644|NCT05989568|BEHAVIORAL|BASIS-T|BASIS-T is designed to address the behavioral components often missing from standard EBPP training and consultation that relate to motivation prior to receiving EBPP training, and volition after EBPP training. It is an EBPP-agnostic implementation strategy designed to be delivered within the Preparation/Adoption phase, immediately prior to Active Implementation (CITE EPIS). BASIS-T targets behavioral intentions via improvement in attitudes, subjective norms, and self-efficacy.
40825645|NCT05989568|BEHAVIORAL|Attention Control (ACC)|Teachers assigned to the ACC will receive pre- and post-training experiences designed to mirror those received in the BASIS-T condition. These training experiences will be virtual, delivered by the same interventionist, and be approximately the same length as the BASIS-T experiences, but will not contain any of the BASIS-T content or mechanisms of change. The ACC pre-training experience will define, describe, and advocate for EBP implementation in schools. Content will be didactic, as is typical in professional development training for teachers.
40825646|NCT00867087|DRUG|inotuzumab ozogamicin (CMC-544)|1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
41344727|NCT04576260|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Weekly CBTI training
41344728|NCT03167827|OTHER|Exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
41344729|NCT03167827|OTHER|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
41344730|NCT03167827|OTHER|placebo|Daily supplementation in 1 capsule per day containing starch of corn.
41344731|NCT04602013|DRUG|Sintilimab|Body weight \<60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W. Every three weeks is a cycle
41490118|NCT03937336|BEHAVIORAL|Bike Intervention Group|A 1-month biking-based program. The biking program consists of 4 sessions/month of 120 min at physical education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training
41490119|NCT02468063|DRUG|Low dose terlipressin|Terlipressin-2mg (low dose )
40825647|NCT00867087|DRUG|rituximab|375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
41344732|NCT04602013|DRUG|Chemotherapy|"Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)"
41490120|NCT02468063|DRUG|Noradrenaline|Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min
40825648|NCT02357862|PROCEDURE|Mitral Valve Annuloplasty|Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
41344733|NCT04602013|RADIATION|Radiation Therapy|The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week).
40825649|NCT05966428|OTHER|Conventional Exercises|"This conventional exercises included stretching and strengthening, balance-coordination, mobility and range of motion exercises.~The control group received conventional therapy 3 days a week for 8 weeks. Each therapy session a day lasted 45 minutes in control group."
41344734|NCT05413356|DRUG|Ruxolitinib|Oral ruxolitinib twice daily
41344735|NCT01327573|DRUG|eculizumab|"* Eculizumab Induction 600mg IV every 7 days for 4 doses~* Eculizumab 900mg IV 7 days later~* Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"
41344736|NCT01389895|DRUG|AMG 557|AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
41344737|NCT01389895|DRUG|AMG 557 Placebo|AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
41490121|NCT02468063|DRUG|Noradrenaline|Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
41490122|NCT00566566|OTHER|sample without DNA|family history, anthropometric measurements and blood sampling
40825650|NCT05966428|OTHER|Sensory Integration Therapy|"The Sensory Integration Therapy was applied to the intervention group in addition to the conventional exercise program. Sensory Integration Therapy included tactile, proprioceptive, and vestibular activities. The tactile sensory activities consisted of materials such as stepping stones, tactile box, brushing, fabric walking path. The vestibular sensory activities consisted of materials such as hammock swings, trampolines, rope nets, rock walls, river stones. Proprioceptive sensory activities consisted of materials such as weight bearing activities, heavy lifting, deep pressure, big ball activities, tug of war and ball pits.~The intervention group underwent each session 45 minute conventional therapy and 15 minutes SIT. The therapy program continued 3 days a week for 8 weeks in intervention group."
41490123|NCT02875158|PROCEDURE|Cyclophotocoagulation protocol|"* Intravenous route is installed~* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~* Pars plana measurement using transillumination (if needed)~* Laser treatment applied approximately 1mm post to limbus~* Dexamethasone 0,5 mg subconjunctival injection~* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h"
41490124|NCT02875158|PROCEDURE|Conventional cyclophotocoagulation|1250 mW for 4 seconds.
41490125|NCT02875158|PROCEDURE|Modified cyclophotocoagulation|2000 mW for 2 seconds.
40825651|NCT03078283|OTHER|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
40825652|NCT04111016|BEHAVIORAL|Integrated child stimulation, nutrition, lead, arsenic, WASH intervention|The content of the intervention curriculum was developed considering the needs of the specific ages of the children attending the group, as well as the feasibility of delivering the package in the community. The pregnancy module encompasses information on significance of prenatal care for child development, physiological symptoms and solutions, maternal diet, education on kangaroo mother care (KMC), breast feeding, thinking healthy, hygiene, and lead and arsenic prevention. The curriculum for lactating mothers focuses on specialized messages for 4 age groups of children: 0-5 months, 6-11 months, 12-18 months and 19-24 months. The overall package includes information regarding WASH, psychosocial stimulation, nutrition, maternal mental health, lead and arsenic. As research evidence showed that psychosocial stimulation provided for 10 or 12 months can significantly improve child development, the psychosocial stimulation component is included in every fortnightly session.
40825653|NCT04753554|DEVICE|ORI group|The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
40825654|NCT04753554|OTHER|Conventional group|In this patient group oxygenation will be managed as usual, using blood gas analysis.
40825655|NCT06456229|DIETARY_SUPPLEMENT|Nestle Isocal|Nestle Isocal
40825656|NCT06456229|DIETARY_SUPPLEMENT|Nestle Boost Optimum|Nestle Boost Optimum
41344738|NCT04281108|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
41344739|NCT04281108|DRUG|Placebo oral tablet|Placebo orally disintegrating tablet.
41344740|NCT04281108|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
41344741|NCT03121456|OTHER|18F-FDG PET SCAN|REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
41344742|NCT03121456|OTHER|MRI DIFFUSION|REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1.
41344743|NCT01066169|BIOLOGICAL|Foceteria® (Novartis)|This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.
40825657|NCT00230802|DRUG|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
40825658|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
40825659|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
40825660|NCT01054040|OTHER|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
40825661|NCT03694873|DRUG|Tramadol Hydrochloride|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
40825662|NCT03694873|DRUG|Celecoxib 200mg|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
40825663|NCT00101764|DRUG|Triamcinolone Acetonide|
41344744|NCT04443868|DRUG|Nitric Oxide-Releasing Drug|Nasal Spray + Nasal Irrigation
41344745|NCT01529827|DRUG|fludarabine phosphate|Given IV
41344746|NCT01529827|DRUG|melphalan|Given IV
41344747|NCT01529827|RADIATION|total-body irradiation|Undergo TBI
41344748|NCT01529827|DRUG|tacrolimus|Given IV or PO
41344749|NCT01529827|DRUG|mycophenolate mofetil|Given IV or PO
41344750|NCT01529827|DRUG|methotrexate|Given IV
41344751|NCT01529827|OTHER|laboratory biomarker analysis|Correlative studies
41344752|NCT01529827|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
41344753|NCT01529827|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
41344754|NCT05766267|DRUG|Rifabutin|Rifabutin (Rb) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
41344755|NCT05766267|DRUG|Delamanid|Delamanid (D or DLM) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
41344756|NCT05766267|DRUG|Bedaquiline|Bedaquiline is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
41344757|NCT05766267|DRUG|Moxifloxacin|Moxifloxacin is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
41344758|NCT05766267|DRUG|Pyrazinamide|Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).
41344759|NCT05766267|DRUG|Isoniazid|Isoniazid is part of control regimen (HRZE).
41344760|NCT05766267|DRUG|Rifampin|Rifampin is part of control regimen (HRZE).
41344761|NCT05766267|DRUG|Ethambutol|Ethambutol is part of control regimen (HRZE).
41344762|NCT02789189|DRUG|nedaplatin and gemcitabine|
41344763|NCT01546090|DRUG|Alprazolam|preoperative administration of an orally 0.50 mg single dose
40825664|NCT06080646|OTHER|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
40825665|NCT00454753|DRUG|Dasatinib|
40825666|NCT02523625|DEVICE|Ultrasound of temporal and axillary arteries|Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
40825667|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
40825668|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
40825669|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
40825670|NCT01559259|DRUG|Ibuprofen|Two caplets of ibuprofen 200 mg
40825671|NCT01559259|DRUG|Placebo|Two caplets of placebo
40825672|NCT05347927|DEVICE|water resistante padding|"* Delta-Dry® Softliner~* Tensoban®~* Delta-Dry®"
40825673|NCT05347927|DEVICE|non water resistante padding|"* Delta-Net® Stockinette~* Delta-Rol®"
40825674|NCT00232388|PROCEDURE|Blood draw|
40825675|NCT05791994|PROCEDURE|Visual cognitive stimulation exercises|Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.
40825676|NCT05791994|PROCEDURE|Broadcast of a television program|Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.
40825677|NCT06242639|OTHER|Clinical examination|clinic and radiographic evaluation
41344764|NCT01546090|DRUG|placebo|placebo capsules were filled with starch
40825678|NCT05245630|PROCEDURE|Robotic arm assisted PET/CT guided biopsy|"After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done."
40825679|NCT05245630|PROCEDURE|PET fused CT-Fluoroscopy guided biopsy|CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
41344765|NCT04884386|DEVICE|robot-assisted gait training|RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
41344766|NCT04884386|BEHAVIORAL|conventional locomotion therapy|locomotion exercise, postural control training, balance training, electrotherapy
41344767|NCT06137989|PROCEDURE|Fill-Up Class ӀӀ restoration|Bulk-fill technique
41344768|NCT06137989|PROCEDURE|QuiXfil Class ӀӀ restoration|Bulk-fill technique
41344769|NCT06137989|PROCEDURE|Tetric N-Ceram Bulk Fill Class ӀӀ restoration|Bulk-fill technique
40825680|NCT03496350|BEHAVIORAL|Internet-delivered CBT|Culturally adapted transdiagnostic internet-delivered CBT in Arabic
40825681|NCT02596373|DRUG|Mitoxantrone Hydrochloride Liposome Injection|
40825682|NCT02624063|DRUG|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
41344770|NCT05165108|DEVICE|Vagal Nerve Stimulator|A handheld device which consists of a battery powered portable stimulator with a digital control user interface that controls signal amplitude and two steel contact electrodes will deliver the nVNS electrical stimulation to the cervical Vagus nerve. The device has been approved by the U.S. Food and Drug Administration (FDA) for non-invasive Vagus nerve stimulator therapy for adjunctive use for the prevention and treatment of migraine and cluster headaches in adult patients.
41344771|NCT00351390|OTHER|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
40825683|NCT02624063|DRUG|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
40825684|NCT00145418|DRUG|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
40825685|NCT03289221|DIAGNOSTIC_TEST|Anal Manometry|"A suppository will be used to clean the rectum 3 to 4 hours prior to the examination. And the pressures of rest and voluntary contraction of the anal sphincter will be evaluated, as well as the behavior of the pubortal muscle during the evacuation maneuver. Retinal inhibitory reflex (RIRA), sensitivity and rectal capacity will also be evaluated.~Questionnaires that evaluate the pre and post HIFU anal physiology will also be applied at the time of manometry."
40825686|NCT01124227|DRUG|icodextrin|2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
41344772|NCT00351390|OTHER|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP \<1000 pg/mL
41344773|NCT00564603|DRUG|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
41344774|NCT00564603|OTHER|0.9% Saline|Saline, in same volume of 2mL
41344775|NCT04871386|BEHAVIORAL|Acceptance and commitment therapy (ACT) exercises|The ACT group received 14 (partially succeeding) daily exercises, with each of the following categories being focused twice: Acceptance, contact with the present moment, cognitive defusion, self as context, personal values and committed action. The exercises consisted of metaphors and questions for self-reflection, explanations about emotions and thoughts with techniques to handle them differently, as well as a body scan.
41344776|NCT04871386|BEHAVIORAL|Positive psychology (PP) exercises|The PP group received 14 daily exercises that were derived from positive psychology interventions that have been proven effective in alleviating clinical symptoms and increasing subjective well-being. In detail, these were: Identifying positive emotions and ways to increase them; Enhancing pleasure from daily activities; Writing a gratitude letter; Identifying and appreciating three personal traits; Receiving a letter of support from one's future self; Taking different perspectives on one's current situation; Envisioning a perfect day; Identifying energy boosters and drainers; Identifying 3 character strengths and using one in a new way; Life review: Writing a legacy; Identifying the positive relationships in one's life; Doing an act of kindness; Three good things; and Coping with failure.
41344777|NCT06431204|OTHER|Obstetric comorbidity index|Obstetric comorbidity index score
41490126|NCT00967291|DRUG|ifosfamide|2,500 mg/mq on days 1-3 every 28 days
40825687|NCT03924583|DIAGNOSTIC_TEST|Duplex ultrasonography|Ultrasound examination of whole vena cava venous system with central venous catheter inserted, using duplex US method to detect catheter related thrombosis
40825688|NCT05300685|DRUG|Standard Buccal Harvest|Our institutions current anesthetic regimen. Comparison group
40825689|NCT05300685|DRUG|Basic buccal procedure + Long acting local|Addition of long-acting local anesthetic to the wound bed following the oral graft harvest.
41490127|NCT00967291|DRUG|mitomycin C|8 mg/mq on day 1 every 28 days
41490128|NCT04253496|OTHER|Tumor samples and MRI|We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
41344778|NCT00250029|DRUG|Oxaliplatin|"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion \& the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 \& the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."
41344779|NCT01998906|DRUG|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
41344780|NCT01998906|DRUG|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
41344781|NCT01998906|DRUG|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
41344782|NCT01998906|DRUG|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
41344783|NCT06185686|OTHER|Cognitive testing|NIH Toolbox Cognitive Battery and the Novel Cognitive Measure (NCM)
41344784|NCT06185686|DEVICE|Resting State MRI/Precision functional mapping|At baseline (before the end of radiation therapy) and approximately 12 months after the completion of radiation therapy.
41344785|NCT02961400|OTHER|PUSH text messages|The intervention is designed to remind participants of treatment components.
41344786|NCT02961400|OTHER|PULL text messages|The intervention is designed to remind participants to recall treatment components.
40825690|NCT05300685|DRUG|Basic buccal procedure + Buccal block|Addition of long-acting local anesthetic as a buccal block after oral graft harvest
41344787|NCT02961400|BEHAVIORAL|TranS-C|The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
41344788|NCT02961400|BEHAVIORAL|PE|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
41344789|NCT00002981|PROCEDURE|positron emission tomography|
41344790|NCT00002981|RADIATION|fludeoxyglucose F 18|
41344791|NCT00002981|RADIATION|methionine C 11|
41344792|NCT00834925|DRUG|low dose diltiazem|Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
41344793|NCT03973749|OTHER|Low salycilate diet|Each arm of the experimental group will be exposed to low and high concentrations of dietary salycilates and urinary LTE4, FEV1, FVC, FEV1/FVC and total inspiratory nasal resistance will be measured at basal level and then two hours after each of the 3 daily meals.
41344794|NCT05726955|OTHER|Exercise training program|an exercise training program applied with conservative treatment and a stretching platform (ETSP) 3 days a week for 6 weeks
41344795|NCT04668365|DRUG|Rituximab|375mg/m2, Intravenous administration on day 0 of each 3-week cycle.
41344796|NCT04668365|DRUG|Zanubrutinib|160mg twice daily continuous oral administration.
41344797|NCT04668365|DRUG|Cyclophosphamide|750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
41344798|NCT04668365|DRUG|Epirubicin|70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
41344799|NCT04668365|DRUG|Vincristine|1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
41344800|NCT04668365|DRUG|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
41344801|NCT05957978|DRUG|LXE408|Film-coated tablets
41344802|NCT05957978|DRUG|sodium stibogluconate|Dosage/Administration: sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d.
40825691|NCT03349424|DRUG|Somatostatin|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
41344803|NCT05957978|DRUG|Paromomycin|Dosage/Administration: paromomycin 15 mg/kg/day IM q.d.
41344804|NCT04420208|PROCEDURE|Modified Pap test|Adding a non-painful step after the most uncomfortable phase of Pap smear
40825692|NCT02351830|OTHER|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
40825693|NCT02351830|PROCEDURE|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
41344805|NCT03846076|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
40825694|NCT01552785|DEVICE|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
41344806|NCT01116349|PROCEDURE|Plate and screws or nailing|Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.
41344807|NCT01116349|DEVICE|Hanging Support System (HSS) brace|Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
40825695|NCT02978963|BEHAVIORAL|Cognitive behavioral therapy|CBT focused on reducing intolerance of uncertainty
40825696|NCT05751590|DEVICE|comined use of gliddescope and fiberoptic broncscopy|endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy
41344808|NCT02282930|DRUG|ACTH (Acthar) Gel|Injected dose of 80 units subcutaneously twice weekly for 6 months.
40825697|NCT05751590|DEVICE|fiberoptic bronscopy|endotrachotreal intubation will be done by Fiberoptic broncscopy
40825698|NCT02470143|BEHAVIORAL|Bike application arm|The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
40825699|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
40825700|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma|Conventional melanoma educational intervention.
40825701|NCT04525924|DEVICE|bright light therapy|please see arm description
40825702|NCT05384535|DIAGNOSTIC_TEST|Bi-parametric MRI|When used for the evaluation of prostate cancer, MRI typically involves multiple sequences and typically includes typical T1 and T2 phases with the addition of diffusion weighted imaging and dynamic contrast enhanced imaging. In this study, we have decided to omit dynamic contrast enhanced imaging due to its decreased diagnostic yield relative to T2 and DWI and associated increased risk of contrast agents, this is a common approach for prostate cancer screening and is referred to as a bi-parametric MRI
41344809|NCT06177015|DRUG|Darolutamide continuous|standard of care
41344810|NCT06177015|DRUG|Darolutamide intermittent|experimental group
41344811|NCT02579902|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
40825703|NCT02645851|DRUG|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
40825704|NCT02645851|DEVICE|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
40825705|NCT02645851|DEVICE|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
41344812|NCT02579902|DIETARY_SUPPLEMENT|placebo|placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
41344813|NCT04996524|DRUG|epidural analgesia|Patients recieving epidural analgesia instead of systemic analgesia for acute pain in the intensive care unit
41344814|NCT01818765|PROCEDURE|Trans-ventricular-septal placement of LV pacing lead|
41344815|NCT01818765|OTHER|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
41344816|NCT01818765|OTHER|Acute response assessment|Cardiac output monitoring
41344817|NCT05642793|DRUG|proactive Anti-VEGF (conbercept) use|preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
41344818|NCT05642793|DRUG|passive Anti-VEGF (conbercept) use|No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
41344819|NCT04164849|DRUG|5-aminolevulinic acid|5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
40825706|NCT02645851|OTHER|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
41344820|NCT04164849|PROCEDURE|Blue light photopheresis|The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.
41344821|NCT04164849|PROCEDURE|Transfusion|The treated cells are transferred back to the patient as a standard blood transfusion
40825707|NCT05530044|BEHAVIORAL|Social diffusion intervention|training in communication skills
40825708|NCT06138444|DIETARY_SUPPLEMENT|Functional beverages from the submerged fermentation of Cordyceps militaris|The Cordyceps militaris submerged fermentation in fruit juice.
40825709|NCT06138444|OTHER|Fruit juice|Fruit juice is used as a placebo.
40825710|NCT00792025|DRUG|sunitinib malate|
40825711|NCT05888792|OTHER|Variant of Defocus Incorporated Spectacle lens (DG2)|DG2 is a variant of Defocus Incorporated Spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously
40825712|NCT04139577|BIOLOGICAL|Fecal Microbiota Transplant|FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
40825713|NCT02303080|OTHER|Control (WPM 0)|85.0 % maltodextrin,15.0% fat, 0% WPM
40825714|NCT02303080|OTHER|WPM 30|43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
40825715|NCT02303080|OTHER|WPM 50|16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
41344822|NCT04164849|PROCEDURE|Continuous Mononuclear Cell Collection (CMNC)|The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
41344823|NCT01462422|DRUG|Misoprostol|Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
41344824|NCT01462422|DRUG|Misoprostol|Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
41344825|NCT05732493|DRUG|Serplulimab|Serplulimab 300mg, d1, q3w
41344826|NCT05732493|RADIATION|short-term radiotherapy|radiation: 25Gy/5Fx
40825716|NCT02303080|OTHER|MC 50|16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
40825717|NCT00159731|DRUG|Pregabalin|
40825718|NCT04503161|DEVICE|Duragen with Collagen Hydrodel and ASCs|Duragen combined with collagen hydrogel and patient's stem cells
40825719|NCT00921414|DRUG|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
40825720|NCT00921414|OTHER|Watch and wait|No treatment patient follow-up every 2 months during 3 years
40825721|NCT05923736|OTHER|Intima media thickness ultrasound|EIM is a non-invasive ultrasound technique in which an ultrasound-generating probe is conventionally placed opposite the right primary carotid artery. By distinguishing between an inner layer, consisting of the intima and media, and the outer layer, the adventitia, the intima-media thickness can be assessed.
40825722|NCT05923736|OTHER|hand ultrasound|Performed by the rheumatologist, to quantify the number of synovial thickenings in B mode and the number of synovitis in Doppler mode. The presence or absence of joint erosions on the metacarpophalangeal (MCP), proximal interphalangeal (PPI) or distal interphalangeal (DIP) joints.
40825723|NCT05923736|OTHER|EndoPAT™ 2000 system|It's a measurement that detects endothelial dysfunction in coronary arteries using reactive hyperemia.This examination will be carried out in accordance with the manufacturer's instructions by the Rheumatology Department nurse. The patient lies down for the duration of the examination (20 minutes). A probe is placed on the index finger of each hand and a cuff on the left arm. Recording begins with a 5-minute baseline period (at rest), followed by a 5-minute period of arm occlusion, and ends with a 5-minute period of return to normal.
40825724|NCT05923736|OTHER|X-ray absorptiometry (DXA)|This X-ray examination will be carried out on the Hologic device and the analyses by APEX 4.0 software. Two-photon X-ray absorptiometry (DXA) is a method commonly used to measure bone mineral density. It is based on a scan of the body by an X-ray beam at 2 different energy levels, which enables 3 compartments to be individualized: mineral mass, lean mass and fat mass. This low-radiation method (less than a conventional chest X-ray) is regarded as a benchmark for accurate measurement of both bone mineral density and the various body compartments. The examination lasts 10 minutes and is carried out by the department's electroradiology manipulators
40825725|NCT03524287|PROCEDURE|Robotic Assisted No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
41344827|NCT05732493|DRUG|Oxaliplatin|130mg/m2 d1 q3w
41344828|NCT05732493|DRUG|Capecitabine|1000mg/m2 d1-14 q3w
41344829|NCT02090218|DEVICE|I-Gel|I-Gel supraglottic airway device
41344830|NCT02090218|DEVICE|LTS, ETI or current airway management practice|Laryngeal tube, endotracheal tube, bag-mask-ventilation
41344831|NCT05479006|DEVICE|Transcranial direct current stimulation (high- definition)|20 minutes, 2 mA stimulation.
41344832|NCT00017927|DRUG|Pegvisomant|
41344833|NCT01208818|DRUG|Cyclophosphamide + Bortezomib + Dexamethasone regimen|"Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~* Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect."
41344834|NCT01208818|DRUG|Bortezomib +Dexamethasone regimen|"Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect."
41344835|NCT01208818|DEVICE|HCO group|TheraliteTM dialyzer of 2.1 m2 in surface
41344836|NCT01208818|DEVICE|conventional high-flux dialyzer|conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient \> 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
40825726|NCT02274272|OTHER|ADR-1|two ADR-1 capsules, once daily, QD
40825727|NCT02274272|OTHER|GMNL-263|two GMNL-263 capsules, once daily, QD
41344837|NCT06292689|DRUG|Cardunolizumab|"1. Not systematically treated:~   Cardunolizumab (10mg/kg) + Cisplatinum (50mg/m2)/ Carboplatinum (AUC 4-5) + Paclitaxel (175mg/m2) ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.~2. Previous systematic treatment:~Cardunolizumab (10mg/kg) + Chemotherapy regimen selected by the investigator ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment."
41344838|NCT00757640|PROCEDURE|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
41344839|NCT05478057|DEVICE|"MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system"|we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
41344840|NCT05625815|DEVICE|Prototypes (816-v1 001) to (816-v1 050)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
41344841|NCT05625815|DEVICE|Prototype (816-v1 051) to (816-v1 100)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
41344842|NCT05625815|DEVICE|Prototypes (816-v1 101) to (816-v1 150)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
40825728|NCT02274272|OTHER|placebo|two placebo capsules, once daily, QD
41344843|NCT05625815|DEVICE|Prototypes (816-v1 151) to (816-v1 200)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
41344844|NCT03102463|DIETARY_SUPPLEMENT|Water Control|120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
41344845|NCT03102463|DIETARY_SUPPLEMENT|Milk derived hydrolysate|Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
41344846|NCT03102463|DIETARY_SUPPLEMENT|Parent Protein|Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
41344847|NCT03102463|OTHER|Lipid Load|100mL oral lipid load
41344848|NCT04880772|OTHER|Prehabilitation|exercise \& multivitamin (nutritional/dietary advice)
41344849|NCT05570708|DRUG|MDMA, LSD, psilocybin|"* MDMA per os (2 x 100mg) in a group setting~* LSD per os (75 and 150 mcg) in a 1:1 setting~* Psilocybin per os (15 mg and 25 mg) in a group setting~* Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting"
41344850|NCT03440892|DRUG|methotrexate|folate antagonist
41344851|NCT03440892|DRUG|sulfasalazine|Immunomodulatory
40825729|NCT06232148|DEVICE|Type of surgery|
40825730|NCT05761366|DRUG|Al18F-PSMA-BCH PET/CT|Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
40825731|NCT01620502|DIETARY_SUPPLEMENT|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
40825732|NCT04394273|OTHER|Exercise|stabilization exercise
40825733|NCT05410847|DRUG|Camrelizumab Nab-Paclitaxel S-1|Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
40825734|NCT00856206|BIOLOGICAL|Rilonacept|Rilonacept 160 mg subcutaneous injection once a week
40825735|NCT00856206|OTHER|Placebo|Placebo subcutaneous injection once a week
40825736|NCT00624819|BIOLOGICAL|GSK1024805A|No vaccination in this trial
40825737|NCT00624819|BIOLOGICAL|Prevenar|No vaccination in this trial
40825738|NCT00624819|BIOLOGICAL|Infanrix hexa|No vaccination in this trial
41344852|NCT03440892|DRUG|abatacept|Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
41344853|NCT03440892|DRUG|tocilizumab|IL-6 receptor antagonist
41344854|NCT03440892|DRUG|tofacitinib/baricitinib|JAK inhibitor
41344855|NCT03563586|OTHER|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
41344856|NCT03563586|OTHER|Bowel Preparation|Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
40825739|NCT00624819|BIOLOGICAL|Havrix|No vaccination in this trial
41344857|NCT03253185|DRUG|SC-007|intravenous
40825740|NCT00624819|BIOLOGICAL|Varilrix|No vaccination in this trial
40825741|NCT06196424|OTHER|study questionnaire to investigate family history|Participants will be given a specific study questionnaire (paper-based) to fill at home, which was specifically designed to collect family history information
41344858|NCT00388375|PROCEDURE|Ultrasound|limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
41344859|NCT05004389|DIAGNOSTIC_TEST|MRI|white matter integrity and brain structural connectivity metrics
41344860|NCT05004389|DIAGNOSTIC_TEST|blood draw|post-stroke serum/plasma levels of BDNF, VEGF, IL-6, IL-10, CRP, TNFalpha, MMPs, IGF-1, cGP
41344861|NCT05004389|OTHER|Clinical assessments|measures of strength, balance, and mobility
41344862|NCT05609162|PROCEDURE|neurosurgical resection|neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
41344863|NCT01718119|DRUG|r-hCG|r-hCG(250mcg) injection subcutaneously
41344864|NCT00996541|BEHAVIORAL|STRIVE family intervention|Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
41344865|NCT04785144|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the Wuhan-Hu-1 strain of SARS-CoV-2. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
41344866|NCT04785144|BIOLOGICAL|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
41344867|NCT01255189|DEVICE|Device: near infrared spectroscopy: INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
41344868|NCT01255189|DEVICE|invos 5100|near infrared spectroscopy: invos 5100
41344869|NCT01605890|DRUG|emtricitabine / tenofovir disoproxil fumarate / raltegravir .|"emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID."
41344870|NCT05522855|DEVICE|EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion. The control version will not display mental workload and brain energy data on the application.
41344871|NCT03067051|DRUG|Verteporfin|In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
41344872|NCT03067051|DEVICE|SpectraCure P18 System|Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
40825742|NCT01665430|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
40825743|NCT01156389|DRUG|Ritonavir and Pyramax|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
40825744|NCT01156389|DRUG|Pyramax|Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
40825745|NCT06552481|DEVICE|NP-PWD|Application of NP-PWD device.
40825746|NCT06552481|DEVICE|Wound Vac|Application of wound vac device.
40825747|NCT01048294|DEVICE|Original Energy Light,|9000 lux, 30 minutes in the morning
40825748|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 20 minutes in the morning
40825749|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 30 minutes in the morning
40825750|NCT06216899|OTHER|Whole-food based smoothie|The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
40825751|NCT06216899|OTHER|Formula|Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
40825752|NCT04332471|PROCEDURE|Radial shockwave therapy|Target intensity will be within a range of 3.5-5.0 bar at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
41344873|NCT02377076|DIETARY_SUPPLEMENT|Dietary calcium supplementation|Dietary calcium supplementation as milk powder
41344874|NCT02377076|DIETARY_SUPPLEMENT|Control|Control (Whey protein, vitamin D, sugar and salt)
41344875|NCT06279975|DIAGNOSTIC_TEST|non-invasive device-supported, automated pupillometry|non-invasive device-supported, automated pupillometry with a precise quantitative measurement of the pupils within the range of micrometers
40825753|NCT04332471|PROCEDURE|Focused shockwave therapy|Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
41344876|NCT05980611|DIAGNOSTIC_TEST|IL B,IL 3 in nasal swap and serum|Interleukin (IL)-1-beta and IL-3 will be measured in patients' serum and supernatant from the nasal swap using enzyme linked immunosorbent assay (ELISA).
41344877|NCT02114398|OTHER|usual treatment|usual treatment
41344878|NCT02114398|OTHER|usual treatment + sophrology|usual treatment + sophrology
41344879|NCT06323499|PROCEDURE|Induction of atypical atrial flutter|Electrophysiological study with induction of atypical atrial flutter. When the induction was successful, ablation of arrhythmia was performed similar to the control group.
41344880|NCT05333536|OTHER|Experimental: Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of Upper Limb and Lower Limb with theraband ,10 reps each.Upper Limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower limb : Flexors of hip, Extensors of hip,Plantar flexors.
41490129|NCT01451086|BIOLOGICAL|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
41490130|NCT01451086|BIOLOGICAL|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
41490131|NCT05576766|PROCEDURE|Routine care|"1. Routine information provided before surgery.~2. No nutritional therapy.~3. No aerobic exercise.~4. No pelvic floor muscle training.~5. No psychiatrist intervention.~6. Bowel preparation with oral cathartic agent.~7. Fasting for over 8 hours; no oral carbohydrate solution (OCS) loading before surgery.~8. Hypothermia prevention not emphasized.~9. General anesthesia; regional block not emphasized.~10. Routine blood pressure management.~11. Mobilization from postoperative day 1.~12. Start oral feeding from postoperative day 1.~13. Patient-controlled analgesia with opioids.~14. Thromboembolism prophylaxis with low-molecular-weight heparin (LMWH).~15. Routine pelvic drainage tube removal (usually at postoperative day 4).~16. Routine urinary catheterization removal (usually at postoperative day 14)."
41490132|NCT05576766|PROCEDURE|ERAS management pathway|"1. Patient consultation and education before surgery.~2. Nutritional intervention for patients whose BMI\<18.5 or BMI\>24 kg/m2.~3. Aerobic exercise for 2 weeks before surgery.~4. Pelvic floor muscle training for 2 weeks before surgery.~5. Psychiatrist intervention for patients with severe depression and anxiety.~6. No bowel preparation before surgery.~7. Provide oral carbohydrate solution 2 hours before surgery.~8. Hypothermia prevention.~9. General anesthesia combined with regional block.~10. Goal-directed fluid infusion and targeted blood pressure management.~11. Early mobilization.~12. Early oral feeding.~13. Multimodal analgesia, including opioids and non-steroid anti-inflammatory drugs.~14. Thromboembolism prophylaxis with low-molecular-weight heparin; rivaroxaban for high-risk patients.~15. Early pelvic drainage tube removal (at postoperative day 2) unless contraindicated.~16. Early urinary catheterization removal (at postoperative day 7) unless contraindicated."
41490133|NCT05217706|DRUG|Ketamine|The treatment group will receive Ketamine 0.2mg/kg IV once
41490134|NCT05217706|DRUG|normal Saline|The placebo group will receive normal saline IV in a matched syringe
41490135|NCT03269331|BEHAVIORAL|CTEP EBP Immersion|36 continuing ed credits, virtual library access, collaboration with expert mentors
41490136|NCT00375349|PROCEDURE|Ultrasound to demonstrate existence of fatty liver|
41490137|NCT00235196|DEVICE|Collagen ORC Antimicrobial Matrix (CAM)|
41490138|NCT03191110|OTHER|No intervention: observational study|
40825754|NCT04332471|DEVICE|Shockwave therapy device|The shockwave therapy device will be used to administer either radial or focused shockwave therapy.
41344881|NCT05333536|OTHER|No Intervention: Control group|control only participates in their yearly swimming trainings.
41344882|NCT00834392|BEHAVIORAL|Exercise|Walking exercise
41344883|NCT00638898|DRUG|busulfan|Given IV
41344884|NCT00638898|DRUG|melphalan|Given IV
41344885|NCT00638898|DRUG|topotecan hydrochloride|Given IV
41344886|NCT00638898|OTHER|laboratory biomarker analysis|Correlative studies
41344887|NCT00638898|BIOLOGICAL|filgrastim|Given IV or subcutaneously
41344888|NCT00638898|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo transplantation
41344889|NCT00638898|OTHER|pharmacological study|Correlative studies
41344890|NCT00638898|PROCEDURE|autologous bone marrow transplantation|Undergo transplantation
41344891|NCT06186024|DEVICE|Bridge|Stent implantation
41344892|NCT00244777|DRUG|Hypo-osmolar ORS|
41344893|NCT04325919|OTHER|No intervention|No intervention
41344894|NCT06173349|DRUG|PLZ4-coated paclitaxel loaded micelles (PPM)|Given PLZ4-coated paclitaxel loaded micelles intravesically
41344895|NCT01755390|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: infusion solution Route of administration: Intravenous
41490139|NCT04428112|BEHAVIORAL|Building Better Caregivers Workshop|"Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require real time attendance at pre-determined times."
40825755|NCT04332471|OTHER|Home therapy|Stretching and ice massage
40825756|NCT03511625|DRUG|Acthar Injectable Product|Acthar is a non-specific melanocortin receptor agonist
41344896|NCT02853786|BEHAVIORAL|LENA and advice|Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
41344897|NCT02853786|OTHER|LENA without advice|Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
40825757|NCT03511625|DRUG|Depo medrol|Depo medrol is an anti-inflammatory glucocorticoid
40825758|NCT00751309|OTHER|Non-interventional|Post-transplantation observational study
41344898|NCT04567953|OTHER|Saliva collection|Use Spectrum Solutions SDNA1000 or Orasure collection kit or dry tube to collect 1-3 ml of saliva
41344899|NCT01388491|DRUG|desogestrel/ethinyl estradiol and ethinyl estradiol|
41344900|NCT01388491|DRUG|desogestrel/ethinyl estradiol|
41344901|NCT00354484|DRUG|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
41344902|NCT00354484|DRUG|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
41344903|NCT06218628|DRUG|Talazoparib|pacritinib in combination with talazoparib
41344904|NCT06218628|DRUG|pacritinib|pacritinib in combination with talazoparib
41344905|NCT00723086|DRUG|docetaxel (XRP6976)|combined treatment with prednisolone
41344906|NCT02725749|RADIATION|Laser|Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
41344907|NCT02725749|OTHER|EXE|"Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
41344908|NCT02725749|RADIATION|Laser + EXE|"Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.~Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
41344909|NCT05122013|BEHAVIORAL|A comprehensive remote multidisciplinary intervention for weight regain after sleeve gastrectomy|A remote 3-months multidisciplinary intervention for weight regain after sleeve gastrectomy including bi-monthly remote consultations with a registered dietitian, physical activity consultant and sleep consultant, combined with weekly text messages meant to enhance happiness and subjective wellbeing.
41344910|NCT05122013|BEHAVIORAL|Control group|Standard nutritional care: One frontal meeting with the study's registered dietitian at the clinic, including nutritional and behavioral assessment and recommendations, followed by guidance to to continue follow up in order to support healthy lifestyle.
41344911|NCT00000281|BEHAVIORAL|Amantadine|
41344912|NCT00666055|DRUG|ARV regimen chosen by treating physician|"Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI)."
41344913|NCT00534924|DRUG|Vit C|
41344914|NCT00534924|PROCEDURE|Postconditioning|
41344915|NCT00534924|OTHER|no intervention|
41344916|NCT01251315|DRUG|Placebo low dose|This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
41344917|NCT01251315|DRUG|N Acetyl cysteine, 600mg (low dose)|The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
41344918|NCT01251315|DRUG|Proimmune 200 (FT061452) 3000mg low dose|The sub-group of four subjects (low dose) will be given a single dose of Proimmune 200 (FT061452) 3000mg low dose'
41344919|NCT01251315|DRUG|Placebo (high dose)|The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
40825759|NCT06353399|PROCEDURE|Intra-marrow penetrations|Intra-marrow penetrations
40825760|NCT06353399|PROCEDURE|No Intra-marrow penetrations|No Intra-marrow penetrations
40825761|NCT02937857|DRUG|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
40825762|NCT02937857|DRUG|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
40825763|NCT03236012|DRUG|Botulinum Toxin Type A (Botox)|Maximum dose up to 400 units given one time
40825764|NCT01065948|DEVICE|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
41344920|NCT01251315|DRUG|N Acetyl cysteine, 1200mg (high dose)|N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
41344921|NCT01251315|DRUG|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
41344922|NCT05297383|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid.|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA).
41344923|NCT05297383|DIETARY_SUPPLEMENT|Safflower Oil|4 grams safflower oil (AlaskOmega®) per day.
40825765|NCT04623268|DIAGNOSTIC_TEST|Ultrasound and questionnaire|One invititation to identified adult offspring to have an ultrasound to detect an AAA. The prevalence in this Group (strata for sex) will be compared to a random selected matched Control group
40825766|NCT03334279|OTHER|Cigarette smokers|frequent cigarette smoking for not less than 5 years
40825767|NCT03334279|OTHER|Simultaneous cigarette and cannabis smokers|frequent cigarette and cannabis smoking for not less than 5 years
41344924|NCT05297383|BEHAVIORAL|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
41344925|NCT05297383|BEHAVIORAL|Flexibility Training|30 min of stretching 3 days/week for 6 weeks
41344926|NCT02174328|DRUG|Acetylsalicylic acid|Acetylsalicylic acid once a day until 36 week
41344927|NCT02174328|DRUG|Placebo|Placebo once a day until 36 week
41344928|NCT03277794|BEHAVIORAL|HOP-C|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
41344929|NCT03277794|BEHAVIORAL|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
41344930|NCT01135394|DRUG|Pioglitazone|30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
41344931|NCT01674972|OTHER|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
41344932|NCT03441555|DRUG|Venetoclax|tablet, oral
41344933|NCT03441555|DRUG|Alvocidib|Intravenous
41344934|NCT01577628|DRUG|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
41344935|NCT04692896|DRUG|lidocaine|different concentrations of lidocaine with same concentration of adrenaline
41344936|NCT01636167|DEVICE|computerized intraoperative keratomer|computerized intraoperative keratomer can analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery
41344937|NCT05480501|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
41344938|NCT05616052|DRUG|Semaglutide|treatment with different dosage regimes
41344939|NCT00454350|DRUG|Hectorol (doxercalciferol injection)|
41344940|NCT00454350|DRUG|Zemplar (Paricalcitol injection)|
41344941|NCT01339104|DRUG|Regorafenib (Stivarga, BAY73-4506)|All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
40825768|NCT01151111|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
41344942|NCT02463227|BIOLOGICAL|VRC01|"40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump."
41344943|NCT00389129|DRUG|acetylsalicylic acid|
40825769|NCT02801721|OTHER|psycho social stimulation|The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
41344944|NCT03826316|DRUG|Nalbuphine|Pharmacokinetic study under fasting conditions
41344945|NCT05758974|PROCEDURE|dental treatment|Extraction, pulp therapy or both
41344946|NCT04531397|DRUG|ACEI treatment|ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
41344947|NCT04531397|DRUG|Dapagliflozin+ACEI treatment|Dapagliflozin will be given 10 mg/day (weight\>30kg) or 5mg/day (weight≤30kg), for 24 weeks ACEI, will be given based on body weight (max 20mg/d), for 24 weeks.
41344948|NCT00681291|DEVICE|Inguinal hernia repair with Ultrapro|surgical mesh (15x15cm) to support Lichtenstein repair
41344949|NCT00681291|DEVICE|Inguinal hernia repair with Strattice|Surgical mesh (10x16) used to support Lichtenstein repair
41344950|NCT02590406|PROCEDURE|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
41344951|NCT02590406|PROCEDURE|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
41490140|NCT04428112|BEHAVIORAL|Attention Control|Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.
41344952|NCT03249558|DRUG|Morphine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
41344953|NCT03249558|DRUG|Duloxetine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
41490141|NCT02318238|OTHER|6 minutes walking test|
41490142|NCT02318238|OTHER|6 minutes step test|
41490143|NCT02318238|OTHER|4 meters gait speed|
41490144|NCT03801538|DRUG|Peginterferon Alfa|Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
40825770|NCT03411200|BEHAVIORAL|Multimodal and exercise-based intervention|"The multimodal and exercise-based intervention is comprised of:~1. Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.~2. Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.~3. Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.~4. A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session."
40825771|NCT01937793|OTHER|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
40825772|NCT01937793|OTHER|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
40825773|NCT02632201|BIOLOGICAL|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
40825774|NCT02632201|BIOLOGICAL|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
40825775|NCT03082573|DRUG|H.P. Acthar gel|H.P. Acthar gel in treatment of Refractory RA
40825776|NCT02504112|OTHER|there is no intervention|
40825777|NCT00837876|DRUG|Sorafenib|400 mg taken by mouth 1 time per day.
40825778|NCT00837876|DRUG|Erlotinb|150 mg taken by mouth 1 time per day.
40825779|NCT02549222|OTHER|Standard of Care|
40825780|NCT02563860|DRUG|Lovastatin|dose escallating
40825781|NCT04510948|BEHAVIORAL|Patient Priorities Care|"Patient Priorities Care (PPC) is an innovative approach to shared decision-making that draws from existing professional training.~PPC requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences. This information will be collected and documented in the EHR by facilitators and shared with the clinicians who will then use the PPC approach with patients to inform and guide treatment decisions.~The PCPs will be trained in decisional strategies that have been shown to help align care with patients' health priorities. While encouraged to use these decisional strategies, PCPs will be free to make the recommendations they feel most appropriate for each patient.~This intervention has been developed to be integrated seamlessly into usual care."
40825782|NCT02615405|DIETARY_SUPPLEMENT|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 \& 2.
40825783|NCT02615405|DIETARY_SUPPLEMENT|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 \& 2.
40825784|NCT02615405|DIETARY_SUPPLEMENT|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
40825785|NCT03349645|BIOLOGICAL|4 mL injection of AMPION™|4 mL injection of AMPION™
40825786|NCT01904916|PROCEDURE|Histological biopsy procedure|
40825787|NCT05404347|DIAGNOSTIC_TEST|Next generation sequencing|NGS is carried out on DNA isolated from paraffin embedded tissue
40825788|NCT00908648|PROCEDURE|Narrow Band Imaging|Narrow Band Imaging
40825789|NCT04441164|OTHER|Observation of Virtual Actions|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
41344954|NCT03249558|DRUG|Placebo|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
41344955|NCT02021474|DRUG|AGX-201|Subcutaneous injection
41344956|NCT02021474|DRUG|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|Subcutaneous injection
41344957|NCT04175431|PROCEDURE|Positron Emission Tomography|Undergo fluciclovine PET/CT
41344958|NCT04175431|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
41344959|NCT04175431|RADIATION|Radiation Therapy|Undergo radiation therapy
41344960|NCT04175431|DRUG|Abiraterone Acetate|Given PO
41344961|NCT04175431|DRUG|Prednisone|Given PO
41344962|NCT04175431|PROCEDURE|Computed Tomography|Undergo fluciclovine PET/CT
41344963|NCT04175431|DRUG|Abiraterone|Given PO
41344964|NCT04175431|PROCEDURE|PSMA PET Scan|Undergo PSMA PET scan
41344965|NCT02289833|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
41344966|NCT05825014|OTHER|No intervention|No intervention
41344967|NCT05628987|OTHER|no intervention|Observational studies, no intervention
41344968|NCT05554744|PROCEDURE|EUS-guided fine-needle injection|Diagnostic evaluation for suspected MEN1-1-related pNETs is conducted by cytology or immunohistochemistry and genetic testing. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol/ lauromacrogol under the guidance of EUS was injected into the tumor The volume of ethanol/ lauromacrogol is administrated based on the tumor size.
41344969|NCT05280236|DRUG|Propofol TIVA|Patients will receive propofol-based TIVA with propofol and remifentanil TCI (target controlled infusion)
41344970|NCT05280236|DRUG|Remimazolam TIVA|Patients will receive remimazolam-based TIVA with remimazolam infusion and remifentanil TCI
40825790|NCT04441164|OTHER|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
40825791|NCT04441164|OTHER|Acceptability questionnaire|It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
40825792|NCT04441164|OTHER|Observation of Virtual Actions (step 4)|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
41344971|NCT05141344|DRUG|Melatonin 3 MG Oral Tablet|it will be given orally one hour preoperatively
41344972|NCT05141344|DRUG|Placebo|sugar-coated tablets will be given one hour preoperatively
41344973|NCT02772835|DEVICE|Medin-cno|Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
41344974|NCT02432690|DRUG|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
41344975|NCT01510561|DRUG|90Y-hPAM4|90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
41344976|NCT01510561|DRUG|90Y-hPAM4|
41344977|NCT01510561|DRUG|90Y-hPAM4 + gemcitabine|
41344978|NCT03645811|BEHAVIORAL|Music Therapy|Music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.
41344979|NCT03645811|BEHAVIORAL|EFT|EFT includes taps, nine gamut sequences, and eye movements on the meridian system, focusing on the individual's inhibiting thoughts, disturbing emotions, or memories. EFT regulates the flow of energy in the meridian system of the individual, causing relaxation in the mind, body, and emotions.
41344980|NCT01194414|DRUG|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
41344981|NCT01194414|DRUG|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
41344982|NCT01194414|DRUG|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
41344983|NCT01194414|DRUG|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
41344984|NCT01194414|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
41344985|NCT03669146|DEVICE|Glasses|Partial refractive correction in a pair of glasses.
41490145|NCT03801538|DRUG|Nucleoside Analog (Substance)|Patients do not need to change their NAs treatment.
40825793|NCT04441164|OTHER|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
40825794|NCT04441164|OTHER|Haptic stimulation|According to the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
41344986|NCT05476757|BIOLOGICAL|rDEN2Δ30-7169|rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.
41344987|NCT05208450|OTHER|Practice support And Community Engagement (PACE)|A practical and sustainable implementation strategy, referred to as Practice Facilitation And social deTerminants of health support utilizing CHWs (PATCH), to support the implementation and evaluation of three multi-level evidence-based interventions: \[nurse case management (NCM) + remote blood pressure monitoring (RBPM) + social determinants of health (SDOH) support\] delivered as an integrated community-clinic linkage model \[Practice support And Community Engagement (PACE)\]
41344988|NCT05024890|OTHER|Splash WASH in Schools programme (Project WISE)|"The Project WISE intervention includes:~WASH infrastructure~* Water storage tanks and water filtration systems~* Durable plastic drinking water and handwashing stations~* New/rehabilitated toilet facilities (gender-segregated, wheelchair-accessible, well-lit, ventilated, durable door and lock)~Behaviour change promotion~* Training of focal teachers to organise student 'hygiene club'~* Annual soap drive and soap restocking~* Behavioural 'nudges' (posters and mirrors at handwashing stations, colourful vests for hygiene clubs)~MHM services~* Toilets have water tap, bucket and waste bin~* Emergency menstrual hygiene products available at school~* Training of focal teachers to organise student 'gender club'~* Education on puberty and menstruation for all pupils above 10 and parent resource guide"
41344989|NCT04282460|BEHAVIORAL|Baduanjin practice|Use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
41490146|NCT06037083|DEVICE|Oxygen saturation probe|The high-accuracy oxygen saturation signal will be continuously acquired for 168 hours post extubation from a separate pulse oximeter (Radical-7®, Masimo ROOT platform, MasimoCorp, Irvine, LA).
40825795|NCT04441164|OTHER|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
41018691|NCT05661292|BIOLOGICAL|Optional collection of tissue, blood and urine for future biomedical research|Subjects may optionally participate in the collection of tissue, blood, and urine samples for future biomedical research. This procedure consists of taking a 15 ml sample of venous blood and 20 ml of urine. The tissue samples to be used will be those that have been taken for diagnostic purposes during the colonoscopy. Additional biopsies not required for medical care will not be taken. These samples will be used as long as they are no longer required to establish a diagnosis.
41344990|NCT04282460|BEHAVIORAL|Regular physical exercise|Take physical exercise for at least half an hour every day in addition to regular physical activities at school.
41490147|NCT06037083|DEVICE|Near infrared spectroscopy sensors|The cerebral and splanchnic regional oxygen saturation signals will be acquired continuously for 168h post extubation using two near infrared spectroscopy sensors (Masimo ROOT platform, MasimoCorp, Irvine, LA), one placed on the forehead for cerebral oxygenation and one on the abdomen (for splanchnic oxygenation).
40825796|NCT02078102|DRUG|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
40825797|NCT02078102|DRUG|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
40825798|NCT00035360|DRUG|PEG-Intron|
40825799|NCT04120857|BEHAVIORAL|Gentle Stretching|60 minutes fo gentle stretching twice weekly for 8 weeks
40825800|NCT05938920|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
40825801|NCT05938920|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
40825802|NCT00541099|BIOLOGICAL|bevacizumab|Avastin 10.0 mg/kg on days 1 and 15
40825803|NCT00541099|DRUG|docetaxel|Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
40825804|NCT02710123|OTHER|Sub-Threshold exercise prescription|Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
40825805|NCT02710123|OTHER|Structured stretching prescription|Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
41344991|NCT01863706|DRUG|Misoprostol|400µg oral misoprostol
40825806|NCT04067037|DRUG|Camrelizumab|30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
40825807|NCT04067037|DRUG|Epirubicin|35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
40825808|NCT04067037|DRUG|Vincristine|1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
40825809|NCT04067037|DRUG|Dacarbazine|375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
40825810|NCT04526145|BEHAVIORAL|Stress and emotion management|Group intervention led by a nurse and dietitian to address stress, emotion management and healthy lifestyle for African American women with hypertension. The weekly sessions will include:how to manage stress during Covid-19, taking blood pressure, interpersonal relationships skills, mindful awareness, restful sleep, physical activity, and healthy eating.
40825811|NCT03846531|DEVICE|Nano-Pulse Stimulation (NPS)|The Pulse generator delivers electrical pulses (nanosecond duration) that are applied directly to targeted lesion using sterile treatment tips with micro-needles.
40825812|NCT00297973|PROCEDURE|Blood pressure measurements|
40825813|NCT00297973|PROCEDURE|Blood samples|
41344992|NCT01863706|DRUG|Oxytocin|20 IU Oxytocin
41344993|NCT00877227|DRUG|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
40825814|NCT03350893|COMBINATION_PRODUCT|Emulsion base with probiotics|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide, Heat-killed L. plantarum powders (1x10\^9 cells/ g-cream)
40825815|NCT03350893|OTHER|Emulsion base|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide
40825816|NCT00129870|DRUG|oxaliplatin|
40825817|NCT03089879|BIOLOGICAL|GVGH Shigella sonnei 1790GAHB vaccine|Single dose administered at Day 1, by intramuscular injection.
40825818|NCT04542668|OTHER|Cycling then running|Ergometer cycling Treadmill running
40825819|NCT04542668|OTHER|Running then cycling|Treadmill running Ergometer cycling
40825820|NCT04542668|OTHER|Inotropy|Adrenaline induced inotropy
40825821|NCT04542668|OTHER|Resting|Subjects must be minimally physically active
41018692|NCT05726656|OTHER|traditional physical therapy session|manual lymph drainage-pneumatic compression and skin care
41018693|NCT05726656|OTHER|wii console based exercise|execise session using the wii console video games
41018694|NCT03324165|OTHER|Proposed Algorithm|Proposed algorithm that uses Alvarado Score to guide CT utilization
41018695|NCT00637169|OTHER|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
41018696|NCT00504244|DRUG|switch to Myfortic|Myfortic 2 dd 720 mg
41018697|NCT00504244|DRUG|continuation of azathioprine|Azathioprine 2 mg/kg
40825822|NCT01657942|DEVICE|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
40825823|NCT02516293|BEHAVIORAL|Exercise, nutritional and pharmaceutical counseling|Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
40825824|NCT00145353|DRUG|Insulin NovoRapid versus Actrapid|
41344994|NCT04510155|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 1 day
41344995|NCT05474768|OTHER|no intervention|no intervention
41344996|NCT00251017|PROCEDURE|Vancomycin|Two hour creatinine clearance before and after vancomycin
40825825|NCT05036382|BEHAVIORAL|Steps data observation|Sending more step data from the experimental group that received the incentive message
40825826|NCT00005764|DRUG|Lamivudine/Zidovudine|
41344997|NCT00251017|PROCEDURE|DNA are extracted from the whole blood of subjects|
41344998|NCT01992328|DRUG|Immune Globulin|6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
41344999|NCT04964804|PROCEDURE|real-time ultrasound-CT fusion imaging|selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging
41345000|NCT04964804|PROCEDURE|ultrasound alone|selective lumbar nerve root block puncture under the guidance of ultrasound alone
41345001|NCT00863317|DRUG|montelukast sodium|4mg granules daily for 14 days
41345002|NCT00863317|OTHER|sucrose|table sugar as placebo daily for 14 days
41345003|NCT02916199|DEVICE|cannulation of ampulla of Vater|Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
41345004|NCT01524926|DRUG|Crizotinib (PF-02341066)|For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
41345005|NCT00853619|OTHER|Service based decision support intervention|Delivering CDS via services
41345006|NCT03714789|OTHER|Blood and spent dialysate collection|A certain amount of blood and spent dialysate are collected during and after dialysis for quantification of drug concentration.
40825827|NCT00005764|DRUG|Abacavir sulfate|
40825828|NCT00005764|DRUG|Lamivudine|
40825829|NCT00405964|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 12 weeks
40825830|NCT00405964|DRUG|Placebo tablet|Placebo tablet, once daily for 12 weeks
40825831|NCT01180816|DRUG|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
40825832|NCT01055665|OTHER|cognitive behavior therapy|6 cognitive behavior therapy groups
40825833|NCT03835884|DRUG|AR-13503 Implant 10.6 Dose|AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
40825834|NCT03835884|DRUG|AR-13503 Implant 21.2 Dose|AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
40825835|NCT03835884|DRUG|AR-13503 42.4 Dose|AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
40825836|NCT03835884|DRUG|AR-13503 63.6 Dose|AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
40825837|NCT02240849|DEVICE|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
40825838|NCT02240849|DEVICE|Placebo general pillow|
40825839|NCT06176495|DIAGNOSTIC_TEST|Educational Text Messages|"The educational content will be targeted about Diabetes Education and will be guideline based with what complies to the standards of care instituted by the American Diabetes Association.~They text messages will comprise content related to general diabetes knowledge, diabetes management and control, coping with diabetes, and guidance on adopting a healthy lifestyle."
41345007|NCT03676465|OTHER|CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. The participants will receive a weekly CloudConnect Report that is based on analysis of the data gathered from the downloads provided by the subject during that week. Participants will both receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
41345008|NCT03676465|OTHER|Will not receive a CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. Participants will receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
41345009|NCT03718468|BIOLOGICAL|GC FLU Quadrivalent|A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.
40825840|NCT01336530|DRUG|oxetacaine, aluminium and magnesium hydroxide|20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
40825841|NCT01336530|DRUG|oxetacaine|20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
40825842|NCT01336530|DRUG|magnesium and aluminium hydroxide|196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
40825843|NCT01336530|OTHER|Vehicle|Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
40825844|NCT03275688|DIAGNOSTIC_TEST|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
40825845|NCT02095665|DRUG|Mirabegron|50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
40825846|NCT02095665|DRUG|Tamsulosin|0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
40825847|NCT02095665|DRUG|Tylenol #3|1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
40825848|NCT02120495|PROCEDURE|condylectomy|The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
40825849|NCT06239246|OTHER|Behavioral|"Psychotherapy: Cognitive-behavioral therapy (CBT), Internet-based cognitive-behavioral therapy (I-CBT), cognitive-behavioral therapy for insomnia (CBT-I), self-management education for heart failure, blended intervention; Drug treatment (cardiovascular drugs: aspirin, clopidogrel, ticagrelor, statins; psychiatric drugs: SSRIs, SNRIs, etc.);"
40825850|NCT03807297|DRUG|Injection dexmedetomidine|alpha 2 a agonist used for sedation, analgesia
40825851|NCT03807297|DRUG|Injection, Propofol, 10 Mg|non barbiturate type of intravenous anaesthetic drug
40825852|NCT03807297|OTHER|sevoflurane|inhalational anaesthetic agent
40825853|NCT03807297|OTHER|nitrous oxide|inhalational anaesthetic agent
40825854|NCT04532593|PROCEDURE|autologous adipose stem cell injection|Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).
40825855|NCT04532593|PROCEDURE|saline injection|saline will be injected underneath skin graft (0.05 ml/cm2).
40825856|NCT06027333|BEHAVIORAL|inpatient rehabilitation|This is an uncontrolled observational study on patients undergoing usual care in pulmonary rehabilitation and care
40825857|NCT00468676|BEHAVIORAL|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
40825858|NCT00468676|BEHAVIORAL|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
41018698|NCT01999010|DEVICE|MHT|MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
40825859|NCT03141788|DEVICE|Clear Aligner|Clear Aligner used to straighten teeth to desired outcome
40825860|NCT05929378|PROCEDURE|Lightweight mesh fixation|Lightweight mesh fixation in 3 points
41018699|NCT01880567|DRUG|Ibrutinib|Given PO
41018700|NCT01880567|OTHER|Laboratory Biomarker Analysis|Correlative studies
41018701|NCT01880567|BIOLOGICAL|Rituximab|Given IV
41345010|NCT03718468|BIOLOGICAL|Fluarix Tetra|A single dose administration of Fluarix Tetra will be through intramuscular injection.
40825861|NCT05058105|DRUG|FL058 500mg and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
40825862|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
40825863|NCT05058105|DRUG|FL058 1000mg（ IV 120min）|D1 qd;
40825864|NCT05058105|DRUG|FL058 Placebo （ IV 120min）|D1 qd;
40825865|NCT05058105|DRUG|Meropenem 1000 mg （ IV 120min）|D4 qd;
40825866|NCT05058105|DRUG|Meropenem Placebo （ IV 120min）|D4 qd;
40825867|NCT05058105|DRUG|FL058 1000mg and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
40825868|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
40825869|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
40825870|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
40825871|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
40825872|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
40825873|NCT05058105|DRUG|FL058 2000mg and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
40825874|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
40825875|NCT04659928|DEVICE|High volume evacuation (HVE)|Intra oral suction will be done and during the procedure,bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
40825876|NCT04659928|DEVICE|Extraoral vacuum aspirator (EVA)|Extraoral suction connected to dental suction will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
40825877|NCT04659928|DEVICE|External evacuation device (EED)|Extraoral suction unit will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
40825878|NCT04659928|DRUG|Hydrogen Peroxide|Subjects will be given 1.5 % Oral Solution of hydrogen peroxide mouth rinse
40825879|NCT06605235|PROCEDURE|Local Anesthesia|In Group A, patients received 20 ml of 1% lignocaine (Xyloaid-lignocaine HCl injection) infiltrated in the gall bladder bed after removal of the gall bladder, along with 10 ml of 1% lignocaine infiltration at the port sites at the end of the procedure. Subjects in Group B received 20 ml of 0.25% bupivacaine (Bupicain-Bupivacaine HCl injection) infiltration in gall bladder bed, along with 10 ml of 0.25% bupivacaine at port sites. In Group C patients received 10 ml of 1% lignocaine along with 10 ml of 0.25% bupivacaine infiltrated in gall bladder bed, and then 5 ml of 1% lignocaine along with 5 ml of 0.25% bupivacaine at the port sites
40825880|NCT04854031|DEVICE|Cochlear Implants|Individuals with cochlear implants will be tested on their hearing ability. Auditory recordings of speech will be played to participants from a loudspeaker. Recordings will be edited to add competing noise sources and to adjust talker voice pitch. Synthetic sounds will be manipulated to control auditory cue salience in detection tasks.
40825881|NCT04363593|BIOLOGICAL|Serological test|Serological testing is performed for patients with confirmed COVID-19 infection by RT-PCR.
41345011|NCT02259127|DRUG|DTG|
40825882|NCT04363593|BIOLOGICAL|Serum test|Use of the serum taken from patients consulted for suspicion of COVID-19 before the beginning of the trial
40825883|NCT02161276|DRUG|TNTL capsule|Patients were asked to taken drugs 3 times a day, with each time 3 grains
40825884|NCT02161276|DRUG|Placebo|Patients were asked to taken drugs 3 times a day, with each time 3 grains
40825885|NCT05266183|OTHER|Simultaneous Variety|3 different foods served
40825886|NCT05266183|OTHER|Single-Food|1 food served
41018702|NCT01123018|BEHAVIORAL|Memtrax Memory screening test|Memory Screening test
41345012|NCT00591396|DRUG|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
40825887|NCT05266183|OTHER|Small Portion|Small meal portion size
40825888|NCT05266183|OTHER|Large Portion|Large meal portion size
41345013|NCT06328855|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
41345014|NCT06328855|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
41345015|NCT06328855|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
41345016|NCT00023205|BEHAVIORAL|11th grade reading level arthritis materials|
41345017|NCT00023205|BEHAVIORAL|Interactive in-person arthritis education|
41345018|NCT01424865|GENETIC|fluorescence in situ hybridization|
40825889|NCT00358332|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
40825890|NCT00358332|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
41345019|NCT01424865|OTHER|immunohistochemistry staining method|
41490148|NCT06037083|DEVICE|Electrical impedance tomography|"The regional lung ventilation will be measured using Electrical Impedance Tomography (TIMPEL, USA) at three time points:~* From 1 hour pre-extubation to 2 hours post extubation (total 3 hours)~* Between 24 and 48 hours post extubation (total 3 hours)~* Between 72 and 96 hours post extubation (total 3 hours)"
41490149|NCT00902031|DRUG|Docusate Sodium, Sennoside|"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."
41345020|NCT01424865|OTHER|immunologic technique|
41345021|NCT01424865|OTHER|laboratory biomarker analysis|
41345022|NCT00554528|DEVICE|cervical disc prosthesis with a mobile insert named Mobi-C|"Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization"
41345023|NCT00554528|PROCEDURE|arthrodesis - cervical disk surgery|discectomy and arthrodesis
41345024|NCT04945304|PROCEDURE|magnetic bariatric surgery|Perform a roux-en-y gastric bypass, sleeve gastrectomy, nissen-sleeve or revisional bariatric procedure with magnetic assistance
41490150|NCT00902031|DRUG|Sennoside + Placebo|"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"
41490151|NCT01959035|DRUG|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
40825891|NCT04094142|DRUG|Acalabrutinib|"Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission."
40825892|NCT01810848|DEVICE|Hylan G-F 20|"Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics."
40825893|NCT01810848|OTHER|Control|Control is puncture of the skin at the site of the knee.
40825894|NCT05731076|BEHAVIORAL|Self-management support nutrition and exercise intervention|Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
40825895|NCT02159222|PROCEDURE|Additional physical therapy|
40825896|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization for one week
40825897|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization for one week
40825898|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization until delivery
41018703|NCT06401681|OTHER|Balance training|The balance exercises consist of single limb stances with eyes open and closed, single-leg hops with stabilization, and single-leg hops and reach. Thirty-second breaks will be provided between exercise sets. Progressions for single-leg stance exercises involve longer durations and introduction of unstable surfaces. Progressions for hopping exercises involve longer hopping distances. To progress to the next level, participants must complete a balance training session without any errors. Errors include 1) touching the floor or bracing with the opposite limb, 2) excessive lateral trunk flexion or hip abduction, 3) hands coming off hips (hop tasks) or shoulders (stance tasks), 4) missing the landing target, 5) using the reach leg for a substantial amount of weight bearing.
41157333|NCT04688086|DIAGNOSTIC_TEST|Thermalytix|Thermalytix is an Artificial intelligence based automated breast screening solution that analyzes thermal distribution on the breast to generate a breast health score automatically. Thermal imaging was performed by a trained technician to capture thermal images of the participant in five views. These thermal images were uploaded to Thermalytix software on the cloud where it was automatically analyzed by AI-based Thermalytix computer-aided detection (CADe) engine. This CADe engine analyzes uploaded thermal images and outputs an interpretation report for each participant with quantitative scores corresponding to computed probability of malignancy based on the structural, vascular, areolar, thermal properties of the observed abnormality. Thermalytix also generates annotated images with markings of abnormal regions and an overall Thermalytix score suggesting likelihood of breast malignancy. The locked AI model Thermalytix algorithm version 3, dated December 2018 was used for the analysis.
41157334|NCT00287183|DRUG|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
41157335|NCT00287183|OTHER|Placebo|Placebo
41490152|NCT05819216|DEVICE|Treadmill|Gait training on treadmill training
41490153|NCT01831765|DRUG|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
41490154|NCT01831765|DRUG|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
40825899|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization until delivery
40825900|NCT03372551|DEVICE|somofilcon A 1 day test lens|Contact lens
40825901|NCT03372551|DEVICE|somofilcon A 1 day control lens|Contact lens
40825902|NCT00003946|DRUG|danazol|
40825903|NCT00659100|DRUG|Gabapentin|Gabapentin 50 mg oral capsule 30 minutes before bedtime
40825904|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d
41157336|NCT06646471|GENETIC|Bio-bank repository|Blood samples taken during the screening phase prior to the first administration of systemic treatment and stored in a repository for a maximum duration of 10 years
41490155|NCT01831765|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
41490156|NCT01831765|DRUG|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
40825905|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
41490157|NCT00063635|DRUG|Metformin|500 mg, twice daily
41490158|NCT00063635|DIETARY_SUPPLEMENT|Vitamin E|400 IU, twice daily
40825906|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
41490159|NCT00063635|DRUG|Matching placebo|Twice daily
41345025|NCT04945304|PROCEDURE|Magnetic gastric bypass|Using the magnetic assistance to perform a gastric bypass
41345026|NCT00659906|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
41345027|NCT00659906|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
41345028|NCT02126527|DRUG|auranofin|Given PO
41345029|NCT02126527|DRUG|sirolimus|Given PO
41157337|NCT06646471|OTHER|Quality of Life (QoL)|"Collection of EORTC QoL questionnaires QLQ-F17, QLQ-LC13 and QLQ-ELD14:~* stage 3 non-operable/non-radiable, stage 4: at inclusion, 12 weeks, 6 months of treatment, first-line progression.~* operable stage 1 to 3b: at inclusion, end of neoadjuvant period before surgery post-operative baseline, at 6 months, at 12 months.~* radiable stages 3a to 3c: at inclusion, at the end of thoracic radiotherapy, at 6 months, at 12 months."
41157338|NCT06646471|PROCEDURE|G-Code|G-CODE: Katz Autonomy Scale (ADL), Instrumental Activities of Daily Living questionnaire (IADL), Charlson score, mini GDS, mini COG, falls history, Timed Get Up and Go test, social environment.
41345030|NCT02126527|OTHER|laboratory biomarker analysis|Correlative studies
41345031|NCT02126527|OTHER|pharmacological study|Correlative studies
41345032|NCT03455504|DRUG|Venetoclax|Venetoclax add in combination with fludarabine, cyratabine and idarubicine
41345033|NCT04823689|PROCEDURE|reductions|"Two reduction techniques are compared: dorsal decubitus and ventral decubitus reduction. The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.~The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula."
41345034|NCT00521118|OTHER|Laboratory Biomarker Analysis|Correlative studies
41345035|NCT00521118|PROCEDURE|Therapeutic Conventional Surgery|Undergo second curettage
41345036|NCT05553652|DIETARY_SUPPLEMENT|ASTARTE™ oral capsules|1 Capsule daily for 6 months
41345037|NCT05553652|DIETARY_SUPPLEMENT|Placebo oral capsules|1 Capsule daily for 6 months
41345038|NCT00139633|DRUG|carboplatin, 5FU, Taxol and radiation|
41345039|NCT05579795|PROCEDURE|Detethering of the spinal cord|Release of the tethered spinal cord
41345040|NCT01975675|DRUG|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
41345041|NCT01975675|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
41345042|NCT03976193|BEHAVIORAL|BfitBwell program|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
41345043|NCT03976193|BEHAVIORAL|6 bi-weekly PA Behavior Change counseling sessions|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
41345044|NCT03061227|DRUG|Intravenous glucagon|Randomized application of glucagon or saline during oral glucose tolerance test
41345045|NCT03061227|DRUG|Intravenous saline|Randomized application of glucagon or saline during oral glucose tolerance test
41345046|NCT01436357|BIOLOGICAL|AdCh3NSmut1|Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10\^10 total virus particles (vp)/dose, intramuscularly on day 0.
41345047|NCT01436357|BIOLOGICAL|MVA-NSmut|Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10\^8 plaque forming units (pfu) intramuscularly on day 56.
41345048|NCT01436357|OTHER|Placebo|Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
41345049|NCT01089751|DRUG|trospium chloride|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
41345050|NCT01089751|DRUG|placebo|Placebo once daily on an empty stomach for 14 weeks.
41345051|NCT02668692|DRUG|LEO 80185 gel|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
41345052|NCT02668692|DRUG|Dovobet ® ointment|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
41345053|NCT04017624|OTHER|Fresh Truck with stipend|"Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location."
41345054|NCT04017624|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
41490160|NCT00527306|DIETARY_SUPPLEMENT|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
41490161|NCT00210990|DRUG|doripenem|
41490162|NCT06477484|DIAGNOSTIC_TEST|Blood biomarker|Blood biomarker
41490163|NCT04730349|BIOLOGICAL|Nivolumab|Specified dose on specified days
41490164|NCT04730349|BIOLOGICAL|NKTR-214|Specified dose on specified days
41490165|NCT04206514|BEHAVIORAL|Person Centered Care - Post Abortion Support|Post abortion phone based support
41345055|NCT05627791|DRUG|Oxytocin|Oxytocin vaginal gel that have oxytocin 400IU/1ml of gel, base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0
41345056|NCT05627791|DRUG|Placebo|Placebo gel that have base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0 without oxytocin
41157339|NCT02473588|DEVICE|Retia Medical Long Time Interval Analysis|"Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter"
41157340|NCT06539520|OTHER|Aerobic training program|Aerobic training program; on interval moderate mode, 3 session per week, for 16 weeks, along 30-40 minutes, plus 5-10 minutes of warm up and 5 minutes cooling down, with 50-80% of maximal heart rate for each patient based on age. that progress every month by 10% directed by rating of perceived exertion.
41490166|NCT04730882|DIETARY_SUPPLEMENT|Mixed Meal|the meal will be 40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively
41490167|NCT01676415|DRUG|Prednisone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days~Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study"
41490168|NCT01676415|DRUG|Topical mometasone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study."
41490169|NCT02982798|DRUG|Metformin + Rosuvastatin|administration of Metformin + Rosuvastatin
41490170|NCT02982798|DRUG|JLP-1310|administration of JLP-1310
41345057|NCT03368079|DEVICE|Negative Pressure Suction Catheter|The negative pressure suction device to be used in the study will be a Foley catheter. The catheter will be placed through the gastrostomy tube site, directed retrograde through the esophagus, and terminating in the PES.
41345058|NCT05533073|DRUG|A1: Etoricoxib / Tramadol Fixed dose combination|Sachet with granules (Laboratorios Silanes S.A. de C.V.). Formula : 90 mg/ 50 mg Pharmaceutical Form: Sachet with granules Dosage: 100 mL (90 mg/ 50mg) Administration way: oral
41345059|NCT05533073|DRUG|A2: Etoricoxib|Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
41490171|NCT06155318|DIAGNOSTIC_TEST|68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included|Patients meeting the inclusion criteria will undergo 68Ga-DOTATOC PET(PET/MRI or PET/CT) as part of their routine work-up, according to the referral clinicians' indication.PET/MRI will be performed on a 3.0T time of flight PET/MRI. Simultaneous PET/MRI will start approximately 60 minutes after the injection of 68Ga-DOTATOC.
41490172|NCT05476913|DEVICE|geko™ device|Neuromuscular electrical stimulation of the peroneal nerve
41490173|NCT03011190|BEHAVIORAL|Emotional regulation|Educate people with difficulty in regulating their emotions and help them acquire skills to do so
41490174|NCT00977379|RADIATION|WBRT|3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
41490175|NCT00977379|DRUG|Capecitabine|825 mg/m\^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
41490176|NCT00977379|DRUG|Standard of Care|The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
40825907|NCT04676165|DEVICE|Smart About Meds (SAM)|"SAM generates a patient-friendly list of prescribed and dispensed medications and offers several features:~* Drug information: Patient-friendly monographs that describe treatment indications and the harms/benefits of medications.~* Adherence alerts: Alerts users to non-adherence, such as when they fill prescriptions that were stopped at hospital discharge, don't fill prescribed medications, or buy medications at the incorrect dose.~* Side-effect checker: Provides a list of side effects associated with individual medications and the patient's overall drug profile.~* Rate my med: Allows patients to rate medications and describe experiences with a medication. Patients can view ratings given by users.~* Caregiver connect: Provides patients' caregivers with access to the app.~* Pharmacy connect: Allows patients to connect with their hospital pharmacist to ask questions regarding their medications and adherence alerts.~* Other: pill images, daily pill reminders, weekly dosing schedule"
40825908|NCT03089944|DRUG|Glecaprevir/Pibrentasvir|Tablet
40825909|NCT02980744|BEHAVIORAL|Sedentary behaviour intervention|The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
41345060|NCT05533073|DRUG|A3: Tramadol|Tradol®, from Grünenthal GMBH. Pharmaceutical Form: Capsule Formula: Each capsule contains 50 mg Dosage: 1 capsule of 50 mg Administration way: oral
41490177|NCT05376709|DIETARY_SUPPLEMENT|Short-Term Calorie Reduction|Align with the R-CHOP regimen, patients in the experimental group will first perform water fast 24 hours before (day 0) and during the first day of R-CHOP (day 1) when they receive Rituximab, Vincristine, Doxorubicin, cyclophosphamide, and prednisolone. On day 2, they will resume normal calorie intake until the day before the next cycle of chemotherapy. While each cycle of R-CHOP takes 21 days, most patients will receive a total of 6-8 cycles over four to six months.
41490178|NCT02203214|DEVICE|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
41490179|NCT02359747|GENETIC|Polymerase Chain Reaction and Whole Genome Amplification|Polymerase Chain Reaction and Whole Genome Amplification
41345061|NCT02261402|OTHER|Medisinstart|"Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine."
41345062|NCT02968966|OTHER|Therapy regime|Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.
41345063|NCT00904111|DRUG|Lidoderm®|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
41345064|NCT00904111|DRUG|Placebo Topical Patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
41345065|NCT05791006|BEHAVIORAL|Neuropsychological tests|"Neuropsychological assessment with:~* NADL-F~* Frontal Assessment Battery (FAB)~* functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)~* Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients~* Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients"
41345066|NCT02352090|DRUG|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
41345067|NCT02352090|DRUG|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
41345068|NCT02352090|DRUG|Dienogest|One tablet orally for 9 weeks, continuous use
41345069|NCT01188811|DRUG|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
41345070|NCT01188811|DRUG|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
41345071|NCT04724213|OTHER|Testing of reliability / validity of new questionnaire|Participants will answer new questionnaire and other, established, generic and chronic generic HrQol instruments
41345072|NCT05699044|DIAGNOSTIC_TEST|Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)|"Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.~DPD-scintigraphy. (Echocardiography)"
41345073|NCT01737138|PROCEDURE|RSD|Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
41345074|NCT01737138|DRUG|medicine|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
41345075|NCT00299416|DRUG|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
41345076|NCT00299416|PROCEDURE|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
41490180|NCT02934763|DRUG|Propranolol|propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals
40825910|NCT04130061|BIOLOGICAL|Human Amniotic Membrane|Epicardial application of human amniotic membrane during cardiac surgery
40825911|NCT02905617|DEVICE|Sientra 207 Silicone Gel Breast Implant|The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.
40825912|NCT03255213|OTHER|Lingual Muscle Training|Lingual Muscle Training using the Iowa Oral Performance Instrument (OIPI) device
41490181|NCT02934763|DRUG|Saline|Saline as placebo
41157341|NCT06539520|OTHER|Selected physical therapy program for post stroke patients|Selected neurorehabilitation for 1 hour session; 3 sessions per week, for 16 weeks. It involves weight shift side to side, reaching toward weak side, shoulder flexion overhead, shoulder external rotation, overhead press, shoulder internal rotation with Thera-band, heel slides, bridging, lying terminal knee extension, toe and heel raises, sensory reeducation exercises, and body awareness therapy.
41345077|NCT02124928|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
41490182|NCT06008366|DRUG|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
41490183|NCT06008366|DRUG|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
41490184|NCT01025544|BIOLOGICAL|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
41490185|NCT01025544|BIOLOGICAL|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
41490186|NCT02351960|DRUG|Dexlansoprazole|Dexlansoprazole capsules
41490187|NCT03850951|DEVICE|Lingual appliances|Patients with moderate crowding will be treated without extraction using lingual appliances.
41490188|NCT03850951|DEVICE|Labial appliances|Patients with moderate crowding will be treated without extraction using labial appliances.
40825913|NCT04699292|PROCEDURE|Surgery|Surgery
40825914|NCT04699292|RADIATION|Preoperative RT 36Gy|Preoperative radiotherapy to 36Gy (equivalent)
40825915|NCT04699292|RADIATION|Preoperative RT 50Gy|Preoperative radiotherapy to 50Gy (equivalent)
40825916|NCT04699292|RADIATION|Postoperative RT 50-66Gy|Postoperative radiotherapy to 50-66Gy (equivalent)
40825917|NCT04699292|RADIATION|RT 36Gy|Definitive radiotherapy to 36Gy (equivalent)
41490189|NCT01264536|DIETARY_SUPPLEMENT|lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
40825918|NCT00715364|DRUG|NTx™-265: rhCG, then rEPO|"* rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
40825919|NCT00715364|DRUG|Saline Placebo|"* Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation"
41345078|NCT03452995|PROCEDURE|PHYSIOTHERAPY|Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
41490190|NCT01264536|DIETARY_SUPPLEMENT|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
40825920|NCT00199316|DRUG|spinal morphine|
40825921|NCT05796115|PROCEDURE|Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS on the basis of Procalcitonin and Presepsin values measured within the first 3 hours of life.
40825922|NCT05796115|PROCEDURE|Antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS.
40825923|NCT05719506|OTHER|normal saline without drug|nebulizer session with normal saline only preoperative
41345079|NCT05533164|DRUG|Rituximab|1000mg rituximab in 250ml NaCl 0.9% intravenously
40825924|NCT05719506|DRUG|Dexmedetomidine|nebulizer session with dexmedetomidine preoperative
40825925|NCT05719506|DRUG|Ketamine|nebulizer session with ketamine preoperative
40825926|NCT04165187|OTHER|Body Awareness Therapy|Body scanning, stretch-release movements, centralization, contact with the ground, postural stability, movement flow and free breathing will be performed during sessions in lying, sitting and standing positions.
40825927|NCT04165187|OTHER|Home exercise program|Home exercise program will consist of joint range of motion, stretching, strengthening and proprioceptive exercises for lower extremity.
40825928|NCT05256784|COMBINATION_PRODUCT|Natural probiotics|Two of the group members use daily Allium Sativum - garlic, one use Natural honey, and 1 Yogurt. It is verifying the immunity of the organism after 40 days of using natural probitotics.
41345080|NCT05533164|DRUG|Placebo|Placebo in 250ml NaCl 0.9% intravenously
41345081|NCT02147691|DRUG|Azelaic acid 15%|Applied to the face each AM and PM
41345082|NCT02147691|DRUG|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
41345083|NCT05125991|PROCEDURE|Prepectoral reconstruction|Prepectoral breast reconstruction
41345084|NCT05125991|PROCEDURE|Submuscolar reconstruction|Submuscolar breast reconstruction
41345085|NCT02462122|DRUG|IDP-118 Lotion|Lotion
41490191|NCT04549714|PROCEDURE|High AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
41490192|NCT04549714|PROCEDURE|Middle AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
41490193|NCT04549714|PROCEDURE|Low AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
40825929|NCT05502159|DRUG|M-TAPA|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 40 ml (20 ml for each side) of %0,25 bupivacaine.
40825930|NCT05502159|DRUG|EOB|In the supine position, a high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the midaxillary line between the spina iliaca anterior superior and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected under the external oblique muscle of the block needle and the block location will be confirmed. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be administered. The same procedure will be applied to the other side (40 ml of 0.25% bupivacaine in total).
40825931|NCT01471418|DRUG|PET/CT with 18-FDG|FDG uptake
40825932|NCT04610892|BIOLOGICAL|MEDI6570|MEDI6570
40825933|NCT04610892|BIOLOGICAL|Placebo|Buffer
40825934|NCT00974688|BEHAVIORAL|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
40825935|NCT00974688|BEHAVIORAL|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
40825936|NCT01976897|OTHER|Knee flexion measurement 1|The angle of knee flexion during resting, supine position is measured by a first person.
40825937|NCT01976897|OTHER|Knee flexion measurement 2|The angle of knee flexion during resting, supine position is measured by a second person.
40825938|NCT01976897|OTHER|Heel - interface pressure measurements|"The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm\^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.~The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media."
40825939|NCT02849782|DRUG|Fampridine|Oral intake of 10 mg twice daily
40825940|NCT04079062|BIOLOGICAL|ONO-4685|Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.
40825941|NCT04079062|BIOLOGICAL|Placebo|Placebo will be administered by intravenous continuous infusion at the designated speed.
40825942|NCT04079062|BIOLOGICAL|KLH|KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.
40825943|NCT04079062|BIOLOGICAL|KLH, ONO-4685|Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.
40825944|NCT04079062|BIOLOGICAL|KLH, placebo|Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
40825945|NCT02510651|PROCEDURE|Melanocyte-keratinocyte suspension|Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
40825946|NCT01643850|DRUG|MCS110|Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
40825947|NCT01643850|DRUG|Placebo|Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
40825948|NCT04183855|DIETARY_SUPPLEMENT|Generation UCAN supplementation|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
40825949|NCT04183855|DIETARY_SUPPLEMENT|Mirexus PhytoSpherix supplementation|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
41490194|NCT05244395|OTHER|Duchenne Muscular Dystrophy Gait Assessment Scale|a special gait assessment scale for Duchenne Muscular Dystrophy patients
41490195|NCT00839592|OTHER|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
41490196|NCT00422981|DRUG|AL-108|5 mg QD
41490197|NCT00422981|DRUG|AL-108|15 mg BID
41490198|NCT00422981|DRUG|Placebo|Placebo
41490199|NCT05716386|DIETARY_SUPPLEMENT|Low salt diet|Low salt diet less than 2 gram per day
40825950|NCT04183855|BEHAVIORAL|satiety ratings|questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
40825951|NCT01477463|DRUG|Vitamin D3|4,000 IU oral vitamin D3
40825952|NCT01477463|DRUG|placebo and vitamin D|
40825953|NCT04966728|DIAGNOSTIC_TEST|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI
40825954|NCT05249881|DRUG|Semaglutide Pen Injector|All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
40825955|NCT02408081|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
40825956|NCT01997814|DRUG|herbal immunomodulator|Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
40825957|NCT01997814|DRUG|Placebo|Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
41018704|NCT01871948|OTHER|"We Want to Know campaign, Patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
41018705|NCT04054648|OTHER|Bedtime administration of the participant's pre-existing antihypertensive medications|Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
41345086|NCT02462122|DRUG|IDP-118 Vehicle Lotion|Lotion
41345087|NCT03570190|OTHER|Coordinator|"A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:~* Determination of the status quo~* Dedicated reflection and training followed by implementation of tailored changes~* Determination of the effect"
40825958|NCT01846195|DEVICE|CM 1500|
40825959|NCT05799001|BEHAVIORAL|Dance therapy|"Patients will be randomized in 2 groups, experimental or control.~The experimental group will have 4 months of dance therapy with a professional dancer and will then resume there usual activities.~The control group will start with their usual activities in the nursing home for the first 4 months and then, they will have dance sessions with a nurse previously trained by the dancer."
41018706|NCT05210920|OTHER|Nail polish application|After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.
41018707|NCT03300245|RADIATION|Maxillofacial CT|clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
41157342|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|Probiotic product were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 15 mL of sterile water were added to the probiotic product.
41345088|NCT00598806|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
41345089|NCT00598806|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
41345090|NCT00598806|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
41018708|NCT02473445|DRUG|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
41018709|NCT04613609|DEVICE|Electronic Cigarette containing nicotine|Non-smokers used an electronic cigarette containing nicotine
41490200|NCT04205019|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
41490201|NCT05328336|DRUG|Tislelizumab Nab paclitaxel|"Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will"
41345091|NCT03424044|DEVICE|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The algorithm has 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to two Omnipod insulin pumps, one filled with insulin and one with glucagon.
41490202|NCT01430793|DRUG|Vitamin D3 600,000 units IM|Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
41490203|NCT01430793|DRUG|Vitamin D3 600,000 Orally|Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
41345092|NCT03424044|DEVICE|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod pump filled with insulin.
41490204|NCT01430793|DRUG|Vitamin D3 200,000 units IM|Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
41490205|NCT01430793|DRUG|Vitamin D3 200,000 Orally|Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
40825960|NCT03622671|PROCEDURE|Skeletonized LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura
40825961|NCT03622671|PROCEDURE|Pedicled LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
41490206|NCT04353765|DRUG|Cabozantinib monotherapy|Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
41490207|NCT04353765|DRUG|All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC|As per authorized FDA label in advanced RCC
41490208|NCT03724526|BEHAVIORAL|Text messaging|"Intervention-Text messaging: Participants will receive regular text messages for 12 months. Each participant will receive 6 text messages per week. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week.~Control: The control group will receive the usual care."
40825962|NCT00832247|GENETIC|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
41018710|NCT04613609|DEVICE|Electronic Cigarette without nicotine|Non-smokers used an electronic cigarette without nicotine
41157343|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota plus inulin|The Syn-inulin products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of inulin (BENEO GmbH) were diluted in 15 mL of sterile water and added to Syn-inulin products.
40825963|NCT04715789|BEHAVIORAL|graded exposure and activity|"1. Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~2. Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner"
40825964|NCT00611468|DRUG|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
41345093|NCT03424044|DEVICE|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod insulin pump filled with insulin.
41345094|NCT03424044|DRUG|XeriSol glucagon|XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode.
41345095|NCT02756741|DRUG|ALBUMIN|Albumin in two different doses
41345096|NCT03428295|DEVICE|Dose Safety AP system|Device will be used to automatically dose insulin
41345097|NCT05143918|OTHER|assessment of quality of life using questionnaire|assessment of quality of life in hypothyroid patients using SF 36 questionnaire
40825965|NCT00611468|DRUG|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
40825966|NCT04700657|DIAGNOSTIC_TEST|corneal sensation test|Thorough ocular surface study including corneal sensation test in the GVHD group, comparing to the normal control group
40825967|NCT00545220|BEHAVIORAL|problem-solving training|
40825968|NCT00545220|BEHAVIORAL|sham intervention|
40825969|NCT00642148|DRUG|GW856553|Active tablet
40825970|NCT00642148|DRUG|Placebo|Placebo tablet and inhaler
40825971|NCT00642148|DRUG|Seretide|Active comparator inhaler
40825972|NCT01739933|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
40825973|NCT01739933|DRUG|Propofol|For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
40825974|NCT00523705|DRUG|escitalopram|10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
40825975|NCT00523705|OTHER|placebo|Placebo tablets matched to drug
40825976|NCT03225768|BEHAVIORAL|Guided Training|Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
40825977|NCT05564884|OTHER|no intervantion|no intervention
40825978|NCT00004729|BEHAVIORAL|Ketogenic diet|
41345098|NCT01802294|BEHAVIORAL|Parenting Program|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
40825979|NCT00966719|OTHER|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
40825980|NCT03353922|DRUG|Cyclobenzaprine 10 Mg Oral Tablet|cyclobenzaprine 10 mg tablets
40825981|NCT03353922|DRUG|Placebo Oral Tablet|sugar pill
41345099|NCT04127240|OTHER|DASH diet containing daily intakes of red meat|Each participant was randomized to consume 3 or 6 ounces of red meat as a part of the DASH dietary pattern for 12-weeks.
40825982|NCT01022372|PROCEDURE|Endometrial biopsy|For all the groups
40825983|NCT03386786|BEHAVIORAL|Health Partner|Health Partner is a combination of a mobile application and a web-based portal.
40825984|NCT03386786|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
40825985|NCT03224871|DRUG|Intralesional IL-2|High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.
40825986|NCT03224871|DRUG|Nivolumab|Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.
40825987|NCT03224871|DRUG|Pembrolizumab|PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.
40825988|NCT03224871|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
40825989|NCT01409083|DEVICE|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
40825990|NCT00780637|DRUG|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
40825991|NCT01552616|PROCEDURE|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
40825992|NCT00005901|DRUG|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
40825993|NCT05162001|DRUG|Disulfiram 250 mg|Disulfiram used qd during nine weeks to observe effects on body weight
40825994|NCT04381325|DRUG|MSB0254 Injection|"An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W)."
40825995|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets|Investigational Medicinal Product
40825996|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets|Evafem 20 (Trademark)
40825997|NCT05756114|BEHAVIORAL|Support Group|Support Group condition, meetings will be held online via HIPAA-compliant Zoom and run by a trained SMART Recovery meeting facilitator
40825998|NCT05756114|OTHER|Psychoeducational Email|Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
41345100|NCT02481323|DRUG|isosorbide mononitrate|slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
41345101|NCT02481323|DRUG|cilostazol|phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
41345102|NCT01573286|DRUG|Glucagon-Like Peptide 2|Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
41345103|NCT01573286|DRUG|Glucagon like peptide-2|"Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.~Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days."
40825999|NCT03207178|BIOLOGICAL|Mixed CD19/CD20 CAR-T Transfer|Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
40826000|NCT03368716|BEHAVIORAL|Acceptance-based Behavioral Treatment (ABBT)|ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
41345104|NCT01017666|DRUG|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
41345105|NCT01017666|DRUG|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
41345106|NCT02408484|BIOLOGICAL|Octafibrin|Plasma-derived Fibrinogen concentrate
40826001|NCT03098251|PROCEDURE|3D typing|typing the patient with 3D typing system and give specific treatment
41345107|NCT05142176|OTHER|Erector spinae catheters insertion|Ultrasound-Guided ESPB The ESPB will be performed with the child in a right lateral decubitus position under aseptic precautions by a high frequency (6-13 MHz) linear ultrasound transducer
41345108|NCT05142176|DRUG|Postoperative pain management|IV acetaminophen 15 mg/kg every 8 hours as a component of multimodal analgesia.
41345109|NCT05094882|PROCEDURE|pulmonary lobectomy|resection of lung lobe
41345110|NCT06313749|DEVICE|Minimally Invasive Micro Sclerostomy Device|During this clinical trial, the Minimally Invasive Micro Sclerostomy (MIMS®) procedure will be performed by investigators using the proprietary MIMS® device developed by Sanoculis Ltd.
41345111|NCT03105869|DIAGNOSTIC_TEST|fluorocholine PET/CT|standard diagnostic PET/CT procedure
41345112|NCT00532064|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40826002|NCT03098251|PROCEDURE|routine typing|typing the patient with routine typing system and give specific treatment
40826003|NCT05708781|OTHER|Core strengthening exercise|"1. Isolated lumbar stabilization muscle training:~2. Bridge track:~3. Dead bug track:~4. Quadruped Track:~5. Supine Track:~6. Side-support Track:~7. Prone Track:~8. Standing Track:"
41157344|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota plus fructans from A. salmiana|The Syn-A. salmiana products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of fructans from A. salmiana were diluted in 15 mL of sterile water and added to Syn-A.salmiana products.
41345113|NCT00532064|OTHER|Questionnaire Administration|Ancillary studies
41345114|NCT00383006|BEHAVIORAL|Skills for affect regulation (behavior)|
41345115|NCT02823613|DIETARY_SUPPLEMENT|High salt diet followed by low salt diet|High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
41345116|NCT02823613|DIETARY_SUPPLEMENT|Low salt diet followed by high salt diet|Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
41345117|NCT01891604|DIETARY_SUPPLEMENT|breast milk with Bifidobacterium Longum subp. Infantis R0033|
41345118|NCT01891604|DIETARY_SUPPLEMENT|breast milk|
41345119|NCT03610867|DRUG|Furaprevir capsule (SAD)|There are four doses in this part, 100 mg, 200 mg, 400 mg, and 600 mg. Each subject will receive the sample once by oral administration.
41345120|NCT03610867|DRUG|Furaprevir capsule (MAD)|There are three doses in this part, 200 mg, 400 mg, and 600 mg. Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
41345121|NCT03610867|DRUG|Placebo (SAD)|Each subject will receive the sample once by oral administration.
41345122|NCT03610867|DRUG|Placebo (MAD)|Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
41345123|NCT03207724|DRUG|Xilonix plus Onivyde and 5FU|Xilonix by IV
41345124|NCT03733106|DIAGNOSTIC_TEST|digital breast tomosynthesis|pseudo three dimension mammography
41345125|NCT03733106|DIAGNOSTIC_TEST|standard two dimension digital mammogram|standard two dimension mammogram
41345126|NCT00039091|BIOLOGICAL|ipilimumab|Given IV
41345127|NCT05063760|BEHAVIORAL|aerobic-strength exercise intervention (6-months)|6 month supervised exercise intervention in TGCT survivors (1 hour sessions 3 x per week),
41345128|NCT03786276|BEHAVIORAL|VR-WMR-Only|Participants will spend up to 30 minutes in a VR-WMR environment during each training session.
41345129|NCT03786276|BEHAVIORAL|Exercise-only|Participants will ride a stationary recumbent bicycle for up to 30 minutes during each training session.
41490209|NCT03276065|DEVICE|Laser depilation|Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
41490210|NCT03276065|OTHER|Standard of care hair depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
41490211|NCT00894101|DRUG|[F-18] FLT|10 mCi \[F-18\] FLT and 10 mCi \[F-18\] FDG will be used for PET imaging.
41490212|NCT02760992|DRUG|IV Baclofen|Baclofen intravenous solution 2 mg/mL manufactured and provided by Allaysis, LLC
41490213|NCT02760992|DRUG|Oral Baclofen|10 mg tablet
41345130|NCT03786276|BEHAVIORAL|Active VR-WMR|Participants will spend up to 30 minutes in a VR-WMR environment while riding a stationary, recumbent bicycle during each training session.
41345131|NCT04733664|DEVICE|VFI using the FAST PV Technology|The bolus IV administered visible fluorescent injectate (VFI) agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
41345132|NCT01660646|BEHAVIORAL|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
41345133|NCT04935372|OTHER|Observational|"Cross sectional analyses The two main variables for the analysis will be: Values of biomarker concentrations in blood and their correlations with CSF biomarkers and the development of prodromal AD for the cognitively unimpaired SCD population. Other variables of interest for the study are, among others, risk factors, cognitive status, measurements of brain structure and function, mental health, chronic diseases, environmental exposures, age and sex.~Longitudinal analyses Longitudinal analyses will estimate the association between the intensity of the subjective complaint and the rate of progression between the diagnostic categories; The association of biomarkers, risk factors and other clinical variables with the rate of progression between the diagnostic categories; The association of cognitive and neuroimaging variables with the rate of progression between the diagnostic categories; The evolution of the complaint itself and its relation to the other variables described."
41345134|NCT03248960|DIAGNOSTIC_TEST|iTreat Flu A+B Test|The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.
41490214|NCT00145275|DRUG|zoledronic acid|
41490215|NCT05648461|RADIATION|Five fraction of post operative radiotherapy|Target volume will include tumor bed \& ipsilateral level I-III levels.
41345135|NCT03248960|DIAGNOSTIC_TEST|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.
41345136|NCT03248960|DIAGNOSTIC_TEST|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
41345137|NCT03248960|DIAGNOSTIC_TEST|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
40826004|NCT05708781|OTHER|intensive dynamic back exercise|"1. Trunk lifting Prone on a couch, hips at the edge, upper part of the body free but supported by the hands against the floor. Strap fixation over the calves. With hands on the forehead, the trunk is lifted to the greatest possible extension in hips and spine. If necessary, starting with support from physical therapist. During pauses a chair in front of the couch supports the patient.~2. Leg lifting Standing by the end of the couch, leaning over to a prone position with the hips against the edge in 90 degree flexion, knees 45 degree and feet on the floor. Strap fixation over the chest. Straps around knees to keep legs together. Both legs are straightened and lifted to the greatest possible extension in hips and spine. Again support from physical therapist is necessary.~3. Pull to neck Sitting on a tool with the arms straight and abducted over the head and hands grasping a weight lever. Against sub-maximal resistance the lever is pulled behind neck and shoulders."
40826005|NCT05708781|OTHER|Control group|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.
40826006|NCT01665079|DRUG|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS\>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 \> 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS \> 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
40826007|NCT04103541|BEHAVIORAL|IP-Colombia|The IP-Colombia program is a multi-component intervention carried out in the context of therapeutic camp, based on EDMR therapies and mindfulness-based interventions. Alongside the interventions, activities are done to facilitate healthy lifestyles, empathy, \[and\] the recognition and expression of emotions through exercise, art workshops, musical creation, dance and theater.
40826008|NCT04182321|DRUG|Metformin & Entecavir|Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
41345138|NCT00474773|DRUG|Celecoxib|
41345139|NCT03445611|DRUG|corticosteroid solution with lidocaine containing parabens.|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
41345140|NCT03445611|DRUG|corticosteroid solution with lidocaine containing no paraben|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
41345141|NCT02664389|GENETIC|Genetic analysis|Sequencing of 200 selected genes in the different study populations
41345142|NCT03149497|PROCEDURE|anterior approach only in cervical spine trauma|evaluation of efficacy of single approach
41345143|NCT04655768|DEVICE|Palmar Plate Fixation|Patients are treated by surgery (palmar plate)
41345144|NCT01125904|DRUG|crizotinib|Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
41345145|NCT01304927|DRUG|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
41345146|NCT01304927|OTHER|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
41345147|NCT02615262|DRUG|Dexamethasone|
41345148|NCT02615262|DRUG|Placebo|0.9% Sodium Chloride
40826009|NCT04182321|DRUG|Placebo & Entecavir|Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
40826010|NCT02257177|DRUG|Inhaled TD139|DPI Galectin-3 inhibitor
41345149|NCT04630444|DRUG|Riluzole|30 PTSD patients with riluzole 100 mg daily (50 mg bid).
40826011|NCT02257177|DRUG|Placebo|DPI placebo
40826012|NCT05401045|BEHAVIORAL|Met exercises|Exercise plan: Each session of the self-designed MET exercise program was divided into 8 components: stretching exercises, chest expansion exercises, kicking exercises, lateral movement exercises, body rotation exercises, whole-body exercises, jumping exercises, and a cool down. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening. For patients with moderate fatigue and an RPFS score of 4 to 6 points, low-intensity exercise was recommended, i.e., patients could choose 1 to 4 metabolic equivalent exercises and repeat them twice; for patients with mild fatigue and an RPFS score of 1 to 3 points, moderate-intensity exercise was recommended, i.e., patients could choose to complete the entire set of metabolic equivalent exercises or 5 to 8 of the exercises and repeat them twice. The exercise frequency was 5 times per week.
40826013|NCT05298995|BIOLOGICAL|GD2-CART01 (iC9-GD2-CAR T-cells)|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
41345150|NCT01131130|DEVICE|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
41345151|NCT01131130|DEVICE|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
41345152|NCT01131130|DEVICE|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
41345153|NCT01814189|DRUG|Sumatriptan+Promethazine (SPr)|
41345154|NCT05833061|OTHER|The Stroke-Specific Quality of Life (SS-QoL) scale|The Stroke-Specific Quality of Life (SS-QoL) scale is a questionnaire-based tool that is used to assess the quality of life of individuals who have experienced a stroke. It was developed to evaluate the impact of stroke on various domains of life, including physical, psychological, and social aspects. The SS-QoL scale contains 49 items, which are organized into 12 domains such as mobility, self-care, work/productivity, language, social roles, and emotional well-being. The scale has been validated and is widely used by healthcare professionals and researchers to assess the effectiveness of interventions and treatments for stroke patients, as well as to evaluate the long-term impact of stroke on their quality of life.
41490216|NCT00536263|DRUG|pegylated interferon alpha-2b|1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
41490217|NCT00536263|DRUG|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 24 weeks
41490218|NCT00536263|DRUG|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 48 weeks
41490219|NCT00146887|PROCEDURE|coronary catheterization|
41490220|NCT04546126|DRUG|Dexamethasone (Group 2)|Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
40826014|NCT04951271|BEHAVIORAL|Solution focused approach|The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
40826015|NCT04006301|DRUG|JNJ-74699157|Participants will receive JNJ-74699157 orally.
40826016|NCT06223256|DRUG|NBL-028|Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
40826017|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention with Reflection|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine. Participants will then reflect on their kind acts after each week.
40826018|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
40826019|NCT05267132|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
41345155|NCT05833061|OTHER|The Stroke Self-Efficacy Questionnaire (SSEQ)|The Stroke Self-Efficacy Questionnaire (SSEQ) is a tool used to measure an individual's perceived self-efficacy or confidence in managing the consequences of a stroke. It consists of 13 items that assess an individual's ability to manage various stroke-related challenges, such as physical, emotional, and social difficulties. The SSEQ is designed to help healthcare professionals and researchers understand how an individual's perceived self-efficacy influences their ability to cope with the consequences of a stroke and manage their recovery effectively. By measuring an individual's perceived self-efficacy, the SSEQ can help identify areas where additional support and interventions may be needed to improve their overall recovery and quality of life.
41490221|NCT04546126|DRUG|Cosyntropin (Group 3)|Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
41490222|NCT04546126|COMBINATION_PRODUCT|PET/CT Scan with FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
41157345|NCT06584682|OTHER|Sub-occipital muscle inhibition technique|Therapist puts finger pads just beneath the superior nuchal line (below the occiput and above the C2 vertebra), and lifts the patient head slightly and apply an anterior force with cephalic traction on cervical spine this area. Then straighten the fingers to press the finger tips into muscle and hold until relaxation(30 sec) and then drop the head into palm in new position, give this technique in 10 rep/2 sets (each set have 5 repetitions).hot packs for 15 minutes prior to session, cervical muscle stretching,cervical mechanical traction for 8-10 minutes, force is applied 1/6th of the patient body weight, for C1-C2 at 0 degree of cervical flexion and for below C2 at 20 degree of cervical spine flexion and cervical muscle METs
40826020|NCT06606418|OTHER|Acupuncture group|The patients in this group received acupuncture treatment 3 times a week for 4 weeks. Acupuncture points selection: bilateral Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), Shangqiu (SP5), Yin Bai (SP5), foot Qioyin (GB44), Li Dui (ST45). Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to skew 0.5\~0.8 inches at the back acupoint, 0.5\~0.8 inches at Shangqiu (SP5), 0.1 inches at Yin Bai (SP5), foot Qiaoyin (GB44) and Li Dui (ST45), and left the needle for 30 minutes to wait for qi.
40826021|NCT06606418|OTHER|Sham acupuncture group|The patients in this group received sham acupuncture treatment 3 times a week for 4 weeks. Sham acupuncture points are selected at sham points close to the acupoints of the acupuncture group: 3 inches beside Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), 1 inches below Shangqiu (SP5), 0.1 inches behind the middle edge of the great toe, second toe and fourth toenail of the foot. Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to pierce the skin shallowly, and left the needle for 30 minutes.
40826022|NCT00789581|DRUG|Doxorubicin|Doxorubicin 60 mg/m2
40826023|NCT00789581|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2
40826024|NCT00789581|DRUG|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
40826025|NCT00789581|DRUG|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
40826026|NCT03994250|OTHER|Kinematic Alignment for total knee replacement surgery|Using Kinematic Alignment for total knee replacement surgery
40826027|NCT03994250|OTHER|Mechanical Alignment for total knee replacement surgery|Using mechanical alignment for total knee replacement surgery
40826028|NCT00234481|DRUG|XL844|
40826029|NCT06352593|DRUG|Intraoperative Dexmedetomidine|Patients will be administered DEX 0.5 μg/kg for 10 min and then 0.4 μg/kg/h adjusted to 0.2-0.6 μg/kg/h.
40826030|NCT06352593|OTHER|Placebo|Patients will receive normal saline.
40826031|NCT03855813|OTHER|Intra rater reliability|Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.
41345156|NCT04989595|DEVICE|MyIUS app|Data will be self-reported by participants through the MyIUS app.
41345157|NCT00058006|DRUG|celecoxib|
41345158|NCT00058006|PROCEDURE|adjuvant therapy|
41490223|NCT01002014|PROCEDURE|Nipple Sparing Mastectomy|Skin sparing mastectomy with preservation of the nipple areolar complex
40826032|NCT03855813|OTHER|Inter rater reliability|Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
40826033|NCT02153346|OTHER|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
41490224|NCT05627167|OTHER|day time cyclic nutrition|Continuous isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100 mL for 10 hours during the day (e.g. 08:00 to 18:00), via nasal or oro-gastric tube
41490225|NCT05627167|OTHER|continuous nutrition|Isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100ml, continuously 24 hours a day by nasal or oro-gastric tube
41490226|NCT01600690|OTHER|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
40826034|NCT02153346|OTHER|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
40826035|NCT06127355|DRUG|500 mg of ursodeoxycholic acid (UDCA)|Administration of 500 mg of ursodeoxycholic acid (UDCA) /day
40826036|NCT06127355|OTHER|500 mg of Placebo|Administration of 500 mg of placebo /day
40826037|NCT02893865|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment during three months with adherence recording
41345159|NCT00120510|DRUG|Efavirenz|Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
41345160|NCT00120510|DRUG|Lamivudine/Zidovudine|Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
41345161|NCT02008396|DRUG|Placebo|Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.
41490227|NCT00752830|DRUG|AZD0328|Oral capsule, single dose
41490228|NCT04112173|BEHAVIORAL|perturbation-based fall-recovery training|Participants will attempt to recover from treadmill-induced balance perturbations as they walk or stand. The size of the perturbations is progressively challenging and dependent upon participant performance.
41490229|NCT01476735|OTHER|individual preparation for colonoscopy|The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
41490230|NCT02373748|DEVICE|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
40826038|NCT02893865|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
40826039|NCT00838825|OTHER|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
40826040|NCT06526390|PROCEDURE|f-URS|f-URS with S-UAS
40826041|NCT06526390|PROCEDURE|mini-PCNL|mini-PCNL
40826042|NCT00346489|DRUG|5-fluorouracil|
40826043|NCT00346489|DRUG|Mitomycin C|
41157346|NCT06584682|OTHER|conventional therapy|stretching of hamstring muscle, METs, sciatic nerve glides, lower limb neurodynamics.
40826044|NCT05479344|BEHAVIORAL|A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection|The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).
40826045|NCT02185157|OTHER|dual -task exercises|physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
40826046|NCT02185157|OTHER|Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
40826047|NCT03023696|PROCEDURE|Bilateral Cervical Keyhole Foraminotomy|Under microscopic or loop magnification, a high-speed burr is used to perform the foraminotomy. The keyhole foraminotomy begins at the lamina-facet junction, with careful consideration of the amount of facet resection. Typically, only the medial one third is drilled. Then a 1- or 2-mm Kerrison punch can be carefully placed over the nerve root and then used to undercut the facet, ensuring that the spine is not destabilized by the foraminotomy. The amount of facet resection must not exceed 50% in order to preserve spine stability.
40826048|NCT03023696|PROCEDURE|Cervical Decompression|Cervical decompression for myelopathy, including the following procedures: laminoplasty, laminectomy, discectomy and fusion
40826049|NCT02177643|DRUG|Diacerein|Diacerein oral capsules
40826050|NCT02177643|DRUG|Placebo|Placebo oral capsules
40826051|NCT03790436|DIETARY_SUPPLEMENT|Betaquik|"Study dietitian will advise each participant on target volume of Betaquik (45g MCT, 225mL Betaquik). Consuming too much MCT too quickly may cause gastrointestinal discomfort such as abdominal pain or diarrhea, this is related to its assimilation to the body. Any symptoms that do occur normally resolve in the majority of patients, and with time and persistence, GI tolerance is usually established.~Therefore the study dietitian will advise on a gradual systematic introduction to minimize any adverse effects. The daily-tolerated amount will be divided into 3-4 equal portions, taken regularly throughout the day. subjects will be advised to always take Betaquik with food, as part of meals and snacks, to help promote gastrointestinal tolerance. The goal is within the first 4 weeks participants will have reached their tolerated target volume of Betaquik."
40826052|NCT04524559|OTHER|conventional physical therapy training|"The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~* Neurodevelopmental based training (NDT)~* Functional stretching exercises to preserve muscle and soft tissues elasticity~* Sequenced trunk co-activation (STA) exercises~* Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity."
40826053|NCT04524559|OTHER|oral motor training.|"Children in the experimental group received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time.~The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol. The utmost aims of the protocol were to decrease hypersensitivity of oral structures, increase jaws movement, and reinforce muscle strength, improve tongue movement and enhance oral motor organization"
40826054|NCT05904522|DIAGNOSTIC_TEST|biopsy|biopsy for histopathological examination
40826055|NCT01711229|DRUG|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
40826056|NCT01711229|DRUG|oral acetaminophen|oral acetaminophen will be given preoperatively
41018711|NCT05404438|OTHER|Oral Appliances|A pre-experimental, single-group pretest-posttest design was performed. At stage one, each participant underwent a 2-day general sleeping test and a 2-day sleeping test with mouth tape. At stage two, participants underwent conventional impressions for TPD and TED appliances and were then randomly assigned to wear the TPD or TED; together for two days of sleeping test with their mouth taped. After a 2-day break (washout), with the same procedure, participants wore the other appliance for another 2-day sleeping test and decided accordingly the optimal appliance that had reduced their ODI scores more. At stage three, participants wore their optimal appliance mouth-taped during sleep for 6 weeks. At the end of the intervention, all participants underwent few days sleeping test for final results.
41345162|NCT02008396|DRUG|Midomafetamine|Participants receive a capsule of 75 or 100 mg during the first of two experimental sessions and a capsule of 100 or 125 mg MDMA during the second experimental session.
41018712|NCT05107986|PROCEDURE|laparoscopic repair|All patients of cohort underwent laparoscopic repair.
41018713|NCT00827892|DRUG|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
41018714|NCT00827892|DRUG|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
41018715|NCT05928221|DEVICE|Thrombectomy|removal of fresh soft emboli and thrombi from the vessels of the venous system
41018716|NCT05435599|DIAGNOSTIC_TEST|Serum regucalcin level|During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
41345163|NCT02008396|BEHAVIORAL|Therapy|Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.
41345164|NCT05389306|DIAGNOSTIC_TEST|MRI Scanning|MRI scanning will be performed with a 3.0-T magnetic resonance imaging system with a head and neck-combined coil employing spin-echo technique. The range of the MRI scanning will be from the suprasellar cistern to the inferior margin of the sternal end of the clavicle. The section thicknesses for the axial plane, the sagittal plane and the coronal plane will be 5 mm, 3 mm and 2 mm, respectively. The intersection gaps will be 1 mm. Before the intravenous injection of the MRI contrast agents, T1 weighted images, T2 weighted images and diffusion weighted images will be obtained in the axial planes, while only T1 weighted images will be obtained in the sagittal and coronal planes. After the intravenous injection of the MRI contrast agents, T1-weighted axial sequence, T1-weighted sagittal sequences and T1-weighted fat-suppressed coronal sequence will be performed.
40826057|NCT05848700|DRUG|SEP-363856|SEP-363856 Tablet
40826058|NCT05848700|DRUG|Placebo|Placebo Tablet
40826059|NCT01909882|OTHER|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
40826060|NCT02855723|OTHER|Surgery: GS strategy|sentinel node biopsy
40826061|NCT02855723|OTHER|Surgery: Classic strategy|systematic lymphadenectomy
40826062|NCT03469830|OTHER|SSCP|Insert
40826063|NCT03469830|OTHER|SPMS|Pressure therapy
40826064|NCT04080986|PROCEDURE|Double Sequential Defibrillation|Defibrillation using pad placement in anterior-posterior position
40826065|NCT04080986|PROCEDURE|Vector Change Defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position and the other with pad placement in anterior-anterior position delivering two rapid sequential shocks.
40826066|NCT01068951|BIOLOGICAL|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
41018717|NCT02359266|DIETARY_SUPPLEMENT|Vitamin D|Given to patients with existing vitamin D deficiency
41018718|NCT03827798|DRUG|CFZ533|s.c.
41018719|NCT03827798|DRUG|Placebo to CFZ533|s.c.
41490231|NCT03063879|DRUG|Sofosbuvir 400 mg and daclatasvir 60 mg|Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness \< 12 KPa) or 24 weeks if cirrhotic
41018720|NCT03827798|DRUG|LYS006|p.o.
41018721|NCT03827798|DRUG|Placebo to LYS006|p.o.
41490232|NCT06157203|DEVICE|Uterine electromyography|electromyographic and fetal electrocardiographic recordings will be obtained during threatened labor
40826067|NCT01611051|DRUG|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
40826068|NCT01611051|DRUG|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
40826069|NCT01611051|DRUG|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
40826070|NCT03794869|OTHER|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
40826071|NCT03794869|OTHER|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of CORE.
40826072|NCT00712218|PROCEDURE|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
40826073|NCT00712218|PROCEDURE|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions \[24, \].
40826074|NCT02943356|DRUG|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
40826075|NCT04511117|OTHER|Control group|ProTaper Next rotary system and iRoot SP sealer with composite restorations.
40826076|NCT04511117|OTHER|Endocrown group|ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
40826077|NCT06309251|OTHER|ketogenic diet (as per clinical practice)|Patients recruited receive a ketogenic diet. The prescription, the type of KD protocol and the route of administration will depend, essentially, on the patient's ability and willingness to feed spontaneously and independently, as well as on compliance with the therapies set and the severity of the clinical conditions.
40826078|NCT01666119|DRUG|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
41018722|NCT03827798|DRUG|MAS825|s.c.
41018723|NCT03827798|DRUG|Placebo to MAS825|s.c.
41018724|NCT03827798|DRUG|LOU064 25mg|p.o.
41018725|NCT03827798|DRUG|LOU064 100mg|p.o.
41018726|NCT03827798|DRUG|Placebo to LOU064|p.o.
41018727|NCT03827798|DRUG|VAY736|s.c.
41018728|NCT03827798|DRUG|Placebo to VAY736|s.c.
41018729|NCT01103531|BEHAVIORAL|Aerobic and Resistance Exercise|Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
41018730|NCT01103531|BEHAVIORAL|Educational information about health topics|A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
40826079|NCT04165655|BEHAVIORAL|Keep Achieving (KA)|The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
41345165|NCT05389306|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasonography|A sonographer equipped with a 6-15 MHz linear array probe will be adopted for contrast-enhanced ultrasonography examination. Conventional high-frequency ultrasonography will be performed firstly before the intravenous injection of the ultrasound contrast agents. Then the ultrasound contrast agents will be injected intravenously, and contrast-enhanced ultrasonography examination will be performed. The mechanical index of contrast-enhanced ultrasonography examination will be 0.23. The wash-in and wash-out process within the lymph node will be dynamically observed during the arterial phase. During the Kupffer-phase, the degree of enhancement will also be observed.
40826080|NCT03730012|DRUG|gilteritinib|Oral tablet
40826081|NCT03730012|DRUG|atezolizumab|Intravenous infusion
40826082|NCT01895933|DEVICE|5ml surgishield|"in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site~merocel in the inflated state maintained for 36\~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site"
40826083|NCT06261736|OTHER|Prophylactic antibiotics|These participants will be given a single dose of an oral antibiotic prior to the procedure.
40826084|NCT06261736|OTHER|No antibiotics|These participants will not be given an antibiotic prior to the procedure.
40826085|NCT04775927|OTHER|education|premarital education
40826086|NCT04580745|DRUG|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
40826087|NCT04580745|DRUG|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
40826088|NCT04243902|DEVICE|Fill and Flush Valve|"The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O"
40826089|NCT01571128|OTHER|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
40826090|NCT01571128|OTHER|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
40826091|NCT01571128|DRUG|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
40826092|NCT01571128|BEHAVIORAL|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
40826093|NCT03593135|DIETARY_SUPPLEMENT|Apple Cider Vinegar and tablet Tagipmet (Metformin + Sitagliptin group)|15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time, for 3 months and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
40826094|NCT03593135|OTHER|Water with Apple Cider vinegar flavor and tablet Tagipmet (Metformin + Sitagliptin group)|Flavor of apple cider vinegar in 200 ml water is added and given to have a placebo effect and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
40826095|NCT04942028|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
40826096|NCT04942028|BEHAVIORAL|Standardized education|Standardized routine care education for individuals suffering from distress related to somatic symptoms, primarily focusing on healthy lifestyle behaviors such as sleep, diet, and exercise
40826097|NCT04942028|BEHAVIORAL|Prolonged assessment|Patients are encouraged to keep a rudimentary symptom diary to track if and how their symptoms interact with mood and lifestyle behaviors
40826098|NCT01550341|DRUG|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
41018731|NCT03745703|BEHAVIORAL|MOCHA|(see above)
41018732|NCT04613297|OTHER|Baseline and during hospitalization blood samples|"Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~* at day 3~* day 5 and~* In case of aggravation~* At the discharge from hospital"
41018733|NCT04613297|OTHER|Baseline blood sample|Blood sample will be performed at the inclusion visit only
40826099|NCT01550341|DRUG|Placebo Oral Tablet|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
40826100|NCT02557958|DRUG|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
40826101|NCT02557958|DRUG|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
40826102|NCT04573426|DRUG|Acetaminophen|1,000mg liquid acetaminophen
40826103|NCT04573426|DRUG|Placebo|Liquid placebo solution
40826104|NCT04573426|BEHAVIORAL|Weight stigma vignette|Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight
40826105|NCT04573426|BEHAVIORAL|Control vignette|Short vignette meant to have no effect on emotion describing a generic promotion process
40826106|NCT05653908|OTHER|StudentMood|StudentMood is an app that uses ecological momentary assessment method to asses mood and other mental health corelates. Participants will have to complete the application (the mood wheel, heart rate and other behavioral data as well as standardized scales) daily throughout the entire semester
40826107|NCT03943680|DEVICE|PRGF|After tooth extraction, the socket will be grafted with PRGF-Endoret
40826108|NCT03943680|DEVICE|ABB|After tooth extraction, the socket will be grafted with Geistlich Bio-Oss® Collagen
40826109|NCT00712569|BEHAVIORAL|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
40826110|NCT00712569|BEHAVIORAL|audio recordings , questionnaires|"Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not."
40826111|NCT00712569|BEHAVIORAL|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
40826112|NCT04766385|DRUG|KHK7791|oral administration
40826113|NCT01560052|DRUG|methylprednisolone|"Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
40826114|NCT01560052|DRUG|Placebo|"Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
40826115|NCT03887065|DRUG|JM-4|Novel small human peptide derived from erythropoietin
40826116|NCT04710407|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
40826117|NCT04058808|OTHER|Weight Watchers|online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.
40826118|NCT04058808|OTHER|Slimming world|online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.
41345166|NCT05389306|DIAGNOSTIC_TEST|Ultrasound-guided Lymph Node Aspiration|After the conventional high-frequency ultrasonography and contrast-enhanced ultrasonography examination was finished, ultrasound-guided aspiration of the target lymph node will be performed. The lymph node tissue obtained from ultrasound-guided lymph node aspiration will be subjected to pathologic evaluation. And the diagnostic performance of MRI and contrast-enhanced ultrasonography will be evaluated using the pathologic diagnosis of the lymph node as the gold standard.
40826119|NCT04058808|OTHER|Leeds 'One You'|a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
40826120|NCT04058808|OTHER|NHS Choices|a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.
40826121|NCT04058808|OTHER|5:2 diet|5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
40826122|NCT04058808|OTHER|Individuals own personal plan|the participant will explain in detail their own designed plan and this will be documented on the paper records.
41018734|NCT02682420|DEVICE|everlinQ endoAVF System|
41157347|NCT04090788|DIETARY_SUPPLEMENT|dried bitter-gourd supplements|intervention with 2.4g/d dried bitter-gourd supplements
40826123|NCT05374577|OTHER|pulmonary vascular dysfunction|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)
41018735|NCT01141296|DRUG|fenofibrate|fenofibrate 200 mg PO daily for 1 year
41018736|NCT01141296|DRUG|placebo|Placebo pill identical to active drug will be given PO once a day for 1 year
41018737|NCT01884298|DRUG|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
41018738|NCT01884298|DRUG|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
41018739|NCT03284268|GENETIC|VCN-01|VCN-01 intravitreal injection
41018740|NCT05581368|OTHER|Chronic Cannabis use|The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
40826124|NCT05374577|OTHER|pulmonary vascular function|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.
40826125|NCT04449146|DIAGNOSTIC_TEST|Scapular positioning in Standing position using Sonography|The localizer ultrasound of the shoulder is performed in an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer.
40826126|NCT05062317|DRUG|Leucovorin|Given by PO
40826127|NCT05062317|DRUG|5-FLUOROURACIL|Given by IV
40826128|NCT05062317|DRUG|Oxaliplatin|Given by PO
40826129|NCT05062317|DRUG|Irinotecan|Given by IV
40826130|NCT05062317|DRUG|Capecitabine|Given by IV
40826131|NCT05062317|DRUG|Bevacizumab|Given by IV
40826132|NCT03158272|BIOLOGICAL|Cabiralizumab|Specified dose on specified days
40826133|NCT03158272|BIOLOGICAL|Nivolumab|Specified dose on specified days
40826134|NCT01244633|DRUG|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
40826135|NCT02789423|PROCEDURE|Direct Pulp Capping using Dycal and Biodentine|The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
40826136|NCT04687592|PROCEDURE|reduction and fixation|"* Reduction: one trial of closed reduction under anaesthesia and image control. Open reduction will be done by anterolateral or lateral approach if closed reduction failed~* Fixation: internal fixation of the fracture by appropriate implant according to the fracture state"
40826137|NCT03670329|DEVICE|URGO2875|Dressing
40826138|NCT05285475|OTHER|Exercise and Water Intake|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
40826139|NCT00799045|DRUG|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
40826140|NCT03215706|BIOLOGICAL|Ipilimumab|Specified dose on specified day
40826141|NCT03215706|BIOLOGICAL|Nivolumab|Specified dose on specified day
40826142|NCT03215706|DRUG|Carboplatin|Specified dose on specified day
40826143|NCT03215706|DRUG|Paclitaxel|Specified dose on specified day
40826144|NCT03215706|DRUG|Pemetrexed|Specified dose on specified day
40826145|NCT03215706|DRUG|Cisplatin|Specified dose on specified day
40826146|NCT05948228|DRUG|giomer based bioactive gel|Application of bioactive gel to prevent white spot lesions in orthodontic patients
40826147|NCT05948228|DRUG|Fluoride gel|Application of fluoride gel to prevent white spot lesions in orthodontic patients
40826148|NCT01804712|DRUG|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
40826149|NCT05061654|DRUG|Ceftolozane-tazobactam IV|Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
41345167|NCT06378606|BEHAVIORAL|cognitive therapy|"intervention : group A: recive computer cognitive traing by rehacom system and omega 3 supplement .~group B: recive smart phone cognitive application and omega 3 supplement . group c recive omega 3 supplement only."
40826150|NCT04627181|DRUG|Ferric carboxymaltose|Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD
40826151|NCT04627181|DRUG|Hydroxycobalamin|Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD
40826152|NCT04627181|DRUG|Placebo|Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
40826153|NCT04627181|DRUG|Placebo|Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
40826154|NCT01713361|DRUG|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
40826155|NCT01713361|DRUG|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
40826156|NCT01713361|DRUG|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). \[Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.\]
40826157|NCT01082510|DRUG|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
40826158|NCT01082510|DRUG|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
40826159|NCT03739489|PROCEDURE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.
40826160|NCT02256267|DRUG|LY2835219|Administered orally
40826161|NCT02256267|DRUG|Rifampin|Administered orally
40826162|NCT02719119|PROCEDURE|monthly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation monthly.
40826163|NCT02719119|PROCEDURE|bi-weekly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation bi-weekly.
40826164|NCT01404013|DRUG|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
40826165|NCT01404013|DRUG|Montelukast|Montelukast 10mg ,every night, for 8 weeks
41157348|NCT04090788|DIETARY_SUPPLEMENT|dried cucumber supplements|reference intervention with 2.4g/d dried cucumber supplements
41157349|NCT04440579|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is neuromodulation that uses electricity to stimulate the nervous system, specifically the posterior tibial nerve, and is minimally invasive.
41157350|NCT04440579|PROCEDURE|Sham Percutaneous Tibial Nerve Stimulation (PTNS)|Patients will be connected to the PTNS device but the device will remain off for the entirety of the procedure
41345168|NCT02735044|DRUG|Insulin glargine,300 U/mL|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])
41345169|NCT02735044|DRUG|Insulin glargine (100 units /mL)|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
41345170|NCT02735044|DRUG|Background therapy|Fast-acting mealtime insulin analogs
41345171|NCT00911066|DRUG|MLN4924|"MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:~* Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)~* Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)~* Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)~* Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)~* Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)"
41345172|NCT00911066|DRUG|Azacitidine|Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
41345173|NCT00302055|BEHAVIORAL|Clinical referral to diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
41345174|NCT00302055|BEHAVIORAL|Clinical referral to group diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
41345175|NCT00004690|DRUG|monolaurin cream|
41345176|NCT01138462|OTHER|intervention|"5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.~Daily direct resident's environmental disinfection during decolonisation."
41345177|NCT05604404|OTHER|Supine|The patient will be positioned supine with head-of-bed at zero degrees.
41345178|NCT05604404|OTHER|Semi-Recumbent|The patient will be placed in a semi-recumbent position with head-of-bed at thirty degrees.
41345179|NCT05604404|OTHER|Semi-Recumbent with Legs Flexed|The patient will be placed in a semi- recumbent position with head-of-bed at thirty degrees and legs flexed.
41345180|NCT06465355|PROCEDURE|pharyngo-esophageal high-resolution manometry|The high resolution manometry (HRM) catheter will be inserted through the more patent nares and positioned such that it covers the pharynx and the esophagus. Affixed to the high resolution catheter will be a single lumen, end-hole catheter (length: 90 cm, outside diameter: 1.58 mm) wherein the end hole of the tube will be secured at a fixed pharyngeal site on the HRM catheter and the other end of the tube will be connected to a stopcock so that the tube may be either open or closed to atmospheric pressure. 3. Study subjects will be asked to swallow their ambient saliva ten times with the stopcock open and ten times with the stopcock closed. There is a 30 second interval between swallows.
41345181|NCT04721275|OTHER|measurement of pronostic sepsis scores|qSOFA, NEWS and MEDS sores are measured to each patient admitted in the emergency department with a suspicion of infection (excluding localized infection as abscess, angina, cystitis).
40826166|NCT01404013|DRUG|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
40826167|NCT04674501|PROCEDURE|Cardiac evaluation and blood sampling|"Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets."
40826168|NCT03833089|COMBINATION_PRODUCT|Targeted serum potassium level|In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Potassium supplementation, 3) mineralocorticoid receptor antagonists,
40826169|NCT03242772|DRUG|Amphetamine|Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward and may be decreased or stopped at any time.
40826170|NCT03242772|BEHAVIORAL|ESDM informed parent coaching|All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).
40826171|NCT03242772|DRUG|Placebo Oral Tablet|Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
40826172|NCT04211987|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
40826173|NCT04211987|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
40826174|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
41345182|NCT02460172|DEVICE|Zip Surgical Skin Closure|Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.
41345183|NCT02460172|DEVICE|Steel Staples|Skin closure device for the closure of the skin layer following surgical incision
40826175|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
41157351|NCT04440579|PROCEDURE|Standard Cystoscopy|Patient will undergo standard cystoscopy
41157352|NCT05325476|OTHER|JomPrEP App|The JomPreP app will be ideally designed to optimize HIV prevention cascade by providing a virtual platform to access to HIV prevention (e.g., HIV testing and PrEP) and other support services (e.g., mental health). The JomPrEP app will be available on the Apple Store and the Google Play Store for the users to download. However, access to the app will be restricted to the research participant using a unique registration code.
41345184|NCT02602704|DRUG|Bazedoxifene|Bazedoxifene 20mg/day (Viviant) for 48 weeks
41345185|NCT02602704|DRUG|Calcium/Vit D|Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day) for 48 weeks
41345186|NCT04202432|DIAGNOSTIC_TEST|Mean systemic filling pressure|"Peri- and postoperative measurement of continuous cardiac output with thermodilution derived pulse contour calculated device (PiCCO).~Estimation of mean systemic filling pressure using a computerized algorithm and by creating venous return curves with inspiratory hold maneuvers, thereby extrapolating the VR-curve until mean systemic filling pressure is calculated."
41345187|NCT00125697|PROCEDURE|3T MRI Scanning|pre-radiation therapy, week 4 radiation therapy, 2 months post radiation therapy and every 4 months for the first year
41345188|NCT03551704|BEHAVIORAL|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
41345189|NCT03551704|BEHAVIORAL|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on abstinence. The schedule will incorporate an increasing magnitude of reinforcement.
41345190|NCT04432324|BIOLOGICAL|Intravenous Immune Globulin|IVIG Intravenous infusion
41345191|NCT04432324|DRUG|Standard Medical Treatment|SMT
41345192|NCT04275492|DRUG|Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)|Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD
41345193|NCT04275492|DRUG|Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)|Siforl® is produced by Boehringer Ingelheim International Gmbh
41345194|NCT00215813|DRUG|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
41345195|NCT00093158|DRUG|Angiomax (bivalirudin) anticoagulant|
41345196|NCT05415527|OTHER|Presence of sarcopenia evaluated prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management(dietician and APA).|"Sarcopenia will be evaluated by CT-scan. This method will be combined with a bone mineral density test which is also a way of entering into a more specific approach to sarcopenia screening.~The patients will receive optimised treatment by nutritional monitoring and adapted physical activity (APA) in addition to follow-up for sarcopenia."
41345197|NCT00632515|BEHAVIORAL|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
40826176|NCT02272751|BEHAVIORAL|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
40826177|NCT02272751|BEHAVIORAL|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
40826178|NCT05997381|DEVICE|Arthroscopic rotator cuff repair with BioBrace® Implant augmentation.|An arthroscopic rotator cuff repair will be performed and augmented with the BioBrace® Implant. The BioBrace® Implant is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in rotator cuff repairs, it is placed on top of the tendons to augment and reinforce the underlying repair. The BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care rotator cuff repair techniques.
40826179|NCT05997381|PROCEDURE|Arthroscopic rotator cuff repair|An arthroscopic rotator cuff repair is performed using standard surgical procedure.
40826180|NCT01480973|RADIATION|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
40826181|NCT01574898|DRUG|V0474 - A mg|Single oral administration
40826182|NCT01574898|DRUG|V0474 - B mg|Single oral administration
40826183|NCT01574898|DRUG|V0474 - C mg|Single oral administration
40826184|NCT01574898|DRUG|V0018 - B mg|Single oral administration
41345198|NCT05089188|OTHER|Immunomarkers|immunohistochemical expression profile of ambiguous melanocytic proliferation.
40826185|NCT01574898|DRUG|Niquitin® Fresh Mint 4 mg|Single oral administration
40826186|NCT04473833|PROCEDURE|Serial Transvaginal Ultrasonography|Participants will undergo transvaginal ultrasonography (TVS) to detect ovarian cancer as part of the Kentucky Ovarian Cancer Screening Program. Those with normal findings will repeat the TVS in one year. Those with abnormal results will repeat the screening in 4-6 weeks.
40826187|NCT03726515|BIOLOGICAL|CART-EGFRvIII T cells|autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
40826188|NCT03726515|BIOLOGICAL|Pembrolizumab|humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
40826189|NCT01236092|OTHER|conservative therapy - traction, vibration, exercise|10 weeks of therapy. 3 treatments per week the first 4 weeks and 2 treatments the final 6 weeks.
40826190|NCT05946291|OTHER|Pressure injury training|Pressure injury training with mulage application on a standardized patient
40826191|NCT05946291|OTHER|Simulated Manneqquin training|Pressure injury training with mulage application on a simulated manneqquin
41345199|NCT00275106|DRUG|asparaginase|
41345200|NCT00275106|DRUG|cyclophosphamide|
40826192|NCT06115382|BEHAVIORAL|Self Cueing Training|Group classes led by a music therapist and using singing as a self-generated cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
40826193|NCT06115382|BEHAVIORAL|External Cueing Training|Group classes led by a music therapist and using music as an external cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
40826194|NCT00427531|OTHER|physiologic testing|
40826195|NCT01007929|DRUG|14C-AZD1236|Oral solution 1mg/mL
40826196|NCT06031142|DEVICE|use wearable devices to monitoring fetal health conditions.|We used wearable devices and clinical cardiotocography (CTG) equipment to monitor pregnant women for 30 minutes to demonstrate the reliability of wearable devices.
41345201|NCT00275106|DRUG|cytarabine|
41345202|NCT00275106|DRUG|daunorubicin hydrochloride|
40826197|NCT00061074|DRUG|Nicotrol|
40826198|NCT04640493|DRUG|Dapagliflozin|If patients have been diagnosed with SDB using the WatchPat device, they will start dapagliflozin. Repeat WatchPat SDB assessment will be performed after 3 and 6 months of continuous dapagliflozin therapy.
40826199|NCT04640493|DEVICE|WatchPat|HF patients undergo SDB testing with the WatchPat device. (non-experimental)
40826200|NCT06293638|DRUG|Alcohol|Alcohol consumption is shown to reduce tremor in individuals with essential tremor. The alcoholic beverage will be dispensed by the a clinician study investigator, and the participant will be administered the alcoholic beverage until their tremor is decreased, as determined by the clinician. Individual sensitivity to the tremor-mitigating effects of alcohol varies, but it is anticipated that only light (1-2 40% ABV drinks, containing 1-2 units of absolute alcohol (10 mL. or 8 g of pure ethanol)) consumption will be necessary. Participants will then repeat motor task and data collection while the alcohol is effective at controlling tremor, beginning approximately 15-20 minutes after consumption.
40826201|NCT06293638|DRUG|Alprazolam|Alprazolam is shown to reduce tremor in individuals with essential tremor. The primary investigator will select the appropriate dose for the patient (0.5mg for patients with a body weight of up to 75kg, and 0.75mg for participants with a body weight of 75kg and higher). Participants will swallow the drug with a glass of water in the presence of the research team. If participants have not reached a sufficient level of tremor improvement, a subsequent dose of up to a total of 1.0mg of alprazolam per participant will be requested. Participants will then repeat motor task and data collection.
41345203|NCT00275106|DRUG|dexamethasone|
41345204|NCT00275106|DRUG|doxorubicin hydrochloride|
41345205|NCT00275106|DRUG|leucovorin calcium|
41345206|NCT00275106|DRUG|mercaptopurine|
41345207|NCT00275106|DRUG|methotrexate|
41345208|NCT00275106|DRUG|prednisolone|
41345209|NCT00275106|DRUG|thioguanine|
41345210|NCT00275106|DRUG|vincristine sulfate|
41345211|NCT00275106|PROCEDURE|radiation therapy|
40826202|NCT06293638|DEVICE|Cold Therapy|One or both of the participant's upper limbs will be wrapped with pre-chilled ice packs or a cold water circulating device such as a cryomanchet (e.g., the Breg PolarCare Glacier), and the skin temperature monitored until it lowers to 15-25°C. Participants will then repeat motor task and data collection while the limb is cool.
41345212|NCT06331273|PROCEDURE|"Liver transplantation with No-touch technique"|"The core principle of no-touch tumor surgery revolves around avoiding direct contact with the tumor or surrounding tissues as much as possible to minimize the release of cancer cells into the bloodstream or nearby tissues."
41490233|NCT05770921|DEVICE|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
41490234|NCT01370135|DRUG|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
41490235|NCT05192694|PROCEDURE|Computed tomography|Positron Emission Tomography
41490236|NCT02080169|DRUG|midazolam|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
41490237|NCT02080169|DRUG|Dexmedetomidine|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
41345213|NCT02967562|OTHER|Inflation Breaths|
41345214|NCT02967562|OTHER|Sustained Inflation|
41345215|NCT02797470|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
41345216|NCT02797470|DRUG|Carmustine|300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.
41345217|NCT02797470|DRUG|Cytarabine|100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
41345218|NCT02797470|DRUG|Etoposide|VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
41490238|NCT02080169|DRUG|Fentanyl|Fentanyl is used as analgesic drug in order to obtain the VAS \<3.
41345219|NCT02797470|OTHER|Laboratory Biomarker Analysis|Correlative studies
40826203|NCT06293638|PROCEDURE|Peripheral Nerve Stimulation|Electrical stimulation will be applied using techniques similar to those applied during standard somatosensory evoked potential testing. Specifically, adhesive surface electrodes will be placed above the median and radial nerves at the wrist. Stimulation paradigms will be tailored to each participant based on the frequency characteristics of their tremor. Participants will receive between 20-60 minutes of stimulation, then will repeat motor task and data collection. Transcutaneous peripheral nerve stimulation may help mitigate tremor, with effects lasting beyond cessation of stimulation1-3.
40826204|NCT00681694|RADIATION|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
40826205|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
40826206|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
40826207|NCT02090049|DIETARY_SUPPLEMENT|Puravita Breakfast|The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
40826208|NCT02090049|DIETARY_SUPPLEMENT|Control|The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
40826209|NCT01011803|OTHER|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were \[diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)\]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
40826210|NCT05819307|DEVICE|OCT/FLIM|OCT/FLIM imaging of the retina
40826211|NCT00777530|DRUG|Bosutinib (SKI-606)|
40826212|NCT03538184|PROCEDURE|Piezosurgery|Preparation of implant beds entirely with piezo surgery implant tips
40826213|NCT03538184|PROCEDURE|Drill|Preparation of implant beds entirely with conventional implant drills
41345220|NCT02797470|BIOLOGICAL|Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
40826215|NCT03003078|DEVICE|OncoSil™|The implantation of OncoSil™
40826216|NCT02725593|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
40826217|NCT02725593|DRUG|Dapagliflozin placebo|matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
40826218|NCT02829892|DEVICE|Light therapy|14-days exposure with an innovative ambient light
40826219|NCT01956045|OTHER|Patient's capacity|
40826220|NCT02974335|BEHAVIORAL|Interviews with Stakeholders|The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
41345221|NCT02797470|DRUG|Melphalan|140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.
41345222|NCT02797470|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
41018741|NCT02694991|OTHER|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
40826221|NCT03832114|DRUG|LNP023|Increasing doses of LNP023 up to 200 mg.
40826222|NCT01567501|DRUG|Levocetirizine Dihydrochloride tablets 5 mg|5 mg tablet once in a day
40826223|NCT01567501|DRUG|Levocetirizine Dihydrochloride|5 mg tablet once in a day
41490239|NCT06289153|DEVICE|Arthrex Internal Brace|The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
41490240|NCT06289153|PROCEDURE|ACL Reconstruction|All patients will undergo ACL reconstruction (ACLR) with or without an internal brace.
41490241|NCT02059018|DRUG|COX-inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
41345223|NCT01481428|BEHAVIORAL|Computer-facilitated HIV intervention|Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.
41345224|NCT01481428|BEHAVIORAL|Attention Control|Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
41345225|NCT06003452|PROCEDURE|surface treatment with Bioactive Glass Air Abrasion|giomer based fissure sealnt will be applied after surface treatment With Bioactive Glass Air Abrasion
41345226|NCT06335160|DRUG|Mebendazole|mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months
41345227|NCT00446797|DRUG|Non-selective NSAIDS|Non-selective NSAIDs administered at usual (standard) doses.
40826224|NCT06367907|OTHER|schema therapy|In this study, we aim to investigate the mode of action of the core therapeutic techniques implemented in schema therapy (ST), a psychotherapy that particularly addresses deficits of emotion regulation and of social interaction in personality disorders.
40826225|NCT05433168|PROCEDURE|SHIATSU|The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
40826226|NCT05433168|PROCEDURE|DUMMY SHIATSU|Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
40826227|NCT05630222|DRUG|Ibuprofen 800 mg|Ibuprofen from Caspian Taamin Company
41345228|NCT00446797|DRUG|Celecoxib|celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
41345229|NCT02381067|OTHER|NuCel with Allograft Bone|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Allograft bone is bone that comes another patient. NuCel and Allograft bone will be combined for this treatment.
41345230|NCT06302608|GENETIC|NGGT001|Safety and Effectiveness of subretinal injection of NGGT001 for treating crystalline retinal degeneration
41345231|NCT00941707|DRUG|JNJ 38518168|JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.
40826228|NCT05630222|DRUG|Morphine Sulfate|Morphine Sulfate from Darupakhsh Company
40826229|NCT05630222|DRUG|Ibuprofen 400 mg plus Acetaminophen 1000 mg|Both from Caspian Taamin Company
40826230|NCT02337972|DRUG|povidone-iodine 4%|Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
41345232|NCT00941707|DRUG|Placebo|Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
41345233|NCT02381262|BEHAVIORAL|Fitbit|The Fitbit is a wrist based wearable technology device designed to monitor physical activity by tracking steps, distance and calories burned as well as sleep patterns and heart rate. It has wireless capabilities to sync with smart devices and summarize data for the user or export for synchronize with electronic health records.
40826231|NCT04349748|BEHAVIORAL|Health education, and regular HIV and STDs testing prompting service|Health education through app for once a week, and regular HIV and STDs testing prompting service (every month through app) are given to the participants at the beginning of the study and last for the whole five observation periods.
40826232|NCT04349748|BEHAVIORAL|Health status inquiry through app (partner notification)|The permission to query health status through app (partner notification) is given to participants (participants can query their potential sexual partner's status of HIV, syphilis, hepatitis B, and hepatitis C respectively through app) at the specific observation period,and the permission is retained until the end of study.
40826233|NCT03249935|DRUG|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
41345234|NCT04434261|DIAGNOSTIC_TEST|PT-PCR test for SARS-CoV-2|Screening test for the diagnosis of SARS-CoV-2 in asymptomatic patients
41490242|NCT02059018|DRUG|Nitroglycerin|Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
40826234|NCT01371240|DRUG|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
40826235|NCT05412290|DRUG|Mosunetuzumab|"Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following."
40826236|NCT00497237|DRUG|Beclomethasone plus formoterol fixed combination|100+6 pMDI
40826237|NCT00497237|DRUG|Fluticasone plus salmeterol fixed combination|diskus 250/50
40826238|NCT01514240|DRUG|D9421-C capsule 3 mg|Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
40826239|NCT01514240|DRUG|Mesalazine tablets|Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
40826240|NCT02963987|OTHER|Food and Beverage Portion Size|Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
40826241|NCT04920721|OTHER|no intervention|no intervention descriptiv study
41018742|NCT03252821|BEHAVIORAL|High-intensity interval training|High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.
41018743|NCT03252821|BEHAVIORAL|Resistance training|Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
41490243|NCT02059018|DRUG|COX-inhibitor + Nitroglycerin|Combination of COX-inhibitor and nitroglycerin interventions.
41490244|NCT04764136|DEVICE|Scoliometer (scolioscope)|Individuals with scoliosis will participate in this study. The device will be used to determine spinal rotation on the transverse plane. Repeated measures will be taken.
40826242|NCT05700292|OTHER|High-intensity Interval Training|Training is based on 5 circuits, with intervals of 1 minute (high intensity) by 2 minutes (low intensity), with a total training time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). The high intervals will be performed with the following exercises: squat, reverse lunge \& knee-up, reverse jump and walkout pushup, while the low intervals were performed jogging. The heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate of 85% to 95%. To monitor heart rate during training, a polar brand chest sensor, model H9, will be used.
41018744|NCT05747846|PROCEDURE|Carpal tunnel release, WALANT technique|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release without a tourniquet.
40826243|NCT05700292|OTHER|Moderate-intensity continuous training|Continuous aerobic training (jogging). Also, the heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate from 60% to 75% and an increase in training time from 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). To monitor heart rate during training, a polar brand chest sensor, model H9, will be used as well.
40826244|NCT01456208|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
40826245|NCT01456208|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
40826246|NCT01456208|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
40826247|NCT06411132|OTHER|observational study|observational study
40826248|NCT00724269|DEVICE|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
40826249|NCT00724269|DEVICE|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
40826250|NCT01989702|OTHER|Fermented blueberry drink|
40826251|NCT01989702|OTHER|Placebo drink|
40826252|NCT01989702|OTHER|Sachets with probiotic bacterial powder|
40826253|NCT01989702|OTHER|Sachets with placebo powder|
40826254|NCT05361499|BIOLOGICAL|Sp_6B|Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)
40826255|NCT05361499|DRUG|Amoxicillin 500 mg|Amoxicillin, 7 days, 2x 500 mg
40826256|NCT05256342|DRUG|Duloxetine 60mg|"Eight weeks treatment, one pill daily.~1st week 30mg; weeks 2-7th -- 60 mg daily."
40826257|NCT05256342|DRUG|Etoricoxib 60 mg|One pill daily for 8 weeks
40826258|NCT05256342|DRUG|omeprazol|20 mg daily; will be taken with Etoricoxib from the second week of treatment
40826259|NCT05644145|BIOLOGICAL|Serological study after yellow fever vaccination|It is a serological survey of the cohort of children who participated in the preliminary investigation and seroconverted after vaccination against yellow fever.
40826260|NCT06350942|PROCEDURE|one trocar-assisted retroperitoneoscopic ureteroureterostomy (OTAU)|A 12 mm transverse incision was made just above the iliac crest, followed by careful dissection of the fascia and muscle layer to expose the Gerota's fascia. Entry into the retroperitoneal space was achieved with a 10-mm balloon trocar, allowing for pneumoretroperitoneum establishment. Using a 10-mm laparoscope equipped with a Maryland dissector, the ureters were dissected and isolated, followed by careful exteriorization of both upper and lower pole moiety ureters with a Babcock grasper. The pathological upper pole moiety ureter was transected, preserving the normal lower pole moiety ureter and shared blood supply, and closed with a Vicryl 4/0 suture. Subsequently, an end-to-side ureteroureterostomy was performed with a 6/0 Polydioxanone running suture, with antegrade insertion of a double J stent if not previously conducted. A final retroperitoneoscopic evaluation ensured proper anastomosis alignment, and the incision was closed without drainage.
41018745|NCT05747846|PROCEDURE|Carpal tunnel release using a tourniquet|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release using a hemostatic cuff. The hemostatic cuff will be insufflated at the level of the arm at a pressure of 100 mmHg higher than the patient's systolic pressure. The cuff will be removed once wound closure is complete.
41018746|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
41018747|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
41018748|NCT04508803|DRUG|HX008，Niraparib，Trastuzumab|Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.
41018749|NCT04508803|DRUG|HX008，Niraparib，Pyrrolitinib|"HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle.~Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle."
41018750|NCT01083433|BEHAVIORAL|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
41018751|NCT01083433|DEVICE|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
41018752|NCT04369469|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.
41018753|NCT04369469|OTHER|BSC|Participants received medications, therapies, and interventions per standard hospital treatment protocols.
41018754|NCT01592513|DEVICE|BIS monitor|"BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs."
41018755|NCT05713916|OTHER|Intervention: Population Health Coordinator|After being notified of the finding of LVH in their patient, the population health coordinator will offer to schedule a dedicated visit for the provider and their patient to discuss this finding through a structured correspondence. Additionally, the population health coordinator will offer to coordinate 24-hour ambulatory blood pressure monitoring before or after the patient visit as part of the evaluation of LVH. Finally, for patients without established cardiovascular care and whose etiology of LVH remains undetermined, the population health coordinator will offer to coordinate a visit with a cardiologist to discuss the finding of LVH.
41018756|NCT03198273|OTHER|Clinical pilates exercises|servical, lumbal, pelvic muscles
40826261|NCT05901363|PROCEDURE|Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy|laparoscopic removal of gallbladder and endoscopic extraction of common bile duct stones
40826262|NCT05901363|PROCEDURE|aparoscopic common bile duct exploration and laparoscopic cholecystectomy|laparoscopic removal of gallbladder and laparoscopic extraction of common bile duct stones
40826263|NCT05482815|DEVICE|Provox Vega Voice prosthesis|Voice prosthesis for speech rehabilitation, Provox Vega Voice prosthesis
40826264|NCT03695380|DRUG|Cobimetinib|Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
40826265|NCT03695380|DRUG|Niraparib|Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
40826266|NCT03695380|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
40826267|NCT01442506|OTHER|biopsies|taking biopsies
40826268|NCT01442506|OTHER|biopsy|biopsy
40826269|NCT04679857|OTHER|TKA|Total Knee Arthroplasty
40826270|NCT01825395|DRUG|3, 4-Diaminopyridine|
40826271|NCT04931290|PROCEDURE|Supracapsular Ahmed Glaucoma Valve plate delivery technique|incision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.
40826272|NCT06487312|DEVICE|Test equipment: Name: Remote automatic ultrasound diagnostic system (Wuhan Cooper Technology Co., Ltd.) Model: CORUS-A30|A clinical trial to evaluate the effectiveness and safety of a remote automated ultrasound diagnostic system for automated ultrasound examination using a remote automated ultrasound diagnostic system (model: CORUS-A30, Wuhan Cooper Technology Co., Ltd., China).
40826273|NCT03593681|DEVICE|Hysteroscopic cell sampling of the fallopian tube|Hysteroscopic fallopian tube biopsy
40826274|NCT05753345|BEHAVIORAL|Aquatic therapy|Children receive aquatic occupational therapy twice a week for 10 weeks. 30 minutes of aquatic therapy in a warm water pool to increase upper extremity function and swim skills; 15 minutes of self care training to increase independence with dressing and showering.
40826275|NCT03789032|DRUG|Vadadustat|Vadadustat 300 mg
40826276|NCT03789032|DRUG|Rabeprazole|Oral Rabeprazole
41157353|NCT05325476|OTHER|Inactivated JomPrEP app|Participants will have access to the JomPrEP app with major intervention features inactivated. Information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The RA will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
41157354|NCT05382390|DRUG|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
41345235|NCT05055037|OTHER|Neurofeedback|In neurofeedback (NF), the brainwave activity is measured by an electro-encephalography and fed back to the person as an auditory or visual signal, rewarding the person each time progress is made toward normalizing dysregulated neural activity. The learning mechanism is at its base considered to be operant conditioning, where the behavior of the participant-in this case, neurological activity-is gradually changed through repeated reinforcement. In neurofeedback, this simple learning mechanism is accelerated by continuous and instant feedback, with rewards occurring as often as every second. The NF intervention included 12 NF training sessions, one session per week, off approximately 12-20 min. The protocol was a replicate of the setup of recent NF studies investigating NF as a treatment for chronic PTSD. The feedback was based on a single channel recording, rewarding brainwave frequencies associated with a calm and relaxed state and inhibiting drowsiness and hyperarousal.
41345236|NCT03205189|OTHER|Comparison between pre-operative prescription and post-operative prescription|The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
41345237|NCT03435276|DRUG|AZD9977|Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
41345238|NCT03435276|OTHER|Placebo|Randomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3
41345239|NCT00034892|DRUG|Olanzapine, risperidone|
41345240|NCT05518136|BEHAVIORAL|exercise-guidance on rehab APP|Training motions included sitting balance, hand support, crawling and squatting training12-14 were scheduled for 1 to 3 months postoperatively, moreover, climbing over obstacles was for 3 to 6 months.
41345241|NCT00744991|DRUG|Enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
41345242|NCT04476615|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet (ProLon®)|Dietary restriction: Fasting-Mimicking Diet (ProLon®). 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).
41345243|NCT04476615|DIETARY_SUPPLEMENT|Placebo bars|"Dietary supplementation: Low-energy bars (L-Nutra®) to integrate the daily nutritional habits - one bar per day.~5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total)."
41345244|NCT04383964|DEVICE|Distraction Osteogenesis for Reconstruction of Ramus-Condyle|transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with TMJ ankylosis to correct the resultant deformity either unilaterally or bilaterally.
41345245|NCT05915104|DRUG|Budesonide MMX®|9 mg delayed and extended-release tablet once daily
41345246|NCT05915104|DRUG|Budesonide controlled ileal release (CR) capsules|three 3 mg capsules daily oral administration for 8 weeks
40826277|NCT04361604|BIOLOGICAL|Biological collection (patients co infected HIV Sras-CoV-2)|Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
40826278|NCT04361604|OTHER|Auto-questionnaires (patients co infected HIV Sras-CoV-2)|4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV
40826279|NCT04361604|OTHER|Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)|Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
40826280|NCT04015037|COMBINATION_PRODUCT|placebo or drug|Group A and B (medicated or placebo)
40826281|NCT06219837|DRUG|bupivacaine injection by ultrasound guided transversalis fascia plane block|With patients in a sitting position and after appropriate skin asepsis, a 25-G pencil-point spinal needle (Pencil Point Spinal Needle Set, Egemen International Ltd., Izmir, Turkey) will be inserted through the L3 to L4 or L4 to L5 intervertebral space and 15 mg of 0.5% hyperbaric bupivacaine (AstraZeneca Pharmaceuticals, Cambridge, United Kingdom) will be injected. Subsequently, the patients will be positioned supine.
40826282|NCT03552536|DRUG|MK-8583|A single oral dose of MK-8583 in capsule form
40826283|NCT00711347|DEVICE|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
40826284|NCT00711347|DEVICE|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
41157355|NCT05382390|DRUG|Decitabine|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
40826285|NCT02076399|DRUG|Fostamatinib disodium|Fostamatinib (100 mg PO bid or 150 mg PO bid)
40826286|NCT02076399|DRUG|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
40826287|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 2-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
41018757|NCT03198273|OTHER|physiotherapy program|hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
41018758|NCT04307758|OTHER|Muscle Strength Assesment-Make Test|For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.
41345247|NCT05418140|OTHER|Ultrasound diagnosis of adenomyosis|The diagnosis of adenomyosis will be made using transvaginal ultrasound scan (TVS) (2D and 3D Ultrasound and applying Morphological Uterus Sonographic Assessment (MUSA) criteria (Van den Bosch et al, 2015).
41345248|NCT01815905|OTHER|Mobile program for occupational and speech therapy|
41345249|NCT01815905|OTHER|Traditional rehabilitation therapy|
41345250|NCT05409092|DIETARY_SUPPLEMENT|Astaxanthin|8 mg/day in one capsule for 4 weeks
41345251|NCT05409092|DIETARY_SUPPLEMENT|Placebo|8 mg/day in one capsule for 4 weeks
41345252|NCT01679340|DRUG|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
41345253|NCT01679340|DRUG|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
41345254|NCT01679340|DRUG|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
40826288|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 1-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 24-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of the participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
40826289|NCT06000631|BEHAVIORAL|Conventional Therapy with a 1-hour session|The other independent OT will be responsible for providing conventional therapy in the same location as the ROC-Stand training for a total of 24-week intervention based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general purpose of the training is to facilitate the developmental scales and improve mobility, socialization, and upper limb use in functional tasks.
40826290|NCT02605811|DRUG|temozolomide|
40826291|NCT02605811|RADIATION|prophylaxis cranial radiotherapy|2
41345255|NCT02264652|DEVICE|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
41345256|NCT02768844|DEVICE|Stochastic Vibrotactile Stimulation (SVS)|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available; designed by Wyss Institute, Harvard University, Cofab Design LLC) to provide gentle vibrations and sounds during mattress stimulations.
41345257|NCT02768844|OTHER|Control|Absence of mattress Stochastic Vibratory Stimulation (SVS)
41345258|NCT01452191|BEHAVIORAL|Injury Prevention Briefing Plus facilitation|Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
41345259|NCT01452191|BEHAVIORAL|Injury Prevention Briefing|Children's centres will receive the Injury Prevention Briefing only.
41345260|NCT04506385|DIETARY_SUPPLEMENT|probiotics|In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).
41345261|NCT05431036|DEVICE|transthoracic ultrasonography|"1. The lung ultrasound score (LUS) will be calculated according to the observed worst ultrasound pattern and Finally, the LUSs of all the parts will added to obtain the total LUS for each patient (maximum36 points)~2. The diaphragmatic ultrasound will performed for assessment of diaphragmatic thickness and motion."
41345262|NCT01147367|BEHAVIORAL|3 month physical activity intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
41345263|NCT02840734|OTHER|Kinesio taping|This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
41345264|NCT04352881|OTHER|Questionary patient|Assessing pain reduction using a 4-step questionary
41345265|NCT03192514|OTHER|Electronic Deprescribing tool|"Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions"
41345266|NCT05980676|BEHAVIORAL|Personalized Two-Week Email-Based Program|Both intervention groups will complete an activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. The Coached group will be able to reply to the emails to give feedback, ask questions, and receive additional support.
41345267|NCT02736474|DRUG|Naltrexone|3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.
41345268|NCT02736474|DRUG|Placebo Naltrexone|Placebo Naltrexone created and masked by the pharmacy to be used as a control.
41345269|NCT02736474|DRUG|Bupropion|1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.
41345270|NCT02736474|DRUG|Placebo Bupropion|Placebo Bupropion created and masked by the pharmacy to be used as a control.
40826292|NCT03032614|DRUG|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
40826293|NCT03032614|DRUG|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
41157356|NCT01965041|DRUG|aflibercept|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
41345271|NCT05661175|PROCEDURE|one-handed technique|Traditional percutaneous nephrolithotripsy usually requires the left hand to hold the nephroscope and the right hand to control the fiber for lithotripsy.Our intervention is to control the depth and direction of the sheath with the left hand, the nephroscope in the right hand and control the fiber optic lithotripsy
41018759|NCT04307758|OTHER|Muscle Strength Assesment-Break Test|For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
41018760|NCT05351606|BEHAVIORAL|Tobacco Use Cessation Counselling Sessions|Counseling sessions will be given in person
41490245|NCT05122936|COMBINATION_PRODUCT|XRXPY-based Obesity Wellness Intervention(SOWI)|It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.
41490246|NCT00649727|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
41490247|NCT00649727|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
41490248|NCT03050060|DRUG|Atezolizumab|Given IV
41490249|NCT03050060|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
41490250|NCT03050060|OTHER|Laboratory Biomarker Analysis|Correlative studies
41490251|NCT03050060|DRUG|Nelfinavir Mesylate|Given PO
41490252|NCT03050060|BIOLOGICAL|Nivolumab|Given IV
41490253|NCT03050060|BIOLOGICAL|Pembrolizumab|Given IV
41490254|NCT04562480|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
41490255|NCT04562480|OTHER|Quality-of-Life Assessment|Ancillary studies
40826294|NCT03032614|DRUG|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
40826295|NCT03505905|DRUG|Pregnenolone|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
41018761|NCT05351606|DRUG|Bupropion|Given orally
41018762|NCT05351606|DRUG|Nicotine patch|Given transdermally
41018763|NCT05351606|DRUG|Nicotine lozenge|Given orally
41018764|NCT05919238|COMBINATION_PRODUCT|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
41018765|NCT06304740|DRUG|IMG-007|Subcutaneous injection of IMG-007
41157357|NCT04597099|DRUG|Micronized progesterone|oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
41157358|NCT04597099|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
41157359|NCT04597099|DRUG|Flutamide|Flutamide, 250 mg taken orally twice daily for four weeks before study admission.
41157360|NCT04597099|DRUG|Estradiol patch|Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
41157361|NCT05547503|DRUG|AFA-281|Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)
41157362|NCT03927742|BEHAVIORAL|Shade + app with messaging|Shade wearable device and application with UV messaging activated
41490256|NCT04562480|OTHER|Questionnaire Administration|Ancillary studies
41490257|NCT04562480|PROCEDURE|Resection|Undergo surgical resection
41490258|NCT02890654|OTHER|First time measure|"* Initial Interview~* Initial Survey,~* Quality of life Scale~* Kinesitherapy Review~* Anxiety Scale"
41490259|NCT02890654|OTHER|Second time measure|"* Kinesitherapy review~* Second survey including numeric scale of pain~* Anxiety scale~* Scoliosis Research Society 22 quality of life scale"
41490260|NCT02890654|OTHER|Third time measure|"* Scoliosis Research Society 22 quality of life Scale~* Anxiety scale~* Numeric scale of pain~* Kinesitherapy review"
41490261|NCT05341882|BEHAVIORAL|Mindfulness|Participants took part in a live, facilitated Zoom-delivered training that involved learning mindfulness and education about moral injury. The participants were interviewed regarding the program.
41490262|NCT05341882|BEHAVIORAL|Educational Support|As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
41490263|NCT05084508|BIOLOGICAL|Investigational varicella vaccine low potency|1 dose of a low-potency investigational varicella vaccine administered subcutaneously in the upper arm
41490264|NCT05084508|BIOLOGICAL|Investigational varicella vaccine medium potency|1 dose of a medium-potency investigational varicella vaccine administered subcutaneously in the upper arm
41490265|NCT05084508|BIOLOGICAL|Investigational varicella vaccine high potency|1 dose of a high-potency investigational varicella vaccine administered subcutaneously in the upper arm
41490266|NCT05084508|BIOLOGICAL|Marketed varicella vaccine Lot 1|1 dose of a marketed varicella vaccine of Lot 1 administered subcutaneously in the upper arm
41490267|NCT05084508|BIOLOGICAL|Marketed varicella vaccine Lot 2|1 dose of a marketed varicella vaccine of Lot 2 administered subcutaneously in the upper arm
41490268|NCT05084508|BIOLOGICAL|Measles, mumps, and rubella vaccine|1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm
41490269|NCT05084508|BIOLOGICAL|Hepatitis A vaccine|1 dose of a hepatitis A vaccine administered intramuscularly in the right anterolateral thigh
41490270|NCT05084508|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the left anterolateral thigh
41490271|NCT04070586|DEVICE|4DCBCT images|Images are acquired and assessed offline
41490272|NCT04881630|BEHAVIORAL|Automated Mobile Contingency Management (CM)|Financial incentives contingent upon smoking abstinence
41345272|NCT00881023|PROCEDURE|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
41345273|NCT00881023|DEVICE|Cartilage Autograft Implantation System|A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
41345274|NCT02081911|PROCEDURE|High Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
41345275|NCT02081911|PROCEDURE|Low Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
41345276|NCT02081911|PROCEDURE|Femoral Nerve Block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
41345277|NCT03127462|BEHAVIORAL|Nurse-led educational intervention|Patients in the intervention group will receive an individual face-to-face conversation with a duration of 45 min. All patients will have access to telephone counselling by their primary nurse when needed and able to arrange a new face-to-face conversation. After 4-6 weeks the face-to-face the nurse will of conversation reach out to the patient by phone to follow up on the earlier conversation. Three months after the face-to-face conversation the nurse will offer the patient a closing face-to-face conversation of 15 min at the same time where the patient has a doctor appointment at the department. Those who are in the control group will continue standard care and not receive any conversation and be used as the control group.
41345278|NCT04314609|DEVICE|Ultrasonography, fluoroscopy|success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy
41345279|NCT04484506|DRUG|pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone|Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.
41345280|NCT01764022|DRUG|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
41345281|NCT01764022|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
41345282|NCT00324272|DRUG|Fibrin Sealant (Tisseel) used in the Experimental Arm.|"For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects)."
41345283|NCT04285177|PROCEDURE|Strabismus surgery|Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy
41345284|NCT04629365|OTHER|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
41345285|NCT04629365|OTHER|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
41345286|NCT02401776|DIETARY_SUPPLEMENT|Monster Energy Drink|Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
41345287|NCT02401776|DIETARY_SUPPLEMENT|Monster energy drink|Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
41345288|NCT02401776|DIETARY_SUPPLEMENT|Monster Energy Drink|Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
41345289|NCT02401776|DIETARY_SUPPLEMENT|Coffee|Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
41345290|NCT04178434|BEHAVIORAL|Internet-based CBT intervention|A nine step intervention including internet-based feedback by psychologists
41157363|NCT03927742|BEHAVIORAL|Shape + app without messaging|Shade wearable device and application without UV messaging activated
41157364|NCT02801916|OTHER|0 grams oat bran|200 milliliters water plus 0 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
41345291|NCT03360942|DEVICE|SCC DBS|Deep Brain Stimulator
41345292|NCT01945788|DRUG|Teriparatide (rDNA origin)|
41345293|NCT05307523|DEVICE|Enriched Play Environment with Partial Body Weight Support Harness|A low-tech portable canopy with a partial-body weight harness system that allows a child and their caregiver to play freely in an 81 square foot space, which provides partial body weight offset to support movement and exploration.
41345294|NCT05307523|OTHER|Enriched Play Environment without Partial Body Weight Support Harness|Child and caregiver will play freely in the 81 square foot play space without being connected to the partial body weight support harness.
41345295|NCT04942769|DRUG|Selenium|selenium 100ug ，take it orally twice daily
41345296|NCT05315973|DEVICE|Testing sensor vs glucometer|Will test accuracy of this sensor; there will be no intervention.
41345297|NCT05394012|BIOLOGICAL|RQ3013|Two doses of 30 μg/0.15 mL at an interval of 28 days, or two doses of 60 μg/0.3 mL at an interval of 28 days
41345298|NCT05394012|BIOLOGICAL|Comirnaty|Two doses of 30 μg/0.3 mL at an interval of 28 days
41345299|NCT01951872|BEHAVIORAL|Manual-based treatment for caffeine dependence|Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.
41345300|NCT00683501|DRUG|DNB-001|four dosages of DNB-001, one placebo dosage
41345301|NCT00926185|DRUG|Lifitegrast|Ophthalmic Solution
41345302|NCT00926185|DRUG|Placebo|Ophthalmic Solution
41345303|NCT01384188|DRUG|ONO-5334|150 mg for 5 days administered in the morning or in the evening
41018766|NCT06304740|DRUG|Placebo|Subcutaneous Injection of Placebo
41490273|NCT04881630|OTHER|Standard Care (SC)|Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)
41345304|NCT01384188|DRUG|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
41345305|NCT00994760|DRUG|Instanyl (Intranasal Fentanyl)|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
41345306|NCT01500421|DEVICE|TH - Endovascular alone (Alsius®, Zoll, USA)|Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).
41345307|NCT01500421|DEVICE|TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)|Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.
41345308|NCT01500421|DEVICE|Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)|Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
41345309|NCT03823898|BEHAVIORAL|Supervised exercise|Two supervised exercise sessions per week from months 4 to 16
41345310|NCT03823898|BEHAVIORAL|Lifestyle intervention from baseline to 4 months|Lifestyle intervention from baseline to 4 months
41490274|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with Listerine|
41018767|NCT06146322|OTHER|WR|Unsweetened preload condition: 240 mL white glutinous rice, 250 kcal, 0 g β-glucan
41345311|NCT03823898|BEHAVIORAL|Monthly behavioral sessions|Monthly behavioral sessions consisted of lifestyle interactive sessions will take place monthly and covered and followed contents that were addressed during the first 4 months of the study
41018768|NCT06146322|OTHER|LB|Unsweetened preload condition: 240 mL low β-glucan barley, 250 kcal, \~4 g β-glucan
41018769|NCT06146322|OTHER|MB|Unsweetened preload condition: 240 mL medium β-glucan barley, 250 kcal, \~5 g β-glucan
41018770|NCT06146322|OTHER|HB|Unsweetened preload condition: 240 mL high β-glucan barley, 250 kcal, \~6 g β-glucan
41345312|NCT04250740|OTHER|Coffee with butter-1|250 mL brewed black coffee with hazelnut flavouring and 50 g water
41345313|NCT04250740|OTHER|Coffee with butter-II|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-I
41018771|NCT06146322|OTHER|WR+50g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL white glutinous rice + 50g HFCS, 391 kcal, 0 g β-glucan
41018772|NCT06146322|OTHER|LB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL low β-glucan barley + 50 g HFCS, 391 kcal, \~4 g β-glucan
41345314|NCT04250740|OTHER|Coffee with butter-III|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-II
41490275|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with CHX|
41490276|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with serum|
41490277|NCT00739986|DRUG|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
41345315|NCT04838639|DRUG|NO-13065|"Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065."
41345316|NCT04838639|DRUG|Placebo|Two subjects per cohort will take a matched placebo.
41345317|NCT04673461|DRUG|STA363 containing 90 mg (60 mg/mL) lactic acid|STA363 (90 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
41345318|NCT04673461|DRUG|STA363 containing 180 mg (120 mg/mL) lactic acid|STA363 (180 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
41345319|NCT04673461|DRUG|Placebo|Placebo will be injected into maximally two pain-generating degenerated intervertebral discs
41345320|NCT02493335|DRUG|Budesonide 0.5mg orodispersible tablet twice daily|
41345321|NCT02493335|DRUG|Budesonide 1mg orodispersible tablet twice daily|
41490278|NCT00739986|DRUG|Semapimod|Semapimod 60 mg IV x 3 days
41490279|NCT00739986|DRUG|Placebo|placebo IV x 3 days
41490280|NCT02408068|DRUG|Dexamethasone|Dexamethasone used to suppress endogenous cortisol secretion
41490281|NCT02408068|DRUG|Chronocort: fasted|single dose of 20mg modified release hydrocortisone in the absence of food
41490282|NCT02408068|DRUG|Immediate release hydrocortisone: fasted|single dose of 20mg immediate release hydrocortisone in the absence of food
41490283|NCT02408068|DRUG|Chronocort: fed|single dose of 20mg modified release hydrocortisone in the presence of food
41490284|NCT02470390|DRUG|Fentanyl|Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
41490285|NCT04238988|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
41490286|NCT04238988|DRUG|Carboplatin|Chemotherapy medication
41490287|NCT04238988|DRUG|Taxol|Chemotherapy medication
41490288|NCT02860221|DRUG|Tranexamic acid (TXA)|IV and topical administration
41490289|NCT02860221|DRUG|Epinephrine|
41490290|NCT02273687|DEVICE|Vivid S6 GE Ultrasound|"Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.~The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe."
41490291|NCT05964712|PROCEDURE|Medical surgery therapy|De novo patients with acromegaly will undergo medical/surgical therapy of this disease, according to the guidelines of the Endocrine Society. In this population (group #1) morpho-functional examinations together with the evaluation of the stage of the disease, with serum dosage of GH and IGF-1, will be performed at baseline and at months 3, 6 and 12 after initiating the treatment.
41490292|NCT04551430|DRUG|Cabozantinib|Cabozantinib will be supplied by Exelixis.
41490293|NCT04551430|DRUG|Nivolumab|Nivolumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
41345322|NCT02493335|DRUG|Placebo orodispersible tablet twice daily|
41345323|NCT02630394|DRUG|Azithromycin|
41490294|NCT04551430|DRUG|Ipilimumab|Ipilimumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
41490295|NCT01662349|DEVICE|MOE Antimicrobial Plasma Treatment System|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
41345324|NCT03745989|DRUG|MK-8353|Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.
41345325|NCT03745989|DRUG|Selumetinib|Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
41345326|NCT03201744|PROCEDURE|Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)|All procedures will start with low insufflation pressure (8 mmHg). Surgical field assessment (scale 1-5) will be performed every 5 minutes (Martini Br J Anaesth 2014). If conditions are poor (rating 1-2), intraperitoneal insufflation will be incrementally increased (10 mmHg, 12 mmHg, 15 mmHg) every 5 minutes as needed.Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
41345327|NCT00985738|DRUG|Dutasteride|Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
41345328|NCT00985738|OTHER|Placebo|The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
41345329|NCT02240992|BIOLOGICAL|PBSC|
41345330|NCT02240992|BIOLOGICAL|MSCs|
41490296|NCT06171607|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
41490297|NCT06171607|DRUG|Perflutren Lipid Microspheres|Given IV
41490298|NCT06171607|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
41490299|NCT03178032|BIOLOGICAL|DNX-2401|Brain infusion of the virus through the cerebellar peduncle
41490300|NCT00861198|OTHER|ERCP as per medical indication|ERCP as per medical indication
41490301|NCT06190535|DRUG|Etamsylate|Enteral administration of Etamsylate as solution galenic form
41490302|NCT02621918|OTHER|Progressive resistance training|
41490303|NCT02621918|OTHER|Aerobic training|
41490304|NCT02621918|OTHER|Placebo training|
41490305|NCT05040438|BIOLOGICAL|Vax-NK/HCC|autologous NK cells expanded ex vivo.
41490306|NCT00000212|DRUG|Desipramine|
41490307|NCT01261286|DRUG|verapamil|
41490308|NCT02554136|DRUG|HGP0918|
41490309|NCT02554136|DRUG|HGP0816|
41490310|NCT02554136|DRUG|HGP0918 + HGP0816|
41490311|NCT06314685|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine|As a experimental vaccine for 6 months to 5 years old.
40826296|NCT03505905|DRUG|Placebo|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
41345331|NCT04447625|DRUG|Oral antibiotic administration|per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
41345332|NCT04447625|DRUG|Intrauterine antibiotic infusion|intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
41345333|NCT05513092|DIAGNOSTIC_TEST|placenta accreta index score|role of placenta accreta index score in prediction of conservative surgery for placenta placenta accreta spectrum
41345334|NCT03624829|OTHER|Shared care|The intervention is an adapted version of shared care with close collaboration by services and professional groups, mainly localized in three GP centers. At each GP center one clinical psychologist specialist from the community mental health center (CMHC) works two and a half day a week, and a psychiatrist from the CMHC work at each GP center 1-2 hours a week. The psychologist and the psychiatrist are available for the GPs for consultation and discussions, and they give assessments and brief treatments to patients as requested by the GPs. Other primary health and social care and other specialized mental health or substance addiction services are involved or consulted according to needs of the patients.
41345335|NCT00000662|DRUG|Zidovudine|
41345336|NCT02656173|DRUG|Mirabegron|Oral tablet
41345337|NCT02656173|DRUG|Placebo|Oral tablet
41345338|NCT02656173|DRUG|Tamsulosin|Oral tablet
41345339|NCT02692560|BEHAVIORAL|I-STAND|Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.
40826297|NCT06194955|DRUG|GIP(1-42)|Infusion
41345340|NCT02692560|OTHER|Healthy Living|Participants receive enhanced usual care based on general healthy living topics that are available to all Kaiser Permanente Washington enrollees.
41345341|NCT06030804|DRUG|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
41345342|NCT06030804|DRUG|Placebo|Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
41345343|NCT04746989|DRUG|Probenecid|Probenecid claim is used as the exposure group.
41345344|NCT04746989|DRUG|Allopurinol|Allopurinol claim is used as the reference group.
41157365|NCT02801916|OTHER|4.5 grams oat bran|200 milliliters water plus 4.5 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
41345345|NCT06437548|DEVICE|Percutaneous spinal cord stimulation|The parameters of percutaneous cervical spinal cord stimulation leads will be adjusted for optimal upper extremity motor function.
41345346|NCT04600427|PROCEDURE|Epidural anesthesia|T11-12 epidural blockade with 0.25% bupivacaine continuous infusion.
40826298|NCT06194955|DRUG|GLP-1|Infusion
40826299|NCT06194955|DRUG|GLP-2|Infusion
40826300|NCT06194955|OTHER|Placebo|Saline
40826301|NCT06157541|BIOLOGICAL|Allogeneic cytomegalovirus-specific T cells|Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors
40826302|NCT06157541|DRUG|Pembrolizumab|A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
40826303|NCT06349187|DIAGNOSTIC_TEST|Interview|Interviewing with using the Hall Emotional Intelligence test, the Maslach emotional burnout test, and the test for determining general and specialized digital competencies
40826304|NCT02649374|BEHAVIORAL|Dietary, Exercise and lifestyle modifications|Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
41345347|NCT06377436|BEHAVIORAL|Experimental training|Through The Dividat Senso intelligent platform, subjects will be subjected to locomotion, cognitive and sensory domain-specific exercise programs. The exercises will be of increasing difficulty. Cognitive exercises will in fact be carried out by interacting with the DIVIDAT device consisting of a monitor and a pressure-sensitive platform through weight shifts, multidirectional steps and jumps.
41345348|NCT05560919|DRUG|Dihydroxycholecalciferols|Injection of Dihydroxycholecalciferols solution in the periodontal ligament for lower anterior segment teeth.
40826305|NCT05130606|BEHAVIORAL|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."|Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.
40826306|NCT05130606|BEHAVIORAL|FORCE Fact Sheet|Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.
40826307|NCT01229943|BIOLOGICAL|Bevacizumab|Given IV
40826308|NCT01229943|DRUG|Everolimus|Given PO
40826309|NCT01229943|DRUG|Octreotide Acetate|Given IM
40826310|NCT04531358|DEVICE|nasal spray|application of nasal spray
40826311|NCT04531358|OTHER|no treatment|no treatment
40826312|NCT05807776|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d1, Q3W
41018773|NCT06146322|OTHER|MB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL medium β-glucan barley + 50 g HFCS, 391 kcal, \~5 g β-glucan
40826313|NCT05807776|DRUG|Tislelizumab, Lenvatinib|"Tislelizumab combined with lenvatinib:~Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd."
41018774|NCT06146322|OTHER|HB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL high β-glucan barley + 50 g HFCS, 391 kcal, \~6 g β-glucan
41345349|NCT05560919|OTHER|dimethyl sulfoxide|Injection of dimethyl sulfoxide in the periodontal ligament for lower anterior segment teeth.
40826314|NCT01633515|PROCEDURE|Intralesional cryotherapy|"The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received)."
40826315|NCT03820453|DIETARY_SUPPLEMENT|Tribulus Terrestris|The experimental arm will receive a dietary supplement to increase the libido and sexual function
40826316|NCT03820453|OTHER|Placebo treatment|The control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics
40826317|NCT02488213|OTHER|Nutritional Counseling|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
41345350|NCT05560919|OTHER|serum|Injection of serum in the periodontal ligament for lower anterior segment teeth.
41018775|NCT02192450|DRUG|Insulin aspart/glargine|
41018776|NCT02192450|DRUG|Insulin aspart/degludec|
41018777|NCT01586442|DRUG|Eplerenone|Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
41345351|NCT06175754|PROCEDURE|Laser ablation|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser
41018778|NCT01586442|DRUG|Spironolactone|Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
41018779|NCT02718105|GENETIC|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
41018780|NCT06377735|PROCEDURE|BAI-BACE|Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
41018781|NCT01675180|OTHER|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
41018782|NCT01675180|OTHER|Control|No intervention
41018783|NCT02899897|DEVICE|echocardiography in IV fluid therapy|
41345352|NCT06175754|PROCEDURE|Laser with Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser plus sclerotherapy
41345353|NCT06175754|PROCEDURE|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy
41345354|NCT05617794|DEVICE|Diffusion Optics Technology (DOT) Pattern Spectacle Lens|DOT Pattern Spectacle Lens
41345355|NCT05617794|DEVICE|Control Spectacle Lens|Control Spectacles
41345356|NCT05990166|OTHER|Mineral-enriched powder|Mineral-enriched powder Mineral-enriched powder to allow for at-home fortification of beverages with 5 mg of ferrous iron and 10 mg of zinc sulfate monohydrate
41345357|NCT05990166|OTHER|Placebo powder|Placebo powder which is identical to the mineral- enriched powder, but does not contain the active ingredients (ferrous iron and zinc sulfate monohydrate)
41345358|NCT05124262|OTHER|Low- FODMAPdiet group intervention|Diet intervention
41345359|NCT00757081|DRUG|phosphatidylcholine and deoxycholate|50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
41490312|NCT06314685|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Vaccine|As a control vaccine for ages 6-11 months and 12-23 months.
41490313|NCT06314685|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|As a control vaccine for ages 2-5 years.
41490314|NCT02608138|OTHER|Iodine status among portuguese school children|
41490315|NCT02502279|DEVICE|Engström Datex-Ohmeda ICU Ventilator|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.
41490316|NCT02502279|DEVICE|Postoperative CPAP mask|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
41490317|NCT03334617|DRUG|Durvalumab|Durvalumab given IV at 1500 mg Q4W ±2 days
41490318|NCT03334617|DRUG|AZD9150|AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
41490319|NCT03334617|DRUG|AZD6738|AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
41490320|NCT03334617|DRUG|Vistusertib|Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
41490321|NCT03334617|DRUG|Olaparib|Olaparib (AZD2281) given orally at 300 mg BD
41490322|NCT03334617|DRUG|Oleclumab|Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
40826318|NCT02488213|OTHER|Usual Diet Guidance|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
41490323|NCT03334617|DRUG|trastuzumab deruxtecan|Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only \& trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days
41490324|NCT03334617|DRUG|cediranib|cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1
41490325|NCT03334617|DRUG|AZD6738 (ceralasertib)|AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.
41490326|NCT03334617|DRUG|AZD6738 (ceralasertib)|AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28
41490327|NCT03334617|DRUG|AZD6738 (ceralasertib) (240 mg or 160 mg)|AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
41490328|NCT03334617|DRUG|AZD6738 (ceralasertib) 7 days monotherapy|AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle
41490329|NCT04567030|DEVICE|Dental monitoring (DM)|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan, etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
41345360|NCT02148952|BEHAVIORAL|WHO Safe Childbirth Checklist Program|The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
41345361|NCT03998241|OTHER|No intervention was provided|No intervention given
41345362|NCT00481377|PROCEDURE|ablation|
41345363|NCT00384449|DRUG|Ranibizumab|Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
41345364|NCT01406158|DRUG|Solifenacin Succinate Formulation A|oral suspension
41345365|NCT01406158|DRUG|Solifenacin Succinate Formulation B|oral suspension
41345366|NCT01406158|DRUG|Solifenacin Succinate|oral tablet
41345367|NCT03510728|BEHAVIORAL|college drinker's check up|The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.
41345368|NCT03510728|BEHAVIORAL|Protective Behavioral Strategies Intervention|This intervention component focuses on educating and promoting PBS activities in future college drinking situations
41345369|NCT03510728|BEHAVIORAL|Ecological Momentary Intervention|This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.
41345370|NCT03422055|DRUG|99mTc-Fucoidan SPECT|Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
41490330|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of 5% dextrose in water (D5W) and administered subcutaneously as a single injection.
41490331|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4 + Montanide|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of D5W, mixed with 0.5 mL of Montanide, and administered subcutaneously as a single injection.
41490332|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4 + Montanide + Poly-ICLC|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) and 1.4 mg of poly-ICLC were emulsified in 1.0 mL of Montanide and administered subcutaneously as two injections.
41490333|NCT06155058|PROCEDURE|SYREBO|Serial ADL training of upper extremities with robotic aid
41490334|NCT06155058|PROCEDURE|Conventional Mirror Method|Serial ADL training of upper extremities assisted by physical therapist
41490335|NCT00286819|DRUG|the FEC75 and 95 regimen|"Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B"
41490336|NCT00943462|RADIATION|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2-Gy fractions, for a total of 30 fractions
41345371|NCT01899001|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
41345372|NCT01899001|BEHAVIORAL|Nutrition Counseling|All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
41345373|NCT00976963|DRUG|TMP/SMX|Take one twice daily for 3 days for urinary tract infection
41345374|NCT00976963|DRUG|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediately
41018784|NCT05751941|DRUG|Abiraterone|1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
41018785|NCT05751941|DRUG|Enzalutamide|160 mg of Enzalutamide will be given orally daily ending at week 4
41345375|NCT05228704|BEHAVIORAL|activities in the Botanical Garden or in urban|activities in the Taipei Botanical Garden or in Urban
41345376|NCT04152668|PROCEDURE|Titanium curette.|Implant debridement.
41345377|NCT04152668|PROCEDURE|Ultrasonic|Implant debridement.
41345378|NCT04152668|PROCEDURE|Air-polishing|Implant debridement and polishing.
41345379|NCT01789255|DRUG|vorinostat|Given PO
41345380|NCT01789255|DRUG|tacrolimus|Given IV or PO
41345381|NCT01789255|DRUG|cyclosporine|Given IV or PO
41345382|NCT01789255|DRUG|methotrexate|Given IV
41345383|NCT01789255|OTHER|laboratory biomarker analysis|Correlative studies
41345384|NCT01789255|OTHER|pharmacological study|Correlative studies
41345385|NCT04328441|DRUG|BCG Vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis
41345386|NCT04328441|DRUG|Placebo|Intracutaneously 0.1ml NaCl 0,9%
41345387|NCT02058251|DRUG|Oxytocin|One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
41345388|NCT02058251|DRUG|Placebo|Each participant will self-administer a 40 IU dose of intranasal saline.
41345389|NCT02630485|BEHAVIORAL|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
41345390|NCT02630485|DIETARY_SUPPLEMENT|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
41345391|NCT02630485|DRUG|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
41345392|NCT01070706|DRUG|Paclitaxel,Gemcitabine,Sunitinib|"To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.~If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15."
41345393|NCT04120350|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
41345394|NCT04120350|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
41345395|NCT04120350|DRUG|Lenalidomide|"In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~\[update 02-Jun-2020: the phase Ib trial has finished,and no MDT was obsevered in 25mg group. So the recommanded phase II dose was 25mg.\] In phase II study, 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21 every 28 days for 1 cycle. The duration of maintenance is 2 years."
41018786|NCT05751941|DRUG|Apalutamide|240 mg of Apalutamide will be given orally daily ending at week 4
41018787|NCT05751941|DRUG|Sipuleucel-T|Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
41018788|NCT06428097|DRUG|Levothyroxine|Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
41018789|NCT06428097|DRUG|Normal saline|Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
40826319|NCT02666456|OTHER|QST, Questionnaires|Assessment of sensory phenotype by QST and questionnaires
40826320|NCT04897919|DRUG|Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet|Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
40826321|NCT04897919|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|Artemether-Lumefantrine is given as recommended by manufacturer
40826322|NCT00505037|DRUG|ASP1585|Oral
40826323|NCT00505037|DRUG|Placebo|Oral
40826324|NCT00505037|DRUG|Sevelamer hydrochloride|Oral
40826325|NCT00042068|DRUG|Meloxicam|
40826326|NCT02870075|BEHAVIORAL|Fed exercise|Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
41157366|NCT02801916|OTHER|13.6 grams oat bran|200 milliliters water plus 13.6 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
41345396|NCT00479934|DRUG|imatinib mesylate|6 month treatment with 400mg/day (per os)
41345397|NCT01069094|DRUG|Progenta|12.5 mg, administered as a once daily oral dose for 90 days.
41345398|NCT01069094|DRUG|Progenta|25 mg, administered as a once daily oral dose for 90 days.
41345399|NCT01069094|DRUG|Progenta|50 mg, administered as a once daily oral dose for 90 days.
41345400|NCT01069094|DRUG|Lucron Depot|3.75 mg IM monthly
41345401|NCT01069094|DRUG|Placebo|Administered as a once daily oral dose for 90 days.
41490337|NCT00943462|DRUG|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
41345402|NCT03052465|OTHER|Test soup meal feeding intervention|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
41345403|NCT02620124|DRUG|Natural cycle: Triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
41345404|NCT02620124|DRUG|Hormone replacement cycle and triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
41345405|NCT01110486|DRUG|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
40826327|NCT02870075|BEHAVIORAL|Fasted exercise|Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
40826328|NCT02858531|OTHER|data retrieval|data retrieval with the Hospital Information System
40826329|NCT00394901|DRUG|Placebo|placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
40826330|NCT00394901|DRUG|Pregabalin|Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
40826331|NCT00394901|DRUG|Pregabalin|Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
40826332|NCT00394901|DRUG|Pregabalin|Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
40826333|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype AA|Hemodialysis
40826334|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype BB|Hemodialysis
40826335|NCT02377570|DEVICE|THERNOVA 400 dialyzer prototype CC|Hemodialysis
40826336|NCT02377570|DEVICE|FX CorDiax 80 dialyzer|Hemodialysis
41157367|NCT02801916|OTHER|27.3 grams oat bran|200 milliliters water plus 27.3 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
41157368|NCT01108484|BEHAVIORAL|Exercise|Supervised exercise: Three 90-minutes sessions per week.
41157369|NCT01108484|BEHAVIORAL|Exercise + Diet counseling|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.
41345406|NCT01110486|DRUG|ABT-348 and carboplatin|An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.
41345407|NCT01110486|DRUG|ABT-348 and docetaxel|ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
41345408|NCT01110486|DRUG|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
41018790|NCT06374147|DEVICE|SVS mattress|The intervention group will receive standard therapy plus continuous SVS stimulation using the Prapela SVS incubator pad. The control group will receive only standard therapy, using an inert pad (identical to the SVS pad, its controller, and green light, but without the transducer and therefore incapable of vibration), in order to mask caregivers. Treatment with the pad will continue until an infant is apnea-free for 3 days and \<2 weeks from anticipated discharge or at the clinician's discretion to discontinue treatment. After ending treatment, clinicians will observe patients 24 hours later and if apnea returns, should re-initiate treatment as needed. At 1 and 2 years of age, parents will be contacted for a brief telephone follow up survey to assess neurological development
41157370|NCT01108484|BEHAVIORAL|Exercise + Diet counseling + psycho-emotional support|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
41345409|NCT01110486|DRUG|ABT-348|An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
41345410|NCT05580237|PROCEDURE|Simultaneous right and left heart catheterization|Pressure recordings across the aortic valve with simultaneous flow measurements by right heart catheterization, during rest and during supine exercise.
41490338|NCT00794391|BEHAVIORAL|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller \& Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
41490339|NCT00794391|BEHAVIORAL|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
41490340|NCT05521139|DIAGNOSTIC_TEST|drug sensitivity results|drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
41490341|NCT01183221|DRUG|Syntocinon|One dose of 24 IU (3 sprays/nostril)
41345411|NCT05977803|RADIATION|MRI with CEST sequence, IVIM and ASL sequence|"Three sequences will be added as part of the protocol (for an additional duration of about 10 minutes) :~* The CEST sequence~* The ASL infusion sequence~* The IVIM sequence"
41345412|NCT03454724|DEVICE|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
41490342|NCT01183221|DRUG|Placebo|Intranasal Placebo
40826337|NCT00941369|DRUG|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."
40826338|NCT04956029|OTHER|There are no any interventions. This is to observe and test hospital cleanliness.|There are no any interventions. This is to observe and test hospital cleanliness.
40826339|NCT03663374|DRUG|Odelepan|Tablets, 125 mg
40826340|NCT03663374|DRUG|Placebo|Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
40826341|NCT04224272|DRUG|ZW25 (Zanidatamab)|Administered intravenously
40826342|NCT04224272|DRUG|Palbociclib|Administered orally
40826343|NCT04224272|DRUG|Fulvestrant|Administered as an intramuscular injection
40826344|NCT03723174|BEHAVIORAL|Oral Health Educational Program|proper introduction to brushing techniques, dietary recommendations and importance of visiting the dentist
41018791|NCT04661176|DIAGNOSTIC_TEST|miR Sentinel™ PCC4 Assay|This study is a prospective clinical utility study. Urine samples will be collected from participants for the miR Sentinel™ PCC4 Assay, which interrogates the expression profile of 442 small non-coding RNAs to classify disease status as having no molecular evidence of prostate cancer (NMEPC) or molecular evidence of low-, intermediate- or high-risk prostate cancer.
41345413|NCT03454724|DEVICE|Xience EES Everolimus Eluting Coronary Stent System|Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
41345414|NCT03555968|DRUG|THC 0|THC dose = 0mg
41345415|NCT03555968|DRUG|THC 5|THC dose = 5mg
41345416|NCT03555968|DRUG|THC 10|THC dose = 10mg
41345417|NCT03555968|OTHER|BAC 0|Blood alcohol concentration = .000%
40826345|NCT05507879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40826346|NCT05507879|OTHER|Electronic Medical Record|Review of medical records
40826347|NCT01151735|DRUG|C-1-esterase|1000 units of C-1-esterase inhibitor
40826348|NCT01151735|DRUG|C-1-esterase|1500 units of C-1-esterase inhibitor
40826349|NCT01151735|DRUG|placebo|placebo
40826350|NCT01480518|GENETIC|DNA analysis|
41345418|NCT03555968|OTHER|BAC .025|Blood alcohol concentration = .025%
41345419|NCT03555968|OTHER|BAC .049|Blood alcohol concentration = .049%
40826351|NCT01480518|GENETIC|comparative genomic hybridization|
40826352|NCT01480518|GENETIC|gene expression analysis|
40826353|NCT01480518|GENETIC|mutation analysis|
41345420|NCT03458234|DEVICE|16 French Foley Catheter|"A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra.~Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag.~Foley catheters are usually constructed out of either silicone or latex."
41345421|NCT05393895|DRUG|CSF-1|One drop bilaterally twice daily for approximately 6 weeks
41345422|NCT05393895|DRUG|Vehicle|One drop bilaterally twice daily for approximately 6 weeks
41345423|NCT04067440|DIAGNOSTIC_TEST|Microbial Swab|Swabs will be taken from peritoneum and jejunum (intraoperatively), rectum, and stool
41345424|NCT00492518|DRUG|Acetylcysteine|
41345425|NCT00492518|DRUG|Theophylline|
41345426|NCT00492518|DRUG|Placebo|
40826354|NCT01480518|GENETIC|polymerase chain reaction|
40826355|NCT01480518|GENETIC|polymorphic microsatellite marker analysis|
40826356|NCT01480518|OTHER|laboratory biomarker analysis|
40826357|NCT05244460|DRUG|Droperidol Injectable Product|Treatment
40826358|NCT05244460|DRUG|Diphenhydramine|Treatment
41018792|NCT00000601|DRUG|estrogen replacement therapy|
41018793|NCT00000601|DRUG|estrogens|
41018794|NCT00000601|DRUG|progesterone|
41018795|NCT00000601|DRUG|hormone replacement therapy|
41018796|NCT05821010|COMBINATION_PRODUCT|Lyophilized fecal microbiota transplantation capsules|Oral administration (capsule)
41018797|NCT05821010|COMBINATION_PRODUCT|Placebo capsules|Oral administration (capsule)
41345427|NCT02870348|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.
41345428|NCT05688540|OTHER|e book|e book
41345429|NCT05688540|OTHER|traditional education booklet|traditional education booklet
41345430|NCT06267495|PROCEDURE|Epithelium-on corneal cross-linking (epi-on CXL)|In epithelium-on corneal cross-linking (epi-on CXL), the cornea is soaked with riboflavin for 10 minutes (Paracel® for 4 minutes and VibeX-xtra® for 6 minutes) . Thereafter, the cornea is subjected to ultraviolet A at a wavelength of 370 nm to give a total dose of 5.4 J/cm² through 10 milliwatt mW/cm² for 9 minutes.
40826359|NCT01956136|BEHAVIORAL|Music-based Neurological Rehabilitation (MBNR)|Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
40826360|NCT01956136|OTHER|Standard Care (SC)|Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
40826361|NCT02081638|DRUG|Aspirin|Daily Asprin daily
40826362|NCT02081638|DRUG|Atorvastatin|Daily Atorvastatin Daily
40826363|NCT00278369|BIOLOGICAL|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
40826364|NCT00278369|BIOLOGICAL|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
40826365|NCT02601092|PROCEDURE|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
40826366|NCT02601092|PROCEDURE|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
40826367|NCT01851486|DRUG|Clonidine|Clonidine 0.15 mg
40826368|NCT01851486|DRUG|Naloxone|naloxone 0.15 mg/kg
40826369|NCT01851486|DRUG|placebo|
41345431|NCT03885076|PROCEDURE|Blood collection and bone marrow aspirate|Blood and bone marrow samples will be collected for the trial alongside routine tests.
41345432|NCT05817591|OTHER|Questionnaires|In current practice, capsaicin patch treatment is offered to patients with a 24-hour average pain level measured by the EN numerical scale : EN scale is \> 4 Pain monitoring questionnaires will be completed by patients every 6 weeks : Neuropathic Pain Symptom Invetory (NPSI Score), Patients' Global Impression of Change (PGIC scale), Numerical pain scale
41345433|NCT01866306|BIOLOGICAL|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
41345434|NCT01866306|DRUG|LABA|Asthmatic participants were treated with LABA as part of their standard of care
40826370|NCT01851486|OTHER|saline|
40826371|NCT01301521|DRUG|water-soluble cinnamon extract (Cinnulin PF)|Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
41345435|NCT00790218|DRUG|CF102|CF102 capsules twice daily by mouth
41345436|NCT00249912|DRUG|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
41345437|NCT00249912|DRUG|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
41345438|NCT00249912|DRUG|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
41345439|NCT03596255|DIAGNOSTIC_TEST|Estimated level of DA|the dental personnel estimated the patient's level of DA (eDA) on a 100mm VAS
41345440|NCT03596255|DIAGNOSTIC_TEST|MDAS|The patient rated their DA using the Modified Dental Anxiety Scale (MDAS)
40826372|NCT01328041|DRUG|dolutegravir|50 mg twice daily
40826373|NCT02003066|PROCEDURE|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
40826374|NCT02003066|PROCEDURE|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
40826375|NCT04126720|DIETARY_SUPPLEMENT|topical corticosteroids and vitamin E suplements|
40826376|NCT04126720|DRUG|Topical corticosteroid and placebo capsules|
40826377|NCT05340634|DIETARY_SUPPLEMENT|Metionac|Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
40826378|NCT05340634|DRUG|Oral contraceptive|Drospirenone 4 mg once a day
40826379|NCT00127283|DRUG|eptacog alfa (activated)|
40826380|NCT00047619|PROCEDURE|Pulsatile Lavage|pulsatile lavage to wound bed
40826381|NCT00047619|OTHER|sham pulsatile lavage|pulsatile lavage to not directed at wound or patient
40826382|NCT01588262|OTHER|Stressmanagement|Individual stepped-care approach stressmanagement by specially trained counsellor
40826383|NCT02181101|DRUG|FEC-DocGemzar adjuvant chemotherapy|
40826384|NCT02181101|DRUG|FEC-Doc adjuvant chemotherapy|
41345441|NCT05677854|OTHER|Health literacy based motivaonal interview|Motivational interviewing technique was used based on health literacy.
41345442|NCT05677854|OTHER|Health literacy based health education|Health education based on health literacy was used.
41345443|NCT05211492|OTHER|Questionnaire|Patients are asked to fill in an online questionnaire concerning their postoperative pain.
41345444|NCT02718625|BIOLOGICAL|Santyl|Collagenase ointment applied topically
41345445|NCT02718625|BIOLOGICAL|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
41345446|NCT04008667|OTHER|Acupoint application|Acupoint application: The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
41345447|NCT04008667|OTHER|Fake acupoint application|Fake acupoint application: The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
41345448|NCT00441012|BIOLOGICAL|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 \& 12 months of age. Duration of treatment is 11 months.
41345449|NCT00441012|BIOLOGICAL|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
41345450|NCT02530827|DRUG|use of lipid-lowering drugs.|The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
41345451|NCT02343952|DRUG|Pembrolizumab|Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
41345452|NCT00398086|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
41345453|NCT00398086|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
41345454|NCT05894889|BIOLOGICAL|Pembrolizumab 200 mg IV infusion|"Biological: Pembrolizumab 200 mg IV infusion~Drug: nab-paclitaxel IV infusion~Drug: Carboplatin IV infusion~Drug: Pemetrexed IV infusion"
41345455|NCT05008367|DRUG|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
41490343|NCT03222752|DEVICE|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
41345456|NCT05008367|DRUG|Isotonic saline|6 ml of isotonic saline
41345457|NCT06371209|PROCEDURE|Modified Amputation|Modified amputation procedure
41345458|NCT06371209|PROCEDURE|Standard Amputation|Standard amputation procedure
41345459|NCT02907411|OTHER|Quadrivas Therapy|Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
41345460|NCT01095328|OTHER|screening|screening for Q-fever with a single blood sampling
41345461|NCT04724291|DEVICE|MAGNET|This study will test the accuracy of a single-use ingestible video capsule (NaviCamTM, AnX Robotica) which is remotely controlled to record images of the inside of your stomach. Participants in this research study will have symptoms for which an evaluation by a traditional tube-based endoscopy (EGD) is indicated.
41345462|NCT04037462|DRUG|Dexamthasone|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
41345463|NCT03634293|DRUG|Alirocumab Injectable Product|Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
41345464|NCT03634293|DRUG|Saline Solution|The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
41345465|NCT02404584|GENETIC|Blood drawn for genotyping|Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).
41345466|NCT02404584|BIOLOGICAL|Blood drawn for pharmacokinetic measures|"Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.\*~\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle."
41345467|NCT00213967|DEVICE|22 gauge 1 1/2 inch needles on a 3 ml syringe|cold needles or needles kept at room temperature
41345468|NCT06183554|DIAGNOSTIC_TEST|CXCR4|Patients with clinical suspected primary aldosteronism will receive a CXCR4 PET imaging.
41345469|NCT00163163|PROCEDURE|Echographic measurements|
41345470|NCT00163163|PROCEDURE|Blood samples|
41345471|NCT05953272|OTHER|EMG Biofeedback therapy and Bobath therapy|"EMG Biofeedback therapy will be used to up-train the ankle dorsiflexors in stroke patients. It will be given for 15 minutes. Patient will practice 2 blocks of Tibialis Anterior muscle contraction trials (holding for 10 seconds per trial with 10 seconds of rest, 20 trials per block with 1 minute 40 seconds of rest in between the blocks) with the heel contacts the floor for a total of 40 trials.~In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
41345472|NCT05953272|OTHER|Bobath therapy|"In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
41345473|NCT03304392|BEHAVIORAL|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
41345474|NCT03304392|BEHAVIORAL|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
41345475|NCT05382806|DRUG|Flumazenil|During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
41345476|NCT05306262|PROCEDURE|Hypnosis session|Comfort hypnosis: accompaniment of a pleasant memory.
41345477|NCT05306262|OTHER|Catalepsy|Catalepsy of the hand.
41345478|NCT06225141|OTHER|Clinical Data reuse|Clinical Data reuse
41345479|NCT04247828|DEVICE|Experimental AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with an adaptive and individualized keyboard to test communication performance.
41345480|NCT04247828|DEVICE|Generic AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with a generic QWERTY keyboard to test communication performance.
41345481|NCT04412668|DRUG|Efzofitimod 1 mg/kg|Concentrate for solution for infusion
41345482|NCT04412668|DRUG|Efzofitimod 3 mg/kg|Concentrate for solution for infusion
41345483|NCT04412668|DRUG|Placebo|Concentrate for solution for infusion
41345484|NCT03073369|DRUG|Ergocalciferol 50000 UNT|Oral Ergocalciferol 50000 IU once daily for 6 weeks
41345485|NCT03073369|DRUG|Placebo|Oral Placebo - one capsule once daily for 6 weeks
41345486|NCT00939055|DEVICE|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
41345487|NCT00939055|PROCEDURE|Sham procedure|False procedure
41345488|NCT06239701|BEHAVIORAL|LPA+Fitbit Intervention|"1. In-Person LPA+Fitbit Orientation. During an initial, orientation (45 minutes), a study interventionist will provide information regarding the acute and long-term psychological and physical benefits of increasing PA, including prenatally.~2. Telephone PA counseling sessions. A study interventionist will call participants at weeks 2, 4, 6, 8, and 10 of the intervention for a 20-min telephone session.~3. Fitbit activity tracker. With participant permission, a Fitbit account (on Fitbit.com) and study-generated password will be created. In doing so, investigators will have access to the participant activity data throughout the intervention. The Fitbit web-based and mobile apps facilitate goal-setting by allowing participants to easily set goals and change these goals at any point. We will customize each participant account to display daily steps and very active minutes, though they will be encouraged to adjust the display according to their preferences."
41345489|NCT06239701|BEHAVIORAL|Fitbit Only|"1. In-person Fitbit Orientation. Participants will be given information on the public health guidelines for PA during pregnancy, and as well as how to determine if their PA is moderate-intensity. In addition, interventionists will orient participants to the proper use of the Fitbit tracker and offer tips for self-monitoring step counts with the tracker and on the app.~2. Fitbit Activity Tracker. Participants will be given the same Fitbit as in the LPA condition. Participants will not be given any specific step count goals to achieve during the 12-week intervention.~3. Brief Telephone Check-ins. As with the LPA+Fitbit participants, those in the Fitbit Only condition will receive phone calls on weeks 2, 4, 6, 8, 10. These calls will last 5 minutes and be focused entirely on answering any problems related to the Fitbit such as syncing issues, charging the battery, and any other technical problems that may arise. No physical activity counseling will be delivered on these calls."
41345490|NCT03356795|BIOLOGICAL|Cervical cancer-specific CAR-T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
41490344|NCT03222752|DEVICE|Sham Cranial Electrotherapy Stimulation|The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
40826385|NCT02181101|DRUG|Zoledronic acid i.v. 2 years|
40826386|NCT02181101|DRUG|Zoledronic acid i.v. 5 years|
41018798|NCT05821010|DIETARY_SUPPLEMENT|A. soehngenii|Oral administration (capsule)
41345491|NCT03665493|DRUG|PD patients H&Y=1.5-2 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
41345492|NCT03665493|DRUG|PD patients H&Y=1.5-2 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
41490345|NCT00548093|DRUG|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
41018799|NCT05821010|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Oral administration (capsule)
41157371|NCT06446999|OTHER|Yoga-Based Breathing Exercise|"Breathing Exercise Protocol Purpose: This protocol is a guide prepared for patients who agree to participate in the study within the scope of scientific research to do breathing exercises.~Materials Required: A comfortable chair/a comfortable bed to lie on and comfortable clothing.~Exercise Duration: Approximately 20 minutes Exercise Time and Frequency: It should be done twice a day, at the same time, in the morning and in the evening.~You can do the exercise before going for a walk in the corridor in the morning and before going to sleep in the evening.~Normal Breathing and Focusing on Breathing (3 minutes) Alternate Nose Breathing-Nadi Shodhana (15-20 times/6 minutes) Normal Breathing and Focusing on Breathing (3 minutes) Bhramari Pranayama-Bee Buzzing Sound(8-10 times/5 minutes) Normal Breathing and Focusing on Breathing (3 minutes)"
41345493|NCT03665493|BEHAVIORAL|Healthy age-matched controls|Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
41490346|NCT00548093|DRUG|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
41490347|NCT01342107|DEVICE|FID 114675A multi-purpose disinfecting solution (MPDS)|Investigational multi-purpose disinfecting solution intended for use as a cleaning, reconditioning, rinsing, disinfecting, and storage solution for silicone hydrogel and soft contact lenses.
41490348|NCT01342107|DEVICE|Soft contact lens|Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.
41490349|NCT01342107|DEVICE|Blister pack solution|Commercially approved storage solution as found in the contact lens blister pack.
41490350|NCT05703373|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|Multiple micronutrient supplementation (MMS) which includes iron, folic acid, and additional micronutrients,
40826387|NCT00867776|BEHAVIORAL|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
40826388|NCT01969500|BEHAVIORAL|Mobile Application|
40826389|NCT01969500|BEHAVIORAL|Treatment as Usual (TAU)|
40826390|NCT02357693|DRUG|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
40826391|NCT05027932|OTHER|IN Placebo|The placebo will be normal saline in two syringes administered IN.
40826392|NCT05027932|OTHER|IM Placebo|The placebo will be normal saline in a syringe administered IM.
40826393|NCT05027932|DRUG|BPL-1357|BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It will be administered either IM or IN depending on the assigned treatment group.
41018800|NCT05821010|DIETARY_SUPPLEMENT|B. animalis subsp. lactis|Oral administration (capsule)
41018801|NCT05821010|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Oral administration (dissolved in water)
41018802|NCT01272167|BEHAVIORAL|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
41018803|NCT00445614|BEHAVIORAL|Effects of trout on CVD risk markers and plasma proteome|
41018804|NCT01183091|PROCEDURE|Ablation of atrial fibrillation|Ablation of atrial fibrillation
41018805|NCT02867605|DIETARY_SUPPLEMENT|Hyaluronan|
41490351|NCT03121430|DEVICE|Drug eluting peripheral vascular stent system|Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
41490352|NCT03121430|DEVICE|Nitinol Stent System|Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
41345494|NCT03665493|DRUG|PD patients H&Y=3 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
41345495|NCT03665493|DRUG|PD patients H&Y=3 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
40826394|NCT03880448|DRUG|Metronidazole|Metronidazole 500mg/8h/7days
40826395|NCT03880448|DRUG|Placebo|Cornstarch 500mg/8h/7days
41345496|NCT04052412|DRUG|18F-AraG|All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
41345497|NCT02349776|OTHER|Providing testimonies from survivors of transplants to patients|"Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.~Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant."
41345498|NCT05405413|OTHER|Treatment recommendations made by Molecular Tumor Board.|"Molecular Tumor Board recommendations may include any of the following:~(A) a tumor-targeted drug (alone or in combination)~(B) an antibody-based immunotherapy (alone or in combination)~(C) neither (A) nor (B).~(D) referral to the Familial Cancer Program~(E) referral for germline genetic testing"
41345499|NCT00935961|DRUG|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
41345500|NCT04028414|OTHER|Early Weight Bearing|Patients will be instruction to weight bear as tolerated while in a boot.
41345501|NCT03644173|BEHAVIORAL|Personal Resilience Empowerment Program including 5 sessions with health coaches|5 coaching sessions that will take place either in-person or over the phone with a research nurse (RN)-Health Coach. During the sessions, the health coach will focus on introducing the 5 pillars of health and well-being: sleep, activity, purpose, nutrition and resilience. Will introduce breathing techniques participants and will teach patients how to acquire mind-body skills to assist in stress management, learn to thrive by building resilience, feel empowered to manage their health, gain self-care skills to decrease anxiety, pain and nausea naturally, control the stress response and trigger the relaxation response to promote well-being and discover what foods fuel the body in preparation for healing, during recovery and overall health.
41345502|NCT04770428|DRUG|MEDI7352|A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.
41345503|NCT04770428|DRUG|Placebo|Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.
41345504|NCT00075413|DRUG|arsenic trioxide|
41345505|NCT00958191|DEVICE|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
41345506|NCT02021149|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
41345507|NCT02021149|BEHAVIORAL|Psychotherapy|Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.
41345508|NCT02021149|OTHER|Questionnaires|Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.
41345509|NCT02021149|DEVICE|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
41345510|NCT02740894|DRUG|Gefitinib|
41345511|NCT05794672|DRUG|Elarekibep|Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
41345512|NCT05794672|DRUG|Placebo|Subjects will receive single or multiple inhaled doses A, B or C.
41345513|NCT03615664|DRUG|Bendamustine|Bendamustine (B) 90 mg/m2 i.v. day 1, 2
41345514|NCT03615664|DRUG|Gemcitabine|Gemcitabine (G) 800 mg/m2 i.v. day 1, 4
41345515|NCT03615664|DRUG|Dexamethasone|Dexamethasone (D) 40 mg i.v./p.o. day 1,2,3,4
41490353|NCT01930318|DRUG|parecoxib|4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
40826396|NCT03880448|PROCEDURE|periodontal surgery|periodontal surgery
41490354|NCT05223296|DEVICE|Compare between two procedure for II-IV degree pile excision|LigaSure or diathermy excision of III-IV degree pile?
41490355|NCT02003521|DEVICE|Lung Flute|A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
41490356|NCT03805100|BIOLOGICAL|Ranibizumab|Intravitreal injection
41490357|NCT06151496|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
41490358|NCT06151496|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
41345516|NCT03615664|DIAGNOSTIC_TEST|PET/CT|"PET scan/CT must be performed after first 2 courses of BGD treatment. Results evaluation:~* in case of a CMR/CR or PMR/PR, ASCT must be performed within 3 months after the end of BGD treatment~* in case of SMD - exclusion from the trial~* in case of PMD - exclusion from the trial"
40826397|NCT02120092|DRUG|Clopidogrel|1x Loading dose 600 mg 6x maintenance dose 150 mg
41345517|NCT03615664|PROCEDURE|Autologous Stem Cell Transplant|"Must be performed within 3 months after the end of BGD treatment.~When it is not possible to perform ASCT, despite CMR or PMR response, within 3 months after second course of BGD treatment, it is permissible to extend the therapy up to 4 cycles. PET scan/CT must be repeated before performing ASCT."
40826398|NCT02120092|DRUG|Ticagrelor|1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
40826399|NCT02120092|DRUG|ASA|"7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)"
40826400|NCT02120092|DRUG|Placebo|7x 300mg acetylsalicylic acid placebo
41018806|NCT06573060|DEVICE|Continuous glucose monitoring|Subjects with T2DM and acute coronary syndrome (n=120) were fitted with continuous glucose monitors (CGM) to closely monitor their blood glucose levels continuously for 14 days.
41018807|NCT03714633|BEHAVIORAL|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Post-discharge intervention to extreme premature infants and their parents
41345518|NCT06347172|BEHAVIORAL|Nudge Intervention|"PCPs will receive an enhanced EHR alert (nudge) that triggers when a PCP opens an encounter for an eligible patient living with dementia (PLWD). The nudge will provide information about the risks of continued medication use as well as tips and tools to help providers discuss medication discontinuation with patients and care partners. Additionally, the providers will receive a brief message in their in-basket 10 days before the patient's appointment as a reminder.~Eligible PLWD of a randomized PCP will receive the nudge intervention which includes a brief recommendation for the PLWD (and care partner, if available) via the linked patient portal prior to upcoming visits (unless explicitly opted out by the PCP) to discuss medications with the PCP at the visit and link to a general handout about medications, unless explicitly opted out by the PCP. For PLWD without a portal account, the handout will be sent to their mailing address recorded in the EHR."
41490359|NCT01965392|OTHER|Health education intervention|'Health education intervention'
41490360|NCT05873010|DIAGNOSTIC_TEST|Manual Compression and Stretching|Manual Compression and Stretching for The Myofascial Trigger Points
41490361|NCT00000117|DRUG|Immunoglobulin|
41490362|NCT01031953|DRUG|fosaprepitant dimeglumine|A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
41490363|NCT01031953|DRUG|systemic chemotherapy|Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
41490364|NCT01031953|OTHER|survey administration|Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
41490365|NCT01031953|PROCEDURE|quality-of-life assessment|Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
41490366|NCT00580216|DRUG|Idrabiotaparinux sodium|"Pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
41490367|NCT00580216|DRUG|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
41490368|NCT00580216|DRUG|Placebo (for idrabiotaparinux)|"Matching pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
41490369|NCT00580216|DRUG|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
41490370|NCT00580216|DRUG|Avidin|"Vial containing 105 mg of lyophilized powder for dilution~Intravenous infusion for 30 minutes"
41490371|NCT00580216|DRUG|Placebo (for avidin)|"Vial containing 105 mg of matching lyophilized powder for dissolution~Intravenous infusion for 30 minutes"
41490372|NCT02317718|OTHER|monitor reproductive outcome|
41490373|NCT01688076|PROCEDURE|Botulinum Toxin A|Forehead will be injected with Botox.
41490374|NCT01081535|DRUG|ketorolac, fentanyl|intravenous PCA
41018808|NCT05154903|DRUG|Citicoline 500 MG|Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.
41490375|NCT01118897|RADIATION|Tomotherapy|"Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)~Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.~Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy."
41490376|NCT02345629|PROCEDURE|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
41490377|NCT02345629|BEHAVIORAL|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
41018809|NCT02875119|DRUG|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
41018810|NCT02875119|DRUG|Placebo Gel|Placebo Gel
41490378|NCT02345629|PROCEDURE|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
41490379|NCT02345629|PROCEDURE|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
41345519|NCT05465967|PROCEDURE|Quadratus lumborum Block|1-Transverse transmuscular Quadratus lumborum block: ultrasound transducer will placed transverse to the abdominal flank to visualise abdominal muscle layers. moving the probe posteriorly, the transverse process of the lumbar vertebra, Quadratus lumborum, Psoas Major and erector spinae muscles identified as a 'Shamrock sign'. the needle will inserted through the back muscles to fascial plane between the Quadratus lumborum and Psoas Major, local anesthetic will injected .2- paraspinous sagittal Quadratus lumborum block: ultrasound transducer will be directed caudally in a sagittal plane lateral to the spinous process of L4. moving laterally until the Quadratus lumborum is evident in its long axis with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, Quadratus lumborum, and Psoas major muscle the needle will be advanced through the muscles, until it pierces the Quadratus lumborum. local anesthetic will be injected.
41345520|NCT03906201|DIETARY_SUPPLEMENT|Ecdysterone|Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic
41345521|NCT03906201|OTHER|Placebo|no pharmacologic effect
41345522|NCT01925482|DRUG|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
41345523|NCT01925482|DRUG|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
41345524|NCT01925482|DRUG|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
41345525|NCT01925482|DRUG|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
41345526|NCT01925482|DRUG|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
41345527|NCT01925482|DRUG|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
41345528|NCT03797157|DIETARY_SUPPLEMENT|H2MF|H2MF is a human milk-based breastmilk fortifier for preterm infants
41345529|NCT03797157|DIETARY_SUPPLEMENT|Bovine milk-based fortifier|Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
41345530|NCT00511108|DRUG|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
41345531|NCT00511108|DRUG|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
41345532|NCT00511108|DRUG|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
41345533|NCT00511108|DRUG|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
41345534|NCT01785290|DRUG|Haloperidol 1 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
41345535|NCT01785290|DRUG|Haloperidol 2 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
41345536|NCT01785290|DRUG|Placebo|Sodium Chloride 0.9%
41345537|NCT00564265|OTHER|Observation|Not applied
41490380|NCT05737342|DIETARY_SUPPLEMENT|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
41490381|NCT05737342|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
41345538|NCT06124352|DIAGNOSTIC_TEST|Gross Motor Function Measurement - 66 (GMFM- 66)|GMFM-66 was performed for participants established on self-independent motion, with importance on allocations, and motion. The emphasis is to detect the grade that greatest reveals the current skills and disabilities of the child regarding motor functions. The new Gross Motor Ability Estimator (GMAE) scoring method for test-retest reliability data showed a high level of stability of the GMFM-66 over time (ICC=0.9932) that did not differ since the original GMFM 88-item test-retest reliability
41345539|NCT06124352|DIAGNOSTIC_TEST|Bruininks- Oseretsky Motor Proficiency|The BOT-2 are scale used to evaluate fine and gross motion skill development. It's used to classify children with movement control limitation. The test is appropriate for those aged 4 to 21 years. The interrater reliability ranging from 0.92 to 0.99 and construct validity. r = 0.78 (0.56 - 0.86) (test grades / chronological age)
41345540|NCT06124352|DIAGNOSTIC_TEST|the Peabody Developmental Motor Scale - Second Edition (PDMS-2|The PDMS-2 is a consistent test that evaluates a child's movement skills. It is norm-referenced and consists of three composites: Fine Motor (FM), Gross Motor (GM), and Total movement composites (TM). GM composite incorporates 151 points from four sub-tests: reflexes, stationary, locomotion, and object manipulation. A 3-point scale scored for each item, with 2 being the highest score. Definite criterion for score of 2 is given when the child achieves the item, 1 is given when the behavior is emerging but not fully met, and 0 is given when the child cannot achieve the point. The highest raw scores of the sub-tests range from 16 to 198. The test-retest reliability of PDMS-2 was found to be r = 0.85 \[24, 25\].
41490382|NCT02058212|DRUG|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
41490383|NCT04662138|DRUG|directly acting antivirals|Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin
41345541|NCT03593564|BEHAVIORAL|KINDER|KINDER is an online course for people assisting an older adult with dementia. It is intended to improve the quality of caregiver's relationship with the care recipient and reduce the chance of risky relationship behavior (e.g., yelling). Courses will cover topics including understanding cognitive impairments, navigating evolving roles, and dealing with frustration. During this course, participants will learn skills to deal with difficult situations caregivers frequently encounter in ways that support a healthy caregiving relationship. Videos will be story-based and represent different types of caregiving relationships and challenges encountered.
41345542|NCT06059274|OTHER|Topical serum|Participants are asked to apply the topical serum twice daily for 84 days.
41345543|NCT02798640|DEVICE|Celliant|100% Celliant garment
41345544|NCT02798640|DEVICE|Control|Control Garment
41345545|NCT00038142|DRUG|Vincristine|2.0 mg/m\^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
41345546|NCT00038142|DRUG|Doxorubicin|90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.
41490384|NCT03110068|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|The Aplio SSA-770A or Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) equipped with a 375BT convex transducer (frequency range, 1.9 to 6.0 MHz). CHI is used with a mechanical index that ranged from 0.06 to 0.10. After activating CHI mode, a bolus injection of 2.4 ml of SonoVue (Bracco, Milan, Italy) is administered intravenously via an antecubital vein, followed immediately by a flush of 5 ml of normal saline solution. The targeted lesion should be observed continuously for 5 minutes, and the entire arterial and portal venous phases and several repetitions of the late phase are stored on the hard disk. The arterial, portal venous and late phases are defined as 0-30 s, 31-120 s and 121-360 s after the injection, respectively.
41490385|NCT03110068|DIAGNOSTIC_TEST|contrast-enhanced computed tomography|The Aquilion 64-slice helical CT machine (Tokyo, Japan) is used. The imaging protocol for CT examinations is as follows: 0.5 mm × 64 mm collimation, 120 kV, 150-200 mAs for 64-slice helical CT examination. The standard triphasic scan procedure is used. An unenhanced helical sequence scan through the liver will be performed first; thereafter nonionic iodinated contrast material (Ultravist, Schering, Berlin, Germany) (1.5 mL/kg) will be administered via antecubital vein with power injection at a rate of 4 mL/s for 64-slice helical CT. The arterial phase sequence is obtained 25-32 s after contrast material administration, followed by a portal venous phase sequence 70 s after contrast agent administration.
41490386|NCT04481321|BIOLOGICAL|Biological/Vaccine|
40826401|NCT02053207|BEHAVIORAL|Cog-Train Intervention|Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
41345547|NCT00038142|DRUG|Cyclophosphamide|2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.
41345548|NCT00038142|DRUG|Dexrazoxane|900 mg/m\^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
41345549|NCT00038142|BIOLOGICAL|ImmTher|900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.
41345550|NCT05399160|BEHAVIORAL|Nurse-led Supportive Care|Nurse-led supportive care was given to women who had breast surgery and planned to receive chemotherapy. Nurse-led supportive care was applied to women for eight weeks in the form of face-to-face clinic and telephone interviews.It took an average of 30 minutes to interview women with breast cancer at the clinic, and 15 minutes on average by phone.
41345551|NCT03463109|OTHER|Electrocutaneous stimulation|Painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the participants' back. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.
41345552|NCT03463109|OTHER|Assessment + Electrocutaneous stimulation|"Patients will be asked to provide information about their lifestyle, level of disability, actual pain and general pain, assessment of kinesiophobia and health status.~Subsequently, painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the patients' back. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
40826402|NCT00622089|DRUG|DIO-902|150mg DIO-902 + 10mg atorvastatin
40826403|NCT00622089|DRUG|DIO-902|300mg dose once per day for 24 weeks
40826404|NCT00622089|DRUG|DIO-902|450mg dose once per day for 24 weeks
40826405|NCT00888329|DRUG|Aprepitant|40 mg administered orally with a sip of water prior to anesthesia induction.
40826406|NCT00888329|DRUG|Placebo|Placebo
40826407|NCT06604780|BEHAVIORAL|Transitional discharge program|"For patients classified in the low-risk group, general measures would be applied. For patients in the medium-risk group, reinforced measures would be implemented. Lastly, for patients considered to be in the high-risk group, intensive case management measures would be applied, and if they meet the inclusion criteria, they would be included in the Post-Discharge Group Psychotherapeutic Intervention.~1. General measures~2. Reinforcement measures~3. Intensive measures~   * Intensive case management measures~  * Post-Discharge Psychotherapeutic Recovery Support Program: For application to patients at high risk of early readmission who meet the inclusion criteria. It consists of a multicomponent group psychotherapeutic intervention from a rehabilitative and recovery-oriented perspective. This intervention will be structured into 20 sessions, each lasting 90 minutes, held weekly in an open format."
40826408|NCT06463028|DRUG|Sapanisertib|Oral
41345553|NCT05364112|DEVICE|Compreflex|The Compreflex standard calf and foot (with basic liner) from Sigvaris (St. Gallen, Switzerland) is an easy-to-use interlacing Velcro wrap device with adjustable compression levels.
41345554|NCT02194192|DRUG|Placebo|Normal saline 10 ml
41018811|NCT06165003|OTHER|Use of broselow tape|"In the research, the nurse is the decision maker in the selection of the catheters to be used in the procedures (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion) for the patients in the control group.~In these procedures, the nurse's choices will be evaluated as control group data as routine clinical practice.~After the control group data is collected, Broselow tape will be used in the selection of catheters to be used in the procedures to be performed on the patients in the experimental group (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion).~Our research will be conducted to examine the effect of nurses' use of Broselow tape in non-resuscitation applications and to minimize errors and application disruptions in procedures involving nurses."
41018812|NCT04849949|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
41018813|NCT04849949|OTHER|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
41345555|NCT02194192|DRUG|Ondansetron|Ondasetron 8 mg IV after spinal anesthesia
41018814|NCT04849949|OTHER|English walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
41345556|NCT02194192|DRUG|Ephedrine|Ephedrine 10 mg IV after spinal anesthesia
41345557|NCT00175838|DRUG|Hydroxyurea|Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
40826409|NCT06463028|DRUG|Serabelisib|Oral
41018815|NCT00400413|PROCEDURE|fMRI|
41018816|NCT02755675|OTHER|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
41018817|NCT05295173|DRUG|Injection of recombinant human tissue plasminogen kinase derivatives|18mg/10ml/stick, provided by Angde Biotech
41018818|NCT05295173|DRUG|Recombinant human tissue plasminogen activator|20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.
41018819|NCT00355875|PROCEDURE|titration of oxygen during resuscitation|
40826410|NCT06463028|DRUG|Paclitaxel|Infusion
41018820|NCT04948944|DEVICE|transcranial direct current stimulation|the tDCS stimulator delivers very low (2mAmp) current with surface electrodes to the skull
41018821|NCT00435123|DIETARY_SUPPLEMENT|Nutritional Supplement ProStat 64 twice a day|
41345558|NCT00175838|DRUG|Aspirin|Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
41345559|NCT04132128|OTHER|carbohydrate counting|taught how to count carbohydrates in their diet with their personal tool
40826411|NCT06081621|BIOLOGICAL|REGEND001|REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.
40826412|NCT06081621|BIOLOGICAL|Placebo|Placebo: Sodium chloride injection administrated by bronchoscopy.
40826413|NCT00081315|DRUG|Amifostine|
41018822|NCT00435123|DIETARY_SUPPLEMENT|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
41018823|NCT06168175|DRUG|Sodium lactate|2 mmol/kg, intravenous, daily for 5 consecutive days
41345560|NCT01122823|BEHAVIORAL|chronic disease self-management program (online)|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
41345561|NCT00705380|BEHAVIORAL|Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents|CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
41490387|NCT02032706|DEVICE|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
41490388|NCT04422353|OTHER|Video Dance classes|The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
40826414|NCT01465217|BEHAVIORAL|text message medication reminders|daily medication reminders for one month
41018824|NCT06168175|DRUG|Placebo|intravenous, daily for 5 consecutive days
41018825|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 1|"Each rater in Reader Group X will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
40826415|NCT01893372|DRUG|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
41018826|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 1|"Each rater in Reader Group Y will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
40826416|NCT01893372|DRUG|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
40826417|NCT01028716|DRUG|Cyclophosphamide|Given IV
40826418|NCT01028716|BIOLOGICAL|Filgrastim|Given SQ
40826419|NCT01028716|DRUG|Fludarabine Phosphate|Given IV
40826420|NCT01028716|DRUG|Mycophenolate Mofetil|Given PO
40826421|NCT01028716|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
40826422|NCT01028716|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
40826423|NCT01028716|DRUG|Tacrolimus|Given IV or PO
40826424|NCT01028716|RADIATION|Total-Body Irradiation|Undergo total-body irradiation (TBI)
40826425|NCT02256410|DEVICE|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
40826426|NCT02256410|OTHER|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
40826427|NCT00373165|DRUG|Ganciclovir|
41345562|NCT00705380|BEHAVIORAL|Waitlist control|During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
41345563|NCT00311090|DRUG|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
41345564|NCT00311090|DRUG|Idraparinux sodium|"0.5 mL pre-filled syringe for 2.5 mg~Subcutaneous injection"
41345565|NCT00311090|DRUG|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
41345566|NCT00311090|DRUG|Placebo (for Avidin)|"Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes"
41345567|NCT03965806|BEHAVIORAL|SURVEY|SURVEY
41345568|NCT05500391|OTHER|Oncological Follow-up|Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)
41490389|NCT04422353|OTHER|Unsupervised physical activities|The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
41490390|NCT00001253|BEHAVIORAL|cognitive tests and scales|
41490391|NCT00584844|BIOLOGICAL|Live F tularensis Vaccine|Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (\< 1:20).
41490392|NCT01911663|DIETARY_SUPPLEMENT|KRG|500 mg Korea red ginseng (KRG)
41490393|NCT01911663|DIETARY_SUPPLEMENT|Placebo|500 mg placebo
41490394|NCT01206114|OTHER|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
40826428|NCT01093781|DRUG|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
40826429|NCT03626636|DRUG|Risuteganib|Subjects injected intravitreally with 1.0mg of Luminate®
40826430|NCT03626636|OTHER|Sham|Sham injection
40826431|NCT00645528|OTHER|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
40826432|NCT05910125|DRUG|Aspirin|See arm/group descriptions.
40826433|NCT05910125|DRUG|Clopidogrel|See arm/group descriptions.
40826434|NCT05910125|DRUG|Alteplase|See arm/group descriptions.
40826435|NCT02426775|DRUG|Carglumic Acid|Carglumic Acid 50 mg/kg/day (twice daily)
40826436|NCT02288962|DRUG|cabergoline|
40826437|NCT05826691|PROCEDURE|Monopolar / Bipolar Transurethral resection of prostate (TURP), photovaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)).|Any procedure advised by the EAU guidelines to ovrecome bladder outlet obstruction
40826438|NCT03645694|DEVICE|Social Support Aid|Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
40826439|NCT01790282|DRUG|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
40826440|NCT01790282|DRUG|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
41345569|NCT03722992|OTHER|MBSR|Guided yoga and meditation practices
41345570|NCT02791477|DEVICE|Attune FB PS knee arthroplasty|
41345571|NCT01060722|DRUG|MOD-4023 (long lasting hGH)|Single subcutaneous dose of MOD-4023
41345572|NCT01060722|DRUG|Placebo|Single subcutaneous dose of placebo material
41345573|NCT02698566|DRUG|Ranibizumab|Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
41345574|NCT04857606|DRUG|AMG 609|Single dose of AMG 609 administered as a subcutaneous injection.
41345575|NCT04857606|DRUG|Placebo|Single dose of placebo administered as a subcutaneous injection.
41345576|NCT00003304|DRUG|temozolomide|
41345577|NCT03219554|DRUG|Palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
41345578|NCT01023516|DRUG|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
41345579|NCT01023516|DRUG|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
41345580|NCT02993783|DRUG|Vedolizumab|Vedolizumab IV infusion
41345581|NCT03238040|OTHER|None, observational study|Observational study, no interventions
41345582|NCT00118040|DRUG|Genistein|Given orally
41345583|NCT00118040|OTHER|Laboratory Biomarker Analysis|Correlative studies
41345584|NCT00118040|OTHER|Pharmacological Study|Correlative studies
41345585|NCT00118040|OTHER|Placebo Administration|Given orally
41345586|NCT00118040|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
41490395|NCT01206114|OTHER|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
41490396|NCT02158312|DEVICE|Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)|2 mA for 20 minutes transcranial direct current stimulation
41345587|NCT04051489|OTHER|Mobile health App - Test|"Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants with knee osteoarthritis (KOA).~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
40826441|NCT03023254|OTHER|Hydrotherapy|3-week Avène hydrotherapy
40826442|NCT06289192|BEHAVIORAL|C-Raven Virtual Tobacco Cessation Counseling|A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.
41345588|NCT02834494|PROCEDURE|3D Shear Wave Elastography (SWE)|Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
41345589|NCT02834494|BIOLOGICAL|Biopsy|Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
41345590|NCT05620485|PROCEDURE|laparoscopic-assisted CDC excision and hepaticojejunostomy|After birth, the liver and gallbladder ultrasound were regularly rechecked. If the maximum diameter of the cyst was greater than 5 cm, surgery was performed.
40826443|NCT06289192|DRUG|Nicotine Replacement Product|Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.
40826444|NCT06289192|OTHER|Community Health Worker|A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.
41345591|NCT02708966|DRUG|Gymnema Sylvestre|Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
41490397|NCT05103189|OTHER|4D-flow sequence|all patients will be referred for a complete cardiac MRI exam with the addition of a 4D Flow sequence (does not require supplementary injection of a contrast agent and does not extend the duration of the examination) followed promptly (within the same hour) by a Doppler-echocardiography.
40826445|NCT06289192|OTHER|Lung Cancer Screening|Eligible participants will be referred to their primary care physician or existing specialist to complete lung cancer screening.
40826446|NCT00610441|DRUG|MK-8777|
40826447|NCT00610441|DRUG|Placebo|
40826448|NCT03018470|OTHER|Analysis of data from NIV built-in software|Analysis of breathing pattern using data obtained from NIV built-in software
41018827|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 2|"Each rater in Reader Group X will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
41345592|NCT02708966|DRUG|Placebo|Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
41345593|NCT05804240|DIAGNOSTIC_TEST|3D TEE RVEF|With TEE package software, the investigators measure and calculate 3D TEE RVEF using mid esophageal 4 chamber view
41345594|NCT00175422|BEHAVIORAL|The Period of PURPLE Crying Program|There are two treatment arms in the study. The first half of all subjects (n=500) will receive the PURPLE intervention materials (a video and a pamphlet) about infant crying. The second arm will receive comparable materials on infant safety and SIDS.
41345595|NCT05774574|DIETARY_SUPPLEMENT|Cannabidiol (CBD) supplementation|Daily supplementation with 1 ml hemp oil containing 60 mg CBD, applied orally
41345596|NCT05774574|DIETARY_SUPPLEMENT|Placebo supplementation|Daily supplementation with 1 ml hemp oil containing 0 mg CBD, applied orally
41345597|NCT05471024|PROCEDURE|Digitized Mounted Articulator Scan|Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator. This positioning will be utilized during design of the occlusal surface of the restoration.
41345598|NCT05471024|PROCEDURE|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
41345599|NCT05471024|PROCEDURE|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
41345600|NCT02462889|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection
41345601|NCT02462889|DRUG|Placebo|Sham injection
41345602|NCT03607994|DEVICE|HIRREM-SOP|HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
41345603|NCT03607994|DEVICE|NCC|Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
41345604|NCT04564690|DIETARY_SUPPLEMENT|QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)|Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks
41345605|NCT04564690|DIETARY_SUPPLEMENT|Regular hen eggs|Consumption of three regular hen eggs per day for three weeks
41345606|NCT05821192|DRUG|Rituximab|375mg/m2 by IV infusion once every 3 weeks
41345607|NCT05821192|DRUG|Gemcitabine|1 g/m2 on Days 1 by IV infusion once every 3 weeks
41490398|NCT06240520|DRUG|Panobinostat 20 MG Oral Capsule|Panobinostat 20mg will be administered once orally
40826449|NCT02908646|PROCEDURE|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
40826450|NCT02908646|PROCEDURE|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
40826451|NCT05178030|OTHER|vena punction|Regular 3-12 monthly follow-up by CT-scan will be compared to results of ctDNA analysis. Blood for analysis of mutation in ctDNA will be collected at the same moment a CT-scan is performed
40826452|NCT03978637|DRUG|Itacitinib|Itacitinib administered orally at the specified dose.
40826453|NCT00916058|DRUG|Bendamustine|30 mg/m\^2 given on day 2 of melphalan
41345608|NCT05821192|DRUG|Dexamethasone|40 mg on Days 1 to 4 of each 3-week cycle by IV infusion
41345609|NCT05821192|DRUG|Cisplatin|75 mg/m2 on Days 1 by IV infusion once every 3 weeks
41345610|NCT05821192|DRUG|PD-1 monoclonal antibody|200mg on Days 2 by IV infusion once every 3 weeks
40826454|NCT00916058|DRUG|Melphalan|100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)
40826455|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 2nd day of melphalan
40826456|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 2nd day of melphalan
40826457|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 1st and 2nd day of melphalan
40826458|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 1st day of melphalan and 60 mg/m\^2 given on the 2nd day of melphalan
41490399|NCT06240520|DRUG|Pyrimethamine 200mg Oral Tablet|Pyrimethamine 200mg will be administered once orally
40826459|NCT00916058|DRUG|Bendamustine|125 mg/m\^2 given on the 1st day of melphalan and 100mg/m\^2 given on the 2nd day of melphalan
40826460|NCT05785637|PROCEDURE|Polygraphy diagnostic at home|Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.
41018828|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 2|"Each rater in Reader Group Y will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
41018829|NCT04159675|BIOLOGICAL|osteoblast biology study|Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
40826461|NCT01605227|DRUG|cabozantinib|Tablets taken orally once-daily
40826462|NCT01605227|DRUG|prednisone|Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
41490400|NCT06240520|DRUG|Lenalidomide 25 MG Oral Capsule|Lenalidomide 25mg will be administered once orally
41490401|NCT00599521|DRUG|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
41490402|NCT00599521|DRUG|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
41345611|NCT01969305|BEHAVIORAL|Kazakhstani Family Together|Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.
41490403|NCT01097525|PROCEDURE|WFG PRK|
41490404|NCT01097525|PROCEDURE|WFG LASIK|
40826463|NCT04304794|PROCEDURE|Administration of iodinated contrast media|Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.
41018830|NCT05100875|BEHAVIORAL|"Social Skills and Emotion Regulation Training SSERT"|The SSERT intervention will broadly consist of the following 10 modules: (1) Introducing the Participant to Treatment; (2-3) Emotional Awareness and Recognition; (4-5) Emotion Regulation and Understanding Emotions in the Context of Psychotic Experiences; (6) Living an Emotionally Engaged Life; (7) Understanding Relationship Patterns in the Context of Psychosis; (8) Changing Undesirable Relationship Patterns; (9) Learning to have agency in Relationships; and (10) Flexibility in Relationships and Transitioning to Trauma-Focused Therapy.
41018831|NCT00679991|DRUG|PRT-201|Applied topically to AVF during surgery
41018832|NCT00679991|DRUG|PRT-201|Dose escalation study. Drug/placebo administered at the time of fistula creation
41157372|NCT04584333|BEHAVIORAL|Brief intervention|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established. Prochaska and DiClemente (1983) proposed a transtheoretical model of change in which different stages of change are identified that have been found to be predictive of adherence to treatment and its efficacy (Prochaska, Norcross and DiClemente, 1994). The RCQ includes three of the stages of change: Precontemplation, Contemplation and Action. In the Precontemplation stage, the person does not consider that he has a problem and has no intention of changing, in the Contemplation stage, he begins to contemplate that he has a problem and the possibility of change is raised and in the action stage, he has already started actively make a change in your behavior.
41490405|NCT01097525|PROCEDURE|WFO PRK|
41490406|NCT01097525|PROCEDURE|WFO LASIK|
41490407|NCT04690517|PROCEDURE|tracheal ultrasound|When checking tracheal ultrasound, several signs are used in judgements. Direct signs include reverberation artifact and double ring sign. Indirect sign means checking the bilateral lung sliding.
41490408|NCT03047798|DRUG|Mouthrinse|"A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen."
40826464|NCT04304794|DRUG|Prophylactic administration of antithyroid drugs before iodinated contrast media exposure|13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
40826465|NCT05696522|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy will be delivered to a volume of ventricular myocardium responsible for the clinical ventricular tachycardia.
40826466|NCT06066905|DRUG|chidamide and azacitidine|"chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally."
40826467|NCT00622947|PROCEDURE|right temporal low frequency (1 hz) rTMS|Right temporal low frequency (1 hz) rTMS.
40826468|NCT00622947|PROCEDURE|Sham-rTMS|The coil is angled 90 degrees away from the scalp
40826469|NCT03594149|DRUG|Levofloxacin|Levofloxacin 500 mg/d p.o.
41490409|NCT01775852|BEHAVIORAL|ACT-IM|1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
41490410|NCT02394730|DRUG|vorapaxar|2.5mg of vorapaxar taken orally once daily for 12 weeks
41157373|NCT03258099|GENETIC|detection of genotype|detection of genotype by next generation sequencing
41345612|NCT01969305|BEHAVIORAL|Usual Care Alone|"Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:~1. Facts and Myth about HIV. HIV/STIs modes of transmission;~2. Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;~3. Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use."
41345613|NCT03363568|BEHAVIORAL|Adaptive Inhibitory Control Training|Playing computerized stop-signal reaction time tasks that had been modified to increase in difficulty as performance increased.
41345614|NCT03363568|BEHAVIORAL|Non-adaptive Inhibitory Control Training|Playing computerized stop-signal reactions time tasks that do not change in difficulty level (non-adaptive).
41345615|NCT00975442|OTHER|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
41345616|NCT00975442|DEVICE|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
41345617|NCT00975442|DEVICE|Forearm band|All patients were instructed to use a forearm band during all daily activities.
41345618|NCT00424840|DRUG|Bortezomib 1.3 mg/m2|"Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2"
41345619|NCT00424840|DRUG|Bortezomib 1.6 mg/m2|Level II (every 21 day cycle, D8), 1.6 mg/m2
41345620|NCT00424840|DRUG|Bortezomib 1.8 mg/m2|Level III (every 21 day cycle, D8) 1.8 mg/m2
41345621|NCT00424840|DRUG|Carboplatin AUC 6|Carboplatin AUC6
41345622|NCT00424840|DRUG|Bevacizumab|Bevacizumab 15 mg/kg
41345623|NCT00424840|DRUG|Taxotere|Taxotere 70 + G-CSF
41345624|NCT00329459|DRUG|sumatriptan succinate/naproxen sodium|
41345625|NCT00329459|DRUG|placebo|placebo to match
41345626|NCT04192318|BEHAVIORAL|Bridging the Gap|Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.
41345627|NCT04192318|OTHER|Communities that Care (CTC)|In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.
41345628|NCT04192318|OTHER|Treatment as usual|Treat and release
41345629|NCT00169338|PROCEDURE|Deep brain stimulation|internal pallidal deep brain stimulation
41490411|NCT02394730|DRUG|Placebo|Sugar pill taken orally once daily for 12 weeks
41490412|NCT05382169|OTHER|Determine the presence of mast cell activation syndrome|"Mast cell activation syndrome will be confirmed if the following three conditions are met (according to Valent et al, 2012) :~* At least two clinical signs compatible with MAS before the first consultation (V1)~* Improvement of symptoms on antihistamines within 2 months of initiation of treatment~* Significant increase in tryptase during crisis~Mast cell activation syndrome will be possible if :~* At least two clinical signs consistent with MAS before the first consultation (V1)~* Improvement of symptoms with antihistamines within 2 months of initiation of treatment~* No significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely."
40826470|NCT05482178|BEHAVIORAL|Resistance exercise training plus hypocaloric diet|"The exercise program included 3 phases of progressive intervention: 1) Adaptation which included 3-4 days per week at 60% of maximum heart rate, 2) Development phase which included 5 days per week at 75-85% of maximum heart rate and the last one, 3) Maintenance phase which included 5 days per week at 75-90% of maximum heart rate. The control and follow up will be through text message exchanges at least once a week or as many as necessary.~On the other hand, the diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day)."
40826471|NCT05482178|BEHAVIORAL|Hypocaloric diet|The diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day).
40826472|NCT01228604|DRUG|methylphenidate (Ritalin®)|The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
40826473|NCT02093988|DRUG|Topical TXA|
41345630|NCT04710992|PROCEDURE|Isolated needling procedure|The needle will be inserted into the common extensor tendon of the epicondyle (dominant elbow) for 90 seconds without galvanic current.
41345631|NCT04710992|PROCEDURE|Low intensity percutaneous electrolysis|Once the needle is located in the common extensor tendon of the epicondyle (dominant elbow), a single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
40826474|NCT02093988|DRUG|Intravenous TXA|
41018833|NCT02634658|OTHER|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
41345632|NCT04710992|PROCEDURE|High intensity percutaneous electrolysis|The needle will be inserted in the target position during the same time as in the other groups (90 seconds). During the first stage of intervention the needle will be imbedded without galvanic current and when the end of the application time approaches (approximately 75 seconds) three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
41345633|NCT00415246|DRUG|Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)|
41345634|NCT01250392|BEHAVIORAL|The Effect of Active Choice on Nurse Visit Participation|"The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.~The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment."
41345635|NCT03249480|BIOLOGICAL|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
41345636|NCT02507050|DRUG|Ivabradine|To start Ivabradine 6 weeks prior to PCI.
41345637|NCT02777034|OTHER|ER|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（\<2000ml/d）."
41345638|NCT02777034|OTHER|UR|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（\>2000ml/d）."
41345639|NCT02451865|DRUG|Binimetinib|Given PO
41345640|NCT02451865|DRUG|Docetaxel|Given IV
41345641|NCT02451865|OTHER|Laboratory Biomarker Analysis|Correlative studies
41345642|NCT02218762|DRUG|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
41490413|NCT02804711|BIOLOGICAL|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)|
41490414|NCT02804711|BIOLOGICAL|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)|
40826475|NCT04246333|OTHER|Mode of Delivery of Feeds|Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
40826476|NCT04389112|OTHER|biopsy|Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
40826477|NCT03356418|OTHER|WBV exercise group|The intervention will consist of a half-squat isometric whole-body vibration exercise with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
40826478|NCT03356418|OTHER|Sham WBV exercise group|The intervention will consist of as half-squat isometric exercise , but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
40826479|NCT05536492|PROCEDURE|A-PRF|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF
40826480|NCT05536492|PROCEDURE|ALLOGRAFT|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
40826481|NCT03276052|DRUG|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
40826482|NCT04239183|DEVICE|Stomatherapy|Demonstrate improvement of quality of life (difference of at least 5 points in the StomaQoL questionnaire (21)) among descending colostomy patients, establishing the following comparisons.
41345643|NCT02218762|DRUG|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
41345644|NCT02218762|DRUG|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
40826483|NCT05179668|DRUG|Dapagliflozin 10 MG|administered orally once daily
41345645|NCT02218762|DRUG|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
41345646|NCT00854568|DRUG|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
41345647|NCT00854568|DRUG|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
40826484|NCT05179668|DRUG|Placebo|administered orally once daily
40826485|NCT03570632|DRUG|Metformin|Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy
40826486|NCT01740089|DRUG|Algeron|1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
40826487|NCT01740089|DRUG|PegIntron|1.5 μg/kg/week subcutaneously in combination with ribavirin
40826488|NCT01740089|DRUG|Ribavirin|800-1400 mg/day orally
40826489|NCT04432493|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
40826490|NCT04432493|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
40826491|NCT01205802|PROCEDURE|MHV reconstruction|MHV reconstruction with PTFE or homograft
40826492|NCT01073540|DRUG|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
40826493|NCT01073540|DRUG|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
41490415|NCT02804711|BIOLOGICAL|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)|
41490416|NCT02804711|BIOLOGICAL|Placebo|
41490417|NCT02349243|DRUG|Entacapone|200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
41490418|NCT02349243|DRUG|Placebo|200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
41490419|NCT01007565|PROCEDURE|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
41490420|NCT03761680|DIETARY_SUPPLEMENT|MEDPass mode of administration|Allocation of 50 ml of ONS four times per day distributed with the medication rounds
40826494|NCT03457506|DIAGNOSTIC_TEST|Digital PET/CT scan|The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
41345648|NCT00381784|BEHAVIORAL|Printed materials|"Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors."
41345649|NCT00381784|BEHAVIORAL|Peer advocates|"Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers."
41345650|NCT02521168|DRUG|Oral triiodothyronine|Oral triiodothyronine is given peri-operatively through naso-gastric tube
41345651|NCT02521168|DRUG|Placebo|Placebo consist of saccharin lactis that has the same appearance as Tetronine
41345652|NCT00786461|PROCEDURE|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
40826495|NCT02904122|OTHER|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
41345653|NCT00786461|PROCEDURE|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
41490421|NCT03761680|DIETARY_SUPPLEMENT|Control Intervention|Patients receive ONS between meals or at their request as usual
40826496|NCT00824551|PROCEDURE|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
40826497|NCT00824551|OTHER|Standard care|Patient will undergo standard care
40826498|NCT01515475|PROCEDURE|Glasses|Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
41345654|NCT00245349|PROCEDURE|F-18 Fluorothymidine|
41490422|NCT06307782|DIETARY_SUPPLEMENT|whey protein intake before surgery|Total Hip Arthroplasty whey protein intake,Total Hip Arthroplasty, whey protein intake,CRP,cortisol insulin resistance
41490423|NCT06307782|DIETARY_SUPPLEMENT|Water before surgery|Total Hip Arthroplasty water before surgery,Total Hip Arthroplasty, water intake,CRP,cortisol insulin resistance
41345655|NCT02681068|OTHER|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
41490424|NCT00714493|BIOLOGICAL|Infliximab|3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
40826499|NCT01453738|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
40826500|NCT01453738|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
40826501|NCT05140837|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score & Stroop test|MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.
40826502|NCT05140837|DRUG|Drug therapy|Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
41490425|NCT05103566|DEVICE|gammaCore|Participants will receive two 2-minute non-invasive stimulations to the cervical branch of the vagus nerve (nVNS) three times daily with gammaCore, an FDA cleared device for the acute treatment and prevention of migraine and cluster headache. Intervention will begin within 72 hours post-rupture and end at 10 days post-rupture or discharge, whichever occurs first. The dosing regimen is supported by preclinical models and clinical data.
41490426|NCT04748523|DRUG|Mirtazapine|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
41490427|NCT04748523|DRUG|Placebo Oral Tablet|arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
41490428|NCT00658749|DRUG|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
41490429|NCT00658749|DRUG|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
41490430|NCT00000408|PROCEDURE|Patient education evaluation|
40826503|NCT06195969|BEHAVIORAL|automated instant message-guided hypertension management intervention group|Participants in intervention group will receive the EMI for 4 weeks. Based on the steps of mobile message development recommended by Abroms, et al., we will develop a message content library and protocol for EMI delivery
40826504|NCT05561465|PROCEDURE|Pterygomaxillary disjunction with interposition Y-shape plate|All patients will be treated under general anesthesia. The pterygoid plate will be fractured, pried up, and pushed backward. A Y-shape plate will be fixed to the lateral maxillary surface with its vertical limb and the other two limbs are turned to fit into the retro maxillary space preventing the reattachment of the fractured pterygoid plate
40826505|NCT04382625|DRUG|Hydroxychloroquine|Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.
41345656|NCT02033252|DEVICE|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
41018834|NCT02634658|OTHER|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
41345657|NCT00948428|DRUG|imiquimod|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
41345658|NCT00948428|DRUG|Aldara™|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
41345659|NCT00948428|DRUG|Vehicle Cream|Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
41345660|NCT06113172|OTHER|Hip flexion|during the delay phase, the patients are asked to bend their knee in order to achieve the maximum degree of hip flexion
41345661|NCT03600220|OTHER|acupuncture|antihypertension drug, acupuncture twice a week for 3 months
41345662|NCT02762136|DRUG|placebo|
41345663|NCT02762136|DRUG|Xiang-sha-liu-jun granules|The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
41345664|NCT00650364|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fasting
40826506|NCT03981666|OTHER|Questionnaires|"To patients who have given their consent for the self-screening, the research assistant will propose 3 questionnaires, which will be completed in the waiting room and returned the same day:~* Ad hoc questionnaire for demographics and medical data;~* Insomnia Severity Index (ISI, 7 items, Savard et al., 2005);~* Edmonton Symptom Assessment System (ESAS, 10 items, Visual Analogue Scale, Bruera et al. 1991) assessing comorbidities as pain, dyspnea, anxiety or depression...~The ISI scoring will be realized by the research assistant (in the research office) immediately after its completion."
40826507|NCT00580125|DRUG|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
40826508|NCT00580125|OTHER|Placebo|Placebo, oral capsule, once daily for 21 days
40826509|NCT00580125|DRUG|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
40826510|NCT00580125|DRUG|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
40826511|NCT00580125|DRUG|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
40826512|NCT03400657|PROCEDURE|Multi-disciplinary Treatment|due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
40826513|NCT04911907|DRUG|utidelone injection|Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle
40826514|NCT05732584|OTHER|structured family voice stimulation|The structured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script.
40826515|NCT05732584|OTHER|unstructured family voice stimulation|The unstructured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death.
40826516|NCT03704662|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
40826517|NCT03704662|RADIATION|Preoperative Fractionated Radiation Therapy and Chemotherapy|Conventional concurrent chemotherapy and radiation therapy.
40826518|NCT00380029|DRUG|Erlotinib|Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
40826519|NCT00380029|PROCEDURE|Radical Cystectomy|Will occur 4 weeks prior to dosing with erlotinib
40826520|NCT00717587|DRUG|motexafin gadolinium|
40826521|NCT00717587|DRUG|sunitinib malate|
40826522|NCT00717587|GENETIC|comparative genomic hybridization|
40826523|NCT00717587|GENETIC|gene expression analysis|
40826524|NCT00717587|GENETIC|mutation analysis|
40826525|NCT00717587|GENETIC|polymorphism analysis|
40826526|NCT00717587|OTHER|immunohistochemistry staining method|
40826527|NCT00717587|OTHER|iodine I-124 girentuximab|
40826528|NCT00717587|OTHER|laboratory biomarker analysis|
40826529|NCT00717587|OTHER|pharmacological study|
41345665|NCT00650364|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fasting
41345666|NCT03655418|OTHER|Resilience Curriculum (RESCUR)|"The method of the present project, developed by experts in Europe, concerns giving children their own self-empowerment, strengthening protective factors, and, in the long run, their resilience. In Sweden, the material has been named Jag vill, jag kan, jag törs!.~The methodology that will be further developed and evaluated in this project is called RESCUR (the resilience curriculum) aimed at increasing children's resilience, i.e., children's ability to cope with crises, changes and stressors without falling apart. The method is rooted in research on human resilience."
40826530|NCT00717587|PROCEDURE|adjuvant therapy|
40826531|NCT00717587|PROCEDURE|neoadjuvant therapy|
40826532|NCT00717587|PROCEDURE|therapeutic conventional surgery|
40826533|NCT02241330|DIETARY_SUPPLEMENT|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
40826534|NCT02241330|DIETARY_SUPPLEMENT|Fortification|Wheat flour is fortified before testmeal preparation
41345667|NCT00985140|RADIATION|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
40826535|NCT02241330|DIETARY_SUPPLEMENT|Control|wheat flour is used as control comparator.
40826536|NCT01022515|OTHER|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
40826537|NCT01022515|OTHER|usual follow up with regular EM66 & Cga levels assessment|"Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels."
40826538|NCT01175200|DRUG|Clopidogrel|antiplatelet agent
40826539|NCT01175200|DRUG|Prasugrel|antiplatelet agent
40826540|NCT01175200|DRUG|Lansoprazole|proton pum inhibitor
40826541|NCT01175200|DRUG|Placebo|placebo comparator similar to lansoprazole
40826542|NCT05209308|DRUG|Zandelisib|Zandelisib taken orally for 7 days of each 28 day cycle
40826543|NCT05209308|DRUG|Rituximab|Rituximab IV for 6 cycles
40826544|NCT05209308|DRUG|Venetoclax|Orally - Ramp up weeks 1-5
40826545|NCT00574665|OTHER|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
40826546|NCT03671707|BEHAVIORAL|Brief AWARD advice|"Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~1. Ask: smokers will be asked about their smoking behaviour~2. Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~3. Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~4. Refer smokers to smoking cessation services if they agree.~5. Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline"
40826547|NCT03671707|DRUG|Nicotine replacement therapy sampling|Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.
40826548|NCT03671707|BEHAVIORAL|Active referral|Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.
40826549|NCT03671707|BEHAVIORAL|Very brief advice|Subjects will receive general advice to quit
40826550|NCT03671707|BEHAVIORAL|Leaflet|Subjects will receive a standard leaflet on perinatal smoking by Department of Health
41018835|NCT02634658|OTHER|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
41018836|NCT06175559|COMBINATION_PRODUCT|Healing Town: Embedded Narrative in Interactive Game Design|"The game-based medication intervention game Wanping Town in this study employed a multidisciplinary participatory design approach rooted in narrative theory and behavioral psychology models. The game consists of two perspectives: narrative decision stories and cognitive games. The investigators initially employed participatory design methods to determine the plot and elements within the game, then embedded the conclusions into the therapeutic elements of the game"
41490431|NCT02964949|DRUG|Edoxaban|Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
40826551|NCT05562349|DRUG|Clavulanic Acid Only Product|Drug will be given in 250mg capsules
40826552|NCT05562349|DRUG|Placebo|Capsule with no active medication - identical to drug capsule
40826553|NCT01549535|DEVICE|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
40826554|NCT01498627|BIOLOGICAL|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
40826555|NCT01498627|OTHER|Data collection|PGRx information system
41345668|NCT00372294|DRUG|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
41345669|NCT00372294|DRUG|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
41345670|NCT00781183|OTHER|pulmonary rehabilitation|6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
41490432|NCT01335386|DRUG|KLYX|
41490433|NCT01335386|DRUG|Glycerine|
41490434|NCT02564081|OTHER|Static Stretching lower limb|
41490435|NCT02564081|OTHER|Static stretching Cervical|
41490436|NCT00757848|DRUG|AZD9668|60 mg, oral tablet, twice daily for 28 days
40826556|NCT04619446|DEVICE|Removable Twin Block|Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia
40826557|NCT04619446|DEVICE|Fixed Functional , AdvanSync Appliance|AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
40826558|NCT03798054|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
40826559|NCT03798054|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
40826560|NCT03798054|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
40826561|NCT03798054|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
40826562|NCT03798054|DRUG|SGLT2 inhibitor|"Pharmaceutical form:tablet~Route of administration: oral"
40826563|NCT02036164|RADIATION|Pelvic radiation|"Radiation:~* Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~* Brachytherapy 30-35 Gy for 4-5 times"
41490437|NCT00757848|DRUG|AZD9668 Placebo equivalent|Match placebo to 60 mg, oral tablet, twice daily for 28 days
41490438|NCT01689818|OTHER|exercise training|exercise training program which included aerobic exercise for 3 times per week.
40826564|NCT02036164|DRUG|Cisplatin|Cisplatin 40 mg/m2 i.v.
40826565|NCT02036164|DRUG|Paclitaxel|Paclitaxel 175 mg m2 i.v.
41490439|NCT04141475|DIETARY_SUPPLEMENT|Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
41490440|NCT04141475|DIETARY_SUPPLEMENT|Placebo - Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
40826566|NCT02036164|DRUG|Carboplatin|Carboplatin AUC 5 i.v.
40826567|NCT02115750|DRUG|Etanercept|Head-to-head comparison
40826568|NCT02115750|DRUG|CHS-0214|
40826569|NCT03884192|DRUG|Consolidation Sintilimab|Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.
40826570|NCT04879394|OTHER|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
40826571|NCT00738764|BIOLOGICAL|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
40826572|NCT03327376|DEVICE|ultrasound-screening|Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
41157374|NCT05598203|BEHAVIORAL|Operative group of nutrition education|The intervention will be carried out with operational nutritional education groups. Four meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished; Encounter 4 = strengthening change, barriers and difficulties in maintaining habits based on the transtheoretical model of change.
40826573|NCT03638908|DRUG|Fluoxetine|
40826574|NCT05768204|DRUG|Prednisolone Acetate|The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.
40826575|NCT05768204|OTHER|placebo|A placebo consistent in appearance with the prednisolone acetate.
40826576|NCT00176176|DEVICE|EEG|
40826577|NCT03934970|DIAGNOSTIC_TEST|Diffusion tensor imaging of peripheral nerves|All subjects underwent evaluation using 1.5T DTI of median nerves and NCS. Patients underwent clinical evaluation using Neuropathy Deficit Score (NDS), Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and Diabetic Neuropathy Examination (DNE) score.
41345671|NCT01662128|DRUG|Xeloda|Xeloda as Adjuvant Therapy
41490441|NCT04666714|DRUG|Praga formulation|Praga formulation tablet
41490442|NCT04666714|OTHER|Placebo pregabalin 75mg|Placebo pregabalin 75mg tablet
41490443|NCT04666714|OTHER|Placebo Pregabalin 150mg|Placebo Pregabalin 150mg tablet
41490444|NCT04666714|DRUG|Pregabalin 75mg|Pregabalin 75mg tablet
41490445|NCT04666714|DRUG|Pregabalin 150mg|Pregabalin 150mg tablet
41490446|NCT04666714|OTHER|Placebo Praga formulation|Placebo Praga formulation tablet
41490447|NCT06402370|DIAGNOSTIC_TEST|PET scan|\[18F\]Vizamyl
41490448|NCT04095949|DIETARY_SUPPLEMENT|Artichokes|Approximately 200 g of cooked artichokes
41490449|NCT04814030|DRUG|PD-1 inhibitor|Transarterial hepatic chemoembolization and FOLFOX-based infusion
41490450|NCT04403711|OTHER|local anesthetic and dexmedetomidine|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and dexmedetomidine
40826578|NCT02156557|BIOLOGICAL|Colon KCC Heptapeptide|"* Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.~* The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.~* The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.~* We will obtain copies of your endoscopy report and any pathology reports."
40826579|NCT04184128|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
40826580|NCT01944566|BIOLOGICAL|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
40826581|NCT04589351|DRUG|Ezetimibe 10mg|Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
40826582|NCT04589351|DRUG|Placebo|Matching placebo
40826583|NCT05048394|DEVICE|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
40826584|NCT05048394|DEVICE|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
40826585|NCT03619928|DEVICE|Dry needling|20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.
40826586|NCT03619928|DEVICE|Massotherapy|A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.
40826587|NCT02664051|DRUG|Nalcrom|"Drug: disodium cromoglycate 100mg 4x2 daily~Other Names:~• Nalcrom"
40826588|NCT02664051|DRUG|placebo|100mg 4x2 daily mannitol
40826589|NCT00000627|DRUG|Fluconazole|
40826590|NCT03978780|PROCEDURE|Erector spinae plane block|80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
40826591|NCT03978780|PROCEDURE|Placebo Block|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
40826592|NCT02209402|BEHAVIORAL|Exercise Training|Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
40826593|NCT02854124|PROCEDURE|Melanoma and peritumoral skin excision|Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
41345672|NCT03674294|DRUG|Aprepitant|Aprepitant is manufactured by Merck \& Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003
41345673|NCT03674294|DRUG|Palonosetron|Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
41345674|NCT03674294|DRUG|Dexamethasone|Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
41345675|NCT03674294|DRUG|Placebo Oral Tablet|In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
41345676|NCT05956028|PROCEDURE|Ultrasound guided SCV cannulation|receive ultrasound guided SCV cannulation
40826594|NCT01342549|DRUG|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
40826595|NCT01342549|DRUG|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
40826596|NCT03051984|DEVICE|Neuromuscular electrical stimulation|NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (\~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
40826597|NCT03797118|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
40826598|NCT01724567|OTHER|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
40826599|NCT01724567|OTHER|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
40826600|NCT00297102|DRUG|Roflumilast|500 mcg, once daily, oral administration in the morning
40826601|NCT00297102|DRUG|Placebo|once daily
40826602|NCT01360398|PROCEDURE|Blood sample|Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.
40826603|NCT01360398|PROCEDURE|Sputum sample|Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.
40826604|NCT01360398|PROCEDURE|Nasopharyngeal swab|Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.
40826605|NCT01360398|PROCEDURE|Urine sample|Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.
40826606|NCT01360398|PROCEDURE|End tidal breath sample|Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.
40826607|NCT01360398|OTHER|Data collection|Patient interview, diary cards review and questionnaires completion
40826608|NCT01360398|OTHER|Tests|Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
40826609|NCT00458042|DRUG|treprostinil sodium|
40826610|NCT03419949|DRUG|oral lamotrigine 100 mg|Pain relief drug Lamotrigine inhibits the voltage-gated sodium and calcium channels. Inhibition of the voltage-gated sodium channel stabilizes the presynaptic neuronal membrane, thus preventing the release of excitatory neurotransmitters such as glutamate and inhibiting sustained repetitive neuronal firing
40826611|NCT03419949|DRUG|oral pregabalin 150 mg|Pain relief using drug Pregabalin is a structural analogue of the inhibitory neurotransmitter gama-aminobutyric acid (GABA), with anticonvulsant, antihyperalgesic, and anxiolytic properties
40826612|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
40826613|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
40826614|NCT00182767|DRUG|ixabepilone|Given IV
41018837|NCT05852353|OTHER|Digital Pediatric Bladder Health Patient Education Curriculum|"Bladder Basics is designed to be a digital health intervention to improve knowledge of healthy bladder practices. It is a video-based bladder health curriculum based on 1) principles of Urotherapy 2) stakeholder need for a gold-standard resource 3) behavioral change theory 4) education design standards for inclusion as a comprehensive school health program (CSHP).~The overall mission of the course is to teach children and their families about pediatric bladder health. The development of the course has followed the NIH's Clear \& Simple standards for patient education. The 7 video lesson plan spans 60 minutes total. The course is designed to support families awaiting medical care, which would provide the continued support. In addition, one lesson shares solutions to common home and school-based barriers to behavioral change. The 4 healthy bladder practices that are promoted are- 1) pee every 3 hours 2) drinking water 3) daily poop without straining 4) toilet postures."
41018838|NCT01428323|DEVICE|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
40826615|NCT00182767|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
40826616|NCT00919867|DRUG|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
40826617|NCT00919867|DRUG|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
40826618|NCT00919867|DRUG|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
40826619|NCT03455829|DRUG|G1T38|CDK 4/6 inhibitor
40826620|NCT03455829|DRUG|Osimertinib|EGFR TKI; 80 mg
41018839|NCT04725175|DRUG|PIPE-307|Single and multiple ascending oral doses of PIPE-307 tablets
41018840|NCT04725175|DRUG|Placebo oral tablet|Single and multiple ascending oral doses of matching Placebo tablets
41345677|NCT05956028|PROCEDURE|Ultrasound guided IJV cannulation|receive ultrasound guided IJV cannulation
41345678|NCT02485860|DEVICE|Melectis G|
41345679|NCT03935685|DRUG|Mirtazapine (Remeron)|Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.
41345680|NCT04935567|OTHER|Statistical model for the prediction of VNS efficacy|statistical model for the prediction of VNS efficacy based on a mathematical and statistical analysis of scalp EEG data
41345681|NCT01525524|DEVICE|Transcranial Direct Current Stimulation|In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
41345682|NCT04396106|DRUG|AT-527|One 550 mg tablet of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
41345683|NCT04396106|OTHER|Placebo|One placebo tablet administered every \~12 hours (twice a day) for a total of 5 days
41345684|NCT04396106|DRUG|AT-527|Two 550 mg tablets of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
41345685|NCT04396106|OTHER|Placebo|Two placebo tablets administered every \~12 hours (twice a day) for a total of 5 days
41018841|NCT03143244|DRUG|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
41018842|NCT03143244|DRUG|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
41345686|NCT03035097|OTHER|Biorepository|One-time blood draw for blood to be stored in a biorepositoy
41345687|NCT05249803|COMBINATION_PRODUCT|Patients with COVID-19 Pneumonia|Patients were offered with usual care of COVID-19 in ICU and we did retrospective study
41345688|NCT01041040|DRUG|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
41345689|NCT06508697|DIAGNOSTIC_TEST|invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement|A consecutive series of patients who underwent Coronary computed tomography angiography (CTA) within 90 days before invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement were candidates for this study at Fujita Health University Hospital, Bantane Hospital, and Nagoya First Red Cross Hospital
41345690|NCT04506879|PROCEDURE|Popliteal Sciatic nerve block|Patients schedule for lower limb surgery under regional anesthesia will receive ultrasound guided subparaneural popliteal sciatic nerve block. After identification of the common peroneal nerve and tibial nerve, local anesthetic agents will be injected close to each nerve below the point of divergence at the popliteal fossa. The spread of the drug and the sensory and motor function of that limb will be assessed regularly till it is ready for surgery.
41345691|NCT00479349|DRUG|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
41490451|NCT04403711|OTHER|local anesthetic and placebo|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and normal saline
41490452|NCT02590250|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
41490453|NCT01629966|DRUG|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
41490454|NCT01629966|DRUG|Vilazodone|Vilazodone, 20mg, oral administration once per day.
41490455|NCT01629966|DRUG|Vilazodone|Vilazodone, 40mg, oral administration once per day.
40826621|NCT04732858|OTHER|Cross sectional e-Survey on surgeons exposed to any educational intervention|"Educational intervention was considered as any procedure or program to facilitate the acquisition of basic skills about the disease, its ramifications and treatment2,6,7:~* Education in infectious disease, including~  * pandemic training for health personnel~ * Personal protective equipment (PPE) and protection.~ * Specific speed-training focusing on environmental control (decontamination area, dressing...), personal protection, hand hygiene, sample management, risky gestures, control measures.~* Intensive care education:~  * mechanical ventilation~ * airways management~ * emergencies and cardiovascular drugs~ * Intensive care monitoring systems~* Basic nurse skills~* COVID-specific clinical management"
40826622|NCT05516784|DRUG|Clopidogrel|Comparison of platelet reactivity between clopidogrel and ticagrelor
40826623|NCT05516784|DRUG|Ticagrelor|Comparison of platelet reactivity between clopidogrel and ticagrelor
40826624|NCT04841161|BEHAVIORAL|Balance function, gait ability, weight- distribution and weight-shifting|Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.
40826625|NCT04841161|BEHAVIORAL|Weight- distribution and weight-shifting training program|The stroke patients received a weight-shifting training program , 30 minutes/time, 2-5 days a week for 2-3 weeks(8 sessions). After training, they accepted a post-test within a week.
40826626|NCT00107315|BIOLOGICAL|bevacizumab|
40826627|NCT00107315|DRUG|capecitabine|
40826628|NCT05945134|OTHER|Visual and auditory feedback STS training|"30 minutes per session, 3 sessions per week, for a total of 3 weeks. The visual and auditory feedback signals will be given throughout the sit-to-stand movement. As the size of circle representing the weight bearing gets more even, and the mobile dot indicating the overall center of pressure moves forward and approaches the midline, the auditory cues will get louder to indicate proximity to the target. It allows the participants to adjust and relearn the correct weight shifting and symmetry.~The intensity will be adjusted based on different chair heights (e.g. 115%, 100%, 80% of lower leg length), various seat materials, and supported level of thigh (progressing from one-third of the length between the greater trochanter of the femur and the knee joint line to full support). The training program will be progressed according to the abilities of the participants."
40826629|NCT05945134|OTHER|Conventional STS training|30 minutes per session, 3 sessions per week, for a total of 3 weeks. All settings will be the same as the experimental group, except for the feedback. In the control group, the verbal cues will be given by the physical therapist and a mirror will be placed in front of the participant for visual feedback. During the sit-to-stand movement, participants will be asked to try to maintain the alignment in the midline.
40826630|NCT02621177|BIOLOGICAL|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
40826631|NCT02621177|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
40826632|NCT03120858|BEHAVIORAL|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
40826633|NCT05265884|DEVICE|Kinesiotaping|The tape is waterproof, porous, and adhesive. The width is 5 cm and thickness of 0.5 mm will be used in this study. This tape is with elastic core wrapped within cotton and capable of stretching up to 140-150%, applies heat-sensitive acrylic adhesive to avoid risk of latex allergy .The tape without medicinal properties is water resistant and can remain on the skin for 3 to 5 days. It will be applied two times per week for one month
40826634|NCT05265884|BEHAVIORAL|traditional therapy intervention|traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
40826635|NCT01309906|DEVICE|Investigational lens|Bausch \& Lomb investigational silicone hydrogel contact lens worn on a daily wear basis for 1 week.
40826636|NCT01309906|DEVICE|Air Optix Aqua lens|Ciba Visions Air Optix Aqua contact lens, worn on a daily wear basis for 1 week.
40826637|NCT04864132|DIAGNOSTIC_TEST|6-minute walk test|This test assesses submaximal exercise capacity.
40826638|NCT04864132|DIAGNOSTIC_TEST|Incremental shuttle walk test|This test assesses maximal exercise capacity.
41018843|NCT03143244|DRUG|Control group (Normal Saline) (C)|Patients received normal saline in two sets
40826639|NCT06224660|GENETIC|SRD-001|SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.
40826640|NCT04261959|OTHER|myoActivation|myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.
40826641|NCT04261959|OTHER|Physiotherapy|Physiotherapy aims to reduce a patient's pain experience and increase their physical function through physical examination, diagnosis, prognosis, physical intervention, rehabilitation and education (including pain neurophysiology education).
40826642|NCT01616940|BEHAVIORAL|Enhanced Peer Intervention|"Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~* Introduction and Assessment~* HIV Transmission \& Viral Life Cycle~* Effective Communication and Self-Advocacy~* Understanding Lab Values~* HIV Medications~* Drug Resistance \& Adherence, and Understanding \& Managing Side Effects~* Disclosure and Stigma~* Harm \& Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~* Are any services needed?~* Have referrals or appointments been made?~* Does patient need accompaniment to a visit?~* Connect patient with services as needed.~* Appointment reminders.~* Overall well-being?~* Schedule next peer contact."
40826643|NCT03614416|DEVICE|EOXY device|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
40826644|NCT03614416|DEVICE|Gold standard oximeter|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
40826645|NCT03614416|PROCEDURE|SaO2 sampling|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
40826646|NCT04920591|OTHER|doll treatment|"The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy."
40826647|NCT04355533|BIOLOGICAL|serology test|volume according to child weight
40826648|NCT04355533|BIOLOGICAL|nasopharyngeal swab|nasopharyngeal swab for PCR
40826649|NCT04355533|BIOLOGICAL|rectal swab|rectal swab for PCR
40826650|NCT04355533|BIOLOGICAL|saliva sample|for biocollection
40826651|NCT03564821|DRUG|Ivosidenib|Ivosidenib is an inhibitor of the protein IDH1
40826652|NCT03250078|DIAGNOSTIC_TEST|MRI/MRCP|An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
40826653|NCT01214304|OTHER|Essential Lavender Oil|Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
40826654|NCT01214304|OTHER|Lavender Scent|Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
40826655|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose
40826656|NCT01098877|DRUG|PF-04634817|Oral solution, 1mg, single dose
40826657|NCT01098877|DRUG|PF-04634817|Oral solution, 3mg, single dose
41018844|NCT00002453|DRUG|Tenofovir disoproxil fumarate|
41018845|NCT04519632|OTHER|Qualitative study|Qualitative interviews
41018846|NCT06029959|DEVICE|Continuous positive airway pressure (CPAP)|Eligible participants with a diagnosis of OSA will be set up with autotitrating CPAP by the study's sleep technologist. The CPAP device includes an auto-titrator that adjusts the delivered pressure between 5 to 15 cm of water to eliminate obstructive events.
41490456|NCT00725205|BIOLOGICAL|PegIntron (Peginterferon alfa-2b)|Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms \[mcg\]/killogram \[kg\]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
40826658|NCT01098877|DRUG|PF-04634817|Oral solution, 10mg, single dose
41157375|NCT04661150|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 3 cycles prior to surgery and 5 cycles after surgery.
41490457|NCT00725205|DRUG|Rebetol (Ribavirin)|Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
40826659|NCT01098877|DRUG|PF-04634817|Oral solution, 30mg, single dose
40826660|NCT01098877|DRUG|PF-04634817|Oral solution, 100mg, single dose
40826661|NCT01098877|DRUG|PF-04634817|Oral solution, 300mg, single dose
40826662|NCT01098877|DRUG|PF-04634817|Oral solution, 600mg, single dose
40826663|NCT01098877|DRUG|PF-04634817|Oral solution, 900mg, single dose
40826664|NCT01098877|DRUG|PF-04634817|Oral solution, up to 900mg, single dose after food
40826665|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose after food
40826666|NCT05610306|OTHER|Qualitative interview|Qualitative interviews to gain insight into the impact of ichthyosis on the biological, psychological, and social quality of life in adult and elderly patients.
40826667|NCT02046850|DRUG|selumetinib|Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
40826668|NCT02046850|DRUG|rifampicin|Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
40826669|NCT02046850|DRUG|selumetinib|On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
40826670|NCT02046850|DRUG|rifampicin|On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
40826671|NCT03383783|DRUG|0 ppm F (placebo, negative control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
40826672|NCT03383783|DRUG|250 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
40826673|NCT03383783|DRUG|500 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
40826674|NCT03383783|DRUG|1100 ppm F as NaF (positive control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
40826675|NCT05008484|DEVICE|NMES|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach
40826676|NCT05008484|DRUG|Vitamin D|2000IU oral vitamin D supplementation daily for 9 months
40826677|NCT05008484|PROCEDURE|Passive movement|Subjects will perform simple passive movement exercise for their legs while sitting in their wheelchairs at their home. The frequency of the training will be twice weekly. .
40826678|NCT04866875|BEHAVIORAL|dieting|The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
40826679|NCT02350387|PROCEDURE|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
40826680|NCT02350387|PROCEDURE|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
40826681|NCT02818348|DRUG|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
40826682|NCT02818348|DRUG|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
40826683|NCT03084913|OTHER|Plant- based, olive oil diet|used as part of daily diet, followed for 8 weeks
41018847|NCT06029959|BEHAVIORAL|CPAP technical support intervention|SCOUTS 3 sleep technologists (ST) will make mask type/size or device adjustments, as needed, and provide training to participants and CPAP partners to improve skills involved with mask placement and device maintenance. For participants with non-acceptance of CPAP over the first night, a standardized desensitization program will be implemented. Persistent problems with CPAP use or mask fit, or any high residual respiratory events will be discussed between the sleep technologist and the study's board-certified sleep medicine physician.
41018848|NCT06029959|BEHAVIORAL|Motivational Enhancement Therapy (MET)|In-person Motivational Enhancement Therapy (MET) sessions by a trained sleep coach will occur within a week of starting CPAP and, with permission, conducted with a CPAP partner, when available. The MET session recordings will be uploaded into the HIPAA compliant Lyssn platform for evaluation, including feedback to the sleep coach. The goal will be 5 total MET sessions, either in-person or by phone, spanning the inpatient and then outpatient settings.
41018849|NCT06029959|BEHAVIORAL|Mobile Health intervention|Study participants will be assisted in registering for and trained on the ResMed myAir app. Participants will also receive mobile health messages based on Self-Determination Theory.
41018850|NCT03459196|DEVICE|THERMOCOOL SMARTTOUCH SF-5D Catheter|radiofrequence ablation with THERMOCOOL SMARTTOUCH® SF-5D catheter used in combination with the nMARQ™ Multi-Channel RF Generator with TGA mode
41018851|NCT06572904|DRUG|Tenoxicam Injectable Product|(EPICOTIL® Tenoxicam 20 mg , Manufactured by: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY, ReStore at a temperature not exceeding 30°C.)
41018852|NCT06572904|DRUG|Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly|\* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)
40826684|NCT03084913|OTHER|Prostate Cancer Foundation diet|followed for 8 weeks
40826685|NCT02998905|DRUG|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
40826686|NCT02998905|DRUG|Acetylsalicylic Acid|Acetylsalicylic acid 81 mg/day
40826687|NCT01655381|DRUG|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
40826688|NCT01395121|DRUG|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
40826689|NCT05190601|DEVICE|uroflowmetry|Qmax(ml/s),Qav(ml/s),Volume (ml)
40826690|NCT05929118|OTHER|Aquatic Rehabilitation|Reviewing the existing literature studies and related books, and combining the post-operative rehabilitation process of ACLR with the opinions of experts from the China Aquatic Rehabilitation Association, the Aquatic rehabilitation program of this study was designed.
40826691|NCT05929118|OTHER|Land-based Rehabilitation|Peking University Third Hospital Anterior Cruciate Ligament (ACL) Postoperative Rehabilitation Guidelines.
40826692|NCT03395301|DEVICE|Coil|Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
40826693|NCT04677426|DRUG|Hyperpolarized Xe129|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
40826694|NCT00252460|DEVICE|Computed Tomography Scan and Magnetic Resonance Imaging|
40826695|NCT03263468|PROCEDURE|Same sitting PCI with complete revascularization|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
40826696|NCT03263468|PROCEDURE|Staged PCI with complete revsacularization >48 hours pf primary PCI|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting \>48 hours to 45 days post primary PCI
40826697|NCT06247774|BEHAVIORAL|Cardiac Rehabilitation|Participation in a 12-week cardiac rehabilitation program
40826698|NCT06247774|BEHAVIORAL|Attention Control|Participants will receive regular phone calls in place of cardiac rehabilitation visits
41490458|NCT05376852|COMBINATION_PRODUCT|based decitabine and olverembatinib（HQP1351)chemotherapy|"AP-CML treated with decitabine 10mg/m2 d1-5 intravenously (IV) over 60 minutes on days 1-5 and HQP1351 40mg qod every 28 days.After completion of HQP1351 lead-in, patients will receive HQP1351 PO qod on days 1-28 of subsequent cycles.~BC-CML:treated with decitabine 20mg/m2 d1-5 IV on days 1-5 and HQP1351 40mg qod every 28 days,with or without other chemotherapy Drugs"
40826699|NCT03381482|DIAGNOSTIC_TEST|CSF drawing during spinal anaesthesia|4mL of CSF by lumbar puncture
40826700|NCT03381482|DIAGNOSTIC_TEST|Fasting blood sample|6x5 mL of fasting blood sample
40826701|NCT03381482|DIAGNOSTIC_TEST|Lumbar puncture|10 mL of CSF by lumbar puncture
40826702|NCT01511328|OTHER|HPV testing|Testing for Human Papilloma Virus
41345692|NCT05408052|PROCEDURE|Dural Puncture Epidural (DPE)|"Using the 18G Tuohy needle in the sitting position, the epidural space will be determined from the L3-L4 or L4-L5 space using the loss-of-resistance method After Dural puncture will be performed using a 25G Whitacre needle from the Tuohy needle to patients in the DPE group and free CSF flow will be observed, but no medication will be applied to the subarachnoid space. Afterwards, epidural catheter will be placed and when the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
41490459|NCT03468075|DRUG|Ascorbate|Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
41490460|NCT03468075|DRUG|Gemcitabine|Administered on Days 1, 8 and 15, after the infusion of ascorbate
41490461|NCT04944719|DIAGNOSTIC_TEST|nasopharyngeal aspirate|nasopharyngeal aspirate to determinate colonization by streptococcus pneumoniae
41490462|NCT01455311|PROCEDURE|EUS Guided Fine Needle Aspiration|EUS-guided fine needle aspiration of the cyst fluid
41490463|NCT01455311|PROCEDURE|EUS Guided EchoBrush Sampling|EUS-guided brushing of the cyst wall
41490464|NCT02702479|OTHER|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
41490465|NCT02702479|OTHER|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
40826703|NCT03144193|OTHER|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
40826704|NCT02654392|DIETARY_SUPPLEMENT|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
40826705|NCT02654392|DIETARY_SUPPLEMENT|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, \& Pumpkin oils) every day for 5 weeks
40826706|NCT01059253|OTHER|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
40826707|NCT03699345|DEVICE|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards CENTERA THV System and accessories
40826708|NCT05665673|OTHER|Physical functions test|Participants; sociodemographic and descriptive data will be recorded. The Standardized Mini-Mental Test will be used for the global cognitive assessment of participants, the Brunnstrom staging to assess lower extremity motor recovery and indicate at what motor level, and the Functional Ambulation Classification to classify them according to the basic motor skills required for functional ambulation. Gait and balance assessment will be evaluated with Tinetti Balance and Gait Assessment (POMA), functional exercise capacity will be evaluated with 6 Minute Walking Test (6MWT), and peripheral muscle strength will be evaluated with knee extension strength.
40826709|NCT06482320|DIAGNOSTIC_TEST|Recording EKG traces on the smartwatch|Upon enrollment, patients are associated with a progressive identification number (ID). They will then be instructed to record a baseline single-lead EKG (EKG 0) to be sent to a dedicated email address. The sender's email address will be recorded and associated with the ID. The main clinical and demographic data will also be collected. Within 30 days of the enlistment date, a 24-hour EKG Holter will be performed. From the date of enlistment and for the following three months, before, after and during the execution of the 24-hour EKG Holter, enrolled patients can send single-lead EKGs (recorder throug the smartwatch) in case of palpitation. The report of the single-lead EKGs will be communicated electively via e-mail (in response to the email sent by the patient and containing the trace in question) in the following days. In case of diagnostic and/or therapeutic measures to be implemented following the reporting of the trace, doctors will take care of it.
40826710|NCT06299982|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W (5 cycles)
40826711|NCT06299982|DRUG|608 Q4W|608 160 mg Q4W (3 cycles)
41490466|NCT00222989|DRUG|PPI|
41490467|NCT05574231|PROCEDURE|Periodontal treatment|It includes surgical and non-surgical procedures depending on patient as well as tooth level.
41490468|NCT03623386|OTHER|PD neurofeedback|PD-neurofeedback subjects will practice motor imagery in the MRI scanner and receive neurofeedback on their performance. There will be a total of 10-12 neurofeedback sessions on two separate days. Subjects will continue practicing motor imagery at home every day throughout the study period for 4-6 weeks.
41490469|NCT03623386|OTHER|PD control|PD-control subjects will practice visual imagery (e.g., of scenery, objects, etc., but not of movement) in the MRI scanner and will not receive neurofeedback on their performance. Subjects will continue practicing visual imagery at home every day throughout the study period for 4-6 weeks.
41490470|NCT02924727|DRUG|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
41490471|NCT02924727|DRUG|Ramipril|Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
41490472|NCT02924727|DRUG|Placebo of LCZ696|Matching placebo of LCZ696 tablets
41490473|NCT02924727|DRUG|Placebo of ramipril|Matching placebo of ramipril capsule
41345693|NCT05408052|PROCEDURE|Standart Epidural|"The neuraxial procedure will be performed in the sitting position using the 18G Tuohy needle, in the L3-L4 or L4-L5 range using the loss-of-resistance method.~The epidural catheter will be placed so that it remains 4 to 5 cm in the epidural space. After the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
41490474|NCT02924727|DRUG|Valsartan|Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
40826712|NCT00826358|DRUG|ABT-143|Once, please see Arm Description for more details.
40826713|NCT00826358|DRUG|ABT-335|Once, see Arm Description for more detail
40826714|NCT00826358|DRUG|rosuvastatin|once, see Arm Description for more detail
40826715|NCT06052111|DRUG|Group F (fentanyl group)|Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation and was stopped 10 minutes before the end of surgery.
40826716|NCT06052111|DRUG|Group D (dexmedetomidine group)|The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of anesthesia followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
40826717|NCT01663324|DEVICE|rTMS intervention 1|"Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS"
40826718|NCT01663324|DEVICE|rTMS intervention 2|"Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS"
41490475|NCT02924727|DRUG|Placebo of valsartan|matching placebo of valsartan for one day to patients who will be randomized to received ramipril
41490476|NCT05051761|DRUG|Jaktinib|Administered orally.
41490477|NCT05051761|DRUG|placebo|Administered orally.
40826719|NCT05452369|DRUG|Rhomboid intercostal plane block|- 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .
41490478|NCT00872885|DRUG|GRT6005|liquid formulation, 200 to 600 µg, single dose, one day
41490479|NCT00872885|DRUG|Morphine|60 mg
41490480|NCT00872885|DRUG|Placebo|single dosage
40826720|NCT04128397|DEVICE|traditional stimulation site continuous theta burst stimulation (cTBS)|before cTBS treatment, MRI was used to confirm the stimulation site
40826721|NCT04128397|DEVICE|precise stimulation site cTBS|before cTBS treatment, rs-fMRI was used to confirm the stimulation site
40826722|NCT03423108|BEHAVIORAL|G150|This group will receive 150 min/week of combined exercise training, structured and supervised.
40826723|NCT03423108|BEHAVIORAL|G300|This group will receive 300 min/week of combined exercise training, structured and supervised.
40826724|NCT05050396|PROCEDURE|Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis|Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). \[16, 17\] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation \[20\]
40826725|NCT00040508|DRUG|Sirolimus|
40826726|NCT01437176|DEVICE|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
40826727|NCT01437176|DEVICE|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
41345694|NCT02396004|DEVICE|Near Infrared Red Spectroscopy (NIRS)|NIRS using INVOS cerebral/somatic oximeter
41345695|NCT01545414|BEHAVIORAL|ICBT|12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
41345696|NCT01545414|BEHAVIORAL|ICONTROL|12 weeks of Internet-based treatment with a focus on relaxation training
41490481|NCT03092739|DIAGNOSTIC_TEST|PD-L1 Immunocytochemistry (ICC)|PD-L1 expression in the cytological specimens will be assessed using different antibodies.
41490482|NCT03092739|DIAGNOSTIC_TEST|PD-L1 Immunohistochemistry (IHC)|PD-L1 expression in the histological specimens will be assessed using different antibodies.
41490483|NCT04644874|DIAGNOSTIC_TEST|Geriatric 8|The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.
41490484|NCT04644874|DIAGNOSTIC_TEST|modified Geriatric 8|The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.
41490485|NCT04644874|DIAGNOSTIC_TEST|30 second chair stand test|Repetitions within 30 seconds
40826728|NCT02914548|DRUG|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
40826729|NCT02914548|DRUG|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
40826730|NCT05349292|OTHER|ANH|one group will be managed with ANH and the other without (control group)
40826731|NCT01628367|PROCEDURE|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
40826732|NCT01628367|DEVICE|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
40826733|NCT01628367|BIOLOGICAL|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
40826734|NCT01628367|BIOLOGICAL|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
41345697|NCT02110472|DEVICE|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
40826735|NCT01628367|BIOLOGICAL|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
40826736|NCT01628367|DRUG|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
40826737|NCT00002955|DRUG|fluorouracil|
40826738|NCT00002955|DRUG|leucovorin calcium|
40826739|NCT00002955|DRUG|trimetrexate glucuronate|
40826740|NCT06605703|BEHAVIORAL|WW Clinic|Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.
40826741|NCT06605703|DRUG|Bupropion-Naltrexone|Bupropion-Naltrexone
40826742|NCT06605703|DRUG|Bupropion-Naltrexone-Metformin|Bupropion-Naltrexone-Metformin
40826743|NCT05798481|DRUG|Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.|Exactly 2.5 mg or 5 mg sodium nitrite and 50 mg N-acetylcysteine are weighed and mixed together just before use. The mixture is placed under the participant's tongue. The powder slowly dissolves in saliva and generate S-nitrosoacetylcysteine. Investigators will ask the subjects not to swallow the drug at least for 30 min. Administration of nitrite and N-acetylcysteine individually at these concentrations is not expected to change any blood NO chemistry or the systemic blood pressure. Hence, investigators will not investigate the effects of nitrite and N-acetylcysteine individually in this study. Placebo control is not needed for this study because the baseline parameters will serve as control. Investigators will assess the drug effect based on the difference between pre-treatment and post-treatment values.
41018853|NCT06180655|BEHAVIORAL|Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™|Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
41018854|NCT03495908|DEVICE|VGo|Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
41018855|NCT05760794|PROCEDURE|Non-barbed delayed absorbable suture|The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.
41018856|NCT05760794|PROCEDURE|Barbed delayed absorbable suture|The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
41157376|NCT04661150|DRUG|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg IV loading dose and then 6 mg/kg IV on Day 1 of a 21-day cycle for 3 cycles before surgery, and administration will continue after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
41345698|NCT04468464|OTHER|Occlusal Splint Treatment|Occlusal splint is used by a dentist during sleep or day time to protect the teeth and temporomandibular joint. Manufactured individually by the technicians according to the dentists measurement procedure.
41345699|NCT04468464|OTHER|Osteopathic Manual Treatment|Osteopathy treats the body as a whole and applied by hands over the related structures of the body. TMJ, Cervical, Thoracal, Lumbar vertebra mobilization was applied as well as the fascial and visceral mobilization. Patients also used occlusal splint for 6 weeks during the intervention.
41345700|NCT00315523|DRUG|Levocetirizine|
41345701|NCT04007367|DRUG|SAGE-217|SAGE-217 capsule
41345702|NCT04007367|DRUG|Placebo|SAGE-217 matching placebo capsule
41345703|NCT00045357|BIOLOGICAL|therapeutic autologous lymphocytes|
41490486|NCT04644874|DIAGNOSTIC_TEST|Handgrip Strength Test|Measured in kilograms
41490487|NCT01440036|PROCEDURE|Carotid endarterectomy|The removal of atherosclerotic plaque from the carotid artery, by surgery
40826744|NCT05324020|BEHAVIORAL|Medication adherence eHealth intervention|"The eHealth intervention consists a Medication Event Monitoring Systems (MEMS®) Helping Hand and MEMS Adherence Software application. The eHealth intervention will support BCS to adhere to their OHT (i) by alerting them to take their OHT, and (ii) by allowing patient-physician communication.~The eHealth intervention comprises a questionnaire that should be filled-out weekly and that informs about the presence and severity of side effects. These data are collected in real-time and monitored on a weekly basis by the clinical research nurse (CRN) in charge of the study. In case of an alert, meaning recurrent non-adherence and/or reporting of side-effects, the CRN will contact the breast cancer nurse (BCN) in charge of the patient. Thus the BCN will contact the patient by phone to check on their health status and together define the future procedures (behavioral strategies)."
40826745|NCT05675267|OTHER|data collection|HEART score calculation
40826746|NCT05403892|DIAGNOSTIC_TEST|level laser lunge test|In order to perform the Level Laser Test, the operator 1 places a laser lever on the ground one metre aside and 50 cm forward the ankle to be examined. This laser (a 2-class laser not harmful to the eyes) maintains a linear laser light beam perpendicular to the floor. The examined leg is placed further forward to the other one, as it happens in the DLT. The teenage performs a forward lunge perpendicularly to the laser line, the heel positioning 50 cm from the laser line. Operator 1 has the subject perform a lunge while operator 2 measures the distance from the kneecap to the laser line. The measurement, deducted by 50 cm, leads to the heel-to-wall distance (value used to DLT).
40826747|NCT05403892|DIAGNOSTIC_TEST|dorsiflexion Lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the teenage stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The teenage is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The teenage steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
40826748|NCT03110653|DRUG|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
40826749|NCT03110653|DRUG|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
40826750|NCT02325063|DRUG|PRP-L Injection|Patients will be treated with an injection of leukocyte and platelet rich plasma.
40826751|NCT02325063|DRUG|Botox injection|Patients will be treated with an injection of Type A Botulinum toxin.
40826752|NCT02325063|DRUG|Corticoid injection|Patients will be treated with an injection of Corticoids.
40826753|NCT00315770|PROCEDURE|weight loss diets for young adults|
40826754|NCT05290454|OTHER|mNGS-guided treatment|mNGS detect the causative microorganisms using appropriate lower respiratory tract (LRT) specimen. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Clinicians apply the definitive treatment based on mNGS results, as well as results of conventional microbiology diagnostic techniques.
40826755|NCT00309699|DRUG|Placebo|Daily for 3 weeks
40826756|NCT00309699|DRUG|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
40826757|NCT00309699|DRUG|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
40826758|NCT04333940|PROCEDURE|periapical surgery|clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
40826759|NCT03114124|DEVICE|MIFI Catheter|Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
40826760|NCT03114124|DEVICE|Standard Ablation Catheter|Standard of care for patients with certain cardiac arrhythmias.
41018857|NCT02198547|DRUG|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
40826761|NCT01007123|DRUG|A3309|A3309 in three different dosage levels or placebo once daily for the duration of the study
40826762|NCT02120963|BEHAVIORAL|Person-centered physical therapy intervention program|Comparison of person-centered physical therapy and control group
40826763|NCT05978076|OTHER|data collection|data collection : mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications.
40826764|NCT03809715|DEVICE|Coroflex® ISAR NEO coronary stent system|"treatment of coronary artery disease with Coroflex® ISAR NEO of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
40826765|NCT02253823|DRUG|EFV|
40826766|NCT02253823|DRUG|TPV/RTV - low dose|
40826767|NCT02253823|DRUG|TPV/RTV - high dose|
40826768|NCT02494089|OTHER|distress analysis|
40826769|NCT03824275|DRUG|18F- DCFPyL PET/CT|A CT scan using a radioactive marker to better image tumors
41018858|NCT02198547|DRUG|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
41018859|NCT04499404|OTHER|Breastfeeding related information delivered by WeChat|Participants in the intervention group will be asked to follow our WeChat public account immoderately after randomization. They will receive breastfeeding related messages three times a week from WeChat, including preparation for breastfeeding after birth and the health benefits of breastfeeding, from baseline until childbirth. After childbirth, intervention group mothers will continue to receive information, which is mainly about breastfeeding, once a week for 6 months. WeChat will send push notifications to remind mothers about the importance of exclusive breastfeeding, build confidence and motivate them to continue exclusive breastfeeding.
40826770|NCT03552211|DRUG|biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
40826771|NCT03552211|OTHER|propensity score|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
40826772|NCT04806490|DIAGNOSTIC_TEST|the diagnosis for Yin Deficiency Syndrome|The measurement of the standard scale for syndrome differentiation of Yin Deficiency Syndrome
41345704|NCT04513106|BEHAVIORAL|"ACP programme Have a Say"|It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
41018860|NCT04499404|OTHER|Non-breastfeeding related information delivered by WeChat|Participants in the control group will be asked to follow our WeChat public account immoderately after randomization. They will receive messages mainly on topics of healthy lifestyle and nutrition during pregnancy, from baseline until childbirth. After childbirth, they will continue to receive information on other topics of interest to mothers, such as immunization, safety, infant growth, and etc., until 6 months postpartum.
41018861|NCT01110915|DEVICE|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
41018862|NCT01110915|DEVICE|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
41018863|NCT04846127|DEVICE|CanGaroo Envelope|Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure.
41345705|NCT04513106|BEHAVIORAL|Attention-control health talks|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants
41345706|NCT02743546|DRUG|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
40826773|NCT05273216|DIAGNOSTIC_TEST|Transcranial Duplex Sonography|Immediately after mechanical thrombectomy, patients will be investigated with bedside neurosonography (including TCD) at the stroke unit or neurointensive care unit. Apart from routine assessment of brain-supplying vessels, experienced sonographers will especially focus on intracranial blood flow velocities and determine the MCA mean blood flow velocity index (recanalized divided by contralateral artery). To assess potential dynamic blood flow changes, these investigations will be repeated at 24-48 hours after thrombectomy and at day 7 when we expect a (more) stable stroke phase. During these neurosonographic assessments, other important and potentially influential (hemodynamic) parameters such as blood pressure, heart rate and use of vasoactive medications will be documented. Assessment of intracranial blood flow will be standardized to dedicated measuring points.
40826774|NCT05273216|DIAGNOSTIC_TEST|Brain MRI|The investigators will use magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) routinely performed on day 1 after thrombectomy to assess (1) the size and location of acute ischemic damage including (vasogenic) cerebral edema formation, (2) hemorrhagic transformation, (3) concomitant chronic ischemic and hemorrhagic brain changes, and (4) patency of intracranial vessels. Contrast-enhanced or arterial spin labeling perfusion MRI will be used to (5) measure cerebral perfusion status. Findings from perfusion MRI will be correlated with blood flow information from TCD. MRI including MRA and perfusion sequences will be interpreted centrally in Graz as successfully demonstrated in previous large multicenter stroke studies.
40826775|NCT05273216|DIAGNOSTIC_TEST|Blood biomarkers|"Apart from the assessment of outcome-relevant routine blood parameters of inflammation, coagulation, glucose metabolism, renal and liver function, the investigators will also investigate novel biomarkers of interest that could be indicative of endothelial damage / blood brain barrier disruption. Candidate markers for this purpose are interleukins (i.e., interleukin-6) and matrix metalloproteinases (i.e., MMP-9). Furthermore, the investigators will also measure neurofilament light chain protein as a marker for neuro-axonal damage that has been shown to indicate cerebral tissue destruction including vascular brain lesions with a very high sensitivity.~For analysis, peripheral blood will be taken by venipuncture on day one and at follow- up three months after MT. Serum will be immediately stored at -80°C according to international consensus guidelines. Markers will be centrally analyzed in the neurological laboratory of the Department of Neurology, Medical University of Graz."
40826776|NCT01053559|DRUG|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
40826777|NCT00591149|DRUG|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
40826778|NCT00591149|DRUG|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
40826779|NCT00591149|DRUG|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
40826780|NCT01620164|OTHER|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
40826781|NCT02709187|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
40826782|NCT02709187|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
40826783|NCT02709187|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
40826784|NCT02688088|DRUG|Drug Cocktail|Administered orally
40826785|NCT02688088|DRUG|Abemaciclib|Administered orally
41018864|NCT05066841|DRUG|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) for 12 weeks
41345707|NCT02743546|DRUG|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
41345708|NCT05905861|PROCEDURE|Skin incision with scalpel.|"A Pfannenstiel skin incision will be performed using a scalpel, extending through the subcutaneous tissue and rectus sheath. After separation of rectus muscles, peritoneum will be visualized and opened. Optimal hemostasis will be achieved by applying pressure to skin blood vessels and ligating any subcutaneous bleeding.~Group A: skin incision with a scalpel."
41345709|NCT05905861|PROCEDURE|Skin incision with a diathermy.|"A Pfannenstiel skin incision will be made using a scalpel. Subsequently, a diathermy pen electrode will be employed for the dissection of deeper tissues.~Optimal hemostasis will be achieved by using the same blade pen electrode, set to coagulation mode.~Group B: skin incision with diathermy."
41345710|NCT05379933|OTHER|Remote health coaching to improve self-care behaviors|Participants will be asked to wear an activity tracker, complete brief surveys, and participate in weekly health coaching sessions remotely for 8 weeks
41345711|NCT00583830|BIOLOGICAL|Mapatumumab|30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
41345712|NCT00583830|BIOLOGICAL|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
40826786|NCT02248207|DRUG|Pramipexole|
41018865|NCT05066841|DRUG|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) and 90% starch for 12 weeks
41157377|NCT04661150|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.
41157378|NCT04661150|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 will be administered by IV on Day 1 of a 21-day cycle.
40826787|NCT05203978|PROCEDURE|colonoscopy|Colonoscopy
40826788|NCT04143217|DRUG|SPN-812|SPN-812 200 to 600 mg/day
40826789|NCT02494843|OTHER|online Hemodiafiltration|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
40826790|NCT02494843|OTHER|Hemodialysis|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
40826791|NCT04664530|DRUG|esketamine|The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.
40826792|NCT04664530|DRUG|Saline|The titration process in the control group with saline are the same as those in the treatment group with esketamine.
40826793|NCT02210689|DRUG|clindamycin phosphate vaginal cream 2%|
41018866|NCT05059457|DEVICE|Blood source: single and pooled capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
41018867|NCT05059457|DEVICE|Blood source: single capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
41345713|NCT00583830|DRUG|Paclitaxel|200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle
40826794|NCT02210689|OTHER|placebo|vehicle used as placebo
40826795|NCT02975414|PROCEDURE|rTARUP technique|obot-assisted rTARUP technique
41345714|NCT00583830|DRUG|Carboplatin|AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
41345715|NCT01428986|DRUG|Maraviroc|Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
41345716|NCT01307228|OTHER|Health Systems Evidence|Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.
41345717|NCT01865838|DEVICE|Seprafilm (Sanofi, USA)|Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
41345718|NCT04005755|DRUG|Maxigesic® IV|acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
41345719|NCT05124067|DRUG|Dexamethasone|patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
41345720|NCT05124067|DRUG|Ondansetron|patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
41345721|NCT05124067|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine (0.3 μg/kg)
41345722|NCT05124067|DRUG|normal Saline|patients will receive normal saline.
41345723|NCT00579462|OTHER|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
41345724|NCT00353340|DRUG|n acetylcysteine|
41345725|NCT00353340|DRUG|sodium bicarbonate|
41345726|NCT00353340|DRUG|sodium chloride|
41345727|NCT03658967|DRUG|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
41345728|NCT03658967|DRUG|Placebo|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
41345729|NCT01492738|PROCEDURE|Acupuncture|After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
41345730|NCT04236531|OTHER|Cognitive tests and neuroimaging|comparison of cognitive performances and brain anatomy
41345731|NCT02909582|PROCEDURE|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
41345732|NCT04739917|BIOLOGICAL|Vaccine PvCS N+C+R 150 mcg|Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
41345733|NCT04739917|OTHER|Placebo SSN Montanide ISA-51 1 mL|SSN Montanide ISA-51 1 mL
41345734|NCT06409507|GENETIC|FKBP12 expression|The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.
41345735|NCT01563406|OTHER|15 second scrub|Scrub catheter hubs for 15 seconds before every access.
41345736|NCT01563406|OTHER|5 second scrub|Scrub catheter hubs for 15 seconds before every access.
41345737|NCT01563406|DRUG|3.15% chlorhexidine/70% isopropyl alcohol|3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
41345738|NCT01563406|DRUG|70% isopropyl alcohol|70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
41345739|NCT00551967|PROCEDURE|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
41345740|NCT04063397|DIAGNOSTIC_TEST|Echocardiogram|Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months
41345741|NCT04063397|DIAGNOSTIC_TEST|Blood draw|Serial blood draws at same time points as echocardiograms for biomarker levels
41345742|NCT01661504|BEHAVIORAL|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
40826796|NCT04159363|OTHER|An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)|The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
40826797|NCT04392908|OTHER|Communication memory|All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.
40826798|NCT04517786|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
40826799|NCT01359605|DRUG|varespladib methyl|500 mg oral suspension
40826800|NCT01204229|BEHAVIORAL|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
40826801|NCT01204229|BEHAVIORAL|Brief Motivational Intervention (BMI)|Integrate drinking intervention
40826802|NCT00000558|DRUG|angiotensin-converting enzyme inhibitors|
40826803|NCT04348045|DRUG|Arm A - Olaparib|"300 mg orally twice daily, for a total daily dose of 600mg~Study treatment can be dose-reduced to :~First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued."
40826804|NCT04348045|DRUG|ARM B - durvalumab plus selumetinib|"Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily~Study treatment can be dose-reduced to :~Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily"
40826805|NCT04348045|DRUG|ARM C FOLFIRI|FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
40826806|NCT06008769|BEHAVIORAL|12 Week Manualized Cognitive-Behavioral Therapy Intervention|The manualized intervention, Cognitive Behavioral Therapy for Opioid Use Disorder, was co-written and developed by the study PI, Dr. Lent (see Appendix). The manual consists of one module (Module 0) on assessment and 12 modules of CBT. This study will focus on delivery of Modules 1-12 that focus on several tenets of CBT, including skill development (cognitive restructuring, refusal skills, problem-solving, coping strategies), functional analysis (triggers, reinforcement) and utilizing the cognitive model.
40826807|NCT01070563|OTHER|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
40826808|NCT04811443|DRUG|Empegfilgrastim|Extimia®
40826809|NCT04015583|BEHAVIORAL|exergaming group|Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
41345743|NCT01287988|DRUG|ocriplasmin|Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
41345744|NCT01287988|DRUG|placebo|Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
41345745|NCT01128452|DRUG|EVT 101|HPMC Capsule, 15 mg, once daily for 28 days
41345746|NCT01128452|DRUG|Placebo|HPMC Placebo capsules, once daily for 28 days
41345747|NCT04265092|DRUG|Incobotulinum toxin A|Treatment consisted of 200 IU of incobotulinum toxinA injected into the TS. Outcome measures were assessed before injection, at 6 weeks and 3 months post-injection, using the Goal Attainment Scale (GAS), Twelve Item MS Walking (MSWS-12) Scale, Timed Up and Go (TUG) Test, 6 Minute Walk Test (6MWT). Spatiotemporal gait data was obtained by GAITRite.
40826810|NCT00688246|OTHER|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture \[Lønning 2005\]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk \[Looker 2000\]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
41018868|NCT05059457|DEVICE|Blood source: pooled capillary and venous blood|"* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
41345748|NCT03019172|COMBINATION_PRODUCT|Lactobacillus reuteri|Sachet one contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica. The products will be taken twice per day, morning and evening. The daily dose in the active group will be at least 5\*10\^8 CFU of L.reuteri DSM16666 and L. reuteri DSM17938), PAC-A and zinc
41345749|NCT03019172|DIETARY_SUPPLEMENT|Sachet with cranberry + placebo|Sachet one contains placebo for probiotics (maltodextrin). Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
40826811|NCT00688246|PROCEDURE|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
41018870|NCT01873482|BEHAVIORAL|Movement to rhythm|Movement to rhythm
41018871|NCT02284997|DEVICE|MGDRx® EyeBag|Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
41018872|NCT01623219|BEHAVIORAL|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
41018873|NCT02090907|DRUG|Levothyroxine|
41018874|NCT02090907|DRUG|Placebo|
41018875|NCT03467958|DRUG|Ozanimod|Specified dose on specified days
41018876|NCT03833544|OTHER|Exercise training|Progressive resistance training of hip, knee, and ankle flexors.
41018877|NCT06474793|OTHER|Aromatherapy Intervention Group-1|For four weeks, once a day, 30 minutes before going to bed, a mixture of 3% chamomile and 3% lavender oil, diluted with 2% jojoba oil, is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the right and left nose for 4 minutes. It is the group that massages the edges of the hole with the index finger in circular movements from top to bottom, and then drops 2 ml of the oil mixture into the palm of the hand, rubs the hands mutually, and gently massages the edges of the ear with the index finger in circular movements from top to bottom behind the right and left ears for 4 minutes.
41018878|NCT06474793|OTHER|Aromatherapy Intervention Group-2|For four weeks, once a day, 30 minutes before going to bed, 3% vetiver oil diluted with 2% jojoba oil is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the edges of the right and left nostrils from top to bottom with the index finger for four minutes. It is a group where massage is applied with a massager and then 2 ml of the oil mixture is dropped into the palm of the hand, the hands are rubbed mutually, and then a gentle massage is applied behind the right and left ears with circular movements from top to bottom for 4 minutes.
41157379|NCT06358339|OTHER|TEEM|The TEEM app will provide four types of gamified intervention elements as Routine Tracker, Mind Care, Social Connectivity, and Achievement \& Rewards which providing services including brief contact intervention, mCBT, health education, venting space, mood sharing, etc. Only enrolled participants have access to log in and use the app.
41157380|NCT03470103|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Use of intravitreal aflibercept in routine clinical practice in Latin America
41157381|NCT01502202|DRUG|Gefitinib|Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
41345750|NCT02799628|BEHAVIORAL|intervention|intervention with recommendation and therapist introduction
41345751|NCT02799628|OTHER|placebo|low back pain education, and physical therapy 3 times per week
41345752|NCT04699240|DRUG|clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
41345753|NCT04699240|DRUG|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months Human Reproductive Tract Active Lactobacillus,4g,qd ,3months
41490488|NCT02945605|OTHER|Early Vestibular Rehabilitation|"Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:~1. Eye-Head coordination, gaze stability and convergence exercises~2. Sitting balance~3. Standing static balance (i.e. feet-in-place)~4. Dynamic balance (feet moving, but not walking)~5. Ambulation (gait exercises)~6. Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others"
40826812|NCT05823844|DRUG|Suvorexant|Suvorexant (Belsomra™) is an orexin receptor antagonist that will be administered as 2 tablets (10mg each) for a starting dose of 20mg. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant.
41345754|NCT00062595|DRUG|phylloquinone (K1)|
41345755|NCT00062595|DRUG|menatetranone (MK4)|
41345756|NCT03780985|PROCEDURE|Intrauterine device insertion|Post-placental insertion of intrauterine device during Cesarean section
41345757|NCT03780985|PROCEDURE|Cesarean section|to delivery of the fetus
41345758|NCT03780985|PROCEDURE|Suture|to fix the intrauterine device
41345759|NCT04729595|DRUG|Tempol|Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.
41345760|NCT04729595|OTHER|Placebo|Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.
41345761|NCT02993289|OTHER|Different well-known treatments|
41345762|NCT01547676|PROCEDURE|robot-assisted laparoscopic surgery|Unclamped partial nephrectomy
41345763|NCT01547676|PROCEDURE|robot-assisted laparoscopic surgery|Undergo clamped partial nephrectomy
41490489|NCT02945605|OTHER|Standard of Care|Standard care as directed by a physician.
41490490|NCT02201238|DRUG|Diclofenac sodium|Diclofenac sodium
41490491|NCT02201238|DRUG|Menthol|Menthol
41490492|NCT01494935|BEHAVIORAL|High Glycemic Diet|NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
41490493|NCT01494935|BEHAVIORAL|Control diet|Normal fat, normal fat diet
41345764|NCT02569645|DRUG|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
40826813|NCT05823844|DRUG|Placebo|The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
41345765|NCT03079518|DRUG|Ferric Carboxymaltose|single shot infusion
41157382|NCT01502202|DRUG|Placebo|Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
41345766|NCT03079518|OTHER|blood withdrawal|for determination of serum and urinary biomarkers of chronic kidney disease metabolism and other parameters
40826816|NCT00428220|DRUG|sunitinib|sunitinib
40826817|NCT00219882|DRUG|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
40826818|NCT02815436|OTHER|Telephone reminder|a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening
40826819|NCT02815436|OTHER|SMS reminder|a one-way, SMS message sent from the centre to the screening participant's mobile phone
41345767|NCT00236106|DRUG|tacrolimus ointment 0.1%|
41345768|NCT00236106|DRUG|mometasone furoate 0.1%|
41345769|NCT03032523|DIAGNOSTIC_TEST|Standard of care glucose test|If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
41345770|NCT06166251|BEHAVIORAL|low ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.
41345771|NCT06166251|BEHAVIORAL|moderate ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.
41345772|NCT06006143|DRUG|Varenicline|All participants will receive a prescription for varenicline and will meet with a clinical pharmacist and addiction psychiatrist for further support
41345773|NCT04490265|BEHAVIORAL|Problem-solving treatment|included in arm descriptions
41345774|NCT04490265|BEHAVIORAL|Supportive Psychotherapy|included in arm descriptions
41345775|NCT06169891|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|one s.c. injection of SSGJ-613 once, on Day 1.
41345776|NCT06169891|OTHER|Placebo|Participants will receive Placebo matching Compound Betamethasone Injection to maintain the blinding of the Investigational Medicinal Products.
41345777|NCT06169891|DRUG|Compound Betamethasone Injection|1 mL i.m. once on Day 1
41345778|NCT06169891|OTHER|Placebo|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
41345779|NCT00090766|DRUG|valganciclovir [Valcyte]|po daily (dose based on body surface area and CrCL)
41345780|NCT02149186|DEVICE|iCTuS-L|
41345781|NCT01404806|DRUG|GSK1349572 (dolutegravir)|Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
41345782|NCT01197495|DEVICE|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.
41345783|NCT00747708|DRUG|Granulocyte-colony stimulating factor|5 days subcutaneous injection
41345784|NCT00747708|PROCEDURE|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
41490494|NCT00561561|BEHAVIORAL|Acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
41490495|NCT06332287|DRUG|combination of Trilaciclib and Pemetrexed|This was a single-arm, exploratory study of the combination of Trilaciclib and Pemetrexed in patients with non-small cell lung cancer with leptomeningeal metastasis. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every six cycles to assess tumor response.
41490496|NCT02620150|DRUG|Escitalopram|10 week trial
41490497|NCT02620150|OTHER|Placebo|10 week trial
40826820|NCT04656795|DRUG|MT-7117|MT-7117
40826821|NCT01217320|DIETARY_SUPPLEMENT|creatine|5g/d throughout 12 weeks
40826822|NCT01217320|DIETARY_SUPPLEMENT|placebo (dextrose)|5g/d throughout 12 weeks
40826823|NCT01636388|BIOLOGICAL|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
40826824|NCT05826730|OTHER|Eccentric Exercises|Eccentric Exercises for neck muscles.
40826825|NCT05999526|OTHER|Reconnection to mechanical ventilation for 1 hour|As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
40826826|NCT05999526|OTHER|Direct extubation|The participant will be extubated immediately after the spontaneous breathing trial.
40826827|NCT04909502|DRUG|EHP-101 25 mg OD|25 mg OD during the first 28 Days of the trial
41345785|NCT00747708|PROCEDURE|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
40826828|NCT04909502|DRUG|EHP-101 25 mg BID|25 mg BID during the first 28 Days of the trial
40826829|NCT04909502|DRUG|EHP-101 50 mg OD|After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
40826830|NCT04909502|DRUG|EHP-101 50 mg BID|After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
41345786|NCT02355925|DRUG|intrauterine injection of uhCG|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
41345787|NCT02355925|DRUG|Placebo|only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
41345788|NCT02355925|OTHER|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
41345789|NCT02798445|OTHER|TAPIRS|Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system
41345790|NCT02798445|OTHER|CONTROL|Multilayer bandages and wound care
41490498|NCT05324826|DEVICE|Butterfly Network handheld ultrasound|Patients would be examined with a handheld US machine which would allow for dynamic imaging chairside and could easily be integrated into both hospital-based and private clinical practices. This would allow the patient to benefit from realtime imaging and a faster preliminary diagnosis with virtually no additional risks.
40826831|NCT00353431|DRUG|Novorapid ®, Novo Nordisk, Denmark|Comparison of a sliding scale with an intensive s.c. scale
40826832|NCT00628589|DRUG|Inhaled loxapine 5 mg|Inhaled loxapine 5 mg
40826833|NCT00628589|DRUG|Inhaled loxapine 10 mg|Inhaled loxapine 10 mg
40826834|NCT00628589|DRUG|Inhaled placebo|Inhaled placebo
41345791|NCT00417391|DRUG|RR110 (Tamibarotene)|1 mg RR110
41345792|NCT00417391|DRUG|RR110 (Tamibarotene)|4 mg RR110
41345793|NCT01185912|PROCEDURE|Ventricle muscle tissue samples|
41345794|NCT06053281|DRUG|Cholecalciferol|Daily Cholecalciferol 1000 IU in 24 weeks
41345795|NCT06053281|OTHER|Placebo|Placebo
41345796|NCT03344562|DEVICE|CES|Patients will receive cranial electrical stimulation once a day for 20 minutes over 7 days. They will be allowed to increase the stimulation level on Day 2. A wrist worn actigraph will record sleep. Patients may elect to receive standard of care sleep medication if not satisfied with sleep.
41345797|NCT03344562|DEVICE|CES|Patient will receive sham electrical stimulation once a day for 20 minutes over 7 days.
41345798|NCT02979340|PROCEDURE|MRI|non-invasive assessment of hepatic fibrosis and steatosis
41345799|NCT01656018|DRUG|TMC278, Long acting (LA)|TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
41345801|NCT02557815|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
41345802|NCT04252391|PROCEDURE|Perineural electrical dry needling|Standard care plus use of perineural electrical dry needling involving use of a monofilament needle of 15 or 30 mm length, 0.25 mm diameter will be placed utilizing the therapist's dominant hand following palpation of correct needle location. An electrical stimulation unit will be used to conduct an electrical impulse. The unit used will be an ES-130 by ITO (Japan) using a DC 9V battery producing an asymmetrical biphasic waveform. The unit has 6 available leads with alligator clamps, connecting to needle shafts. Parameters of PNED will include intensity set at a strong yet comfortable setting according to patient feedback. Treatment duration will be 15 minutes. Treatment frequency will be set to Medium at level 8 (80 Hz). Parameters will be set to elicit a sensory response.
41345803|NCT04252391|PROCEDURE|Standard Care|cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, electrical trigger point dry needling , soft tissue release and prescribed therapeutic exercises .
41345804|NCT01968915|DRUG|LCL161|Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
41345805|NCT01968915|DRUG|Paclitaxel|Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
41345806|NCT05353907|RADIATION|Whole Body MRI|Once recruited, the participant will undergo a WB-MRI scan as part of their usual standard-of-care. As part of the research study, the participant will be consented to undertake an additional WB-DECT research scan at a time of their choosing (on the same day as the MRI scan, or on another day, if preferred)
41345807|NCT03942640|OTHER|subctaneous perineural injection|"Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection"
41345808|NCT03942640|OTHER|deep prolotherapy|The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine
41345809|NCT03194204|DRUG|Doxycycline Tablets|MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
41345810|NCT03954184|BEHAVIORAL|NIATx-TI with Product Training/On-line Support|NIATx-TI framework includes the product training as well as a preimplementation phase and a post-implementation phase. A NIATx-TI coach will provide the training for this arm. The coach will also assist the organizations with applying the NIATx-TI framework.
41345811|NCT01006694|OTHER|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
41345812|NCT01006694|DRUG|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
41345813|NCT05875012|OTHER|action observation physical training|Action observation training 3 sessions per week for 3 successive months
41345814|NCT05875012|OTHER|Traditional physical therapy training|Traditional physical therapy training 3 sessions per week for 3 successive months
41345815|NCT00469040|DRUG|GW642444M for 14 days|M salt
40826835|NCT04465318|OTHER|E-cigarette (EC)|NJOY Daily E-cigarettes are self-contained and non-refillable. Each DAILY provides approximately 300 puffs, comparable to a full pack of cigarettes.
40826836|NCT04465318|OTHER|Nicotine Replacement Therapy (NRT)|Participants in the NRT arm will receive 21 mg nicotine patch (for those with CPD \>= 20) or 14 mg nicotine patch (for those with CPD \< 20) + 4 mg nicotine gum. CPD stands for Cigarettes Per Day.
40826837|NCT04465318|BEHAVIORAL|Smoking Harm Reduction Counseling Sessions|Counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects know to contribute to smoking among people with COPD (e.g., tips on dealing with depression)
40826838|NCT01144260|DRUG|bafetinib|250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
40826839|NCT05004038|BIOLOGICAL|BCG Vaccine AJVaccines|Single intradermal injection of BCG Vaccine according to published Summary of Product Characteristics
41490499|NCT04001920|OTHER|Training program|12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
40826840|NCT02020772|OTHER|coordinating primary health care|
41490500|NCT03538119|OTHER|High Intensity Interval Training Program|"The HIIT group performed 4 × 4-minute high-intensity intervals at 85%-95% HRpeak followed by a 1-minute recovery interval at 40% HRpeak, predicted with a supervised graded exercise test on a treadmill with the Bruce protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
40826841|NCT02020772|OTHER|usual primary health care|
41490501|NCT03538119|OTHER|Moderate Intensity Continuous Training Program|"The MICT protocol (usual care) consisted of a continuous bout of moderate-intensity exercise to elicit 70-75% HRpeak, rating of perceived exertion 3 to 5 (fairly light to somewhat hard), for 27.5 minutes to equate the energy expenditure with the HIIT protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
41345816|NCT03607604|GENETIC|Next generation sequencing (NGS)|Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
41490502|NCT02803229|DRUG|Adderall-XR|
41490503|NCT02803229|DRUG|Matched placebo|matched placebo provided for placebo arm
41490504|NCT03712839|OTHER|Cognitive-functional evaluation|The participants will be evaluated with a set of tools within the context of meaningful ADL.
41490505|NCT04671030|DRUG|Neostigmine and Glycopyrrolate|Intravenous followed by transdermal administration of the two drug combination.
41490506|NCT04671030|DEVICE|Iontophoresis|Application of direct current to skin using an FDA-approved device
40826842|NCT02061397|DRUG|Simvastatin|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
40826843|NCT02061397|DRUG|Sirolimus Oral Product|Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
40826844|NCT02061397|DRUG|Everolimus Oral Product|Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
40826845|NCT01976858|DRUG|PEX168|A injection administered subcutaneously
40826846|NCT04053751|PROCEDURE|closed suctioning system|a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
40826847|NCT01892761|DRUG|Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups|
40826848|NCT05891886|DRUG|Oxygen Therapy|Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
40826849|NCT05891886|DEVICE|Non-rebreather mask|Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
41345817|NCT00858975|PROCEDURE|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
40826850|NCT05526144|DRUG|Synthroid|Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.
41345818|NCT04024735|DIAGNOSTIC_TEST|Spirometry, Forced Oscillation Technique, Step-counter, sputum and blood samples|We will be collecting demographic and clinical information including daily physical activity level, lung function, blood and sputum samples. These measurements will be collected at patient admission, discharge and at follow-up of 30 and 90 days.
41018879|NCT06474793|OTHER|Aromatherapy Placebo Control Group|For four weeks, once a day, 30 minutes before going to bed, 2 ml of jojoba oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the edges of the right and left nostril with circular movements from top to bottom with the index finger for four minutes and apply jojoba oil to the palm again. It is a group in which 2 ml is dropped and the hands are rubbed together and then gently massaged behind the right and left ears with circular movements from top to bottom for 4 minutes.
41345819|NCT02095249|DRUG|Pimonidazole|Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
41345820|NCT01836549|DRUG|imetelstat sodium|Given IV
41345821|NCT04745689|DRUG|Durvalumab|"IV infusions through induction phase.~IV infusions through maintenance phase until PD or other discontinuation criteria."
41345822|NCT04745689|DRUG|AZD2811|IV infusions through maintenance phase until PD or other discontinuation criteria.
41345823|NCT04745689|DRUG|Carboplatin|IV infusions through induction phase if chosen by Investigator.
41345824|NCT04745689|DRUG|Cisplatin|IV infusions through induction phase if chosen by Investigator.
40826851|NCT05526144|DRUG|Placebo|Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
41345825|NCT04745689|DRUG|Etoposide|IV infusions through induction phase.
41345826|NCT02049294|BIOLOGICAL|Omalizumab (Xolair)|
41345827|NCT02049294|DRUG|Placebo|
41345828|NCT05126550|BIOLOGICAL|SARS-CoV-2 vaccine (Vero cell) inactivated|"Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with Vaksinasi Gotong Royong (mutual cooperation vaccination program)"
40826852|NCT01206283|PROCEDURE|Modified Lund concept|"After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:~* Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);~* Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;~* Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;~* Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.~* Control of ICP, which can be in majority of patients, kept at values below 15 mmHg."
40826853|NCT01206283|PROCEDURE|Cerebral perfusion pressure-targeted therapy|"* ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);~* Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);~* No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;~* Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes \[Na, Cl and K\]);"
41345829|NCT05776355|BIOLOGICAL|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
41345830|NCT01654393|OTHER|Triage nurses applying the OAR|Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
41018880|NCT05409924|DRUG|ATR-258|Single Ascending Dose
41018881|NCT05409924|DRUG|ATR-258|Multiple Ascending Dose
41018882|NCT05409924|DRUG|ATR-258|Repeat Dose
41018883|NCT00123981|PROCEDURE|Off-Pump Coronary Artery Bypass Grafting|
41018884|NCT02096055|DRUG|Cladribine|Given IV
41345831|NCT01594086|DIETARY_SUPPLEMENT|green tea powder|Consuming 2 g/day of green tea powder in three times divided for 3 months
41018885|NCT02096055|DRUG|Guadecitabine|Given SC
41018886|NCT02096055|DRUG|Idarubicin|Given IV
41018887|NCT05809895|DRUG|Ociperlimab|900 mg intravenously (IV) every 3 weeks (Q3W)
41018888|NCT05809895|DRUG|Tislelizumab|200 mg intravenously (IV) Q3W
41345832|NCT03844139|DEVICE|Feeding pump and glycerin syringe|The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.
41345833|NCT00669513|BEHAVIORAL|Partial sleep deprivation|Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
41345834|NCT06289504|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously once weekly.
41345835|NCT06289504|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
41345836|NCT06289504|DRUG|Atorvastatin|Atorvastatin will be administered as a single dose orally 2 times during the study.
41345837|NCT06289504|DRUG|Warfarin|Warfarin will be administered as a single dose orally 2 times during the study.
41345838|NCT01427127|DRUG|Ramosetron|Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
41345839|NCT06245304|DEVICE|Dual chamber Medtronic pacemaker implantation.|"All patients will undergo a dual chamber Medtronic pacemaker implantation meeting approved indications for pacemaker implantation per Centers for Medicare \& Medicaid Services (CMS) guidelines.~Pacemaker Model: Azure XT W1DR01. Right ventricular lead model: Medtronic 3830."
41345840|NCT06245304|OTHER|DDD-50 pacing program|This device programming attempts to increase the amount of ventricular pacing via the Medtronic 3830 lead. Since the enrolled patients have a prolonged PR interval, this programming attempts to synchronic atrial and ventricular contractions.
41490507|NCT05007314|BEHAVIORAL|Biocriminological Evidence|Participants in each of the two main groups see a case with and a case without a neurobiological explanation for criminal offending.
41490508|NCT05986331|DRUG|BCD-201|up to 8 treatment cycles
41345841|NCT06245304|OTHER|AAI-DDD 50 pacing program|This device programming attempts to encourage native conduction and minimize ventricular pacing via the Medtronic 3830 lead. This programming attempts to minimize ventricular pacing, which has been associated with worse outcomes by causing ventricular dyssynchrony between the left and right ventricles.
41345842|NCT06244524|OTHER|High indoor CO2 exposure|The participants will stay and sleep for eight hours in a closed bedroom.
41345843|NCT01614275|BEHAVIORAL|Technology-Enhanced Parent Training|"The training for the parents of children with autism assigned to the EIBI group will begin with completion of a structured parent-training program for 6 weeks that includes 16 to 18 sessions (three, 90-minute sessions per week). When a new topic is introduced, the initial training will include viewing a Power Point presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a parent recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
41490509|NCT05986331|DRUG|Keytruda|up to 8 treatment cycles
41490510|NCT03456895|OTHER|Light perception|We will be using Wi-Fi/IP programmable LED lighting systems that will replace conventional lighting systems and may be in canned lights, spot lights, light chains or table lights. These lighting systems can be fully controlled by web based applications on smart phones tablets and computer systems and can be combined with input systems such as switches, motion detection or voice activated. Differences in lighting perception will be explored by varying lighting color and brightness.
40826854|NCT03470129|DEVICE|fissure sealing|sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
40826855|NCT03592719|BEHAVIORAL|Experimental Intervention (MI-PrEP)|The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
40826856|NCT03592719|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
40826857|NCT00031746|DIETARY_SUPPLEMENT|soy protein isolate|25 mg daily
41345844|NCT01614275|BEHAVIORAL|Technology-Enhanced Tutor Training|"The training for the tutors to work with children diagnosed with autism, who were assigned to the EIBI group, will complete a 40-hour structured training program for 4 to 8 weeks that includes approximately 32 sessions. When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a tutor recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
41490511|NCT03456895|OTHER|Sound perception|We will be using Wi-Fi/Bluetooth addressable sound systems that will be linked with sound sources such as media players on smart devices or computer systems. Differences in sound perception will be explored by varying sound types (i.e. different music types, ambient noise, etc.).
41490512|NCT03456895|OTHER|Smell perception|We will explore the use of consumer grade ventilation systems that can be equipped to distribute packaged scents. Differences in smell perception will be explored by varying the types of scents.
40826858|NCT00031746|DIETARY_SUPPLEMENT|casein proteins|25 mg daily
41490513|NCT03456895|OTHER|Vibration perception|We will explore the use of chairs or blankets that enable subjects to perceive vibrations. An initial implementation will be the use of on relaxing/massage chair that enables the experience of vibration sensation in the back or leg area. We may use also potentially vibration blankets in the arm or neck area. Differences in vibration perception will be explored by varying the location, frequency, etc. of vibrations with the subject being placed in a chair on an imaging table/bed.
41490514|NCT03456895|OTHER|Voice activation|We will explore the use and linkage of voice activation system such as Amazon Echo, Google home or similar devices. Some participants may be asked to use voice activations to verbally select and/or change the environmental settings according to their preferences. We are evaluating the feasibility of voice activation with the imaging environment.
41490515|NCT00006235|DRUG|carboplatin|
41490516|NCT00006235|DRUG|pegylated liposomal doxorubicin hydrochloride|
41490517|NCT00230074|DRUG|TCH346|
40826859|NCT04847895|DRUG|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription that have started before inclusion of the patient into the study will be enrolled.
40826860|NCT00383734|DEVICE|Newfill|1 to 7 injections of drug
40826861|NCT00383734|DEVICE|Eutrophill|1 to 7 injections of drug
41345845|NCT01614275|BEHAVIORAL|Technology-enhanced Early Intensive Behavioral Intervention|After training, the ABA tutor and parents will assist in the implementation of early intervention services that will be tailored to the particular needs of the family's child. These programs could include conducting a paired-stimulus preference assessment, using a natural language program to increase spoken communication, and using matching-to-sample methods to teach categorization skills. We will record and review at least an hour of the ABA tutor's and parents' interactions with the child per week during unstructured and structured teaching situations. The purpose of these observations is to determine whether the parents are implementing the teaching strategies or behavior-management programs as designed (i.e., treatment integrity measures). If the ABA tutor or parent implements a program with less than 80% accuracy across two consecutive observations, an additional scripted role-play will be conducted as a booster session for the targeted skills.
41345846|NCT01614275|BEHAVIORAL|No-Intervention|The ABA tutors, parents/caregivers, and children will be randomly assigned to a wait-list control group.
41345847|NCT00517634|DRUG|FP|Fluticasone Propionate 100 mcg BD
41345848|NCT00517634|DRUG|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
41345849|NCT00517634|DRUG|Placebo|Matching Placebo
41345850|NCT00378534|DEVICE|Miltenyi reagent system|Miltenyi Clinimax CD34 Reagent System for CD34 selection and delayed T cell depletion add back
41345851|NCT00378534|DRUG|Fludarabine|Therapeutic
41345852|NCT00378534|DRUG|Cyclosporine|Therapeutic
41345853|NCT00378534|DRUG|Cyclophosphamide|Therapeutic
41345854|NCT00378534|OTHER|FILGRASTIM (G-CSF)|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. Stem cell Donors will receive G-CSF for stem cell mobilization. The stem cell collection aspect of this protocol is not investigational.
41345855|NCT00921570|DRUG|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
41345856|NCT00921570|DRUG|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
41345857|NCT06153628|OTHER|Virtual reality glasses|Videos consisting of nature and undersea images will be played through virtual reality glasses, which the woman wants to watch and can change whenever she wants.
41345858|NCT00194415|BEHAVIORAL|Safer-sex counseling|Subjects will receive safer-sex counseling during pregnancy
41345859|NCT00194415|PROCEDURE|Type specific serologic HSV testing|Subjects will be testing for HSV by Western Blot
41345860|NCT02515773|DRUG|Metformin|Metformin - to achieves maximum insulin-sensitizing effects
41345861|NCT02515773|BEHAVIORAL|healthy lifestyle intervention (LIFE)|Healthy Life style intervention
41345862|NCT04827173|PROCEDURE|transcutaneous medium-frequency alternating current|Patients receive nerve block of right forearm through transcutaneous medium-frequency alternating current
41490518|NCT03703648|RADIATION|Radiotherapy (curative) for head and neck cancer|Curative intent radiotherapy for head and neck cancer. Doses will be prescribed by an independent Clinical Oncology team. There will be no alteration or experimentation of radiotherapy dosage
40826862|NCT00961246|BEHAVIORAL|general health information|participants received general health information
40826863|NCT00961246|BEHAVIORAL|individually-tailored intervention|participants received individually-tailored intervention
41345863|NCT02651376|COMBINATION_PRODUCT|Conventional plus AAIT|Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
41345864|NCT01602744|OTHER|STOPP/START screening tools for medication intervention|In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
41345865|NCT03745391|DIAGNOSTIC_TEST|MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)|After randomization, a MULTIMODAL MR will be performed to select treatment patient
41345866|NCT03745391|DIAGNOSTIC_TEST|MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)|After randomization, a MULTIMODAL CT will be performed to select treatment patient
41345867|NCT00381108|DRUG|Placebo Tablet|Two tablets, twice daily.
41345868|NCT00381108|DRUG|Pomegranate Tablet|Two tablets, twice daily.
41345869|NCT03885674|OTHER|Video Call Reminder Condition|Receive daily video call reminders from Kessler Foundation research staff directly at the time of each medication dose and instructed to take the medication while on the video call.
40826864|NCT00884910|DEVICE|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
41345870|NCT03885674|OTHER|Automated Text Message Reminder Condition|Receive daily automated text messages at the time of each medication dose and will be instructed to take the medication at that time. Each text message reminder will also contain a photo of the medication to be taken. On a weekly basis, study personnel will contact participants in this group to make sure they are receiving the text messages appropriately.
41345871|NCT00608244|DRUG|LCP Tacro|"In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.~LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.~Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL."
41490519|NCT00816361|DRUG|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
41490520|NCT02161120|OTHER|Traditional Finnish rye bread|
41490521|NCT02161120|OTHER|Low FODMAP rye bread|
41490522|NCT00397306|DEVICE|Bioimpedance Analysis|
41490523|NCT00797329|OTHER|chart review|"* cholesterol~* cognitive profiles~* violent behavior"
40826865|NCT05176002|DRUG|Camrelizumab|Neoadjuvant Camrelizumab combined with radiotherapy
40826866|NCT02962596|OTHER|ADNEXMR SCORING system|Scoring system used to standardize the imaging report for sonographically indeterminate adnexal masses.
40826867|NCT05773261|DEVICE|MobilLINK TrabecuLINK cup|THA with MobilLINK TrabecuLINK cup and LCU stem
41490524|NCT03682224|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site
41490525|NCT03682224|DRUG|Bupivacaine-Epinephrine|Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
41345872|NCT00608244|DRUG|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
41345873|NCT00349024|DRUG|polyvinylpyrrolidone-sodium hyaluronate gel|
41345874|NCT06256094|DIETARY_SUPPLEMENT|a2 Platinum Premium Infant Formula Stage 1|Oral intake of a2 Platinum Premium Infant Formula Stage 1 milk powder (dissolved in water)
41345875|NCT06256094|DIETARY_SUPPLEMENT|Frisolac Infant Formula Stage 1 (Dutch Edition)|Oral intake of Frisolac Infant Formula Step 1 (Dutch Edition) milk power (dissolved in water)
41345876|NCT01733524|BEHAVIORAL|Pet Fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
41345877|NCT01733524|BEHAVIORAL|Picture of a fish|Participants will receive a picture of a betta fish.
41345878|NCT01782612|PROCEDURE|Multimodal analgesic techniques|Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
41345879|NCT01782612|PROCEDURE|Total uni-Hip Replacement|All subjects will undergo standard Total uni-Hip Replacement
41345880|NCT02084875|DRUG|tofacitinib modified-release (MR) formulation|A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.
41345881|NCT02084875|DRUG|tofacitinib modified-release (MR) formulation|tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
41345882|NCT01326910|DRUG|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
41345883|NCT01326910|DEVICE|Topical Cream|Topical cream applied twice daily (or as needed)
41345884|NCT04526444|DEVICE|Fitness tracker|Fitness tracker Mi Smart Band 5 with the computational algorithm PAI
41345885|NCT04526444|OTHER|Online training|Les Mills On Demand
41345886|NCT04526444|OTHER|Peer support via social media|Facebook group
41345887|NCT01424306|OTHER|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.
41345888|NCT01424306|OTHER|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.
41345889|NCT01424306|OTHER|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.
41345890|NCT03486184|DIAGNOSTIC_TEST|Cystatin-C|"* Laboratory values will be obtained, including level of preoperative serum creatinine, complete blood count, coagulation profile and Cystatin-C (5 ml. venous sample).~* Serum creatinine and hemoglobin will be measured after operation, and thereafter at least once a day as a part of routine clinical care. Postoperative serum Cystatin-C will measured only once."
41345891|NCT02355665|DRUG|Nicotine Spray|Nicotine Spray
41345892|NCT02355665|DRUG|Placebo|Placebo to match nicotine spray
41345893|NCT05247060|OTHER|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
41345894|NCT04246489|DRUG|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, death, unacceptable toxicity and study withdrawal.
41490526|NCT05258630|BEHAVIORAL|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool to the patient's needs/goals and tailored diabetes education as needed.
41345895|NCT01028040|DRUG|AZD3043|Intravenous, single dose
41345896|NCT01028040|DRUG|AZD3043|Infusion, single dose
41345897|NCT00674024|DRUG|Pazopanib|
41345898|NCT00674024|DRUG|Pazopanib (GW786034)(GW786034)|
41345899|NCT00251186|DRUG|Capecitabine and Cetuximab|
41345900|NCT04168905|DEVICE|AOTI Inc. TWO2 topical oxygen therapy equipment|Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
41345901|NCT04684160|DEVICE|Fixed-bearing TKA|
41345902|NCT04684160|DEVICE|Mobile-bearing TKA|
41345903|NCT01572480|DRUG|Carfilzomib|Carfilzomib intravenous (IV) 20-36 mg/m\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.
41345904|NCT01572480|DRUG|Revlimid|Revlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.
41345905|NCT01572480|DRUG|Dexamethasone|Dexamethasone by mouth (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
41018889|NCT05809895|DRUG|Paclitaxel|90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
40826868|NCT05773261|DEVICE|Pinnacle Gription cup|THA with Pinnacle Gription cup and Coral stem
41345906|NCT02930811|DRUG|Sildenafil 100 mg oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
40826869|NCT00815191|DEVICE|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
40826870|NCT00815191|DEVICE|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
40826871|NCT04149223|OTHER|Evidence-based standardized Cirrhosis order set|Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
41345907|NCT02930811|DRUG|Placebo oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
41345908|NCT02721290|PROCEDURE|Femoral nerve block using Ultrasound and neurostimulator|
41345909|NCT02721290|PROCEDURE|Femoral nerve block using Ultrasound|
41345910|NCT02721290|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
41345911|NCT00054756|DRUG|TRH (Thyrotropin Releasing Hormone)|
41345912|NCT00998985|DRUG|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
41345913|NCT00998985|DRUG|Placebo|Placebo tablet, orally, once a day for 7 days
41345914|NCT03827070|DRUG|Afatinib|Used Afatinib particles of which had an average size of 22 μm and a volume concentration of small particles (\<5 μm) - only 19%
41345915|NCT03827070|DRUG|Talcum powder|Used Talcum powder particles of which had an average size of 24.5 μm and a volume concentration of small particles (\<5 μm) - only 11%
41345916|NCT00028964|DIETARY_SUPPLEMENT|Chinese herbs|
41345917|NCT00028964|DRUG|cyclophosphamide|
41345918|NCT00028964|DRUG|doxorubicin hydrochloride|
41345919|NCT00028964|PROCEDURE|adjuvant therapy|
41490527|NCT05258630|BEHAVIORAL|Enhanced usual care|Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
41490528|NCT00653679|OTHER|exercise|1 hour of endurance or resistance exercise
41490529|NCT01846013|BEHAVIORAL|Stand|Stand at least half of the workday at work.
40826872|NCT01274780|DRUG|Darunavir / Ritonavir + Tenofovir / Emtricitabine|oral, 800/100 mg, qd + oral, 300/200 mg, qd
41345920|NCT01655940|DEVICE|Somanetics cerebral oximeter|Somanetics cerebral oximeter
41345921|NCT01655940|DEVICE|CASMED cerebral oximeter|CASMED cerebral oximeter
41345922|NCT04162912|BEHAVIORAL|Motivational Interviewing tailored Advance Care Planning|The trained interventionist who is experienced in MI techniques will explore their illness experiences, emotions and beliefs about their health conditions and future care in an empathetic manner and explore their ambivalence for ACP behaviours.
41345923|NCT00439894|PROCEDURE|Blood draw|blood draw at baseline, week 12 and week 24
40826873|NCT01274780|DRUG|Atazanavir / Ritonavir + Tenofovir / Emtricitabine|oral, 300/100 mg, qd + oral, 300/200 mg, qd
40826874|NCT04963114|BEHAVIORAL|art therapy|guided art tour and workshop
41345924|NCT04570228|DEVICE|Pulmonary artery denervation|The TIVUS system will be used for pulmonary artery denervation using non focused ultrasound
41345925|NCT04570228|DEVICE|Sham procedure|A sham procedure would be performed using the TIVUS system without delivering the non focused ultrasound
41345926|NCT03605225|DEVICE|mobile cellphone application test|Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
41345927|NCT02270190|DEVICE|Percutaneous Tibial Nerve Stimulation (PTNS)|
41345928|NCT01675856|OTHER|Urgent endoscopy|Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
41345929|NCT01675856|OTHER|Early endoscopy|Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
41345930|NCT00783549|DRUG|an undetermined dose of GSK1292263|GSK investigational product or placebo
41345931|NCT00783549|DRUG|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
41345932|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposure
41345933|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposures.
41345934|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposure
41345935|NCT02899104|DRUG|Xofigo (Radium-223 dichloride, BAY88-8223)|Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
41345936|NCT00654368|BIOLOGICAL|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
41345937|NCT00654368|DRUG|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
41345938|NCT03617471|PROCEDURE|Venopuncture for PK profiling|Blood samples at T0, T0.5, T1, T2, T4, T6
41345939|NCT04568434|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
41345940|NCT04568434|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
41345941|NCT02302586|DRUG|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
41345942|NCT02302586|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
41345943|NCT03021928|OTHER|Time-To-Treatment Randomization|The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 72 (+/- 24) hours, 132 (+/- 12) hours, 228 (+/- 12) hours, and 324 (+/- 12) hours.
41345944|NCT05987514|DIAGNOSTIC_TEST|multimodal ultrasound|contrast-enhanced ultrasound and shear wave elastography on liver target lesion
41345945|NCT02845440|OTHER|Academic Detailing|Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. AD helps clinicians understand and adopt targeted evidence-based practices and is one of the few Continuing Medical Education (CME) interventions that has consistently demonstrated improved alignment of physician prescribing behavior with evidence-based practice.
41345946|NCT02845440|OTHER|Community Health Worker|Community Health Worker (CHW) The CHW will offer to support patients and prescribers in health promotion and preventive care in general and specifically to support communication between the primary care provider and patient regarding smoking status, smoking cessation, and to aid implementation of any smoking cessation treatments recommended by prescribers. CHWs will complete the standard CHW certificate training program in general preventive medicine, available through the Boston Public Health Commission. CHWs will then receive the additional specialized training.
41345947|NCT02845440|OTHER|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services.
41345948|NCT04793243|DIETARY_SUPPLEMENT|Vitamin D3|Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
41345949|NCT05574712|DRUG|Neoadjuvant treatment|Each drug will be dosed at its respective FDA-approved dose. These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily. All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to blunt its associated mineralocorticoid side effects
41345950|NCT00241657|BIOLOGICAL|BCG|
41345951|NCT03329664|BIOLOGICAL|Cytokine-induced killer cell|Immune-cell therapy with CIK cells
41345952|NCT03329664|OTHER|Chemotherapy AND/OR Radiation Therapy|Routine treatments for colon cancer patients according to their stage
41345953|NCT02204111|OTHER|Intervention|Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
41345954|NCT02675582|OTHER|Herbal Beverage|Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
41345955|NCT05203328|DEVICE|Vapotherm|Monitored anesthesia care with oxygen supplementation through a high-flow nasal cannula
41345956|NCT05203328|DEVICE|Regular nasal canula|Monitored anesthesia care with oxygen supplementation through a regular nasal cannula
41345957|NCT00565006|DRUG|MK0859|
41345958|NCT05617248|BEHAVIORAL|Self-efficacy App|The training starts with a psychoeducational video and instructions to define two autobiographical self-efficacy The individuals will then receive three self-efficacy trainings per day based on their autobiographical memories and combined with a slow breathing exercise. Additionally, they will receive 10 daily EMA questionnaires on mood, social contacts, and virtual context.
40826875|NCT02014480|DEVICE|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
40826876|NCT02014480|DEVICE|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
41345959|NCT03973632|DRUG|SH-1028 Tablets|200mg of SH-1028 Tablets, orally once every cycle.
41345960|NCT04971993|DEVICE|Wearable Cardiac Monitor|Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.
41490530|NCT01846013|BEHAVIORAL|Move|Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
40826877|NCT02014480|DEVICE|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
41018890|NCT05809895|DRUG|Nab-paclitaxel|100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
41018891|NCT05809895|DRUG|Carboplatin|AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
41018892|NCT05809895|DRUG|Placebo|normal saline intravenously (IV) Q3W
41018893|NCT05809895|DRUG|Pembrolizumab|200 mg intravenously (IV) Q3W
41345961|NCT03948594|DIETARY_SUPPLEMENT|resource|1 packet resource(237ml), 1.05kcal/ml, 53.6g carbohydrate and 9g protein
41490531|NCT01846013|BEHAVIORAL|Stand and Move|Increase standing time to half of workday (4h) and increase movement time at work.
40826878|NCT06019247|OTHER|Individual placement support (IPS)|IPS is the most studied psychiatric rehabilitation intervention in the world. It is based on eight principles: inclusion of all clients who have declared a desire to work, no pre-vocational training, benefits counseling, rapid job search, treatment team-level integration of vocational and clinical services, consideration of client preferences in all decisions, assistance in job development, provision of follow-up supports after finding employment, and a focus on competitive employment. We propose to adapt and pilot the IPS to improve employment and health among people with severe mental disorders in Mexico.
40826879|NCT02404922|DRUG|CTP-730|
41018894|NCT05809895|DRUG|Gemcitabine|1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
40826880|NCT02404922|DRUG|Placebo for CTP-730|
40826881|NCT02470754|DEVICE|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
40826882|NCT02470754|DEVICE|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
41157383|NCT01502202|DRUG|Pemetrexed plusCIsplatin|Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
40826883|NCT05146713|DIETARY_SUPPLEMENT|Propolis nanoparticles extract solution|20 mg/ml propolis nanoparticles in the form of solution prepared from honeybee from various plants.
40826884|NCT05146713|DRUG|sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
40826885|NCT02533765|DRUG|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
41157384|NCT00946088|DRUG|Progesterone|Progesterone 400 mg per vagina qhs.
40826886|NCT04492709|DRUG|Midazolam|The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.
41345962|NCT03948594|OTHER|plain water|250ml plain water
40826887|NCT04492709|DRUG|AZD5718|The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.
41490532|NCT01680497|DEVICE|Crosslinked hyaluronic acid dermal filler|All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
41345963|NCT05213676|DRUG|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
41345964|NCT05213676|OTHER|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
41345965|NCT03879694|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
41345966|NCT03879694|DRUG|Octreotide Acetate|Given IM
41345967|NCT03879694|BIOLOGICAL|Sargramostim|Given SC
40826888|NCT02851407|DRUG|Defibrotide|
40826889|NCT02851407|OTHER|Best Supportive Care|
40826890|NCT02073357|PROCEDURE|Light general anaesthesia (BIS = 50)|
40826891|NCT02073357|PROCEDURE|deep general anaesthesia (BIS = 35)|
41490533|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m\^2 for normal hepatic function.
41490534|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m\^2 for mild hepatic impairment (Child-Pugh A)
41490535|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m\^2 for moderate hepatic impairment (Child-Pugh B)
40826892|NCT00144924|PROCEDURE|laparoscopy pyloromyotomy|laparoscopic pyloromyotomy
40826893|NCT00144924|PROCEDURE|open pyloromytomy|open pyloromyotomy
41345968|NCT03879694|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
41345969|NCT01344304|DRUG|Aprepitant / Fosaprepitant|"Aprepitant:~125 mg PO on day 1 80 mg PO on days 2 to 3~Fosaprepitant:~150 mg IV on day 1"
41345970|NCT03930277|DIAGNOSTIC_TEST|Electroencephalogram|Electroencephalogram for fetal brain activity monitoring.
41345971|NCT05689749|DEVICE|Superb Microvascular Imaging (SMI) (Toshiba)|To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.
41345972|NCT04371913|RADIATION|600cGY x 5 fractions|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using EBRT.
41345973|NCT03254849|DRUG|Empagliflozin|1 tablet
41345974|NCT03254849|DRUG|Hydrochlorothiazide 25 mg|1 tablet
41345975|NCT05221489|OTHER|listening to lullabies or self-selected music|listening to lullabies for lullaby group and listening to music of their choice among various music for mix music group
40826894|NCT02700789|PROCEDURE|Transvaginal ultrasound scan|The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
40826895|NCT01012921|DEVICE|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
40826896|NCT01012921|DEVICE|MembraGel|Device application at surgery
40826897|NCT01012921|OTHER|Bio-Gide® membrane|Device application at surgery
40826898|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
40826899|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
40826900|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
40826901|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
41345976|NCT00000895|DRUG|Nelfinavir mesylate|
41345977|NCT00000895|DRUG|Nevirapine|
41345978|NCT00000895|DRUG|Azithromycin|
41345979|NCT03626389|OTHER|Physiotherapy|
41345980|NCT00262639|DRUG|Flumazenil and Gabapentin|2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
41345981|NCT00262639|DRUG|Placebo|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
41345982|NCT00846911|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
41345983|NCT00979472|DRUG|Solifenacin|oral
41345984|NCT04481711|PROCEDURE|Total Knee Arthroplasty|Osteoarthritis (OA) is one of the most common chronic peripheral joint diseases increasing among the aging population.Pathogenesis is not fully known.One of the most common risk factors and causes are loss of pain and function. Knee joint osteoarthritis adversly affects the person's life quality. Total Knee Arthroplasty (TKA) is a surgical approach to restore tibiofemoral joint alignment, especially in the severe level of knee OA.
41345985|NCT03652506|DEVICE|regional oxymetry probe|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
41345986|NCT03652506|PROCEDURE|Quadratus Lumborum block|Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
41345987|NCT03652506|PROCEDURE|Thoracic Epidural block|Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
41345988|NCT02252328|DRUG|Simvastatin|Simvastatin 80mg once daily
41345989|NCT02252328|DRUG|Placebo|Placebo tablets once daily
41345990|NCT00135993|DRUG|Rotigotine|
41345991|NCT03934489|BEHAVIORAL|PERSIST|12-week group, adapted from Dialectical Behavior Therapy, that focuses on emotion regulation skills training and practice.
41345992|NCT03934489|BEHAVIORAL|Facilitated Peer Support|12-week group, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
41345993|NCT05298410|OTHER|Limitless|Participants will be instructed to take Limitless for 30 days.
41345994|NCT00164788|DRUG|Intravenous bolus injection of esomeprazole|80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
41345995|NCT00164788|DRUG|Oral esomeprazole|40mg every 12 hours for 24 hours
41345996|NCT05010863|OTHER|Blood collection|The subject will be drawn a 5ml blood sample
41345997|NCT04507490|DEVICE|Whole body vibration|315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration
41345998|NCT05535790|OTHER|Naturalistic LED light|Naturalistic LED light (bright light therapy) which affects Melanopic Equivalent Daylight Illuminance.
41345999|NCT05535790|OTHER|Standard/traditional lighting|Standard/tradtional lighting environment with fluorescent tubes
41346000|NCT01126567|OTHER|Sampling Rate|Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.
41346001|NCT02362256|DRUG|Naltrexone|
41346002|NCT02362256|DRUG|Clonidine|
41346003|NCT02362256|DRUG|Lorazepam|
41346004|NCT02384785|DEVICE|Transcutaneous Electric Nerve Stimulation|Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
41346005|NCT06386367|BEHAVIORAL|Monastery-based health education by Buddhist monks|During the three-month intervention from July to September 2022, a total of 18 health education sessions were conducted across the three intervention villages, with an average of 50 attendees per session, totaling 921 attendees across all sessions.
41346006|NCT00935662|DRUG|AZD8329|Oral solution, single ascending doses
41346007|NCT00935662|DRUG|Placebo|Oral solution, placebo
41346008|NCT01556789|BIOLOGICAL|ONT-10|ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
41346009|NCT00997828|DEVICE|everolimus-eluting stent|Xience V stent
41346010|NCT00997828|PROCEDURE|coronary artery bypass graft surgery|coronary artery bypass graft surgery
41346011|NCT04476108|DRUG|LY3016859|Administered IV
41346012|NCT04476108|DRUG|Placebo|Administered IV
41346013|NCT03100006|DRUG|Nivolumab|240mg of IV Nivolumab is administered over 30 mins every 2 weeks
41346014|NCT03100006|DRUG|Oregovomab|IV Oregovomab is administered over 20 mins every 4 weeks at dose levels: 2mg, 1mg, or 0.5mg
41346015|NCT05129111|DEVICE|PHYSICAL VIBRATION OF THE PAROTID GLANDS|The system will be placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation
40826902|NCT06229665|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
41346016|NCT02397772|DRUG|albendazole|Single dose of albendazole (400 mg)
41346017|NCT06248944|OTHER|observational-retrospective and prospective|observational-retrospective and prospective
41346018|NCT03898752|DIETARY_SUPPLEMENT|Omega 3|Omega 3: 1g daily for 3 months CoQ10: 100 mg daily for 3 months Multivitamin: 1 normal multivitamin tablet daily for 3 months
41346019|NCT01437059|DRUG|ALN-PCS02|Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
41346020|NCT01437059|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
41346021|NCT00113906|DRUG|melatonin|
41346022|NCT02738346|DRUG|Carboplatin|Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles
41346023|NCT02738346|DRUG|Etoposide|Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles
41490536|NCT04271579|PROCEDURE|Salvage Lymphnode dissection|"A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)"
41490537|NCT06024200|OTHER|transcutaneous electrical acupoint stimulation|Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.
41490538|NCT06024200|OTHER|transcutaneous electrical acupoint stimulation sham stimulation|Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.
41490539|NCT00796679|DRUG|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH \<500pg/mL or 2 microgram once daily if iPTH \>=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
41157385|NCT00946088|DRUG|Polyethylene glycol&hydrogenated vegetable oil.|Placebo Comparator: Polyethylene glycol 400 distearate \& hydrogenated vegetable oil per vagina qhs.
41346024|NCT02738346|DRUG|Topotecan|Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles
41346025|NCT02738346|DEVICE|CT scans|The CT scan evaluations will be conducted during chemotherapy every 6 weeks
41346026|NCT01084473|DRUG|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
41346027|NCT01084473|DRUG|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
41346028|NCT01084473|DRUG|Placebo|0.9 % NaCl will be infused.
41346029|NCT03389867|DIETARY_SUPPLEMENT|Kaempferia parviflora extract|
41490540|NCT04948060|OTHER|Enhanced lung cancer screening services|A theoretically sound and evidence-based, multi-component implementation strategy will be applied which includes care quality benchmarking and regular performance feedback, academic detailing provided by specially trained primary care clinicians, practice facilitation provided by trained and certified Practice Facilitators (PFs), health information technology (HIT) support, and facilitated professional networking to promote the cross-pollination and rapid dissemination of solutions and best practices in primary care settings
40826903|NCT06463704|OTHER|There is no intervention|There is no intervention
41346030|NCT04929847|OTHER|Self-prepared emollient|The emollient is hypo-allergenic, free of perfume and has very high hydrating capacities together with antioxidants.
41346031|NCT02209259|OTHER|PROMIS Upper Extremity Function|
41346032|NCT02209259|OTHER|Pain intensity|
41346033|NCT02209259|OTHER|PROMIS depression|
41346034|NCT02209259|OTHER|Positive affect negative affect scale (PANAS)|
41346035|NCT02209259|OTHER|standard PCS|
41346036|NCT02209259|OTHER|positively-adjusted version of the PCS|
41346037|NCT03236506|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet|Drugs will be given to participants to treat hepatitis C infection
41346038|NCT03236506|BEHAVIORAL|Psychological intervention|"Participants randomised to fortnightly pick-up with psychological intervention will have an interview with the study nurse designed to aid their compliance with the drug regimen. During the intervention participants will be guided by their trial nurse in the completion of a personalised booklet, Hepatitis C and Me. The booklet uses the principles of node-link mapping to structure the intervention."
41490541|NCT06144151|DEVICE|NeurOptics® NPi®-300 Pupillometer|The pupilometer is a non-invasive device which will be placed in front of your eyes, one at a time. It looks like a handheld spotlight or scanner, with a small plastic guide sticking out that will be placed against your cheek to help keep the device in place during the scan. It will not touch your eye. Both your left and right eyes will be measured with the device each time. Scanning with the pupilometer will take less than 5 minutes total for both eyes.
40826904|NCT05788705|DIETARY_SUPPLEMENT|"apigenin and glycyrrhizin"|"apigenin will be administered as capsule (10mg,eq 200mg Matricaria chamomilla L extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
41346039|NCT03236506|DRUG|Sofosbuvir 400 MG|Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection
41346040|NCT06329713|PROCEDURE|Group I: 30 Min Interval Time|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every 30 minutes, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 15 minuts may be administered
41346041|NCT06329713|PROCEDURE|Group II: 60 Min Interval Time|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programme
41346042|NCT04609215|OTHER|ALECSAT|"Patients will receive concurrent chemotherapy with carboplatin/gemcitabine with cycles repeated every 3 weeks.~During the loading phase, patients will receive ALECSAT at 28 days intervals at weeks 5, 9, and 13. Hereafter (the maintenance phase), ALECSAT will be administered every 12 weeks until disease progression, death, unacceptable toxicity, investigator/patient decision or EOT visit at 18 months."
41346043|NCT01995422|OTHER|Physical activity program|One hour sessions of active walking occurring three times a week during three months
41490542|NCT04981496|OTHER|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs
41490543|NCT04300140|DRUG|Batiraxcept|Batiraxcept is experimental drug
41346044|NCT05927623|BEHAVIORAL|Multifaceted Virtual Fracture Prevention Program|"* Personalized exercise prescription: Comprised of muscle strengthening and balance exercises to perform three times a week, delivered and monitored remotely via the MisterFit app, a branded version of the secure commercially available Physiotec app (physiotec.com) and monthly virtual exercise consultations.~* Virtual nutrition counseling from a registered dietitian in months 2, 4 and 6: to encourage participants to meet daily targets for calcium and vitamin D (preferably from diet), and protein intake to support muscle accretion and target weight maintenance~* Virtual interactive information sessions in month 4 and 8: to education participants on topics identified as important by the Misterfit patient partner advisory committee."
41346045|NCT05927623|BEHAVIORAL|Attention Control|"* Encouraged to meet the 24-Hour Movement Guidelines for adults aged 65 years or older (https://csepguidelines.ca) with telephone contacts at the same frequency that the Misterfit online group receives virtual exercise consultations~* Nutritional fact sheets: sent by e-mail at the same frequency that the Misterfit online group meets with the research dietitian.~* Educational fact sheets: sent by e-mail at the same frequency that the Misterfit Online group has virtual interactive information sessions"
41346046|NCT03993119|DRUG|Non-vitamin K antagonist oral anticoagulant|Non-vitamin K antagonist oral anticoagulant
41346047|NCT03649386|DEVICE|Heated and humidified breathing circuit on|Heated and humidified breathing circuit will be turned on.
40826905|NCT05788705|DIETARY_SUPPLEMENT|"glycyrrhizin and boswellic acid"|"boswellic acid will be administered as capsule (200mg,eq 250mg Boswellia serrata extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
40826906|NCT05788705|DIETARY_SUPPLEMENT|"placebo"|"Placebo capsule will be administered two times daily for 6 months"
41346048|NCT03649386|DEVICE|Heated and humidified breathing circuit off|Heated and humidified breathing circuit will be turned off.
41490544|NCT04300140|DRUG|Cabozantinib (Cabo)|Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC
41490545|NCT04300140|DRUG|Nivolumab|Nivolumab is standard of care in the first line treatment of ccRCC
40826907|NCT02775331|OTHER|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
40826908|NCT02775331|OTHER|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
41490546|NCT04465773|PROCEDURE|general anesthesia for scheduled gynecological surgery|
41490547|NCT04465773|DRUG|Propofol|continuous infusion, target concentration adjusted to maintain bispectral index between 45 and 55
41490548|NCT04465773|DRUG|Remifentanil, Ultiva®|continuous infusion, target concentration 1 ng/ml
41490549|NCT04465773|PROCEDURE|tetanic stimulations|10-20-30-40-50-60 milliamps, 5 seconds, 100 Hertz 2 minutes between stimulations delivered via the standard neuromuscular blocking agents monitor
41490550|NCT04465773|DEVICE|VideoAlgesiGraph|non invasive infrared camera placed in front of the left eye of the patients during the study period, connected to a laptop. No part of the device touches the eye.
40826909|NCT00460954|DRUG|Sinemet® controlled release (Carbidopa/levodopa)|
40826910|NCT03781219|DRUG|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
40826911|NCT03781219|DRUG|Vemurafenib|Vemurafenib ( Tablet) is BRAF inhibitor,
41490551|NCT04989712|OTHER|Exposure|Participants randomised to one of the three exposures
41490552|NCT06300814|OTHER|Progressive relaxation exercise group|A video containing the progressive relaxation exercise was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group to whom progressive relaxation exercise would be applied, and the children applied progressive relaxation exercise (15 minutes of progressive relaxation exercise before bedtime for a total of 4 weeks, 5 days a week).
41490553|NCT06300814|OTHER|Music recital group|The link of the music recital (link) was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group, where the music concert will be applied, and the children listened to it (music concert was applied for 15 minutes before going to bed, 5 days a week for a total of 4 weeks).
40826912|NCT04431310|OTHER|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic|The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.
40826913|NCT03742999|PROCEDURE|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip. Children were trained for 60 minutes per session, three times a week for three consecutive months.
40826914|NCT03742999|DEVICE|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months
40826915|NCT03742999|COMBINATION_PRODUCT|physical therapy program and ELink Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months
41490554|NCT02925585|OTHER|Pre/post imaging|
41490555|NCT00001993|DRUG|Butyldeoxynojirimycin|
40826916|NCT00943475|PROCEDURE|circumcision|circumcision by plastbell
40826917|NCT02182908|OTHER|PET-Scan|PET-Scan
41490556|NCT00001993|DRUG|Zidovudine|
40826918|NCT04773873|DEVICE|PFM Crowns on gold coping cast-on|Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
40826919|NCT04773873|DEVICE|hybrid abutment lithium disilicate crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase
41346049|NCT01369069|DRUG|IV insulin to maintain target glucose concentration of 80-130 mg/dL|Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
41490557|NCT04078880|DIETARY_SUPPLEMENT|Sucrosomial iron plus ascorbic acid|A number of 41 subjects are supplemented with 30 mg of iron plus 70 mg of ascorbic acid daily for 30+/-5 days before orthopedic surgery.
41490558|NCT01547949|DIETARY_SUPPLEMENT|tart cultivar Montmorency cherry juice|
41490559|NCT01547949|DIETARY_SUPPLEMENT|placebo cherry fruit drink|
41490560|NCT03595631|OTHER|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
41490561|NCT03595631|OTHER|Physical Therapy plus Neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
41490562|NCT05255796|PROCEDURE|one-piece|Patients underwent phacoemulsification cataract surgery with one-piece IOL implantation.
41346050|NCT01369069|DRUG|Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL|Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
41346051|NCT03424616|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.
41346052|NCT00338429|BEHAVIORAL|FHP Sleep Program|Cognitive-Behavioral Intervention
41346053|NCT02652546|DRUG|Assess Safety|Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
41346054|NCT02652546|DRUG|Effect of drug on viral load|Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
41346055|NCT02652546|DRUG|Effect of drug on T-cell count|Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
41346056|NCT02652546|DRUG|Effect of drug on inflammatory biomarkers|Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-\^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
41490563|NCT05255796|PROCEDURE|plate-haptic|Patients underwent phacoemulsification cataract surgery with plate-haptic IOL implantation.
41490564|NCT02770677|OTHER|Modified Dantien Salee Yoga Training Program|The intervention aims to improve pulmonary function and functional fitness.
41490565|NCT03717714|DIETARY_SUPPLEMENT|Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
40826920|NCT04773873|DEVICE|hybrid abutment ceramic polymer infiltrated crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
40826921|NCT01563120|DRUG|metformin|metformin up to 2550mg per day.
40826922|NCT01563120|DRUG|glybenclamide|glybenclamide up to 20mg per day.
40826923|NCT03162510|DRUG|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
40826924|NCT03162510|DRUG|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
40826925|NCT03162510|DRUG|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
41346057|NCT03288623|DIETARY_SUPPLEMENT|Dark Chocolate (85% cocoa)|Dark chocolate (85% cocoa) in tablet
41346058|NCT03288623|DIETARY_SUPPLEMENT|White/Milk chocolate (<35% cocoa)|white or milk chocolate (\<35% cocoa) in tablet
41346059|NCT04255992|DIETARY_SUPPLEMENT|Calcium Arm|1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
41346060|NCT04255992|DIETARY_SUPPLEMENT|Vitamin D/Calcium|1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
41346061|NCT02717676|PROCEDURE|Episiotomy|episiotomy will be done after crowning of the fetal head
41346062|NCT00300612|BIOLOGICAL|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
41490566|NCT03717714|DIETARY_SUPPLEMENT|Polycan 50mg + Glucosamine 750 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks
41490567|NCT03717714|DIETARY_SUPPLEMENT|Polycan 50mg + Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
41346063|NCT01365091|DRUG|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
41346064|NCT01365091|DRUG|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
41346065|NCT01365091|DRUG|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
41346066|NCT01365091|DRUG|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
41346067|NCT01365091|DRUG|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
41346068|NCT04705350|DRUG|Zampilimab|Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
41346069|NCT04705350|DRUG|Placebo|Participants will receive matching placebo at a pre-specified time point to maintain the blinding.
41346070|NCT02682576|PROCEDURE|Brachial artery ultrasound imaging|
41346071|NCT01662986|DRUG|tiotropium bromide|18 mcg once a day (QD)
41346072|NCT01662986|DRUG|Placebo|Once a day (QD)
41346073|NCT01847872|DRUG|IPV IM Needle|
41346074|NCT01847872|DRUG|IPV ID Needle|
41346075|NCT01847872|DRUG|IPV IM Device|
41490568|NCT00815256|PROCEDURE|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
41490569|NCT03993730|DEVICE|ICD|Insertion of ICD in patients with LVEF \<45% and LGE on CMR.
41346076|NCT01847872|DRUG|IPV ID Device|
41490570|NCT03993730|DEVICE|ILR|Insertion of ILR in patients with LVEF \<45% and LGE on CMR.
41490571|NCT00960115|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram \[mcg\]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
41490572|NCT00960115|DRUG|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg/m\^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
41490573|NCT00960115|BIOLOGICAL|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
40826926|NCT03162510|DRUG|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
40826927|NCT00554619|DRUG|GSK1325760A|2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
41346077|NCT02035410|PROCEDURE|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
41346078|NCT01223690|DRUG|Clarithromycin|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
41346079|NCT01223690|DRUG|Dextrose 5%|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
41346080|NCT05255497|DEVICE|Biodex Balance Exercise System|Patients in the intervention group (n=14) performed exercises using the computerized BBS. The control group (n=13) was just informed about diabetes self-management.
41346081|NCT01572636|DRUG|Laronidase|Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
40826928|NCT05973786|DRUG|Escitalopram|ATC code: N06AB10
41346082|NCT02941042|DRUG|NNC9204-1177|A single dose administered subcutaneously ( s.c. under the skin)
41346083|NCT02941042|DRUG|Placebo|A single dose administered subcutaneously ( s.c. under the skin)
41346084|NCT03003013|PROCEDURE|Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF)|
41346085|NCT00057928|DRUG|cisplatin|
41346086|NCT00057928|DRUG|gemcitabine hydrochloride|
41346087|NCT00057928|DRUG|paclitaxel|
41346088|NCT06235229|BIOLOGICAL|GC012F|GC012F is a BCMA/CD19 dual CAR product
41346089|NCT01181297|OTHER|Extensively Hydrolyzed Formula with a Probiotic|
41346090|NCT01181297|OTHER|Extensively Hydrolyzed Formula without a Probiotic|
41346091|NCT05679440|BEHAVIORAL|Postural interventions based on pulmonary imaging|The main difference between the intervention group and the control group was the position during oxygen therapy. Patients in the intervention group were placed in the appropriate position for oxygen therapy according to pulmonary imaging, while patients in the control group were placed in the appropriate position for oxygen therapy according to conventional treatment principles and the patient's wishes.
41346092|NCT04008940|DEVICE|Distal femur plates|By assessing the rate and mode of mechanical failures we aim to identify risk factors for mechanical failures among the analysed plate types. This, finally, is depending on the overall number of cases and number of failure cases.
41346093|NCT06500234|DRUG|Megestrol Acetate and olanzapine|megestrol acetate, 160 mg, oral everyday; olanzapine 2.5 mg, oral everyday
41346094|NCT06500234|DRUG|Starch powder 50 mg|Starch powder 50 mg, oral, everyday
41346095|NCT06336447|OTHER|Experimental: Group #1: Virtual Reality Headset|Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the device for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.
40826929|NCT05973786|DRUG|Sertraline|See arm description
40826930|NCT05973786|DRUG|Venlafaxine|See arm description
40826931|NCT05973786|DRUG|Lithium|See arm description
40826932|NCT05973786|DRUG|Valproate acid|See arm description
41346096|NCT06336447|OTHER|Group 2 No Virtual Reality Headset|Group 2 will receive standard care without the use of the Virtuality Reality Heaset.
41346097|NCT00726167|DEVICE|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
41346098|NCT02788825|PROCEDURE|Targeted biopsies using Magnetic Resonance Imaging guiding|Prostate biopsies targeted by findings on MRI where findings are classified according to PI-RADS v2.
41346099|NCT00578396|DIETARY_SUPPLEMENT|grapes|1 pound of seedless red grapes
41346100|NCT00578396|DIETARY_SUPPLEMENT|grapes|2/3 lb/day fresh red grapes
41346101|NCT00578396|DIETARY_SUPPLEMENT|grapes|1/3 lb/day fresh red grapes
41346102|NCT01608555|DRUG|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
41346103|NCT00441194|DEVICE|Visual Field (Octopus 311 and the HFA 700 series)|
41346104|NCT02812329|BEHAVIORAL|HIV prevention videogame|Assess acceptability and efficacy of a HIV prevention videogame
41346105|NCT01480791|DRUG|Aliskiren vs. hydrochlorothiazide|Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
41346106|NCT01480791|DRUG|Hydrochlorothiazide|Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
41346107|NCT04840849|BIOLOGICAL|nirsevimab|Drug: injection, a single fixed IM dose on day 1 only.
41346108|NCT04840849|OTHER|Placebo|Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.
40826933|NCT05973786|DRUG|Quetiapine|See arm description
41346109|NCT03933306|DRUG|Dexmedetomidine|Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.
41346110|NCT03933306|DRUG|Placebo|Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.
41346111|NCT03933306|OTHER|Goal-directed blood pressure management|Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
41346112|NCT03933306|OTHER|Routine blood pressure management|Blood pressure is maintained according to routine practice, i.e., systolic blood pressure \> 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.
41346113|NCT03262064|COMBINATION_PRODUCT|Pulmonary function tests,Bronchiectasis severity index score|"Pulmonary function tests: including spirometry, DLCO, and lung volumes. Sputum investigations: The following investigations will be performed on fresh sputum samples; gram stains and culture, smear and culture for mycobacteria and fungi and antibiotic sensitivity tests Bronchoscopy: Bronchoscopy with bronchoalveolar lavage will be used to obtain specimens for staining and culture to identify type of colonization.~Radiology: All patients will have a chest radiograph (PA and lateral) and high-resolution computed tomography (HRCT) scan.~Bronchiectasis severity index score parameters FACED Score"
41346114|NCT03567590|PROCEDURE|Pulsed Radiofrequency treatment|The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.
41346115|NCT03567590|PROCEDURE|Nerve Block treatment|A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.
41346116|NCT02162264|DRUG|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
41346117|NCT00886691|BIOLOGICAL|Bevacizumab|Given IV
41346118|NCT00886691|DRUG|Everolimus|Given PO
41346119|NCT00886691|OTHER|Laboratory Biomarker Analysis|Correlative studies
41346120|NCT00886691|OTHER|Placebo|Given PO
41346121|NCT02894788|OTHER|ICU admission|
41346122|NCT03742271|DEVICE|senofilcon A|TEST Lens
40826934|NCT04442321|OTHER|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
40826935|NCT04442321|OTHER|Sham PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The electrical current will not be working, and the needles will be placed during 30 minutes:~- Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
40826936|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
40826937|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
40826938|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
41346123|NCT04191252|DIAGNOSTIC_TEST|A multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
41346124|NCT01253941|OTHER|Mud bath Therapy|patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment
41346125|NCT03862586|DRUG|N-acetyl cysteine|
41490574|NCT00960115|OTHER|Saline|A single dose of saline (sodium chloride, 9 grams per liter \[g/L\]) will be administered intravenously, 3 days prior to the start of placebo.
40826939|NCT00953524|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
41346126|NCT03862586|DRUG|Placebos|
41490575|NCT05697926|OTHER|No intervention|This is a preclinical study. No intervention will be performed.
40826940|NCT01242306|DRUG|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
41346127|NCT00123786|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
41346128|NCT05458492|DRUG|Sirolimus|"Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks"
41346129|NCT03317912|DRUG|Lidocaïne 2%|Continuous infusion during per and postoperative periods
41490576|NCT04790838|DRUG|Test|2 inhalations of Test and Reference product in each study period
41490577|NCT04790838|DRUG|Reference|2 inhalations of Test and Reference product in each study period
40826941|NCT04378829|DIAGNOSTIC_TEST|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
41346130|NCT03317912|DRUG|Placebo (for Lidocaïne)|Continuous infusion during per and postoperative periods
41346131|NCT01935570|DRUG|Magnesium chloride (ChronoMag Smart Tablet®)|
41346132|NCT01935570|DRUG|Magnesium carbonate (Mag2® Tablet)|
41346133|NCT02949414|PROCEDURE|Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells|The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
41346134|NCT03540641|DEVICE|MagVenture MagPro R30|the subjects will receive 1500 or 5000 pulses at 5Hz
41346135|NCT04759612|OTHER|Action Observation|Participants will watch an upper extremity functionality test.
41346136|NCT01132768|DRUG|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
41346137|NCT01132768|DRUG|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
41346138|NCT05264740|BEHAVIORAL|Motivational interviewing|The intervention group will receive motivational interviewing sessions with a trained study nurse plus educational material
40826942|NCT05959629|DEVICE|Waterlase Express™, BIOLASE®|Er,Cr:YSGG laser 2780nm (Waterlase Express™, BIOLASE®) with 300μm tip (EdgePro #3) will be placed into the mid-root of the canal. The tip will be activated and slowly withdrawn to the orifice (1-2mm/sec) following the manufacturer settings (energy 15 Millijoule (mJ), repetition rate 50 Hertz (Hz), 0% air, 0% water).
41346139|NCT05264740|BEHAVIORAL|Educational materials|The control group will receive educational material only.
41346140|NCT03966664|DIAGNOSTIC_TEST|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.|Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
41346141|NCT03966664|DIAGNOSTIC_TEST|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood|Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
41346142|NCT03966664|DIAGNOSTIC_TEST|Biomolecular analysis of plasma proteins.|Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
41346143|NCT01776372|DEVICE|Medela Thopaz Thoracic Drainage System|
41346144|NCT01776372|DEVICE|Atrium Express Dry Seal Chest Drain|
41346145|NCT05793424|OTHER|Cerebrospinal fluid (CSF) sample and additional blood samples|Lumbar puncture (Spinal Tap) and additional blood samples
41346146|NCT05200104|DRUG|PXL065|PXL065 22.5 mg QD
41346147|NCT04941976|DRUG|0.3% benzydamine hydrochloride spray oromucosal solution|"Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
41490578|NCT06423638|BEHAVIORAL|Virtual Tai Chi Easy|"The TCE intervention will be delivered asynchronously online. Participants can complete the classes at a time and in a location that is convenient for them. The classes will be offered for one hour twice weekly and were developed and recorded by a certified Tai Chi Easy practice leader.~TCE is a simple form of mind-body self-care that focuses on four components:~* Mindful movements that help to stretch, and relax the body while improving balance and coordination~* Breathing practices that reduce stress by inducing a relaxation response while improving energy and circulation and enhancing innate healing responses~* Self-applied massage to stimulate blood flow, relax the body, and improve circulation and energy~* Meditation practices to relax the body, center the mind, and calm the emotions"
41490579|NCT06140043|OTHER|Patient consultation|Providing information about the current clinical problem of orthognatic surgery patients and the proposed treatment for it.
40826943|NCT05959629|OTHER|Sodium Hypochlorite|Root canals will be instrumented up to size 30/0.04 taper using 1.5cc of 3% NaOCl in between files.
41346148|NCT04941976|DRUG|Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)|"Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
41490580|NCT02448264|DRUG|BCX7353|
41490581|NCT02448264|DRUG|Placebo to match BCX7353|
41490582|NCT05757739|PROCEDURE|Tenex|In the Tenex procedure, the surgeon inserts a special needle into the damaged portion of the tendon under ultrasound guidance. Ultrasonic energy vibrates the damaged tissue and it can be suctioned out. This procedure is done with local anesthesia in surgeon's office.
41490583|NCT02993692|DEVICE|Direct laryngoscopy and fiberoptic bronchoscopy|These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
41490584|NCT01375153|DRUG|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
40826944|NCT00474864|DRUG|GW856553|
40826945|NCT01357824|PROCEDURE|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
41490585|NCT01375153|DRUG|0.9% NaCl|0.9% NaCl administered as a continuous intravenous infusion during four hours
41490586|NCT00099710|DIETARY_SUPPLEMENT|Curcumin C3 Complex|
41490587|NCT04023903|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
41490588|NCT04023903|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
40826946|NCT02741570|BIOLOGICAL|Nivolumab|
41346149|NCT03660280|DIETARY_SUPPLEMENT|Probiotics|Specific probiotic lactobacilli (added to stabilized ongoing treatment)
41346150|NCT03660280|OTHER|Placebo|Placebo
41346151|NCT03608462|DEVICE|repetitive transcranial magnetic stimulation(DLPFC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.
41346152|NCT03608462|DEVICE|repetitive transcranial magnetic stimulation(LPC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
41346153|NCT02591836|DRUG|Gemcabene|Gemcabene
41346154|NCT02591836|DRUG|Atorvastatin|Atorvastatin
41346155|NCT02591836|DRUG|Placebo|
41346156|NCT05740891|DRUG|BCMA CAR-T cells injection|Autologous hematopoietic stem cell transplantation combined with BCMA CAR-T cells
41346157|NCT01092364|BEHAVIORAL|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
41346158|NCT03261037|OTHER|Spirometry|Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
41346159|NCT03261037|OTHER|Accelerometry|Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
41346160|NCT03261037|OTHER|6MWT|The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
41346161|NCT00262327|DRUG|Antangiogenesis|
41346162|NCT00262327|GENETIC|endostatin gene|
41346163|NCT05942872|OTHER|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.
41346164|NCT04129190|BIOLOGICAL|Glucose|Oral Intake of Glucose
41346165|NCT05345704|OTHER|cardiopulmonary resuscitation (CPR)|Data from observation and collected from simulation mannequin during simulated CPR of an infant and child.
41346166|NCT01145404|DRUG|Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
41346167|NCT01145404|DRUG|Lapatinib plus capecitabine|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
41346168|NCT01809691|DRUG|TAK-700|300 mg, PO, twice daily
41346169|NCT01809691|DRUG|Bicalutamide|50 mg, PO, q daily
40826947|NCT02741570|BIOLOGICAL|Ipilimumab|
40826948|NCT02741570|DRUG|Cetuximab/Erbitux|
40826949|NCT02741570|DRUG|Cisplatin/Platinol|
40826950|NCT02741570|DRUG|Carboplatin/Paraplatin|
40826951|NCT02741570|DRUG|Fluorouracil/Adrucil|
41346170|NCT01336595|DEVICE|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
41346171|NCT01336595|DEVICE|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
41346172|NCT01079208|OTHER|test starter infant formula|infants are fed for 6 months with this starter formula
41346173|NCT01079208|OTHER|test starter infant formula with synbiotics|infant are fed for 6 months with this formula
41346174|NCT01079208|OTHER|control standard formula|infant are fed 6 months with this formula
41346175|NCT00613340|PROCEDURE|Cervical medial branch blocks|Cervical medial branch blocks done with 0.25 ml of local anesthetic and contrast
41346176|NCT00613340|PROCEDURE|Cervical medial branch blocks|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
41346177|NCT06099028|OTHER|no intervention|no intervention
41346178|NCT04064944|DEVICE|blood purification equipment|The subjects enrolled in this study will undergo blood purification treatment, and will be randomized into either immunoadsorption group or plasma exchange group, and the following indicators will be evaluated: (1) changes in EDSS scores and visual acuity before and after treatment; (2) changes in AQP4-IgG levels; (3) the safety of immunoadsorption treatment.
41346179|NCT03034109|DEVICE|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
41346180|NCT03820206|DRUG|Tranexamic Acid|1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
41346181|NCT03820206|PROCEDURE|Cesarean section|Lower segement transverse cesarean section
41346182|NCT06026423|OTHER|Clinical examination and pictures|A clinical examination is needed to assess the healing process for the three groups. After assessing the healing process, we will take pictures of the tear for documentation.
41490589|NCT04972123|DRUG|CPC - Capsaicin, Phenylephrine, Caffeine|CPC is a combination of Capsaicin, Phenylephrine and Caffeine
40826952|NCT04415879|DEVICE|N-95 Respirator|N-95 mask will be worn as personal protective equipment during a graded exercise test
40826953|NCT04415879|DEVICE|Cloth Face Mask|A cloth mask will be worn as personal protective equipment during a graded exercise test
41018895|NCT02497768|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
41018896|NCT06328959|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
41018897|NCT06328959|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
41018898|NCT02114970|OTHER|Randomized- paper consent|
41018899|NCT02114970|OTHER|Randomized- Tablet-delivered consent|
41157386|NCT04284592|PROCEDURE|Remote ischemic post-conditioning (RIP)|The limb RIP was applied after leaving of cardiopulmonary bypass and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on an arm and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff.
41346183|NCT06026423|OTHER|Questionnaire|The participant will answer questions, serving as a baseline questionnaire, when arriving at the clinical examination one month post-partum. At three and 9-12 months post-postpartum, they will receive another questionnaire. The questionnaire will consist of validated questions regarding body image, pain, Urogynecological problems as symptoms of prolapse, urinary and anal incontinence, and questions about sexual problems.
41346184|NCT02117492|PROCEDURE|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
41346185|NCT02828189|OTHER|Physical Exercise|The patients were instructed to perform autonomous physical exercise program based preferences (progressive march on flat ground, dancing, cycling, etc.). They will receive written information. The program is 9 weeks with a frequency of 3 days per week and sessions about 50 minutes long.
40826954|NCT04415879|DIAGNOSTIC_TEST|Graded exercise test|No personal protective equipment during a graded exercise test
40826955|NCT04690920|DRUG|Tocilizumab|Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
40826956|NCT01420172|OTHER|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
40826957|NCT00650455|DRUG|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
40826958|NCT00650455|DRUG|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
40826959|NCT00650455|DRUG|placebo|placebo tablet every morning and capsule every evening for 12 weeks
40826960|NCT05967546|OTHER|Observational|No interventions will be given to patients.
41018900|NCT02114970|OTHER|Focus Group- paper and tablet consent|
41018901|NCT02838420|DRUG|Alectinib|Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
41157387|NCT06324188|OTHER|Early atrial fibrillation ablation|Patients randomised to early atrial fibrillation ablation will undergo pulmonary vein isolation within 2 months after randomisation.
40826961|NCT02648451|DIETARY_SUPPLEMENT|AYMES ROME|AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
41018902|NCT02838420|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
41018903|NCT05161676|DIETARY_SUPPLEMENT|Ketone monoester|Commercially available ketone supplement
41018904|NCT05161676|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
41018905|NCT02851576|OTHER|Infusion of ADV specific T cells|Cell engineering
41346186|NCT02828189|BEHAVIORAL|Therapeutic Education|Individual Therapeutic Education about healthy habits and exercise on breast cancer.
41346187|NCT02828189|OTHER|Therapeutic exercise-Physiotherapy|"1. Cardiovascular exercise~2. Individualized progressive strength and resistance exercises of principals muscle groups of the lower limbs, upper limbs and trunk.~3. Flexibilization exercises"
41346188|NCT05651074|DRUG|Vicagrel and omeprazole|18 mg vicagrel capsules and 40 mg omeprazole magnesium enteric-coated tablets
41346189|NCT03426449|PROCEDURE|posterolateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 5 o'clock position for 8-10 mm
41346190|NCT03426449|PROCEDURE|lateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 3 o'clock position for 8-10 mm
41346191|NCT05008549|DIETARY_SUPPLEMENT|Cranberry Juice Product|"The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)~The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)~The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)~The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)~L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)~The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum."
41346192|NCT02278380|OTHER|Low GI Standard Breakfast|Low GI Standard Breakfast
41346193|NCT02278380|OTHER|Medium GI Standard Breakfast|Medium GI Standard Breakfast
41346194|NCT02278380|OTHER|Enfamama A+|Nutritional pregnant milk supplement
40826962|NCT04591548|DIAGNOSTIC_TEST|proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample|All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
40826963|NCT05250050|DRUG|Esomeprazole|20mg bid
41346195|NCT02278380|OTHER|Glucerna Triple Care|Nutritional product for diabetics
41346196|NCT02278380|OTHER|Dumex Precima|Pregnant and lactation women milk powder
41346197|NCT02278380|OTHER|Diasip|Nutritional drinks for diabetics
41346198|NCT02278380|OTHER|Test product|Test product not patented yet
41346199|NCT06347692|OTHER|antigravity treadmill|An Alter G treadmill (Alter G Pro 200, Alter G Inc, USA) was used to provide training to the patients in the antigravity treadmill group. The Alter G allows the patient to change their body weight from 20% to 100% in 1% increments. The air pressure inside the lower body positive pressure chamber can be adjusted from 0 to 2.0 kilopascal above atmospheric pressure. They are very comfortable to train in for long periods of time and have simple controls for adjusting body weight, speed, and inclination.
41346200|NCT06347692|OTHER|physical therapy exercise program|Both groups received the same traditional physical therapy program for 12 weeks, three times a week, for 30 min each. The conventional physical therapy treatment consisted of acupuncture transcutaneous electrical nerve stimulation, Hot moist pack, Ultrasound and quadriceps setting
41346201|NCT01440972|OTHER|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
41346202|NCT01440972|OTHER|low intensity resistance training|low intensity resistance training without partial blood flow restriction
41346203|NCT06179355|PROCEDURE|manual astigmatic keratotomy|manual astigmatic keratotomy using a diamond knife
41346204|NCT06179355|PROCEDURE|femtosecond laser astigmatic keratotomy|astigmatic keratotomy using femtosecond lase
40826964|NCT05250050|DRUG|Bismuth potassium citrate|0.6g bid
40826965|NCT05250050|DRUG|Metronidazole|0.4g qid
40826966|NCT05250050|DRUG|Clarithromycin|0.5g bid
40826967|NCT05250050|DRUG|Levofloxacin|0.5g qd
40826968|NCT05250050|DRUG|Amoxicillin|1g bid
40826969|NCT05250050|DRUG|Tetracycline|0.5g qid
41018906|NCT04180202|DEVICE|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
41018907|NCT00909805|DEVICE|cutaneous suture (Surjet)|cutaneous surjet suture
41346205|NCT01365013|BEHAVIORAL|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
40826970|NCT03032653|OTHER|Late Rehabilitation|"Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:"
41018908|NCT00909805|DEVICE|2-octyl-cyanoacrylate (Dermabond® glue)|the cutaneous suture is made with glue only
41346206|NCT01365013|BEHAVIORAL|Control group|Standard advice for lifestyle change
41346207|NCT00654394|DRUG|Rosuvastatin|
41346208|NCT00021281|DRUG|FOLFIRI regimen|
41346209|NCT00021281|DRUG|fluorouracil|
40826971|NCT03032653|OTHER|Early Rehabilitation|Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
40826972|NCT05940298|DRUG|Intravenous injection of [99mTc]Tc-DB8|One single intravenous injection of \[99mTc\]Tc-DB8, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
40826973|NCT05529979|DEVICE|EPIONE® CT-Guided Percutaneous procedures|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
40826974|NCT01766349|BEHAVIORAL|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
40826975|NCT03369899|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
40826976|NCT04436471|BIOLOGICAL|Gam-COVID-Vac|adenoviral-based vaccine against SARS-CoV-2
40826977|NCT06461052|PROCEDURE|music therapy|The patient will benefit from viewing the video and the music therapy session in the waiting room of the operating room. The patient will be asked again for their anxiety score using an anxiety scale. This will define the main outcome of the study. Following this collection and in order not to influence the response, investigators will collect from the patient his compliance with the two proposed techniques as well as his appreciation of the tool.
40826978|NCT04367103|DRUG|Norepinephrine|prophylaxis for hypotension
40826979|NCT04367103|DRUG|Phenylephrine|standerd prophylaxis for hypotension
40826980|NCT00549029|GENETIC|DNA|withdraw 5\~10mL blood from vein only once during the whole design
40826981|NCT00121394|PROCEDURE|Chlorhexidine vaginal and infant wash|
40826982|NCT03861572|OTHER|Isokinetic eccentric training|Training sessions will be performed in the same isokinetic dynamometer used in previous evaluations, twice a week, with a minimum interval of 72 hours between sessions.
40826983|NCT03861572|OTHER|Traditional eccentric training|Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions.
40826984|NCT04904809|DEVICE|Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System|The Perclose ProGlide SMC and Perclose ProStyle SMCR in this study will be used for multiple access site closures in a single vein in the ablation procedure.
40826985|NCT02011620|OTHER|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
40826986|NCT06325293|DRUG|Azithromycin Pfizer®|Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm: 1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5
40826987|NCT06325293|DRUG|Placebo|Control comparator arm: 5 days of placebo
40826988|NCT00765882|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
40826989|NCT00765882|DRUG|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
40826990|NCT00765882|DRUG|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
40826991|NCT01900301|DRUG|Scopolamine|Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
40826992|NCT01900301|DRUG|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
40826993|NCT06477471|OTHER|MetProrenes|Take one slow-release capsule twice a day, after meal.
40826994|NCT00670891|PROCEDURE|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~1. Air or Gas Embolus~2. Decompression Illness~3. Carbon Monoxide poising~4. Clostridial Myonecrosis (Gas Gangrene)~5. Necrotizing Fasciitis~6. Crush Injury (Compartment syndromes)~7. Selected Problem Wounds~8. Compromised Skin Flaps or Grafts~9. Refractory Osteomyelitis~10. Exceptional Anemia due to Blood loss~11. Osteoradionecrosis~12. Thermal Burns and Radiation Tissue Damage~13. Diabetic Wounds~14. Intra-Cranial Abscess~15. Brain Injury and other Head Trauma~16. Cerebral Palsy~17. High Altitude Sickness~18. Lyme disease"
41018909|NCT03997903|DRUG|Imatinib Mesylate|"The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months."
40826995|NCT06218381|OTHER|Very Brief Exposure to Combat Images|In VBE, a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.
40826996|NCT04704427|DEVICE|Non-invasive BCI training|In the experimental group, the participants receive non-invasive rehabilitative BCI training. The training using the lower limb orthosis targeted the patient's ability to walk.
40826997|NCT04704427|OTHER|Traditional Physiotherapy protocol|In the control group，the participants receive the traditional physiotherapy protocol, including muscle strength training, balance training and walking training, etc.
41346210|NCT00021281|DRUG|irinotecan hydrochloride|
41346211|NCT00021281|DRUG|leucovorin calcium|
41346212|NCT00021281|DRUG|semaxanib|
41346213|NCT01207804|DEVICE|ValenTx Endo Bypass System|Patient is implanted with device and followed for 12 weeks
41346214|NCT04536350|DRUG|Aviptadil 67μg|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
41346215|NCT04536350|DRUG|Placebo 0.9% NaCl solution|Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days
41490590|NCT04972123|DIAGNOSTIC_TEST|Tilt Table Test|Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitroglycerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).
41490591|NCT04972123|DRUG|Placebo|Placebo for CPC
41490592|NCT04161846|BEHAVIORAL|Virtual Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered remotely over 10 weeks using an internet based approach.
41490593|NCT04161846|BEHAVIORAL|In Person Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered in person over 10 weeks.
41490594|NCT02880020|BIOLOGICAL|Ipilimumab|Given IV
41490595|NCT02880020|OTHER|Laboratory Biomarker Analysis|Correlative studies
41490596|NCT02880020|BIOLOGICAL|Nivolumab|Given IV
41490597|NCT04145453|BEHAVIORAL|Intervention genotype personalized nutritional recommendations|Participants will receive personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the beginning of study
41490598|NCT04145453|BEHAVIORAL|Control Group 1 personalized nutritional recommendations|Participants will receive genotype personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the end of study
40826998|NCT04585711|DRUG|Etanercept Optimal dosing|Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.
40826999|NCT02362204|BEHAVIORAL|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
40827000|NCT01283906|DEVICE|MuGard|Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
40827001|NCT01283906|DEVICE|Control Rinse|Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
40827002|NCT00005636|DRUG|cisplatin|
41346216|NCT01377324|OTHER|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with \~200MBq 18F-FES
41346217|NCT01718366|DRUG|Deferasirox, Vitamin D and Azacitidine|association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
41346218|NCT01308489|PROCEDURE|therapeutic conventional surgery|Undergo posterior spinal tumor resection
41346219|NCT01308489|PROCEDURE|therapeutic conventional surgery|Undergo anterior and posterior spinal tumor resection
41346220|NCT01308489|PROCEDURE|quality-of-life assessment|Ancillary studies
41346221|NCT01935167|DRUG|DW1029M 600mg|DW1029M 150mg 2 tablets b.i.d
41346222|NCT01935167|DRUG|DW1029M 1200mg|DW1029M 300mg 2 tablets b.i.d
41490599|NCT04145453|BEHAVIORAL|Control Group 2 general nutritional recommendations|Participants will receive general nutritional recommendations to increase fruit and vegetables consumption
41490600|NCT02735850|DRUG|L19-IL2|L19-IL2 added to SBRT
41490601|NCT02735850|RADIATION|SBRT|
41490602|NCT02735850|OTHER|No intervention|
41490603|NCT02302664|PROCEDURE|PRP Injection into Achilles tendon rupture gap|PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
41018910|NCT02700230|PROCEDURE|Computed Tomography|Undergo CT scan
41490604|NCT02302664|PROCEDURE|Imitation Injection into Achilles tendon rupture gap|Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
41490605|NCT02655744|RADIATION|Standard treatment protocol with combined chemoradiation|
41490606|NCT00714961|DRUG|Clopidogrel (SR25990)|plus acetylsalicylic acid (ASA)
41490607|NCT00714961|DRUG|Placebo|plus acetylsalicylic acid (ASA)
41490608|NCT05571865|DIETARY_SUPPLEMENT|Probiotic|Oral administration of a probiotic
41490609|NCT01789827|OTHER|Laboratory Biomarker Analysis|Correlative studies
41490610|NCT01789827|PROCEDURE|Radionuclide Imaging|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
41346223|NCT01935167|DRUG|Placebo|Placebo 2 tablets b.i.d.
41490611|NCT01789827|BIOLOGICAL|Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
41490612|NCT05200546|DIAGNOSTIC_TEST|molecular assays to screen for eXDR|"VRE detection will be performed using VIASURE Vancomycin resistance Real Time PCR Detection Kit.~BD MAX Check-Points CPO will be used to detect carbapenemase-producing organisms."
41490613|NCT03891186|BEHAVIORAL|Metacognitive Training in Schizophrenia (MCT)|"MCT is a group program with eight modules referring to common cognitive and biases in solving problems in schizophrenia. The following topics of MCT are: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 and 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5) and depression and low self-esteem (module 8). Each session lasts 45 to 60 minutes and follows a protocol defined in the manual Metacognitive Training for Psychosis (MCT) that is currently available in 35 languages (available in www.uke.de/mkt)."
41490614|NCT03891186|OTHER|Treatment As Usual (TAU)|In both groups will be maintained the TAU.
41490615|NCT00114166|DRUG|topotecan hydrochloride|
41490616|NCT05211414|BEHAVIORAL|Yoga Based Daily Excercise|Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
41346224|NCT06039904|DEVICE|Natural rubber knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either natural rubber and inserted at the front of the support body (to cover the patellar).
40827003|NCT00005636|DRUG|pemetrexed disodium|
40827004|NCT05799989|PROCEDURE|Surgical fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
41018911|NCT02700230|OTHER|Laboratory Biomarker Analysis|Correlative studies
41018912|NCT02700230|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
41018913|NCT02700230|OTHER|Quality-of-Life Assessment|Ancillary studies
41018914|NCT02700230|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT imaging
41018915|NCT02700230|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41018916|NCT02700230|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
41018917|NCT02700230|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41018918|NCT02700230|PROCEDURE|Biopsy|Undergo tissue biopsy
41018919|NCT02700230|OTHER|Questionnaire Administration|Ancillary studies
40827005|NCT05799989|PROCEDURE|Atraumatic fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with atraumatic fixation
40827006|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with the digital method
40827007|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with a speculum
40827008|NCT03165123|DRUG|Oral Azithromycin tablet|Oral azithromycin tablet will be given one hour before induction of anaesthesia.
40827009|NCT03165123|DRUG|Intravenous dexamethasone|5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
40827010|NCT02075632|DRUG|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
40827011|NCT00933920|DRUG|Aliskiren|
40827012|NCT00933920|DRUG|Aliskiren|
40827013|NCT00096525|DRUG|lenalidomide|
40827014|NCT00230282|DRUG|Alemtuzumab|3 to 30 mg, IV
40827015|NCT00230282|DRUG|Fludarabine|\[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl\]methoxyphosphonic acid
40827016|NCT00230282|DRUG|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
40827017|NCT01414764|OTHER|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
40827018|NCT01414764|DRUG|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
40827019|NCT02073032|OTHER|No intervention, only observation|
40827020|NCT05553964|DIAGNOSTIC_TEST|In Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
40827021|NCT04617886|OTHER|Sadness induction|"Sadness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
40827022|NCT04617886|OTHER|Happiness induction|"Happiness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
41346225|NCT06039904|DEVICE|Sponge knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either sponge and inserted at the front of the support body (to cover the patellar).
41346226|NCT01700647|OTHER|Breath test- sampling using ENose|Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
40827023|NCT03369041|DRUG|Irinotecan-Eluting Beads|
40827024|NCT02059759|DRUG|Placebo|Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
40827025|NCT02059759|DRUG|1.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
40827026|NCT02059759|DRUG|2.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
40827027|NCT03168243|DIETARY_SUPPLEMENT|High Energy High Protein Tube Feed|Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
40827028|NCT04371640|DRUG|Sirolimus 1 MG/ML|Oral solution
40827029|NCT04371640|DRUG|Placebo|Oral solution
40827030|NCT02793830|OTHER|Daily reminders of taking medications|Reminders. Participants will receive medication-taking reminders from the researcher. These reminders are sent through the mobile application-BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher). BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications. The daily reminders will be sent to participants 15 minutes before every dose of their medications.
40827031|NCT02793830|OTHER|Educational materials|Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (\< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
40827032|NCT03683654|OTHER|Identify Biomarkers of Dietary Intake in Healthy Subjects|Observational study. No intervention.
40827033|NCT03075722|DEVICE|Saturn nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
40827034|NCT05491369|OTHER|Epilepsy application|Nanacara is an epilepsy application which helps people with epilepsy to self-manage their conditions.
40827035|NCT00359944|DRUG|AC-3933|5mg twice daily
40827036|NCT00359944|DRUG|AC-3933|AC-3933, 20 mg twice daily
40827037|NCT00359944|OTHER|Sugar Pill|Sugar Pill twice daily
40827038|NCT02868450|BIOLOGICAL|Blood Sample|
40827039|NCT03671408|OTHER|clinical measurements|only clinical parameters were recorded
40827040|NCT02367391|BEHAVIORAL|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
40827041|NCT02367391|BEHAVIORAL|Control|Usual Care. All participants receive the active medication, Varenicline.
40827042|NCT03419273|PROCEDURE|bariatric surgery|We are recruiting only those going through bariatric surgery
40827043|NCT03467490|BEHAVIORAL|DED self-management|This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
40827044|NCT01344044|DEVICE|BCI|24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
40827045|NCT04094649|DEVICE|Ultrasound Vagus Nerve Stimulation (DECIMA)|This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
41157388|NCT06324188|OTHER|Usual Care|Usual care will consist of optimal AF therapy based on guideline recommendations and local protocols and usage.The choice of therapies and medications follows routine care in line with medical guidelines and local policies at the discretion of the treating physician and should be based on the individual medical status of each study patient.
41157389|NCT00850798|DRUG|Intensive glycemic control|Intensive glycemic control
41346227|NCT01700647|OTHER|Laryngoscopy and bronchoscopy|Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
40827046|NCT05235347|BIOLOGICAL|Sotrovimab|500mg IV
40827047|NCT04774900|PROCEDURE|Administration of oxygen|Administration of high-flow oxygen via face mask to a high fidelity mannequin.
40827048|NCT04774900|PROCEDURE|Administration of drug in a nebulizer|Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.
40827049|NCT04774900|PROCEDURE|Securing intravenous line|Securing an intravenous line at the forearm of high fidelity mannequin.
40827050|NCT04774900|PROCEDURE|Administration of IV drug|Administration of bronchodilator via IV line to a high fidelity mannequin.
41157390|NCT00850798|DRUG|Conservative glycemic control|OADs and insulin
41157391|NCT05512234|DIETARY_SUPPLEMENT|L. reuteri|Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
41157392|NCT05512234|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days
40827051|NCT04774900|PROCEDURE|Needle decompression of tension pneumothorax|Needle decompression of tension pneumothorax on a high fidelity mannequin.
40827052|NCT03159507|DIETARY_SUPPLEMENT|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
40827053|NCT02363374|DRUG|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
40827054|NCT02363374|RADIATION|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
40827055|NCT02363374|RADIATION|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
40827056|NCT02363374|DRUG|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
40827057|NCT02363374|PROCEDURE|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
40827058|NCT04600336|DRUG|Oxybutynin Chloride|Given PO
40827059|NCT04600336|DRUG|Placebo Administration|Given PO
40827060|NCT04600336|OTHER|Quality-of-Life Assessment|Ancillary studies
40827061|NCT04600336|OTHER|Questionnaire Administration|Ancillary studies
40827062|NCT01911312|DEVICE|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
40827063|NCT01911312|DEVICE|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
40827064|NCT05110469|DRUG|Magnesium sulfate|"IV Magnesium sulphate 30 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
40827065|NCT05110469|DRUG|Meperidine|"IV Meperidine 0.5 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
40827066|NCT01988545|OTHER|1,5 nmol/kg,GLP-1 sc injection|
40827067|NCT01988545|OTHER|1,5 nmol/kg GLP-1 9-36amide, sc injection|
40827068|NCT01988545|OTHER|Exendin-4 ;10 ug,sc injection|
40827069|NCT01988545|OTHER|saline|
40827070|NCT03208920|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.
40827071|NCT03208920|OTHER|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
40827072|NCT05762861|OTHER|Experimental|Patients will be every two weeks monitored by the researchers' team, taking into consideration lung function, symptoms, physical activity, pulse oximetry, body temperature, need for relief medication and Sputum characteristics. Over the 18 months, they will be the target of health education interventions, 2 individual and 2 in group.
40827073|NCT05070910|BEHAVIORAL|Therapy|The intervention performed in the practicum will not be able to be influenced by the study investigators and the intervention may be different for each child based on their needs
40827074|NCT04274153|BIOLOGICAL|Gardasil9|Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).
40827075|NCT04461574|DEVICE|Orcellex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
40827076|NCT04461574|DEVICE|Cervex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
40827077|NCT02306304|OTHER|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
40827078|NCT02754115|OTHER|Hyperthermic intraperitoneal chemotherapy|Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively
40827079|NCT03866538|DRUG|Withdrawal of Oral Budesonide|The intervention arm will taper and stop budesonide therapy (withdrawal).
40827080|NCT00279097|DEVICE|High Frequency Chest Wall Oscillation|
40827081|NCT03999138|DIAGNOSTIC_TEST|MRI|MRI studies (non-contrast) will consist of a free-breathing localizer (\~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of \< 3 minutes.
40827082|NCT03897946|BIOLOGICAL|Birth dose hepatitis B vaccine|Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
41157393|NCT04896502|BEHAVIORAL|Standard of Care Education|Education regarding recognition and removal of in-home asthma triggers
40827083|NCT04185974|RADIATION|C12 re-irradiation|51 Gy(RBE) or 54 Gy
40827084|NCT04185974|RADIATION|Photon re-irradiation|54 Gy(RBE) or 60 Gy
40827085|NCT00058526|BIOLOGICAL|Immunotherapeutic SB719125 (Primary)|Intramuscular injection
40827086|NCT05765149|OTHER|No intervention|This is an observational study, no intervention will be implemented.
40827087|NCT05378932|OTHER|Actigraphy|Sleep efficiency recording at home by means of actigraphy during 10 consecutive days.
40827088|NCT05378932|OTHER|Recording of proximal and distal skin temperature and temperature of the bedroom|"Recording of proximal and distal skin temperature at home by data loggers placed on the skin during 10 consecutive days.~Recording of temperature of the bedroom by a data logger during 10 consecutive days."
40827089|NCT05378932|OTHER|Questionnaires assessing subjective sleep quality|"One-off questionnaires assessing subjective sleep quality. The Pittsburgh Sleep Quality Index (PSQI) evaluates sleep quality with questions about sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction during the last month.~The Epworth Sleepiness Scale evaluates daytime sleepiness and comprises 8 items (situations) during which individuals assess how likely they would fall asleep."
41346228|NCT04383535|OTHER|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
40827090|NCT05378932|OTHER|Sweat test|One-off measurement of sweating by a sweat test at the hospital.
40827091|NCT05378932|OTHER|Urine melatonin assay|Two urine melatonin at home during 24 hours, one during a week day and one during the weekend
40827092|NCT05378932|OTHER|Polysomnography|Sleep architecture assessed by a polysomnography during one night at home.
41346229|NCT04383535|OTHER|Placebo|Single infusion of saline solution, in addition to standard care. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
41346230|NCT05525065|DRUG|GlucoCorticoid|Glucocorticoid as calculated in prednisone oral equivalents.
40827093|NCT05378932|OTHER|Standardized psychological and neuropsychological assessment|One-off psychological and neuropsychological assessment of patients with HED during a hospital visit
40827094|NCT05877040|DRUG|Rituximab|Open label proof-of-concept study with intravenous Rituximab, given at the dose of 1g in one day, followed by the same dose after two weeks
40827095|NCT02498067|BEHAVIORAL|rPlan dual protection waiting room app intervention|
40827096|NCT03283098|DRUG|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.
40827097|NCT03283098|DRUG|Placebo|Placebo supplied to match active intervention.
41346231|NCT04012762|DEVICE|Whole body vibration training|Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.
41346232|NCT00592176|DRUG|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
41346233|NCT00149110|PROCEDURE|Sleep deprivation|3 days with a normal night between
40827098|NCT01960543|DRUG|fentanyl 15 microg|
40827099|NCT01960543|DRUG|Bupivacaine 7 mg|
40827100|NCT01960543|DRUG|Bupivacaine 9 mg|
40827101|NCT01960543|DRUG|Levobupivacaine 7 mg|
40827102|NCT01960543|DRUG|Levobupivacaine 9 mg|
40827103|NCT03024138|RADIATION|Repeat CT scan|
41018920|NCT00061048|BIOLOGICAL|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
41018921|NCT01752933|DRUG|SGI-110|SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
41018922|NCT05455567|DIAGNOSTIC_TEST|OCTA|Choriocapillary vessel density calculated with OCTA
40827104|NCT02764528|BEHAVIORAL|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
40827105|NCT02764528|BEHAVIORAL|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
40827106|NCT02764528|BEHAVIORAL|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
40827107|NCT05669586|DRUG|Antitumor therapy guided by organoid drug sensitivity test|Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
40827108|NCT03076086|OTHER|Induced sputum procedure|induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
40827109|NCT03023826|DRUG|LY3202626 (R-Fasting)|Administered orally
40827110|NCT03023826|DRUG|LY3202626 (T1-Fasting)|Administered orally
40827111|NCT03023826|DRUG|LY3202626 (T1-Fed)|Administered orally
40827112|NCT03054597|DEVICE|Circular light motion|Exercise with circular light motion
40827113|NCT03054597|DEVICE|Diagonal light motion|Exercise with diagonal light motion
40827114|NCT03054597|DEVICE|Peripheral light motion|Exercise with peripheral light motion
40827115|NCT03054597|PROCEDURE|Exercise|
40827116|NCT02710435|DEVICE|Reducer System|An aid in the management of chronic refractory angina pectoris
40827117|NCT02209948|DRUG|Temozolomide|
40827118|NCT02885857|DRUG|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
41509012|NCT02899195|DRUG|Durvalumab|On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration. Maintenance: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
40827119|NCT02299570|BIOLOGICAL|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
40827120|NCT02299570|OTHER|Placebo|A suspension of saline and cryoprotectant
40827121|NCT06356012|DRUG|Imiquimod|Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.
40827122|NCT06356012|PROCEDURE|Loop Electrosurgical Excision Procedure|Active comparator group will be treated with LEEP.
40827123|NCT01975337|DRUG|Alisporivir|Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
40827124|NCT02372708|DRUG|dinitrophenyl(DNP)|
40827125|NCT02372708|RADIATION|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
40827126|NCT04465877|DRUG|JTT-662|Active drug tablets containing JTT-662
40827127|NCT04465877|DRUG|Placebo|Placebo tablets matching in appearance to the active drug tablets
40827128|NCT00854217|PROCEDURE|acute normovolemic hemodilution|
40827129|NCT03415698|DRUG|G-CSF|G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
40827130|NCT03415698|DRUG|Standard Medical Therapy|Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
40827131|NCT01457950|DRUG|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
40827132|NCT01457950|DRUG|placebo|double-blind phase: placebo subcutaneous injection, single dose
40827133|NCT01457950|DRUG|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
41018923|NCT05265949|BEHAVIORAL|diet and physical activity intervention|Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring
41018924|NCT04840095|DRUG|Ketones|Sports supplement that is administered mid-scan.
41346234|NCT00149110|PROCEDURE|Light therapy|Daily light therapy for 29 weeks
41509013|NCT05429866|DRUG|Checkpoint Blockade, Immune|Immune checkpoint blockade drugs target the immune system by blocking control pathways regulating anti-tumor immunity and thereby reinvigorate their activities against cancer.
41346235|NCT00149110|PROCEDURE|Diurnal rhythms|Keeping the day-night cycle constant by use of educational measures
41346236|NCT00149110|BEHAVIORAL|Exercise|Moderate intensity daily exercise for 30 minutes at least
41346237|NCT00149110|DRUG|duloxetine|60 mg daily
41346238|NCT00149110|DRUG|duloxetine|60 mg daily
41346239|NCT03850210|DEVICE|Short Splint|Short Splint that permits maximal wrist flexion and up to 45° of wrist extension with a block to 30° of MCP joint extension.
41509014|NCT01229137|DEVICE|SRD-1 conversion|
41018925|NCT04840095|DRUG|Glucose|Supplement is administered mid-scan.
40827134|NCT05425654|DRUG|Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide|The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1. On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes. Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle. During each cycle, you will be in the hospital. After the second cycle of chemotherapy, PBPCs will be collected. You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions. Busulfan, carmustine and cyclophosphamide will be given to you for 5 days. After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein. You will be in the hospital for at least 3 weeks.
40827135|NCT01703117|DRUG|Riluzole|20-22 subjects between the ages of 60-85 will receive study drug.
40827136|NCT01703117|DRUG|Placebo|20-22 subjects between the ages of 60-85 will receive placebo
40827137|NCT01715350|DRUG|PM012|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
41346240|NCT03850210|DEVICE|Traditional Long Splint|Traditional splint is a forearm-based dorsal thermoplastic splint that immobilizes the wrist in neutral position with a block to 30° of metacarpophalangeal (MCP) joint extension
40827138|NCT01715350|DRUG|Placebo|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
40827139|NCT02187523|DRUG|Hydrochlorothiazide|
40827140|NCT02187523|DRUG|Telmisartan|
40827141|NCT02187523|DRUG|Telmisartan/HCTZ FDC|
40827142|NCT00336167|DRUG|bezafibrate (drug)|
40827143|NCT02168972|DEVICE|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
40827144|NCT01230515|OTHER|Individual patient interview, focus group and structured survey|
40827145|NCT01230515|OTHER|interview, focus group and structured survey|
41509015|NCT03166137|DEVICE|Carbon dioxide laser|Radiation by carbon dioxide laser
40827146|NCT01230515|OTHER|interview, focus group and structured survey|
40827147|NCT01230515|OTHER|interview, focus group and structured survey|
40827148|NCT04338724|DRUG|CS1002|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
40827149|NCT00293904|BIOLOGICAL|CYT005-AllQbG10|
40827150|NCT01725230|DRUG|Fostamatinib|100-mg tablet
40827151|NCT01725230|DRUG|Rosuvastatin|20-mg tablet
40827152|NCT01725230|DRUG|Simvastatin|40-mg tablet
40827153|NCT01291693|BEHAVIORAL|Personal Counseling|At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
40827154|NCT01291693|BEHAVIORAL|Computer-generated feedback letters|At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
40827155|NCT04638842|BEHAVIORAL|Online Intervention Grief COVID-19|The online Intervention Grief COVID-19 aims to provide to the target population a self-applied intervention based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of normal grief, advice and guidance on how to find emotional relief, with the aim that survivors allow themselves to validate their experience of emotional pain and recognize it as a normal part of their process of adaptation to loss, what does grief deprived of rights consist of, specifically from the contingency of COVID-19, establish self-care measures for people in different areas of their life (physical, emotional, cognitive and spiritual), direct the survivor to relocate the died in his life without his memory causing suffering, in addition to beginning to resume his life project, adjusting according to his needs and goals. The sessions will be delivered in a frequency of one session every three days.
41018926|NCT00588913|BIOLOGICAL|aldesleukin|
41018927|NCT00588913|BIOLOGICAL|therapeutic autologous lymphocytes|
41346241|NCT01045876|DRUG|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
41346242|NCT01045876|OTHER|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
41346243|NCT03362216|DRUG|Compound Methyl Salicylate Liniment|Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days
41346244|NCT03362216|DRUG|Diclofenac Sodium Liniment|Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
41346245|NCT02520141|OTHER|Laboratory Biomarker Analysis|Correlative studies
41346246|NCT02520141|BIOLOGICAL|Ramucirumab|Given IV
41509016|NCT03166137|DEVICE|Cryotherapy|Device using cooling effect
40827156|NCT05145855|OTHER|Patient-tailored multimodal neglect rehabilitation|Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.
40827157|NCT02031081|DRUG|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
40827158|NCT02031081|DRUG|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
41157394|NCT04896502|OTHER|Interactive Video (IAV) Telemedicine|Interactive video assessment of asthma triggers in the home.
41346247|NCT04140474|DEVICE|Archimedes procedure|All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN
41346248|NCT01490333|DIETARY_SUPPLEMENT|Vitamin D3|The vitamin D3 will be taken daily.
41346249|NCT03832023|OTHER|Screening and initiating preventive therapy in communities|Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.
41346250|NCT03602638|DRUG|Sitagliptin|Sitagliptin 100mg QD
40827159|NCT03162484|BEHAVIORAL|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
40827160|NCT00408096|PROCEDURE|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
40827161|NCT06120361|DIAGNOSTIC_TEST|Plasma APS 2 score|APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
41018928|NCT00588913|DRUG|zoledronic acid|
41346251|NCT03602638|DRUG|Acarbose|Acarbose
41346252|NCT02927535|DRUG|TNF blockers monotherapy|
41018929|NCT02659865|DRUG|Placebo|Administered orally
41018930|NCT02659865|DRUG|LY3039478 original formulation|Administered orally
41018931|NCT02659865|DRUG|LY3039478 new formulation|Administered orally
41018932|NCT04231435|DRUG|Fedratinib|Oral
41346253|NCT03824457|DRUG|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
41346254|NCT03824457|DRUG|Ringer lactate|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
41018933|NCT04231435|DRUG|Digoxin|Oral
41018934|NCT04231435|DRUG|Rosuvastatin|Oral
41018935|NCT04231435|DRUG|Metformin|Oral
41018936|NCT06257784|PROCEDURE|Oxygen Therapy|Patients who have SpO2 \< 92% on room air will undergo oxygen therapy (nasal cannula or Venturi-mask).
40827162|NCT06120361|DIAGNOSTIC_TEST|Plasma p-tau217/np-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
41157395|NCT01075100|DRUG|Ixabepilone|20 mg/m2 on Days 1 and 8
41157396|NCT01075100|DRUG|Carboplatin|carboplatin AUC=2.5 on Days 1 and 8
40827163|NCT06120361|DIAGNOSTIC_TEST|Plasma p-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
40827164|NCT06120361|DIAGNOSTIC_TEST|Plasma neurofilament light (NfL)|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
40827165|NCT06120361|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
40827166|NCT06120361|DIAGNOSTIC_TEST|MRI and CT of the brain|Structural brain imaging
41157397|NCT03994900|DIAGNOSTIC_TEST|Blood sampling for HbNO assessment|Blood sampling
41157398|NCT04714411|DRUG|Omadacycline|Omadacycline monotgherapy
40827167|NCT06120361|DIAGNOSTIC_TEST|Different cognitive tests|Both standard paper-and-pen tests as well as digital cognitive tests will be evaluated.
40827168|NCT05497258|DEVICE|Artificial intelligence assistant system|The AI-assisted diagnosis system can provide the direction of disease diagnosis in real time and assist the doctor to give the final diagnosis
41346255|NCT02186535|DIETARY_SUPPLEMENT|Vitamin D and Calcium|
40827169|NCT06296160|OTHER|Intervention Group|"A- (Intervention Phase= (Day-1) + (Day-15)~1. Obtain a lung ultrasound after the midweek dialysis session.~2. The 8-zone lung ultrasound method calculates the number of B-line scores.~3. Reduce the dry weight by 500 g if the B-line score is \>0.54/zone (BLS\>5). considered a day one.~4. The dry weight will be reduced only if the arterial blood pressure at the end of the session is BP \>110/60 mmHg and the patient had no hypotension episode during the session.~5. The adjustment of dry weight based on lung ultrasound should not be made on the same day as the standard approach adjustment (Regular monthly clinical standards modification.~6. Check the Blood Pressure 3 times/ day on the non-dialysis following the ultrasound.~7. Check the ambulatory blood pressure for 48 hours (Baseline on day 1 and Follow-up on Day 60).~B - Observational Phase= (Day-30) + (Day-45) + (Day-60)\]."
41157399|NCT05005338|DRUG|BIIB122 (DNL151)|Oral doses
41157400|NCT05005338|DRUG|[14C] BIIB122 ([14C] DNL151)|Intravenous doses
41157401|NCT03682237|DEVICE|Carbohydrate counting, automated bolus calculation|Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.
41157402|NCT03682237|DEVICE|Flash glucose monitoring (FGM)|Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.
41346256|NCT04724772|DRUG|Tranexamic acid injection|Injection of tranexamic acid preoperatively
41346257|NCT01129414|DRUG|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
41509017|NCT01128309|BEHAVIORAL|Stress Reduction Intervention|eight week group program, plus daily homework practice
41509018|NCT01128309|BEHAVIORAL|Active Control intervention|weekly group meetings for eight weeks, plus daily homework practice
40827170|NCT03186391|OTHER|Data collected|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
40827171|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
40827172|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
40827173|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
40827174|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
40827175|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
41157403|NCT03594578|BEHAVIORAL|Episodic future thinking|Prospective thinking intervention
41157404|NCT03594578|BEHAVIORAL|Episodic recent thinking|Sham episodic thinking
41157405|NCT05943379|DRUG|RC48-ADC in Combination with gemcitabine|RC48-ADC IV (intravenous) 2.0mg/kg IV, Q2W, 8W; Q4W, 40W Gemcitabine Intravesical 1000mg induction QW,8W; maintenance Q4W,40W
41346258|NCT01129414|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
41346259|NCT01129414|DRUG|Omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration: oral"
41509019|NCT02117739|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
41509020|NCT02117739|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
40827176|NCT00979368|DRUG|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
40827177|NCT03385265|BEHAVIORAL|DIPPer Academy|The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
40827178|NCT03385265|OTHER|Standard of Care|Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
40827179|NCT01773343|PROCEDURE|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
41157406|NCT05833776|PROCEDURE|spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with fentanyl (25ug)|group I (30 patients) received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with IPACK Block using plain bupivacaine 0.5% (15ml).
41509021|NCT02371655|PROCEDURE|Diet|A low-fibre diet for three days before the examination
40827180|NCT05499338|PROCEDURE|Stretching program|The stretching programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. The final stretching position was that which generated a sensation of moderate-intense tightness in the muscles, but without exceeding the pain threshold. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
41346260|NCT04048057|OTHER|Exercise|"Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power."
41346261|NCT03510403|DEVICE|nastent™|Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.
41346262|NCT06390293|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete. The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
41346263|NCT06390293|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
41346264|NCT03202589|OTHER|FOCUS Echocardiography|FOCUS Echocardiography
41346265|NCT01165294|DRUG|Placebo|An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
41346266|NCT01165294|DRUG|ketamine|An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
41346267|NCT04075955|DRUG|Zyprexa® (OLANZapine 5MG)|"Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)"
41346268|NCT04075955|DRUG|Emend® (Aprepitant)|"Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)"
41346269|NCT01917591|DEVICE|Punch biopsies treated with MariGen Wound ECM dressing|Weekly dressing changes and review of wounds.
41346270|NCT01917591|DEVICE|Punch biopsies treated with Oasis ECM dressing|Weekly dressing changes and wound review
41346271|NCT00467948|DRUG|cefazolin|
41346272|NCT05846269|OTHER|Educational Intervention|Educational intervention addressing trauma-informed care and resiliency.
41346273|NCT00357240|DRUG|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
41346274|NCT00357240|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
41346275|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
41346276|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
41346277|NCT00357240|DRUG|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
41346278|NCT00357240|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
41346279|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
41346280|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
41346281|NCT06168981|OTHER|Chewing Gum|The patient will be asked to chew gum before the surgery during the 2 minutes. Anxiety level will evaluated before and after chewing gum.
41346282|NCT01518673|PROCEDURE|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
41346283|NCT02167490|PROCEDURE|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
41346284|NCT01867580|DEVICE|V.A.C.Ulta with Prontosan instillation|NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)
41346285|NCT01867580|DEVICE|V.A.C.Ulta without instillation|NPWT only
41346286|NCT04582162|OTHER|Unsplinted implants|Patients received ball abutments on each implant without splinting for retaining an implant retained mandibular overdenture.
41346287|NCT04582162|OTHER|Splinted implants|Patients had their implants splinted using Rhein bars with ball extension for retaining an implant retained mandibular overdenture.
41346288|NCT04399304|PROCEDURE|simultaneous bilateral high tibial osteotomy|One-stage simultaneous bilateral high tibial osteotomy
41346289|NCT04399304|PROCEDURE|Staged bilateral high tibial osteotomy|Two-stage bilateral high tibial osteotomy
41346290|NCT06281314|DEVICE|Vespa software|The Vespa2.0 project refers to the production of tasks useful for neuropsychological rehabilitation, aimed at subjects suffering from Alzheimer's Dementia, Parkinson's and Multiple Sclerosis. It is a neuropsychological rehabilitation project using Virtual Reality (VR).
41346291|NCT05174351|OTHER|beta blocker discontinuation|beta blocker discontinuation
41346292|NCT03557229|DRUG|Melatonin 5 mg|Oral: 50 mg once daily for 5 days
41346293|NCT03557229|DRUG|Vitamin C 1 GM Oral Tablet|Oral: 1 GM every 6 hours for 5 days
41346294|NCT03557229|DRUG|Vitamin E 400 UNT|Oral: 400 UNT every 8 hours for 5 days
41018937|NCT06257784|PROCEDURE|Non-Invasive Ventilation (NIV)|Patients with P/F \< 250 or Ph \< 7,35 with PCO2 \> 50 mmHg will undergo Non-Invasive Ventilation (NIV) (high flow nasal cannula or CPAP).
41346295|NCT03557229|DRUG|N-acetylcysteine|Oral: 1200 mg every 12 hours for 5 days
41346296|NCT04323098|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
41346297|NCT04840394|DRUG|BDB018|BDB018 is an immunotherapy agent.
41346298|NCT04840394|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
41346299|NCT06339281|DRUG|apatinib mesylate+Capecitabine Tablets|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;"
41346300|NCT06339281|DRUG|apatinib mesylate+Fulvestrant injection|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Fulvestrant injection 500 mg, intramuscular injection, q4w, once on d1 and d15 in the first cycle;"
41018938|NCT06257784|PROCEDURE|Invasive Ventilation|Patients with P/F \< 150 associated to dyspnea at rest (moderate to severe, shortness of breath and/ or tachypnea (\>24 breaths/min) despite NIV for at least 2 hours or patients with Ph \< 7,2 with PCO2 \> 60 mmHg despite NIV for at least 2 hours will undergo invasive ventilation (intubation).
41018939|NCT02305303|PROCEDURE|Diary|A diary written prospectively during the ICU stay by the staff and relatives
41157407|NCT06209905|PROCEDURE|Alveolar ridge augmentation|Alveolar ridge augmentation in the three dimensions with either intervention; Ti-PTFE + bone mixture, or Khoury (Bone-plate) technique + bone mixture.
41490617|NCT04787874|BEHAVIORAL|Prehabilitation Program|"Nutrition component: Participants will receive information on how to follow a healthy diet (Mediterranean-style diet) with emphasis on whole foods, plants, lean protein, olive oil; restriction of red meats, processed meats, processed foods, added sugar)~Exercise component: Participants will receive an activity tracker to use during the study period (3+ weeks before surgery, and 30 days after surgery). Participants will be assigned strength exercises to work on core strength and proximal muscle strength (biceps/triceps, quads, hamstrings, calves).The exercises will mainly be focused on strengthening the abdominal wall. Exercises will be tailored to patients' individual capabilities. They will also be assigned cardio exercises - either low-intensity steady state cardio vs High Intensity Interval training. Level of cardio exercise will be tailored based on patient's Duke Activity score and baseline activity."
41157408|NCT01553578|OTHER|questionnaire administration|Ancillary studies
41157409|NCT01553578|PROCEDURE|therapeutic touch|Receive healing touch therapy
41157410|NCT01553578|BEHAVIORAL|management of therapy complications|Receive healing touch therapy
41157411|NCT01553578|BEHAVIORAL|management of therapy complications|Receive guided imagery audiotapes
41157412|NCT01553578|PROCEDURE|standard follow-up care|Receive standard care
41157413|NCT06642337|OTHER|Educational program +Oral Iron therapy|The Nutritional Education Program is a structured intervention designed to enhance caregivers' understanding of nutrition and improve dietary practices for children suffering from iron deficiency anemia. The program comprises six weekly workshops lasting 1.5 hours each, focusing on essential topics such as the importance of iron in child development, identifying and preparing iron-rich foods, and practical meal planning strategies. Participants will engage in hands-on cooking demonstrations and receive educational materials, including recipe cards and meal planning tools, to support their learning. Knowledge assessments will be conducted at the beginning and end of the program to measure improvements in caregivers' nutritional knowledge.
41157414|NCT01242033|DIETARY_SUPPLEMENT|red raspberries|single serving of one, two or four cups red raspberries
40827181|NCT01637389|OTHER|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
41157415|NCT01242033|DIETARY_SUPPLEMENT|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
41157416|NCT02391571|DRUG|Oxycodone/Naltrexone Capsules|Oxycodone/Naltrexone to be taken with stable dose of Methadone
41157417|NCT02391571|DRUG|Oxycodone|Oxycodone to be taken with stable dose of Methadone
41157418|NCT02391571|DRUG|Placebo|2 day placebo run in prior to test and active drug phase of study
41346301|NCT04646850|OTHER|Color duplex ultrasound of the carotid arteries|Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).
41346302|NCT06263400|BEHAVIORAL|psychoeducation and follow-up study|In the study, we hypothesized that the caregiver psychoeducation program (consisting of six sessions over a 3-week period) would improve depressive symptoms in depressed patients, increase recovery levels, reduce the caregiver's burden, and reduce emotional expression levels in the family.
41346303|NCT03086148|DRUG|Ketamine|Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
41346304|NCT03086148|DRUG|Normal saline|Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
41346305|NCT02531919|DRUG|Sodium Bicarbonate|Given PO
41346306|NCT03978286|DRUG|Vortioxetine|10 mg per day
41346307|NCT03978286|DRUG|Sertraline|75 mg per day
41346308|NCT04024449|OTHER|Group A|ovarian function test in control group
41346309|NCT02474628|DIETARY_SUPPLEMENT|sodium bicarbonate|
41346310|NCT02474628|DIETARY_SUPPLEMENT|calcium carbonate|
41346311|NCT03527836|DRUG|Lidocaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with lidocaine
41346312|NCT03527836|DRUG|Bupivacaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with bupivacaine
41346313|NCT03527836|DRUG|Mixture brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
41346314|NCT00000405|PROCEDURE|Exercise intervention|
41157419|NCT05827809|BEHAVIORAL|Unified Protocol (UP-C/A) for children and youth with anxiety disorders and /or depression|A transdiagnostic psychological group treatment, Unified Protocol (UP-C/A), one intervention, is tested for children and youth with anxiety disorders and/or depression seeking help in routine care in two primary care locations. Parents are at the same time offered parent training in a group format coupled with the module the children are working on. Feasibility, acceptability and effect of the intervention will be studied, with child self-report, parent-report and therapist assessment.
41157420|NCT01379521|DRUG|everolimus|
41157421|NCT01379521|DRUG|everolimus placebo|
41157422|NCT00428441|DRUG|Warfarin|tablets, based on INR levels, according to D-dimer levels
41157423|NCT04981184|DEVICE|Gait and balance measurement|Virtual gait training procedures are included. Balance training procedures with Biodex Balance system are included too.
41346315|NCT05465668|DRUG|DWP16001 Drug A|DWP16001 Drug A
41346316|NCT05465668|DRUG|DWP16001 Drug C|DWP16001 Drug C
41346317|NCT01910272|DEVICE|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
41346318|NCT00284167|BEHAVIORAL|tailored web-based weight management intervention|
41346319|NCT04258449|DEVICE|DOvEEgene Fleur Sampling|Patients will undergo uterine sampling with DOvEEgene Fleur endometrial sampling device prior to surgical intervention, in addition to standard of care treatment.
41509022|NCT02371655|DRUG|Faecal Tagging|Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
41346320|NCT00902512|DRUG|Treatment A|Viagra® 100 mg tablet, administered with water single dose
41346321|NCT00902512|DRUG|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
41346322|NCT00902512|DRUG|Treatment B|Sildenafil 100 mg CT administered with water single dose
41346323|NCT00902512|OTHER|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
41346324|NCT00902512|DRUG|Treatment C|Sildenafil 100 mg CT administered without water single dose
41346325|NCT00902512|OTHER|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
41346326|NCT06002997|OTHER|Pregnancy and/or delivery complications|Analysis of post-delivery reports for pregnancy and/or delivery complications.
41346327|NCT06002997|OTHER|Periodontal disease|Measuring clinical periodontal parameters for assessing presence of periodontal disease.
41346328|NCT03257306|PROCEDURE|ureteral double-J stent removal using magnet|Double-J ureteric stent removed using magnet
41346329|NCT03257306|PROCEDURE|ureteral double-J stent removal using cystoscopy|Double-J ureteric stent removed using cystoscopy
41346330|NCT00741767|DRUG|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
41346331|NCT01624974|DRUG|MK-1029|MK-1029 150 mg tablets taken QD
41346332|NCT01624974|DRUG|Placebo|Placebo tablets (matching the MK-1029 150 mg tablets) QD
41346333|NCT01624974|DRUG|Montelukast (ML)|ML 10 mg tablets QD
41509023|NCT02371655|DRUG|Bowel cleansing|Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
41509024|NCT02371655|PROCEDURE|CT colonography|CT Examination of the colon aimed to detect polyps and cancer
41509025|NCT01914692|DRUG|Somatostatin|Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
40827182|NCT01637389|OTHER|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
40827183|NCT03117946|OTHER|Biological samples|blood and tumor tissue sample
40827184|NCT03445728|DRUG|Nicorandil|After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h
41346334|NCT01877811|DRUG|RXDX-105|"During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment."
40827185|NCT03445728|OTHER|Placebo|After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h
40827186|NCT04257175|BIOLOGICAL|CAR-T CD19|The CAR-T infusion will be given in IV infusion. The target dose is 1 X 106 positive CAR / kg T cells (range: 0.5-1.5X 106 CAR / kg positive T cells).
40827187|NCT00320749|DRUG|Capecitabine|Will be give on days 8-21
40827188|NCT00320749|DRUG|Docetaxel|Will be given on days 1 and 8,
41346335|NCT05930444|DIAGNOSTIC_TEST|Multimodal Machine Learning Program for Auxiliary Diagnosis of Eye Diseases|Patients presenting with eye-related chief complaints initially complete a mobile phone application. This application utilizes patient medical history and relevant images (such as selfies and photos from eye examinations) to provide intelligent diagnosis. The diagnosis remains undisclosed to the patients. Subsequently, patients seek medical attention and undergo clinical examination by a skilled clinician. The clinical diagnosis is subsequently reviewed by a second experienced clinician. If the diagnoses align, it is considered the gold standard. In cases of discrepancy, the consensus reached by the two clinicians becomes the gold standard.
41346336|NCT04485468|OTHER|Questionnaire|The patient answers the questionnaire directly following his consultation or teleconsultation or may arrange a telephone appointment with the clinical research associate a little later.
41346337|NCT03017040|DEVICE|CT scan|A CT scan of the wrist
41346338|NCT03017040|DEVICE|Fluoroscopy Scan|A fluoroscopy scan of the wrist.
41346339|NCT00554853|DRUG|pioglitazone|daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily
41346340|NCT00554853|DRUG|Sublingual nitroglycerine|Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.
41346341|NCT01521260|PROCEDURE|placebo|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
41346342|NCT01521260|PROCEDURE|Chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
41346343|NCT02999360|BEHAVIORAL|Language therapy|There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
41490618|NCT02399930|OTHER|Respiratory & Heart Rate Data Collection|"This is a purely observational study - no intervention is being administered. Data is being collected from the medical record and patient monitoring devices.~Participants will wear the cableless device on their chest. This is a lightweight, small device that sticks onto the skin. We will record breathing rate and respiratory rate from this device. We will also collect this information from the medical record.~If a participant is placed on telemetry monitoring during the study period, we will collect information about alarm alerting patterns."
41490619|NCT02821052|DRUG|insulin degludec/insulin aspart|Enrolled patients will be treated with Ryzodeg® under routine clinical practice.
41346344|NCT02999360|BEHAVIORAL|Background Music|30 minutes background music only
41346345|NCT02999360|BEHAVIORAL|Aerobic Exercise|There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
41346346|NCT02777164|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
41346347|NCT02026934|DEVICE|CliniMACS CD34 Reagent System|Following screening and enrollment, peripheral blood or bone marrow collection will be performed on the donor followed by subsequent CD34+ cell selection using the Miltenyi CliniMACS device. There is no limit to the number of CD34+ progenitors that can be administered. The CD34+ selected cells will be infused within 12 hours of the initiation of processing.
41490620|NCT05061186|OTHER|Resistive Expiratory muscle Training Group|"Mild Resistive Expiratory Technique \[Expiratory Muscle Strength Training (EMST150)- six-week training protocol approximately 20 min per day\] The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for six weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
41490621|NCT05061186|OTHER|Conventional Breathing Exercise Group|"Breathing Exercises: (approximately 20 minutes per day)~● Pursed lip breathing: (Sit with your back straight. Inhale through your nose for two seconds. Purse your lips like you're blowing on hot food and then breathe out slowly, taking twice as long to exhale as you took to breathe in. 4-5 times a day)~● Diaphragmatic breathing: (Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs. Breathe in slowly through your nose Tighten your stomach muscles, letting them fall inward as you exhale through pursed lips. Practice this exercise 5-10 minutes about 3-4 times per day).~● Incentive spirometer: (Hold in an upright position. Breathe in slowly and as deeply as possible. Hold your breath as long as possible (at least for 5 seconds). Then exhale slowly Rest for a few seconds and at least 10 times every hour)"
41490622|NCT06394349|COMBINATION_PRODUCT|PRP+308nm|PRP+308nm
41490623|NCT06394349|COMBINATION_PRODUCT|NS+308nm|NS+308nm
40827189|NCT00320749|DRUG|Gemcitabine|A fixed dose rate will be give on days 8 and 15.
40827190|NCT00002440|DRUG|Indinavir sulfate|
40827191|NCT00002440|DRUG|Ritonavir|
40827192|NCT00002440|DRUG|Abacavir sulfate|
40827193|NCT00002440|DRUG|Amprenavir|
40827194|NCT00002440|DRUG|Nelfinavir mesylate|
40827195|NCT00002440|DRUG|Saquinavir|
41346348|NCT02845115|DEVICE|Conventional implantation|"Usual implantation technique of a middle ear implant. The principle of the ossicular stimulator middle ear transducer MET 7000 (Middle Ear Transducer, METTM) is to directly transmit sounds on the ossicles bypassing the outer ear. Their constraint is the surgical placement of the implant.~MET 7000 system (OTOLOGICS LLC, USA) is the implant that the investigators will use for their patients. The stimulator is usually placed against the body of the anvil by simple contact in the case of sensorineural hearing loss. In the case of mixed hearing loss, the stimulator will come in contact with the bracket using a titanium clip (ossicular prosthesis used in otologic surgery for ossiculoplasties). The optimized version corresponds to the use of the conventionally used in mixed deafness and applied to neurosensory deafness art. It is screwed onto the mastoid bone, the motor is suspended in the mastoid cavity and transmits vibrations to the body of the anvil by simple contact of the transducer."
41346349|NCT02845115|DEVICE|optimized implantation with laser velocimetry|
41346350|NCT02510976|DRUG|prucalopride|
41346351|NCT02510976|DRUG|placebo|
41346352|NCT01555541|DRUG|Ofatumumab|1000 mg IV days 0, 7, 14, 21
41346353|NCT01555541|DRUG|Etoposide|10 mg/Kg IV over 24 hours daily, days 1-4
41346354|NCT01555541|DRUG|Cytarabine|2000 mg/m2 IV twice daily, days 1-4
41346355|NCT05743725|DRUG|Dexmedetomidine|dexmedetomidine loading 1 microgram/kg bolus in 10 minutes followed by 0.2-1 microgram/kg/hour till the end of surgery
41346356|NCT05743725|DRUG|Magnesium sulfate|2 gm magnesium infusion for 30 minutes
41346357|NCT01245972|PROCEDURE|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
41346358|NCT06248710|DRUG|Oxytocin nasal spray|Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be used to induce an oxytocin (OT) release. Participants will apply three sprays in each nostril which will result in a dose of 24 I.U of oxytocin per participant
41346359|NCT06248710|OTHER|Animal-Assisted Intervention|The dogs involved in the study are trained and used to work with different people in animal-assisted interventions. The dog will be familiarized with the room and the material as well as the staff of the study. The dog will be specifically trained for this study. The dog will be involved for a maximum of 3 sessions per day (approx. 20 minutes in total) and 2 days per week.
41346360|NCT06248710|DRUG|Placebo|The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.
41346361|NCT00489502|BEHAVIORAL|Brief Counseling|
41346362|NCT00489502|DEVICE|REE Assessment|
41346363|NCT04307589|OTHER|Observation|An observational follow-up study will be implemented over a period of 2 years, consisting of 3 test occasions with a fixed time interval of 1 year in between (T0 = baseline, T1 = 12 months, T2 = 24 months). Data will be collected in participants who provide grandchild care in a non-residential grandparent context as well as in a sample of non-caregiving grandparents and a sample of middle-aged and older adults not being a grandparent. All three samples will thus be prospectively monitored over a period of 2 years.
41346364|NCT00732654|DRUG|Milk Protein Extract Immunotherapy goal of 4mg/day|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
41346365|NCT00732654|DRUG|Milk Protein Extract Immunotherapy goal of 7mg/day|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
41346366|NCT00732654|DRUG|Milk Powder Immunotherapy goal dose 2000 mg/day|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
41346367|NCT00732654|DRUG|Milk Powder Immunotherapy goal dose 1000mg/day|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
41346368|NCT03211104|DIETARY_SUPPLEMENT|curcumin|
41346369|NCT03211104|DIETARY_SUPPLEMENT|Placebo|
41346370|NCT03884127|DRUG|Ezetimibe 10mg|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
41346371|NCT03884127|DRUG|Orlistat 120 MG|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
41346372|NCT02283346|RADIATION|HDR brachytherapy + hypofractionated EBRT|"Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).~+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints)."
41346373|NCT04207125|BEHAVIORAL|Multilevel psychotherapeutic intervention programme|"Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called therapy recommendations and coping strategies, effective implementation. 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme.~Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes."
41346374|NCT04431141|DRUG|Teneligliptin|Teneligliptin alone
41346375|NCT04431141|DRUG|Empagliflozin|Empagliflozin alone
41509026|NCT06382532|DIAGNOSTIC_TEST|Niacin skin reaction test|Nicotinic skin reaction, also known as nicotinic flush reaction, occurs when a solution of nicotinic acid methyl ester briefly contacts the skin. Following penetration through the skin barrier into the subcutaneous tissue, it generates nicotinic acid (vitamin B3). Under the action of phospholipase A2 (PLA2), cyclooxygenase (COX), and other enzymes, arachidonic acid (AA) on the cell membrane is cleaved to produce prostaglandins, leading to local vasodilation, increased blood perfusion, and the transient appearance of erythema on the skin.
41346376|NCT04431141|DRUG|Teneligliptin and Empagliflozin|Teneligliptin and empagliflozin
41346377|NCT03780088|BEHAVIORAL|mTranS-C|mobile health
41346378|NCT01661231|DEVICE|Astron/Pulsar-18 stent|Peripheral Vascular Intervention
41346379|NCT00380406|DRUG|Leuprolide acetate|
41346380|NCT01192100|BEHAVIORAL|Breakfast Skipping|Participants will continue to skip breakfast each morning.
41346381|NCT01192100|BEHAVIORAL|Normal Protein Breakfast Meals|Participants will consume normal protein breakfast meals each morning.
40827196|NCT02813668|BEHAVIORAL|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
40827197|NCT01391598|DRUG|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
40827198|NCT01391598|DRUG|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
40827199|NCT03211793|DRUG|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
40827200|NCT03211793|OTHER|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
40827201|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Oral Solution
41346382|NCT01192100|BEHAVIORAL|Protein-rich Breakfast Meals|Participants will consume protein-rich breakfast meals each morning.
41346383|NCT00438776|DRUG|olanzapine|2.5mg to 15mg daily
41346384|NCT00438776|DRUG|sugar pill|matching placebo to olanzapine
41346385|NCT00528840|BIOLOGICAL|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
41346386|NCT04432376|DRUG|miconazole 2% oil|Drug treatment of otomycosis for 14 days
41157424|NCT06611813|DRUG|Adjuvant treatment combined with Toripalimab|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the third week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of trastuzumab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative and postoperative adjuvant therapy for a total of 1 year.
41157425|NCT06611813|DRUG|HR+ HER2 breast cancer|During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of trastuzumab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative and postoperative adjuvant therapy for a total of 1 year.
41346387|NCT04432376|DRUG|vehicle oil|Placebo treatment of otomycosis for 14 days
41346388|NCT00410514|DRUG|Mirabegron|oral
41346389|NCT00410514|DRUG|Placebo|oral
41346390|NCT01748903|DEVICE|Target 360°, 2D Coils, Nano Coils|
41346391|NCT03665987|BEHAVIORAL|consultation in preoperative assessment clinic|The treatment group will be seen in the preoperative clinic before hospitalization, while the control group will get anesthetic consultation after hospitalization without clinic service. No additional interventions will be given during and after surgery.
41346392|NCT04369586|DRUG|meplazumab for injection|single dose: 6 dose level, multiple dose: 0.3mg/kg/dose
41346393|NCT04369586|DRUG|Placebo|placebo
41346394|NCT04161313|OTHER|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test.
41346395|NCT04161313|OTHER|pulmonary function test|It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75
41157426|NCT05657613|DRUG|CYP450 Cocktail and Transporter Substrates with Pacritinib|"Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)~Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg)~Days 8-22: Oral doses of pacritinib 200 mg BID approximately 12 hours apart~Day 17: Single oral dose of transporter substrates (digoxin 0.25 mg and rosuvastatin 5 mg) will be coadministered with the AM dose of pacritinib 200 mg.~Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg) will be coadministered with the AM dose of pacritinib 200 mg."
41157427|NCT05657613|DRUG|Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of bosentan 125 mg BID"
41157428|NCT05657613|DRUG|Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of fluconazole 200 mg QD."
41346396|NCT04161313|OTHER|Functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
41346397|NCT04161313|OTHER|Peripheral muscle strength|Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.
40827202|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 125 mg|Oral Solution
40827203|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 250 mg|Oral Solution
41157429|NCT05580783|OTHER|Test meal labelled with 54Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe
41157430|NCT05580783|OTHER|Test meal labelled with 57Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe
41157431|NCT05580783|OTHER|Test meal labelled with 58Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
41157432|NCT01033097|DRUG|DNK333 5 mg|5 mg oral
41346398|NCT04161313|OTHER|Respiratory muscle strength|Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
41346399|NCT05802290|DRUG|Nivolumab 240 MG in 24 ML Injection|nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
41157433|NCT01033097|DRUG|Placebo to 5 mg|5 mg placebo oral
41157434|NCT01033097|DRUG|DNK333 25 mg|25 mg oral
41157435|NCT01033097|DRUG|Placebo to 25 mg|25 mg placebo oral
41157436|NCT01033097|DRUG|DNK333 100 mg|100 mg oral
40827204|NCT03554772|DRUG|Placebo|Oral Solution
40827205|NCT03788447|OTHER|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
40827206|NCT03788447|OTHER|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
41157437|NCT01033097|DRUG|Placebo to 100 mg|100 mg placebo oral
41157438|NCT01033097|DRUG|Betamethasone 4 mg|4 mg oral
41157439|NCT01033097|DRUG|DNK333 1mg|1 mg oral
41346400|NCT04831606|PROCEDURE|debridement|Cleaning of the wound area
40827207|NCT05126160|DIAGNOSTIC_TEST|Immune Score Based Radiomics|To establish an immune score based radiomic staging system for nasopharyngeal carcinoma
40827208|NCT02889679|PROCEDURE|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
41157440|NCT01033097|DRUG|Placebo to 1mg|1 mg placebo oral
41157441|NCT01507753|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
41157442|NCT01507753|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
40827209|NCT02889679|PROCEDURE|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
40827210|NCT02889679|PROCEDURE|Standard polypectomy|Standard polypectomy will be performed for diminutive (\<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
40827211|NCT04894643|RADIATION|Proton Ions|According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
40827212|NCT04894643|DRUG|Nab-PACLitaxel|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes."
40827213|NCT04894643|DRUG|Gemcitabine|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel."
41346401|NCT04831606|DEVICE|Offloading|Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
41346402|NCT04831606|DEVICE|Advanced dressing|Protect the wound with Advanced dressing
40827214|NCT04894643|DRUG|Capecitabine|Concomitant to proton-radiotherapy (on the same days, within week 14-19)
40827215|NCT04894643|PROCEDURE|Surgical resection of the pancreas (when feasible)|Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
40827216|NCT01024582|PROCEDURE|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
40827217|NCT01024582|PROCEDURE|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
40827218|NCT01024582|RADIATION|accelerated partial breast irradiation|
41157443|NCT01507753|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
41346403|NCT04831606|DEVICE|Blue Light Photobiomodulation|2 minutes irradiation of blue light performed with EmoLED device
41346404|NCT03652090|PROCEDURE|cell sampling|nasal brushing to collect cells
41346405|NCT05546749|DEVICE|RelieVRx|The virtual reality device that will be piloted is called RelieVRx, which incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. RelieVRx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences.
41346406|NCT05546749|DEVICE|Sham VR|The sham VR control is a non-immersive set of 56 daily virtual experiences, tuned to the length of the RelieVRx.
41346407|NCT00597532|DIETARY_SUPPLEMENT|Soy|soy (soy protein supplementation 50 grams/day)
40827219|NCT01024582|RADIATION|image-guided radiation therapy|
40827220|NCT01545882|DRUG|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
41346408|NCT00597532|DIETARY_SUPPLEMENT|Milk|placebo (milk protein supplementation 50 grams/day)
41346409|NCT05604066|DIAGNOSTIC_TEST|Magnetic Resonance (MR) Elastography|Magnetic resonance imaging (MRI) imaging technique that creates a visual map (Elastogram) to show the stiffness of body tissues
41346410|NCT05604066|DIAGNOSTIC_TEST|MRI structural imaging|MRI structural imaging will be done at the same time as MR elastography.
40827221|NCT02220023|DRUG|INOmax Inhalation|
40827222|NCT00970450|DRUG|Paracetamol|Paracetamol 1 g i.v. once
40827223|NCT00970450|DRUG|Tropisetron|Tropisetron 5 mg i.v. once
40827224|NCT00970450|DRUG|Placebo|Saline
40827225|NCT00002319|DRUG|Doxorubicin hydrochloride (liposomal)|
41346411|NCT05077280|RADIATION|stereotactic body radiotherapy|Stereotactic Body radiotherapy will be given to 1-5 target metastases in 3 doses over 8 days or less. Each dose will be 15Gy for a total dose of 45GY
41490624|NCT06295848|BEHAVIORAL|Exercise|An individual program will be organized for each patient according to the exercise test result. Since the patients have both arthritis and HTN, aerobic exercises will be given at moderate intensity (40-60% VO2 reserve) according to ACMS recommendations. Xrcise Runner Med treadmill and Xrcise Care 2.5.8.3 software will be used for aerobic exercises. Resistant exercises will be given under the supervision of a physiotherapist, calculating 1 repetitation maximum (1-RM) in the main muscle groups.Patients will perform isotonic exercises with 3 sets of 15 repetitions with a resistance of 60% of 1-RM. The education sessions will be conducted by a multidisciplinary team of health professionals (nurse, physiotherapist and dietician) under the leadership of a clinician experienced in CR. Education topics will consist of 60-minute sessions covering heart-healthy eating, setting health-related goal, exercise, diet, healthy weight loss, smoking cessation, and stress/coping.
41490625|NCT04299451|OTHER|Open dialogue about CAM|1-hour dialogue about CAM with a nurse specialist as an integrated part of conventional oncology care
40827226|NCT04140201|DRUG|Simvastatin 40mg|Drugs that lower lipid level
40827227|NCT04140201|DRUG|Fenofibrate 200mg|Drugs that lower lipid levels
40827228|NCT04140201|DRUG|Omega 3 fatty acid|Drugs that lower lipid levels
40827229|NCT02265419|DEVICE|Extracorporeal treatment with the Cytosorb adsorber|The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
40827230|NCT02229214|DRUG|Qsymia|
40827231|NCT02229214|DRUG|Placebo|
40827232|NCT02495064|DRUG|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
40827233|NCT05226364|PROCEDURE|Rubber tourniquet|The blood sample is taken with a rubber tourniquet
40827234|NCT05226364|PROCEDURE|Fabric tourniquet|The blood sample is taken with a fabric tourniquet
40827235|NCT05226364|PROCEDURE|Without tourniquet|The blood sample is taken without tourniquet
40827236|NCT03488589|DIAGNOSTIC_TEST|serum samples for HEV RNA PCR|serum samples HEV RNA PCR
40827237|NCT02996799|OTHER|Umbilical cord milking|Milking of the umbilical cord at delivery
40827238|NCT03351686|DRUG|Tranexamic Acid|Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
41346412|NCT05077280|DRUG|Immunotherapy|Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
41346413|NCT02421640|DRUG|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
41346414|NCT02421640|DRUG|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
41346415|NCT04574141|DIETARY_SUPPLEMENT|a prolonged release tablet and a spray containing melatonin|prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.
41346416|NCT01699776|DRUG|Ivabradine|7.5 my b.id. by mouth for 12-14 weeks
41346417|NCT01699776|DRUG|Digoxin|1.25 mg once a day by mouth, for 12-14 weeks.
41346418|NCT01628718|BEHAVIORAL|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
41346419|NCT01628718|BEHAVIORAL|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
41346420|NCT02165644|DRUG|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
41346421|NCT02165644|DRUG|Nimodipine|Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
41346422|NCT00002041|DRUG|Amphotericin B|
40827239|NCT03058666|DRUG|Aerosolized Calfactant|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
40827240|NCT03058666|DEVICE|Solarys|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
40827241|NCT05220280|DRUG|Imatinib|Oral imatinib 400 mg tablet once a day for 14 days.
40827242|NCT05220280|DRUG|Infliximab|Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
40827243|NCT01215617|BEHAVIORAL|Aerobic Interval training|Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
40827244|NCT01215617|BEHAVIORAL|Control|Standard medical treatment
40827245|NCT03800589|PROCEDURE|phacoemulsification with implantation of the Ex-Press|The conjunctiva is dissected with the base in the limbus. A square scleral flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Mini seton was implanted at 12 o'clock according to the standard technique.
40827246|NCT03800589|PROCEDURE|deep sclerectomy, phacoemulsification, ExPress implantation|The conjunctiva is dissected with the base in the limbus. Superficial flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Deep scleral is dissected just below the trabeculo-Descemet membrane. The seton is implanted in the anterior chamber at the height of Schlemm's Canal.
40827247|NCT04906967|PROCEDURE|flaps|coverage of soft tissue defect around ankle
40827248|NCT01442064|DRUG|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
40827249|NCT00139763|PROCEDURE|Educational Materials|
40827250|NCT03512431|DIAGNOSTIC_TEST|Micro sampling|Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
40827251|NCT00871039|DRUG|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
40827252|NCT00871039|DRUG|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
40827253|NCT05030064|DRUG|Intestinal flora capsule|"This research group has independently researched and created a human intestinal flora capsule based on intestinal bacteria transplantation: Intestinal flora capsule, which has been declared a national invention patent (patent number: 2015103040414)."
40827254|NCT05030064|PROCEDURE|placebo capsule|Each placebo capsule is the two-layer empty capsule shell of the Intestinal flora capsule, which is made of titanium dioxide and iron oxide yellow. It is non-toxic and has the same appearance as the authentic Intestinal flora capsule.
40827255|NCT05304143|OTHER|Virtual Immersive Reality Glasses|"The day of the examination, the patient will go to the MRI room and he will be fitted with virtual reality glasses compatible with the MRI equipment. The patient will visualize relaxing contents in open spaces with music and verbal instructions during all the procedure. The contents will be previously validated by the clinical psychologist of the center with experience in this regard.~During the test, the patient's heart rate will be monitored."
40827256|NCT05304143|OTHER|Conventional nurse support|Patients will be treated using the usual support technique to reduce anxiety in the Diagnostic Imaging service
40827257|NCT03627065|DRUG|Parsaclisib|Parsaclisib administered orally once daily at the protocol-defined dose.
41509027|NCT01916174|DRUG|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira B5
40827258|NCT02502513|BEHAVIORAL|Brief computerized intervention|"Computer game Tetris"
40827259|NCT03180437|PROCEDURE|IRE surgery|IRE surgery will be used in local tumor
40827260|NCT03180437|BIOLOGICAL|IRE plus γδ T cells|Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer
40827261|NCT05028517|OTHER|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
40827262|NCT05028517|OTHER|Coaching|A text-based coaching module is added to the FMF Connect app. Coaches support continued use of the app and individualized goal setting.
41346423|NCT02576093|DRUG|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
40827263|NCT04895722|BIOLOGICAL|Pembrolizumab|400 mg or 200 mg pembrolizumab administered via IV infusion.
40827264|NCT04895722|BIOLOGICAL|Pembrolizumab/Quavonlimab|Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.
40827265|NCT04895722|BIOLOGICAL|Pembrolizumab/Favezelimab|Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion
40827266|NCT04895722|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion
40827267|NCT04895722|BIOLOGICAL|MK-4830|800 mg MK-4830 administered via IV infusion
40827268|NCT05857449|DRUG|LPM3480392|Intravenous infusion
40827269|NCT00002650|DIETARY_SUPPLEMENT|folic acid|
40827270|NCT00307567|BIOLOGICAL|Pneumococcal (vaccine)|
40827271|NCT02485925|DEVICE|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
40827272|NCT03624426|DEVICE|Automated Somatosensory Evoked Potential device (EPAD@)|After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
40827273|NCT01887119|DRUG|Eplerenone|
40827274|NCT01887119|OTHER|Placebo|Eplerenone-matched placebo
40827275|NCT05766904|BIOLOGICAL|4CMenB vaccine|Four-component MenB vaccine
40827276|NCT05766904|OTHER|Placebo|0.9% Sodium Chloride Inj. B.P.
40827277|NCT05569538|DRUG|Bomedemstat|Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
40827278|NCT01154283|DEVICE|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
40827279|NCT01696617|DRUG|Aripiprazole 6-week group|
40827280|NCT01696617|DRUG|Aripiprazole 8-week group|
40827281|NCT06036615|OTHER|Exercise Intervention|Patients that will be randomly assigned to this group will be invited to attend up to 72 exercise sessions (3 sessions per week) for 24 weeks (6 months) following a combined aerobic, strengthening and mobility-flexibility exercise program. After the exercise intervention, the will follow a 3-month de-training period, continuing their normal physical activity.
40827282|NCT00085982|DRUG|Metreleptin|Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
41346424|NCT02576093|DRUG|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
41346425|NCT02576093|DRUG|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
40827283|NCT00532025|DRUG|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
40827284|NCT03739957|DEVICE|BPCO Media Kit|Telemonitoring system for patients with COPD
41346426|NCT02576093|DRUG|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
41346427|NCT05789914|PROCEDURE|Flap surgery+bone graft+guided tissue regeneration|after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.
41346428|NCT03769389|DIETARY_SUPPLEMENT|Birhi|"Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt"
41346429|NCT03769389|DIETARY_SUPPLEMENT|Khassab|34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt
41346430|NCT03769389|DIETARY_SUPPLEMENT|placebo|50g of pure glucose dissolved in 100ml of water
41346431|NCT02886338|DEVICE|capsule endoscopy|The magnetic navigated CE would enable detailed investigations of the whole upper gastrointestinal tract, including the esophagus, stomach and duodenum. Using this remote magnetic manipulation, capsule endoscope might improve diagnostic accuracy and extend the examination of specific area of interest in the gastrointestinal tract.
41346432|NCT00379873|DEVICE|ProAdjuster|
41346433|NCT00003991|BIOLOGICAL|aldesleukin|
41346434|NCT00003991|DRUG|histamine dihydrochloride|
41346435|NCT01642004|BIOLOGICAL|Nivolumab|
41346436|NCT01642004|DRUG|Docetaxel|
41346437|NCT00307892|DRUG|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
40827285|NCT03998748|OTHER|Sham Genetic Feedback|Participants will be told either that they have or do not have a genetic predisposition to developing depression.
40827286|NCT01223898|DRUG|Tasigna|
40827287|NCT06394752|DEVICE|Visual Saline Infusion|Visual Saline Infusion (VSI) is a new intrauterine imaging procedure to identify uterine pathology. The VSI device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).
41346438|NCT00307892|DRUG|Placebo|placebo remedy
41346439|NCT01467024|OTHER|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
41346440|NCT05143736|DIAGNOSTIC_TEST|gut and nasal microbiota detection|The nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.
41346441|NCT04222257|DRUG|Antibiotics|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
40827288|NCT06394752|DEVICE|Hydrosonography|Hydrosonography is an ultrasound based intrauterine imaging technique with sensitivity and specificity ranging from 90% to 100% for identifying uterine pathology. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus and using abdominal ultrasound to visualize the uterus.
41346442|NCT04222257|DRUG|Antibiotics|Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
41346443|NCT03531762|DRUG|Tepotinib|Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.
41346444|NCT03531762|DRUG|Omeprazole|Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.
41346445|NCT01958268|PROCEDURE|Pretest and validation of a translated questionnaire|
40827289|NCT04412733|DEVICE|Therapeutic Pulsed Ultrasound|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2). Pulsed ultrasound treatment were applied with 5-cm2 head Enraf-Nonius Sonopuls 434 ultrasound device.
40827290|NCT04412733|DEVICE|Sham Ultrasound|Control group received sham ultrasound treatment
41346446|NCT01271127|RADIATION|CT coronary angiography|patient will undergo one CT coronary angiography
41346447|NCT01816386|OTHER|Acupuncture Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
41346448|NCT01816386|OTHER|Acupressure Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
41346449|NCT00273806|BEHAVIORAL|Intervention for 4 behavioral risks by medical assistants.|
41346450|NCT01864486|DEVICE|Intelligent Retinal Implant System|
41346451|NCT03140722|DRUG|vadadustat|vadadustat
41346452|NCT03140722|DRUG|epoetin alfa|epoetin alfa
41346453|NCT00947089|DEVICE|oxidized regenerated cellulose (Fibrillar SURGICEL)|one gauze made of ORC
41346454|NCT00947089|DEVICE|iodoform gauze|one iodoform gauze
41346455|NCT04416191|OTHER|Limb immobilization|Participants will undergo a 2-week period of leg immobilization
41346456|NCT02098148|DRUG|Xenon|
41346457|NCT02098148|DRUG|Placebo|
41346458|NCT00486148|OTHER|Infant formula (with GOS)|Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
40827291|NCT01920893|DRUG|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
40827292|NCT01920893|DRUG|Dupilumab|Solution for injection; Subcutaneous injection.
41346459|NCT01250301|OTHER|De-nicotinised cigarettes + standard treatment|"Participants will receive de-nicotinised cigarettes to use as required for 2 weeks after their quit day. These cigarettes are intended to provide a replacement for the behavioural and sensory aspects of smoking without supplying nicotine.~Participants will also receive standard NHS Stop Smoking Service treatment. This is a combination of weekly behavioural support and medication (e.g. nicotine replacement therapy/varenicline)."
41346460|NCT01250301|OTHER|Standard Treatment|Participants will receive standard treatment from the NHS Stop Smoking Service.
41346461|NCT03699527|BEHAVIORAL|Multiple questionnaires administered|This is an observational trial
41509028|NCT01916174|DRUG|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira V2
40827293|NCT01920893|DRUG|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
40827294|NCT00623545|DRUG|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
40827295|NCT01945645|BEHAVIORAL|Ready to act|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
41346462|NCT05949463|OTHER|Intermittent teaching unit|The intermittent group students performed an intermittent teaching unit twice a week for eight weeks aimed at promoting healthy physical activity habits. Specifically, the last 15 minutes of each lesson were used. The rest of lessons' time other contents were worked on with no relation to any health physical activity habit (i.e., acrosport, badminton, basketball, volleyball, soccer and athletics).
41346463|NCT05949463|OTHER|No intervention group|The control group students also carried out two Physical Education lessons a week during the intervention period. During these lessons, contents of handball, basketball, alternative sports and traditional games were developed. However, this group did not wear physical activity activity wristbands or receive any behavior modification specific strategy.
41490626|NCT02148679|OTHER|DASH/SRD|Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
40827296|NCT06594796|BEHAVIORAL|Combined lifestyle intervention and LBP care (physiotherapy, exercise therapy)|One of five recognized combined lifestyle interventions (BeweegKuur, CooL, SSIB, SLIMMER, X-Fittt) integrated with LBP care.
40827297|NCT03205852|OTHER|questionnaire|fulfillment of questionnaire
40827298|NCT02825420|DRUG|trabectedin|
40827299|NCT05021562|DRUG|Niraparib|Niraparib capsules
40827300|NCT03508193|OTHER|Nutritional therapy|Whole-foods based smoothie designed to emulate formulas used in EEN
40827301|NCT04695054|DEVICE|Buzzy device plus EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure
40827302|NCT04695054|DRUG|Only EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure
40827303|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
40827304|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
40827305|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
41346464|NCT04692233|BEHAVIORAL|Qigong Baduanjin|Qigong Baduanjin will comprise eight standardized movements. It is practiced as a combination of body movements, breath control, and mindful meditation, which is designed to improve qi function.
41490627|NCT02148679|OTHER|Usual care|Standardized advice to restrict dietary sodium intake to \< 2000 mg/day
41490628|NCT00057993|BIOLOGICAL|trastuzumab|
40827306|NCT00776464|DEVICE|Noveon laser|Two wavelenghts of light
40827307|NCT02526823|DRUG|R-CHOP/CHOPE or ABVD chemotherapy regimen|"R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
40827308|NCT02526823|DRUG|R-CDOP/CDOPE or DBVD chemotherapy regimen|"R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
40827309|NCT06484920|DRUG|ATRA|150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1)
40827310|NCT06484920|DRUG|Pembrolizumab|200mg Q3W pembrolizumab
40827311|NCT00536016|DRUG|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
41490629|NCT00057993|DRUG|exemestane|
41490630|NCT03663439|PROCEDURE|modified shell technique|divided block of bone into two shells and grafting one shell in anterior maxilla
41490631|NCT05094245|PROCEDURE|Stellate Ganglion Block Group|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
40827312|NCT04133896|DIAGNOSTIC_TEST|IL-6, Clusterin, Irisin Level|Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
40827313|NCT04376047|OTHER|Reverse Trendelenburg position|The Reverse Trendelenburg position is a position in which patients' hip and knee are not flexed but the head and chest are elevated at 30° than the abdomen and legs.
40827314|NCT04376047|OTHER|Semi-recumbent position|The semi-recumbent position is an upright positioning of the head and torso at an angle of 45° while legs are lying on the bed.
41346465|NCT04692233|BEHAVIORAL|Light flexibility exercise|Each session will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, back, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
40827315|NCT05879770|OTHER|suture material|Some patients have had a shouldice repair with wire in the past and others with Prolene.
41346466|NCT03552900|BEHAVIORAL|7cups Mobile App|Participants who receive the 7 Cups mobile app will get access to direct online social support by messaging with a listener, participating in group chats as well as evidence-based information and exercises to promote their mental health.
40827316|NCT02442791|DRUG|Byetta (Lilly, Exenatide)|See description of Arms
40827317|NCT02442791|OTHER|20% Human Albumin|See description of Arms
40827318|NCT00911092|PROCEDURE|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
40827319|NCT00911092|RADIATION|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
40827320|NCT00911092|DRUG|Chemotherapy (Fluorouracil and Cisplatin)|"At weeks 1, 5, 8 and 11~* Day 1 to day 4: Fluorouracil 1 gr/m²/day~* Day 1 or 2: Cisplatin 75 mg/m²"
40827321|NCT02588703|BEHAVIORAL|Cognitive Behavioral Therapy|Coping Skills Treatment
40827322|NCT02588703|BEHAVIORAL|Usual Care|Existing DUI program group counseling
40827323|NCT01688947|DRUG|V116517 50-mg tablets|Taken orally twice daily
40827324|NCT01688947|DRUG|V116517 30-mg tablets|Taken orally twice daily
40827325|NCT01688947|DRUG|Pregabalin capsules|1-2 capsules taken orally twice daily
40827326|NCT01688947|DRUG|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
41346467|NCT03552900|BEHAVIORAL|Bliss|Participants who receive the Bliss app will get access to an app that that provides access to important community, health, wellness, academic, and support resources.
41346468|NCT05190757|OTHER|Airway and Ventilation|Insertion of Laryngeal Mask airway for ventilation or use of Face Mask
41346469|NCT04418739|DRUG|Human albumin|Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
41346470|NCT00883649|DIETARY_SUPPLEMENT|Hydroeye|2 Capsules BID
41346471|NCT00883649|OTHER|Inactive Capsule|2 Capsules BID
41490632|NCT03416803|RADIATION|Radiotherapy|Radiotherapy
41490633|NCT01338948|PROCEDURE|preoperative 3D-CT reconstruction|Robotic Surgery with CT reconstruction images using Tile-pro program.
40827327|NCT03396679|OTHER|Ultrasound examination|Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)
40827328|NCT01551290|DRUG|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
41346472|NCT00957723|DEVICE|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
41346473|NCT05648006|BIOLOGICAL|OH2|Oncolytic Type 2 Herpes Simplex Virus
41346474|NCT05648006|DRUG|Capecitabine|1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
41490634|NCT04275882|DIAGNOSTIC_TEST|Electrocardiogram|There will be no new intervention performed for the patients.
41346475|NCT05648006|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.
41346476|NCT03849014|PROCEDURE|Dynamic Hip Screw|Dynamic Hip Screw fixation: Fracture will be reduced under image intensifier. The incision will be made 7-10 cm with a lateral approach. The fascia lata will be incised and the vastus lateralis muscle will be splited along the axis of the femur, without stripping the periosteum. A135° angle guide will be inserted in the lower half of the femoral neck. The barrel of the plate will be guided to the hip screw by direct palpation to minimize the soft-tissue injury. After the insertion of the cortical screw, soft tissue will be protected with 4.5mm drill sleeve during drilling and tapping.
41346477|NCT03849014|PROCEDURE|Proximal Femoral Nail|Proximal Femoral Nail fixation: Fracture will be reduced under image intensifier. The incision 2-3 cm with a lateral approach that extended from the cranial part to the tip of the greater trochanter. After palpating the greater trochanter tip, the nail will be then introduced manually into the femoral shaft. The guide wire of the anti-rotational hip blade then introduced. The hip blade should be introduced in the direction of the lower half of the femoral neck. Drilling will be performed under soft-tissue protection with a retractor. The blade will be inserted, and a distal static locking screw and end cap will be inserted under soft tissue protection with a drill sleeve.
41490635|NCT00621049|DRUG|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
41490636|NCT00621049|DRUG|Docetaxel/Carboplatin|"Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."
41490637|NCT03356574|PROCEDURE|Single-ventricle palliation surgery|Single-ventricle palliation surgery
41490638|NCT00870597|PROCEDURE|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
41490639|NCT00870597|PROCEDURE|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
41490640|NCT03038594|DRUG|Somatropin|
41490641|NCT03038594|DRUG|0.09% Saline Solution|
41490642|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6)|0.5 mL suspension for injection x 2 with 2 months interval
41490643|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
41490644|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
41490645|NCT04390295|DRUG|Placebo|Once daily, 24 weeks
40827329|NCT01551290|DRUG|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
40827330|NCT00144768|DRUG|laronidase|dose of 0.58mg/kg body weight IV every week
41346478|NCT00396968|DRUG|AMD3100|
41346479|NCT00396968|PROCEDURE|Allogeneic Stem Cell Transplantation|
41346480|NCT04683133|DIAGNOSTIC_TEST|Optical coherence tomography assessment|Optical coherence tomography assessment of coronary arteries with intermediate to severe stenosis
41346481|NCT00026039|DRUG|estrogen|
41346482|NCT04624529|OTHER|Self evaluation tool|This self-evaluation tool to evaluate cognitive function, developed by the occupational therapy department, is a paperwork task with guidelines for semi-structured interpretation.
41346483|NCT02496390|BIOLOGICAL|Autologous|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
41490646|NCT04390295|DRUG|SHR3824|Once daily, 52 weeks
41490647|NCT04390295|DRUG|metformin|Three times daily, 52 weeks
41490648|NCT06453135|DRUG|Eculizumab|On the Day 0, participants received a single dose of eculizumab before the transplant surgery: 900 mg (blood type antibody titer ≥ 1:64 and/or body weight ≥ 60 kg) or 600 mg (blood type antibody titer \< 1:64 and body weight \< 60 kg). Plasmapheresis was not planned. When participants developed AMR, they may receive additional dose of eculizumab.
41490649|NCT01630213|DIETARY_SUPPLEMENT|Vitamin D3 + fish oil/fish oil placebo|Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day
41490650|NCT01630213|DIETARY_SUPPLEMENT|Vitamin D3 placebo + fish oil/fish oil placebo|Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
41490651|NCT03202979|DRUG|Trazodone 20 mg|"Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.~After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions."
41490652|NCT03202979|DRUG|Trazodone 10 mg|"Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.~In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
41346484|NCT02496390|BIOLOGICAL|Allogeneic|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
41490653|NCT03202979|DRUG|Placebo|"Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
41346485|NCT01832389|DEVICE|PiCCO|
41490654|NCT02287207|DEVICE|transcranial direct current stimulation (tDCS)|
41490655|NCT01551888|DRUG|Aclidinium/formoterol 400/12μg|Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
41490656|NCT01551888|DRUG|Formoterol|Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
41490657|NCT00670163|BEHAVIORAL|Enhanced Partner Therapy (EPT)|EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
41490658|NCT00670163|BEHAVIORAL|Communidades Positivas (CPOS)|The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
41490659|NCT00670163|BEHAVIORAL|Standard Care|Standard care will consist of usual care for STIs.
41490660|NCT05145881|DIETARY_SUPPLEMENT|Low dose probiotics|Taking 1 package of low dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
40827331|NCT02885870|PROCEDURE|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
40827332|NCT04972227|DRUG|CY6463|oral tablets
41346486|NCT01627041|DRUG|Cytarabine|Given IV
41346487|NCT01627041|DRUG|Daunorubicin Hydrochloride|Given IV
41346488|NCT01627041|DRUG|Decitabine|Given IV
40827333|NCT04972227|DRUG|Placebo|oral tablets
40827334|NCT00495521|DRUG|4-Aminosalicylic acid extended release granules|Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
40827335|NCT00278902|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
40827336|NCT01740479|PROCEDURE|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
41346489|NCT01627041|OTHER|Laboratory Biomarker Analysis|Correlative studies
41346490|NCT01627041|OTHER|Pharmacological Study|Correlative studies
41490661|NCT05145881|DIETARY_SUPPLEMENT|Normal dose probiotics|Taking 1 package of normal dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
41346491|NCT06298838|DEVICE|AURA10® Specimen PET/CT imager|The AURA10 PET-CT specimen imager detects and measures the electron density distribution of a specimen and the radiotracer distribution within a specimen. The function of the system is to acquire and visualize PET and CT images of a specimen, based on which a healthcare professional can rapidly verify whether the correct tissue has been resected. It can be used in any condition that requires resection surgery to visualize the resected specimen. The device is automated and semi-quantitative, i.e., qualitative regarding visualization of structure and radiotracer distribution and quantitative regarding tissue density (Hounsfield units) and radiotracer uptake in the specimen (Bq/ml). The type of specimen required is resected tissue from a patient undergoing resection surgery.
41346492|NCT02296229|RADIATION|stereotactic body radiation therapy|Undergo SBRT
41346493|NCT02296229|OTHER|quality-of-life assessment|Ancillary studies
41346494|NCT02296229|OTHER|laboratory biomarker analysis|Correlative studies
41346495|NCT02296229|DRUG|androgen deprivation therapy|up to 9 months at the discretion of the treating physician
41346496|NCT01396031|BEHAVIORAL|Physical Therapy|Standard of care
41346497|NCT00879788|DRUG|Ramipril 10mg capsules|
41346498|NCT04837781|PROCEDURE|Micro-osteoperforation|Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.
41346499|NCT03518580|OTHER|real-time assessment of biopsychosocial functioning|the participants were asked to provide biopsychosocial data using the mobile device
41346500|NCT02161224|DRUG|FG-4592|Oral
41346501|NCT04022291|BIOLOGICAL|Humulin ®70/30|"Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
41490662|NCT05200000|BIOLOGICAL|SygeLIX-Coll-T|Reconstituted suspension made of Trehalose and chemically treated, grinded, freeze-dried and sterilized Wharton's Jelly used by the patient as eye drops.
41490663|NCT02251691|DRUG|Advagraf|Compare the drug compliance between once daily or twice daily regimen
41490664|NCT02251691|DRUG|Prograf|Compare the drug compliance between once daily or twice daily regimen
41490665|NCT04051112|DRUG|SCB-313|10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
41490666|NCT01697566|DRUG|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
40827337|NCT05863923|BEHAVIORAL|mHealth Messaging to Motivate Quitline use and Quitting among Persons Living With HIV (PLWH) in Vietnam (M2Q2-HIV)|Participants in the intervention group will be exposed to the texting intervention through a series of culturally tailored assessments and motivational text messages from the text messaging system sent throughout the 6 months of duration of the study.
41018940|NCT06391996|DRUG|After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.|During the treatment period, participants received either ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48, or secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The dose of ustekinumab/secukinumab was referenced to the dose used for moderate to severe plaque psoriasis. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category ( \<50 kg, ≥50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.
40827338|NCT05863923|BEHAVIORAL|M2Q2-HIV Comparison|Participants in the comparison group will be exposed to a brief set of five texts with facts about smoking risks and assessment messages that are not culturally tailored from the text messaging system.
41018941|NCT05976698|DRUG|LSD 10 μg|0.5 h after the start of each study session the participants will be administered 10 μg LSD per os in the form of vials containing 1ml 20% EtOH (ethanol).
41018942|NCT05976698|DRUG|LSD 20 μg|0.5 h after the start of each study session the participants will be administered 20 μg LSD per os in the form of vials containing 1ml 20% EtOH.
41018943|NCT05976698|DRUG|Placebo|0.5 h after the start of each study session the participants will be administered placebo per os in the form of vials containing 1ml 20% EtOH.
41346502|NCT04022291|BIOLOGICAL|Biocon Insulin 70/30|"Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
41346503|NCT02829606|OTHER|small scotoma using Head Mounted Display No re-mapping|re-mapping software turned off
41346504|NCT02829606|OTHER|Large scotoma using Head Mounted Display PLUS re-mapping|re-mapping software turned on
41346505|NCT00403390|DRUG|Brand Name Levothyroxine (Synthroid)|Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
41346506|NCT00403390|DRUG|Generic formulation of Levothyroxine|Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
41346507|NCT05667194|DRUG|KH617|KH617 is s freeze-dried powder injection
41346508|NCT01723124|PROCEDURE|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
41346509|NCT05790967|OTHER|Sexual Education|Women in the experimental group will be given education on sexual life during pregnancy. Before the training, preliminary data will be collected and then the participants will be given two hours of individual and face-to-face training.
41346510|NCT02513394|DRUG|Palbociclib|
41490667|NCT01697566|OTHER|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
41490668|NCT01697566|PROCEDURE|Endometrial Biopsy|Endometrial biopsies obtained at baseline and after 4 months.
41490669|NCT01697566|BEHAVIORAL|Lifestyle Intervention|Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
41490670|NCT01697566|BEHAVIORAL|Questionnaires|Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
41346511|NCT02513394|DRUG|Standard Adjuvant Endocrine Therapy|
41346512|NCT04372979|DRUG|Transfusion of SARS-CoV-2 Convalescent Plasma.|2 Convalescent Plasma units of 200-230mL each, inactivated by amotosalen.
41346513|NCT04372979|DRUG|Transfusion of standard Plasma.|2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.
41346514|NCT00791011|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
41346515|NCT00791011|OTHER|Vorinostat|Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
41346516|NCT00791011|OTHER|Bortezomib|A dipeptide boronic acid analogue with antineoplastic activity.
41346517|NCT01983046|DRUG|Three different mixture of acetate, butyrate and propionate and palcebo|
41346518|NCT00182234|BEHAVIORAL|Community Interlink Program|The study intervention is a referral to a specialized oncology nursing program. The standardized care provided by this program includes comprehensive assessment and care planning specific to breast and colorectal cancers during the initial phases of treatment, with a minimum of two home visits. Through consultation with the patient, nurses either provide direct (non-medical) care to address needs identified and/or coordinate linkage to services in the community.
41346519|NCT04782492|PROCEDURE|graft configuration in coronary artery bypass grafting|Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting
41346520|NCT02928081|PROCEDURE|Extended lymphadenectomy|Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
41490671|NCT04421586|BEHAVIORAL|VISTA|VISTA will be an educational intervention.
41490672|NCT00077545|DRUG|triapine|Given IV
41490673|NCT00077545|DRUG|cisplatin|Given IV
41490674|NCT05428410|OTHER|IL-4R|IL-4R was injected subcutaneously.
41490675|NCT05428410|OTHER|Placebo|Placebo was injected subcutaneously.
41490676|NCT00144664|DRUG|MRA(Tocilizumab)|
41490677|NCT00348452|DRUG|tramadol HCl ER; celecoxib|
41509029|NCT04477070|PROCEDURE|Air-polishing with ultrasonic debridement|Use of air-polishing and ultrasonic device (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) to remove plaque and calculus from the surface of the roots of teeth.
41490678|NCT05191303|DEVICE|Mobile intervention of breastfeeding counseling|The mobile intervention of breastfeeding counseling includes an evidence-based information of breastfeeding, which is based on Ten steps of breastfeeding of Baby Friendly Hospital Initiative (BFHI) and Finnish Institute for Health and Welfare recommendation. The links provide more information and videos related to breastfeeding topic. The mobile intervention of breastfeeding counseling allows the client to write comments or notes that can be used in counseling at maternity clinic or hospital. The mobile intervention of breastfeeding counseling also provides an e-mail to non-urgent questions related to breastfeeding. Questions will be answered within 3 or 4 days by a lactation consultant (IBCLC).
41490679|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 90 days)|90 days
41490680|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 180 days)|180 days
41490681|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 270 days)|270 days
41490682|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 90 days)|90 days
41490683|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 180 days)|180 days
41490684|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 270 days)|270 days
41490685|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 90 days)|90 days
41490686|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 180 days)|180 days
41490687|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 270 days)|270 days
41490688|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 90 days)|90 days
41490689|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 180 days)|180 days
41490690|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 270 days)|270 days
41490691|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 90 days)|90 days
41490692|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 180 days)|180 days
41490693|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 270 days)|270 days
41490694|NCT00044109|DEVICE|Magnets|
41490695|NCT05713968|OTHER|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM
41490696|NCT05713968|OTHER|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2 examined by HRIM
41490697|NCT01229644|DRUG|Crenolanib (CP-868,596)|Highly potent inhibitor of both PDGFR receptors alpha and beta
41490698|NCT05414292|DRUG|Rapamune (sirolimus) 1Mg Tablet|Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.
41490699|NCT05414292|BEHAVIORAL|Unilateral resistance exercise training|Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum
41490700|NCT01523223|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo CD8 memory T-cell infusion
40827339|NCT02477735|DEVICE|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
40827340|NCT01165320|DRUG|Caspofungin|
40827341|NCT02046174|BIOLOGICAL|RENCA macrobeads|
41509030|NCT04477070|PROCEDURE|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
41509031|NCT05565079|BIOLOGICAL|Regenerative tissue matrix and enamel matrix derivative|Subjects in this group will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM) and a porcine-derived enamel matrix derivative (Emdogain).
40827342|NCT02275117|BIOLOGICAL|ALD403|
40827343|NCT02275117|BIOLOGICAL|Placebo|
41346521|NCT02928081|PROCEDURE|Standard lymphadenectomy|Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
41346522|NCT01197781|DRUG|FOSTAMATIN|Oral tablets - single dose
41346523|NCT01197781|DRUG|Verapamil|Oral tablets - administered 3 times daily over 4 days
41346524|NCT05714254|DRUG|MEDI0618|Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.
41346525|NCT05714254|DRUG|Placebo|Four doses of IV placebo or SC placebo administered once every two weeks.
41346526|NCT01047462|PROCEDURE|Surgery for acute perforated diverticulitis|Primary resection vs laparoscopic lavage
41346527|NCT03973567|DRUG|selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants|On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
41346528|NCT03973567|OTHER|conventional therapy|Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
41346529|NCT00831857|OTHER|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
41346530|NCT06048913|DRUG|Nimotuzumab|Nimotuzumab 400mg plus normal saline 250ml intravenous infusion for not less than 60 minutes. Starting from week 1 of radiotherapy, 1 dose of the same dose each time for a total of 6 doses. The use of Taixinsen is not interrupted due to interruption of radiotherapy during the administration until the end of radiotherapy.
40827344|NCT06351319|DIAGNOSTIC_TEST|SVM model|Bronchoscopic ultrasound images were analyzed according to SVM mode
40827345|NCT02526862|DEVICE|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
40827346|NCT02526862|DEVICE|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
41018944|NCT02605512|OTHER|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
41018945|NCT04844385|DRUG|Toripalimab|Toripalimab 240 mg, d1, Q3w for two cycles
41018946|NCT04844385|DRUG|Paclitaxel-albumin|Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles
41346531|NCT06048913|DRUG|Tigio|Oral chemotherapy with the tigio regimen is given on days 1 to 2 of radiotherapy, with the drug dose calculated based on body surface area, and the oral tigio course from Monday to Friday is synchronized with radiation therapy.
41346532|NCT06048913|RADIATION|Concurrent radiation therapy|Outline the target area layer by layer on the enhanced CT image, PGTV, PTV. The endangered organs are delineated layer by layer on the cross-section, and extended 0.3cm to form a corresponding plan to endanger the organs. The reverse intensity modulated radiotherapy plan was designed on the Monaco treatment plan system, with a prescribing dose of 56Gy/30F for PTV and 60Gy/30F for pGTV, and the target dose distribution and organ exposure dose were evaluated layer by layer on a cross-sectional surface, and combined with dose-to-volume histogram (DVH) evaluation and optimal treatment plan, the maximum dose of radiation in the spinal cord \< 40 Gy and lung V20\<30%. After the treatment plan is confirmed, the dose is verified on the treatment machine, and the treatment plan is executed after it is accurate. govern
41509032|NCT05565079|BIOLOGICAL|Regenerative tissue matrix|Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
41509033|NCT01320384|OTHER|O2 conventional|standard low flow therapy
41509034|NCT01320384|DEVICE|O2-HFN : high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 50 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
40827347|NCT02526862|DEVICE|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
40827348|NCT01234805|PROCEDURE|yoga therapy|Participates in yoga classes and yoga at home
40827349|NCT01234805|OTHER|questionnaire administration|Ancillary studies
40827350|NCT01234805|PROCEDURE|quality-of-life assessment|Ancillary studies
40827351|NCT02839577|DRUG|High Volume injection without corticosteroid|"Injection with 10 mls 0.5% bupivacaine hydrochloride and~• 40 ml saline around the tendon."
40827352|NCT02839577|DRUG|High Volume injection with corticosteroid|Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
40827353|NCT01294462|DRUG|Ticagrelor|90 mg, oral dose twice daily
40827354|NCT01294462|DRUG|Clopidogrel|75 mg, oral dose once daily
40827355|NCT01294462|DRUG|Acetylsalicylic acid ASA|Low Dose ASA
41018947|NCT04844385|DRUG|Nedaplatin|Nedaplatin 75mg/m2, d1, Q3w for two cycles
41018948|NCT04844385|RADIATION|radiation therapy at a total dose 60 Gy|Radiation therapy at a total dose 60 Gy
41018949|NCT04844385|DRUG|Capecitabine|Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy
41018950|NCT04844385|RADIATION|radiation therapy at a total dose 50 Gy|Radiation therapy at a total dose 50 Gy
41018951|NCT03140891|DEVICE|NHFOV|NHFOV is used as the noninvasive mode after extubation
41490701|NCT03678324|OTHER|Functional MRI and fast bound-pool fraction imaging|"Use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, we would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD.~Neuropsychological assessements will include Wechsler Adult Intelligence Scale, WAIS-III (Digit Span, Symbol-Digit/Coding, and Symbol Search), the Connors Continous Performance text (CPT-II). The Health Questionnaire form, the Center for Epidemiologic Studies Depression Scale (CES-D), the RAND 36-Item Health Survey."
41490702|NCT03641391|PROCEDURE|Intraoperative direct cortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate cortex, was performed using a 5-mm wide bipolar electrode with a pulse frequency of 60 Hz and an amplitude of 1.5 to 6 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
40827356|NCT01344538|DRUG|Ginger Root Extract (Pure Encapsulations)|2.0 g per day (10:1 extract)
40827357|NCT01344538|DIETARY_SUPPLEMENT|Placebo Capsule|2.0 g per day
40827358|NCT02743780|DRUG|MGV354 ophthalmic suspension|
41346533|NCT03998891|OTHER|restricted dietary salt intake|These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
41346534|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
41346535|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|systemic FOLFIRI chemotherapy
41346536|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|bevacizumab
41346537|NCT05155410|DIETARY_SUPPLEMENT|Exogenous Ketone Monoester|Participants will consume 15g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
41346538|NCT05155410|DIETARY_SUPPLEMENT|Placebo|Participants will consume an equivalent volume (30ml) of the active intervention supplement 15 minutes prior to each meal for 14 days. All meals will be provided throughout the 14-day placebo supplementation period.
41346539|NCT01635387|DRUG|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
41346540|NCT04916106|DEVICE|Transcutaneous Electroacupuncture|give diffrent parameter TEA treatment for 4 weeks.
41346541|NCT04514406|DEVICE|APERTO OTW DCB|Drug Coated Balloon Angioplasty
41346542|NCT00122317|DRUG|eculizumab|
41346543|NCT02639754|BEHAVIORAL|Social Network Leader Endorsement|Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.
41346544|NCT02639754|BEHAVIORAL|HIV Counseling|At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
41490703|NCT03641391|PROCEDURE|Intraoperative direct subcortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate subcortical pathways, was performed using a biphasic square-wave pulse delivered at 60 Hz with a current amplitude ranging from 1.5 to 10 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
40827359|NCT02743780|DRUG|MGV354 placebo|Inactive ingredients used as placebo comparator
40827360|NCT00898924|GENETIC|molecular diagnostic method|
40827361|NCT00898924|GENETIC|mutation analysis|
40827362|NCT02491034|BEHAVIORAL|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
40827363|NCT02444546|OTHER|Laboratory Biomarker Analysis|Correlative studies
40827364|NCT02444546|BIOLOGICAL|Sargramostim|Given SC
40827365|NCT02444546|BIOLOGICAL|Wild-type Reovirus|Given IV
40827366|NCT00300482|DRUG|ABT-335|135 mg, daily, 12 weeks
41346545|NCT05472376|OTHER|Retrospective study|Retrospective study
41346546|NCT01968304|OTHER|Iron status follow up|
41346547|NCT02468804|DEVICE|rTMS|TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
41346548|NCT02468804|DEVICE|Sham TMS|Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
41346549|NCT06296043|PROCEDURE|Progressive Muscle Relaxation Exercise Group|Exercise Group
41346550|NCT06296043|PROCEDURE|Su-Jok Intervention|Hand massage with seeds
41346551|NCT01001143|DRUG|Decitabine|
41346552|NCT01001143|DRUG|Bexarotene|
41346553|NCT05307081|DRUG|Artificial Tears|Artificial Tears are an FDA approved intervention
40827367|NCT00300482|DRUG|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
40827368|NCT00300482|DRUG|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
40827369|NCT03208114|OTHER|Receiving written information on breast milk substitute|Receiving written information on breast milk substitute
40827370|NCT01701479|DRUG|ch14.18/CHO|
40827371|NCT01701479|DRUG|Aldesleukin|
41346554|NCT03640520|OTHER|FACETS: Pediatric Resuscitation|Family-centered \& Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of FCC practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
40827372|NCT01701479|DRUG|Isotretinoin|
40827373|NCT00140699|BEHAVIORAL|Balance|
40827374|NCT02141490|DRUG|Ferumoxytol|7.5mg/kg intravenous (IV) infusion
40827375|NCT02141490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|3 MRIs: pre-infusion, 24 and 48 hours post-infusion
41346555|NCT03640520|OTHER|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs (including a brief mention of family-centered care as one of these standards), with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness
41346556|NCT04146402|DRUG|SCT-I10A+chemo|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
41346557|NCT04146402|DRUG|Placebos+chemo|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
41490704|NCT05483803|BEHAVIORAL|Adhera® Caring digital intervention for Type 1 Diabetes|The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).
40827376|NCT00771732|DEVICE|light therapy|6 minute light therapy
40827377|NCT00771732|DEVICE|light therapy|combination of wavelengths
40827378|NCT01143051|DRUG|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
40827379|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
40827380|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
41018952|NCT03140891|DEVICE|NCPAP|NCPAP is used as the noninvasive mode after extubation
41018953|NCT02629406|OTHER|Hypoxia|Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
41018954|NCT00934271|RADIATION|fractionated stereotactic radiotherapy|Audit of outcome
41018955|NCT03372408|OTHER|Chart review|Retrospective chart review of program participation and socio-demographic \& psychosocial characteristics
41018956|NCT00651482|DRUG|Everolimus|
41490705|NCT01935466|DRUG|Pioglitazone|Ever users of Pioglitazone
41018957|NCT00651482|DRUG|Bevacizumab|
41346558|NCT05687292|DEVICE|Clinical decision support system (CDSS) for ventilator weaning|A clinical decision support system (CDSS) will be integrated into a software program (the T3 platform) that is present on all patient bedside computers. The T3 platform is a tool that compiles data from a patient's existing physiologic monitors, ventilator, and laboratory results and graphically displays them on a bedside monitor. The CDSS will be active on all patients receiving mechanical ventilation, but primary use and evaluation will focus on patients meeting study criteria. Twice daily (on morning rounds and evening rounds), patients will be screened for eligibility. During each rounds, teams will review the CDSS and associated risk analytics data used to inform the associated recommendations for ventilator weaning, extubation readiness assessment, and extubation. The clinical team will consider the CDSS in decision making around ventilator weans. If the decision is made not to follow the CDSS recommendations, the clinician will complete a brief survey with rationale.
41346559|NCT05591430|PROCEDURE|Ganglion Impar Neurolysis|block of Ganglion Impar by neurolytic drug
40827381|NCT01410669|BEHAVIORAL|Motivational interviewing (MI)|"MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline."
40827382|NCT01693380|BIOLOGICAL|Influenza vaccine|"Influenza vaccine: schoolchidren in the experimental group received IM administered:~* From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~* 9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart."
40827383|NCT01693380|BIOLOGICAL|Control vaccine|"Schoolchildren from 6 to 8 years of age:~- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered."
40827384|NCT02594098|DRUG|Secukinumab|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
41346560|NCT05591430|PROCEDURE|Bilateral S2, S3 and S4 Pulsed radiofrequency|Bilateral S2, S3 and S4 Pulsed radiofrequency
41346561|NCT05272306|OTHER|Number of attempts for successful transesophageal echocardiography|Transesophageal echocardiography probe will be inserted after induction of anesthesia. Number of attempts for successful transesophageal echocardiography will be recorded.
40827385|NCT02594098|DRUG|Placebo|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
40827386|NCT06046469|DIAGNOSTIC_TEST|CT with contrast|CT abdomen and pelvis with IV contrast
40827387|NCT06046469|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis with contrast
40827388|NCT06046469|PROCEDURE|TURBT|transurethral resection of bladder tumor
40827389|NCT04656041|DRUG|FOLFOX/ nal-IRI|"A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2) Oxaliplatin via IV, predetermined dosage per protocol~* 3) Leucovorin via IV, predetermined dosage per protocol~* 4) 5-Fluorouracil via IV, predetermined dosage per protocol"
40827390|NCT04656041|DRUG|Paclitaxel|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
41346562|NCT05272306|DIAGNOSTIC_TEST|A questionnaire for cardiologist satisfaction|A questionnaire for cardiologist satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
41346563|NCT05272306|DIAGNOSTIC_TEST|A questionnaire for patient satisfaction|A questionnaire for patient satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
41346564|NCT00374101|DRUG|omeprazole|
41346565|NCT00374101|DRUG|pantoprazole|
41346566|NCT03739099|DEVICE|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
40827391|NCT04656041|DRUG|Carboplatin|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
40827392|NCT04656041|RADIATION|Proton Radiation Therapy|Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
40827393|NCT05207332|DIETARY_SUPPLEMENT|CHO+PRO|A vegan product containing carbohydrate and protein
40827394|NCT05207332|DIETARY_SUPPLEMENT|CHO|containing carbohydrate
40827395|NCT00539513|DRUG|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
40827396|NCT00539513|DRUG|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
40827397|NCT02794987|DEVICE|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
41018958|NCT05481112|DRUG|Extended-Release Buprenorphine Injection|Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.
41346567|NCT04358991|DRUG|Ceftazidime-avibactam|collection of blood samples around clinical dosing immediately pre-dose, then at the following times thereafter: 1, 2, 4, 6, 8, and 12 hours and EMR review.
41346568|NCT00589602|PROCEDURE|peripheral blood lymphocyte therapy|T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg.
41346569|NCT00589602|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
41346570|NCT00589602|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation
41346571|NCT00589602|RADIATION|total-body irradiation (TBI)|Treatment will be delivered using 6MV photons twice daily for 3 days
41346572|NCT04021628|OTHER|No intervention- not applicable|No intervention - not applicable
41346573|NCT00031915|DRUG|imatinib mesylate|
41346574|NCT01401985|DRUG|TD-1211|Capsules
41346575|NCT01401985|DRUG|Placebo|Capsules
41346576|NCT00372489|DRUG|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
41346577|NCT01097434|DEVICE|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
41346578|NCT01097434|DEVICE|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
41346579|NCT02039128|DIETARY_SUPPLEMENT|Krill oil or Fish oil|
41346580|NCT02039128|DIETARY_SUPPLEMENT|Placebo|
41346581|NCT05126654|DIETARY_SUPPLEMENT|Partially Hydrolyzed Guar Gum (PHGG)|Partially Hydrolyzed Guar Gum 5 gram/day for 1 month
41346582|NCT04440085|DRUG|Midodrine Hydrochloride|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
41346583|NCT04440085|DRUG|Placebo|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
41018959|NCT02451826|DRUG|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
41018960|NCT05301933|BEHAVIORAL|Behavioral Parent Training (BPT)|BPT is an evidence-based psychosocial intervention that is directed exclusively to parent of children with ADHD and related disorders. BPT focuses on instructing parents to use approaches to enhance the parent-child relationship (e.g., quality time, praise) and proactive discipline strategies (e.g., time out, reward systems) to reduce challenging child behavior.
41346584|NCT00860704|DRUG|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
41346585|NCT00134342|OTHER|T-SPOT TB ELISPOT test|ELISPOT test for detecting T cell responses to tuberculosis antigens.
41346586|NCT03971292|GENETIC|RNA sequencing|Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
41346587|NCT05415449|DEVICE|Gus gear protective wearable device|Gus gear protective wearable device for central line.
41346588|NCT00688389|OTHER|case/control|case: infected dengue fever people control:healthy people
41346589|NCT00981292|DIETARY_SUPPLEMENT|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
41346590|NCT00981292|DIETARY_SUPPLEMENT|Placebo|Pharmaceutical grade silica was utilized as placebo
41346591|NCT03669744|OTHER|telephone survey|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018.
41346592|NCT05263401|DIETARY_SUPPLEMENT|3-hydroxybutyrate|Orally administered pre-meal drinks.
41346593|NCT02174809|BEHAVIORAL|Use of 5As to discuss gestational weight gain|
41346594|NCT02174809|BEHAVIORAL|Usual care|
41346595|NCT05800613|OTHER|Survey|Questionnaire
41346596|NCT03432936|DEVICE|MRI guided procedure software evaluation|MRI guided ablation/biopsy using standard MR imaging along with Philips Interventional iSuite software tools.
41346597|NCT04174872|DRUG|Dexmedetomidine|it has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
41346598|NCT04174872|DRUG|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
41346599|NCT00806650|GENETIC|gene expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
41346600|NCT00806650|GENETIC|protein expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
41346601|NCT00806650|DIAGNOSTIC_TEST|diagnostic laboratory biomarker analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
41346602|NCT00806650|OTHER|immunoenzyme technique|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
41346603|NCT00806650|OTHER|immunohistochemistry staining method|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
41346606|NCT05339035|BEHAVIORAL|Training based on IMB model, motivational interview technique, hippotherapy program|"In the first stage of the research, the Digital Game Addiction Scale for Children will be applied to the entire universe and participants with a digital game addiction score of 73 and above will be determined. According to the criteria of inclusion in the research, students will be informed and those who volunteer to participate in the study will be determined and listed. After the experimental and control groups are determined, the participants will be contacted and data collection forms will be applied. The students in the experimental group will be trained according to the IMB model, the students in the experimental group will be given a 6-session motivational interview program and the students will be taken to the hippotherapy program, which lasts 1 hour once a week for 8 weeks. Hippotherapy applications will be carried out at the horse farm in Amasya, accompanied by expert horsemen."
41346607|NCT00693420|DRUG|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
41346608|NCT00693420|DRUG|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
41018961|NCT05896592|DIAGNOSTIC_TEST|Invasive electrophysiological study|Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
41346609|NCT02072733|OTHER|Comprehensive geriatric assessment|Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
41346610|NCT01902654|OTHER|Cardiovascular risk factors diagnoses collection.|We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
41346611|NCT01902654|OTHER|History of cardiovascular disease|In all patient we collect the history of cardiovascular disease.
41346612|NCT01902654|OTHER|Cardiovascular risk factors association|We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
40827398|NCT04175574|OTHER|Music|The music has no lyrics, has a sustained melodic quality, has no strong rhythms and percussion or base, rate of 60-80 beats per minute, promotes relaxation, calming and soothing, neutral and is unbiased towards any culture or age. The volume of the music will be pre-adjusted to the patients' preference (preferable 30 dB) by the research assistant.
41346613|NCT03609710|DEVICE|Transanal tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
41346614|NCT03609710|PROCEDURE|Left colic artery preservation|Left colic artery preservation during operation for lower rectal cancer
41346615|NCT03609710|PROCEDURE|Anastomotic reinforcing sutures|Anastomotic reinforcing sutures during operation for lower rectal cancer
41346616|NCT03609710|DEVICE|Robotic surgery|Robotic low anterior resection for rectal cancer
41346617|NCT01469637|DRUG|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
41346618|NCT01469637|DRUG|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
41346619|NCT02572089|DRUG|Naloxone|
41346620|NCT02001922|OTHER|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
41346621|NCT01308853|DEVICE|Macrolane|Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
41346622|NCT02258191|DEVICE|telemonitoring|
41346623|NCT02258191|DEVICE|sham telemonitoring|
41346624|NCT01548209|DRUG|Dexmedetomidine|A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
41346625|NCT01548209|DRUG|Placebo|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
41346626|NCT05352321|DRUG|Gemcitabine|for induction chemotherapy
41346627|NCT05352321|DRUG|Cisplatin|for induction and concurrent chemotherapy
41346628|NCT05352321|RADIATION|regular intensity-modulated radiotherapy|in active comparator arm
41346629|NCT05352321|PROCEDURE|surgery|in experimental arm
41346630|NCT05352321|RADIATION|Target-reduction intensity-modulated radiotherapy|in experimental arm
41346631|NCT02272244|BEHAVIORAL|Decision Support & Navigation|
41346632|NCT02272244|BEHAVIORAL|Standard|
41346633|NCT04348786|DRUG|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid
41346634|NCT04348786|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
41346635|NCT05300958|DRUG|Deferoxamine Plus Chemotherapy|Deferoxamine：50mg/kg+500ml normal saline (NS)
41346636|NCT01886352|DRUG|Standard Injection of Levobupivacaine in portal sites.|All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
41346637|NCT01886352|DRUG|Additional injection of 0,5% levobupivacaine.|Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
40827399|NCT05393414|DRUG|Opioid based protocol|Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient
40827400|NCT05393414|DRUG|Opioid sparing protocol|Use of combination of drug dosage frequency and duration of ketorolac injection with acetaminophen oral as standard postoperative pain control for up to 72 hours as requested by each patient
40827401|NCT00820482|DRUG|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
40827402|NCT00820482|DRUG|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
41346638|NCT01886352|DRUG|Intraperitoneal atomization of levobupivacaine.|"Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~1. Each subdiaphragmatic area 0.05 ml/kg~2. Dome of abdomen then settling onto bowel 0.05 ml/kg~3. Surgical dissection site 0.05 ml/kg~4. At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg."
41346639|NCT00655122|DRUG|Dalteparin sodium|Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
41346640|NCT00655122|DRUG|Placebo|Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
41346641|NCT01222936|DRUG|LBH581|25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
41346642|NCT04290260|OTHER|Use of breast bra|Patients will use a breast from admission to hospital discharge
41346643|NCT04290260|OTHER|Usual care (not use of bra)|
41346644|NCT05261594|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 150 mg, oral intake
41346645|NCT05261594|DRUG|Placebo|Placebo capsule, oral intake
41346646|NCT06065241|DIETARY_SUPPLEMENT|LLP-01|Participants in the experimental group will take 2 capsules daily containing 1,000mg of the formulation, LLP-01, for 60 days.
41346647|NCT06065241|OTHER|Placebo|Participants in the placebo group will take 2 capsules daily containing rice flower and small amount of Curcuma Longa for 60 days.
41346648|NCT04555811|DRUG|FT596|FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.
41346649|NCT04555811|DRUG|Rituximab|Rituximab 375 mg/m\^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion
41346650|NCT04258904|COMBINATION_PRODUCT|Skin Care Program|The intervention consists of a Skin Care Program including neat information regarding dermatological complications to the device use, prevention of these and moisturizer to keep healthy skin.
41346651|NCT02894294|OTHER|implementation of seasonal malaria chemoprevention|administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine \[SP\] + Amodiaquine \[AQ\]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
41346652|NCT02942693|DRUG|Apatinib|Apatinib will be used as induction therapy in experimental arm.
41346653|NCT02942693|RADIATION|Particle Therapy|Same total dose and fractionation will be used in both arms.
41346654|NCT03988894|DEVICE|mDASHNa App|The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
41346655|NCT02393612|DRUG|DP-R202|Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks
41346656|NCT02393612|DRUG|Anplag tab|Anplag tab 100mg is administrated to patients with PAD for 12 weeks
41346657|NCT04933253|PROCEDURE|Saline irrigation|Mediastinal irrigation with 2 L of 37 degree Celsius saline prior to chest closure
41346658|NCT00262353|DEVICE|Dialysis with different artificial devices|
40827403|NCT05918653|OTHER|Home Healthcare|No intervention in this study
40827404|NCT01994772|PROCEDURE|Targeted controlled temperature between 32.5 and 33.5°C|Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
40827405|NCT01994772|PROCEDURE|Targeted controlled temperature between 36.5 and 37.5°C|Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
40827406|NCT04231760|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
41018962|NCT05896592|DIAGNOSTIC_TEST|Extracardiac vagal stimulation|"Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon.~Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia."
41346659|NCT04040166|DIAGNOSTIC_TEST|PET/MRI of carotid arteries with 68Ga DOTATATE|PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
41346660|NCT05278936|OTHER|The cataract surgery and the anterior vitrectomy|Surgical
40827407|NCT04231760|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
40827408|NCT03259048|DIAGNOSTIC_TEST|Abdominal ultrasound|Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
41346661|NCT05371132|PROCEDURE|Positron Emission Tomography|Undergo PET
41346662|NCT05371132|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41346663|NCT05371132|DRUG|Zirconium Zr 89-Df-Crefmirlimab|Given IV
41346664|NCT05371132|RADIATION|Intensity Modulated Radiation Therapy|IMRT for Lymphoma patients only
41346665|NCT05414669|DRUG|Allopurinol Tablet 300 mg|Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
41346666|NCT05414669|DRUG|Control Group|Placebo was given orally for a total of 3 days, beginning a day before ESWL.
41346667|NCT04483128|DEVICE|Electrical stimulation: Interferential Current (IFC): Experimental Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. Intensity will depend on subjet's tolerance but without generate visible muscle twitches.~5. Session duration: 25 minutes"
41346668|NCT04483128|DEVICE|Electrical stimulation: Interferential Current (IFC): Control Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. NO intensity (0 mA)~5. Session duration: 25 minutes"
41346669|NCT05193929|DEVICE|OptiPulse™|TheOptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an off loader and shin pumping unit, and the other acts as pressure reducing footwear.Both active and non-active footwear should be worn to give balanced gait
41346670|NCT05193929|DEVICE|Standard of Care offloading device|CAM boot
41346671|NCT04050475|DIETARY_SUPPLEMENT|Fasting Mimicking Diet|The Fasting Mimicking Diet is a low-calorie, five-day eating program meant to promote weight loss and provide the same benefits as more traditional fasting methods.
40827409|NCT01504633|DIETARY_SUPPLEMENT|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
40827410|NCT01304368|PROCEDURE|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
41346672|NCT03592394|DEVICE|Immersive Virtual Reality (Gear VR)|Immersing the user in a total visual environment.
41346673|NCT03270163|DIAGNOSTIC_TEST|Transcutaneous electrical stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple electrical stimulations,~* three electrical doublets at the frequency of 100Hz~For each type of electrical stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
41346674|NCT03270163|DIAGNOSTIC_TEST|Magnetic stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple magnetic stimulations,~* three magnetic doublets at the frequency of 100Hz~For each type of magnetic stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
41346675|NCT03270163|DIAGNOSTIC_TEST|ultrasound measurement|The ultrasound measurement of the thickness of the quadriceps muscle will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening.
41346676|NCT02375464|DRUG|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
41346677|NCT06411106|DRUG|IMIQUIMOD cream 50mg/g|5 mg imiquimod (100mg Aldara®) per treatment site with a 12mm Finn chamber
41346678|NCT04825704|DRUG|Bupivacaine|Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
41346679|NCT04825704|DRUG|Sodium chloride|Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
41346680|NCT04934293|PROCEDURE|Virtual reality|Before proton therapy, virtual reality sessions will be performed.
41346681|NCT02138162|DRUG|enzalutamide|oral
41346682|NCT04202796|PROCEDURE|Catheter ablation|Catheter ablation of arrhythmia
41346683|NCT05232097|BEHAVIORAL|Behavioral therapy|Diaphragmatic breathing exercises
41346684|NCT05232097|BEHAVIORAL|Physiotherapy|Body awareness aiming at the patient becoming aware of the tensed thoracic and abdominal muscles and to reduce the tension by relaxation exercises taught by the psychophysical physiotherapist
40827411|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
40827412|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|250 mg weekly x 4
41346685|NCT04716712|DRUG|Azithromycin|Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
41346686|NCT04716712|DRUG|Placebo|Matching identical placebo in packaging, appearance, and taste.
41346687|NCT04131244|PROCEDURE|In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator|After laparoscopic unilateral oophorectomy, ovarian medulla would be dissected from cortex. After fragmentation of 2 cm square ovarian cortex into smaller pieces they would be incubated PTEN inhibitor and AKT stimulator for 48 hours. Finally we will auto graft these fragments beneath to the fallopian tube peritoneal surface.
41346688|NCT03298048|BIOLOGICAL|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
41346689|NCT03298048|BIOLOGICAL|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
41346690|NCT03298048|BIOLOGICAL|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
40827413|NCT00223977|DRUG|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
40827414|NCT06127043|DRUG|Rosnilimab|PD-1 agonist antibody
40827415|NCT06127043|DRUG|Placebo|Administered via SC
40827416|NCT05523596|DRUG|ICM20|small molecules
40827417|NCT05523596|DRUG|Benznidazole|small molecule
40827418|NCT06162195|DEVICE|The H1 Implant|Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.
40827419|NCT06162195|DEVICE|Cementless total hip replacement|Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
40827420|NCT04912895|DEVICE|PneumoniaCheck|Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
40827421|NCT00159913|DRUG|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
40827422|NCT00159913|DRUG|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
40827423|NCT00159913|DRUG|Placebo|oral; 3 times a day(TID)
40827424|NCT00159913|DRUG|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
41346691|NCT01739374|OTHER|reduced mesh implants|mesh for pelvic floor reinforcement
41346692|NCT03592134|OTHER|esophageal pressure measurement|Measurement of esophageal pressure to determine the optimal non invasive respiratory support
41346693|NCT01858506|PROCEDURE|I-ACE intervention|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
41346694|NCT01858506|PROCEDURE|Standard Lifestyle Advice|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
41346695|NCT04383171|DEVICE|Motomed cycle ergometer (MOTOmed letto2 - Reck, Reckstr 1-5, Betzenweiler 88422, Germany).|
41346696|NCT03644589|BIOLOGICAL|Pembrolizumab|200mg,Given intravenous (IV) infusion, every 21 days
41346697|NCT03644589|DRUG|Cisplatin|75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
41346698|NCT04644965|DIAGNOSTIC_TEST|CombynTM Function & Spaces ECG|Multi-frequency impedance measurement to assess the muscle and fat mass
41346699|NCT04644965|DIAGNOSTIC_TEST|Blood Taking|Sampling of blood of the finger pad to assess liver function
41346700|NCT04644965|DIAGNOSTIC_TEST|Spiroergometry|Spiroergometry to assess cardiopulmonary capacity. The intensity will be raised in steps until total exhaustion. In between each step we will take blood of the ear lobe to determine the lactate level
41346701|NCT04644965|DIAGNOSTIC_TEST|Dordel Koch Test (DKT)|Dordel Koch Test (DKT) to evaluate the motor activity. The DKT is a heterogeneous test battery for children and adolescents and consists of seven parts: lateral jumping, sit and reach, situps, long stand jump, one-legged stand, push-ups and 6-min-run
41346702|NCT04644965|DIAGNOSTIC_TEST|Ultrasound|Ultrasound for abdominal wall muscles
41346703|NCT04644965|DIAGNOSTIC_TEST|Stance and gait analyses|Stance and gait analyses for measuring the core stability
41346704|NCT04340089|BEHAVIORAL|squatting on the toilet|the patients could go to squatting on the toilet at any time as they want to after taking the capsule
41346705|NCT06059833|DIAGNOSTIC_TEST|Magnesium|The aim of the study is to evaluate serum Mg level in type 2 DM patients.
41346706|NCT05013099|BIOLOGICAL|zirconium Zr 89 crefmirlimab berdoxam|Up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First (PETbaseline) within 14 days prior to the onset of IOT, and a second (PETEOC1) 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan (PETEOC1) should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
41346707|NCT04298749|DRUG|GX-P1 or Placebo (dose level 1)|GX-P1 dose level 1 or placebo
41346708|NCT04298749|DRUG|GX-P1 or Placebo (dose level 2)|GX-P1 dose level 2 or placebo
41346709|NCT04298749|DRUG|GX-P1 or Placebo (dose level 3)|GX-P1 dose level 3 or placebo
41346710|NCT01709604|PROCEDURE|CVVH|Ultrafiltration at 35ml/h/Kg
41346711|NCT01709604|PROCEDURE|Standardized therapy regimens|"Standardized therapy regimens included the followings:~1. Remove all contaminated clothing~2. Gastric lavage~3. Receive activated charcoal as quickly as possible~4. Hemoperfusion with activated charcoal(160g)~5. Immunosuppression with methylprednisolone~6. Antioxidants (glutathione,1.2 gram iv twice a day)~7. Supportive care"
41346712|NCT01135004|PROCEDURE|Thoracoscopic bullectomy|Thoracoscopic wedge resection of the diseased lung
41346713|NCT01639300|BIOLOGICAL|GNbAC1|Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
41346714|NCT01639300|BIOLOGICAL|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
41346715|NCT04739995|DRUG|Low-dose naltrexone|4.5 mg LDN/day for 1 year
41346716|NCT00000767|BIOLOGICAL|TBC-3B Vaccine|
41346717|NCT00000767|BIOLOGICAL|Smallpox Vaccine|
41346718|NCT00865995|PROCEDURE|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
41346719|NCT04591873|OTHER|telemedicine|Using telemedicine system to communicate
41346720|NCT04591873|OTHER|traditional communication tools|Use telephone or direct verbal communication
40827425|NCT01669421|DRUG|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
40827426|NCT02024022|DRUG|Standard approach|bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
40827427|NCT02024022|DRUG|Individualized approach|
41346721|NCT04046276|BEHAVIORAL|High Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
40827428|NCT03184363|DRUG|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
40827429|NCT06306690|DIAGNOSTIC_TEST|OCT, OCT angiography, flicker ERG and Ultra Wide Field retinography and autofluorescence.|"the best visual acuity will be evaluated using decimal tables and then converted to logMar.~Ocular fundus examination will be evaluated following pharmacological mydriasis with Tropicamide 1%.~OCT will be essential to quantify the central macular thickness and the thickness of the RPE.~OCT angiography is a non-invasive method to assess the presence or absence of neovascular membrane and macular flow density.~Color and ultra wide field autofluorescence images of the retina will be performed with Zeiss Clarus retinography to search for signs that identify different types of RP and predict their activity and evolution.~Electroretinogram flicker (ERG) is a common measure of cone pathway function that is used to study the normal visual system and that of patients with inherited and acquired retinal dysfunction Measurements will be performed using an electrophysiological recording system (CSO). Intermittent stimuli are presented using a Ganzfeld dome (CSO)."
40827430|NCT05292209|DRUG|Riluzole 50 MG|Riluzole 50mg tablets
41346722|NCT04046276|OTHER|Conventional Physical Therapy|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
41346723|NCT04046276|BEHAVIORAL|Medium Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
41346724|NCT06111040|OTHER|Measurement|The only interventions are at the measurement level and consist of two behavioral protocols designed to assess children's eating behavior, where food stimuli are provided and children's behavioral responses are recorded.
40827431|NCT06105086|OTHER|Semi-structured interview|Participants will be asked pre-defined questions and are allowed to elaborate on the subject.
41346725|NCT00927576|BEHAVIORAL|Digit span testing|Testing of short-term verbal memory with digit span
41346726|NCT00927576|BEHAVIORAL|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
41346727|NCT00927576|BEHAVIORAL|Finger tapping|Testing motor speed with a finger tapping test.
41346728|NCT00927576|BEHAVIORAL|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
41346729|NCT00927576|BEHAVIORAL|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
40827432|NCT06321198|BIOLOGICAL|iMSC|Subjects will receive 4 or more times of iMSC injection
40827433|NCT05533463|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
41346730|NCT00927576|BEHAVIORAL|Verbal fluency|Evaluating how many words are produced in 90s.
40827434|NCT05981079|DRUG|Piperacillin/tazobactam|Piperacillin Sodium and Tazobactam Sodium for Injection
41346731|NCT00927576|BEHAVIORAL|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
41346732|NCT00927576|BEHAVIORAL|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
41346733|NCT00927576|BEHAVIORAL|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
41346734|NCT00927576|BEHAVIORAL|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
41346735|NCT05002036|DEVICE|Trium eyedrops|given three times daily from day 1 after surgery to end of Week 4
41346736|NCT02023541|RADIATION|Proton beam therapy|
40827435|NCT04024332|DRUG|ACT-541468|ACT-541468 25 mg; administered orally
40827436|NCT06428565|DIAGNOSTIC_TEST|Low-level laser therapy (LLLT) or cold laser therapy|Low-level laser therapy (LLLT) or cold laser therapy
40827437|NCT01913665|OTHER|B.lactis|
40827438|NCT01913665|OTHER|Inulin|
40827439|NCT01913665|OTHER|B.Lactis +Inulin|
40827440|NCT01913665|OTHER|Placebo|
40827441|NCT00355342|DRUG|Salmeterol 50 mcg BID|Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
40827442|NCT00355342|DRUG|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
40827443|NCT00355342|DEVICE|DISKUS inhaler|Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
41157444|NCT06397950|OTHER|Assessment of potential fatigue factors|"3 visits will be carried out: V0: Inclusion V1: Familiarization visit V2: Experimental visit~V1~* Completion of MFI-20 questionnaire for familiarisation.~* Information about accelerometry and activity journal use will be delivered to the patient.~* The participant will be equipped with an accelerometer and asked to complete the activity journal for seven days.~V2~* Completion of questionnaires: MFI-20, GATS tobacco consumption questionnaire, caffeine consumption questionnaire, Fatigue Catastrophizing Scale, PSQI.~* Assessment of cognitive function: Sustained Attention to Response Task (SART), AX-Continuous Performance Task (AX-CPT) and verbal fluency test (animals and P categories).~* Assessment of physical evaluation: isometric evaluation of maximal handgrip strength, one-minute sit-to-stand test, isometric evaluation of maximal quadriceps strength, QIF test.~Negative symptoms will be assessed. Calf circumference will be measured for sarcopenia risk."
40827444|NCT02509572|BEHAVIORAL|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
41157445|NCT04979234|DEVICE|Endomina- Endoscopic Sleeve Gastroplasty|Endoscopic gastric reduction
41346737|NCT05168423|DRUG|CART-EGFR-IL13Ra2 Cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2
41346738|NCT03928509|OTHER|No intervention|No intervention
41490706|NCT05229653|DRUG|Ketamine|Participants in this arm will receive intravenously (IV) ketamine (0.6 mg/kg) while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver 0.6 mg/kg ketamine over at least 30 minutes.
41490707|NCT05229653|DRUG|Placebo|Participants in this arm will receive intravenously (IV) matching equal dose of placebo while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver equal volume saline over at least 30 minutes.
41157446|NCT04979234|BEHAVIORAL|Diet|Multidisciplinary follow up
41157447|NCT06646861|OTHER|Exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included.
41490708|NCT03325465|DRUG|Pembrolizumab|Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
40827445|NCT05037487|DRUG|Placebo Cannabis|Smoked placebo cannabis
40827446|NCT05037487|DRUG|20 mg CBD Cannabis|Smoked cannabis with CBD
40827447|NCT05037487|DRUG|20 mg CBD + 20 mg THC Cannabis|Smoked cannabis with CBD and THC
40827448|NCT05037487|DRUG|20 mg THC Cannabis|Smoked cannabis with THC
40827449|NCT00006078|DIETARY_SUPPLEMENT|lycopene|
40827450|NCT02695823|DEVICE|Ultrasound|"Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.~Search of any neurological complication during the 5 postoperative days."
41157448|NCT05676931|DRUG|Domvanalimab|Administered as specified in the treatment arm
41157449|NCT05676931|DRUG|Quemliclustat|Administered as specified in the treatment arm
41157450|NCT05676931|DRUG|Zimberelimab|Administered as specified in the treatment arm
40827451|NCT01967823|BIOLOGICAL|Anti-NY ESO-1 mTCR PBL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
41490709|NCT03325465|DRUG|Epacadostat|Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
41490710|NCT06296654|BEHAVIORAL|Empowerment-Based Interventions|The Empowerment-Based Interventions was used for the study group. It is an integrative educational program under the patient-centered care approach emphasizing collaborative patient interaction. The EBI was implemented through structured (a) small-group d
41490711|NCT06296654|BEHAVIORAL|Standard Health Education|Patients in the control group received standard health education from SCD clinics in the HC. The clinic employs a multidisciplinary team, including a nurse, a physician, a health record clerk, a laboratory technician, a social worker, and a health promotion specialist, to provide integrated patient health services. It consists of both preventative and curative services. The nurses at the health center provide patients with information regarding factors that may cause vaso-occlusion and precipitate VOCs when to seek emergency care and educate patients on the significance of regular medical examinations and screening using different standardized audiovisual aids.
41490712|NCT01490983|BEHAVIORAL|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
41490713|NCT01490983|BEHAVIORAL|eMedonline access|patients will be given access to eMedonline use for 3 months
41490714|NCT05327192|OTHER|No intervention, only sampling|No intervention
41490715|NCT02854111|OTHER|ice cream|The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
41490716|NCT02854111|OTHER|75 g-glucose|The 75-g glucose is used for standard oral glucose tolerance test.
41490717|NCT00707382|GENETIC|(1) Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described."
40827452|NCT01967823|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenously (IV) in 250 mL dextrose 5% in water (D5W) infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
40827453|NCT01967823|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
40827454|NCT01967823|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenously (IV) (based on total body weight) over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
40827455|NCT04244864|BEHAVIORAL|Cross-sectoral psychosocial intervention|The intervention seeks to integrate working with social stressors alongside treatment for trauma-related mental health problems. This is done in two ways; by a cross-sectoral collaboration with the patient's case counsellor in the municipality including three collaborative meetings and by a systematic focus on social stressors during the treatment.
40827456|NCT04244864|BEHAVIORAL|Treatment as usual (TAU)|"Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy."
40827457|NCT02390674|DRUG|Ciclosporin|Comparison between ciclosporin and placebo
40827458|NCT02390674|DRUG|Saline|
40827459|NCT06055465|DRUG|Sacituzumab Govitecan|"* 4 cycles, each cycle lasting for 3 weeks~* 10mg/kg given every day 1 and day 8 each cycle~* IV infusion"
40827460|NCT06055465|DRUG|Pembrolizumab|"* 4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~* 200mg fixed dose every day 1 each cycle~* IV infusion"
41157451|NCT05676931|DRUG|Docetaxel|Administered as specified in the treatment arm
41157452|NCT05676931|DRUG|Platinum-Based Doublet|Administered as specified in the treatment arm
40827461|NCT02416986|BEHAVIORAL|6 hour smoking abstinence|
41157453|NCT01209936|DEVICE|D2O|All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
41157454|NCT05127122|DRUG|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Injectable
41157455|NCT05127122|OTHER|Saline|Placebo Saline
41157456|NCT06578247|DRUG|Quizartinib|Participants will receive quizartinib at 60 mg/day orally once daily
41157457|NCT06578247|DRUG|Placebo|Participants will receive placebo at 60 mg/day orally once daily
41157458|NCT06578247|DRUG|Chemotherapy|Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
41157459|NCT06644391|DIAGNOSTIC_TEST|Carebot AI Bones|The use of a deep learning-based artificial intelligence software, Carebot AI Bones version 1.2.2, designed to aid in the detection of fractures on musculoskeletal radiographs. The AI model analyzes digital X-ray images to identify fractures, highlighting areas of interest with bounding boxes.
41346739|NCT06367049|DIAGNOSTIC_TEST|Methylation-specific PCR|"Methylation-specific PCR is the simplest and quickest method for qualitative detection of methylation status.~The unmethylated C base is converted to U by bisulfite conversion, which is subsequently amplified by PCR with primers (methylation-specific and non-methylation-specific primers) and subsequently detected by agarose gel electrophoresis or a probe. The key to MSP is to design PCR primers for specific gene regions. The research team of this project has previously found the sequence sites of methylation of H4C6, Septin9 and RASSF1A genes in nasopharyngeal carcinoma tissues through methylation sequencing, and designed specific MSP amplification primers and probes accordingly, which can perform methylation detection easily and quickly."
41346740|NCT00131534|BEHAVIORAL|Individual therapy|Stage-based individual therapy for trauma survivors
41346741|NCT00131534|BEHAVIORAL|Group therapy|Stage-based group therapy for trauma survivors
41346742|NCT03004833|DRUG|Nivolumab|Infusion of Nivolumab
41346743|NCT03004833|DRUG|Adriamycin|Infusion of Adriamycin
41346744|NCT03004833|DRUG|Vinblastine|Infusion of Vinblastine
41346745|NCT03004833|DRUG|Dacarbazine|Infusion of Dacarbazine
41157460|NCT01933659|DRUG|DSW|ingesting DSW 200 cc four times a day (one hour before meal and bed time)
41346746|NCT00161746|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
41346747|NCT02240524|PROCEDURE|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
41346748|NCT02240524|PROCEDURE|Systemic chemotherapy|
41346749|NCT02240524|PROCEDURE|HIPEC|
41346750|NCT03317366|DRUG|ARQ 092|Open-label expanded access for ARQ 092 capsules
41346751|NCT04971980|DRUG|hUC-MSC infusion (BC-U001)|The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10\^6 cells/kg body weight, 1.0x10\^6 cells/kg body weight, 1.5x10\^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
41157461|NCT06551064|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
41346752|NCT05010395|BEHAVIORAL|Letter intervention|Letter intervention
41346753|NCT00766181|BEHAVIORAL|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
41346754|NCT00954824|BIOLOGICAL|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
41346755|NCT01501162|DRUG|hepatitis, alcohol, probiotics|7 days of probiotics (1500 mg/day)
41346756|NCT01501162|DRUG|alcohol, hepatitis, Placebo|Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
41346757|NCT04797494|DEVICE|acrylic removable appliance|"Hand-made, dental laboratory-manufactured, acrylic removable appliances were made on the mandible after intraoral impressions (Alginate, Cavex).~Patients were asked to wear the RA for a period of 3 weeks prior to restorative treatment, for 24 h per day, except for when eating."
41346758|NCT03879954|DEVICE|Catetherization approach|Out of plane inetrnal jugular vein Vs in plane supraclavicular subclavian vein catetherization
41346759|NCT04171167|DRUG|Fluticasone Propionate|three visits: 0, after washout, after FP usage
41346760|NCT03256006|OTHER|Blood sample|Blood sample to study per and post effort evolution markers of systemic inflammation
41346761|NCT01946568|DRUG|Dalbavancin|Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients \<5 years of age.
41346762|NCT02389218|DEVICE|single ablation (CryoBalloonAblation (CBA)|Cryoablation at entry, after randomization to this group
41346763|NCT02389218|DRUG|sequential drug adjustment (propafenone, sotalol or flecainide)|Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
41346764|NCT04535258|DEVICE|Blend-A|Treatment for alcohol use disorders will be offered also as an internet-based option.
41346765|NCT05589766|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside supplementation up to 3000mg daily in total.
41346766|NCT05589766|OTHER|Placebo|Placebo tablet identical in taste, form and appearance to NR tablets, administered twice daily for a total of 12 weeks.
41346767|NCT01841086|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
41346768|NCT01841086|DRUG|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
41346769|NCT02253992|BIOLOGICAL|Urelumab|
41346770|NCT02253992|BIOLOGICAL|Nivolumab|
41346771|NCT05111184|BEHAVIORAL|Education groupe|Education
41346772|NCT06388460|OTHER|Asthma Link|Providers enroll patients to receive school-supervised asthma therapy and an asthma educational workbook
41346773|NCT06388460|OTHER|Enhanced Usual Care|Providers enroll patients to receive an asthma educational workbook
41346774|NCT01901367|DIETARY_SUPPLEMENT|nutritional intervention|Receive nutritional intervention
41346775|NCT01901367|BEHAVIORAL|exercise intervention|Receive exercise intervention
41346776|NCT01901367|OTHER|follow-up care|Receive booster follow-up sessions from the nutritionist and exercise physiologist
41346777|NCT01901367|BEHAVIORAL|counseling intervention|Receive phone counseling with a trained health coach
41346778|NCT01901367|OTHER|quality-of-life assessment|Ancillary studies
41346779|NCT01901367|OTHER|laboratory biomarker analysis|Correlative studies
41346780|NCT01901367|OTHER|questionnaire administration|Ancillary studies
41346781|NCT02633111|OTHER|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
41346782|NCT02633111|OTHER|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
41346783|NCT02633111|DEVICE|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
41346784|NCT03228992|DRUG|Ibuprofen 400 mg|Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
41346785|NCT03228992|OTHER|Placebo|Subjects will receive 4 doses of placebo over a 24 hour period.
41346786|NCT02656524|DRUG|Regorafenib (Stivarga, BAY73-4506)|Product is used in accordance with SmPC
41346787|NCT02550119|DRUG|Aprepitant|Given PO
41346788|NCT02550119|DRUG|Dexamethasone|Given PO or IV
41346789|NCT02550119|DRUG|Dolasetron Mesylate|Given PO or IV
41346790|NCT02550119|DRUG|Placebo|Given PO
41346791|NCT00152841|DRUG|Iron supplement 300-600 mg/day|
41346792|NCT00152841|DRUG|Vitamin E 800IU|
41346793|NCT06396689|DIETARY_SUPPLEMENT|Synbiotic|The capsule contains Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, and Bifidobacterium bifidum R0071 (3 billion bacteria per capsule), as well as zinc oxide, potato starch fructooligosaccharides, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
41346794|NCT06396689|DIETARY_SUPPLEMENT|Placebo|The capsule contains zinc oxide, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
41346795|NCT02252588|DRUG|Chlorhexidine|Oral Rinse
41346796|NCT02252588|OTHER|Placebo|Oral Rinse
41346797|NCT05563259|RADIATION|Cognitive assessment, functional magnetic resonance imaging|Our study investigated cognitive function, MRI measures of brain structure and activation in patients undergoing liver biopsy. We aimed to evaluate the changes of cognition during the process of NAFLD and explore the association between brain alterations and cognition.
41346798|NCT05655728|DRUG|Metformin|The participants will receive treatment of metformin (initial dose of 500 mg/day, within 2 weeks reaching the maximum tolerated dose \[maximum: 1500 mg/day\]).
41346799|NCT05655728|OTHER|Placebo|The participants will receive treatment of placebo.
41346800|NCT06263790|DEVICE|Intubating laryngeal mask|Intubation through a laryngeal mask
41346801|NCT06263790|DEVICE|Direct laryngoscopy|Intubation by using a direct laryngoscope
41346802|NCT05580185|DEVICE|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
41157462|NCT06551064|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
41157463|NCT00951574|DRUG|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
41157464|NCT00951574|DRUG|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
41346803|NCT00824967|OTHER|Training and valuation of the treating personnel|Training and valuation of the treating personnel
41346804|NCT05509491|BEHAVIORAL|A postural awareness program with exercises|A program about postural awareness, bad posture, good posture and their effects on daily life
41346805|NCT05375240|DRUG|Propranolol|Propranolol will be given at a dose of 10 mg orally, 3 times per day, for 7 consecutive days after stroke onset.
41346806|NCT05375240|DRUG|Ceftriaxone|Intravenously 2.0g/day for 7 consecutive days.
41346807|NCT01234311|DRUG|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
41346808|NCT01234311|DRUG|Placebo|
41346809|NCT00805038|BEHAVIORAL|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
41346810|NCT00805038|BEHAVIORAL|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
41346811|NCT03164122|DRUG|injection of microfat and plasma rich platelet PRP|intra-articular injections
41346812|NCT03164122|DEVICE|MRI|MRI 3T
40827462|NCT02416986|BEHAVIORAL|Delay to Smoking Task (smoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard smoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
40827463|NCT02416986|BEHAVIORAL|Delay to Smoking Task (nonsmoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard nonsmoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
40827464|NCT02908685|DRUG|Placebo|Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
41346813|NCT00986804|DRUG|Decitabine|
41346814|NCT01879475|DEVICE|032-11|Topical haemostat
41346815|NCT01879475|DEVICE|Floseal (R)|Topical haemostat
41157465|NCT00702234|BIOLOGICAL|Corifollitropin alfa|Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
40827465|NCT02908685|DRUG|Risdiplam|Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
40827466|NCT03905434|GENETIC|miRNA sampling|Blood samples for miRNA testing will be collected from all subjects (control and patients diagnosed with acute ischemic stroke)
40827467|NCT03362788|DRUG|VKA|VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
41157466|NCT00702234|BIOLOGICAL|GnRH antagonist|SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
41346816|NCT04272762|PROCEDURE|Cryoablation|Pulmonary vein isolation with cryoablation
41346817|NCT04272762|PROCEDURE|Placebo|Placebo procedure
41346818|NCT01221662|DRUG|Siwu Tang|Siwu Tang 3 g bid(oral) continuously two weeks
41346819|NCT05974891|OTHER|Pilot application|"Pilot application will be carried out with at least 10 students. A pre-test will be applied to the experimental group. After the scales are applied, the experiment will be applied to the experimental group with the Geriatric Medication Game simulation.~Students simulating the elderly patient role during this simulation will gain a better understanding of age-related health problems and how older adults feel when confronting them. After the application, debriefing, which is the last stage of the simulation training, will be done to evaluate the application. After the application and analysis session is completed, the post-test will be applied to the experimental group. A 3-week clinical practice will be planned for the students in the experimental groups in order to evaluate the continuation of the acquired skills and acquired awareness. In this application, students will be asked to care for the elderly patient and the pre-test will be repeated at the end of the application."
41346820|NCT06016335|DIAGNOSTIC_TEST|CT scan|Participants receive a CT scan of the head as part of their regular care. A larger part of the head will be scanned than for standard care.
41346821|NCT06016335|DIAGNOSTIC_TEST|MRI scan|Participants receive an MRI scan, specifically for the purpose of the study.
41346822|NCT06016335|OTHER|Synthetic CT scan|Synthetic CT scans will be generated from MRI scans, using the trained machine learning algorithm.
41157467|NCT00702234|BIOLOGICAL|(rec)hCG|SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
41346823|NCT05223686|DRUG|Human CD19-CD22 Targeted T Cells Injection|One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.
41346824|NCT05488106|DIETARY_SUPPLEMENT|Placebo|Placebo
41346825|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 1.6mg/d|Riboflavin 1.6mg/d
40827468|NCT03362788|DRUG|NOAC|NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
41346826|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 5mg/d|Riboflavin 5mg/d
41346827|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 20mg/d|Riboflavin 20mg/d
40827469|NCT06430190|DRUG|Peginterferon α-2b injection|Participants receive CO2 laser treatment followed by local injection of 36mcg of Peginterferon α-2b directly into the base of each treated wart, repeated weekly for 12 weeks, and then followed for another 12 weeks.
40827470|NCT06430190|DRUG|Peginterferon α-2b injection|Participants undergo CO2 laser treatment and then receive a weekly subcutaneous injection of 180mcg of Peginterferon α-2b for 12 weeks, and then followed for another 12 weeks.
41346828|NCT01868594|DRUG|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
41490718|NCT00707382|OTHER|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
41490719|NCT00707382|OTHER|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
40827471|NCT06430190|OTHER|CO2 laser|On the day (baseline), CO2 laser treatment was performed to remove all warts, and the treatment range was 0.2cm around the lesion and the depth was up to the dermis. Wound disinfection after laser. Participants are treated with CO2 laser therapy only and are observed for 12 weeks, followed by another 12-week observation period without any additional adjuvant therapy.
40827472|NCT04304170|DIETARY_SUPPLEMENT|VES002|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
40827473|NCT04304170|OTHER|Placebo|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
41490720|NCT03137927|BIOLOGICAL|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
41490721|NCT03137927|OTHER|Placebo|Placebo
40827474|NCT02850263|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
40827475|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
40827476|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
41346829|NCT01868594|DRUG|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
41346830|NCT03991468|DIAGNOSTIC_TEST|Whole Slide Imaging|Scanning of a glass slide to create a digital image that can be viewed on a monitor
40827477|NCT00110071|DRUG|fludarabine phosphate|Given IV
40827478|NCT00110071|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
40827479|NCT00110071|RADIATION|iodine I 131 tositumomab|Given IV (dosimetric dose) or via central line (therapeutic dose)
40827480|NCT00110071|OTHER|laboratory biomarker analysis|Correlative studies
40827481|NCT00110071|OTHER|flow cytometry|Correlative studies
41157468|NCT00702234|BIOLOGICAL|FSH|SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
41157469|NCT00702234|DRUG|Progesterone|Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
41346831|NCT03991468|DIAGNOSTIC_TEST|Light Microscopy|Use of traditional light microscopy per institutional standard practice
41346832|NCT02276794|OTHER|Thrust Manipulation|After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.
41346833|NCT02276794|OTHER|Non-thrust manipulation (NTM)|A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
41346834|NCT04054219|DEVICE|Bone graft substitute|Evaluation of a device made of deproteinized bovine bone material as bone graft substitute in different indications requiring bone grafting procedures before implant placement
41346835|NCT00736606|DRUG|simvastatin|One single dose of 40mg
41346836|NCT00736606|DRUG|AZD9056 + simvastatin|AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
41490722|NCT04757701|OTHER|Social Behavioral surveys, interviews, and focus groups|Surveys with dentists/hygienists, interviews/focus groups with service learning center directors and key staff at federally qualified health centers.
41490723|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas."
40827482|NCT00110071|GENETIC|polymerase chain reaction|Correlative studies
40827483|NCT00344734|DRUG|Ng-monomethyl-L-arginine (drug)|
40827484|NCT01716338|DRUG|Glyburide|
40827485|NCT01716338|DRUG|Placebo|
40827486|NCT06608992|DRUG|SURGICEL® Powder|SURGICEL® Powder are hemostatic product made of compacted, regenerated oxidized cellulose fine fiber aggregates, produced using a patented process. These particles are pre-loaded into an applicator device for application to the target bleeding site. SURGICEL® Powder are white with a slight yellow tint and have a faint caramel-like scent.When SURGICEL® Powder are fully saturated with blood, they expand into a brown or black gel-like substance that helps form a blood clot. This substance acts as a hemostatic adjunct to control localized bleeding.
40827487|NCT03355560|DRUG|Nivolumab|Nivolumab 480 mg IV infusion
40827488|NCT00420810|DRUG|MK0928 / Duration of Treatment : 8 Weeks|
40827489|NCT01838265|PROCEDURE|Transrectal Ultrasound-Guided Biopsy|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
40827490|NCT01838265|PROCEDURE|MRI Ultrasound Biopsy|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
40827491|NCT01838265|BEHAVIORAL|Expanded Prostate Cancer index Composite Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
40827492|NCT01838265|BEHAVIORAL|Short-Form 12 of Health Related Quality of Life Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
40827493|NCT01838265|BEHAVIORAL|Memorial Anxiety Scale for Prostate Cancer|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
40827494|NCT01838265|PROCEDURE|Plasma/Serum Sample for biomarkers|Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)
41346837|NCT01508793|BEHAVIORAL|Optimize Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
41346838|NCT04347434|DRUG|Atorvastatin 80mg|Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy
41346839|NCT00964639|DRUG|Ropivacaine|During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
40827495|NCT01838265|PROCEDURE|Urine Sample for Biomarkers|Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)
40827496|NCT01838265|PROCEDURE|Blood Tests for Blood Urea Nitrogen and Creatinine|Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse
41346840|NCT00964639|DRUG|Saline|During the surgery infiltration with saline. Thereafter bolus 3 times a day
41346841|NCT01381289|DRUG|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
41346842|NCT00520091|DRUG|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
41346843|NCT00520091|DRUG|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
41346844|NCT00520091|DRUG|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
41509035|NCT01320384|DEVICE|O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
41509036|NCT02130622|DRUG|Promethazine|
41346845|NCT00520091|RADIATION|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
41346846|NCT00520091|PROCEDURE|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
41346847|NCT05224752|OTHER|Online Survey|Online survey void of individual traceable identifiers, and launched via the Survey Monkey® portal
41346848|NCT05104749|DRUG|Homeopathic Medication|Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.
41346849|NCT05104749|OTHER|Placebo|Inert lactose pellets
41346850|NCT00671515|DRUG|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
41018963|NCT05896592|PROCEDURE|Cardioneuroablation|CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
41346851|NCT00844415|DRUG|dabigatran etexilate|2.14 mg/kg BID to a max 150 mg BID
41346852|NCT05576415|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.
41346853|NCT04166955|BEHAVIORAL|Promoting Physical Activity through mobile application|Students will be randomly assigned to either the intervention or the control group. WhatsApp groups will be formed within each study group. The control participants will have the WhatsApp group only for communications. And they will keep their usual activity for 10 weeks. The intervention participants will have the intervention WhatsApp group which will be for communication and providing the intervention materials. The intervention group will receive a brief (15-minute) orientation on exercise, and benefits of keeping a healthy life pattern. They will receive 3-4 health-promotional (Physical activity) messages per week via WhatsApp for 10 weeks; group interaction is optional without adding more messages aiming to promote physical activities from any participants.
41346854|NCT03363789|BIOLOGICAL|Brisement injection|An injection of Lidocaine into the tendon sheath to break up adhesions that could be causing the condition.
41346855|NCT03363789|PROCEDURE|Physical Therapy|Patients will receive a prescription for physical therapy.
41346856|NCT05232292|BIOLOGICAL|Ultrix Quadri|vaccination by Ultrix Quadri against flu
41346857|NCT05537272|DRUG|Tadalafil 5mg|Administration of Tadalafil 5mg once daily seven days before and seven days after prostate biopsy
41346858|NCT05537272|DRUG|Tamsulosin Hydrochloride 400 Microgram Prolonged-Release Oral Capsule|Administration of Tamsulosin 0.4mg once daily seven days before and seven days after prostate biopsy
41346859|NCT05537272|OTHER|Placebo|Administration of placebo ( Vitamin C \[ascorbic acid\] 500mg tablet) once daily seven days before and seven days after prostate biopsy
41018964|NCT05896592|PROCEDURE|Redo cardioneuroablation|It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
41346860|NCT04520295|GENETIC|ctDNA screening|Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.
41346861|NCT02909920|OTHER|Telerehabilitation|Initial Videoconference following telerehabilitation programs self-workout exercise with video support.
41346862|NCT02909920|OTHER|Traditional Physiotherapy|Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
41346863|NCT02044822|DRUG|Idelalisib|150 mg tablets administered orally twice daily
41346864|NCT02044822|DRUG|Rituximab|375 mg/m\^2 administered intravenously once weekly x 8 weeks
40827497|NCT01838265|PROCEDURE|Blood Test for Serum PSA|Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
40827498|NCT00442832|DRUG|TD-1792|TD-1792 2 mg/kg/day IV
41346865|NCT04925544|DRUG|VK-2019|VK-2019 binds to EBNA1 and inhibits EBNA1 DNA binding activity. VK-2019 API is synthesized by Anthem BioSciences Pvt. Ltd and formulated into capsules by Emerson Resources Inc,
41346866|NCT05682326|DRUG|Daprodustat|Daprodustat will be administered up to Week 52.
41346867|NCT02983851|PROCEDURE|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.
41346868|NCT02983851|PROCEDURE|Invasive mechanical ventilation|Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
41346869|NCT03605836|DRUG|Centanafadine SR|100 mg, BID, oral tablets
41346870|NCT03605836|OTHER|Placebo|BID, oral tablet
40827499|NCT00442832|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
40827500|NCT01620515|DRUG|NX-1207 2.5 mg|A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
41346871|NCT03605836|DRUG|Centanafadine SR|200 mg, BID, oral tablets
41509037|NCT02130622|DRUG|Sugar pill|
41346872|NCT03374891|OTHER|Educational video and/or handout|The intervention includes a video and/or handout (whichever is easier for the participant) that will give information about defibrillators and about other patients' experiences with their decisions about defibrillators.
41346873|NCT03564327|PROCEDURE|Wide antrum circle ablation|As standard hospital policy
41346874|NCT03564327|PROCEDURE|External electric cardioversion|Three attempts (200-250 joules)
41346875|NCT00275041|BIOLOGICAL|cetuximab|
41346876|NCT00275041|DRUG|irinotecan hydrochloride|
40827501|NCT01620515|DRUG|NX-1207 15 mg|A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
40827502|NCT00102297|DRUG|FG-3019|
41346877|NCT03855761|BEHAVIORAL|Occupational Therapy|Detailed narrative assessment and person-centered participation in meaningful activities
41346878|NCT03855761|BEHAVIORAL|Case management; psychological services|Weekly consultation with case managers to address housing and therapy needs
41346879|NCT03122249|BEHAVIORAL|Advanced Cancer Symptom Management|For a period of eight weeks patients will use the OASIS web-application daily to help them get better control of their cancer symptoms. In addition, to daily symptom and strategy tracking, participants will have eight e-visits with the nurse-coach via the Zoom application through the UIHC eHealth and eNovation Center to evaluate their progress with managing their symptoms, assess for barriers to implementing strategies, and offering coaching on how to improve symptom management. Questionnaires and blood samples will be collected at baseline (week 0) and follow-up (weeks 4, 8, and 12).
41346880|NCT05993572|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessments include functional status, fraility comorbidity, cognition, mental health, social support, nutrition, and geriatric syndromes
41346881|NCT02243306|DRUG|GSK1278863|Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
40827503|NCT00354107|BIOLOGICAL|monoclonal antibody SGN-30|Given IV
40827504|NCT00354107|DRUG|therapeutic hydrocortisone|Given IT
41346882|NCT05905705|DIAGNOSTIC_TEST|Electroencephalography (EEG)|High-density EEG will be acquired during resting wakefulness before each ECT session.
41346883|NCT05905705|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Overnight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.
41346884|NCT03192228|OTHER|Treatment adequacy score|Evaluation of the program rate of success rate by a score evaluating the different criteria that the patient was supposed to modify following the therapeutic education program: practice of a physical activity, reduction of the amount of fat in Diet, practice of self-monitoring blood sugar as a motivational tool and decreased distress related to diabetes
41346885|NCT04214106|DRUG|intravenous Thiamine|patients who received Thiamine,100-500 mg/day for at least one day
41346886|NCT02645136|OTHER|Pilates|Pilates exercises
41346887|NCT02645136|OTHER|PFMT and AES|conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
41346888|NCT02645136|OTHER|Control|
41346889|NCT02995811|OTHER|Observational Cohort|Ultrasound assessment of 4 muscles, activity monitoring, daily global peripheral skeletal muscle strength
40827505|NCT00354107|DRUG|ifosfamide|Given IV
40827506|NCT00354107|DRUG|carboplatin|Given IV
40827507|NCT00354107|DRUG|etoposide|Given IV
40827508|NCT00354107|DRUG|methotrexate|Given IT
40827509|NCT00354107|DRUG|cytarabine|Given IT
40827510|NCT00354107|OTHER|pharmacological study|Correlative studies
40827511|NCT00354107|OTHER|laboratory biomarker analysis|Correlative studies
40827512|NCT01709942|DRUG|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
40827513|NCT01709942|DRUG|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were \>300pg/ml
40827514|NCT06201793|DRUG|Mesalazine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
41018965|NCT05896592|PROCEDURE|Implantation of the implantable loop recorder|Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
41018966|NCT05896592|DIAGNOSTIC_TEST|Pacemaker check|It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
41018967|NCT05896592|DIAGNOSTIC_TEST|Implantable loop recorder check|Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
41018968|NCT05896592|DIAGNOSTIC_TEST|Holter ECG|24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
40827515|NCT06201793|DRUG|Minocycline|Minocycline is a tetracycline antibiotic medication used to treat a number of bacterial infections such as pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis.
41018969|NCT05896592|DIAGNOSTIC_TEST|Anamnesis|Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
41018970|NCT03154619|DRUG|0.1% TR 987|TR 987 0.1%
41018971|NCT03154619|DRUG|Placebo gel|Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
41018972|NCT01581593|BIOLOGICAL|Kedrion IVIG 10%|Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
41346890|NCT05914376|BIOLOGICAL|Recombinant human IL-21 oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
40827516|NCT00150228|DRUG|CP-526,555 (varenicline)|
41018973|NCT00277602|DRUG|Riluzole|
41018974|NCT05921773|DEVICE|AI-fNIRS neurofeedback device|The device, with AI-fNIRS signals serving as brain monitor to indicate the level of anxiety, provides mindfulness training through visual and auditory cues to help participants modulate their brain activity, and thus alleviates anxious states.
41018975|NCT05921773|DEVICE|AI-fNIRS neurofeedback device with sham signals|The sham control consists of playbacks of someone else's real AI-fNIRS neurofeedback and will be provided 3 times a week, for a total of 4 weeks.
41018976|NCT00134368|DRUG|Etanercept|
40827517|NCT05607498|DRUG|EMB07|EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
40827518|NCT00579046|DRUG|Darbepoetin alfa|"Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).~Frequency: every week for 2 months: 8 injections"
40827519|NCT03473964|DRUG|H.P. Acthar gel|"H.P. Acthar gel:~Injection 40 mg twice weekly"
41018977|NCT03775005|RADIATION|standard treatment|3000 cGy in 10 daily fractions
40827520|NCT05285124|DRUG|Melatonin|Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00
41346891|NCT04350918|DEVICE|Muscle Enery Techniques|Group of patients that underwent muscle energy technique as a mean of treatment for the complaint
41346892|NCT04350918|DEVICE|Static Stretching|Set of patients that had static stretching technique for the treatment for the complaint
41346893|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
41346894|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
41346895|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
41490724|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal."
40827521|NCT05285124|OTHER|Placebo|Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS
40827522|NCT05285124|OTHER|HD-tDCS|Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes
41018978|NCT03775005|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
41018979|NCT05840965|OTHER|Foot muscle strengthening|"A specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The exercises are: short foot exercise, toe spread out, first toe extension, second to fifth toe extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles."
41346896|NCT01445002|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
41346897|NCT04484038|RADIATION|hypofractionated postoperative radiation therapy|The patients included in the study will undergo intensity-modulated radiotherapy, of any modality, and image-guided (IGRT) with an emphasis on tissue preservation and administration precision through the use of devices that guarantee the stability and reproducibility of the same.
41346898|NCT06251544|GENETIC|HTR2 T Cells|"Arm A -- Two dose levels will be evaluated:~Dose level One: 1.00E+06~Dose level Two: 1.00E+07"
40827523|NCT02070393|RADIATION|Proton|14-24 Radiation treatments using Protons
40827524|NCT02324140|OTHER|Whole blood analysis|In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
41346899|NCT06251544|GENETIC|HTR2 T Cells|"Arm B -- Two dose levels will be evaluated:~Dose level Two: 1.00E+07~Dose Level Three: 1.00E+08"
40827525|NCT00088790|DRUG|AZD5438|
41346900|NCT00574366|DRUG|erlotinib|"Levels:~* 1 Erlotinib 50 mg/d~* 2 Erlotinib 50 mg/d~  * 1 Erlotinib 100 mg/d~ * 2 Erlotinib 100 mg/d~ * 3 Erlotinib 150 mg/d~ * 4 Erlotinib 150 mg/d"
41509038|NCT00121537|DEVICE|Wound Care -Wound Vacuum Assisted Closure (VAC)|
41509039|NCT00121537|PROCEDURE|Wound Care - Wet to Dry Dressing Changes|
40827526|NCT03856008|OTHER|Exercises focused on flexor muscles|Exercises emphasis flexor muscles.
40827527|NCT03856008|OTHER|Exercises focused on extensor muscles|Exercises emphasis extensor muscles.
41018980|NCT05840965|OTHER|Foot orthotics|Custom-made foot orthotics
41018981|NCT04978038|DRUG|mRNA- COVID-19|Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
41018982|NCT04978038|DRUG|Prevnar13|Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
41018983|NCT02923375|BIOLOGICAL|Mesenchymoangioblast-derived mesenchymal stem cells|The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
41346901|NCT00574366|DRUG|RAD001|"Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~1. RAD001 2.5 mg per day~2. RAD001 5 mg per day~3. RAD001 10 mg per day~4. RAD001 10 mg per day"
41346902|NCT00649610|DRUG|valdecoxib|valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
41346903|NCT00649610|DRUG|diclofenac|diclofenac 75 mg twice daily (BID) for 7 days
40827528|NCT01556776|DRUG|lenalidomide|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
41018984|NCT01302964|DRUG|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
41018985|NCT01302964|DRUG|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
41490725|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation."
41018986|NCT00136708|PROCEDURE|Neonatal Resuscitation|
41018987|NCT01020916|PROCEDURE|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
40827529|NCT01556776|DRUG|Placebo|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
41018988|NCT01020916|PROCEDURE|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
41018989|NCT01512719|PROCEDURE|POEM|Per Oral Endoscopic Myotomy for achalasia
41018990|NCT02460640|PROCEDURE|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
41018991|NCT02460640|PROCEDURE|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
41018992|NCT02460640|DRUG|Morphine|
41018993|NCT02460640|DRUG|Ropivacaine|
41018994|NCT01850004|DRUG|Dasatinib|
41018995|NCT00151359|DEVICE|SoleSensor|
41018996|NCT01094275|DRUG|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
41018997|NCT00726115|DRUG|SAM-531|
41018998|NCT00726115|DRUG|placebo|
41346904|NCT00850265|DEVICE|Volumatic spacer|A spacer is a plastic device to inhaler medication
41018999|NCT05389124|BEHAVIORAL|Partial abstinence from oral hygiene|One quadrant of the dentition will be protected from oral hygiene for 3 weeks.
41019000|NCT05299541|DIETARY_SUPPLEMENT|Food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months~Group A - will receive a dish of food every evening by a person employed by a rescue organization for 6 months~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
41019001|NCT05299541|DIAGNOSTIC_TEST|Indirect calorimetric|• The patient will be measured with an indirect calorimetry device (Fitmate - COSMED Srl. Rome, Italy) to assess the nutritional requirement.
41019002|NCT05299541|DIAGNOSTIC_TEST|Bioimpedance|• The body composition test will be performed by the Bodystat®4000 Bioimpedance Device (BIA 4000, Bodystat, UK). .
41019003|NCT05299541|BEHAVIORAL|Questioners|"At 3 times point , in the recruit + 3 month and 6 month 3 questioners will be given:~HADS, Quality of life 36SF and FIM"
41019004|NCT05299541|DIETARY_SUPPLEMENT|Plated food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months Group b - will receive a food dish every evening by a person employed by a rescue organization with improved appearance of a plate for 6 months.~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
41346905|NCT01654328|DRUG|Sodium chloride tablets|sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
41346906|NCT01654328|DRUG|Isotonic saline intravenously|isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
41346907|NCT06119568|DEVICE|Robot assisted laparoscopic Radical/simple nephrectomy (RN), Partial nephrectomy (PN) or Radical Prostatectomy (RP).|Three different surgery interventions: 1. Radical Nephrectomy: Complete remove of the kidney; 2. Partial Nephrectomy: Partial remove of a section in the kidney. 3. Radical Prostatectomy: Complete remote of the prostate gland. During each of these procedures removal of regional lymph nodes (lymphadenectomy) and lysis of abdominal lesions may be performed according to patient medical condition and/or surgeon criteria.
40827530|NCT03546166|DRUG|Picato 0.05% Topical Gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
40827531|NCT05122923|DEVICE|Serious Game S'TIM|Video Game S'tim : the patient is inside a bedroom and he has to find a friend outside. this game will study the orientation, the memory of the patient
40827532|NCT05235958|OTHER|non-linear periodized exercise (NLPE)|Aerobic training derived from professional sports, that is characterized by variable periodization of training frequency, volume and intensity according to individual factors, such as physical and mental readiness, training progress and performance level
40827533|NCT05235958|OTHER|Exercise counselling|Standard recommendations for exercise and physical activity, that are individualized according to a medical health and fitness profile
41019005|NCT06573437|DEVICE|Vascular Stent - Vesto Endoprosthesis|Vascular Stent Implant - Vesto Endoprosthesis
41019006|NCT02265705|DRUG|Baricitinib|Administered orally
41346908|NCT03696849|OTHER|polished emax Press|lithium disilicate glass ceramic crowns subjected to polishing only
41346909|NCT03701061|BIOLOGICAL|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
41346910|NCT03701061|BIOLOGICAL|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
41346911|NCT05249465|BEHAVIORAL|Core behavioral weight loss intervention|"All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely."
41346912|NCT05249465|BEHAVIORAL|Self-monitoring diet|Participants randomized to receive this component will be instructed to self-monitor their dietary intake daily via the Fitbit mobile app. Participants will receive a daily calorie goal.
41346913|NCT05249465|BEHAVIORAL|Self-monitoring weight|Participants randomized to receive this component will be instructed to self-monitor their body weight daily via a wireless e-scale (e.g., the Fitbit Aria Scale).
41346914|NCT05249465|BEHAVIORAL|Self-monitoring steps|Participants randomized to receive this component will be instructed to self-monitor their step count daily via a wrist-worn Fitbit activity monitor. A daily step goal will be given that will adapt based on progress.
41346915|NCT03846089|PROCEDURE|Graft reperfusion|antegrade (forward) or retrograde (backward) blood reperfusion of the liver graft
41346916|NCT03189810|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).
41346917|NCT03189810|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).
41346918|NCT03189810|BEHAVIORAL|Weekly Counselling Session|In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
41346919|NCT01758640|DRUG|Warfarin|Low dose warfarin of 5mg or less per day
41346920|NCT01758640|DRUG|phenindione|Phenindione of 100mg or less per day
41346921|NCT02132169|DRUG|Drug: AC-170 0.24%|
41346922|NCT02132169|DRUG|AC-170 0%|
41346923|NCT00411970|DEVICE|20- and 23 gauge vitreoretinal surgery systems|
41019007|NCT02265705|DRUG|Placebo|Administered orally
41019008|NCT00861419|DRUG|Sorafenib|Sorafenib 400 mg PO (BID)
41019009|NCT00861419|DRUG|AMG 706|AMG 706 125 mg PO (QD)
41019010|NCT00861419|DRUG|AMG 706|AMG 706 75 mg PO (QD)
41019011|NCT00861419|DRUG|AMG 386|AMG 386 10 mg/kg IV (QW)
41346924|NCT03461705|DEVICE|Volcano Verrata Pressure Wire|"Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature."
41346925|NCT03461705|DEVICE|St. Jude Medical (SJM) Aeris Pressure Wire System|The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.
41346926|NCT02384928|PROCEDURE|Shinbaro pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. One Hyeopcheok (Huatuo Jiaji, EX B2) acupoint most relevant to patient symptoms with reference to MRI will be administered Shinbaro pharmacopuncture.
41346927|NCT02384928|DEVICE|Acupuncture|Five acupoints will be needled to about 1cm depth assisted by an acupuncture guide tube with no manual stimulation such as twirling or lifting and thrusting.
41346928|NCT02384928|DRUG|Conventional medicine|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
41490726|NCT01550276|OTHER|Placebo control|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
41490727|NCT01294826|DRUG|AUY922|Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.
41019012|NCT00861419|DRUG|Sunitinib|Sunitinib 50 mg PO (QD)
41019013|NCT00861419|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
41019014|NCT00861419|DRUG|AMG 386|AMG 386 3 mg/kg IV (QW)
41019015|NCT04025918|DEVICE|Vasopressor automated delivery system|"Novel closed-loop system incorporating:~1. Continuous non-invasive arterial pressure (CNAP) monitor that measured and recorded hemodynamic data in real time.~2. Controller algorithm loaded onto a laptop computer that monitored the hemodynamic data from CNAP and determined if vasopressors should be administered.~3. Two syringe pumps loaded with phenylephrine and ephedrine that was activated by the controller algorithm."
41019016|NCT04025918|DRUG|Phenylephrine|Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
41157470|NCT05803525|OTHER|Intra-canal medication protocol|"Copious gentle irrigation will be provided without canal instrumentation using 20 mL 1.5% NaOCl in a slow flowing rate by a 27-gauge irrigating side vented needle positioned 2 mm from the root end followed by 20 mL saline.~After root canal dryness using paper points , double antibiotic paste (DAP) containing 500 mg of metronidazole and ciprofloxacin mixed with 0.5 mL polypropylene glycol giving a creamy paste will transported into root canal via lentulo spiral filler positioned 2 mm shorter than the WL apically and to level just below the cement-enamel junction (CEJ) coronally. Access cavity will be sealed response to the initial treatment will be assessed after 3 weeks.(21) In the next visit, If the patient is asymptomatic, the DAP will be removed using 10 mL of NaOCl according to the concentrations mentioned in each study group, followed by copious irrigation with 10 mL of 17% EDTA (22) and normal saline then drying the canals with sterile paper points."
41157471|NCT03680508|DRUG|TSR-022 and TSR-042|immunotherapy
41019017|NCT04025918|DRUG|Ephedrine|Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
40827534|NCT02129478|DRUG|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
41346929|NCT02384928|PROCEDURE|Physical therapy|Physical therapy will be prescribed with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics.
41346930|NCT02384928|BEHAVIORAL|Educational program|Educational program sessions supervised by physicians will be provided once a week for 4 weeks.The education program will inform the patient of the favorable prognosis of LDH, and instructions for everyday activities and self-management. The education program will consist of handbooks handed out to each participant, and weekly reminders and encouragement from the physician.
41346931|NCT05042570|OTHER|Instrument Assisted Soft Tissue Mobilization|"* This technique will be performed using instruments of different sizes, shapes and treatment styles.~* During the application, instruments will be applied to loosen the muscle tissue and fascia by gliding on the tissue at certain angles.~* The muscle groups to be treated with IASTM are gastrocnemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* The instrument will be sterilized before treatment.~* IASTM treatment will be applied without damaging the tissue after massaging cream is applied to the muscle fibers with the instrument."
41346932|NCT05042570|OTHER|Stretching Exercises|"* The muscle groups to be applied stretching exercises are gastrocinemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* 3 different functional stretching exercises will be applied;~* With the hands supported on the wall and with the help of the physiotherapist, the affected extremity is behind the knee in full extension m. gastrocnemius stretching exercise,~* With the hands supported on the wall and with the help of the physiotherapist, the knee is partially flexed, with the affected extremity behind. soleus stretching exercise,~* It is a stretching exercise that will be applied by asking the patient to squat without lifting his heels, with the patient's hands supported by the physiotherapist."
41346933|NCT05042570|OTHER|Control Group / NDT program|"* Efforts to eliminate tone disorders,~* Sensory-perception-motor integrity development studies,~* Activities aimed at facilitating movements in daily life,~* Stretching and strengthening exercises due to muscle shortness and weakness,~* Studies to increase lower and upper extremity functionality,~* It will include the training of activities such as standing up, walking and balance."
41346934|NCT06287931|DRUG|Ursodoxycholic acid group|Ursodoxycholic acid, 250mg po tid x 6 months
41346935|NCT06287931|DRUG|Bifidobacterium group|Bifidobacteria, 210 mg po tid x 6 months
40827535|NCT00839462|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
40827536|NCT00839462|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
40827537|NCT02716701|BEHAVIORAL|Exercise Group|
40827538|NCT02716701|OTHER|Control Group|
40827539|NCT02716701|OTHER|wristband activity tracker|
40827540|NCT06300723|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
41346936|NCT02980263|DRUG|Canakinumab|
41346937|NCT02339441|DRUG|Methotrexate|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
41346938|NCT02339441|DRUG|Mycophenolate mofetil|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
40827541|NCT00869050|DRUG|Capecitabine|"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
41490728|NCT01294826|DRUG|Cetuximab|Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
40827542|NCT00869050|DRUG|Temozolomide|"Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
40827543|NCT03627312|COMBINATION_PRODUCT|Omega-3|1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
40827544|NCT03627312|COMBINATION_PRODUCT|Placebo|Fruit juice drink only
40827545|NCT03627312|OTHER|Treatment as Usual|Young Offenders Intervention Programme
41019018|NCT04025918|DEVICE|Manual vasopressor delivery system|"Manual dosing system consisting:~1. Non-invasive intermittent blood pressure monitor that measured and recorded blood pressure at 1-minute intervals.~2. Attending anesthesiologist that noted the blood pressure readings and manually administered phenylephrine or ephedrine according to the algorithm."
41019019|NCT00777517|DRUG|Lipitor|A single dose of 10 mg Lipitor tablet
41346939|NCT02339441|DRUG|Cyclophosphamide|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
41346940|NCT03458962|GENETIC|Genetic Enrollees|Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
41346941|NCT06424483|BEHAVIORAL|Awareness, Courage, and Love Group Psychotherapy|Awareness, Courage, and Love (ACL) groups are an outgrowth of functional analytic psychotherapy, which is an empirically-based behavioural therapy that emphasizes the principle of positive reinforcement within relationships (Holman et al., 2017; Kanter et al., 2010; Kohlenberg \& Tsai, 1991; Tsai et al., 2009a). Awareness involves the practice of mindfulness, and in particular, the noticing of emotions within oneself and in others (Tsai et al., 2009b). Courage refers to engaging in vulnerable self-disclosures and practicing boundaried support. Love encompasses healthy caring for oneself and others, and in particular, responding affirmingly to another person's self-disclosures.
41346942|NCT03117699|DEVICE|New device for seated-standing passages|"Phase 1 : The subject perform different seated-standing passages (see Arm)~Phase 2 : After being seated, the subject performs a course comprising:~* A standing pass from sitting on a chair~* A straight line movement~* A succession of left and right turns~* An upward and downward travel of less than 1%.~* Standard doorway~* Standing on the toilet~* A sitting pass from the toilet~* One way to a bed~* A sitting pass on the bed~* A passenger seat sitting upright from the bed~* A return to the starting point~* A sitting pass on the starting chair"
41346943|NCT06488014|PROCEDURE|Erector spina plan block (ESP)|"In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9."
41490729|NCT01301586|DRUG|Doxycycline and S-equol|Oral doxycycline and s-equol twice a day
41490730|NCT01301586|DRUG|Doxycycline|ORAL DOXYCYCLINE TWICE A DAY
40827546|NCT06101602|OTHER|Dynamic Stretching with Floss Band|"Floss band involves wrapping a band made of natural rubber around the targeted joint or muscle for 1-3 minutes through active movement. The mechanism behind flossing is thought to have a three-fold effect, compression may stimulate the mechanoreceptors of the underlying fascia layer which causes the hyperemia of the targeted tissue, and leads to increased blood flow.~This intervention was applied in addition to dynamic stretching which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise."
40827547|NCT06101602|OTHER|Dynamic Stretching without Floss Band|In this group, only dynamic stretching was applied which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.
40827548|NCT03302117|OTHER|Wood smoke exposure|Healthy volunteers will exposed to filtered air alternate with wood smoke generated from incomplete wood smoke combustion to assess the local and systemic effect of theses exposures
40827549|NCT05985278|DRUG|[ Lu-177]-Catalase|\[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
40827550|NCT04357509|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
40827551|NCT02281487|PROCEDURE|Hysterectomy plus Tubectomy|hysterectomy with tubectomy
40827552|NCT02281487|PROCEDURE|Hysterectomy|standard hysterectomy
40827553|NCT02281487|DEVICE|light microscopy|analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
40827554|NCT01175642|BEHAVIORAL|Cognitive Remediation|Computer-based, therapist-lead cognitive remediation
40827555|NCT01175642|BEHAVIORAL|FAST|Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
41490731|NCT05965115|DIAGNOSTIC_TEST|Sample of Blood|All participants will receive M-protein screening by serum electrophoresis. Individuals with detected M-protein will undergo further diagnostic tests to determine their accurate diagnosis. Patients with monoclonal gammopathy of undetermined significance (MGUS) would be carefully assessed and followed up.
41019020|NCT00777517|DRUG|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
41019021|NCT05240534|BEHAVIORAL|ET-Text (Laptop)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Text arm will access ET on Laptop."
41019022|NCT05240534|BEHAVIORAL|ET-Voice (Smart System)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Voice arm will access ET on a smart speaker. Voice-activated devices can potentially be easy to use, even by those with limited dexterity or computer experience."
41346944|NCT06488014|PROCEDURE|Paravertebral block|"In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9."
41019023|NCT04104139|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
41019024|NCT04104139|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41019025|NCT04104139|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
41019026|NCT05809453|DRUG|Cocaine|Cocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
41019027|NCT05809453|DRUG|Lidocaine|Lidocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
41019028|NCT01599650|DRUG|Ranibizumab|
41019029|NCT01599650|PROCEDURE|Laser|laser photocoagulation
41019030|NCT04151810|DRUG|CDP1|"Single dose part:~Cohort 1:400 mg/m2; Cohort 2: 500 mg/m2; Cohort 3: 750 mg/m2;~Multi-dose Part:~Starting dose: Cohort 1:400 mg/m2; Cohort 2/3: 500 mg/m2; Maintenance dose: Cohort 1:250 mg/m2, QW; Cohort 2/3: 500 mg/m2, Q2W;"
41346945|NCT01930669|OTHER|Gravitational sympathetic stimulus|"Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.~Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.~MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique."
41019031|NCT04151810|DRUG|CDP1|Starting dose: 400 mg/m2; Maintenance dose: 250 mg/m2,QW;
41346946|NCT06049628|BEHAVIORAL|FIFA 11+ exercise program|FIFA 11+ program; It consists of simple, easily remembered, and time-consuming, sport-specific exercises underlying fair play. The F 11+ consisted of 3 parts: the first part consisted of running exercises (part 1); the second part included six exercises, which were made up of three levels of difficulty and aimed at enhancing balance, strength, muscle control, and core stability (part 2). The final and the third part covered advanced running exercises (part 3) .
41490732|NCT02430779|PROCEDURE|rreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
41490733|NCT02430779|DEVICE|NanoKnife|
41490734|NCT00042458|DRUG|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
41490735|NCT00042458|DRUG|Placebo|The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
41346947|NCT06049628|BEHAVIORAL|routine program|This program consists of jogging, and stretching exercises.
41019032|NCT04151810|DRUG|TIP chemotherapy|Paclitaxel: 175 mg/m2 in day 1, Q3W; Ifosfamide: 1200 mg/m2 in day 1, day 2 and day 3, Q3W; Cisplatin: 25 mg/m2 in day 1, day 2 and day 3, Q3W; Participants received TIP chemotherapy up to 6 cycles (21 days per cycle).
41019033|NCT05518279|DRUG|Tranexamic Acid Pill|Patients will receive 1950mg of an oral tranexamic acid pill (3 pills total) while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the oral TXA and are medically optimized, they will be taken to the operating room for fracture fixation.
41019034|NCT05518279|DRUG|Placebo Oral Tablet|Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
41019035|NCT06043557|PROCEDURE|Drain Placement|Surgical placement of drain based on subject randomization.
41490736|NCT02540759|DIETARY_SUPPLEMENT|Buglossoides oil|
41490737|NCT02540759|DIETARY_SUPPLEMENT|High Oleic Sunflower Oil|
41490738|NCT03842579|OTHER|Resistance training|Supervised progressive explosive type heavy-resistance training two times per week
41490739|NCT03842579|OTHER|High-protein diet|Daily supplementation with milk-based protein-rich products
41490740|NCT03842579|OTHER|Recommendations|Provided with the official national recommendations on nutrition
41490741|NCT04588311|DRUG|Epoetin Alfa 40000 UNT/ML|Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.
41490742|NCT04588311|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.
41490743|NCT02603718|OTHER|Rehabilitation treatment|
41346948|NCT02668328|BEHAVIORAL|Social Cognitive Theory Tailored Behavioral Intervention|The intervention will enhance self-efficacy
40827556|NCT06309511|DIAGNOSTIC_TEST|Arterial tonometry|Arterial transcutaneous tonometry
41346949|NCT00291460|DEVICE|inspiratory muscle training|
41346950|NCT03185091|OTHER|rapid ventricular pacing|
41346951|NCT03185091|PROCEDURE|Surgery|
41346952|NCT06279052|BEHAVIORAL|Phone interview|Phone interview during which the experience of the transition to adulthood among adolescents and young adults with Prader Willi Syndrome will be retrieved
41346953|NCT03675919|DEVICE|Scale|self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal
41346954|NCT03675919|DEVICE|Step counter|self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal
41346955|NCT03675919|DEVICE|Blood glucose meter with test stripes|self-monitoring of blood glucose; with automatic data transfer into the personalized and secured online portal
41346956|NCT03675919|OTHER|Access to the online portal|self-monitoring of health parameters
41346957|NCT03675919|OTHER|Telemedical coaching|regular telephone calls providing information about T2DM, healthy lifestyle, low-carbohydrate diet and physical activity
41490744|NCT05860205|BEHAVIORAL|Multiple Component Mobile-Aid Pain Reduction Intervention|1.Posture training through the wearable device, UPRIGHT GO. The participant wears the device on their neck. The device provides biofeedback to poor posture with vibrations and tracks posture. 2. A daily core muscle training and stretching exercise program including trunk rotation, lumbar rotation, hip flexor stretch, side plank, glute bridge, suitcase carry, and palloff press. 3. Participants will practice stress reduction through breath focus which will help them to concentrate on deep breathing to help them ignore distracting thoughts and sensations. 4. Strategies to improve daily level of activity including wearing a Garmin device that tracks their daily physical activity and reminds them to walk and the use of the communication principle to assist participants in overcoming barriers to physical activity.
41490745|NCT05860205|OTHER|Osteopathic Manipulation Treatment|Osteopathic Manipulation Treatment (OMT) will be conducted by putting pressure on certain muscles in the back and performing OMT exercises on the patient. The physician will treat participants with OMT twice during month 1 and once during month 2 and 3.
41490746|NCT05860205|OTHER|Sham Osteopathic Manipulation|The sham osteopathic manipulation treatment (OMT) will be performed by the medical team. Hands will be placed on the patient as if the OMT is being performed. The physician will treat participants with sham OMT twice during month 1 and once during month 2 and 3.
41346958|NCT00610714|DRUG|AZD0530|oral once daily dose
41346959|NCT00610714|DRUG|Carboplatin|intravenous injection
41346960|NCT00610714|DRUG|Paclitaxel|intravenous infusion
41346961|NCT01805674|DIETARY_SUPPLEMENT|isoflavones combined with magnolia|1 tablet/day duration: 12 weeks
41346962|NCT06432491|BEHAVIORAL|Drinking cold water|Volunteers in the intervention group will be asked to drink up 500 ml 4℃ water within 10 minutes four times per day throughout the study.
41346963|NCT04783376|DRUG|: Insulin, lispro and regular insulin|"* A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~* B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~* C: the same as intervention B but the 40% of the total dose will be given as regular insulin."
41346964|NCT03001765|OTHER|"Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System."|Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
41346965|NCT03371303|OTHER|collection of prescription data|collection of prescription data before and after a hospitalization
41346966|NCT05305625|PROCEDURE|remote ischemic postcondioning|remote ischemic postcondioning twice daily, for three consecutive days，the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning
41346967|NCT05305625|DRUG|standard therapy|received standardized treatment
41346968|NCT01308528|DRUG|Sodium enoxaparin|40 mg/mL
40827559|NCT05270902|DEVICE|CytoSorb Adsorber|Polymer based adsorber system for the elimination of cytokines
40827560|NCT03946982|PROCEDURE|low thoracic epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces
41346969|NCT01308528|DRUG|Sodium Enoxaparin clexane|clexane 40 mg/ 0,4 mL
40827561|NCT03946982|PROCEDURE|lumbar epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces (conventional)
40827562|NCT03180398|DEVICE|Multiparametric MRI|MRI will be acquired before, during and after radiation treatment to evaluate treatment response
41346970|NCT02116738|PROCEDURE|Flap Transposition Procedures|Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
41346971|NCT01922518|PROCEDURE|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
41346972|NCT01922518|PROCEDURE|Apex pacing|Put RV lead around the apex
41346973|NCT04576663|DRUG|Normal saline|Normal saline infusion simultaneous with subarachnoid block
41346974|NCT04576663|DRUG|Phenylephrine|Different infusion dose of phenylephrine simultaneous with subarachnoid block
41346975|NCT01209117|DRUG|GSK2248761 WBM Capsule|200 mg GSK2248761 WBM capsule (reference) 2 X100mg
41490747|NCT00797537|PROCEDURE|Echography|Echography
41490748|NCT05331157|DEVICE|ultrasound|the efficacy of prepuncture ultrasonography to facilitate epidural block in pediatric patients undergoing elective urological operations compared with the conventional anatomical landmark technique
41019036|NCT05971108|DIAGNOSTIC_TEST|Elecsys® GAAD|Elecsys® GAAD is a CE marked in vitro diagnostic (IVD) multivariate index assay, intended as an aid in the diagnosis of early-stage HCC. It provides a semi quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP (alpha-fetoprotein) and Elecsys® PIVKA-II (protein induced by vitamin K absence II) levels in serum and plasma, with gender and age. Clinical evidence showed that Elecsys® GAAD had high performance in detecting HCC (sensitivity 86.5%), particularly early stage (sensitivity 78.9%), with 91.4% specificity for both early and all stages, out-performing current standard of care (Chan et al. 2021). Elecsys® GAAD may be integrated into current surveillance practice to increase early-stage HCC detection rate, reduce unnecessary onward investigations and patient anxiety.
41019037|NCT05368207|DRUG|Pembrolizumab|Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
41019038|NCT01042964|DRUG|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
41019039|NCT06572358|OTHER|MetProUltima|"Test product Name: MetProUltima Marketed By\| Manufactured By: Meteoric Biopharmaceuticals Private Limited Mode of Usage: Take one capsule after each meal, twice daily. Frequency: Twice a Day Route of Administration: Oral"
41019040|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (90% triglycerides)|
41019041|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (60% triglycerides)|
41019042|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (ethyl esters)|
41346976|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 1|GSK2248761 WBM Tablet 200mg manufacturing process 1
41019043|NCT00804427|DIETARY_SUPPLEMENT|Soy oil|
41346977|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 2|GSK2248761 WBM Tablet 200mg manufacturing process 2
41346978|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 3|GSK2248761 WBM Tablet 200mg manufacturing process 3
41019044|NCT04926753|DRUG|5-Fluorouracil, Cisplatin, Toripalimab|Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
41019045|NCT03033797|DEVICE|MoviLetrando|Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
41346979|NCT01209117|DRUG|GSK2248761 WBM Tablet|GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
41346980|NCT04347252|DRUG|Glucagon|Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
41346981|NCT00200889|DEVICE|active TEAS|non-painful active transcutaneous electro-acupoint stimulation will be delivered to the abdomen and leg
41346982|NCT01166386|BEHAVIORAL|FANCI|comprehensive neurobehavioral sessions with therapist administrating treatment components
41346983|NCT01166386|BEHAVIORAL|FANCI|Watching DVDs chosen by participants on various topics.
41346984|NCT02193854|DEVICE|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
41346985|NCT01614522|DRUG|ASLAN001|ASLAN001 500mg BID
41346986|NCT00957190|DRUG|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
41490749|NCT02902783|OTHER|Data Collection|Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
41490750|NCT01394952|DRUG|Dulaglutide|Administered subcutaneously
41490751|NCT01394952|DRUG|Placebo|Administered subcutaneously
41490752|NCT06217861|BIOLOGICAL|VGM-R02b|Administered as specified in the treatment arm.
41490753|NCT00714129|OTHER|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
41490754|NCT00714129|OTHER|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
41019046|NCT03033797|DEVICE|MoveHero|Half of the participants will play 2 minutes of the game MoveHero.
41346987|NCT05056636|DIAGNOSTIC_TEST|Plasma α-Gal A activity; Plasma Lyso-GB3; GLA genetic sequencing.|"Screening Visit 1:~1. Male patient will first screened by enzymatic assay (Cutoff: 1.3 μM /hr)~2. Female patient will first screened by lyso-GB3 (Cutoff: \> 5ng/ml)~Screening Visit 2:~If both male and female who has deficient enzymatic level (Cutoff: 1.3 μM /hr) or lyso-GB3 level (Cutoff: \> 5ng/ml) respectively, those patients will be confirmed whether they have carried Fabry Disease causing mutation by whom GLA genetic sequencing."
41346988|NCT00432354|DRUG|atorvastatin|
41346989|NCT03200795|OTHER|Rebound exercise|"Each participant will undergo 3 sessions a week for 8 weeks with each session lasting 20 minutes. Bouncing frequency will be determined by signals from an metronom and will be set at between 90 and 120 bounces per minute. Heart rate training zone will be maintained, during the exercise, at moderate intensity of 40-60% and will be calculated using the Karvonen formula (\[Heart rate reserve x training percentage\] + resting heart rate)(Nuhu \& Maharaj, 2017).~The exercise will involve bouncing on the center portion of the mini trampoline (Portable 2013 Model Half-Fold Cellerciser with feet slightly apart and knees in full extension. Each foot strike equaled one step or bounce with step height, this will be defined as the distance between the foot at maximum height of jump and the bed of the center of the trampoline ranging between 10 and 15 cm (Nuhu \& Maharaj, 2017)."
41490755|NCT00616629|DRUG|AZD1305|Intravenous infusion
41490756|NCT01155024|DEVICE|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
41346990|NCT03200795|OTHER|Circuit training exercise|"Participants will be instructed to exhale while lifting a weight and inhale while lowering it, to minimize blood pressure excursions, and to rest for 2 to 3 minutes between sets. Participants will perform 1 set per resistance exercise three time weekly for the first 2 weeks and 4 sets of each resistance exercise three time weekly during weeks 3 and 4. Resistance will be increase by 5 to 10 kg when the participant could perform more than 15 repetitions while maintaining proper form.~All aerobic activities of the circuit training will be performed on a cycle ergometer or treadmill. Participants are free to vary the machine used from one visit to the next. Exercise intensity will be standardized by using heart rate monitors (Polar Electro Oy) that will display the participant's heart rate and emitted a warning signal when the heart rate was outside the prescribed training zone, thus guiding the participant in adjusting the workload up or down to achieve the desired intensity."
41346991|NCT03249441|BEHAVIORAL|Compassion-focused therapy|"Session-by-session summary of CFT:~Week 1: Understanding your relationship with food Week 2: Making sense of overeating Week 3: The Compassionate Mind/ Preparing your mind for compassion Week 4: Developing the skill of self-compassion Week 5: Why we overeat - a Compassionate approach Week 6: Understanding your current eating pattern Week 7: Motivating yourself to change Week 8: Determining what your body needs Week 9: Towards a new way of eating Week 10: Compassionate letter writing and developing a compassionate focus on eating.~__________________________________________________________________________"
41346992|NCT05355324|OTHER|no intervention|no intervention
41346993|NCT03696628|OTHER|Electrocardiogram|heart testing
41346994|NCT03696628|OTHER|physical examination|done by the investigator
40827563|NCT02978105|OTHER|self-conditioning techniques|Self-hypnosis to increase self-control before meals and every food compulsion episode
40827564|NCT02978105|OTHER|standard care (diet, exercise and behavioral therapy)|dietary recommendations, exercise recommendations, and behavioral recommendations
41490757|NCT01155024|DEVICE|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
41490758|NCT02669758|DRUG|ALKS 3831|Tablets were administered for daily dosing
41490759|NCT03621358|OTHER|Control gummy with free flavour (without encapsulating)|12 g/day (3 gummies)
41019047|NCT06571461|DRUG|Liposomal Irinotecan|Liposomal Irinotecan：i.v. infusion
41019048|NCT06571461|DRUG|Oxaliplatin|Oxaliplatin;：i.v. infusion
41346995|NCT03696628|OTHER|echocardiography|heart testing
41346996|NCT03696628|BIOLOGICAL|blood test|A sample of blood will be taken to each patient or healthy children in order to generate hiPSC-cardiomyocytes
41346997|NCT05493436|DIAGNOSTIC_TEST|MII pH-meter|using multichannel impedance pH-meter
41346998|NCT01466062|DRUG|Palivizumab|
40827565|NCT05010941|DEVICE|Hypotension Prediction Index|Hypotension Prediction Index monitored via radial arterial line
40827566|NCT00559468|DRUG|Sugammadex|Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
40827567|NCT00559468|DRUG|Rocuronium|Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
40827568|NCT00559468|DRUG|Sevoflurane|Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
40827569|NCT00559468|DRUG|Propofol|Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
41019049|NCT06571461|DRUG|S-1|S-1: Oral
41019050|NCT06571461|DRUG|Gemcitabine|Gemcitabine: i.v. infusion
41346999|NCT01243203|DRUG|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
41490760|NCT03621358|OTHER|Experimental gummy with 50% free/50% encapsulated flavour|12 g/day (3 gummies)
41490761|NCT03621358|OTHER|Experimental gummy with 100% encapsulated flavour|12 g/day (3 gummies)
40827570|NCT04303143|BEHAVIORAL|Self-Hypnosis|Self-Hypnosis
41019051|NCT06571461|DRUG|Capecitabine|Capecitabine: Oral
41019052|NCT05676697|DRUG|Linperlisib|The phosphatidylinositol 3-kinase delta (PI3Kδ) signaling pathway plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases. B cells play an essential role in immune system function and dysfunction (e.g., autoimmunity) by producing antibodies and by acting as antigen-presenting cells (APCs) for T cells. Signaling via PI3K controls many essential B cell functions and is therefore a promising target for preventing aberrant B cell activation.
41347000|NCT05982444|PROCEDURE|water vapor thermal therapy (Rezum) for prostate|all patients underwent rezum therapy for bph are evaluated for its effectiveness for long period
41347001|NCT02649075|OTHER|Serum-derived Bovine Immunoglobulin / Protein Isolate|Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.
41347002|NCT02649075|OTHER|Placebo|Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
41347003|NCT03286634|DRUG|Daunorubicin|Given IV
41157472|NCT04987034|DEVICE|EchoTip® Insight™|Patients will undergo procedure where HVPG is obtained under mild sedation, next the patients will undergo anesthesia and mechanical intubation where HVPG measurements will be obtained simultaneously with the EchoTip Insight measurement. For patients receiving a transjugular intrahepatic portosystemic shunt (TIPS), direct portal vein pressure measurements will be obtained by the EchoTip® Insight™ and compared to the transjugular direct portal vein measurement obtained during the interventional radiology (IR) procedure.
41157473|NCT01341444|DEVICE|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
41347004|NCT03286634|DRUG|Prednisolone|Given PO or IV
41347005|NCT03286634|DRUG|Vincristine|Given IV
41347006|NCT03286634|DRUG|Epirubicin|Given IV
41347007|NCT03286634|DRUG|E-coli L-asparaginase|Given IM or IV
41347008|NCT03286634|DRUG|6-Mercaptopurine|Given PO
40827571|NCT04303143|BEHAVIORAL|Direct Autonomic Experience Control|Direct Autonomic Experience Control. Use of learned mental tool/process to affect outcome measure of SUDS discomfort experience. (eg. Squeeze hand as pre-learned mental anchor to relieve discomfort in lower legs)
40827572|NCT05529355|DRUG|Envafolimab plus Endostar and S-1|Immunotherapy combined with chemotherapy and anti VEGFR therapy
41019053|NCT01557075|DRUG|Atorvastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~* Atorvastatin 40 mg daily for 12 months after randomization"
41019054|NCT01557075|DRUG|Pravastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization"
41019055|NCT03891082|PROCEDURE|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border
41019056|NCT03891082|PROCEDURE|BALLOON INSERTION|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
41019057|NCT00265811|DRUG|Folfox|
41019058|NCT00265811|DRUG|Cetuximab|
40827573|NCT05529355|DRUG|Envafolimab plus Endostar|Immunotherapy combined with anti VEGFR therapy
40827574|NCT05529355|DRUG|Envafolimab plus S-1|Immunotherapy combined with chemotherapy
40827575|NCT00241514|DRUG|Esomeprazole|
41157474|NCT01341444|OTHER|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
41157475|NCT04476849|DRUG|fezolinetant|Oral
41157476|NCT06324357|DRUG|Zongertinib|Zongertinib
41347009|NCT03286634|DRUG|Methotrexate|Given IV, PO or IT
41347010|NCT03286634|DRUG|Hydrocortisone|Given IT
41347011|NCT03286634|DRUG|Cytarabine|Given IV, IT or SC
41347012|NCT03286634|DRUG|Cyclophosphamide|Given IV
41347013|NCT00246285|DRUG|risperidone|
41347014|NCT02628899|DEVICE|Transfemoral TAVR|
41347015|NCT02628899|DEVICE|SAVR|
41347016|NCT06118190|DRUG|Lidocain|All participants treated with procaine and lidocaine injection for treatment.
41347017|NCT01985204|DIETARY_SUPPLEMENT|Iodine tablet|Iodine tablets containing 200 ug iodine as potassium iodate
41347018|NCT01985204|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet without iodine
41347019|NCT01614366|DRUG|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
41347020|NCT01614366|DRUG|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
41347021|NCT01614366|DRUG|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
41347022|NCT01614366|DRUG|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
41347023|NCT04868331|BEHAVIORAL|Exercise|Two trials of 7-min High Intensity Interval Training (HIIT) with 12 different exercises. Each exercise lasts for 30 seconds continuously with 10 seconds rest interval.
41347024|NCT05821374|DRUG|Deucravacitinib|6 mg tablet
41347025|NCT02853123|DRUG|Tiotropium|fixed dose combination once daily
41347026|NCT02853123|DRUG|Olodaterol|fixed dose combination once daily
41347027|NCT02853123|DRUG|Tiotropium|
41347028|NCT05402111|DRUG|SEP-363856|SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.
41019059|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme|"A 12 week programme of exercise and education~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist only)"
41347029|NCT05402111|DRUG|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
41347030|NCT04383106|OTHER|no intervention|no intervention
41347031|NCT04457661|DIETARY_SUPPLEMENT|Bacillus coagulans TCI711|Using Bacillus coagulans TCI711 for one month and implementing alcohol testing at weeks 0, 1, and 4.
41347032|NCT05863806|OTHER|Mulligan Mobilzation|"Participants were instructed that MWM, including shoulder movement, must be pain-free and should be immediately stopped if any pain is experienced during the treatment.~The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets."
41347033|NCT05863806|OTHER|Trasverse Friction Massage|"Deep friction massage was given to rotator cuff tendon with the tip of index finger, which is reinforced by middle finger.~It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was Given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration."
41347034|NCT00005577|DRUG|gemcitabine hydrochloride|
41347035|NCT00440102|DRUG|Ketamine|Ketamine
41347036|NCT00440102|DRUG|Etomidate|Etomidate
41347037|NCT03613168|DRUG|Trastuzumab|Trastuzumab plus gemcitabine/cisplatin
41347038|NCT04022590|DEVICE|E-clothes|The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.
41347039|NCT04022590|BEHAVIORAL|Healthy consultation|Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
41490762|NCT05386082|OTHER|Modified Delphi process|The study involves a brief demographics survey and Delphi process, i.e. three rounds of information and surveys, in which participants will be asked to score/rank potential metrics.
41490763|NCT02199340|OTHER|iStep exercise test|newly developed submaximal exercise test
41490764|NCT02199340|OTHER|CPET exercise test|maximal gold standard exercise test
41347040|NCT03377569|OTHER|Sleep, PD and DBS|Sleep, PD and DBS
41347041|NCT01186315|BEHAVIORAL|Prolonged Exposure Therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
40827576|NCT02640625|DIETARY_SUPPLEMENT|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
40827577|NCT00812201|DEVICE|No intervention is used. Collection of signals only.|Device received per standard of care.
41157477|NCT06324357|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan
41347042|NCT01186315|BEHAVIORAL|Prolonged Exposure therapy + VR/ER|The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use \& CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
41347043|NCT02052908|OTHER|Laboratory Biomarker Analysis|Correlative studies
41347044|NCT02052908|DRUG|Naproxen|Given PO
41347045|NCT02052908|OTHER|Placebo Administration|Given PO
41347046|NCT01897259|DRUG|Placebo Injection|Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
41347047|NCT01897259|BEHAVIORAL|Physical Therapy|Subjects participating in the physical therapy group will attend physical therapy and be prescribed to NSAIDS. No prolotherapy or corticosteroid injections.
41490765|NCT03599271|DEVICE|Drug-Coated Device|3000 mcg mometasone furoate-coated sinus dilation device
41490766|NCT03599271|DEVICE|Control Device|Sinus dilation device without drug
41490767|NCT04988074|DRUG|Cemiplimab|Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
41490768|NCT01191983|DRUG|Methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
41490769|NCT01998672|DRUG|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
41490770|NCT01998672|DRUG|Placebo|Drinking solution
41490771|NCT01379001|DRUG|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
40827578|NCT04039607|DRUG|Nivolumab|Participants will receive nivolumab as intravenous (IV) infusion.
40827579|NCT04039607|DRUG|Ipilimumab|Participants will receive ipilimumab as IV infusion.
40827580|NCT04039607|DRUG|Sorafenib|Participants will receive sorafenib as oral tablets.
41490772|NCT01379001|DRUG|Placebo|IM or PO placebo
41490773|NCT01379001|DRUG|Donepezil|donepezil 5mg PO x 1
41490774|NCT04819035|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
40827581|NCT04039607|DRUG|lenvatinib|Participants will receive lenvatinib as oral capsules.
41157478|NCT06324357|DRUG|Trastuzumab emtansine|Trastuzumab emtansine
41157479|NCT05562492|DEVICE|CamAPS FX|"The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data."
41490775|NCT03468335|DRUG|Irinotecan Liposomal Injection [Onivyde]|"Cancer treatment for PDAC:~* Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~* 5-FU 2400 mg/m2 as 46 hour infusion~* Folinic acid 400 mg/m2 as 0.5 hour infusion~* all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
40827582|NCT05839340|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen, to which proportion is set by the clinician as the NAVA level.
40827583|NCT05839340|DEVICE|Assist Control Ventilation|ACV delivers fixed oxygen pressure set by the clinician at the start of each inspiratory breath.
40827584|NCT05075395|DEVICE|PARO therapy seal|PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
41157480|NCT05562492|OTHER|Standard insulin therapy with CGM|Usual insulin therapy and study CGM.
41157481|NCT03635437|DRUG|Gamma-Aminobutyric Acid (GABA)|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
41347048|NCT01897259|DRUG|Corticosteroid Injections|Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.
40827585|NCT02792491|DRUG|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
40827586|NCT00196586|DRUG|Interleukin 2|
40827587|NCT00196586|DRUG|pegylated interferon alpha 2a|
40827588|NCT00196586|DRUG|ribavirin|
40827589|NCT05825924|DEVICE|E-Cigarette|E-cigarettes have been designed to resemble tobacco cigarettes. They include an aerosol generator, sensor, battery and storage area for liquid. They are either disposable or rechargeable. According to a study, e-cigarettes can deliver an average of 1.3 mg (range 0.4 to 2.6 mg) of nicotine from 15 puffs. Average Cmax after e-cigarette use is recorded as 8.4 ng/mL and Tmax achieved between 2 to 5 minutes
40827590|NCT05825924|DRUG|Nicotine patch|The nicotine patches are applied on the skin and nicotine is delivered at a steady rate. After administration, the peak blood levels are achieved within 6-10 hours. The levels remain constant, reducing by 25-40% with use of patches once daily. The patch is typically administered every 24 hours for no longer than 12 weeks. The dose of the patches is often determined by daily cigarette consumption and level of addiction.
40827591|NCT00418275|GENETIC|Recombinant Human Plasminogen Activator (HTUPA)|
41157482|NCT03635437|DRUG|Alprazolam|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
41347049|NCT01897259|DRUG|Prolotherapy|Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
41490776|NCT02296853|DRUG|TAF|25 mg tablet administered orally
41490777|NCT04393090|OTHER|eHealth platform CANKADO|The patients were asked to use the open eHealth platform CANKADO as a digital supporting tool.
40827592|NCT02723006|DRUG|TAK-580|TAK-580 tablets
40827593|NCT02723006|DRUG|TAK-202|TAK-202 infusion
40827594|NCT02723006|DRUG|vedolizumab|vedolizumab infusion
40827595|NCT02723006|DRUG|nivolumab|nivolumab infusion
40827596|NCT02723006|DRUG|ipilimumab|ipilimumab infusion
41347050|NCT01545089|OTHER|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
40827597|NCT01847105|OTHER|RevitaLens|Multi-purpose disinfecting solution
40827598|NCT01847105|OTHER|OptiFree PureMoist|Multi-purpose disinfecting solution
40827599|NCT05713903|PROCEDURE|Laparoscopic right colectomy|Resection of the ascending colon via a laparoscopic approach, adhering to the CME principles
40827600|NCT05713903|PROCEDURE|Open right colectomy|Resection of the ascending colon via an open approach, adhering to the CME principles
40827601|NCT05466500|PROCEDURE|Ultrasound guided axillary block with intravenous dexamethasone|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine plus 0.1mg/kg dexamethasone intravenous
40827602|NCT05466500|PROCEDURE|Ultrasound guided axillary block|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine
40827603|NCT01414205|DRUG|Obinutuzumab|Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
40827604|NCT01414205|DRUG|Corticosteroids|Participants were administered corticosteroids IV prior to the initial dose.
40827605|NCT00600041|DRUG|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
41347051|NCT01545089|OTHER|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
41347052|NCT01378091|DRUG|Lenalidomide|"Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."
41347053|NCT01378091|DRUG|Docetaxel|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."
41347054|NCT01378091|DRUG|Prednisone|"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily."
41347055|NCT01376505|BIOLOGICAL|HER-2 vaccine|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
41347056|NCT01376505|BIOLOGICAL|Extension HER-2 vaccine trial at OBD|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
41347057|NCT01387594|PROCEDURE|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
41347058|NCT01387594|DRUG|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
41347059|NCT02377271|DRUG|bosentan|treatment by bosentan or placebo is randomized , 125 mg twice a day
41347060|NCT02377271|DRUG|placebo|treatment by bosentan or placebo is randomized
41347061|NCT05321589|OTHER|impression techniques for implant used for maxillary screw retained hybrid prosthesis|"conventional splinted open tray impression technique was done for maxillary implants to fabricate screw retained hybrid prosthesis and digital intra oral impression was done for the same patients after screwing scan bodies to the implants intra orally.~evaluation of accuracy and 3D deviation between the two techniques was done"
41347062|NCT00471315|DRUG|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
41347063|NCT05414175|DRUG|Mavacamten|Specified dose on specified days
41347064|NCT01531686|PROCEDURE|Intraosseous delivery of CT contrast dye|Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
41347065|NCT04962490|PROCEDURE|Repair: suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich)|Repair tendon flexor sections in the hand: Suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich). The surgery depends on the anatomical area of the tendon section and the time between the injury and the operation.
41347066|NCT05178680|OTHER|relaxation session combining music and soft light|The caregiver will install a device consisting of a light bubble column, a multicolored light projector, and relaxing music chosen by the patient from a proposed panel. This session will last 30 minutes the day after the surgery
41347067|NCT04085991|DRUG|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
41347068|NCT04331210|DRUG|Diclofenac Sodium|Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
41347069|NCT05135091|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
41347070|NCT05135091|PROCEDURE|Sham Comparator|Sham Comparator.
41347071|NCT01801124|DRUG|EXPAREL|single dose 266 mg of undiluted EXPAREL
40827606|NCT00600041|DRUG|Placebo|Identical infusion manner like experimental arm
40827607|NCT02010736|OTHER|Single treadmill gait training with additional loading|
40827608|NCT06174389|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program.
41157483|NCT00260702|DRUG|Omalizumab (Xolair)|
41347072|NCT00000199|DRUG|Piracetam|
41347073|NCT03739060|DEVICE|Transcutaneous electric nerve stimulation|Conventional transcutaneous electric nerve stimulation
41347074|NCT00673816|DRUG|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
41347075|NCT02505269|DRUG|Brentuximab Vedotin|
41347076|NCT02505269|DRUG|Adriamycin|
41347077|NCT02505269|DRUG|Dacarbazine|
41347078|NCT02608892|BEHAVIORAL|BSweet2Babies video|Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
41490778|NCT06063265|BEHAVIORAL|Integrated Attention Training Program|Integrated Attention Training Program (IATP) specifically aims at training attentional control, which involves the coordination of complex behaviours, such as planning, reasoning, selection and information inhibition.
41490779|NCT03653117|DEVICE|Transperineal laser ablation|Minimal invasive coagulation of prostatic tissue by laser
41490780|NCT00132171|DRUG|Sequential therapy|
41490781|NCT00472862|BEHAVIORAL|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
41490782|NCT04221139|BEHAVIORAL|Virtual Reality games|Participants will play the following four virtual reality games for 15 minutes each: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
41490783|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, placebo powder and sunflower oil|High saturated fat meal with a blueberry flavored shake and sunflower oil
40827609|NCT04449393|DEVICE|Emdogain® FL|Emdogain® FL is an enamel matrix derivative intended for subgingival and topical application in conjunction with scaling and root planing procedures to provide regeneration of tooth support lost due to periodontal disease. Emdogain® FL has been shown to be effective in residual pockets with probing depths from 5mm to 9mm with no furcation involvement in patients with adequate plaque control. Emdogain® FL has also been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
40827610|NCT04449393|OTHER|Scaling and root planing|Scaling and root planing procedures as part of non-surgical periodontal therapy involves mechanical removal of dental plaque and calculus using curettes and sonic scalers.
40827611|NCT05878756|OTHER|Functional Strength Training|In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
41347079|NCT01215786|DRUG|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
40827612|NCT06551129|DRUG|Mavacamten|As prescribed by treating physician
41019060|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme and Behavioural Change|"A 12-week programme of exercise, education and behavioural change techniques to support exercise adherence and exercise self-efficacy~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist and participant)~Additional techniques addressing behavioural regulation include firstly, an exercise diary completed independently at home, secondly, the rationale and the intended functional benefit and expectations of the exercise programme clearly explained, thirdly individual weekly conversations to reflect on progress, expectations, solutions to barriers, and goals. Finally, peer support is strongly encouraged through the in-class support, and a social media networking group."
41019061|NCT02746614|OTHER|Psychomotor Therapy|Psychomotor Therapy
41347080|NCT01215786|DRUG|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
41347081|NCT01215786|DRUG|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
41490784|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, blueberry powder and sunflower oil|High saturated fat meal with blueberry powder shake and sunflower oil
41347082|NCT00731952|DRUG|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
41490785|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, placebo powder and DHA|High saturated fat meal with a blueberry flavored shake and DHA
41490786|NCT04629417|DEVICE|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) while patients are performing physiotherapy exercises.
41490787|NCT05746065|DRUG|PrEP|Eligible women will be prescribed PrEP intake in accordance to standard of care should they choose. We are interested in observing adherence, barriers to adherence, and other factors that effect sexual health.
41490788|NCT03894748|DRUG|Botulinum Toxin Type A|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
41347083|NCT02625363|OTHER|Glucose Ref - Std|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
41490789|NCT00070057|DRUG|celecoxib|Given orally
41490790|NCT00070057|PROCEDURE|therapeutic conventional surgery|Undergo surgery
40827613|NCT06138405|BEHAVIORAL|Immediate intervention Group|The immediate intervention group will be video recorded in office and participate in the training workshop and assessment methods two months after.
40827614|NCT06138405|BEHAVIORAL|Delayed intervention (control) Group|The delayed training group will also be video recorded in office but will wait an additional two months and then participate in the training and assessment methods as with the original training group.
40827615|NCT00003772|PROCEDURE|quality-of-life assessment|
41490791|NCT00070057|OTHER|pharmacological study|Correlative studies
41490792|NCT00070057|OTHER|laboratory biomarker analysis|Correlative studies
41490793|NCT02070874|BEHAVIORAL|telehealth enhanced pain management|
41490794|NCT04414761|DRUG|Progesterone|oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger
41490795|NCT04414761|DRUG|GnRH Antagonist|GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
41490796|NCT02129296|DEVICE|Air filled balloon|Balloon filled with air according to the manufacturing company orders
41490797|NCT02129296|DEVICE|Bioenteric BIB® balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
41019062|NCT01950143|DIETARY_SUPPLEMENT|Standard broccoli soup|Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.
41347084|NCT02625363|OTHER|Glucose Ref and 450 ml water|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
40827616|NCT06289088|OTHER|First Intervention|Firstly, For individuals with low back pain, all measurements will be evaluated without wearing any orthosis. The waist circumference of individuals with low back pain will be measured and the orthosis was adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the measurements will be repeated. Then, the person will be asked to wear the orthosis without any intervention.
40827617|NCT06289088|OTHER|Second Intervention|Firstly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be repeated. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis.
40827618|NCT06289088|OTHER|Third Intervention|Firstly, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be done. The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis. Lastly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotis. After waiting with the orthosis for half an hour, all measurements will be evaluated.
40827619|NCT03985982|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
41019063|NCT01950143|DIETARY_SUPPLEMENT|Beneforte broccoli soup|Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.
41347085|NCT02625363|OTHER|White Bread with 250 ml water|First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
41347086|NCT02625363|OTHER|White Bread and 700 ml water|"Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
41347087|NCT02625363|OTHER|White Bread with 125 ml water (twice)|"Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
41490798|NCT04068415|OTHER|Constipation risk assessment scale|questionnaires
40827620|NCT03985982|DRUG|Placebo|injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
40827621|NCT05053841|DRUG|Metformin|
40827622|NCT00960037|DIETARY_SUPPLEMENT|Oral vitamin D3|Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
41019064|NCT01950143|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
41019065|NCT04496258|BEHAVIORAL|Positive Emotion Induction|Participants are expected to have a positive emotional response to the more positive beach scene.
41019066|NCT04496258|BEHAVIORAL|Neutral Emotion Induction|Participants are expected to have a neutral emotional response to the neutral office scene.
41019067|NCT03120650|OTHER|Scalp acupuncture|Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.
40827623|NCT00960037|DIETARY_SUPPLEMENT|Placebo equivalent|One capsule daily for 8 weeks
40827624|NCT05420220|BIOLOGICAL|KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)|5 mg/kg Q3W IV
41347088|NCT04544436|DRUG|Ocrelizumab|"The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (participants's body weight \<75 kg) or 1800 mg (participant's body weight \>/=75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion every 24 weeks.~During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total)."
41347089|NCT04544436|DRUG|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 milligram (mg) every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
41347090|NCT04544436|DRUG|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
41347091|NCT04544436|DRUG|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
41347092|NCT04344015|OTHER|Plasma Donation|Previously infected COVID-19 patients will be recruited to donate convalescent plasma.
41347093|NCT00255983|DRUG|Faropenem medoxomil|600 mg BID for 5 days
41347094|NCT00255983|DRUG|placebo|placebo tablets BID for 5 days
41490799|NCT03603379|DRUG|C225-ILs-dox|C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.
40827625|NCT05420220|COMBINATION_PRODUCT|Axitinib|5mg bid po
41019068|NCT03120650|OTHER|Conventional rehabilitation|Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
40827626|NCT00764257|DEVICE|PREVELLE Shape|
40827627|NCT00764257|DEVICE|Restylane|
40827628|NCT03267173|DRUG|Chimeric antigen receptor T cell|Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
41019069|NCT05251233|DRUG|Placebo|Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
41019070|NCT05251233|DRUG|Pantoprazole|The study will use commercial supply.
41019071|NCT03231384|DEVICE|Remote ischemic conditioning|"In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.~Doctormate, IPC-906"
41019072|NCT02841423|PROCEDURE|neuropsychological test battery|
40827629|NCT04662073|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
40827630|NCT04662073|DRUG|Placebo|Placebo to match camostat administered orally four times daily
40827631|NCT01036529|DEVICE|Precision Spinal Cord Stimulator|Programming settings will be specific to the individual needs in accordance with the labeling
40827632|NCT01036529|PROCEDURE|Back Surgery|Different types of back surgery may be performed
41347095|NCT04224909|DIAGNOSTIC_TEST|Video Head Impulse Test|Diagnosis of dysfunction of the semicircular canals using the vHIT
41347096|NCT04142762|DRUG|ABI-H2158|ABI-H2158 tablets
41347097|NCT04142762|DRUG|Itraconazole|Itraconazole capsules
41347098|NCT04142762|DRUG|Rifampin|Rifampin capsules
41347099|NCT04142762|DRUG|Midazolam|Midazolam syrup
41347100|NCT04142762|DRUG|Ethinyl Estradiol / Levonorgestrel|Ethinyl Estradiol / Levonorgestrel tablets
41347101|NCT04142762|DRUG|Esomeprazole|Esomeprazole capsules
41347102|NCT04142762|DRUG|Placebo matching oral contraceptive|Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
41347103|NCT05820282|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing delivery of behaviour change interventions
41490800|NCT01429116|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
41490801|NCT00453557|DRUG|rhGH|
41347104|NCT05820282|OTHER|Control condition|Participants are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
40827633|NCT00267605|BEHAVIORAL|FHPADHD|Evidence-based psychological and behavioural distance intervention
40827634|NCT00267605|BEHAVIORAL|ADHD Standard Care|
41347105|NCT03094494|OTHER|none intervention|none intervention
41347106|NCT00478595|DRUG|Rimonabant|Tablet, oral administration
41347107|NCT00478595|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
41347108|NCT00478595|DRUG|Anti-diabetic monotherapy|Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
41347109|NCT04189380|OTHER|HLQ (Health literacy questionnaire)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
41347110|NCT04189380|OTHER|MoCA (Montreal Cognitive Assessment)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
41347111|NCT05393661|OTHER|inpatient physical therapy poststroke|routine care
41347112|NCT03189563|DRUG|DA-9805 45mg|DA-9805 15mg tid
40827635|NCT00717522|DRUG|Pomalidomide|
40827636|NCT06214520|BEHAVIORAL|App-based Motivational Interviewing & Human health coaching|"Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.~App-based Motivational Interviewing \& Human health coaching:~The health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call."
40827637|NCT06214520|BEHAVIORAL|Empower+ App & Smartwatch wearable tracker|Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.
40827638|NCT01752790|DRUG|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
40827639|NCT01752790|DRUG|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
41347113|NCT03189563|DRUG|DA-9805 90mg|DA-9805 30mg tid
41347114|NCT03189563|OTHER|Placebo|Placebo, tid
41347115|NCT04409496|BEHAVIORAL|Chat-based instant messaging support|"Subjects will receive personalised instant messaging support for 12 weeks after baseline, address the five problems that contributed to smoking relapse:~(1) lack of support for cessation, (2) negative mood or depression, (3) strong or prolonged withdrawal symptoms, (4) weight gain, and (5) smoking lapses. Updated information about the negative effect of smoking on risk of COVID-19 infection and prognosis will also be delivered."
41347116|NCT04409496|BEHAVIORAL|SMS message support|Subjects will receive regular SMS on generic smoking cessation for 3 months.
41347117|NCT04409496|BEHAVIORAL|Self-help booklet|Subjects will receive a standard self-help booklet on smoking relapse prevention.
41347118|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
41347119|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
41347120|NCT00702741|DRUG|Placebo|Intra-articular injection of Hyaluronan
41347121|NCT02431793|BEHAVIORAL|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.
41347122|NCT02431793|BEHAVIORAL|SMS Text Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
41347123|NCT02111954|DIAGNOSTIC_TEST|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9|Each patient will have two PET/CT
41347124|NCT00686699|DRUG|Preladenant|capsules
40827640|NCT02878525|PROCEDURE|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
41490802|NCT00500747|BIOLOGICAL|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
41490803|NCT00500747|DRUG|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
41490804|NCT02148341|OTHER|Community of Practice Facilitation|
41490805|NCT02148341|OTHER|Usual Care|
41490806|NCT06402617|PROCEDURE|Pulmonary vein isolation|Standard clinical radio-frequency ablation isolation of pulmonary veins
41490807|NCT06402617|DIAGNOSTIC_TEST|RETRO-Mapping without adjunctive ablation|RETRO-Mapping performed using research equipment and software, but without any adjunctive ablation
41490808|NCT06402617|PROCEDURE|Adjunctive ablation guided by RETRO-Mapping|Radio-frequency ablation using a European conformity (CE)-marked ablation catheter of sites of focal activation identified by RETRO-Mapping
41490809|NCT05201352|DRUG|trifluridine/tipiracil + XB2001|trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks
40827641|NCT02878525|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
40827642|NCT02727556|BEHAVIORAL|visual images|
40827643|NCT00220493|DRUG|Ritalin|
41019073|NCT00098215|BEHAVIORAL|Pediatric residency training on tobacco|
41490810|NCT05201352|DRUG|trifluridine/tipiracil + placebo|trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
41490811|NCT00573404|DRUG|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
41490812|NCT00573404|DRUG|sunitinib malate|
41490813|NCT00573404|OTHER|pharmacological study|
41490814|NCT03253835|DIAGNOSTIC_TEST|Single Group Assignment|
41490815|NCT02563587|OTHER|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
40827644|NCT01158144|DRUG|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
41019074|NCT02267655|DRUG|inhaled Nitric Oxide - 30 mcg/kg IBW/hr|inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
41019075|NCT02267655|DRUG|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
41490816|NCT02563587|OTHER|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
41019076|NCT02267655|DRUG|inhaled nitric oxide 75 mcg/kg IBW/hr|inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
41019077|NCT01823029|DRUG|erythropoietin|
41019078|NCT01823029|DRUG|enteral nutrition.|
41490817|NCT02563587|DRUG|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
41490818|NCT00548509|DRUG|Menatetrenone (Vitamin K2)|
41490819|NCT06060808|GENETIC|gene polymorphism|gene polymorphism of NFKBIA and PTPN22 genes
41490820|NCT02448706|DEVICE|Hearing Aid Fitting A|
41490821|NCT02448706|DEVICE|Hearing Aid Fitting B|
41490822|NCT00107705|BIOLOGICAL|Tree MATA MPL|
41490823|NCT00363753|DRUG|aspirin versus clopidogrel|
41490824|NCT03764761|DEVICE|AAC Technology - Standard of Care|Story Book is separate from AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and non-integrated presentation
41490825|NCT03764761|DEVICE|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and but integrated presentation
41490826|NCT03764761|DEVICE|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is optimal arrangement and but integrated presentation
41490827|NCT06238596|PROCEDURE|rehabilitation|The rehabilitation intervention will be led by a Physiotherapist and will include: a 12 weeks standardized multicomponent exercise (aerobic, resistance, balance and flexibility, and impact exercise if indicated), supervised by the physiotherapist, on an outpatient basis or in telerehabilitation. This program will be adapted to single patient needs. Every exercise session will last almost 60 minutes and patients will be supervised twice a week. One more exercise session per week will be self-managed by patients.
41490828|NCT01207505|BEHAVIORAL|Enhancing Emotion Regulation|12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
41490829|NCT00662948|DRUG|Rituximab|375 mg/m2 every 8 weeks during 24 months
41490830|NCT00662948|DRUG|Ibritumomab tiuxetan|One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
41490831|NCT02140723|RADIATION|preoperative short course radiation|
41490832|NCT00186758|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -"
41347125|NCT00686699|DRUG|Placebo|capsules
41490833|NCT02000661|DEVICE|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
41490834|NCT03668561|DEVICE|Caligaloc|15 days of wearing of the Caligaloc orthosis
41490835|NCT02208674|OTHER|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
41490836|NCT03097835|DRUG|Hyper-Diluted Botox|"0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle"
41490837|NCT03097835|DRUG|Topical anesthesia|Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
40827645|NCT01158144|DRUG|Paclitaxel/Carboplatin|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
40827646|NCT04579302|PROCEDURE|Serratus anterior block (SAB)|Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
40827647|NCT04579302|PROCEDURE|Erector spinae block|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
41019079|NCT01823029|DRUG|injection of iron|
41347126|NCT00776373|DRUG|Rapamycin + high dose etoposide and cytarabine|Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
41347127|NCT00600236|PROCEDURE|blood sample|
41347128|NCT01700140|DRUG|SyB D-0701|Study drug patches \[Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch\] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
41347129|NCT01700140|DRUG|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
41347130|NCT00840385|DRUG|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
41347131|NCT04660006|PROCEDURE|Cataract surgery|Patients undergoing uneventful cataract surgery were recruited to this study if they met the inclusion criteria of the three groups. Postoperative retinal vasculature measures, as recorded by the optical coherence tomography angiography imaging technique, were compared to baseline measures.
41347132|NCT00806494|DRUG|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
41347133|NCT01860794|DRUG|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
41347134|NCT01742663|DRUG|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
41347135|NCT01742663|DRUG|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
41347136|NCT01742663|DRUG|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
41347137|NCT06258265|DRUG|TAK-279|TAK-279 capsule.
41490838|NCT03097835|OTHER|0.9% saline solution|0.1ml of 0.9% saline solution will be administered to the side of the face
41490839|NCT01508754|PROCEDURE|Continuous positive airway pressure treatment|Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
41490840|NCT00440466|DRUG|epoetin alfa|Continue pre-study once weekly dose of epoetin alfa for 36 weeks
40827648|NCT04579302|DRUG|Saline (as a placebo)|Patients will receive a sham block with 20 ml saline (as a placebo)
40827649|NCT04579302|DRUG|Bupivacaine|bupivacaine
40827650|NCT00085254|DRUG|cilengitide|Given IV
40827651|NCT00085254|DRUG|temozolomide|Given orally
40827652|NCT00085254|RADIATION|radiation therapy|Undergo radiotherapy
40827653|NCT00085254|OTHER|laboratory biomarker analysis|Correlative studies
40827654|NCT00085254|OTHER|pharmacological study|Correlative studies
40827655|NCT00431951|DRUG|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
40827656|NCT00431951|DRUG|Placebo|Capsules to match experimental drug
40827657|NCT03243214|DEVICE|TMS|Real or Sham TMS will be given to the PD-MCI patient
41347138|NCT06258265|DRUG|TAK-279 Placebo|TAK-279 matching placebo capsule.
41347139|NCT06258265|DRUG|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
40827658|NCT03243214|DEVICE|Sham-TMS|Real or Sham TMS will be given to the PD-MCI patient
40827659|NCT00174863|DRUG|SR31747A|
40827660|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
40827661|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
40827662|NCT04355897|BIOLOGICAL|Convalescent COVID 19 Plasma|Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma
41019080|NCT02798848|DEVICE|Tablet computer|iPad
41019081|NCT05972434|OTHER|Sunscreen A|Participants will apply sunscreen A topically.
41019082|NCT05972434|OTHER|Sunscreen B|Participants will apply sunscreen B topically.
41019083|NCT04090944|PROCEDURE|the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position|-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
41019084|NCT04041505|BEHAVIORAL|(feeding modality)|The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
41019085|NCT04428632|DRUG|Berotralstat|One 150mg capsule administered orally once daily
41019086|NCT00162136|DRUG|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
41019087|NCT03145272|DRUG|Oxycodone|A single weight-adjusted oxycodone dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines
41019088|NCT04510116|BEHAVIORAL|Adults in the Making program|The AIM prevention program, modeled after an existing family-based skills-training intervention in a group format for rural African American preadolescents, consists of six consecutive weekly group meetings held at community facilities, with separate parent and youth skill-building curricula and a family curriculum. Each of the six meetings includes separate, concurrent training sessions for parents and youth, followed by a joint parent-youth session during which the families practice the skills they learned in their separate sessions. Concurrent and family sessions each last 1 hour. Thus, both parents and youth receive 12 hours of prevention training.
40827663|NCT02836782|PROCEDURE|Blood sample withdrawal|Blood withdrawal for HIV-DNA or HCV resistance test
41019089|NCT05916755|DIAGNOSTIC_TEST|Whole Genome Sequencing|Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.
40827664|NCT05737420|DIAGNOSTIC_TEST|Video call|The on-call neurologist can see and communicate with the patient via live stream video-call.
41019090|NCT05916755|DIAGNOSTIC_TEST|RNA-Sequencing|RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).
41019091|NCT05916755|DIAGNOSTIC_TEST|Microbiome analysis|Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.
41019092|NCT05916755|DIAGNOSTIC_TEST|ctDNA analysis|ctDNA analysis will be performed in plasma before and during NACT.
41019093|NCT05916755|DIAGNOSTIC_TEST|TCR-β repertoire sequencing|TCR-β repertoire sequencing will be performed in plasma before and during NACT.
41019094|NCT05916755|DIAGNOSTIC_TEST|PBMCs phenotyping|PBMCs phenotyping will be performed in plasma before and during NACT.
41019095|NCT05916755|DRUG|Pembrolizumab|Pembrolizumab will be given in combination with standard NACT.
41019096|NCT05916755|DRUG|Chemotherapy|Standard NACT will be given.
41019097|NCT03003676|BIOLOGICAL|ONCOS-102|Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)
41019098|NCT03003676|DRUG|Cyclophosphamide|Pre-treatment
41019099|NCT03003676|DRUG|Pembrolizumab|PD1 blockade
41019100|NCT06126055|DEVICE|Band Ligation|Placing bands in distal esophagus
41019101|NCT04530682|BIOLOGICAL|Biological samples|Serum and plasma samples. At baseline, 6, 12 and 24 months
41019102|NCT01543269|DRUG|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
41019103|NCT01543269|DRUG|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
41019104|NCT01170780|DRUG|Dexamethasone|single use of dexamethasone IV 8 mg/2 ml
41019105|NCT01170780|DRUG|Saline|2 ml IV
41019106|NCT00129259|BIOLOGICAL|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
41019107|NCT00129259|OTHER|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
40827665|NCT02203383|DEVICE|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
41019108|NCT00129259|DIETARY_SUPPLEMENT|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
41019109|NCT02442700|DRUG|pitavastatin|Treatment A = administration pitavastatin for 12 weeks
40827666|NCT01710527|DRUG|Metformin 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
40827667|NCT01710527|DRUG|Glucophage 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
40827668|NCT01158027|OTHER|gait evaluation|The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
41490841|NCT00440466|DRUG|epoetin alfa|Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
40827669|NCT01174277|OTHER|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
41019110|NCT02442700|DRUG|placebo|Treatment B = administration placebo for 12 weeks
41019111|NCT04027660|DEVICE|Immediate Zirconia Dental Implant|"For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~1. Administration of Articain 1:200.000~2. No flap procedure~3. Place a Zirconia Implant on the alveolar post extraction socket~4. Place xenograft biomaterial in the jumping gap~5. Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~* Final Impression with a IOS~* Placement of the Final Crown~* 3 month post crown post op~  3 IOS will be made for volumetric evaluation :~ 1. before tooth extraction~ 2. 3 month of Osseointegration for final impression~ 3. 3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements"
41347140|NCT06258265|DRUG|Moxifloxacin Placebo|Moxifloxacin matching placebo capsule.
41347141|NCT02813434|BIOLOGICAL|florbetapir|18F-AV-45 or 18F-Florbetapir
41347142|NCT01936428|OTHER|interview|
40827670|NCT02479581|PROCEDURE|ERAS group|Intravenous infusion of flucloxacillin sodium 1g an hour before operation
40827671|NCT02479581|PROCEDURE|ERAS group|"1. No routine bowel preparation;~2. Normal eating 1 days before the operation;~3. No drinking 2h and solid food 6h before the operation;~4. Drink 10% glucose 250ml 3h before operation ;~5. Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);"
41347143|NCT00005629|BIOLOGICAL|AFP gene hepatocellular carcinoma vaccine|"Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"
41490842|NCT00440466|DRUG|epoetin alfa|Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
41019112|NCT00131287|DRUG|Extract of Agaricus blazei Murill|
41019113|NCT01339533|DEVICE|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
41019114|NCT04231344|DEVICE|Laryngoscopy|Laryngoscopic examination of patients with GERD by two physicians
41019115|NCT02124590|OTHER|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
41490843|NCT05295238|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
41019116|NCT02124590|OTHER|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
41019117|NCT04892901|PROCEDURE|c-ESPB|In the c-ESPB group an ultrasound-guided ESPB will be performed by the attending anaesthesiologist at the end of surgery, immediately after the last surgical stitch and before extubation. After an initial bolus of 20 ml 0,2% ropivacaine, a catheter will be left in place into the fascial plane deep to the erector spinae muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
41019118|NCT04892901|PROCEDURE|c-SAPB|In the c-SAPB group SAPB will be performed by surgeons intraoperatively, immediately before the closure of chest wall muscle planes, by injection of 20 ml 0,2% ropivacaine into the fascial plane above the Serratus Anterior muscle. After the initial bolus, a catheter will be left in place into the superficial fascial plane of the Serratus Anterior muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
41347144|NCT05598840|OTHER|Care for today Mobile Application|"C4T (Care for Today) Education is a digital application (app) designed to offer quality educational materials.~The APP will be provided to the patients in the outpatient centre four months before surgery. Patients will be able to download the APP using a QR code that will be provided during the visit. They'll realize the download immediately or at home, in both cases a detailed explication of how to use the APP and its contents will be provided using an example version."
41347145|NCT05312385|DRUG|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
40827672|NCT02479581|PROCEDURE|ERAS group|Emphasize the preoperative psychological preparation for patients.
40827673|NCT02479581|PROCEDURE|ERAS group|Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
40827674|NCT02479581|PROCEDURE|ERAS group|No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
40827675|NCT02479581|PROCEDURE|ERAS group|Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
40827676|NCT02479581|PROCEDURE|ERAS group|"1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction;~2. Goal-directed fluid management."
41019119|NCT04892901|PROCEDURE|ICNB|"In the ICNB-group ICNB will be performed by surgeons intraoperatively, immediately before chest drain placement, by injection of 20 ml of 0,2% ropivacaine into the intercostal spaces (III-VII), below the parietal pleura, under direct visualization of the neurovascular bundle. The one-shot ICNB will be associated in this group with intravenous administration of tramadol (300 mg/48 h) by elastomeric pump."
41019120|NCT05511714|DRUG|L-(11C) methionine|Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).
41019121|NCT06345508|DIAGNOSTIC_TEST|Quantitative Ultrasound|Research quantitative ultrasound
41347146|NCT05312385|DRUG|Propofol|Intravenous infusion of propofol
41019122|NCT06345508|DIAGNOSTIC_TEST|B-mode Ultrasound|B-mode US performed according to the clinical standard of care.
41019123|NCT06345508|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
41019124|NCT06345508|DIAGNOSTIC_TEST|Liver Biopsy|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
41019125|NCT06573593|DRUG|Tofacitinib|In the real-world settings, patients with AA treated with tofacitinib.
41019126|NCT06573593|DRUG|Baricitinib|In the real-world settings, patients with AA treated with Baricitinib.
41019127|NCT06573593|DRUG|Ruxolitinib|In the real-world settings, patients with AA treated with Ruxolitinib.
41157484|NCT06639594|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|RTMS is a non-invasive procedure in which a coil is placed over the scalp, and powerful, focused magnetic pulses are applied to parts of the brain through the coil.
40827677|NCT02479581|PROCEDURE|ERAS group|"1. Infusion of Human Albumin Grifol®20% 50ml;~2. Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));~3. Shorten the Cardio-pulmonary Bypass line；~4. Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)"
40827678|NCT02479581|PROCEDURE|ERAS group|Monitor urine volume closely, over 0.5ml/kg·h.
40827679|NCT02479581|PROCEDURE|ERAS group|Protective ventilation strategy：Low tidal volume about 6\~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
41019128|NCT06573593|DRUG|Upadacitinib|In the real-world settings, patients with AA treated with Upadacitinib.
41019129|NCT06573593|DRUG|Abrocitinib|In the real-world settings, patients with AA treated with Abrocitinib.
41019130|NCT06573593|DRUG|Ritlecitinib|In the real-world settings, patients with AA treated with Ritlecitinib.
41157485|NCT05411471|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain|The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
41347147|NCT00733473|DRUG|Budesonide 0.5 mg/ml nebules|Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
41347148|NCT00733473|DRUG|% 0.9 Saline solution|Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
41019131|NCT06572540|DEVICE|Transthoracic cryoablation|Transthoracic cryoablation will be performed under the guidance of CT.
41019132|NCT06572540|DEVICE|Transbronchial cryoablation|Transbronchial cryoablation will be performed under the guidance of navigation bronchoscopy and CBCT.
41019133|NCT04489095|DIAGNOSTIC_TEST|Electrophysiology Study|After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.
41157486|NCT02785900|DRUG|33A|33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push
41157487|NCT02785900|DRUG|placebo|Volume equivalent to 10 mcg/kg, every 4 weeks via IV push
41157488|NCT02785900|DRUG|azacitidine|75 mg/m2 given subcutaneously (SC) or IV x 7 days, every 4 weeks
41019134|NCT05805280|DEVICE|intravascular ultrasound-guided group|intravascular ultrasound use
41019135|NCT05805280|DEVICE|angiography-guided group|angiography-guided use
41157489|NCT02785900|DRUG|decitabine|20 mg/m2 given IV x 5 days, every 4 weeks
41157490|NCT05063552|BIOLOGICAL|Atezolizumab|Given IV
41157491|NCT05063552|BIOLOGICAL|Bevacizumab|Given IV
41347149|NCT06037265|DEVICE|PAVmed PortIO™ Intraosseous Infusion System|The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
41347150|NCT02706795|BIOLOGICAL|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
41347151|NCT02219737|DRUG|Carboplatin|Given IVPB
41347152|NCT02219737|DRUG|Etoposide|Given IVPB
41347153|NCT02219737|DRUG|Ibrutinib|Given PO
41347154|NCT02219737|DRUG|Ifosfamide|Given IV
41347155|NCT02219737|OTHER|Laboratory Biomarker Analysis|Correlative studies
41347156|NCT02219737|OTHER|Pharmacological Study|Correlative studies
41490844|NCT03251963|DRUG|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
40827680|NCT02479581|PROCEDURE|ERAS group|"1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia:~   * Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1\~0.4ug/kg·min, Propofol Injection 2\~6mg/kg·h, Sevoflurane 0.5\~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06\~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
41157492|NCT05063552|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40827681|NCT02479581|PROCEDURE|ERAS group|"1. Drink water after 6h, 200ml once, 2\~3 times / day，~2. early ambulation，mobilization within 48 h,~3. Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；~4. Intravenous the lansoprazole 30mg q12h."
41347157|NCT02219737|BIOLOGICAL|Rituximab|Given IV
41347158|NCT03921606|BEHAVIORAL|Motivational Interviewing (i-BMI)|A brief MI via WhatsApp/WeChat
41347159|NCT03921606|BEHAVIORAL|Individual face-to-face generic health advice|Individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese). A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs.
40827682|NCT02479581|PROCEDURE|Conventional control group|Routine preoperative psychological preparation for patients.
41157493|NCT05063552|DRUG|Carboplatin|Given IV
41347160|NCT06192264|DRUG|ASC40|ASC 40 tablets orally once daily
41347161|NCT00994890|DRUG|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
41347162|NCT00994890|DRUG|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
41347163|NCT00994890|DRUG|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
41490845|NCT03251963|DRUG|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
40827683|NCT02479581|PROCEDURE|ERAS group|After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
41157494|NCT05063552|BIOLOGICAL|Cetuximab|Given IV
41157495|NCT05063552|DRUG|Cisplatin|Given IV
41490846|NCT04688931|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
41347164|NCT03873428|OTHER|FES PET|FES injection
41347165|NCT01572844|DEVICE|Fractionated Carbon Dioxide (FCO2) Laser|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
41157496|NCT05063552|PROCEDURE|Computed Tomography|Undergo CT scan
41347166|NCT01572844|DRUG|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
41347167|NCT03888976|PROCEDURE|Cholecystectomy|Cholecystectomy with repair of duodenal wall.
41347168|NCT00438490|DRUG|Recombinant Human Prolactin|
41347169|NCT03128255|OTHER|Assessment of already preacquired I-124 PET/US|Assessment of preacquired I-124 PET/US by review of anonymous digital case files
41347170|NCT04547491|DEVICE|HPI - hypotension prediction index|treatment of hypotension before the appearance following HPI algorithm
41347171|NCT04547491|DEVICE|GDT|cardiac optimization and treatment of hypotension following standard clinical practice
41347172|NCT04060433|BEHAVIORAL|Family Therapy|Swedish version of the evidence based manualized Family Therapy
41347173|NCT03489538|PROCEDURE|laparoscopic long limb roux-en-Y gastric bypass|standard laparoscopic roux-en-Y gastric bypass (biliopancreatic limb 40 to 60 cm, alimentary limb 150 cm)
41347174|NCT03453346|DRUG|Sofosbuvir|Generic sofosbuvir tablet 400 mg
41347175|NCT03453346|DRUG|Ribavirin|Ribavirin was provided in 100-mg tablets.
40827684|NCT02479581|PROCEDURE|Conventional control group|"1. Routine bowel preparation;~2. Liquid food eating 2 days before the operation;"
40827685|NCT02479581|PROCEDURE|Conventional control group|Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
40827686|NCT02479581|PROCEDURE|Conventional control group|"1. Induction use Sufentanil 0.5\~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2\~0.6mg/kg,Midazolam0.05\~0.1mg/kg ;~2. Maintain use Sufentanil 1\~2ug/kg·h, Propofol 4\~12mg/kg·h, Sevoflurane 1\~3(minimal alveolar concentration)， Vecuronium 0.06\~0.12mg/kg·h;"
40827687|NCT02479581|PROCEDURE|Conventional control group|Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
40827688|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of dexamethasone 20mg during the surgery
41347176|NCT01569724|OTHER|oral glucose tolerance test (OGTT)|patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
41347177|NCT01949792|DRUG|eptacog alfa (activated)|Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)
40827689|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of flucloxacillin sodium 1g before the operation
40827690|NCT03589391|DEVICE|LOR measurement via device|The epidural technique is totally performed in a sterile field without any harm to the patient. The LOR measurement is monitored via the bespoke device used during the epidural procedure.
41347178|NCT01949792|DRUG|eptacog alfa (activated)|Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)
41490847|NCT04688931|PROCEDURE|TURBT|The current standard of care for treatment of LG-IR-NMIBC is TURBT under general anesthesia.
40827691|NCT01731730|DRUG|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
40827692|NCT01731730|DRUG|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
41019136|NCT01736280|OTHER|Standard of Care|Any evaluation or treatment under this protocol will be based on standard practice as related to the subjects's digestive disorder.These include but are not limited to biobehavioral interventions including bowel retraining, biofeedback, and other lifestyle interventions, all of which have been shown to be beneficial in the treatment of this type of chronic functional bowel disorder.
41347179|NCT02407691|OTHER|Primary care 101 plus mental health|A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
41490848|NCT04841018|DRUG|High dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.5mg/kg of intravenous dexamethasone
40827693|NCT01731730|DRUG|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
41347180|NCT02407691|OTHER|Standard Primary Care 101|Standard Primary Care 101 guideline with standard training
40827694|NCT03000504|DEVICE|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
40827695|NCT03054805|DRUG|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight \< 15 kg, 500 mg per day for weight \<15-30 kg, and 1000 mg per day for weight \> 30 kg
40827696|NCT03054805|DRUG|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight \< 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight \> 30 kg
40827697|NCT02085525|OTHER|Nurse Practitioner Clinic|"The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs."
40827698|NCT02952482|PROCEDURE|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
40827699|NCT01884493|DEVICE|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
41157497|NCT05063552|DRUG|Docetaxel|Given IV
41157498|NCT05063552|PROCEDURE|Echocardiography|Undergo ECHO
41157499|NCT05063552|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41157500|NCT05063552|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41347181|NCT03260062|BEHAVIORAL|Parent-Child Early Approaches to Raising Language Skills|The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).
41347182|NCT03260062|OTHER|Standard Care Speech therapy|Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
41347183|NCT04456803|DRUG|Ferric citrate tablet|250mg/tablet, manufactured by Sinomune Pharmaceutical
41490849|NCT04841018|DRUG|Low dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.15mg/kg of intravenous dexamethasone
41490850|NCT03081234|DRUG|Ribociclib|Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
41490851|NCT03081234|DRUG|Placebo|Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
40827700|NCT01884493|DEVICE|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
40827701|NCT00016367|BIOLOGICAL|Trastuzumab|"Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15."
40827702|NCT00016367|DRUG|Cisplatin|"Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1."
40827703|NCT00016367|DRUG|Gemcitabine Hydrochloride|"Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab."
40827704|NCT00377546|DRUG|Nepafenac|
40827705|NCT00377546|DRUG|Ketorolac LS, Bromfenac|
40827706|NCT00196859|DRUG|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
41490852|NCT03081234|DRUG|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
40827707|NCT00196859|DRUG|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
40827708|NCT06099470|OTHER|Real-time synchronized telerehabilitation program (STP).|patient education, core stabilization exercises, strengthening exercises, stretching exercises
41490853|NCT05142098|DRUG|Dexamethasone|Intramuscular
40827709|NCT06099470|OTHER|Pre-recording non-synchronized telerehabilitation program (NSTP)|Pre-recording non-synchronized telerehabilitation program (NSTP)
40827710|NCT06099470|OTHER|Home non-supervised control group (HCG)|Home non-supervised control group (HCG)
40827711|NCT02131376|PROCEDURE|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
40827712|NCT02131376|PROCEDURE|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
41347184|NCT04456803|DRUG|Sevelamer carbonate tablet|800 mg/tablet, manufactured by Genzyme Ireland Limited
41347185|NCT05790902|DRUG|Silodosin|The patients used Silodosin for Medical expulsive therapy of ureteric calculi
41347186|NCT05790902|DRUG|Tamsulosin|The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi
41347187|NCT03933072|PROCEDURE|obtaining of autologous human olfactory bulb, autologous sural nerve preparation|The operative procedure will be aimed to obtain one of the patient's olfactory bulbs. The operation will be performed using a minimally invasive intracranial microsurgical endoscopy-assisted or transnasal endoscopic approach. During the same operation the patient sural nerve will be prepared for a future grafting.
41347188|NCT03933072|BIOLOGICAL|production of Glial Neuropatch|The human autologous olfactory ensheathing glia and olfactory fibroblast isolated from the olfactory bulb will be used for production of Glial Neuropatch in a laboratory facility in accordance with good manufacture procedures (GMP). The final Product will consist of the aforementioned cell suspension embedded with collagen scaffold. The European Medicines Agency/Committee for Advanced Therapies (EMA/CAT) considers that the Product Glial Neuropatch falls within the definition of a tissue engineered product of an advanced therapy medicinal product (decision EMA/CAT/293903/2018 from 22 June 2018: Scientific recommendation on classification of advanced therapy medicinal products Article 17 - Regulation (EC) No 1394/2007).
41490854|NCT05142098|DRUG|Etoricoxib 60 mg|Orally
40827713|NCT03433820|OTHER|Observation of wound healing|Observation of wound healing after skin biopsy
40827714|NCT05910034|DRUG|Trilaciclib+Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
40827715|NCT05910034|DRUG|Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
40827716|NCT05910034|DRUG|Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
40827717|NCT03230812|DRUG|Carnitene (L-Carnitine or Levocarnitine)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
40827718|NCT04538274|BEHAVIORAL|peer-driven intervention|Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
40827719|NCT00011414|DRUG|Tariquidar|IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
41347189|NCT03933072|PROCEDURE|microsurgical reconstruction of the transected spinal cord with autologous Glial Neuropatch-nerve bridges|The surgery will consists of laminectomy/laminotomy, midline durotomy above the area of spinal cord lesion, detethering of the spinal cord from fibrotic adhesions, resection of the posttraumatic spinal cord glial scar, delivering of cultured OEC/ONFs explants (Glial Neuropatch) to the area of spinal cord injury and finally bridging of the spinal cord gap by harvested autologous sural nerve grafts.
40827720|NCT00902018|DRUG|Eltrombopag|The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
41347190|NCT03330093|BEHAVIORAL|Sleep Health in Preschoolers|In-person, family-based behavioral intervention
41347191|NCT03330093|BEHAVIORAL|Health and Safety Intervention|In-person, family-based behavioral intervention
41347192|NCT01601990|DRUG|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
41347193|NCT01601990|DRUG|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
40827721|NCT00902018|DRUG|Romiplostim|three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
41347194|NCT01172704|BEHAVIORAL|Skills Building - Motivational Interviewing|"SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values."
41347195|NCT02175433|DRUG|AGS67E|intravenous (IV) infusion
40827722|NCT00902018|OTHER|healthy controls|single blood draw for all measures included in the intervention arms
41347196|NCT00942656|OTHER|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
41347197|NCT00942656|OTHER|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
41347198|NCT00942656|OTHER|VA|base diet plus 3.0% energy added from vaccenic acid
41347199|NCT00942656|OTHER|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
40827723|NCT05011214|DRUG|Sevoflurane|All patients received 0.01 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained
40827724|NCT05011214|DRUG|Esketamine|All patients received 0.1 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
40827725|NCT02926092|DIAGNOSTIC_TEST|Observation|Observation of progression of disease over time
41347200|NCT00608803|DRUG|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
41347201|NCT03234075|OTHER|Regional organization for promotion of renal transplantation|"Early identification of candidates for renal transplantation~* with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation~* delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway~* Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation)~* Helping to carry out the pre-graft assessments of patients by a care coordinator"
41347202|NCT01929512|DRUG|HCP1201 750/20mg|750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
41347203|NCT01929512|DRUG|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
40827726|NCT00525629|DIETARY_SUPPLEMENT|Walnuts|48 Grams of Walnuts Daily
40827727|NCT00525629|DIETARY_SUPPLEMENT|Control|Control Diet with No Walnuts
41157501|NCT02176902|BEHAVIORAL|behavioral dietary intervention|Receive dietary counseling
41157502|NCT02176902|BEHAVIORAL|behavioral dietary intervention|Receive guidelines for low-fat diet
40827728|NCT04377802|DIAGNOSTIC_TEST|molecular testing for virus RNA using RT-PCR|Serological testing will be performed using SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US) to check for the immunity. The IgG serology test (200 individuals per run) will be done using ARCHITECT i2000SR system which provides the results within 60 minutes
40827729|NCT01943838|DRUG|SAR245408|Pharmaceutical form: tablet Route of administration: oral
40827730|NCT05451173|RADIATION|Stereotactic body radiotherapy|An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.
40827731|NCT05451173|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.
40827732|NCT05451173|DRUG|Durvalumab|an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
40827733|NCT00746915|DEVICE|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
40827734|NCT01173029|DRUG|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
40827735|NCT03604874|DRUG|Oxytocin|intravenous infusion
40827736|NCT01500369|OTHER|sphygmomanometer cuff inflations|": Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
40827737|NCT01500369|OTHER|standard of care|Placebo Comparator
40827738|NCT02383420|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
40827739|NCT04790513|BIOLOGICAL|lerodalcibep|anti-PCSK9 small binding protein
40827740|NCT04790513|BIOLOGICAL|evolocumab|monoclonal antibody to PCSK9
40827741|NCT04790513|BIOLOGICAL|alirocumab|monoclonal antibody to PCSK9
40827742|NCT03454815|PROCEDURE|Apical patency|Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
40827743|NCT04732130|BEHAVIORAL|Time-Restricted Feeding|Participants are instructed to limit food intake to maximum 8 hours per day.
40827744|NCT04732130|BEHAVIORAL|Alternate Day Fasting|Participants are instructed to fast every other day.
40827745|NCT00459693|DRUG|[11C]PBR28|
41157503|NCT02176902|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO
41157504|NCT02176902|OTHER|laboratory biomarker analysis|Correlative studies
41157505|NCT03036124|DRUG|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
41157506|NCT03036124|DRUG|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg.
41157507|NCT01107353|DRUG|Imipramine Pamoate|75 mg capsule
40827746|NCT03496233|DRUG|Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]|Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
40827747|NCT03436641|OTHER|No intervention|No intervention
40827748|NCT01303146|DRUG|rhARSA|intravenous infusion 100U/kg every other week for 18 months
40827749|NCT01777555|DRUG|CVT-301|
40827750|NCT01777555|DRUG|Placebo|
40827751|NCT04997265|OTHER|Low intensity anticoagulation|Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.
40827752|NCT04997265|OTHER|Moderate Intensity Anticoagulation|"Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers."
41347204|NCT01929512|DRUG|Rosuvastatin 20mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
41347205|NCT04172376|PROCEDURE|Minimally invasive puncture aspiration plus rt-PA|Stereotactic puncture aspiration to evacuate basal ganglion hematoma with use of thrombolytic agent
41157508|NCT06219161|DIETARY_SUPPLEMENT|NAD3|NAD3 supplement (per capsule): 344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy)
41157509|NCT06645808|BIOLOGICAL|89Zr-DFO-N-Suc-F8scFv|89-Zirconium labeled short-chain variable fragment F8 targeting oncofetal CS.
41347206|NCT04172376|DRUG|Conservative medical treatment|Drugs for symptomatic treatment such as hemostasis and nerve nourishing.
41347207|NCT06135454|PROCEDURE|Open Wedge High Tibial Osteotomy|For OWHTO,The osteotomy plane, directed from 30 to 35 mm distal to the medial tibial plateau to 10-15 mm distal to the lateral tibial plateau in the coronal plane, was marked by two Kirschner wires with threaded tips. A transverse osteotomy was performed, leaving the lateral cortex intact as a hinge. After the ascending osteotomy and opening. The medial opening gap was filled with two β-TCP wedges and fixed with a TomoFix anatomical plate and locking screws .
41347208|NCT06135454|PROCEDURE|Double Level Osteotomy|The DLO was started from a lateral DFO. A 5-6-cm incision was made proximally at the distal femur from the lateral femoral epicondyle.Two Kirschner wires with threaded tips were inserted to make a length between the wires that was preoperatively planned as the lateral closed osteotomy. Transverse and ascending osteotomies were performed using a Precision Oscillating Tip Saw. The gap was closed and fixed using a TomoFix medial distal femur anatomical plate , which was bent for the lateral distal femur. The subsequent OWHTO was performed as described above.
41347209|NCT05719415|OTHER|Measurement of pulmonary functional capillary surface area|Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro
41347210|NCT01487928|DIETARY_SUPPLEMENT|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
41347211|NCT03442933|OTHER|3 hours Road Cycling Time Trial|The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.
41347212|NCT03442933|OTHER|3 hours Mountain Biking Time Trial|The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
41347213|NCT00954473|OTHER|laboratory biomarker analysis|Correlative studies
41347214|NCT04454749|DIAGNOSTIC_TEST|Blood test|Mesurement of E2, P4, LH, FSH hormones
41347215|NCT04454749|DIAGNOSTIC_TEST|Ultrasound|Follicular measurement and endometrium measurement
40827753|NCT02612701|OTHER|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
40827754|NCT02612701|OTHER|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
41157510|NCT06645808|BIOLOGICAL|89Zr-DFO-N-Suc-C9scFv|89-Zirconium labeled short-chain variable fragment C9 targeting oncofetal CS.
40827755|NCT02612701|OTHER|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
40827756|NCT02612701|OTHER|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
40827757|NCT05297487|DEVICE|early use of intermittent positive pressure breathing|standard care associated with daily and early use of intermittent positive pressure breathing
40827758|NCT04906720|DRUG|Colchicine|colchicine 0.6mg oral twice daily for 7 days
40827759|NCT01357876|OTHER|Metformin|withdrawral
40827760|NCT01819987|BEHAVIORAL|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
40827761|NCT01819987|BEHAVIORAL|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
40827762|NCT05535738|DRUG|Squaric Acid Dibutyl Ester|Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
40827763|NCT05535738|OTHER|Known patch test allergens|Positive patch test allergens during the course of clinical patch testing will be re-applied on the back followed by skin sampling
40827764|NCT05535738|DRUG|Dupilumab|300mg
41347216|NCT01565460|OTHER|Sample Collection|Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
40827765|NCT05535738|DRUG|Adalimumab|40mg
40827766|NCT05535738|DRUG|Ustekinumab|45mg
40827767|NCT05535738|DRUG|Guselkumab|100mg
40827768|NCT05535738|DRUG|Canakinumab|150mg
40827769|NCT05535738|DRUG|Sarilumab|200mg
40827770|NCT05535738|DRUG|Triamcinolone Acetonide|0.1% ointment
40827771|NCT05535738|DRUG|Betamethasone Valerate|0.1% ointment
40827772|NCT05535738|DRUG|Fluticasone Propionate|0.005% ointment
41490855|NCT05552079|OTHER|No intervention|Patients will be asked to show their consultation slip to confirm they attend to clinic on the day. The will also be asked to show their HKID card to comfirm they are aged 40 or above. The purpose of the study will be explained. If patient agrees to proceed, he/she will be given a self-administered questionniare. An interviewer-administered questionnaire will be provided for subjects who have poor sightedness or are illiterate. Since only anonymous data and no identifiable information will be collected, participants cannot be identified from the questionnaire. Therefore, inform consent will not be obtained.
41490856|NCT02906930|DRUG|semaglutide|Oral administration once daily.
41490857|NCT02906930|DRUG|placebo|Oral administration once daily.
40827773|NCT05535738|DEVICE|Microneedle|Painless and non-scarring skin sampling with a 7mm x 7mm patch of hydrogel-coated poly-l-lactide microneedles (\<2mm length) will be used to collect interstitial fluid
40827774|NCT05535738|DEVICE|Suction blistering|Suction blistering is a technique to induce and collect blister fluid using a negative pressure instrument (Electronic Diversities Finksburg, MD). It does not require local anesthetic, stitches or pain medication following the procedure. The blisters will be no greater than 1cm in diameter and no deeper than the epidermis (\<1mm deep). This process of inducing blisters is typically less than 1 hour. After the formation of blisters, the blister fluid will be extracted using a syringe. The blister roofs will be left attached to the skin and covered with petrolatum and a bandage.
40827775|NCT05535738|PROCEDURE|Skin punch biopsy|A skin biopsy is the removal of a small piece of tissue, under local anesthetic.
40827776|NCT06361602|OTHER|inapplicable|inapplicable
40827777|NCT00650520|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
40827778|NCT00650520|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
40827779|NCT06472869|OTHER|NJOY ACE e-cigarette|Patients will be provided with NJOY ACE electronic cigarettes and 5% nicotine e-liquid cartridges in tobacco flavor for 4 weeks and asked to use the electronic cigarette as a substitute for smoking combustible cigarettes during the 4 weeks
40827780|NCT04956055|OTHER|Reflexology|The patient will be kept in a lying position. First, the patient will be given four minutes of hand reflexology on each hand with warming and stimulation techniques.Reflexology will be applied to the left hand with the thumb of the right hand, the thumb of the left hand and the special points in the right hand. It will be applied to the fingers, palm, back of the hand, and finally the wrists, respectively, starting with the fingertips and using special reflexology techniques (a total of six minutes for each hand separately). By sending a moderate stimulus, a total of 20 minutes of reflexology session will continue.Since the patient reveals and uses his own internal energy at the end of the session, nobody should talk to the patient until five minutes after the procedure. Survey questions and vital signs would be examined five minutes after the session and the research with the participant would end.
40827781|NCT02479165|DRUG|Ibuprofene|The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
40827782|NCT02479165|DRUG|Oxycodone|The opioid group is given an oxycodone based analgesic regimen.
40827783|NCT01744678|BEHAVIORAL|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
40827784|NCT01744678|BEHAVIORAL|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
40827785|NCT00694096|DRUG|Sunitinib|"Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans"
40827786|NCT00200538|DRUG|memantine|
40827787|NCT02378194|DRUG|Placebo|24 weeks, once daily oral administration
40827788|NCT02378194|DRUG|HD-003 (800mg/day)|24 weeks, once daily oral administration
40827789|NCT02378194|DRUG|HD-003 (1600mg/day)|24 weeks, once daily oral administration
40827790|NCT06480175|PROCEDURE|cervical plexus block|patients will receive cervical radiofrequency ablation on both sides then after 2 weeks they will be readmitted and will receive superficial cervical plexus block on one side only
40827791|NCT06180681|BEHAVIORAL|Team-Enhanced Collaborative Life Skills Program|We will integrate three team-based implementation strategies to enhance team effectiveness in CLS, including Team Charters, Team Communication Training via Student Handoff Protocols, and Team Performance Monitoring. These interventions have been shown to improve cognitive (e.g., shared mental models) and affective ((e.g., trust, collective efficacy) team-based emergent states and enhance team-based processes, such as communication and coordination.
40827792|NCT06180681|BEHAVIORAL|Standard Collaborative Life Skills Program|CLS is a school-delivered intervention coordinating three empirically-supported approaches: teacher consultation and a daily behavior report card, behavioral parent training and child skills training. The three components are integrated over a 10-12 week period to improve symptoms and functional impairment among youth with ADHD.
40827793|NCT04536948|OTHER|Cooling Gel|Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle
40827794|NCT04536948|OTHER|Cold Pack|Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
40827795|NCT00953680|DRUG|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
41347217|NCT01703715|DEVICE|The Hydrant|"The Hydrant is a new form of drinking system that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant."
40827796|NCT00953680|DRUG|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
40827797|NCT00953680|DRUG|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
40827798|NCT03049267|DRUG|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
40827799|NCT03049267|DRUG|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
40827800|NCT01359761|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
40827801|NCT00283972|DEVICE|LAP-BAND System|
40827802|NCT02574013|DEVICE|Endoractor®|Endoscopic sponge for retraction of small intestine
40827803|NCT02630017|DRUG|ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
40827804|NCT02630017|DRUG|ADHD placebo first, methylphenidate second|double-blind, counter-balanced administration
40827805|NCT02630017|DRUG|Non-ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
40827806|NCT02630017|DRUG|Non-ADHD placebo first, methylphenidate second|
40827807|NCT06208189|BEHAVIORAL|High-effort session|Participants will perform 3 sets per exercise (total of 21 sets) with as many repetitions they can each set. We anticipate participants will perform \~10 repetitions per set in this session, with a total tempo of \~2.5 seconds per rep, averaging \~25 seconds per set. Resting period between exercises and sets will be 120 seconds. This will lead to a total session time of \~50 min. Their glycemic control will be evaluated during the following \~48 hours.
41490858|NCT03120533|DRUG|Iontophoresis of treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site
40827808|NCT06208189|BEHAVIORAL|Low-effort session|Participants will perform 6 sets per exercise (total of 42 sets) but perform half of the anticipated number of repetitions of the HIGH session (i.e., 5 reps). Repetition tempo at \~2.5 seconds will result in \~12.5 seconds per set. Resting period between exercises and sets will be 60 seconds. This prescription will also lead to a total session time of \~50 min. Thus, both the HIGH and LOW session will have similar total volume-load and session density, but differ in perceived effort after each set. Their glycemic control will be evaluated during the following \~48 hours.
40827809|NCT06208189|BEHAVIORAL|Control|The control session all procedures will be identical to the HIGH session, with the exception of performing the resistance exercises. However, to simulate all other procedures participants will follow all instructions, be positioned on the equipment for the same amount of time as the HIGH session, but will not perform any repetition. Interval between fake sets and exercises will be 120 seconds. Their glycemic control will be evaluated during the following \~48 hours.
40827810|NCT02753127|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
40827811|NCT02753127|DRUG|Fluorouracil|
40827812|NCT02753127|DRUG|Leucovorin|
40827813|NCT02753127|DRUG|Irinotecan|
40827814|NCT02753127|DRUG|Bevacizumab|
40827815|NCT01922063|BEHAVIORAL|Physiotherapy Intervention|20x 30 min sessions of physiotherapy
40827816|NCT01922063|BEHAVIORAL|Sham neck massage|20x 30 minutes sessions of neck massage
41347218|NCT00562536|PROCEDURE|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
40827818|NCT06053957|PROCEDURE|early mobilization|early mobilization program
40827819|NCT01470690|DRUG|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
41347219|NCT00949949|DRUG|everolimus|Given PO
41347220|NCT00949949|DRUG|gemcitabine hydrochloride|Given IV
41347221|NCT00949949|DRUG|cisplatin|Given IV
41347222|NCT03194256|BEHAVIORAL|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
40827820|NCT01470690|DRUG|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
40827821|NCT00889889|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
40827822|NCT00889889|BIOLOGICAL|Placebo|Placebo
40827823|NCT02168738|DRUG|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
40827824|NCT02168738|DRUG|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
40827825|NCT02168738|DRUG|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
40827826|NCT03659773|BIOLOGICAL|immune biomarkers to evaluate vaccine response in HSCT recipients|a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
40827827|NCT01961960|BIOLOGICAL|ASP7374|intramuscular
40827828|NCT04962607|OTHER|Neo-Putty® as dressing agents in pulpotomized primary molars|"Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM"
40827829|NCT05513664|DRUG|Osimertinib|80 or 160 mg/qd
40827830|NCT02055261|DEVICE|Low frequency DBS of the pedunculopontine nucleus|
40827831|NCT03128268|DEVICE|Imaging software for 4 dimensional images for Cardiac MRI|All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI
40827832|NCT03618628|DEVICE|Carbon Fiber Off Loading Orthosis (CFO)|A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
41019137|NCT05389592|PROCEDURE|Active tDCS and cognitive training|Electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strenght is set at 2mA for 20 minutes, daily for 5 continuous days (with a 2-day pause) for 4 weeks. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
41347223|NCT04684849|OTHER|APP Diary|Subjects keep a multi- item electronic digital App survey of symptoms for 2 weeks
41347224|NCT04684849|OTHER|Paper Diary|Subjects keep a multi-item paper survey of symptoms for 2 weeks
41490859|NCT03120533|DRUG|Iontophoresis of placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil; it's like a design of cross-over study
40827833|NCT04594265|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
40827834|NCT04594265|DIETARY_SUPPLEMENT|Science in Sport Go Enegy|Dosis isocaloric to the KetoneAid Arm
41157511|NCT06645808|RADIATION|PET/CT scan|IMP administration will be followed by PET/CT scans on day 1, 2 and 4.
41347225|NCT02936362|OTHER|Consumption of sourdough bread|Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
41347226|NCT02936362|OTHER|Consumption of white bread|Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
41490860|NCT01921530|PROCEDURE|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
41490861|NCT01921530|PROCEDURE|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
40827835|NCT05562180|BEHAVIORAL|Customized meal plan and grocery delivery|Participants will use an app to customize their meal plans
40827836|NCT00481312|DRUG|Dexmedetomidine|Continuous Infusion
40827837|NCT00481312|DRUG|Midazolam|Continuous Infusion
40827838|NCT00753805|DIETARY_SUPPLEMENT|mare's milk|The participants received 250 ml mare's milk or placebo daily. The placebo drink was based on a hypoallergenic infant formula.
40827839|NCT00787930|DRUG|Valproic Acid|Tablets, 250mg-3000mg
40827840|NCT01090934|DEVICE|High Resolution EEG|High Resolution EEG
40827841|NCT01090934|DEVICE|Stereo-electroencephalography|SEEG
40827842|NCT00301548|DRUG|perioperative chemotherapy|
40827843|NCT03411252|DRUG|Mirabegron 50 MG|Myrbetriq (Mirabegron) tablet
40827844|NCT03411252|DRUG|Placebo|Sugar pill manufactured to mimic Mirabegron
40827845|NCT03352453|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
40827846|NCT03352453|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
40827847|NCT03204799|OTHER|Metformin|newly diagnosed type 2 diabetes patients who start to metformin monotherapy
40827848|NCT03204799|DRUG|SGLT2 inhibitor|newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
40827849|NCT03204799|DRUG|ezetimibe|newly diagnosed dyslipidemia patients who start to ezetimibe therapy
40827850|NCT04341987|BEHAVIORAL|brief Imagery Rehearsal Therapy|Two-sessions of behaviorally-based imagery rehearsal therapy.
40827851|NCT04341987|OTHER|Treatment As Usual|may include medication treatment or behavioral treatment for nightmares other than imagery rehearsal therapy
40827852|NCT04070196|DIAGNOSTIC_TEST|Periplex|Periplex test strip will be used to examine the PD effluent for peritonitis, in addition to the routine leucocyte testing of PD effluent
41157512|NCT05289375|DRUG|Vacucis autovaccine|A sample will be taken from all participants in group T following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory. After 1 month from the sample collection, the laboratory will send in a container/dispenser (with the same appearance in both groups) to the T group will be administered the complete autovaccine ((with two applications per day for 7 weeks)
40827853|NCT02945553|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
40827854|NCT02945553|DEVICE|Microstimulation|Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
40827855|NCT02139735|OTHER|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
40827856|NCT02139735|OTHER|Ultrasound associated with stretching|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
40827857|NCT02139735|OTHER|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
40827858|NCT03087942|DRUG|QAW039|450 mg
40827859|NCT03087942|DRUG|QAW39A|450 mg
40827860|NCT03087942|DRUG|QAW39A2107|450 mg
40827861|NCT03087942|DRUG|QAW39A2107|450 mg
40827862|NCT04536922|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
40827863|NCT04536922|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
40827864|NCT04536922|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
40827865|NCT04536922|DRUG|Pembrolizumab (KEYTRUDA(R))|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
40827866|NCT04536922|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
40827867|NCT02157792|DRUG|M6620|
40827868|NCT02157792|DRUG|Gemcitabine|
40827869|NCT02157792|DRUG|Cisplatin|
40827870|NCT02157792|DRUG|Etoposide|
40827871|NCT02157792|DRUG|Carboplatin|
40827872|NCT02157792|DRUG|Irinotecan|
40827873|NCT01037049|OTHER|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
40827874|NCT04185649|BIOLOGICAL|BAT8001 for injection|3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.
40827875|NCT04185649|DRUG|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
40827876|NCT04185649|DRUG|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
40827877|NCT04975737|BIOLOGICAL|GamTBvac|The subunit recombinant tuberculosis vaccine GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose)
40827878|NCT04975737|BIOLOGICAL|Placebo|Placebo for subcutaneous administration
40827879|NCT04611425|DRUG|Remimazolam|Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
40827880|NCT01243684|DEVICE|DTI - Diffusor Tensor Imaging|Radiology intervention
40827881|NCT02084680|BEHAVIORAL|community health workers|community health workers offering individual prenatal education to pregnant women
40827882|NCT02109523|BEHAVIORAL|Motivational Interviewing (MI|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
40827883|NCT02109523|BEHAVIORAL|volitional intervention|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
40827884|NCT02109523|BEHAVIORAL|Routine discharge counseling|
40827885|NCT05139199|BEHAVIORAL|Auricular Point Acupressure group|A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
40827886|NCT05362591|PROCEDURE|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
40827887|NCT05362591|PROCEDURE|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation of tooth enamel
40827888|NCT04199364|DRUG|Poractant Alfa 80 mg/mL Intratracheal Suspension|Exogenous surfactant (Poractant Alfa) administration at a dose of 200 mg/kg.
40827889|NCT00537732|DRUG|omeprazole|20 mg daily
41490862|NCT04530630|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.
40827890|NCT00537732|DRUG|omeprazole|20 vs. 60 mg daily, genotype dependent
40827891|NCT03109808|OTHER|e-health strategy|"* First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.~* Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment."
40827892|NCT03109808|OTHER|Traditional Oral Hygiene Education|traditional oral hygiene education
40827893|NCT03080545|DRUG|Enstilar 0.005%-0.064% Topical Foam|Topical foam
40827894|NCT03515551|DRUG|IMCnyeso|Weekly IV infusions of IMCnyeso
40827895|NCT02279719|DRUG|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
40827896|NCT02279719|DRUG|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
40827897|NCT02279719|DRUG|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
40827898|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair with TAP block|Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery
40827899|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair without TAP block|No block administered during Laparoscopic ventral hernia surgery
40827900|NCT01330979|DRUG|AR-12286 0.5% Ophthalmic Solution|Ophthalmic Solution
41347227|NCT04822090|OTHER|Supportive treatment with or without red cell transfusion/intravenous immune globulin (IVIG)|red cell transfusion; plasma exchange; renal replacement therapy; intravenous immunoglobulin. plasma exchange
41490863|NCT00692718|DRUG|Epadel, Eicosapentaenoic acid|Epadel 900mg, 2 times a day, during hospitalization
41347228|NCT06444997|DRUG|Oxycodone Hydrochloride|Oxycodone hydrochloride will be administered at a continuous infusion dose of 0.03-0.2 mg/kg/h.
41347229|NCT06444997|DRUG|Remifentanil|Remifentanil will be administered at a continuous infusion dose of 2-9 μg/kg/h.
41347230|NCT03971019|DRUG|statins|On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).
41347231|NCT03971019|BEHAVIORAL|Dietary intervention group (control group)|Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol \< 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2\~3 g/d Water soluble dietary fiber 10\~25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day
41347232|NCT03542890|DEVICE|Baska Mask|used in adult low risk females undergoing elective gynecological operations
41347233|NCT03542890|DEVICE|I-gel|used in adult low risk females undergoing elective gynecological operations
41347234|NCT03500536|BEHAVIORAL|IntelliCare|A suite of mobile apps that use principles of computerized therapy to decrease symptoms of depression.
40827901|NCT03383757|DEVICE|SpO2 Sensor application & blood draw|At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
40827902|NCT02474537|DRUG|INC280|Single 200 mg dose INC280
40827903|NCT02539498|DEVICE|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
41019138|NCT05389592|PROCEDURE|Sham tDCS and cognitive training|Sham electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining session time. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
41347235|NCT04520919|OTHER|anesthesia;Radial artery puncture|we chose the patients who need to monitor invasive blood pressure to obtain high-fidelity arterial waveforms
41347236|NCT02608294|DEVICE|Kinesio Taping|The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.
41019139|NCT05747118|BEHAVIORAL|Physical training|A 12 week supervised training intervention with 1 hour physical training two times a week.
41019140|NCT05194176|DEVICE|Virtual Reality|For all VR exercises a head mounted display (HMD), the PICO G2 4K (Barcelona, Spain) will be used. Together with SyncVRMedical (Utrecht, Netherlands) a VR dashboard has been created from which patients can chose the different exercises.
41347237|NCT02608294|DEVICE|Kinesio Taping Sham|The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
41347238|NCT05937490|DRUG|Enantone|administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle.
41019141|NCT04077034|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis DE111®|Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
40827904|NCT03100812|BEHAVIORAL|More intensive CHW Intervention|Group A participants will attend 4 monthly 90 minute group health education sessions that provide the tools and strategies to promote heart health to Filipino American individuals, families, and communities on high blood pressure and CVD. The CHWs will lead these sessions utilizing NHLBI's Healthy Heart Healthy Family, A CHW's Manual for the Filipino Community. Each of the group health education sessions will discuss different content related to CVD, hypertension, and other CVD risk factors. The first session focuses on assessing heart disease risk and recognition of heart attack signs. The second session focuses on physical activity and weight management and blood pressure control. The third session addresses control of cholesterol, and diabetes. The final 4th session teaches participants about nutrition and living smoke free.
40827905|NCT03100812|BEHAVIORAL|Less Intensive CHW Intervention|Individuals randomized to the less intensive CHW intervention will have the baseline, 4 month, and 8 month interviews and blood pressure measurements will be collected in those succeeding time points. Participants will also receive a 30 minute one on one session from the CHW and a referral to a physician if needed.
40827906|NCT03648372|DRUG|TAK-981|Intravenous infusion.
40827907|NCT04151251|BEHAVIORAL|Patient Empowerment|Group to receive a 5 minute video about typical hospital sleep disruptions and what they can do to prevent them, as well as a brochure outlining the importance of sleep
40827908|NCT04151251|OTHER|Sleep Kit|Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
40827909|NCT04736160|OTHER|collect data|The data for this project will be obtained directly from the IVI digital work platform (SIVIS) where the characteristics and scans performed to each patient are recorded. Furthermore, it will be recollected information from the time-lapse incubator. For the current study will be used Embryoscope and Geri time-lapse incubators
40827910|NCT04495868|DRUG|Bacteriostatic Normal Saline|A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
40827911|NCT04495868|DRUG|1% Lidocaine|A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
40827912|NCT04685629|DIAGNOSTIC_TEST|25 post ICU-patients|patients who were hospitalized in an intensive care unit
40827913|NCT04685629|OTHER|25 post non-ICU patients|patients who were not hospitalized in an intensive care unit
40827914|NCT00136968|DRUG|Voriconazole|
40827915|NCT00227318|DRUG|ATACAND|
40827916|NCT03663530|BEHAVIORAL|Meal times|Meal times vary based on the arm: aligned or misaligned
40827917|NCT04643639|DEVICE|CytoSorb hemoperfusion|Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.
40827918|NCT03816280|PROCEDURE|Elective cardiopulmonary bypass (CPB)|All groups undergo elective cardiopulmonary bypass (CPB)
40827919|NCT03816280|PROCEDURE|Alpha-stat acid-base management|Acid-base status during CPB will be maintained using the alpha-stat regime
40827920|NCT03816280|PROCEDURE|pH-stat acid-base management|Acid-base status during CPB will be maintained using the pH-stat regime
40827921|NCT02111135|BIOLOGICAL|b-OPV|
40827922|NCT02111135|BIOLOGICAL|m-OPV2|
40827923|NCT02111135|BIOLOGICAL|m-IPV HD|
40827924|NCT02111135|BIOLOGICAL|t-IPV|
40827925|NCT01371643|DRUG|Octreotide LAR|
40827926|NCT01371643|PROCEDURE|transsphenoidal surgery|
40827927|NCT01871155|DIETARY_SUPPLEMENT|Nutri-jelly|"an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement"
41347239|NCT05937490|DRUG|Dienogest 2 MG (milligram)|Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle).
40827928|NCT01904643|DRUG|lenalidomide|Given PO
40827929|NCT01904643|DRUG|mitoxantrone hydrochloride|Given IV
40827930|NCT01904643|DRUG|etoposide|Given IV
40827931|NCT01904643|DRUG|cytarabine|Given IV
40827932|NCT03818347|DEVICE|oxyhydrogen generator (AMS-H-03)|Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively. The patients inhale 3 hours each day through a cannula or mask, and persist for long term
40827933|NCT03818347|DEVICE|analogue machine|This machine has the same apperance and gas condition
40827934|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
40827935|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
40827936|NCT05497102|DRUG|Lenalidomide maintenance|Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
40827937|NCT05498233|DRUG|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
40827938|NCT02142283|DEVICE|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
40827939|NCT02142283|OTHER|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
41019142|NCT04077034|DIETARY_SUPPLEMENT|Placebo comparator|Placebo comparator, once a day for 8 weeks
41347240|NCT05937490|DRUG|Enantone|COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times).
41347241|NCT05937490|DRUG|long GnRH agonist or flexible GnRH antagonist protocol.|During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
40827940|NCT05608525|DEVICE|transcranial current stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
41019143|NCT02912481|PROCEDURE|posterior tibial artery|
41019144|NCT02912481|PROCEDURE|radial artery|
41019145|NCT02912481|PROCEDURE|dorsalis pedis artery|
40827941|NCT05608525|BEHAVIORAL|GRASP|A standardized occupational therapy- GRASP will be performed daily together with tDCS over the period between the Pre Assessment and the Post Assessment. GRASP exercise will be administered concurrently with or immediately after tDCS stimulation. GRASP is a self-directed arm and hand exercise program for which is supervised by a therapist, but done independently by the participant (and with their family if possible). GRASP has been shown to improve arm and hand function and strength in stroke patients in community \[22-27\]. The versions of the program- Home GRASP will be used. All occupational tasks will be selected from the GRASP task pool and be progressed according to the GRASP protocol (https://neurorehab.med.ubc.ca/grasp). Each GRASP session will take about 1 hour. A total of 20 GRASP sessions will be administered.
40827942|NCT01185964|BIOLOGICAL|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
40827943|NCT01185964|DRUG|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
40827944|NCT00536874|DRUG|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
40827945|NCT00536874|DRUG|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
40827946|NCT00536874|GENETIC|protein expression analysis|
40827947|NCT00536874|GENETIC|proteomic profiling|
40827948|NCT00536874|OTHER|diagnostic laboratory biomarker analysis|
41347242|NCT01466439|PROCEDURE|high-frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 20 Hz
41347243|NCT01466439|PROCEDURE|low frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 1 Hz
41347244|NCT05977374|OTHER|experimental and conventional group|Static stretchings of the lower limb, Ultrasound 1 MHz 1.5W/cm2 7 mins, knee isometrics, open chain activities, knee mobilizations grade 1 and 2, and home care plan.
40827949|NCT00536874|PROCEDURE|adjuvant therapy|
40827950|NCT00536874|PROCEDURE|neoadjuvant therapy|
40827951|NCT00536874|PROCEDURE|therapeutic conventional surgery|
40827952|NCT06351098|BEHAVIORAL|nap|Children are nap promoted
40827953|NCT03859518|OTHER|blood and skin samples|To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
40827954|NCT04449939|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
40827955|NCT01889134|DRUG|Sedron (alendronate)|
40827956|NCT01889134|PROCEDURE|Parathyroidectomy|
41347245|NCT03518775|DEVICE|Biometry|Measurement of Cornea
41347246|NCT03209986|PROCEDURE|mesenchymal stem cell transplantation via peripheral vein|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
40827957|NCT02282371|DRUG|Cetuximab|
40827958|NCT02282371|DRUG|BYL719|
40827959|NCT02282371|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
40827960|NCT00225589|DRUG|Rosuvastatin calcium|
40827961|NCT00410319|BEHAVIORAL|Fear-reducing Information|
40827962|NCT00410319|BEHAVIORAL|Symptom-based exercise|
40827963|NCT00301535|DRUG|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
40827964|NCT06139562|BEHAVIORAL|Time-Restricted Feeding|Time-restricted feeding (TRF) is a dietary approach that includes a fasting protocol and a fasting period ranging from 3 to 21 hours during the day . Since there is no standard definition of TRF, fasting/feeding periods vary. In this study, 12-hour fasting and 12-hour feeding period defined by Pureza et al.(11) were taken as the TRF model. In the first 4-week arm of the study, applied a time-restricted feeding program from sunrise to sunset. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
40827965|NCT06139562|BEHAVIORAL|Extended-Time Feeding|Extended-time feeding program was suggested that allows them to eat at any time of the day. During dietary interventions, a weight loss diet was applied to the participants. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
40827966|NCT03430505|DEVICE|Bilevel|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
40827967|NCT03430505|DRUG|Albuterol|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
41347247|NCT03209986|OTHER|mesenchymal stem cell|mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
41347248|NCT05885906|DRUG|Aloevera|Mouthwash
41347249|NCT05885906|DRUG|Thyme honey|Mouthwash
40827968|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|"An initial loading dose will be administered intravenously over a period \<= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always \>= 0.4 mL/h."
40827969|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period \<= 5 minutes (maximum infusion rate, 10 mL/min).
40827970|NCT00690807|DRUG|PH-10|PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
40827971|NCT00235391|DRUG|Deferasirox|125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
40827972|NCT03453255|DRUG|Chemotherapy|chidamide, decitabine, homoharringtonine, cytarabine
40827973|NCT00609791|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
40827974|NCT00609791|OTHER|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
40827975|NCT00609791|OTHER|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
40827976|NCT00609791|OTHER|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
40827977|NCT00609791|OTHER|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
40827978|NCT00609791|PROCEDURE|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
40827979|NCT00609791|PROCEDURE|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
40827980|NCT02542891|OTHER|Blended CBT|
40827981|NCT02542891|OTHER|Treatment as Usual (TAU)|
40827982|NCT00970814|BEHAVIORAL|BBCET|11 BBCET sessions
40827983|NCT00970814|BEHAVIORAL|BBCET|11 BBCET Sessions
40827984|NCT00970814|DRUG|Levetiracetam XR|500mg - 2000mg Once per day 16 weeks
40827985|NCT00970814|DRUG|Sugar Pill|500mg - 2000mg Once per day 16 weeks
40827986|NCT05947279|BEHAVIORAL|Comparing motor adaptation reaching performance|By comparing motor adaptation reaching performance between these three groups, the investigators can examine how stimulation to each specific area of the brain modulates different aspects of motor adaptation
40827987|NCT02529748|OTHER|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
40827988|NCT02529748|OTHER|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
40827989|NCT02529748|OTHER|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
40827990|NCT00989521|DRUG|PUR003|PUR003 for inhalation
40827991|NCT00989521|DRUG|Placebo|Normal saline for inhalation
40827992|NCT00827281|DRUG|D-cycloserine|Single dosage prior to sessions 3, 4 \& 5
40827993|NCT00827281|DRUG|Placebo|Single dosage prior to sessions 3, 4 \& 5
40827994|NCT04923646|OTHER|Primer|Mailed postcard notifying Veteran of upcoming FIT kit for annual CRC screening.
40827995|NCT01663428|OTHER|Sup-ER Splint|
40827996|NCT01663428|OTHER|Currently accepted treatment|
41347250|NCT05885906|DRUG|Saline|Mouthwash
41490864|NCT03889067|BIOLOGICAL|Salmonella Typhi challenge|The challenge agents will be delivered in 30 ml of sodium bicarbonate solution, preceded by 120 ml of solution of sodium bicarbonate to neutralise gastric acid.
41490865|NCT04921020|OTHER|Photography|Facial photographs and blinking videos are taken
41490866|NCT05010044|BEHAVIORAL|mindfulness-based cognitive therapy (MBCT)|Mindfulness- Based Cognitive Therapy (MBCT) It involves practicing to be present 'in the moment' and an attitude of non- judgmental acceptance with the aim to maintain awareness, disengaging oneself from strong attachment and thereby developing a greater sense of emotional balance and well-being.
40827997|NCT05628051|PROCEDURE|ultrasonographic measurement of carotid artery corrected flow time (FTc)|Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 \~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+\[1.29× (HR-60)
40827998|NCT02460913|PROCEDURE|Acupuncture|Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
40827999|NCT02460913|DRUG|Morphine titration|Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
40828000|NCT03211026|OTHER|No intervention|No intervention
40828001|NCT06374576|BEHAVIORAL|Lecture on eHealth literacy|There will be a lecture on eHealth literacy. The lecture will be delivered by one well-trained lecturer. , the lecture will be held for old adults in small groups, including a structured curriculum consisting of 4 parts: 5 minutes for the introduction, 40 minutes for the lecture and demonstration, and 40 minutes for hands-on session, 5 minutes for wrapping up. The contents covered in the 40-minute lecture were as follows: 1) smartphone internet basics; 2) introduction of the website prepared for this study; 3) evaluation of the credibility of online health information.
40828002|NCT06374576|BEHAVIORAL|Digital intervention on eHealth literacy|1-week digital intervention, which are multiple messages about the lecture topic will be provided
40828003|NCT06374576|BEHAVIORAL|Lecture on general health|A lecture session that focus on the general health but not eHealth literacy will be provided
40828004|NCT06374576|BEHAVIORAL|Digital intervention on general health|1-week digital intervention, which are multiple messages about the lecture topic will be provided
40828005|NCT04879849|DRUG|Pembrolizumab|IV infusion.
40828006|NCT04879849|DRUG|TAK-676|IV infusion.
40828007|NCT04879849|RADIATION|Image-guided radiation therapy|Radiation therapy.
41347251|NCT05870397|DIAGNOSTIC_TEST|HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times|Carbon 13 breath tests are generally performed 4-6 weeks after eradication therapy. The control group will perform breath urea test at 4-6 weeks after treatment. The experimental groups will perform the same test at different times after the same treatment, 6-8weeks and 8-10 weeks, respectively.
40828009|NCT00650026|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
40828010|NCT01341691|OTHER|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
40828011|NCT02125357|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
40828012|NCT02125357|DRUG|Enzalutamide|160mg PO OD as per standard of care.
40828013|NCT00793572|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
40828014|NCT00793572|DRUG|Bortezomib|Given SC
40828015|NCT00793572|DRUG|Cyclosporine|Given IV
40828016|NCT00793572|DRUG|Cyclosporine|Given PO
40828017|NCT00793572|DRUG|Fludarabine Phosphate|Given IV
40828018|NCT00793572|OTHER|Laboratory Biomarker Analysis|Correlative studies
40828019|NCT00793572|DRUG|Melphalan|Given IV
41490867|NCT05010044|OTHER|Antipsoriatic treatment|The routine drug therapy for psoriasis.
41490868|NCT05385159|DRUG|AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION|Adipose tissue removal, ADSVF production and injection of ADSVF will be done on the same day during a short hospital stay
41490869|NCT05385159|DRUG|Placebo|Adipose tissue removal, ADSVF production, cryopreservation of ADSVF and injection of placebo will be done on the same day during a short hospital stay.
40828020|NCT00793572|DRUG|Mycophenolate Mofetil|Given PO
40828021|NCT00793572|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
40828022|NCT00793572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
40828023|NCT00793572|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo transplantation
40828024|NCT00793572|RADIATION|Total-Body Irradiation|Undergo radiotherapy
40828025|NCT00164385|BEHAVIORAL|Adolescent Impact|
40828026|NCT02767479|DRUG|rabeprazole-based regimen|This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
40828027|NCT02767479|DRUG|esomeprazole^based regimen|This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
40828028|NCT00517439|DRUG|Copegus|1000/1200mg po daily for 24 weeks
40828029|NCT00517439|DRUG|Pegasys|180 micrograms sc weekly for 24 weeks
40828030|NCT00517439|DRUG|Pegasys|90 micrograms sc weekly for 24 weeks
40828031|NCT00517439|DRUG|RO4588161|1000mg po bid for 24 weeks
40828032|NCT00517439|DRUG|RO4588161|500mg po bid for 24 weeks
40828033|NCT00517439|DRUG|RO4588161|1500mg po bid for 24 weeks
40828034|NCT00701298|BIOLOGICAL|peginterferon alfa-2b|Given SC
40828035|NCT00701298|DRUG|decitabine|Given IV
40828036|NCT00701298|OTHER|laboratory biomarker analysis|Correlative studies
40828037|NCT01640418|DEVICE|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
40828038|NCT00846040|OTHER|Reduced fat diet|RF (selective reduction of 85% of baseline fat calories per day)
40828039|NCT00846040|OTHER|Reduced carbohydrate diet|RC (selective reduction of 60% of baseline carbohydrate calories per day)
40828040|NCT00846040|DRUG|Drug: f-18 fallypride|Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
41347252|NCT01003067|DEVICE|Mesh implementation|Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
41347253|NCT03106857|OTHER|Group A|Group A Physical activity and low caloric diet for
41490870|NCT02453776|DRUG|PRECISION dosing Infliximab|Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
41347254|NCT00789659|OTHER|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
40828041|NCT00846040|DEVICE|fMRI|Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
40828042|NCT00846040|DEVICE|PET|Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
40828043|NCT04093765|DIAGNOSTIC_TEST|Ultrasensitive Rapid Diagnostic Test (URDT)|"Investigation will consist in 1 URDT.~For P. falciparum URDT positive:~* collection of 3x1cm dried blood spots on filter paper~* administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT.~Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo:~* collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention.~* 1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12."
40828044|NCT04093765|DRUG|Antimalarials|"A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~* The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~* Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~* Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~* Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~* Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary."
40828045|NCT04205851|DRUG|KIN-1901|KIN-1901 is a fully human monoclonal antibody (mAb).
40828046|NCT04205851|DRUG|Placebo|Saline
40828047|NCT03476876|COMBINATION_PRODUCT|Dermacell|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
40828048|NCT03476876|COMBINATION_PRODUCT|Integra|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
40828049|NCT03112967|OTHER|low-volume preparation, oral sulfate solution|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
40828050|NCT03112967|OTHER|large-volume preparation, 4L polyethylene glycol|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
41347255|NCT01640067|BIOLOGICAL|Human Neural Stem Cells|Surgical microinjection of human neural stem cells on spinal cord of ALS patients
41347256|NCT05194215|DEVICE|Ada WRA|The Ada WRA is a study-only device based on the Ada mobile app. The patient will use this device to answer questions regarding their symptoms but will not be given any feedback by the app.
41347257|NCT03067064|OTHER|no intervention|Clinical examination
41490871|NCT04047914|DEVICE|Antimicrobial Photodynamic therapy|"Application 0.01% methylene blue with sterile swabs in each nostril with a 10-minute pre-irradiation~• Light-emitting diode (λ = 660 nm), for 300 seconds, with an irradiance of 400 mW / cm2"
40828051|NCT05744375|DRUG|Trastuzumab deruxtecan|"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
41490872|NCT04047914|DRUG|Mupirocin ointment|Performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
41490873|NCT02922881|OTHER|Ulcerative Colitis Diet (UCD)|The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission
40828052|NCT00000729|DRUG|Foscarnet sodium|
40828053|NCT01540448|PROCEDURE|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
40828054|NCT01540448|PROCEDURE|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
41019146|NCT03873051|BEHAVIORAL|Challenge-Focused Program|Participants receiving the Challenge-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. Among participants with high autonomous motivation, those receiving the Challenge-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Rewards-Focused intervention.
41347258|NCT02003768|DRUG|Propofol|80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
41347259|NCT02003768|DRUG|Desflurane|80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
41347260|NCT02933372|DRUG|Varenicline|Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
41347261|NCT03224156|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
41347262|NCT02169960|BEHAVIORAL|Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Cognitive Behavioral Therapy based online intervention for depression
41347263|NCT02169960|BEHAVIORAL|Breaking Free|Online based intervention for Drug and Alcohol Use
41347264|NCT02169960|BEHAVIORAL|This Way Up|Cognitive Behavioral Therapy online intervention for Depression and Anxiety
41347265|NCT02169960|BEHAVIORAL|Resiliency Training|Op Volle Kracht (OVK)
40828055|NCT01540448|PROCEDURE|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
40828056|NCT03913832|DEVICE|sirolimus drug coated balloon (SCB)|"Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology Nanolute. It is indicated (CE approved) for ISR, small vessels, bifurcation lesions \& de novo lesions."
40828057|NCT03913832|DEVICE|paclitaxel releasing coronary balloon catheter|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.
40828058|NCT05985213|OTHER|data collection and follow-up|"Main measures and data collection methods:~1. Recording of baseline demographic and clinical information of the participants.~2. Multimodal magnetic resonance imaging~3. blood pressure variability.~4. neuropsychological testing~5. Blood samples collection"
40828059|NCT02115841|DEVICE|"Enraf-Nonius Muscle stimulator"|The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
40828060|NCT02960646|DRUG|Cyclophosphamide|Given IV
40828061|NCT02960646|BIOLOGICAL|Filgrastim|Given SC
40828062|NCT02960646|DRUG|Fludarabine Phosphate|Given IV
40828063|NCT02960646|OTHER|Laboratory Biomarker Analysis|Correlative studies
40828064|NCT02960646|DRUG|Melphalan|Given IV
40828065|NCT02960646|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA depleted peripheral blood stem cell transplantation
40828066|NCT02960646|BIOLOGICAL|Rituximab|Given IV
40828067|NCT02960646|DRUG|Tacrolimus|Given IV or PO
41019147|NCT03873051|BEHAVIORAL|Rewards-Focused Program|Participants receiving the Rewards-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, group-based walking program, and individual-based goal-setting and behavioral skills training with partner-based contracts and financial incentives. Among participants with high controlled motivation, those receiving the Rewards-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Challenge-Focused intervention.
40828068|NCT02960646|RADIATION|Total-Body Irradiation|Undergo TBI
40828069|NCT01192503|DRUG|rasagiline|1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
40828070|NCT01192503|DRUG|placebo (sugar pill)|1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
40828071|NCT02362230|DRUG|Icotinib|Icotinib 125 mg BID
40828072|NCT01902563|OTHER|Osteopathic Manipulative Treatment|
40828073|NCT04072367|DEVICE|NeVa Stent Retrievers|thrombus removal
40828074|NCT04072367|DEVICE|Solitaire Stent Retrievers|thrombus removal
40828075|NCT00221806|DEVICE|endothelialised prosthesis|
40828076|NCT05138068|DRUG|MDMA|Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.
40828077|NCT05138068|BEHAVIORAL|Psychotherapy|Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions
40828078|NCT00824005|BIOLOGICAL|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
40828079|NCT00824005|BIOLOGICAL|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
40828080|NCT04481802|DEVICE|RadiaAce gel|Patients will apply the RadiaAce to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
40828081|NCT04481802|DEVICE|Biafine|Patients will apply the Biafine to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
40828082|NCT00762567|DRUG|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
40828083|NCT03984149|OTHER|Observational study|Observational study: There is no intervention.
40828084|NCT06462534|BEHAVIORAL|Band-Frail Program|"Participants will complete 16 weeks of elastic band resistance training and diabetes management education.~Exercise Component:~The elastic band resistance training involves 12 exercises: chair sit-to-stands, seated chest press, seater upper back reverse fly, seated single arm row, seated single arm lateral raise, seated single arm bicep curl, seated single arm triceps extension, seated single leg quadriceps extension, standing hamstring curl, standing leg extension, and seated abdominal crunches.~There will be a one-minute rest between each set and a self-determined rest period between exercises.~Education Component:~A certified Diabetes Educator and registered dietitian will present information to participants covering topics relating to T2D management and nutritional information."
40828085|NCT02823132|BIOLOGICAL|blood sample|
40828086|NCT01777542|DRUG|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
40828087|NCT01777542|DRUG|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
41347266|NCT01914991|PROCEDURE|dynamic extension contracture orthotic|A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
41347267|NCT01914991|PROCEDURE|conventional treatment Physical Therapy|Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
41347268|NCT00603876|DIETARY_SUPPLEMENT|Almonds|100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
41347269|NCT03450486|OTHER|exercise|one 30 minute bout of mild exercise
41347270|NCT02230787|DEVICE|Recession coverage without Emdogain|In the control group subjects the recession coverage surgery will be performed without Emdogain.
41347271|NCT02230787|DEVICE|Recession coverage with Emdogain|In the test group subjects the recession coverage surgery will be performed with Emdogain.
41347272|NCT03050606|OTHER|Pilates|Exercises performed on the mat and apparatus, following the six principles of the Pilates method. The exercises will be performed in three levels of difficulty: basic, intermediate and advanced, according to the capacity of the patient.
40828088|NCT05241197|OTHER|Low Load Training with Blood Flow Restriction|A 12-cm-wide pneumatic nylon tourniquet will be proximally positioned with a snug fit on each thigh. Previously, arterial occlusion pressure (AOP) will be determined using a handheld Doppler Ultrasound in a standing position for each participant. For training routines, cuff pressure will be set to 50% of each individual´s AOP and will be keep inflated during the entire session including the interset rest period of 1 minute. Between the two exercises, the cuff will be deflated for 3 minutes.
40828089|NCT05241197|OTHER|High Load Training|All participants in this arm will do two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions with a interset rest period of 1 minute and 3 minutes rest between exercises.
40828090|NCT02956759|PROCEDURE|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
40828091|NCT04326036|PROCEDURE|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content
40828092|NCT04326036|DEVICE|Centricyte 1000|Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
40828093|NCT04326036|PROCEDURE|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
40828094|NCT04326036|DRUG|Liberase Enzyme (Roche)|Sterile Collagenase Blend to separate cSVF from the AD-SVF
40828095|NCT04326036|DRUG|Sterile Normal Saline for Intravenous Use|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
41347273|NCT03050606|OTHER|Aerobic|Aerobic exercise will be carried out individually on treadmills or stationary bikes. The intensity of the training will be mild to moderate (57% to 76% of the maximal heart rate monitored by the frequencymeter).
40828096|NCT05391425|OTHER|no intervention|no intervention planned, since it is an observational study
40828097|NCT00295230|PROCEDURE|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
40828098|NCT01480609|DRUG|Retigabine / Ezogabine|Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
40828099|NCT00853125|BIOLOGICAL|therapeutic allogeneic lymphocytes|Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
40828100|NCT00853125|DRUG|sunitinib malate|Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
40828101|NCT02707081|DRUG|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
41019148|NCT05304559|DRUG|S-Ketamine|S-Ketamine0.1mg/kg was injected intravenously during anesthesia induction and S-Ketamine0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
41019149|NCT05304559|DEVICE|Continuous iliac fascia space block|After admission, the iliac fascia space block and catheterization were performed under the guidance of ultrasound, and the analgesia was continued until two days after operation.
41019150|NCT05304559|DRUG|Normal saline|Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
41347274|NCT05283499|DRUG|OPIOID|Analgesic assignment
41347275|NCT05283499|DRUG|NON-OPIOID|Analgesic assignment
41347276|NCT06406790|DEVICE|CraniSeal|CraniSeal is a PEG Dural Sealant
40828102|NCT02707081|DRUG|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
40828103|NCT02707081|DRUG|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
40828104|NCT02707081|DRUG|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
40828105|NCT02252185|DEVICE|Johnson&Johnson Medical Suzhou made Spine Fusion System|interventional device is Spine Fusion System that is manufactured by Johnson \& Johnson Medical Suzhou Ltd.
40828106|NCT02252185|DEVICE|Imported EXPEDIUM screws and OPAL cage|Comparator in this study is active comparator.
41019151|NCT00004926|DIETARY_SUPPLEMENT|vitamin D3 analogue ILX23-7553|
41019152|NCT01723904|DRUG|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
41019153|NCT02259608|BIOLOGICAL|BCG vaccine SSI|BCG vaccination
41019154|NCT04255095|PROCEDURE|experiment|Treatment was randomly selected according to preoperative grouping. After ERCP, naso-pancreatic drainage was chosen as treatment。
41019155|NCT04255095|PROCEDURE|control|Treatment was randomly selected according to preoperative grouping. After ERCP, nasobiliary drainage was chosen as treatment。
41347277|NCT06406790|DEVICE|DuraSeal|DuraSeal is a PEG Dural Sealant
41347278|NCT01940549|DEVICE|Trauma Focused Therapy + tDCS|
40828107|NCT03557346|DEVICE|the WAM-5500 binocular autorefractor/keratometer (Grand Seiko Co. Ltd., Hiroshima, Japan)|: Subjects underwent a basic ophthalmic examination and the accommodative response to refractive stimuli was measured. Refractive stimuli were given at 0.25 diopters (D) (4 m distance), 2D (50 cm), 3D (33 cm), and 4D (25 cm) and stimulation was applied with the eyes in binocular, monocular (dominant eye, non-dominant eye, ipsilateral, and contralateral), and pinhole conditions. In addition, changes in the astigmatic value and direction of the astigmatism axis under binocular stimulus were evaluated.
40828108|NCT03655327|OTHER|reach to grasp a cup|reach to grasp a cup of different weights located at different heights of table
40828109|NCT01749592|DEVICE|cochlear implant|Surgical implantation of a cochlear implant device
40828110|NCT01819558|BIOLOGICAL|recwt1-A10+AS01B|
40828111|NCT00420173|PROCEDURE|Laboratory analysis|blood withdrawal
40828112|NCT02238314|DRUG|Tipranavir low dose|
40828113|NCT02238314|DRUG|Tipranavir high dose|
40828114|NCT02238314|DRUG|Ritonavir|
40828115|NCT02238314|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
40828116|NCT02238314|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
40828117|NCT01194843|DRUG|Ropivacaine|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
40828118|NCT01194843|DRUG|Physiological serum|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
41490874|NCT06219226|PROCEDURE|Chlorine dioxide mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
41490875|NCT06219226|PROCEDURE|Chlorhexidine mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
40828119|NCT05445908|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
40828120|NCT05445908|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
40828121|NCT05916625|OTHER|neuropsychological assessment|a consultation to assess cognitive and psycho-behavioral functions with questionnaires
40828122|NCT05916625|OTHER|biological sample|10 mL intravenous whole blood collection in EDTA tube
41490876|NCT02813057|PROCEDURE|Stoppa inguinal hernia repair|Stoppa inguinal hernia repair
41490877|NCT02813057|PROCEDURE|Total extraperitoneal inguinal hernia repair|Total extraperitoneal inguinal hernia repair
41490878|NCT05087862|PROCEDURE|Ultrasound-guided pericapsular nerves group of the hip block|After the ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% bupivacaine.
41490879|NCT05087862|PROCEDURE|Pericapsular local anesthetic infiltration of the hip|Intraoperatively, 60 mL of adrenalized 0.25% bupivacaine plus ketorolac 30 mg will be infiltrated by the surgeon.
40828123|NCT05916625|PROCEDURE|medical imagery|Pet scan with the specific radioligand \[11C\]SB207145 and MRI
40828124|NCT04450628|PROCEDURE|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
40828125|NCT04450628|DEVICE|EndoFLIP 1.0 System EF-100|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
40828126|NCT04200768|OTHER|Prospective data and sample collection|Performance of measurements of adiposity, extra collection of blood samples
40828127|NCT03366103|BIOLOGICAL|Navitoclax|Given PO
40828128|NCT03366103|DRUG|Vistusertib|Given PO
40828129|NCT02627287|DEVICE|FlexPen®|For subcutaneously (s.c. under the skin) injection.
40828130|NCT02627287|DEVICE|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
40828131|NCT02627287|DRUG|placebo|For subcutaneously (s.c. under the skin) injection
40828132|NCT05027334|OTHER|DiaMon - Mobile Application for Type 2 Diabetes mellitus and pre-diabetes|Each participant will be provided with a mobile application aimed at monitoring their clinical markers such as FBG and HbA1c. The mobile application consists of medical details and demographics as well as a section dedicated to daily glucose levels and record of physical activity.
41490880|NCT00370357|DRUG|3% w/w SPL7013 Gel (VivaGel™)|
41490881|NCT03692390|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
41490882|NCT04407091|DRUG|14C]AZD4831 Oral Solution|10 mg dose of \[14C\]AZD4831 Oral Solution
41490883|NCT00763438|DRUG|Sertindole|Flexible dose
41490884|NCT02369900|DRUG|Esmolol|
41490885|NCT02369900|OTHER|Saline|
40828133|NCT00497328|DRUG|N-acetylcysteine|
40828134|NCT00497328|DRUG|Sodium Bicarbonate|
40828135|NCT05824975|DRUG|GI-102|"Dose escalation phase:~GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles)."
40828136|NCT05824975|DRUG|GI-102|"Dose expansion phase:~GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles)."
40828137|NCT03594916|DEVICE|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
40828138|NCT03594916|DEVICE|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
41019156|NCT02709395|DEVICE|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
41019157|NCT05875584|DIAGNOSTIC_TEST|rbcDNA test|fecal immunochemical test
41490886|NCT05854888|PROCEDURE|Perineal Massage and Warm Compresses (PeMWaC)|Perineal Massage was performed in the II Hodge Plan, between maternal contractions and regardless of maternal position. Warm Compresses were applied by the midwife between Hodge plans III and IV, during pushing and regardless of maternal position.
40828139|NCT03303859|DIAGNOSTIC_TEST|Bacterial vaginosis|
40828140|NCT01174004|DRUG|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
40828141|NCT01174004|DRUG|placebo|placebo, tablet, once daily by mouth for 6 weeks
40828142|NCT04124458|DEVICE|Radiofrequency ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
40828143|NCT03505489|PROCEDURE|Deep inhalation technique|Use of deep inhalations for administration of inhalant
40828144|NCT03505489|PROCEDURE|Tidal breathing technique|Use of tidal breathing for administration of inhalant
40828145|NCT03505489|DRUG|Methacholine|Methacholine direct bronchoconstrictor used for bronchoprovocation challenge
41019158|NCT05306106|OTHER|Glucose|Each subject will consume the reference product during visits V1 and V5. A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume the glucose solution. The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
40828146|NCT03505489|DRUG|Mannitol|Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge
40828147|NCT06180330|OTHER|Aquatic baby class|The intervention will consist of exercises for infants. They will be in the water together with parents
40828148|NCT04125056|DRUG|Hydronidone Capsule(Specification: 30 mg / grain）|Test group
40828149|NCT04125056|DRUG|Hydronidone Capsule(Specification: 15 mg / grain）|Control group
41347279|NCT05578560|PROCEDURE|Prehabituation|chemical labyrinthectomy with intratympanically installed gentamicin
40828150|NCT06429163|PROCEDURE|Infiltration of the anterior abdominal wall|Infiltration of the anterior abdominal wall is performed with 0.2% ropivacaine diluted with physiological saline on a syringe in the volume of 20 ml - 5 ml for each incision. The drug is injected with a 22-gauge needle at a 90-degree angle.
40828151|NCT06429163|PROCEDURE|Upper hypogastric plexus blockade|At the beginning of the operation the camera is used to visualise the area of the promontorium. Next, a 1 mm laparoscopic puncture needle is inserted through a trocar in the suprapubic region and plunged into the upper part of the formed dome to a depth of no more than 1 cm. After positioning the needle retroperitoneally, an aspiration test is performed to prevent intravascular injection. Then, 20 ml of 0.2% ropivacaine diluted with physiological saline is slowly injected. At the end of the procedure, the retroperitoneal space swollen by the local anaesthetic is visualised in the promontorium.
40828152|NCT05694338|OTHER|Frailty survey|Frailty survey using the Clinical Risk Analysis Index (RAI-C).
40828153|NCT05476432|PROCEDURE|HAIC|The microcatheter was advanced into the hepatic artery, and patients were transferred to the inpatient ward for drug infusion via the hepatic artery
40828154|NCT05476432|DRUG|FOLFOX 2d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
40828155|NCT05476432|DRUG|FOLFOX 1d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 23 hours
40828156|NCT02630420|DRUG|cetuximab and savolitinib|Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
40828157|NCT04175457|OTHER|e-cigarette|E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
40828158|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
41347280|NCT05578560|PROCEDURE|3D optokinetic stimulation in virtual reality space|3D optokinetic stimulation via virtual reality goggles with the software designed by Pro-Zeta comp.
41347281|NCT05578560|PROCEDURE|Vestibular training|vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.
40828159|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
40828160|NCT00167596|DEVICE|Near Infrared Spectroscopy|resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
40828161|NCT00167596|DEVICE|conventional|resuscitation will be based according to Surviving Sepsis Campaign
40828162|NCT03606447|DRUG|Uproleselan|\[14C\]-Uproleselan
41347282|NCT03109444|DIAGNOSTIC_TEST|Hip Ultrasound|Both hips will be examined. The diagnostic examination for developmental dysplasia of the hip (DDH) incorporates 2 orthogonal planes: a coronal view in the standard plane at rest and a transverse view of the flexed hip at rest. It is acceptable to perform the examination with the infant in a supine or a lateral decubitus position. The anatomic coronal plane is approximately parallel to the posterior skin surface of an infant. The imaging plane is through the deepest part of the acetabulum (which includes visualization of the triradiate cartilage and the ischium posteriorly), the resulting image will be a coronal view in the standard plane. The standard plane is defined by identifying a straight iliac line, the tip of the acetabular labrum, and the transition from the os ilium to the triradiate cartilage. Acetabular morphology is assessed in this view and may be validated by measuring the acetabular alpha angle (≥60°). The femoral head coverage by the bony acetabulum should be \>50%.
41347283|NCT00510575|DEVICE|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
41347284|NCT01326676|DRUG|Polypill: Red Heart Pill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2."
41490887|NCT05854888|PROCEDURE|Control Group (Hands-on)|"The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum."
40828163|NCT06405074|DEVICE|low intensity focused ultrasound (LIFU)|"Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects."
40828164|NCT01166958|DRUG|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
40828165|NCT01166958|DRUG|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
40828166|NCT05296460|DRUG|Dapsone gel|The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
40828167|NCT05250076|DEVICE|Kinesio Tape|"The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination."
40828168|NCT02092051|DEVICE|Continuous glucose monitoring with DexCom G4 platina|
40828169|NCT00000429|DRUG|Calcium carbonate|
40828170|NCT00585546|DRUG|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
40828171|NCT05596617|DRUG|Oral bedtime melatonin|Different doses of oral bedtime melatonin
41347285|NCT01326676|DRUG|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
40828172|NCT04612543|DEVICE|Genial Posterior Composite with Polyethylene Fiber|Placing restorations,Genial Posterior Composite with Polyethylene Fiber, after bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus, Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
40828173|NCT04612543|DEVICE|Genial Posterior Composite|Placing Genial Posterior Composite, the enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
40828174|NCT05460598|OTHER|beddings with cooling effects|beddings with cooling effects (mattress topper and bed linen)
40828175|NCT05460598|OTHER|commonly used bedding|commonly used bedding
40828176|NCT01386541|DRUG|BYK324677|capsules, administered orally
40828177|NCT03484832|DEVICE|Walter Ritter Ethyl Chloride Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.
40828178|NCT03484832|OTHER|Placebo Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
40828179|NCT03484832|OTHER|Placebo Cream|Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
40828180|NCT03484832|DRUG|EMLA Cream|Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
40828181|NCT01445522|DRUG|ABT-888|
40828182|NCT01445522|DRUG|Cyclophosphamide|
40828183|NCT00070681|PROCEDURE|Polysomnography|
40828184|NCT01946672|PROCEDURE|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
40828185|NCT03067493|BIOLOGICAL|Neo-MASCT|Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
40828186|NCT02810301|OTHER|Probiotic ES1|B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
40828187|NCT02810301|OTHER|Placebo|The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
41347286|NCT02792036|DRUG|Carboplatin|"Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of stable seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye)."
41347287|NCT02792036|DRUG|Maxitrol®|Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
41347288|NCT02792036|PROCEDURE|Focal Therapy|Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
41347289|NCT02792036|PROCEDURE|Plaque Radiotherapy|Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
41347290|NCT00730249|DRUG|methylphenidate hydrochloride|sustained release, twice daily, dosage according to an individual titration schedule
41347291|NCT00730249|DRUG|Placebo|twice daily according to an individual titration schedule
40828188|NCT04014140|PROCEDURE|Coronary artery bypass grafting surgery (CABG)|Patients with MVCAD will undergo CABG as per standard of care.
40828189|NCT05473351|OTHER|Questionnaire|Visual Analogic Scale
40828190|NCT01480713|DRUG|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
40828191|NCT01480713|DRUG|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
41347292|NCT00537459|DRUG|16448|
41347293|NCT04672317|DRUG|Immunotherapy combined with chemotherapy|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
40828192|NCT04283565|OTHER|Systematic screening of AOMI by BPI measurement.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
40828193|NCT04283565|OTHER|Management of CVRF by a motivationnal interviewing.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
40828194|NCT06444152|OTHER|Sample analysis|This study is analyzing stored samples
40828195|NCT06136572|DIAGNOSTIC_TEST|Rathus Assertiveness scale|Questionnaire completion
40828196|NCT05415592|DEVICE|DePuy Synthes Radial Head Replacement System|DePuy Synthes Radial Head Replacement System will be used for radial head replacement or partial replacement of the elbow joint.
40828197|NCT00054951|DRUG|MTC-DOX for Injection|
40828198|NCT02606435|PROCEDURE|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
40828199|NCT02606435|DEVICE|thrombus aspiration|thrombus aspiration with export catheter
40828200|NCT06214819|DEVICE|VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion|VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion
40828201|NCT06214819|DEVICE|XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion|XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion
40828202|NCT03209232|DRUG|Infliximab|Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
40828203|NCT01575093|OTHER|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
40828204|NCT05620979|BEHAVIORAL|Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.|Providing financial navigation to blood cancer survivors.
40828205|NCT01738113|OTHER|Open Kinetic Chain exercise|"1. Hamstrings strengthening exercise~2. Quadriceps strengthening exercise~3. Hamstrings stretch~4. Hip extensors and abductors strengthening~5. Calf-muscles stretching~6. Strength exercise of ankle dorsiflexors \& plantar flexors"
40828206|NCT01738113|OTHER|Closed kinetic chain exercise|"1. Foot sliding from sitting~2. Seated Toe Raises~3. Hamstrings and quadriceps co-contraction from sitting~4. Bridging exercise~5. Sitting-to-standing~6. Side-to side, forward and backwards weight shifting~7. Lunge exercise~8. Squatting exercise~9. Standing Toe Raises~10. Standing Hamstrings Stretch"
40828207|NCT01869361|DRUG|Indomethacin|Study drug
40828208|NCT01869361|DRUG|Placebo|Control drug
40828209|NCT04290793|DRUG|Pyrotinib|400mg administered as continuous oral once daily from the first day of the study
40828210|NCT04290793|DRUG|Epirubicin|90mg/m\^2 d1 iv Q2W for 4 cycles
41347294|NCT02935907|DRUG|APG-115|Multiple dose cohorts, PO, every other day of a 28 day cycle
40828211|NCT04290793|DRUG|Cyclophosphamide|600 mg/m\^2 d1 iv Q2W for 4 cycles
40828212|NCT04290793|DRUG|Taxanes|Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
40828213|NCT04290793|BIOLOGICAL|Trastuzumab|the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
40828214|NCT00607113|DRUG|Avastin|15 mg/kg By Vein Over 90 Minutes Every 21 Days
40828215|NCT00607113|DRUG|RAD001|10 mg By Mouth Daily For 21 Days
40828216|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|oral consumption in beverage
40828217|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|Oral consumption in beverage
40828218|NCT01375803|OTHER|Placebo|Oral consumption in beverage
40828219|NCT04206475|OTHER|rehabilitation|"the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes."
41347295|NCT03114670|BIOLOGICAL|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
41347296|NCT00881686|DRUG|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
41490888|NCT04684004|OTHER|To report number of HF events and deaths|In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
40828220|NCT04206475|OTHER|Intensive Memory-Focused Training Program (IM-FTP)|During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
40828221|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Immediately|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
40828222|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Waitlisted|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
40828223|NCT04883840|DRUG|Rosuvastatin 10mg|Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).
40828224|NCT03812926|DEVICE|Compuflo assited procedure|number of needle entry required to identify the ligamentum flavum
40828225|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the reception area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the treatment room after meeting the child in the reception area while wearing the friendly attire.
40828226|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the treatment area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the treatment room after meeting the child in the reception area while wearing the conventional attire.
40828227|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in both reception and treatment areas in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the reception area and treatment room.
41157513|NCT05289375|DRUG|Placebo|A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
40828228|NCT06122883|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the reception area and treatment room.
40828229|NCT01231321|DRUG|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
40828230|NCT02002936|DRUG|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle."
40828231|NCT00885638|DRUG|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
40828232|NCT00885638|DRUG|placebo|A placebo tablet is given before ingestion of macronutrients
41157514|NCT00421122|DRUG|budesonide/formoterol (Symbicort)|inhalation therapy
41157515|NCT00421122|DRUG|budesonide (Pulmicort)|inhalation
41157516|NCT00421122|DRUG|terbutaline sulfate (Bricasol)|inhalation therapy
40828233|NCT05781958|DRUG|Cadonilimab+Gem/Cis|Cadonilimab (500mg, iv, Q3W, Day1) with gemcitabine(1000mg/m\^2, iv, Q3W, Day1and Day8) plus cisplatin(25mg/m\^2, iv, Q3W, Day1and Day8) up to 8 cycles followed by cadonilimab (500mg, iv, Q3W, Day1) plus capecitabine（1000 mg/m\^2 orally according to Body Surface Area (BSA)，BID，Q3W，on Days 1-14）as maintenance therapy until disease progression or other discontinuation criteria, up to 24months.
40828234|NCT02830204|DEVICE|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
40828235|NCT04755413|OTHER|Medical/Behavioral therapy|"* Sedentary lifestyle: Advise increasing exercise to at least 30 minutes of moderate-intensity aerobic activity 5 days a week.~* Overweight/Obese: Advise calorie reduction, dietician consultation.~* Smoking: standard smoking cessation advice and literature and medical therapy as indicated to include Wellbutrin, nicotine patch etc.~* High LDL cholesterol: a) Start high dose statin if patient not on high dose statin.~  b) If on high dose statin, add ezetimibe 10mg daily c) If statin intolerant, start ezetimibe 10mg, colestid or other bile sequestrant combination.~  d) If still not at goal, start PCSK-9 inhibitor e) LDL cut off of \<55mg/dl in diabetes~* Blood Pressure optimization treatment following 2020 International Society of Hypertension Global Hypertension Practice Guidelines.~* Diabetes management: HbA1c goal 6.5%"
40828236|NCT04755413|OTHER|Standard of Care|Participants will receive standard of care therapy prescribed by their primary care physician and/or cardiologist.
40828237|NCT04755413|OTHER|Registry|Participants with BRS of 0 will get measurements of BRS at the time-points specified for the randomized subjects and also for adverse events.
40828238|NCT01061047|DRUG|Ertapeneme|
40828239|NCT01025362|BEHAVIORAL|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
40828240|NCT01025362|BEHAVIORAL|Standard care|Child Health Services offered standard care
40828241|NCT00022724|DRUG|temsirolimus|
40828242|NCT03461406|BIOLOGICAL|Fibrin Sealant Grifols|The FE Grifols solution was applied topically via drip or spray application.
40828243|NCT03461406|BIOLOGICAL|EVICEL|The EVICEL solution was applied topically via drip or spray application.
40828244|NCT03385278|OTHER|rTMS|20HZ Repetitive Transcranial Magnetic Stimulation
40828245|NCT04026269|DRUG|MOAP|the new chemotherapy regimen for r/r cHL
40828246|NCT05013658|BEHAVIORAL|pressure measurement|pressure measurement with pilot balloon palpation
40828247|NCT03630302|DEVICE|DBS|Deep Brain Stimulation
41157517|NCT05530928|OTHER|Reproductive life plan counseling|The intervention group will receive in addition to the standard contraceptive counseling, a reproductive life plan counseling: midwives will discuss the different options with the woman depending if she wants or not more children, and she will give her general information about preconception health.
40828248|NCT00773240|DRUG|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
40828249|NCT00773240|DRUG|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
40828250|NCT05953116|DIETARY_SUPPLEMENT|Nutrition supplementation|Blinded researchers will provide the randomly assigned supplement product to the trial participants for a period of 90 days. Used packaging will be collected at the end of every week from each trial participant to monitor compliance.
40828251|NCT05953116|OTHER|Exercise|Trained researchers will facilitate resistance-based exercises two to three times a week in an enclosed venue (gym). Trial participants will be assessed at baseline for one repetition maximum (1RM) which will serve as a basis for load progression. A target of 3 sets and 6-15 repetitions with at least 30 seconds rest in between sets will be performed by the trial participants under supervision of a trained researcher.
40828252|NCT04588506|PROCEDURE|Lower Trapezius Tendon Transfer Technique|Lower Trapezius tendon used in repairing cuff tear
40828253|NCT04588506|PROCEDURE|Latissimus Dorsi Tendon Transfer Technique|Latissimus Dorsi tendon used in repairing cuff tear
40828254|NCT04588506|PROCEDURE|Pectoralis Tendon Transfer Technique|Pectoralis tendon used in repairing cuff tear
40828255|NCT03036462|DRUG|Iron|i.v. iron administration
40828256|NCT03036462|DRUG|Saline|i.v. NaCl administration
40828257|NCT03410797|DEVICE|Inclusion of semi-occluded mask in voice therapy|Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
41490889|NCT02556983|RADIATION|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
41490890|NCT05690503|DRUG|CI-581a|Medication infusion intravenously over 90 minutes.
40828258|NCT00000504|DRUG|encainide|
41157518|NCT03467789|DRUG|Dietary Vitamin D3 pre-treatment|The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Duration of pretreatment will be 14 days if the D3 level is \< 31 ng/mL, and 5 days if the D3 level is \> 31 ng/mL
40828259|NCT00000504|DRUG|moricizine|
41490891|NCT05690503|DRUG|CI-581b|Medication infusion intravenously over 90 minutes.
40828260|NCT00000504|DRUG|flecainide|
40828261|NCT00000504|DRUG|imipramine|
40828262|NCT06355115|DRUG|Cefazolin 1000 MG Injection|Cefazolin 1000 mg given intravenously
40828263|NCT00247442|BEHAVIORAL|Decision aid|
40828264|NCT06395402|DRUG|Lutetium Lu 177 dotatate therapy|LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.
40828265|NCT04552548|OTHER|regional nerve block|Abdominal field blocks have been used in anesthesia for surgery involving the anterior abdominal wall with ultrasound-guided technique. TAP block is a regional anesthetic technique that blocks neural afferents of the anterolateral abdominal wall. Using anatomical landmark guidance or with the aid of ultrasound (US), local anesthetic is injected into the transversus abdominis fascial plane, where the nerves from T6 to L1 are located. Ultrasound-guided quadratus lumborum (QL) block is considered now as one of the novel truncal abdominal blocks, as it is effective in preventing somatic pain associated with upper and lower abdominal surgeries.
40828266|NCT03622021|DRUG|AK111 or Placebo|All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
40828267|NCT05037500|DRUG|Decitabine and Cedazuridine|Given PO
40828268|NCT05037500|DRUG|Enzalutamide|Given PO
40828269|NCT02821377|DRUG|intravenous furosemide|treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
40828270|NCT02821377|DRUG|Hypertonic saline solutions|Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
40828271|NCT02821377|PROCEDURE|Seriated paracentesis|repeated paracentesis from the first day after admission until 3 days before discharge
41490892|NCT02673996|DRUG|Phenylephrine|incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
41490893|NCT02673996|DRUG|Isoproterenol|incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
41490894|NCT01280409|DRUG|Metformin|Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks
40828272|NCT04793997|BIOLOGICAL|Microbiome spray|Throat spray containing 3 beneficial lactobacilli strains
40828273|NCT04793997|BIOLOGICAL|Placebo spray|Throat spray
40828274|NCT02004145|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
41490895|NCT01280409|DRUG|Placebo|Subjects will receive a placebo (similar in size, taste, color) once daily for 7 days, then twice daily for the next 5 weeks.
41347297|NCT05437692|DRUG|zimberelimab combined With concurrent radiotherapy and chemotherapy|zimberelimab: 240 mg Q2W Intravenous drip，The maximum duration of medication shall not exceed one years; chemotherapy: Starting from the first week of radiotherapy and chemotherapy, cisplatin 40mg/m2 and paclitaxel 35mg/m2 were given intravenously for 30-60min; Radiotherapy: intensity modulated radiation therapy (IMRT) was used for external irradiation. The total dose of pelvic cavity and lymph drainage planning target area (PTV) was 45-50 gy/25-28f. The metastatic lymph nodes should be able to supplement or synchronously push 10-15 Gy; The internal irradiation was started within 2 weeks after the end of external irradiation treatment. The image-guided three-dimensional brachytherapy was used, and 30-40gy was added to make the total dose of point a reach 80-85 Gy, twice a week, 5-6gy each time. All radiotherapy was completed within 8 weeks.
41347298|NCT03632304|PROCEDURE|Local anesthesia with minimal sedation|The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
41347299|NCT04829006|DEVICE|Understand Me For Life|The aim of the current investigation is to test the efficacy of an app to measure sentence intelligibility in noise in speakers with Parkinson's disease and in healthy controls.
41347300|NCT06366854|PROCEDURE|Personalised fluid and haemodynamic resuscitation|individualised resuscitation
41347301|NCT06491992|DRUG|Chitosan Phonophresis|Chitosan Phonophresis, three times per week for four weeks.
41347302|NCT06491992|OTHER|selected physical therapy exercise|selected neck exercise and electrotherapy on cervical region
41347303|NCT02449915|DRUG|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
41347304|NCT02449915|DRUG|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
41347305|NCT01085773|BEHAVIORAL|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
41347306|NCT01085773|BEHAVIORAL|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
41347307|NCT03846622|OTHER|Calculation of scoring systems for bleeding|
41347308|NCT01282190|BEHAVIORAL|Motivational interview|Motivational interview
41347309|NCT03053713|BEHAVIORAL|Mediterranean diet pattern|Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
41347310|NCT03053713|BEHAVIORAL|Habitual diet (control)|Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
41347311|NCT03669107|DRUG|Gum|no gum
41347312|NCT06305819|BEHAVIORAL|self-management support program|The SEMPO program is inspired by established self-management principles and established rehabilitation strategies. The program is manualized and integrates components from rehabilitation strategies within relevant functional domains. The program includes elements, such as tailored psychoeducational content, action planning, guided skills mastery, learning and practicing helpful compensatory strategies, problem solving techniques and sharing of experiences. The intervention is delivered by a multidisciplinary team and the participants are provided with written materials and a work book containing information about each session and work tasks.
41347313|NCT06305819|OTHER|Control group|Treatment as usual
41347314|NCT02125812|OTHER|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
41347315|NCT02125812|OTHER|scaling and root planing|scaling and root planing
41490896|NCT05892939|DRUG|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
40828275|NCT02004145|BEHAVIORAL|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
41490897|NCT05892939|DRUG|intranasal Placebo|Administration of intranasal Placebo
41490898|NCT01540773|DRUG|Amino acid supplement|An orally administered supplement of the proprietary amino acid derivative
40828276|NCT03697278|DEVICE|Smith medical CADDsolis|This group will be monitoring from a network.
40828277|NCT02933567|OTHER|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
41347316|NCT03824964|BIOLOGICAL|Anti-CD19/CD22 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19/CD22 CAR NK cells will be administered at day0
41490899|NCT01540773|DRUG|Placebo|A non-active orally administered supplement of the proprietary amino acid derivative
41490900|NCT03698266|PROCEDURE|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP
40828278|NCT04545047|BIOLOGICAL|COVID-19 convalescent plasma|Convalescent plasma collected from individuals who have recovered from COVID-19
41490901|NCT03267875|PROCEDURE|Blood Test|draw out 2 blood tubes from a patient
41490902|NCT00002040|DRUG|Fluconazole|
40828279|NCT01592617|DRUG|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
41347317|NCT05237414|DEVICE|Active tDCS|20 minutes of 2.0 mA direct current applied over the right DLPFC
41157519|NCT03467789|RADIATION|Photodynamic therapy|Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.
41157520|NCT03467789|DRUG|Serum Maintenance Vitamin D3|2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.
41347318|NCT05237414|DEVICE|Sham tDCS|15 seconds of 2.0 mA direct current applied over the right DLPFC
41347319|NCT05237414|BEHAVIORAL|Active CT|Active memory inhibition CT (i.e., training of memory inhibition specifically for alcohol-related memories).
41347320|NCT05237414|BEHAVIORAL|Sham CT|Sham memory inhibition CT (i.e., participants have to categorize alcoholic and non-alcoholic images but they do not have to inhibit the memories related to these images).
41347321|NCT00683774|DRUG|diazoxide|100mg orally three times per day for 10 days
40828280|NCT05976022|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
40828281|NCT02335632|DRUG|Probiotics (Lacidofil®)|7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
41347322|NCT00075660|DRUG|triapine|
41347323|NCT02365506|DRUG|Eleclazine|Tablets administered orally in a single dose
41347324|NCT02365506|DRUG|Placebo|Placebo to match tablets administered orally in a single dose
41347325|NCT05555251|DRUG|BI-1607|administered at different doses in Phase I by intravenous infusions every 3 weeks.
41347326|NCT05555251|DRUG|BI-1607|administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
41347327|NCT05555251|DRUG|Trastuzumab|administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
40828282|NCT02335632|DRUG|Placebo|For probiotics
40828283|NCT04348175|DRUG|Setmelanotide|Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.
41490903|NCT00902720|OTHER|Tissue sample storage|The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
40828284|NCT02907749|DRUG|Spironolactone and carvedilol|Patients are treated with carvedilol in combination with spironolactone.
41347328|NCT06004089|PROCEDURE|V NOTES Sacrocolpopexy|The procedure involved a single-port laparoscopic surgery through the vaginal route, aiming to restore pelvic floor function by suspending the vagina to the anterior longitudinal ligament. The surgical approach differs from conventional methods, as these procedures are conducted through abdominal or vaginal routes without the aid of laparoscopic cameras, However, in our approach, we uniquely combine the widely acknowledged gold standard sacrocolpopexy procedure using vaginal route with laparoscopic camera assistance. No experimental drugs or devices were employed; only the surgical approach was modified.
41347329|NCT00428103|PROCEDURE|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
41490904|NCT04215848|DRUG|Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.
41347330|NCT04080349|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
41347331|NCT04080349|DRUG|Misoprostol 200Mcg Tab|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
41347332|NCT04080349|DRUG|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
41347333|NCT02678156|DEVICE|Lyoplant Onlay|
41347334|NCT04459442|PROCEDURE|Umbilical cord clamping at birth.|Umbilical cord clamping after delivery.
41347335|NCT04865224|DIAGNOSTIC_TEST|hemoglobin estimation|In this method, in which different deep learning models are used together, the age range is intended to be as wide as possible to provide a quick solution with a high accuracy and low error values.
41347336|NCT04591704|OTHER|hospitalisation, necessity of ICU, mortality rate, lung involvement|hospitalisation, necessity of ICU, mortality rate, lung involvement
41347337|NCT05220293|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.
41347338|NCT05220293|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
41347339|NCT03659240|OTHER|Cranberry beverage|During the intervention period, research participants will consume a cranberry beverage daily.
41347340|NCT03659240|OTHER|Placebo beverage|During the intervention period, research participants will consume a placebo beverage daily.
41157521|NCT05394727|DEVICE|Needle-free injection device, Then traditional insulin pen|Patients first received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks.
41157522|NCT05394727|DEVICE|Traditional insulin pen , Then Needle-free injection device|Patients first received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks.
41157523|NCT01497951|OTHER|Aminolaevulinic acid|Photodynamic therapy
41157524|NCT01497951|OTHER|Methylcellulose Placebo|Methylcellulose
41347341|NCT04154111|DEVICE|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; double blinded
41347342|NCT04154111|DEVICE|Sham TBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
41347343|NCT04154111|DEVICE|Real TBS to the dlPFC|This will be delivered with the Magventure Magpro system (double blinded).
41490905|NCT04215848|DRUG|Budesonide 200Mcg Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily
41490906|NCT03024658|OTHER|positive end expiratory pressure (PEEP)|Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
41490907|NCT00351975|DRUG|Belinostat|Given IV
40828285|NCT02907749|DRUG|Carvedilol|Patients are treated with carvedilol only.
41347344|NCT04154111|DEVICE|Sham TBS to the dlPFC|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
41347345|NCT05506306|OTHER|Assessment|Clinical, biological and imagery before and after 6 weeks of using AtalanteTM exoskeleton
41347346|NCT04874350|DRUG|LPCN 1148|LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
41347347|NCT04874350|DRUG|Placebo|Oral matching placebo capsule
41490908|NCT00351975|DRUG|Azacitidine|Given SC
41490909|NCT00351975|OTHER|Laboratory Biomarker Analysis|Correlative studies
40828286|NCT06034067|PROCEDURE|Osseodensification osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using osseodensification technique using Versah burs and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
40828287|NCT06034067|PROCEDURE|Standardized osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using either conventional surgical drills provided by Straumann implant systems and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
40828288|NCT02102126|PROCEDURE|Renal denervation|
40828289|NCT04350021|DRUG|Capecitabine, Cyclophosphamide|Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily
40828290|NCT03773172|DRUG|MEDI6012|MEDI6012 is recombinant human lecithin-cholesterol acyltransferase (rhLCAT), an approximately 60 kilodalton, glycosylated, single-chain protein consisting of 416 amino acids produced via Chinese hamster ovary cell culture. It is being explored as an acute treatment to reduce the risk of recurrent cardiovascular events as an adjunct to the standard of care in patients with acute myocardial infarction (MI). MEDI6012 and ACP501 have the identical amino acid sequence and are therefore considered the same molecular entity.
40828291|NCT03773172|DRUG|Placebo|The placebo will mimic the active treatment.
40828292|NCT06518642|DEVICE|Sooma tDCS portable device - active stimulation|"The Sooma tDCS has been certified to comply with the EU Medical Device Regulation (MDR certification), and has been approved for both clinic and at-home use, specially customized for our study, such that it allows for doubleblinding: participant, investigator and assessor.~For the tDCS stimulation, saline-soaked, 25cm2 diameter sponge electrodes will be used."
40828293|NCT06518642|DEVICE|Sooma tDCS portable device - sham stimulation|"The Sooma tDCS has been certified to comply with the EU Medical Device Regulation (MDR certification), and has been approved for both clinic and at-home use, specially customized for our study, such that it allows for doubleblinding: participant, investigator and assessor.~For the tDCS stimulation, saline-soaked, 25cm2 diameter sponge electrodes will be used."
40828294|NCT02303782|DRUG|OTX015|
40828295|NCT02303782|DRUG|Vidaza (azacitidine)|
40828296|NCT02723370|BEHAVIORAL|Staff multi-component implementation strategy|Staff will receive a multi-component implementation strategy for evidence based practices (EBPs) for colonoscopy, including split-dosing of bowel preparation, low literacy education materials for patients, and teach-back procedure. The implementation strategy includes a supply of low-literacy patient education materials for split-dosing the medication of their choice, poster and pocket-card with teach-back prompts, consultation to integrate materials and teach-back into workflow and a website with additional training and patient materials.
40828297|NCT05716893|BEHAVIORAL|Adaptive Aerobic Training/AT Dosing|o In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week using an adaptive dosing schedule that starts at 90 min/wk and is escalated 30 min/wk every 2 weeks to a maximal dose of 300 mins/wk. In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
40828298|NCT05716893|BEHAVIORAL|Standard (fixed) Aerobic Training/AT dosing|In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week to achieve a cumulative total duration of: 90 min/wk (standard fixed dosing). In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
40828299|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Medtronic 4th gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Medtronic 4th gen balloon
40828300|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Boston 2nd gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Boston 2nd gen balloon
40828301|NCT00711113|DEVICE|OsseoSpeed™|OsseoSpeed™, all dimensions
40828302|NCT00174174|DRUG|Modafinil|
40828303|NCT02609048|DRUG|Placebo Comparator|Placebo Capsule (2 taken once daily)
40828304|NCT02609048|DRUG|Experimental: Seladelpar / MBX-8025 50 mg|MBX-8025 50 mg capsule (1 taken once daily)
40828305|NCT02609048|DRUG|Experimental: Seladelpar / MBX-8025 200 mg|MBX-8025 100 mg capsules (2 taken once daily)
40828306|NCT00747344|DRUG|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
40828307|NCT00747344|DRUG|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
40828308|NCT00747344|DRUG|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
41019159|NCT05306106|OTHER|truffle match|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 221.2 g of truffle match (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
41157525|NCT04950049|DRUG|Dexamethasone|receive 2ml dexamethasone (5mg/ml)
41157526|NCT04950049|OTHER|Diluted dexamethasone 5ml|receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose
41157527|NCT04950049|OTHER|Diluted dexamethasone 10ml|receive 10ml dexamethasone (1mg/ml) diluted with 5% glucose
40828309|NCT00747344|DRUG|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
40828310|NCT02356094|PROCEDURE|Pentacam|Corneal topography using Scheimpflug Pentacam examination
40828311|NCT04264650|BEHAVIORAL|an mHealth intervention|The Care \& Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program
40828312|NCT03668054|DRUG|Bevacizumab (Lumiere®)|The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
41347348|NCT02055729|BIOLOGICAL|3mm tissue punch biopsy|Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
40828313|NCT00005647|DRUG|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
40828314|NCT00005647|DRUG|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
40828315|NCT04119622|DRUG|Toripalimab|toripalimab 240 mg d1; q3w, up to two cycles.
40828316|NCT04119622|DRUG|oxaliplatin|oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles
40828317|NCT04119622|DRUG|capecitabine|apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
40828318|NCT05026892|OTHER|no intervention|no intervention, only collection of data
40828319|NCT01765426|BIOLOGICAL|TDV|TDV suspension for intradermal administration
40828320|NCT01765426|DRUG|Placebo|Phosphate buffered saline (PBS)
40828321|NCT03968159|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
40828322|NCT03968159|DRUG|Placebo|Placebo (2×placebo tablets \[size- and color-matched to pimavanserin\]) administered orally as a single dose once daily
40828323|NCT04024215|DEVICE|intravascular ultrasound|IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
41157528|NCT04950049|OTHER|Diluted dexamethasone 20ml|receive 20ml dexamethasone (0.5mg/ml) diluted with 5% glucose
41157529|NCT03698305|DRUG|ASP5354|Intravenous
41157530|NCT03698305|DRUG|Placebo|Intravenous
41347349|NCT02055729|BIOLOGICAL|Superficial bedsore sample|Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 \& 28)
40828324|NCT03121170|OTHER|extracorporeal shock wave therapy|Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25), Guilai(ST29) and Zigong(EX-CA1) at the right and left sides of the lower abdomen. All acupuncture points should be placed according to participants' feedback during treatment.
40828325|NCT03121170|OTHER|hot compress paste|Hot compress pastes will be sticked on the lower abdomen.
40828326|NCT00115999|DRUG|alfimeprase|
40828327|NCT04831528|DRUG|Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others|After PD, patients received ctDNA testing, and different research protocols were selected according to different gene states of ctDNA, as follows: 1.No secondary changes related to drug resistance were found. Cetuximab cross-line + second-line chemotherapy (FOLFOX/FOLFIRI/ Irinotecan monotherapy, etc.) was used.2. If there is a RAS secondary mutation, change of beacizumab bead sheet resistance + second-line chemotherapy (FOLFOX/XELOX/stand for kang single-agent FOLFIRI mXEIRI/Iraq, etc.);3. If BRAF secondary mutation occurs, replace it with vimofenib + cetuximab + irinotecan;4. If HER2 amplification occurs, replace it with trastuzumab + lapatinib or trastuzumab + pertuzumab;5. In case of other secondary mutations, bevacizumab plus second-line chemotherapy should be replaced.
40828328|NCT01919047|DRUG|Betanis|Oral
40828329|NCT04836416|OTHER|Observational|Observational
40828330|NCT02608450|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
40828331|NCT02608450|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
40828332|NCT02291848|BIOLOGICAL|TAA-specific CTLs|"Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10\^6 cells/m2 and Day 14: 5 x 10\^6 cells/m2~Dose Level Two:~Day 0: 1 x 10\^7 cells/m2 and Day 14: 1 x 10\^7 cells/m2~Dose Level Three:~Day 0 2 x 10\^7 cells/m2 and Day 14 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
40828333|NCT02291848|BIOLOGICAL|TAA-specific CTLs- fixed dose|"Fixed dose of 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
40828334|NCT05181202|OTHER|Blood sampling|Collect blood before drug injection. we do not intervene the clinical administration or drug choice or other clinical treatment.
40828335|NCT00652899|BIOLOGICAL|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
40828336|NCT00652899|DRUG|Cyclophosphamide|60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
40828337|NCT00652899|DRUG|Fludarabine phosphate|25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.
40828338|NCT00652899|RADIATION|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
40828339|NCT00652899|BIOLOGICAL|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 \* 10\^7/kg
40828340|NCT00652899|BIOLOGICAL|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
40828341|NCT02252809|DRUG|adalimumab|
40828342|NCT02252809|DRUG|methylprednisolone|
40828343|NCT02691403|DRUG|levo-bupivacaine|
40828344|NCT02691403|DRUG|normal saline|
40828345|NCT05347940|OTHER|mirror therapy|A Mirror box will be used to easily create illusion. It' is a box with one mirror in the center where on each side of it, the hands are placed in a manner that the affected limb is kept covered always and the unaffected limb is kept on the other side whose reflection can be seen on the mirror.
40828346|NCT05347940|OTHER|traditional physiotherapy protocol for flexor tendon repair|include stretching exercises and active ROM exercises
40828347|NCT03497091|OTHER|Enteral Formula|Enteral Feeding with an amino acid-based formula
40828348|NCT03691350|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
40828349|NCT03691350|DRUG|Cigarette|Smoke usual brand
40828350|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC with nicotine
40828351|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC without nictoine
40828352|NCT03691350|OTHER|Laboratory Biomarker Analysis|Correlative studies
40828353|NCT03691350|DRUG|Nicotine Replacement|Receive NRT comprising patch, gum, or lozenge
40828354|NCT03691350|OTHER|Questionnaire Administration|Ancillary studies
40828355|NCT06128980|DRUG|GDMT|Sequential weaning starting with SGLT2i - MRA - BB - ACEi/ARB/ARNi
40828356|NCT01292083|DRUG|azacitidine|Given IV
40828357|NCT01292083|OTHER|laboratory biomarker analysis|Correlative studies
40828358|NCT01292083|OTHER|immunohistochemistry staining method|Correlative studies
40828359|NCT01292083|GENETIC|polymerase chain reaction|Correlative studies
40828360|NCT01292083|GENETIC|western blotting|Correlative studies
40828361|NCT01292083|GENETIC|nucleic acid sequencing|Correlative studies
40828362|NCT01292083|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
40828363|NCT00791401|DRUG|ER OROS Paliperidone|
40828364|NCT01831440|BEHAVIORAL|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
40828365|NCT01831440|DRUG|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
40828366|NCT00094718|BIOLOGICAL|WN/DEN4-3'delta30|Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
40828367|NCT00094718|BIOLOGICAL|Placebo|Placebo for WN/DEN4-3'delta30 vaccine
40828368|NCT02446418|DRUG|Fluticasone Furoate|FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
40828369|NCT02446418|DRUG|Vilanterol|Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
40828370|NCT02446418|DRUG|Fluticasone propionate|FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
40828371|NCT02446418|DRUG|Salmeterol|Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
40828372|NCT02446418|DRUG|Budesonide|Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
40828373|NCT02446418|DRUG|Formoterol Fumarate|Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
40828374|NCT04077372|BEHAVIORAL|Serious Illness Conversation Guide (SICG)|The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
40828375|NCT04077372|BEHAVIORAL|Quality of Life (QOL) survey|Quality of life survey by questionnaire (FACT-G) given every three months
40828376|NCT04253990|PROCEDURE|Precut EMR|"For treating of 10\~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
40828377|NCT04253990|PROCEDURE|Conventional MER|EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current.
40828378|NCT00987896|DEVICE|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
40828379|NCT00545532|DRUG|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
40828380|NCT00545532|OTHER|placebo|Placebo matched to oseltamivir po twice daily for 10 days
40828381|NCT05853315|PROCEDURE|Surgery|Surgical Excision
40828382|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|High dose Diclofenac
40828383|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|Low Dose Diclofenac
40828384|NCT05709522|BEHAVIORAL|Neurocognitive tools|Neurocognitve and psychological tools
40828385|NCT01182974|DRUG|paracetamol|1 gr of paracetamol PO/PZ/PR
40828386|NCT01182974|DRUG|dypirone|1 gr PO/PZ/PR/IM
40828387|NCT02878668|PROCEDURE|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
40828388|NCT04688541|DEVICE|Optitip Catheter (LinC Medical)|The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.
40828389|NCT04688541|DEVICE|Foley catheter|Foley catheter
40828390|NCT01216943|DRUG|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
40828391|NCT03489967|OTHER|Induced-hypoglycemia test|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.
40828392|NCT00236418|DRUG|topiramate|
40828393|NCT03507959|OTHER|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
40828394|NCT03507959|OTHER|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
40828395|NCT03507959|OTHER|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
40828396|NCT03507959|OTHER|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
40828397|NCT01063842|DRUG|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
40828398|NCT01063842|DRUG|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
40828399|NCT03732365|COMBINATION_PRODUCT|Ultrasonic Drug Delivery|A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.
40828400|NCT03732365|DRUG|Standard of Care Antibiotic Treatment|Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
41157531|NCT03129971|PROCEDURE|conventional surgery|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
40828401|NCT03504241|BIOLOGICAL|Donor-derived Mesenchymal Stromal Cells|These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
41019160|NCT05306106|OTHER|hazelnut chocolate cookie|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 142.8 g of hazelnut chocolate cookie (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
41019161|NCT05306106|OTHER|Paris Brest style eclair|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 277.7 g of Paris Brest style eclair (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
40828402|NCT03504241|DRUG|alemtuzumab|Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
40828403|NCT03504241|DRUG|belatacept|Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
40828404|NCT03504241|DRUG|sirolimus|Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
40828405|NCT03504241|DRUG|mycophenolate mofetil|Per protocol, and, only permitted in cases of sirolimus intolerance.
40828406|NCT03504241|DRUG|mycophenolate acid|Per protocol, and, only permitted in cases of sirolimus intolerance.
40828407|NCT03504241|DRUG|prednisone|Per protocol, and, only permitted in cases of sirolimus intolerance.
40828408|NCT03022500|DRUG|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
40828409|NCT04673916|DRUG|Healing evaluation|Treatments were topically applied for 5 days
40828410|NCT01229748|BEHAVIORAL|Standard Care|Clients attend two 90-minute group sessions per week.Treatment lasts for three months.
40828411|NCT01229748|BEHAVIORAL|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
40828412|NCT01229748|BEHAVIORAL|Family Motivational Interviewing Intervention|Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
40828413|NCT05118802|OTHER|Interview|Attends Interviews
41019162|NCT05306106|OTHER|hazelnut chocolate finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 312.5 g of hazelnut chocolate finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
40828414|NCT05118802|OTHER|Survey Administration|Complete Survey
40828415|NCT02372552|DEVICE|CROMA|Microwave coagulation of small blood vessels
40828416|NCT04438876|OTHER|Functional Power Training|The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.
40828417|NCT04438876|OTHER|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
40828418|NCT04175522|DRUG|Immunoglobulin G|IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.
40828419|NCT03628638|OTHER|Blood Sample Collection|Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
41347350|NCT02055729|BIOLOGICAL|Stool sample|Stool samples will be collected on days 0 and 28.
40828420|NCT03917069|DRUG|Chemotherapeutic Combinations|nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d
40828421|NCT03917069|DRUG|chemotherapy|paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
40828422|NCT01478841|DRUG|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
40828423|NCT01478841|DRUG|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
40828424|NCT02773771|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive \>3g of HMB/ day.
40828425|NCT02773771|DIETARY_SUPPLEMENT|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
40828426|NCT02773771|DIETARY_SUPPLEMENT|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
40828427|NCT03655223|DIAGNOSTIC_TEST|Confirmatory Testing|If a newborn's screening test is positive, an experienced genetic counselor will contact the infant's mother by phone to explain the positive screening result and arrange for confirmatory testing and a follow-up appointment. If the confirmatory test is positive, then the child receives a diagnosis of the disease. Children identified with a disorder are referred for treatment, their parents receive information and counseling on what a positive diagnosis means for their child, and they are offered participation in follow-up and registry activities for the disorder.
40828428|NCT00872378|DRUG|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
40828429|NCT00872378|DRUG|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
40828430|NCT03148145|BEHAVIORAL|Step Goal Delivery by Smartphone|Step Goal Delivery by Smartphone
40828431|NCT03148145|BEHAVIORAL|Message Delivery by Smartphone|Message Delivery by Smartphone
40828432|NCT02327936|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
40828433|NCT02327936|DRUG|Oxybutynin XL|Administer medication to patients with overactive bladder
40828434|NCT00841399|BIOLOGICAL|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
41347351|NCT02055729|BIOLOGICAL|Urine sample|Urine samples will be collected on days 0 and 28.
40828435|NCT04900610|DIETARY_SUPPLEMENT|MenaQ7 ®, Nattopharma, ASA, Hovik, Norway|daily per os supplementation of 1mg MK-7
40828436|NCT00801476|PROCEDURE|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
40828437|NCT03294135|BIOLOGICAL|Encepur Adults|One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
40828438|NCT01630551|DIETARY_SUPPLEMENT|Fishoil supplement|1 capsule per day
40828439|NCT01630551|DIETARY_SUPPLEMENT|Olive Oil|1 capsule per day
40828440|NCT00000262|DRUG|30% Nitrous oxide|
40828441|NCT00000262|DRUG|0.4% Sevoflurane|
40828442|NCT00000262|DRUG|0.2% sevoflurane|
40828443|NCT00000262|OTHER|Placebo|
40828444|NCT01503996|BEHAVIORAL|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
40828445|NCT06456125|DEVICE|amber SEL-P Peripheral Liquid Embolic System|Transcatheter arterial or venous embolization with the liquid embolic agent amber SEL-P embolization across seven different indications for peripheral embolization.
40828446|NCT04820634|OTHER|Virtual Reality Job Interview Training|The treatment group (TX) will complete 7 sessions of VR-JIT (1 sessions per week for 7 weeks), designed to teach the skills \& concepts of job interviews. Sessions are approximately 90 minutes long.
40828447|NCT04820634|OTHER|Wonderworks|The control group (CT) will complete 7 sessions of Wonderworks (1 session per week for 7 weeks) using skills in an office environment.
40828448|NCT05597644|PROCEDURE|Trans-arterial uterine artery embolization|transarterial angioembolization of uterine artery
40828449|NCT06268327|DRUG|Cisplatin injection and gemcitabine|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with gemcitabine plus cisplatin Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
41490910|NCT00987753|DRUG|L-377202|For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
40828450|NCT06268327|DRUG|Capecitabine tablets|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with capecitabine Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
41157532|NCT03129971|PROCEDURE|autologous platelet-rich plasma|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
40828451|NCT02761694|DRUG|Vevorisertib|Administered as an oral dose every day or every other day.
40828452|NCT02761694|DRUG|Fulvestrant|Administered as an intramuscular (IM) injection.
40828453|NCT02761694|DRUG|Paclitaxel|Administered as an intravenous (IV) infusion.
41157533|NCT02214771|DRUG|Fidaxomicin|oral
41490911|NCT03929341|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography (CCTA)|Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
40828454|NCT05655273|DRUG|Prograf|Participants randomized to the Prograf (control) arm will continue with their current twice daily dosing of Prograf.
40828455|NCT05655273|DRUG|Envarsus|Participants randomized to Envarsus arm will have their current daily dose of Prograf converted to once-daily Envarsus dose according to the following ratio: 0.7 x the current daily Prograf dose. Envarsus is available in 3 dose strengths- 0.75mg, 1.0mg, and 4.0mg. The actual dose of Envarsus will be rounded to an amount that can be administered using the above tablet strengths.
40828456|NCT00146185|DRUG|ALGRX 3268|
40828457|NCT02863523|BEHAVIORAL|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
40828458|NCT02562209|DIETARY_SUPPLEMENT|PACER Diet|Pacer diet to be followed for 8 weeks
40828459|NCT02562209|OTHER|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
40828460|NCT02740543|DRUG|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
40828461|NCT00260065|DRUG|Decitabine|20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
40828462|NCT03596073|DRUG|Topical Calcipotriene Ointment|Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
40828463|NCT03596073|OTHER|Topical Vaseline|Placebo
40828464|NCT01873053|DRUG|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
40828465|NCT01873053|DRUG|Placebo|
41490912|NCT03929341|OTHER|Cardiac Link|Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
41490913|NCT01484262|DRUG|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
41490914|NCT01484262|DRUG|insulin|Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
40828466|NCT01444027|BEHAVIORAL|Problem Solving Therapy|Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
40828467|NCT02435290|BEHAVIORAL|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~."
40828468|NCT05990699|BEHAVIORAL|Mindfulness-Based Relapse Prevention program|"This program consists of eight sessions spanning across four weeks, each focusing on specific techniques and skills to aid in substance use disorder treatment. The first session emphasizes the correlation between the unconscious pilot and substance use, incorporating a corporeal examination technique to promote intentional concentration. The second session focuses on mindfulness to identify stimuli and observe accompanying sentiments, thoughts, and feelings. The third session introduces the ABSTEMIOUS space technique, urging patients to pause, observe their experiences, concentrate on breathing, broaden cognizance, and choose judicious responses in trying or hazardous situations. The remaining sessions address coping mechanisms for relapse risks, taking pragmatic action in high-risk situations, integrating healthy activities into life, and sustaining mindfulness practice through the development of a support network."
40828469|NCT04421872|OTHER|receiving general anesthesia|patients receiving surgery under general anesthesia
40828470|NCT03854890|DRUG|Indocyanine Green|Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
41157534|NCT02214771|DRUG|Treatment for CDI other than fidaxomicin Type|Oral
41157535|NCT01129115|BEHAVIORAL|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
41157536|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
41490915|NCT00826449|DRUG|Dasatinib|Starting dose of 70 mg by mouth daily for 21 day cycle.
41490916|NCT00826449|DRUG|Erlotinib|150 mg by mouth daily every 21 day cycle.
41490917|NCT01433549|DEVICE|Lotrafilcon B|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
41490918|NCT01433549|DEVICE|Senofilcon A|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
41490919|NCT04628520|PROCEDURE|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
41490920|NCT04628520|PROCEDURE|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
40828471|NCT05502666|BEHAVIORAL|¡Salud! Por la Vida|Lay health worker (LHW) delivered educational intervention for colorectal cancer screening (CRCS). The intervention consisted in having the participant complete a tailored interactive multimedia intervention (TIMI). TIMI consisted of a series of educational videos that addressed common barriers to colorectal cancer screening as well as provided information about colorectal cancer (CRC) and CRCS tests. Participants were able to tailor the TIMI for sex (male/female) and CRC family history. After TIMI completion, the LHW provided participant with a copy of the SPLV newsletter and printed infographics on CRC, CRCS, and an action plan tailored by type of CRCS (FOBT/FIT or colonoscopy). The Intervention Group subject participation took approx. up to 2 hours and Control Group up to 1 hour (half hour for each: baseline and follow-up interview). Follow-up data was collected 6 months post education session (intervention group) or post-baseline survey (control group).
40828472|NCT04291794|DRUG|Propofol|2mg/kg single bolus
40828473|NCT04291794|DRUG|Propofol Injection [Diprivan]|Tritiated Target-Controlled Infusion
40828474|NCT05492760|DEVICE|cryoballoon ablation|Patients with AF will accept cryoballoon ablation.
40828475|NCT03116542|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
40828476|NCT04504890|DEVICE|EYE-SYNC|Nystagmograph used to measure eye movement
40828477|NCT00623662|OTHER|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
40828478|NCT00623662|OTHER|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
40828479|NCT03844113|DRUG|Carnosine|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
40828480|NCT03844113|DRUG|Placebo|Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
40828481|NCT03109262|PROCEDURE|Computed Tomography (CT)|As part of PET/CT and SPECT/CT scans.
40828482|NCT03109262|PROCEDURE|Positron Emission Tomography (PET)|As part of PET/CT scan
40828483|NCT03109262|DEVICE|90-Yttrium (Y-90) Glass Microspheres|Radiolabel for PET/CT scan
41347352|NCT06117956|DIAGNOSTIC_TEST|Rapid urease test for h pylori|"Tonsillectomy will be done with the dissection method and one tonsil per patient will be collected. A 2 mm gross specimen will be washed with normal saline. The specimen will be placed in a test tube well containing Rapid Urease Enzyme (GASTRO CURE SYSTEM RUT DRY TEST Batch No. A1060).~The initial color will be read at 0 min. Subsequent color changes will be read at 30 min, 6 hours, and 24 hours. Any color change from the initial yellow color to either pink or red will be recorded as positive. Any test that will be remained yellow after 24 hours will be recorded as negative.~Tonsillar tissue samples will be fixed in 10% formalin for 24 h Each slide will be separately evaluated for the presence or absence of Helicobacter-like organisms at a high-power magnification"
41347353|NCT00374127|DRUG|Marijuana blunt|Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
40828484|NCT03109262|DIAGNOSTIC_TEST|Technetium 99mTc albumin aggregated (99mTc-MAA)|Radiolabel for 99mTc-MAA SPECT/CT Scan
40828485|NCT03109262|PROCEDURE|Single-photon emission computerized tomography (SPECT) scan|As part of SPECT/CT scan
40828486|NCT00491660|BEHAVIORAL|supine positioning|
40828487|NCT00491660|BEHAVIORAL|lateral positioning|
41157537|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
41490921|NCT04628520|PROCEDURE|Maintenance|Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
41490922|NCT02926430|BIOLOGICAL|Ad26.RSV.preF 5*10^10 vp|Ad26.RSV.preF will be given at a concentration of 5\*10\^10 vp/0.5 milliliter (mL).
41490923|NCT02926430|BIOLOGICAL|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be given at a concentration of 1\*10\^11 vp/0.5 milliliter (mL).
40828488|NCT03703310|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
40828489|NCT03703310|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
40828490|NCT00552630|DEVICE|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
40828491|NCT00552630|DRUG|placebo|placebo with same characteristics as drug
40828492|NCT00461994|BEHAVIORAL|diet|
40828493|NCT00461994|BEHAVIORAL|exercise|
40828494|NCT00461994|BEHAVIORAL|diet and exercise|
40828495|NCT00664560|DRUG|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
40828496|NCT00664560|DRUG|celebrex|200 mg celecoxib qd
40828497|NCT00664560|DRUG|Placebo|sugar pill bid
40828498|NCT00664560|DRUG|Rescue Antacid|Antacid Tablets
40828499|NCT00573560|DEVICE|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
40828500|NCT00219037|DRUG|aliskiren|
40828501|NCT00994591|DRUG|Pharmacokinetic dosing|Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
40828502|NCT01544413|PROCEDURE|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
41157538|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
41347354|NCT00374127|DRUG|marijuana cigarette|Marijuana cigarettes were provided by the National Institute on Drug Abuse.
41347355|NCT03520894|RADIATION|Neoadjuvant radiotherapy|single 21 Gy fraction of Radiotherapy before surgery
41490924|NCT02926430|DRUG|Placebo|Participants will receive placebo as formulation buffer.
41490925|NCT05068089|PROCEDURE|Nissen fundoplication|Nissen fundoplication, numbers, reasons and length of hospitalizations, gastrointestinal symptoms and survival
40828503|NCT04783649|DIAGNOSTIC_TEST|Papanicolaou cytological test|Cervical smear stained using conventional Papanicolaou technique.
40828504|NCT04783649|DIAGNOSTIC_TEST|Local cytological test (H&E stain)|Cervical smear stained using conventional hematoxylin and eosin staining techniques
40828505|NCT04783649|DIAGNOSTIC_TEST|Validated HPV DNA Test|Digene HC2 HPV DNA Test
40828506|NCT04783649|DIAGNOSTIC_TEST|Local HPV test|RealBest DNA HPV HR genotype (differential detection of human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 DNA)
40828507|NCT04783649|DIAGNOSTIC_TEST|Colposcopy|Women with positive cytology results are referred to colposcopy and biopsy
40828508|NCT03378089|BEHAVIORAL|Music Therapy|No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy session. Music therapy sessions will be administered by a board certified music therapist (MT-BC) and last approximately 45 minutes. Involvement in sessions will be based on therapist and patient availability.
40828509|NCT03378089|BEHAVIORAL|No Music Therapy|Participants will fill the same 45 minute period in any way they choose; however, they will be asked to refrain from listening to recorded music during this time.
41490926|NCT05068089|BIOLOGICAL|Enteral nutrition|Type and switch of enteral nutrition formula (tube, PEG, PEJ)
41490927|NCT03052959|BEHAVIORAL|Immediate Intervention|The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
41490928|NCT03052959|OTHER|Wait List Intervention|The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
41490929|NCT03149939|DRUG|Febuxostat 40 milligramsTablet|Febuxostat 40 milligramsTablet every other day for 3 months
41490930|NCT00158756|BIOLOGICAL|Tritanrix™-HepB|GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.
41490931|NCT00158756|BIOLOGICAL|Rotarix™|GSK Biologicals' live attenuated human rotavirus vaccine
40828510|NCT02728960|PROCEDURE|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
40828511|NCT05497856|OTHER|Integrated neuromuscular inhibition technique|Ischemic compression will be applied for 90 seconds followed by the SCS technique with a reduction in pain of at least 70%. it will be held for 20-30 sec followed by the Muscle energy technique in which the isometric contraction will be held for 7-10 sec and then the stretch will be held for 30 sec. This will be repeated 5 times per session with a 30-second rest interval in between each repetition Session will be held 3 times per week for 2 consecutive weeks
40828512|NCT05497856|OTHER|Myofascial Release|Deep sustained pressure on the trigger points will be applied with thumb in 5-7/10 pain tolerance and maintained for 60 seconds and then will be released in a vertical direction followed by stretch of the rhomboid muscle held for 30 sec. This Sustained manual pressure will be applied for 3 times each followed by a stretch per session with a 30 sec rest interval in between .Session will be held 3 times per week for 2 consecutive weeks.
40828513|NCT05516849|DRUG|Oxandrolone|Oxandrolone is a synthetic anabolic androgenic steroid that induces its responses by binding to androgen receptors which modulates gene expression to increase protein synthesis and efficient utilisation of amino acids. Oxandrolone was first synthesized in 1962 through 17alpha-alkylation of testosterone resulting in a formal composition of (4bS,7S,9aS,9bR,11aS)-tetradecahydro-7-hydroxy-4aS,6aS,7-trimethyl- cyclopentanaphthopyran-2(1H)-one and molecular formula of C19H30O3.
40828514|NCT05516849|OTHER|Placebo|As there is currently no approved medication to aid in soft-tissue regeneration, we will be using a placebo control.
40828515|NCT01382004|DRUG|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
40828516|NCT01382004|DRUG|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
40828517|NCT05242666|DIAGNOSTIC_TEST|3T MR Imaging of the cervical spinal cord|Patients will undergo either Magnetic Resonance Imaging of the Spinal Cord
40828518|NCT05242666|OTHER|Positron Emission Tomography using [11C]PIB|Patients will undergo combination MRI/PET using a \[11C\]PIB radiotracer
40828519|NCT05242666|OTHER|3T MR Imaging of the Brain|3T MR Imaging of the Brain
40828520|NCT05242666|OTHER|7T MR Imaging of the Spinal Cord|7T MR Imaging of the Spinal Cord
40828521|NCT00496197|DRUG|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
40828522|NCT00496197|DRUG|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
40828523|NCT00496197|DRUG|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
40828524|NCT01778322|PROCEDURE|Intracranial aneurysm embolization|Treatment of intracranial aneurysms
40828525|NCT04391595|DRUG|Abemaciclib|100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
40828526|NCT04391595|DRUG|LY3214996|400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
40828527|NCT02388594|DRUG|ZFN Modified CD4+ T Cells|
40828528|NCT02388594|DRUG|Cyclophosphamide|
40828529|NCT00596115|DRUG|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
40828530|NCT05969717|DRUG|GD-iExo-001|One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
41490932|NCT00158756|BIOLOGICAL|Zilbrix™|GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine
40828531|NCT05969717|OTHER|normal saline|One drop (about 50 μL) of normal saline was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
40828532|NCT01615601|DRUG|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
40828533|NCT01615601|DRUG|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
40828534|NCT01615601|DRUG|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
40828535|NCT01615601|DRUG|Other antiretroviral medications|Given as per Canadian Product Monograph
41490933|NCT00158756|BIOLOGICAL|Triple Antigen™|Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.
40828536|NCT04143165|DRUG|Epidural block with lidocaine and triamcinilone|caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
40828537|NCT02590601|DRUG|Bromocriptine|
41490934|NCT00158756|BIOLOGICAL|Engerix™-B|GSK Biologicals' hepatitis B vaccine
41490935|NCT00158756|DRUG|Placebo|Placebo for the Rotarix™ vaccine
41347356|NCT05773716|BEHAVIORAL|Pelvic floor muscle training|Participants will receive daily pelvic floor muscle training for 6 consecutive weeks. In specific, they will be instructed to perform 3 training sessions (morning, afternoon and evening) per day with an emptied bladder in a relaxed state. During each session, 10 muscle stretches are required with each contraction duration of 2\~6-second and a 2\~6-second relaxation following each one.
41347357|NCT05773716|OTHER|Electroacupuncture|Participants will also receive electroacupuncture at bilateral Zhongliao (BL33), Huiyang (BL35), Zhongji (CV3), Guanyuan (CV4) and Dahe (KI12). During each therapy session, the electroacupuncture stimulation of acupoints in the abdomen and sacral regions will last for 30 minutes in total (15 minutes for each region) with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
41347358|NCT05773716|OTHER|Sham electroacupuncture|Sham electroacupuncture will be carried out with pragmatic placebo needles on the same acupoints in the experimental group. Procedures, electrode placements, and other treatment settings will also stay the same but with no electrical stimulation output.
41347359|NCT00777686|PROCEDURE|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
41347360|NCT02105168|PROCEDURE|Blood sample|Optional
40828538|NCT02590601|OTHER|Guideline-driven medical therapy (GDMT)|
41019163|NCT05306106|OTHER|lemon finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 263.1 g of lemon finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
41347361|NCT02105168|PROCEDURE|Tumorous biopsy|Optional
41347362|NCT02105168|PROCEDURE|Healthy material sample|Optional
41347363|NCT05725161|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
41347364|NCT05725161|BEHAVIORAL|Wait-list control group with psychoeducation materials provided|The wait-list control group will receive care as usual with psychoeducation materials provided during the study period and receive ACT sessions after the study period ends
41347365|NCT02633917|BEHAVIORAL|Motor control exercises|exercises to strength the lumbar musculature and control the posture
41347366|NCT02633917|BEHAVIORAL|Standard exercises|general exercises
41347367|NCT02812394|DRUG|CVT-301 (Dose Level 1)|All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.
41347368|NCT02812394|DRUG|CVT-301 (Dose Level 2)|All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.
41347369|NCT02812394|DRUG|Sinemet®|All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
41347370|NCT00441727|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg once daily
41157539|NCT03238599|BEHAVIORAL|Pedometer-based activity monitoring after ASCT|Measurement of physical daily activity using a digital step counter (Pedometer-based activity monitoring) and assessment of patient well-being using a web-based patient reported tool.
41157540|NCT05274100|DRUG|Risankizumab|Subcutaneous Injection via prefilled syringe (PFS)
41157541|NCT05274100|DRUG|Risankizumab|Intravenous Infusion
41347371|NCT00441727|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
41347372|NCT00441727|DRUG|Placebo|Placebo once daily
41347373|NCT03687710|BEHAVIORAL|Multidomain precision medicine intervention|Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
41490936|NCT05702671|DIAGNOSTIC_TEST|Total Immunoglobulin E, Obtained From Fingerstick Sample|The Kenota 1 System is intended to be a specialized tool in a professional allergist setting. It will help streamline the patient testing process by bringing quantitative, minimally invasive fingerstick IgE blood testing to the allergy clinic.
41490937|NCT00997139|DRUG|Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)|2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
41347374|NCT04065815|OTHER|Resistance Training|"Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week"
41347375|NCT04065815|OTHER|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~* Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
41347376|NCT04065815|OTHER|High-intensity interval training (HIIT)|"HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 2 training sessions per week"
41347377|NCT04065815|OTHER|Combined HIIT and Resistance Training (Combi)|"HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 1 training session per week~Resistance Training:~* five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 1 training session per week"
41019164|NCT05306106|OTHER|elderflower madeleine|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 294.1 g of elderflower madeleine (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
41347378|NCT03508245|OTHER|Wearable short wavelength light therapy|Wearable short wavelength (i.e., blue-green) light-emitting glasses worn for two weeks
41490938|NCT03253523|PROCEDURE|Occipital neurolysis|Surgical occipital nerve decompression
41019165|NCT01590914|PROCEDURE|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
41019166|NCT01590914|PROCEDURE|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
41019167|NCT00000571|DEVICE|ventilators, negative pressure|
41019168|NCT01714024|DEVICE|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
41019169|NCT01714024|DEVICE|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
41019170|NCT02421458|RADIATION|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
41019171|NCT02421458|RADIATION|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
41019172|NCT04824534|OTHER|Motion analysis|Motion analysis is performed in the Motionlab using Vicon systems. Surgery (in case of SI patients) is performed with iFuse implant system for sacroiliac joint fusion
41019173|NCT02261116|DRUG|Telmisartan|
41019174|NCT02261116|DRUG|Candesartan|
41019175|NCT02261116|DRUG|Placebo|
40828539|NCT06521073|BEHAVIORAL|education|"Patient Information Form (HBF): This form, prepared by scanning the literature, includes the patient\&#39;s age, gender, marital status, education level, profession, social security, place of residence, presence of caregivers in the family, from whom he/she receives care, chronic diseases, the side on which knee prosthesis is applied, knee prosthesis. It is a form consisting of questions about your training status, who you received your training from, and your satisfaction with the training.~Barthel Index (BI): Barthel activities of daily living index is an evaluation scale used to measure an individual\&#39;s performance in daily living activities. The index is used for activities of daily living in 10 domains. The Turkish validity and reliability of the Barthel index, developed by Barthel and Mahoney (1965), was determined by Küçükdeveci et al. (17)."
40828540|NCT02513758|OTHER|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
40828541|NCT05889442|DRUG|Levcromakalim|Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
40828542|NCT05889442|OTHER|Placebo|Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
40828543|NCT04477629|DRUG|Belatacept|Belatacept will be given in the following way - 10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks.
40828544|NCT04477629|DRUG|Tacrolimus|Non-experimental: Tacrolimus will be given in the following way - trough level at month 1, 10-12ng/mL; month 2-3, 6-10ng/mL; month 4-6, 4-6ng/mL; months 7-9 taper off.
40828545|NCT04477629|DRUG|Mycophenolate Mofetil|Non-experimental: MMF is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at 500-1500mg twice a day (BID) (dosed to tolerance and effect).
40828546|NCT04477629|DRUG|Corticosteroid|Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
40828547|NCT05709925|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|The Graston Technique which is the Instrument Assisted Soft Tissue Mobilization is the use of a firm instrument to break tissue adhesions and mobilize scar tissue thus improving pain, range of motion and disability.
40828548|NCT05709925|PROCEDURE|myofascial release|myofascial release through stripping technique to the lumbar region.
40828549|NCT01286987|DRUG|Talazoparib|Oral capsule with multiple dosage forms given once daily
40828550|NCT02903758|OTHER|cross sectional|
40828551|NCT05166382|BEHAVIORAL|Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit.
40828552|NCT05166382|BEHAVIORAL|Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit.
40828553|NCT01852825|BIOLOGICAL|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
40828554|NCT01852825|OTHER|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
40828555|NCT01852825|BIOLOGICAL|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
40828556|NCT00600691|DRUG|Finasteride|one tablet (5mg) of finasteride
40828557|NCT02110888|DEVICE|Subcutaneous peripheral nerve stimulation|
40828558|NCT02110888|OTHER|SCS Only|
41019176|NCT01223079|DRUG|r-hFSH|r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
41019177|NCT01223079|DRUG|r-hFSH and r-hLH|Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
41347379|NCT05295836|OTHER|PLACEBO|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + placebo one and half hours before the test.
41347380|NCT05295836|DIETARY_SUPPLEMENT|GLYCEROL|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + 1.2 g of glycerol one and half hours before the test.
41347381|NCT04460391|BEHAVIORAL|Intensive rehabilitation|Early standing training and routine rehabilitation
41347382|NCT03938558|OTHER|MS-Dance|The experimental group will perform 10 weeks of dance training
40828559|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure devices used: Proglide® (Abbott)
40828560|NCT03192033|DEVICE|Proglide® (Abbott)|Arterial closure device used: Proglide® (Abbott)
40828561|NCT03192033|DEVICE|Femoseal® (Terumo)|Arterial closure device used: Femoseal® (Terumo)
40828562|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure device used: Femoseal® (Terumo)
40828563|NCT01564095|DRUG|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
40828564|NCT01564095|DRUG|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
40828565|NCT03354832|OTHER|Foetal death|A midwife is in charge to interview the mother during the month following the lost of her infant.
40828566|NCT03354832|OTHER|New-born death|A midwife is in charge to interview the mother during the month following the lost of her infant.
40828567|NCT03354832|OTHER|Birth control for foetal death|A midwife is in charge to interview the mother during her hospital stay
40828568|NCT03354832|OTHER|Birth control for new-born death|A midwife is in charge to interview the mother during her hospital stay
41157542|NCT05274100|DRUG|Risankizumab|Subcutaneous Injection via on-body delivery system (OBDS)
41347383|NCT03938558|OTHER|MS-Art|The other group will contribute to the production in various ways (e.g. word art, photography, painting, ...)
41347384|NCT03195686|DEVICE|PLE100(Inbody®)|PLE100(Inbody®) monitoring in children to be operated under the total intravenous anesthesia (Propofol)
40828569|NCT02526082|OTHER|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
40828570|NCT02867618|DRUG|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
40828571|NCT02867618|DRUG|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
40828572|NCT05752227|PROCEDURE|Transthoracic biopsy|Us guided transthoracic biopsy
40828573|NCT05752227|RADIATION|CT chest|Computed tomography
40828574|NCT03906656|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
40828575|NCT03906656|DEVICE|KAFO/SCO|Current knee ankle foot orthosis that the subject was wearing at baseline
40828576|NCT04174651|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
40828577|NCT04174651|BEHAVIORAL|Landscape Video|Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
40828578|NCT05023616|OTHER|Real-time home CPR training|The participants in the intervention group will have Little Anne QCPR mannequins (Laerdal, Stavanger, Norway) delivered to their homes. The participants will use an online platform specifically developed for CPR training (HEROS Remote app). The training program will provide video-based self-instruction training followed by hands-on chest compression training with the instructor. The hands-on chest compression training session provides real-time chest compression quality measurement followed by real-time feedback from the instructor. Chest compression quality will be measured by Little Anne QCPR mannequins.
40828579|NCT05023616|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequins will be provided to measure and give feedback on the participants chest compression performance."
40828580|NCT01659281|DRUG|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
41157543|NCT02222532|DRUG|Tetronine|Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
40828581|NCT01659281|DRUG|Artesunate|4 mg/kg/day for 3 days
40828582|NCT01659281|DRUG|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
40828583|NCT01659281|DRUG|Mefloquine|8 mg/kg daily for 3 days
40828584|NCT01283490|DEVICE|DASD Group|Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
40828585|NCT01283490|DEVICE|Sonic Vibration (SV)|Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
40828586|NCT06234436|BIOLOGICAL|Plasma exchenge|Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
40828587|NCT02426190|OTHER|Anti-gravity treadmill|The intervention is to ask study participants to ambulate using an anti-gravity treadmill that integrates patented, NASA Differential Air Pressure (DAP) technology -- a precise air calibration system -- to uniformly reduce gravitational load and body weight during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
40828588|NCT02426190|OTHER|PENS - neuro-muscular stimulation|The intervention is to ask study participants to warm up using Patterned Electrical Neuromuscular Stimulation (PENS) - that closely replicates the body's normal muscle and nerve firing patterns -- on his/her surgical leg in conjunction with a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
40828589|NCT02426190|OTHER|Anti-gravity treadmill & PENS - neuro-muscular stimulation|The intervention is to ask study participants to ambulate using an anti-gravity treadmill in conjunction with use of Patterned Electrical Neuromuscular Stimulation (PENS) during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
40828590|NCT02426190|OTHER|Recumbent or Nu-step bike|This is the active comparator of the trial that participants are asked to use either a recumbent or Nu-step bike normally seen in an outpatient physical therapy clinic to warm-up during a physical therapy session following a single total knee replacement.
40828591|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
40828592|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
40828593|NCT01095653|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
40828594|NCT01095653|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
40828595|NCT03097575|DRUG|ICG Intervention|Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
40828596|NCT03097575|DEVICE|Near Infrared Imaging|A near-infrared camera device will be used to detect indocyanine green following injection.
40828597|NCT03928288|DRUG|Cabergoline 0.5 MG|Medication
40828598|NCT03928288|DRUG|Placebo - Cap|Placebo capsule
40828599|NCT02362126|DEVICE|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
40828600|NCT04233658|DRUG|Placebo|3x2 capsules / day
40828601|NCT04233658|DRUG|Cynara Scolymus|3x2 capsules / day
40828602|NCT00791557|DRUG|Infliximab|IV drug given at weeks 1,2,14,22
40828603|NCT00114023|DRUG|Imiquimod 5% cream|
40828604|NCT05622266|PROCEDURE|Pulpotomy|The patients who are randomly assigned to the experimental group receive pulpotomy.
40828605|NCT05622266|PROCEDURE|Root Canal Therapy|The patients who are randomly assigned to the Active Comparator group receive root canal therapy.
40828606|NCT00136006|BEHAVIORAL|Study to determine the burden of disease|
40828607|NCT02252601|OTHER|HFDT test|
40828608|NCT02252601|OTHER|Pure tone Audiogram|
40828609|NCT03801746|DRUG|vadadustat|Oral dose 300 mg
40828610|NCT03801746|DRUG|Rifampin|IV Rifampin
40828611|NCT03801746|DRUG|Probenecid|Oral Probenecid
40828612|NCT03801746|DRUG|Cyclosporins|Oral Cyclosporine
40828613|NCT00575432|RADIATION|diffusion MRI|diffusion MRI
40828614|NCT00575432|RADIATION|BOLD MRI|BOLD MRI
40828615|NCT00575432|OTHER|Clinical Outcome|Clinical outcome
40828616|NCT05694910|OTHER|Reiki|Reiki has based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distance Reiki, Reiki practitioners followed the traditional Usui Reiki protocol healing.
40828617|NCT03093974|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d dosing).~The 1 MIU/mL CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (\~10 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d (morning and evening) over a period of 12 months.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g., salbutamol /albuterol), supplied by the Sponsor, could be taken to improve tolerability."
40828618|NCT03093974|OTHER|Placebo|1 ml saline solution 0.45%. the placebo was made up of identical empty glass vials to which the same saline diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to maintain the blind.
40828619|NCT02750384|DRUG|DSM265 50% SDD granules|Single oral dose 400 mg
40828620|NCT02750384|DRUG|DSM265 25% SDD powder for suspension|Single oral dose 400 mg
40828621|NCT02898961|DRUG|30 mg/kg amikacin or 8 mg/kg gentamicin|"In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion."
40828622|NCT01079013|DRUG|treosulfan|12 g/m2 x 3 days
40828623|NCT01198457|DRUG|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
40828624|NCT00360932|DEVICE|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
40828625|NCT06078111|BEHAVIORAL|Prism 10 + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with 10 degrees of visual field deviation
40828626|NCT06078111|BEHAVIORAL|Neutral Prism + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with no visual field deviation
40828627|NCT04424056|DRUG|Anakinra +/- Ruxolitinib (stages 2b/3)|administration of Anakinra +/- ruxolitinib, depending of evolution
40828628|NCT04424056|DRUG|Anakinra and Ruxolitinib (Advanced stage 3)|administration of Anakinra and ruxolitinib
41490939|NCT05578365|OTHER|Pilates method|Individuals in the Pilates group will perform specific exercises online. There will be 16 sessions, lasting 60 minutes, with 10 minutes of warm-up, 30 to 40 minutes of exercises focusing on the trunk stabilizers muscles, and 10 minutes of cool-down with relaxation, stretching, or meditation. In addition, the individuals will have access to the same information of the control group.
40828629|NCT04424056|DRUG|Tocilizumab +/- ruxolitinib (stages 2b/3)|administration of Tocilizumab +/- ruxolitinib, depending of evolution
40828630|NCT04424056|DRUG|Tocilizumab and Ruxolitinib (Advanced stage 3)|administration of Tocilizumab and Ruxolitinib
40828631|NCT04424056|OTHER|Standard of care|Treatment with drugs or procedures in routine clinical practice
40828632|NCT04370990|DEVICE|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
40828633|NCT00554398|DRUG|MK-0518 400mg twice a day|Raltegravir, MK-0518
40828634|NCT02211118|DRUG|Intranasal dexemdetomidine (IN-DEX)|
40828635|NCT01958021|DRUG|LEE011|Ribociclib was administered orally at a dose of 600 mg once daily (three 200 mg capsules).
40828636|NCT01958021|DRUG|Letrozole|Letrozole 2.5 mg tablets taken orally.
40828637|NCT01958021|DRUG|LEE011 Placebo|Matching ribociclib placebo was the control drug and was administered orally once daily.
40828638|NCT02608580|OTHER|Survey|
40828639|NCT05586698|PROCEDURE|Auricular acupressure|We conducted auricular acupressure at zero acupoints on the left ear with Vaccaria ear seed (Group A) or removed seed (Group B) in 20 minutes, with 2 times of auricular acupressure. The stimulation was performed for 30 seconds each time, with two pressure movements per second, resulting in a total of 60 pressure movements per stimulation.
40828640|NCT05995223|OTHER|Submaximal exercise protocol|Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.
40828641|NCT03763344|BEHAVIORAL|Perceptual Cognitive Training (PCT)|Perceptual Cognitive Training (PCT) will be performed by having individuals work with a visual perceptual training software program called NeuroTracker. This device uses Multiple Object Tracking at increasing difficulties to develop high-level brain functions critical to recovery \& cognitive health. By increasing in difficulty with each correct response and decreasing in difficulty when mistakes are made, brain function is constantly challenged. Each session (6 mins) delivers a series of mini-tests where the patient needs to remember key targets, then track them moving among distractors for several seconds and then identify them. Simple to do, but always challenging, NeuroTracker adaptively optimizes difficulty to each patient's level, maximizing cognitive stimulation every step of the way.
40828642|NCT00823745|DRUG|[14C]-PF-00868554|solution, single dose
40828643|NCT02753621|BEHAVIORAL|Group singing|Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.
40828644|NCT02753621|BEHAVIORAL|Facilitated Discussion Group|Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
40828645|NCT03727087|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
40828646|NCT04646161|DRUG|Misoprostol|misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
40828647|NCT02421601|DRUG|Condoliase|1.25 U, intradiscal injection, one time
40828648|NCT01420627|BIOLOGICAL|EZN-2279|Weekly administration of EZN-2279 via IM injection
41157544|NCT02222532|DRUG|Placebo|Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
40828649|NCT01420627|BIOLOGICAL|Adagen|
41490940|NCT05578365|OTHER|Pain education|Individuals in the control group will receive information on self-management of low back pain, pain education, and changes in lifestyle habits once a week during 8 weeks.
41490941|NCT01020344|PROCEDURE|Lung volume reduction surgery|Lung volume reduction surgery
40828650|NCT00244348|DRUG|Oxaliplatin (via HAI)|
40828651|NCT00244348|DRUG|5 Fluorouracil (systemic)|
40828652|NCT04634708|OTHER|No intervention|No intervention due to observational design
41019178|NCT05634616|DEVICE|Motor imagery and motor execution based BCI|We designed a motor imagery and motor execution-based BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed
41490942|NCT00001586|BIOLOGICAL|Rituximab|Rituxan
40828653|NCT02917213|OTHER|Doppler echocardiogram exam|A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
40828654|NCT02917213|OTHER|Carotid duplex ultrasound exam|A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
41019179|NCT05634616|DEVICE|Sham BCI|The training equipment was the same, but the program was changed to record only the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set training performance data of the previous pretest patients, i.e., sham neurofeedback.
41019180|NCT04640311|DRUG|Daprodustat|Daprodustat will be available as oral tablets.
41157545|NCT02931240|DEVICE|Revivent TC|Treatment of LV scar
41157546|NCT01845558|DRUG|Wobenzym® plus|
41157547|NCT01845558|OTHER|Placebo|
41157548|NCT02113150|DRUG|remifentanil|renal function
41157549|NCT02113150|DRUG|Ketamine|renal function
41157550|NCT05201170|DRUG|Vehicle Ophthalmic Solution|Ophthalmic Solution
41157551|NCT05201170|DRUG|PL9643 Ophthalmic Solution|Ophthalmic Solution
41157552|NCT00019136|BIOLOGICAL|MOv-gamma chimeric receptor gene|
41157553|NCT00019136|BIOLOGICAL|aldesleukin|
41347385|NCT01878175|BEHAVIORAL|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
40828655|NCT02917213|OTHER|Cardiac MRI|"A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained."
40828656|NCT02917213|OTHER|Brain MRI|A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
40828657|NCT02917213|PROCEDURE|Reveal LINQ insertable cardiac monitoring system|A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
40828658|NCT02917213|OTHER|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.
40828659|NCT02917213|OTHER|Transcranial Doppler monitoring|A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
40828660|NCT03313284|PROCEDURE|RMT|RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
40828661|NCT03313284|PROCEDURE|RMT + IH|RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
40828662|NCT03313284|PROCEDURE|Control|No intervention
40828663|NCT02674282|PROCEDURE|ACL reconstruction|ACL reconstruction with hamstrings autograft.
40828664|NCT04956094|DIAGNOSTIC_TEST|GGT/Uric Acid|Standard laboratory blood testing for GGT and uric acid levels.
41019181|NCT05011903|BEHAVIORAL|Cross-tailored Dynamic Feedback|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to alcohol use and related sexual behaviors.
41157554|NCT00019136|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41347386|NCT02259764|DRUG|KUC 7483 CL - single rising dose|
41347387|NCT02259764|DRUG|Placebo|
41347388|NCT02259764|OTHER|standardized high fat meal|
40828665|NCT04453813|DRUG|Toripalimab plus concurrent chemo-radiotherapy|"1. Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles).~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
40828666|NCT04453813|DRUG|Concurrent chemo-radiotherapy|"1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
40828667|NCT05499793|DIETARY_SUPPLEMENT|Zingiber Officinale powder|Ginger powder
40828668|NCT05499793|DIETARY_SUPPLEMENT|Placebo|Starch powder
40828669|NCT03970174|OTHER|Care Connector care transition module|Care Connector is an electronic interprofessional communication and collaboration tool. Its features include Physician Sign-Out, documentation, interprofessional care planner, messaging, and flow planner. The newest module is a care transition module which allows physicians to electronically generate discharge summaries as well as incorporation of allied health recommendation, but also will pull information into the PODS (Patient Oriented Discharge Summary) format designed by University Health Network. This results in a patient friendly discharge instruction sheet that can be provided to patient. The intervention arm will have access to the care transition feature, while the control wards do not.
40828670|NCT00263640|BIOLOGICAL|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
40828671|NCT00263640|DRUG|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
40828672|NCT05016167|PROCEDURE|Replacement every 24 hours|"Processing Steps:~1. The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours. During the 24-hour follow-up, patients whose electrodes were removed for any reason were excluded from the sample.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd intercostal space (ICA), left 2nd ICA, and midclavicular 5th ICA regions.~3. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~4. The data were recorded."
40828673|NCT05016167|PROCEDURE|Replacement every 12 hours|"Processing Steps:~1. Monitoring electrodes were removed at the end of the 12th hour. When removing the monitoring electrodes, the area was first wetted using a disinfectant and dried using a sponge after removing the electrodes.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd ICA, left 2nd ICA and midclavicular 5th ICA regions.~3. The skin condition was evaluated from these areas monitored using the skin condition score by the researcher and another independent observer.~4. Monitored again.~5. Monitoring electrodes were removed at the end of the 24th hour. Cleaning and drying were done immediately after removal.~6. Immediately after drying, skin moisture was measured from the monitored areas.~7. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~8. The data were recorded."
40828674|NCT05629637|BEHAVIORAL|Mindfulness-Based Resilience Training (MBRT)|MBRT is designed to enhance resilience in the presence of acute and chronic LEO stressors. MBRT will be delivered in a hybrid format. An intensive, 22-hour in-person training will be offered, followed by 4 weekly 90-minute zoom classes. The in-person portion of the training will span 3 days: 4 hours day 1, 6 hours day 2, and 6 hours day 3. MBRT contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions. MBRT is designed to address stressors inherent to police work, including critical incidents, job dissatisfaction, public scrutiny, and interpersonal, affective and behavioral challenges.
40828675|NCT03444766|DRUG|Nivolumab|specified dose on specified days
40828676|NCT02810938|DEVICE|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
41019182|NCT05011903|BEHAVIORAL|Personalized Feedback Intervention|Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.
41019183|NCT05011903|BEHAVIORAL|Dynamic Feedback on General Health Behaviors|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to general health behaviors.
41019184|NCT01511887|DRUG|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
41019185|NCT06037889|DRUG|Tirofiban|Tirofiban, a GPIIb/IIIa receptor inhibitor. Intravenous administration.
41019186|NCT06037889|DRUG|Aspirin tablet|Aspirin. Oral administration.
41019187|NCT06037889|DRUG|Clopidogrel tablet|Clopidogrel. Oral administration.
41019188|NCT04313192|DEVICE|pulse rate of 2 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
41019189|NCT04313192|DEVICE|pulse rate of 10 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
41019190|NCT04313192|DEVICE|pulse rate of 150 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
41019191|NCT03509701|DIAGNOSTIC_TEST|VZV-specific antibody response from blood|Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva
41019192|NCT01915277|DRUG|Dexmedetomidine|
41019193|NCT05676242|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
41019194|NCT06572280|DEVICE|PNS group|non-invasive phrenic nerve stimulation
41019195|NCT00219128|DRUG|aliskiren|
41019196|NCT02488044|DRUG|AEB1102|modified human arginase I
41490943|NCT00001586|DRUG|Fludarabine phosphate|Fludara
41490944|NCT00001586|OTHER|Leukemic or stroma cells|Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).
41490945|NCT05335733|DIAGNOSTIC_TEST|Intraoral examination, saliva, dental plaque and serum collection.|"Probing pocket depth will be defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) will be measured as distance from cementoenamel junction to the base of pocket and will be recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva will be obtained by each participant. Subgingival dental plaque will be collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Serum samples will be also collected at the time of visit."
41490946|NCT02390141|DRUG|ZP4207|
41490947|NCT02390141|DRUG|Placebo|
41157555|NCT03212183|BEHAVIORAL|EPI-TAVIE|ÉPI-TAVIE is a web-based intervention focusing on epilepsy self-management. This interactive session (25 minutes) is facilitated by a virtual nurse.
41490948|NCT00306943|BIOLOGICAL|Influsplit SSW®|
41490949|NCT00415766|DRUG|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
41490950|NCT00415766|DRUG|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
41490951|NCT00415766|DRUG|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
41490952|NCT03163004|BEHAVIORAL|Implementation of standing desks|Three standing desks will be introduced to the classroom
40828677|NCT04889768|DRUG|HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"1. HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~2. Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~3. Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~4. After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
40828678|NCT02118597|DRUG|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
41157556|NCT03212183|OTHER|Websites|The conventional websites offers reliable information about epilepsy. Their content were validated by experts.
41157557|NCT04135469|OTHER|Referral for tax preparation services|Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.
41157558|NCT04135469|OTHER|Navigator assisted tax preparation services at BMC|A study navigator will assist the participant in accessing the BMC located tax preparation services.
41490953|NCT01867944|BEHAVIORAL|Perineal Self-Acupressure|The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
41490954|NCT01867944|BEHAVIORAL|Educational Control|Education on conventional treatment options for chronic constipation.
41490955|NCT04672486|BEHAVIORAL|POD Adventures|"Participants in the intervention arm will receive information about local services/national helplines and a brief problem-solving intervention that is delivered through a smartphone app with telephone guidance from a lay counsellor. The intervention is grounded in stress-coping theory, with a technical focus on practical problem solving. The emphasis on problem solving reflects the primacy of psychosocial stressors in adolescent help-seeking. Moreover, problem-solving is among the most commonly used practice elements in evidence-based psychological interventions for children and adolescents globally.~The content of the app comprises two sections: 'Adventures' which teaches problem-solving concepts and methods through contextually-appropriate games; and 'My POD' which scaffolds the student through the application of step-by-step problem-solving procedures to their own prioritized problems."
41490956|NCT05341466|OTHER|Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
41490957|NCT05341466|OTHER|SHAM Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 21% O2 (SHAM AIH) alternating with 21% O2 at 1 min intervals
40828679|NCT02118597|DRUG|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
40828680|NCT02118597|DRUG|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
40828681|NCT02118597|DRUG|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
40828682|NCT05097508|DRUG|Atracurium Besylate|Anesthesia will be induced by atracurium (dose 0.5 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given
40828683|NCT05097508|DRUG|Rocuronium Bromide|Anesthesia will be induced by rocuronium (dose 0.6 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given.
40828684|NCT05097508|DEVICE|Entropy|No premedication will be given. After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system , starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
40828685|NCT05097508|DEVICE|train of four|After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system, starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
40828686|NCT01512680|BEHAVIORAL|Education to Functional Insulin Therapy|"* Intake of Continuous Glucose Monitor for 5 to 7 days~* Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~* 1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~* 3 months after the training: Blood sampling, vital signs and data on diabetes~* 6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~* 9 months after the training: Blood sampling, vital signs and data on diabetes~* 1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~* 12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary"
40828687|NCT06037850|DEVICE|Test orthokeratology lens|Randomized to test orthokeratology lens worn during sleep every night
40828688|NCT06037850|DEVICE|Control orthokeratology lens|Randomized to control orthokeratology lens worn during sleep every night
40828689|NCT00183963|DRUG|Tamoxifen|20mg
40828690|NCT00183963|DRUG|Fulvestrant|250mg
40828691|NCT00183963|DRUG|Fulvestrant|500 mg IM
40828692|NCT01798641|DEVICE|MIETHKE proGAV® / MIETHKE proSA®|The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
40828693|NCT05359900|OTHER|Pain neuroscience education|Pain neuroscience education lecture
40828694|NCT05359900|OTHER|Red Flag Education|Red Flag education lecture
40828695|NCT03952117|DEVICE|transcranial direct current stimulation|tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
41019197|NCT05824884|BEHAVIORAL|Visual Feedback|Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.
41019198|NCT05824884|BEHAVIORAL|Self-efficacy enhancement:|specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).
41019199|NCT05824884|BEHAVIORAL|placebo intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).
41019200|NCT05824884|BEHAVIORAL|No visual feedback|Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.
41157559|NCT01705951|OTHER|Resistance Training (RT)|Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
41157560|NCT01705951|BIOLOGICAL|Nicotine Replacement Therapy (NRT)|Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
41157561|NCT01948882|DEVICE|ESS505 (BAY1454033)|
41157562|NCT02773407|DRUG|Azithromycin|
40828696|NCT05985876|BEHAVIORAL|KULEA-NET application|African American/Black (AA/B) women recruited at 3 distinct stages of pregnancy - i.e. 1) 29 to 34 weeks gestational age, 2) 35 to 40 weeks gestational age, and 3)immediately post-partum, will be assigned to the intervention group and start using the KULEA-NET platform. Women in the intervention arm #1 will use KULEA-NET for a total duration of approximately 9 months (3 months prenatal and 6 months post-partum; women in the intervention arm #2 will use KULEA-NET for a total duration of approximately 7 months (1 month prenatal and 6 months post-partum); and women in the intervention arm #3 will use KULEA-NET for a total duration of approximately 6 months (only post-partum). Each woman will have access to all components of the KULEA-NET platform: the text messages, knowledge base, 3 different types of videos, and breastfeeding-friendly spaces and breastfeeding classes near them.
41347389|NCT01961128|BEHAVIORAL|Exercise Intervention|
41347390|NCT00004147|DRUG|incyclinide|
40828697|NCT05985876|BEHAVIORAL|Control Group: Usual Care|Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive standard Babyscripts app only without the KULEA-NET tile. Information from the ACOG about the maternal and infant health benefits of breastfeeding will also be provided (e.g., they will get pamphlets on the importance of breastfeeding as well as lactation consultation).
40828698|NCT04091984|DIAGNOSTIC_TEST|Prospera|No Interventions, this is an observational study.
40828699|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
40828700|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
40828701|NCT03790358|DRUG|Lysergic Acid Diethylamide|Drug will be administered in solution form.
40828702|NCT03783104|DIETARY_SUPPLEMENT|B12 Supplement|Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
40828703|NCT02966795|DRUG|Glecaprevir/Pibrentasvir|Fixed-dose combination tablets taken orally once a day.
40828704|NCT05545202|OTHER|Pentaisomaltose|Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
40828705|NCT03908190|BEHAVIORAL|Personalized Support for Progress|Participants will receive the Personalized Support for Progress Intervention from a peer support provider including sessions with the peer support provider to complete a prioritization task, develop a personalized care plan, and receive support for implementing the personalized care plan.
40828706|NCT00993109|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
40828707|NCT00993109|DRUG|Diovan (Valsartan)|Valsartan 160 mg OM (Two Valsartan 80mg tablets)
40828708|NCT05026372|BEHAVIORAL|Mindfulness Compassion (MC)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
41157563|NCT02773407|DRUG|Co-trimoxazole|
41157564|NCT05181891|BEHAVIORAL|Contingency Management|Incentives for submitting negative-alcohol urine samples
41347391|NCT03450824|OTHER|No intervention|The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.
40828709|NCT05026372|BEHAVIORAL|Mindfulness Gratitude (MG)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
40828710|NCT05026372|BEHAVIORAL|Mindfulness Value-Based Living (MV)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
40828711|NCT02958202|DRUG|BMN 044 IV 6 mg/kg|
40828712|NCT02958202|DRUG|BMN 044 IV 9 mg/kg|
40828713|NCT02958202|DRUG|BMN 044 SC 6 mg/kg|
40828714|NCT03598205|COMBINATION_PRODUCT|DIABEC plus intravitreal dexamethazone|Patients with diabetic macular edema undergoing to intravitreal dexamethazone will be randomized to curcumin formulation (DIABEC)
40828715|NCT04828291|BEHAVIORAL|Benign Behavioral Interventions|This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.
41157565|NCT05181891|BEHAVIORAL|Non-contingent control|Incentives for submitting urine samples
41157566|NCT05139576|DIAGNOSTIC_TEST|serum 25OHD testing|Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels \>150 ng/ml were contacted via telephone.
41347392|NCT00542139|DRUG|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
41347393|NCT00542139|DRUG|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
41347394|NCT01768702|BIOLOGICAL|Injection of C3BS-CQR-1|Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
41347395|NCT01768702|BIOLOGICAL|Sham, no injection|Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
40828716|NCT00462735|DRUG|Cetuximab|250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients
40828717|NCT00462735|DRUG|Hydroxyurea|500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
40828718|NCT00462735|DRUG|Fluorouracil|continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
40828719|NCT00462735|PROCEDURE|radiotherapy|"Radiotherapy was administered at 1.5 Gy per fraction twice daily with treatments separated by at least 6 hours on Days 1 through 5 on an alternating week schedule.~Radiation was delivered with intensity-modulated radiation therapy (IMRT) planning for all patients."
40828720|NCT03875807|PROCEDURE|ACLR done at 0 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)
40828721|NCT03875807|PROCEDURE|ACLR done at 30 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
40828722|NCT01638208|DRUG|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
40828723|NCT03990207|DEVICE|PowerSpiral Enteroscopy System|Motorized spiral enteroscopy system
41157567|NCT06646458|OTHER|Healthy Elderly Volunteers|Take the elderly milk power 2 times every day up to 28 days
41347396|NCT05855421|DEVICE|Auricular Acupuncture|Aplication of semi-permanents needls in the ear by an experient and specialized professional using tradicional chinese maps and a specific device to find acupuncture points. There is a gap of one day minimum between sessions and two non-consecutive absences are allowed.
41347397|NCT02676050|OTHER|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
41347398|NCT02676050|DEVICE|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
41347399|NCT02676050|DEVICE|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
40828724|NCT00004142|DRUG|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
41347400|NCT02661256|DEVICE|NCPAP|Does NCPAP induce dysphagia in neonates? Each baby will be evaluated for dysphagia (using fluoroscopy) while on NCPAP and off NCPAP.
41347401|NCT02661256|DIETARY_SUPPLEMENT|Varibar® Thin Liquid Barium Sulfate for Suspension|Liquid barium is used as a contrast material to allow visualization of swallowed boluses under fluoroscopy.
40828725|NCT00004142|DRUG|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
40828726|NCT00004142|PROCEDURE|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
40828727|NCT00004142|PROCEDURE|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
40828728|NCT03297489|PROCEDURE|Diagnostic Microscopy|Undergo observation via intravital microscopy
40828729|NCT03297489|DRUG|Fluorescein Sodium Injection|Given IV
40828730|NCT03297489|OTHER|Laboratory Biomarker Analysis|Correlative studies
40828731|NCT00205543|PROCEDURE|uvulopalatopharyngoplasty with or without sutures|standard UPPP
41347402|NCT00846027|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
41347403|NCT00846027|DRUG|Paclitaxel|Paclitaxel was supplied as a sterile liquid in glass vials.
40828732|NCT00733135|DEVICE|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
40828733|NCT01225965|DEVICE|Ectoin Inhalation Solution|Once daily inhalation of Ectoin Inhalation Solution
41347404|NCT00846027|DRUG|Gemcitabine|Gemcitabine was supplied as a sterile liquid in glass vials.
41347405|NCT03419351|DIAGNOSTIC_TEST|Smartphone|Smartphone based measurement of refractive error and visual acuity testing using these measurements.
41347406|NCT03419351|DIAGNOSTIC_TEST|Autorefractor|Autorefractor based measurement of refractive error and visual acuity testing using these measurements.
41347407|NCT03419351|DIAGNOSTIC_TEST|Individual|Individual, human measurement of refractive error and visual acuity testing using these measurements.
41347408|NCT01919086|DRUG|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\^2, days 1, 8, 15 and 22
41347409|NCT01919086|DRUG|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
41347410|NCT01919086|DRUG|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
41347411|NCT04341025|BEHAVIORAL|Mindfulness based psychosexual therapy ( MBPST)|The group treatment sessions will integrate empirically supported elements of psychoeduation, cognitive behavioural therapy, and mindfulness skills. Each of the six sessions will follow the well-defined manualized treatment protocol. The treatment is adapted from the study team's previous mindfulness-based treatment group (H15-03172), for situational ED which has been shown to be effective. Participants will be provided with handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and/or behavioural exercises between sessions. During the 2 follow-up sessions, participants will be invited to share their experience since the conclusion of group, ask questions, and participate in troubleshooting.
41347412|NCT00691054|DRUG|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
41347413|NCT06161233|DEVICE|CAPABLE cohort|The CAPABLE cohort receives the mobileapplication and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months. The CAPABLE app serves three main functionalities for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing
41347414|NCT06455423|PROCEDURE|Thoracic Manipulation|Thoracic manipulation will be administered at hypomobile or stiff segments.
41347415|NCT06455423|PROCEDURE|Chin tuck in exercises|Chin tuck in exercises
41347416|NCT06455423|PROCEDURE|Thoracic Extension Exercise|Thoracic Extension Exercise
41347417|NCT06455423|PROCEDURE|Scapular Retraction Exercises|Scapular Retraction Exercises
41347418|NCT06455423|DEVICE|Hot Pack|Hot Pack
40828734|NCT01225965|DEVICE|Placebo|Once daily inhalation of Placebo Inhalation Solution
40828735|NCT00477269|DRUG|Imatinib mesylate|
40828736|NCT00477269|DRUG|Placebo|
40828737|NCT01161095|DEVICE|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
40828738|NCT03035253|DRUG|OMP-305B83|
40828739|NCT03035253|DRUG|FOLFIRI|Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
40828740|NCT03035253|DRUG|FOLFOX|Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
40828741|NCT01684644|BEHAVIORAL|New Forest Parenting Programme|
40828742|NCT01684644|BEHAVIORAL|Treatment as usual|
40828743|NCT04774471|DIAGNOSTIC_TEST|Evaluation of BIT-Motion software|Software program to discern benign versus malignant breast lesions.
40828744|NCT05295823|DEVICE|Butterfly portable ultrasound device with bladder ultrasound images|Point-of-care PVR measurement using existing ultrasound technology (3 consecutive measurements during the same encounter) the Butterfly portable ultrasound device with bladder ultrasound images
40828745|NCT05295823|DEVICE|Butterfly portable ultrasound device with abstract bladder images|Point-of-care PVR measurement using the Butterfly portable ultrasound device with abstract bladder images
41019201|NCT06573424|COMBINATION_PRODUCT|Tislelizumab+anlotinib|Patients who have been treated with anlotinib + tislelizumabline
41019202|NCT06573424|DRUG|anlotinib|Patients who have been treated with anlotinib monotherapy
41347419|NCT06455423|DEVICE|TENS|Trans Cutaneous Electric Nerve Stimulation (TENS)
41347420|NCT06455423|PROCEDURE|ELDOA|ELDOA exercises
41019203|NCT04879303|BEHAVIORAL|Robot-assisted social skill intervention|Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.
41019204|NCT04879303|BEHAVIORAL|Human-only instruction programme on social skill training|The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
41019205|NCT05478213|DEVICE|Monophasic Action Potential (MAP) Catheter|The EasyMap catheter is a temporary quadripolar catheter for recording monophasic action potentials and for intracardiac pacing. During a standard of care VT ablation, the MAP catheter will be used to study cellular action potential of the ventricular myocardium, which cannot be done on traditional catheters. The catheter is placed on the myocardium (similar to other traditional catheters) and a recording signal is transmitted to the workstation. Using the MAP catheter the will not interrupt or distort any of the standard treatment procedures.
41347421|NCT03765177|BIOLOGICAL|CLIC-1901|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.
41347422|NCT00859716|BIOLOGICAL|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
41019206|NCT03063450|DRUG|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
41347423|NCT00859716|BIOLOGICAL|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
41347424|NCT01312285|DEVICE|Resonator device|low level magnetic fields
41347425|NCT05529862|GENETIC|Pre-treatment biopsy|Pre-treatment fragments will be collected during the biopsy visit organised as part of routine medical practice, prior to the start of treatment with ribociclib + ET
41347426|NCT05529862|GENETIC|Post treatment biopsy|Post-treatment fragments will be collected during a biopsy visit specifically planned for Trans-RosaLEE study.
41347427|NCT05529862|GENETIC|Pre treatment blood sampling|Sampling of 4 EDTA Tubes (4ml) and 2 Streck tubes (10ml)
41019207|NCT03063450|OTHER|Placebo|Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
41347428|NCT05529862|GENETIC|Post treatment blood sampling|Sampling of 2 Streck tubes (10ml)
40828746|NCT06185842|BEHAVIORAL|breathing exercise, walking exercise and vaccination counseling|"Participants will perform diaphragmatic breathing exercises and pursed lip breathing exercises two days a week for eight weeks.~Participants will be asked to walk for 20-30 minutes every day for eight weeks. Monitoring will be done weekly.~Participants will be counseled about infectious diseases, modes of transmission and the importance of vaccination, and will be advised to receive influenza and pneumococcal vaccines recommended for this age group.~The 5A model guide will be used regarding behavioral change towards physical activity and vaccination."
40828747|NCT03151798|BEHAVIORAL|Phase II: Lifestyle treatment|Subjects will undergo energy restriction and exercise training over a 9 month period.
40828748|NCT03151798|BEHAVIORAL|Phase II: Control treatment|Subjects will receive dietary advice and receive information on a stretching program.
40828749|NCT03151798|OTHER|Phase I: Observational studies|The liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will undergo in vitro assays to determine the capacity of the tissue to burn fat
40828750|NCT02273635|DRUG|Andrographolides|140 mg andrographolides coated tablets twice a day orally administered for 24 months.
40828751|NCT02273635|DRUG|placebo|140 mg excipients coated tablets twice a day orally administered for 24 months
40828752|NCT00023686|PROCEDURE|surgery|
40828753|NCT00023686|RADIATION|radiation|
40828754|NCT01256463|BEHAVIORAL|HIV prevention intervention|
40828755|NCT04316078|OTHER|patient engagement platform|"1. Allows patients to receive the action plan as educational videos on demand.~2. Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan."
40828756|NCT03452904|DEVICE|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
40828757|NCT03452904|DEVICE|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
41347429|NCT06064552|DIAGNOSTIC_TEST|blood sugar|"High and low risk women will undergo measuring fasting blood sugar after fasting 6-8hours with good hydration. then measuring blood sugar 1hrs and 2hrs postprandial. for patient with high results (FBS\>95mg/dl, 1hr postprandial\>126mg/dl, 2hrs postprandial \>140mg/dl) should do HA1C if \>5.6 consider it diabetic and dealing with whom positive as regard lifestyle management like diet and exercise 150 min. per week and whom not well controlled will be enrolled in pharmacological regimen as metformin.~For whom measures normal will be tested by the same method at 20- 24 wks of gestation"
41347430|NCT02430389|DRUG|Remifentanil|Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
41347431|NCT02430389|DRUG|Normal Saline|Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
40828758|NCT02126566|DEVICE|Administration of light therapy - measurement of results before and after therapy|
40828759|NCT05978128|BEHAVIORAL|Health Education|Access electronic patient portal with educational material
40828760|NCT05978128|OTHER|Health Promotion and Education|Receive materials on breast/lung cancer screening
40828761|NCT05978128|BEHAVIORAL|Patient Navigation|Interact with a patient navigator
40828762|NCT05978128|OTHER|Survey Administration|Ancillary studies
40828763|NCT05685563|DIAGNOSTIC_TEST|DIERS formetic 4D|Assessment of mentioned tests and their comparison.
40828764|NCT06254872|BEHAVIORAL|Peer Mentors|Peer mentors provide daily guidance and encouragement to mentees via smartphone app based on training.
40828765|NCT05804630|DRUG|Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)|As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
40828766|NCT06008496|PROCEDURE|Day case surgery|Operation, surgical group, magnitude of surgery, anaesthetic type.
40828767|NCT05013268|DRUG|Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin|"* Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles~* Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none~* Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none"
41019208|NCT04645212|BIOLOGICAL|ADVM-022|Long term follow-up of subjects that received ADVM-022
41019209|NCT02164396|DEVICE|Spectacle Lens|Spectacle Lens Only
41019210|NCT02164396|DEVICE|Habitual Soft Contact Lens|subject's own contact lens
41019211|NCT02164396|DEVICE|Test Lens|senofilcon A or narafilcon A
40828768|NCT03871452|PROCEDURE|Ankaferd Blood Stopper in theTraumatic Bleeding|"ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses"
40828769|NCT00457977|BIOLOGICAL|Pneumovax (PPSV23)|Injection
40828770|NCT00457977|BIOLOGICAL|Prevnar (PCV7)|Injection
40828771|NCT01568372|OTHER|Telephone follow-up|The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
40828772|NCT00276627|BEHAVIORAL|communication lecture|lecture on communication skills with oncology patients
41347432|NCT03990441|DEVICE|TENS|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
40828773|NCT00276627|BEHAVIORAL|lecture plus CD-ROM|Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
40828774|NCT04346979|OTHER|Telerehabilitation-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. Respiratory exercise was added to the training protocol. Individuals were asked to participate in the study via telerehabilitation system and aimed to do their exercises with a physiotherapist.
40828775|NCT04346979|OTHER|Video-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The respiratory exercise was added to the training protocol. Video recordings containing only yoga and mindfulness training were sent to individuals. The participants were supervised by the researcher.
41347433|NCT03990441|DEVICE|TENS Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
41347434|NCT00772889|BIOLOGICAL|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
40828776|NCT04216940|DEVICE|mechanical preparation of root canal system|Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems
40828777|NCT01133626|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
40828778|NCT01133626|DRUG|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
41347435|NCT00772889|BIOLOGICAL|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
40828779|NCT01133626|DRUG|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
40828780|NCT01133626|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
40828781|NCT06072716|DRUG|Chitosan|chitosan loaded with miconazole nanoparticles gel
40828782|NCT00569088|DRUG|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
40828783|NCT00569088|DRUG|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
40828784|NCT01437644|DRUG|botulinum toxin intramuscular injection|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo."
40828785|NCT03024645|BEHAVIORAL|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
40828786|NCT03024645|OTHER|Treatment as usually (TAU)|performed in primary care settings
40828787|NCT02262442|DEVICE|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
41347436|NCT05601765|OTHER|Standard communication pathways after discharge|Standard communication pathways after discharge
41347437|NCT05601765|OTHER|Digital team-based communication after discharge|Standard communication pathways plus digital team-based communication after discharge
41347438|NCT03809195|BEHAVIORAL|Clinical Hypnosis|See information in arm/group description. Four different audio recordings are provided electronically, each approximately 20 minutes in length. Participants are encouraged to listen to one daily.
41347439|NCT03712670|DRUG|Aflibercept|monthly intravitreal injections
40828788|NCT02262442|DEVICE|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
40828789|NCT04539522|BEHAVIORAL|Three-dimensionally corrective exercise for scoliosis|Three-dimensionally corrective exercise for scoliosis is based the theory of physiotherapeutic scoliosis specific exercises, which focus on 3-dimension self-correction and consists of two parts:1)outpatient treatment including stretching, three-dimensional auto-correction(combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.), balance and stability training, combined with manual fascia relaxation therapy, and and breathing training; 2)family rehabilitation: combines self-correcting gymnastics with daily posture management, etc., forming the individual exercise approach for each patient.
40828790|NCT04539522|BEHAVIORAL|Conventional exercise|Conventional exercise consists a series of spine exercises focusing on core strength training.
40828791|NCT02418312|DRUG|histamine-2 receptor antagonist|famotidine 40 mg qd plus thienopyridine
41347440|NCT03712670|DRUG|Pranoprofen|0.1% pranoprofen 3 times a day topical eye drops administration
41347441|NCT03712670|DIETARY_SUPPLEMENT|Carotenoids|daily supplementation of nutraceutical tablets containing the AREDS2 formulation
41347442|NCT05939076|DEVICE|Pulmonary vein isolation|Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation
41347443|NCT05939076|DRUG|dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™|Antiarrhythmic drugs
41347444|NCT04264494|PROCEDURE|PRP intra articular injection|Fifty RA patients were injected intra-articularly with 3 doses of PRP at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6 months post the last injection regarding the same evaluating tools.
25728176|NCT05710081|BIOLOGICAL|Bacterial Lysate|Bacterial Lysate
25728177|NCT05710081|DRUG|Placebo|Placebo
41347445|NCT04264494|PROCEDURE|NACL intra articular injection|and 50 patients who serve as a control and injected intra-articularly with 3 doses of placebo (NaCl saline) at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6months post last injection regarding the same evaluating tools.
40828792|NCT02418312|DRUG|Placebo|placebo plus thienopyridine
40828793|NCT01332838|PROCEDURE|Compression stockings|standard 30to 40 mm Hg thigh high compression stockings
41347446|NCT04830657|OTHER|Distant reiki|In order to determine the sample size of the study, it is planned to study with a total of 62 patients, including at least 31 patients in each group, in the power analysis based on the statistics of the statistician and previous studies. The remote reiki group will be given remote reiki 3 times a week for 4 weeks by the researcher who has a reiki application certificate. Remote reiki sessions will be performed by the reiki practitioner the night before the hemodialysis day of the patient, and the session duration will take approximately 36-40 minutes. After the individuals receive 12 sessions of remote reiki (1 month later), the questionnaire will be filled in for the second measurement. In order to determine whether reiki has an effect in the long term, 4 weeks (1 month) after the second measurement, the questionnaire for the third measurement will be completed and the research will be completed.
40828794|NCT01332838|DEVICE|compression stockings (Sigvaris )|Specialized monoleg compression
40828795|NCT01452139|GENETIC|Point-of-Care Genetic Testing|Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)
40828796|NCT01452139|DRUG|Prasugrel|Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
40828797|NCT03019978|OTHER|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
40828798|NCT02956850|OTHER|Placebo|Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
40828799|NCT02956850|DRUG|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
40828800|NCT01656226|DEVICE|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
40828801|NCT01656226|OTHER|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
41490958|NCT05282186|BEHAVIORAL|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
41490959|NCT05282186|BEHAVIORAL|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
41490960|NCT01196676|DRUG|AZD4451|1 mg capsules, 5 mg capsules, and 25 mg capsules
41490961|NCT01196676|DRUG|Placebo|1 mg capsules, 5 mg capsules, and 25 mg capsules
41490962|NCT04914221|DRUG|JLP-2002|administration of JLP-2002
40828802|NCT00712621|BEHAVIORAL|Counseling|• Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
40828803|NCT00712621|BEHAVIORAL|Written materials|• Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
40828804|NCT02897531|PROCEDURE|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
40828805|NCT02897531|PROCEDURE|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
40828806|NCT00531297|PROCEDURE|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
40828807|NCT05114122|PROCEDURE|Vonlay Ceramic restorations|vonlay is a hybrid of an onlay with an extended buccal veneer surface for use in bicuspid regions where there is mostly enamel to bond to. The vonlay is less invasive, more readily repairable, less technique-sensitive to attain adequate bonding, and will leave sounder tooth structure remaining if further treatment is required in the future
41347447|NCT02128958|DRUG|CF102|orally q12h
40828808|NCT05114122|PROCEDURE|Onlay Ceramic restorations|Onlays are used to restore large areas of decay and also used to replace old restorations, whether they are defective amalgam fillings, old cast-gold onlays, or fabricated from some other material
40828809|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after anaesthesia induction|after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
40828810|NCT02757443|DRUG|5% Glucose after anaesthesia induction|after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
41347448|NCT02128958|DRUG|Placebo|orally q12 hours
41347449|NCT04881110|DRUG|Liraglutide|Patients in this arm will receive one daily subcutaneous injection of liraglutide. The starting dose is 0.6 mg/dl per day. The dose has to be increased to 1.2 mg/dl per day after the first week of treatment and to 1.8 mg/dl after the second one.
41347450|NCT04881110|OTHER|Control|Patients in this arm will be strictly monitored for atherosclerosis major risk factors, such as hypertension and dyslipidemia, and treated according to current clinical practice.
41490963|NCT04914221|DRUG|Comparator|administration of comparator
41490964|NCT02728752|DRUG|Octagam 10%|Patients to be treated with Octagam 10%
41490965|NCT02728752|OTHER|Placebo|Patients to be treated with a Placebo
41490966|NCT04477772|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|Part A: including dose escalation (1mg/kg JS004; 3mg/lg JS004; 10mg/kg JS004), dose expansion (3mg/kg JS004 and 200mg JS004) and indication expansion. Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
41490967|NCT04477772|BIOLOGICAL|Drug：JS001, Intravenous infusion|Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
41347451|NCT00667940|BEHAVIORAL|Rater training workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
41347452|NCT02591251|DRUG|Povidone-iodine solution|
41347453|NCT02591251|DRUG|Normal saline solution|
40828811|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate added to cardioplegia|together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
40828812|NCT02757443|DRUG|5% Glucose|together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
40828813|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
41347454|NCT04268706|DRUG|CD30.CAR-T|Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.
41347455|NCT04268706|DRUG|Fludarabine|Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days
41347456|NCT04268706|DRUG|Bendamustine|Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days
41347457|NCT03973502|DRUG|18F-DOPA PET|One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA. PET emission data acquisition in 3-dimensional mode will be started at 60 minutes after tracer injection for 30 minutes.
41347458|NCT02415829|DRUG|capecitabine plus oxaliplatin|The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
41490968|NCT05109806|BEHAVIORAL|problem prevention therapy with CHD|The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.
41490969|NCT02086630|BEHAVIORAL|Heart to Heart|
40828814|NCT02757443|DRUG|5% Glucose after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
40828815|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after ICU admission|immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
40828816|NCT02757443|DRUG|5% Glucose after ICU admission|immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
40828817|NCT06107439|BIOLOGICAL|Bood and urine sampling|Bood and urine sampling
40828818|NCT01615055|DRUG|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
40828819|NCT01615055|OTHER|Placebo|20-40 mg pharmacologically inactive tablets for 6 months
40828820|NCT05094479|BEHAVIORAL|Health information delivered via health app|Intervention group will use a health app with non-personalized information on health-promoting lifestyle habits during pregnancy. Control group will use a health app without health information. Intervention effects on the lifestyle habits (gestational weight gain, diet quality, physical activity) will be investigated.
40828821|NCT02249494|OTHER|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
40828822|NCT02249494|OTHER|nutritional counseling|Performing routine nutritional counseling in their clinical practice
40828823|NCT02249494|DEVICE|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
40828824|NCT00385398|DRUG|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
40828825|NCT00385398|DRUG|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
40828826|NCT00385398|RADIATION|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
40828827|NCT02228343|OTHER|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
40828828|NCT01678352|BIOLOGICAL|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
40828829|NCT01678352|DRUG|Imiquimod|Cohort 1 Cohort 2 Cohort 3
40828830|NCT05462977|BEHAVIORAL|Group exercise program|Participants will be asked to join a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace in synchrony with music.
40828831|NCT06363318|PROCEDURE|Laparoscopic appendicectomy|In group A laparoscopic appendicectomy was done while in group B Open appendicectomy was done
40828832|NCT03361904|PROCEDURE|Colonoscopy|Total colonoscopy : All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were: patients scheduled for partial colonoscopy, interventional colonoscopy (for stent insertion, stenosis dilation).
41347459|NCT03188302|OTHER|Collection of stool samples|The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
41347460|NCT00191386|DRUG|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
41347461|NCT03137173|DRUG|ceftobiprole medocaril|ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
41347462|NCT03137173|DRUG|vancomycin+aztreonam|"Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.~Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit."
40828833|NCT04364061|OTHER|Moderate Intensity Continuous Exercise|Participant completed a moderate intensity continuous cycling exercise (MICE) during 35 min at 60-65% thPHRmax
40828834|NCT04364061|OTHER|High-Intensity Interval Exercise (1)|Participant completed a high-intensity interval cycling exercise (HIIE 1) during 20min with 60 cycles of speeding up for 8s and pedaling slowly for 12s at 80-90% thPHRmax
41490970|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal and postpartum phases
41490971|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
41490972|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
40828835|NCT04364061|OTHER|High-Intensity Interval Exercise (2)|Participant completed a high-intensity interval cycling exercise (HIIE 2) during 20min with 10 x 1-min bouts at 80-90% thPHRmax, separated by 1-min recovery bouts
40828836|NCT03590132|BEHAVIORAL|Strong African American Families Program|SAAF is a 7 session family skills training program
41490973|NCT01120041|BEHAVIORAL|health education|Traditional health education given during the prenatal phase and the postpartum phase
41490974|NCT00002353|BIOLOGICAL|P3C541b Lipopeptide|
41490975|NCT00658658|BIOLOGICAL|Panitumumab|Panitumumab administered by intravenous infusion
40828837|NCT03590132|BEHAVIORAL|Strong African American Families--Teen Program|SAAF-T is a 5 session family skills training program
40828838|NCT04580277|DRUG|Tofacitinib 10 mg|Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
40828839|NCT03900923|DRUG|98% pure CBD|A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
40828840|NCT01459991|OTHER|Walnut|Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.
41490976|NCT05405972|BEHAVIORAL|The Connected Family Series - For Foster Families|A 4-week program involving videos and activities for both the parent and child in the home.
41490977|NCT02605993|BIOLOGICAL|Ravulizumab|All treatments were given as IV infusions.
41490978|NCT03956810|OTHER|On-demand transportation|On-demand scheduling via telephone, web portal, or the broker's mobile application.
41490979|NCT03956810|OTHER|Usual transportation|Usual transportation scheduling via call-center.
41490980|NCT04575766|DRUG|FT-7051|"Dose levels: Dose Level -1 through Dose Level 7, assigned per the protocol using a BOIN design. Additional dose levels may be explored as applicable.~Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level."
41490981|NCT05384639|DEVICE|Dual-task Group|Participant will cycle and perform cognitive training simultaneously.
41490982|NCT05384639|DEVICE|Cycling Group|Participant will cycle only.
41490983|NCT05384639|DEVICE|Cognitive Group|Participant will perform cognitive training only.
41490984|NCT04316507|PROCEDURE|Genetic Counselling and Testing|Oncologist-initiated brief genetic counselling and testing
41490985|NCT04320654|OTHER|exercise|The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
41490986|NCT02549235|OTHER|Ultrasound|Routine 2D/3D ultrasound assessment
41490987|NCT03305406|OTHER|Focus groups|Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
41490988|NCT03305406|OTHER|Interviews|Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
40828841|NCT01459991|OTHER|MyPyramid|Participants will follow a USDA MyPyramid style diet for lactating moms.
40828842|NCT03373032|OTHER|Stiper|"Stiper silicon tablets, for acupunture's stimulation of meridian points, the Stiper's chemical composition is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points, duration of 05 minutes."
40828843|NCT03373032|OTHER|Acupuncture|Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top,duration of 30 minutes.
40828844|NCT03373032|OTHER|Exercise|Will perform pre-defined kinesiotherapy based on the stretching of cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.
40828845|NCT03373032|OTHER|Follow Up|Use of the therapeutic massager, in hands and feet, to stimulate region's sensitivity, women who were submitted to the chemotherapy treatment with Taxane and continued with changes in sensitivity. Once in each dermatome, adding time of 5 minutes of application on average.
40828846|NCT03373032|OTHER|Observation|The waiting room (observation) group did not receive any intervention. Conduct evaluations of the research protocol as groups A, B and C.
40828847|NCT06115694|DEVICE|TCI Articulating Introducer|use
41019212|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+CS + PO)|The enucleation procedures, which were meticulously carried out in order to remove the odontogenic keratocyst in one piece without breaking its lining or leaving any epithelial remnants.The peripheral ostectomy treatment will be carried out with a large spherical bur and plenty of irrigation.After filling the bone cavity with more sterile gauze, the Carnoy's solution was slowly injected into it with a plastic syringe. The gauze was continuously injected with CS until it was fully saturated without leaking too much into the surrounding tissues. The CS was held in place for 3 minutes.
41347463|NCT04114773|OTHER|SCARF (Survivors of Cardiac Arrest Rehabilitation focused on Fatigue)|"The intervention will be delivered by a multidisciplinary team. There will be individual testing and feedback on physical capacity and cognitive ability. Group sessions will include education on the consequences of cardiac arrest, promotion of techniques to ameliorate these consequences, for example, increasing physical activity or energy conservation. Additional sessions will cover psychological reactions; family life; work life; intimacy; and existential considerations.~Participants will have a course information book with a physical activity training diary and problem-solving therapy worksheets to use at home for 12-weeks. They will receive one phone call from the clinical team during this period. The 2-day return stay will revisit the subjects from the first 5-day stay.~Participating survivors who have a relative that wishes to attend will be included in all the group sessions and individual feedback but will not take part in the physical capacity or cognitive ability tests."
41347464|NCT03960385|BIOLOGICAL|CYD-TDV|Dengue vaccine
41347465|NCT05302804|DRUG|Menthol Gel|5% menthol gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
41347466|NCT05302804|DRUG|Control Gel|Hypoallergenic gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
41490989|NCT04126213|BIOLOGICAL|RSV MAT 60 µg|One single dose of RSV MAT 60 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
41490990|NCT04126213|BIOLOGICAL|RSV MAT 120 µg|One single dose of RSV MAT 120 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
40828848|NCT06115694|DEVICE|GlideRite® Rigid Stylet|use
40828849|NCT06022081|DIAGNOSTIC_TEST|Lung ultrasound to detect pneumothorax.|Within a maximum of two hours after chest tube removal, the sonographic exam will be performed with an ultrasound device to assess residual PNX using a portable ultrasound device. The examination will require patients to lie face upward and will be performed at three different sites on both sides of the patient's chest. Each chest site will be imaged for approximately 10-20 seconds, allowing a complete examination of each side in approximately 30-60 seconds. The total study time for the LUS exam is approximately 2 minutes. The results of this assessment will be compared to the standard chest x-ray performed by a radiologist who is unaware of the study.
41019213|NCT06133764|PROCEDURE|Decompression/ marsupialization (D/M)|A surgical window will be created in the cyst wall to drain the contents while retaining continuity between the cyst and the oral cavity
41347467|NCT05375656|OTHER|Cross-over study|Traditional Inuit Diet and Western Diet.
41490991|NCT04126213|DRUG|Placebo|One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
41490992|NCT06088056|DRUG|Combination use of SRT with T-DXd|"Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.~Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg"
41490993|NCT00698880|PROCEDURE|Right hepatic vein embolization|Embolization of the right hepatic vein
41490994|NCT05437926|DEVICE|Arrhythmia Analysis Software (software) which runs on a mobile application (Huawei Phone) and uses input from a wearable device (smart watch or smart band).|Subjects with or without cardiac arrhythmias and of light skin tone (melanin index \<150) or dark skin tone (melanin index \>350). Subjects will be divided based on their heart rhythm in three groups: approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
41490995|NCT04632160|DEVICE|IASD System II|The implant is placed across the interatrial septum using a percutaneous transcatheter approach.
41490996|NCT03158974|DRUG|East Indian Sandalwood Oil Cream|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
41490997|NCT02763371|OTHER|Dietary: high GI lunch|High GI: High-GI rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
41490998|NCT02763371|OTHER|Dietary: low GI lunch|Low-GI: Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
41490999|NCT02536326|DEVICE|LEPU Renal Denervation System|LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
41491000|NCT03994497|OTHER|Blood samples|Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
41491001|NCT04846036|DRUG|Sonlicromanol|Oral administration of sonlicromanol twice daily
41491002|NCT04846036|DRUG|Placebo|Oral administration of matching placebo twice daily
41491003|NCT01475058|BIOLOGICAL|allogeneic cytomegalovirus-specific cytotoxic T lymphocytes|Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV
41491004|NCT06174870|OTHER|Inspiratory muscle training|Inhale against 60% of Maximal inspiratory pressure 30breaths/day 5days/week for 6 weeks
41347468|NCT03271411|BEHAVIORAL|EMDR-based Flash technique|Initial EMDR session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
41491005|NCT03589586|OTHER|DermACELL AWM|DermACELL AWM is a sterile, ready to use acellular dermal matrix
41491006|NCT04229459|DRUG|Cisplatin|Cisplatin 100mg/m2 IV on day 1 of induction chemotherapy, 75mg/m2 IV on day 1 and 29 of chemoradiation
41491007|NCT04229459|DRUG|5-FU|5-FU 1000mg/m2/d IV on days 1-5 of induction chemotherapy, 1000mg/m2/d IV on days 1-4 and days 29-32 of chemoradiation
41491008|NCT04229459|RADIATION|Radiation therapy|1.8 Gy/fraction, 5 days a week for a total of 28 days
41491009|NCT04229459|DRUG|Cetuximab|Cetuximab 400mg/m2 IV on day 1 followed by 250mg/m2 IV weekly on induction chemotherapy, 250mg/m2 IV weekly on chemoradiation, 500mg/m2 IV on day 1 of each treatment cycle, every two weeks during immunotherapy
41491010|NCT04229459|DRUG|Nivolumab|Nivolumab 3mg/kg IV on day 1 of each treatment cycle, every two weeks during immunotherapy
41347469|NCT03271411|BEHAVIORAL|PC-based Flash technique|Initial PC session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
41491011|NCT01064154|DRUG|Carvedilol|Carvedilol Tablets 25 mg
41491012|NCT00918138|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily, 4 weeks
41491013|NCT00918138|DRUG|Metformin XR|Tablets, Oral, 1500 mg, once daily, 4 weeks
41491014|NCT00918138|DRUG|Placebo matching Metformin XR|Tablets, Oral, 0 mg, once daily, 4 weeks
41491015|NCT00918138|DRUG|Metformin XR|Tablets, Oral, 500 mg, once daily, 4 weeks
41491016|NCT00918138|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0 mg, once daily, 4 weeks
41491017|NCT00814918|DRUG|5-ALA with Blu-U Light|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
41491018|NCT00814918|DRUG|5-ALA with Candela V-beam Pulse Dye Laser|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
41019214|NCT06133764|PROCEDURE|Enucleation (E)|The enucleation will be accomplished in the same manner that it will be performed in the group of Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
41347470|NCT03710291|DRUG|TRC101|Oral, non-absorbed, polymeric hydrochloric acid binder
41347471|NCT03710291|DRUG|Placebo|Placebo comparator
41347472|NCT01092949|DEVICE|MRI|MRI, 45 minutes
41347473|NCT02210455|BEHAVIORAL|Strongest Families FASD intervention|
41347474|NCT02210455|OTHER|Psychoeducation|
41347475|NCT05164250|DRUG|REGN5458|
41347476|NCT01376908|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
41491019|NCT05717530|PROCEDURE|wound site local anesthesic infiltration|: at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site.
41491020|NCT05717530|PROCEDURE|Erector spina plane block|Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction.
41491021|NCT03681236|PROCEDURE|Alveolar recruitment maneuver|Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
40828850|NCT04768959|BEHAVIORAL|FelizMente|The intervention aims to improve well-being, without denying the existence of symptoms or problems, focusing on generating positive emotions and actions congruent with the person's values through 11 weekly 90-minute group sessions. The multi-component intervention manual was composed of evidence-based exercises of Positive Psychoterapy Interventions, Acceptance and Commitment Therapy and Mindfulness and was theory driven according the broaden-and-build-theory (Fredrickson, 2001) and the self-serving model of paranoia (Murphy et al., 2018). It was also informed by previous pilot studies carried out on people with paranoid tendencies (see Valiente et al., 2020) and with Severe Psyquiatric Condition samples.
41491022|NCT01447420|DRUG|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
41491023|NCT01447420|DRUG|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
41491024|NCT05565092|DRUG|ALXN1820|ALXN1820 will be administered subcutaneously.
41491025|NCT03327636|DEVICE|Echopulse|This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
41491026|NCT05071027|OTHER|Endovascular Neurosurgery|Custom Dual Antiplatelet Therapy reminders for patients receiving endovascular treatment of cerebral unruptured aneurysms. The app utilized to generate reminders is available on the Apple app store.
41491027|NCT01753466|DIETARY_SUPPLEMENT|Hydration|
41509040|NCT06443723|DIAGNOSTIC_TEST|USG, blood tests, waist, hip, height and blood pressure measurements|"MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction.~Metabolic dysfunction (two or more of the following)~1. waist circumference ≥ 90 cm in men and 88 cm in women,~2. blood pressure ≥ 130/85 mmHg or on specific drug treatment,~3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment,~4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment,~5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%),~6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5."
40828851|NCT00018382|DRUG|rosiglitazone|
40828852|NCT03209648|DRUG|Debio 1450|Debio 1450, 40 mg capsule.
40828853|NCT03209648|DRUG|Itraconazole|Itraconazole, 20 mL of 10 mg/mL solution.
40828854|NCT06102356|OTHER|Questionnaire|DLQI TSQM v.II PHQ-9 DS14
40828855|NCT02156817|OTHER|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
40828856|NCT00640640|DEVICE|Pascal Dynamic Contour Tonometer|Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
40828857|NCT00640640|DRUG|Ranibizumab|measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
40828858|NCT00640640|DRUG|Bevacizumab|measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
40828859|NCT00262678|DRUG|EN3267|
40828860|NCT05280327|OTHER|Virtual Reality Application|The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
41347477|NCT01376908|OTHER|Phenylalanine (Phe)-restricted diet|Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
41347478|NCT02019004|DRUG|Onabotulinum Toxin A|
41347479|NCT02019004|DRUG|Incobotulinum Toxin A|
41347480|NCT06174116|DRUG|Lumateperone|Subject will take lumateperone (Caplyta) for 12 weeks, in addition to their regular medications.
41347481|NCT06174116|DRUG|Placebo|Subject will take placebo for 12 weeks, in addition to their regular medications.
41347482|NCT01638676|DRUG|Vemurafenib|Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma
41347483|NCT01638676|DRUG|Metformin|Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
41347484|NCT01392014|DRUG|dihydroartemisinin-piperaquine|This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
41347485|NCT01392014|DRUG|dihydroartemisinin-piperaquine + primaquine|For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
41347486|NCT01379430|BIOLOGICAL|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intramuscularly
41347487|NCT01379430|BIOLOGICAL|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intradermal
41347488|NCT00910936|BEHAVIORAL|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
41347489|NCT00003465|DRUG|temozolomide|
41347490|NCT05743413|PROCEDURE|Armeo Spring physiotherapy|Study subjects will undergo physiotherapy sessions using the Armeo Spring device.
41347491|NCT05743413|PROCEDURE|Standard physiotherapy|Study subjects will undergo standard physiotherapy sessions.
41347492|NCT02142712|DRUG|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
41347493|NCT02142712|DRUG|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
41347494|NCT02142712|DRUG|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
41347495|NCT02142712|DRUG|Dextromethorphan|Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
41347496|NCT05742789|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
41347497|NCT05742789|DRUG|Isoflurane|В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.
41347498|NCT05742789|DRUG|Sevoflurane|в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.
41347499|NCT04561050|OTHER|Comparison of score performances (Overall performance, discrimination and calibration)|"Our Study is an observational non-interventional study based on a multicentric anonymized registry. It's an external validation of pre-existing prognostic scores of traumatic haemorrhages at different times of care (Scene of Injury, admission at the trauma room) in order to assess their overall performance, discrimination and calibration in the prediction of massive transfusion and haemorrhagic death.~The statistic intervention will be a comparison of score performances (Overall performance, discrimination and calibration)."
41347500|NCT03643198|DRUG|ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
41347501|NCT03643198|OTHER|CONTROL|NO treatment
41347502|NCT00006062|DRUG|oxaliplatin|
41347503|NCT03424213|OTHER|No interventions - retrospective data collection|No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
41347504|NCT00762528|DRUG|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
41347505|NCT00762528|DRUG|Sodium monofluorophosphate toothpaste|Twice daily usage
41019215|NCT06133764|PROCEDURE|Enucleation+Carnoy's solution (E+CS)|Both enucleation and Carnoy's solution will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
41347506|NCT02325804|BEHAVIORAL|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
41347507|NCT01102946|DRUG|Ranibizumab|Ranibizumab (Lucentis), intravitreal injections of 0.05ml
41347508|NCT01102946|PROCEDURE|Panretinal Photocoagulation|Panretinal photocoagulation with green laser according to ETDRS
40828861|NCT02900638|BEHAVIORAL|Mentoring|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
41347509|NCT01785940|PROCEDURE|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
41347510|NCT05925829|BIOLOGICAL|SVF and aaPRP|Stromal vascular fraction and autologous activated platelet-rich plasma
40828862|NCT03661736|OTHER|Food for Specific Medical Purpose|Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides
41347511|NCT05367362|DRUG|Minocyclin|200 mg intravenous/oral minocycline hydrochloride for a total of 21 days
40828863|NCT00043823|DRUG|Avastin|7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
41347512|NCT02181504|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
41347513|NCT02181504|DRUG|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
41347514|NCT02181504|OTHER|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
41347515|NCT03551392|DEVICE|Medx Console System|This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
41347516|NCT03551392|DEVICE|Sham Medx Console System|This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
41347517|NCT03551392|DEVICE|Vielight 810 intranasal stand alone unit|Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
41347518|NCT03551392|DEVICE|Sham Vielight 810 intranasal stand alone unit|"Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week."
41347519|NCT03044743|DRUG|Fludarabine|To modify immune micro-environment
41347520|NCT03044743|DRUG|Cyclophosphamide|To modify immune micro-environment
41347521|NCT03044743|DRUG|Interleukin-2|To sustain the survival of infused T cells
41347522|NCT00617162|DEVICE|Deep Brain Stimulation, Libra Deep Brain Stimulation System|DBS Active Treatment Group - implanted with investigational device and activated for stimulation
41347523|NCT00617162|DEVICE|Deep Brain Stimulation, Libra Deep Brain Stimulation System|implanted with investigational device, but will not receive active stimulation for the first 6 months of the study
41347524|NCT05847387|DIAGNOSTIC_TEST|V-Check|Preoperative analysis of endothelial tissue staining with vital dye (Trypan Blue 0.05%) and image analysis to identify the percentage of Trypan Blue Positive Areas, corresponding to dead endothelial cells and/or denuded areas of endothelium, in tissues destined to keratoplasty
41347525|NCT01107340|DEVICE|AMIStem Hip System|
41509041|NCT02369198|DRUG|TargomiRs|"TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected."
40828864|NCT00043823|DRUG|Tarceva|100 mg By Mouth Daily for 3 Weeks
41347526|NCT00086489|DRUG|CP-675,206|pts treated at 10 mg/kg dose level on a monthly regimen
41347527|NCT00086489|DRUG|CP-675,206|pts treated at 15 mg/kg dose level on a quarterly regimen
40828865|NCT01269385|BIOLOGICAL|alemtuzumab|Given subcutaneously
40828866|NCT01269385|BIOLOGICAL|rituximab|Given IV
40828867|NCT01269385|DRUG|PGG beta-glucan|Given IV
40828868|NCT01269385|OTHER|flow cytometry|Correlative studies
40828869|NCT01269385|OTHER|laboratory biomarker analysis|Correlative studies
40828870|NCT01269385|GENETIC|DNA analysis|Correlative studies
40828871|NCT01269385|GENETIC|fluorescence in situ hybridization|Correlative studies
40828872|NCT01269385|GENETIC|polymerase chain reaction|Correlative studies
40828873|NCT01269385|GENETIC|polymorphism analysis|Correlative studies
40828874|NCT01269385|GENETIC|mutation analysis|Correlative studies
41347528|NCT03199014|DEVICE|deploying the Drug-eluting Stents with a prolonged time|the inflation time was more than 30 seconds when the Drug-eluting Stents deploying.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
41347529|NCT03199014|DEVICE|deploying the Drug-eluting Stents with a conventional time|the actual inflation time was within 10s determined by interventional cardiologist.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
41509042|NCT00131599|DRUG|5FU/LV|5FU/LV
41347530|NCT04957810|BEHAVIORAL|WeChat Mini Program|Through the WeChat applet, it provides services such as visit content configuration, self-image configuration, self-image measurement configuration, and visit reminders.
41347531|NCT02251028|BEHAVIORAL|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
41347532|NCT05162833|DEVICE|TheraNova Neuromodulation Device|TENS device
41347533|NCT06216769|DRUG|Rivaroxaban|"Those in the non-interrupted anticoagulation group, anticoagulation is continued regardless of atrial fibrillation recurrence.~Those in the pill-in-the POCKET anticoagulation group will receive direct oral anticoagulation only if they have atrial fibrillation recur over 6 hours."
41491028|NCT04436887|PROCEDURE|positioning of polypropylene strips for prophylactic purposes in closing the middle laparotomies to prevent the incisional hernia|Sub-lay mesh supported closure A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above arcuate line, posterior layer was performed suturing peritoneum and posterior rectus sheath; below arcuate line, posterior layer was performed suturing peritoneum and trasversalis fascia. Anterior layer was performed suturing anterior rectus sheath. A suture length to wound length ratio of 4:1 is recommended. A 4-cm Parietex Progrip Mesh strip was placed between the posterior rectus sheath and rectus muscle with an overlap of at least 2 cm at each side, suture less. In laparotomies \>20 cm two stripes of 15 cm each were designed. The midline anterior rectus sheath was closed using a running slowly absorbable suture, covering the mesh. A suture length to wound length ratio of 4:1 is recommended.
41491029|NCT00955526|DRUG|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
40828875|NCT04029389|DEVICE|Injection|Local corticosteroid injection
40828876|NCT04029389|DEVICE|Tibial nerve block|Tibial nerve block
40828877|NCT04029389|OTHER|Conservational therapy|Only exercise and foot insoles
41019216|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy (E+ PO)|Both enucleation and peripheral ostectomy will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+ Carnoy's solution chemical cauterization (E+ PO+ CS).
41019217|NCT00991601|PROCEDURE|FNAC (fine needle aspiration cytology)|UL guided biopsy
41019218|NCT02041026|DIETARY_SUPPLEMENT|probiotic yoghurt|The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
41347534|NCT05731362|OTHER|MDCIT Intervention|"The MidWest Multidisciplinary Community Intervention Teams (MDCIT) comprise of specialist, healthcare teams that provide a rapid and integrated response to a patient with an acute episode of illness who requires enhanced services/acute intervention for a defined short period of time. This is provided in the patient's home after an acute hospital admission, thereby facilitating early discharge. The MDCIT intervention is composed of occupational therapy, physiotherapy, and healthcare assistants, with nursing support as required.~The MDCIT therapists aim to make their first visit to patients within 24-48 hours of hospital discharge. Patients receive two-three visits per week, over a period of two to four weeks dependant on the patient's rehabilitation needs. Upon discharge from the MDCIT service, patients can be referred to community services as indicated by therapists."
41347535|NCT03088332|PROCEDURE|Endoscopic gastroplasty|Vertical endoscopic gastroplasty
41491030|NCT00955526|DRUG|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
41347536|NCT05178511|DRUG|Ensartinib|Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
41347537|NCT00068822|DEVICE|Percutaneous vertebroplasty|Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
41491031|NCT00955526|DRUG|Placebo|Two placebo tablets once daily for 12 weeks
41491032|NCT06447311|OTHER|Hyaluronic acid gel|Hyaluronic acid is involved in tissue repair and wound healing by stimulating cell proliferation, migration and interaction with several growth factors. Furthermore, HA has a crucial role in space-filling owing to its hygroscopic nature.
40828878|NCT00002598|BIOLOGICAL|recombinant interferon alfa|
41347538|NCT00068822|PROCEDURE|Sham vertebroplasty|Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
40828879|NCT00002598|BIOLOGICAL|sargramostim|
40828880|NCT00002598|DRUG|cyclophosphamide|
40828881|NCT00002598|DRUG|cytarabine|
40828882|NCT00002598|DRUG|etoposide|
40828883|NCT00002598|DRUG|methotrexate|
40828884|NCT00002598|DRUG|mitoxantrone hydrochloride|
40828885|NCT00002598|PROCEDURE|bone marrow ablation with stem cell support|
40828886|NCT00002598|RADIATION|radiation therapy|
40828887|NCT02621398|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
40828888|NCT02621398|DRUG|Carboplatin|Given IV
40828889|NCT02621398|RADIATION|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
40828890|NCT02621398|OTHER|Laboratory Biomarker Analysis|Correlative studies
41347539|NCT04691349|DRUG|CAR-T|The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.
41491033|NCT02069483|BEHAVIORAL|Motivational Interviewing|Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.
41491034|NCT02069483|BEHAVIORAL|Tailored Feedback|Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
41491035|NCT02951468|PROCEDURE|LCP plus iliac crest autograft|After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed \[14\]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
41019219|NCT04155320|BEHAVIORAL|IMPART|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.
41019220|NCT04155320|BEHAVIORAL|Standard Care|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
41491036|NCT06404658|PROCEDURE|Genicular nerve block|patients who receive Genicular nerve block with spinal anathesia .
41019221|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
41019222|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
41347540|NCT01713907|DEVICE|Ulthera® Treatment|Focused ultrasound energy delivered below the surface of the skin.
41347541|NCT01834469|DRUG|iv injection of ICG|An iv injection will be performed for the ovarian cancer patient before the operation.
41491037|NCT02640053|PROCEDURE|Cryotherapy|Applied topically
41491038|NCT02640053|DRUG|Paclitaxel|Given IV
41491039|NCT02640053|OTHER|Quality-of-Life Assessment|Ancillary studies
41491040|NCT02640053|OTHER|Questionnaire Administration|Ancillary studies
41491041|NCT06253026|OTHER|Search and rescue mission|Air search and rescue missions lasting 15 consecutive days
41019223|NCT05075252|PROCEDURE|laparoscopic lavage|This study aims to investigate the impact of laparoscopic lavage on the incidence of postoperative abscesses stratifying patients on the grade of appendicitis and peritoneal contamination.
41019224|NCT00466323|BEHAVIORAL|Family Member Provider Outreach|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
41019225|NCT00466323|BEHAVIORAL|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
41157568|NCT05182827|OTHER|Tactile stimulation|"The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.~It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.~To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).~Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.~This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness."
41157569|NCT05249426|DRUG|BI 765063|BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))
41157570|NCT05249426|DRUG|Ezabenlimab|Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
41019226|NCT03455075|DRUG|Dimethandrolone-Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
41157571|NCT05249426|DRUG|BI 836880|BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
41157572|NCT05249426|DRUG|Cetuximab|Cetuximab
41157573|NCT05249426|OTHER|Investigator´s Choice Chemotherapy|Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof
41157574|NCT05615896|DEVICE|Imaging Session|Various scans will be captured on both devices
41347542|NCT06161324|OTHER|PFM exercises program through the Mobile app in cooperation with the superficial sensor|"The mobile app will offer a personalized progressive protocol to the user based on his needs, via 12 levels of games(from the easiest to the hardest).The cooperating PFM superficial sensor will indicate the activity of the PFMs during the contraction.Νο face-to-face meetings will be incurred between participants and therapist.~Participants will follow a program for 12 weeks(3 times weekly, 1-5 sessions daily, each session's duration approximately 20 minutes).Endurance training will involve slow velocity contraction and speed training will involve quick (i.e.1 sec duration) strong contractions.Knack maneuver training will contain a pre-contraction before the increment of the intra-abdominal pressure during coughing. The exercise positions will change every 2 weeks (supine, side, prone, quadruped support, sitting and standing position)."
41347543|NCT06161324|OTHER|Face-to face PFM exercises program in Healthcare environment|"The therapy will include face-to-face meetings weekly, regarding the progress of the treatment and its smooth transition (intra-vaginally assessment when it needs, correction, encouragement, motivation, etc).~Participants will follow a personalized progressive PFM exercise program for 12 weeks (3 times weekly, 1-5 sessions daily, each session's duration approximately 20 minutes).The endurance training will involve slow velocity contraction and the speed training will involve quick (i.e.1 sec duration) strong contractions. The Knack maneuver training will contain a pre-contraction before the increment of the intra-abdominal pressure during coughing. The exercise positions will change every 2 weeks.It will be followed the order of supine, side, prone, quadruped support, sitting and standing position"
40828891|NCT02621398|DRUG|Paclitaxel|Given IV
41019227|NCT03455075|DRUG|Levonorgestrel 0.03 MG|Single doses of LNG administered in 30 mcg capsules.
41019228|NCT03455075|DRUG|Placebo oral capsule|Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
41157575|NCT05931289|BEHAVIORAL|Enhanced Crisis Response Planning (ECRP)|Using supportive listening, a therapist conducts a brief interview to gather information about lifetime suicide attempt history and recent SI. The therapist then works with the client to identify a) warning signs for being in crisis, b) self-management/distraction strategies, c) reasons for living, d) sources of social support the client could contact in the event of a crisis, and e) crisis resources (e.g., veterans crisis line, contact information for current providers and local emergency resources). Steps for each of these, as well as specific contacts for social support and professional services are written on an index card provided to the patient and the patient is encouraged to keep the card in an accessible place (e.g., wallet) so it can be utilized in the event of a crisis.
41157576|NCT05931289|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)|This weekly, 12-session intervention involves completion of an enhanced crisis response plan, as well as emotion regulation skills training, learning strategies to identify and challenge thinking patterns that contribute to suicide risk, and increased engagement in personally meaningful activities.
41157577|NCT03483597|OTHER|TSQM-II|Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups
41157578|NCT04985747|OTHER|Polished palatal surface|Polishing of the anterior palatal surface using a polisher
41157579|NCT04985747|OTHER|Roughened palatal surface|Roughening of the anterior palatal surface using a sandblaster
41347544|NCT06161324|OTHER|PFM exercises program via home-leaflet(without suprevision)|"The participants of the CG will be advised to follow a personalized PFM exercise program at home based on their 1st meeting assessment. They will receive a comprehensive leaflet, with instructions and images about the PFM exercises at home. The PFM exercise program will last 12 weeks (3 times weekly, 1-5 sessions daily), without meetings, guidance and supervision by the physiotherapist. Similarly to the other two intervention groups, the program will contain endurance training (slow velocity contraction), speed training (quick contractions), Knack maneuver training (pre-contraction before coughing), and changing positions every 2 weeks (supine, side, prone, quadruped support, sitting and standing position)"
41347545|NCT01557127|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
41019229|NCT04707235|DRUG|Hydroxycarbamide|Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
41157580|NCT04985747|OTHER|Opened palatal surface|Opening of the anterior palatal surface using acrylic bur
41019230|NCT01537341|BEHAVIORAL|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
41019231|NCT01537341|BEHAVIORAL|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
41347546|NCT05484726|OTHER|perioral sensory motor stimulation|"Step 1 - 6 over 5 minutes~1 With the help of the index finger, on the external surface of the cheek, make a circle starting from the angle of the mouth towards the ear then back 7x each cheek~2 While holding both sides of the cheek with help of the thumb and index finger repeat step 1 7x each cheek~3 Move index finger from one corner to opposite one over both lips separately 7x each lip~4 Gentle massage and compress the gums from center to back of mouth 7x each half of the gum~5 Move the finger from front to back on the hard palate while applying gentle pressure 7x~6 Displace the center of the tongue with gentle pressure 7x~7 Offer pacifier at the end 2 minutes~Note: 7x means 7 times"
40828892|NCT02621398|BIOLOGICAL|Pembrolizumab|Given IV
40828893|NCT01811576|DRUG|TV-1106|
40828894|NCT01811576|DRUG|Recombinant human growth hormone|Subcutaneous once daily
40828895|NCT06352528|DRUG|Repotrectinib|Specified dose on specified days
41019232|NCT05239676|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells|The patient receives ECHOP chemotherapy or other chemotherapy regimens； G-CSF in the low cell stage mobilizes hematopoietic stem cells and freezes them for later use after collection； Autologous hematopoietic stem cells and prepared CD19 CAR-T cells are reinfused into the patient
41019233|NCT01623440|COMBINATION_PRODUCT|Placebo and fMRI|Pill form, participant dosed one time an hour before fMRI.
41019234|NCT01623440|COMBINATION_PRODUCT|Naltrexone and fMRI|50 mg pill given one time, one hour before fMRI
41157581|NCT05458154|OTHER|questionnaires|Participants were recruited from the Baheya Centre for Early Detection and Treatment of Breast Cancer institution. Patients were eligible if they had a previously post-mastectomy pain syndrome (PMPS), and were presented with pain within the surgical area lasting more than 3 months. They were evaluated by questionnaires and methods of pain assessment then received their physiotherapy program specific for pain relief for six sessions, and so re-evaluation. All women gave informed written consent in Arabic and English forms.
41157582|NCT05954156|OTHER|injectable composite|The introduction of injectable composites, according to available literature, offers a simple and efficient solution for the cementation of veneers. This versatile, injectable restorative composite unites easy handling, high physical properties and excellent aesthetics. Generally used as a restorative material, it can also be used for the cementation of veneers and some inlays/onlays, thus considered as good alternative to preheated composite. (Alajrash MM et al., 2020)
41347547|NCT04488991|OTHER|Cervical Cancer Rate|In the end of the Research, we will compare cervical cancer rates between groups
41347548|NCT00865202|DRUG|L-tryptophan supplementation|L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
41347549|NCT00865202|DRUG|placebo|Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
41347550|NCT04574076|DRUG|Turoctocog alfa pegol (N8-GP)|Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
41347551|NCT03330548|BEHAVIORAL|TeleMOVE!|Active comparator- telehealth treatment program for weight management and health promotion
41347552|NCT03330548|BEHAVIORAL|Culinary Rx|Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
41347553|NCT00420212|DRUG|BG00012|
41347554|NCT00420212|DRUG|Placebo|
41347555|NCT05947695|BEHAVIORAL|Palliative and Survivorship Care Model|The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.
41347556|NCT04273568|OTHER|Scapular PNF|Rhythmic initiation and repetitive stretching techniques in scapula anterior elevation-posterior depression and anterior depression-posterior elevation patterns were applied twice a week for 6 weeks.
41347557|NCT04273568|OTHER|Exercise program|An exercise program consisting of exercises used in the conservative treatment of shoulder impingement syndrome for both groups was applied twice a week for 6 weeks.
41157583|NCT01171885|DRUG|0.9% saline|20 ml of 0.9% saline
41157584|NCT01171885|DRUG|Ropivacaine|20 ml of Ropivacaine 0.25%.
41157585|NCT01171885|DRUG|Ropivacaine|20 ml of Ropivacaine 0.5%.
41157586|NCT06089486|DIAGNOSTIC_TEST|ICA|Patients will undergo annual CAV surveillance with ICA
41347558|NCT00099606|DRUG|Dasatinib|Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
41491042|NCT02870387|OTHER|Comprehensive Care with Inpatient consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
41491043|NCT02870387|OTHER|Usual Inpatient Care|High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
41491044|NCT04493320|DRUG|Carbidopa/levodopa|150-450mg carbidopa/levodopa 3 times daily
41347559|NCT01100658|DRUG|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
41347560|NCT01100658|DRUG|Placebo|1 capsule per day for 1 week.
41347561|NCT02617706|DEVICE|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
41347562|NCT01987752|DRUG|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
41157587|NCT06089486|DIAGNOSTIC_TEST|PET|Patients will undergo annual CAV surveillance with PET
41157588|NCT03738397|BIOLOGICAL|Upadacitinib|Extended release tablet
41157589|NCT03738397|BIOLOGICAL|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection
41157590|NCT03738397|DRUG|Placebo to dupilumab|Placebo administered as a subcutaneous injection
41157591|NCT03738397|DRUG|Placebo to upadacitinib|Tablet
41157592|NCT05913583|DRUG|Immune checkpoint inhibitor|"Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells.One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called PD-1 or its partner protein PD-L1."
41157593|NCT02592044|PROCEDURE|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
41157594|NCT02592044|PROCEDURE|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
41157595|NCT02592044|PROCEDURE|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
41347563|NCT05260190|DEVICE|tSMS|30-minute tSMS application in a comfortable seated position. The material used in the stimulation was a MAGxx1.1 helmet (Neurek Spain Toledo), with a Neodymium (NdFeB) magnet of 60mm diameter and 30mm height with Nickel (Ni-Cu-Ni) coating MAG60r+ (Neurek Spain, Toledo), placed over the primary motor cortex (M1) of the left cerebral hemisphere.
41347564|NCT05260190|DEVICE|Sham tSMS|30-minute sham tSMS application in a comfortable seated position. The device used in sham stimulation had the same weight and shape as the real stimulation helmet.
41347565|NCT03061149|OTHER|Low-level laser therapy|
41347566|NCT03061149|OTHER|Ultrasound treatment|
41347567|NCT05386004|OTHER|Birth-Specific Stereogram Cards (BSSC)|Focus on Birth-Specific Stereogram Cards (BSSC) during uterine contractions in latent active and transitional phase
41347568|NCT00036946|BIOLOGICAL|ziv-aflibercept|
41347569|NCT02054663|DRUG|Clopidogrel|Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
41019235|NCT06220396|PROCEDURE|Right Heart Catheterization with Hemodynamics and Limited Echocardiogram|"Right Heart Catheterization (RHC) with Hemodynamics and Limited Echocardiogram is an invasive procedure that involves insertion of a catheter through a blood vessel in the neck, groin, or arm to the right side of the heart. Hemodynamic measurements such as the blood pressure inside the veins, heart, and arteries as well as measurements of blood flow and how much oxygen is in the blood will be completed during the catheterization procedure. It is a way to see how well the heart is working during your procedure. During the RHC procedure a limited echocardiogram, using ultrasound waves, will be collected to evaluate the structure and function of the heart.~All measurements will be conducted at rest and during exercise using a supine cycle ergometer"
41347570|NCT02096471|DRUG|PD-0325901|
41347571|NCT03930810|PROCEDURE|Surgical biliary diversion|Surgical interruption of enterohepatic circulation
41347572|NCT00472043|DRUG|PDT with Metvix 160 mg/g cream|
41347573|NCT00472043|DRUG|Placebo|
41347574|NCT03085212|BEHAVIORAL|Stress Free Now|Online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavioral therapy to help individuals manage their stress.
41347575|NCT06388356|OTHER|Educational intervention - Yksityisyyttä ensihoitoon / Informational privacy for preospital emergency care|"Educational intervention is a self-study, online course on Koulumaali platform about patient's informational privacy (IP) in prehospital emergency care (PEC).~It comprises three separate educational modules approximately 30 min. long: module I) the meaning and significance of IP and its protection, module II) legislation regarding IP and its protection in healthcare and module III) breaches of IPand its protection in PEC.~Each module contains theoretical sections as well as case-exercises and tests.~Participants will have four weeks time to execute the entire course independently. Participants can execute the modules according to their own schedule. The modules need to be completed in certain order by following the numerical order from first to third. Only one of the modules is open at a time and the second module activates after the previous modules has been completed. Already completed modules become inactive."
41347576|NCT05724147|BEHAVIORAL|Mandala Activity|Three sessions of mandala activity, once a week, will be applied to the participants from the elderly people in the nursing home included in the study. The mandala activity planned to be done with the group will be done in addition to the standard monitoring applied in the institution, so it will be held at an appropriate time according to the flow in the institution. Before leaving the individuals, the most appropriate time for the next mandala session will be determined by taking into account the preferences of the individuals. Individuals to be included in the study will be grouped in groups of 10. Mandala activity application time is planned to last approximately 2 hours. If individuals have any physical symptoms, the time of the mandala activity is rescheduled, and each individual is expected to attend five sessions during the total study period.
41347577|NCT02269904|DRUG|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
41347578|NCT02269904|DRUG|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
41347579|NCT03912324|PROCEDURE|Unipolar voltage subtraction map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury~3. Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture~4. the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)~5. Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map~6. Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map~7. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~8. Evaluate time to complete isolation after additional ablation~9. Evaluation of Procedure and Ablation time, and perfusion saline dose~10. Rhythm follow-up after the procedure in accordance with the study design."
41347580|NCT03912324|PROCEDURE|CT myocardial thickness map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.~4. Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map~5. Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map~6. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~7. Evaluate time to complete isolation after additional ablation~8. Evaluation of Procedure time, Ablation time, and perfusion saline dose~9. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
41347581|NCT03912324|PROCEDURE|Empirical PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~4. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~5. Evaluate time to complete isolation after additional ablation~6. Evaluation of Procedure time, Ablation time, and perfusion saline dose~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
41347582|NCT01254786|PROCEDURE|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min."
41491045|NCT04493320|DRUG|Placebo|Carbidopa/levodopa-matched placebo tablet 3 times daily
41491046|NCT02105974|DRUG|Fluticasone Furoate/Vilanterol|100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
41347583|NCT01254786|PROCEDURE|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min"
41347584|NCT01609491|DRUG|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
41347585|NCT01609491|DRUG|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
41347586|NCT00125229|DRUG|Mannitol|
41347587|NCT00125229|DRUG|Hypertonic Saline|
41347588|NCT02340936|DRUG|LR-ESHAP (lenalidomide 5 mg)|3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
41347589|NCT02340936|DRUG|LR-ESHAP (lenalidomide 10 mg)|3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
41347590|NCT02340936|DRUG|LR-ESHAP (lenalidomide 15 mg)|3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
41347591|NCT02340936|DRUG|LR-ESHAP (lenalidomide 20 mg)|3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
41347592|NCT02857205|OTHER|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
41491047|NCT02105974|DRUG|Vilanterol|25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
41491048|NCT03002662|OTHER|colonoscopy|
41491049|NCT02944383|DRUG|Gemcabene|Gemcabene tablets administered orally once daily, for 12 weeks.
41019236|NCT06220396|PROCEDURE|Magnetic Resonance Imaging (MRI)|"MRI is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body. CMR Imaging will assess myocardial structure, function, and fat content.~An additional limited MRI sequence of the the abdomen and one sequence in the thigh will be used to evaluate for visceral adipose tissue (VAT) as a measurement of body composition."
41491050|NCT02944383|DRUG|Placebo|Placebo tablets administered orally once daily, for 12 weeks.
40828896|NCT02116114|OTHER|Aerobic training|The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
40828897|NCT01094353|PROCEDURE|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
40828898|NCT01094353|PROCEDURE|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
40828899|NCT04326725|DRUG|Plaquenil 200Mg Tablet|health workers under risk who took this medications
41347593|NCT05532462|PROCEDURE|Trans-nasal complete nasalabial cyst excision|The surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. Submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). An incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. The mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. During dissection, cyst content is usually drained. The whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. Finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. If mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. Endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.
41347594|NCT03966872|BEHAVIORAL|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness.
41347595|NCT03966872|BEHAVIORAL|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
41347596|NCT00872781|DRUG|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
41347597|NCT00409396|PROCEDURE|Urinary PGEm level|Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.
41347598|NCT00409396|PROCEDURE|fecal calprotectin|Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
41347599|NCT00364832|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
41491051|NCT02915965|DRUG|DCX|docetaxel, cisplatin and capecitabine
41491052|NCT02915965|PROCEDURE|surgery|Ivor Lewis Esophagectomy
41491053|NCT05318430|DEVICE|Subcutaneous closed-suction drainage device|This subcutaneous closed-suction drainage device was designed to be placed subcutaneously when surgeons have completed all intra-abdominal operations and are about to suture subcutaneous layer and skin
41019237|NCT06220396|PROCEDURE|Dual X-ray absorptiometry (DEXA) scan|A DEXA scan measures the amount of fat in the body using an x-ray that measures bone, calcium and fat.
41019238|NCT03377621|DEVICE|Whole Body Vibration|Whole Body Vibration Machine from the company Confidence Fitness
41019239|NCT01978405|DRUG|Alpha lipoic acid|
41347600|NCT02482389|RADIATION|Single fraction of 7 Gy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
41347601|NCT04237610|BEHAVIORAL|behavioral assessment|Probabilistic learning task
41347602|NCT01432665|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
41347603|NCT01432665|DRUG|Sildenafil|Solid Oral Dosage. Maximum every other day (on an as needed basis)
41347604|NCT01432665|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
41347605|NCT04918069|DRUG|Capsaicin|Topical capsaicin ointment
41347606|NCT04918069|DRUG|Placebo|Topical placebo ointment
41347607|NCT02195947|DRUG|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
41347608|NCT06059521|DEVICE|Software refraction with Eye Test Technology in a mobilerone|Refraction is done by software App by a mobilerone software installed.
41347609|NCT06059521|DEVICE|Retinoscopy|Retinoscopy is an objective refraction method with retinoscope.
41347610|NCT01875666|DRUG|Trastuzumab|8 mg/kg IV, single dose
41347611|NCT01875666|DRUG|pertuzumab|840 mg IV single dose
41347612|NCT01875666|DRUG|lapatinib|1000 mg daily for 7 days
41347613|NCT00621244|DRUG|LBH589|
41491054|NCT02852720|DRUG|Levobupivacaine|After the block procedure, 2 ml blood samples will be taken in defined times to determine the plasma blood levels of levobupivacaine.
41491055|NCT02852720|PROCEDURE|Spinal anesthesia|Spinal anesthesia in the L3-L4 or L4-L5 interspace with hyperbaric bupivacaine 0,75% 1,4 ml plus 20 ug fentanyl to achieve a bilateral anesthetic level of T4 determined by pinprick.
41491056|NCT02852720|PROCEDURE|Peripheral vein canulation|An intravenous (18-gauge) catheter will be placed under local anesthesia for co hydration and a second IV catheter for venous sampling
41491057|NCT02852720|PROCEDURE|Ultrasonography|TAP blocks will be performed using a ultrasound Sonosite M-Turbo US machine (Sonosite Inc, Washington) with an L38x 10-5 megahertz (MHz), 38-mm broadband linear array probe.
41347614|NCT05283785|PROCEDURE|End To End or End to side sutures|End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
41491058|NCT02852720|DEVICE|Holter|A portable 12-lead Holter (NorthEast Monitoring®, Boston, USA) will record continuously the electrocardiogram (ECG) after the TAP block, for 24 hrs.
41347615|NCT00224497|DRUG|SB-742457|
41491059|NCT00856219|DIETARY_SUPPLEMENT|Enteral Continuous|Continuous Tube Feeding for 72 hours
41347616|NCT02820480|DEVICE|Rehab in a Crate System|"The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.~Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use."
41491060|NCT00856219|DIETARY_SUPPLEMENT|Enteral Intermittent|Intermittent Tube Feedings
41491061|NCT00856219|DIETARY_SUPPLEMENT|Parenteral Continuous|Parenteral Continuously for 72 hours
41157596|NCT04804228|OTHER|Electrical dry needling|The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 6 weeks.
41347617|NCT02144090|DEVICE|Fractional flow reserve measurement|Fractional flow reserve measurement
41347618|NCT04653727|OTHER|Cross-sectional survey|No intervention.
41347619|NCT06246344|RADIATION|MRI Guided Simultaneous Integrated Boost Radiotherapy|MRI Guided Simultaneous Integrated Boost Radiotherapy
41347620|NCT03709914|DRUG|ZTI-01 100 mg/kg|ZTI-01 intravenous (IV)
41347621|NCT03709914|DRUG|ZTI-01 75 mg/kg|ZTI-01 intravenous (IV)
41347622|NCT03378973|DRUG|Dexmedetomidine|Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.
41491062|NCT03402555|OTHER|Stool pattern|Collection of stool images
41491063|NCT06084962|BIOLOGICAL|DeepTag-GPRC5D Targeted CAR T-cells|Each subject receive DeepTag-GPRC5DTargeted CAR T-cells by intravenous infusion
41491064|NCT02095808|PROCEDURE|Imaging Biomarkers|Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
41347623|NCT04080700|PROCEDURE|Distal radial approach|Operator puncture the distal radial artery with open needle or venipuncture catheter needle for coronary angiography and percutaneous coronary intervention.
41347624|NCT01453686|DRUG|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
41347625|NCT01453686|DRUG|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
41491065|NCT01470768|OTHER|Amino Acid-based Formula with high DHA and ARA|
41491066|NCT01470768|OTHER|Amino Acid-based Formula with lower DHA and ARA|
41491067|NCT03151408|DRUG|Pracinostat|60 mg capsule
41491068|NCT03151408|DRUG|Placebos|capsule
41491069|NCT03151408|DRUG|Azacitidine|SC or IV injection
41491070|NCT04406597|DEVICE|the New Tissue Containment System|Laparoscopic Ovarian Cystectomy using the New Tissue Containment System
41491071|NCT01678053|DRUG|onabotulinumtoxinA|Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
40828900|NCT04599868|DRUG|Magnesium sulfate|"Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h\& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed."
40828901|NCT05737277|DRUG|Gabapral|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period."
40828902|NCT05737277|DRUG|Placebo|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period"
41019240|NCT01416805|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
41157597|NCT04804228|OTHER|Ischemic compression, analytical stretching and postural habits educational dossier|The control group G2, formed by 40 subjects, will perform an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifidus and iliocostal muscles, 1 weekly session for 6 weeks, in addition to providing them with a training dossier on postural education in their activities of daily life.
41491072|NCT01678053|DRUG|omeprazole (proton pump inhibitor)|Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
41491073|NCT02155543|DRUG|AGN-223575 Formulation A|One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
41491074|NCT02155543|DRUG|AGN-223575 Formulation B|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
40828903|NCT00106691|DRUG|Toremifene 20 mg|The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
41347626|NCT04299750|PROCEDURE|Tooth extraction and Alveolar ridge preservation|Tooth extraction and alveolar ridge preservation with deproteinized bovine bone mineral and a collagen matrix seal
41347627|NCT04299750|PROCEDURE|Tooth extraction|Tooth extraction and socket natural healing
41347628|NCT02807155|BEHAVIORAL|Transition Empowerment Program|Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
41347629|NCT02807155|BEHAVIORAL|Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC)|Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
41347630|NCT02807155|BEHAVIORAL|Online Transition Empowement Program Access|Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
41347631|NCT04346004|DRUG|Normal saline|"Participants in Control group are administered IV 100cc normal saline \& IM normal saline (1cc) 1 day before surgery."
41347632|NCT04346004|DRUG|Iron isomaltoside|"Participants in Iron isomaltoside group are administered IV Iron maltoside diluted in 100 cc normal saline (20mg/kg, maximum dose: 1g) \& IM Vitamin B12 (1mg) 1 day before surgery."
41347633|NCT02685449|DRUG|Insulin glulisine|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
41019241|NCT01416805|BEHAVIORAL|Treatment as usual|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
41019242|NCT00211081|DRUG|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
41019243|NCT02879461|PROCEDURE|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
41347634|NCT02685449|DRUG|Insulin aspart|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
41347635|NCT02685449|DRUG|Insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
41347636|NCT02802657|PROCEDURE|Treat-and-Extend regimen|For the T\&E regimen,investigators recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.
41347637|NCT02802657|PROCEDURE|Pro Re Nata|For the PRN group, investigators recorded patients'data after retreatment by 3 monthly intravitreal injections of Conbercept.Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four to five weeks after the third and last injection, all patients in the PRN group underwent an examination, including ETDRS visual acuity, fundus photography,and OCT. In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
41491075|NCT02155543|DRUG|AGN-223575 Formulation C|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
41491076|NCT02155543|DRUG|AGN-223575 Vehicle|One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
41491077|NCT03805646|OTHER|Mobile Phone-based Triage Tool|The proposed intervention is a mobile phone-administered survey. Participants that have been admitted to participating hospitals for treatment of injury will be contacted by mobile phone approximately two weeks after discharge. A seven-question survey will be administered over the phone to each participant. Cross-validation with a separately administered in-person physical exam will be performed to assess the survey tool's prediction of who needs further care for treatment of their injury.
41491078|NCT03402750|BEHAVIORAL|Meds to Beds|Medications will be delivered to patient bedside before discharge
40828904|NCT00106691|DRUG|Placebo|The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
41491079|NCT03402750|BEHAVIORAL|Electronic Prescription|Patient or surrogate can pick up medication from pharmacy
41347638|NCT02802657|DRUG|Conbercept|
40828905|NCT05825144|DEVICE|Robotic exoskeleton-assisted gait rehabilitation|Use a robotic exoskeleton for gait rehabilitation in addition to conventional rehabilitation
40828906|NCT05825144|OTHER|Conventional rehabilitation|Regular post-stroke rehabilitation
41347639|NCT04607291|OTHER|Community Health Service|Receive Witness CARES services
41347640|NCT04607291|OTHER|Survey Administration|Ancillary studies
41347641|NCT02184390|OTHER|On LIne Parent Training Tutorial|Interactive on line tutorial for parenting skills for autism
41347642|NCT00017524|DRUG|pelitrexol|
41347643|NCT02132689|DRUG|Actilyse (Thrombolytic therapy)|
41347644|NCT02132689|DRUG|Heparine (Standard anticoagulation therapy)|
41347645|NCT00267657|DRUG|Reserpine|
40828907|NCT05834491|DEVICE|minimal shoes and foot strengthening and flexibility exercises|Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
41019244|NCT06573086|OTHER|Resistance Training|12-week resistance training
41347646|NCT04610320|DRUG|Daratumumab-SC|\>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.
41491080|NCT02218125|BIOLOGICAL|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
41491081|NCT02218125|BIOLOGICAL|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
41491082|NCT04547530|DIETARY_SUPPLEMENT|Vitamin D|as above
41019245|NCT04242316|BEHAVIORAL|Mirror Therapy|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.
41157598|NCT06645548|OTHER|Weight estimation using 3D camera|Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
41491083|NCT04547530|DIETARY_SUPPLEMENT|Placebo|as above
41491084|NCT05897385|DRUG|Lignocaine|Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
41491085|NCT05897385|DRUG|Normal Saline|Intraperitoneal 20ml of 0.9% normal saline
40828908|NCT05834491|DEVICE|Supportive Footwear, foot orthotic device and foot flexibility exercises|sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
41491086|NCT00170664|DRUG|Paclitaxel|
41347647|NCT01172340|BEHAVIORAL|Behavioral and support intervention|Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support
41347648|NCT01172340|BEHAVIORAL|Wait-listed control group|Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
41347649|NCT05375838|BIOLOGICAL|mRNA-1073|Sterile liquid for injection
41347650|NCT05375838|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
41491087|NCT00170664|DRUG|Carboplatin|
41491088|NCT05846867|DRUG|AK119|AK119 IV every 2 weeks.intravenous infusion
41491089|NCT05846867|DRUG|AK112|AK112 IV every 2 weeks.intravenous infusion
40828909|NCT02366117|BEHAVIORAL|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
40828910|NCT00526110|DRUG|5-Fluorouracil|2.2 Gm/m\^2 IV over 48 hours on Day 1.
40828911|NCT00526110|DRUG|Docetaxel|20 mg/m\^2 IV over 60 minutes
40828912|NCT00526110|DRUG|Oxaliplatin|85 mg/m\^2 IV over 120 minutes on Day 1.
41491090|NCT05846867|DRUG|Oxaliplatin|Oxaliplatin: 85mg/m2, intravenous infusion
41491091|NCT05846867|DRUG|Irinotecan|Irinotecan 180mg/m2, intravenous infusion
41491092|NCT05846867|DRUG|Calcium folinate|Calcium folinate: 400mg/m2, intravenous infusion
41491093|NCT05846867|DRUG|Fluorouracil|Fluorouracil 400mg/m2, intravenous injection
41491094|NCT04178070|BIOLOGICAL|GB224 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
41491095|NCT04178070|BIOLOGICAL|GB224 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
40828913|NCT05858957|DRUG|Magnesium sulfate|magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M
40828914|NCT05858957|DRUG|Saline|100 ml saline infusion apply to the Group S
40828915|NCT02877654|PROCEDURE|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
41347651|NCT05375838|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
41347652|NCT05375838|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
41491096|NCT04178070|BIOLOGICAL|GB224 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
41491097|NCT04178070|BIOLOGICAL|GB224 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
41491098|NCT04178070|BIOLOGICAL|GB224 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
41491099|NCT04178070|BIOLOGICAL|GB224 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
41491100|NCT04178070|OTHER|Placebo, 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
41019246|NCT04242316|BEHAVIORAL|Bilateral arm training|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
41347653|NCT02525809|DEVICE|Novae E®|
41347654|NCT02525809|DEVICE|Sunfit®|
41347655|NCT02525809|DEVICE|Quartz®|
41347656|NCT02020304|DRUG|combined spinal epidural|Combined Spinal Epidural
41347657|NCT04143789|DRUG|AP-002|Dose escalation
41347658|NCT05570136|BEHAVIORAL|Functional Exercise|Treatment group will receive the 12-week STEP by a trained interventionist. During the intervention period, an occupational therapist will help the participant to learn the STEP exercise and principles and help the older adults to be more independent on functional exercising.
41347659|NCT05570136|BEHAVIORAL|Education|In the education group, participant will receive weekly health newsletters containing general health aging materials. A staff member will call the control group participants weekly to document any new exercise programs from usual community services.
41347660|NCT02890511|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
41347661|NCT00022906|DRUG|Iodine-131 Anti-B1 Antibody|
41347662|NCT02482415|OTHER|Psycho-educational|
41347663|NCT04814706|DIETARY_SUPPLEMENT|Carbohydrate drinking|Administration of carbohydrate fluid
41347664|NCT03080701|BEHAVIORAL|Auto Mailing Plus Money|Participant receives money as a thank you for completing CRC screening within 6 months.
41347665|NCT03080701|BEHAVIORAL|Auto Mailing Plus Lottery|Participant has a 1 in 10 chance of winning money in a lottery for completing CRC screening within 6 months.
41347666|NCT05373810|OTHER|Surgery|all interventions are allowed
41347667|NCT02565576|DRUG|Placebo|
41347668|NCT02565576|DRUG|CFZ533|
41347669|NCT04574765|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab for COVID-19
41347670|NCT04574765|OTHER|Questionnaire collection|Fill out questionnaires regarding exposures and travel history, occupation category, any symptoms in the past 21 days, any face-to-face care of a known COVID-19 positive patients in past 14 days or any children at home who are less than 12 years of age.
41347671|NCT04574765|OTHER|Optional blood completion|Provide blood samples to look for COVID-19 specific antibodies and/or proteins at the time of enrollment and after 8 weeks.
41347672|NCT04574765|OTHER|Optional questionnaire completion|Fill out an optional mental health questionnaire.
41347673|NCT02960308|RADIATION|Computed Tomography Perfusion Imaging|Undergo WNCTP scan
41347674|NCT02196090|BEHAVIORAL|Exposure and Response Prevention|A procedure where patients with OCD test out their fears without responding by compulsive act.
41347675|NCT02196090|DEVICE|Cold face gel mask|Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
41347676|NCT01594411|DIAGNOSTIC_TEST|Corus CAD|Age/Sex/Gene Expression Score (ASGES)
41347677|NCT00639496|DRUG|n-acetylcysteine|600 mg x 3, for 12 months
41347678|NCT00639496|DRUG|placebo|Placebo
41347679|NCT02158962|BEHAVIORAL|Behavioral - Education|"Behavioral - Education~3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections"
41491101|NCT04178070|OTHER|Placebo, 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
41347680|NCT04742621|PROCEDURE|Liver transplant|Eligibility for liver transplantation will be limited to patients with histologically confirmed metastatic colorectal adenocarcinoma who have achieved stability of liver metastasis on chemotherapy for at least 6 months prior to transplantation. All patients who undergo liver transplantation will start immunosuppressive therapy per protocol. Patients who undergo a successful liver transplant will not receive adjuvant therapy.
41347681|NCT03734770|DRUG|Subcutaneous Progesterone|Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).
41347682|NCT03734770|DRUG|Vaginal progesterone|Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
41347683|NCT01222416|RADIATION|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
41347684|NCT01222416|RADIATION|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
40828916|NCT04081961|DEVICE|Anamed OEM device; Air Next mobile spirometry device|Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
40828917|NCT05446792|OTHER|PFMT|The PFMT will consist of 10 maximum voluntary contractions that must be maintained for at least 6 seconds. Participants will be encouraged to sustain the maximum contraction for a longer time each week. The interval time between contractions will be the same seconds as the contraction. Participants will perform 4 sets of 10 contractions, and at the end of each set of 10 contractions, five fast contractions will be performed. Each series will be performed in one position: lying in lateral decubitus; seated; on all fours and standing.
40828918|NCT05446792|OTHER|PE|"The PE group will be instructed and reminded to voluntarily contract the PFMs during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction.~The stretching and strengthening exercises will be performed in a single series of 10 repetitions, totaling 10 exercises aimed at the main muscle groups."
40828919|NCT05703620|DEVICE|Renal Denervation|All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels
40828920|NCT04557475|DRUG|Aspirin|Two tablets daily with dinner
40828921|NCT02954419|OTHER|No intervention|No intervention
40828922|NCT04720274|DEVICE|Electromyopathy (EMG) Shorts|Participants will be asked to complete physical activities while wearing EMG shorts
40828923|NCT03026478|DRUG|Betamethasone Dipropionate|
40828924|NCT03026478|DRUG|Clobetasol Propionate|
40828925|NCT05950061|DRUG|Sertraline|Sertraline (200 mg/day) capsule
40828926|NCT05950061|DRUG|Escitalopram|Escitalopram (10 mg/day) capsule
40828927|NCT00534378|DRUG|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
41347685|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1\*10\^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
41347686|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5\*10\^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
41347687|NCT03303625|DRUG|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
41347688|NCT01200563|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
41347689|NCT01200563|DEVICE|Vacuum Assisted Closure|Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
40828928|NCT02901925|DRUG|ABY-029|Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
41347690|NCT01200563|DEVICE|MIST Therapy and Negative Pressure Wound Therapy|MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
41347691|NCT05692986|DIAGNOSTIC_TEST|A vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery is completed.|This is a randomized control trial that will compare chlorhexidine vaginal prep with iodine vaginal prep. Our primary outcome will be assessed using a vaginal swab test to look for aerobic and anaerobic cultures. Positive cultures will be defined as colony forming count of \>5000cfu. All patients will receive preoperative antibiotics. Patients will receive a vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery was completed.
41347692|NCT03817931|DRUG|Anticholinergic|Tablet taken once daily.
40828929|NCT02076360|BEHAVIORAL|Preoperative Video|Patients will watch preoperative instructional video
40828930|NCT02419131|BEHAVIORAL|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
40828931|NCT02419131|BEHAVIORAL|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
41157599|NCT02958813|BEHAVIORAL|IMARA|Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride. IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation. Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program. At the end of day 1, mothers and daughters receive homework for the week. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
41157600|NCT02958813|BEHAVIORAL|FUEL|FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
41157601|NCT06585293|DEVICE|Mitra Microsampling Device|Microsampling tool for finger-prick blood collection
41347693|NCT03817931|DRUG|Beta-3 Agonists, Adrenergic|Tablet taken once daily.
41347694|NCT03817931|DIAGNOSTIC_TEST|Functional magnetic resonance imaging (fMRI)|All subjects have fMRI at baseline and again after 30 days
41347695|NCT03817931|DIAGNOSTIC_TEST|Rey Auditory Verbal Learning Test (RAVLT)|All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
41347696|NCT06141889|DRUG|Azelaprag|oral, apelin receptor (APJ) agonist
41347697|NCT02274311|DRUG|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
41347698|NCT00159653|DRUG|Xalacom|
41347699|NCT00159653|DRUG|Xalatan|
41019247|NCT01946061|DRUG|S-1 plus oxaliplatin|Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
41019248|NCT04947397|DIAGNOSTIC_TEST|Pupillometry|Pupillometry prior to extubation
41019249|NCT05600114|DRUG|Cannabidiol oral solution|CBD 150 mg BID
41157602|NCT06052345|DEVICE|Garmin smartwatch|"* Physical activity (Activity sessions, type and length of activity, activity intensity estimations)~* Meal detection and meal characteristics (accelerometry and gyroscope data)~* Oxygen saturation (pulse oximetry)~* Number of steps (pedometer)~* Stress level indicators (based on heart-rate analytics)~* Sleep patterns (sleep and wake-up time, sleep quality)"
41157603|NCT06052345|OTHER|REBECCA Mobile application|"* GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection)~* Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3~* Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)"
41157604|NCT06052345|OTHER|REBECCA PC plug-in|"* the developed plug-in monitors online activity, collecting anonymized data from web-browsers (Chrome) and social media (Facebook, Youtube and Instagram).~* These are relevant to current and historical data on: i) keywords in searches, ii) types of websites visited, iii) reactions to posts, iv) participation in online groups, v) types of bookmarked websites"
41019250|NCT05600114|DRUG|Cannabidiol oral solution|CBD 300 mg BID
41347700|NCT00159653|DRUG|Timolol|
41019251|NCT05600114|DRUG|Placebo|Placebo BID
41347701|NCT06392867|DEVICE|intermittent theta-burst stimulation (iTBS)|"iTBS treatment will be performed as comprising 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. Repeat trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20) which equals the standard number of pulses in a daily iTBS treatment session, as approved by the FDA. The stimulation site over the left DLPFC will be determined using the international 10-20 system for EEG electrodes corresponding to the F3 location. 20 daily treatment sessions will be performed from Mondays to Fridays for four weeks for all included patients.~Treatments will be performed at the brain stimulation laboratory at the Hong Kong Polytechnic University. Stimulation will be delivered using a MagPro X100 model (details about MagPro X100: magventure.com/en_eur/products/magpro-x100/ ) and a Cool-B70 A/P Butterfly Coil, available at each participating centre."
41491102|NCT04178070|OTHER|Placebo, 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
41491103|NCT04178070|OTHER|Placebo, 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
41019252|NCT04682600|DEVICE|Liver Incytes System|The Liver Incytes System uses the Shear Wave Absolute Vibro-Elastrography (S-WAVE) method. The imaging procedure of the Liver Incytes system is similar to a traditional ultrasound scanning procedure or FibroScan, in which the patient is asked to lie supine on an examination bed, with the operator seated next to them. A vibration source is placed under the patient, between the patient and the bed to induce shear waves in the liver. Ultrasound imaging through the patient ribs is used to track the displacements of these waves. Through tracking of the displacements, the shear wave velocity and tissue stiffness can be calculated. The use of volumetric multi-frequency imaging increases the amount of liver scanned
40828932|NCT02419131|BEHAVIORAL|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
41347702|NCT06503133|OTHER|Birth preparation training|Birth preparation training is based on Albert Bandura's self-efficacy theory. It is a 60-minute training once a week. The first 10 minutes of the training are devoted to the initial activity, 40 minutes to sharing the training content, and 10 minutes to answering the participants' questions and receiving feedback. The training will be conducted in closed groups via the online meeting program (Zoom®).
41347703|NCT06503133|OTHER|Prenatal yoga practice|Prenatal yoga practice is a 60-minute practice once a week. The first 5 minutes of the prenatal yoga practice are devoted to guided meditation, 40 minutes to active asanas (yoga pose), 5 minutes to pranayama practice (breathing exercise) and 10 minutes to savasana (relaxing yoga pose). Prenatal yoga practice will be conducted in closed groups via the online meeting program (Zoom®)
41347704|NCT03285061|DEVICE|Deterra Drug Deactivation System|A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
41347705|NCT04128072|DRUG|Mogamulizumab|• Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
41347706|NCT04128072|RADIATION|Total Skin Electron Beam Therapy (TSEB)|"* After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).~* In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.~* If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.~* Mogamulizumab is stopped during TSEB administration."
41347707|NCT04128072|DRUG|Mogamulizumab (subsequent cycles post TSEB)|"• Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.~Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion."
41347708|NCT03827980|OTHER|no intervention, only clinical examination|standardised interview and clinical examination
41347709|NCT05256290|DRUG|BDTX-1535 monotherapy|BDTX-1535 is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
41019253|NCT01336738|DRUG|Placebo|Tablets (n=6), 0 mg, once daily for 84 days
41157605|NCT05584761|DRUG|unrelated umbilical cord blood|"A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion 24-72 hours after the end of injection."
41347710|NCT04290403|DEVICE|Pull Ups|Participants will be asked to wear pull-ups continence products for the duration of four weeks
41347711|NCT04290403|DEVICE|Styled Briefs with tapes|Participants will be asked to wear styled briefs with tapes for the duration of four weeks
41347712|NCT06041191|DIAGNOSTIC_TEST|Assessment|The children included in the study were evaluated in terms of hypermobility and then divided into two groups. Children in both groups were evaluated in terms of sensory processing skills.
41347713|NCT03525821|DRUG|Ketamine Hydrochloride|intranasal use of ketamine 1mg/kg with nitrous oxide
41347714|NCT01081951|DRUG|olaparib|Tablets Oral BID
41347715|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
41347716|NCT01081951|DRUG|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
41347717|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
41347718|NCT01081951|DRUG|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
41347719|NCT04683952|DEVICE|Exercise training with Humified High Flow Nasal Cannula|The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.
41347720|NCT04683952|OTHER|Exercise training - Control Group|The control group will perform exercise training in spontaneous breathing.
41347721|NCT01660529|BIOLOGICAL|hTERT|
41347722|NCT04451694|OTHER|nutritional intervention|nutritional evaluation and intervention and orientation towards adapted care establishment
41347723|NCT00004833|DRUG|Immune globulin|
41347724|NCT03968588|DRUG|Tacrolimus(reduced), Mycophenolate mofetil(standard)|tacrolimus target trough blood level: 3\~8ng/mL MMF dose: 1.5\~2g/d
41347725|NCT03968588|DRUG|Tacrolimus(standard), Mycophenolate mofetil(reduced)|tacrolimus target trough blood level: 5\~15ng/mL MMF dose: 0.5\~1g/d
41347726|NCT00141206|DRUG|varenicline (CP-526,555)|
41347727|NCT00948194|DRUG|Nitric Oxide|Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
41347728|NCT00099840|PROCEDURE|Procalcitonin guided antibiotic therapy|
41347729|NCT03566992|PROCEDURE|Gastric|Placement of a nasoenteric tube
41347730|NCT02513355|BIOLOGICAL|Endostar|Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
41347731|NCT02513355|DRUG|Changchun marina|25mg/m2,d1 and d8,q21d×4
41347732|NCT02513355|DRUG|cisplatin|80mg/m2,d1, q21d×4
40828933|NCT05944562|DRUG|Tulmimetostat|Patients should take CPI-0209 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following CPI-0209 dosing). Each dose of CPI-0209 should be taken with a glass of water and consumed over as short a time as possible.
41347733|NCT02513355|DRUG|Taxol|135-175mg/m2,d1,q21d×4
41491104|NCT04178070|OTHER|Placebo, 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
41491105|NCT04178070|OTHER|Placebo, 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
41491106|NCT00085423|BIOLOGICAL|aldesleukin|‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course
41491107|NCT00085423|BIOLOGICAL|sargramostim|GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.
41491108|NCT00085423|DRUG|cyclophosphamide|Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.
40828934|NCT00527020|DRUG|GSK1018921|GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
41347734|NCT02513355|DRUG|parapl|AUC=5-6,d1,q21d×4
41347735|NCT01321658|OTHER|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
41347736|NCT02308553|DRUG|Nintedanib|Nintedanib (150 mg or 200 mg BID)
41347737|NCT02308553|DRUG|Nintedanib-Placebo|Placebo (150 mg or 200 mg BID)
41347738|NCT02308553|DRUG|Paclitaxel|Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
41347739|NCT02892734|BIOLOGICAL|Ipilimumab|Given IV
41347740|NCT02892734|OTHER|Laboratory Biomarker Analysis|Correlative studies
41491109|NCT00085423|DRUG|fludarabine phosphate|Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3
41491110|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
40828935|NCT00527020|DRUG|Nicotine Lozenges|Nicotine Lozenges will be supplied as 4 milligrams lozenges.
40828936|NCT00527020|DRUG|Placebo|Placebo tablets will be given to the subjects.
41347741|NCT02892734|BIOLOGICAL|Nivolumab|Given IV
41347742|NCT01774227|PROCEDURE|The pops-titration group|The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
41347743|NCT01774227|PROCEDURE|The slow-coagulation group|The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
41491111|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
41491112|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
41491113|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
41491114|NCT01675661|DRUG|N-Acetylcysteine|Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
41491115|NCT01675661|DRUG|Placebo|Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
41491116|NCT06194032|DRUG|Baxdrostat|Participants will receive baxdrostat as two separate doses.
41491117|NCT06194032|DRUG|Placebo|Participants will receive baxdrostat matching placebo.
41491118|NCT06194032|DRUG|Moxifloxacin|Participants will receive a single dose moxifloxacin
41491119|NCT04930419|DEVICE|Videolaryngoscopy group|Tracheal intubation will be performed using Videolaryngoscope in first intention and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
41509043|NCT04833530|DIAGNOSTIC_TEST|Gastric Ultrasound|"In the operating room, a gastric ultrasound will be performed in the supine position and the antral cross sectional area will be measured. Anesthesia will be induced in standard procedure and positive pressure will be instituted according to the standard protocol accepted in our hospital.~At the end of the procedure, the gastric ultrasound circumference will be measured again."
41509044|NCT06440993|DRUG|Gemcitabine|Gemcitabine, 1,000 mg/m2 IV
41509045|NCT06440993|DRUG|Cisplatin|Cisplatin, 25 mg/m2 IV
40828937|NCT00612742|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
40828938|NCT00612742|DRUG|placebo gel|once daily transdermal placebo gel
40828939|NCT04811105|PROCEDURE|steam ablation|32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
40828940|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up with wearable devices|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
41019254|NCT01336738|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
41019255|NCT01336738|DRUG|450 mg PF-04991532|Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
41019256|NCT01336738|DRUG|750 mg PF-04991532|Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
41019257|NCT01336738|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
41019258|NCT02370888|DRUG|Lenalidomide|Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
41347744|NCT02672306|BIOLOGICAL|UCMSCs|Biological: Human UCMSCs 20 million cells per subject (0.5×10\^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
41347745|NCT02672306|BIOLOGICAL|Placebo|Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
41347746|NCT03501381|DRUG|Entinostat|Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
41347747|NCT03501381|DRUG|Interleukin-2|In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
41347748|NCT00957060|DRUG|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
41157606|NCT02640807|DRUG|Interleukin-7|IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) \>2.5 or platelet count \< 35,000
41347749|NCT00957060|DRUG|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
40828941|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up in traditional ways|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
41491120|NCT04930419|DEVICE|Direct laryngoscopy group|Tracheal intubation will be performed using Direct laryngoscopy with Macintosh blades in first intention. and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
40828942|NCT03958591|DRUG|Traditionally upgrading therapy, followed up in traditional ways|The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
40828943|NCT00005013|DRUG|Sertraline|
40828944|NCT00005013|DRUG|Hypericum perforatum (St. John's wort)|
40828945|NCT03551977|BEHAVIORAL|iCanCope with Pain|The participants are free to use the Norwegian iCanCope with Pain app as much as they want during the 8 week intervention period. The only support available is technical support.
40828946|NCT03551977|BEHAVIORAL|iCanCope with Pain control|The participants are free to use the Norwegian iCanCope with Pain control app as much as they want during the 8 week intervention period. The only support available is technical support.
40828947|NCT04615260|DEVICE|NanoBone|Nanobone® Synthetic Bone Graft is a nanocrystalline hydroxyapatite imbedded in a silica gel matrix. The nanocrystalline structure accurately replicates autologous hydroxyapatite and the silica gel matrix that rapidly transforms into an osteogenic matrix post-implantation. NanoBone promotes remodeling by acting as a strong osteoinductive material. NanoBone® is available as a putty.
40828948|NCT03008135|OTHER|Elderly Mobility Scale|The Elderly Mobility Scale was devised to assess the mobility of fragile elderly people, and contains seven items considered as essential for performing the basic activities of the daily routine: Lying down to sitting, sitting to lying down, sitting to standing, standing, Gait/ work on body posture, timed walk (6 meters) and work on Functional Reach/movements?
40828949|NCT03008135|OTHER|Frailty scale|"6 questions are asked to the person about his or her living conditions to determine the level of frailty. The scale is produced by the board High Health Authority"
41347750|NCT03194672|BEHAVIORAL|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
41347751|NCT06146140|DIETARY_SUPPLEMENT|Oral herbal supplement|Take one capsule daily
41347752|NCT06146140|DIETARY_SUPPLEMENT|Oral placebo supplement|Take one capsule daily
41347753|NCT04096404|GENETIC|Genotype- based personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their genotype via email
41347754|NCT04096404|BEHAVIORAL|Non genetic personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
40828950|NCT04384380|DRUG|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
41019259|NCT04318210|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
41019260|NCT03762135|OTHER|Full version of the LIITah App.|Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.
41019261|NCT03762135|OTHER|Partial App. (ELI and SNAP only)|Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
41019262|NCT02248922|DRUG|TIS or TIP|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
41019263|NCT01831687|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
41019264|NCT01831687|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
41157607|NCT02640807|DRUG|Placebo|IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
41347755|NCT01680562|OTHER|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
41347756|NCT03809156|DRUG|Riociguat Oral Product|Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
41347757|NCT06446830|DRUG|multimodal analgesia and vitamin B|B1, B6 , B9 , B12 in addition to the routine paracetamol and NSAID
40828951|NCT04932603|OTHER|Standard of care, with intervention of the multidisciplinary team|Patients with AF, aged of 75 years or more, with evaluation of their antithrombotic treatment by the multidisciplinary team. The review of patient's file by the multidisciplinary team is based on physician decision. These patients are hospitalized in one of the 6 geriatrics units participating in the study and / or are hospitalized in another ward but their clinical file is reviewed by the multidisciplinary team.
41347758|NCT06446830|DRUG|standard multimodal analgesia|Routine Paracetamol and NSAID
41347759|NCT01537523|PROCEDURE|community-care program|community nurse care, physiotherapy
41347760|NCT05626465|OTHER|Blood test|Proteomic analyses on serum
41347761|NCT01957215|DRUG|Indomethacin|Topical indomethacin
41347762|NCT01957215|DRUG|Placebo|Placebo patch
41347763|NCT03097497|OTHER|Physiotherapy re-education program|Physiotherapy Program based on the Re-education of Pre-activation of the Transverse Abdominal Muscle
41347764|NCT03097497|OTHER|Conventional treatment by GP|Patients will follow the general practitioner's advice including medication if needed
41347765|NCT02981173|DRUG|0.143 mg/kg Psilocybin or 10 mg Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
41347766|NCT02981173|DRUG|0.0143 mg/kg Psilocybin or 1 mg Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
41347767|NCT02981173|DRUG|Placebo|Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
41347768|NCT00005555|BEHAVIORAL|Exercise|
41347769|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 \& -5), fludarabine (25 mg/m2 days -7, -6, \& -5) and total body irradiation (days -3, -2, \& -1, total 1200 cGy) followed by cord blood infusion on day 0.
41347770|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 \& -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4), total body irradiation (days -3 \& -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
40828952|NCT01312389|BIOLOGICAL|OC-L/Montanide ISA 51 VG|All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.
40828953|NCT01312389|BIOLOGICAL|Ampligen|All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.
40828954|NCT01312389|BIOLOGICAL|Prevnar|A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
40828955|NCT00034229|DRUG|Felbamate|
40828956|NCT00612859|DRUG|levetiracetam|
41157608|NCT06646887|OTHER|Electroporation|Unlike traditional thermal ablation techniques such as radiofrequency (RF) and cryoablation, the electroporation systems used in this study rely on pulsed electric fields (PEF) to selectively target and ablate cardiac tissue. This non-thermal mechanism reduces the risk of collateral damage to nearby structures, such as the esophagus, phrenic nerve, and coronary arteries.
40828957|NCT03397134|DRUG|Placebo Oral Tablet|Placebo administered as a single dose once daily
40828958|NCT03397134|DRUG|Roluperidone 32 mg|Roluperidone administered as a single dose once daily
41347771|NCT03080441|DEVICE|pressure stockings|pressure stockings worn during dialysis throughout treatment period
41347772|NCT03080441|DRUG|Midodrine|administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.
41347773|NCT03080441|OTHER|pressure stockings and midodrine|combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period
41347774|NCT01228838|DRUG|NGX-1998|Capsaicin topical liquid to be applied for 5 minutes one time only.
41347775|NCT01228838|DRUG|Placebo Liquid|Placebo topical liquid to be applied for 5 minutes one time only.
41347776|NCT02896751|DEVICE|3D printed NIV mask|use of 3D printed mask
41347777|NCT02006394|DIETARY_SUPPLEMENT|Fish Oil|fish oil capsules
41347778|NCT02006394|DIETARY_SUPPLEMENT|Polyphenol Capsules|delphinidin polyphenol capsules
40828959|NCT03397134|DRUG|Roluperidone 64 mg|Roluperidone administered as a single dose once daily
40828960|NCT01905722|OTHER|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
40828961|NCT01905722|OTHER|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
41157609|NCT01369147|DRUG|Parenteral Nutrition|The PN dose will be written for each 24-hr period taking into account any kilocalories (kcal) provided as part of standard of care from propofol, clevidipine, dextrose-containing IV fluid exceeding 500 mL/day, and enteral feedings.
41347779|NCT02006394|DIETARY_SUPPLEMENT|Corn Oil Capsules|Corn Oil Capsules
41347780|NCT02006394|DIETARY_SUPPLEMENT|Corn starch capsules|Maltodextrin capsules
41347781|NCT02006394|OTHER|Reduced glycemic index bread products|Made by Zone Labs
41347782|NCT02006394|OTHER|Market variety bread products|placebo bread products
41347783|NCT00003992|BIOLOGICAL|trastuzumab|
41347784|NCT00003992|DRUG|cyclophosphamide|
41347785|NCT00003992|DRUG|doxorubicin hydrochloride|
41347786|NCT00003992|DRUG|paclitaxel|
41347787|NCT00003992|DRUG|tamoxifen citrate|
41347788|NCT02233608|BEHAVIORAL|Advanced Pelvic Floor Muscle Exercise (APFX)|
41347789|NCT05905679|DIETARY_SUPPLEMENT|Dietary Supplement: Probiotics|6 Billion CFU
41347790|NCT05905679|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|0 CFU per day
41347791|NCT01762592|DRUG|Iodine (124I) Girentuximab|i.v.
41347792|NCT02073227|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
41347793|NCT02073227|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
41347794|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
41347795|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
41347796|NCT04135391|BEHAVIORAL|Aerobic exercise training|All recruited subjects underwent 36 times of moderate-intensity continuous training (MICT) at 60% of peak oxygen consumption (VO2peak) for 30 mins, and 10or had high-intensity interval training (HIIT) at alternative 80% and 40% VO2peak with the same training times and duration.
41347797|NCT00146224|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
41347798|NCT00146224|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
41347799|NCT00005054|DRUG|temozolomide|
41347800|NCT02729402|OTHER|Cognitive Testing|We will use a battery of neurocognitive tests to assess cognitive function before and after surgery
41347801|NCT01289561|DRUG|Alcohol + Caffeine Beverage|14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
41347802|NCT01289561|DRUG|Alcohol + Caffeine-placebo|14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
41157610|NCT01369147|DRUG|Propofol|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL).
41157611|NCT01369147|DRUG|Clevidipine|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in clevidipine (2 kcal/mL).
41157612|NCT01369147|DRUG|Dextrose-containing IV Fluids|The PN dose will be written for each 24-hr period taking into account calories provided from dextrose-containing IV fluid orders exceeding 500 mL/day.
41157613|NCT01369147|DRUG|Enteral feeding|Enteral nutrition is caloric intake through the gastrointestinal (GI) tract via food consumed through the mouth or a feeding tube delivering nutrition directly to the stomach or small intestines. The PN dose will be written for each 24-hr period taking into account calories provided from any enteral feedings.
41347803|NCT05837234|DEVICE|ULF SCS|Ultra low frequency spinal cord stimulation
41347804|NCT04717167|OTHER|Dry Needling|
40828962|NCT05066646|DRUG|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
40828963|NCT05648149|BEHAVIORAL|hierarchical multi-dimensional cognitive training scheme based on computer|The scheme was constructed five main categories of cognitive function: (1) attention, memory, numeracy, thinking response and perception; (2) There are 10 training items, which are drawing, quick matching, flash memory, number memory, face memory, color tracking, number span, word naming, symbol number form, quick arithmetic; (3) Each training item is divided into basic and advanced training. Only if the basic training reaches more than 80%, can the advanced training be entered; (4) In order to facilitate patient training, all items were embedded in the wechat mini program, and corresponding cognitive training was carried out in the mini program; (5)Small program background can monitor training results.
41347805|NCT04717167|OTHER|Sham Needling|
41347806|NCT00086242|BEHAVIORAL|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, \~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
41491121|NCT05445674|COMBINATION_PRODUCT|Plasma Exchange Procedure|Plasma exchanges will be performed with 5% albumin as the replacement fluid. The typical schedule prescribed will be an exchange of 1 volemia. Blood will be separated into cells and plasma; the cells will be combined with reconstituted 5% human serum albumin and reinfused into the patient with normal saline
40828964|NCT04270058|DRUG|inotersen|TEGSEDI injection, for subcutaneous use
40828965|NCT00892359|DRUG|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
41347807|NCT05905601|BEHAVIORAL|NORTH|NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.
41347808|NCT05905601|BEHAVIORAL|"NORTH Lite"|"NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources."
41347809|NCT01424267|DEVICE|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
41347810|NCT05575024|DEVICE|oXiris membrane|Perform continuous renal replacement therapy with oXiris membrane
41347811|NCT05575024|DEVICE|Polysulfone membrane|Perform continuous renal replacement therapy with polysulfone membrane
41347812|NCT00599222|BIOLOGICAL|ranibizumab|0.5 mg intravitreal injection
41347813|NCT00599222|PROCEDURE|TTT|Transpupillary thermotherapy (TTT)
41347814|NCT00599222|PROCEDURE|Sham TTT|Sham Transpupillary thermotherapy (TTT)
41347815|NCT06322589|DIETARY_SUPPLEMENT|SOD like Super Drink|consume 1 bottle per day
41347816|NCT06322589|DIETARY_SUPPLEMENT|placebo drink|consume 1 bottle per day
41347817|NCT04261218|DRUG|tomivosertib|Tomivoserib is supplied as a 100 mg capsule, to be taken orally.
41347818|NCT04261218|DRUG|paclitaxel|Taken weekly according to the current market label in combination with experimental tomivosertib.
41347819|NCT02367690|DRUG|Selinexor|Topical gel
41347820|NCT02367690|OTHER|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
41347821|NCT02367690|OTHER|Vehicle Gel|Topical vehicle gel with no active ingredients.
41157614|NCT05329649|BIOLOGICAL|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
40828966|NCT02744612|DRUG|Brentuximab Vedotin|Given IV
40828967|NCT02744612|DRUG|Ibrutinib|Given PO
40828968|NCT01617135|DRUG|CVT-301|
40828969|NCT01617135|DRUG|Placebo|
40828970|NCT01617135|DRUG|Sinemet (carbidopa/levodopa)|
41157615|NCT04245839|DRUG|Fludarabine|Fludarabine
41157616|NCT04245839|DRUG|Cyclophosphamide|Cyclophosphamide
41157617|NCT04245839|DRUG|JCAR017|JCAR017
41157618|NCT00124137|DEVICE|Aquadex system|
41157619|NCT00124137|DRUG|IV diuretic|
41347822|NCT03476928|DRUG|Vilaprisan (BAY1002670)|2mg, once daily, oral
41347823|NCT02835235|DRUG|NNC9204-0530|Administered daily subcutaneously (s.c., under the skin)
41347824|NCT02835235|DRUG|placebo|Administered daily subcutaneously (s.c., under the skin)
41347825|NCT00345956|BIOLOGICAL|Human rotavirus liquid vaccine|
41347826|NCT03380169|OTHER|Prophylactic advance wound dressing|A combination of dressing including occlusive moist wound dressing to provide a barrier from the external environment and silver-containing dressing to reduce the inflammation of wounds and promotes healing
41347827|NCT03380169|OTHER|Prophylactic conventional wound dressing|Conventional gauze dressing
41347828|NCT03708484|OTHER|Aerobic Interval Training|"Aerobic Interval Training Patients in this group will perform 6 minutes of cycling followed by 3 minutes of pause and again 6 minutes of cycling followed by 3 minutes of pause and finally 6 minutes of treadmill followed by 3 minutes of rest.~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
41347829|NCT03708484|OTHER|Aerobic + Resistive Interval Training|"Aerobic + Resistive Interval Training Patients in this group; first set will perform 3 minute of cycling ,1 set of hand grippers 1.5 to 2.5 lbs (10 to 12 reps) and 1 set of biceps resistive exercises 1 Kg to 3 kg (10 to 12 reps) followed by 3minute of pause. In second set patient will perform 3 minutes of stationary cycling , 1 set of quadriceps resistive exercises 1 to 3 Kg (10 to 12 reps) again followed by 3 minutes of pause and in third set patient will perform 3 minutes of treadmill walk at 1.5 to 4 speed, and 1 set of standing ankle pumps (10 to 12 reps).~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
41347830|NCT02912741|DRUG|Vanish xt Extended Contact Varnish|resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
41347831|NCT02912741|DRUG|resin infiltration|low viscous light cure resin applied in layers and cured
41347832|NCT03875872|DRUG|Propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
41347833|NCT03875872|DRUG|inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
41347834|NCT05405855|BEHAVIORAL|eLIFEwithIBD|eLIFEwithIBD program is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients.
41347835|NCT00133185|DRUG|telmisartan 40 mg/hydrochlorothiazide 12.5 mg|
41347836|NCT00133185|DRUG|losartan 50 mg/hydrochlorothiazide 12.5 mg|
41347837|NCT03946644|DEVICE|EVLA with keeping of securuty distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
41347838|NCT03946644|DEVICE|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
41347839|NCT02410746|OTHER|targeted chirocaine pec block|10ml 0.25% chirocaine in a specifically targeted in a nerve block
41347840|NCT02410746|OTHER|standard chirocaine infiltration|10ml 0.25% chirocaine is infiltrated into breast pocket in a non targeted fashion
41347841|NCT02410746|OTHER|standard post-operative analgesia|A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.
41509046|NCT06440993|DRUG|Durvalumab|Durvalumab, 1,500 mg IV
41509047|NCT06440993|PROCEDURE|ID-RFA|endoscopic intraductal RFA
41347842|NCT02628366|OTHER|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
40828971|NCT01617135|DRUG|CVT-301|
41347843|NCT05439304|OTHER|No intervention|No intervention
41347844|NCT02150291|DIETARY_SUPPLEMENT|Folic acid|
41347845|NCT02150291|DRUG|Neurobion|
40828972|NCT06185634|OTHER|Dietary intervention - Pasta at dinner|"The pasta at dinner nutritional intervention will consist, as the name suggests, in eating pasta at dinner for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
40828973|NCT06185634|OTHER|Dietary intervention - Pasta at lunch|"The pasta at lunch nutritional intervention will consist, as the name suggests, in eating pasta at lunch for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
40828974|NCT05683574|DRUG|FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo|Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
40828975|NCT05683574|DRUG|etoricoxib 90 mg (Arcoxia®) +FDC placebo|Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
40828976|NCT05683574|DRUG|cyclobenzaprine hydrochloride + etoricoxib placebo|Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
40828977|NCT03688698|RADIATION|PET/MRI|PET/MRI scans
40828978|NCT01754298|PROCEDURE|Retro-articular drilling|"* Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.~* Use a 0.045 K-wire for drilling.~* Minimum of 8 wire passes per square centimeter with no maximum number of wire passes."
40828979|NCT01754298|PROCEDURE|Trans-articular drilling|"* Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)~* Use a 0.045 K-wire for drilling~* A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter"
41019265|NCT04401007|OTHER|Erector Spinae Plane Block with 1.5% lidocaine|Erector spinae plane (ESP) block is a new regional nerve block technique that involves a percutaneous injection of local anesthetic as a bolus through a needle or catheter into the fascial plane between the erector spinae muscle and the transverse processes in the upper or mid back.
40828980|NCT00849602|DRUG|Placebo|Placebo bid for three days
40828981|NCT00849602|DRUG|Chloroquine|Chloroquine bid for three days
40828982|NCT04976218|BIOLOGICAL|TGFβR-KO CAR-EGFR T Cells|Enrolled patients will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner. The infused CAR+ T cell dose in phase IA will be started initially at 1-2×10\^5/kg, dose 2 will be 1×10\^6/kg，and dose 3 will be 1×10\^7/kg, if DLT occurs in dose level 3, the following dose will return to 5×10\^6/kg. In expansion period, the dose of infused CAR+ T cells will be determined by the recommended cell dose from phase IA.
40828983|NCT03943550|DRUG|RO7049665|Multiple ascending doses of RO7049665 will be administered SC.
40828984|NCT03943550|DRUG|Placebo|Matching placebo will be administered SC.
41019266|NCT04121403|BIOLOGICAL|Rituximab|Biosimilar rituximab concentrate for solution for infusion
41019267|NCT04121403|DRUG|Cladribine|Mavenclad oral cladribine tablets
41019268|NCT04657159|OTHER|Pain rehabilitation program|Effect on health related quality of life och health-care consumption after rehabilitation
41019269|NCT03239041|BEHAVIORAL|Social navigation team|Social navigation team
41019270|NCT05789875|OTHER|aDOT-CEI|For the design and development of the mobile health app, we have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence and track incentives for this behavior in real-time.
41347846|NCT02150291|DRUG|placebo|
41347847|NCT03092622|OTHER|Exercise|Exercise training intervention as described earlier.
41347848|NCT03564210|BEHAVIORAL|Screen time permitted|Cohort will not be directed to abstain from screen time
41347849|NCT03564210|BEHAVIORAL|Screen Time Abstain|Cohort will be directed to abstain from screen time
41347850|NCT05565599|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.
41347851|NCT00263406|DRUG|Administration of an ACE-inhibitor or not|
41347852|NCT03398174|BEHAVIORAL|Motor Control Exercise|"Exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
41019271|NCT03502603|DIAGNOSTIC_TEST|Railroad Test|This is a test designed to evaluate visual perception capacities and requires the participant to match photographs with railroads as a central theme. The participant is presented with a photograph image at the top of the screen and is asked to match it to one of the two, three or four choices in the lower portion of the display.
41019272|NCT03502603|DIAGNOSTIC_TEST|Swamp Test|This is a test of immediate visual memory/attention for photographs with swamp wetlands as a central theme. The participant is briefly presented with a photograph which is replaced by two, three or four choices, one of which the participant is asked to select as the initially presented image.
41347853|NCT03398174|BEHAVIORAL|Patient Education|"Patient education to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
41347854|NCT03709940|DRUG|MPH|Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.
41347855|NCT02074397|PROCEDURE|Distant extrafascial injection|
41491122|NCT05445674|OTHER|Sham Plasma Exchange Procedure|For sham plasma exchange procedures, a sound behind the curtain will be performed imitating the sound of the cell processing platform. In these cases, only one infusion of 200 to 250ml of sterile saline solution 0.9% will be performed during the time stablished for all procedures. Albumin will not be necessary for those patients in the Sham plasma exchange arm
41491123|NCT01830491|DRUG|Clopidogrel|
40828985|NCT01099657|BEHAVIORAL|Virtual Reality Hypnosis for chronic pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
40828986|NCT01099657|BEHAVIORAL|Virtual Reality Distraction for Chronic Pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
40828987|NCT02516826|DRUG|Rosuvastatin|
41019273|NCT03502603|DIAGNOSTIC_TEST|Presidents Recognition Test|This is a test of history knowledge and facial recognition using pictures of US presidents and non-president distractors. The participant is presented with two photographs and is asked to identify which is the picture of a US president
41019274|NCT03502603|DIAGNOSTIC_TEST|Judgment of Line Orientation|This test requires participants to visually match the orientation of line segments. This is a test of visual perception and was included as a relative equivalent of the Railroad Test.
41019275|NCT03502603|DIAGNOSTIC_TEST|Symbol Span subtest of the Wechsler Memory Scale-IV|This test requires participants to immediately recall a sequence of designs after a brief presentation. This is a test of immediate visual memory/attention and was included as a relative equivalent of the Swamp Test
41347856|NCT02074397|PROCEDURE|Subfascial injection|
41491124|NCT01830491|DRUG|aspirin 100mg|
41491125|NCT06040775|DEVICE|Theta Burst Transcranial magnetic Stimulation using real MCF-B65 coil|"Site of stimulation will be predetermined at Dorsolateral prefrontal cortex of non-dominant side using the BeamF3 method.1 burst will be - 3 pulses at 50 Hz, burst will be set at 5Hz i.e. interburst interval 200ms .~At100% of resting motor threshold of dominant side - 5 trains (each 40sec on and 20 sec off) will be given at each session with a pause of 1 minute in between 2 trains Standard therapy with Applied Behavior Analysis and sensory integration would continue"
40828988|NCT02516826|DRUG|Olmesartan|
40828989|NCT02516826|DRUG|Combination|Rosuvastatin/Olmesartan(Combination)
40828990|NCT02516826|DRUG|Placebo of Rosuvastatin|
40828991|NCT02516826|DRUG|Placebo of Olmesartan|
40828992|NCT02516826|DRUG|Placebo of Rosuvastatin/Olmesartan(Combination)|
40828993|NCT00257595|DRUG|Cetirizine Dry Syrup|
41157620|NCT00990821|DRUG|90 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
40828994|NCT04463628|BEHAVIORAL|Questionnaire|"The study questionnaire was constructed as follows:~* One part is composed of validated questionnaires: Cystic fibrosis specific self-questionnaire for quality of life, questionnaire for screening for anxiety disorder.~* The other part, which was not validated, was constructed as follows: questionnaire on knowledge of Covid-19 adapted to the new exceptional situation (Covid-19 pandemic) and specific questions adapted to the research objective on Covid-19 from the questionnaire of the French Public Health survey, to monitor changes in behaviour and mental health during lockdown"
41019276|NCT03502603|DIAGNOSTIC_TEST|Information subtest of the Wechsler Adult Intelligence Scale-IV:|This test requires participants to answer factual knowledge questions. This is a test of fund of knowledge and was included as a verbal equivalent for the non-verbal Presidents Recognition Test.
41019277|NCT03502603|DIAGNOSTIC_TEST|Digit Span subtest of the Wechsler Adult Intelligence Scale-I|This test requires the participant to repeat sets of digits forward, backward, and to sequence digits in ascending order. This is a test of immediate memory/attention and was included to investigate possible attentional correlates of the Swamp Test. This test includes a performance validity indicator that will permit analyses of validity indicators included with the experimental tests
41019278|NCT03502603|DIAGNOSTIC_TEST|Reading subtest of the Wide Range Achievement Test|This test requires participants to read words printed on a card. This is a test of word knowledge/academic achievement and was included to investigate the academic achievement concomitants of the Presidents Recognition Test.
40828995|NCT04463628|BEHAVIORAL|Interview|Two interviews in the human and social sciences, conducted by recorded video-conference, will be proposed to 15 patients during and after the lockdown.Two interviews will take place: one during the lockdown and one at 6 months from the first interview (or at the end of the confinement if it lasts more than 6 months). The interviews will be conducted independently of the results of the questionnaire.
40828996|NCT03279523|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
40828997|NCT00892606|DRUG|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
40828998|NCT00892606|DRUG|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
41019279|NCT03502603|DIAGNOSTIC_TEST|Symbol Digit Modalities Test:|This test requires participants to visually match abstract symbols with numbers within a certain time period. The participant either verbalizes or writes the response on an answer sheet. This is a test of speed of information processing and was included to assess speed of response factors pertaining to all of the experimental tests as reflecting speed of information processing.
41019280|NCT03502603|DIAGNOSTIC_TEST|Dot Counting Test|This test requires participants to count arrays of dots presented on a card while being timed. This is a performance validity test and was included to ascertain validity factors pertaining to each of the experimental tests.
41019281|NCT00358267|PROCEDURE|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
41019282|NCT00358267|PROCEDURE|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
41157621|NCT00990821|DRUG|100 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
41347857|NCT03422757|DEVICE|adaptive Deep Brain Stimulation|"The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal."
41347858|NCT03422757|DEVICE|conventional Deep Brain Stimulation|"The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation."
41347859|NCT03206983|DEVICE|Cana's Ring|The device is used during cataract surgery to help dilate small pupils (under 5mm)
41347860|NCT00470873|DRUG|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
41347861|NCT01118884|DRUG|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
40828999|NCT03184610|DEVICE|OCT-scanning|All participants will be scanned with a OCT-device
40829000|NCT04109131|OTHER|Samples collection: Plasma|"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Every 3 months (+/- 1 month)"
41019283|NCT01534468|BIOLOGICAL|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
40829001|NCT04109131|OTHER|Samples collection: CSF|Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice
40829002|NCT04109131|OTHER|Samples collection: Non-CNS Metastatic Tumour Tissue|Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis
41019284|NCT01195467|DRUG|Truvada/Raltegravir|All subjects currently on Atripla® will switch to Truvada/Raltegravir
41019285|NCT06367582|DEVICE|Vertebroplasty (VP)|Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
41019286|NCT06367582|DEVICE|Kyphoplasty (KP)|Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
41347862|NCT05843344|DRUG|erector spinae plane block with a combination of ropivacaine and morphine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. Serratus Anterior Plane Block (SAPB) will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine + 2 mg (1mL) of morphine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 6 mg of morphine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
41347863|NCT05843344|DRUG|erector spinae plane block with a combination of ropivacaine and dexmedetomidine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +0.5 mcg/kg (1mL) of dexmedetomidine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 200 mcg of dexmedetomidine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
41019287|NCT06367582|DEVICE|Pedicular Screw Augmentation (PSA)|Pedicular Screw Augmentation is a procedure in which a special medical-grade cement mixture is injected into pedicular screws in order to augment fixation strength
41019288|NCT05949086|BEHAVIORAL|Work Chat|Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
41019289|NCT05902845|DRUG|RD13-02 cell infusion|CAR-T cells
41019290|NCT00141960|DRUG|Famotidine|
41019291|NCT00374777|DRUG|zolpidem MR|oral
41019292|NCT00374777|DRUG|nitrazepam|oral
41019293|NCT00374777|DRUG|placebo|oral
40829003|NCT04109131|OTHER|Brain MRI|"Part A:~* Brain MRI at inclusion is allowed within 45 days before enrolment~* Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month)~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)"
40829004|NCT04109131|OTHER|Samples collection: Serum|"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis for cohorts 1-5."
41019294|NCT01235455|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
41019295|NCT01590641|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
41019296|NCT01590641|DRUG|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
41019297|NCT05030922|OTHER|Antiatherogenic diet|Participants instructed in antiatherogenic diet during pregnancy with frequent follow-ups to ensure compliance
41019298|NCT01243385|DRUG|Metformin|Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
41019299|NCT05589545|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
41157622|NCT00990821|DRUG|100 MK-0517 (PS80) + 2 mg midazolam|MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
40829005|NCT05920044|OTHER|balance and proprioception training program.|"The program will include exercises focused on improving ankle stability and joint position sense, such as single-leg stance, wobble board, and resistance band exercises.~Participants will attend two supervised sessions per week and perform home-based exercises 3-4 times per week.~Progression of exercises will be individualized based on participant performance and tolerance."
41347864|NCT05843344|DRUG|erector spinae plane block with ropivacaine only|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +1 mL of normal saline will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 3 mL of normal saline will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
41347865|NCT02477540|DRUG|Cellgram-CLI|"Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip~Main ingredient: Autologous bone marrow-derived mesenchymal stem cells~Dosage: 50,000,000 cells/10ml, 2-time injection~Storage: An airtight container, 20\~25℃~Injection Method: Intramuscular"
41491126|NCT06040775|DEVICE|Sham magnetic stimulation using sham MCF-B65 coil|"Similar set parameters using a sham coil which simulates sound and tactile effect of real coil but no electromagnetic induction is produced.~Standard therapy with Applied Behavior Analysis and sensory integration would continue"
41491127|NCT00914914|DRUG|p28|p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
41491128|NCT02038907|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine IM injection
41491129|NCT02038907|BIOLOGICAL|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
41491130|NCT05920512|DRUG|Sodium valproate extended-release tablets|Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
41491131|NCT03485183|DEVICE|White/Pink Noise|White and/or pink noise will be played from 2200 to 0700 using the PicTek® white noise machine.
41491132|NCT03485183|OTHER|Control Group|Standard of care including lights on during the day and off at night, getting the patient out of bed for meals, presence of a large wall clock in the room, updating the whiteboard with current day, consistent reorientation of patient, geriatrician consults as needed, and pain management.
41491133|NCT05451186|OTHER|Eye patch and headphones|Patients in the experimental group will be asked to use an eye mask and earplugs from 22:30 to 6:30 in the morning on the 1st, 2nd and 3rd nights.
41491134|NCT03514849|PROCEDURE|prophylactic cranial irradiation (PCI)|Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation （PCI） by 25 gy/10 fx.
41491135|NCT03514849|PROCEDURE|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
41491136|NCT03514849|DRUG|postoperative adjuvant chemotherapy|If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
41491137|NCT03601650|BEHAVIORAL|Mindful eating|Attending to the sensory properties of food as it is eaten
41491138|NCT03601650|BEHAVIORAL|Eating without distractions|Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
41491139|NCT03012984|DRUG|Dexmedetomidine supplemented morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
40829006|NCT05920044|OTHER|Usual care|"Participants will continue their usual care, including general strength and flexibility exercises.~No specific balance and proprioception training will be provided."
41157623|NCT00990821|DRUG|115 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
41157624|NCT00990821|DRUG|150 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
41491140|NCT03012984|DRUG|Morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
41491141|NCT01555008|DRUG|LX4211|Subjects will receive LX4211 once daily for 7 days
41491142|NCT01555008|DRUG|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 7 days
41157625|NCT00990821|DRUG|40 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
41157626|NCT00990821|DRUG|100 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
41347866|NCT00772980|DRUG|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
41347867|NCT00772980|DRUG|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
41347868|NCT06078306|DRUG|Azacitidine Injection|Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection
41347869|NCT06078306|DRUG|Venetoclax|Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral
41347870|NCT06078306|DRUG|CD19CD22 CAR-T|After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion
41347871|NCT01146262|OTHER|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR1 ou CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
41347872|NCT01146262|PROCEDURE|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
41347873|NCT00320632|DRUG|Desipramine|
41347874|NCT03185169|COMBINATION_PRODUCT|Replens and coconut oil|
41347875|NCT03990051|DRUG|Pro-ocular™ topical gel|Topical gel for forehead dermal application
41347876|NCT03990051|DRUG|Placebo topical gel|Topical gel for forehead dermal application
41347877|NCT02653989|BIOLOGICAL|MDV9300|MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
41347878|NCT02621008|OTHER|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
41347879|NCT00112567|DRUG|fludarabine phosphate|
41347880|NCT00112567|DRUG|thiotepa|
41347881|NCT00112567|PROCEDURE|peripheral blood stem cell transplantation|
40829007|NCT01587638|DRUG|carvedilol|carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
40829008|NCT01587638|DRUG|cardio selective betablocker|atenolol, metoprolol succinate, and metoprolol tartrate
40829009|NCT00590824|DRUG|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
40829010|NCT00590824|DRUG|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
40829011|NCT04855955|DRUG|Adipose-Derived Mesenchymal Stem Cells|
40829012|NCT02650128|DEVICE|Shockwave Coronary Rx Lithoplasty® System|The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
41347882|NCT00112567|RADIATION|radiation therapy|
40829013|NCT04027270|OTHER|Physical Therapy|Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
41491143|NCT05303337|OTHER|Stool sampling|Stool samples will be collected from participants at baseline and W52
40829014|NCT03002623|DRUG|CUDC-907|60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
40829015|NCT01163773|OTHER|MILK|"Consumption of the 2 experimental diets~1. Milk diet~2. Control diet"
40829016|NCT01215110|DRUG|TMC207|
40829017|NCT01215110|DRUG|Rifafour e-275 mg|
40829018|NCT06287619|DRUG|Monoferric Injectable Product|Ferric derisomaltose will be prepared by an unblinded research pharmacist as per standard of care procedures. Specifically, 10 mL (containing 1000 mg ferric derisomaltose) will be diluted in 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing. The 1000 mg doses of ferric derisomaltose will be administered by a bedside nurse over 60 minutes via an infusion pump through a dedicated IV.
41157627|NCT00990821|DRUG|150 mg MK-0517 (Non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
41347883|NCT05690711|DRUG|HRS8179|HRS8179 injection
41347884|NCT05690711|DRUG|Placebo|physiological saline
41347885|NCT02543606|DRUG|Esomelone|powder for injection/ infusion Esomeprazole 40mg
41347886|NCT02543606|DRUG|Nexium|powder for injection/ infusion Esomeprazole 40mg
41347887|NCT06187051|DEVICE|FEVAR|Relining the EVAR with FEVAR
41347888|NCT06187051|DEVICE|Explantation|open surgery to explant the previous EVAR
41347889|NCT06415916|PROCEDURE|Cardiac ultrasound|Performed 5 times between 0 and 120 minutes
41347890|NCT06415916|PROCEDURE|Lung ultrasound|Performed 5 times between 0 and 120 minutes
41347891|NCT05791773|PROCEDURE|the robot assisted total knee arthroplasty|the robot assisted total knee arthroplasty
41347892|NCT05791773|PROCEDURE|the conventional jig-based total knee arthroplasty|the conventional jig-based total knee arthroplasty
41347893|NCT02839044|DIETARY_SUPPLEMENT|Menaquinone-7|
41347894|NCT02839044|DIETARY_SUPPLEMENT|Placebo|
41347895|NCT03685643|BEHAVIORAL|Intervention - Dating application topic|The intervention will consist of multimedia content to promote the safe usage of dating applications and raise awareness of the risks associated with dating application usage. The intervention will be delivered one-time in a classroom setting.
41347896|NCT03685643|BEHAVIORAL|Control - Health and exercise topic|The placebo control will consist of multimedia content regarding exercise and healthy living. It will be delivered once-time in a classroom setting.
41347897|NCT01199640|DRUG|MLN1202|Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
41347898|NCT00003282|DRUG|EF5|Given IV
41347899|NCT00003282|PROCEDURE|therapeutic conventional surgery|Undergo resection
41347900|NCT00003282|PROCEDURE|biopsy|Undergo biopsy
41347901|NCT00003282|OTHER|pharmacological study|Correlative studies
41347902|NCT04585113|RADIATION|CT-scanning|All participants will receive dual-energy CT scanning and cone-beam CT scanning prior surgery.
41347903|NCT03237390|DRUG|Gemcitabine Hydrochloride|Given IV
41347904|NCT03237390|OTHER|Laboratory Biomarker Analysis|Correlative studies
41347905|NCT03237390|OTHER|Pharmacological Study|Correlative studies
41347906|NCT03237390|DRUG|Ribociclib|Given PO
41347907|NCT04543630|PROCEDURE|Sinus floor augmentation|Sinus floor augmentaion using the lateral window technique
41347908|NCT03793790|BEHAVIORAL|Conditioning with partial reinforcement|Conditioning with partial reinforcement (PRF) provides an uncertain pairing of unconditioned high pain stimuli and conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device). During PRF only 70 percent of unconditioned stimuli are paired to conditioned stimuli. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device and are also used in the 30 percent of unreinforced trials.
41347909|NCT03793790|BEHAVIORAL|Conditioning with continuous reinforcement|During conditioning with continuous reinforcement (CRF) unconditioned high pain stimuli are paired to conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) in 100 percent of conditioning trials. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device.
41347910|NCT03793790|BEHAVIORAL|Counterconditioning|During counterconditioning, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) to thermal pain stimuli of low intensity.
40829019|NCT06287619|OTHER|0.9% sodium chloride solution|Patients in the control group will receive placebo, which will be 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing according to good manufacturing practice (GMP).
40829020|NCT06508710|DRUG|Ketamine|Patients randomized in this group will receive an intravenous ketamine in addition to venlafaxine for one week (on Days 1, 4 and 7)
40829021|NCT06508710|DRUG|Placebo|Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)
41157628|NCT00990821|DRUG|Placebo|Placebo matching MK-0517
41347911|NCT03793790|BEHAVIORAL|Extinction|During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) only to control stimuli of moderate intensity (previously paired to the deactivation of the mock device).
41347912|NCT03793790|BEHAVIORAL|Sham Conditioning|In the sham group, participants receive different instructions (namely, that the activation of the device is not expected to affect their pain sensitivity). Additionally, during sham conditioning unconditioned stimuli are not consistently paired to conditioned stimuli, thereby preventing the formation of an association between high pain stimuli and the activation of the mock medical device. In the attenuation phase participants undergo an extinction procedure.
41347913|NCT06386536|DEVICE|Intelligent stationary bike|A stationary motorized bike prototype that can evaluate lower limb functions such as strength, coordination, range of motion, and tonus. Based on the evaluation results, the iBike proposes a training program that is specific to each individual needs. Moreover, the intelligent bike offers diverse pedaling modes such as forward and backward pedaling, assisted pedaling, isotonic pedaling and pedaling with sensory stimulations.
41347914|NCT06386536|DEVICE|Conventional stationary bilke|A conventional stationary bike that can be found in gyms or rehab centers.
41347915|NCT04002206|OTHER|Muscle Energy Technique|In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
41347916|NCT04002206|OTHER|Static Stretch|Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
41347917|NCT05692206|OTHER|evaluation|Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
41347918|NCT02033291|PROCEDURE|Dynamic contrast enhanced Brain MRI|DCE-MRI is used to quantify the BBB permeability
41347919|NCT00945269|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
41347920|NCT00945269|BIOLOGICAL|aldesleukin|Given SC
41347921|NCT00945269|BIOLOGICAL|denileukin diftitox|Given IV
40829022|NCT03620357|DEVICE|CGM|CGM Group: Dexcom G6 CGM
40829023|NCT03620357|DEVICE|SMBG|SMBG Group: Blood Glucose Meter
40829024|NCT05639322|DRUG|Ketamine Hydrochloride|Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.
41347922|NCT00945269|PROCEDURE|biopsy|Optional correlative studies
41347923|NCT00945269|OTHER|immunohistochemistry staining method|Correlative studies
41347924|NCT00945269|OTHER|laboratory biomarker analysis|Correlative studies
41347925|NCT00945269|GENETIC|polymerase chain reaction|Correlative studies
41347926|NCT04184921|DRUG|Aspirin 100mg|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
40829025|NCT05639322|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioural Therapy/ Mindfulness Based Meditation therapy (CBT/MM) remotely for 16 hours between weeks 1 to 16 inclusive + in-person sessions on weeks 2, 7 and 12
41157629|NCT00990821|DRUG|40 mg Aprepitant|Aprepitant, oral, tablet, single dose
40829026|NCT05639322|OTHER|Ketamine + Cognitive Behavioral Therapy|Ketamine-HCL + CBT/MM according to the same directions specified in Arm 1 and Arm 2.
41157630|NCT00990821|DRUG|125 mg Aprepitant|Aprepitant oral tablet, single dose
41157631|NCT00990821|DRUG|2 mg Midazolam|Midazolam oral tablet, single dose
41347927|NCT04184921|DRUG|Osimertinib 80 MG|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
41347928|NCT00419237|DRUG|GW685698X|GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
41347929|NCT05868408|OTHER|Control Formula|Infant formula made with intact protein - minimum 1.8g protein/100kcal
41347930|NCT05868408|OTHER|Experimental Formula 1|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
40829027|NCT03997474|BIOLOGICAL|ATL001|ATL001 infusion
41347931|NCT05868408|OTHER|Experimental Formula 2|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
41347932|NCT02890940|BEHAVIORAL|Pet Therapy|"Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study."
41347933|NCT02094612|DEVICE|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
41347934|NCT02094612|BEHAVIORAL|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
41347935|NCT05202002|BEHAVIORAL|Video clip|"After obtaining written informed consent, participants received a sealed envelope containing a preprinted paper referral to an online website, with a unique identifier.~After entering the online website, participants will be asked to enter the unique identifier they have received into a text box. Only those whose identifiers were predetermined to be associated with the intervention group will receive the intervention.~The intervention is twenty minutes long educational video clip, in which a brief discussion was presented, by an obstetrician, pediatrician, dietitian, and a breastfeeding consultant, each presenting the benefits of breastfeeding for mother and newborn."
40829028|NCT03997474|DRUG|Checkpoint Inhibitor|Nivolumab
40829029|NCT00549185|DRUG|SAR3419|Intravenous infusion
41491144|NCT05303337|OTHER|Blood plasma collection|Blood plasma collection to assess persistent inflammation, immune activation and HIV reservoir at baseline,W24,W52
41491145|NCT03252912|BIOLOGICAL|blood samples|Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
41491146|NCT02728570|OTHER|High Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
40829030|NCT02338934|DRUG|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if \>2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
41019300|NCT03548870|OTHER|CWRT with low frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional"
41019301|NCT03548870|OTHER|CWRT with sham-low frequency transcutaneous electrical nerve stimulation|4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
41019302|NCT05381792|DIAGNOSTIC_TEST|Bacterial gene markers test|Bacterial gene markers test using qPCR
41491147|NCT02728570|OTHER|Low Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
41491148|NCT02460367|DRUG|Docetaxel|
41491149|NCT02460367|BIOLOGICAL|Tergenpumatucel-L|
40829031|NCT00819377|DRUG|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
40829032|NCT00819377|DRUG|Normal saline|5 ml normal saline by inhalation over 15 min
40829033|NCT03426475|PROCEDURE|interprof ACT measures|Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
40829034|NCT05866120|OTHER|Physiotherapy on the ground|Physical therapy will be performed on the ground, in 12 weeks, twice a week. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
40829035|NCT05866120|OTHER|Aquatic physiotherapy|Aquatic physiotherapy will be performed in 12 weeks, twice a week, in shallow water. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
40829036|NCT00450671|PROCEDURE|Collagen Plug Placement|
40829037|NCT00450671|PROCEDURE|Seton placement|
40829038|NCT02675192|OTHER|Proof cohort : muscular assessment|Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
41019303|NCT02388321|DRUG|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
41019304|NCT02388321|DRUG|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
41019305|NCT06142201|DRUG|JT001|oral administration
41157632|NCT06290141|DRUG|riliprubart|Pharmaceutical form:Solution-Route of administration:IV solution
41347936|NCT05202002|BEHAVIORAL|No video clip|Participants in this group will receive a unique identifier that belongs to the control group, thus no video clip will be displayed.
41491150|NCT02460367|DRUG|Indoximod|
41347937|NCT02084472|OTHER|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
41347938|NCT02084472|OTHER|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
41491151|NCT05549908|BIOLOGICAL|rabies vaccine|The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared
41491152|NCT03858595|DEVICE|Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. We will also measure weight gain of the mothers at monthly basis."
41491153|NCT02125162|DRUG|BCX4161|Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
41347939|NCT02084472|OTHER|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
41347940|NCT05086094|DRUG|BHV3241, verdiperstat|BHV3241/Verdiperstat 600mg BID
41347941|NCT02750501|DEVICE|RELiZORB (immobilized lipase) cartridge|Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge
41347942|NCT02750501|OTHER|Impact Peptide 1.5|Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
41347943|NCT03305913|DRUG|TAS 102|TAS-102 tablet
41347944|NCT03305913|DRUG|Regorafenib|Regorafenib tablet
41347945|NCT05265585|DIAGNOSTIC_TEST|Ultrasound - Cardiac Acquisition|"The evaluation of the algorithm takes place on patients with an indication for echocardiography.~This examination is done in a standard way with the potential specific explorations related to the indication of the examination. During the echocardiography, the operator records the search phase for the following reference views:~* Parasternal window (Parasternal long axis, Parasternal minor axis)~* Apical window (Apical 4 cavities, Apical 3 cavities, Apical 2 cavities~* Sub costal window, Sub costal 4 cavities, Inferior vena cava)"
41347946|NCT03531710|BIOLOGICAL|UB-311|Intramuscular injection
40829039|NCT05524610|BEHAVIORAL|Sexual Function Screening Approach|"The screening approach will consist of:~1. Standardized use of the PROMIS SexFS Brief in a clinic setting. This tool assesses sexual interest/desire, arousal, discomfort/pain, climax, and satisfaction, among other SD concerns and has comparable sex-specific versions. It has been validated in adult cancer populations.~2. An implementation package to aid in successful implementation. The implementation package will be finalized in the non-trial portion of this study, which will include iterative intervention adaptation. The protocol will be amended as needed to include any relevant updates to the screening approach. Some components may vary per site."
41347947|NCT03531710|DRUG|Placebo|Intramuscular injection
41491154|NCT01157780|DRUG|Lovaza (fish oil)|Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
41491155|NCT03499886|DRUG|Ketamine Hydrochloride 50Mg/1mL Solution for Injection|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
41491156|NCT03499886|DRUG|Ketamine Hcl 50Mg/Ml Inj|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
41491157|NCT01118286|DRUG|Nifedipine (Adalat, BAYA1040)|Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
41491158|NCT02008786|DRUG|ramipril|5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)
40829040|NCT00504790|DRUG|GSK923295|anti-mitotic compound
41019306|NCT05789615|DRUG|Letermovir|Letermovir has achieved excellent therapeutic benefits globally but is still in its infancy in China. Letermovir obtained an implied license for a clinical trial in June 2020, and in November 2020, Letermovir submitted and accepted four new drug marketing applications in China, including injection and tablet formulations. On December 31, 2021, the China National Medical Products Administration (NMPA) approved letermovir for cytomegalovirus (CMV) seropositive adult recipients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) \[R+\] prevention of cytomegalovirus infection and cytomegalovirus disease. The commercial launch of letermovir is estimated to be in August 2022.
41019307|NCT05468840|DRUG|Ketamine Hydrochloride|see study arm description
41019308|NCT05468840|DRUG|Normal saline|see study arm description
41347948|NCT03421262|DIAGNOSTIC_TEST|IADPSG Criteria|One-step: 2 hr 75 gr OGTT
41347949|NCT03421262|DIAGNOSTIC_TEST|NDDG Criteria|Osullivan test + 3 h 100 g OGTT
41347950|NCT05608200|DRUG|Lenvatinib, sintilimab plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
41491159|NCT02008786|DRUG|rosuvastatin|10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
41491160|NCT02008786|DRUG|placebo|Placebo
41491161|NCT06367491|OTHER|Registration in a database|All patients with bone metastasis enrolled at the centre will be entered into the database and followed until death or interruption of follow-up for any another cause
41491162|NCT04509882|DRUG|bear bile pill|Bear bile pill (15 pills) taken orally three times a day after meals with water.
41347951|NCT05608200|DRUG|Lenvatinib plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. The interruption, dose reduction and discontinuation of lenvatinib depended on the presence and severity of toxicities according to the drug directions.
41347952|NCT04216511|DIAGNOSTIC_TEST|Tumor autoantibody detection|Level of a set of autoantibodies potentially relative with lung cancer will be tested for each of the participants.
41347953|NCT03410602|PROCEDURE|Full-mouth supragingival scaling|Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.
41347954|NCT03410602|PROCEDURE|Subgingival scaling|Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.
41347955|NCT03410602|DRUG|Subgingival irrigation|Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
41347956|NCT04634318|OTHER|Respiratory rehabilitation program (RR).|"Patients in the RR group will follow the respiratory rehabilitation program during a 4-week hospitalization in the respiratory diseases department of Renée Sabran hospital (Hyères, France).~The program includes for each week:~One medical consultation Four 40-min sessions of aerobic exercises on an ergocycle Four 1-hour sessions of walking in Renée Sabran Hospital's park Three 1-hour sessions of muscle strengthening exercises One 1-hour session of sophrology One 1-hour session of occupational therapy One 1-hour session of psychomotricity"
41347957|NCT04634318|OTHER|Respiratory tele-rehabilitation program (TRR).|Patients in the TRR group will realize the 4-week respiratory tele-rehabilitation program at home. The TRR program for each week includes the same sessions as RR program. But, medical consultation, sophrology, occupational therapy, psychomotricity and muscle strengthening sessions are carried out through live videoconferences. Additionally, aerobic and walking sessions are carried out outside home. The intensity of each session will be controlled by heart rate monitor.
40829041|NCT05981937|DRUG|ICG solution|ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH \& Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
41347958|NCT01655641|DRUG|Tranexamic acid|"Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
41347959|NCT01655641|OTHER|Standard of care|Includes routine surgical care involved in preventing blood loss during and after surgery.
41347960|NCT03733249|DRUG|Rimiducid|Rimiducid is administered to treat chronic graft versus host disease
40829042|NCT01248754|PROCEDURE|Surgical neuronavigation with 18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
40829043|NCT02537262|DIETARY_SUPPLEMENT|carbohydrate beverage|Carbohydrate group drinks carbohydrate beverage 400ml(9PM\~MN) the day before the surgery and 200ml three hours before the surgery.
41347961|NCT03733249|BIOLOGICAL|rivogenlecleucel|donor T-cells modified with iCasp safety switch
41347962|NCT00853112|DRUG|PF-00489791|tablet form, 1 mg, single dose (Day 1)
41347963|NCT00853112|DRUG|PF-00489791|tablet form, 2 mg, single dose (Day 1)
41347964|NCT00853112|DRUG|PF-00489791|tablet form, 4 mg, single dose (Day 1)
41347965|NCT00853112|DRUG|PF-00489791|tablet form, 10 mg, single dose (Day 1)
41347966|NCT00853112|DRUG|PF-00489791|tablet form, 20 mg, single dose (Day 1)
41347967|NCT00853112|DRUG|placebo|tablet form, single dose (Day 1)
40829044|NCT02537262|DIETARY_SUPPLEMENT|NPO(None Per Oral)|NPO group does not drink any water from the MN before the surgery.
40829045|NCT02568098|DRUG|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
41019309|NCT03888313|OTHER|Pretreatment group consultation|A consultation in group with several patients and one surgeon
41347968|NCT00853112|DRUG|sildenafil|tablet form, 20 mg, single dose (Day 1)
40829046|NCT02568098|DRUG|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
40829047|NCT02568098|DRUG|DHA-PQP|Regimen 6: DHA-PQP
41019310|NCT04331080|DRUG|Granexin® gel 100 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
41347969|NCT04469556|DRUG|Folfirinox|Chemotherapy
41347970|NCT04469556|DRUG|Gemcitabine/nab-paclitaxel|Chemotherapy
41347971|NCT05347563|PROCEDURE|Electrical impedance tomography|All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment...)
41347972|NCT03894267|DEVICE|Cutimed Siltec Heel and Sacrum dressing|The dressing has been developed to facilitate exudate management in the treatment of wounds. Newly formed tissue enjoys optimal protection under a moist environment. The foam core with super-absorbers ensures reliable absorption in slightly to heavily exuding wounds. This core has an excellent retention capacity, even under compression. Hydrogen bridges bind the water so securely that, even when subject to pressure, the water is not released. Vertical absorption through the polyurethane foam and the hydro- phobic wound contact layer minimizes the risk of macerations in the peri-ulcer skin.
41347973|NCT02309216|OTHER|Whol-Body MRI scan|
41347974|NCT01646736|DRUG|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
41347975|NCT01646736|DRUG|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
41347976|NCT01646736|DRUG|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
41491163|NCT04509882|DRUG|placebo|Placebo(15 pills) taken orally three times a day after meals with water.
41347977|NCT03857464|DIAGNOSTIC_TEST|Near Patient Testing|Near-patient testing will be conducted at Foothills Hospital rapid response lab. Negative results using C. DIFF QUIK CHEK COMPLETE® will be reported immediately to the patient wards. Positive results will be confirmed using nucleic acid testing at the centralized testing facility.
41347978|NCT03857464|DIAGNOSTIC_TEST|SOP for C. difficile diagnostics|Two-step testing algorithm for Clostridium difficile at centralized testing facilities. No change from the current protocol.
41347979|NCT01960556|OTHER|Simulation Training|Simulation training provided to one group
41347980|NCT05197985|BEHAVIORAL|IECD Intervention|The Nurturing Care curriculum contains: 1) responsive caregiving, 2) the important role everyone plays in raising a child, 3) maternal health and nutrition, 4) responsive feeding and good nutrition, 5) how children grow and develop, 6) hygiene, 7) language development, 8) the importance of play, 9) managing the stress of parenting, 10) protecting your child from harm. Modules will be delivered through group sessions for caregivers, individualized home visits and Social Behavior Change Communication. IECD will build families' capacity to grow and raise healthy food to consume themselves, and connect them to agricultural markets. Specifically, IECD will provide agriculture technical training to Village Model Farms and households, and will facilitate linkages to markets by identifying buyers and connecting them to the farmers. IECD will train and support volunteers to conduct disability screening, and train disability interventionists to provide appropriate therapies and support services.
41347981|NCT02374359|OTHER|follow-up|
41491164|NCT06458842|DRUG|Ketamine|
41491165|NCT06458842|OTHER|Placebo|
40829048|NCT03700450|DRUG|Cyclophosphamide|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
40829049|NCT06198101|OTHER|Myofascial Release Technique|The treatment will be applied by the therapist standing at the side of the patient with different levels according to subject's tolerance for duration of 3 minutes in each sitting. Level one will be performed by longitudinal movements without causing any tension to the tissues. The level two will be performed by longitudinal movements with light pressure to the tensed muscle. The level three will be performed by compressing the treatment area then passively fullest possible range of motion will be performed and then longitudinal movement will be done with same compression. In level four, the patient will actively move the tissue through the fullest possible range of motion. The taut band will palpate and then firm pressure will be maintained and then longitudinal movements will be performed. Treatment will be applied for two intervention sessions per week and a total of 12 sessions over 6 weeks.
40829050|NCT06198101|OTHER|Myofascial Release Technique along with segmental vibrator|this group will receive vibratory stimulations through segmental vibrator along the muscle fibers of upper limb flexors, extensors, and wrist flexors for 10-minutes each session with low amplitude (0.3-0.5 mm peak to peak) at fixed frequency of 150 Hz(23). Along with segmental vibrator group B will also receive myofascial release technique through the same method to the upper limb flexors, extensors, and wrist flexors. Group B will receive both treatments for two intervention sessions per week and a total of 12 sessions over 6 weeks.
40829051|NCT05507632|COMBINATION_PRODUCT|Donafenib plus Sintilimab in combination with transarterial chemoembolisation|Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE)
40829052|NCT03270267|OTHER|Questionnaires|
41491166|NCT04544501|BEHAVIORAL|Culturally-Targeted Video|"Culturally targeted narrative video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. With R03 funding (R03CA191543) we developed a culturally targeted narrative video for at-risk Latinas. A multidisciplinary team of researchers collaborated with filmmakers to develop the script and video. The script was informed by health behavior conceptual models, evidence-based risk communication strategies, and formative research (40 interviews with providers and at-risk Latinas). The script addressed identified knowledge gaps (e.g., incorrect belief that pap smears screen for ovarian cancer), facilitators (e.g., inform family cancer risk), barriers (e.g., emotional concerns), and cultural factors (e.g., respect). The 18-minute video illustrates the GCRA process with the story of Rosa, a Latina cancer survivor at increased risk of HBOC. Rosa learns about HBOC risk factors, overcomes barriers, and attends genetic counseling."
41491167|NCT04544501|OTHER|FORCE Fact Sheet|A publically available Spanish-language fact sheet about HBOC and GCRA developed by FORCE.
40829053|NCT06496438|DIETARY_SUPPLEMENT|Psychobiotics|Dietary Supplement: A four probiotic regime, containing Lactobacillus rhamnosus, Bifidobacterium animalis subsp. lactis, Bifidobacterium breve, and Bifidobacterium longum at a concentration of 1, 000,000,000 CFU.
41019311|NCT04331080|DRUG|Granexin® gel 200 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
41019312|NCT04331080|DRUG|Vehicle gel|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
41019313|NCT04480164|DRUG|NDMC|Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts
41019314|NCT00534352|DRUG|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
41491168|NCT01374126|DRUG|Artesunate|Artesunate alone
41491169|NCT01374126|DRUG|Azithromycin + Artesunate|Combination of azithromycin + artesunate
41509048|NCT01044121|OTHER|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
41019315|NCT05743166|PROCEDURE|Bariatric surgery|JDF11 JDF41 JDF97
41019316|NCT03698955|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following the vegan diet.
41019317|NCT03698955|OTHER|Mediterranean Diet|Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
41019318|NCT03323099|BEHAVIORAL|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
41157633|NCT06290141|DRUG|Placebo|Pharmaceutical form:Solution-Route of administration:IV solution
41347982|NCT03401216|DEVICE|SYNERGY 48 mm|Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)
41019319|NCT03323099|BEHAVIORAL|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
41019320|NCT06566274|DEVICE|thumbtack needle|As a kind of intradermal needle, thumbtack needle (TTN) is a method of shallow puncture and long-term needle.After the TTN is attached into the acupoints, it will be reserved in the acupoints for 3 days. After 3 days of retention of TTN, the patient is instructed to go to the hospital, where the doctor removes the needle, disinfect the local skin of acupoints and conducts the next TTN treatment. A total of 5 treatments were applied for a duration of 15 days.
41019321|NCT06566274|DEVICE|sham thumbtack needle|"The sham TTN used in the sham TTN group has no needle body and its appearance and shape are similar to the real TTN. But it does not produce a needle-like effect.~The acupoints of sham TN group are the same as those of TN group. The use of sham TN is the same as that of the TN group. After 3 days retention of sham TN, the patient will be instructed to go to the hospital, where the doctor remove the sham TN, and conduct the next treatment after local skin disinfection. A total of 5 treatments will be applied for a duration of 15 days."
41019322|NCT03384446|OTHER|Tooth-borne treatment|Titanium curettes
41019323|NCT03384446|OTHER|Implant-specific treatment|Implant brush
41019324|NCT05831852|OTHER|no intervention|no intervention
40829054|NCT06496438|OTHER|Placebo|The placebo regime, containing powdered glucose polymer, will be identical in packaging, appearance, consistency, and solubility in drinking water, thus making it impossible to recognize which are placebo and which the therapeutic formulation. Both will be identically standardized by the same pharmaceutical company \[Uni-Pharma, Greece\].
40829055|NCT01981863|DRUG|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
40829056|NCT01981863|DRUG|Placebo|Placebo administered in same volume as in experimental arm.
40829057|NCT06391281|OTHER|Education|The patient receiving hemodialysis treatment will be given fistula self-care training in 2 sessions. An educational booklet will be provided after the training.And routine care
40829058|NCT00875056|DRUG|Vorinostat|Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle
40829059|NCT05172453|OTHER|comprehensive management algorithm for preventing mother-to-child transmission of HBV|"To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the Management algorithm for prevention of mother-to-child transmission of hepatitis B virus based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents."
40829060|NCT01298102|BIOLOGICAL|Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)|intramuscular injection of 1 dose vaccine
41019325|NCT03735420|DRUG|Xanthohumol|The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.
41019326|NCT03735420|DRUG|Placebo oral capsule|The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
40829061|NCT05482659|BEHAVIORAL|Health education on healthy nutrition and regular physical activity based on the transtheoretic model|An announcement was made by visiting all the faculties at Nuh Naci Yazgan University, stating the content of the research and the duration of the research. Among the volunteer students, students who met the inclusion criteria were included in the study. Afterwards, the students were assigned to the groups by the statistician using a simple randomization method. As a result of the pre-test, it was determined which change stage each student was in according to the Transtheoretic model (TTM). The students were not given information about which group they were in and what stage they were in according to TTM. Health education was given to university students once a week by online education method and it took 4 weeks-30 days to complete the research. The average duration of the health education given to each student is 30-45 minutes. When the training process was over, the post-test questions were sent to the students by the online survey method.
40829062|NCT01898104|RADIATION|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
40829063|NCT01898104|DRUG|Valproic Acid|
40829064|NCT01898104|DRUG|Capecitabine|
41019327|NCT06032715|BEHAVIORAL|BI (Brief Intervention)|Short structured individual behavioral intervention to reduce inappropriate usage of Z-hypnotics
41019328|NCT04512937|DEVICE|Computer-assisted navigation surgery|Computer navigation-assisted surgery has two main elements; the pre-procedural planning to create accurate 3D images of the pelvis allowing the surgical team to achieve an accurate perception of the operative field, and intraoperative navigation where these images are used for anatomical guidance to enhance surgical precision. Accordingly, computer software is used in this study to outline the tumour and other pelvic organs on pre-operative images which are subsequently used for intraoperative navigation.
41347983|NCT03401216|PROCEDURE|PCI|Standard PCI procedure
41347984|NCT03401216|PROCEDURE|3 month OCT follow-up|Optical coherence tomography imaging of target vessel within 3 month after PCI
41347985|NCT03401216|PROCEDURE|6 month OCT follow-up|Optical coherence tomography imaging of target vessel within 5 month after PCI
41347986|NCT04453618|DRUG|FE-SYHA1402 100mg|in either a fasted state or with a meal
41347987|NCT04453618|DRUG|SYHA1402-25mg|SYHA1402 25mg, oral tablets
41347988|NCT04453618|DRUG|Placebo-25mg|Matching placebo tablets
41347989|NCT04453618|DRUG|SYHA1402-50mg|SYHA1402 50mg, oral tablets
41347990|NCT04453618|DRUG|Placebo-50mg|Matching placebo tablets
41347991|NCT04453618|DRUG|SYHA1402-150mg|SYHA1402 150mg, oral tablets
41347992|NCT04453618|DRUG|Placebo-150mg|Matching placebo tablets
41347993|NCT05084768|DIAGNOSTIC_TEST|Donor-derived cell-free DNA|As mentioned previously
41347994|NCT01738074|BIOLOGICAL|trivalent rotavirus genetic reassortment vaccine|
41347995|NCT01738074|BIOLOGICAL|Placebo|
41347996|NCT03338452|BEHAVIORAL|Low energy ketogenic diet|Low energy ketogenic diet lasting 12 weeks with a previous preparation period including detailed instructions during classes and individual counselling by a dietitian. Participants were provided with a list of suitable foods with very low carbohydrate content. Furthermore, the subjects shared cooking recipes and links to helpful webpages. They were free to follow a KD according to their personal preferences but limit their carbohydrate intake to 5-10 % of total energy from carbohydrates, but derive at least 70 % of total energy from fat.
41347997|NCT03898323|DEVICE|Alcohol Approach Bias Modification|Computerized training
41347998|NCT02958033|RADIATION|Whole Breast irradiation Plus simultaneous tumor bed Boost|hypo-fractionated irradiation for experimental group and normal fractionated irradiation for comprator group
41347999|NCT02462811|DRUG|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
41491170|NCT01957176|DRUG|Eltrombopag (ELT)|Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.
41491171|NCT02831608|BIOLOGICAL|Influenza vaccine|
41491172|NCT02831608|BIOLOGICAL|Placebo|
40829065|NCT01603797|BEHAVIORAL|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
40829066|NCT04902664|BEHAVIORAL|Patient education materials|Patients receive a text-message and email with educational materials about medical testing.
40829067|NCT04902664|BEHAVIORAL|Physician peer-comparison email|Physicians receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals.
40829068|NCT04902664|BEHAVIORAL|Physician education materials|Physicians receive reference materials on medical test interpretation and incidental findings.
40829069|NCT04902664|BEHAVIORAL|General visit preparation materials|Patients receive a text-message and email with general visit preparation tips.
40829070|NCT02231762|DRUG|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
41348000|NCT02462811|DRUG|Placebo|
41348001|NCT02462811|DRUG|Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)|
41348002|NCT03541590|PROCEDURE|Percutaneous transhepatic biliary drainage|When ERCPs failed or was not possible to be performed due to an altered anatomy in patients with malignant extrahepatic bile duct obstruction, PTBD was performed next in all patients. Percutaneous bile duct puncture was guided by Color Doppler ultrasound. The further procedure was guided by fluoroscopy. A self-expandable metal stent (SEMS) was inserted into the obstructed bile duct by endoscopic luminal guidance in the first session. After successful SEMS implantation, the percutaneous external catheter was removed at the end of the procedure.
41348003|NCT06462716|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
40829071|NCT02231762|DRUG|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
40829072|NCT03770494|DRUG|LY3405105|Administered orally.
40829073|NCT02961790|DRUG|Oxybutynin Chloride|Given PO
40829074|NCT02961790|OTHER|Placebo|Given PO
40829075|NCT02961790|OTHER|Quality-of-Life Assessment|Ancillary studies
40829076|NCT02961790|OTHER|Questionnaire Administration|Ancillary studies
41348004|NCT01693289|DRUG|metformin plus letrozole|
41348005|NCT01693289|PROCEDURE|ovarian drilling|
41348006|NCT02368730|DRUG|desmopressin|
41348007|NCT00957034|DRUG|placebo|placebo patch
41348008|NCT00957034|DRUG|testosterone|300 or 450 micrograms/day transdermal testosterone patch
41491173|NCT04366934|OTHER|Nasal swab|Nasal swab
41491174|NCT04366934|OTHER|Taste and olfactory function evaluation|Taste and olfactory function evaluation
41491175|NCT02483143|DRUG|NAC|3 gr NAC was made up to 1000 ml with NS; a 1 ml/3 mgr NAC solution was obtained and 3 ml/kg NAC+NS solution was administered for 1 h before CTPA and a 1 ml/kg per hour NAC+NS solution was administered for a minimum 6 h after CTPA.
41491176|NCT02483143|DRUG|NaHCO3|132 mEq NaHCO3 was made up to 1000 ml with NS; and 3 ml/kg NaHCO3+NS solution was administered for 1 h before CTPA and 1 ml/kg per hour NaHCO3+NS solution was administered for a minimum of 6 h after CTPA.
40829077|NCT04070326|DRUG|Lanadelumab|Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
41348009|NCT06464289|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
41348010|NCT06464289|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation.
41348011|NCT01708915|DRUG|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
40829078|NCT01912157|BEHAVIORAL|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
40829079|NCT01218451|BIOLOGICAL|Meningococcal group C polysaccharide conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
40829080|NCT01218451|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
40829081|NCT01218451|BIOLOGICAL|Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
40829082|NCT06306664|DEVICE|Bioptron|Bioptron safely treats arthritis, neck \& back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.
40829083|NCT06306664|OTHER|Placebo Comparator|Patients will receive ice application+Exercises program designed for jumper knee
40829084|NCT01389531|PROCEDURE|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
40829085|NCT00016744|DRUG|Sodium 4-Phenylbutyrate (4PBA)|The standard oral adult dose is 20g/day (tablets) for 4 days.
40829086|NCT00016744|DRUG|Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)|Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
41019329|NCT02648087|DEVICE|With and without SDB|Screening of sleep-disordered breathing (SDB)
40829087|NCT00016744|DRUG|Placebo|The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
40829088|NCT06426368|DIAGNOSTIC_TEST|ST2|ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure
40829089|NCT03117608|BIOLOGICAL|injection of autologous micro-fragmented adipose tissue (aMAT)|adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
40829090|NCT03117608|BIOLOGICAL|injection of Platelet-rich Plasma (PRP)|injection of platelet-rich plasma
41019330|NCT05943301|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care
41019331|NCT02880852|DRUG|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
41491177|NCT02483143|DRUG|Normal Saline|3 ml/kg NS was administered for 1 h before CTPA and 1 ml/kg per hour was administered for a minimum of 6 h after CTPA.
40829091|NCT02838901|DRUG|Beet it Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
40829092|NCT02838901|DRUG|Beet It Placebo Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
40829093|NCT01410292|OTHER|GI and fiber meals|meals with different fiber content and glycemic index
40829094|NCT01410292|OTHER|meals|four different meal regarding GI and fiber content
40829095|NCT02146703|DRUG|Gemcitabine, and S-1|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m2 iv on day 1, 8~2. S-1 60 mg/day po on day 1-14"
40829096|NCT05044104|DEVICE|Consumer-facing wearable smart watch|Wearable watch technology that has the ability to measure heart rate, respiratory rate, single-lead electrocardiography, and blood oxygen saturation.
41019332|NCT00985348|DRUG|Levetiracetam (Keppra)|"Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
41019333|NCT05790343|BEHAVIORAL|BAPHYC|Nine weekly peer led group meetings
41019334|NCT06440772|DRUG|Ringer's Lactate Crystalloid Solutions|7 ml/kg ml of Ringer's Lactate is given in 10 min amongst initially tolerant fluid responders.
41019335|NCT05174767|DEVICE|AMDS|AMDS Implantation
41019336|NCT01994395|DEVICE|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
41019337|NCT01994395|OTHER|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
41019338|NCT04832555|RADIATION|Non elective radiotherapy|Simultaneous integrated boost on CTV volumes, delineated as per guidelines, with the exception of intermediate-low risk, where the CTVs are experimental.
41491178|NCT05141539|DEVICE|Rehabilitation assessment software|"In phase 2, this software will be tested in occupational therapists, and head and neck cancer patients results for reliability and validity.~In phase 3, the experiment in the oropharyngeal dysphagia specialists results in content validity, the comparison between the developed software, and VFSS and FOIS results in criterion-related validity, and the experiment in head and neck cancer patients results in reliability."
40829097|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy|The experimenter gives the subject psychoeducation about emotional regulation and distraction strategy with the help of a conversation and a presentation.
41491179|NCT05141539|DEVICE|VFSS and FOIS|In phase 3, this study applies VFSS and FOIS for the head and neck cancer patients for comparison with the developed rehabilitation assessment software for criterion-related validity.
41019339|NCT05166967|DRUG|Individual Antithymocyte globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
41491180|NCT03738514|OTHER|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks
41019340|NCT05166967|DRUG|Antithymocyte globulin|A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
41348012|NCT01708915|DRUG|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
41348013|NCT01708915|DRUG|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
41491181|NCT03738514|OTHER|5% potassium nitrate dentifrice|5% potassium nitrate dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
41491182|NCT03738514|OTHER|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks
41491183|NCT01489631|DRUG|naropin|ropivacaine 0,2%, 3x 50 ml during surgery
41491184|NCT01489631|DRUG|marcaine|bupivacaine 0,125%
41019341|NCT01235910|DRUG|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
41019342|NCT00018109|DRUG|glutamine|
40829098|NCT06197464|DEVICE|Using the FLOAT app on a virtual reality device|The subject should wear the VR device, and use the FLOAT application.
40829099|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy + Application|psychoeducation on emotional regulation and distraction strategy + Application
40829100|NCT04225091|DIETARY_SUPPLEMENT|Testing product|consume 1 bottle (50 mL) per day for 28 days
41019343|NCT00018109|DRUG|creatine monohydrate|
41019344|NCT03449303|OTHER|EOI|Topically-applied oil
40829101|NCT04225091|DIETARY_SUPPLEMENT|Blank|consume 1 bottle (50 mL) per day for 28 days
41019345|NCT03449303|OTHER|Placebo|Topically-applied oil
41019346|NCT00206063|DRUG|EXANTA|
41019347|NCT05051644|BEHAVIORAL|Steps 2 Change (S2C)|Participants assigned to S2C and health education control will be scheduled for 60-minute weekly group sessions held over four consecutive weeks in the outpatient OAT clinic. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain. Session 2 and 3 will introduce a progressive walking program with individual goals and weekly step count benchmarks and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior.. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting in Session 2. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
41019348|NCT05051644|BEHAVIORAL|Control|The control will be matched for treatment exposure and individual attention. Treatment discussion will explicitly avoid problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
41019349|NCT01802411|DRUG|EXPAREL 266 mg|
41019350|NCT01802411|DRUG|Placebo|
41348014|NCT01708915|DRUG|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
41491185|NCT01489631|DRUG|sufentanil|sufentanil 1mcg/ml
41491186|NCT01489631|DRUG|neurontin|gabapentin 600 mg pre-operative 3 dd 300 mg
41491187|NCT04642937|DRUG|Treatment with hP1A8|Treatment with hP1A8
41491188|NCT05948514|OTHER|The complications related to central venous access device|The complications related to central venous access device were collected when occurs : from time of catheter insertion, until first complication, or removal for another type of catheter, or until death.
41491189|NCT05116462|DRUG|Pemetrexed|500 mg/m2 D1 IV Q3W
41491190|NCT05116462|DRUG|Carboplatin|AUC 5 or 6 mg/ml/min D1 IV Q3W
41491191|NCT05116462|DRUG|Paclitaxel|175 or 200 mg/m2 D1 IV Q3W
41491192|NCT05116462|DRUG|Sintilimab|200 mg D1 IV Q3W
41019351|NCT02720484|OTHER|Laboratory Biomarker Analysis|Correlative studies
41019352|NCT02720484|DRUG|Nivolumab|Given IV
41019353|NCT02697019|BEHAVIORAL|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
41019354|NCT05423509|OTHER|Dynamic myofascial manipulation|Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation
41019355|NCT05423509|OTHER|Standard AIS treatment with observation or bracing|Observation with radiographs and bracing of curves greater than 20 degrees
41019356|NCT01423513|OTHER|Fibular Taping|Tape with be applied with tension.
41019357|NCT01423513|OTHER|Sham Taping|Tape will be applied without tension
41019358|NCT05611528|DRUG|Evinacumab|Evinacumab 15 mg/kg administered intravenously every 4 weeks
41348015|NCT05234190|DRUG|QEL-001|QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
41348016|NCT05071222|GENETIC|ARTEGENE drug product|Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.
41348017|NCT02234024|DIETARY_SUPPLEMENT|Supplementation of dairy-derived concentrated gangliosides.|
41491193|NCT05116462|DRUG|Cisplatin|75 mg/m2 D1 IV Q3W
41491194|NCT05116462|DRUG|Nab paclitaxel|100 mg/m2 D1, 8, 15 IV Q3W
41491195|NCT05116462|DRUG|Placebo|20 ml D1 IV Q3W
41491196|NCT02951091|OTHER|biomarker screening|immunohistochemistry and in situ hybridization
41348018|NCT06359886|PROCEDURE|B-Lynch Transverse Compression Suture|closure of uterine and utero ovarian arteries bilaterally with one suture
41348019|NCT00369928|DRUG|PG-760564|100 mg BID, of oral PG-760564
41348020|NCT00369928|DRUG|Placebo dose|placebo, BID, oral for 12 weeks
41348021|NCT00369928|DRUG|PG-760564|25 mg BID, of oral PG-760564
40829102|NCT06450860|OTHER|Nutrition Interventions|Individualized food provision and/or supplemental referral based on participant's unique needs/responses to assessment (NSAT). Food provision interventions include medically tailored meals, home delivered prepared meals, grocery boxes, grocery delivery services, food pantries, and soup kitchens/meal sites. Supplemental interventions include SNAP benefit enrollment support, nutrition education, and cooking education.
41491197|NCT06276049|OTHER|custom GPT supported self-directed learning|"The intervention in our study involved a LearnGuide utilization guide course along with a 12-week integrated training program that incorporated LearnGuide. In the first two-hour session, instructional staff introduced LearnGuide through a hands-on demonstration, teaching students how to use ChatGPT effectively by crafting high-quality prompts. The team emphasized LearnGuide's role as an AI facilitator in self-directed learning (SDL). Following the introduction, students were assigned various tasks including online learning, literature reviews, case analyses, and Problem-Based Learning (PBL) activities. Over the 12-week SDL phase with LearnGuide, students were required to complete at least one of these tasks weekly. This setup allowed students to consult mentors for any LearnGuide-related questions, enhancing their learning experience."
41348022|NCT05961397|DRUG|baxdrostat|single oral dose of baxdrostat 10 mg
41348023|NCT05017987|DRUG|ATB-101, ATB-1011, ATB-1012|"1. Test drug~   - Code name: ATB-101~2. Control drug1~   * Code name: ATB-1011~  * Active ingredient: Olmesartan~3. Control drug2~   * Code name: ATB-1012~  * Active ingredient: Dapagliflozin"
40829103|NCT04433559|DRUG|Tadalafil 1,5 mg oral tablets|Use of tadalafil in the treatment of FSIAD
41348024|NCT02574520|DRUG|SABER-Bupivacaine (Part 1)|5 ml once at end of surgery
41348025|NCT02574520|DRUG|SABER-Bupivacaine (Part 2)|5 ml once at end of surgery
41348026|NCT02574520|DRUG|Saline Placebo|5 ml once at end of surgery
41348027|NCT02574520|DRUG|Bupivacaine HCl|0.5%, 15 ml, once at end of surgery
41348028|NCT00706264|DEVICE|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
41348029|NCT02411006|BEHAVIORAL|Prediction mailing|Ask people to predict their upcoming medication adherence
41348030|NCT02411006|BEHAVIORAL|Commitment mailing|Ask people to commit to their upcoming medication adherence
41348031|NCT02411006|BEHAVIORAL|Reminder|Remind people to take their medicine
41348032|NCT02411006|BEHAVIORAL|Anonymity|Keep patient predictions and commitment anonymous
41348033|NCT02411006|BEHAVIORAL|Identification|Ask patients to report their predictions and commitments
40829104|NCT04433559|DRUG|Placebo oral tablets|Use of placebo in control group
40829105|NCT05577832|PROCEDURE|Helfer Skin Tap Technique|In a single-group design, 3 technique injections will be administered to the patients, to be randomized. The HST technique will be applied to patients in any one of 1days in a randomized fashion.
40829106|NCT05577832|PROCEDURE|ShotBlocker Technique|In a single-group design, 3 technique injections will be administered to the patients, 1 technique per week, to be randomized. The ShotBlocker technique will be applied to patients in any one of 1 weeks(3 days) in a randomized manner.
41019359|NCT01903694|DRUG|Sorafenib + Pravastatin|
41019360|NCT01903694|DRUG|Sorafenib|
41348034|NCT01736930|DEVICE|Pump suspension|The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
41348035|NCT01875874|BIOLOGICAL|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
41348036|NCT03881644|DRUG|Imigran|All patients will undergo this intervention on one of two study days
41348037|NCT03881644|OTHER|Isotonic Saline|All patients will undergo this intervention on one of two study days
41348038|NCT03881644|OTHER|Pituitary adenylate cyclase-activating peptide-38|All patients will undergo this intervention on both study days
41348039|NCT04949776|DIAGNOSTIC_TEST|Mammograms|"In the women participating in the study, two strategies for reading mammograms will be carried out:~Strategy 1: Standard reading of the program. Double independent and non-consensual reading of all cases, without any artificial intelligence system (standard strategy).~Strategy 2: Reading strategy based on the global Score granted by Transpara® (strategy based on artificial intelligence):~* In studies with a Score \<8 (studies with a low probability of cancer): They will not be evaluated by any radiologist.~* In studies with a Score\> 7 (studies with a high probability of cancer): double reading will be carried out, assisted by Transpara®."
41348040|NCT02773511|PROCEDURE|Surgical treatment|Closed reduction and Kirschner wire fixation
41348041|NCT00132522|DRUG|EMD 273066|"dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.~Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2."
41348042|NCT05646160|OTHER|Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)|IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
41348043|NCT01245127|DRUG|Ilaris|"* Canakinumab 150 mg (or 2 mg/kg for patients weighing \<40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~* At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing \<40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing \<40 kg) every 8 weeks beginning at Week 8.~* Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~* If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
41348044|NCT01910649|DRUG|Drisapersen|Subcutaneous and Intravenous
41348045|NCT03727776|DRUG|Adrenocorticotropic Hormone|Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone that is normally produced in the pituitary gland and acts as a major regulator of adrenal cortex function. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®).
41348046|NCT05880303|PROCEDURE|Nonsurgical periodontal therapy|Oral Hygiene education, scaling and root surface debridement at baseline and 3 months
41348047|NCT02145754|OTHER|MKP media|one half of skin specimen was put in MKP media
41348048|NCT02145754|OTHER|BSK-H media|one half of skin specimen was put in BSK-H media
41348049|NCT04761575|OTHER|Validation of the FFQ65+ via eNutri app|All participants will provide two eNutri FFQ datasets within a 14-day interval along with three 24-hour dietary recalls and dried blood spot samples.
41348050|NCT02158195|BIOLOGICAL|blood samples|
41348051|NCT01711437|DEVICE|PEG-4000 with citrates and simethicone|1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.
41348052|NCT01711437|DEVICE|polyethylene glycol 4000 solution with simethicon|patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
41348053|NCT01711437|DEVICE|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid|patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
41348054|NCT01711437|DEVICE|sodium picosulphate plus magnesium oxide and citric acid|patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
41491198|NCT01021358|DRUG|ABT-263|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
41491199|NCT01021358|DRUG|Ketoconazole|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
41491200|NCT01574482|OTHER|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
41491201|NCT01574482|OTHER|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
41348055|NCT02216292|OTHER|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
41348056|NCT02216292|OTHER|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
41348057|NCT02640924|RADIATION|Proton radiotherapy|
41348058|NCT02640924|PROCEDURE|Radiofrequency Ablation|
41348059|NCT03315702|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
41348060|NCT04225806|DEVICE|BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)|The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
41348061|NCT05319886|DRUG|Anlotinib and Penpulimab|Anlotinib 12mg, po, qd, with 2 weeks off for 1 week. Penpulimab 200mg, ivgtt, q3w. Efficacy was evaluated every 2 cycles. Efficacy evaluation was performed every 2 cycles during the follow-up study. Patients with disease control (CR+PR+SD) and tolerable adverse reactions continued to take the drug until the investigator considered that the patient was not suitable to continue the drug or the efficacy was evaluated as PD. Safety evaluations were performed concurrently with the dosing period. No other antitumor therapy can be administered until PD.
41491202|NCT03587389|BIOLOGICAL|Rotarix vaccine|In this study, the 1st dose of Rotarix vaccine will be administered when infants are at ages between weeks 8-9 and the 2nd dose is 28-37 days after the 1st dose, which means that there is an interval of 28-37 days or 4-5 weeks between doses. A reminding call will be set at about 4 weeks after the 1st dose to remind parents to bring their children back to Hung Vuong Hospital for the 2nd dose of Rotarix to ensure the completion of the 2nd dose of Rotarix vaccine.
41491203|NCT03525743|DEVICE|NICOM (Non invasive cardiac output monitor)|Non invasive hemodynamic device utilizing bioreactance
41491204|NCT03584724|DRUG|Norflo Oro|Norflo Oro is highly bioavailable curcumin complexed into phytosomes
41491205|NCT03584724|DRUG|Placebo for Norflo Oro|Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
41491206|NCT04613674|DRUG|Camrelizumab Plus Chemotherapy|camrelizumab+chemotherapy
41491207|NCT04613674|DRUG|placebo+chemotherapy|placebo+chemotherapy
41491208|NCT05101837|DEVICE|Home program|Regular mindfulness guided face-to-face program, by using the technology with android to receive mindfulness sessions for daily practice and to assess the feasibility and the effectiveness of behavioural approach base on mindfulness delivered with this modality
41491209|NCT03233230|DRUG|M2591 25 mg QD|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.
41491210|NCT03233230|DRUG|M2951 75 mg QD|Participants received 75 mg of M2951 orally QD for 12 weeks.
41157634|NCT06290141|DRUG|riliprubart|Pharmaceutical form:Solution-Route of administration:SC solution
41491211|NCT03233230|DRUG|M2951 50 mg BID|Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.
41491212|NCT03233230|DRUG|Placebo|Participants received placebo matched to M2951 orally for 12 weeks.
41491213|NCT01297465|DRUG|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
40829107|NCT05577832|PROCEDURE|Standard Technique|Standard Technique In a single-group design, 3 technique injections will be administered to the patients, 1 technique per days, to be randomized. The standard technique will be applied to patients in any one of 1 weeks in a randomized fashion.
40829108|NCT00084019|DRUG|Atazanavir|
40829109|NCT00084019|DRUG|Ritonavir|
40829110|NCT04393272|DEVICE|Three dimensional sensor system designed for fall detection (Fearless)|Detection of falls in nursing home residents and acute geriatric hospital patiients
40829111|NCT03986047|DEVICE|Thermal care|Wearing of a light elastic lower back heating wrap, which heats up to 40°C within 30 minutes and maintains this temperature continuously for 8 hours. Heat wrap will be worn during the day for 8 hours on 7 consecutive days.
40829112|NCT03986047|OTHER|Exercises|In addition of exercises performed with the physiotherapist at the first session, exercises will be performed at home five times over the next 7 days, for approximately 30 minutes each performing day. Three different categories of exercises will be given: 1) Functional activities exposure (sitting, sit-to-stand, lifting, bending, etc.); 2) cognitive contraction of trunk muscles and basic trunk motor control exercises; 3) mobility of the lumbar spine and preferential direction of movement. Exercises will be chosen and adapted for each participant by a physiotherapist, in function of pain presentation and intensity, and response to exercises.
40829113|NCT03986047|DEVICE|Sham|The same lower back wrap as the Thermal care group will be used, but cooled down to room temperature (opened in advance). The wrap will be worn following the same parameters (duration, frequency) than the Thermal care group.
40829114|NCT03986047|BEHAVIORAL|Education for the management of acute low back pain|Participants will receive education on the management of acute low back pain by a physiotherapist . The main topics addressed will be patient reassurance, staying active, avoiding bed rest, activity modification, and sitting and bed postures/transfer. Participants will received a document that details advices covered during the session and the physiotherapist will answer any questions.
40829115|NCT00682136|PROCEDURE|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
40829116|NCT03694392|BIOLOGICAL|Flublok Quadrivalent|Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
40829117|NCT03694392|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine (SD-IIV)|For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
40829118|NCT02111655|DEVICE|Second generation surveillance of AVF|"Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.~QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound."
40829119|NCT02111655|PROCEDURE|vital signs|Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
40829120|NCT02111655|PROCEDURE|physical examination of AVF|Predialysis physical examination of AVF every dialysis session.
40829121|NCT02111655|PROCEDURE|ktv test|Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
41348062|NCT06000215|DIAGNOSTIC_TEST|Perineal/introital ultrasound examination, two different examiners. The examiners are blinded to each other and to the previous prolapse surgery.|"Each examiner to answer:~1. Is there a mesh or not: Yes or No~2. If Yes:~   * Which type of mesh? Uphold, Pinnacle Posterior or Artisyn® Y-Shaped Mesh~  * What is the length of the mesh in a single midsagittal view image~3. Examination record time is to be registered."
41491214|NCT01297465|DRUG|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
41157635|NCT06290141|DRUG|Placebo|Pharmaceutical form:Solution-Route of administration:SC solution
41491215|NCT01297465|DRUG|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
41348063|NCT06000215|DIAGNOSTIC_TEST|Perineal/introital ultrasound examination, two different examiners. The examiners is now being informed of the previous prolapse surgery.|"Each examiner to answer:~1. Is there a mesh or not: Yes or No~2. If Yes:~   * Which type of mesh? Uphold, Pinnacle Posterior or Artisyn® Y-Shaped Mesh~  * What is the length of the mesh in a single midsagittal view image~3. Examination record time is to be registered."
41491216|NCT01297465|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles \>= 18 mm).
40829122|NCT02111655|PROCEDURE|urea method|Quarterly recirculation with urea method.
41491217|NCT01463735|DIETARY_SUPPLEMENT|Vitamin E supplement (tocofersolan)|700 mg per day per os (i.e. 350 mg twice a day with meals)
41491218|NCT01602965|PROCEDURE|Counseling Monthly Phone Calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
41491219|NCT01602965|PROCEDURE|Self Help Informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
41491220|NCT04625725|DRUG|AZD7442|"* Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366"
41491221|NCT04625725|DRUG|Placebo|Single dose (× 2IM injections) of saline placebo on parent study Day 1.
40829123|NCT01335750|OTHER|Multipurpose Solution #1|B\&L Renu Fresh Multipurpose Solution
40829124|NCT01335750|OTHER|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
41491222|NCT04060043|DRUG|Goserelin Acetate|The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
40829125|NCT01335750|OTHER|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
40829126|NCT01335750|OTHER|Multipurpose Solution #4|Saline Solution
41019361|NCT05913804|BIOLOGICAL|YTS104 Cells injection|YTS104 Cell injection is a new STAR-T cell transfected by lentivirus.The study required that lymphocytes were collected from the subjects and cultured for 2-3 weeks to obtain YTS104 cell injection. Subjects were treated with fludarabine and cyclophosphamide chemotherapy prior to reinfusion, followed by a 2-day rest period before cell infusion.
41491223|NCT05583838|DRUG|rhTPO|initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 \~ 600U/kg every other day depends on platelet count.
41491224|NCT05583838|DRUG|Eltrombopag|initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 \~ 75mg daily or every other day depends on platelet count.
41491225|NCT02494609|DRUG|sotagliflozin|400 mg sotagliflozin
41491226|NCT02494609|DRUG|oral contraceptive|0.25 mg norgestimate/0.035 mg ethinyl estradiol
41491227|NCT02494609|DRUG|oral contraceptive + sotagliflozin|0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin
41491228|NCT06489457|DRUG|Semaglutide|Semaglutide subcutaneous injection once weekly titrated to 1 mg in concordance with Summary of product characteristics (SmPC) (0.25 mg once weekly in the first month, 0.5 mg once weekly in the second month and 1 mg once weekly from the third month onward)
41491229|NCT06489457|DRUG|Testosterone Undecanoate|Testosterone Undecanoate intramuscular injection 1000 mg once per 10-12 weeks
41491230|NCT00742924|DRUG|cisplatin|Given IV
41491231|NCT00742924|DRUG|dexrazoxane hydrochloride|Given IV
41491232|NCT00742924|DRUG|doxorubicin hydrochloride|Given IV
41491233|NCT00742924|DRUG|etoposide|Given IV
41491234|NCT00742924|DRUG|ifosfamide|Given IV
41491235|NCT00742924|DRUG|leucovorin calcium|Given IV or orally
41491236|NCT00742924|DRUG|methotrexate|Given IV
40829127|NCT03065842|BEHAVIORAL|Abortion- and contraceptive-use stigma reduction program|"An abortion- and contraceptive-use stigma reduction intervention (3-weeks), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.~The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions."
40829128|NCT03065842|BEHAVIORAL|Usual Standards|Usual standards according to the school curriculum in Kenya.
40829129|NCT01327274|DEVICE|Magnetic Mini-Mover Procedure (Magnimplant)|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI \> 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery. The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (\< 3.25). Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
40829130|NCT01667562|DRUG|Erlotinib|Daily oral doses administered until disease progression or unacceptable toxicity or death.
41491237|NCT00742924|DRUG|zoledronic acid|Given IV
41491238|NCT00742924|PROCEDURE|adjuvant therapy|
41491239|NCT00742924|PROCEDURE|neoadjuvant therapy|
41491240|NCT00742924|PROCEDURE|therapeutic conventional surgery|Surgery of the primary tumor is scheduled for 12 weeks after the commencement of chemotherapy.
41491241|NCT00742924|BIOLOGICAL|filgrastim|Given SC
41491242|NCT00742924|DRUG|Mesna|Given IV
41491243|NCT04031638|OTHER|Radioactive Iodine treatment|Patients with a thyroid tumor who received radioactive Iodine treatment.
41491244|NCT04144478|OTHER|Web based education|Web based education
41348064|NCT01541540|BEHAVIORAL|e-Counseling plus Usual Care|28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
41348065|NCT01541540|BEHAVIORAL|Control|The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
41348066|NCT02542566|PROCEDURE|Physiotherapy rehabilitation|Physiotherapy rehabilitation
41348067|NCT06357429|OTHER|Cold Application|Cold application was applied to the LI4 acupressure point on the patients' hands using an ice battery.
41348068|NCT05793372|OTHER|Retrospective study of clinical features|Retrospective study of clinical features
41348069|NCT05637541|DRUG|GST-HG141|The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment
41348070|NCT01359111|DEVICE|PATH ID Adapter|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
41348071|NCT04930536|DRUG|Acalabrutinib capsule|The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily
41348072|NCT05736042|DEVICE|Lens fragmentation|Lens fragmentation with the microinterventional microfilament loop device (miLOOP)
41348073|NCT04673630|BIOLOGICAL|Tezepelumab|Single dose subcutaneous injection
41348074|NCT04323917|DIAGNOSTIC_TEST|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
41348075|NCT04602299|OTHER|Set the minimum time of gastroscopy|This study contains 2 stages. At the first stage, no interventions are implemented. The researchers just observe the actual procedure time of gastroscopy. At the second stage, a minimal procedure time is set based on the observational results of the first stage.
41348076|NCT00792857|DRUG|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
41348077|NCT00792857|DRUG|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
41348078|NCT04856969|DRUG|Olmesartan|First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
41491245|NCT03321630|DRUG|Lenvatinib|Lenvatinib 20 mg orally each day on days 1-7
41491246|NCT03321630|DRUG|Pembrolizumab|Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
41491247|NCT00703573|DRUG|S-777469 400 mg|S-777469 400 mg BID
41491248|NCT00703573|DRUG|S-777469 800 mg|S-777469 800 mg BID
41491249|NCT00703573|DRUG|Placebo|Placebo BID
41491250|NCT03255655|DEVICE|Intense Therapeutic Ultrasound Treatment - ITU|
41019362|NCT02829359|DRUG|Entecavir therapy|Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
41348079|NCT04856969|DRUG|Dapagliflozin|First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
41019363|NCT01876121|DRUG|Celecoxib|oral
41348080|NCT06099808|OTHER|Audit and Feedback Emails|Monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. This will include rates of GDMT utilization and percentage of patients on \>50% of the target dose of GDMT stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard.
41348081|NCT06099808|OTHER|Patient Specific Targets|Monthly emails include a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. This data will be obtained from VHA national HF dashboard.
41348082|NCT06099808|OTHER|Educational Resources|Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.
41348083|NCT05858437|DIETARY_SUPPLEMENT|Sodium propionate|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
41491251|NCT03550105|DEVICE|Gentle Jogger|Gentle Jogger is a passive simulated jogging device to be used 3 times per day for at least 30 mins for 7 days in this study
41157636|NCT06290141|DRUG|IVIg|Pharmaceutical form:Concentrate for solution for infusion (or any other formulation approved locally)-Route of administration:IV solution
41491252|NCT02229123|DRUG|Intravenous Levetiracetam|Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
41491253|NCT05841927|DIETARY_SUPPLEMENT|Docosahexaenoic acid supplement|Docosahexaenoic acid supplement
41491254|NCT05841927|DIETARY_SUPPLEMENT|ASD placebo|ASD placebo
41491255|NCT01018589|OTHER|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.~To the patient will be explained the technique of the application."
41491256|NCT04181749|DRUG|aspirin and atorvastatin|Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
41491257|NCT03041324|BIOLOGICAL|SB-913|Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
41491258|NCT02562105|PROCEDURE|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
41491259|NCT01126411|PROCEDURE|immunoadsorption / immunglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
41348084|NCT05858437|OTHER|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
41019364|NCT03754699|BEHAVIORAL|Educational intervention|"During the usual pre-anesthesia assessment (performed between D-30 and D0 of the intervention), the anesthesiologist will deliver to the intervention group patient oral and visual information on:~* the numerical scale of pain ranging from 0 to 10 with examples of perceptions corresponding to each level of the scale (calibration)~* nature of postoperative pain (inflammatory character, dynamic over time)~* average pain level incurred by the intervention~* the difference between anti-inflammatory and opioid analgesics~* principles of systematic treatment and pain anticipation~* principles of overdose and side effects prevention This information is standardized and delivered orally, accompanied by a visual support (patient diary), which will be given to the patient upon discharge from the hospital"
41348085|NCT01362049|OTHER|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
41491260|NCT05194878|DRUG|neoadjuvant chemotherapyI|mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
41491261|NCT05194878|PROCEDURE|Colectomy|Radical colectomy
41509049|NCT05833087|BEHAVIORAL|Schema therapy|30 sessions of schema therapy. The therapy was developed by Jeffrey Young and others and encompasses elements from cognitive behavioral, psychodynamic, and gestalt therapies, as well as attachment theory.
41019365|NCT03754699|BEHAVIORAL|Standard information|Standard information on pain For patients in the control group the standardized information is based on the SG/DGM/DSS 1/41-2010 scheme of the AFSSAPS-CFETD repository.
41019366|NCT01448759|OTHER|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
41019367|NCT04459416|OTHER|Acupuncture|Acupuncture treatments will be scheduled to cover the period of high symptom burden. Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. Electrical stimulation (e-acupuncture) may be applied to the ST36 and SP6 points when appropriate as per standard acupuncture practice.
41019368|NCT04459416|DRUG|opioid|All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.
41019369|NCT04459416|OTHER|Assessments|Participants will be asked to complete patient reported outcomes assessments online using REDCap or, If they prefer, via pencil and paper or over the phone. Assessments at baseline (within 4 weeks before HiChemo) and on or about days 7, 15, 30, and 90 after the first dose of HiChemo.
41019370|NCT02673697|DEVICE|Perceval valve|Sutureless Aortic Biological Valve
41348086|NCT01362049|OTHER|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
40829131|NCT00803413|BEHAVIORAL|Back School Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
40829132|NCT00803413|BEHAVIORAL|Supervised Walking Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.
40829133|NCT00803413|BEHAVIORAL|Back School and Walking|Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities
40829134|NCT00803413|BEHAVIORAL|Control Group|Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
40829135|NCT01360372|DRUG|Methylnaltrexone|Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
41019371|NCT02673697|DEVICE|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
41019372|NCT06383182|PROCEDURE|endovascular treatment|all patients with anterior circulation large vessel occlusion will receive endovascular treatment.
41019373|NCT02760186|PROCEDURE|Altitude Exposure|Altitude Exposure
41019374|NCT02647359|DRUG|Ataluren|Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.
41019375|NCT02647359|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
41019376|NCT05459298|DIETARY_SUPPLEMENT|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
41019377|NCT05459298|DIETARY_SUPPLEMENT|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/day are provided as part of usual care (started when infants receive full feedings of about 120-160 mL/kg/day). At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
41019378|NCT05459298|OTHER|Usual Care|Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
41019379|NCT03065881|DEVICE|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV \[1\] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
41019380|NCT01166932|DRUG|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
41019381|NCT01166932|DRUG|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
41019382|NCT01699997|DRUG|Oxytocin|Intranasal spray with 40 IU of OXT
41019383|NCT01699997|DRUG|Placebo|Intranasal spray with placebo solution
41019384|NCT00058240|DRUG|alvocidib|Given IV
41157637|NCT06290141|DRUG|Placebo|Pharmaceutical form:Placebo to match intravenous immunoglobulin IVIg for IV infusion-Route of administration:IV solution
41157638|NCT06290141|DRUG|IVIg premedication|Pharmaceutical form:Per respective labels-Route of administration:Per respective labels
41348087|NCT04315298|DRUG|Sarilumab|Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
41348088|NCT04315298|DRUG|Placebo|Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
40829136|NCT01360372|DRUG|Saline injection|Saline 0.4 to 0.8 ml injection
41157639|NCT06223841|DRUG|IAP0971|IAP0971 should be subcutaneous injected，q3w
41157640|NCT05452837|PROCEDURE|FDFG|FDFG is applied to the parotidectomy bed after superficial parotidectomy
41157641|NCT05452837|PROCEDURE|SMAS|SMAS flap is applied to the parotidectomy bed after superficial parotidectomy
41157642|NCT02392429|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41348089|NCT03551106|OTHER|Web based learning module|Web based learning module available on a especially designed website
41348090|NCT02954952|DEVICE|PSI Rev 1.X|PSI Rev 1.X is an older version of the PSI measurement.
41348091|NCT02954952|DEVICE|PSI Rev 2.X|PSI Rev 2.X is a newer version of the PSI measurement.
41348092|NCT05193890|GENETIC|retrospective analysis of a panel result|retrospective analysis of a exome clinical solution
41348093|NCT06002490|DRUG|P1101|"The subjects will be treated with P1101(ropeginterferon alfa-2b), starting at a dose of 250 micrograms. The dose of P1101 will be increased to 350 micrograms 2 weeks later and to 500 micrograms another 2 weeks later, and then P1101 will be administered at a fixed dose of 500 micrograms throughout the treatment period. Although the dose may be reduced to the prior dose for reasons related to the safety or tolerability, the increased dose should be preferably maintained throughout the treatment period.~The dose of P1101 will be increased or decreased appropriately depending on the pathological condition in the range up to 500 micrograms."
41348094|NCT06002490|DRUG|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
41348095|NCT06002490|PROCEDURE|Phlebotomy|Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
41348096|NCT04819724|DIAGNOSTIC_TEST|3D motion analysis|30° arm abduction in the scapular plane will be performed with and without a handheld weight of 1, 2, 3, and 4 kg. All movements will be done bilaterally. Electromyographic (EMG) data of arm and trunk muscles will be recorded using surface electrodes. Participants will be asked to perform full arm abduction with different rotations (internal, neutral and external rotation), flexion and internal-/external rotations movements (without additional handheld weight).
41348097|NCT04819724|DIAGNOSTIC_TEST|isometric shoulder strength by dynamometer|isometric shoulder strength for abduction and internal/external rotation will be assessed with a isometric shoulder strength for abduction and internal/external rotation will be assessed with a dynamometer
41348098|NCT04819724|DIAGNOSTIC_TEST|fluoroscopic images of each shoulder|fluoroscopic images (Multitom Rax, Siemens Healthineers, Erlangen, Germany) of each shoulder will be taken during the 30° arm abduction test with and without a handheld weight (0, 2, and 4kg)
41348099|NCT04819724|DIAGNOSTIC_TEST|Bilateral shoulder Magnetic Resonance Imaging (MRI)|MRI of both shoulders will be taken
41348100|NCT04819724|OTHER|data collection by health questionnaires|data collection by health questionnaires
41348101|NCT04663828|OTHER|Structured counseling|Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder
41348102|NCT04663828|DEVICE|Hearing aids|Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.
41348103|NCT04663828|OTHER|Cognitive behavioral therapy|This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups
41348104|NCT04663828|OTHER|Sound therapy|Several sounds and music are used for tinnitus disorder
41348105|NCT01644019|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
41348106|NCT05431335|OTHER|Structured exercise program|"It consists of aerobic exercise combined with breathing, strengthening exercises, and stretching exercises. Aerobic exercise will be performed similarly to the other group, only consisting of a five-minute warm-up period and a 15-minute aerobic load period.~Strengthening exercises consist of deep cervical flexor muscles and shoulder region resistive exercises. Each exercise will be repeated as 15 repetitions, 2 sets.~Stretching exercises are neck region stretching exercises. Each exercise will be performed with 10 seconds of stretching and 5 repetitions."
41348107|NCT05431335|OTHER|Aerobic exercise program|Aerobic exercise intensity will be determined by the Perceived Fatigue Scale (Borg scale). It consists of a ten-minute warm-up period (Borg 11), a 15-minute aerobic load (Borg 13-14), and a five-minute cool-down period(Borg 11). The warm-up and cool-down periods include brisk walking combined with breathing, and calisthenic exercises involving the upper and lower extremities; the loading period consists of exercises using a step-dance board accompanied by music. The number of repetitions will be increased progressively to keep the exercise intensity constant.
41348108|NCT02892305|PROCEDURE|Hepatic Resection or Ablation with Pancreaticoduodenectomy|"Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care."
41348109|NCT04157751|DRUG|Empagliflozin|Film-coated tablet
41348110|NCT04157751|DRUG|Placebo to Empagliflozin|Film-coated tablet
41348111|NCT04366089|OTHER|Oxygen-ozone therapy, probiotic supplementation and Standard of care|- systemic autohemotherapy with Ozone 30 mcg / ml 250ml 2 times / day for 7 days
41491262|NCT05194878|DRUG|adjuvant chemotherapy|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
41491263|NCT04317209|DRUG|SHR0410|administered intravenously
41491264|NCT04317209|DRUG|Placebo|administered intravenously
41491265|NCT01284296|DRUG|Lidocaine digital block|One dose of lidocaine 2% injected locally into one finger (2 mls total)
41491266|NCT01284296|DEVICE|Masimo SpHb continuous hemoglobin monitor|Masimo SpHb continuous hemoglobin monitor
41157643|NCT02392429|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
41491267|NCT06324851|DRUG|Drospirenone / Estetrol|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Drospirenone/Estetrol at any time of the menstrual cycle
41157644|NCT02392429|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
41157645|NCT02392429|DRUG|Chemotherapy|Given anthracycline IV
41157646|NCT02392429|PROCEDURE|Computed Tomography|Undergo FLT PET/CT
41157647|NCT02392429|DRUG|Cytarabine|Given IV
41157648|NCT02392429|OTHER|Fluorothymidine F-18|Undergo FLT PET/CT
40829137|NCT04014543|OTHER|gastronomy|"to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times."
40829138|NCT00821249|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
41019385|NCT03865277|RADIATION|dose-escalated radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm.~Radiotherapy is always applied with 5 fractions per week."
41019386|NCT03865277|RADIATION|dose-escalated radiochemotherapy with carbon ion boost|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial.~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and treated in the study site Heidelberg, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm using a carbon ion boost.~Radiotherapy is always applied with 5 fractions per week."
41348112|NCT04366089|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
41348113|NCT04366089|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
41348114|NCT04366089|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
41348115|NCT06237218|BEHAVIORAL|COTID program|COTID is a support program for people with Alzheimer's disease, designed to help them remain at home, including their primary caregiver.
41348116|NCT05926596|DEVICE|Wearable Robotic Exoskeleton|"* Participant preparation, placement of wearable sensors and monitoring, and wearable device fitting.~* Lower-limb joint rotations and leg stretching protocol (40-60 minutes). The wearable exoskeleton and its control algorithm are evaluated to rotate leg joints and apply stretching similarly to the forces applied by nurses and caregivers when providing manual forces. Joint rotation and limb stretching is conducted while participants sit down (e.g., in a wheelchair, on a chair, on one side of a bed, or on a clinical mat) or lay down on a bed/mat. The protocol involves ankle plantarflexion and dorsiflexion, knee extension, hip flexion with the knee flexed, and toe flexion and extension (bilaterally) assisted by the exoskeleton, and each movement is repeated at a low-to-moderate rate of 10-30 cycles/minute.~* Treadmilll and Overground Walking (60-90 minutes including rest periods)~* Cool down (5-10 minutes)"
41348117|NCT03797794|DEVICE|Pulsating Electrostatic Field|A pulsating electrostatic field is generated by the New Health 9000 (Akern). During the session the patients sits on a chair which contains the apparatus for 30 minutes.
41348118|NCT03797794|DEVICE|SHAM Pulsating Electrostatic Field|The same apparatus which produces the pulsating electrostatic field contains a 'sham-inlet'. This inlet will be used as placebo.
40829139|NCT00821249|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.
40829140|NCT00821249|DRUG|Dexamethasone, steroid; oral|Part 3: standard of care.
40829141|NCT05436587|GENETIC|The whole-exome sequencing|Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.
40829142|NCT00413374|DRUG|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
40829143|NCT01812369|DRUG|GEMCITABINE CISPLATINE|
41019387|NCT03865277|RADIATION|standard radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region and 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes.~Radiotherapy is always applied with 5 fractions per week."
41157649|NCT02392429|OTHER|Laboratory Biomarker Analysis|Correlative studies
41157650|NCT02392429|PROCEDURE|Positron Emission Tomography|Undergo FLT PET/CT
41157651|NCT02929316|DRUG|Vedolizumab|IV infusion week 0, 2 and 6
41348119|NCT00177606|BEHAVIORAL|withdrawal of life sustaining treatments|
41348120|NCT01881906|OTHER|Usual care|
41348121|NCT01881906|OTHER|Exercise|
41348122|NCT00742391|DRUG|PEP005 (ingenol mebutate) Gel|two day treatment
40829144|NCT01812369|DRUG|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
40829145|NCT03687957|DRUG|rhIL-7-hyFc|-Given by intramuscular injection
41157652|NCT01988883|DRUG|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
41348123|NCT00742391|DRUG|Vehicle gel|two day treatment
40829146|NCT03687957|DRUG|Placebo|-Given by intramuscular injection
40829147|NCT03687957|DRUG|Temozolomide|-Standard of care
40829148|NCT03687957|RADIATION|Radiation therapy|-Standard of care
40829149|NCT03687957|PROCEDURE|Blood sample|"* Week 1 (prior to the 1st dose of rhIL-7-hyFc)~* Week 2 (one week after rhIL-7-hyFc)~* Week 3 (two weeks after rhIL-7-hyFc)~* Week 4 (three weeks after rhIL-7-hyFc)~* Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~* Week 14 (one week after rhIL-7-hyFc)~* Week 16 (three weeks after rhIL-7-hyFc) - optional~* Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~* If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~* At the time of tumor progression"
41348124|NCT02208505|DRUG|Dexmedetomidine + Remifentanil-low dose|single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
41348125|NCT02208505|DRUG|Remifentanil-high dose|maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
41348126|NCT00180206|DEVICE|Birmingham Hip Resurfacing|
41348127|NCT05761236|OTHER|Exercise|Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
41348128|NCT00011375|DRUG|Rolipram|
41348129|NCT03378128|PROCEDURE|Diagnostic laparoscopy|The patient will initially undergo a diagnostic laparoscopy by a minimally invasive approach and entry method. The decision of which approach and entry to perform will be dictated by the primary surgeon of record's preference and their assessment of pre-operative patient factors. Once the primary surgeon determines the areas of macroscopic disease, he/she will make an assessment as to the need to convert to a laparotomy or continue laparoscopically. At the completion of the procedure, it will be noted whether an optimal cytoreduction (≤ 1 cm residual disease) or a sub-optimal cytoreduction (\>1 cm residual disease) was performed.
41348130|NCT03968211|BIOLOGICAL|Salmonella typhi polysaccharide vaccine|Salmonella typhi polysaccharide vaccine
41348131|NCT02244125|DRUG|PCD|"STUDY TREATMENT PHASE: All patients~* 4x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle\]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~* Melphalan 200mg/m2 followed by Autologous Transplantation~* 2x 28 days cycles of PCD, three months post transplantation~Arm B:~* 5x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle\]~MAINTENANCE PHASE: All patients~- Until progression/relapse or discontinuation for any other reason~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle\]"
40829150|NCT01731834|OTHER|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
40829151|NCT04999865|OTHER|4-part educational program to build patient-engagement methodology capacity|We created four online training sessions. Our first training for patients/caregivers only (Research 101) was an exception, however, in which we produced a 25-minute asynchronous, self-directed learning seminar intended to be viewed before the subsequent interactive PCOR sessions. Of the three following synchronous interactive training sessions, two included both learner working groups (patients/caregivers and researchers/providers) together (PCOR 101 and PCOR Team Dynamics) and one session (PCOR Study Design) was for researchers/healthcare providers only.
40829152|NCT03958656|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
40829153|NCT03958656|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
40829154|NCT03958656|DRUG|Rimiducid|0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
41019388|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA\~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
41157653|NCT01988883|DRUG|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
40829155|NCT03958656|BIOLOGICAL|Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 12.0x10\^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
40829156|NCT00004206|DRUG|FOLFOX regimen|
40829157|NCT00004206|DRUG|fluorouracil|
40829158|NCT00004206|DRUG|leucovorin calcium|
40829159|NCT00004206|DRUG|oxaliplatin|
40829160|NCT03212417|OTHER|Educational intervention|Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
40829161|NCT04819230|BEHAVIORAL|Cognitive Bias Modification|A four-week computerized attentional and interpretive bias modification protocol in which participants complete both ATT and ITT tasks twice per week, totaling to eight experimental sessions (see experimental arm for more detail.)
41019389|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA\~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
41019390|NCT03160703|OTHER|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA\~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
40829162|NCT04819230|BEHAVIORAL|Cognitive Bias Control|A four-week computerized attentional and interpretive stimuli protocol in which participants complete both ATT-C and ITT-C tasks twice per week, totaling to eight control sessions (see placebo control arm for more detail.)
41019391|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA\~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
41019392|NCT05801978|BIOLOGICAL|Live Attenuated Yellow Fever 17D Vaccine|The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial. The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative. Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.
41019393|NCT05801978|BIOLOGICAL|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
41019394|NCT01736852|DEVICE|CRB|Labor induction using the CRB
41019395|NCT01736852|DRUG|Pitocin|Labor induction using Pitocin
41019396|NCT03454594|DEVICE|low level laser hemotherapy|semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
41019397|NCT01383681|OTHER|No treatment|There was no treatment in this study.
41019398|NCT01826825|BEHAVIORAL|Cognitive Screen|Cognitive Screen
41348132|NCT02244125|PROCEDURE|Autologous transplantation (ASCT)|"Arm A:~•Melphalan 200mg/m2 followed by Autologous Transplantation"
41348133|NCT00312741|PROCEDURE|empirical versus microbiological guided treatment|
41491268|NCT06324851|DRUG|Nomegestrol Acetate / Estradiol|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol at any time of the menstrual cycle
41491269|NCT06324851|DRUG|Ethinylestradiol / Dienogest|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest at any time of the menstrual cycle
40829163|NCT01221025|DRUG|Parecoxib|The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
41019399|NCT01826825|BEHAVIORAL|Mini-Cog|Cognitive Screen
41019401|NCT04273100|COMBINATION_PRODUCT|PD-1 mAb combined with TACE and lenvatinib|the combination of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib)
41019402|NCT00812929|DRUG|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
41019403|NCT00812929|DRUG|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
41019404|NCT00909259|DEVICE|Phrenic stimulation device|In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
41157654|NCT01988883|DRUG|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
41348134|NCT00609167|DRUG|bortezomib|"First 33 patients: 1.3 mg/m\^2 IV Days 1, 4, 8 \& 11~Remaining 30 patients: 1.5 mg/m\^2 IV Days 1, 8, 15 \& 22"
41348135|NCT00609167|DRUG|cyclophosphamide|300mg/m\^2 PO days 1, 8, 15 \& 22
41348136|NCT00609167|DRUG|dexamethasone|"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20~Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"
41348137|NCT02245230|DRUG|Angiotensin (1-7)|Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
41348138|NCT02245230|DRUG|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
41491270|NCT05876663|OTHER|Kinesio Taping|Kinesio Taping will be applied for 6 weeks and it will be changed with new one after every two days
41491271|NCT05876663|OTHER|Conventional physiotherapy protocol|"Stretching exercise for pectoralis minor and major:10 sets and 2 sessions per day for 6 weeks.~Strengthening of Rhomboids and Trapezius muscle: 10 sets and 2 sessions per day for 6 weeks.~Deep Breathing: 10 rep and 2 sessions per day for 6 weeks."
41509050|NCT05833087|BEHAVIORAL|Other psychotherapy|In this arm, psychotherapy can be psychodynamic, cognitive behavioral, interpersonal or other evidence-based psychotherapies, aimed at changing cognitions, behavior, improve social relations and uncover unconstructive psychological patterns.
41348139|NCT02245230|DRUG|Phenylephrine|Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
41348140|NCT06139094|DEVICE|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
41348141|NCT01800162|DRUG|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
41491272|NCT03720379|DEVICE|Fluor Protector S|. All of the elements of a clinical trial and the varnish applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
41491273|NCT03720379|DEVICE|Placebo|All of the elements of a clinical trial and the placebo applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
41491274|NCT00317252|DRUG|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
41491275|NCT06191393|DIAGNOSTIC_TEST|Aptitude Medical Systems Metrix COVID/Flu Test|The Metrix COVID/Flu Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2, Influenza A, and Influenza B via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result, detection of the Flu A gene target will produce a positive Flu A result, and detection of the Flu B gene target will produce a positive Flu B result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
41491276|NCT03106831|DRUG|Pituitrin infusion|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
41491277|NCT03106831|DRUG|Norepinephrine infusion|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
41491278|NCT02433262|OTHER|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
41491279|NCT02433262|OTHER|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
41019405|NCT02233049|DRUG|Erlotinib|
41019406|NCT02233049|DRUG|Everolimus|
41019407|NCT02233049|DRUG|Dasatinib|
40829164|NCT01827813|PROCEDURE|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
40829165|NCT01827813|PROCEDURE|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
40829166|NCT01827813|PROCEDURE|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
40829167|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
40829168|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
40829169|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
40829170|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/ Alhydrogel/GLA-AF|3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals
40829171|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
40829172|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
41019408|NCT03351894|PROCEDURE|Femtosecond laser assisted cataract surgery|Ziemer Z8 femtosecond laser assisted cataract surgery
41348142|NCT01800162|PROCEDURE|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
41491280|NCT04579016|OTHER|PAIGE2 lifestyle intervention|Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
41491281|NCT04579016|OTHER|Standard care|Care routinely provided to all pregnant women diagnosed with GDM
40829173|NCT01261130|BIOLOGICAL|Butang® hepatitis B vaccine|3 doses Butang® hepatitis B vaccine administered at 56 day intervals
40829174|NCT05057715|BIOLOGICAL|VCN-01|Intravenous administration of VCN-01
40829175|NCT05057715|BIOLOGICAL|huCART-meso Cells|Intravenous administration of huCART-meso cells
40829176|NCT01744717|OTHER|Pain measurement|"Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.~The procedures to be studied are the following:~* TURNING / POSITIONING (moving side to side or up or down in bed)~* ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)~* NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)"
41019409|NCT03351894|PROCEDURE|Conventional phacoemulsification|conventional phacoemulsification with infinity phaco
41019410|NCT05914467|DRUG|Teicoplanin|Dose will be adjusted in the study arm using MIPD guided TDM- dosing
41019411|NCT01166984|DRUG|AB103|Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes
41019412|NCT01166984|DRUG|Placebo|Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes
41019413|NCT06221969|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
41019414|NCT06221969|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
41348143|NCT01800162|OTHER|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
41491282|NCT04203875|DRUG|Orencia® (Abatacept)|Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
41491283|NCT02969681|DRUG|ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
41491284|NCT02969681|DRUG|Chemotherapy|"* mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
40829177|NCT05315427|OTHER|one music therapy session|Edmonton Symptom Assessment System (ESAS) scale (before and after music therapy session), Numerical pain scale (before and after music therapy session)
40829178|NCT01482897|DRUG|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
41019415|NCT06221969|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
41019416|NCT06346093|PROCEDURE|Fecal Microbiota Transplantation Capsules|FMT Capsules in Combination with Chemotherapy and Anti-PD-L1 Therapy
41019417|NCT06346093|PROCEDURE|Placebo|Mainly composed of starch, the appearance, shape, color, and size are exactly the same as FMT capsules
41019418|NCT00643955|OTHER|muscle strength|muscle strength
40829179|NCT01482897|DRUG|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
40829180|NCT01482897|DRUG|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
40829181|NCT01530841|DEVICE|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
41019419|NCT03950492|DEVICE|Deep Brain Simulator|This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have DBS targeting the NAc/VC.
41019420|NCT01180075|DRUG|tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
41019421|NCT01180075|DRUG|tenofovir/emtricitabine (TDF/FTC)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
40829182|NCT02057094|DIETARY_SUPPLEMENT|Protein, High-Protein, and Control|
41019422|NCT01180075|DRUG|Atazanavir (ATV)|Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
41019423|NCT01180075|DRUG|Ritonavir|Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
41019424|NCT01180075|PROCEDURE|Phlebotomy|Multiple blood draws will be performed in the study, and vary depending on the group.
41019425|NCT01889589|OTHER|Surveillance|
40829183|NCT06200922|OTHER|Pelvic physiotherapy|All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.
40829184|NCT03466619|DEVICE|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
40829185|NCT00201591|BEHAVIORAL|Exercise training for 10 weeks|
40829186|NCT02467920|DRUG|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
40829187|NCT02467920|DRUG|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
40829188|NCT01488214|OTHER|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
41019426|NCT04550962|DRUG|Dupilumab SAR231893|"Pharmaceutical form:solution Route of administration: subcutaneous~Dose regimen:"
41019427|NCT00485537|PROCEDURE|oocyte retrieval and ICSI procedure|
41019428|NCT05068765|OTHER|Communication skills psychoeducation|Intervention explanations are explained in the groups section.
41019429|NCT05068765|OTHER|General psychoeducation|İntervention descriptions are explained in the intervention groups section.
41019430|NCT01142258|DRUG|Trazodone|Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
41019431|NCT01142258|DRUG|Placebo|Inactive or inert pill which will be used as a comparator
41157655|NCT00356213|PROCEDURE|sleeve gastrectomy|laparoscopic sleeve gastrectomy
41157656|NCT00356213|PROCEDURE|Roux-Y-gastric bypass|laparoscopic gastric bypass
41019432|NCT03003520|DRUG|Durvalumab|"Durvalumab was supplied in single use vials as a liquid solution containing 500 mg (nominal) of durvalumab at a concentration of 50 mg/mL to be infused by intravenous (IV) injection.~Day 1 of each treatment cycle (Induction Period and Consolidation Period) started with the administration of IV durvalumab followed by a 2-hour observation period post infusion."
41019433|NCT03003520|DRUG|Rituximab|Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice. Rapid infusion of rituximab was not allowed in this clinical study.
41019434|NCT03003520|DRUG|Doxorubicin|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
40829189|NCT02429713|PROCEDURE|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
40829190|NCT02429713|PROCEDURE|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
40829191|NCT06246019|DIAGNOSTIC_TEST|Early adoption of blood-based biomarkers for Alzheimer's disease|A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.
40829192|NCT01129882|DRUG|Aripiprazole|Aripiprazole IM depot - 300 mg or 400 mg
40829193|NCT00279838|PROCEDURE|Computer Assisted Navigation Knee Replacement|
40829194|NCT03710239|DEVICE|Dilapan-S|Synthetic osmotic dilator
40829195|NCT03710239|DEVICE|Laminaria|Seaweed-based osmotic dilator
40829196|NCT00533858|DRUG|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
40829197|NCT03414112|BIOLOGICAL|Intranasal oxytocin|oxytocin is a peptide hormone that influences social affiliation
40829198|NCT01219933|DRUG|methylprednisolone|starting dose \>/= 1 mg and \</= 20 mg orally daily, according to dose-reduction schedule
40829199|NCT01219933|DRUG|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
41019435|NCT03003520|DRUG|Vincristine|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
41019436|NCT03003520|DRUG|Cyclophosphamide|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
41348144|NCT03031990|BEHAVIORAL|In-person yoga for fertility group|The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.
41348145|NCT03031990|BEHAVIORAL|Online yoga for fertility group|The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
40829200|NCT02266277|OTHER|Arm 1: E-portal message with IVR call|Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
40829201|NCT02266277|OTHER|Arm 2: E-portal message with no IVR call|Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
40829202|NCT02266277|OTHER|Arm 3: No e-portal message with IVR call|Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
40829203|NCT02266277|OTHER|Arm 5: IVR call|Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
40829204|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 1|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
40829205|NCT06465264|DRUG|Amlodipine group 1|"One Amlodipine (5 mg) tablet and one placebo of Allisartan Isoproxil/Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
41348146|NCT03031990|BEHAVIORAL|In person discussion only group|The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
41348147|NCT03686527|PROCEDURE|stenosis aortic valve|"The exams to be realized :~* a clinical examination with blood pressure~* a 12-lead surface electrocardiogram~* a standard biological assessment including NTproBNP (Brain Natriuretic Peptide)~* Transthoracic echocardiography at baseline and 12 months after the aortic valve intervention on the (according to recommendations)~* a cardiac MRI looking for fibrosis myocardial"
41348148|NCT00422968|DEVICE|Percutaneous coronary intervention|Using silorimus eluting stent
41348149|NCT00422968|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
41157657|NCT04611048|DIAGNOSTIC_TEST|Thermal QST (CDT, WDT, CPT, HPT) with the method of limits|The testing will be carried out using the classical method of limits, i.e. a continuous heating/cooling stimulus will be applied to the skin at a rate of 1°C/s, until the subject signals that he/she felt the targeted sensation by pressing a button (Rolke, Baron, et al., 2006). The temperature reached by the time the subject pressed the button will be considered the threshold. Baseline temperature will be set at 32°C. The stimuli will not go lower than 0°C and higher than 50°C.
41348150|NCT02180191|OTHER|Comparison of the gut microbiota composition|
41348151|NCT05578326|DRUG|Trilaciclib|240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle
41348152|NCT05578326|DRUG|Lurbinectedin|3.2 mg/m2, over 60 minutes at day 1 of each cycle
41348153|NCT05993585|OTHER|Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -Control|(Control Group): One test of the Starling mechanism Visit 1: Sign consent form, doctor assessment, electrocardiogram (ECG), Starling Test. If patients are in this category, this will be their only research visit
41348154|NCT05993585|OTHER|Other: Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -CRT|(CRT Group): Two tests of the Starling mechanisms Visit 1: Sign consent form, assessment by doctor, electrocardiogram (ECG), Test of the Starling mechanism Visit 2: CRT upgrade procedure - your Cardiologist will explain this procedure to you. Visit 3: CRT pacing check at 6 weeks post-procedure Visit 4: Assessment by doctor, ECG, Echocardiogram, Test of the Starling mechanism at 6 months post-procedure.
41348155|NCT05350800|DRUG|BMS-986369|Specified dose on specified days
41348156|NCT04989140|DRUG|Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone|Treatment was continued until disease progression, unacceptable toxicity
41348157|NCT00636506|DEVICE|AMS 700 IPP with MS Pump|AMS 700 Series Inflatable Penile Prosthesis with MS Pump
40829206|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 2|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Allisartan Isoproxil (240 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
41348158|NCT01888965|DRUG|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
41348159|NCT00004205|DRUG|letrozole|Letrozole 2.5 mg daily oral administration.
41348160|NCT00004205|DRUG|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
41348161|NCT06024291|OTHER|8-week HIIT programme|See arm description
41348162|NCT06024291|OTHER|Physical activity recommendation|See arm description
40829207|NCT06465264|DRUG|Allisartan Isoproxil group 2|"One Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
41348163|NCT04993755|DRUG|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
41348164|NCT04993755|DRUG|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
41348165|NCT04371549|PROCEDURE|Glue (Dermabond®; Ethicon, Somerville, NJ).|Arm 1: Skin after cesarean section will be closed by glue
41348166|NCT04371549|PROCEDURE|Monocryl|Arm 2: Skin after cesarean section will be closed by running subcuticular sutures using synthetic absorbable monofilament
41348167|NCT04583228|DRUG|HLX71|Single-dose, intravenous infusion
41348168|NCT04583228|OTHER|Placebo|Single-dose, intravenous infusion
41348169|NCT05822284|DIAGNOSTIC_TEST|NGS and ctDNA-MRD detection|NGS and ctDNA-MRD detection
41348170|NCT04601181|BIOLOGICAL|ThisCART22 cells injection|"Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10\^6 CAR-T cells per kg body weight.~Intervention study"
41348171|NCT04111185|DEVICE|Receive Blood Volume Analysis Guided Treatment|The health care team will be given the results of the blood volume analysis along with guidance on how to provide treatment based on the analysis
41348172|NCT05675475|OTHER|Exposure|Higher education students from health technologies field exposed to digital devices.
41348173|NCT05675475|DIAGNOSTIC_TEST|Orthoptic assessment (Outcome measure)|The orthoptic assessment is a non-invasive assessment that will last for 30 min to determine visual parameters related to binocular vision. It will be carried out by the research team in the orthoptics and vision sciences laboratories of the Lisbon School of Health Tecnology.
41348174|NCT05675475|DIAGNOSTIC_TEST|Tear film Break Up Time (BUT) test (Outcome measure)|The BUT test is a tear film rupture assessment test that allows the stability of the tear film to be evaluated. To perform these tests, it is necessary to instill fluorescein and then it is observed in the slit lamp under illumination with a cobalt blue filter, to count the break-up time.
41348175|NCT00722475|DRUG|Intravenous immunoglobulin|Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
41348176|NCT00722475|DRUG|Human albumin|Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
41348177|NCT00470977|DRUG|ranibizumab injection (0.5 mg)|ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
41348178|NCT05560074|DEVICE|Buzzy|In the Buzzy® group, 30 seconds before the blood collection procedure and during the procedure, the Buzzy® device ist placed 3-5 cm above the area from where the blood would be taken by the PhD qualified nurse researcher
41348179|NCT05560074|OTHER|DistrACTION® Cards|In the DistrACTION® Cards group, picture cards containing various hidden pictures and patterns are used during blood collection by the PhD qualified nurse researcher
41348180|NCT05148429|OTHER|Ultrasound exam|Ultrasound exam
41348181|NCT05148429|OTHER|Fetal MRI|Fetal MRI
41348182|NCT05148429|OTHER|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
41348183|NCT05148429|OTHER|Pediatric Follow up|Pediatric Follow up
41348184|NCT00515944|DRUG|Botulinum neurotoxin type A, free of complexing proteins|
41509051|NCT05833087|OTHER|Standard care package content|"The patient is offered prescription and monitoring of psychopharmacological treatment of up to 5 hours by a psychiatrist, when appropriate.~Additionally, patients have up to 3 hours of preparatory and diagnostic sessions and up to 4 hours of meetings with the participation of next-of-kin and/or collaboration partners in other public instances."
40829208|NCT00900146|DRUG|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
40829209|NCT00900146|DRUG|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
41348185|NCT03260673|OTHER|specular microscope|The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
41348186|NCT03773016|BEHAVIORAL|Art apps|Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The intervention will be delivered to the participants at a quiet room in the care home by two co-investigators, one will be the facilitator, and the other one will be the observer. The intervention is a 30-minutes of individual sessions, with 10 minutes of app use. The additional 20 minutes will include the setup of the equipment and preparation of the participant at the beginning of the session; and questions for the participants at the end.
41348187|NCT04942522|BIOLOGICAL|probiotics PS128|6×10\^10 CFU/capsule
41348188|NCT04942522|DRUG|placebo (Microcrystalline cellulose )|450 mg/capsule
41348189|NCT00926263|BIOLOGICAL|CP-751,871|single dose, 1-hr IV infusion
40829210|NCT00900146|DRUG|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
40829211|NCT02583100|BEHAVIORAL|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
40829212|NCT02583100|BEHAVIORAL|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
40829213|NCT01828138|DIETARY_SUPPLEMENT|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
41348190|NCT00926263|BIOLOGICAL|CP-751,871|single dose, 1-hr IV infusion
41348191|NCT00926263|BIOLOGICAL|CP-751,871, moxifloxacin, saline|Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
41348192|NCT01770093|OTHER|Questionnaire|
41348193|NCT06338813|DEVICE|Digital Manometry|"The Compass Lumbar Puncture Pressure Transducer (Mirador Biomedical, Seattle, WA, USA) was used as a digital manometer. After the bladder was completely emptied, the catheter was clamped again. 25 cc of sterile saline was injected into the bladder through the urine sample port. The digital manometer was connected to the urine sample port. The IAP value in cmH2O on the digital screen of the device was noted."
41019437|NCT03003520|DRUG|Prednisone|"Prednisone was administered as an IV infusion or by mouth (PO) on Day 1, followed by PO administration on Days 2-5 of each cycle.~Prednisone could be given prior to other drugs of the CHOP therapy. It was administered after lenalidomide dosing in the R2-CHOP treatment arm."
41348194|NCT03746145|DIETARY_SUPPLEMENT|Bifidobacterium longum 1714|This is a double-blind randomized placebo-controlled pilot study. Participants under extreme conditions of hypoxia, confinement and isolation receive Bifidobacterium longum 1714 on a daily basis over one year in order to test improvements on stress resilience and immune functions.
41348195|NCT03746145|DIETARY_SUPPLEMENT|placebo sachet containing maltodextrin and magnesium stearate.|placebo sachet containing maltodextrin and magnesium stearate.
41348196|NCT05789706|BEHAVIORAL|Dayamed Arthur a novel intelligent medication adherence platform|Novel smart phone adherence application configured with subject pharmacy data providing accurate reminders of when to take medications and providing auditable user feed back to clinical care teams for patient response directed provider intervention.
41348197|NCT04588376|BEHAVIORAL|Peer comparison feedback monthly|Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only
41509052|NCT05229536|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
40829214|NCT01828138|DIETARY_SUPPLEMENT|Placebo|Placebo are given in 5 days
41019438|NCT03003520|DRUG|Lenalidomide|Lenalidomide was administered orally in capsule form on Days 1-14 of the DUR+R2-CHOP treatment arm only.
41348198|NCT01948323|BEHAVIORAL|HEDUAfrica IT package+ standard care|"The HEDUAfrica website aims to target disadvantaged pregnant women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, South Africa). A trained healthcare worker will assist women by means of a touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes.~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
41509053|NCT05229536|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
40829215|NCT01902888|DEVICE|GORE® VIABAHN® Endoprosthesis|
40829216|NCT06237920|DRUG|Nivolumab|Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
41019439|NCT02182284|DRUG|low dose BI 201335 NA soft gelatine capsule (SGC)|
41019440|NCT02182284|DRUG|high dose BI 201335 NA soft gelatine capsule (SGC)|
41019441|NCT02182284|DRUG|low dose BI 201335 NA powder in bottle (PIB)|
41019442|NCT02182284|DRUG|high dose BI 201335 NA powder in bottle (PIB)|
41019443|NCT03175042|DEVICE|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
41019444|NCT01813526|OTHER|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
41019445|NCT06560541|OTHER|UKMRC9|UKMRC9 is a low glycemic index and polyphenol-rich red pigmented rice
41019446|NCT06560541|OTHER|White rice|White rice refers to a local polished rice
41019447|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.
40829217|NCT06237920|DRUG|Relatlimab|Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
40829218|NCT03929289|BEHAVIORAL|Social Facilitation|During the functional Magnetic Resonance Imaging (fMRI) scans, the subject will perform cognitive tasks measuring eye movements and attention alternatively observed by a familiar peer (in an adjacent room) or not.
40829219|NCT05254405|DRUG|Brexanolone Injection [Zulresso]|Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
40829220|NCT00906139|DRUG|Propofol|Propofol dose: 0.5 mg/kg up to 400 mg
41019448|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.
41019449|NCT04400552|DIETARY_SUPPLEMENT|Usual intake Pre-op + ONS Post-op|Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital
41019450|NCT04555746|BEHAVIORAL|Physical activity|Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
41019451|NCT02894203|BEHAVIORAL|Mindfulness|
41019452|NCT02894203|BEHAVIORAL|Yoga|
41019453|NCT02329405|DRUG|Rifampicin|
41019454|NCT02329405|DRUG|Placebo|
41019455|NCT00661063|DRUG|ketamine|ketamine 150 mcg/g bid
41019456|NCT00661063|DRUG|vehicle gel|bid - 12 weeks
41157658|NCT04611048|DIAGNOSTIC_TEST|Thermal QST (cold and warm detection, heat pain) with the psi method|The Psi algorithm is a method using Bayesian statistics to determine not only the threshold but also the slope of the psychometric function (relationship between the intensity of a stimulus and its detection probability; Kingdom \& Prins, 2010). The algorithm selects the next stimulus intensity to be the most informative on the parameters of interest, based on the prior probability density. After each stimulation, the subject will be asked if he/she felt it (as painful) or not. Based on that answer, a posterior probability density is computed. This posterior is then used as prior for the next stimulation. The stimuli will last maximum 1 s and temperature will be kept between 0°C and 60°C.
41348199|NCT04487418|PROCEDURE|Electro cautery surgery|"Pre-anesthetics with therapeutic topic (benzocaine) will be administered and, as an anesthetic, or use of anesthetic drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline).~The surgery will be carried out with cauterization for incision of the lingual brake, division of the brake fibers and release, removing the brake fibers that are stored in the anterior ventral free parts of the tongue until reaching the base of the tongue, which are removed or cleaned, lingual movement, and the anterior axis of the tongue is repositioned or lingual brake in that region. No sutures will be performed and should be oriented on the formation of a pseudo-membranous repair plate in the second intention that will be formed between the first and the third day after surgery.~Postoperative care:~Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
41019457|NCT00661063|DRUG|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
40829221|NCT00906139|DRUG|Midazolam|Midazolam dose: 0.1 mg/kg
40829222|NCT00906139|DRUG|Fentanyl|Fentanyl dose: 0.05 mg
40829223|NCT05544942|DIETARY_SUPPLEMENT|Lactobacillus plantarum|1 capsule once a day
40829224|NCT05544942|OTHER|maltodextrin|1 capsule once a day
40829225|NCT01497821|DRUG|AMG 172|AMG 172 is an antibody drug conjugate
40829226|NCT04086797|DIETARY_SUPPLEMENT|IQP-AE-103|1980 mg
40829227|NCT04086797|DIETARY_SUPPLEMENT|Placebo|Placebo
40829228|NCT04364607|DRUG|Neostigmine|Participants will receive 0.5 mg IM neostigmine
40829229|NCT04364607|DRUG|NaCl 0.9%|Participants will receive IM NaCl 0.9% as a placebo
41019458|NCT00661063|DRUG|clonidine gel 1%|bid 12 weeks
40829230|NCT01667146|OTHER|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH \> 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
41491285|NCT05912361|BEHAVIORAL|receiving a one hour theoretical and hands on training session before using an AI-based platform|The students at the experimental group will receive a one-hour hands-on training session before logging in to the online platform. The session will be presented by a dentist with AI experience and this session will present basic aspects of AI in radiology, deep learning (DL) applications for cariology and endodontics, as well as basics of excavation therapy and pulp exposure. the theoretical part will be followed by a hands on session on which each participant will check 11 cases of teeth with deep caries and will find the closest line between caries and pulp. their performance will be supervised by the training session presenter and the correct line will be shown them in case of making wrong line.
40829231|NCT01667146|OTHER|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
40829232|NCT00871546|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
40829233|NCT00871546|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
41491286|NCT02352779|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Given PO
40829234|NCT00871546|BIOLOGICAL|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
40829235|NCT05388838|BIOLOGICAL|Blood sample|Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
41348200|NCT04487418|PROCEDURE|High power diode laser surgery|"Pre-anesthetics with therapeutic topic (benzocaine) and as anesthetic or use of anesthetic eye drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline) will be administered. The surgery will be performed with a high power diode laser (TW Surgical, MMOptics - São Carlos - Brazil). 808 nm wavelength, which can be operated in continuous or interrupted mode. Wattages from 1 to 1.5 W, up to a maximum of 2 W, can be used and must carefully respect the histological characteristics of the target tissue and the signs of overheating and carbonization, so that the choice of parameters is dynamic and very dependent on experience, mastery and care for the operator.~Preoperative care: Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
41348201|NCT02871570|DRUG|Rivipansel|A single dose of IV Rivipansel over 20 minutes
40829236|NCT06363578|DRUG|Dexmedetomidine 0.5 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg diluted in saline.
41491287|NCT02352779|OTHER|Placebo|Given PO
40829237|NCT06363578|DRUG|Dexmedetomidine 1 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 1 μg/kg diluted in saline.
41019459|NCT01529645|BIOLOGICAL|Acellular pertussis vaccine|Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
41019460|NCT01529645|BIOLOGICAL|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)|Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
41348202|NCT04759898|DEVICE|transcranial direct current stimulation (noninvasive recording)|Subjects will enter the EEG lab and be seated in a chair. The 26-electrode EEG array will be placed using a conductive paste. The electrodes will be connected to a clinical grade EEG machine used in standard of care routine EEG monitoring. Next, a soft cloth cap will be placed over the subject's head with the tDCS electrodes pre-positioned in place. The cap will be positioned so that the tDCS electrodes cover the scalp without disturbing the underlying EEG electrodes. Conducting gel will be applied in direct contact with the scalp to facilitate stimulation. In addition, lidocaine jelly will be added topically to provide local anesthesia. The tDCS electrodes will be connected to a low-current generator. Participants receive 2.0 milliamps in electrical stimulation from the tDCS machine for 20 minutes. The device will be manually controlled by study personnel assisting with the experiment. A virtual reality environment will be utilized to collect kinematic data during the study.
40829238|NCT03379987|DRUG|PVB morphine|The PVB was performed under ultrasonographic guidance in the sitting position. Surgical disinfection of thoracoabdominal paravertebral area was done. A linear high-frequency transducer (10-12 MHz, Sonosite, Bothell, WA, USA) was used. The scanning process (Longitudinal out-of-plane technique) was started at 5-10 cm lateral to the spinous process of thoracic vertebrae to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until the transverse processes are identified as more squared structure deeper to the ribs. A 100 mm needle was inserted out-of-plane to contact the transverse process of thoracic vertebra and then, walked off above the transverse process 1-1.5 cm deeper searching for loss of resistance injecting 10 ml of 0.25% bupivacaine + 3 mg morphine for group PVB morphine in incremental doses of 3 ml.
40829239|NCT03379987|DRUG|PVB bupivacaine|the same steps mentioned in group PVB morphine but the solution used for paravertebral block contain bupivacaine only 10 ml of 0.25% bupivacaine injected in in incremental doses of 3 ml.
40829240|NCT01920763|OTHER|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
40829241|NCT02823184|BIOLOGICAL|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
40829242|NCT02217371|OTHER|Neuropsychological tests|"The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
40829243|NCT01845584|DRUG|NPB-01|
40829244|NCT00914563|DEVICE|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
40829245|NCT00914563|OTHER|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
40829246|NCT04023357|OTHER|PEEK|New polyetheretherketones material
40829247|NCT04023357|OTHER|Emax|standard etchable glass ceramic used for Endocrowns
41348203|NCT04759898|DEVICE|sham transcranial direct current stimulation (noninvasive recording)|Subjects receiving sham undergo the same setup as the stimulation group with the exception that sham subjects experience stimulation for one minute only (30 second ramp-up to 2 milliamps immediately followed by 30 second ramp-down to 0 milliamps for the remaining 19 minutes). This provides similar sensory feedback to sham subjects that treatment subjects experience. The same electrode array, soft cloth cap, conducting gel application, and lidocaine are applied as in a stimulation subject. The tDCS electrodes will be connected to a low-current generator. A virtual reality environment will be utilized to collect kinematic data during the study.
41348204|NCT04759898|DEVICE|transcranial direct current stimulation (invasive recording)|Subjects are brought into the operating room. The scalp is prepped with a sterilizing solution. Following infiltration with local anesthetic and incision, a 6-contact electrocorticography strip is inserted into the burr hole covering primary motor cortex. Electrocorticography strip terminals are connected to an amplifier for signal recording. Gas-sterilized transcranial direct current stimulation electrodes are placed on the scalp directly overlying primary motor cortex. tDCS electrodes are connected to a low-current generator. During electrocorticographic recording, stimulation is turned on while subjects are asked to flex each arm. At the conclusion of the experiment, the electrocorticography strip and tDCS electrodes are removed and the surgery proceeds as planned.
40829248|NCT04763486|DRUG|Cefazolin (Cefamezin)|Cefamezin 2 gr within 6 hour of delivery
40829249|NCT01247935|OTHER|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
40829250|NCT01247935|OTHER|Transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
40829251|NCT01247935|OTHER|Control|Patients are monitored for pain and discomfort
40829252|NCT03538444|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique which is currently FDA-approved as a treatment for major depressive disorder
40829253|NCT03538444|DEVICE|Sham rTMS|Participants will undergo procedures that mimic rTMS, but that are inactive.
40829254|NCT00168103|BIOLOGICAL|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
40829255|NCT00168103|BIOLOGICAL|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
40829256|NCT06105294|BEHAVIORAL|time-restricted eating|Restrict eating to a 10-hour window.
40829257|NCT00002427|DRUG|Hydroxyurea|
41019461|NCT01529645|BIOLOGICAL|Licensed TdaP booster vaccine|Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
40829258|NCT00002427|DRUG|Stavudine|
40829259|NCT00002427|DRUG|Didanosine|
41491288|NCT02352779|OTHER|Questionnaire Administration|Ancillary studies
41491289|NCT02352779|OTHER|Laboratory Biomarker Analysis|Correlative studies
41491290|NCT01833091|OTHER|artificial night|Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand \& arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
41491291|NCT03814616|DRUG|Pyronaridine tetraphosphate 180mg:artesunate 60mg|ACT
41491292|NCT04328857|DEVICE|pseudoelastic orthosis|The subject will be given specific physiotherapy including activities oriented to multimodal exploration and refinement of gross and fine motor skills, customized according to the functional status of the individual patient.
41491293|NCT05672823|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|Comparing different accessory access sites for TAVI: the temporary pacemaker access site and the diagnostic access site.
41491294|NCT01224730|DRUG|perifosine|100 mg daily
41491295|NCT02589483|PROCEDURE|The rectal anastomosis will be reinforced with HemoPatch.|Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
41491296|NCT02589483|DEVICE|Hemopatch|The rectal anastomosis reinforced with Hemopatch
41491297|NCT06052930|DEVICE|HTC Vive™ Pro|"A commercially available head-mounted display. Each VR session has approximately 20 minutes, performed 3 times per week.~Both groups maintain similar PD specialized physiotherapy sessions throughout the duration of the study (3 times per week, 60 minutes per session)."
41491298|NCT04492020|DRUG|Ubrogepant 100 mg|For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
41491299|NCT04492020|DRUG|Placebo|For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
41491300|NCT01715064|BEHAVIORAL|Exercise|1 hour of moderate-intensity exercise
41491301|NCT01083810|DRUG|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
40829260|NCT04220112|PROCEDURE|Real-Time Functional Magnetic Resonance Imaging (RT-fMRI)|RT-fMRI neurofeedback targeting down-regulation of the amygdala
40829261|NCT04220112|PROCEDURE|Sham Procedure|RT-fMRI with feedback non-contingently tied to their activation patterns (activation patterns from a prior participant)
40829262|NCT03879044|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
40829263|NCT05819073|OTHER|Plain water|Subjects will use plain water as an oral rinse twice a day for 3 days.
40829264|NCT05819073|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
41491302|NCT01710553|OTHER|Glucophage 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
41491303|NCT01710553|OTHER|Metformin GSK 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
41491304|NCT05296356|DRUG|OSU6162|OSU6162
41491305|NCT04752046|PROCEDURE|maxillary cancer resection|patient with maxillary cancer will resected and reconstructed
40829265|NCT04072679|DRUG|Sintilimab+IBI305|It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
40829266|NCT01537081|DRUG|Mucinex|Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
41491306|NCT06017310|DIAGNOSTIC_TEST|Evaluate the performance of IFN I/III|Evaluate the response in diagnosing non-respiratory viral infection.
41491307|NCT03982472|OTHER|transcutaneous electric stimulation|transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects
40829267|NCT01537081|DRUG|Immediate-release Guaifenesin|Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
40829268|NCT01537081|DRUG|Placebo|Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
41019462|NCT01529645|BIOLOGICAL|Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)|To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
41019463|NCT01529645|OTHER|Saline solution|Subjects received one injection of saline solution at one month after vaccination.
41491308|NCT00253695|DEVICE|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
41491309|NCT02384135|OTHER|Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off|
41491310|NCT00715936|BEHAVIORAL|Control|
41491311|NCT00715936|BEHAVIORAL|ECD|
41491312|NCT00715936|BEHAVIORAL|Enhanced Nutrition|
41491313|NCT00388401|DRUG|Alvimopan|
41491314|NCT03011736|OTHER|Laboratory Biomarker Analysis|Correlative studies
41491315|NCT03011736|PROCEDURE|Parathyroidectomy|Undergo parathyroidectomy
41509054|NCT01273896|DRUG|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
40829269|NCT03008902|PROCEDURE|Near-infrared passive motion capture recording|Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
41348205|NCT02250391|DRUG|NPB-06|5 days continuous-infusion
41348206|NCT02250391|DRUG|Placebo|5 days continuous-infusion
40829270|NCT02805400|OTHER|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
40829271|NCT04401956|OTHER|bread|Different types of bread
40829272|NCT02737644|OTHER|observation|This is an observational study
40829273|NCT05618730|DEVICE|punctum plug insertion|"EXP-TC delivers the anti-inflammatory drug tacrolimus that acts as inhibitor of T lymphocytes and may therefore lead to the inhibition of release of inflammatory cytokines.~EXP-TC has a Pangolin design and has 3 different designs: big, medium and small with drug content ranging from 194 to 348 µg.~After plug insertion preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) is taken 4 times daily."
41491316|NCT02545348|PROCEDURE|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
40829274|NCT05618730|DRUG|Eye Drops, Lubricant|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
41348207|NCT04011137|OTHER|Exercise|Arm-cranking exercise
41348208|NCT05592145|DEVICE|ViOptix|ViOptix machine
41348209|NCT01732861|DRUG|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
41348210|NCT01732861|DRUG|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
41348211|NCT01921959|BEHAVIORAL|Intervention|Postpartum women are randomized to intervention or control group
41348212|NCT01408732|DRUG|Sclerotherapy|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
41348213|NCT01408732|OTHER|Standard Treatment|Normal standard of care followed by Drug interevention
41348214|NCT01197872|OTHER|Preimplantation Genetic Diagnosis|Genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia).
41348215|NCT04602611|OTHER|Oncology Nurse Navigation|Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
41348216|NCT02655211|PROCEDURE|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
41348217|NCT02655211|PROCEDURE|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
41348218|NCT02655211|OTHER|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
41348219|NCT03797144|DEVICE|CD HORIZON® Fenestrated Screw System with Fenestrated Screw Cement|The CD HORIZON® Legacy™ and Solera™ Fenestrated Screw Spinal System consists of a variety of cannulated screws with a series of fenestrations to allow polymethylmethacrylate (PMMA) bone cement (Fenestrated Screw Cement) to be injected into the treated site. The Fenestrated Screw Cement is used to augment screw fixation in subjects with compromised bone quality.
41348220|NCT06041230|DEVICE|Ozone Generator|Ultrasound guided ozone therapy
41348221|NCT06041230|DEVICE|Extracorporeal shock wave therapy device|Extracorporeal shock wave therapy device
41348222|NCT03628040|DRUG|Ropivacaine Injection [Naropin]|Ropivacaine will be injected in the erector spinae plane
41348223|NCT03628040|DRUG|Normal saline|Normal saline will be injected in the erector spinae plane
41348224|NCT01911884|BEHAVIORAL|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
41348225|NCT00572065|DRUG|arsenic trioxide|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
41491317|NCT04293094|DRUG|AMG 650|AMG 650 administered orally as a tablet.
40829275|NCT02051153|DRUG|Modafinil|Modafinil (2-\[(Diphenylmethyl) sulfinyl\]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg \& Carter, 2008).
41019464|NCT06561113|OTHER|Caffeine intake|One cup of Turkish coffee contains 60 mg/65 ml (1 Turkish coffee cup) of caffeine. Participants will be instructed to sit for 10 minutes before drinking coffee. To prepare the Turkish coffee, 5 g of ground dry coffee will be mixed in 100 mL of tap water and left to boil in a coffee machine. When the first boil starts, it will be removed from the machine and poured into the cup. Then, 65 ml of Turkish coffee will be given to the subjects to ensure oral caffeine intake.
41019465|NCT03586869|DRUG|Aldoxorubicin HCl|Aldoxorubicin Hydrochloride
41019466|NCT03586869|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
41491318|NCT02304627|DRUG|insulin 338 (GIPET I)|Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
41019467|NCT03586869|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
41019468|NCT03586869|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
41157659|NCT04611048|DIAGNOSTIC_TEST|Neurological examination|A standardized neurological examination will be performed to assess all the items included in the Utah Early Neuropathy Scale (UENS ) (Singleton et al., 2008) and the Toronto Clinical Neuropathy Score (TCNS)(Perkins, Olaleye, Zinman, \& Bril, 2001). This will include: questions about symptoms (presence or absence of foot pain, numbness, tingling, weakness, imbalance and upper limb symptoms); evaluation of knees and ankles deep tendon reflexes; evaluation of pinprick, temperature, light touch, vibration (128 Hz tuning fork) compared to that of an unaffected sites (e.g., sternum); position sensation in the big toes; mapping of pinprick sensitivity in the lower leg; and evaluation of the active extension of the big toes. Pinprick evaluation will be performed using a disposable pin designed for that purpose (Medipin, The United-Kingdom).
41157660|NCT02787135|BEHAVIORAL|emotion-oriented Cognitive Behavior Therapy|Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
41491319|NCT04057469|DRUG|Tulobuterol Hydrochloride|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
41509055|NCT00492440|BIOLOGICAL|recombinant interleukin-7|
40829276|NCT02051153|DRUG|Placebo|
41019469|NCT03586869|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
41019470|NCT03586869|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
41019471|NCT03586869|BIOLOGICAL|GI-4000|RAS yeast
41019472|NCT03586869|BIOLOGICAL|GI-6207|Carcinoembryonic Antigen (CEA) yeast
41019473|NCT03586869|BIOLOGICAL|GI-6301|Brachyury yeast
41348226|NCT00572065|DRUG|cytarabine|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
41348227|NCT02495584|DIETARY_SUPPLEMENT|Fortified milk (10µg vitamin D3)|
41348228|NCT02495584|DIETARY_SUPPLEMENT|Unfortified milk (placebo)|
41348229|NCT02495584|DIETARY_SUPPLEMENT|10µg vitamin D3 supplement|
41348230|NCT02495584|DIETARY_SUPPLEMENT|Placebo supplement|
41348231|NCT01803529|OTHER|heat-pack with massage|
41491320|NCT04057469|DRUG|Placebo transdermal patch|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
40829277|NCT01071005|DRUG|Lorelin Depot Bergamo|Lorelin Depot Bergamo, 3,75 mg, single dose.
40829278|NCT01071005|DRUG|Lupron Depot - Abbott|Lupron Depot 3,75 mg, single dose.
40829279|NCT03897296|DIAGNOSTIC_TEST|High resolution anorectal manometry, water perfused catheter|High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
40829280|NCT00041171|DRUG|Hypericum perforatum|
40829281|NCT00041171|DRUG|docetaxel|
40829282|NCT00041171|OTHER|placebo|
40829283|NCT03084354|OTHER|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
40829284|NCT02680574|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
40829285|NCT02680574|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
40829286|NCT00407004|DEVICE|MARS (Molecular Adsorbents Recirculating System)|
41348232|NCT01803529|OTHER|heat-pack only|
41348233|NCT01590810|DRUG|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
41348234|NCT01590810|DRUG|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
41348235|NCT01590810|DRUG|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
41348236|NCT01590810|DRUG|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
41348237|NCT01590810|DRUG|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
41348238|NCT01590810|DRUG|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
41348239|NCT01590810|DRUG|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
41348240|NCT01590810|DRUG|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
41348241|NCT01590810|DRUG|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
41348242|NCT01590810|DRUG|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
41348243|NCT01590810|DRUG|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
41348244|NCT01590810|DRUG|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
41348245|NCT01590810|DRUG|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
41491321|NCT03246646|BEHAVIORAL|Coaching|Telephone coaching was provided in a series of telephone based sessions with CSO participants
41491322|NCT03157648|OTHER|observing for shivering symptom|In the PACU investigators measure body temperature of all patients at tympanic membrane, forehead, and dorsal of hand. Investigators calculate the difference between body temperature measure at tympanic membrane and forehead/dorsal of hand. Investigators observe the shivering symptom and grading for severity.
41491323|NCT04475783|COMBINATION_PRODUCT|Percutaneous Transluminal Angioplasty (PTA)|PTA with an drug-coated balloon catheter (DCB) in the femoropopliteal artery
41157661|NCT01719055|DEVICE|neurostimulation system|Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
41157662|NCT05878990|BEHAVIORAL|Culturally-tailored Tobacco Treatment|Weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences.
41157663|NCT05878990|BEHAVIORAL|Culturally-tailored Content Newsletters|Weekly newsletters covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics.
41348246|NCT01590810|DRUG|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
41157664|NCT05878990|BEHAVIORAL|Control Preference Scale|Survey to elicit preference on the decision-making interaction with healthcare provider. The survey uses a 5 point scale from 1 to 5 with 1 or 2 points representing Active Control Preference; 3 or 4 representing a Collaborative Control Preference and 5 representing a Passive Control Preference.
41348247|NCT01590810|DRUG|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
41348248|NCT01590810|DRUG|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
41348249|NCT01590810|DRUG|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
41348250|NCT01590810|DRUG|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
40829287|NCT00407004|DEVICE|Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)|
40829288|NCT06305195|DIAGNOSTIC_TEST|heart rate variability test|"First, the patient is required to lie on their back to have a 5-minute continuous ECG recorded, without performing any maneuvers.~Following this, deep breath test, Valsalva and stand test are performed."
40829289|NCT02818036|DRUG|Naltrexone|
40829290|NCT02818036|DRUG|Placebo|
40829291|NCT01034371|PROCEDURE|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
41348251|NCT01590810|DRUG|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
41348252|NCT01020994|DRUG|LAS41003|Once daily, topically
41348253|NCT01020994|DRUG|LAS189962|Once daily, topically
41348254|NCT01020994|DRUG|LAS189961|Once daily, topically
41348255|NCT00899366|GENETIC|microarray analysis|
41348256|NCT00899366|GENETIC|mutation analysis|
41348257|NCT00899366|OTHER|immunologic technique|
41348258|NCT02325089|DEVICE|Mandibular advancement device|Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.
41509056|NCT00492440|GENETIC|gene expression analysis|
40829292|NCT01034371|PROCEDURE|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
41348259|NCT02325089|DEVICE|Placebo|Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
41348260|NCT04410835|DIAGNOSTIC_TEST|Online Survey|Psychological questionnaires
41491324|NCT00654290|DRUG|Amiodarone + Propranolol|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
41491325|NCT00654290|DRUG|Amiodarone|Amiodarone treated 7 days pre-operation to 5 days post CABG
40829293|NCT01034371|PROCEDURE|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
41348261|NCT04034069|DEVICE|Theta burst stimulation (TBS)|Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
41348262|NCT04034069|BEHAVIORAL|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
41491326|NCT00654290|DRUG|Propranolol|Propranolol from 7 days pre-operation to 5 days post CABG
41491327|NCT06415877|OTHER|Episio Training|episio repair training
41491328|NCT05869461|BEHAVIORAL|KP Specific Wellness Sessions|The sessions will include content on yoga, nutrition, legal issues, medical information, and community resources from the original Chetana intervention (further described below). They will also include expanded content informed by our previous studies and focus group discussions with MSM and TGW that addresses the needs for sessions on mental health, financial literacy, substance use, legal rights for key populations and coping skills for interacting with the legal system, and community resources for MSM and TGW. Sessions will include specifically tailored content related to the needs of MSM or TGW.
41491329|NCT05869461|BEHAVIORAL|Peer Navigation|Participants will be assigned to a peer navigator (PN) who will be their principal point of contact for the intervention. Within a week, the navigator will set up an initial introductory meeting, either in person or via video chat. This will serve as the first monthly check-in to monitor a participant's progress. During these in-person digital meetings, the navigator will work with a participant to identify their unique barriers that currently affect engagement in care and train participants to identify and break down solutions into manageable steps. Special attention will be paid to barriers associated with intersectional stigma and PNs will draw on their own experiences as members of stigmatized groups in identifying and brainstorming successful coping strategies. While this is not a structural intervention, PNs will work with their clients to develop ways of coping with structural barriers, including transportation and referrals to social services.
41491330|NCT06354010|GENETIC|Genotyping|Genotyping to determine if patients present mutations to the gene GJB2.
41491331|NCT06354010|OTHER|Audiological assessments|Audiological assessments
41491332|NCT04993014|DRUG|Pertuzumab|Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)
41491333|NCT04993014|DRUG|Trastuzumab|Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts
41491334|NCT04993014|OTHER|Circulating tumor cells|Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.
41491335|NCT06432049|OTHER|restoration for endodontically treated molar|prefabricated stainless steel crown or endocrown
41019474|NCT03586869|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
41019475|NCT03586869|BIOLOGICAL|bevacizumab|Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
41491336|NCT01674127|DRUG|Methyldopa|
41491337|NCT01674127|DRUG|Placebo|
41509057|NCT00492440|GENETIC|polymerase chain reaction|
41509058|NCT00492440|GENETIC|protein expression analysis|
41509059|NCT00492440|OTHER|flow cytometry|
40829294|NCT03250039|DRUG|PF-04965842|14C labeled PF-04965842
40829295|NCT03250039|DRUG|Absolute Bioavailability|Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
40829296|NCT01878110|BEHAVIORAL|COMB|
41509060|NCT00492440|OTHER|immunoenzyme technique|
41509061|NCT00492440|OTHER|immunologic technique|
41509062|NCT00492440|OTHER|laboratory biomarker analysis|
41509063|NCT00492440|OTHER|pharmacological study|
41509064|NCT02625597|DEVICE|Cotton Pellet|
41509065|NCT02625597|DEVICE|Polytetrafluoroethylene Tape|
41509066|NCT02625597|DEVICE|Synthetic Foam|
41509067|NCT02625597|DEVICE|Polyvinylsiloxane|
40829297|NCT01257490|BEHAVIORAL|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
40829298|NCT03571672|DRUG|DEFINITY|All subjects will receive a single dose of DEFINITY®
40829299|NCT03811847|DRUG|Methylphenidate Extended Release Oral Capsule|"Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg"
41019476|NCT03586869|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
40829300|NCT03811847|OTHER|Placebo|Placebo comparator MPH Matched Placebo Tablet
40829301|NCT06023628|OTHER|Danish Helicopter Emergency Service|Patients with traumatic cardiac arrest assessed by the Danish HEMS
40829302|NCT00002652|DRUG|suramin|
40829303|NCT05173428|BEHAVIORAL|Smoking Cessation Program Based on Transtheoretic Model|Conducting motivational interviews based on the transtheoretic model according to the stages of change that individuals are in.
41348263|NCT01238705|DRUG|Felodipine add Irbesartan|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074."
41491338|NCT04995692|BEHAVIORAL|Telehealth Education for Asthma Connecting Hospital and Home|TEACHH aims to provide educational support to families managing childhood asthma throughout the transition from hospital to home, and includes several core components: 1) Health literacy-informed inpatient teaching for child and caregiver including pictorial materials, hands-on demonstration, and use of teach-back/show-back techniques; 2) Facilitated identification of rescue and controller medications using color- and shape-coded medication labels and a pictorial asthma action plan; and 3) A pair of virtual follow-up visits after discharge to reinforce inpatient teaching and support families during the shift from acute exacerbation to preventive care management. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices, 2-4 days after discharge (first visit) and 3 weeks after discharge (second visit). All intervention activities will be completed within 1 month of discharge.
41348264|NCT01238705|DRUG|Felodipine add Metoprolol|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061."
41348265|NCT05127356|DEVICE|DIAGNOdent|Laser fluorescence device
41348266|NCT05127356|DIAGNOSTIC_TEST|ICDAS II|International Caries Detection and Assessment System (ICDAS II)
40829304|NCT03619226|OTHER|test patch|the test patch consists of an adhesive patch
41348267|NCT04898088|BIOLOGICAL|Mesenchymal Stem Cells Transplantation|Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals
40829305|NCT05867290|BEHAVIORAL|Mindful music-listening with sleep hygiene|5 week intervention consisting of sleep hygiene (week 1) and daily bedtime mindful music-listening for 30 minutes or until about to fall asleep, if sooner (weeks 2-5)
40829306|NCT06333743|PROCEDURE|laser ablation|Research has confirmed that laser ablation treatment of cervical HSIL is effective and feasible.
40829307|NCT06333743|PROCEDURE|LEEP or Conization|The most common treatment for HSIL is LEEP or conization of the cervical lesion, but there are several perinatal complications involved in this surgery.
40829308|NCT03283969|OTHER|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
40829309|NCT03283969|OTHER|Isocaloric powder|Isocaloric powder
40829310|NCT05000268|OTHER|Progressive Myofascial Relaxation Exercise|"Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~* First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed."
41348268|NCT00693563|BEHAVIORAL|Scheduled Telephone Intervention|Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
41491339|NCT04995692|BEHAVIORAL|Standard Care (SC) Comparison Group|Patients in the SC group will receive standard impatient management, including pre-recorded asthma education videos shown prior to discharge and the hospital action plan. PCP follow-up with be scheduled within a week of discharge. All SC measures will also be provided to subjects randomized to TEACHH.
40829311|NCT04290468|DEVICE|Dynamic ultrasound|"The ultrasound examination will be carried out blinded to the results of MRI using the Affiniti 70 ultrasound machine by Philips (USA) via a 5-12MHz linear transducer.~MRI was performed on a high field system (1.5 Tesla) magnet units (Philips Acheiva)."
41348269|NCT05727631|OTHER|gentle human touch|Mother will apply gentle human touch touch technique during venous blood collection from preterm babies between 32-37 weeks of gestation
41348270|NCT03431623|BIOLOGICAL|CKD-11101(Darbepoetin alfa)|
41491340|NCT01406392|DRUG|Misoprostol 25mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
40829312|NCT05210868|DRUG|CM355|"1. Dose Escalation Phase CM355 will be taken by patients and will be treated follow the 3+3 dose escalation scheme~2. Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug"
41348271|NCT03431623|BIOLOGICAL|NESP(Darbepoetin alfa)|
41348272|NCT01646255|DRUG|Rotigotine|"Transdermal Patch~Content:~4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
41348273|NCT01646255|DRUG|Placebo Patch|"Transdermal Patch~Size:~20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
41348274|NCT01646255|DRUG|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
41348275|NCT06425406|DEVICE|high-flow nasal cannula|In group H, mask ventilation was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 90 %. The lower mask was taken and HFNC was used to record the patient 's safe apnea time.
40829313|NCT04993729|DRUG|T89 capsule|"T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID."
41348276|NCT01989936|DRUG|Placebo|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
41348277|NCT01989936|DRUG|Eletriptan 40 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
40829314|NCT04993729|DRUG|Placebo capsule|Placebo capsules, p.o. TID.
40829315|NCT00160199|DRUG|PROMETRIUM® 300 mg|300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
40829316|NCT00160199|DRUG|PROMETRIUM® 400 mg|400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
40829317|NCT01810068|PROCEDURE|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
40829318|NCT01810068|PROCEDURE|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
40829319|NCT01810068|PROCEDURE|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
40829320|NCT01810068|PROCEDURE|Diagnostic cystoscopy|Cysto-urethroscopy
41491341|NCT01406392|DRUG|Sublingual Misoprostol|Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
41491342|NCT05154630|DRUG|TQB2858 injection|TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
41491343|NCT06478264|DRUG|Etoposide|100mg/m\^2, intravenous infusion for 1-3 days,21 days/cycle, 4 cycles
41491344|NCT06478264|DRUG|Cisplatin|25mg/m\^2 ,intravenous infusion for 1-3 days ,21 days/cycle, 4 cycles
40829321|NCT05922410|RADIATION|cone beam computed tomography|cone beam computed tomography
40829322|NCT05185895|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
40829323|NCT05185895|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
40829324|NCT05773365|OTHER|PENG block with or without local anaesthetic infiltration|As mentioned.
40829325|NCT04836390|DRUG|Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions|Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
40829326|NCT06358560|OTHER|Therapeutic exercises|Rehabilitation exercises designed to achieve the treatment goal
40829327|NCT01188148|DRUG|Memantine|5 mg per day of memantine
40829328|NCT01188148|DRUG|Placebo|
40829329|NCT00989235|DRUG|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
40829330|NCT00989235|DRUG|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
40829331|NCT04418336|PROCEDURE|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
40829332|NCT05637489|BEHAVIORAL|PING|Brief survey of goals and preferences
40829333|NCT03377738|DIAGNOSTIC_TEST|spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.
40829334|NCT04485689|DRUG|Capsaicin Topical - alone|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours
40829335|NCT04485689|DRUG|Placebo - alone|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
40829336|NCT04485689|DRUG|Capsaicin Topical - ice|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
40829337|NCT04485689|DRUG|Placebo - ice|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
40829338|NCT04268875|DEVICE|Optical Coherence Tomography (OCT)|"The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same."
40829339|NCT04213144|DEVICE|Magdent Cap MED|Magdent is intended to be used for accelaration of soft tissue and bone healing
40829340|NCT04213144|DEVICE|Sham MED|Sham MED is intended to be used for soft tissue healing
40829341|NCT00025168|DRUG|gemcitabine hydrochloride|
40829342|NCT00025168|DRUG|irinotecan hydrochloride|
40829343|NCT00025168|RADIATION|radiation therapy|
40829344|NCT02639338|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
40829345|NCT02639338|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
41348278|NCT01989936|DRUG|Eletriptan 80 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
41348279|NCT01220596|DRUG|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
41491345|NCT06478264|DRUG|Carboplatin|Carboplatin (AUC = 5) on 1 Day,21 days/cycle, 4 cycles ;
41491346|NCT06478264|DRUG|Adebrelimab|1200mg adebrelimab was given intravenously on 2 day after chemotherapy,21 days/cycle, continuous use.
41491347|NCT06478264|RADIATION|radiotherapy|Stage I-IVa , prescription dose: PTV 50Gy/25f. Stage IVb ,prescribed dose: PTV 30Gy/10f.
41348280|NCT01220596|DRUG|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
41348281|NCT01751269|DRUG|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
41348282|NCT01751269|DRUG|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
41491348|NCT01268501|DEVICE|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
40829346|NCT00828399|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine 30g/day
40829347|NCT00828399|DIETARY_SUPPLEMENT|Whole protein|Oral whole protein 30 g/day
40829348|NCT00961792|DRUG|Ethanol|Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
40829349|NCT00961792|DRUG|Placebo|Beverage containing 0.0 g/kg alcohol to act as placebo
40829350|NCT00961792|DRUG|Diphenhydramine|Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
40829351|NCT00961792|DRUG|Caffeine|Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
41491349|NCT02933021|OTHER|Blood sample taken|
41491350|NCT02933021|OTHER|Answering a lifestyle questionnaire|
41509068|NCT04077580|DRUG|Methenamine Hippurate 1000 MG|Methenamine and placebo is taken 1 tablet morning and evening for 180 days
41019477|NCT03586869|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
41019478|NCT03586869|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
41491351|NCT02933021|OTHER|Follow-up phone call from researcher (two years after first visit)|To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
41491352|NCT00852969|DRUG|Niacin|1000 mg tablets once per day
41491353|NCT00852969|DRUG|Active Placebo|100 mg Niacin tablets once per day
41491354|NCT03482349|PROCEDURE|Total Knee Robotically-Assisted|The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
41019479|NCT03586869|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
41019480|NCT03586869|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
41019481|NCT03586869|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
41509069|NCT03456141|PROCEDURE|third molar surgery|The patient is asked to complete the diary each post-surgery day for 14 days. Recovery is organized into three QOL domains: lifestyle, oral function, and pain.
40829352|NCT04773561|DEVICE|Corneal tomography, optical coherence tomography and optical coherence tomography angiography|Ocular investigations were performed in one time during 30-36 weeks of gestational age. Due to avoidance of diurnal variation, all examinations were done between 10 am - 12 pm.
40829353|NCT05516030|OTHER|HIFT for people with MRD|12-wk, 3x/week HIFT participation for individuals with MRD
40829354|NCT05123521|DIAGNOSTIC_TEST|urine analysis|Urine was then tested for evidence of substance abuse using the multi-drug screen panel dip steak ABONtm (Abon Biopharm (Hangzhou) CO., Ltd) which is a lateral flow chromatographic immunoassay . It allowed for qualitative detection of multiple drugs in a single run. This kit was chosen for its ability to detect the most commonly abused substances in Egypt, namely: opioids, benzodiazepines, hashish, and tramadol. A single coloured line at region C for of a specific drug indicated a positive result, whilst two coloured lines at both regions C and T indicated a negative result. The absence of coloured lines was an indication of the invalidity of the particular kit, and the kit was discarded.
40829355|NCT00029757|DRUG|Estrogen|
41491355|NCT04383236|OTHER|Probiotics|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
41019482|NCT03586869|BIOLOGICAL|Avelumab|Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
41348283|NCT02220530|DRUG|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
40829356|NCT03351556|BEHAVIORAL|Active Arm 1|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
41019483|NCT03586869|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
41019484|NCT05663489|BEHAVIORAL|Bergen 4-Day Treatment (B4DT)|A concentrated and exposure-based psychological treatment over four consecutive days
41019485|NCT02340559|BEHAVIORAL|Meta-cognitive Training|
41019486|NCT02340559|BEHAVIORAL|Psychoeducational group|
41019487|NCT05605366|DRUG|Minocycline|Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.
41019488|NCT05605366|DRUG|Placebo|This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.
41019489|NCT04700514|DRUG|Dexmedetomidine|Dexmedetomidine (1 mcg/kg loading for 10 min, then 1 mcg/kg/min continuous infusion) is used with sevoflurane in every time of general anesthesia
41348284|NCT06243289|OTHER|Tolerance induction|Exposure of peripheral blood mononuclear cells extracted from donated patient blood to a combination of vitamin D3 and interleukin 10 to test whether tolerogenic dendritic cells can be generated and have the same functional capacity between donors with and without kidney disease (exposure of PBMC to the uremic environment)
41509070|NCT04422041|OTHER|Time to discharge less than 24 hours|Allow the joint medical discharge of the newborn together with its mother in less than 24 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
40829357|NCT03351556|BEHAVIORAL|Active Arm 2|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
40829358|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
40829359|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
40829360|NCT04890587|DRUG|AL8326 tablets|Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
40829361|NCT04397913|DRUG|Paracetamol|15 mg/kg, q6h
41348285|NCT06022497|OTHER|Tidal Model Based Emotion Regulation Interventions|The Tidal Model is a nursing model and was developed by Phil Barker. It is an important model for psychiatric nursing care. In the research, nursing interventions for emotion regulation were structured by using the Tidal Model.At each session, emotion regulation interventions were applied within the Tidal Model care domains.
41491356|NCT04383236|DRUG|Oracure oral gel|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
41491357|NCT01654133|DEVICE|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft|Repair of thoracoabdominal aortic aneurysms
41491358|NCT01654133|DEVICE|Endovascular repair of ascending/arch aortic aneurysm using branched stent graft|Repair of ascending/arch aortic aneurysms
41491359|NCT03857750|DRUG|Rocuronium|0.6 mg/kg
41491360|NCT02494180|DRUG|fentanyl|arm A receiving iv fentanyl
41348286|NCT05363618|DIETARY_SUPPLEMENT|Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)|Active study product
40829362|NCT04397913|DRUG|Ibuprofen|10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
40829363|NCT05302258|DIAGNOSTIC_TEST|Attenuation imaging in ultrasonography|Attenuation imaging in ultrasonography
41348287|NCT05363618|OTHER|Placebo 1.4 ml|Placebo
41348288|NCT04961502|BIOLOGICAL|Blood test to describe the humoral and cellular response to vaccination BNT162b2 in the elderly|3 blood samples taken to compare the immunization response of the elderly with that of younger adults (priority caregivers): the first carried out before the anti-Coronavirus Disease 2019 (COVID-19) vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
41348289|NCT01975376|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
41491361|NCT02494180|DRUG|pethidine|arm B receiving iv pethidine
41491362|NCT02494180|DRUG|Diazepam|arm B receiving iv diazepam
41491363|NCT02494180|DRUG|Midazolam|arm A receiving iv midazolam
41491364|NCT05068453|DRUG|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|OH2：less than 8mL/time，Q2W，i.t.；
41491365|NCT05068453|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody for injection|HX-008：200mg/time，Q3W，i.v.；
41491366|NCT05068453|RADIATION|RT|3 times radiation，totally 24-30 Gy for each lession.
41491367|NCT03301532|DRUG|Triheptanoin|Dietary supplementation with triheptanoin
40829364|NCT03282110|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.
40829365|NCT03282110|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
40829366|NCT03282110|DRUG|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
40829367|NCT00836459|BEHAVIORAL|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
40829368|NCT00836459|BEHAVIORAL|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
40829369|NCT03523273|DRUG|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
40829370|NCT03523273|DRUG|Placebo|Placebo administration will match the study drug.
41348290|NCT01975376|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
41348291|NCT05057884|BEHAVIORAL|Breathing training|Slow nasal breathing with intermittent end-expiratory apnoea for 15 min twice per day over 12 weeks.
41348292|NCT01174589|OTHER|Strength training|to compare if there is a difference between 6 or 12 weeks of physical strength training
41348293|NCT00821756|BEHAVIORAL|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
41348294|NCT00218283|DRUG|Nicotine Lozenge|Oral Nicotine replacement product
41348295|NCT00218283|BEHAVIORAL|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
41348296|NCT01646346|RADIATION|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
41348297|NCT03413228|OTHER|Questionnaire|An interview to collect some informations will be done: demographic informations, medical history, vaccination against influenza status, symptoms and virological informations. Then, a nasal swab was performed in order to identified the influenza virus.
41348298|NCT02726607|BEHAVIORAL|HIV Infant Tracking System (HITSystem) 2.0|The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.
41348299|NCT02726607|BEHAVIORAL|Standard of PMTCT care|Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
41348300|NCT01921699|PROCEDURE|taking blood samples from healthy people|
41348301|NCT05700760|BEHAVIORAL|ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns)|Evidence-based 5 session psychosocial intervention that has been found to prevent \~50% of postpartum depression among low-income, at risk women.
41348302|NCT05700760|BEHAVIORAL|Enhanced Care as Usual (CAU)|Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
41348303|NCT00085358|DRUG|carboplatin|Given intraperitoneally
40829371|NCT01960127|BEHAVIORAL|Aerobic Exercise|Aerobic exercise
40829372|NCT01960127|BEHAVIORAL|No Intervention|No Intervention
40829373|NCT00858897|OTHER|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-\[3,3-2H2\]cysteine
40829374|NCT00858897|DRUG|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
41348304|NCT00085358|DRUG|paclitaxel|Given IV or intraperitoneally
41348305|NCT00085358|DRUG|docetaxel|Given IV
41348306|NCT00085358|BIOLOGICAL|bevacizumab|Given IV
41491368|NCT04505293|DEVICE|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
40829375|NCT05630651|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose level is 5.0×10\^12vg/kg.
40829376|NCT04150731|RADIATION|16α-18F-fluor-17β-estradiol|16α-18F-fluor-17β-estradiol PET/CT scan
40829377|NCT03579446|DRUG|Hydrocodone|Given by PO
40829378|NCT03579446|DRUG|Hydromorphone|Given by PO
40829379|NCT03579446|DRUG|Levorphanol|Given PO
40829380|NCT03579446|DRUG|Morphine|Given by PO
40829381|NCT03579446|DRUG|Oxycodone|Given by PO
40829382|NCT03579446|DRUG|Oxymorphone|Given by PO
41348307|NCT01960452|BEHAVIORAL|Serial awakenings|The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
41348308|NCT04752228|OTHER|Philadelphia ACE Survey|The Philadelphia ACE survey assesses the three major domains featured within the original ACE Study Questionnaire developed by Felitti et al. (abuse, neglect, and family dysfunction), in addition to five community-level stressors.
41348309|NCT04752228|OTHER|Lifestyle Assessment|The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.
41491369|NCT00938249|DIETARY_SUPPLEMENT|Monascus Garlic Fermented Extract|
41491370|NCT00938249|DIETARY_SUPPLEMENT|Placebo|
41491371|NCT01345006|BIOLOGICAL|MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
40829383|NCT03579446|OTHER|Questionnaire Administration|Ancillary studies
40829384|NCT03236168|DRUG|Ivermectin|A single weight based dose of ivermectin
40829385|NCT03236168|DRUG|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
40829386|NCT03236168|DRUG|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
40829387|NCT02671149|DIETARY_SUPPLEMENT|Water|Participants will receive two cups of 150ml plain water
40829388|NCT03638869|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
40829389|NCT03638869|DRUG|Placebo|
40829390|NCT02238340|DRUG|Extended-release oxycodone|10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery
40829391|NCT02238340|DRUG|Extended- release Oxycodone|
41348310|NCT01020929|DEVICE|Blunt Coude|Type of needle tip
41491372|NCT03065218|DRUG|99mTc sestamibi|The administration of the diagnostic radioisotope, 99mTc sestambi, to image possible metastases in patients with differentiated thyroid cancer.
41491373|NCT04809935|DRUG|98% dehydrated alcohol|"* coeliac plexus is identified and punctured~* Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol."
41491374|NCT04809935|DEVICE|19G EUSRA needle, Taewoong Medical, Korea|"* 10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s~* Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan"
41491375|NCT01006226|DRUG|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
40829392|NCT02238340|DRUG|ketoprofen|
40829393|NCT02238340|DRUG|dipirone|
40829394|NCT02238340|DRUG|dexametasone|
40829395|NCT02238340|DRUG|Morphine IV (rescue)|
40829396|NCT05203367|DRUG|BAR502|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg)."
40829397|NCT05203367|DRUG|Placebo|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
40829398|NCT02738476|PROCEDURE|Patellofemoral arthroplasty|
40829399|NCT05202665|PROCEDURE|ICON DMG Resin Infiltration (micro-invasive approach)|A plastic wedge located below the contact point to apart from the surface from adjacent tooth. A 15% HCl etching gel (Icon, DMG, Hamburg, Germany) was applied by syringe below the contact point for 120 s. After, the gel was washed off with air-water-spray for 30 s. The lesion was desiccated by air-blowing for 10 s, application of ethanol for 30 s and air-blowing again for 30 s. A resin infiltrant (Icon, DMG, Hamburg, Germany) was applied with another plastic holder during 3 min. Following the penetration, excess of material was removed by air blowing and flossing. The resin was light-cured for 40 s total from the buccal, occlusal, and lingual/palatal aspects. It was needed to reapplicate the resin infiltration for once because of infiltrating remaining porosities during 1 minute. Excess material removing process was again repeated and light cured for 40 s.
41348311|NCT01020929|DEVICE|Quincke|Type of needle tip
41348312|NCT01020929|DEVICE|Trucath|Type of needle tip
41491376|NCT05528835|PROCEDURE|Frozen embryo transfer|All women in both groups will receive oral estradiol valerate 8 mg/ day from the second day of the menstrual cycle. Endometrial thickness will be assessed by vaginal ultrasonography at the tenth day of treatment. When endometrial thickness reached ≥ 7 mm all subjects, in addition to estrogen, they will receive progesterone vaginal suppositories 400 mg twice daily and 100 mg of progesterone intramuscularly daily. Frozen thawed embryo transfer will be at day 6 of progesterone. Estrogen and progesterone will be continued until 9-10 weeks of gestation
41491377|NCT01103726|DRUG|PF-02545920|1 and 5 mg tablets, 6 mg single dose
41491378|NCT01103726|DRUG|placebo|matching placebo tablets, single dose
40829400|NCT05202665|PROCEDURE|ClinproTM White Varnish, 3M ESPE Fluoride Varnish (non-invasive approach)|Tooth surfaces were cleaned thoroughly and isolated with cotton rolls. According to the manufacturer's instructions, the unit dose packages were opened, and the contents were dispensed onto the application guide and mixed to avoid the separation of sodium fluoride components. A thin coat of varnish (ClinproTM White Varnish, 3M ESPE, USA) with 22600 ppm fluoride was applied to the tooth interface with a brush tip applicator and waited for 5 minutes. Aproximal areas were coated with dental floss. The patient was instructed not to rinse or apply suction immediately after application. Patients were advised to avoid eating hard and sticky foods or drinking hot beverages for the next 2 hours, to consume a soft diet immediately after 30 minutes and to avoid brushing and flossing for the rest of the day.
40829401|NCT02818439|OTHER|evaluation of frailty|
40829402|NCT01253265|DRUG|LY2439821|Administered subcutaneously
40829403|NCT01253265|DRUG|Placebo|Administered subcutaneously
40829404|NCT00701636|DRUG|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
40829405|NCT05332249|PROCEDURE|Surgery|Patients who undergo spinal surgery for degenerative spinal disease
40829406|NCT05640206|PROCEDURE|i-PRF|Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly
40829407|NCT05640206|PROCEDURE|Arthrocentesis|Arthrocentesis performed with two-needle technique
40829408|NCT05736705|PROCEDURE|Endoscopic Submucosal Dissection|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the monopolar electrocautery knife.
40829409|NCT05736705|DEVICE|Bipolar electrocautery knife|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the bipolar electrocautery knife.
40829410|NCT05018806|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
40829411|NCT05018806|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
40829412|NCT03100721|BEHAVIORAL|PNE+Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
40829413|NCT03100721|PROCEDURE|Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques.
40829414|NCT02590562|OTHER|Routine clinical practice|
40829415|NCT06344910|OTHER|Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies|"An algorithm will check if the patients if the patient has an age \>18 year and is treated at the cardiology department for HFrEF. The use of GDMT is determined using prescriptions data electronic health records (EHR). If the patient does not receive treatment for all 4 drug classes (ACE/ARB/ARNi, beta-blocker, MRA, SGLT2-inhibitor), an electronic alert will be displayed suggesting the clinician to prescribe additional medication when clinically indicated, including relevant recent laboratory results (renal function and electrolytes) and other relevant measures (LVEF, blood pressure and heart rate). The alert is linked to an order set to aid in the prescription of GDMT according to current guidelines.~Results will compared to a retrospective cohort (t=-12 to t=-6) months, and a silent mode cohort (t=-6 to t=0 months, in which a paired and a before and after analysis will be performed to evaluate the effect of the alert."
40829416|NCT02536066|BEHAVIORAL|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
40829417|NCT02448979|PROCEDURE|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
40829418|NCT02448979|PROCEDURE|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
40829419|NCT04197063|BEHAVIORAL|Sweetened beverage portion size limit|
40829420|NCT03109028|BEHAVIORAL|Peer-to-Peer-Groupintervention|"Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.~Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.~Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors."
41348313|NCT05585983|BIOLOGICAL|Vaxigrip Tetra Sanofi Pasteur Europe|We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.
40829421|NCT03109028|BEHAVIORAL|Smartphone-based-Intervention|"Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.~Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.~Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology."
40829422|NCT03109028|BEHAVIORAL|Gendersensitive-Groupintervention|"Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.~Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors."
41348314|NCT03404219|BEHAVIORAL|Motivation and Skills Support (MASS)|Mobile phone-based application to support social skills and social motivation
41348315|NCT03828864|DEVICE|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
41348316|NCT03828864|DEVICE|Placebo Pulsed Shortwave Therapy|Placebo Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
41491379|NCT01103726|DRUG|PF-02545920|1 mg tablets, 3 mg single dose
41491380|NCT01103726|DRUG|PF-02545920|5 mg tablets, 15 mg single dose
40829423|NCT03109028|BEHAVIORAL|Empowerment-Groupintervention|"Target group: Gender-sensitive group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for three months with continued supervision during the intervention.~Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.~Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;"
40829424|NCT03109028|BEHAVIORAL|Adolescent-Groupintervention|"Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.~Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)"
40829425|NCT03109028|OTHER|Treatment as Ususal|Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
40829426|NCT04094233|DIETARY_SUPPLEMENT|Beetroot extract|Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).
40829427|NCT04094233|OTHER|Placebo|Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
40829428|NCT06085755|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan will be administered 6.4mg/kg or 5.4mg/kg iv infusion q 3weeks as one cycle.
40829429|NCT06085755|DRUG|Afatinib|Afatinib will be administered orally 20mg \~40mg once a day or three times a week(Monday, Wednesday, Friday \[MWF\]) or twice weekly (Monday, Thursday \[MT\]) for 3weeks as one cycle.
40829430|NCT03251586|DIAGNOSTIC_TEST|oVEMP - infra-orbital electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
40829431|NCT03251586|DIAGNOSTIC_TEST|oVEMP - belly-tendon electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
40829432|NCT05933642|DRUG|Aminophylline|aminophylline 150mg
40829433|NCT05933642|DRUG|Frusemide|frusemide 120mg
40829434|NCT04287803|DRUG|Methoxyflurane|Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores \>=4
40829435|NCT06360081|DRUG|Zongertinib|Zongertinib
40829436|NCT01696344|PROCEDURE|PVAI|
40829437|NCT01696344|PROCEDURE|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
40829438|NCT04451824|DEVICE|CL-100|Red Light LED device for circumferential reduction
40829439|NCT03198195|PROCEDURE|cyclophosphamide|on days +3，+4,using cyclophosphamide 50mg/kg
41348317|NCT04955574|OTHER|SH-DS01 + Antibiotic Placebo|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
41491381|NCT01103726|DRUG|Placebo|matching placebo tablets, single dose
40829440|NCT02282800|GENETIC|Vitamin D receptor|50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
40829441|NCT00051467|GENETIC|TNFerade|
40829442|NCT00868218|BIOLOGICAL|Influenza vaccine|"Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
40829443|NCT02582281|DEVICE|intrauterine device TCu 380A|
40829444|NCT00004437|DEVICE|Multichannel Auditory Brain Stem Implant|
41348318|NCT04955574|DRUG|SH-DS01 + Metronidazole|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of 500mg metronidazole twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
40829445|NCT01068782|DRUG|XL184|given orally as capsules
40829446|NCT02699450|DRUG|Faricimab|Faricimab will be administered by IVT injection in the study eye.
40829447|NCT02699450|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
40829448|NCT06044805|DRUG|Chloroquine|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
40829449|NCT06044805|DRUG|Primaquine|Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
40829450|NCT04022681|OTHER|BALLETS|Cohort were not exposed to any intervention. There information will be analysed from database searches.
40829451|NCT05109221|DEVICE|ultrasound|using of ultrasound in prediction of difficult intubation in obese surgical patients
40829452|NCT01140568|DRUG|nilotinib|400mg po (orally) BID (twice daily)
40829453|NCT02594800|DRUG|Rosuvastatin|standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
40829454|NCT04603222|DEVICE|SUMMIT BRUSH|SUMMIT BRUSH used for the treatment of blepharitis
40829455|NCT04603222|OTHER|Ocusoft Lid Scrub Original Foaming Eyelid Cleanser|treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
40829456|NCT05231200|BEHAVIORAL|QI Team Building|Each NICU will create a core QI team composed of 6-8 multidisciplinary members including a parent advisor, when feasible. This team will lead the QI activities and education, and champion the culture and practice change in the unit.
40829457|NCT05231200|BEHAVIORAL|QI education|Each NICU QI team will receive standardized QI education using the 6-hour EPIQ Workshop which involves hands-on approach to enable teams to successfully implement QI projects together. EPIQ 10 Steps and QI Tools will be used to build the team's understanding of QI using realistic improvement opportunities based on the standardized care bundles identified in the trial.
40829458|NCT05231200|OTHER|Standardized care bundle- respiratory care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for stabilization and respiratory care in moderate and late preterm infants (MLPIs) including~1. establishing effective ventilation in the delivery room~2. prevention of hypothermia~3. early diagnosis and management of respiratory distress with continuous positive airway pressure (CPAP)~4. standardized approach for surfactant indications and administration~5. standardized approach for early extubation."
40829459|NCT05231200|OTHER|Standardized care bundle- nutritional care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for nutritional support in MLPIs including~1. early initiation of enteral or parenteral nutrition;~2. standardized tables for feeding initiation and progression~3. optimizing breastfeeding and use of mother's own milk~4. standardized approach for a transition from enteral nutrition via tube feeds to oral feeds."
41019490|NCT06572878|OTHER|Cognitive training|Cognitive training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The cognitive training task components will specifically focus on attention, learning and memory, executive function, perceptual-motor skills, and language.
40829460|NCT05231200|BEHAVIORAL|QI mentoring|Each NICU in the intervention arm will have one or more assigned members of the study team who are experienced in collaborative QI and EPIQ methods. The mentors will help local QI teams to engage frontline staff in QI and navigate the unit-specific challenges.
40829461|NCT05231200|BEHAVIORAL|Collaborative networking|The study team will conduct virtual meetings every 2 months for the NICUs in intervention arm allowing local QI teams to discuss progress, and share data. The investigators will arrange annual in-person or virtual meetings for the NICUs in the intervention arm to present projects, successes, and lessons learned. These NICUs will have continuing access to the data and will receive quarterly reports using statistical process control charts outlining the unit's performance compared to other units and to the group average.
40829462|NCT05231200|OTHER|Current practice- standard of care|All participating NICUs will be in the control arm during the first year prior to randomization to create a baseline of the current practices and between-units variation. NICUs in the control arm can continue conducting QI activities relevant to current practice, but without receiving the interventions outlined above until they transition to the intervention arm. The investigators will capture these activities and account for them in the analysis.
40829463|NCT04542096|DEVICE|Lung electrical impedance tomography monitoring|A belt for recording changes in electrical impedance in the skin will be fastened for the purpose of this study with no other additional procedures
41348319|NCT04955574|OTHER|Probiotic Placebo + Antibiotic Placebo|Participants will be instructed to take 2 capsules of placebo for probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of placebo for probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
41348320|NCT04781725|DRUG|INT230-6|INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
41348321|NCT04781725|OTHER|Saline injection|Standard 0.9 % NaCl Normal Saline
41019491|NCT06572878|OTHER|Physical training|Physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The physical training task components will specifically focus on strength, balance, agility, gait, low-volume aerobic, and flexibility.
41157665|NCT05878990|BEHAVIORAL|Active Content Newsletter or Passive Content Newsletter|Based on the answers to the Control Preference Scale, participants will receive the appropriate weekly newsletter (active content or passive content). Newsletters are covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics presented in a more passive or active manner.
41157666|NCT06639022|DRUG|Serratus posterior superior intercostal plane block|"Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
41348322|NCT02418728|OTHER|subcutaneous adipose tissue microdialysis under local beta/alpha blockade|adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
41348323|NCT02812290|PROCEDURE|Lung transplant biopsy bites.|In the second phase of the study, two biopsy bites from the same patient will be collected to assess tissue sampling variability.
41348324|NCT00665691|OTHER|Nutritional Screening Tools|To compare the nutrition risk identification abilities of two nutrition screening tools: PEDSGA tool and the standard assessment tool.
41491382|NCT01212354|RADIATION|Radiotherapy|7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)
41491383|NCT03401125|OTHER|Medical file data collection|The information described in the 'outcome measures' section will be collected from the medical files of the patients.
41491384|NCT01194986|OTHER|[11C]AZ12807110|Radioligand
41491385|NCT01194986|DRUG|AZD5213|
41348325|NCT04300842|DEVICE|smart bracelet|to measure the stress, fatigue, and activity.
41348326|NCT03355976|DRUG|Nivolumab|240mg flat dose every 2 weeks
41491386|NCT03957070|DEVICE|Liver Incyte|Ultrasound elasticity imaging
41491387|NCT00000723|DRUG|Methotrexate|
41491388|NCT00000723|DRUG|Leucovorin calcium|
41019492|NCT06572878|OTHER|Combined cognitive and physical training|Combined cognitive and physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The combined cognitive and physical training components will specifically focus on a single cognitive task and simultaneously handle a single physical task.
41348327|NCT03355976|DRUG|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks
41348328|NCT04949633|DRUG|Prostaglandins|Second cervical ripening lasting a maximum of 24 hours
41348329|NCT04949633|DRUG|Oxytocin|Induction of labor with oxytocin.
41348330|NCT03501615|DRUG|Moxetumomab Pasudotox|A recombinant conjugated immunotoxin composed of a disulfide-stabilized anti-CD22 Ig Fv genetically fused to a truncated form of Pseudomonas exotoxin, PE38
41348331|NCT05525286|DRUG|SOT102|SOT102 is an antibody-drug conjugate (ADC) targeting CLDN18.2 with the anthracycline PNU as cytotoxic moiety.
41348332|NCT01788111|OTHER|Low back exercises 1|Excentric / concentric extension type exercises
41491389|NCT00000723|DRUG|Zidovudine|
41491390|NCT00000723|DRUG|Dexamethasone|
41491391|NCT00003538|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
41491392|NCT00003538|PROCEDURE|allogeneic bone marrow transplantation|
41491393|NCT00704574|DRUG|insulin detemir|No extra intervention, only normal clinical practise for treatment of type 1 diabetes
41491394|NCT05263622|OTHER|Split-mouth administration for group B|"* Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q1 and Q3) and with Mectron handpiece (quadrants Q2 and Q4)~* Calculus removal with EMS ultrasound handpiece (Q1 and Q3) and with Mectron handpiece (Q2 and Q4)"
41491395|NCT05263622|OTHER|Split-mouth administration for group A|"* Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q2 and Q4) and with Mectron handpiece (quadrants Q1 and Q3)~* Calculus removal with EMS ultrasound handpiece (Q2 and Q4) and with Mectron handpiece (Q1 and Q3)"
40829464|NCT04405544|DIAGNOSTIC_TEST|CT-scan|chest CT-scan
40829465|NCT04405544|DIAGNOSTIC_TEST|EEG|Electroencephalography
41019493|NCT06572878|OTHER|Passive information activities|In passive informational activities, which include a variety of puzzles, audiobooks, and diverse reading materials such as newspapers or listening to news content.
41019494|NCT04257877|PROCEDURE|Blood sampling|Blood samples for proteomic analysis in plasma of both groups
41491396|NCT04735757|OTHER|Contrast-enhanced MRI|Contrast-enhanced MRI
40829466|NCT04405544|DIAGNOSTIC_TEST|EP|Evoked potential
40829467|NCT04405544|DIAGNOSTIC_TEST|Pulse oximetry|Pulse oximetry
40829468|NCT04405544|DIAGNOSTIC_TEST|Blood tests|Blood tests
40829469|NCT00330044|DRUG|Premetrexed (Alimta)|
40829470|NCT00330044|DRUG|Carboplatin|
40829471|NCT04988282|DRUG|Methylprednisolone Tablet|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
40829472|NCT05523505|DEVICE|Sham intervention|Use of the non-invasive brain stimulation device to simulate peripheral experience of stimulation without actually stimulating the brain.
40829473|NCT05523505|DEVICE|RLN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the left angular gyrus and left temporal pole using transcranial alternating current stimulation (tACS).
40829474|NCT05523505|DEVICE|CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the bilateral dorsolateral prefrontal cortex using transcranial alternating current stimulation (tACS).
40829475|NCT05523505|DEVICE|RLN and CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the bilateral dorsolateral prefrontal cortex and left angular gyrus using transcranial alternating current stimulation (tACS).
40829476|NCT00661024|PROCEDURE|intraoperative RLN visualization|intraoperative RLN visualization
40829477|NCT00661024|PROCEDURE|intraoperative neuromonitoring of the RLN|IONM
40829478|NCT04288258|BEHAVIORAL|Telehealth-Based Health and Wellness Program (POWERS-TBI)|The treatment program is interactive and will be delivered via the internet, along with ongoing telephone health coaching calls designed to motivate, problem-solve challenges, reinforce skills learned, and prevent relapse.
40829479|NCT02154048|DRUG|Ropivacaine|
40829480|NCT02154048|DRUG|Dexamethasone|
40829481|NCT02154048|OTHER|Placebo|
40829482|NCT06100094|OTHER|semi-structured qualitative interviews|"During the interview, a list of semi-open questions will be asked :~* What were your expectations/state of mind before the group?~* How would you describe your experience overall?~* If you had to describe the group how would you do it?~* Between two group sessions, how did it go for you?~* What do you think of the group ultimately?~Interviews will be carried out until data saturation.~Collection of socio-demographic data (age), medical history and criminal history in the patient's file"
40829483|NCT00003358|DRUG|chemotherapy|
40829484|NCT00003358|DRUG|cisplatin|
40829485|NCT00003358|DRUG|gemcitabine hydrochloride|
40829486|NCT02523768|DRUG|ATG-F|
40829487|NCT02523768|DRUG|Simulect|
40829488|NCT00900185|GENETIC|mutation analysis|
40829489|NCT00900185|GENETIC|polymerase chain reaction|
40829490|NCT00900185|GENETIC|polymorphism analysis|
40829491|NCT02466074|DRUG|Acetazolamide|see arm description
41019495|NCT04987918|DIAGNOSTIC_TEST|Applied Biosystems TaqPath COVID- 19 Combo Kit|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
41019496|NCT06041477|DRUG|Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU|Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
41019497|NCT06041477|DRUG|Concurrent Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the first cycle
41348333|NCT01788111|OTHER|Low back exercise 2|Traditional low back training
41491397|NCT04735757|OTHER|Measurement of respiratory muscle force|Measurement of the maximum inspiratory and expiratory pressure.
41491398|NCT03312595|DEVICE|Restrata TM Wound Matrix|The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
40829492|NCT02466074|DRUG|Placebo|Placebo arm
41348334|NCT03562689|OTHER|Delirium and with septic encephalopathy.|Delirium or septic encephalopathy survivors will be analized in the same way: Cognitive tests, EEG and MRI.
40829493|NCT01113489|DRUG|beclomethasone dipropionate|400 mcg/1 ml b.i.d.
40829494|NCT01113489|DRUG|placebo|1 ml b.i.d.
40829495|NCT05388773|PROCEDURE|therapeutic conventional surgery|Transoral surgical resection of tumor(s).
40829496|NCT05388773|OTHER|laboratory biomarker analysis|Correlative studies
40829497|NCT05388773|OTHER|quality-of-life assessment|Ancillary studies.
40829498|NCT05388773|RADIATION|intensity-modulated radiation therapy|Low-dose IMRT
40829499|NCT05388773|DRUG|Cisplatin|Given IV.
40829500|NCT05388773|DRUG|Carboplatin|Given IV
40829501|NCT03908645|DEVICE|Artificial intelligence assisted bowel preparation quality scoring system|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
40829502|NCT03908645|DEVICE|Conventional human scoring|After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
40829503|NCT04502121|BEHAVIORAL|EXPECT: Preoperative optimization of cardiac valve patient's expectations|The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
41348335|NCT02292888|OTHER|Passive Leg Raising (PLR) test|Passive Leg Raising (PLR) test
41348336|NCT05859581|PROCEDURE|Beyond complete mesocolic excision surgery|If the participants were diagnosed with positive retroperitoneal resection margin (RPRM), they underwent beyond complete mesocolic excision surgery to ensure the R0 resection.
41348337|NCT03734133|OTHER|Foot insoles|Different foot insoles of different hardness
41348338|NCT00506740|DEVICE|Ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
41348339|NCT00506740|DEVICE|monopolar electrosurgery generator and tip|
41348340|NCT01784250|DRUG|Clonidine|Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
40829504|NCT05908708|DEVICE|Medtronic 780G® hybrid closed loop|"Medtronic 780G® hybrid closed loop system uses the commercial auto-mode with an insulin pump and continuous glucose monitoring."
40829505|NCT05947630|DEVICE|Ankle Foot Orthosis (AFO)|3D treatment (AFO will be printed) versus traditional made AFO
40829506|NCT05947630|DEVICE|Knee Ankle Foot Orthosis (KAFO)|3D treatment (KAFO will be printed) versus traditional made KAFO
40829507|NCT03995056|BEHAVIORAL|high-intensity aerobic interval training|"The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices."
40829508|NCT03070197|OTHER|Exposure of interest: Brain MRI|Brain MRI will be conducted in all participants
40829509|NCT03070197|OTHER|Exposure of interest: neurodevelopmental assessments|neurodevelopmental testing will be conducted in all participants.
40829510|NCT04035564|DRUG|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1
40829511|NCT04035564|DRUG|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
41019498|NCT06041477|DRUG|Concurrent PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the first cycle (dosage and frequency according to instructions)
41019499|NCT06041477|DRUG|Sequential Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR)
41019500|NCT06041477|DRUG|Sequential PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR) (dosage and frequency according to instructions)
41348341|NCT01784250|DRUG|Propranolol|Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
41348342|NCT01784250|DRUG|Placebo|Sugar pill manufactured to mimic a drug
41348343|NCT01731756|OTHER|Leaf extract of A. indica|Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
41348344|NCT01731756|DRUG|Salicylic Acid (6%)|Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
41348345|NCT01731756|OTHER|Petroleum jelly|Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
40829512|NCT06196398|DRUG|Standard Medical Treatment on the basis of anti-platelet therapy|"1. Anti-platelet therapy: aspirin 75mg+clopidogrel 100mg will be applied for patients with severe ICAS stenosis (70%-90%) suffering stroke or TIA within 30 days. After 90 days, single anti-platelet therapy will be continued.~2. Intensive statin therapy: Statins with high doses~3. Blood pressure: below 140/90mmHg~4. LDL: less than 1.81mmol/L(70mg/dl)~5. Fasting blood glucose controlled to 5.9mmol/L, and glycosylated hemoglobin A1c reduced to less than 7%~6. Cigarette and alcohol quitting~7. Oral anticoagulants for atrial fibrillation"
40829513|NCT00886119|DEVICE|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
40829514|NCT00886119|DEVICE|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
40829515|NCT04393688|COMBINATION_PRODUCT|Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter|"Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
40829516|NCT01550393|GENETIC|proteomic profiling|
40829517|NCT01550393|OTHER|enzyme-linked immunosorbent assay|
40829518|NCT01550393|OTHER|laboratory biomarker analysis|
40829519|NCT01550393|OTHER|medical chart review|
40829520|NCT02989051|OTHER|Restrictive fluid regimen|In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
40829521|NCT02989051|OTHER|Liberal fluid regimen|This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of \>85% of normal fluid recommendations (for a healthy child).
40829522|NCT05873179|OTHER|role-playing for learning the clinical interview|role-playing for learning the clinical interview
40829523|NCT02403895|DRUG|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
40829524|NCT02403895|DRUG|paclitaxel|Taxane
40829525|NCT05863234|DRUG|PPMX-T003|The therapeutic agent is administered continuously intravenously
40829526|NCT05084560|DRUG|AWZ1066S|Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
40829527|NCT05084560|DRUG|Placebo|Placebo
40829528|NCT01829282|BEHAVIORAL|Risk Reduction|
40829529|NCT01016314|DEVICE|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
40829530|NCT01016314|DEVICE|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
40829531|NCT02428920|BEHAVIORAL|Peer Groups|The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
41348346|NCT01442090|DRUG|Everolimus|Everolimus will be administered orally at a 10 mg daily dose.
41348347|NCT01442090|DRUG|GDC-0980|GDC-0980 will be administered orally at a 40 mg daily dose.
41348348|NCT05135182|DRUG|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
41348349|NCT05135182|DRUG|Metronidazole|metronidazole-tetracycline-containing quadruple regimens
41491399|NCT04058249|DEVICE|Accelerated intermittent theta-burst stimulation over right DLPFC|"All participants will receive accelerated intermittent theta-burst stimulation to the right DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to right-DLPFC using the Brainsway stimulator."
40829532|NCT05363761|COMBINATION_PRODUCT|Neurotronic Infusion Catheter|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
40829533|NCT03417596|OTHER|Control|Routine treatment
40829534|NCT03417596|BEHAVIORAL|Vestibular Rehabilitation|Exercise and rehabilitation programme was individualized
40829535|NCT05993780|OTHER|No drugs or biologial agents were used in our trial|Before the measurement, a recruitment maneuver was performed for 30-40 s at a PEEP level of 20 cmH2O. At four different PEEP levels of 15, 10, 5, and 0 cmH2O, a decreasing PEEP trial was performed, and the measurement results were recorded.The measurement time at each PEEP level was chosen as 10 minutes. At the end of the measurement, static compliance was measured by applying an end-inspiratory pause. Respiratory system elastance,static strain volume gain was calculated.The estimated lung volume recovered was calculated using the formula ∆EELV - (∆PEEP x Compliance PEEPlow) and compared with the volume gain.
40829536|NCT02770976|DEVICE|Increasing and decreasing NAVA levels with 10-min intervals|
40829537|NCT04526873|BEHAVIORAL|Postcard|Mailed
40829538|NCT04526873|BEHAVIORAL|Phone call|May be automated or by human
40829539|NCT04526873|BEHAVIORAL|Humor/Salience|Funny cartoon + health risk examples
40829540|NCT04526873|BEHAVIORAL|Telehealth|Information about video visit
40829541|NCT01921413|DEVICE|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
40829542|NCT04129905|BIOLOGICAL|BNP blood sample test|Performed during normal recommended follow-up of the HCM patients.
40829543|NCT04129905|DIAGNOSTIC_TEST|Electrocardiogram|Performed during normal recommended follow-up of the HCM patients.
41019501|NCT03250962|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
41019502|NCT03250962|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
41019503|NCT05062291|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target Lesion Primary Patency (TLPP)
40829544|NCT04129905|DIAGNOSTIC_TEST|Holter ECG|Performed during normal recommended follow-up of the HCM patients.
40829545|NCT04129905|DIAGNOSTIC_TEST|Echocardiography|Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
40829546|NCT04129905|DIAGNOSTIC_TEST|Air venous plethysmography|Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
40829547|NCT04129905|DIAGNOSTIC_TEST|Upper member arterial Doppler echography with analysis of FMD|Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
40829548|NCT04129905|BIOLOGICAL|Endothelial function biomarkers|Performed specifically for the research. Blood sample test, 5 minutes.
40829549|NCT01977443|DRUG|APD-209 Eye drops|
40829550|NCT01977443|DRUG|APD-209 Placebo Eye drops|
40829551|NCT03216486|DRUG|BPS804|IV administration of BPS804 in 5% Dextrose solution
40829552|NCT01811602|OTHER|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
40829553|NCT01811602|OTHER|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
40829554|NCT05837949|BEHAVIORAL|MS FIT: Falls Insight Track|Participants will respond to a set of surveys every two weeks to increase communication on falls with their clinician.
40829555|NCT00002368|DRUG|Nevirapine|
40829556|NCT00002368|DRUG|Lamivudine|
40829557|NCT05132257|PROCEDURE|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
40829558|NCT02106247|DRUG|BI 1181181 high dose|two tablet
40829559|NCT02106247|DRUG|BI 1181181 low dose|one tablet
40829560|NCT02106247|DRUG|Placebo|tablet
40829561|NCT00740714|DRUG|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
40829562|NCT00740714|DRUG|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
41348350|NCT00088595|DRUG|Pasireotide (SOM230)|Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.
41348351|NCT01599819|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
41348352|NCT01599819|BIOLOGICAL|PEGylated Recombinant Factor VIII|1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
41348353|NCT05225649|BEHAVIORAL|Behavior Change Intervention|Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.
41348354|NCT01945190|DEVICE|Electroacupuncture|
41348355|NCT06147544|DRUG|PB-718|Administered subcutaneously once a week
41348356|NCT06147544|DRUG|Placebo|Administered subcutaneously once a week
41348357|NCT05686876|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
41019504|NCT05776108|DRUG|Cabotegravir IR Formulation (reference)|Cabotegravir IR Formulation (reference) will be administered.
41019505|NCT05776108|DRUG|Cabotegravir DT Formulation (test 1)|Cabotegravir DT Formulation (test 1) will be administered.
41019506|NCT05776108|DRUG|Cabotegravir DT Formulation (test 2)|Cabotegravir DT Formulation (test 2) will be administered.
41019507|NCT04560803|DEVICE|CelluTomeTM Epidermal Harvesting System|Autologous epidermal grafts that will be placed at the treatment site
41491400|NCT03673527|DRUG|topical formulation of tacrolimus|Topical application of tacrolimus twice daily for 14 days (one dose on Day 14).
41491401|NCT03591523|DIAGNOSTIC_TEST|Quantitative MR angiography|Quantitative MR angiography: A standard axial 3-dimensional time-of-flight (TOF) MRA of intracranial and cervical arteries will be obtained. Then, the acquired images will be transmitted to the workstation to reconstruct 3D surface-rendered vessel images. After determining optimal perpendicular scan plane and setting the baseline coordinates , retrospectively gated, fast 2-dimensional phase-contrast sequence will be performed. Velocity encoding will be automatically adjusted by NOVA software.
40829563|NCT06035744|DRUG|CLN-617|Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences
40829564|NCT06035744|DRUG|Pembrolizumab|Humanized IgG4 anti-PD-1 monoclonal antibody
40829565|NCT03734068|DEVICE|Chemoembolization Using LifePearl|Chemoembolization Using LifePearl
40829566|NCT03734068|DRUG|Doxorubicin|Doxorubicin is loaded to LIfePearl
40829567|NCT01562405|DRUG|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
40829568|NCT01562405|DRUG|Lenalidomide|15 to 25 mg days 1-21, given orally
40829569|NCT01562405|DRUG|Dexamethasone|40 mg days 1,8,15,22; given orally
40829570|NCT01562405|DRUG|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
40829571|NCT00525824|DRUG|Rosuvastatin (Crestor)|10mg and 20 mg
40829572|NCT00525824|DRUG|Ezetimibe|10 mg
40829573|NCT00525824|DRUG|Simvastatin|40mg and 80 mg
40829574|NCT03393507|DRUG|Apatinib|500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
40829575|NCT03393507|DRUG|Taxus + platinum|Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time\> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
40829576|NCT00975065|DRUG|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
40829577|NCT00975065|DRUG|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
41348358|NCT04162262|OTHER|Instrumental-assisted soft tissue mobilization (IASTM)|Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.
41491402|NCT03591523|DIAGNOSTIC_TEST|Duplex sonography|Duplex sonography of cervical arteries will be performed using 5 - 12 MHz linear duplex probe and transcranial color-coded duplex sonography will be performed using 2 - 5 MHz transcranial duplex probe. Peak systolic velocity, end diastolic celocity, mean blood flow velocity and arterial diameter will be measured with automatic calculation of blood flow velocity in each arterial segment.
41491403|NCT02838511|OTHER|Modified Frailty Index (MFI)|non-cardiac surgical patients will have frailty evaluated
41019508|NCT02741947|DRUG|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
41491404|NCT02838511|OTHER|Hopkins Frailty Score (HFS)|non-cardiac surgical patients will have frailty evaluated
41491405|NCT04271735|DIETARY_SUPPLEMENT|Niagen|Participants will take two capsules of nicotinamide riboside (NR) by mouth (250mg NR or placebo) twice daily for a total of 4 weeks.
41491406|NCT04271735|OTHER|Placebo|Placebo capsule to match the active supplement. Participants will take two capsules, twice daily for a total of 4 weeks.
40829578|NCT01945736|DRUG|Methadone|To determine the PK of enteral methadone in children \> or = 90 days and \<18 years treated for opiate withdrawal per routine medical care.
40829579|NCT05128162|DRUG|Psilocybin|Two oral doses of psilocybin in a capsule formulation taken approximately 2 weeks apart.
41019509|NCT02741947|DRUG|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
40829580|NCT05128162|BEHAVIORAL|Psychotherapy|1. Pre-dose preparatory sessions; 2. Dosing day monitoring; and, 3. Post-dose integration sessions.
40829581|NCT04540458|OTHER|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
40829582|NCT04540458|OTHER|Placebo|Mother or Mother/Father is given a picture of 3D ultrasound of fetus
40829583|NCT01239888|DRUG|Oxytocin|20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
40829584|NCT01239888|DRUG|Oxytocin and Tibolone|20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
40829585|NCT01239888|DRUG|Placebo|20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
40829586|NCT05892367|OTHER|Transbrachial Access for Interventions|Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
40829587|NCT03720665|COMBINATION_PRODUCT|Caffeine_TMS|Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\]
40829588|NCT04551001|PROCEDURE|Cold forcep polypectomy|Removal of appropriate polyps using cold forceps until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
40829589|NCT04551001|PROCEDURE|Cold snare polypectomy|Removal of appropriate polyps using cold snare until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
40829590|NCT06337474|DRUG|anti-CD19 CAR NK cells (KN5501)|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3. Doses of 9×10\^9 cells, 13.5×10\^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the dose-escalation strategy
41157667|NCT06639022|DRUG|Erector spinae plane block|"Erector spinae plane block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
41157668|NCT06639022|DRUG|Group without peripheral nerve block|In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
40829591|NCT01697150|DEVICE|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
40829592|NCT06491290|OTHER|No intervention administered|NA (not applicable)
40829593|NCT03202108|DIETARY_SUPPLEMENT|Krio|"Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian."
40829594|NCT05148416|RADIATION|High intensity laser treatment|20 patients received high power laser therapy . Zimmer High power laser applied by laser probe perpendicular to and in slight contact with the skin around knee joint , the total energy was delivered to the patient during one session was 1060 j in 3 phases of treatment.
40829595|NCT05148416|DEVICE|sham HILT.|"20 patients received placebo laser  sham laser . The same treatment protocol of HILT was given to the sham group, but the laser instrument was switched off during applications. All laser applications were performed by the same physiotherapist."
40829596|NCT05148416|OTHER|knee osteoarthritis conventional exercises program|"knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
41491407|NCT03322735|DRUG|Fludarabine|25-30mg/m2/day IV for 3 days
40829597|NCT02351349|OTHER|multidisciplinary intervention|multidisciplinary intervention
40829598|NCT00445939|BIOLOGICAL|adalimumab|160 mg at Week 0, 80 mg at Week 2
40829599|NCT00445939|BIOLOGICAL|adalimumab|80 mg at Week 0, 40 mg at Week 2
40829600|NCT00445939|BIOLOGICAL|placebo|Placebo at Week 0 and Week 2
40829601|NCT03747900|DRUG|Botulinum Toxin Type A|200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
40829602|NCT03747900|COMBINATION_PRODUCT|Botulinum Toxin Type A and dry needling.|Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.
40829603|NCT01083498|DEVICE|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
40829604|NCT02798991|DRUG|GSK3179106|It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
40829605|NCT02798991|DRUG|Matched Placebo|It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
40829606|NCT02638207|DRUG|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
40829607|NCT04686760|DRUG|Nitroglycerin|2 mg/ml solution of nitroglycerin used for nebulization four hourly
40829608|NCT03692351|DEVICE|Uncemented acetabular cup with screw holes|
41157669|NCT04893902|DEVICE|medit intra oral scanner|ear scanning with intra oral scanner
40829609|NCT03692351|DEVICE|Uncemented acetabular cup without screw holes|
40829610|NCT02845778|DRUG|Melatonin|Each sachet contains 0.5 g
40829611|NCT04741191|OTHER|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown), 3x/week on alternate days for 6 weeks at 40-60% of VO2max.
40829612|NCT04741191|OTHER|Conventional therapy|In bed activities (Active ankle and hand pumping exercise\* 15 Rep\* BD AROMS of extremities\* 15 Rep\* BD, Deep breathing exercises\* 15 Rep\* BD, Ambulation (walk 10-15 minutes below fatigue and onset of symptoms level\* BD) for 6 weeks.
40829613|NCT06356779|PROCEDURE|Local ablative therapy (LAT)|Surgical metastasectomy, stereotactic ablative radiotherapy, thermal ablation, or electroporation to all oligometastatic lesions
40829614|NCT01296074|DRUG|Corticosteroid|500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
40829615|NCT00034164|DRUG|S-8184 Paclitaxel Injectable Emulsion|
40829616|NCT03608072|DRUG|BI 690517|3 sequential dose groups
40829617|NCT03608072|DRUG|Placebo|3 sequential dose groups
40829618|NCT00001065|DRUG|Amphotericin B|
41491408|NCT03322735|DRUG|Cyclophosphamide|cyclophosphamide 0.6-0.8g/m2/day IV for 2 days
41491409|NCT03322735|BIOLOGICAL|BCMA CAR-T|BCMA CAR-T cells will be administered after completion of the chemotherapy.
41491410|NCT05199168|PROCEDURE|intraoperative nerve monitoring|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
41491411|NCT04439695|BIOLOGICAL|Low dose|Low dose of KBP-V001
40829619|NCT05739695|DIAGNOSTIC_TEST|Virtual bronchoscopy navigation|It is planned to use VBN as the only navigation technique to compare it with rEBUS
40829620|NCT05739695|DIAGNOSTIC_TEST|radial EBUS|It is planned to use rEBUS as the only navigation technique to compare it with VBN
41348359|NCT04162262|OTHER|High-Load Strength Training|Participants will perform a heel raise exercise used by Rathleff et al (2015). The exercise will be performed twice daily. While standing with the forefoot on a step, the toes will rest on a partially folded towel, placing them in a maximally dorsiflexed position. The exercise will consist of a maximum ankle plantar flexion followed by maximal dorsiflexion. The concentric plantar flexion and eccentric lowering phases will be 3 seconds, with a 2 second isometric pause in between. The exercise will be performed unilaterally if tolerated by the subject. Otherwise, a bilateral calf raise will be performed until the subject is able to perform the unilateral version. The exercise will be performed every other day and progressed throughout the trial as described by Rathleff and colleagues.
40829621|NCT04488744|DRUG|Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s|Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
40829622|NCT06252896|OTHER|INSTRUMENTAL-ASSISTED SOFT TISSUE MOBILIZATION TECHNIQUE|After all evaluations were made, IASTM was applied to the individuals in the intervention group for five minutes each, for a total of 20 minutes, on the quadriceps and hamstring muscles of both extremities, respectively.
41491412|NCT04439695|BIOLOGICAL|Intermediate dose|Intermediate dose of KBP-V001
41491413|NCT04439695|BIOLOGICAL|High dose|High dose of KBP-V001
41491414|NCT04439695|BIOLOGICAL|Placebo|Buffered Saline Solution
41491415|NCT01141244|DRUG|temsirolimus|Given IV
41491416|NCT01141244|DRUG|temozolomide|Given orally
40829623|NCT06252896|OTHER|NO INTERVENTION|The control group waited for 30 minutes after the initial measurements and all measurements were repeated.
40829624|NCT02270762|OTHER|Rest in bed|
40829625|NCT02270762|OTHER|Passive verticalization|
40829626|NCT02270762|OTHER|Rest in bed|
41157670|NCT01321073|DEVICE|Model 10642 Implantable Intravascular Catheter|This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
41491417|NCT01141244|DRUG|irinotecan hydrochloride|Given IV
41491418|NCT01141244|OTHER|laboratory biomarker analysis|Correlative studies
41491419|NCT01299259|BEHAVIORAL|Text Message Reminders|Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
41491420|NCT02705404|GENETIC|Multifocal Tissue Banking|
41491421|NCT02066103|DRUG|Paclitaxel|
40829627|NCT05184465|PROCEDURE|spinal anesthesia|"The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back."
40829628|NCT01162174|DIETARY_SUPPLEMENT|Oligonol|
40829629|NCT03243578|OTHER|None as this is an observational study|
41491422|NCT02422771|OTHER|FIFA 11+ warm-up|A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
41491423|NCT06214169|DRUG|Cisatracurium Besylate|Addition of cisatracurium to plain lignocaine for IVRA.
41491424|NCT06214169|DRUG|Lignocaine|Plain Lignocaine for IVRA
41491425|NCT04016441|OTHER|Survey|Participants will complete a survey online
41491426|NCT00309725|DRUG|galantamine|
41491427|NCT01175031|OTHER|Manipulation of Positive Airway Pressure (PAP)|Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
41491428|NCT03337165|BIOLOGICAL|tolerogenic dendritic cells|dose-escalation
40829630|NCT04378400|PROCEDURE|Sacrocolpopexy|Sacrocolpopexy is offered to patients with symptomatic prolapse (≥stage II) of the vaginal apex (vault or cervix). The procedure involves dissection of the promontory and the vaginal vault, suturing of two meshes to the anterior and posterior aspect of the vagina using minimally three rows of sutures on each side, and one row at the apex. Thereafter the mesh is fixed with staples to the promontory and the peritoneum closed, with staples and a running suture.
40829631|NCT05995977|BEHAVIORAL|Nursing interventions based on protection motivation theory in patients with hypertension|The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on the Protection Motivation Theory. The second component is the sending of regularly delivered Protection Motivation Theory-based SMS messages aimed at reminding, encouraging, and motivating patients to maintain medication adherence and healthy lifestyle changes.
41491429|NCT01480843|DRUG|Glargine|Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
40829632|NCT03927352|BIOLOGICAL|SCT630|Administered by subcutaneous injection
40829633|NCT03927352|BIOLOGICAL|Adalimumab|Administered by subcutaneous injection
41491430|NCT03677076|OTHER|Ancillary/Correlative|Collection of research blood and urine
40829634|NCT02986243|OTHER|Exercise|6 months worth of exercise regimen
40829635|NCT02986243|DIETARY_SUPPLEMENT|Diet Plan|Each subject will receive a personalized diet plan from nutritionist.
40829636|NCT04416607|DRUG|Corifollitropin Alfa|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
40829637|NCT04416607|DRUG|Menotropins|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
40829638|NCT05528367|DRUG|Nab-PTX,S-1,Tirelizumab|"S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w."
40829639|NCT05528367|RADIATION|Chemoradiation|45-50Gy/25F
41157671|NCT02815137|OTHER|Digital Polymerase Chain Reaction|Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
40829640|NCT04642924|DRUG|SGM-101|Fluorescence-guided surgery
41348360|NCT04162262|OTHER|Plantar Flexor and Gastrocnemius Stretching|For the plantar flexor stretch (DiGiovanni et al, 2006), subjects will sit and cross the affected leg over the contralateral leg. Placing the affected side fingers on the plantar toes, distal to the metatarsophalangeal joints, they will passively dorsiflex the toes until they feel stretching in the arch of the foot. Subjects will be instructed to hold this stretch for 10 seconds and repeat it 10 times. The gastrocnemius stretch will be performed in supine with a towel placed around the distal foot and the foot actively inverted. With the knee extended, the subject will flex the hip while passively dorsiflexing the foot using the towel. This stretch will be held for 30 seconds and repeated 3 times. Subjects will be asked to perform both stretches three times each day.
41348361|NCT05752461|DRUG|SHR-2004 injection|low dose subcutaneous injection once
41348362|NCT05752461|DRUG|SHR-2004 injection|medium dose subcutaneous injection once
41348363|NCT05752461|DRUG|SHR-2004 injection|high dose subcutaneous injection once
41348364|NCT05752461|DRUG|Enoxaparin sodium injection|40 mg administered as subcutaneous injection once daily
41348365|NCT02491528|BIOLOGICAL|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
41348366|NCT02491528|BIOLOGICAL|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
41348367|NCT02749552|BEHAVIORAL|Acceptance and Commitment Therapy|weight-related interventions using values, acceptance, and mindfulness based on Acceptance and Commitment Therapy
41348368|NCT02393989|PROCEDURE|posterior restoration|restorations for caries effected teeth
41491431|NCT02905214|DEVICE|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
41491432|NCT05418530|OTHER|with pause- without pause|start with pause expiration
41491433|NCT05418530|OTHER|without pause-with pause|start without pause expiration
40829641|NCT02276118|DEVICE|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
40829642|NCT02276118|DEVICE|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
41348369|NCT05850962|OTHER|Individualised MAP target|The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.
41491434|NCT01562340|OTHER|Pomegranate juice|Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
41491435|NCT01562340|OTHER|Pomegranate fruit extract|Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
41491436|NCT02344719|DRUG|Taurin 6g per day per oral for 28 days|Taurin 6g per day per oral for 28 days
40829643|NCT05712304|DIAGNOSTIC_TEST|second examination of the proximal colon|For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
41348370|NCT03037333|PROCEDURE|Transvenous cardiac pacing guided by fluoroscopy|Transvenous cardiac estimulation
41348371|NCT03037333|PROCEDURE|Transvenous cardiac pacing guided by ECG/ECHO|Transvenous cardiac estimulation
41348372|NCT05028166|DRUG|Mirdametinib (MEK Inhibitor)|Patients will receive oral mirdametinib.
41348373|NCT03755362|PROCEDURE|Standard Treatment|Dental evaluation at baseline, 3, 6, and 9 months.
41348374|NCT03755362|PROCEDURE|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to \<20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
41348375|NCT00882362|DRUG|OPC-14597 (Aripiprazole)|administered orally once daily, 3 to 15 mg daily, 52 weeks
41348376|NCT03228836|DRUG|Sintilimab|Sintilimab (IBI308) 200mg IV Q3W
41348377|NCT03787901|OTHER|Morula Vitrification|Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
41491437|NCT02344719|PROCEDURE|HVPG Measurement baseline|On day 1 (baseline) and day 28 HVPG measurement will be performed
41491438|NCT02344719|PROCEDURE|HVPG Measurement day 28|On day 1 (baseline) and day 28 HVPG measurement will be performed
41491439|NCT02344719|DRUG|Placebo 6g per day per oral for 28 days|Placebo to Taurin 6g per day per oral for 28 days
41491440|NCT00254228|DEVICE|Electrotactile sensory substitution|
41491441|NCT04663295|DEVICE|MiniMed™ 670G system|Hybrid closed loop insulin pump with associated CGM and blood glucose meter
41491442|NCT01996332|DRUG|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
41491443|NCT02730351|DRUG|Fluticasone furoate/ Vilanterol 100 mcg/25 mcg|FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening
41491444|NCT02730351|DRUG|Fluticasone propionate 250 mcg|FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening
41491445|NCT02730351|DRUG|Placebo via ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler once daily in the evening
41348378|NCT03196973|DRUG|DF289 plus DF277|1 vial into the affected ear twice daily for 7 days
41348379|NCT03196973|DRUG|DF289|1 vial into the affected ear twice daily for 7 days
41348380|NCT03196973|DRUG|DF277|1 vial into the affected ear twice daily for 7 days
41348381|NCT04543565|DRUG|Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet|Once daily
41348382|NCT04543565|DRUG|Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate|Once daily
41348383|NCT06092840|DIETARY_SUPPLEMENT|Transform Burn|Study product Transform Burn contains dihydrocapsiate, red pepper (Capsicum annuum) fruit extract, citrus (Citrus spp) peel extract, coleus (Coleus forskholi) root extract, and african mango (Irvingia gabonensis) seed extract.
41348384|NCT05841069|PROCEDURE|Adhesiolysis|Median laparotomy with subsequent detection of intestinal obstruction cause and adhesiolysis.
41348385|NCT05841069|RADIATION|X-ray examination|Plain X-ray of abdomen (1-4 times) with water insoluble contrast.
40829644|NCT04983836|PROCEDURE|Serratus anesthesia technique|locoregional anaesthesia allowing analgesia of the hemi-thorax by ultrasound guided single injection of naropeine 5mg/ml
40829645|NCT04983836|PROCEDURE|Paravertebral anesthesia technique|Ultrasound guided single injection of of naropeine 5mg/ml dose into the paravertebral space next to the thoracic spine
41348386|NCT05841069|PROCEDURE|Conservative treatment|A set of measures aimed at non-operative resolution of acute intestinal obstruction - nasogastric tube, infusion therapy.
41348387|NCT03225651|BIOLOGICAL|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
41348388|NCT03225651|BEHAVIORAL|Psychological therapy and Rehabilitation|Psychological Therapy and Rehabilitation for autism children around 3 months
41491446|NCT02730351|DRUG|Placebo via DISKUS / ACCUHALER|Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
41348389|NCT03053973|DEVICE|nocturnal noninvasive ventilation|Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.
41348390|NCT03053973|OTHER|Standard Care|Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)
41348391|NCT02330471|PROCEDURE|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
41491447|NCT05934955|DRUG|BI 1839100|BI 1839100
41491448|NCT05934955|DRUG|Placebo matching BI 1839100|Placebo matching BI 1839100
41491449|NCT03884543|PROCEDURE|Individualized high PEEP strategy|Patients are randomized and intra-operatively ventilated with an individualized high PEEP strategy (Highest PEEP with the lowest driving pressure with recruitment maneuvers)
41491450|NCT00792363|DRUG|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
41491451|NCT00792363|DRUG|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
41491452|NCT06248008|DRUG|ASC40|ASC40 tablets orally once daily
41491453|NCT05157867|OTHER|Amylase trypsin inhibitors|Intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (wheat), dissolved in physiological saline.
41491454|NCT05157867|OTHER|Placebo|Intraduodenal administration of placebo (physiological saline).
41491455|NCT03908177|DEVICE|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
40829646|NCT03885765|DIAGNOSTIC_TEST|Predictive data|"The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans:~(i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration \[I\] of the section to be excised / \[I\] total."
40829647|NCT03885765|PROCEDURE|Lung resection|Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.
40829648|NCT03753100|OTHER|Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint|The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
40829649|NCT01371149|OTHER|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
40829650|NCT01657136|DRUG|Ivabradine|comparison of different drugs
40829651|NCT01657136|DRUG|Beta blocker|comparison of different drugs
41348392|NCT02330471|PROCEDURE|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
41348393|NCT01599949|DRUG|Ibrutinib|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
41348394|NCT00381524|BEHAVIORAL|Increase condom use|Voluntary increase in condom use
41348395|NCT03742687|RADIATION|Heterogeneously Hypofractionated Radiotherapy|A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
41348396|NCT03388554|DEVICE|tDCS|
41348397|NCT03042494|DIETARY_SUPPLEMENT|Control|Isocaloric food without the test prebiotic.
41348398|NCT03042494|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic consumed as 7 g/d in a snack food in Group 1 and consumed as 2.5-3 g/d in a snack food in Group 2.
41491456|NCT03908177|DEVICE|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
40829652|NCT00057434|DRUG|multivitamin|
40829653|NCT02312765|BEHAVIORAL|AirCare App|Tablet software to encourage adherence and support
40829654|NCT03197428|OTHER|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
40829655|NCT03197428|OTHER|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
40829656|NCT00917072|BEHAVIORAL|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
40829657|NCT00917072|BEHAVIORAL|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
41348399|NCT04028024|DRUG|Ulinastatin|Ulinastatin 5000U/Kg in 20 ml NS i.v. before occlusion of aorta
41348400|NCT03416517|DRUG|Anlotinib|Anlotinib 12 or 8 mg/d po D1-14 q3w
41348401|NCT03416517|DRUG|Irinotecan|Irinotecan 20 or 15mg/m\^2/d IV over 60 minutes on days 1-5 and 8-12, q3w
41491457|NCT02216513|DRUG|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
41491458|NCT02216513|DRUG|placebo|normal saline IV for 4 hours for 5 consecutive days
41491459|NCT03208361|DRUG|Penicillin V|
41491460|NCT03208361|DRUG|Amoxicillin|
41509071|NCT04422041|OTHER|Discharge time between 24 and 48 hours|Allow the joint medical discharge of the newborn together with its mother between 24-48 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
41509072|NCT01491451|DEVICE|rhBMP-2/ACS/INTERFIX™|INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
40829658|NCT00917072|BEHAVIORAL|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
40829659|NCT01862341|DIETARY_SUPPLEMENT|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
41348402|NCT03794011|DEVICE|fetoscopy|The fetoscopic arm is described above. Patients who have an appropriate window (posterior placenta) and choose fetoscopic surgery will be offered the two fetoscopic options, (i) laparotomy assisted and, (ii) totally percutaneous expandable port assisted. Patients with an anterior placenta will only be offered the lapartotomy assisted approach. All patients will undergo a fetoscopic repair of the fetal open neural tube defect including a the use of a Durepair patch.
41348403|NCT01481714|DRUG|Sodium picosulphate, magnesium oxid and citric acid|"* A sachet mixed with 250 mL of water at 18:00 pm~* A sachet mixed with 250 mL of water at 21:00 pm~* A minimum of 4 litres of fluid were recommended throughout the preparation"
41348404|NCT01481714|DRUG|Sodium picosulphate/magnesium oxide and citric acid|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~* A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~* A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
41491461|NCT03827746|OTHER|Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale|"Tampa Kinesiophobia Scale: The TSK is a 17-item self report checklist using a 4-point Likert scale that was developed as a measure of fear of movement or (re)injury.~Berg-Balance Test: 14-item scale designed to measure balance of the older adult in a clinical setting.~International Physical Activity Questionnaire-Short Form: This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting.~Falls Efficacy Scale: A 16- item self-administered questionnaire designed to assess fear of falling in mainly older population"
41491462|NCT02286596|DEVICE|heparin-induced extracorporeal LDL precipitation|Lipid apheresis for 3 hours
41348405|NCT03180021|PROCEDURE|MRI|"This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers."
41491463|NCT02286596|DEVICE|dextran sulfate adsorption|Lipid apheresis for 3 hours
41491464|NCT01323465|DRUG|Sativex and rifampicin|Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
41491465|NCT01323465|DRUG|Sativex and rifampicin|Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
41491466|NCT01323465|DRUG|Sativex and ketoconazole|Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
41491467|NCT01323465|DRUG|Sativex and ketoconazole|Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
41491468|NCT01323465|DRUG|Sativex and omeprazole|Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
41491469|NCT01323465|DRUG|Sativex and omeprazole|Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
41491470|NCT00002883|DRUG|cisplatin|
41491471|NCT00002883|DRUG|fluorouracil|
41491472|NCT00002883|PROCEDURE|adjuvant therapy|
41491473|NCT00002883|PROCEDURE|conventional surgery|
40829660|NCT02671539|GENETIC|rAAV2.REP1|single subretinal injection
41157672|NCT06646302|OTHER|Low frequency burst sound stimulation|Patients will be given low frequency burst sound stimulation at 10 dB above the threshold of the minimum masking level of tinnitus for a duration of 1 minute.
41491474|NCT00002883|PROCEDURE|neoadjuvant therapy|
19632562|NCT06438341|BIOLOGICAL|SPOT-mRNA01|SPOT-mRNA01 (COL1A1 mRNA-loaded EVs) ,single-dose subcutaneous injection
19632563|NCT06438341|OTHER|Placebo|Sterile isotonic solution
41491475|NCT05042115|OTHER|Education in pain neurosciences and clinical hypnosis|Will be performed education in pain neurosciences and clinical hypnosis, in 4 sessions during 4 weeks
41491476|NCT05042115|OTHER|Education in pain neurosciences and clinical hypnosis plus osteopathic manipulative treatment|Will be performed education in pain neurosciences and clinical hypnosis, and only for this group will be delivered osteopathic manipulative treatment, in 4 sessions during 4 weeks
40829661|NCT00004446|DRUG|fluoxetine|
40829662|NCT00926133|OTHER|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
41157673|NCT06646302|OTHER|Tinnitus frequency-centered narrowband noise stimulation|Patients will be given tinnitus frequency-centered narrowband noise stimulation at 10 dB above the threshold of the minimum masking level of tinnitus for a duration of 1 minute.
41157674|NCT05244226|DRUG|Fentanyl/Hydromorphone|Per routine care
41157675|NCT05244226|DRUG|Methadone|Initial dosing 0.1mg/kg, potential to escalate to 0.15mg/kg following interim analysis
41491477|NCT04682769|OTHER|Other|Patients with Coronary Heart Disease and Depressive Disorder are receiving routine treatment by their physician.
41491478|NCT04770467|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
41491479|NCT04770467|DRUG|Placebo|Placebo given by intravenous administration
41491480|NCT00429195|BEHAVIORAL|Dietary Fatty Acid Modification|
41491481|NCT00540293|DRUG|Atorvastatin|Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
41491482|NCT05932992|OTHER|Mother education on how to perform MUAC assessment|Mothers will be trained to perform MUAC weekly on their children
41348406|NCT03603574|DEVICE|EWA through the needle|In the EWA-N group, 5 mL of normal saline are injected through the epidural needle after the occurrence of loss-of-resistance (LOR). The needle is connected to the pressure transducer. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of normal saline through the epidural needle and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection, the operator removes the needle and reattempts the epidural block at a different intervertebral level. A maximum of 3 levels is permitted: if waveforms are still absent at the third level, the operator simply accepts LOR as the technical endpoint.
41491483|NCT05321511|DRUG|Triptorelin acetate (a-GnRH)|Adminsitration of triptoreline acetate 0.2 mg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
41491484|NCT05321511|DRUG|Ovitrelle® (hCG)|Adminsitration of coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
41491485|NCT05321511|DRUG|Decapeptyl 0.1 mg® (a-GnRH) and Ovitrelle® (hCG) used together|Adminsitration of triptoreline acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
41491486|NCT00446836|DRUG|Paclitaxel polyglumex (Xyotax)|biologically enhanced chemotherapeutic
41491487|NCT00355810|DIETARY_SUPPLEMENT|placebo followed by Lactobacillus plantarum MF 1298|placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks
41491488|NCT00355810|DIETARY_SUPPLEMENT|Lactobacillus plantarum MF1298 followed by placebo|Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
40829663|NCT03838016|BEHAVIORAL|Babble Boot Camp|The Babble Boot Camp is an experimental study to investigate whether earliest and proactive activities and routines can positively influence the speech and language development of children who were diagnosed with classic galactosemia at birth. A speech-language pathologists implements the intervention by teaching parents to foster and expand earliest signals of communication, prespeech activities such as coo and babble, vocabulary growth, sentence complexity, and use of language to communicate. Examples are intentional eye contact, reinforcing babble with rewarding play activities, and repeating a child's rudimentary sentence with slight expansions to scaffold longer sentences.
40829664|NCT00450736|DRUG|celecoxib|
40829665|NCT00450736|PROCEDURE|adjuvant therapy|
40829666|NCT00450736|RADIATION|radiation therapy|
41348407|NCT03603574|DEVICE|EWA through the catheter|In the EWA-C group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of saline through the catheter and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection are still absent at the third level, the operator simply accepts this position for catheter placement (intent-to-treat analysis).
41348408|NCT04729010|OTHER|Acupuncture to treat anxiety in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
41348409|NCT05386641|OTHER|measurement of tissue stiffness (N/m)|Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
41348410|NCT05386641|OTHER|measurement of passive muscle tone (Hz)|muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain
41348411|NCT05386641|OTHER|measurement of creep of tissue|creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
41348412|NCT05386641|OTHER|measurement of the range of shoulder joint motion|The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
41348413|NCT05386641|OTHER|measurement of skin temperature|measurements will be taken by the thermographic camera
41348414|NCT05386641|OTHER|measurement of pain|Pain will be evaluated by visual analog scale (VAS)
41348415|NCT05386641|OTHER|measurement of pain pressure threshold|Pain pressure threshold will be evaluated by a digital algometer
41348416|NCT05386641|OTHER|measurement of grip strength|"The grip strength of both hand will be evaluated by hand-held dynamometer."
41348417|NCT04076904|DIAGNOSTIC_TEST|transvaginal us with 2D and 3D SHG|transvaginal us is made to all women with SHG
40829667|NCT03132103|DIETARY_SUPPLEMENT|Oral Vitamin D3|
40829668|NCT03132103|DIETARY_SUPPLEMENT|Placebo Oral Vitamin D3|
41019510|NCT01541657|OTHER|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
41019511|NCT01541657|OTHER|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
41348418|NCT04179370|OTHER|N/A - no intervention. Observational study.|N/A - no intervention. Observational study.
40829669|NCT03132103|RADIATION|Solar simulated radiation (SSR)|
40829670|NCT03132103|RADIATION|Placebo SSR|
40829671|NCT05801406|DEVICE|Tornado (Cook)|Fiducial marker endobronchial positioning under augmented fluoroscopy to mark ground glass opacities.
40829672|NCT02445937|BEHAVIORAL|PARTNER II|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
40829673|NCT04128982|PROCEDURE|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
40829674|NCT05003661|BEHAVIORAL|Parents' Voice|the intervention is recording of parents voice of reading children's book.
40829675|NCT04546373|DRUG|Niraparib|Patient's medical records will be screened by local clinical staff to assess for eligibility according to selection criteria. The study comprises a single study visit, in which the patient will give her informed consent to participate (when the patient is alive) and the physician will extract the study data from the patient's medical charts. All eligible deceased and consenting living patients at the participating centers will be included. Data will be directly retrieved from hospital medical records and reported in the electronic Case Report Form (eCRF).
40829676|NCT05079750|BIOLOGICAL|ChAdOx1 biEBOV|ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
41491489|NCT03554213|BIOLOGICAL|Typhoid Conjugate Vaccine|Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited
40829677|NCT04808206|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for the creation of anastomoses during laparoscopic bariatric surgery manufactured by Ezisurg Medical.
40829678|NCT05690204|DRUG|SAP001|Test the efficacy and safety of SAP 001 versus placebo
40829679|NCT06327893|OTHER|Submersion or immersion in liquid|The patient must have been submersed or immersed in liquid.
40829680|NCT03147313|DEVICE|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
41348419|NCT06108440|OTHER|action observation training|Patients in Group A will receive action observation training with conventional treatment. All participants will undergo the training for 25 minutes per session, 5 days per week for 8 weeks.
41348420|NCT06108440|OTHER|motor imagery training|Patients in Group B will receive motor imagery with conventional treatment. All participants will receive interventions for twenty-five minutes per session, five times a week, for eight weeks.
40829681|NCT03147313|DEVICE|Sham|Extracorporeal shock wave treatment will be faked.
41348421|NCT03474939|DRUG|Midazolam Oral Tablet|Midazolam Oral tablet
41348422|NCT03474939|OTHER|Placebo Oral Tablet|Glucose 1000mg tablet night before surgery and 60 minutes before surgery
41348423|NCT00674687|DRUG|2-weeks placebo then gabapentin|Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
41348424|NCT00674687|DRUG|1-week placebo then gabapentin|Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
41491490|NCT00786994|DRUG|Oleogel-S10 100 mg/g|topical use once or twice daily
41491491|NCT00786994|DRUG|Placebo (petroleum jelly)|topical use once or twice daily
40829682|NCT04604197|OTHER|Angiography and Clinical Follow up|Angiography and Clinical Follow up
41348425|NCT00374062|BEHAVIORAL|relaxation therapy 1|relaxation therapy 1
41348426|NCT00374062|BEHAVIORAL|relaxation therapy 2|relaxation therapy 2
41491492|NCT01251029|DRUG|N-acetylcysteine|1200 mg orally; 600mg i.v.
41491493|NCT01251029|DRUG|Siran (N-acetylcysteine)|
41491494|NCT04242914|DRUG|Ketamine|Intravenous Ketamine, dose 0.5mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
41491495|NCT04242914|DRUG|Midazolam|Intravenous Midazolam, dose 0.03mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
40829683|NCT04604197|OTHER|Clinical Follow up|Clinical Follow up
41348427|NCT00374062|BEHAVIORAL|relaxation therapy 3|relaxation therapy 3
40829684|NCT01449773|DIETARY_SUPPLEMENT|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
40829685|NCT01449773|DIETARY_SUPPLEMENT|Placebo|5 capsules/day containing corn and soybean oil
40829686|NCT05135858|DRUG|Glucarpidase|Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)
40829687|NCT05135858|DRUG|Methotrexate (MTX)|MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration
40829688|NCT05082350|DIETARY_SUPPLEMENT|black garlic|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
40829689|NCT04231214|DRUG|Olodaterol-Tiotropium|5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24
41348428|NCT03227601|DEVICE|posture adapter|continued use of the device at home for 2 months after instructions of how to do it
41348429|NCT05399589|COMBINATION_PRODUCT|use on1 abutment instead of healing cap in test group|We will use on1 abutment instead of healing cap in a implant operation, since the former can protect the soft tissue barrier to a certain extent.
41348430|NCT05399589|COMBINATION_PRODUCT|use healing cap in control group|use healing cap in control group
41348431|NCT04409691|DRUG|prednison and Sirolimus|If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months
41491496|NCT01267994|DRUG|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
41491497|NCT02131597|DRUG|Guadecitabine|Given SC
41491498|NCT02878486|DEVICE|Jawbone Up|Jawbone Up is a wrist wore water resistant activity monitor.
41491499|NCT02878486|BEHAVIORAL|Physical Activity Education|A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
41491500|NCT02878486|DEVICE|ActivPAL|Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
41491501|NCT03821870|DIAGNOSTIC_TEST|Inditreat|Tumoroid formation and drug sensitivity analysis
41491502|NCT03821870|DRUG|Experimental drug|Second line treatment based on drug sensitivity analysis
41491503|NCT03760003|DRUG|ABX464 25mg|ABX464 25mg (One capsule of ABX464 25 mg + One capsule of placebo) once daily for 16 weeks
41491504|NCT03760003|DRUG|ABX464 50mg|ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks
41491505|NCT03760003|DRUG|ABX464 100mg|ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks
41491506|NCT03760003|DRUG|Placebo|Two capsules of placebo once daily for 16 weeks
41491507|NCT01781819|PROCEDURE|ARFI SVI Ultrasound Imaging|Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
41491508|NCT03548649|DEVICE|exoskeleton robot training|subjects will learn to independently use the exoskeleton robot to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
41491509|NCT01647672|DRUG|Abraxane|Abraxane for neoadjuvant chemotherapy
41491510|NCT00600808|DRUG|BPLG-003|
41491511|NCT03277482|DRUG|Durvalumab|Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.
41509073|NCT01491451|DEVICE|Autogenous bone/INTERFIX™|INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
40829690|NCT06351709|OTHER|Stretching|Static stretching technique was applied to the quadriceps and hamstring muscle groups in both the dominant and non-dominant extremities of the participants in the stretching group. All stretches were performed twice for 20 seconds with a 3-second rest.
40829691|NCT06351709|OTHER|Hot pack application|Hot pack application was applied to the participants in the hot group to warm the extremities locally after the pre-tests were completed. For the application of hotpack, which is a superficial and moist temperature agent, a Chattanooga ® brand hotpack pad (DJO Global, Chattanooga; CA, USA) with 10 slices and a size of 28 cm x 39 cm was used. The hotpack pad was taken with the help of tongs from the Chattanooga ® brand hot pack boiler (DJO Global, Chattanooga; CA, USA) at 80° temperature and wrapped in a total of 5 layers with the help of 2 towels. A hotpackpad was placed on each knee of the participant. Hotpack pads were applied for 15 minutes in total.
40829692|NCT06351709|OTHER|Cold pack application|For participants in the cold group, MSD ® brand cold pack gel (MVS Inmotion, MSD cold pack; Weftdijk 1502830, Belgium), 15 cm x 25 cm in size, was used to cool the extremities locally. The cold pack gel, kept in the freezer, was wrapped in a paper towel and placed on the knee area. Cold pack was applied to both knees for a total of 15 minutes.
41019512|NCT01541657|OTHER|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
40829693|NCT00349687|BEHAVIORAL|self-control practice|
41348432|NCT04409691|DRUG|prednison|Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.
40829694|NCT01151605|DRUG|insulin infusion|insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl
40829695|NCT01151605|DRUG|Dextrose infusion|Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl
40829696|NCT01151605|DRUG|Saline Infusion|Saline will be infused at 100ml/hr
40829697|NCT00353873|DRUG|Fluticasone propionate|200μg twice daily
40829698|NCT00353873|DRUG|Fluticasone propionate/salmeterol|50/100μg twice daily
40829699|NCT01120314|DRUG|OTAMIXABAN (XRP0673)|"Form: solution for injection~Route: intravenous"
40829700|NCT03990103|DRUG|S1|80-120 mg/day, PO, D1-14, every 21 days
40829701|NCT03990103|DRUG|Paclitaxel|20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
41348433|NCT05260450|DEVICE|1064 nm Nd:YAG-laser therapy|"All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy."
41348434|NCT02746991|DRUG|Sham Injection|Placebo
41019513|NCT04371276|OTHER|No intervention|Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)
41019514|NCT04338815|OTHER|Exoskeleton optimization|Participants will walk 10 times of 1 minute duration while an optimization algorithm changes the assistance profile of an exoskeleton.
41019515|NCT04338815|OTHER|Endurance evaluation|Participants will walk 2 times at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes.
41348435|NCT02746991|DRUG|FAI Insert|Fluocinolone Acetonide
40829702|NCT03990103|DRUG|Bevacizumab|200 mg, IP, D1, every 21 days
40829703|NCT03990103|DRUG|Oxaliplatin|130 mg/m2, IV, D1, every 21 days
40829704|NCT01449110|DIETARY_SUPPLEMENT|Placebo in primary cardiovascular prevention (PP)|"12 months follow-up:~1. capsule/day of placebo (350 mg maltodextrin) for 6 months~2. capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
41348436|NCT02339454|DEVICE|Active treatment group|Energy Density - 0.09 mJ/mm2 Device: Active Applicator
41348437|NCT02339454|DEVICE|Placebo group|Placebo Applicator
40829705|NCT01449110|DIETARY_SUPPLEMENT|Placebo in secondary prevention|"12 months follow-up:~1. capsule/day (350 mg maltodextrin) for 6 months~2. capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
40829706|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in primary prevention (PP)|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
40829707|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in SP|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
41019516|NCT01318564|DRUG|Metformin|500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
41019517|NCT01318564|BEHAVIORAL|Questionnaires|Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
41348438|NCT00638274|PROCEDURE|Air|3 mls used for identifying epidural space
41348439|NCT00638274|PROCEDURE|Saline|3 mls of saline used to identify epidural space
41348440|NCT00717951|DRUG|docetaxol, cisplatin, capecitabine|docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
41348441|NCT04176328|DRUG|Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.|Teicoplanin Sandoz administered by inhalation (aerosol).
40829708|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in PP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
41348442|NCT01440829|DRUG|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
41348443|NCT01905514|DEVICE|internet mobile application|
41348444|NCT04780594|PROCEDURE|The study evaluates all surgical patients operated, both elective scheduled and emergent cases|Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)
41348445|NCT04743869|DEVICE|Kyphos FS™ Bone Substitute|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KyphOs FS™ bone cement will be introduced in the fractured vertebral body.
41348446|NCT04743869|DEVICE|KYPHON ActivOs® Bone Cement with Hydroxyapatite|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KYPHON ActivOs® Bone Cement with Hydroxyapatite will be introduced in the fractured vertebral body.
41348447|NCT03273699|DEVICE|Mindfulness|Clients will use a consumer grade EEG device that provides guided mindfulness home practices
41348448|NCT01378676|DRUG|Placebo (Part A)|Placebo tablets once daily for 14 days (Part A)
41348449|NCT01378676|DRUG|CK-2017357 (Part A)|One 125 mg CK-2017357 tablet once daily for 14 days (Part A)
40829709|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in SP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
40829710|NCT01189058|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS can affect discrete functional ares of motor cortex offering non-invasive, painless mapping and modulation of motor systems. Inhibitory rTMS (1Hz)has been shown to safely lower motor cortex excitability in normal patients as well as adult and pediatric stroke patients. Dose is 20 minutes per day (1200 stimulations) x 10 days administered over the non-lesioned M1.
40829711|NCT01189058|PROCEDURE|Constraint-induced movement therapy (CIMT)|CIMT uses gentle restraint of the fully functional upper extremity to promote functional gains in the affected upper extremity. CIMT is well established to be safe and is likely effective in children with hemiplegic cerebral palsy, many of whom have perinatal stroke as studied here. A custom-fitted, bivalved cast is applied and worn for \>90% of waking hours for the 2 weeks of active treatment according to protocol with daily assessments for comfort.
41348450|NCT01378676|DRUG|CK-2017357 (Part A)|Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)
41348451|NCT01378676|DRUG|CK-2017357 (Part A)|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)
41348452|NCT01378676|DRUG|Riluzole 50 MG (Part B)|One 50 mg tablet once daily for 14 days (Part B)
41348453|NCT01378676|DRUG|Placebo (Part B)|Placebo tablets once daily for 14 days (Part B)
40829712|NCT03190265|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
40829713|NCT03190265|DRUG|Nivolumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
41348454|NCT01378676|DRUG|CK-2017357 (Part B)|One 125 mg tablet once daily for 14 days (Part B)
41348455|NCT01378676|DRUG|CK-2017357 (Part B)|Two 125 mg tablets once daily for 14 days (Part B)
41348456|NCT01378676|DRUG|CK-2017357 (Part B)|Three 125 mg tablets once daily for 14 days (Part B)
41348457|NCT03821350|OTHER|Information leaflet|The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
41348458|NCT04185740|DEVICE|CloudUPDRS - Tapping Task|The TTT, consisting of two targets, will be presented on the screen of the smartphone. Participants will be instructed to alternate between the two targets using their index finger for 30 seconds. The task will always be performed with the left hand first and then with the right hand. The touch-sensitive screen of the smartphone will measure the timing of each touch event, its duration, the coordinates on the phone screen and the amount of pressure applied.
41348459|NCT01358006|DRUG|JNJ-40411813|Cohort 1: Type=2 to 3, unit=mg, number=200 to 300, form=capsule, route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.
41348460|NCT01358006|DRUG|JNJ-40411813|Cohort 2: Type=up to 7, unit=mg, number=up to 700 mg, form=capsule, route=oral use. Capsule(s) taken in the fed state.
41348461|NCT00921908|OTHER|2 mBq radioactive technetium diluted in 20 mL saline|
41348462|NCT00333931|DRUG|Phenytoin|
41348463|NCT00333931|BEHAVIORAL|Cognitive Behavioral Therapy|
41348464|NCT00606229|DRUG|Aripiprazole|oral, 24mg/day
41348465|NCT04065295|DRUG|BI 1356225|Oral Dose
41348466|NCT04065295|DRUG|Placebo|Oral dose
41348467|NCT03486769|DEVICE|M1 stimulation|stimulating primary motor cortex with anodal transcranial direct current stimulation
41348468|NCT03486769|DEVICE|PMC stimulation|stimulating premotor cortex with anodal transcranial direct current stimulation
41019518|NCT03313596|DRUG|ADV-Tk|The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
41348469|NCT03486769|DEVICE|aIPS stimulation|stimulating anterior intraparietal sulcus with anodal transcranial direct current stimulation
41348470|NCT03486769|BEHAVIORAL|hand motor task|hand motor task for 30 minutes during transcranial direct current stimulation
41348471|NCT04347902|DRUG|Intravenous Lipid Emulsion|Various types of intravenous lipids
41348472|NCT05726643|OTHER|resistive training|"5 minutes warming up exercise for various parts of the body as moderately energetic walking.~5 to 10 minutes stretching exercise for (pectorals major, hamstring, hip flexors, and calf muscles) with each static stretch held for at least 20 seconds in first week and then 30 seconds for the remaining 5 weeks and this will be repeated about four times.~10 to 15 minutes strengthening exercise by using weights for lower limbs (knee extensors, hip abductors, and hip extensors) at first session for each patient. Ten repetitions maximum (10 RM) will be determined, which is the maximal weight can be lifted through the entire range of motion 10 times."
41019519|NCT03313596|PROCEDURE|LT|Orthotopic LT and subsequent immunosuppression therapy
41019520|NCT06573125|BEHAVIORAL|MoodMover|MoodMover is a 9-week app-based program aimed at increasing physical activity (PA) among individuals with depression, delivered via Pathverse. The current version of MoodMover includes one introductory module for baseline self-monitoring, eight primary modules, and eight optional supplementary modules. The program uses a variety of formats to deliver educational content, including videos, podcasts, and illustrated articles. In addition to its structured psychoeducational content, the app provides a range of behavioral features.
41019521|NCT00491244|DRUG|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
41348473|NCT05726643|OTHER|kinesiotaping|Tape will be applied to each participant in the treatment group for the sartorius, rectus femoris, hamstrings, tibialis anterior, fibularis brevis, and the patella bilaterally using strips of the standard 2-inch Kinesio Tex Tape. The first and last inch of each strip will be applied without tension. The length of the strip will be applied with a 20%- 25% stretch and downward pressure to the insertion. Each of the sartorius, rectus femoris, hamstrings, tibialis anterior and fibularis brevis tapings used an I-strip. AY strip will be utilized for the patellar taping.
41348474|NCT02044367|DRUG|Dabigatran etexilate|Pellets (multiple dose of dabigatran)
41348475|NCT02044367|DRUG|Dabigatran etexilate|Granules resolved in reconstitution solution (multiple dose of dabigatran)
41348476|NCT02044367|DRUG|Dabigatran etexilate|Hard capsule (multiple dose of dabigatran)
41348477|NCT04139772|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
41348478|NCT04139772|DRUG|Abiraterone Acetate or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
41348479|NCT05275127|OTHER|changes of gingival crevicular fluid miRNA|Evaluation of changes of gingival crevicular fluid miRNA after periodontal treatment
41348480|NCT05327244|OTHER|Real-world vibration feedback gait retraining|Participants will walk with a vibration feedback tool attached to their shoelaces. A small force sensing resistor is taped to the foot bed of the shoe under the lateral foot and a vibration motor is placed over the outside of the ankle with a strap. When a participant walks on the outside of their foot, they will exceed the pressure threshold and activate the feedback which signifies an incorrect foot placement. The feedback is intended to prompt a correct foot placement on the subsequent step. Participants will use the same feedback tool for 6 real world training sessions.
41348481|NCT06148818|OTHER|Progressive neck motor control exercise therapy|The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.
41348482|NCT06148818|OTHER|Patient education|The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
41348483|NCT06096012|DRUG|Anti-MRSA therapy|chart review to determine the clinical outcomes of patients with osteomyelitis who were placed on definitive anti-MRSA treatment, despite no identified MRSA cultures.
41348484|NCT03288311|OTHER|Protocolized post-extubation respiratory support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
41348485|NCT03288311|OTHER|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
41348486|NCT03705741|BEHAVIORAL|Resistance exercise|Resistance exercise twice a week during pregnancy week 23-34.
41348487|NCT06139939|PROCEDURE|Double layer technique|Double layer technique for alveolar ridge augmentation (first layer autograft followed by xenograft second layer).
41348488|NCT01487694|DRUG|cimicifuga racemosa|Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
41348489|NCT01487694|DRUG|placebo|matching placebo without active ingredient 1 tab daily for 12 weeks
41348490|NCT05711511|PROCEDURE|conventional obturation technique|cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer
41348491|NCT05711511|DEVICE|Obtura II|"is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle"
41348492|NCT05616572|BEHAVIORAL|OncoWhiz|OncoWhiz is an online educational tool designed to supplement current institutional caregiver education. OncoWhiz requires low graphical demands, has no-end user downloads, and is compatible with both desktop and mobile phones. Questions are derived from the institutional binder and are written at a fifth-grade reading level for user accessibility.
41348493|NCT02315833|DRUG|Acetium|Capsule for oral administration contains L-cysteine 100mg
41348494|NCT02315833|DRUG|Placebo|A placebo capsule matching Acetium for oral administration.
40829714|NCT03190265|DRUG|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
41348495|NCT03160066|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus (JB-1)|Lactobacillus Rhamnosus (JB-1) capsule
41348496|NCT03160066|DIETARY_SUPPLEMENT|Placebo|Placebo
40829715|NCT03190265|DRUG|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
40829716|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
40829717|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
41348497|NCT04990531|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
41348498|NCT04990531|DIAGNOSTIC_TEST|Blood sample|Blood sample for diagnostic testing
41348499|NCT05976906|BIOLOGICAL|Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)|"1. Dose Escalation: After enrollment, participants will recieve preconditioning by lymphodepletion or not, and then will be treated with CNK-UT cells with a 3 +3 design to determine the maximum tolerated dose. 3 dose level of CNK-UK cells will be tested: 4.6E6/kg，1.5E7/kg，4.6E7/kg. The participants will first receive a single ascending dose(SAD) mode of administration. During the DLT observation period (21 days), if the participants do not experience DLT, they will receive a multiple ascending dose(MAD) mode of administration.~2. Indications Expansion: It will be carried out after all participants have completed the DLT observation in the Dose Escalation phase. The target population, dosage and frequency of drug administration in the indication expansion stage can be adjusted and determined according to the previous research results."
41348500|NCT00611416|DIETARY_SUPPLEMENT|green tea|different catechin combinations
41348501|NCT00611416|DIETARY_SUPPLEMENT|Mix of catechins and caffeine|3 tablet a day
41348502|NCT00611416|DIETARY_SUPPLEMENT|EGCG|3 tablets a day
40829718|NCT02658747|OTHER|No intervention|No intervention administered in this study
40829719|NCT03413098|DEVICE|Nasal CPAP mask|Investigative Nasal Mask to be used for OSA therapy
40829720|NCT02267330|PROCEDURE|Exposure Recording|Patient undergoing fracture surgery will have radiation exposure recorded
40829721|NCT05909774|DEVICE|"Test with Atalante exoskeleton in continuous walk type"|"The continuous walk is smoother and more physiologic than the push and swing walk"
40829722|NCT05458895|OTHER|ECIG lab session 1|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
40829723|NCT05458895|OTHER|ECIG lab session 2|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
41019522|NCT00491244|DRUG|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
41019523|NCT06572670|OTHER|Progressive relaxation exercise before coronary angiography|Patients in the intervention group will undergo progressive relaxation before undergoing angiography.
41019524|NCT06573216|DEVICE|Wrist Ambulatory Blood Pressure Monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
41019525|NCT04226638|DIAGNOSTIC_TEST|Dynamic ultrasound|Diagnosis was based on clinic suspicion and positive ultrasonography dynamic maneuvers by reproducing pain and slipping rib exam
41019526|NCT05515562|DRUG|Omadacycline Injection|All participants will receive Intravenous (IV) omadacycline
41019527|NCT05630937|DRUG|NMS-01940153E|Route of administration: intravenous (IV) solution
41019528|NCT03594591|DRUG|Antidiabetic treatment by usual care|Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
41348503|NCT00611416|DIETARY_SUPPLEMENT|EGC|3 tablets a day
41348504|NCT00611416|DIETARY_SUPPLEMENT|Caffeine|3 tablets a day
41348505|NCT00611416|DIETARY_SUPPLEMENT|Placebo|3 tablets a day
41348506|NCT02669446|DEVICE|Medical devices|
41348507|NCT02669446|DEVICE|traditional household remedy|
41348508|NCT01395966|DRUG|DF289|Ear drops
41348509|NCT01395966|DRUG|DF277|Ear drops
41348510|NCT01395966|DRUG|DF289 plus DF277|Ear drops
41348511|NCT02282774|DRUG|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
41348512|NCT02282774|DRUG|Sham subtenon block|
41348513|NCT01579162|DEVICE|Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)|"The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days"
41348514|NCT05119790|DRUG|[14C] BIIB122 ([14C] DNL151)|Oral dose
41348515|NCT05245695|OTHER|Observational study, no intervention|Observational study, no intervention
41348516|NCT03988790|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
41348517|NCT01994109|DRUG|MYOBLOC|"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use."
41348518|NCT01994109|OTHER|PLACEBO|
40829724|NCT05458895|OTHER|ECIG lab session 3|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
40829725|NCT05458895|OTHER|ECIG lab session 4|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
41348519|NCT04807244|PROCEDURE|Selective Caries Removal with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; peripheral caries is removed until only hard dentin is left, while the pulp wall is excavated until reaching leathery dentin~4. Disinfection of the leathery dentin 5 ml 1% NaOCl (speed: 1 ml per min)~5. Indirect pulp capping (layer of 1-2 mm) of the carious lesion with Biodentine™ (15 min setting time after mixing)"
41348520|NCT04807244|PROCEDURE|Partial Pulpotomy with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of 2-3 mm pulp tissue; irrigation with 2 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, transfer of the case to Intervention: full pulpotomy with Biodentine~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
41348521|NCT04807244|PROCEDURE|Full Pulpotomy with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of the entire pulp chamber roof; full pulpotomy to stump level with a high-speed round bur under continuous irrigation with 5 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, exclusion.~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
41491512|NCT03277482|DRUG|Tremelimumab|Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour
41491513|NCT03277482|RADIATION|Radiation Therapy|Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.
41348522|NCT04807244|PROCEDURE|Direct composite filling after selective caries removal/full pulpotomy/partial pulpotomy|"1. Dentin cleaning with a low-speed round bur~2. Use of Scotchbond Universal™ and Filtek Supreme XTE™ according to manufacturer's recommendation"
41348523|NCT03279146|DRUG|Tenofovir exalidex (TXL)|Oral formulations
41348524|NCT00476515|DRUG|Rituximab|the recommended dosage of Rituximab is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
41348525|NCT01869452|BEHAVIORAL|therapeutic education|knowledge of disease, risk factors, diet, medication, alert symptoms
41348526|NCT00614042|DRUG|TRU-016 (anti-CD37 protein therapeutic)|TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
41491514|NCT01106664|DRUG|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
41491515|NCT01106664|DRUG|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
40829726|NCT05458895|OTHER|ECIG lab session 5|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
40829727|NCT05458895|OTHER|ECIG lab session 6|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
41348527|NCT02204059|DRUG|hMAb BIWA 4|
41348528|NCT03248817|DRUG|single shot phenylephrine|a single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously
41491516|NCT05211661|DIAGNOSTIC_TEST|Respiratory Muscle Testing|Comprehensive assessment of respiratory muscle function. Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
41491517|NCT03349008|DRUG|Entecavir|Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
41491518|NCT03349008|DRUG|Magnesium Isoglycyrrhizinate|Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based
41491519|NCT03349008|DRUG|Diammonium Glycyrrhizinate|Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
41491520|NCT03349008|DRUG|Magnesium Isoglycyrrhizinate Placebo|Magnesium Isoglycyrrhizinate Injection Placebo
41491521|NCT03349008|DRUG|Diammonium Glycyrrhizinate Placebo|Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
41491522|NCT01288053|BIOLOGICAL|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
40829728|NCT05458895|OTHER|ECIG lab session 7|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
41348529|NCT03248817|DRUG|fixed infusion phenylephrine|fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min.
41348530|NCT03248817|DRUG|variable infusion phenylephrine|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
41348531|NCT03248817|DRUG|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
41491523|NCT04832516|OTHER|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
41348532|NCT03931590|DRUG|[14C]-Omaveloxolone|\[14C\]-Omaveloxolone 50 mg capsules
41348533|NCT06028906|DIAGNOSTIC_TEST|Multimodal physiological monitoring and cerebral autoregulation monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) and ECG.~Non-invasive cerebral autoregulation index Mx will by calculated as a Pearson correlation coefficient between slow ABP and slow CBFV waves.~Invasive cerebral autoregulation index (Pressure reactivity index PRx) will by calculated as a Pearson correlation coefficient between slow ABP and slow ICP waves.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
41348534|NCT00070837|DRUG|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
41348535|NCT00004256|BIOLOGICAL|sargramostim|
41348536|NCT00004256|PROCEDURE|quality-of-life assessment|
41157676|NCT00647283|PROCEDURE|Gradual immunosuppression drug withdrawal|After the obtention of biological samples (peripheral blood, liver tissue), enrolled patients undergo gradual weaning of all immunosuppressive therapy over a 6-9 month period under close medical supervision.
41348537|NCT00004256|RADIATION|radiation therapy|
41348538|NCT04801355|PROCEDURE|full-thickness laparo-endoscopic colon adenomas excision|Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.
41348539|NCT04801355|PROCEDURE|laparoscopic colon resection|Standard laparoscopic colon resection
41348540|NCT00045045|PROCEDURE|positron emission tomography|
41348541|NCT00045045|RADIATION|fludeoxyglucose F 18|
41491524|NCT04832516|OTHER|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
41348542|NCT00343395|DRUG|AVANDAMET|2/500 mg
41348543|NCT00394654|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
41348544|NCT00394654|OTHER|Placebo|Placebo administered as a single intravenous infusion
41348545|NCT03445962|DIAGNOSTIC_TEST|Assessment of OSAS predictive factors|"All subjects of the two groups realized the same assessment:~* Anthropometric evaluation~* biological examination (hormonal, inflammatory and complete blood count, and lipidic profile)~* rest electrocardiogram~* motor assessment (strenght, flexibility and balance)~* actigraphy~* Autonomic nervous system assessment during sleep~* Autonomic nervous system assessment during head up tilt test before and after physical exercise~* maximal treadmill test (VO2 max measure)~* polysomnography~* seismocardiography~* questionnaires :sleep and physical activity"
41348546|NCT00654576|DRUG|Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole|patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
41348547|NCT00654576|BEHAVIORAL|psychosocial intervention|the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
41348548|NCT02278159|PROCEDURE|Peritoneal dialysis|
41348549|NCT02278159|PROCEDURE|Home hemodialysis|
41348550|NCT03148899|DRUG|Oxytocin Intranasal Spray|In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.
41491525|NCT02302547|DRUG|triple therapy|Dosage treatment and usual prescription
41491526|NCT02302547|DRUG|dual therapy|1 tablet (200mg/245mg) daily for 48 weeks
41157677|NCT04482270|DRUG|fezolinetant|Oral
41348551|NCT03148899|DRUG|Placebo Intranasal Spray|The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
41348552|NCT03946189|DIAGNOSTIC_TEST|Obtaining arterial blood gases|Obtaining arterial blood sample
41491527|NCT00202423|DRUG|Sativex|
41348553|NCT05393544|BEHAVIORAL|Digitally assisted peer recovery coach|The certified peer recovery coach utilized an existing care coordination smartphone app to provide support to the patient during and after an inpatient detoxification treatment for alcohol use disorder. The coach utilized the telephone or text messages to send daily motivational messages, remind about upcoming appointments, and checked-in if responses were concerning. Follow-up by the coach continued for 30 days.
41348554|NCT00024128|BIOLOGICAL|anti-thymocyte globulin|
41491528|NCT03832881|DIAGNOSTIC_TEST|ADAMTS13, VWF assay|
41491529|NCT00239044|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
41491530|NCT02760524|BEHAVIORAL|NET Intervention|Neuro-emotional Technique
41491531|NCT03792724|DRUG|Urelumab + Nivolumab|Treatment with intratumoral urelumab after which Nivolumab will be given.
41491532|NCT02586142|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
41491533|NCT02586142|OTHER|Stretching exercise|After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
40829729|NCT05458895|OTHER|ECIG lab session 8|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
40829730|NCT00732355|DEVICE|Syph-Check POC|Rapid membrane test for syphilis antibodies
40829731|NCT04626089|DRUG|metformin glycinate|Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
40829732|NCT04626089|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
40829733|NCT03404908|PROCEDURE|TAP (transversus abdominis plane block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
41491534|NCT05390918|BEHAVIORAL|TAILOR|"The first TAILOR session will assess existing sleep problems from both the adolescent's and parent/legal guardian's perspectives, concluding with offering a CBT strategy to try. Session 2 will involve getting feedback from the family on that specific strategy and then offering additional CBT strategies. The remaining sessions will be devoted to refining the use of CBT strategies. MI will be integrated as the communication style throughout, including reflective listening, rolling with resistance, and showing deference to the family's ultimate decisions. The interventionist will also use the elicit-provide-elicit approach from MI. The interventionist will elicit the family's own ideas for improving the adolescent's sleep, ask for permission to provide his/her own suggestions, and then gauge the family's reactions to those suggestions, versus simply recommending a CBT strategy and problem-solving barriers to implementation."
41491535|NCT05390918|OTHER|Enhanced Usual Care|The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
41491536|NCT06424249|OTHER|Virtual Reality|A progressive rehabilitation protocol (different levels according to success scores) consisting of several exercises using virtual and augmented reality with mechanical perturbations (pitching of the treadmill), interaction with the virtual environment, interaction with the virtual environment and augmented reality (projection of obstacles on the treadmill), and modification of the gait pattern with visual and/or audio biofeedback
41491537|NCT06424249|OTHER|Standard rehabilitation|A treadmill walking protocol with virtual reality to immerse the patient in a 3 x 5-minute walking session, without visual, mechanical or auditory disturbances, and without prompting the patient to modify their walking pattern.
41491538|NCT01305395|DRUG|Sirolimus|Will initiate sirolimus within 6 months of heart transplant
41491539|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by angiogram
41491540|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
41491541|NCT01305395|DRUG|Sirolimus|Will start sirolimus after they develop CAV by angiogram
41491542|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
41491543|NCT05676281|BEHAVIORAL|Healthy Together (Control)|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals"
41491544|NCT05676281|BEHAVIORAL|Healthy Together + Promotora Support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)"
41491545|NCT05676281|BEHAVIORAL|Healthy Together + Parenting Training|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 6-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
40829734|NCT03404908|PROCEDURE|QL (quadratus lumborum block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
40829735|NCT03404908|DRUG|Ropivacaine|In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
40829736|NCT03404908|DEVICE|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
40829737|NCT03404908|DRUG|paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
40829738|NCT03404908|DRUG|metamizole|Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
40829739|NCT03404908|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
40829740|NCT03404908|DRUG|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
40829741|NCT00739180|OTHER|Control|Standard care control (no exercise)
40829742|NCT00739180|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
40829743|NCT00739180|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
40829744|NCT05750810|OTHER|Severe exacerbation frequency|A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms.
41348555|NCT00024128|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41348556|NCT00024128|DRUG|cyclophosphamide|
41348557|NCT00024128|DRUG|cyclosporine|
41019529|NCT03533400|DEVICE|Jamboxx Respiratory Therapy Device|Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece containing a breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
41019530|NCT03533400|DEVICE|Jamboxx Musical Device|Jamboxx musical device is a hands free, breath controlled music device designed for people with quadriplegia. It resembles a common harmonica in that the user slides a mouthpiece along its horizontal axis to change the pitch of the instrument. The device connects to a personal computer via a mini USB to USB cable to interface with software that provides visual feedback for playing notes and sends the information to the computer speakers. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx musical device can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key
41491546|NCT05676281|BEHAVIORAL|Healthy Togethers + Parenting Training + Promotora support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)~* 8-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
41019531|NCT01540227|DRUG|Regular Treatment for Syphilis|"Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes"
41019532|NCT03266445|DRUG|buprenorphine/naloxone|The intervention will be to either continue taking buprenorphine/naloxone or to have the medication reduced perioperatively.
41019533|NCT05501197|OTHER|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
41157678|NCT06434571|BEHAVIORAL|Telehealth cognitive behavioral therapy for insomnia (tCBT-I)|"The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention"
41157679|NCT06434571|BEHAVIORAL|Web-based cognitive behavioral therapy for insomnia (wCBT-I)|Participants receive a daily e-mail reminder to access the program and to complete a sleep log for the prior night's sleep. After completing the sleep log, the daily lesson is made available. Each participant will be provided with a unique password to access the online program.
41491547|NCT00166907|BEHAVIORAL|Balance and Exercise|
41491548|NCT04964518|DRUG|APG 2575 ramp up arm|APG2575 ramp up + Azacitidine
41491549|NCT01909830|DRUG|Arm A : Gemcitabine + Pemetrexed|"Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
41491550|NCT00997568|DEVICE|PET-511BTM|Transesophageal Transducer
41491551|NCT02953470|BEHAVIORAL|Individual tailored functional exercise|Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.
41491552|NCT02953470|BEHAVIORAL|Standard care|Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.
41491553|NCT04183075|DIETARY_SUPPLEMENT|FontActiv Superprotein/Hypercaloric Fiber|The product under study has a liquid presentation, in 200 ml bottles, ready to take
41491554|NCT04183075|DIETARY_SUPPLEMENT|Carbohydrates and C Vitamin|The control product will be prepared with equal presentation and taste as similar as possible tan study product
41491555|NCT00000583|BIOLOGICAL|hepatitis B vaccines|
41348558|NCT00024128|PROCEDURE|peripheral blood stem cell transplantation|
41348559|NCT00024128|RADIATION|radiation therapy|
41348560|NCT01037140|DRUG|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
41348561|NCT01037140|DRUG|placebo|oral placebo tablets similar to active comparator
41348562|NCT04501965|COMBINATION_PRODUCT|Hydroxychloroquine/Azithromycine|Dual treatment with Hydroxychloroquine and Azythromycin
41348563|NCT04501965|COMBINATION_PRODUCT|Quinquina-Stevia/Azythromycin|Dual treatment with Quinquina/Stevia (3/0,5) and Azythromycin
41348564|NCT04501965|COMBINATION_PRODUCT|4Plants/Azythromycin|Dual treatment with 4 plant species drug and Azythromycin
41348565|NCT02903745|OTHER|observational|
41348566|NCT03174808|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
41348567|NCT00553618|DRUG|Proleukin and Dacarbazine|"IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks."
41348568|NCT01740765|OTHER|24-hour energy expenditure|To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
41348569|NCT03333434|DEVICE|Carbon Ankle Seven spring (A7 - Otto Bock, Germany)|
40829745|NCT06473974|DRUG|Test cosmetic product|"Test cosmetic product: Test cosmetic product will be applied to affected hyperpigmented areas twice daily at AM and PM.~Cleanser and sunscreen: A facial cleanser will be used twice daily (morning and evening) by gently rubbing it on face and neck, then rinse and pat dry. Sunscreen of SPF 50, apply evenly on face and neck, 20 minutes before stepping out."
40829746|NCT01898949|OTHER|Cold Exposure|Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
41348570|NCT03333434|DEVICE|Hinged AFO|
41348571|NCT02710110|DEVICE|PowerLung trainer|PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
41348572|NCT02710110|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
41348573|NCT02710110|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
41491556|NCT04738474|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|"Develops personal resilience resources through 1:1 sessions with a PRISM coach."
41491557|NCT04738474|OTHER|Usual Care|No additional study-specific interaction with subjects. Subjects continue to receive usual medical care.
41491558|NCT04557020|DRUG|PD-1 antibody|neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy
41491559|NCT04557020|DRUG|Gemcitabine|neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles
41491560|NCT04557020|DRUG|Cisplatin|neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
41491561|NCT04557020|RADIATION|IMRT|70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions
40829747|NCT01610596|DRUG|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
40829748|NCT01610596|DRUG|Placebo|
41348574|NCT02710110|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
41348575|NCT02710110|OTHER|Swallowing Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
41348576|NCT02710110|DEVICE|Iowa Oral Pressure Instrument|The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
41348577|NCT02710110|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
41491562|NCT04401865|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
41491563|NCT02517086|OTHER|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
41491564|NCT02517086|OTHER|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
41491565|NCT02517086|OTHER|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
41348578|NCT04892394|OTHER|Information Types Before Endodontic Treatment|The first aim of this study is to compare the effect of detailed video information or basic verbal information on the anxiety levels of patients by using anxiety scales before treatment. The second aim is to evaluate the effect of pretreatment video or verbal information on the stress level occurring in patients during the endodontic treatment steps by using electrodermal activity. The third aim is to investigate the relationship between patients' pretreatment anxiety levels and socio-demographic characteristics which are thought to play a role in anxiety's etiology.
41348579|NCT02551328|DRUG|sevofluorane|Continuous infusion of sevofluorane
41491566|NCT02041156|OTHER|aerobic and resistance training|
41491567|NCT02041156|OTHER|aerobic combined with balance training|
40829749|NCT01816906|DEVICE|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
41491568|NCT01123837|OTHER|Intravenous fluid|"The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.~The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery."
41491569|NCT01123837|OTHER|D5LR or lactated ringers|"The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.~The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction."
41491570|NCT04856124|DRUG|Intranasal esketamine|Subjects with a clinically meaningful response to IV racemic ketamine were switched to IN esketamine
41491571|NCT05203718|BEHAVIORAL|Food Response Training (FRT)|All patients will complete the 12-week FRT intervention consisting of one in-person session (during the baseline visit) and three weekly sessions at home, one delivered via video conference (WebEx) and two self-guided. Food Response Training (FRT) is a computer-based attention bias modification intervention. The intervention will be delivered on a computer or smart device (e.g. iPhone). Patients will use the FoodTrainer application available for Android and iPhone (https://www.exeter.ac.uk/foodt/about/).
41491572|NCT04990596|BIOLOGICAL|additional blood sample|One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
41491573|NCT00699374|DRUG|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
41491574|NCT00699374|DRUG|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
40829750|NCT01816906|DEVICE|Footwear: MCP|One group of patients will receive footwear with MCP insoles
40829751|NCT00304018|BIOLOGICAL|anti-thymocyte globulin|
40829752|NCT00304018|BIOLOGICAL|sargramostim|
40829753|NCT00304018|DRUG|busulfan|
40829754|NCT00304018|DRUG|etoposide|
41019534|NCT05501197|OTHER|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
41491575|NCT04648332|DRUG|Bupivacaine Hydrochloride|compartment psoas block
40829755|NCT00304018|DRUG|fludarabine phosphate|
40829756|NCT00304018|DRUG|prednisone|
40829757|NCT00304018|DRUG|tacrolimus|
40829758|NCT00304018|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40829759|NCT00304018|PROCEDURE|umbilical cord blood transplantation|
40829760|NCT02194920|PROCEDURE|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
40829761|NCT00712530|BIOLOGICAL|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
40829762|NCT00712530|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
40829763|NCT00000652|DRUG|Zidovudine|
40829764|NCT00000652|DRUG|Didanosine|
41348580|NCT03908463|DEVICE|Percutaneous coronary intervention|All coronary intervention procedures will be performed according to current standard techniques.
41348581|NCT04493489|DRUG|Propranolol Hydrochloride|Trial group: BCG + propranolol: after TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
40829765|NCT03833570|DIETARY_SUPPLEMENT|Rapid Release Capsules Melatonin, 10 mg|Melatonin is a dietary supplement which is naturally produced in the body and closely involved in the natural sleep cycle. recently topical and systemic melatonin supplements. have been proposed as a new therapeutic modality for oral mucositis due to its anti-cancer, anti-inflammatory, and anti-oxidant effects.
40829766|NCT03833570|DRUG|Miconaz oral gel|Antifungal agent
41019535|NCT03524391|BEHAVIORAL|Counselling based on yoga|Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
41348582|NCT04493489|DRUG|BCG|Control group: BCG vaccine: After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
41491576|NCT00084448|DRUG|celecoxib|
40829767|NCT03833570|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
41491577|NCT00084448|DRUG|paclitaxel|
40829768|NCT03833570|DRUG|Oracure gel|Topical analgesic gel
40829769|NCT03833570|OTHER|Alkamisr sachets|Sodium bicarbonate mouthwash
40829770|NCT00390481|PROCEDURE|EC-IC Bypass in the COSS study|EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
40829771|NCT04868487|OTHER|Health Literacy Education|Health literacy education, consisting of four sessions, was given to the intervention group.
40829772|NCT01390324|DRUG|Fixed-dose combination of naratriptan+naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
41348583|NCT01834638|DRUG|ABT-126|capsule(s)
41348584|NCT05844254|PROCEDURE|novel overlapping rotated double (NORD) flap|"After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. Patients will be randomly allotted to either group by stratified block randomization after taking baseline measurement with respect to periodontal phenotype(PP) \[using transparency of periodontal probe through the gingival margin, when probe is visible, thin PP and when not visible, thick PP\] so that patients with thick and thin PP get an equal chance of being allocated to NORD and Sub epithelial connective tissue group.~1. Group 1(NORD group)- Patients treated with NORD flap~2. Group 2 (Sub epithelial connective tissue group)- Patients treated with sub epithelial connective tissue graft Patients will be followed up after 1 month,6, 12 and 15 months. 30 patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification."
41348585|NCT00776581|PROCEDURE|CSEA with PCA|Records regarding combined spinal-epidural analgesia with patient-controlled pump
41348586|NCT00776581|PROCEDURE|CSEA with IBI|Records regarding combined spinal-epidural analgesia with intermittent bolus injection
41348587|NCT00776581|PROCEDURE|EA with PCA|Records regarding epidural analgesia with patient-controlled pump
40829773|NCT01390324|DRUG|Naratriptan|Tablets containing naratriptan 2,5 mg
40829774|NCT01390324|DRUG|Naproxen|Tablets containing naproxen 500 mg
40829775|NCT01582737|DRUG|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner
40829776|NCT02251132|DRUG|TPV low 1|
40829777|NCT02251132|DRUG|TPV low 2|
40829778|NCT02251132|DRUG|TPV medium|
40829779|NCT02251132|DRUG|TPV high 1|
40829780|NCT02251132|DRUG|TPV high 2|
40829781|NCT02251132|DRUG|RTV low|
40829782|NCT02251132|DRUG|Ritonavir high|
40829783|NCT02251132|DRUG|Radiolabelled erythromycin|
40829784|NCT04528615|BEHAVIORAL|CCK In-Person Sessions|This group attended eight weeks of nutrition education-focused experiential learning.
40829785|NCT04528615|BEHAVIORAL|CCK Printed Materials|This group did not attend any in-person sessions and was only provided with select CCK written materials.
40829786|NCT04192968|OTHER|Cortical auditory evoked potentials|Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.
41019536|NCT03524391|DRUG|Chemotherapy|Usual Care group had standard chemotherapy regimens
41019537|NCT06321484|BIOLOGICAL|Cytokine-Induced Memory-like Natural Killer Cells|Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.
41019538|NCT06321484|BIOLOGICAL|IL-15 Superagonist|Recombinant human protein, single-use 1mL vial, via subcutaneous injection per protocol.
41019539|NCT06381986|DRUG|SHJ002|Topical ophthalmic
41019540|NCT06381986|OTHER|Vehicle|Topical ophthalmic
41019541|NCT06425172|DEVICE|Cranial Remolding Orthosis|A custom made FDA-approved cranial remolding orthosis will be retrofit with sensors used in the research.
41019542|NCT04693364|OTHER|Decision Aid|Use 3D printed breast model
41019543|NCT04693364|PROCEDURE|Discussion|Participate in consultation
41019544|NCT04693364|OTHER|Questionnaire Administration|Complete questionnaires
41019545|NCT00165282|BEHAVIORAL|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
41491578|NCT03958123|DRUG|100 μg cebranopadol|Encapsulated 100 μg cebranopadol tablet.
41491579|NCT03958123|DRUG|200 μg cebranopadol|Encapsulated 200 μg cebranopadol tablet.
41491580|NCT03958123|DRUG|400 μg cebranopadol|Encapsulated 400 μg cebranopadol tablet.
41491581|NCT03958123|DRUG|Placebo to cebranopadol encapsulated tablets|Matching placebo to cebranopadol encapsulated tablet.
41491582|NCT03958123|DRUG|400 mg Moxifloxacin|Encapsulated 400 mg moxifloxacin tablet.
41491583|NCT03958123|DRUG|Placebo to moxifloxacin encapsulated tablets|Matching placebo to moxifloxacin (400 mg) encapsulated tablet.
41491584|NCT06236243|DIETARY_SUPPLEMENT|Korean Red Ginseng Extract Powder 120 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
41019546|NCT00165282|BEHAVIORAL|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
41348588|NCT00776581|PROCEDURE|EA with IBI|Records regarding epidural analgesia with intermittent bolus injection
41348589|NCT03887286|DEVICE|Philips EPIQ 7 ultrasound machine|Standard transthoracic echocardiography
41348590|NCT03887286|DEVICE|Philips Lumify Broadband sector array transducer|Portable hand-held ultrasound device
41348591|NCT02455440|DRUG|Esmolol|effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.
41348592|NCT02455440|DRUG|Placebo|
41348593|NCT02455440|DRUG|Propofol and sevoflurane|
41348594|NCT00004127|DRUG|FOLFOX regimen|
41348595|NCT00004127|DRUG|fluorouracil|
41348596|NCT00004127|DRUG|leucovorin calcium|
41348597|NCT00004127|DRUG|oxaliplatin|
41348598|NCT00397631|DRUG|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d|Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.
41348599|NCT00397631|DRUG|Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
41348600|NCT05756894|DEVICE|Neurostimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
41348601|NCT05756894|OTHER|Repiratory training|Respiratory exercises will be completed immediately after completing neurostimulation. Respiratory exercises will involve inspiratory muscle training performing four sets of 6-10 breaths per day with two minutes of rest.
41348602|NCT00436722|DRUG|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
41348603|NCT02747329|DEVICE|BuMA Supreme™ stent|
41348604|NCT02747329|DEVICE|Xience V/Prime stent|
41348605|NCT01731808|BEHAVIORAL|Nursing counseling|The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
41348606|NCT01137448|BEHAVIORAL|Weight Loss|Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
41019547|NCT02044081|DRUG|C16G2 Rinse|Active rinses are 1.6 mg/mL C16G2.
41019548|NCT02044081|DRUG|Placebo|Placebo is the vehicle without C16G2
41019549|NCT02044081|DRUG|C16G2 Gel|Active C16G2 Gel is 3.2 mg/mL
41019550|NCT00087568|DRUG|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
41019551|NCT00087568|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
41019552|NCT00718718|DRUG|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
41019553|NCT00718718|DRUG|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
41019554|NCT00718718|DRUG|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
41019555|NCT00718718|DRUG|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
41348607|NCT05098249|DRUG|Verum|The participant takes two capsules Phoscap® (3mmol/capsule) orally three times a day over 30 days beginning the day of Ferinject administration.
41348608|NCT05098249|DRUG|Placebo|The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.
41348609|NCT00726492|OTHER|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
41348610|NCT00726492|OTHER|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
41348611|NCT01018615|DRUG|silymarin|capsules, 700 mg, twice daily, 12 days
41348612|NCT01018615|DIETARY_SUPPLEMENT|green tea extract (EGCG)|capsules, 196.5 mg, twice daily, 12 days
41348613|NCT02202161|DRUG|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
41348614|NCT02202161|DRUG|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
41348615|NCT02202161|DRUG|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
41348616|NCT02202161|DRUG|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
41348617|NCT06009406|OTHER|Physiotherapy|This group will be applied to the soleus, gastrocnemius muscle and Achilles tendon with Graston, an instrumental myofascial mobilization technique, until they feel warmth in the skin and tonus relaxation in the target muscles. The control group will be subjected to 3 repetitions of passive stretching for 30 seconds for the same structures.
41348618|NCT06117072|OTHER|diet plan|One group (n = 30) received the DASH diet and the other group received a salt-free diet (n = 30) and was followed for 2 months
41348619|NCT04327895|BEHAVIORAL|evaluation of the need for training|analyse of results of survey
41348620|NCT02946151|DEVICE|UNEEG implantable EEG electrode and data storage device|The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.
41348621|NCT02446028|DRUG|BIOD-531|
41348622|NCT02446028|DRUG|Humalog® Mix 75/25|
40829787|NCT04192968|OTHER|Additional exams|"* Cortical auditory evoked potentials Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.~* Recording of cortical auditory evoked potentials in response to a click~* Realization of electrical potentials via the implant Followed up once a year during a visit scheduled for usual care, for 3 years, that to say up to 6 years post-implant."
40829788|NCT02956304|OTHER|PMv stimulation (iTBS)|PMv stimulation (iTBS)
40829789|NCT02956304|OTHER|PMv inhibition (cTBS)|PMv inhibition (cTBS)
40829790|NCT02956304|OTHER|Control (SHAM)|Control (SHAM)
41019556|NCT00718718|DRUG|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
41348623|NCT02050828|DRUG|AKB-9778|
41348624|NCT02050828|DRUG|ranibizumab|
41348625|NCT02050828|DRUG|Placebo|
41348626|NCT02050828|DRUG|Sham|
41019557|NCT02506998|BIOLOGICAL|DLE|Adjuvant treatment
41348627|NCT00641745|DRUG|Lurasidone HCl|40 - 120mg per day
41348628|NCT00641745|DRUG|Risperidone|Risperidone
41348629|NCT01960179|DRUG|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
41348630|NCT03582033|DRUG|SEA-BCMA|Given into the vein (IV; intravenously)
41348631|NCT03582033|DRUG|dexamethasone|Given by mouth (orally) or by IV
41348632|NCT03582033|DRUG|pomalidomide|Given orally
41019558|NCT02506998|OTHER|Second generation anti histamines + Nasal corticosteroids|Standard treatment
41019559|NCT03865121|DRUG|Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
41019560|NCT05577897|OTHER|Education|"A separate room in Chest Diseases Clinic was used for the education of the patients in this group for a quiet environment and for the education not to be interrupted. The education of a patient lasted approximately 45 minutes. The education booklet COPD Guide on COPD management prepared in line with the literature was given to the patients by the researcher. After the content of the education was explained to the patients, 45-minute of education was given through face-to-face verbal presentation and demonstration method."
41019561|NCT05898087|DRUG|Marcaine 0.25 % Injectable Solution|Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia
41348633|NCT02255955|DRUG|550 mg naproxen sodium and 30mg codeine|Postoperative contramal consumption, pain intensity, side effects
41348634|NCT02255955|DRUG|300 mg paracetamol and 30 mg codeine|Postoperative contramal consumption, pain intensity, side effects
41348635|NCT02255955|DRUG|placebo tablet|Postoperative contramal consumption, pain intensity, side effects
41348636|NCT00537810|DRUG|Sibutramine|15 mg daily
41348637|NCT00537810|DRUG|Placebo|Daily
41348638|NCT00537810|BEHAVIORAL|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
41348639|NCT00537810|BEHAVIORAL|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
41348640|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
41348641|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + LVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
40829791|NCT03160469|DEVICE|intragastric Elipse Device|"Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) \& class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less."
40829792|NCT02133664|DRUG|lipoic acid and omega-3 fatty acids|alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
40829793|NCT02133664|DRUG|Placebo|placebo lipoic acid and placebo oil
40829794|NCT06375785|OTHER|Otago-based (slow rhythmic) exercise group|"Slow Rhythmic Exercises (Otago based) A.Strength training~1. Knee flexion and extension~2. Ankle dorsiflexion and plantar flexion~3. Toes flexion and extension~4. Hip abduction and adduction B. Balance training~1. Stepping backwards, walking and turning 2.Side walking 3. Octet walking 4.Tandem walking 5. Standing up from a sitting position"
40829795|NCT06375785|OTHER|LSVT BIG-based (large amplitude) exercise group|"Large Amplitude Exercises (based on LSVT-BIG)~1. Bending towards the floor and rising towards the ceiling (opening) while sitting~2. While sitting, turn to the right and left with the body and reach out~3. Sit down~4. Step forward~5. Sidestepping~6. Stepping back~7. Step forward and extend arm towards the ceiling~8. Step sideways and extend arm towards the ceiling~9. Walking with big steps~10. Turning from right to left and left to right while walking"
41019562|NCT05898087|DRUG|Saline|Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
41019563|NCT04614259|DRUG|Bupivacain|"The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). \[104\] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis"
41157680|NCT06434571|BEHAVIORAL|Treatment as usual (TAU)|They will be encouraged to avoid starting any new treatment for their sleep unless recommended by their physician. They will be offered access to the web-based CBT-I program following the 6-month reassessment to complete if they wish.
41348642|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + BiVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
41348643|NCT04959786|DRUG|Ivermectin,ribavirin ,nitazoxanide and zinc|oral intake of the 3 drugs ivermectin ,ribavirin and nitazoxanide plus zinc
41348644|NCT00355615|DRUG|Rosuvastatin|oral
41348645|NCT00355615|DRUG|Placebo|oral
41348646|NCT02213081|DRUG|Ulipristal|Patient will take 15mg every other day, or every 4 days per week.
41348647|NCT03462030|DRUG|Baked non-fat cow's milk powder|Oral immunotherapy with increasing quantities of baked milk.
41348648|NCT03462030|DRUG|Placebo: Tapioca Powder|Placebo control.
41348649|NCT02866773|BEHAVIORAL|PA1: Education sessions, Reminders, Whataps group|"The intervention includes three components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
41348650|NCT02866773|BEHAVIORAL|PA2: Education sessions, Reminders|"The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise"
41491585|NCT06236243|DIETARY_SUPPLEMENT|Korean Red Ginseng Extract Powder 500 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
41491586|NCT06236243|DIETARY_SUPPLEMENT|Placebo|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
41348651|NCT02866773|BEHAVIORAL|PA3: Education sessions, Whataps group|"The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
41348652|NCT02866773|BEHAVIORAL|PA4: Education sessions|"The intervention includes one component only:~- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior"
40829796|NCT01361074|BEHAVIORAL|In Vivo Exposure for Animal Phobia following Öst´s guidelines|"In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way."
40829797|NCT01361074|BEHAVIORAL|Augmented Reality Exposure for Animal Phobia following Öst´s guidelines|"Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli."
40829798|NCT00205842|DRUG|alvimopan|
40829799|NCT00202813|DEVICE|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
40829800|NCT00938977|DEVICE|CPAP|Before and after effect of treatment with CPAP
40829801|NCT00938977|DEVICE|Bilevel Support Ventilation (Non-Invasive Ventilation)|before/after effect of Bilevel support ventilation
40829802|NCT01172730|DEVICE|Ultrasound scanning|Ultrasound scanning is used to define needle insertion point and depth of epidural space.
40829803|NCT02830607|DEVICE|Xiaomi Mi Band|participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
40829804|NCT00996801|DRUG|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
41019564|NCT04614259|COMBINATION_PRODUCT|i.v. analgesia|"Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes"
41348653|NCT02866773|BEHAVIORAL|HD1: Education sessions, Reminders, Whataps group|"The intervention includes two components:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.~- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
41491587|NCT05367479|DRUG|Antibiotic|Peri-operative, intravenous antibiotic for surgical site infection
41491588|NCT00671138|BIOLOGICAL|Necator americanus|10 necator americanus larvae will be inoculated at week 0 with a further 5 larvae inoculated at week 12
40829805|NCT00996801|DRUG|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
40829806|NCT00996801|DRUG|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
40829807|NCT00996801|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
41157681|NCT06370143|BEHAVIORAL|Questionnaire|The questionnaire on clinical, environmental, lifestyle, and dietary risk factors will be administered
41348654|NCT02866773|BEHAVIORAL|HD2: Education sessions, Reminders|"The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake."
41348655|NCT02866773|BEHAVIORAL|HD3:Education sessions, Whataps group|"The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
41348656|NCT02866773|BEHAVIORAL|HD4: Education sessions|"The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake."
41348657|NCT01449344|DRUG|Rituximab|Rituximab 375mg/m² IV , day 1
41348658|NCT01449344|DRUG|High dose Ara-C|Ara-C 2000 mg/m² (patients \>65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
41348659|NCT01449344|DRUG|Dexamethasone|Dexamethasone 40 mg PO, day 1-4
41348660|NCT01449344|DRUG|Bortezomib|Bortezomib 1.5 mg/m² IV, day 1 and 4
41348661|NCT04453891|DEVICE|Monitoring physiological data with the Hexoskin smart shirt|Participants will be monitored using a validated biometric garment (Hexoskin smart shirt). Cardiorespiratory and activity data will be collected over a 28-day monitoring period. Participants will be invited to wear the shirt during the day and at night.
41348662|NCT00886587|DEVICE|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
41348663|NCT00886587|DEVICE|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
41348664|NCT02249260|BEHAVIORAL|High intensity interval training|Group-based high-intensity aerobic interval training and lifestyle counseling
41348665|NCT03537001|OTHER|Penthrox|Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
41348666|NCT03381352|RADIATION|Chemo-radiotherapy with IMRT technique|IMRT radiation technique; 50.4-54Gy/25F
41348667|NCT03381352|DRUG|Capecitabine|Capecitabine 825mg/m2 PO BID
41348668|NCT03381352|DRUG|Mitomycin C|Mitomycin C 10mg/m2 D1,29 iv
41348669|NCT02440828|DRUG|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
41348670|NCT02440828|DRUG|placebo|NaCl 0.9% inhalation 4 ml twice daily
41348671|NCT00279266|DRUG|Thiamine|
41348672|NCT03675594|DEVICE|CAD/CAM titanium denture base|metallic denture base made of titanium
41348673|NCT03675594|DEVICE|CAD/CAM cobalt/chromium denture bases|metallic denture bases made of cobalt/chromium
41348674|NCT02038790|DRUG|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
41348675|NCT02038790|DRUG|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
41348676|NCT00218452|BEHAVIORAL|Lifestyle counseling|assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
41348677|NCT02407665|BEHAVIORAL|Tai Chi|Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM
41348678|NCT06011785|DRUG|Silica 12CH|Participants will freely elect to be in either the intervention group. Individuals in the experimental group will receive the intervention while also following the standard-care protocol. All individuals will be encouraged to continue with any concurrent conventional medical treatment for their Silicosis-related symptoms. Individuals in either group may freely leave the study at any time with no consequence. Additionally, participants may freely elect to decide opt out at any time.
41348679|NCT06188728|DIETARY_SUPPLEMENT|effect of 10 gm psyllium husk fiber twice a day, 30 minutes before breakfast and dinner|comparing the effect of psyllium husk fiber and lifestyle modification alone with the combined effect of psyllium husk fiber on metabolic health of centrally obese school teachers
41348680|NCT06188728|BEHAVIORAL|Effect of life style modification (Diet, Behavior and physical activity)|To assess the effect of life style modification (Diet, Behavior and physical activity) on centrally obese school teachers
41348681|NCT06188728|COMBINATION_PRODUCT|Combined effect of 10 gm Psyllium husk fiber and lifestyle modification|To evaluate the combined effect of 10 gm psyllium husk fiber in gel form, 30 minutes before breakfast and dinner along with dietary, behavioral and physical activity modification on centrally obese school teachers
40829808|NCT00996801|DRUG|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
41348682|NCT06188728|OTHER|Control|No intervention
41348683|NCT05044351|DEVICE|Fluobeam LX|See arm description
41348684|NCT05044351|OTHER|Conventional surgery without NIRAF assistance|Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
41348685|NCT05225792|BEHAVIORAL|Promis Physical Function Questionnaire|Patient reported physical function outcomes
41348686|NCT05225792|BEHAVIORAL|L Test|Performance based measure assessing general physical function and balance ability.
41348687|NCT05225792|BEHAVIORAL|Narrowing Beam Walking Test|Subjects attempt to walk along 4 progressively narrower beam segments with their arms crossed over their chest.
41348688|NCT05225792|BEHAVIORAL|PEQ-A|Survey on confidence, stumbles and falls.
41348689|NCT02921906|OTHER|High protein meal|Breakfast with high protein / low carbohydrate content
41348690|NCT02921906|OTHER|High carbohydrate meal|Breakfast with high carbohydrate / low protein content
41348691|NCT02921906|DRUG|Paracetamol|Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
41348692|NCT02921906|OTHER|Fasting state - sulphonylurea only|People with diabetes take sulphonylurea medication in the absence of any food stimulus
41348693|NCT02092506|DRUG|10 day triple therapy|10 day triple therapy
40829809|NCT00996801|DRUG|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
41348694|NCT02092506|DRUG|10 day sequential therapy|10 day sequential therapy
41348695|NCT02092506|DRUG|10 day concomitant therapy|10 day concomitant therapy
41348696|NCT02473016|DRUG|Carbon Dioxide Drug Delivery System (CDDS)|Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\].
41348697|NCT01748006|OTHER|Standard of care therapy for severe decompensated heart failure|
41348698|NCT05387135|DEVICE|Transcutaneous Vagus Nerve Stimulation|Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).
41348699|NCT01653756|DRUG|IPI-145, a PI3K Inhibitor|Active drug
40829810|NCT00493428|DRUG|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
40829811|NCT02648022|BEHAVIORAL|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
40829812|NCT00188851|DRUG|therapeutic management strategy|
40829813|NCT04909892|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
41348700|NCT01653756|DRUG|Placebo to match IPI-145|Comparator
41348701|NCT04744766|PROCEDURE|major duct excision|2 methods of major/central mammary duct excision are compared as regard the outcome
41491589|NCT00671138|OTHER|Sham inoculation|A diluted amount of McIlhenny \& Co Tabasco Pepper Sauce will be applied via a gauze dressing at weeks 0 and 12.
40829814|NCT05133869|DEVICE|Metacognitive training + direct training|"The intervention will consist of a combination of direct training of the impaired cognitive function(s) and metacognitive strategy training for 42 days (6 weeks). Direct training will be done with the computer program Rehacom for 20 minutes, 5 times a week. Metacognitive strategy training will be given on a weekly or biweekly basis (6-10 sessions) by a trained therapist at Adelante.~Rehacom is a brain training program developed to improve a variety of cognitive functions with the use of game-like cognitive training modules. During the intervention the participant should train with Rehacom for approximately 600 minutes in total.~In addition to the direct training, the participant receives six to ten sessions of metacognitive strategy training. During this training they are taught strategies by a therapist to improve their performance on the Rehacom modules and on daily life functioning. Each metacognitive strategy is linked to one of the Rehacom modules."
41348702|NCT02783651|OTHER|Other|No intervention other than routine medical care
41348703|NCT01004874|DRUG|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
41348704|NCT01004874|DRUG|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
41348705|NCT01004874|RADIATION|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
41348706|NCT01004874|DRUG|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
41348707|NCT05661838|PROCEDURE|transfusion|transfusion
41491590|NCT00442039|DRUG|Lithium Carbonate|The starting dose of lithium was 300 mg for patients weighing \< 20 kg
41491591|NCT00442039|DRUG|Lithium Carbonate|"The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability"
41019565|NCT01933334|DRUG|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
41019566|NCT05226078|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral treatment of insomnia
40829815|NCT00644618|DRUG|gemcitabine|a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
40829816|NCT00644618|OTHER|125I brachytherapy PLUS gemcitabine|125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
41491592|NCT00442039|DRUG|Lithium Carbonate|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
40829817|NCT01817101|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
40829818|NCT04982497|BEHAVIORAL|Video game based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker \& Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).
40829819|NCT04982497|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
40829820|NCT01522144|BEHAVIORAL|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
40829821|NCT05472545|BEHAVIORAL|Neurofeedback|Real-time functional magnetic resonance imaging dyadic neurofeedback
40829822|NCT05845047|BEHAVIORAL|PICTURE-IT|"The speech-language pathologist (SLP) will provide one of the following stimuli hierarchically:~1. Single words depicted in the picture, then with written and spoken labels~2. 2-word phrases depicted in the picture and then with written and spoken word~3. Subject-Verb-Object sentence depicted in the picture and then with written and spoken sentences~4. Two-sentence event, depicted with photos and subsequently with two written and spoken sentences~5. Short story depicted with a video clip and subsequently with printed and spoken narrative.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
40829823|NCT05845047|BEHAVIORAL|CoDeLT|"The speech-language pathologist (SLP) will facilitate the computer-delivered naming treatment, consisting of a picture/seen and heard spoken word verification task.~A picture will be presented for two seconds on a laptop computer screen and will be immediately followed by an audio-visual display of a speaker's mouth saying a noun. The spoken word either will or will not match the preceding picture, and the participant must indicate whether the picture and video match or do not match. The computer will provide immediate visual feedback following a response.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
40829824|NCT00137696|BIOLOGICAL|Vaccination with inactivated polio vaccine|
40829825|NCT00137696|PROCEDURE|Collection of serum|
40829826|NCT06489704|OTHER|Echocardiography|Echocardiography will be performed according to clinical standards
40829827|NCT03467984|BIOLOGICAL|LBVE|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
40829828|NCT03467984|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
41019567|NCT01364064|DRUG|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
41019568|NCT02683759|DIETARY_SUPPLEMENT|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
41491593|NCT00442039|DRUG|Placebo|During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
41019569|NCT02683759|DRUG|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
41019570|NCT02348489|DRUG|SGI-110 (guadecitabine)|Investigational medicinal product
41019571|NCT02348489|DRUG|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
41019572|NCT02786615|BEHAVIORAL|Peer Unity|A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
41019573|NCT06457152|OTHER|EHR-Emedded Alert|For patients randomized to the intervention group, an automated, EHR-embedded alert will be visible in the patient's chart that promotes appropriate medical therapy for patients with HFrEF.
41019574|NCT04250324|BIOLOGICAL|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
41348708|NCT05983679|DIAGNOSTIC_TEST|Blood sample|Blood sample
41019575|NCT04574622|DEVICE|radial Extracorporeal Shockwave Therapy|rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
41348709|NCT01212120|BIOLOGICAL|Genetic profiling of bacterial cultures|Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients
41348710|NCT01263470|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
41348711|NCT01263470|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
41491594|NCT03544710|OTHER|preoperative bathing with antiseptic|"Preoperative bathing with antiseptic was done as follows; Given warm water and a tablet soap containing chloroxylenol antiseptic.~Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
41019576|NCT06567327|DRUG|Danuglipron|Danuglipron oral tablets
41019577|NCT06567327|DRUG|Atorvastatin|Atorvastatin oral tablets
41019578|NCT06567327|DRUG|Rosuvastatin|Rosuvastatin oral tablets
41019579|NCT04418206|OTHER|patients COVID 19|Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
41019580|NCT05748639|OTHER|Mobile health application|Participants randomized to receive the QG-A (Experimental) intervention will receive monthly appointments with a medical provider, access to naltrexone, and weekly and bi-weekly appointments with a licensed clinical counselor through an integrated digital health application.
41019581|NCT05748639|OTHER|Medical Management|Participants randomized to receive the MM (Control) intervention will receive monthly appointments with a medical provider and access to naltrexone.
41348712|NCT01263470|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
41348713|NCT01263470|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
41348714|NCT01263470|DRUG|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
41348715|NCT01263470|DRUG|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
41348716|NCT05631730|DRUG|Flecainide|Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.
41348717|NCT05631730|DRUG|Metoprolol|Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
41348718|NCT02444806|OTHER|Full polysomnography|Full sleep and respiratory monitoring with EEG
41348719|NCT02444806|OTHER|Oximetry-capnography|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
41348720|NCT00885729|PROCEDURE|stem cells|Stem cells or chondrocytes under a commercial available membrane
41348721|NCT00885729|PROCEDURE|Chondrocytes|Implantation of chondrocytes
41348722|NCT00885729|OTHER|Rehabilitation program|Strength exercises, neuromuscular exercises
41348723|NCT05489718|BIOLOGICAL|IBI324|Dose 2 IBI324 of multiple IVT injection
41348724|NCT05489718|BIOLOGICAL|IBI324|Dose 2 IBI324 of single IVT injection
41348725|NCT05489718|BIOLOGICAL|IBI324|Dose 1 IBI324 of single IVT injection
41348726|NCT05489718|BIOLOGICAL|IBI324|Dose 3 IBI324 of single IVT injection
41348727|NCT05489718|BIOLOGICAL|IBI324|Dose 3 IBI324 of multiple IVT injection
41348728|NCT01942395|BEHAVIORAL|DASH/sodium-restricted diet (DASH/SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
40829829|NCT04902521|DEVICE|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (TMS) is a safe non-invasive technique that stimulates the brain using repetitive magnetic pulses to enhance neuroplasticity. TMS has been shown to produce lasting modulation of cortical activity and improve clinical symptoms of children with neurodevelopmental disorders including CP
40829830|NCT04902521|DEVICE|Sham Transcranial Magnetic stimulation|Sham Transcranial Magnetic stimulation will be given to the control group. During the Sham procedure patients will sit near the TMS but will not receive any magnetic pulses.
40829831|NCT06446908|BEHAVIORAL|Telehealth coaching for liver disease|"This study is an open-label, mono-centred, single-case experimental design with multiple base levels. The study will comprise 3 phases, alternating periods of observation (A) and 1 period of counselling (B) with an A1-B-A2 design.~PA will be assessed continuously using an accelerometer for 7 to 14 days per (A) phase. During phase (B), participants will receive the intervention, i.e. 6 x 45-minute, real-time, face-to-face, virtual sessions with a PA counsellor."
40829832|NCT00159575|DRUG|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
40829833|NCT05290272|DEVICE|ViFIVE Digital Care Progrma|ViFive DCP (Digital Care Program) is a highly structured, protocolized, and individually tailored intervention consisting of personalized exercise therapy modules. ViFive DCP is delivered by a physical therapy team consisting of DPTs and a personal coach. The DCP consists of ten modules and its advancement will be determined by each patient's progress after the treatment team's review every week.
40829834|NCT00758121|DEVICE|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
40829835|NCT01329614|BEHAVIORAL|Cue Extinction Training|Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
41019582|NCT06572202|BEHAVIORAL|Positive Psychology Intervention|The 14-session intervention program is designed to enhance various internal resiliency factors. It begins with an orientation to positive psychology and setting group guidelines. Cognitive resilience is developed through identifying personal and signature strengths, reappraising memories, and learning savoring techniques. Emotional resilience is strengthened by focusing on forgiveness, managing decision fatigue, and fostering positive communication. Spiritual resilience is cultivated through gratitude practices and exploring hope and optimism. Behavioral resilience is addressed by recognizing strengths in others and engaging in altruism. The final session integrates all these elements to promote lasting positive changes in engagement, relationships, meaning, and accomplishments. Mid-session feedback ensures the program's effectiveness and responsiveness to participants' needs.
41019583|NCT01299233|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
41019584|NCT05807841|PROCEDURE|percutaneous coronary intervention|IVUS-guided stent implantation
41019585|NCT04413318|DEVICE|Electronic device (VBM©)|Continuous control of tracheal cuff pressure using an electronic device (VBM©) for 6-hours followed by continuous control using a pneumatic device (Nosten©) for 6-hours.
41019586|NCT04413318|DEVICE|Pneumatic device (Nosten©)|Continuous control using a pneumatic device (Nosten©) for 6-hours followed by 6-hours of continuous control using an electronic device (VBM©).
41157682|NCT04708041|BIOLOGICAL|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
41157683|NCT03603223|BIOLOGICAL|Pembrolizumab|Given IV
41157684|NCT00902226|DRUG|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
41157685|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 10 mg
41157686|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 5 mg
41157687|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 2.5 mg
41157688|NCT06004063|DIETARY_SUPPLEMENT|Enteral nutrition (EN)|Given by Nasogastric Tube
41157689|NCT06004063|OTHER|Standard care parenteral nutrition (PN)|Given by PO or Given by IV (vein)
40829836|NCT01329614|DRUG|Nicotine Replacement Therapy|Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
40829837|NCT01329614|BEHAVIORAL|Cue Extinction Therapy|Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
41157690|NCT05102656|OTHER|Best Practice|Physician conversations occur in-person
41157691|NCT05102656|PROCEDURE|Discussion|Physician conversations occur via video call
41157692|NCT05102656|OTHER|Questionnaire Administration|Ancillary studies
41157693|NCT05418335|OTHER|Clinical examination, functional status evaluation|Barthel Index, Oral Health Impact Profile 14, Beck Depression Inventory, Stroke Impact Scale 3, Plaque Index, Calculus Index, Periodontal Disease Index, Simplified Oral Hygiene Index assesment, DMFT Index
41157694|NCT02324309|DRUG|BIOD-531|
41157695|NCT02324309|DRUG|Humalog Mix 75/25|
41157696|NCT02324309|DRUG|Humulin R U-500|
41157697|NCT02324309|DRUG|BIOD-531|
41157698|NCT01797705|DEVICE|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
41157699|NCT03152500|DEVICE|FEMTIS 313G IOL|Haptic design that enclaves the capsulorrhexis
41157700|NCT03152500|DEVICE|Acrysof SN60WF IOL|IOL in the bag
41157701|NCT04260256|DRUG|[18F]F-AraG|\[18F\]F AraG injection and PET Scan Two tumor biopsies of single lesion
41157702|NCT06646601|OTHER|Intervention of prevention|A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops.
41348729|NCT01942395|BEHAVIORAL|Control Diet|The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
41348730|NCT00536640|DRUG|Erlotinib|150 mg per os, given daily until tumor progression
40829838|NCT01329614|BEHAVIORAL|Progressive Muscle Relaxation|Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
41157703|NCT06551116|DIAGNOSTIC_TEST|CE-10-IVD|Leftover tumor tissue from a routine biopsy will be sent for analysis.
41157704|NCT06016764|DEVICE|Continuous Theta Burst in Transcranial Magnetic Stimulation|This application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial magnetic stimulation; to determine if hyper-excitability of the brain directly correlates with symptoms of catatonia and social-emotional impairment in autism
41157705|NCT01529541|DRUG|Anagliptin|Anagliptin 100mg, tablet, twice a day (BID)
41157706|NCT01529541|DRUG|Sitagliptin|Sitagliptin 100mg, tablet, once a day (QD)
41157707|NCT05230095|BEHAVIORAL|social cognition tests|"The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene.~Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery.~Healthy volunteers will be evaluated only one time."
41157708|NCT05230095|BEHAVIORAL|Quality of life self-questionnaire|Quality of life will be assessed using a self-administered questionnaire in the patients group only.
41348731|NCT00536640|DRUG|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
41348732|NCT00536640|DRUG|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
41348733|NCT00536640|DRUG|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
41348734|NCT01266070|DRUG|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
41348735|NCT06010992|DRUG|Nitazoxanide|Nitazoxanide oral capsules 500 mg twice daily
41491595|NCT02330315|DEVICE|transcranial direct current stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
41491596|NCT02330315|DEVICE|transcranial ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
41509074|NCT03331835|BIOLOGICAL|Brodalumab|"Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).~Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis."
40829839|NCT00303446|DRUG|Dutasteride|Dutasteride 0.5 mg/day
40829840|NCT00303446|DRUG|Placebo|Matched placebo
40829841|NCT02262078|DRUG|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
40829842|NCT02262078|OTHER|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
40829843|NCT06507501|OTHER|Low Load Blood Flow Restriction Exercise Training (LL-BFRE)|Blood Flow Restriction exercise training, also known as occlusion training or KAATSU training, is a contemporary exercise training method based on partially restricting arterial and venous blood flow for short periods.
41157709|NCT04355052|DRUG|hydroxychloroquine in combination with camostat mesylate|Two drugs which may act as antivirals against SARS CoVid 2 (Hydroxychloroquine may also act as an immunomodulator, Camostat mesylate is a protease inhibitor)
41157710|NCT04355052|DRUG|Hydroxychloroquine in combination of Azithromycin|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
41157711|NCT02025985|DRUG|Selinexor|"Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles."
41157712|NCT00206609|PROCEDURE|Oxygen and air administration|
41157713|NCT00598858|DRUG|Docetaxel|Given IV
41157714|NCT00598858|DRUG|Prednisone|Given PO
41348736|NCT00821054|DRUG|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
41348737|NCT06014476|OTHER|questionnaires|Sent questionnaires to caregivers and used CRS-R to assess patients with DoC
41348738|NCT00590941|PROCEDURE|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
41348739|NCT06259591|BEHAVIORAL|Pedometer follow-up|The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.
41348740|NCT06259591|BEHAVIORAL|Ambulation coaching|Patients will receive coaching text messages every Monday, Wednesday and Friday between day 8 and day 30 after surgery, based on a pre-fixed template.
40829844|NCT06507501|OTHER|High Load Resistive Exercise Training (HL-RE)|HL-RE is a conventional, well known exercise method to enhance muscle strength and improve physical performance. It's performed by using resistance bands or weights applying on the extremity.
41157715|NCT05990283|PROCEDURE|Socket shield technique|For the patients in the shield group, shields were prepared with the Root Membrane Kit. After the palatal part was removed, the buccal fragment was prepared at the crest level, and an internal bevel chamfer was formed on the fragment. Implants were placed 3-4 mm apical to the gingival margin of the adjacent teeth. Healing caps were placed, and the periphery of the caps was covered with an absorbable gelatin sponge.
41157716|NCT05990283|PROCEDURE|Guided bone regeneration|For the patients in the regeneration group, teeth were extracted atraumatically, implants were placed 3-4 mm to the gingival margin, and the space between the implant and buccal bone was filled with anorganic bovine bone graft at the time of implant placement. The graft particles were covered by a pericardium membrane. The membrane was fixed to the bone with titanium pins.
40829845|NCT01219036|DRUG|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
41157717|NCT05737940|DRUG|AZD3427|The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
41157718|NCT05737940|DRUG|Placebo|The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
40829846|NCT02696499|DRUG|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
41157719|NCT04177732|DIAGNOSTIC_TEST|Collection of sulcular (crevicular) fluid|Sterile paper strips will be used for collecting crevicular fluid
40829847|NCT02696499|DRUG|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
40829848|NCT05093543|BEHAVIORAL|physical rehabilitation/physiotherapy and psychosocial group sessions|physical rehabilitation/physiotherapy and psychosocial group sessions
40829849|NCT03597178|DEVICE|senofilcon A|ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
40829850|NCT03481920|DRUG|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.
41157720|NCT04177732|DIAGNOSTIC_TEST|Probing depth|Williams SE manual probe will be used to measure the probing depth
40829851|NCT03481920|DRUG|Avelumab|Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.
40829852|NCT04612660|BEHAVIORAL|Education on cervical cancer prevetnion|Motivational group education by trained bilingual community health educators (CHEs) on cervical cancer prevention
40829853|NCT04612660|BEHAVIORAL|Dynamic group interaction|Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;
41019587|NCT02137200|PROCEDURE|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
41019588|NCT02137200|PROCEDURE|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
41157721|NCT04177732|DIAGNOSTIC_TEST|Bleeding on probing|Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction
41157722|NCT04177732|DIAGNOSTIC_TEST|Gingival index|Modified Löe and Silness criteria will be used for evaluating the gingival index score
41157723|NCT04177732|DIAGNOSTIC_TEST|Bone loss rate of alveolar bone|Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment
40829854|NCT04612660|BEHAVIORAL|Physician engagement|Engaging community bilingual physicians in cervical cancer screening and referral;
40829855|NCT04612660|BEHAVIORAL|Patient Navigation|Patient navigation assistance will be provided to participants who tested HPV positive for further diagnostic testing and treatment.
40829856|NCT04612660|BEHAVIORAL|General Health Education|general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
40829857|NCT01448824|DRUG|LY2484595|Administered orally
40829858|NCT01448824|DRUG|Placebo|Administered orally
40829859|NCT01448824|DRUG|Ketoconazole|Administered orally
40829860|NCT03417362|OTHER|Animation|3 minute video describing and explaining early medical abortion, followed by questionnaire
41019589|NCT00875394|DRUG|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
41157724|NCT05540262|DRUG|Edaravone|Edaravone injection 30mg three times a day
41157725|NCT04836338|DEVICE|orotracheal intubation|orotracheal intubation
41157726|NCT06415747|OTHER|Observational pain and motor function assessments, and also comorbidities assessments with x-ray.|There was no intervention in our study, only observational and quantitative clinical evaluations.
41348741|NCT02237144|OTHER|Cash transfer|1500 taka ($18.75) per household distributed monthly
41348742|NCT02237144|OTHER|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
40829861|NCT02261129|DRUG|Telmisartan film-coated tablet|
40829862|NCT02261129|DRUG|Telmisartan uncoated tablet|
41019590|NCT00875394|DRUG|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
41019591|NCT00875394|DRUG|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
41019592|NCT00875394|DRUG|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
41157727|NCT01653171|DRUG|Water (Placebo)|Water 100 mL
41157728|NCT01653171|DRUG|Simethicone|200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
41348743|NCT02237144|OTHER|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
40829863|NCT04373499|BEHAVIORAL|Virtual Teach to Goal|Virtual Teach-to-Goal is an educational module that teaches children how to use their inhaler properly; this is done with an IPAD. In the module, the child will complete a series of questions as a pre-assessment, watch a video about how to use the inhaler properly, and then answer a series of questions as a post-assessment. If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions.
40829864|NCT04373499|BEHAVIORAL|Brief Intervention|There is a handout that describes proper inhaler technique. The RA reads the handout to the child.
41348744|NCT02237144|BEHAVIORAL|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
41348745|NCT01446991|DRUG|Degarelix|240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
41348746|NCT01446991|DRUG|Degarelix|240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
40829865|NCT04674306|BIOLOGICAL|α-lactalbumin vaccine|"α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1e: 10 mcg~D1f: 20 mcg~D1g: 20 mcg (D1g will only be utilized if D1c is deemed too toxic)"
40829866|NCT04674306|BIOLOGICAL|Zymosan|"Adjuvant used in vaccine preparation~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 10 mcg~DL3: 10 mcg~D1b: 10 mcg~D1e: 20 mcg~D1f: 20 mcg~D1g: 1o mcg (D1g will only be utilized if D1c is deemed too toxic)"
40829867|NCT03208530|BEHAVIORAL|Brief motivational interview intervention|A brief (\<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
40829868|NCT01421316|RADIATION|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
40829869|NCT02634606|DRUG|Gamma Delta Tocotrienols - Low Dose|250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
40829870|NCT02634606|DRUG|Gamma Delta Tocotrienols - High Dose|250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
40829871|NCT02634606|DRUG|Sugar Pill|250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
40829872|NCT06087263|DRUG|Regorafenib|Given by PO
40829873|NCT02182609|DRUG|Kit for the Preparation of 99mTc-rhAnnexin V-128|Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
41019593|NCT02360540|OTHER|Gestalt estimation|
41348747|NCT05379764|OTHER|Embodiment|Embodiment of a real human in a virtual human (avatar) means that the real human feels incarnated in the avatar. This happens when the real human sees the VRscenario from first person perspective, that the real human can make the avatar move (=agency over the avatar), multi-sensorial integration (=there is a link between the brain of the real human and the avatar. Example, when the avatar sits on a chair, the real human will too and he feels that he is sitting on a chair. Or when the avatar is moving the real human is doing the same movement (and of course the brain of the real human is aware of this movement)) and co-location (= avatar and real human have the sane posture).
40829874|NCT04947878|OTHER|Prompt list|The patients in the intervention group will review a prompt list before their visit.
40829875|NCT03084042|DEVICE|fMRI|
41019594|NCT04955808|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
41019595|NCT04955808|OTHER|Laboratory Biomarker Analysis|Correlative studies
41019596|NCT03083288|DRUG|[18F]FluorThanatrace|\[18F\]FluorThanatrace is a radiotracer for PET/CT
41157729|NCT01653171|DRUG|N-acetylcysteine 500 mg|500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
41348748|NCT05379764|OTHER|Observation|The person is looking at the VR scenario as if s/he was looking at a TV
41509075|NCT03331835|DRUG|Fumaric acid esters|Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
40829876|NCT02579694|DEVICE|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
40829877|NCT00266929|PROCEDURE|surgical|surgical treatment of odontoid fractures
40829878|NCT00266929|PROCEDURE|conservative treatment|conservative stabilization of fractures
40829879|NCT05810714|OTHER|Best Practice|Receive usual care
40829880|NCT05810714|OTHER|Fecal Immunochemical Test|Receive FIT kit
40829881|NCT05810714|BEHAVIORAL|Health Education|Receive audio brochure
40829882|NCT05810714|BEHAVIORAL|Health Education|Receive video brochure
40829883|NCT05810714|OTHER|Scheduled Notification|Receive scheduled reminder
40829884|NCT05810714|OTHER|Survey Administration|Ancillary studies
40829885|NCT03257163|DRUG|Capecitabine|Given PO
40829886|NCT03257163|OTHER|Laboratory Biomarker Analysis|Correlative studies
40829887|NCT03257163|BIOLOGICAL|Pembrolizumab|Given IV
41019597|NCT00335244|DRUG|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
41019598|NCT00335244|DRUG|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
41157730|NCT01653171|DRUG|N-acetylcysteine 1000 mg|1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
41348749|NCT03935594|BIOLOGICAL|PRP Injection|1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.
41509076|NCT01696760|DRUG|acetylsalicylic acid|325 mg twice a day
40829888|NCT03257163|RADIATION|Radiation Therapy|Undergo radiation therapy
40829889|NCT03000491|OTHER|No intervention|Variations in clinical practice as assessed by data relating to asthma extracted from patient electronic health records.
40829890|NCT00376805|DRUG|Fludarabine|administered intravenously 25 mg/m\^2 times 5 doses
40829891|NCT00376805|DRUG|Cyclophosphamide|administered intravenously 60 mg/kg days times 2 doses.
40829892|NCT00376805|RADIATION|Total body irradiation|200 cGy (gray) on day -1
40829893|NCT00376805|OTHER|Natural killer cell infusion|Infused cell dose is within the range of 1.5-8.0 x 10\^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
41157731|NCT06176378|OTHER|traditional pulpotomy|After complete deroofing, the coronal pulp was amputated to the level of the orifice using a high-speed size #2 round bur followed by rinsing the pulp chamber thoroughly with 5ml 0.9% saline solution.Hemostasis was then achieved by placing a sterile cotton pellet moistened with saline in the access cavity for 6 min.Retro MTA capping material was then applied,
41157732|NCT06176378|DEVICE|diode laser pulpotomy|after establishing hemostasis, low-level laser energy at (970nm, power .5W, duty cycle 50%, and frequency 5H) was applied to each pulp stump for 10 sec. through 320 microns optical fiber tip . The laser was used in pulsed non-contact mode at the level of the occlusal surface of the tooth.Retro MTA capping material was then applied,
41157733|NCT00676429|DRUG|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
41157734|NCT00676429|DRUG|Placebo|Placebo as oral solution, individually titrated
40829894|NCT00376805|BIOLOGICAL|Interleukin-2|administered subcutaneously (10 MU) 3 times per week for 6 doses
41019599|NCT06256497|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Revita System is a hydrothermal ablation system, (CE) certified, intended to impart insulin-sensitizing properties to the body via ablation \& rejuvenation of the duodenal mucosa. As an adjunct to diet and exercise, Revita is intended to 1. improve glycemic control in patients with T2D who have preserved pancreatic beta cell function and whose diabetes is inadequately controlled despite oral and/or injectable glucose lowering medications and/or long-acting insulin therapy, 2. Reduce liver fat in patients with T2D and Non-Alcoholic Fatty Liver Disease (NAFLD). The single use Revita Catheter and Line Set are provided sterile and are not implantable or reusable. These disposables are used with the Revita Console an electromechanical device that controls the ablation cycle and submucosal expansion. The Revita System is used in a suitably equipped endoscopy suite. The Catheter contacts the patient's digestive tract for approximately 45-60 minutes.
41157735|NCT04390893|DEVICE|ultrasound|Anesthesiologist would scan three planes of the neck to position the LMA
41157736|NCT04390893|DIAGNOSTIC_TEST|air leakage test|Anesthesiologist would use air leakage test to position the LMA
41157737|NCT02998918|DIETARY_SUPPLEMENT|PolyResveratrol Supplementation|Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
41157738|NCT02998918|DIETARY_SUPPLEMENT|Curcumin Supplementation|Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
41157739|NCT02968654|PROCEDURE|Restrictive Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
41157740|NCT02968654|PROCEDURE|Liberal Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
41157741|NCT02542800|BEHAVIORAL|Episodic memory task|
41157742|NCT02542800|DEVICE|fMRI|
41348750|NCT03935594|DRUG|Saline Injection|1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.
41348751|NCT02520102|DRUG|sargramostim GZ402664|"Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous"
41348752|NCT01855139|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg OD or 20 mg OD
41348753|NCT05071391|PROCEDURE|Roux-en-Y gastric bypass|"Gastric bypass, also called Roux-en-Y gastric bypass, is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine. After gastric bypass, swallowed food will go into this small pouch of stomach and then directly into the small intestine, thereby bypassing most of your stomach and the first section of your small intestine.~Gastric bypass is one of the most commonly performed types of bariatric surgery. Gastric bypass is done when diet and exercise haven't worked or when you have serious health problems because of your weight."
41348754|NCT03807128|OTHER|No interventional study|No interventional study
41348755|NCT01687049|DRUG|Red yeast rice|
40829895|NCT04220437|OTHER|no interventin|Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
40829896|NCT04412213|OTHER|Stuttering severity instrument for school-age children (SSI-3 Arabic version)|Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
40829897|NCT03150069|OTHER|Interview|In-person or telephone in-depth interview
40829898|NCT05586672|DEVICE|EEG-HR|Passation EEG-HR
40829899|NCT05586672|DIAGNOSTIC_TEST|ADI-R|Passation of ADI-R scale
40829900|NCT05586672|DIAGNOSTIC_TEST|ADOS-2|Passation of ADOS-2 scale
40829901|NCT05586672|DIAGNOSTIC_TEST|IDE|Passation of IDE scale
40829902|NCT05586672|DIAGNOSTIC_TEST|MSEL|Passation of MSEL scale
40829903|NCT05586672|DIAGNOSTIC_TEST|Dunn|Passation of Dunn scale
41157743|NCT04596241|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
41348756|NCT00952588|DRUG|AZD1152|1200 mg, iv, 7 day infusion
41348757|NCT00952588|DRUG|LDAC|20 mg, sc, bd, 10 days
41348758|NCT05704595|OTHER|Initial outpatient management strategy, including outpatient IV diuretics in clinic|Management strategy including IV diuretic in the outpatient clinic
41348759|NCT05704595|OTHER|Initial hospitalization-based management strategy|Direct admission to the hospital
41348760|NCT05581927|DEVICE|modified Whole-Body Hypothermia|patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure
41348761|NCT05581927|DEVICE|standard Whole-Body Hypothermia|patients were allocated to standard Whole-Body Hypothermia
41348762|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use bergamot essential oil
41348763|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use chamomile essential oil
41348764|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use ginger essential oil
41348765|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use almond essential oil
41348766|NCT03858855|OTHER|Subject Diary|Complete journal
41348767|NCT01631006|DEVICE|CPAP|A low or high CPAP pressure is delivered for 20 minutes
41348768|NCT02139280|DRUG|Cyclophosphamide|Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
41348769|NCT02186886|DRUG|Golimumab|Physiological Intermolecular Modification Spectroscopy
41348770|NCT03793270|DIAGNOSTIC_TEST|for patients and healthy donors|"1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry~2. Determine the serum level of IL 10 using ELISA plate"
41348771|NCT00281385|BEHAVIORAL|traditional vs. lifestyle exercise|
41348772|NCT04050891|DEVICE|combined supraclavicular and interscalene block|"Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block."
41348773|NCT04839328|DRUG|60mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
41348774|NCT04839328|DRUG|Placebo|Placebos are the same as drugs, but contain no Hemay005.
41348775|NCT01966406|DEVICE|Nasogastric tube|
40829904|NCT04862897|OTHER|Patient-controlled admissions|Patients are allowed to admit themselves to inpatient care when needed (standard procedure, four days of inpatient care at a time, up to three times a month)
40829905|NCT01920152|BIOLOGICAL|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
40829906|NCT01920152|DEVICE|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
40829907|NCT04859244|DRUG|GS-441524|750 mg administered as a solution
41348776|NCT01966406|OTHER|No nasogastric tube|
41348777|NCT00909883|DRUG|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
41348778|NCT00909883|DRUG|Placebo|Placebo injection
41348779|NCT05707195|OTHER|Questionnaire|"A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection.~This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit"
41348780|NCT03170089|BEHAVIORAL|Oral Health Educational Program|Oral Hygiene methods learned
41348781|NCT02080494|DRUG|Tranexamic Acid|
41348782|NCT02613338|DEVICE|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
41348783|NCT02913885|DRUG|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
41348784|NCT02913885|DRUG|fluoride varnish|fluoride inhibit the progression of white spot lesion
41348785|NCT03309865|DIETARY_SUPPLEMENT|semi-vegetarian diet|semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;
41348786|NCT03309865|DRUG|Vedolizumab Injection|vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks
41348787|NCT01654406|DEVICE|Fractional CO2 laser and pulsed dye laser|Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
41348788|NCT01654406|DEVICE|Pulsed dye laser|Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
41348789|NCT02972294|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
40829908|NCT00168077|DRUG|Prothrombin Complex Concentrate|
40829909|NCT03561701|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
40829910|NCT03561701|DRUG|Placebo|matching placebo capsule
41019600|NCT00900484|OTHER|biologic sample preservation procedure|
41348790|NCT02972294|DRUG|Tranexamic Acid|Tranexamic acid will be use.
41348791|NCT02972294|DRUG|Placebos iron isomaltoside 1000|placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
41348792|NCT02972294|DRUG|Placebos tranexamic acid|placebo of tranexamic acid correspond to a saline solution.
41509077|NCT01696760|DRUG|enoxaparin|40 mg once daily
40829911|NCT00868673|DIETARY_SUPPLEMENT|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
41348793|NCT05624892|DIAGNOSTIC_TEST|Mirror Therapy with Virtual Reality Application|Researchers will apply Mirror Therapy with Virtual Reality Application to increase individuals' quality of life and motor sense gains.
40829912|NCT00868673|DIETARY_SUPPLEMENT|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
40829913|NCT02525939|DRUG|dalcetrapib|Cholesterol Ester Transfer Protein inhibitor
40829914|NCT02525939|DRUG|Placebo|matching placebo tablets
40829915|NCT04965922|BEHAVIORAL|Multimodal intervention|"The intervention consists of identifying the individual needs of each caregiver and patient and identifying sources of improvement in the management of daily life, including the optimization of social support. This optimization requires the involvement of people in the environment (family, friends, neighbours) who can provide help, support of any kind, recurrent or punctual, minimizing negative family interactions and maximizing positive contributions by each in supporting and supporting the individual.~The intervention is personalized in the sense that the content of each session seeks to adapt itself to the specificities of the couple situation and its surroundings.~interviews/meetings involving a psychologist social worker."
40829916|NCT01281098|PROCEDURE|Panretinal Photocoagulation (PRP)|Panretinal Photocoagulation (PRP)
41348794|NCT01937468|OTHER|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
40829917|NCT01281098|DRUG|Intravitreous injection of pegaptanib|Intravitreous injection of pegaptanib
40829918|NCT01767493|DRUG|[18F]Florbetapir PET imaging|\[18F\]Florbetapir and PET imaging
40829919|NCT04118569|BEHAVIORAL|Narrative Intervention|Research staff conducts an open-ended, audio-recorded interview with the patient about their illness and how this illness has affected their psycho-social-spiritual well-being. The investigators will use the interview transcription to create a meta-narrative, which is then uploaded to the electronic medical record and the patient's primary nurse is notified that it is available to read.
40829920|NCT00033709|DRUG|temozolomide|
40829921|NCT00033709|DRUG|thalidomide|
41019601|NCT00900484|OTHER|immunohistochemistry staining method|
41019602|NCT00900484|OTHER|laboratory biomarker analysis|
41019603|NCT02822794|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
41019604|NCT02822794|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
41019605|NCT03645200|DRUG|Fluzoparib combined with Apatinib|"Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle"
41348795|NCT01937468|DRUG|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
41348796|NCT06086886|DRUG|BMS-986454|Specified dose on specified days
40829922|NCT01268917|DRUG|aspirin|aspirin 100mg daily until the surgery day
40829923|NCT01268917|DRUG|aspirin|aspirin is stopped 5-7 days before operation
41019606|NCT01696435|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
41019607|NCT01696435|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
41019608|NCT01696435|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
41019609|NCT01696435|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
41019610|NCT03049163|DRUG|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
41019611|NCT05155735|PROCEDURE|Replantation|Surgical reattachment of a severed body part
41019612|NCT05155735|PROCEDURE|Primary wound closure|Primary wound closure with removal of exposed bone
41019613|NCT04540536|OTHER|Continuous Glucose Monitoring|Participants will be provided with a Dexcom G6 continuous glucose monitor for the duration of the study.
41348797|NCT06086886|OTHER|Placebo|Specified dose on specified days
41348798|NCT05091918|DEVICE|MotionSense|MotionSense Wearable: Remote patient monitoring
41348799|NCT03986476|DIETARY_SUPPLEMENT|Probiotics|5x10\^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
41348800|NCT03986476|OTHER|Placebo|Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
41348801|NCT05830240|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
41348802|NCT00000244|DRUG|Dynorphin 1 - 13|
40829924|NCT02580383|PROCEDURE|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
41157744|NCT01561885|OTHER|Pathway-Based Care|Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
40829925|NCT06073639|PROCEDURE|Autogenous dentin graft|Dentin graft is made from the participant extracted tooth by using Kometa Smart Dentin Grinder
40829926|NCT03094858|DEVICE|Smartphone with prompts|Smartphone will be used to prompt randomly selected participants in intervention group to be active
41157745|NCT04872101|DRUG|Delgocitinib cream|Cream for topical application
41157746|NCT04872101|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
41157747|NCT02328209|DRUG|ranibizumab|0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
40829927|NCT03094858|DEVICE|Wristband|Wristband will monitor activity of all participants
41157748|NCT06103721|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine will be diluted in 20 ml of Normal Saline to produce a concentration of 20 mcg/ml. Then it will be taken from the dilution at a dose of 1.0 mcg/kg and that will be added in 2-3 ml of Normal Saline to make it a final volume of 10ml. The resultant mixture will be used to nebulize the patients for 5 minutes, 15 minutes prior to induction of General Anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
41348803|NCT03731975|PROCEDURE|CTZ Paste|Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).
41348804|NCT03731975|PROCEDURE|GP Paste|Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
41348805|NCT05059184|OTHER|This is an observational cross-sectional study, there is no need for intervention|This is an observational cross-sectional study. There is no need for intervention
41348806|NCT06232187|BEHAVIORAL|Artificial Intelligence feedback for ultrasound EFW standard plane images|AI feedback in two levels, in aid of the participants, to obtain the right standardplane images used in fetal ultrasound EFW calculation.
41348807|NCT00820963|DRUG|temozolomide|Given orally
40829928|NCT03094858|DEVICE|Smartphone|Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
40829929|NCT03071991|PROCEDURE|study group|local anesthetic drug will be used
40829930|NCT03071991|PROCEDURE|control group|no local anesthetic drug will be used
40829931|NCT02196415|DEVICE|Biplanar Radiography|standard biplanar radiography of the foot
40829932|NCT04660721|COMBINATION_PRODUCT|sFilm-FS|sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.
41348808|NCT00820963|RADIATION|hypofractionated radiation therapy|Patients undergo hypofractionated radiotherapy
40829933|NCT04660721|COMBINATION_PRODUCT|TACHOSIL®|TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.
40829934|NCT01718249|OTHER|Implantable neurostimulation system|
40829935|NCT04031274|DEVICE|TAVI|Trascatheter aortic valve implantation
40829936|NCT04031274|DEVICE|TMVR/r|Transcatheter mitral valve replacement/repair
40829937|NCT00366028|BEHAVIORAL|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
40829938|NCT00366028|BEHAVIORAL|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
40829939|NCT03897894|BEHAVIORAL|Child Friendly Space|Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.
40829940|NCT00349258|DRUG|Leuprolide acetate|
40829941|NCT00904618|PROCEDURE|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
41348809|NCT00820963|RADIATION|radiation therapy|Patients undergo standard radiotherapy
41348810|NCT01235494|OTHER|polarised 3 helium|1 inhalation (= 1 litre)
41348811|NCT06330766|PROCEDURE|No preoperative dental screening|Discontinuance of mandatory preoperative dental screening prior TAVI which also can include oral surgery.
41348812|NCT04220658|OTHER|Biomarker study|Biomarkers of aging including NAD+ levels in whole blood, interleukins, inflammatory cytokines, growth factors, omega-3 polyunsaturated fatty acids, and patterns in DNA methylation
41348813|NCT01097733|OTHER|Randomization of Pre-knowledge of CT coronary venography|
41348814|NCT01609673|DRUG|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
40829942|NCT00904618|PROCEDURE|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
40829943|NCT00904618|DRUG|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
40829944|NCT02607540|OTHER|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
40829945|NCT02607540|OTHER|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
40829946|NCT02607540|RADIATION|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
40829947|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .
40829948|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples of control subjects were collected.
40829949|NCT06013956|DEVICE|Neurostimulation|Electrical stimulation delivered via deep brain stimulation electrodes based on measurements of brain activity.
40829950|NCT06013956|DRUG|Carbidopa 25/Levodopa 100Mg Tab|Anti-parkinsonian medication.
41348815|NCT05384990|DEVICE|Stochastic Resonance Electric Stimulation|Subjects will be asked to perform postural transitions like sit to stand, gait initiation, sit to walk and Timed up and the Go (TUG) functional test. This will entail a subsensory electrical signal with a white noise frequency distribution. Proprioceptive SR electrical stimulation will be delivered by BIOPAC Systems, Inc. stimulators that are current limited to deliver less than 10 milli ampere of current. Electrical stimulation will be delivered to muscles and joints along the legs and hips. The stimulation intensity will be very low, below the sensory threshold of the participant.
40829951|NCT03187834|DRUG|Azithromycin|Children in this arm will receive Azithromycin once a day.
40829952|NCT03187834|DRUG|Amoxicillin|Children in this arm will receive Amoxicillin twice a day.
40829953|NCT03187834|DRUG|Cotrimoxazole|Children in this arm will receive co-trimoxazole once a day.
40829954|NCT03187834|DRUG|Placebo|Children in this arm will receive Placebo once a day.
40829955|NCT04338633|DRUG|Conventional calcium hydroxide paste|Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.
41019614|NCT04540536|OTHER|Secure texting|A secure platform (TigerConnect) will be used for three-way communication between parents, participants, and clinical personnel
41019615|NCT01108744|DRUG|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
41019616|NCT01108744|DRUG|Mannitol|Mannitol 20% intravenous solution, dosed by patient's ideal body weight
41019617|NCT03976440|OTHER|Renal Replacement Therapy (RRT) start|At the discretion of the nephrologist, treatment modality will be selected among CVVH, CVVHDF or SLED. Whatever the RRT modality, the investigators will adopt RCA as the standard anticoagulation strategy
41019618|NCT01412424|DRUG|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
41019619|NCT00097591|DRUG|Prasugrel|Administered orally
40829956|NCT04338633|DRUG|Calcium hydroxide nanoparticle|Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.
40829957|NCT04338633|DRUG|Combined Calcium hydroxide with silver nanoparticle|Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
40829958|NCT06276218|DEVICE|Clavicular brace|Clavicular brace for conservative treatment of closed midshaft clavicular fractures
40829959|NCT02165293|DRUG|RO7033877 + Bronchoscopy|Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
40829960|NCT04713618|PROCEDURE|Pelvic Examination|Undergo pelvic exam
40829961|NCT04713618|OTHER|Survey|Complete surveys
40829962|NCT01278784|DEVICE|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
40829963|NCT01278784|DEVICE|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
41019620|NCT00097591|DRUG|Clopidogrel|Administered orally
41019621|NCT00000781|DRUG|Nevirapine|
41019622|NCT00000781|DRUG|Zidovudine|
41348816|NCT01270113|BEHAVIORAL|contingency management|
41509078|NCT01696760|DEVICE|PCD|Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
40829964|NCT05870917|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, the double infusion intravenously at a target dose of (2-4)±20％ x 10\^6 anti-BCMA CAR+T cells/kg respectively
40829965|NCT00212186|DRUG|Selenium Supplements (essential nutrient)|
40829966|NCT01034618|DIETARY_SUPPLEMENT|Protein hydrolyzation|
41019623|NCT00000781|DRUG|Zalcitabine|
41019624|NCT00000781|DRUG|Didanosine|
40829967|NCT04104685|COMBINATION_PRODUCT|FCD105|Experimental combination
40829968|NCT04104685|DRUG|3% Minocycline Foam|Active Comparator
40829969|NCT04104685|DRUG|0.3% Adapalene Foam|Active Comparator
40829970|NCT04104685|OTHER|Vehicle Foam|Placebo
41348817|NCT03961139|OTHER|Method of feeding; continuous feeding OR bolus feeding|"CF: Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~BF: Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes."
40829971|NCT02744807|OTHER|Chronic endometritis|with or without Chronic endometritis
41348818|NCT01603615|BIOLOGICAL|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
40829972|NCT01307202|DRUG|Gabapentin|600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
40829973|NCT01307202|DRUG|Placebo|Placebo will match the the gabapentin pill and will be given orally.
40829974|NCT03558074|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
40829975|NCT02791412|PROCEDURE|percutaneous coronary intervention or coronary-artery bypass graft|
40829976|NCT03693313|BEHAVIORAL|CrossFit Kids exercise program|Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
40829977|NCT01901965|BEHAVIORAL|Neuromuscular electrical stimulation|
40829978|NCT01901965|BEHAVIORAL|eccentric training|
40829979|NCT00503334|DIETARY_SUPPLEMENT|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
40829980|NCT00700583|DRUG|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
40829981|NCT00487370|PROCEDURE|Implantation of gold beads around a knee through needles|
41019625|NCT06270121|BEHAVIORAL|Living-lab digital intervention group|Older adults will receive individualized daily health feedback via the mobile applications, which will be shared with caregivers. They will also receive support for health emergency by the platform sending automatic emergency push alarm to community and family caregivers.
41157749|NCT06103721|DRUG|Normal Saline|Patients in the placebo group will be nebulized with 10 ml of Normal Saline, 15 minutes prior to induction of general anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
41348819|NCT03484052|OTHER|Jugular ultrasound|Performing a jugular ultrasound by 2 operators before and after transfusion
40829982|NCT00487370|PROCEDURE|Sham implantation: Insertion of needles around a knee|
40829983|NCT01563289|DRUG|Ibuprofen|3 times a day
40829984|NCT01563289|DRUG|Placebo|3 times a day
40829985|NCT04888143|OTHER|questionnaires|evaluation of hearing performance and quality of life questionnaires
40829986|NCT04888143|OTHER|Evolutionary algorithm|application of the evolutionary algorithm and customized frequency allocation on a separate program.
40829987|NCT04851821|DRUG|Quercetin|Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
40829988|NCT03729193|BEHAVIORAL|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
41348820|NCT01560754|DRUG|nicotine transdermal patch|Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
41348821|NCT00439309|DEVICE|Gelfoam/Thrombin|Gelfoam/Thrombin
41509079|NCT04342195|PROCEDURE|Blood draw|Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.
40829989|NCT01669018|PROCEDURE|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
40829990|NCT01669018|PROCEDURE|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
40829991|NCT01801176|OTHER|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
40829992|NCT02624193|BEHAVIORAL|MBSR Program|Mindfulness-based stress reduction, as described previously.
41348822|NCT00439309|DEVICE|VascuSeal|VascuSeal
40829993|NCT02624193|BEHAVIORAL|HT Program|Health education curriculum, as described previously
41019626|NCT04353297|OTHER|EEG-based BCI system for (hand) Motor Imagery training|The Promotoer is an all-in-one BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback (EEG and EMG activity monitoring) and screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. As such, this software allows the therapists to create an artificial reproduction of a given patient's hand/forearm by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hand/forearm. Training consists of the MI tasks only of the affected hand, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
41348823|NCT03151538|BEHAVIORAL|Exercise Training Mixed With Play|To assess effects of training program which includes mixed exercises with playing.Study included 90 pre-school children who suffer from pes planus and increased femoral anteversion angle. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak Index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used. CSI measurements were positive correlation with severity of pes planus.
41348824|NCT03151538|OTHER|Controlled|First and last measurements will be done. There will be no intervention. Study will include 30 healthy pre-school children. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used.
40829994|NCT00363727|DRUG|ropinirole controlled-release (REQUIP CR) for RLS|
41019627|NCT04353297|OTHER|Motor Imagery training|Training consists of MI tasks only of the affected hand, grasping or finger extension in separate runs. MI training will be delivered without BCI support (ie., the Promotoer system will not provide real-time feedback of MI performance; hand/forearm visual representation will remain standstill) with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
41019628|NCT05841810|OTHER|mHealth Outreach|Community outreach using mHealth messaging will be led by community weavers via SMS and voice messages about COVID-19 vaccines and preventive care engagement in languages spoken by patients (i.e., Spanish, Arabic, Vietnamese).
41019629|NCT05841810|OTHER|Care Coordination|Inclusive of standard of care coordination with added focus on completing outstanding preventive care practices. Care coordination will be focused on collaborative problem-solving and case management to help patients schedule and attend recommended annual preventive health care, including a routine physical exam, recommended preventive screenings and COVID-19 vaccination
40829995|NCT05129514|OTHER|Manual Lymphatic Drainage (MLD)|The participant will be placed in a supine position and manual lymphatic drainage will be performed for 50 minutes. During the three intervening days, daily 50 minute sessions of manual lymphatic drainage will be provided.
41019630|NCT01159301|DRUG|entinostat|Given orally (PO)
41019631|NCT01159301|DRUG|sorafenib tosylate|Given PO
41019632|NCT01159301|OTHER|pharmacological study|Correlative studies
41019633|NCT01159301|OTHER|laboratory biomarker analysis|Correlative studies
41019634|NCT06214455|OTHER|Low sugar diet and 10-12 hour eating window|Low sugar diet and 10-12 hour eating window for four weeks
41019635|NCT06214455|OTHER|Low sugar diet, 8 hour eating window and fasting|Low sugar diet, 8 hour eating window and a 36-60 hour fast once per week for four weeks.
41019636|NCT00451763|DRUG|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
41019637|NCT06571357|BEHAVIORAL|Pranic Healing|The Pranic Healing intervention will be applied according to the advanced protocol by Master Choa Kok Sui, involving seven key techniques: sensitizing the hands, scanning the aura, cleansing the aura, increasing receptivity, energizing with prana, stabilizing the projected prana, and releasing. The intervention will take place in three stages: 5 minutes before, during, and 5 minutes after venipuncture.
41019638|NCT05536947|OTHER|Bread product (standard milled)|Bread rolls made from standard milled flour.
41019639|NCT05536947|OTHER|Bread Product (micro-milled)|Bread rolls made from micro-milled whole grain flour.
41019640|NCT05536947|OTHER|Bread Product (standard aleurone)|Bread rolls made from white flour/standard milled aleurone mix
41019641|NCT05536947|OTHER|Bread product (micro-milled aleurone)|Bread rolls made from white flour/micro-milled aleurone mix.
41019642|NCT03921541|DRUG|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
41348825|NCT04854785|OTHER|[18F]FEPPA PET scan|One \[18F\]FEPPA PET for TSPO VT, and one MRI scan
41348826|NCT04854785|OTHER|[11C]SL25.1188 PET scan|One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan
40829996|NCT00832130|DEVICE|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
40829997|NCT00832130|DEVICE|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
40829998|NCT02813642|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
40829999|NCT02813642|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
40830000|NCT02813642|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by X-ray of the lateral abdominal aorta
40830001|NCT05837858|OTHER|whole grain-wheat flour food+standardized meals|whole grain food made by 50 g whole grain wheat flour
40830002|NCT05837858|OTHER|refined wheat flour food+standardized meals|refined grain food made by 50 g refined wheat flour
40830003|NCT04082910|DRUG|Metoprolol|Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
41348827|NCT04576273|DIAGNOSTIC_TEST|Pathology examination|Gross and microscopic evaluation
41348828|NCT00025090|DRUG|cisplatin|
41348829|NCT00025090|DRUG|fluorouracil|
40830004|NCT04082910|DRUG|metoprolol, infliximab, etanercept, tocilizumab and/or other agents|During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
41348830|NCT00025090|DRUG|mitomycin C|
41348831|NCT00025090|RADIATION|radiation therapy|
40830005|NCT02961192|BEHAVIORAL|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
40830006|NCT02961192|BEHAVIORAL|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
40830007|NCT02961192|BEHAVIORAL|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
40830008|NCT01394614|BIOLOGICAL|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
40830009|NCT05617300|BEHAVIORAL|Mindfulness-Based Dementia Caregiving|Mindfulness Based Stress Reduction (MBSR) is a standardized program that is both psychoeducation and skills-based, which uses mindfulness meditation practices to help people better cope with their emotions. This study uses a version of MBSR designed specifically for care partners of people living with dementia (PLWD) called Mindfulness Based Dementia Caregiving. Mindfulness Based Dementia Caregiving (MBDC) is a program with 8 weekly 2 hour sessions (plus one extended practice 4 hour retreat) including both formal and informal mindfulness practices, role play, and lectures combined with some dementia-specific education. Participants learn how to incorporate mindfulness practices into day-to-day life to help cope with the challenges and stresses of dementia care.
40830010|NCT02255565|DRUG|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
40830011|NCT02255565|DRUG|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
40830012|NCT02255565|DRUG|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
40830013|NCT06155734|DRUG|Fluorescence guided identification using indocyanine green|During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to identify and treat paragangliomas
41019643|NCT03921541|DRUG|Placebo|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
41348832|NCT05232461|DRUG|PrimeC-ER 748 mg|PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
41348833|NCT05232461|DRUG|Ciprofloxacin 750 MG|Ciprofloxacin
41348834|NCT05232461|DRUG|Celecoxib 200mg|Celecoxib
41348835|NCT01886092|DEVICE|Active rTMS 1|repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
41348836|NCT01886092|DEVICE|Active rTMS 2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
41348837|NCT01886092|DEVICE|Active rTMS 3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
40830014|NCT06157320|DRUG|Shen-Fu|Within 24 hours of sepsis diagnosis, patients received a daily intravenous infusion of 100 ml of Shenfu Injection for a continuous duration of 7 days.
40830015|NCT06157320|DRUG|Norepinephrine (NE)，antibiotics，fluid resuscitation|empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine (NE)), which are employed to maintain mean arterial pressure above 65 mmHg and reduce the risk of fluid overload
40830016|NCT04643119|DEVICE|Medial Congruent Insert|The Medial Congruent Bearing (MC Bearing) design was introduced in 2016 for use with the Zimmer-Persona Cruciate-Retaining Femur: the design facilitates greater stability through increased anterior lip height compared to the original Cruciate Retaining Bearing (CR Bearing), allowing for greater anterior constraint and subluxation resistance that aids in full extension and deep flexion. Furthermore, the MC Bearing has been suggested for use in patients presenting with more complicated surgical histories (e.g prior high tibial osteotomies or patellectomies), whereas the original CR Bearing is strictly suggested for use only in patients undergoing knee surgery for the first time, where the posterior cruciate ligament may still be intact.
41019644|NCT02334748|DRUG|canakinumab|canakinumab
41348838|NCT01886092|DEVICE|sham condition|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
41348839|NCT02110550|OTHER|IPS.emmax endocrown|
41348840|NCT00811395|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
41348841|NCT00811395|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
41348842|NCT00811395|DRUG|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
41348843|NCT00811395|DRUG|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
41348844|NCT04334902|DEVICE|mPDia|Clinical decision support system for diagnosing neurodegenerative parkinsonism
41348845|NCT04502394|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
41348846|NCT04502394|DRUG|acalabrutinib|acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
41348847|NCT05319158|OTHER|MIT-PB, movement imitation therapy for preterm.|The instant an infant showed CS or PR movements, the therapists (or a therapist and a parent) intervened by gently guiding the infants' limbs so as to maneuver and smoothen their movements, thereby imitating normal GM sequences as closely as possible, adding variability to the movement
41348848|NCT02313506|BEHAVIORAL|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
40830017|NCT04643119|DEVICE|Cruciate-Retaining Insert|The Cruciate-Retaining Bearing (CR Bearing) design was launched together with the use of the Cruciate-Retaining Femoral Components (CR Femur) of the Zimmer-Biomet Persona® Total Knee system. The design not only stabilises the knee through medial conformity and anterior constraint, but also allows for freer and more natural deep flexion through freer movement of the lateral condyle.
40830018|NCT00716378|BEHAVIORAL|Teen Passenger Presence|
41157750|NCT04281875|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
41157751|NCT03692689|BIOLOGICAL|SCT200|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
41157752|NCT06457347|PROCEDURE|Ultra early (<24 hours) ruptured aneurysm clipping|Aneurysms are clipped with open surgery in less than 24 hours after rupture to prevent early rebleeding.
41157753|NCT06457347|PROCEDURE|Early (24-72 hours) ruptured aneurysm clipping|Aneurysms are clipped with open surgery in 24 to 72 hours after rupture to prevent early rebleeding.
41157754|NCT04349657|DEVICE|Supera Peripheral Stent System treatment group|Percutaneous endovascular stenting with the Supera Peripheral Stent System
41157755|NCT04349657|PROCEDURE|Endarterectomy treatment group|Surgical treatment through endarterectomy
41348849|NCT02313506|BEHAVIORAL|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
40830019|NCT01545232|BIOLOGICAL|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
40830020|NCT01545232|BIOLOGICAL|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
40830021|NCT06036381|DIAGNOSTIC_TEST|Radiomic analysis of imaging - MRI, PET, CT|Radiomic analysis of imaging will be undertaken as a standard of care to develop computational algorithms for patients treated in our institution.
40830022|NCT05864131|BEHAVIORAL|Lying|After the urethral catheter is inserted, the participant lies on an examination table lined with paper towels and diapers.
40830023|NCT05864131|BEHAVIORAL|Holding|Holding is performed as a non-pharmacological intervention to relieve pain in children during cystometry. After the urethral catheter is inserted, the participant's parent sits in the chair, placing a paper towel and diaper on their lap. The researcher lifts the participant by the shoulder and puts them on their parent's lap, and the parent holds the participant in their arms.
40830024|NCT01537146|DRUG|Ropivacaine|Bolus infusion via catheter/6H for 24H
40830025|NCT01537146|DRUG|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
41157756|NCT01365351|OTHER|Growth hormone|Drug given by prescription
40830026|NCT01457677|DRUG|Placebo|matching placebo to RO4995819 oral once daily for 6 weeks
40830027|NCT01457677|DRUG|RO4995819|5 mg oral once daily for 6 weeks
40830028|NCT01457677|DRUG|RO4995819|15 mg oral once daily for 6 weeks
40830029|NCT01457677|DRUG|RO4995819|30 mg oral once daily for 6 weeks
41157757|NCT00271466|DRUG|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
41157758|NCT03912298|OTHER|Opioid Taper Pain perception|Pain Responses: The primary dependent variable, pain, will be measured using two highly reliable and valid pain induction techniques, the CPT and QST, employing procedures consistent with those described in the literature. Order of pain testing will vary, and three aspects of the pain response will be captured at each study session: evoked pain; temporal summation; and conditioned pain modulation, which map on to the hypothesized peripheral, spinal and supra-spinal mechanisms of OIH. Protocols for each assay have been uploaded.
41157759|NCT01705223|BIOLOGICAL|DNA vaccine|4mg/dose, three doses at week 0,4,8
41157760|NCT01705223|BIOLOGICAL|DNA vaccine prime with the addition of electroporation|4mg/dose, three doses at week 0,4,8
41348850|NCT00004141|DRUG|Cisplatin|
41348851|NCT00004141|DRUG|dacarbazine|
41348852|NCT00004141|DRUG|Granulocyte-macrophage colony-stimulating factor|
41348853|NCT00803296|OTHER|Oral glucose tolerance test (OGTT)|
41157761|NCT01705223|BIOLOGICAL|rTV boost|at week 16
41157762|NCT01705223|BIOLOGICAL|rTV boost|at week 24
41157763|NCT01705223|BIOLOGICAL|rTV boost|at week 32
41157764|NCT03775278|DRUG|PHP-303|Investigational drug
41157765|NCT03775278|OTHER|Placebo|Matching placebo
41157766|NCT04021147|BEHAVIORAL|Exercise plus action observation|Orofacial exercise plus action observation (video) of the same exercise
41157767|NCT04021147|BEHAVIORAL|Exercise plus motor imagery|Orofacial exercise plus motor imagery of the same exercise
41157768|NCT04021147|BEHAVIORAL|Exercise plus visual mirror feedback|Exercise plus visual mirror feedback
41157769|NCT04021147|BEHAVIORAL|Exercise|Orofacial exercises
41157770|NCT02728947|DRUG|ROTIGOTINE|1 week at each dose
41157771|NCT04237675|PROCEDURE|surgery and anesthesia|patients with MS who received general or regional anesthesia for a surgery or labor
41348854|NCT00803296|OTHER|Isoglycemic intravenous glucose infusion|
40830030|NCT04688918|PROCEDURE|Retrolaminar block|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The spinous process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vertebral lamina. A 50 mm 22-gauge needle will be inserted in an in-plane technique from cranial to caudal direction and will be advanced till hitting the laminae of fourth thoracic vertebrae and then we will try to inject the local anesthetic, if the resistance to injection is very high, hence we will withdraw the needle slowly and its tip will be kept in its position immediately after disappearance this high resistance. Bupivacaine 0.25%, 0.4mL/kg will be injected.
40830031|NCT04688918|PROCEDURE|paravertebral group|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The transverse process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vcostotransverse ligament, 0.4mL/kg will be injected
40830032|NCT01041443|DRUG|5-fluoro-2-deoxycytidine|Given IV
40830033|NCT01041443|DRUG|tetrahydrouridine|Given IV
40830034|NCT01041443|OTHER|laboratory biomarker analysis|Correlative studies
40830035|NCT01041443|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
40830036|NCT01041443|GENETIC|DNA methylation analysis|Correlative studies
40830037|NCT00434759|BEHAVIORAL|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
41157772|NCT06051097|DIAGNOSTIC_TEST|sleep study|over-night polysomnography
41348855|NCT02391298|BEHAVIORAL|Mindfulness Meditation|
40830038|NCT00434759|BEHAVIORAL|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
40830039|NCT01316952|DRUG|Carvedilol immediate release only|All dosages of carvedilol immediate release
40830040|NCT01316952|DRUG|Carvedilol extended release only|All dosages of carvedilol extended release
40830041|NCT01316952|DRUG|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
40830042|NCT01316952|DRUG|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
40830043|NCT01316952|DRUG|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
40830044|NCT01316952|OTHER|No β-blocker|No β-blocker within the month prior to the index date
40830045|NCT02251717|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
40830046|NCT00300677|DRUG|voriconazole|Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
40830047|NCT03198806|OTHER|Treadmill aerobic exercise in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
40830048|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
40830049|NCT03198806|OTHER|Treadmill aerobic exercise in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.
40830050|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
40830051|NCT01155466|DRUG|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
40830052|NCT01155466|DRUG|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
40830053|NCT01155466|DRUG|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
40830054|NCT01155466|DRUG|Placebo to Preladenant Tablet|one tablet orally twice daily
40830055|NCT01155466|DRUG|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
40830056|NCT01155466|DRUG|Placebo to Rasagiline capsule|one capsule orally in AM
40830057|NCT03918226|PROCEDURE|exploratory laparotomy|Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
41157773|NCT00981929|DRUG|Tramadol|50 mg single oral dose
41157774|NCT00981929|DRUG|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
41348856|NCT00233324|DRUG|Surfactant|Intubation and administration of surfactant by 1 hour of age.
41348857|NCT00233324|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
41157775|NCT00981929|DRUG|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
41348858|NCT00233324|DRUG|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
41348859|NCT00233324|DRUG|Supplemental oxygen with target saturation of 91 to 95%|Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
41348860|NCT03662789|DRUG|Iron Isomaltoside 1000|Intravenous infusion
41348861|NCT03662789|OTHER|Placebo: NaCl 0,9%|Intravenous infusion
41348862|NCT05953103|DRUG|Synbixin/Placebo|Synbixin/Placebo
40830058|NCT05246826|OTHER|Clinical Pilates Exercises|Pilates exercises; warm-up and cool-down exercises will be performed for 5 repetitions, while other exercises will be performed by the same physiotherapist as 10 repetitions depending on the patient's pain and fatigue. The exercises will be advanced at the end of the 3rd week.
40830059|NCT05246826|OTHER|Clinical Pilates Exercises and Conventional Treatment|In addition to pilates exercises, a conventional treatment program will be applied. As part of the conventional treatment program, 20 minutes of Hotpack to the cervical area, 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation (TENS) to the painful area (80 Hertz (Hz), 100 microseconds (μs), until tingling is felt, asymmetrical biphasic rectangular waveform), 8 minutes to the cervical area Ultrasound (US) (4 minutes + 4 minutes, 1.5 watts/cm2, 1 MHz, continuous) will be applied.
40830060|NCT01839019|DRUG|ODM-102|Single dose escalation
40830061|NCT01839019|DRUG|Placebo for ODM-102|Single dose escalation
40830062|NCT04739397|DEVICE|Glare Testing|Vision in Cataract patients were tested with and without the EpiGlare Tester
40830063|NCT02776033|DRUG|GSK2982772|GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
41019645|NCT04016168|BIOLOGICAL|Blood sample collection|Three additional blood tubes (3 x 8mL) will be collected for this study. They will be added to the traditional diagnostic assessment carried out for their IPF, during their consultation at the competence centre for rare lung diseases. These samples will be taken by a registered nurse in the presence and under the responsibility of the investigator.
41019646|NCT02705950|DRUG|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
41019647|NCT02705950|OTHER|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
41019648|NCT02810834|BEHAVIORAL|Walking/Running program|"Participants will receive a behavioral intervention that consists of a school-based, walking/running/jogging program. Participants work to accumulate miles towards a goal of at least 100 miles, over the course of the school year. Program will be implemented through a champion in the school and structured/scheduled according to the schools resources (before, during, or after school). Miles are tracked at the school level, and incentives are provided for participants' completion of set milestones (25, 50, 75, and 100 miles).~The intervention will run over two school years (approximately 16 months)"
41019649|NCT02810834|BEHAVIORAL|Classroom physical activity break program|"Participants will receive a behavioral intervention that consists of a classroom-based, physical activity break program. Classroom teachers, paraprofessionals, and other school staff will lead short (5-15 minute) activity breaks that include both higher intensity (ex. jumping jacks, squats) and low-intensity (ex. stretching, yoga) activities. Classrooms will be encouraged to integrate at least one short break per day. Activities are connected to national Common Core academic standards so that breaks can be integrated with academics.~The intervention will run over two school years (approximately 16 months)"
41019650|NCT03390322|DEVICE|DiaGone™|Duodenal Glycemic Control™ using the DiaGone™ system
41019651|NCT03384667|DRUG|Maekmoondong-tang|MMDT is a Herbal medicine consist of six herbs.
41019652|NCT03384667|DRUG|Placebo|The granules do not contain any active ingredients.
41019653|NCT04526691|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle (starting datopotamab deruxtecan dose of 4.0 mg/kg)
41019654|NCT04526691|DRUG|KEYTRUDA®|Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
41019655|NCT04526691|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (AUC 5)
41019656|NCT04526691|DRUG|Cisplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (75 mg/m\^2)
41348863|NCT06380556|DEVICE|ShotBlocker|The protruding surface of the ShotBlocker was placed on the heel lance procedure site. While applying pressure on the skin through the ShotBlocker, the nurse performed heel lancing with the needle through the opening in the center of the ShotBlocker. During the 10-second waiting phase, the ShotBlocker was kept at the procedure site with the same pressure. Then ShotBlocker was removed from the skin and routine capillary blood collection procedure was performed.
40830064|NCT02776033|DRUG|Placebo|Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
40830065|NCT01582048|DRUG|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
40830066|NCT02707211|BIOLOGICAL|Anti-oxLDL IgM antibody|Immunization
40830067|NCT06120595|DRUG|REBECCA-assisted intervention 1|The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).
40830068|NCT06120595|BEHAVIORAL|REBECCA-assisted intervention 2|The intervention will include dietary advice, to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH).
40830069|NCT06120595|OTHER|Standard follow-up|Standard follow-up
40830070|NCT04337736|OTHER|Physical exercise|
41157776|NCT04056117|BIOLOGICAL|Shigella 4V|Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
41019657|NCT05977595|OTHER|Quick DASH Score Visual Analog Scale Scar quality Healing Number of surgeries|Functional and aesthetic criteria : Quick DASH Score at 3 month and 6 months, Visual Analog Scale at 3 month and 6 months, scar quality (assessment by surgeon), healing (discontinuation of dressings), need for a second surgical procedure.
41348864|NCT06380556|DEVICE|Mechanical vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the baby's extremity and routine capillary blood collection procedure was performed.
41348865|NCT01486940|DRUG|insulin detemir|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
41348866|NCT01486940|DRUG|insulin aspart|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
41348867|NCT01486940|DRUG|insulin NPH|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
41348868|NCT01486940|DRUG|human soluble insulin|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
41348869|NCT03760302|OTHER|analgesics|analgesics given to a patient treated from HEMS
41348870|NCT03760302|OTHER|hypnotics|hypnotics given to a patient treated from HEMS
41348871|NCT01563952|DEVICE|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
41348872|NCT01563952|DEVICE|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
41348873|NCT01563952|DEVICE|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
41348874|NCT01563952|DEVICE|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
41348875|NCT00758004|DRUG|Atorvastatin|A single dose of 80 mg atrovastatin tablet
41348876|NCT00758004|DRUG|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
41348877|NCT05181215|DRUG|Monomethyl Fumarate 190 Mg|2 x oral 95 mg capsules, delayed-release
41348878|NCT05181215|DRUG|Diroximel Fumarate 462 mg|2 x 231 mg capsules, delayed-release
41348879|NCT01573611|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
41348880|NCT01573611|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
41348881|NCT03601091|DRUG|Precedex 200 MCG in 2 ML Injection|Infusion therapy of the drug
41019658|NCT02037503|DRUG|Ketamine|
41019659|NCT02037503|DRUG|Saline|
41019660|NCT03265405|DRUG|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
41348882|NCT03601091|DRUG|DORMICUM 5MG/5 ML|Infusion therapy of the drug
41348883|NCT05076552|DRUG|TACH101|Orally via capsules
41348884|NCT02227901|DRUG|Tipifarnib|Given PO
41348885|NCT02227901|RADIATION|External Beam Radiation Therapy|Undergo EBRT
41348886|NCT02227901|DRUG|Temozolomide|Given PO
41348887|NCT02227901|OTHER|Laboratory Biomarker Analysis|Correlative studies
41348888|NCT04449718|DIETARY_SUPPLEMENT|Vitamin D|200,000 IU on admission
41019661|NCT03265405|DRUG|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
41019662|NCT01835782|DRUG|L-Serine|
41019663|NCT01849341|DRUG|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
41019664|NCT01849341|DRUG|Roflumilast 500 mcg per day|
41019665|NCT03980847|DRUG|Alendronate 20 mg|The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction
41019666|NCT03980847|PROCEDURE|Nanocrystal hydroxyapatite|Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
41019667|NCT03243916|RADIATION|TACE plus Cyber knife|Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
41019668|NCT02409485|BEHAVIORAL|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
41019669|NCT05383170|DRUG|CyPep-1|Intratumoral injection
41019670|NCT05383170|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
41019671|NCT00403455|DRUG|Paroxetine|SSRI
41019672|NCT00900991|BIOLOGICAL|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
41019673|NCT00103649|DRUG|xaliproden (SR57746A)|
41348889|NCT04449718|DIETARY_SUPPLEMENT|Placebo|200,000 IU on admission
41348890|NCT02660060|DRUG|Pramipexole Dexa Medica|Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
41348891|NCT02660060|DRUG|Pramipexole Boehringer Ingelheim Pharma|Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH \& Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
41491597|NCT04902092|BEHAVIORAL|High Intensity Interval Training|Exercise sessions will commence with an initial 3-week accustomization period whereby training load will increase incrementally from 2 x 45min sessions with effort peaking at 60% VO2 max (week 1) increasing to 3 x 45minute with effort peaking at 80% VO2max (week 3). Participants will transition to the full HIIT protocol for the remaining weeks. The HIIT component will comprise a work-rest ratio of ≥1:1minutes, with alternating exertion epochs at \>80% VO2max and \<60% VO2max. As VO2max is likely to increase as fitness improves toward the end of the 3-month program, adjustments to HIIT will be made by the exercise physiologist based on real-time heart rate monitoring, ensuring greater accuracy in participants achieving their heart rate targets.
41491598|NCT04902092|BEHAVIORAL|Strength and Resistance Training|Exercise sessions will comprise a combination of strength, coordination and mobility exercises. The strength component will consist of 2-3 sets of resistance exercises at ≤70% of a predicted 1 repetition maximum, targeting all body segments. Heart rate tracking will occur to ensure participants do not exceed 70% v02 (or exceed Lactate Threshold).
41491599|NCT04158661|PROCEDURE|thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)|preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
40830071|NCT03001700|DEVICE|Serranator™ Alto PTA Serration Balloon Catheter|The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
41019674|NCT02275286|DRUG|Trabectedin|"Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks.~Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery."
41019675|NCT02275286|RADIATION|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).
41019676|NCT02610192|DEVICE|nSTRIDE Autologous Protein Solution (APS) Kit|Intra-articular injection of APS
41019677|NCT06531603|DRUG|bupivacaine wound infilteration|drug was given at the end of surgery
41019678|NCT06531603|DRUG|Bupivacaine plus dexmedetomidine wound infilteration|drug was given at the end of surgery
41019679|NCT02874547|BEHAVIORAL|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
41019680|NCT01581203|DRUG|Asunaprevir (ASV)|
41019681|NCT01581203|DRUG|Daclatasvir (DCV)|
41019682|NCT01581203|DRUG|Pegylated-interferon alfa 2a (PegIFN)|
41019683|NCT01581203|DRUG|Ribavirin (RBV)|
41019684|NCT04825223|DRUG|Multicomponent Meningococcal B Vaccine|Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
41019685|NCT04825223|DRUG|Meningococcal Group B Vaccine MenB|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
41019686|NCT04825223|DRUG|Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
41019687|NCT04825223|DRUG|Placebo|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
41019688|NCT04825223|DRUG|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
41019689|NCT06246149|DRUG|Tebentafusp|Tebentafusp will be administered weekly i.v.
41019690|NCT06145828|DEVICE|Cytokine Adsorption|During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.
41019691|NCT05283291|BEHAVIORAL|Directed Imagery Technique|"The sound recording will include a soothing light background music for approximately 30 minutes.~Imagination will be practiced, starting with the patient's focusing his/her attention on his/her breath, relaxation, and relaxation with the suggestions given in the recording with the accompaniment of relaxing music."
41019692|NCT05637151|OTHER|clamp time of umbilical|The umbilical cord was clamped immediately or late for more than 30s
41019693|NCT05976334|DRUG|[14C] Subasumstat|\[14C\] Subasumstat IV infusion.
41157777|NCT04056117|BIOLOGICAL|MenACWY|Control vaccine administrated to adults and infants
41157778|NCT04056117|BIOLOGICAL|Rabies|Control vaccine administrated to children
41491600|NCT04158661|PROCEDURE|thymectomy by means of median sternotomy (transsternal)|with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
41491601|NCT04158661|PROCEDURE|no thymectomy (control)|routine medical care
41491602|NCT00675753|GENETIC|Blood spot specimens will be drawn|Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
41491603|NCT00593047|DRUG|KB2115|tablet formulation given once daily for 12 weeks
41491604|NCT02119286|DRUG|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
41019694|NCT05976334|DRUG|Subasumstat|Subasumstat IV infusion.
41019695|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in Sodium chloride|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in sodium chloride
41157779|NCT04056117|BIOLOGICAL|Diphtheria, Tetanus and Pertussis (DTaP)|Control vaccine administrated to infants
41157780|NCT04056117|BIOLOGICAL|Placebo|Control administrated to adults
40830072|NCT04710914|DRUG|Prolonged sedation with isoflurane|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
40830073|NCT04710914|DRUG|Prolonged sedation with midazolam|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
40830074|NCT00197145|DRUG|GW873140|400 mg twice daily
41157781|NCT01363297|DRUG|Inotuzumab Ozogamicin|"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m\^2 to 2.0 mg/m\^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m\^2."
41157782|NCT04263883|DEVICE|Study or Experimental Group|3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
41157783|NCT02798276|PROCEDURE|AGTP-treatment|Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
41157784|NCT02798276|OTHER|Control|Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
41157785|NCT04787900|DEVICE|iPhone measurement application|The iPhone measurement application will be used to ensure validity and reliability.
41157786|NCT04787900|DEVICE|Bubble inclinometer|Bubble inclinometer with proven validity and reliability will be used for this study.
41157787|NCT01516606|DRUG|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
41157788|NCT02727647|DRUG|FVIII|FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months
41157789|NCT02727647|DRUG|FVIII|FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months
40830075|NCT05665400|DEVICE|Bloomlife Lovelace FT|Bloomlife Lovelace FT is a non-invasive, wireless, external measurement system used to measure accelerometer and electrophysiological signals on pregnant women with a singleton pregnancy, by acquiring biopotential signals from abdominal surface electrodes.
40830076|NCT02833792|DRUG|Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Intravenous administration
41157790|NCT04357522|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
41157791|NCT04357522|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
41157792|NCT06414681|DRUG|Tagraxofusp|Tagraxofusp Patients will receive 12 micrograms/kg of Tagraxofusp (TAG) by IV infusion once daily for 3 consecutive days.
40830077|NCT02833792|OTHER|Placebo|Intravenous administration
40830078|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
40830079|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
40830080|NCT02635334|DRUG|Montelukast 10 mg orally|
41019696|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in dextrose 5%|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in dextrose 5%
40830081|NCT02635334|OTHER|Placebo|
40830082|NCT00627536|DRUG|Avotermin|A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
40830083|NCT00627536|DRUG|Placebo|Matched to avotermin dosage strength
40830084|NCT01332188|DRUG|AC-170 0.05%|1 drop in each eye at 3 separate times during a 21 day period
41019697|NCT06534697|DRUG|Dextrose 10 % in Water|Preoperative fascia iliaca block with 40 ml volume of dextrose 10%
40830085|NCT01332188|DRUG|AC-170 0.1%|1 drop in each eye at 3 separate times during a 21 day period
40830086|NCT01332188|DRUG|AC-170 0.24%|1 drop in each eye at 3 separate times during a 21 day period
40830087|NCT01332188|DRUG|AC-170 0%|1 drop in each eye at 3 separate times during a 21 day period
41019698|NCT04638790|DRUG|Doxorubicin|25 mg/m2 i.v. day 1,15 for ABVD/AVD
41019699|NCT04638790|DRUG|Bleomycin|10,000 units/m2 i.v. days 1,15 for ABVD
41019700|NCT04638790|DRUG|Vinblastine|6 mg/m2 i.v. days 1,15 for ABVD/AVD
41019701|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. days 1,15 for ABVD/AVD
41019702|NCT04638790|DRUG|Etoposide|100 mg/m2 i.v. days 1-3
41019703|NCT04638790|DRUG|Doxorubicin|50 mg/m2 i.v. day 1 for EACODD-14
41019704|NCT04638790|DRUG|Cyclophosphamide|650 mg/m2 i.v. day 1
41019705|NCT04638790|DRUG|Vincristine|1,4 mg/m2 i.v. day 8
41019706|NCT04638790|DRUG|Dexamethasone|20 mg i.v. days 1-3
41019707|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. day 1 for EACODD-14
41019708|NCT02366572|OTHER|Control|Non pulse extruded cereal
41019709|NCT02366572|OTHER|Pea protein|Pulse extruded cereal
41019710|NCT02366572|OTHER|Pea starch|Pulse extruded cereal
41019711|NCT02366572|OTHER|Pea fibre + pea starch|Pulse extruded cereal
41019712|NCT02366572|OTHER|Pea protein + pea starch|Pulse extruded cereal
41019713|NCT02366572|OTHER|Pea fibre + pea starch + pea protein|Pulse extruded cereal
40830088|NCT03157583|OTHER|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
41491605|NCT02119286|DRUG|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
41019714|NCT02864641|BEHAVIORAL|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
41019715|NCT04595838|DEVICE|Chemo Mouthpiece|Frozen tube that fills the oral cavity used during and after chemotherapy to ease and prevent symptoms of oral mucositis
41019716|NCT04595838|OTHER|Best Supportive Care only|Standard Oral care for Chemotherapy
41157793|NCT06414681|DRUG|Pacritinib|Pacritinib Pacritinib (PAC) will be given orally, 200 mg twice per day starting at C2D4 and administered continuously (Subsequent cycles start on Day 1 of the Cycle).
41157794|NCT01665014|RADIATION|Total marrow irradiation|Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
41157795|NCT06646224|DEVICE|CorVad Percutaneous Ventricular Assist System|The CorVad Percutaneous Ventricular Assist System provides circulatory support for patients with cardiogenic shock.
41157796|NCT04702399|DEVICE|GEL GROUP|Application of an anti-adhesion gel (HYALOBARRIER® GEL ENDO) in the uterine cavity
41157797|NCT05533645|OTHER|Questionnaire|These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
41491606|NCT02119286|DRUG|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
41491607|NCT02119286|DRUG|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
41491608|NCT04162054|OTHER|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).
41019717|NCT05686408|DRUG|TNX-601 ER|Patients will take 1 pill orally once daily for 6 weeks.
41019718|NCT05686408|DRUG|Placebo|Patients will take 1 pill orally once daily for 6 weeks.
41157798|NCT05190224|OTHER|Neural mobilization of the deep peroneal, posterior tibial and medial medial and lateral dorsocutaneous nerves.|In lateral decubitus the patient with the help of the clinician will perform neuromeningeal mobilization of the posterior tibial dorsocutaneous lateral, intermediate and medial nerves and deep peroneal nerve too.
41157799|NCT06171945|BEHAVIORAL|AYA Connect intervention|Participants will receive a smart scale, activity tracker, an individual kickoff videochat session with a health coach, and access to a mobile smartphone app that includes weekly behavioral lessons, dietary tracking log, daily weight-related behavioral goals, tailored feedback summaries, and in-app health-related messages.
41157800|NCT06171945|BEHAVIORAL|Positive Psychology (PP) intervention|Participants will receive lessons about positive psychology (PP) strategies, weekly goals for PP exercises, and in-app health-related messages that include reminders to practice PP exercises.
41157801|NCT06171945|BEHAVIORAL|Positive Psychology Plus (PP+) intervention|Participants will receive weekly individual videochat sessions with a health coach.
41491609|NCT04398264|OTHER|COVID-19 positive via testing|Pregnant women admitted to Obstetric Units undergo RT-PCR testing for the detection of SARS-Cov2 (COVID-19 infection)
41491610|NCT06291350|OTHER|Plaque sampling and stool collection|Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
41491611|NCT06291350|OTHER|periodontal examination|Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
41157802|NCT06575153|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
41491612|NCT05199519|DRUG|IBI345|IBI345 CAR-T cell injection by intravenous infusion
41491613|NCT05152628|DRUG|Tacrolimus granules|Oral
41491614|NCT05979649|BEHAVIORAL|behavioral corrective tasks|"After each personalized conversation, the interveners will, based on a clear understanding of the participants' completion status and personal experiences with the previous behavioral corrective tasks, assist in formulating future behavioral corrective tasks for the next two weeks. These tasks will be selected from our designated To Do List, requiring at least one task from each category: social support, coping strategies, and emotional intelligence."
41157803|NCT02336113|BEHAVIORAL|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge, as well as written drug information to the next level of care
41491615|NCT05979649|OTHER|Counselling on psychological knowledge|Counselling on psychological knowledge includes weekly personalized feeds, as well as the methods and techniques for coping with challenges provided by the interveners.during personalized conversations with the participants.
41491616|NCT05979649|OTHER|placebo-controlled study|"feel-good articles without professional psychological knowledge will be sent to the control group participants weekly."
41491617|NCT05979649|OTHER|Peer Interventionist Training|The training is a one-day course, encompassing a broad range of topics, including but not limited to counseling techniques and specialized medical psychology knowledge.
40830089|NCT03157583|OTHER|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
41157804|NCT06334120|DRUG|Darolutamide (Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
40830090|NCT03157583|OTHER|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
40830091|NCT03157583|OTHER|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
40830092|NCT03157583|OTHER|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
40830093|NCT03157583|OTHER|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
40830094|NCT03157583|OTHER|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
41157805|NCT06646315|BEHAVIORAL|Early Intervention|The Early Intervention consists of the proper attention given to those patients who participate in a Phase I Clinical Trial. The attention will be based on a monthly assessment of their physical, psychological/emotional symptoms and, also their sociofamiliar needs. After having discussed patients's needs in a multidisciplinary committee, each professional (paliiative physician, clinical psychologist and/or wocial orker) will proportionate them the required attention in order to increase their quality of life.
41348892|NCT04835051|BEHAVIORAL|Breastfeeding promotion|The intervention included training of health workers in private health facilities to provide in-person breastfeeding counseling to pregnant women and women with a child \<6 months during clinic visits. The health workers also offered a mobile phone support component for appointment reminders, breastfeeding SMS and WhatsApp messages, WhatsApp breastfeeding support groups, informational materials (posters and foldable pocket-sized cards), and family engagement activities. Breastfeeding-related mass media through television and radio spots was available state-wide, including to women in intervention and comparison facilities.
41348893|NCT00992485|DRUG|ADIPOPLUS|autologous adipose-derived stem cell
41348894|NCT05807815|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
41348895|NCT00053105|DRUG|cisplatin|
40830095|NCT05286372|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
40830096|NCT01262170|DIETARY_SUPPLEMENT|CigRx Lozenge|lozenge made of dietary supplements
40830097|NCT01262170|OTHER|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
41157806|NCT00312871|DRUG|Epoetin alfa|
41157807|NCT05607732|DIAGNOSTIC_TEST|MyCog|MyCog uses well-validated, self-administered, iPad-based measures from the NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery to provide an efficient and sensitive cognitive screen that can be easily implemented in primary care. Preliminary data shows these tests can discriminate between cognitively normal older adults and those with CI (specifically mild cognitive impairment); enabling physicians to assess CI in ways currently not available.
41157808|NCT02136797|BIOLOGICAL|CMVpp65 Specific T-cells|
41157809|NCT00612716|DRUG|busulfan|For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
41348896|NCT00053105|DRUG|cytarabine|
41348897|NCT00053105|DRUG|methylprednisolone|
41348898|NCT00053105|DRUG|pixantrone dimaleate|
41348899|NCT04764838|OTHER|Yoga|"Breath Awareness Training (5 minutes) Asanas (20 minutes)~* Bending sideways in Mountain Stance~* Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~* Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)"
41348900|NCT03426644|BEHAVIORAL|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
41348901|NCT03731169|GENETIC|Voriconazole genotype-specific dosing|"Those in the intervention arm will receive an experimental dosage regimen of voriconazole based on their genetic status.~URM: 6 mg/kg voriconazole twice on the first day followed by 5 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~EM: 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~HEM and PM: 6 mg/kg voriconazole twice on the first day followed by 2 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy."
41491618|NCT03131492|DIAGNOSTIC_TEST|Blood test|C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.
40830098|NCT05482581|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,awareness of e-cigarettes sheet;,willingness to use e-cigarettes sheet, knowledge, attitudes and cognitions related to e-cigarettes sheet, awareness of new regulations on e-cigarette control sheet.
40830099|NCT00028431|BIOLOGICAL|MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine|
40830100|NCT01540409|DRUG|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
40830101|NCT02601547|DEVICE|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
40830102|NCT05911438|DRUG|Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)|Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
40830103|NCT05911438|OTHER|Basic Treatment|Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
40830104|NCT00003671|DRUG|asparaginase|
40830105|NCT00003671|DRUG|cyclophosphamide|
41348902|NCT03731169|DRUG|Standard of Care|Participants are given 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy. After TDM is conducted on day 4 for all patients, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
41348903|NCT03932591|PROCEDURE|kinesio taping method|Kinesio tape is an elastic, adhesive, hypo-allergenic, latex-free tape. Kinesio taping method is rehabilitative taping technique. One of the purposes of this technique is to facilitate or inhibit the muscles.
40830106|NCT00003671|DRUG|cytarabine|
40830107|NCT00003671|DRUG|daunorubicin hydrochloride|
40830108|NCT00003671|DRUG|dexamethasone|
40830109|NCT00003671|DRUG|leucovorin calcium|
40830110|NCT00003671|DRUG|mercaptopurine|
40830111|NCT00003671|DRUG|methotrexate|
40830112|NCT00003671|DRUG|thioguanine|
40830113|NCT00003671|DRUG|vincristine sulfate|
40830114|NCT02258555|DRUG|GS-9901|GS-9901 tablets administered orally
41348904|NCT03932591|PROCEDURE|Sham kinesio taping|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be a
41348905|NCT05715840|DRUG|SG001 injection|360 mg，Q3W，IV infusion
41491619|NCT03972267|PROCEDURE|Free gingival graft|Free Gingival Graft removal from the palate donor area for socket preservation
41491620|NCT03972267|DEVICE|Enamel Matrix Derivate|EMD in contact with the palate wound for 5 min. After this time, palatal area will be covered with an individualized acetate plate which will stay in position for 2 hours after the procedure
40830115|NCT04141189|PROCEDURE|weekly|fetal surveillance frequency
40830116|NCT04141189|PROCEDURE|bi-weekly|fetal surveillance frequency
41157810|NCT00612716|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
41348906|NCT05715840|DRUG|Paclitaxel|175 mg/m\^2，Q3W，IV infusion
41348907|NCT05715840|DRUG|Cisplatin|50 mg/m\^2，Q3W，IV infusion
41348908|NCT05715840|DRUG|Carboplatin|AUC=5，Q3W，IV infusion
41348909|NCT05715840|DRUG|Bevacizumab injection|15 mg/kg，Q3W，IV infusion
41348910|NCT05715840|DRUG|SG001 placebo|Q3W，IV infusion
41348911|NCT01623856|OTHER|laboratory biomarker analysis|Correlative studies
41348912|NCT06097975|DRUG|Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV|Participants will receive neo-adjuvant administration of intravenous immunotherapy on day 1 + day 22: ipilimumab + nivolumab IV.
40830117|NCT03213574|OTHER|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
40830118|NCT03213574|OTHER|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
40830119|NCT06442748|DRUG|Levetiracetam|Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.
40830120|NCT03365141|DRUG|Triamcinolone acetonide 0.4mg/cc|"* Intralesional injection of dilute triamcinolone acetonide with 2% lidocaine (400mg/20 mL) would be performed to reduce pain when injecting the drug.~* Once weekly, for a total of 12 weeks"
40830121|NCT03365141|DEVICE|Phototherapy (NBUVB or excimer laser)|NBUVB or excimer laser treatment weekly
40830122|NCT03365141|DRUG|Topical tacrolimus|Application of topical tacrolimus ointment twice a day
40830123|NCT03514498|PROCEDURE|Dental surgery|All types of dental surgery
40830124|NCT04286672|DIAGNOSTIC_TEST|Metadherin|study alterations of MTDH gene expression in the serum of bladder cancer patients
40830125|NCT05239221|DRUG|AZP-3601|Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
40830126|NCT05239221|DRUG|Placebo|Saline solution visually matching active medication
40830127|NCT04000334|OTHER|MAP increased to optimize cerebral blood flow|MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
40830128|NCT04000334|OTHER|MAP between 65 and 85 mmHg|MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
40830129|NCT03993223|BEHAVIORAL|Upper trapezius muscle fatigue|Isometric contraction of scapular elevation
40830130|NCT00266838|DRUG|Maxidex; Lacrystat|6 times daily, for 20 weeks.
40830131|NCT01047800|BEHAVIORAL|Counseling|"Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions."
40830132|NCT05117619|BEHAVIORAL|HOME for Us|HOME is an in-home, family inclusive, rehabilitation intervention in 8 sessions. Six of the sessions will be in-home and 2 will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
40830133|NCT05117619|BEHAVIORAL|Attention-control condition|The Attention-control condition consists of educational materials presented over 8 contacts. Two of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
41157811|NCT00612716|BIOLOGICAL|Stem cell infusion|Infused on Day 0
41157812|NCT00612716|RADIATION|Total body irradiation|165 cGy morning and evening on days -4 through -1.
40830134|NCT01768156|OTHER|Experimental arm|"Serum samples are collected:~* at time of diagnosis of recurrence (before 1st chemotherapy)~* during each cycle of chemotherapy~* after the end of chemotherapy~* every 3 month until treatment failure (3-6 samples)~* stop at the progression or after 18 months post chemotherapy"
41348913|NCT06097975|PROCEDURE|Neurosurgery and intracavitary injection nivolumab and ipililumab|The neo-adjuvant therapy will be followed by a maximal safe surgery resection of the glioblastoma. Immunotherapy (nivolumab + ipililumab) will be injected into the brain tissue, followed by insertion of an Ommaya reservoir
41348914|NCT06097975|DRUG|Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary|Postoperatively, administration of immunotherapy will be continued, on day 15 postoperatively and every 2 weeks thereafter patients will receive nivolumab IV as well as ipililumab + nivolumab intracavitary.
41348915|NCT05085327|DRUG|ChapStick Lip Moisturizer Original|Sunscreen lip balm.
40830135|NCT05993273|PROCEDURE|Epidural|The epidural catheter is placed while the patient is awake, before the induction of general anesthesia. The intervertebral spaces used for catheter insertion are alternatively T4-T5, T5-6 or T6-T7. After locating the epidural space through the technique of the loss of resistance, a catheter is introduced for about 5 cm and left in place for the administration of drugs into the epidural space. Once the correct functioning of the epidural catheter has been verified with a negative test for cerebrospinal fluid aspiration and a negative bolus test for the onset of signs and symptoms from intrathecal infusion, the catheter is used intraoperatively for administration of local anesthetics in refracted boluses (Lidocaine and Ropivacaine ) at anesthetic dosage and postoperatively for continuous infusion of Ropivacaine 0.15% at 5 mL/h.
40830136|NCT05993273|PROCEDURE|ESP block|Erector spinae plane (ESP) block is performed after induction of general anesthesia, with the patient in a lateral decubitus position. With the aid of the ultrasound guide with linear probe, the transverse process of T5 ipsilateral to the site of the operation is identified. With the in-plane technique, the lower fascia of the ESP muscle is hydrodissected through the administration of Ropivacaine 0.5% 3 mg/Kg lean body weight. Subsequently, a catheter is introduced and left in place for continuous postoperative infusion of Ropivacaine 0.2% at 12 mL/h.
40830137|NCT05993273|PROCEDURE|Cryoanalgesia|Cryoanalgesia is performed after the induction of general anesthesia, single lung ventilation and after performing the first thoracoscopic surgical access. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access. The active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8 and kept resting for 4 ½ minutes on each nerve at a temperature of -70°C, under direct thoracoscopic vision, generating an interruption of the sensory functions.
40830138|NCT05579249|DRUG|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
40830139|NCT05579249|DRUG|Orlistat|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
40830140|NCT05579249|DRUG|Phentermine/Topiramate|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
40830141|NCT05579249|DRUG|Naltrexone/Bupropion|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
40830142|NCT05579249|DRUG|Liraglutide|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
40830143|NCT03745183|OTHER|Senna alata leaf decoction|"Preparation of the akapulko decoction~1. Remove the leaflets from the rachis of a mature leaf.~2. Wash the mature leaflets thoroughly to remove dust, dirt and debris.~3. In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~4. Cook the leaves and bring to a rolling boil.~5. When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~6. Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~7. Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko."
40830144|NCT03244319|DRUG|Edoxaban|Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight \<60kg or concomitant use of certain P-glycoprotein inhibitors).
41019719|NCT03318614|DIETARY_SUPPLEMENT|Probiotics M-63|B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
41019720|NCT03318614|OTHER|Control group|No probiotic intervention was given to the control group for three months.
41019721|NCT02104089|DEVICE|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
41157813|NCT00449202|DRUG|oleoyl-estrone (MP 101)|
41157814|NCT02078778|DEVICE|CPAP|3 months of CPAP treatment
41348916|NCT05085327|DRUG|ChapStick Lip Moisturizer Mint|Sunscreen lip balm.
41348917|NCT05085327|DRUG|ChapStick Lip Moisturizer Black Cherry|Sunscreen lip balm.
41348918|NCT05085327|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
41491621|NCT00688376|DRUG|Donepezil hydrochloride|"During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.~During the Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
41491622|NCT00688376|DRUG|Placebo|"During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
40830145|NCT03244319|DRUG|Warfarin|All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
40830146|NCT03244319|DRUG|parenteral anti-coagulant (UFH)|parenteral anti-coagulant (UFH)
40830147|NCT02822131|DIETARY_SUPPLEMENT|sodium phosphate|
40830148|NCT02822131|DRUG|sevelamer, sodium bicarbonate, sodium chloride|
40830149|NCT00100230|DRUG|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
40830150|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)
40830151|NCT06138925|OTHER|Analysis of running|analysis of running on flat ground at different speeds (comfortable and fast)
40830152|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).
40830153|NCT02443493|DEVICE|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
40830154|NCT02443493|DEVICE|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
40830155|NCT02443493|RADIATION|radiotherapy|
40830156|NCT01431937|DRUG|GSK2018682|Active Drug
40830157|NCT01431937|DRUG|Placebo|Placebo
40830158|NCT01388751|PROCEDURE|night splinting|splint finger at night for 4 weeks
41157815|NCT05882344|PROCEDURE|Device Implantation- Boston Scientific, VERCISE GENUS™ system|Participants will be implanted with DBS leads bilaterally, targeting the Nucleus Basalis of Meynert. The study team will record Local Field Potentials with and without stimulation, intraoperatively. These results will help the team determine at the end of the study whether LFP desynchronization (decrease in 5-15 Hz power), or other physiological signature, can be used to predict the location that provides the most effective intervention. Finally, the team will also ascertain the safety of the procedure and NB stimulation itself.
41157816|NCT05882344|DEVICE|DBS Stimulation - Boston Scientific, VERCISE GENUS™ system|Daily intermittent stimulation (60 Hz x 20s/min)
41157817|NCT00375778|DRUG|memantine (drug)|
41157818|NCT00877188|OTHER|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
41348919|NCT00216086|DRUG|Capecitabine|"Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~\*For calculated creatinine clearance of 30-50 mL/min or patients \> 70 years old, capecitabine starting dose is 825 mg/m2 po bid"
41348920|NCT00216086|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV, day 1
41491623|NCT05433727|DIAGNOSTIC_TEST|videodermoscopy, lesional capillaroscopy|videodermoscopy and lesional capillaroscopy will be performed under different magnification levels to the skin lesions and data will be recorded.
41491624|NCT02539862|OTHER|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
40830159|NCT01971268|DEVICE|Dental Implant|place dental implants according to manufacturer guidelines
41019722|NCT01136824|OTHER|Questionnaires|"Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic \& health Trait anxiety Quality of life Nausea Expectations Anxiety \& total mood disturbance Nausea \& vomiting Multiple symptoms"
41019723|NCT03779841|DRUG|AGN-151607|Injections were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
41157819|NCT02982096|DEVICE|Cellutome Device|Use of FDA approved Cellutome treatment on burn wounds
41157820|NCT02982096|OTHER|Standard of Care|Acellular burn wound management
41157821|NCT03184519|DIAGNOSTIC_TEST|Pregnancy test|Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
41348921|NCT00216086|PROCEDURE|EUS|biopsy per EUS
41348922|NCT00216086|DRUG|Neoadjuvant Chemotherapy|"* Irinotecan 200 mg/m2 IV, day 1~* Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles"
41348923|NCT00216086|PROCEDURE|Preoperative Radiation|Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
41348924|NCT00216086|PROCEDURE|Surgery|Surgery within 8 weeks following chemoradiotherapy
41348925|NCT00216086|PROCEDURE|Adjuvant Chemotherapy|Adjuvant chemotherapy at investigator's discretion
40830160|NCT01971268|DEVICE|Platform-Switch Dental Implant|Place Dental Implant with an abutment narrower than the implant platform
40830161|NCT01971268|DEVICE|Platform-Matched dental implant|Place Dental Implant with abutment with same size as the platform
40830162|NCT03356977|DRUG|Crisaborole ointment 2%|Applied BID
40830163|NCT04798742|PROCEDURE|Gluteus maximus transfer|Gait analysis study of 15 patients with gluteus medius disruption
40830164|NCT02646839|DEVICE|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
40830165|NCT02572232|DEVICE|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
40830166|NCT01903395|BEHAVIORAL|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
40830167|NCT01881022|BEHAVIORAL|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
40830168|NCT01533090|DRUG|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
41019724|NCT03779841|DRUG|Placebo|Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
41348926|NCT02194452|RADIATION|gallium Ga 68-edotreotide|Undergo gallium Ga 68-edotreotide PET/CT
41491625|NCT02539862|OTHER|psychoeducation|the psychoeducation is delivered by a doctor
41491626|NCT03599492|DIAGNOSTIC_TEST|SMART Pill Pre-TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
40830169|NCT01533090|DRUG|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
40830170|NCT04008121|COMBINATION_PRODUCT|Fluorescein sodium and Zeiss FF450 fundus camera|Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
40830171|NCT04008121|COMBINATION_PRODUCT|MB-102 and Zeiss FF450 fundus camera|MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
40830172|NCT04008121|COMBINATION_PRODUCT|Fluorescein sodium and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
40830173|NCT04008121|COMBINATION_PRODUCT|MB-102 and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
40830174|NCT00571636|DRUG|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is \> 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
40830175|NCT00571636|DRUG|5% glucose solution|ev continuous infusion
40830176|NCT05845944|OTHER|Video-supported education group|Providing training on nutrition with a nasogastric tube in pediatric patients with a video-supported education method
40830177|NCT01004016|DRUG|KPS-0373|
40830178|NCT01004016|DRUG|Placebo|
41157822|NCT05004805|DRUG|Methylene Blue|MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.
41157823|NCT05004805|DRUG|Saline nasal spray|Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
41157824|NCT03963583|BEHAVIORAL|HEROIC|"The HEROIC intervention will include individualized, nurse-led sessions focused on;~1. a whole-person assessment including preventive health behaviors, personal goals, and purpose in life~2. discussion of caregiving in the context of the caregiver's identified 'purpose' which supports meaning-making and provides rationale for goal-setting~3. co-development of a plan to address caregiver goals to improve preventive health behaviors and/or reduce caregiver burden~4. 'walking meetings' to model the importance of exercise while discussing incremental action plans to help caregivers achieve goals."
41157825|NCT06647238|OTHER|Pharmacist Intervention in lipid therapy|Pharmacist intervention may include but is not limited to prescribing (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, etc.), patient education, and medication access.
41157826|NCT04176926|DIAGNOSTIC_TEST|Electrocardiogram|Diagnostic Test: Simultaneous assessment of heart rhythm by 12-lead ECG and wearable device characterization of heart rhythm.
41157827|NCT03369652|BEHAVIORAL|Medication review|Conducted by the pharmacist and discussed with hospital physician
41157828|NCT02650934|PROCEDURE|Percutanous coronary intervention|
41157829|NCT03022734|DRUG|chemotherapy|cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
41491627|NCT03599492|DIAGNOSTIC_TEST|SMART Pill Post TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
41491628|NCT03011138|PROCEDURE|Gait velocity|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.
41491629|NCT04780282|OTHER|Scapular Stabilization Group|Participants will apply the 5 exercises given.
41491630|NCT05136300|BEHAVIORAL|Pulmonary rehabilitation|"Patients in the intervention group will receive physical therapy, scheduled pain monitoring and coaching by a social worker.~The intensity of the rehabilitation training program will be determined separately for each patient by a steepramp and 1-repetition test within 3 weeks post-operative. The intervention group will be trained and educated in 2 sessions of 2 hours per week, for a period of 3 months."
41491631|NCT01080443|DRUG|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
41491632|NCT05291065|BEHAVIORAL|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
40830179|NCT00330928|DEVICE|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
41348927|NCT02194452|PROCEDURE|positron emission tomography|Undergo gallium Ga 68-edotreotide PET/CT
41348928|NCT02194452|PROCEDURE|computed tomography|Undergo gallium Ga 68-edotreotide PET/CT
41348929|NCT02194452|OTHER|laboratory biomarker analysis|Correlative studies
41348930|NCT03639688|PROCEDURE|Threading on the left lip commissure|Threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
41348931|NCT03639688|PROCEDURE|Threading on the right lip commmissure|Threading of the endotracheal tube over the fiberoptic bronchoscope from the right lip commissure
40830180|NCT00330928|DEVICE|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
40830181|NCT04355858|DRUG|SHR7390|MEK1/2 inhibitor
40830182|NCT04355858|DRUG|Famitinib|Multi-target tyrosine kinase inhibitor
41491633|NCT05291065|BEHAVIORAL|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
41491634|NCT05291065|BEHAVIORAL|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
41491635|NCT04809883|DIAGNOSTIC_TEST|Endoflip measurement of gastric and pyloric function|Endoflip device to measure gastric and pyloric functions
40830183|NCT04355858|DRUG|SHR3162|PARP inhibitor
40830184|NCT04355858|DRUG|Pyrotinib|HER1 / HER2 receptor tyrosine kinase inhibitor
40830185|NCT04355858|DRUG|Capecitabine|In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.
40830186|NCT04355858|DRUG|SHR1210|PD-1 antibody
40830187|NCT04355858|DRUG|Everolimus|mTOR inhibitor
40830188|NCT04355858|DRUG|Nab paclitaxel|Albumin bound paclitaxel
40830189|NCT04355858|DRUG|SHR2554|EZH2 inhibitor
40830190|NCT04355858|DRUG|SHR3680|AR inhibitor
40830191|NCT04355858|DRUG|SHR6390|CDK4/6 inhibitor
40830192|NCT04355858|DRUG|SHR1701|anti-PD-L1/TGF-βRII bifunctional fusion protein
40830193|NCT04355858|DRUG|SERD|Fulvestrant
40830194|NCT04355858|DRUG|AI|aromatase inhibitor
40830195|NCT04355858|DRUG|VEGFi|Bevacizumab
40830196|NCT01646619|DRUG|Magnesium Sulphate|"10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%."
40830197|NCT01646619|DRUG|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
40830198|NCT00005632|BIOLOGICAL|MUC1-KLH vaccine/QS21|
40830199|NCT00334360|DRUG|dexmedetomidine|Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
41157830|NCT03022734|RADIATION|radiotherapy|After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
41348932|NCT00989664|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
41348933|NCT01551628|DRUG|Recombinant human arginase 1 Peg5000|Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
41348934|NCT03553264|DEVICE|Virtual Reality Rehabilitation|Track Speed Racing 3D game will run with HMD 'Revelation' 3D VR Headset and each HMD group patient will be instructed to perform the game protocol uninterruptedly for 20min/day, while sitting on a chair or sofa.
40830200|NCT00334360|DRUG|buspirone|Buspirone, 60 mg orally, will be given during controlled hypothermia.
40830201|NCT00334360|DRUG|Bus and Dex|the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
40830202|NCT00334360|DRUG|Control|No drugs given during controlled hypothermia
40830203|NCT05455580|BEHAVIORAL|Nurses Taking On Readiness Measures (N-TORM)|The intervention will begin with instructing the participant to complete the Family Disaster Plan booklet. The principal investigator will talk about the different sections of the booklet and instruct the participants how to fill out their emergency plans. Participants will write their medical history, medications, physician, next of kin, pharmacy contact information, evacuation plan information, family communication plan, and insurance policy numbers and contact information. The booklet includes household emergency preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. The participants will be provided with a disaster supply kit after successful completion of the booklet. The disaster supply kit is part of the intervention and is not considered compensation.
40830204|NCT06051747|PROCEDURE|Three-dimensional patient-specific bioprinting trachea implantation|The intervention entails the creation of a 3D cell-printed tracheal organ, achieved through the fusion of biopolymer materials and the bioprinting (3D cell printing) technique. This process involves distribution of nasal cavity stem cells (hNTSCs) and nasal septum cartilage cells (hNCs) within hydrogel matrices, culminating in the formation of a personalized tracheal structure.
40830205|NCT06455410|DRUG|GP|gemcitabine + cisplatin
40830206|NCT06455410|DRUG|Adebrelimab|a PD-L1 inhibitor
40830207|NCT06455410|DRUG|concurrent chemoradiotherapy (CCRT)|concurrent chemoradiotherapy (CCRT)
41491636|NCT00500136|PROCEDURE|mortality salience|
41491637|NCT01423656|DRUG|LEO 29102|
40830208|NCT06522438|COMBINATION_PRODUCT|Hyaluronic Acid (HA) and Octenidine gel|A thermosensitive gel with Hyaluronic Acid (HA) and Octenidine (Pocket-X®, Geistlich, Wolhusen, Switzerland) will be applied in the periodontal pockets ≥5mm immediately after the subgingival PMPR, by means of a pre-filled syringe bearing a thin plastic tip and following manufacturer's instructions.
40830209|NCT06522438|PROCEDURE|Non-surgical periodontal treatment (NSPT)|Full mouth supragingival professional mechanical plaque removal (PMPR) and subgingival PMPR at sites with PPD ≥4mm will be performed with the aid of manual and power-driven instruments under local anaesthesia.
40830210|NCT06299722|OTHER|STEEL|Relatively heavy strength training
41491638|NCT01423656|DRUG|Placebo|Placebo Comparator: LEO 29102 vehicle
41491639|NCT04958317|OTHER|Early exercise|Participants will exercise for 30 minutes prior to an evening meal.
40830211|NCT06299722|OTHER|Circuit training|Circuit training
40830212|NCT00320255|DRUG|Apixaban|Oral tablets administered once daily in 5-, 10-, or 20-mg dose
40830213|NCT00320255|DRUG|Placebo|Oral tablets administered once daily
40830214|NCT01778374|OTHER|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
40830215|NCT01778374|OTHER|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
41157831|NCT05562583|BEHAVIORAL|SAGE LEAF|"SAGE LEAF covers 8 skills and each skill has related home-practice activities that unlock every week. Each week will consist of 1-2 days of didactic material and 5-6 days of real-life home practice. Participants can access the skills at their own leisure and as often as they'd like within that week. Participants cannot skip modules with didactic material and can only progress to the next lesson if they have completed the current one. However, participants can return to old lessons or exercises if they choose to do so at a later time."
41157832|NCT02704026|OTHER|Assesment of nutritional status and body composition|At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
41157833|NCT03709485|OTHER|rectal swab for microbial culture.|Rectal swab and culture.
41491640|NCT04958317|OTHER|Late exercise|Participants will exercise for 30 minutes after an evening meal.
41491641|NCT00399880|BEHAVIORAL|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
41491642|NCT03449550|OTHER|Home Respiratory Polygraphy (HRP)|Randomizing to start with home respiratory polygraphy
41491643|NCT03449550|OTHER|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
40830216|NCT03994016|BEHAVIORAL|WiseGuyz|"The WiseGuyz program was developed by the Centre for Sexuality (Calgary, AB), and aims to reduce male-perpetrated adolescent dating violence, improve mental and sexual health, and support youth to build healthier, more inclusive relationships in their peer groups, schools and communities, by helping participants identify and deconstruct gender role norms.~WiseGuyz is offered during instructional time by community-based facilitators from the Centre for Sexuality. WiseGuyz is comprised of 20 sessions across four modules. These sessions typically take the full school year (September-May) to implement."
40830217|NCT01962987|DRUG|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
40830218|NCT01962987|OTHER|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
40830219|NCT02857192|BIOLOGICAL|Blood samples|
41019725|NCT03274479|DRUG|PBF-1129|PBF-1129 once a day by oral administration
41019726|NCT06523270|RADIATION|Computed Tomography (CT) using Photon Counting CT scanner (Neaotom Alpha, Siemens) and Magnetic Resonance (MRI)|"All adult (≥18 y.o) subjects (until 50000 individuals) presenting to the U.O of Radiologia DiMer Advanced Imaging for Personalized Medicine to be submitted to imaging study on advanced scanner"
41019727|NCT02572271|PROCEDURE|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
41019728|NCT02572271|PROCEDURE|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
40830220|NCT04609930|DRUG|Anti-PD-1 or anti-PD-L1|Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.
41019729|NCT05775198|BIOLOGICAL|PBMC immunomodulated with IFNt|Autologous peripheral blood mononuclear cells (PBMC) isolated using a standard protocol will be cultured in the presence of interferon tau (IFNt) for 24 hours at 37 ˚C and administered in the uterine cavity of patients 1 day prior to embryo transfer.
41019730|NCT04034589|DRUG|Pyrotinib combined with fulvestrant|Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
41019731|NCT06573177|OTHER|Referral to the gender identity service.|Referral to the national gender identity service consisting of the Sexological Clinic, Child and Adolescent Mental Health Center, and Department of Growth and Reproduction in the Capital Region of Denmark.
41019732|NCT03941093|DRUG|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX|"Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
41019733|NCT03941093|DRUG|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX|"Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
41019734|NCT03403634|DRUG|Celecoxib|Given PO
41019735|NCT03403634|OTHER|Laboratory Biomarker Analysis|Correlative studies
41019736|NCT03403634|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
41019737|NCT03403634|DRUG|Rintatolimod|Given IV
41019738|NCT06116253|DEVICE|Magnetic Resonance Imaging (MRI) Scan|Participants will undergo a 1-hour research MRI scan.
41019739|NCT06116253|DRUG|Tc-99m Pentetate|Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
41019740|NCT06515548|DRUG|Vitamin D3 mouth wash|topical vitamin D oral mouth wash as every 10ml of the solution contains 3000 IU
41019741|NCT01581346|OTHER|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
41491644|NCT03449550|OTHER|Home Respiratory Polygraphy (HRP)|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)
41491645|NCT03449550|OTHER|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
40830221|NCT05255783|DEVICE|subcutaneous continuous glucose sensor|Dexcom G6 continuous glucose monitoring system
40830222|NCT05622435|DEVICE|T10070, Plastic tube with a roll-on applicator filled with an ointment|6 times per day on both (upper and lower) eyelids of right eye during 7 to 9 days.
41019742|NCT04741659|DEVICE|Ventimask|The patients will be asked to breathe spontaneously using their actual low oxygen flow
41348935|NCT03553264|OTHER|Vestibular Rehabilitation|The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
41348936|NCT04864184|BEHAVIORAL|Normal physiologic rate breathing|2-minute breathing exercises will be completed every 15 minutes.
41019743|NCT04741659|DEVICE|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe using high flow nasal cannula (HFNC). Air flow will set up to 60 l/m, temperature according to patient's comfort and FiO2 in order to obtain SpO2 values \>/= 92%
41019744|NCT04741659|DEVICE|Helmet CPAP|The patients will be asked to breathe with Helmet. CPAP will set at 10 cmH2O and FiO2 in order to obtain SpO2 values \>/= 92%
41019745|NCT04741659|DEVICE|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
41019746|NCT02537080|DRUG|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
41019747|NCT02537080|DRUG|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
41019748|NCT05425810|DEVICE|Apply ENABLE sensing pad|The developed ENABLE system is integrated into the standard prosthetic liner and measures the pressure distribution during locomotion. Using the ENABLE system may lead temporary increase in the temperature inside the prosthetic socket and it is expected that the total exposition during the experimental procedure will be less than 10 min.
41019749|NCT05425810|DEVICE|Insert small pads at pressure tolerant locations|To change the pressure distribution inside the socket, four fitting conditions are introduced by adding small pads at patella tendon (PT), lateral tibial crest (LTC), medial tibial crest (MTC), and popliteal fossa (PF) respectively. Including the no pads scenario, totally of five fitting conditions are simulated.
41019750|NCT06186388|DIAGNOSTIC_TEST|TEMPO iMOvifa|Screening test with 28 testing points
41019751|NCT00767000|DRUG|MK-0941|MK-0941 tablets three times daily
41491646|NCT03579966|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
41491647|NCT01916590|DRUG|Bupivicaine|After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
40830223|NCT02144987|BIOLOGICAL|Bone Marrow CD133+ Stem Cell Transplantation|"1. Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.~2. BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.~   The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.~3. CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization~4. Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients~5. Hysteroscopy will be performed 2-3 months after stem cell transplantation~6. Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation"
41019752|NCT00767000|DRUG|Comparator: Placebo|Matching placebo to MK-0941 three times daily
41019753|NCT00767000|BIOLOGICAL|Lantus|Lantus injection once daily
41019754|NCT00767000|DRUG|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
41019755|NCT04382326|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
41019756|NCT04382326|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
41157834|NCT01290783|DRUG|Irintoecan|"* Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks.~* 8 months of treatment."
41348937|NCT04864184|BEHAVIORAL|Slow breathing|2-minute breathing exercises will be completed every 15 minutes.
40830224|NCT03404804|DRUG|Amoxicillin|Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
41019757|NCT00970086|DRUG|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
41019758|NCT05226104|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated twice over the affected areas, once each month for a total of two months.
41019759|NCT04090814|DEVICE|HeatTens (HV-F311-E)|(1) 2\~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
41348938|NCT01758172|DRUG|6% hydroxyethyl starch 130/0.4|
41019760|NCT04336579|BEHAVIORAL|Diaphragmatic Breathing|Simple diaphragmatic breathing exercise
41019761|NCT03614013|OTHER|Immunotherapy responders/non-responders|paraffin samples will be collected retrospectively along with clinical data
41019762|NCT02379598|DIETARY_SUPPLEMENT|Aminoacid based formula|Formula based on aminoacid
41019763|NCT02379598|DIETARY_SUPPLEMENT|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
41019764|NCT03243331|DRUG|Gedatolisib|Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.
41019765|NCT03243331|DRUG|PTK7-ADC|PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
41348939|NCT01758172|DRUG|Albumin|
41491648|NCT01916590|DRUG|placebo|
41157835|NCT01290783|DRUG|HA-Irinotecan solution for Infusion|"* HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks~* 8 months of treatment."
41157836|NCT01724047|BEHAVIORAL|Playground Intervention|Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
41157837|NCT01724047|BEHAVIORAL|STAT Intervention|This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
41157838|NCT06072963|DRUG|Semaglutide|The medication is available in 3, 7, and 14-mg tablets for oral use. Participants will be instructed to start with an initiating dose of 3 mg once daily. If they do not experience adverse events (nausea, vomiting, and abdominal pain) then the dose will be titrated to 7 mg once daily after 30 days. Again, if the participant does not experience adverse events, the dose will be further titrated after 30 days to 14 mg once daily. This does will continue until the end of the study, at 12 months.
41157839|NCT06072963|DRUG|Intranasal insulin|The study will use the ViaNase; Kurve Technology intranasal device to administer insulin intra-nasally. This device has been used in other studies of persons with AD and has shown insulin penetration into the brain via CSF studies. Through sniffing, the medication crosses the blood-brain barrier (BBB) at the top of the nasal cavity. Participants will be instructed to press a switch that will turn on the device, engaging a pump that releases a nebulized stream of insulin through a nose piece into a nostril for 20 seconds (the device includes an electronic timer), after which the device switches off. The process is then repeated in the other nostril. The investigators decided on administration of 20IU of INI twice per day as the literature suggests this as the optimal dosage.
41157840|NCT06072963|OTHER|Semaglutide placebo|Rybelsus semaglutide - this medicine will simulate taking the pill Rybelsus /semaglutide once a day. A pill identical to the medicine pill will be given.
41157841|NCT06072963|OTHER|Intranasal insulin placebo|The placebo used in this study is saline. The investigators will administer saline, with exactly the same methods as the INI insulin (twice per day, 20 seconds each sniff, in each nostril.
41157842|NCT03170947|DEVICE|Custom Insoles|"Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. All this needs the assistance of a computer. From the digital image of a positive of the limb in foam the insole will be obtained.~Custom insoles make with direct adaptation technique (TAD) being of pvc resin. Once the resins are cut and with a temperature of 90º, they will be adapted to the foot (which will be protected with a sock) of the patient with the help of a vacuum. To this technique subtalar joint will be in a neutral position and metatarsal joints will be aligned."
41157843|NCT03170947|DEVICE|Standardized insoles|Standardized insoles were done by EVA material with shore of 18 and 180 kg/cm3 and manufactured, with an extension of 3/4. It was in contact with heel and plantar arch.
41157844|NCT03936075|BEHAVIORAL|the Guided Imagery and Music method|the method involves listening to the music while describing the experience to the therapist, any visual imagery that is evoked by the music, emotions, body sensations, thoughts or memories. after the music listening session, there is discussion upon making meaning of the experience and finding resources as potential coping skills
41157845|NCT03936075|BEHAVIORAL|standard care and verbal counselling|the participants receive their usual cancer treatment and two individual counselling sessions
41157846|NCT00372099|DRUG|Salmon calcitonin|nasal salmon calcitonin 200UI/day during 2 years
41157847|NCT00168805|DRUG|enoxaparin|40 mg once daily
41157848|NCT00168805|DRUG|dabigatran etexilate|150 mg once daily
41157849|NCT00168805|DRUG|dabigatran etexilate|220 mg once daily
41157850|NCT04645953|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3mg)
41157851|NCT04645953|COMBINATION_PRODUCT|1mg AZ010|Subject will receive a single inhaled dose (1mg)
41157852|NCT04645953|COMBINATION_PRODUCT|Staccato Placebo|Subject will receive a single inhaled dose (Staccato Placebo)
41348940|NCT06352502|DRUG|Furmonertinib|Patients treated with Furmonertinib mesilate tablets orally
41348941|NCT04027140|DEVICE|M/L Taper with Kinectiv Technology Stems and Necks|Patients that have been implanted with a M/L Taper with Kinectiv Technology Stem and/or neck to repair hip malfunction/disease.
41019766|NCT04003727|DEVICE|Mcgrath Mac Videolaryngoscope|Patient's laryngoscopy will be done using McGrath Mac video laryngoscope
41019767|NCT04978857|OTHER|autobiographic movie|viewing an autobiographic film through a virtual reality headset
41019768|NCT06573736|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 combines protein markers tPSA, fPSA, KLK2, PSP94 and GDF15, genetic markers and clinical data to estimate risk for clinically significant prostate cancer.
41019769|NCT00718172|PROCEDURE|Liver Biopsy|
41019770|NCT00718172|DRUG|Peginterferon &amp; Ribavirin for Hepatitis C|
41019771|NCT00718172|DRUG|Pre-treatment Ribavirin|
41019772|NCT06492304|BIOLOGICAL|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
41491649|NCT01501864|BEHAVIORAL|School Support Intervention|Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
40830225|NCT05988320|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
40830226|NCT01742572|BEHAVIORAL|Diet|Change in dietary intake
40830227|NCT01510184|DRUG|Zevalin|Zevalin administered intravenous infusion.
40830228|NCT01510184|DRUG|Y-90-Zevalin|Y-90-Zevalin administered by intravenous infusion.
40830229|NCT01510184|DRUG|Rituximab|Rituximab administered by intravenous infusion.
40830230|NCT01510184|DRUG|In-111 Zevalin|In-111-Zevalin administered by intravenously.
40830231|NCT04095689|DRUG|Docetaxel|Microtubule-targeting drug (inhibits microtubule depolymerization)
40830232|NCT04095689|DRUG|Pembrolizumab|Programmed cell death-1 (PD-1) inhibitor
40830233|NCT04095689|DRUG|IL-12 gene therapy|Adenoviral-mediated IL-12
40830234|NCT00453947|DEVICE|CPAP and Non Invasive Ventilation|
40830235|NCT05472077|DIAGNOSTIC_TEST|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop."
40830236|NCT02772796|DRUG|SENS-218|Oral Administration
40830237|NCT04583202|OTHER|Exposure to placebo|Patients are exposed to a placebo for 4h in the Alyatec EEC
40830238|NCT04583202|OTHER|Exposure to allergen|Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
40830239|NCT05471102|PROCEDURE|Study group: lower segment resection with ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection with ligation ((suturing)) of the anterior division of the internal iliac artery (4 cm distal to the bifurcation of the common iliac artery); in addition to the bilateral uterine artery ligation at 2 levels; bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision.
40830240|NCT05471102|PROCEDURE|Control group: lower segment resection without ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection without ligation of the anterior division of the internal iliac artery. (i.e., only bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision).
40830241|NCT01646203|BIOLOGICAL|IMC-TR1|Administered intravenously
40830242|NCT06329882|DRUG|Sitagliptin 100mg|Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes
40830243|NCT06329882|DRUG|Doxycyclin|Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.
40830244|NCT03308045|BIOLOGICAL|pEYS606|pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
41348942|NCT01027065|DRUG|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
41491650|NCT05012163|BEHAVIORAL|Reminder|Letter, short message service (SMS) text, phone, and/or email
40830245|NCT00997425|DEVICE|Door cover/Floor cover|"Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.~Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2 white duct tape placed at 2 intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door."
40830246|NCT06375642|DRUG|Adebrelimab|Adebrelimab, Surufatinib and HAIC
40830247|NCT02657564|DRUG|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
40830248|NCT00359567|DRUG|palonosetron|intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
40830249|NCT00359567|DRUG|granisetron hydrochloride|intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
40830250|NCT01986387|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
40830251|NCT04881851|DIETARY_SUPPLEMENT|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
40830252|NCT04881851|DIETARY_SUPPLEMENT|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
40830253|NCT04881851|DIETARY_SUPPLEMENT|Folic acid (placebo comparator)|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
41491651|NCT05012163|BEHAVIORAL|Financial incentive|Letter, SMS, phone, and/or email
41491652|NCT05012163|BEHAVIORAL|Lottery|Letter, SMS, phone, and/or email
40830254|NCT02138240|BEHAVIORAL|Social network intervention|The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
40830255|NCT01012206|BEHAVIORAL|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
40830256|NCT06113705|DIAGNOSTIC_TEST|18F-GE-180 PET|PET examination of glioblastoma using 18F-GE-180 PET radio-metabolic marker
40830257|NCT06113705|DIAGNOSTIC_TEST|Advanced MRI|MRI examination using advanced sequences to characterize tumor microstructure and function
40830258|NCT06113705|OTHER|Collection of hematopoietic stem cells|Hematopoietic stem cells will be collected by the aspiration of bone marrow during the surgical intervention for tumor resection
41157853|NCT01314014|DRUG|Imexon|Amplimexon will be administered daily on Days 1-5 of 21-day treatment cycles as an intravenous infusion over a time course of 60 minutes. Subjects will receive 17 cycles of therapy for a total of one year on treatment. The Amplimexon starting dose for each subject in this study is 1000 mg/m² on each treatment day. Dose may be reduced by 25% for toxicity; after 2 dose reductions, subjects must be withdrawn from treatment.
41157854|NCT06299956|OTHER|Supervised exercise therapy|Walking on a treadmill at increasing elevation and pace.
41157855|NCT02513810|DEVICE|BioFreedom with 1 month DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
40830259|NCT06113705|OTHER|Blood withdrawal|blood withdrawal for evaluation of plasma biomarkers of inflammation, circulating microvesicles, and RNA
40830260|NCT06113705|OTHER|Collection of Cancer Stem Cells|Glioblastoma stem cells (GSCs) will be isolated from the tumor
40830261|NCT02702531|DEVICE|FloShield Defogging and Cleaning System|
40830262|NCT03209076|PROCEDURE|Robotic|Robotic low anterior resection
40830263|NCT03209076|PROCEDURE|Laparoscopic|Laparoscopic low anterior resection
41157856|NCT02513810|DEVICE|BioMatrix or Ultimaster with 6 to 12 months DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
41157857|NCT04320199|DIETARY_SUPPLEMENT|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
41491653|NCT03963024|DRUG|"Conditioning treatment Treosulfan-TMI"|Treosulfan i.v.: 14 g/m²/d (day -6 to -4) Fludarabine i.v.: 30 mg/m²/d (day -6 to -2) Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2) Mabthera i.v.: 200/0\* mg/m2 (day -1) TMI: (10 Gy) 2 Gy bis in die (BID) (day -2 to -1) or TMI: (12 Gy) 2 Gy BID (day -3 to -1) or TMI: (14 Gy) 2 Gy BID (day -3 to -1)
41491654|NCT03963024|PROCEDURE|SCT|Stem Cell Transplant
41491655|NCT03963024|DRUG|GvHD prophylaxis|Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7) Mycofenolate mofetile: 10 mg/kg tid, (Maximum dose 720 mg/tid) (starting from day 0)
40830264|NCT05942378|DRUG|HRXG-K-1939|HRXG-K-1939
40830265|NCT05942378|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody
40830266|NCT00221624|DRUG|Peginterferon alfa-2a|
40830267|NCT00221624|DRUG|ribavirin|
40830268|NCT00221624|DRUG|amantadine|
40830269|NCT05315375|DEVICE|corpectomy|vertebral corpectomy using expandable cage
40830270|NCT00539617|DRUG|Erlotinib|Tarceva single agent therapy: 150 mg/day PO
41157858|NCT04320199|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks
41157859|NCT00760877|DRUG|Nilotinib|Supplied in 200 mg capsules
41491656|NCT00170794|DRUG|Everolimus (RAD001)|
40830271|NCT00539617|DRUG|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
41157860|NCT00760877|DRUG|Imatinib|Supplied in 100 mg and 400 mg capsules
40830272|NCT00539617|DRUG|Leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
40830273|NCT00539617|DRUG|Oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
40830274|NCT04178993|DRUG|Methamphetamine|In each arm, subjects will receive doses of methamphetamine.
40830275|NCT04178993|DRUG|Methylphenidate|In each arm, subjects will receive methylphenidate capsules.
40830276|NCT04178993|DRUG|Placebo oral capsule|In each arm, subjects will receive placebo capsules.
40830277|NCT04178993|DRUG|Duloxetine|Subjects will receive duloxetine capsules in the duloxetine arm.
40830278|NCT04007289|DRUG|Apixaban|Administration of Apixaban ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography, Biological samples collections to identify predictors of thrombosis and liver related events
41157861|NCT04369300|BEHAVIORAL|Registery Data Collection|Observational Data Collection
41157862|NCT06115642|DRUG|HLX43|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
41157863|NCT01151878|DIETARY_SUPPLEMENT|Glucomannan|1.26 g per sachet; 2 sachets per day for 4 weeks.
41157864|NCT01151878|DIETARY_SUPPLEMENT|maltodextrin|prepared in sachets (1.3g); 2 sachets per day for 4 weeks
41157865|NCT02084355|DRUG|oral oxycodone|
41491657|NCT04366427|COMBINATION_PRODUCT|L-HBO|as previously described.
41491658|NCT04366427|COMBINATION_PRODUCT|HBO|as previously described.
41491659|NCT04366427|COMBINATION_PRODUCT|30% O2|as previously described
41491660|NCT04366427|COMBINATION_PRODUCT|50% O2|as previously described
41491661|NCT03487952|OTHER|Questionnaire Administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.
41491662|NCT06317090|PROCEDURE|guided bone regeneration|a non-resorbable membrane was used as a space maintainer, filled with a particulated bone graft.
40830279|NCT04007289|DRUG|Placebo|Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,
41491663|NCT01830218|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
40830280|NCT05536856|DRUG|a new effervescent mixture 5-florouracil formula|30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
40830281|NCT05536856|DRUG|5-Fluorouracil plain powder|30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
40830282|NCT01786460|OTHER|Blood draw at Days 0, 7, 14, and 21|
40830283|NCT01649544|DEVICE|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
40830284|NCT01649544|DRUG|Amiodarone|
41491664|NCT03583632|OTHER|visual acuity testing|testing of visual ycuity by ETDRS charts
41491665|NCT03583632|DEVICE|optical coherence tomography|optical coherence tomography generates sectional slides of the retinal tomography with light
40830285|NCT04698135|OTHER|Biological samples collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
40830286|NCT04698135|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
40830287|NCT04698135|OTHER|Medical/laboratory examinations|Blood pressure measurement, abdominal and thoracic physical examination, body composition through bioimpedance analysis and metabolic, cardiovascular and respiratory variables; OGTT 75gr for blood glucose and insulin at times 0, 30, 60, 90 and 120', and a nocturnal oximetry and subsequently, if necessary, overnight polysomnography for the diagnosis of obstructive sleep
41019773|NCT05770544|DRUG|Entrectinib|"Adult and paediatric participants with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric participants with BSA \<1.51 m\^2 will receive entrectinib at a dose of 100 mg (BSA=0.43-0.50 m\^2) or 200 mg (BSA=0.51-0.80m\^2) or 300 mg (BSA=0.81-1.10 m\^2) or 400 mg (BSA=1.11-1.50 m\^2).~Each cycle of treatment will consist of 28 days and participants may continue until disease progression, unacceptable toxicity or withdrawal of consent."
41491666|NCT03961048|DRUG|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally|Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.
41019774|NCT03704545|OTHER|Pharmaceutical consultation at the hospital|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
41491667|NCT03961048|DRUG|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally|Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
41491668|NCT01853631|GENETIC|Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells|"Three dose levels will be evaluated.~Group 1: CD19.CAR/28137ζ at 1×10\^6 cells/m\^2 and CD19.CAR/28ζ at 1×10\^6 cells/m\^2~Group 2: CD19.CAR/28137ζ at 5×10\^6 cells/m\^2 and CD19.CAR/28ζ at 5×10\^6 cells/m\^2~Group 3: CD19.CAR/28137ζ at 2×10\^7 cells/m\^2 and CD19.CAR/28ζ at 2×10\^7 cells/m\^2"
41491669|NCT01853631|GENETIC|Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells|The primary goal of the expanded cohort is to further study the safety profiles of CAR-T cells in each of the disease settings, both with or without lymphodepleting chemotherapy given before CAR-T cell infusion.
41491670|NCT02808689|BEHAVIORAL|Lifestyle Factors|Will look at nutrition and exercise that influence long-term health and chronic diseases.
41491671|NCT02808689|OTHER|Customized use of Dietary Supplements|Reduce ongoing biologic imbalances from deficiencies in dietary oxidants/ antioxidants via vitamin supplementation. Approach is customized based on results for laboratory testing.
41491672|NCT02808689|OTHER|Currently Accepted Asthma Care Guidelines|Use of asthma care guidelines set forth by the National Institutes of Health/National Heart, Lung and Blood Institute (NIH/NHLBI) and Global Initiative for Asthma
41491673|NCT01303757|BEHAVIORAL|Dietary counselling|
41491674|NCT00022542|DRUG|ixabepilone|Given IV
41491675|NCT00315731|BIOLOGICAL|Follicular Lymphoma|For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
41491676|NCT02565173|DRUG|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
41491677|NCT02565173|DRUG|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
41491678|NCT02565173|DRUG|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
40830288|NCT00964847|BEHAVIORAL|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
41019775|NCT03704545|OTHER|Pharmaceutical consultation at the pharmacy|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
41019776|NCT03704545|OTHER|Follow-up pharmaceutical consultation at the pharmacy|During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
41019777|NCT00812292|DRUG|TMC278|
41157866|NCT02084355|DRUG|oral hydromorphone|
41157867|NCT02084355|DRUG|fentanyl patch|
41491679|NCT02565173|DRUG|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
40830289|NCT00964847|BEHAVIORAL|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
41491680|NCT02565173|DRUG|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
40830290|NCT05563116|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium (CAC) score (part of routine workup)|Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
40830291|NCT03972319|DIETARY_SUPPLEMENT|2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day|4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
40830292|NCT05453162|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.
40830293|NCT00882908|DRUG|TMC435|TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
40830294|NCT00882908|DRUG|Ribavirin (R)|Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
40830295|NCT00882908|DRUG|PegIFNα-2a (P)|PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
40830296|NCT00882908|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
40830297|NCT05066945|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
40830298|NCT00670176|BEHAVIORAL|REHAB (Pre- and postoperative cardiopulmonary rehabilitation)|
41019778|NCT06083220|BEHAVIORAL|Smart Start - School Readiness Program|Participants will complete 64 hours of intervention focused on goal directed school readiness. Each of the five domains will be addressed in each session, and the activities will be tailored to support the individual goals of the participant using a goal-directed training approach. A goal-directed training approach includes the child, caregiver, and researcher collaboratively setting goals that are meaningful to the child and their family. Intervention strategies for goal attainment will include both remediation of skills (i.e. learning to button a button) or the accommodation of skills (i.e. using Velcro instead of a button) depending on the child's goals and current ability. The primary focus of the intervention will be goal attainment related to school readiness.
41348943|NCT01027065|DRUG|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
41491681|NCT03983083|BEHAVIORAL|Physical activity|Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
41491682|NCT05763108|DIAGNOSTIC_TEST|genetic test|COL1A1 or COL5A1 genetic test
41491683|NCT05763108|OTHER|Beighton joint laxity test|Based on Beighton scale.
41491684|NCT02093130|DIETARY_SUPPLEMENT|Pomegranate Juice|
41491685|NCT02093130|DIETARY_SUPPLEMENT|Placebo|
40830299|NCT05424263|DRUG|Calcium Acetate Oral Solution|Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.
40830300|NCT05424263|DRUG|Calcium Carbonate Oral Suspension|Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
40830301|NCT03873506|DRUG|transplantation of hUC-MSCs|Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
40830302|NCT05256797|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
40830303|NCT05256797|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
41019779|NCT03766321|BIOLOGICAL|Fecal microbiota transplantation|Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.
41019780|NCT03766321|BIOLOGICAL|Placebo|patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
41491686|NCT02571192|DRUG|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
41491687|NCT02571192|RADIATION|5.95 μCi RAD|
41491688|NCT02894437|OTHER|qualitative interviews|semi-structured interviews as a conceptual frame work
40830304|NCT02159118|DEVICE|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
40830305|NCT02159118|DEVICE|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
40830306|NCT02775942|BIOLOGICAL|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
40830307|NCT02775942|BIOLOGICAL|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
40830308|NCT02775942|BIOLOGICAL|IPOVAC, 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
40830309|NCT02775942|BIOLOGICAL|IPOVAC, 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
40830310|NCT06511297|DIAGNOSTIC_TEST|comprehensive metabolic phenotyping|The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
40830311|NCT00242333|DRUG|AD 237|
40830312|NCT02351687|DIETARY_SUPPLEMENT|Lipid Nutrient Supplement|
41348944|NCT02276690|BIOLOGICAL|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
40830313|NCT02351687|DRUG|Sulfadoxine-pyrimethamine|
41348945|NCT02276690|BIOLOGICAL|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
41348946|NCT06030154|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
41348947|NCT06030154|BEHAVIORAL|Amplification of Positivity Therapy|Amplification of Positivity Therapy
40830314|NCT02351687|DRUG|Albendazole|
40830315|NCT02351687|DRUG|Zinc|
40830316|NCT02351687|OTHER|Insecticide-treated bednet|
40830317|NCT01369082|DRUG|Maintenance Immunosuppressive Treatment|All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
41348948|NCT06030154|BEHAVIORAL|Surveys and Interviews|Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.
41348949|NCT04409340|DEVICE|Magnetic Resonance Viscoelastography|Magnetic Resonance Viscoelastography
41348950|NCT04409340|DEVICE|QUS|QUS
41348951|NCT00685828|DRUG|imatinib mesylate|By mouth
41491689|NCT00179816|DRUG|High-Dose Chemotherapy with Tandem PBSC Rescue.|Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
40830318|NCT03855202|BIOLOGICAL|CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
40830319|NCT03855202|BIOLOGICAL|PS+CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
40830320|NCT03855202|BIOLOGICAL|PS|PS,dose is 70mg/kg
40830321|NCT03855202|OTHER|Placeo|0.9% sodium chloride installation after 24 hours
40830322|NCT01341301|RADIATION|Total Body Irradiation|Undergo TBI
40830323|NCT01341301|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
40830324|NCT01341301|DRUG|Cyclophosphamide|Given IV
40830325|NCT01341301|DRUG|Tacrolimus|Given IV or PO
40830326|NCT01341301|DRUG|Mycophenolate mofetil|Given IV or PO
40830327|NCT01341301|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
40830328|NCT01341301|OTHER|Laboratory biomarker analysis|Correlative studies
40830329|NCT03722654|BEHAVIORAL|MTFS-I Installation|MTFS-I Installation will focus on introducing MTFS-I components including weekly training modules and mock video segments to be coded, as well as monthly feedback reports summarizing therapist self-reported FT and CBT implementation in active cases. Facilitation will also be included to review progress and provide regular support.
40830330|NCT01544452|PROCEDURE|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
40830331|NCT01544452|PROCEDURE|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
40830332|NCT03194191|DEVICE|Acupuncture needles|The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
41348952|NCT05102344|BEHAVIORAL|Behavioral Social Skills Training|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation.
41348953|NCT05102344|BEHAVIORAL|Animal Assisted Intervention|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation accompanied by trained therapy dogs
41348954|NCT04234399|DIAGNOSTIC_TEST|Fluciclovine PET/CT using a digital PET/CT|Fluciclovine is a radiotracer that will be used in conjunction with the high resolution digital Vereos PET/CT scanner.
41491690|NCT04863222|DEVICE|Biodentine|During a patients procedure, one tooth will receive Biodentine instead of MTA.
41491691|NCT04863222|BIOLOGICAL|mineral trioxide aggregate (MTA)|mineral trioxide aggregate (MTA)
41491692|NCT04901598|OTHER|Running anaerobic sprint test and aerobic test|subjects walk a mile with maximum steps and their heart rate will not exceed 180 beats per minute during the test and the execution time will not be less than 9 minutes (RAST test)
41491693|NCT04975009|BEHAVIORAL|Fear conditioning|Participants will learn to associate neutral stimuli with a mildly uncomfortable electrical stimulation to the wrist. The intensity of the electrical stimulus is calibrated prior to the start of the experiment to a level deemed highly annoying but not painful by the participant.
41491694|NCT05533762|DEVICE|arch insole and sham insole|children wear insoles on feet
41019781|NCT05059015|DIAGNOSTIC_TEST|CERVICAL HPV|A screening test with an HPV test is performed by a health professional plus cytology taking, if it reports positive, colposcopy and biopsy are taken, those with a CIN2 + report are directed to receive treatment.
41491695|NCT04295135|BEHAVIORAL|Chronic Pain OneSheet|The Chronic Pain OneSheet (OneSheet) is an EHR decision support tool that uses behavioral economics to increase adoption of chronic pain guideline recommendations. OneSheet works by aggregating and structuring information that is already collected, that PCPs often need while caring for patients with chronic pain conditions. By aggregating and structuring this information in a more convenient manner, the goal of OneSheet is to make the information that is important in clinical decision making more readily available, and to reduce the amount of time that PCPs need to spend locating this information.
41491696|NCT04259983|OTHER|Maximal exercise test|The maximal exercise test will be performed on an electronically braked bicycle ergometer.
41491697|NCT04259983|OTHER|Endothelial dysfunction assessment|Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.
41491698|NCT04259983|OTHER|Arterial stiffness assessment|Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.
41491699|NCT04188301|DRUG|IVM w/ ALB|Participants will be given a single dose of oral IVM (150 µg/kg) plus ALB (400 mg) (IVM/ALB)
41491700|NCT04188301|DRUG|Single dose of IDA|Participants will be given a single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
41491701|NCT04188301|DRUG|Three daily doses of IDA|Participants will be given one daily dose for 3 days of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
41491702|NCT05695677|PROCEDURE|Capacitive-Resistive Radiofrequency therapy of the neck muscles|Capacitive-Resistive Radiofrequency therapy of the neck muscles as a non-invasive technique for treating PDPH.
41491703|NCT00006395|DRUG|St. John's Wort|
41491704|NCT05837013|PROCEDURE|Spinal anesthesia (with nerve block)|Spinal Anesthesia and Nerve Block: No premedication will be applied. Spinal anesthesia will be administered to the patients in this group in the sitting position with a 27G Quincke needle (15 mg hyperbaric 0.5% bupivacaine) to be entered through the L2-L3 or L3-L4 interval. If hypotension develops, it will be corrected with a crystalloid infusion and ephedrine. These patients will be administered intravenous sedation with increasing doses of midazolam to provide adequate sedation. According to Hadzic, II and IH nerve block will be performed by applying 10 mL of 0.75% ropivacaine 2 cm above and 2 cm medial to the anterior superior iliac spine.
41491705|NCT05837013|PROCEDURE|General anesthesia (GA)|General anesthesia: No premedication will be applied. In the waiting room, 10 mL/kg of Ringer's lactate solution will be infused IV in 30 minutes. In Group I, 2-2.5 mg/kg propofol and 1 μg/kg fentanyl IV will be given for induction; 0.6 mg/kg rocuronium will then be used to provide the muscle relaxation needed for intubation. After intubation, the tidal volume will be set to 6-8 mL/kg and the respiratory frequency PetCO2 32-36 mmHg in volume-controlled ventilation (VCV) mode. Anesthesia will continue to be provided with sevoflurane (1.5%-2%), oxygen-air mixture (FiO 2 = 0.4) and repeated doses of rocuronium (0.015 mg/kg). At the end of the surgery, neostigmine (2-2.5 mg) and atropine (1 mg) will be given IV to antagonize the residual neuromuscular block.
41491706|NCT06387485|DEVICE|3D Printed Anatomic Model|Patient-specific 3D printed anatomic model for pre-surgical planning
41348955|NCT04581291|OTHER|Moderate Intensity Aerobic Exercises|Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).
41348956|NCT02334137|BEHAVIORAL|iPad app|"Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others."
41348957|NCT02334137|BEHAVIORAL|Educator sessions|A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
41348958|NCT02334137|BEHAVIORAL|Retinal photos|A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
41348959|NCT01138293|DEVICE|motion detection with a motion sensor|To asses physical activity and eating habits electronic health technology was used (Fraunhofer-Institute). The system consists in a motion sensor integrated in a mobile phone (DiaTrace). The system analyses kind, intensity and duration of physical activity and eating habits.
41348960|NCT03062670|OTHER|Retreat|Full day off-site training session
41348961|NCT03439722|OTHER|Polysomnography|Participants will be admitted for 1 night at the Danish Center of Sleep Medicine for polysomnography.
41348962|NCT02711410|DRUG|Clopidogrel|
41348963|NCT03506828|PROCEDURE|Surgical sympathectomy|thoracoscopic sympathectomy
41348964|NCT03506828|PROCEDURE|Radiofrequency ablation with phenol injection|All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
41348965|NCT02655263|DRUG|Somatropin|Somatropin infusion (Genotropin®)
41348966|NCT02655263|OTHER|Ketone bodies|ketone bodies infusion
41348967|NCT05686629|DRUG|Jaktinib hydrochloride tablets|2 doses per day, each containing two 50mg Jaktinib or placebo tablets
41348968|NCT01790763|DEVICE|Keramatrix|Dressing for second degree burn
41348969|NCT01790763|DEVICE|Mepilex|Dressing for second degree wound
41348970|NCT06322108|DRUG|Botensilimab + Balstilimab|Botensilimab is a fragment crystallizable (Fc)-engineered human immunoglobulin G1 (IgG1) monoclonal antibody that targets cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
41348971|NCT05357924|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
41491707|NCT06387485|DIAGNOSTIC_TEST|CT/MRI|Standard imaging type for bony tumors
41491708|NCT01687426|DRUG|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
41491709|NCT01687426|DRUG|Vehicle|1 drop in each eye daily four times a day for 14 days
41491710|NCT05396261|DEVICE|Film forming silicone gel (7-0940)|Anecdotal evidence suggests that genital conditions in women associated with vaginal atrophy improve with the use of film-forming silicone dressings.
41491711|NCT05973266|BEHAVIORAL|Mobile Application-Based Bowel Preparation Training|The contents of the training in the mobile application where the patients receive bowel preparation training before the procedure are; short videos, images and slides about colonoscopy, bowel preparation drugs, liquid-clear diet and foods recommendations.A mobile application-based training will be provided to guide patients, where user (patient) usage activities are monitored by the researcher, sending notifications or reminders to the patient in accordance with the colonoscopy procedure date.
41491712|NCT05739552|OTHER|Telerehabilitation program|Application of customised respiratory and/or motor rehabilitation exercises to be carried out directly at the patients' home after hospital discharge in order to evaluate its effects.
41491713|NCT04296058|OTHER|microvessel density|the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
41491714|NCT03123458|BIOLOGICAL|clonal fetal MSCs|
41491715|NCT00959361|BEHAVIORAL|pharmaceutical care|consultation with the pharmacists and usual care
41491716|NCT05600790|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
41491717|NCT00117208|DRUG|mannitol|400mg BD for 12 weeks
41491718|NCT00117208|DRUG|mannitol + pulmozyme|combination
41491719|NCT00117208|DRUG|Dornase alpha|2.5mg daily for 2 weeks
41491720|NCT01751763|DRUG|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator.
41491721|NCT01877226|DRUG|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
41348972|NCT05357924|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
41348973|NCT02233140|DEVICE|Extra-corporeal pulsed-activated therapy or shockwave therapy|
41491722|NCT06049459|DEVICE|Optical Correction|Optical correction (if needed)
41348974|NCT00388128|DRUG|Caffeine 6mg/kg|Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
41348975|NCT02268760|DRUG|BILN 2061 ZW single rising doses|
41348976|NCT02268760|DRUG|Placebo|
41348977|NCT02268760|DRUG|BILN 2061 ZW fixed dose|
41348978|NCT02268760|OTHER|Standardized breakfast|
41348979|NCT05435092|RADIATION|3D-reconstruction CT|Three dimensional CT (3D CT):Method of surface rendition of anatomy by means of a special computer software to capture 3D bone models used to improve the outcomes of Total Knee Arthroplasty (TKA).
41348980|NCT02935595|DRUG|Ketamine|Ketamine Hydrochloride Injection
41348981|NCT03517735|DEVICE|EasyTiva (algorithm is the property of Medsteer SAS)|Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.
41348982|NCT03517735|DRUG|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
41491723|NCT06049459|DEVICE|Therapeutic Dichoptic Virtual Reality Games|Virtual Reality Game play for amblyopia treatment
41491724|NCT03056157|BEHAVIORAL|Adaptive Disclosure for Moral Injury and Loss|AD-MIL is a manualized, 12-session individual psychotherapy designed to improve functioning and to reduce PTSD symptoms by facilitating Veterans doing corrective things in their life to heal and repair traumatic loss and moral injuries. The change agents are: (1) emotional-processing of traumatic loss and moral injuries and motivating a healing and action plan by writing therapeutic letters (e.g., to a lost unit member, to victims of personal transgressions, to people who transgressed); (2) skills training and behavioral contracting to improve functioning and targeting moral injury- and traumatic loss-related psychological and behavioral obstacles to positive and potentially habilitative engagements in occupational, relationship, and family roles; and (3) teaching self- and other-compassion and mindfulness. The goal is to redress the functional impact of moral emotions (anger, shame).
41348983|NCT03517735|DRUG|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
41348984|NCT01910142|DIETARY_SUPPLEMENT|vitamin K|A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
41348985|NCT01910142|DIETARY_SUPPLEMENT|calcium|
41019782|NCT05059015|DIAGNOSTIC_TEST|SELF SAMPLING HPV|A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.
41019783|NCT05771519|BEHAVIORAL|HIV disclosure intervention|This will be a biobehavioral intervention focused on helping men with HIV to disclose their HIV status to a personal confidant inclusive with specific focus on sexual partners.
41019784|NCT06531460|DIETARY_SUPPLEMENT|Fish oil enteral supplementation|Omega-3 (4.2 g), administered through an enteral feeding tube, three days before surgery
41019785|NCT06531460|DIETARY_SUPPLEMENT|Fish oil oral supplementation|Omega-3 (4.2 g), orally administered enriched nutritional formula, drinking at home three days before surgery
41019786|NCT06531460|DIETARY_SUPPLEMENT|Enteral nutrition without fish oil|Enteral formula without omega-3 administered through an enteral feeding tube, three days before surgery
41019787|NCT06531460|DIETARY_SUPPLEMENT|Oral nutritional supplement without fish oil|Oral nutritional supplement without omega-3 orally administered, drinking at home three days before surgery
41019788|NCT02738775|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
41019789|NCT02738775|DRUG|Placebo|
41019790|NCT06269328|OTHER|Total ıntravenous anesthesia with propofol and remifentanil for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia maintained with propofol iv 75-100 µg kg-1 min-1 and remifentanyl iv 0.05-0.2 µg kg-1 min-1 infusion.
41348986|NCT04488601|DRUG|Rapamycin|Rapamycin in 2 different dosage forms.
41348987|NCT04488601|DRUG|Placebo|Placebo capsules
41348988|NCT03663972|BEHAVIORAL|articulation therapy|children receive instruction in producing new sounds at the isolation, syllable and word level.
41348989|NCT03663972|BEHAVIORAL|phonologic treatment|children receive instruction in producing new sounds at the word level
41348990|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 1|Pharmaceutical form:liquid Route of administration: intramuscular
40830333|NCT05409859|OTHER|Manual therapies|Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
40830334|NCT04668924|PROCEDURE|Epi-on PiXL in high oxygen|After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for \< 45 Diopters (D) 7.2J/cm\^2 will be used; for 45-50D 10J/cm\^2 will be used; for \> 50D 15 J/cm\^2 will be used.
40830335|NCT05063266|OTHER|Deep Breathing Exercise|control groups received deep breathing exercise 6 days a week for two weeks. Deep breathing exercises includes diaphragmatic breathing and pursed lip breathing.
40830336|NCT05063266|OTHER|Inspiratory muscle Training|Treatment group received inspiratory muscle training 20 minutes 6 days a week for two weeks.IMT was done by using pressure threshold device.
40830337|NCT05014503|OTHER|Adaptive Therapeutic gaming|All children will be asked to use the adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
40830338|NCT05014503|OTHER|Non-adaptive Therapeutic gaming|All children will be asked to use the non-adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
40830339|NCT03723538|DRUG|Dexmedetomidine|patients undergoing tracheal resection and reconstruction surgery were enrolled in this prospective observational pilot study to evaluate dexmedetomidine-based sedation after tracheal surgery in an Intensive Care Unit (ICU). Patients remain electively intubated with an uncuffed nasal endotracheal tube, awake and exhibit spontaneous breathing The neck was maintained in flexion through chin-to-chest sutures. Infusion of dexmedetomidine was started from a dosage of 0.7 μg kg-1 h-1 followed by dose titration to the target level of the sedation Richmond Agitation Sedation Scale, (RASS) score -1/-2 using a dose range of 0.2-1.4 μg kg-1 h-1.
40830340|NCT04500236|OTHER|General anesthesia|Surgery under general anesthesia with the use of propofol
40830341|NCT04500236|OTHER|Hypno-analgesia|Surgery under Hypnosis session and analgesics
40830342|NCT00074373|OTHER|No intervention; observational|
40830343|NCT01579487|DEVICE|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
40830344|NCT00276094|DRUG|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
40830345|NCT00276094|DRUG|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
40830346|NCT00276094|DRUG|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
40830347|NCT00276094|DRUG|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
40830348|NCT02441140|PROCEDURE|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
41019791|NCT06269328|OTHER|Inhalation anesthesia with sevoflurane for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia was maintained with inhalation anesthetic (50% O2/Air with Sevoflurane 2% )
41019792|NCT01312467|DRUG|metformin hydrochloride|
41019793|NCT03246529|DRUG|BL-8040 1.25 mg/kg + G-CSF|Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
41019794|NCT03246529|DRUG|Placebo +G-CSF|Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
41019795|NCT03660956|BEHAVIORAL|Exercise|Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
41348991|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 2|Pharmaceutical form:liquid Route of administration: intramuscular
41348992|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 3|Pharmaceutical form:liquid Route of administration: intramuscular
41348993|NCT04398706|BIOLOGICAL|Varicella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
41348994|NCT04398706|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
41348995|NCT04398706|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Pharmaceutical form:liquid Route of administration: intramuscular
41348996|NCT04398706|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)|Pharmaceutical form:liquid Route of administration: intramuscular
40830349|NCT02441140|PROCEDURE|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
40830350|NCT02441140|PROCEDURE|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
40830351|NCT02441140|PROCEDURE|Blood collection|Intravenous blood collection will be drawn from an IV
40830352|NCT02441140|PROCEDURE|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
40830353|NCT05881720|DRUG|Sacubitril / Valsartan Oral Tablet|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
40830354|NCT05881720|DRUG|Valsartan 80 mg|group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
40830355|NCT06258057|OTHER|Not applicable / database analysis|Not applicable / database analysis
40830356|NCT00993499|DRUG|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
40830357|NCT00993499|DRUG|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
40830358|NCT05615194|DRUG|Dexmedetomidine|0.6 mcg/kg in infusion over 10 minutes
40830359|NCT05615194|DRUG|Placebo|Volume equivalent in infusion over 10 minutes
40830360|NCT04637919|BIOLOGICAL|IN-B001 EV71 A dose|Inactivated vaccine against EV71, three doses, 28 days interval
40830361|NCT04637919|BIOLOGICAL|IN-B001 CVA16 B dose|Inactivated vaccine against CVA16, three doses, 28 days interval
40830362|NCT04637919|BIOLOGICAL|IN-B001 Bivalent C dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
40830363|NCT04637919|BIOLOGICAL|Placebo|Placebo, three doses, 28 days interval
41348997|NCT04398706|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:liquid Route of administration: oral
41348998|NCT04398706|BIOLOGICAL|Hepatitis B Vaccine* [Recombinant] *as applicable|Pharmaceutical form:liquid Route of administration: intramuscular
41348999|NCT06101290|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
40830364|NCT00374894|DRUG|2,3-dimercaptosuccinic acid|
40830365|NCT04896203|PROCEDURE|rotational thromboelastometry|Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
40830366|NCT02192229|DRUG|50.000 IU vitamin D3 (Biodal 50,000 IU)|
40830367|NCT02192229|DRUG|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
40830368|NCT02421913|DRUG|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
40830369|NCT00044187|DRUG|Sibutramine|
40830370|NCT02358044|DRUG|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
40830371|NCT02358044|BIOLOGICAL|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
40830372|NCT02358044|DRUG|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
40830373|NCT02358044|DRUG|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
40830374|NCT01300819|OTHER|Placebo|"Placebo patches of 2, 4, 6 \& 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
40830375|NCT01300819|DRUG|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
40830376|NCT02827500|DRUG|ivabradine|Active Comparator: ivabradine
41019796|NCT03660956|BEHAVIORAL|Back counselling|Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
41019797|NCT00499369|DRUG|irinotecan hydrochloride|Given IV
41019798|NCT00499369|DRUG|leucovorin calcium|Given IV
41019799|NCT00499369|DRUG|fluorouracil|Given IV
41019800|NCT00499369|BIOLOGICAL|cetuximab|Given IV
41019801|NCT00499369|BIOLOGICAL|bevacizumab|Given IV
41019802|NCT05093452|BEHAVIORAL|Motivational Interviewing|Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a midwife. The midwife will have first received a standardized 3 days training session on the content and techniques of MI. The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.
41019803|NCT05093452|OTHER|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the midwife.
41349000|NCT04363723|OTHER|Pulmonary Rehabilitation|Patients performed a comprehensive pre-lung transplant inpatient pulmonary rehabilitation program for 4 to 5 weeks duration.
41349001|NCT02161614|DRUG|Estradiol valerate|
40830377|NCT02827500|OTHER|Usual Care|Placebo Comparator: usual care
40830378|NCT00024310|DIETARY_SUPPLEMENT|folic acid|
40830379|NCT00024310|DRUG|lometrexol|
41349002|NCT02161614|DRUG|Placebo|
41349003|NCT05480631|PROCEDURE|autograft|autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap
41349004|NCT05480631|PROCEDURE|autograft with addition of concenterated growth factor|the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.
41349005|NCT05480631|PROCEDURE|xenograft with concentrated growth factor|xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.
41491725|NCT03056157|BEHAVIORAL|Present Centered Therapy|Participants randomized to the PCT arm will receive 12 sessions of therapy focused on day-to-day functional problems with no focus on trauma or re-visiting past experiences
41491726|NCT04128020|DRUG|Nivolumab|Nivolumab
40830380|NCT00024310|DRUG|paclitaxel|
40830381|NCT03514680|BEHAVIORAL|CIPN Assessment and Management Algorithm|The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
40830382|NCT00902421|DRUG|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
40830383|NCT00902421|DRUG|Antimuscarinics|Antimuscarinics for 3 months
40830384|NCT03889236|OTHER|Fasting mimicking diet Prolon|5-day fasting mimicking diet
40830385|NCT03889236|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Food supplement
41349006|NCT03681873|DIAGNOSTIC_TEST|Extremely Low Dose CT|Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
41349007|NCT02936115|OTHER|TruSkin®|
41349008|NCT02936115|OTHER|Wound Cover|
41349009|NCT03621124|PROCEDURE|Resting Energy Expenditure|During each visit, the participant will be assessed in a resting state in a stable temperature controlled environment, and will undergo tests to find out how the body adjusts its metabolism to different temperatures.
41349010|NCT03621124|OTHER|Thermal Comfort Questionnaire|Patients will be given a questionnaire to assess their thermal response (whether they felt warmer or colder) during each study visit.
41349011|NCT01162967|DRUG|Benznidazole|Standard dosage
41349012|NCT01162967|DRUG|Posaconazole|
41349013|NCT06129006|PROCEDURE|hydrodilatation with steroid in group A versus hyalase in group B|"Hydrodilatation technique:~the ultrasound transducer will be placed on the posterior surface of the shoulder in the longitudinal plane to identify the posterior glenohumeral joint, bony glenoid, humeral head, and infraspinatus muscle.Then, after sterilizing the area to be injected, the needle will be advanced to the target point between the humeral head cartilage and the infraspinatus tendon using the ultrasound-guided in-plane technique.To ensure the injection into the glenohumeral joint, the Doppler mode will be used to confirm the widening of the space between the humeral cartilage and the innermost synovial line of the infraspinatus muscle by the injected solution."
41349014|NCT01446549|OTHER|High intensive antigravity locomotor exercise|High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
41349015|NCT01446549|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation implantation
41349016|NCT05723276|DRUG|Psilocybin|Psilocybin 25mg PO
41349017|NCT04458311|DRUG|Abiraterone Acetate|Supplied as 125 mg tablets
40830386|NCT03889236|DIETARY_SUPPLEMENT|Placebo|Placebo
40830387|NCT03205904|DIETARY_SUPPLEMENT|Diet|Nutrition booklet with guidelines on types of fats and glycemic index
40830388|NCT02897752|DEVICE|gait training with WA|Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
40830389|NCT02897752|OTHER|usual gait training|Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
41349018|NCT04458311|DRUG|Tildrakizumab|Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.
41491727|NCT04128020|DRUG|Azacitidine|Azacitidine
41491728|NCT06404892|PROCEDURE|Single-lung ventilation|Patients undergoing thoracic surgery and intraoperative single-lung ventilation.
41491729|NCT04856150|DRUG|Q-1802|Q-1802 will be administered intravenously.
41491730|NCT02286310|OTHER|Kinetic Chain Exercises|Exercises include kinetic chain segments.
41491731|NCT02286310|OTHER|Traditional Exercises|Stretching, strengthening exercises.
41491732|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
41349019|NCT01774838|DRUG|Prasugrel|3 months treatment
41491733|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
40830390|NCT03825692|DRUG|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
41491734|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
40830391|NCT03825692|DRUG|Zhizhu Kuanzhong Placebo Capsule|Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
40830392|NCT03090074|BEHAVIORAL|Diet regime|Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.
40830393|NCT03090074|BEHAVIORAL|Type of psychological support|Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
40830394|NCT02677844|DRUG|Abemaciclib|Administered orally
40830395|NCT02677844|DRUG|Placebo|Administered orally
40830396|NCT02677844|DRUG|Loperamide|Administered orally
40830397|NCT04008992|DRUG|BMS-986259|Single and Multiple ascending dose from Dose 1 to Dose 5
41491735|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
40830398|NCT04008992|OTHER|Placebo|Placebo matching BMS-986259
40830399|NCT04008992|DIAGNOSTIC_TEST|P-Aminohippurate|Diagnostic Agent
41491736|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
41491737|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
41491738|NCT00103818|DRUG|gaboxadol|Duration of Treatment: 3 months
41491739|NCT00103818|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 3 months
41491740|NCT05219123|OTHER|ERCP with no PD cannulation|ERCP with no PD cannulation
41491741|NCT05219123|OTHER|ERCP with single PD cannulation|ERCP with single PD cannulation
40830400|NCT04008992|DIAGNOSTIC_TEST|Iohexol|Diagnostic Agent
40830401|NCT03225261|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
40830402|NCT03225261|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
41349020|NCT01774838|DRUG|Clopidogrel|3 months treatment
40830403|NCT05751889|BEHAVIORAL|Serious Game|Serious Game embedded with healthcare information regarding HCV and safe sexual practice.
40830404|NCT05751889|BEHAVIORAL|Traditional Health Education|Reading materials regarding HCV and safe sexual practice.
40830405|NCT04225442|OTHER|Fatty meal to challenge the physiological chronobiome in healthy young and old|The intervention consists of a fatty meal
40830406|NCT02166645|OTHER|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
40830407|NCT02166645|OTHER|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
40830408|NCT04843098|DRUG|TL117|TL117 capsules orally once daily
40830409|NCT04843098|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.
41349021|NCT03619369|PROCEDURE|Circumcision|Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
41491742|NCT01850186|DEVICE|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
41491743|NCT01850186|DRUG|Stabilized kilnman trio|The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
41491744|NCT03830827|DRUG|Vortioxetine|8-week 10-20mg/day vortioxetine; 2-hour MBRP intervention per week in 8 weeks
41491745|NCT05183386|PROCEDURE|dental socket regeneration|after a dental extraction the fresh socket is filled with graft materials and compared with the spontaneous healing (control)
41491746|NCT02184559|DRUG|Ropivacaine|comparaison of two methods of administration for analgesia using the same drugs in the same indication after Caesarean section
41491747|NCT02184559|DEVICE|The infiltration continues catheter|
41491748|NCT03906396|DEVICE|Xbox 360 Kinect|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant. Games uses for the activity are Sports Kinect and Sports Kinect 2. Xbox 360 Kinect - the players themselves become the ''game controller'' via their body movements and gestures, Kinect-enabled game titles lend themselves comfortably to the class of exercise games.
41491749|NCT03107026|DRUG|dasotraline 4mg|dasotraline 4mg tablet once daily
40830410|NCT05179083|OTHER|High-Impact Aerobic Exercise|Participants will be submitted to a 12-week high-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (80% of maximum) is reached, followed by 10 minutes of cool down.
40830411|NCT05179083|OTHER|Low-Impact Aerobic Exercise|Participants will be submitted to a 12-week low-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (40% of maximum) is reached, followed by 10 minutes of cool down.
40830412|NCT05229796|DRUG|Empagliflozin 10 mg Tab|The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
41491750|NCT03107026|DRUG|dasotraline 6mg|dasotraline 6mg tablet once daily
40830413|NCT03282773|DEVICE|Deferred stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
40830414|NCT03282773|DEVICE|Immediate stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
40830415|NCT05913102|DRUG|PDLLA|Administer PDLLA/saline every 2 weeks for 2.5 months
40830416|NCT00162461|DRUG|Phenytoin single dose (300 mg)|
40830417|NCT01015235|DRUG|Placebo|Subcutaneous infusion-once over 4 hours
40830418|NCT01015235|DRUG|KAI-1678|Subcutaneous infusion-once over 4 hours
40830419|NCT01015235|DRUG|Ketorolac Tromethamine|Active comparator, IV infusion, once
40830420|NCT01929720|BEHAVIORAL|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
40830421|NCT02174523|DRUG|40mg lurasidone|
40830422|NCT02174523|DRUG|placebo|
40830423|NCT03159689|OTHER|Mixed Tree Nuts|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz mixed tree nuts
40830424|NCT03159689|OTHER|Pretzels|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz pretzels
40830425|NCT01256281|PROCEDURE|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
41349022|NCT05509556|OTHER|talocalcaneal angle measurement|talocalcaneal angle measurement on lateral foot radiographs
41349023|NCT01084811|PROCEDURE|biopsy|One or more biopsies from nasal mucosa will be harvested during surgery
41349024|NCT00671476|DRUG|pegylated liposomal doxorubicin hydrochloride|
41349025|NCT00671476|GENETIC|DNA methylation analysis|
41349026|NCT00671476|GENETIC|TdT-mediated dUTP nick end labeling assay|
41349027|NCT00671476|GENETIC|fluorescence in situ hybridization|
41349028|NCT00671476|GENETIC|loss of heterozygosity analysis|
41349029|NCT00671476|GENETIC|polymerase chain reaction|
41349030|NCT00671476|OTHER|immunoenzyme technique|
41349031|NCT00671476|OTHER|immunohistochemistry staining method|
41349032|NCT00671476|OTHER|laboratory biomarker analysis|
41349033|NCT00671476|PROCEDURE|breast duct lavage|
41491751|NCT03107026|DRUG|Placebo|Placebo tablet once daily
40830426|NCT02389205|OTHER|kinesio group|"kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc."
40830427|NCT00272688|DRUG|Levodopa (drug), intraduodenal administration|
40830428|NCT01964599|DIETARY_SUPPLEMENT|PF-RS|n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
40830429|NCT01964599|DIETARY_SUPPLEMENT|PF-RO1|n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
40830430|NCT01964599|DIETARY_SUPPLEMENT|PF-RO2|n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
40830431|NCT01964599|DIETARY_SUPPLEMENT|Control|
40830432|NCT04711941|BEHAVIORAL|Rehabilitation training|Rehabilitation with behavioural stimuli
40830433|NCT04053595|DIAGNOSTIC_TEST|Dynamic parameters of fluid responsiveness protocol|Dynamic parameter of fluid responsiveness (pulse pressure variation/stroke volume variation) are used to optimize hemodynamics intraoperatively and during the first 6 hours postoperatively when appropriate. A cutoff of 12% is used to predict an increase of stroke volume \>10% after fluid administration.
41019804|NCT04972435|DIAGNOSTIC_TEST|Contrast sensitivity|All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
41019805|NCT04919499|DRUG|BI 765128|BI 765128
41019806|NCT04919499|OTHER|Sham comparator|Sham comparator
41019807|NCT06444113|DRUG|Ofatunumab|No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
41019808|NCT03098446|BEHAVIORAL|Prolonged sitting with exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
41157868|NCT03911141|BEHAVIORAL|Gamification|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
41157869|NCT03911141|BEHAVIORAL|Financial|"Participants are informed that each week money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
41157870|NCT01952106|OTHER|play computer game|
41157871|NCT00148616|DRUG|Memantine|Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
41157872|NCT00148616|DRUG|Placebos|Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone
41157873|NCT02919397|DEVICE|Wearable technology|Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
41349034|NCT00671476|PROCEDURE|neoadjuvant therapy|
41349035|NCT00671476|PROCEDURE|therapeutic conventional surgery|
41349036|NCT05738928|DIAGNOSTIC_TEST|blood and sputum culture|Noninvasive sampling ( Endo Tracheal Aspiration) for staining and culture. Blood culture .
41349037|NCT06191991|DRUG|Atorvastatin|40 mg
41349038|NCT06191991|DRUG|ALG-055009|0.9 mg
41349039|NCT06191991|DRUG|Rosuvastatin|10 mg
41349040|NCT02291328|OTHER|High Brassica|Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.
41349041|NCT02291328|OTHER|Low Brassica|Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.
41349042|NCT03713151|OTHER|Dividat FIT|The study intervention is a blended therapy approach of face-to-face physiotherapy sessions with an interactive tablet-based home exercise program.
41349043|NCT05963165|BEHAVIORAL|Non-phonatory exercises|Muscle exercises that favor glottic adduction without vocal emissions
41349044|NCT05830656|BEHAVIORAL|Exposure to nearby nature|Participants spend a minimum of 20 minutes in their favourite place in nearby nature.
41349045|NCT05830656|BEHAVIORAL|Exposure to virtual nature|Participants spend a minimum of 20 minutes watching virtual nature videos.
41349046|NCT04225936|DRUG|BMS-986263|Single Dose
41157874|NCT02919397|BEHAVIORAL|Diabetes Prevention Programme educational material|Educational material accessed through smartphone application
41157875|NCT02919397|BEHAVIORAL|Motivational messaging|Messages sent via smartphone application
41157876|NCT01284634|DRUG|GWP42003 200 mg/day Dose|GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
41157877|NCT01284634|DRUG|GWP42003 400 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
41349047|NCT02429089|DRUG|LEE011|"The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients."
41349048|NCT00175318|BEHAVIORAL|Motivational Interviewing|Beginning at 12 months of age, regular application of fluoride varnish will be an option that a mother in the MI group may choose for her child. Control families will receive dental health information from a pamphlet, and will have access to fluoride varnish at local dental clinics.
41349049|NCT01509157|DEVICE|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
41349050|NCT01509157|PROCEDURE|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
41349051|NCT05487092|DRUG|Letrozole|Letrozole 2.5mg daily for 6 months
41349052|NCT05487092|OTHER|Placebo|Placebo
41349053|NCT05799911|DIETARY_SUPPLEMENT|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
41349054|NCT05799911|DIETARY_SUPPLEMENT|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
41349055|NCT03309293|BIOLOGICAL|blood samples|blood samples
41349056|NCT05874700|DRUG|Sivelestat sodium was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
41349057|NCT05874700|DRUG|Placebo was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
41491752|NCT04227353|BEHAVIORAL|HEAL ABC|Participants will be assigned their first booklet based on the one they perceive to be the easiest for setting an incremental goal and achieving it. After the participant achieves successful behaviour change, he or she can move more confidently to the next booklet. Support will be provided every two weeks over the phone for 12 weeks. During the follow-up period, participants will use the follow-up booklet which helps them to continue with changes they have made and encourage them to set new goals.
41491753|NCT05278728|DRUG|Nimotuzumab|200,400,600 or 800mg weekly until progression or AEs
41491754|NCT05278728|DRUG|Irinotecan|180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
41349058|NCT02717429|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn. The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices. For example, for the first two weeks, the investigators use breath as an anchor for attention. With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
41491755|NCT02931006|OTHER|water|
41491756|NCT02931006|OTHER|bovine milk|
41491757|NCT00773734|DRUG|Apremilast 10mg|
41491758|NCT00773734|DRUG|Apremilast 20mg|
41491759|NCT00773734|DRUG|Apremilast 30 mg|
41491760|NCT00773734|DRUG|Placebo|
41491761|NCT00773734|DRUG|Apremilast 30mg|
41491762|NCT00773734|DRUG|Apremilast 20mg|
41491763|NCT00413686|DRUG|AZD7762|intravenous infusion
41491764|NCT00413686|DRUG|Gemcitabine|weekly intravenous infusion
41157878|NCT01284634|DRUG|GWP42003 800 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
40830434|NCT04053595|DIAGNOSTIC_TEST|Estimated oxygen extraction protocol|Oxygen extraction is estimated by the difference of arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation. A cutoff of 27% is used as a marker of inadequate tissue perfusion requiring hemodynamic optimization.
40830435|NCT02667782|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
40830436|NCT02667782|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
40830437|NCT02688582|OTHER|TCI group|Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
40830438|NCT03401567|OTHER|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
40830439|NCT02492360|PROCEDURE|Blood sample collection|Six tubes of blood will be collected during one blood draw.
40830440|NCT02492360|BEHAVIORAL|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
40830441|NCT02876497|OTHER|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
40830442|NCT02653495|BIOLOGICAL|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
40830443|NCT02536300|DRUG|Idelalisib|Idelalisib tablet administered orally
40830444|NCT00662376|DIETARY_SUPPLEMENT|PreOP Booster (oral nutritional supplement, food for special medical purposes)|3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
40830445|NCT05358431|OTHER|Neuroimaging and electrophysiology|Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG
40830446|NCT00456066|DEVICE|Export Aspiration System|Patients scheduled for emergency angioplasty
41157879|NCT01284634|DRUG|Placebo|Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
41157880|NCT00212862|OTHER|Patients with chemotherapy induced anemia|Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
41157881|NCT05191186|DRUG|Grass pollen extract - Alutard Phleum pratense, ALK|injection in lymph node
41157882|NCT03336749|BEHAVIORAL|Sensory group|The sensory re-learning consists of touch detection practice, i.e., touch discrimination to identify different materials, shapes, textures, weights and temperatures, proprioception and tactile object recognition in combination with task-specific training.
41157883|NCT03336749|OTHER|Control group|Traditional task-specific training
41157884|NCT03273283|BEHAVIORAL|Brief Intervention|Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
41157885|NCT00169585|DRUG|Levofloxacin oral tablets|
41491765|NCT05178381|DEVICE|Continuous theta burst transcranial magnetic stimulation|Participants will receive cTBS (50Hz stimulation at 80% AMT for 40 seconds). Stimulation will be applied to either the target area (frontal pole or IFG) or control area (vertex). Targeting of each region will be achieved using a frameless neuronavigation system with a Polaris Spectra infrared camera that enables stimulation to be centered on specific coordinates in Montreal Neurological Institute space. We will use coordinates \[x,y,z\] = \[35,50,15\] for frontal pole and \[x,y,z\] = \[56,16,22\] for right IFG based on the location of our activations in the young pilot group (Figure 4). The vertex control site is defined as the Cz position of a 10-20 EEG system. After receiving TMS, participants will stare at a white wall for 1 minute before performing the Horizon Task for 45 minutes.
40830447|NCT01173549|DRUG|Canagliflozin/Placebo Placebo/Canagliflozin|Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
40830448|NCT01173549|OTHER|no intervention|Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
40830449|NCT02695368|DEVICE|Novaerus NV800 on|The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.
41157886|NCT03389321|DRUG|Riociguat (Adempas)|Riociguat film-coated tablets for oral administration at a strength of 1 mg
41157887|NCT03389321|DRUG|Macitentan (Opsumit)|Macitentan film-coated tablets for oral administration at a strength of 10 mg
41157888|NCT00166361|DEVICE|Memokath 051 Ureteral Stent|The Memokath 051 ureter stent is used for the treatment of malignant or benign ureteric strictures in both men and women. The stent design consists of a tightly-coiled nickel-titanium alloy, with a diameter of 10.5 French (Fr) and a fluted proximal diameter expanding to 22 Fr. The stent is manufactured in multiple lengths which are chosen to position the device across the narrowed area rather than crossing the ureteropelvic or ureterovesical junction. It has a thermal memory system for its predetermined shape; the stent softens at temperatures below 10 degrees Celsius but regains its shape when heated above 55 degrees Celsius.
41157889|NCT00166361|DEVICE|JJ Stent|A JJ stent is a flexible plastic tube that drains urine from the kidney to the bladder and is supposed to stay in place temporarily. There is a coil on each end to keep the stent in place, preventing the stent from migrating down and out from the kidney or up from the bladder into the ureter. The stent can stay in place for few weeks to 3 months or more depending on the indication. If left for more than 6-9 months some stents may get encrusted leading to stone formation around the stent.
41157890|NCT06212934|OTHER|Acupuncture|"Chou's Tiaoshen acupoints includes Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1), Sanyinjiao (SP-6), Shenmen (HT-7) . Using stainless steel needles (0.32×40)mm, HuaTuo, China). Then some other points like, Danzhong(CV-17), Daling(PC-7), Taixi (KI-3), Qihai (CV-6), Taichong (LR3), and Qiuxu(GB-40) are chosen. Operation: Patients in supine position. Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1) are punctured at a depth of 20-25mm obliquely. Sanyinjiao (SP-6) and Shenmen (HT-7) are inserted 15mm perpendicularly. Until feeling tactile sensation then manually manipulated by rotation methods to produce a characteristic sensation known as De Qi; Technique: Mild reinforcing and attenuating, retaining the needle for 30minutes. The treatment will be givenonce a day and 5 times a week in weekdays, the course will last two weeks."
41157891|NCT06212934|DRUG|Estazolam|Participants will take estazolam 1mg 30min prior to bedtime everyday. The course of treatment is two weeks.
41157892|NCT02683356|OTHER|OCT-guided PCI|Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
41157893|NCT02683356|OTHER|Angiography-guided PCI|Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
41157894|NCT04104724|OTHER|Self-help|self-help materials - cognitive behavioural and compassion-focused; psychoeducation, practical help re. attending cervical cancer screening
41349059|NCT02717429|BEHAVIORAL|Computerized Cognitive Training|The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach. In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability. The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
41349060|NCT02094196|OTHER|Alcohol detoxification|Detoxified alcohol- dependent patients in an inpatient setting
41349061|NCT03006926|DRUG|lenvatinib|4 mg capsules
40830450|NCT02695368|DEVICE|Novaerus NV800 off|The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.
41349062|NCT03006926|DRUG|pembrolizumab (200 mg)|30-minute intravenous infusion
40830451|NCT02695368|DEVICE|Novaerus NV800 on or off|Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.
40830452|NCT01689623|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
41349063|NCT03844529|DEVICE|Sunmax FULLSGEN with Lidocaine|Subject who voluntarily sign the informed consent form (day -14\~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
41349064|NCT03232502|DIAGNOSTIC_TEST|Pharmacogenetic testing|Basic pharmacogenetic panel
40830453|NCT01689623|DRUG|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
40830454|NCT01689623|DRUG|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
40830455|NCT01670565|DRUG|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
40830456|NCT01670565|DRUG|Mycophenolate Mofetil|Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
40830457|NCT01670565|OTHER|Placebo Infusion|Infusion of normal saline
41019809|NCT03098446|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
41019810|NCT03864497|PROCEDURE|Myocardial perfusion imaging|
41019811|NCT03465540|DRUG|AMG 397|AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
41019812|NCT03465540|DRUG|Dexamethasone|Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
41019813|NCT03465540|DRUG|Azacitidine|Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
41019814|NCT02616003|DRUG|Liraglutide|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
41019815|NCT02616003|OTHER|Aminosteril hepa 8%|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
41349065|NCT03511924|BEHAVIORAL|Intradialytic resistance training|Progressive resistance training programme performed during haemodialysis, taking into account subject´s medical review summarizing: A. full medical history, B. clinical examination including cardiovascular assessment, C. detailed medication usage history, D. review of recent biochemistry and haematology records and results of lower extremity muscle strength assessments. Construction of intradialytic training programme followed recommendations published by the Exercise \& Sports Science Australia (Smart et al., 2013).
41349066|NCT04853056|DEVICE|virtual reality|wearing virtual reality glasses
41349067|NCT04853056|DEVICE|Cold vibration|Buzzy
41349068|NCT02506972|OTHER|Classic Quaker Quick Oats|Various doses of oats without or with sugar
41349069|NCT02506972|OTHER|Cream of Rice Cereal|Various doses of cereal without sugar
41349070|NCT02217449|OTHER|Prediction of histology|
41349071|NCT00104273|DRUG|Rasagiline|
41349072|NCT03376776|PROCEDURE|Vitrectomy|
41349073|NCT02875366|DRUG|LUM/IVA|
41349074|NCT02875366|DRUG|Placebo|
41349075|NCT03740139|OTHER|The Police-Mental Health Linkage System|When, during an encounter, the police officer decides to call the number provided in the notice, the Linkage Specialist (a licensed mental health provider from the mental health service where the subject was recruited, who has access to the clinic's EMR) can provide telephonic support to the officer.
41349076|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
41349077|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
41349078|NCT01995786|DEVICE|Goal Directed Fluid Therapy FloTrac/Vigileo|
41349079|NCT05022706|OTHER|Community-based accompaniment and home visits|"Trained health promoters will accompany adolescents to their first appointments; facilitate enrollment in public health insurance and completion of other administrative requisites (e.g. obtaining a foreign identification card for migrants; transferring to a different health facility); help troubleshoot new logistical and/or social challenges; and will foster communication between the adult care providers and the patient.~Health promoters will visit the participant's home or another mutually-agreed upon location at least monthly, to review ART adherence, identify barriers to care and adherence, remind patients of upcoming medical encounters, screen and follow-up for clinical and social problems, and offer social support."
41349080|NCT05022706|BEHAVIORAL|Directly Observed Therapy|Among adolescents who have already initiated combination antiretroviral therapy (cART), directly observed therapy (DOT) will be provided to the subset of adolescents identified as being at high risk of non-adherence, defined by meeting at least one of the following criteria: 1) identified by the pediatric health provider as having unstable adherence; or 2) having a detectable viral load at one of their two previous measurements. In adolescents newly initiating cART, there will not be an adherence precedent. This group will choose whether they wish to receive DOT. As part of this research, trained community health workers (CHWs) will deliver DOT in participant's homes or in a mutually agreed upon location. CHWs will observe ingestion of cART daily, ensure it is taken as prescribed and record each dose as DOT, self-administered, not taken or not prescribed.
40830458|NCT00825396|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
40830459|NCT05767580|OTHER|evaluation|The Timed Get Up and Go test to assess dual-tasking, the 4m Walk Test to assess gait, and the Footprint Method to assess cadence
40830460|NCT03099148|DRUG|Reference Formulation (R)|Administered PO
40830461|NCT03099148|DRUG|LY3337641 (T1)|20 mg PO
40830462|NCT03099148|DRUG|LY3337641 (T2)|20 mg PO
40830463|NCT03251859|DRUG|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
40830464|NCT03251859|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg daily
40830465|NCT04424992|OTHER|Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.|Describe the natural history and clinical evolution of hospitalized patients over time affected by SARS-COV-2 infection, understand the pathogenesis of the disease and improve the aids and therapeutic procedures.
41019816|NCT02616003|DIETARY_SUPPLEMENT|Caloric diet with 1000 kcal|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 1000 kcal from day 1 onwards till technical operability is achieved (about 21 days)
41349081|NCT05022706|BEHAVIORAL|Monthly Peer Support Groups|The investigators will assign ALWH to a social support group with 9 to 11 other adolescents also participating in the research. The goal of the social support groups is to provide a venue for participants to share experiences and resources and provide encouragement and support to one another. Each group will last approximately 3 to 4 hours. Support groups will be led by adult peers or trained community health workers. The final group session will incorporate a discussion about the group experience, how it may change behavior, recommendations for improvement, and unmet needs that should be considered for a future intervention.
41349082|NCT03870893|BEHAVIORAL|hippotherapy|16weeks hippotherapy program
41349083|NCT06442085|OTHER|Teaching of trauma resuscitation by using virtual reality simulation|"The intervention was teaching of trauma resuscitation by using VRS. Following welcome and a video lecture by Advance Trauma Life Support certified physician, the intervention group participants were orientated (15 minutes) to the VRS environment, head-mounted display (Oculus Rift S or Oculus Quest, Oculus, USA) and hand controllers by playing game First Steps (Oculus, USA). Then the participants were training by using the Internal Hemorrhage scenario in Trauma Simulator."
41349084|NCT06442085|OTHER|Teaching of trauma resuscitation by using mannequin based simulation|Volunteers were trained in groups of three or four by using mannequin-based rapid cycle deliberate practice simulation facilitated by a critical care physician. Next, the volunteers had 50 min training of the same trauma scenario as the intervention group. The simulation facility was set-up as close as possible to the virtual reality environment.
41019817|NCT03717532|PROCEDURE|Placebo|Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.
41019818|NCT03717532|PROCEDURE|Personalized Tourniquet System for Blood Flow Restriction|Patients will be receiving blood flow restriction therapy with a pressure cuff
40830466|NCT02387125|BIOLOGICAL|CMB305|
40830467|NCT02387125|BIOLOGICAL|G100|
40830468|NCT02387125|DRUG|Metronomic CPA|
40830469|NCT03546504|BEHAVIORAL|Procedure alteration and occupational therapy|Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
40830470|NCT02585648|DEVICE|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
40830471|NCT02585648|DEVICE|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
40830472|NCT00645879|DRUG|ornithine alpha ketoglutarate|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
40830473|NCT00645879|DRUG|glutamine|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
40830474|NCT00645879|DRUG|disodium citrate|Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
40830475|NCT04861246|DEVICE|Laser|The device will be used to do Laser treatment. To compare the therapeutic effect to laser treatment before and post treatment for 14 and 60 days.
41019819|NCT02162628|DEVICE|Exair Prolapse Repair System|
41019820|NCT02162628|PROCEDURE|Total Native Tissue Repair|
41019821|NCT02670629|PROCEDURE|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
40830476|NCT04861246|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain OCT images before and after laser treatment of skin.
40830477|NCT04861246|DEVICE|VISIA®|The device is skin analysis system and will be used to obtain before and after images of laser treatment.
41019822|NCT02670629|PROCEDURE|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
41019823|NCT02820194|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
41491766|NCT00628537|DEVICE|BION stimulation|"BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises."
40830478|NCT04594460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
41157895|NCT04906707|DEVICE|EaseVRx|EaseVRx is a commercially available pain management program. It is a multi-modal, skills-based, 8-week, VR, mind-body approach to daily management of chronic pain that is designed for home use to be worn over the eyes. The program contains five types of modules that are as follows: Interoception, Education, 360-degree relaxation videos, Games, and Dynamic breathing. All program content is mapped to a therapeutically designed curriculum with weekly themes. The following core themes are infused into the curriculum: Acceptance, Attention shifting, Awareness, Rehabilitation, Self-compassion, Healthy Movement, Deep relaxation, Visualization, Knowledge of pain, Distraction, and Immersive enjoyment.
40830479|NCT04594460|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
40830480|NCT04104919|DRUG|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
40830481|NCT04104919|DRUG|Placebo 6 mL|Single preoperative intrathecal injection
40830482|NCT05606419|DIETARY_SUPPLEMENT|CDED+PEN|Dietary intervention (Liquid food replacement intervention and specific exclusion diet). Focus on 24 hour diet recalls to asses adherence.
40830483|NCT05606419|DIETARY_SUPPLEMENT|PEN+usual care|Liquid food replacement intervention and regular diet. Focus on 24 hour diet recalls and FFQ to asses dietary habits.
41491767|NCT05535985|DEVICE|acupuncture|treatment of pain or disease by inserting the tips of needles at specific points on the skin
40830484|NCT05606419|DIETARY_SUPPLEMENT|CDED+dairy|Dietary intervention (Specific exclusion diet plus early dairy introduction). Focus on 24 hour diet recalls to asses adherence.
40830485|NCT06099106|DEVICE|SEPIOLA System|Implantation of the SEPIOLA device into the left atrial appendage.
41491768|NCT05535985|DEVICE|placebo acupuncture|placebo acupuncture
41491769|NCT02266134|BEHAVIORAL|Tailored Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.
41019824|NCT02820194|PROCEDURE|Microwave Ablation|Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
41019825|NCT03976986|DEVICE|continuous-flow portable oxygen concentrator (cPOC)|SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).
41019826|NCT03976986|DEVICE|pulsed-flow portable oxygen concentrator (pPOC)|InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
40830486|NCT04092192|DEVICE|IVC filter removal|"In the clinic, it will be explained to patient that they are asked to participate in a study that would randomize them to one of two established techniques for IVC filter removal. It will be explained these are both techniques that are used by interventional radiologists normally used for IVC filter retrieval.~One technique would be the utilization of an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.~The other technique described will be the usage of a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed."
40830487|NCT00088283|DRUG|pegaptanib sodium|
41019827|NCT05980312|OTHER|Splint Immobilization|Patients will be randomized to receive a splint following their surgical procedure.
41019828|NCT05980312|OTHER|Early Motion|Patients will be randomized to receive no splint following their surgical procedure.
41019829|NCT04955938|DRUG|Ivosidenib|A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1).
41019830|NCT04955938|DRUG|Enasidenib|A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy.
41491770|NCT02266134|BEHAVIORAL|Standard Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.
41349085|NCT05960786|DEVICE|Otoband Experimental|Participants will be randomly assigned to use the Otoband to determine effectiveness in providing temporary relief to symptoms of vertigo.
41491771|NCT05962580|PROCEDURE|Isolated anterior cruciate ligament reconstruction with lateral extra articular tenodesis|Anatomical single bundle ACLR with modified Lemiere technique
41491772|NCT05962580|PROCEDURE|Isolated anterior cruciate ligament reconstruction only|arthroscopic anatomical single bundle ACL Reconstruction
41491773|NCT02939833|PROCEDURE|Scalp Nerve Blocks With Ropivacaine|
41019831|NCT04955938|DRUG|Fedratinib|This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
41019832|NCT05491733|DRUG|APX001|Low-load oral tablet
41019833|NCT05491733|DRUG|APX001A|High-load oral tablet
41019834|NCT05613634|DEVICE|Repetitive transcranial magnetic stimulation|A high frequency (10 Hz) rTMs on the dominant dorsolateral prefrontal cortex (DLPFC) was applied with the Magstim Rapid Magnetic Stimulator, Magstim Company. Patients were seated in a chair, arms and legs relaxed, head stable, and no movement was allowed during the procedure. Motor threshold (MT) was determined before each session and was defined as the percent intensity output of the stimulator that generated a 50µV motor evoked response in the abductor pollicis brevis (APB) muscle in five out of 10 trials. The DLPFC of dominant hemisphere was localized on the scalp 5.5 cm anterior to the hot spot for the contralateral APB muscle along the parasagittal plane. The average MT was 50 % (range, 45-55%) of the maximal output of the stimulator. The initial mapping procedure was completed with the coil oriented at 45° lateral diagonal orientation roughly perpendicular to the central sulcus and the center of the coil applied tangentially to the scalp.
41349086|NCT05960786|DEVICE|Otoband Sham|Participants will be randomly assigned to use the Otoband sham to determine effectiveness in providing temporary relief to symptoms of vertigo.
41349087|NCT00906828|DRUG|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
41349088|NCT00906828|DRUG|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
41349089|NCT00906828|DRUG|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
41349090|NCT02489851|PROCEDURE|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
41349091|NCT02489851|PROCEDURE|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
41491774|NCT02939833|PROCEDURE|Scalp Nerve Blocks With Saline|
41491775|NCT00856973|DRUG|eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
41491776|NCT00856973|DRUG|eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
41491777|NCT00856973|DRUG|Placebo|1 tablet per day for 12 weeks
41491778|NCT04342468|OTHER|non-interventional|No intervention
41157896|NCT04906707|BEHAVIORAL|Audio-only version of EaseVRx|Participants in the control group will be asked to use the audio-only version of EaseVRx, which excludes references to visual content, to complete 7 sessions weekly. They will receive an electronic link to the recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer.
41157897|NCT06425094|DIETARY_SUPPLEMENT|Microalgae Extract Capsules|Tetrasol extract
41349092|NCT03102424|DEVICE|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
41349093|NCT03102424|DEVICE|Sham DW1330 device|The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
41349094|NCT02469597|DRUG|Furosemide|1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
41349095|NCT02469597|DRUG|Placebo|0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
41349096|NCT03066687|DRUG|Erdafitinib|Erdafitinib 9 mg (provided as one 4-mg tablet \[G-024\] and one 5-mg tablet \[G-025\]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
41491779|NCT01989988|PROCEDURE|LMGB|
41491780|NCT01989988|PROCEDURE|LRYGB|
41491781|NCT01989988|PROCEDURE|SADJB|
41491782|NCT03512860|DRUG|E4/DRSP|Administered as specified in the treatment arm.
41491783|NCT03512860|DRUG|VAL|Administered as specified in the treatment arm.
41491784|NCT04193306|DRUG|Alirocumab|Alirocumab 150 mg s.c. every 2 weeks
41491785|NCT04193306|OTHER|Placebo|Placebo s.c. every 2 weeks
41491786|NCT04091659|OTHER|Virtual Reality Education|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
41491787|NCT04091659|OTHER|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
41491788|NCT02517437|DRUG|Suprascapular & axillary blocks|After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
41491789|NCT02517437|DRUG|Interscalene block|After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
41491790|NCT00953641|DRUG|Misoprostol|Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
41491791|NCT00953641|DRUG|Placebo|Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
40830488|NCT01813838|DRUG|ACADESINE 140mg/kg/d|"3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d"
40830489|NCT01813838|DRUG|ACADESINE 210mg/kg/d|"3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d"
40830490|NCT01813838|DRUG|ACADESINE 315mg/kg/d|"3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d"
40830491|NCT01873729|DRUG|Naltrexone|Adults with ADHD
41157898|NCT06425094|DIETARY_SUPPLEMENT|Placebo|maltodextrin \& vegetable magnesium stearate
40830492|NCT06103318|BEHAVIORAL|ICOgnition|"The ICOgnition intervention for breast cancer patients consists of three levels:~Level 1: Monthly assessments using FACT-Cog PCI and Cognifit. Scores \<54 (PCI) or ≤250 (Cognifit) escalate to Level 2.~Level 2: Specialized content includes Cognitive Psychoeducation, validating experiences and improving health literacy; Behavioral Guidance, offering practical strategies for daily tasks; and Embracing Cognitive Deficits, promoting self-compassion and acceptance through mindfulness and metaphors.~Level 3: Online cognitive training focuses on enhancing cognitive skills through gaming exercises, completing the comprehensive intervention approach."
41157899|NCT04809298|DEVICE|Free-hand therapeutic CT-guided punction for lumbar pain|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
41157900|NCT04809298|DEVICE|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
41157901|NCT04007848|DRUG|Cobimetinib|Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets
41157902|NCT04007848|DRUG|Placebo oral tablet|Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
41157903|NCT03565302|DRUG|Formoterol|Subjects are treated with daily inhalation of formoterol
41157904|NCT03565302|DRUG|Terbutaline|Subjects are treated with daily inhalation of terbutaline
41349097|NCT03795051|DEVICE|Navigated Transcranial Magnetic Stimulation|This study is a feasibility trial. Each participant will receive 30sessions of 10 Hz or 20 Hz rTMS over the left DLPFC. The rTMS interventions will be guided by a neuronavigation system (StimGuide TMS Navigation System, Magstim, Ltd. Carmarthenshire, UK) for navigation to the treatment location and to ensure consistent placement and orientation of the coil during and between each session. For the purpose of this protocol, these sessions are referred to as nTMS.
41349098|NCT05555914|OTHER|Neurostimulation|Implantation of 3 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
41349099|NCT00364611|DRUG|Bevacizumab|"Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~* On Day 1 of the 1st cycle over 120 minutes~* On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~* On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~* On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses"
41157905|NCT03565302|OTHER|Placebo|Subjects are treated with placebo
41157906|NCT02039297|OTHER|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation|Computer aided checklist and rounding tool implemented in the Intensive care unit environment
41157907|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted vaccine of 7.5 μg|120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
41157908|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
41157909|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted vaccine of seasonal influenza|120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
41157910|NCT01247870|DRUG|Metformin|Metformin 1 g twice daily for 28-35 days
41157911|NCT01247870|DRUG|Placebo|Placebo
41157912|NCT06053047|DEVICE|Bluedrop Monitoring Service (BMS)|Remote use of ThermoVisual monitoring
41157913|NCT01309113|DRUG|VAC BNO 1095 film coated tablets|3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
41157914|NCT04330261|OTHER|Exposure (not intervention) - SARS-CoV-2 infection|Exposure is infection with the virus. There is no intervention
41157915|NCT03662854|BIOLOGICAL|Hair Stimulating Complex (HSC)|Patients will receive 2 mL of HSC separated by 6 weeks (total of 4 mL of HSC)
41157916|NCT03662854|OTHER|Phosphate Buffered Saline|Patients will receive 2 mL of Phosphate Buffered Saline separated by 6 weeks (total of 4 mL of Phosphate Buffered Saline)
41349100|NCT00364611|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
41349101|NCT00364611|DRUG|Trastuzumab|"* A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~* For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion"
41349102|NCT02396264|OTHER|mediterranean diet|50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
41349103|NCT02396264|OTHER|normocaloric diet|50 pcos women will be assigned to standardized normocaloric diet for 6 months
41349104|NCT02828462|OTHER|CAPRI|
41349105|NCT04451486|DRUG|SB cells|1x10\*5 CD61-Lin- cells /0.25mL DPBS
40830493|NCT01355263|DRUG|iron and vitamin a|
41157917|NCT05065918|BEHAVIORAL|sexual violence and alcohol use harm reduction text message content|The multi-target sexual violence harm reduction and alcohol use intervention will use a similar model to the alcohol use reduction intervention previous developed and implemented. Students will be: 1) queried via TM prior to typical drinking days regarding both alcohol use and SV harm reduction goal setting; 2) provided with goal reminders during drinking period; and 3) assessed for goal attainment and given feedback following drinking episodes. As with the control condition, post-drinking assessment happens weekly on Sundays. Monday thru Saturday participants will randomly receive or not receive one appropriate message pathway from the message library using the pre-determined pathways for messages.
41157918|NCT05065918|BEHAVIORAL|alcohol use reduction content|"The control condition will be a previously tested TM-delivered alcohol use reduction intervention. Prior to typical drinking occasions, individuals planning a drinking event are prompted to consider committing to a drinking limit goal, i.e.: Would you be willing to set a goal to drink less than X drinks when drinking?. Based on willingness to commit to the goal, a feedback message is provided. During typical drinking periods, individuals receive a goal reminder. Each week, the program provides goal success/failure feedback or drinking quantity feedback. For example, those occasions where an individual committed to a drinking limit goal triggers either messages to reinforce goal successes or reframe goal failures. When an individual did not commit to a drink limit goal, they are provided feedback based on alcohol quantity (e.g. high risk drinking feedback)."
41349106|NCT04451486|DRUG|SB cells|1x10\*6 CD61-Lin- cells /0.25mL DPBS
41349107|NCT04451486|DRUG|SB cells|1x10\*7 CD61-Lin- cells /0.25mL DPBS
41349108|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (self-report questionnaires)|"All participants will be asked to fill in the PID-5-BF+M and the LPFS-BF 2.0 to examine personality disorders as defined by the AMPD and ICD-11.~PID-5-BF+M consists of 36 self-report items. It has 18 facet scales and 6 domain scales (Anankastia, Negative Affectivity, Antagonism, Disinhibition, Psychoticism and Detachment).~The LPFS-BF 2.0 has 12 items, measuring 4 domains of personality functioning (identity, intimacy, self-direction and empathy)."
41349109|NCT05548946|OTHER|Secondary Questionnaires (self-report and informant questionnaires)|"The patients fill in a standard test battery during the first weeks of their admission in the institutions, including questionnaires and interviews. The research team will analyze the results retrospectively.~This includes:~YSQ- SF16 (Young \& Brown, 1994; Pauwels et al., 2018) GPS (van Alphen et al., 2006) HoNOS 65+ (Burns et al., 1999) HAP 2.0 (Barendse \& Thissen, 2006) SCL-90-R (Derogatis, 1983; Dutch version: Arrindell, \& Ettema, 1975, 1986, 2005) ADP-IV (Schotte \& De Doncker, 1998) CERQ (Garnefski et al., 2007) UCL (Scheurs et al., 1994; 1988) BIS/BAS Scales (Carver \& White, 1994) EC Scale of the ATQ (Rothbart et al., 2000) BSI (Derogatis, 1975; Dutch version: Beurs, 2008) SIPP-SF (derived from the SIPP-118; Verheul et al., 2008) SMI (Young et al., 2008) WHO-5 (Dutch version: WHO, 1998) SQ3-SF (Young \& Brown, 2005) SCID-5-P (First et al., 2017; Dutch translation: Arntz et al., 2017)"
41491792|NCT05806918|DRUG|Recombinant Human Interferon α-2b Gel (After the Alteration)|Recombinant human interferon α-2b gel (after the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
41491793|NCT05806918|DRUG|Recombinant Human Interferon α-2b Gel (Before the Alteration)|Recombinant human interferon α-2b gel (before the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
41491794|NCT00664131|OTHER|Neurological Examination/Questionnaires|See Detailed Description section for description of treatment plan.
41491795|NCT03008486|DEVICE|Real soft splint (6 cm)|
41491796|NCT03008486|DEVICE|Placebo soft splint (1 cm)|
40830494|NCT04401345|DRUG|Glycopyrrolate 0.2 MG/ML|In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
40830495|NCT04401345|DRUG|Normal saline|In this group, the patients will receive 1 ml of 0.9% normal saline
40830496|NCT02630368|DRUG|Cyclophosphamide and JX-594 dose escalation|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
40830497|NCT02630368|DRUG|Cyclophosphamide and JX-594|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
40830498|NCT02630368|DRUG|Cyclophosphamide|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
41157919|NCT05530460|DEVICE|retinal imaging with low-cost OCT device|Retinal imaging with low-cost OCT device
41157920|NCT05530460|DEVICE|retinal imaging with commercial OCT device|retinal imaging with commercial OCT device
41157921|NCT01014663|BEHAVIORAL|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
41157922|NCT01014663|BEHAVIORAL|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
41157923|NCT03999710|RADIATION|Radiation Therapy|Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
41157924|NCT03999710|DRUG|Durvalumab|A dose of 1500mg (for patients \>30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
41157925|NCT06222034|DRUG|Filgotinib|Film-coated mini-tablets administered orally once daily
41157926|NCT06222034|DRUG|Filgotinib|Commercially developed film-coated tablet administered orally once daily
41157927|NCT03504371|DEVICE|bilateral erector spinae block|The patient placed in a lateral position and transducer placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony acoustic shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side and preformed in the same way to achieve sensory block T5-T10 .
41157928|NCT03504371|DEVICE|Thoracic epidural anesthesia|patients will receive TEA where an epidural catheter will be placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine with 1:200,000 epinephrine will be injected followed by 5-6 ml of bupivacaine 0.25%.
41157929|NCT05098197|BIOLOGICAL|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
41157930|NCT02133183|OTHER|Laboratory Biomarker Analysis|Correlative studies
41157931|NCT02133183|OTHER|Pharmacological Study|Correlative studies
41157932|NCT02133183|DRUG|Sapanisertib|Given PO
41157933|NCT02133183|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41157934|NCT00958633|DRUG|Escitalopram|"Escitalopram will be prescribed in the dose range 10-30 mg daily.~* In patients randomized to the 8-week group, escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~* The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points."
41157935|NCT00958633|DRUG|Wellbutrin XL|"Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~* In patients randomized to the 8-week group, bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~* The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points."
41157936|NCT01158716|OTHER|Remote Ischemic Preconditioning|Patients are subjected to a 5-minute ischemia of the non-dominant arm with the use of a blood pressure cuff (inflated at 200mm Hg)
41157937|NCT04934124|DRUG|ITI-333|ITI-333 oral solution
41157938|NCT04934124|OTHER|Placebo|Matching placebo
41157939|NCT06530498|DIAGNOSTIC_TEST|Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale|Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale in 9 body regions rated from 0 (no growth of terminal hair) to 4 (extensive hair growth), thus with a score ranging from 0 (the lowest score - no hirsutism) to 36 points (the highest score - the greatest severity of hirsutism)
41349110|NCT05548946|DIAGNOSTIC_TEST|Clinical Ratings of the dimensional model|"Clinical ratings of criteria A and B will also be collected. Only a small part of the patients will be selected for this, in order to make the research more feasible. The rater (a clinician or researcher) assesses the patient (in terms of level of personality functioning and personality traits) by means of (structured) clinical interviews. Given clinical ratings of the dimensional criteria are not part of the standard care in either institution, the ratings can be conducted by the doctorandus and Master Thesis students, trained by the doctorandus (in order not to overburden the clinicians).~The clinical interviews that will be used for the ratings are:~* The Semigestructureerd Interview voor Persoonlijkheidsfunctioneren DSM-5 (STIP) (Hutsebaut et al., 2014).~* The Structured Clinical Interview for the DSM-5 (SCID-5-AMPD) (First et al., 2018), only if a Dutch translation is available by the time of this intervention."
41349111|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (Informant questionnaires)|In the clinical population, participants will be asked to include an informant (family member, partner, friend, acquaintance), to fill in an informant version of the PID-5-BF+M and LPFS-BF 2.0 questionnaires. It is also possible for the patient to participate in the study without giving permission to include an informant. The informant will be asked to fill in the informant versions of the questionnaires, which contain the exact same items as the self-report versions, adjusted to the third person.
41349112|NCT00518739|DRUG|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 \& beyond).
41491797|NCT05597956|PROCEDURE|white defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
40830499|NCT02630368|DRUG|Avelumab and JX-594 and Cyclophosphamide|"Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections ."
40830500|NCT06027411|DEVICE|qER (qER EU 2.0)|Qure.ai's emergency room software solution qER (qER EU 2.0) is an AI medical device, developed by training a deep-learning algorithm using over 300,000 scans labelled by expert radiologists. qER has been shown to be accurate in identifying a range of abnormalities in NCCT head scans as well as prioritising them for urgent review and radiologist reporting. It is designated as a clinical support tool and, when used with original scans, can assist the clinician to improve efficiency, accuracy, and turnaround time in reading head CTs.
40830501|NCT03777709|BEHAVIORAL|FAITH! App|Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
40830502|NCT05152706|OTHER|Aerobic training|Cycling at the aerobic intensity
40830503|NCT05152706|OTHER|Photobiomodulation|Photons therapy
41157940|NCT06530498|DIAGNOSTIC_TEST|Assessment of the severity of endogenetic alopecia using the visual Ludwig Scale|"Visual assessment of baldness on the Ludwig scale from I (least severe baldness) to III (most severe baldness):~Type I - minimal thinning of the mid-line parting in the hair; Type II - gradual thinning and noticeable widening of the mid-line parting in the hair; Type III - Heavy to total thinning of the mid-line"
41157941|NCT05970783|DRUG|Jincaopian Tablets|Jincaopian Tablets 0.2g tid p.o.
41491798|NCT05597956|PROCEDURE|yellow defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
41491799|NCT05597956|PROCEDURE|brown defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
41157942|NCT05970783|OTHER|Placebo|Placebo 0.2g tid p.o.
41157943|NCT06268431|OTHER|Oxytocin rest|60-minute oxytocin rest
41157944|NCT06349317|COMBINATION_PRODUCT|Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib|"1. Preoperative IMRT targeting PVTT and intrahepatic tumor lesions with a prescribed dose for 18Gy in 6 fractions delivered by using 6-MV X-rays with a linear accelerator at 5 fractions per week;~2. Perioperative combination of camrelizumab and apatinib Preoperatively, camrelizumab (200mg, every 2 weeks) combined with apatinib (250mg, daily) for 2 cycles (2 weeks as one cycle); Postoperatively, camrelizumab (200mg, every 3 weeks) combined with apatinib (250mg, daily) for 8 cycles (3 weeks as one cycle)."
41157945|NCT04760327|COMBINATION_PRODUCT|Electrochemotherapy with bleomycin or cisplatin|Electrochemotherapy with cisplatin or bleomycin of gynecological cancers
41349113|NCT02902692|OTHER|Brief Mindfulness|15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
41349114|NCT02339376|DEVICE|Low-frequency repetitive transcranial magnetic stimulation|
41349115|NCT02339376|DEVICE|High-frequency repetitive transcranial magnetic stimulation|
41349116|NCT02339376|DEVICE|Sham repetitive transcranial magnetic stimulation|
41349117|NCT00289302|DEVICE|Cardiac resynchronization therapy device|
41349118|NCT01558791|OTHER|TBI handout|The intervention is an educational handout which covers key concepts found in the empirical literature and explicated in the VA/DoD mTBI practice guideline; (1) the meaning of a positive screen, (2) symptoms may be due to another condition, (3) most people with mTBI recover.
41157946|NCT00890214|DRUG|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
41157947|NCT00890214|DRUG|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
41157948|NCT05583734|DEVICE|Portomar(TM) Device|Portomar(TM) access device for bone marrow biopsy
41157949|NCT06343779|DRUG|Deucrictibant, Placebo|Deucrictibant Soft Capsules for Oral Use
41157950|NCT05514054|DRUG|Imlunestrant|Administered orally.
41349119|NCT02000544|DEVICE|Modular Cardiopulmonary Bypass Circuit|Open heart surgery with a novel hybrid modular extracorporeal circulation circuit which is a closed cardiopulmonary bypass circuit with enhanced safety as it can be instantly converted to an open circuit.
41349120|NCT00740428|PROCEDURE|Pregnants for receive the physical therapy guide|pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
41349121|NCT03139773|DIETARY_SUPPLEMENT|Control Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
41349122|NCT03139773|DIETARY_SUPPLEMENT|Omega-3 Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
41349123|NCT03746340|DRUG|Propofol|Propofol group: intravenous Propofol (2.0mg / kg) for general anesthesia induction, maintained for 30\~60s. Continuous intravenous infusion of Propofol (7\~8 mg·kg-1·h-1) with a syringe pump maintains a smooth general anesthetic sedative effect.
41349124|NCT03746340|DRUG|Sevoflurane|Sevoflurane group: Inhalation of 1-8% sevoflurane for induction.Then Inhalation of sevoflurane (2.0\~2.5Vol%) was maintained
41349125|NCT00779116|DRUG|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
41349126|NCT00779116|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
40830504|NCT03177447|BEHAVIORAL|ENABLE CHF-PC|An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
40830505|NCT02819960|DRUG|Probio-Tec® BG-VCap-6.5|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
40830506|NCT02819960|DRUG|Placebo|Maltodextrin
40830507|NCT00000630|BIOLOGICAL|HIVAC-1e|
40830508|NCT00000630|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
40830509|NCT01852383|DRUG|Duloxetine|"Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.~Adverse events: All adverse events and serious adverse events were documented.~The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.~Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial."
40830510|NCT04969848|OTHER|Wearable sensor|IMU sensor (as part of eMSGait device) worn at the hip during T25FW
41349127|NCT05638776|DRUG|REGEND001 Autologous Therapy Product|Transplantation of Autologous Therapy Product by
41349128|NCT05638776|DRUG|Placebo|Transplantation of Placebo
41349129|NCT00672139|DRUG|Methylnaltrexone bromide|
40830511|NCT05238259|DEVICE|kinesiotaping|Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
41349130|NCT03735017|OTHER|Non-Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
41349131|NCT03735017|OTHER|Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
41349132|NCT04330040|DRUG|Olaparib|Tablet
41349133|NCT00103779|DRUG|SGN-40 (anti-huCD40 mAb)|1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
41349134|NCT00619216|DRUG|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
41349135|NCT04050228|DEVICE|Quantitative ultrasound to guide adaptive chemotherapy|Quantitative ultrasound results will be used to measure chemotherapy response and guide an adaptive chemotherapy strategy for patients who are found to be nonresponders to their chemotherapy.
41349136|NCT02114918|BEHAVIORAL|Attention Modification Program|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe."
41349137|NCT02114918|BEHAVIORAL|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word."
41157951|NCT05514054|DRUG|Tamoxifen|Administered per local approved label.
41157952|NCT05514054|DRUG|Anastrozole|Administered per local approved label.
41157953|NCT05514054|DRUG|Letrozole|Administered per local approved label.
41157954|NCT05514054|DRUG|Exemestane|Administered per local approved label.
40830512|NCT05238259|DEVICE|wrist wheel|Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the pateint to easily roll wrist back and forth focusing on the wrist and arm
41157957|NCT03071900|DIAGNOSTIC_TEST|circulating tumor cell analysis|Detect circulating tumor cells with CellCollector in SCCHN and control group.
41157958|NCT03769129|DRUG|Pembrolizumab|Pembrolizumab
40830513|NCT01573637|DRUG|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
40830514|NCT01573637|DRUG|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
40830515|NCT05458089|DIAGNOSTIC_TEST|18F-FDG|18F-FDG intravenous injection
41019835|NCT05613634|OTHER|Cawthorne Cooksey exercises|Cawthorne Cooksey exercises were carried in the following sequence: First, bed exercises; eye movements (up and down, side to side, focusing on a finger that is one feet distance); head movements (bending up and down, side to side first with eye opened then closed). Second, sitting exercises involved same eye and head movements, shoulder shrugging, turning head and trunk alternately to the right and left, bending head and trunk forward, and pick an object from the ground. Third, standing exercises involved same eye, head, and shoulder movements, changing position from sitting to standing with eye open then closed, throw a ball from hand to hand above eye level, throw a ball from hand to hand beneath knee, changing position from sitting to standing and turn around in between. Fourth, moving around exercises where the patient revolved around a person sitting in the center who throw him a ball and to whom it was returned.
41019836|NCT02352324|OTHER|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
41019837|NCT01914432|DRUG|YH16410|
41157959|NCT03769129|PROCEDURE|microwave ablation|microwave ablation
41157960|NCT01881100|OTHER|resin infiltration|The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
41349138|NCT05187494|OTHER|Conventional local palatine injection|Conventional palatal injection with anesthetic (lidocaine HCL2% with Epinephrine 1:80000, Korea) Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
41491800|NCT03508505|DEVICE|Venoarterial extracorporeal oxygenation|Veno-arterial extracorporeal oxygenation (VA-ECMO) is inserted in the acute setting in case of cardiac low output after adult cardiac surgery in order to provide cardiopulmonary support to recovery or as bridge to transplantation.
41491801|NCT02109419|OTHER|HHT-G|Helping Hands Technology global cognitive function assessment
41019838|NCT01914432|DRUG|Rosuvastatin|
41019839|NCT01914432|DRUG|Telmisartan|
41157961|NCT01881100|OTHER|fluoride varnish|All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
41157962|NCT01521221|OTHER|Hand grip maneuver|Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
41019840|NCT01914432|DRUG|YH16410 placebo|
41019841|NCT01914432|DRUG|Rosuvastatin placebo|
41157963|NCT05107999|DRUG|Zhizhu Kuanzhong capsules (ZZKZ)|FD patients were treated with ZZKZ and omeprazole for 4 weeks.
41157964|NCT05107999|DRUG|Doxepin Hydrochloride (Doxepin)|FD patients were treated with doxepin and omeprazole for 4 weeks.
41157965|NCT00185783|DRUG|Hydrocortisone Administration (Standard of Care Therapy)|
41157966|NCT00930683|DRUG|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
41157967|NCT00930683|DRUG|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
41157968|NCT00930683|DRUG|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
41157969|NCT00930683|DRUG|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
41157970|NCT00930683|DRUG|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
41157971|NCT00930683|DRUG|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
41157972|NCT00930683|DRUG|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
41157973|NCT00930683|DRUG|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
41491802|NCT02109419|OTHER|HHT-D|Helping Hands Technology depression assessment
41491803|NCT02109419|OTHER|Geriatric Depression Scale (DGS)|Geriatric Depression Scale (DGS)
41491804|NCT02109419|OTHER|MMSE|Mini Mental State Exam
41491805|NCT01868893|DRUG|Obinutuzumab|
41491806|NCT01868893|DRUG|Chlorambucil|
40830516|NCT03697993|DRUG|Fosfomycin tromethamine|Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.
40830517|NCT03697993|DRUG|Levofloxacin|750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.
41157974|NCT00930683|DRUG|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
41349139|NCT05187494|DRUG|EMLA cream only|Emla cream will be applied at a distance of 1 mm from the palatine gingival edge by cotton buds for 3 minutes within the application area 14\*14 mm and the mouth will be open throughout the procedure and the saliva will be controlled by a saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
41349140|NCT05187494|DRUG|chemical permeability enhancer DMSO with EMLA cream|Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes while the child is opening his mouth and the saliva is controlled by saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
41349141|NCT05187494|DRUG|Oral patches with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an oral patch 14\*14 mm for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
40830518|NCT05682989|PROCEDURE|Urodynamic investigations before and after a mesh surgery protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.
41349142|NCT05187494|DRUG|Micro-needle patches dissolved with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an micro-needle patch 14\*14 mm, 0,25 micron for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
41349143|NCT06098794|DIETARY_SUPPLEMENT|Sodium Bicarbonate|Capsules containing 0.3 g/kg of body weight of sodium bicarbonate were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
41491807|NCT02317614|BEHAVIORAL|SteadyRx|The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
41491808|NCT03155321|OTHER|It's an observational study - no intervention is planned|No intervention is planned
41491809|NCT00107510|BIOLOGICAL|pegfilgrastim|
41491810|NCT00107510|DRUG|carboplatin|
41491811|NCT00107510|DRUG|docetaxel|
41491812|NCT00107510|PROCEDURE|conventional surgery|
41019842|NCT01914432|DRUG|Telmisartan placebo|
41019843|NCT01194297|BIOLOGICAL|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
41019844|NCT01194297|BIOLOGICAL|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
41019845|NCT01116089|DRUG|Bramitob® administered by PARI LC® PLUS nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
41019846|NCT01116089|DRUG|Bramitob® administered by PARI eFlow® rapid electronic nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
41019847|NCT01672125|OTHER|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
41019848|NCT05867394|OTHER|Stress ball|Stress ball squeeze
41157975|NCT04822025|BIOLOGICAL|MVC-COV1901 (High-Dose)|Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
41157976|NCT04822025|BIOLOGICAL|MVC-COV1901(Mid-Dose)|Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
41019849|NCT00538005|BIOLOGICAL|bevacizumab|
41019850|NCT00538005|DRUG|oxaliplatin|
41019851|NCT00538005|DRUG|sorafenib tosylate|
41019852|NCT00003341|BIOLOGICAL|epoetin alfa|
41019853|NCT00003341|PROCEDURE|quality-of-life assessment|
41019854|NCT04273464|PROCEDURE|Brava-group|Breast reconstruction by external tissue expansion and multiple fat transplantations(Brava group); Breast reconstruction with microsurgical DIEP-flap transfer.
41019855|NCT04273464|PROCEDURE|DIEP-group|Microsurgical reconstruction by DIEPO method
41157977|NCT02271737|BEHAVIORAL|Training HC/VHSG, Health Education, and Supportive Supervision|1. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
41157978|NCT03501888|BEHAVIORAL|Cognitive Behavior Therapy|18 sessions of individual treatment, no manual.
41157979|NCT03501888|BEHAVIORAL|Acceptance and Commitment Therapy|18 sessions of group treatment, manual based.
41157980|NCT00396214|DRUG|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
41349144|NCT06098794|DIETARY_SUPPLEMENT|Placebo|Capsules containing 0.3 g/kg of body weight of celulose were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
40830519|NCT05682989|PROCEDURE|Urodynamic investigations before and after a robotic-assisted sacrocolpopexy protocol.|All surgeries were performed using a DaVinci robotic system (Intuitive® Surgical Inc., Sunnyvale, California,US) with standardized technique and materials. Patients were positioned in dorsal lithotomy and steep Trendelenburg position. Trocars were placed bilaterally, and an assistant port was placed laterally. The peritoneum was opened medial to the ureter to develop an avascular space. The mesh was placed on the posterior and anterior vaginal wall and fixed at the level of anterior longitudinal ligaments S1/S2 by sutures. An intraoperative clinical examination was performed to ensure the mesh was in a tension-free position.
40830520|NCT05682989|PROCEDURE|Urodynamic investigations before and after a hysterectomy with trans-vaginal mesh repair|In summary, a vertical incision was made in the anterior vaginal wall to access the vesicovaginal space. The sacrospinous ligament was dissected, and an applicator was inserted and positioned over the SSL. The anchor was fixed to the SSL and the thread was attached to the mesh. The mesh was then adjusted in a tension-free manner, excess mesh was cut, and the incision was closed with suture.
40830521|NCT02071420|BEHAVIORAL|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
40830522|NCT02071420|BEHAVIORAL|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
40830523|NCT02071420|BEHAVIORAL|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
40830524|NCT02071420|DEVICE|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
40830525|NCT00810901|BEHAVIORAL|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
40830526|NCT00810901|BEHAVIORAL|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
40830527|NCT05960305|OTHER|P1213416|Tobacco Flavor
40830528|NCT05960305|OTHER|P1213422|Tobacco Flavor
40830529|NCT05960305|OTHER|P1213716|Tobacco Flavor
40830530|NCT05960305|OTHER|P1213722|Tobacco Flavor
40830531|NCT05960305|OTHER|P1211216|Menthol Flavor
40830532|NCT05960305|OTHER|P1211222|Menthol Flavor
41019856|NCT01500824|DRUG|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
41157981|NCT00396214|DRUG|Quetiapine|Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
41349145|NCT02619058|BIOLOGICAL|NKT cells|autologous natural killer T cell
41349146|NCT04200391|OTHER|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
41491813|NCT06086418|DRUG|0.9 % Sodium Chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
41019857|NCT00966498|PROCEDURE|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
41157982|NCT00396214|DRUG|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
41157983|NCT02536547|DEVICE|VAP|all patients with suspected VAP : biochemestry microbiology lung ultrasound
41157984|NCT04271514|DRUG|RPT193|Antagonist of the CCR4 chemokine receptor
41157985|NCT04271514|DRUG|Placebo|Matching placebo
41491814|NCT06086418|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
40830533|NCT05960305|OTHER|P1213616|Menthol Flavor
40830534|NCT05960305|OTHER|P1213622|Menthol Flavor
40830535|NCT05960305|OTHER|P1213816|NTNM Flavor
40830536|NCT05960305|OTHER|P1213822|NTNM Flavor
41019858|NCT00541762|DIETARY_SUPPLEMENT|Fat perfusion to the small intestine|"1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~2. Orlistat perfused to the small intestine~3. DEXLOX as CCK-1 receptor antagonist"
41019859|NCT05514834|DEVICE|Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)|Injections with platelet-rich plasma and hyaluronic acid
41019860|NCT05514834|OTHER|PRP Only|platelet rich plasma without hyaluronic acid
41019861|NCT05514834|OTHER|Placebo|Neither PRP nor hyaluronic acid
41019862|NCT01391117|DRUG|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
41157986|NCT03604289|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
41157987|NCT03604289|DRUG|Saline|Saline will be used as the placebo comparator
40830537|NCT05960305|OTHER|P1211916|NTNM Flavor
40830538|NCT05960305|OTHER|P1211922|NTNM Flavor
40830539|NCT01041300|DEVICE|Magstim Rapid2 Stimulator|"Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).~Total Duration of device: 15 minutes"
41019863|NCT01391117|DRUG|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
41019864|NCT01391117|DRUG|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
41019865|NCT01391117|DRUG|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
40830540|NCT01041300|DEVICE|Brainsway Multi-channel Stimulator|"Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).~Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).~Total Duration with Device: 2 hours and 30 minutes"
40830541|NCT06200974|RADIATION|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate.
40830542|NCT03816839|DRUG|Amcenestrant (SAR439859)|"Pharmaceutical form: Capsules~Route of administration: Oral"
40830543|NCT00554099|DRUG|Mesalamine|6 - 400 mg tablets once daily
40830544|NCT00554099|DRUG|Probiotic|Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
40830545|NCT00554099|DRUG|Placebo|6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
41491815|NCT06086418|DRUG|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05mg/kg Dexamethasone for the popliteal nerve block
40830546|NCT00554099|OTHER|Dietary Advice|Dietary advice
40830547|NCT00554099|DRUG|Antibiotic for Diverticulitis|Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
40830548|NCT01228292|DRUG|Unfractionated heparin|dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
40830549|NCT01228292|DRUG|Citrasate|Citrasate is infused as a dialysate
41349147|NCT04841681|BEHAVIORAL|Video-based Psychotherapy|"Participants in the group watched three short videos. Therapeutic elements in the three consecutive short videos included relaxation therapy, managing thoughts and feelings, and mindfulness. Each video has a duration of just over 10 minutes.~In the first video, the participants were introduced to the purpose and benefits of relaxation techniques. These included rhythmic breathing techniques, progressive muscle relaxation, imagining a comforting and quiet place, and positive self-talk. In the second video about managing thoughts and feelings, the participants were introduced to the notion of acceptance of their condition. They were invited to recognize the emergence of negative feelings and thoughts related to acceptance. In the last video about mindfulness, patients were introduced to three basic mindfulness skills: observation, elaboration, and participation."
41349148|NCT02650193|DRUG|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
41349149|NCT02812615|DIETARY_SUPPLEMENT|Egg|After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
41349150|NCT02812615|DIETARY_SUPPLEMENT|Milk|After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
41349151|NCT02812615|DRUG|Albendazole/Pyrantel Pamoate|As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
41349152|NCT02812615|BEHAVIORAL|Nutritional counselling|Parents/caregivers will be given nutritional counselling
40830550|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
41019866|NCT01391117|DRUG|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
41019867|NCT01391117|DRUG|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
41349153|NCT02812615|DIETARY_SUPPLEMENT|Micronutrient sprinkles|For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
41349154|NCT02573012|DRUG|Placebo matched to prednisone|Participants will receive placebo matched to prednisone orally for 24 weeks.
41349155|NCT02573012|DRUG|Prednisone|Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
41491816|NCT04229927|DRUG|BPDO-1603|"Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug"
41019868|NCT01391117|DRUG|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
41019869|NCT01391117|DRUG|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
41019870|NCT01391117|DRUG|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
41491817|NCT05036356|OTHER|Headspace App|"A mobile-application (app) focusing on teaching and sustaining mental well-being."
41491818|NCT04902625|DRUG|Naltrexone-Bupropion Combination|Naltrexone-bupropion will be added to the BOT module in the interventional arm.
40830551|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
40830552|NCT00456976|DRUG|Selegiline|
41349156|NCT02573012|BIOLOGICAL|Tocilizumab|Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
41349157|NCT03700086|DEVICE|Disposable negative wound pressure device (PICO)|Application of a disposable negative wound pressure device for surgical site infection prevention.
41349158|NCT03700086|DEVICE|OPsite post-op visible standard sterile dressing|Application of a standard sterile wound dressing.
41349159|NCT01563224|DRUG|Baclofen 10mg|Baclofen 10mg single dose po
41349160|NCT01563224|DRUG|Baclofen 60mg|Baclofen 60mg single dose po
41349161|NCT01563224|DRUG|placebo|placebo
41349162|NCT03245944|PROCEDURE|early Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs
41349163|NCT03245944|PROCEDURE|late Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
41349164|NCT02447952|DEVICE|Faros Sensor (FS) and LifeInsight Hub|Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.
41349165|NCT02447952|DEVICE|Fast Fix electrode patch|The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.
41349166|NCT02447952|PROCEDURE|Quantitative Measure of Speech (Core Phase Only)|Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.
41491819|NCT02254213|OTHER|EEG recording|A short EEG recording is performed 10 times over the span of three months.
41491820|NCT01659866|DRUG|Ciprofloxacin|500 mg orally 2 hours before prostate biopsy
41491821|NCT01659866|DRUG|trimethoprim-sulfamethoxazole|1 double strength tablet orally 2 hours before the procedure and again 12 hours later
40830553|NCT04595877|DRUG|Dipyrone administration|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
40830554|NCT04595877|BEHAVIORAL|Pain assessment|"Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain)."
40830555|NCT04595877|BIOLOGICAL|beta-endorphin immunoreactivity|Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.
40830556|NCT04595877|OTHER|Placebo administration|Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
41491822|NCT01659866|DRUG|cefuroxime|500 mg orally 2 hours before the procedure then again 12 hours later
41491823|NCT01659866|DRUG|ceftriaxone|500 mg intramuscularly 2 hours before the procedure
41491824|NCT01659866|DRUG|gentamicin|2 mg/kg intramuscularly 2 hours before the procedure
41491825|NCT01659866|DRUG|amikacin|5 mg/kg intramuscularly 2 hours before the procedure
40830557|NCT03749096|DRUG|Intravenous Immunoglobulins, Human|Immunoglobulins are fractionated blood products made from pooled human plasma.
40830558|NCT03749096|DRUG|Placebos|Normal Saline
41349167|NCT00011128|BEHAVIORAL|Antiretroviral Treatment Interruption|
41349168|NCT04400669|OTHER|Mechanical Bowel Preparation|oral sodium phosphate (NaP) enema
41491826|NCT01659866|DRUG|aztreonam|500 mg intramuscularly 2 hours before the procedure
41491827|NCT01659866|DRUG|imipenem|500 mg intramuscularly 2 hours before the procedure
41491828|NCT01659866|DRUG|ceftriaxone|2000 mg intravenously 1 hour before the procedure
41491829|NCT01659866|DRUG|gentamicin|2 mg/kg intravenously 1 hour before the procedure
41491830|NCT01659866|DRUG|amikacin|5 mg/kg intravenously 1 hour before the procedure
41491831|NCT01659866|DRUG|aztreonam|2000 mg intravenously 1 hour before the procedure
41491832|NCT01659866|DRUG|imipenem|1000 mg intravenously 1 hour before the procedure
40830559|NCT02323152|BEHAVIORAL|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
40830560|NCT02323152|OTHER|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
40830561|NCT01244789|DRUG|carboplatin and paclitaxel|6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2
40830562|NCT01244789|OTHER|observation|active observation
41491833|NCT03529461|DEVICE|Non-invasive positive pressure ventilation through nasal mask|Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
40830563|NCT03589365|OTHER|Magnetic resonance imaging (MRI)|"Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume"
40830564|NCT01053013|BIOLOGICAL|RENCA macrobeads|
40830565|NCT00769028|DRUG|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
40830566|NCT00769028|DRUG|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
40830567|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
40830568|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
40830569|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
40830570|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
40830571|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
40830572|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
40830573|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
40830574|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
40830575|NCT02751034|DEVICE|Neuramis® Deep Lidocaine|HA filler
40830576|NCT02751034|DEVICE|Restylane® PERLANE-L|HA filler
40830577|NCT05491746|DEVICE|Eye4|Patients will see if the device helps them see better at distance and near and if it improves their contrast sensitivity.
41491834|NCT03529461|DEVICE|Rescue non-invasive positive pressure ventilation through nasal mask|If desaturation below 90 %, nasal cannula removed and non invasive positive pressure nasal mask connected to machine: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
40830578|NCT05491746|OTHER|Placebo|This is the patient's best corrected vision with or without glasses/contact lenses
40830579|NCT04317053|BEHAVIORAL|RELAY|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
40830580|NCT05118984|DRUG|Azithromycin capsule (Zithromax, Pfizer) (250 mg)|Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.
40830581|NCT05118984|DRUG|Placebo|A treatment that has no active properties
40830582|NCT03050515|BIOLOGICAL|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
40830583|NCT00494377|DRUG|duloxetine|
40830584|NCT02983591|DRUG|Misoprostol after delivery|Patients will receive 1000 mcg Misoprostol per rectum
40830585|NCT02983591|DRUG|Oxytocin after delivery|Patients will receive 20 units oxytocin intravenously in one liter of Lactated Ringer solution at a rate of 150ml/h
40830586|NCT02983591|DRUG|Oxytocin before delivery|All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor
40830587|NCT02787590|DRUG|Simvastatin|
40830588|NCT02787590|DRUG|Matched Placebo (for Simvastatin)|
40830589|NCT00642369|DRUG|quetiapine fumarate|600-750mg/day
40830590|NCT00642369|DRUG|haloperidol|6-40mg/day
40830591|NCT03405935|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
40830592|NCT05543018|DIAGNOSTIC_TEST|Electroretinogram|Retinal function assessment using electroretinogram
40830593|NCT05543018|PROCEDURE|Vitrectomy operation|Vitrectomy operation to treat retinal detachment
40830594|NCT01174017|RADIATION|Iodine 125 standard loose brachytherapy seeds|radioactivity 0.4 U per seed, prescribed dose 144 Gy
40830595|NCT01174017|RADIATION|AnchorSeed Iodine 125 brachytherapy prostate implant|activity 0.4 U per seed, prescribed dose 144 Gy
41019871|NCT01391117|DRUG|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
41019872|NCT04166305|GENETIC|Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:|"DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism"
41019873|NCT04561362|DRUG|BT8009|Bicyclic Toxin Conjugate (BTC) administered either weekly (i.e., on Days 1, 8, 15, and 22) or biweekly (Days 1 and 15) on a 28-day cycle or on Days 1 and 8 of a 21-day cycle for participants in A-1. Participants in Cohorts A-2 and B-7 will receive BT8009 weekly on 21-day cycle. Participants in Parts B-1-B-6 will receive BT8009 weekly either on a 21-day or 28-day cycle. Participants in Parts B-8 and B-9 will receive BT8009 on Days 1 and 8 of a 21-day cycle. Participants in Cohort C will receive a 60-minute IV infusion of BT8009 once weekly (i.e., on Days 1, 8, 15, and 22) on a 28-day cycle. Participants in Part D will receive BT8009 once weekly on a 28-day cycle.
40830596|NCT05040906|DRUG|H02+CHOP|"Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
41349169|NCT04400669|DIETARY_SUPPLEMENT|Low fibre diet|3 days
40830597|NCT05040906|DRUG|Rituxan +CHOP|"Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
40830598|NCT00946725|DRUG|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
40830599|NCT00946725|DRUG|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
40830600|NCT00252226|DRUG|Quetiapine|
40830601|NCT05223062|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
40830602|NCT05223062|OTHER|Compliance-Questionnaire-Rheumatology (CQR)|"The CQR is a self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as low adherers (taking \<80% of their medication correctly). The four point Likert answering scale ranges from; Definitely don't agree (scored 1) to Definitely agree (scored 4) with lower scores indicating lower levels of adherence. Total score is between 0 and 100."
40830603|NCT05223062|OTHER|The Brief Illness Perception Questionnaire (BIPQ)|The Brief Illness Perception Questionnaire (BIPQ) is a questionnaire that assesses a number of beliefs about illness which are thought to be related to coping and help-seeking behavior. Each item is scored between 0 and 10. Maximum total score is 80. Higher scores represents that the patient has a concerned perception of illness.
40830604|NCT05223062|OTHER|The Beliefs About Medicines Questionnaire (BMQ)|The Beliefs About Medicines Questionnaire (BMQ) is a tool for evaluating people's beliefs about medicines. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. It has a total of 18 questions scored with a 5-point Likert scale. Higher scores represent more powerful beliefs.
40830605|NCT05223062|OTHER|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS) determines the levels of anxiety and depression that a person is experiencing. The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
40830606|NCT05223062|OTHER|The Psoriatic Arthritis Quality of Life (PsAQoL)|The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient's quality of life. It is a self-administered, 20-item questionnaire that takes about three minutes to complete. The answers are restricted to true or false.A high score on the PsAQoL indicates a lower quality of life. Total score is between 0 and 20.
40830607|NCT00468936|DRUG|Myfortic|enteric coated Cellcept pills in applicable dose for patient
40830608|NCT01363180|BEHAVIORAL|Trier Social Stress Test (TSST)|The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
40830609|NCT01363180|OTHER|No stress condition|
40830610|NCT01057056|OTHER|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
41019874|NCT04561362|DRUG|Pembrolizumab|Participants in Cohorts A-2 and B-7 will receive 200 mg IV over 30-minute infusion of pembrolizumab on Day 1 of each Q3W.
41019875|NCT03009110|DEVICE|Prophylactic NPWT|The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
41019876|NCT03009110|DEVICE|Standard Dressing|Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
41019877|NCT01229436|DRUG|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
41019878|NCT03847181|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban at a dose of 15 or 20 mg once daily
41157988|NCT03781583|DEVICE|No HMD used|Participants will use their existing mobility skills and strategies to navigate toward a goal. If the participant cannot perform this task, the participant will not be forced to.
41157989|NCT03781583|DEVICE|HMD worn but not active|Participants will wear the HMD, but the HMD will not be active. This will test whether or not the HMD physical components obscure the participants remaining vision and reduce the participants ability to navigate toward a goal.
41349170|NCT04400669|OTHER|MBP plus low-fibre diet|3 days low fibre diet preoperative mechanical bowel preparation
41349171|NCT04694794|OTHER|Educational Brochure|Participants will be provided with Education Brochure developed by the study team to provide information to patients about managing side effects related to chemotherapy
41491835|NCT03529461|OTHER|Secondary rescue maneuvers|If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat \> 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase \> 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist
41157990|NCT03781583|DEVICE|HMD worn and active|Participants will wear the HMD and the HMD will be active. This will test the HMD function for navigation toward a goal.
41157991|NCT03799289|BEHAVIORAL|Behavioral weight loss followed by yoga instruction|12-week standard behavioral weight loss program followed by a 12-week yoga intervention
41157992|NCT03799289|BEHAVIORAL|Behavioral weight loss followed by cooking/dietary education instruction|12-week standard behavioral weight loss program followed by a 12-week cooking/dietary education intervention
41157993|NCT02971683|DRUG|Abatacept subcutaneous|Specified dose of Abatacept subcutaneous on specified days
41157994|NCT02971683|DRUG|Placebo|Placebo of Abatacept subcutaneous
41157995|NCT03246256|OTHER|Group 1|
41157996|NCT00376207|BEHAVIORAL|Physical exercise|
41157997|NCT02895854|RADIATION|Hypofractionated RT 5 x 7,25 Gy|
41157998|NCT02895854|RADIATION|LDR-brachytherapy with I125 seeds|
41157999|NCT05730036|DRUG|Linvoseltamab|REGN5458 will be administered by intravenous (IV) infusion
41158000|NCT05730036|DRUG|Elotuzumab|Elotuzumab will be administered by IV infusion
41158001|NCT05730036|DRUG|Pomalidomide|Pomalidomide capsules will administered by mouth (PO)
41158002|NCT05730036|DRUG|Dexamethasone|Dexamethasone tablets/capsules will be administered PO and/or by IV infusion
41158003|NCT00002471|DRUG|asparaginase|
41158004|NCT00002471|DRUG|cyclophosphamide|
41158005|NCT00002471|DRUG|cytarabine|
41158006|NCT00002471|DRUG|daunorubicin hydrochloride|
41158007|NCT00002471|DRUG|dexamethasone|
41158008|NCT00002471|DRUG|etoposide|
41158009|NCT00002471|DRUG|leucovorin calcium|
41491836|NCT03172663|DEVICE|pure tone audiometry|for estimate the type and degree of hearing loss
41491837|NCT02414438|OTHER|FirstStepDX PLUS and NextStepDX PLUS Webinar|A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS
41158010|NCT00002471|DRUG|methotrexate|
41158011|NCT00002471|DRUG|methylprednisolone|
41158012|NCT00002471|DRUG|therapeutic hydrocortisone|
41491838|NCT02414438|OTHER|FirstStepDX PLUS and NextStepDX PLUS Test Results|Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
41491839|NCT04808401|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
41491840|NCT00837473|DEVICE|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
41491841|NCT01857141|DRUG|preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
41491842|NCT01857141|DRUG|normal saline|patients in the control groups received the equivalent volume of normal saline.
41491843|NCT05944380|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the PENG block
41158013|NCT00002471|DRUG|thiotepa|
41158014|NCT00002471|DRUG|vincristine sulfate|
41158015|NCT06160986|BEHAVIORAL|Horizons Group Intervention|The Horizons Group intervention in English or Spanish language (per participant preference) contains 8 weekly group sessions delivered via video conference by a bone marrow transplant clinician and behavioral health specialist, over approximately 8 weeks, approximately 1.5 hours per session every week. The intervention pairs state-of-the-science information about survivorship and chronic graft versus host disease with self-management strategies. Intervention sessions will be delivered via video conference (Zoom), which participants may access by computer, laptop, tablet, or smart phone. As part of the intervention, participants will have access to an intervention manual and audio-recorded relaxation exercises to support learning and skills practice.
41158016|NCT02364609|DRUG|Afatinib Dimaleate|Given PO
41158017|NCT02364609|BIOLOGICAL|Pembrolizumab|Given IV
41158018|NCT04557865|DIAGNOSTIC_TEST|18F-PMPBB3 (APN-1607) PET imaging|"1. Name: 18F-PMPBB3 (APN-1607, MNI-958, or APN-0000455)~2. Dosage form: injection form~3. Strength: 5mCi/dose~4. Dosage and administration: 5mCi, intravenous injection~5. Mechanism of action (if known): bind to tau protein in the brain~6. Pharmacological category: radiopharamceutical"
41158019|NCT01930877|DRUG|Lidocaine|Lidocaine iv bolus followed by infusion
41158020|NCT01930877|OTHER|Placebo (normal saline)|Normal saline bolus followed by infusion
41158021|NCT06549218|DIAGNOSTIC_TEST|newborn genetic screening and whole genome sequencing|newborn genetic screening (panel of treatable diseases); whole genome sequencing (if newborn develops symptoms suggestive of a genetic disease)
41158022|NCT03194789|DEVICE|Footwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy|Participants will have FGBMM using shoes with pertupods along with traditional pelvic floor therapy over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
41158023|NCT03194789|OTHER|Traditional Pelvic Floor Therapy|Participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
41158024|NCT00009789|RADIATION|accelerated conformational radiotherapy|
41158025|NCT00658801|RADIATION|Respiratory gated proton beam radiotherapy|"Prescription dose to PTV as according to the following dose escalation schema:~1. Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.~2. Group 2: 5cm \<Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week."
41158026|NCT00456183|BIOLOGICAL|MVA 85A|
41158027|NCT01372826|DRUG|NKTR118 Group1|Oral dose, 25 mg
41158028|NCT01372826|DRUG|NKTR118 Group 2|Oral dose, 25 mg
41158029|NCT01372826|DRUG|NKTR118 Group3|Oral dose, 25 mg
40830611|NCT01741714|OTHER|Sham chiropractic manipulative therapy|Sham manipulation
40830612|NCT01741714|OTHER|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
40830613|NCT00046150|DRUG|Insulin glulisine (HMR1964)|
40830614|NCT01451229|DRUG|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
40830615|NCT00795912|DRUG|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
40830616|NCT04534101|BEHAVIORAL|Virtual Reality Mindfulness|This study is designed to test the feasibility, acceptability and effectiveness of VR mindfulness in patients as they undergo various medical therapies to treat their acute or chronic conditions.
41349172|NCT02679430|DEVICE|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
40830617|NCT00681980|DRUG|Valproic acid|15 mg/kg/day
41349173|NCT02299206|DRUG|CeraVe Baby Diaper Rash Cream|Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
41349174|NCT02299206|DRUG|Desitin Maximum Strength Original Paste|Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
40830618|NCT00681980|DRUG|costicosteroids|metypredsolone 1 g/day
41349175|NCT00661414|BIOLOGICAL|ASONEP (sonepcizumab/LT1009)|"ASONEP \[sonepcizumab/LT1009\] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.~The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis."
41349176|NCT04530318|OTHER|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
41349177|NCT04530318|OTHER|Placebo|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
41349178|NCT04489940|DRUG|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
41349179|NCT06317415|BEHAVIORAL|WeChat-based health education on antibiotic use|Health education based on the WeChat platform includes popular science articles on WeChat public Platform and health education videos.
41349180|NCT06317415|BEHAVIORAL|Regular public health education|Health education information on the prevention and control of common chronic diseases
41349181|NCT04764591|OTHER|Lateral sagittal approach|Lateral sagittal approach for ultrasound guided infraclavicular brachial plexus block
40830619|NCT00681980|DRUG|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
40830620|NCT05187754|OTHER|Mindfulness-based breathing therapy program|Participant caregivers of palliative patients were randomized into the intervention and the control groups. Prior to randomization, participants and nurses were informed online abut the aim of the research and their written consent was obtained. Once the study ended, mindfulness-based breathing therapy were recommended to the patients in the control group. Data were collected online via Google forms survey and the interviews were conducted online via Zoom.
40830621|NCT00246506|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
40830622|NCT00246506|PROCEDURE|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
40830623|NCT01479595|DRUG|QBX258|QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
40830624|NCT01479595|DRUG|Placebo|The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
40830625|NCT00933244|DIETARY_SUPPLEMENT|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
40830626|NCT00933244|DIETARY_SUPPLEMENT|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
40830627|NCT00933244|DIETARY_SUPPLEMENT|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
40830628|NCT03239782|BEHAVIORAL|Calorie restriction|Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
40830629|NCT05491421|DRUG|ZT002|"Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
40830630|NCT05491421|OTHER|Placebo|"Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
40830631|NCT04484623|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
41019879|NCT03847181|DRUG|Apixaban (Eliquis)|Apixaban at a dose of 2.5 or 5 mg twice daily
41349182|NCT04764591|OTHER|Costoclavicular approach|Costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
41349183|NCT04443257|OTHER|assessment of the sequelae after hospitalization for Sars-COV-2|the incidence of chronic respiratory failure and fibrosis, as well as of comorbidities including cardiovascular, metabolic, renal, hepatic, neurological, and psychological diseases
40830632|NCT04484623|DRUG|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
40830633|NCT04484623|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
40830634|NCT04484623|DRUG|Bortezomib|Proteasome Inhibitor will be administered.
41019880|NCT03847181|DRUG|Warfarin|Warfarin dose as prescribed by medical practitioner
41019881|NCT04886921|BEHAVIORAL|Abdominal muscle training|Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
41019882|NCT03606161|OTHER|Questionnaire Administration|Ancillary studies
41019883|NCT03606161|PROCEDURE|Transcranial Magnetic Stimulation|Undergo nrTMS
41019884|NCT06573541|DEVICE|Use of ultrasound|Use of ultrasound in the initial management of patients in shock
41158030|NCT01372826|DRUG|NKTR118|Oral dose, 25 mg
41158031|NCT05580302|OTHER|Transcranial Magnetic Stimulation (TMS)|An anatomical T1 magnetic resonance image (MRI) with high resolution will be acquired on a separate day before the TMS experiment. The image will be imported into the neuronavigation system (Nexstim, Helsinki, Finland) to guide the localization of the primary motor cortex (M1) for laryngeal muscle representation. Prior to M1 mapping for laryngeal muscle representation, mapping of the representation for hand muscle representation will be performed. Hand region excitability (abductor pollicis brevis, APB) will be evaluated by using surface electrodes attached to the right-hand APB muscle. The cSP threshold is defined as the lowest TMS intensity that elicits a cSP in 5 out of 10 consecutive trials. Single-pulse cortical stimulations will be performed during the vocalization of sustained /i/ sound.
41491844|NCT05944380|DRUG|0,9% normal saline|20 mL 0.9% normal saline will be injected for the PENG block
40830635|NCT02989844|DRUG|N-803|N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.
40830636|NCT02317809|DRUG|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
40830637|NCT02317809|DRUG|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
40830638|NCT05433740|DEVICE|Proseal Laryngeal mask fixation|fixation with Proseal Laryngeal mask adjustable ligament
40830639|NCT04862728|OTHER|- Strong kids screening tool - Stamp screening tool - PYMS screening tool|Screening Tool for the Assessment of Malnutrition in Pediatrics (STAMP) evaluates patient's clinical diagnosis, nutritional intake during hospitalization and anthropometric measurements, developing a care plan based on the child's overall malnutrition risk (low, medium or high).Screening Tool for Impaired Nutritional Status and Growth (STRONG kids). It consists of four items: subjective clinical assessment, high-risk diseases, nutritional intake and losses, weight loss or poor weight gain. Patients classified at high nutritional risk have a longer hospitalization and a negative standard deviation score (SDS) for weight-for-height (WFH), which indicated a state of acute malnutrition.The Pediatric Yorkhill Malnutrition Score (PYMS) is adopted among medical and surgical patients between 1 and 16 years of age. The PYMS assesses four items: BMI, history of recent weight loss,
40830640|NCT03344640|DRUG|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
40830641|NCT03344640|OTHER|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
40830642|NCT00769717|BEHAVIORAL|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
40830643|NCT00769717|BEHAVIORAL|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
40830644|NCT02737995|DRUG|Ferric carboxymaltose infusion|Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
40830645|NCT01628614|OTHER|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
40830646|NCT03177811|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
40830647|NCT03177811|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
40830648|NCT05593614|DRUG|ATX01 10%|A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
41158032|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
41158033|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
41158034|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
41158035|NCT06646055|DRUG|AK112, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
41158036|NCT06646055|DRUG|nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
41158037|NCT01823640|OTHER|placebo|
41158038|NCT01823640|OTHER|Human Rhinovirus strain 16 (HRV-16)|100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
41491845|NCT01674153|PROCEDURE|Intra-dialytic exercise|Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
41158039|NCT05191121|BEHAVIORAL|FTP Alone|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins).
41158040|NCT05191121|BEHAVIORAL|FTP+Con-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing conventional parameter FES.
41158041|NCT05191121|BEHAVIORAL|FTP+WPHF-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing wide pulse, high frequency parameter FES.
41158042|NCT04117477|DRUG|Xylitol|Xylitol dental wipes
41158043|NCT04117477|OTHER|Placebo|Placebo dental wipes
41158044|NCT03455569|BEHAVIORAL|Behavioral sleep education|This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
41349184|NCT02696590|DIETARY_SUPPLEMENT|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
41491846|NCT01226771|DRUG|"Ribavirin loading dose given"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
41349185|NCT04002258|DRUG|Antipsychotic|any antipsychotic medicine that would have the effect on prolactin level, such as amisulpride, risperidone, olanzapine and so on.
41349186|NCT03644875|DEVICE|etacoat|Etacoat is a HPMC formulation intended to be used in ophthalmic anterior segment cataract surgery.
41349187|NCT02325128|BEHAVIORAL|Sleep-enhancement of extinction memory|Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
41349188|NCT05399329|DRUG|Palbociclib|Palbociclib plus ET as first-line/second-line treatment for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) ABC
41491847|NCT01226771|DRUG|"Priming dose of ribavirin given"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
41158045|NCT03455569|BEHAVIORAL|Education only|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
40830649|NCT05593614|DRUG|ATX01 15%|A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
40830650|NCT05593614|DRUG|Placebo|A 100 mL bottle of hydrogel formulation containing no active substance
40830651|NCT00058149|DRUG|gemcitabine hydrochloride|
40830652|NCT00058149|DRUG|oxaliplatin|
41491848|NCT01226771|DRUG|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
40830653|NCT05364736|DIETARY_SUPPLEMENT|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks
41158046|NCT03319719|DEVICE|Belotero® Balance with integral lidocaine|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
41349189|NCT05399329|DRUG|Endocrine therapy|Palbociclib plus ET as first-line/second-line treatment for HR+/HER2- ABC
41349190|NCT00171067|DRUG|valsartan|
41349191|NCT00171067|DRUG|lisinopril|
41349192|NCT01228695|OTHER|sleep study|The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
41349193|NCT02880930|DIETARY_SUPPLEMENT|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
41491849|NCT04646941|OTHER|regular treatment|The patients with or without OSA received regular hypoglycemic drugs.
41349194|NCT04690556|DRUG|Lucentis (ranibizumab)|Lucentis® 0.5 mg via intravitreal injection once monthly
41349195|NCT04690556|DRUG|LUBT010 (proposed ranibizumab biosimilar)|LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly
41491850|NCT00365131|DRUG|Cerezyme (imiglucerase for injection)|
41491851|NCT01121666|DRUG|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
41491852|NCT03522610|BEHAVIORAL|ADAPT|Two hour, once a week in-person parenting program for 14 weeks plus use web-enhanced supplemental ADAPT materials
41491853|NCT03052218|DEVICE|Pupillometry|Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department
41349196|NCT02946268|DRUG|Ropivacaine|Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
41491854|NCT05656651|BEHAVIORAL|High intensity interval exercise training|Endurance training adapted to age, resting heart rate
41491855|NCT06002737|DEVICE|Occlusion of blood vessels with a diameter greater than 5mm and less than or equal to 7mm using harmonic scalpel|Screening of lung or esophageal surgery patients who meet the inclusion criteria but do not meet the exclusion criteria, and evaluating the effectiveness and safety of ultrasound scalpel in the process of coagulation of blood vessels with a diameter greater than 5mm but not equal to 7mm.
41491856|NCT01884311|BIOLOGICAL|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
40830654|NCT05364736|OTHER|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
41019885|NCT02585739|GENETIC|blood sample|
41019886|NCT03642821|DEVICE|intracranial aneurysm coiling|endovascular treatment of intracranial aneurysm by coiling procedure using OPTIMA coils system
41349197|NCT02937090|OTHER|Blood Draw|Blood sample will be drawn from participants at study entry.
41349198|NCT02937090|OTHER|Stool collection|Stool will be collected from participants at study entry.
41349199|NCT02463331|DRUG|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
41349200|NCT02463331|DRUG|prednisone|Prednisone 5-15 mg/day until the end of the study
41349201|NCT02463331|DRUG|azathioprine|azathioprine 1-2mg/Kg/day until the end of the study
41349202|NCT03729908|BEHAVIORAL|Animal assisted mindfulness based intervention|A mindfulness based intervention in the presence of an animal
41491857|NCT03528083|OTHER|Bronchiolitis quality improvement|Patients in the intervention group will undergo a quality improvement process to improve care quality for bronchiolitis at our hospital.
41491858|NCT03312556|DEVICE|continuous positive airway pressure (CPAP)|Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
41491859|NCT03312556|DRUG|Placebo|Placebo pill or patch. Single dose
41491860|NCT04969510|DRUG|10 mg PRAX-114|Once daily oral treatment
41349203|NCT03729908|BEHAVIORAL|Anti-stress program|A mindfulness based intervention with no reference to animals
41491861|NCT04969510|DRUG|20 mg PRAX-114|Once daily oral treatment
41491862|NCT04969510|DRUG|40 mg PRAX-114|Once daily oral treatment
41158047|NCT03319719|DEVICE|Belotero® Balance|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
41158048|NCT05065892|BIOLOGICAL|COVAX|2 doses of Covid-19 vaccine
41158049|NCT03393065|OTHER|Fluid management guided by BLS|We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.
41349204|NCT05988086|PROCEDURE|platelet rich fibrin|12 children in whom nasal layer of alveolar cleft will be repaired using autologous platelet rich fibrin with autogenous chin bone.
41349205|NCT05988086|PROCEDURE|collagen membrane|12 children in whom nasal layer of alveolar cleft will be repaired using collagen membrane with autogenous chin bone.
41349206|NCT02159365|DRUG|Elotuzumab|
41349207|NCT02159365|DRUG|Lenalidomide|
41349208|NCT02159365|DRUG|Dexamethasone|
41349209|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
41349210|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
41349211|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
41349212|NCT00808028|OTHER|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
41491863|NCT04969510|DRUG|60 mg PRAX-114|Once daily oral treatment
41491864|NCT04969510|DRUG|Placebo|Once daily oral treatment
41491865|NCT00612430|DRUG|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG \& 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data \& order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
41491866|NCT05920733|BEHAVIORAL|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
41491867|NCT00006438|DEVICE|Shoes with Rocker Soles|
41491868|NCT03177174|DRUG|Cisplatin|radiotherapy combined with Chemotherapy Drugs, Cancer
41491869|NCT03177174|DRUG|Docetaxel|Docetaxel
41158050|NCT01126879|DIETARY_SUPPLEMENT|genistein|Given orally
41158051|NCT01126879|OTHER|placebo|Given orally
41158052|NCT01126879|PROCEDURE|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
41349213|NCT04557995|PROCEDURE|Erythropheresis|Draw blood from patient's vein and remove red blood cells as other components would be transfused back.
41349214|NCT01096966|DRUG|Bupivacaine TTS (Bupivacaine Patch)|Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.
41349215|NCT01096966|DRUG|Placebo patch|Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
41349216|NCT01744340|DRUG|Head and neck|"Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
41349217|NCT01744340|DRUG|Colon- Closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
41349218|NCT05701085|OTHER|Educational Intervention|The intervention will occur at a separate dedicated in-person visit with the patient navigator estimated to last 30-45 minutes. The Pre-Intervention Survey will be scored to generate a list of barriers identified for each patient. This list of barriers will be reviewed by the patient navigator prior to the intervention date. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.
41349219|NCT04625530|DRUG|ferric carboxymaltose|Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7. The colour of ferric carboxymaltose is dark brown. A single Ferinject administration should not exceed 20 mg iron/kg body weight.
41349220|NCT04625530|DRUG|tranexamic acid|Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively. The colour of the medicament is transparent.
41491870|NCT06345989|DEVICE|Alginate impression|Alginate impression
40830655|NCT05173415|DEVICE|Sirius Pintution|The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.
40830656|NCT05173415|DEVICE|HydroMARK (C) Clip|The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
40830657|NCT01361932|OTHER|Video of ED discharge instructions for patient's ED discharge diagnosis|Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
40830658|NCT03783741|BEHAVIORAL|Questionnaire|Interview
40830659|NCT03738059|DRUG|Dexmedetomidine Injection [Precedex]|will receive intravenous Dexmedetomidine
41349221|NCT04625530|DRUG|ferric carboxymaltose and tranexamic acid|Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
41349222|NCT05898854|DRUG|68Ga-FAPi-46|Gastric or gatro-esophageal junction cancer patients undergo 68Ga-FAPi-46 PET/CT at primary staging and at restaging
41349223|NCT03874208|OTHER|MRI sequence|An additional sequence to conventional MRI exam (Diffusion tensor imaging) lasting less than 10 min (depending on the MR scanner type and sequence used).
41349224|NCT03874208|OTHER|MRI|MRI exam
41349225|NCT03498989|OTHER|preterm formula milk|"A. complete blood picture~B. C-reactive protein~C. Serum electrolytes~D. Plain x-ray and abdominal ultrasound."
41349226|NCT03498989|OTHER|exclusive breast milk|exclusive breast milk
41349227|NCT06084065|DEVICE|CART-I Plus|Photoplethysmography based ring-type blood pressure measurement device
41349228|NCT04742140|DRUG|Magnesium sulfate|each patient injected 0.5ml in each TrPs of magnesium sulphate according to the treatment group by the same operator
41491871|NCT06345989|DEVICE|Intraoral scan|Intraoral scan with Trios 3Shape Scanner
41491872|NCT00527865|DRUG|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
41349229|NCT04742140|DRUG|Saline|each patient injected 0.5ml in each TrPs of saline according to the treatment group by the same operator
41349230|NCT00017173|BIOLOGICAL|Ad5CMV-p53 gene|2 intraoperative and one post-operative injection of Ad5CMV-p53.
41491873|NCT00527865|DRUG|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
41491874|NCT03301623|OTHER|Clinical Decision Support|The CDS intervention will test the use of existing guideline-based EHR alerts related to the prescription of opioids. CDS alerts employ computer algorithms that account for patient characteristics and diagnoses to deliver reminders of appropriate use when a provider enters an order for a medication.
40830660|NCT03738059|OTHER|normal saline 0.9%|will receive intravenous normal saline 0.9%
41349231|NCT00017173|DRUG|cisplatin|100 mg/m2 IV Day 1 every 21 days for 3 cycles
41349232|NCT00017173|PROCEDURE|conventional surgery|conventional surgery
41491875|NCT03301623|OTHER|Patient Education and Activation Tools|"The patient education materials selected for this study: Pain Management: Which Treatment is Right for You, Preparing for Your Health Care Visit, and a video from the American Chronic Pain Association (ACPA) named A Car with Four Flat Tires, which helps to give patients a better understanding of how multi-modal treatment can be more effective than relying on one source of treatment (e.g., pain medication)."
41491876|NCT03131674|OTHER|Cervical physical therapy|Patients receive a multimodal cervical physical therapy treatment
41491877|NCT04186923|OTHER|F-SPOKE|This project includes communicative, emotional, and also organizational support with outreach across different sectors and phases (F-SPOKE - family-centered, cross-sector and cross-phase organizational, communicative, and emotional support).
41491878|NCT05316883|DRUG|Clozapine|clinical doses adjusted to sideeffects and clinical effect
41158053|NCT05043428|BEHAVIORAL|The roles of peers and functional tasks in enhancing exercise training for adults with COPD: a pilot randomized controlled trial|An 8 week two-arm pilot randomized control trial aimed to evaluate the effects of an online exercise and peer support intervention for people living with COPD.
41349233|NCT00017173|RADIATION|radiation therapy|200 cGy per day Days 105 every week for 6 weeks
41349234|NCT01877005|DRUG|Ruxolitinib|
41349235|NCT01250782|DRUG|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
41349236|NCT01250782|DRUG|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
41349237|NCT05365906|OTHER|Delphi-procedure consisting of four survey rounds|This study will use a modified Delphi approach, consisting of a set of iterative questionnaires. In round 1, an expert panel will grade the relevance of UTI-related items, after which a smaller core research team will compose a reference standard in a series of (online) meetings. In round 2, clinical vignettes will be used to party validate the reference standard and expert panel agreement with the new reference standard will be assessed.
41349238|NCT04780191|DEVICE|MyoRegulator®|Trans-spinal DC stimulation paired with peripheral DC stimulation
41349239|NCT02448095|DRUG|Ponatinib|Observation of tolerability and safety profiles
41349240|NCT05819502|DRUG|Restylane line of injectables|Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
41349241|NCT02744781|DEVICE|Lumbar disc degeneration; LDD|All MR images, taken at 5 lumbar intervertebral disc levels from the first lumbar (L1) vertebra to the first sacral vertebra (S1), were independently evaluated by 2 experienced orthopedic specialists in a random order using a grading system for LDD assessment. Using a comprehensive grading system for LDD, discs were classified into 5 grades, as described by Pfirrman et al. This system uses characteristics of disc structure, distinction between the nucleus and annulus, MRI signal intensity, and intervertebral disc height for grading, and has been accepted as a standardized and reliable evaluation tool for assessment of MRI disc morphology.
41349242|NCT02875782|BEHAVIORAL|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
40830661|NCT05650138|OTHER|Jacobson's progressive muscular relaxation technique|subjects will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis for four weeks.
41349243|NCT02875782|BEHAVIORAL|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
40830662|NCT05650138|OTHER|30 min walk|30 minutes walk twice a week for 4 weeks
40830663|NCT02976025|OTHER|Longitudinal Remote Consultation|Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.
41491879|NCT02963441|DEVICE|LumineticsCore (formerly IDX-DR)|Prospective analysis on an existing subgroup of subjects in the US pivotal study, version 01 and version 02.
40830664|NCT02976025|OTHER|Collaborative Care|Standard collaborative care implementation training and support.
41491880|NCT00281671|DRUG|nesiritide|nesiritide 0.015 mcg/kg/hour x 10 hours
41491881|NCT00281671|DRUG|Placebo|0.9% sodium chloride infusion
40830665|NCT03263312|BEHAVIORAL|Exercise|Exercise training all patients enrolled.
40830666|NCT06219733|DRUG|Vactosertib|200 mg PO BID 5 days on / 2 days off
40830667|NCT06219733|DRUG|Imatinib|Imatinib 400 mg PO QD daily
40830668|NCT04147598|OTHER|LFD|Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.
40830669|NCT04147598|OTHER|SAD|Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.
40830670|NCT01050374|DRUG|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
40830671|NCT01050374|DRUG|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
41349244|NCT00261378|DEVICE|Transarterialchemoembolisation (TACE)|
41349245|NCT00261378|DEVICE|DC Bead with Doxorubicin|
41349246|NCT00494195|GENETIC|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
41349247|NCT00494195|GENETIC|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
41491882|NCT04096508|BEHAVIORAL|Music listening|Patients sit comfortably in a chair for 20 min listening music before the procedure.
41491883|NCT00231647|DRUG|topiramate|
41491884|NCT05711836|GENETIC|HLA-genotyping|HLA genotyping in DNA samples from peripheral blood of patients and controls
41491885|NCT02507544|DRUG|TRX-818 capsules|
41491886|NCT02130583|BEHAVIORAL|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
40830672|NCT05518370|OTHER|Hippotherapy simulator training|Hippotherapy simulator training will be designed for the individual basis.
40830673|NCT05518370|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
40830674|NCT02433873|DIETARY_SUPPLEMENT|Isomalto-oligosaccharide|Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
40830675|NCT00520013|DRUG|bevacizumab|
40830676|NCT00520013|DRUG|erlotinib|
40830677|NCT00520013|DRUG|paclitaxel|
40830678|NCT00520013|DRUG|carboplatin|
40830679|NCT04547114|DIAGNOSTIC_TEST|Multicapillary column coupled ion mobility spectrometry|sampling of nasal air via a foam cuffed oxygen catheter
40830680|NCT05725460|PROCEDURE|dextrose 5% median nerve hydrodissection|planned to be a good alternative to steroid hydrodissection
41491887|NCT02130583|BEHAVIORAL|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
41491888|NCT01930955|DRUG|Amoxicillin|β-lactam antibiotics
41349248|NCT01174940|DRUG|extracorporeal photopheresis|"Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC \> 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient."
41349249|NCT01402375|DRUG|Hydrocodone (first trial)|Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
41349250|NCT01402375|DRUG|Codeine (first trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
41349251|NCT01402375|DRUG|Oxycodone (for second trial)|Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
41019887|NCT06191679|BEHAVIORAL|Decision Aid for Education and Support about Cancer Treatment (DECIDES)|DECIDES is a developmentally appropriate, engaging and interactive web-based decision support application designed to address health literacy through education about cancer and cancer treatment, and provide support for AYA patients, their caregivers, and oncology health care providers to make informed decisions about cancer treatment together.
41349252|NCT01402375|DRUG|Codeine (for second trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
41349253|NCT01402375|DRUG|Oxycodone (third trial)|Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
41349254|NCT01402375|DRUG|Hydrocodone (third trial)|Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
41491889|NCT04492865|DEVICE|MSCT|"-Laboratory tests: All routine indicators of CBC are evaluated~* Nasopharyngeal and oropharyngeal swabs are obtained from each patient to confirm the positivity to Covid-19 by performing RT-PCR to detect the viral RNA.~* MSCT Chest images of all patients are evaluated by three radiologists with variable experiences in CT chest interpretation. The readers are blinded of the RT-PCR results and the CBC indices of the patients and they have access only to the epidemiological history, clinical symptoms, and signs. By consensus, the radiologists score the chest CT as positive or negative for COVID-19 viral pneumonia. When the chest CT is classified as positive, the main CT features are recorded as present or absent (ground-glass opacity, crazy paving, consolidation, nodules, air bronchogram, air trapping, halo sign, reversed halo sign, bronchial wall abnormalities, vascular enlargement, pleural effusion, and lymphadenopathy."
41491890|NCT00859586|DEVICE|Miltenyi Magnetic cell sorter for CD3|Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
41491891|NCT06167590|DIAGNOSTIC_TEST|GAPsy protocol|Each participant will undergo a 7 T multimodal neuroimaging session, including T1-weighted, 1H-MRS and fMRI. Each participant will also be assessed through a structured clinical interview (SCID-I e SCID-II) and will be administered scales such as HAM-A, HAM-D, BPRS and MADRS.
41349255|NCT00813774|BIOLOGICAL|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
41349256|NCT00813774|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
41349257|NCT00813774|BIOLOGICAL|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
41349258|NCT05768568|DEVICE|Manual Toothbrush and Powered Toothbrush|Manual Toothbrush will be mechanically (hand) driven Powered Toothbrush will be battery operated
41491892|NCT02785536|BEHAVIORAL|RITCh Treatment|"The RITCh treatment increased the emphasis on stress management, negative affect management and utilized language and activities to foster an internal locus of control. Activities were added to address impulsive decision-making, develop home smoking policies, increase the positive valance of treatment, and address barriers to use of the nicotine patches. The treatment materials were also tailored with numerous examples relevant to lower SES groups and African Americans. For example: stress management components specifically address financial stress, discrimination, and micro-aggressions; treatment utilization components include reinforcing the value of individual contributions to the group, structured positive feedback among group members at every session, sending missed you post cards signed by all group members to participants who miss a treatment session, specifically addressing myths about nicotine patch use, and practicing the application of nicotine patches together."
41491893|NCT02785536|BEHAVIORAL|Standard Treatment|The components of the standard treatment include education and activities in which participants gain an understanding of the biopsychosocial underpinnings of tobacco dependence and the cue-urge-response cycle of smoking. Interventions include self-monitoring, guided scheduled rate reduction, treatment goal setting, medication education, stress management, cognitive and behavioral strategies for managing cravings and cues, problem-solving, conflict management, enhancing social support, relapse prevention, and cigarette refusal training. A participant workbook was provided that corresponded to the activities in the treatment sessions.
41491894|NCT06273839|DRUG|Tafamidis 61 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
41491895|NCT06273839|DRUG|Tafamidis 70 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
41491896|NCT06273839|DRUG|Tafamidis 61 mg free acid capsule (Reference)|Tafamidis 61 mg free acid capsule (Reference)
41491897|NCT04746300|PROCEDURE|Biopsy|A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing
41491898|NCT04746300|PROCEDURE|Blood sample|Blood samples will be taken for additional translational research
40830683|NCT00550433|DEVICE|Bazedoxifene/Conjugated Estrogens|
41158054|NCT00383864|DRUG|Pegylated interferon and ribavirin|
41158055|NCT02490878|DRUG|bevacizumab|IV
41158056|NCT02490878|DRUG|corticosteroids|IV
41158057|NCT02490878|OTHER|placebo|IV
41491899|NCT00986063|GENETIC|Genetic test for NVP induced rash|The genotype statuses that capable of predict the cutaneous side effects from nevirapine
41491900|NCT00986063|OTHER|3TC/D4T/NVP or 3TC/AZT/NVP|Standard HAART for AIDS patients in Thailand
41491901|NCT00587990|BIOLOGICAL|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10\^7 cells. The injections will be administered following completion of CABG surgery.
41491902|NCT00587990|GENETIC|Placebo|Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
41491903|NCT00587990|BIOLOGICAL|Higher dose MSC injection|Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10\^8 cells. The injections will be administered following completion of CABG surgery.
41491904|NCT02861742|OTHER|Delivery of questionnaires|After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
41491905|NCT02861742|BEHAVIORAL|Questionnaire T1 to fill|T1 is to fill before chemotherapy.
41491906|NCT02861742|BEHAVIORAL|Questionnaire T2 to fill|T2 is to fill after the 6th cycle of chemotherapy.
41491907|NCT02861742|BEHAVIORAL|Questionnaire T3 to fill|T3 is to fill at the end of radiotherapy.
41491908|NCT02861742|BEHAVIORAL|Questionnaire T4 to fill|T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.
41491909|NCT02861742|BEHAVIORAL|Questionnaire T5 to fill|T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
41491910|NCT03009630|PROCEDURE|RFA|Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
41491911|NCT03009630|DEVICE|ENB|ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
41491912|NCT03792763|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
41491913|NCT03792763|DRUG|Placebo 1.7 ml Subcutaneous Solution|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
41491914|NCT02485171|DEVICE|SAFEWALKER|Medical device walking aids.
41491915|NCT03409393|OTHER|The COPUS intervention|The COPUS intervention consists of 8 weeks of High-Intensity Functional Training (HIFT). The frequency of the training is 3 sessions per week and the duration is one hour per session. The intervention is group-based and supervised. Each training session includes warm-up (15 min), followed by 30 minutes of HIFT based on a range of varied functional exercises, including elements of strength training and aerobic exercise. The sessions are supervised by a trained physiotherapist and exercise physiologist supported by 2 two trained bachelor students in Sports Science.
41491916|NCT03409393|OTHER|Usual Care (OPUS treatment)|Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.
41491917|NCT00148642|DEVICE|silver salts coated endotracheal tube|intubation with silver coated tube
41491918|NCT00148642|DEVICE|uncoated endotracheal tube|intubation
41491919|NCT01388166|PROCEDURE|Education|Education
41491920|NCT02991677|BEHAVIORAL|aerobic exercise intervention|Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
40830684|NCT00003136|BIOLOGICAL|filgrastim|
41491921|NCT02991677|OTHER|control group|weekly contact by study staff with survivorship information offered not related to neuropathy.
41491922|NCT02991677|BEHAVIORAL|resistive training|Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
41491923|NCT05214703|OTHER|cold therapy application|cold therapy
41491924|NCT05500196|DEVICE|Per Oral Endoscopy Myotomy (POEM)|POEM is a form of natural orifice transluminal endoscopic surgery that is completed by creating a submucosal tunnel in the lower part of esophagus to reach the inner circular muscle bundles of the LES to perform myotomy, while preserving the outer longitudinal muscle bundles. The result is decreased resting pressure of the LES, facilitating the passage of ingested material.
40830685|NCT00003136|DRUG|amifostine trihydrate|
40830686|NCT00003136|DRUG|carboplatin|
40830687|NCT00003136|DRUG|cyclophosphamide|
40830688|NCT00003136|PROCEDURE|peripheral blood stem cell transplantation|
40830689|NCT01009346|DRUG|RAD001|"Dose Level -1 2.5mg/day~Dose Level 1 5mg/day\*~Dose Level 2 10mg/day~MTD RAD001"
40830690|NCT01009346|DRUG|Cetuximab|250mg/m2/week
40830691|NCT01009346|DRUG|Cisplatin|40mg/m2 Day 1, 8 every 28 days
41491925|NCT04438226|PROCEDURE|Surgical approach|The surgical approach of hemiarthroplasty after femoral neck fracture
41491926|NCT06019520|DRUG|N-Acetylcysteine|Patients in the NAC arm will receive1200 mg of NAC (water-soluble granule Preparation) administered orally once daily at night for 7 consecutive days (1 days before chemotherapy, on the day of chemotherapy, and 5 days after chemotherapy) in each cycle of chemotherapy.
41491927|NCT06019520|DRUG|Chemotherapy|Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.
41491928|NCT06258798|RADIATION|Taking a dental X-ray|Dental X-rays taken in patients with indications confirmed by a written referral.
41349259|NCT04715659|DIAGNOSTIC_TEST|Performance of step test (number of steps) for the assessment of exercise capacity|"The development of the step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
41019888|NCT06191679|BEHAVIORAL|Decision Aid for Education and Support about Cancer Treatment with Coach-Assisted Support (DECIDES + coach)|Live support in the form of a coach is provided to support navigation of DECIDES and promote involvement in decision-making. DECIDES is a developmentally appropriate, engaging and interactive web-based decision support application designed to address health literacy through education about cancer and cancer treatment, and provide support for AYA patients, their caregivers, and oncology health care providers to make informed decisions about cancer treatment together.
41349260|NCT00743184|DRUG|ozarelix|One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
41349261|NCT00743184|DRUG|Placebo|Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
41349262|NCT04722263|RADIATION|Radiotherapy|15 Gy in 3 fractions
41349263|NCT01649752|BIOLOGICAL|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
41349264|NCT01649752|BIOLOGICAL|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
41349265|NCT00911144|BIOLOGICAL|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
41349266|NCT00911144|BIOLOGICAL|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
41491929|NCT00993837|PROCEDURE|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
41491930|NCT05578196|DRUG|fecal bacteria solution|The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
41349267|NCT00911144|BIOLOGICAL|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
41349268|NCT05017727|DEVICE|Closed-loop automated oxygen control with Oxygenie Auto-O2 software (SLE6000)|The 'Oxygenie' is a closed loop automated oxygen control system that has been incorporated into a software module for the SLE6000 infant ventilators. This software control system allows targeting SpO2 values by controlling FiO2.
41349269|NCT00024544|DRUG|anti-IL-4 monoclonal antibody (pascolizumab)|
41349270|NCT06063837|BEHAVIORAL|Live Instruction and Fitness Tracking (LIFT-up)|A 12-week combined aerobic and resistance training exercise protocol
41349271|NCT02483351|OTHER|Liberal Red Blood Cell Transfusion Strategy|RBC Transfusion strategy with hemoglobin trigger of 100g/L
41349272|NCT02483351|OTHER|Restrictive Red Blood Cell Transfusion Strategy|Optional RBC Transfusion with hemoglobin trigger of \<=80g/L
41349273|NCT01323933|DRUG|AB0024|Comparison of different dosages of drug
41349274|NCT02910492|DEVICE|enLighten Laser|Dual-pulse duration laser for the treatment of skin rejuvenation
41349275|NCT05516264|BEHAVIORAL|Dog visits/control visits|See arm description above
41349276|NCT05516264|BEHAVIORAL|Control visits/dog visits|See arm description above
41349277|NCT02316379|DRUG|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
41349278|NCT02316379|DEVICE|MRI|
41349279|NCT03155776|DIAGNOSTIC_TEST|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
41349280|NCT01191138|PROCEDURE|Infracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery
41491931|NCT05578196|DRUG|physiological saline solution|physiological saline solution 20ml
40830692|NCT01009346|DRUG|Carboplatin|"Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:~Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance."
40830693|NCT00964340|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
40830694|NCT00964340|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
40830695|NCT00129610|BEHAVIORAL|Virtual Reality Therapy|
40830696|NCT00129610|BEHAVIORAL|Cognitive Behavior Therapy|
40830697|NCT01680692|DRUG|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
40830698|NCT01680692|DEVICE|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
41349281|NCT01191138|PROCEDURE|Supracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
41349282|NCT02728310|DRUG|Levobupivacaine|An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
41349283|NCT02728310|DRUG|Saline|An infusion rate of 10 ml/h of 300 ml of saline solution for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
41349284|NCT00164099|DRUG|Synbiotic 2000|See protocol - 4 bacteria, 4 fiber mixture
40830699|NCT01680692|DEVICE|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
40830700|NCT01591863|DRUG|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
41349285|NCT05834179|OTHER|cold endotracheal tube|patients who were intubated with an ETT which kept in the fridge.
41349286|NCT00474136|DRUG|Intravenous diclofenac sodium (DIC075V) 18.75 mg|DIC075V 18.75 mg
41349287|NCT00474136|DRUG|Intravenous diclofenac sodium (DIC075V) 37.5 mg|DIC075V 37.5 mg
41349288|NCT00474136|DRUG|Oral diclofenac potassium 50 mg|Oral diclofenac potassium 50 mg
41349289|NCT05817422|BIOLOGICAL|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
41349290|NCT05817422|OTHER|Placebo|0.9% NaCl solution for injection.
41491932|NCT04098939|DIAGNOSTIC_TEST|Diaphragm evaluation|Ultrasound and radiographic evaluation of diaphragm function
41491933|NCT04769063|OTHER|Kinesio Tape|Gluteus medius facilitation and knee spiral taping techniques will be applied to treat dynamic knee valgus
41491934|NCT03493386|DRUG|Daprodustat 2 mg tablet|Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.
40830701|NCT02443194|DRUG|duloxetine|after randomization the patient will receive cymbalta/ placebo for 3 months
41349291|NCT06101355|OTHER|Telerehabilitation|"Intervention group is home exercise program supplemented with visual and video resources using telerehabilitation. With the exercises, there will be video links, exercise visuals, and written explanations. Videos and visuals of the exercises recorded by the physiotherapist and uploaded to the Rehab My Patient application.~Digital exercise forms will be prepared through the Rehab My Patient application. The intervention group will receive exercises, which prepared from the Rehab My Patient application ,digitally through WhatsApp. In this group, exercise sessions will be conducted with the physiotherapist once a week through video calls. Additionally, there will be one instance of messaging and one phone call for follow-up. Video calls and messaging will be conducted through WhatsApp."
41349292|NCT06101355|OTHER|Standard Home Based Exercise Group|Control group, standard home exercise program group , will receive the program as brochures. Although there will be no video supplement, the brochure will include visuals of the exercises. The control group will be monitored through three weekly voice calls.
41349293|NCT04696328|BIOLOGICAL|Human (allogeneic) iPS cell derived-cardiomyocyte sheet|Transplantation
41349294|NCT00796549|DRUG|BiBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
41349295|NCT01478581|DRUG|PCI-32765|
41349296|NCT01478581|DRUG|Dexamethasone|
41491935|NCT03493386|DRUG|Daprodustat 4 mg tablet|Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.
41349297|NCT03247218|DRUG|Memantine Hydrochloride|a low-moderate affinity, uncompetitive, NMDAR antagonist
41491936|NCT05360940|DIAGNOSTIC_TEST|H.pylori stool antigen rapid test and stool parasitological examination|200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done
41491937|NCT04399044|PROCEDURE|Prophylactic muscle flap|"A muscle flap refers to taking an expendable muscle with its vascular supply and moving it to a new area. In this case, the investigators will take a muscle from the leg or abdomen that is redundant (other muscles perform the same function) and moving it to cover vascular grafts to provide healthy tissue to prevent infection."
41491938|NCT06437483|PROCEDURE|Sustained Natural Apophyseal Glides|"SNAGs:~Therapist will apply an antero-superior accessory glide to the superior spinous process of the involved motion segment (between C3 to C7) by pushing it towards the direction of eyeball at approximately a 45 degree angle, using the thumb. The other thumb will reinforce the glide. Painless accessory glide will be maintained and subject will slowly turn their head towards the painful or restricted side (that elicited symptoms) and sustain the position for a few seconds. In case of symptom-free, the subject will apply overpressure at the end of restricted range of motion. The glide will be maintained till the head returns to the midline.~Each session will consist of three sets of six to ten repetitions."
40830702|NCT02443194|DRUG|PLACEBO|after randomization the patient will receive cymbalta/ placebo for 3 months
41019889|NCT03323268|DEVICE|PetCO2 monitoring|CO2 analyzer on ventilator expiratory lane. On-line, continuous, and noninvasive monitor. Routine use in anesthesia and intensive care units.
41349298|NCT02488356|DIETARY_SUPPLEMENT|Litramine|
41349299|NCT01728649|OTHER|Mild Hypothermia|Hypothermia will be achieved using the Zoll Thermoguard XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 4 3cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
41349300|NCT00636038|DIETARY_SUPPLEMENT|corn beta-carotene|yellow corn beta-carotene in a 1 mg level to be taken as corn porridge in one meal by volunteers
41491939|NCT06437483|PROCEDURE|Kinesiotaping|"Kinesiotaping (KT):~Subject will be in comfortable sitting position. Neck of the subject will be thoroughly cleaned with alcohol and sterile gauze pads before the application of Kinesiotape.The layers of KT will be applied in the form of two strips i.e. Y strip and I strip. and applied over the neck in a position of cervical flexion and contralateral rotation and, pasted up and over either ridge of the spine covering the cervical muscles.It extends from T1-T2 to either side of C1-C2.The second layer is I-strip:The overlaying I-strip will be placed perpendicular to the Y-strip, It will be stretched from the both ends, and the middle portion of the tape will be applied first after which tension is released and ends are applied without tension."
41491940|NCT06437483|PROCEDURE|Conventional Treatment|Hot pack (moist heat) and TENS will be applied, each for 10 minutes.
41491941|NCT01250197|DRUG|AR-12286|Ophthalmic Solution
41491942|NCT00297726|BEHAVIORAL|Self-Management Program|
41491943|NCT02365194|BEHAVIORAL|Prehabilitation|information included in arm description
41491944|NCT02365194|BEHAVIORAL|Standard counseling|information included in arm description
41491945|NCT00251225|DRUG|Gleevec|Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m\^2 administered IV
41491946|NCT00251225|DRUG|Docetaxel|60 mg/m\^2 administered IV on day 0
41491947|NCT04470336|OTHER|Collagen Supplement|Three capsules post-breakfast Three capsules post-dinner
41491948|NCT04470336|OTHER|Glucosamine chondroitin|Three capsules post-breakfast Three capsules post-dinner
41491949|NCT04470336|OTHER|Placebo|Three capsules post-breakfast Three capsules post-dinner
41491950|NCT06189547|OTHER|different prior cancer history type|different types of prior cancer history
41491951|NCT01741051|DEVICE|HEPA Filter|
41491952|NCT03214796|DRUG|Human albumin|Infusion of human albumin
41491953|NCT01324674|OTHER|Bach´s Flower Remedy|The subjects will have 4 drops 4 times per day, for approximately 8 months.
41491954|NCT01324674|OTHER|Placebo group|The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
41491955|NCT03924206|DEVICE|Smoke evacuation system|The smoke evacuation system removes the surgical smoke directly near the electrocautery tip, where it is generated
41491956|NCT00221611|DRUG|Administration of intrathecal baclofen|
41491957|NCT02619435|DRUG|regorafenib|Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
41349301|NCT03001791|PROCEDURE|Excisional biopsy with Er:YAG laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
41349302|NCT03001791|PROCEDURE|Excisional biopsy with CO2 laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
41491958|NCT01246011|DRUG|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
40830703|NCT02617940|OTHER|fissure sealant|"Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil)."
41349303|NCT03001791|PROCEDURE|Excisional biopsy with scalpel|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
41349304|NCT04316286|PROCEDURE|Tele-multidisciplinary care|Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists
41349305|NCT04316286|OTHER|Standard care|Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists
41349306|NCT01711476|BEHAVIORAL|Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2|In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
41349307|NCT01711476|OTHER|Active Comparator: Lifestyle counseling ARM 1|In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
41349308|NCT02956031|OTHER|Screening|Cervical specimen obtained using speculum examination and cervical collection bush.
41349309|NCT02956031|OTHER|Colposcopy|Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
41349310|NCT02956031|PROCEDURE|LLETZ|The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
41349311|NCT03530189|DRUG|10% dextrose|After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
41349312|NCT03530189|DRUG|bolus of dextrose, reducing the glucose infusion, insulin|"Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion."
41349313|NCT06362928|DEVICE|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
41491959|NCT03785392|PROCEDURE|Group 1 In-plane|"Group 1: Study will involve total of 15 patients with the procedure done in-plane. Before the block placement and after the block placement lung function will be measured.~FEV1 (forced expiratory volume in 1 second ) and FVC ( forced vital Capacity ) values will be recorded. Block will be performed in plane and postprocedure lung function test will be repeated. New values of FEV1 and FVC will be obtained after the placement of the nerve block."
41491960|NCT03785392|PROCEDURE|Group 2 out of plane|Group 2 study will adopt the out of plane technique and will involve a total of 15 patients in this group. We will do the procedure out of plane and will have lung function FEV1 and FVC measured bedside.FEV1 and FVC values will be recorded. Block will be performed out of plane and postprocedure lung function test will be measured. New values of FEV1 and FVC will be obtained
41491961|NCT00662623|BEHAVIORAL|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
41491962|NCT00662623|BEHAVIORAL|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
41019890|NCT06247163|RADIATION|PET based Raditherapy boost|An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.
41019891|NCT05371210|OTHER|SAIF|Participants interacted with SAIF system at least 2-3 times per week; each session took up to 20 minutes.
41019892|NCT01431508|DRUG|Losartan 50 mg / HCTZ 12.5 mg|Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
41349314|NCT03266367|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin (NAGL)|Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)
41349315|NCT00794859|DRUG|Sorafenib|400mg twice daily
41019893|NCT02294201|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent product
41019894|NCT02294201|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
41019895|NCT02294201|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
41019896|NCT01260610|DRUG|Tenofovir|300 mg of Tenofovir daily
41019897|NCT01260610|DRUG|Telbivudine|600 mg of Telbivudine daily
40830704|NCT02617940|OTHER|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
40830705|NCT04871802|DIETARY_SUPPLEMENT|Taxifolin Aqua|Dietary supplement
41349316|NCT06177223|BEHAVIORAL|Cognitive Behavioral therapy|CBT-based treatment plan would be designed to address PTSD and associated problems.
41349317|NCT04118140|OTHER|Somatic Acupressure|7-week self-acupressure plus usual care (an education booklet)
41349318|NCT04118140|OTHER|Sham acupressure|Same dose as the true acupressure group but on the sham acupoints plus usual care (an education booklet)
41349319|NCT04118140|OTHER|Usual care|Usual care only (an education booklet)
41349320|NCT06247475|OTHER|Answers generated by ChatGPT|Participants will assign a satisfaction score based on the appropriateness of each answer.
41349321|NCT02703649|DRUG|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
41349322|NCT01363154|OTHER|Mozart K448|Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
41349323|NCT01363154|OTHER|Beethoven's Für Elise|Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
41349324|NCT01363154|OTHER|No music exposure|Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
41349325|NCT04652349|DRUG|HGP1910|Take it once daily for 8 weeks orally.
41349326|NCT04652349|DRUG|HCP1903|Take it once daily for 8 weeks orally.
41349327|NCT04652349|DRUG|HGP1909|Take it once daily for 8 weeks orally.
41349328|NCT04652349|DRUG|HGP1911|Take it once daily for 8 weeks orally.
40830706|NCT01561755|DRUG|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
40830707|NCT01561755|DRUG|Placebo|Placebo - 2gr/kg over 2 days of saline
40830708|NCT06385093|DRUG|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
40830709|NCT06385093|DRUG|Alfacalcidol tablets|Oral Alfacalcidol 0.5μg daily
40830710|NCT06385093|DRUG|Calcium carbonate tablets|1.5g Calcium carbonate daily
40830711|NCT03227068|OTHER|PEDSS - symptom management|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
41019898|NCT01260610|DRUG|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
41019899|NCT06573320|OTHER|physical exercise|physical exercise
41019900|NCT03722875|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
41019901|NCT03722875|DRUG|apatinib|Apatinib is a selective VEGFR2 inhibitor
41019902|NCT05435573|DRUG|1000 mL of ringer's acetate solution|1000 mL of ringer's acetate solution
41019903|NCT05435573|DRUG|250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)|500 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride plus 500 mL of ringer's acetate solution
41019904|NCT06023641|DRUG|Vincristine|"Low -risk Administer IV push over 1 minute (or infusion via minibag as per institutional standards) on Day 1 of Weeks 1,8, 15 (3) doses. The maximum dose is 2 mg for all participants.~Intermediate-risk Administer IV, over 1 minute, 3 doses, weekly on day1 High-risk Administer by IV infusion over 1 minute, 3 doses, weekly on day 1,8,15"
41019905|NCT06023641|DRUG|Dactinomycin|"Low-risk Administer by slow IV push over 1-5 minutes on Day 1 of Weeks 1, (1) dose. The maximum dose is 2.5 mg for all participants.~Intermediate-risk Administer by slow IV over 1-5 minutes., 1 doses weekly on day 1 High-risk Administer by slow IV over 1-5 minutes, day1"
41019906|NCT06023641|DRUG|Cyclophosphamide|"Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1"
41019907|NCT06023641|PROCEDURE|Surgical Resection|Low, Intermediate and High-risk
41019908|NCT06023641|PROCEDURE|Proton beam radiation or external beam radiation or brachytherapy|Low, Intermediate and High-risk
41019909|NCT06023641|DRUG|Liposomal irinotecan|Intermediate and High-risk Administer by IV infusion over 90 minutes, 1 dose on day 1 Liposomal irinotecan should be premedicated with dexamethasone (or an equivalent corticosteroid) if not contraindicated. Premedication with diphenhydramine and an H2 receptor antagonist (i.e., famotidine) are also encouraged.
41019910|NCT06023641|DRUG|Vinorelbine|Intermediate and High-risk Administer via slow IV push over 6-10 minutes (or infusion via minibag as per institutional standards) on Day 1 of Weeks 43-45, 47-49, 51-53, 55-57, 59-61, 63-65.
41019911|NCT06023641|DRUG|Temozolomide|High-risk Administer PO (or by NG or G tube) 5 doses, on Days 1-5 When administering with liposomal irinotecan, administer temozolomide prior to liposomal irinotecan. Preferably, administer on an empty stomach (at least 1 hour before and 2 hours after food) to improve absorption. When using temozolomide capsules, round dose to the nearest 5 mg capsule. The capsule may be opened, and contents mixed with applesauce or apple juice. A compounded oral suspension is also available. If emesis occurs within 20 minutes of taking a dose of temozolomide, then the dose may be repeated once.
41349329|NCT02950311|DRUG|Intranasal xylitol spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
41349330|NCT02950311|OTHER|Intranasal saline spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
41349331|NCT01635244|DEVICE|Aortic valve replacement|Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
41349332|NCT01370772|DRUG|Rituximab|"* Cycle 1 Rituximab : 375 mg/m² i.v on day 1~* Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days"
41349333|NCT01370772|DRUG|Rituximab|"* Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15~* Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days"
41349334|NCT01370772|DRUG|Cyclophosphamide|•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
41491963|NCT06389357|BEHAVIORAL|training and counselling|It includes 4 modules that develop children's communication, coping and social life skills and psychosocial preparation for the return to school process. The modules include theoretical explanations, stories, workshops and counselling sessions.
41491964|NCT02352545|DRUG|Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
41491965|NCT03254381|BEHAVIORAL|Resistance Training|Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
41491966|NCT03254381|BEHAVIORAL|Balance and Tone Training|Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
41491967|NCT05951855|DRUG|Selinexor|Selinexor 60mg/day, weight≥70kg (40mg/day, weight\<70kg) orally on d1,4,8,11,
41158058|NCT03653689|DIETARY_SUPPLEMENT|FODMAP|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
41491968|NCT05951855|DRUG|Chidamide|Chidamide 10mg/day, orally on day 1 to 28
41491969|NCT01767961|PROCEDURE|diagnostic imaging|Undergo MBS
41491970|NCT01767961|OTHER|questionnaire administration|Correlative studies
41491971|NCT01767961|PROCEDURE|quality-of-life assessment|Correlative studies
41349335|NCT01370772|DRUG|Fludarabine|FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
41349336|NCT04101162|DIAGNOSTIC_TEST|shear waves elastography; liver biopsy|Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
41349337|NCT00081263|DRUG|Celecoxib|Given orally
41349338|NCT00081263|OTHER|Laboratory Biomarker Analysis|Correlative studies
41349339|NCT00081263|OTHER|Placebo|Given orally
41349340|NCT03478592|OTHER|reference technique|Slow-freezing procedure is the reference technique, actually use at the Toulouse hospital, to cryopreserve embryos. Embryon are frozen with a slow freezing.
41349341|NCT03478592|OTHER|vitrification technique|Vitrification is the new technique to freeze embryons. In this study, the GAVI system will be use for for embryos automatically vitrification
41349342|NCT00376675|DRUG|methylphenidate hydrochloride|Given orally
41349343|NCT00376675|OTHER|placebo|Given orally
41349344|NCT00391495|PROCEDURE|Blood drawing|
41349345|NCT05411263|DIAGNOSTIC_TEST|Comprehensive transthoracic echocardiography, Doppler echography & Kino-cardiograph (Kino)|As per inclusion criteria, all patients undergo right heart catheterisation to obtain a full profile of invasive hemodynamic measurements, including pulmonary arterial wedge pressure (PAWP), pulmonary artery pressure, right ventricular pressure, right atrial pressure (RAP), superior and/or inferior vena cava pressure, hepatic vein pressure with/without balloon occlusion. Immediately after the invasive hemodynamic exam, a comprehensive 2D, Color Doppler and Doppler echocardiography exam, including a Doppler study of the Vv. hepaticae, V. portae and V. renalis is performed. Based upon logistic feasibility, ballistocardiography and seismocardiography with the completely non-invasive Kino device (HeartKinetics, Waterloo, Belgium) is performed in a subpopulation of patients envisioned to be at least 50 patients.
41349346|NCT03952689|DEVICE|Serenno Medical Automatic Urine Output measuring device|"Device that measures ongoing urine output will be connecter to the patients catheter. The urine count of the device will be compared to the gold standard measurement technique (nurse count)."
41349347|NCT02380703|BEHAVIORAL|Aggression Prevention Training (APT)|
41491972|NCT06149715|DEVICE|Bottle Filter|The household is given a Sawyer Squeeze Water Filtration System.
41491973|NCT06149715|DEVICE|Bucket Filter|The household is given a Sawyer International Bucket System, which is a Squeeze Water Filtration System that is integrated with a hose and bucket.
41491974|NCT06149715|DEVICE|Tap Filter|The household is given a Sawyer Tap Water Filtration System.
41491975|NCT00409448|BEHAVIORAL|Counselor-assisted problem solving (CAPS)|In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
41491976|NCT00409448|BEHAVIORAL|Internet-resource comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
41349348|NCT02380703|OTHER|Enhanced Usual Primary Care (EU-PC)|
41349349|NCT02824315|DRUG|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
41349350|NCT02824315|DRUG|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
41349351|NCT02824315|DRUG|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
40830712|NCT03227068|OTHER|PEDSS - support for the caregiver|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
40830713|NCT03564405|DEVICE|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
40830714|NCT04942665|DRUG|Indocyanine green|Low dose or standard dose ICG will be administered by the anesthesiologist as guided by the study coordinator at the beginning of the case, at two points during the operation (1- prior to the dissection of the biliary tract and 2- upon completion of the dissection and establishment of the critical view of safety).
40830715|NCT04942665|DEVICE|PINPOINT Endoscopic Fluorescence|The PINPOINT Endoscopic Fluorescence Imaging System (Stryker Corporation, Kalamazoo, Michigan) will be used. This device enables the surgeon to simultaneously see real-time, high-definition visible-range and NIR fluorescence videos and to superimpose them. It is currently approved by the FDA for intraoperative near-infrared fluorescence imaging.
40830716|NCT06076096|OTHER|Suprainguinal fascia iliaca block|The design of this study involved the retrospective analysis of data. Data was gathered from adult patients falling into the American Society of Anesthesiology (ASA) categories I to III, who were scheduled for elective lower limb surgical procedures. More specifically, patients who had undergone SIFIB either as the primary anesthesia approach or as part of their anesthesia regimen were included. Those who had received general anesthesia, neuraxial anesthesia, or infiltration anesthesia were excluded from the study. Importantly, all patients who participated in the study provided written informed consent for both their involvement in the study and the publication of their data.
40830717|NCT00186212|BEHAVIORAL|workbook/journal on coping with breast cancer|
40830718|NCT00186212|BEHAVIORAL|standard educational materials on breast cancer|
40830719|NCT04676867|DRUG|Dalcetrapib|Dalcetrapib 300 mg Film-Coated Tablets
40830720|NCT04676867|OTHER|Placebo|Placebo Tablets
40830721|NCT06366542|OTHER|Vestibular Rehabilitation Therapy (VRT)|The VRT exercises were composed of gaze stabilization, head motion and postural stability exercises with static and dynamic balance exercises.
40830722|NCT06366542|OTHER|Virtual reality exercises|The VR exercises included watching theraputic videos using the virtual reality goggles with static and dynamic balance exercises.
40830723|NCT06366542|OTHER|Optokinetic Stimulation exercises|Optokinetic Stimulation is a type of visual stimulation used to improve visual function and balance in patients with vestibular disorders.
40830724|NCT03897218|DIETARY_SUPPLEMENT|oatmeal flakes with prebiotic food supplements|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
40830725|NCT03897218|DIETARY_SUPPLEMENT|millet flakes|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
40830726|NCT01196494|PROCEDURE|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
40830727|NCT05740917|DRUG|XZB-0004|XZB-0004 orally Twice daily of every 28-day cycle
40830728|NCT03143673|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
40830729|NCT03684304|DEVICE|Abdominal binder|The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
41019912|NCT06023641|DRUG|Filgrastim, peg-filgrastim|"Low, Intermediate and High-risk:~Prophylactic myeloid growth factor support (Filgrastim or Pegfilgrastim) should be used after all VAC cycles for patients on the high-risk arm. Start myeloid growth factor support (for example, filgrastim 5 mcg/kg/dose SubQ daily until the ANC is ≥ 2000/μL after the expected nadir OR pegfilgrastim 0.1 mg/kg/dose \[for patients \< 45 kg\] or 6 mg/dose \[for patients ≥ 45 kg\] SubQ x 1 dose) 24-48 hours after VAC cycles. Filgrastim may be continued without regard to VCR. Discontinue filgrastim at least 24 hours before the start of the next cycle. Prophylactic myeloid growth factor support should NOT be used after VLIT cycles or during maintenance chemotherapy."
41349352|NCT01751373|BEHAVIORAL|Optimal muscle activation therapy|The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
41019913|NCT04865822|BEHAVIORAL|Single session pain education class|Pain education classes will be provided in person group or virtual settings
41019914|NCT03570736|PROCEDURE|Minimal invasive surgical technique|Minimal Invasive Surgical technique using either Modified Papilla Preservation or Simplified Papilla Preservation Technique.
41349353|NCT01751373|BEHAVIORAL|Standard Therapy|
41158059|NCT03653689|DIETARY_SUPPLEMENT|Gluten|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
41158060|NCT03653689|DIETARY_SUPPLEMENT|Placebo|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
41158061|NCT05584709|BIOLOGICAL|STI-6129|Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).
41158062|NCT05340439|DRUG|IncobotulinumtoxinA 100 UNT [Xeomin]|"In cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs.~In cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2.~In cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 600U) may be administered in the cycle 3 (if the patient has been treated with 16U/kg in cycle 2, a dose of 19U/kg may be injected in cycle 3)."
41158063|NCT03093597|OTHER|virgin coconut oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin coconut oil application twice daily for 2 weeks.
41158064|NCT03093597|OTHER|virgin jojoba oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin jojoba oil application twice daily for 2 weeks.
41158065|NCT03093597|OTHER|virgin almond oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin almond oil application twice daily for 2 weeks.
41158066|NCT03093597|OTHER|white petrolatum ointment|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive white petrolatum ointment application twice daily for 2 weeks.
41158067|NCT02840812|DRUG|Nemonoxacin|Nemonoxacin Malate Capsules 500mg single dose oral
41158068|NCT01407302|OTHER|Head rotation|Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
41349354|NCT05074394|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody that is a neutralizing antibody to SARS-CoV-2
41349355|NCT05074394|DRUG|Placebo|Diluent solution
41349356|NCT04224350|DRUG|TacroBell SR cap.|"* Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment."
41349357|NCT04224350|DRUG|Tacrolimus cap.|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
41491977|NCT06483841|BEHAVIORAL|Parents as Partners|The Parents as Partners program consists of 8 weekly group sessions attended by couples and was developed to strengthen the coparental relationship and promote paternal involvement. After consenting to their participation, couples will be randomly assigned to one of two conditions: intervention group or waitlist-control group. Participants will be assessed before and after the intervention on (co)parental, dyadic and work-family dimensions. Baseline (before intervention), post-test (2 months after baseline) and a follow-up assessment 6 months after the program will be performed. The intervention group will participate in the program, focusing on 5 family domains: Parents as Individuals; Parent-Child Relationships; Couple Relationship; Family of Origin Patterns; Stressors and Supports. Parents in the waitlist-control group will receive the intervention once their participation in the study is finished and if positive outcomes are found.
41491978|NCT03169712|BEHAVIORAL|Cognitive Behavioral Therapy for PTSD|Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
41491979|NCT03169712|BEHAVIORAL|Imagery Rehearsal Therapy|IRT protocol published by Nappi and collaborators (2010)
41491980|NCT00914953|DRUG|oxytocin (Pitocin)|40 IU OT intranasally (IN) once-daily for 10 consecutive days
41491981|NCT05882292|DRUG|ABN401|ABN401 800 mg will be administered orally once daily immediately after a meal \[should be within 1 hour post-meal (fed state)\] at approximately the same time each day in a 21-day cycle.
41491982|NCT03465124|DEVICE|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order. Contralateral eye will receive conventional cataract surgery
41491983|NCT03465124|OTHER|Manual Cataract Surgery|conventional cataract surgery as control
41491984|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) powder formulation|T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate
41349358|NCT01657214|DRUG|SAR125844|"Pharmaceutical form:Concentrate for solution~Route of administration: intravenous"
41349359|NCT04844970|DRUG|Anamorelin Hydrochloride|Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.
41349360|NCT04844970|DRUG|Placebo|Anamorelin placebo
41349361|NCT02116582|DRUG|Enzalutamide|Participants received 160 mg of enzalutamide (soft capsules) orally once daily.
40830730|NCT02042534|DRUG|Rivaroxaban|"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."
41349362|NCT00002394|DRUG|Terbinafine hydrochloride|
40830731|NCT02042534|DRUG|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
40830732|NCT01437527|BEHAVIORAL|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
40830733|NCT01437527|BEHAVIORAL|therapy as usual|Body image therapy as usual
41349363|NCT04177394|DEVICE|MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system.
41349364|NCT02299544|DEVICE|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
41349365|NCT03523806|BEHAVIORAL|Solution-Focused Coaching in Pediatric Rehabilitation|A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
41349366|NCT03307213|DEVICE|BioFreedom™ CoCr Biolimus A9™ stent|Stent implantation
40830734|NCT01161550|DRUG|Granulocyte colony-stimulating factor (G-CSF)|
40830735|NCT01161550|DRUG|Cladribine|
40830736|NCT01161550|DRUG|Cytarabine|
40830737|NCT01161550|DRUG|All-Trans Retinoic Acid (ATRA)|
40830738|NCT01161550|DRUG|Midostaurin|
40830739|NCT01900977|OTHER|Universal Testing with immediate ART|"• Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units"
41019915|NCT03570736|PROCEDURE|Open Flap Debridement|Buccal and lingual intrasulcular incisions will be done extending at least one tooth mesial and distal to the tooth associated with the intrabony defect. Full thickness mucoperiosteal flaps will be reflected to allow access for debridement of the defect.
41019916|NCT03590977|OTHER|licorice extract mouthwash|mouth rinse that contains a natural herbal licorice root extract used as a preventive measure that reduce caries index.
41019917|NCT03590977|OTHER|chlorohexidine mouthwash|mouth wash that contains chlorohexidine as an active component
41019918|NCT00634413|DRUG|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
41349367|NCT03307213|DEVICE|BioFreedom™ SS Biolimus A9™ stent|Stent implantation
41349368|NCT04145505|PROCEDURE|COLORECTAL CANCER SURGERY|SENTINEL NODE DETECTION
41349369|NCT04272372|DRUG|Ketoprofen|PO and local therapy
41349370|NCT03364062|PROCEDURE|cemented shoulder replacement|proximal humeral fracture receiving hemi-shoulder replacement with cement when inserting the stem
41349371|NCT03336476|DEVICE|Videolaryngoscopy|Patients will be intubated with the video laryngoscope
41349372|NCT03336476|DEVICE|Direct laryngoscopy|Patients will be intubated with the direct laryngoscope
41349373|NCT04916301|BEHAVIORAL|Early Mother-Infant Attachment|Early Mother-Infant Attachment Indicators will be observed.
41349374|NCT04498390|DRUG|LY3493269|Administered orally.
41349375|NCT04498390|DRUG|Placebo|Administered orally.
41349376|NCT04211857|DEVICE|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.
41349377|NCT05829915|DEVICE|ROXPro© system (A-Champs)|The intervention consisted in 24 sessions (3/week) of a cognitive-multisensory-physical exercise program carried out in the patient's own home. The exercise program was designed by qualified personal trainers and psychologists, and implemented with the ROXPro© system (A-Champs) (https://a-champs.com; accessed on 8 January 2022). This system consists of small devices that provide visual, auditory and vibration stimuli with which the patient interacts. Through its mobile application, it allows the development of numerous sensory-cognitive-motor exercises adapted to the characteristics of the patients.
41491985|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Oil based tincture formulation|30 mg CBD isolate in MCT oil (1:1 ratio of CBD to Medium Chain Triglycerides oil)
41491986|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation|10% CBD Gum Arabic, maltodextrin base
41491987|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Gum Arabic, sorbitol base formulation|10% CBD Gum Arabic, sorbitol base
41491988|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Isolate in water formulation|formulation
41491989|NCT04971837|DIETARY_SUPPLEMENT|CBD matching Placebo|Matching Placebo
41491990|NCT05060354|OTHER|Blood draw|Approximately 120 mL whole blood will be collected from each subject at each timepoint
41491991|NCT03609723|PROCEDURE|CABG|CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
41491992|NCT04128280|PROCEDURE|TUDP|a surgery: transurethral dilation of prostate with a columnar balloon
41491993|NCT04128280|PROCEDURE|TUIB|a surgery: transurethral incision of bladder neck
41491994|NCT05589532|DEVICE|Prosthetic single-tooth prosthesis using PEEK|A single tooth implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis.
41491995|NCT05134753|BIOLOGICAL|Advanced PRF|Advanced PRF will be placed for patients undergoing sinus augmentation
41491996|NCT05134753|BIOLOGICAL|Control|PRF will be placed for patients undergoing sinus augmentation
41491997|NCT02516553|DRUG|BI 894999|film-coated tablets
41491998|NCT04147923|DIETARY_SUPPLEMENT|Floradapt Mature Immune Defense + Multivitamin|The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of \>1 x 10\^9 CFU. Participants will also consume a multivitamin.
41491999|NCT04147923|DIETARY_SUPPLEMENT|Placebo + Multivitamin|No active ingredients + a multivitamin supplement
41492000|NCT04325035|DRUG|Istaroxime|Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion
41492001|NCT04325035|DRUG|Placebo|Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
41492002|NCT02836938|OTHER|Collection of exhaled breath volatile organic compounds|
41492003|NCT03823014|DEVICE|Elator|Measurement for device, use of device
40830740|NCT01900977|OTHER|Universal Testing with ART eligibility according to National Guidelines|"Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units."
41019919|NCT00634413|DRUG|Placebo|Inhaled matching placebo administered twice daily for 28 days
41019920|NCT00634413|DRUG|Budesonide|Inhaled budesonide twice daily for 28 days
41492004|NCT00322504|PROCEDURE|Accupuncture|
41492005|NCT05656001|OTHER|Real-time functional magnetic resonance imaging Neurofeedback and Real-time Biofeedback|Participants will take part in three runs of real-time functional magnetic resonance imaging feedback (rt-fMRI-NF) training with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive biofeedback will take part in three runs of biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
41492006|NCT05656001|OTHER|Sham functional magnetic resonance imaging neurofeedback and sham biofeedback|Participants will take part in three runs of sham neurofeedback with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive sham biofeedback will take part in three runs of sham biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
40830741|NCT01900977|OTHER|Standard of Care|
41019921|NCT00917059|DRUG|Escitalopram|Fixed dose of 10 mg per day
41019922|NCT00917059|DRUG|Bupropion XL|Fixed dose of 150 mg per day
41019923|NCT01275924|DEVICE|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
40830742|NCT02345356|GENETIC|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
40830743|NCT02345356|OTHER|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
40830744|NCT04813172|BEHAVIORAL|Symptom Assessment|"Examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation by completing the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN), the Brief Pain Index (BPI)and the Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H\&N). They will also be asked to complete the Hearing Handicap Inventory for Adults - Screening (HHIA-S) and the Tinnitus Handicap Inventory - Screening (THI-S) as well as the Flourishing Measure.~Each patient enrolled will be followed by a nurse and speech-language pathologist, twice a week, throughout their treatment (from start until 3-month post completion) All assessments are collected on a secure Ipad through REDcap database. If any significant changes occur, within 2 points from their last assessment, the nurse will notify the oncology physician and provide plan of care to avoid emergency room or hospital visit."
40830745|NCT00533065|DRUG|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
40830746|NCT06444217|PROCEDURE|skin biopsy|skin biopsy
40830747|NCT03094286|DRUG|Durvalumab|Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
40830748|NCT04254016|DIETARY_SUPPLEMENT|HIBISTEVER1|During 8 weeks, administration of a Hibiscus-Stevia drink for 8 weeks at a dose of 4 mg / kg / day for Stevia and 4 g / day for Hibiscus. Evaluation will take place the 30th and 60th days.
40830749|NCT03920059|DRUG|Mycophenolate Mofetil|"Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with MMF on cap and 250 on body) x 10 x 10's.~Storage Store below 30 degree Celcius."
40830750|NCT00438854|DRUG|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
40830751|NCT01822535|DRUG|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
40830752|NCT03923582|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing knowledge, attitude change and skill development. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, LGBT and sexual violence, clinical skills training, ethics and policy writing, and community resources and cultural considerations."
41349378|NCT05829915|OTHER|No exercise program|The control group did not received the physical exercise program
41349379|NCT02108795|DRUG|Remifentanil|Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
41349380|NCT02108795|DRUG|Placebo|
41349381|NCT03595982|DRUG|Procardia XL 30Mg|Procardia XL 30 mg XL Q 12h
41349382|NCT03595982|DRUG|Procardia XL 60Mg|Procardia XL 60 mg Q 24h
40830753|NCT01300351|DRUG|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
40830754|NCT01300351|DRUG|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
41349383|NCT05762965|DIETARY_SUPPLEMENT|GOS 1|1 sachet each morning
41349384|NCT05762965|DIETARY_SUPPLEMENT|GOS 2|1 sachet each morning
41349385|NCT05307965|DEVICE|Retriever Thrombectomy|The SolitaireTM X revascularisation device is a self-expanding stent designed for dynamic clot integration with radiopaque markers that enhance visualisation of the optimal working length. After a thrombotic occlusion has been identified and crossed with a guidewire, the stent-retriever thrombectomy proceeds. A microcatheter (e.g., PhenomTM, MarksmanTM) is advanced over the guidewire and once it has traversed the thrombotic occlusion, the SolitaireTM X device is advanced through the microcatheter until the usable length of the stent extends past each side of the thrombus in the vessel. As the microcatheter is retracted to the proximal radiopaque marker of the stent, the stent self-expands and entangles the thrombus. The microcatheter and SolitaireTM X Revascularisation Device are withdrawn as a unit into the guide catheter under continuous aspiration. PCI then proceeds driven by clinical decision making and department guidelines.
41349386|NCT05307965|PROCEDURE|Percutaneous Coronary Intervention|Standard of care
41019924|NCT01275924|DEVICE|Syndesmotic screw|Quadricortical syndesmotic screw
41019925|NCT02061241|PROCEDURE|Pacing in vein at site of latest mechanical activation|Pacing in vein at site of latest mechanical activation
41019926|NCT02061241|PROCEDURE|Pacing in other suitable vein|Pacing in other suitable vein
41019927|NCT05500976|OTHER|Semi-controlled dietary intervention - Western|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Western diet foods (eg, beef, potatoes, bread, sour cream) provided during each intervention and will be repeated twice.
41019928|NCT05500976|OTHER|Semi-controlled dietary intervention - MiniMed|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Mediterranean foods (eg, oatmeal, salmon, nuts, basil, olive oil, fruits) provided during each intervention and will be repeated twice.
41349387|NCT05307965|PROCEDURE|Thrombus Aspiration|Standard of care treatment with manual thrombectomy catheter
41492007|NCT05935111|BEHAVIORAL|Physical Activity Self-efficacy (PAS) intervention|The PAS intervention will be a web-based intervention to address the unique barriers to physical activity in adults with obesity, based on self-efficacy theory and effective behavioral change techniques. Self-efficacy is specified as a mediating psychological variable in the conceptual model for the promotion of physical activity. Self-efficacy refers to domain-specific beliefs (e.g., job-, transport-, domestic-, leisure-related physical activity) about their ability to execute differing levels of performance given situational demands. There is a rich literature on the importance of targeting self-efficacy as a modifiable mediating variable in PA-promoting interventions. Also, the PAS intervention will consist of effective behavioral change techniques (e.g., action planning, teach to use prompts/cues, goal setting, etc.).
41492008|NCT05029401|DRUG|DMX-1002|Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)
41492009|NCT05029401|DRUG|Placebo|Matching placebo to the IMP (DMX-1002)
40830755|NCT02768025|OTHER|Traditional & Complementary Medicine treatment|Body acupuncture, Ear acupuncture and aromatic therapy
41349388|NCT03947099|DRUG|Ketamine Hydrochloride|Participants are treated with six one-hour infusions of ketamine hydrochloride over a three week period in hopes of treating symptoms of PTSD.
41349389|NCT00909194|BEHAVIORAL|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
41492010|NCT00539227|PROCEDURE|NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
40830756|NCT02768025|OTHER|NRT, counselling|Nicotine Replacement Therapy, counselling
40830757|NCT03080883|DRUG|Apixaban|Given PO
41019929|NCT00997997|DRUG|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
41019930|NCT02930434|DIETARY_SUPPLEMENT|cholecalciferol|Administration of vitamin D3
41349390|NCT05573906|COMBINATION_PRODUCT|Cognitive behavioral therapy for anxiety plus benzodiazepine taper|11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.
41349391|NCT05573906|COMBINATION_PRODUCT|Health education control plus benzodiazepine taper|11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
41349392|NCT04299256|BEHAVIORAL|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
41492011|NCT00539227|BEHAVIORAL|Questionnaire|Questionnaires taking about 20-30 minutes to complete.
41492012|NCT06168877|DIAGNOSTIC_TEST|Execution of 18F-FDG PET/CT and contrast-enhanced CT scan.|PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer).
41492013|NCT04571151|DRUG|LEXETTE 0.05% Topical Foam|Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
41492014|NCT04571151|DRUG|Sorilux 0.005 % Topical Foam|Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
41492015|NCT04571151|OTHER|Vehicle Foam|Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
41492016|NCT00663767|DRUG|Placebo; oral|dose 1, dose 2
41492017|NCT00663767|DRUG|Placebo; oral|dose 1
41492018|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels
41349393|NCT03452397|DRUG|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
41492019|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels; dose 2
40830758|NCT02242175|DEVICE|Glucose breath test (hydrogen breath test)|Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
40830759|NCT01538940|BIOLOGICAL|Intradermal vaccine|15ug
40830760|NCT01538940|BIOLOGICAL|Intramuscular vaccine|15ug
40830761|NCT03674099|DRUG|Imatinib Mesylate|Tablets 400 mg
40830762|NCT03674099|DRUG|Methylprednisolone|1 g tablets or infusion
40830763|NCT02087813|DRUG|Alpha1-antitrypsin|
40830764|NCT02087813|DRUG|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
41349394|NCT03452397|DRUG|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
40830765|NCT02320851|BEHAVIORAL|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
40830766|NCT02320851|BEHAVIORAL|Self-help group (SHG)|(see description of corresponding study arm)
40830767|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
41349395|NCT03452397|DRUG|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
41349396|NCT03452397|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
41349397|NCT01406730|OTHER|exercise|16 week of periodized progressive running exercise 2-4 times/week
41349398|NCT02627196|DEVICE|BAROSTIM NEO® System|
41349399|NCT02627196|DRUG|Medical Management|
41349400|NCT05346380|DEVICE|Olympus VE2 NIR Imaging System|A prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm.
41349401|NCT05346380|DRUG|Indocyanine green|intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm
41349402|NCT00058773|DRUG|Infusion of EBV Specific Cytotoxic T-Lymphocytes|"EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.~Each patient will receive two injections, 14 days apart."
41349403|NCT05835167|PROCEDURE|Inferior part-sternotomy|A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward.
41349404|NCT05835167|PROCEDURE|Full median sternotomy|A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.
41349405|NCT02098629|DRUG|Milrinone|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
41349406|NCT02098629|DRUG|Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
41492020|NCT00663767|DRUG|Celecoxib, COX-2 inhibitor; oral|dose 1
41492021|NCT00663767|DRUG|Placebo; oral|dose 2
40830768|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
40830769|NCT01386242|OTHER|Saline Injection|Saline Injection, 1mL, im,three times per week
40830770|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
40830771|NCT04526717|DRUG|MPT0B640|Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640)
40830772|NCT03859739|DRUG|MK-8558|Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
40830773|NCT02492074|DRUG|Delta-9-tetrahydrocannabinol|oral administration of delta-9-tetrahydrocannabinol
40830774|NCT02492074|DRUG|Cannabidiol|oral administration of cannabidiol
40830775|NCT02492074|DRUG|Placebo|oral administration of placebo
40830776|NCT01143896|OTHER|Depression collaborative care model|The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
40830777|NCT05132517|DIAGNOSTIC_TEST|Kölner Neuropsychologische Screening für Schlaganfall-Patienten|The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.
40830778|NCT02844335|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
40830779|NCT02844335|BIOLOGICAL|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
40830780|NCT02391376|OTHER|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
40830781|NCT02391376|OTHER|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
40830782|NCT02391376|OTHER|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
40830783|NCT01789528|DRUG|CAZ-AVI|IV infusion
40830784|NCT01789528|DRUG|CXL|IV infusion
40830785|NCT03237130|PROCEDURE|preoperative enhanced chest CT examination|Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
40830786|NCT01376479|BIOLOGICAL|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
41349407|NCT02098629|DRUG|Saline Infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
40830787|NCT01376479|BIOLOGICAL|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
41158069|NCT03230110|DIAGNOSTIC_TEST|WP200U home sleep study device|WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
41349408|NCT01017549|RADIATION|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
41349409|NCT04844450|DRUG|JNJ-75220795|JNJ-75220795 will be administered subcutaneously.
41349410|NCT04844450|DRUG|Placebo|Matching placebo will be administered subcutaneously.
41349411|NCT04511091|PROCEDURE|VATS lobectomy|VATS lobectomy allows surgeons to carry out exactly the same operation within the chest that is performed by thoracotomy, but it is done through 3-4 small incisions without rib spreading rather than the large incision with rib spreading that a thoracotomy entails. The surgeon gains his view inside the chest from a small video camera inserted through one of the small incisions, and the procedure is carried out with long instruments passed through the other small incisions.
41349412|NCT05349474|DRUG|Metformin 500 Mg Oral Tablet, up to 4 tablets a day|Metformin 500 mg oral tablets to be titrated to 2000 mg/day divided over two doses or maximum tolerated dose
41349413|NCT05349474|DRUG|Placebo oral tablet identical to metformin, up to 4 tablets a day|Placebo tablets identical to metformin tablets. To be titrated to four tablets divded over two doses or maximum tolerated dose
41349414|NCT04966091|OTHER|Completion of questionnaires|The quality of life questionnaire will be completed before starting the treatment and then during the embryo transfer and will be followed up at each embryo transfer over a maximum period of 18 months. We will also evaluate by means of a specific questionnaire the importance of work/life interactions management and consequences of absenteeism at work, consequences on professional evolution, anxious repercussions in the professional and private domains).
41349415|NCT05903391|DEVICE|3D-Printed Finger Splints|The intervention is wearing a novel finger splint produced by a 3D-printer
41349416|NCT05903391|DEVICE|Conventional Finger Splints|This intervention is wearing a finger splint produced by a conventional method using thermoplastic material typically used in a clinical setting
40830788|NCT01376479|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
40830789|NCT05774184|BIOLOGICAL|barzolvolimab|subcutaneous administration
40830790|NCT05774184|DRUG|Matching Placebo|subcutaneous administration
40830791|NCT04266509|DRUG|PF-06651600|50 milligram (mg) tablet
41349417|NCT02057276|DEVICE|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
40830792|NCT04266509|DRUG|Rifampin|600 mg provided as two 300 mg capsules.
40830793|NCT00594542|DRUG|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
40830794|NCT04767165|DIAGNOSTIC_TEST|MRI|Dynamics of Bone marrow fat fraction by mDixon-quant (%)
40830795|NCT01134406|DEVICE|Hydros Joint Therapy|Single intra-articular injection.
40830796|NCT01134406|DEVICE|Hydros-TA Joint Therapy|Single intra-articular injection
40830797|NCT01134406|DEVICE|Synvisc-One|Single intra-articular injection.
41158070|NCT03571347|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
41158071|NCT03571347|OTHER|Enhanced Treatment As Usual|Routine social support and/or care, and information about freely available mental health services, social services, NGOs, and community networks providing support to asylum seekers and refugees
41158072|NCT04407533|OTHER|Diet tracking and survey|Mobile AI-based food diary application and online questionnaires
41158073|NCT03941990|DRUG|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
41349418|NCT02057276|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|
41349419|NCT02057276|OTHER|Occupational Therapy|
41349420|NCT00740090|DRUG|AMA1-C1/Alhydrogel plus CPG 7909|
40830798|NCT03323736|COMBINATION_PRODUCT|Iontophoresis & tube placement|Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.
40830799|NCT03323736|DEVICE|Tube placement|Subjects will have tubes placed in the OR using the Tube Delivery System in all ears indicated for tube placement.
40830800|NCT04750980|OTHER|food allergy|food allergy
40830801|NCT04750980|OTHER|respiratory allergy|respiratory allergy
40830802|NCT04750980|OTHER|healthy controls|healthy controls
40830803|NCT02311569|DRUG|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
40830804|NCT00534508|DRUG|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
40830805|NCT04423588|DIAGNOSTIC_TEST|dexlansoprazole serum concentration|6 blood samples are collected at fixed time Points after oral Administration of 1 dose of dexilant at regular patients visits preoperatively and 3 and 6 months post-surgery.
40830806|NCT04423588|DIAGNOSTIC_TEST|upper endoscopy|6 and 12 months after surgery the occurrence of marginal ulcers in the same Patient Group is examined by upper endoscopy. The 12-month endoscopy is part of the Routine postoperative diagnosis, the 6-month endoscopy is for study purpose.
40830807|NCT03358641|OTHER|level of physical activity|According to the result of IPA-Q questionnaire, participants are divided in three groups: low level, moderate level, high level of physical activity.
41349421|NCT05182294|DEVICE|AIRVO 2, the new asymmetric nasal cannula|The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..
40830808|NCT04962230|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1
40830809|NCT04962230|DRUG|Carbamazepine|In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.
40830810|NCT04962230|DRUG|PF 07321332/ritonavir|In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
40830811|NCT06195267|DRUG|Sivelestat|The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.
40830812|NCT00287937|DRUG|vorinostat|Given orally
40830813|NCT00287937|DRUG|paclitaxel|Given IV
41158074|NCT03941990|OTHER|Placebo|inhale medical air (22% O2 - 78% N2)
41349422|NCT02729870|DRUG|Oral Glucose Gel|This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
40830814|NCT00287937|DRUG|carboplatin|Given IV
40830815|NCT00287937|OTHER|laboratory biomarker analysis|Correlative studies
40830816|NCT00287937|OTHER|pharmacological study|Correlative studies
40830817|NCT00659217|BIOLOGICAL|mesenchymal stem cell|Autologous MSC transplantation
40830818|NCT01276444|DEVICE|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
40830819|NCT01276444|DEVICE|transpulmonary thermodilution + central venous saturation|Described in details above
40830820|NCT00509093|DRUG|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
40830821|NCT00509093|GENETIC|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
40830822|NCT00509093|GENETIC|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
40830823|NCT00509093|GENETIC|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
40830824|NCT00509093|OTHER|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
40830825|NCT00509093|PROCEDURE|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
41019931|NCT01340339|DEVICE|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
41019932|NCT01340339|DEVICE|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
41019933|NCT06331208|DIAGNOSTIC_TEST|non-contrast chest CT|patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
41019934|NCT06331208|DIAGNOSTIC_TEST|spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
41492022|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 2
41492023|NCT02585934|DRUG|RVT-101|once daily, oral, 35 mg tablets
40830826|NCT05489627|PROCEDURE|Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement|"Medial knee instabilities will be addressed in this arm as described in the published technique: K. Malinowski, K. Hermanowicz, A. Góralczyk, R.F. LaPrade, Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Instability of the Knee, Arthrosc. Tech. 8 (2019) e807-e814. https://doi.org/10.1016/j.eats.2019.03.019.~Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with concomitant ACL QTB reconstruction and abovedescribed MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well."
40830827|NCT02488291|DRUG|0.25 sufentanil|with different dosage
40830828|NCT02488291|DRUG|0.5µg/ml sufentanil|0.5µg/ml sufentanil
40830829|NCT02488291|DRUG|0.1% ropivacaine|0.1% ropivacaine
40830830|NCT01293643|DRUG|100 mg clindamycin /800 mg ketoconazole vaginal ovule|1 vaginal ovule for 3 consecutive days
40830831|NCT01293643|DRUG|100 mg tetracycline hydrochloride /50 mg amphotericin B cream|1 applicator (4 g) full of cream intravaginally for 7 to 10 days
40830832|NCT01603381|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
40830833|NCT05357963|PROCEDURE|Sternotomy application|The chronic pain findings of the patients who underwent sternotomy will be questioned at the postoperative 3rd month.
41158075|NCT00144716|DEVICE|Insect Repellent plus Insecticide Treated Net|
41158076|NCT06402916|DIETARY_SUPPLEMENT|Blueberry drink|Blueberry drink equivalent to 240g fresh blueberries.
41158077|NCT06402916|DIETARY_SUPPLEMENT|Placebo drink|Drink containing no active ingredient.
41158078|NCT00223132|DEVICE|Absorbable sutures|
41492024|NCT02585934|DRUG|Placebo|once daily, oral, pill manufactured to match RVT-101 35 mg tablet
41492025|NCT04626583|BIOLOGICAL|Allogeneic MSC|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells
40830834|NCT03153072|BIOLOGICAL|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
40830835|NCT02670798|PROCEDURE|Thromboelastography laboratory testing|Laboratory test that monitors clotting properties of blood
41158079|NCT00161902|DRUG|Fibrin Sealant Vapor-Heated Solvent/Detergent-treated|
41158080|NCT03334071|BEHAVIORAL|Exercise|"High intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session.~The supervised in-hospital exercise training sessions will last \<1 hour, exercise training intensities will be individually tailored to each CPET. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high intensity (50%Δ) for a predetermined amount of time.~The home-based training programme will involve stair climbing (where possible) and brisk walking to achieve heart rates commensurate with those achieved during the in-hospital exercise training sessions."
41349423|NCT02729870|OTHER|Placebo|This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
41492026|NCT01819974|OTHER|Stratified medication review|A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
41492027|NCT01237925|DRUG|Dexchlorpheniramine 1% gel|Small amount applied over the lesion twice a day for 7 days
41492028|NCT01237925|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
41492029|NCT05080101|OTHER|Conventional Therapy Program|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
41492030|NCT05080101|OTHER|Basic Body Awareness Therapy Group Program|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
40830836|NCT00866671|DRUG|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
40830837|NCT02606227|BEHAVIORAL|Financial incentive|Vouchers
40830838|NCT02606227|OTHER|No financial incentive|No financial intervention
40830839|NCT00868530|BIOLOGICAL|Xyntha|Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
41158081|NCT03178318|PROCEDURE|ultrasound|ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
41158082|NCT03143634|BEHAVIORAL|The Modular Protocol for Mental Health|This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.
41158083|NCT03143634|BEHAVIORAL|Treatment-as-usual|This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
41158084|NCT00778141|DRUG|metformin HC1 750 mg extended-release tablets|
40830840|NCT02847858|BEHAVIORAL|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
40830841|NCT00689000|DRUG|CHR-2797 (tosedostat): Aminopeptidase inhibitor|"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"
40830842|NCT00866346|BIOLOGICAL|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
40830843|NCT06270251|BEHAVIORAL|CBIT|"8sessions of CBIT following a published treatment manual delivered over 10 weeks (the last two sessions are biweekly)~CBIT is a well-established behavioral treatment that is considered by the American Academy of Neurology to be the first-line intervention for tics."
40830844|NCT05950438|PROCEDURE|Esophagectomy|Esophagectomy is a complex surgical procedure performed to treat various esophageal disorders. The surgery involves the removal of all or part of the esophagus and reconstruction using other parts of the gastrointestinal tract.
40830845|NCT04218162|DRUG|Lasmiditan 50mg|Lasmiditan 50mg
40830846|NCT04218162|DRUG|Lasmiditan 100mg|Lasmiditan 100mg
40830847|NCT04218162|DRUG|Placebo|Placebo
40830848|NCT03251040|DEVICE|Autologous activated fibrin sealant|Application of fibrin sealant
40830849|NCT03035773|BEHAVIORAL|Care Plan Only|Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
40830850|NCT03035773|BEHAVIORAL|Care Plan During a Visit|Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
40830851|NCT03035773|BEHAVIORAL|Care Plan During a Visit with an Additional Visit|Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
40830852|NCT06131944|BEHAVIORAL|Rested & Ready to Learn|The intervention arm targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
40830853|NCT01170598|OTHER|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
40830854|NCT00137826|DRUG|Erlotinib|Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
40830855|NCT00137826|DRUG|Bevacizumab|Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.
40830856|NCT05618782|DRUG|LEVI-04|Intravenous infusion
40830857|NCT05618782|OTHER|Placebo:|Placebo dose intravenous infusion
40830858|NCT05183269|DEVICE|Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)|Use of the Oncomfort virtual reality monitor
41492031|NCT02098096|OTHER|Negative Work|"Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:~1. Familiarization~2. Acclimatization~3. Progression~Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.~All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer."
41492032|NCT02098096|OTHER|Stretching|Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
40830859|NCT06012279|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin is a drug that works through inhibition of sodium glucose transporter-2 resulting in glucosuria.
40830860|NCT05805748|BEHAVIORAL|serious game rehabilitation|The SG rehabilitation was proposed to be played four times per week for three weeks, for a total of 12 sessions, with 15 min per session (= 60 minutes per week). Conventional rehabilitation comprised five sessions of 45 min of neuropsychological rehabilitation using classical exploration training (= 225 minutes per week).
41158085|NCT01709643|DIETARY_SUPPLEMENT|High fat breakfast|"The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands)."
41158086|NCT01709643|DIETARY_SUPPLEMENT|HF breakfast with protein|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
41158087|NCT04364022|DRUG|Lopinavir/ritonavir|2x 200mg/50mg, twice daily for 5 days (bid, PO)
41492033|NCT02631967|PROCEDURE|Kono anastomosis|Kono anastomosis
41492034|NCT02631967|PROCEDURE|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
41492035|NCT05453773|OTHER|Questionnaire Administration|Ancillary studies
41492036|NCT05453773|BEHAVIORAL|Tobacco Smoking|Smoke waterpipe tobacco
41349424|NCT04904991|PROCEDURE|Chan-Chuang qigong|"This study applied the Chan-Chuang qigong program, which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice, core qigong of four moves, and cool down after qigong practice.~The movements should be repeated and maintained for 10 minutes per time, 3 time a day (Yeh et al., 2006), totally 90 minutes per week, for 3 months. The guideline booklet of Chan-Chuang qigong (Chen et al., 2019; Chuang, Yeh, \& Chung, 2017) was modified and provided to the participants, which had major sections of introduction to qigong, preparation and precautions, practical procedures with description and photos, normal physical reactions from practicing core Chan-Chuang qigong, precautions of daily life, a confirmation sheet, and a checklist of qigong performance."
41492037|NCT06490874|DEVICE|CGM device - Metformin group|Individuals randomized to metformin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
41492038|NCT06490874|DEVICE|CGM device - Insulin group|Individuals randomized to insulin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
41492039|NCT04681066|DRUG|CM-4620 Injectable Emulsion or CM-4620-IE|Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
41492040|NCT04681066|OTHER|Placebo|Matching Placebo is to be administered as an IV infusion and is supplied as a translucent, white to yellowish, sterile, non-pyrogenic emulsion carrier containing no active pharmaceutical ingredient. Placebo is supplied as an 80 mL fill in a 100 mL single-use vial. Placebo contains the same ingredients as Auxora except that it does not contain CM4620.
41492041|NCT03326609|DRUG|Ropivacaine|Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
41492042|NCT03282474|DRUG|Sofosbuvir|Sofosbuvir 400 MG Oral Tablet \[Sovaldi\]
41492043|NCT03131544|DEVICE|MRI Guided Transrectal Periuretheral Transitional Zone Ablation|Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
41492044|NCT06008743|BEHAVIORAL|Belt Accelerations|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control. The speed of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg.
41349425|NCT01814891|OTHER|Orange maize feeding|This group was fed orange maize.
41492045|NCT06008743|BEHAVIORAL|Belt accelerations combined with an exoskeleton|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control, and using a hip exoskeleton. The velocity of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg. At the same time, they will be interacting with a wearable motion assistive device (i.e., exoskeleton). The exoskeleton will apply forces to the leg to resist hip extension during accelerations, reducing hip extension relative to the values of that participant at baseline.
41492046|NCT06008743|BEHAVIORAL|Variable Stiffness treadmill|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with identical speed control. A variable stiffness mechanism under one belt will change the vertical stiffness of one side of the treadmill for one or multiple steps. The walkers will be informed before stepping on the softer surface on one side, which can be either the left or the right side.
40830861|NCT02839161|BIOLOGICAL|Na-GST-1/Alhydrogel|
40830862|NCT02839161|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel|
40830863|NCT02839161|BIOLOGICAL|Hepatitis B Vaccine|
40830864|NCT05566457|DRUG|Huangqi Guizhi Wuwu decoction (HGWD) infusion packs|Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
40830865|NCT05919641|OTHER|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.
41349426|NCT01814891|OTHER|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
41349427|NCT01814891|OTHER|Oil only|This group received a small amount of plain oil without vitamin A.
41349428|NCT03227692|DEVICE|Persona Knee System|Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
40830866|NCT00512018|DEVICE|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
40830867|NCT00512018|OTHER|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
40830868|NCT05104619|PROCEDURE|tongue surgery|In squamous cell carcinoma of the tongue, complete surgical resection of the tumor
40830869|NCT01339715|PROCEDURE|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
40830870|NCT00619346|DRUG|Placebo|Placebo tablets, BID X 14 days
41349429|NCT03227692|PROCEDURE|Total Knee Arthroplasty|Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.
41349430|NCT03227692|DEVICE|iAssist Knee|Osteotomy of TKA is navigated by iAssist system, iAssist requires pin inserted in bone.
41349431|NCT01142791|DEVICE|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
41349432|NCT05997173|OTHER|Control|Investigation of scale of control
41349433|NCT05997173|OTHER|Non erosive OLP|Investigation of cale of non erosive OLP patients
40830871|NCT00619346|DRUG|pafuramidine maleate|Pafuramidine maleate, 100 mg tablet BID X 14 days
40830872|NCT04867941|DRUG|ACP-196|All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
41349434|NCT05997173|OTHER|Erosive OLP|Investigation of cale of erosive OLP patients
41349435|NCT00685308|PROCEDURE|Stenting of atherosclerotic intracranial stenosis|"Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.~All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%."
41349436|NCT00252499|DRUG|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
41349437|NCT00252499|DRUG|fenofibrate|PPAR-alpha agonist, reduces triglycerides
41349438|NCT00252499|DRUG|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
41349439|NCT00252499|DRUG|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
40830873|NCT06096506|BEHAVIORAL|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($30 per class = $150 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions
40830874|NCT05411861|DRUG|Analgesic Non Narcotic|Injection of protocol-specified volume of local analgesic
41158088|NCT05433311|OTHER|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
41158089|NCT03074097|DRUG|Bupivacaine 0.25%|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
41158090|NCT01799785|BEHAVIORAL|Aerobic exercise|Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
41158091|NCT01799785|OTHER|Usual Care|
41158092|NCT03373500|OTHER|Dietary salt reduction|Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
41158093|NCT02977468|DRUG|Merck 3475 Pembrolizumab|Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.
41158094|NCT02977468|RADIATION|Intraoperative radiation therapy (IORT)|Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
41158095|NCT05261347|PROCEDURE|mulligan mobilisation|an active mobilisation with movement on elbow according to mulligan's protocol
41158096|NCT05261347|PROCEDURE|sham|a lateral glide
41158097|NCT04230993|OTHER|Sea water solution|Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
41349440|NCT02144376|DIETARY_SUPPLEMENT|Ispaghula|
41349441|NCT02144376|DIETARY_SUPPLEMENT|Maltodextrin|
41349442|NCT05564754|DEVICE|Feedback-controlled temperature device|If core body temperature exceeds 37.7°C a feedback controlled-device will be used and set at 37.5°C.
41349443|NCT05564754|OTHER|High MAP|A MAP target of \>85mmHg will be used. Vasopressors will be titrated to this target during 36h.
41349444|NCT05564754|OTHER|Deep sedation|Deep sedation for at least 36h
41492047|NCT03249974|DEVICE|Enlite sensor communicating with Minimed 640G pump|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
41492048|NCT05357092|DEVICE|Appliance. Orthodontic appliance to carry out dentoalveolar movement|"A digital 3D model obtained with a 3D scanner: (T1,baseline), (T2, aprox 8 weeks), and at the end of othopedic treatment previous to primary lip surgery (T3, aprox 16 weeks).~Once a week, clinical check."
40830875|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in experimental group will receive stimulation of DBS system within 1 month after surgery.
40830876|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in control group will receive stimulation of DBS system at 3 months after surgery.
41349445|NCT05564754|OTHER|Fever control without a device|Management of fever in the ICU without a device
40830877|NCT05551676|PROCEDURE|transforaminal group|Epidural steroid injection will be applied with transforaminal approach accompanied by fluoroscopy.
40830878|NCT05551676|PROCEDURE|Lateral parasagittal group|Epidural steroid injection will be applied with lateral parasagittal approach accompanied by scopy.
41158098|NCT02511808|BEHAVIORAL|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
41158099|NCT02511808|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.
41158100|NCT02511808|BEHAVIORAL|Behavioral Self-Control Training|Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
41158101|NCT00001436|DRUG|OncoLAR® (Registered Trademark)|
41158102|NCT00001436|DRUG|tamoxifen|
41158103|NCT02488070|PROCEDURE|Computed Tomography|Part of PET/CT scan
41158104|NCT02488070|DRUG|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)|Intravenously-administered (IV) radioisotope
41158105|NCT02488070|PROCEDURE|Magnetic Resonance Imaging|Part of PET/MRI scan
41349446|NCT05564754|OTHER|Low MAP|A MAP target of \>65mmHg will be used. Vasopressors will be titrated to this target during 36h.
41349447|NCT05564754|OTHER|Minimal sedation|A strategy of minimal sedation in the ICU, used only as needed to facilitate transport, imaging and invasive procedures.
41349448|NCT03072368|OTHER|Photograph|Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age
41492049|NCT02243839|DRUG|Thrombolytic Therapy|Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
41492050|NCT02243839|PROCEDURE|Surgery|Redo valve surgery is performed for obstructive valve thrombosis
41492051|NCT00134693|DRUG|Prednisolone|
41492052|NCT00134693|DRUG|SB-681323|
41492053|NCT02373033|OTHER|Natural food folate|Consumed folate-rich foods (providing additional 250 μg/d folate).
41492054|NCT02373033|OTHER|Folic acid|Received a folic acid supplement (providing additional 500 μg/d folic acid).
41492055|NCT02373033|OTHER|Apple juice|Received apple juice containing no folate or folic acid.
41492056|NCT01284621|DRUG|BI 10773|medium dose, oral administration
40830879|NCT00704561|DEVICE|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
40830880|NCT00704561|DEVICE|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
40830881|NCT00704561|DEVICE|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
40830882|NCT00704561|DEVICE|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
41349449|NCT02537275|DEVICE|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
41492057|NCT01284621|DRUG|Ramipril|Medium dose oral administration on day 2-5
41492058|NCT01284621|DRUG|BI 10773|medium dose oral administration
41492059|NCT01284621|DRUG|Ramipril|Low dose oral administration on day 1
40830883|NCT00532571|DRUG|CoQ10|
40830884|NCT03905317|DRUG|Bevacizumab Injection|Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
40830885|NCT03905317|RADIATION|chest radiation|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.
40830886|NCT03905317|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
40830887|NCT03745352|DRUG|Azacitidine|Given IV or SC
41158106|NCT02488070|PROCEDURE|Positron Emission Tomography|Part of PET/CT and/or PET/MRI scans
41158107|NCT01443546|DRUG|HCG|hCG Trigger
41158108|NCT01443546|DRUG|Lupron Trigger|leuprolide acetate 2 mg SQ
41158109|NCT01443546|DRUG|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
41158110|NCT04761341|DRUG|NUTROF TOTAL|1 per day over a course of 3 months
41158111|NCT03895892|BEHAVIORAL|20 km time trial|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
41158112|NCT03895892|BEHAVIORAL|Wingate test|30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output
41158113|NCT03895892|DIETARY_SUPPLEMENT|Ketone/Caffeine|Dietary supplement containing ketone salts and caffeine
41158114|NCT03895892|DIETARY_SUPPLEMENT|Ketone|Dietary supplement containing only ketone salts
41158115|NCT03895892|DIETARY_SUPPLEMENT|Water Placebo|Dietary supplement containing only water
41158116|NCT05453877|OTHER|No intervention will be applied.|This is an observational study.
41349450|NCT02537275|DEVICE|EyeLIKe Shine, Koryo Eyetech Co|clear lens
41349451|NCT04957745|BEHAVIORAL|Binocular visual confusion (unilateral opaque)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the binocular visual confusion condition, the non-transparent (opaque) peripheral target will be displayed on only one eye (unilateral opaque display)."
41492060|NCT01284621|DRUG|Ramipril|Low dose oral administration on day 1
41492061|NCT01284621|DRUG|Ramipril|Medium dose oral administration on day 2-5
41492062|NCT00250796|DRUG|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
41492063|NCT00250796|DRUG|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
41492064|NCT04319718|COMBINATION_PRODUCT|MK-2048 High Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and either 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)"
41492065|NCT04319718|COMBINATION_PRODUCT|MK-2048 Low Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)"
41492066|NCT03317886|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
41492067|NCT04309318|PROCEDURE|Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
40830888|NCT03745352|DRUG|Pevonedistat|Given IV
40830889|NCT01376570|BEHAVIORAL|Abstinence-reinforcing contingency management intervention|The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. When participants have urines with opiates or cocaine, the value of the voucher is reset. The vouchers are part of the intervention, they are not participant compensation.
41158117|NCT02404012|DIETARY_SUPPLEMENT|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
41158118|NCT00829647|DRUG|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
41158119|NCT00185848|RADIATION|[18F]FHBG|\< 7mCi and 2 ug, iv
41492068|NCT04309318|PROCEDURE|High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
41492069|NCT04785859|DIAGNOSTIC_TEST|BPD prediction|"The following lung ultrasounds will be performed on the patients included in the study: first 24 hours of life, 3rd day of life (DOL) and 7th DOL. At one week of life detection of proteins in nasopharyngeal aspirates will be performed. During the first week of life, an echocardiography will be performed in all patients to evaluate the possibility of a patent ductus arteriosus and its hemodynamic significance.~In the first 20 patients who remain intubated at one week of life, tracheal aspirates will be obtained too, to compare protein determination in both aspirates at the same time."
41492070|NCT05918731|BEHAVIORAL|Self Management|"A training book was given to this group, which was created for the study. The implementation process followed a five-step approach including sessions once a month for five consecutive months with a coach and follow-up phone calls after the end of the sessions.To inspire and engage patients, the sessions included a variety of educational techniques, including knowledge transfer, discussion, hands-on training, and homework. Additionally, coaches received training in motivational interviewing methods. The self-management program and all the process of data collection is described in detail on the supplementary file."
40830890|NCT01376570|BEHAVIORAL|Performance Feedback intervention|Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
40830891|NCT02649855|BIOLOGICAL|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
40830892|NCT02649855|BIOLOGICAL|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
40830893|NCT02649855|DRUG|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
40830894|NCT04079543|OTHER|NPO past midnight|NPO after midnight (solids and liquids), except for a sip of water with medication.
40830895|NCT04079543|OTHER|NPO|No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
41349452|NCT04957745|BEHAVIORAL|Unilateral monocular visual confusion (unilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the unilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on only one eye (unilateral see-through display)."
41349453|NCT04957745|BEHAVIORAL|Bilateral monocular visual confusion (bilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For bilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on both eyes (bilateral see-through display)."
41349454|NCT04802395|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
41349455|NCT04098016|BEHAVIORAL|Digital Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, 3) skills training.
41349456|NCT03908931|RADIATION|MRI|Follow up of osteochondral surgery by MRI and clinical examination
41349457|NCT04955652|BEHAVIORAL|Health Maintenance Topic|Alert
41349458|NCT04955652|BEHAVIORAL|Actionable Sidebar Item|Alert
41349459|NCT04955652|BEHAVIORAL|Best Practice Alert|Alert
41349460|NCT04188210|OTHER|Presence of elbow pain in patients with end stage renal disease|The Beck Depression Inventory (BDI), the Nottingham Health Profile (NHP) scores were measured for all patients to evaluate depression symptoms and health-related quality of life. The elbow pain presence was asked to all the patients, the patients with elbow pain were also evaluated with The Disabilities of the Arm, Shoulder and Hand Score (Q-DASH) and Visual Analogue Scale (VAS). VAS detected as pain during rest, activity, night and pain at last week.
41349461|NCT05431972|DEVICE|Cardea SOLO|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
40830896|NCT00624780|DRUG|Pregabalin|Pregabalin 150-300 mg given twice a day
40830897|NCT00624780|DRUG|Lorazepam|Lorazepam 3-4 mg given twice a day
40830898|NCT00624780|DRUG|Pregabalin|Pregabalin 450-600 mg given twice a day
41349462|NCT05431972|DEVICE|12 Lead EKG|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
41349463|NCT01435122|DRUG|Axitinib|Axitinib Administration as outlined in Arm description
41349464|NCT04061304|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
41349465|NCT04061304|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
41349466|NCT01158885|DRUG|Clofarabine|20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
41349467|NCT01158885|DRUG|Cytarabine intravenous|1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
41349468|NCT01158885|DRUG|Methotrexate|"Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
40830899|NCT00624780|DRUG|Placebo|Placebo
40830900|NCT00951522|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
40830901|NCT00951522|DRUG|Placebo|Inhaled placebo in sterile saline
40830902|NCT05928611|PROCEDURE|Inferior alveolar nerve block with dexamethasone|Using articaine for inferior alveolar block with intraligmentary dexamethasone
40830903|NCT05928611|PROCEDURE|Buccal infiltratation with dexamethasone|Using articaine for buccal infiltratation with intraligmentary dexamethasone
40830904|NCT05928611|PROCEDURE|Inferior alveolar nerve block|Using articaine for injection
40830905|NCT03542916|DRUG|CJ-40001 60ug|CJ-40001 60ug SC, IV injection
40830906|NCT03542916|DRUG|NESP 60ug|NESP 60ug SC, IV injection
41158120|NCT01557699|BIOLOGICAL|PMV via Puffhaler® device|The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
41492071|NCT06169501|BEHAVIORAL|App-based Mindfulness Intervention|Participants in the trial will engage in a 30-day app-based mindfulness program called Unwinding Anxiety that they can complete over a maximum of 60 days. During this time, they will practice short daily mindfulness lessons and respond to a set of brief questions regarding their anxiety levels. Ultimately, we want to assess whether this intervention helps these caregivers feel less stressed and anxious.
41492072|NCT01551108|BEHAVIORAL|Intervention: limited behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
41349469|NCT01158885|DRUG|Intrathecal (IT) Cytarabine|"Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.~If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.~Dose should be given according to age as defined below:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age"
41349470|NCT00515554|DRUG|Rituximab|addition of Rituximab to BEACOPP escalated
41492073|NCT01551108|BEHAVIORAL|Intervention: advanced behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
41492074|NCT00148824|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (vaccine)|
40830907|NCT05590000|DEVICE|Gemini SCS neuromodulation system|This neurostimulation system is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain, angina pectoris and peripheral vascular disease.
40830908|NCT04789161|PROCEDURE|double kissing crush stenting|Patients with true bifurcation lesion treating with double kissing crsuh stenting technique
40830909|NCT04789161|PROCEDURE|double kissing culotte stenting|Patients with true bifurcation lesion treating with double kissing culotte stenting technique
40830910|NCT00871117|BIOLOGICAL|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
41158121|NCT01557699|BIOLOGICAL|PMV via SoloventTM device|The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
41158122|NCT01557699|BIOLOGICAL|Licensed Subcutaneous Measles Vaccine|This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.
41492075|NCT00148824|BIOLOGICAL|23-valent pneumococcal conjugate vaccine (vaccine)|
41492076|NCT02447796|DRUG|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
41492077|NCT02447796|DRUG|Dexmedetomidine|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
40830911|NCT00871117|BIOLOGICAL|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
40830912|NCT00871117|BIOLOGICAL|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
40830913|NCT01011933|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
40830914|NCT01011933|DRUG|Selumetinib|Given PO
40830915|NCT03068416|BIOLOGICAL|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
41158123|NCT03739333|OTHER|11C-Methionine PET-MRI|Implementation 11C-Methionine PET-MRI performed for each patient in one place (department of nuclear medicine of Hospices Civils de Lyon). The 11C-Methionine PET-MRI will be performed after radiochemotherapy in patients with MRI suspicious of pseudoprogression.
41158124|NCT05624697|PROCEDURE|sticky bone housed in PEEK Shell|Patient specific Sticky Bone/Implant housing PEEK shell in Anterior Atrophic Maxilla
41158125|NCT02537236|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
41158126|NCT02537236|BEHAVIORAL|TLC nutritional intervention|nutritional orientation.
41158127|NCT02537236|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
41158128|NCT03175835|DRUG|Rosuvastatin 20 mg|Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5
41158129|NCT03175835|DRUG|CKD-519 200 mg|Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9\~Day21
41158130|NCT03175835|DRUG|Rosuvastatin 20 mg & CKD-519 200 mg|Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26
41349471|NCT00515554|DRUG|BEACOPP escalated|chemotherapy with BEACOPP escalated
41492078|NCT04871763|OTHER|Retainers' Cleansing with Geldis®|Patients will clean their essix retainers with Geldis® using a toothbrush every night for 2 months.
41492079|NCT04871763|OTHER|Retainers' Cleansing with tablets|Patients will leave their essix retainers in a glass with water and Polident tablets every night for 2 months.
41492080|NCT04871763|OTHER|Retainers' cleansing with water|Patients will brush their essix retainers with a toothbrush under water every night for 2 months.
40830916|NCT04533399|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
40830917|NCT04533399|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
40830918|NCT04262713|OTHER|Radiographs|Radiographs of the implanted hip with Meije duo size1 or 2 are performed in eligible patients ( Weigh\>60, Long neck stem, Varus; DEVANE score ≥ 4)
40830919|NCT04949568|BEHAVIORAL|Diabetes Self-Management Behaviors|The intervention is to be delivered by a diabetes educator.
40830920|NCT05675761|DRUG|Azorubine|Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
40830921|NCT06545266|PROCEDURE|micro-fragmented adipose tissue injection|Micro-fragmented adipose tissue was obtained through the Lipogems kit and intraarticularly injected after an arthroscopic debridement.
40830922|NCT00908115|BIOLOGICAL|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
40830923|NCT03545711|DRUG|Anlotinib Hydrochloride with Irinotecan|Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.
40830924|NCT03973463|BEHAVIORAL|Elastic knee joint movement|Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.
40830925|NCT01705158|DRUG|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
40830926|NCT04101617|BEHAVIORAL|Oral Health education including printed educational material|Printed and online educational materials were developed and provided to pediatricians so they can share relevant information about caries control to parents of toddlers. A previous interview was performed to pediatricians as focus groups to know how they are doing their evaluations and what do they take into account during the children visits in order to identify where to focus for the training what it is necessary to change. After that pediatricians were trained to give oral health recommendations. So, to the intervention group, the pediatricians will give these recommendations to the parents and also they will give them a printed educational material previously developed for the project.
40830927|NCT00763906|DEVICE|norepinephrine infused at the clinician's discretion|
41158131|NCT00201214|DRUG|Citrulline|Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
41349472|NCT05680090|DIAGNOSTIC_TEST|Artificial intelligent system for eye emergency triage and primary diagnosis|An intelligent triage and diagnostic system for ophthalmic emergencies has been developed. In the prospective test, patients with acute ocular symptoms can achieve remote self-triage and primary diagnosis after uploading metadata and ocular images.
41349473|NCT00449995|PROCEDURE|confocal laser microscopy|
41349474|NCT02319564|DRUG|Beclomethasone|
41349475|NCT02319564|DRUG|Beclomethasone and Salbutamol|
41492081|NCT03735069|PROCEDURE|IPT (Indirect pulp treatment)|Indirect pulp treatment involves complete caries excavation from the dentin-enamel junction using a round bur. Caries near the pulp is removed with caution using spoon excavator until the remaining dentine shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material is placed, followed by resin-modified glass ionomer (RMGI) build-up material, and the final restoration; a preformed Stainless Steel Crown (SSC).
40830928|NCT00763906|DEVICE|norepinephrine infused under computerized fuzzy logic control|
40830929|NCT02152514|DRUG|Intrathecal Morphine/Sufentanil|
40830930|NCT02152514|DEVICE|PCA|
40830931|NCT06521437|DEVICE|TMS targeting the hippocampus indirectly via its network|Subjects will receive high-frequency repetitive TMS to a parieto-occipital location defined in each subject based on high resting-state fMRI connectivity with the hippocampus at baseline
40830932|NCT03043677|BIOLOGICAL|Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab|"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."
40830933|NCT00162279|DRUG|Abatacept|
41019935|NCT06331208|DIAGNOSTIC_TEST|Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
40830934|NCT04414124|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
40830935|NCT04414124|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
40830936|NCT00000357|DRUG|Buprenorphine|
40830937|NCT00685646|DRUG|antiandrogen therapy|Up to 24 courses of therapy
40830938|NCT00685646|DRUG|zoledronic acid|Up to 24 courses of therapy
40830939|NCT00099229|DRUG|Licarbazepine|
41019936|NCT06331208|DIAGNOSTIC_TEST|supine bike exercise during right heart catheterisation|subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
41019937|NCT06331208|DIAGNOSTIC_TEST|Lung ventilation/perfusion SPECT|subgroup of HF subjects will undergo ventilation/perfusion SPECT
41158132|NCT00141908|DRUG|17-alpha Hydroxyprogesterone Caproate|250 mg IM weekly
41158133|NCT00141908|DRUG|Castor oil|weekly IM injections
41158134|NCT05354557|DRUG|Iberdomide|Patients will receive 12 cycles of iberdomide as maintenance therapy. Cohort 1: Cycle 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles Cohort 2: Cycles 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles
41349476|NCT02319564|DRUG|Placebo|
41349477|NCT02319564|DEVICE|Aerochamber Max®|
41349478|NCT00501930|DRUG|GSK189075|
41349479|NCT03595176|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
41349480|NCT00549354|DEVICE|Endoluminal Graft|
41349481|NCT02148601|OTHER|Fecal Microbiota Transplantation|
41349482|NCT02148601|DRUG|Standard Antibiotic Therapy|
41349483|NCT02148601|DRUG|Vancomycin (before randomization)|Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
41349484|NCT01213849|DRUG|Fluticasone furoate 50 mcg (4 inhalations)|4 inhalations of 50 mcg strength
41349485|NCT01213849|DRUG|Fluticasone furoate 100 mcg (4 inhalations)|4 inhalations of 100 mcg strength
41349486|NCT01213849|DRUG|Fluticasone furoate 200 mcg (4 inhalations)|4 inhalations of 200 mcg strength
41349487|NCT01213849|DRUG|Vilanterol 25 mcg (4 inhalations)|4 inhalations of 25 mcg strength
41349488|NCT04752631|DRUG|Tenecteplase|The participants received TNK-tPA thrombolytic therapy
41349489|NCT01337791|DRUG|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
41349490|NCT03999333|DEVICE|Virtual Reality (Oculus Go)|Participants will self-administer virtual reality intervention, in addition to standard of care treatment for pain. There will be 6 weeks of weeks of monitoring period (2 weeks before, 4 weeks during, and 2 weeks after the virtual reality intervention).
41349491|NCT00337740|PROCEDURE|endoscopic variceal banding|
41349492|NCT00337740|DRUG|propranolol|
41349493|NCT00896662|OTHER|immunologic technique|immunologic technique
41349494|NCT00896662|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
41349495|NCT00896662|OTHER|pharmacological study|pharmacological study
41349496|NCT05655416|PROCEDURE|Endovenous chemical ablation with Trendelenburg's operation (eCAT)|Endovenous chemical ablation with trendelenburg's operation (e CAT) is a method for the treatment of varicose veins
41349497|NCT04790734|DRUG|Sedation drugs|Different sedation drugs
41349498|NCT00274352|DRUG|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
41349499|NCT01550770|DRUG|propofol|peripheral IV of propofol at increasing dose levels
41349500|NCT05634837|BEHAVIORAL|Decision Support System counseling|Decision Support System counseling to improve diet and lifestyle in pregnancy
41349501|NCT05634837|BEHAVIORAL|Standard nutritional counseling|Counseling to improve diet and lifestyle in pregnancy
41349502|NCT05575583|DEVICE|repetitive transcranial magnetic stimulation|The neural navigation system was used to accurately locate the stimulus target.Continuous theta short rapid pulse mode was used. CTBS mode consisted of a slave stimulus delivered every 0.2 seconds (5Hz), and each slave stimulus consisted of three bursts of 50Hz. A single stimulus lasts about 40 seconds and totals 600 pulses.
41349503|NCT05575583|DEVICE|pseudo repetitive transcranial magnetic stimulation|Participant in control group receive pseudo repetitive transcranial magnetic stimulation
41349504|NCT04812665|BEHAVIORAL|mHealth solution based on emotional and behavioral change techniques|"Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change.~The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs."
41492082|NCT03735069|PROCEDURE|Cvek/partial pulpotomy|Cvek/partial pulpotomy involves removal of inflamed pulp tissue to depth until healthy pulp tissue is reached (depth of 2-4 mm), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
40830940|NCT05586958|DRUG|Tigulixostat|Xanthine Oxidase Inhibitor
40830941|NCT05586958|DRUG|Placebo|Matching placebo
41349508|NCT00597857|DRUG|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
41349509|NCT00597857|DRUG|placebo|receipt of a placebo pill for 16 days
41349510|NCT00262561|DRUG|Aspirin|The effect of Aspirin on platelet function was assessed.
41349511|NCT00468624|DRUG|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
41349512|NCT00468624|PROCEDURE|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
41349513|NCT00468624|PROCEDURE|blood sampling before and after pegvisomant/placebo|
41349514|NCT00468624|PROCEDURE|arginine stimulation test after each limb|
41349515|NCT02336191|PROCEDURE|living donor liver transplantation|living donor liver transplantation
41349516|NCT00726310|DEVICE|SpineLink® , SpineLink® II|Spine plate system for lumbar spinal fusions
41019938|NCT01688336|DRUG|FOLFIRINOX|"FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~* Oxaliplatin (85 mg/m2)~* Leucovorin (400mg/ m2)~* Irinotecan (180 mg/m2)~* 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours"
40830942|NCT02330523|DEVICE|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
41349517|NCT03209791|OTHER|Biopsies|Biopsy will be done on the Vastus Lateralis muscle in all groups
41349518|NCT06258772|DRUG|Mepolizumab Auto-Injector|Mepolizumab 100 mg in pre-filled injector
41349519|NCT03416036|BIOLOGICAL|TetraVax-DV-TV003 (TV003)|TV003 contains 10\^3.3 plaque-forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. Administered by subcutaneous injection in the deltoid region of the upper arm
41349520|NCT03416036|BIOLOGICAL|rDEN2Δ30-7169 (DENV-2)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
41349521|NCT03416036|BIOLOGICAL|rDEN3Δ30 (DENV-3)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
41349522|NCT03416036|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
41349523|NCT05592444|DIAGNOSTIC_TEST|Low iodine Spectral Detector CT Pulmonary Angiography|Low iodine Spectral Detector CT Pulmonary Angiography
41349524|NCT05473442|DRUG|EQU-001|20 mg pills of EQU-001
41349525|NCT05473442|OTHER|Matching Placebo|20 mg matching placebo pills
41349526|NCT01349842|BIOLOGICAL|Blood sampling|20ml of patient peripherical blood will be collected
40830943|NCT02330523|DEVICE|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
40830944|NCT03254914|PROCEDURE|Home Blood Pressure|Measure Home Blood Pressure
40830945|NCT00569309|BIOLOGICAL|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
40830946|NCT00569309|OTHER|laboratory correlative studies|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
40830947|NCT00569309|OTHER|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
41349527|NCT01349842|OTHER|Usual clinical and radiological criteria|Clinical examination, tumoral evaluation
40830948|NCT02262819|DRUG|S. aureus|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
40830949|NCT04947631|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
40830950|NCT04947631|DRUG|Dutasteride|Dutasteride 0.5 mg once daily for 48 weeks
41349528|NCT02085486|DEVICE|Ultrasound-assisted puncture|Portable ultrasound device
41349529|NCT02085486|OTHER|Standard|Standard inspection, palpation.
41349530|NCT00547989|DRUG|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
40830951|NCT04947631|DRUG|Tadalafil|Tadalafil 5 mg once daily for 48 weeks
40830952|NCT04947631|DRUG|DKF-313 placebo|Once daily for 48 weeks
41349531|NCT00547989|DRUG|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
41349532|NCT00547989|DRUG|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
41349533|NCT03399786|DRUG|evinacumab|IV administration of evinacumab
41349534|NCT03399786|DRUG|Placebo|IV administration of placebo
41349535|NCT02017067|PROCEDURE|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
41349536|NCT03644316|DEVICE|BandGrip skin closure device|topical skin closure device
41349537|NCT06014021|BEHAVIORAL|Pelvic floor muscle training with biofeedback device|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure.
41349538|NCT06014021|BEHAVIORAL|Pelvic floor muscle training|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature.
41349539|NCT06014021|BEHAVIORAL|Information about pelvic floor and communication with health professionals|Use of the Smartphone application with access to information about pelvic floor and direct communication with healthcare team.
41349540|NCT03198728|DRUG|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
41349541|NCT03198728|DRUG|AndroGel|topical testosterone gel 1.62%
41349542|NCT05972577|OTHER|Health Promotion and Education|Undergo GO!
41349543|NCT05972577|OTHER|Medical Device Usage and Evaluation|Wear accelerometer
41349544|NCT05972577|OTHER|Quality-of-Life Assessment|Complete quality of life assessments and diary entries
41349545|NCT05972577|OTHER|Questionnaire Administration|Complete questionnaires
41349546|NCT01984294|DRUG|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
40830953|NCT04947631|DRUG|Dutasteride placebo|Once daily for 48 weeks
40830954|NCT04947631|DRUG|Tadalafil placebo|Once daily for 48 weeks
40830955|NCT02053662|PROCEDURE|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
40830956|NCT03173911|DEVICE|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
40830957|NCT04126889|OTHER|questionnaire survey|questionnaire survey
40830958|NCT05118815|OTHER|Slim abutment|Use a narrower abutment to see if they present a better biological seal.
40830959|NCT05118815|OTHER|Standard abutment|Use a standard abutment
40830960|NCT05448404|DRUG|18F-PSMA-1007|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.
40830961|NCT05448404|DRUG|18F-FDG|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
40830962|NCT01044316|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
40830963|NCT00390117|DRUG|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
40830964|NCT00390117|OTHER|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
40830965|NCT01336751|DRUG|Insulin glargine|solution for subcutaneous injection
40830966|NCT01336751|DRUG|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
40830967|NCT03146780|PROCEDURE|Conventional impression|"A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays)."
40830968|NCT03146780|PROCEDURE|Digital Scan 1|Direct intra-oral digital scans using Sirona Omnicam software.
40830969|NCT03146780|PROCEDURE|Digital Scan 2|Direct intra-oral digital scans using Planmeca Planscan software.
40830970|NCT03146780|PROCEDURE|Digital Scan 3|Direct intra-oral digital scans using 3M True Definition software.
40830971|NCT02549352|DRUG|LEO43204 gel|
40830972|NCT02549352|DRUG|Vehicle gel|
40830973|NCT00983736|DRUG|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
41349547|NCT01984294|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
41349548|NCT01984294|DRUG|GS-9669|GS-9669 tablet(s) administered orally once daily
40830974|NCT00983736|DRUG|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
40830975|NCT02754583|BEHAVIORAL|Water, sanitation, and hygiene (WASH) intervention|WASH arm: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction and maintenance, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
40830976|NCT02754583|BEHAVIORAL|Standard of care WASH intervention|Stand of care WASH arm
40830977|NCT02754583|DRUG|Azithromycin|20mg/kg
40830978|NCT02754583|DRUG|Tetracycline|Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.
40830979|NCT02754583|OTHER|Control|The control group will receive no intervention during the trial. They will be enrolled in mass antibiotic treatment at the conclusion of the trial.
40830980|NCT06157944|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
40830981|NCT02267954|OTHER|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
40830982|NCT04304911|BEHAVIORAL|Blended intervention (UP-APP)|Unified Protocol (UP) for transdiagnostic treatment of EDs in the blended intervention (UP-APP)
40830983|NCT04304911|BEHAVIORAL|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
41349549|NCT05051527|DRUG|Legalon® 140 mg|Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision
41349550|NCT01307046|DRUG|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
40830984|NCT00806442|DRUG|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
41349551|NCT01307046|DRUG|Losartan|Tablet containing losartan potassium (100 mg), once daily
40830985|NCT00806442|DIETARY_SUPPLEMENT|Corn Oil|9 g/day of corn oil
40830986|NCT02998047|DRUG|Lintuzumab AC 225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.
40830987|NCT02893826|DRUG|EG-1962 (nimodipine microparticles)|
40830988|NCT02893826|DRUG|Enteral Nimodipine|
40830989|NCT04382521|BEHAVIORAL|Text Message Intervention|Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
40830990|NCT04202146|BEHAVIORAL|Contingency Management + Motivational Interviewing|Seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling on cannabis use and relapse.
41349552|NCT01307046|DRUG|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
41349553|NCT01307046|DRUG|Placebo to losartan 100 mg|Placebo tablet to match losartan 100 mg, once daily
40830991|NCT02623075|BIOLOGICAL|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
40830992|NCT03780959|DRUG|Etanercept|Administered twice weekly by subcutaneous injection
40830993|NCT03780959|DRUG|Placebo|Administered twice weekly by subcutaneous injection
41492083|NCT03735069|PROCEDURE|Cervical pulpotomy|Cervical pulpotomy involves removal of inflamed pulp tissue from all pulp chamber as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 6 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber (2-3mm) thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
40830994|NCT02370095|DRUG|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
40830995|NCT02370095|DRUG|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
40830996|NCT05418153|DEVICE|Tecnis Synergy IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
40830997|NCT05123404|DIAGNOSTIC_TEST|multi parametric MRI|In our study we aim to evaluate role of Multiparametric MRI in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score.
40830998|NCT05123404|PROCEDURE|transurethral resection of bladder tumor|detection of degree of invasion to test accuracy of ViRADS score
40830999|NCT04579094|OTHER|Feces sampling at inclusion (J0)|Feces sampling at inclusion (J0)
40831000|NCT01169688|OTHER|Pupil dilation with phenylephrine 10% vs cyclopentolate 2%|
40831001|NCT03343080|DRUG|1.8% lidocaine plus 0.76% sodium bicarbonate|At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
40831002|NCT03343080|OTHER|Air|At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
40831003|NCT04973345|DRUG|Terbutaline|management of asthma symptoms
40831004|NCT00546260|DRUG|placebo|administration of iv bolus prior to angiography
40831005|NCT00546260|DRUG|PRT060128 Potassium|administration of iv bolus prior to angiography
40831006|NCT05309213|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level:5 x 10\^4 CAR+ T cells/kg,1x 10\^5 CAR+ T cells/kg,3 x 10\^5 CAR+ T cells/kg,1 x 10\^6 CAR+ T cells/kg
40831007|NCT02189499|DEVICE|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
40831008|NCT06323798|DIAGNOSTIC_TEST|MRI|Standard paranasal sinus MRI
40831009|NCT00787137|DRUG|PG102|A single intravenous infusion
40831010|NCT00787137|DRUG|Placebo comparator|Phosphate-buffered saline
40831011|NCT01236872|DIETARY_SUPPLEMENT|Beetroot juice|250ml once of beetroot juice
40831012|NCT01236872|DIETARY_SUPPLEMENT|Water|250ml once of low-nitrate mineral water
40831013|NCT01287221|DRUG|Rifampicin|300 mg, 2 times daily
40831014|NCT01287221|DRUG|placebo|placebo
40831015|NCT01688739|DRUG|Erenumab|Administered by subcutaneous injection or intravenous injection
40831016|NCT01688739|DRUG|Placebo|Administered by subcutaneous injection or intravenous injection
40831017|NCT05019612|PROCEDURE|Laparoscopy: A minimal invasive surgery|A low-risk minimal invasive surgery performed in the pelvis using small incisions. With the aid of a laparoscope, the operator views the affected area in real-time. Beyond that, the camera sends images to a video monitor. The operator obtains endometriosis and biopsy samples with small surgical instruments. Before laparoscopy, individuals are provided with a general anaesthetic to relax muscles and prevent pain during surgery.
40831018|NCT03047018|BEHAVIORAL|The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program|The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
40831019|NCT04545437|OTHER|Admission to ICU|Exposure is admission to an Intensive Care Unit
40831020|NCT02087202|DRUG|Magnesium Sulfate|magnesium sulfate is added to the patients
40831021|NCT02087202|DRUG|ketamine|ketamine is added to the patients.
40831022|NCT05352269|BIOLOGICAL|XBI-302|Fecal Microbiota Transplantation Capsules
40831023|NCT05352269|BIOLOGICAL|XBI-302 Placebo|XBI-302 Placebo
40831024|NCT06252818|DEVICE|ReHub|ReHub provides support to rehabilitation professionals by offering information for the design, monitoring, and analysis of therapeutic exercise programs for respiratory functional rehabilitation.
40831025|NCT03356509|BEHAVIORAL|Exercise|Exercise will be performed on a stationary bicycle ergometer.
40831026|NCT04174300|PROCEDURE|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
40831027|NCT03854292|PROCEDURE|Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopicelectrocoagulating roller ball.
41158135|NCT00741351|DRUG|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
41158136|NCT00741351|DRUG|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
41158137|NCT00741351|DRUG|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
41158138|NCT03142893|DRUG|Ketoconazole Pill|Ketoconazole pill is taken 4 times per Inpatient Stay
41158139|NCT03142893|DRUG|Ganirelix|Ganirelix subcutaneous injection is administered twice per Inpatient Stay
41158140|NCT03142893|DRUG|Dexamethasone|Dexamethasone Pills is taken twice per Inpatient Stay
41158141|NCT03142893|DRUG|Dexamethasone Injection|Dexamethasone IV injection is given twice per Inpatient Stay
41158142|NCT03142893|DRUG|Cosyntropin Injectable Product|cosyntropin injection is given twice per Inpatient Stay
41158143|NCT03142893|DRUG|Recombinant Human Luteinizing Hormone|Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
41158144|NCT03142893|DRUG|Hydrocortisone Injection|Hydrocortisone IV push is given twice per Inpatient Visit
41158145|NCT03142893|DRUG|Gonadorelin|Gonadorelin IV injection is given twice per Inpatient Stay
41158146|NCT03142893|DRUG|Corticorelin|Corticorelin IV injection is given twice per Inpatient Stay
41158147|NCT03142893|DRUG|Placebo oral capsule|Placebo for ketoconazole are given 4 times per Inpatient Stay
41158148|NCT03142893|DRUG|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
41158149|NCT03142893|DRUG|Saline Solution for Injection|Saline Solution (placebo) for ganirelix subcutaneous injection
41158150|NCT06052683|RADIATION|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant|Low-dose rate brachytherapy with Iodine-125 to a total dose of 144 Gy
41158151|NCT06052683|RADIATION|Stereotactic Body Radiation Therapy to the prostate|Prostate Stereotactic Body Radiation Therapy using 36.25 Gy in 5 fractions
41158152|NCT01641289|DRUG|Paracetamol|\>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate \<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
41158153|NCT01641289|DRUG|No Paracetamol|"No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
41158154|NCT00806741|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
41158155|NCT00806741|DRUG|Phenylephrine|1μg/kg/min, infusion period 20 minutes
41158156|NCT00806741|DRUG|Physiological saline solution (as placebo)|infusion period 20 minutes
41158157|NCT00806741|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
41158158|NCT00806741|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
41158159|NCT00806741|OTHER|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
41158160|NCT01292317|OTHER|application of intravenous volume|weight based intravenous application of volume
41158161|NCT01292317|OTHER|oral fluid application|oral fluid application
41158162|NCT01378481|DRUG|Vorinostat|Given PO
41158163|NCT01378481|RADIATION|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
41158164|NCT01378481|OTHER|Laboratory Biomarker Analysis|Correlative studies
41158165|NCT01378481|OTHER|Pharmacological Study|Correlative studies
41158166|NCT01378481|PROCEDURE|Therapeutic Conventional Surgery|Undergo neurosurgery
41158167|NCT02093117|PROCEDURE|Recruitment maneuver|continuous positive airway pressure of 30 cm of water for 30 seconds
41158168|NCT02093117|PROCEDURE|Sham recruitment maneuver|Continuous positive airway pressure of 5 cm of water for 30 seconds
41158169|NCT05927714|OTHER|Amnion-chorion Membrane|Amnio-chorion membranes specifically for palatal wound healing following free soft tissue autografts (FTSA) procedures.
41158170|NCT05927714|OTHER|ActCel Cellulose Gauze|When these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. ActCel is water-soluble and dissolves over a short time period. It can be removed easily when water, saline or hydrogen peroxide is applied.
41158171|NCT05620654|DRUG|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|The starting dose for paclitaxel was 175 mg/m2, with escalation in 25 mg/m2 increments until the MTD was determined or the maximum dose level of 225 mg/m2 was reached. The target dose-limiting toxicity (DLT) rate was 25%, and the total sample size was 30 patients. HIPEC was delivered immediately following the debulking surgery using the closed technique with a target temperature of 43 ℃ for 90 minutes.
41158172|NCT05854056|PROCEDURE|Accelerated rehabilitation protocol|See Arms section
41158173|NCT05854056|PROCEDURE|Conservative rehabilitation protocol|See Arms section
41158174|NCT02207322|OTHER|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
41158175|NCT04990973|BEHAVIORAL|Average American Diet (AAD)|"Participants will follow specified diet requirements.~Macronutrient targets for the AAD will be approximately 35-37% of energy from fat (13.5% from saturated fat), 15% from protein, and 48-50% from carbohydrates (10 g fiber/d for an average 2000 kcal/d diet)."
41158176|NCT04990973|BEHAVIORAL|Mediterranean Diet|"Participants will follow specified diet requirements.~Macronutrient targets for the Mediterranean diet will be approximately 40% of energy from fat (8.5% from saturated fat), 20% of energy from protein, and 40% from carbohydrates (40 g fiber/d for an average 2000 kcal/d diet)."
41158177|NCT03411044|DEVICE|Fitmore Hip Stem|
41158178|NCT03198416|DEVICE|High-resolution pharyngeal manometry catheter|The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
41158179|NCT02053740|DRUG|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
41158180|NCT02053740|DRUG|Routine western medicine|
41158181|NCT03627130|DRUG|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
41158182|NCT03627130|DRUG|Potassium Chloride|Potassium Chloride capsules for 5 days
41158183|NCT04313036|DRUG|Defibrotide|25 mg/kg/day at 4 divided doses of 6.25 mg/kg, 2-h infusion given for 5 days, if not in CR treatment continued for \>/= 21 days or per discretion of enrolling physician.
41158184|NCT03965247|DRUG|Lithium|
41158185|NCT03965247|OTHER|Placebo - Rayotabs|
41349554|NCT01307046|DRUG|Placebo to losartan 50 mg|Placebo tablet to match losartan 50 mg, once daily
41349555|NCT06246136|PROCEDURE|ELIOS|Following cataract surgery, surgeon will proceed to ELIOS treatment.
41349556|NCT06246136|PROCEDURE|Competitor Device|Following cataract surgery, surgeon will proceed to Competitor treatment.
41349557|NCT05947890|BIOLOGICAL|MTBVAC|The MTBVAC vaccine is a freeze-dried lyophilized pellet containing live attenuated strain MTBVAC01 derived from Mycobacterium tuberculosis (M.tb). Excipients include sucrose and sodium glutamate.
41349558|NCT05947890|BIOLOGICAL|BCG|The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer. The powder is white and crystalline and may be difficult to see due to the small amount contained in each vial.
41349559|NCT03304769|DEVICE|Virtual Reality|Virtual Reality Headset applied to the patient during placement of IV. Control is patient group without headset applied.
41349560|NCT02971072|PROCEDURE|Subacromial injection|A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
41349561|NCT02971072|OTHER|Physical Therapy|A standardized six-week exercise protocol supervised by a physical therapist
41349562|NCT04195685|PROCEDURE|Neurofeedback (NFB)|Participants are seated in a comfortable chair and have common EEG electrodes with a pre-application of EEG adhesion conductive paste placed on scalp. The participant will receive coaching as they look at the game training screen and focus on the image. The game training screen provides almost instantaneous feedback (within 200 milliseconds) to participants about brain functioning. Twenty, one-hour, NFB training sessions will be provided by a trained NFB specialist over an 8-10-week period with up to 5-sessions but usually 3 sessions a week. The specific NFB special use system that will be used is the Cygnet NFB System from Bee Medic Corporation. The latest technological advances in this system has enabled training frequencies in the infra-low frequency range as well as in all other relevant frequency ranges which is a breakthrough capacity not available on any other NFB system. This will enable the individualized training to the person's brain training preference.
41349563|NCT01885104|DRUG|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
41349564|NCT01885104|DRUG|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
41349565|NCT01885104|DRUG|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
41349566|NCT01247012|DIETARY_SUPPLEMENT|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
41349567|NCT01247012|DIETARY_SUPPLEMENT|Lipid minimization|"1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)"
41349568|NCT01697189|BEHAVIORAL|Fatigue management training|Experimental group took part in a single half-day (4 hours) fatigue management training grounded on Problem Based Learning (PBL).
41349569|NCT06348862|BEHAVIORAL|Listening to either Quran, Music, and or Natural sound|Patients will be assigned into one of the four groups based on their preferences. These groups are people who will listen to either Quran, Music, Natural sound, and or nothing (control group).
41349570|NCT01430689|BIOLOGICAL|Inactivated Influenza Vaccine Trivalent Types A and B|"Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
41349571|NCT01430689|BIOLOGICAL|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine|"Pregnant Women - Randomized to receive IM injection of Menactra once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
41158186|NCT00719277|DEVICE|Sleuth Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
41158187|NCT00727259|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
41158188|NCT00727259|DRUG|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
41158189|NCT02811042|DEVICE|Ambu AuraOnce|Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).
41158190|NCT02811042|DEVICE|Ambu AuraGain|The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
41158191|NCT02625168|DRUG|Afatinib|Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
41158192|NCT02625168|DRUG|Erlotinib|Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
41158193|NCT02865135|DRUG|DPX-E7 vaccine|Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.
41349572|NCT02531633|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
41349573|NCT02531633|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
41349574|NCT02531633|DRUG|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
41349575|NCT02531633|DRUG|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
41349576|NCT03371589|DRUG|Dexamethasone|Solution for otic injection
41349577|NCT02495714|BEHAVIORAL|Active learning|Physical activity one hour a day as part of academic learning
41349578|NCT02495714|BEHAVIORAL|Dietary councelling|Teaching children and parents about a healthy diet
41349579|NCT03491852|BEHAVIORAL|BOOST Intervention|A cognitive and behavioural group therapy designed to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.
41349580|NCT03491852|BEHAVIORAL|Waitlist Control|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis.
41349581|NCT03507270|DIAGNOSTIC_TEST|FABP|Assessment of changes in FABP concentrations
41349582|NCT05698394|DRUG|Esketamine|0.2 mg/kg S-ketamine in 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth
41349583|NCT05698394|DRUG|Placebo|20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
41349584|NCT00044694|DRUG|Placebo 0.01 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
41349585|NCT00044694|DRUG|Placebo 0.02 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily
41349586|NCT00044694|DRUG|Placebo 0.03 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
41349587|NCT00044694|DRUG|Placebo 0.04 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
41349588|NCT00044694|DRUG|AC2993 2.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
41349589|NCT00044694|DRUG|AC2993 5.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
41349590|NCT00044694|DRUG|AC2993 7.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
41349591|NCT00044694|DRUG|AC2993 10.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
41349592|NCT05684367|BEHAVIORAL|Center-Based Walking Exercise|Each exercise session will begin with a short warm-up followed by 30 min of walking. Participants will initially be instructed to walk at a moderate intensity, equivalent to a 5-6 on Borg category-ratio (CR) scale. Participants will be encouraged to, if possible, incorporate brief periods of vigorous walking (7-8 on CR10 scale) with a goal of achieving at least 10 min of vigorous walking per session.
41349593|NCT05684367|BEHAVIORAL|Home-Based Walking Exercise|Participants will be asked to walk for exercise in their community five days/week. Participants will be instructed to begin with 10-15 minutes of walking exercise/session in the first month of the intervention and to increase exercise duration by five minutes/session each week, facilitating reasonable but steady progress toward the goal of 30 minutes per session.
41158194|NCT02865135|DRUG|Cyclophosphamide|Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
41349594|NCT00955344|BEHAVIORAL|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
41349595|NCT00955344|BEHAVIORAL|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
41349596|NCT04272814|OTHER|Compression therapy|Compression application
41492084|NCT03269318|DRUG|Montelukast or Salmeterol or Theophylline or Steroid|Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
41158195|NCT05648448|DRUG|Oseltamivir|Oral oseltamivir 75mg BD for 5/7
41158196|NCT05648448|DRUG|Favipiravir|Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
41349597|NCT04272814|DIAGNOSTIC_TEST|initial clinical assessment|Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
41349598|NCT02559115|RADIATION|68Ga-RM2 (RM2)|
41349599|NCT02559115|DEVICE|PET/CT Scan|
41349600|NCT05130229|BEHAVIORAL|Sleep Well Bee Well|Sleep program to help toddlers sleep better
41349601|NCT02591511|DEVICE|smart phone and pad|Smart phone and pad is the mobile include the smart phone and pad, that can download the APP from internet.
41349602|NCT02591511|OTHER|stroke-related health education manual|stroke-related health education manual is the manual mainly contained information regarding the prevention of stroke risk factors.
41349603|NCT03325933|OTHER|High Load/Low Rep Resistance Training|Participants will be prescribed High Load/Low Rep resistance training.
41349604|NCT03325933|OTHER|Low Load/High Rep Resistance Training|Participants will be prescribed Low Load/High Rep resistance training.
41349605|NCT00002590|BIOLOGICAL|filgrastim|
41349606|NCT00002590|DRUG|cyclophosphamide|
41349607|NCT00002590|DRUG|cytarabine|
41349608|NCT00002590|DRUG|daunorubicin hydrochloride|
41349609|NCT00002590|DRUG|doxorubicin hydrochloride|
41349610|NCT00002590|DRUG|etoposide|
41349611|NCT00002590|DRUG|leucovorin calcium|
41019939|NCT05328362|BEHAVIORAL|CanCope|Messages prompted participants to use mindfulness-based or distraction-based coping strategies, or a thank-you message which served as an attention control. If participants reported elevated craving (4 or greater) prior to a decision point, they received either a coping strategy message or a control message. If participants reported craving levels of less than 4 they received a control message.
41492085|NCT06412263|PROCEDURE|Routine root canal treatment/ retreatment|It is a routine clinical procedure involving root canal treatment/ retreatment and pain assessment after the treatment
41492086|NCT03552094|OTHER|Blood donations of hemochromatosis or polycythemia patients|Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
41158197|NCT05648448|DRUG|Zanamivir|Inhaled zanamivir 10mg BD for 5/7
41349612|NCT00002590|DRUG|methotrexate|
41349613|NCT00002590|DRUG|pegaspargase|
41349614|NCT00002590|DRUG|prednisone|
41349615|NCT00002590|DRUG|thioguanine|
41349616|NCT00002590|DRUG|vincristine sulfate|
41349617|NCT00002590|RADIATION|radiation therapy|
41349618|NCT03215745|BEHAVIORAL|Delirium prevention program|Delirium prevention program Placard with the names of the care team and the calendar days; cognitively stimulating activities three times a day. Pictures, radio, robe. Visual aids large print books, with daily reinforcement of use Maintain adequate lighting opening blinds and curtains during the day, and darken their environment at night. Dissipation wax and special techniques of communication, with daily reinforcement of these adaptations. Go to the patient by name and tone of voice appropriate. Always listen. Use simple and clear language, face-to-face. Avoid excessive familiarity and childish. Promote family involvement in self-care and caregivers and the reorientation of the patient, contact with extended family during the stay.
41349619|NCT03565926|OTHER|Manual Therapy|"1. Articulation technique L4-S1~2. Lumbar neuromuscular technique~3. Fascial technique of crossed hands~4. Posteroanterior mobilizations of the lumbar vertebrae"
41349620|NCT03565926|OTHER|Hypopressive exercises|Protocol 5 Hypopressive exercises
41349621|NCT02034539|DEVICE|VADOplex system|intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
41349622|NCT02098915|DRUG|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
41349623|NCT02098915|OTHER|Placebo|equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
41492087|NCT03552094|OTHER|Blood donations of healthy donors|Blood samples are from blood donations of healthy donors.
41492088|NCT01975727|DRUG|Placebo|Injection of placebo (saline 0.9%)
41019940|NCT02760238|OTHER|Observational|
41019941|NCT01524640|BIOLOGICAL|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
41019942|NCT01524640|BIOLOGICAL|Placebo|1.5 ml oral administration on day 0 and day 14
41019943|NCT01243944|DRUG|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
41158198|NCT05648448|DRUG|Baloxavir|"Oral baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
41158199|NCT05648448|DRUG|Molnupiravir|Oral molnupiravir 800mg BD for 5/7
41158200|NCT05648448|DRUG|Peramivir|Intravenous peramivir 600mg once only
41158201|NCT05648448|DRUG|Laninamivir|Inhaled laninamivir 40mg once only
41158202|NCT05648448|DRUG|Oseltamivir and Baloxavir|"Oseltamivir 75mg BD for 5/7 and~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
41158203|NCT05648448|DRUG|Oseltamivir and Favipiravir|"Oseltamivir 75mg BD for 5/7 and~favipiravir 1800mg BD D0 and 800mg BD for a further 4/7"
41158204|NCT05648448|DRUG|Favipiravir and Baloxavir|"favipiravir 1800mg BD D0 and 800mg BD for a further 4/7~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
41158205|NCT04665037|DRUG|Posaconazole IV 6 mg/kg|POS 6 mg/kg body weight by IV infusion
41158206|NCT04665037|DRUG|Posaconazole PFS 6 mg/kg|POS nominal 6 mg/kg body weight based on weight bands taken orally
41349624|NCT02413086|PROCEDURE|Early-stage amputation|Individuals with DFU were given early-stage amputation.
41349625|NCT02413086|PROCEDURE|Amputation|Individuals with DFU were given amputation.
41349626|NCT02413086|OTHER|External herbs chitosan|Wound was given external herbs chitosan after amputation.
41349627|NCT02413086|OTHER|Traditional gauze|Wound was given traditional gauze after amputation.
41349628|NCT02516891|DEVICE|Drug-Eluting Stents implantation in bifurcation lesions|
41349629|NCT01225211|DRUG|Lumacaftor|Tablet
41349630|NCT01225211|DRUG|Ivacaftor|Tablet.
41349631|NCT01225211|DRUG|Lumacaftor Placebo|Matching placebo tablet.
41349632|NCT01225211|DRUG|Ivacaftor Placebo|Matching placebo tablet.
41349633|NCT04882124|DRUG|CSJ117|CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
41349634|NCT04882124|DRUG|Placebo|Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
41349635|NCT01281774|BIOLOGICAL|CSL112|reconstituted high density lipoprotein
41349636|NCT01281774|BIOLOGICAL|Placebo|Normal saline (0.9%)
41349637|NCT05482594|DIAGNOSTIC_TEST|ELISA|During routine blood sampling, serum after centrifugation will be stored and frozen at -80°C in the immunology laboratory in order to carry out analyzes by the ELISA method to measure the levels of SCF.
41492089|NCT01975727|DRUG|Dexamethasone 3 mg|10 ml Seringue with Dexamethasone
41492090|NCT01975727|DRUG|Dexamethasone 6 mg|10 ml Seringue with Dexamethasone
41492091|NCT01975727|DRUG|Dexamethasone 12 mg|10 ml Seringue with Dexamethasone
41492092|NCT04573517|PROCEDURE|Amniotomy|Artificial rupture of amniotic membranes
41492093|NCT04573517|DEVICE|Foley balloon|The Foley balloon is inserted transcervically and inflated to a volume of 60 cc. It may be spontaneously expelled or manually removed if in place for 12 hours.
41492094|NCT01884818|OTHER|Manipulation vs. TNS thoracic pain|
40831028|NCT05990023|OTHER|Traditional vestibule rehabilitation training|"* Standing, using a gaze tracking system on a force plate to track a continuously moving target, with alerts when body sway exceeds a certain threshold.~* Standing, wearing an inertial sensor on the head and performing left-right or up-down head movements while maintaining gaze on a target, with a screen providing feedback on head movement speed.~* Standing, controlling body weight distribution on the force plate to reach a target position, with a screen displaying the current center of gravity position.~* Walking, synchronizing head movements with a rhythm or performing up-down head nods, with auditory cues indicating the desired head movement frequency.~* During continuous head rotations, stepping in a regular sequence of forward, backward, left, and right movements."
41492095|NCT06429579|PROCEDURE|Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy|Potts-shunt procedure is the surgery that connect the descending aorta and the left/main pulmonary artery by direct anastomosis, a Gore-tex tube or a Gore-tex tube with flap.
40831029|NCT05990023|OTHER|Dual-task vestibule rehabilitation training|"* Adding a dual task of digit countdown and recitation to clinical balance training exercises.~* Incorporating a numerical calculation task into interactive screens during clinical balance training, with the participant's responses input by the researchers.~* Introducing upper limb exercises, such as button pressing or arm swinging, during clinical balance training.~* During continuous head rotations, following visual prompts on the display to perform forward, backward, left, and right displacements."
40831030|NCT03135925|OTHER|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
40831031|NCT02128243|DRUG|S-1 de-escalation|S-1 30 mg/m² bid d1-14 q21d
40831032|NCT02128243|DRUG|Chemotherapy by Investigator's choice|"Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT"
40831033|NCT04008511|DRUG|Regorafenib|Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.
40831034|NCT04008511|DRUG|Regorafenib|Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.
40831035|NCT04008511|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid po for 14 days.
40831036|NCT04008511|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2, day 1, every 3 weeks
40831037|NCT03706690|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/ deterioration or confirmed radiological progression.
40831038|NCT03706690|OTHER|Placebo|Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression
40831039|NCT00042432|DRUG|cinacalcet (AMG 073)|Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
40831040|NCT01768104|PROCEDURE|ESTD|"1. A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~2. Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~3. Dissection was done along the margin of the tumor.~4. After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~5. Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors... Endoscopy 2012; 44: 231-235)"
40831041|NCT01768104|PROCEDURE|VATS|"1. General anesthesia with double lumen intubation.~2. Three to four cameras or working ports are placed over the chest wall.~3. After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~4. The mass is exposed after the overlying muscle is split longitudinally.~5. The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~6. The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)"
40831042|NCT05786339|DRUG|Tested Irbesartan Tablet|T
40831043|NCT05786339|DRUG|Reference Irbesartan Tablet|R
40831044|NCT04104022|BEHAVIORAL|Prolonged Exposure Therapy|Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.
40831045|NCT04104022|BEHAVIORAL|Attendance-based monetary incentives|Participants will earn vouchers that have monetary value for attending scheduled PET appointments. Each consecutive attended session will increase the voucher amount so that each consecutively attended appointment is worth an incrementally higher dollar amount. To support completion of the full 12-week PET protocol, we will also incorporate additional strategically-placed bonuses into the reinforcement schedule with the goal of maximizing the percentage of subjects who complete the full 12-session protocol. First, to support consistent (vs. sporadic) attendance, participants will receive a bonus for every two consecutive sessions attended. Second, to support completion of the full PET protocol, participants will receive an additional bonus upon completion of Session 12.
40831046|NCT02673567|DRUG|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
40831047|NCT02673567|DRUG|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
40831048|NCT02673567|DRUG|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
41492096|NCT06429579|DRUG|Only conventional drug therapy|Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
41492097|NCT03204708|DEVICE|catheter|catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
41349638|NCT05482594|DIAGNOSTIC_TEST|Videocapillaroscopy|Videocapillaroscopy is a non-invasive and safe method for the morphological examination and the analysis of abnormalities of the microcirculation linked in particular to systemic scleroderma. Here it is a digital capillaroscopy used routinely at the CHU Brugmann, in the follow-up of patients and whose results will be collected in this study.
41349639|NCT02978911|PROCEDURE|preoperative cerebral MRI and operative findings|
41349640|NCT03037112|BEHAVIORAL|Education|The first intervention is an educational intervention regarding appropriate diagnosis and treatment of common respiratory infections. This education will be delivered in an interactive lecture format for providers with follow up short informational video clips available over the course of the project.
41349641|NCT03037112|BEHAVIORAL|Communication Skills|The second intervention is an education plus communication skills training intervention. This training session will include identical antibiotic education training, good and bad communication examples, training on negative behavioral framing, and education regarding key drivers of patient satisfaction. Additionally providers will be informed of parent's desire for antibiotics rating prior to their consultation with the patient.
41349642|NCT04745065|BEHAVIORAL|Connect2BWell|Please see the description provided for arm 1.
41349643|NCT04631016|BIOLOGICAL|MEDI3506|Dose 1
41349644|NCT04631016|OTHER|Placebo|Dose 1
40831049|NCT02673567|DRUG|Placebo|Matching Placebo
40831050|NCT02564861|DRUG|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
40831051|NCT02564861|DRUG|Placebo|Placebo matching DS-1971a suspension
40831052|NCT00046163|DRUG|midodrine hydrochloride (ProAmatine®)|
40831053|NCT04728594|BEHAVIORAL|Social Proof|Email
40831054|NCT04728594|BEHAVIORAL|Reframing|Email
41019944|NCT01243944|OTHER|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
41019945|NCT04693663|PROCEDURE|Relex-Smile surgery|surgery using Relex-Smile
41158207|NCT05861323|BEHAVIORAL|Comfort Measures Only Time out (CMOT)|This is a brief intensive care unit team (nurse, physician, advanced practice provider, respiratory therapist) intervention to improve communication and care of patients at end of life in the intensive care unit setting.
41158208|NCT06646276|BIOLOGICAL|BMS-986489 (BMS-986012+Nivolumab)|Specified dose on specified days
41158209|NCT06646276|BIOLOGICAL|Atezolizumab|Specified dose on specified days
41158210|NCT06646276|DRUG|Carboplatin|Specified dose on specified days
41158211|NCT06646276|DRUG|Etoposide|Specified dose on specified days
41158212|NCT01225705|DRUG|raltegravir|Patients will be randomized 1:1 to either the experimental or the active control arm
41158213|NCT01225705|DRUG|Atazanavir/ritonavir|Patients will be randomized 1:1 to either the experimental or the active control arm
41158214|NCT03809806|PROCEDURE|4-arm polypropylene mesh surgery|Pelvic reconstructive procedures were performed with the use of 4-arm mesh:upper arms through- anterior part of obturator foramens, lower arms-ischiorectal fossas and sacrospinal ligaments.
41158215|NCT03809806|DIAGNOSTIC_TEST|The Female Sexual Function Index (FSFI) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
41158216|NCT03809806|DIAGNOSTIC_TEST|King Health Questionnaire (KHQ)|patients fulfilled questionnaire before and 1 year after procedure
40831055|NCT04728594|BEHAVIORAL|Scarcity Message|Email
40831056|NCT00331227|DRUG|Isotonix OPC-3 (flavonoid supplement)|
40831057|NCT04333602|DIAGNOSTIC_TEST|Urinary culture and treatment if asymptomatic bacteriuria is detected|Urinary culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. Based in the assigned group If we detect asymptomatic bacteriuria specific treatment will be instituted or No treatment.
40831058|NCT03345524|OTHER|Peer-Buddy System|"2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed"
40831059|NCT03345524|OTHER|Usual Care|"Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)"
40831060|NCT05945056|OTHER|Frog Leg Exercise|The patient lies supine with legs flexed, knees apart and the soles of the feet put together on couch. The physiotherapist stands at the side of the table, moves one arm between the legs to place the hand under the sacrum and cup it. The fingers spread to accommodate the spinous process of the fifth lumbar vertebra. The tips of the fingers contact and grasp the junction of the fifth lumbar vertebra and the base of the sacrum. This hand will give traction in a caudal direction throughout the procedure to move the sacral base posteriorly and the apex interiorly. patient is asked to take a deep breath and hold it, while at the same time they steadily slide the feet downward toward the end of the table.Then patient brings their legs back to the frog leg position, but as they do so the therapist maintains traction preventing the sacrum from moving cephalad. Procedure is repeated for a total of 8 repetitions.
41019946|NCT05010759|DEVICE|NanoTherm Ablation|Iron nanoparticles are instilled into the prostate cancer lesion and then the particles are heated using a magnetic field and this heating ablates the prostate cancer lesion.
41349645|NCT04562038|BEHAVIORAL|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|The Young Children's Participation in Environment Measure (YC-PEM) is an evidence-based option for comprehensive proxy assessment of a young child's current and desired participation in occupations across home, daycare, and community settings. The YC-PEM is an electronic patient-reported outcome (e-PRO) that provides individual caregivers a valid, reliable, and feasible way to communicate information about their child's current participation in home and community activities and areas of participation need. The gained information is then summarized and shared with the child's EI provide team to identify intervention priorities and goal attainment strategies in partnership with families. For quality improvement, EI programs can aggregate the YC-PEM e-PRO data to examine trends in participation as a function of EI service use. It is therefore a promising electronic health systems intervention to enhance the parent-practitioner relationship, and an NIH common data element for trials.
41349646|NCT02846766|DRUG|Lenvatinib|Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
41349647|NCT05956990|BEHAVIORAL|multidimensional rehabilitation|Multidimensional lifestyle interventions
41492098|NCT03204708|DRUG|iv analgesia|patients were given 100 ml of tramadol 30 minutes before extubation
41492099|NCT04948164|DRUG|sumatriptan 85mg and naproxen sodium 500mg|Subjects took 1 tablet of the study drug (each containing sumatriptan 85mg and naproxen sodium 500mg) within 1h of an acute migraine attack of mild severity, and if the headache progressed to moderate severity within 2 hours, they could take the remedial drug phenol chai (each containing acetaminophen 500mg and caffeine 65mg).
41492100|NCT04948164|DRUG|Placebo|"subjects were given one tablet of placebo within 1 h of an acute migraine attack with mild severity, and if the headache progressed to moderate severity within 2 hours, they were given the remedial drug phenol chai (each tablet contains acetaminophen 500 mg and caffeine 65 mg)."
41492101|NCT02175576|DEVICE|Vanguard XP Bicruciate Knee System|The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.
40831061|NCT05945056|OTHER|Electrotherapy(Transcutaneous Electrical Nerve Stimulator)|TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.
40831062|NCT05945056|OTHER|Exercise Therapy|Stretching of tight muscles(hip flexors and lower back extensors) Abdominal Curl-Ups and Bridging exercises.
41158217|NCT03809806|DIAGNOSTIC_TEST|Pelvic Organ Prolapse Quantification (POPQ) staging|Pelvic Organ Prolapse staging before and 1 year after the procedure
41158218|NCT03809806|DIAGNOSTIC_TEST|Postoperative questionnaire|Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure
41158219|NCT03809806|DIAGNOSTIC_TEST|The Short Form Health Survey (SF 36) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
41349648|NCT01430910|DRUG|CAZ104|IV infusion
41349649|NCT01430910|DRUG|Avibactam|IV infusion
41349650|NCT01430910|DRUG|Ceftazidime|IV infusion
41349651|NCT06269406|DIETARY_SUPPLEMENT|ibuprofen 400 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 400 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
41349652|NCT06269406|DIETARY_SUPPLEMENT|ibuprofen 200 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 200 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
41349653|NCT06269406|OTHER|The combination of ibuprofen 400 mg and placebo in patients after 2-4 molars procedure|The combination of ibuprofen 400 mg and placebo 100 mg in patients after 2-4 molars procedure
41349654|NCT02453139|BEHAVIORAL|Exercise|6 month supervised and home based aerobic exercise intervention
41349655|NCT04502199|OTHER|non interventional study|observational study
41492102|NCT02175576|DEVICE|Vanguard CR Knee System|The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
41492103|NCT04040023|DRUG|Iron and vitamin Deficiencies Correction Program|"Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation"
41349656|NCT03944551|DEVICE|Bubble CPAP|Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater.
41492104|NCT04040023|OTHER|PBMi: Training program to improve transfusion practices|Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
41492105|NCT02925507|OTHER|Swallowing Screen|Patient will be ask to undergo a swallowing screen by study staff
40831063|NCT05162261|DEVICE|Tixel C|Tixel C by Novoxel®, Israel is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
40831064|NCT05162261|DEVICE|LipiFlow|Thermal pulsation (LipiFlow) consists of the localized application of heat and therapeutic pressure on the four eyelids (upper and lower) with the aim of improving drainage of the Meibomian glands.
40831065|NCT03758313|OTHER|CO2 measurements|Distal etCO2, tcCO2 and paCO2 values will be recorded simultaneously in ventilated preterm infants. We will measure etCO2 in a distal position using a double lumen tube connected to an external side-stream capnometer.
40831066|NCT02046070|DRUG|Cyclophosphamide|Cyclophosphamide tablets
40831067|NCT02046070|DRUG|Ixazomib|Ixazomib capsules
40831068|NCT02046070|DRUG|Dexamethasone|Dexamethasone tablets
40831069|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
40831070|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
41349657|NCT03944551|OTHER|Standard Therapy|For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 \< 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group.
41349658|NCT02814799|OTHER|bone removal|
41349659|NCT06102928|DRUG|Combined therapy of anlotinib and aumolertinib|Participants were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day,and anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily.
41349660|NCT01592110|DRUG|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
41158220|NCT05291585|DEVICE|the dedicated venous sinus thrombectomy stent|the dedicated venous sinus thrombectomy stent in conjunction with aspiration for CVST patients within 28 days of symptom onset.
41492106|NCT03664648|BIOLOGICAL|HEPLISAV-B|This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
41492107|NCT06125132|PROCEDURE|Restoration with-tooth colored material|Restoration of abrasions with different composite resin materials
41492108|NCT01377675|OTHER|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
40831071|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
40831072|NCT00047333|DRUG|erlotinib hydrochloride|Given PO
40831073|NCT00047333|OTHER|laboratory biomarker analysis|Correlative studies
41158221|NCT05291585|DEVICE|balloon catheter thrombectomy|Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.
41349661|NCT01592110|OTHER|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
40831074|NCT00047333|OTHER|pharmacological study|Correlative studies
40831075|NCT01434329|GENETIC|DNA methylation analysis|
40831076|NCT01434329|GENETIC|gene expression analysis|
41349662|NCT01592110|DRUG|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
41349663|NCT01592110|DRUG|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
41492109|NCT06160297|PROCEDURE|Modified Otago Exercise|"The exercises are as follows;~Warm-up exercises (5 min)~Strengthening exercises (weight attached to ankle)~* Knee extension while sitting on a chair~* Knee flexion while standing with support from a chair~* Hip abduction while standing with support from the chair~Strengthening exercises (weight removed from ankle)~* Standing on tiptoe with support from a chair~* Rising on the heels with support from a standing chair~Balance Exercises (progressively, with support - without support)~* Mini squats~* Toe walking~* Walking on heels~* Tandem stance~* Tandem walking~* Walking backwards (10 steps)~* Standing on one leg~* Assisted side walking~* Side walking without support~* Sit and stand on the chair~* Figure eight walking"
41492110|NCT06160297|PROCEDURE|Neuromuscular Exercise|"* Proprioceptive stabilization of the knee with ball~* Bridging with ball~* Stepping forward, sideways and backwards by holding on to a fixed support while standing~* Doing the same movements with the support leg on a different surface~* Hip abduction-adduction with resistance band~* Knee flexion-extension with resistance band~* Climbing and descending steps by taking steps~* Balancing on the step~* Standing up from the chair"
40831077|NCT01434329|GENETIC|microarray analysis|
40831078|NCT01434329|OTHER|laboratory biomarker analysis|
40831079|NCT01434329|OTHER|medical chart review|
40831080|NCT02922166|DRUG|SRX246|oral capsule
41349664|NCT02508506|DRUG|ALKS 5461|Single dose, given orally
41349665|NCT06412640|DRUG|Keverprazan|Potassium-competitive acid blocker
41349666|NCT06412640|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
41349667|NCT01536418|DRUG|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
41349668|NCT01536418|DRUG|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
40831081|NCT02922166|DRUG|Placebo|oral capsule
40831082|NCT02978703|DRUG|COPD Pharmacologic Substance|COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
40831083|NCT05945459|DIETARY_SUPPLEMENT|High-calorie density formula (1 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
40831084|NCT05945459|DIETARY_SUPPLEMENT|Standard formula (0.67 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
40831085|NCT02386215|BEHAVIORAL|HIV self-test|"Two self-test kits will be distributed to women, each containing the following:~* One standard OraQuick ADVANCE I/II test kit~* Written pre-test information including test instructions in written and pictorial form~* A phone number that participants can call to obtain additional information~* Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing"
40831086|NCT04846530|DEVICE|RHA® 1, RHA® 2, RHA® 3, and RHA® 4|For each subject, two spaced boluses (0.2 mL each) of the product will be implanted on the same side (left or right side) in the post auricular area of the subject per treatment assignment. The assignment will specify one of the RHA® products to the left ear and another product to the right ear. Each subject will have a total of four boluses.
40831087|NCT05088993|OTHER|Antigravity treadmill training|This group received antigravity treadmill training 100% weight bearing
40831088|NCT05088993|OTHER|Conventional exercise program|This group received the conventional exercise program only.
40831089|NCT02953236|PROCEDURE|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
40831090|NCT02953236|PROCEDURE|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
41158222|NCT00449488|DRUG|epoetin alfa|epoetin alfa 60.000 IU one i.v. bolus
41158223|NCT01984853|OTHER|OBSERVATIONAL REGISTRY|
41349669|NCT03095157|DIETARY_SUPPLEMENT|fractionated marine lipid concentrate derived from anchovy and sardine oil|Patients will be randomized to receive perioperative treatment versus placebo
41349670|NCT03075865|DEVICE|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
41019947|NCT05245968|DRUG|Pimitespib|Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
41019948|NCT05245968|DRUG|Imatinib|Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
41158224|NCT06647225|DEVICE|Artificial intelligence augmented ultrasound|"The hip ultrasound is performed using a handheld device (Exo Iris) that uses a pocket-sized ultrasound probe and is run through an application on an IoS (Apple mobile) operation system. . A real-time algorithm detects and records the anatomical landmarks. When there are enough images for analysis the operator is notified that the scan is complete. From here, the images are then classified as: the hips as healthy, follow-up recommended, or suboptimal (repeat scan)."
41158225|NCT04030988|DRUG|Oral dexamethasone minipulse|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
41349671|NCT05993234|DRUG|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~T-DXd to be administered according to the SmPC. Conventional therapy (eg. platinum-fluoropyrimidine doublet chemotherapy, nivolumab, ramucirumab-paclitaxel, ramucirumab monotherapy, taxane or irinotecan, and pembrolizumab monotherapy) to be administered according to the SmPC."
41349672|NCT06154759|OTHER|Watson Human Caring Model-based psychoeducation|It is a psychoeducation program based on the Watson human care model, one of the theories of the nursing profession, that includes healing processes, and consists of sessions that address the hopelessness, death anxiety and care burden of individuals.
41349673|NCT05714852|BEHAVIORAL|Healthy eating|Promotion of healthy eating
41349674|NCT00348192|DRUG|SB-742457|
41349675|NCT00348192|DRUG|donepezil|
41349676|NCT04205474|DIAGNOSTIC_TEST|graded bicycle test|the subjects perform an exercise test on a reclining bicycle, and perform against increasing afterload
41349677|NCT06364306|PROCEDURE|Robotically-assisted ventral hernia repair (RVHR)|"3 8mm robotic trocars are placed intraabdominally and the DaVinci Xi-robotic system is docked. Adhesiolysis from any adherent structures to the abdominal wall is performed. Incision of the lateral verge of the retromuscular space and retromuscular dissection. Superior and inferior cross-over to the contralateral retromuscular space and dissection of the hernia sac.~Unilateral or bilateral transversus abdominis release (TAR) is performed, if necessary. Running suture with absorbable barbed suture of the posterior rectus sheath and peritoneum, as appropriate. Synthetic retromuscular mesh placement with a mesh-size as large as the prepared surface allows. Closure of the anterior rectus sheath with absorbable barbed running suture. Port extraction, skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes."
41349678|NCT06364306|PROCEDURE|Open ventral hernia repair (OVHR)|Median laparotomy with a minimal length of the previous scar (in case of incisional hernia) and adhesiolysis is performed, where necessary, to liberate the abdominal wall and the ventral hernia from adhesions. Bilateral dissection of the posterior rectus sheath under visualisation and sparing of the epigastric vessels and neurovascular bundles. Closure of the posterior rectus sheath with a slowly-absorbable running suture. Indication for a uni- or bilateral TAR identical to the intervention group. Retromuscular synthetic mesh placement with a mesh-size as far as the prepared surface allows. Mesh fixation optional with either absorbable sutures to the posterior sheath or with glubran glue. Closure of the anterior rectus sheath with a slowly-absorbable running suture. Skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes.
41349679|NCT02626299|DRUG|Docosahexaenoic acid - 800mg/day|All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
41349680|NCT02626299|DRUG|Docosahexaenoic acid - 200mg/day|The control group will receive 1-capsule containing 200 mg DHA/d.
41349681|NCT02626299|OTHER|Placebo|Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
41349682|NCT02659137|OTHER|HV measurement|Electrophysiology (EP) study during the TAVI procedure
41349683|NCT00608894|DRUG|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
41349684|NCT00608894|DRUG|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
41349685|NCT02358928|OTHER|Diet Intervention|
41349686|NCT00141167|DRUG|varenicline|
41349687|NCT03477344|DRUG|Dexmedetomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
41349688|NCT03477344|DRUG|Sodium chloride 0.9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
41349689|NCT03702166|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. CPT is delivered in three phases: education, processing, and challenging.
41349690|NCT04492306|OTHER|Dimethyl Sulfoxide|DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
41349691|NCT04492306|OTHER|3M ESPE Single bond 2|Total etch adhesive bond
41349692|NCT04492306|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
41349693|NCT04492306|OTHER|3m ESPE etch|32% phosphoric acid
41349694|NCT04661891|OTHER|Isometric contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of applying joint torque to reach a pre-defined torque level based on the subject's maximal voluntary contraction (i.e., 25%, 60%, 70%, 80%, 90%). The participant will control torque intensity by responding to a biofeedback displayed on a screen. The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
41349695|NCT04661891|OTHER|Isokinetic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of moving a joint to completing a set of contractions (10-20 contractions) at various velocities (i.e., 10 degrees per second, 30 degrees per second, 60 degrees per second). The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
41349696|NCT04661891|DEVICE|Dynamic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Multi-joint tasks (i.e. walking, squatting, cycling) will be performed at a given frequency. A motion capture system will be used to record the joint angles and ground reaction forces simultaneously.
41349697|NCT04661891|DEVICE|Isometric contraction with muscle fatigue|"An identical experiment will be performed as stated in Isometric contraction with the addition of induced muscle fatigue by repeatedly maintaining 40% of muscle torque until failure to maintain a contraction for 5 seconds."
41492111|NCT03261986|RADIATION|Radiostereometric Analysis|RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery
40831091|NCT06437886|OTHER|opioid-sparing protocol|Patients in the OSA group was administrated with 0.5 to 1 mcg·kg-1 sufentanil and received PIFB combined with RSB after anesthetic induction. Patients in the control group were recommended to receive 2 to 3 mcg·kg-1 opioid-based sufentanil. PIFB was conducted at the T2 to T5 levels under ultrasound guidance. Each side received 20 ml 0.3% ropivacaine containing 2.5 mg dexamethasone. Bilateral RSB was conducted after the PIFB and the needle was inserted into the plane between the rectus abdominal muscle and its posterior sheath using an in-plane approach. After verifying needle placement, 15 ml 0.3% ropivacaine containing 2.5 mg dexamethasone was delivered to each side. In the control group, patients received no procedure and were administrated with traditional anesthetic protocol. Patients received continuous intravenous sufentanil (50 to 100 mg) and tropisetron (5 to 10 mg) at 2 ml·h-1 for the first 48 hours after surgery.
40831092|NCT05761678|OTHER|Questionnaire quality of life|"Quantitative - Validated online self-questionnaires scientifically to assess quality of life and support perceived social. Items created for the study concerning socio-demographic characteristics and satisfaction of health services concerning the accompaniment of the transidentity.~Qualitative - Semi-structured interviews based on a guide maintenance."
40831093|NCT04702906|OTHER|standard treatment|Standard treatment if indicated.
40831094|NCT04702906|DRUG|"trimetazidine hydrochloride metacardia ® 20 mg tablet"|"trimetazidine hydrochloride metacardia ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)"
40831095|NCT02252549|DEVICE|SPIES+WLI assisted TURB|
40831096|NCT02252549|DEVICE|WLI assisted TURB|
41492112|NCT03261986|PROCEDURE|total hip arthroplasty with RSA bead implantation|Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
41492113|NCT05942053|DRUG|Placebo|Placebo match vitamin K2 capsules once per day.
40831097|NCT01794741|DRUG|Dymista Nasal Spray|
40831098|NCT01794741|DRUG|Fluticasone propionate nasal spray|
40831099|NCT01150201|DRUG|Aliskiren|For CKD treatment
40831100|NCT01150201|DRUG|Losartan|Control
40831101|NCT05445206|DEVICE|CardioPulmonary Management Device (CPM)|CPM device is used in tangent with reference capnography device.
40831102|NCT04175925|DRUG|BMS-986322|Specified Dose on Specified Days
40831103|NCT04175925|OTHER|BMS-986322 Placebo|Specified Dose on Specified Days
40831104|NCT04175925|DRUG|famotidine|Specified Dose on Specified Days
40831107|NCT04412122|OTHER|Kinesio Taping|In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique (Figure 1.). In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension (Figure 2). No tension was applied to the starting and ending points of the tape. Pain level was evaluated with VAS before and after 45 minutes of tape application. Pain level was evaluated by VAS on the 1st, 2nd and 3rd postoperative day. Kinesio tape remained on women for 72 hours.
40831108|NCT04412122|OTHER|Breathing Exercise|Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
40831109|NCT04412122|OTHER|Kinesio Taping+Breathing Exercise|In the study, kinesio taping method was applied immediately after the surgical operation. . Pain level was evaluated with VAS before and after 45 minutes of tape application.Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
40831110|NCT04412122|OTHER|Control Group|No intervention was performed to reduce pain in the control group.
41019949|NCT05245968|DRUG|Sunitinib|Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
41019950|NCT05966831|BEHAVIORAL|Metacognitive Self-Control Training (MCT)|"Metacognitive Self-Control Training (MCT) was originally developed by the Michigan Skills Project for students in middle/high school. The MCT training intervention has been updated to be suitable for adults. MCT is a lecture style intervention that encompasses 13 modules (over the course of 4 weeks) on improving self-control that is to be delivered in a community setting. Across the training, participants will learn new tools for improving self-control."
41349698|NCT04661891|DEVICE|Multi-joint functional activities while wearing exoskeleton|Participants will be measured and fitted with the bilateral exoskeleton, and sufficient range of motion to used exoskeleton will be confirmed. HD-EMG grids will be applied to the lower limb muscles of interest. The participant will perform single-joint movements to calibrate the decoder parameters. The participant will then perform multi-joint activities (e.g., standing, squatting, walking overground or on a treadmill, cycling, or stair climbing) in a movement analysis laboratory
41158226|NCT04030988|DRUG|Placebo oral tablet|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
41158227|NCT04975932|OTHER|TACE+ICIs|TACE plus ICIs ( with or without molecular targeted therapies)
41158228|NCT04975932|PROCEDURE|TACE|TACE without combination of ICIs ( with or without molecular targeted therapies)
41349699|NCT04661891|OTHER|Clinical Assessments|Subjects may complete a 10 meter walk test (10MWT) overground or over a pressure-sensitive walkway, 6 minute walk test (6MWT), Berg Balance scale (BBS), and/or Functional Gait Assessment (FGA). They may also complete step ups or squats.
40831111|NCT04266470|DEVICE|Lara Scan|"Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan."
40831112|NCT04266470|DIAGNOSTIC_TEST|PET/CT Scan - Pre-treatment and Post-treatment|The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.
41349700|NCT05333289|BIOLOGICAL|mRNA-1030|Sterile liquid for injection
40831113|NCT02369666|DIETARY_SUPPLEMENT|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
40831114|NCT02369666|DIETARY_SUPPLEMENT|Placebo|Contains MCT oil.
41158229|NCT03185910|BEHAVIORAL|MBCP education|MBCP education involves mindfulness breathing and other skills with mindfulness meditations.
41158230|NCT03185910|BEHAVIORAL|Hospital-based antenatal education|Hospital-based antenatal education involves all aspects of pregnancy, childbirth and postpartum.
41158231|NCT05559164|DRUG|Lipitor 40mg Tablet|LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
41158232|NCT01159990|BIOLOGICAL|rAd5 Gag-Pol Env A/B/C|1×10\^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
41158233|NCT01159990|BIOLOGICAL|rAd5 Gag-Pol|5×10\^9 PU rAd5 Gag-Pol delivered via intramuscular injection
41349701|NCT05333289|BIOLOGICAL|mRNA-1020|Sterile liquid for injection
41349702|NCT05333289|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
41349703|NCT05333289|BIOLOGICAL|Active Comparator|Sterile liquid for injection
41349704|NCT00249522|BEHAVIORAL|Contingency management|
41349705|NCT03593005|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
41349706|NCT03593005|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
40831115|NCT01328262|OTHER|Calculated red blood cell transfusion|The subjects receive an amount of red blood cells that has been calculated from their body surface area.
40831116|NCT01328262|OTHER|Standard red blood cell transfusion|The subjects in this group receive the prescribed number of red blood cell units.
41158234|NCT06468462|DRUG|WHO-recommended periodic presumptive treatment|400 mg po cefixime plus 1 gram azithromycin po under direct observation
41349707|NCT00491751|DRUG|atorvastatin|atorvastatin 40 or 80 mg/day
41349708|NCT00491751|DRUG|ascorbic acid|ascorbic acid 500 mg/day
40831117|NCT04794647|OTHER|Cervical mobilization|A kind of manual therapy tecnique applied to the cervical region
40831118|NCT04794647|OTHER|Placebo mobilization|It was applied to the randomly selected cervical faset without any pushing or pulling in the same position and the same grip with cervical mobilization.
41158235|NCT06468462|DRUG|Doxycycline post-exposure prophylaxis|200 mg po doxycycline within 24-72 hours after condomless anal or vaginal sex as frequently as daily
41158236|NCT00717925|DRUG|Inotuzumab Ozogamicin (CMC-544)|Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
41158237|NCT01838447|DIETARY_SUPPLEMENT|Cholecalciferol|The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
41158238|NCT00652496|DRUG|Bimatoprost 0.01% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
41349709|NCT00491751|DRUG|Placebo|matching placebo
41349710|NCT02309372|BEHAVIORAL|Beating the Blues|Computerized depression treatment intervention
41349711|NCT01015066|DRUG|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
41349712|NCT01015066|DRUG|Naltrexone|Oral tables, 50 mg/d, once a day for six months
41349713|NCT00221689|DRUG|baclofen (drug)|
41349714|NCT03607292|PROCEDURE|Anterior sciatic nerve block|A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.
41492114|NCT05942053|DRUG|Vitamin K 2|Patients will be treated with vitamin K2 (menaquinone-7) 90 mcg/day.
41349715|NCT03607292|PROCEDURE|Posterior sciatic nerve block|Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
41349716|NCT04281823|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.
40831119|NCT03182595|DRUG|Paracetamol|Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
40831120|NCT04937335|OTHER|intratumoral hemorrhage|Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
40831121|NCT01247532|BEHAVIORAL|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
40831122|NCT01613352|OTHER|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
40831123|NCT03815994|DEVICE|Neuromuscular Electrical Stimulation|This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
40831124|NCT02130336|BEHAVIORAL|Aerobic interval training|
40831125|NCT02130336|BEHAVIORAL|Continuous moderate-intensity exercise|
41158239|NCT00652496|DRUG|Bimatoprost 0.015% formulation 1 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
40831127|NCT00100295|DRUG|Hypericum perforatum|300 mg capsule taken three times a day
41492115|NCT00725751|BIOLOGICAL|Pegylated interferon alfa-2b (PegIFN-2b)|PegIFN-2b administered according to European labeling.
41492116|NCT00725751|DRUG|Ribavirin|Ribavirin administered according to European labeling.
41492117|NCT05464043|DIAGNOSTIC_TEST|evaluation of second line glucose homeostasis|blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires
41492118|NCT02187510|PROCEDURE|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
40831128|NCT00100295|OTHER|Placebo|300 mg given three times a day, containing rice protein powder
40831129|NCT03831945|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
40831130|NCT03831945|BIOLOGICAL|10-1074|10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
40831131|NCT03831945|BIOLOGICAL|Normal Saline Placebo|2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
40831132|NCT02652416|DRUG|BI 1026706|oral administration
40831133|NCT02652416|DRUG|Placebo|placebo
40831134|NCT05593276|BEHAVIORAL|Empower@Home|Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
40831135|NCT04299763|DIETARY_SUPPLEMENT|Oat Beta-glucan as a Supplement in Type 2 Diabetics|44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
40831136|NCT05400902|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Sintilimab and Bevacizumab treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Sintilimab 200 mg ivdrip, Q3W; Bevacizumab 15 mg/kg ivdrip, Q3W"
40831137|NCT04606433|DRUG|GNC-038|Administration by intravenous infusion.
41492119|NCT02187510|PROCEDURE|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
40831138|NCT06168851|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
41158240|NCT00652496|DRUG|Bimatoprost 0.015% formulation 2 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
40831139|NCT00579995|DRUG|Oral N-Acetylcysteine|600 milligrams (mg)
41349717|NCT06250452|COMBINATION_PRODUCT|Halotherapy (Salt Therapy)|"Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room. Scales and SPO2 measurement will be performed before, during and after therapy. The same procedure will be applied to the children in the control group, but no therapy will be applied. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week."
41509080|NCT05810428|PROCEDURE|GKRS-VR training|One month after radiosurgery, GKRS-VR subjects will receive neuromodulation treatment twice a week (30' per time), for 8 consecutive weeks followed by 9 months of remote rehabilitation. GKRS-VR group will perform neuromodulation based on VR sensorimotor rehabilitation using an immersive system developed ad-hoc. Treatments will include voluntary mimic movements reinforced by VR augmented feedback, consisting in the reflection of a real-time avatar animation, multiplied when needed, associated with different targets to reach based on specific facial gestures. The execution of motion multiplier on avatar will be allowed in order to personalize treatments, emphasizing a graded exposure to pain perception. In addition, the investigators will develop a dedicated mobile-application for remote rehabilitation with the aim of prescribing VR augmented feedback home exercises and immersive VR pain neuromodulation.
41158241|NCT00652496|DRUG|Bimatoprost 0.02% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
40831140|NCT00579995|DRUG|Sodium Bicarbonate|3 milliliters per kilogram per hour (mL/kg/hr) for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
40831141|NCT03701997|DEVICE|EXCOR Pediatric|Mechanical circulatory support using ventricular assist device
40831142|NCT06162091|OTHER|Data collection|"The study will involve at the time of entry into the rehabilitation setting, the collection of data related to demographic and clinical variables assessing:~1. The Level of responsiveness (Coma Recovery Scale -revised (CRS-r);~2. Cognitive functioning (Levels of Cognitive Functioning, LCF);~3. disability (Disability Rating Scale, DRS);~4. level of care needed (Early Rehabilition Barthel Index, ERBI)~The Final outcome measure will be the Glasgow Outcome Scale- Extended (GOSE). It will also collect data on clinical variables and presence of medical devices (e.g. decompressive craniectomy, hydrocephalus, tracheostomy, respiration). For all evaluations, two monthly timepoints will be conducted for a total of 12 timepoints until discharge (0 -6 months). If the patient will be hospitalized for more than 6 months, the assessment will be done monthly up to 12 months."
40831143|NCT05326360|DRUG|Ramosetron Hydrochloride|we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
40831144|NCT00666497|DRUG|Azacitidine|75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
40831145|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
41158242|NCT00652496|DRUG|Bimatoprost 0.03% ophthalmic solution|Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
41158243|NCT06588725|BEHAVIORAL|Play Nicely|Multimedia tool and handbook designed to educate parents about healthy discipline strategies.
41158244|NCT06588725|BEHAVIORAL|Cavity Prevention Handout|Two page handout with information about how to prevent cavities.
41158245|NCT06641128|DRUG|MTX SC or IM|IM or SC Methotrexate
41158246|NCT06641128|DRUG|Empagliflozin 25mg tab|Empa tablets 25 mg once daily for 3 months.
41158247|NCT04127019|DRUG|Paclitaxel|Paclitaxel chemotherapy (injection)
41158248|NCT04127019|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
41158249|NCT04127019|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
41158250|NCT04127019|DRUG|Epirubicin|Epirubicin chemotherapy (injection)
41158251|NCT04127019|DRUG|5-fluorouracil|5-fluorouracil chemotherapy (injection)
41158252|NCT05648136|BIOLOGICAL|blood sample|"Blood sampling by venipuncture will be performed :~* for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~* for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~* for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~* for patients and controls undergoing embryo transfer: on the day of embryo implantation"
41158253|NCT01378533|DRUG|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d\*8cycles
41158254|NCT05404139|DRUG|Enzalutamide|Second-generation androgen pathway inhibitor (ARAT), oral tablet
40831146|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
40831147|NCT00767234|PROCEDURE|Observation|Standard of Care
40831148|NCT05385445|BEHAVIORAL|Audit and Feedback|The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit \& Feedback interventions to change prescribing and laboratory ordering.
41158255|NCT05404139|OTHER|Standard of Care SBRT and ADT|Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
41158256|NCT06646133|DIAGNOSTIC_TEST|3D camera weight estimate|Weight estimation using 3D camera system
41158257|NCT06646133|DIAGNOSTIC_TEST|Standard methods of weight estimation|Standard methods of weight estimation will be used
41158258|NCT04506086|DRUG|Blinatumomab|Participants will receive blinatumomab continuous IV infusion for a maximum of 4 cycles. Each cycle is 6 weeks in duration consisting of 4 weeks of treatment and 2 weeks of rest.
41158259|NCT04506086|DEVICE|Current Wearable Heatlth Monitoring System (CWHMS)|The study will use the CWHMS device to monitor participants' vital signs while they are at home.
41158260|NCT06577259|DRUG|BMS-986435|Specified dose on specified days
41158261|NCT03941769|BIOLOGICAL|Recombinant Interleukin-7|Given IM or SC
41158262|NCT05809726|OTHER|Manual lymph drainage|one session 20 minutes
41158263|NCT06399640|DRUG|Eltanexor|Eltanexor will be taken by mouth
41158264|NCT06399640|DRUG|Venetoclax|Venetoclax will be taken by mouth
41349718|NCT04722692|DIAGNOSTIC_TEST|Delayed SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients have received SPIO in the breast at the first operation, prior to dissection and resection and the SLN has already been marked with SPIO. These SLNs are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the radioactive counts are registered for each SLN that has been excised. When the procedure is completed successfully with SPIO, then background axillary isotope counts are registered and, if present, SLND continues as described above with the isotope as primary tracer."
41349719|NCT04722692|DIAGNOSTIC_TEST|Late SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients will be injected with radioisotope in the operated breast before SLND according to standard of care. Any SLNs detected with this intervention are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the magnetic counts are registered for each SLN that has been excised. When the procedure is completed successfully with the isotope, then background axillary iSPIO counts are registered and, if present, SLND continues as described above with the SPIO as primary tracer."
41158265|NCT06399640|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
41158266|NCT06399640|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41349720|NCT01620658|DEVICE|0.5mm XPF cap|"Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
41492120|NCT06442306|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) is a cognitive-based education intervention that aims to change pain beliefs in patients experiencing CMP. Researchers have found PNE beneficial in assisting patients to reframe their understanding, attitudes, thoughts, and beliefs regarding their pain experience. PNE directs patients to relate chronic pain to overly sensitive nerves rather than assumed tissue damage. Further, PNE encourages patients to perform daily activities, work, and function in society, all despite pain. This facilitates behavior changes that are key in amending a patient's biopsychosocial state. Multiple sources make a strong case for the incorporation of PNE in having positive effects on reducing physical disability and modulating fear and anxiety in patients with CMP. Researchers have established a positive influence of PNE toward decreased kinesiophobia and have demonstrated a relation between increased self-efficacy and increased functional ability.
41158267|NCT06645639|OTHER|Pediatric Integrated Nutrition Pathway for Acute Care Pathway (P-INPAC)|"The pediatric working group of Canadian Malnutrition Task Force has developed an evidence-informed algorithm named the Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC). The P-INPAC outlines a process to improve nutrition care by:~1. implementing nutrition screening at point-of-admission~2. introducing standard care measures to prevent the development of malnutrition in children admitted with normal nutrition status, including standardizing the process of monitoring food intake early and systematically to identify when standard care measures are not sufficient~3. ensuring the moderately and severely malnourished patients receive timely specialized care in the form of a comprehensive assessment and treatment; and~4. ensuring moderately and severely malnourished patients receive adequate post discharge follow-up and nutrition care.~In this pilot study, we will be implementing the first two steps of P-INPAC only (screening and assessment)."
41158268|NCT06352424|DRUG|BI 456906|BI 456906
41349721|NCT01620658|DEVICE|0.3mm XPF cap|"Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
41349722|NCT01620658|DEVICE|Standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
41349723|NCT04473495|DEVICE|educational video|educational video before intervention
41492121|NCT06442306|OTHER|General Health Education|General Health Education included: 20 Benefits of Walking 30 Minutes a Day; Why You Should Quit: Smoking Cessation; Heat vs. Cold: How to Use it For Pain Control; Sleep Hygiene.
41492122|NCT01016886|DRUG|perindopril OR bisoprolol OR placebo|"perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg"
41492123|NCT03340207|DEVICE|Pneumaglide|The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
41158269|NCT06352424|DRUG|BI 1820237|BI 1820237
41349724|NCT00807989|DRUG|Carbamazepine|
41349725|NCT00807989|DRUG|Lamotrigine/Valproate|
41349726|NCT02582151|DEVICE|EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine|Percutaneous patch electrodes are used to deliver low level electrical currents.
40831149|NCT05236985|DRUG|Oxytocin bolus or oxytocin infusion|"On the day of surgery, the patients will be randomized to either bolus or infusion administration of oxytocin.~On the day of the procedure, periprocedural data and patient satisfaction (single question) will be recorded."
40831150|NCT06076928|DEVICE|Brain Computer Interface integrated HandyRehab platform (BCI-HR)|To test the usability, safety and efficacy of an experimental prototype of a wearable hand robotic glove integrated with brain computer interface system being developed and researched.
40831151|NCT06076928|DEVICE|HandyRehab (HR)|A wearable hand robotic glove approved by Health Sciences Authority, class I commercial device
41158270|NCT06352424|DRUG|Placebo for BI 1820237|Placebo for BI 1820237
41158271|NCT06352424|DRUG|Placebo for BI 456906|Placebo for BI 456906
41158272|NCT05819983|DRUG|Ivermectin Tablets|Ivermectin 200µg/kg BW
41158273|NCT05819983|DRUG|Permethrin Cream|Permethrin cream 5%
41158274|NCT04814992|BEHAVIORAL|Computer-Assisted Preoperative CBT Intervention (PAINTrainer)|Subjects will be asked to complete eight (8) 30- to 45-minute educational sessions during the 4 weeks prior to your surgery. In addition to the computer based training sessions, there is a motivational interviewing component that requires subjects to meet with a member of the study team weekly for a total of four (4) 30- to 45-minute meetings to help manage opioid medication use. It is expected that subject participation in this arm of the study will be a total of 12 hours over the course of the entire study.
41158275|NCT03487341|OTHER|Cord drainage|Cord drainage
41158276|NCT03487341|OTHER|Cord clamping|Cord clamping
41158277|NCT02694588|DRUG|Infliximab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
41158278|NCT02694588|DRUG|Vedolizumab|HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody
41158279|NCT04188119|DRUG|Avelumab|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)
41158280|NCT04188119|DRUG|Aspirin|300mg tablets
41349727|NCT03887325|DRUG|Maxipost|To investigate the role of maxipost on cerebral hemodynamic and headache in healthy volunteers and migraine patients
41349728|NCT03887325|DRUG|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
41158281|NCT04188119|DRUG|Lansoprazole|30mg
41158282|NCT04713878|OTHER|Mesenchymal stem cells|Intravenous infusion of Mesenchymal stem cells
41158283|NCT02539238|OTHER|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
41158284|NCT05497037|DEVICE|PRF stimulation|One time 500 kHZ stimulation for 15 min
41158285|NCT05497037|DEVICE|Sham stimulation|Sham stimulation for 15 min
41158286|NCT03342170|GENETIC|G20210A prothrombin gene mutation and Factor 5 Leiden mutation|blood sample
41158287|NCT01007721|DRUG|BI 67100 ED 25 mg|2 capsules of BI 671800 ED 25 mg
41349729|NCT01628458|PROCEDURE|radiofrequency ablation (RFA)|RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
41158288|NCT01007721|DRUG|BI 671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
41349730|NCT03998995|DEVICE|Immersive Virtual Reality|"An Oculus Rift VR Headset and a set of Oculus Touch Controllers was used as interactivity device. Two scenarios of IVR rehabilitation game were offered to the patients: 1) Archery based on behind-the-neck overhead press, using a quiver on the user back to encourage bending their arm and firing the arrow to help with stretching exercises and 2) Climbing based on an overhead arm raise exercise.~Each child will took part in a single IVR trial during their rehabilitation care with the physiotherapist, supported by IP, the games expert/researcher. Timing of participation was approximately 15 minutes of trial with each scenario of game. A short interview was conducted with each child and their parent (together) after each trial, and a focus group was conducted with the clinical staff."
41492124|NCT02528513|DRUG|midazolam|Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
41492125|NCT02528513|DRUG|Fentanyl|Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
41492126|NCT02528513|DRUG|propofol|After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
40831152|NCT06076928|OTHER|Standard Treatment of Care|Standard Conventional Occupational Therapy
40831153|NCT04562597|DRUG|Dose Response Curve Placebo|5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
40831154|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 50 mg/kg|5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
41158289|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
41158290|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
41158291|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
41158292|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
41158293|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
41158294|NCT01007721|DRUG|BI 671800 ED 100 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
41158295|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
41158296|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
41158297|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
41158298|NCT01007721|DRUG|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
41158299|NCT01007721|DRUG|671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
41158300|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
41158301|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
41158302|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
41158303|NCT01007721|DRUG|montelukast 10 mg tablet|1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
41158304|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
41158305|NCT01007721|DRUG|fluticasone propionate nasal spray placebo|fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
41158306|NCT01007721|DRUG|Fluticasonepropionate nasal spray 200 mcg|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)
41158307|NCT04636099|DEVICE|CT angiography（CTA）|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
41158308|NCT03212755|DIAGNOSTIC_TEST|serum immunoglobulin G level|measurement of the serum level as a marker of diabetic complications
41158309|NCT06643884|DRUG|AU-011|AU-011 Via Suprachoroidal Administration with laser treatment
41158310|NCT06643884|DEVICE|SCS Microinjector|Suprachoroidal Injection Device
41158311|NCT06643884|DEVICE|Laser|Laser Administration
41158312|NCT03448354|PROCEDURE|HIPEC|HIPEC(paclitaxel 175mg/m2, 90min; open or closed technique) after IDS . IDS is recommended within 4 weeks after the 3rd NAC cycle. HIPEC procedure is allowed only in case of residual disease less than 5mm.
41158313|NCT06036797|DRUG|Hydromorphone|For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone
41158314|NCT06036797|DRUG|Sufentanil|For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil
41158315|NCT06036797|DRUG|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
41349731|NCT04230590|OTHER|Observational|"Participants will not receive any study intervention.~During the 24-week study period, participants will complete five assessment visits and passive digital data from participant's smartphone and study-provided wrist wearable device will be collected."
41349732|NCT01784211|DRUG|LY2605541|
41349733|NCT01784211|DRUG|Insulin Glargine|
41492127|NCT02528513|DRUG|Dexmedetomidine|After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
41492128|NCT02528513|PROCEDURE|Procedure:sedation assessment|The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
40831155|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 100 mg/kg|5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
40831156|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 150 mg/kg|5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
40831157|NCT04562597|DRUG|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteinedose is identified, 15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
40831158|NCT04562597|DRUG|Placebo|15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
40831159|NCT00966849|OTHER|Conditional Cash Transfer|"Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:~* An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.~* All children under 5 years in the household must be up-to-date with vaccinations.~* All children under 5 years must attend a growth monitoring clinic twice per year.~* All children 6-17 years in the household attended school at least 90% of days in the last month.~* At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes."
41158316|NCT05436145|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of two types of message sets: 1) Support, or 2) Consequences. Within each message set the core content is adapted to provide either 1) Emotional Support or Practical Support, or 2) Gain or Loss-Framed Consequences.
41158317|NCT05576727|OTHER|Unruptured intracranial aneurysms|Extensive clinical, biological and imaging data of unruptured intracranial aneurysm patients will be recorded during a 5 years follow-up.
41158318|NCT01049984|DRUG|Rasagiline|1mg tablet daily for 18 weeks
41158319|NCT01049984|DRUG|Placebo|one tablet daily for 18 weeks
41158320|NCT05723289|DEVICE|MI-E Telemonitoring|Daily telemonitoring using a ad-hoc communicating device
41158321|NCT03134937|DEVICE|High-Flow Heated and Humidified Oxygen Therapy (HFHHNO)|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
41158322|NCT04627441|DEVICE|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
41158323|NCT04627441|DEVICE|Epidural spinal cord stimulator system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
41158324|NCT05234645|OTHER|Kefir consumption|Following confirmation of eligibility and the provision of informed consent, recruited participants were provided with a 4-week supply of kefir (Live Kefir Company, Pontefract, UK) being instructed to consume 150ml of Kefir per day for the whole 4-week period. No break periods of kefir consumption were offered to any of the participants. In addition, they were instructed to not change their usual dietary habits and exercise routine for the study duration.
41349734|NCT02672150|BEHAVIORAL|Core|
41349735|NCT02672150|BEHAVIORAL|Enhanced|
41349736|NCT03164746|OTHER|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
41492129|NCT02528513|PROCEDURE|Procedure:Weaning|the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
41158325|NCT04464434|PROCEDURE|Upfront autologous HSCT|"HSCT comprises the following consecutive steps:~1. Mobilisation~   * Infusions of CYC 2g/m2 on 1 day.~  * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~  * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~   * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~  * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~   Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~   I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg."
41158326|NCT05389319|BIOLOGICAL|Prime-2-CoV_Beta|1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
41349737|NCT03164746|OTHER|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
41349738|NCT03733132|DRUG|Metformin Hydrochloride|Metformin treatment of 2500mg for 10 months in the Metformin group
41349739|NCT03733132|DRUG|Placebo Oral Tablet|Placebo treatment of identical tablets to metformin group
41349740|NCT05497622|DIAGNOSTIC_TEST|Quantitative Ultrasound|Ultrasound assessment of Trapezius muscle
41349741|NCT05497622|DIAGNOSTIC_TEST|Osteopathic TART Assessment|"Evaluation of the 4 diagnostic criteria:~1. Tissue Texture abnormality~2. Asymmetry~3. Restriction of Motion~4. Tenderness"
41349742|NCT05497622|PROCEDURE|Osteopathic Manipulation Treatment|Use of manual techniques such as soft tissue stretching, resisted isometric stretches, fascial relaxation and counter strain.
41349743|NCT05348564|BEHAVIORAL|Direct contact of family members for cascade screening of relevant variants|Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
40831160|NCT00966849|OTHER|Unconditional Cash Transfers|Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.
40831161|NCT00966849|OTHER|Standard Agricultural Package|A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
40831162|NCT00966849|OTHER|Parenting Skills Classes|2-3 parenting skills classes will be held annually in each study cluster.
40831163|NCT03675425|OTHER|Group 1: non chest shielding|non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
40831164|NCT03675425|OTHER|Group 2: chest shielding|chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
40831165|NCT04102553|DRUG|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
40831166|NCT04102553|DRUG|F-18-Fluorocholine|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
40831167|NCT06255067|DRUG|Minocycline hydrochloride with noisome carrier|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
40831168|NCT06255067|DRUG|Minocycline Hydrochloride only|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
40831169|NCT00000765|DRUG|Zidovudine|
41349744|NCT03145506|DEVICE|Multimodal Spectroscopy|optical measurement of excised tissue
41349745|NCT02094664|DEVICE|Heated and humidified oxygen|
41349746|NCT03942172|DEVICE|SpotOn balance glasses|SpotOn Balance Glasses comprising of personalized visual stimuli placed on the glasses's lenses
41349747|NCT03318900|BIOLOGICAL|Aldesleukin|Given IV
41349748|NCT03318900|DRUG|CD8-Positive T-Lymphocyte|Given IV
41019951|NCT05966831|BEHAVIORAL|Virtual Reality Job Interview Training (VR-JIT)|VR-JIT provides trainees with an opportunity to repeatedly practice interviewing for a job at fictional company 'Wondersmart'. Prior to interviewing, trainees review self-guided e-learning materials on how to find, prepare for, succeed in, and follow-up on job interviews that includes the review of 10 job interview skills. Trainees also complete an online job application for one of 14 jobs (e.g., cashier, clerical, customer service, food services, inventory, janitorial, web developer) that informs the virtual interview experience.
41019952|NCT04028388|DRUG|Docetaxel in Parenteral Dosage Form|Treatment with IV docetaxel at 75 mg/m2 given as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily
41158327|NCT06158971|DEVICE|Flexible Bronchoscopic Microwave Ablation|The phenoWave flexible microwave ablation system will be used to perform soft tissue ablation in the lungs under image guidance.
41158328|NCT03121599|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
41349749|NCT03318900|DRUG|Cyclophosphamide|Given IV
41349750|NCT03318900|PROCEDURE|Leukapheresis|Undergo leukapheresis
41349751|NCT03318900|BIOLOGICAL|Utomilumab|Given IV
41349752|NCT03612674|PROCEDURE|Standard colonoscopy|Current standard of care colonoscopy.
41349753|NCT03612674|DEVICE|ARC Endocuff Vision|Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
41349754|NCT03114072|DEVICE|Blue-blocking glasses|Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
41349755|NCT03114072|DEVICE|Light grey control glasses|Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
41349756|NCT06380036|PROCEDURE|video assisted fistula tract surgery|in one group pt recieved VAAFTS
40831170|NCT03141463|BIOLOGICAL|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
40831171|NCT01618617|DIETARY_SUPPLEMENT|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
40831172|NCT01618617|DIETARY_SUPPLEMENT|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
40831173|NCT01985490|PROCEDURE|epiretinal membrane and internal limiting membrane removal|fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
41349757|NCT01564485|DIAGNOSTIC_TEST|Cardiac CT|A cardiac CT involves a non-invasive test of the coronary arteries.
41349758|NCT01564485|BEHAVIORAL|Usual medical care|Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.
41349759|NCT01076270|DRUG|plerixafor|Given SC
41349760|NCT01076270|BIOLOGICAL|filgrastim|Given SC
40831174|NCT04306289|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, neuropathic pain.
40831175|NCT02008513|BIOLOGICAL|AFFITOPE® AD02|
41349761|NCT01076270|PROCEDURE|peripheral blood stem cell transplantation|Infusion of peripheral blood stem cells
41349762|NCT01076270|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Infusion of hematopoietic stem cells
41349763|NCT00198731|BEHAVIORAL|Care Seeking for Obstetric Complication|This is a descriptive study of knowledge, practices and outcomes related to maternal morbidity during pregnancy, childbirth and postpartum.
40831176|NCT02008513|BIOLOGICAL|Placebo|
40831177|NCT05281094|BIOLOGICAL|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
40831178|NCT05281094|BIOLOGICAL|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
40831179|NCT01028066|OTHER|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
40831180|NCT01028066|BEHAVIORAL|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
40831181|NCT05110560|BEHAVIORAL|"Stay at Home Take a Step Program (SHTSP)"|The Stay at Home Take a Step Program consisting of video or audio calls four times, sending Short Message Service messages containing reminders to encourage walking, and daily step count and weight tracking will be implemented.
41019953|NCT04028388|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
41019954|NCT02044887|OTHER|physical activity|The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
41019955|NCT01542866|OTHER|Health Management Tool (HMT)|Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
41019956|NCT04886141|BEHAVIORAL|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
41019957|NCT03808610|DRUG|Cyclophosphamide|Given IV
41019958|NCT03808610|DRUG|Cytarabine|Given IV
41019959|NCT03808610|DRUG|Dexamethasone|Given IV or PO
41019960|NCT03808610|DRUG|Methotrexate|Given IV
41019961|NCT03808610|DRUG|Nelarabine|Given IV
41019962|NCT03808610|DRUG|Pegaspargase|Given IV
41019963|NCT03808610|DRUG|Prednisone|Given PO
41019964|NCT03808610|BIOLOGICAL|Rituximab|Given IV
41019965|NCT03808610|DRUG|Venetoclax|Given PO
41019966|NCT03808610|DRUG|Vincristine|Given IV
41019967|NCT00944775|BEHAVIORAL|Exercise training|10-month exercise training program during hemodialysis sessions
41019968|NCT02453451|OTHER|2D-/3D-TTE|recording of 3 cardiac cycles
41019969|NCT02453451|OTHER|3D-TEE|with colour-Doppler techniques for recording the ASD and the mitral valve
41158329|NCT02209688|DRUG|ESR 1150 CL|
41492130|NCT02528513|DRUG|midazolam(used for passing the SBT safety screen)|After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
41349764|NCT03185325|OTHER|bone marrow puncture and venous blood samples|bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
41349765|NCT03185325|OTHER|venous blood samples|venous blood samples are collected in healthy voulnteers
41349766|NCT01415973|DIETARY_SUPPLEMENT|3 ounces of cooked, 85% lean ground beef|Consumed once per subject.
41349767|NCT01415973|DIETARY_SUPPLEMENT|20 grams beef protein isolate|Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
41349768|NCT02528799|BIOLOGICAL|Nexvax2|Nexvax2 intra-dermal injections twice weekly
41349769|NCT02528799|BIOLOGICAL|Nexvax2 placebo|Sodium chloride 0.9% intra-dermal injections twice weekly
41158330|NCT02209688|DRUG|Placebo|
41349770|NCT03687827|DRUG|Insulin degludec|Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
41019970|NCT02453451|OTHER|Walking Test|for 6 minutes
41158331|NCT05044065|OTHER|Physical exercise|The intervention group will receive an exercise program consisting of a combination of supervised and home-based exercise with a focus to induce metabolic stress (blood flow restriction exercise) during both a pre- and postoperative period consisting of a total of 6-10 weeks. Protein supplementation will be given to exclude insufficient intake.
41349771|NCT03687827|DRUG|Insulin glargine|Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
41349772|NCT00050570|BEHAVIORAL|Web-based intervention to reduce eating disorder risk factors|
41349773|NCT06361706|BEHAVIORAL|VR-Enhanced Psychoeducational Program for Chronic Pain|Participants undergo eight weekly sessions that include VR to learn pain physiology, mindfulness, and self-management techniques. Each session is 90 minutes, with 15-20 minutes of VR activities designed to complement the educational content. Activities simulate pain management exercises and mindfulness meditation. The program, led by pain management and VR specialists, aims to improve pain management skills, emotional well-being, and quality of life.
41492131|NCT02569112|DEVICE|multipolar RF, varipulse|Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).
41492132|NCT02569112|DEVICE|cryolipolysis|Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
41492133|NCT05561530|DRUG|ALG-125755|single or multiple doses of ALG-125755
41492134|NCT05561530|DRUG|Placebo|single or multiple doses of placebo
41492135|NCT01698827|OTHER|Tube assessment visits|Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
41492136|NCT03428828|BEHAVIORAL|Amygdala Neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
41492137|NCT03428828|BEHAVIORAL|Parietal Neurofeedback|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
40831182|NCT06108648|DRUG|Lavender essential oil 10%, diluted in 90% olive oil|"Lavender chest wrap:~Before the first application pour 10-15 ml of lavender essential oil 10% evenly on the cotton cloth.~Put the soaked cotton in the plastic bag, close it and put it to heat in two heating pads (2-5 minutes) so that the oil is distributed on all the fabric. Place the cotton cloth around the patient's chest.~Cover the cotton cloth with a woolen fabric that is 2 cm larger than the cotton cloth."
40831183|NCT06108648|OTHER|Control|Standard care according to national standards.
41019971|NCT02453451|PROCEDURE|MitraClip procedure|catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
41019972|NCT03553745|BEHAVIORAL|Gentle Yoga Intervention|10-week exercise program structured around gentle yoga practice.
41019973|NCT03553745|BEHAVIORAL|Rigorous Yoga Intervention|10-week exercise program structured around rigorous yoga practice.
41019974|NCT03553745|BEHAVIORAL|Physical Exercise Intervention|10-week exercise program structured around cardiovascular exercise.
41019975|NCT00497120|DRUG|acetazolamide|
41019976|NCT00497120|DRUG|placebo|
41019977|NCT00497120|PROCEDURE|uvulopalatopharygoplasty|
41019978|NCT01002599|DEVICE|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
41019979|NCT01002599|DEVICE|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
41019980|NCT01033747|DRUG|Deferasirox|10 mg/kg or 30 mg/kg orally daily
41019981|NCT01033747|DRUG|Deferasirox|5 mg/kg or 30 mg/kg orally daily
41019982|NCT02894021|PROCEDURE|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
41158332|NCT01364545|DIETARY_SUPPLEMENT|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
41158333|NCT01364545|DIETARY_SUPPLEMENT|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
41158334|NCT02574351|BIOLOGICAL|blood draw, breathing test|A blood draw,breathing test will be performed on every participant
41158335|NCT04505488|BEHAVIORAL|ASD Screening Parent ENgagement Intervention Program (ASPEN)|The ASPEN intervention is based on naturalistic developmental behavioral intervention strategies to support the development of social communication and play skills and reduce challenging behavior.
41492138|NCT06080256|DRUG|Alirocumab|alirocumab (75 mg every 2 weeks)
41019983|NCT02894021|PROCEDURE|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
41019984|NCT04543422|DIETARY_SUPPLEMENT|Green tea|Green tea extract capsules
41492139|NCT06080256|DRUG|Atorvastatin|Atorvastatin 20-40mg
41492140|NCT03906162|BEHAVIORAL|Motivational interviews|"During the 12-week intervention, the participants will receive seven telephone calls from a physical therapist. The interviews will be held in week 1, 2,3,5,7,9, and 12.~The telephone call will consist of a motivational interview focused on enhancing the daily level of physical activity in the participants.~MI is a form of counselling aiming at prompting increases in self-efficacy, which may leave people more open to and invested in changing their behaviours and shows potential for significant effects for exercise behaviour change.~In addition to the telephone based motivational interviews, the experimental group will also receive the base intervention which is described in detail under the control intervention paragraph."
41492141|NCT03906162|BEHAVIORAL|Base intervention|"The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity."
41492142|NCT00296634|DRUG|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
41492143|NCT00296634|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
41492144|NCT00372411|DEVICE|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
41492145|NCT00372411|OTHER|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
41492146|NCT00372411|OTHER|Usual Care|The usual chronic stroke care as delivered at each participating medical center
41492147|NCT00491140|GENETIC|Gene mutations analysis and FISH|FISH and mutation analysis of multiple genes
41492148|NCT03179163|DRUG|Captopril Pill|ACEi+SH
41492149|NCT03179163|DRUG|Enalapril Pill|ACEi
41492150|NCT03179163|DRUG|Hydrochlorothiazide|diuretic
41492151|NCT02400242|DRUG|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
41492152|NCT02400242|DRUG|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
41492153|NCT02400242|DRUG|Dexamethasone|40 mg qd on days 1, 8, 15, 22
41492154|NCT03758404|BIOLOGICAL|adeno-associated virus vector AAV- CNGA3|Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene
41492155|NCT00837772|DEVICE|Standard cutting guide for TKA|Use of the usual cutting guide for surgical replacement of a diseased knee
41492156|NCT00837772|DEVICE|Otismed MRI generated cutting guide for TKA|Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
41492157|NCT06299020|BEHAVIORAL|intermittent fasting|fasting from predawn to sunset (no eating and no drinking), for approximately 16 hours.
41492158|NCT00152724|DEVICE|pressure strain system, iontophoresis|
41492159|NCT00152724|DRUG|scopolamin|
41492160|NCT00152724|DRUG|emla|
41492161|NCT00152724|DRUG|capsaicin|
41492162|NCT00152724|DRUG|aspirin|
41492163|NCT00152724|DRUG|clopidogrel|
41492164|NCT00152724|DRUG|celecoxib|
41492165|NCT00152724|DRUG|indomethacin|
41492166|NCT00152724|DRUG|acetylcholine|
41492167|NCT00152724|DRUG|sodium nitroprusside|
41492168|NCT00152724|DRUG|brethyllium|
41492169|NCT00152724|DEVICE|general and local heating|
41019985|NCT04543422|OTHER|Placebo|Placebo containing inert material.
41019986|NCT03050086|DRUG|BPX-04 1% minocycline topical gel|once daily administration of topical minocycline gel to face
41019987|NCT03050086|DRUG|BPX-04 2% minocycline topical gel|once daily administration of topical minocycline gel to face
41019988|NCT03050086|DRUG|BPX-04 vehicle topical gel|once daily administration of topical minocycline gel to face
41019989|NCT00898911|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
41019990|NCT00003945|DRUG|cisplatin|
41019991|NCT00003945|DRUG|topotecan hydrochloride|
41019992|NCT03400397|OTHER|Cool Kids programme|A manualised cognitive behavioural treatment programme that consists of 10 session within 12-16 weeks each lasting 2 hours.
41019993|NCT06573411|DRUG|ACEI/ARB+ finerenone|The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.
41019994|NCT06573411|DRUG|ACEI/ARB+ Placebo|Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.
41019995|NCT04726982|DRUG|Acetazolamide|250 mg once daily
41019996|NCT04726982|DRUG|Acetazolamide|500 mg once daily
41019997|NCT04726982|OTHER|Placebo|Once daily
41019998|NCT05924828|OTHER|no intervention|no intervention
41349774|NCT04116619|OTHER|Guided Imagery Laboratory Session|"On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol."
41349775|NCT05705960|OTHER|Chestnut|Daily consumption of roasted chestnut (150g) for 14 days
40831184|NCT05801055|DRUG|Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone|The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
41349776|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for subcutaneous administration.
41349777|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for sublingual administration.
41349778|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 9.000 UTm/mL for sublingual administration.
41349779|NCT05400811|BIOLOGICAL|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
41349780|NCT05400811|BIOLOGICAL|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
41349781|NCT05067114|DEVICE|Screening, detection and referral for atrial fibrillation|In-pharmacy cardiovascular risk assessment plus AliveCor KardiaMobile reading
41349782|NCT05061758|DRUG|LY3056480|LY3056480 is an inhibitor of gamma-secretase
41492170|NCT00895414|DRUG|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
40831185|NCT04313322|BIOLOGICAL|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
40831186|NCT00768404|DRUG|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
40831187|NCT01925911|DRUG|IPI-145|25 mg BID Oral Capsule
40831188|NCT01925911|DRUG|Midazolam|2 mg midazolam syrup
40831189|NCT04159272|BEHAVIORAL|Mindfulness Training|"The programme consists of 8 90-min sessions held once a week for 8 consecutive weeks. Each session consists of guided experiential mindfulness exercises, sharing of experiences of these exercises, reflections in small groups, psycho-education, and review of home practices. An overview of the core elements in each session is given in Van der Gucht et al. (2017). The in-class MT programme will be supported with a mindfulness for adolescents smartphone application to support practice at home.~The curriculum is available in an open source platform. The training is supported by the use of homework assignments and audio material. The programme has already been piloted and reviewed in an expert group of mindfulness trainers and scientists working with youth in mental health care (Van der Gucht et al., 2017) and in refugee centres (Van der Gucht et al., 2019). The MT will be delivered by certified trainers (\>3 years of experience). During the trial they will receive regular supervision."
40831190|NCT02668861|DRUG|Vitamin D|Vitamin D 4000IU/day for 8 weeks
41349783|NCT04474392|OTHER|N/A (Observational Study)|Observational study, no intervention will be administered.
41349784|NCT00307944|DRUG|Pantoprazole|
41349785|NCT01626755|PROCEDURE|Sciatic name block|Ultrasound-guided sciatic nerve block.
41349786|NCT00703781|DRUG|bromfenac ophthalmic solution|sterile ophthalmic solution
41349787|NCT00703781|DRUG|placebo|sterile ophthalmic solution
41349788|NCT00898950|DRUG|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
41349789|NCT00898950|DRUG|Aspirin|300mgs/day orally for 2 weeks
41349790|NCT00898950|DRUG|Aspirin|aspirin 900mgs QID orally for 2 weeks
41492171|NCT00895414|DRUG|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
41509081|NCT05810428|PROCEDURE|Control Group|Control Group will undergo only radiosurgery with no rehabilitation and they will perform only clinical evaluation at study entry, after three months and one year.
41509082|NCT01289379|PROCEDURE|High Frequency Jet Ventilation|
41509083|NCT01289379|PROCEDURE|HFJV|
40831191|NCT02668861|DRUG|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
40831192|NCT02668861|OTHER|placebo|placebo for 8 weeks
41019999|NCT00927745|DEVICE|AutoFlow mode on Evita 4 Dräger ventilators|Activation of AutoFlow mode during assist-controlled ventilation
41020000|NCT00927745|DEVICE|Evita 4 Dräger ventilators|Assist-controlled ventilation without activation of AutoFlow mode
41020001|NCT05334108|DRUG|Ecopipam|ecopipam HCl \~2mg/kg/day
41020002|NCT05334108|COMBINATION_PRODUCT|Cohort 1 Probe Substrate Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
41020003|NCT05334108|DRUG|Cohort 2 Probe Substrate|bupropion
41020004|NCT05334108|COMBINATION_PRODUCT|Cohort 3 Probe Substrate Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
41349791|NCT00898950|OTHER|placebo tablet|placebo tablet with lactose and excipients.
41492172|NCT05631353|DEVICE|Carriere Motion Appliance|"Patient will be randomly allocated into two groups:~Group I: conventional mandibular anchorage using passive lingual arch. Group II: anchorage by direct mini-screws. In the group I, Class II elastics will be attached from the maxillary canine to the mandibular first molar bilaterally with passive lingual arch in the lower arch as anchorage means.~In the group I, Class II elastics will be attached from the maxillary canine to mandiular miniscrews bilaterally.~For each patient, two CBCT radiographs will be obtained: one preoperatively and another after completion of distalization."
41492173|NCT01462773|DRUG|Bortezomib|VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
41492174|NCT01462773|DRUG|Interferon Alfa-2b|I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
41492175|NCT01561430|DRUG|LY2886721|
41492176|NCT01561430|DRUG|Placebo|
41158336|NCT06178471|DIAGNOSTIC_TEST|Transesophageal Echocardiography|The use of transesophageal echocardiography to diagnose cardiopulmonary failure in ICU patients with suboptimal or inadequate transthoracic echocardiography examinations.
40831193|NCT06373770|DIAGNOSTIC_TEST|Ayres sensory integration therapy|"A. Jean Ayres, is a theory and practice that targets a person's ability to process and internally integrate sensory information from their body and environment. Sensory information may be visual, auditory, tactile, proprioceptive, and/or vestibular in nature. ASI uses individually tailored activities that utilize just right challenges to an individual's existing patterns of sensory processing and motor planning and encourage movement and organization of self in time and space. ASI incorporates specialized equipment and materials in purposeful and playful activities in order to improve adaptive behavior."
41158337|NCT01114217|DRUG|Ferumoxytol|IV Ferumoxytol
41158338|NCT06647511|DEVICE|Nokia-Withings BPM Connect Blood Pressure Monitor|At-home blood pressure (BP) measurements will be weekly via a blood pressure cuff (e.g., Nokia-Withings BPM (Beats per Minute) Connect), with measurements being manually entered into the study specific smartphone app.
41158339|NCT06647511|DEVICE|Smartwatch Devices|Passive continuous collection of digital data (e.g., daily heart rate trends, activity levels, sleep measurements) for exploratory outcomes will occur via Apple Watches and Fitbit Versa 3s, which are synced to a smartphone application.
40831194|NCT06373770|DIAGNOSTIC_TEST|Behaviour Therapy|The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with this diagnosis. Risperidone and aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis.
41158340|NCT06646718|PROCEDURE|Close kinetic chain exercise group|●Close kinetic chain exercise group: group A will receive forward step-ups, lateral step-ups, squats, sit-to-stand, and stoop-and-recover exercises. session will be initiated with a 10 min warm-up period, including stretching of the major muscles and muscle groups, then 40 min different exercises and terminated with a 10 min cool-down period in the form of aerobic exercises.
41349792|NCT04726566|PROCEDURE|Tendon graft|Anatomical surgery for chronic lateral ankle instability under arthroscopy with tendon graft
41349793|NCT04726566|PROCEDURE|Suture with biological reinforcement|Anatomical surgery for chronic lateral ankle instability under arthroscopy by suture with biological reinforcement
41349794|NCT00807443|DRUG|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp \& Dohme. A dose of 400 mg will be administered every 12 hours
41349795|NCT00242944|DRUG|Pitavastatin|Pitavastatin 4mg per day
41349796|NCT00242944|DRUG|Atorvastatin|Atorvastatin 20mg per day
41349797|NCT04142840|DRUG|Dexmedetomidine|a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia
41349798|NCT04142840|DRUG|Propofol|a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.
41509084|NCT00840489|DRUG|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
41509085|NCT00840489|DRUG|Colchicine|Colchicine 0.5 mg bd for 24 weeks
41509086|NCT02344082|OTHER|Telemedicine|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
41158341|NCT06646718|PROCEDURE|Traditional physical therapy.|●Traditional physiotherapy: group B will receive stretching for the lower extremity muscles, namely hip flexors and adductors, hamstrings, and calf muscles; and strengthening exercises for core muscles, hip extensors, flexors and abductors, internal and external rotators of the hip, flexors and extensors of the knee, ankle dorsi flexors, kneeling exercises, and standing and gait training
40831195|NCT00722202|DRUG|ERB-257|
40831196|NCT00722202|OTHER|placebo|
40831197|NCT01276366|OTHER|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
40831198|NCT01276366|OTHER|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
40831199|NCT01276366|OTHER|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
40831200|NCT00970983|PROCEDURE|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
41158342|NCT01269190|PROCEDURE|High-Resolution Microendoscopy|Undergo evaluation of oral lesions using a high-resolution microendoscope
41158343|NCT01269190|PROCEDURE|Multispectral Imaging|Undergo evaluation of oral cavity using a widefield multispectral imaging
41158344|NCT01269190|DRUG|Proflavine|Proflavine) used to stain the mouth tissue after initial imaging.
41158345|NCT04402632|PROCEDURE|Surgical Management|SDH Evacuation (Control)
40831201|NCT00970983|PROCEDURE|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
40831202|NCT05105893|OTHER|Dates group|Seven dates to be provided to patients
40831203|NCT04959812|DRUG|Sufentanil|Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
40831204|NCT04959812|OTHER|Placebo|Subjects will receive a placebo pill while the effects of this placebo on tolerance to a hemorrhagic insult will be assessed.
40831205|NCT04297189|BEHAVIORAL|Coaching and health information intervention|8 session intervention with,group meetings with coaching tools and health information on nutrition and physical activity and coping with stress.
40831206|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant group(A)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+selenium and vitamin E (A).
40831207|NCT02980094|DIETARY_SUPPLEMENT|Milk Oil group(O)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
40831208|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant and oil(AO)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets:control (C)+selenium, vitamin E and sunflower oil (AO).
40831209|NCT02980094|DIETARY_SUPPLEMENT|Milk Control group(C)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)
40831210|NCT01666639|BEHAVIORAL|Behavioral Medical Rehabilitation plus behavioral exercise therapy|"The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity."
40831211|NCT01666639|BEHAVIORAL|Usual Behavioral Medical Rehabilitation|"The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each."
40831212|NCT05081063|COMBINATION_PRODUCT|Routine labs|Routine labs will be performed with CBC, BMP, Fox screen, ROTEM viscoelastic test, PT/INR, PTT and venous lactate for standard of care for all patients.
40831213|NCT06398964|DIETARY_SUPPLEMENT|3-hydroxybutyrat|The intervention is administered as a drink.
40831214|NCT06398964|DIETARY_SUPPLEMENT|Isocaloric placebo drink|The intervention is administered as a drink.
40831215|NCT02144545|PROCEDURE|Bougie Size 33 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
40831216|NCT02144545|PROCEDURE|Bougie Size 42 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
40831217|NCT02144545|PROCEDURE|Distance pylorus 2 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
41158346|NCT04402632|DEVICE|Surgical Management + Treatment|SDH Evacuation + Onyx™ LES Embolization
41158347|NCT04402632|OTHER|No Treatment|Observation Only (Control)
41158348|NCT04402632|DEVICE|Treatment|Onyx™ LES Embolization
41158349|NCT06095154|RADIATION|CTV Delineation Based on Geometric Expansion From GTV in Nasopharyngeal Carcinoma|CTVp2 is generated by expanding GTVp by 10 mm and including the nasopharyngeal mucosa.
41158350|NCT06205407|DRUG|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris|Manufactured at Viatris
41158351|NCT06205407|DRUG|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.|Manufactured at Neolpharma.
41158352|NCT04995406|DIAGNOSTIC_TEST|ISIT-TB prototype|Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour
41349799|NCT05784545|DIETARY_SUPPLEMENT|Blueberry powder supplement|The intervention in this study is 12 weeks of daily blueberry supplementation which is comprised of freeze-dried powdered whole blueberries i.e., blueberries with water removed.
40831218|NCT02144545|PROCEDURE|Distance pylorus 5 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
41349800|NCT05784545|DIETARY_SUPPLEMENT|Maltodextrin supplementation|The intervention in this study is 12 weeks of daily maltodextrin supplement used to mimic the carbohydrate composition of whole blueberries.
41349801|NCT00594789|OTHER|Information letters|Information letters under Manitoba Health letterhead will be sent out to physician(s) and/or patient connected with a fracture that meets specific criteria. To address concerns over discontinuous care of patient seen at the time of fracture and for subsequent follow-up, the physician notification will specifically target the individual involved in the initial report to Manitoba Health as well as the primary care physician (using an algorithm developed by the Manitoba Centre for Health Policy). The notification will provide a general recommendation for osteoporosis assessment in addition to a copy of the BMD testing requisition since BMD testing is usually justified in this setting. The notification will not dictate what testing or treatment needs to be performed.
41492177|NCT01593943|BEHAVIORAL|CHARM|CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
41492178|NCT02472327|BEHAVIORAL|Pre-operative support|
41492179|NCT04175535|PROCEDURE|Percutaneous Posterior Endoscopic Cervical Discectomy|The most common alternative in the case of soft cervical disc herniations.
41492180|NCT04175535|PROCEDURE|Anterior cervical decompression and fusion|The standard procedure for operation of cervical disc herniations.
41492181|NCT03127644|DRUG|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
40831219|NCT05318612|PROCEDURE|Laser Interstitial Thermal Therapy (LITT)|LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.
40831220|NCT05318612|PROCEDURE|Biopsy|A sample of tissue from the tumor is obtained to confirm the diagnosis.
40831221|NCT06463353|OTHER|trilinolein cream group|Apply trilinolein cream evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
40831222|NCT06463353|OTHER|cream base group|Apply cream base evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
41492182|NCT03127644|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
40831223|NCT00601913|DRUG|erlotinib hydrochloride|
40831224|NCT00601913|GENETIC|protein analysis|
40831225|NCT00601913|GENETIC|western blotting|
40831226|NCT00601913|OTHER|immunohistochemistry staining method|
40831227|NCT00601913|OTHER|laboratory biomarker analysis|
41158353|NCT03826147|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Daily supplementation with \~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).
41349802|NCT02647892|DRUG|lidocaine|local anesthesia
41349803|NCT02647892|DRUG|sodium bicarbonate|additional drug added to lidocaine
41492183|NCT03127644|DRUG|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
41349804|NCT03615690|OTHER|Fasting Mimicking Diet|5 day reduced calorie diet
41349805|NCT03615690|OTHER|Regular Diet|Regular Diet
41509087|NCT04237272|OTHER|Pod System E-cig|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
41509088|NCT04237272|OTHER|Customizable Tank E-cig|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week
41509089|NCT04237272|OTHER|Control|Participants will not receive any e-cigarette
40831228|NCT00601913|OTHER|liquid chromatography|
40831229|NCT00601913|OTHER|mass spectrometry|
40831230|NCT00601913|PROCEDURE|neoadjuvant therapy|
40831231|NCT00601913|PROCEDURE|therapeutic conventional surgery|
40831232|NCT01403545|DRUG|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
40831233|NCT01403545|OTHER|Placebo|5% glucose infusion over 120 minutes
40831234|NCT01974752|DRUG|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
40831235|NCT01974752|DRUG|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
40831236|NCT01974752|DRUG|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
40831237|NCT03381313|BEHAVIORAL|Conditioned word repetition training|In the classical conditioning training the onset of the visual stimulus preceded that of the auditory stimulus with a short onset asynchrony, and both stimuli co-terminated. By contrast, in the training without conditioning the auditory stimulus was administered first and the visual stimulus appeared short after the off-set of the auditory one.
41158354|NCT03826147|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|Daily supplementation with \~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).
41349806|NCT00890396|DRUG|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
41349807|NCT06391970|DEVICE|Cognitive screening|The cognitive abilities of participants will be assessed using two different interventions: the first utilizing the new digital device, and the second employing the gold standard method.
41349808|NCT04563624|DRUG|composite blocks|cad cam composite blocks
41349809|NCT04563624|DRUG|ceramic cad cam blocks|ceramic cad cam blocks
41509090|NCT03222856|DRUG|Pembrolizumab|MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
40831238|NCT01283308|BEHAVIORAL|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
41158355|NCT05173506|OTHER|Computer decision support for physician|The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.
41158356|NCT04494425|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
41158357|NCT04494425|DRUG|Capecitabine|Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
41158358|NCT04494425|DRUG|Paclitaxel|Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.
40831239|NCT01283308|BEHAVIORAL|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
40831240|NCT00084175|BEHAVIORAL|Behavior Therapy|
41158359|NCT04494425|DRUG|Nab-Paclitaxel|Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
41158360|NCT06538220|BEHAVIORAL|Questionnaires and focus group|"To evaluate the Chronic Disease Unit care pathway, patients will respond to questionnaires : quality of life (SF-12), personal efficacy scale (GSES), Specific self Efficacy related to Weight Management (SEWM), Rosenberg self-esteem, body image satisfaction (QIC), state of anxiety and depression (HAD), Chronic Disease Unit satisfaction. Some patients will also participate to focus group."
41158361|NCT04244708|DRUG|Radiotherapy plus temozolomide|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
41158362|NCT04244708|OTHER|Radiotherapy plus placebo|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus placebo
41158363|NCT06645769|DRUG|Sodium Phenylbutyrate|will be compared to placebo
40831241|NCT00162240|DRUG|Muraglitazar|
40831242|NCT03693339|DRUG|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
41158364|NCT06645769|OTHER|Placebo|will be compared to NaPB
40831243|NCT04214431|BEHAVIORAL|Mindfulness-Based Childbirth Education|8-week mindfulness-based childbirth education
41349810|NCT00245635|DRUG|Fluoxetine|Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
41349811|NCT00245635|DRUG|Placebo|Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
41349812|NCT01728766|OTHER|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at \>37 weeks by and birth weight \<2500 g
41158365|NCT01225159|DRUG|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
41158366|NCT01225159|DRUG|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
41158367|NCT06647277|COMBINATION_PRODUCT|Fecal Microbiota Transplant|Fecal Microbiota Transplant
41158368|NCT03672383|DEVICE|BAY987534|Form: cream; Route of Administration: topical; Frequency of Administration: twice daily ; Duration of Treatment: 4 weeks .
41349813|NCT01728766|OTHER|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at \>37 weeks and birth weight \>2800 g
41349814|NCT06435117|OTHER|Patient Navigation|CO-CAPTAIN focuses on co-designing and piloting and evaluating the implementation of patient navigation (PN) for primary cancer prevention in people with mental ill-health. Patient Navigators, trained professionals with experience working with people with mental ill-health, will assist people with mental ill-health in gaining access to and utilizing appropriate primary cancer prevention measures offered within the respective healthcare and social system (including smoking cessation and physical activity and nutritional interventions). For this purpose, Patient Navigators will offer regular appointment with participants, apply motivational interviewing and aid in accessing appropriate materials while aiming at empowering participants in taking an active role and making better and more informed decisions regarding their health.
41349815|NCT04444323|OTHER|3D Telemedicine|The intervention is a consultation conducted using a 3D form of telemedicine
41349816|NCT02455843|OTHER|Microwave ablation|Patients assigned to the combination group will be treated with microwave in the primary tumor site
41349817|NCT03997552|PROCEDURE|Non-incised papillae surgical approach (NIPSA)|Periodontal reconstructive surgery
41349818|NCT03997552|PROCEDURE|marginal approach by palatal incision|Periodontal reconstructive surgery
41349819|NCT03997552|PROCEDURE|Minimally invasive surgical technique (MIST)|Periodontal reconstructive surgery
41349820|NCT01353066|DRUG|Intensive Medical Treatment|
41349821|NCT01353066|OTHER|IMM+Roux-en-Y Gastric Bypass (RYGBP)|
41349822|NCT00692393|PROCEDURE|Hartmann intervention|sigmoid resection, peritoneal and rectal lavage, terminal stoma
40831244|NCT01484834|BEHAVIORAL|Exercise and Education|"Exercise were prescribed three times a week with duration of fifteen minutes for three months.~Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors"
41158369|NCT05469867|DEVICE|CorNeat EverPatch|The CorNeat EverPatch will be implanted subconjunctivally over an ocular implant (e.g. glaucoma shunt, exposed suture tags) and fixed to the eye wall. The overlying conjunctiva will be closed over the patch.
40831245|NCT01484834|BEHAVIORAL|Exercise|Exercise were prescribed three times a week with duration of fifteen minutes for three months.
40831246|NCT01484834|BEHAVIORAL|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
40831247|NCT01484834|OTHER|Control Company|No intervention was applied for the participants of this group
40831248|NCT04349241|DRUG|favipiravir|pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor
40831249|NCT04349241|DRUG|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
41509091|NCT03222856|DRUG|Eribulin|Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
40831250|NCT04927104|DEVICE|PEEK Knee Prosthesis|After subjects drop out of the study for any reason, the researchers can perform revision surgery using the prosthetic joint that is now routinely used.
40831251|NCT05484817|DIAGNOSTIC_TEST|Assessment of cardiovascular risk factor, endocrine hormones and related biomarker|Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
40831252|NCT03066362|OTHER|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
40831253|NCT01928823|BEHAVIORAL|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
40831254|NCT01928823|DRUG|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
40831255|NCT05734274|OTHER|Probiotics|Probiotics lozenge containing at least 200 million active Limosilactobacillus reuteri.
40831256|NCT05734274|OTHER|Negative control|Sugar-free negative control lozenges.
40831257|NCT00289198|DRUG|FF|fluticasone furoate 110 μg nasal spray
40831258|NCT00289198|DRUG|Placebo|placebo nasal spray
40831259|NCT05213208|DRUG|Propofol|Using \> 200 mg of propofol sedation colonoscopy is performed. 90-120 minutes after colonoscopy subjects go home. Within 1 week patients will be asked about their condition and satisfaction for colonoscopy.
40831260|NCT03340194|RADIATION|Radiography|Radiography of the hand and feet (face incident) the day of the inclusion
40831261|NCT03340194|PROCEDURE|Veinous punction|Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
40831262|NCT04764734|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
40831263|NCT06162533|BIOLOGICAL|Vaccination against SARS-CoV-2|Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2
40831264|NCT00334906|DRUG|memantine HCl|
41020005|NCT06534216|DIAGNOSTIC_TEST|Intestinal ultrasound|This study employs intestinal ultrasound (IUS) to assess disease activity in Inflammatory Bowel Disease (IBD) patients. Ultrasound parameters include bowel wall thickness measurement, evaluation of vascularization via color Doppler, assessment of wall stratification, and identification of mesentery features and complications (e.g., strictures, fistulas, abscesses). For ulcerative colitis, disease activity is gauged using the Milan Ultrasound Criteria (MUC), where a score \>6.3 indicates active disease based on bowel wall thickness and vascularization. In Crohn's disease, the Bowel Ultrasound Score (BUSS) and International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) assess bowel wall thickness, vascularization, stratification, and inflammatory fat, with scores \>3.52 (BUSS) and \>48.7 (IBUS-SAS) indicating active disease. IUS evaluations occur at baseline, 2-6 weeks, 12 weeks, and 6-12 months to track disease progression and treatment response.
41158370|NCT04086719|DRUG|BMS-986165|Oral administration of tablet BMS- 986165
41509092|NCT04681716|OTHER|ELDOA|For Spinal Segment L4-L5 and L5-S1 proper ELDOA position was instructed to the experiment group patients.ELDOA stands for Elongation Longitudinaux Avec Decoaption Osteo Articulaire, or LOADS (Longitudinal Osteo-articular De-coaptation Stretching). ... They can be described as fascial stretch that localizes tension at the level of a specific spinal segmental.
40831265|NCT04181580|DEVICE|Made-to-measure compression garment|Made-to-measure compression garment
40831266|NCT05558462|DRUG|XC8|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
40831267|NCT03067285|DRUG|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
40831268|NCT03067285|DRUG|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
41020006|NCT06085105|BEHAVIORAL|CPIPE Training|A two day training covering the following topics: understanding stress \& burnout and developing positive coping mechanisms, bias awareness \& mitigation, person-centered maternity care mindfulness, dealing with difficult situations, emergency obstetric and neonatal care, teamwork and communication, mentorship and peer support.
41020007|NCT06085105|BEHAVIORAL|Peer support groups|Groups for healthcare providers to meet with other healthcare providers of their cadre, and discuss issues they are facing, brainstorm solutions, and provide support to one another.
41158371|NCT04086719|DRUG|Pyrimethamine|Oral administration of Pyrimethamine in combination with BMS-986185
41158372|NCT06538649|DRUG|Rosuvastatin|Statin provided at 10mg start; 5mg for Asians. Dose will be increased to 20mg for those tolerating and without contraindication.
41349823|NCT00692393|PROCEDURE|Protected anastomosis resection|sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
41349824|NCT00542217|BIOLOGICAL|Imprime PGG|
41349825|NCT04296929|OTHER|Complex Decongestive Physiotherapy|Complete decongestive therapy (CDT), also called complex decongestive therapy, is an intensive program that combines many of the different treatment approaches, including bandaging, compression garments, manual lymphatic drainage, exercise, and self care.
41349826|NCT01252992|GENETIC|Genetic analysis|"1. identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;~2. Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.~One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction."
41349827|NCT01252992|RADIATION|Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM|at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist
41349828|NCT01252992|OTHER|Immunologic analysis|For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+
41349829|NCT01252992|OTHER|QuantiferonTB Gold test|at M0, M2, M6 and in case of PR+.
41349830|NCT04539665|PROCEDURE|Extended mesenteric resection.|Patients will undergo an ileocolic resection involving high ligation of the ileocolic pedicle, complete mobilization of the mesentery off of the retroperitoneum, and resection of the entire mesentery related to the specimen.
41349831|NCT01531933|DRUG|DLBS3233|For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
41349832|NCT01531933|DRUG|Placebo of DLBS3233|For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
41349833|NCT01271595|OTHER|sham acupuncture|12 sessions of sham acupuncture over 8 weeks
41349834|NCT01097564|GENETIC|COL4A1 genetic testing|genetic testing
41349835|NCT04883099|DEVICE|APIOC for Presbyopia and APIOC for Presbyopia for Astigmatism|Contact Lenses for Presbyopia
41349836|NCT05446181|BEHAVIORAL|Postoperative delirium|Postoperative delirium
41349837|NCT05446181|PROCEDURE|Hip surgery|Orthopedic hip joint surgery under spinal anesthesia
41349838|NCT03837821|DRUG|Abemaciclib|Abemaciclib 200 mg oral, every 12 hours
41349839|NCT00057265|DRUG|telbivudine or lamivudine|
41349840|NCT05705687|DRUG|BEP Protocol|anticancer therapy
41349841|NCT05705687|DRUG|Dose-dense regimen|T-BEP-Oxaliplatin followed by Cisplatin - Ifosfamide - Paclitaxel
41349842|NCT05705687|PROCEDURE|Early tumor resection or HD-CT|TIP protocol + early surgery or high-dose chemotherapy if surgery not feasible or metastatic disease
41349843|NCT03659708|PROCEDURE|Lyon-VTE score|follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.
41349844|NCT03659708|PROCEDURE|recommendations currently available|follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
41349845|NCT04376736|OTHER|Home visit|Home visit by medical provider
41349846|NCT00606710|DEVICE|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
41349847|NCT04012294|DRUG|Allopurinol Pill|"Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant."
41349848|NCT02884193|PROCEDURE|Brief Cooling|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
41020008|NCT06085105|BEHAVIORAL|Mentorship|Mentor-mentee relationships that provide the opportunity to coach junior healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. Mentors develop their mentorship and leadership skills.
41020009|NCT06085105|BEHAVIORAL|Leadership engagement|Engagement of County leadership at the onset of the project through a community advisory board, regular updates of the study and findings, and discussing systemic gaps that impact provider stress and bias.
41020010|NCT06085105|BEHAVIORAL|Embedded champions|To facilitate ongoing engagement and sustainability at the facility level, we identified facility champions who lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
41020011|NCT02762591|DRUG|Pimavanserin tartrate|Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
41020012|NCT04424121|DIAGNOSTIC_TEST|CCTA|Coronary Computed Tomography Angiography
40831269|NCT06484010|OTHER|SNAPPS Model of case presentation|"The intervention was the implementation of the SNAPPS model as a method of case presentation in out-patient settings.~All preceptors and residents in the SNAPPS group were sensitized and trained one week before the beginning of case presentations and data collection by a training session that was carried out by the authors at Brayati Primary Health Center training hall for a duration of more than two hours, the session included a preview of the traditional method, introduction to the SNAPPS method, role play and doubts clarification.~The training materials included a presentation explaining the SNAPPS method in details with examples, instructional videos, and handouts highlighting the six steps of the SNAPPS method.~Before the beginning of the presentation by 72 hours, there was a double check by the principal investigator with all participants regarding the method and all doubts were clarified."
40831270|NCT04239300|BEHAVIORAL|Delivery in water|Participants delivery in water
40831271|NCT03140982|DIAGNOSTIC_TEST|FOUR coma scale and frontal espectrograpy evaluation|systematic evaluation using the validated FOUR coma scale during propofol administration
40831272|NCT04340193|DRUG|nivolumab|Specified dose on specified days
40831273|NCT04340193|DRUG|ipilimumab|Specified dose on specified days
40831274|NCT04340193|PROCEDURE|TACE|TACE (Trans-arterial ChemoEmbolization)
40831275|NCT01741337|PROCEDURE|Adaptive servo-ventilation post-operative treatment for 6 months|
40831276|NCT02511600|OTHER|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
40831277|NCT02511600|OTHER|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
40831278|NCT02511600|BEHAVIORAL|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
40831279|NCT03692481|RADIATION|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
40831280|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
40831281|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
40831282|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
40831283|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
41349849|NCT02884193|PROCEDURE|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
41349850|NCT02884193|PROCEDURE|Sham Ice Bag|"Placebo application through an ice bag empty."
41349851|NCT03186040|DRUG|Lacosamide|Sodium channel blocker
40831284|NCT00787202|OTHER|placebo|Administration via oral route twice daily for the duration of treatment
40831285|NCT04401670|OTHER|HPV screening and triage tests|The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt \[Hologic, Inc., Bedford, MA, USA\] and a visual inspection by acetic acid (VIA) by a nurse.
40831286|NCT04401670|BEHAVIORAL|HPV self-sampling|"The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler \[Preventive Oncology International, Cleveland, OH, USA\]."
40831287|NCT04720768|DRUG|Binimetinib|MEK inhibitor
40831288|NCT04720768|DRUG|Encorafenib|BRAF inhibitor
40831289|NCT04720768|DRUG|Palbociclib|CDK4/6 inhibitor
40831290|NCT02439567|DEVICE|Fibroscan: Liver and Spleen elastography|In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
40831291|NCT03412149|PROCEDURE|Mini Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
40831292|NCT03412149|PROCEDURE|Roux en Y Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
40831293|NCT03542851|DRUG|Pentetrazol (PTZ)|BTD-001 is an oral capsule of PTZ.
40831294|NCT03542851|DRUG|Placebo oral capsule|Placebo will be presented as oral capsule.
40831295|NCT06153433|DRUG|Rosuvastatin Immediate-Release Tablet (IRT) 10mg|Rosuvastatin Immediate-Release Tablet (IRT) 10mg
40831296|NCT06153433|DRUG|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
41020013|NCT01103297|DEVICE|Variable Angle Distal Radius Plate ® (Surgery)|Fracture reduction with distal radius plate
41492184|NCT05315635|OTHER|Questionnaire|"Patients treated for substance use disorders and patients treated for eating disorders will have to complete self-questionnaires and a clinical psychiatric (MINI) at the inclusion.~Patients suffering from substance use disorder will be assessed 3 weeks after inclusion.~Questionnaires are :~* Modified Yale Food Addiction (mYFAS 2.0) and Impulsive Behavior Scale (UPPS-P)~* Trait Meta-Mood Scale (TMMS), Hospital Anxiety and Depression Scale (HADs), Emotional Appetite Questionnaire (EMAQ), Perceived Stress Scale (PSS-10), Multidimensional Assessment of Interoceptive Awareness (MAIA) and Five Facet Mindfulness Questionnaire (FFMQ)~* Mini International Neuropsychiatric Interview (MINI), Eating Disorder Examination-Questionnaire (EDE-Q), Rosenberg's Self Esteem (RSE) and Ruminative Response Scale for Eating disorders (RRS-ED)~* Pittsburgh Sleep Quality Index (PSQI) and Montreal Cognitive Assessment (MoCA)"
41492185|NCT00446901|DIETARY_SUPPLEMENT|Selenium|Selenized yeast, 300 ug/day
41492186|NCT04771403|DEVICE|FMPD AP algorithm|The Fading Memory Proportional Derivative (FMPD) insulin infusion algorithm determines insulin delivery rates based on proportional error, defined as the difference between the current CGM level and the target CGM level, and the derivative error, defined as the rate of change of the CGM. The FMPD algorithm utilizes derivative and proportional glucose errors to determine delivery rates of insulin.
41349852|NCT04111926|DRUG|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
41492187|NCT04771403|DEVICE|MPC AP system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
40831297|NCT01342744|DRUG|Metformin|Metformin(850 mg) 1tab oral twice aday
41349853|NCT04111926|DRUG|Placebo|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
41349854|NCT01165463|BEHAVIORAL|SOPT basic training|10 hours of basic training
41349855|NCT01165463|BEHAVIORAL|Crossword Puzzles|Subjects train with puzzles 10 hrs in lab.
41349856|NCT01165463|BEHAVIORAL|SOPT booster training|4 hours of subsequent booster-training
41349857|NCT03202667|DRUG|Empagliflozin 25mg|Treatment with empagliflozin 25mg once daily for 28 days
40831298|NCT01342744|DRUG|Placebo|Placebo 1 tab oral twice a day
41020014|NCT01845155|BEHAVIORAL|Neuro-Music-Therapy according to the Heidelberg Model|"The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.~For more details on the music therapy see Argstatter et al. 2012"
41020015|NCT01845155|BEHAVIORAL|Counselling|Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
41020016|NCT03192891|DIAGNOSTIC_TEST|Stress cardiac magnetic resonance (CMR) perfusion imaging|Gadolinium-enhanced stress CMR perfusion imaging is a tool increasingly used for the risk assessment and diagnosis of coronary artery disease.
41349858|NCT03202667|DRUG|Placebo|Treatment with Placebo oral tablet once daily for 28 days
41492188|NCT04771403|DEVICE|Dexcom G6 Continuous Glucose Monitoring (CGM) System|The Dexcom G6 CGM measures interstitial glucose through a sensor transmitter. This glucose value is reported to the MPC algorithm during this intervention.
41020017|NCT05800288|DRUG|Propofol|Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature
41349859|NCT05990140|OTHER|peppermint flavored mouthwash|The Effect of Peppermint Flavored Mouthwash Applied to Patients in the First 30 Days After Bariatric Surgery on Nausea-Vomiting, Anxiety and Biochemical Parameters
41349860|NCT03394196|DIAGNOSTIC_TEST|HIV-2 Genotypic Drug Resistance Testing using DBS|Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.
41492189|NCT04555850|DRUG|Recombinant Human Thymosin β4|Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.
41349861|NCT03394196|DRUG|2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)|1. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling
41349862|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )|2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling
41349863|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)|3. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
41349864|NCT01633775|PROCEDURE|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
41349865|NCT04861506|PROCEDURE|endovascular treatment|All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
41349866|NCT03377829|PROCEDURE|PLA|During the PLA, the patient is in supine position with head extended: the physician, ultrasound assistant and trained nurse work within the sterile field. Under constant ultrasound image guidance and after local anesthesia by means of 2% xylocaine infiltration, thin needles (21G) are positioned in the thyroid lesion, within safety distance from the surrounding anatomical structures. A plane-cut tip fiber optics is inserted into the PTMC through the needle. The laser at 1064 nm wavelength is turned on for 10 minutes until the pre-established energy dose is attained. There is usually no pain or very limited pain.
41349867|NCT03377829|PROCEDURE|Thyroid Surgery|Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat, placenta muscle are incised successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process. Finally patient is performed total thyroidectomy or subtotal thyroidectomy.
41349868|NCT02499640|OTHER|immersion cold water|immersion cold water at different temperatures and exposure times
41349869|NCT04009824|BIOLOGICAL|AGS-v PLUS Vaccine|Administered by subcutaneous injection
41349870|NCT04009824|BIOLOGICAL|Montanide ISA-51 Adjuvant|Administered by subcutaneous injection
41349871|NCT04009824|BIOLOGICAL|Alhydrogel® Adjuvant|Administered by subcutaneous injection
41349872|NCT04009824|BIOLOGICAL|Saline Placebo|Administered by subcutaneous injection
41349873|NCT05162300|COMBINATION_PRODUCT|Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)|Same-Day combination of VI Peel applied to the full face, followed by Botox injection per label to the face.
41349874|NCT03351140|OTHER|Qualitative Interviews|Subjects will participate in a qualitative interview lasting up to 90 minutes. The interviews will include a concept elicitation component to explore details of the subject's perceived disease condition, functional limitations and impacts on daily life and health-related quality-of-life (HRQoL). In addition, a card sorting exercise will be used to evaluate the relevance and comprehension of PROMIS Physical Function items.
41349875|NCT03351140|OTHER|PROMIS Physical Function Items|PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
41349876|NCT01032265|BEHAVIORAL|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
41349877|NCT01032265|BEHAVIORAL|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
41349878|NCT00418444|BEHAVIORAL|Group Therapy Intervention|
41349879|NCT00432263|DRUG|Genotropin (PN-180,307) Somatropin|
40831299|NCT06247228|BEHAVIORAL|Click2Move|One year multicomponent intervention including a wearable, and a mobile phone application downloaded in the own mobile phone. Participants will have activity tracking and app provision, sedentary reminders, cooperative challenges, organisational support and motivational messages, educational material, self-monitoring, feedback provision, demonstration videos and strategies.
40831300|NCT00153829|BEHAVIORAL|Multifaceted outreach facilitation for chronic illness care|
40831301|NCT01711281|DEVICE|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
40831302|NCT00857948|DRUG|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
40831303|NCT00857948|DRUG|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
41158373|NCT06538649|OTHER|Placebo|Placebo pill
41349880|NCT02010567|DRUG|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
41349881|NCT02010567|DRUG|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
40831304|NCT03795090|COMBINATION_PRODUCT|Regular Patient privacy curtain|Laundered curtains, used in the hospital, coming from the hospital inventory.
40831305|NCT03795090|COMBINATION_PRODUCT|Antimicrobial Coated curtains|Antimicrobial coating consist of active polymers that are approved by USFDA and USEPA.
40831306|NCT04148508|BEHAVIORAL|Tailored Emotional Competence Self-help|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion. Interventions are personalised to the individual based on emotional competence skills. Intervention is in addition to self-monitoring in the app. Intervention components include selection of 2 from 4 of : targeting worry and rumination; increasing emotional knowledge and perception skills; improving achievement appraisals including attribution retraining and growth mindset; improving social appraisals including positive interpretations of ambiguous social events
40831307|NCT04148508|BEHAVIORAL|Cognitive-behavioural Approach|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion, based on cognitive-behavioural principles such as increased activity and challenging negative thinking. Interventions are generic and common to all participants. Intervention is in addition to self-monitoring in the app.
41020018|NCT04651959|DRUG|AVICOD 200 MG Film Tablet|AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
41020019|NCT04651959|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
41020020|NCT02752412|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41020021|NCT02752412|DRUG|Insulin glargine U100 (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41020022|NCT02752412|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
41020023|NCT02863016|DEVICE|SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
41020024|NCT06368128|BEHAVIORAL|Indoor Rock Climbing Exercise Training Program|Training will occur 2-3 days per week for 60 minutes; ratings of perceived exertion between 3-7 on a scale of 0-10 will be targeted for the desired intensity throughout the program. Minutes of rock climbing will also be monitored to develop the progression strategy.
41020025|NCT01815671|PROCEDURE|colonoscopy in the lateral horizontal position|colonoscopy in the lateral horizontal position with tilt down
41349882|NCT02010567|RADIATION|Radiotherapy|"This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if \<T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume."
41349883|NCT02010567|PROCEDURE|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
41349884|NCT01814228|PROCEDURE|transcatheter ablation of ganglionated plexi in right atrium|
41349885|NCT05230069|OTHER|Interview|Patients will be interviewed post an emergency call and evaluation.
40831308|NCT04148508|BEHAVIORAL|Self-monitoring|Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
40831309|NCT02750865|BEHAVIORAL|Embodied Conversational Agent (ECA)|The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
41349886|NCT01265173|DRUG|Cefotaxime|3 g
41349887|NCT01265173|DRUG|Ceftriaxone|2 g
41349888|NCT01265173|DRUG|Ciprofloxacin|400 mg
41349889|NCT01633528|DRUG|Asprin|100 mg
41158374|NCT00885859|DEVICE|TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]|Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
40831310|NCT01228994|DRUG|Baclofen 30 mg/day|Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease
40831311|NCT01228994|DRUG|placebo pill|placebo pill
41158375|NCT06646042|DRUG|ibuzatrelvir|2x 300 mg tablet
41349890|NCT01633528|DRUG|placebo|100mg
41349891|NCT00880958|DIETARY_SUPPLEMENT|Mixture of various probiotics and fermentation products|
41020026|NCT02426671|DEVICE|MuteButton sensory stimulation device|Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
41020027|NCT02510157|DRUG|Dexamethasone|active comparator
41020028|NCT02510157|DRUG|Normal Saline|placebo controlled intervention
41349892|NCT00880958|DIETARY_SUPPLEMENT|Placebo|
41349893|NCT02933489|DIAGNOSTIC_TEST|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
41349894|NCT02933489|DIAGNOSTIC_TEST|Digital Tomosynthesis Mammography|Undergo DBT
41349895|NCT02933489|OTHER|Quality-of-Life Assessment|Ancillary studies
41020029|NCT02510157|DRUG|sugammadex|sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
41158376|NCT06646042|DRUG|carbamazepine ER|100 mg BID (Day 1-3) 200 mg BID (Day 4-7) 300 mg BID (Day 8-15)
41158377|NCT00938288|DRUG|KW-3357|50IU/mL, IV single dose
41158378|NCT06645509|DRUG|TTB gel (dose 1)|A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days
41349896|NCT02933489|OTHER|Questionnaire Administration|Ancillary studies
41349897|NCT04283773|COMBINATION_PRODUCT|p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)|Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
41349898|NCT04283773|COMBINATION_PRODUCT|Ki67 antibody (DAKO) for malignant cases only|Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
41349899|NCT04516629|DIAGNOSTIC_TEST|heart rate variability, pulse diagnosis device|check heart rate and pulse rate
41349900|NCT00748176|PROCEDURE|spinal anesthesia|spinal anesthesia with bupivacaine
41349901|NCT04966611|DRUG|Anlotinib|This is an observational study
41349902|NCT01310985|DRUG|Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)|Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
41349903|NCT02898792|DRUG|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
40831312|NCT01228994|DRUG|Baclofen 60 mg/day|baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
41020030|NCT03516916|OTHER|Questionnaires on HRQoL and sociodemography|All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
41158379|NCT06645509|DRUG|TTB gel (dose 2)|A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days
41492190|NCT04555850|OTHER|Placebo|3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
41492191|NCT02844400|DEVICE|Biometric Devices|Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
40831313|NCT05691023|DEVICE|Vivistim System|Paired VNS during rehabilitation, facilitated by a rehab therapist in the subject's home (at-home treatment)
40831314|NCT02916407|DRUG|Sevoflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%."
40831315|NCT02916407|DRUG|Desflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%."
40831316|NCT00442091|DRUG|dandelion juice|10 ml bid for 20-30 days
40831317|NCT01107561|OTHER|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire
40831318|NCT01107561|DEVICE|Surgical Airway Approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
40831319|NCT00020462|BIOLOGICAL|aldesleukin|
41020031|NCT03319927|BEHAVIORAL|IPM educational workshop and consultation|The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
41020032|NCT06457958|DRUG|Sevoflurane Group|"Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Sevoflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Sevoflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR."
41020033|NCT06457958|DRUG|Desflurane Group|"Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Desflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Desflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR."
41020034|NCT04650828|DRUG|TDF|TDF combined with telbivudine (LDT) for 12 months
41020035|NCT04650828|DRUG|Tenofovir Disoproxil Fumarate 300 MG|TDF monotherapy was continued for 12 months
41020036|NCT04492033|DRUG|CTX-009 (ABL001)|CTX-009 (ABL001) will be administered biweekly.
41020037|NCT04492033|DRUG|Paclitaxel|Paclitaxel will be administered weekly.
41020038|NCT04492033|DRUG|Irinotecan|Irinotecan will be administered biweekly.
41020039|NCT05884437|PROCEDURE|Chiropractic adjustment|Participants will receive 6 weeks of chiropractic care. The frequency of care will be determined by the field clinician. Participants will have their spine assessed for the presence of vertebral subluxations per their clinician's normal and customary procedures. The adjustment technique(s) utilized by the field clinician will be at their discretion.
41020040|NCT01902017|DRUG|Ketotifen|5 mg PO bid
41020041|NCT01902017|DRUG|Placebo|5 mg placebo PO bid
41020042|NCT06520748|OTHER|Hand rehabilitation program using the computerized glove|The patient extended finger to reach from grey to green to red colour and heard the beep providing knowledge of result (KR), whereas the increase of range of finger extension reached every session provides knowledge of performance (KP). As the patient's performance improved, the range of their finger's movement will also be increased due to the augmented feedback provided to the patient and the therapist through the glove software
41349904|NCT04829864|BEHAVIORAL|STEP|"The program is offered by two facilitators to groups of three to seven women, in-person or online. The program is divided in three phases entitles Becoming a mother; A look at my own history and Looking ahead. The first phase aims to explore and normalize the emotions experienced by the participants in the course of their pregnancy and to support the use of healthy emotion regulation strategies. The second phase aims to support mentalization of trauma, by discussing the nature of trauma and its impact; by validating participants' feelings as understandable responses to trauma; by supporting a reflection on positive and harsh experiences with significant others and the ways both types of experiences influenced participants' mental states; and identifying how participants coped with trauma. In the last phase, discussions focus on participants' needs and strengths, on available resources to support resilience and envision positive and challenging moments with the child."
41349905|NCT06094686|DIAGNOSTIC_TEST|epicardial adipose tissue thickness|EATT measured via transthoracic echocardiography
41349906|NCT02515851|DRUG|Exparel|
41349907|NCT02515851|DRUG|Placebo|
41349908|NCT02710422|BIOLOGICAL|Amniotic Membrane Placement|Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
41349909|NCT02710422|BEHAVIORAL|EPIC 26|Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
41349910|NCT02710422|OTHER|PSA Measurement|Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
40831320|NCT00020462|BIOLOGICAL|autologous tumor cell vaccine|
40831321|NCT01878669|DRUG|N-acetyl cysteine|
40831322|NCT01878669|DRUG|Saline|
40831323|NCT01107119|OTHER|integrated care pathway|communication and follow-up program for integrated care
40831324|NCT01107119|OTHER|usual care|
40831325|NCT04316741|BEHAVIORAL|Snapcoach|A brief motivational interviewing-based intervention combined with health coaching via social media for 4 weeks
40831326|NCT02476110|DIETARY_SUPPLEMENT|Oral nutritive supplements|
40831327|NCT03873961|DEVICE|High-intensity laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
40831328|NCT03873961|DEVICE|Low-level Laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
41158380|NCT06645509|DRUG|Placebo|A topical administration of a vehicle (Placebo) gel to both hands, once daily for 28 days
41158381|NCT06632769|DEVICE|No intervention|No intervention
41349911|NCT02710422|BEHAVIORAL|Sexual History Inventory for Men|SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
41020043|NCT06520748|OTHER|Selected hand program|Distal key point of Bobath, approximation of affected arm, to control spasticity of wrist/ finger flexor (5 minutes). Dynamic splint to facilitate wrist and finger extension (10 repeat\*5 sets). Passive range of motion exercise (10 repeat\*5 sets) for each joint. Mud exercise (spherical, clyndrical , hook). Thera band exercises.
41020044|NCT01921972|DRUG|Galantamine CR|24 mg/day with dose-titration over twelve weeks
41020045|NCT01921972|DRUG|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
41020046|NCT01921972|DRUG|Placebo|Placebo will be similar in appearance to Memantine
41020047|NCT01497379|PROCEDURE|surgical implantation of subretinal device|surgical implantation of subretinal device
41020048|NCT01497379|PROCEDURE|surgical implantation of subretinal device|intra-individual implant OFF
41020049|NCT06515860|DIAGNOSTIC_TEST|Liquid biopsy for MPNST development|Participants will be asked to complete a blood sample (liquid biopsy) at baseline (15 mL, approximately 1 tablespoon) and every 6 months (10 mL) for the five-year follow-up period.
41020050|NCT01066559|PROCEDURE|High flux polymethylmetacrylate membrane|Patients will be hemodialysed with high flux polymethylmetacrylate membranes
41020051|NCT01066559|PROCEDURE|Polysulfone membrane|Patients be hemodialysed with polysulfone membranes
41020052|NCT01066559|BIOLOGICAL|Hepatitis B serological control|It will be assessed at week 16, week 20 and week 40
41020053|NCT01066559|BIOLOGICAL|Seric sCD40 level|Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
41020054|NCT02710526|DRUG|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
41020055|NCT05906407|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy
41020056|NCT00550784|BIOLOGICAL|filgrastim|
41158382|NCT00144378|DRUG|Irinotecan|
41158383|NCT02686125|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
41158384|NCT03325608|OTHER|POISED Care|Program of dementia care management.
41158385|NCT04509583|DIETARY_SUPPLEMENT|PROFortil|Multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months
41020057|NCT00550784|DRUG|cisplatin|
41158386|NCT04509583|OTHER|Vitamin E|Only Vitamin E (Enat 400, once per day) in 3 months
41158387|NCT05210374|DRUG|Disulfiram|"To be taken orally (PO) daily in the AM, rounded for pill size (max 480mg/day).~To be administered day 1-7 of lead-in week and day 1-28 cycles~Cycle length: 28 days,~maximum 12 cycles Level -1 (150mg/m\^2/day) Level~0 (225mg/m\^2/day) Level 1 (300mg/m\^2/day), max~480mg/day"
41158388|NCT05210374|DRUG|Copper Gluconate|"To be taken orally (PO), 5.2mg/m2/day daily in the PM, rounded~for pill size (max 9mg/day) To be administered day 1-7~Lead-in week and day 1-28 cycles Cycle length: 28~days, maximum 12 cycles"
41349912|NCT03756285|DRUG|AZD4831|AZD4831 tablet taken orally for 90 days.
41349913|NCT03756285|DRUG|Placebo|Placebo tablet taken orally for 90 days.
41349914|NCT03953690|OTHER|use of e-Health service|use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation
41020058|NCT00550784|DRUG|cyclophosphamide|
41020059|NCT00550784|DRUG|melphalan|
41020060|NCT00550784|DRUG|paclitaxel|
41020061|NCT00550784|DRUG|topotecan hydrochloride|
41020062|NCT00550784|GENETIC|TdT-mediated dUTP nick end labeling assay|
41020063|NCT00550784|GENETIC|gene expression analysis|
41020064|NCT00550784|OTHER|immunohistochemistry staining method|
41020065|NCT00550784|OTHER|pharmacological study|
41020066|NCT00550784|PROCEDURE|peripheral blood stem cell transplantation|
41020067|NCT03847428|DRUG|Durvalumab|Durvalumab IV (intravenous)
41020068|NCT03847428|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
41020069|NCT03847428|OTHER|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
41020070|NCT02974361|DRUG|Ibuprofen|
41020071|NCT02974361|DRUG|Ibuprofen Lysine|
41349915|NCT00656994|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
41349916|NCT00656994|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
41349917|NCT01291511|DRUG|Iloperidone|Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
41349918|NCT01291511|DRUG|Placebo|Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
41349919|NCT04130880|DIAGNOSTIC_TEST|Turkish Montreal Children's Hospital Feeding Scale|The Turkish version of the Montreal Children's Hospital Feeding Scale, and the Behavioral Pediatrics Feeding Assessment Scale will be completed.
41349920|NCT03849092|BEHAVIORAL|Financial incentives|Cessation programs in municipalities will offer a financial incentive of 1200 DKK to smokers who achieve continuous abstinence from smoking when attending a group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
41349921|NCT03849092|BEHAVIORAL|Campaigns|Municipalities will design anti-smoking campaigns targeting smokers, recommending to use a municipal free group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
41349922|NCT05907005|BEHAVIORAL|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
41349923|NCT06178458|OTHER|No intervention|To collect data of pain score and opioid consumption of index and previous cesarean delivery
41349924|NCT02092324|OTHER|Laboratory Biomarker Analysis|Correlative studies
41349925|NCT02092324|OTHER|Quality-of-Life Assessment|Ancillary studies
41349926|NCT02092324|OTHER|Questionnaire Administration|Ancillary studies
41492192|NCT02844400|OTHER|Physical Performance Testing|Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
41492193|NCT04473911|DRUG|FLUDARABINE|predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles
41492194|NCT04473911|DRUG|CYCLOPHOSPHAMIDE|◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
41492195|NCT04473911|RADIATION|TBI|Total body irradiation (TBI) once per cycle.
41492196|NCT04473911|DRUG|Melphalan|Melphalan, infusion, determined dosage, once per cycle
41020072|NCT02974361|DRUG|Ibuprofen-LDH|
41349927|NCT02092324|DRUG|Ruxolitinib Phosphate|Given PO
41020073|NCT06573554|OTHER|Total Contact Cast|TCC will be applied to the Charcot patients
41349928|NCT02938975|OTHER|Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|"One application of Lipo DEET protects for up to 12 hours and has a pleasant odour and non-greasy feel on the skin. DEET is a broad spectrum insect repellent and was selected this study because it has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors. DEET was first registered in 1957 and has been conclusively proven to be safe for use on adults, children, pregnant and lactating mothers.~This Liposome-based repellent is the newest advancement in insect repellent technology. The Liposome envelops the active ingredient, DEET, and slowly time-releases it as needed, thereby extending the effectiveness of the repellent and reducing dermal absorption."
41349929|NCT02938975|OTHER|Permethrin Factory-Treated Army Combat Uniforms|Permethrin is the U.S., Australian and United Kingdom (UK) military's standard repellent for application to fabric and is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings; an objective easily met through factory treatment of uniforms, which demonstrates 99-100% bite protection up to 50 launderings (the expected lifetime of the uniform).
41492197|NCT04473911|DRUG|Sirolimus|Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism
41492198|NCT04473911|DRUG|Mycophenolate mofetil|◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
41492199|NCT04473911|DRUG|RGI-2001|IV, predetermined dose, weekly to 6 total doses
41492200|NCT04473911|DRUG|CYCLOPHOSPHAMIDE|◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
41492201|NCT06306586|BEHAVIORAL|Digital Treatment for Adolescents With Eating Disorders|"The main aim of the digital treatment is to reduce symptoms of eating disorders and increase life-coping skills. The digital treatment aims to help adolescents with eating disorders to:~* Gain knowledge about the symptoms of eating disorders and the consequences it has on everyday life.~* Be motivated to carry out the treatment.~* Gain knowledge of and skills in regulating food and activity in a more balanced way.~* Gain knowledge of and skills in managing emotions.~* Get tools to develop a better self-esteem.~* Gain awareness of the function of the eating disorder.~* Gain skills in coping with social challenges.~* Get a more realistic image of their bodies and handle information from social media."
41020074|NCT06573554|OTHER|Posterior Slab|Posterior Slab will be applied to the Charcot patients
41020075|NCT04412902|DRUG|adjuvant therapy|Adjuvant chemotherapy and/or radiotherapy
41020076|NCT05269524|BEHAVIORAL|Internet-delivered tailored cognitive behavior therapy|Therapists-supported tailored 10-week treatment for depression in older adults.
41020077|NCT06573515|DEVICE|high tone power therapy|female patients will receive high-tone power therapy using a device (HiTop 191 Medizintechnik, Rimbach, Germany) duration 30 minutes at 2 sessions per week for 6 weeks
41158389|NCT05210374|DRUG|Liposomal Doxorubicin (Doxil)|"To be given IV, 30mg/m2/dose~To be administered day 1 of cycles~Cycle length: 28 days, maximum 12 cycles"
41349930|NCT02938975|OTHER|Placebo lotion|A liposome lotion with no DEET
41349931|NCT02938975|OTHER|Army combat uniform|Army combat uniform with no permethrin
41158390|NCT04778683|PROCEDURE|Virtual Reality|The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing. Before commencement of the study, the VR applications were administered to five children aged between five and ten years, and these children shared no negative feedback about the VR programs. Before the surgery, the children were allowed to watch the VR program of their choice, the average duration of which was 4.5 minutes, using the VR glasses. Parts of the device that come in contact with the children's faces were cleaned before each application
41158391|NCT04788277|PROCEDURE|Biospecimen Collection|Undergo collection of urine samples
41349932|NCT01758367|DRUG|Deciatbine(DAC)|
41349933|NCT02837055|DEVICE|VivaSight intubation|patients are intubated with an endotracheal tube with an integrated camera
41158392|NCT01405521|BIOLOGICAL|Vaccine placebo (excipients only)|single oral dose,
41158393|NCT01405521|BIOLOGICAL|Ty21a|3 oral doses, alternate days
41158394|NCT01405521|BIOLOGICAL|M10ZH09 vaccine|single oral dose
41158395|NCT06453174|OTHER|Adherence to the first prescribed antipsychotic medication|We shall compare adherence to the first prescribed antipsychotic medication and pragmatic clinical and functional outcomes between two cohorts of patients with first-episode psychosis. One cohort will be comprised of patients treated before the implementation of an early intervention in psychosis model of Personalised Precision Psychiatry including pharmacogenetics, and the other of patients treated under this new model. Also, we shall compare the pharmacogenetic profiles and possible phenocopies (variations of phenotypes produced environmentally, e.g., due to polypharmacy, rather than genetically) between these first episode psychosis patients and a national cohort of patients with longer-term psychotic disorders or with other mental health conditions, to evaluate potential implications for clinical management at different stages of a psychotic illness, and across mental disorders.
41158396|NCT06036784|DRUG|MBX 1416 (Part A)|Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg
41158397|NCT06036784|DRUG|MBX 1416 (Part B)|Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg
41158398|NCT06036784|DRUG|Placebo|Single dose or repeated subcutaneous (SC) dose of placebo.
41158399|NCT06036784|DRUG|MBX 1416 (Part C)|Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
41158400|NCT06584838|PROCEDURE|ACL reconstruction|Patients that underwent ACL reconstruction using either allograft or autograft tendons, at least 2 years of follow-up, gender male and female, no comorbidities
41158401|NCT04994158|COMBINATION_PRODUCT|Drugs, procedures|standard of care only. non interventional registry.
41158402|NCT00053391|BIOLOGICAL|recombinant CD40-ligand|
41158403|NCT00053391|BIOLOGICAL|therapeutic autologous dendritic cells|
41158404|NCT03600519|DEVICE|NOTAL OCT V2.5|AMD Patients
41158405|NCT02229396|DRUG|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
41158406|NCT02229396|DRUG|Exentide|2 mg
41158407|NCT02229396|DRUG|Dapagliflozin|10 mg once daily Dapagliflozin
41492202|NCT01673243|OTHER|Questionnaire|Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.
41492203|NCT06283576|DIAGNOSTIC_TEST|Liquid biopsy|"Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for ground truth"
41158408|NCT00776984|DRUG|tiotropium 5mcg/day|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
41349934|NCT02837055|DEVICE|conventional intubation|patients are intubated with a conventional endotracheal tube
41349935|NCT03199131|PROCEDURE|Right ventricular biopsies|a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
41349936|NCT00408785|DRUG|Botulinum Toxin Type A|botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
41349937|NCT00408785|DRUG|sodium chloride|sodium chloride 0.9 mg
41349938|NCT05385172|OTHER|No any intervation.|This research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years.
41349939|NCT01969565|DRUG|Carfilzomib|
41349940|NCT01969565|DRUG|Dexamethasone|
41349941|NCT03640728|DRUG|Tenofovir Alafenamide|Tenofovir alafenamide 25 mg/day orally
41349942|NCT03640728|DRUG|Entecavir|Entecavir 0.5 mg/day orally
41349943|NCT03640728|DRUG|Tenofovir disoproxil fumarate|Tenofovir Disoproxil Fumarate 300 mg/day orally
41349944|NCT00732472|DRUG|GSK573719|7 day repeat dose
41349945|NCT04677803|DRUG|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
41349946|NCT04451395|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
41349947|NCT05910983|PROCEDURE|Bipolar enucleation of the prostate (BipolEP)|Bipolar enucleation of the prostate (BipolEP)
41349948|NCT05910983|DRUG|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
41349949|NCT00381472|DRUG|Ropinirole|
41349950|NCT03983304|DEVICE|The ZELTIQ System|The EMS device will be used to perform the treatments.
40831329|NCT04592172|BEHAVIORAL|Bedtime Routine Education|The intervention aims to promote healthy sleep and improved developmental outcomes in infants. Individualized bedtime routine education, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling will be implemented by research assistants at the 12-month well-child visit. Reinforcement of the bedtime routine education will be implemented at the 15-month visit. Each individualized bedtime routine will incorporate 3-5 steps and a bedtime routine chart depicting those steps will be created and provided to the families. Families will receive materials for their bedtime routines, including a CuddleBright kit, 1-2 additional bedtime books, toothbrush/toothpaste , and the created bedtime chart. On top of that, families will also receive a children's book provided by Reach Out and Read through the study period.
40831330|NCT03515941|DRUG|Oxaliplatin|130 mg/m2 by IV (Arm 1)
40831331|NCT03515941|DRUG|Capecitabine|625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
40831332|NCT03515941|DRUG|Leucovorin|400 mg/m2 by IV (Arm 1 \& Arm 2)
41349951|NCT06118944|DEVICE|ICB00 IOL|Bilateral implantation of ICB00 IOL
41349952|NCT06118944|DEVICE|ZCB00 IOL|Bilateral implantation of ZCB00 IOL
41349953|NCT06118944|DEVICE|CNA0T0 IOL|Bilateral implantation of CNA0T0 IOL
41349954|NCT05483764|DEVICE|Ultrasonographic evaluations|"Ultrasonographic evaluations of the talar cartilage will be performed with an 8 MHz linear probe (B-K Medical Ultrasound Scanner Class I Type B) by the same physiatrist according to the European Musculoskeletal Ultrasound Study Group (EURO-MUSCULUS).~Ultrasonographic evaluations of the Achilles tendon will be performed by the same physiatrist with an 8 MHz linear probe (B-K Medical Ultrasound Scanner Class I Type B) according to the European Musculoskeletal Ultrasound Study Group (EURO-MUSCULUS)."
41349955|NCT01894685|DRUG|Mesalazine|Mesalazine 3 grams, once daily for six months
41349956|NCT01894685|DRUG|Placebo|Placebo 3 grams, once daily for six months
41158409|NCT00776984|DRUG|placebo|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
41349957|NCT06377215|DEVICE|Open-source master hearing aid|The investigators will administer the intervention by fitting the device to the participant's audiometric profile. Testing will be counter-balanced across conditions with half the conditions requiring no intervention and the other half with the intervention.
41349958|NCT02048852|OTHER|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
41349959|NCT02048852|OTHER|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
41349960|NCT02048852|OTHER|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
41349961|NCT02048852|OTHER|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
41349962|NCT00366106|DRUG|bortezomib|Patients will be treated with bortezomib at 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
41349963|NCT00366106|DRUG|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
41349964|NCT00366106|DRUG|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m\^2 on Day 4 every 28 days (cycle).
41349965|NCT01021839|PROCEDURE|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
40831333|NCT03515941|DRUG|5-fluorouracil|400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
40831334|NCT03515941|RADIATION|radiation|45 Gy in 1.8 Gy/fraction
40831335|NCT01023386|DRUG|YM155|I.V.
41349966|NCT04262557|DIAGNOSTIC_TEST|Sunrise® solution|Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.
41349967|NCT04262557|DIAGNOSTIC_TEST|Polysomnography|Gold standard method to diagnose SAS used as comparator
41349968|NCT02868801|DRUG|Placebo|same intervention as the experimental group
41349969|NCT02868801|DRUG|Pregabalin SR tablet 165mg/day|According to the efficacy and safety in titration
41349970|NCT02868801|DRUG|Pregabalin SR tablet 330mg/day|According to the efficacy and safety in titration
41349971|NCT02868801|DRUG|Pregabalin SR tablet 660mg/day|According to the efficacy and safety in titration.
41492204|NCT00150943|DEVICE|Renal artery stent|
40831336|NCT05270226|BEHAVIORAL|The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)|"The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists)."
40831337|NCT05214989|BEHAVIORAL|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
40831338|NCT05598723|DRUG|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
40831339|NCT05598723|DRUG|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
40831340|NCT00493636|DRUG|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
40831341|NCT00493636|DRUG|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
40831342|NCT00493636|DRUG|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
40831343|NCT00493636|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
40831344|NCT05854953|DEVICE|Hawley retainers in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
40831345|NCT05854953|DEVICE|Hawley retainers in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
40831346|NCT05854953|DEVICE|VFRs in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
40831347|NCT05854953|DEVICE|VFRs in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
40831348|NCT05854953|DEVICE|Baseline characteristics|Hawley retainers and VFRs that are newly constructed will be used as baseline samples. The samples will be taken for microbial, physical and mechanical tests.
40831349|NCT04883528|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
40831350|NCT04883528|DRUG|Placebo|sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
40831351|NCT04927767|DEVICE|denture adhesive|Denture adhesive is a commercially available denture care product used to adhere a denture to the oral mucosa, in order to improve the retention and stability.
41020078|NCT06573515|DEVICE|interferential current therapy|female patients will receive interferential current therapy using Enraf-Nonius (ENDOMED 484, Germany)The electrode pairs will placed at a distance of at least 2.5 cm from each other. The utilized parameters will have a base frequency of 4,000 Hz, a modulation frequency range of 10 Hz-20 Hz, spectrum mode triangular, and slope 1/1 in a quadripolar manner with a beat frequency of 80 Hz. duration of treatment session 20 minutes 2 sessions per week for 6 weeks
41349972|NCT00740688|PROCEDURE|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
41349973|NCT00740688|PROCEDURE|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
41349974|NCT04605458|COMBINATION_PRODUCT|Contingency Management|Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
41349975|NCT04605458|COMBINATION_PRODUCT|Standard Care|Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
41492205|NCT06138236|DRUG|Collagen hydrolyzed peptides|infiltration near the heal spur of 2ml of Arthrys
40831352|NCT04783857|DRUG|Progesterone 200 MG Oral Capsule|Progesterone, 200mg, once daily, oral tablet/capsule
40831353|NCT04217161|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement
41020079|NCT06573515|DEVICE|conventional physical therapy|female patients will receive conventional physical therapy modalities in the form of (ultrasound, massage, stretching, and strengthening exercises) 2 sessions per week for 6 weeks
41349976|NCT05415865|COMBINATION_PRODUCT|Alkalinized Lidocaine|20 ml of Lidocaine Hydrochloride and 10 ml of Sodium hydrogen carbonate will be pulled up and mixed in a syringe on site, and 30 ml mixed solution in total will afterwards be installed in the bladder with a catheter.
41492206|NCT04091711|DEVICE|ReX-C system|Oral oncolytic medications are dispensed to patients via ReX-C system
41492207|NCT05882279|OTHER|No Intervention|This is a non-interventional study.
40831354|NCT05879367|DRUG|Eflornithine (Dose Level 1)|Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
40831355|NCT05879367|DRUG|Eflornithine (Dose Level 2)|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
40831356|NCT05879367|DRUG|Eflornithine (Dose Level -1)|Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
41020080|NCT05071755|PROCEDURE|Gastrectomy|Radical Total Gastrectomy, Radical Partial gastrectomy (Proximal / Subtotal)
41020081|NCT04283734|DEVICE|iFR pullback with Syncvision software (Volcano company)|iFR pullback with Syncvision software permit us to analyze the vessel completely and to predict the physiological significance of every lesion and segment, to predict the benefit of the revascularization in terms of iFR improvement, and to predict the minimum stent length necessary to achieve this improvement.
41492208|NCT05002660|BEHAVIORAL|Group 1 (Intervention)|The investigators will evaluate the efficacy of the CC curriculum in a 24-months community-based randomized controlled trial. They will compare changes in CVD-related anthropometric, behavioral, and psychosocial parameters between subjects in intervention and control communities.
41349977|NCT05415865|DRUG|Placebo Sodium Chloride 0.9% Inj|20 ml of Sodium Chloride 9 g/L and 10 ml of Sodium Chloride 9 g/L will be pulled up and mixed in a syringe on site, and 30 ml solution in total will afterwards be installed in the bladder with a catheter.
41349978|NCT03504384|OTHER|questionnaire|All patients will be interviewed using a semi-structured questionnaire detailing patients' demographic characteristics (age, sex, education, occupation, residence), and the factors that could affect their quality of life such as pain and neurological symptoms, orthopedic disorder in another part of the body and history of spinal surgery.
41349979|NCT04545086|BEHAVIORAL|Video Based Education, Music Therapy|Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
41349980|NCT01587599|BEHAVIORAL|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
41349981|NCT02233491|BEHAVIORAL|Active lifestyle intervention|Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.
41349982|NCT02233491|OTHER|Control|No additional support other than lifestyle advice by clinician
41349983|NCT02924987|DRUG|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
41349984|NCT03431415|PROCEDURE|Anatomical Segmentectomy, Lobectomy or Bilobectomy|Lung Cancer Anatomical Resection
41349985|NCT03431415|RADIATION|Stereotactic Body Radiation Therapy|SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
41349986|NCT04264182|OTHER|ICD programming|Re-programming of the ICD device for VA detection (see above)
41349987|NCT01601873|DEVICE|PROPATEN|Heparin-bonded graft implantation for hemodialysis vascular access
41349988|NCT01601873|DEVICE|Standard Graft|non-heparin bonded conventional hemodialysis vascular access graft
41349989|NCT00332046|DRUG|GW679769|
41349990|NCT01979328|DEVICE|geko|
41349991|NCT01979328|DEVICE|Plaster cast|
41349992|NCT05138965|PROCEDURE|the mCP with alginates dressing|The method is to use gauzes folded onto the RVF wound surface to compact the deep wound so as to solid and durable,when the gauzes surface will be covered by alginates dressing.
41349993|NCT05138965|PROCEDURE|only alginates dressing|Only alginates dressing will be placed above the RVF wound without any pressure.
41349994|NCT00676728|DRUG|JNJ-26481585|In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
41349995|NCT03042195|OTHER|Parenteral Nutrition|Supplementary parenteral nutrition to achieve 100% coverage of estimated needs
41349996|NCT02689141|DRUG|Bendamustine|Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
41349997|NCT02689141|DRUG|Ofatumumab|"Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v."
41349998|NCT02689141|DRUG|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
41349999|NCT01314456|DEVICE|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
40831357|NCT05879367|DRUG|Temozolomide|Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
40831358|NCT03647111|DRUG|Crizotinib|Crizotinib 250mg po bid
41350000|NCT06147232|DRUG|Sotagliflozin|Sodium-glucose-co-transporter 1 and 2 inhibitor
41350001|NCT06147232|DRUG|Placebo|Placebo tablet
41350002|NCT05985616|OTHER|High Intensity Resistance Training|High intensity resistance training will be performed 3 times a day for sixteen weeks
41350003|NCT02804685|OTHER|exercise protocol|The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
41350004|NCT01431456|DRUG|Dabigatran|Dabigatran
41350005|NCT01431456|DRUG|Rivaroxaban|Rivaroxaban
41350006|NCT01431456|DRUG|Nadroparin|Nadroparin
41350007|NCT05143255|BEHAVIORAL|KNOW|KNow the Optimal Way (KNOW) is a manualized ADRD patient-care partner intervention designed to increase engagement in advance care planning (ACP) and completion of advance directives among early stage ADRD patients and their care partners using theoretically grounded distress tolerance techniques (inhibitory learning theory) and communication skills (cognitive-social processing theory) consistent with recommended guidelines for discussions about ACP in ADRD care.
41350008|NCT02514213|BIOLOGICAL|2mg INO-5150 and electroporation device CELLECTRA®-5P|2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
41350009|NCT02514213|BIOLOGICAL|8.5mg INO-5150 and electroporation device CELLECTRA®-5P|8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
41350010|NCT02514213|BIOLOGICAL|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
41492209|NCT05002660|BEHAVIORAL|Group 2 (Control)|Group 2 will be offered the same activities as Group 1 after the conclusion of the research study.
40831359|NCT04919460|OTHER|clinical observation combined with pathological biopsy|Inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
40831360|NCT04919460|OTHER|Clinical observation, in vivo staining (reagent: toluidine blue) combined with pathological biopsy|(2) Inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
40831361|NCT05221112|OTHER|diagonal pattern training|patients will receive proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.
40831362|NCT05221112|OTHER|single plane training|patients will receive single plane training of proprioceptive neuromuscular facilitation in control group
40831363|NCT00714766|PROCEDURE|Intravascular volume administration|Infusion of colloid to reestablish CVP under heat stress
40831364|NCT00991328|PROCEDURE|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
40831365|NCT03728491|DEVICE|Simulator|US Mentor simulator, lung module, provided by 3D Healthcare Systems
40831366|NCT03728491|DEVICE|Healthy figurants|Medical students or volunteers without any pathology in thorax
40831367|NCT02119039|DEVICE|RGTA OTR 4120 (CACICOL20)|
40831368|NCT02119039|DEVICE|Genteal HA eye drops|
40831369|NCT04920006|BEHAVIORAL|Enhancing Active Caregiver Training|The intervention has three components within each session. Step 1, View, involves group viewing of a caregiving scenario, developed during previous research, which portrays a situation in which a caregiver is dealing with a challenging behavioral symptom. Step 2, Practice, involves small-group rehearsal activities that facilitate understanding, making choices, and examining possible responses. Step 3, Reflect, involves self-reflection and group processing surrounding choices and observations.
40831370|NCT03950687|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
40831371|NCT03950687|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
41350011|NCT02514213|BIOLOGICAL|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
40831372|NCT00657371|DEVICE|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
40831373|NCT06508307|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors|The maximum number of lesions that each participant is allowed to inject at one time is two.
40831374|NCT03919227|PROCEDURE|empty bladder before inserting UAS|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS, so that we can see if the empty bladder is easier for inserting UAS.
40831375|NCT03919227|PROCEDURE|do not interfere with the filling degree of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS, so that we can see if the filling degree of bladder has impact on the insertion of UAS.
41350012|NCT02514213|DEVICE|Electroporation using CELLECTRA®-5P|Electroporation device CELLECTRA®-5P
41350013|NCT05049642|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
41350014|NCT01816542|OTHER|patch tests on healthy skin|Patches will be placed on healthy skin.
41492210|NCT03009916|DRUG|"cholestagel® (Colesevelam)"|3750mg
41492211|NCT03009916|DRUG|Placebos|3750mg
41492212|NCT04395144|PROCEDURE|Awake Prone Positioning|Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h
40831376|NCT05577364|DRUG|Selinexor|"Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);~Selinexor is added from the second cycle of R-CHOP regimen."
40831377|NCT05577364|DRUG|R-CHOP Protocol|"Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;"
40831378|NCT00040807|DRUG|docetaxel|
40831379|NCT00040807|DRUG|irinotecan hydrochloride|
40831380|NCT05331703|OTHER|designed physical therapy program in addition to program of virtual reality.|physical therapy program in addition to program of virtual reality.
40831381|NCT05331703|OTHER|designed physical therapy program in addition to program of mirror therapy.|physical therapy program in addition to program of mirror therapy.
41492213|NCT04395144|PROCEDURE|Standard care|Patients will not receive any special instructions with regards to proning.
41492214|NCT01483053|DRUG|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
41492215|NCT01483053|DRUG|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
41492216|NCT03321435|OTHER|placenta previa patient|women had placenta previa either major or minor degree
41350015|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises|All participants received a six-month intervention consisting of two phases: the first month was a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months were a formal practice phase of 45 minutes per session, once a day. In the first phase, participants learn four new movements per session and consolidate these exercises in the next session. After learning all the movements, the remaining time of the first phase was used to consolidate the exercises. In the second phase, participants perform a full Health Qigong - 12-Step Daoyin Health Preservation Exercises practice in each session.
41350016|NCT06454565|BEHAVIORAL|Locked exercise|All participants received a six-month intervention of 45 minutes once a day. All participants performed blocked aerobic exercise.
41350017|NCT06454565|BEHAVIORAL|Multiplayer open exercise|All participants received a six-month intervention in the form of a balloon game competition. The intervention consisted of two phases: the first month consisted of a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months consisted of a formal competition phase of 45 minutes per session, once a day. In the first phase, coaches taught participants the technical movements and rules. In the second phase, participants competed in groups during each session, with the coaches acting as referees.
41350018|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with locked exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed blocked exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Blocked Exercise group.
41350019|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with open exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed multiplayer Open Exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Multiplayer Open Exercise group.
41350020|NCT03523715|DIETARY_SUPPLEMENT|Prunes|12 oz of prunes daily
41350021|NCT03523715|DRUG|Docusate Sodium|Oral docusate sodium twice daily
41350022|NCT01183104|DRUG|Sitagliptin|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=\< \<50).
41350023|NCT01183104|DRUG|Glimepiride|Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
41350024|NCT05564715|DEVICE|NeuroElectric StarStim|10 sessions of active stimulation (1 mA anodal HD-tDCS targeting preSMA/dACC for 20 min) across 2 weeks
41350025|NCT05564715|DEVICE|Sham Treatment|Sham stimulation for 10 sessions over 2 weeks
41350026|NCT05815862|DRUG|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor.
41350027|NCT02814812|PROCEDURE|CT scan|
41350028|NCT02169726|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
41350029|NCT05973240|OTHER|Participation in an web-based survey|Patients who agree to participate will access a web-based survey (SurveyMonkey) via social media, mobile messages, or emails. The invitation will provide study details, eligibility criteria, and tasks. Patients will confirm inclusion/exclusion criteria upon access, and those ineligible will opt out. Data collection will take approximately 10 minutes per patient. Collected data will be sent to an electronic data collector and saved as an eCRF file in REDCap. The study will conduct two cross-sectional data collection rounds using web surveys to ensure anonymity. Convenience sampling will target anticoagulated patient associations' webpages and social media (e.g., Feder-AIPA, AICCA). In the second round, participants will be informed not to resubmit if they have already completed the survey to avoid overlapping responses.
41350030|NCT04367740|DIAGNOSTIC_TEST|To assess for development of IgG antibodies against SARS-CoV2|Swabs will be collected to assess for COVID-19 if PPE supplies allow.
41350031|NCT01355224|GENETIC|Genetic|Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.
41350032|NCT01355224|BEHAVIORAL|Lifestyle|Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
41350033|NCT02871791|DRUG|Palbociclib|
41350034|NCT02871791|DRUG|Everolimus|
41350035|NCT02871791|DRUG|Exemestane|
41350036|NCT02400840|PROCEDURE|cardiac MRI|Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
41350037|NCT02400840|DRUG|gadobenic acid intravenous injection 0.2 ml/kg|gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
41350038|NCT03386006|BEHAVIORAL|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks.
41350039|NCT05083364|DRUG|ARO-C3|ARO-C3 for sc injection
41350040|NCT05083364|DRUG|Placebo|sterile normal saline (0.9% NaCl) for sc injection
41350041|NCT05018273|BIOLOGICAL|VB10.NEO|The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.
41350042|NCT00949104|DRUG|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
41350043|NCT00949104|DRUG|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
41350044|NCT03283891|OTHER|Educational intervention - humanistic nursing practice|"Four educational sessions:~* Acquisition of core concepts of caring practice (I)~* Acquisition of core concepts of caring practice (II)~* Search for meaning: Influencing hope in persons through humanistic practice~* Enacting different caring attitudes and behaviours in an intermediary simulation exercise with actor"
41350045|NCT02352428|OTHER|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
41350046|NCT03284151|RADIATION|Cyberknife|
41350047|NCT01332851|BEHAVIORAL|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
41492217|NCT03321435|OTHER|normal women|those women had not placenta previa
40831382|NCT01340508|RADIATION|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
40831383|NCT04437719|OTHER|Obvio-19 app|"As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.~Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months.~To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months.~To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months."
41158410|NCT06472414|BEHAVIORAL|Individualized Counselling Sessions|Four counselling sessions led by an experienced exercise physiologist will be provided. At the first session, benefits of cardiovascular rehabilitation (CR), functioning of the CR program, barriers to attendance, strategies to overcome them will be explained and discussed, leading to the choice of the best suitable CR modality/schedule. Physical activity (PA) recommendations will be discussed and an action plan to increase/maintain PA levels and decrease sedentary behaviour will be given. WFG will receive access to an online platform where 4 pre-recorded different exercise sessions will be placed, and a booklet to register weekly PA. The second session will be to discuss barriers and facilitators. For the third session PA goals will be re-established, a new action plan constructed and strategies to overcome barriers given. For the final session, overall feedback, results of the intervention, satisfaction, doubts, knowledge acquired and recommendations for the future will be discussed.
41158411|NCT06472414|BEHAVIORAL|Educational Women-Focused Sessions|Five pre-recorded women-focused educational sessions will be placed in an online platform at the end of each month. There will be a first short session explaining the importance of cardiovascular rehabilitation, followed by four sessions regarding: women and cardiovascular disease, benefits of physical exercise in women, women and mental health and women and healthy eating. Each session will have a duration of 10/15 minutes and will be delivered by specialized professionals according to the theme (cardiologists, exercise physiologists, nutritionists, psychologists). After every session, a short Likert-type questionnaire will be applied to assess what they thought of the topic in terms of importance and what they have learned.
41158412|NCT06472414|BEHAVIORAL|Supervised Exercise Training Sessions|Participants will exercise 2-3 times/week (60 min/session), on non-consecutive days, for 6 months (weekly target of 10 kcal/kg). Blood pressure and heart rate (HR) will be measured before and after each session. During exercise, a HR chest strap (POLAR H10) will be used to monitor HR and control intensity. Aerobic prescription will be based on the baseline cardiopulmonary exercise test, each session will start with a 5'-10' minutes warm-up - low to moderate intensity \[\<40% of HR Reserve (HRR), 9-10 Rated Perceived Exertion Borg Scale (RPE)\], mobility and low impact exercises, followed by a 30'-45' minutes of combined training with an aerobic component - moderate intensity (40% to 59% of HRR; 12-14 RPE) using ergometers, aerobic exercises, walking/jogging; and a strength component - 8/10 exercises, 30-80% of 1-Repetition Maximum, 12-15 repetitions, 2 sets - ending with a 5'-10' minute cool down - static/dynamic stretching exercises for all major muscle groups.
41158413|NCT04608006|DRUG|Bupivacaine-fentanyl|Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl
41350048|NCT01332851|BEHAVIORAL|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
41350049|NCT00944476|PROCEDURE|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
41350050|NCT01955785|DEVICE|pressure controlled ventilator|
40831384|NCT03041142|BEHAVIORAL|Interdisciplinary intervention|Physical Activity, nutrition and Psychological
40831385|NCT03041142|OTHER|Routine|The participants continued to maintain their routine
40831386|NCT04900948|DRUG|Pimecrolimus cream 1%|Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
41020082|NCT03727893|BEHAVIORAL|Roller-based Intervention Group (IG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.
41020083|NCT03727893|BEHAVIORAL|Control Group (CG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
41020084|NCT06562595|BEHAVIORAL|Education Intervention|Training will be provided to the participants, with the objective of determining the most accurate training method on HPV and cervical awareness.
41020085|NCT06134375|DRUG|Tetrathiomolybdate|Tetrathiomolybdate (TM): Ammonium tetrathiomolybdate (TM), an oral copper lowering agent, has been established as safe in patients with Wilson's disease and advanced cancer. TM forms stable copper-molybdenum clusters sequestering copper and thereby limiting its availability, for the proper functioning of angiogenic factors, including secreted metalloenzymes. TM inhibits several copper containing enzymes including ceruloplasmin, cytochrome oxidase, tyrosinase and downregulates cytokines such as MMP9 and VEGF as well as transcription factors such as NF-kB. Both pre-clinical and clinical data suggest that TM may effectively reduce both overt and sub-clinical tumor load by both targeting the metastases initiating stem cell component of primary tumors inactivating Complex IV, shifting oxphos to glycolysis and through stromal remodeling.
41020086|NCT06134375|DRUG|Capecitabine|1000mg/m2 twice daily, Days 1-14 Q21days for 6 months
41020087|NCT06134375|DRUG|Pembrolizumab|If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)
40831387|NCT04900948|DRUG|cream 0.1% methylprednisolone aceponate|Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
41158414|NCT04419961|BEHAVIORAL|Educational program|"The educational program includes a group discussion and a booklet.~The group discussion lasts for 90 minutes, discussing importance of sexual activity during pregnancy, improving sexual experience during pregnancy, physical and mental changes of pregnant women, and measures to cope with discomfort, anxiety, fear and other issues. It includes a 30-minutes presentation, followed by 1-hour discussion.~The booklet is a color-printed A5-size booklet containing in-depth information of the content given during the discussion. Each participant can only receive one copy of the booklet, and the booklet is not given to the control participants."
41350051|NCT01955785|DEVICE|Pressure Regulated Volume Controlled Ventilator|
41020088|NCT04796610|BEHAVIORAL|Mopati|The intervention will provide training to health care providers on how to guide unsuppressed HIV patients in the selection of treatment partners. The Mopati program will provide education to patients and their treatment partners about HIV treatment and how treatment partners can support patients in treatment adherence.
41020089|NCT05663398|DRUG|Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
41020090|NCT05663398|DRUG|Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
41020091|NCT04866394|RADIATION|SBRT|Patients will be planned with the aim of delivering 30 Gy in 5 fractions.
41020092|NCT05042622|DEVICE|Cytokine adsorber filter|• Intervention group #1 a cytokine adsorber will be used (30 patients): patients on ECMO - subgroup A; septic patients - subgroup B.
41020093|NCT05042622|DEVICE|Extracorporeal hemoperfusion cartridge|• Intervention group #2 an extracorporeal hemoperfusion cartridge will be used (30 patients): patients on ECMO - subgroup C, septic patients - subgroup D.
41020094|NCT00490425|DRUG|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
41020095|NCT06435429|DRUG|Zanidatamab|Administered by intravenous infusion
41020096|NCT06435429|DRUG|Trastuzumab|Administered by intravenous infusion
41020097|NCT06435429|DRUG|Eribulin|Administered by intravenous infusion
41020098|NCT06435429|DRUG|Vinorelbine|Administered by intravenous infusion
41020099|NCT06435429|DRUG|Gemcitabine|Administered by intravenous infusion
41020100|NCT06435429|DRUG|Capecitabine|Given orally
41020101|NCT06057129|DEVICE|Supervised and minimally-supervised therapy with ReHandyBot|During the familiarization phase at the rehabilitation clinic, participants perform one week of supervised and one week of minimally-supervised therapy with the ReHandyBot under the supervision of a supervisor (i.e., therapist or researcher). Minimally-supervised therapy means that participants try to perform therapy with the device by themselves, while the supervisor is still present but helps only in case participants encounter problems or if they have any questions. During the supervised and minimally-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. These sessions are performed in addition to the conventional therapy plan. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes.
41020102|NCT06057129|DEVICE|Unsupervised therapy|"After the familiarization phase, participants train without supervision at the clinic until discharge and then at home for two weeks.~If the therapist thinks that the participant have properly learnt how to use the device and can train with it safely, the participant can keep training with the device unsupervised (both at the clinic and at home).~If participants are not ready for unsupervised therapy with the device, they receive a booklet of exercises to perform without supervision (both at the clinic and at home). These exercises do not imply the use of the robot but are exercises discussed with the therapists and meaningful for the specific patient."
41020103|NCT00865527|OTHER|Fecal occult blood test|FOBT
41020104|NCT00865527|PROCEDURE|Virtual colonoscopy|computed tomographic colonography
41020105|NCT00865527|PROCEDURE|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
41020106|NCT00009230|DRUG|Celecoxib|
41020107|NCT03189914|DRUG|RX-3117|RX-3117 will be administered orally in combination with Abraxane.
41020108|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.015%)|QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
41020109|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.03%)|QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
41158415|NCT01060163|DRUG|Tranexamic Acid|A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery
41158416|NCT01060163|DRUG|Saline|Saline served as placebo
40831388|NCT02426151|DRUG|BEPO-A|BEPO-A (Bioreactor manufacturing process)
40831389|NCT02426151|DRUG|REPO-A|REPO-A (Roller bottle manufacturing process)
40831390|NCT04069377|DEVICE|LUCAS™ 2 Chest Compression System|LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.
41158417|NCT04783883|DEVICE|Vestal DM|Battery powered non-invasive neurostimulation device (1.5mA)
41158418|NCT00975130|BIOLOGICAL|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
41158419|NCT00975130|BIOLOGICAL|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
41158420|NCT04206384|DEVICE|Ultrasound|Ultimate Contour Body Sculpting Device
41158421|NCT05011617|DEVICE|Non-intubation and monitoring anesthesia care (MAC)|Non-intubation and monitoring anesthesia care (MAC) consisted of non-intubation technique, local anesthesia at the site of sternotomy, sedation with dexmedetomidine, analgesia with remifentanil/sufentanil, and electroacupuncture.
41158422|NCT04985071|PROCEDURE|Pancreaticoduodenectomy|Patient with periampullary cancer will be underwent pancreaticoduodenectomy in 2 types of pancreatic-jejunal anastomosis reconstructions. We describe the postoperative complications (pancreatic fistula and bleeding) and analysis the risk factors relate to those complications
40831391|NCT04069377|OTHER|Manuel chest compressions by human efforts|In this way chest compressions will be handled by humans themselves.
40831392|NCT02679625|DEVICE|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
40831393|NCT00583791|DEVICE|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
41020110|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.075%)|QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
41158423|NCT03005483|DRUG|Gabapentin|Orthopedic Surgery was applied for the treatment of osseous disorders
41350052|NCT03227094|DIAGNOSTIC_TEST|Standard OGTT|Standard-OGTT Plasma glucose : 0, 30, 60, 90, 120 minutes Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.) Questionnaires CGMS training \& delivery of Jelly-Bean/75g glucose beverage
41350053|NCT03227094|DIAGNOSTIC_TEST|Home-based OGTT (Beverage)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
41020111|NCT06016972|OTHER|QLS-111 ophthalmic vehicle solution|Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
41020112|NCT02570321|PROCEDURE|Corneal Cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
41020113|NCT02570321|DRUG|Anti Fungal Drug|Topical Amphotericin B vs Topical Natamycin
41020114|NCT06567808|DRUG|Cefazolin|administration as outlined
41020115|NCT06567808|DRUG|Vancomycin|administered as outlined
41020116|NCT00785226|DRUG|RDEA119|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
41020117|NCT00785226|DRUG|Sorafenib|Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
41020118|NCT03624361|DEVICE|Glaucoma device implantation in a stand-alone procedure|"MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
41020119|NCT04917198|PROCEDURE|median sternotomy|median sternotomy
41020120|NCT00004867|PROCEDURE|conventional surgery|
41020121|NCT00004867|PROCEDURE|positron emission tomography|
41020122|NCT00004867|PROCEDURE|radionuclide imaging|
41020123|NCT00004867|RADIATION|fludeoxyglucose F 18|
41020124|NCT00004867|DRUG|chemotherapy|
41020125|NCT00004867|RADIATION|Radiotherapy|
41158424|NCT03005483|OTHER|Placebo|Orthopedic Surgery was applied for the treatment of osseous disorders
41158425|NCT06253715|DRUG|Isoniazid|Once daily weight-based dose
41158426|NCT06253715|DRUG|Rifampin|Once daily weight-based dose
41158427|NCT06253715|DRUG|Pyrazinamide|Once daily weight-based dose
41350054|NCT03227094|DIAGNOSTIC_TEST|Home-based OGTT (Candy)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
41350055|NCT05724654|DIETARY_SUPPLEMENT|Skin roasted peanuts|Study volunteers will receive daily 60 g of skin roasted peanuts for 16 weeks.
41350056|NCT04212611|DRUG|INFRA ORBITAL BLOCK|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L) or ropivacaine (group R).
41350057|NCT06482892|DRUG|TP03HN106|"During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection.~During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia."
41492218|NCT05236283|DIAGNOSTIC_TEST|Blood Culture|Blood Culture
41492219|NCT04914858|OTHER|Education|Its validity and reliability is a reliable scale in Turkey
41158428|NCT06253715|DRUG|Ethambutol|Once daily weight-based dose
41158429|NCT06253715|DRUG|Rifapentine|Once daily weight-based dose
41158430|NCT06253715|DRUG|Moxifloxacin|Once daily weight-based dose
41158431|NCT05765838|DIAGNOSTIC_TEST|(NPS right - Nasal swab left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41492220|NCT01167322|DRUG|NPC-07 for oral administration|NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
41492221|NCT00397163|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation
41492222|NCT00397163|PROCEDURE|Placebo|Deflated cuff on upper arm and thigh for 20 min
41492223|NCT04683666|PROCEDURE|Bariatric surgery|Laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), as primary bariatric procedures, were performed. \^Postoperative complications were assessed.
41492224|NCT01414595|GENETIC|DNA analysis|
41492225|NCT01414595|GENETIC|DNA methylation analysis|
41492226|NCT01414595|GENETIC|RNA analysis|
41492227|NCT01414595|GENETIC|gene expression analysis|
41492228|NCT01414595|GENETIC|polymorphism analysis|
41492229|NCT01414595|OTHER|laboratory biomarker analysis|
41492230|NCT01414595|OTHER|medical chart review|
41492231|NCT04885465|BEHAVIORAL|web-based psychoeducational support|Caregivers in the experimental group will have access to psycho-educational support through a web-based plattform during 3 months.
41492232|NCT03698448|DRUG|OligoG Dry powder for inhalation|10 capsules Dry Powder for Inhalation, BID
41020126|NCT01396616|DEVICE|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
41020127|NCT05990049|DRUG|Hyadent BG|Hyadent BG is a cross-linked hyaluronic acid. 1,6% cross-linked hyaluronic acid (xHA), 0,2% native hyaluronic acid (HA)
41020128|NCT03073616|DEVICE|Lung ultrasound|Lung ultrasound and chest RX
41020129|NCT01075321|DRUG|everolimus|Given orally
41492233|NCT02321735|BEHAVIORAL|Quality of life questionaire|Patients will participate in a QOL questionaire followed by a phone interview
41020130|NCT01075321|DRUG|lenalidomide|Given orally
41020131|NCT01075321|OTHER|laboratory biomarker analysis|Correlative studies
41020132|NCT01075321|GENETIC|polymorphism analysis|Correlative studies
41020133|NCT01075321|OTHER|immunohistochemistry staining method|Optional correlative studies
41492234|NCT02715544|OTHER|Healthy lifestyle|The families will receive a designed for these purposes intervention
41492235|NCT02715544|OTHER|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
41020134|NCT01075321|GENETIC|microarray analysis|Optional correlative studies
41020135|NCT01075321|GENETIC|fluorescence in situ hybridization|Optional correlative studies
41020136|NCT05041166|DRUG|Hyperpolarized [13C] Pyruvate|Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
41020137|NCT02680691|OTHER|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
41020138|NCT02680691|OTHER|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
41158432|NCT05765838|DIAGNOSTIC_TEST|(NPS left - Nasal swab right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41158433|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab right - NPS left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41158434|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab left - NPS right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41158435|NCT05765838|DIAGNOSTIC_TEST|(NPS right - OPS - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41492236|NCT01205386|DEVICE|1. CROSSER System|The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
41492237|NCT01325181|DRUG|Verteporfin|a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
41492238|NCT01325181|DRUG|ranibizumab|Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
41492239|NCT00000130|DRUG|Intravitreal Antibiotics|
41492240|NCT00000130|PROCEDURE|Initial Pars Plana Vitrectomy|
41492241|NCT04647721|DEVICE|Radiesse injectable implant (dermal filler)|Subdermal injection.
41492242|NCT04647721|DEVICE|Restylane injectable implant (dermal filler)|Subdermal injection.
41492243|NCT05296486|PROCEDURE|phacovitrectomy surgery with silicone oil tamponade|Patients in this study will receive phacovitrectomy surgery with silicone oil tamponade.
41492244|NCT05296486|PROCEDURE|phacovitrectomy surgery with gas tamponade|Patients in this study will receive phacovitrectomy surgery with gas tamponade
41492245|NCT05296486|PROCEDURE|phacovitrectomy surgery with balanced saline solution tamponade|Patients in this study will receive phacovitrectomy surgery with balanced saline solution tamponade
41158436|NCT05765838|DIAGNOSTIC_TEST|(NPS left - OPS - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41158437|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab right - OPS - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41350058|NCT04454840|BIOLOGICAL|Plasma from healthy young people treatment + Riluzole|Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.
41350059|NCT04454840|DRUG|Riluzole|The basic treatment is Riluzole 25\~50mg twice daily
41020139|NCT02091167|DEVICE|transcranial Direct Current Stimulation|Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
41020140|NCT04900974|DRUG|Doravirine|100mg
41020141|NCT02616224|OTHER|No intervention|No intervention was administered in this study.
41020142|NCT01736566|OTHER|Family History + Whole Genome Sequencing|"Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~1. The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~2. The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~\*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm."
41020143|NCT01736566|OTHER|Family History Only|Doctors and their patients receive a Family History report.
41020144|NCT01717417|DEVICE|miniscrew|
41020145|NCT01717417|DEVICE|TPA|
41020146|NCT04180462|OTHER|Practice Facilitation|Practice facilitation to support quality improvement methods to effect practice change to develop a sustainable HPV vaccine delivery system.
41020147|NCT04180462|OTHER|Education|An educational video to increase the provider's knowledge about guideline recommendations and patient and practice benefits of vaccination by age 13.
41020148|NCT04180462|OTHER|Audit and Feedback|Audit and feedback of vaccine coverage to increase motivation to engage in practice change.
41020149|NCT04180462|OTHER|Communication Strategy|A communication strategy to improve the provider's communication skills and their self-efficacy to address parental hesitation.
41350060|NCT04647695|DRUG|Interferon beta-1b|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
41020150|NCT02252081|DRUG|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR \> 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =\< 45 ml/min
41350061|NCT04647695|DRUG|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
41350062|NCT04437602|DIAGNOSTIC_TEST|Contrast Enhanced Mammography (CEM)|Additional CEM in preoperative staging
41158438|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab left - OPS - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41158439|NCT05765838|DIAGNOSTIC_TEST|(OPS - NPS right - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41158440|NCT05765838|DIAGNOSTIC_TEST|(OPS - NPS left - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41350063|NCT03800433|DRUG|Trental 400 MG Extended Release Oral Tablet|oral tablets
41350064|NCT00451074|DRUG|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
41350065|NCT02865681|DRUG|Menopur|Nasal versus injectable
41350066|NCT02865681|DRUG|Synarel|nasal
41020151|NCT02252081|DRUG|Placebo|placebo pill(s) orally per day for 16 weeks
41020152|NCT00734305|DRUG|MM-121|Dose escalation Frequency - once weekly
41020153|NCT06521502|OTHER|Blood collection|"Blood will be collected from a catheter (IV) that is already in place or using a needle stick into a vein.~Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort)."
41158441|NCT05765838|DIAGNOSTIC_TEST|(OPS - Nasal swab left - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41350067|NCT02865681|DRUG|HCG trigger|injectable
41350068|NCT02865681|DRUG|Clomiphene citrate|oral
41350069|NCT02865681|DRUG|Letrozole|Oral
40831394|NCT03476616|DRUG|Eplerenone (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
40831395|NCT03476616|DRUG|Valsartan (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
41158442|NCT05765838|DIAGNOSTIC_TEST|(OPS - Nasal swab right - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
41158443|NCT04532008|BEHAVIORAL|Group based treatment|12 sessions of group based therapy that included cognitive restructuring, behavioral activation, and interpersonal therapy
41158444|NCT04881045|BIOLOGICAL|PF-07257876|CD47-PDL-1 bispecific antibody
41158445|NCT04664985|DEVICE|Mucogyne® ovule|hyaluronic acid, vaginal ovule
41158446|NCT06141772|OTHER|Measure of the circulating tumor DNA|Blood assessment to measure the kinetics au circulating tumor DNA
40831396|NCT03797092|BIOLOGICAL|Allogeneic adipose-derived stromal cells (CSCC_ASC)|Active group
40831397|NCT03797092|OTHER|Control group|No treatment
40831398|NCT05961176|DEVICE|Skiin pediatric band and Skiin biometric pod|Infants that meet the inclusion criteria will be equipped with a Skiin pediatric band appropriate for their chest size. Heart rate, respiratory rate, temperature, and electrocardiogram will be monitored from 2 to 12 hours through the Skiin pediatric band and a standard of care device (Phillips Intellivue MX750) commonly used in the CCCU at SickKids.
40831399|NCT05655143|BEHAVIORAL|Balance training|"Participants will undergo a 4-week balance training protocol modified from that described previously.~Participants will undergo supervised exercise three times per week for approximately 30 minutes per session. The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task."
41158447|NCT06079203|BEHAVIORAL|Emergency Care Redesign (ECR)|"Care Process Redesign: Care process redesign with a shared structured worksheet for data gathering, standardized assessment and referral. Education of all providers (Physician, Nurse, and Social Work Champion) on new processes at huddles and via on-line training, smart phone-compatible animated videos, faculty meetings, e-mail and from ED champions on shift~CDS System: Alerts and new workflow to refer the dyad to social work or care manager. Continued use throughout study period and beyond~Follow up: Within 72 hours of ED visit if discharged home Social Work Champion will have a single phone call. Triadic telephone encounter to ensure understanding of discharge plan, medication management and connection to community services"
41158448|NCT06079203|BEHAVIORAL|Nurse-led Telephonic Care (NLTC)|Telephonic support for dyad for safe ED to home care transition, and to enhance knowledge and management of AD/ADRD and co-morbid conditions. First call to dyad within 72 hours of index ED visit from Registered nurses. Each call \~30 minutes depending on needs and willingness of dyad. Calls also occur at 14 days, and at least monthly thereafter for 6 months. Dyad or nurse can initiate additional as-needed calls and coordinate care and care needs with other providers
41158449|NCT06079203|BEHAVIORAL|Community Paramedic-led Transitions Intervention (CPTI)|Community paramedics to provide coaching with dyad to improve medication management, outpatient follow up, understanding of red flags necessitating medical care. Home visit within \~5 days of index ED visit. One home visit and three telephone encounters over 30 days
41158450|NCT00847158|PROCEDURE|phacoemulsification alone|phacoemulsification alone
41158451|NCT00847158|DEVICE|iStent Trabecular Micro-Bypass Stent|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
41158452|NCT04159051|DEVICE|Regional Hyperthermia|Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
41158453|NCT04610645|DEVICE|OCT|3x3 OCT volume scans on treated and opposite side of the irreadiated area on head and neck
41158454|NCT04610645|DEVICE|Dermatoscope|2x2 pictures taken with a dermatoscope
41350070|NCT02118402|DIETARY_SUPPLEMENT|Fortified maize porridge|Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
41158455|NCT04610645|GENETIC|3-Colour FISH|Blood sample is examined for breaks per metaphase to determine radiation sensibility of the individual
41158456|NCT05255250|BEHAVIORAL|PLAYshop|The intervention includes: 1. Educational Training - the 60 min virtual workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be sent physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
41158457|NCT02801747|BEHAVIORAL|Heart to Heart2 (HTH2)|The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
41158458|NCT00949221|DEVICE|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE|"* group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~* group 2: intensive strategy using continuous glucose monitoring for 12 months;~* group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring)."
41158459|NCT01803789|DEVICE|Single Kirschner Wire|
41158460|NCT01803789|DEVICE|Double Kirschner Wire|
41158461|NCT06353009|OTHER|NOVA4 meal|"NOVA (a name, not an acronym) is a food classification system divided into four groups, based on the level of processing.~Group 4 - Ultra-processed foods. They are the ones that use many ingredients including food additives that improve palatability, processed raw materials (hydrogenated fats, modified starches, etc.) and ingredients that are rarely used in home cooking such as soy protein or mechanically separated meat. These foods are mainly of industrial origin and are characterized by a good pleasantness and the fact that they can be stored for a long time."
41350071|NCT04731194|BEHAVIORAL|Performance-based financial incentive program|"1. Enhance policy awareness through verbal communication with patients, distributing picture-rich fliers to patients, and putting up large posters in public places of the villages.~2. Support patients' registration in the reimbursement system~3. Follow-up patients after the first, third, and sixth months after the start of the study, measuring blood pressure and blood glucose level. Encourage patients to purchase medications from public institutions and to take their medications on time.~4. Receive financial incentives based on performance in the amount of 3 RMB per patient enrolled (first month) and 5 RMB per patient (at third and sixth month) buying medications with reimbursement from the policy."
41350072|NCT01751243|OTHER|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
41350073|NCT01751243|OTHER|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
41350074|NCT00712764|DRUG|Adenosine|
41350075|NCT00712764|DRUG|Placebo|
41350076|NCT05659004|BEHAVIORAL|Qualitative interview|No intervention
41350077|NCT04139421|BEHAVIORAL|Shinrin-Yoku|Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.
41350078|NCT02483611|DRUG|Magnesium Sulfate|
41350079|NCT02483611|DRUG|Lidocaine|
41350080|NCT02483611|DRUG|Isotonic Solution|
40831400|NCT06275750|DEVICE|Spinal decompression with BTL-6000 spinal decompression system (BTL Industries Ltd.)|The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
40831401|NCT03503292|DRUG|Granisetron|Rapid metabolizer will receive 1mg IV Granisetron
40831402|NCT03503292|DRUG|Ondansetron|Poor or normal metabolizers will receive 4mg Ondansetron IV
40831403|NCT03305380|OTHER|No interventions|As this is a patient registry, there are no interventions.
41350081|NCT02483611|DRUG|Cisatracurium|
41350082|NCT03930927|DRUG|Self Assembling peptide|enamel regeneration
41350083|NCT03930927|DRUG|remineralizing agent|enamel regeneration
40831404|NCT03597607|BEHAVIORAL|Intensive Smoking Cessation Group|This group will meet with the pharmacist more frequently and for longer periods than other groups.
41350084|NCT00652522|DEVICE|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
41350085|NCT00652522|PROCEDURE|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
41350086|NCT00652522|OTHER|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
41350087|NCT00861302|BEHAVIORAL|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
41492246|NCT05296486|PROCEDURE|phacoemulsifacation surgery without vitrectomy|Patients in this study will receive phacoemulsifacation surgery without vitrectomy.
41350088|NCT04726124|DEVICE|Microwave Ablation Therapeutic Apparatus|The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.
41350089|NCT06210165|DRUG|Sugammadex|IV Sugammadex 4mg/kg stat once TOF ratio 0.7-0.9 after completing surgery
41350090|NCT06210165|DRUG|Neostigmine and atropine|IV neostigmine 40mcg/kg in combination with IV atropine 10mcg/kg stat once TOF ratio 0.7-0.9 after completing surgery
40831405|NCT03597607|BEHAVIORAL|Abbreviated Smoking Cessation Group|This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
41350091|NCT06016829|DIAGNOSTIC_TEST|Nutrition Risk Screening 2002 (NRS-2002)|Nutritional status assessment tool
41350092|NCT06016829|DIAGNOSTIC_TEST|Global Leadership Initiative on Malnutrition (GLIM)|Nutritional status assessment tool
41158462|NCT06353009|OTHER|NOVA1-3 meal|"NOVA (a name, not an acronym) is a food classification system divided into four groups, based on the level of processing.~Group 1 - Unprocessed or minimally processed foods (fruit, vegetables, eggs, meat, milk, etc.)~Group 2 - Foods processed in the kitchen with the aim of extending their shelf life. In practice, these are ingredients to be used in the kitchen such as fats, aromatic herbs, etc. to be kept in jars or in the refrigerator to be able to use them later.~Group 3 - Processed foods. These are the foods obtained by combining foods of groups 1 and 2 to obtain the many food products for domestic use (bread, jams, etc.) made up of a few ingredients"
40831406|NCT03412097|OTHER|active surveillance|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
40831407|NCT00902148|DEVICE|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
40831408|NCT02096666|DRUG|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
41158463|NCT03539705|OTHER|There is no intervention|There is no intervention
41158464|NCT04673799|DRUG|MV088 injection|MV088 injection (60mg) by subcutaneous injection once on the first day
41158465|NCT04673799|DRUG|Prolia® injection|Prolia® injection (60mg) by subcutaneous injection once on the first day
41158466|NCT06001827|DEVICE|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during arteriovenous fistula (AVF) creation surgery. It provides mechanical support to improve maturation and patency of AVFs.
41158467|NCT06001827|PROCEDURE|Untreated AVF Control|AVF creation surgery without any intervention
41158468|NCT03659890|DIETARY_SUPPLEMENT|Low nucleotide|2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose
41158469|NCT03659890|DIETARY_SUPPLEMENT|High nucleotide|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose
41350093|NCT06016829|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
40831409|NCT04965961|DRUG|EPO|Please refer to the arm description
40831410|NCT04965961|OTHER|Control group - saline injection|Please refer to the arm description
41158470|NCT03659890|DIETARY_SUPPLEMENT|High nucletide + Ribose|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose
41350094|NCT06016829|DIAGNOSTIC_TEST|Dietary inflammatory index (DII)|The Dietary Inflammatory Index (DII) is a scoring algorithm that indicates the inflammatory potential of the diet.
41350095|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Quality of life assessment tool
41350096|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer 29 (EORTC-QLQ-CR29)|Quality of life assessment tool
41350097|NCT06016829|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
40831411|NCT05206955|DRUG|Tadalafil|10 mg once daily orally week 1, 20 mg once daily orally during week 2, and 40 mg once daily orally during weeks 3 through 52
40831412|NCT05206955|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
40831413|NCT01071356|BEHAVIORAL|Intensive MI|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
40831414|NCT01071356|BEHAVIORAL|Single session MI|Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
40831415|NCT05120947|RADIATION|42 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.2 Gy.
40831416|NCT05120947|RADIATION|39 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.875 Gy.
41158471|NCT01873573|PROCEDURE|Dilation|Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
40831417|NCT05120947|RADIATION|32.5 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 6.5 Gy.
41350098|NCT06016829|DIAGNOSTIC_TEST|Neutrophil-Lymphocyte Ratio (NLR)|The neutrophil-to-lymphocyte ratio (NLR) is calculated as the simple ratio between neutrophil and lymphocyte counts.
41158472|NCT01873573|OTHER|Triamcinolone Injection|Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
41350099|NCT06336876|OTHER|Survey|Online survey launched via the Survey Monkey® portal
41350100|NCT03596320|PROCEDURE|colonoscopy|description of the results of colonoscopy im managment of children with rectal bleeding
41158473|NCT01873573|PROCEDURE|Esophagogastroduodenoscopy (EGD)|EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
41350101|NCT03960372|BEHAVIORAL|ICT activities|Public education activities using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
41350102|NCT03581565|OTHER|zinc polycarboxylate (with the requirements of ISO 9917)|intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
41350103|NCT01960764|DRUG|Pre-Treatment with Dial liquid antibacterial soap|This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
41350104|NCT01960764|OTHER|Control|
41350105|NCT02596425|PROCEDURE|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
41350106|NCT02596425|PROCEDURE|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
41350107|NCT02596425|PROCEDURE|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
41350108|NCT03140267|DIAGNOSTIC_TEST|Difficult to wean patients|Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
41350109|NCT02253680|PROCEDURE|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
41350110|NCT02052154|BIOLOGICAL|Prime-boost pneumococcal immunization|2 months between the 2 vaccines
41350111|NCT04170374|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
41350112|NCT04170374|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
41350113|NCT05592600|BEHAVIORAL|Neurofeedback|Participants will visualize real-time feedback of signals recorded from their brains as measured with functional MRI.
41350114|NCT05651269|DRUG|Milciclib Dose: 150 mg/day Mode of administration: oral|milciclib plus gemcitabine
40831418|NCT01309022|DRUG|Sirolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
40831419|NCT01309022|DRUG|Tacrolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
40831420|NCT01309022|DRUG|Mycophenolate mofetil|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
41350115|NCT01251081|OTHER|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
41350116|NCT01251081|OTHER|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
40831421|NCT01309022|DRUG|Mycophenolic acid|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
40831422|NCT05295147|OTHER|Palmar Grasp Reflex Stimulation|The palmar grasp reflex is an involuntary flexion-adduction movement involving the hands and fingers.
40831423|NCT05346146|DRUG|Sintilimab; Gemcitabine; Albumin-paclitaxel|Sintilimab: 200mg IV Q3W D1; Gemcitabine: 1000mg/m2 IV Q3W D1,8; Albumin-paclitaxel：125mg/m2,IV,D1,D8,Q3W
41350117|NCT01057394|DEVICE|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
41350118|NCT01057394|DEVICE|RF PVI Ablation|Radiofrequency ablation
41350119|NCT04551378|OTHER|Quality-of-Life Assessment|Ancillary studies
41350120|NCT04551378|OTHER|Survey Administration|Complete survey
41350121|NCT06099678|BEHAVIORAL|Elastic Band Training|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises.
41350122|NCT06099678|BEHAVIORAL|Elastic Band Training with Maximal Mental Effort|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises, where participants will perform maximal mental effort by imagining maximal muscle contraction during each exercise.
41350123|NCT05011331|DEVICE|MedCline Shoulder Relief System|Patients will receive a customized pillow to aid with sleep
41350124|NCT04693312|DRUG|Depo medrol|local injection
41350125|NCT06238349|DRUG|Oral bifidobacterium triple live powder|The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also were assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
41492247|NCT03166423|DRUG|MU001 patches (Investigational)|Patches containing snail slime, calendula extract and propolis extract
41492248|NCT03166423|DEVICE|Conventional patches (Control)|Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
41492249|NCT01102062|DIETARY_SUPPLEMENT|orange juice|
41492250|NCT00498901|DRUG|goserelin|
41492251|NCT00498901|DRUG|letrozole|
41492252|NCT00498901|DRUG|leuprolide acetate|
41492253|NCT00498901|PROCEDURE|conventional surgery|
40831424|NCT02263456|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
41350126|NCT06238349|OTHER|Sunbathing|The sunbathing group will receive all interventions prescribed for the control group and be assigned to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
41350127|NCT06238349|OTHER|Sunbathing and the Oral bifidobacterium triple live powder|The combination group will receive all interventions of both the group sunbathing and the Bifidobacterium group as well as all interventions prescribed for the control group.
41350128|NCT06238349|OTHER|Conventional treatment|Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30℃ and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.
41350129|NCT03166189|BIOLOGICAL|bone marrow-derived MSC and HRT|"* Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~* Three cycles of HRT following MSC transplantation;~* Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~* Frozen/thawed embryo transfer 3-6 months after transplantation."
41350130|NCT03166189|OTHER|hormonal replacement therapy|"standard treatment of hypoplastic endometrium or Asherman's syndrome:~* Three cycles of HRT preceding frozen/thawed embryo transfer;~* Frozen/thawed embryo transfer."
41350131|NCT02131389|DEVICE|Iconacy Hip System|
41350132|NCT05320224|OTHER|Patient-Oriented Music Intervention (POMI)|The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).
41350133|NCT05762224|OTHER|Effect of kinesio taping on upper limb lymphedema|Group A received Kinesio taping 2 times a week for 3 weeks to reduce lymphedema and Group B received pressure garments(20-60 mm Hg) for at least 15 to 18 hours per day for 3 weeks
41350134|NCT02254304|DRUG|Rebif|Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
41350135|NCT00469976|DRUG|bevacizumab|
41350136|NCT00469976|DRUG|carboplatin|
41350137|NCT00469976|DRUG|enzastaurin hydrochloride|
41350138|NCT00469976|DRUG|gemcitabine hydrochloride|
41350139|NCT02552823|OTHER|Group1|
41350140|NCT02552823|OTHER|Group2|
41350141|NCT03737396|PROCEDURE|Self-administered electronic health screening|Health assessment using an electronic device
41350142|NCT05569356|BIOLOGICAL|Prospective|-Additional blood samples -Myocarditis biopsy sample (routine care) -Additional pericardial fluid sample (routine care)
41350143|NCT05569356|OTHER|Retrospective|None (only data collection)
41350144|NCT02089178|PROCEDURE|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
41350145|NCT02089178|PROCEDURE|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
41350146|NCT02089178|DRUG|propofol-remifentanil|
41350147|NCT02089178|DRUG|sevoflurane-remifentanil|
41350148|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
41350149|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
41350150|NCT03163940|BEHAVIORAL|Laughter Yoga|A LY group will be composed of 8-12 participants. Each sessions will include 4 essential elements steps of laughter yoga, laughter meditation and grounding exercises. The 4 steps of laughter yoga are 1) warm up exercise, 2) deep breathing exercises, 3) childlike playfulness and 4) laughter exercises. The laughter meditation is a deeper experience of unconditional laughter in which laughter often comes in natural waves and it becomes infectious and set off a chain reaction to infect other people. The grounding exercises allow individuals to ground the energy of laughter and relax. The LY intervention will be facilitated by a certified lead LY trainer.
41350151|NCT03239769|PROCEDURE|thyroidectomy|Thyroidectomies have different approaches. The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
41350152|NCT03072849|PROCEDURE|Pulmonary function testing|Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.
41350153|NCT03072849|DRUG|FAM Therapy|All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC \<0.8.
41350154|NCT05268601|DRUG|Bamlanivimab|Administration of monoclonal antibody against SARS-CoV-2
41350155|NCT05268601|DRUG|Bamlanivimab and Etesevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
41350156|NCT05268601|DRUG|Casirivimab and Imdevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
41350157|NCT05268601|DRUG|Sotrovimab|Administration of monoclonal antibody against SARS-CoV-2
41350158|NCT00269620|DRUG|ethinyl estradiol/etonogestrel vaginal ring|vaginal ring for cyclic use (3 weeks in, 1 week out)
41492254|NCT01962480|PROCEDURE|The hernia gap is sutured intracorporally|The hernia gab is closed with non-absorbable suture (Ethibond Excel 2-0, Ethicon, Johnson \& Johnson©) performed by an intracorporally interrupted sutured technique using an Auto Suture© Endo-Slide knot-tying instrument. The stitches are placed with a distance of 0.5 - 1 cm from the fascial edges and with a distance of 0.5-1 cm. between the stitches, performed under a 6-8 mmHg intrabdominal pressure.
41492255|NCT03525158|BEHAVIORAL|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
40831425|NCT00044889|DRUG|clofarabine (IV formulation)|
40831426|NCT00603070|OTHER|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
41492256|NCT03880435|DEVICE|Hyalobarrier® gel endo|Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, peroperatively immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception
40831427|NCT00603070|OTHER|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
40831428|NCT00797238|OTHER||No intervention in this study
41020154|NCT06521502|OTHER|Urine Collection|"Urine will be collected through a urinary catheter that is already in place or by urinating into a cup.~Urine will be collected in hospital only (Cohorts A, B)"
41020155|NCT06521502|OTHER|Nasal, oral, and rectal swabs|"Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.~Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B)."
41020156|NCT06521502|OTHER|Stool collection|"Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.~Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort)."
41020157|NCT06521502|OTHER|Heat Moisture Exchange Filter collection|"An HME filter is a sponge that is placed in the tubing between a patient and breathing machine. It reduces the amount of heat and moisture a patient loses when on a breathing machine. Moisture from breath is collected in this filter. The filter is changed every few hours. When the filter is changed, it will be saved to collect the moisture that it contains and run tests on it.~HME filters will be collected in hospital on intubated patients only (Cohorts A, B)."
41020158|NCT06521502|OTHER|Tracheal Aspirate sample collection|"Patients on a breathing machine have a breathing tube in their trachea that connects their lungs to the breathing machine. A smaller tube, called a suction catheter, will be placed through the larger tube and fluid will be gently sucked out.~Tracheal aspirate will be collected in hospital on intubated patients only (Cohorts A, B)"
41020159|NCT06521502|PROCEDURE|Non-bronchoscopic bronchoalveolar lavage (NBBAL)|"The NBBAL procedure involves putting a flexible rubber tube through the breathing tube into the airway of one of the lungs. A small amount of fluid is injected into the lung and then a gentle suction is used to collect fluid. Only patients who pass a safety screen showing that they are not at high risk for complications will have the NBBAL procedure performed.~NBBAL will be performed in hospital on intubated patients only (Cohort A)"
41020160|NCT06521502|OTHER|Surveys|Participants will be contacted by email, text, and /or phone to give updates about their health. These surveys will ask questions about quality of life, mental health, return to work, and re-admission to the hospital. (Cohort A)
41020161|NCT06521502|OTHER|Short physical performance battery|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort)~Chair Stand Test: For this test the participant will sit in a chair. They will then stand as quickly as possible without using their upper body to assist them.~Balance Test: For this test the participant will stand unsupported for 10 seconds with their feet in 3 different positions.~4-meter walk: For this test the participant will walk 4 meters as quickly as possible."
41020162|NCT06521502|OTHER|Hand grip strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will squeeze a machine called a hand-held dynamometer 3 times with all their strength."
41020163|NCT06521502|OTHER|CNS Vital Signs|"At visits 3, 6, and 12 months following hospitalization (Cohort A - Long-term Outcomes Cohort):~The participant will sit at a computer and follow the prompts on the screen. This test takes about 45 minutes."
41020164|NCT06521502|OTHER|Muscle Ultrasound|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo ultrasound on the quadriceps muscle on the dominant side of their body."
41020165|NCT06521502|OTHER|Muscle Strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~A dynamometer will be used to measure muscle strength in the dominant leg."
41020166|NCT06521502|OTHER|Spirometry|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip placed on their nose and will be given a plastic mouthpiece that is connected to a machine called a spirometer. They will place their lips tightly around the mouthpiece and take in as big and deep of a breath as possible and then blow out as hard and fast as they can."
41158474|NCT02541799|PROCEDURE|Audio-visual telemedicine|Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link
41158475|NCT02541799|PROCEDURE|Standard care|Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
41492257|NCT03174262|BEHAVIORAL|Ergonomic Computer Workstation Training|Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
41492258|NCT05832528|OTHER|Low-FODMAP diet|6-week Low-FODMAP diet in patients with functional dyspepsia
40831429|NCT04104659|DRUG|MK 6240|"PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush."
40831430|NCT01743404|DIETARY_SUPPLEMENT|Inflaminat|
40831431|NCT01743404|DRUG|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
41158476|NCT05833399|DRUG|Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone|Medications are prescribed orally for outpatient or inpatient treatment of addicted patients.
41158477|NCT03487653|BIOLOGICAL|microbiology:Blood culture and sensitvity test .Serology|Gram stain ,Blood culture ,sensitivity test ,biochemical reactions and serological study will be done
41158478|NCT01785771|DRUG|ITCA 650 (exenatide in DUROS)|
41158479|NCT00639964|OTHER|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
41158480|NCT00639964|OTHER|diet questionnaire|questions about nutrition before and during pregnancy
41158481|NCT00639964|OTHER|umbilical cord blood collect|collected at the delivery
41158482|NCT00639964|OTHER|placenta collect|collected at the delivery
41350159|NCT00269620|DRUG|ethinyl estradiol/norelgestromin transdermal contraceptive|contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
41350160|NCT04760691|DRUG|Truvada alone|TDF/FTC 300 mg (milligrams) / 200 mg by mouth once daily
41350161|NCT04760691|DRUG|Truvada plus Leuprolide|TDF/FTC 300mg/ 200 mg by mouth once daily Leuprolide 11.25 mg im once
41492259|NCT03683368|DEVICE|YpsoPump Orbit soft|Insulin infusion sets will be used for up to 7 days or until failure
41492260|NCT03683368|DEVICE|YpsoPump Orbit micro|Insulin infusion sets will be used for up to 7 days or until failure
41492261|NCT05526261|PROCEDURE|Hemithyroidectoy|Hemithyroidectomy it is a surgical procedure where half of the thyroid gland is operated.
41350162|NCT04760691|DRUG|Truvada plus Estradiol 1 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 1 mg by mouth once daily
41350163|NCT04760691|DRUG|Truvada plus Estradiol 6 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 3 mg by mouth twie daily
41350164|NCT04760691|DRUG|Estradiol 6 mg alone|Estradiol 3 mg by mouth twice daily
41350165|NCT03726749|DRUG|Tocilizumab|Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor
41350166|NCT03726749|DRUG|Prednisone|Prednisone is an anti-inflammatory medication
41350167|NCT01625611|DRUG|Naltrexone|Naltrexone 100 mg titrated over one week
41350168|NCT05957328|DRUG|Ferric Pyrophosphate Liposomal|Liposomal iron, a form of ferric pyrophosphate is transported within a phospholipid membrane, absorbed by the intestinal M cells, reaches to the liver directly through lymphatics and finally released. Due to this mechanism, liposomal iron has been reported to have better bioavailability than traditional iron preparations thus requiring lesser dose and producing fewer adverse effects The group would be given liposomal iron syrup at a dose of 1mg per kg per day once a day for 3 months
41350169|NCT05957328|DRUG|ferrous ascorbate|one of the most commonly used forms of iron syrup in children. The group would be given ferrous ascorbate syrup at a dose of 3mg per kg per day once a day for 3 months
41350170|NCT00242814|DRUG|Micardis|
41158483|NCT01463514|PROCEDURE|Right heart catheterization|Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
41350171|NCT00242814|DRUG|Amlodipine|
41350172|NCT00242814|PROCEDURE|Abdominal biopsy|
41350173|NCT02833610|DRUG|Denosumab Q4W|
41350174|NCT02916628|BEHAVIORAL|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
41350175|NCT02916628|DEVICE|Auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously
41350176|NCT02916628|DEVICE|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
41350177|NCT01742182|OTHER|Light exposure|
41020167|NCT06521502|OTHER|Lung Diffusion Testing (DLCO)|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip on their nose. They will put their mouth over a mouthpiece that is attached to a machine. This machine will deliver a small amount of carbon dioxide when they breathe in and will also record the results of the test. They will then take a few normal breaths. Next they will inhale deeply and exhale completely. They will breathe in quickly through their mouth and hold their breath for 10 seconds or as long as they can. Then they will breathe out."
41350178|NCT05565209|OTHER|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
41020168|NCT06521502|RADIATION|Chest CT Scan|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo a Chest Computed Tomography (CT) scan which uses special X-ray equipment to take detailed pictures of the lungs."
41020169|NCT05721105|OTHER|Quality of life assessment using questionnaires|Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.
41350179|NCT01810289|BEHAVIORAL|START|"INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level \< 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.~This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design."
41350180|NCT02839590|DEVICE|HiFU|Ciliary Ablation Treatment ( HiFu ultrasound treatment)
41350181|NCT02839590|DEVICE|Baerveldt implant|External (sub-conjunctival) Drainage Surgery (Baerveldt implant)
41350182|NCT02839590|DEVICE|Ahmed implant|External (sub-conjunctival) Drainage Surgery (Ahmed Implant)
41350183|NCT02839590|DEVICE|STARflo|Suprachoroidal Shunt Surgery (STARflo)
41350184|NCT02839590|DEVICE|Hydrus Microstent implant|Trans-trabecular meshwork implants (Hydrus Microstent implant).
41350185|NCT02839590|DEVICE|iStent implant|Trans-trabecular meshwork implants (iStent implant).
41350186|NCT02839590|DEVICE|Kahook Dual Blade|It removes part of the trabecular meshwork
41350187|NCT05375786|BIOLOGICAL|Vaccination completion status|the relation between vaccination completion status and the target population
41350188|NCT06277609|DRUG|Lu AF28996|Capsule
41350189|NCT06277609|DRUG|Acetylsalicylic Acid|Tablet
41350190|NCT06277609|DRUG|Mefenamic Acid|Tablet
41350191|NCT06277609|DRUG|Amoxicillin/clavulanic acid|Tablet
41350192|NCT02231489|DRUG|JNJ-42756493 Tablet|Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
41350193|NCT02231489|DRUG|JNJ-42756493 Capsule|Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
41350194|NCT02231489|DRUG|JNJ-61818549|Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
41350195|NCT02031510|DRUG|placebo|transversus abdominis plane block with saline 0.9%
41350196|NCT02031510|DRUG|bupivacaine|transversus abdominis plane block bupivacaine 0.25%
41350197|NCT02031510|DRUG|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
41350198|NCT02274766|DRUG|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
41350199|NCT02274766|OTHER|Placebo|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
41350200|NCT04287205|DRUG|Dydrogesterone|79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment
41350201|NCT05876949|BIOLOGICAL|AVT03|AVT03 will be given as 1 time subcutaneous injection
41350202|NCT05876949|BIOLOGICAL|Denosumab|Xgeva (denosumab) will be given as 1 time subcutaneous injection
41350203|NCT01289028|DRUG|Nilotinib|
41350204|NCT02074475|OTHER|Control group|A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
41350205|NCT04317794|DRUG|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
41350206|NCT00586833|PROCEDURE|O2 consumption max bike test|Single visit exercise study
41350207|NCT06134076|OTHER|Unfermented chickpea|Frozen meals containing 100 g unfermented chickpeas
41492262|NCT05340543|PROCEDURE|Confocal optical coherence tomography - OCTAVE|"An ex vivo examination of cutaneous resection with the OCTAV® prototype integrating the dermoscope function"
41492263|NCT03979781|DRUG|tailored antiplatelet selection|antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes
41020170|NCT04731129|DEVICE|Probe based confocal laser endomicroscopy of the pleura|Every patient referred for medical thoracoscopy will be screened. The pCLE of the pleura will be performed 2 times. First, just before the thoracoscopy, through the Boutin's needle or the thoracentesis catheter and second through the working chanel of the pleuroscope. This last acquisition allows visual control to target the pleural endomicroscopy assessment. These two acquisitions will be compared between each other and with the histological samples of the pleuroscopy.
41020171|NCT05053282|OTHER|endurance running exercise|regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
41158484|NCT01463514|PROCEDURE|Near-infrared spectroscopy|For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
41350208|NCT06134076|OTHER|Fermented chickpea|Frozen meals containing 100 g fermented chickpeas
41350209|NCT03201133|DIAGNOSTIC_TEST|Neuromuscular evaluation|(1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
41350210|NCT00718991|DEVICE|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
41350211|NCT00112840|DRUG|CCI-779|CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
41350212|NCT00112840|DRUG|Bevacizumab|Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
41350213|NCT04060628|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|
41350214|NCT02986165|DIETARY_SUPPLEMENT|Placebo control|The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions
41350215|NCT02986165|DIETARY_SUPPLEMENT|Low dose pomace extract|Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
41350216|NCT02986165|DIETARY_SUPPLEMENT|High dose pomace extract|Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
41350217|NCT02432911|DRUG|CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
41350218|NCT02432911|DRUG|low dose cytarabine|cytarabine 20mg bid for 10 days.
41350219|NCT04770259|OTHER|Timely pre-surgical conditioning|Timely pre-surgical conditioning seeks to prepare frail, pre-frail and / or dependent older patients for the surgery process. For which a work plan has been designed according to your needs and health conditions.
41158485|NCT00938132|DRUG|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
41350220|NCT04849676|OTHER|visual neurofeedback|"Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity."
41350221|NCT05622656|DRUG|Dexmedetomidine|Dexmedetomidine 0.0005%
41350222|NCT05622656|DRUG|Placebo|0.9% Sodium Chloride Solution
41492264|NCT03979781|DRUG|standard of care|antiplatelet selection using standard of care
40831432|NCT01074333|DRUG|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
40831433|NCT05512702|DRUG|Tissue Plasminogen Activator, Alteplase|Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.
40831434|NCT05512702|DRUG|Low-molecular weight heparin|Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
41350223|NCT03602742|DEVICE|EZYPRO®|Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
41350224|NCT02545049|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
41492265|NCT02650479|DRUG|Exenatide|6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
41492266|NCT02650479|DRUG|Placebo|6 hour IV infusion.
41020172|NCT06574321|BEHAVIORAL|Teen Talk High School Refresher (TTHSR)|"TTHSR is designed to equip 11th and 12th grade students with the knowledge and skills necessary to make informed sexual health decisions as they transition from high school into adulthood, in order to prevent behavioral risk factors that contribute to unintended pregnancy and sexually transmitted infections.~As a result of the California Healthy Youth Act, which mandates sexual health education (SHE) in public schools, most students this age will have received prior SHE. TTHSR is a 5-hour booster intervention, delivered in five 1-hour sessions during late high school, intended to enhance the effectiveness of previous SHE."
41020173|NCT05337059|OTHER|PEEP and Tidal Volume Titration|PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures
41020174|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
41020175|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
41020176|NCT06100068|BEHAVIORAL|Mental Exercises and Temporal Alteration|Mental exercises during L-DIBH to distort the awareness of passage of time
41492267|NCT02650479|DRUG|Moxifloxacin|400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide
40831435|NCT05009602|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
40831436|NCT05009602|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery.
41492268|NCT02650479|DRUG|Palonosetron|0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
40831437|NCT05009602|DIAGNOSTIC_TEST|Exercise Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery, following the participant completing 50 consecutive repetitions of active dorsiflexion whilst standing.
41020177|NCT03042312|DRUG|177Lu-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
41492269|NCT05423444|BEHAVIORAL|TF-CBT|evidence-based psychotherapy for trauma in youth
41020178|NCT00710502|PROCEDURE|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
41020179|NCT00710502|PROCEDURE|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
41350225|NCT02545049|DRUG|Placebo|Matching placebo to be taken orally, once daily.
41350226|NCT00230373|DRUG|imiquimod 5% cream (Aldara)|
41350227|NCT00408772|BIOLOGICAL|bevacizumab|
41350228|NCT00408772|DRUG|capecitabine|
41350229|NCT00408772|DRUG|oxaliplatin|
41492270|NCT05423444|BEHAVIORAL|TAU|treatment as usual
41492271|NCT04896749|OTHER|Nerve mobilization|"Moist pack all over cervical spine for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.~Median, ulnar and radial nerve stretch with 3 sets of 10 repetitions , with 3 sec hold at final stretched position.~Following nerve mobilizations are used in experimental group/group A:~Median Nerve: Glenohumeral abduction, wrist extension, supination, glenohumeral lateral rotation, elbow extension, neck lateral bending to opposite side. Radial Nerve: Glenohumeral depression, elbow extension, whole arm internal rotation, wrist flexion Ulnar Nerve: Wrist extension, forearm pronation elbow flexion, glenohumeral lateral rotation, glenohumeral depression, shoulder abduction each with 3 sets of 10 repetitions , with 3 sec hold at final stretched position."
41492272|NCT04896749|OTHER|Conventional physical therapy|Moist pack for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.
40831438|NCT05009602|DIAGNOSTIC_TEST|Audible handheld Doppler|Audible CW Doppler interrogation of the dorsalis pedis and posterior tibial artery.
40831439|NCT05009602|DIAGNOSTIC_TEST|Visual handheld Doppler|Visual CW interrogation of the dorsalis pedis and posterior tibial artery was performed using the handheld Huntleigh Digital Dopplex device.
41158486|NCT05181878|DEVICE|The AcQMap 2.1 System with Electro-Magnetic Tracking Feasibility System|Demonstrate the ability of the AcQMap 2.1 System to support EMT in conjunction with the existing impedance localization capabilities. The new EMT technology is expected to continuously provide fully synchronized and similar localization information to the impedance-based localization information associated with the location of the catheter's magnetic sensor position.
41158487|NCT02860559|BIOLOGICAL|TBX-1400|Hematopoietic stem cells transplantation
41350230|NCT00408772|PROCEDURE|conventional surgery|
41350231|NCT00408772|PROCEDURE|neoadjuvant therapy|
41350232|NCT00408772|PROCEDURE|radiofrequency ablation|
41350233|NCT03675685|BIOLOGICAL|CCH (collagenase clostridium histolyticum)|A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
41350234|NCT04569890|DRUG|Certolizumab Pegol 200 MG/ML [Cimzia]|CZP 200mg twice a week subcutaneous.
41492273|NCT06408883|DEVICE|Vibrabot capsule|"Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation."
41492274|NCT02248038|PROCEDURE|open surgery|Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
40831440|NCT05009602|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|"Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.~To be used in 3 participating centers only."
40831441|NCT00229580|BEHAVIORAL|3 session brief intervention with health behavior feedback|
40831442|NCT00229580|OTHER|treatment as usual|
41158488|NCT04147091|OTHER|ApaCare & Repair|Initial cariuos lesions were treated.
41158489|NCT02200029|DRUG|Ademetionine IV+tablet|IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
41158490|NCT02200029|DRUG|Ademetionine tablet|oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
41158491|NCT06438705|DIAGNOSTIC_TEST|SPECT-CT imaging|The subjects were intravenously injected with 99mTc labeled FAPI imaging agent, and drank 300-500ml of water after administration. SPECT-CT imaging was performed 60 minutes later
41158492|NCT04052932|DRUG|SHR4640 dose1|tablets，dose1，QD
41158493|NCT04052932|DRUG|SHR4640 dose2|tablets，dose2，QD
41158494|NCT04052932|DRUG|Placebo oral tablet|tablets，QD
41350235|NCT04569890|DRUG|Hydroxychloroquine|400mg HCQ orally daily
41350236|NCT04569890|DRUG|Prednisone|10mg GC orally daily
41350237|NCT03178175|PROCEDURE|Acupuncture|"In the acupuncture with De Qi group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) until the De Qi phenomenon occurs. The duration is about 30 minutes, and all patients will receive the procedure 16 times within 2 months."
41350238|NCT03178175|PROCEDURE|Needle Insertion|"In the Sham acupuncture group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) but the needle doesn't reach the exact depth and De Qi phenomena doesn't occur. The duration is about 30 minutes, and all patients will receive this procedure 16 times within 2 months."
41350239|NCT05939700|DRUG|Mavacamten|Observational study of individuals exposed to at least 1 dose of mavacamten at any time during pregnancy and/or breastfeeding
41350240|NCT02972736|RADIATION|Radiation dose expressed as DAP|
41350241|NCT01108224|BEHAVIORAL|Psychosocial support|Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
41350242|NCT01557140|DRUG|RASi plus carvedilol|Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
41350243|NCT00596895|DIETARY_SUPPLEMENT|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
41350244|NCT02825238|OTHER|Supervised exercise program|
41350245|NCT02570581|OTHER|Jelly with:Paracetamol|"A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions."
41350246|NCT02570581|OTHER|Jelly with Furosemide|
41350247|NCT02570581|OTHER|Jelly with Levothyroxine sodium salt|
41350248|NCT02570581|OTHER|Jelly with Memantine|
41350249|NCT02570581|OTHER|Jelly with Zopiclone|
41350250|NCT02570581|OTHER|Jelly with Alprazolam|
41350251|NCT02570581|OTHER|Jelly with Oxazepam|
41350252|NCT02570581|OTHER|Jelly with Donepezil|
41350253|NCT02570581|OTHER|Jelly with Clopidogrel|
41350254|NCT02570581|OTHER|Jelly with Ramipril|
40831443|NCT04944368|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
41350255|NCT02570581|OTHER|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
41350256|NCT02570581|OTHER|Plain jelly control|
41492275|NCT02248038|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
40831444|NCT04944368|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
40831445|NCT06263049|PROCEDURE|transurethral resection of prostate|resection of prostate by using bipolar cautarization
40831446|NCT02000011|OTHER|comprehensive geriatric assessment (CGA)|
40831447|NCT02000011|OTHER|Geriatric intervention plan (GIP)|
41350257|NCT02570581|OTHER|Apple compote Paracetamol|
41492276|NCT01259115|DRUG|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
40831448|NCT03781791|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily.
40831449|NCT03781791|DRUG|Placebo Treatment|Placebo will be administered in tablet form, once daily.
40831450|NCT05767502|DIAGNOSTIC_TEST|GCS-Pupil score|"GCS+attributed verbal score- Step 1 to obtain pupillary score:~* Patients with a motor (M) and eye-opening response (E) total score between 2 and 6 are assigned a verbal score of +1~* Patients with an M+E score of 7 are assigned a verbal score of +2~* Patients with an M+E score of 8-9 are assigned a verbal score of +4~* Patients with an M+E score of 10 are assigned a verbal score of +5~GCS+attributed verbal score- Step 2 to obtain the pupillary score:~The total score is obtained by subtracting the pupil score from the score obtained in the 1st step. Pupil score is scored as follows;~* 0 points if both pupils react to light,~* 1 point if a pupil does not react to light and has anisocoria,~* 2 points if both pupils do not react to light"
41350258|NCT02570581|OTHER|Apple compote Furosemide|
41350259|NCT02570581|OTHER|Apple compote Levothyroxine sodium salt|
41158495|NCT04052932|DRUG|Allopurinol 300 MG|tablets，300mg，QD
41350260|NCT02570581|OTHER|Apple compote Memantine|
41350261|NCT02570581|OTHER|Apple compote Zopiclone|
41350262|NCT02570581|OTHER|Apple compote Alprazolam|
41350263|NCT02570581|OTHER|Apple compote Oxazepam|
41350264|NCT02570581|OTHER|Apple compote Donepezil|
41350265|NCT02570581|OTHER|Apple compote Clopidogrel|
41350266|NCT02570581|OTHER|Apple compote Ramipril|
41350267|NCT02570581|OTHER|Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
41350268|NCT02570581|OTHER|Plain apple compote control|
41350269|NCT05202184|PROCEDURE|Percutaneous thermal ablation|All thermoablation procedures were performed percutaneously under ultrasound and/or CT guidance
41350270|NCT03253029|DIETARY_SUPPLEMENT|Pure Encapsulations Branched Chain Amino Acid powder|
41350271|NCT03253029|DIETARY_SUPPLEMENT|control group (no BCAAs provided)|
41350272|NCT02416765|OTHER|15-hour intervention|Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
41350273|NCT02416765|DRUG|Insulin (Lispro, Aspart or guilisine)|Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
41492277|NCT01259115|DRUG|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
41492278|NCT01259115|DRUG|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
41492279|NCT06033638|OTHER|Score assessment|PBS Score
41492280|NCT04784910|DRUG|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 24 weeks
41350274|NCT02416765|DRUG|Glucagon (Eli Lilly)|In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
41492281|NCT04784910|DRUG|Lansoprazole 15 mg|Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks
40831451|NCT05529992|DRUG|Velaglucerase Alfa|VPRIV intravenous infusion every other week for 60 minutes.
40831452|NCT05259644|DEVICE|laparoscopic sleeve gastrectomy|Surgical procedure - laparoscopic sleeve gastrectomy.
40831453|NCT05259644|OTHER|conservative treatment of obesity|Diet and exercise
41158496|NCT04310800|PROCEDURE|LIFT-plug technique|Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures
41158497|NCT02504502|OTHER|enhanced genomic report|a patient-centered version of a genomic results report delivered to patient through the electronic record portal
41492282|NCT04784910|DRUG|DWP14012 20mg placebo|DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks
41492283|NCT04784910|DRUG|Lansoprazole 15 mg placebo|Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks
40831454|NCT05259644|DEVICE|endoscopic gastric plication|Endoscopic procedure - endoscopic gastric plication
40831455|NCT02017145|DRUG|Chloraprep|
40831456|NCT05713084|OTHER|mandibular setback using BSSRO|mandibular setback using BSSRO
40831457|NCT04218357|DRUG|Probenecid|safety
40831458|NCT04218357|DRUG|Matching placebo|Placebo
40831459|NCT00841750|PROCEDURE|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
40831460|NCT00841750|PROCEDURE|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
41350275|NCT02416765|OTHER|Closed-loop strategy|Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
41350276|NCT04420065|DEVICE|Preferential left ventricular pacing|Activation of an algorithm attempting to provide preferential left ventricular pacing in an anticipatory manner, thus potentially preventing iatrogenic, pacing-related, right ventricular dysfunction, and improving coupling and outcomes in dyssynchronous heart failure patients
41350277|NCT04420065|DEVICE|Biventricular pacing|Standard biventricular pacing, with V-V delay programmed based on stroke volume maximization, and A-V delay delegated to the device
41350278|NCT02765191|OTHER|Plasma expansion with Ringer's Acetate|7,5 ml/kg mL Ringer's acetate during 5-10 minutes will be administered intravenously
41492284|NCT04343326|PROCEDURE|perform corneal collagen cross linking accelerated and delivery of systemic oxygen|CXL is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
41492285|NCT04343326|PROCEDURE|perform corneal collagen cross linking accelerated and without additional oxygen therapy|corneal collagen cross linking with accelerated protocol without additional oxygen therapy
40831461|NCT02860624|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
40831462|NCT02860624|DRUG|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
40831463|NCT00849875|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
40831464|NCT00849875|DRUG|Dacarbazine|Intravenous administration Chemotherapy
40831465|NCT01565395|DRUG|Incobotulinum Toxin A|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
40831466|NCT01565395|DRUG|placebo|Sterile preservative free 0.9% saline
40831467|NCT01752400|DRUG|AUY922|
40831468|NCT00259298|DRUG|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
40831469|NCT00066469|BIOLOGICAL|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: \< 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: \< 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
40831470|NCT00066469|DRUG|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
40831471|NCT00066469|DRUG|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
41350279|NCT03592589|DEVICE|high flow nasal canula|high flow nasal canula to obtain a positive expiratory pressure
41350280|NCT02981238|DIETARY_SUPPLEMENT|Phytostandard® Eschscholtzia / Valerian|
41350281|NCT00192712|DRUG|irinotecan, gemcitabine|
41492286|NCT04343326|PROCEDURE|perform Conventiona corneal collagen cross linking|Conventional CXL using 30 mW/CM2 UV-A ablation for 30 minutes
40831472|NCT00066469|DRUG|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
40831473|NCT01460407|DRUG|LY2216684|Administered orally
40831474|NCT01460407|DRUG|Clarithromycin|Administered orally
41350282|NCT00002274|DRUG|Didanosine|
41350283|NCT05505539|DRUG|5-fluorouracil|Given intralesionally by injection
40831475|NCT02513823|DIETARY_SUPPLEMENT|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
40831476|NCT02193087|DRUG|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
40831477|NCT02193087|DRUG|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
41158498|NCT06176183|PROCEDURE|Arthroscopic meniscus repair|"A traditional two-portal arthroscopic approach is utilized. The meniscal edges are examined using a probe, and any meniscal tears that are not stable are evaluated for potential repair. For meniscus repair, sutures have been made using the all-inside or outside-inside and inside-outside techniques.~If the procedure involving the addition of a fibrin clot is being carried out, a volume of approximately 60 milliliters of blood is taken and thereafter transferred into a basin. An assistant is able to stir the blood using a glass syringe for approximately fifteen minutes to ensure sufficient coagulation surrounding the syringe. After a sufficient clot has developed at the end of the syringe, a grasper is used to insert the clot through the anterolateral arthroscopy portal. The meniscal sutures are intentionally loosened to accommodate the clot in the meniscus, ensuring optimal contact with the lesion. Subsequently, the sutures are fastened and knotted."
41350284|NCT02411266|OTHER|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
41350285|NCT02409264|OTHER|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
40831478|NCT02193087|DRUG|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
40831479|NCT02193087|DRUG|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
40831480|NCT02395055|DRUG|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
40831481|NCT02395055|DRUG|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
41350286|NCT00578890|PROCEDURE|Medical/surgical treatment versus medical treatment|A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
41350287|NCT00926562|DRUG|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
41350288|NCT00926562|DRUG|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
41492287|NCT03145636|DEVICE|vBloc Maestro Rechargeable System|Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
41492288|NCT03145636|OTHER|vBloc Achieve Weight Management Program|Remotely accessible web-based program to add additional support to subjects with vBloc therapy
40831482|NCT02485652|DRUG|HM61713|"800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
40831483|NCT04420962|DIAGNOSTIC_TEST|Visual Acuity|Best corrected visual acuity utilizing the Snellen method
40831484|NCT05349838|DRUG|Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy|Daily oral tablet
40831485|NCT02703870|DEVICE|verum tDCS|real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
40831486|NCT02703870|DEVICE|sham tDCS|sham transcranial direct current stimulation, 10 sessions, for 20 minutes
40831487|NCT02703870|BEHAVIORAL|VRT|Vision restoration training, 10 sessions, 20 minutes
40831488|NCT03653572|DEVICE|Ultrasound exam|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
40831489|NCT05396729|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
40831490|NCT04837989|BEHAVIORAL|Diabetes Body Project|Six virtually delivered Diabetes Body Project groups over six weeks (one hour a week); 5-6 participants and 2 group facilitators
40831491|NCT04837989|BEHAVIORAL|Psychoeducation|Individuals assigned to the psychoeducational control condition will receive an educational brochure, and complete similar assessments and assessment time points as the experimental condition. Individuals in the control group will be offered Diabetes Body Project group participation after six months.
41158499|NCT01868516|DRUG|dexmecamylamine|
41158500|NCT01868516|DRUG|Placebo|
41350289|NCT04863118|OTHER|Strength training in shallow water and dry land|"Dry land: The intervention will last for 60 minutes, consisting of exercises to strengthen the global extensor musculature, that is, involving the upper limbs, trunk and lower limbs. Weights and equipment for strength training will be used. The sessions will start with 10 minutes of warm-up, the central part of exercises to strengthen the extensor muscles and the last part will consist of oriented stretches. In the central part, a typical strength training will be performed (2-6 series; 85% of RM), using submaximal subjective effort and with repetition control.~Shallow water: The intervention performed on dry land will be adapted and produced in an aquatic environment. Aquatic implements will be used for strength training."
41350290|NCT04863118|OTHER|High-intensity training in shallow and deep water|"Shallow water: The intervention will last 60 minutes. The exercises consist of: immersion, balance, strength, agility and displacement in the water. As they will start with 10 minutes of warm-up and the last part will consist of stretches oriented along the edge of the pool and on the depth reduction platform. In the main part of the intervention, different styles of exercises will be performed, with or without the use of implements. Displacements will have varying speeds in the same session, defined by Borg's Scale of subjective sensation of effort.~Deep water: The intervention carried out in shallow water will be adapted with the use of floating belts and reproduced in deep water."
41350291|NCT05455645|OTHER|targeted intrinsic foot muscle exercises|4 targeted intrinsic foot muscle exercises
41158501|NCT05354726|OTHER|Assessments parameters|Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength
41350292|NCT04585633|OTHER|Quality of Recovery-15|Quality of Recovery-15 is a scale consisting of 15 questions indicating the recovery quality of the patient after anesthesia and a score between 0-150.
41158502|NCT06035237|OTHER|Cold Spray|Cold Spray: Cold sprays, composed of liquefied gases under high pressure, rapidly evaporate from the applied area, causing a sudden drop in skin temperature. This condition leads to the temporary desensitization of pain receptors or the activation of ion channels, resulting in the brief alleviation of pain sensation. Various medical, non-medical, and surgical methods are employed to manage pain. Cold sprays are among non-medical methods, including massage, cold application, and distraction techniques. Therefore, cold sprays cannot be prescribed like medication. They are used for local anesthesia in cases of acute trauma, injections, blood collection, vein puncture, and similar situations.
41350293|NCT04585633|OTHER|Glasgow Result Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
41350294|NCT04585633|OTHER|Risk Factors|Pre-operative: medical histories, drugs used, demographic features, additional diseases, ASA class, pre-operative routine parameters, operation history, GCS, tumor histology, location, dimensions and intracerebral radiological data, laboratory values Intraoperative; hemodynamic data of patients; highest and lowest values of heart rate, diastolic, systolic and mean arterial pressures, fluid and blood products given, anesthetic and other drugs administered, duration of anesthesia, duration of surgery, surgical position, blood loss, urine output and blood gas samples Post-operation; extubation time, MAS score, use of mechanical ventilation, post-operative complications, hemodynamic data, blood gas data
41350295|NCT03018340|DRUG|Pimavanserin|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
41158503|NCT05422742|PROCEDURE|SRP + MM|Subjects will be randomized into either SRP only or SRP +MM. Periodontal therapy will consist of one visit full-month SRP alone or in-combination with MM placed at all sites regardless of probing pocket depth. Each site will recieve 1mg of MM for a total of 6mg of MM per tooth.
41158504|NCT05422742|PROCEDURE|Scaling and Root Planing (SRP)|Procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation.
41158505|NCT04668534|DEVICE|taVNS 10|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
41350296|NCT03018340|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
41158506|NCT04668534|DEVICE|taVNS 25|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
41158507|NCT04668534|DEVICE|Control|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
40831492|NCT05240768|DIAGNOSTIC_TEST|Fractional flow reserve, instantaneous wave-free Ratio|Clinical outcomes observed for patients with moderate coronary lesions in whom coronary revascularization was deferred due to a negative physiologic study.
41158508|NCT00540384|DRUG|Placebo|Placebo
41158509|NCT00540384|DRUG|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
41158510|NCT00757978|DRUG|memantine|memantine 10mg twice a day
41158511|NCT00757978|DRUG|placebo|1 capsule of placebo twice a day
41158512|NCT00433498|DRUG|carboplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
41158513|NCT00433498|DRUG|cisplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
40831493|NCT00004174|BIOLOGICAL|filgrastim|
41350297|NCT02061163|DEVICE|Contrast Enhanced Ultrasound|Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.
41350298|NCT02061163|DRUG|Optison|Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
41350299|NCT01832844|PROCEDURE|"Group  with scan prior to infiltration "|Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
41492289|NCT03145636|OTHER|Control Weight Management (CWM) program|In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
41350300|NCT01832844|PROCEDURE|"Group  without scan "|
41350301|NCT05972122|DRUG|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
41350302|NCT00432289|PROCEDURE|Acupuncture|Acupunture treatment 3x per week for 6 weeks.
41350303|NCT03833349|BEHAVIORAL|Spinning Class|Spinning Class twice a week for six weeks.
41350304|NCT03833349|BEHAVIORAL|Yoga Class|Yoga Class twice a week for six weeks.
41350305|NCT03833349|BEHAVIORAL|Dance Class|Dance Class twice a week for six weeks.
41350306|NCT05238558|BIOLOGICAL|FMPV-1|Intradermal administration
41350307|NCT05238558|BIOLOGICAL|GM-CSF (as adjuvant)|Intradermal administration
41492290|NCT04301908|DRUG|interferon|Antiviral therapy for patients with chronic hepatitis B and cirrhosis. Antiviral therapies included interferon and / or nucleoside (acid) analogs, and patients who were continuously treated for more than 6 months were included in the study.
41492291|NCT02881138|DRUG|RC48-ADC|
41492292|NCT04141124|OTHER|breathing exercise/HRV-biofeedback|5 min of relaxing breathing, coupled with biological feedback.
41350308|NCT02573506|RADIATION|split-course radiotherapy|Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor.
40831494|NCT00004174|DRUG|cyclophosphamide|
41350309|NCT02573506|DRUG|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
41350310|NCT03021044|OTHER|physical activity intervention|30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program
41350311|NCT03021044|OTHER|standard of care|30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
41350312|NCT03773601|OTHER|Sleep Profiler|A 4-days sleep monitoring with the use of the Sleep Profiler. Data on objective sleep behavior will be collected.
41350313|NCT03773601|OTHER|PSQI|Fill the Pittsburgh Sleep Quality Index (PSQI) for the subjective evaluation of sleep.
41350314|NCT03773601|OTHER|TQR|Fill the Total Quality of Recovery Scale (TQR), every morning for 4 consecutive days, to collect data on subjective perception of recovery,
41350315|NCT03661983|DRUG|Aripiprazole|Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.
41492293|NCT04141124|OTHER|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
41492294|NCT04141124|OTHER|Control|5 minutes of reading fictitious biological medical results
40831495|NCT00004174|DRUG|paclitaxel|
40831496|NCT00004174|DRUG|thiotepa|
40831497|NCT00004174|PROCEDURE|peripheral blood stem cell transplantation|
41158514|NCT00433498|DRUG|etoposide phosphate|Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
41158515|NCT00433498|DRUG|pravastatin sodium|40mg daily oral tablet taken for a maximum of 2 years
41350316|NCT03661983|DRUG|Placebo|Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.
41350317|NCT01203111|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
41492295|NCT00801580|DRUG|doxorubicin liposomal|"* Cyclophosphamide~* Mesna~* Methotrexate~* Doxorubicin liposomal~* Vincristine~* Dexamethasone~* Rituximab~* Cytarabine"
40831498|NCT00004174|RADIATION|radiation therapy|
40831499|NCT04483115|DRUG|TPN171H|Tablets; Oral; Single dose
40831500|NCT04483115|DRUG|Placebo|Tablets; Oral; Single dose
40831501|NCT04483115|DRUG|Tadalafil|Tablets; Oral; Single dose
40831502|NCT01046604|DRUG|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
41350318|NCT01203111|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
41350319|NCT04296721|BEHAVIORAL|Intensive weigh-loss program|Intervention group: Intensive weight-loss program: 0-3 months very low calorie diet, 15 days substituting three meals for low calorie shakes, from 15 to 120 days substituting 1 meal and from 120 days to 12 months on a low calorie diet while starting a progressive exercise programme. Recommendations for good sleep habits will be given. The program will be carried out through group and individual sessions with the hospital dietician. After 3 months: group sessions with a nurse in the basic area. Group sessions led by hospital dietician. From 3 to 12 months: group sessions led by primary care nurse.
41350320|NCT04296721|BEHAVIORAL|Standard Dietary recommendations|Patients will be managed according to the usual recommendations: The common written diet (designed by a hospital nutritionist) and an exercise advice will be given according to patient age and level of activity, without any other assessment or additional visits.
41350321|NCT04144933|DRUG|Acetaminophen, Gabapentin|975 mg, 300 mg
41350322|NCT04144933|DRUG|Acetaminophen, Gabapentin|975 mg, 300 mg
41350323|NCT04144933|DRUG|Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine|1.5 mg/kg, 0.5 mcg/kg, 0.5 mg/kg
40831503|NCT02977845|BEHAVIORAL|Qigong|"Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients."
40831504|NCT01533467|DEVICE|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
40831505|NCT04580706|OTHER|this is an observational study with none intervention|this is an observational study with none intervention
40831506|NCT02993042|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
40831507|NCT03738501|OTHER|Chest physiotherapy with SET|Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
40831508|NCT03738501|OTHER|Standard Treatment|Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
40831509|NCT03425721|OTHER|No Intervention|No Intervention is administered in this study.
41350324|NCT04144933|DRUG|Dexamethasone, Ondansetron|6 mg, 4 mg
40831510|NCT00148785|DRUG|Indinavir/Ritonavir/Fosamprenavir|
40831511|NCT02552251|BIOLOGICAL|Hormonal balance measurements|
40831512|NCT02552251|BIOLOGICAL|metabolic balance measurements|
40831513|NCT02552251|BIOLOGICAL|bone balance measurements|
40831514|NCT02552251|BEHAVIORAL|quality of life assessment|
41350325|NCT04144933|DRUG|Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate|Dose titrated to effect, 1.5 mg/kg/hr, 0.15 mg/kg/hr, 0.3 -1 mcg/kg/hr (titrated to effect), 30 mg/kg bolus over 30 minutes
41350326|NCT04144933|DRUG|Lidocaine 1% Injectable Solution, Sufentanil|0.5 mg/kg, 0.25-0.5 mcg/kg (titrated to effect)
41350327|NCT04144933|DRUG|Sevoflurane, Sufentanil|Dose titrated to effect, As needed (dose at anesthesiologist's discretion)
41350328|NCT01536938|DRUG|LEO 90100|
41350329|NCT01536938|DRUG|Calcipotriol|
40831515|NCT04421859|OTHER|EyeCU Mobile Application|Augmented reality glaucoma education mobile phone application
40831516|NCT01826266|DRUG|PER977, Placebo|
40831517|NCT01863134|DRUG|Eptifibatide|
40831518|NCT01863134|DRUG|Placebo|
40831519|NCT05215015|BIOLOGICAL|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
40831520|NCT00070252|DRUG|Capecitabine|Given PO
40831521|NCT00070252|DRUG|Docetaxel|Given IV
40831522|NCT00070252|OTHER|Laboratory Biomarker Analysis|Correlative studies
40831523|NCT00070252|OTHER|Pharmacological Study|Correlative studies
40831524|NCT00070252|DRUG|Tipifarnib|Given orally (PO)
40831525|NCT05270291|PROCEDURE|rectal swab|rectal swab
40831526|NCT03904498|DRUG|Tolcapone|Tolcapone 100 mg tablets
41350330|NCT01536938|DRUG|Betamethasone|
41350331|NCT01512329|BEHAVIORAL|pacing|3 one-on-one sessions weekly for 3 consecutive weeks
41350332|NCT01512329|BEHAVIORAL|relaxation|3 one-on-one sessions weekly for 3 consecutive weeks
41350333|NCT00177008|DRUG|Aripiprazole|
41350334|NCT05807191|OTHER|Kangaroo care based on kangaroo care guide|Under the supervision of the researcher, a kangaroo care practice was applied to premature babies by their mothers based on the kangaroo care guide. This practice took 65 minutes. In addition, before the application, the kangaroo application information was explained to the mothers through a brochure.
41350335|NCT00766272|DEVICE|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
41492296|NCT00630890|RADIATION|External beam radiation and Cyberknife radiosurgery boost and capecitabine|External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
41158516|NCT04757961|BEHAVIORAL|LifeStories|The content of LifeStories is divided thematically into core ACT concepts across the four episodes as follows: 1) cultivating awareness of the transient nature of mood experiences and the benefit of trying out various strategies to cope with depression when it arises; 2) clarifying one's own values and setting personal goals related to these values; 3) developing a more accepting and nonjudgmental stance towards difficult thoughts and feelings and practicing self-compassion;and 4) living more mindfully in the present moment.
41350336|NCT05283122|PROCEDURE|Mostafa Maged Technique|pfannestiel incision . dissection of the bladder downwards , and Ligation of the uterine arteries on both sides then , we turn over the upper part of the lower uterine segment onto the lower part of the lower uterine segment from the inside of uterine cavity .We do this turnover (flipping ) by our hands and holding the imaginary line by two Allis forceps and by making three knots by three needles in the lower edge of the uterine incision and we enter the needles of simultaneously into the lower segment through the uterine cavity , at the same level of , the inside wall of lower uterine segment to drag the upper (half) part of the lower uterine segment on the lower part of lower uterine segment ( sandwich - like ) Third , we stitch the both sides of the flipped lower uterine segment , then we do plication of the anterior lower uterine segments to strengthen the wall of the flipped lower uterine segment and place a drain in the doglus pouch
41350337|NCT01035216|DRUG|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
41350338|NCT04422197|BIOLOGICAL|Botox|effect of botox injection in abdominal wall muscle post major abdominal surgery in terms of postoperative pain, incidence of incisional hernia.
41350339|NCT04422197|PROCEDURE|surgery without botox injection|surgery without botox injection
41350340|NCT01320527|DIETARY_SUPPLEMENT|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
41350341|NCT01320527|OTHER|Placebo|A mixture of 6 vitamins and nutriceuticals
41492297|NCT01159197|BEHAVIORAL|cognitive behavioral therapy|Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
41492298|NCT05043844|DEVICE|abdominal binder|Wearing an abdominal binder postoperatively
41350342|NCT05444829|DEVICE|specific screw holes locating surgical guide and pre-bent plates|Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the pre-bent plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.
41350343|NCT05444829|DEVICE|classical reduction and internal fixation.|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
41350344|NCT02417935|DRUG|Duloxetine|Administered orally
41350345|NCT02417935|DRUG|Pregabalin|Administered orally
41158517|NCT05542225|PROCEDURE|Strength training|Strength training will be performed with the patient in supine lying position as per FITT guidelines in which resistance will be given with the help of resistance bands on major muscle groups including shoulder flexors and extensors, hip and knee flexors and extensors, hip abductors and adductors,foot plantar flexors and dorsiflexors at an intensity of 8-15 repetitions, 2-3 times per week for 30 minutes.
41350346|NCT02417935|DRUG|Placebo|Administered orally
41350347|NCT00646191|DRUG|adalimumab|40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
41350348|NCT00646191|DRUG|adalimumab|40 mg weekly through Week 48 (OL Week 12 - 48)
41350349|NCT00646191|DRUG|adalimumab|80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
40831527|NCT03904498|DRUG|Placebo|Placebo tablets
41158518|NCT05542225|PROCEDURE|Flexibility training|Flexibility training will be performed with the patient in supine lying position as per FITT guidelines. Static stretching will be applied to the major muscle groups( trapezius, latissmus dorsi, gluteus maximus and medius, gastrocnemus, soleus, hamstrings and paraspinals( errector spinae and multifidi. Session will be completed in 10-15 minutes with a hold of 15 secs, 5 times per week. Stop before it becomes painful.
41158519|NCT05542225|PROCEDURE|Standard therapy|TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
41158520|NCT04739293|DRUG|ON123300|ON 123300 hard gelatin capsules
41350350|NCT05391295|OTHER|Short daily questionnaire|This study includes 1 survey that needs to be filled out by the patient on his/her phone daily during the course of corticosteroid treatment. The investigators will start the survey few days before the corticosteroid treatment and it will continue till the end of the treatment regime. The treatment regime is regular care and patient specific, but will approximately have a duration of 40 days. In case of prolonged treatment with steroids it is decided to have a limit for our study: either until 7 days after the end of corticosteroid treatment or a maximum of 60 days.
41350351|NCT06186622|DRUG|Orforglipron|Administered orally.
41350352|NCT06186622|DRUG|Simvastatin|Administered orally.
41350353|NCT06186622|DRUG|Digoxin|Administered orally.
41350354|NCT06186622|DRUG|Rosuvastatin|Administered orally.
41350355|NCT06186622|DRUG|Acetaminophen|Administered orally.
41492299|NCT01409161|DRUG|Arsenic Trioxide|Given IV
41492300|NCT01409161|DRUG|Gemtuzumab Ozogamicin|Given IV
41492301|NCT01409161|OTHER|Laboratory Biomarker Analysis|Correlative studies
41492302|NCT01409161|DRUG|Tretinoin|Given PO
41492303|NCT03899441|OTHER|Video|Two short animated videos - one that reviews minimally-invasive surgery and sentinel lymph node mapping and biopsy for endometrial cancer treatment. This video as reviews possible complications. The second video reviews peri-operative instructions.
41492304|NCT00525447|DRUG|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
41492305|NCT00525447|DRUG|lenalidomide|Up to 25 mg daily of a 21-day cycle.
41492306|NCT00525447|DRUG|dexamethasone|40 mg administered weekly.
40831528|NCT03204552|OTHER|No intervention (observational study)|No intervention (observational study)
41158521|NCT02125656|OTHER|High Intensity Interval Training|6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
41350356|NCT06186622|DRUG|Midazolam|Administered orally.
40831529|NCT02333149|DIETARY_SUPPLEMENT|Melatonin|"Children \<40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
40831530|NCT02333149|DRUG|Placebo|Placebo frequency and volume are identical to the experimental arm
41158522|NCT03331848|DRUG|Placebo oral capsule|BID
41158523|NCT03331848|DRUG|PXT002331 - 20mg|Oral
41158524|NCT01890798|DRUG|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
41158525|NCT00088075|DRUG|Risperidone|
41158526|NCT01065493|OTHER|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
41158527|NCT01065493|BEHAVIORAL|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
41158528|NCT02832219|DIETARY_SUPPLEMENT|Molecular hydrogen|
41158529|NCT02832219|DIETARY_SUPPLEMENT|Placebo|
41158530|NCT06445361|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement to determine steatosis and fibrosis.
41158531|NCT05407675|DRUG|BMS-986408|Specified dose on specified days
41158532|NCT05407675|BIOLOGICAL|Nivolumab|Specified dose on specified days
41158533|NCT05407675|BIOLOGICAL|Ipilimumab|Specified dose on specified days
41158534|NCT05407675|BIOLOGICAL|Platinum-doublet chemotherapy|Specified dose on specified days
41158535|NCT05407675|DRUG|Rabeprazole|Specified dose on specified days
41158536|NCT05615662|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
41158537|NCT05615662|BEHAVIORAL|Treatment as Usual|Treatment as Usual in this study will include all of the regular standards of care for mental health needs. These standards of care may include, but are not limited to psychotherapy, pharmacotherapy, or complementary therapy.
41158538|NCT02160561|OTHER|Intervention Arm|Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
40831531|NCT01527383|BIOLOGICAL|V212|V212 viral antigen for HZ
41158539|NCT06646081|PROCEDURE|Greater Occipital Nerve Block|The patient is placed prone with the head neutral or slightly flexed. After sterile preparation, a high-frequency linear probe is positioned transversely at the upper nuchal line in the occipital region. The Greater Occipital Nerve, exiting from the posterior root of C2, is located near the occipital artery. Using an in-plane technique, a 25-gauge needle is inserted into the fascial plane around the artery. After confirming no intravascular placement by negative aspiration, 5 mL of a mixture of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
41350357|NCT06186622|DRUG|Sodium Bicarbonate|Administered orally.
40831532|NCT01527383|BIOLOGICAL|Placebo|Placebo comparator to V212 vaccine
41350358|NCT04773964|DRUG|MET642|MET642 active treatment
41350359|NCT04773964|DRUG|Placebo|Placebo comparator
40831533|NCT04656106|DRUG|Ryzodeg®|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
40831534|NCT03346265|OTHER|Treatment A combined exercise program and gait training with sensory cues|Treatment A consisted in a combined exercise program of 40 min duration RMP
40831535|NCT03346265|OTHER|Treatment B Conventional physiotherapy|Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code)
41350360|NCT04787835|PROCEDURE|Forearm nerve block|Local anesthesia will be used to perform a forearm block of the median, radial, and ulnar nerves.
40831536|NCT02001896|DRUG|gemcitabine; cisplatin or carboplatin; erlotinib|
40831537|NCT02001896|DRUG|erlotinib|
40831538|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
40831539|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
41350361|NCT04787835|PROCEDURE|Local anesthetic infiltration|Local anesthesia will be infiltrated at the site of injury
41350362|NCT05494736|DRUG|MK-8527|MK-8527 capsule taken by mouth.
41350363|NCT04768049|OTHER|Tool Translation|Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with help of two professional translators and then it will be back translated into English to cross check the clarity of text. The translation will focus more on the context and understanding of the text rather literal word-to-word meanings. The translation will be done according to the WHO guidelines
41350364|NCT03474237|OTHER|Hormone study and Imaging study|"1. Blood (basal hormone and follow up hormone study)~2. Imaging examination including computed tomography scan or magnetic resonance imaging"
41492307|NCT00698893|BIOLOGICAL|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
40831540|NCT04542460|PROCEDURE|PCI|"A loop recorder is implanted i all patients in both study groups to investigate:~* Prevalence and severity of cardiac arrhythmias.~* Effect on detected arrhythmia, in particular ventricular tachyarrhythmia, of optimal medical therapy vs. coronary revascularization by PCI.~* Prevalence and severity of cardiac arrhythmias in CTO-patients with failed PCI.~* Indication for prophylactic ICD implantation in CTO-patients treated conservatively or by PCI and after failed PCI.~* Relation of arrhythmias to angina pectoris symptoms (CCS class), Quality of life questionnaire results and presence of myocardial reversible perfusion defects by CMRI."
41350365|NCT05852470|DEVICE|Clareon Vivity/Vivity Toric Extended Vision IOL|Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
41350366|NCT05852470|DEVICE|Clareon/Clareon Toric Aspheric IOL|Ultraviolet-absorbing and blue light-filtering intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
41350367|NCT04387695|RADIATION|SBRT+TACE+Sorafenib|SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later
41350368|NCT04387695|DRUG|Sorafenib|Sorafenib 800 mg/day orally
41350369|NCT01522196|DRUG|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
41350370|NCT01522196|OTHER|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
41350371|NCT00486590|PROCEDURE|Prolact-Plus Human Milk Fortifier|
41350372|NCT00566332|DRUG|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
41350373|NCT00566332|DRUG|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
41350374|NCT05422833|OTHER|Evaluation and analysis of clinical data|Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.
41350375|NCT04451590|OTHER|VR-based simulation|Participants will experience a novel interactive and immersive VR full size trauma bay with an adult patient and healthcare professionals. Immersed in the environment, learners undertake the decision-making steps in managing the medical care for a patient with an airway injury. Learners are first given the case scenario from which they form their own learning goals/plans. They then navigate through the scenario that will provide feedback depending on their actions in the form of either the patient's hemodynamic changes or prompts from healthcare avatars in the scenario. These feedback processes are built-in and designed to promote reflection and reorganization of the learner's decision-making strategies. As learning progresses, fewer prompts will be given. At the end of the scenario, evaluation algorithms pre-programmed into the VR-based simulation will be displayed.
41350376|NCT04451590|OTHER|Mannequin-based simulation|Participants will experience a mannequin-based scenario practice which is the current gold standard in medical education. The trauma airway management scenario will match the VR environment and sequence of events.
41350377|NCT00204802|BEHAVIORAL|Patient-Centered Advance Care Planning|
41350378|NCT02881151|DEVICE|Deep brain stimulation|Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
41350379|NCT03083470|DRUG|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
41492308|NCT02868918|DRUG|biodentine|tricalcium silicate cement used to replace the carious dentin
40831541|NCT01565564|BEHAVIORAL|Shared glycaemic control care within the local three-tier's antenatal care network|"* Individualized dietary and physical activity consultation plus group diabetes education~* Self blood glucose monitoring~* Insulin therapy if indicated~* Self blood glucose monitoring~* Insulin therapy institutions if indicated;"
41492309|NCT02868918|DRUG|glass ionomer cement|high viscosity glass ionomer used as a base material
40831542|NCT02036736|DRUG|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~* Sufentanil (0.15 mg / kg intravenously (IV))~* Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
40831543|NCT02036736|DRUG|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)~* Sufentanil (0.15 mg / kg IV)~* Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
40831544|NCT02981524|DRUG|CY|CY is administered intravenously at 200 mg/m2
40831545|NCT02981524|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting
40831546|NCT02981524|DRUG|Pembrolizumab|Pembrolizumab is administered intravenously at 200 mg
41492310|NCT02868918|DEVICE|DigoraH optium|digital Xray for follow up
41492311|NCT02296021|DRUG|Berberine|Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
41492312|NCT02296021|DRUG|Bismuth|Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
41492313|NCT02296021|DRUG|esomeprazole|Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
41350380|NCT03083470|OTHER|SOR007 Ointment Vehicle|SOR007 ointment vehicle will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of Ointment vehicle that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
41350381|NCT03066661|DRUG|Entrectinib|Open-label expanded access, capsules
41350382|NCT00411879|DRUG|Vasopressin, Epinephrine, and Steroids|During resuscitation, study group patients receive vasopresssin \[20 IU IV maximum dose = 100 IU\] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
41350383|NCT00411879|DRUG|Placebo, Epinephrine, Placebo|Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
41350384|NCT02045979|DRUG|BI 695501|BI 695501 single s.c. injection
41350385|NCT02045979|DRUG|adalimumab-EU source|adalimumab-EU source single s.c. injection
41350386|NCT02045979|DRUG|adalimumab-US source|adalimumab-US source single s.c. injection.
41350387|NCT03750344|DEVICE|Diagnostic test|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
41350388|NCT04419597|DEVICE|HEMOPATCH|The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).
41350389|NCT04419597|DEVICE|Standard of care|Usual clinical practice techniques for reinforcing primary dural closure.
41492314|NCT02296021|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
41492315|NCT02296021|DRUG|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
41492316|NCT04934449|DEVICE|Occlusal splint|Using occlusal splints during sleep for 2 months
41492317|NCT05437640|BEHAVIORAL|Protein Redistribution Diet|PD participants will be instructed by a Registered Dietitian to consume 10 grams or less of protein until their evening meal. They will then consume a high protein evening meal to meet their protein needs. They will receive one-on-one education and supportive materials to follow diet plan.
41492318|NCT05437640|BEHAVIORAL|Protein Consistent Diet|PD participants will be instructed by a Registered Dietitian to consume 20-30 grams of protein per meal. They will receive one-on-one education and supportive materials to follow diet plan.
41492319|NCT05284396|RADIATION|IFRT vs NFRT|involved field irradiation versus nodal field irradiation
41492320|NCT06178432|GENETIC|CRG003 injection|The dose of CRG003 will be calculated according to the participant's weight with single intravenous infusion.
41492321|NCT01323049|PROCEDURE|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia
41492322|NCT01323049|PROCEDURE|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia
41158540|NCT06646081|PROCEDURE|Stellate Ganglion Block|The patient lies supine with a pillow under the shoulders, and the head slightly extended, neck gently turned opposite to the blockade. After sterile preparation, a high-frequency linear probe is placed transversely at the C6 vertebra (Chassaignac's tubercle). Ultrasound identifies the C6 vertebra, Longus colli muscle, carotid artery, and internal jugular vein. The Stellate Ganglion is located within the prevertebral fascia over the Longus colli. Using an in-plane technique, a 25-gauge needle is inserted and advanced into the prevertebral fascial plane. After confirming no intravascular placement by negative aspiration, 5 mL of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
41492323|NCT01944176|DRUG|simvastatin, placebo|
41158541|NCT06632340|PROCEDURE|TUR-BT|Transurethral resection of bladder tumor
41350390|NCT00564915|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
41492324|NCT00883623|DRUG|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
41350391|NCT04366128|DRUG|CAPA indution immunotherapy|"1. Camelirumab 200mg Intravenous injection on day 1.~2. Apatinib 250mg taken orally once daily.~3. Pegaspargase 2000U/m2 Intramuscular injection on day 1."
41350392|NCT04700228|DRUG|Bupivacaine Hydrochloride|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
41492325|NCT05219461|DRUG|Single dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
41492326|NCT05219461|DRUG|Single dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
41158542|NCT05397106|DEVICE|CODMAN CERTAS Plus Programmable Valve|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
41492327|NCT05219461|DRUG|Single dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
41492328|NCT05219461|DRUG|Multiple dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
41492329|NCT05219461|DRUG|Multiple dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
41492330|NCT05219461|DRUG|Multiple dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
41492331|NCT02138019|PROCEDURE|Fibrin Glue assisted external eye surgery|
41492332|NCT02138019|DEVICE|Fibrin glue|
41350393|NCT04700228|DRUG|Dexmedetomidine|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
41350394|NCT01620437|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
41350395|NCT01050140|DIETARY_SUPPLEMENT|high sugar diet|25% of dietary energy from fructose or glucose
41350396|NCT05550857|OTHER|eccentric resistance exercise|The subject will lying prone on a treatment table. One end of eccentric resistance band will tie around the mid of the foot of indvidual, the other end of the resistance band will be attach to the table and the band is adjusted so that it will tight and there will be no slack present in it. It will provide a smooth eccentric resistance throughout the dorsiflexion range
41350397|NCT05550857|OTHER|myofascial release|The subject will lye prone on a treatment table. Deep longitudinal massage with the help of both thumbs reinforcing eachother will be given on the subject's calf muscles.
41350398|NCT02461849|DRUG|Imatinib|Imatinib 400mg qd daily
41350399|NCT00419029|BEHAVIORAL|telephone-administered motivational interviewing|telephone motivational interviewing
41350400|NCT00419029|BEHAVIORAL|control|brief telephone check-in (no motivational interviewing)
41350401|NCT01112189|PROCEDURE|Autologous transplant|Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
41350402|NCT01112189|OTHER|Compressed sleeve treatment|"Week 1-2: With compressed sleeve treatment.~Week 3 -4: Without treatment.~Week 5 - 6: With compressed sleeve treatment"
41350403|NCT01590446|DRUG|BMN 111|SC injection, Part 1 single dose and Part 2 multiple dose.
41350404|NCT01590446|DRUG|Normal Saline|SC injection, Part 1 single dose and Part 2 multiple dose
41350405|NCT04618549|PROCEDURE|Direct Anterior Approach Hemiarthroplasty|Hemiarthroplasty to elderly patients with femoral neck fracture through a direct anterior approach
41350406|NCT04618549|PROCEDURE|Mini Posterior Approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a mini posterior approach
41350407|NCT04618549|PROCEDURE|Lateral approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a lateral approach (Hardinge)
41350408|NCT01414439|BEHAVIORAL|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
40831547|NCT06126367|DIAGNOSTIC_TEST|Thrombotic assessment|"The Global Thrombosis Test (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~Thromboelastography is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Plasma will be stored for subsequent analysis of other thrombotic, fibrinolytic, inflammatory and coagulation markers as deemed appropriate.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
41350409|NCT05371795|DEVICE|Comfort Marker 2.0|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the experimental group, patients' markings are tattooed using an electric marking device developed for set-up marking, the Comfort Marker 2.0® (CM), designed by CIVCO medical solutions, using the 0.2mm deep application depth and the brand-included black pigment. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
41350410|NCT05371795|DEVICE|Lancets|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the control group, patients' markings are tattooed using a 28-gauge disposable lancet and india ink. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
41350411|NCT00078455|DRUG|ILX651|
41350412|NCT01749436|OTHER|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
41492333|NCT04781101|OTHER|conventional therapy|Conventional therapy sessions that were planned by a physiotherapist for the children were conducted by a physiotherapist experienced in paediatrics. The therapy sessions mainly focused on functions such as the regulation of muscle tone, correction of posture, elimination of stiffness, muscle strengthening, balance/coordination training and mobilisation (Figure 2). The sessions were planned to last 40 minutes.
41492334|NCT04781101|OTHER|RoboGait®|The RoboGait®-assisted gait system was used for the robot-assisted gait training. In addition to conventional therapy, 16 robot-assisted gait training sessions were conducted, each lasting 25 minutes for 2 days a week (400 minutes in total). Gait speed was 1.5 km/h in all sessions. Considering conditions such as joint limitations and spasticity, gait training was performed with patients bearing 45% to 75% of their weight.
41158543|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 1|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2).
41492335|NCT02598258|OTHER|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
41350413|NCT02286752|DRUG|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
41350414|NCT02286752|DRUG|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
41492336|NCT02014207|OTHER|dietary treatment|
40831548|NCT06126367|DIAGNOSTIC_TEST|Measurement of Lp(a)|"Lp(a) will be measured by particle enhanced immunotubidimetricassay. Human lipoprotein (a) agglutinates with latex particles coated with anti-Lp(a) antibodies. The precipitate is determined turbidimetrically at 800 / 660 nm. The platform employed will be the Roche® Immunoassay Analyser (Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim). Traceability: This method has been standardized against the IFCC (International Federation of Clinical Chemistry) reference material SRM2B for nmol/L.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
41158544|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 2|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2).
41158545|NCT06182124|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
41158546|NCT04700488|DIAGNOSTIC_TEST|6D-MRI|Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI
41158547|NCT04547166|DRUG|HLX10|a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.
41158548|NCT04547166|DRUG|HLX04、|7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
41158549|NCT02775175|BEHAVIORAL|Modified Ramadan Fasting|The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
41158550|NCT01745718|OTHER|Cytological imprints|Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
41158551|NCT04389996|OTHER|No intervention|Patients will be sent a survey incl. EORTC QLQ-C30
41158552|NCT06646549|OTHER|No intervention|No intervention
41350415|NCT01871233|DRUG|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
40831549|NCT02086201|BEHAVIORAL|Problem Solving Therapy|PST is a behavioral intervention for depression that is delivered by trained therapists over a 9 week period. It consists of a process to help patients understand and then solve the problems in their lives they feel is contributing to their depression.
40831550|NCT02086201|BEHAVIORAL|Engage|Engage is a weekly behavioral intervention that is delivered over a 9 week period of time by trained therapists. The focus of Engage is to help patient reconnect with activities that they have lost interest in pursuing due to depression.
41158553|NCT03900715|DRUG|Luspatercept|Luspatercept
41158554|NCT04781543|DRUG|HZN-825 BID|300 mg oral tablets BID
41158555|NCT04781543|DRUG|Placebo|Placebo BID
41158556|NCT04781543|DRUG|HZN-825 QD|300 mg oral tablets QD
41350416|NCT00869063|DRUG|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
41350417|NCT00869063|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
41350418|NCT06005233|DEVICE|Smartwatch|Smartwatch with PPG- and 1-lead ECG derived analysis of cardiac arrhythmia. Analysis will be performed centrally at the Cardiology Core Lab at the Klinikum Rechts der Isar.
41350419|NCT05791669|DRUG|Silver diamine fluoride|Silver diamine fluoride is a topical medication composed of 25% silver, 5% fluoride, 8% ammonia, and 62% Deionized water, used to treat and prevent dental caries and relieve dentinal hypersensitivity.
41492337|NCT02727881|DRUG|Squalamine lactate ophthalmic solution, 0.2%|Squalamine lactate ophthalmic solution, 0.2%
41158557|NCT02137239|DRUG|Thymoglobulin|
41158558|NCT02137239|DRUG|Belatacept|
41158559|NCT02137239|DRUG|mycophenolate mofetil(MMF)|
41158560|NCT02137239|DRUG|Corticosteroids|
41158561|NCT02137239|DRUG|Everolimus(EVL)|
41158562|NCT02137239|DRUG|Tacrolimus(TAC)|
41158563|NCT03604835|OTHER|No Intervention|Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
41158564|NCT06488222|DRUG|Docetaxel|Subjects will receive 40 mg docetaxel intravesically.
41158565|NCT06488222|DRUG|Gemcitabine|Subjects will receive 1 mg gemcitabine intravesically.
41158566|NCT06632444|DRUG|Survodutide|Subcutaneous injection
41158567|NCT06632444|DRUG|Placebo|Subcutaneous injection
41158568|NCT05493228|DRUG|Precedex Injectable Product|Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical
41158569|NCT05493228|DRUG|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
41350420|NCT05791669|DRUG|Sodium fluoride varnish|It is a topical application with an active ingredient of 5% sodium fluoride(22,600ppm fluoride).it prolongs the contact time between the fluoride and tooth surface and promotes remineralization and inhibits demineralization.
41350421|NCT00320619|DRUG|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
41350422|NCT00320619|DRUG|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
41350423|NCT05675124|DEVICE|Needlescopic laparoscopic adrenalectomy|Compared with traditional laparoscopic surgery using 5-12 mm instruments, the wound of needlescopic laparoscopic surgery is smaller. Postoperative pain and recovery are also better than traditional laparoscopic surgery.
41350424|NCT05675124|DEVICE|conventional laparoscopic adrenalectomy|conventional laparoscopic adrenalectomy
41350425|NCT04697888|DRUG|Omegaven|Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
41350426|NCT01464398|BEHAVIORAL|Stress reduction|8 weekly sessions
41350427|NCT01464398|BEHAVIORAL|Stress reduction with Health education|8 weekly sessions
41350428|NCT02811640|OTHER|Study Participants|IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
41350429|NCT04295668|BEHAVIORAL|Usual care|The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool ≥2).
41350430|NCT04295668|BEHAVIORAL|Prehabilitation|"i) Exercise training: Ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training and strength muscular training.~ii) Promotion of physical activity: Pedometer-based program using a physical activity tracker linked to a mobile app.~iv) Nutritional optimization: Recommendations of a healthy balanced diet or adapted to their digestive symptoms. Daily amount of protein intake will be close to 2 g•Kg-1•day-1.~iv) Smoking cessation: Use of both cognitive behavioral intervention and pharmacological therapy by varenicline or nicotine replacement therapies.~v) Cognitive behavioral therapy: Weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment."
41350431|NCT01789099|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
41350432|NCT05820776|OTHER|pulmonary rehabilitation|The intervention is PR delivered via a telemedicine. The intervention is PR delivered via a telemedicine. The program is delivered by the multidisciplinary via a remote application for two sessions per week for ten weeks. Remotely supervised exercise includes: 1) deep breathing reinforcing pursed lip and diaphragmatic breathing; 2) warm up breathing and stretching exercise; 3) a cardiorespiratory aerobic exercise battery; 4) resistance training, and; stretching cool down. There is also an educational component. The secondary (maintenance) program includes ongoing remotely supervised exercise and education once a week for six months (24 sessions). All patients successfully completing the initial PR are offered the maintenance program.
41350433|NCT03659695|DIETARY_SUPPLEMENT|Grape Powder|69 g/d freeze dried grape powder
41350434|NCT03659695|DIETARY_SUPPLEMENT|Placebo Powder|69 g/d placebo powder matched for taste and appearance
41492338|NCT02727881|DRUG|Placebo Ophthalmic solution|Placebo Ophthalmic solution
41492339|NCT02727881|DRUG|ranibizumab|ranibizumab
40831551|NCT06243120|DRUG|Lidocaine IV|The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points , it will be considered as a failure.
41350435|NCT06496789|DRUG|Serplulimab+SOX|Serplulimab+Oxaliplatin+S1
41350436|NCT05746689|DRUG|Sirolimus|Sirolimus The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
41350437|NCT02840552|DRUG|18F-Fluoromethylcholine (18F-FCH)|FCH PET/CT
41350438|NCT05801016|BEHAVIORAL|Emerging Technologies and Training in Neurosciences|Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall
41492340|NCT02716935|DIETARY_SUPPLEMENT|Fortified lipid based nutrient supplement|6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
41350439|NCT05168189|DRUG|Ivabradine|follow up chronic coronary syndrome patients receiving Ivabradine for ( 6 months ) if the participants develop atrial fibrillation using 24 hours holter .
41350440|NCT05168189|DIAGNOSTIC_TEST|transthoracic echo|performing baseline transthoracic echo for all patients to exclude any chamber dilatation
41350441|NCT05168189|DEVICE|24 hours holter|perform 24 hours Holter monitoring for all patients at the start of the study and follow up after 6 months
41350442|NCT00362141|DRUG|levetiracetam (add-on)|
41350443|NCT04837690|PROCEDURE|UEMR|(1) the colorectal lumen was completed deflated with 500-1000 mL sterile water using a flushing pump; (2) the lesion and 2-3 mm of normal mucosa surrounding the base of the polyp were snared and subsequently resected with an electrosurgical generator
41350444|NCT05685849|DEVICE|Echocardiography|Maternal and fetal echocardiography：Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of five echocardiographic examinations will be performed in the first trimester(11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester(29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
41350445|NCT03512028|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
41350446|NCT03512028|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
41350447|NCT03512028|BEHAVIORAL|Muscle strength training|All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8
41350448|NCT03512028|BEHAVIORAL|Driving training|All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.
40831552|NCT03069287|BEHAVIORAL|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
40831553|NCT02720601|DRUG|Irinotecan & Capecitabine|Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
40831554|NCT03913845|DRUG|lidocaine with epinephrine|One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.
40831555|NCT03913845|DRUG|Normal saline with epinephrine|Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
40831556|NCT04159532|DIETARY_SUPPLEMENT|MAG-EPA/MAG-DHA|monoglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
40831557|NCT04159532|DIETARY_SUPPLEMENT|TG-EPA/TG-DHA|Triglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
40831558|NCT04159532|DIETARY_SUPPLEMENT|EE-EPA/EE-DHA|Ethyl ester of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
40831559|NCT05544032|DRUG|axatilimab|Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks
40831560|NCT00979355|DEVICE|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
40831561|NCT02332772|OTHER|Data Collection|Data collected from endoscopy procedures.
41350449|NCT03512028|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
41350450|NCT03432585|BEHAVIORAL|Applicant Survey|This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
41350451|NCT02227433|DRUG|Brentuximab Vedotin|
41350452|NCT04056715|DEVICE|Zio XT|ambulatory cardiac monitoring device
41492341|NCT02716935|DIETARY_SUPPLEMENT|lipid based nutrient supplement|Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
41350453|NCT01228435|DRUG|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
41158570|NCT06255899|BEHAVIORAL|Education Program on Injury Prevention|The didactic component of the injury prevention education program includes information on prevalence of injuries in female athletes, biomechanical risk factors for injury, and effectiveness of injury prevention programs (IPP) for mitigation of injury risk. Examples of different activities from the IPP, including proper and improper movement strategies will be provided. Athletes will be instructed as a group on how to properly perform of each activity of the IPP, and will be given an opportunity to practice. Athletes, coaches, and staff will be provided with links to written instructions and videos of proper performance for each activity. The IPP will be performed at least 3 times/week prior to practice. Coaches, staff, and athletes will be encouraged to provide supervision and feedback on performance of the IPP throughout the season.
40831562|NCT01897545|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
40831563|NCT01897545|PROCEDURE|PV isolation+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
40831564|NCT05873036|DIAGNOSTIC_TEST|Aerobic Training|Aerobic Training to Improve Functional Ability After Breast Cancer Surgery
40831565|NCT05873036|DIAGNOSTIC_TEST|Progressive Resistance Training|Progressive Resistance Training to Improve Functional Ability After Breast Cancer Surgery
40831566|NCT06423391|OTHER|NeuOst|As above
40831567|NCT06423391|OTHER|Control Intervention|As above
40831568|NCT06423391|OTHER|Usual Care|As above
40831569|NCT04247126|DRUG|SY-5609|An oral CDK7 Inhibitor
40831570|NCT04247126|DRUG|Fulvestrant|Estrogen receptor antagonist
40831571|NCT04247126|DRUG|Gemcitabine|Nucleoside metabolic inhibitor
41350454|NCT03147495|DIAGNOSTIC_TEST|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiograph.|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiographs will be taken for the participants in both groups. The standing anteroposterior knee radiographs will be obtained with the knee extended. The proximal tibiofibular joint radiographs will be acquired with the knee of the participants in approximately 45°-60° of internal rotation.
40831572|NCT04247126|DRUG|Nab-paclitaxel|Taxane-type chemotherapy
40831573|NCT05092165|DRUG|Methylene Blue|1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
40831574|NCT05092165|OTHER|Control|Usual care during renal replacement therapy
40831575|NCT00099281|DRUG|YMB 1002|
40831576|NCT03118999|DIETARY_SUPPLEMENT|OM3-FFA|Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design
40831577|NCT03118999|DIETARY_SUPPLEMENT|OM3-MAG|Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design
40831578|NCT03118999|DIETARY_SUPPLEMENT|OM3-EE|Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design
40831579|NCT04590690|OTHER|Special diet|The research clinic will provide subjects with a special diet for six days. After six days of isocaloric sodium, calcium and fluid intake, the study team will analyze three sequential 24-hour urine compositions including supersaturation of calcium oxalate, calcium, and urine volume, as well as stool collections. We will also evaluate components of 24-hour urine composition, specifically supersaturation, and the microbial contributions to urinary composition in 72-hour stool samples simultaneously collected using shot-gun metagenomic sequencing in men and women 1 year after surgery.
40831580|NCT00143533|DRUG|Irinotecan, Cefpodoxime|See Detailed description section for treatment details.
40831581|NCT00123266|DRUG|Microplasmin|2 mg/kg, IA over 75 mins
40831582|NCT05588037|PROCEDURE|FLACS +PPV+IOL + air|The procedures are combined the FLACS +PPV+IOL + air.
40831583|NCT05588037|PROCEDURE|FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex|The procedures are combined the FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex.
40831584|NCT05588037|PROCEDURE|FLACS + PPV+IOL + internal limiting membrane peeling + air|The procedures are combined the FLACS + PPV+IOL + internal limiting membrane peeling + air.
40831585|NCT05588037|PROCEDURE|FLACS + PPV+IOL|The procedures are combined the FLACS + PPV+IOL.
40831586|NCT02048215|DRUG|Caffeine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
41350455|NCT00010244|RADIATION|radiation therapy|
41350456|NCT02773914|OTHER|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessment intervention
41350457|NCT02607865|DRUG|semaglutide|Oral administration once-daily
41350458|NCT02607865|DRUG|sitagliptin|Oral administration once-daily
41158571|NCT06255899|BEHAVIORAL|Individualized Feedback + Education Program on Injury Prevention|In addition to the education program, participants in this group will receive individualized feedback on performance of the IPP. The participant will be videotaped while performing the IPP, and movement errors and compensations will be identified to provide a basis for feedback sessions to correct movement. The session will include different forms of feedback including showing the athlete their video, identifying the error or compensation, and providing verbal, tactile, and visual feedback to correct the error or compensation. Common errors and compensations, along with verbal cues and corrections, have been identified and manualized for the study. Two additional feedback sessions will be scheduled at regular intervals during the season to provide feedback on performance throughout the season. Participants in this group will be encouraged to provide peer feedback to one another.
41158572|NCT00317759|BIOLOGICAL|therapeutic autologous lymphocytes|
41158573|NCT00317759|DRUG|fludarabine phosphate|
41158574|NCT05895110|BIOLOGICAL|Recombinant Novel Coronavirus vaccine (CHO Cells)|The experimental vaccine dose used in this study is 25μg/0.5mL. All subjects recruited should have received two doses of novel Coronavirus inactivated vaccine on the market for 6-9 months, and all eligible subjects will receive one dose of recombinant Novel Coronavirus vaccine (CHO cells).
41158575|NCT03707418|DRUG|Heparin Sodium|Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels
41158576|NCT03707418|DRUG|Bivalirudin Injection [Angiomax]|Intravenous Bivalirudin titrated to Activated Clotting Time (ACT) levels
41158577|NCT06641362|DEVICE|Ultra High Frequency Electrocardiogram (UHF-ECG)|Electrocardiograms used on participants scheduled to undergo pacemaker implantation for bradycardia and/or heart failure.
41158578|NCT01063127|OTHER|Study on insulin sensitivity after diet or bariatric surgery|Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
41158579|NCT01063127|OTHER|gastric bypass|Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
41158580|NCT04237987|DRUG|Interleukin-2|Interleukin-2 was produced by Beijing Shuanglu Pharmaceutical Co., Ltd
41158581|NCT04237987|DRUG|ciclosporin and corticosteroid|ciclosporin and corticosteroid
41158582|NCT04193397|BEHAVIORAL|Exercise training|Resistance training program performed during 6 months, 3 sessions per week
41158583|NCT04416321|DEVICE|Surgery with the Keos Lumbar Interbody Fusion Device|All subjects will received the Keos Lumbar Interbody Fusion Device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease, spondylolisthesis and retrolisthesis
41158584|NCT00415025|PROCEDURE|adjuvant therapy|
40831587|NCT02048215|DRUG|Placebo|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
41158585|NCT00415025|PROCEDURE|management of therapy complications|
41158586|NCT00415025|PROCEDURE|quality-of-life assessment|
41158587|NCT00415025|RADIATION|intensity-modulated radiation therapy|
41158588|NCT01801813|OTHER|Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications|
41158589|NCT04388917|PROCEDURE|Patial nephrectomy|Partial nephrectomy assisted with robot to remove kidney cancer
41158590|NCT06038383|DEVICE|Group A - Intervention with Virtual Reality (VR)|Group of people with kidney disease that performed VR intervention during hemodialysis.
41492342|NCT04607330|OTHER|High protein liquid|After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
40831588|NCT02048215|DRUG|Ephedrine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
40831589|NCT02048215|OTHER|Hypocaloric diet|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
41492343|NCT05225532|OTHER|Radiofrequency ablation|Radiofrequency ablation of ganglionated plexi located in the left or right atrium
41492344|NCT02954263|DRUG|TD-1439|
41492345|NCT02954263|DRUG|Placebo|
41492346|NCT01449097|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-blockade with Ropivacaine
41492347|NCT01449097|PROCEDURE|The femoral nerve block|US-guided femoral nerve block with ropivacaine
41492348|NCT01449097|PROCEDURE|Placebo|US-guided Adductor-Canal-Blockade/femoral nerve block with saline
41492349|NCT00146497|DRUG|Budesonide-Surfactant|
41492350|NCT00167687|DRUG|prazosin|"Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg"
41350459|NCT02607865|DRUG|placebo|Oral administration once-daily
41492351|NCT02929186|BEHAVIORAL|Opt-In Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.
41492352|NCT02929186|BEHAVIORAL|Opt-Out Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
41492353|NCT05913089|DRUG|TQB2450 injection + Chemotherapy|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Chemotherapy is a systematic treatment that kill fast growing cells."
41492354|NCT05913089|DRUG|TQB2450 injection + Anlotinib Hydrochloride Capsule|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
41492355|NCT02717858|DRUG|liraglutide|Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
41492356|NCT02717858|DRUG|placebo|Injected s.c./subcutaneously (under the skin) once daily.
40831590|NCT00281190|PROCEDURE|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
41492357|NCT01949961|OTHER|Ultrasound|SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for \~30 minutes, using a Bracco infusion pump.
41492358|NCT01949961|OTHER|Sham ultrasound|Mounting the ultrasound headframe but connecting this to a non-operative channel
41492359|NCT04952636|PROCEDURE|arthroscopic Cuistow|peforming the Cuistow Procedure under arthroscopy
41492360|NCT04952636|PROCEDURE|open Cuistow|peforming the Cuistow Procedure with the traditional open process
41492361|NCT04354116|DEVICE|Rapid maxillary expansion|Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.
41158591|NCT06038383|DEVICE|Group B - Intervention with Stationary Bike (SB)|Group of people with kidney disease that performed SB intervention during hemodialysis.
41350460|NCT00554346|DRUG|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
41350461|NCT05344235|OTHER|SBRT|stereotactic radiotherapy of the primary prostate
41350462|NCT01675141|DRUG|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
41350463|NCT01644812|BEHAVIORAL|Aerobic exercise|
41350464|NCT01644812|BEHAVIORAL|Stretching|
41492362|NCT04354116|DEVICE|Maxillary Protraction|Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).
41492363|NCT00805753|DRUG|ACTH|comparison of different dosages of drug
41350465|NCT01829867|DRUG|sNN0031|
41350466|NCT06074133|PROCEDURE|Blood collection|Undergo blood draw
41350467|NCT06074133|PROCEDURE|Chest Computed Tomography|Undergo standard of care chest Computed Tomography
41158592|NCT06038383|DEVICE|Group A - Intervention with Stationary Bike (SB) - Crossover|Group of people with kidney disease that performed SB intervention during hemodialysis after the washout period.
41350468|NCT04638036|DRUG|Cetuximab-IRDye800|Intravenous administration of a pre-dose of 75 mg unlabeled Cetuximab followed by 15 mg Cetuximab-IRDye800 prior to the study procedures
41350469|NCT04638036|DEVICE|Fluorescent molecular endoscopy and surgery|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe can be inserted through the standard working channel of the standard clinical endoscope for fluorescent endoscopy. Fluorescence imaging will be performed post the chemoradiotherapy.
41350470|NCT04714554|DRUG|Relugolix/E2/NETA FDC|Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.
41350471|NCT04714554|DRUG|Relugolix|Relugolix 120-mg tablets; oral administration.
41158593|NCT06038383|DEVICE|Group B - Intervention with Virtual Reality (VR) - Crossover|Group of people with kidney disease that performed VR intervention during hemodialysis after the washout period.
41158594|NCT02907398|DEVICE|Inspire therapy|
41158595|NCT02907398|OTHER|No intervention|
41350472|NCT04714554|DRUG|Erythromycin|Erythromycin 500-mg tablets; oral administration.
41350473|NCT03640715|OTHER|ENVU|"ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations."
41350474|NCT01804504|BEHAVIORAL|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
41350475|NCT04124952|DEVICE|Panoptix|Alcon Acrysof(R) Panoptix(R) intraocular lens (IOL)
41350476|NCT04670042|DEVICE|SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)|Same as Arm Description.
41350477|NCT01841164|DRUG|Montelukast|
41350478|NCT01841164|DRUG|Placebo for montelukast|Sugar pills manufactured to mimic Singulair
41350479|NCT01841164|OTHER|Inhaled leukotriene E4|Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
41350480|NCT03497390|OTHER|EMERALD intervention|EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.
41350481|NCT03497390|OTHER|Usual care|Usual care without any workshop or program
41350482|NCT04837768|DRUG|Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \>9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the traditional twice-daily vaginal progesterone supplementation till 12 weeks gestation.
40831591|NCT00281190|PROCEDURE|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
40831592|NCT01891344|DRUG|Oral rucaparib|600 mg BID
40831593|NCT05768243|DRUG|Hyaluronic acid|hyaluronic acid is used as an adjunctive treatment to scaling and root planing
40831594|NCT05768243|PROCEDURE|red injectable platelet rich fibrin (i-prf)|injecting red i-prf into the pocket after scaling and root planing
40831595|NCT04798040|OTHER|cold application|To reduce pain, cold application is applied around the drain before the drain is removed.
40831596|NCT04798040|OTHER|lavender oil inhalation|To reduce pain, lavender oil is inhaled prior to drain removal.
40831597|NCT04798040|OTHER|oxygen administration|To reduce pain, oxygen is inhaled prior to drain removal.
40831598|NCT04596332|OTHER|no intervention measures|Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
40831599|NCT01007422|BEHAVIORAL|telephone-based intervention|
40831600|NCT01007422|OTHER|communication intervention|
40831601|NCT01007422|OTHER|intervention by caregiver|
40831602|NCT01007422|OTHER|medical chart review|
41350483|NCT04837768|DRUG|Twice-weekly intramuscular + Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \<9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the twice-daily vaginal progesterone in addition to twice-weekly intramuscular progesterone supplementation till 12 weeks gestation.
40831603|NCT01007422|OTHER|survey administration|
40831604|NCT01007422|PROCEDURE|end-of-life treatment/management|
40831605|NCT01007422|PROCEDURE|pain therapy|
40831606|NCT01007422|PROCEDURE|psychosocial assessment and care|
40831607|NCT06096974|DRUG|YL-17231|YL-17231 will be administered orally once daily in a continuous regimen
40831608|NCT03254277|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS
40831609|NCT03254277|DRUG|Placebo|Placebo
40831610|NCT00111540|DRUG|exenatide|subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
40831611|NCT00808535|PROCEDURE|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
40831612|NCT03324425|DRUG|Simvastatin 80mg|Participants will receive simvastatin 80 mg by mouth daily at bedtime
40831613|NCT01100567|DEVICE|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
40831614|NCT04272333|DRUG|Motolimod|Intratumoral microdose injection by the CIVO device.
40831615|NCT04272333|BIOLOGICAL|Nivolumab|Intratumoral microdose injection by the CIVO device.
40831616|NCT04272333|COMBINATION_PRODUCT|Motolimod + Nivolumab|Intratumoral microdose injection by the CIVO device.
40831617|NCT04388046|DEVICE|Herbst fixed functional appliance|Herbst appliance could be considered as an artificial joint working between maxilla and mandible. The appliance consists of a bilateral telescope mechanism attached to upper and lower jaws keeping the mandible in an anterior jumped position.
41350484|NCT03000764|OTHER|skin biopsies|"Biopsies (12 G) will be performed :~* in non-irradiated breast skin~* in irradiated breast skin"
41350485|NCT03000764|OTHER|blood samples|"blood samples are collected:~* 10 ml in EDTA tube~* 2,5 ml in PAXgene Blood RNA tube~* 4 ml in EDTA tube"
41350486|NCT05451602|DRUG|HEC169096|Multiple doses of HEC169096 during Phase 2；Oral dose of HEC169096 as determined during Phase 2.
41350487|NCT00515905|DRUG|Sevoflurane/propofol|Sevoflurane/propofol
41350488|NCT04211649|DRUG|3 days of antibiotherapy|Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
40831618|NCT00711802|DRUG|Daptomycin|
40831619|NCT00711802|DRUG|Standard of Care (SOC)|
40831620|NCT03283150|DRUG|Remifentanil|Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.
40831621|NCT03283150|DRUG|Propofol|Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
40831622|NCT03283150|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
40831623|NCT02253056|OTHER|Fasting / Caloric Restriction|
40831624|NCT02253056|OTHER|Healthy Diet|
40831625|NCT00049777|DRUG|Drotrecogin Alfa (Activated)|
40831626|NCT00049777|DRUG|Unfractionated heparin|
40831627|NCT00049777|DRUG|Low molecular weight heparin|
41158596|NCT05046652|BIOLOGICAL|Convalescent Plasma Therapy|In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.
40831628|NCT06508450|BEHAVIORAL|Just Do You|Just Do You Core Intervention utilizes creative arts and a provider team of a licensed clinician and professional peer to increase young adult engagement in adult outpatient mental health programs. Content addresses recovery, advantages of using mental health services, working with providers, stigma, and mental health literacy.
40831629|NCT06508450|BEHAVIORAL|Component A|Content addresses participant cultural identities and how they may be barriers and facilitators to on-going engagement with services.
40831630|NCT06508450|BEHAVIORAL|Component B|Content addresses identity-based motivations for on-going engagement with services and hope for the future.
40831631|NCT06508450|BEHAVIORAL|Component C|Content addresses community and environmental barriers and facilitators to on-going engagement with services and self-efficacy.
40831632|NCT00440856|BEHAVIORAL|Presentation of excised intervertebral disc fragments|
40831633|NCT02659553|PROCEDURE|steatosis|Liver Transplantation with graft steatosis
40831634|NCT01357954|OTHER|Regular physiotherapy|The child's regular physiotherapy
40831635|NCT01357954|OTHER|Targeted Training|Targeted training, 5 days a week for 6 months, up to 30 minutes a day
40831636|NCT03869333|BIOLOGICAL|Invaplex[AR-DETOX]|Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\[AR-Detox\]) Vaccine
40831637|NCT03869333|OTHER|Placebo|Saline
40831638|NCT06518707|OTHER|Phrenic nerve stimulation|A commercial phrenic nerve stimulation equipment will be used during surgery. Phrenic nerve stimulation intensity will be determined before surgery, ensuring significant diaphragm contraction under stimulation. The use of an electric knife will be avoided during surgery. Tidal volume, airway pressure, and vital signs will be monitored continuously.
40831639|NCT01188616|BEHAVIORAL|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
40831640|NCT05528900|DIAGNOSTIC_TEST|allergy test|allergy test are oral food challenge , prick test and IgE blood rate
40831641|NCT03002688|OTHER|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
40831642|NCT00151034|DRUG|Trastuzumab|
40831643|NCT00151034|DRUG|Paclitaxel|
40831644|NCT00151034|DRUG|Carboplatin|
40831645|NCT00151034|DRUG|Gemcitabine|
41158597|NCT02201147|PROCEDURE|Cold biopsy polypectomy|removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy
40831646|NCT05696574|DRUG|Vaginal Misoprostol|Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
40831647|NCT05696574|DRUG|Oral Misoprostol|Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
40831648|NCT01708447|DRUG|L.M.X.4.® cream|A lidocaine topical anesthetic cream
40831649|NCT01708447|OTHER|A placebo cream|Placebo cream containing no anesthetic properties.
40831650|NCT01708447|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
40831651|NCT06087900|OTHER|Moderate continuous training (MICT)|The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.
40831652|NCT06087900|OTHER|High intensity interval training (HIIT)|The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.
41158598|NCT02201147|PROCEDURE|Cold snare polypectomy|removal of eligible polyps using cold snare polypectomy technique
41158599|NCT02201147|DEVICE|Cold snare polypectomy|mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
41158600|NCT02201147|DEVICE|Cold biopsy polypectomy|standard- capacity forceps with narrow band imaging endoscopy
41158601|NCT03868930|BEHAVIORAL|STEP-Home|This group will meet for 2 hours a week for 12 weeks. The core skills of Emotional Regulation (ER) (45-minutes) and Problem Solving (PS) (45-minutes) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention Training (AT) augments PS and ER core skills and is interspersed throughout group and individual sessions.
41158602|NCT03868930|BEHAVIORAL|PCGT|The PCGT group will also meet for 2 hours a week for 12 weeks. It is a nonspecific and supportive intervention to control for the nonspecific benefits of the group experience (e.g., therapist contact, instillation of hope, expectation of improvement). It will focus on identifying and discussing current life stressors that contribute to reintegration difficulties, psychoeducation, and promotion of wellness and physical health.
41158603|NCT01401036|DEVICE|Biolimus A9 eluting stents|implantation of Biolimus A9 eluting stents
41158604|NCT01401036|PROCEDURE|uncoated stent|implantation of any uncoated bare metal stents currently available in Japan
40831653|NCT06087900|OTHER|Inspiratory muscle training (IMT)|The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory
40831654|NCT06087900|OTHER|Control|The CON group did not have any intervention but usual care.
40831655|NCT05008757|OTHER|no drug|no intervention
40831656|NCT04928209|OTHER|Speech-Language Teletherapy|Access to speech-language teletherapy will be provided as a supplement to Usual Care for subjects randomized to this group. Access is provided by way of 1) direct referral by the clinical team to a teletherapist; 2) availability of a teletherapy slot. All teletherapy providers will be licensed speech-language pathologists (SLPs) and/or credentialed teachers of the deaf (TODs) with specialized training to work with children who are D/HH using an LSL approach. Fluent English and Spanish speaking providers will be matched to the child's home, native language. Teletherapy itself is within routine clinical care and is not considered a research activity. Children who randomize to the Low TT study arm will receive access to an 18-month course of weekly teletherapy, in accordance with the centers' standard of care. The exact details of the therapy course and frequency will be determined based on individual family needs.
40831657|NCT03964532|DRUG|Talazoparib|Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.
40831658|NCT03964532|DRUG|Avelumab|Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
40831659|NCT02706561|BEHAVIORAL|questionnaires|
40831660|NCT02706561|BEHAVIORAL|three in-person sessions|
40831661|NCT02706561|BEHAVIORAL|monthly phone calls|
40831662|NCT02706561|BEHAVIORAL|Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)|
40831663|NCT02706561|BEHAVIORAL|Enhanced Monitoring and Education (EME)|
40831664|NCT00894478|PROCEDURE|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~1. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~2. Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
40831665|NCT00894478|PROCEDURE|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
40831666|NCT03762967|BIOLOGICAL|Lipoaspiration and SVF introduction.|Lipoaspiration, isolation of SVF and introduction into testis Interstitium.
40831667|NCT03762967|DRUG|Standard therapy.|Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
41158605|NCT03735641|PROCEDURE|Expanded Pedicled Deltopectoral Flap|Expanded Pedicled Deltopectoral Flap is a type of surgical flap
41158606|NCT00156377|DRUG|Mupirocin|
41158607|NCT02991781|OTHER|Biofeedback and Neurofeedback Training|The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
41350489|NCT05064943|DIAGNOSTIC_TEST|2-minute step test|"The participant stands and counts for 2 minutes. The minimum height to raise the knee is determined for each participant by calculating the midpoint between the patella and the anterior superior iliac spine. They are instructed to complete as many steps as possible during the 2-minute period. A verbal command is given every 30 seconds to encourage performance: You're doing great, keep it up. If the claudication symptom becomes unbearable, the patient can stop during the test, but the time is not stopped. Patients who discontinue testing due to symptoms of claudication are encouraged to return to testing as soon as possible. An evaluator records the number of steps in the right leg."
41350490|NCT04979338|OTHER|Ultrasound guided Continuous Infraclavicular Brachial Plexus Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
41158608|NCT02991781|DRUG|Varenicline use for smoking cessation|The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
41158609|NCT02991781|OTHER|Sham Neurofeedback|Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.
40831668|NCT00490139|DRUG|Lapatinib|Small molecule inhibitor
40831669|NCT00490139|BIOLOGICAL|Trastuzumab|Antibody
41158610|NCT02991781|OTHER|Passive Control|Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
41158611|NCT01068223|DRUG|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
41158612|NCT01068223|DRUG|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
41158613|NCT01068223|DRUG|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
41350491|NCT04979338|OTHER|Ultrasound guided Continuous Femoral Nerve Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
41350492|NCT04979338|OTHER|Ultrasound guided Pudendal Nerve Block|20-40cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist, pre-incision\]
41350493|NCT04979338|DRUG|Bupivacaine|0.25% or 0.5% with or without 1:200K epinephrine
41158614|NCT02117856|PROCEDURE|1 implant placed surgically in the mandibular midline|Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
41350494|NCT04979338|OTHER|Bilateral ultrasound guided Transversus Abdominis Plane Block|40-60cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist post-op or at end of surgery\]
41350495|NCT04979338|OTHER|Bilateral spermatic cord block|10cc per spermatic cord of 0.5% bupivacaine \[administered by surgeon @ intraop\]
40831670|NCT01067599|OTHER|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
41158615|NCT02117856|PROCEDURE|2 implants placed surgically in the mandibular canine sites|Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
41158616|NCT02117856|PROCEDURE|Soft reline (Coe Comfort) of the existing complete lower denture|Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
41350496|NCT04979338|OTHER|Pecs I & II Block|0.25% bupivacaine: 15-30mL per side for Pecs I-III
41350497|NCT04979338|OTHER|Local anesthetic|0.25% or 0.5% bupivacaine into the appropriate surgical site
41350498|NCT00005623|DRUG|cyproterone acetate|
41158617|NCT02117856|DEVICE|2.25mm ball patrix placed on 1 healed implant|A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
41350499|NCT00005623|PROCEDURE|quality-of-life assessment|
41350500|NCT03637166|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
41350501|NCT03637166|OTHER|Exposure to High Altitude (2500m above sea level)|"Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours"
41350502|NCT02093741|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|The investigators shall determine all treatment regimens according to product labeling information and standard practice.
40831671|NCT01067599|OTHER|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
40831672|NCT01067599|OTHER|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
41158618|NCT02117856|DEVICE|2.25mm ball patrices placed on 2 healed implants|2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
41158619|NCT02117856|PROCEDURE|Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
41158620|NCT02117856|PROCEDURE|Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
41158621|NCT01520285|DRUG|Zanidip|Lercanidipine hydrochloride (10mg/tablet)once per day
41158622|NCT01520285|DRUG|Felodipine sustained-release tablet|Felodipine sustained-release tablet (5mg/tablet)
41350503|NCT03307473|BEHAVIORAL|E6BIKE|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
41350504|NCT05504018|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction surgery
41158623|NCT05996458|OTHER|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, RNF180/Septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
41158624|NCT05996458|OTHER|Risk factor investigation;|Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.
41350505|NCT01814449|OTHER|18FMISO PET/CT scan|The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
41492364|NCT06258603|OTHER|oral care bundle|"In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, an oral care bundle containing an oral care combination was applied to the experimental group. According to this bundle application, patients were received tooth brushing (with chlorhexidine solution) and ice water application twice a day and moisturizing attempts 4 times a day.~In the 3rd stage, saliva pH, dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee."
41158625|NCT05996458|OTHER|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
41350506|NCT01814449|DRUG|Letrozole|Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
41350507|NCT04888195|OTHER|Questionnaire|Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
41492365|NCT06258603|OTHER|clinical oral care|"In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, routine oral care protocol used in intensive care unit was applied to patients by the patients' primary nurse. According to this application, patients were received oral care using tongue depressor with wrapped in gauze and chlorhexidine solution 4 times a day.~In the 3rd stage, saliva pH (power of hydrogen), dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee."
41492366|NCT03830918|BIOLOGICAL|Atezolizumab|Given IV
41492367|NCT03830918|DRUG|Niraparib|Given PO
41492368|NCT03830918|OTHER|Quality-of-Life Assessment|Ancillary studies
41492369|NCT03830918|OTHER|Questionnaire Administration|Ancillary studies
41158626|NCT02113540|DRUG|Atorvastatin|
41350508|NCT02581098|OTHER|No interventions|No interventions
41350509|NCT05006651|DEVICE|McGrath MAC|Intubaion with McGrath MAC
41492370|NCT03830918|DRUG|Temozolomide|Given PO
41492371|NCT01209130|DRUG|DCDT2980S|Intravenous repeating dose
41492372|NCT01209130|DRUG|rituximab|Intravenous repeating dose
41350510|NCT05006651|DEVICE|Trachway|Intubaion with Trachway
40831673|NCT02846246|OTHER|Person-centred and health-promoting home care service|Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.
40831674|NCT02846246|OTHER|Care as usual|The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
40831675|NCT00002514|BIOLOGICAL|sargramostim|
40831676|NCT00002514|DRUG|asparaginase|
40831677|NCT00002514|DRUG|cyclophosphamide|
40831678|NCT00002514|DRUG|cytarabine|
40831679|NCT00002514|DRUG|daunorubicin hydrochloride|
40831680|NCT00002514|DRUG|dexamethasone|
40831681|NCT00002514|DRUG|etoposide|
40831682|NCT00002514|DRUG|imatinib mesylate|
40831683|NCT00002514|DRUG|leucovorin calcium|
40831684|NCT00002514|DRUG|mercaptopurine|
40831685|NCT00002514|DRUG|methotrexate|
40831686|NCT00002514|DRUG|prednisone|
40831687|NCT00002514|DRUG|thioguanine|
40831688|NCT00002514|DRUG|vincristine sulfate|
40831689|NCT00002514|PROCEDURE|allogeneic bone marrow transplantation|
40831690|NCT00002514|PROCEDURE|autologous bone marrow transplantation|
40831691|NCT00002514|PROCEDURE|peripheral blood stem cell transplantation|
41158627|NCT06329011|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
41350511|NCT04277052|DEVICE|Determination muscles sections by Ultrasonography|Determination muscles sections by Ultrasonography
41350512|NCT05567679|DRUG|Tazverik|Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
41350513|NCT00323479|DRUG|Anastrozole|1mg/Day oral
40831692|NCT00002514|RADIATION|radiation therapy|
40831693|NCT01066780|DEVICE|ClearVoice|ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
40831694|NCT05341999|OTHER|cold saline (cryotherapy)|using 20ml of 2.5°C cold saline for 5 min
40831695|NCT05341999|DRUG|Ibuprofen 400 mg|patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
40831696|NCT05341999|OTHER|Final irrigation with normal saline|final irrigation will be done using normal saline at room temperature.
40831697|NCT00467675|DEVICE|CGM System for Type 1 and Type 2 Diabetes Mellitus|
40831698|NCT06112652|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
40831699|NCT06112652|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
40831700|NCT06112652|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
40831701|NCT06112652|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
40831702|NCT06112652|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
40831703|NCT01209871|BIOLOGICAL|Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|Given ID
40831704|NCT01209871|OTHER|Laboratory Biomarker Analysis|Correlative studies
40831705|NCT00266344|DRUG|MK0928, gaboxadol / Duration of Treatment 3 Weeks|
40831706|NCT00266344|DRUG|Placebo / Duration of Treatment 3 Weeks|
40831707|NCT01532544|DRUG|Ilomedin and Integrilin|Continuous infusion
40831708|NCT01532544|DRUG|low molecular weight heparin.|
40831709|NCT00319657|BIOLOGICAL|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from the living donor.
40831710|NCT00319657|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
40831711|NCT06090032|DEVICE|Ultrasound|We will use ultrasongraphy as a part of assessment in respiratory intensive care unit patients with ventilator associated pneumonia
40831712|NCT02568449|DRUG|Nintedanib|Given PO
40831713|NCT02483130|DIETARY_SUPPLEMENT|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
40831714|NCT02483130|OTHER|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
40831715|NCT03927313|DRUG|Linezolid|For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days
40831716|NCT03927313|DRUG|High dose rifampicin|For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment
40831717|NCT03927313|DRUG|Aspirin|For only one of the experimental arms: 1000mg of aspirin daily for 56 days.
41492373|NCT04730089|DEVICE|Electrical impedance tomography|A bolus of 10ml 10% NaCl was injected during a respiratory pause (≥10s) through the central venous catheter.The results of arterial blood gas analysis and the data of EIT were collected before the first prone session (time baseline), the end of prone positioning (time P).
40831718|NCT03927313|DRUG|Standard of Care anti-tuberculous therapy|10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
41158628|NCT06329011|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
41158629|NCT06329011|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
41158630|NCT06329011|BEHAVIORAL|Placebo Transcranial direct current stimulation|The Transcranial direct current stimulation will be performed without being turned on.
41158631|NCT02155218|OTHER|Standard Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
41158632|NCT02155218|OTHER|Patient Tailored Injection Rate|"Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves."
41158633|NCT02155218|OTHER|gadolinium contrast|
41158634|NCT01643902|DRUG|tPA|IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
41158635|NCT03089502|OTHER|Exercise Rehabilitation|The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
41158636|NCT06045221|DRUG|Orforglipron|Administered orally
41158637|NCT06045221|DRUG|Semaglutide|Administered orally
41158638|NCT04291703|DRUG|Antithymocyte Globulin|Thymoglobulin
41158639|NCT04291703|DRUG|Placebo (for ATG)|Normal Saline administered by IV infusion to mimic ATG
41492374|NCT01612026|PROCEDURE|arterial cannulation by angiographic imaging|comparing successful arterial cannulation in case of non-cardiac vascular patient population.
41492375|NCT06168786|DRUG|Fruquintinib|Fruquintinib:5mg ,qd,po, d1-d14, q3w
41492376|NCT06168786|DRUG|Cadonilimab|Cadonilimab:10mg/kg, ivgtt, d1, q3w
41492377|NCT06168786|RADIATION|SBRT|SBRT:8-10Gy×5F，qod， in 10 days
41492378|NCT04581174|DIAGNOSTIC_TEST|24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated|Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
40831719|NCT03927313|DRUG|Dexamethasone|Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
40831720|NCT02714270|PROCEDURE|modified partograph|
40831721|NCT02714270|PROCEDURE|paperless partograph|
40831722|NCT01046227|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
41350514|NCT05108311|OTHER|Manual therapy and therapeutic exercise|"1. Gliding over the deltoid superficial fascia.~2. Anterior-Posterior mobilization of the clavicle.~3. myofascial release of the shoulder joint complex techniques.~4. Myofascial release external rotation with glenohumeral decoaptation will be carry out in prone position facility the triangular space, quadrangular space and triceps hiatus.~5. anterior and posterior, superior and inferior glenohumeral inferior glide mobilization in adduction will perform in a prone position to facilitate glenohumeral re centration.~6. scapular musculature myofascial release including mobilization with a scapulothoracic joint decoaptation, and angular of the scapula.~7. Supine mobilization of the posterior capsule in 90º shoulder flexion and the adduction.~Finally the patient will be instructed to adapt the daily active biological stimulus at home to maximize the benefits of the manual therapy"
41492379|NCT06064019|DEVICE|Nevisense|The Nevisense system is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Since skin tissues have different electrical properties depending on cell structure and medical conditions, the resulting electrical impedance spectra will reflect the properties of the skin tissue.
40831723|NCT04671082|DRUG|Tolperisone Hydrochloride|TID
40831724|NCT04671082|DRUG|Placebo|TID
41158640|NCT01747837|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
41350515|NCT00731666|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
41350516|NCT05614700|RADIATION|Brachytherapy|High Dose-Rate Brachytherapy
41350517|NCT05614700|RADIATION|Sterotactic Body Radiotherapy|Hypofractionated External Beam Radiotherapy
41158641|NCT02312622|DRUG|Pegylated Irinotecan|Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)
41158642|NCT05249309|DRUG|Ketamine|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
40831725|NCT01289223|DRUG|Bendamustine IV|
40831726|NCT01289223|OTHER|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
40831727|NCT02576665|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-fluorocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
40831728|NCT02576665|DRUG|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
40831729|NCT06256354|OTHER|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An upper- or lower-body forced-air cover will be positioned over an appropriate non-operative site but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further. The target nasopharyngeal temperature is 35.5°C.
40831730|NCT06256354|OTHER|Target temperature management|"Pre-warming is performed with a full-body forced-air cover and electrically heated blanket for about 30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to about 43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be warmed during surgery using two forced-air covers or combining forced-air covers with electric heating blanket when clinically practical. All intravenous fluids will be warmed to body temperature. There is no need to control ambient temperature since ambient temperature has little effect on core temperature in patients warmed with forced air. The target nasopharyngeal temperature is 36.8℃."
41158643|NCT05979402|OTHER|Training group Face-to-face pressure ulcer training|Face-to-face presure ulcer training
41158644|NCT05979402|OTHER|Control group|No intervention
41158645|NCT04482647|OTHER|Media Intervention|View instructional video
41158646|NCT04482647|PROCEDURE|Meditation Therapy|Perform meditation
41350518|NCT00366444|DRUG|diclofenac potassium (XP21L)|25 mg every 6 hours
41350519|NCT00366444|DRUG|Placebo|Placebo every 6 hours
41350520|NCT05790915|COMBINATION_PRODUCT|Standardized interventions|Standardized interventions according organ dysfunction
41492380|NCT05916261|BIOLOGICAL|Personalized neoantigen tumor vaccine|neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
41158647|NCT04482647|OTHER|Quality-of-Life Assessment|Ancillary studies
41158648|NCT04482647|OTHER|Questionnaire Administration|Ancillary studies
41158649|NCT04482647|PROCEDURE|Yoga|Perform breathing techniques
41158650|NCT01052870|DRUG|Finasteride|Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
41350521|NCT00002024|DRUG|Ganciclovir|
41350522|NCT05757466|DRUG|Prolgolimab|Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles
41350523|NCT05757466|DRUG|Combination with prolgolimab and bendamustine|Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;
41350524|NCT04337528|OTHER|Osteopathic manipulation type thrust|The osteopathic manipulation type thrust is applied to solve the sacroiliac joint dysfunction. This technique applies a high velocity and intensity push in a specified direction to correct the dysfunction produced by a not correct position or movement of one joint.
41492381|NCT04525235|COMBINATION_PRODUCT|phenotyping cocktail|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
41492382|NCT04525235|DRUG|rifampicin|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
41492383|NCT03720327|BEHAVIORAL|Get FIT|The Get FIT arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; and one 45 minute behavioral counseling session to set personal goals and provide education by a health coach.
41492384|NCT03720327|BEHAVIORAL|Get FIT+|The Get FIT+ arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; one 45 minute behavioral counseling session to set personal goals and provide education by a health coach; and personalized text messaging for 3 months by a health coach. The health coach will have access to these participants' daily food and activity data through the smartphone application, and will monitor progress and send push-only text messages to participants in this group based on the participant's goals and progress in the areas of physical activity, nutrition, and weight loss.
41350525|NCT04337528|OTHER|Osteopathic manipulation type muscle-energy|The muscle-energy manipulation is applied to solve the sacroiliac joint dysfunction. This technique applies a movement with an intermittent resistance in a specified direction to correct the position or movement of one joint. The therapist applies the movement in the correct direction since he feels a limitation of movement. When he feels the limitation he requests to the participant pushing in the contrary direction without movement. After five or seven seconds the participant finishes the contraction and the therapist continues the correct movement since he feels once again the limitation, and he request to the participant contraction another five or seven seconds. The therapist request to the participant only three times, when he finish the three contraction and the therapy applies the last movement to correct direction the intervention finishes.
41492385|NCT04968665|DIAGNOSTIC_TEST|gait testing, functional MRI|diagnostic tests including the gait testing and functional MRI
41492386|NCT02445976|DRUG|Seviteronel: given orally once daily in 28-day cycles|Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
41492387|NCT04778553|DIAGNOSTIC_TEST|iMOST X-1 Hematology Analyzer|The X-1 is a point of care automated hematology analyzer
41492388|NCT03257514|DRUG|alpha lipoic acid drug (thioctic acid acid)|Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.
40831731|NCT04336371|DIAGNOSTIC_TEST|Self-administered questionnaires|Self-administered questionnaires by the patient will be given during visits in the following order:the self-administered questionnaires concerning the announcement consultation will be completed by the patient after consultation waiting room; self-questionnaires will be given in just before the operation waiting room (D0) just before the suture removal points (J10) and just before the follow-up visit (M3).
40831732|NCT05182580|DIAGNOSTIC_TEST|Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema|If patients receive a negative result they do not see the retina specialist
40831733|NCT03422692|BIOLOGICAL|BioXclude amnion-chorion membrane|BioXclude will be used for the prevention of alveolar ridge resorption via socket bone graft and amnion-chorion membrane closure
40831734|NCT03422692|BIOLOGICAL|Mem-Lok collagenous membrane|Mem-Lok will be used for the prevention of alveolar ridge resorption via socket bone graft and collagenous membrane closure
40831735|NCT02876328|BIOLOGICAL|Ad26.ZEBOV|0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
40831736|NCT02876328|BIOLOGICAL|MVA-BN-Filo|0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
40831737|NCT02876328|BIOLOGICAL|rVSVΔG-ZEBOV-GP|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
40831738|NCT02876328|BIOLOGICAL|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
40831739|NCT02876328|BIOLOGICAL|rVSV boost|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
40831740|NCT01442792|DRUG|UFH|Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
40831741|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg single dose Rivaroxaban (per os)
40831742|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg single dose Rivaroxaban (per os)
40831743|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939) and UFH|10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
40831744|NCT05778773|PROCEDURE|TAVR (Transcatheter Aortic Valve Replacement)|Percutaneous aortic valve replacement, also known as percutaneous aortic valve implantation, transcatheter aortic valve implantation or transcatheter aortic valve replacement, is the replacement of the aortic valve of the heart through the blood vessels.
40831745|NCT05778773|PROCEDURE|AVR (Aortic Valve Replacement)|Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve through an open-heart surgery.
40831746|NCT00873535|DRUG|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
41158651|NCT06140576|DRUG|Sindilimab|Sindilimab, 200mg, Intravenous，every three weeks
41158652|NCT06140576|DRUG|Nab-paclitaxel|Nab-paclitaxel，125mg/m\^2, d1,8, every three weeks
41158653|NCT06140576|DRUG|Lenvatinib|Lenvatinib 8mg, 12mg, 16mg everyday
41158654|NCT05979818|DRUG|Propranolol hydrochloride|10 mg, PO, BID, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
41158655|NCT05979818|DRUG|Sintilimab|intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
41158656|NCT05979818|DRUG|Chemotherapy|"Platinum-based chemotherapy:~For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1-3, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4-6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent."
41158657|NCT01994135|OTHER|Reference food|Reference food will be used to which test food samples will be compared to.
41158658|NCT01994135|OTHER|Test food dose 1|Will contain low dose of a mixture of polyphenols in addition to the reference food
41158659|NCT01994135|OTHER|Test food dose 2|Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
41158660|NCT02014415|PROCEDURE|Liver Biopsy (Biopsy Group Only)|A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
41158661|NCT06274892|OTHER|Remote monitoring PROs|Attendance at RT review appointments triaged based on remotely monitored PROs
41158662|NCT01366144|DRUG|Carboplatin|Given IV
41158663|NCT01366144|OTHER|Laboratory Biomarker Analysis|Correlative studies
41158664|NCT01366144|DRUG|Paclitaxel|Given IV
41158665|NCT01366144|OTHER|Pharmacological Study|Correlative studies
41158666|NCT01366144|DRUG|Veliparib|Given PO
41158667|NCT06258447|DEVICE|Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system|the ABM MNC is obtained from the study patient via bone marrow aspiration in the hip and processed and delivered using the CardiAMP cell therapy system during the cardiac catheterization.
41158668|NCT06146088|BIOLOGICAL|EV71 Vaccine|Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30
41158669|NCT05820087|DEVICE|HistoSonics Edison System|Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
41158670|NCT02062281|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
41158671|NCT02062281|BIOLOGICAL|trivalent influenza vaccine|Single 0.5ml trivalent influenza vaccine was administered IM
41158672|NCT02062281|BIOLOGICAL|23vPPV+TIV|Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
41158673|NCT06555432|DRUG|LIVTENCITY|LIVTENCITY tablet.
41158674|NCT03709316|DRUG|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
41158675|NCT03709316|DRUG|Placebo Comparator|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
41158676|NCT01287416|BEHAVIORAL|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
41158677|NCT01287416|BEHAVIORAL|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
41158678|NCT03964038|DRUG|gilteritinib|oral
41158679|NCT03964038|DRUG|gilteritinib mini tablet|oral
41158680|NCT03657537|DRUG|Ketone infusion|β-hydroxybutyrate is infused intravenously.
41158681|NCT03657537|DRUG|Saline infusion|saline is infused intravenously.
41158682|NCT06269393|DRUG|Placebo|Placebo group: 10 mg/kg of placebo on Day 1, followed by 20 mg/kg, q3W of placebo for the following 3 infusions.10 mg/kg of IBI311 at Week 12, followed by 20 mg/kg, q3W of IBI311 for the remaining 3 infusions.
41158683|NCT06269393|DRUG|IBI311|IBI311 group: 10 mg/kg of IBI311 on Day 1, followed by 20 mg/kg, q3W of IBI311 for the remaining 7 infusions; .
41350526|NCT04337528|OTHER|Placebo technique|The therapist simulates a false technique. The therapist applies movement in the sacroiliac joint without dysfunction, he applies movement since ninety degrees of pelvic flexion, and he wait sixty seconds. Whit this placebo technique the sacroiliac joint with the dysfunction is not altered.
41350527|NCT00740194|DRUG|Aromatase inhibition|Letrozole
41350528|NCT00740194|DRUG|Estradiol|Dermestril
41350529|NCT03180294|DRUG|Bupropion 150 mg XL|By mouth
41158684|NCT01939821|BEHAVIORAL|Educational and counselling program|"Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice."
41158685|NCT01939821|BEHAVIORAL|Educational program|"Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals."
41158686|NCT06285058|DIAGNOSTIC_TEST|No interventions|The high-throughput extraction of large amounts of quantitative image features from medical images
41158687|NCT01706393|DIETARY_SUPPLEMENT|probiotics (six probiotic cultures)|Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
41158688|NCT01706393|DIETARY_SUPPLEMENT|Placebo|Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
41158689|NCT00543634|DRUG|Premarin/MPA|0.625 mg/2.5 mg X4
41158690|NCT00543634|DRUG|Premarin/MPA|0.625 mg/5 mg X 2
41158691|NCT00543634|DRUG|Provera 10 mg|2.5 mg of MPA, 4 tablets dissoved in water
41158692|NCT02281214|OTHER|blood sample, biopsy|Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
41158693|NCT06170983|DRUG|Azithromycin|500 mg once daily for 3 days
41158694|NCT06170983|DIAGNOSTIC_TEST|Biopsy|Skin punch biopsy
41158695|NCT06170983|OTHER|Skin inflammation model|LPS- or imiquimod induced skin inflammation
41158696|NCT00162058|DRUG|Peflutren Lipid Microsphere Injectable Suspension|
41158697|NCT06544642|DRUG|ASP5502|Oral
41158698|NCT06544642|DRUG|Placebo|Oral
41158699|NCT02581137|OTHER|Laboratory Biomarker Analysis|Correlative studies
41158700|NCT02581137|DRUG|Metformin Hydrochloride|Given PO
41158701|NCT06108687|OTHER|water spray application|cold water kept in the refrigerator at +4 degrees
41158702|NCT01675050|DRUG|Cyproheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
41158703|NCT01675050|DRUG|sugar pill|4 weeks of cyproheptadine or placebo with crossover to the other
41158704|NCT03451526|PROCEDURE|Surgeries|Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
41158705|NCT03828877|OTHER|Group A ( Group Acupuncture)|Group A; Acupunctur will be done with Pres Needle (0.22x1.5 mm).Acupuncture will be done points fo SP 6, LI 4 , ST 36 , LİV 3, LU 9 ,LU 7.
41158706|NCT02540343|OTHER|questionnaires|fill out all questionnaires twice
41158707|NCT05216952|DRUG|Ulipristal Acetate Tablets|90mg (three 30mg tablets) administered orally once
41158708|NCT05216952|DRUG|Misoprostol Pill|800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate
41158709|NCT03979235|DIAGNOSTIC_TEST|Motor function assessment|perform motor function assessment by using scales, sEMG, and inertia sensors
41350530|NCT03180294|DRUG|Placebo|By mouth
41350531|NCT02465541|PROCEDURE|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
41158710|NCT04238559|OTHER|Self-report questionnaire|Fill in the SWAMECO questionnaire
41158711|NCT03743987|PROCEDURE|control group|a procedure used to prevent or resolves apical periodontitis.
41158712|NCT03743987|PROCEDURE|MTA group|a procedure used to prevent or resolves apical periodontitis.
41158713|NCT03743987|PROCEDURE|PRF group|a procedure that is used for wound healing
41158714|NCT03743987|PROCEDURE|MTA + PRF group|a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
41350532|NCT02465541|OTHER|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
41350533|NCT02465541|OTHER|educational intervention|Undergo enhanced usual care
41350534|NCT02465541|OTHER|quality-of-life assessment|Ancillary studies
41350535|NCT02465541|OTHER|questionnaire administration|Ancillary studies
41350536|NCT02809846|DEVICE|Quell|
41350537|NCT02809846|DEVICE|Sham Quell|
41158715|NCT05087667|DEVICE|Implantation of Ortholoop cerclage|implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention
41158716|NCT05087667|DEVICE|Implantation of Cerclage used in current practice|implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention
41158717|NCT02544113|DRUG|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
41158718|NCT02544113|DRUG|Placebo|Normal transplant immunosuppression
41158719|NCT04284774|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41158720|NCT04284774|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
41158721|NCT04284774|PROCEDURE|Computed Tomography|Undergo a CT scan
41158722|NCT04284774|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41158723|NCT04284774|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
41158724|NCT04284774|PROCEDURE|Radionuclide Imaging|Undergo a MIBG scintigraphy scan
41158725|NCT04284774|DRUG|Tipifarnib|Given PO or via nasogastric or gastric tube
41492389|NCT03257514|DRUG|Placebo Oral Tablet|placebo oral drug have the same shape of thiotacid tablet
41492390|NCT05209217|DRUG|Ketamine|Intranasal administration of their customary prescribed dose
40831747|NCT00873535|DRUG|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
40831748|NCT01998893|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
40831749|NCT00678535|DRUG|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m\^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
40831750|NCT00678535|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
40831751|NCT00678535|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
40831752|NCT05121025|DIAGNOSTIC_TEST|Analysis of gut microbiome and immune signatures|The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.
40831753|NCT00343863|DRUG|palonosetron hydrochloride|Given IV
40831754|NCT00343863|DRUG|cyclophosphamide|Given orally
40831755|NCT00343863|DRUG|dexamethasone|Given orally or IV
40831756|NCT00343863|DRUG|doxorubicin hydrochloride|Given IV
40831757|NCT00343863|PROCEDURE|quality-of-life assessment|Ancillary studies
40831758|NCT00343863|PROCEDURE|nausea and vomiting therapy|Given IV
40831759|NCT00343863|PROCEDURE|management of therapy complications|Given IV
40831760|NCT00343863|DRUG|ondansetron hydrochloride|Given IV
41020180|NCT05947539|BEHAVIORAL|"Kisoboka Mukwano (It is possible, my love!) Intervention"|The intervention consists of 5 bi-weekly sessions each lasting 60 to 90 minutes. It uses motivational interviewing, peer navigation, and behavioral economics to promote strategies for economic strengthening, reductions in male partner alcohol use, coping with relationship conflict and stress, changing norms that reduce intimate partner violence and support engagement in HIV care and antiretroviral therapy (ART) adherence among adolescent girls and young women living with HIV, and, thereby, enhances future sustained viral suppression and benefits of treatment as prevention.
40831761|NCT00343863|OTHER|survey administration|Ancillary studies
40831762|NCT02726191|BEHAVIORAL|Spatial Match Exercise|
40831763|NCT02726191|BEHAVIORAL|Temporal Sequence Reconstruction Exercise|
40831764|NCT02726191|BEHAVIORAL|Token Task Exercise|
40831765|NCT02726191|BEHAVIORAL|Story Recall Exercise|
40831766|NCT02726191|BEHAVIORAL|Sample-Match (Within Modality) Exercise|
40831767|NCT02726191|BEHAVIORAL|Pair-Match (Across-Modality) Exercise|
40831768|NCT02726191|BEHAVIORAL|Triad-FiguresExercise|
41158726|NCT05829278|PROCEDURE|Acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36(Zusanli ), KI3 (Taixi), and etc.
40831769|NCT02726191|BEHAVIORAL|Monster Garden Exercise|
40831770|NCT02726191|BEHAVIORAL|Memory Match Exercise|
40831771|NCT02726191|BEHAVIORAL|Memory Matrix Exercise|
40831772|NCT02726191|BEHAVIORAL|Familiar Faces Exercises|
40831773|NCT02726191|BEHAVIORAL|Lost in Migration Exercise|
40831774|NCT02726191|BEHAVIORAL|Playing Koi Exercise|
40831775|NCT04952038|BEHAVIORAL|sleep disorder|ALS patients with or without sleep disorder
40831776|NCT04275609|OTHER|AI generated report|After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.
40831777|NCT04275609|OTHER|physicians writing report|After the endoscopic procedure, the physicians writing the report in computer according the procedure.
40831778|NCT03612843|OTHER|Observational dry needle|No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
40831779|NCT04229212|DEVICE|hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)|In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System \[HAS\], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
40831780|NCT02838615|PROCEDURE|epidural steroid (dexamethasone) injection|spinal injections performed in epidural space to relieve chronic low back pain or leg pain
40831781|NCT01463111|DRUG|Lithium|Open label treatment per standard of care for bipolar disorder for six weeks.
40831782|NCT01463111|DRUG|Valproate|Open label treatment per standard of care for bipolar disorder for six weeks.
41020181|NCT05947539|BEHAVIORAL|Screening and Referral|Intimate partner violence screening, alcohol screening, and referral
40831783|NCT01463111|DRUG|Lamotrigine|Open label treatment per standard of care for bipolar disorder for six weeks.
41020182|NCT05446311|DRUG|Dinalbuphine sebacate|After giving the birth, subjects are intramuscularly injected with a single dose of 150 mg of dinalbuphine sebacate (DS). DS is a prodrug of nalbuphine. After injeciton, DS are released to blood stream and hydrolyzed immediately. The onset of action is 12 to 24 hours and the analgesic effect can last about 5 to 7 days.
41020183|NCT01061060|DRUG|Prostaglandin I2|oral
41020184|NCT01061060|DRUG|Placebo|oral
40831784|NCT03403985|DRUG|Calcium Hydroxide (Ca(OH)2)|Ca(OH)2 will be used in this group
40831785|NCT03403985|DRUG|Mineral Trioxide Aggregate|MTA will be used in this group
40831786|NCT00823212|DEVICE|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
40831787|NCT00823212|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS \[XIENCE V\] stent).
40831788|NCT00823212|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
40831789|NCT00823212|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
40831790|NCT04076345|DIAGNOSTIC_TEST|Prespesin assay on PATHFAST analyser|"Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence."
40831791|NCT03529097|DRUG|0.9% Sodium-chloride|2 liters of 0.9% NaCl IV fluids
40831792|NCT03529097|DRUG|Placebos|2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
40831793|NCT03529097|DRUG|Optalgin, Voltaren, Morphine|Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
40831794|NCT00241098|DRUG|valsartan|
41020185|NCT02268591|DEVICE|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
41350538|NCT02611934|PROCEDURE|Mild Therapeutic Hypothermia (MHT)|The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
41020186|NCT05102994|DIAGNOSTIC_TEST|mutation test|detect the tumor-related mutation in introcular fluid
41020187|NCT01306136|BEHAVIORAL|Prolonged Exposure|15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories
41020188|NCT01306136|BEHAVIORAL|Usual care|Per usual care, patients are referred to a mental health provider within the health care setting.
41020189|NCT05548075|DRUG|Psilocybin|Up to 25mg of Psilocybin on 2 occasions.
41020190|NCT05548075|BEHAVIORAL|Therapeutic support|Psychological and physical therapeutic support
41020191|NCT00145834|BEHAVIORAL|community based trial|
41020192|NCT03485287|DRUG|Midomafetamine|Three sessions of MDMA-assisted therapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
41020193|NCT03485287|BEHAVIORAL|Therapy|Non-directive therapy
41020194|NCT06533397|PROCEDURE|Sinus floor elevation (SFE)|Patients rinse with 0.2% chlorhexidine solution for one minute before surgery. Under local anesthesia, a mucoperiosteal flap is raised from a midcrestal incision and two relieving incisions. Lateral window osteotomies are carried out using diamond burs. The Schneiderian membrane is carefully elevated and the synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) (2-3 cm3) is packed in the defect with light force. The buccal flap is then mobilized to allow tension-free primary closure. The margins are stabilized with single interrupted sutures. Antibiotics (1 g amoxicillin-clavulanate twice a day for 5 days, or in case of side effects or known allergy to penicillin, 300 mg clindamycin 4 times a day for 4 days), anti-inflammatory drugs (50 mg diclofenac 3 times a day for 3 days), and chlorhexidine mouthwash (twice a day for 21 days from the first day after surgery) are prescribed. Suture removal takes place after 10 days.
41020195|NCT06533397|DIAGNOSTIC_TEST|preoperative cone beam computed tomography (CBCT)|A CBCT scan is performed before SFE surgery to evaluate the anatomy and pathologies of the maxillary sinus.
41350539|NCT02620631|DRUG|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
41020196|NCT06533397|DIAGNOSTIC_TEST|postoperative CBCT|A CBCT scan is performed following the 3- or 6-month-long healing period after SFE to evaluate the anatomy and healing of the augmented bone and the maxillary sinus.
40831795|NCT01609335|DRUG|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
41350540|NCT02620631|DRUG|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
41350541|NCT01606332|PROCEDURE|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
41350542|NCT01487863|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
41350543|NCT01487863|DRUG|abiraterone acetate|Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
41350544|NCT00065221|DRUG|Ginger|
41350545|NCT06257394|DRUG|Dasatinib(Sprycel) arm|"▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance~ 2. If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab~     * In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib."
41492391|NCT01378455|OTHER|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
41492392|NCT01378455|OTHER|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
41492393|NCT03596151|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
40831796|NCT01609335|DRUG|C-11 PiB|One time intravenous administration of 10-20 mCi
40831797|NCT04139278|OTHER|Observational|Observational retrospective study
40831798|NCT02559661|OTHER|Training on a virtual simulator in eye surgery|
40831799|NCT03912701|DIAGNOSTIC_TEST|Vitalpac early warning score (VIEWS)|The Vitalpac early warning score (ViEWS) is an early warning system aimed primarily at prediction of the first 24-hour mortality in emergency patients and has not been used to assess intensive care unit discharge.
40831800|NCT02181660|DRUG|Gilteritinib|oral
40831801|NCT03778320|DRUG|CTP-692|Single oral dose
40831802|NCT03778320|DRUG|D-Serine|Single oral dose
41492394|NCT04164914|DIETARY_SUPPLEMENT|Prebiotic|Soluble prebiotic fiber (resistant dextrin 14 g/d x 4 weeks)
41492395|NCT03533738|OTHER|Food sequence 1|Vegetables first then meat \& rice together
41492396|NCT03533738|OTHER|Food sequence 2|Meat first then vegetables \& rice together
40831803|NCT03622034|OTHER|posterior condylar offset measurement|the tangent to the medial tibial plateau is considered to be the proximal reference line. This is the line connecting the highest anterior and posterior points of the medial plateau. The second reference is the axis of the tibia, defined as a line through the middle of the shaft at 10 and 20 cm. The angle between these two lines is the tibial slope
40831804|NCT02876874|DRUG|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
40831805|NCT04042272|DIAGNOSTIC_TEST|S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)|S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
41492397|NCT03533738|OTHER|Food sequence 3|Vegetables first then meat followed by rice
41492398|NCT03533738|OTHER|Food sequence 4|Vegetables first followed by meat and rice together
40831806|NCT05744726|BIOLOGICAL|A-PRF|0.5 to 1g of Advance Platelet-Rich Fibrin (A-PRF) clot for each dental socket.
40831807|NCT05744726|COMBINATION_PRODUCT|Bone-wax|0.5 to 1g of Bone-wax for each dental socket
40831808|NCT03839836|OTHER|Backpack child's body weight|Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
40831809|NCT05260333|DEVICE|Butterfly iQ transperineal ultrasound exam|Transperineal ultrasound
40831810|NCT01690351|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
41020197|NCT06533397|DIAGNOSTIC_TEST|bone core biopsy|At the time of dental implant placement, the first step of the implant bed preparation is performed using a trephine drill to harvest a bone core biopsy sample from the augmented bone. The biopsy sample is harvested from the implant bed, this way the patient is spared of excess surgical burden as this bone would be removed even if no biopsy sample was harvested during dental implant placement. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.
41020198|NCT06533397|PROCEDURE|dental implant placement|Following the 3- or 6-month-long healing period following SFE, dental implants are placed non-submerged in the augmented bone under local anesthesia.
41350546|NCT06257394|DRUG|Non-Dasatinib(Sprycel) arm|"▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT~ 2. If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3‡ → Allogeneic HSCT~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab"
41350547|NCT02306148|OTHER|Foot and ankle strengthening|Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
41350548|NCT02117973|PROCEDURE|iAssist Technique using Persona system vs. the conventional technique using Persona system|
41350549|NCT04698954|BEHAVIORAL|Adherence Improving self-Management Strategy|The AIMS intervention is a conversation between a patient and a trained nurse, imbedded in the usual care. It consists of structured modules with visual materials, developed based on a sound understanding of the factors that drive non-adherence and potent behaviour change techniques to modify those. These modules aim to enhance patient knowledge, motivation, self-efficacy, and skills for self-managing their treatment. As part of the intervention, patients use electronic monitors to track their own behaviour, namely a medication and a physical activity monitor. Together with the nurse they examine these results to identify adherence problems and solutions and make a plan.
41350550|NCT04698954|OTHER|Treatment-as-usual|Participants in the control group will receive treatment as usual. They will visit the nurse in the out patient clinic each 3 or 6 months for 30 minutes.
41350551|NCT01950364|DRUG|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
41492399|NCT03533738|OTHER|Food sequence 5|Rice first followed by vegetables \& meat together
41492400|NCT02767830|BEHAVIORAL|Excercise and Nutrition Program|
41492401|NCT03203564|DRUG|Modufolin (arfolitixorin)|Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
41492402|NCT02045082|PROCEDURE|Corneal sampling|Slit lamp corneal sampling with a Swab
41492403|NCT00701961|DRUG|Mefloquine-artesunate|Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
41492404|NCT06244849|BIOLOGICAL|Blood samples|A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine
41492405|NCT06244849|BIOLOGICAL|Stool simple|A fresh stool sample will be collected and conserved at room temperature until shipment
40831811|NCT01690351|DRUG|PF-05089771|Capsules TS formulation- fasted
40831812|NCT01312649|BEHAVIORAL|Experimental psychology methods (computer tests)|
40831813|NCT03315169|OTHER|External dressing|Application of external dressing whilst perianal abscess cavity heals.
40831814|NCT03315169|OTHER|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity - standard treatment.
40831815|NCT00839865|DRUG|herb ointment|a kind of ointment made from herb
40831816|NCT03919513|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
40831817|NCT05394532|OTHER|Education|Common Education
40831818|NCT00378599|DRUG|Combination of (a) pegylated interferon alfa-2b and (b) rebetol|"1. Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks"
40831819|NCT03812185|DEVICE|Suctioning orogastric tube which is attached to TEE probe cover|Suctioning orogastric tube which is atttached to TEE probe cover.
40831820|NCT00913393|DRUG|FG-3019|3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
41492406|NCT06244849|BIOLOGICAL|Ileocolonic biopsies|An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed
41492407|NCT04645810|PROCEDURE|High-Dose-Rate Brachytherapy|High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion
41492408|NCT06219590|PROCEDURE|Acetylcholine Iontophoresis|Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
41492409|NCT06219590|PROCEDURE|Shame Acetylcholine Iontophoresis|Shame Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
41492410|NCT04418843|PROCEDURE|Standard Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
41492411|NCT04418843|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
40831821|NCT00913393|DRUG|FG-3019|10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
41350552|NCT01950364|DRUG|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
41350553|NCT04972890|BIOLOGICAL|stem cells|Using umbilical cord stem cells 15x10\^6 cells in 2 cc saline/NaCl 0,9% solution
41350554|NCT04972890|OTHER|placebo|using 2 cc saline/NaCl 0,9% solution
41350555|NCT02789800|BEHAVIORAL|DIMAC02|Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups(FMG) related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
41350556|NCT06015191|BEHAVIORAL|Remote Cardiac Rehabilitation|Participants will engage in a ramp-up period (weeks 0-2) where participants will attend 1-on-1 live, remote in-home exercise sessions (20-35 min./session, 3-days/wk.) delivered by a health coach via telehealth video conferencing. Participants will be provided a tablet computer and a small set of equipment. Following the ramp-up period, participants will be asked to attend live, in-home, group-based exercise sessions (weeks 3-12, 3-5 participants/group, 45-min, 3-days/wk. minimum). Sessions will be offered 4-days/wk. in the afternoons and early evenings allowing participants to select the most convenient 3 days per week to attend. Sessions will include a variety of dynamic aerobic and anaerobic (resistance) exercises with a target heart rate corresponding to 60-75% of VO2peak. In the group-based exercise sessions, participants will be able to see, hear, and verbally interact with the health coach and the other participants, allowing for supervision and encouraging social support.
41350557|NCT06015191|BEHAVIORAL|Active Control|Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.
41350558|NCT06100367|COMBINATION_PRODUCT|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
41350559|NCT04984070|DRUG|Oral Contraceptives, Combined|One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.
41350560|NCT04984070|DRUG|Metformin Pill|Metformin is used to lower insulin resistance or to modulate hyperinsulinism.
41350561|NCT04984070|OTHER|lifestyle intervention|Weight control including calorie restriction and moderate exercise will be recommended to obese PCOS patients
41350562|NCT02374944|PROCEDURE|Hardware removal|Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
41350563|NCT05469152|DIAGNOSTIC_TEST|ds-MCE and EGD|"Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD: The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
41350564|NCT00338806|BEHAVIORAL|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
41350565|NCT00338806|BEHAVIORAL|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
41350566|NCT06237361|OTHER|Pilates exercises|participants underwent a 12-week intervention involving three Pilates sessions per week. The Pilates exercises comprised warm-up activities, Pilates routines, and cool-down exercises.
41350567|NCT06237361|OTHER|traditional physical therapy program|The program included a variety of exercises such as range of motion exercises, aerobic exercises, resistance exercises, scar management, occupational therapy, and hand therapy.
41492412|NCT06230718|OTHER|Motor Imagery (MI)|mental process where an individual visualizes or imagines themselves performing a movement without actually executing it physically. This cognitive process involves the mental rehearsal of motor actions, engaging similar neural pathways that are used when physically performing the action.
41492413|NCT06230718|OTHER|Action Observation (AO)|rehabilitation technique based on the principle of observing actions to improve motor function and learning. This approach is rooted in the concept of the mirror neuron system, a group of neurons that are activated both when a person performs an action and when they observe the same action performed by others.
41492414|NCT06230718|OTHER|Control condition- placebo|Recording with images of landscapes without the presence of any person or animal that could evoke MI or OA.
41492415|NCT00006267|DRUG|rubitecan|
41492416|NCT00822796|DEVICE|Thermogard™|Those who have a Thermogard™ central venous warming catheter placed prior to surgery
41492417|NCT00822796|DEVICE|Standard central venous catheter|Those who have a standard central venous catheter placed prior to surgery
40831822|NCT00913393|DRUG|Placebo|Placebo IV every 2 weeks for 22 weeks
41020199|NCT06533397|PROCEDURE|fixed dental prosthesis (FDP) fabrication|3 months after dental implant placement, fixed dental prostheses are delivered on the dental implants.
41020200|NCT06533397|DEVICE|bone grafting|A synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) is used during SFE.
41492418|NCT01164345|DRUG|Plerixafor|Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
41492419|NCT01672112|DRUG|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
41350568|NCT00965744|DEVICE|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
41350569|NCT00134589|BEHAVIORAL|Academic Detailing (Medical Practices)+Decision Aids (Patients)|
41492420|NCT01672112|DRUG|Codeine|Oral Codeine 60mg 6hrly/prn
41492421|NCT05515692|PROCEDURE|Biospecimen Collection|Correlative studies
41492422|NCT05515692|PROCEDURE|Computed Tomography|Undergo radiotherapy simulation using CT
41492423|NCT05515692|COMBINATION_PRODUCT|Electron Beam Therapy|Undergo electron beam radiotherapy
41492424|NCT05515692|PROCEDURE|High Frequency Ultrasound Imaging|Undergo HFUS
40831823|NCT05302141|BEHAVIORAL|Wear 3D printing assistive device|"Wear 3D printing aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
40831824|NCT05302141|BEHAVIORAL|Wear universal cuff device|"Wear universal cuff aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
41492425|NCT05515692|OTHER|Questionnaire Administration|Ancillary studies
41492426|NCT05515692|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo radiotherapy simulation using clinical setup
40831825|NCT02456636|BEHAVIORAL|Fee-for-Service Model (FFS, In clinic individual visits)|To be performed by participant's doctor or other healthcare professional in their doctor's office.
40831826|NCT02456636|BEHAVIORAL|Patient Centered Medical Home (PCMH, In clinic group visits)|To be performed by a registered dietitian, a nurse or other healthcare professional in their local setting.
40831827|NCT02456636|BEHAVIORAL|Disease Management (DM, Phone group visits)|To be performed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling via telephone.
40831828|NCT04654871|DIETARY_SUPPLEMENT|Chondroitin Sulfate|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
41020201|NCT01532687|DRUG|Gemcitabine|Given IV
41020202|NCT01532687|DRUG|Gemcitabine Hydrochloride|Given IV
41020203|NCT01532687|OTHER|Laboratory Biomarker Analysis|Correlative studies
41020204|NCT01532687|DRUG|Pazopanib|Given PO
41020205|NCT01532687|DRUG|Pazopanib Hydrochloride|Given PO
41020206|NCT01532687|OTHER|Placebo Administration|Given PO
41350570|NCT05099718|PROCEDURE|palatal soft tissue harvesting|A 6x2mm palatal soft tissue graft will be harvested.
41350571|NCT05099718|DEVICE|Hyaluronic acid|application 3-times per day for 7 days
41350572|NCT05099718|OTHER|Saline solution (placebo)|application 3-times per day for 7 days
41350573|NCT02207738|DEVICE|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
41492427|NCT05515692|PROCEDURE|Skin Biopsy|Undergo biopsy
41492428|NCT02502773|DRUG|Hydroxethyl starch|
41492429|NCT00160641|BIOLOGICAL|Certolizumab Pegol|"Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
41492430|NCT04419792|OTHER|Assessment of physical performance variables|"Other:~Assessment of physical performance indices using the following outcome measures:~Cardiopulmonary fitness: YMCA submaximal bike test Upper Body: ACSM press up test, Dynamometry Lower body: Wall squat test, Countermovement jump test"
41492431|NCT01983917|BEHAVIORAL|Diabetes Mobile Application|
41492432|NCT03080753|DEVICE|Sphinkeeper|Intersphincteric implants in the anal sphincter
41492433|NCT00040053|DRUG|Ondansetron|
41350574|NCT02207738|DEVICE|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
40831829|NCT04654871|PROCEDURE|Resistance exercise training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
40831830|NCT04654871|PROCEDURE|Manual therapy / Joint Mobilization|Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization
40831831|NCT04654871|PROCEDURE|THE therapy|Interferential and Heating for 20 min
41158727|NCT06646627|DRUG|B7-H3CART|"Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg"
41158728|NCT06646809|DIETARY_SUPPLEMENT|Alpha-ketoglutarate|Alpha-ketoglutarate supplements
41158729|NCT06646809|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
41350575|NCT01007318|PROCEDURE|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
41350576|NCT01007318|PROCEDURE|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
41350577|NCT03083964|BEHAVIORAL|Usual Care|Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.
41492434|NCT02038465|DEVICE|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for patient
41492435|NCT02038465|DEVICE|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for healthy volunteers
41492436|NCT04285593|OTHER|Bulgarian squats|The intervention using Bulgarian squat exercises will consist in the application of the protocol described by Aguilera-Castells et al. The technique will be done with the footballer standing. The athlete with one foot in front and the other behind the body, arms crossed over her chest, and her upper body, will remain upright with a natural swing in the lower back during the entire exercise. The players will lower the body (eccentric phase) until the front knee flexes to 90º. Subsequently, they will return to the initial position with a full extension of the knee of the front leg (concentric phase), maintaining an erect trunk position. The front foot will be placed in a fixed position contacting the ground, and the rear foot will rest on a horizontal press bench.
41492437|NCT04953936|DIETARY_SUPPLEMENT|HMB-enriched Nutritional Supplements|The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.
41492438|NCT04953936|DIETARY_SUPPLEMENT|Placebo|Placebo (maltodextrin 65 g once daily) with the same package as the intervention.
41492439|NCT04953936|BEHAVIORAL|Caloric Restrition Diet|Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies
41492440|NCT03829696|DRUG|Mifeprex® (Mifepristone 200 mg)|Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
41492441|NCT03829696|DRUG|Misoprostol 800 mcg|Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
41492442|NCT03829696|DRUG|ella® (ulipristal acetate emergency contraception 30 mg)|Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.
41492443|NCT03829696|DIAGNOSTIC_TEST|AccuHome® Pregnancy OTC Test|Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
41492444|NCT02178280|OTHER|liver transplantation combined with neoadjuvant therapy|liver transplantation combined with neoadjuvant radiochemotherapy
41492445|NCT00311402|DRUG|Aggrenox capsule|extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
41492446|NCT00311402|OTHER|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
41492447|NCT03670693|DIAGNOSTIC_TEST|Muscle strength and fatigue assessment|Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
41492448|NCT03670693|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DEXA scan)|Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)
41492449|NCT03670693|DIAGNOSTIC_TEST|Supine cardiorespiratory fitness assessment|VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)
40831832|NCT01740544|OTHER|Cathodal tDCS|Cathodal tDCS applied over the right PPC
41158730|NCT06646809|OTHER|Standard care|Standard care
41158731|NCT06095518|DIAGNOSTIC_TEST|DIC markers and Thrombin Generation Parameters|Observation of DIC markers and thrombin generation parameters in patients with and without thrombotic and hemorrhagic complications
41350578|NCT03083964|BEHAVIORAL|Priming|The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
41350579|NCT02355860|BEHAVIORAL|assessment|assessment
41350580|NCT03042585|RADIATION|Total body irradiation|When radiation is given in a way to cover the whole body, it is called total body irradiation.
41350581|NCT00094640|DRUG|Intramuscular Olanzapine Depot|
41350582|NCT01641354|PROCEDURE|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
41350583|NCT04971759|DRUG|Levobupivacaine|Levobupivacaine 5%
41350584|NCT04971759|DRUG|Dexmedetomidine Hydrochloride|Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
41350585|NCT04971759|DRUG|Fentanyl|Levobupivacaine 5% + 1µg/kg fentanyl
41350586|NCT03648502|DIAGNOSTIC_TEST|Cognitive tests and hearing tests|Several cognitive and hearing (peripheral and (central) auditory process) tests
41350587|NCT00823186|DRUG|Phyxol(Paclitaxel)|"Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine"
41350588|NCT01665040|DEVICE|Neurostimulation device implantation|"Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.~Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan."
41350589|NCT06245395|DEVICE|Virtual Reality|Meta Quest 2 Headset
41350590|NCT00571051|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course in mindfulness training
41350591|NCT04377399|DRUG|Vitamin D|Patients will be randomised to receive either high dose vitamin D (40,000 IU weekly) or low dose vitamin D (5,000 IU weekly) for 24 weeks
41350592|NCT00118924|BIOLOGICAL|LGT(TP21)/DEN4|Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)
41350593|NCT00118924|BIOLOGICAL|Placebo|Placebo for LGT(TP21)/DEN4 vaccine
41350594|NCT04177186|OTHER|Strength training|Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention
41350595|NCT04177186|COMBINATION_PRODUCT|Strength training with botulinum toxin|Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
41350596|NCT03769857|DIETARY_SUPPLEMENT|NEM® + BIOCURC®|Dietary supplement combination for the support of joint health.
41350597|NCT03769857|DIETARY_SUPPLEMENT|Placebo|Placebo
41350598|NCT04507516|OTHER|Water-only Fasting|Water-only fasting for at least 10 days followed by 5 days of refeed.
41350599|NCT04926870|OTHER|picture archiving and communication system|PACS administration during teaching
41350600|NCT04926870|OTHER|traditional|Clinical experience administration during teaching without PACS
41350601|NCT00561301|DRUG|GemDOx|gemcitabine oxliplatin
41350602|NCT06019091|DEVICE|Compass Health TENS 3000, 3 mode Analog Unit|The TENS unit Compass Health TENS 3000, 3 mode Analog Unit will be configured based on randomization to 20 Hz, 50 Hz, or 100 Hz. Pulse width 200 microseconds, Normal (N) Mode. It will be used on the posterior tibial nerve via a patch that is supplied each day for 30 minutes of the day. These 30 minutes of intervention will occur at the participants most painful time of the day for their pain.
41350603|NCT03935893|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
41350604|NCT03935893|DRUG|Fludarabine + Cyclophosphamide combination|Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
41350605|NCT06077136|OTHER|whole body vibration|"3 sessions per week consisted of different types of exercises, all of which were performed while the child will be is under WBV using (Galileo® MED 25 TT, Germany; 2021 model) with the following parameters:~* WBV session duration: 10 minutes (rest periods can be incorporated (1-2 minutes maximum 3 times during the session)~* frequency: 12 Hz~* Amplitude: 2 (fixed)~* duration of each exercise: 2-3 minutes~* starting positions differ according to each exercise; upper limb weight-bearing and weight shift (from prone, prone on elbows, sitting, standing).~* upper limb active exercises using toys/ balls / wand. Involving throwing, catching, transfer between both hands (according to the abilities of each child).~* coordination exercises by asking the child to approximate the index finger of both hands together, perform finger-to-nose (eyes open and closed), and finger-to-therapist finger exercises."
41350606|NCT06077136|OTHER|standard physical therapy|all children will receive regular exercises according to their developmental abilities such as stretching, strengthening, facilitation, or inhibition as well as functional exercises. exercise sessions will be 3 times per week fo
41350607|NCT00684463|DRUG|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
41350608|NCT00912496|BIOLOGICAL|MF-59|Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
41350609|NCT00912496|BIOLOGICAL|A/Anhui/05|Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal \[0.01%(w/v)\] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
41350610|NCT00912496|DRUG|Placebo|Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
41350611|NCT01970735|BIOLOGICAL|Blood test|
41020207|NCT05403047|DRUG|Fumarate, Tenofovir Disoproxil|all participants receive the intervention
41020208|NCT04606238|OTHER|Decision Aid|Oncologists and patients will use the decision aid in the same situation (change of treatment needs to be discussed with the patient - either because of disease progression or treatment toxicity or other reasons (e.g. change of care setting).
41020209|NCT05690958|OTHER|Survey|Filling in a survey
41350612|NCT05267899|DRUG|WGI-0301|WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
41350613|NCT03371394|OTHER|no intervention|no intervention
41350614|NCT05161624|DIAGNOSTIC_TEST|Accuracy evaluation|The design of the diagnostic trial will include 160 cases of liver tumors with indications for microwave ablation after a multidisciplinary consultation with clinicians (Multiple Disciplinary Team, MDT), including primary liver cancer and metastatic liver tumors, and the tumor diameter is less than 3 cm. The test subjects consist of three groups: a. path planning model, b. junior ablation specialists, c. senior ablation specialists. The three groups will perform microwave ablation path planning on 160 selected cases of liver tumors. The attending professor of the clinical medical group of the department is responsible for scoring, evaluating whether the design of the plan is reasonable, and then comparing the scoring results by using statistical methods to evaluate the accuracy and effectiveness of the path planning model established in this study.
41350615|NCT06136910|DRUG|Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy|"1. Recombinant human adenovirus type 5 injection : 21 days is one treatment cycle, in principle, 4 cycles of administration, 1 injection on day 1 (d1) of each cycle; the number of injections is determined according to the patient's tolerance and the ease of operation of the injection site, no less than 2 times.~2. tirelizumab: 200mg intravenous, d1, Q21d, administered until disease progression or intolerable side effects occur~3. platinum-containing two-drug chemotherapy: adenocarcinoma, pemetrexed combined with carboplatin, 4-6 cycles, d2, Q21d; non-adenocarcinoma, paclitaxel/gemcitabine combined with carboplatin, 4-6 cycles, d2, Q21d."
41350616|NCT03318822|DEVICE|Q-Collar|An externally-worn medical device that applies mild jugular compression
41350617|NCT05656131|DRUG|Fluzoparib|Arms A will be treated with fluzoparib alone
41350618|NCT05656131|DRUG|Fluzoparib+Camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
41350619|NCT05008302|PROCEDURE|hand motor coordination in a sitting positin|Before each test, the patient was instructed on how the exercise should be done. The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
41350620|NCT01341925|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
41020210|NCT05520476|DEVICE|Neuroliten MVP system|The Neuroliten MVP system will be an App that gets uploaded to the patients iPhone from the App Store.
41158732|NCT02411214|OTHER|survey|questionnaire survey sent by regular mail for 3 groups
41350621|NCT01341925|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
41350622|NCT01341925|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
41350623|NCT06282302|OTHER|Group control|Group control The control session will consist of keeping the volunteer sitting in a calm, air-conditioned environment for 40 minutes.
41350624|NCT06282302|OTHER|Isometric Exercise|The intervention with isometric exercise for the lower limbs, the volunteers will start in a vertical position, with shoulders and hips in contact with the wall, feet parallel and shoulder-width apart and hands at the sides of the body. Then (second phase), the volunteers, maintaining contact with the wall, squatted and advanced their feet in the desired position until the knee joint angle reached the previously determined value. The third phase referred directly to the isometric effort of the isometric exercise session. For the isometric wall squat exercise session, volunteers will be asked to perform 4 repetitions of 2 minutes, with a 2-minute rest interval in a seated position for adequate rest between each repetition.
41350625|NCT06282302|OTHER|Aerobic Exercise|Volunteers will perform 50 minutes of horizontal exercise cycling (brand: pro-user), continuously and at moderate intensity (50% to 60% of HR reserve).
41350626|NCT00517725|DRUG|carvedilol|
41350627|NCT00517725|DRUG|bisoprolol|
41350628|NCT00517725|DRUG|Nebivolol|
40831833|NCT01740544|OTHER|Sham tDCS|Sham tDCS applied over the right PPC
40831834|NCT04835376|DEVICE|Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis|Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
40831835|NCT03340896|DRUG|Docetaxel|Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
40831836|NCT03340896|DRUG|Cisplatin|Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
41158733|NCT03398434|DRUG|MAA868|3 MAA868 doses, single administration, subcutaneous,
41350629|NCT00201058|BEHAVIORAL|Tailored Web-based Asthma Management|Web-based asthma management
41492450|NCT03670693|DIAGNOSTIC_TEST|fMRI Exercise assessment|Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.
41492451|NCT03670693|DIAGNOSTIC_TEST|Muscle deconditioning assessment|Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
41492452|NCT06213935|DRUG|Norepinephrine|after spinal anesthesia, norepinephrine will be injected intravenous as bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min to prevent post spinal hypotension
41492453|NCT06213935|DRUG|Midodrine|10 mg tablets of midodrine 1 hour before spinal anesthesia to prevent post spinal anesthesia hypotension
40831837|NCT03340896|DRUG|Fluorouracil|5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
41158734|NCT03398434|DRUG|Apixaban|Apixaban 5 mg b.i.d
41158735|NCT01189370|DRUG|sorafenib|"Dose Level:~1. 400mg twice daily, continuous.~2. 600mg twice daily, days 1-5 of each week.~3. 800mg twice daily, days 1-5 of each week."
41158736|NCT04466059|DIAGNOSTIC_TEST|Automated AI-Guided Diagnosis of Hematological Malignancies|In BELUGA, we want to investigate whether the automated analysis of blood (from peripheral blood and bone marrow aspirates) smears and flow-cytometry-based analyses can provide a benefit for diagnostic quality and, ultimately, patient care.
41350630|NCT00201058|BEHAVIORAL|Generic web-based asthma education|4 computer sessions over a period of 180 days
41350631|NCT03231592|OTHER|CSA Group|Already included in the arm descriptions.
41350632|NCT03231592|OTHER|Enhanced Usual Care Group|Already included in the arm descriptions.
41350633|NCT05813405|OTHER|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors
41492454|NCT05961865|DIAGNOSTIC_TEST|Markers of inflammation and fibrosis|"Will be analyzed the following inflammation markers:~Interleukin 6, N-terminal propeptide of type 1 procollagen (P1NP), chitinase-3-like protein 1 (YKL-40), tumor necrosis factor (TNF-alpha), GlycA, proprotein convertase subtilisin/kexin type 9 and omega-3 fatty acids."
40831838|NCT03340896|RADIATION|radiotherapy|Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
40831839|NCT00405379|DEVICE|Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty|new porous metal tibial component with potential to result in improved bone in-growth and implant integration with proximal tibia
40831840|NCT02570243|DRUG|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
40831841|NCT02570243|DRUG|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
41492455|NCT04822753|PROCEDURE|Platelet Rich Plasma injection to the lumbar facet joint|Using standard fluoroscopic view, place a needle at the target facet joint. Inject about 1ml of study injectate.
40831842|NCT00633230|DRUG|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
40831843|NCT00633230|OTHER|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
40831844|NCT01146288|DRUG|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
40831845|NCT01146288|DRUG|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
41492456|NCT02021370|DRUG|BAY85-3934|25mg Tablet
41492457|NCT02021370|DRUG|Placebo|Matching placebo tablet
41492458|NCT03777423|DEVICE|PEEK framework partial dentures|Polymer-based framework recently introduced made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
40831846|NCT03149952|OTHER|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
40831847|NCT01754194|PROCEDURE|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
40831848|NCT01754194|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
40831849|NCT00860015|DRUG|Alimta|"500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer."
40831850|NCT00860015|DRUG|Gemcitabine|"1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy."
41020211|NCT05278156|DRUG|CPL500036 - low dose|CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
41020212|NCT05278156|DRUG|CPL500036 - high dose|CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
40831851|NCT05920473|DEVICE|rTMS with Magstim Rapid 2 magnetic stimulation device|The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.
41350634|NCT04572724|DRUG|Sacubitril / Valsartan Oral Tablet|Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP\>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.
41350635|NCT04572724|DRUG|RAS Inhibitors|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP\>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
41350636|NCT03224832|PROCEDURE|Artery-first Approach|"Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.~* The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.~All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.~Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .~Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas."
41350637|NCT03224832|PROCEDURE|Standard Approach|In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
41350638|NCT05337735|DRUG|XmAb20717|Given by vein (IV)
40831852|NCT05920473|DEVICE|sham control with Magstim Rapid 2 magnetic stimulation device|In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.
40831853|NCT00741702|OTHER|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP \>=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP\>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP\>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP\>=13/80 mm Hg, increase verapamil to 240 mg/d
40831854|NCT00573807|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
40831855|NCT04292717|BEHAVIORAL|Gait training|All participants will receive training three times a week for 6 weeks (18 training sessions) at the University Hospital Balgrist, Spinal Cord Injury Centre. Each exercise session will last for 1 hour and will be conducted and supervised by an experienced physical therapist.
40831856|NCT06002984|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
41020213|NCT05278156|DRUG|Placebo|Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
41020214|NCT04380584|DIAGNOSTIC_TEST|plasma Apelin level|blood sample for detection of plasma Apelin level
41020215|NCT00672438|DRUG|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
41020216|NCT00672438|OTHER|Saline placebo infusion|Intravenous infusion of normal saline
41350639|NCT02005211|DRUG|AZD3293|Oral solution
41350640|NCT02005211|DRUG|Placebo|Oral solution
41350641|NCT01416506|OTHER|No Drug|It's a surveillance
41350642|NCT00002852|DRUG|paclitaxel|Given IV
41350643|NCT00002852|DRUG|carboplatin|Given IV
41350644|NCT00002852|PROCEDURE|therapeutic conventional surgery|Undergo surgery
41350645|NCT02603939|PROCEDURE|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
41350646|NCT04310592|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
41350647|NCT06142162|DIAGNOSTIC_TEST|flow cytometry|Determination of monocytes subpopulations (classical monocytes (CD14++CD16-, intermediate monocytes (CD14++CD16+ and non-classical monocytes (CD14+/-CD16++) in the blood of patients, evaluation of the HLA-DR expression on monocytes, evaluation of CD64 expression on neutrophils
41350648|NCT06142162|DIAGNOSTIC_TEST|ELISA|estimation of the TNF-α, LPS, IL-2, IL-4, IL-6, IL-8, IL-10 levels in the serum
41350649|NCT06142162|DIAGNOSTIC_TEST|RFLP|assessment of polymorphism TNF-α, LTA, IL-4, IL-6, IL-8, IL-10, TLR-2, TLR-4 genes with restriction fragment length polymorphism technique
41492459|NCT03777423|DEVICE|Cobalt- chromium framework partial dentures|It's a bio-compatible metal used in thin sections so less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and resistance to corrosion.Drawbacks of metal frameworks can include hypersensitivity, aesthetics because of metal metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production
41350650|NCT05143645|OTHER|Plasma vancoymcin measurements|
41350651|NCT02859480|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg tablet, q.d., for 30 months
41350652|NCT02859480|DRUG|Rosuvastatin 20mg|Rosuvastatin 5mg tablet, q.d., for 30 months
41350653|NCT00258596|DEVICE|sirolimus-eluting stent|
41492460|NCT04351048|PROCEDURE|Stepwise Excavation|"* stepwise excavation includes selective caries removal to soft dentine on pulpal wall in the first stage of the excavation and~* after six months, the second stage of intervention includes re-entring the cavities and wall selective removal to firm dentine on pulpal wall."
41350654|NCT01627379|DRUG|Cisplatin, 5-FU|"Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled."
41492461|NCT04351048|PROCEDURE|One Step Excavation|\*one step excavations is completed in the first stage via performing selective removal to soft dentine on pulpal wall of the cavities.
41350655|NCT01627379|DRUG|Panitumumab|"Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled."
41350656|NCT04387591|PROCEDURE|Fu's subcutaneous needling(FSN)|In this study, the doctor will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin of the middle of medial epicondyle and radial styloid process. Then the doctor will push forward the needle parallel to the skin surface (maintaining in the subcutaneous layer), towards the subject's medial epicondyle. The docotr will sway the needle 50 times in 30 seconds. After swaying the needle, the doctor will instruct the subject to do elbow flextion for 10 seconds resisting the doctor's opposite force, then the subject take a rest for 10 seconds. The above actions(elbow flexion and rest) are 3 repetitions. Then the subject do palmar flexion in the position of elbow flexion for 10 seconds resisting the doctor's opposite force, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the doctor will take out the needle to finish the treatment.
41492462|NCT04669847|OTHER|Trunk-oriented exercise program|The trunk-oriented exercise program was performed by a physiotherapist two days of the week for 8 weeks.Trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises.
41492463|NCT04669847|OTHER|Conventional exercise program|Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).
41492464|NCT05020613|PROCEDURE|Procedure: Early removal group|Participants assigned this arm will have their urethral catheters removed at 2 days after low anterior resection of the rectum
40831857|NCT06529848|OTHER|Exercise training|"The training sessions are consist of cycling and as follows: a 10 min warm-up at a light intensity, 20-35 min of cycling exercise in intervals at varying intensities from light (\~60% of max heart rate) to more intensive (80-90% of max heart rate) and ending with 5 min of warm-down at a light intensity. The training intensity will be progressive during the course of the intervention period. The cycling training sessions are supervised .~Home training is allowed up to once a week if participants are able to adhere to the prescribed intensity levels.~Training sessions are closely monitored to ensure effectiveness and safety. This includes heart rate monitoring, perceived exertion assessment."
40831858|NCT00913614|DRUG|Eplivanserin (SR46349)|Oral administration
40831859|NCT04292990|DRUG|Fentanyl|Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.
40831860|NCT04292990|DRUG|Morphine|Tablets taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: starting at 30 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
41350657|NCT04387591|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced bya device to stimulate the nerves for therapeuticpurposes. TENS, by definition, covers the completerange of transcutaneously applied currents usedfor nerve excitation although the term is often usedwith a more restrictive intent, namely to describe thekind of pulses produced by portable stimulators usedto treat pain. The unit is usually connected to theskin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied athigh frequency (\>50 Hz) with an intensity below motorcontraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction
41350658|NCT02439866|DRUG|placebo|gelatinous capsules filled with sugar as placebo
41350659|NCT02439866|DRUG|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
41350660|NCT02439866|DRUG|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
41350661|NCT05874947|DEVICE|linear measurement|Linear measurements from digital caliper ,CBCT and EOS generated digital dental models
41350662|NCT06145438|DRUG|Dienogest|Drug is administered orally at the same time every day
41350663|NCT06145438|DRUG|Depo Medroxyprogesterone acetate|Drug is injected intramuscularly on the buttock
41350664|NCT06145438|DRUG|Leuprolide (as Leuprolide Acetate)|Drug is injected intramuscularly on the buttock
40831861|NCT02156544|DRUG|CKD-519|
41158737|NCT06431646|BEHAVIORAL|A web-based education intervention developed for university students with PMS|The content of the web-based education program includes the definition, prevalence, importance, causes, symptoms, diagnosis, risk factors, management strategies and treatment options of PMS. The education emphasizes non-pharmacological strategies for managing PMS, including diet, exercise and body mass index (BMI), sleep hygiene, smoking cessation, stress management, as well as vitamin and mineral supplements, herbal therapy, acupuncture, acupressure and reflexology.
40831862|NCT02156544|DRUG|placebo|
41350665|NCT06145438|DRUG|Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)|Drug is administered orally at the same time every day
41350666|NCT03814057|DIAGNOSTIC_TEST|24 hour urine creatinine excretion|two age corrected calculations of creatinine height index were obtained
41350667|NCT01110928|DRUG|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
41350668|NCT02945852|DRUG|apatinib|apatinib 500mg/d until progressive Disease
41350669|NCT02458352|DEVICE|Ultra low dose non-contrast enhanced CT|Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure
41158738|NCT00226746|DRUG|Paclitaxel and gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions) Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
41350670|NCT02458352|DEVICE|Standard dose non-contrast enhanced CT|Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
41350671|NCT01832051|DRUG|89Zr-trastuzumab injection|
41350672|NCT03066492|OTHER|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
41350673|NCT03066492|OTHER|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
41350674|NCT04735211|PROCEDURE|Surgery|Pediatric Surgery with hospitalized
41350675|NCT02962102|DRUG|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
41350676|NCT02962102|DRUG|Calcitriol|Calcitriol 4mcg orally daily x 5
41350677|NCT02962102|DRUG|Placebos|Placebo (medium chain triglyceride oil) orally daily x 5
41350678|NCT04052594|DRUG|LY3475766 - IV|Administered IV
40831863|NCT00011011|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
40831864|NCT04946617|DRUG|undefined|Rinsing with mouthwashes
40831865|NCT03622320|OTHER|Blood sample|Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
40831866|NCT03927287|DIAGNOSTIC_TEST|Free PSA ratio test in patients after definitive treatment for localized prostate cancer|Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence.
40831867|NCT01011972|DRUG|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
41350679|NCT04052594|DRUG|LY3475766 - SC|Administered SC
41350680|NCT04052594|DRUG|Placebo - IV|Administered IV
41350681|NCT04052594|DRUG|Placebo - SC|Administered SC
41350682|NCT04733040|DRUG|MOR202|5 or 2 doses of MOR202 will be administered as an intravenous infusion
41350683|NCT00098865|DRUG|temozolomide|The lower 150/m2 Temozolomide dose was for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal raditation.
41492465|NCT05020613|PROCEDURE|Procedure: Late removal group|Participants assigned this arm will have their urethral catheters removed after 48.th hours after Low anterior resection of the rectum
41492466|NCT02149108|DRUG|Nintedanib (BIBF 1120)|
41492467|NCT02149108|DRUG|Placebo|
41492468|NCT02149108|DRUG|BSC|
41492469|NCT02149108|DRUG|BSC|
41492470|NCT05699486|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
41492471|NCT05699486|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
41492472|NCT01688570|DRUG|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
41492473|NCT01688570|DRUG|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
41492474|NCT01688570|DRUG|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
41492475|NCT05571735|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Pfizer-BioNTech COVID-19 vaccine, Messenger RNA (mRNA) based vaccine encoding the viral spike glycoprotein (S) Formulation: Frozen concentrate before dilution with 0.9% sodium chloride solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.3 mL per dose) (at least 3 weeks apart)
41492476|NCT05571735|BIOLOGICAL|AstraZeneca vaccine|AstraZeneca vaccine, a replication-deficient simian adenoviral vector expressing the spike (S) protein of SARS-CoV-2 Formulation: Aqueous solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.5 mL per dose) (at least 12 weeks apart)
41492477|NCT05571735|BIOLOGICAL|Janssen Ad26.COV2.S COVID-19 vaccine|"Janssen Ad26.COV2.S COVID-19 vaccine, recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.~Formulation: Suspension for injection Route of Administration: Intramuscular (IM) Dosing regimen single dose (0.5 mL)"
41492478|NCT01248689|OTHER|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
41350684|NCT00098865|DRUG|thalidomide|Calculated dose was rounded down to the nearest 50mg, or up to 50mg if calculated dose was less than 50mg. Patients increased the daily dose by 50mg (one capsule) on a weekly basis unitl either unacceptable toxicity or a maximum dose.
41350685|NCT03727386|OTHER|Coconut oil|Participants will receive 30 ml of virgin coconut oil to replace their normal oil intake for a period of 6 months.
41492479|NCT01248689|OTHER|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
41350686|NCT03727386|OTHER|Sunflower oil|Participants will receive 30 ml of sunflower oil to replace their normal oil intake for a period of 6 months.
41350687|NCT02292524|OTHER|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
41350688|NCT04003415|DEVICE|Investigational Device: Contactless heart rate and respiratory rate monitor|Participant will be seated next to the investigational device. The device is contactless, and will measure the patient's heart rate and respiratory rate through use of radio-waves.
41350689|NCT04003415|DIAGNOSTIC_TEST|Heart Rate (EKG) Monitor|Participant will undergo 3-lead EKG testing to measure heart rate during testing.
41492480|NCT01248689|OTHER|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
41492481|NCT04271553|OTHER|Video|In addition to standard workflow, participants will also receive the PFO bundle which consists of: 1) A cartoon video of about 6 minutes duration illustrating the events occurring during admission, anaesthesia and surgery and 2) Sets of activity sheets which have been tailored for different age groups. Families would be encouraged to complete activity sheets together.
41492482|NCT03576482|OTHER|Transport on foot|Patients go to operating room walking with their families and with their normal clothes
40831868|NCT02449018|DRUG|QBW251|QBW251 capsule(s) taken orally twice per day
40831869|NCT02449018|DRUG|Placebo|Matching placebo capsule(s) taken orally twice per day
41350690|NCT04003415|DIAGNOSTIC_TEST|Respiratory rate Monitor|Participant will have an elastic band around their chest for monitoring respiratory rate during testing.
41350691|NCT04003415|DIAGNOSTIC_TEST|Pulse Oximetry|Participants will wear a finger pulse oximeter during the testing for monitoring of heart rate, respiratory rate, and pulse oximetry.
41350692|NCT01998854|DEVICE|VizAblate System|The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
41350693|NCT00536354|OTHER|Postural Orientation|
41350694|NCT00866606|BIOLOGICAL|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
41350695|NCT05206682|DRUG|Leuprorelin|Leuprorelin will be used to postpone period after vaginal repair.
41492483|NCT05268263|DEVICE|Artificial Intelligence Algorithm|The enrolled population will include patients with a history of lung pathologies. Artificial intelligence-based models are developed for classification of wheezes, crackles and normal lung sounds. These AI models will be tested and assessed on local lung sounds clinical data.
41350696|NCT03719768|DRUG|Avelumab|Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
41350697|NCT03719768|RADIATION|Whole Brain Radiotherapy|Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks
41350698|NCT05231928|PROCEDURE|Argon Laser Iridoplasty|"Argon Laser is applied to the anterior iris surface at sites and with parameters tailored according to iris configuration, pupil size, iris colour.~The device used is Nidek Argon Laser device with YAG capsulotomy or Abraham Iridotomy lens as auxilliary lenses.~-Topical Pilocarpine 2% and ocular surface anesthetic are applied prior to the procedure and Brimonidine 0.2% bid is used fo a week after the procedure together with topical dexamethasone ophthalmic solution."
41350699|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 30 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
41350700|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 20 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 20 mL 0.25 % bupivacaine
41492484|NCT02901964|OTHER|Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
41492485|NCT02901964|OTHER|Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
41350701|NCT01188785|DRUG|siG12D LODER|"Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.~Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle."
41350702|NCT02444689|BEHAVIORAL|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
41350703|NCT02444689|BEHAVIORAL|Standard of care education|
41350704|NCT05937399|BEHAVIORAL|Intervention video|This intervention is an integrated health video provides individual (smoking) and environmental risk communication on intention to obtain lung cancer screening.
41350705|NCT05937399|BEHAVIORAL|Control video|This intervention is an integrated health video provides individual (smoking) risk communication on intention to obtain lung cancer screening.
41350706|NCT06360510|PROCEDURE|%5 dextrose injection|hydrodissection with %5 dextrose
41350707|NCT06360510|PROCEDURE|betamethasone injection|perineural betamethasone injection
41350708|NCT05835544|OTHER|Active Comparator: HIIT Control|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets.
41350709|NCT05835544|OTHER|Experimental: HIIT + BFR between cycling sets|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied for 2 minutes during the passive rest at 80% of limb occlusion pressure.
41350710|NCT05835544|OTHER|Experimental: HIIT + BFR moderate occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 50% of limb occlusion pressure and deflated during passive rest periods.
40831870|NCT06058455|BEHAVIORAL|IDEA3 Sexual Assault Resistance Intervention|Internet-delivered EAAA (IDEA3), adapted from an in-person sexual assault resistance education intervention: Enhanced Assess, Acknowledge, Act (EAAA) intervention that was found in a randomized trial to reduce sexual assault victimization by about 50% at follow-up. IDEA3 designed for female identifying university students and focuses on resisting sexual assault committed by males in 4, 3-hour units: 1-ASSESS builds ability to detect risk with male acquaintances and develop risk reduction strategies. 2-ACKNOWLEDGE explores overcoming emotional barriers preventing women from acknowledging risk and employing effective resistance strategies with males. 3-ACT shows effectiveness of resistance strategies and teaches verbal and physical self-defense in common situations. 4-RELATIONSHIPS \& SEXUALITY adapts the Our Whole Lives curriculum to increase women's comfort in talking about sex/sexuality and identify sexual values/desires.
41350711|NCT05835544|OTHER|Experimental: HIIT + BFR high occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 80% of limb occlusion pressure and deflated during passive rest periods.
41350712|NCT01943396|PROCEDURE|rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
41350713|NCT00405275|DRUG|Etanercept|etanercept, subcutaneous injection
41350714|NCT00405275|DRUG|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
41350715|NCT00405275|DRUG|Sulfasalazine|sulfasalazine, oral
41350716|NCT00405275|DRUG|Hydroxychloroquine|hydroxychloroquine, oral
41350717|NCT00405275|DRUG|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
41350718|NCT00405275|DRUG|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
41350719|NCT02839655|DEVICE|Da Vinci Xi|
41350720|NCT00000641|DRUG|Ciprofloxacin hydrochloride|
41350721|NCT00000641|DRUG|Ethambutol hydrochloride|
41350722|NCT00000641|DRUG|Amikacin sulfate|
41350723|NCT00000641|DRUG|Azithromycin|
41350724|NCT00000641|DRUG|Rifampin|
41350725|NCT00000641|DRUG|Clofazimine|
40831871|NCT06058455|BEHAVIORAL|Consent Workshop|Participant pairs assigned to the control arm will receive a 60-minute session consisting of a 60-min interactive, virtual consent workshop. The workshop will include information on a) what consent is, including the idea that consent is about bodily autonomy and applies to interactions beyond sex, b) how to give and ask for consent, and c) examples of what it looks like to ask for and give/not give consent. This presentation will be given by a well-trained Research Assistant.
40831872|NCT05782192|DRUG|SAL067|SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
40831873|NCT05782192|DRUG|Alogliptin|Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)
40831874|NCT05782192|DRUG|Placebo|placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
40831875|NCT05017129|BEHAVIORAL|Inmates Care|The single intervention is a computer-based learning program.
41492486|NCT04380766|PROCEDURE|Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer|Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
41492487|NCT04966273|DEVICE|Microcatheter|Only to be used if Biosensor Microcatheter does not perform accordingly
41492488|NCT01204450|DRUG|Temsirolimus|60-230mg/m2 weekly during each 28 day course, for up to 12 courses
41492489|NCT01204450|DRUG|Valproic Acid|All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
40831876|NCT00859339|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
40831877|NCT00859339|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
41350726|NCT00198510|DRUG|Vitrase|7.5 IU of Vitrase
41492490|NCT02894281|DEVICE|pupillary light reflex|measure with infra-red cameras
41492491|NCT00006083|DRUG|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
41492492|NCT00006083|OTHER|placebo|placebo injected subcutaneously daily
41492493|NCT03457467|DRUG|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity
41492494|NCT03457467|RADIATION|SBRT|according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment
40831878|NCT00859339|DRUG|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
40831879|NCT00859339|PROCEDURE|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
40831880|NCT01209663|OTHER|Postoperative Intermediate Care|Comparison of postoperative Intermediate Care versus Ward Care.
40831881|NCT02130986|OTHER|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
40831882|NCT02130986|OTHER|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (\<1 hour goal) provide clinicians the procalcitonin result.
41350727|NCT00198510|DRUG|Vitrase|55 IU of Vitrase
41350728|NCT00198510|DRUG|Vitrase|75 IU of Vitrase
41350729|NCT00298311|BEHAVIORAL|mci guidance peer support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
41492495|NCT05782959|BIOLOGICAL|BCD-245|BCD-245 is administered as prolonged intravenous infusions during each cycle
41492496|NCT06160700|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|MoCA is a method for evaluating cognition. This assessment will be conducted at baseline, month 3, and month 6.
41492497|NCT00057421|DRUG|prednisolone|
41492498|NCT01914068|OTHER|Supervised exercise in hospital|
41492499|NCT01724580|DRUG|Baricitinib|Administered orally
41492500|NCT03036254|DEVICE|HBOT intervention|"HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2"
41492501|NCT03036254|DEVICE|Sham intervention|"Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff."
41492502|NCT03183492|BIOLOGICAL|Havrix®|One challenge dose of Havrix® administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
41492503|NCT04021849|OTHER|Face-to-face Class|The principal investigator will dictate a course about Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University using PowerPoint Presentation
41492504|NCT04021849|OTHER|Asynchronous Virtual Class|Every student will have the access to a platform with an Asynchronous Virtual Class that will use the same PowerPoint Presentation of the intervention with an audio recorded by the principal investigator
40831883|NCT02130986|OTHER|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~\< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~\> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~\> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~1. Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~2. For outpatients, antibiotic duration based on level (\> 0.25-0.5 ug/L:3 days; \> 0.5-1.0 ug/L:5 days; \>1.0 ug/L:7 days). Physician follow-up is recommended."
40831884|NCT02130986|OTHER|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
40831885|NCT04194918|BEHAVIORAL|Computer-Assisted Smoking Cessation Intervention|Use the Flexiquit+ program
40831886|NCT04194918|OTHER|Text Message|Receive text messages
40831887|NCT04194918|OTHER|Handout|Receive handouts via email
40831888|NCT04194918|OTHER|Questionnaire Administration|Ancillary studies
40831889|NCT04194918|OTHER|Quality-of-Life Assessment|Ancillary studies
41350730|NCT06328608|DRUG|PRX-102 1 mg/kg every two weeks|Drug: PRX-102 1 mg/kg every two weeks
40831890|NCT04194918|OTHER|Survey Administration|Ancillary studies
40831891|NCT06055816|DRUG|Endostar and Envafolimab|Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
41158739|NCT04260984|PROCEDURE|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
41158740|NCT04260984|PROCEDURE|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
41158741|NCT01393314|DEVICE|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
41158742|NCT04392297|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells
41158743|NCT04392297|DIAGNOSTIC_TEST|CMV specific T-cells|CMV specific T-cells detected by flow cytometry
40831892|NCT03125811|OTHER|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
40831893|NCT03125811|DRUG|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
40831894|NCT03454867|DEVICE|Hemofiltration|
41158744|NCT04392297|DIAGNOSTIC_TEST|serum CMV IgM / IgG antibodies|serum CMV IgM / IgG antibodies detected by ELISA
40831895|NCT03454867|PROCEDURE|Standard acute ischemic stroke treatment|
41158745|NCT03371706|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
41158746|NCT03371706|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
41158747|NCT01381614|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
40831896|NCT00671372|DRUG|FOLFIRI regimen|Intravenous repeating dose
40831897|NCT00671372|DRUG|bevacizumab|Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
40831898|NCT00671372|DRUG|cetuximab|Intravenous repeating dose
40831899|NCT00671372|DRUG|dulanermin|Intravenous repeating dose
40831900|NCT00671372|DRUG|irinotecan|Intravenous repeating dose
40831901|NCT03671629|OTHER|Enhanced clinical pharmacist service|The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
40831902|NCT03289169|DRUG|MEDITOXIN®|20U of Meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
40831903|NCT04690192|BIOLOGICAL|CNCT19|2×10\^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion
40831904|NCT04690192|DRUG|Gemcitabine Injection|600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,
40831905|NCT04690192|DRUG|busulfan|105mg/m2, day -7 until -5,
41492505|NCT02767154|DEVICE|A colloid Dextran 40 solution for extracorporeal circulation|The oncotic pressure of the PrimECC solution is higher than that of a crystalloid Ringer-acetate/mannitol solution. It should maintain the plasma oncotic pressure during and after cardiopulmonary bypass (CPB). Subsequently, the leakage of fluids from the systemic circulation to the interstitial compartment during CPB can be reduced, and a higher plasma volume and a better fluid balance can be achieved.
41492506|NCT02767154|DEVICE|Ringer-Acetate and Mannitol|Currently clinic standard for priming the CPB circuit.
40831906|NCT04690192|DRUG|Melphalan Injection|60mg/m2, day -3, -2
40831907|NCT05764031|OTHER|Clinical pilates exercise|Clinical pilates is an exercise modality in which postural muscles are worked out with various body movements, and involves multi-muscle synergies that improve spinal stabilization, flexibility and endurance.
40831908|NCT05764031|OTHER|Aerobic exercise|Aerobic exercise (also known as endurance activities, cardio or cardio-respiratory exercise) is physical exercise of low to high intensity that depends primarily on the aerobic energy-generating process.
40831909|NCT00086502|DRUG|Comparator: Sitagliptin|Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
40831910|NCT00086502|DRUG|Comparator: Placebo|Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
40831911|NCT00086502|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
40831912|NCT00086502|DRUG|Metformin|"Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"
40831913|NCT03164083|BIOLOGICAL|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
40831914|NCT03164083|BIOLOGICAL|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
41158748|NCT06475235|DRUG|Pembrolizumab|Humanized immunoglobin G4 monoclonal antibody, 4 mL vials, via intravenous infusion (into the vein) per protocol.
40831915|NCT05828420|OTHER|White noise|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
41158749|NCT06475235|DRUG|Methotrexate|Anti-metabolite, 50 mL vials, via intravenous infusion per protocol.
41158750|NCT06475235|DRUG|Temozolomide|Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsules, taken orally per protocol.
41350731|NCT05165186|OTHER|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video.
41350732|NCT02663115|OTHER|Biopsy of the diaphragmatic muscle|
41492507|NCT04568473|OTHER|PRG Barrier Coat (By SHOFU Inc., Japan)|PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol
41492508|NCT04568473|OTHER|EMBRACE™ Varnish by (Pulpdent Corporation, USA)|5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.
41492509|NCT06116084|OTHER|Ericksonian Hypnosis|An Ericksonian hypnosis session given to patients during a scintigraphic or PET examination, in a conventional manner, i.e. the hypnotherapist (MERM) is close to the patient in the examination room at the time of the session and communicates with him/her without any special device dedicated to this purpose.
41492510|NCT06116084|OTHER|Hypnosis|A hypnosis session given to patients during a scintigraphic or PET examination, in a remote manner, i.e. the hypnotherapist (MERM) is in the control room at the time of the session and communicates with the patient via a microphone and the patient has headphones.
41492511|NCT01293838|DRUG|Cipralex®|"Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:~* 10 mg tablets: 28~* 20 mg tablets: 84~Total for 30 participants:~* 10 mg tablets: 840~* 20 mg tablets: 2520~Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:~\*20 mg tablets: 84~Total for continuation study for all participants (assuming a 60% response rate, N=18):~\*20 mg tablets: 1512"
41492512|NCT02303041|DRUG|Buparlisib|Administered orally at starting dose of 80 mg/day
41492513|NCT02303041|DRUG|Sonidegib|Administered orally at starting dose of 200 mg/day
41492514|NCT01560481|DRUG|Step A: metformin glycinate 620 mg single dose|metformin glycinate 620 mg single dose
41492515|NCT01560481|DRUG|Step A: metformin glycinate 1240 mg single dose|metformin glycinate 1240 mg single dose
41492516|NCT01560481|DRUG|Step A: metformin glycinate 2480 mg single dose|metformin glycinate 2480 mg single dose
41492517|NCT01560481|DRUG|Step A: metformin hydrochloride 1000 mg single dose|metformin Chlorhydrate 1000 mg single dose
41492518|NCT01560481|DRUG|Step A: metformin glycinate 1240 mg,food intake|metformin glycinate 1240 mg, intake of food
41492519|NCT01560481|DRUG|Step B: metformin glycinate 620 mg BID|metformin glycinate 620 mg BID, 8 days
41492520|NCT01560481|DRUG|Step B: metformin hydrochloride 500 mg BID|metformin Chlorhydrate 500 mg BID, 8 days
41158751|NCT06475235|DRUG|Rituximab|Anti-CD20 antibody, 10 or 50 mL single-use vials, via intravenous infusion per standard of care.
41158752|NCT05459688|DRUG|CIN-107|2 mg of CIN-107, once a day for 52 weeks
41492521|NCT05498675|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
41492522|NCT05498675|DRUG|ACEI/ARB|"There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan."
41158753|NCT04728217|DRUG|Efmoroctocog Alfa Injection [Eloctate]|Efmoroctocog alfa should be administered according to Summary of Product Characteristics (SmPC)/ Instruction on Medical Use approved by Russian Ministry of Health ЛП-006034 (13.01.2020).
41350733|NCT02663115|OTHER|Skeletal muscle biopsy|
41350734|NCT02404038|DRUG|Nur-Isterate|Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
41492523|NCT00429156|DEVICE|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
41492524|NCT00429156|DEVICE|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
41492525|NCT00718913|DRUG|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
41492526|NCT00718913|DRUG|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
41492527|NCT00718913|DRUG|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
40831916|NCT05828420|OTHER|Heart sound|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
41350735|NCT02404038|DEVICE|Nuvaring|Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
41350736|NCT02404038|DRUG|Triphasil|"Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert"
41350737|NCT01246921|DRUG|Fluticasone proprionate 0.05% cream|Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
41350738|NCT04214470|OTHER|No intervention|There is no intervention for this study
41350739|NCT05890755|OTHER|Mechanical pertubation|Acceleration or deacceleration of one treadmill gait belt.
41350740|NCT06295822|DRUG|Nuan-gong-ye|In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
41158754|NCT05153642|PROCEDURE|Microsurgical intervention|The EC-IC bypass distal to the occlusion will be prepared in patients with a failure to pass the lesion using microwire and subjects with a failure to reach the occlusion. Middle cerebral artery exploration and eventual embolectomy will be performed before the bypass. A transverse arteriotomy will be used in the M1 segment occlusion, while a longitudinal arteriotomy with optional subsequent lesion retrieval using a Fogarty catheter will be used in the upper or lower M2 trunk occlusions. Minimally invasive and rapid surgical embolectomy technique will be used in cases with atrial fibrillation as the suspected source of emboli. In cases with successful passage using a microwire or catheter, but with failure of thrombus retrieval, a calcified cerebral embolus can be an example of failure. In cases with suspected occlusion due to intracranial atherosclerosis, the superior temporal artery will be always dissected and EC-IC bypass was performed.
41350741|NCT06295822|OTHER|Placebo|The placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400.
41350742|NCT06053086|RADIATION|Treatment ETHOS radiotherapy|• Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin
41350743|NCT06053086|RADIATION|Conventional IMRT|• Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin
41350744|NCT04735432|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
40831917|NCT05828420|OTHER|Music|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
40831918|NCT01018095|DRUG|Metronidazole|2 gm single dose versus 7 day 500 mg BID dose
41350745|NCT04735432|BIOLOGICAL|efgartigimod IV|Intravenous infusion of efgartigimod
41350746|NCT04650685|DEVICE|The novel Salvadora persica toothbrush|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
41158755|NCT00413634|DRUG|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
41350747|NCT04650685|DEVICE|The Salvadora persica (miswak) chewing stick|The Salvadora persica chewing stick will be used twice daily without the application of toothpaste. The Salvadora persica chewing sticks need to be prepared prior to use. A five-finger grip technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
41350748|NCT04650685|DEVICE|Standard toothbrush and toothpaste (control)|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
41350749|NCT00392210|GENETIC|Voiding Trial|Post-void residual and uroflow study will be done twice
41350750|NCT02393365|OTHER|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
41350751|NCT02393365|PROCEDURE|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
40831919|NCT01776671|DRUG|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
41350752|NCT00784459|DRUG|abatacept|Treatment with abatacept, 10 mg/kg IV, for 5 doses.
41350753|NCT00784459|DRUG|Placebo|Treatment with Placebo, IV
41350754|NCT01495260|DRUG|N-acetylcysteine|N-acetylcysteine, 800-2400 mg daily for 2 months
41350755|NCT01495260|DRUG|lipoic acid|lipoic acid, 300-600 mg daily for 2 months
41350756|NCT01495260|DRUG|vitamin E|vitamin E, 150-300 mg daily for 2 months
41350757|NCT04809649|DRUG|SUBA-itraconazole|Participant will receive treatment with SUBA-itraconazole
40831920|NCT00535158|DRUG|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
40831921|NCT03994315|OTHER|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
40831922|NCT03994315|OTHER|Lacto-N-tetraose (LNT)|LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
40831923|NCT04348019|BEHAVIORAL|Fasting|Fasting was defined as no foods or caloric beverages.
41350758|NCT01022918|DRUG|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
41492528|NCT00718913|RADIATION|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
41158756|NCT00413634|DRUG|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
41158757|NCT02961777|OTHER|implementation of care pathway|implementation of a care pathway
41158758|NCT01325818|DRUG|pravastatin, rosuvastatin|"1. Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~2. Active Comparator Intervention: Drug: rosuvastatin 20mg/day"
41158759|NCT06645886|DRUG|KQB198|Oral KQB198
41158760|NCT06645886|DRUG|Dasatinib|Oral dasatinib
41158761|NCT02246634|OTHER|Diffusion Weighted MRI scan|Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.
41158762|NCT05923359|OTHER|Apple Watch|Apple Watch
41158763|NCT01475370|DRUG|OCV-501|"1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."
41158764|NCT05242913|DIETARY_SUPPLEMENT|Resistant Potato Starch|Unmodified potato starch containing \>60% resistant starch Type 2
41158765|NCT05242913|DIETARY_SUPPLEMENT|Placebo|Fully digestible corn starch
41158766|NCT03135821|DIAGNOSTIC_TEST|TCM|
41158767|NCT05740969|DRUG|5Fluorouracil|Cream
41158768|NCT05740969|DRUG|Imiquimod|Cream
41158769|NCT05740969|DRUG|Melatonin|Cream
41158770|NCT04155333|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
41158771|NCT00234221|BEHAVIORAL|Strengths Based Case Management|
41158772|NCT00234221|BEHAVIORAL|Motivational Enhancement Therapy|
41350759|NCT01022918|DRUG|Temodal/radiotherapy|
41350760|NCT02879864|DEVICE|light therapy|The light therapy, 6 month's program, is occurring at patient's home the day after device's reception and during at least 7 days before chemotherapy's beginning. The ambulatory light program is daily exposure to a high-intensity light (10,000 lux) in the morning, at a time adapted to the patient according to his chronotype for 30 minutes. The light source should be placed at eye level (distance of about 40 cm). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24, which will be completed the same day or the day before, and / or before any chemotherapy. These questionnaires will be also completed during the follow-up visit 1 month after the last visit (week 28).
41492529|NCT00718913|DRUG|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
41158773|NCT00234221|BEHAVIORAL|Brief Informational Feedback|
41492530|NCT03201250|DRUG|Cabozantinib|"Cabozantinib:~Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28~Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16~Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)"
41158774|NCT01370564|DRUG|Diuretics|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
41158775|NCT05143437|BEHAVIORAL|Love Together Parent Together|A brief, low-intensity writing intervention adapted for parents of young children, designed to reduce conflict-related distress, prevent relationship deterioration and encourage the use of conflict reappraisal strategies designed to reduce conflict-related distress, etc.
41158776|NCT03230071|DRUG|TMBCZG|0.1g per pill which contains 14mg TMBCZG
41158777|NCT03230071|OTHER|placebo|0.1g per pill which contains 0mg TMBCZG
41158778|NCT01536535|DRUG|Mesalazine|Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
41158779|NCT01536535|DRUG|IV Corticosteroid|Treatment with IV Corticosteroid
41158780|NCT01536535|DRUG|Oral Corticosteroids|Treatment with oral corticosteroids
41158781|NCT01536535|OTHER|Additional Therapies|Anti-TNFα, Calcineurin inhibitor, Immunomodulator
41158782|NCT01536535|PROCEDURE|Colectomy|Colectomy
41158783|NCT01949649|BEHAVIORAL|Peer-Led Group Intervention|
41158784|NCT01949649|BEHAVIORAL|Internet-Based Intervention|
41158785|NCT01949649|BEHAVIORAL|Clinician-Led Group Intervention|
41158786|NCT01949649|BEHAVIORAL|Education Video|
41350761|NCT02879864|DEVICE|Usual care|The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before. A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before.
41350762|NCT03923829|DRUG|Zinc Sulfate|systemic administration of Zinc sulfate with scaling and root planing
41350763|NCT03923829|PROCEDURE|scaling and root planing|scaling and root planing
40831924|NCT05226091|BEHAVIORAL|Letter|Selected GP practices currently registered with CPRD will receive correspondence by both email and mail informing them about the result of the PLEASANT study and advising them how to implement what has been learnt. Included in the mailing would be a suggested letter and SMS text.
40831925|NCT04926090|BEHAVIORAL|Emotional Support Plan - Clinician Guided (ESP-C)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-C is delivered by a clinician in 2 sessions.
41020217|NCT05279261|PROCEDURE|The axillary approach|The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
41350764|NCT01078779|DRUG|Chloroquine|Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
41350765|NCT01078779|DRUG|Placebo|Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
41350766|NCT04366739|DRUG|CHLORPROMAZINE (CPZ)|"Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.~Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).~Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.~Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum"
41350767|NCT04366739|COMBINATION_PRODUCT|Standard of Care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm"
41350768|NCT03336281|DRUG|Ustekinumab|All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
41350769|NCT02516306|DRUG|EV06 Ophthalmic Solution|
41350770|NCT02516306|DRUG|Placebo Ophthalmic Solution|
41350771|NCT05786976|OTHER|Lotion BNO 3732|Crem body lotion twice daily
41020218|NCT05584449|OTHER|Counseling|Attend online group facilitated by two oncology social workers
41020219|NCT05584449|PROCEDURE|Discussion|Discuss survivorship issues/concerns
41020220|NCT05584449|OTHER|Informational Intervention|Receive young adult cancer survivorship information
41020221|NCT05584449|OTHER|Medical Chart Review|Ancillary studies
41020222|NCT05584449|OTHER|Quality-of-Life Assessment|Ancillary studies
41020223|NCT05584449|OTHER|Questionnaire Administration|Ancillary studies
41350772|NCT05786976|OTHER|Body Lotion Benchmark product|Crem body lotion twice daily
41350773|NCT05565066|DEVICE|FNB group|Fine-needle-biopsy (Echotip ProCore Needle)
40831926|NCT04926090|BEHAVIORAL|Emotional Support Plan - Self Guided (ESP-S)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-S is created by the participant on their own, with the support of self-guided materials.
40831927|NCT03825250|DRUG|Sodium Valproate|Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control
40831928|NCT04090034|PROCEDURE|Peptide Receptor Radionuclide Therapy|a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs
41020224|NCT04762888|PROCEDURE|Computed Tomography|Undergo PET/CT
41350774|NCT05565066|DEVICE|FNA group|Fine-needle-aspiration (Echotip Needle)
41350775|NCT00928733|DEVICE|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
41492531|NCT04536532|DRUG|HEC121120 tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
41020225|NCT04762888|DRUG|Gallium Ga 68 Gozetotide|Given IV
41020226|NCT04762888|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
41020227|NCT04762888|PROCEDURE|Positron Emission Tomography|PET/MRI or PET/CT
41020228|NCT02416323|OTHER|AIM HI Training|
41020229|NCT04486378|DRUG|RO7198457 intravenous (IV)|RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
41020230|NCT04486378|OTHER|Observational group (no intervention)|watchful waiting
41158787|NCT04764877|OTHER|Osteopathic Manipulative Medicine|Provided 15-20 minute long OMT session for patients in the OMT arm
41158788|NCT03344913|BEHAVIORAL|Walking|walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
41492532|NCT04536532|DRUG|HEC121120 placebo tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
41492533|NCT04536532|DRUG|entecavir tablets|Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state
41492534|NCT04536532|DRUG|entecavir placebo tablets|Patients with chronic hepatitis B：Administered Entecavir placebo orally once daily for consecutive 28 days in fasted state
40831929|NCT05736003|PROCEDURE|Laparoscopic cholecystectomy|Removal of gallbladder laparoscopically
40831930|NCT05764668|DRUG|Zihua Wenfei Zhisou Granule|14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
41350776|NCT00646347|OTHER|Conventional upper limb stroke rehabilitation|"Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.~Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks."
41350777|NCT00646347|DEVICE|Neuro Hand Orthosis Program (NHOP)|"The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;~1. NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.~2. The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.~The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis."
41350778|NCT03333512|BEHAVIORAL|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
41350779|NCT06246864|OTHER|Hydrocolloid dressing|After the oral gastric tube is placed on the premature baby and fixed with a Hydrocolloid dressing, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
41350780|NCT06246864|OTHER|Hypoallergenic Flexible|After the oral gastric tube is placed on the premature baby and fixed with a hypoallergenic flexible patch, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
41350781|NCT04397757|BIOLOGICAL|COVID-19 Convalescent Plasma|2 units of COVID-19 convalescent plasma compatible with their blood type
41350782|NCT00643851|DRUG|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
41350783|NCT00643851|DRUG|Metformin XR|Tablets, Oral, Once daily, 24 weeks
41350784|NCT06125626|DIETARY_SUPPLEMENT|Probiotical|A daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03 will be given to this group
41350785|NCT06125626|OTHER|Placebo|A daily sachet of placebo will be given to this groups
41350786|NCT05192044|OTHER|Fast track Care pancreatico-duodenectomy.|Enhanced recovery after pancreatico-duodenectomy, with early oral intake, mobilization \& discharge
41350787|NCT05192044|OTHER|Conventional Care|Conventional Care
41350788|NCT03714256|DEVICE|Device, patient mobility, powered|Pediatric mobility device
41492535|NCT06316648|DIETARY_SUPPLEMENT|whey intake group|It was prepared at the bedside by the first investigator for the patients in the oral whey intervention group by mixing 54 grams of 70% demineralized whey powder taken from the herbalist into 600 ml of drinking water six hours before the surgery, and the patients were given 400 ml six hours before the surgery and 200 ml two hours before the surgery. They were given ml and allowed to drink.
41492536|NCT06316648|PROCEDURE|control group|The patients were left fasting after 00:00.
40831931|NCT05764668|DRUG|Placebo|14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
40831932|NCT02288013|PROCEDURE|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
40831933|NCT06216314|OTHER|Heart rate (HR)|Runners ran according to speeds and HR associated with ventilatory thresholds. Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold.
40831934|NCT06216314|OTHER|Race pace based approach (RP)|"Runners ran respecting three intensity zones.~The average speed achieved in the 7-km was calculated. From this, three intensity zones were calculated, adhering to the % of the race pace of the 7-km test.~Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace"
41158789|NCT05381077|OTHER|MRI|Whole body MRI (ZTE sequence)
41492537|NCT03663634|OTHER|Cytochalasin B use in ICSI handling medium|A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate
41492538|NCT06030219|DRUG|Omadacycline|10-day course
41492539|NCT06030219|DRUG|Vancomycin Pill|10-day course
41492540|NCT06030219|DRUG|Moxifloxacin|10-day course
41492541|NCT02953951|OTHER|blood transfusion|blood transfusion different sources
41492542|NCT05094492|COMBINATION_PRODUCT|Curodont Repair Fluoride Plus|P11-4 self assembling peptide combined with fluoride
41350789|NCT00561067|DRUG|Erythropoietin|EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
41350790|NCT00561067|DRUG|Methylprednisolone|MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
41350791|NCT02425891|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
41350792|NCT02425891|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
41350793|NCT02425891|DRUG|Placebo|Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
41492543|NCT05094492|OTHER|Bifluorid 10 fluoride varnish|5% Sodium Fluoride varnish (equal to 22,600 ppm fluoride)
41492544|NCT00004450|DRUG|glyceryl trierucate|
41492545|NCT00004450|DRUG|glyceryl trioleate|
41492546|NCT00004450|DRUG|interferon beta|
41492547|NCT00004450|DRUG|thalidomide|
41492548|NCT01682863|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
41492549|NCT01682863|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
40831935|NCT06216314|OTHER|Heart rate + heart rate variability (HRV)|Runners completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. High-intensity training was performed only under optimal HRV conditions, thus only when each participant had HRV values in their reference range. If HRV was not optimal, low-intensity training was prescribed. If HRV was not optimal for two days consecutively, rest was prescribed.
41158790|NCT05818995|DRUG|angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker|Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.
41158791|NCT05516836|OTHER|Multicomponent exercise program|"Each exercise session will have a duration of forty minutes in which the thirty minutes of intervallic work will be distributed as follows: twenty seconds until reaching 60% of their maximum load in the first seven sessions, adding five watts each day until reaching 80% of their maximum load in the fourteen sessions and seventy seconds of rest at 20% of their maximum load.~At the end of the sessions, strengthening exercises will be performed with elastic bands, adapting their resistance according to the characteristics of the patients, of the lower limbs and of the upper limbs. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed."
41350794|NCT00407251|DRUG|Patupilone|
41350795|NCT05178329|BEHAVIORAL|Lifting exercise|Patients are instructed for a light lifting exercise after mastectomy.
41350796|NCT05178329|BEHAVIORAL|Standard exercise|Standard exercise program after mastectomy
41492550|NCT01682863|DRUG|QAB149|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
41492551|NCT01682863|DRUG|Placebo|To mimic QAB149
41492552|NCT04732481|PROCEDURE|passive leg lift test|passive leg lift test
41492553|NCT04425135|DRUG|Camrelizumab|200mg,D1,ivgtt, Q3w.
41492554|NCT04425135|DRUG|Apatinib|250mg,Qd,Q3W.
40831936|NCT04312607|DIAGNOSTIC_TEST|BCR-ABL gene PCR|peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells
41492555|NCT04425135|DRUG|Pemetrixed|500 mg/m2,D1,ivgtt, Q3w.
41492556|NCT04425135|DRUG|Carboplatin|AUC=5\~6,D1,ivgtt, Q3w.
41492557|NCT03996148|DRUG|Remifentanil, Propofol, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC
41492558|NCT03996148|DRUG|Remifentanil, Dexmedetomidine, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
41492559|NCT03996148|DRUG|Remifentanil and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
41492560|NCT05117983|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Real-time MRI-guided neuronavigation with a Visor neuronavigation system (ANT Neuro, Enschede, Netherlands) will be used for coil positioning. Left dorsolateral prefrontal cortex target is located in each participant.
41492561|NCT00196625|DRUG|Amprenavir (drug)|
41492562|NCT00196625|DRUG|ABT-378/r (drug)|
41492563|NCT00196625|DRUG|Ritonavir (drug)|
41492564|NCT00119067|BIOLOGICAL|Anthrax Vaccine Adsorbed|
41492565|NCT00119067|BIOLOGICAL|Saline injection|
41492566|NCT01513382|PROCEDURE|Pilonidal sinus excision|The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
41492567|NCT05644015|OTHER|escape room game|Escape room game is a live action team based game where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal (usually by escaping the room) in limited time.
41492568|NCT02351583|DEVICE|CytoCam|The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
41492569|NCT02351583|DEVICE|NIRS Artinis PortaLite with OxySoft softwear|. The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
41492570|NCT01330771|DRUG|hMG-HP/r-FSH|
41492571|NCT06013410|DIAGNOSTIC_TEST|colonoscopy|colonoscopy
41492572|NCT01157806|RADIATION|short course of palliative radiotherapy|5x5 Gy + XELOX 7 days after radiotherapy
41492573|NCT00003916|RADIATION|radiation therapy|
41492574|NCT00003916|RADIATION|stereotactic radiosurgery|
41492575|NCT04714983|BIOLOGICAL|DNX-2440|DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.
41492576|NCT01561508|DRUG|gamma-amino-butyric acid|gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
41492577|NCT01561508|DIETARY_SUPPLEMENT|Xylitol|The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
41492578|NCT05739344|BEHAVIORAL|Cognitive behavioral approach based resilience development program for schizophrenic individuals|The intervention will be administered as sessions of 2 hours once a week.
41492579|NCT02538848|DRUG|HTD4010|injectable solution
41492580|NCT03282630|PROCEDURE|Sphenopalatine ganglion acupuncture|"* active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~* sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment."
41492581|NCT00506129|DRUG|Fludarabine|25 mg/m\^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
41492582|NCT00506129|DRUG|Melphalan|70 mg/m\^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
41492583|NCT00506129|PROCEDURE|Allogeneic Transplant|Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
41492584|NCT00506129|DRUG|Thymoglobulin|2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
41350797|NCT04528693|BEHAVIORAL|Circuit training (combination of strength and endurance exercises)|The intervention will last 3 months, exercises will take place 3 times a week and will consist of strength exercises, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software for a total of 30 minutes per session.
41492585|NCT01879748|DRUG|Rasagiline|"Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)"
41492586|NCT01879748|DRUG|Placebo|"Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)"
41492587|NCT00807248|DRUG|Escitalopram placebo|Once daily before bedtime for 8 weeks
41492588|NCT00807248|DRUG|Gaboxadol placebo|Once daily before bedtime for 8 weeks
41492589|NCT00807248|DRUG|Escitalopram 20 mg|Once daily before bedtime for 8 weeks
41492590|NCT00807248|DRUG|Gaboxadol 5 mg|Once daily before bedtime for 8 weeks
41492591|NCT00807248|DRUG|Gaboxadol 10 mg|Once daily before bedtime for 8 weeks
41492592|NCT03898518|OTHER|12-week jump rope exercise program|Each jump rope exercise session of the program was performed for 50 minute, with a 5 minute warm-up and cool-down. Sessions were performed once a day, 5 days a week, for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool-down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased form 40-50% heart rate reserve (HRR) in weeks 1-4 and 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Ever subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
41492593|NCT02563106|DRUG|SYN-004|
41492594|NCT02563106|DRUG|Placebo|
41492595|NCT04847349|DIETARY_SUPPLEMENT|OL-1, standard dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
41492596|NCT04847349|DIETARY_SUPPLEMENT|OL-1, high dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
41492597|NCT04847349|DIETARY_SUPPLEMENT|Placebo|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics.
41492598|NCT04721444|DIAGNOSTIC_TEST|Machine Learning Classification of parenchymal lung change cause|Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.
41492599|NCT04721444|DIAGNOSTIC_TEST|Machine Learning Classification of recurrence and non-recurrence|Arm C: Radiomics and deep-learning approaches will be used on patient's imaging to develop a risk-signature for recurrence of malignancy following radical treatment
41492600|NCT02328222|DRUG|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
40831937|NCT01653899|DRUG|IDN-6556|14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
41158792|NCT05516836|OTHER|Tele-health primary care rehabilitation program|A once a week telemedicine session will be carried out with the case group only before the face-to-face sessions, consisting of education, respiratory exercise, mobility and stretching, giving them a place to provide feedback and re-evaluate patients mid-treatment and will be aimed at assessing improvement and improving therapeutic adherence.
41350798|NCT02438670|DEVICE|PID control algorithm|
41492601|NCT05124197|OTHER|prone position|extension of prone position duration
41158793|NCT03740737|DRUG|Follitropin delta|"FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 12 µg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 µg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 µg, and the maximum daily dose was 24 µg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed."
41158794|NCT03740737|OTHER|Placebo|"Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed."
41350799|NCT02438670|DEVICE|MPC control algorithm|
41492602|NCT01616953|BIOLOGICAL|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
41492603|NCT01616953|PROCEDURE|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
40831938|NCT04026360|OTHER|no intervention|
41350800|NCT05071794|DRUG|Propofol|Antiemetic effect of propofol
41350801|NCT05071794|DRUG|saline 0.9%|Placebo
41350802|NCT00124696|DRUG|Cocaethylene|
41350803|NCT01562379|DIETARY_SUPPLEMENT|Wheat Soy Blend (WSB++)|A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.
41350804|NCT01562379|DIETARY_SUPPLEMENT|Chickpea based complementary food supplement|A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
41350805|NCT01562379|DIETARY_SUPPLEMENT|Rice based complementary food supplement|Locally developed rice based complementary food with and added vitamins and minerals.
41492604|NCT00150891|PROCEDURE|Kidney transplantation|
41492605|NCT00150891|DRUG|cyclosporine A|
41492606|NCT00150891|DRUG|tacrolimus|
41492607|NCT00150891|DRUG|azathioprine|
41492608|NCT00150891|DRUG|mycophenolate mofetil|
41492609|NCT05233930|PROCEDURE|TKR with augmented reality-based navigation system|Surgery
41020231|NCT06572176|BEHAVIORAL|With fluorescent concretization group|"Nurses were given the fluorescent lotion and asked to apply it all over their hands. The CE-certified test lotion is in gel form and is safety-approved. The lotion disperses particles the same size as bacteria on the skin. These particles settle on the skin, similar to the behavior of microorganisms, but disappear with hand washing under the influence of fluorescent light. They were then asked to wash their hands with 4 ml of soap. Two researchers marked the hand washing steps independently using the Hand Washing Skill Checklist. The duration of hand washing was recorded with a mobile stopwatch for each participant. Hand washing efficiency was evaluated using the Derma Litecheck device. UV rays were used after using the test lotion and drying the hands. Since any fluorescent material left on the hands would shine under UV light, it was possible to judge how well the hands were cleansed. The dirty spots were shown to the participants, and the reason for this was discussed."
41350806|NCT01562379|DIETARY_SUPPLEMENT|Plumpy Doz|Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
41350807|NCT06115512|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
41158795|NCT05816811|OTHER|Power-focused resistance training|Participants will undergo 10 weeks of power-focused resistance training.
41158796|NCT05382871|BIOLOGICAL|BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|intramuscular injection in the deltoid muscle
41158797|NCT05382871|BIOLOGICAL|WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|intramuscular injection in the deltoid muscle
41158798|NCT05382871|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
41158799|NCT01403805|BIOLOGICAL|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
41158800|NCT01403805|BIOLOGICAL|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
41158801|NCT01403805|BIOLOGICAL|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
41158802|NCT01403805|OTHER|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
41350808|NCT06115512|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
41350809|NCT04071639|DRUG|Haloperidol 2Mg Tab|Haloperidol take 0.5mg\~2mg three time a day.
41350810|NCT04071639|DRUG|Risperidone 1Mg Tab|Risperidone take 1mg once at night.
41350811|NCT04071639|DRUG|Zoloft 50Mg Tablet|Zoloft take 50mg once in the morning.
41350812|NCT04071639|DRUG|Idebenone|Idebebone take 30mg three times a day.
41350813|NCT04071639|DRUG|Deutetrabenazine Oral Tablet [Austedo]|The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.
41350814|NCT02691078|OTHER|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
41350815|NCT04155866|OTHER|Measurement of muscle activation.|Measurement of lower-limb muscle activation during walking for healthy participants.
41350816|NCT00504452|DRUG|KP-1461|Oral dosage, 1600 mg bid for 124 days
41020232|NCT02886572|RADIATION|Stereotactic radiosurgery|Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
41020233|NCT03176810|DEVICE|OCT|OCT is used to guide PCI.
41020234|NCT03176810|DEVICE|Angiography|Angiography is used to guide PCI.
41020235|NCT06280300|OTHER|health services intervention|Health services intervention
41020236|NCT02984995|DRUG|Quizartinib|Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
41020237|NCT01590823|DRUG|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
41020238|NCT00807781|BIOLOGICAL|Mammaglobin-A DNA vaccine|
41020239|NCT06268821|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
41158803|NCT00946998|DRUG|Sertraline|Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
41158804|NCT00946998|DRUG|placebo|Placebo tablet will be identical and matched to sertraline tablet.
41350817|NCT01880879|DEVICE|helios stent|the group with helios stent implanted
41350818|NCT05789940|PROCEDURE|hysteroscopy|The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.
41492610|NCT05233930|PROCEDURE|TKR with traditional mechanically aligned technique|As per local practice and standard guidelines.
41492611|NCT02264470|OTHER|Not relevant|Not relevant
40831939|NCT04268433|OTHER|N/A - Non-interventional study|"Stages:~1. Patient information and written informed consent (3 Copies. To be carried out \>24 hours after receiving the patient information sheet)~2. Physiological recording set up (ECG, BP, sensor and respiratory band)~3. Control period - no music played~4. Series of pieces of music without tempo control~5. Repeat series of pieces of music with tempo control~6. Participant leaves the study"
41158805|NCT00215631|DRUG|tadalafil|
41020240|NCT06108934|DEVICE|Hip stem prosthesis|The Insignia hip stem prosthesis will be used in cementless total hip replacement surgery (THA). The surgery typically takes approximately two hours. All study participants will receive the Insignia hip stem and compatible components. Experienced Orthopaedic Surgeons trained in THA will perform the surgeries as per the standard surgical technique guide for this prosthesis.
41158806|NCT02103816|DEVICE|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
41158807|NCT05211986|DRUG|IMM01-STEM|IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
41158808|NCT04649242|DRUG|Rimegepant/BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
41158809|NCT04649242|DRUG|Matching placebo|Matching 75 mg or 50 mg ODT placebo
41158810|NCT01615107|DEVICE|COOK RIPENENIG BALLOON+PITOCN|GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
41158811|NCT01615107|DRUG|PITOCIN|: Oxytocin infusion alone (Standard Protocol
41158812|NCT01615107|OTHER|double balloonand oxytocin|balloonand oxytocin
41158813|NCT01615107|OTHER|ballon and oxytocin|double- balloon catheter device with concurrent oxytocin
41158814|NCT01615107|PROCEDURE|double balloonand and oxytocin|balloon catheter device with concurrent oxytocin
41158815|NCT01379261|PROCEDURE|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
41158816|NCT06321900|DIAGNOSTIC_TEST|Personalized risk model|WE will test the hypothesis that interpretable artificial intelligence models including clinical, bio-humoral, genetic, electrocardiography, echocardiography, cardiac magnetic resonance, and nuclear imaging data will predict the risk of SCD in patients with left ventricular dysfunction more accurately than NYHA class and LVEF, and this will translate in a more cost-effective use of ICDs compared to current clinical practice.
41158817|NCT01048983|DRUG|Armodafinil|Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
41158818|NCT01048983|DRUG|Bupropion|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
41158819|NCT01048983|DRUG|Minocycline|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
41158820|NCT01048983|DRUG|Curcumin|Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
41158821|NCT01048983|BEHAVIORAL|Telephone Questionnaire|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
41350819|NCT05789940|PROCEDURE|Aspiration|The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.
41350820|NCT06144411|OTHER|prevalence of preoperative malnutrition|prevalence of preoperative malnutrition
41492612|NCT04588714|BEHAVIORAL|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|The program includes unlimited website access and 10 scheduled phone calls with an assigned peer mentor.
41492613|NCT03781284|DIAGNOSTIC_TEST|[18F]-FDG PET/MRI|
41020241|NCT04852094|OTHER|Qualitative focus group|A qualitative focus group is performed with staff members and parents of hospitalised newborns in a NICU during Family-centered rounds management. The transcribed interviews are analyzed with qualitative content analysis in order to illuminate the experience, feelings and thoughts arisen among the staff members and the parents.
41020242|NCT04121962|BEHAVIORAL|Peer Mentor|Participants will be trained to be Peer Mentors and promote home-based testing to their social network
41020243|NCT04121962|BEHAVIORAL|Website only|Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
41020244|NCT02875106|DEVICE|12-point-ECG|routine recording will be 300 seconds
41020245|NCT02875106|DEVICE|Polar V800|routine recording will be 300 seconds
41020246|NCT02875106|DEVICE|360° eMotion FAROS SET + Belt|routine recording will be 300 seconds
41020247|NCT02875106|DEVICE|Adidas Micoach smart run|routine recording will be 300 seconds
41020248|NCT02875106|DEVICE|TomTom Runner Cardio HRM|routine recording will be 300 seconds
41020249|NCT03174340|BEHAVIORAL|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
41020250|NCT06039085|DEVICE|custom device to demonstrate a significant difference in electrical impedance signatures|Custom device will be used to measure electrical impedance signatures.
41020251|NCT01156324|BEHAVIORAL|Online Stress Management Group (Upliv)|Personalized online stress management program
41158822|NCT04658771|DEVICE|MR-HIFU treatment|"MR-HIFU is an innovative technology that allows for non-invasive thermal ablation of tissues and tumors by integrating an external high intensity focused ultrasound (HIFU) transducer with a conventional MRI scanner.~The focused ultrasound transducer is placed outside of the body and generates and focuses acoustic energy to heat tumors or other pre-defined focal regions of tissues inside the body. Because the acoustic energy is precisely focused over tiny areas of tissue, potential thermal injury to surrounding tissues is minimal. Cell death inside the selected treatment area occurs via coagulative necrosis while avoiding injury to intervening and adjacent tissues."
41158823|NCT05044078|OTHER|Autogenic Inhibition MET|If a sub-maximal contraction of the muscle is followed by stretching of the same muscle it is known as Autogenic Inhibition MET.
41158824|NCT05044078|OTHER|Reciprocal Inhibition MET|If a submaximal contraction of a muscle is followed by stretching of the opposite muscle then this is known as Reciprocal Inhibition MET.
41158825|NCT03950596|OTHER|Acute resistant load exercises|"Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises"
41158826|NCT03950596|BEHAVIORAL|Background Questionnaire|Background questionnaire will be filled out by participants
41158827|NCT03950596|OTHER|Pain Questionnaire|Pain questionnaire regarding pain in the knee during previous 3 months
41158828|NCT03950596|GENETIC|DNA and RNA test|DNA and RNA tests will be sent to a genetic laboratory for analysis
41158829|NCT03950596|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the knee joint and the quadriceps muscle and the pica tendon
41350821|NCT04317898|PROCEDURE|serratus plane block by ultra-sound|To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.
41492614|NCT03781284|DIAGNOSTIC_TEST|Colonoscopy|
41020252|NCT01156324|BEHAVIORAL|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
41020253|NCT03258476|DRUG|Guanfacine Extended Release|Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
41020254|NCT03258476|BEHAVIORAL|Mindfulness Skills Therapy|Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
41020255|NCT03258476|DRUG|Placebo|Placebo oral capsule
41020256|NCT04842240|PROCEDURE|Pre- or sub-pectoral implant based immediate breast reconstruction|All study participants will undergo skin sparing mastectomy (with or without nipple preservation) for breast cancer or for risk reduction. Patients will undergo immediate breast reconstruction using an implant or a tissue expander. The device will be placed in pre- or sub-pectoral plane which will be supported by mesh (Tiloop/Surgimend Acellular Dermal Matrix) and/or a dermal flap.
41020257|NCT03581136|DEVICE|Dose Fractionation|Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
41020258|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
41350822|NCT04317898|PROCEDURE|paravertebral block by ultra-sound|TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.
41020259|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
41020260|NCT05447988|DEVICE|Breast Tissue Expander|tissue expander based breast reconstruction
41020261|NCT03348267|DIETARY_SUPPLEMENT|Milk protein isolate|Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water
41158830|NCT03950596|DIAGNOSTIC_TEST|Percutaneous Needle Core Biopsy|Core Biopsy will be taken from the quadriceps femoris muscle
41158831|NCT01630395|PROCEDURE|protective ventilation|low tidal volume and PEEP
41158832|NCT01630395|PROCEDURE|Recruitment maneuver combined with protective ventilation|Low tidal volume, PEEP and recruitment maneuver
41158833|NCT06031415|DRUG|GS-0272|Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
41158834|NCT06031415|DRUG|Placebo|Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
41158835|NCT05758376|BEHAVIORAL|Recovery Bridge|Recovery Bridge is a Peer Specialist facilitated intervention designed to help Veterans being discharged from an inpatient psychiatric hospitalization bridge the gap to outpatient care and community living
41350823|NCT02460042|PROCEDURE|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
41350824|NCT02460042|DEVICE|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
41492615|NCT03123432|DIETARY_SUPPLEMENT|immunomodulating nutrients enriched diet|
41492616|NCT03123432|DIETARY_SUPPLEMENT|standard diet|
41492617|NCT01170013|BEHAVIORAL|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
41492618|NCT01170013|BEHAVIORAL|Parent psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use
41492619|NCT03054558|OTHER|Pelvic ultrasound both two dimensional and three dimentional|
41158836|NCT03298633|OTHER|ICSI|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
41158837|NCT03298633|OTHER|Conventional IVF|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
41158838|NCT03700463|OTHER|BRIEF parental survey|Estimate incidence of executive functions disorders in preterm children in 3 to 4 year old, born less than 34 weeks of gestation
41158839|NCT05683886|DRUG|KC1036|Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
41158840|NCT04965090|DRUG|Amivantamab|Amivantamab 1050mg IV once weekly for the first 28 days (Cycle 1) and every other week thereafter. For subjects who weigh ≥80 kg, they will receive 350mg IV on C1D1 and 1050 mg on C1D2. They will continue to receive amivantamab 1400 IV once weekly for the first 28 days and every other week thereafter. Each cycle is 28 days in length.
41158841|NCT04965090|DRUG|Lazertinib|Lazertinib 240 mg orally once daily and take this continuously, starting C1D1. For patients who weigh \<80 kg, on C1D1, patients will receive amivantamab 350 mg IV, with 700 mg given on C1D2.
41158842|NCT02186015|DRUG|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
41158843|NCT06646380|BEHAVIORAL|Multicomponent Training|The multicomponent training (MCT) program comprised aerobic, resistance, flexibility, and balance exercises, following recommendations by Carvalho et al. (23). Sessions lasted 50 to 60 minutes, including warm-up, aerobic exercise, resistance training, balance training, and cool-down. Training intensity gradually increased over time. The experimental group will have three 60-minute sessions weekly for 32 weeks, while the control group will not participate in any exercise program, but they will maintain the daily physical activity. Both groups will be evaluated at two time points: initial assessment (M1) at the start of training and final assessment (M2) after 32 weeks
41158844|NCT06646380|OTHER|Maintenance|Participants were instructed to maintain daily life activities regarding physical activity.
41158845|NCT00806299|DRUG|Loperamide / Red Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without red grapefruit juice
41158846|NCT00806299|DRUG|Loperamide/ White Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without white grapefruit juice
41020262|NCT03348267|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
41020263|NCT04685135|DRUG|MRTX849|21 day cycles
41158847|NCT00806299|DRUG|Loperamide / Pink Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
41020264|NCT04685135|DRUG|Docetaxel|21 day cycles
41020265|NCT04487340|BEHAVIORAL|Education|Provide each center with relevant education of guidelines, and help the clinicians to improve medical quality.
41020266|NCT04114058|DRUG|liposomal bupivicaine|local field infiltration
40831940|NCT01333670|DEVICE|Prontosan wound irrigation solution|"* cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes~* dressing with Prontosan Wound Irrigation solution"
41020267|NCT04114058|PROCEDURE|Fascia iliaca blockade|fascia iliaca compartment blockade
41158848|NCT04801784|PROCEDURE|Increased net ultrafiltration with advanced hemodynamic monitoring|A net ultrafiltration rate of 100 ml/h or more will be applied during the first 72 hours of study participation. To insure the hemodynamic security of the intervention, it is associated with an advanced hemodynamic monitoring protocol which encompasses cardiac index, preload dependence assessment (using postural maneuvers), lactate levels and central venous pressure evaluation. The hemodynamic monitoring protocol allows the decrease or suspension of the neutral ultrafiltration rate in case of hemodynamic instability or of hemodynamic status considered at risk of worsening if net ultrafiltration rate is maintained.
41158849|NCT04801784|PROCEDURE|Zero or near-zero net ultrafiltration|The active control group aims to represent the present standard of care of net ultrafiltration management in the first 72 hours of study participation in patients with critical illness. This will be performed by setting the net ultrafiltration rate to 0 up to 25 ml/h.
41158850|NCT06084260|DIETARY_SUPPLEMENT|Diet group|Individual diet, with caloric restriction, associated with weekly meetings about eating habits modifications.
41158851|NCT06084260|BEHAVIORAL|Self-compassion group|Weekly meetings using self-compassion techniques to improve body dissatisfaction and eating behavior.
41350825|NCT05848752|BEHAVIORAL|psychophysics|Subjects will be shown a pair of jars each filled with the same absolute number but different ratios of red/blue balls. Three blocks of trials exist, short-term inference (subjects must identify which of the equally likely jars is currently in use), long-term inference (subjects must predict the subsequent jar in use on the next trial, where jar switches are correlated across trials), or multi-timescale inference (subjects must both report the current jar and predict the subsequent jar, combining the short and longterm inferences). Subjects will draw balls as many balls as they wish with replacement (free response) during the short-term and multi-timescale blocks but will know the current jar in use for long-term inference.
40831941|NCT01333670|DRUG|Isotonic solution (saline or lactated ringer)|"* cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes~* dressing with isotonic solution"
40831942|NCT04701580|DIAGNOSTIC_TEST|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
40831943|NCT04701580|DIAGNOSTIC_TEST|18F-FDG PET-MR|Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
40831944|NCT04139720|BEHAVIORAL|e-book|sexual harassment prevention via education e-book
40831945|NCT02944565|BIOLOGICAL|Daratumumab|Given IV
40831946|NCT02002468|OTHER|Test result sent by letter|
40831947|NCT02002468|OTHER|Test result conveyed by general practitioners|
40831948|NCT05429645|PROCEDURE|setting up of the pace maker|Setting up of a pace maker using a 3-dimensional (3D) guidance technique
41020268|NCT05866094|BEHAVIORAL|Nutritional Intervention|"Nutrition training will be provided to home care staff to deliver the intervention via the participating Home Care Providers from two localities (South and North of England).~This phase will involve identification of people with dementia on their caseload, preliminary assessment of potential impact via collection of quantitative data at baseline (pre-intervention), and at 4 months follow-up (4 months after the first visit by trained home care workers, following baseline).~A process evaluation will be conducted to gather data on intervention fidelity and implementation (quantitative and qualitative)."
41020269|NCT05320653|DIETARY_SUPPLEMENT|Medical nutrition|Nutrition therapy of the critically ill patients
41020270|NCT06207682|DRUG|Avacopan|Orally via capsules
41020271|NCT06207682|DRUG|Simvastatin|Orally via tablets
41020272|NCT04634916|DEVICE|EndoAVF Creation|Subjects will have an endoAVF created using the WavelinQ EndoAVF System
41158852|NCT06288256|OTHER|No Intervention|No Intervention
41158853|NCT06647303|BEHAVIORAL|Training on communication framework|Surgeons will receive training on the Better Conversations framework
41350826|NCT00527046|DRUG|CP-424,391|
41350827|NCT02221570|DRUG|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
41350828|NCT04198311|BEHAVIORAL|CBT-I|CBT-I will be delivered individually, in five weekly sessions. Intervention components include sleep hygiene, sleep restriction, stimulus control, relaxation, cognitive therapy.
41350829|NCT00083616|BIOLOGICAL|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
41350830|NCT03832166|OTHER|Fruits and Vegetables|Fruits and vegetables delivery, once/week for 24 weeks
41350831|NCT03832166|OTHER|Cooking|Nutrition education and cooking instruction class, one class/week for 6 weeks
41350832|NCT02239029|DRUG|platelet rich plasma|Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
41350833|NCT02239029|DRUG|Normal saline|The normal salin as the placebo intervention was injection in the other side of knee.
41350834|NCT03656536|DRUG|Pemigatinib|Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).
40831949|NCT00170196|DRUG|prednisone|
40831950|NCT04524650|DIAGNOSTIC_TEST|the level of vWF|the peripheral level of vWF
41020273|NCT03158558|BEHAVIORAL|Accelerated, Multi-Couple Group CBCT for PTSD|Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson \& Fredman, 2012)
41020274|NCT05631080|PROCEDURE|Anatomical Endoscpic enucleation of the Prostate|Transurethral endoscopic enucleation of the prostate adenoma
41020275|NCT03615651|DIETARY_SUPPLEMENT|Probiotic|The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.
41020276|NCT03615651|OTHER|Placebo|Placebo intervention.
41020277|NCT05071261|DIAGNOSTIC_TEST|Hepatitis C Virus Screening|1-2 Blood Screenings for Hepatitis C Virus
41020278|NCT05070897|OTHER|Questionnaires|"* Approved French version of the FCCHL scale~* Questionnaire on the use of digital tools adapted from the questionnaire on digital tools"
41158854|NCT06647303|OTHER|Focus Group|Participants will attend a focus group to discuss the survey instruments used in this study which will help with future study design
41158855|NCT06647303|OTHER|Surveys|Participants will complete surveys regarding the surgeon's communication skills
41158856|NCT05604040|BEHAVIORAL|Lifestyle Modifications|Home BP monitoring with self-monitoring of emotions, diet, physical activity, with shared medical appointment program for lifestyle changes and coping skills
41158857|NCT05253911|DRUG|TUKYSA®|tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.
41158858|NCT02162771|BIOLOGICAL|Rituxan|
41492620|NCT02495259|DEVICE|ZU-bend stylet|Laryngoscopy and intubation after induction of anesthesia will be done using the GlideScope and the ZU-bend stylet. The ZU-bend is a specific shaping technique of the intubating stylet that is closely related to the GlideScope blade curvature. Zu-bend stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
41492621|NCT02495259|DEVICE|GlideScope|Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
41492622|NCT02495259|DEVICE|GlideRite stylet|Laryngoscopy and intubation after induction of anesthesia will be done with the GlideScope using the GlideRite stylet. The GlideRite stylet is specifically designed to work with the GlideScope and provides the necessary rigidity and curvature to an otherwise flexible tube. GlideRite stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
41492623|NCT02495259|DEVICE|Macintosh blade|Direct laryngoscopy and intubation after induction of anesthesia will be done with the Macintosh blade and a regular double-lumen endobronchial tube (DLT) stylet. The Macintosh blade is used to facilitate visualization of the larynx during double or single lumen endobronchial tube placement. After intubation the Macintosh laryngoscope is removed and the confirmation of the successful placement of the double-lumen endobronchial tube in done in the standard fashion.
41492624|NCT02495259|DEVICE|Regular Double-lumen endobronchial tube (DLT) Stylet|Direct laryngoscopy and intubation after induction of anesthesia will be done with a regular double-lumen endobronchial tube (DLT) stylet and the Macintosh blade. The DLT stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, Macintosh laryngoscope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
41492625|NCT05100979|OTHER|The Art of Medicine Series|The Art of Medicine Series is a smartphone-based educational tool focused on teaching communication strategies to clinicians and patients.
41020279|NCT05768503|DRUG|Experimental drug|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
41020280|NCT05768503|DRUG|Control Rx|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
41020281|NCT06055322|BEHAVIORAL|Adapted Dialectical Behavior Therapy|DBT includes skills training groups, unlike other suicide-specific treatments, with modules on distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 2014)
41509093|NCT04681716|OTHER|CONVENTIONAL PHYSIOTHERAPY|"Transcutaneous Electrical Nerve Stimulation (TENS):~120Z dual channel TENS unit made in Japan was used in the research. Electrodes of TENS were placed on lumbar region and TENS was given for 15 minutes on Constant mode. Intensity was adjusted according to patient's comfort.~Hot pack was applied on the lumbar region for 10 - 15 minutes.Lumbar Mobilization (CPA) was given on spinous process of L1- L5 vertebrae and L5-S1. For every session given 3 sets of 10 repetitions of each lumbar vertebra was performed."
41020282|NCT05966025|DRUG|Itopride|itopride will be taken by pateints one time per day by dose 100 mg
40831951|NCT01930552|DRUG|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
40831952|NCT01930552|DRUG|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
40831953|NCT01930552|DRUG|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
40831954|NCT01930552|DRUG|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
41020283|NCT05966025|DRUG|conventional therapy|will taken by patient in control group
41020284|NCT05946668|PROCEDURE|Biospecimen Collection|Undergo vaginal specimen self-collection via vaginal swab collection kit
41020285|NCT05946668|OTHER|Electronic Health Record Review|Medical records reviewed
41020286|NCT05946668|OTHER|Questionnaire Administration|Complete questionnaires
41020287|NCT00834301|DIETARY_SUPPLEMENT|Oral Multivitamin|Oral Multivitamin
41020288|NCT02197546|OTHER|Acupuncture & acupressure|Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
41020289|NCT04488276|OTHER|In-depth interviews|In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.
41158859|NCT02162771|BIOLOGICAL|CT-P10|
41158860|NCT02162771|DRUG|Cyclophosphamide|
41158861|NCT02162771|DRUG|Vincristine|
41158862|NCT02162771|DRUG|Prednisone|
41350835|NCT03656536|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
41158863|NCT05278065|OTHER|Nicotine|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at weekly assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose commercially available e-liquid flavors (tobacco) at each weekly assessment.
41158864|NCT04899778|DRUG|Oral Contraceptive Pill, norethindrn a-e estradiol-iron|tablet
41020290|NCT05257265|DRUG|Centanafadine Hydrochloride|Capsule
40831955|NCT05394480|DIAGNOSTIC_TEST|Blood pressure (Systolic, Diastolic), Pulse value, O2 saturations were measured.|Salivary cortisol was measured by electrochemiluminescence (ECLIA) method using the Cobas Cortisol ll kit.
41158865|NCT04927338|DIETARY_SUPPLEMENT|BacoMind® (Bacopa monnieri standardized extract)|BacoMind® (Bacopa monnieri standardized extract) 300 mg daily capsule.
41158866|NCT04927338|DRUG|Placebo|Daily placebo capsule identical in size, color, and shape to that of the Bacopa capsules.
41350836|NCT03656536|DRUG|Cisplatin|Cisplatin 25 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
41350837|NCT04844567|DEVICE|COVVR_Synch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Synch provided synchronous feedback: participants receive real-time feedback of their respiration."
41350838|NCT04844567|DEVICE|COVVR_Asynch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration."
41350839|NCT03483012|DRUG|Atezolizumab|Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway
41350840|NCT03483012|PROCEDURE|Stereotactic radiosurgery (SRS)|Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors
41350841|NCT02324049|DRUG|SBC-103|
41350842|NCT03894306|OTHER|Medication lock box|given a lock box and instructed on how to use the device.
41350843|NCT03894306|OTHER|medication lock bag|given a lock bag and instructed on how to use the device.
41350844|NCT03894306|OTHER|brief counseling|After completing the per-intervention survey, a research assistant or investigator will perform brief counseling, including educational handouts and information on safe medication storage
41350845|NCT00801216|DRUG|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 \& 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
41350846|NCT01732133|DEVICE|Nexfin|
41350847|NCT05749276|DRUG|Darzalex|"DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~* Dose level 1 : 1800 mg Day 1~* Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~* Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"
41350848|NCT03140046|PROCEDURE|photorefractive keratectomy (PRK)|"The cornea will be ablated while the patient fixating on target light under constant eye-tracking control. The ablations will be made using the ALLEGRETTO X 500WAVE excimer laser (WaveLight Laser Technologie AG)."
41350849|NCT03493373|OTHER|Exercise|The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.
41350850|NCT03493373|OTHER|Neural mobilization|Neural gliding mobilization will target mainly the lower limb nerves and will be performed in series of 10 repetitions with 1 minute interval between series.
40831956|NCT01812356|DEVICE|Cryomaze procedure using Nitrous oxide|Cryomaze procedure using Nitrous oxide
40831957|NCT01812356|DEVICE|Cryomaze procedure using Argon|Cryomaze procedure using Argon
40831958|NCT03303898|PROCEDURE|Blood sampling|sampling of 7 blood tubes
41020291|NCT05257265|OTHER|Placebo|Capsule
41020292|NCT00870311|DRUG|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
41020293|NCT05658926|BEHAVIORAL|Mindfulness|Patients will learn how to use diaphragmatic breathing with mindfulness
41020294|NCT05658926|OTHER|Education|Patients will be provided with education regarding the Gate Control Theory of Pain.
41020295|NCT00216840|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
41020296|NCT04140669|DEVICE|Automated Myocardial Performance Index (MPI)|Automated Myocardial Performance Index will be performed using Samsung HERA W10 prior too fetal surgical interventions, during surgery, and following surgery.
40831959|NCT00901797|PROCEDURE|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
41350851|NCT03575780|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
40831960|NCT00901797|PROCEDURE|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
40831961|NCT03971604|DRUG|Vitamin A|treated with Vitamin A
40831962|NCT03971604|DRUG|Vitamin E|treated with Vitamin E
40831963|NCT02066506|OTHER|asymptomatic group|2 visits with MRI
41350852|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results available|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
40831964|NCT02066506|OTHER|symptomatic group|2 visits with MRI
40831965|NCT01444586|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
40831966|NCT00189943|BIOLOGICAL|MVA-BN|
40831967|NCT03386747|BEHAVIORAL|Home visits to improve parenting behaviors|Caregivers will be visited twice per month starting from the third trimester in pregnancy up to age three to discuss important health and development behaviors.
41020297|NCT02426632|DRUG|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
41020298|NCT02426632|DRUG|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
41020299|NCT02426632|DRUG|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
41020300|NCT02426632|DRUG|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
41020301|NCT02426632|DRUG|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
41020302|NCT02426632|DRUG|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
41020303|NCT02426632|DRUG|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
41350853|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results unavailable|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
41020304|NCT02426632|DRUG|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
41020305|NCT02426632|DRUG|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
41020306|NCT02426632|DRUG|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
41350854|NCT00040066|PROCEDURE|Cocaine (IV)|
41350855|NCT06415955|OTHER|None, pure observationnal study|None, pure observationnal study
41350856|NCT01939067|DEVICE|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
41350857|NCT01939067|DEVICE|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
41350858|NCT04992000|OTHER|4-free app + PHN intervention|same mentioned in groups
41350859|NCT02618512|DRUG|SBC-103|SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
41020307|NCT02426632|DRUG|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
41020308|NCT02426632|DRUG|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
41158867|NCT05729347|BEHAVIORAL|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
40831968|NCT03386747|BEHAVIORAL|Center based parenting groups|Caregivers will be invited to early childhood development groups. Groups will meet at nearby centers twice per month. Caregivers will be invited to participate starting from the third trimester up to age 3 of the child.
40831969|NCT05692310|OTHER|placing a standard central venous line|Patients will benefit from the technique of central venous line placement by conventional ultrasound.
41020309|NCT04419909|DRUG|CD19 redirected autologous T cells (CTL019 or CTL119 cells)|Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.
41020310|NCT06272916|DRUG|Aminophylline , magnesium sulphate and placebo|Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section
41350860|NCT02788851|DRUG|Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine|Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
41350861|NCT02788851|BEHAVIORAL|Aerobic Exercise|Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
41350862|NCT04839679|BEHAVIORAL|Culturally Oriented Educational Brochure|Culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner
41350863|NCT04839679|BEHAVIORAL|Mayo Clinic Educational Booklet|"An Introduction to Radiation Simulation and Treatment- Barbara Woodward Lips, Patient Education Center"
41350864|NCT04411225|DRUG|Cannabidiol oral solution|Both the active drug (cannabidiol) and placebo will be in oral solution.
41350865|NCT01406366|BEHAVIORAL|Group 1: Bright Futures Oral Health Curriculum|Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
40831970|NCT05692310|OTHER|placement of a central venous line using an ultraportable ultrasound device|Patients will have a central venous line placed using an ultraportable ultrasound device
40831971|NCT02463032|DRUG|GTx-024|To determine whether either or both doses result in an acceptable clinical benefit rate.
40831972|NCT02839902|DRUG|TAK-085|Omega-3-acid ethyl esters (TAK-085) capsule
40831973|NCT02839902|OTHER|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
40831974|NCT01243567|DRUG|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
41020311|NCT04409756|OTHER|shoulder rating questionnaire|to investigate reliability of turkish version of shoulder rating questionnaire
41020312|NCT00180739|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
41020313|NCT01018264|DRUG|solifenacin succinate (VESIcare)|up to 10mg every day orally
41020314|NCT01018264|DRUG|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
41020315|NCT01901380|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|
41020316|NCT02549144|DIETARY_SUPPLEMENT|Low fat/cholesterol diet|The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.
41158884|NCT04116541|DRUG|HDM201|HDM201 120mg, Every 3 weeks, Per os
41158885|NCT04116541|DRUG|Ribociclib|Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
41350866|NCT01406366|BEHAVIORAL|Group 2: Iron Deficiency Training Module|Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
41350867|NCT03775473|DIAGNOSTIC_TEST|progastrin|PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
41492626|NCT01169428|BEHAVIORAL|Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
41492627|NCT01169428|BEHAVIORAL|Behavioral: Standard Behavioral Weight-Loss Maintenence|Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors \[e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information \& education\]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
41158886|NCT04116541|DRUG|Cabozantinib|Cabozantinib, 60 mg /day, continuous, Per os
41350868|NCT00404326|DRUG|Hydralazine and magnesium valproate|
40831975|NCT01243567|DRUG|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
41350869|NCT00404326|PROCEDURE|Punch biopsy of the primary tumor|
41350870|NCT04995731|BEHAVIORAL|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia (EH)|Bleeding type, age, race, parity, early menarche or late menopause, body mass index, body composition, hypertension, type II diabetes, anovulation, polycystic ovary syndrome and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
41350871|NCT04995731|PROCEDURE|transvaginal ultrasound examination|All patients will undergo a standard transvaginal ultrasound examination followed by power Doppler endometrial vascularity assessment. After ultrasound examination, all patients will undergo endometrial sampling either through hysteroscopy or dilatation and curettage operation (D, C) or will have histopathological evaluation of biopsy specimens obtained by hysterectomy. Histopathological evaluation will serve as a gold standard for the ﬁnal diagnosis.
40831976|NCT03985007|DRUG|CDIAG regimen|Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
40831977|NCT03411109|DRUG|Hydromorphone Hydrochloride|All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.
41020317|NCT02549144|DIETARY_SUPPLEMENT|High fat/cholesterol diet|The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day
41020318|NCT00189085|DRUG|simvastatin and ezetimibe|
41350872|NCT02721654|DRUG|Plasma-Lyte 148®|Plasma-Lyte 148 (approx pH 7.4) IV infusion is a sterile, clear nonpyrogenic isotonic solution \& when administered intravenously it is a source of water, electrolytes \& calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
41020319|NCT04498897|DRUG|Vortioxetine|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
41020320|NCT04498897|DRUG|Acamprosate|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
41020321|NCT03047161|DEVICE|fetal MCG|assess fetal heart rate and rhythm
41020322|NCT04995640|PROCEDURE|open cardiovascular repair or endovascular treatment (TEVAR)|Surgery type: open cardiovascular repair and endovascular treatment (TEVAR)
41158887|NCT04116541|DRUG|Alectinib|Alectinib, 600mg twice daily, Per os
41158888|NCT04116541|DRUG|Regorafenib|Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
41158889|NCT04116541|DRUG|Trametinib|Trametinib 2 mg/day, continuous, Per os
41158890|NCT04116541|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily, Per os
41158891|NCT04116541|DRUG|Avapritinib|300 mg/day,continuous, Per os
41158892|NCT02651883|BEHAVIORAL|Screening invitation (with education)|The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
41158893|NCT02651883|BEHAVIORAL|Self-collection for HPV testing|Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
41158894|NCT04070183|BEHAVIORAL|POST Facilitation|Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected. The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions. Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care. The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.
41158895|NCT04070183|BEHAVIORAL|Home Safety Evaluation|Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and carbon monoxide (CO) detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
41158896|NCT00613132|DRUG|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort \& will be increased to 600 mg po/day \& then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 \& hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
41350873|NCT02721654|DRUG|0.9% sodium chloride|The active ingredient is sodium chloride formulated in Water for Injections. The chemical name is sodium chloride with molecular formula NaCl. Sodium Chloride (0.9%) intravenous infusion preparation is a sterile \& non-pyrogenic solution \& is indicated for extracellular fluid replacement \& in the management of metabolic alkalosis in the presence of fluid loss, \& for restoring or maintaining the concentration of sodium \& chloride ions. As sodium chloride intravenous infusion is administered to the systemic circulation by intravenous infusion, the bioavailability (absorption) of the active components is complete (100 per cent).
41350874|NCT00032110|DRUG|erlotinib hydrochloride|Given orally
41350875|NCT00032110|OTHER|pharmacological study|Correlative studies
41350876|NCT00032110|OTHER|laboratory biomarker analysis|Correlative studies
41350877|NCT04857840|DRUG|Firibastat (QGC001) Period 1|1000 mg (2 x 500 mg) tablets QD per Os
41350878|NCT04193605|BEHAVIORAL|Mindfulness|The traditional MBSR intervention consists of the following: (1) a series of eight weekly session of 2.5 to 3 hours; (2) a silent retreat during the sixth week; (3) daily home assignments including formal and informal mindfulness practices; and (4) didactic presentations on stress and the consequences of stress. We are culturally tailoring the intervention with the goal of maintain fidelity.
41350879|NCT02194634|DRUG|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
41350880|NCT02194634|OTHER|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
41350881|NCT02194634|PROCEDURE|Laser|Laser treatment at first month, then repeated as needed.
41492628|NCT04358289|OTHER|Basic antimicrobial stewardship education|Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines
41492629|NCT04358289|OTHER|Participatory action research group in commune health center and community|"* Establish a participatory action research group~* Engagement with the group through participatory action research involving problem identification, planning change strategies, implementing strategies, and evaluation"
41350882|NCT02194634|OTHER|Sham laser|Sham laser at first month, then repeated as needed.
41492630|NCT04358289|OTHER|Antimicrobial stewardship program in hospitals|"The intervention activities in hospitals will include: training a health-worker in each of the participating hospitals to act as a facilitator or activator; forming an antibiotic stewardship group; meeting regularly and following an action-research cycle that includes problem identification, planning change strategies, implementing strategies, and evaluating strategies"
41492631|NCT04358289|OTHER|Community education|Development of educational materials for the community and farmers; Disseminated of messages through posters, leaflets and local media channels
41492632|NCT05934240|OTHER|Manual therapy group|Manual therapy will be applied to the diaphragm and thoracic region.
41492633|NCT05934240|OTHER|Sham-manual therapy|Sham-manual therapy will be applied to the diaphragm and thoracic region.
41492634|NCT00045539|DRUG|leucovorin calcium|
41492635|NCT00045539|DRUG|methotrexate|
41492636|NCT00045539|DRUG|thiotepa|
41492637|NCT01928706|OTHER|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
41492638|NCT01928706|OTHER|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
41492639|NCT02674321|DRUG|SD-809|
41492640|NCT05650190|DEVICE|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
41492641|NCT05650190|DEVICE|Spectacle lenses|Single vision, impact resistant spectacle lenses
41492642|NCT00088621|DRUG|Lurasidone 80mg tablet|
41492643|NCT00525551|DRUG|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
41158897|NCT04589689|BEHAVIORAL|Insul-In This Together|Session 1: Introduction to Parental Monitoring Session 2: Advanced Parental Monitoring Session 3: Introduction to Parental Involvement Session 4: Advanced Parental Involvement Session 5: Introduction to Parent-Teen Conflict Management Session 6: Advanced Parent-Teen Conflict Management
41158898|NCT06531811|DRUG|AZD8630 (test formulation) via test inhaler|Participants will receive AZD8630 via test inhaler.
41158899|NCT06531811|DRUG|AZD8630 (reference formulation) via Monodose inhaler|Participants will receive AZD8630 via Monodose inhaler.
40831978|NCT02469714|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
41020323|NCT02259621|DRUG|Nivolumab|Anti-PD-1 Therapy
41350883|NCT01941212|BEHAVIORAL|Music therapy|Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
41350884|NCT03918213|DIAGNOSTIC_TEST|High-Resolution anorectal manometry with the use of solid-state catheter|High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
41350885|NCT02638740|PROCEDURE|SCALING AND ROOT PLANING (SRP)|Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
41350886|NCT02638740|PROCEDURE|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
41350887|NCT00948714|BEHAVIORAL|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
41492644|NCT00525551|DRUG|Placebo (NaCl)|300 mL 0.9% NaCl
41492645|NCT00259272|DRUG|olanzapine|5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
41492646|NCT04561687|DRUG|Montelukast|Montelukast and nasal budesonide
41158900|NCT06531811|DEVICE|Test inhaler|Participants will receive AZD8630 via test inhaler.
41350888|NCT00948714|BEHAVIORAL|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
41492647|NCT04561687|DRUG|Azelastine|Azelastine and nasal budesonide
41492648|NCT04561687|DRUG|Budesonide|To all groups
41492649|NCT04561687|DRUG|Placebo|Placebo and nasal budesonide
41492650|NCT01546376|RADIATION|Radiation therapy|External photon beam radiation therapy dosage 4000-7000 CGy
41492651|NCT01546376|OTHER|Venepuncture|Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
41020324|NCT02259621|DRUG|Carboplatin|Anti-PD-1 Therapy
41158901|NCT06531811|DEVICE|Monodose inhaler|Participants will receive AZD8630 via Monodose inhaler.
41158902|NCT05331716|PROCEDURE|Cardiac ablation therapy|In a subset of patients with known therapy refractory arrhythmia sole LAVA modification is fashioned
41158903|NCT02824029|DRUG|Ibrutinib|Given PO
41158904|NCT02824029|OTHER|Laboratory Biomarker Analysis|Correlative studies
41492652|NCT00040768|DRUG|bortezomib|Given IV
41492653|NCT03694366|OTHER|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers"
41492654|NCT03543436|DRUG|Temocillin|Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h) .
41020325|NCT02259621|DRUG|Paclitaxel|Anti-PD-1 Therapy
41020326|NCT02259621|DRUG|Ipilimumab|Anti-PD-1 Therapy
41020327|NCT05780983|BEHAVIORAL|education and coaching on developing healthy nighttime sleep and daytime activity behaviors|The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
41492655|NCT03543436|DRUG|meropenem or imipenem|Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)
41020328|NCT04688840|PROCEDURE|hip arthropalsty|follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
41020329|NCT01516268|DRUG|Sufentanyl|"As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block."
41020330|NCT03930745|OTHER|Placebo|Placebo vaginal inserts.
41158905|NCT02824029|OTHER|Pharmacological Study|Correlative studies
41350889|NCT00948714|OTHER|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
41350890|NCT04042311|OTHER|High-intensity interval training|a high-intensity interval training programme completed 3 times a week for 6 weeks using a stationary Wattbike.
40831979|NCT04376957|BEHAVIORAL|Multinational Association of Supportive Care in Cancer Oral agent Teaching Tool|"This tool was developed by an expert panel of oncology nurses and was further revised following external review of health care providers world-wide. This tools involves four key modules 1) patient's baseline knowledge, 2) patient education of oral cancer drugs 4) patient education tailored to a specific cancer drug 4) evaluation of the educational material.~It was originally studied in 30 patients with lung cancer and was shown to be feasible with acceptable knowledge retention. Similarly, in a single center cohort study of general oncology patients, medication adherence self-efficacy appeared to improve with MOATT. The MOATT interventional tool incorporates key components of patient education and also has the advantage of being a potentially feasible tool that can be incorporated into future routine clinical practise."
40831980|NCT04376957|BEHAVIORAL|Standard of care consisting of standard counselling|Consists of instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered.
40831981|NCT03074266|DIAGNOSTIC_TEST|GEM Hemochron 100 ACT|Activated Clotting Time
41020331|NCT03930745|DRUG|TOL-463|TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
41350891|NCT00205374|DRUG|Cidofovir|With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
41350892|NCT00205374|DRUG|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
41350893|NCT04099225|DIAGNOSTIC_TEST|Multiple breath washout (MBW) testing|Lung clearance index (LCI), acinar (Sacin) and conductive (Scond) ventilation heterogeneity were derived from triplicate SF6-MBW measurements. Global ventilation heterogeneity was calculated for the 2.5% (LCI2.5) and 5% (LCI5) stopping points.
41350894|NCT02321163|DEVICE|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
41350895|NCT02321163|DEVICE|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
41350896|NCT02321163|DEVICE|NMES no stimulation|Placebo, electrode pad on, no stimulation
41350897|NCT03420989|OTHER|Active snack food|snack enriched with seaweeds and carob
40831982|NCT02177513|DRUG|Placebo + Placebo|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
41020332|NCT03705754|DEVICE|carbon black suspension colonic tattoo injection|Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
41350898|NCT03420989|OTHER|Control snack food|the same snack food without seaweeds and carob
41350899|NCT00739440|BIOLOGICAL|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
41350900|NCT02460094|DRUG|BIIB092|See Arm Descriptions for dosing information.
41350901|NCT02460094|DRUG|Placebo|See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
41158906|NCT06385314|OTHER|Collecting data with oral health related quality of life, dental anxiety and state anxiety|Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.
41158907|NCT04153422|DRUG|Panzyga IVIG|Immune Globulin Infusion 10% (Human)
41350902|NCT04384991|DRUG|HU007|Cyclosporine 0.02% with Trehalose 3%
41350903|NCT04384991|DRUG|Restasis eye drop|Cyclosporine 0.05%
41350904|NCT01321736|DIETARY_SUPPLEMENT|dietary fiber|mixture of fiber sources added to liquid nutrition product
41350905|NCT04748250|DEVICE|Acupuncture needles|Standard acupuncture needle which is 3 cm long with diameter o.3 mm
41350906|NCT04748250|DIETARY_SUPPLEMENT|Soy phytoestrogens|100 millilitre of soy milk every day or 100 gram of cooked soy beans per day.
41158908|NCT04153422|DRUG|Placebo|0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
41020333|NCT06211647|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at fixed dose levels at an interval of 6 weeks between each dose.
41158909|NCT06588283|DRUG|Ixekizumab|Administered SC
41158910|NCT06588283|DRUG|Tirzepatide|Administered SC.
41350907|NCT05499689|DRUG|Bupivacaine Hydrochloride|2.5 cc bupivacain injection will be administered by approaching the greater occipital nerve under ultrasound guidance.
41020334|NCT00116389|DRUG|talabostat mesylate tablets|
41350908|NCT05499689|OTHER|Transcutaneous pulsed radiofrequency qurrent|Pulsed radiofrequency current will be applied through transcutaneous pads adhered over the greater occipital nerve trace on the nape.
41350909|NCT01577927|OTHER|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
41350910|NCT01577927|BEHAVIORAL|PT-assisted home rehabilitation|"Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.~Every two weeks, PT phones the patient for an educational reinforcement."
41350911|NCT02933411|OTHER|Genetic Analysis|Blood sample will be drawn to assess the number of participants enrolled that have sequence variation in the von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel biology.
41350912|NCT02933411|OTHER|Medical Record Data Abstraction|"The subject's response to intranasal or intravenous desmopressin (DDAVP) challenge performed as part of standard of care will be recorded. The desmopressin is a drug that increases the clotting factor in blood to prevent bleeding.~Medical and family history including and not limited to age, diagnoses, race/ethnicity, lab values, HMB and low VWF activity diagnoses, and treatment history and outcome will also be recorded."
41350913|NCT02933411|OTHER|Pictorial Blood Assessment Chart (PBAC) score|PBAC is a pictorial tool to assess menstrual blood loss. Study team will complete the PBAC assessment with each study participant evaluating and measure response to different treatments for menstrual blood loss in the clinic setting between those with VWD versus other bleeding disorders.
41020335|NCT00116389|DRUG|gemcitabine|
41158911|NCT04364503|DEVICE|Multiple interventions depending on diagnostic test being run.|Remnant samples and corresponding data from multiple diagnostic tests will be stored for future research and development.
41158912|NCT02751645|PROCEDURE|Acute Normovolemic hemodilution|ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
41158913|NCT01849679|OTHER|Evaluation of Swallowing|Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
41158914|NCT05488002|BEHAVIORAL|Pharmaceutical intervention|Pharmacists will provide clinical recommendations to patients allocated to the intervention group. Furthermore, they will monitor patients' parameters and follow-up with them. These interventions include daily medication review, weight, heart monitoring, blood glucose level, follow-up on medication adherence, and even mental status.
41350914|NCT02933411|OTHER|Complete Bleeding Symptom ISTH Bleeding Assessment Tool|Study participants will complete the ISTH BAT assessment. The ISTH BAT is a questionnaire to aid in the standardized evaluation of the presence and severity of bleeding symptoms.
41350915|NCT01808365|PROCEDURE|Posterior pharyngeal swab|Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
41350916|NCT01808365|OTHER|Data collection|Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
41350917|NCT03698929|OTHER|Dietary Effect of Cholesterol - Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
41492656|NCT05855083|DRUG|Biological: narsoplimab|Treatment with narsoplimab 4 mg/kg will be administered
40831983|NCT02177513|DRUG|Oral Cannabis + Placebo|Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
41020336|NCT03460340|DEVICE|prefrontal deep rTMS of H1 Coil|prefrontal deep rTMS of H1 Coil
41158915|NCT05645900|BIOLOGICAL|Quadrivalent influenza virus subunit vaccine|This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
41158916|NCT05645900|BIOLOGICAL|Quadrivalent influenza virus subunit vaccine|This vaccine（0.25ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
41158917|NCT05645900|BIOLOGICAL|Quadrivalent split influenza virus vaccine|This vaccine（0.25ml） is produced by HUALAN BIO。Subjects will receive two doses of quadrivalent split influenza virus vaccine administered 28 days apart by intramuscular injection
41350918|NCT03698929|OTHER|Dietary Effect of Cholesterol - Non-Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
41350919|NCT00003606|DRUG|cisplatin|
41350920|NCT00003606|DRUG|cyclophosphamide|
41350921|NCT00003606|DRUG|epirubicin hydrochloride|
41350922|NCT00003606|DRUG|etoposide|
41350923|NCT00003606|RADIATION|radiation therapy|
41350924|NCT05103501|DRUG|PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）|immunotherapy:PD-1 inhibitor chemotherapy:5-Fu and DDP
40831984|NCT02177513|DRUG|Placebo + Inhaled Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
40831985|NCT02177513|DRUG|Placebo + Smoked Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
41020337|NCT05491629|OTHER|type of parallel data in a convergent parallel hash pattern (near time)|"The quantitative part of the study is a descriptive study with the Perceived Perioperative Competence Scale-Revised to determine the perceptions of operating room nurses about their competencies.~It is a case study in order to reveal the opinions of the surgical team members about the competencies of the operating room nurses and the affecting factors through individual in-depth interviews and to better explain the current situation at the qualitative stage, which is carried out simultaneously."
40831986|NCT02177513|DRUG|6.9% cannabis oral|Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
41020338|NCT02589119|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
40831987|NCT04448015|OTHER|Perinatal Opioid Use Disorder Education and Enhanced Perinatal Care|University of Utah clinicians will provide face-to-face, online, and written training materials for health, mental health, and substance use service providers in Carbon and Emery Counties, UT.
40831988|NCT05656833|DEVICE|Fractional 1927nm Low-Powered Diode Laser|Clear \& Brilliant Permea® Laser used on the side of the face randomized to receive laser
40831989|NCT05656833|OTHER|Topical Cysteamine|Topical Cysteamine cream will be used on the entire face.
41020339|NCT03756220|DRUG|Combination therapy of vitamin C and thiamine|Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
41350925|NCT05873452|DEVICE|Kaitoh Atherectomy System|The Kaitoh Atherectomy System is a handheld device which initiates mechanical rotation of the blade to debulk atherosclerotic lesions.
41350926|NCT03323086|BEHAVIORAL|Brief Intervention (BI) with Technology Extender|One, 45-60 minute BI, followed by three months of access to technology extenders
41350927|NCT03323086|OTHER|Brochure|Brochures provided one time
41350928|NCT03934515|OTHER|etCO2|"At the end of the procedure, therefore, for each patient two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values at the endotracheal level and the esophageal level values. The authors will find the threshold value of etCO2 collected when the NGT is well positioned in trachea. The study manager is not directly involved in the measurement and recording of etCO2 values."
41350929|NCT03934515|OTHER|pH|"At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at esophageal level and a value at the gastric level. The authors will find the threshold value of pH collected when the NGT is positioned in the esophagus and in the stomach. The study manager is not directly involved in the measurement and recording of pH values."
41350930|NCT01890733|DEVICE|Best Repair of torn Rotator Cuff|
40831990|NCT01632241|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
40831991|NCT01632241|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
40831992|NCT01632241|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
40831993|NCT05259761|OTHER|Unmanned ariel vehicle|Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)
41020340|NCT03756220|DRUG|Normal saline solution|Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
41020341|NCT01152723|DRUG|Nicotine|2 mg, Single Dose
41350931|NCT01890733|DEVICE|InSpace™ system|
41350932|NCT01641341|DRUG|Bifidobacterium infantis|once a day for seven to eight weeks
41350933|NCT01641341|DRUG|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
41350934|NCT01641341|DRUG|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
41350935|NCT01641341|DRUG|Placebo|Placebo capsule will not contain active treatment ingredients.
41350936|NCT01711944|BEHAVIORAL|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
41350937|NCT05637567|DRUG|Acetylsalicylic acid|100 mg per os once daily
41350938|NCT05637567|DRUG|Placebo|Placebo pill per os once daily
40831994|NCT01025570|DRUG|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
40831995|NCT03333395|DRUG|Nebulized heparin and salbutamol|HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
41158918|NCT04085445|DEVICE|AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter|To compile the real-world clinical outcome data for the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter (Agent DCB) used in percutaneous coronary intervention (PCI) in Chinese patients.
41158919|NCT01946529|DRUG|vincristine|Dosage and route of administration: Infants \< 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m\^2 IV day 1 (max. dose 2 mg).
41158920|NCT01946529|DRUG|doxorubicin|Dosage and route of administration: Infants \< 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants \> 1 year of age 75 mg/m\^2 CI over 48 hours, days 1-2.
41158921|NCT01946529|DRUG|cyclophosphamide|Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
41350939|NCT05894486|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Lutetium\[177Lu\] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
41020342|NCT06061211|OTHER|TREADMILL(PRECOR 964i treadmill) with TENS|"TENS:~MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms~treadmill: PRECOR 964i treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min."
41020343|NCT06564376|DIAGNOSTIC_TEST|total magnesium|Treatment based on total Magnesium
41020344|NCT06564376|DEVICE|ionized magnesium|Treatment based on ionized magnesium
41020345|NCT03737461|DRUG|Allogenic BM-MSCs Injection|Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
41020346|NCT03737461|OTHER|Sham Procedure|sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
41020347|NCT06046534|OTHER|None (Observational study)|Not applicable since this is observational study.
41020348|NCT00533949|BIOLOGICAL|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
41020349|NCT00533949|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
41158922|NCT01946529|DRUG|ifosfamide|Dosage and route of administration: Infants \< 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants \> 12 months of age 1800 mg/m\^2 IV over 60 minutes x 5 days, days 1-5.
41158923|NCT01946529|DRUG|etoposide|Dosage and route of administration: Infants \< 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children \> 1 year 100 mg/m\^2 daily IV over 60 minutes days 1-5.
41158924|NCT01946529|DRUG|temozolomide|Dosage and route of administration: Temozolomide 100 mg/m\^2 PO once daily, days 1-5.
41158925|NCT01946529|DRUG|temsirolimus|Dosage and route of administration: Temsirolimus 35 mg/m\^2 IV once day 1 and day 8.
41158926|NCT01946529|DRUG|bevacizumab|Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
41350940|NCT05678504|DEVICE|The phlebotomy procedure|The process of blood collection with a vascular imaging device
41350941|NCT04741867|OTHER|Education|Patients will be educated to determine their level of coping with stress and their adaptation.
41350942|NCT05608265|DEVICE|OSNAT 800 IO|Real-time, combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for retinal imaging
41020350|NCT00533949|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
41020351|NCT00533949|RADIATION|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
41020352|NCT00533949|RADIATION|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
41158927|NCT01946529|DRUG|sorafenib|Dosage and route of administration: 90 mg/m\^2/dose PO BID
41158928|NCT01946529|PROCEDURE|surgery|If participant meets the criteria, they will have surgical resection of their tumor.
41158929|NCT01946529|RADIATION|radiation|If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
41158930|NCT03315988|OTHER|Adoption of a vegan diet|Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
41492657|NCT03893435|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
41492658|NCT05957406|DEVICE|Acumen HPI Smart Alerts and Smart Trends Software|Device: Acumen HPI Smart Alerts and Smart Trends Software The Acumen HPI Smart Alerts and Smart Trends Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The Acumen HPI Smart Alerts and Smart Trends Software suite is enabled by the minimally invasive Acumen IQ sensor.
41492659|NCT05960318|DEVICE|KalobaNaso spray|Nasal spray, 2 puff per nostril, 3 times a day
41350943|NCT01392391|PROCEDURE|Task Oriented Exercise Training|"Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines"
40831996|NCT03333395|DRUG|Nebulized salbutamol|S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
40831997|NCT04126265|DEVICE|Artificial intelligence assisted colonoscopy|The colonoscopy is connected to the real-time polyp detection system. If the polyp is detected by enteroscopy, the alarm will be given.
40831998|NCT03791853|DIAGNOSTIC_TEST|Light-CT|Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
40831999|NCT00410826|DRUG|erlotinib hydrochloride|Given orally
40832000|NCT00410826|DRUG|cisplatin|Given IV
40832001|NCT00410826|RADIATION|3-dimensional conformal radiation therapy|35 fractions
40832002|NCT00410826|RADIATION|intensity-modulated radiation therapy|35 fractions
40832003|NCT00410826|PROCEDURE|quality-of-life assessment|Ancillary studies
41158931|NCT02582034|RADIATION|Optimized Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~* An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~* A dose at the treated healthy liver \< 120 Gy in case of lobar treatment~* Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve \> 30%~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments."
40832005|NCT04149678|DRUG|Ozanimod|Ozanimod
41158932|NCT02582034|RADIATION|Standard Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~* An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments."
41350944|NCT01392391|PROCEDURE|"Stroke Care Get with the Guidelines"|"Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica"
41350945|NCT04994275|OTHER|no intervention, but presence of ID or not|This is an observational study regarding patients admitted to undergo a major elective surgery supposed to last more than an hour. Investigators will analyzed the incidence of postoperative infections up to 90 days after surgery according to the preoperative iron status: iron deficiency (defined as a ferritin of less than 100 µg/L or \<300 µg/L And TSAT\<20%) or no iron deficiency
41350946|NCT03094338|BEHAVIORAL|stress, psychological|students respond to questionnaires
40832006|NCT04149678|DRUG|Cyclosporine|Cyclosporine
40832007|NCT02436408|DRUG|Vismodegib|
40832008|NCT06358586|DRUG|Tachipirina® 120 mg/5 mL oral suspension, new flavour|A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
40832009|NCT05289583|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
41492660|NCT05960318|DEVICE|KalobaNaso junior spray|Nasal spray, 1 puff per nostril, 3 times a day
41492661|NCT02893202|OTHER|Therapeutic Horseback riding|An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
41492662|NCT01439750|DRUG|Rituximab|375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
41350947|NCT04850885|DRUG|inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml|The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
41350948|NCT05673382|BEHAVIORAL|Internet-based cognitive behavioral therapy|The intervention (the treatment) within this study is based on cognitive behavioral therapy principles and adapted to target psychological symptoms related to life crises. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
41350949|NCT01051856|DEVICE|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
41350950|NCT01051856|PROCEDURE|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
41350951|NCT02428387|BEHAVIORAL|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
41350952|NCT03148249|OTHER|interview|control group: interview, study group: explanation and exploration
41350953|NCT00584987|DRUG|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
41350954|NCT00584987|DRUG|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
41350955|NCT00584987|DRUG|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
41350956|NCT00584987|DRUG|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
41350957|NCT04783961|PROCEDURE|Cold snare endoscopic resection|Cold snare endoscopic resection
41350958|NCT04818112|BEHAVIORAL|ATVV|A 15-minute behavioral intervention that mothers administer once daily to their infant for 3 months providing Auditory, Tactile, Visual, and Vestibular (ATVV) stimulation. Multisensory stimuli are presented in gradual progression. Mother-infant engagement is attempted throughout ATVV so that mothers learn to identify, interpret and adapt to their infants cues. ATVV can be given without eye to eye gaze making it appropriate for newborns. ATVV is offered contingent on infant cues to promote self-regulation and withdrawn if any persistent disengagement cues. Mothers are taught how to adapt ATVV as their infant grows. Fidelity to the intervention is checked with weekly phone calls and monthly study visits. Mothers also receive a daily text from REDCap to document an intervention frequency log.
41350959|NCT04818112|BEHAVIORAL|Attention control|Mothers in the Attention Control group receive a similar amount of daily texts, weekly phone call and in-person study visit attention as mothers in the ATVV group, but with distinctly different content. Over the first 3 postnatal months, mothers learn safe infant-care that includes content on diapers, infant clothing, blankets, infant care including bathing, sleep positions, sleep habits, holding the baby, safety of infant equipment, breastfeeding, formula, and age appropriate toys.
41350960|NCT05348499|OTHER|Questionnaire/Interview|Questionnaire/Interview
41350961|NCT05917392|DIETARY_SUPPLEMENT|Fermented Vegetables (Kimchi) supplementation|Fermented Vegetables (Kimchi) supplementation with 50 gm daily for two months and effects of DNA methylation, serum proteome and microbiota
41350962|NCT05917392|DIETARY_SUPPLEMENT|probiotic|Supplementation with Kimchi plus LGG 50 grams daily for two months
41350963|NCT05917392|DIETARY_SUPPLEMENT|polyphenol|Supplementation with Kimchi plus polyphenol 50 grams daily for two months
41350964|NCT05798702|PROCEDURE|roux -en-y- gastric bypass|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.
41350965|NCT05798702|DIETARY_SUPPLEMENT|intensive life style modification|Weight loss will be induced using a VLCD (800-850 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) with replacement meals for 2 months, followed by structured food reintroduction every 2-8 weeks (about 50% carbohydrate, 35% total fat, and 15% protein), and an ongoing structured program with follow-up visits up to 25% body weight loss
41350966|NCT05235802|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) (including functional MRI)|"Patients will undergo magnetic resonance imaging including the following protocols:~* 3D T1w MPRAGE~* 3D T2w FLAIR SPACE~* 3D T2w SPACE~* 3D T1w PSIR (cortical visualization)~* 2D synthetic MRI (quantitative T1, T2, PD and myelin quantification)~* Resting-state fMRI (6 min, human connectome protocol, 2 mm iso)~* 3D SWI~* DWI b1000 32 directions and b3000 64 directions."
41350967|NCT05235802|DIAGNOSTIC_TEST|Blood sampling (serum/plasma preparation)|Blood will be screened for genetic modifications. Serum will be analyzed for auto-antibodies and other inflammatory and neurodegenerative biomarkers.
40832010|NCT04723225|OTHER|Cat-Cow Yoga|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided
41020353|NCT03294369|OTHER|Observational|This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
41020354|NCT03952039|DRUG|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
41020355|NCT03952039|DRUG|Best Available Therapy (BAT)|Best available therapy (BAT)
41020356|NCT03652324|OTHER|method|to compare the use of general anesthesia and deep sedation
41020357|NCT03206021|DRUG|5 Azacytidine|Dose escalation of carboplatin combined with 5'azacytidine
41020358|NCT05754086|BEHAVIORAL|Clear Speech|"This behavioral modification asks participants to speak more clearly, as if they were speaking to someone with a hearing loss."
41020359|NCT05754086|BEHAVIORAL|Less Clear Speech|"This behavioral modification asks participants to speak less clearly, as if they were in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear."
41020360|NCT01548690|DRUG|Ornithine Phenylacetate|"Up to 36 patients will be enrolled into 2 groups \[\~18 with minimal renal dysfunction (Cohort 1) \& \~18 w/ comprised renal function (Cohort 2)\] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (\~6 Cohort 1 \& \~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
41020361|NCT05999409|OTHER|practice on birth simulator|making attempts at labor
41020362|NCT05521893|OTHER|Telemedicine care|"In the telemedicine group, the appointments are performed online via scheduled videoconferences, on a monthly basis.~All women in the telemedicine group receive a smartphone with the installed application that enable transfer of the measured capillary glucose concentration."
41350968|NCT05235802|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF)|CSF will be analyzed for inflammatory and neurodegenerative biomarkers.
41020363|NCT05521893|OTHER|Standard care|In the standard care group, visits are scheduled at the diabetes clinic on a monthly basis.
41020364|NCT04720534|DRUG|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
41350969|NCT05235802|DIAGNOSTIC_TEST|Clinical assessments / questionnaires|"* Glasgow Outcome Scale Extended (functional outcome)~* Short-Form 36 (quality of life),~* EQ-5D (quality of life),~* Mini-Mental State Extended (MMSE) (mental state assessment).~* Barthel Index (daily living disabilities),~* Montgomery-Åsberg Depression Score (MADRS-S) (level of depression)~* Fatigue Severity Scale (FSS) (level of fatigue)~Other than that, neurological assessments focusing on the Unified Parkinson's Disease Rating Scale (UPDRS) will be performed."
41020365|NCT04720534|DRUG|Placebo|calculated volume to match active treatment by sc injection
41350970|NCT04467866|BEHAVIORAL|A Ride-on Car with a Standing Posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
41350971|NCT04467866|BEHAVIORAL|Regular Therapy Program|The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the hallway/public space and interact with the therapist and caregivers depending on his/her motor abilities.
41350972|NCT04257006|DEVICE|oXiris membrane|Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT
41020366|NCT00274716|DRUG|MK0736|
41020367|NCT00274716|DRUG|MK0916|
41350973|NCT04509635|DRUG|Cetuximab|Cetuximab is used for only patients with ctDNA test RAS wild type.
41350974|NCT04509635|DRUG|Chemotherapy|The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
40832011|NCT01555554|DRUG|Propranolol Hydrochloride|"Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.~On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).~On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).~On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).~On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).~This will complete the course of propranolol."
41020368|NCT00274716|DRUG|Placebo|
41020369|NCT05988216|BIOLOGICAL|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
41158936|NCT03799354|OTHER|Maximal strenght training (MST) plus endurance training (ET)|"Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of:~1. MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press.~2. ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression."
41350975|NCT03236649|DRUG|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
40832012|NCT01555554|OTHER|Placebo|"The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.~On post operative days #1-13, patients will take one placebo pill (once daily by mouth).~This will complete the course of the placebo."
41158937|NCT03799354|OTHER|Endurance training (ET)|"Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session.~Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician."
41158938|NCT05764642|DRUG|Definity|Ultrasound contrast agent administered intravenously
41158939|NCT05764642|DIAGNOSTIC_TEST|Super-resolution ultrasound imaging|Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
41158940|NCT06536374|DRUG|Trimethoprim Tablets|Trimethoprim 150mg is administered once daily for 3 months
40832013|NCT05363865|BEHAVIORAL|Virtual Community Intervention|Modules of community building, HIV/HCV prevention, drug and service stigma, identification of mental health problems
41020370|NCT04660123|DRUG|Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication|"Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.~Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).~Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.~Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.~Antibiotic Program:~Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d."
41158941|NCT01297452|DRUG|BKM120 days 1 - 21 plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.
41158942|NCT01297452|DRUG|BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.
41350976|NCT03236649|DRUG|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
41350977|NCT06397157|OTHER|Virtual Reality|Participants will recieve treatment(Virtual reality) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
41350978|NCT06397157|OTHER|Motor Imagery|Participants will recieve treatment(Motor Imagery) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
41350979|NCT06397157|OTHER|Routine Physical therapy|Participants will recieve treatment(Routine physical therapy) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
40832014|NCT05363865|BEHAVIORAL|Standard of Care|health websites and county information provided to participants
40832015|NCT00349830|PROCEDURE|blood draw|
40832016|NCT05510882|OTHER|different treatment modalities for OSA|Group I: patients will be treated with CPAP. Group II: patients will be treated with digitally fabricated MAD. Group II: patients will be treated with physical therapy.
40832017|NCT05667805|DRUG|Platelet Concentrate|Liberal use (standard treatment)
40832018|NCT05667805|DRUG|Prothrombin Complex Concentrate|Liberal use (standard treatment)
41020371|NCT02012387|BIOLOGICAL|Active|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
41020372|NCT02012387|BIOLOGICAL|Placebo|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
41158943|NCT01297452|DRUG|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A
41158944|NCT01297452|DRUG|BKM120, Paclitaxel + Carboplatin|BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
40832019|NCT05667805|OTHER|Restricitve Use|Restrictive use of human prothrombin complex and platelet concentrates. No prophylactic substitution.
40832020|NCT03224065|DIAGNOSTIC_TEST|Genotype detected through GenSeizer high-throughput gene capture technology|The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
41158945|NCT00346177|BIOLOGICAL|Autologous Stem Cells|Intramyocardial injections
41158946|NCT06646016|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
41158947|NCT06646016|DRUG|Infliximab or Vedolizumab|Infliximab or vedolizumab will be administered intravenously.
41350980|NCT03837301|PROCEDURE|NESS-EFTR with sentinel lymph node navigation|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection with sentinel lymph node navigation (basin dissection) for early gastric cancer patients
41350981|NCT00554840|DRUG|varenicline|Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
40832021|NCT00693004|DRUG|PRX-03140|
40832022|NCT00693004|DRUG|Donepezil|
40832023|NCT00693004|DRUG|Placebo|
41350982|NCT00554840|DRUG|placebo|At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
41350983|NCT01996228|DEVICE|Stem Cell Educator|
41350984|NCT00806611|PROCEDURE|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
41492663|NCT01439750|DRUG|bortezomib|1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
41350985|NCT03686579|RADIATION|chest trauma|clinical and radiological study
41350986|NCT01842191|DIETARY_SUPPLEMENT|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
41492664|NCT01439750|DRUG|Cladribine|Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
41492665|NCT03557879|GENETIC|Exome sequencing|DNA extracted from samples will undergo exome sequencing, i.e. sequencing of the coding regions of all known human genes (about 22,000)
41492666|NCT00465465|BIOLOGICAL|MVA 85A|i.d. injection
41492667|NCT04664790|DEVICE|Hyperbaric Oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
40832024|NCT01399632|BEHAVIORAL|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
40832025|NCT01399632|BEHAVIORAL|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
40832026|NCT04287088|DIAGNOSTIC_TEST|A shared decision making|Based on prostate cancer risk calculation (age, usage of 5-ARI medication, baseline PSA, IMPROD bpMRI Likert, prostate volume) a shared decision making whether to perform prostate biopsies or not
40832027|NCT04886947|PROCEDURE|stem cell transplantation|After surgical repair of alveolar cleft using gingivoperiosteoplasty, processed and stored autologous stem cells will be added at the repair site. After which the patient will be followed up for bone regeneration and this will be compared to control where no stem cell is added.
40832028|NCT06520631|OTHER|Ice packs (cryotherapy)|"One group of patients receives ice pack applied on the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.~The second group of patients receives ice pack applied on contralateral to the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis."
40832029|NCT03849690|DRUG|TAK-906|TAK-906 capsules.
40832030|NCT03849690|DRUG|Esomeprazole|Esomeprazole capsules.
40832031|NCT02012088|DRUG|RCOMP|Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
41158948|NCT05561751|DRUG|GPC-100|GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min
41158949|NCT05561751|DRUG|Propranolol|propranolol
41158950|NCT05561751|DRUG|G-CSF|G-CSF
41158951|NCT02640222|DRUG|VKA|
41158952|NCT02640222|DRUG|Apixaban|
41158953|NCT02640222|DRUG|dabigatran|
41158954|NCT02640222|DRUG|rivaroxaban|
41350987|NCT01842191|DIETARY_SUPPLEMENT|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
41350988|NCT04533360|DIAGNOSTIC_TEST|VITROS Anti-SARS-CoV-2 IgG test|The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
41492668|NCT04664790|BEHAVIORAL|Cognitive training|Neuropsychologist guided BrainHQ training
41020373|NCT02012387|BIOLOGICAL|Open labeled|Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
41020374|NCT01312545|DEVICE|3DP|intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
41020375|NCT01312545|DEVICE|Medpor|commercial porous polyethylene
41350989|NCT01118585|PROCEDURE|TIF Procedure|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
41020376|NCT00110266|DRUG|Deferasirox|20 mg/kg/day over one year in patients with MDS
41020377|NCT05403827|DRUG|K-161|K-161 Ophthalmic Solution
41350990|NCT03231228|DRUG|Cefazolin 1 g Infusion|1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to \<60 kg
41350991|NCT03231228|DRUG|Cefazolin 2 g Infusion|2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
41350992|NCT03229876|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
41492669|NCT04880824|BEHAVIORAL|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
41492670|NCT01476618|OTHER|No Intervention|No Intervention
41492671|NCT04864470|BEHAVIORAL|Stroke Odysseys|"The participants will take part in a twelve-week performance programme that takes place online/in a community halls/arts centre. Sessions run for three hours and during these sessions, participants devise a dance and music performance work from their own stories. The culmination of the programme will be a public facing performance to an audience of carers, health care practitioners, friends, family and the wider community, done online through Zoom.~After the performance is completed, participants will be invited to a training programme where they learn to act as advocates for life after stroke - termed 'stroke ambassadors'. The training will be a four-day programme. The programme will take place once weekly and is led by a team of artists supported by a leadership coach, on Zoom.~Following training, ambassadors will support artists in recruitment, befriend the newly discharged stroke survivors and take part in small scale performance tours to challenge the perception of disability."
41492672|NCT03986138|DRUG|gadopiclenol|Single intravenous bolus injection
41492673|NCT03986138|DRUG|Gadobutrol 1 MMOLE/ML Intravenous Solution|Single intravenous bolus injection
41492674|NCT01879865|OTHER|Non-stimulation|The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
41492675|NCT01879865|OTHER|Stimulation|The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
41492676|NCT02912650|DRUG|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
40832032|NCT02012088|DRUG|RCHOP|Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
41020378|NCT05403827|DRUG|Placebo|Vehicle Solution
41020379|NCT03388073|OTHER|Berry extract I|Seabuckthorn berry proanthocyanidin extract 250 mg single dose
41020380|NCT03388073|OTHER|Berry Extract II|Seabuckthorn berry proanthocyanidin extract 500 mg single dose
41020381|NCT03388073|OTHER|Berry extract blend|Seabuckthorn berry blend with other berry-based antioxidants
41020382|NCT03388073|OTHER|Placebo|Placebo
41350993|NCT00278967|DRUG|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
41350994|NCT00278967|DRUG|HalfLytely - Reformulation|
41350995|NCT00266695|DRUG|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
41350996|NCT02709941|OTHER|Inspiratory muscle strength training|Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.
41350997|NCT02709941|OTHER|Placebo|
41350998|NCT02563886|OTHER|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
41492677|NCT02912650|DRUG|Ibuprofen 250 mg|2 caplets of Ibuprofen 125 mg
41020383|NCT04286594|DRUG|CBD|Participants will receive CBD solution during the open-label phase of the trial.
41020384|NCT06572319|DRUG|Disitamab Vedotin(RC48) Plus Tratuzumab|Disitamab Vedotin: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Tratuzumab: RP2D，ivgtt，D1, every 2 weeks for a treatment cycle.
41158955|NCT02250183|DEVICE|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
41158956|NCT02250183|DEVICE|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
41158957|NCT04087070|DEVICE|Biosignal measurements|"Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~1. PAT(time between R peak of ECG and beginning of the pulse of PPG)~2. PEP(time between R peak of ECG and peak of accelerometer signal)~3. PTT(PAT-PEP)"
41158958|NCT03334773|BEHAVIORAL|Nutrition education|
41158959|NCT01902381|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
41158960|NCT06646744|BIOLOGICAL|mRNA COVID-19 vaccine|Children will be vaccinated according to standard local procedure
41158961|NCT06297590|DRUG|LY3954068|Administered IT
41158962|NCT06297590|DRUG|Placebo|Administered IT
41158963|NCT06297590|DRUG|Flortaucipir F18|Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan
41492678|NCT02912650|DRUG|Acetaminophen 650 mg|2 tablets of Acetaminophen 325 mg
41020385|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + placebo gel|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.
41020386|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
41020387|NCT01167946|DRUG|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
41020388|NCT01167946|DRUG|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
41020389|NCT01167946|DRUG|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
41020390|NCT03905057|DEVICE|Dornier Aries 2 (with active applicator)|Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
41020391|NCT03905057|DEVICE|Dornier Aries 2 (with sham applicator)|Sham ESWT - No shockwave administered
41158964|NCT00815919|DRUG|bortezomib|Given intravenously at a dose of 1.3 mg/m\^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
41158965|NCT00815919|DRUG|Prednisone|Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
41158966|NCT06625320|DRUG|RMC-6236|Oral Tablets
41158967|NCT06625320|DRUG|Gemcitabine|intravenous (IV) infusion
41158968|NCT06625320|DRUG|nab-paclitaxel|IV infusion
41158969|NCT06625320|DRUG|Irinotecan|IV infusion
41492679|NCT02912650|DRUG|Placebo|2 caplets of Placebo
41492680|NCT04674748|DRUG|INCB086550|Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.
41492681|NCT03035344|OTHER|Metabolome study|Metabolome study in ALL patients compared to healthy controls
41492682|NCT04732273|OTHER|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests depending on examined organ system (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels).
41492683|NCT04732273|OTHER|Personal history, questionnaire|Personal history and focused questionnaires per organ system including symptoms, medication use, physical activity, and general wellbeing.
41492684|NCT01156142|DRUG|doxepin hydrochloride|Oral rinse
41492685|NCT01156142|OTHER|placebo|Oral rinse
40832033|NCT01902459|BIOLOGICAL|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
41350999|NCT02563886|OTHER|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
41351000|NCT04974944|DRUG|Camrelizumab|IV injection
41351001|NCT04974944|DRUG|Apatinib|Oral
41351002|NCT04974944|DRUG|Paclitaxel|IV injection
40832034|NCT01902459|OTHER|Standard of Care|Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
41351003|NCT04974944|DRUG|Cisplatin|IV infusion
41351004|NCT04974944|DRUG|Carboplatin|IV infusion
41351005|NCT04974944|DRUG|Bevacizumab|IV infusion
41351006|NCT04741204|DRUG|Metformin Extended Release Oral Tablet|initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.
41020392|NCT06451523|OTHER|Alliance180 Program|The Alliance180 Program promotes feelings of neuropsychological safety and trust in the context of a 3-day program, which includes the transformative equine experience.
40832035|NCT02230683|DRUG|IDN-6556|25 mg BID
40832036|NCT02352636|OTHER|magnetotherapy|The magnetic pellets will contain an average of \~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm
40832037|NCT02352636|DEVICE|laser auriculotherapy|A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.
40832038|NCT02352636|OTHER|Placebo|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
41020393|NCT06574243|BEHAVIORAL|Social media education|"The intervention consisted of daily positive messages about aging posted on an Instagram account (@laetapaplateada), created specifically for this study, and was conducted over the course of a week. Examples included The ability to make decisions improves with age and Emotional regulation improves with age (David, 2017). These posts were accompanied by their respective author references"
41020394|NCT02167035|DRUG|Combigan Two Times Daily (BID)|
41020395|NCT02167035|DRUG|Simbrinza Three Times Daily (TID)|
41351007|NCT01843933|DEVICE|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
41351008|NCT04754906|OTHER|Sequence 1|perform arm movements towards a target
41351009|NCT04754906|OTHER|Sequence 2|judge the verticality of an object
41351010|NCT04754906|OTHER|Sequence 3|In standing position, point as quickly as possible with the right arm at the diode that will light up in front of the participant.
41351011|NCT04754724|DIAGNOSTIC_TEST|GIMate|Use of GIMate to detect lactose malabsorption
41351012|NCT04754724|DIAGNOSTIC_TEST|H2 Check|Use of H2 Check to detect lactose malabsorption
41351013|NCT02170558|DEVICE|TM- Ardis implant and Metal Reduction CT software|TM- Ardis implant and Metal Reduction CT software
41351014|NCT03192384|BEHAVIORAL|Educational programme|Educational programme for ward staff
41351015|NCT02557867|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
41351016|NCT00865358|BEHAVIORAL|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
41351017|NCT00423267|DRUG|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
41351018|NCT00423267|DRUG|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
41351019|NCT00240929|DRUG|MEDI-493|Active Comparator
40832039|NCT05536622|DIAGNOSTIC_TEST|High resolution infrared imaging|High resolution infrared imaging of limb of concern and unaffected limb (control).
40832040|NCT01656369|PROCEDURE|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
40832041|NCT01656369|PROCEDURE|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
40832042|NCT00975819|DRUG|sirolimus|liquid dosing based on trough levels
40832043|NCT03079401|BIOLOGICAL|MPC; rexlemestrocel-L|MPCs will be injected into the patient's myocardium during planned surgical procedures.
40832044|NCT01430676|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
40832045|NCT00143780|BIOLOGICAL|The polysaccharide vaccine used is Pneumovax (Merck vaccines)|
40832046|NCT00143780|BIOLOGICAL|The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)|
40832047|NCT05517902|BIOLOGICAL|StrataGraft|StrataGraft® Construct
40832048|NCT04716075|DRUG|Acalabrutinib 2x100 MG Oral Capsule + alloSCT|Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.
40832049|NCT01804569|OTHER|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
40832050|NCT05162742|DRUG|Colchicine|ATC: M04AC01
40832051|NCT05162742|DRUG|Placebo|Placebo tablets
40832052|NCT02317952|OTHER|Experimental Extensively Hydrolyzed Formula|
41351020|NCT05010291|BEHAVIORAL|Standard of Care (SOC) text message reminder to attend clinic appointment|SOC one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
41351021|NCT05010291|BEHAVIORAL|Loss aversion framed text message reminder to attend clinic appointment|Loss aversion framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
40832053|NCT02317952|OTHER|Active Comparator Formula|
40832054|NCT05379114|OTHER|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
40832055|NCT05379114|OTHER|Comparator device|well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
41020396|NCT04317586|DEVICE|Trident II Tritanium Acetabular Shell for Revision|A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)
41020397|NCT02432365|DRUG|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
41020398|NCT02432365|DRUG|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
41020399|NCT02432365|PROCEDURE|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
41020400|NCT01975844|OTHER|Individualized Anemia Mangement Protocol|"Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
41020401|NCT02486406|DRUG|Ombitasvir/paritaprevir/ritonavir|Film-coated tablet for oral use
41020402|NCT02486406|DRUG|Dasabuvir|Film-coated tablet for oral use
41020403|NCT02486406|DRUG|Ribavirin|Film-coated tablet for oral use
41351022|NCT05010291|BEHAVIORAL|Social norms framed text message reminder to attend clinic appointment|Social norms framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
40832056|NCT02023021|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
40832057|NCT02023021|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
40832058|NCT00780286|DEVICE|Polymer based lubricating liquid|5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
40832059|NCT00780286|DEVICE|Moi-Stir|2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
40832060|NCT04912323|DEVICE|Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold|Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
40832061|NCT00685373|DRUG|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
40832062|NCT05705752|OTHER|Balance training|12 sessions of balance training en 4 weeks, with a duration of 40-45 min each.
40832063|NCT05705752|OTHER|Pilates training|12 sessions of Pilates training en 4 weeks, with a duration of 40-45 min each.
40832064|NCT00240110|DRUG|Valproate|Valproate with dose titration to achieve blood levels within the therapeutic range
40832065|NCT00240110|DRUG|Placebo|Control arm
40832066|NCT00240110|DRUG|Lithium Carbonate|All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
41020404|NCT02486406|DRUG|Ombitasvir mini tablet|Film-coated tablet for oral use
41158970|NCT06625320|DRUG|Liposomal irinotecan|IV infusion
41492686|NCT04992429|PROCEDURE|SphinkeeperTM|The SphinkeeperTM includes up to 10 self-expandable prostheses, which get inserted into the intersphincteric place. They are made of inert Hyexpan (polyacrylonitrile)
41158971|NCT06625320|DRUG|5-fluorouracil|IV infusion
41158972|NCT06625320|DRUG|leucovorin|IV infusion
41158973|NCT06625320|DRUG|Oxaliplatin|IV infusion
41158974|NCT06373146|DRUG|Tirzepatide|Administered SC
41158975|NCT06373146|DRUG|Mibavademab|Administered SC
41351023|NCT05010291|BEHAVIORAL|Altruism framed text message reminder to attend clinic appointment|Altruism framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
41492687|NCT00042536|DRUG|Naltrexone HCL/ Yohimbine HCL|
41020405|NCT02486406|DRUG|Paritaprevir mini tablet|Film-coated tablet for oral use
41020406|NCT02486406|DRUG|Ritonavir mini tablet|Film-coated tablet for oral use
41158976|NCT06373146|DRUG|Tirzepatide-Placebo|Administered SC
41351024|NCT05390034|BEHAVIORAL|ART|Session 1: Description of the group \& Psychoeducation Session 2: Breathing and muscle relaxation Session 3: Importance of practice/motivation Session 4: Nonjudgemental awareness Session 5: Acceptance and tolerance Session 6: Self-support Session 7: Analysis of emotions Session 8: Modification of emotions Session 9: Practice and contextual applications + end of group
41351025|NCT05390034|BEHAVIORAL|Relaxation|Session 1: Description of the groupe \& Psychoeducation Session 2: Breathing control 1 Session 3: Breathing control 2 Session 4: Muscle relaxation Session 5: Visualisation Session 6: Stretching Session 7: Schultz relaxation Session 8: Schultz relaxation Session 9: Summary and end of group
41351026|NCT02140762|BIOLOGICAL|MenABCWY|Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.
41351027|NCT02140762|OTHER|Placebo|0.5 mL saline solution (IM)
41351028|NCT02140762|BIOLOGICAL|MenACWY|Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
41351029|NCT03172013|DIAGNOSTIC_TEST|Platelet indices|MPV, PDW
41351030|NCT03508973|OTHER|Sculpta|
41020407|NCT02486406|DRUG|Dasabuvir mini tablet|Film-coated tablet for oral use
41020408|NCT02486406|DRUG|Ribavirin solution|Oral solution
41020409|NCT01168999|OTHER|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
41020410|NCT01168999|OTHER|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
41351031|NCT04096469|BEHAVIORAL|Motivational Interviewing|The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
41351032|NCT04096469|BEHAVIORAL|Traditional Education|Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
41492688|NCT04211727|DIAGNOSTIC_TEST|Capillary finger prick blood sample|Patients will have a blood finger prick sample
41492689|NCT03596892|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
41020411|NCT01168999|OTHER|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
41158977|NCT06373146|DRUG|Mibavademab-Placebo|Administered SC
41158978|NCT06440109|OTHER|Emotional freedom technique (EFT)|İntervention groups will be followed for six months and one of the six EFT therapies will be applied, one session every week.
41158979|NCT06440109|OTHER|Therapeutic touch (TD)|İntervention groups will be followed for six months and one of the six TD therapies will be applied, one session every week.
41158980|NCT06455202|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
41158981|NCT06455202|BIOLOGICAL|Matching placebo|Matching placebo Subcutaneous Administration
41351033|NCT00819052|DRUG|Nevirapine XR|Nevirapine XR
41492690|NCT03596892|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
41492691|NCT03596892|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
41492692|NCT04689867|BEHAVIORAL|Cognitive Behavioral Suicide Prevention for psychosis CBSPp)|Cognitive and behavioral approach to suicide prevention among individuals with psychosis
41158982|NCT06646653|DEVICE|Alma System|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
41351034|NCT00819052|DRUG|Nevirapine XR|Nevirapine extended release
41351035|NCT00819052|DRUG|Nevirapine IR|Nevirapine Immediate Release
41492693|NCT01454271|PROCEDURE|Total Hip Arthroplasty Replacement|Total Hip Arthroplasty Replacement
40832067|NCT01741831|DRUG|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
40832068|NCT04255043|DEVICE|IVUS guidance|IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment
40832069|NCT04255043|DEVICE|Angiography guidance|DCB (Sequent® Please) treatment
40832070|NCT00601861|DRUG|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
40832071|NCT04214912|COMBINATION_PRODUCT|Personalized Survivor Care Plan (PSCP)|Based the above literature review and our previous 10 years' efforts in OC patients' distress and care needs survey, we categorize OC patients' distress and needs into 6 major dimensions (1) symptoms management and dysfunction prevention (different kind of symptom, such as swallowing difficulty, eating difficulty, speaking difficulty, difficulty in opening mouth/trismus, shoulder dysfunction, mucositis, pain, fatigue, etc), (2) enhancing physical function (exercise skills, types for major parts of muscle training), (3) Confronting and dealing with psychological distress (fear, anxiety, depression, uncertainty), (4) nutrition assessment and counseling, (5) Social connection and RTW counseling (attitudes and skills for returning to work), and (6) overall needs assessment and supports.
40832072|NCT03980821|DRUG|AZD4635|AZD4635 taken orally
40832073|NCT03112746|BEHAVIORAL|Cognitive Orientation to Daily Occupational Performance|In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.
40832074|NCT05360329|PROCEDURE|Transarterial geniculate artery embolization|The procedure will be performed in local anaesthesia. An antegrade percutaneous transfemoral approach with super-selective catheterisation of geniculate neovesselswill be performed and subsequently the target will be pruned with microspherical embolic material.
40832075|NCT00050973|DRUG|bexarotene|
41351036|NCT03030261|DRUG|Elotuzumab|During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg.
41351037|NCT03030261|DRUG|Pomalidomide|During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.
41492694|NCT03986827|BEHAVIORAL|Cool Kids Anxiety Program - Social Enhanced|Specific G-CBT intervention for adolescents with social anxiety disorder
40832076|NCT01479946|DRUG|Electrochemotherapy|bleomycin together with electroporation
40832077|NCT04248894|OTHER|Exercise training of High Intensity|High intensity
41492695|NCT03986827|BEHAVIORAL|Cool Kids Anxiety Program|Generic G-CBT intervention for adolescents with anxiety disorders
41492696|NCT02973230|OTHER|Dosage of VEGF serum concentration|Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
40832078|NCT04248894|OTHER|Exercise training of Moderate Intensity|Moderate intensity
40832079|NCT04248894|OTHER|Untraining|Sedentary
40832080|NCT01564524|PROCEDURE|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
41158983|NCT06591767|DIETARY_SUPPLEMENT|Quercetin|200 mg supplemental Quercefit®
41158984|NCT06591767|COMBINATION_PRODUCT|Berberol K®|"Berberine Phytosome® 730 mg~+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract"
41158985|NCT00309621|DRUG|alitretinoin|
41492697|NCT02272634|DRUG|YPL-001 80 mg|twice daily \[BID\]
41492698|NCT02272634|DRUG|YPL-001 160 mg|twice daily \[BID\]
41492699|NCT02272634|DRUG|Placebo|twice daily \[BID\]
41492700|NCT02724930|BEHAVIORAL|Enhanced facilitation of COPES|Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
40832081|NCT05788315|OTHER|Cultural Formulation Interview|The Cultural Formulation Interview will be used at the start of treatment in the intervention group against a standard practice intake in the control group.
40832082|NCT01750359|DRUG|curcumin|500 mg/day for 6 week
40832083|NCT04588155|DEVICE|Functional assessment|Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution
40832084|NCT04588155|OTHER|Clinical assessment|"Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution"
40832085|NCT06348914|BEHAVIORAL|Knowledge assessment|survey on knowledge of a group of dental students regarding vital pulp therapy
40832086|NCT06348914|OTHER|Educational Material|An awareness lecture on vital pulp therapy will be given to a group of the students right after they answer the questionnaire for the first time.
40832087|NCT04289077|OTHER|Questionnaires|- Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
40832088|NCT05551624|DRUG|Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet|Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
40832089|NCT00319475|PROCEDURE|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
40832090|NCT06195995|DEVICE|Transcranial alternating current stimulation-true stimulus|Three conductive electrodes are placed overhead. In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side. The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. The frequency of stimulation is 77.5Hz, and the current is 15mA.
40832091|NCT03819608|DEVICE|real iTBS|Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
40832092|NCT03819608|BEHAVIORAL|real APT|APT-III is an attention processing training program
40832093|NCT03819608|BEHAVIORAL|placebo APT|computerized cognitive training
40832094|NCT03819608|DEVICE|placebo iTBS|delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
40832095|NCT04315636|DRUG|Surfactant nebulisation|200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
40832096|NCT06184841|DRUG|HAIC combined with intravenous PD-1|Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
40832097|NCT03078933|DEVICE|Standard of Care|Standard of Care arm which includes wound care, dressings and debridement.
40832098|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
40832099|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
40832100|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
40832101|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
40832102|NCT04327635|DRUG|PEP|A biological drug made of certain parts of blood from living blood donors obtained from a certified blood bank. At the time of cardiac catheterization patients will undergo one-time intracoronary infusion of 10 milliliters of PEP dosage consisting of approximately 5%, 10%, or 20% PEP. PEP dose will be infused immediately distal to the newly placed stent over approximately 5 minutes.
41351038|NCT03030261|DRUG|Dexamethasone|During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
41492701|NCT03746431|DRUG|[111In]-FPI-1547 Injection|\[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
41020412|NCT00844545|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
41158986|NCT01261455|PROCEDURE|Location of the autograft taken following pterygium excision|Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
41351039|NCT02005679|BEHAVIORAL|application of the mini-mental state test|
41351040|NCT04722289|BEHAVIORAL|Together on Diabetes|Social and emotional support'; 'Assistance in daily management'; and 'Linkage to healthcare services'
41351041|NCT03323372|DRUG|3% potassium nitrate and 0.25% sodium fluoride|
41351042|NCT03323372|DRUG|5% potassium nitrate and 2% sodium fluoride|
41158987|NCT03130816|BIOLOGICAL|allogeneic cord blood transplantation|UCB with total nucleated cell count ≤ 7x108/kg will be used for this clinical trial. Suitable UCB (i.e., containing total nucleated cell count ≥2x107/kg with three or less mismatch among HLA-A, -B, and -DR) will be selected. This criterion was selected upon the rationale that even though minimal HLA mismatch is preferred, prior studies indicate significant effects of UCB therapy for patients with 3 HLA mismatches.
41158988|NCT06647251|PROCEDURE|Q-MODE : radiofrequency ablation up to 50W|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 50W."
41158989|NCT06647251|PROCEDURE|Q-MODE+ : radiofrequency up to 90W|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE+ option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 90W."
41351043|NCT03930394|DIAGNOSTIC_TEST|Contrast ultrasound perfusion imaging|Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.
41351044|NCT01979380|DRUG|KD101|200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning
41351045|NCT01979380|DRUG|placebo|PO, once in the morning
41351046|NCT04394013|BEHAVIORAL|Mindfulness intervention|Gentle body stretching with the incorporation of breathing technique
41351047|NCT04394013|BEHAVIORAL|Non-Mindfulness intervention|Gentle body stretching without the incorporation of breathing technique
41351048|NCT01058395|DRUG|Minocycline|Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
41492702|NCT03746431|DRUG|[225Ac]-FPI-1434 Injection multi-dose|\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.
41020413|NCT06358898|BEHAVIORAL|Standard dCBT-I|This standard digital CBT-I intervention will cover (1) psycho-education about sleep, circadian and sleep hygiene education, (2) stimulus control, (3) sleep restriction, (4) relaxation techniques, (5) structured worry time, (6) cognitive restructuring (targeting sleep-related dysfunctional cognitions), and (7) relapse prevention. In order to have comparable dosage as modified CBT-I, the treatment will be dispersed to 8 modules (8-week) which is still in the range of standard CBT-I duration (usually last for 6-8weeks).
41020414|NCT06358898|BEHAVIORAL|Modified Mood enhanced CBT-I (M-dCBT-I)|Additional depression specific components will be added to the standard CBT-I, including behavioral activation and problem solving.
41351049|NCT05914233|DEVICE|Non-invasive ultrasound retinal stimulation Device|Record user feelings during the device is working
41020415|NCT01593618|BEHAVIORAL|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
41020416|NCT01593618|OTHER|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
41020417|NCT05812482|PROCEDURE|Drug balloon dilatation|The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated
41351050|NCT00326976|DRUG|FX06|400 mg as intravenous injection in two divided boluses
41020418|NCT05812482|PROCEDURE|Direct vision internal urethrotomy (DVIU)|A control subject will choose DVIU surgery until the desired effect is achieved
41020419|NCT06101927|DRUG|Whole body study and SPECT with [99mTc]Tc-BQ0413|One single intravenous injection of \[99mTc\]Tc-BQ0413, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
41020420|NCT05691491|PROCEDURE|Biopsy|Undergo biopsy
41020421|NCT05691491|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41020422|NCT05691491|PROCEDURE|Computed Tomography|Undergo CT scan
41020423|NCT05691491|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41158990|NCT06647251|PROCEDURE|Hybride Q-MODE/Q-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE/Q-MODE+ option: the intensity of radiofrequency delivered to isolate the pulmonary vein is limited to 50W in the anterior part and to 90W in the posterior part."
41158991|NCT06646757|BEHAVIORAL|APP|1) My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs
41158992|NCT06646757|BEHAVIORAL|CBT|"2) Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)"
41351051|NCT00326976|PROCEDURE|Percutaneous coronary intervention|
41351052|NCT04806165|BEHAVIORAL|Repeated Administration|A discussion with the chatbot, including follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
41351053|NCT04806165|BEHAVIORAL|Personalized Recommendation|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder.
41351054|NCT04806165|BEHAVIORAL|Motivational Interviewing|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
41351055|NCT04806165|BEHAVIORAL|Core Modules Only|A discussion with the chatbot, including only the core modules.
41492703|NCT03746431|BIOLOGICAL|FPI-1175 Infusion|FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.
41020424|NCT05691491|DRUG|Temozolomide|Given orally (PO)
41020425|NCT05691491|DRUG|Tuvusertib|Given PO
41020426|NCT05558410|DRUG|VX-548|Tablets for oral administration.
41020427|NCT05558410|DRUG|HB/APAP|Capsules for oral administration.
41020428|NCT05558410|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
41020429|NCT05558410|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
41020430|NCT05280574|DEVICE|GE Portrait Monitor|All patients will be monitored
41020431|NCT05280574|DEVICE|GE Portrait Monitoring with intervened by clinician|Monitoring might be intervened if clinician believe that the alarm is clinically meaningful
41020432|NCT05280574|DEVICE|GE Portrait Monitoring randomized to blinded or unblinded|Without intervention
41020433|NCT00000465|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
41020434|NCT00000465|PROCEDURE|coronary artery bypass|
41020435|NCT02483247|DRUG|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
41020436|NCT02483247|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
41020437|NCT02483247|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 body surface area is administered intravenously once every three weeks (21-days).
41020438|NCT02483247|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
41020439|NCT02483247|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
41020440|NCT02483247|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
41492704|NCT03746431|DRUG|[225Ac]-FPI-1434 Injection single-dose|\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of \[225\]-FPI-1434 Injection. Dose is per cohort assignment.
41492705|NCT02297698|BIOLOGICAL|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
41492706|NCT02297698|DRUG|Trastuzumab|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
41492707|NCT02297698|DRUG|GM-CSF|For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
41492708|NCT05988684|DRUG|Metformin|Patients randomized to metformin group will be instructed to take 500 mg metformin daily for 1 week before titrating up to twice a day
41492709|NCT00746018|DEVICE|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
41492710|NCT00521040|DRUG|Levocetirizine dihydrochloride|
41158993|NCT06646757|BEHAVIORAL|HELP|3) IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost
41158994|NCT06646757|BEHAVIORAL|PEER|4) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation
41158995|NCT02222337|BEHAVIORAL|Nueva Vida Intervention|The psycho-educational format of the Nueva Vida Intervention is led by trained interventionists who have the survivors and caregivers go into different rooms to discuss the same topic. This format will allows them each to express their thoughts and feelings without inhibitions or concerns over how their survivor or their caregiver might respond. The specific topics for each wave of the intervention participants will be determined from a larger list of possible topics, with each group including the following core topics: Impact of Cancer on the Family, Spirituality and Cancer, Stress Management, Balancing Physical and Emotional Needs and Improving Communication.
41020441|NCT02483247|DRUG|Sunitinib|Sunitinib 37.5 mg is administered once daily.
41020442|NCT04592705|DEVICE|Therapeutic plasma exchange|"TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP."
41020443|NCT04661033|DRUG|Isatuximab SAR650984|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
41020444|NCT03327480|OTHER|orthosis|Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
41020445|NCT02885363|OTHER|Clinical examination|
41020446|NCT02885363|OTHER|Blood sample|
41020447|NCT02885363|PROCEDURE|Echocardiography|
41020448|NCT03120091|DEVICE|Real-time continuous blood glucose monitoring system(CGMS)|A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
41020449|NCT06071845|DEVICE|Cytosponge Procedure|Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.
41020450|NCT06071845|DIAGNOSTIC_TEST|Endoscopic Assessment|Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
41020451|NCT04982029|DRUG|Cannabidiol 100 MG/ML [Epidiolex]|600mg
41020452|NCT04982029|DRUG|Placebo|Matching placebo
41020453|NCT03802097|PROCEDURE|No use of antimicrobial prophylaxis|Do not use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
41020454|NCT03802097|PROCEDURE|Use of antimicrobial prophylaxis|Use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
40832103|NCT04041206|DEVICE|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated \[Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)\]. The acupoint microcirculation will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian"
40832104|NCT04460586|DRUG|Omadacycline Injection [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
40832105|NCT04460586|DRUG|Omadacycline Oral Tablet [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
40832106|NCT00892203|DRUG|BGG492|
40832107|NCT00892203|DRUG|Sumatriptan|
40832108|NCT00892203|DRUG|Placebo|
40832109|NCT01509677|DRUG|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
40832110|NCT01509677|DRUG|Placebo|tablet, once daily, oral administration in the morning after breakfast
40832111|NCT02220751|DRUG|non-surgical periodontal therapy + systemic doxycycline|"A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group."
41158996|NCT06308731|DIETARY_SUPPLEMENT|Caffeine-Based Energy Drink|Energy drink with 200 mg caffeine
41158997|NCT06308731|OTHER|Placebo|Placebo
41351056|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
41351057|NCT04806165|BEHAVIORAL|Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
41351058|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and identifying a personalized recommendation for accessing help for their eating disorder.
41351059|NCT04806165|BEHAVIORAL|Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
41351060|NCT04806165|BEHAVIORAL|Psychoeducation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders.
41351061|NCT04806165|BEHAVIORAL|Psychoeducation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
41351062|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and identifying a personalized recommendation for accessing help for their eating disorder.
41351063|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
41351064|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and identifying a personalized recommendation for accessing help for their eating disorder.
41492711|NCT02846272|PROCEDURE|Observation|Observation of MRI changes in subjects
41351065|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
41351066|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
40832112|NCT02220751|PROCEDURE|Non-surgical periodontal therapy|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
40832113|NCT05254561|BIOLOGICAL|Intralesional antigen immunotherapy|Randomized double-blinded comparative effectiveness and safety clinical trial
40832114|NCT02699268|OTHER|Lung function measurement|The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
40832115|NCT05407961|DRUG|LY3532226|Administered SC.
40832116|NCT05407961|DRUG|Placebo|Administered SC.
40832117|NCT05407961|DRUG|Dulaglutide|Administered SC.
40832118|NCT04500340|BEHAVIORAL|Group CBT for test anxiety|The cognitive-behavioral therapy protocol developed by Flaxman, Bond \& Keogh (2004) will be used as the intervention protocol. This protocol consists of 10 Sessions which are provided twice a week (each group will have 10 students).
41351067|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
40832119|NCT03323606|BEHAVIORAL|Gambling Internet Intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
40832120|NCT03323606|BEHAVIORAL|Check Your Drinking|A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
40832121|NCT04142151|DRUG|Sanchitongshu|SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
41351068|NCT02382887|PROCEDURE|tracheal intubation|tracheal intubation with the Airtraq
41351069|NCT02382887|DEVICE|Airtraq|
41492712|NCT06035263|OTHER|FUNCTIONAL REEDUCATION AND ENVIRONMENTAL ADAPTATION PROGRAMME|the prescription of reeducation in activities of daily living and the prescription of assistive devices and environmental adaptations, for one month from the first baseline assessment at the time of hospital discharge.
40832122|NCT04142151|DRUG|Aspirin|Aspirin produced by Bayer Co., Ltd.
41351070|NCT02382887|DEVICE|fiberscope|
41492713|NCT06035263|OTHER|Health education programme:|"instructions and recommendations for maintaining an active and healthy life will be given as part of a health education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow, as well as the importance of nutrition and hydration in a healthy lifestyle.~They will receive the dossier of instructions and recommendations of the health education programme, as in the experimental group."
41492714|NCT04644835|DEVICE|Low Energy Shock Wave Treatment|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
41492715|NCT04644835|DEVICE|Sham Treatment|The patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
41492716|NCT00299936|DRUG|Ribavirin, PEG-Intron|
41351071|NCT00715949|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
41492717|NCT03101982|DRUG|HBO|Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
41492718|NCT04811586|PROCEDURE|coronary revascularization|to improve the blood supply for coronary arteries by using either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
41492719|NCT01176708|DRUG|dipeptidyl peptidase 4 (DPP4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
41492720|NCT01176708|OTHER|oral glucose|50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol
41492721|NCT01176708|OTHER|intravenous glucose|1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
41492722|NCT01264731|BIOLOGICAL|MELITAC 12.1|Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants in cohort 1 will receive MELITAC 12.1 (100 mcg each of the12-MP and 200 mcg of Peptide-tet) administered subcutaneously (1 ml) and intradermally (1 ml) in Montanide ISA-51 VG adjuvant at a single vaccination site.
40832123|NCT04142151|DRUG|Clopidogrel|Clopidogrel produced by Shenzhen Salubris Co., Ltd.
40832124|NCT04142151|DRUG|placebo of Sanchitongshu|SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
41158998|NCT06645613|DEVICE|Transcranial Magnetic Stimulation Device|Transcranial magnetic stimulation uses FDA-approved coils to generate varying magnetic fields in the brain of the participant and induce an electric field in the underlying brain tissue. The standard intermittent Theta Burst Stimulation (iTBS) TMS protocol will be applied in this study. The same coil can be applied to generate sham stimulations that only generate sound and stimulations to the scalp without stimulating the brain.
41351072|NCT00514592|OTHER|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
41351073|NCT04789005|DRUG|Norepinephrine|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
41351074|NCT04789005|DRUG|Phenylephrine|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
41492723|NCT01264731|DRUG|Imiquimod|Topical Imiquimod regimen: Beginning on day 1, patients in cohorts 1 and 2 will have one or more cutaneous melanoma metastases treated topically with 5% imiquimod cream, with a dose of 1 to 3 packets of imiquimod daily, (depending on the extent of cutaneous metastases). Each packet contains 250 mg of cream and may be used for a surface area of up to 20 cm2. The number of lesions that are treated will be dependent on the availability and size of the lesions. In addition, if available, at least two lesions will be followed without treatment with the plan that they will be excised at week 3 (day 22) and week 6 (day 43), respectively, as controls. Imiquimod will be applied daily for seven days each week for 12 weeks. One course of treatment will be three weeks in duration, with evaluation by a clinician after every treatment course.
41492724|NCT02322463|DRUG|Arab children|Treatment with Oxycodone
41492725|NCT03914911|DEVICE|Smart Biopsy Device|The radiologist will perform a routine ultrasonic guided biopsy procedure using the smart biopsy system, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
41492726|NCT00019786|DRUG|isolated perfusion|
41492727|NCT00019786|DRUG|melphalan|
41158999|NCT01903928|BIOLOGICAL|ASP0113|injection
41351075|NCT03698695|DRUG|THN 201|THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
41351076|NCT03698695|DRUG|Donepezil|Donepezil 5 mg/d and Mefloquine placebo
41351077|NCT03698695|DRUG|Placebo|Donepezil placebo and Mefloquine placebo
41351078|NCT02640430|DEVICE|standard treatment|20 minutes, twice a day for 10 sessions
41351079|NCT02640430|DEVICE|Free Aspire|20 minutes, twice a day for 10 sessions
41351080|NCT01818128|DEVICE|Neutral shape of bronchial tip|Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
41492728|NCT00019786|PROCEDURE|conventional surgery|
41492729|NCT01931696|DEVICE|Verum acupuncture|100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
41492730|NCT01931696|DEVICE|Sham acupuncture|100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
41492731|NCT01177059|GENETIC|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
40832125|NCT04064645|DEVICE|Measurement of respiratory rate with DUT and comparison with reference|"The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation."
40832126|NCT00543296|DRUG|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
41159000|NCT03030378|PROCEDURE|Biopsy|Undergo a tumor biopsy
41159001|NCT03030378|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41159002|NCT03030378|PROCEDURE|Computed Tomography|Undergo a CT scan
40832127|NCT00103519|DRUG|DITPA (3,5-diiodothyropropionic acid)|
40832128|NCT00103519|DRUG|Placebo|Placebo
40832129|NCT04342689|DRUG|Dietary Supplement containing resistant starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
41159003|NCT03030378|BIOLOGICAL|Edodekin alfa|Given SC
41159004|NCT03030378|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
41159005|NCT03030378|BIOLOGICAL|Pembrolizumab|Given IV
41159006|NCT03030378|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
41351081|NCT01818128|DEVICE|Bent shape of bronchial tip|Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
41492732|NCT03547076|DIAGNOSTIC_TEST|Focused ultrasound diagnostics|"Patients first be examined by nurses using a pocket-sized imaging device. Secondly, by a General Practitioner using the pocket-sized imaging device. Thirdly, reference echocardiography will be performed by cardiologist using a high-end echocardiographic scanner. Only tools (ultrasound equipment and dedicated software) approved for clinical practice will be used.~The focused ultrasound examination includes three standard apical views (4-chamber, 2-chamber and long axis) with and without color Doppler, in addition to recordings from both pleural cavities and the inferior vena cava. The reference imaging includes the same recordings, but in addition all other chambers and valves are assessed (grey scale, color Doppler, pulsed wave and continuous wave Doppler and tissue Doppler)."
41492733|NCT03752463|DRUG|DAOI-A group|DAOI with A dose
41492734|NCT03752463|DRUG|DAOI-B group|DAOI with B dose
41492735|NCT03752463|DRUG|DAOI-C group|DAOI with C dose
41492736|NCT03752463|DRUG|Placebo oral capsule|Placebo
41492737|NCT01682395|PROCEDURE|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
40832130|NCT04342689|DIETARY_SUPPLEMENT|Placebo Starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
40832131|NCT03378648|DRUG|CHF6366|"Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366"
40832132|NCT03378648|DRUG|Placebo CHF6366|"Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366"
40832133|NCT03378648|DRUG|umeclidinium bromide and vilanterol trifenatate|Part 3 Single dose
40832134|NCT05891028|DRUG|68Ga-EB-ss-CPT|68Ga-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
40832135|NCT05891028|DRUG|64Cu-EB-ss-CPT|64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
41492738|NCT01682395|PROCEDURE|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
40832136|NCT04907968|DRUG|XMT-1536 (Upifitamab Rilsodotin)|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
40832137|NCT04907968|DRUG|Carboplatin|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
41351082|NCT06048068|BEHAVIORAL|Educational Informational Platform|This intervention contains many informational articles for surrogates about cardiac arrest, the subsequent hospitalization, and the emotional journey following cardiac arrest. All articles are available in both English and Spanish.
41351083|NCT02934061|DEVICE|Tizaspray® administered intranasally|0,5 mg Tizaspray® administered intranasally
41351084|NCT02934061|DRUG|Sirdalud® 2 mg tablets administered|Sirdalud® 2 mg tablets administered in patients with acute low back pain
41351085|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
41351086|NCT03062644|DRUG|MR308|four times daily; Mode of Administration:oral
41351087|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
41351088|NCT03062644|DRUG|MR308|given four times daily to maintain the blind; Mode of Administration:oral
41351089|NCT03761628|DEVICE|pHyph, Gedea pessary|pHyph is a vaginal tablet for the treatment of VVC
41492739|NCT01682395|PROCEDURE|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
41492740|NCT01327261|DRUG|Levodopa + benserazide|Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
41492741|NCT05451992|DIETARY_SUPPLEMENT|Placebo|The group will have to consume a jar every day (approx. 75 ml) which contain (water, malt-dextrins, 0.1% starch, 0.1% guar gum, flavorings and colorants)
40832138|NCT03283436|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution|10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
40832139|NCT02374658|BEHAVIORAL|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
41351090|NCT01066637|DRUG|[18F](+/-)NOS|Injection of radiotracer \[18F\](+/-)NOS for PET imaging and kinetic data analysis
41351091|NCT04395989|DRUG|A1: Pyrotinib with nab-paclitaxel|A1: pyrotinib(EGFR-TKI) 400mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
41351092|NCT04395989|DRUG|A2: nab-paclitaxel|A2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
41492742|NCT05451992|DIETARY_SUPPLEMENT|SuperFood|The group will have to consume a jar of superfood (vegetable smoothie) every day. The jar will be filled with approx. 75 ml which corresponds to about 75 g. The superfood formulated by the University of Bolzano on the basis of the results and evidence acquired in collaboration with the Istituto Superiore di Sanità. Composition: pomegranate, walnuts, moringa, broccoli, according to the proportions indicated in Annex 2. This mixture has been analyzed by an external laboratory and authorized for human use
41492743|NCT04673682|DRUG|D309|D309(Testosterone) 1 vial, Once, IM injection
41492744|NCT04673682|DRUG|CKD-845|CKD-845(Testosterone) 1 vial, Once, IM injection
41159007|NCT06647329|BIOLOGICAL|CAR-T Therapy|CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological Lymphomas
41159008|NCT04924088|BEHAVIORAL|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
41159009|NCT04924088|BEHAVIORAL|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
41159010|NCT05201976|OTHER|Virtually administered Cardiac Rehab program|Virtual cardiac rehab program delivered through the CardaHealth platform.
41159011|NCT05201976|OTHER|Standard of Care in person Cardiac Rehab Program|Clinically ordered standard of care cardiac rehab program (in-person).
41351093|NCT04395989|DRUG|B1: everolimus with nab-paclitaxel|B1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
41351094|NCT04395989|DRUG|B2: nab-paclitaxel|B2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
41351095|NCT04395989|DRUG|C1: PD-1 with nab-paclitaxel and famitinib|C1: PD-1 antibody SHR1210 200mg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt + famitinib 20mg po qd, 4 weeks as a cycle
41351096|NCT04395989|DRUG|C2: nab-paclitaxel|C2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
41351097|NCT04395989|DRUG|D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
41351098|NCT04395989|DRUG|D2: nab-paclitaxel, with maintenance of capecitabine|D2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
41351099|NCT04395989|DRUG|E1: everolimus with nab-paclitaxel|E1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
41351100|NCT04395989|DRUG|E2: nab-paclitaxel|E2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
41492745|NCT00398996|DRUG|Early versus intermediate versus late initiation of ART|Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
41351101|NCT05853172|DRUG|AK104|Subjects will receive AK104 until disease progression or for up to 6 cycles.
41351102|NCT05853172|DRUG|Apatinib|Subjects will receive apatinib until disease progression or for up to 6 cycles.
41351103|NCT05853172|DRUG|Paclitaxel|Subjects will receive paclitaxel until disease progression or for up to 6 cycles.
41351104|NCT05853172|DRUG|S-1|Subjects will receive S-1 until disease progression or for up to 6 cycles.
41351105|NCT06335589|OTHER|EBP-Massed|CPT or PE will be delivered in a massed format (e.g., sessions at least 3 days per week)
41351106|NCT06335589|OTHER|EBP-TAU|CPT or PE will be delivered treatment as usual, which is typically once per week.
41351107|NCT00879593|DEVICE|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
41492746|NCT02918253|RADIATION|targeted focal HDR brachytherapy|
41492747|NCT02918253|RADIATION|Whole-gland HDR Brachytherapy|Control/Standard of Care
41492748|NCT02889471|PROCEDURE|ERCP with NB|ERCP with NB catheter for introperative tans-nasobiliary cholangiography
41492749|NCT02889471|PROCEDURE|ERCP alone|ERCP alone followed with standard laparoscopic cholecystectomy
41492750|NCT04260438|DRUG|CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T|single oral administration under fed condition
41492751|NCT04260438|DRUG|CKD-393 0.5/100/1000mg formulation 1 Tab. 1T|single oral administration under fed condition
40832140|NCT03823872|OTHER|Time restricted feeding|Time restricted feeding= consume food only from 12:00pm-8:00pm
40832141|NCT03823872|OTHER|Normal feeding|Normal feeding= consume food per normal schedule
41492752|NCT04260438|DRUG|CKD-393 0.5/100/1000mg formulation 2 Tab. 1T|single oral administration under fed condition
41492753|NCT00700830|DRUG|insulin detemir|Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
41509094|NCT00658879|DRUG|Somavert (Pegvisomant)|"Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration."
41509095|NCT02896790|OTHER|Interviews with 2 oncologists and 10 patients|
41509096|NCT02896790|OTHER|Interviews with 15 patients|
40832142|NCT04988997|DRUG|Vurolenatide 50mg/PBO|Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
40832143|NCT04988997|DRUG|Vurolenatide 100mg/PBO|Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks
40832144|NCT04988997|DRUG|Vurolenatide 50/50 mg|Vurolenatide - 50 mg weekly SC administration
40832145|NCT04988997|DRUG|Placebo|PBO - weekly SC administration
40832146|NCT05001841|PROCEDURE|Lung Transplantation|Double lung transplant
40832147|NCT00321997|DRUG|Pegaptanib sodium|
40832148|NCT00487448|DRUG|Fludarabine|
40832149|NCT00487448|DRUG|Cytarabine|
40832150|NCT00487448|DRUG|G-CSF|
40832151|NCT00487448|DRUG|Idarubicin|
40832152|NCT00487448|PROCEDURE|Peripheral blood stem cell transplantation|
40832153|NCT00487448|PROCEDURE|Bone marrow transplantation|
40832154|NCT03186014|DEVICE|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
41509097|NCT05108402|DIAGNOSTIC_TEST|Phenotyping|"After inclusion in the study, between V1 and V4, patients will be phenotyped among: NaCl sensitive patients and non-NaCl sensitive patients. they will have a low sodium diet for 2 weeks. The first week without salt supplementation and the second with salt supplementation. At the end of V4, if patient is NaCl sensitive he will continue into treatment period and go through randomization, and for patient non-NaCl sensitive they will drop out of study."
40832155|NCT01707589|DEVICE|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
40832156|NCT03783611|BEHAVIORAL|MyPlan 2.0.|eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
40832157|NCT00571207|DEVICE|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
40832158|NCT00571207|BEHAVIORAL|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
40832159|NCT04754685|DRUG|Intra-articular injection of platelet-rich plasma|The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
40832160|NCT05079399|OTHER|Blood draw|Blood samples will be collected via venipuncture
40832161|NCT02127034|DRUG|Mirabegron|oral
40832162|NCT02127034|DRUG|Solifenacin|oral
40832163|NCT02127034|DRUG|Digoxin|oral
40832164|NCT03839992|DIAGNOSTIC_TEST|spirometry|measure spirometry and lung CT
40832165|NCT03883334|DRUG|Metisoprinol|Immunodulator
40832166|NCT03201692|DEVICE|Virtual Reality Treadmill Training|Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.
40832167|NCT03201692|DEVICE|Treadmill training|Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
41351108|NCT06505681|PROCEDURE|Pharmacopuncture|"The selection of acupoints, depth of insertion, and other parameters will be determined based on the clinical judgment of the Korean medicine practitioner, considering the patient's symptoms, imaging results, and degree of improvement. All acupoints where pharmacopuncture is administered will be recorded at the time of treatment.~The type and dosage of pharmacopuncture solution to be used during treatment will be determined entirely based on the clinical judgment of the Korean medicine practitioner performing the pharmacopuncture. Retrospective chart reviews will be conducted to record the type of pharmacopuncture solution used and the total amount administered (in ml).~The treatment will be administered twice a week for a total of 3 weeks, and all sessions will be documented for accurate evaluation."
40832168|NCT01842594|DRUG|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days."
40832169|NCT02680210|OTHER|Questionnaires and cognitive measures|
40832170|NCT04058704|DRUG|Icotinib|125mg Tid/375mg per day
40832171|NCT04058704|RADIATION|SRS/WBRT/HA-WBRT/SMART|\>3 with WBRT/HA-WBRT/SMART or 1-3 with SRS
40832172|NCT02689076|OTHER|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
40832173|NCT02689076|OTHER|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
41020455|NCT06573918|DIAGNOSTIC_TEST|EMG-based assessment of paratonia|EMG-assessed paratonia was analyzed and compared to assess motor response efficiency in three groups of healthy young adults with different levels of physical activity: professional athletes engaged in closed and open skills sports, amateurs, and sedentary individuals. To analyze EMG-assessed paratonia, two surface electrodes were attached to the biceps and triceps brachii muscles during passive flexion-extension movements of the elbow while the participant remained in a state of maximum relaxation. Any EMG activity detected during these movements was attributed to an inability to relax, thereby reflecting their degree of paratonia.
40832174|NCT04660227|PROCEDURE|Exercise Trainning|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour. Before starting the exercise, the risk of possible injury will be minimized by doing warm-up exercises and preparations will be made to start the exercise. Then, the exercise program will be started with aerobic exercise. Strengthening exercises will be planned for large muscle groups, targeting body parts such as hips, knees, shoulders, abdomen and trunk. In exercises, it is planned to do 2 sets of 10-15 repetitions using elastic band, free weights or body weight. The exercise program will be created according to the condition of the people and progression will be provided every 2 weeks. After the exercises are completed, cool down will be done with relaxation and stretching exercises.
40832175|NCT04660227|OTHER|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks. After the final evaluations, they will be directed to the exercise group.
40832176|NCT04412694|DRUG|Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).|Preoperative oral dexamathasone supplementation in a single dose of 8mg.
40832177|NCT04412694|DRUG|Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).|Preoperative oral supplementation of sweetener in a single dose.
40832178|NCT04412694|DIAGNOSTIC_TEST|Preoparative blood laboratory tests|Preoperative parameters such as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronin will be measured in serum.
41020456|NCT02681874|BEHAVIORAL|SSC Program|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
41020457|NCT02681874|BEHAVIORAL|Written Handouts|The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
41020458|NCT06532123|DEVICE|continence muscles resistance device|The c-RED consists of a noncompliant cylindrical balloon (intra-anal balloon) that is connected to a small compliant balloon (external balloon) by a 2 mm diameter tube and a stopcock to allow for air to be filled and sealed in the system. The system is prefilled with air to determine the amount of air needed for a given internal pressure, or desired resistance of the intra-anal balloon. This is determined using a sphygmomanometer gauge in a sealed system.
41159012|NCT01289197|BEHAVIORAL|Family Check Up|Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
41351109|NCT06505681|PROCEDURE|Physical therapy|"The selection of physical therapy methods, treatment areas, and treatment duration will be determined based on the clinical judgment of the physician, considering the patient's symptoms, imaging results, and degree of improvement. The type, frequency, and areas of prescribed and administered physical therapy will be recorded.~The treatment will be administered twice a week for a total of 3 weeks, and all sessions will be documented for accurate evaluation."
41351110|NCT02850276|DRUG|Pyridostigmine|
41351111|NCT00113555|DEVICE|ACT (Adjustable Continence Therapy)|surgically implanted device
41351112|NCT03441516|DRUG|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
41351113|NCT03441516|DRUG|Aripezil® Tab.|Donepezil 10 mg Oral Tablet qd for 24 weeks
41509098|NCT05108402|DIETARY_SUPPLEMENT|Drug intake|"After being phenotyped, NaCl sensitive patients will continue the study in one of the 2 treatments arms : royal water (bottle) or salt sachet."
41159013|NCT06566209|DEVICE|Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)|Receive 18F-FDG PET/CT
41159014|NCT00445861|BIOLOGICAL|cetuximab + docetaxel + cisplatin|Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment repeats every 3 weeks for 2 courses.
41159015|NCT00445861|BIOLOGICAL|Treatment level 1|Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in weeks 7-11.
41351114|NCT02332694|DEVICE|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
41509099|NCT04597697|DRUG|Insulin icodec|Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
41159016|NCT00445861|BIOLOGICAL|Treatment level 2|Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in weeks 7-11.
41159017|NCT00445861|PROCEDURE|conventional surgery|Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and radiotherapy, patients undergo surgery.
41159018|NCT04506359|OTHER|Experimental Group|The Ex group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1).
41159019|NCT03721978|BIOLOGICAL|VGX-3100|1 milliliter (mL) VGX-3100 injected IM.
41159020|NCT03721978|BIOLOGICAL|Matched Placebo|1 mL of matched Placebo injected IM.
41351115|NCT04562233|BEHAVIORAL|Online-delivered physical activity intervention.|Participants randomized to the intervention arm will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer.
41351116|NCT04562233|BEHAVIORAL|Printed, individualized resistance-based physical activity program.|Without the supervision of an exercise trainer, participants will be given a printed, individualized resistance-based physical activity program to complete over the course of 12 weeks.
41351117|NCT01982669|OTHER|No Intervention|
41351118|NCT00967863|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
41351119|NCT00967863|RADIATION|intensity-modulated radiation therapy|Patients undergo radiotherapy
41509100|NCT05285904|OTHER|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab, that have started before inclusion of the patient into the study will be enrolled.
40832179|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 6 hour|At 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum.
40832180|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 24 hour|At 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum.
41159021|NCT03721978|DEVICE|CELLECTRA™-5PSP|CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.
41159022|NCT00812123|DRUG|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
41159023|NCT00812123|DRUG|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
41159024|NCT00812123|DRUG|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
41159025|NCT00812123|DRUG|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
41159026|NCT00812123|PROCEDURE|Protocol biopsies|protocol kidney biopsies at month one and three
41351120|NCT06375694|DIETARY_SUPPLEMENT|Herbiotics Oral + Ent Probiotic|Chewable Tablets containing Lactobacillus species.
41351121|NCT06375694|DIETARY_SUPPLEMENT|Placebo|Honest Placebo Pills by Zeebo
41351122|NCT04613635|DEVICE|Stratafix|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Stratafix USP (United States Pharmacopoe) 2-0 thread
41351123|NCT04613635|DEVICE|Vicryl|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Vicryl USP 2-0 thread
41351124|NCT00453453|DRUG|Nesiritide|Nesiritide given orally in the emergency department
41351125|NCT02870244|BIOLOGICAL|Escalating Doses|"Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10\^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10\^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10\^7/kg TIL 1383I TCR transduced T cells."
41351126|NCT04778865|DIETARY_SUPPLEMENT|Vitamin D-correction|Capsule with 50.000 UI cholecalciferol
41351127|NCT04778865|DIETARY_SUPPLEMENT|Vitamin D-RDA|Capsule with 4.2000 UI cholecalciferol
41351128|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccine 202210001|Immunization program and dosage:3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
41351129|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210002|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
41351130|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210003|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
41351131|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210004|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
41351132|NCT05939219|BIOLOGICAL|13 valent pneumococcal polysaccharide conjugate vaccine|Immunization program and dosage: 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
41351133|NCT05864391|DRUG|AZD7503|Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
41351134|NCT06369584|PROCEDURE|prone position|The process of prone positioning requires 5-6 people, with one person acting as the commander responsible for directing and monitoring. The process of monitoring includes ECMO flow and the vital signs. The second person is in charge of the patient's head, including endotracheal intubation, ventilator lines, and jugular ECMO cannula. The third person is responsible for femoral ECMO cannula and central venous line. The fourth to sixth individuals are responsible for rotating the patient's torso towards the side without an ECMO tube. Before initiating prone ventilation, pressure ulcer protection patches should be placed on the patient's forehead, ears, anterior chest, and iliac crest to protect areas under pressure. During ECMO support period, each patient needs to undergo at least four sessions of prone ventilation until their condition improves enough to discontinue ECMO support. Each session should last between 16 to 24 hours.
41351135|NCT04819711|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is an evidence-based intervention that is based on principles of cognitive behavioral therapy. It includes strategies that incorporate behavioral activation, active listening, collaboration with the family, guided discovery, and homework. The adapted THP consists of 5 integrated sessions. Session 1 introduces the programme and focuses on engagement of participants, introduction of THP, and breathing exercises. Session 2 focuses on psychoeducation and problem solving. Session 3 focuses on the mother's well-being and introduces activities such as physical exercises, good sleep practices and ensuring a balanced diet. Session 4 focuses on the mother's relationship with the unborn baby. Session 5 focuses on activating social support from family, friends and peers and provides closure of therapy.
41351136|NCT01970124|DRUG|KPS-0373, High dose|
41351137|NCT01970124|DRUG|KPS-0373, Low dose|
41351138|NCT05419284|OTHER|GAPP+Care|"standard physiotherapy 45 minutes per day, 5 day a week (GAPP)~+ 3 extra exercise sessions led by a caregiver (+Care)"
41509101|NCT06550609|DRUG|Miltefosine Oral Capsule|Miltefosine 3 pill per day during 28 days AND pentamidine inhaled 300 mg / d during 10 dosis
40832181|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory drainage fluid tests at 24 hour|At 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid.
40832182|NCT04412694|PROCEDURE|Total thyroidectomy|Patients will undergo total thyroidectomy under general anesthesia.
40832183|NCT04412694|OTHER|Symptomatic hypocalcaemia at 6 hour|At 6 hour after surgery patients will be assessed for signs of hypocalcaemia.
40832184|NCT04412694|OTHER|Symptomatic hypocalcaemia at 24 hour|At 24 hour after surgery patients will be assessed for signs of hypocalcaemia.
41351139|NCT05419284|OTHER|+Care|"3 extra exercise moments led by a caregiver: one physiotherapist-caregiver-patient exercise session: the physiotherapist will educate and train the caregiver on the exercises and hands-on skills.~Two caregiver-patient exercise sessions"
41159027|NCT06521294|OTHER|Mulligan SNAG mobilization tecnique|Mulligan SNAG mobilization tecnique
41351140|NCT05419284|OTHER|Observation of GAPP+Care|Healthcare workers in the geriatric rehabilitation ward will be interviewed on their opinions on GAPP+Care
41351141|NCT04829591|OTHER|observational|Heart failure, non interventional
41351142|NCT01913015|DRUG|abiraterone acetate|Given PO
41351143|NCT01913015|DIETARY_SUPPLEMENT|dietary intervention|Receive low fat breakfast
41351144|NCT01913015|DIETARY_SUPPLEMENT|dietary intervention|Receive high fat breakfast
41351145|NCT01913015|OTHER|pharmacological study|Correlative studies
41159028|NCT06521294|OTHER|Conventional Physiotherapy|Conventional Physiotherapy
41351146|NCT01913015|OTHER|questionnaire administration|Ancillary studies
41351147|NCT01913015|OTHER|laboratory biomarker analysis|Correlative studies
41351148|NCT01856179|DIETARY_SUPPLEMENT|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
41351149|NCT04479306|DRUG|Alisertib|Given PO
41351150|NCT04479306|DRUG|Osimertinib|Given PO
41351151|NCT04479306|DRUG|Sapanisertib|Given PO
41351152|NCT04559867|PROCEDURE|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP.
41351153|NCT04559867|PROCEDURE|Sphincterotomy|A sphincterotomy uses a heated metal wire to cut the opening to the bile duct after a wire has been passed into it.
41351154|NCT00004064|BIOLOGICAL|oregovomab|
41351155|NCT00585104|DRUG|levosimendan|10-minute infusion
41351156|NCT04590963|DRUG|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
41492754|NCT05310695|OTHER|NSAC - rapid|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment within 4 weeks of referral.
41509102|NCT01228617|DRUG|Nicotine|Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day
40832185|NCT04412694|OTHER|Postoperative pain at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
41159029|NCT00630552|OTHER|Placebo|Inactive dummy of AMG 655.
41159030|NCT00630552|DRUG|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
41159031|NCT00630552|DRUG|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
41351157|NCT04590963|DRUG|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
41351158|NCT04590963|OTHER|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
41351159|NCT04648995|DEVICE|High energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
41351160|NCT04648995|DEVICE|Low energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
41351161|NCT04995666|DEVICE|Phonak Audeo hearing aid|Rechargeable hearing aid
41351162|NCT01495689|BEHAVIORAL|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
41351163|NCT01495689|BEHAVIORAL|Usual care|Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
41351164|NCT04742764|COMBINATION_PRODUCT|Standard medical therapy|Standard medical therapy (according to the Surviving Sepsis Campaign) will include standard monitoring (pulseoximetry, 5-lead ECG, continuous invasive blood pressure monitoring, central venous cannulation and 24 with PiCCO-technology. Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.
41351165|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours|Standard medical therapy, as discussed above will be applied. Furthermore, Cytosorb will be administered as soon as it is possible after randomization but not later than 2 hour (start of the treatment, T0). In a blood pump circuit in pre-haemofilter position, using a kidney replacement device of Fresenius Multifiltrate as a solo therapy or in combination with renal replacement therapy. It will be run in CVVHD, CVVHDF or CVVH mode with a 150 and 200 ml/min blood flow. Anticoagulation will be applied intravenously with heparin, low molecular weight heparin or citrate. The aim of the pump flow rate will be 100-400 mL/min, and the flow rate will be recorded. Possible shock reversal will be assessed by the physician attending. Adsorber cartridges will be changed in every 12 hours. End of the study period (Te): 12 hours after shock reversal, death of the patient, or maximum of five days, whichever happens first.
40832186|NCT04412694|OTHER|Postoperative pain at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
40832187|NCT04412694|OTHER|Postoperative nausea and vomiting at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
41159032|NCT06646367|OTHER|Conventional therapy|All participants in the two groups will receive conventional therapy in the form of TENS and moist heat for 5 weeks.TENS will be applied 5 times a week for 5 weeks at a frequency of 80Hz with 10- to 30-mA intensity for 25 minutes. Four surface electrodes (5x5 cm each) were situated over the painful region in the neck (two electrodes will be placed in either side of the spine high on neck, just underneath the skull and the other two electrodes will be placed about 5cm underneath them) with intensity in the tactile sensation threshold. The hot packs will be applied for 30 minutes on the cervical area, 5 times per week for 5 weeks.
41159033|NCT06646367|OTHER|Alexander technique|Women in the experimental group will attend 10 Alexander Technique classes (60 minutes each, twice a week for 5 weeks). The Alexander Technique focuses on body awareness, reducing muscle tension, and improving coordination through three principles: enhanced awareness, purposeful inhibition, and mental imagery. Participants will learn to release habitual muscle tension and explore alternative movement patterns, covering biomechanics and ergonomics of the neck, spine, and limbs. The sessions involve hands-on guidance, verbal instruction, and group activities. Daily practice in a semi-supine position is encouraged to improve posture, coordination, and overall well-being.
41351166|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours|The standard medical therapy and method of Cytosorb treatment as detailed above will be applied. Adsorber cartridges will be changed in every 24 hours.
41351167|NCT01608139|DRUG|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
41492755|NCT05310695|OTHER|NSAC - ordinary|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment at 10-14 weeks after referral.
41492756|NCT05310695|OTHER|NSAC - active control|The active control intervention is provided by the NSAC personnel, but patients are offered a single monodisciplinary examination close to the end of the diagnosis-specific deadline suggested in guidelines, which will vary between 8-26 weeks. Employment counsellors may not be involved in consultations, other cross-disciplinary consultations are restricted, and work-related factors are not to be focused on during examination. Clinicians are provided survey information only on the patient's potential health problems prior to consultation. Patients are provided a health-focused examination, with the aim of symptom-relief.
41509103|NCT01228617|DRUG|Nicotine Gum|Following a 12-hour nicotine abstinence period, subjects will be instructed to chew the gum once every 2 seconds, for 30 minutes.
41509104|NCT03883503|OTHER|Beer 5%o|Weight adjusted beer to reach 0.8 blood alcohol content will be given over the time course of 1 hour to the participants
41509105|NCT03883503|OTHER|Beer 8.5%o and water|Weight adjusted beer to reach 0.8 blood alcohol content and water will be given over the time course of 1 hour to the participants
40832188|NCT04412694|OTHER|Postoperative nausea and vomiting at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
40832189|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
41159034|NCT05611658|OTHER|MR, PET CT|diagnostic method
41351168|NCT01608139|DRUG|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
41509106|NCT03883503|OTHER|Beer 8.5%o and stock|Weight adjusted beer to reach 0.8 blood alcohol content and stock will be given over the time course of 1 hour to the participants
40832190|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
40832191|NCT04104074|RADIATION|Radiotherapy|"Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.~Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy."
40832192|NCT04104074|DRUG|Sintilimab|Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
40832193|NCT02044601|DRUG|Onartuzumab|"Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I."
40832194|NCT02044601|DRUG|Erlotinib|Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
40832195|NCT02044601|DRUG|Paclitaxel|Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
40832196|NCT02044601|DRUG|Carboplatin|Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
40832197|NCT02044601|RADIATION|Radiation Therapy|Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
40832198|NCT02066415|BIOLOGICAL|Erenumab|Administered once a month subcutaneously by authorized investigational site study staff.
40832199|NCT02066415|DRUG|Placebo|Administered once a month subcutaneously by authorized investigational site study staff.
40832200|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 10 mg/d|L-Ergothioneine 10 mg/d
40832201|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 25 mg/d|L-Ergothioneine 25 mg/d
40832202|NCT04556032|OTHER|Placebo|0 mg/d L-Ergothioneine
40832203|NCT01706042|OTHER|legume meal|
41492757|NCT05173675|BEHAVIORAL|Empathy in Action for life with diabetes.|"In Phase 1 (Months 1-6) participants receive (Program):~1. Empathetic communications: A dedicated partner (lightly-trained lay person) who communicates with them via phone with timing and frequency defined by the participant within certain parameters. Two letters mailed during the 6 months that compile anonymized learnings from all participants in the callers panel of 10-20 participants, written as a newsletter to share back with the participant.~2. Material Incentives: One choice of health tool (weight scale or pedometer) selected with the caller in week 1 and expected to be received in weeks 3-5. Two small recognition gifts (valued at US$25) chosen by the caller based on their understanding of the participants preferences, and sent at month 2.5 and 4.5.~3. Educational Materials: Printed DM management educational materials mailed right after enrollment and randomization, and expected to be received in weeks 1-2."
41492758|NCT05173675|BEHAVIORAL|Control Phase 2 Materials Only|"1. Material Incentives:~   a. Choice of health tool (weight scale or pedometer) and 2 health promoting gifts chosen by the caller at the end of their 6 month measurement visit.~   i. Health tool is mailed out within the 7th month ii. Health promoting gifts are mailed out in the 8th and 10th month~2. Educational Materials a. The same educational materials mailed to participants in the intervention arm Program will be mailed to control arm participants after they complete their 6 months visit"
41492759|NCT03712215|OTHER|Rehabilitation|diaphragmatic electrical stimulation
40832204|NCT01706042|OTHER|white bread|
40832205|NCT00830713|PROCEDURE|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
40832206|NCT06183372|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
40832207|NCT06183372|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
40832208|NCT02356887|DIAGNOSTIC_TEST|Jugular venous ultrasound|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions at rest, jugular occlusion and valsalva maneuver. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
40832209|NCT04922931|PROCEDURE|scheduled surgery|Patients undergoing scheduled surgery with lung ultrasound before surgery and determination of lung compliance during general anesthesia
40832210|NCT02452853|PROCEDURE|HR|"HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus"
40832211|NCT02452853|DRUG|FOLFOX4|"FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks"
40832212|NCT05961449|BEHAVIORAL|Cycling exercise|Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
40832213|NCT05961449|BEHAVIORAL|Cycling control|The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase \>25% from baseline.
40832214|NCT04816383|OTHER|"Breastfeeding at AU Apple-Based Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
40832215|NCT06146868|OTHER|Doing questionnaire|Participants will provide their opinions in a questionnaire
41159035|NCT06640491|DRUG|IO Administration of Cefazolin|Intraosseous injection of cefazolin to guard against infection.
41159036|NCT06640491|DRUG|IO Administration of Vancomycin|Intraosseous injection of vancomycin to guard against infection.
41159037|NCT06640491|DRUG|IV Administration of Cefazolin|Intravenous dose of cefazolin to guard against infection.
41159038|NCT06640491|DRUG|IV Administration of Vancomycin|Intravenous dose of vancomycin to guard against infection.
41159039|NCT01993576|DRUG|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
41159040|NCT01372683|OTHER|Dietary Intervention|Comparison of oat based breakfast cereals
41509107|NCT03883503|OTHER|Water|Water equivalent to the calculated volume of beer will be given over the time course of 1 hour to the participants
41509108|NCT02977819|OTHER|Meditation practice|18 months
41351169|NCT01608139|DRUG|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
41351170|NCT01021293|BIOLOGICAL|Poliorix™|3 doses, intramuscular administration
41351171|NCT01021293|BIOLOGICAL|Oral Poliovirus vaccine|3 doses, oral administration
41351172|NCT01241318|DRUG|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
41351173|NCT01241318|PROCEDURE|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
41351174|NCT00840528|OTHER|ozone|0.4 ppm ozone for 2 hours
41351175|NCT04029649|DRUG|Beta-1,3/1,6-D-Glucan|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
41351176|NCT04029649|DRUG|Placebo|Placebo capsule three times daily for 90 days
41351177|NCT03678506|DRUG|Apixaban|Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
41351178|NCT03538899|DRUG|AProArt|Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary deoxyribonucleic acid DNA, after receiving sub-ablative, exposure-targeted busulfan conditioning.
41351179|NCT03538899|DEVICE|CliniMACS® CD34 Reagent System cell sorter device|Processing of hematopoietic progenitor cells to select CD34 cells, using the CliniMACS® CD34 Reagent System, prior to infusion.
41351180|NCT03538899|DRUG|Busulfan|Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Patients will receive low-dose busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg\*hr/L.
41351181|NCT04749368|DRUG|BRII-835 (VIR-2218)|BRII-835 (VIR-2218) will be given by subcutaneous injection
41351182|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601) with IFN-α|BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
41351183|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601)|BRII-179 (VBI-2601) will be administered by intramuscular injection
41351184|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active high)|Higher dose of probiotic supplement
41351185|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active low)|Lower dose of probiotic supplement
41351186|NCT01728610|DIETARY_SUPPLEMENT|Placebo|Placebo
41351187|NCT02048774|BEHAVIORAL|Designation of Social Positioning|
41351188|NCT03566849|OTHER|KC group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Ball modified prone Cobra, Ball prone V-raise, Ball prone row, Ball side plank, Ball one-leg bridging~2. 2nd week: each 10 rep/set, 3 set/day. Half sit-up with rotation to left/right, Side plank with ER, Prone extension with rotation to left/right, Bilateral one-leg squat with flexion, Squat to row~3. 3rd week: 5 rep/set, 3 set/day (sling exercise). Prone shoulder protraction, Supine shoulder retraction, Side-lying hip ABD/ADD, Supine pelvic lift, Prone bridging~4. 4th week: each 10 rep/set, 3 set/day. Lateral lunges with shoulder ABD/ER, Lunge with trunk rotation, Forward punch plus with serape effect, Spiking exercise, One-quarter vertical squat jump"
41351189|NCT03566849|OTHER|CT group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Knee push up plus, Modified prone Cobra, Prone V-raise, Prone row, Side-lying ER~2. 2nd week: each 10 rep/set, 3 set/day. Supine punch, Prone horizontal ABD, Prone V-raise, Prone row, Side-lying ER~3. 3rd week: each 10 rep/set, 3 set/day. Sitting chest press, Sitting ABD in scaption, Sitting overhead press, Long-sitting resisted extension, Sitting ER~4. 4th week: each 10 rep/set, 3 set/day. Standing horizontal pull-apart, Standing retraction plus ER, Standing resisted extension, Ball pushed on wall and controlled rolling, Wall push-up"
41351190|NCT06410794|DEVICE|Virtual Reality with Beat Saber|The VR activity used in the intervention was an add-on activity that did not replace any other activities in the programme. The off-the-shelf product Beat Saber (Beat Games, Prague, The Czech Republic) is the VR game of choice in our study. In collaboration with the participating clinics a systematic VR activity plan will be developed. This includes the selection of games and designing a plan that is interesting and motivating both for patients and clinicians.
41351191|NCT05098808|OTHER|Acoustic features (from signals obtained during phonation)|"Acoustic features will be obtained via phonation files.~A voice recorder application provided by Apple was used, and the sampling frequency of the sound was 44,100 Hz. The digitized cough sound signals were band-pass-filtered between 20 to 16,000 Hz to use data from the whole frequency band gathered by the iPad. In each case, the smart device was positioned 20cm from the patient"
41351192|NCT04919694|PROCEDURE|combination of orbital compression surgery and strabismus surgery|combination of orbital compression surgery and strabismus surgery at the same time
41351193|NCT04919694|PROCEDURE|orbital compression|orbital compression
41351194|NCT01030757|RADIATION|Tomotherapy treatment|"* A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days~* Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours~* Dose will be prescribed to the isodose line which covers at least 90% of the PTV~* Dose homogeneity +/- 5%"
41351195|NCT00767494|DRUG|Travoprost/Brinzolamide fixed combination|Eye Drops, suspension once daily
41509109|NCT02977819|OTHER|Learning English as a foreign language|18 months
41351196|NCT00767494|DRUG|Azopt|Eye Drop Suspension, 1 drop BID
41351197|NCT00767494|DRUG|Travatan|Eye Drop Solution, 1 drop BID
41351198|NCT05372289|DIETARY_SUPPLEMENT|Immuno-nutrition|The experimental group of 68 older adults will be subjected to a preoperative immuno-nutrition for 30 days prior to surgery and up to 3 days after surgery. The oral feed provides energy, omega-3 fatty acids, arginine, nucleotides, and soluble fibre.
41351199|NCT02918422|OTHER|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
41351200|NCT00096824|BEHAVIORAL|Neurological assessment|All participants will undergo neurological examinations and neuropsychological assessments.
41351201|NCT05466240|DRUG|AT-752|AT-752 for 5 days
41351202|NCT05466240|DRUG|Placebo|Placebo for 5 days
41351203|NCT03208504|DEVICE|Nexus™ Aortic Arch Stent graft|surgical implantation of Nexus™ Aortic Arch Stent graft
41351204|NCT04448340|DIAGNOSTIC_TEST|machine learning model|Two classification algorithms, logistic regression and K-Nearest Neighbors (K-NNs), were investigated for their ability to predict successfully whether patients suffered from PDD or DLB.
40832216|NCT04401839|DRUG|Oxytocin IV shot|Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby
40832217|NCT04401839|DRUG|Oxytocin IV drip|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation
41351205|NCT03827967|BIOLOGICAL|PalloV-CC|The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
40832218|NCT04401839|PROCEDURE|Amr maneuver|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds
40832219|NCT00463463|DRUG|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
40832220|NCT04933760|DIAGNOSTIC_TEST|Cytovale IntellipSep test|The Cytovale IntelliSep test measures a series of physical properties that indicate activation of leukocytes obtained from a venous K2-EDTA anti-coagulated whole blood sample.
40832221|NCT00493519|PROCEDURE|chocolate cake|
41492760|NCT01796613|DEVICE|Vaginal Ring - intermittent regimen|NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
41509110|NCT01619566|DRUG|Duloxetine|oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
40832222|NCT00037674|DRUG|Topiramate|
40832223|NCT01635764|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
40832224|NCT02486991|PROCEDURE|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
40832225|NCT02486991|PROCEDURE|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
40832226|NCT03843944|DRUG|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
40832227|NCT01260025|DRUG|PEDylated Recombinant Human Endostatin|The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
40832228|NCT03587753|OTHER|Dietary fatty acid partitioning|There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
40832229|NCT00690170|DRUG|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
40832230|NCT00690170|DRUG|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
40832231|NCT00690170|DRUG|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
41159041|NCT04151706|DRUG|CD8+ Memory T Cell Infusion|Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation
41351206|NCT06423404|BEHAVIORAL|the Experimental Group, receiving a 12-week program of video-guided active breaks with curricular content in the school classroom|The \&#34;Active Classes + School Climate and Mental Health\&#34; program was crafted following a comprehensive review by the research team on active breaks in the child school population. Based on the findings of this review, the optimal type and duration of intervention, frequency and intensity of the most effective exercises, and video-guided modalities with curricular content for active breaks will be established. Subsequently, a collaborative network was formed, involving researchers from education, sports science, social sciences, medicine, primary school teachers within the Chilean public school system, teams of educational leaders, parents, guardians, pedagogy students, and graduate students. The purpose was to create a team that systematically supports the development of various stages of the project from a multi and interdisciplinary perspective
41351207|NCT03200028|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets executive function, memory and attention.
41351208|NCT01278810|DRUG|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
41351209|NCT02664740|DRUG|Topical anti-Staphylococcus bacteriophage therapy|Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10\^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
41351210|NCT02664740|DRUG|Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy|Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
41351211|NCT05547594|BEHAVIORAL|Multimodal surgical prehabilitation|Participants will be encouraged to engage in regular physical activity (endurance and resistance exercise), eat healthily and undergo cognitive behavioural therapy (the latter only if required) during the weeks prior to surgery.
41351212|NCT00783263|DRUG|Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
41351213|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
41351214|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
41351215|NCT00783263|DRUG|Comparator: rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
40832232|NCT00690170|DRUG|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
40832233|NCT01416441|DRUG|Aripiprazole|Aripiprazole tablets orally once daily.
40832234|NCT02144155|DRUG|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
40832235|NCT02144155|DRUG|Placebo|placebo drug
40832236|NCT03641846|OTHER|DornierAries2 LiST device + 5 mg Tadalafil|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks
40832237|NCT03641846|OTHER|DornierAries2 LiST device + Placebo Pill|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
40832238|NCT05295615|DEVICE|ECHS AD Device|Pulsed electromagnetic therapy device
40832239|NCT05295615|DEVICE|ECHS Sham AD Device|Non-functioning electromagnetic therapy device
40832240|NCT00542737|BEHAVIORAL|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
40832241|NCT01399892|DIETARY_SUPPLEMENT|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
40832242|NCT01237262|DRUG|Adalimumab, etanercept, infliximab|"Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.~Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks."
41159042|NCT04151706|DRUG|Thiotepa|5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)
41159043|NCT04151706|DRUG|Fludarabine|25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)
40832243|NCT05730647|OTHER|None intervention (observational study)|None intervention (observational study)
40832244|NCT04409717|PROCEDURE|Type II endoleak treatment|Type II endoleak endovascular treatment
40832245|NCT06260137|PROCEDURE|Rhomboid intercostal block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle before surgery.
40832246|NCT06260137|PROCEDURE|Rhomboid intercostal and subserratus plane block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle and the serrates anterior muscle before surgery.
41159044|NCT04151706|RADIATION|Hyperfractionated TBI|Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)
41351216|NCT00106366|DRUG|insulin detemir|
41351217|NCT00106366|DRUG|insulin glargine|
41509111|NCT00852202|DRUG|cariprazine|Drug: cariprazine (0.25 - 0.75 mg/day)
41509112|NCT00852202|DRUG|cariprazine|Drug: cariprazine (1.5 - 3.0 mg/day)
41351218|NCT00106366|DRUG|insulin aspart|
41492761|NCT01796613|DEVICE|Vaginal Ring - continuous regimen|NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
41159045|NCT04151706|DRUG|Busulfan|6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg
41159046|NCT04151706|DRUG|Cyclophosphamide|60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
41492762|NCT03052868|OTHER|Cognitive Assessment|Cognitive testing session
40832247|NCT05324423|DRUG|Colchicine|Colchicine0.5 mg Oral Tablet Day-7\~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
40832248|NCT04911764|DIAGNOSTIC_TEST|Three-min Step Test and Exercise desaturation detection in COPD|For this research, 2 visits will be scheduled (V1 and V2) for each patient. During V1, after collecting the filled and signed consent form from the patient, anthropometric measurements and pulmonary function assessment will be performed before the realization of a maximal graded test. This inclusion visit will be carried out as part of an inclusion within a respiratory rehabilitation program. During V2, each patient will randomly perform a 6-minute walking test and a 3-minute step test, in similar standard conditions. A 30-minute resting period will be allowed between the two field tests. During the realization of the tests, cardio-respiratory adaptations will be monitored throughout both tests with portable gas analyzer and pulsed oxymetry system.
40832249|NCT02190305|DEVICE|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
40832250|NCT00563095|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|
41159047|NCT04928482|BEHAVIORAL|Backward Walking Training|Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
41159048|NCT04928482|BEHAVIORAL|Backward Walking Training|Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
40832251|NCT00563095|PROCEDURE|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
41159049|NCT05825547|PROCEDURE|Cryotherapy treatment|Cryotherapy treatment administered by an interventional radiologist: the cryotherapy needle is placed under local anesthesia, ultrasound monitoring in real time. A complete cryotherapy cycle is performed with: freezing until the entire tumor is frozen as judged by ultrasound, then thawing for the same duration and refreezing according to the same principle.
41159050|NCT03402321|DRUG|Gelatin Sponge Sheet|sheets act as a mechanical barrier used to protect the denuded area of the palatal donor site
40832252|NCT02896036|PROCEDURE|Veress needle entry with concomitant CO2|The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.
41159051|NCT03402321|DRUG|Alvogyl|paste form with analgesic action to protect the palatal donor site and help to relief pain
41159052|NCT05012397|DRUG|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
41351219|NCT02442765|DRUG|AVP-786|
41351220|NCT02442765|DRUG|Placebo|
41351221|NCT01172990|PROCEDURE|Immediate Invasive Management|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (\< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines
41351222|NCT01172990|PROCEDURE|Conventional Management|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
41351223|NCT01377038|OTHER|Phenotype assessment|Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
41351224|NCT06439004|OTHER|Quantitative Sensory Testing|Performing QST on the dominant hand, right forearm, right flank and lower back.
41351225|NCT04493229|DRUG|Oxytocin|IM Oxytocin
41351226|NCT04493229|DRUG|Placebo|Placebo IM
41351227|NCT02149628|DRUG|propofol|
41351228|NCT02149628|DRUG|Desflurane|
41351229|NCT04532281|DRUG|Murine CD19 CAR-T cells|Each subject receive murine CD19 CAR T-cells by intravenous infusion
41351230|NCT05136209|PROCEDURE|PCCC procedure without A-vit|In this randomized clinical trial, patients receive cataract surgery on both eyes on the same day. For each patient, one eye is randomly assigned to undergo PCCC+A-Vit procedure, while the fellow eye is undergoing PCCC procedure without A-Vit.
41351231|NCT05136209|PROCEDURE|PCCC+A-Vit procedure|PCCC+A-Vit procedure
41351232|NCT03869489|DEVICE|Anodal left dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants
41492763|NCT03815734|PROCEDURE|motor imagery|motor imagery during the postoperative immobilization period
41492764|NCT04866732|BEHAVIORAL|Physical Activity Cardiac Health Program|The investigators anticipate that the physical activity program will include the following components: a) physical activity component - the investigators propose an incremental physical activity component whereby participants will gradually increase their physical activity ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to Cardiovascular disease risk factors prevention; c) daily diary, which will be used to document record about any barriers for completing various components of the intervention; d) problem-solving sessions whereby participants will meet once a week with the investigators to talk about the barriers and facilitators of their weekly activity and any adherence issues.
41509113|NCT00852202|DRUG|placebo|placebo capsules, oral administration, once daily dosing
41509114|NCT03962283|DRUG|Rifaximin|Rifaximin 200mcg four times daily
41351233|NCT03869489|DEVICE|Anodal right dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants
41509115|NCT03962283|DRUG|Placebo oral tablet|Placebo Rifaximin four times daily
40832253|NCT02896036|PROCEDURE|Veress needle entry with subsequent CO2|A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
40832254|NCT00322946|BIOLOGICAL|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
40832255|NCT00322946|BIOLOGICAL|Placebo|Placebo for rDEN4delta30-4995
40832256|NCT05389501|BEHAVIORAL|Social policy intervention to support women of reproductive years|"The project team will attempt to address this challenge by delivering the following interventions through social workers in underdeveloped primary healthcare settings to promote maternal and child health:~1. Developing a database on a digital app of participants in the study and use the data for development of an Index for Maternal Health and Wellbeing~2. Conducting a Community Assessment Needs~3. Conduct a psychosocial needs assessment~4. Develop interprofessional health workforce collaboration~5. Measure basic clinical health indicators~6. Provide health awareness and literacy training to participants"
40832257|NCT05976451|COMBINATION_PRODUCT|melatonin with collagen matrix|(CMX) with melatonin in the esthetic zone using Modified Coronally Advanced Tunneling Technique (MCAT)
41351234|NCT03869489|DEVICE|Sham tDCS stimulation|Sham tDCS stimulation will be applied
41351235|NCT05038111|DRUG|Dexmedetomidine|perioperative dexmedetomidine infusion
41351236|NCT06450782|OTHER|Post-isometric Relaxation Technique|"Sternocleidomastoid muscle Participants are asked to stretch their necks in a spuni position and then turn their heads as far to the side of the target muscle (right side) as possible until a sensation occurs that causes discomfort in the targeted SCM. In this case, the participants are asked to moderately isometrically contract the SKM muscle for 5 seconds and then relax for 3 seconds and the cervical spine is moved to the new barrier.~Masseter muscle Participants are positioned in a sitting position. The jaw is opened as wide as possible. The index and middle fingers of one hand are placed over the lower teeth. The weight of the hand is allowed to provide flexion and traction is applied directly to the midline. In this case, the participants are asked to moderately isometrically contract the bilateral masseter muscles for 5 seconds, then relax for 3 seconds and the participant moves his chin to the new barrier."
40832258|NCT05976451|COMBINATION_PRODUCT|connective tissue graft (CTG)|control group connective tissue graft using Modified Coronally Advanced Tunneling Technique (MCAT)
40832259|NCT05841199|DIAGNOSTIC_TEST|Pressure and flow measurement during simulated VT|Participants undergoing coronary angiography will have measurements of blood pressure, coronary pressure and coronary flow during simulated VT. VT will be simulated using pacing at a range of heart rates.
40832260|NCT02031224|BEHAVIORAL|Conventional low protein diet|
40832261|NCT02031224|DIETARY_SUPPLEMENT|Very low protein diet supplemented with Ketosteril|
40832262|NCT04154319|BEHAVIORAL|HPV Vaccination|Mothers assigned to this arm participated in educational/behavior change sessions to promote HPV vaccination among their unvaccinated 9-12 year old daughters
41351237|NCT06450782|OTHER|Myofascial Release Technique|"Sternocleidomastoid muscle The head is slightly elevated with the help of a folded towel to prevent discomfort that may develop depending on the position. The researcher sits in a chair next to the participant's head. The chair is placed at approximately 45° to the participant's neck. The participant's head is rotated 30° towards the opposite side of the treated side. The Graston instrument contacts the upper part of the SCM approximately 2 cm below the mastoid process.~Masseter muscle It works both ways. The Graston instrument is placed on the zygomatic process of the temporal bone, approximately 1 cm in front of the ear. The soft tissue is pressed until the bone is contacted. This connection with the periosteum is maintained and a lower tension line is created towards the mandible angle. This line of tension is continued up to the mandible, where the periosteum also comes into play. It is repeated several times."
41351238|NCT06450782|OTHER|Control|Participants will rest for thirty minutes.
41351239|NCT05813860|DRUG|Azathioprine|azathioprine in combination with Infliximab, with a dose of 1-2 mg/kg/d.
41351240|NCT05813860|DRUG|Infliximab|5mg/kg for the first dose, and the same dose at weeks 2 and 6 after the first dose and every 8 weeks thereafter. Treatment with single Infliximab or combined azathioprine, respectively.
41351241|NCT03049852|DRUG|CBT-001 single dose|One drop in the study administered one time
41351242|NCT03049852|DRUG|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
41351243|NCT03049852|DRUG|CBT-001 Multi-dose|One drop in the study administered three times daily (TID) for 4 weeks
41351244|NCT01812395|DEVICE|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
40832263|NCT04154319|BEHAVIORAL|Healthy Eating|Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels
41159053|NCT04979156|PROCEDURE|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
41159054|NCT05814822|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Participants randomized to CBTi-CB-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn cognitive and behavioral strategies for insomnia.
41351245|NCT01812395|PROCEDURE|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
40832264|NCT00186537|DRUG|Rosiglitazone|
40832265|NCT00186537|DRUG|Fenofibrate|
40832266|NCT00186537|BEHAVIORAL|Weight Loss|
40832267|NCT05595018|OTHER|End user|Participants will provide their opinions in two rounds to reach consensus
40832268|NCT05595018|OTHER|Demand side- management|Participants will provide their opinions in two rounds to reach consensus
40832269|NCT05595018|OTHER|Supply side|Participants will provide their opinions in two rounds to reach consensus
41351246|NCT01359527|DEVICE|Hip Resurfacing|
41351247|NCT01359527|DEVICE|Total Hip Arthroplasty|
41351248|NCT00854685|DRUG|ART621|3.0mg/kg s.c. - weekly
40832270|NCT05595018|OTHER|Funder|Participants will provide their opinions in two rounds to reach consensus
40832271|NCT05595018|OTHER|Academia|Participants will provide their opinions in two rounds to reach consensus
40832272|NCT06103487|GENETIC|No Intervention|Observational study
40832273|NCT01341626|BEHAVIORAL|Treatment Foster Care (TFCO)|Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
41020459|NCT01409694|DRUG|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
41159055|NCT05814822|BEHAVIORAL|Sleep Hygiene Education (SHE-TM)|Participants randomized to SHE-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn sleep hygiene and educational strategies for insomnia.
41351249|NCT00854685|DRUG|ART621|3.0mg/kg s.c. - fortnightly
41351250|NCT00854685|DRUG|ART621|1.5mg/kg s.c. - weekly
41351251|NCT00854685|DRUG|ART621|1.5mg/kg s.c. - fortnightly
41351252|NCT00854685|DRUG|Placebo|Placebo s.c. - weekly
41351253|NCT00854685|DRUG|Placebo|Placebo s.c. - fortnightly
41351254|NCT00854984|BEHAVIORAL|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
41351255|NCT02811081|PROCEDURE|Passive Deflation|In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.
41351256|NCT02811081|PROCEDURE|Normal Saline Instillation|In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.
41351257|NCT02811081|PROCEDURE|Normal Saline Instillation + Pulmonary Recruitment|In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
41020460|NCT01409694|DRUG|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
41020461|NCT01409694|DRUG|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
41351258|NCT06485661|DRUG|Captopril Tablets|Patients will be given captopril to see effect on global longitudinal strain
41351259|NCT00945594|DEVICE|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
41351260|NCT05841277|DRUG|LY3819469|Administered SC.
41351261|NCT00711412|DRUG|Induction Therapy - Capecitabine|Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
41351262|NCT00711412|DRUG|Induction Therapy - Oxaliplatin|Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.
41509116|NCT05772546|DRUG|Avatrombopag|Thrombopoietin receptor agonist, tablet taken orally.
41509117|NCT05772546|DRUG|Matching Placebo|Lactose monohydrate, tablet taken orally.
41351263|NCT00711412|DRUG|Combination Therapy - Capecitabine|Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
41351264|NCT00711412|DRUG|Combination Therapy - Oxaliplatin|Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.
41351265|NCT00711412|RADIATION|Combination Therapy - Radiation|1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.
41351266|NCT00711412|PROCEDURE|Evaluation for response and surgery|Four to eight weeks following the completion of therapy subjects will undergo evaluation for response and surgical resection.
41351267|NCT01119924|DRUG|Smilon®|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
41351268|NCT01119924|DRUG|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
41351269|NCT00001925|DRUG|Alcohol|
41351270|NCT00003958|BIOLOGICAL|dactinomycin|Given IV
41351271|NCT00003958|DRUG|vincristine sulfate|Given IV
41351272|NCT00003958|DRUG|cyclophosphamide|Given IV
41351273|NCT00003958|PROCEDURE|therapeutic conventional surgery|Undergo surgery
41351274|NCT00003958|RADIATION|radiation therapy|Undergo radiotherapy
41351275|NCT00003958|DRUG|topotecan hydrochloride|Given IV
41351276|NCT00003958|BIOLOGICAL|filgrastim|Given SC
41351277|NCT00003958|BIOLOGICAL|sargramostim|Given SC
41351278|NCT00003958|OTHER|laboratory biomarker analysis|Correlative studies
41351279|NCT03896087|DIAGNOSTIC_TEST|Abbott RealTime HCV assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
41020462|NCT05834140|OTHER|Traditional Physical Therapy|"TENS (transcutaneous electrical nerve stimulation) on continuous mode at 80-120 Hz for 15-20 min and Heating pads for 10-15 min~Total 4 sessions will be given in 2 days"
41492765|NCT06420544|BEHAVIORAL|JAPI: Cognitive, Emotional and Social Stimulation for Preschool Children|"Those children in the intervention group will play with the gaming platform Japi using a tablet device in a designated time given from schools' authorities. Early Year Educators will be present to help with the discipline and motivation of the students and Research Assistants will be there as well to provide technical support for the use of the equipment.~The intervention has 24 sessions, and the dosage will be two sessions of 15 minutes each per week for 12 weeks. Sessions number 1 to number 8 are focused on emotional regulation and inhibitory control. Sessions number 9 to 16 work on working memory and problem-solving. Sessions number 17 to 24 promote empathy and planification skills. Each session will have eight activities with increasing levels of difficulty."
41492766|NCT05984875|OTHER|Collection of tumor samples, blood and vaginal and rectal swabs|The following biological samples will be collected at different time points, according to the specified cohort and after signing the inform consent form: tumor tissue (fresh and archival) or normal tissue (cohort E), ascites (when present), peripheral blood, rectal swab, vaginal swab.
41351280|NCT03896087|DIAGNOSTIC_TEST|HCV for use on the cobas® 6800/8800 Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 6800/8800 Systems for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
41351281|NCT03896087|DIAGNOSTIC_TEST|Aptima® HCV Quant Dx Assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays Aptima® HCV Quant Dx Assay from DBS for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
41351282|NCT03896087|DIAGNOSTIC_TEST|HCV for use on the cobas® 4800Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 4800 for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
41351283|NCT05546957|DRUG|Aspirin|Administered orally once per day (QD)
41351284|NCT05546957|DRUG|rivaroxaban low dose|Administered orally twice per day (BID)
41020463|NCT05834140|OTHER|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) along with TENS and Heating pads.~* MET of the scaleni~* MET of Sternocleidomastoid~* MET of Levator Scapulae~* MET of Upper fibers of Trapezius~Total 4 sessions will be given in 2 days"
41020464|NCT05676047|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
41351285|NCT05546957|DRUG|rivaroxaban high dose|Administered orally QD
41492767|NCT01584843|DRUG|GSK1358820|IM injection of Botulinum Toxin Type A
41509118|NCT05708989|PROCEDURE|Caudal Block|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
41020465|NCT05676047|OTHER|Education|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
41020466|NCT04555577|DRUG|Peposertib|Given PO
41020467|NCT04555577|RADIATION|Radiation Therapy|Undergo radiation therapy
41020468|NCT04555577|PROCEDURE|Resection|Undergo surgical resection
41020469|NCT04555577|DRUG|Temozolomide|Given PO
41020470|NCT06173154|OTHER|Care system to prevent ID|The caregivers of this unit receive training about iatrogenic dependency and how prevent it. They set up this prevention and the research compare evolution of dependence hospitalized patients.
40832274|NCT01341626|BEHAVIORAL|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
41351286|NCT05487976|DRUG|Recombinant human activated coagulation factor VII for injection|Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.
41351287|NCT01213511|PROCEDURE|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
40832275|NCT03299543|DEVICE|LEVL (Medamonitor)|Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
41351288|NCT01213511|PROCEDURE|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
41351289|NCT04562727|DRUG|Chemotherapy|perioperative chemotherapy or postoperative chemotherapy
41351290|NCT01780285|DEVICE|Nitinol-framed lightweight PTFE mesh for hiatal repair|"The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair."
41351291|NCT01780285|DEVICE|Partially absorbable lightweight mesh for hiatal repair|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure)."
41351292|NCT05010434|DRUG|Sintilimab and Bevacizumab Combined with Radiotherapy|Before radiotherapy: Bevacizumab+Sintilizumab, Q3w, 2 cycles in total. Radiation therapy: 30-50Gy/10 fractions. After radiotherapy: Bevacizumab+Sintilizumab, Q3w until disease progression or toxicity is intolerable.
41351293|NCT03928106|OTHER|pharmacists' recommendation|For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.
41492768|NCT03373773|PROCEDURE|Foley catheter removal|After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
41492769|NCT02314091|PROCEDURE|onlay mesh hernioplasty|
41492770|NCT04443348|RADIATION|Radiation Therapy Boost|Participants randomized to the low-dose or high-dose RT boost group will be receiving treatment on Day 1-3 of Cycle 1 of pembrolizumab. Proton therapy may be used in the high dose RT group.
41492771|NCT04443348|DRUG|Pembrolizumab|"Neoadjuvant Phase: Day 1 (once every 6 weeks) of Cycles 1-4 (by intravenous infusion) over about 30 minutes.~Adjuvant Phase: Pembrolizumab may be given post-surgery for up to 4 cycles (once every 6 weeks) by intravenous infusion over about 30 minutes. Pembrolizumab after surgery is optional and should be discussed with the study doctor."
41492772|NCT04443348|DRUG|Paclitaxel|Starting Week 3 and administered once per week for 12 weeks (up to 12 doses) by intravenous infusion over about 30 minutes.
40832276|NCT02986100|DRUG|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib
40832277|NCT02986100|DRUG|Rucaparib|200 \& 300 mg tablet
40832278|NCT01969617|DRUG|Nalmefene 18 mg, then placebo|One single oral dose Nalmefene on Day 1 and Placebo on Day 8
40832279|NCT01969617|DRUG|Placebo, then Nalmefene 18 mg|One single oral dose Placebo on Day 1 and Nalmefene on Day 8
41020471|NCT06173154|OTHER|Routine care|standard care without any specific system in place
40832280|NCT01483534|DEVICE|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
40832281|NCT02673320|PROCEDURE|Early surgery within 48 hours|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
40832282|NCT02673320|PROCEDURE|Delayed surgery at 15 days|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
40832283|NCT04757948|PROCEDURE|Acupuncture|Acupuncture of acupoints P-6 and St-36
40832284|NCT04757948|DEVICE|TENS|TENS of acupoints P-6 and St-36
41159056|NCT06620432|PROCEDURE|Low segment hysterotomy|A low segment hysterotomy is a surgical procedure in which an incision is made in the lower segment of the uterus, typically during a cesarean section or other uterine surgeries. This approach is preferred because the lower uterine segment is thinner and less vascular, reducing the risk of bleeding and complications during and after the procedure. The incision is typically horizontal.
41159057|NCT06620432|PROCEDURE|High segment hysterotomy|A high segment hysterotomy is a surgical procedure involving an incision in the upper segment of the uterus.
41351294|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
41351295|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
41351296|NCT00425191|DRUG|Gemcitabine cisplatin followed by docetaxel|Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
41351297|NCT03245840|DRUG|Budesonide oral suspension|BOS 10 mL twice daily.
41351298|NCT01962116|DRUG|Citrate 4%|
41351299|NCT01962116|DRUG|unfractionated heparin|
40832285|NCT04757948|DEVICE|Sham-TENS|Sham-TENS of acupoints P-6 and St-36
40832286|NCT06144697|DRUG|BMS-986465|Specified dose on specified days
40832287|NCT06144697|OTHER|Placebo|Specified dose on specified days
40832288|NCT06144697|DRUG|Pegasys|Specified dose on specified days
40832289|NCT06144697|DRUG|Famotidine|Specified dose on specified days
40832290|NCT01950585|DRUG|Hydroxyurea|
40832291|NCT03720600|BEHAVIORAL|MAB Intervention|The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, \& Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
40832292|NCT03220607|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
40832293|NCT05677503|DIAGNOSTIC_TEST|CBC|measurement of CBC will be performed at the time of admission and by the time of discharge
40832294|NCT05677503|DIAGNOSTIC_TEST|(NT-proBNP)|measurement of serum NT-proBNP levels will be performed at the time of admission and by the time of discharge
40832295|NCT05677503|DIAGNOSTIC_TEST|(cTnT)|measurement of cTnT levels will be performed at the time of admission and by the time of discharge
41159058|NCT06620432|PROCEDURE|Crossed hysterorrhaphy|Crossed hysterorrhaphy is a surgical technique used to close the uterine incision following a hysterotomy, particularly during cesarean sections. In this method, the sutures are placed in a crossed or X-shaped pattern, which helps to evenly distribute tension across the incision site.
41159059|NCT06620432|PROCEDURE|Non-Crossed hysterorrhaphy|Non-crossed hysterorrhaphy is a surgical technique used to close a uterine incision, typically after a hysterotomy, such as during a cesarean section. In this method, the sutures are placed in a linear, parallel fashion rather than in a crossed or X-shaped pattern
41159060|NCT06213974|OTHER|No Intervention|This is non-interventional study.
41159061|NCT05165563|PROCEDURE|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
41351300|NCT01425528|DRUG|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
41351301|NCT05613192|DRUG|Cholecalciferol|patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
41492773|NCT04443348|DRUG|Carboplatin|"Carboplatin is optional for TNBC patients and should be discussed with the study doctor.~Starting Week 3 and administered once per week for 12 weeks (up to 12 doses) by intravenous infusion over about 30 minutes."
41492774|NCT04443348|DRUG|Cyclophosphamide|Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion).
41492775|NCT04443348|DRUG|Doxorubicin|Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion). Doxorubicin will be administered after pembrolizumab.
40832296|NCT01430325|DRUG|Hyperbaric Oxygen (1.5 atm abs)|Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.
40832297|NCT01430325|DRUG|Sham Chamber Session|Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs
41159062|NCT03698071|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
41351302|NCT02844075|DRUG|MK-3475(pembrolizumab)|"Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery."
41351303|NCT02357524|DRUG|Oritavancin|
41351304|NCT04543201|BEHAVIORAL|Early START visit using checklist over telephone or zoom|"Prior to visit subject receives pre-visit educational guide and copy of advance directive form~Follow up surveys:~Immediate: provider feedback survey~2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey~After subject death: caregiver/family survey"
41351305|NCT03592927|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
41351306|NCT03592927|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
41351307|NCT05728424|DRUG|Vonoprazan, Amoxicillin, Levofloxacin|No additional information
41020472|NCT04734353|DRUG|Prasugrel 5mg|Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months
41020473|NCT04734353|DRUG|Ticagrelor 60mg|Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months
41020474|NCT04150575|DRUG|HLX10+Albumin-Bound Paclitaxel|HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
41159063|NCT03698071|BIOLOGICAL|urine sample|6 ml
41159064|NCT00631098|PROCEDURE|venous cannulation|External jugular and cubital vein cannulation
41159065|NCT06647342|DRUG|Bleomycin|In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.
41159066|NCT02579278|OTHER|Blood sample (mrEMVI positive patient)|Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
41351308|NCT00294229|PROCEDURE|manipulative therapy|
41351309|NCT05780164|OTHER|Research readiness tool|Online/paper based tool containing information about lung cancer clinical trials
41351310|NCT05933993|OTHER|Elective cesarean section|The study does not contain an intervention in itself, but women are included if they undergo an elective cesarean section
41351311|NCT03628391|DRUG|Haloperidol|haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
41351312|NCT03628391|DRUG|Placebo|placebo for ICU delirium, titrated on validated screening tool-based diagnosis
40832298|NCT03817073|DEVICE|Iowa Oral Performance Instrument (IOPI)|Using biofeedback to attain repetitions of 80% of baseline MIP.
40832299|NCT05305105|DRUG|Psilocybin|Dosing at the first session will be 15mg. For the second session participants will either remain at the initial dose, or increase to 25mg.
40832300|NCT04298866|OTHER|Experimental Arm|"* 3T MRI, maximum 1H30 long duration, including diffusion tensor imaging, susceptibility weighted imaging, multiparametric acquisitions, without contrast perfusion acquisitions.~* 7T MRI, maximum 1H30 long duration, including contrast enhanced acquisitions~* Neuropsychological battery including chronometric measures obtained through a computer interface"
40832301|NCT05006209|OTHER|One visit root canal treatment|
40832302|NCT05006209|OTHER|Two visit root canal treatment|
40832303|NCT04032080|COMBINATION_PRODUCT|Drug 1: LY3023414; Drug 2: Prexasertib|"Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry.~Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m\^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses."
40832304|NCT02576860|DRUG|CLS001 (Omiganan)|Topical gel
40832305|NCT02576860|DRUG|Vehicle|Vehicle gel
40832306|NCT03821623|DRUG|Nicotinamide riboside|Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial dysfunction in aged mice, suggesting that declining NAD+ may play a key role in cardiovascular aging.
41020475|NCT04770805|PROCEDURE|Fetoscopy|After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
41020476|NCT00647192|DRUG|Eplerenone|50 mg per day
41020477|NCT00647192|DRUG|Placebo|50 mg per day
41020478|NCT01034917|DRUG|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
41020479|NCT01034917|DRUG|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
41020480|NCT00501449|BEHAVIORAL|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
41159067|NCT02579278|OTHER|Blood sample (mrEMVI negative patient)|
40832307|NCT03821623|OTHER|Placebo|Subjects will take placebo pills twice a day for 3 months
40832308|NCT06133296|OTHER|Conventional fixed treatment|Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment
41159068|NCT06023888|OTHER|Mapping strategy|The ablation strategy was based on the mapping results of periodicity.
41159069|NCT06023888|OTHER|Mapping strategy|PVI+ non-PV trigger
41351313|NCT06413576|DIAGNOSTIC_TEST|homocysteine measurement|measuring the serum level of homocysteine
41351314|NCT03184766|DRUG|Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules|2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
41351315|NCT03184766|DRUG|Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets|2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
41351316|NCT03184766|DRUG|Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules|2 x 200 mg solubilised ibuprofen
41351317|NCT04182165|DEVICE|Gili BioSensor System/ Gili Pro X BioSensor System|Usability study
41351318|NCT01497665|DRUG|GRN1005|650 mg/m2 IV every 3 weeks
40832309|NCT06133296|OTHER|Clear aligner treatment|After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments
40832310|NCT00386477|PROCEDURE|Vaginal cleansing before cesarean delivery|Cleansing vagina with 1% betadine scrub before cesarean.
41351319|NCT04272996|PROCEDURE|Craniotomy only|evacuation of SDH
41351320|NCT04272996|PROCEDURE|Craniotomy + Endovascular embolization of the middle meningeal vessels|evacuation of SDH + Embolization of middle meningeal vessels using standard techniques.
40832311|NCT05860491|OTHER|dietary fiber|Retrospective analysis of the relationship between patient dietary fiber intake and hyperkalemia
40832312|NCT03724981|DRUG|Dulaglutide Pen|Injected on a practice pad.
40832313|NCT03724981|DRUG|Semaglutide Pen|Injected on a practice pad.
41351321|NCT04945499|DRUG|d-glucose|using d-glucose as an contrast agent on CEST MR Imaging
40832314|NCT00316888|BIOLOGICAL|cetuximab|Given IV
40832315|NCT00316888|DRUG|cisplatin|Given IV
41159070|NCT06647485|PROCEDURE|PF-only PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing only PF energy for ablation
41159071|NCT06647485|PROCEDURE|Hybrid PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing both PF and RF energy for ablation. Specifically, PF energy is used for the posterior segments and RF energy for the anterior segments of the pulmonary veins
41351322|NCT06168929|DRUG|SHR4640|SHR4640, 2.5mg\*4 - 10mg\*1
41351323|NCT06168929|DRUG|SHR4640|SHR4640, 10mg\*1 - 2.5mg\*4
40832316|NCT00316888|DRUG|fluorouracil|Given IV
40832317|NCT00316888|RADIATION|radiotherapy|Given once daily 5 days a week for 5 weeks
40832318|NCT03381417|DRUG|pegcyte|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
40832319|NCT03381417|DRUG|Neulastim|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
40832320|NCT03921333|DIETARY_SUPPLEMENT|Low dose response efficacy of plant extracts|300mg
40832321|NCT03921333|DIETARY_SUPPLEMENT|Middle dose response efficacy of plant extracts|500mg
41351324|NCT02411669|OTHER|Operational patient centered care tools|"The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.~They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done."
40832322|NCT03921333|DIETARY_SUPPLEMENT|High Dose response efficacy of plant extracts|700mg
41351325|NCT00939094|DRUG|AZD2066|Capsule, once daily
40832323|NCT03921333|DIETARY_SUPPLEMENT|Placebo|Cellulose microcrystalline
40832324|NCT01797380|DRUG|Placebo|Placebo daily for duration of double-blind portion of trial
40832325|NCT01797380|DRUG|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
40832326|NCT05255042|OTHER|organ and tissue sample collection only|Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology
40832327|NCT04304183|PROCEDURE|total colectomy, ileorectal anastomosis|all patients underwent total colectomy and ileorectal anastomosis.The anastomosis was stapled in all patients.
40832328|NCT03659058|DRUG|silymarin|silymarin 140 three times daily
40832329|NCT03659058|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid 500
40832330|NCT03659058|DRUG|Antioxidants|Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
40832331|NCT03659058|DRUG|Colchicine|Colchicine 0.6
40832332|NCT03659058|OTHER|FOLLOW UP|follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
40832333|NCT05729698|DEVICE|Baby warmer swaddle|Baby Swaddle with Heating System
40832334|NCT05729698|OTHER|polyethylene bag|polyethylene food bag
40832335|NCT04110470|DIAGNOSTIC_TEST|X-ray|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
40832336|NCT04110470|DIAGNOSTIC_TEST|No-Xray|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
40832337|NCT01459913|DRUG|Telaprevir|Tablet
40832338|NCT01459913|DRUG|Pegylated Interferon Alfa-2a|Subcutaneous Injection
40832339|NCT01459913|DRUG|Ribavirin|Tablet
40832340|NCT04790487|DRUG|CPM|one spray dose (\~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
40832341|NCT04790487|DRUG|Placebo|Saline
40832342|NCT01981889|DRUG|Prednisone|Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
40832343|NCT03895177|DIAGNOSTIC_TEST|contrast enhanced computed tomography|pancreatic protocol CT with 80kVp tube voltage and more than 500mA tube current acquire late arterial phase and portal venous phase using volus tracking method
40832344|NCT00284713|PROCEDURE|intracoronary infusion of BMC|catheter delivery of stem cells
40832345|NCT03582904|PROCEDURE|tDCS|real or sham tDCS delivered to primary motor cortex
40832346|NCT04326660|OTHER|SCOPE-Chinese Women|SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.
40832347|NCT06030492|DRUG|packing placental site with hydrogen peroxide soaked towels|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution"
40832348|NCT06030492|DRUG|normal Saline|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done.~Packing the placental bed with a towel soaked with normal Saline solution"
40832349|NCT05189249|OTHER|No intervention performed|No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.
40832350|NCT02927262|DRUG|Gilteritinib|Oral tablet
40832351|NCT02927262|DRUG|Placebo|Oral tablet
40832352|NCT02547493|BIOLOGICAL|pneumococcal polysaccharide vaccine|Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
40832353|NCT02547493|BIOLOGICAL|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
40832354|NCT02547493|DRUG|Abatacept|Abatacept started on frst day
41351326|NCT00939094|DRUG|Placebo|Capsule, once daily
41351327|NCT05822349|BEHAVIORAL|picograms-enriched label|The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
41351328|NCT02701569|OTHER|Rebound exercise|Repeated jumping on a mini trampoline was administered
41351329|NCT01951326|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
40832355|NCT05869422|DIETARY_SUPPLEMENT|Iron|90 ± 5 days of daily oral iron supplementation.
41492776|NCT04443348|DRUG|Capecitabine|"Capecitabine after surgery is optional for TNBC patients and should be discussed with the study doctor.~Starting 3-6 weeks after surgery, administered orally twice daily for 6 courses, each 3 weeks long (for a total of 18 weeks)."
41492777|NCT03122080|DEVICE|Electroacupuncture(EA)|"Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients."
41492778|NCT03122080|DEVICE|Placebo acupuncture|Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.
41492779|NCT03122080|OTHER|Standard care|Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
41492780|NCT02490267|OTHER|Quality of Life questionnaire|
41492781|NCT05807516|OTHER|Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)|Combined both retrospective and prospective observational design
40832356|NCT05869422|OTHER|Placebo|90 ± 5 days of daily oral placebo intake.
41351330|NCT01951326|DRUG|Placebo|5 placebo capsules administered orally BID
41351331|NCT04614194|DRUG|Letrozole|Oral. Tablets should be taken at the same times every day, with or without food.
41351332|NCT04614194|DRUG|Abemaciclib|Oral. Tablets should be taken at the same times every day, with or without food.
40832357|NCT04782947|DEVICE|Exoskeletal assisted walking|Exoskeletal assisted walking includes the use of robotic suit to train participant to walk with different level of assistance.
41351333|NCT02016586|DIETARY_SUPPLEMENT|Maternal Nutritional Supplement|S348S0
41351334|NCT02056665|DRUG|MINOCYCLINE|Pill Minocycline 50 mg capsule
40832358|NCT04782947|DEVICE|Epidural Stimulation|lumbo-sacral epidural simulation at the beginning of the study.
40832359|NCT04782947|PROCEDURE|Resistance Training|Using two forms of resistance training to increase muscle size. The first form includes seated leg extension exercise for 12 weeks followed by a second form that includes sit-to-stand exercise using participant's body weight.
41351335|NCT02056665|DRUG|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
41351336|NCT00720720|DIETARY_SUPPLEMENT|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
41351337|NCT00720720|DIETARY_SUPPLEMENT|placebo margarine|
41351338|NCT00634751|DRUG|Oxaliplatin|On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.
41351339|NCT00634751|DRUG|Capecitabine|Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
41492782|NCT06002841|BIOLOGICAL|intravenous treatment with EVs|intravenous treatment with extracellular vesicles
40832360|NCT04782947|DEVICE|delayed-ES|lumbo-sacral epidural simulation starting 6 months after the beginning of the study.
40832361|NCT04782947|PROCEDURE|no-Resistance training|The participants will perform 24 weeks of passive movement or passive stretching from seated position.
40832362|NCT00990912|DRUG|Carboplatin|IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
41020481|NCT06498050|DRUG|intravitreal injection of Brolucizumab 6 mg in study eye|After disinfecting the conjunctival sac and administering a topical anesthetic, an intravitreal injection of Brolucizumab at a dose of 6 mg is given.
41159072|NCT06647485|PROCEDURE|RF-only PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing only RF energy for ablation
41492783|NCT06002841|BIOLOGICAL|intravenous treatment with placebo solution|intravenous treatment with placebo solution (without extracellular vesicles)
41159073|NCT03305471|DRUG|DS-2330b PIB|DS-2330b as powder in bottle with stock solution (PIB)
41351340|NCT00634751|DRUG|Sorafenib|"Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).~Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length~Sorafenib 200 mg BID Oral Daily Every 28 days~If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.~Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length~Sorafenib 400 mg BID Oral Daily Every 28 days"
41351341|NCT01893879|DRUG|placebo for study drug|Given PO
41351342|NCT01893879|DRUG|(RS)2-(3-benzoylphenyl)-propionic acid|Given PO
40832363|NCT00990912|DRUG|Irinotecan|IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
41159074|NCT03305471|DRUG|Placebo|Placebo matching stock solution in bottle
41492784|NCT02336035|PROCEDURE|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
41159075|NCT03305471|DRUG|Sevelamer|Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.
41159076|NCT03305471|DRUG|DS-2330b Tablet|DS-2330b as tablet formulation
41159077|NCT04269434|OTHER|No Screening|the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
41159078|NCT00058942|DEVICE|home drinking water treatment device|
41159079|NCT04574661|OTHER|Static Stretching|In Control group all the individuals will be asked to perform static stretching for 10 mints, 1 set . Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual.
41159080|NCT04574661|OTHER|Intermittent Occlusion|Individuals of Interventional group will be asked to lay down in supine position, apply proximal thigh cuff, 220mg for 12 minutes for intermittent occlusion. During this procedure discomfort will be checked on numeric pain rating scale, if we get 6 on scale, will stop the occlusion. Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual
41351343|NCT01893879|OTHER|laboratory biomarker analysis|Correlative studies
41351344|NCT03416972|RADIATION|Standard platinum-based chemoradiotherapy|Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).
41351345|NCT00218569|DRUG|Naltrexone|Naltrexone
41351346|NCT00218569|DRUG|Placebo|Placebo
40832364|NCT00990912|DRUG|Irinotecan|IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
40832365|NCT04311398|DIAGNOSTIC_TEST|New QIAstat-Dx fully automatic multiple PCR detection platform|We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients
40832366|NCT02322294|DIETARY_SUPPLEMENT|Glucodia™|
40832367|NCT02322294|OTHER|Placebo|
40832368|NCT00151788|DRUG|Pactimibe sulfate|
41159081|NCT00257764|BEHAVIORAL|behavioral swallowing exercises/ strategies|
41351347|NCT01858337|OTHER|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
41351348|NCT01858337|OTHER|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
41351349|NCT01858337|OTHER|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
41351350|NCT01858337|OTHER|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
41351351|NCT03113799|DEVICE|Smart External Drain - SED|Subject will be treated on Day 2 with the SED. ICP and CSF volumes will be recorded at prespecified intervals while subject is stationary and while subject is engaged in protocol-driven directed movements.
41351352|NCT04771650|OTHER|CAMI|The CAMI is a culturally adapted motivational interview. It is a single 75 minute session that focuses on promoting motivation to change drinking and drug use behavior.
41351353|NCT04395521|BEHAVIORAL|Diabetic foot self-management support|Daily educational organic or inorganic posts (2 to 5) released in a timed sequence through a Hootsuite application plus peer interactions/support for three months.
41492785|NCT04838548|DRUG|MRG003|Administered intravenously
41492786|NCT04779515|PROCEDURE|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
41492787|NCT04779515|PROCEDURE|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
40832369|NCT04616209|BIOLOGICAL|donor-derived NK cell infusion|PB103 administrations will be separated by 4-week interval
41159082|NCT06646289|BIOLOGICAL|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered sub-retinally.
41159083|NCT06646289|OTHER|No intervention (Follow-Up assessment)|Participants will not receive any intervention and will undergo follow-up assessment.
41159084|NCT02421939|DRUG|gilteritinib|tablet, oral
41159085|NCT02421939|DRUG|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
41159086|NCT02421939|DRUG|Azacitidine|SC or IV injection
41159087|NCT02421939|DRUG|MEC (Mitoxantrone, Etoposide, Cytarabine)|IV injection
41159088|NCT02421939|DRUG|FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)|SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
41159089|NCT06645600|DIAGNOSTIC_TEST|Fracture risk|To calculate fracture risk, the percentages for major and hip fracture risks will be calculated using the Fracture Risk Assessment Tool (FRAX®). The one-leg stance test, used to assess static posture and balance, and the 30-second sit-to-stand test, used to evaluate endurance and lower extremity strength, will be applied to the patients.
41159090|NCT01994538|OTHER|Longer therapy duration|14 days of antimicrobial treatment
41159091|NCT01994538|OTHER|Shorter therapy duration|7 days of antimicrobial treatment
41351354|NCT02819583|BIOLOGICAL|PCAR-019 (anti-CD19 CAR-T cells)|
41351355|NCT04709406|DRUG|deep neuromuscular blockade in bariatric surgery|obese patients who underwent bariatric surgery
41351356|NCT02543762|PROCEDURE|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
41351357|NCT03752840|OTHER|Visual acuity (presenting and pinhole)|Presenting and pinhole visual acuity will be assessed using the Peek Acuity mobile application. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
41351358|NCT03752840|OTHER|Optical coherence tomography (OCT)|OCT will be used to image the anterior segment, the macula, and the retinal nerve fiber layer. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
41509119|NCT05708989|PROCEDURE|Ultrasound-guided Pudendal Block|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
40832370|NCT01313819|DRUG|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
40832371|NCT02990195|OTHER|Chyme reinfusion|
40832372|NCT05281536|OTHER|Ppostural change from 45° to 10° in supine position|The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
41020482|NCT06573476|BEHAVIORAL|PRC supported text + AI driven CSDH-enhanced text|"In interventional Arm-1, PRC-supported text check-ins to participants (3x/week) will be provided by PRC study staff in addition to automated AI-driven texts. The PRC will personalize text check-ins to participants based on: (a) baseline CSDH needs (e.g., food insecurity, legal aid); (b) initial intake visit in primary care or challenges with service entry; and (c) content outlined in the CSH training addressing emerging participant challenges."
41351359|NCT03752840|OTHER|Intraocular pressure|Intraocular pressure will be measured using an iCare tonometer. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
41351360|NCT03752840|OTHER|Active linkage to care|Referred participants will be followed closely by study staff to ensure completion of follow-up visits.
41351361|NCT01637792|OTHER|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
41351362|NCT01637792|OTHER|Four 2-liter exchanges daily CAPD|CAPD regimen of four 2-liter daily exchagnes
41351363|NCT02730546|DRUG|Carboplatin|Given IV
41351364|NCT02730546|PROCEDURE|Computed Tomography|Undergo CT scan
41351365|NCT02730546|DRUG|Fluorouracil|Given IV
41351366|NCT02730546|OTHER|Laboratory Biomarker Analysis|Correlative studies
41351367|NCT02730546|DRUG|Leucovorin Calcium|Given IV
41351368|NCT02730546|DRUG|Oxaliplatin|Given IV
41351369|NCT02730546|DRUG|Paclitaxel|Given IV
41351370|NCT02730546|BIOLOGICAL|Pembrolizumab|Given IV
41351371|NCT02730546|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41351372|NCT02730546|RADIATION|Radiation Therapy|Undergo radiation therapy
41351373|NCT02730546|PROCEDURE|Therapeutic Conventional Surgery|Undergo curative-intent surgery
41351374|NCT06164743|DRUG|VVN461 Ophthalmic Solution 1.0%|Topical ocular drug
41351375|NCT06164743|DRUG|VVN461 Ophthalmic Solution 0.5%|Topical ocular drug
41351376|NCT06164743|DRUG|Vehicle|Topical ocular drug
41351377|NCT02203916|DRUG|Azilsartan medoxomil|Azilsartan medoxomil tablets
41351378|NCT02203916|DRUG|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
41351379|NCT02951728|DRUG|Rituximab|
41351380|NCT02951728|DRUG|Cyclophosphamide|
40832373|NCT02532712|DRUG|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
40832374|NCT02532712|DRUG|Placebo|Placebo with same shape and size
40832375|NCT02250664|OTHER|Very low nicotine content cigarettes|Very low nicotine content cigarettes
40832376|NCT01483209|DRUG|Injection of botulinum toxin A|One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
41020483|NCT06573476|BEHAVIORAL|AI driven CSDH-enhanced text only|In interventional Arm-2, participants will receive the AI-driven CSDH-enhanced text messaging only. Participants in this arm will not receive text support from the PRC.
41020484|NCT06573476|BEHAVIORAL|Treatment as Usual (TAU)|In Arm-3, the control group, individuals randomized to the control arm will receive treatment as usual (i.e., verbal instructions and NYC Dept of Health pamphlets detailing access to OUD and social services). No services will be provided except for social/clinical service referrals given at the end of each REDCap visit.
41020485|NCT03995004|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.
41020486|NCT03995004|DRUG|Dexamethasone Sodium Sulphate 4mg/1mL|Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
41020487|NCT05715645|PROCEDURE|Unilateral prosthetic knee surgery|Unilateral prosthetic knee surgery
41020488|NCT05715645|PROCEDURE|Analgesia|Analgesic management by adductor canal block
41020489|NCT04427098|DRUG|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Subcutaneous enoxaparin 40 mg once daily for 14 days.
41020490|NCT04427098|DRUG|Enoxaparin|Subcutaneous enoxaparin for 14 days: 60 mg once daily in case of body weight of 45 to 60 kg; 80 mg once daily in case of weight from 61 to 100 kg; 100 mg once daily in case of bodyweight \>100 kg
41020491|NCT04279925|DEVICE|ORIF (Open reduction internal fixation): locally-made miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia. The plate used in the study is a straight plate with 4 and 5 holes with the dimension of 17mm long, 4 mm wide and 0.56 mm thick.
41351381|NCT02951728|DRUG|Doxorubicin|
41492788|NCT01300910|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
41492789|NCT01300910|PROCEDURE|Male circumcision|A conventional surgical procedure will be performed, per WHO recommendations, involving: drawing a line to mark the amount of foreskin to be cut; cutting off the foreskin; hemostasis; and wound closure with sutures.
41492790|NCT06310824|DRUG|MAB-22|60mg dose of a single subcutaneous injection
40832377|NCT03983772|DIETARY_SUPPLEMENT|RS blend|The intervention is a proprietary resistant starch blend.
40832378|NCT03983772|OTHER|Placebo|The placebo is starch.
40832379|NCT05693051|OTHER|Prone position ventilation|Turning the patient prone for 16 hours
40832380|NCT06427070|OTHER|Irrigating solution|Saline, sodium hypochlorite, chlorohexidine
40832381|NCT03484364|BEHAVIORAL|ENACTS|Peer-facilitated, self-care BP education delivered every other week for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $50 of groceries every other week (4 times) over 8 weeks.
40832382|NCT02316210|DEVICE|electrical stimulation|
40832383|NCT06008899|PROCEDURE|US assisted caudal epidural pulsed radiofrequency|patients will receive US assisted caudal epidural pulsed radiofrequency and followed up to 8 weeks
40832384|NCT03371173|DRUG|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
40832385|NCT02982018|DEVICE|senofilcon A with new UV blocker|Investigational Contact Lens
40832386|NCT02982018|DEVICE|senofilcon A|J\&J Marketed Contact Lens
40832387|NCT05766033|OTHER|Enamel conditioning with a novel etchant paste|The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).
40832388|NCT03987932|BEHAVIORAL|NEAT!2|Participants randomized to NEAT!2 will have their NEAT!2 app turned on after randomization. When 30 minutes of continuous non-movement or sedentary time is detected, the NEAT!2 app will provide a vibration or audio notification as well as display a reminder on the phone's lock/home screen. Participants will be asked to use the app for the 3 months of the intervention. Participants will be given an initial goal to reduce total sedentary time by 30 minutes/day, ultimately progressing to a 90 minute/day reduction by 3 months. After the 3-month assessment, participants randomized to NEAT!2 will have the option to continue using the app until 6 months.
40832389|NCT03987932|BEHAVIORAL|NEAT!2+Calls|Participants in this group will have their NEAT!2 app turned on after randomization. In addition, to receiving the identical app and given the same goals as participants randomized to NEAT!2, NEAT!2+Calls participants will receive 10-15 minute bi-weekly coaching calls. After the 3-month assessment, participants will have the option to continue using the app until 6 months. During this time, participants will not receive any coaching calls.
40832390|NCT03987932|BEHAVIORAL|Delayed NEAT!2|Participants randomized to Delayed NEAT!2 will not receive any contact or app between baseline and 3 months. However, after completing the 3-month assessment, participants will receive the NEAT!2 application. Participants will then have the option to use the app between 3 and 6 months.
40832391|NCT02226198|DRUG|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
40832392|NCT02226198|DRUG|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
41020492|NCT04279925|DEVICE|ORIF: Imported miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using Biomet® miniplate 1.5 produced by Biomet, included in the Lorenz® Plating System Midface. The particular plate used in the study is a straight plate with 4 holes, 17mm length and 0.6mm thick, coded 01-7047 in the catalog. Biomet® screw 1.5 utilized in this study is also produced by Biomet, included in the Lorenz® Plating System Midface. The dimension of the screw is 4mm length, 1.5 mm diameter, and coded 91-6104 1.5 mm X-Drive Self drilling screws.
41020493|NCT01850199|OTHER|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
41020494|NCT01850199|OTHER|Usual management|Usual care will be provided, including face-to-face visits
41020495|NCT05126888|DRUG|SCI-110|SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
41020496|NCT05126888|OTHER|Placebo|Pill that matches in taste, odour and appearance to SCI-110 active pills
41492791|NCT06310824|DRUG|EU-Prolia®|60mg dose of a single subcutaneous injection
41020497|NCT04692246|OTHER|Plant-based oral rinse|Oral rinse enriched with plant-based essential oils.
41020498|NCT04692246|OTHER|Placebo oral rinse|Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
41351382|NCT02951728|DRUG|Vincristine|
41351383|NCT02951728|DRUG|Prednisone|
41492792|NCT06310824|DRUG|US-Prolia®|60mg dose of a single subcutaneous injection
41492793|NCT05033093|DRUG|Root Canal Sealants|it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
41492794|NCT00004180|DRUG|rosiglitazone maleate|
41492795|NCT05331196|DIAGNOSTIC_TEST|Preoperative cardiopulmonary exercise tetsing|Patients underwent a cardiopulmonary exercise test prior to surgery.
41492796|NCT04462211|PROCEDURE|Implementation of management pharmacological protocol of constipation|"first 48 hours:~* polyethylene glycol 3350 (about 17 grams) 1 every 8 hours enterally.~* Patients who have vomiting and / or gastric residue greater than 500 mL (in a timely measurement every 6 hours) will also be given domperidone 10 mg every 8 hours intravenously.~* Patients who have excessive abdominal distension will be administered in addition, levosulpiride 25 mg every 8 hours intravenously.~  48 hour evaluation:~* Patients who do not have bowel movements will be administered lactulose or sodium phosphate enema.~* For patients who do not have a bowel movement, administration of neostigmine intravenously or of naloxone enterally will be evaluated.~* Every patient who uses one or more prokinetics will have an electrocardiogram.~* Any patient who has bowel movements during management, doses of polyethylene glycol 3350 will be adjusted according to the daily goal of bowel movements, the days of treatment of the prokinetics will be adjusted, for a maximum of 5 consecutive days."
41492797|NCT04462211|PROCEDURE|Implementation of bundle of prevention and non-pharmacological management|"Bundle of prevention:~* Start early enteral nutrition.~* Optimize and / or decrease opioid doses.~* Start early mobilization.~Non-pharmacological management bundle~* Select laxative and/or prokinetic/s to manage constipation.~* Optimize and / or decrease doses of opioids and sedatives.~* Start early mobilization.~* Pharmacological reconciliation."
41492798|NCT04955535|PROCEDURE|Arthroscopic synovectomy|Arthroscopic synovectomy
41492799|NCT04259463|PROCEDURE|Third molars extraction|Third molars extractions with concious sedation or general anesthesia
41492800|NCT05712421|DRUG|North Star|North Star
41492801|NCT05712421|DRUG|Levothyroxine|Levothyroxine
41492802|NCT03370809|RADIATION|Brain PET/CT step|a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
41492803|NCT04819399|DRUG|Catumaxomab|"Procedure: 6 weekly intravesical administration at each dose level; 3 sequential cohorts consisting of 3 patients (part I)~1. cohort 50 µg~2. cohort 70 µg~3. cohort 100 µg~Part II will be treated at recommended dose"
41492804|NCT04516759|DRUG|AZD1656|50mg film-coated tablets (at daily dose of 100mg BID)
41492805|NCT04516759|OTHER|Placebo|Matched placebo tablets
41492806|NCT01753947|OTHER|Deliberate Practice|
41492807|NCT05710939|OTHER|exercises|
41509120|NCT05708989|DRUG|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
40832393|NCT05832112|PROCEDURE|VATS/RATS lobectomy|"Consenting patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, aside from the ports that will be placed in the subcostal plane. The characteristics of both the patient and the case, will determine the number of incisions from 1-4.~The Davinci Xi® surgical system will be used to perform the lobectomy through the ports using the standard technique with an anterior approach. Once the procedure is completed, the robotic arms and ports will be removed from the chest and figure-of-8 stitches with non absorbable sutures will be placed to close the diaphragm at the site of insertion. A 24 Fr soft chest tube will be left in place, as in the standard VATS/RATS lobectomy procedure. The incision closure will be done in a standard manner."
40832394|NCT06245239|DEVICE|perfusion index|measurement of perfusion index
40832395|NCT04944732|DIAGNOSTIC_TEST|laboratory examination, auxiliary examination, pathological results|Personal information (sex, age), medical history of present disease, past medical history, family history, symptoms and signs, supplementary examination items (including laboratory examination, impact examination)
41020499|NCT03104504|BEHAVIORAL|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
41159092|NCT02618785|PROCEDURE|hysterosalpingography|Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
40832396|NCT00134732|BIOLOGICAL|Live attenuated human rotavirus vaccine|
40832397|NCT03597477|DRUG|Dexmedetomidine|participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
40832398|NCT04884542|DEVICE|Revision Total Knee Arthroplasty|Total Knee Arthroplasty in case of failure of a previous operation.
40832399|NCT00012090|DRUG|bicalutamide|
40832400|NCT00012090|DRUG|goserelin acetate|
40832401|NCT01636713|DRUG|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
41020500|NCT03104504|BEHAVIORAL|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
41020501|NCT03104504|BEHAVIORAL|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
41020502|NCT03104504|BEHAVIORAL|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
41159093|NCT00541671|DRUG|Saline|10 c of saline
41159094|NCT00541671|DRUG|Phenergan|Physician ordered dose
41351384|NCT02951728|DRUG|Decitabine|
41351385|NCT05970146|DRUG|Ultrasound guided Stellate ganglion block|Under visualization with ultrasound, a 22-gauge, 5-cm needle inserted perpendicular to the skin to rest anteriorly to the precervical fascia. 6 mL lidocaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL is used. After injection of a 0.5-mL test dose to exclude intravascular positioning, the remainder of the appropriate dose was administered. The patient will be encouraged to lie flat for 3 minutes after the injection and then to sit up.
41351386|NCT05970146|DRUG|unilateral cervical epidural|Aseptic betadine skin preparation will be performed and sterile drapes will be applied. Local anesthetic infiltration of the skin at C7-T1 interspace will be done using 2-3 mL of lidocaine 2% with guidance of the C-arm an 18-gauge. Tuohy needle will be inserted at C7-T1 interspace and directed towards either right or left epidural recess according to the site of the operation. Identification of entering the epidural space will be confirmed by hanging drop technique. The position of the needle is the confirmed by injection of 1 mL of non-ionized diluted dye (omnipause 300) to confirm unilateral spread of the dye. After that, a test dose was administrated, consisting of 2 mL of 2% lidocaine with 1:200,000 epinephrine.
41351387|NCT03377166|DIAGNOSTIC_TEST|Bucket test and Smartphone-based evaluation of SVV|Bucket test and Smartphone-based evaluation of SVV
41351388|NCT05140694|DRUG|Empagliflozin|Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)
41351389|NCT05140694|DRUG|Dulaglutide|Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)
41159095|NCT03550183|BIOLOGICAL|mesenchymal stem cells|Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.
41351390|NCT05140694|DRUG|Empagliflozin and Dulaglutide|Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly
41351391|NCT02619929|DRUG|Vinorelbine oral|
41351392|NCT01002040|BIOLOGICAL|Arepanrix|Group A receives one dose of Arepanrix
41351393|NCT01002040|BIOLOGICAL|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
41351394|NCT06069622|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure|24-hour ambulatory blood pressure, blood, and urine will be obtained prior to semaglutide therapy and after 20 weeks of semaglutide therapy.
41351395|NCT06069622|DIETARY_SUPPLEMENT|Liberal salt diet|Participants will be on a liberal salt (about 200 mEq sodium/day) diet for 7 days.
41351396|NCT01997333|DRUG|CDX-011|
41351397|NCT01997333|DRUG|Capecitabine|
41351398|NCT00856115|OTHER|medical chart review|Patient charts are reviewed to obtain medical data.
41351399|NCT00856115|OTHER|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
41351400|NCT00856115|OTHER|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
40832402|NCT01636713|DRUG|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
40832403|NCT01636713|DRUG|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
40832404|NCT03605069|DRUG|QR-313|QR-313 will be applied topically once daily for 8 weeks of treatment.
40832405|NCT03605069|DRUG|Placebo|Placebo will be applied topically once daily for 8 weeks of treatment.
41020503|NCT00905333|DRUG|Candesartan (test)|16 mg oral tablet, single dose
41020504|NCT00905333|DRUG|Felodipine (test)|5 mg oral extended release tablet, single dose
41020505|NCT00905333|DRUG|Candesartan Cilexetil|16 mg oral tablet, single dose
41020506|NCT00905333|DRUG|Felodipine|5 mg oral extended release tablet, single dose
41020507|NCT06493890|OTHER|Validation PEQ-DLV|Validation of the Dutch Language version of the Prosthesis Evaluation Questionnaire
41020508|NCT05631639|DEVICE|PillSense System|The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
41020509|NCT05531214|BEHAVIORAL|Multidisciplinary Care Coordination Team|The intervention group will be patients whose primary care clinicians will be receiving guidance and recommendations from the multidisciplinary team consisting of cardiologists, nephrologists, and specialty pharmacists.
41020510|NCT05797805|DRUG|Tegavivint|"The first part is a phase 1 single-agent dose escalation, optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.~Tegavivint single agent dosing regimen: Tegavivint will be administered weekly on Days 1, 8, 15, and 22 of a 28-day cycle"
41020511|NCT05797805|DRUG|Pembrolizumab|"In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus pembrolizumab combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 of a 21-day cycle; Pembrolizumab will be administered on Day 1 of a 21- day cycle"
41020512|NCT05429476|DRUG|Tissue Plasminogen Activator (Alteplase)|"Tissue Plasminogen Activator (Alteplase) 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour~Other Names:~Actilyse Activase tPA r-tPA"
41020513|NCT00767546|DRUG|Botulinum toxin|60- 100 units Local injection to the rash area
41020514|NCT01025700|DRUG|Cesemat|1 mg capsule per day for 21 days
41020515|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
41020516|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
41020517|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
41020518|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
41020519|NCT04349852|BEHAVIORAL|BrainHQ Cognitive Training Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The subtests exercises include 6 modules for the experimental group: 1) Sound Sweeps: which is identify whether sound pitches are going up or down; 2) Memory Grids: matching pairs of words; 3) Syllable Stack: recognition of sequences of confusable syllables; 4) Fine Tuning: recognition of the order of confusable syllables; 5) To-Do List Training: reconstruction of sequences of verbal instructions; 6) In The Know: identification of details in a verbally presented story. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
41159096|NCT05896696|DEVICE|BeShape One|Single treatment with the BeShape One device. Participants will receive treatment on at least 4 abdomen/flanks treatment areas and up to 6 treatment areas, at the discretion of the investigator. The subject will receive one treatment on each treatment area.
41159097|NCT04433286|OTHER|Questionnaire|"This is a cross-sectional survey which will be distributed online between surgeons. The survey was proposed by a consensus of consultants of surgery and revised by an improvement consultant. It consists of a semi-structured questionnaire that is provided in English language. A subsequent translation in different Language will provided based on geographical distribution. The survey will be conducted online through an online survey development cloud-based software (SurveyMonkey®; San Mateo, CA, USA). Participants will be aware of the nature of the survey and informed that they will be listed as co-authors. Collected data will be confidential and anonymous.~The first sector of the questionnaire includes trainee demographics and baseline characteristics. Then the questionnaire aims to compare the trainee experience before and after the pandemic with focus on research activities, clinical, and surgical practice."
41159098|NCT03726125|DRUG|LY3374849 - SC|Administered SC
41351401|NCT00856115|OTHER|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
41492808|NCT01495156|DRUG|Lithium treatment in combination with a SGA (Second Generation Antipsychotic)|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L)."
40832406|NCT01702740|DRUG|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
40832407|NCT01702740|DRUG|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
40832408|NCT01702740|DRUG|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
40832409|NCT01702740|DRUG|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
40832410|NCT00906724|PROCEDURE|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise."
40832411|NCT01452295|DRUG|ELAD (Extracorporeal Liver Assist System)|ELAD (Extracorporeal Liver Assist System)
40832412|NCT02811783|DRUG|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
40832413|NCT02811783|DRUG|Placebo Lotion|Topical TID for 2 weeks
40832414|NCT01971216|BEHAVIORAL|Relaxation|
40832415|NCT01863251|DRUG|Atomoxetine|
40832416|NCT03221790|OTHER|Low FODMAP Diet followed by a High FODMAP Diet|3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
40832417|NCT06434129|DIAGNOSTIC_TEST|DTI|Diffusion MRI imaging
40832418|NCT01945775|DRUG|talazoparib|Until progression or unacceptable toxicity develops
40832419|NCT01945775|DRUG|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
41159099|NCT03726125|DRUG|Insulin Degludec - SC|Administered SC
41159100|NCT03726125|DRUG|LY3374849 - IV|Administered IV
41159101|NCT03726125|DRUG|Insulin Degludec - IV|Administered IV
41351402|NCT03530059|OTHER|Home-based rehabilitation|Observational study
41351403|NCT05131659|BEHAVIORAL|Executive function group therapy|This executive function group therapy curriculum for adolescents uses cognitive behavioral therapy techniques, and focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support.
41351404|NCT05308537|BEHAVIORAL|Mindful Compassion Care Program|The intervention is a proven effective mindfulness programme based on well-known scientific programmes such as mindfulness-based stress reduction mindfulness-based cognitive therapy and compassion focused therapy.
40832420|NCT04708132|PROCEDURE|Screw retained restoration|Hybrid prosthesis
40832421|NCT04708132|PROCEDURE|implant-retained ball overdentures|Removable prosthesis
40832422|NCT00180297|DEVICE|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
40832423|NCT02804308|BEHAVIORAL|Combined Training|
40832424|NCT04317157|DIETARY_SUPPLEMENT|Caffeine|Specific dosage of caffeine for each participant (6 mg.kg-1).
40832425|NCT04317157|OTHER|Placebo|Placebo pill.
40832426|NCT02989805|BEHAVIORAL|Care Management|Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
40832427|NCT05100823|PROCEDURE|Nasal cells sampling|Nasal epithelium brushing in intermediate turbinate using a specific curette following a local anesthesia with Xylocaine 5% nebulizer.
40832428|NCT05100823|PROCEDURE|Rectal biopsy sampling|Forceps Biopsy Procedure (Servidoni et al., 2013) Only for volunteer patients included in the Montpellier center.
40832429|NCT05828875|OTHER|questionnaire investigation|Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology
40832430|NCT01496105|DRUG|Lidocaine|
40832431|NCT01496105|DRUG|saline|
40832432|NCT00700102|DRUG|Chemotherapy|As prescribed
40832433|NCT00700102|DRUG|Bevacizumab|Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
41159102|NCT05640973|OTHER|Evaluation|Evaluation of ease of use
41159103|NCT04885426|DRUG|low-dose metformin|Metformin Pill 250mg/day
41159104|NCT04885426|DRUG|high-dose metformin|Metformin Pill 500mg/day
41159105|NCT04885426|DRUG|Placebo|Placebo
41159106|NCT02577848|DRUG|GLP-1|GLP-1 were taken daily for 7 days
41159107|NCT02577848|DRUG|Placebo|Placebo were taken daily for 7 days
41159108|NCT05128539|DRUG|JS001(Toripalimab)+JS002|"Part A: In this phase, 3 dose levels will be preliminarily set up. The dose level of Toripalimab is fixed as 240 mg, intravenous infusion, Q3W. The dose levels of JS002 are fixed at 75 mg,150 mg and 300 mg subcutaneously, and the traditional 3+3 design will be used for dose escalation with 21 days as entire treatment cycle. In addition, the period of 21 days after the first administration is defined as the DLT observation period.~Part B: Based on the data of the safety, PK and preliminary efficacy in Part A patients, the dosage will be determined for advanced tumor patients who had received at least first-line therapy in this part. Two to three groups with different tumor types will be further enrolled, and about 30 patients will be included in each group (the specific number and cohort will be adjusted according to the research progress). Toripalimab is a humanized IgG4κ mAb specific against human PD-1."
41159109|NCT04355013|DEVICE|Core emperature monitoring|Monitoring core temperatures with probes placed in the arterial outlet and venous inlet of extracorporeal pump, pulmonary artery, bladder, nasopharinx and forehead using a doublé-sensor probe
41159110|NCT04222335|OTHER|Blood samples|"Each participant will be followed-up regularly as part of the usual practice for imaging and medical consultations. During their visits, from inclusion (T0) to the end of study participation (T progression), each patient will have a blood sampling specifically for the research to analyze tumor DNA and circulating tumor cells: T0, T1month, T3 months, Tn months, T DNA C+, T progression.~This research does not include any other act or intervention specifically required for its purposes."
41159111|NCT00223561|DRUG|methylphenidate|
41159112|NCT00266747|DRUG|SR58611A|
41159113|NCT02944526|DRUG|Ropivacaine Monohydrochloride|Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
41159114|NCT02944526|DRUG|Placebo - Concentrate|Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
41159115|NCT03752489|DIAGNOSTIC_TEST|Treatment-specific InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between clusters of patients who respond similarly to fluids treatment according to the nature of their disease progression.
41159116|NCT03752489|DIAGNOSTIC_TEST|InSight|The non-customized InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis.
41159117|NCT05263206|DRUG|Dupilumab|Injection solution subcutaneous
41351405|NCT06367335|DRUG|Ribociclib, palbociclib, abemaciclib|evaluate the presence of predictors useful to predict the development of DILI during treatment with CKI
41351406|NCT00225628|BEHAVIORAL|Computerized Reminders Medications Monitoring|
41351407|NCT00225628|BEHAVIORAL|Computerized Test Results Management Application|
41492809|NCT01495156|DRUG|Placebo/Adjunctive SGA treatment|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA."
41351408|NCT00225628|BEHAVIORAL|Computerized Reminders Hypertension Management|
41351409|NCT00225628|BEHAVIORAL|Computerized Reminders Osteoporosis Screening and Mgt|
41351410|NCT04106011|DRUG|Gabapentin|Titration of gabapentin will be standardized as 300mg QHS and increased by 300mg every 3 days until taking 1200mg TID or maximum tolerable dose. Subjects will undergo cognitive evaluation prior to initiation of the medication, at 1 week (when titrated to approximately 900mg/day), 3 weeks (when titrated to approximately 2100mg/day), and at 6 weeks (when titrated to 3600mg/day or maximum tolerable dose).
41351411|NCT04106011|DIAGNOSTIC_TEST|BTACT|Cognition measure: Brief Test of Adult Cognition by Telephone
41351412|NCT04106011|DIAGNOSTIC_TEST|BPI|Pain severity and interference at baseline using the Brief Pain Inventory
41351413|NCT04106011|DIAGNOSTIC_TEST|HADS|Assessment of depression and anxiety with the Hospital Anxiety and Depression Scale
41492810|NCT00201955|DRUG|Rebamipide|
41509121|NCT05708989|DRUG|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
41159118|NCT05263206|DRUG|Placebo|Injection solution SC
41159119|NCT05263206|DRUG|Fexofenadine (loratadine if not available)|Tablet or capsule Oral
41159120|NCT05263206|DRUG|Moisturizer|Topical
41159121|NCT05012618|DRUG|LUNA18|LUNA18 Capsule
41159122|NCT05012618|DRUG|Cetuximab|Cetuximab as a IV infusion
41159123|NCT02162914|DRUG|Regorafenib/active|Subjects randomized to be treated with Regorafenib/active will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
41159124|NCT02162914|DRUG|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib/placebo will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
41351414|NCT04106011|DIAGNOSTIC_TEST|SLP9|Assessment of Sleep
41351415|NCT04106011|DIAGNOSTIC_TEST|NPSI|Assessment of neuropathic components
41351416|NCT05529134|DRUG|PTW-002 10 mg/g gel|poloxamer hydrogel for topical administration
41351417|NCT05529134|DRUG|Placebo|placebo poloxamer hydrogel for topical administration
41351418|NCT02445352|DRUG|Rosuvastatin 5mg|
41351419|NCT02445352|DRUG|DP-R207 5/10mg|
41351420|NCT02445352|DRUG|Rosuvastatin 10mg|
41351421|NCT02445352|DRUG|DP-R207 10/10mg|
41351422|NCT02445352|DRUG|Rosuvastatin 20mg|
41351423|NCT02445352|DRUG|DP-R207 20/10mg|
41351424|NCT02445352|DRUG|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
41351425|NCT02445352|DRUG|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
41159125|NCT03568708|DRUG|Transdermal Estrogen|In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
41351426|NCT02445352|DRUG|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
41351427|NCT00370825|DRUG|Combination therapy with AmBisome and miltefosine|
41351428|NCT04890730|OTHER|Esophagogastroduodenoscopies|Each enrolled patient needs to undergo Esophagogastroduodenoscopies and elastography
40832434|NCT02212171|OTHER|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~1. Administrative staff:~   Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~2. Nursing staff:~   They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~3. GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
40832435|NCT02726750|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41351429|NCT01657253|DRUG|PRO-148|Instill 1 drop in each eye four times a day, for 60 days
40832436|NCT02726750|OTHER|Laboratory Biomarker Analysis|Correlative studies
40832437|NCT00997399|DRUG|panobinostat (LBH589)|
40832438|NCT00385723|DIETARY_SUPPLEMENT|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
40832439|NCT00385723|DIETARY_SUPPLEMENT|Placebo|matching placebo capsule daily for 4 months
40832440|NCT06443346|OTHER|Eosinophilic Esophagitis|Eosinophilic Esophagitis patients with a proper diagnosis
40832441|NCT02246192|PROCEDURE|sinus pilonidal excision+ PRGF|open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
40832442|NCT02246192|PROCEDURE|sinus pilonidal excision and standard cares|sinus pilonidal excision and postoperative standard care with povidone daily
41351430|NCT01657253|DRUG|Systane|Instill 1 drop in each eye four times a day, for 60 days
41351431|NCT03866239|DRUG|Obinutuzumab|Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).
41351432|NCT03866239|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
41351433|NCT03866239|DRUG|Cibisatamab|Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
41351434|NCT03866239|DRUG|Tocilizumab|Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)
41351435|NCT02219516|DRUG|RDEA3170|
41351436|NCT04068220|OTHER|intraoperative FVEPs monitoring|During the surgery, a pair of goggles (similar to the swimming goggles) will be placed on patient's closed eyes. The goggles equipped with red LEDs will apply no pressure or minimal pressure on patient's closed eyes. Patient's left eye then right eye will be stimulated with flashing red light emitted by the goggles. Two subdermal needle electrodes will be placed under the skin behind patient's ears, and one subdermal needle electrode will be placed under the skin above the bridge of patient's nose. The two electrodes placed behind patient's ears, will record intraoperative flash visual evoked potentials (FVEPs) resulted from red light stimulation of patient's visual pathway through the eyes and the electrode above the bridge of the nose will record, at the same time, the activity of each eye's retina.
41351437|NCT03851224|PROCEDURE|control group|immediate implant with immediate loading using no graft
41351438|NCT03851224|PROCEDURE|study group|immediate implant with immediate loading using autogenous bone graft
40832443|NCT03930550|PROCEDURE|Tracheal intubation by endoscopy with flexible bronchoscope|A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
40832444|NCT05525754|PROCEDURE|computed tomography-guided nasotracheal intubation|Before intubation, the lower part of the nasal valve region, aka the narrowest area of the nasal passage, was measured by calculating the distance between the anterior border of the inferior concha and the septal cartilage
40832445|NCT05107973|OTHER|Baduajin|The intervention will consist in a 1 hour supervised Baduajin sessions conducted once a week a certified instructor with more than 10 years of experience. Each session will start with 5 min of warm up, 50 minutes of Baduajin and 5 min of cool down. In the main part the participants exercise the wholes set of Baduajin that consist of eigth forms.
40832446|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
40832447|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
41159126|NCT02519829|PROCEDURE|Monocryl closure|Total Hip Arthroplasty with monocryl closure of wound
41159127|NCT02519829|PROCEDURE|Vicryl and Staple closure|Total Hip Arthroplasty with vicryl and staple closure of wound
41159128|NCT02519829|PROCEDURE|Tegaderm dressing|Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing
41159129|NCT02519829|PROCEDURE|Gauze dressing|Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
41159130|NCT00065234|PROCEDURE|Acupuncture|
41159131|NCT03317899|PROCEDURE|Hematopoietic Cell Transplantation|Undergo auto HSCT
41159132|NCT03317899|DRUG|Tbo-filgrastim|Given subcutaneously
41159133|NCT03317899|OTHER|Laboratory Biomarker Analysis|Correlative Studies
41159134|NCT01971424|DIETARY_SUPPLEMENT|Mg oxide|
41159135|NCT01971424|OTHER|healthy diet|
41351439|NCT03851224|PROCEDURE|study group 2|immediate implant with immediate loading using (Geistlich Bio-Oss®) xenograft
41159136|NCT06138834|DRUG|Low-dose Y-6 sublingual tablets|Take one Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
41159137|NCT06138834|DRUG|High-dose Y-6 sublingual tablets|Take two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
41159138|NCT06138834|DRUG|Low-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol) for 28 days continuously.
40832448|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
40832449|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
41159139|NCT06138834|DRUG|High-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol) for 28 days continuously.
40832450|NCT00128713|PROCEDURE|Medium Dose Prophylactic Platelet Transfusions|2.2 x 10\^11 platelets per m\^2 BSA
40832451|NCT00128713|PROCEDURE|Lower Dose Prophylactic Platelet Transfusions|1.1 x 10\^11 platelets per m\^2 BSA
41159140|NCT06138834|DRUG|Placebo|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
41159141|NCT01711554|BIOLOGICAL|Dinutuximab|Given IV
41159142|NCT01711554|DRUG|Isotretinoin|Given PO
41159143|NCT01711554|OTHER|Laboratory Biomarker Analysis|Correlative studies
41159144|NCT01711554|DRUG|Lenalidomide|Given PO
41159145|NCT01711554|OTHER|Pharmacological Study|Correlative studies
41159146|NCT02402465|DRUG|Placebo|Patients will be treated by placebo
41159147|NCT02402465|DRUG|Fluticasone propionate|Patients will receive fluticasone nasal spray
41159148|NCT02402465|DRUG|Fluticasone/Azelastine nasal spray|Patients will receive Dymista nasal spray
41159149|NCT02402465|PROCEDURE|Nasal Allergen Challenge|All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
41159150|NCT06141902|OTHER|Jing Si Herbal Drink|Jing Si Herbal Drink
41159151|NCT03192202|DRUG|AFM13|AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
41351440|NCT03310099|BEHAVIORAL|Increasing daily unsaturated fatty acid consumption|Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
41351441|NCT05124600|DEVICE|SavvyHealth|Participants will use the new app, SavvyHealth, for 21 days.
40832452|NCT00128713|PROCEDURE|Higher Dose Prophylactic Platelet Transfusions|4.4 \* 10\^11 platelets per m\^2 BSA
41159152|NCT01420900|DEVICE|THA with ABG II / Trident|Surgery with total hip arthroplasty in the form of ABG II / Trident
41159153|NCT01420900|DEVICE|THA with CLS / Trilogy|Surgery with total hip arthroplasty in the form of CLS / Trilogy
41159154|NCT00404599|DRUG|atrorvastatin 10mg|Atorvastatin 10 mg once a day
40832453|NCT04316806|DIETARY_SUPPLEMENT|Probiotic|Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)
41159155|NCT00404599|DRUG|simvastatin 40mg|simvastatin 40mg once a day
41159156|NCT03480919|DEVICE|Shen Men acupuncture|20-minute acupuncture session
41159157|NCT03480919|PROCEDURE|Epidural injection|Epidural injection for the relief of back pain
41509122|NCT05795647|DRUG|Pentoxifylline+Tocopherol|Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
40832454|NCT04316806|DRUG|Rifaximin|Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
40832455|NCT00248430|BIOLOGICAL|aldesleukin|
41159158|NCT02815735|DEVICE|comfilcon A|contact lens
41159159|NCT02815735|DEVICE|lotrafilcon B|contact lens
41159160|NCT04091919|DIAGNOSTIC_TEST|2D- Transthoracic Echocardiography (TTE)|2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging
41159161|NCT01259440|BEHAVIORAL|Video Teleconferencing Care|The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
41159162|NCT01259440|BEHAVIORAL|Usual Care|Consists of one week telephone call and one month clinic visit
40832456|NCT00248430|BIOLOGICAL|therapeutic allogeneic lymphocytes|
40832457|NCT00248430|DRUG|melphalan|
40832458|NCT00248430|PROCEDURE|bone marrow ablation with stem cell support|
40832459|NCT00248430|PROCEDURE|peripheral blood stem cell transplantation|
40832460|NCT04046172|PROCEDURE|supra/sub gingival root surface debridement|The test group will undergo Intensive periodontal treatment (IPT)
40832461|NCT04046172|PROCEDURE|supra-gingival scaling and polishing|Control group will receive the Control periodontal treatment (CPT).
40832462|NCT02914288|OTHER|High resolution magnetic resonance imaging for intracranial vessel walls|High resolution magnetic resonance imaging for intracranial vessel walls at initial (optional), 1 month, 3 month, 6 month (optional), and 12 month
40832463|NCT00364533|DRUG|Tapentadol IR (CG5503)|Fixed Dose 50, 75, \& 100 mg BID for 3 days
40832464|NCT00364533|DRUG|Placebo|Fixed Dose Matching placebo for 3 days
40832465|NCT00364533|DRUG|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
40832466|NCT00364533|DRUG|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days
40832467|NCT04399954|DIETARY_SUPPLEMENT|Ketoflo|Ketoflo is a ready to use liquid feed for the dietary management of epilepsy and other conditions that may require a ketogenic diet. It has a 4:1 ratio of fat to carbohydrate and protein and can be administered enterally via a tube feeding or oral consumption.
41351442|NCT05424744|BEHAVIORAL|Telemedicine Management of Hypertension|Telemedicine Management of high blood pressure using home blood pressure monitoring and telemedicine based hypertension self- management support and pharmacotherapy. This will be supplemented by support from community health workers.
41351443|NCT06286267|DIAGNOSTIC_TEST|imaging|Patient medical imaging materials including ultrasound, mammography, CT, MRI
41351444|NCT01586286|DRUG|Nifedipine|Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
41351445|NCT01586286|DRUG|Placebo Ointment Base|Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
41351446|NCT05673785|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
40832468|NCT00769249|OTHER|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
40832469|NCT00769249|OTHER|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
40832470|NCT00769249|PROCEDURE|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
40832471|NCT01411358|BIOLOGICAL|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
40832472|NCT01411358|BIOLOGICAL|elderly aged over 60|one dose of 0.5mL AdimFlu-S
40832473|NCT04272008|DRUG|Segesterone Acetate and Ethinyl Estradiol|Annovera taken alone
40832474|NCT04272008|OTHER|Tampon|Annovera with tampon use
40832475|NCT04598126|OTHER|Traditional physical therapy|Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
40832476|NCT04598126|OTHER|patient education manual +traditional physical therapy|"Patient educational Manual~+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/"
41351447|NCT05673785|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion
40832477|NCT03110445|BIOLOGICAL|rVV-740CTA|non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
40832478|NCT02428621|DEVICE|Twicare® appliance|"Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
40832479|NCT02428621|DEVICE|Removable Herbst appliance|"Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
40832480|NCT06506006|BIOLOGICAL|Covid infection|outcome with and without covid infection
41351448|NCT05673785|DRUG|Doxorubicin|Doxorubicin IV infusion
41351449|NCT05673785|DRUG|Prednisone|Prednisone tablets
41351450|NCT03013426|DRUG|NVX-508|Administration of NVX-508 emulsion intravenously
40832481|NCT05609344|BEHAVIORAL|SBIRT|Low risk individuals will receive an educational pamphlet about alcohol use and the impact on health. Moderate Risk individuals will receive a brief alcohol intervention. High risk individuals will receive the brief alcohol intervention and be referred to specialty treatment.
40832482|NCT00277394|DRUG|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
40832483|NCT00277394|DRUG|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
40832484|NCT01690624|DRUG|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
41351451|NCT05528159|PROCEDURE|Intraabdominal CO2 insufllation|Patients will receive intraabdominal CO2 insufflation and will be operated under trendelenburg position
41351452|NCT04932694|OTHER|Core stabilization training|Exercise training will be given to the participants in the study group in the form of core training exercises for 8 weeks.
41492811|NCT05906108|BEHAVIORAL|Self-initiated learning|A WeChat Subscription will be created for delivering the intervention. The educational materials involving introduction to internet addiction, the impact of internet addiction and strategies in coping with IA will be posted to the account at the beginning of the intervention. The materials will be prepared in different format including text and video followed by 3 to 5 multiple choice questions (MCQs), and one post for one topic. Relevant materials can be found by typing the keywords in the account or searching under the content list. Participants will be required to follow the account to study the materials at their own pace and complete the MCQs. There will be no limited access to the materials and attempts for MCQs.
40832485|NCT05569876|OTHER|Controlled hypoglycemic state|Voice sampling is performed in different glycemic states (euglycemia and hypoglycemia).
40832486|NCT05251532|OTHER|Kinesio Taping|In addition to Kinesio Tex tape distortion taping, conventional rehabilitation is applied.
40832487|NCT05251532|OTHER|Conventional Rehabilitation|Conventional rehabilitation practices are carried out
40832488|NCT05186441|OTHER|DMPFC iTBS|The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
40832489|NCT05186441|OTHER|DLPFC iTBS|The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
40832490|NCT03920267|DRUG|BMS-986165|Specified dose on specified days
40832491|NCT01206686|BEHAVIORAL|Planning Prompt|Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
40832492|NCT01206686|BEHAVIORAL|Default Appointment|Patients were given a suggested date and time for receiving a flu shot.
41492812|NCT05906108|BEHAVIORAL|Personalized and interactive behavioural support|The intervention group will receive 3-month personalized and interactive behavioural support via WeChat, which including regular messages and real-time conversation. The regular messages will cover the generic information about abstinence support, health warnings, benefits of reducing internet time, knowledge reinforcement, goal setting, encouragement and reminders for self-initiated online learning. The messages will be personalised according to baseline demographic characteristics and internet addiction level, and continually adapted to any change in internet behaviours change reported by subjects during the conversations. A total of 19 messages with a tapering schedule. Personalized real-time conversation via WeChat will be available based on participants' demand.
41492813|NCT05906108|BEHAVIORAL|General health information|Participants in control group will receive WeChat messages on general health information (similar frequency as the intervention group) and reminders on follow-up surveys via WeChat. Various topics will be involved in the general health information such as healthy diet, sleep management, exercise and mood management.
41492814|NCT02782793|PROCEDURE|Endoscopic Mucosal Resection|
41492815|NCT06344663|OTHER|motivational interview|Before starting the interview, mothers will be informed about the interview intervals, duration, how many times it will be held, and that, unlike other interviews, the topic will be determined and the mother's opinions on this subject will be obtained. Each meeting will last approximately 15-30 minutes
41492816|NCT01754337|OTHER|Closed-loop system|Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
41492817|NCT00095316|DRUG|Caspofungin|Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.
41492818|NCT00095316|OTHER|Placebo|Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
40832493|NCT01206686|BEHAVIORAL|Control|Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
40832494|NCT02242981|DRUG|LY2623091|Administered orally
40832495|NCT02699151|DRUG|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
40832496|NCT02699151|PROCEDURE|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
40832497|NCT02699151|OTHER|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
40832498|NCT06400732|DEVICE|Fitbone Transport and Lengthening System|Implantation of the intramedullary Fitbone Transport Nail and subsequent bone segment transport and, optionally, lengthening.
40832499|NCT04278937|DRUG|Azithromycin Tablets|one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks
40832500|NCT03043495|PROCEDURE|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
40832501|NCT03043495|DRUG|Dexamethasone|Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs
40832502|NCT04326855|OTHER|Incremental shuttle walking protocol (ISWT)|Patients will perform an incremental shuttle walk test to the limit of tolerance to establish peak walking speed. The test will be developed in a 10-m course corridor, and it will be externally-paced via a recorded metronome that gives a signal for each stride. The walking pace will be increased every minute and the test will be terminated when the individual is no longer able to keep up the pace. Pulmonary variables will be recorded breath-by-breath. Cardiac output will be assessed every min. Arterial oxygen saturation will be measured by a pulse oximeter. Patients will score the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every minute.
41159163|NCT04891159|OTHER|Shared decision making|The intervention consists of 5 components: 1) Online shared decision making training (2 hours, e-learning); 2) Individual coaching for doctors by a shared decision making expert; 3) Implementation of the shared decision making; 4) Link to institutional approaches to patient engagement; 5) Integration of the shared decision making into the multidisciplinary consultation meetings of the Cystic Fibrosis Centers Competences.
41159164|NCT04017637|BEHAVIORAL|Resistance Training|Static resistance training including two arm and two leg movements will be performed twice per week for 12 weeks.
40832503|NCT04326855|OTHER|Endurance shuttle walking (ESW) protocol|Subsequently, during the second visit all patients will perform the continuous endurance shuttle walk (ESW) protocol to the limit of tolerance at a walking speed corresponding to 85% of VO2 peak derived by the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions to walk for as long as possible although there will be a predetermined 6 minute maximum point. No further encouragement will be provided during the exercise performance. The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
40832504|NCT04326855|OTHER|First Intermittent shuttle walking protocol|All patients will perform an intermittent shuttle walking protocols to the limit of tolerance (visit 3) by alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak (equivalent to the continuous ESW protocol) with 1-min rest periods.The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point.Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
41159165|NCT01935193|DRUG|lysine acetylsalicylate|
40832505|NCT04326855|OTHER|Second Intermittent shuttle walking protocol|To obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses this intermittent shuttle walking protocol will be repeated on a different day (visit 4). The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
40832506|NCT04326855|OTHER|Focus group study|Semi-structured interviews to explore patients' preferences of undertaking the intermittent or continuous ESW protocols and healthcare professionals' perceived factors affecting the implementation of these protocols in the PR setting. These semi-structured interviews consist of questions in some degree predetermined order but still ensures flexibility in the way issues are addressed to the patients. Conversation is sustained in an informal tone and lasts for about an hour. Participants are allowed for an open response in their own words.
40832507|NCT02165462|OTHER|Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
40832508|NCT00004751|PROCEDURE|Surgery|
40832509|NCT00004751|PROCEDURE|Physical therapy|
40832510|NCT03515174|OTHER|Supportive Care Program|This program takes place within one month post-diagnosis of cancer. It will include three info-educational session. After that, recommendations for further consultation with specific healthcare professionals will be made based on the concerns and needs of patients at baseline. Patient will also be given usual care.
40832511|NCT03515174|OTHER|Usual Care|Patients will be provided with an information booklet by the study team on self-management of cancer- and treatment-related symptoms, which is routinely provided by the National Cancer Centre of Singapore (NCCS) after cancer diagnosis. Usual general advice is provided by the medical oncologists during the routine consultations.
40832512|NCT00967161|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
40832513|NCT00967161|PROCEDURE|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
41159166|NCT04741854|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
41159167|NCT04714697|DRUG|Cabometyx|Cabometyx 60mg once daily, oral , up to Progression disease
41159168|NCT05811455|OTHER|Aerobic exercises|To compare the effects of aerobic exercise and progressive muscle relaxation exercises on pain and quality of life in premenstrual syndrome
41492819|NCT03967496|PROCEDURE|Types of Anesthesia|"General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively."
41492820|NCT03967496|PROCEDURE|Access of Surgery|Type of surgical access
41492821|NCT03967496|OTHER|Comorbidities|A patient may have more than one comorbidity
41492822|NCT03967496|DRUG|Preoperative Medication|Preoperative medications
40832514|NCT03622177|PROCEDURE|biopsie|Additional colorectal mucosal biopsies during rectoscopy or colonoscopy
40832515|NCT03622177|BIOLOGICAL|blood drawn|Additional blood drawn by venepuncture
40832516|NCT02654418|PROCEDURE|Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)|
40832517|NCT05680155|DRUG|Ecnoglutide|Subcutaneous Injection
40832518|NCT05680155|DRUG|Placebo|Subcutaneous Injection with matched volume
41159169|NCT05811455|OTHER|Progressive muscle relaxation|progressive muscle relaxation exercises.
41159170|NCT06642363|DRUG|"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"|"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"
41159171|NCT06642363|DRUG|Placebo|The placebo group will take one capsule containing corn starch in a wrapped and covered form and the appearance of ASX supplementation (blinding).
41159172|NCT06204614|DEVICE|Implantable Micro-Device|The implantable microdevice will release microdoses of specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against bladder cancer.
41159173|NCT06204614|DRUG|Methotrexate|Methotrexate will be placed in reservoir 1 of the implantable microdevice.
41159174|NCT06204614|DRUG|Carboplatin|Carboplatin will be placed in reservoir 2 of the implantable microdevice.
41492823|NCT03967496|DIAGNOSTIC_TEST|Routine blood test|Preoperative and Intraoperative Investigations
41492824|NCT01770392|DRUG|Nintedanib|single dose administration
41492825|NCT01770392|DRUG|Rifampicin|single dose once daily for 7 days
41492826|NCT01770392|DRUG|Nintedanib|single dose administration
41492827|NCT00485680|DRUG|Olanzapine Hydrochloride|
41492828|NCT00485680|DRUG|Lithium Carbonate|
41351453|NCT02261246|PROCEDURE|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
41351454|NCT05481944|DIAGNOSTIC_TEST|MRI in patients|Injected MRI
41351455|NCT05481944|DIAGNOSTIC_TEST|MRI in healthy volunteers|non injected MRI
41351456|NCT00912639|DRUG|Paclitaxel loaded Polymeric micelle|Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
41351457|NCT03844061|DRUG|Belimumab|Belimumab decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. The background above provides a robust rationale for the investigation of belimumab in the treatment of dcSSc.
41351458|NCT03844061|DRUG|Rituximab|Rituxan® (rituximab) is a genetically engineered IgG1 kappa chimeric murine/human monoclonal antibody containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B cells, and established B cell lines. Studies have shown that rituximab binds via its Fc domain to human complement and lyses lymphoid B cell lines by complement dependent cytotoxicity through the induction of apoptosis and via antibody-dependent cell mediated cytotoxicity. Rituximab is approved by the U.S. Food and Drug Administration (FDA) to treat some types of cancer, rheumatoid arthritis and vasculitis.
41492829|NCT01212588|DRUG|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
41492830|NCT01212588|DRUG|Placebo|3 tablets once daily for seven days
41492831|NCT03914092|DRUG|triamcinolone acetonide injection|,1 mm percutaneous intralesional injection
41492832|NCT03914092|BEHAVIORAL|Smith Accent method of voice therapy|regular sessions of smith accent voice therapy (about 24 sessions, twice session / week) for 3 months
40832519|NCT01590069|BIOLOGICAL|Aerosolized Aldesleukin|Breathe aerosolized aldesleukin
40832520|NCT01590069|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
40832521|NCT01354704|DRUG|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
40832522|NCT04194723|PROCEDURE|Antireflux Mucosectomy|ARMS aimed at resection of mucosa at gastric cardia to induce fibrosis and tighten the gastroesophageal junction and reduce acid reflux
41159175|NCT06204614|DRUG|Avelumab|Avelumab will be placed in reservoir 3 of the implantable microdevice.
41159176|NCT06204614|DRUG|Paclitaxel|Paclitaxel will be placed in reservoir 4 of the implantable microdevice.
41159177|NCT06204614|DRUG|Vinblastine|Vinblastine will be placed in reservoir 5 of the implantable microdevice.
41159178|NCT06204614|DRUG|Gemcitabine/Cisplatin I|Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.
41159179|NCT06204614|DRUG|Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.
41159180|NCT06204614|DRUG|Gemcitabine/Cisplatin II|Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.
41492833|NCT03545035|DRUG|idelalisib and rituximab|patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
41492834|NCT01425918|BEHAVIORAL|Social Enhancement Intervention|The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
41492835|NCT01425918|BEHAVIORAL|Parent Education|Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
40832523|NCT01592019|DRUG|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
40832524|NCT01592019|DEVICE|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
40832525|NCT01592019|DRUG|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
40832526|NCT01592019|DEVICE|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
40832527|NCT04235569|DRUG|Warfarin Sodium 5 MG|warfarin sodium 5mg tablets
40832528|NCT04235569|DRUG|Warfarin Sodium 3 MG|warfarin sodium 3mg tablets
40832529|NCT04235569|DRUG|Enoxaparin Sodium 100 MG/ML Prefilled Syringe|"Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours."
40832530|NCT00841048|DRUG|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
40832531|NCT00841048|DRUG|Placebo|
41159181|NCT06204614|DRUG|Cisplatin|Cisplatin will be placed in reservoir 9 of the implantable microdevice.
41159182|NCT06204614|DRUG|Nivolumab|Nivolumab will be placed in reservoir 10 of the implantable microdevice.
41351459|NCT03844061|OTHER|Placebo Subcutaneous Injection|Normal Saline
41351460|NCT03844061|OTHER|Placebo Infusion|Normal Saline
41351461|NCT03844061|DRUG|MMF|MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.
41351462|NCT03200418|OTHER|Standard hydrocolloid adhesive|This patch is made of standard hydrocolloid adhesive
40832532|NCT02315508|DRUG|AUT00063|800 mg orally, once a day, for 4 weeks
40832533|NCT02315508|DRUG|Placebo|orally, once a day, for 4 weeks
40832534|NCT05682300|PROCEDURE|peripheral nerve block|After signing the informed consent by the patient, specific for this observational study, the peripheral regional anesthesia technique will be performed following the usual practice of the anesthesiologist responsible for the surgery. Under standard monitoring and taking into account the necessary aseptic measures, either peripheral nerve blocks (for surgeries involving extremities) or fascial blocks (for surgeries involving the chest wall, abdomen, or spine) will be performed.
40832535|NCT05128006|OTHER|New patient teledermatology visit|new patient teledermatology visits
40832536|NCT01502150|OTHER|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
40832537|NCT01502150|OTHER|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
40832538|NCT02111291|BIOLOGICAL|Collagenase SANTYL® Ointment|Daily application directly to the ulcer bed, approximately 2 mm thick.
40832539|NCT02111291|BIOLOGICAL|Hydrogel (if needed) and foam dressing|Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
41351463|NCT03200418|OTHER|P-4|This patch is made of new adhesive
41351464|NCT03200418|OTHER|P-15|This patch is made of new adhesive
41351465|NCT03200418|OTHER|P-16|This patch is made of new adhesive
41351466|NCT06193161|BEHAVIORAL|Therapist-supported internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure for eight weeks.
41351467|NCT05392101|DRUG|Deferasirox 360 MG|Deferasirox 360 MG p.o. once daily
40832540|NCT04264143|DRUG|Infusate with MTX110 and gadolinium|Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
40832541|NCT04264143|DEVICE|Convection-Enhanced Delivery (CED)|CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
40832542|NCT03808753|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
40832543|NCT03808753|OTHER|mini fluid challenge (mFC)|The mFC is performed by injecting a first aliquot of 100 ml of crystalloid over 1 minute before completing the 4 ml/kg-FC over the residual 9 minutes.
40832544|NCT00840580|DRUG|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
40832545|NCT00840580|DRUG|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
40832546|NCT00343915|BIOLOGICAL|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, \& 6)
40832547|NCT00343915|BIOLOGICAL|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 \& 6)
40832548|NCT00343915|BIOLOGICAL|placebo|In the primary study: 1 deep intramuscular injection (month 1)
40832549|NCT05154760|OTHER|Pelvic floor muscle training, diaphragmatic breathing exercise, core exercises|An exercise program consisting of pelvic floor muscle training, diaphragmatic breathing exercise and core exercises will be applied to the patients.
40832550|NCT01020162|DRUG|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
40832551|NCT01020162|PROCEDURE|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
40832552|NCT04173195|OTHER|Comfort Talk|A short and brief conversation based on the principles of clinical hypnosis.
40832553|NCT04276688|DRUG|Lopinavir/ritonavir|400mg/100mg twice daily for 14 days
40832554|NCT04276688|DRUG|Ribavirin|400mg twice daily for 14 days
40832555|NCT04276688|DRUG|Interferon Beta-1B|0.25mg subcutaneous injection alternate day for 3 days
40832556|NCT01134926|DRUG|misoprostol|8oo mcg intravaginal, second dose after one day if there is no response
40832557|NCT02187315|DEVICE|Chrono-chemotherapy pump:Melodie|
40832558|NCT02187315|DEVICE|Routine intravenous drip|
41351468|NCT02095028|BEHAVIORAL|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
40832559|NCT02187315|DRUG|induction chemotherapy|
40832560|NCT02187315|DRUG|cisplatin chrono-chemotherapy|
40832561|NCT02187315|RADIATION|intensity-modulated radiation therapy|
40832562|NCT02187315|DRUG|cisplatin routine-chemotherapy|
40832563|NCT03974204|PROCEDURE|Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.
40832564|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are Lack of evidence according to EANO-ESMO classification"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* When suspected metastatic meningitis symptoms arise and~* at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases."
40832565|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are confirmed, probable or possible, leading to leptomeningeal metastase specific treatment"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* 1 month after the beginning of the specific treatment,~* 3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment."
40832566|NCT03480789|DRUG|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
40832567|NCT03480789|DEVICE|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
40832568|NCT00524589|DIETARY_SUPPLEMENT|calcitriol|IV
40832569|NCT00524589|DRUG|dexamethasone|Oral
40832570|NCT00524589|GENETIC|protein expression analysis|Correlative Study
40832571|NCT00524589|OTHER|laboratory biomarker analysis|Correlative Study
40832572|NCT00274560|DRUG|Tiotropium|
40832573|NCT00274560|DRUG|Salmeterol|
40832574|NCT01751776|DRUG|Placebo matching BI 655064|Placebo matching BI 655064 injected subcutaneous.
40832575|NCT01751776|DRUG|BI 655064|BI 655064 injected subcutaneous
41159183|NCT06204614|DRUG|Pembrolizumab|Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.
41159184|NCT06204614|DRUG|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.
40832576|NCT06315881|PROCEDURE|Biospecimen Collection|Undergo blood sample and oral mucosa sample collection
40832577|NCT06315881|DRUG|Cigarette|Smoke usual brand cigarette
40832578|NCT06315881|DRUG|Nicotine Oral Pouch|Insert low FBN R/S ONP
40832579|NCT06315881|DRUG|Nicotine Oral Pouch|Insert low FBN \> 99% S ONP
40832580|NCT06315881|DRUG|Nicotine Oral Pouch|Insert high R/S ONP
40832581|NCT06315881|DRUG|Nicotine Oral Pouch|Insert high FBN \> 99% ONP
40832582|NCT06315881|DRUG|Smokeless Tobacco|Insert ST
40832583|NCT06315881|OTHER|Survey Administration|Ancillary studies
41159185|NCT06204614|DRUG|Methotrexate/Vinblastine/Doxorubicin/Cisplatin|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.
41159186|NCT06204614|DRUG|Gemcitabine/Cisplatin/Nivolumab|(Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.
41159187|NCT06204614|DRUG|Erdafitinib|Erdafitinib will be placed in reservoir 15 of the implantable microdevice.
41159188|NCT06204614|DRUG|Paclitaxel/Docetaxel/Ifosfamide|(Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.
41351469|NCT05391412|DRUG|Fibrinogen Concentrate Human|Patients in the intervention group will receive single administration of fibrinogen concentrate intravenously at a dose of 20-30 mg/kg (depending on body weight and clinical condition, according to SmPC). The medicinal product will be diluted in a 100 ml infusion bag and administered after induction of anaesthesia prior beginning of surgery. The infusion rate should not exceed approximately 5 ml per minute.
40832584|NCT06315881|OTHER|Text Message-Based Navigation Intervention|Receive text with a link to daily diary surveys
40832585|NCT05690750|OTHER|No intervention|No intervention as this is an observational study.
40832586|NCT04373447|PROCEDURE|lap fundus-calot cholecystectomy|use laparoscopic fundus-calot approach
40832587|NCT04373447|PROCEDURE|open cholecystectomy|use open approach
40832588|NCT00586443|DRUG|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab~* 3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~* 2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~* 1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~  1. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~ 2. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD\* RPTD\* RPTD\* 3b 10 RPTD\*\* RPTD\*\* RPTD\*\*~     * Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. \*\*Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
40832589|NCT01504581|BIOLOGICAL|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
40832590|NCT01504581|BIOLOGICAL|HM10660A placebo|Single dose of HM10660A Placebo
40832591|NCT01504581|BIOLOGICAL|Pegasys|Single dose of Pegasys 180ug
40832592|NCT02227823|DRUG|Pyridostigmine Bromide|
40832593|NCT01680627|BEHAVIORAL|CASI|
40832594|NCT03331783|OTHER|Standard hydrocolloid adhesive patch|This patch is made of a standard hydrocolloid adhesive
40832595|NCT03331783|OTHER|LT-2|This patch is made of a new adhesive
40832596|NCT03331783|OTHER|LT-21|This patch is made of a new adhesive
40832597|NCT03331783|OTHER|33-20|This patch is made of a new adhesive
40832598|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 70% 1RM combined with complex training|This group of subjects first performed 3 sets of 70% 1RM squats after a routine warm-up, 3 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
41509123|NCT05607654|DEVICE|active iTBS|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
41351470|NCT05747768|DRUG|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate, 10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
41159189|NCT06204614|DRUG|Gemcitabine|Gemcitabine will be placed in reservoir 17 of the implantable microdevice.
41492836|NCT00681512|DIETARY_SUPPLEMENT|berry powder|"All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.~The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.~All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks."
40832599|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 80% 1RM combined with complex training|This group of subjects first performed 3 sets of 80% 1RM squats after a routine warm-up, 2 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
41159190|NCT06204614|DRUG|Gemcitabine/Carboplatin/Nivolumab|(Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.
41159191|NCT06204614|DRUG|Enfortumab|Enfortumab will be placed in reservoir 19 of the implantable microdevice.
41159192|NCT06204614|DRUG|Sacituzumab|Sacitzumab will be placed in reservoir 20 of the implantable microdevice.
41159193|NCT04567771|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
41159194|NCT04567771|OTHER|Questionnaire Administration|Complete adverse event assessments
41351471|NCT04081051|OTHER|diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)|Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers
41159195|NCT04567771|RADIATION|Radiation Therapy|Undergo proton or intensity modulated radiation therapy
41351472|NCT05190328|OTHER|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Muscle energy technique."
41351473|NCT05190328|OTHER|Active Release Technique|"Experimental: Active Release Technique: Therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient is instructed to actively move the muscle from the shortened to a lengthened position and thereby breaking adhesions. 1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Active Release Technique."
41492837|NCT03360591|DEVICE|Physiologically-guided strategy|"The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches \>2.5mm, with a % coronary stenosis\>50% as evaluated by visual estimation.~The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR \>0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, and using the same study end-points.~Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values \>0.80 that show a discrepancy with positive (\<0.89) iFR values to investigate the reliability of the FFR in the aortic stenosis setting. Both groups will receive the same TAVI strategy and optimal medical therapy"
41492838|NCT03164421|DRUG|N-Acetylcysteine|N-Acetylcysteine in clomiphene resistant pcos women
41492839|NCT03164421|DRUG|L-carnitine|L-carnitine in clomiphene resistant pcos women
41492840|NCT03300544|DRUG|Capecitabine|Given PO
41492841|NCT03300544|DRUG|Fluorouracil|Given IV
41492842|NCT03300544|DRUG|Leucovorin|Given IV
41492843|NCT03300544|DRUG|Oxaliplatin|Given IV
41492844|NCT03300544|RADIATION|Radiation Therapy|Undergo chemoradiation
41492845|NCT03300544|BIOLOGICAL|Talimogene Laherparepvec|Given intralesionally
41351474|NCT04050540|DRUG|Doxycycline|200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
41351475|NCT04489602|OTHER|ObsQoR-10F Questionnaire|The ObsQoR-10F questionnaire consists of 10 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. It takes two minutes to complete all the items. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. If the patient has returned home with her child, she can be contacted by phone to complete the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
41492846|NCT03982979|DEVICE|HM3 LVAS|HeartMate® 3 (HM3) Left Ventricular Assist System (LVAS)
41492847|NCT04097236|OTHER|Qualitative and quantitative assessment of gastric content volume with bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
41492848|NCT04097236|OTHER|Qualitative and quantitative assessment of gastric content volume without bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
41492849|NCT04781192|DRUG|Durvalumab|Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\])
41492850|NCT04781192|DRUG|Regorafenib|Oral once per day, Days 1 - 21 every 28 days
41492851|NCT04607161|OTHER|no intervention|no intervention
41492852|NCT04600778|OTHER|placebo|placebo
41492853|NCT04600778|DRUG|Cavosonstat 5 mg|Cavosonstat (low dose)
41492854|NCT04600778|DRUG|Cavosonstat 10 mg|Cavosonstat (medium dose)
41492855|NCT04600778|DRUG|Cavosonstat 25 mg|Cavosonstat (high dose)
41492856|NCT00655876|DRUG|cetuximab|Weekly with external beam radiation therapy for a total of six doses. The initial dose of cetuximab is 400 mg/m\^2 intravenously administered over 120 minutes on day 1, followed by weekly infusions of 250 mg/m\^2 intravenously over 60 minutes on days 8, 15, 22, 29, and 36. The infusion rate of cetuximab must never exceed 5 mL/min.
41492857|NCT00655876|DRUG|cisplatin|Weekly with external beam radiation therapy for a total of six doses. Patients receive 25 mg/m\^2 as an intravenous infusion over 30-60 minutes on days 1, 8, 15, 22, 29 and 36.
41159196|NCT03854214|DEVICE|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc). Bilateral glutei, quadriceps and hamstrings will be stimulated. The stimulation parameters will be set as follows: waveform biphasic, charged balanced; phase duration of 250 microseconds; pulse rate 33-45 pps. The stimulus intensity will be adjusted for individual patients and muscle group so that a tolerable stimulation is provided that will generate a cycling action. Target cycling speed is 50 RPM. Resistance will be automatically adjusted by the FES bike according to the subject's performance. When fatigue occurs, participants will continue cycling with electrical stimulation and motor support. FES therapy will be administered for one hour per session 3 times a week.
41351476|NCT05288049|BEHAVIORAL|Enhancing cognitive reserve|The CR enhancement protocol consists of 12 weekly sessions in a group format with audiovisual and technological devices support. All sessions are held separately for parents and children, adolescents and young adults. All material is adapted to different ranges of age. This same protocol will be adapted for patients with a first affective or non-affective episode. Two sessions are about to promote healthy lifestyle by implementing healthy habits, two more sessions about training and practice mindfulness with virtual reality devices, two sessions about improving leisure-time activities, focused on promoting of intellectual and/or cultural activities as leisure time as well as physical exercise, the rest of sessions are about to promote vocational and educational activities, metacognition, social skills, problem-solving techniques and how to detect and act on warning signs, a brief psychoeducative session about the main early warning signs of general psychopathology.
41351477|NCT05288049|BEHAVIORAL|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention.
41351478|NCT05067010|OTHER|Detailed ophthalmologic examination|"* Visual acuity~* Eye pressure measurement~* Eye crystalline examination~* Fundus examination~* Optical coherence tomography of the retina~* Retinophotos"
41351479|NCT01352624|BEHAVIORAL|$AFE|$teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
41351480|NCT00003684|DRUG|theophylline|
41351481|NCT00003684|PROCEDURE|quality-of-life assessment|
41492858|NCT00655876|DRUG|paclitaxel|Weekly with external beam radiation therapy for a total of six doses. Patients receive 50 mg/m\^2 as an intravenous infusion over 1 hour on days 1, 8, 15, 22, 29 and 36.
41492859|NCT00655876|RADIATION|radiation therapy|1.8 Gy daily for 28 days (over 5-6 weeks) for a total dose of 50.4 Gy.
41492860|NCT05302830|BEHAVIORAL|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
41492861|NCT05302830|BEHAVIORAL|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
41492862|NCT04125849|PROCEDURE|Thoraco-laparoscopic esophagectomy|Thoraco-laparoscopic esophagectomy surgery
41492863|NCT04125849|PROCEDURE|Mediastinoscopy-assisted transhiatal esophagectomy|Mediastinoscopy-assisted transhiatal esophagectomy surgery
41492864|NCT03624608|DEVICE|AuryzoN Family of Devices|The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
41492865|NCT00754403|DRUG|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
41492866|NCT00754403|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
41492867|NCT03756467|BEHAVIORAL|Girl Empower Program|Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
41492868|NCT03771937|OTHER|Education and telephone follow-up intervention|A telephone follow up and a pre-discharge education
41509124|NCT05607654|DEVICE|sham rTMS|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
41159197|NCT03854214|DEVICE|Passive cycling|The passive cycling group will use the same RT300 ergometer however during this period stimulation will not be turned on. Instead, continuous motor support will be activated resulting in passive cycling. Target cycling speed is 50 RPM. Participants assigned to passive cycling will be required to have one hour of passive therapy 3 times a week for the entire duration of treatment assignment.
41509125|NCT06263452|DRUG|Propranolol|Tablet encapsulated to visually look identical to the placebo.
41351482|NCT02612792|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
41351483|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
41351484|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
41351485|NCT00748111|OTHER|Blood sample|Blood sample and thrombus sample
41351486|NCT02030457|DRUG|Beclomethasone dipropionate BAI|Breath Activated Inhaler (BAI)
41351487|NCT02030457|DRUG|Beclomethasone dipropionate MDI|Metered Dose Inhaler (MDI)
41351488|NCT03623204|OTHER|Dyspnea evaluation|
41492869|NCT00988442|BEHAVIORAL|Enhanced nursing telephone support|Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses could schedule more frequent calls at their discretion. Calls provided information, motivational enhancement, problem-solving skills, and affective support.
41492870|NCT00988442|BEHAVIORAL|Standard care|Usual ACTG site care.
41492871|NCT03881956|BEHAVIORAL|Health-promoting lifestyle education program|The intervention group were included in the health-promoting lifestyle education program. The education program consisted of three 45-min sessions, which included a face-to-face lecture with the dissemination and presentation of written and visual materials. Each participant in the intervention group was given the Health-Promoting Lifestyle Booklet and the Diary of a Woman with GDM card. The booklet features all of the health-promoting practices (self-monitoring of blood glucose, nutrition, physical activity, stress, sleeping, smoking, self-care and breastfeeding). The Diary of a Woman with GDM card features the daily program that women should follow (the hours for main meals and snacks, insulin hours, etc.). The education and counseling were maintained through follow-up via phone for intervention group.
41492872|NCT03849287|DRUG|CKD-333, formula I|Test drug
41492873|NCT03849287|DRUG|CKD-333, formula II|Test drug
41492874|NCT03849287|DRUG|CKD-330, D090|Reference Drug
41492875|NCT01195103|DRUG|Fospropofol disodium|10 mg/kg bolus
41159198|NCT05662683|OTHER|Virtual Reality (VR)|Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. During the PAP-SMEAR application to be made with this device, watching a nature video with VR is within the framework of midwifery care applications and is not a treatment option for any treatment method, agent or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason.
41159199|NCT05662683|OTHER|Distraction Cards Practice Group|It will take about 3-5 minutes to show the cards. The selection of the cards to be used is based on the cards suggested in the literature.
41351489|NCT00939341|DRUG|Symbicort (Budesonide/Formoterol)|Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
41351490|NCT03611946|BIOLOGICAL|rZIKV/D4Δ30-713 (Administered at a dose of 10^3 plaque-forming units (PFUs) by subcutaneous injection)|Administered at a dose of 10\^3 plaque-forming units (PFUs) by subcutaneous injection
41351491|NCT03611946|BIOLOGICAL|Placebo|Administered by subcutaneous injection.
41351492|NCT03611946|BIOLOGICAL|rZIKV/D4Δ30-713 (Administered at a dose of using 10^4 plaque-forming units (PFUs) by subcutaneous injection).|Administered at a dose of using 10\^4 plaque-forming units (PFUs) by subcutaneous injection.
41351493|NCT02967406|BEHAVIORAL|4 x 4 lifestyle modification|Participants in the intervention group will be given 4x4 lifestyle modification intervention, which will address four health behaviors (diet, physical activity, alcohol drinking and smoking) at four different levels: individual, household, knowledge management and community levels. A new computer program called 'iActive' adapted from the GPAQ with add-on functions to allow real-time assessment and presentation of the energy expenditure along with recommendations specific to each individual will be used. Dietary counseling will be given individually following assessment using a new dietary assessment program called Dietary Assessment Scanning Calculator. Home visit will be done every 3 months by responsible nurses and village health volunteers. Knowledge management will be done through meetings between participants and villages with support from trained nurses. Situation analysis and community action will be encouraged to address four health behaviors.
41492876|NCT01195103|DRUG|Fospropofol disodium|6.5 mg/kg bolus
41492877|NCT01195103|DRUG|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients \<60 kg; 1.5 mg for patients ≥60 kg to \<90 kg; or 2 mg for patients ≥90 kg
41492878|NCT01195103|DRUG|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
41492879|NCT00889382|DRUG|OSI-906|Administered orally
41492880|NCT00889382|DRUG|Paclitaxel|Administered intravenously
41492881|NCT00888823|RADIATION|Stereotactic Radiotherapy|Stereotactic Radiotherapy
41492882|NCT00724048|DRUG|ACR16|ACR16 will be administered per dose and schedule specified in the arm description.
41351494|NCT00458601|DRUG|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
41351495|NCT00458601|DRUG|Temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
41492883|NCT00724048|OTHER|Placebo|Placebo matching to ACR16 will be administered per schedule specified in the arm description.
41492884|NCT00291980|BIOLOGICAL|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
41492885|NCT00291980|BIOLOGICAL|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
41492886|NCT00045292|DRUG|acyclovir|
41492887|NCT00045292|DRUG|acyclovir sodium|
41492888|NCT00045292|DRUG|valacyclovir|
41492889|NCT04074616|DEVICE|High Dose|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
41492890|NCT04074616|DEVICE|Low dose|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
41492891|NCT00085475|DRUG|imatinib mesylate|
41351496|NCT04800484|DEVICE|Tall Soft|Tall heel wedge made of soft foam
41492892|NCT00085475|PROCEDURE|conventional surgery|
41492893|NCT00278252|DRUG|etoposide|
41351497|NCT04800484|DEVICE|Tall Firm|Tall heel wedge made of firm foam
41351498|NCT04800484|DEVICE|Short Soft|Short heel wedge made of soft foam
41351499|NCT04800484|DEVICE|Short Firm|Short heel wedge made of firm foam
41351500|NCT02675829|DRUG|ado-trastuzumab emtansine|Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
41351501|NCT05849064|BEHAVIORAL|Behavioral Control|Participants will receive standardized behavioral management strategies for their concussion symptoms including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion.
41351502|NCT05849064|BEHAVIORAL|Targeted Intervention|Participants will be prescribed one or more interventions, tailored to their domains. Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.
41492894|NCT00278252|PROCEDURE|conventional surgery|
41492895|NCT02468752|DRUG|Oxygen|
41492896|NCT02468752|OTHER|Air|
41492897|NCT01108211|DEVICE|Vibration Platform|The patients receive treatment by standing on the Vibration Platform 20 minutes a day, five days a week. The platform will deliver a vibration of 0.3g with a vertical displacement of 0.085mm at 35 Hz.
41492898|NCT02865421|DRUG|stem cells|adipose tissue derived stromal vascular fraction
41492899|NCT02865421|DRUG|platelet rich plasma|platelet rich plasma transplanted in bald area at a distance
41492900|NCT01207648|DRUG|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
41492901|NCT05656586|OTHER|observational-- no intervention|observational
41492902|NCT05172466|DEVICE|BeCare application|Participants will complete activities on the application 3 times a week for 2 weeks when they first join the study. They will then attend 4 in-person visits where they complete clinical and application based assessments. Activities are clearly marked in the application and participants are assigned specific assessments by the study team. The application analyzes user input during each evaluation to provide an outcome measure for that assessment.
41159200|NCT05662683|OTHER|Virtual Reality (VR) Breathing Exercise Group|From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
41159201|NCT02384083|DRUG|Filanesib, pomalidomide and dexamethasone|Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 \& 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 \& 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
41159202|NCT00659971|DRUG|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
41159203|NCT01137552|DRUG|AMG 780|AMG 780 will be administered by IV infusion every 2 weeks
41159204|NCT05347121|DIAGNOSTIC_TEST|difficult airway|ultrasonography of airway
41159205|NCT03578419|DEVICE|Small-Volume Blood Collection Tubes|Small-volume vacuum (\< 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
41159206|NCT03578419|DEVICE|Standard-Volume Blood Collection Tubes|Standard-volume (≥ 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
41159207|NCT02127983|BEHAVIORAL|Early intervention|"Training non-paid informal healthcare providers (such as store-keepers) in TB and HIV disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness.~Front line public health personnel and community leaders were sensitised to support the intervention"
41159208|NCT02127983|BEHAVIORAL|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
41159209|NCT02091297|DRUG|TAP Block|This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
41351503|NCT01714336|DRUG|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
41492903|NCT02755077|PROCEDURE|Head rotation during mask ventilation|Patient's head position is axially rotated 45 degrees to the right.
41509126|NCT06263452|DRUG|Placebo|Encapsulated sugar pill to visually look identical to the experimental condition.
41159210|NCT02091297|DRUG|Ropivacaine|The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
41159211|NCT02091297|DRUG|Acetaminophen|"Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia"
41159212|NCT02091297|DRUG|Morphine|
41159213|NCT06640998|DEVICE|Matrix Pro|Study subjects received up to three (3) study treatments with the Matrix Pro applicator
41159214|NCT05470218|OTHER|Meal|Liquid mixed meal with different amounts of protein and leucine
41159215|NCT06547840|DRUG|MOv18 IgE|MOv18 IgE is an anti-FRα monoclonal antibody (mAb) of the IgE class
41159216|NCT05674578|BEHAVIORAL|Patient Navigation|Assigned a patient navigator and receive coaching
41159217|NCT05674578|OTHER|Quality-of-Life Assessment|Ancillary studies
41159218|NCT05674578|OTHER|Questionnaire Administration|Ancillary studies
41351504|NCT01714336|DRUG|placebo|A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
41351505|NCT01724164|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
41351506|NCT01724164|BEHAVIORAL|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
41159219|NCT02936739|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
41159220|NCT02936739|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / Rotaio.|Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
41159221|NCT00744796|PROCEDURE|DSAEK|Endothelial Keratoplasty
41351507|NCT01724164|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
41159222|NCT00744796|DIAGNOSTIC_TEST|Anterior Segment Optical Coherence Topography (OCT)|Non-contact, high resolution, cross sectional imaging of the anterior segment of the eye.
41159223|NCT00744796|DIAGNOSTIC_TEST|Best Spectacle Corrected Visual Acuity (BSCVA)|Visual acuity determined using a combination of detecting hand motion, counting fingers displayed and reading Snellen charts at specific distances.
41159224|NCT00569036|DRUG|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
41159225|NCT04283396|COMBINATION_PRODUCT|systemic treatment|Oxygen therapy, antiviral therapy, antibiotics, hormones, globulin
41159226|NCT03787719|OTHER|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment
41159227|NCT02093897|BIOLOGICAL|rVIII-SingleChain|
41159228|NCT03053635|DRUG|TLD1433 infusion and photodynamic therapy (PDT) treatment|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
41020520|NCT04349852|BEHAVIORAL|BrainHQ People Skills Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The BrainHQ will provide 3 training modules for the control group: 1) Recognition: a picture of a face is presented briefly and then the subject picks the recognized face from 3 pictures. 2) Face to Face: matching the emotional expression of 3 pictures to the emotional expression of the picture previously presented; 3) Face Facts: recalling 3 facts about a person that was previously presented. Participants will spend 45 minutes at each training session. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
41159229|NCT02503306|DRUG|AVANAFIL|Pharmaceutical form:tablets Route of administration: oral
41159230|NCT02503306|DRUG|placebo|Pharmaceutical form:tablets Route of administration: oral
41351508|NCT01724164|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
41351509|NCT01724164|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
41351510|NCT02745795|BEHAVIORAL|Motivational Interview|Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
41351511|NCT02745795|BEHAVIORAL|Conventional Interview|Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
41351512|NCT02112149|BEHAVIORAL|LIVESTRONG|The LIVESTRONG at the YMCA is a twelve-week, small group (\< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
41351513|NCT00264628|DRUG|GW679769|
41351514|NCT01345825|OTHER|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
41351515|NCT02758106|DEVICE|Vest Airway Clearance System Model 105|HFCWO for 15 minutes then sputum suction.
41351516|NCT02758106|DEVICE|placebo intervention|CCPT for 15 minutes then sputum suction.
41351517|NCT06292429|OTHER|Complex Training|"Week 1-4: Foundation Phase Lower Body Resistance Training Squats (Back Squats or Goblet Squats) Deadlifts Lunges~Paired with:~Box Jumps Depth Jumps~Upper Body Resistance Training Bench Press Overhead Press~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw Rows (Barbell or Dumbbell)~Week 5-8: Strength and Power Phase Lower Body Resistance Training Power Cleans Front Squats Romanian Deadlifts~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Push Press Pull-Ups or Lat Pulldowns Bent Over Rows~Paired with:~Plyometric Push-Ups Medicine Ball Slam~Week 9-12: Power and Speed Phase Lower Body Resistance Training Snatch Split Squats Jumping Lunges~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Speed Bench Press Face Pulls Plyometric Pull-Ups~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw"
41351518|NCT06292429|OTHER|Conventional Training|"Week 0-4 Session 1 Rotator cuff wall compression Forearm flexor compression Alpha ball tricep scrape Band assisted pushups Session 2 Soft ball thoracic breathing Neck ball arm rotations ITb compressions Middle quard compressions~Week 4-8 Session 1 Kneeling pall of band hold Kneeling pall of partner proturbations Leg lower with mediball neutral Half lying arm speed and swing drill Session 2 Single leg band hold Trunk activated psoas lowers Split clam Bulgarian split iso hold~Week 8-12 Session 1 Point kneel thoracic rotations Side lying single arm thoracic abduction Banded side lying clams Side lying abduction from glute Session 2 Low back mobility Kneeling pall off band hold Clean and jerks power drill movements Weighted bench press Session 3 Standing band rotations thoracic only Band pull aparts Tennis ball in trap arm flexion ext thumb to floor Bulgarian weighted"
41351519|NCT06292429|OTHER|Control Group|No intervention given
41351520|NCT05395728|OTHER|Deflate the tracheostomy cuff early|The tracheostomy cuff will be early deflated, on beginning the weaning mechanical ventilation
41351521|NCT05395728|OTHER|Deflate the tracheostomy cuff after complete weaning mechanical ventilation|The tracheostomy cuff will be deflated onl twenty four hours after complete weaning mechanical ventilation
41020521|NCT01421875|GENETIC|DNA methylation analysis|
41159233|NCT05753241|OTHER|no intervention|It's only observational study. No interventions.
41159234|NCT04031118|DEVICE|Apioc Contact Lens|Measurement of corneal oxygen uptake with contact lens wear.
41159235|NCT06181929|DIAGNOSTIC_TEST|Low dose CT|A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent
41351522|NCT05747664|DRUG|DWP16001|0.3mg
41509127|NCT01799044|DEVICE|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
41020522|NCT01421875|GENETIC|RNA analysis|
41020523|NCT01421875|GENETIC|gene expression analysis|
41159236|NCT05645744|BIOLOGICAL|Prior MB-102 CAR-T cell investigational product.|No investigational product will be administered.
41159237|NCT05645744|BIOLOGICAL|Prior MB-106 CAR-T cell investigational product.|No investigational product will be administered.
41159238|NCT00247117|DRUG|Metformin|
41492904|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
41492905|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
41492906|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
41492907|NCT02312518|DEVICE|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
41492908|NCT02312518|OTHER|Usual and Customary Practice|Usual and Customary Practice for non-healing venous leg ulcers
41492909|NCT04268316|DEVICE|Virtual Reality Behavioral Activation|"Participants will choose four activities to complete in virtual reality over the course of the week. These activities are video 360 and range from viewing animals, to viewing nature scenes, to traveling to a different location in the world, to viewing adrenaline-pumping activities."
41492910|NCT04268316|BEHAVIORAL|Behavioral Activation in real-life|Participants will choose four pleasurable and/or mastery activities to complete over the course of the week in real life.
41492911|NCT02387515|OTHER|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
41492912|NCT05465239|DEVICE|SurePace Powered Walker User|Participants will be asked to perform one baseline 5-minute trial with the lab's instrumented walker in passive mode (no powered locomotion) and two 5-minute trials with the walker in active mode (powered locomotion).
41492913|NCT01297387|OTHER|PTA BPG procedure,|Surgery PTA or BPG Procedure, according usual local clinical practice
41492914|NCT02757365|DRUG|aspirin|
41492915|NCT02757365|DRUG|Levofloxacin|
41492916|NCT00317707|DRUG|N-3 Polyunsaturated Fatty Acids|Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
41492917|NCT00317707|DRUG|Placebo: Olive oil|Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
41492918|NCT05107141|PROCEDURE|Ridge preservation|Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane
41492919|NCT05107141|DEVICE|bone graft plus a collagen membrane|
41492920|NCT02593682|DRUG|suvorexant|
41020524|NCT01421875|GENETIC|microarray analysis|
41492921|NCT02593682|DRUG|placebo|
41492922|NCT00780910|DRUG|MP-424|750 mg every 8 hours for 12 weeks
41492923|NCT00780910|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
41492924|NCT00780910|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
41492925|NCT03018210|PROCEDURE|Surgical repair of the rotator cuff|
41492926|NCT00002608|DRUG|cisplatin|
41492927|NCT00002608|DRUG|doxorubicin hydrochloride|
41492928|NCT00002608|DRUG|tamoxifen citrate|
41020525|NCT01421875|GENETIC|nucleic acid sequencing|
41020526|NCT01421875|OTHER|laboratory biomarker analysis|
41492929|NCT00002608|PROCEDURE|conventional surgery|
41492930|NCT00002608|RADIATION|radiation therapy|
41492931|NCT02870218|DRUG|Smoking research cigarettes with e-cigarette|Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
41492932|NCT02870218|DRUG|Nicotine discrimination thresholds|Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.
41492933|NCT05604456|PROCEDURE|secondary ear reconstruction based on Nagata method|Secondary auricular reconstructions based on Nagata method were conducted on patients who sought for secondary revision.
40832600|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 90% 1RM combined with complex training|This group of subjects first performed 3 sets of 90% 1RM squats after a routine warm-up, 1 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
41492934|NCT05912283|DEVICE|Synthetic Nitrile Condoms (53mm)|53mm width synthetic nitrile condoms
41020527|NCT00441337|BIOLOGICAL|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
41492935|NCT05912283|DEVICE|Synthetic Nitrile Condoms (56mm)|56mm width synthetic nitrile condoms
41492936|NCT05912283|DEVICE|Control Latex Condom|Commercial natural rubber latex condom
41020528|NCT04839497|COMBINATION_PRODUCT|Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees|Autologous Volar Fibroblasts Treatment- harvested from patient's biopsied volar skin. Intradermal injection of Volar fibroblasts in the residual limb of transtibial amputees.
40832601|NCT06083532|BEHAVIORAL|Routine warm-up combined with complex training|This group of subjects first completed a 30-minute routine warm-up, then rested for 6 minutes, and then performed complex training consisted of maximum strength training (back squats) and plyometric training (drop jump). Back squat intensity \& repetition is 80% 1RM × 4, 4 sets, with an interval of 2 minutes; after resting for 3 minutes, perform a drop jump, Intensity \& Repetition is 50cm (height) × 10, 4 sets, with an interval of 2 minutes. Intervention training was conducted twice weekly for 12 weeks, and the intensity was gradually increasing over the 12 weeks.
40832602|NCT02042313|OTHER|continuous epidural infusion|
41509128|NCT03209817|DIETARY_SUPPLEMENT|Red cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
41492937|NCT06160505|DEVICE|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
40832603|NCT02042313|OTHER|combined paravertebral infusion and single shot of TAP block|
41351523|NCT02721446|BEHAVIORAL|Standard|"Investigators will develop a standard informational stroke risk message that will not undergo iterative review. This will inform the patient that based on information in the healthcare system, the patient is at higher risk of stroke than many others receiving care in the patient's healthcare system; it will describe options for working with their health care team to reduce the risk of stroke; and encourage the patient to call the health navigator to discuss these options and make a decision about next steps to take to reduce the patient's risk of stroke."
41351524|NCT02721446|BEHAVIORAL|Incentive|Investigators anticipate that the baseline incentive stroke risk message will inform the patient that they are at higher risk of stroke than many others receiving care in the patient's healthcare system, and will provide information about obtaining an incentive if the patient calls to make contact with a health navigator who will help them plan a next step to reduce their stroke risk. The investigators also anticipate including information that all patients who call will also be entered in a random drawing to receive an additional incentive, with up to six patients receiving this incentive.
41351525|NCT02721446|BEHAVIORAL|Salience|"Investigators anticipate that the baseline salience stroke risk message will inform the patient that they are at higher risk of stroke than many other patients receiving care in the patient's healthcare system, and will specifically focus on the patient's own risk factors (rather than all stroke risk factors). The salience message will also include visual depictions of stroke patients that are gender and ethnically matched to each subject. This is intended to prompt action by emphasizing that stroke is a real possibility for patients like me."
41351526|NCT02721446|BEHAVIORAL|Incentive + Salience|Combined message of incentive plus salience.
41492938|NCT00207675|DRUG|infliximab|
40832604|NCT05929339|DRUG|Oxytocin|Intravenous oxytocin
40832605|NCT00837018|OTHER|physical exercise program|45 min, 3times a week
40832606|NCT03752268|BEHAVIORAL|Enhancing Cancer Pain Management|Patients will learn and practice an enduring framework of cognitive-behavioral strategies, to enhance adherence behavior, reduce intentional and unintentional deviations from the prescribed regimen.
41492939|NCT02856438|DRUG|Elotuzumab|Specified dose on specified days
40832607|NCT04459806|PROCEDURE|intracranial pressure monitoring|Invasive monitoring of intracranial pressure by using CereLink monitor.
40832608|NCT06414421|OTHER|Transcuten Electriacal Nerve Stimulation|In TENS group patients, 4 electrodes of the TENS device were placed 3-5 minutes before the biopsy procedure, and the application was started and TENS was applied throughout the procedure. continued. TENS was applied again for 30 minutes 2 hours after the procedure.
40832609|NCT05785260|BEHAVIORAL|ACT MINDFULNESS|"Mindfulness (MCBT) practices were offered to patients with the aim of fostering the elderly's pro-active role in health prevention by making them~aware of the relationship between thoughts, emotions and symptomatology of the disorder. The exercises will also be used as a motivational work tool within a protocol of Acceptance and Commitment Therapy (ACT), a new generation cognitive behavioral approach, in which commitment components are added to mindfulness, suitable for lifestyle modification."
41492940|NCT02856438|DRUG|Lenalidomide|Specified dose on specified days
41492941|NCT02856438|DRUG|Dexamethasone|Specified dose on specified days
41492942|NCT03878771|BIOLOGICAL|Platelet rich fibrin gel in Orabase|applied on oral mucositis and /or ulcer 3 times per day
40832610|NCT03618914|BIOLOGICAL|Dultavax and Vaxigrip|All the women got an influenza/DTP vaccine in order to induce acute inflammation
40832611|NCT00089986|DRUG|Intravenous GR270773- Phospholipid Emulsion|
40832612|NCT00089986|OTHER|Placebo|
40832613|NCT06396715|DEVICE|Transcranial direct current stimulation|tDCS is a type of non-invasive brain stimulation that in a standard paradigm, low intensity current (1-2 mA) is applied continuously through a battery connected to two 20 to 35 cm2 surface electrodes located on the scalp: an anode and a cathode. In the interhemispheric competition model, tDCS can serve as a means to increase ipsilesional cortical excitability through anodal stimulation, to decrease contralesional cortical excitability through cathodal stimulation, or to do both through a montage of bi-hemispheric electrodes.
40832614|NCT05060380|OTHER|Exercise training|Progressive muscle resistive exercise will be performed by the experimental group only. Control group will maintain their normal level of daily activity.
41492943|NCT03878771|DRUG|Dermovate cream in Orabase|applied on oral mucositis and /or ulcer 3 times per day
41492944|NCT03222583|DRUG|Placebo|Matching placebo tablet for oral administration
41492945|NCT03222583|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
41509129|NCT03209817|DIETARY_SUPPLEMENT|Yellow cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
41509130|NCT01837134|DEVICE|telemedical (TM) group|telemedical devices (weighing machine and step counter)
41509131|NCT01837134|BEHAVIORAL|telemedical coaching (TMC) group|care calls once per week for 12 weeks
40832615|NCT00379977|BIOLOGICAL|diphtheria, tetanus, pertussis & Hib vaccine|
40832616|NCT00069524|DRUG|oyster mushroom|
40832617|NCT03078738|DRUG|OMT-28|OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
41492946|NCT05262998|PROCEDURE|Plate fixation|"Procedure: plate fixation~Plate fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. A standard surgical protocol was used, the approach was moved inferiorly, the fracture was reduced, sometimes with osteosutur and fixed with an antero-superior anatomical plate. 3.5mm Locked and cortical screws were used on both sides of the fracture. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
41492947|NCT05262998|PROCEDURE|Intramedullary Screw|"Procedure: Intramedullary screw fixation~Intramedullary screw fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. Intramedullary screw fixation was performed by using a 1.6 or 2.8 mm-diameter threaded guide pin and a 85-100 mm long, 4.5 or 6.5 mm-diameter cannulated screw tapped in along the guide pin. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin.~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
41492948|NCT02080013|OTHER|radiofrequency|ClosureFAST
41159239|NCT06158412|DRUG|All-trans Retinoic Acid in combination with the KPD Regimen|"Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~1. ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~   The last ATRA dose will be given in the evening on the day of carfilzomib administration.~2. Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~3. Pomalidomide 4mg orally daily, d1-21;~4. Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; \>75 years: 20 mg/day."
41492949|NCT00003875|DRUG|busulfan|Given PO or IV
41492950|NCT00003875|DRUG|etoposide|Given IV
41492951|NCT00003875|BIOLOGICAL|aldesleukin|Given SC
41492952|NCT00003875|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous or syngeneic stem cell rescue
41492953|NCT04120571|OTHER|Sleep Audiological Intervention Device (SleepAID)|subtle sound stimulation in phase with the slow oscillations
41492954|NCT04120571|OTHER|sham control|no noise
40832618|NCT03078738|OTHER|Matching Placebo|Microcrystalline cellulose
40832619|NCT02783378|DRUG|Gaviscon Syrup|
40832620|NCT03548454|DRUG|Duloxetine|Open label prescription
40832621|NCT03548454|DRUG|Desipramine|Open label prescription
40832622|NCT01340781|PROCEDURE|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
41159240|NCT04456049|DRUG|Enzalutamide|40 mg oral tablets once daily for a maximum of 28 days.
41159241|NCT02274519|OTHER|Tai Chi|Arm 1
41159242|NCT02274519|OTHER|Education|Arm 2
41159243|NCT01842542|DEVICE|NeuroStar Transcranial Magnetic Stimulation (TMS)|"Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.~3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician."
41492955|NCT03560648|DEVICE|High definition surface electromyography combined with accelerometer|HD-sEMG and accelerometer data will be collected by Mobita 32® (TMSi) device.
40832623|NCT00403780|DRUG|pregabalin|"Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.~Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily."
40832624|NCT00403780|DRUG|placebo|Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
40832625|NCT06163794|OTHER|Nutritional postprandial test|Metabolic responses to several test meals
40832626|NCT03679637|BEHAVIORAL|Tablet-based aphasia therapy|patients will independently practice with a speech app during hospitalisation
40832627|NCT05615857|DEVICE|Use of Endocuff during colonoscopy|We will be adding the Endocuff device to the proximal end of the colonoscope, adding an additional tool to facilitate the visualization of the difficult-to-see mucosal areas as well as the rectum. There will be no need for retroflexion to evaluate the colon
40832628|NCT04438499|DEVICE|eSense 7fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
41020529|NCT04468295|PROCEDURE|Bonding|Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch
41020530|NCT04468295|PROCEDURE|Leveling and alignment|Leveling and alignment till 0.016 x0.022 Ni Ti
41020531|NCT04468295|PROCEDURE|Extraction|Extraction of maxillary 1st premolars
41159244|NCT00221481|DRUG|divalproex or olanzapine|
41020532|NCT04468295|PROCEDURE|Retraction|En-masse retraction using 0.017x0.025 TMA T loop
41020533|NCT04468295|PROCEDURE|Digital models|impression taking and digital scanning
41020534|NCT04468295|PROCEDURE|measurement|Assessment the rate of retraction for 6 months
41020535|NCT05685485|PROCEDURE|Standard Implantation|Traditional Ahmed plantation without vicryl ligature
41492956|NCT05940155|DIAGNOSTIC_TEST|RT PCR test of COVID 19|diagnostic test by naso-pharyngel swab to confirm the diagnosis of covid-19 at moderate and severe cases.
41492957|NCT05788614|DEVICE|Reverse shoulder arthroplasty|Reverse shoulder arthroplasty
41492958|NCT05982717|OTHER|No intervention|As this is an observational study, no intervention will be administered.
41492959|NCT00093119|DRUG|ABI-007|
41492960|NCT02651779|PROCEDURE|Open reduction and internal plate fixation|
41492961|NCT02651779|OTHER|Closed reduction and plasterimmobilisation|
41492962|NCT06391255|OTHER|scintigraphy|oesophageal and gastric emptying
40832629|NCT00003963|BIOLOGICAL|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
40832630|NCT00003963|DRUG|vinorelbine ditartrate|"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
41020536|NCT05685485|PROCEDURE|Tied off Tube|Ahmed implantation with vicryl ligature
41020537|NCT03352115|DRUG|Prednisolone|5 day course of oral prednisolone
41020538|NCT03352115|DRUG|Placebos|Placebo syrup
41020539|NCT06026566|DRUG|Dos of Afentanil 20|the dosage of Afentanil is 20 ng/ml for TCI
41020540|NCT06026566|DRUG|Dos of Afentanil 30|the dosage of Afentanil is 30 ng/ml for TCI
41020541|NCT06026566|DRUG|Dos of Afentanil 40|the dosage of Afentanil is 40 ng/ml for TCI
41020542|NCT06026566|DRUG|Dos of Afentanil 50|the dosage of Afentanil is 50 ng/ml for TCI
41020543|NCT06026566|DRUG|Dos of Afentanil 60|the dosage of Afentanil is 60 ng/ml for TCI
41020544|NCT06026566|DRUG|Dos of Afentanil 70|the dosage of Afentanil is 70 ng/ml for TCI
41020545|NCT06026566|DRUG|Dos of Afentanil 80|the dosage of Afentanil is 80 ng/ml for TCI
41020546|NCT06026566|DRUG|Dos of Afentanil 90|the dosage of Afentanil is 90 ng/ml for TCI
41020547|NCT06026566|DRUG|Dos of Afentanil 100|the dosage of Afentanil is 100 ng/ml for TCI
41020548|NCT00733824|DRUG|AMD3100|
41020549|NCT00733824|DRUG|G-CSF|
41020550|NCT00733824|PROCEDURE|Apheresis|
41020551|NCT00320216|DRUG|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
41020552|NCT00320216|DRUG|Placebo|Patients in the placebo group will receive placebo medication.
41020553|NCT02580526|PROCEDURE|V-E mask ventilation for one minute|"V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
41020554|NCT02580526|PROCEDURE|C-E mask ventilation for one minute|"Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
41020555|NCT00077259|DRUG|epothilone D|
41020556|NCT03495960|DRUG|Rituximab|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy."
41020557|NCT03495960|DRUG|Methotrexate|During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30
41020558|NCT03495960|DRUG|Procarbazine|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks."
41020559|NCT03495960|DRUG|Lenalidomide|"Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks."
41020560|NCT03495960|RADIATION|Radiotherapy|Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
41020561|NCT03495960|DRUG|Temozolomide|"PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.~PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,"
41020562|NCT00515333|DRUG|TRx0014|Hard capsule; 60 milligrams; t.i.d.
41020563|NCT00515333|DRUG|TRx0014|Hard capsule; 30 milligrams; t.i.d.
40832631|NCT05351723|OTHER|Exercise + cognitive training + education|"The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention."
40832632|NCT05932121|PROCEDURE|Thyroid lobectomy via trans-axillary approach|Patient with PTC underwent thyroid lobectomy via trans-axillary approach
40832633|NCT05932121|PROCEDURE|Thyroid lobectomy via open approach|Patient with PTC underwent thyroid lobectomy via open approach
40832634|NCT03541187|BIOLOGICAL|German cockroach allergenic extract|Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).
40832635|NCT03541187|BIOLOGICAL|Placebo for German cockroach allergenic extract|Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).
41020564|NCT00515333|DRUG|Placebo|Hard capsule; 0 milligrams; t.i.d.
41159245|NCT04131699|DEVICE|Cardiotronic ICON continuous non-invasive cardiac output monitor.|cardiac index, cardiac output \& stroke volume measured and recorded with every change in intrathoracic pressure.
41159246|NCT01979757|OTHER|Puregraft|
41351527|NCT01115114|BEHAVIORAL|TAU|A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.
41159247|NCT01979757|OTHER|Centrifugation|
41159248|NCT06647433|OTHER|Observation|case study will be observed participants, methods will include observation, interview and video reflexive ethnography
41351528|NCT01115114|BEHAVIORAL|IMBED|After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.
41351529|NCT01115114|BEHAVIORAL|Liaison|Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
41351530|NCT03826992|DRUG|Vyxeos|Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
41492963|NCT02440113|DEVICE|Nellix|Nellix Implantation
41492964|NCT06102083|DRUG|TDI01 suspension|"Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily."
41020565|NCT00515333|DRUG|TRx0014|Hard capsule, 100 milligrams, t.i.d.
41020566|NCT04632446|OTHER|Early diagnosis|Early diagnosis. Upgrade program implementation.
41020567|NCT02864797|OTHER|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
41020568|NCT00094380|DRUG|CTLA4-IgG4m (RG2077)|
41020569|NCT00094380|DRUG|Cyclophosphamide|
41020570|NCT05484401|DRUG|Ibuprofen 200Mg Oral Cap|2 x 200mg Liquid Capsules once in 12 hours
41020571|NCT05484401|DRUG|Ibuprofen 200Mg Oral Tablet|2 x 200mg Tablets once in 12 hours
41020572|NCT05484401|OTHER|Placebo Liquid Capsule|2 x Liquid Capsules once in 12 hours
41020573|NCT05484401|OTHER|Placebo Tablets|2 x Tablets once in 12 hours
41020574|NCT02755935|DEVICE|Cochlear Nucleus CI532|cochlear implantation
41020575|NCT03459417|PROCEDURE|intrathecal morphine+LA|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
41020576|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 50|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
40832636|NCT02892721|OTHER|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
41159249|NCT06404047|BEHAVIORAL|Personalized Cardiopulmonary Rehabilitation|"Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training."
41159250|NCT06404047|BEHAVIORAL|Structured Pacing|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
41159251|NCT06404047|OTHER|Education|Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
41159252|NCT06404047|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
41159253|NCT06647316|OTHER|Physiotherapy|The subjects will receive the first physiotherapy session : early mobilization, postural and joint ergonomics, sensory stimulation, temporal-spatial orientation and health education for the patient and the main caregiver are carried out.The plan will progress with postural control in a seated position, head and trunk control, re-education of transfers, balance, standing and walking, depending on the subject's abilities.The second physical therapy session incorporates taste and preference-based elements into the therapy itself. The third physiotherapy session is planned to take place in the physiotherapy unit. Following the individualized session, group interaction is encouraged, whether with other patients, the rehabilitation team and/or the patient's primary caregiver.In the fourth physiotherapy session, it is promoted therapeutic compliance.
41351531|NCT03826992|DRUG|Venetoclax|"Venetoclax Dose:~1. Dose Level 0 - weight based daily dosing for 21 days~2. Dose Level -1 - weight based daily dosing for 14 days~3. Dose Level -2- weight based daily dosing for 10 days~4. Dose Level -3- weight based daily dosing for 7 days"
41351532|NCT05408403|OTHER|Regional anesthesia TFPB|Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
41351533|NCT05408403|OTHER|Regional anesthesia QLB|Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
40832637|NCT04097496|BEHAVIORAL|Act Out! Intervention|Data included in the description of the intervention arm.
40832638|NCT05458661|DEVICE|Clinical Prototype BioBase (SN 07 and SN 08)|Scheimpflug- or OCT based corneal tomographers with the ability to measure anterior and posterior corneal curvature maps \>6mm diameter and corneal pachymetry maps \>6mm.
41159254|NCT04392479|DRUG|Aflibercept-FOLFIRI|Aflibercept-FOLFIRI
41159255|NCT04392479|DRUG|Aflibercept-mFOLFIRI3|Aflibercept-mFOLFIRI3
41159256|NCT05009147|OTHER|Home-based massage by caregivers for dementia|A total of 40 patients with dementia and their family caregivers will be included and randomly allocated to experiment (n=20) or control group (n=20). The experiment and control group will receive whole body manual massage and placebo intervention (30 minutes once per week for 8 continuous weeks), respectively.
41351534|NCT03593720|PROCEDURE|Measurement in Office|Penile length and glans size in 3 dimensions
41351535|NCT03593720|PROCEDURE|Measurement in OR|Penile length and glans size in 3 dimensions
41159257|NCT04745455|OTHER|Infant formula containing prebiotics, probiotics and postbiotics|Infant formula containing prebiotics, probiotics and postbiotics
41159258|NCT00375583|DRUG|DEC/Albendazole|
41159259|NCT04739462|BEHAVIORAL|mHealth Platform|All participants randomized to the intervention group will receive 2-4 informational texts each week and will also receive interactive health screening questions throughout enrollment. A participant will also receive appointment reminder texts. All SMS text messages will be transmitted through a local organization known as The Medical Concierge Group (TMCG) via an electronic system that allows for bulk messaging. TMCG also staffs a 24-hour call line for those using TMCG services to call in for medical related questions. This call line is staffed by doctors and nurses; SMS Maama participants randomized to the interventional group will be able to access this call line free of charge as part of their enrollment in SMS Maama.
41159260|NCT01741636|OTHER|educational intervention|Undergo Survivorship Care Planning
41159261|NCT01741636|OTHER|questionnaire administration|Ancillary studies
41159262|NCT01741636|PROCEDURE|quality-of-life assessment|Ancillary studies
41159263|NCT03154684|OTHER|STARK intervention|"The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~* Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~* Inspection of the environment at the patient's home~* Care and autonomy support~* Social life support~* Secondary prevention strategies:~* Home exercise program (3x/weeks)~* Protein enriched food preparation (20g whey protein/day)~* Support to take vitamin D supplementation (2000 IU/day)~* Recommendation and support to eat calcium rich foods~* Motivation to be physically active"
41159264|NCT03154684|OTHER|Standard of Care|Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
41159265|NCT00674258|BIOLOGICAL|URLC10, TTK and KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
41159266|NCT06080919|DEVICE|Drug coated-balloon percutaneous coronary intervention.|Patients will undergo DCB-PCI under IVUS guidance (OpticrossTMHD 60 MHz). Target lesion will be predilated with semi-compliant balloons or non-compliant balloons.The lesion will be then treated with DCB with a reference vessel diameter/balloon diameter ratio of 1.
41159267|NCT06080919|DEVICE|Angiography-derived coronary physiology (IMRangio)|Angiography-derived coronary physiology will be assessed after the procedure using Angio Plus software (Pulse Medical Imaging Technology, Shanghai, China). The angiography images will be used to obtain the IMRangio values, prior and post to DCB-PCI
41159268|NCT06473480|DEVICE|Abott FreeStyle Libre System 2|The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
41159269|NCT06473480|DEVICE|Abott Freestyle Libre Pro|The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
41159270|NCT05414201|DRUG|Adalimumab|Subcutaneous Injection
41159271|NCT02314169|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41159272|NCT02314169|PROCEDURE|Computed Tomography|Undergo CT scan
40832639|NCT04311827|OTHER|Serratus Anterior Plane Block|Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
41159273|NCT02314169|BIOLOGICAL|Ipilimumab|Given IV
41159274|NCT02314169|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41159275|NCT02314169|BIOLOGICAL|Nivolumab|Given IV
41159276|NCT03289416|COMBINATION_PRODUCT|Pure PRP II|The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
41159277|NCT03289416|COMBINATION_PRODUCT|PureBMC|The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
41159278|NCT02370199|DEVICE|670 nm light|670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
41159279|NCT02370199|DRUG|octafluropropane|Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
41159280|NCT04686370|OTHER|laser treated implant surface|Better marginal bone stability is expected for this type
41159281|NCT03779126|DEVICE|Electrical stimulation|1) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.
41159282|NCT03669900|PROCEDURE|a minimally invasive surgery (SERI)|The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
41351536|NCT04236440|DRUG|BAY2586116 (A1)|160 μg BAY2586116 (nasal spray administration)
41351537|NCT04236440|DRUG|Placebo (A2)|Placebo matching BAY2586116 (nasal spray administration)
41159283|NCT05180487|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be provided.
41159284|NCT05928858|DRUG|Premixed Bio-ceramic MTA|Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
41159285|NCT05928858|DRUG|Calcium hydroxide|Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
41159286|NCT04405856|DEVICE|Intra Aortic Balloon Pump|Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle.
41351538|NCT04236440|DRUG|BAY2586116 (B1)|160 μg BAY2586116 (nasal drops)
41351539|NCT04236440|DRUG|BAY2586116 (B2)|80 μg BAY2586116 (nasal spray)
40832640|NCT03399357|BIOLOGICAL|Influenza Vaccine|Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus
40832641|NCT05666232|DIAGNOSTIC_TEST|renal resistive index and myocardial performance index|"Transthoracic echocardiography and transabdominal ultrasonography will be performed before induction of anesthesia, after termination of operation and before transmission to ICU and then daily for the early seven postoperative days.~RRI = (peak systolic velocity - end diastolic velocity) ∕ peak systolic velocity: Then, we will obtain the mean RRI from the above three measurements.~We will consider RRI ≥0.7 as abnormal and define it as subclinical AKI.~Myocardial performance index (using tissue doppler) =~(isovolumetric contraction time + isovolumetric relaxation time) / ejection time. We will consider MPI ≥0.4 as abnormal and define it as subclinical LV dysfunction."
40832642|NCT01825278|DEVICE|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
40832643|NCT02609685|OTHER|Active Surveillance|Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
40832644|NCT01433302|PROCEDURE|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
40832645|NCT05546255|DRUG|Eribulin Mesylate|The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
40832646|NCT05546255|DRUG|Lobaplatin|The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
40832647|NCT00755534|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
40832648|NCT00755534|DRUG|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
40832649|NCT00755534|DRUG|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
40832650|NCT00755534|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
40832651|NCT04808271|DIETARY_SUPPLEMENT|Bifidobacterium breve Bif195|1 capsule daily for 8 weeks
40832652|NCT04808271|DIETARY_SUPPLEMENT|Placebo|1 capsule daily for 8 weeks
40832653|NCT03632603|RADIATION|No intervention|No intervention during study period.
40832654|NCT04579172|PROCEDURE|Cervico- isthmic compression suture|Circular isthmic-cervical sutures will be applied . To avoid ureter and bladder injury, the bladder will be reflected downward. A silastic drain will be inserted into internal and through the external os , so as to drain the uterine cavity and to keep the cervical canal open. Firstly, at the left side of the uterus, a Vicryl number two (No..2) stitch will be inserted very close to the cervix from the anterior to the posterior side of the broad ligament.
40832655|NCT04579172|PROCEDURE|Anterior wall uterine resection:|After fetal delivery, two corners of the uterine incision and the superior and inferior lips will be clamped immediately by four Mayo clamps. Blunt dissection downward to the bladder-uterus peritoneal reflection will perform, to the partial anterior wall of the uterine myometrium where the placenta was deeply adherent (a myometrium defect, with only the serous layer of the uterus) will be respected, together with the placenta. It is important to ensure that sufficient myometrium above the peritoneal reflection will be available for an optimum closure. Then, as much remaining placenta as possible will be removed piecemeal from the edge of the uterine incision. Clamps and multiple hemostatic sutures will be applied rapidly
41020577|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 100|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
41020578|NCT02595684|DRUG|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
41351540|NCT04236440|DRUG|BAY2586116 (B3)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
41351541|NCT04236440|DRUG|BAY2586116 (C)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
40832656|NCT02179255|DRUG|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
40832657|NCT02179255|DRUG|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
41020579|NCT02595684|DRUG|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
41020580|NCT03658720|DRUG|200 mg Ibuprofen acid orodispersible tablet|orodispersible tablet
41020581|NCT04738708|OTHER|Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients are given a series of questions evaluating cognitive and psychosocial outcomes, either via hardcopy in-person or online internet-facing questionnaire.
41351542|NCT03607461|DEVICE|Smartphone App|Smartphone App Users will engage with the app at least daily and follow along with the prescriptive exercises as instructed.
41351543|NCT03607461|COMBINATION_PRODUCT|Control Group|Home Health users will have received traditional home health physical therapy and skilled nursing services.
40832658|NCT00731965|BIOLOGICAL|Measles, Mumps, Rubella vaccination|Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
40832659|NCT03159364|BIOLOGICAL|pathogen-specific CTLs|Patients will receive approximately 1x10\^5\~1x10\^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
41020582|NCT01344057|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
41020583|NCT04276272|OTHER|Imaging scan|PET/CT scan
41020584|NCT01048138|DRUG|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
41020585|NCT01048138|DRUG|Placebo|5mg IV(in the vein)every 6 hours for 10 days
41020586|NCT00402389|DRUG|Omega-3 Fatty Acids (EPA plus DHA)|Four capsules will be taken daily for 8 weeks.
41020587|NCT00402389|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
41020588|NCT00402389|DRUG|Placebo|Four capsules will be taken daily for 8 weeks.
41020589|NCT03251924|DRUG|BMS-986226|specified dose on specified days
41020590|NCT03251924|BIOLOGICAL|Nivolumab|specified dose on specified days
41020591|NCT03251924|BIOLOGICAL|Ipilimumab|specified dose on specified days
41020592|NCT03251924|BIOLOGICAL|Tetanus Vaccine|specified dose on specified days
41020593|NCT01379092|DEVICE|Trident Specimen Radiography System|MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
41020594|NCT01379092|DEVICE|Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia|All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
41020595|NCT06572917|DRUG|Indomethacin|Single dose of 0.1 mg/kg dose intravenous indomethacin as a slow infusion over 20 mins
41020596|NCT06572917|DRUG|Placebo|Single dose of intravenous normal saline placebo as a slow infusion over 20 mins
41159287|NCT03229356|OTHER|Best Practices Advisory (BPA)|"1. BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.~2. Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement."
41351544|NCT00641979|DRUG|budesonide|Current product
41351545|NCT00641979|DEVICE|Budesonide|New type device
41351546|NCT00641979|DRUG|Placebo|
41020597|NCT05164705|OTHER|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
41020598|NCT05164705|OTHER|Sham Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and breathe normal air (21 percent O2) for 30-minutes.
41020599|NCT02640794|DRUG|Clopidogrel|Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
41020600|NCT02640794|DRUG|Aspirin|Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
41351547|NCT03998345|DRUG|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
41351548|NCT00443534|DRUG|SU011248|Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
41351549|NCT00748332|DIETARY_SUPPLEMENT|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
41020601|NCT04754581|OTHER|Maximal ATP Production (ATPmax)|ATPmax will be measured in order to determine in vivo mitochondrial capacity. The magnetic resonance scans to measure mitochondrial energetics will also be performed.
41020602|NCT04754581|OTHER|Exercise Testing (VO2max)|Aerobic fitness level will be assessed while participant pedals on a stationary bicycle/walk on a treadmill. The volume of oxygen intake and carbon dioxide (CO2) production will be measured.
41020603|NCT04754581|PROCEDURE|Muscle Biopsy|Sample muscle cells from the left leg Vastus Lateralis (thigh) muscle.
41020604|NCT04754581|PROCEDURE|Adipose Tissue Biopsy|Sample fat tissue from the abdomen.
41020605|NCT04754581|OTHER|Hyperinsulinemic euglycemic clamp|Measurement of insulin sensitivity.
41020606|NCT04754581|OTHER|PET imaging|After an overnight fast, an intravenous catheter will be placed in each arm (one with arterial line for PET infusion, and the other for infusion of insulin, glucose, and 6,6 D2 glucose tracer. FDG-glucose will be injected followed by 90-minute PET scanning of the thigh.
41020607|NCT01827904|DEVICE|Transcranial ExAblate|
41351550|NCT00748332|DIETARY_SUPPLEMENT|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
41351551|NCT01828463|DRUG|Nitisinone|doses 1, 2, 4 \& 8 mg plus no treatment arm
41492965|NCT04701112|DEVICE|Temporary His bundle pacing|"Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration."
41492966|NCT03632863|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic PDA is an interactive website with 3 main sections:~1. Review of depression treatment options (non-pharmacological and pharmacological) along with their respective risks and benefits.~2. Interactive values clarification exercises to help women determine which risks and benefits are most important to them.~3. Exercises to help women consider how partners, family, providers and the social context impacts decision-making.~A summary of how a woman feels about each option along with risks and benefits is generated which can be provided to treating clinicians for use in follow-up.~A printable pdf with standard published information and resources is also included."
41492967|NCT03632863|BEHAVIORAL|Standard Resource Sheet|A control group aims to isolate the PDA's effects from time and clinical care. Controls login to the study website and receive the same printable pdf as in the PDA so that they can access standard publicly available information/resources, even if they will not receive the PDA.
41020608|NCT01827904|DEVICE|Sham Transcranial ExAblate|
41020609|NCT05951816|DRUG|99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.|Peptide p5+14 is a pan-amyloid reactive, synthetic 45 L-amino acid polypeptide with a net +12 positive charge that can bind two major components of all extracellular amyloid deposits: (i) hypersulfated heparan sulfate glycosaminoglycans (proteoglycans) and (ii) amyloid fibrils. The polypeptide, labeled with iodine-124, has been shown (study AMY1001) to bind amyloid in all organs including the heart. This study will evaluate a Tc-99m-labeled version of the peptide for gamma imaging.
41020610|NCT05951816|DRUG|99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.|99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine. 99mTC-PYP imaging is used clinically for the diagnosis of cardiac ATTR amyloidosis.
41020611|NCT00827372|DRUG|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
41020612|NCT02317640|DRUG|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
41020613|NCT02317640|OTHER|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
41020614|NCT02317640|DEVICE|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
41020615|NCT03435094|DRUG|Binosto 70Mg Effervescent Tablet|Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.
41020616|NCT03435094|DRUG|Fosamax 70Mg Tablet|Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.
41020617|NCT05729022|DEVICE|Ultrasound microendoscopic technique|Ultrasound-guided microendoscopic lumbar transforaminal epidural steroid injection
41020618|NCT05729022|RADIATION|Fluoroscopy|Fluoroscopy-guided lumbar transforaminal epidural steroid injection.
41020619|NCT01271881|OTHER|PTA alone without use of the GORE VIABAHN|PTA alone with no stent used
41020620|NCT01271881|DEVICE|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|Covered stent produced by GORE VIABAHN
41020621|NCT01105247|DRUG|PCI-32765|420 mg daily or 840 mg daily
41020622|NCT01813604|BIOLOGICAL|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
41020623|NCT01813604|BIOLOGICAL|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
41020624|NCT01813604|BIOLOGICAL|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
41159288|NCT03229356|OTHER|BPA + Enhanced Education|BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
41159289|NCT03081351|PROCEDURE|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
41159290|NCT03081351|PROCEDURE|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
41159291|NCT06194786|BEHAVIORAL|Group D|Usual care
41159292|NCT04443881|DRUG|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra (100 mg/ 6 hours) i.v infusión during 15 days
41159293|NCT00405002|PROCEDURE|Helium dilution technique, lung CT scan|Helium dilution technique and lung CT scan
40832660|NCT04410744|DIAGNOSTIC_TEST|Ultrasonographic examination|All clinical examinations (physical exam) and ultrasounds are performed by a single surgeon and a single radiology resident supervised by the same abdominal radiology consultant, respectively.
40832661|NCT04945967|PROCEDURE|New Method|Physiological flexion in therapeutic positioning, oral stimulation, stimulation of synergistic movements, and stimulation for non-nutritive sucking by using special designed pacifier for premature infant.
40832662|NCT04945967|PROCEDURE|Conventional Method|Oral stimulation and non-nutritive sucking stimulation using usual pacifier.
41159294|NCT04624399|DRUG|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
40832663|NCT02836873|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
40832664|NCT02836873|DRUG|Placebo|Placebo (inactive) tablet to match the active comparator
40832665|NCT02698904|BEHAVIORAL|Guided Relaxation Technique|
41159295|NCT02298855|BEHAVIORAL|Individualised follow-up|Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
41159296|NCT01498523|OTHER|Camel milk|600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
41159297|NCT01498523|OTHER|camel milk powder solution|72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
41492968|NCT01568138|DEVICE|PliCath HF System|To evaluate the safety and feasibility of the BioVentrix PliCath HF Epicardial Catheter-based Ventricular Reduction (ECVR) System for left ventricular (LV) volume reduction in heart failure (HF). The System utilizes anchors that are implanted into the scarred portion of the heart, rendering the ventricle smaller.
40832666|NCT02698904|OTHER|Documentary Movie|
40832667|NCT01344629|DRUG|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
40832668|NCT01344629|DRUG|Telmisartan|Telmisartan 80 mg tablet
40832669|NCT01344629|DRUG|Amlodipin|Amlodipin 5mg tablet
40832670|NCT04907435|PROCEDURE|simultaneous operations|simultaneous operations
40832671|NCT02009293|OTHER|Cough monitor|questionnaires about cough and quality of life
40832672|NCT05236712|BEHAVIORAL|Mobile app|The app sends reminder 'push' notifications to complete weekly surveys. The survey is a series of questions about foods and drinks participants had in the last week. Once the weekly survey is completed the app generates a personalized weekly report showing foods we encourage participants to eat more of, eat less of, or keep eating the same amount of. The app will also show menu recommendations for breakfast, lunch, dinner, and snacks that will help participants to eat healthier. Finally, the app also has a feature that allows chatting with the research team by sending and receiving in-app texts.
41159298|NCT01498523|OTHER|raw cow milk|50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
41159299|NCT01498523|OTHER|Glucose solution|25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
41159300|NCT00581009|OTHER|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
41159301|NCT00581009|DRUG|sertraline, lithium|"Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks."
41159302|NCT00581009|RADIATION|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
41159303|NCT03845335|DEVICE|dental implant-supported restoration|During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
41159304|NCT00068835|BEHAVIORAL|Lindamood-Bell training for dyslexia|
41159305|NCT05204472|DEVICE|Burst DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -\> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
41159306|NCT05204472|DEVICE|Tonic DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -\> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
41159307|NCT05116085|DRUG|Tislelizumab|Administered intravenously
41159308|NCT01591668|DRUG|Single Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
41159309|NCT01591668|DRUG|Multiple Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
41159310|NCT06639698|DIETARY_SUPPLEMENT|Diosgenin|Patients will take a tablet containing diosgenin (120 mg), alpha-lactalbumin (100 mg) and vitamin D (50 mcg) - two times per day for six months
41159311|NCT04373356|DEVICE|Resin Infiltration|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with a rubber dam and ICON will be applied following the manufacturer's instructions. After that, the rubber dam will be removed and 5% NaF Varnish will be applied.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
41159312|NCT04373356|DEVICE|Sodium Fluoride Varnish|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with cotton roll and 5% NaF varnish will be applied following the manufacturer's instructions.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
40832673|NCT04333056|OTHER|Biometric measurement agreement|Patients scheduled for cataract surgery were measured with both ss-OCT devices. The following biometry parameters were compared: anterior keratometry, central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT) and axial length (AL).
41159313|NCT06646913|DEVICE|Transcutaneous Electrical Nerve Stimulation|Patients will utilize the TENS device for 45 minutes, two times per day for the 4 week treatment period.
41159314|NCT04877132|DRUG|olipudase alfa (GZ402665)|Patients will receive intravenous (IV) infusion of olipudase alfa
41159315|NCT00136175|DRUG|Paclitaxel|
41159316|NCT00136175|DRUG|Carboplatin|
40832674|NCT06346249|OTHER|Electrical Stimulation Therapy|Ten Electrical Stimulation Therapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
41159317|NCT00136175|DRUG|Gemcitabine|
41159318|NCT06404073|BEHAVIORAL|Structured Pacing|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
41159319|NCT06404073|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
41159320|NCT04436484|DIAGNOSTIC_TEST|Peripheral blood sampling|Non-interventional study
41159321|NCT05343819|DRUG|AON-D21|AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
41159322|NCT05343819|DRUG|Placebo|Isotonic glucose solution identical in appearance to AON-D21.
41159323|NCT06505239|DIETARY_SUPPLEMENT|FSD-F2R6-A-CP|FSD-F2R6-A-CP is a unique dietary supplement with natural ingredients, vitamins and minerals that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism and may accelerate alcohol metabolism in the body.
41159324|NCT06505239|DIETARY_SUPPLEMENT|Placebo|Placebo drink designed to match FSD-F2R6-A-CP in color and taste.
41159325|NCT02791126|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
41159326|NCT02791126|OTHER|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
41159327|NCT01613183|DRUG|Chinese herbal Medicine|The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
41159328|NCT01613183|OTHER|the dummy of a Chinese Medicine prescription|Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
41159329|NCT03390933|DRUG|Fluoxetine|Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
40832675|NCT06346249|OTHER|Manual Therapy|Manual Therapy consistin of soft tissue mobilization and release techniques over the neck and craniocervical regions. Ten sessions.
41159330|NCT05657275|DIAGNOSTIC_TEST|CRP dosage|multimodal algorithm
41159331|NCT05657275|DIAGNOSTIC_TEST|multiplex PCR|multimodal algorithm
41159332|NCT05657275|DIAGNOSTIC_TEST|chest scan without injection|multimodal algorithm
41159333|NCT06646432|PROCEDURE|Tunnel with connective tissue graft and injectable platelet rich fibrin|Tunnel with connective tissue graft and injectable platelet rich fibrin
41159334|NCT06646432|PROCEDURE|Tunnel with connective tissue graft only|Tunnel technique with connective tossue graft only without injectable platelet rich fibrin
41159335|NCT03696732|OTHER|Anxiety questionnaire|Spielberger. State-Trait Inventory questionnaire
41351552|NCT00698139|DEVICE|Medtronic Pacemaker|Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
41351553|NCT01702402|BEHAVIORAL|Educational and Behavior Change intervention|"Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM."
40832676|NCT06346249|OTHER|Exercise Therapeutic|The exercise therapeutic program consisting of neck movement control and stretching exercise. Ten sessions.
40832677|NCT03123614|DRUG|Loteprednol Etabonate 0.5% Oph Gel|
40832678|NCT03123614|DRUG|Prednisolone Acetate 1% Oph Susp|
40832679|NCT00918268|BIOLOGICAL|Influenza vaccine|One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
41351554|NCT01702402|OTHER|Comparison Group|A comparison area received standard government health services.
41351555|NCT00000995|DRUG|Zidovudine|
41351556|NCT00000995|DRUG|Ganciclovir|
41351557|NCT01077310|DRUG|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
41351558|NCT01077310|DRUG|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
41351559|NCT00631969|DRUG|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
41351560|NCT00631969|DRUG|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
41351561|NCT00000231|DRUG|Buprenorphine|
40832680|NCT02723890|DEVICE|Tyto Device|
40832681|NCT03550404|BEHAVIORAL|Seasons of Care App|A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
40832682|NCT03800914|OTHER|High intensity interval training|36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling
40832683|NCT03800914|OTHER|Traditional pulmonary rehabilitation|30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
40832684|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram \[mcg\]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
40832685|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
40832686|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
41351562|NCT05412693|DEVICE|Functional orthosis|See arm descriptions
41351563|NCT05412693|DEVICE|Cast immobilization|See arm descriptions
41159336|NCT03696732|OTHER|VAS questionnaire|verbal numerical scale (VNS) anxiety score
41351564|NCT05516615|OTHER|4 minute breathing maneuver|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.
41351565|NCT02159001|DEVICE|electroconvulsive therapy|10-course, three times a week bilateral frontotemporal ECT
41351566|NCT02411994|DRUG|Pyronaridine-artesunate|
41351567|NCT02411994|DRUG|Artemether-lumefantrine combination|
41159337|NCT06645561|PROCEDURE|X-ray|defined radiographic semiological criteria to determine an analytical methodology to facilitate the dating of long bone fractures of infants under one year of age
41351568|NCT04615728|PROCEDURE|laparoscopic or open appendicectomy|Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
40832687|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
41492969|NCT04314414|OTHER|PRC brief motivational interview intervention|The intervention will involve the following elements: establishing rapport, asking permission to discuss drugs, discussing the pros and cons associated with drug use, uncovering the gaps between current and desired quality of life and determining readiness to change. The intervention will last approximately 20 minutes and take place at the time of the clinical visit while participants are waiting to be seen by a clinician or are awaiting laboratory testing.
41492970|NCT04314414|OTHER|Phone contact|The PRC will remain in at least weekly contact by phone with each participant.
41159338|NCT01770314|BEHAVIORAL|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
41159339|NCT01729091|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
41492971|NCT05342701|BEHAVIORAL|Motor Skills Intervention|"The behavioral motor skill intervention (CHAMP) is an intervention strategy that uniquely address differences in children's development. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to development improvement in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP consists of 35 minutes/day X 3-4 days/week for 19 weeks (dose of 1995 - 2240 minutes). Each session will consist of three parts: (a) 3-5 min of motor skill introductory activity, (b) 25 min of motor skill instruction and practice, and (c) 3-5 min motor skill closure activity."
40832688|NCT02546960|BIOLOGICAL|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
41159340|NCT01729091|BIOLOGICAL|Elotuzumab|Given IV
41159341|NCT01729091|OTHER|Laboratory Biomarker Analysis|Correlative studies
41159342|NCT01729091|DRUG|Lenalidomide|Given PO
41159343|NCT01729091|DRUG|Melphalan|Given IV
41159344|NCT01729091|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
41159345|NCT01729091|BIOLOGICAL|Umbilical Cord Blood-Derived Lymphocyte Therapy|Given IV
41492972|NCT05950230|DIAGNOSTIC_TEST|Assess Periodontal Health Status|"For all patients who are suitable for the study, the following clinical evaluation parameters will be recorded:~* Plaque index (PI)(Silness and Löe, 1964).~* Sulcus bleeding index(BOP)(Perez et al., 2008).~* Probing depth (PD) (Polson et al., 1980).~* Clinical attachment level (CAL) (Glavind and Löe, 1967).~* Standardized Periapical Radiograph."
40832689|NCT02546960|DRUG|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
40832690|NCT03285958|BEHAVIORAL|STEPS Intervention|Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
40832691|NCT01231815|RADIATION|15O-H2O PET -|Assessment of coronary reserve using PET
40832692|NCT01231815|RADIATION|MRI|Assessment of coronary reserve using MRI
40832693|NCT00215215|DEVICE|Vagus Nerve Stimulation Therapy|
40832694|NCT01347255|DRUG|LEO90100 cutaneous spray, ointment|once daily application, 4 weeks
40832695|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate|once daily application, 4 weeks
40832696|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle|once daily application, 4 weeks
40832697|NCT01347255|DRUG|Daivobet® ointment|once daily application, 4 weeks
40832698|NCT03452826|DEVICE|Antibiotic therapy according to the result of mPCR (device)|"* Phone call at D28 and D90, unless the patient is still hospitalized;~* Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~* Collection of an additional respiratory tract sample for biological banking in both arms."
41020625|NCT01813604|BIOLOGICAL|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
41020626|NCT01813604|BIOLOGICAL|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
41351569|NCT06077123|DEVICE|Contigo Application|Contigo, a smartphone application, aims to achieve two main objectives: monitoring cancer patients for early detection of oncology drug toxicity signs and providing educational content to empower patients in handling clinical challenges tied to their diagnosis and treatment. Monitoring involves modules and sub-modules where patients input experiences through oncology-related questionnaires. Weekly checks for chemotherapy toxicity-associated symptoms use a validated questionnaire (PRO-CTCAE). Severe toxicity triggers immediate alerts, while milder cases receive educational guidance. Data collected is shared with healthcare providers. Educational health content has been created by professionals, encompassing cancer-specific topics, healthcare processes, administration, health coverage, self-awareness, and self-care practices. The content is based on scientific evidence, official reports, and group sessions involving healthcare professionals and cancer patients.
41351570|NCT05607446|DRUG|TQC3564 tablets|TQC3564 tablets are CRTH2 antagonists.
41351571|NCT05607446|DRUG|Placebo tablets|The intervention drug is placebo.
41351572|NCT05607446|DRUG|TQC3564 tablets, montelukast sodium tablets|The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.
41351573|NCT05607446|DRUG|Placebo tablets, montelukast sodium tablets|The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.
41351574|NCT01430364|DEVICE|BIOSS LIM implantation|BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
41351575|NCT01430364|DEVICE|BIOSS Lim|
41351576|NCT01430364|DEVICE|CarloS|
41351577|NCT04543656|BEHAVIORAL|AI-Based Lifestyle Recommendations|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
41351578|NCT04543656|OTHER|No Lifestyle Recommendations|The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
41351579|NCT05495009|OTHER|Standard of care+virtual reality glasses|At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
41351580|NCT03109535|BEHAVIORAL|Fitbit + Maptrek|Users receive a Fitbit Zip to wear daily. Users aslo receive the mHealth MapTrek game that places users in weekly walking races and sends automated text messages to users on a daily basis for the purpose of increasing daily physical activity.
41351581|NCT03109535|BEHAVIORAL|Fitbit only|Users receive a Fitbit Zip to wear daily.
41351582|NCT02840903|DRUG|Iopromide (Ultravist, BAY86-4877)|8 settings for CT Angiography as described in group description.
41351583|NCT02062099|DRUG|[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment|
41351584|NCT01149161|PROCEDURE|Routine central neck dissection|Level VI neck node dissection during thyroid operation
41351585|NCT06432361|BEHAVIORAL|Resource Allocation|Those in the intervention condition will receive weekly personalized information summarizing the previous week's resource allocation (e.g., personalized information on how they spent their time and money) in relation to their personal goals, interests, and alcohol use. They will also see a summary of how they spent their time and money in relation to their set goals for the week The information in the intervention feedback will be obtained from participant's responses to the daily surveys on how they spent their time and money each day. Reviewing the intervention feedback should take no longer than 10 minutes.
41020627|NCT05495750|DRUG|Bupivacaine 0.25% Injectable Solution|ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg.
41351586|NCT06432361|OTHER|assessment only control|participants will complete a 3 week monitoring period of daily surveys assessing time spent in various domains during the time, alcohol use, personal goals, and money spent on alcohol and substance-free activities. Each daily survey should take no longer than 5 minutes to complete.
40832699|NCT03785951|DIETARY_SUPPLEMENT|Whey Protein Isolate|"Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
40832700|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein|"Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
41020628|NCT01522859|DEVICE|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
41159346|NCT06625645|COMBINATION_PRODUCT|Modified triple antibiotic paste (TAP) mixed with chlorehexidine|M-TAP with CHX 2%
41351587|NCT03631849|PROCEDURE|peri implantitis sanitation surgery|"an intrasulcular vestibular and lingual / palatal incision with respect to the implant-supported restoration involved is performed, it extends to at least one tooth on either side in order to give laxity to the flap. The use of an incision of discharge will be necessary if the muco-periosteal detachment of the flap (that is to say of full thickness) is considered insufficient to access and unclamp the peri-implant lesion.~Then, the debridement will be carried out using manual curettes in titanium: the products (waste) removed with this curette will constitute the peri-implant pocket specimens. This sample will be deposited in a Roswell Park Memorial Institute Medium (RPMI) supplemented with serum.The surface of the titanium implant will then be disinfected with betadine, or with hydrogen peroxide for patients with an allergy to polyvidone iodine.~The flap will then be repositioned and sutured with simple stitches made with a resorbable suture of Vicryl type 5.0."
41351588|NCT03631849|OTHER|Care|descaling and maintenance of implants
41351589|NCT03842761|DRUG|BI 685509|Tablet
41351590|NCT03842761|DRUG|Placebo|Tablet
41351591|NCT00939146|OTHER|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
41351592|NCT00939146|OTHER|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
41351593|NCT01351714|PROCEDURE|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
41492973|NCT05950230|OTHER|Collecte GCF samples by paperstrip|GCF samples will be collected from all participating individuals to assess the levels of MMP-8 from the deepest periodontal pocket in the area. The sample areas will be insulated with cotton rolls, saliva contamination will be prevented, all supragingival plaque will be eliminated. The paper strips will placed into the periodontal pocket until resistance is felt and then permitted to remain for 30s(Offenbacher et al., 1984, Megson et al., 2010).
41492974|NCT03283319|BIOLOGICAL|3.75 ug Panblok H7|0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
41492975|NCT03283319|BIOLOGICAL|7.5 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
41020629|NCT02848118|DEVICE|A nasal-oral cannula of capnography|After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.
41020630|NCT02848118|OTHER|Observer Assessment of Alertness and Sedation scale|After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.
41159347|NCT06625645|COMBINATION_PRODUCT|Modified Triple Antibiotic Paste mixed with saline|M-TAP mixed with saline
41159348|NCT06625645|COMBINATION_PRODUCT|Calcium Hydroxide mixed with chlorohexidine Intracanal medication|calcium hydroxide powder mixed with CHX 2% solution as intracanal medication
41159349|NCT06625645|COMBINATION_PRODUCT|calcium hydroxide mixed with saline as intracanal medication|calcium hydroxide mixed with saline as intracanal medication for necrotic primary molars
41351594|NCT02615561|DEVICE|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
41351595|NCT02615561|OTHER|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
41351596|NCT02615561|OTHER|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
41492976|NCT03283319|BIOLOGICAL|15 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
41492977|NCT03283319|BIOLOGICAL|MF59|0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
41492978|NCT03283319|BIOLOGICAL|AS03|0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
41492979|NCT05490290|OTHER|Active|In the active intervention condition, decision support is provided during the referral procedure of medical imaging exams.
40832701|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein with Leucine|"Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks."
40832702|NCT02421263|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
41159350|NCT05501665|PROCEDURE|Biospecimen Collection|Correlative studies
41159351|NCT05501665|DRUG|Carboplatin|Given carboplatin
40832703|NCT06187025|OTHER|Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)|Standardized clinical evaluations and screening of substance use using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST)
41159352|NCT05501665|PROCEDURE|Computed Tomography|Undergo PET/CT
41159353|NCT05501665|OTHER|Fludeoxyglucose F-18|Given IV
41159354|NCT05501665|DRUG|Nab-paclitaxel|Given nab-paclitaxel
41159355|NCT05501665|BIOLOGICAL|Pembrolizumab|Given pembrolizumab
41351597|NCT04340687|DEVICE|Pancreatic duct stenting|A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice
41351598|NCT05265494|DEVICE|Non invasive neuromodulation NESA (XSIGNAL device)|"The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions).~• The skin must be clean, free of creams and grease, lectrodes are connected to the control console and the targeting electrode located in over the intervertebral area between C7 and T1 (cervical area) and will follow the central treatment pattern with the following combination:~* 2 sessions: Program 1 (30 min), Program 7 (15min) and Program 8 (15min).~* 4 sessions: Program 2 (15min), Program 7 (30 min) and Program 8 (15min)~* 4 sessions: Program 7 (60min)"
41351599|NCT00840684|DRUG|amsacrine|
41351600|NCT00840684|DRUG|busulfan|
41351601|NCT00840684|DRUG|cytarabine|
41492980|NCT00469144|DRUG|Busulfan|"Fixed Dose = 130 mg/m\^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m\^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%."
41492981|NCT00469144|DRUG|Fludarabine|40 mg/m\^2 IV Daily Over 1 Hour x 4 Days
41492982|NCT02827838|BIOLOGICAL|Durvalumab|Given IV
41492983|NCT02827838|OTHER|Laboratory Biomarker Analysis|Correlative studies
41492984|NCT02827838|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
40832704|NCT06187025|OTHER|Ecological Momentary Assessment (EMA)|Daily EMA evaluations during 12 weeks
41159356|NCT05501665|DRUG|Pemetrexed|Given pemetrexed
41159357|NCT05501665|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41159358|NCT05501665|RADIATION|Radiation Therapy|Undergo radiation therapy
41159359|NCT05501665|OTHER|[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan|Undergo PET scan
41159360|NCT05501665|BIOLOGICAL|Ipilimumab|Given Ipilimumab
40832705|NCT02471768|PROCEDURE|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
40832706|NCT02295241|OTHER|No intervention|This is an observational trial, no interventions are being used.
40832707|NCT03504813|OTHER|Physical activities program|To implement this line, the protocol of the VIVIFRAIL Project will be used as a reference. That protocol has different physical exercises, divided into itineraries, in order to adapt it to a person's capability. Several sessions of this research line will employ the use of videogames so that the elderly can explore new forms of physical activity and thus establish contact and expertise with new technologies. It is estimated that two sessions per week over two months are needed for each person to continue doing physical activity independently and with autonomy.
41159361|NCT05501665|BIOLOGICAL|Nivolumab|Given Nivolumab
41159362|NCT05501665|BIOLOGICAL|Cemiplimab|Given Cemiplimab
41159363|NCT05501665|BIOLOGICAL|Atezolizumab|Given Atezolizumab
41159364|NCT06645795|COMBINATION_PRODUCT|Robot assisted gait training plus conventional physical therapy|Participants will complete 8 weeks of intervention of robot assisted gait training with the ATLAS 2030 exoskeleton (Marsi Bionics) owned by the school which they attend to. They will have 2 weekly sessions (16 sessions in total) for 4 weeks. Each session will last up to 1 hour (depending on the child's tolerance) although a minimum of 30 minutes per session and a minimum of 12 sessions will be set in this time. The training mode will be automatic. In addition, they will continue to carry out the rest of their usual treatments.
41351602|NCT00840684|DRUG|daunorubicin hydrochloride|
41351603|NCT00840684|DRUG|laromustine|
41351604|NCT00840684|DRUG|melphalan|
41351605|NCT00840684|DRUG|mitoxantrone hydrochloride|
41351606|NCT00840684|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41351607|NCT00840684|PROCEDURE|autologous hematopoietic stem cell transplantation|
41351608|NCT05759949|DRUG|RLY-5836|RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.
41351609|NCT05759949|DRUG|Fulvestrant|Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.
41351610|NCT05759949|DRUG|Palbociclib|Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
41351611|NCT05759949|DRUG|Ribociclib|Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
41351612|NCT05759949|DRUG|Abemaciclib|Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
41492985|NCT00191113|DRUG|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
41492986|NCT00191113|DRUG|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
41492987|NCT00191113|DRUG|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
40832708|NCT03504813|OTHER|Relaxation training|Will take place with those participants who are included in the research lines of insomnia and risk of falls. It is estimated that two sessions per week for one month are needed.
40832709|NCT03504813|OTHER|Training of the pelvic floor|the intervention will apply to participants enrolled in the research line dealing with urinary incontinence during the six months of intervention, with a frequency of two sessions per week
40832710|NCT03504813|BEHAVIORAL|Counseling about occupational performance|After the physical activity and relaxation programs, the counselling will start. With each participant, routines and daily activities will be planned that will be adequate according to different recommendations about urinary incontinence, insomnia and risk of falls. Different performance guidelines will be established in order to establish a good balance between activities. The guidelines can include the recommendations about adjustments to the environment. It is estimated that three sessions per week for two months are needed to incorporate advice and routines into the daily lives of participants.
40832711|NCT04024904|DEVICE|OncomfortTM device|The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
40832712|NCT02247180|BEHAVIORAL|cognitive rehabilitation|
40832713|NCT02247180|BEHAVIORAL|standardized cognitive training|
40832714|NCT05053412|DIAGNOSTIC_TEST|Helio Liver Test|A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.
40832715|NCT00973102|DRUG|Premarin IV|One time dose of Premarin IV
40832716|NCT00973102|DRUG|Placebo|One time dose of placebo.
40832717|NCT00686842|DRUG|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
40832718|NCT00686842|GENETIC|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
40832719|NCT00686842|GENETIC|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
40832720|NCT00686842|GENETIC|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
40832721|NCT00686842|OTHER|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
41351613|NCT04905563|DRUG|Acetaminophen-Hydrocodone|Narcotic
41351614|NCT04905563|DRUG|Acetaminophen and Ibuprofen|Non-narcotic
41351615|NCT05986890|PROCEDURE|Roux-en-Y Bypass|laparoscopic Roux-en-Y
41351616|NCT05986890|PROCEDURE|gastrojejunostomy|surgical gastrojejunostomy
41351617|NCT03114462|RADIATION|Stereotactic Hypofractionated Radioablation|Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
41351618|NCT03114462|BEHAVIORAL|Questionnaires|Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
41351619|NCT01238276|DRUG|Cefazolin|Cefazolin is approved for clinical use for some bacterial infections. The standard routes of administration are Intramuscular (IM) and intravenous (IV). For this study, the route of administration will be delivered using the Silberg TPS, which delivers the cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The concentration delivered is one gram/100 ml saline. Cefazolin can safely be given IM at the much higher concentration of 1 gram/2.5 ml of saline. The maximum dose that may be administered is 3 grams in 300 ml, which is within the approved guidelines of a daily dose. The concentration of antibiotic will be the same; only the dose may vary depending on the size of the wound or area of induration. Each subject will receive only one treatment in this study.
41351620|NCT01238276|DEVICE|Silberg Tissue Preparation System|The TPS is FDA cleared for the subcutaneous infusion and ultrasonic dispersion of tumescent fluid excluding the parenteral delivery of drugs. Under this study, the TPS is a device to deliver cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The TPS consists of a medical grade peristaltic pump that is used to infuse antibiotic solution using a sterile blunt-tipped infusion cannula into a superficial subcutaneous plane. After the cannula has been removed, high frequency external ultrasound is delivered transcutaneously over the area of infusion in order to disperse the antibiotic solution. The power density is within the range allowed for physical therapy.
41351621|NCT03323385|DRUG|N1539|Once Daily
41492988|NCT00967044|DRUG|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
41492989|NCT00967044|DRUG|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
41351622|NCT03323385|DRUG|Placebo|Once Daily
41351623|NCT00898690|GENETIC|cytogenetic analysis|
41351624|NCT00898690|GENETIC|gene expression analysis|
41351625|NCT00898690|GENETIC|microarray analysis|
41492990|NCT03256279|DEVICE|".014 NiTi heat-activated archwire"|".014 NiTi heat-activated archwire In the lower arch during the first three months of the orthodonci treatment"
40832722|NCT00686842|OTHER|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
40832723|NCT00686842|OTHER|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
40832724|NCT00686842|PROCEDURE|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
41351626|NCT00898690|GENETIC|mutation analysis|
41159365|NCT06645795|OTHER|Conventional pjysical therapy|Participants will complete 8 weeks of conventional therapy, with 2 sessions per week (16 sessions total). During the conventional treatment period, participants will continue with the conventional physical therapy they have received thus far. The content of the usual care treatment does not specifically address gait training, but consists of elements addressing range of motion, tone reduction, balance, activities of daily living, etc. The conventional intervention may be different for each individual based on their needs (to represent usual care), however, participants will be advised not to change the intervention, type, and frequency during the study.
40832725|NCT00576030|OTHER|hab cof with water|habitual coffee drinker provided with water
41159368|NCT06155487|DRUG|AJH-2947 100 mg (SAD)|Oral Tablet, Single dose of AJH-2947 100 mg
41351627|NCT00898690|GENETIC|reverse transcriptase-polymerase chain reaction|
41351628|NCT00898690|OTHER|immunohistochemistry staining method|
41351629|NCT00190606|DRUG|Duloxetine|
41492991|NCT03256279|DEVICE|".014 NiTi Superelastic archwire"|".014 NiTi superelastic archwireIn the lower arch during the first three months of the orthodonci treatment"
41159369|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 100 mg
41351630|NCT00190606|PROCEDURE|Pelvic Floor Muscle Training (PFMT)|
41351631|NCT00190606|PROCEDURE|Imitation PFMT|
41351632|NCT00190606|DRUG|placebo|
41351633|NCT05840627|OTHER|Fruit juice|Daily consumption of 200 mL of fruit juice at lunch for 14 consecutive days, provided by the research team.
41351634|NCT03519776|DIAGNOSTIC_TEST|Progesterone variation|The potential gain for medical caretakers and patients would be a certainty if the progesterone level is affected by variations during daytime
41351635|NCT02983695|DRUG|TIL-TC150|The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
41492992|NCT00923273|DRUG|FDG-PET|PET CT will be performed at baseline and after two cycles of treatment.
41492993|NCT00923273|DRUG|Pemetrexed|
41492994|NCT00923273|DRUG|Sirolimus|
41492995|NCT00923273|DIETARY_SUPPLEMENT|Vitamin B12|1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed
41492996|NCT00923273|DIETARY_SUPPLEMENT|Folic acid tablets|1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.
40832726|NCT00576030|OTHER|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
40832727|NCT00576030|OTHER|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
40832728|NCT00576030|OTHER|non-hab cof with water|non-habitual coffee drinkers given water
40832729|NCT00576030|OTHER|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
40832730|NCT00576030|OTHER|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
41492997|NCT00923273|DRUG|Dexamethasone tablets|4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
41492998|NCT06021535|OTHER|No intervention|No intervention
40832731|NCT01683513|DRUG|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
40832732|NCT00392808|BIOLOGICAL|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
40832733|NCT01672099|DIETARY_SUPPLEMENT|nutrient enriched product|The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
40832734|NCT01672099|DIETARY_SUPPLEMENT|basic dairy product|The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
41492999|NCT04987697|BEHAVIORAL|counseling|nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
41159370|NCT06155487|DRUG|AJH-2947 200 mg (SAD)|Oral Tablet, Single dose of AJH-2947 200 mg
41159371|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 200 mg
41159372|NCT06155487|DRUG|AJH-2947 300 mg (SAD)|Oral Tablet, Single dose of AJH-2947 300 mg
41159373|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 300 mg
41159374|NCT06155487|DRUG|AJH-2947 400 mg (SAD)|Oral Tablet, Single dose of AJH-2947 400 mg
41159375|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 400 mg
41351636|NCT00572663|DRUG|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
41351637|NCT02289118|DRUG|[18F]-T807 imaging tracer|Tau Imaging tracer
41351638|NCT02239562|DRUG|sPIF|
41351639|NCT02239562|DRUG|Placebo|
40832735|NCT00951249|BEHAVIORAL|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
41351640|NCT05191615|BEHAVIORAL|Job crafting training|"Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work.~In the second part of the intervention, participants will have the opportunity to discuss their current health status and receive preventive health recommendations from a preventive care specialist."
40832736|NCT00951249|BEHAVIORAL|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
40832737|NCT00951249|BEHAVIORAL|Peer health care system navigators|HIV/STI treatment and other medical and social services
40832738|NCT00951249|BEHAVIORAL|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
40832739|NCT00002055|DRUG|Pentamidine isethionate|
41159376|NCT06155487|DRUG|AJH-2947 600 mg (SAD)|Oral Tablet, Single dose of AJH-2947 600 mg
41159377|NCT06155487|DRUG|Placebo|Oral Tablet,Single dose of Placebo 600 mg
41159378|NCT06155487|DRUG|AJH-2947 800 mg (SAD)|Oral Tablet, Single dose of AJH-2947 800 mg
41159379|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 800 mg
41159380|NCT06155487|DRUG|AJH-2947 200 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg
41159381|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 200 mg
41159382|NCT06155487|DRUG|AJH-2947 400 mg (MAD)|Oral Tablet,Multiple (once daily for 7days) oral dose of AJH-2947 400 mg
41351641|NCT06305923|OTHER|colostrum cream|the intervention in our study is everyday using a cream with active ingridient
41351642|NCT06305923|OTHER|placebo cream|using a placebo cream
41351643|NCT02029365|OTHER|Autoquestionnary|autoquestionnary completed during the consultation for infertility
41351644|NCT02029365|OTHER|semi-structured interview|phone interview
40832740|NCT03286777|DIETARY_SUPPLEMENT|Placebo|Mannitol and silicon dioxide capsules
40832741|NCT03286777|DIETARY_SUPPLEMENT|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide capsules
40832742|NCT03286777|DIETARY_SUPPLEMENT|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
40832743|NCT04721340|OTHER|Test Group|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
41159383|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 400 mg
41159384|NCT06155487|DRUG|AJH-2947 600 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 600 mg
41159385|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 600 mg
41159386|NCT04095598|DIAGNOSTIC_TEST|Comparative Ankle Tomography with Stress Maneuvers|All diagnostic imaging exams and FAAM questionnaire will be applied in a standard way in both groups.
41159387|NCT04701528|DRUG|Voclosporin|Temporarily switching of tacrolimus maintenance immunosuppression to voclosporin maintenance immunosuppression with possible additional anti-viral activity
41159388|NCT04701528|DRUG|Tacrolimus|Comparator
41159389|NCT05954312|DRUG|VVD-130037|Oral tablets
41159390|NCT02062671|PROCEDURE|renal denervation|
41159391|NCT05668000|OTHER|Bluetooth-connected monitoring devices and a feedback system|"AIDA/KT-app with devices and feedback:~The mobile application provide self-management interventions with devices including sphygomanometer and body water meter and a feedback system"
41159392|NCT05668000|OTHER|Mobile application|The mobile application provide only self-management interventions.
40832744|NCT04721340|OTHER|Control Grup|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
40832745|NCT00572611|DRUG|[14C]-bilastine|Single oral dose of 20 mg \[14C\]-bilastine. 1 capsule. 1 day dosing only
40832746|NCT00313768|DRUG|paclitaxel + carboplatin + bevacizumab|paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
40832747|NCT00313768|DRUG|carboplatin + paclitaxel + bevacizumab + PF-3512676|carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
40832748|NCT02262104|BEHAVIORAL|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
40832749|NCT02262104|BEHAVIORAL|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
40832750|NCT00051220|BEHAVIORAL|One-Session Treatment for Specific Phobias|
40832751|NCT02798770|OTHER|No Intervention Foreseen|
40832752|NCT05143866|BEHAVIORAL|Cognitive behavioral therapy guided self help (CBTgsh)|Based on evidence based cognitive behavioral treatment for eating disorders. Self-help version described in self-help book. Participant follows self-help program with encouragement and support of a non specialist guide
40832753|NCT03294070|COMBINATION_PRODUCT|Fimasartan plus amlodipine besylate|Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
40832754|NCT05976464|DRUG|Magnesium sulfate in erector spinae plane block|"Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.~General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period.~BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery."
40832755|NCT00123773|PROCEDURE|Positron Emission Tomography|
40832756|NCT02677636|DRUG|MSRD-100|MSRD-100 is a topical gel.
40832757|NCT02677636|DRUG|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
40832758|NCT04402294|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will create individualized TMS targets using deep learning methods on task and resting fMRI data to target working memory augmentation. The individualized target will be stimulated in a subsequent fMRI scan involving working memory task performance interleaved with repetitive TMS (rTMS) delivered at a variety of stimulation frequencies. Based on activation readouts in response to rTMS, an optimal and sub-optimal brain state frequency to impact working memory performance will be selected for each participant. Participants will receive rTMS at each frequency separately for three days (six days total), with the order of frequency randomly assigned and counterbalanced. Following each three day protocol, another fMRI working memory readout will be conducted to support the targeting and frequency selection algorithms.
41159393|NCT06549699|OTHER|Medically Tailored Meal Program with Traditional Navajo Foods|Patients will receive medically-tailored meals incorporating local traditional Navajo foods
41159394|NCT06549699|OTHER|Usual Care|Usual care plus healthy recipes provided
41159395|NCT04491136|DRUG|ACEI/ARB|Oral ACE/ARB drug according to the investigator's discretion for the first 6 months in this study
41159396|NCT04491136|DRUG|ARNI|Oral sacubitril/valsartan at the dosage of investigators discretion, whit a target dose of 200mg bid for the next 6 months of this study
41351645|NCT04711395|DEVICE|measure the preoperative DLI、 SS-OCT image of the lens,、take photos of the anterior segment and self-scoring of the preoperative visual quality assessment scale.|subjects in the observation group and Healthy used iTrace ocular aberration analyzer（itracey Technologies）and IOL-Master 700 biometer to measure the preoperative DLI(Dysfunctional lens index) and SS-OCT image of the lens, and The researchers used the anterior segment slit lamp to take photos of the anterior segment of the subject's lens in a state of dilated pupils .and self-scoring of the preoperative visual quality assessment scale.
41351646|NCT04682795|DEVICE|Needle-free injector|Using needle-free injector as insulin carrier to treat T2DM
40832759|NCT01688843|DEVICE|INGEVITY lead|
41159397|NCT03643705|OTHER|Multi-component intervention|4 components as described
41351647|NCT04682795|DEVICE|Insulin pen|Using insulin pen as insulin carrier to treat T2DM
41351648|NCT01381731|DRUG|diquafosol tetrasodium ophthalmic solution 2%|opthalmic solution 2 drops in each eye QID
41351649|NCT01381731|DRUG|placebo|opthalmic solution 2 drops in each eye QID
40832760|NCT00430001|DRUG|docetaxel|
40832761|NCT00430001|DRUG|vinorelbine|
41020631|NCT01431768|DEVICE|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
41020632|NCT00003326|DRUG|paclitaxel|
41351650|NCT06307210|OTHER|inpatient rehabilitation|physiotherapy (strength and endurance training), occupational therapy and neuropsychological training
41159398|NCT03643705|OTHER|General prevention education|General education as described
41159399|NCT06575699|PROCEDURE|Rectus sheath block|bilateral rectus sheath block under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side deposited between the rectus abdomens muscle and the posterior rectus sheath.
41159400|NCT06575699|PROCEDURE|Thoracic Epidural Analgesia|Low thoracic Epidural Analgesia.
41020633|NCT05390502|BEHAVIORAL|manual monitoring and general education on use|Patients will receive a standard blood pressure monitor and education on how to use it. Data will be reported as part of usual care.
41159401|NCT06575699|DRUG|Liposomal bupivacaine|133 mg liposomal bupivacaine per side for rectus sheath block
41351651|NCT05951374|PROCEDURE|Madany triangle|"After dissection of the proximal part of the gallbladder from its bed and scarification of the cystic artery and its branches, the traction applied to the Hartman pouch created an angle between the skeletonized cystic duct and the skeletonized posterior surface of the GB (Fig. 3).~Also, this traction creates a dynamic triangle visualized from both the left and right sides according to the traction applied to the Hartman pouch to the right or left and the direction of the angled scope of the camera lens. From the left-side view, when right traction is applied to the Hartman pouch, it is bound laterally by the skeletonized proximal part of the cystic duct. Superiorly, it is bound by the posterior surface of the proximal part of the skeletonized gallbladder. It was bounded medially by an imaginary line between a point at the junction of the cystic duct with the CBD and a point at the anterior end of the dissected cystic plate (the Madany triangle)"
41351652|NCT01116128|DRUG|dasatinib|100 mg QD continuously (from day 1 to day 28)
41351653|NCT01116128|DRUG|melphalan|0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
41351654|NCT01116128|DRUG|prednisone|1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
41351655|NCT01357720|BIOLOGICAL|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
41351656|NCT01357720|BIOLOGICAL|Quinvaxem/Tritanrix|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
41351657|NCT03098576|OTHER|Matched targeted drug treatment|Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
41351658|NCT03098576|OTHER|Unmatched standard of care|"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
41351659|NCT03869632|DRUG|YL-13027|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
41351660|NCT05257668|OTHER|High Intensity Interval Exercise Training|High Intensity Interval Training Group
41493000|NCT03688438|DEVICE|Closed-Incision Negative-Pressure Therapy|A foam or gauze dressing is put directly on the wound. This foam acts as a filter to keep any large particles (such as blood clots or dead, sloughed off tissue) from clogging the vacuum system. A clear, occlusive, adhesive film covers and seals the dressing and wound, creating an airtight seal. A drainage tube leads from under the adhesive film and connects to a portable vacuum pump. This pump removes air pressure over the wound. The pump is programmed for strength of suction, amount of time it is to be applied and if it is to be intermittent or continuous. A chamber on the pump collects drainage and moisture is drawn away from the wound site.
41493001|NCT03972202|DIAGNOSTIC_TEST|MRI|Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
40832762|NCT00430001|DRUG|trastuzumab|
41351661|NCT05257668|OTHER|Moderate Intensity Exercise Training|Moderate Intensity Training Group
41159402|NCT06575699|DRUG|Bupivacaine Hydrochloride|20 mL bupivacaine 0.25% per side for rectus sheath block
41351662|NCT00414973|DRUG|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
41020634|NCT05390502|BEHAVIORAL|integrated monitoring and local wrap-around hypertension program|Patients will receive a standard blood pressure monitor and a local wrap-around hypertension program. Data will be sent directly to their participating health system.
41159403|NCT06575699|DRUG|Bupivacaine-Hydromorphone Cassette|Bupivacaine 0.625% with hydromorphone 10 mcg/ml for the epidural solution
41351663|NCT00414973|DRUG|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
41351664|NCT02311140|OTHER|nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms|
41159404|NCT02394925|DEVICE|Multifocal Test Contact lens|Used in a daily wear modality
41159405|NCT06072833|BEHAVIORAL|Patient Financial Education / Navigation|The investigator anticipates that this will include a baseline financial assessment and educational content, likely using a virtual platform. Participants will be connected with a PAF case manager. There will be monthly follow-ups to the participant for 6-months to address any financial concerns through additional counseling/navigation.
41159406|NCT01886391|BEHAVIORAL|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 \[5-min DBR\], 1 for week 2 \[10-min DBR\], 1 for weeks 3-8 \[15-min DBR\]), developed by the PI, to use to practice their deep breathing.
41159407|NCT03056755|DRUG|Alpelisib|300 mg of alpelisib film-coated tablets administered orally once daily
41159408|NCT03056755|DRUG|Fulvestrant|500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days
41159409|NCT03056755|DRUG|Letrozole|2.5 mg of letrozole film-coated tablets administered orally once daily
41493002|NCT03972202|DEVICE|TMS|Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.
41493003|NCT03972202|BEHAVIORAL|Speech-motor behavioral testing|Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
41493004|NCT00147953|DRUG|Rituximab|
41493005|NCT00147953|PROCEDURE|Total nodal irradiation|
41493006|NCT02677714|RADIATION|99mTc-rhAnnexin V-128|Kit for the preparation of 99mTc-rhAnnexin V-128
41159410|NCT03056755|DRUG|Goserelin|3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.
41351665|NCT03656146|OTHER|Food Insecurity Screening Tablet|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
41493007|NCT00721630|DRUG|capecitabine, lapatinib|Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
41493008|NCT05227911|PROCEDURE|Abdominal Surgery|Abdominal surgery (laparotomy or laparoscopy) ,which includes proper inspection of the abdominal cavity.
41493009|NCT02330536|DEVICE|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
41020635|NCT01132079|DRUG|cream treatment|
41020636|NCT05040763|DIAGNOSTIC_TEST|Buccal Swabc- Copan flocked swab|All participants will have a buccal swab sampled collected from the inside of the mouth either by themselves or by their caregiver
41020637|NCT05040763|DIAGNOSTIC_TEST|Standard of Care COVID-19 swab|All participants will receive a standard of care COVID-19 swab collected by a qualified healthcare professional
41020638|NCT01895894|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 20\~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
41159411|NCT03056755|DRUG|Leuprolide|7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.
41159412|NCT02598934|DRUG|Ibandronate|Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
41351666|NCT03656146|OTHER|Food Insecurity Screening Verbal|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
41351667|NCT03703661|PROCEDURE|Needle-Aspirated Negative Pressure Dressing|dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure
41351668|NCT03703661|PROCEDURE|Control|dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
41351669|NCT06355206|COMBINATION_PRODUCT|endoscopic intervention, surgery or conservative treatment|Personal information and treatment of the enrolled subjects will be collected.
41351670|NCT00231491|DRUG|Botulinum Toxin A (Botox )|
41351671|NCT00302575|BEHAVIORAL|Collaborative Behavioral Management|
41351672|NCT00302575|PROCEDURE|Integrated parole and outpatient addiction treatment|
41351673|NCT03441399|OTHER|Financial incentives|Providing money for taking antidepressant medication
41351674|NCT04048876|DRUG|CC-90001|oral
41509132|NCT03280381|OTHER|Nifty feeding cup|The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
41351675|NCT04048876|DRUG|Placebo|oral
41351676|NCT03960593|OTHER|Evaluation of the influence of geriatric factors|Follow-up of patients\> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients\> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.
41351677|NCT03773068|DRUG|BAY1817080 - Formulation A|Formulation A
41351678|NCT03773068|DRUG|BAY1817080 - Formulation B|Formulation B
41351679|NCT03773068|DRUG|[13C715N]-BAY 181708 stable isotope label (SIL)|0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
41351680|NCT03075930|DEVICE|Extended Electrocardiogram|ECG with 3 additional leads and a 5 minute recording
41351681|NCT03075930|DEVICE|Body surface potential map|ECG with 184 leads and a 5 minute recording
41351682|NCT01513694|PROCEDURE|Instrumented posterolateral arthrodesis|"Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery."
40832763|NCT03291262|OTHER|Follow up for death and recurrence|Patients are followed up to determine the specific date of diagnosis, recurrence and death.
40832764|NCT00167180|PROCEDURE|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg
40832765|NCT00167180|DRUG|Induction Chemotherapy|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
40832766|NCT00737594|DRUG|Placebo|Matching placebo capsules for oral administration
40832767|NCT00737594|DRUG|Cobiprostone|Cobiprostone capsules for oral administration
40832768|NCT04641949|PROCEDURE|Lower body negative pressure (LBNP)|LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
40832769|NCT00031980|DRUG|cyclosporine|
41351683|NCT02492542|DEVICE|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50\*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
41351684|NCT03781154|BEHAVIORAL|Group Exercise|Patients will exercise in a virtual group for 60 minutes, twice a week. Five social-cognitive theory-based discussion sessions with the group, and group exercise instructor will be held throughout the course of the intervention, lasting 30 to 60 minutes. The goal of these sessions is to enhance long-term physical activity behavior change.
41020639|NCT04054167|DRUG|Low Dose Radiation Therapy|Undergo ultra low dose radiation
41351685|NCT02497599|DRUG|Indium-111-DOTA-Girentuximab-IRDye800CW|Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
41351686|NCT02497599|RADIATION|SPECT/CT|4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
41351687|NCT02497599|PROCEDURE|Intraoperative dual-modality imaging|7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
40832770|NCT02852941|DEVICE|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
40832771|NCT02852941|DEVICE|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
40832772|NCT00989391|DRUG|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
40832773|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
41351688|NCT04101786|OTHER|Hip adductors exercise variations|The participants will perform different exercise variations targeting hip adductors in randomized order.
41351689|NCT03035409|DRUG|Anamorelin Hydrochloride|Given PO
41351690|NCT03035409|BEHAVIORAL|Exercise Intervention|Undergo physical activity
41351691|NCT03035409|OTHER|Laboratory Biomarker Analysis|Correlative studies
41020640|NCT04962269|DIAGNOSTIC_TEST|MRI|monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model
41020641|NCT05505981|OTHER|Immediate PT|Patients will start PT immediately
41020642|NCT05505981|OTHER|Rest until pain resolves|Patients will wait to start PT until their pain resolves
41020643|NCT02139644|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
41351692|NCT03035409|OTHER|Nutritional Assessment|Undergo nutritional counseling
41351693|NCT03035409|OTHER|Quality-of-Life Assessment|Ancillary studies
41351694|NCT03035409|OTHER|Questionnaire Administration|Ancillary studies
41159413|NCT05482256|DIAGNOSTIC_TEST|Esophageal String Test (EST)|Non-invasive, FDA-registered sampling method to evaluate eosinophilic inflammation in the esophagus. The EST is performed by having an individual swallow a capsule attached to a string which captures secretions from the esophagus. The end of the string is taped to the cheek and the capsule is swallowed with water. After 1 hour, the EST will be removed, and the string will be processed for laboratory analysis.
41351695|NCT00303719|BIOLOGICAL|anti-thymocyte globulin|"ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.~Those that should/will receive ATG in the preparative regimen:~* Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should~* Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will~* Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should~* Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG."
41159414|NCT05482256|OTHER|Colgate|2 grams of toothpaste (pea sized amount) for 2 minutes
41159415|NCT05482256|DIAGNOSTIC_TEST|High Resolution Esophageal Manometry (HREM)|Thin flexible tube with sensors placed in the nose and swallowed for esophagus placement to conduct reading regarding the lining of the esophagus taken for approximately 10 minutes
41159416|NCT04368533|DRUG|Livionex Dental Gel|The subjects will brush their teeth with Livionex Dental Gel twice a day for up to 12 months.
41159417|NCT04368533|DRUG|A standard children's toothpaste containing 1500 ppm fluoride|The subjects will brush their teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months.
40832774|NCT00989391|DRUG|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
40832775|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
40832776|NCT00989391|DRUG|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
40832777|NCT00989391|DRUG|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
40832778|NCT01668641|DRUG|GLPG0634|
40832779|NCT01668641|DRUG|Placebo|
40832780|NCT02402686|DRUG|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
40832781|NCT00699218|DEVICE|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
41351696|NCT00303719|DRUG|cyclophosphamide|Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
41509133|NCT03280381|OTHER|Generic medicine cup|The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
41020644|NCT02139644|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
41020645|NCT02139644|DRUG|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
41159418|NCT06647199|PROCEDURE|the plaque index (PI)|Peri-implant soft tissue changes as regards plaque was assessed employing the modiﬁed plaque index (PI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
41351697|NCT00303719|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of \>200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
41351698|NCT00303719|DRUG|fludarabine|Fludarabine 30 mg/m\^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m\^2 for 5 days.
41493010|NCT01381250|BEHAVIORAL|cognitive behavior therapy|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur \& Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
41493011|NCT03449680|PROCEDURE|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
41493012|NCT03449680|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
41493013|NCT05325307|OTHER|Acupressure|The experimental group will start with HT7 points and continue LI4 and EX-NH3 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
41493014|NCT05325307|OTHER|Placebo acupressure|In the placebo acupressure group , the points 1.5 cm away from the HT7, LI4, and EX-NH3 points will be applied for an average of 15 minutes. Less pressure will be applied.
41020646|NCT02139644|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
41020647|NCT02139644|DRUG|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
41020648|NCT02564471|DRUG|Chloroquine|FDA approve dosing schedule
41351699|NCT00303719|DRUG|mycophenolate mofetil|Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if \< 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) \> 0.5 x 109 /L).
41493015|NCT01551225|DRUG|Escitalopram|Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
41493016|NCT06308614|DRUG|20 mg estetrol monohydrate|Active treatment
41493017|NCT06308614|OTHER|Placebo|Matching Placebo to E4
41493018|NCT00369655|BIOLOGICAL|ziv-aflibercept|
41351700|NCT00303719|PROCEDURE|stem cell transplantation|On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
41159419|NCT06647199|PROCEDURE|the bleeding index (BI)|Peri-implant tissue changes as bleeding score was assessed employing the bleeding index (BI) . Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
41159420|NCT06647199|PROCEDURE|simpliﬁed gingival index(GI),|Peri-implant soft tissue changes as regards gingival scores was assessed simpliﬁed gingival index(GI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD
41159421|NCT05442424|BEHAVIORAL|Produce Voucher|see arm/group description
40832782|NCT05553977|DRUG|Bowel preparation for colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
40832783|NCT05553977|PROCEDURE|Colonoscopy|Colonoscopy will be performed to every patient included in the study
40832784|NCT06378645|DRUG|General Anesthesia: Propofol|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Propofol will be administered intravenously using the target-controlled infusion algorithm with effect site concentrations between 1.5-4.0 µg/ml necessary."
40832785|NCT06378645|DRUG|General Anesthesia: Sevoflurane|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Sevoflurane will be given in gaseous form via the endotracheal tube in concentrations between 1.5-2.5% Vol."
40832786|NCT01001546|BEHAVIORAL|Internet-based|Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
40832787|NCT01001546|BEHAVIORAL|Standard Clinic-Based|Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
40832788|NCT05133713|DEVICE|Catheter directed therapy|Thrombectomy
41020649|NCT02564471|DRUG|Atovaquone and Proguanil|FDA approve dosing schedule
41020650|NCT02564471|DRUG|Doxycycline|FDA approve dosing schedule
41020651|NCT02564471|BIOLOGICAL|Rabies Vaccine|FDA approve dosing schedule
41020652|NCT05813054|DIETARY_SUPPLEMENT|HA matrix ingredient|1 capsule/day
41020653|NCT05813054|DIETARY_SUPPLEMENT|Placebo|1 capsule/day
41020654|NCT00863538|DRUG|KPS-0373|
41020655|NCT05949983|OTHER|APA Program|Patients treated and monitored for their breast cancer following the 6-month APA program.
41020656|NCT05949983|OTHER|Recommendations for physical activity|Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion
41020657|NCT06573567|DEVICE|Bioimpedance|Experimental: use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month
41020658|NCT06573567|DEVICE|Control|Placebo Comparator: the measurements will also be obtained once per month, but not revealed to the participants and the care providers
41159422|NCT05442424|BEHAVIORAL|Wait-List Control|see arm/group description
41351701|NCT00303719|RADIATION|total body irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
40832789|NCT05133713|DRUG|Systemic anticoagulation|Conservative therapy
41020659|NCT01192594|BEHAVIORAL|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
41020660|NCT01192594|BEHAVIORAL|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
41020661|NCT04928222|COMBINATION_PRODUCT|Doxorubicin-containing MNA|A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent
41020662|NCT04928222|DRUG|Placebo-containing MNA|A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
41020663|NCT02978144|RADIATION|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT-CT
41020664|NCT02978144|DRUG|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
41020665|NCT06454981|DEVICE|Hemodiafilter|"The enrolled patients were randomly divided into the experimental group and the control group, using the hemodiafilter (experimental device) produced by Shinva Medical Instrument Co.,Ltd."
41020666|NCT06454981|DEVICE|Fresenius Medical Care AG & Co.KGaA|The enrolled patients were randomly divided into the experimental group and the control group, using the FX 800HDF hollow fiber hemodialysis/filter (control device) produced by Fresenius Medical Care AG \& Co.KGaA (registered agent: Fresenius Medical Care (shanghai) Company Limted).
41020667|NCT05592210|OTHER|Questionnaires|Participants will be asked to fill out the the Demographic Information Sheet, Karitane parenting confidence scale, Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU) and Dyadic Coping Inventory.
41493019|NCT03816566|DEVICE|patch|A standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject. The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy.
41493020|NCT00190190|PROCEDURE|With Peeling of Limiting the Intern of the Retina|With Peeling of Limiting the Intern of the Retina
41493021|NCT00190190|PROCEDURE|Internal limiting membrane peeling|Traditional Procedure Without Peeling of Limiting
41351702|NCT00303719|DRUG|filgrastim|Patients with white blood cell (WBC) counts \< 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) \> 2500 for 2 consecutive days.
41351703|NCT05091073|DRUG|NNC0385-0434|All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days
41351704|NCT02198313|DRUG|BIIX 1 XX - D1|
40832790|NCT02333981|DEVICE|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
41020668|NCT04929561|BEHAVIORAL|Video-conferencing group|No intervention
41020669|NCT01310413|BIOLOGICAL|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
41493022|NCT01706237|DEVICE|Nexisvision shield|A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
41493023|NCT00954330|PROCEDURE|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
41493024|NCT00954330|DEVICE|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
41020670|NCT01310413|BIOLOGICAL|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
41351705|NCT02198313|DRUG|BIIX 1 XX - D2|
41351706|NCT02198313|DRUG|BIIX 1 XX - D3|
41351707|NCT02198313|DRUG|Placebo|
41351708|NCT00444951|BIOLOGICAL|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
41493025|NCT00883909|DRUG|dutasteride|A follow-up study in adult male subjects who have received investigational product
41493026|NCT03652558|DEVICE|Ozone application with the Ozonytron XL device|An ozone generator (Ozonytron; Bionix, Munchen, Germany) with an KPX probe (CA Probe; Ozonytron, Bionix, Munchen, Germany) was used for OT. Topical gaseous ozone was applied into the periodontal pocket twice a week for 2 weeks based on the manufacturer's instructions. Ozone applications were at 75% power for 30 seconds (75 µg/ml). Ozone applications were performed by an experienced investigator. Ozone applications in the control side were simulated without starting the ozone generator
41493027|NCT00357084|DRUG|methotrexate|
41493028|NCT00357084|DRUG|methylprednisolone|
41493029|NCT00357084|DRUG|prednisone|
41493030|NCT04293328|DEVICE|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
40832791|NCT05890378|OTHER|Testing water|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
41493031|NCT04293328|DEVICE|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
41493032|NCT02759601|DRUG|Tefinostat|Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
41493033|NCT03810755|OTHER|Personalized Supervised physical activity|personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
40832792|NCT04720716|DRUG|IBI310|IBI310 IV d1, Q6W
40832793|NCT04720716|DRUG|Sintilimab|sintilimab IV d1, Q3W
40832794|NCT04720716|DRUG|Sorafenib|Sorafenib 400mg po
41020671|NCT04486859|DRUG|LMWH/Rivaroxaban|combined prevention
41351709|NCT00444951|BIOLOGICAL|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
41351710|NCT00444951|BIOLOGICAL|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
41493034|NCT06483139|PROCEDURE|Plasma exchange|Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
41493035|NCT06483139|DRUG|Daratumumab|Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
41493036|NCT02246439|DRUG|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
41493037|NCT02246439|DRUG|Placebo Oral Tablet|Placebo
41493038|NCT05476419|OTHER|Direct intra-oral scanning technique for the post space.|scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner
40832795|NCT05693142|GENETIC|RGX-202|RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin
41493039|NCT01673438|DRUG|aldoxorubicin|
41159427|NCT00003926|DRUG|amifostine trihydrate|"Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined."
41159428|NCT00003926|DRUG|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
41159429|NCT00003926|DRUG|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
41159430|NCT00003926|DRUG|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
41159431|NCT00003926|DRUG|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
41159432|NCT00003926|PROCEDURE|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
41159433|NCT04199676|DIAGNOSTIC_TEST|Glucose tolerance test|Oral administration of a 75g glucose tolerance test during the postpartum hospitalization
41159434|NCT06645730|DIAGNOSTIC_TEST|hypertension|diagnosed with hypertension
41159435|NCT06645730|DIAGNOSTIC_TEST|diabetes|diagnosed with diabetes
41159436|NCT06645730|DIAGNOSTIC_TEST|fatty liver|diagnosed with fatty liver on CT
41493040|NCT00004089|BIOLOGICAL|filgrastim|
41493041|NCT00004089|DRUG|fluorouracil|
41493042|NCT00004089|DRUG|hydroxyurea|
41493043|NCT00004089|DRUG|paclitaxel|
41493044|NCT00004089|PROCEDURE|conventional surgery|
40832796|NCT04528459|DEVICE|Stryker© ADAPT™ platform|The ADAPT system is a software platform that utilizes augmented reality to assist surgeons with implant alignment, lag screw length and positioning, and distal interlocking screw placement for cephalomedullary fixation of peritrochanteric femur fractures.
40832797|NCT04528459|RADIATION|Traditional fluoroscopy|For patients in the control group, traditional fluoroscopy will be utilized for placement of the cephalomedullary nail.
40832798|NCT02840786|DEVICE|plaque excision system|
41159437|NCT02977780|DRUG|Temozolomide|Temzolomide capsules
41159438|NCT02977780|DRUG|Neratinib|Neratinib tablets
41159439|NCT02977780|DRUG|QBS10072S|QBS10072S administered intravenously
40832799|NCT02840786|DEVICE|balloon and Stent|
41159440|NCT02885883|DEVICE|MRI 3T|
41493045|NCT00004089|RADIATION|radiation therapy|
41493046|NCT06367608|DEVICE|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's dystonia . The ExAblate uses ultrasound to heat a small spot in the brain called globus pallidus internus(GPi). Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
41493047|NCT00428636|PROCEDURE|ileostomy|
41493048|NCT02567318|DEVICE|MRI-scan|Magnetic resonance imaging scan of the brain
41493049|NCT03008876|DRUG|Acetaminophen|infants receive acetaminophen for treatment of their PDA
40832800|NCT00598078|DRUG|Sodium Oxybate|Dose 1
40832801|NCT00598078|DRUG|Sodium Oxybate|Dose 2
40832802|NCT00598078|OTHER|Placebo|Dose 3
40832803|NCT01246479|PROCEDURE|Blood draw|blood draw at Month 12, Month 24 and Month 36.
41159441|NCT02621424|DEVICE|RTMS|stimulation of the brain with magnetic pulses
41159442|NCT02621424|DEVICE|sham|sham noise to block the sound of stimulation
41159443|NCT05472519|BIOLOGICAL|blood samples|"Only one visit for each participant: A large majority of visits will be part of patients' usual care.~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
41159444|NCT05472519|BIOLOGICAL|blood samples|"Only one visit for each participant:~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
41159445|NCT06624072|DRUG|Nerandomilast, Formulation 1|Reference treatment (R)
41159446|NCT06624072|DRUG|Nerandomilast, Formulation 2|when taken without food: Test Treatment 1 (T1) when taken with food: Test Treatment 2 (T2)
41159447|NCT06645821|DRUG|EVO101|EVO101 topical cream 0.1%
41159448|NCT03226106|BEHAVIORAL|Physical Activity Behavior Intervention|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
41493050|NCT03008876|DRUG|Ibuprofen|infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
41493051|NCT02427035|BIOLOGICAL|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
41493052|NCT02427035|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
41493053|NCT02823418|PROCEDURE|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
41493054|NCT02823418|PROCEDURE|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
41159449|NCT03226106|OTHER|Attention Control|Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
41159450|NCT03924778|BEHAVIORAL|DASH diet|brief description
41159451|NCT03924778|BEHAVIORAL|standard American diet|describe
40832804|NCT01246479|BIOLOGICAL|IC51 has given in the parent study IC51-322|No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
41159452|NCT06263296|BEHAVIORAL|Self Management Education|Smartphone assisted self management education incorporated with the concept of motivational interviewing
41159453|NCT06645925|PROCEDURE|One Step Protocol|FGG will be done simultaneous with implant placement
41159454|NCT06645925|PROCEDURE|Two Steps Protocol|Conventional FGG protocol, prior to implant placement
41159455|NCT02538471|RADIATION|Radiation therapy|Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
40832805|NCT03627169|DEVICE|MATRx plus|The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
40832806|NCT02749942|DEVICE|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
40832807|NCT02749942|DEVICE|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
40832808|NCT06103227|DRUG|Prednisone 5Mg|Prednisone administered for three weeks. If pregnant women weighs less than 90 kg , she will receive prednisone on altering days instead of every morning for pregnant women weighing more than 90 kg.
40832809|NCT02578433|BEHAVIORAL|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
40832810|NCT02578433|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
40832811|NCT02496169|DEVICE|eucaLimus|Percutaneous Coronary Intervention (PCI)
41020672|NCT04486859|DEVICE|IPC|mechanical prevention
40832812|NCT00570934|DIETARY_SUPPLEMENT|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
40832813|NCT00570934|DIETARY_SUPPLEMENT|Calcium|1 gm calcium as calcium carbonate
40832814|NCT00570934|DIETARY_SUPPLEMENT|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
40832815|NCT00570934|DRUG|Placebo|Placebo
40832816|NCT01869413|DRUG|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
40832817|NCT01869413|DRUG|Placebo|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
40832818|NCT00568477|DRUG|MabThera|"Rituximab (MabThera):~375 mg/m² as IV infusions over \>=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
40832819|NCT06508463|PROCEDURE|Biopsy|Undergo tumor biopsy
41020673|NCT04891679|DRUG|Oral misoprostol solution (OMS)|"Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~1. hour= 20ml~2. hour= 30ml~3. hour= 30ml~4. hour= 30ml~5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity."
41159456|NCT02538471|DRUG|Study Drug|Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
41351711|NCT03737344|DRUG|IL-1Ra Kineret®|Kineret® 100 mg in 0.67 ml Prefilled Syringe
41351712|NCT03737344|OTHER|IL-1Ra Placebo|Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
41351713|NCT04651751|BEHAVIORAL|Facilitating an Exercise Habit and Identity via the Multi-Process Action Control Model- A Randomized-Controlled Trial|Participants attended a workshop which consisted of a presentation and an exercise planning exercise.
41351714|NCT02060903|DRUG|Abametapir Lotion 0.74% w/w|Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
41351715|NCT02060903|DRUG|Vehicle Lotion|Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
41351716|NCT05309499|DRUG|ferric carboxymaltose|ferric carboxymaltose is i.v. iron, 121 patiants will be randomised to this group
41351717|NCT05309499|DRUG|ferrous sulphate|ferrous sulphate is oral iron, 121patiants will be randomised to this group
41493055|NCT02468570|OTHER|Administration of CANTAB and Subject Global Assessment|At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire
41159457|NCT06645665|BIOLOGICAL|Bivalent RSV Vaccine (IN006)|Formulation for injection
41351718|NCT03583502|DIETARY_SUPPLEMENT|krill oil and fish oil supplement|Administration of 2 gelatin soft capsules per day of a combined krill and fish oil supplement, providing 250 mg/day of DHA and 70 mg/day of EPA, for overall 30 days.
41351719|NCT02878135|PROCEDURE|fast application|
41351720|NCT02878135|PROCEDURE|slow application|
41493056|NCT01777360|DEVICE|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY|radiofrequency catheter for bronchial THERMOPLASTY
41493057|NCT02799368|DRUG|CJ Plasma Solution A Injection|Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
41493058|NCT02799368|DRUG|CJ 0.9% Normal Saline Injection|Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
41493059|NCT01189487|DRUG|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
41493060|NCT04363840|DRUG|Aspirin 81 mg|Aspirin 81 mg to be taken orally once daily for 14 days.
41159458|NCT06645665|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
41493061|NCT04363840|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 50,000 IU to be taken orally once weekly for 2 weeks
41351721|NCT01879891|OTHER|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
41351722|NCT00648973|DRUG|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet"
41351723|NCT00648973|DRUG|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet"
41351724|NCT00648973|DRUG|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet"
41351725|NCT03845010|DRUG|Sotalol|Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)
41351726|NCT03845010|DRUG|Flecainide and verapamil|Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day
41351727|NCT03845010|PROCEDURE|Catheter ablation|Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine
41351728|NCT03166228|DRUG|Normal Saline 0.9% Infusion Solution Bag|0.9% saline as distension medium as long as diathermy is not in use
41159459|NCT06646874|BEHAVIORAL|VR game|Each participant in the VR group completed a five-minute familiarization session with the VR game before the experimental session. Following the familiarization session, participants in the VR group were instructed to complete the Montreal Cognitive Assessment (MoCA) Arabic version (pre-test: Arabic version 8.1 and post-test: Arabic version 8.2)
41159460|NCT04778449|OTHER|Medical Chart Review|Medical charts are reviewed
41159461|NCT04778449|OTHER|Questionnaire Administration|Complete questionnaires
41159462|NCT05512910|DRUG|Minocycline|200 mg minocycline orally or via nasogastric tube prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting.
41159463|NCT06363409|OTHER|Cereal Bar as a recovery food snack|Cereal bar as a recovery snack food
41493062|NCT04171206|OTHER|Free From Abuse|Participants in the treatment arm will watch a 15-minute talk given by an adult female survivor of IPV who tells the story of her abusive relationship. After watching the video, participants will read information on 10 signs of an unhealthy relationship. The intervention will take approximately 25 minutes to complete.
41020674|NCT03724604|DIAGNOSTIC_TEST|Neuron-Specific Enolase to Albumin Ratio|Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
41020675|NCT04378075|DRUG|Vatiquinone|Vatiquinone will be administered per the treatment arm description.
41020676|NCT04378075|OTHER|Placebo|Vatiquinone-matching placebo will be administered per the treatment arm description
41020677|NCT04020731|BEHAVIORAL|Hypnosis|several blocks of hypnosis including entry into a hypnotic state (= induction), the hypnotic trance and the exit from hypnosis (= reassociation).
41020678|NCT01968434|DEVICE|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
41020679|NCT01968434|DRUG|carbocisteine cough syrup|Mucolytic
41020680|NCT00931905|DRUG|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
41020681|NCT00931905|OTHER|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
41020682|NCT06394128|DRUG|Cangpo Liujun Prescription|Based on the diagnostic criteria of spleen deficiency and dampness excess syndrome, Cangpo Liujun Prescription could be used to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy.
41020683|NCT02409615|OTHER|Hypnosis Therapy|A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
41020684|NCT02409615|OTHER|Healing Touch Therapy|Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
41159464|NCT06363409|OTHER|Almond|Almond as a recovery snack food
41159465|NCT05262439|DEVICE|New generation CPAP mask|All participants entered into the study will be couriered a new generation ResMed mask system to be used with their own CPAP machine and in place of their own mask.
41159466|NCT01093222|DRUG|Erlotinib Hydrochloride|Given PO
41159467|NCT01093222|DRUG|Sorafenib Tosylate|Given PO
41159468|NCT05359926|OTHER|Experimental|Early urethral foley removal after the surgery
41493063|NCT04171206|OTHER|Technology and crime|Participants in the placebo control arm will watch a 19-minute talk on technology development and crime. After watching the video, participants will read 10 facts about cyber security. The intervention will take approximately 25 minutes to complete.
41493064|NCT00294463|DRUG|Tibolone|
41020685|NCT03948685|DRUG|Carvedilol SR|blood pressure, heart rate based titrated carvedilol SR for 24 weeks
41020686|NCT03948685|DRUG|Placebo|Placebo
41020687|NCT05890027|DRUG|Phenylephrine Ophthalmic|One drop of Phenylephrine 2.5% ophthalmic solution to be administered to the eye with ptosis to evaluate for surgical repair.
41020688|NCT05890027|OTHER|Eyelid Tape|Participants will have the affected eye with ptosis manually lifted using tape.
41159469|NCT05359926|OTHER|Active comparator|Delayed urethral foley removal after the surgery
41159470|NCT05335668|PROCEDURE|Clinical Testing|Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
41159471|NCT02948205|PROCEDURE|3D group|infertility patient get TU-LESS by 3D Laparoscopy
41159472|NCT02948205|PROCEDURE|normal group|infertility patient get normal laparoscopic surgery
41159473|NCT00694135|DRUG|EGP-437 1.6 mA-min at 0.4 with EyeGate® II System|Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
41159474|NCT00694135|DRUG|EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
41159475|NCT00694135|DRUG|EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
41351729|NCT03166228|DRUG|1.5% Glycine only|1.5% Glycine alone during hysteroscopy as long as diathermy is in use
41493065|NCT00294463|DRUG|Estradiol|
41351730|NCT01571167|DRUG|Placebo|Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
41351731|NCT01571167|DRUG|Varenicline|For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
41351732|NCT01571167|DRUG|Varenicline|For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
41351733|NCT01830829|DRUG|Jalyn|study drug
41351734|NCT01830829|DRUG|Placebo|Placebo
41351735|NCT04540614|OTHER|Strengthening exercises programme|Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
41351736|NCT00114764|DRUG|filgrastim|Filgrastim given daily after induction chemotherapy
40832820|NCT06508463|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40832821|NCT06508463|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
40832822|NCT06508463|PROCEDURE|Computed Tomography|Undergo SPECT/CT
40832823|NCT06508463|PROCEDURE|Positron Emission Tomography|Undergo PET scan
40832824|NCT06508463|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
40832825|NCT06508463|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
40832826|NCT06508463|BIOLOGICAL|Cemiplimab|Given IV
40832827|NCT06508463|BIOLOGICAL|Ipilimumab|Given IV
40832828|NCT01689545|BEHAVIORAL|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
40832829|NCT01689545|BEHAVIORAL|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
40832830|NCT01689545|BEHAVIORAL|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
41020689|NCT05901129|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
41020690|NCT04689386|OTHER|"Group I (GE-I) - Stimulation of reflex rolling from the Vojta method"|"This manoeuvre does not require the newborn to be moved, but only a slight rotation of the head towards the side from which the stimulus is delivered. The starting position for performing the first phase of reflex rolling is the asymmetric supine position, with the limbs freely lying on the resting surface.~A digital pressure will exert on the chest area, where the mammillary line crosses the insertion of the diaphragm, either at the level of the 6th rib, or between the 5th and the 6th, or between the 6th and the 7th. A one minute stimulus will be performed on each side. The intervention will be repeated twice a day, ensuring that the period between one intervention and another is at least two hours."
41159476|NCT00694135|DRUG|EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
41159477|NCT06345703|DRUG|Placebo|NS-136 matching placebo
41159478|NCT06345703|DRUG|NS-136 tablet|Investigational product NS-136
41159479|NCT04139239|DIAGNOSTIC_TEST|Coma Recovery Scale-revision|Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
41159480|NCT00507429|DRUG|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
41159481|NCT00507429|DRUG|paclitaxel|200mg/m squared on Day 1
41159482|NCT00507429|DRUG|carboplatin|6 AUC on Day 1 following paclitaxel
41351737|NCT00114764|DRUG|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
41351738|NCT02564562|DRUG|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + \[14C\] PF-06463922
41351739|NCT06456411|PROCEDURE|Functional Near-Infrared Spectroscopy|Undergo fNIRS
41351740|NCT06456411|OTHER|Questionnaire Administration|Ancillary studies
41351741|NCT06456411|OTHER|Virtual Technology Intervention|Undergo relaxation period using VR
41351742|NCT05320211|DEVICE|3D-printed hand orthosis|3D-printed hand orthoses (intervention) will be compared with custom-fabricated conventional orthoses (control condition at baseline)
41351743|NCT05012709|BEHAVIORAL|multisensory stimulation therapy|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
41351744|NCT05454709|DRUG|Dasiglucagon|Use of dasiglucagon in the AP system.
41351745|NCT05454709|DRUG|GlucaGen|Use of GlucaGen in the AP system.
41351746|NCT03407027|DRUG|Quadratus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
41351747|NCT03407027|DRUG|Gluteus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
41351748|NCT03407027|DRUG|quadratus without triamcinolone.|10ml of levobupivacaine 0,25%.
41351749|NCT01396486|DRUG|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
41493066|NCT00294463|DRUG|Estradiol + Medroxy Progesterone Acetate|
41159483|NCT00347425|DRUG|Aripiprazole|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
41351750|NCT01396486|DRUG|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
41351751|NCT00032305|DRUG|Visilizumab|
41020691|NCT04689386|OTHER|Group II (GE-II) - expiratory flow increase technique|The technique adapted to the premature infant will be performed. This maneuver consists of slowly applying light pressure to the infant's chest with one hand, obliquely, starting from the end of the inspiratory plateau until the end of expiration, which is prolonged. The hand should be placed between the sternal notch and the xiphoid process of the newborn's sternum. The therapist's other hand is placed on the last ribs (without applying pressure) as a bridge, of which the columns are the thumb and forefinger (or middle finger). Therefore, contact with the infant's abdomen is avoided and the expansion of the lower rib is limited, allowing a better displacement of the diaphragm and avoiding an increase in intra-abdominal pressure. The maneuver will be repeated three times, respecting the infant's responses and their physiological constants. The intervention will be repeated twice a day, trying to ensure that the period between one intervention and another is at least 2 hours.
41020692|NCT01771406|DRUG|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
41020693|NCT01771406|DEVICE|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
41020694|NCT02602574|OTHER|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
41351752|NCT02881892|OTHER|Measure plasma and dialysate level of IL-6, procalcitonin and VEGF|correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.
41351753|NCT03233672|RADIATION|Hypo-fractionated postoperative IMRT-SIB|intensity-modulated radiation treatment with simultaneous integrated boost
41020695|NCT05116722|DEVICE|Shoulder Pacemaker|Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
41020696|NCT03717337|PROCEDURE|Single visit pulp regeneration|Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.
41020697|NCT03717337|PROCEDURE|Two visit pulp regeneration|first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
41020698|NCT03221413|DEVICE|transcranial alternating current stimulation (tACS)|
41020699|NCT05171777|DRUG|Atezolizumab|Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.
41020700|NCT05211219|DIETARY_SUPPLEMENT|Probiotics|According to the groups, they were involved simultaneously with the treatment, kefir group was advised to consume kefir as a liquid once a day in 14 days; the probiotics group was advised to consume as a chewable tablet once a day in 14 days; the control group was advised without additional food supplements.
41020701|NCT05211219|DIETARY_SUPPLEMENT|AOÇ Kefir|AOÇ Kefir
40832831|NCT01689545|BEHAVIORAL|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
41020702|NCT05211219|OTHER|Food without additional food supplements|Food without additional food supplements
41159484|NCT00347425|DRUG|Olanzapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
41159485|NCT00347425|DRUG|Risperidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
41351754|NCT02949687|PROCEDURE|ileal interposition with sleeve and sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
41159486|NCT00347425|DRUG|Quetiapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
41351755|NCT04594889|PROCEDURE|angioplasty|Balloon releasing a drug inflated in the target vessel
41351756|NCT03643276|DRUG|Blinatumomab|Experimental therapy in randomizations R-HR and R-MR
41351757|NCT03643276|DRUG|Bortezomib|Experimental therapy in randomization R-eHR
40832832|NCT02033590|DEVICE|Biodegradable (purified) surgical silk scaffold|
40832833|NCT00029458|DRUG|Clozapine|
40832834|NCT01116427|BIOLOGICAL|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
41159487|NCT00347425|DRUG|Ziprasidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
41159488|NCT00347425|DRUG|Aripiprazole|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
41159489|NCT00347425|DRUG|Olanzapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
41351758|NCT03643276|DRUG|Cyclophosphamide|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
40832835|NCT01116427|DRUG|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
40832836|NCT05493189|OTHER|Additional autonomous training sessions|The duration of the autonomous training will be 30 minutes, using a feedback CPR training simulator (eg Laerdal Little Anne QCPR).
40832837|NCT02361424|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
40832838|NCT02361424|DRUG|placebo|
40832839|NCT03000777|DIETARY_SUPPLEMENT|melatonin plus zinc|Melatonin 1 mg plus Zinc 10 mg o.d. 1 hour before going to bed during 16 weeks
40832840|NCT03000777|OTHER|Placebo|Isomaltose o.d. 1 hour before going to bed during 16 weeks
40832841|NCT01995955|PROCEDURE|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
40832842|NCT01470833|PROCEDURE|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
40832843|NCT04947306|DEVICE|Tetragraph® (Senzime, Uppsala, Sweden)|The Tetragraph® is a recently marketed electromyographic neuromuscular monitor that uses a disposable electrode array (TetraSens) that combines stimulating and recording electrodes
40832844|NCT04947306|DEVICE|TOF Watch® SX (Organon Teknika B.V., Boxtel, Holland)|The TOF Watch® SX is a common used neuromuscular monitor
40832845|NCT04564248|OTHER|Website access|website access will be provide to families
40832846|NCT05455008|BEHAVIORAL|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
40832847|NCT01199276|DRUG|Xenon|Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
40832848|NCT01199276|DRUG|Sevoflurane|Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
40832849|NCT05958823|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block
40832850|NCT05958823|PROCEDURE|PECS I-II|PECS I-II
40832851|NCT05481424|OTHER|Biodynamic|This will be a nine-hour lighting scheme that includes three modes: morning, noon, and afternoon. It mimics natural lighting by providing blue-enriched bright lighting in the morning and yellowish dimmed lighting in the afternoon. The lighting scheme is designed to satisfy the visual lighting needs of office workers while maintaining a robust circadian clock.
40832852|NCT05481424|OTHER|Active Placebo|"We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness during working hours. This condition is designed to serve to requirements: (1) to simulate a conventional, well-lit office lighting in compliance with the WELL standard V1 recommendations for circadian lighting design, and (2) to provide an Equivalent Melanopic Lux (EML) equal to the geometric average of EML delivered by the Biodynamic condition. Participants will receive a similar dose of lighting under both the Placebo and Biodynamic conditions; however, the time factor is ignored in the Placebo, and hence the method of delivery is different (constant versus dynamic)."
40832853|NCT03916016|BEHAVIORAL|Enhanced Integrated Behavioral Health Care|The intervention involved moving from HFHC's previous collaborative model, where medical and behavioral providers worked with each other episodically, to a more fully integrated collaborative care model with care coordination, shared treatment plans, shared service provision, and shared record keeping. To achieve this enhanced level of integration, HFHC changed its current primary care workflow to include a behavioral health specialist who conducted assessments, provided initial counseling (individual or group), and coordinated referrals to care management and/or community-based health services.
41159490|NCT00347425|DRUG|Risperidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
41493067|NCT04320121|DIETARY_SUPPLEMENT|Nelutri™|Nelutri™ 2,000 mg/day for 12 weeks
40832854|NCT03916016|BEHAVIORAL|Usual Care|A collaborative model where medical and behavioral providers worked with each other episodically
40832855|NCT04161378|DIAGNOSTIC_TEST|Cardiac imaging|"* Transthoracic echocardiography~* Late gadolinium enhancement CMR"
40832856|NCT04161378|DIAGNOSTIC_TEST|Laboratory analysis|"* complete blood count~* biochemistry~* hs-CRP, MMPs, IL6, NT-pro-BNP"
41159491|NCT00347425|DRUG|Quetiapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
41159492|NCT00347425|DRUG|Ziprasidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
41159493|NCT00801450|DRUG|Triamcinolone acetonide|4 mg
41159494|NCT00801450|DRUG|Triamcinolone acetonide|40 mg
41493068|NCT04320121|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,000 mg/day for 12 weeks
41351759|NCT03643276|DRUG|Cytarabine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
41351760|NCT03643276|DRUG|Daunorubicin|Part of standard chemotherapy
41351761|NCT03643276|DRUG|Myocet|Part of intensification block Myocet-FLA for patients with very high relapse risk
40832857|NCT02584387|BEHAVIORAL|3D Video Virtual Reality Exposure Therapy|The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
40832858|NCT04575818|DRUG|GLPG4059 oral suspension|GLPG4059 for oral administration
40832859|NCT04575818|DRUG|Placebo|Placebo oral suspension
40832860|NCT04575818|DRUG|GLPG4059 tablet|GLPG4059 for oral administration
41159495|NCT00507975|DRUG|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
41159496|NCT04608032|OTHER|[Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder|The first group will have \[Eco-Sz\] Ecological Cognitive training program for schizophrenia spectrum disorder
41159497|NCT04608032|OTHER|Recovery-Oriented Therapy|The second group will have \[THoR\] Recovery-Oriented Therapy
41159498|NCT04602039|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum (Neovite)
41159499|NCT01914458|PROCEDURE|Low-dose computed tomography (LDCT)|Low-dose computed tomography scan
41351762|NCT03643276|DRUG|Dexamethasone|Part of standard chemotherapy
41351763|NCT03643276|DRUG|Doxorubicin|Part of standard chemotherapy
41351764|NCT03643276|DRUG|Etoposide|Part of standard chemotherapy
41351765|NCT03643276|DRUG|Fludarabine Phosphate|Part of intensification block Myocet-FLA for patients with very high relapse risk
41351766|NCT03643276|DRUG|Ifosfamide|Part of standard chemotherapy
41351767|NCT03643276|DRUG|6-Mercaptopurine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
41351768|NCT03643276|DRUG|Methotrexate|Part of standard chemotherapy
41351769|NCT03643276|DRUG|Pegaspargase|Part of standard chemotherapy
41351770|NCT03643276|DRUG|Prednisolone|Part of standard chemotherapy
41351771|NCT03643276|DRUG|Tioguanin|Part of standard chemotherapy
41351772|NCT03643276|DRUG|Vincristine|Part of standard chemotherapy
41351773|NCT03643276|DRUG|Vindesine|Part of standard chemotherapy
41351774|NCT03643276|DRUG|Erwinase|Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
41351775|NCT01926652|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
41351776|NCT05141565|OTHER|No intervention|No intervention
41351777|NCT01018251|OTHER|3'-deoxy-3'-[18F]fluorothymidine|Given IV
40832861|NCT06244836|OTHER|Implementation of a bundle of care|
40832862|NCT06169800|DEVICE|MPFL repair with Biobrace augmentation|MPFL repair with Biobrace augmentation
40832863|NCT05281770|DRUG|Erenumab|treatment with erenumab as chosen by treating physician
40832864|NCT05281770|DRUG|Fremanezumab|treatment with fremanezumab as chosen by treating physician
40832865|NCT05281770|DRUG|Galcanezumab|treatment with galcanezumab as chosen by treating physician
40832866|NCT00350428|PROCEDURE|Laser Preipheral Iridotomy and phacoemulsification|
40832867|NCT05210634|DIETARY_SUPPLEMENT|THCv|THCv in MCT oil
40832868|NCT02360644|DIETARY_SUPPLEMENT|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
40832869|NCT05020756|DIETARY_SUPPLEMENT|Isosource Junior Mix|Single arm study, collecting data on those who have been on Isosourcr Junior mix tube feed formula for 30 days
40832870|NCT02606760|DRUG|P-3073|
40832871|NCT02606760|DRUG|Vehicle of P-3073|
40832872|NCT02441348|BEHAVIORAL|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
40832873|NCT01611220|BEHAVIORAL|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
41351778|NCT01018251|PROCEDURE|Positron Emission Tomography/computed tomography|
40832874|NCT00711490|DRUG|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
40832875|NCT00031018|DRUG|Aricept|
40832876|NCT00031018|DRUG|IFN-alpha2A|
41351779|NCT01018251|RADIATION|FLT-PET/CT|
41351780|NCT01585909|PROCEDURE|Gastroscopy|When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
41351781|NCT01202643|DRUG|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
41351782|NCT01202643|DRUG|Saline|One intrauterine saline infusions of 1 cc
41351783|NCT00424099|DRUG|Methylphenidate|5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
41351784|NCT00424099|BEHAVIORAL|Nursing Telephone Intervention|Call from study nurse 3 times weekly to ask about side effects and other symptoms.
41351785|NCT00424099|DRUG|Placebo|One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
41351786|NCT00424099|BEHAVIORAL|Non NTI|Non NTI are calls from research staff 3 times weekly.
41351787|NCT05015062|BEHAVIORAL|Mobile-based HIV-related educational message delivery|HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.
41493069|NCT06313190|RADIATION|Stereotactic body radiotherapy|Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week.
40832877|NCT00556179|DRUG|Lactoserum (Dermacyd Femina®)|Once a day during three months
40832878|NCT02736513|DRUG|AZD9291|Patients will receive AZD9291 at a dose of 80 mg once daily.
40832879|NCT02864173|GENETIC|Whole genome small nucleotide polymorphism genotyping|
40832880|NCT03188835|DIETARY_SUPPLEMENT|Diet|A 2 weeks of hypercaloric diet supplemented with fructose or glucose
40832881|NCT03188835|OTHER|cold exposure|Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
40832882|NCT03188835|RADIATION|18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
40832883|NCT03188835|RADIATION|11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
40832884|NCT03188835|RADIATION|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
40832885|NCT03188835|OTHER|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
40832886|NCT03188835|OTHER|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
40832887|NCT03188835|DEVICE|MRI/MRS|Visceral and cervico-thoracic MRI and MRS acquisition.
40832888|NCT03188835|DEVICE|Electromyogram (EMG)|Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
40832889|NCT03188835|DEVICE|DXA|Lean mass will be determined by dual-energy X-ray absorptiometry
40832890|NCT03188835|DEVICE|Indirect calorimetry|VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
40832891|NCT00617955|DRUG|Aprotinin|compare outcomes of Aprotinin versus Amicar
40832892|NCT00617955|DRUG|Amicar|compare outcomes of Aprotinin versus Amicar
40832893|NCT04149860|DRUG|Lu AF87908|Lu AF87908 concentrate for solution for intravenous (IV) infusion
41493070|NCT06313190|DRUG|Sintilimab|Patients received sintilimab 200 mg every 3 weeks for up to 6 cycles, with the first dose within 1 week after the completion of SBRT.
41351788|NCT05015062|BEHAVIORAL|Incentive policies evaluation|village doctors in Intervention A and B will receive different types of monetary compensation. Doctors in Intervention A will receive standardized compensation for completing their assigned tasks. Doctors in Intervention B will receive performance-based compensation whose amount depends on how well the participants perform on the follow-up questionnaires.
41351789|NCT00443365|PROCEDURE|Mitral valve repair|mitral valve annuloplasty
41351790|NCT04151758|DRUG|Docosahexaenoic Acid Supplementation|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
41351791|NCT04151758|OTHER|Promotion of physical activity|All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
41351792|NCT04151758|OTHER|Promotion of healthy food habits|All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
41493071|NCT03833401|PROCEDURE|Autologous tissue transplantation|Root canal disinfection and revascularization with patient's own minced pulp tissues
41493072|NCT03833401|PROCEDURE|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation
40832894|NCT04149860|DRUG|Placebo|Concentrate for solution for IV infusion
40832895|NCT05304429|BEHAVIORAL|nutrition education|Educational sessions with topics that will address the management and prevention of frailty syndrome focusing on protein intake and physical activity
40832896|NCT05304429|BEHAVIORAL|nutritional counseling|nutritional counseling system based on the com-b model through three strategies: goal setting, self-monitoring and social support
40832897|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intracoronary)
40832898|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intravenous)
40832899|NCT04023123|OTHER|Ophthalmic imaging|Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
40832900|NCT00110487|DRUG|ERB-041|
41351793|NCT04474366|DRUG|Ropivacaine 0.2% Injectable Solution|Ropivacaine 0.2% Injectable Solution injected as part of the Pectoralis Nerve Block
41351794|NCT04474366|OTHER|Saline (0.9%)|Saline injection as sham block in identical fashion as Pectoralis Nerve Block
41493073|NCT01190553|DRUG|Amantadine|Initiation: IV amantadine 200mg/500ml \* 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months
41493074|NCT03781037|BEHAVIORAL|GIVE Module|The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
41351795|NCT05780229|PROCEDURE|Conservative treatment|The rehabilitation is based on restoring the balance of the shoulder joint. Aiming to diminish pain and restore function, pain control and inflammation are addressed during the firsts 3-6 weeks. Before week 3, pendulum movements are allowed to initiate mobilization of the shoulder joint. Aiming to gain (almost) complete shoulder joint mobility, a passive and active mobility exercise program is carried out. Lastly, the focus is on muscle reinforcement, performing a series of active exercises with weights or bands to exercise different muscles of the shoulder or the shoulder girdle.
41493075|NCT02879357|BEHAVIORAL|Training|"1. Clinician training~2. System for patient selection~3. System of triggering and tracking conversations~4. Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~5. Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR."
40832901|NCT06344572|DEVICE|SAT-001|Device: SAT-001(a Software as Medical Device) Using SAT-001 application for 48 weeks and wearing single vision spectacles
40832902|NCT06344572|OTHER|Single vision spectacles|Wearing single vision spectacles
40832903|NCT02124512|DRUG|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
40832904|NCT02124512|OTHER|Placebo|80 mg placebo once daily
40832905|NCT02571660|DRUG|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
40832906|NCT02571660|DRUG|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
40832907|NCT00552448|DEVICE|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
40832908|NCT04164641|DEVICE|Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic|Physical therapy evaluation (range of motion, strength, mobility, scale). Noraxon based gait assessment on treadmill while barefoot and with instrumented inner soles. Over ground walking assessment (with wireless instrumented inner soles, observational gait analysis while climbing stairs, ramps, curbs). Noraxon gait assessment and walking on treadmill will be video recorded for assessment. Standard measure of functionality and 6 minute walk test will be conducted. Patient will be fitted with corrective orthotics, based on usual care. Physical therapy re-evaluation. Noraxon based gait assessment and foot assessment (any areas of irritation, callus formation, swelling, ulcer formation, and gait mobility irregularities will be monitored and reassessed) throughout the study.
40832909|NCT00801060|DRUG|Lumiliximab + FCR|Dose, schedule, and duration in the protocol
41351796|NCT05780229|PROCEDURE|Arthroscopic Decompression Surgery|Arthroscopic decompression surgery of the rotator cuff tear consists of cleaning the subacromial space. The procedures that are sometimes performed to diminish pain may include, removing the inflamed bursa, releasing the long head of the biceps (if injured), or lightly burring the acromion bone under which the tendons slide.
41351797|NCT05780229|PROCEDURE|Reverse Prosthesis|The reverse prosthesis consists of shoulder articular joint replacement. The humeral head is sectioned, and, on the scapular side, a metal tray is placed, which is fixed with screws, and a metal half-sphere fixed to the metal tray. On the humeral side, a metal stem with a concave plastic component is placed to articulate with the metal half-sphere, allowing shoulder mobility without the need of rotator cuff muscles.
41351798|NCT05780229|DRUG|Pain-Relief Medication|In the reverse prosthesis procedure and arthroscopic decompression surgery, the pain-relief medication plan is a standard regimen for all patients, which can be modified as needed. This plan is based on 50mg of dexketoprofeno, 1g of paracetamol, and 100mg of tramadol.
41351799|NCT05780229|DEVICE|Reverse Prosthesis Device|In the reverse prosthesis procedure, a Delta III reverse shoulder prosthesis is applied. The original design was developed by Grammont in 1980's, and has 2 components: 1) a metal tray fixed with screws, and a metal half-sphere fixed to the metal tray, and 2) a concave polyethylene component.
41493076|NCT00960635|DRUG|1,25-dihydroxy-vitamin D3 (calcitriol)|
41493077|NCT00960635|DRUG|placebo|pill without agent
41493078|NCT01104909|PROCEDURE|Clinical|Each patient will be submitted a clinical evaluation, considering signals of overload.
41493079|NCT01104909|DEVICE|electrical bioimpedance|From electrical bioimpedance data, will be fixed a revised dry weight for each patient.
41493080|NCT04015323|DEVICE|Interferential current|An electrotherapy current with different carrier frequencies
40832910|NCT00801060|DRUG|FCR|Dosage, schedule, and duration in the protocol
40832911|NCT00432744|DRUG|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
40832912|NCT00432744|DRUG|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
40832913|NCT04584346|DIETARY_SUPPLEMENT|Liquigen MCT oil|MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values
40832914|NCT04584346|OTHER|Standard American Diet|Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%
40832915|NCT01169584|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
40832916|NCT00214474|BEHAVIORAL|ATSM Intervention|Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.
40832917|NCT00214474|BEHAVIORAL|GMV Intervention|GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
40832918|NCT02295007|BEHAVIORAL|text message|
40832919|NCT06519461|BEHAVIORAL|Family-centered teaching model|The program comprised two parts: (1) Didactic lessons: and (2) Hands-on practice. The didactic lessons were designed to prepare interns' knowledge and skills. The hands-on practice were designed to provide opportunities of family-centered experience to work with caregivers and children.
41493081|NCT00000474|BEHAVIORAL|behavior therapy|
41493082|NCT02648295|PROCEDURE|Effects of IV TXA on TEG in patients undergoing THA or TKA|Subjects will undergo surgery per standard of care. All subjects will have 3 additional vials of blood drawn to evaluate TEG.
41351800|NCT03667573|DEVICE|tsDCS Dosage (A)|mild electrical stimulation delivered to lumbosacral spinal cord
41351801|NCT03667573|DEVICE|tsDCS Dosage (B)|mild electrical stimulation delivered to lumbosacral spinal cord
41351802|NCT03667573|OTHER|textured shoe insoles|textured shoe insoles
41351803|NCT02685839|DEVICE|Intelligent POWER Rehabilitation Cluster Machine|
41351804|NCT02685839|OTHER|general physical therapy|
41351805|NCT00827125|DEVICE|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
41351806|NCT06091306|BEHAVIORAL|Psychotherapy|"Multifamily therapy (MFT), which involves bringing several families together to address the problem of anorexia nervosa, has proved effective for several years now.~Since January 2019, multifamily therapy has been offered to adolescents aged 12 to 18 who are being treated for anorexia nervosa at the Maison de Solenn-Maison des Adolescents at Cochin Hospital, and to their families.~Each group brings together 5 to 7 families and comprises 10 3-hour sessions, with 3 weeks between each session. 2 groups are offered per year. Multifamily therapy therefore involves 10 to 14 families per year. It complements the other approaches available in the department."
41351807|NCT04276831|DEVICE|Laryngoscope McCoy|Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy
41493083|NCT02125253|DRUG|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
41493084|NCT02125253|DRUG|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
41493085|NCT02125253|DRUG|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
41493086|NCT05630690|DEVICE|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
41351808|NCT04276831|DEVICE|Laryngoscope Macintosh|Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
41493087|NCT01681602|OTHER|Aerobic exercise|Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
41493088|NCT00006199|DRUG|R115777 (farnesyl transferase inhibitor)|
41493089|NCT00006199|DRUG|Topotecan|
41493090|NCT03968445|DRUG|[18F]DPA-714-PET/MRI|\[18F\]DPA-714-PET/MRI
41351809|NCT01829672|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration"
41351810|NCT04043416|OTHER|Motivating reminiscence technology|The jDome BikeAround uses Google Street View, a stationary bike and a domed screen. Residents are seated in front of the screen; their destination is typed into the computer and when loaded the image appears on the screen. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
41351811|NCT04233957|DIETARY_SUPPLEMENT|High Sodium|10 days of 3900 mg of sodium/day in excess of normal dietary intake delivered via enteric capsules filled with table salt.
41351812|NCT04233957|OTHER|Placebo|10 days of enteric capsules filled with dextrose.
41351813|NCT00000756|DRUG|Lymphocytes, Activated|
41351814|NCT04838340|OTHER|Standart care|This group will leave in the hospital's usual care and no intervention will be applied.
41351815|NCT04838340|BEHAVIORAL|Hypnobirthig training|"Hypnobirthing training of the Hypnobirthing group will carry out with its partner. Hypnobirthig training will be given in small groups of 5 or 6 couples for 4 weeks and 3 hours a week. In addition, the usual care will be provided by healthcare professionals to this group.~Breathing, relaxation exercises, birth stories and birth videos will be used to reduce fears of chlildbirt women.~Deepening and endorphin massage techniques will be given for labor pain. After the endorphin massage technique will be applied individually by the researcher, it will be applied by the couples and they will ask for repeating all exercises at home.~In the last week of the training, there will be a birth rehearsal with Hynobirthing methods with the partners.~The second meeting will take place when labor begins and after labor."
41493091|NCT03336177|OTHER|Semi-structured face to face interviews.|Patients will be interviewed by open-ended questions face to face concerning their past experiences. The recorded interview will be transcribed and analyzed by psychodynamic and semio-pragmatic approach.
41493092|NCT00294775|DRUG|Candesartan|
41493093|NCT04321330|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by IV on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
41351816|NCT04248972|DEVICE|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
41351817|NCT04248972|OTHER|PLACEBO PBM|A placebo whole body red light will be carried out during 20 minutes
41351818|NCT00633425|DRUG|GLIMEPIRIDE|
40832920|NCT02221518|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
40832921|NCT02688868|DEVICE|FirehawkTM 2.25mm|Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
41493094|NCT01405716|BEHAVIORAL|Mindfulness Meditation|8-week mindfulness based program will be compared to and education control group
41493095|NCT01405716|BEHAVIORAL|Health Education|8-week health education program
41493096|NCT00541216|DRUG|Ephedrine|
41493097|NCT03056586|DEVICE|vaginal pessary|A vaginal pessary will be inserted at the end of the operation, for genital prolapse, and will be sutured to the vaginal wall. The pessary will stay in the vagina for 4 weeks.
41493098|NCT06170437|BEHAVIORAL|Smoke-free home resident intervention|Study staff delivered intervention on how to adopt a smoke free home using a pamphlet
41493099|NCT06170437|BEHAVIORAL|Lay Health Worker coaching|Brief tobacco cessation coaching by lay health worker housing staff with residents within 2 weeks of the smoke-free home resident intervention, and on a monthly schedule as part of their routine encounters with residents (total 6 sessions).
41493100|NCT03086837|BEHAVIORAL|Mobile phone based intervention|Participants will receive supporting messages through a mobile phone based intervention.
40832922|NCT00736775|DRUG|anti-Abeta|Intravenous single and multiple doses
40832923|NCT00736775|DRUG|placebo|Intravenous single and multiple doses
40832924|NCT02051023|DRUG|FML 0.1% eyedrops|Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
40832925|NCT02051023|DRUG|Liquifilm artificial tears eyedrops|Liquifilm instillation 4 times a day for 22 days
40832926|NCT03345719|DIAGNOSTIC_TEST|3D Cone-Beam Imaging|
40832927|NCT02032641|DEVICE|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
40832928|NCT06294938|OTHER|Cacao fruit pulp|Cacao pulp puree
40832929|NCT06294938|OTHER|Dextrose|Dextrose beverage
40832930|NCT03527628|DRUG|Adriamycin|25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
40832931|NCT03527628|DRUG|Cyclophosphamide|400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
41351819|NCT05841953|DEVICE|Transcutaneous neuromuscular electrical stimulation|Transcutaneous electrical stimulation will be delivered to the anal sphincter and anal resting and squeezing pressures as a result of the stimulation will be recorded for different stimulation protocols using approved electrotherapy units
41351820|NCT04202029|DEVICE|thoracic impedance monitoring|Thoracic impedance measurement identifies the respiratory frequence using the changes of impedance during inspiration and expiration via an ECG.
41351821|NCT04202029|DEVICE|pulseoxymetry|Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood
41351822|NCT04202029|DEVICE|non-invasive blood preassure monitoring|Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.
41351823|NCT02504606|DRUG|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
41351824|NCT02504606|DRUG|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
41351825|NCT00284609|BEHAVIORAL|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month"
41493101|NCT03286010|BEHAVIORAL|Women@Heart Program|The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.
41493102|NCT05379907|OTHER|SIGNATERA™ ctDNA testing|Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.
41493103|NCT06494345|BIOLOGICAL|Genolair, solution for subcutaneous administration, 150 mg|Genolair (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
40832932|NCT03527628|DRUG|Vinblastine|6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
40832933|NCT03527628|DRUG|Dacarbazine|375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
40832934|NCT03527628|DRUG|Brentuximab Vedotin|1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
40832935|NCT03527628|DRUG|ABVD|All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
40832936|NCT05308498|DIAGNOSTIC_TEST|ESView software with proscan|Each reviewer will review random video and record all lesions/findings with the ESView software with ProScan.
40832937|NCT05308498|DIAGNOSTIC_TEST|Rapid software with SBI|Each reviewer will review random video and record all lesions/findings with the PillCam Rapid software with SBI.
41351826|NCT00284609|BEHAVIORAL|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month"
40832938|NCT01397682|OTHER|blood sample collection|A blood sample will be drawn within 24 hours from admission for determination of biomarkers and genetic analyses
40832939|NCT03059771|BEHAVIORAL|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
40832940|NCT03059771|BEHAVIORAL|Control|The control group will only engage in a goal-setting session.
40832941|NCT06013280|OTHER|Progresive Muscle Relaxation and Breathing Exercise|"Intervention protocol contains 40 minuntes sessions, which involved tensing and relaxing the body along with deep breathing.~Protocol consisted with; Warm-up (5 minutes breathing exercise) Progressive Muscle Relaxation Exercises (The participants performed PMR for each body part in a particular order, beginning with the face muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet. This muscle tensing and relaxing procedures were performed in accompaniment with deep breathing.) Cool-down (5 minutes breathing exercise)"
40832942|NCT03757130|DRUG|AMG 598|AMG 598 administered by subcutaneous injection
40832943|NCT03757130|DRUG|Placebo|Placebo matching to AMG 598 administered by subcutaneous injection
41351827|NCT06278584|DEVICE|iLUX Treatment System|Local heat using an electrical warming mask for 5 minutes.
41351828|NCT01786278|RADIATION|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
41493104|NCT06494345|BIOLOGICAL|Genolair, lyophilisate for the preparation of solution for subcutaneous administration|Genolair (omalizumab), lyophilisate for the preparation of solution for subcutaneous administration, 150 mg for single subcutaneous administration
41493105|NCT06494345|BIOLOGICAL|Xolair®, solution for subcutaneous administration, 150 mg|Xolair® (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
41351829|NCT01786278|PROCEDURE|Endoscopic stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
41351830|NCT04626570|OTHER|Cognitive and Behavioral Therapy|12 sessions of CBT using a standardized approach
41351831|NCT00090623|DRUG|rhuFab V2 (ranibizumab)|
41351832|NCT04509297|DIETARY_SUPPLEMENT|high protein milk|This intervention consisted of high protein milk consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
41351833|NCT04509297|DIETARY_SUPPLEMENT|Placebo|This intervention consisted of the consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
41351834|NCT03296072|DRUG|0.254% w/w sodium fluoride and 5% KNO3|Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres \[mL\] of tap water for 10 seconds before expectorating again.
41351835|NCT03296072|DRUG|0.454% w/w stannous fluoride|Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
41351836|NCT03296072|DRUG|5% KNO3|Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
41351837|NCT03049085|DRUG|Aspirin|preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
41351838|NCT03049085|DRUG|vitamin C|preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
41493106|NCT02570516|PROCEDURE|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
41493107|NCT03933436|OTHER|Iodine swabs.|Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.
41493108|NCT03933436|OTHER|Saline flush.|Children will then have their periurethral region gently cleansed for ten seconds with saline flush.
41351839|NCT06373224|OTHER|Flush|After identifying the lymph node or lesion to be biopsied on ultrasound, using the endobronchial ultrasound scope, two 60mL syringes of cold saline will be inserted, through the biopsy channel of the endobronchial ultrasound scope, directly onto the bronchial wall where the biopsies are to be performed. The saline will then be sucked out of the airway using the endobronchial ultrasound scope.
41351840|NCT00276354|DRUG|PEG 4000 (Forlax ®)|
41493109|NCT01905748|OTHER|Laboratory tests|Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
41509134|NCT04308057|PROCEDURE|Aquatic exercise|Participants belonging to Group D (sedentary group) will be randomised 1-to-1 between remaining sedentary (n=20) and following a self-managed, 8-week, aquatic-based exercise programme (n=20). The latter group will be offered an 8-week access to pool facilities. For Group D participants, all baseline assessments will be repeated at 8 weeks.
41509135|NCT02413567|DEVICE|DMR Procedure (Fractyl)|Endoscopic procedure
41509136|NCT04363957|OTHER|Brachytherapy video|Patients will watch a video that contains information about brachytherapy
41351841|NCT05788718|DRUG|Sugammadex|As this is a non-interventional study designed to collect data as part of routine clinical practice, the type and dose of neuromuscular blocking agents are all based on the clinician's judgment.
41493110|NCT06142123|OTHER|3-D Ankle Mobility Exercises(A)|"The techniques will be first performed in prone lying against the resistance of the therapist and then in crook lying.~1. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the prone position according to the resistance of therapist.~2. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the prone position according to the resistance of therapist.~3. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the crook-lying position according to the resistance of therapist.~4. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the crook-lying position according to the resistance of therapist."
41266492|NCT04664348|OTHER|Posteroanterior mobilization (extension)|"Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain."
41351842|NCT00397449|BIOLOGICAL|GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)|
41351843|NCT03869931|DRUG|Fenofibrate|Fenofibrate 100 mg or 300 mg (according to CrCl)
41351844|NCT00150514|DRUG|Oralgen|
41351845|NCT00150514|PROCEDURE|Nasal biopsy|
41351846|NCT00150514|PROCEDURE|Nasal washing|
41351847|NCT00150514|PROCEDURE|Peak nasal inspiratory flow|
41351848|NCT06425224|DEVICE|Tens therapy|"There will be 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance. TENT therapy will be performed as follows:~1. The active electrode (cathode - red) is placed and adhered 3 - 5 cm above the internal malleolus and 1 cm behind the tibia.~The second reference electrode (anode - black) is attached to the calcaneus.~The equipment must previously be programmed under the following parameters:~Continuous current Frequency: 20 Hz. Pulse width: 200 µsec Time: 30 min. Intensity: to the patient's tolerance, gross motor perception to verify correct application, upon reaching it, increase the intensity to clearly sensory activation."
41351849|NCT06425224|DRUG|Dapoxetine placebo|Patients in this group will receive dapoxetine placebo (capsules with only excipients without active ingredient) as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention.
41351850|NCT06425224|DRUG|Standard treatment (dapoxetine 30 mg as needed)|Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study
41351851|NCT06425224|DEVICE|Placebo therapy|In addition to the medication, patients will receive three weekly sessions of placebo therapy for twelve continuous weeks, lasting 30 minutes each. For this, the black electrode will be placed on the external malleolus and the red one 4 finger widths towards the head on the lateral edge of the tibia. 20 Hertz with a pulse width of 200 µsec will be administered in each session.
41351852|NCT00959829|OTHER|Music and message|Experimental group: music and message Control group: silence
41351853|NCT04605068|PROCEDURE|Transverse preputial island flap (Duckett's technique)|
41351854|NCT04605068|PROCEDURE|Double-faced preputial flap (DFPF)|
41351855|NCT06102291|OTHER|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
40832944|NCT03757130|DRUG|Liraglutide|Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
40832945|NCT04347980|DRUG|Dexamethasone and Hydroxychloroquine|"Patients included in the Hydroxychloroquine / Dexamethasone group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before."
40832946|NCT04347980|DRUG|Hydroxychloroquine|Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.
40832947|NCT00369226|DRUG|Bortezomib (Velcade)|Infusion for a total of 3 doses
40832948|NCT00369226|DRUG|Tacrolimus|Taken until Doctor determines it is not necessary any more
40832949|NCT00369226|DRUG|Methotrexate|Infusion for a total of 4 doses
41351856|NCT06102291|OTHER|Acupuncture|The main acupoints are Ashi points, Shenshu (BL23), Guanyuanshu (BL26). There are three sessions per week with each session lasting for 20 min. There will be 4 weeks of treatment for each participant in total.
41351857|NCT00857116|DRUG|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
41351858|NCT00857116|DRUG|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
41351859|NCT02330601|PROCEDURE|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
41351860|NCT00095394|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
41351861|NCT00095394|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
41351862|NCT02692976|BIOLOGICAL|mDC vaccination|Intranodal mDC vaccination
41351863|NCT02692976|BIOLOGICAL|pDC vaccination|Intranodal pDC vaccination
41351864|NCT02692976|BIOLOGICAL|mDC and pDC vaccination|Intranodal mDC/pDC vaccination
41351865|NCT02540655|BIOLOGICAL|Stemchymal®|Patients will receive Stemchymal® through intravenous infusion
41351866|NCT02540655|PROCEDURE|Excipients|Patients will receive excipients through intravenous infusion
41351867|NCT04759040|DIETARY_SUPPLEMENT|Migraineguard|2 Capsules per day for 7 Months
41351868|NCT02658149|DRUG|Ropivacaine with NaCl|50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
41351869|NCT02658149|DRUG|Epinephrine|"0.15 mg Epinephrine are injected as part of the drug cocktail"
41351870|NCT02658149|DRUG|Morphine|"4 mg Morphine are injected as part of the drug cocktail"
41351871|NCT02658149|DRUG|Ketorolac Tromethamine|"30 mg morphine are injected as part of the drug cocktail"
41351872|NCT02658149|DRUG|Ropivacaine|"30 mL 0.5% Ropivicaine are injected as part of the drug cocktail"
41351873|NCT04510844|DRUG|Evolocumab|Evolocumab is commercially available in the United States and is manufactured by Amgen. Drug and placebo, will be supplied by the manufacturer. The SureClick® pre-filled auto injector contain Evolocumab (140 mg) acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in water for Injection. Evolocumab will be administered at a dose of 420 mg subcutaneously once monthly.
41351874|NCT04510844|OTHER|Placebo|Placebo will be supplied by the manufacturer. Placebo auto injectors will be identically packaged but will lack the active ingredient. Placebo will be administered at an equivalent volume to Evolocumab and given subcutaneously once monthly.
41351875|NCT05013385|DRUG|Spesolimab|Spesolimab
41351876|NCT05013385|DRUG|Placebo|Placebo
41351877|NCT04105595|DEVICE|Septal defect closure|Device closure of atrial septal defect
41351878|NCT04004000|DRUG|Losmapimod|"The main study includes a treatment period of approximately one year. Subjects will receive 15 mg of losmapimod twice daily by mouth; for a total of 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.~Only subjects who participated in and completed all procedures for the main study (Week 60) will be eligible to participate in the extension.~For the extension, subjects will receive 15 mg of losmapimod by mouth twice daily for a total of 30 mg by mouth daily. Participation will continue until 90 days after commercial drug is available post regulatory approval or study termination."
41351879|NCT01792024|DEVICE|Visualase Thermal Therapy|MR guided laser ablation of prostate cancer
41351880|NCT01792024|PROCEDURE|magnetic resonance imaging|Undergo MR-guided LITT
41351881|NCT05597111|DIAGNOSTIC_TEST|DHA levels of blood and cervical mucus|DHA levels of blood and cervical mucus of the control and the study groups will be measure
41351882|NCT00089505|DRUG|Emtricitabine|200 mg taken orally
41351883|NCT00089505|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200/300 mg taken orally
41351884|NCT00089505|DRUG|Lopinavir/Ritonavir|400/100 mg taken orally
41351885|NCT00089505|DRUG|Nevirapine|200 mg taken orally
41493111|NCT06142123|OTHER|Eccentric Heel Drop Training(B)|": Group B will be treated with Eccentric Heel Drop Training. It will comprise of following exercises (14).~1. Eccentric loading exercises of calf muscles.~2. Conventional physiotherapy treatment including Ultrasound Plantar fascia stretching Calf muscle stretching Intrinsic muscles strengthening"
40832950|NCT00369226|PROCEDURE|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
40832951|NCT03777124|DRUG|SHR-1210|Subjects receive SHR-1210 intravenous every 2 weeks
40832952|NCT03777124|DRUG|Apatinib|Subjects receive Apatinib orally every day
40832953|NCT03777124|DRUG|Pemetrexed|Subjects receive Pemetrexed intravenous every 3 weeks
41351886|NCT00089505|DRUG|Tenofovir disoproxil fumarate|300 mg taken orally
41351887|NCT00606931|DEVICE|Stereo Navigator Accessory to PEM Flex PET Scanner|For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
41351888|NCT04143490|OTHER|Exercise|60 minutes of continuous exercise at 65% VO2peak and drink ingestion
41351889|NCT00381836|DRUG|Darbepoetin Alfa|
41351890|NCT03756142|DIAGNOSTIC_TEST|Motion Analysis|Analysis of orthostatic posture, initiation of walking and walking by a motion analysis system
41351891|NCT00467506|DRUG|bispecific antibody and di-DTPA-131I|
41351892|NCT02453828|PROCEDURE|Non-cardiac surgery|patients having non-cardiac surgery
41351893|NCT03871764|DIAGNOSTIC_TEST|blood sample , doppler of uterine vessel and placenta|blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum
41351894|NCT02705547|DRUG|Rosuvastatin|Daily oral administration of Rosuvastatin (10 mg) for 3 months
41351895|NCT01636739|BIOLOGICAL|Oral Rotarix®|2 doses administered orally.
41351896|NCT01636739|OTHER|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
41351897|NCT03322540|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
41351898|NCT03322540|DRUG|Epacadostat|Epacadostat administered orally twice daily.
41351899|NCT03322540|DRUG|Placebo|Matching placebo administered orally twice daily.
41351900|NCT05538585|DRUG|Galicaftor|Oral
41493112|NCT00015769|DRUG|levetiracetam|
41351901|NCT05538585|DRUG|Navocaftor|Oral
41351902|NCT02263742|BEHAVIORAL|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
41351903|NCT02263742|BEHAVIORAL|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
41351904|NCT04211740|DRUG|OCH-NCNP1|OCH-NCNP1 3mg is supplied as granules and take orally once a week.
41351905|NCT04211740|DRUG|Placebo|Placebo is supplied as granules and take orally once a week.
41493113|NCT03511326|DRUG|Methyl Aminolaevulinate 16% Cream|Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy
41351906|NCT00490126|OTHER|Laparoscopic Surgery Data Collection|Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.
41351907|NCT04950933|DRUG|Huolingshengji Granules|1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;
41351908|NCT04950933|DRUG|Riluzole tablet|Huolingshengji granules simulation agent 1 bag each time + Riluzole tablet 1 tablet each time, 2 times a day, orally.
41351909|NCT06135766|BEHAVIORAL|A Lust for Life|A Lust for Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
41351910|NCT06135766|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life (ALFL) programme.
41351911|NCT00004844|PROCEDURE|tissue implantation|
41351912|NCT00138853|DEVICE|Tibial component|Tibial component inserted at the time of surgery
41351913|NCT00997607|BIOLOGICAL|Ebola vaccine|4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
41351914|NCT00997607|BIOLOGICAL|Marburg vaccine|4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
41351915|NCT00997607|OTHER|Placebo injection|4 mg of saline injection delivered at Weeks 0, 4, and 8
41351916|NCT00423540|DRUG|Intravenous Infusion of Magnesium Sulfate|See Detailed Description.
41351917|NCT06184165|PROCEDURE|Personalized rTMS|"5 personalized targets accessible to TMS (at less than 3.5 cm distance from the scalp or the coil's hot spot) are placed in the hyper-perfused premotor regions.~The patient is installed on the robotic device. The technician puts a neuro-navigation tracker on the subject's forehead and proceeds to the co-registration. The motor threshold is defined, and stimulator output's intensity is adjusted accordingly (120%) The robotic system ensures that the actual stimulation is performed according to the personalized protocol. This adequacy will be evaluated secondarily based on the recordings of the coil positions during each"
41351918|NCT01240772|DEVICE|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
41351919|NCT01240772|DEVICE|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
41351920|NCT05647928|OTHER|no intervention|no intervention
40832954|NCT03777124|DRUG|Carboplatin|subjects receive carboplatin intravenous every 3 weeks
41351921|NCT04319835|DEVICE|OnZurf Probe|
40832955|NCT00499746|DRUG|tramadol|oral dose, once per day
40832956|NCT00499746|DRUG|placebo|oral dose, once per day
40832957|NCT00499746|DRUG|Hydromorphone|oral dose, once per day
40832958|NCT00499746|DRUG|Methylphenidate|oral dose, once per day
40832959|NCT03826680|PROCEDURE|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by awake flexible fiberoptic laryngoscopy and during surgery by direct laryngoscopy under general anesthesia
40832960|NCT03826680|PROCEDURE|Direct laryngoscopy|Patients who will undergo thyroidectomy evaluated before by ENT physician, will be evaluated by anesthesiologist in means of MCL score by direct laryngoscopy during surgery under general anesthesia
40832961|NCT06179420|OTHER|total cumulative gonadotrophin usage|total dosage in IU
40832962|NCT03397992|OTHER|Changing dialysate temperature|Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
41351922|NCT02233894|DRUG|Atrovent® - inhalets|
41351923|NCT02518568|DRUG|V0355|Oral administration (2 tablets)
41351924|NCT01845766|OTHER|exercise rehabilitation|
41351925|NCT01085695|DRUG|rabeprazole|10 mg normal tablet
41351926|NCT01085695|DRUG|rabeprazole|Type 1 granule containing rabeprazole 10 mg
41351927|NCT01085695|DRUG|rabeprazole|Type 2 granule containing rabeprazole 10 mg
41351928|NCT01085695|DRUG|rabeprazole|Type 3 granule containing rabeprazole 10 mg
41351929|NCT06135142|OTHER|Connective Tissue Massage|It involves manipulating the soft and deep tissues of the body.
41351930|NCT06135142|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.
41351931|NCT06135142|OTHER|Classical Massage|It involves manipulating the soft tissues of the body.
41351932|NCT06135142|DEVICE|Therapatic Ultrasound|The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.
41493114|NCT04425538|DRUG|Infliximab|Either infliximab or infliximab-abda will be used at the discretion of the investigator
41493115|NCT03219619|DEVICE|Cap-EGD|Undergoing cap-assisted endoscopy
41493116|NCT03219619|DEVICE|Duo|Undergoing side-viewing duodenoscope
41493117|NCT05748249|DRUG|Vertistop® D|Vitamin D supplementation
41493118|NCT00423683|DRUG|Arixtra alone|Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)
41493119|NCT00423683|DEVICE|Arixtra + filter|Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.
41493120|NCT04190810|BEHAVIORAL|Inhibition|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
41493121|NCT04190810|BEHAVIORAL|Classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
41493122|NCT04190810|BEHAVIORAL|Control|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
41493123|NCT00266396|BEHAVIORAL|Recommend full weight-bearing|The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
41493124|NCT00266396|BEHAVIORAL|Recommend parital weight-bearing|The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
41493125|NCT05362734|BEHAVIORAL|obstetric outcomes after fresh versus cryopreserved embryo transfer|measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence, drop out rate
41493126|NCT05234593|DIETARY_SUPPLEMENT|EmpowerPlus Lightning Sticks|multinutrient supplement containing vitamins, minerals, amino acids and antioxidants taken one Stick daily by dissolving the powder on or under the tongue
41493127|NCT00581126|DRUG|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
40832963|NCT06213142|OTHER|CBToolkit|CB Toolkit Mindful Awareness module to increase awareness and tolerance of physical sensations and emotional experiences using mindfulness practices. The module involves videos with motion graphics, video demos, voiceover, music, and sound effects intermixed throughout with a variety of interactive exercises tailored to specific core components. The module aims to establish understanding of the intervention concept (psychoeducation), increase self-efficacy in mindfulness skills via active practice and personalized feedback, and facilitate self-reflection and understanding of strengths and improvement areas related to mindfulness. CBToolkit Flexible Problem Solving module to promote cognitive flexibility, applying problem-solving strategies in difficult scenarios, and learning to modify behavioral action tendencies. Videos and activities will be tailored to provide examples of effective problem-solving techniques and provide personalized reinforcing and/or scaffolded feedback.
40832964|NCT00771797|DIETARY_SUPPLEMENT|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
40832965|NCT00771797|DIETARY_SUPPLEMENT|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
40832966|NCT01390207|OTHER|16mm triggering|"Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:~• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound."
40832967|NCT00817648|DRUG|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
40832968|NCT00817648|DRUG|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
40832969|NCT00801047|DRUG|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
41159500|NCT04461314|BEHAVIORAL|peer-led counselling|"About 50 university students will be trained as peer counsellors through a structured training programme. A pre and post and 6-month self-administered questionnaire will be conducted before, immediately and 6-month after the training programme to examine their changes of knowledge and attitudes. A satisfaction survey will also be conducted to measure participants' perception of the quality of the training programme.~Drug-abusing youth and young adults will receive telephone-based, Peer-led Brief Motivational Interviewing (BMI) counselling to rehabilitate from drug abuse. The peer counsellors will give referral advice if the youth and young adult needs appropriate treatment and rehabilitation services.~The drug abusers will be counselled and invited to complete the follow-up questionnaires at 1 week, 1 month, 3 months, 6 months, 9 months and 1 year. Self-reported quitters at 6-month and 1-year follow-ups will be invited to have a urine test to validate the drug abuse abstinence."
41493128|NCT04373044|DRUG|Baricitinib|Given PO
41493129|NCT04373044|DRUG|Hydroxychloroquine|Given PO
41159501|NCT02223507|DRUG|BIIR 561 CL|
41493130|NCT04373044|DRUG|Placebo Administration|Given Po
41493131|NCT03936426|DRUG|Cu-64 SARTATE and Cu-67 SARTATE|Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug
41493132|NCT01908816|DRUG|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
41493133|NCT00421395|BIOLOGICAL|90Y-hLL2|weekly dosing for either 2 or 3 weeks
41493134|NCT02280668|OTHER|Icing Therapy|Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
41493135|NCT02280668|OTHER|the eccentric muscle damage exercise|
40832970|NCT00801047|DRUG|Remifentanil|40-50 mic per 1-2 min via PCA
41159502|NCT02223507|DRUG|Placebo|
41493136|NCT03837743|DRUG|DUR-928 Topical Solution|Topical solution containing active drug
41351933|NCT06135142|OTHER|Heat Treatment|Applying heat to an affected area to treat damaged muscles, joints or tissues in the body.
41351934|NCT03727802|DRUG|TRK-250|single and multiple doses (4 weeks)
41351935|NCT03727802|DRUG|Placebo|single and multiple doses (4 weeks)
41351936|NCT05557240|DRUG|NeoPep Vaccine1 plus Poly-ICLC|"NPVAC1： NPVAC1 drug products are composed of 5 peptides from the HCMV warehouse， NPVAC1 vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with NPVAC1 drug products during 6 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
41493137|NCT03837743|DRUG|Vehicle Topical Solution|Topical solution containing no active drug
41493138|NCT01877746|DRUG|Combination of prednisone and azathioprine|"* Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
41493139|NCT01877746|DRUG|Combination of prednisone and azathioprine|"* Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
41159503|NCT03644784|DIAGNOSTIC_TEST|Standardized protocol for assessing aortic regurgitation using videodensitometry|Standardized protocol for assessing aortic regurgitation using videodensitometry
41159504|NCT04043806|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
41351937|NCT05557240|DRUG|NeoPep Vaccine2 plus Poly-ICLC|"NPVAC2： NPVAC2 will be ready for use 2 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. NPVAC2 drug products are composed 20 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with NPVAC2 drug products beginning on day 33 of the 6 maintenance TMZ cycle.Patients will receive 9 vaccinations within 12 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
41351938|NCT04839913|DIAGNOSTIC_TEST|Antibodies testing|Serologic test for both SARS-COV-2 IgG and IgM
41351939|NCT01249521|DRUG|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
41351940|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control Form 1|Participants will use their Radicle Rest Placebo Control Form 1 as directed for a period of 6 weeks.
41493140|NCT01877746|OTHER|No intervention|No intervention, only standard medical therapy
41493141|NCT04149106|DRUG|Sulfadoxine pyrimethamine + Amodiaquin|Monthly dose of SPAQ over three days for SMC
41493142|NCT04149106|DRUG|Dihydroartemisinin piperaquin|Monthly dose of DHAPQ for SMC
41493143|NCT00975403|DEVICE|Dead space breathing|Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test
41493144|NCT00975403|DEVICE|Room air breathing|Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
41493145|NCT03033966|DEVICE|NIRS based Cerebral Oximetry|Cerebral Oximetric measurement before and after decompressive craniectomy
41493146|NCT03654820|DEVICE|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
41493147|NCT03654820|DEVICE|SDF solution|Annual application of 38% SDF solution
41493148|NCT02011386|DRUG|Treatment|
41493149|NCT04326205|DEVICE|transcranial direct current stimulation, tDCS|"The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice."
41509137|NCT04363957|OTHER|Standard Brachytherapy Consent Process|Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
41509138|NCT02175901|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
41509139|NCT02175901|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
41509140|NCT02175901|DRUG|Amoxicillin|antibiotic of each quadruple therapy
41351941|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 1.1 Usage|Participants will use their Radicle Rest Active Study Product 1.1 as directed for a period of 6 weeks.
41351942|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control Form 2|Participants will use their Radicle Rest Placebo Control Form 2 as directed for a period of 6 weeks.
41351943|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 2.1 Usage|Participants will use their Radicle Rest Active Study Product 2.1 as directed for a period of 6 weeks.
41351944|NCT01066611|DRUG|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
41159505|NCT04043806|DRUG|IVA|Tablet for oral administration.
41159506|NCT02536885|PROCEDURE|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
41266493|NCT05611073|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
41351945|NCT01066611|DRUG|Placebo|CAL-263 10 mg or placebo once daily for 7 days
41351946|NCT05273294|DEVICE|Portable color Doppler ultrasound system|In the ultrasound group, the catheter type was selected according to the results of ultrasonic measurement of transverse diameter of cricoid cartilage after induction of general anesthesia, and tracheal intubation was performed with ordinary laryngoscope after measurement
41351947|NCT01865136|OTHER|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
41266494|NCT05611073|DIAGNOSTIC_TEST|Biometric Data Collection|Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.
41351948|NCT01427829|BEHAVIORAL|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
40832971|NCT03808363|OTHER|High Intensity Interval Training|Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the Borg rating of perceived exertion (RPE) scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
40832972|NCT00755469|PROCEDURE|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
40832973|NCT01330966|DRUG|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
40832974|NCT04108715|PROCEDURE|Erector spina plain block for mastectomy analgesia|After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
41351949|NCT02405091|DRUG|NBI-98854|
40832975|NCT04108715|PROCEDURE|Deep serratus anterior plane block|After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
40832976|NCT04668235|DRUG|AZVUDINE|5 tablets QD + standard treatment for up to 14 days
40832977|NCT04668235|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment for up to 14 days
41351950|NCT00362440|DRUG|Leptin|
41351951|NCT00362440|DRUG|Pioglitazone or metformin|
41351952|NCT00362440|DRUG|Placebo|
41351953|NCT01511692|DRUG|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
41351954|NCT01511692|DRUG|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
40832978|NCT00377559|DRUG|Non pegylated liposomal doxorubicin and docetaxel|max. 6 courses
40832979|NCT02546089|OTHER|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
40832980|NCT02546089|OTHER|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
40832981|NCT02546089|OTHER|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
41351955|NCT01511692|DRUG|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
41351956|NCT01511692|DRUG|glimepiride|Dose individually adjusted, administered orally for 4 weeks
41493150|NCT04326205|DEVICE|functional electrical stimulation, FES|"The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice."
41351957|NCT05240781|DEVICE|Zotarolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used by CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and Chronic Coronary Syndrome (CCS). Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
41493151|NCT04326205|OTHER|no stimulation|Both tDCS and FES will not be used in this section.
40832982|NCT02080325|OTHER|High Protein-Weight loss-Soy diet|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).
40832983|NCT02080325|OTHER|High Protein-Weight loss-Meat|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
40832984|NCT06391853|DRUG|Insulin|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
40832985|NCT06391853|DRUG|Placebo|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
40832986|NCT02995226|OTHER|Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires|Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
40832987|NCT02995226|OTHER|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
40832988|NCT03384823|DRUG|EDP-938|Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).
40832989|NCT03384823|DRUG|Placebo|placebo to match EDP-938
40832990|NCT04527419|PROCEDURE|Systematically mediastinal lymph node dissection|Systematically mediastinal lymph node dissection will be performed.
40832991|NCT04527419|PROCEDURE|No mediastinal lymph node dissection|No mediastinal lymph node dissection will be performed.
40832992|NCT00145691|DRUG|Oxcarbazepine|
40832993|NCT00784732|DRUG|QAV680|
40832994|NCT00784732|DRUG|QAV680|
40832995|NCT00784732|DRUG|Mometasone Furoate|
40832996|NCT00272116|DRUG|Zinc and vitamin A single dose at enrollment|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
40832997|NCT00272116|DRUG|Placebo and vitamin A single dose at enrollment|Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
40832998|NCT04670393|DIETARY_SUPPLEMENT|FertyBiotic Woman Plus|4g Myo-Inositol, 421 mg D-Chiro-Inositol, 400 mcg folic acid, 55 mcg selenium, 15 mcg vitamin D, 1,8 mg melatonin,2x109 Lactobacillus rhamnosus, 2x109 Lactobacillus crispatus and 2x109 Lactobacillus plantarum
40832999|NCT04670393|OTHER|Placebo|400 mcg folic acid
40833000|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, irradiation|Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
40833001|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, no irradiation|Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
41266495|NCT05611073|OTHER|Patient Questionnaire|Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.
41266496|NCT02718378|DRUG|estetrol|
41266497|NCT02718378|DRUG|placebo|
41266498|NCT00472693|DRUG|Bevacizumab, Abraxane|Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
41266499|NCT00052390|BIOLOGICAL|bevacizumab|
41266500|NCT00052390|DRUG|doxorubicin hydrochloride|
41020703|NCT06572696|DIAGNOSTIC_TEST|Shulder Ultrasound|"Ultrasound Shoulder Pathology Rating Scale (USPRS) will be used in the evaluation. While the participants are in a sitting position; A total of 5 variables, including bicipital tendinopathy, supraspinatus tendinopathy, greater tuberculum cortical surface irregularity, supraspinatus dynamic and subscapularis dynamic examination, are evaluated and scored according to the level of pathology; The total USPRS score is obtained by adding the scores of all variables.~Another parameter evaluated by ultrasonography in this study is the acromiohumeral distance measurement. In AH distance measurement with MSK-US, two measurements will be made with all participants in a neutral resting position and their hands at the top of the circle with the elbow angle of 110 °. In both positions, the probe will be placed longitudinally at the lateral point of the acromion determined by palpation, the distance determined between the acromion and the humeral head will be displayed and measured."
41020704|NCT04989257|DRUG|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
41020705|NCT04989257|DRUG|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
41020706|NCT01700816|DEVICE|Bright light therapy|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
41020707|NCT01700816|DEVICE|Sham light|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
41159507|NCT02536885|PROCEDURE|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
41159508|NCT06309849|OTHER|Manual physiotherapy intervention( cervical traction, suboccipital release, muscle energy technique)|Manual physiotherapy intervention( cervical traction, suboccipital release, muscle energy technique) strengthening exercises for neck muscles, ultrasound with parameters 5 min × 3 times × 4 weeks, 1 MHz, continuous: 1.5 W/cm2; pulsed: 2.5 W/cm2.
41159509|NCT01150019|OTHER|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
41159510|NCT05672498|DRUG|Traditional Chinese Medicine Formulation|The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.
41159511|NCT05672498|OTHER|Placebo Treatment|Placebo Treatment Group:The patient are given placebo, taking 150 ml of liquid placebo every morning and evening for 7 days. All medications and placebo are packed identically in packing bags with the same labeling form.
41351958|NCT05240781|DEVICE|Sirolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used in accordance with the CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and CCS. Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
41159512|NCT05028153|DRUG|Azithromycin Oral Liquid Product|10 mg/kg for 3 consecutive days
40833002|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, irradiation|Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
40833003|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, no irradiation|Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
40833004|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
41020708|NCT01360034|DRUG|Nifedipine|Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
41020709|NCT01360034|DRUG|Indomethacin|Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
41020710|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 and 29 for vaccine naive cohorts.
40833005|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, no irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
40833006|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, irradiation|Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
40833007|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, no irradiation|Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
41493152|NCT05537194|DRUG|dihydropyridine calcium channel inhibitors use|administration of dihydropyridine calcium channel inhibitors
41493153|NCT02395952|DRUG|carboxymethylcellulose sodium|frequent topical lubrication with artificial tears
41493154|NCT02395952|DEVICE|Acuvue Oasys Bandage Contact Lens|
40833008|NCT03899064|DRUG|Challenge: Control, irradiation|No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
40833009|NCT03779503|DEVICE|midafilcon A|midafilcon A 1 day daily disposable contact lens
40833010|NCT03779503|DEVICE|somofilcon A|somofilcon A 1 day daily disposable contact lens
40833011|NCT01510171|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
40833012|NCT01510171|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
40833013|NCT00316693|BIOLOGICAL|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
40833014|NCT00316693|BIOLOGICAL|Aimmugen™|Intramuscular injection, 3 doses
40833015|NCT00668590|BEHAVIORAL|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
40833016|NCT00668590|BEHAVIORAL|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
41351959|NCT01590524|BEHAVIORAL|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
41351960|NCT00348075|DEVICE|Neurovision|
41493155|NCT02395952|DEVICE|Ambiodisk|
41493156|NCT02395952|DEVICE|Prokera|
41493157|NCT04447950|PROCEDURE|Type 2/posterior Quadratus Lumborum block|Injection of local anaesthetic into posterior boundry of Quadratus Lumborum muscle.
41493158|NCT04447950|PROCEDURE|Placebo block with Saline|Injection of saline into posterior boundary of Quadratus Lumborum muscle.
41493159|NCT01064050|DEVICE|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
41493160|NCT00265395|DRUG|Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)|"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
41493161|NCT00265395|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks"
41493162|NCT00589329|DRUG|erythromycin and metronidazole (antibiotics)|"Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days"
41493163|NCT00589329|DRUG|placebo|IV and pill placebo
41493164|NCT01517230|BEHAVIORAL|Local radio campaign to reduce under-five child mortality|"The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years."
40833017|NCT03331822|OTHER|Bright Light|high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day\*Light Classic Light will be positioned at each nursing station in the ICU hallway.
41159513|NCT05028153|OTHER|Placebo mixture|Placebo mixture containing no active substance
41159514|NCT00511459|DRUG|AMG 386 Placebo|AMG 386 Placebo \[blinded\]
41351961|NCT00333736|DEVICE|Biojector|All patients received biojector to use with BID enfuvirtide doses
41351962|NCT00836316|DRUG|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
41509141|NCT02175901|DRUG|Metronidazole|antibiotic of the amoxicillin/metronidazole-based quadruple therapy
41509142|NCT02175901|DRUG|Clarithromycin|antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
41509143|NCT04493567|DRUG|BMS-986036|Specified dose on specified days
41509144|NCT03334461|COMBINATION_PRODUCT|Exposure to oral antiseptics or enamel remineralisation agent|
41509145|NCT02029196|OTHER|E-vapour product|Smokers of conventional cigarettes who switch to use an e-vapour product.
40833018|NCT04533074|BIOLOGICAL|Single-visit regeneration protocol|In a single visit, access opening, minimal instrumentation and irrigation will be done. After irrigation and drying, the apical tissue will be irritated to evoke bleeding in the canal, using a precurved K-file 2mm past the apical foramen, with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. The bleeding will be stopped at a level that allows for 3-4 mm of restorative material. Three millimeters of Biodentine will then be placed directly over the blood clot of each tooth. A 3-4 mm layer of glass ionomer is flowed gently over the capping material. Each access cavity will be restored using composite resin.
40833019|NCT04533074|BIOLOGICAL|Multiple-visits regeneration protocol|In the first visit, access opening, minimal instrumentation and irrigation will be done. The root canal will be then dried and filled with calcium hydroxide paste. The tooth will be sealed with an intermediate restorative material (IRM), and the patient will be dismissed for 1-4weeks. In the second appointment, response to initial treatment will be assessed and the steps will be repeated if symptoms are persistent. If there are no symptoms, evoking bleeding to the level of the cemento-enamel junction will be done followed by Biodentine application over the blood clot with final glass ionomer and composite restorations.
41351963|NCT05299216|OTHER|Manual Diaphragm Technique|Treatment group will receive Manual Diaphragm Technique in addition to Conventional Physical Therapy. Therapist will make physical contact to the underside of the 7th to 10th rib costal cartilages. During the inspiratory phase, the therapist will use both hands to gently pull the points of contact in the direction of the head. During exhalation, the therapist will maintain resistance. The procedure will be done in two sets of ten deep breaths, separated by a one-minute pause.
41351964|NCT05299216|OTHER|Conventional Physical Therapy|"Conventional Physical Therapy group comprises electrotherapeutic treatment and exercise plan. Subjects will undergo a thermal continuous ultrasound, conventional transcutaneous electrical nerve stimulation and a hot pack.~Stretching activities for the back, iliopsoas, and hamstring muscles, as well as abdominal muscle strengthening exercises, will be included in the workout."
41351965|NCT05299216|OTHER|Sham Diaphragm Manual Technique|The Control group will also receive a sham diaphragm release technique. The therapist and participant will have the same manual contacts, duration, and placement as the treatment group, but the therapist will simply use a light touch with the same anatomical landmarks and will not apply pressure.
41509146|NCT02029196|OTHER|Conventional cigarette|Smokers of conventional cigarettes who continue smoking conventional cigarettes.
40833020|NCT05481099|BEHAVIORAL|Intervention|Cognitive-behavioural-based intervention combined with mindfulness (attention focus), psychoeducation, and relaxation techniques (short version of Jacobson's progressive relaxation, breathing exercises)
40833021|NCT05610956|DRUG|Empagliflozin|Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)and conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months.
40833022|NCT05610956|DRUG|conventional treatment|conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months
40833023|NCT04135859|BEHAVIORAL|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
40833024|NCT04135859|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
40833025|NCT01020708|DRUG|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
41159515|NCT00511459|DRUG|AMG 386|AMG 386 3mg/kg IV QW \[blinded\]
41159516|NCT00511459|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV Q2W
41351966|NCT02532829|OTHER|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
40833026|NCT01020708|DRUG|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
40833027|NCT01020708|DRUG|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
40833028|NCT02358655|OTHER|Retrospective review of OAC prescription|
40833029|NCT02358655|OTHER|Prescription of OAC in ED|
40833030|NCT02358655|OTHER|Community AF clinic|
41493165|NCT05737316|BEHAVIORAL|Combat PD|CombatPD is an aerobic exercise programme hosted on a mobile application that pairs with motion sensors and heart rate monitor, which connects to a web-based portal for remote monitoring. The wearable sensors consist of (i) 2 motion sensors worn across one thigh and attached to an exercise ring which is held by the participant during the exergame and (ii) 1 heart rate sensor worn across the participant's chest. They will receive once weekly physiotherapy sessions at the study site for the first 4 weeks where they will be guided through the use of the CombatPD. Participants will be instructed to perform 2 sessions of 30-minute exergames in addition to a session of 30-minute brisk walking every week for 12 weeks at home. They will be instructed to exercise at a target heart rate zone at moderate intensity (i.e., 40% - 60% Heart Rate Reserve), which will be gradually increased.
41020711|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 for vaccine booster cohorts. Participants may receive up to 3 booster injections on study.
41020712|NCT04847050|DIAGNOSTIC_TEST|ECG|Baseline (-28 days/Day 1); and Day 29 (+/- 3 days).
41493166|NCT05737316|BEHAVIORAL|Usual Care|Participants in the control group (usual care) will receive once weekly physiotherapy sessions for first 2 weeks and another session at week 6 where they will be taught home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises , as well as brisk walking techniques. Participants in the control group will be instructed to perform these home exercises twice a week, in addition to a 30-minute brisk walk for 12 weeks.
41159517|NCT00511459|DRUG|AMG 386|AMG 386 10mg/kg IV QW \[Open-Label\]
41020713|NCT04847050|OTHER|Antibiotics|Use of prophylactic antibiotics is recommended according to institutional standards.
41020714|NCT04847050|OTHER|Anti-viral agents|Use of prophylactic antiviral agents is recommended according to institutional standards.
40833031|NCT05818761|DEVICE|virtual reality|wearing virtual reality glasses
40833032|NCT05818761|BEHAVIORAL|stress ball|squeezing the stress ball during the attempt
40833033|NCT06072092|DEVICE|BIS Monitor|No interventions will be administered, but in addition to the standard of care according to the Guidelines of the European Resuscitation Council 2021, a frontal EEG-monitoring (BIS), a CPRMeter and a FlowMeter will be installed. The study will be observational only; the readings of the BIS monitor will be blinded to the treating PRU team.
40833034|NCT06217419|DEVICE|Radio Frequency IDentification (RFID) device|"RFID devices monitor breathing patterns by means of temperature measurements of the respiratory airflow. The temperature gradient of the air flow in and out of the airways can be correlated to the flow-based respiratory patterns. Accordingly, a temperature-based breath monitoring can be achieved by means of on-skin RFID sensors attached below the nose. Finally, a bilateral measurement of nostrils respiratory flow can provide more information since nasal cavities do not behave in the same way during a respiratory cycle.~In this project we will evaluate the possibility to perform domestic breath flow analysis by exploiting thin, lightweight and battery-less sensing plasters directly attached under the nose. The system includes a proper external reader interrogating the face sensors that is capable to directly communicate with smartphone/pc/tablet/cloud environment."
40833035|NCT01072825|OTHER|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
41020715|NCT04847050|OTHER|Anti-fungal agent|Use of prophylactic antifungal agents is recommended according to institutional standards.
41020716|NCT04847050|OTHER|Anti-emetics|Use of prophylactic anti-emetics is recommended according to institutional standards.
41020717|NCT03900949|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
41020718|NCT03900949|DRUG|Cytarabine|Given IV
41020719|NCT03900949|DRUG|Daunorubicin Hydrochloride|Given IV
41020720|NCT03900949|DRUG|Gemtuzumab Ozogamicin|Given IV
41159518|NCT00511459|DRUG|AMG 386|AMG 386 10mg/kg IV QW \[blinded\]
41159519|NCT00511459|DRUG|Paclitaxel|Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
40833036|NCT01072825|BIOLOGICAL|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if\> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
40833037|NCT01072825|OTHER|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
40833038|NCT01072825|OTHER|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
40833039|NCT01072825|OTHER|Bone evaluation|PQCT scanner, BMD assessment
40833040|NCT04467970|PROCEDURE|Unicompartmental Knee Replacement|Unicompartmental Knee Replacement involves replacement of the medial compartment of the knee in patients with anteromedial osteoarthritis.
40833041|NCT04467970|PROCEDURE|High Tibial Osteotomy|High Tibial Osteotomy involves medial wedge opening high tibial osteotomy in cases of anteromedial osteoarthritis.
40833042|NCT05748704|OTHER|Short-term modified fasting|STMF regimen consists of a low-calorie diet aimed at providing 800-1,000 kcal/day, lasting five days and with the following composition: 10% carbohydrates, 15% proteins, 75% lipids. During the days of STMF, patients will be required to write down the foods consumed in a food diary in order to calculate calorie and nutrients intake. The STMF regimen will be administered tentatively on a monthly basis (depending on the therapeutic regimen the patient undergoes) and in any case no more frequently than once every three weeks.
40833043|NCT04623515|OTHER|REDCap Questionnaires|Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .
40833044|NCT03813004|DIAGNOSTIC_TEST|Reaction for gait perturbation|"Participants were subjected to four different perturbation types while walking on the treadmill:~1. left treadmill belt deceleration for right leg toe off~2. right treadmill belt deceleration for left leg toe off~3. left treadmill belt acceleration for right leg heel strike~4. right treadmill belt acceleration for left leg heel strike~Motion analysis was conducted to analyze effect of the intervention on gait."
40833045|NCT04276155|DRUG|non-systematic prescription of anticoagulant therapy|the prescription of anticoagulant is managed by an implantable device follow up
40833046|NCT05015790|DEVICE|virtual reality Bliss Solution|use virtual reality Bliss Solution
40833047|NCT02759224|DRUG|BRI-1501|
40833048|NCT02759224|DRUG|Lafutidine|
40833049|NCT02759224|DRUG|Irsogladine maleate|
41159520|NCT04134221|DIAGNOSTIC_TEST|Ultrasound assessment|Ultrasound assessment of internal carotid artery blood flow
40833050|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
40833051|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
40833052|NCT03510351|DRUG|Ceftolozane-Tazobactam|Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
40833053|NCT02871687|DRUG|Simvastatin|Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure
40833054|NCT02871687|DRUG|Pravastatin|Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure
40833055|NCT02871687|OTHER|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
40833056|NCT03801330|OTHER|Usual Care Pulmonary Rehabilitation Program|Participants in the Usual Care Pulmonary Rehabilitation Program group will complete an 8 week clinic based Pulmonary Rehabilitation Program (usual care).
40833057|NCT03801330|OTHER|Pulmonary Rehabilitation Software-Based Home Program|Participants in the Pulmonary Rehabilitation Software-Based Home Program group will complete an 8-week home-based Pulmonary Rehabilitation Program using a software app (software)
40833058|NCT05551975|OTHER|Control Product|Fed from Study Day 1
40833059|NCT05551975|OTHER|Experimental Product 1|Fed from Study Day 1
40833060|NCT05551975|OTHER|Experimental Product 2|Fed from Study Day 1
40833061|NCT03634371|DRUG|Drug Levothyroxine 150 mcg|Administration of a 600 mcg levothyroxine dose
40833062|NCT03634371|DRUG|Drug Eutirox 150 mcg|Administration of a 600 mcg levothyroxine dose
40833063|NCT02060994|OTHER|No intervention|No intervention
40833064|NCT03234439|BEHAVIORAL|myStrength|myStrength is a digital self-care behavioral and wellness platform
40833065|NCT06508138|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus|"About 1 month before donating blood, donors are required to come to outpatient clinic once a week to receive the following vaccine series:~Week 1: PVX1 (1 of 3): intramuscular injection (IM) of 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 2: PVX1 (2 of 3): IM 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 3: PVX1 (3 of 3): IM TA-HPV vaccinia boost Pause for 2 weeks Peripheral blood collection and possible bone marrow harvest depending on randomization"
40833066|NCT05665699|DRUG|D-0120|increasing dose of D-0120
40833067|NCT05665699|DRUG|Allopurinol|standard dosing
40833068|NCT05471180|OTHER|protective spray film|Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film.
40833069|NCT05471180|DEVICE|photobiomodulation therapy|application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days.
41351967|NCT04491331|PROCEDURE|prone position|Unsupported prone position with arms along the body in neutral position will be used first without any supportive device except support of heels with a soft cylindrical device, head will be held in a neutral position using prone head rest. After recording of all measered values, the prone position using the prone position support system will be tested. The support system allows free movement of the lower thorax and abdomenal wall, upper arms are elevated and angled in 90 degrees (in shoulders and elbows). Heels will be positioned at the level of the heart using a supportive cylindrical device. Head will be held in a neutral position using prone head rest.
41351968|NCT05869526|DIETARY_SUPPLEMENT|Fish oil|EPA rich fish oil
41351969|NCT05869526|DIETARY_SUPPLEMENT|Kril oil|Superba Krill Oil
41351970|NCT05869526|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
41351971|NCT03793894|BEHAVIORAL|Smoking Cessation Counseling|All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.
41351972|NCT03793894|BEHAVIORAL|Decision Aid|"The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)"
41351973|NCT03793894|BEHAVIORAL|Shared decision making (SDM)|"During the smoking cessation consultation, the nurse practitioner (NP) will conduct SDM, using the 4-page AHRQ Is Lung Cancer Screening Right for me? decision aid as a guide. The purpose of SDM is three-fold: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with Centers for Medicare \& Medicaid Services (CMS) requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context."
41351974|NCT03793894|BEHAVIORAL|CHW Navigation|The CHW will meet with the participant after the SDM to initiate the coordination of outpatient tobacco treatment, referral to LCS, and resources to address the barriers to preventive services. The CHW will follow patients subjects in the intervention arm for 3 months to help navigate and address negative social determinants of health that are barriers to LCS and tobacco treatment. For patients who agree to screening, the CHW will schedule the appointment, arrange the transportation to appointment, and meet participant at the appointment to facilitate the screening.
41351975|NCT01183130|DEVICE|Compliance monitoring with electronic device|Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
41351976|NCT04599660|OTHER|Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
41351977|NCT01741584|BEHAVIORAL|stationary bike exercise|
40833070|NCT04523350|DEVICE|Instylla HES|Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)
40833071|NCT04523350|OTHER|TAE or cTACE|Bland TAE or cTACE
41351978|NCT01741584|BEHAVIORAL|aerobic|
41351979|NCT02385292|DEVICE|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
40833072|NCT00002824|BIOLOGICAL|gene therapy|
40833073|NCT00002824|DRUG|chemotherapy|
40833074|NCT00002824|DRUG|ganciclovir|
40833075|NCT00002824|PROCEDURE|conventional surgery|
40833076|NCT00002342|DRUG|Tecogalan sodium|
40833077|NCT05785507|OTHER|PriskA tool|PriskA tool is an algorithm that generates a risk score of having PCOS.
40833078|NCT02834923|BEHAVIORAL|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
41020721|NCT03900949|DRUG|Midostaurin|Given PO
41020722|NCT02420860|BIOLOGICAL|Elotuzumab|Given IV
41020723|NCT02420860|DRUG|Lenalidomide|Given PO
41020724|NCT02420860|OTHER|Questionnaire Administration|Ancillary studies
41020725|NCT03228238|DRUG|Vitamin C and Vitamin E|Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
41020726|NCT03228238|DRUG|Statin|Atorvastatin calcium 10mg
41493167|NCT04310969|DEVICE|MiBoFlo Thermoflo|Each treatment for each eye takes 10 minutes and is treated every two weeks for a total of three times. The device was preheated to 42.2℃ and the eyelid was cleaned and smeared with a small amount of ultrasound gel in order to reduce friction between the device and eyelid skin. Then massage the outer skin of the upper and lower eyelids for a period of 10 minutes. The patient's eyes keep closed during therapy.
40833079|NCT02834923|BEHAVIORAL|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
40833080|NCT00468845|DRUG|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
40833081|NCT00468845|DRUG|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
40833082|NCT00468845|DRUG|matched placebo|matched placebo
40833083|NCT01193166|DRUG|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 12 months
41351980|NCT01607749|BEHAVIORAL|Educational Program|"Schools in the intervention group received the educational program Asthma, Sport and Health, as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.~Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days."
41493168|NCT04310969|PROCEDURE|forceful expression of the meibomian glands|Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force
40833084|NCT01193166|DRUG|risperidone|flexible dosing as prescribed by the study doctor for 12 months
40833085|NCT01193166|DRUG|olanzapine|flexible dosing as prescribed by the study doctor for 12 months
40833086|NCT01193166|DRUG|aripiprazole|flexible dosing as prescribed by the study doctor for 12 months
40833087|NCT01193166|DRUG|haloperidole|flexible dosing as prescribed by the study doctor for 12 months
40833088|NCT01193166|DRUG|quetiapine|flexible dosing as prescribed by the study doctor for 12 months
40833089|NCT01193166|DRUG|perphenazine|flexible dosing as prescribed by the study doctor for 12 months
40833090|NCT01193166|DRUG|paliperidone|flexible dosing as prescribed by the study doctor for 12 months
40833091|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
40833092|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
40833093|NCT01318070|DRUG|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
40833094|NCT03234348|DEVICE|Percutaneous coronary intervention|PCI + stent implantation
40833095|NCT02610491|DIETARY_SUPPLEMENT|Hesperidin|Citrus peel extract
40833096|NCT02610491|DIETARY_SUPPLEMENT|Placebo|Cellulose
40833097|NCT01362452|GENETIC|T-Cell Infusion|Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
41493169|NCT04310969|DEVICE|LipiFlow|LipiFlow treatment applies heat to the palpebral surface of eyelids while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands during heating.
41493170|NCT03043859|BEHAVIORAL|Pure Prairie Living Program|Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
41020727|NCT03228238|DRUG|Standard medication for variant angina|Calcium Channel blocker or NG
40833098|NCT01362452|PROCEDURE|Cord Blood Infusion|Cord blood infusion on Day 0.
40833099|NCT05466695|DRUG|Tadalafil 5mg/sildenafil 25 mg|patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
40833100|NCT01605318|DRUG|Labetuzumab Govitecan (LG)|Administered as a slow intravenous (IV) infusion.
40833101|NCT03423290|DEVICE|FRED and FRED Jr|Flow Re-Direction Endoluminal Device
40833102|NCT00170625|DRUG|Hycamtin|Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
40833103|NCT02385916|OTHER|EstroSense®/MD|A natural product already approved by Health Canada
40833104|NCT02385916|OTHER|Placebo|Placebo
40833105|NCT02127294|DEVICE|transcatheter patent foreman ovale closure|
40833106|NCT01255007|OTHER|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
40833107|NCT01741532|DRUG|Deferiprone oral solution|Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
40833108|NCT01741532|DRUG|Placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
40833109|NCT05957029|DEVICE|NuEra Tight RF system|monopolar radiofrequency device
40833110|NCT03322423|DEVICE|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
40833111|NCT03322423|DEVICE|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
41493171|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 11)|lenalidomide 25 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
40833112|NCT03322423|DEVICE|Spherical Contact Lens 2|BioTrue ONEDay Spherical
40833113|NCT00174538|DRUG|Codeine (30 mg)|
40833114|NCT01460719|BIOLOGICAL|V212|V212 viral antigen for HZ
40833115|NCT00494559|DRUG|Pioglitazone|Actos 15mg once a day before breakfast
40833116|NCT00494559|DRUG|Placebo|Placebo drug with the same appearance as actos
40833117|NCT05510661|DEVICE|Export Catheter|Manual thrombus aspiration with the use of export catheter during primary PCI
40833118|NCT05510661|DEVICE|Balloon catheter|Predilatation with balloon catheter
40833119|NCT00539422|GENETIC|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
40833120|NCT03278431|DRUG|Albendazole|Albendazole (400 mg) from Janssen, donated by the World Health Organization
40833121|NCT03278431|DRUG|Pyrantel Pamoate|Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
40833122|NCT03278431|DRUG|Oxantel Pamoate|Oxantel pamoate (20mg/kg) will be produced by the University of Basel
40833123|NCT03278431|DRUG|Mebendazole|Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
40833124|NCT03095586|OTHER|News items with spin|Interpretation of news items with spin
40833125|NCT03095586|OTHER|News items without spin|Interpretation of news items without spin
40833126|NCT00030771|DRUG|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
40833127|NCT00030771|RADIATION|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
40833128|NCT00030771|PROCEDURE|Surgery|3-4 weeks after termination of radiotherapy
40833129|NCT00152568|BEHAVIORAL|Car Seat Check (behavior)|At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
41351981|NCT01607749|OTHER|Usual Asthma Information for teachers|Common asthma information for teachers
41351982|NCT00716040|BEHAVIORAL|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
41351983|NCT00716040|OTHER|Usual care|The control group will be submitted to the usual care of the health service
40833130|NCT04855071|DEVICE|Non-ablative radiofrequency application|Non-ablative radiofrequency application will be applied with MJS intracavitary probe, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a frequency that will be individualized according to the maximum level of energy absorption by the patient's tissues (between 0.8-1.2MHz) and with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session). In addition, they will be applied 1 session per week. The treatment will last 8 weeks.
40833131|NCT04855071|OTHER|Usual intervention|The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
40833132|NCT05661305|OTHER|Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
41351984|NCT04849338|DIAGNOSTIC_TEST|Bleeding score ( questionnaire )|Bleeding score is done for children diagnosed as von Willebrand's disease .
41493172|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 21)|lenalidomide 15 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
41493173|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 31)|lenalidomide 10 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
41493174|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 41)|lenalidomide 10 mg/day D1-D14 and gemcitabine 800 mg/m2 D1, D8
41493175|NCT04054960|DEVICE|Active tPCS|Active anodal tPCS will be given for 20 mins to motor cortex (M1) or supplementary motor area (SMA), based on our quantitative EEG findings.
40833133|NCT04810936|DIETARY_SUPPLEMENT|oral nutritional supplements|Oral nutritional supplements is usually administrated to improve nutritional status in cancer patients.
40833134|NCT04239794|DRUG|Propofol|General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.
41493176|NCT04054960|DEVICE|Sham tPCS|For the sham condition, the electrode placement will be the same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation.
40833135|NCT04239794|DRUG|Sevoflurane|General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
40833136|NCT06110455|OTHER|Neuromuscular Training exercises|The 8 week exercise intervention consists of 25 minute group sessions of Neuromuscular training supervised by a physical therapist.
40833137|NCT06110455|OTHER|Hip and Knee Muscular Strength exercises|The 8 week exercise intervention consists of 25 minute group sessions of progressive resistance training, supervised by a physical therapist.
40833138|NCT00563862|PROCEDURE|Conventional RT|
40833139|NCT00563862|PROCEDURE|Accelerated RT|
40833140|NCT00563862|DRUG|Cisplatin|
40833141|NCT00563862|DRUG|5-fluorouracil|
40833142|NCT01933126|DRUG|HCG injection|
40833143|NCT01933126|DRUG|Placebo|
40833144|NCT00199225|DRUG|Rupatadine|
40833145|NCT00199225|DRUG|moxifloxacin|
40833146|NCT00199225|PROCEDURE|Continous electrocardiographic register|
40833147|NCT00199225|PROCEDURE|Pharmacokinetic profile|
40833148|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of low dose casein (5 gram)
40833149|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of high dose casein (15 gram)
40833150|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
40833151|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
40833152|NCT01509469|OTHER|Saline|Ileal infusion with saline (180mL in total)
40833153|NCT01509469|DIETARY_SUPPLEMENT|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
40833154|NCT03342352|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
40833155|NCT03342352|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
40833156|NCT03342352|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
40833157|NCT03342352|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
40833158|NCT03342352|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
40833159|NCT03342352|DRUG|Cetuximab|Cetuximab administered intravenously at the protocol-defined dose weekly.
41493177|NCT04054960|DRUG|Levodopa tablet|We will give 3 tablets of Levodopa-Carbidopa (100/25).
40833160|NCT03342352|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
40833161|NCT05956808|DEVICE|Phonak Naida BTE hearing aid|Newest generation of ultra-power Phonak BTE hearing aids
40833162|NCT05956808|DEVICE|Phonak Naida legacy BTE hearing aid|Previous model/generation of the Naida BTE hearing aid
40833163|NCT00023751|DRUG|fluorouracil|
40833164|NCT00023751|DRUG|leucovorin calcium|
40833165|NCT00023751|PROCEDURE|conventional surgery|
40833166|NCT00023751|RADIATION|radiation therapy|
40833167|NCT05359133|DRUG|Tetrodotoxin|TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5
40833168|NCT05359133|DRUG|Placebo|"Placebo for injection is a sterile 0.9% sodium chloride injection or normal saline for injection. To ensure blinding, subjects receiving placebo will receive the same volume (1.0 mL) for injection to match the volume used for the cohorts assigned to receive active trial drug.~Route and frequency: 1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days in each treatment Cycle."
40833169|NCT05562362|DRUG|RE-021, sparsentan|RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
40833170|NCT03223467|PROCEDURE|Bariatric surgery|Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
40833171|NCT02510183|DEVICE|Acupressure Wrist Band|Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
40833172|NCT02510183|DEVICE|Placebo Acupressure Wrist Band|Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
41493178|NCT03960203|DIAGNOSTIC_TEST|InSight|Clinical decision support (CDS) system for severe sepsis detection and prediction
41493179|NCT02866006|DRUG|BVAC-C|Autologous B cells and monocytes transfected with E6E7 gene of HPV
41493180|NCT02866006|DRUG|Topotecan|
41493181|NCT01969292|OTHER|Colometer|Real time software based image analysis tool.
41351985|NCT01373099|PROCEDURE|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
41493182|NCT01969292|OTHER|Sham Software|Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
41493183|NCT04008849|OTHER|Safety and efficacy assessments|Long term safety and clinical outcomes
41351986|NCT01373099|PROCEDURE|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
41351987|NCT00645190|DRUG|Galantamine HBr|
41493184|NCT02299024|BEHAVIORAL|Additional Opioid Information|Patients receiving this intervention are given additional information about the opioid pain medication that they are receiving in the form of a one page handout. The hand out was written in a health-literacy appropriate manner. A research assistant read the handout to them out loud, and they were given a copy to take home with them.
41493185|NCT04414462|OTHER|exergaming training|"* HEADING: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TIGHTROPE TENSION: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* SNOWBOARD SLALOM: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TABLE TILT: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)"
41020728|NCT02192684|DRUG|Pioglitazone|45 mg daily Insulin sensitizing
40833173|NCT04682990|DEVICE|Tor Vergata Electronic Nose (TV eNose)|Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
41020729|NCT02192684|DRUG|placebo|Compare with pioglitazone
40833174|NCT04682990|OTHER|Survey & Physical Exam|Perform a oriented survey for risk factors, symptoms and a complete physical exam.
41020730|NCT03767959|PROCEDURE|Chen's U-Suture|Chen's U-Suture is a new technique of the invaginated end-to-end pancreaticojejunostomy with transpancreatic transverse U-sutures
41020731|NCT03767959|PROCEDURE|Classic pancreatic duct to mucosa|A Classical anastomosis technique for Pancreaticojejunostomy
41351988|NCT06237608|BEHAVIORAL|Dialectical behavioural therapy (DBT)-informed skills group|16 week 1.5hr DBT-informed skills group facilitated by the lead researcher and two charity facilitators
41351989|NCT00820014|DRUG|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
40833175|NCT04682990|DIAGNOSTIC_TEST|TB LAMP test|Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
41351990|NCT04297176|DRUG|Vancomycin-traditional dosing|The dose is calculated based on 2 vancomycin serum levels
41351991|NCT04297176|DRUG|Vancomycin- Trough-only based dosing|The dose is calculated based on 1 vancomycin serum level (i.e. trough)
41351992|NCT02079415|OTHER|Prevention of complications in infants of diabetic mothers|strict glycemic control in diabetic pregnancies
41351993|NCT02132416|DRUG|NSAID|Will be used if tolerated.
41351994|NCT02132416|DRUG|Opioids|Initially intravenous administration and when tolerated oral slow-release pils will be used.
41351995|NCT02132416|DRUG|Thoracic Epidural anaesthesia|Given by specialists in anaesthesiology and intensive care.
41351996|NCT02132416|DRUG|Paracetamol|1g QID will be given to all patients unless allergies.
41351997|NCT02132416|PROCEDURE|Surgical management|Fracture stabilization
41351998|NCT05892406|DEVICE|Static guide|A static guide will be designed and fabricated based on CBCT and intra-oral scan. Implant will be placed under the assistance of statistic guide through the whole procedure.
41351999|NCT05892406|DEVICE|Dynamic navigation|Implant will be placed under the assistance of dynamic navigation.
41352000|NCT05892406|DEVICE|Robotic system|Implant will be placed under robotic arm and human collaboration.
41352001|NCT02738294|DEVICE|ME-NBI observation and ME-NBI targeted biopsy|The endoscopist assessed lesions which were suspected EGC carefully with ME-NBI. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
41352002|NCT00736450|BIOLOGICAL|oblimersen sodium|Given IV
41352003|NCT00736450|BIOLOGICAL|rituximab|Given IV
41352004|NCT00736450|DRUG|cyclophosphamide|Given IV
41352005|NCT00736450|DRUG|doxorubicin hydrochloride|Given IV
41352006|NCT00736450|DRUG|vincristine sulfate|Given IV
40833176|NCT04682990|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
40833177|NCT04682990|OTHER|Chest X-Ray|Perform anteroposterior chest X-ray (if required by the medical staff)
40833178|NCT04682990|OTHER|Follow Up 5 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
41352007|NCT00736450|DRUG|prednisone|Given orally
41352008|NCT00736450|PROCEDURE|biopsy|Correlative studies
41352009|NCT00736450|GENETIC|microarray analysis|Correlative studies
41352010|NCT00736450|OTHER|immunohistochemistry staining method|Correlative studies
41352011|NCT00736450|GENETIC|gene expression analysis|Correlative studies
41352012|NCT00736450|GENETIC|cytogenetic analysis|Correlative studies
41352013|NCT05779176|PROCEDURE|Therapeutic hypothermia|The study intervention is therapeutic hypothermia. After intubation, patients assigned to therapeutic hypothermia will receive central venous catheterization through right jugular vein or femoral vein depending on the cooling application and the unique needs, a flexible catheter will be inserted and iced saline was circulated through the multiple balloons of the catheter in a closed-loop design to induce therapeutic hypothermia. This system also has a hydrophilic coating with heparin and a triple-lumen central venous catheter to satisfy the need of fluid or drug infusion, blood draw and central venous pressure monitoring. After central venous catheterization, patients assigned to TH will receive intravascular temperature management to achieve the target temperature of 34-35 °C.
41352014|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of cells|"Bone marrow is aspirated at patients in all arms.~Arm TNC receives injection of total nucleated cells into ischemic muscle"
41352015|NCT00753025|PROCEDURE|Bone marrow aspiration , injection of isolated CD 133+ cells|"arm CD133 receives injection of isolated CD 133+ cells"
41352016|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of saline|"arm placebo receives injection of saline"
41352017|NCT05571852|DEVICE|CogniFit's CCT Post COVID-19|The computerized cognitive training (CCT) program is tailored to each person's specific cognitive strengths and weaknesses detected in the Cognitive Assessment Battery (CAB)™ PRO (CogniFit Inc., San Francisco, US; https://www.cognifit.com/cab) by a patented Individualized Training System™ (ITS) software.
41352018|NCT00026195|DRUG|irinotecan hydrochloride|
41352019|NCT05027776|BIOLOGICAL|2-doses Group among 9-14 years|Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.
41352020|NCT05027776|BIOLOGICAL|3-doses Group among 9-19 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
41352021|NCT05027776|BIOLOGICAL|3-doses Group among 20-26 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
41352022|NCT05412160|DRUG|Arginine|During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
40833179|NCT04682990|OTHER|Follow Up & 15 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
40833180|NCT04682990|OTHER|Follow Up & 30 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
40833181|NCT00247832|BEHAVIORAL|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
41352023|NCT05412160|DRUG|Placebo|During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
41352024|NCT02822924|PROCEDURE|Prostate artery embolization (PAE)|Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
41352025|NCT02872090|DRUG|Indacaterol|inhalation
41352026|NCT02872090|DRUG|Glycopyrronium|inhalation
41352027|NCT02872090|DRUG|Tiotropium|inhalation
41352028|NCT02872090|DRUG|Placebo|
41352029|NCT02872090|PROCEDURE|photoplethysmography|inhalation
41352030|NCT02828644|DEVICE|EVO|videogame-like digital therapy
41352031|NCT02171806|DRUG|BI 1744 CL|
41352032|NCT02171806|DRUG|Placebo|
41352033|NCT03683095|PROCEDURE|Lymphovenous bypass|"Lymphovenous bypass will be performed under general anesthetic. Indocyanine green lymphangiography will be performed by injecting indocyanine green into each finger / toe web of the lymphedematous limb and mapping the lymphatic system with the NOVADAQ SPY Fluorescence Imaging (Mississauga, Canada).~Subdermal dissection of lymphatics and venules will be carried out under a surgical microscope. Lymphatic vessels will be anastomosed to adjacent recipient venules to create the bypass between the lymphatic and the venous systems. In total, 1-5 anastomoses will be performed. This will require 1-5 incisions, each with a length of 2-3 cm.~Postoperatively, the limb will be wrapped loosely with compression bandages. No special postoperative monitoring is required.~The surgery will be performed on an outpatient basis with no planned hospital stay."
41352034|NCT04239573|PROCEDURE|Computed Tomography|Undergo CT
41352035|NCT04239573|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
41352036|NCT04239573|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41352037|NCT04239573|OTHER|Quality-of-Life Assessment|Ancillary studies
41352038|NCT04239573|OTHER|Questionnaire Administration|Ancillary studies
40833182|NCT00247832|BEHAVIORAL|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
40833183|NCT00238784|DRUG|Budesonide/formoterol Turbuhaler|
41352039|NCT04191694|OTHER|Chewing Gum|Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.
41352040|NCT04191694|DRUG|Ondansetron 4 MG|Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
40833184|NCT05302856|DIAGNOSTIC_TEST|Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)|Peripheric blood extraction
40833185|NCT05027685|DEVICE|The Paradise Ultrasound Renal Denervation System|The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
40833186|NCT03359707|OTHER|survey|no intervention just survey
40833187|NCT02726880|BEHAVIORAL|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
40833188|NCT02726880|BEHAVIORAL|Referral for care|Referral for mental health issues and family support services
40833189|NCT01555515|PROCEDURE|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
40833190|NCT01555515|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
41020732|NCT03835858|OTHER|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
41020733|NCT01415661|OTHER|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
41020734|NCT03508089|OTHER|Ocular fundus on patient with Multiple Sclerosis|Ocular fundus on patient with Multiple Sclerosis
40833191|NCT06056544|BEHAVIORAL|Client Centered Care Coordination|During the initial C4 sessions, participants will be offered PrEP. For participants who initiate PrEP, C4 staff will provide an individualized PrEP initiation plan. During subsequent C4 sessions, C4 staff will review the prevention plan and goals with participants and use autonomy supportive counseling to address the barriers that are identified by participants that impact their motivation to use PrEP and adhere to PrEP through referrals to support services (e.g, PrEP access programs, addiction medicine services, housing, and job resources). In addition, the C4 staff will ensure any medical issues related to PrEP adherence are addressed by the site medical providers.
40833192|NCT05229263|DIAGNOSTIC_TEST|Non- contrast Enhanced Multiparametric Renal Magnetic Resonance|MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.
40833193|NCT02410824|DEVICE|stenfilcon A toric lens|toric contact lens
40833194|NCT02410824|DEVICE|etafilcon A toric lens|toric contact lens
40833195|NCT02775110|OTHER|Natalizumab discontinuation|Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
40833196|NCT05794711|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
40833197|NCT01811303|OTHER|D-fagomine|Measure the changes produced on the postprandial Glycaemic response
40833198|NCT00025116|DRUG|gefitinib|
40833199|NCT01883752|PROCEDURE|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
40833200|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: OPD-Scan|Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
40833201|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: Pentacam|Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
40833202|NCT04423458|DEVICE|3D imaging|"The study will focus on the accuracy of ultrasound technology in assessing renal transplants.~The entire assessment should not take more than 25 minutes."
40833203|NCT00907296|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection
40833204|NCT00907296|DRUG|Placebo|Administered by subcutaneous injection
40833205|NCT04051554|OTHER|Neuromuscular and Proprioceptive Training|Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
41020735|NCT03508089|OTHER|Ocular Fundus on voluntary person|Ocular Fundus on voluntary person
41020736|NCT05696015|BEHAVIORAL|Standard education|Without telehealth education, this group has only postdischarge education.
41020737|NCT05696015|BEHAVIORAL|Ampiled Education|With telehealth education, in addition of discharge education.
41020738|NCT03568916|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
41352041|NCT01517828|DRUG|Sedation by ketamine|"Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
41493186|NCT04414462|OTHER|training - Group II|"* Wobble board for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Habituation exercises for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Double leg stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Single leg stance with eyes open and eyes open on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Tandem walk stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks."
41493187|NCT05847686|OTHER|Counseling|Participate in therapy visits
41493188|NCT05847686|DRUG|Psilocybin|Given PO
41352042|NCT01517828|DRUG|Sedation with Midazolam|"Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
40833206|NCT04051554|OTHER|Conventional Training|Running, Sprinting, Agility training and Dynamic stretching for five weeks
40833207|NCT03271047|DRUG|binimetinib|Orally, twice daily.
41493189|NCT05847686|OTHER|Questionnaire Administration|Ancillary studies
41020739|NCT03568916|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
41352043|NCT04270890|DEVICE|Abdominal compression belt system|"The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position."
41493190|NCT04180163|DRUG|Lanadelumab|Lanadelumab solution, SC
41493191|NCT02524730|DEVICE|Primary total knee replacement (Scorpio NRG CR Total Knee System)|Scorpio NRG CR Total Knee System
41493192|NCT05001932|PROCEDURE|Cataract surgery|Randomized Clinical Trial
40833208|NCT03271047|DRUG|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
40833209|NCT03271047|DRUG|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
41020740|NCT03568916|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
41020741|NCT03844191|DRUG|RUC-4 Compound|single subcutaneous administration of RUC-4
41020742|NCT02506114|BIOLOGICAL|PROSTVAC V/F|PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
41020743|NCT02506114|DRUG|Ipilimumab|
41493193|NCT02784444|DRUG|MSDC-0602K|MSDC-0602K capsules
41493194|NCT02784444|DRUG|Placebo|Placebo capsules
41493195|NCT00787397|BEHAVIORAL|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
41493196|NCT05107388|DEVICE|FreeStyle Libre Pro|Measurements of interstitial glucose variations with FreeStyle Libre Pro
41493197|NCT00063219|DRUG|MAC-321|
41493198|NCT04831073|PROCEDURE|Surgery on the ascending aorta with or without repair of the aortic root and/or aortic arch|Surgical repair of the ascending aorta with or without surgical repair of the aortic root and/or aortic arch
41493199|NCT02629354|DRUG|Ibuprofen|
41493200|NCT02629354|DRUG|Caffeine|
41493201|NCT02629354|DRUG|Ibuprofen|
41493202|NCT03653910|DEVICE|Airtraq|Airtraq is a kind of videolaryngoscope for intubation
41159521|NCT04613622|DRUG|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
41159522|NCT01076322|DRUG|Meptin® Swinghaler|"Meptin® Swinghaler®~* Ingredient: Procaterol HCL~* Dosage form: 10g/puff~* Dose(s): 10g~* Dosing schedule: 20g (total 20g)"
41159523|NCT01076322|DRUG|Ventolin® MDI|"Ventolin® MDI~* Ingredient: Salbutamol sulfate~* Dosage form: 100g/puff~* Dose(s): 100g~* Dosing schedule: 200g (total 200g)"
41159524|NCT00397202|DEVICE|Diva Cup TM|See Detailed Description.
41159525|NCT05262218|DRUG|PBF-680 10mg|PBF-680 10mg administered orally once a day
41352044|NCT01835236|DRUG|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
41352045|NCT01835236|DRUG|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.~- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
41352046|NCT01835236|DRUG|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
41352047|NCT01835236|DRUG|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion~* then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
41352048|NCT01835236|DRUG|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
41352049|NCT00717561|DRUG|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
41352050|NCT00717561|DRUG|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
41352051|NCT04838587|OTHER|No intervention will be done|No intervention,Only passive surveillance of Diarrhoea cases will be done
41352052|NCT04409990|DIAGNOSTIC_TEST|Shear Wave Elastography|SWE value of rectal lesions
41352053|NCT02485431|DRUG|Deflazacort|
41352054|NCT00624741|DRUG|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
41352055|NCT00945685|DEVICE|Endymion Imagine™ System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~* Pulse energy (J);~* RF frequency (1MHz);~* Pulse duration (30 sec);~* Treatment hand piece (skin tightening);"
41352056|NCT01804413|DRUG|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
41352057|NCT01804413|DRUG|Regular insulin|0.1-0.15 units/kg
41352058|NCT00995215|PROCEDURE|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
41352059|NCT00995215|DEVICE|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
41352060|NCT04835740|OTHER|High intensity Interval Training|All the participants underwent 5 weeks of High intensity interval training.
41352061|NCT00033293|OTHER|Clinical Observation|Undergo observation
41352062|NCT00033293|DRUG|Cyclophosphamide|Given IV
40833210|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
40833211|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
40833212|NCT05581095|BEHAVIORAL|Mindful Eating Self-Help Program|10-week exposure to mindful eating principles and practices outlined in the Eat What You Love, Love What You Eat for Binge Eating book
41159526|NCT05262218|DRUG|Placebo|Placebo administered orally once a day
41352063|NCT00033293|OTHER|Laboratory Biomarker Analysis|Correlative studies
41352064|NCT00033293|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
41352065|NCT00033293|DRUG|Prednisone|Given orally
41352066|NCT00033293|BIOLOGICAL|Therapeutic Immune Globulin|Given IV
41493203|NCT03653910|DEVICE|Macintosh|Macintosh is a traditional laryngoscope for intubation
41352067|NCT05757791|DRUG|Empagliflozin|The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.
41352068|NCT03480841|BEHAVIORAL|Language ENhancement Assessment/intervention system|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
41352069|NCT00325949|DRUG|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
41352070|NCT00325949|DRUG|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
41352071|NCT00325949|DRUG|placebo|2 tablets BID
40833213|NCT05581095|BEHAVIORAL|Mindful Eating Smartphone Application (Am I Hungry? Virtual Coach)|10-week exposure to using a mindful eating mobile phone application daily.
41493204|NCT01236586|DRUG|RO4929097|
40833214|NCT01702168|OTHER|Provider training: Cognitive Processing Therapy (CPT)|
41352072|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
41493205|NCT01236586|DRUG|Dexamethasone|
41493206|NCT01768013|DRUG|LEO 90105|Once daily for four weeks
41493207|NCT00505089|DRUG|ACZ885|
41493208|NCT00505089|DRUG|ACZ885|
40833215|NCT04250766|PROCEDURE|Echo-guided uterine biopsy|"Echo-guided uterine biopsy will be performed by a specialized radiologist by transvaginal and exclusive transuterine approach. 4 to 5 samples will be made.~Local anesthesia will be performed. A pain assessment will be performed during the biopsy (visual or verbal scale)."
41493209|NCT00505089|DRUG|ACZ885|
41493210|NCT00505089|DRUG|ACZ885|
41493211|NCT04206982|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
41493212|NCT04206982|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
41493213|NCT04206982|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
41493214|NCT03848637|DRUG|CKD-375|Test drug
41493215|NCT03848637|DRUG|D387|Reference drug
40833216|NCT01890395|OTHER|Blood draws|Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
41020744|NCT04302571|BEHAVIORAL|combined aerobic and resistance physical activity|Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.
41020745|NCT04302571|BEHAVIORAL|sham exercise|general recommendation to perform regular aerobic physical activity
41352073|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
41352074|NCT00644033|DRUG|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
41352075|NCT04251377|DEVICE|Defensive Antiadhesive Coating DAC®, Novagenit SRL|"DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room.~The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture."
41352076|NCT03453528|DRUG|68Ga-PSMA|68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
41352077|NCT05093244|DEVICE|SeQuent Please ReX|The SeQuent Please ReX is a conventional rapid exchange balloon tip catheter with a drug-coated balloon (DCB). The surface of the SeQuent Please ReX balloon is coated with paclitaxel, embedded in a soluble matrix (resveratrol).
41352078|NCT05093244|DEVICE|Plain old balloon angioplasty (POBA)|Any commercially available semi-compliant PTCA balloon may be used per the investigator's discretion.
41352079|NCT00112554|DRUG|cytarabine|Given IV
41352080|NCT00112554|DRUG|laromustine|Given IV
41352081|NCT00112554|OTHER|placebo|Given IV
41352082|NCT06228781|PROCEDURE|Autologous haemopoietic stem cell transplantation|"Immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT).~Stem cell mobilization with cyclophosphamide 2g/m2 and filgrastim 10 ug/kg/d x 5 day.~Stem cell collection with cobe cpectra stem cell purification with Miltenyi CliniMACS Stem cell transplant conditioning with busulphan 3.2 mg/kg ; fludarabine 30mg/m2 or cladribine 10mg ；cytarabine 1-2g/m2 or idarubicin 8mg/m2；cyclophosphamide 40mg/kg followed by CD34 selected autologous hematopoietic stem cell transplant."
41352083|NCT00058448|DRUG|docetaxel|
41352084|NCT03059511|DRUG|Nalbuphine|Opioid Pain Medicine
41352085|NCT03689270|PROCEDURE|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
41352086|NCT03689270|PROCEDURE|Divide and conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
41352087|NCT02858596|DIETARY_SUPPLEMENT|Semi-solid feed (Terumo PG soft)|
41352088|NCT02858596|DIETARY_SUPPLEMENT|Liquid feed (Meibalance)|
41352089|NCT03755167|DRUG|IPL344|IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
41352090|NCT04919135|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval
41352091|NCT04919135|DRUG|standard frailty treatment and supplementary medication|Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
41352092|NCT03833336|OTHER|Placebo|The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.
41352093|NCT03833336|DRUG|Ferric carboxymaltose|The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo
41352094|NCT03833336|DRUG|Ferroglycine Sulfate|One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
41352095|NCT03833336|DRUG|Sucrosomial Iron|One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
40833217|NCT01495468|BIOLOGICAL|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
40833218|NCT04352257|RADIATION|pelvic Ultrasound|pelvic and transrectal ultrasound
41020746|NCT05280119|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein
41352096|NCT04139603|OTHER|Lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
41352097|NCT04139603|OTHER|Abdominal supported lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region and abdominal area will stay 3 days. They will be removed from the sites, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
41352098|NCT04139603|OTHER|Placebo tapng|"Placebo tapes (just like Kinesio tapes) applied to the lumbopelvic region without any tension will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
41352099|NCT03128372|DEVICE|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
41352100|NCT04196049|PROCEDURE|fragmatome|Patients with massive subretinal hemorrhage from age related macular degeneration and organized subretinal blood clot were managed by inferior retinectomy. The subretinal organized blood clot was dragged to the preretinal space and removed by fragmatome. The retinal was reattached with perfluorocarbon liquid and laser was applied at the margin of retinectomy. Silicon oil was infused at the end of surgery.
41352101|NCT06093152|DRUG|Salbutamol|Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.
41493216|NCT02351271|DEVICE|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
41493217|NCT02351271|DEVICE|Manual capsulorhexis&lens fragmentation|Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
41493218|NCT00295295|DEVICE|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
41493219|NCT00295295|OTHER|Standing|Standing 10 min/day
41493220|NCT02328235|OTHER|High Saturated Fat Diet|"Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to lead-in to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study."
41493221|NCT03418090|DRUG|129Xe MRI|Evaluation of pulmonary function
41493222|NCT03418090|DRUG|133XE scintigraphy|Evaluation of pulmonary function
41352102|NCT05131035|BEHAVIORAL|SCORES (Specific COgnitive Remediation with Support)|"This study evaluates the effectiveness of a 10-week cognitive remediation program plus group coaching and therapy to improve processing speed and, in turn, social functioning and attenuated positive symptoms in CHR subjects. The SCORES (Specific COgnitive Remediation with Support) intervention is a novel CR program combined with group coaching, performance-based rewards, game-like tasks, and therapy elements to increase engagement and retention.~In the 2 year, R61 phase, all participants will complete 40 hours of CR (4 hrs per week) with a mid-point assessment (20 hours of CR at 5 weeks) to determine the impact of CR on processing speed as measured by the MCCB.~The second phase of the study (R33) will compare the 40 hours of speeded brain training to 40 hours of non-speeded brain training. This three year study will allow for a replication and assessment of specificity of the targeted intervention."
41352103|NCT01242072|DRUG|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
41493223|NCT06053918|OTHER|additional follow-up extension at home|additional interview when leaving the sector, and the extension of follow-up of the patient at home
41493224|NCT01229163|DEVICE|Automated Contingency Management (ACM) software|
41493225|NCT00015340|DRUG|Buprenorphine/naloxone|
41493226|NCT02048930|DEVICE|Budesonide Easyhaler|
41493227|NCT02048930|DEVICE|Budesonide dry powder inhaler|
41493228|NCT05671016|PROCEDURE|MRI scans and questionnaires|Extra baseline MRI scan performed and questionnaires (EORTC validated questionnaires involving EORTC QLQ C-30, EORTC BN20 and EORTC ELD14) to assess quality of life at baseline, 4 weeks and 8 weeks after treatment
41020747|NCT05280119|DEVICE|Ultrasound device routinely used in the department.|Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.
41020748|NCT05280119|PROCEDURE|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
41352104|NCT04835935|OTHER|microbiome pattern|microbiome pattern in neonatal period
41020749|NCT00633984|BEHAVIORAL|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
41493229|NCT04549103|OTHER|Baduanjin exercise program|Baduanjin (BDJ), also known as Eight-Section Brocades, is one of the forms of traditional Chinese Qigong exercises, characterized by symmetrical physical posture, movements, mindfulness, and breathing. Its primary focus is on the release of 'Qi' or internal body energy with the intent of improving health outcomes. BDJ encompasses eight simple movements involving combinations of postures, meditation, slow relaxing movements, and breathing exercises. It is a low intensity exercise, which have been found to improve range of motion, strength and general health. The simplicity and low intensity level is ideal for older adults to practice at home using instructional videos.
41493230|NCT05736627|OTHER|Online|Online research course delivered live digitally at a distance.
41493231|NCT02143635|DRUG|HDM201|
41493232|NCT02143635|DRUG|ancillary treatment|
41493233|NCT00030992|DRUG|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m\^2/day for a total per cycle dose of 30 mg/m\^2
41493234|NCT00030992|DRUG|Ranitidine|50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
41493235|NCT00030992|DRUG|Diphenhydramine|50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
41493236|NCT02637661|OTHER|earlobe crease positive|
41493237|NCT02637661|OTHER|earlobe crease negative|
41493238|NCT05827835|DRUG|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
41493239|NCT05827835|OTHER|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
41493240|NCT05898321|DRUG|Zoladex|Patients with fibroid remained will be enrolled and divided into three groups. one group wii be administrated with Zoladex (3.60mg/28 days) for three to six months.
41493241|NCT05898321|DRUG|Mifepristone Oral Tablet|Patients with fibroid remained will be enrolled and divided into three groups. one group will be administrated with mifepristone(10.0mg/d) for three to six months.
41493242|NCT00258050|DRUG|Midazolam|Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
41493243|NCT00258050|DRUG|Lapatinib|Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
41493244|NCT00496353|DRUG|MK2461|MK2461 treatment, bid, 28-day
41493245|NCT05509816|DRUG|Midazolam|Administered orally.
41493246|NCT05509816|DRUG|Imlunestrant|Administered orally.
41493247|NCT05935241|BEHAVIORAL|mPATH|The active mPATH intervention takes 6 months including (1) The physical activity education session , (2)mHealth learning and practice; (3)Personalized physical activity training, plan, and biweekly phone calls over 24 weeks (4) mHealth strategies to encourage physical activity and facilitate intervention adherence (5) (5) mPATH during 6-12 months: mPATH will be delivered mainly in 24 weeks before the 6-month data collection. During 6-12 months, the participants will have access to study mHealth strategies, and exercise videos. No additional physical activity training by staff will be supported.
41493248|NCT05935241|OTHER|Attention Control|A registered nurse from the study team will provide 6 monthly home visit (approximately 55-60 minutes each) to provide physical activity education, physical activity safety at home evaluation, feedback, and social activity (meaningful or enjoyable activities as identified by the participants, such as playing cards, doing arts and crafts, listening to music, talking about life history, etc.).
41493249|NCT00006243|BIOLOGICAL|tyrosinase peptide|Given SC
41493250|NCT00006243|BIOLOGICAL|MART-1:27-35 peptide vaccine|Given SC
41493251|NCT00006243|BIOLOGICAL|gp100 antigen|Given SC
41493252|NCT00006243|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
41493253|NCT00006243|BIOLOGICAL|sargramostim|Given SC
41493254|NCT00006243|OTHER|laboratory biomarker analysis|Correlative studies
41493255|NCT03577483|PROCEDURE|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).
41159527|NCT01178281|DRUG|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
41493256|NCT00470067|DRUG|carboplatin|IV
41493257|NCT00470067|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
41493258|NCT04814212|DEVICE|Percutaneous coronary intervention using drug-coated balloon|"SeQuent Please (BBraun) + tailored antithrombotic regimen:~1. Stable patients without OAC: perioperative SAPT (preferably) or perioperative DAPT followed by lifelong SAPT~2. Stable patients with OAC: perioperative SAPT (preferably) or perioperative DAPT and lifelong OAC~3. ACS patients without OAC: 1-month DAPT followed by lifelong SAPT~4. ACS patients with OAC: perioperative DAPT followed by 1-month SAPT and lifelong OAC"
41493259|NCT04814212|DEVICE|Percutaneous coronary intervention using drug-eluting stent|"Biofreedom (Biosensors), Synergy (Boston Scientific), Ultimaster Tansei (Terumo) and Integrity Onyx (Medtronic), Xience Pro S (Abbott) or Promus Elite (Boston Scientific) or any other DES can also be used provided that it has a CE mark for 1-month DAPT, combined with tailored antithrombotic regimen:~1. Stable patients without OAC: 1-month DAPT followed by lifelong SAPT~2. Stable patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and life-long OAC~3. ACS patients without OAC: 3-month DAPT followed by lifelong SAPT~4. ACS patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and lifelong OAC"
41493260|NCT01857843|DEVICE|Zotalolimus Eluting Stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1."
41493261|NCT01857843|DEVICE|Everolimus eluting stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1."
41493262|NCT01857843|DRUG|Ezetimibe 10mg & Simvastatin 40mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)"
41493263|NCT01857843|DRUG|Pravastatin 20mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)"
41493264|NCT04326114|DEVICE|Inspiratory training device|Inspiratory training by a Power-breath device
41493265|NCT04326114|DEVICE|Expiratory training device|Expiratory training a Winner-flow device
41493266|NCT05704244|DRUG|FE 999326|75 mL FE 999326 (3 x 10\^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter
41493267|NCT03375203|DRUG|Placebo|Matching placebo will be administered once daily based upon dosing group.
41493268|NCT03375203|DRUG|JNJ-42847922, 5 mg|JNJ-42847922 will be administered as 5 mg (2\*2.5 mg capsule) oral capsules once daily.
41493269|NCT03375203|DRUG|JNJ-42847922, 10 mg|JNJ-42847922 will be administered as 10 mg oral capsule once daily.
41493270|NCT03375203|DRUG|JNJ-42847922, 20 mg|JNJ-42847922 will be administered as 20 mg oral capsule once daily.
41493271|NCT03375203|DRUG|Zolpidem|Zolpidem will be administered as 5 mg or 10 mg (2\*5mg capsule) oral capsule once daily based upon the local labeling information.
41493272|NCT05894967|BEHAVIORAL|C1 - Standard Perceptual Learning (SPL)|Each trial starts with a fixation point (500ms) after which a Gabor (1° radius, at cut-off SF of 25% accuracy, estimated from Pre-Test CSF, at either 45° or 135°) appears for 128ms. The task is to indicate whether the Gabor was tilted left or right. Gabor contrast will be controlled by a 3/1 staircase (converging on approximately \~80% contrast threshold) across all training sessions.
41493273|NCT05894967|BEHAVIORAL|C2 - Long Training (LT)|Will be the same as the SPL with the exception that each session in LT will be twice as long as in SPL.
41493274|NCT05894967|BEHAVIORAL|C3 - Short Staircases (SS)|"Will be largely the same as SPL with the only difference being a change to the adaptive procedure. SS will use so-called short-staircases, which are initialized at 60% contrast with steps of .05 log units and employs a 3/1 staircase that after every 40 trials is reset (the short in short-staircases) back to 60% contrast."
41493275|NCT05894967|BEHAVIORAL|C4 - Mixed Difficulty (MD)|This condition will be identical to SPL with the exception that two staircases - one a 2/1 staircase producing difficulties centered around 60-70% accuracy, the other a 4/1 staircase producing difficulties centered around 85-95% accuracy - will be utilized to control the stimuli.
41020750|NCT00633984|DRUG|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
41159528|NCT01178281|DRUG|Placebo|Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
41020751|NCT00633984|DRUG|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
41020752|NCT05016102|OTHER|Exercise type|Aerobic exercise and Resistance exercise
41352105|NCT04558385|DIAGNOSTIC_TEST|IgG SARS CoV2|IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population
41352106|NCT01500265|BIOLOGICAL|plasma and urine samples, sample with ADN|plasma and urine samples every three months Sample with ADN at baseline
41352107|NCT06081387|OTHER|Resistance training|Sarcoplasm stimulating training system. This program will run for 15 weeks and three sessions a week. This exercise plan is designed in three 5-week periods.
41352108|NCT04173481|OTHER|Rood's Group|"ROOD'S sensory motor training~Brushing \& strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy."
41352109|NCT04173481|OTHER|Conventional Physical Therapy Group|Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
41352110|NCT06141239|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
41352111|NCT06141239|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration
41352112|NCT06141239|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
41352113|NCT03705156|DRUG|ZL-2306(nirapairb)|The starting dose is 300 mg or 200 mg based on patient's body weight.
41352114|NCT03705156|DRUG|Placebos|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
41352115|NCT01594749|DRUG|Fosaprepitant dimeglumine|
41352116|NCT01594749|DRUG|Fosaprepitant Placebo|
41493276|NCT05894967|BEHAVIORAL|C5 - Noise Training (NT)|The NT condition will be the same as SPL with the exception that contrast thresholds will be estimated in 5-different levels of external noise (10%, 15%, 20%, 25%, 30%).
41493277|NCT05894967|BEHAVIORAL|C6 - Training with Flankers (TWF)|TWF will be reasonably different from the standard SPL task. Here, on 50% of trials a target Gabor will be presented at either 45° or 135° (as in SPL) and will be flanked by two collinear Gabors. On the remaining 50% of trials, flankers will be present without a target. TWF is thus a yes/no detection task, which is necessary since the collinear flankers fully indicate the target orientation. In different 20-trial mini-blocks the flankers will appear either lambda, 1.5 lambda, or 2 lambda from the target (i.e., closer or further from the target) and target contrast will be controlled by a 3/1 staircase separately for each spacing.
41020753|NCT06456021|BEHAVIORAL|The Relational Playbook|The Relational Playbook consists of 5 chapters and hosts research-based resources and 50 evidence-based interventions presented in short, digestible content to create supportive learning environments. Implementation is guided by 4-steps: Step 1) Assess the current state: CCL managers assesses the current state of their learning environment through a 13-item Learning Environment Assessment Tool. Results are automatically scored and grouped by Playbook chapters. A summary report is immediately available with guidance on how to interpret results. Step 2) Select areas for improvement: CCL managers determine which Playbook chapters and interventions to adopt. Step 3) Implement/adapt interventions: Over the 6-month intervention period, CCL managers are required to implement interventions from 2-3 Playbook chapters. They may adapt the delivery method/implement additional interventions. Step 4) Evaluate the impact: CCL managers develop feedback loops to monitor intervention performance.
41159529|NCT01178281|DRUG|Pomalidomide|Pomalidomide 0.5 mg capsule taken by mouth once daily.
41352117|NCT01594749|DRUG|Dexamethasone|
41352118|NCT01594749|DRUG|Ondansetron|
41159530|NCT02660034|BIOLOGICAL|Tislelizumab|
41352119|NCT01594749|DRUG|Dexamethasone Placebo|
41352120|NCT01594749|DRUG|Ondansetron Placebo|
41352121|NCT01594749|DRUG|Rescue Therapy|
41352122|NCT03469206|PROCEDURE|intra-arterial thrombectomy|It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)
41159531|NCT02660034|DRUG|Pamiparib|
41352123|NCT03469206|DRUG|Intravenous thrombolysis|alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
41352124|NCT03723811|DRUG|SJP002 BID|1 drop b.i.d for 12 weeks
41352125|NCT03723811|DRUG|SJP002 QID|1 drop q.i.d for 12 weeks
41352126|NCT03723811|DRUG|SJP002 Placebo 1|1 drop q.i.d for 12 weeks
41352127|NCT03723811|DRUG|SJP002 Placebo 2|1 drop q.i.d for 12 weeks
41352128|NCT03177954|BEHAVIORAL|Patient Oriented Discharge Summary|Participants will undergo a Patient Oriented Discharge Summary (PODS). The PODS is a personalized summary of the discharge plan presented in an easy to understand worksheet that covers (1) medication instructions; (2) follow-up appointments with phone numbers; (3) normal expected symptoms, warning signs, and what to do if they experience a problem; (4) lifestyle changes and when to resume activities; and (5) information and resources to have handy. The meeting will take place one week prior to discharge.
41352129|NCT00141544|DRUG|esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|ESTRATEST® administered orally QD
41352130|NCT00141544|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
41352131|NCT05621876|DEVICE|IgG deficiency rapid screening test|We will be testing patients who have already been diagnossed iwth primary immunodeficiency (PID) disease. there are 400 types of PID. We will test their blood before they receive antibody transfusion to evaluate the accuracy of our new screening test. We are trying to develop easy to use, low-cost screening tests for doctors to use with patients to detect those with low IgG levels before they are given the oral polio vaccine. These patients must be prioritized for intramuscular injections of a polio vaccine to prevent potential spread of wild type polio.
41352132|NCT06028178|DIAGNOSTIC_TEST|Droplet digital PCR|Droplet digital PCR has potential in resolving polymicrobial infection because it simultaneously achieves unprecedented high sensitivity , high specificity, and absolute quantification without the need for a standard curve.
41352133|NCT05847556|OTHER|video game hearing tests|Video game hearing tests (as a non-medical device) used to monitor ototoxicity
41352134|NCT05847556|OTHER|Audio-training|Audio-training (as a non-medical device) used to determine if it can improve spatial hearing perception.
41352135|NCT02831894|DRUG|0% Hypnotic Medication Taper|Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period
41352136|NCT02831894|DRUG|25% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
41493278|NCT05894967|BEHAVIORAL|C7 - Parafoveal Training (PT)|The PT condition is the baseline for C8-C11 (all of which involve parafoveally presented targets). In PT, we utilize the same task as in SPL, however, in PT, in addition to central training, targets will also appear in one of two peripheral locations (5° eccentricity; angles = 135° and 270°). The location of targets will be randomized trial-wise so as to discourage eye-movements and independent 3/1 staircases will be run at each location. By training only 2 peripheral locations we can measure the extent to which training gives rise to location transfer (e.g., in transfer tasks examining performance at 8 different locations - 2 trained locations and 6 untrained locations). Furthermore, training at the central location facilitates comparisons between PT and SPL.
41493279|NCT05894967|BEHAVIORAL|C8 - Stimulus Variety (SV)|"The base task for SV is the PT condition. However, SV employ 20 trial mini-blocks of different SFs (.75, 1.5, 3, 6, 12, 24 cpd) and locations (45°, 135°, 225°, 315° - i.e., more locations than PT, but not the full set tested in the transfer battery) with separate staircases for each SF and location. Orientations will also be drawn from a larger set (22.5°, 45°, 67.5° - for which participants respond clockwise and 112.5°, 135°, 157.5° - for which participants respond counter-clockwise) and will vary on a trial-by-trial basis. This design holds-out 4 locations and 2 orientations to address transfer."
41493280|NCT05894967|BEHAVIORAL|C8a - Complex Features (CF)|This is the same as C8, however we will use band-pass filtered stimuli similar to what has been done by a number of groups including Hussein et al.
41159532|NCT01637337|PROCEDURE|laparoscopic pyelolithotomy|laparoscopy
41352137|NCT02831894|DRUG|10% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
41159533|NCT01637337|PROCEDURE|percutaneous nephrolithotomy|percutaneous nephrolithotomy
41159534|NCT02924558|OTHER|Egg protein/unsaturated fatty acid|Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
41159535|NCT02924558|OTHER|Control|Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
41493281|NCT05894967|BEHAVIORAL|C9 - Exogenous Attention Training (ExAT)|Stimuli will be presented in a similar manner as in PT. However, in ExAT, a 100% valid cue, a small black dot - 48ms duration with an 96ms SOA prior to stimulus onset - will appear above the target location on each trial.
41159536|NCT00945178|DRUG|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
41159537|NCT00945178|DRUG|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
41159538|NCT00945178|DRUG|Naproxen|Tablet, single oral dose, 500mg
41159539|NCT00945178|DRUG|Placebo for Naproxen|Tablet, single oral dose
41159540|NCT02081196|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
41159541|NCT01599377|DRUG|tofacitinib 10 mg|Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
41159542|NCT01599377|DRUG|tofacitinib 5 mg|Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
41159543|NCT00733564|DRUG|Lidocaine|Paracervical injection of 2% Lidocaine to block associated nociception input
41352138|NCT02554201|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
41352139|NCT02554201|DEVICE|Transvaginal electrical stimulation|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
41020754|NCT06456021|BEHAVIORAL|Leadership Coaching|Leadership coaching is a novel implementation strategy that enables proactive, knowledgeable, and supportive leadership behaviors. Although coaching has been embraced in the VA, through Whole Health and the VA Leadership Coaching Program, no studies have examined the impact on innovation implementation with clinical managers.
41020755|NCT03097068|DRUG|Lucentis|0.3mg Lucentis
41020756|NCT06152276|OTHER|Diverting loop ileostomy|Diverting loop ileostomy following low anterior resection of colorectal cancer
41352140|NCT04627805|BEHAVIORAL|MyPath tool|MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research \& Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
41352141|NCT02939196|PROCEDURE|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
41352142|NCT02939196|PROCEDURE|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
41352143|NCT01512693|DRUG|MK-0822|A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
41352144|NCT02241356|DEVICE|bifocals|bifocal glasses with an addition of 2.5 Dioptres
41352145|NCT02241356|DEVICE|single vision glasses|single vision glasses
41352146|NCT06497231|OTHER|Beautifil II LS|Beautifil II LS is a low shrinkage bioactive giomer resin composite.
41020757|NCT05951491|DEVICE|Wearable Shoulder Exoskeleton|The wearable shoulder exoskeleton prototype is under development at the University of Idaho to provide gravity support to the shoulder. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
41159544|NCT00733564|DRUG|Propofol|Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
41493282|NCT05894967|BEHAVIORAL|C10 - Endogenous Attention Training (EnAT)|Stimuli will be presented in a similar manner as in PT. However, in EnAT, a 100% valid cue (letter UL, LR; standing for upper left and lower right, respectively) - 150ms duration with an 500ms SOA prior to stimulus onset - will appear at the fixation point.
41493283|NCT05894967|BEHAVIORAL|C11 - Multisensory Facilitation (MF)|MF utilizes the same basic task structure as in ExEAT, however, rather than a visual cue, an auditory cue will be used (50ms, 1000hz tone with sound location determined by convolving sound with generic head-related transfer function, kemar large ears.
41493284|NCT05894967|BEHAVIORAL|No Contact Control|"While not a training condition one type of experience that could be part of a condition is a no contact control (i.e., where participants do no training activities over the same rough time span as for the other training tasks)."
41493285|NCT01776697|DRUG|pelubiprofen (30mg) tablet IR|
41352147|NCT06497231|OTHER|Nanohybrid resin composite material|Nanohybrid resin composite is a type of restorative material that features nano-sized fillers as a main component.
41020758|NCT05951491|DEVICE|Wearable Hand Exoskeleton|The wearable hand exoskeleton prototype is under development at the University of Idaho to provide hand-opening support. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
41020759|NCT05368597|PROCEDURE|PCI in native vessel or in bypass graft|Native vessel PCI,which choose native coronary artery as the target vessel, while the bypass graft PCI choose graft vessel as the target vessel.
41020760|NCT04095234|PROCEDURE|Acupuncture|Acupuncture, a therapy of traditional Chinese medicine (TCM), involves penetrating the skin with thin, solid, metallic needles that are manipulated by hand or electrical stimulation. If the patient has an electronically charged device, they will not receive TENS stimulation.
41159545|NCT00733564|DRUG|Sevoflurane|Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
41352148|NCT03754842|OTHER|Placebo (twice daily)|Matching placebo
41352149|NCT03754842|OTHER|Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)|Elysium Basis TM, Elysium Health, Inc., NY, USA
41352150|NCT03479203|DRUG|Electronic Cigarette Aerosol|16 two-second-long puffs from a non-nicotinized electronic cigarette.
41352151|NCT04990999|PROCEDURE|Vestibular Root Extraction|a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface
41352152|NCT04990999|PROCEDURE|Atraumatic extractions using periotomes followed by conventional forceps|a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.
41352153|NCT03977506|DIAGNOSTIC_TEST|On-road driving evaluation|"The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions."
41352154|NCT02863406|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage in order to determine rate of dust
41493286|NCT01776697|DRUG|pelubiprofen SR (as a pelubiprofen 90 mg) tablet|
41493287|NCT00236366|DRUG|fentanyl|
41493288|NCT00201409|DRUG|Placebo|Placebo will be administered by slow intravenous infusion once daily for 14 days.
41493289|NCT00201409|DRUG|GM-CSF|Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
41493290|NCT03598335|DEVICE|Ultrasound|Ultrasound imaging of women arriving at clinic for routine care
41493291|NCT02130882|DRUG|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
41493292|NCT02130882|OTHER|Placebo|A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
41493293|NCT06026774|BIOLOGICAL|iNeo-Vac-R01 in combination with standard adjuvant therapy|Personalized mRNA vaccine encoding neoantigen, IH injection
41493294|NCT00479778|DRUG|Bazedoxifene/conjugated estrogens|
41493295|NCT01290562|RADIATION|Stereotactic Body Radiotherapy (SBRT)|One or more high dose(s) of radiation to treat the tumour.
41493296|NCT05809167|DRUG|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."
41493297|NCT03370016|PROCEDURE|Amount of Pneumoperitoneum Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)
41493298|NCT01717716|DIETARY_SUPPLEMENT|water with Sucralose|
41493299|NCT01717716|DIETARY_SUPPLEMENT|water with HFCS|
41493300|NCT01717716|DIETARY_SUPPLEMENT|water with glucose|
41493301|NCT01717716|DIETARY_SUPPLEMENT|water with sucrose|
41493302|NCT00684892|DEVICE|Chartis System|Assessment of airway flow and pressure
41493303|NCT05634850|DEVICE|Kinder|Participants will test at their urine with at home with in the device. Results are sent via an app back to the clinic for reporting.
41493304|NCT01377376|DRUG|ARQ 197 and Erlotinib|Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib
41493305|NCT01377376|DRUG|Placebo and Erlotinib|Oral twice daily administration of placebo and oral once daily administration of erlotinib
41493306|NCT00132093|DRUG|Eplerenone|
41493307|NCT05011747|PROCEDURE|single-site rigid probe viscotrabeculotomy (VT)|single-site VT by the rigid probe trabeculotome is performed through a superonasal triangular scleral flap.
41493308|NCT05011747|PROCEDURE|two-site rigid probe viscotrabeculotomy (VT)|Two-site VT by the rigid probe trabeculotome is performed through a superonasal and an inferotemporal triangular scleral flap.
41159546|NCT03220776|DRUG|N-Acetylcysteine|5 day trial of N-acetylcysteine with titration to 2,400mg
41493309|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|"1. Cohort A: PBC treatment group: (1) PBC patients with poor response to UDCA after treatment: 30 patients continued to take UDCA（13-15mg/kg）, 30 patients took UDCA（13-15mg/kg）+SASP (0.5g orally three times a day), 30 patients took SASP (0.5g orally three times a day) for 12 months, and 12 months of follow-up observation.~(2) Newly treated PBC patients: 30 patients took UDCA（13-15mg/kg） and 30 patients took UDCA（13-15mg/kg）+SASP (0.5g orally three times a day) for 12 months and were followed up for 12 months.~2. Cohort B-D: 60 cases were collected from each group, 30 cases continued the current treatment(people with hepatitis B cirrhosis and hepatitis C cirrhosis continue to take antivirals), and 30 patients were taking sulfasalazine for 12 months of follow-up observation.~After 12 months of treatment, at the time of enrollment and the 1st/2nd/3rd/6th/9th/12 months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected。"
41493310|NCT04405843|DRUG|Ivermectin Oral Product|Ivermectin oral suspension, 6 mg/mL
41493311|NCT04405843|DRUG|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
41493312|NCT06281327|DRUG|Avatrombopag|"After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding.~Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L."
41493313|NCT02377518|RADIATION|Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media|
41493314|NCT00258700|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
41493315|NCT03473626|DRUG|Alicaforsen|Alicaforsen tablet
41493316|NCT00563576|DRUG|Femring®|"Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months."
41493317|NCT00563576|DRUG|DepoProvera ®|Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
41493318|NCT02068664|BEHAVIORAL|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
41493319|NCT05621408|BEHAVIORAL|Attention Training Technique|Attention Training Technique is a six weeks psychological intervention provided by trained professionals
41493320|NCT04376762|DRUG|Fibrinogen|Fibrinogen Concentrate (Human) Injection \[Fibryga\] (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
41159547|NCT03220776|DRUG|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
41159548|NCT03220776|DRUG|Placebo Oral Tablet|5 day trial of matched placebo
41159549|NCT03224689|DEVICE|PEEK-Optima Femoral Component|TKA Surgery
41159550|NCT02261285|DRUG|ONO-4538|
41352155|NCT03971227|DEVICE|Acuity 200 (Fluoroxyfocon A) contact lens|Daily wear rigid gas permeable contact lens
41352156|NCT03971227|DEVICE|Acuity 100 (Hexafocon A) contact lens|Daily wear rigid gas permeable contact lens
41352157|NCT05277194|BEHAVIORAL|KeepCalm app|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism.
41020761|NCT04095234|PROCEDURE|Massage|Massage, which involves the manual manipulation of muscles and other soft tissue areas of the body, is one of the earliest known forms of pain relief.
41493321|NCT04376762|DRUG|Cryoprecipitate|Cryoprecipitate group (dose: 10 ml/kg; active control group) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
41493322|NCT04176406|DEVICE|rTMS|excitatory 5Hz rTMS will be used
41493323|NCT04176406|DEVICE|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
41352158|NCT01196091|DRUG|LY2127399|120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
41352159|NCT01196091|DRUG|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
41352160|NCT01196091|DRUG|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
41352161|NCT01196091|DRUG|Standard of Care|
41352162|NCT03669263|DRUG|Fentanyl buccal soluble film (FBSF)|"After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed."
41352163|NCT03619902|BIOLOGICAL|Imsidolimab|Humanized monoclonal antibody
41352164|NCT04755699|DEVICE|Transcutaneous Electrical Stimulation|The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
41352165|NCT04019197|DRUG|Semaglutide Injectable Product|semaglutide subcutaneous injection
41493324|NCT02273791|DRUG|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
41493325|NCT02273791|DRUG|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
41352166|NCT04019197|DRUG|Placebo|placebo injection
41352167|NCT03531918|DRUG|Cladribine|Given IV
41352168|NCT03531918|DRUG|Cytarabine|Given IV
41352169|NCT03531918|DRUG|Gemtuzumab Ozogamicin|Given IV
41352170|NCT03531918|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
41352171|NCT03531918|OTHER|Laboratory Biomarker Analysis|Correlative studies
41352172|NCT03531918|DRUG|Mitoxantrone Hydrochloride|Given IV
41352173|NCT06408987|PROCEDURE|arthroscopically assisted|Arthroscopically-Assisted reduction through anterolateral portal for visualization and other accessory portals for instrumentation to achieve reduction and postoperative immobilization in a hip spica.
41493326|NCT00045188|DRUG|imatinib mesylate|Given PO
41493327|NCT00045188|OTHER|laboratory biomarker analysis|Optional correlative studies
41493328|NCT03859765|BEHAVIORAL|HCT Symptoms and Steps|HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
41352174|NCT06408987|PROCEDURE|open surgical reduction|Open reduction through a bikini incision anterior approach and postoperative immobilization in a hip spica.
41352175|NCT03640104|BEHAVIORAL|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
41493329|NCT01872026|DRUG|ASP7991|oral
41020762|NCT02738021|BEHAVIORAL|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
41020763|NCT00127790|BEHAVIORAL|CBT for Insomnia (CBT-I)|
41020764|NCT00127790|BEHAVIORAL|CBT for Pain (CBT-P)|
41020765|NCT02970968|DRUG|VLY-686 (Tradipitant)|oral capsule
41020766|NCT02970968|OTHER|Placebo|placebo oral
41020767|NCT00005861|DRUG|pegylated liposomal doxorubicin hydrochloride|
41020768|NCT00452504|DRUG|SRA-444|
41020769|NCT05383846|OTHER|Experimental Narrative Exposure Therapy|"NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for complex trauma, aiming to reduce symptoms of traumatic stress in individuals. NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.~This is a multiple baseline single case series design which focuses on assessing the posited exposure and autobiographical memory integration components of Narrative Exposure Therapy; no comparator will be included."
41352176|NCT03640104|BEHAVIORAL|Nutrition guidelines|Nutritional recommendations based on international guidelines
41159551|NCT06378918|PROCEDURE|puncture|Local anesthesia is previously carried out with 2-5 cc of 1% lidocaine. The puncture is then carried out using a 16 gauge needle. Antibiotic coverage will be offered. A work stoppage is recommended until the day after the puncture/aspiration but the duration is left to the discretion of the surgeon. A visit is systematically realised 15 days after the puncture/aspiration with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. In the event of fistulization following the puncture, associated with discharge and skin necrosis, local nursing care is recommended. The definitive resection procedure is then planned 4 to 6 weeks after the puncture/aspiration if the evolution is favorable.
41266501|NCT03153839|BEHAVIORAL|Aquatic physical activity in babies|"A programme based on four different types exercises realized in a swimming pool for twelve months.~Before the beginning of the aquatic physical activity, the infants will be evaluated. Afther that, the study group will practise the exercises with their parents in 20 minutes sessions twice a week and when they finish the programme they will be evaluated again."
41020770|NCT06549049|BEHAVIORAL|TranS-C for PTSD|The Transdiagnostic sleep and circadian intervention (TranS-C), developed by Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the goal of improving sleep and related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for veterans with PTSD. The modified approach, TranS-C for PTSD (TSC-PTSD), elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for veterans in the VA healthcare system.
41020771|NCT06549049|BEHAVIORAL|Sleep Psychoeducation Control|Participants will receive psychoeducation about sleep.
41352177|NCT05663827|DRUG|Ruxolitinib|A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.
40833219|NCT01519999|BEHAVIORAL|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
40833220|NCT06225947|DRUG|Lemborexant 5 MG|The recommended dosage of Lemborexant(LEM) is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability.
41352178|NCT04678193|DRUG|Coromec Registry with ECL-19|Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
41352179|NCT06471088|DRUG|Dovprela|Daily dose: 200 mg
41352180|NCT00000952|DRUG|Ritonavir|
41352181|NCT00000952|DRUG|Lamivudine|
41352182|NCT00000952|DRUG|Zidovudine|
41352183|NCT00794989|DIETARY_SUPPLEMENT|Ground Flaxseed|Given orally
41352184|NCT00794989|OTHER|No Intervention|Participants randomized to Arm 2 do not receive any intervention
41352185|NCT00313742|DRUG|insulin detemir|
41352186|NCT00313742|DRUG|insulin glargine|
41352187|NCT00313742|DRUG|insulin NPH|
41352188|NCT03316755|BEHAVIORAL|Exposure|Exposure to pamphlet
41352189|NCT04033029|DEVICE|Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)|CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
41352190|NCT04033029|DRUG|Antibiotics|Antibiotic concentration-time data will be collected and analyzed.
41352191|NCT05956327|PROCEDURE|Aerobic Endurance Training|Aerobic endurance training on a bicycle ergometer (week 1 to 6: three units per week á 40 minutes, week 7 to 12: three units á 45 minutes, in groups of up to three patients over 13 weeks)
41352192|NCT05956327|PROCEDURE|Flexibility, strengthening and balance training|Flexibility, strengthening and balance training (exercises from the areas of stretching, strength, balance and relaxation, 3x40 min from week 1-2, 3x45 min from week 3-4 and 3x50 min from week 5-13, in groups of up to three patients over 13 weeks)
41352193|NCT01731197|DIETARY_SUPPLEMENT|Dry-Blended Beverage|
41352194|NCT06351735|PROCEDURE|Deep cervical lymph node-vein bypass surgery|Deep cervical lymph node-vein bypass surgery, connecting deep cervical lymph node input lymphatic vessel
41352195|NCT04437329|DRUG|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
41493330|NCT00686530|PROCEDURE|MR Imaging|Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
41493331|NCT00686530|PROCEDURE|Autopsy|Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
41493332|NCT03393806|DRUG|GSK3772847|GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.
41159552|NCT06378918|PROCEDURE|incision of the abscess|This is carried out according to the habits of the department: in the operating room under general or local anesthesia or in consultation (or emergencies) under local anesthesia. The procedure is carried out on an outpatient basis but, if necessary, short-term hospitalization is carried out. Daily drying is then carried out with nursing care at home until healing. A work stoppage is recommended for a period of approximately 10 days. A visit is systematically realised 15 days after the incision with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. The definitive resection procedure is then planned 4 to 6 weeks after the initial operation if the evolution is favorable.
41159553|NCT03199261|DRUG|rE-4 Injection|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
41493333|NCT03393806|DRUG|Placebo|Commercially sourced sterile normal saline will be provided as Placebo
41493334|NCT03310411|DRUG|Lasmiditan|Administered orally
41493335|NCT03310411|DRUG|Sumatriptan|Administered orally
41020772|NCT03109834|DIETARY_SUPPLEMENT|Meal replacement (MR)|"MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).~During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
41159554|NCT03199261|DRUG|rE-4 Freeze-dried Powder|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
41159555|NCT02376322|RADIATION|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
41352196|NCT04437329|DRUG|Docetaxel, cisplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
41352197|NCT04437329|DRUG|Nedaplatin|Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
41352198|NCT04437329|DRUG|Cisplatin|Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
41352199|NCT04437329|RADIATION|Intensity modulated-radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
41352200|NCT01914510|DRUG|ENMD-2076|
41352201|NCT05474924|DRUG|Budesonide intrapolyp injection|intrapolyp injection of budesonide in cases of nasal polyps and assessment of side effects compared to systemic steroids
41352202|NCT05474924|DRUG|Budesonide nasal wash|Budesonide Nasal wash in cases of nasal polyp 0.5 mg/2ml added to 250 ml normal saline using squeeze bottle.
41352203|NCT05474924|DRUG|Prednisolone tablets|oral prednisolone tablet dosage 1 mg/kg/d tapered daily for 2 weeks.
41352204|NCT05669573|PROCEDURE|Early feeding group|Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories.
41159556|NCT05087953|DIAGNOSTIC_TEST|Head-Up Tilt table test|Autonomic response assessment in the orthostatic head up tilt test.
41352205|NCT05669573|PROCEDURE|Standard fasting group|Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period.
41352206|NCT00457093|DRUG|glargine|
41352207|NCT00457093|DRUG|detemir|
41352208|NCT01688427|BEHAVIORAL|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
41352209|NCT01688427|BEHAVIORAL|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
41352210|NCT00407420|DEVICE|Mandometer|A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
41352211|NCT00407420|BEHAVIORAL|Lifestyle|Typical dietary and activity advice as normally provided in clinic (control).
41352212|NCT06319677|DEVICE|ECMO treatment|Critically ill patients were treated with ECMO while receiving antimicrobial therapy
41352213|NCT01159886|PROCEDURE|Ileal intubation|"After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.~Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed."
41493336|NCT03310411|DRUG|Placebo for Lasmiditan|Administered orally
41493337|NCT03310411|DRUG|Placebo for Sumatriptan|Administered orally
41493338|NCT02439931|BEHAVIORAL|Remote psychosocial intervention|
41159557|NCT05087953|DIAGNOSTIC_TEST|Heart Rate Variability|Assessment of heart rate variability on 24-hour Holter monitoring..
41159558|NCT00660764|DRUG|Rosuvastatin|Oral
41493339|NCT04197427|DEVICE|Experimental Oral Rinse|Experimental Oral Rinse is a proprietary formulation of GRAS ingredients
41493340|NCT04197427|DEVICE|Placebo|Placebo formulation without the active ingredients
41493341|NCT04569396|DIAGNOSTIC_TEST|Biochemistry analysis|Biochemistry analysis of liver parameters were analyzed among the study subjects before and after the surgery.
40833221|NCT03622437|BEHAVIORAL|Patient-led follow-up|"1. Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~2. The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~- access to stoma care by specialist nurses"
41159559|NCT03047278|PROCEDURE|Serial Blood Samples|Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
41493342|NCT04569396|DIAGNOSTIC_TEST|NAFLD fibrosis score|NAFLD fibrosis score was determined among the study subjects before and after the surgery.
41493343|NCT04569396|OTHER|BMI measurement|BMI was measured among the study subjects before and after the surgery.
41493344|NCT04569396|DIAGNOSTIC_TEST|Fibrosis 4 Index|Fibrosis 4 Index was determined among the study subjects before and after the surgery.
41493345|NCT04569396|DIAGNOSTIC_TEST|Fatty Liver Index|Fatty Liver Index was determined among the study subjects before and after the surgery.
41493346|NCT05988632|DRUG|Regular Human Insulin then Placebo|Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
41493347|NCT05988632|DRUG|Placebo then Regular Human Insulin|Placebo: 0.9% saline solution (administered intranasally) THEN Insulin: 80 IU (administered intranasally)
41493348|NCT04141358|DIAGNOSTIC_TEST|Advanced ultrasound measurements|"Clinical interventions and procedures:~* Consent at 0 week~* Clinical data collection at 0 week~* Strain for native artery at 0 week~* Young's modulus for native artery at 0 week~* Intimal medial thickness for native artery at 0 week~* Ultrasound blood volume flow measurement at 0 week~* Vessel diameter at 0 week~* Blood pressure at 0 week~* BMI at 0 week~* Intra-operative blood volume flow measurement at AVF surgery time~* Strain for native artery at 6 weeks~* Young's modulus native artery at 6 weeks~* Intimal medial thickness native artery arteries at 6 weeks~* Ultrasound blood volume flow measurement at 6 weeks~* Vessel diameter at 6 weeks~* Blood pressure at 6 weeks~* BMI at 6 weeks"
41159560|NCT03047278|PROCEDURE|Serial Urine Samples|Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
41159561|NCT03047278|DRUG|Gabapentin 300 mg|All patients were treated with oral single dose of gabapentin 300 mg.
41159562|NCT03047278|DRUG|Cetirizine Hydrochloride 10 mg|Patients of control group were treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
41159563|NCT00094497|DRUG|Etoposide|
41159564|NCT00094497|DRUG|Doxorubicin|
41159565|NCT00094497|DRUG|Cisplatin|
41159566|NCT00094497|DRUG|Streptozotocin|
41159567|NCT00094497|DRUG|Mitotane|
41159568|NCT00067548|DRUG|EKB-569|
41159569|NCT02206087|DRUG|PER977|Reversal of heparin-induced anticoagulation
41159570|NCT02206087|DRUG|Placebo|Reversal of heparin-induced anticoagulation
41159571|NCT02206087|DRUG|Heparin Sodium|
41159572|NCT05858398|BIOLOGICAL|pharmacokinetics blood sample assessment|pharmacokinetics blood sample assessment during the first exposure to docetaxel
41159573|NCT00189683|PROCEDURE|Monitoring|
41493349|NCT04695145|BEHAVIORAL|Aerobic exercise in group|"Progression~The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~* Week 1-6: 12-18 reps x 2 set per exercise and muscle 30 s rest between exercises~* Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises~Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~* Week 1-6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises~* Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises~Mixed sessions~* Week 1-6: 35 s work time per exercise 25 s rest between exercises x 2 rounds~* Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
41493350|NCT04695145|BEHAVIORAL|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
41493351|NCT04269538|DRUG|PF-06480605|PF-06480605 150 mg and 450 mg SC dosing
41493352|NCT04269538|DRUG|Placebo|Placebo SC dosing
41493353|NCT04620135|DRUG|Netarsudil ophthalmic solution 0.02%|Topical sterile ophthalmic solution Other Name: Rhopressa®
41493354|NCT04620135|DRUG|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|Other Name: Glanatec®
41352214|NCT05882435|OTHER|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
41352215|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 6 months
41352216|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 6 months
41352217|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
41352218|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 3 months
41352219|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
41352220|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 3 months
41352221|NCT05664828|DRUG|SN132D|Manganese-based macromolecular MRI contrast agent
41352222|NCT00435929|DRUG|Ritonavir|100mg po bid
41352223|NCT00435929|DRUG|saquinavir [Invirase]|1000mg po bid
41352224|NCT05499091|PROCEDURE|Skin biopsy, blood sample, urine sample|blood samples, urine samples, skin samples.
41352225|NCT01343576|DIETARY_SUPPLEMENT|milk fat|45 g milk fat per day in 4 weeks
41352226|NCT01937949|DEVICE|Custom-made Zenith® Fenestrated AAA Endovascular Graft:|The graft will be inserted through arteries in the groin (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
41352227|NCT04830176|OTHER|dentifrice|use of dentifrices for brushing
41352228|NCT02064829|DRUG|Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
41352229|NCT02064829|DRUG|IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
41352230|NCT02668679|PROCEDURE|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
41352231|NCT02668679|DEVICE|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
41352232|NCT02668679|BIOLOGICAL|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
41352233|NCT02668679|OTHER|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
41352234|NCT00982111|DRUG|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
41352235|NCT00982111|DRUG|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
41352236|NCT00982111|BIOLOGICAL|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
41352237|NCT02215486|OTHER|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
41352238|NCT02215486|OTHER|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
41352239|NCT02511691|DRUG|18F-PSS232|Diagnostic PET Tracer
41352240|NCT02734849|DRUG|AK001 low dose|25 mg AK001 will be administered as multiple doses
41352241|NCT02734849|DRUG|AK001 high dose|250 mg AK001 will be administered as multiple doses
41352242|NCT02734849|DRUG|Placebo|Placebo will be administered as multiple doses
41493355|NCT05458180|DRUG|Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)|"Drug: Liposomal mitoxantrone hydrochloride (15 mg/m2, 18 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.~Drug: Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3 of each 21-day cycle.~Drug: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle."
41159574|NCT00189683|PROCEDURE|Xeloda|
41352243|NCT01986049|DRUG|Bupivicaine|
41352244|NCT05504928|OTHER|School nurse program|School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
41352245|NCT00492739|BIOLOGICAL|Vaccination with VZV vaccine|Varicella vaccination 2 doses 2 months apart.
41352246|NCT06144333|DIAGNOSTIC_TEST|RIPH2|"* Blood sampling by capillary~* Swab sampling~* Blood sampling by venous punction~* Salivary sample, sputum, expectoration:"
41352247|NCT02471586|PROCEDURE|Coronary PCI guided by IVUS|Imaging type
41352248|NCT02471586|PROCEDURE|Coronary PCI guided by OCT|Imaging type
41352249|NCT02471586|PROCEDURE|Coronary PCI guided by Angiography|Imaging type
41352250|NCT01293214|PROCEDURE|Limb transplantation|
41352251|NCT02996240|DIETARY_SUPPLEMENT|Omega-3 FFA|Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
41352252|NCT05876689|DEVICE|DREAM OCT|Swept Source OCT (similar to Zeiss Plex Elite)
41352253|NCT02990065|DIETARY_SUPPLEMENT|PROTEIN SUPPLEMENTATION|
41352254|NCT03223129|OTHER|Oral glucose tolerance test|Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
41352255|NCT03223129|OTHER|Graded intravenous glucose infusion|Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
41352256|NCT02749643|DEVICE|Vibrotactile feedback system|
41159575|NCT01963858|PROCEDURE|Functional relaxation|Functional relaxation during colonoscopy
41159576|NCT01963858|PROCEDURE|No relaxation|No relaxation during colonoscopy
41352257|NCT02114528|DRUG|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
41352258|NCT02114528|PROCEDURE|Catheter ablation|Ventricular tachycardia catheter ablation.
41352259|NCT03655015|PROCEDURE|Lung Tumor Resection|Lung Tumor Resection
41159577|NCT00306878|DRUG|Abatacept|
41266502|NCT05238376|BEHAVIORAL|Exercise training|12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)
41266503|NCT05910229|OTHER|Phone call|In the experimental arm the patient will be called 3 days before the CT scan
41266504|NCT01864408|OTHER|"Usual practice counseling"|
41352260|NCT00779818|DEVICE|Electrical acupuncture|Treatment by electrical acupuncture
41352261|NCT00779818|DEVICE|Laser|Treatment by laser
41352262|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 1mg once daily
41352263|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 2mg once daily
41352264|NCT00256204|OTHER|Placebo|Placebo
41493356|NCT05735041|BEHAVIORAL|Multi-domain cognitive digital therapy|Patients in the cognitive digital therapy group received multi-dimensional targeted cognitive function training electronically, involving attention, memory, executive function, thinking, processing speed and perception. The system will adjust the training difficulty and training plan adaptively according to the patient's current training time and performance, and train the patient's weak cognitive ability as far as possible. The patients had the same total amount of training each day.
41493357|NCT05735041|BEHAVIORAL|Basic cognitive therapy|The training content of the positive control group was cognitive training tasks with weak difficulty or no difficulty change. The patients underwent cognitive function training with fixed programs, including 15 training items, and the internal difficulty of the training items remained constant without change. The system presents the training content randomly according to the training scheme. The patients had the same total amount of training each day.
41352265|NCT04129242|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) + Task Specifc Training|A closed-loop taVNS system that delivers taVNS with upper-limb rehabilitation training in a chronic stroke population.
41352266|NCT02790749|PROCEDURE|Adjunctive hip arthroscopy to accompany PAO|This is the experimental group: those patients who undergo adjunctive hip arthroscopy in addition to periacetabular osteotomy (PAO).
41352267|NCT02790749|PROCEDURE|PAO without adjunctive hip arthroscopy|This is the control group: those patients who undergo periacetabular osteotomy (PAO) alone, without adjunctive hip arthroscopy.
41352268|NCT02205229|DRUG|Multi-ingredient, topical compounded medications|
41493358|NCT00440960|DRUG|propofol|
41352269|NCT00682292|DRUG|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
41352270|NCT00682292|DRUG|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
41493359|NCT00440960|DRUG|midazolam|
41352271|NCT04481724|DIETARY_SUPPLEMENT|gamma-linolenic acid|3 capsules per day of GLA for 24 months
41352272|NCT04481724|DIETARY_SUPPLEMENT|placebo|3 capsules per day of placebo for 24 months
41352273|NCT01739868|OTHER|Biopsies of muscular and fat tissue|"3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:~* 1 visit the first year (inclusion visit)~* 1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes~* 1 intermediary visit (in 3 years) or activated by the following conditions:~  * Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)~ * Normalization of the glycemia (fasting blood glucose \< 1 g/l)"
41352274|NCT00869375|DEVICE|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
41352275|NCT01749865|BIOLOGICAL|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells treatment for 4 cycles
41352276|NCT03349840|DRUG|Insulin Degludec U100|Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin
41493360|NCT00440960|DRUG|alfentanil|
41493361|NCT00440960|DRUG|lidocaine|
41493362|NCT03048188|OTHER|wound dressing|Manuka honey wound dressing
41352277|NCT03349840|DRUG|Insulin Glargine|Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
41352278|NCT06320964|BEHAVIORAL|TARANG|For newly married women, the intervention had one introductory rapport-building session, followed by 16 group sessions facilitated by trained female moderators over 5 months. The intervention aimed to empower participants by enhancing their understanding of fundamental topics such as menstruation, conception, and contraception, choice of a method among others. Sessions also covered topics to strengthen participants' sense of agency and their ability to make informed decisions regarding family planning and the timing of their first childbirth. Similarly, for husbands, a male moderator delivered sessions on four topics: Love, Relationships and Expectations; Conception and Health; Contraception Methods, and how to choose family planning methods. For MILs, a female moderator covered four sessions: Nutrition flag, Conception and Health, communication between family members, and the final session on relationships with daughter-in-law.
41352279|NCT02335567|OTHER|there is no intervention|
41352280|NCT00264511|OTHER|Hyperbaric Oxygen Treatment|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
41352281|NCT00697255|DRUG|corifollitropin alfa|SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
41352282|NCT00697255|BIOLOGICAL|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
41352283|NCT00697255|BIOLOGICAL|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
41352284|NCT00697255|BIOLOGICAL|hCG Bolus injection|Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
41352285|NCT03460665|PROCEDURE|Arteriography|knee arteriography
41352286|NCT03436095|OTHER|bundle measures|Implementation of bundle measures to improve the successful rate of weaning ventilator
41352287|NCT05039411|BIOLOGICAL|PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|All patients will receive a total of 60 million PF2020-CELL (UC-MSCs) cells per treatment visit.
41352288|NCT00003556|BIOLOGICAL|ALVAC-hB7.1|
41352289|NCT00003556|BIOLOGICAL|canarypox-hIL-12 melanoma vaccine|
41352290|NCT05315531|DIETARY_SUPPLEMENT|Water Intake|Participants will increase plain water consumption to at least 70% of the daily adequate intake for Americans depending on their sex.
40833222|NCT03622437|OTHER|Standard follow-up|"Patients with sphincter-preserving resection:~- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~* outpatient visits at 3, 12 and 36 months~* access to stoma care by specialist nurses~All patients:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years"
41352291|NCT02050256|OTHER|continuing medical education and electronic decision support|
41352292|NCT02050256|OTHER|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
41352293|NCT01063361|DIETARY_SUPPLEMENT|Low glycemic index diet with pulses|Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
41352294|NCT01063361|DIETARY_SUPPLEMENT|High Cereal Fibre|Subjects will be advised to follow a healthy high fibre diabetic diet.
41352295|NCT03974711|OTHER|"In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort."|There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
41352296|NCT05920109|PROCEDURE|ESP block|Patients in the experimental group will have a continuous Erector Spinae Plane Block within the first 6 hours post-admission, with a continuous 1ml/h infusion of Ropivacaine (2mg/ml) associated with a 25 ml bolus every 6h. The catheter will be used from the trauma bay to the ICU as long as possible with a dedicated infusion pump (with a bolus mode). In case of accidental catheter removal, a second introduction of ESP block catheter is allowed within the first 24 hours. In case of continuous ESP block failure (incidence \< 5% of the total experimental group), patients will be switched to the control group.
41352297|NCT04011462|DEVICE|prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
41352298|NCT04011462|DEVICE|prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
41352299|NCT03524586|PROCEDURE|Ipsilateral rotation of head|Ipsilateral rotation of head against fixed tube
41493363|NCT05220189|DIAGNOSTIC_TEST|EarlyTect® Bladder Cancer test|A highly accurate and sensitive real-time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE-qMSP) for measuring PENK methylation in urine DNA to detect bladder cancer in hematuria patients.
41493364|NCT05882994|BEHAVIORAL|rom exercise|At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks. Evaluation will be done. At the end of the study, rom exercises will be applied to the patients in the control group.
41493365|NCT01584557|DRUG|Tolvaptan or Samsca|uncoated tablet, 30mg, once per day, for up to 7 days.
40833223|NCT04334213|DRUG|CKD-501|QD, PO
41493366|NCT01584557|DRUG|placebo or sugar pill|sugar pill
40833224|NCT04334213|DRUG|D745, D150|QD, PO
40833225|NCT04334213|DRUG|CKD-501, D745, D150|QD, PO
40833226|NCT04621500|DRUG|cholecalciferol|Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
40833227|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq|RNA-seq analysis will be used to (a) identify changes in transcriptional profiles and biological pathways in the prostate between African American and Caucasian men and (b) compare Allostatic Load results to determine stress response and (c) identify changes in the molecular signature in relation to vitamin D levels
41352300|NCT03524586|PROCEDURE|Contralateral rotation of head|Contralateral rotation of head against fixed tube
41352301|NCT00056628|DEVICE|The COGNIShunt® System|
41352302|NCT03381703|DRUG|YH12852|YH12852 administration
41352303|NCT03381703|DRUG|14C-labeled YH12852|14C-labeled YH12852 administration
41352304|NCT00942292|DIETARY_SUPPLEMENT|Lipidem- fish oil emulsion BBraun UK|
41352305|NCT00942292|PROCEDURE|Digital Contrast MRI scan|
41352306|NCT00654056|DRUG|Actrapid (human insulin)|On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
41493367|NCT06460207|OTHER|fMRI neurofeedback|fMRI neurofeedback is a technique that allows individuals to observe real-time feedback of their brain activity as measured by fMRI scans. During a session, the participant lies inside an MRI scanner while their whole brain is scanned. This data is processed in real-time by a computer and then presented to the participant in the form of visual feedback. This feedback might be presented as a graph, a color-coded representation, or some other easily interpretable format. The participant is instructed to modulate their brain activity based on the feedback they receive. This can involve various mental strategies, such as focusing attention on specific thoughts, images, or sensations. Over repeated sessions, participants learn to consciously influence their brain activity based on the feedback they receive. Through trial and error, they discover which mental strategies are most effective for achieving their desired changes in brain activity.
41493368|NCT04645186|DEVICE|bone graft substitute|Filling bone defects in current clinical practice
41352307|NCT05932160|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
41493369|NCT03633734|DRUG|Sequential Treatment|One cycle of the treatment lasts for 56 days. Patients will receive chemotherapy based on Nab-paclitaxel Plus Gemcitabine and modified Folfirinox in sequence order. The cycle will repeat until progression or intolerance of toxicity.
41493370|NCT00117325|DRUG|GW685698X|Aqueous Nasal Spray 100mcg
41493371|NCT04053920|BEHAVIORAL|Low Load Resistance exercise|leg extension, leg press, leg curl and calf press
41493372|NCT04053920|BEHAVIORAL|High Load Resistance exercise|leg extension, leg press, leg curl and calf press
41493373|NCT01331226|BEHAVIORAL|telephone counseling 3 sessions|3 sessions of telephone counseling
41493374|NCT01331226|BEHAVIORAL|telephone counseling 1 session|1 session of telephone counseling
41352308|NCT05932160|OTHER|lactated ringers|Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.
41352309|NCT06308562|DEVICE|Fuzzy Wale Compression Stockinet|EdemaWear is a tubular, circular knit elastic stockinet fabricated with elastic, vertically oriented fuzzy wales, with the compression provided by the elastic, horizontal oriented Lycra® spandex yarns knitted in between. The stockinet is applied from the foot to the popliteal crease, over the affected area. EdemaWear can be applied in direct contact with the skin or over a wound care dressing. Sizing is based on leg circumference. EdemaWear is indicated for edema management of various etiologies (lymphedema, chronic venous insufficiency, congestive heart failure), and optimizing wound healing. The stockinette is often combined with other boxed compression sets. The manufacturer's stated dosage of EdemaWear is 8-12mmHg when used alone.
40833228|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation|Pathology results of the prostate biopsies will be analyzed for changes in the (a) Gleason Score (b) the number of positive cores (0 to 12) and (c) the highest percentage of positive core involvement (0 to 100%).
41352310|NCT01987609|DRUG|Hylenex|
41352311|NCT01987609|DRUG|Normal Saline|
41352312|NCT01173328|BEHAVIORAL|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
41352313|NCT01173328|BEHAVIORAL|Normal Breathing|
41352314|NCT02663206|PROCEDURE|peroral endoscopic myotomy|peroral endoscopic myotomy
41352315|NCT02663206|PROCEDURE|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
41352316|NCT04528836|DRUG|BBP-398 (Formerly known as IACS-15509)|oral capsules
41352317|NCT04891510|DEVICE|REVOLVE Advanced Adipose System|The REVOLVE system is an all-in-one fat processing device that harvests, filters, actively washes, and removes strands from lipoaspirate and allows for reinjection without any additional manipulation (REVOLVE 2020).
41352318|NCT04891510|DEVICE|LipoGrafter|The LipoGrafter system is designed to be a start-to-finish closed system with minimal processing of the lipoaspirate, minimizing the risk of contamination and fat cell damage (LipoGrafter 2020).
41352319|NCT04891510|PROCEDURE|Viality|The Viality system uses the AuraClens solution that acts as a surfactant to bring impurities like blood, free oil, and cellular debris into solution, where they can be flushed out through suction.
41352320|NCT02296528|DEVICE|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
41493375|NCT01331226|BEHAVIORAL|written materials only|written materials only
41493376|NCT03122067|DRUG|oxytocin treatment|intranasal administration of oxytocin
41352321|NCT01276873|DEVICE|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
41352322|NCT02005718|DRUG|Cholecalciferol|
41352323|NCT01896466|DEVICE|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
41352324|NCT01896466|BEHAVIORAL|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
41352325|NCT03611179|DRUG|Bevacizumab|"The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)"
41352326|NCT06299683|BEHAVIORAL|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population and tested in a prior study. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
41493377|NCT03122067|DRUG|placebo treatment|intranasal administration of placebo
41493378|NCT02195453|DRUG|Yangzhengxiaoji Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.~Yangzhengxiaoji Capsule four granules t.i.d po."
41493379|NCT02195453|DRUG|Placebo Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po."
41493380|NCT02337023|RADIATION|Brain scintigraphy with injection of Neurolite® (ECD)|Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
41493381|NCT00110526|GENETIC|Ad.hIL-12|Ad.hIL-12 intraprostatic injection IND
41493382|NCT03996161|OTHER|patient position|After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.
41493383|NCT04185051|DRUG|JNJ-67953964|Participants will receive JNJ-67953964 as oral capsules.
41493384|NCT04185051|DRUG|Placebo|Participants will receive matching placebo oral capsules.
41493385|NCT01154816|DRUG|Alisertib|Given orally
41493386|NCT01154816|OTHER|Laboratory Biomarker Analysis|Correlative studies
41493387|NCT01154816|OTHER|Pharmacological Study|Correlative studies
41493388|NCT00822341|DRUG|TG-0054|0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion
41493389|NCT03707665|DIAGNOSTIC_TEST|Compression ultrasound testing|Compression ultrasound testing, screening technique for diagnosing deep venous thrombosis
41493390|NCT02485119|DRUG|BAY94-9343|Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
41159578|NCT04236622|OTHER|Periodontal clinical exam|"The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis."
41159579|NCT03795935|OTHER|No side-effect stimulator settings with directional lead|Individuals in this arm will have their stimulator settings programmed to the point in which they have maximum tremor control with no side effects.
41352327|NCT06299683|OTHER|Pelvic Floor Physical Therapy|The pelvic floor physical therapy condition consists of 10 weekly 45-minute individual visits with an assigned trained physical therapist. In IC/BPS, pelvic floor physical therapy (PT) uses manual manipulation to release localized muscle tension, trigger points, and correct other scars and restrictions to reduce pain and urgency symptoms. Specific techniques will include external connective tissue manipulation to the abdominal wall, back, buttocks and thighs, myofascial trigger point release, and internal transvaginal/transrectal treatment of the soft tissues of the pelvic floor with connective tissue and myofascial manipulation to pelvic floor musculature
41493391|NCT05338216|BEHAVIORAL|Traditional EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name 9 pictures back-to-back four times/day."
41493392|NCT05338216|BEHAVIORAL|Micro-Interaction EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name one picture at a time, 36 times/day."
41493393|NCT06109337|DIAGNOSTIC_TEST|drow blood|Participants will be taken peripheral blood about 5 ml
41493394|NCT04576299|OTHER|Group 1|Survey about social networks, notification of adverse events, multidisciplinary teams, the doctor-patient relationship, the role of the ethics and patient safety committees, protocol compliance and suspension of outpatient procedures
41493395|NCT00671918|DRUG|Lymphoseek|Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
41493396|NCT04384744|DRUG|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
41352328|NCT05744830|OTHER|Overdenture|15 patients will receive removable complete dentures, then a single implant is placed in the midline of the mandible, then loaded with the denture.
41352329|NCT05744830|OTHER|Complete Denture|15 patients will only receive removable complete dentures
41352330|NCT04624581|DEVICE|Electrophysiological measurement of reflex nociceptive flexion threshold (RIII reflex) using Nicolet Vicking device|"This intervention measures the response to electrical stimulation of the sural nerve using a pair of percutaneous electrodes placed at the external malleolar retro passage of the nerve (2 cm apart) and connected to the stimulation device (Nicolet Vicking). Reflex muscle responses will be collected using surface electrodes placed on the femoral biceps muscle of the participant and connected to an Electromyogram recording device.~The RIII will be determined twice (rest period between each 10-minute). In order to induce the reflex nociceptive flexion response, repeated cutaneous electrical stimulations (30 to 40) will be applied at the level of the sural nerve following a variable interval of 6 to 10 seconds in order to overcome the phenomena of habituation and predictability. Each stimulus test will consist of a single rectangular pulse of 0.5 ms, of variable intensity (0-100mA) until a reflex nociceptive flexion threshold is detected or a maximum current of 100 mA is reached"
41352331|NCT02814591|DEVICE|spatially offset Raman spectrometer (SORS)|Raman spectra will be collected non-invasively from patients using a lower power 830 nm laser. A probe is brought into gentle contact with the patients skin and measurements taken. The laser power has a pre-defined safe threshold of 30 mW into a 3.5 mm diameter aperture. Built in device safety features prevent this threshold from being exceeded. The probe that comes into patient contact is suitable for disinfecting.
41352332|NCT02660073|DEVICE|NMES+FES|12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
41352333|NCT02660073|DEVICE|Control+FES|12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
41352334|NCT05536544|OTHER|IBDMED|The IBDMED program will be applied for 8 weeks and include education on MED diet and lifestyle components, focused on increasing and diversifying dietary fiber intake, reduction of ultra-processed food intake and promoting an active lifestyle. This intervention is digitally supported by an interactive website application and step trackers to monitor lifestyle parameters.
41352335|NCT05536544|OTHER|Control|Dietary counseling according to the local dietary guidelines for patients with IBD
41352336|NCT04025749|BEHAVIORAL|Computerized Executive Functions training|Home-based executive function training with adaptive difficulty, through NeuronUp (https://www.neuronup.com) over 12 weeks (30 min/day, 5 days per week, 30h in total).
41352337|NCT04025749|OTHER|Care as usual|Care as usual
41352338|NCT03140033|DRUG|Misoprostol Oral Tablet|at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
41352339|NCT03140033|DRUG|Ranitidine Oral Tablet|at cord clamping the patient will recieve ranitidine sublingually
41352340|NCT00004084|RADIATION|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
41352341|NCT00004084|RADIATION|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
41352342|NCT06250192|OTHER|Virtuel education|Randomization to virtuel education based on a tool of small videos accessible via smartphones
41352343|NCT05961514|DIAGNOSTIC_TEST|Target biopsies|MRI/Fusion target biopsies combine magnetic resonance imaging (MRI) with ultrasound-guided biopsy techniques to obtain tissue samples from areas of the prostate gland that appear abnormal on MRI.
41352344|NCT05961514|DIAGNOSTIC_TEST|systemic biopsies|transrectal ultrasound (TRUS) guided prostate systemic biopsies
41352345|NCT03479840|PROCEDURE|PCI|treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
41352346|NCT02134912|DRUG|crizotinib|Given PO
41352347|NCT02134912|DRUG|pemetrexed disodium|Given IV
41352348|NCT02134912|OTHER|laboratory biomarker analysis|Correlative studies
41352349|NCT02134912|OTHER|pharmacological study|Correlative studies
41159580|NCT01099150|DIETARY_SUPPLEMENT|Dark chocolate enriched in flavan-3-ols and procyanidins|Acute consumption (within 15 minutes) of 60 g of chocolate containing \~900 mg of total flavan-3-ols and procyanidins.
41352350|NCT05801185|OTHER|Unilateral lower limb suspension|Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
41352351|NCT03233308|DRUG|Netarsudil Ophthalmic Solution 0.02%|1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
41352352|NCT03233308|OTHER|Placebo Comparator|1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
41352353|NCT03389594|OTHER|Surgical guide|Surgical Guide for this group will designed from 0.4mm voxel size
41352354|NCT02882451|DIETARY_SUPPLEMENT|pinaverium bromide|
41352355|NCT02882451|DIETARY_SUPPLEMENT|Vitamin C|
41352356|NCT06199492|DEVICE|tVisio-1|Standard of Care Biopsy
41352357|NCT04875195|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.
41352358|NCT01468844|DRUG|Minocycline|100 mg pink opaque capsule
41352359|NCT01468844|DRUG|Placebo|Placebo
41352360|NCT01468844|DRUG|Bevacizumab|1.25 mg bevacizumab injection
41352361|NCT00006185|DRUG|Avandia administration for 6-12 weeks|
41352362|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg
41352363|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg with aluminum hydroxide (alum)
41352364|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg
41352365|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg, with aluminum hydroxide (alum)
41352366|NCT05245838|BIOLOGICAL|Shingrix|a suspension for injection supplied as a single-dose vial of 50 mcg varicella zoster virus (VZV) glycoprotein E (gE) antigen and AS01B adjuvant
41352367|NCT00071604|BEHAVIORAL|Medication Adherence Therapy|
41352368|NCT00071604|BEHAVIORAL|Friendly Support Group|
41493397|NCT01995305|GENETIC|human whole exome|he exome is the part of the genome formed by exons, coding portions of genes in the genome that are used in the synthesis of proteins, therefore, it is most likely to contribute to the phenotype of an organism. The exome of the human genome, is estimated to comprise 1.5% of the total genome (The human exome is about 30 MB).
41493398|NCT01995305|GENETIC|whole genomic|This study propose to find the genes that are sensitive to DNA crosslink repair, and genes that have key roles in hematopoietic cell development and maturation.
41493399|NCT06287749|BIOLOGICAL|Blood sample/Liquid Biopsy|ctDNA analysis
41352369|NCT01549028|BEHAVIORAL|mobile-based PR program.|Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
41493400|NCT05596721|DRUG|Azithromycin|Treat patient with azithromycin for 12w.
41493401|NCT05596721|DRUG|ICS/LABA|Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.
41493402|NCT05549518|OTHER|Core stabilization + Traditional Physical Therapy|"In addition to the traditional physical therapy training, core stabilization exercises will be applied 3 days a week for 6 weeks, and 20 minutes in each session under the supervision of a physiotherapist. Core stabilization exercises; will gradually progress from easy exercises to difficult ones. Exercises will be performed in supine, hook position, sitting position, on stable and mobile surfaces. Exercises will progress from 1 set to 3 sets, from 7 to 10 reps, contractions from 3 seconds to 10 seconds. All exercises will be performed with breathing control.~The exercises will be progressed by gradually increasing them every week."
41493403|NCT05549518|OTHER|Traditional Physical Therapy|"Traditional physical therapy training will be given for 40 minutes each session, 3 times a week for 6 weeks under the supervision of a physiotherapist. As a traditional physical therapy program, a rehabilitation program that increases mobility and daily living activities will be applied to patients.~* Joint range of motion exercises~* Stretching exercises~* Strengthening exercises~* Bobath-based neurophysiological approaches~* Task-oriented training~* 15 minutes of neuromuscular electrical stimulation (NMES) application"
41493404|NCT01359969|DRUG|rhC1INH|Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
41493405|NCT03867461|PROCEDURE|Venous Sinus Stenting|Venous sinus stenting is performed under general anesthesia. Patients are loaded with aspirin and clopidogrel before the procedure. After induction, the right femoral vein is accessed and an 8 F sheath is placed. Intravenous heparin is administered. A 0.070-0.088 guide catheter is navigated into the ipsilateral jugular vein near the jugular bulb. Pre-stenting manometry is performed in every patient. To do so, a Renegade Hi-Flo microcatheter is navigated into the superior sagittal sinus and then used to measure ipsilateral venous pressures across the site of outflow obstruction (this will be the time point where the study intervention will be performed).
41352370|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
41352371|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
41493406|NCT03867461|OTHER|Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the End-tidal carbon dioxide concentrations will be adjusted to fall in the 38-40 mmHg range
41493407|NCT03867461|OTHER|Adjustment to Mean Arterial Pressure (100-110 mmHg range)|Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range
41020773|NCT03109834|OTHER|Control (C)|"During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.~During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
41352372|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
41352373|NCT03267511|DRUG|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
41493408|NCT03867461|OTHER|Adjustment to Mean Arterial Pressure (60-80 mmHg range)|Mean arterial pressure will be adjusted to fall in the 60-80 mmHg range
41493409|NCT03867461|OTHER|Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the 24-26 mmHg range
41352374|NCT02912832|DEVICE|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
41352375|NCT00086385|DRUG|Nicotine polacrilex, Bupropion|Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
41352376|NCT01685060|DRUG|LDK378|Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
41352377|NCT04134689|DEVICE|DOT Selfie Intervention|This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
41159581|NCT01099150|DIETARY_SUPPLEMENT|Standard dark chocolate|Acute consumption (within 15 minutes) of 60 g of chocolate containing \~400 mg total flavan-3-ols and procyanidins.
41493410|NCT00831766|DRUG|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
41493411|NCT00831766|DRUG|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
41493412|NCT00831766|DRUG|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
41493413|NCT06303037|DRUG|Remimazolam besylate and low-dose Esketamine|Esketamine was injected intravenously 0.25mg/kg and the initial dose of Remimazolam was 0.3mg/kg
41493414|NCT06303037|DRUG|Remimazolam besylate and Medium dose Esketamine|Esketamine was injected intravenously 0.5mg/kg and the initial dose of Remimazolam was 0.2mg/kg
41493415|NCT00369317|DRUG|asparaginase|Given IM
41493416|NCT00369317|DRUG|daunorubicin hydrochloride|Given IV
41493417|NCT00369317|DRUG|cytarabine|Given IV or IT
41493418|NCT00369317|DRUG|thioguanine|Given orally
41493419|NCT00369317|DRUG|etoposide|Given IV
41493420|NCT00369317|OTHER|laboratory biomarker analysis|Correlative studies
41493421|NCT02107820|BEHAVIORAL|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
41493422|NCT02107820|DEVICE|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
41493423|NCT04505137|DRUG|GMA301 Injection|GMA301 Injection administered as a single dose of 1500 mg
41493424|NCT04505137|OTHER|GMA301 Placebo Injection|GMA301 Injection without GMA301 administered as a single intravenous dose
41493425|NCT04505137|DRUG|GMA301 Injection|GMA301 Injection administered as a single dose of 2000 mg
41493426|NCT00893737|DRUG|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
41493427|NCT03534843|PROCEDURE|Liver resection|Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
41493428|NCT03534843|OTHER|Transcatheter arterial embolization|Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
41493429|NCT02908282|DEVICE|REMOGEN OMEGA|Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.
41493430|NCT02908282|DEVICE|Povidone|Artificial tears: preservative-free eye drops containing 2% povidone.
41493431|NCT01597466|DEVICE|Epidural catheter placement|Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
41493432|NCT01597466|PROCEDURE|Epidural catheter placement|Epidural space is located using loss of resistance technique (saline solution)
41352378|NCT04134689|OTHER|In-person DOT|Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
41352379|NCT05143853|PROCEDURE|non-absorbable tape fixation around AC joint|fixation around AC joint with tape in different configurations
41352380|NCT05143853|PROCEDURE|no fixation around AC joint|there will be no additional fixation around AC joint in this group
41352381|NCT05143853|PROCEDURE|coracoclavicular (CC) fixation|mandatory coracoclavicular fixation with to suspensory systems, comprised of non-absorbable tapes and metal buttons
41352382|NCT05760651|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test and osteoporosis awareness scale
41352383|NCT05760651|DIAGNOSTIC_TEST|Timed up - and - go test|. The timed up-and-go test involves rising from a seated position, walking a distance of 3 meters, pivoting, returning to the initial point, and resuming a sitting position. It demonstrates strong inter-rater and intra-rater reliability, offering a reliable means of quantifying functional mobility and balance.
41352384|NCT02847000|DRUG|Tetrahydrouridine|"Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
41493433|NCT03335449|OTHER|Protective ventilation group|Application of a protective ventilation strategy in order to improve gas exchange and respiratory mechanics during Robotic surgery in deep Trendelenburg position.
41493434|NCT02379780|PROCEDURE|USG guided Subcostal TAP block|"Ultrasonography Assisted Subcostal TAP blockage: In plane technique was applied and 22 G needle (BRAUN Stimuplex D Plus 0,71\*50 mm 22G\*2) was used. Intravascular injection was eliminated after the passage of rectus sheath by negative aspiration. 0,5-1 ml local anesthetic was applied directly to confirm the right place. 10 cc bupivacain ( 0,5 % Marcain flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site. The same procedure was applied to the opposite site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
41493435|NCT02379780|PROCEDURE|USG guided Paravertebral Block|"Ultrasonoraphy assisted Thoracic Paravertebral blockage application: In-plane or out-of-plane technique was used with stimuplex needle (BRAUN Stimuplec D Plus 0,71\*50 mm 22 G\* 2'', 15°). Popping sensation that was felt by the penetration of the internal intercostal membrane, guided to paravertebral space. Intravascular injection was eliminated by negative aspiration. 0,5 - 1 ml local anesthetic injection was administered to show the displacement of pleura downward that confirmed the place of the needle in the right place. Then 10 cc bupivacain (% 0.5 Marcaine® flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
41493436|NCT05387538|PROCEDURE|One-layer Duct-to-mucosa Pancreaticojejunostomy|To create the anterior suturing layers, double needles with a 4/0 or 3/0 Prolene line will be used; one side of the needles will be inserted from the anterior inner side of the pancreatic duct and out through the ventral parenchyma of the pancreatic stump to the anterior surface of the pancreas about 3 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel but its done after completion of the posterior layer. The posterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be used
41493437|NCT05387538|PROCEDURE|Two-layer Duct-to-mucosa Pancreaticojejunostomy|The same double needle and 4/0 or 3/0Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the interrupted suturing method. The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the interrupted suturing method with Prolene line, and a suitable internal pancreatic duct stent will used . The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the interrupted method.
41493438|NCT05267743|DRUG|Tegoprazan 50mg QD|Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
41159582|NCT01099150|DIETARY_SUPPLEMENT|White chocolate|Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
41159583|NCT02652715|OTHER|Laboratory Biomarker Analysis|Correlative studies
41493439|NCT05267743|DRUG|Lansoprazole 30mg QD|Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
41493440|NCT03205891|DRUG|Brentuximab Vedotin|1.8 mg/kg by vein on Day 1 per cycle by vein over about 30 minutes on Day 1 of each cycle.
41352385|NCT02847000|DRUG|Decitabine|"Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested \~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
41352386|NCT02680366|DEVICE|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
41493441|NCT03205891|DRUG|TAK228|Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
41493442|NCT03205891|DEVICE|Glucose Monitor|Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug.
41159584|NCT02652715|OTHER|Quality-of-Life Assessment|Ancillary studies
41493443|NCT02334592|RADIATION|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
41493444|NCT04636060|DIETARY_SUPPLEMENT|Eisen|Treatment with low-dose iron in the form of tablets containing 6mg of iron. Treatment consists of twice-daily oral administration of iron-tablets for 8 weeks in total.
41020774|NCT03109834|DIETARY_SUPPLEMENT|Verum|"Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)~Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).~Duration: 6 months (6.month / baseline II - 12.month)"
41020775|NCT03109834|OTHER|Placebo|"Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.~Placebo contains no micronutrients and omega-3 fatty acids.~Duration: 6 months (6.month / baseline II - 12.month)"
41020776|NCT03285477|DRUG|Placebo|Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
41020777|NCT03285477|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
41020778|NCT06245070|DEVICE|Active transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Active stimulations will be delivered by a 9 MxN Soterix HD-tES device for 20 minutes( 2 mA) per day for 5 days.
41493445|NCT03330210|PROCEDURE|3D printing|Manufacturing and use of a model printed in 3D
40833229|NCT04621500|DIAGNOSTIC_TEST|Allostatic Load Measurements at baseline and after one year vitamin D3 supplementation|Allostatic Load measurements to determine body stress compared at baseline and after one year of vitamin D3 supplementation. Also compared with RNA-seq results to determine stress response.
40833230|NCT04268277|DRUG|Rituximab|100 mg concentrate for solution for infusion
40833231|NCT04268277|DRUG|Pembrolizumab|100 mg/ 4mL concentrate for solution for infusion
41020779|NCT06245070|DEVICE|Sham transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Sham stimulations will be delivered by a 9 MxN Soterix HD-tES device. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
41159585|NCT02652715|OTHER|Questionnaire Administration|Ancillary studies
41159586|NCT02652715|DIETARY_SUPPLEMENT|Salvia hispanica Seed|Given PO
41352387|NCT02680366|DEVICE|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
41352388|NCT00508820|BIOLOGICAL|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
41352389|NCT05270265|BIOLOGICAL|Pvs25-IMX313/Matrix-M1|Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
41352390|NCT04686929|DRUG|Abatacept s.c.|subcutaneous abatacept: 250mg (d-1) , 125mg (d+5, +14, +21, +28, +35, +42, +49, +56) combined with CsA, MTX, MMF.
41352391|NCT04154761|PROCEDURE|Resection of inferior vena cava and reconstruction|Resection of inferior vena cava and reconstruction with primary repair, resection with autologous or prosthetic patch repair, and circumferential resection with graft replacement
41352392|NCT06246162|DRUG|Lipo-MIT combination regimen|"Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed."
41352393|NCT03475355|BEHAVIORAL|Live movement observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the upper limbs. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to look carefully at the therapist who shows 20 different daily routine activities (actions) performed with the upper limb."
41352394|NCT03475355|BEHAVIORAL|Video Observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the video observation of upper limbs movements. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to carefully watch a video showing 20 different daily routine activities (actions) performed with the upper limb."
41020780|NCT03844893|PROCEDURE|Mini bal|Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.
40833232|NCT04447599|OTHER|photography of conjunctival vessels|patient will have photo of their bulbar conjunctival of each eye and photography of fundus without dilatation
40833233|NCT01439074|DEVICE|Mepilex Ag|Dressing
40833234|NCT01439074|DRUG|Silver Sulphadiazine Ag cream|A cream used on burnt areas.
41159587|NCT04457245|PROCEDURE|Computed Tomography|Undergo whole body PET/CT
41159588|NCT04457245|OTHER|Fluorine F 18 DCFPyL|Given IV
41159589|NCT04457245|PROCEDURE|Positron Emission Tomography|Undergo whole body PET/CT
41159590|NCT04457245|RADIATION|Radiation Therapy|Undergo standard of care definitive radiation therapy
41159591|NCT05607485|PROCEDURE|Randomized video numbers|See arm/group description
41352395|NCT03475355|BEHAVIORAL|Live Movement Observation (Lowe Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the lower limbs. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking.~Every day, before starting the physical training, the patient will be asked to carefully watch the therapist who will show 20 different movement strategies to avoid episodes of freezing the pace (FOG)."
41352396|NCT03475355|BEHAVIORAL|Video Observation (Lower Limbs)|All participants will be subjected to two 15-minute sessions per day of the video observation of lower limbs movements. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking. Every day, before starting the physical training, the patient will be asked to carefully watch a video that will show 20 different movement strategies to avoid episodes of freezing the pace (FOG).
41352397|NCT03475355|BEHAVIORAL|Static Picture Observation and Upper Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of upper limbs, and simulating that performed by the experimental groups."
41352398|NCT03475355|BEHAVIORAL|Static Picture Observation and Lower Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of lower limbs, and simulating that performed by the experimental groups."
41352399|NCT03990922|PROCEDURE|Continuous Paravertebral block with ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
41352400|NCT03990922|PROCEDURE|"Continuous Paravertebral block with saline"|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
41352401|NCT03990922|DRUG|Patient-controlled analgesia with morphine|Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
41352402|NCT01128855|DRUG|3 mg/kg GSK2402968|Weekly subcutaneous injection
40833235|NCT04467476|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
40833236|NCT03329963|BEHAVIORAL|Healthy Lifestyle Intervention|Participants in the this group will receive group educational sessions that focus on diet, exercise, and social support once a month throughout the study. The sessions will provide an opportunity for participants to discuss issues related to living with obesity and aging.Participants will also attend regular scheduled clinic visits for assessment of outcomes.
41020781|NCT06098755|BEHAVIORAL|Transcendence Research: Holistic Education|With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.
41159592|NCT06162637|DEVICE|femoral neck locking plate|femoral neck fractures fixation by femoral neck locking plate
41159593|NCT06162637|DEVICE|multiple cannulated cancellous screws|femoral neck fractures fixation by multiple cannulated cancellous screws
41352403|NCT01128855|DRUG|6 mg/kg GSK2402968|Weekly subcutaneous injection
41352404|NCT01128855|DRUG|9 mg/kg GSK2402968|Weekly subcutaneous injection
41352405|NCT01128855|DRUG|12 mg/kg GSK2402968|Weekly subcutaneous injection
41352406|NCT01128855|OTHER|Placebo|Weekly Placebo
41352407|NCT05229575|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
41352408|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 300 mg|300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
41159594|NCT00678132|DRUG|AZD 2281|
41159595|NCT00678132|DRUG|Cisplatin|
41159596|NCT00678132|DRUG|Gemcitabine|
41020782|NCT06573866|BEHAVIORAL|Participatory workplace intervention|The Participatory Workplace Intervention (PWI) is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. Following consensus, the stakeholders formulate and agree upon a plan of action and execute the plan. Subsequently, the implementation (process) of the plan of action will be evaluated. Six months after the evaluation, a follow-up will take place to determine whether new obstacles have emerged and whether a new cycle of process steps should be initiated.
41352409|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 600 mg|600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
41352410|NCT04697589|DIETARY_SUPPLEMENT|Placebo|Colored maltodextrin
41352411|NCT01156012|DRUG|T2345|One drop of T2345
41352412|NCT01156012|DRUG|Prostaglandin|One drop
41352413|NCT05496166|COMBINATION_PRODUCT|chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy|Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
41352414|NCT02180464|DRUG|LAS41004|
41352415|NCT02180464|DRUG|control|
41352416|NCT06085040|BEHAVIORAL|Multidisciplinary weight loss|12-months multidisciplinary behavioral intervention combining physical activity (3 times 60 minutes per week), nutritional guidance (balanced meals) and psychological support (60 minutes per week)
41352417|NCT04321291|OTHER|Generic information leaflet|The information about the biosimiliars is realized only by the transmission of the information leaflet in addition to the information given by the investigator.
41493446|NCT02564146|DRUG|nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
41493447|NCT02564146|DRUG|gemcitabine mono and nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.~Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.~Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
41493448|NCT01844232|DRUG|arbaclofen|Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
41493449|NCT02636426|DRUG|sorafenib|In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
41020783|NCT05002101|DIETARY_SUPPLEMENT|zinc|The zinc syrup was prepared with a concentration of 7 mg zinc in each 5 ml solution. Accordingly, children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
41493450|NCT00993486|BIOLOGICAL|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
41493451|NCT00246142|BIOLOGICAL|Botulinum toxin type A|
41493452|NCT00673244|DRUG|Furosemide|One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
41493453|NCT02838654|PROCEDURE|cervical epidural injection|sensitivity, specificity, positive predictive value, negative predictive value
41493454|NCT04023643|OTHER|Ventilation Weaning|Use of different weaning strategies
41020784|NCT05002101|DRUG|Placebo|Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
41020785|NCT03713489|PROCEDURE|platelet|Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
41493455|NCT03597659|GENETIC|phenome-wide association study (PheWAS)|Phenome-wide association study (PheWAS) identifying clinical diagnoses associated with a polygenic predictor of TSH levels identified by a previously published genome-wide association study (GWAS) which included North American and European participants. A phenome-wide scanning of 1,318 phenotypes will be performed, using a cohort of 37,154 North American individuals of European ancestry with electronic-health-record (EHR) data.
41493456|NCT01716624|DRUG|Oxybutynin|standard oral therapy
41493457|NCT01716624|DRUG|Botulinum Toxin A injection|10 units/kg injected into the detrusor muscle using cystoscopy
41493458|NCT04582461|DEVICE|multislice computed tomography|All patients will undergo a preoperative multiphasic multidetector CT scan before surgery.The unenhanced scan will be used to generate a CT reconstruction of the upper abdomen (from the diaphragm to the kidneys) with a 5mm thickness. Two different radiologists (D.F. and D.I.), blinded to patient information, measured total fat volume (TFV), visceral fat volume (VFV), and analyzed pixels with densities in the - 190 hounsfield units (HU) to - 20 HU range. the ratio between the density of the pancreas over the density of the spleen will be calculated and the maximum diameter of the pancreatic duct will be measured using the arterial phase in order to better identify the entire length of the duct.
41493459|NCT01436799|DRUG|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.
41020786|NCT03765281|OTHER|Navigation|Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.
41020787|NCT03765281|OTHER|Resource List|Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
41020788|NCT04997642|BEHAVIORAL|neuropsychiatric and cognitive testing questionnaires|"Demographic data such as race, sex, age Family History Risk Factor Questionnaire Hoehn and Yahr Stage UPDRS Parkinson's symptom checklist Medication list Neuropsychological Test Battery Behavioral Exams~* Geriatric Depression Scale Quality of Life Questionnaire~* PDQ-39, SF-12"
41020789|NCT06074016|DRUG|Zolmitriptan intranasal.|Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
41020790|NCT06074016|DRUG|Zolmitriptan oral.|Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
41020791|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
41020792|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
41352418|NCT04321291|OTHER|Individual information by nurse on biosimilars|Delivery of the same information leaflet, completed if asked by the patient, by individual meeting with specialist nurse, including generic and standardized informations on specificities, advantages and current scientific knowledge about biosimilars in inflammatory rheumatic diseases. This is in addition to the information given by the investigator
41352419|NCT00935467|DRUG|Saxagliptin|Tablets, oral, 2.5 mg, twice daily, 7 days
41352420|NCT05839002|PROCEDURE|nCRT|ESCC patients that recieved surgery and nCRT.
41493460|NCT01436799|DRUG|Desflurane|anaesthesia was maintained by desflurane 4-7vol%
41020793|NCT04479891|DRUG|pyrotinib tablet|single oral dose of SHR6390 or co-administered with itraconazole
41020794|NCT04479891|DRUG|Itraconazole capsule|200 mg itraconazole QD
41020795|NCT05378867|BIOLOGICAL|TRS003|"* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period"
41020796|NCT05378867|BIOLOGICAL|China-approved Bevacizumab|• Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle
41352421|NCT01428414|DRUG|Trastuzumab|2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
41352422|NCT01428414|DRUG|Paclitaxel|75mg/m2, iv d1, 8,15. qw; 4-6 cycles
41352423|NCT01428414|DRUG|Epirubicin|75mg/m2, iv d1, q3w, 4-6 cycles
41352424|NCT01428414|DRUG|Carboplatin|AUC 2, qw, iv d1, 8,15. 4-6 cycles
41352425|NCT02070081|PROCEDURE|Roux-en-Y gastric bypass surgery or sleeve surgery|
41352426|NCT01236131|OTHER|no intervention|Not Applicable- no intervention
41352427|NCT04373616|BIOLOGICAL|ACI-24|injections
41352428|NCT04373616|BIOLOGICAL|Placebo|injections
41020797|NCT05378867|DRUG|mFOLFOX6|"The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus."
41020798|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
41020799|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
41020800|NCT06572267|DRUG|Mepolizumab low dose group|Meperizumab (0.05 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
41020801|NCT06572267|DRUG|Mepolizumab middle dose group|Meperizumab (0.1 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
41020802|NCT06572267|DRUG|Mepolizumab high dose group|Meperizumab (0.2 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
41020803|NCT06572267|DRUG|Saline|Intravenous infusion of saline 100 mL shall be completed within 30 to 60 min.
41352429|NCT06227416|OTHER|Biopsy|punch biopsy (2-4 mm) depending on the size of the AK lesion.
41352430|NCT01676649|BIOLOGICAL|Ipilimumab|3 mg/kg
41020804|NCT01496651|PROCEDURE|Percutaneous coronary intervention|"PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.~There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement."
41352431|NCT01676649|DRUG|Carboplatin|AUC = 6
41352432|NCT01676649|DRUG|Paclitaxel|175 mg/m2
41352433|NCT05591573|DIETARY_SUPPLEMENT|Low glycemic index drink|Fruit flavoured drink with low glycemic index sugar (300 ml)
41352434|NCT05591573|DIETARY_SUPPLEMENT|High glycemic index drink|Fruit flavoured drink with high glycemic index sugar (300 ml)
41352435|NCT02894892|DRUG|(A)Bismuth|
41352436|NCT02894892|DRUG|(B)Bismuth|
41352437|NCT02894892|DRUG|(C)Bismuth|
41352438|NCT02894892|DRUG|(D)Esomeprazole and Bismuth|
41352439|NCT02894892|DRUG|(E)Esomeprazole and Bismuth|
41352440|NCT02894892|DRUG|(F)Esomeprazole and Bismuth|
41352441|NCT02894892|OTHER|(G)Control|
41493461|NCT01436799|DRUG|alfentanil|administration of alfentanil 10 μg kg-1 for anesthetic induction
40833237|NCT03329963|BEHAVIORAL|Lifestyle Intervention|"The lifestyle modification will be achieved by group behavior therapy sessions designed to have older adults acquire positive weight-control skills/attitudes, and practice weight-maintenance skills.Participants will attend weekly group sessions (10-15 persons), which will last \~75-90 minutes. Visit frequency will be decreased to every 2 wks. from 6 to 12 mos. to prevent treatment fatigue. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~The exercise sessions are of \~90 min duration (\~15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for one year. Aerobic exercises consist of treadmill, stationary cycling, and stair climbing."
41020805|NCT01496651|PROCEDURE|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
40833238|NCT05440136|DRUG|LY3462817 (SC)|Administered SC.
41020806|NCT05615467|DRUG|LY3556050|Administered orally.
40833239|NCT05440136|DRUG|Placebo (SC)|Administered SC.
40833240|NCT05440136|DRUG|LY3462817 (IV)|Administered IV.
40833241|NCT05440136|DRUG|Placebo (IV)|Administered IV.
40833242|NCT01735708|BEHAVIORAL|HIVPASS|
40833243|NCT01735708|OTHER|Health Education|
40833244|NCT05434013|BEHAVIORAL|Cigarillo warnings-Surgeon General Text-Only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.
40833245|NCT05434013|BEHAVIORAL|Cigarillo warnings-FDA proposed text-only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.
40833246|NCT05434013|BEHAVIORAL|Cigarillo warnings-Pictorial|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
40833247|NCT03847857|BIOLOGICAL|Porcine Fibrin Sealant (PFS)|McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
40833248|NCT03847857|PROCEDURE|McKeown esophagectomy|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
40833249|NCT04172961|DRUG|nanomicellular cyclosporine 0.09%|topical ophthalmic drop prior to elective surgery for eligible patients
40833250|NCT04172961|DRUG|Lifitegrast|topical ophthalmic drop prior to elective surgery for eligible patients
40833251|NCT00746733|DRUG|Lisdexamfetamine Dimesylate|50mg capsule
40833252|NCT00746733|DRUG|Adderall XR (mixed salts amphetamine)|20mg capsule
40833253|NCT00005079|PROCEDURE|conventional surgery|
40833254|NCT00944736|DIETARY_SUPPLEMENT|VSL#3|1 packet BID
40833255|NCT00944736|DIETARY_SUPPLEMENT|Placebo|1 inactive packet BID
40833256|NCT03700619|OTHER|BRIEF parental survey|estimate incidence of executive functions disorders in preterm children in 11 to 12 year old, born less than 34 weeks of gestation, with the BRIEF parental questionnaire. Effects are potentially important because this study could objectify an increase of risk of executive functions disorders f in preterm children in 11 to 12 year old, and identify associated risk factors. This work could eventually alert pediatrician to be careful at the executive functions and to propose adapted supportive cares.
40833257|NCT06125691|BIOLOGICAL|ARCT-2138|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
40833258|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for younger adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
41020807|NCT05615467|DRUG|Metformin|Administered orally.
41020808|NCT05615467|DRUG|Iohexol|Administered IV.
41020809|NCT04275648|DIAGNOSTIC_TEST|AsthmaTuner exercise field test|AsthmaTuner consist of a a bluetooth spirometer and smartphone app with protocol for measuring lung function (FEV1) and perform 8 min exercise challenge test and a healthcare web interface.
40833259|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for older adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
40833260|NCT04332614|BEHAVIORAL|Less-is-better|Email
40833261|NCT04332614|BEHAVIORAL|Social proof|Email
40833262|NCT04332614|BEHAVIORAL|Endowment / decision staging|Email
40833263|NCT04332614|BEHAVIORAL|Standard email|Email
40833264|NCT02011490|DRUG|sugammadex|sugammadex 4 mg/kg IV bolus
41020810|NCT06063941|DRUG|1% Lugol's iodine solution|1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.
41352442|NCT01183572|DIETARY_SUPPLEMENT|Multivitamins, Folic Acid, and Iron|Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
41352443|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid and Iron|Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
41352444|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid
41352445|NCT04229082|OTHER|observational|
40833265|NCT06296641|BEHAVIORAL|Needs navigation intervention|The investigator anticipates that this will include a baseline financial, education and vocational assessment, likely using a virtual platform. Participants who screen positive will be connected to community resources and for consultation. There will be a 1-month, 3-month and 6-month check-in to address any financial concerns through additional counseling/navigation.
40833266|NCT04503590|DEVICE|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
41352446|NCT04993430|DRUG|HRS8807|HRS8807 monotherapy
41493462|NCT01436799|DRUG|Rocuronium|administration of rocuronium 0.6 mg kg-1 for anesthetic induction
41493463|NCT03400943|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily up to 2 x 12 weeks
41159597|NCT04937205|BEHAVIORAL|MOVE|The MOVE physical activity support program is based on the Self-Determination Theory and targets autonomous motivation for physical activity by encouraging 1) choice in physical activity type (e.g. walking, household chores, yoga), 2) a meaningful, value-based rationale for engaging in physical activity, and 3) physical activity that is intrinsically enjoyable. MOVE was delivered during two, 60-75 minute group-based classes and one, 45 minute individualized 1:1 support session to enhance adherence to physical activity recommendations within a lifestyle weight loss program. The group-based classes included a combination of PowerPoint slides, participant handouts, and group-based discussions. All MOVE content was delivered by trained study staff.
41352447|NCT04993430|DRUG|HRS8807|HRS8807 monotherapy
41352448|NCT04993430|DEVICE|HRS8807、SHR6390|HRS8807 in combination with SHR6390
41352449|NCT04993430|DRUG|HRS8807、SHR6390|HRS8807 in combination with SHR6390
41352450|NCT00162630|PROCEDURE|Fascia Iliaca Compartment Blockade|
41352451|NCT04241536|PROCEDURE|Blood draw and urine collection|Patients will collect blood and urine for metabolome analysis
41352452|NCT03108742|DEVICE|INSORB|dermal stapler for skin closure
41352453|NCT03108742|PROCEDURE|classic intradermal suture|intradermal suture for skin closure
41352454|NCT00757354|PROCEDURE|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
41352455|NCT04779476|OTHER|Socket Dressing|Following dental extraction immediately, the socket will be dressed with one of the materials tested
41493464|NCT03400943|DRUG|Placebo|Matching placebo was administered to group B1 and B2.
41493465|NCT02866526|OTHER|Patient questionnaire|quantitative and qualitative data collection will be proposed.
40833267|NCT01956370|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
40833268|NCT01956370|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
41159598|NCT04258215|DEVICE|Experimental: Routine positive pressure airway management.|The use of the PSA extraglottic airway for routine general anesthesia will be assessed for quality of airway management by measuring the seal pressure when using the device in 20 participants.
41159599|NCT00742898|OTHER|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
41352456|NCT02348931|DEVICE|Use of customized nasal brace (Nasella) for nose deformities|
41352457|NCT02348931|PROCEDURE|corrective surgery|
41352458|NCT04271202|DRUG|Emgality 120 MG in 1 ML Prefilled Syringe|Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.
41352459|NCT03782467|BIOLOGICAL|ATOR-1015|Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134)
41352460|NCT04589117|BEHAVIORAL|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to cultivate compassion \& forgiveness~* Week 3: Writing to nurture positive emotions~* Week 4: Writing to invite insight, perspective, \& growth"
41493466|NCT00375830|PROCEDURE|Bone scan|Scan to diagnose a number of bone conditions including cancer or metastasis
41493467|NCT00375830|DRUG|99mTc-methyl diphosphonate|Radiolabel for bone scan procedures
41493468|NCT00375830|PROCEDURE|Positron Emission Tomography (PET) scan|Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F
41493469|NCT00375830|DRUG|18F-Fludeoxyglucose (18F-FDG)|Radiolabel for positron emission tomography scan procedures
41493470|NCT00375830|PROCEDURE|Computed Tomography (CT) scan|Scan to detect \& analyze X-rays
41493471|NCT00375830|DRUG|18F-Sodium Fluoride (18F-NaF)|Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.
41493472|NCT00375830|PROCEDURE|Whole Body Magnetic Resonance Imaging (WB-MRI) scan|Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.
41493473|NCT00375830|DRUG|Gadopentetate dimeglumine|A gadolinium-based contrast agent for MRI
41493474|NCT00375830|DRUG|Gadofosveset|A gadolinium-based contrast agent for MRI
41352461|NCT03748875|BEHAVIORAL|mindfulness-based relapse prevention|mindfulness-based relapse prevention, 8 weeks
41352462|NCT02369211|DRUG|Acetaminophen (Ofirmev)|The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.
41352463|NCT02369211|OTHER|Placebo|The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.
41352464|NCT01881724|BEHAVIORAL|Sleep education|
41493475|NCT00375830|DRUG|Gadobutrol|A gadolinium-based contrast agent for MRI
41493476|NCT01070771|DEVICE|Radi pressure wire (pressure wire assessment)|Intracoronary insertion of pressure wire at the time of diagnostic angiography.
41159600|NCT00489489|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
41493477|NCT03858634|DRUG|KPL-716|A loading dose of KPL-716 720 mg (2x maintenance dose) administered via 2 subcutaneous (SC) injections within 30 minutes on Day 1. All subsequent doses of KPL-716 (360 mg maintenance dose) administered via a single SC injection.
41493478|NCT03858634|DRUG|Placebo|Placebo dose administered via 2 SC injections within 30 minutes on Day 1. All subsequent doses of placebo administered via a single SC injection.
41493479|NCT06288503|OTHER|Hydrolysed Rice Protein Formula|Infants randomised onto this arm will be taking the hydrolysed rice protein formula, with a minimum prescription of 30% of their energy requirements.
41159601|NCT00489489|DRUG|Placebo (for Teriflunomide)|"Film-coated tablet~Oral administration"
41159602|NCT00489489|DRUG|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
41352465|NCT02280109|DRUG|Tenofovir Gel|single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)
41352466|NCT02280109|DRUG|Tenofovir Film|single dose of 1.3% tenofovir film (equivalent to 40 mg)
41352467|NCT00090246|DRUG|MK0869, aprepitant|
41352468|NCT00090246|DRUG|Comparator: ondansetron IV|
41352469|NCT03884049|PROCEDURE|Embolization|transcatheter arterial embolization of neovessels around the knee
41352470|NCT03884049|PROCEDURE|Sham embolization|Sham transcatheter arterial embolization of neovessels in the knee
41352471|NCT02541994|DEVICE|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
41352472|NCT02541994|DEVICE|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
41493480|NCT06288503|OTHER|Cow's Milk Based Extensively Hydrolysed Formula|Infants randomised onto this arm will be taking the control product, with a minimum prescription of 30% of their energy requirements.
41493481|NCT03550573|DEVICE|CardioInsight™ Noninvasive 3D Mapping System|"The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, voltage, composite and phase maps. The vest wearing is coupled with a CT scan.~This exam will be performed only at baseline visit."
41493482|NCT02340130|BIOLOGICAL|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
41352473|NCT04771390|DRUG|Selitrectinib (BAY2731954) Adult tablet|Tablet, oral administration
41352474|NCT04771390|DRUG|Selitrectinib (BAY2731954) Pediatric tablet|Tablet, oral administration
41352475|NCT04771390|DRUG|Selitrectinib (BAY2731954) Oral solution|Oral solution after reconstitution
41159603|NCT05367024|OTHER|Broccoli soup|Participants will consume one broccoli soup three times a week for one 12-week intervention period as part of their normal diet.
41159604|NCT05367024|OTHER|Courgette soup|Participants will consume one courgette soup three times a week for one 12-week intervention period as part of their normal diet.
41352476|NCT04771390|DRUG|Selitrectinib (BAY2731954) Oral suspension|Oral suspension after reconstitution
41352477|NCT05366374|OTHER|Swallowing assessment with Swallis DSA™ Device|The WALLIS DSA™ investigative device is designed to capture and display pharyngolaryngeal activity in subjects with or at risk of swallowing disorders. The DM is non-invasive: a miniaturized microphone and accelerometer are integrated into the form of a necklace, which will be positioned around the patient's neck to capture the vibroacoustic signals of swallowing during mealtime.
41352478|NCT04003064|DIAGNOSTIC_TEST|Blood|3ml blood
41352479|NCT00984152|DRUG|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
41352480|NCT00984152|DRUG|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
41352481|NCT01693562|DRUG|MEDI4736|Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
41352482|NCT06058338|BEHAVIORAL|Produce Prescription|Produce prescriptions mitigate health and food access inequities by partnering with healthcare providers to prescribe fruits and vegetables via financial incentives to patients experiencing food insecurity, low income, and/or chronic disease(s) risk.
41352483|NCT03151772|DRUG|Disulfiram|200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
41352484|NCT03151772|DRUG|Metformin|Metformin 850 mg x 3 taken preoperatively
41352485|NCT00114257|DRUG|decitabine|
41352486|NCT00114257|DRUG|romidepsin|
41352487|NCT04686539|DRUG|CBD|CBD oil not containing THC, to be administered sub-lingual.
41352488|NCT04686539|DRUG|Placebo|Placebo Oil
41352489|NCT03616470|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
41352490|NCT03616470|DRUG|Placebo|Saline, 0.9% Sodium Chloride
41352491|NCT03430726|OTHER|Probiotic yogurt drink|Food product; yogurt drink containing a multi-strain probiotic.
41352492|NCT02347202|OTHER|Online counseling via Zoom teleconferencing|
41352493|NCT02347202|OTHER|Telephone support as needed|
41493483|NCT02340130|BIOLOGICAL|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
41493484|NCT02016703|OTHER|Erythritol drink|
41493485|NCT02016703|OTHER|Placebo drink|
41493486|NCT00010621|PROCEDURE|Acupuncture|
41493487|NCT00010621|PROCEDURE|chiropractic therapy|
41493488|NCT00010621|PROCEDURE|bodywork therapy|
41493489|NCT01023191|PROCEDURE|Percutaneous Insertion catheter|Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
41493490|NCT01023191|PROCEDURE|Open insertion Catheter|Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
41159605|NCT05486871|PROCEDURE|laparoscopic partial nephrectomy|"This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study:~Group \[A\] : 15 patients with T1 RCC (≤ 7 cm). Group \[B\] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes."
41159606|NCT03971799|BIOLOGICAL|CD33CART autologous|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by autologous CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
41493491|NCT05965453|DEVICE|the Castor single branch stent graft|Participants who received thoracic endovascular aortic repair by meant of the Castor single branch stent graft from June 2018 to June 2022 were enrolled in our study.
41493492|NCT05491876|OTHER|Chest physiotherapy with breathing exercises and ACBT|Group A got chest physiotherapy with breathing exercises and ACBT
41493493|NCT05491876|OTHER|Chest physiotherapy with breathing exercises|Group B got chest physiotherapy with breathing exercises.
41493494|NCT00794755|DIETARY_SUPPLEMENT|Vitamin K1 (Phytonadione)|Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
41493495|NCT00794755|DIETARY_SUPPLEMENT|Placebo|Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
41493496|NCT06162104|OTHER|No intervention|No intervention
41493497|NCT05778136|OTHER|Resistance training|Supervised resistance training. 2 sessions/week for 12 weeks. The exercises are one-legged leg-press and one-leg knee extension. Resistance training start-up phase comprises 3 sets of 10 repetitions in each of the two exercises with 50% of 1RM. Resistance training progressive phase comprises 3 sets (leg-press) of 5-8 repetitions (70-90% 1 RM) and 6 sets (knee extension) of 8 repetition (75% 1RM). Rest between sets: 3 minutes
41493498|NCT05973292|OTHER|resin cement containing phosphate ester monomer 10-methacryloyloxydecyl dihydrogen phosphate|Adhesive resin cement containing an MDP agent that is added to bonding agents to enhance bonding to ceramics like Ziconia and E-max
41493499|NCT05973292|OTHER|Non MDP containg resin cement|Adhesive resin cement not containing an MDP agent
41493500|NCT00574912|DRUG|Placebo|single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
40833269|NCT06182605|DEVICE|multifunctional instruments|Ophthalmic retractors can be used to lift the lens during surgery to assist in lens sucking or resection; Intraoperative injection of reagent, which has the advantage of retractable, micro-incision. Ophthalmic hooks can be used to secure support capsular bags; auxiliary cleavage; polishing capsule; Viscoelastic agent is injected as needed. The front end of the membranous cataract scissor is a capsular tearing forceps, and the capsule tearing and capsule scissors can be flexibly switched. All three instruments have the functions of two or three traditional instruments, which can be designed to reduce the number of times the instruments enter and exit the incision during surgery, improve surgical efficiency,
40833270|NCT06182605|DEVICE|traditional instruments|traditional Cataract-assisted instruments for cataract operation.Puncture knives, microscissors, microscopic forceps, nucleus hooks, lens graft forceps, are used to cut the cornea, assist in removing the cloudy lens, suturing wounds.
40833271|NCT00948948|DEVICE|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:~* Gel-filled device which is available in smooth surface and textured surface (Siltex®)~* Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version~Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
41266505|NCT01864408|OTHER|"Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad)."|"After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling."
41493501|NCT00574912|DRUG|Insulin Glargine 0.5 u/kg body wt SC|8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
41493502|NCT00574912|DRUG|Insulin Glargine 1.0 u/kg body wt SC|
41493503|NCT00574912|DRUG|Insulin Glargine 1.5 u/kg body wt SC|
41493504|NCT00574912|DRUG|Insulin Glargine 2.0 u/kg body wt SC|
41352494|NCT06205979|DRUG|Ranibizumab Injection [Lucentis]|Three consecutive monthly intravitreal injections of Ranibizumab at a dosage of 0.5mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
41352495|NCT06205979|DRUG|Aflibercept Injection [Eylea]|Three consecutive monthly intravitreal injections of Aflibercept at a dosage of 2mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
41352496|NCT00533780|PROCEDURE|Healing Touch|A gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy.
41352497|NCT03056209|DRUG|KL1333 25 mg|oral administration, single dose, 25 mg 1 tab
41493505|NCT04226326|OTHER|Directly measure microvascular function using direct coronary flow measurements|The study will enroll subjects who have been scheduled for a clinically-indicated cardiac catheterization, and will evaluate coronary microvascular function in all subjects meeting inclusion criteria with a coronary flow wire. Evaluation of coronary microvascular function may be performed using indirect methods, however the rationale behind the present study is to directly measure microvascular function using direct coronary flow measurements, since the subjects in the study are to undergo a clinically-indicated cardiac catheterization. The overall purpose of the study is to define the presence and severity of coronary microvascular dysfunction subjects with CTO.
41493506|NCT03728855|BEHAVIORAL|Self-administration of medication (SAM)|Patients use medication from their own stock, self-administered.
41493507|NCT00998478|OTHER|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
41493508|NCT00778024|DRUG|fluoxetine HCL 40 mg capsules|
41493509|NCT05041881|DEVICE|Trifocal lens AT LISA TRI, Zeiss|lens is made of hydrophilic acrylic material with square edge technology and having diffractive optic design
41493510|NCT05041881|DEVICE|Accommodating Tetraflex HD lens, Lenstec inc.|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
41493511|NCT05041881|DEVICE|Monofocal lens, Softec HD|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
41493512|NCT02134743|PROCEDURE|Implant surgery|Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
41493513|NCT05921357|OTHER|Questionnaire|Questionnaire and examine
41493514|NCT06182761|DRUG|Sunvozertinib combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle.
41493515|NCT04280705|OTHER|Placebo|The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.
41159607|NCT03971799|BIOLOGICAL|CD33CART allogeneic|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by allogeneic CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
41159608|NCT00000137|PROCEDURE|Histocompatibility Matching|
41159609|NCT05169814|DRUG|Micro/nanobubble (MNB) - Irrigation|An MNB solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The MNB solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
41159610|NCT05169814|OTHER|0.9% Normal Saline - Irrigation|A normal saline solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The normal saline solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
41159611|NCT05169814|DRUG|Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with MNB will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
41159612|NCT05169814|OTHER|0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with normal saline will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
41159613|NCT02702739|DRUG|Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks|Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
41352498|NCT03056209|DRUG|KL1333 50 mg|oral administration, single dose, 25 mg 2 tabs
41352499|NCT03056209|DRUG|KL1333 100 mg|oral administration, single dose, 100 mg 1 tab
41352500|NCT03056209|DRUG|KL1333 200 mg|oral administration, single dose, 100 mg 2 tabs
41352501|NCT03056209|DRUG|KL1333 400 mg|oral administration, single dose, 100 mg 4 tabs
41352502|NCT03056209|DRUG|KL1333 600 mg|oral administration, single dose, 100 mg 6 tabs
41352503|NCT03056209|DRUG|KL1333 800 mg|oral administration, single dose, 100 mg 8 tabs
41352504|NCT03056209|DRUG|Placebo|oral administration, placebo
41493516|NCT04280705|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
41493517|NCT01671332|DRUG|Docetaxel|IV over 60 minutes, 75 mg/m2
41493518|NCT01671332|DRUG|Suramin|IV over 30 minutes
41493519|NCT01671332|DRUG|Docetaxel|IV over 60 minutes. 56 mg/m2
41159614|NCT06472882|DEVICE|tDCS targeting DLPFC|The anodic electrode will be placed on the left DLPFC (area F3) and the cathode on the right orbitofrontal cortex (area Fp2). Participants will receive 20 minutes of tDCS at 2 mA while seated.
41020811|NCT06063941|DRUG|5% Lugol's iodine solution|Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.
41159615|NCT06472882|DEVICE|tDCS targeting M1|The anodes will be placed over C3 and C4 (according to EEG 10-20 system), and the cathodes over the ipsilateral shoulders. Participants will receive 20 minutes of tDCS at 2 mA while seated.
41159616|NCT06472882|DEVICE|SHAM tDCS|The electrodes will be placed as in the other conditions, but the stimulation will be switched off after 30 seconds, providing an initial stinging sensation without continuous stimulation.
41159617|NCT06221800|DIAGNOSTIC_TEST|Microbiome|Stool and saliva samples will be collected
41159618|NCT04507581|OTHER|electrical impedance tomography during anaesthesia|Before induction of the anaesthesia, before the radiological procedure when the induction is terminated, after the termination of the radiological procedure, before transport to the Post anaesthesia Care Unite (PACU), and before the discharge from the PACU after 2 hours of monitoring ventilation distribution changes by thoracic electrical impedance tomography are measured (each measurement will last 1 min). For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated by an automated linearized Newton-Raphson reconstruction algorithm (9). Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity such as the global inhomogeneity index will be calculated as described previously, using customised software (Matlab R2013a, The MathWorks, Nattick, Massachusetts, USA)(10-12).
41159619|NCT00692250|DRUG|Colesevelam hydrochloride film-coated tablets (Cholestagel)|
41159620|NCT04105764|DRUG|Rocuronium|DEEP block to PTC 1-3
41159621|NCT04105764|DRUG|Rocuronium bromide|MODERATE block to TOF1-2
41159622|NCT00175045|DRUG|Lansoprazole|Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
41159623|NCT00175045|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
41159624|NCT01020487|DRUG|Paricalcitol|Paricalcitol capsules taken with water.
41159625|NCT01020487|DRUG|Placebo|Placebo capsules taken with water
41352505|NCT03086954|BIOLOGICAL|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
41352506|NCT00630318|DEVICE|MRI|15-20 minutes MR imaging
41352507|NCT01730625|BEHAVIORAL|Cognitive behavioral therapy for anxiety|
41352508|NCT01730625|BEHAVIORAL|Attention Bias Modification Treatment|
41352509|NCT01633372|DRUG|itacitinib|
41020812|NCT00439400|DRUG|doxycycline|
41020813|NCT00439400|DRUG|placebo|
41020814|NCT05090449|DRUG|Chlorthalidone (HIGROTON® 50)|Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
41352510|NCT02951585|DEVICE|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
41352511|NCT02951585|DEVICE|PLACEBO|Intra-articular injection of physiological serum (saline solution)
41352512|NCT03446664|DEVICE|Microburst Stimulation|Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
41493520|NCT02323516|DRUG|Acetylsalicylic acid + loperamide|In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
41352513|NCT05472194|BEHAVIORAL|InSchool Training Program|The goal of the intervention is to promote and boost the development of executive functions in preschool and elementary school-aged children by means of engagement in meaningful and challenging activities. The method to achieve this consists on weekly intervention sessions run by teachers with a set of games specially developed to train executive functions.
41352514|NCT05472194|BEHAVIORAL|Regular school activities|Children in the control group will be playing with the regular school activities.
41352515|NCT05705024|BIOLOGICAL|Mesenchymal Stromal Cells|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cellsmasked clinical trial, patients with non-resolving corneal epithelial disease (i.e., refractory to standard treatments for at least two weeks) will receive a single subconjunctival injection of bone marrow-derived allogeneic MSCs or vehicle (CS5 freezing media, BioLife Solutions Inc, Bothell, WA, USA), with continued follow-up for up to 90 days.
41352516|NCT05705024|OTHER|Control Solution|For the control group, 150 µL of injectable normal saline (0.9% NaCl). will be injected.
41352517|NCT00017225|BIOLOGICAL|filgrastim|
41352518|NCT00017225|DRUG|carboplatin|
41352519|NCT00017225|DRUG|cisplatin|
41352520|NCT00017225|DRUG|cyclophosphamide|
41352521|NCT00017225|DRUG|dacarbazine|
41352522|NCT00017225|DRUG|doxorubicin hydrochloride|
41493521|NCT02323516|DRUG|diosmectite + loperamide|In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
41493522|NCT00769093|DRUG|Ferumoxytol|2 mg/kg
41493523|NCT00003577|DRUG|CMF regimen|
41352523|NCT00017225|DRUG|etoposide|
41352524|NCT00017225|DRUG|ifosfamide|
41352525|NCT00017225|DRUG|melphalan|
41020815|NCT05090449|DRUG|Losartan (COZZAR®)|Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
41020816|NCT05090449|DRUG|A1+ A2 Co-administration of Chlorthalidone and Losartan|50mg chlorthalidone + 100 mg losartan potassium
41352526|NCT00017225|DRUG|tretinoin|
41352527|NCT00017225|DRUG|vincristine sulfate|
41352528|NCT00017225|DRUG|vindesine|
41352529|NCT00017225|PROCEDURE|autologous bone marrow transplantation|
41352530|NCT00017225|PROCEDURE|conventional surgery|
41493524|NCT00003577|DRUG|cyclophosphamide|
41493525|NCT00003577|DRUG|epirubicin hydrochloride|
41493526|NCT00003577|DRUG|fluorouracil|
41493527|NCT00003577|DRUG|methotrexate|
41493528|NCT00003577|PROCEDURE|adjuvant therapy|
41493529|NCT00003577|RADIATION|radiation therapy|
41352531|NCT00017225|PROCEDURE|peripheral blood stem cell transplantation|
41352532|NCT00017225|RADIATION|radiation therapy|
41493530|NCT02492880|DEVICE|Precision Spectra™ SCS system programming features|Precision Spectra™ SCS system programming features using the CoverEdge surgical lead.
41352533|NCT04321590|DIETARY_SUPPLEMENT|Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)|Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
41352534|NCT00696540|DRUG|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
41352535|NCT00696540|DRUG|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
41493531|NCT05371860|OTHER|Omit breast radiation|Omit breast radiation for 3 years after surgery
41493532|NCT05612373|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
41020817|NCT05090449|DRUG|Chlorthalidone + Losartan Fixed-Dose combination|Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
41020818|NCT02097992|DRUG|Roflumilast Placebo|Placebo pill
41020819|NCT02097992|DRUG|Roflumilast|500 Ug ORAL TABLET
41020820|NCT03290508|DIAGNOSTIC_TEST|Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
41020821|NCT01788501|DRUG|Tacrolimus|D-1\~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20\~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
41020822|NCT01788501|DRUG|Cyclosporine|D-1\~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20\~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
41352536|NCT05373186|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure
41493533|NCT03378050|BEHAVIORAL|HEART|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages. By using a comprehensive assessment targeting five components, an individualized intervention plan will be developed to address identified problems and unmet needs. Those five components consist of: Health, Emotion, Activities, Resources and Training."
41493534|NCT03378050|OTHER|Usual Care|"Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
41493535|NCT05341349|BIOLOGICAL|Ipilimumab|Given IV
41493536|NCT05341349|BIOLOGICAL|Nivolumab|Given IV
41493537|NCT05341349|BIOLOGICAL|Pembrolizumab|Given IV
41493538|NCT05341349|RADIATION|Stereotactic Radiosurgery|Undergo SRS
41493539|NCT05341349|PROCEDURE|Tumor Treating Fields Therapy|Undergo TTFields
41493540|NCT02972918|DRUG|Levosimendan|24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
41493541|NCT04735861|DRUG|Sintilimab|Sintilimab 200mg iv. q3w, up to 2 years.
41493542|NCT04735861|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
40833272|NCT05045170|DRUG|Influence of propofol sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
40833273|NCT05045170|DRUG|Influence of dexmedetomidine sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
40833274|NCT05045170|DRUG|Influence of spinal anesthesia on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
40833275|NCT00449449|DRUG|Pertubation with Lidocain Solution|
40833276|NCT06326749|OTHER|Modified Graded Motor Imagery and Conventional Treatment Group|A modified form of graded motor imagery training and conventional rehabilitation will be applied.
40833277|NCT06326749|OTHER|Graded Motor Imagery and Conventional Treatment Group|Graded motor imagery training and conventional rehabilitation will be applied.
40833278|NCT06326749|OTHER|Conventional Treatment Group|conventional rehabilitation will be applied.
40833279|NCT05517798|PROCEDURE|Alveolar ridge preservation|Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement
40833280|NCT06213337|OTHER|Foot care training with virtual classroom|Providing foot care training once every two weeks in virtual classes created via the Google meet application.
40833281|NCT06213337|OTHER|Foot care training with SMS support|Total of 60 SMS messages containing foot care information will be sent, one every day.
40833282|NCT06213337|OTHER|Foot care training with virtual classroom and SMS support|Providing foot care training once every two weeks in virtual classes created via the Google meet application. Furthermore, total of 60 SMS messages containing foot care information will be sent, one every day.
41020823|NCT01788501|DRUG|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
41493543|NCT04433338|OTHER|14-day Low Calorie Diet|"Participants will be asked to:~* Use 4 (women) or 5 (men) Modifast meal replacements per day.~* Daily consume a minimum of 250 grams of (raw) vegetables without dressing.~* Daily consume 100 grams of lean meat/fish/meat analogues.~* Daily consume two spoons of liquid oil~* Daily drink at least 2.0 litres of water, coffee or tea without added sugar or milk, bouillon or sugar-free drinks."
41493544|NCT01550029|BEHAVIORAL|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle."
41493545|NCT01550029|BEHAVIORAL|Counseling/Managing Mood|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
41493546|NCT03674086|DEVICE|eAdjust 0.2 hearing aid smartphone application (or app)|The app connects to the Audeo B-90 Direct hearing aids via Bluetooth. The intended use for the app to enable hearing aid users to fine-tune their hearing aids. The app contains a series of sound modifiers, factory presets, sound modifier presets.
41493547|NCT05925075|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound to be performed at scheduled intervals as described in individual cohorts.
41493548|NCT04719520|BEHAVIORAL|wireless vibrating caller|using the wireless vibrating caller to notify the patient's family to the operating room
41493549|NCT04719962|PROCEDURE|Targeted proteomics in skin +/- cerebrospinal or synovial fluid to diagnose disseminated Lyme disease|"Following a 2-days course of local daily clobetasol propionate 0,05% cream application, a skin biopsy (3 mm punch-biopsy ) of healthy-looking skin of the upper part of the thigh will be performed in all patients,.~Arthrocentesis (in patients with Lyme arthritis only) and lumbar puncture to collect cerebrospinal fluid (in patients with neuroborreliosis only) will be performed in the usual care setting as appropriated.~All biological samples will be subject to Borrelia culture, PCR and SRM-MS proteomics."
41493550|NCT02183207|PROCEDURE|Percutaneous Endoscopic Gastrostomy|Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
41493551|NCT00732550|PROCEDURE|Single trocar cholecystectomy|Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach
41493552|NCT00732550|PROCEDURE|Standard laparoscopic cholecystectomy|Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy
40833283|NCT02012686|DEVICE|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
40833284|NCT03922256|OTHER|molded brace|The moldable brace utilized in the current study will be pre-fabricated and of the short-arm brace variety , which is primarily indicated for non-displaced fractures of the distal radius or distal ulna. The braces are available in multiple sizes for both right and left hands.
40833285|NCT02241187|DRUG|PEGPH20|
40833286|NCT02241187|DRUG|Cetuximab|
40833287|NCT02241187|DEVICE|DW & DCE-MRI|
41493553|NCT01367652|DRUG|Letrozole|2.5 mg tablet
41493554|NCT01367652|DRUG|Letrozole|2.5 mg Tablet
41493555|NCT00667030|BEHAVIORAL|Weight loss and aerobic exercise training|Weight loss and aerobic exercise training
41352537|NCT05373186|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure
41352538|NCT05373186|DRUG|Euglycemic clamp with Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus® during an euglycemic clamp procedure
41352539|NCT03590613|DRUG|GSK2982772|GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
41020824|NCT01284647|DRUG|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
41352540|NCT03590613|DRUG|Placebo|Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
41020825|NCT01284647|DRUG|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
41352541|NCT04009252|BEHAVIORAL|3D Model Education|A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
41020826|NCT01816139|DRUG|Vehicle|Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
41020827|NCT01816139|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
40833288|NCT02241187|OTHER|blood draws|Blood samples will be drawn at various time points.
41020828|NCT05739500|OTHER||no intervention, just observation
41159626|NCT00302406|DRUG|methylphenidate hydrochloride|
41159627|NCT00302406|DRUG|OROS methylphenidate hydrochloride (CONCERTA)|
41159628|NCT01676883|DEVICE|Bioelectric impedance|removal of calluses and corns by pedicure
41352542|NCT00681902|DRUG|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
41352543|NCT00681902|DRUG|Placebo|Jet saline
41352544|NCT00562081|BEHAVIORAL|Education|24/7 access to a Certified Asthma Educator
41352545|NCT00562081|BEHAVIORAL|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
41352546|NCT04453345|DRUG|thalidomide + prednisone + methotrexate|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
41352547|NCT01462851|DRUG|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
41352548|NCT01462851|DRUG|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
41352549|NCT01462851|DRUG|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
41352550|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
41352551|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
41493556|NCT02447744|BEHAVIORAL|Mindfulness based intervention|The intervention is an 8-week structured mindfulness based behavioral intervention program that teaches mindfulness meditation, mindful yoga and psychological knowledge about stress.
41493557|NCT02752763|DRUG|%40 diluted Autologous serum|Serum that obtained after centrifugation of blood sample
41493558|NCT02752763|DRUG|Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)|Preservative free artificial tears is a group naming for drops commonly used for drye disease
41493559|NCT01715792|OTHER|Data collection|Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
41493560|NCT03785366|DRUG|VeraCept|VeraCept Intrauterine Device (IUD)
41493561|NCT03785366|DRUG|ParaGard|ParaGard intrauterine copper contraceptive
41493562|NCT00986713|DRUG|Amphotericin B|Aerosolized Amphotericin B,2mg/day or 10mg/day
41493563|NCT01599065|OTHER|Magnet or Off-On|Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
41493564|NCT03884452|DRUG|Atorvastatin|Tablets taken orally once daily in the morning
41493565|NCT03884452|DRUG|Simvastatin|Tablets taken orally once daily in the morning or evening
41493566|NCT03884452|DRUG|Ezetimibe|Tablet taken orally once daily in the morning or evening
41493567|NCT03884452|DRUG|Placebo for Ezetimibe|Tablets taken orally once daily in the morning or evening
41493568|NCT04706286|DRUG|CKD-501, D759, D150|CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
41493569|NCT04706286|DRUG|CKD-393 0.5/100/1000 mg|CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
41493570|NCT05900128|BEHAVIORAL|workshop|Patients will receive workshops and they will encourage to practice physical activity
41493571|NCT05900128|OTHER|no workshop|patients won't receive educative workshops
41493572|NCT01675843|PROCEDURE|Intrauterine insemination (IUI)|The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
41493573|NCT00523965|DRUG|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
41493574|NCT00523965|DRUG|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or \> 25 kg Miltefosine 50 mg once daily if patient weighs \<25 mg
41493575|NCT00523965|DRUG|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
41493576|NCT00523965|DRUG|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
41493577|NCT04917653|DEVICE|Heart rhythm monitoring with wearable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel."
41493578|NCT04917653|OTHER|Blood samples and biomarkers|"Several blood samples will be collected during the study protocol in pre-defined times before and after the cardioversion intervention.~Atrial peptides and cardiac troponins will be analyzed and kinetics estimated to predict the duration of early-onset AF period."
41493579|NCT04276363|BEHAVIORAL|Thrive Professional Learning plus ParentCorps|led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
41493580|NCT04276363|BEHAVIORAL|Thrive Professional Learning only|Part of the Professional Learning Track system for all Pre-K for All teachers and leaders. The NYC DOE schedules Thrive Professional Learning training days for staff on non-attendance days. Teachers attend four Professional Learning days annually, and leaders attend three days annually, over a two-year period.
41493581|NCT04276363|BEHAVIORAL|Inspire Professional Learning|Delivered to leaders in groups of 20 - 40 three times a year over the same two-year period. Content covers best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders
41493582|NCT00386763|DRUG|Artemether-lumefantrine|
41493583|NCT02519738|DRUG|Silver Nitrate|Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
41493584|NCT02519738|DRUG|Kenalog (Triamcinolone)|Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
41493585|NCT02519738|OTHER|Washcloth Abrasion|Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
41493586|NCT04023162|BEHAVIORAL|Graded Activity|Active participation of participants, Overcoming and eliminating negative behaviors, Encouraging positive behavior in pain, Overcoming the fear of the movement, Motivation to implementation pre-set specific goals.
41493587|NCT04023162|BEHAVIORAL|Group-based Therapy Exercise|Aerobic exercise, Stretching exercise and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercise Muscle strength training exercise
41493588|NCT04023162|BEHAVIORAL|Back School|Basic information of Low Back Pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.
41493589|NCT01045213|OTHER|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
41493590|NCT01459562|DRUG|NI-0501|
41493591|NCT01459562|DRUG|Placebo|
40833289|NCT01301105|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
40833290|NCT01301105|BEHAVIORAL|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
40833291|NCT06508684|DRUG|BTK inhibitor|BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
41020829|NCT03115424|DRUG|Saxenda|Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
41020830|NCT03115424|DRUG|Placebos|Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
41020831|NCT03115424|PROCEDURE|RYGB|Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
41020832|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
41020833|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
41020834|NCT05781035|PROCEDURE|dexmedetomidine|patients will recieve moderate sedation by dexmedetomidine as study group
41159629|NCT01676883|DEVICE|Air displacement plethysmography|
41352552|NCT05540015|PROCEDURE|Third molar extraction by cutting and rotary tools|Extraction of the impacted lower third molar will be conducted using cutting and rotary tools under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). Scalpel will be used for the incision of the soft tissues, rotary instruments will be used for the bone tissue and tooth fragmentation. After the extraction the wound will be sutured by the suture material.
41352553|NCT05540015|PROCEDURE|Third molar extraction by erbium laser with wavelength 2.94 nm|Extraction of the impacted lower third molar will be conducted using erbium laser with wavelength 2.94 nm under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). The soft tissue and bone tissue will be dissected by erbium laser with wavelength 2.94 µm (Erbium laser Smart 2940D plus with the wavelength 2,94 µm, company- DEKA, Italy, registration № 2005/1245). After the extraction the wound will be sutured by the suture material (registration № ФСЗ 2010/06040; 07.08.2018)
41352554|NCT01695928|DEVICE|Extracorporeal shockwave therapy|1000 impulses
41352555|NCT01695928|DEVICE|ESWT placebo|0 impulses, acoustic effect
41493592|NCT01523457|DRUG|Folfirinox|"* Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~* Leucovorin 400 mg/m2 IV over two hours~* Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~* 5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."
41493593|NCT01478386|OTHER|Orthovisc|Subjects will receive a series of three Orthovisc injections into their affected knee
41159630|NCT03746483|DRUG|MS1819|MS1819, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
41352556|NCT04170491|DIAGNOSTIC_TEST|Continuous EEG|Continuous EEGs will be performed with 21 electrodes and polygraphy (ECG and EMG) placed according to the international 10-20 system. In case of extensive neurosurgical defects, a reduced montage may be applied in patients from either group. This information will be added in CRF. The reduced montage in these cases is not expected to reduce the diagnostic accuracy and the outcome, as the neurophysiological changes are generally diffuse and will be detected by adjacent electrodes.
41352557|NCT05510791|DIETARY_SUPPLEMENT|Nuun Sport Drink|Subjects will consume a total of 24 ounces water and 1.5 tablets of Nuun SPORT. Specifically, subjects will drink 12 ounces of Nuun drink 15 minutes prior to the 60 min run and 4 ounces of Nuun drink at 15 min, 30 min, and 45 min during the run.
41493594|NCT01478386|DEVICE|DonJoy HA lite knee brace|Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
41493595|NCT01478386|DEVICE|Orthovisc injections and DonJoy HA lite knee brace|Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
41493596|NCT05213338|DEVICE|Wear-documentation microchip|Microchip embedded in the appliance
41493597|NCT05617937|OTHER|Massage|The connective tissue massage was started from the lumbosacral region (baseline) and was applied to the lower thoracic, scapular, inter-scapular and cervico-occipital region according to the vascular response of the connective tissue.
41493598|NCT00562575|DRUG|SLx-4090|
41493599|NCT00562575|DRUG|Placebo|
40833292|NCT04473365|OTHER|Intestinal parasite|Pre-existing intestinal parasite infection present or absent at time of admission
40833293|NCT04034940|OTHER|Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients|Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
40833294|NCT04384107|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in PCV13 plus 2 additional serotypes (22F, 33F) in each subcutaneous 0.5 mL single dose.
40833295|NCT04384107|BIOLOGICAL|PCV13|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each subcutaneous 0.5 mL single dose.
40833296|NCT00120055|DRUG|Atorvastatin (Lipitor)|
40833297|NCT01671774|DRUG|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
41493600|NCT06199063|OTHER|Self-Streching Exercises|The participants in the SSE group; received 1 session SSE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
40833298|NCT01671774|DRUG|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
40833299|NCT01671774|DRUG|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
40833300|NCT01671774|DRUG|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
40833301|NCT02411786|BIOLOGICAL|pTVG-AR|Given ID
41020835|NCT05781035|PROCEDURE|general anesthesia|general anesthesia with neuromuscular blockade under controlled ventilation as control group.
41493601|NCT06199063|OTHER|Post-Isometric Relaxation Exercises|The participants in the PIRE group; received 1 session PIRE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
41493602|NCT06199063|OTHER|Reciprocal-Inhibiton Exercises|The participants in the RIE group; received 1 session RIE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
41493603|NCT03293407|DRUG|Iloprost (Ventavis, BAYQ6256)|Using Breelib device
41493604|NCT03293407|DEVICE|Breelib nebulizer|Used for inhalation of Ventavis
40833302|NCT02411786|BIOLOGICAL|gm-csf|Given ID
41493605|NCT05157958|BIOLOGICAL|ALLO-ASC-SHEET|Weekly administration
41493606|NCT05157958|OTHER|Vehicle Control|Weekly administration
41493607|NCT01372774|RADIATION|stereotactic radiosurgery|Undergo RT
40833303|NCT03301064|BEHAVIORAL|Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)|Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
40833304|NCT03301064|OTHER|Alcohol education brochure|The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
40833305|NCT03107923|DIAGNOSTIC_TEST|Dobutamine stress test|Test of myocardial reserve
41020836|NCT05565586|DIETARY_SUPPLEMENT|High-Fiber Diet (HFD)|Participants are assigned to the high fiber diet, all meals and snacks will be provided to participants during the study. This diet includes fruits, vegetables and whole grains, a maximum of 18 oz. cooked red meat (including beef, pork, and lamb) per week, and little or no processed meats or added sugars.
41493608|NCT01372774|RADIATION|whole-brain radiation therapy|Undergo radiotherapy (RT)
41493609|NCT01595386|DRUG|Hydrocortisone|The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
41020837|NCT05565586|DIETARY_SUPPLEMENT|Prebiotic Food-Enriched Diet (PreFED)|Participants are assigned to the prebiotic food enriched diet, participants will receive 2 prepared snacks and 1 meal component (a key prebiotic ingredient to incorporate into meals and simple recipes) each day. Participants will also receive a handout that includes key prebiotic foods to incorporate into your own diet.
41020838|NCT01170897|DRUG|PEGPH20|PEGylated Recombinant Human Hyaluronidase
41493610|NCT01595386|DRUG|Normal Saline|This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
41493611|NCT04331561|BEHAVIORAL|sensory re-weighting|Participants will be supported in quiet standing by a safety harness and crisscrossing strap system. A cervical collar will be used to maintain consistent alignment between the head and trunk. A virtual reality headset is used to create a virtual environment in which visual stimuli will be presented. Three different body positions will be used during training: earth-vertical and clockwise and counterclockwise tilted 16º in the frontal plane. Sensory re-weighting will be driven by priming upregulation of somatosensory cues. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity.
41493612|NCT06504420|DRUG|Sirolimus|Subjects will receive Sirolimus 1.5mg/d for 48 weeks in addition to their ongoing APS treatment regimen
41493613|NCT06504420|DRUG|Placebo|Subjects will receive Placebo 1.5mg/d for first 24 weeks and Sirolimus 1.5mg/d for next 24 weeks in addition to their ongoing APS treatment regimen
41493614|NCT02041910|BIOLOGICAL|Stem Cells|MSCs injection intratesticular
41493615|NCT02041910|BIOLOGICAL|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
41493616|NCT04332965|PROCEDURE|Non-Surgical Periodontal Treatment|Scaling and root planing and polishing with specific curettes were performed to patients and oral hygiene education was provided to each patient.
41493617|NCT03768726|DRUG|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
41020839|NCT03864614|DRUG|SAGE-217|SAGE-217
41020840|NCT06434532|OTHER|v-Care Online Game|A regular 2 hours traditional learning mode session - case study session and 2-hour online game session with peer-led discussion and interprofessional project submission. This spreads in 3 weeks interval
41020841|NCT06434532|OTHER|Case-based online discussion|A 2-hour traditional learning mode session with online peer-led discussion and submission of an interprofessional worksheet as an assignment
41020842|NCT04541433|DRUG|AZD9833|AZD9833 taken orally
41020843|NCT01696032|DRUG|SGI-110|
41020844|NCT01696032|DRUG|Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)|Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
41020845|NCT01696032|DRUG|Carboplatin|
41020846|NCT06214585|PROCEDURE|Intermittent heat and cold versus heat-only therapy|for the experimental group, a cyclical method of alternating heat and cold application will be used on the lumbosacral and lower abdominal area of the laboring women. The process involves applying a hot pack with a temperature range of 38-40°C on their lower abdomen and low back for 30 minutes during contractions and a relaxing period using a 2-litre rubber hot water bag. Subsequently, reusable ice packs typically contain water, covered with a towel and with a temperature range of 0-5°C will be applied to the same areas for 10 minutes. After a 30-minute interval, the heat application will be reapplied, and this alternating heat and cold cycle will be repeated throughout the first stage of the laboring process.
40833306|NCT01335529|DRUG|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"* Screen period from Week-8~* Standard treatment from day 0 to week 4 (W4)~* Three-drug-regimen (Boceprevir introduction) from W4 to W8~* HCV RNA determination at W8 determines treatment group and participation duration:~  * If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~ * If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
40833307|NCT04319744|OTHER|other|Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
41159631|NCT03746483|DRUG|Porcine PERT|Porcine PERT is being used as a comparator to MS1819 as a second drug/intervention
41159632|NCT03375697|DRUG|JNJ-63733657|Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.
41159633|NCT03375697|DRUG|Placebo|Subjects will receive matching placebo intravenously.
41493618|NCT03768726|DRUG|Placebo|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
40833308|NCT01366612|DRUG|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1"
40833309|NCT01366612|DRUG|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1"
40833310|NCT00404170|DRUG|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
41159634|NCT00214318|DRUG|Terbutaline plus Metoprolol or carvedilol|
41493619|NCT01197755|DRUG|fostamatinib|fostamatinib 100 mg twice daily
41493620|NCT01197755|DRUG|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
41493621|NCT01197755|DRUG|placebo|Placebo twice daily
41493622|NCT05975138|PROCEDURE|implant insertion|a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant will be placed according to the manufacturer's recommendations. The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus
41493623|NCT04466241|DRUG|Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|2 tablets morning and evening from Day 1 to Day 10
41493624|NCT04466241|DRUG|Telmisartan 40Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
41493625|NCT04466241|DRUG|Atorvastatin 20 Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
41493626|NCT04467801|DRUG|Ipatasertib|Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.
41493627|NCT02135653|RADIATION|Radiotherapy|
41493628|NCT02135653|OTHER|Eischens Yoga|
41493629|NCT01915706|PROCEDURE|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
41493630|NCT06081426|OTHER|Non-ketogenic Diet|Consuming a non-ketogenic diet
41493631|NCT06081426|OTHER|Ketogenic Diet|Consuming a ketogenic diet
41493632|NCT06081426|OTHER|No diet|Participants without Bipolar Disorder will not participate in the diet phases of the study
40833311|NCT04794764|DEVICE|McGrath Mac|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
40833312|NCT04794764|DEVICE|Macintosh Laryngoscope|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
40833313|NCT00302016|DRUG|AMN107|
40833314|NCT03926312|DEVICE|Smart device-based cardiac rehabilitation|A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
40833315|NCT01529736|PROCEDURE|High torque insertion|Osseotite implant placed with high insertion torque forces
40833316|NCT01529736|PROCEDURE|Low torque insertion|Osseotite implant placed with low insertion torque forces
40833317|NCT01521299|DRUG|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
40833318|NCT04403594|OTHER|dry needling|dry needling followed by functional electrical stimulation and treadmill training
41159635|NCT06480851|PROCEDURE|Ecoguided Percutaneous Neuromodulation|Ecoguided Percutaneous Neuromodulation over the posterior branch of the cervical multifidus, for 10 minutes, with a frequency of 10 HZ.
41266506|NCT02111733|OTHER|Hs-TNT dosage|Bloodwork before and after hemodialysis for high sensibility troponins T blood level
41493633|NCT03149445|DRUG|Tesofensine/Metoprolol|Study medication will be administered for 91 days.
41493634|NCT03149445|DRUG|Placebos|Study medication will be administered for 91 days.
41493635|NCT00886223|PROCEDURE|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
41493636|NCT04851652|OTHER|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
41493637|NCT00009009|DRUG|immunosuppressive regimen designed to complement HAART|
40833319|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
40833320|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
41493638|NCT01181960|DRUG|Risperidone long acting injectable - New Starts|Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
40833321|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
40833322|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
40833323|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
40833324|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
41493639|NCT01181960|DRUG|Risperidone long acting injectable - Continuous Users|Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
41493640|NCT01181960|DRUG|Paliperidone Palmitate -New and Continuous Users|Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
41493641|NCT01181960|DRUG|Other Antipsychotics - New Starts|Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
40833325|NCT01356342|BIOLOGICAL|AdimFlu-S 2010-2011, inactivated|"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections"
41493642|NCT00687089|OTHER|Sexual, cognitive functional tests and measurement weight|
40833326|NCT02631733|DRUG|Ferumoxytol|Given IV
41493643|NCT00989820|DRUG|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
41493644|NCT00171301|DRUG|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
41493645|NCT02808156|OTHER|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
41493646|NCT02808156|OTHER|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
41493647|NCT01076686|DRUG|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
40833327|NCT02631733|DRUG|Irinotecan Sucrosofate|Given IV
40833328|NCT02631733|OTHER|Laboratory Biomarker Analysis|Correlative studies
40833329|NCT02631733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41493648|NCT03924089|DIETARY_SUPPLEMENT|Oral nutritional supplement with probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.
41493649|NCT03924089|DIETARY_SUPPLEMENT|Oral nutritional supplement without probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.
41493650|NCT03924089|OTHER|Dietary recommendations|Dietary recommendations
41493651|NCT00912483|BIOLOGICAL|heparin sodium - Blausiegel|Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
41493652|NCT00912483|BIOLOGICAL|Heparin sodium - APP|Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
40833330|NCT02631733|DRUG|Veliparib|Given PO
40833331|NCT03997643|RADIATION|Radiotherapy to all dissected areas|Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
41493653|NCT04526886|OTHER|Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy|Chemotherapy dose-adjustment algorithm for FOLFOX chemotherapy
41493654|NCT02413216|BEHAVIORAL|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
41493655|NCT02413216|OTHER|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
41493656|NCT05238818|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocyte Injection (GT202)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. T cells then are manufactured to express mbIL-12. After lymphodepletion, patients are infused with GT202 followed by IL-2.
41493657|NCT04053686|BEHAVIORAL|Breaks|3-min breaks every half hour at work
41493658|NCT06080100|DRUG|Xenon|inhalation of xenon in a sub-narcotic dosage
41493659|NCT06080100|OTHER|premedication hydroxyzine 25 mg|taking anxiolytic 30 minutes before surgery
41493660|NCT03524989|DEVICE|Hyperbaric Oxygen Therapy|40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 2 months.
41493661|NCT03524989|DEVICE|SHAM treatment|40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week for 2 months.
41493662|NCT04493086|DIAGNOSTIC_TEST|FFRCT-angio|According to invasive coronary angiography (CAG) images, image databases of critical lesions, diffuse lesions, left main trunk lesions, ostium lesions and bifurcation lesions were established. In order to ensure that the position of the pressure guide wire sensor is consistent with that of FFRCT-angio, a professional with unknown FFR results is used to mark the position of the pressure wire sensor on the CAG image. The clinical information and characteristics of coronary artery lesions were collected, and the baseline data of patients were completed. The accuracy and diagnostic performance of FFRCT-angio in the diagnosis of functional stenosis (FFR \< 0.8) were evaluated with FFR value measured by pressure guide wire as reference standard.
41493663|NCT06301061|DEVICE|Equistasi®|Four devices will be attached to the skin according the indication of the investigators for 6 hours/day every day except Thursday and Sunday
41493664|NCT06301061|DEVICE|Sham|Four devices similar to the active one but not able to deliver the microvibration will be applied to the patients
40833332|NCT03997643|RADIATION|Omit radiation to pN0 neck|post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
41493665|NCT06301061|DRUG|Gabapentin; Pregabalin; Duloxetine; Amitriptyline|Patients will be treated with drugs (gabapentinoids, Serotonin-norepinephrine reuptake inhibitor, tricyclic antidepressants, opioids) according to guidelines.
41493666|NCT00796263|DRUG|HAART|"2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily~Dolutegravir(DTG) 50 mg orally once daily"
41493667|NCT01866059|DEVICE|Calcium silicate cement|Calcium silicate cement
40833333|NCT03910166|PROCEDURE|drug-coated balloon catheter（Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
41493668|NCT01866059|DEVICE|Glass Ionomer Cement|Glass Ionomer Cement
40833334|NCT03910166|PROCEDURE|Intracranial artery stent system（APOLLO）|stent assisted angioplasty
41493669|NCT01866059|DEVICE|Resin Modified Glass Ionomer Cement|Resin Modified Glass Ionomer Cement
41493670|NCT00373698|BEHAVIORAL|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
41493671|NCT01986010|BIOLOGICAL|V160 Low Dose IM|V160 administered as a 0.75 mL intramuscular injection
41493672|NCT01986010|BIOLOGICAL|V160 Medium Dose IM|V160 administered as a 0.75 mL intramuscular injection
41493673|NCT01986010|BIOLOGICAL|V160 High Dose IM|V160 administered as a 0.75 mL intramuscular injection
40833335|NCT04832139|DRUG|Marstacimab PFP|300 milligrams (mg) subcutaneous injection marstacimab PFP
40833336|NCT04832139|DRUG|Marstacimab PFS|300 mg subcutaneous injection of marstacimab PFS
41493674|NCT01986010|BIOLOGICAL|V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
41159636|NCT03638401|PROCEDURE|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
41159637|NCT04289714|DEVICE|Novel Electronic Monitoring Device|Four Novel electronic Monitoring Devices were trialled
41159638|NCT04734847|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Non-invasive magnetic stimulation of the brain
41493675|NCT01986010|BIOLOGICAL|V160 High Dose plus MAPA 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
41493676|NCT01986010|BIOLOGICAL|V160 Maximum Dose IM|V160 administered as a 0.75 mL intramuscular injection
41493677|NCT01986010|OTHER|Placebo IM|Placebo administered as a 0.75 mL intramuscular injection
41493678|NCT01986010|BIOLOGICAL|V160 Medium Dose ID|V160 administered as a 0.1 mL intradermal injection
41493679|NCT01986010|OTHER|Placebo ID|Placebo administered as a 0.1 mL intradermal injection
41493680|NCT04435535|PROCEDURE|PEP|Positive expiratory pressure 10 cmH2O 15 min
41493681|NCT03193073|DIAGNOSTIC_TEST|detailed echocardiography|Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
41493682|NCT03193073|DIAGNOSTIC_TEST|serum fibroblast growth factor-23|serum levels of FGF-23
41493683|NCT03193073|DIAGNOSTIC_TEST|flow mediated dilatation of forearm|superficial sonar assess the diameter of brachial vessel on exposure to stress
41493684|NCT03507023|DIETARY_SUPPLEMENT|Metabolaid®|500 mg per day, in fasting conditions.
41493685|NCT03507023|DIETARY_SUPPLEMENT|Placebo|500 mg per day, in fasting conditions.
41493686|NCT05912907|OTHER|potassium nitrate in polycarboxilate cement|5% potassium nitrate in polycarboxylate; pre-weighed 95 mg zinc oxide powder and 5mg of KNO3 will be placed on a glass slab followed by mixing by polyacrylic acid (liquid) in a 1:1 P/L ratio
41493687|NCT02316665|DEVICE|continuous positive airway pressure|continuous positive airway pressure treatment during three months with adherence recording
41493688|NCT02316665|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
41493689|NCT00406744|DRUG|Intravitreal injection of Bevacizumab|
41493690|NCT05903456|PROCEDURE|TACE（transcatheter arterial chemoembolization）|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
41493691|NCT05903456|DRUG|lenvatinib|Ronvastinib is an orally administered multi-receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2, and VEGF-3, in addition to inhibiting other pro-angiogenic and oncogenic signaling pathways associated with tumor proliferation ，has been approved as a first-line treatment for liver cancer
40833337|NCT03939078|RADIATION|CO2 fractional ablative laser|3 intravaginal fractional ablative CO2 laser sessions, with one month interval between them.
40833338|NCT03483870|DRUG|Morphine Sulfate|200 ug morphine sulphate will be injected intrathecally
40833339|NCT03483870|DRUG|Placebo|2 mL of normal saline 0.9% IV injection
40833340|NCT03483870|DRUG|Granisetron|2 mL of 2 mg granisetron IV injection
40833341|NCT01186107|DEVICE|Endeavor Resolute stent|zotarolimus-eluting stent
40833342|NCT01186107|DEVICE|Cypher stent|sirolimus-eluting stent
41352558|NCT05510791|DIETARY_SUPPLEMENT|Control|Subjects will consume a total of 24 ounces water. Specifically, subjects will drink 12 ounces of water 15 minutes prior to the 60 min run and 4 ounces of water at 15 min, 30 min, and 45 min during the run.
41493692|NCT05903456|DRUG|Icaritin soft capsules|Icaritin soft capsule is a flavonoid compound extracted from traditional Chinese medicinal materials. It is a new type of small molecule immunomodulator. It is a 1.2 class of innovative Chinese medicine with global independent intellectual property rights. By inhibiting inflammatory signaling pathway and reducing the release of inflammatory factors, the immune microenvironment can be regulated to play an anti-tumor role. At present, it has been approved for first-line treatment of advanced liver cancer, with good efficacy and safety.
41493693|NCT02537366|DRUG|Dexmedetomidine|
41493694|NCT02537366|DRUG|Placebo|
41493695|NCT06389643|PROCEDURE|Four-point scleral fixation of Akreos AO60 IOL|Intrascleral tunnels were marked at a distance of 2 mm from the corneal limbus, 6 mm apart (4 in number) after retrobulbar anesthesia. Next corneal incisions were performed. An artificial lens was then implanted into the anterior chamber. The 6-0 polypropylene suture was introduced into the anterior chamber through openings in the cornea. The next stage was to perform a sclerotomy using a 30G needle. Then the needle was passed through the hole in the haptic and 6-0 polypropylene suture was inserted into the needle hole and guided outside. The other end of the suture, passed through the opening in the haptic, was placed in the lumen of the needle and carried out through another sclerotomy and then externalised. This maneuver was repeated with another haptics as well. Correct position of the IOL in the eye was achieved by pulling on the ends of the monofilament. The ends of sutures were trimmed and cauterized. The melted tips of the sutures were then fixed subconjunctivally.
41493696|NCT06389643|PROCEDURE|Sutureless scleral fixation of AcrySof MA60AC IOL with Yamane technique|The surgery was performed under retrobulbar anesthesia. The first step of the procedure was to mark the locations of the intrascleral tunnels (2 mm from the corneal limbus) and locate them at a distance of 180° from each other to prevent the lens from tilting in the eyeball. Openings in the cornea were done. Three-piece IOL was implanted into the anterior chamber. The first sclerotomy was performed through the conjunctiva using a 30G needle 2 mm from the limbus. One of the haptics was inserted into the needle lumen and then brought out. Same procedure was performed with another haptic at a distance of 180°. The next step was to perform cautery of the tips of the haptics, obtaining a 0.3 mm collar that prevents the risk of the haptic coming out of the tunnel and displacing the lens inside the eyeball. The tips of the haptics were finally gently inserted into the scleral canals and covered with conjunctiva.
41493697|NCT02712060|OTHER|No intervention|
41493698|NCT03059004|BEHAVIORAL|TeMPO Home Exercise Program|This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
41493699|NCT03059004|BEHAVIORAL|Motivational SMS Messages|The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
41493700|NCT03059004|BEHAVIORAL|In-Clinic Topical Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.
41493701|NCT03059004|BEHAVIORAL|In-Clinic Exercise Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
41020847|NCT06214585|PROCEDURE|Heat- only Therapy|hot water bag will be used to provide heat to the lower back of primigravida women during the first stage of labor. The water in the bag will be maintained at a temperature of 40-42ºC. The application of heat will last for 20 minutes, and it will be repeated every hour until the cervix is fully dilated.
41266507|NCT02407535|DEVICE|Intraoperative ultrasound|Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
41266508|NCT05976256|OTHER|Kinesio taping|Kinesio tape is a thin, elastic tape that applies pressure to the skin (because of the elasticity of the tape), reducing pain by reducing nociceptive stimulation.
41266509|NCT05976256|OTHER|sham tape (leukotape classic)|leuko tape classic is used in this study to explore the possible placebo effect of kinesiotape
41266510|NCT05976256|OTHER|standard treatment|standard treatment is the treatment with oral analgesics and a sling (if shoulder injury)
41266511|NCT00188630|DRUG|N-acetylcysteine|
41266512|NCT00188630|OTHER|5% dextrose solution|
41266513|NCT02582996|DRUG|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
41266514|NCT02582996|DRUG|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
41266515|NCT05436548|OTHER|Supervisor-employee frequent check-ins to identify and address work stressors|Supervisors will complete three training modules: 1) how and why the check-ins are expected to address burnout; 2) how to demonstrate supportive supervision during the check-ins process, and 3) principle of quality improvement applied to the check-ins
41266516|NCT05436548|OTHER|Usual practice waitlist controls|If the check-ins are successful in reducing burnout, supervisors at the control clinics will be offered the training modules
41266517|NCT02803957|DEVICE|NeoChord DS1000|Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
41266518|NCT02803957|DEVICE|Surgical Mitral Valve Repair|Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
41266519|NCT03530384|OTHER|Cognitive training|Computerized cognitive training targeting inhibitory control of motor response used during 45 minutes sessions twice a week for 6 weeks
41266520|NCT03530384|OTHER|Control training|Fictitious computerized training used during 45 minutes sessions twice a week for 6 weeks
41266521|NCT03924401|DRUG|Abatacept|All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
41266522|NCT06312813|DRUG|Imipramine|4% imipramine
41266523|NCT06312813|DRUG|Amitriptyline|4% amitriptyline
41266524|NCT06312813|DRUG|Vehicle|0.1ml propylene glycol
41266525|NCT00931164|DRUG|Sodium Oxybate|dosage is by weight
41352559|NCT00657748|DRUG|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
41352560|NCT04490499|BIOLOGICAL|HBVAXPRO™|Single 0.5 mL intramuscular dose
41352561|NCT02053649|BEHAVIORAL|Triple Chronotherapy|triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
40833343|NCT00584571|PROCEDURE|Sensory Adaptation Training|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
40833344|NCT00584571|DRUG|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
41352562|NCT02053649|OTHER|Usual Care|UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
41352563|NCT03552809|DEVICE|Gigaa Cheese 810 nm Diode Laser|Diode Laser assisted frenectomy operation.
41493702|NCT05971654|DRUG|azithromycin|azithromycin.:500 mg PO once for 5 days every month
41493703|NCT05808673|BIOLOGICAL|Post-change CMAB807X|for subcutaneous injection only
41493704|NCT05808673|BIOLOGICAL|Pre-change CMAB807X|for subcutaneous injection only
41493705|NCT05808673|BIOLOGICAL|Xgeva®|for subcutaneous injection only
41493706|NCT03694600|DIAGNOSTIC_TEST|Multi-analyte blood Test|intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
41493707|NCT02889055|DEVICE|patient requiring the MIRUS (mechanical ventilation)|
41493708|NCT00054808|DRUG|gallium nitrate|
40833345|NCT00641342|DEVICE|onlay mesh|StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
41159639|NCT04734847|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)|Device that appears identical to the active rTMS device, but does not produce any magnetic field and does not stimulate the brain.
41352564|NCT03552809|PROCEDURE|Conventional Frenectomy Operation|Frenectomy operation performed by surgical blades with suturing.
41352565|NCT04207944|DRUG|Sulindac 400 MG|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
41493709|NCT00758680|DRUG|MK-1006|MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
41493710|NCT00758680|DRUG|Comparator: Placebo comparator|Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
41493711|NCT00309894|BIOLOGICAL|sargramostim|
41493712|NCT00309894|DRUG|ketoconazole|
41493713|NCT00309894|DRUG|therapeutic hydrocortisone|
41493714|NCT03024008|BIOLOGICAL|BonoFill-II|"Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion.~A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed.~internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union."
41493715|NCT02454660|BEHAVIORAL|SMS (Text messages)|Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
41159640|NCT01414543|OTHER|Information Sheet|Providing the Participant with information regarding the aim of the experiment
41159641|NCT01414543|OTHER|Consent|Providing a consent form for participants. The participant is aware of his or her rights
41159642|NCT01414543|OTHER|interview|participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
41352566|NCT04207944|OTHER|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
41352567|NCT05505201|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
41352568|NCT05505201|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
41352569|NCT03721549|BIOLOGICAL|Norwalk GI.1 Virus|Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
41352570|NCT02796495|DEVICE|Operation of hand prosthesis with direct nerve stimulation|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
41493716|NCT02455050|DRUG|Carboxymethylcellulose Sodium Based Eye Drops|1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops \[New Eye Drop Formula\] in each eye.
41493717|NCT02455050|DRUG|Systane® Gel Drops|1 to 2 drops of Systane® Gel Drops in each eye.
41493718|NCT02455050|DRUG|Genteal® Lubricant Gel Drops|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
41352571|NCT05481190|BEHAVIORAL|Tele-Exercise Program|Data collection tools were applied to the tele-exercise group and control group at the beginning of the study. For the tele-exercise group, by the researcher, Exp. A 6-week exercise program was created under the consultancy of a physiotherapist. Children who met the research criteria were asked to do these exercises for 20 minutes, 3 times a week for 6 weeks. The exercises were performed online with the researcher at the scheduled time one day a week, and by the children twice a week. On the days they exercised, diaries consisting of semi-structured questions were sent to the children's addresses by cargo and they were allowed to keep a diary. Phone calls were made once a week to provide motivation and increase compliance with exercise. A smart watch was sent to the children by cargo to increase motivation. The children were asked to fill in the follow-up form, which was sent via weekly google forms.
41352572|NCT05481190|BEHAVIORAL|Just observation|Standard care was given to the children in the control group.
41352573|NCT03784716|OTHER|Ketogenic Diet|Ketogenic diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 70% fat, 25% protein, and 5% carbohydrate for the ketogenic diet.
41493719|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A|One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
41493720|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
41493721|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
41493722|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
41493723|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
41352574|NCT03784716|OTHER|Standard Weight Loss Diet|Standard weight loss diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 30% fat, 20% protein, and 50% carbohydrate for the standard weight loss diet.
41493724|NCT01529918|OTHER|CANRISK (Canadian Diabetes Association Assessment)|Self-risk assessment questionnaire for diabetes
41493725|NCT01041183|DRUG|intravenous ramosetron|0.3 mg IV ramosetron (group I)
41493726|NCT01041183|DRUG|oral ramosetron|0.1 mg oral ramosetron (group II)
41493727|NCT01041183|DRUG|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
41493728|NCT01428050|DRUG|3% NaCl Solution|1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
41493729|NCT01428050|DRUG|Lactated Ringers Solution|15cc/kg/hr for intraoperative fluids
41493730|NCT04551833|DRUG|Levobupivacaine|Tramadol versus Dexamethasone as adjuvant to Levobupvacain
41493731|NCT03790150|OTHER|Evidence-based practices|Implementation of evidence-based practices
41493732|NCT03333590|BIOLOGICAL|rAAVrh74.MCK.GALGT2|Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)
41493733|NCT02279134|RADIATION|Adjuvant Chemoradiation|Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Prophylactic polyethylene glycol recombinant human G-CSF is administered 48 hours after chemotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
41493734|NCT02279134|RADIATION|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
41493735|NCT02279134|DRUG|Paclitaxel|135-150mg/m2 (D1 and D29)
41493736|NCT02279134|DRUG|Cisplatin or Nedaplatin|50-75mg/m2 (D1 and D29)
41493737|NCT03030820|PROCEDURE|Dental Cleaning|This is standard of care dental cleaning as is guided by the initial dental evaluation
41352575|NCT02098655|OTHER|Stabilometric platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
41352576|NCT04475029|DRUG|Methadone|One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
41493738|NCT00654758|DRUG|M200 (Volociximab), Carboplatin, Paclitaxel|Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
41493739|NCT01914627|DRUG|Dimethicone|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
41493740|NCT01914627|DRUG|Salicylic Acid|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
41493741|NCT04317859|BEHAVIORAL|Behavioural Activation|Behavioural Activation (BA) is a therapy previously shown to be effective in depressive disorders. This form of therapy involves modification of activities in order to change perceptions of specific situations, thereby improving mood. The BA treatment program will consist of 18 two-hour visits over 14 weeks (twice weekly group visits for the first 8 weeks, followed by two individual visits over 6 weeks).
41493742|NCT00062543|PROCEDURE|Hepatic artery infusion of CD34+ cells|Donor's cells infused directly into liver through a groin catheter (hepatic artery).
41493743|NCT00062543|DEVICE|Cobe Spectra|Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
41493744|NCT03824496|DIAGNOSTIC_TEST|Cranial Accelerometry Measurement|Measuring the HeadPulse using cranial accelerometry
41493745|NCT05791513|OTHER|Using the MAP-Knee Tool|Using the MAP-Knee Tool
41352577|NCT04475029|DRUG|Morphine|One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
41493746|NCT05791513|OTHER|Usual practice|The consultation between clinician and adolescent is conducted as per usual practice.
41493747|NCT04056286|DIETARY_SUPPLEMENT|Whey|45 g whey protein + 20 g maltodextrin
41493748|NCT04056286|DIETARY_SUPPLEMENT|3-OHB/whey|50 g 3-OHB + 45 g whey protein + 20 g maltodextrin
41493749|NCT06514690|OTHER|Sedation|Different degrees of intravenous sedation according to the Ramsay scale
41493750|NCT03449927|OTHER|Specialized menu|-Specialized menu that will guide participant food choices if the participant experiences nausea or diarrhea
40833346|NCT01157208|OTHER|Diet A|Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
40833347|NCT01157208|OTHER|Diet B|Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
41352578|NCT05421585|OTHER|observational drug study|Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery
41352579|NCT03245099|OTHER|cross sectional|Electroencephalograph will be done to all patients who fulfill the inclusion criteria to detect presence of electrical discharge with in the brain.Complete blood count ,liver function test ,kidney function test ,blood glucose level and serum electrolytes will be done to selected cases according to the clinical presentation
41352580|NCT02599324|DRUG|ibrutinib|Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
41352581|NCT02599324|DRUG|everolimus|Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
41352582|NCT02599324|DRUG|paclitaxel|Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m\^2, once weekly, in continual 3 weekly cycles.
41493751|NCT03449927|OTHER|Standard of care menu|-Standard registered dietitian support
41493752|NCT03449927|OTHER|Self report dietary intake worksheet|-Self report nausea and diarrhea
41493753|NCT03449927|OTHER|Post study questionnaire|-Completed upon count recovery and prior to discharge
41493754|NCT00549289|DRUG|cyclosporine A|
41493755|NCT03354767|PROCEDURE|Aortic and aortic valve surgery|
41493756|NCT03897985|DEVICE|Narcotrend TM|Measurement of anesthesia depth
41493757|NCT02991326|OTHER|Osteopathic Manipulative Treatment|"The Osteopathic manipulative treatment will follow the approach bellow (using latex gloves for intra oral techniques):~* Compression of the fourth ventricle;~* inhibitory intra-oral pressure technique (IPT) of the temporal muscle;~* inhibition of the inferior head of the lateral pterygoid muscle;~* intra-oral inhibition of the masseter muscle;~* Balanced ligamentous tension (BLT) of the accessory ligaments - sphenopalatine;~* BLT of the accessory ligaments - pterygomandibular raphe;~* sphenopalatine ganglion technique;~* Craniosacral rebalancing;"
41493758|NCT02991326|OTHER|Sham intervention|The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
41493759|NCT00441506|DRUG|daily interruption of sedatives|
41352583|NCT02599324|DRUG|docetaxel|Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m\^2 (according to local institutional standard of care), given continually in 21-day cycles.
41352584|NCT02599324|DRUG|cetuximab|Cetuximab 400 mg/m\^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m\^2 infused over 60 minutes.
41020848|NCT04933435|OTHER|Quality of life questionnaires|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
41352585|NCT02599324|DRUG|pembrolizumab|Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
41352586|NCT05297292|DRUG|MW02|MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.
41352587|NCT05297292|DRUG|Lucentis|a recombinant anti-VEGF humanized monoclonal antibody injection
41352588|NCT01104922|DRUG|Cetuximab|Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: \* Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) \* Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery.
41352589|NCT01104922|DEVICE|Stereotactic radiosurgery|Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy)
41352590|NCT03324867|DRUG|Regular insulin|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
41352591|NCT03324867|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
41352592|NCT05588011|DEVICE|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
41493760|NCT03112785|DEVICE|Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)|The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
41493761|NCT05520320|DEVICE|Hypothermic oxygenated machine perfusion (any device)|After static cold storage, all grafts included in this study are subjected to \>1 hour of hypothermic oxygenated machine perfusion at 4-12°C with an acellular perfusion solution.
41266526|NCT01487369|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
41493762|NCT05354570|RADIATION|Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
41493763|NCT02736877|PROCEDURE|Lumera Microscope with OCT RESCAN|corneal transplantation guided by Lumera Microscope with OCT RESCAN
41493764|NCT02736877|PROCEDURE|Conventional Microscope|corneal transplantation guided by Conventional Microscope
41493765|NCT04460859|OTHER|Specific lung recruitment maneuvers|Specific lung recruitment maneuvers will be performed to measure the potential for lung recruitment at different levels of positive end-expiratory pressure (PEEP) provided by the mechanical ventilator. Electrical impedance tomography signals, synchronized signals of airway pressure and flow, esophageal pressure (if available), and volumetric capnography (if available) will be recorded continuously, during the time span of the protocol for offline analysis.
41493766|NCT04683315|DRUG|mFOLFIRINOX Treatment Regimen|This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
41020849|NCT02509741|BEHAVIORAL|Education|
41020850|NCT02509741|DIETARY_SUPPLEMENT|Food replacement|
41020851|NCT02509741|BEHAVIORAL|IOT monitoring|
41020852|NCT03269591|DEVICE|Pulsed electromagnetic field|EASY Qs portable (by ASA, Italy)
41020853|NCT03269591|DRUG|diclofenac tablets|drugs
41020854|NCT03269591|DIAGNOSTIC_TEST|Visual analogue scale|a graphic rating scale
41020855|NCT03269591|DIAGNOSTIC_TEST|Progesterone blood level|blood test
41020856|NCT03269591|DIAGNOSTIC_TEST|Menstrual symptom questionnaire|questionnaire
41266527|NCT04070794|DRUG|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)|Fasting conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water after an overnight fasting for at least 8 hours.
41266528|NCT04070794|DRUG|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)|Fed conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water at 30 minutes after the start of standardized HFHC breakfast.
41266529|NCT03648918|OTHER|Blood Collection|Blood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.
41266530|NCT05797714|DRUG|Tenofovir Amibufenamide（TMF）|TMF, 25mg QD, from baseline to 144 weeks
41266531|NCT03628027|DEVICE|Computerised decision support algorithm|The algorithm is integrated into the EMIS computer system used by GPs. The algorithm advises on which antidepressants should be prescribed based on a patient's treatment history.
41266532|NCT02978482|DRUG|durvalumab|durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity
41266533|NCT02978482|DRUG|tremelimumab + durvalumab|20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
41266534|NCT02145962|DEVICE|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
41020857|NCT01821781|DRUG|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
41352593|NCT05588011|DEVICE|LivaNova|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
41352594|NCT01906814|DRUG|3 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
41493767|NCT04683315|DRUG|Gemcitabine/Nab-paclitaxel Treatment Regimen|This regimen will be nab-paclitaxel and gemcitabine.
41493768|NCT04683315|RADIATION|Chemoradiation|50.4 Gy in 28 fractions.
41493769|NCT05533827|OTHER|Kaleidoscope|Kaleidoscope
40833348|NCT05788237|BIOLOGICAL|RSVpreF+qIRV|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
40833349|NCT05788237|BIOLOGICAL|qIRV|Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
40833350|NCT05788237|BIOLOGICAL|RSVpreF|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B
41020858|NCT05122845|BIOLOGICAL|Blood sample|"Blood test (10 tubes of 5mL) :~- 6 tubes for : complete blood count, platelets, reticulocyte count, TP-INR, AST, ALT, GGT ferritin, serum iron, CRP, transferrin, soluble transferrin receptors, transferrin saturation coefficient enzymatic creatinine, MDRD, ionogram calcemia, phosphoremia, PTH, 25 (OH) D3, 1.25 (OH) 2D3.~2 dry tubes 2 tube EDTA"
41020859|NCT01260922|DRUG|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
41020860|NCT01260922|DRUG|Aricept®|10 mg Orally Disintegrating Tablet
41020861|NCT06254144|BEHAVIORAL|functional magnetic resonance imaging (fMRI)|The investigators will utilize standard BOLD fMRI in blocked-design tasks and resting state (participant is given no overt task) in the study. Anatomical scans with T1-weighted contrast, quantitative measurement of spin relaxation times, and diffusion tensor imaging (DTI) are also used as an anatomical reference for functional activation as well as to investigate a brain structural relationship with the participants' task performance, including successful emotion regulation.
41020862|NCT05885347|OTHER|360 videos|Caregivers will receive 2h session of 360 videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in 360 videos instantly after the education and after 6 months.
41020863|NCT05885347|OTHER|VR|Caregivers will receive 2h session of VR about caring and medication errors. Then Caregivers will be recorded performed the task worked inVR instantly after the education and after 6 months.
41020864|NCT05885347|OTHER|AR|Caregivers will receive 2h session of AR videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in AR videos instantly after the education and after 6 months.
41020865|NCT05885347|OTHER|Control group|Caregivers will follow the routine and then will be recorded performing their labour as a caregiver after 6 months.
41020866|NCT03637998|BEHAVIORAL|Problem-solving Pain to Enhance Living Well (PROPEL)|PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit.
41020867|NCT02787616|GENETIC|buccal swab|cheek swab for DNA sampling
41020868|NCT01751568|DRUG|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
41020869|NCT04704245|DRUG|epidermal growth factor (EGF)-containing ointment|The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
41020870|NCT04704245|DRUG|Vehicle ointment|To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
41352595|NCT01906814|DRUG|6 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
41352596|NCT03841773|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
41352597|NCT03841773|DRUG|Placebo SL Tablets|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
41493770|NCT05533827|OTHER|Music|Music
41493771|NCT05533827|OTHER|Virtual reality glasses|Virtual reality glasses
41493772|NCT00173550|PROCEDURE|Hysterectomy and Bilateral salpingo-oophorectomy|
41493773|NCT00224926|PROCEDURE|Scalp Brushing|sterile, soft-head toothbrush massaged on scalp
40833351|NCT05788237|DRUG|Placebo|0.9% saline for injection
41352598|NCT02871232|OTHER|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
41352599|NCT06159049|DIAGNOSTIC_TEST|68Ga-FAPI dimer(68Ga-LNC1013)|68Ga-LNC1013 was evaluated in a pilot clinical PET imaging study involving seven patients with gastrointestinal cancer.
41352600|NCT00476502|GENETIC|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
41352601|NCT02139176|BEHAVIORAL|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
41493774|NCT01096030|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
41020871|NCT04704245|PROCEDURE|Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening."
41020872|NCT01190241|DRUG|desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib|The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
41020873|NCT05071417|DRUG|Semaglutide|Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
41020874|NCT05669092|DRUG|Toripalimab|3mg/Kg iv d1q2w
41020875|NCT05669092|RADIATION|CRT|IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
41020876|NCT05669092|RADIATION|SCRT|25Gy/5fx
41020877|NCT05669092|DRUG|XELIRI|Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
41020878|NCT05669092|DRUG|FOLFRINOX|Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
41020879|NCT06574282|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(1-4 weeks after the 1st measurement)
41020880|NCT04819685|DRUG|KANG FU PEN|FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays
41020881|NCT03054844|DRUG|Lidocaine|Lidocaine will be administered before administration of midazolam.
41020882|NCT03054844|DRUG|Lidocaine and midazolam (PREMIX)|Lidocaine will be administered as a mixture with midazolam.
41020883|NCT03054844|DRUG|Midazolam|Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
41020884|NCT01826149|DRUG|Propofol 1.0mcg|Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
41020885|NCT01826149|DRUG|Propofol 2.0mcg|Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
41020886|NCT01826149|DRUG|Propofol 3.0mcg|Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
41020887|NCT06396728|DIETARY_SUPPLEMENT|GI BIOTICS 100B UFC|Consumption of GI BIOTICS 100B UFC.
41352602|NCT02139176|BEHAVIORAL|patient referral|A patient agrees to recruit their partner using the invitation.
41352603|NCT00696644|DRUG|Teriparatide|20 mcg daily subcutaneous for 18 months.
41352604|NCT05367921|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - 4 measurements on both legs of each healthy volunteer will be performed
41352605|NCT05488249|DIAGNOSTIC_TEST|Cardiac imaging tests|"* 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics."
41020888|NCT06396728|DIETARY_SUPPLEMENT|Placebo Consumption|Consumption of a placebo capsule.
41020889|NCT03893513|DEVICE|Transthoracic Electrical Bioimpedance|Non-invasive hemodynamic monitor
41020890|NCT03893513|DEVICE|Pulse Contour Analysis|Invasive hemodynamic monitor
41020891|NCT05920941|DRUG|[14C]JAB-21822|Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
41020892|NCT05628740|DRUG|3 mg NOC-100 (via nebulizer)|Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
41352606|NCT05488249|DIAGNOSTIC_TEST|Venous blood sample collection|Venous blood sample collection during CCTA image acquisition for evaluation of serum levels of hsCRP, IL-6, matrix metalloproteases - MMP9, Adhesion molecules (VCAM, ICAM, e-selectin, p-selectin) periostin.
41020893|NCT05628740|DRUG|1 mg NOC-110 (via DPI) [1x 1 mg capsule]|Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
41020894|NCT05628740|DRUG|3 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
41020895|NCT05628740|DRUG|Placebo (via DPI)|Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
41020896|NCT05628740|DRUG|6 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule
41020897|NCT05628740|DRUG|Placebo (via DPI) [2x Placebo capsules]|Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
41020898|NCT02621905|DRUG|Sporanox|At least 2 capsules twice a day for 3 weeks
41020899|NCT02621905|DRUG|Lozanoc|At least 2 capsules twice a day for 3 weeks
41020900|NCT01145079|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent
41020901|NCT01145079|DEVICE|Zotarolimus-eluting stent for ACS and DM|Zotarolimus-eluting stent for ACS and DM
41020902|NCT01145079|DEVICE|Everolimus-eluting stent for long lesion|Everolimus-eluting stent for long lesion
41020903|NCT01145079|DEVICE|Sirolimus-eluting stent for short lesion|Sirolimus-eluting stent for short lesion
41020904|NCT06572254|OTHER|Early Childhood Development Newborn Parenting Education Program|Investigators will be adapting the model used here at the tertiary care of newborn parenting which investogators have developed based on the nurturing care framework and keys to the caregiving framework. Both models have shown reliable evidence of their effectiveness.
41493775|NCT00813631|OTHER|silver-releasing dressings|Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
41020905|NCT01719965|OTHER|Interviews and Focus Group Discussions|
41352607|NCT03479541|BEHAVIORAL|Rehabilitation|"Participants will see a physiotherapist one-on-one twice per week for 2 weeks and once per week for 4 weeks for a total of 6 weeks. These sessions will consist of cardio, cervical flexion exercises and vestibule-ocular exercises for one hour. Participants will also have similar daily home exercises to complete for approximately 30 minutes. Both the one-on-one physiotherapy and home exercises will be individualized and progressive in the sense that each exercise can increase in the level of difficulty at the discretion of the physiotherapist depending on the performance of the participant.~For the group allocated to home monitoring, they will perform the vestibular exercises while wearing one wireless sensor on the head and one on the sternum. When the participant brings the sensors in to the physiotherapy session each week, the physiotherapist will examine the home data and likely make a more informed decision as to whether or not to increase the level of difficulty of the task."
41352608|NCT01204489|BEHAVIORAL|Intensified dietary counseling at child wellfare clinics.|The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
40833352|NCT05788237|BIOLOGICAL|RSVpreF + qIRV 1.0 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection
40833353|NCT05788237|BIOLOGICAL|RSVpreF + qIRV 0.5 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains)
40833354|NCT01840358|OTHER|Observation of hypoglycemias frequency 3 days before and after pump initiation|
41352609|NCT04463914|BEHAVIORAL|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
41493776|NCT04859621|DRUG|Vitamin D3 4000 IU|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
41493777|NCT04859621|DRUG|Vitamin D3 2000 IU|Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks
41493778|NCT04859621|DRUG|Placebo|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
41493779|NCT04859621|OTHER|standard antibiotic therapy|standard antibiotic therapy
41493780|NCT00401986|DEVICE|Bronchial thermoplasty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY (NCT00214539).
40833355|NCT00620152|BEHAVIORAL|1|Low glycemic load diet by telephone counseling
40833356|NCT00620152|BEHAVIORAL|2|Low fat diet by telephone counseling
40833357|NCT06328452|DEVICE|FibroScan|All the study population will be submitted to Fibroscan examination with CAP (Echosens FibroScan® Compact 530). To evaluate steatosis and fibrosis, participants will be asked to fast for at least 3 hours before the test. To capture a controlled attenuation parameter (CAP) score and liver stiffness measurement (LSM), 10 valid scans per subject will be needed.
40833358|NCT05275946|DRUG|Targeted alpha therapy|Single intravenous administration
40833359|NCT00980304|DRUG|Rituximab|
41020906|NCT05635747|DEVICE|Relizorb Enzyme Cartridge|Tube feeds run across device to digest fats.
41020907|NCT05507710|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Imaging with ICG near-infrared fluorescence is performed besides clinical judgement of the DIEP flap for perfusion evaluation. Based on fluorescence imaging, additional malperfused area(s) are resected.
41020908|NCT01578551|DRUG|Paclitaxel|200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.
41020909|NCT01578551|DRUG|Carboplatin|"Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy"
41159643|NCT01414543|OTHER|Debrief|at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
41159644|NCT02236702|OTHER|Positron Emission Tomography (PET) imaging|Positron Emission Tomography (PET) imaging
41352610|NCT04463914|BEHAVIORAL|Behavioral Activation Therapy app + EHR|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. The participant's primary care provider at MUSC will be provided access to a Moodivate provider portal that was developed by study team. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
41352611|NCT04463914|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
41352612|NCT06065410|OTHER|Baseline|Walking without any instruction or sound
41352613|NCT06065410|OTHER|Intrinsic focus|Walking focusing on ensuring equal step lengths and step durations on both sides and symmetry between both steps
41352614|NCT06065410|OTHER|White noise|Intrinsic focus accompanied by white noise
41493781|NCT06486961|DEVICE|BeatMove Application|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
40833360|NCT06284616|BEHAVIORAL|JASP-1|patients following the Juvenile Arthritis Support Program at the Pediatric Rheumatology Clinic
40833361|NCT02079935|BEHAVIORAL|Cognitive Behaviour Therapy|Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.
40833362|NCT02079935|BEHAVIORAL|Physical Activity and Dietary Therapy|Guided physical activity and dietary therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
40833363|NCT06266104|PROCEDURE|Image Enhanced Endoscopy Filters|Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).
40833364|NCT02869412|OTHER|Computer-Assisted Intervention|Use BCG website
40833365|NCT02869412|OTHER|Computer-Assisted Intervention|Use passive website
40833366|NCT02869412|OTHER|Quality-of-Life Assessment|Ancillary studies
40833367|NCT02869412|OTHER|Questionnaire Administration|Ancillary studies
40833368|NCT05479149|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
40833369|NCT05479149|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
40833370|NCT04651010|OTHER|Multimodal MRI|Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
40833371|NCT03096873|BEHAVIORAL|Combined Exercise Training|The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
40833372|NCT02227836|DEVICE|Allergy Patch Testing|
40833373|NCT02302183|DEVICE|FreeO2 v2.0 automatic adjustment|
40833374|NCT02302183|DEVICE|FreeO2 v2.0 data collecting|
40833375|NCT00418431|DRUG|Intravitreal injection of Bevacizumab|
40833376|NCT01241760|DRUG|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
40833377|NCT01241760|DRUG|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
40833378|NCT01241760|DRUG|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
40833379|NCT01241760|DRUG|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
40833380|NCT04258995|BIOLOGICAL|Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)|2 formulations at 1 dose level
40833381|NCT05052437|DRUG|Utidelone Injection; capecitabine|8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
41352615|NCT06065410|OTHER|environmental sound|Intrinsic focus accompanied by environmental sound
41352616|NCT02365272|DRUG|Amikacin|Amikacin administered in a single dose for critical care patients
41352617|NCT06160362|BIOLOGICAL|CART-19 and 20 cells|Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
41352618|NCT06160362|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
41352619|NCT06160362|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
41352620|NCT00355381|BEHAVIORAL|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
40833382|NCT05052437|DRUG|Utidelone|8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
40833383|NCT00139217|DRUG|iNO|
40833384|NCT00139217|PROCEDURE|Non-invasive nitric oxide|
40833385|NCT00138047|DRUG|zinc supplementation|
40833386|NCT02466113|OTHER|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
40833387|NCT02466113|OTHER|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and \<12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
40833388|NCT02983422|DRUG|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
40833389|NCT02983422|DRUG|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
40833390|NCT02983422|DRUG|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
41352621|NCT02492789|BIOLOGICAL|INCSHR01210 injection|"Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.~Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study."
41352622|NCT00051194|DRUG|Combination IOP Lowering Therapy|
41352623|NCT04361721|DRUG|Erenumab|First injection of erenumab 70 mg subcutaneously was administered in hospital. The second injection of erenumab 70 mg was administered in hospital after 28 days, while the third and last dose of erenumab 70 mg was self-administered at home by the patients themselves after an additional 28-day interval.
41352624|NCT05021666|DRUG|Placebo|matching placebo
41352625|NCT05021666|DRUG|PB 718|dose in the next group will be determined following a review of data from the previous group
41352626|NCT04913792|DEVICE|ZXR00|This prospective comparative study included 60 eyes undergoing cataract surgery with implantation of an extended range of vision IOL.(Abbott Medical Optics, Inc.)
41020910|NCT01578551|DRUG|Bevacizumab|All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
41020911|NCT01578551|DRUG|Metformin|1000 mg twice daily with food.
41020912|NCT02934139|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
41020913|NCT02934139|OTHER|Placebo|Matched placebo
41020914|NCT04229719|DRUG|N-acetyl-5-methoxytryptamine|1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
41020915|NCT02624102|BEHAVIORAL|Trial based cognitive therapy|Patients with MDD, in use of antidepressants plus Trial Based Cognitive Therapy
41020916|NCT02624102|BEHAVIORAL|Behavioral Activation|Patients with MDD, in use of antidepressants plus Behavioral Activation
41020917|NCT02624102|DRUG|Antidepressants|Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
41266535|NCT02145962|DEVICE|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
41266536|NCT00085280|DRUG|erlotinib hydrochloride|Given orally
41266537|NCT00085280|OTHER|laboratory biomarker analysis|Correlative studies
41266538|NCT00141947|DRUG|bexarotene (Targretin)|
41266539|NCT05206448|DRUG|Letrozole|Letrozole tablet
41352627|NCT02994199|OTHER|Active video gaming|Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
41352628|NCT00914095|DRUG|methylphenidate|10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
41352629|NCT00914095|DRUG|placebo|tablets of placebo 3 times a day
41352630|NCT01808040|DRUG|TAK700|dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
41352631|NCT04262674|OTHER|Cognitive-motor training|Simultaneous cognitive-motor training and strength training
41352632|NCT04713644|DRUG|Standardized Propofol Administration|Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
41352633|NCT03256123|DIETARY_SUPPLEMENT|red palm shortening group|Biscuits made of red palm shortening will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The biscuits for each subject will contain \~200 kcal with 10 g of red palm shortening/day (630 µg RE/day). This biscuit would be given four days a week on schooling days for a duration of 6 months. On average in a week, subject is expected to receive 630 µg RE of vitamin A/day. This would fulfill \~70% of the RNI of vitamin A for children aged 7-11 years old.
41020918|NCT05520216|DEVICE|Spinal mouse (idiag m360)|A noninvasive Spinal Mouse device will be used to measure the thoracic kyphosis and lumbar lordosis angle of the spinal column in the sagittal plane. It will be displayed on the computer aided software screen where the thoracic and lumbar region angles are calculated by swiping over the spinal processes from top to bottom with the Spinal Mouse (IDIAG m360) device. Measurements will be taken while standing on a flat surface. The volunteer will take off his upper clothes and shoes during the examination. Relax your arms and torso will be positioned next to you. The distance between the feet will be approximately waist width and parallel to each other, the knees will be straight and face motionless. He will stand where he feels comfortable. A Spinal Mouse examination will be performed and data will be recorded.
41352634|NCT03256123|DIETARY_SUPPLEMENT|palm shortening group|Biscuits made of palm shortening (control group) will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The palm shortening biscuits contain corresponding fatty acids as red palm shortening group.
41493782|NCT06486961|DEVICE|BeatMove Application without synchronized music|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
40833391|NCT04534907|COMBINATION_PRODUCT|The combination of exposure and response prevention (ERP) and VR|The combination of exposure and response prevention (ERP) and VR aimed to investigate the combination of an immersive virtual reality environment (VRE) alongside therapist delivered CBT to reduce anxiety when the OCD patients were induced by virtual scene.Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get VR+ERP session twice a week. From the fourth week to the seventh week, patients weill get VR+ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
40833392|NCT04534907|BEHAVIORAL|Traditional ERP|Patients will achieve the exposure based CBT for total 10 times excluding 8 sessions of ERP. Structured protocol described by Foa et al., 2012. Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get ERP session twice a week. From the fourth week to the seventh week, patients weill get ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
40833393|NCT03262207|OTHER|Extraction genomic DNA|
40833394|NCT03262207|OTHER|Analysis of methylation profiles of numerous GSI and TE|
40833395|NCT03262207|OTHER|Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)|
41266540|NCT05206448|DRUG|Clomiphene Citrate|Clomiphene Citrate tablet
40833396|NCT03262207|OTHER|Method of protein detection by immunostaining and flow cytometry|
40833397|NCT00329927|BIOLOGICAL|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
40833398|NCT00725244|DEVICE|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
40833399|NCT00725244|DEVICE|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
41266541|NCT02109159|OTHER|A short online video with emotional content|
41266542|NCT02109159|OTHER|A short online video with less emotional content|
41266543|NCT03700099|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks, for 6-10 cycles.
41266544|NCT03700099|DRUG|Enzalutamide|Upon disease progression after treatment with docetaxel, patients will receive Enzalutamide 160 mg P.O. daily until disease progression or limiting toxicity.
41352635|NCT02350192|BEHAVIORAL|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
41352636|NCT00775138|DRUG|280 mg Arikayce™|Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
41352637|NCT00775138|DRUG|Matching Placebo for Cohort 1|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
41493783|NCT06486961|DEVICE|BeatMove Application without music|The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
41493784|NCT00187382|DRUG|Multiple vs. single courses of antenatalcorticosteroids|
41020919|NCT05520216|BEHAVIORAL|chest circumference measurement|Measurements will be taken from the axillary (4th rib level - two fingers below the axilla), epigastric (xiphoid process level) and subcostal (9th rib level) regions at the time of normal, maximal inspiration, and maximal expiration using a tape measure while the patient is in a sitting position. The tape measure will be placed in the area to be measured. Care will be taken that there is no folding or horizontal level difference in the tape measure and that the fingers are not under the tape measure. Normal respiration will be measured first and recorded in centimeters (cm). The patient will then be asked to take a deep, long breath towards the bottom of the tape measure. The value obtained will be recorded as the deep inspiration value. Immediately after deep inspiration, the patient will be asked to make a deep and long expiration. The obtained value will be recorded as deep expiration.
41020920|NCT05520216|BEHAVIORAL|Maximum Breath Hold Test|During the breath-hold measurement, the subject will sit in a chair with a backrest. He will take a deep breath through his nose. We do not want maneuvers (Valsalva and Müller) and diaphragm contractions that will affect the breath-hold time, so volunteers will be observed throughout the test. The test will be terminated as soon as involuntary diaphragm contractions are seen. This test will be applied 3 times by resting the volunteer with breaks for 5 minutes. The average of 3 test results will be taken (Lin, Y. C.: Effect of O2 and CO2 on breath hold breaking point. In The Physiology of Breath Hold Diving. (eds): CEG Lundgren, M Ferringo, Undersea and Hyperbaric Medical Society Inc, Bethesda, Maryland, p: 75-87 1987.).
41020921|NCT05520216|BEHAVIORAL|Sit and Reach|While the participant is sitting on the floor with his back to the wall and his legs are fully extended in front of him, his knees should be in full contact with the floor. The box will be placed on the sole of the participant's feet (without shoes) in full contact with the volunteer's feet. The participant will be instructed to lean forward as slowly as possible, keeping their fingertips level with each other and their legs straight on the floor. He will be asked to slowly lie down along the ruler three times, and on the third attempt the volunteer will be instructed to reach out as far as possible and hold for 2 seconds. This value will be saved
41020922|NCT02595567|DEVICE|Indwelling tunneled pleural catheter (ITPC)|ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
40833400|NCT03304067|BEHAVIORAL|Tueo Program|The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view metrics from the devices, educational and clinical context content, and an asthma coach.
41020923|NCT00459134|DIETARY_SUPPLEMENT|ArginMax|Given orally
41020924|NCT00459134|DIETARY_SUPPLEMENT|Placebo|Given orally
41020925|NCT04606953|BEHAVIORAL|Attention Process Training (APT-II)|The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
41020926|NCT03556319|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
41020927|NCT03556319|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
41493785|NCT05933980|DRUG|Rego+Tori+Cele|combination of Toripalimab,regorafenib and celecoxib
41493786|NCT02149329|DRUG|Discontinuation of imipenem-cilastatin or meropenem|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
40833401|NCT01400243|DRUG|Nicotine|Nicotine patch 7mg
40833402|NCT01400243|DRUG|Placebo Patch|Placebo patch
40833403|NCT04789694|OTHER|Physiological intervention|"* Rehabilitation specialist consultation (3x)~* Individualized home-based exercise plan~* Functional capacity measuring"
40833404|NCT04789694|BEHAVIORAL|Psychological intervention|"* Clinical psychologist consultation (3x)~* Anxiety and depression scoring~* Psychological support"
40833405|NCT04789694|DIETARY_SUPPLEMENT|Nutritional intervention|"* Nutritional specialist consultation (3x)~* Malnutrition scoring~* Dietary supplementation"
40833406|NCT00842101|DEVICE|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
41020928|NCT03663114|DRUG|Lenvatinib|Lenvatinib capsule
41020929|NCT02229955|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
41020930|NCT05223543|DIAGNOSTIC_TEST|Blood sample|extraction of blood samples from women undergoing ovarian cystectomy or oophorectomy due to suspected Dermoid cyst and analysing plasma for antibodies
41020931|NCT01317953|DIETARY_SUPPLEMENT|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
41352638|NCT00775138|DRUG|560 mg Arikayce™|Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
41493787|NCT02815358|OTHER|Segmental Stabilization Exercises|The stabilization program focuses on the reestablishment of motor control and coordination between deep and superficial trunk muscles. The exercise program is based on the following criteria progression: 1) Precise contraction of the transverse abdominal and multifidus muscles, keeping the lumbar spine in a neutral position (as the middle way between maximum flexion and extension, repeated three times); 2) Keep the neutral position for 10 repetitions of 10 seconds; 3) Perform exercises with lower limbs in different postures.
41493788|NCT02815358|OTHER|Home Exercises|Home exercises include passive stretching and active mobilization of the spine.
40833407|NCT05096754|DEVICE|OCS Liver|Transplant with an OCS preserved liver.
40833408|NCT02043119|BEHAVIORAL|Breastfeeding Clinic|
41020932|NCT01124890|DEVICE|early percutaneous coronary intervention|
41020933|NCT01124890|DEVICE|late percutaneous coronary intervention|
41020934|NCT06572345|DIETARY_SUPPLEMENT|Low-energy diet|For the first 12 weeks during the LED, participants will have 4 meal replacement products each day. The following 12 weeks consists of a gradual reintroduction of food one meal at a time, in a structured stepwise progression, under the supervision of a dietitian. They will then undergo 28 weeks of weight maintenance to see if they are able to keep their weight stable.
41020935|NCT06572345|OTHER|Qualitive interview - LED participants|Semi-structured interviews with 10 of the LED participants and their relative/carer.
41020936|NCT06572345|OTHER|Qualitive interview - Participants declining LED|Semi-structured interviews with 10 participants who declined the LED, and their relative/carer.
41020937|NCT06572345|OTHER|Qualitive interview - Health Care Professionals (HCPs)|Semi-structured interviews with 10 HCPs involved in delivery of the trial.
41352639|NCT00775138|DRUG|Matching Placebo for Cohort 2|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
41352640|NCT03224936|DEVICE|PSI|The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
41352641|NCT01711333|DRUG|Pletaal SR capsule|two capsules once a day of Pletaal SR 100mg Capsules
41352642|NCT05237609|DIETARY_SUPPLEMENT|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group
41352643|NCT05237609|OTHER|rehabilitation with muscle strengthening|Physical activity with only muscle strengthening
41352644|NCT00822640|DEVICE|Total Knee Arthroplasty|All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
41352645|NCT03371004|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
41352646|NCT02310724|OTHER|TODAY cohort|This protocol is observation only and involves no intervention, care, treatment, or management.
41020938|NCT00142909|DRUG|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
41020939|NCT00142909|DRUG|Placebo|Lofexidine Placebo
41020940|NCT03708341|DRUG|Melatonin 5 mg|Systematic daily administration of melatonin 5 mg during patient's ICU stay
41020941|NCT03708341|DRUG|Placebo Oral Tablet|Systematic daily administration of placebo during patient's ICU stay
41352647|NCT00836953|BIOLOGICAL|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
41352648|NCT06049706|DEVICE|Active Priming|"It will be applied an active priming stimulation in the supplementary motor area previously to the main stimulation to analyse if that will enhance the response to TMSr, compared to inactive priming.~To apply intervention, it will be used Repetitive Transcranial Magnetic Stimulation Model MagPro R20 (MagVenture Brazil, country Brazil) and the butterfly coil MCF-B70 (MagVenture Brazil, country Brazil).~Each session will last around 20 minutes, and it will be used a 1 Hz frequency, 1200 pulses/day, with 100% of Motor Threshold, once a day, 5 days a week, for two consecutive weeks.~Active Priming group participants will be previously stimulated for 10 minutes (20 trains of 5 seconds with intertrain interval of 25 seconds), with 6Hz frequency over Supplementary Motor Area, receiving 80% of Motor Threshold, with a total of 600 stimulations."
41352649|NCT06049706|DEVICE|Sham Priming|Sham Priming group participants will receive a placebo stimulation for ten minutes, with the same parameters and target area as the active group, they will hear the equipament noise and might feel any sensation in the scalp, but there won't be effective stimulation.
41352650|NCT03566563|OTHER|Screening|Patients tested positive for Hepatitis C will be referred to Hospital through the conventional health care services and by an alternative direct access method to determine if this improves linkage to care
41352651|NCT01227252|DRUG|LY2886721|5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
41020942|NCT02800044|DEVICE|Wearing a non-invasive glucose sensor|Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
41020943|NCT03082339|OTHER|Cortisone|Observation of QTc-interval
41020944|NCT02424916|BIOLOGICAL|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
41020945|NCT00389818|BIOLOGICAL|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
41020946|NCT00389818|BIOLOGICAL|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
41020947|NCT00389818|BIOLOGICAL|rituximab|375 mg/m2 IV Day 1 of each cycle
41352652|NCT01227252|DRUG|Placebo|Administered orally as capsules, daily for 14 days
41352653|NCT05243940|DRUG|dexmedetomidine-ketamine-lidocaine (DKL)|"patients will be administered 0.25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1 mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
41352654|NCT05243940|DRUG|remifentanil infusion|remifentanil infusion under the Minto model (target controlled infusion-TCI aiming at 4ng/ml blood concentration
41352655|NCT04853264|DEVICE|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
41020948|NCT00389818|BIOLOGICAL|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
41352656|NCT04853264|DEVICE|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by a registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture instituted in the hospital where the study will be conducted.
41352657|NCT02765854|DRUG|Dexamethasone|Given PO
41352658|NCT02765854|DRUG|Ixazomib|Given PO
41352659|NCT02765854|DRUG|Lenalidomide|Given PO
41352660|NCT01393665|DRUG|PENNEL capsule|"hard capsule DDB 25mg \& GO 50mg in cap .......... 1 capsule~1 or 2 capsule, T.I.D"
41020949|NCT00389818|DRUG|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
41020950|NCT00389818|DRUG|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
41352661|NCT01393665|DRUG|Placebo|Placebo
41352662|NCT03725566|DRUG|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
41020951|NCT00389818|DRUG|prednisone|100 mg PO Days 1-5 of each cycle
41020952|NCT00389818|DRUG|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
41020953|NCT00389818|OTHER|immunohistochemistry staining method|tissue specimen collected at baseline
41020954|NCT00389818|OTHER|laboratory biomarker analysis|tissue specimen collected at baseline
41020955|NCT02535195|DIETARY_SUPPLEMENT|Ginger supplement|
41020956|NCT02535195|DIETARY_SUPPLEMENT|Placebo (starch)|
41020957|NCT05069662|OTHER|Directive Interview|One directive interview conducted by telephone
41020958|NCT04666441|DRUG|REGN10933+REGN10987 combination therapy|Administered IV or SC single dose
41020959|NCT04666441|DRUG|Placebo|Administered IV or SC single dose to match
41020960|NCT04715594|DEVICE|1st-generation drug-eluting stent|Implantation of 1st-generation drug-eluting stent
41020961|NCT04715594|DEVICE|2nd-generation drug-eluting stents|Implantation of 2nd-generation drug-eluting stent
41159645|NCT03410095|DIAGNOSTIC_TEST|Brain MRI, cognitive testing, bloodwork|"Participants will undergo 3-Tesla MRI. Scan time will be about 1 hour and 15 minutes per subject per session at the Sunnybrook site. The protocol is designed to image SVD burden by quantifying PVS and WMH volumes, and image various physiological estimates on the brain.~Participants will undergo the following cognitive tests: Behavioural Neurology Assessment-R (BNA-R), Montreal Cognitive Assessment (MOCA), Center for Epidemiologic Studies Depression Scale (CES-D), and BrainScreen.~Blood samples will be assayed for inflammatory and endothelial function. Classical vascular risk factors will also be assessed. Once data collection is complete, DNA will be extracted from the frozen PBMC fraction and will be genotyped for APOE genotype and a panel of other single nucleotide polymorphisms known to be associated with cognition and cerebrovascular disease."
41352663|NCT00550615|DRUG|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
41020962|NCT04498884|DRUG|Rinsulin® mix 30/70|one subcutaneous injection at a dose of 0.4 IU/kg
41020963|NCT04498884|DRUG|Humulin® M3|one subcutaneous injection at a dose of 0.4 IU/kg
41159646|NCT04257942|PROCEDURE|carotid endarterectomy|carotid endarterctomy that is being used for carotid stenosis disease
41352664|NCT00550615|DRUG|Dasatinib Maximum Tolerated Dose|An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
41352665|NCT00715039|DRUG|lorazepam|1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
41352666|NCT00715039|DRUG|placebo|placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
41159647|NCT05787171|DEVICE|WE-MBVMS using suture Vicryl (Polyglactin 910; Johnson & Johnson International, USA);|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
40833409|NCT03950713|BEHAVIORAL|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|The MBSR-T is focused on strategies to manage diabetes distress for new residents by three new techniques. Firstly, it involves practicing body and meditation exercises for openness to the awareness and acceptance of transferred life experiences, such as mindful attention exercise, which is assumed to allow the residents to behave in a less reactive and more reflective manner when confronted with transferred life stressors. Second, mindfulness meditation techniques were provided for difficult thoughts and feelings related to diabetes, such as paying full attention to the present moment of life and choosing to respond skillfully rather than reacting automatically to external events, thoughts or emotions as they arise. Third, a specific topic, for example on how to be mindful when life style is changed, or how to pay attention to the present moment within Chinese culture of peacefulness was discussed in each session.
40833410|NCT02159677|DEVICE|EIM Measurements|
40833411|NCT04842474|OTHER|Gaze stability exercises and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
40833412|NCT00371969|BEHAVIORAL|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
40833413|NCT00371969|BEHAVIORAL|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
40833414|NCT05501613|DIAGNOSTIC_TEST|Multimodal Neuromonitoring|Invasive Multimodal Neuromonitoring
40833415|NCT03462186|OTHER|Healthfinder invitation|Invitation to use healthfinder (healthfinder.gov/myhealthfinder
41159648|NCT05787171|DEVICE|WE-MBVMS using suture PDS (polydioxanone; Johnson & Johnson International, USA)|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
41352667|NCT00715039|DRUG|paroxetine|20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
41352668|NCT04686110|OTHER|angiographic optical coherence tomography|angiographic optical coherence tomography
41352669|NCT00309192|DRUG|Triamcinolone Acetonide|Intravitreal Injection 4mg single dose
41352670|NCT00309192|PROCEDURE|Grid laser|Grid laser as specified in ETDRS
41352671|NCT00309192|PROCEDURE|Sham Injection|Simulation procedure for triamcinolone injection
41352672|NCT02845284|BEHAVIORAL|enhanced group support|Routine Care plus enhanced group support, and peer education beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
41159649|NCT05787171|DEVICE|WE-MBVMS using suture Ethibond (polyester; Johnson & Johnson International, USA）|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
41159650|NCT02176837|DRUG|Sodium Nitrite|Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
41352673|NCT02845284|BEHAVIORAL|enhanced individual support|Routine Care plus individual peer education and support beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
41352674|NCT05248100|BEHAVIORAL|Conditional Cash Transfer|The intervention is a one-time cash transfer of 22,500 Tanzanian Shillings (\~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
41352675|NCT00908050|DRUG|Botulinum toxin type A|Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally.
40833416|NCT04577079|DEVICE|Evaluation of the need of emergency medical services|The main aim of this study is to validate the use of IPFM in a hospital setting by evaluating the association of IPFM output with 1) clinical urgency and severity of the conditions (using Emergency Severity Index \[ESI\], an international triaging protocol for emergency units, and an assessment by triage nurse); and 2) actual diagnoses made by the hospital doctors. The objective is also to assess the correlation of IPFM output with redirection or referral to various specialties
40833417|NCT01310959|OTHER|Database|Database
40833418|NCT03242252|DRUG|Placebo|"Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral"
40833419|NCT03242252|DRUG|Sotagliflozin|"Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral"
41159651|NCT06006897|OTHER|Physical Evaluations of post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis with post-COVID-19 individuals. The data to be obtained from all these evaluations will be collected from the individuals at one time and over a period of approximately 1 hour at the most. Step count tracking with pedometer will be done for each individual for 3 days.
41159652|NCT06006897|OTHER|Physical evaluations of non-post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis without post-COVID-19 individuals.
41159653|NCT02411253|DRUG|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
41159654|NCT02411253|DRUG|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
40833420|NCT06279702|OTHER|SERIOUS GAME|Students will play serious game that about first aid.
41159655|NCT03104309|DEVICE|Levonorgestrel intrauterine system|Levonorgestrel intrauterine system for adenomyosis
41159656|NCT04783597|DIAGNOSTIC_TEST|Arterial Stiffness and Wave Reflection|Arterial stiffness and wave refection, a non-invasive test, will be collected and combined with standard clinical markers (blood biomarkers, ultrasound imaging) as well as medical and psychosocial questionnaires in order to test a comprehensive, multi-marker approach for pre-eclampsia prediction in high risk pregnant women.
41352676|NCT00908050|DRUG|Placebo arm|Placebo comparator
41352677|NCT05706610|BEHAVIORAL|Tailored Program|Participants in the tailored program will participate in 4 sessions with a coach, 1 every other week. During these sessions, the AYA will work with their coach to identify a barrier to adherence to target and create an action plan using evidence-based behavior change techniques to address this barrier. In between sessions (on alternating weeks), the coach will check-in with a text including a reminder about the action plan and a calendar of the AYA's eCAP adherence data.
41352678|NCT05706610|BEHAVIORAL|Feedback Program|Participants in the Feedback Program will receive weekly text messages including: a calendar depicting their weekly adherence (per eCAP data) and guidance for requesting additional support as desired.
41352679|NCT03523403|OTHER|Apples|3 whole Ontario-grown Gala apples
40833421|NCT06279702|OTHER|COMICS|students will learn comics that about first aid.
40833422|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
40833423|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
40833424|NCT01155921|DRUG|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
41159657|NCT00577096|DRUG|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
41159658|NCT00577096|BEHAVIORAL|Exercise|A home-based individualized exercise program that incorporated aerobic and strength resistance training.
41352680|NCT02477800|DRUG|Aducanumab (BIIB037)|Low dose
41493789|NCT03948139|DEVICE|Functional Brace|The study will generate five standardized sized braces based on measurements from prior scans that will be stocked at each institution and modified by the local orthotist to fit the needs of each patient. This will facilitate expedited care while obtaining the same clinical and radiographic results as the fully customized braces. This idea has the potential to be extrapolated to the wider clinical community, creating a true shift in pediatric orthopaedic clinical practice throughout the country.
41493790|NCT03948139|DEVICE|Hip Spica Cast|Traditional spica casts, the current standard of care for diaphyseal femoral shaft fractures with minimal shortening in children age 0-5 years old. Although spica cast immobilization is standard of care for femur fractures in young children, caring for a child in a spica cast presents a significant socioeconomic burden on families and the healthcare system. Basic hygiene and transportation for a child in a spica cast requires burdensome adjustments for caretakers, as well as the added expenses of specialized car seats or transportation services. Improper spica cast care can lead to skin complications, additional visits for cast adjustments, or even revision casting in the operating room.
41352681|NCT02477800|DRUG|Aducanumab (BIIB037)|High dose
41352682|NCT02477800|DRUG|Placebo|Placebo
41493791|NCT01431911|DRUG|Early maintenance treatment|Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
41493792|NCT01431911|DRUG|Delayed Maintenance treatment|Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
41493793|NCT03173144|OTHER|Primary exposure variable|"1. Upper tertile (33.3% of the total sample) based on the ratio: fibre/meat intake is associated with better treatment outcome~2. Low intake of red and processed meat (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of dietary fibres (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with better treatment outcome, and their synergy (interaction between the factors meat and fibres) gives the best treatment outcome"
41352683|NCT00403689|DIETARY_SUPPLEMENT|Beta-D-Glucan|1,5 g Beta-D-Glucan daily
41493794|NCT03173144|OTHER|Other (exploratory) exposure variables|"* Lifestyle factors independently or combined (red and processed meat, vegetable, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/ fat, protein/ fat from red and processed meat, glucemic index)~* Pretreatment lifestyle-associated biomarkers~* Combinations of lifestyle factors and lifestyle-associated biomarkers~* Gene-environment interaction analyses~* Pretreatment levels of inflammatory molecules"
41352684|NCT00403689|DIETARY_SUPPLEMENT|placebo|1.5 g waxy maize starch daily
41352685|NCT01087073|BEHAVIORAL|Patient Activation|Culturally tailored patient activation training classes providing education and communication strategies to empower patients to be proactive in their diabetes self-management behavior. Participants attend a 10 week interactive class. Diabetes support groups after the completion of these classes help patient maintain self-management and adherence to healthy behaviors.
40833425|NCT02528357|DRUG|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
40833426|NCT02528357|DRUG|Pembrolizumab|Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
40833427|NCT02278614|DRUG|T2347|T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
40833428|NCT02278614|DRUG|Xalacom|Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
40833429|NCT00202033|BEHAVIORAL|frequency of self monitoring blood glucose|Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
41159659|NCT00577096|BIOLOGICAL|Autologous Peripheral Blood Stem Cell Transplantation|Standard PBSCT for multiple myeloma
41159660|NCT00577096|BIOLOGICAL|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
41159661|NCT00577096|DRUG|Thalidomide|Fifty percent of the participants received 400 mg daily
41159662|NCT00577096|DRUG|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
41159663|NCT00577096|BIOLOGICAL|Platelet Transfusion|Platelet transfusions were administered as needed
41159664|NCT00577096|DRUG|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
41159665|NCT00577096|DRUG|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
41352686|NCT01087073|BEHAVIORAL|Provider Training|Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.
41159666|NCT00577096|DRUG|Total Therapy II|Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
40833430|NCT03432416|DRUG|NES-E2 CVR|NES-E2 CVR
41020964|NCT03069690|BEHAVIORAL|HABITpreg|"Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
41020965|NCT03069690|BEHAVIORAL|HABITpost|"Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
41020966|NCT02693444|DRUG|Lidocaine|
41020967|NCT02693444|DRUG|Saline|
41020968|NCT00338026|DRUG|ECO-4601|Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
41020969|NCT03892941|DEVICE|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
41020970|NCT02158039|DRUG|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
41020971|NCT02158039|DRUG|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
41159667|NCT00577096|BIOLOGICAL|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
40833431|NCT02642965|DRUG|Cytarabine|Given IT or IV
41020972|NCT05008055|DRUG|Capivasertib|Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.
41159668|NCT00577096|DRUG|Thalidomide|Fifty percent of participants received 400 mg daily
41159669|NCT00577096|DRUG|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
41159670|NCT00577096|BIOLOGICAL|Platelet Transfusion|Platelet transfusions were administered as needed
41352687|NCT01087073|BEHAVIORAL|Quality Improvement|Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.
40833432|NCT02642965|BIOLOGICAL|Filgrastim|Given SC or IV
40833433|NCT02642965|DRUG|Fludarabine Phosphate|Given IV
40833434|NCT02642965|OTHER|Laboratory Biomarker Analysis|Correlative studies
40833435|NCT02642965|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
40833436|NCT02642965|OTHER|Pharmacological Study|Correlative studies
41352688|NCT01087073|BEHAVIORAL|Community Outreach|The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
41352689|NCT03079999|DRUG|Aspirin|Twice daily aspirin
41352690|NCT03079999|DRUG|Placebo|Twice daily placebo
41352691|NCT06172829|DEVICE|Advantage MX Module|no intervention will be provided.
41352692|NCT02525835|DIETARY_SUPPLEMENT|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
41159671|NCT00577096|DRUG|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
41352693|NCT02525835|DIETARY_SUPPLEMENT|High Dietary Sodium|Participants will be randomized to a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
41352694|NCT02814747|OTHER|quantitive study: 500 patients likely to be candidates for HTS|
41352695|NCT02814747|OTHER|qualitative study: 30 patients who have benefited from HTS|
41020973|NCT03402243|OTHER|Menthol ban on cigarettes|Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes
41020974|NCT03402243|OTHER|Menthol ban on cigarettes and e-cigarettes|Participants will have neither menthol flavored cigarettes or e-cigarettes available
41020975|NCT03402243|OTHER|No menthol ban|Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available
41020976|NCT03000465|PROCEDURE|Laparoscopic colorectal surgery|Minimizing intra-abdominal insufflation pressure in laparoscopic colorectal surgery as an individualized strategy
41020977|NCT06391827|DRUG|DA-7503 Single dose|Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).
41020978|NCT06391827|DRUG|DA-7503 Multiple dose|Oral administration once daily for 7 days; Dose strength or target volunteer is different for each cohort(Cohort 1,2,3, and 4)
41020979|NCT06391827|DRUG|Placebo Single dose|Oral administraion for once.
41352696|NCT01775995|BEHAVIORAL|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
41352697|NCT01775995|OTHER|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
41352698|NCT00428285|PROCEDURE|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
41352699|NCT03560479|DRUG|alpha1H, 7.4 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
41352700|NCT03560479|OTHER|placebo|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
41352701|NCT03560479|DRUG|alpha1H, 37 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
41352702|NCT03560479|DRUG|alpha1H, 74 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
41352703|NCT01620801|BIOLOGICAL|AAV8-hFIX19|One-time IV vector administration.
41020980|NCT06391827|DRUG|Placebo Multiple dose|Oral administration once daily for 7 days
41020981|NCT00597805|BEHAVIORAL|questionnaires/interviews|All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
41020982|NCT03832192|BEHAVIORAL|care.coach Avatar (HELP-Protocolized)|care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
41020983|NCT01334931|RADIATION|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
41020984|NCT01334931|RADIATION|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
41020985|NCT01079234|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily
41020986|NCT01079234|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
41352704|NCT00029666|DEVICE|Neopulse Magnetic Stimulator|
41352705|NCT06189027|DRUG|MDMA|Adjunctive administration of MDMA to assist psychotherapeutic process
41352706|NCT06189027|BEHAVIORAL|Psychotherapy|Psychotherapy aimed at assisting with PTSD symptom reduction
41352707|NCT04691622|BIOLOGICAL|Norovirus -specific T-cell (NST) therapy|"Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion."
41352708|NCT04778644|DRUG|CBD|Oral gel capsule CBD
41352709|NCT04778644|DRUG|Placebo|Oral gel capsule placebo
41352710|NCT00236574|DRUG|Galantamine hydrobromide|
41352711|NCT00528814|OTHER|Active Hand Sanitizer|Active Hand Sanitizer
41352712|NCT00316212|DRUG|INS50589 Intravenous Infusion|
40833437|NCT05927545|PROCEDURE|Patient education and preventive exercise|Educational training program and prevention exercises about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
40833438|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with Manual Therapy protocol|Manual therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
40833439|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with BETY approach|BETY therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
40833440|NCT03417817|DEVICE|Bravo|wireless pH monitoring over 96 hours
40833441|NCT04047420|DRUG|TAF/EVG Insert|TAF/EVG Insert (20/16 mg) administered rectally by study staff
40833442|NCT02593708|DRUG|Neratinib|
40833443|NCT02593708|DRUG|Paclitaxel|
40833444|NCT02593708|DRUG|Pertuzumab|
40833445|NCT02593708|DRUG|Trastuzumab|
40833446|NCT03167489|BEHAVIORAL|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
40833447|NCT01275092|DEVICE|CorPath robotic-assisted PCI|CorPath 200® robotic-assisted percutaneous coronary intervention
40833448|NCT05271825|DEVICE|Broadband amplification from hearing aids|Amplification from 125 Hz to 10 kHz
40833449|NCT05271825|DEVICE|Band-limited amplification from hearing aids|Amplification from 25 Hz to 3-4 kHz
40833450|NCT05942118|PROCEDURE|Breast conservative surgery|Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization
40833451|NCT00661388|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
41020987|NCT01079234|DRUG|insulin aspart|At least three daily doses at meal-time
41352713|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp.1: 3 mg/kg IV (single dose)
41159672|NCT04722848|DRUG|Ponatinib + Blinatumomab|"Patients aged 18-65 will receive Ponatinib at the dose of 45 mg/day for the first 22 days and then will reduce the dose to 30 mg (depending on the morphologic and molecular response), whereas patients older than 65 years will start Ponatinib at 30 mg/day, in order to avoid TAEs. Patients will continue treatment with Ponatinib up to day 70 (10 weeks of treatment), except for disease progression, intolerable toxicity, or withdrawal from study. Thereafter:~* Patients will receive Blinatumomab (minimum 2 cycles, up to a maximum of 5).~* Patients not achieving a CHR after 2 cycles of Blinatumomab will go off-study. After the 2 cycles of Blinatumomab patients aged 18-65 will be stratified for transplant allocation"
41020988|NCT06250725|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention protocol will include CBTi principles like stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring. It will be done over 6 weeks with one session weekly via videoconference.
40833452|NCT03442517|BEHAVIORAL|Behavior Lifestyle Intervention|Participants will be involved in group-based counseling. Sessions will be about 1 hour each and comprise up to 10 people. The sessions will be led by a trained health educator. The calls will be a chance for participants to discuss challenges with breastfeeding, problem solving skills, educational information, and discuss balanced diet topics.
41020989|NCT01351129|DRUG|Formulation 1|150-mg immediate release tablet (single dose)
41020990|NCT01351129|DRUG|Formulation 2|150-mg modified release capsule, short duration (single dose)
41020991|NCT01351129|DRUG|Formulation 3|150-mg modified release capsule, long duration (single dose)
41020992|NCT06131931|OTHER|CLP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Connecting Latinxs en Pareja (CLP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
41159673|NCT04722848|DRUG|Chemotherapy + Imatinib|patients aged 18-65 will receive chemotherapeutic scheme combined with Imatinib. Elderly patients will receive Imatinib plus mild chemotherapy.
41159674|NCT00994396|DIETARY_SUPPLEMENT|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
41159675|NCT00994396|DIETARY_SUPPLEMENT|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
41159676|NCT01911936|DRUG|LM716|
41159677|NCT02802579|RADIATION|standard protocol|tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
41159678|NCT02802579|RADIATION|enhanced protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
41159679|NCT02802579|RADIATION|enhanced obesity protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
41159680|NCT04604951|DEVICE|Transcutaneous Spinal Cord Stimulation|This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.
41159681|NCT03168425|OTHER|Tailored prescription|Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
41159682|NCT03168425|OTHER|Control|Participants will be prescribed 30 tablets of oxycodone 5mg
41159683|NCT05054517|DIETARY_SUPPLEMENT|Glutamine|Oral Supplement
41266545|NCT05773677|DIETARY_SUPPLEMENT|Specific Diet|"A specific diet will be developed for each patient, which will also take into account any food allergies or intolerances.~Each diet will be then eventually modified and revised throughout the pregnancy, according to the evolution of the same."
41352714|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 2: 15 mg/kg IV (single dose)
41352715|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 3: 30 mg/kg IV (single dose)
41352716|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 4: 3 mg/kg IM (single dose)
40833453|NCT03442517|OTHER|Usual prenatal care|Participants will receive the standard education given by their OBGYN or other healthcare provider. No additional breastfeeding, nutrition or postpartum weight loss education will be provided to participants by the investigators during pregnancy. After delivery, participants will follow normal pediatric visit schedule.
41352717|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp.5: 3 mg/kg IM (two doses)
41352718|NCT03066505|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
41352719|NCT03066505|DEVICE|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
41352720|NCT00933387|DRUG|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
41352721|NCT06435455|DRUG|GH21|GH21 Capsules, Oral Drug Specification: 3mg/capsule; 10mg/capsule
41352722|NCT06435455|DRUG|D-1553|D-1553 Film-coated Tablets, Oral Drug Sepcification: 200mg/tablet
41352723|NCT03681808|DEVICE|Control|Contact Lens
41352724|NCT03681808|DEVICE|Test|Soft Contact Lens
41352725|NCT05260476|OTHER|Reablement|The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.
41493795|NCT05275803|DIETARY_SUPPLEMENT|Probiotics|The participant would receive non-surgical periodontal treatment, after which the participant uses probiotics (BioGaia Prodentis, L. reuteri DSM 17938+L. reuteri ATCC 5289, 0.8g, qn) for another 30 days.
41493796|NCT05275803|DIETARY_SUPPLEMENT|Control|The participant does not use probiotics after non-surgical periodontal treatment.
41493797|NCT04331938|DRUG|Regional anesthetic SPG block-bilateral|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)
41493798|NCT02521935|DEVICE|Complete traditional dentures|"Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):~Appointment 1: Examination \& diagnosis \& initial impressions.~Appointment 2: Secondary impressions.~Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)~Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.~Appointment 5: Wax-trial denture try-in.~Appointment 6: Insertion and instructions for care of definitive prostheses.~Appointments 7-9 Post adjustments"
41493799|NCT02521935|DEVICE|Complete CADCAM dentures|"Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):~Appointment 1: Exam, diagnosis, \& tray selection (begin impressions)~Appointment 2: Definitive impressions and Maxillomandibula relations~Appointment 3: Wax-trial arrangement~Appointment 4: Insertion and instructions for care of definitive prosthesis~Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage"
41493800|NCT05255874|OTHER|Aromatherapy|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
41493801|NCT06057441|DEVICE|Auditory noise stimulation|Auditory white noise stimulation delivered at 78dB through earphones
41493802|NCT06057441|DEVICE|Visual noise stimulation|Visual white pixel noise stimulation, backgound pixel noise visible at computer screen
41493803|NCT01437943|DRUG|Aliskiren|Take 1 tablet (150 mg) by mouth daily for 180 days
41493804|NCT01437943|DRUG|Placebo|Take 1 tablet (0 mg) daily for 180 days.
41493805|NCT02181426|DRUG|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
41493806|NCT06262230|BEHAVIORAL|Online Inclusive Companionship Intervention|After prior intervention, professionals will conduct a lecture for ordinary children, which includes basic knowledge of ASD and communication skills with ASD children. These ordinary children will be paired with ASD children then. The entire intervention including 12 sessions will last for 3 months. Researchers will prepare a series of themes that the ASD children could choose, and the ordinary children need to ask their paired ASD children what activities they want to choose before each session. Then, they will carry out this entertainment online together through Tencent WeMeet. A researcher will supervise online at the same time and record the communication through instant video. The Researcher will turn off the video and sound throughout the process and will not intervene in the conversation between the ASD children and ordinary children except for special circumstances.
41493807|NCT02931903|OTHER|Vita Enamic (hybrid dental ceramic)|Vita Enamic (hybrid dental ceramic) are provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology,
40833454|NCT02696408|DEVICE|Laser treatment|"Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.~If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only."
41159684|NCT03383029|BEHAVIORAL|iEAT Program|The iEAT Program is a six-month long behavioral intervention consisting of 10 biweekly outpatient appointments of about 1 hour in length. The iEAT manual will guide behavioral intervention targeting severe feeding disorders and will involve some combination of escape extinction, reinforcement, and antecedent manipulation of food presentation to lessen the aversive quality of the meal.
41159685|NCT04184856|DIAGNOSTIC_TEST|fMRI|(Imaging while) performing reward related tasks.
41352726|NCT00041535|DRUG|OGT 918|
41352727|NCT00001302|DRUG|PSC 833|
41352728|NCT05158244|DRUG|PF-07081532|Study Drug, once daily for 42 days
41352729|NCT05158244|DRUG|Placebo|Placebo, once daily for 42 days
41352730|NCT01833026|DEVICE|Spirometry test|For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
41352731|NCT01833026|DRUG|Levalbuterol|The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
41352732|NCT02250586|BEHAVIORAL|CBT-CSO|Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
41159686|NCT01653093|PROCEDURE|3-Tesla magnetic resonance imaging (3T MRI)|Undergo 3T MRI
41352733|NCT02984735|OTHER|Evaluation|Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
41352734|NCT01637844|DRUG|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
41352735|NCT06374316|DEVICE|Ceiling-Mounted Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
41352736|NCT06374316|DEVICE|Portable Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
41352737|NCT06374316|DEVICE|Portable or Ceiling Mounted Air Purifiers|The Ceiling-Mounted and Portable devices will alternate weekly between being activated and deactivated in the three classrooms. Each classroom will also have three weeks with no purifier activated.This alternating pattern aims to assess the impact of the various air purifiers on air quality. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
41352738|NCT04408716|PROCEDURE|Ablation Index Guided High-Power Short-Duration Strategy|Point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
41493808|NCT02931903|OTHER|lithium disilicate glass-ceramic|All ceramic crowns (Lithium disilicate glass ceramic) milled by Computer aided design/Computer aided manufacturer (CAD/CAM) technology
41493809|NCT03077555|DRUG|Zoely|quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
41493810|NCT03077555|DRUG|Meliane ED|quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
41493811|NCT05779423|DRUG|Ipilimumab|Monoclonal antibody administered through intravenous infusion
41159687|NCT01653093|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
41159688|NCT01653093|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
41159689|NCT01653093|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo MR spectroscopy
41159690|NCT06330857|PROCEDURE|Laparoscopic vaginorectopexy|Modified laparoscopic anterior rectopexy for multiple pelvic prolapses
41159691|NCT00132925|DRUG|Triamcinolone|
41159692|NCT04428983|DIETARY_SUPPLEMENT|Hericium erinaceus mycelium|Hericium erinaceus capsules 3 tables per day for 24 months
41159693|NCT03974100|BIOLOGICAL|GP2411|60 mg /mL subcutaneous injection every 6 months
41159694|NCT03974100|BIOLOGICAL|EU-Prolia (EU-authorized Prolia®)|60 mg /mL subcutaneous injection every 6 months
41159695|NCT00069277|DRUG|E7389|
41159696|NCT00131183|DRUG|Nebido|
41159697|NCT03862105|OTHER|Mobile Health app tool - Twistle|The investigators propose to use radical cystectomy as a model to examine the utilization of an electronic, internet-based mobile health intervention that can prospectively collect Patient Reported Outcome data while providing timely feedback to patients and clinicians. This mobile health intervention will utilize a well-established platform (Twistle) that can be accessed through multiple technologies, including laptops, smartphones, and other computer-based systems.
41159698|NCT03857516|DEVICE|Multipolar left ventricular lead implantation|Multipolar left ventricular lead implantation with measurements of pacing thresholds in varrious pacing configurations.
41159699|NCT02657954|BEHAVIORAL|CCT|10-week Compensatory Cognitive Training
41159700|NCT02657954|BEHAVIORAL|HCE|10-week Holistic Cognitive Education
41493812|NCT05779423|DRUG|Nivolumab|Monoclonal antibody administered through intravenous infusion
41493813|NCT05779423|PROCEDURE|Cryoablation|Procedure of freezing a tumor performed via CT-guidance by interventional radiologist.
41493814|NCT03479567|OTHER|Gait accelerometry|accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)
41493815|NCT03479567|OTHER|balance accelerometry|accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
41493816|NCT03479567|OTHER|Fine motor skill test|assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual
41493817|NCT03479567|DIAGNOSTIC_TEST|Paratonia Assessment Instrument (PAI)|diagnosis of paratonia based on passive movement of the four limbs
41493818|NCT03479567|OTHER|myotonometric measurement of muscle tone|MyotonPRO measurement of muscle tone
41352739|NCT04408716|PROCEDURE|Standard Radiofrequency Ablation Technique|Point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
41352740|NCT02994576|DRUG|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
41493819|NCT02771886|BEHAVIORAL|Surf the Urge|"The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.~Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors."
41352741|NCT03187210|DRUG|Brentuximab Vedotin|Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
41352742|NCT03187210|DRUG|BeEAM Regimen|standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
41352743|NCT05823389|PROCEDURE|Re-instrumentation with flapless Emdogain application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD
41352744|NCT05823389|PROCEDURE|Re-instrumentation with placebo application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
41352745|NCT05520489|DEVICE|Repetitive Transcranial Magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. . Hot spot localization was performed by stimulation with 50%:n intensity and found the maximum response area, where the coil was placed using the navigator cursor. The motor threshold was found using Maximum-Likelihood Strategy -algorithm of MTAT system.~Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
41352746|NCT05520489|DEVICE|Robot Assisted Therapy|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
41352747|NCT05520489|OTHER|Enhanced upper limb therapy programme|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section.
41352748|NCT02403089|OTHER|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
41352749|NCT02403089|OTHER|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
41352750|NCT05539742|DIETARY_SUPPLEMENT|Coconut oil|Coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
41352751|NCT05539742|DIETARY_SUPPLEMENT|Palm oil|Palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
41352752|NCT05506813|OTHER|cognitive training and conventional training|cognitive training along with conventional therapy
41352753|NCT05506813|OTHER|motor dual task training along with conventional therapy|motor dual task training along with conventional therapy
41352754|NCT00002336|DRUG|Clarithromycin|
41352755|NCT00187733|OTHER|Fasting blood and urine collection|Not applicable no drugs dispensed
41352756|NCT00877890|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
41352757|NCT00877890|DRUG|exenatide twice daily|subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
41352758|NCT02425995|PROCEDURE|Arthroscopic intercondylar and posteromedial portal|Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
41352759|NCT05701475|PROCEDURE|Subcutaneous disinfection|After incision, the subcutaneous tissue will be disinfected for 60 seconds using iodine before continuing the surgical approach.
41352760|NCT05701475|PROCEDURE|Benzoyl peroxide preparation|In the days prior to surgery, the skin will be prepared using Benzoyl Peroxide gel according to a standardised protocol.
41352761|NCT04815291|DEVICE|Receives SCOUT at biopsy|SCOUT Reflector
41352762|NCT04411472|BIOLOGICAL|Recombinant human alkaline phosphatase|patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
41352763|NCT04411472|OTHER|Placebo|Placebo
41352764|NCT03491475|DRUG|Ajmaline test|Administration of Ajmaline
41159701|NCT03861585|OTHER|Semantic group|"The semantic task has to categorise semantically (i.e., type of contexts or type of objects) one image at each trial."
41020993|NCT06131931|OTHER|WP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Wellness Promotion (WP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
41020994|NCT01294618|DRUG|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
41352765|NCT01252927|OTHER|ASIST|The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
41352766|NCT04723303|DRUG|Umbilical Cord Lining Stem Cells|An IV infusion of ULSCs will be administered.
41352767|NCT04958551|OTHER|No intervention|No intervention
41493820|NCT03578666|OTHER|Massage|The intervention will be applied to both legs to a constant distal to proximal stroking rhythm. Firstly, participants will be lying in a prone position for 22 min: 1 min on the sole of the foot, 1 min on the Achilles tendon, 1 min on the soleus muscle, 3 min on the triceps muscle, 4 min on the hamstring muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings. Then they will assume a supine position for 18 min: 1 min on the sole of the foot, 3 min on the tibialis anterior and peroneus lateralis muscles and 4 min in the quadriceps, adductors and lata muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings.
41493821|NCT03578666|OTHER|Cold water immersion|The cold water immersion group immersed their lower limbs (ensuring that the iliac crests were fully immersed) in an ice bath filled with cooled water for 10 min. The water was maintained at a mean temperature of 10 degrees (±0.5°) by the addition of ice.
41493822|NCT06032403|BEHAVIORAL|flexible patient centred consultations|In the intervention group, the set-up will be flexible patient-centred consultations. The first consultation for the participant will be with the doctor and depending on the participant's need, the following consultations can be scheduled as either a doctor- or a nurse consultation. After each consultation, it will be decided in collaboration between the healthcare professionals and the participant whether a nurse or a doctor consultation will be relevant next. The consultations (whether it is with the doctor or nurse) will be centered around the participant's choice of topics by use of an atopic dermatitis dialogue tool developed in the department. Additionally, the nurse consultation will focus on therapeutic patient education (TPE) in atopic dermatitis. The interval between consultations will depend on the participant's need
41020995|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline + L-arginine|L-citrulline + L-arginine - sachet dissolved in water
41020996|NCT03378596|DIETARY_SUPPLEMENT|L-arginine|L-arginine - sachet dissolved in water
41020997|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline - sachet dissolved in water
41020998|NCT03378596|DIETARY_SUPPLEMENT|Placebo|Placebo (corn starch) - sachet dissolved in water
41020999|NCT04943926|OTHER|Energy restricted diet|Nutritional complete formula diet followed by an energy restricted diet
41021000|NCT04943926|OTHER|Low carbohydrate high fat diet|Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)
41159702|NCT03861585|OTHER|Emotional group|"The emotional task has to evaluate the emotional content (i.e., neutral, positive or negative) of one image at each trial."
41352768|NCT04062240|DEVICE|BIS sensor|BIS sensors will be labeled L and R. The degree of variability between the concurrent use of the sensors will be assessed .
41352769|NCT06274775|OTHER|Educational Video|Educational video about the nail biopsy procedure
41352770|NCT00166244|DRUG|Mycophenolate Mofetil|"1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma."
41352771|NCT02736149|DRUG|ubenimex|
41352772|NCT01009333|DEVICE|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
41352773|NCT01009333|DEVICE|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
41352774|NCT01009333|DEVICE|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
41352775|NCT05439629|DRUG|BAT5906 injection|4.0 mg/eye/time, 50 μl, intravitreal injection
41352776|NCT05439629|DRUG|Lucentis|0.5 mg/eye/time, 50 μl, intravitreal injection
41352777|NCT03704428|DRUG|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
41352778|NCT05209204|DIAGNOSTIC_TEST|ASOCT|Anterior segment imaging using RTVue XR 100 Avanti OCT platform (Optovue Inc.,Fairmont, CA).
41352779|NCT05209204|DIAGNOSTIC_TEST|Pentacam|Anterior segment imaging using Oculus Pentacam HR (Oculus Optikgeräte, Wetzlar, Germany).
41493823|NCT05876988|DEVICE|Chinese acupuncture|"Disposable acupuncture needles(0.30mm in diameter and 25-40mm in length) will be inserted at a depth of 10-30mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation was additionally delivered on the 6 pairs of the frontal acupoints. The output peak current and voltage of the machine would be 6V and 48mA, respectively, with constant wave at frequency of 2Hz and phase duration of 100µs for 30min. Electrical stimulation lasted 30min. The needles on body acupoints will be also retained for 30min.~Acupuncture intervention will be conducted for 2 sessions per week over 8 consecutive weeks. The determination of 8 weeks of the treatment duration will be based on the fact that the robust eﬀects of acupuncture in cancer patients will be generally observed within 8 weeks of treatment."
41493824|NCT02264288|BIOLOGICAL|3 x 10^6 cells|3 x 10\^6 cells administered on Study Days 1 and 8
41493825|NCT02264288|BIOLOGICAL|10 x 10^6 cells|10 x 10\^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
40833455|NCT02696408|DEVICE|Placebo|"Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.~If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only."
40833456|NCT06187168|PROCEDURE|exposure to hypotension during the Endoscopic Retrograde Cholangiopancreatography (ERCP) for obstructive jundice.|This is not an intended intervention in the study. This cohort study will study the exposure to intraoperative hypotension and the occurrence of sepsis after the ERCP procedures.
41493826|NCT02264288|BIOLOGICAL|30 x 10^6 cells|30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
40833457|NCT03845972|PROCEDURE|SSFTB|Patients who underwent major knee surgery and had already planned to perform subsartorial femoral triangle block (SSFTB) were included in the study. They were measured the outcomes the night before surgery. The saphenous nerve and nerve to vastus medialis were blocked at the subsartorial femoral triangle level by experienced anesthesiologists. After standard monitor, the distal femoral triangle was identified 2 cm proximal to the opening of adductor canal by ultrasound guidance. At this level, The location of nerve to vastus medialis was confirmed by nerve stimulator and it was blocked with 0.5% levobupivacaine 5 ml. Then, 0.5% levobupivacaine 10 ml would be injected perifemoral artery. The outcomes were re-assessed 30 min after block.
40833458|NCT03618940|BEHAVIORAL|Knowledge and Attitude on burn prevention|"1.Introduction to Home Safety~2 Fire Safety \& Burn Safety (Cooking Safety, Safety around Motorcycle Exhaust \&First Aid for Minor Burns~3 Electrical Safety (Safety around Electrical \& Appliances \& Outlets)~4 Firecrackers Safety (Safety around Firecrackers \& Open Flames)~5. Escaping from Fire (Escaping from Fire, Calling for Help, Stop, Drop \& Roll, Emergency Calling Number (By Fire Department Kuala Lumpur), Show equipment/gear that firefighters use, Demonstrate how to use the fire extinguisher, Crawl low in smoke"
40833459|NCT03419390|DEVICE|combined Coaxial Optical Coherence Tomography (OCT) System|The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
40833460|NCT00136825|DRUG|N-Acetylcysteine|
40833461|NCT00136825|DRUG|Placebo|
40833462|NCT04515953|DRUG|ND-340|ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
40833463|NCT04515953|DRUG|IV-PCA|IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
40833464|NCT04792333|DRUG|firibastat|Single oral dose of 500 mg administration on Day 1
40833465|NCT03730077|DRUG|18F-FMISO|18F-FMISO PET/CT
40833466|NCT05789186|DRUG|CAVO aromatherapy patch at 3% concentration+Fluoxetine hydrochloride mimetic|CAVO aromatherapy patch at 3% concentration enhances neuroelectrical activity in the brain (especially in the prefrontal cortex), exerting an antidepressant effect.Fluoxetine hydrochloride mimetic without drug treatment effect.
40833467|NCT05789186|DRUG|Fluoxetine hydrochloride tablet+CAVO aromatherapy patch at 0.1% concentration|Fluoxetine hydrochloride tablet was widely used selective 5-HT reuptake inhibitor (SSRI) that selectively inhibits the 5-HT transporter, blocks the reuptake of 5-HT by the presynaptic membrane, and prolongs and increases the effects of 5-HT, resulting in antidepressant effects.CAVO aromatherapy patch at 0.1% concentration without drug treatment effect.
40833468|NCT05789186|DRUG|Fluoxetine hydrochloride mimetic+CAVO aromatherapy patch at 0.1% concentration|Placebo without drug treatment effect
40833469|NCT00693472|DRUG|Preladenant|Preladenant, one 25 mg capsule, administered orally every 12 hours
41352780|NCT04091451|BIOLOGICAL|Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)|2 doses of the HZ/su vaccine in a 0,2 Months schedule, administered intramuscularly
40833470|NCT00693472|DRUG|Placebo|Matching placebo capsule administered orally every 12 hours
40833471|NCT00693472|DRUG|Anticholinergic agents or propanolol|"Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol."
40833472|NCT00693472|DRUG|Haloperidol|Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
40833473|NCT00376701|DRUG|Avastin (Bevacizumab)|Avastin 1.25 mg intravitreal
40833474|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
41352781|NCT04091451|DRUG|Placebo|2 doses of the placebo in a 0,2 Months schedule, administered intramuscularly
41352782|NCT06231251|OTHER|upper gastrointestinal endoscopy|reduction of ghrelin rich gastric mucosa with band ligation or argon plasma
41352783|NCT00471276|DRUG|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
41493827|NCT02264288|OTHER|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
41493828|NCT03258073|OTHER|Medical simulation using scenario execution|Each team of students will be exposed to simulation two times in a semester totaling to four times a year. In a scenario execution, participants are placed in a simulated experience of a medical emergency. Participants are required to respond and their reactions are observed by the investigators. After the experience, participants will have a debriefing session to learn from their experience of handling this emergency.
41352784|NCT03908866|OTHER|PICC(Peripherally inserted central catheter)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.
40833475|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
40833476|NCT00376701|DRUG|Bevacizumab|Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
40833477|NCT02225912|OTHER|PrevinC|
40833478|NCT02225912|DRUG|placebo|
40833479|NCT00228046|DRUG|Divalproex Sodium|
40833480|NCT00228046|DRUG|Methylphenidate|
40833481|NCT00228046|DRUG|Dextroamphetamine|
40833482|NCT00228046|DRUG|Mixed Amphetamine Salts|
41021001|NCT02283216|DEVICE|noise sound stimulation (Tucker-Davis Technologies)|Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
41021002|NCT02283216|DEVICE|body electrical stimulation (Digitimer device)|Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
41352785|NCT03908866|OTHER|CVC(Central venous catheter )|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, using the Seldinger technique. A suitable sterile field will be established.
41352786|NCT04041258|PROCEDURE|pseudoarthrosis of clavicle|Pseudoarthrosis represents a complication following a fracture, resulting in persistent symptoms and functional limitation, which prolongs the recovery time for the patient and necessitates new surgery. The purpose of surgery for pseudoarthrosis is to re-establish the length and alignment of the clavicle in an environment favorable to the union of bone fragments.
41352787|NCT02504957|PROCEDURE|Photodynamic therapy using polyhematoporphyrin|
41352788|NCT05804071|DRUG|Niferex|"Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions"
41352789|NCT04495322|DRUG|TG-1000|Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
41352790|NCT04495322|DRUG|Placebo|Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
41352791|NCT03799133|DEVICE|Florence device|The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
41493829|NCT05110482|DRUG|Syntocinon|uterotonic drugs
41493830|NCT05110482|DRUG|Carbetocin|uterotonic drug
40833483|NCT00228046|BEHAVIORAL|Family Counseling|
40833484|NCT00228046|BEHAVIORAL|Behavior Management Training with Parents|
40833485|NCT04095130|DIAGNOSTIC_TEST|23Na Magnetic resonance imaging|Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.
40833486|NCT00755547|OTHER|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
40833487|NCT00137189|PROCEDURE|Resource-oriented music therapy|
40833488|NCT00137189|PROCEDURE|Standard care|
40833489|NCT00764907|DRUG|asparaginase|Given IV during reinduction
40833490|NCT00764907|DRUG|cyclophosphamide|Given IV during reinduction
40833491|NCT00764907|DRUG|cytarabine|Given IV during reinduction
40833492|NCT00764907|DRUG|daunorubicin hydrochloride|Given IV during reinduction
40833493|NCT00764907|DRUG|dexamethasone|Given IV or orally during reinduction
40833494|NCT00764907|DRUG|doxorubicin hydrochloride|Given IV during reinduction
40833495|NCT00764907|DRUG|etoposide|Given IV during reinduction
40833496|NCT00764907|DRUG|ifosfamide|Given IV during reinduction
40833497|NCT00764907|DRUG|leucovorin calcium|Given IV during reinduction
40833498|NCT00764907|DRUG|mercaptopurine|Given orally during reinduction
41021003|NCT02283216|DEVICE|transcranial magnetic stimulation (Magstim)|Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
41021004|NCT00263692|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3|
41021005|NCT01184352|DEVICE|TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
41159703|NCT02672514|DEVICE|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
41159704|NCT02672514|DEVICE|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
41352792|NCT01601093|DRUG|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
41352793|NCT01601093|DRUG|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
41352794|NCT01601093|DRUG|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
41493831|NCT04959318|OTHER|Professional nutrition counseling|Published multi-cohort genome-wide association studies provided genes and genetic variants that are credibly associated with aspects of metabolic syndrome (MetS), CVD, overweight/obesity, and vitamin D metabolism. Registered dietitian (RD) counseling will review potentially harmful and protective variants for risk of MetS with subjects and make evidence-based recommendations to improve diet quality and achieve weight loss goals. Each of the 6 weekly sessions covered a specific component of MetS. Counseling will take place once a week either in-person or via phone/virtual platform based on preference and availability of the subject. Counselors will review digital app data entries for food intake prior to this interaction for the first 2 weeks.
41493832|NCT04959318|OTHER|No professional nutrition counseling|Participants receive pamphlets with evidence-based general health, healthy nutrition, exercise and sleep content. They receive information on genetic variants related to MetS at end of study period.
41493833|NCT02632461|BEHAVIORAL|Podcasts|Participants will receive twice weekly podcasts that will cover topics related to weight loss.
41493834|NCT02632461|BEHAVIORAL|Mobile Diet Application|Participants will use a mobile application on their smartphone to track their diet.
41493835|NCT02632461|BEHAVIORAL|Bite Counter|Participants will use a wrist-worn Bite Counter to track the number of bites in their diet per day.
41493836|NCT05739214|DEVICE|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
40833499|NCT00764907|DRUG|methotrexate|Given orally during reinduction
40833500|NCT00764907|DRUG|prednisone|Given intrathecally during reinduction
40833501|NCT00764907|DRUG|thioguanine|Given orally during reinduction
40833502|NCT00764907|DRUG|vincristine sulfate|Given IV during reinduction
41352795|NCT04681573|DIAGNOSTIC_TEST|blood tests|"Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day."
41352796|NCT01132391|DRUG|Rectogesic® (glyceryl trinitrate 0.4% ointment)|375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
41352797|NCT05960656|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
41352798|NCT05960656|OTHER|Placebo|Inert tablet
41352799|NCT05960656|DRUG|Pioglitazone 30mg|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinedione class of medications
41352800|NCT05960656|DRUG|Pioglitazone 30mg + Empagliflozin (25 mg)|Combination of two medications used in the management and treatment of type 2 diabetes mellitus in the thiazolidinedione and sodium-glucose co-transporter (SGLT-2) class of medications, respectively.
41159705|NCT01549249|DEVICE|optical coherence tomography|spectral-domain optical coherence tomography
40833503|NCT00764907|DRUG|vindesine|Given IV during reinduction
41159706|NCT00635011|BEHAVIORAL|psychotherapy|Cognitive Behavioral therapy
41159707|NCT00329498|DRUG|L-Ascorbic Acid|
41352801|NCT03800758|BEHAVIORAL|Expressive Helping|Expressive Helping (EH) is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using previously-tested EH instructions, adapted for this population.
41352802|NCT03800758|BEHAVIORAL|Factual Writing|Factual Writing has been used with cancer patients and in the investigators' prior EH trial. It is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using standard Factual Writing instructions.
41352803|NCT05008718|OTHER|38% SDF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
41352804|NCT05008718|OTHER|5% NaF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
40833504|NCT04724330|BEHAVIORAL|Healthy for Two/Healthy for You|\~10 month (early pregnancy to 12 weeks postpartum), remotely-delivered, behavioral lifestyle intervention including health coach contacts (via phone, videoconference, and email/MyChart) and an interactive web-based platform.
40833505|NCT01747200|PROCEDURE|Sham rTMS|
41493837|NCT02393443|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
41493838|NCT02393443|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
41493839|NCT05003934|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
40833506|NCT01747200|PROCEDURE|Bilateral rTMS at same frequency and in phase|
40833507|NCT01747200|PROCEDURE|Bilateral rTMS at different frequencies|
41159708|NCT04186117|OTHER|Blood sample|Blood sample before any treatment
41159709|NCT03802487|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
41352805|NCT03653286|OTHER|NMES and Run|"NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance."
41352806|NCT03653286|OTHER|Only Run|RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
41159710|NCT03802487|DRUG|14C-microtracer|"Pharmaceutical form: Solution for injection~Route of administration: Intravenous"
41352807|NCT05066802|DRUG|neoadjuvant modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks) before surgery.
41493840|NCT04008654|BEHAVIORAL|ERAS Protocol|"Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
41493841|NCT04008654|BEHAVIORAL|Conventional care|This group of patients will not receive the specific ERAS protocol but will receive conventional care.
41493842|NCT05484037|OTHER|CANATEXTS|Canadian Asthma Text Messaging (CANATEXTS) is a TH intervention facilitating access to an electronic AAP (eAAP) via a mobile device.
41493843|NCT00132028|DRUG|vorinostat|Given orally
41493844|NCT00132028|OTHER|laboratory biomarker analysis|Correlative studies
41493845|NCT01058460|PROCEDURE|HPV-cytology co-testing|Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
41493846|NCT03839030|OTHER|MBHP-Educa|This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
41493847|NCT00001365|DRUG|dextromethorphan|
41493848|NCT00000717|DRUG|Primaquine|
41493849|NCT00000717|DRUG|Clindamycin|
41493850|NCT05009680|DRUG|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day
41493851|NCT05009680|DRUG|Placebo|Placebo is administered orally twice a day
41493852|NCT02044406|DRUG|BI 1181181|single dose (low to high dose)
41493853|NCT02044406|DRUG|BI 1181181, R|powder for oral solution
41493854|NCT02044406|DRUG|BI 1181181, T2|tablet, fasted
41493855|NCT02044406|DRUG|Placebo to BI 1181181|Placebo to BI 1181181
41493856|NCT02044406|DRUG|BI 1181181, T1|tablet, fed
41493857|NCT04589416|OTHER|Dental adhesive materials.|It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.
40833508|NCT01747200|PROCEDURE|Bilateral rTMSat same frequency and out of phase|
41493858|NCT00002752|RADIATION|iodine I 131 monoclonal antibody 81C6|
41493859|NCT03870867|OTHER|No intervention|No intervention
41493860|NCT01682616|DRUG|ABT-199|ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
40833509|NCT01747200|PROCEDURE|rTMS over TP8|
40833510|NCT01747200|PROCEDURE|rTMS over TP7|
40833511|NCT03452033|DRUG|H-1337 Placebo|H-1337 Placebo Vehicle
41493861|NCT01682616|DRUG|Rituximab|Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
41493862|NCT03503526|BEHAVIORAL|Receptive music therapy|12 weekly trauma-focused Group therapy sessions of a length of 2.5 hours. The core element is receptive music psychotherapy with music listening, art making, and other art based methods.
41493863|NCT05097313|DIETARY_SUPPLEMENT|Yeast β-glucan fiber|The study is designed to determine if β-glucan is safe and if it presents an antioxidant and immunomodulatory response in healthy adults in Colombia.
41493864|NCT05097313|OTHER|Placebo|oral consumption of 200 mg (one capsule) or 400 mg (two capsules) of soy protein powder for 84 days.
41493865|NCT00144911|DRUG|Salmeterol|
40833512|NCT03452033|DRUG|H-1337 [1]|H-1337 Ophthalmic Solution Concentration 1
41493866|NCT00144911|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
41493867|NCT04166448|OTHER|Fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
41493868|NCT02392351|DEVICE|Renal Denervation (Vessix)|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
41493869|NCT02392351|DEVICE|Renal Angiography|Percutaneous renal angiography
40833513|NCT03452033|DRUG|H-1337 [2]|H-1337 Ophthalmic Solution Concentration 2
40833514|NCT03452033|DRUG|H-1337 [3]|H-1337 Ophthalmic Solution Concentration 3
40833515|NCT03738319|GENETIC|Sequencing of miRNA/lncRNA|Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
40833516|NCT01983280|OTHER|Healing Touch|
40833517|NCT06458244|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
40833518|NCT06458244|DRUG|Chemotherapy|Chemotherapy for AML consolidation treatment
41159711|NCT03802487|DRUG|Charcoal|"Pharmaceutical form: Granules for suspension~Route of administration: Oral"
41352808|NCT00901849|DRUG|Tarceva and Rapamycin|Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
40833519|NCT04981028|OTHER|Questionnaires (including PHQ-9, TYM and SF-36)|For the acute group, a questionnaire is completed on neurological symptoms at presentation plus specific questions to include brain imaging performed, treatments received and whether they survived the hospital admission (AQ1). There will be a healthcare practitioner led questionnaire (AQ2) and 3 patient led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (AQ3) completed at 1 week, 1 month, 3 months, 6 months and 12 months following diagnosis. For the chronic TTP group, participants will have a questionnaire completed (CQ1) and 3 patient-led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (CQ2). Where neurological symptoms are present, questionnaires will be completed 6 monthly; where there are no neurological symptoms questionnaires are completed every 12 months. The healthy volunteers will complete participant led questionnaires (namely PHQ-9, TYM, SF-36) plus a supplementary baseline questionnaire at two time points 12 months apart.
41352809|NCT03847272|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4 and W16)
40833520|NCT04243395|OTHER|Pork|1 oz lean pork
40833521|NCT04243395|OTHER|Egg|1 large whole egg
41021006|NCT05572905|OTHER|Exercise|Patients after overnight fast will cycle on ergo-meter for 60 minutes. No per-oral food intake will be allowed during the test. Level of the intensity of exercise will be determined as individual range of heart frequency (HF), oxygen consumption (VO2) and respiratory quotient (RQ) just bellow the aerobic threshold of the given participant (close to anticipated fatmax). These values will be obtained during maximal capacity stress test on cyclo-ergo-meter. This maximum stress test will be performed at least one week prior to the 60 minutes exercise to eliminate potential carry-over effect. Power output will be modulated during the 60 minutes of exercise to ensure keeping participants values of HF, RQ and VO2 in the given range. Blood will be sampled at 5 time points with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-exercise.
40833522|NCT04243395|OTHER|Black beans|0.5 cups cooked black beans
40833523|NCT04243395|OTHER|Almonds|0.5 oz almonds
40833524|NCT04086446|DEVICE|high-definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
40833525|NCT04086446|DEVICE|Sham tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the first and last 15 seconds.
40833526|NCT04665115|DRUG|Ibrutinib|Given PO
40833527|NCT04665115|OTHER|Quality-of-Life Assessment|Ancillary studies
40833528|NCT00596141|DEVICE|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
40833529|NCT00288457|DEVICE|Ureteral Stent|Ureteral stents are not investigatory but rather part of standard of care. In this study, we were interested in having patients fill out pre and post-operative questionnaires so that we could compare their symptoms with the length of their ureter and the stent placed.
40833530|NCT06508931|DRUG|zamtocabtagene autoleucel (MB-CART2019.1)|Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.
40833531|NCT03324919|BEHAVIORAL|HRQL|Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
41021007|NCT05572905|OTHER|Fasting control|The same participants will be monitored while resting for 120 minutes in calm environment. No peroral food intake will be allowed during the test. Fasting control will take place at least one week apart of the exercise. Blood will be sampled at 5 timepoints with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-control.
40833532|NCT05952401|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (patient smoking cessation handout and brief advice).
40833533|NCT05952401|BEHAVIORAL|"Nudges"|"Patients in the experimental arm will receive practice guidelines (patient smoking cessation handout and brief advice) and Nudges to Quit, guideline-informed messages immediately following patient tobacco treatment needs assessment."
41021008|NCT01019681|BIOLOGICAL|Cord blood stem cell injection|"The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois)."
41352810|NCT03847272|OTHER|Ophthalmologic examination|Best corrected visual acuity (BCVA) testing, Slit Lamp Exam, tonometry, dilated indirect ophthalmoscopy, optical coherence tomography (OCT), Fluorescein angiography and Indocyanin green angiography
41352811|NCT03847272|OTHER|Questionnaires|VFQ-25 and SF-36
40833534|NCT04214886|DRUG|Fludarabine|Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.
40833535|NCT04214886|DRUG|Cyclophosphamide|Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
40833536|NCT04214886|BIOLOGICAL|CD19-CD34 CAR transduced T cells|CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.
40833537|NCT01352637|DRUG|DCS (D-Cycloserine ) + Prolonged Imaginal Exposure|50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
40833538|NCT01352637|DRUG|DCS (D-Cycloserine ) + Virtual Reality Exposure|50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
41352812|NCT03847272|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
41352813|NCT04218513|DRUG|Compound Edaravone Injection|30 min intravenous infusion
41352814|NCT04218513|DRUG|Edaravone Injection|30 min intravenous infusion
41352815|NCT04218513|DRUG|2-Aminoethanesulfonic Acid Injection|30 min intravenous infusion
40833539|NCT01352637|DRUG|Placebo + Prolonged Imaginal Exposure|Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
40833540|NCT01352637|DRUG|Placebo (sugar pill) + Virtual Reality Exposure|Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
40833541|NCT01180517|PROCEDURE|Percutaneous coronary intervention (PCI)|balloon angioplasty
41021009|NCT06111092|OTHER|Design Thinking|Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.
41021010|NCT06111092|OTHER|Focus Groups|Participants attend the FG that includes the introduction. discussion, and reflection.
41352816|NCT02265445|DRUG|Deescalation therapy|Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
41352817|NCT02265445|DRUG|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
41021011|NCT04132349|DRUG|Ulipristal Acetate 5 mg|Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
41021012|NCT03526224|DRUG|Dimethyl Fumarate|Individuals with MS treated with dimethyl fumarate (Tecfidera)
41021013|NCT03526224|DRUG|Teriflunomide|Individuals with MS treated with teriflunomide (Aubagio)
41352818|NCT01335438|DEVICE|Cementless (Nexgen)|Cementless fixation of Nexgen CR TKR
41352819|NCT01335438|DEVICE|Cemented (Nexgen)|Cemented fixation of Nexgen CR TKR
40833542|NCT01180517|PROCEDURE|PCI|balloon angioplasty
40833543|NCT01676519|PROCEDURE|PCI|percutaneous coronary intervention
41021014|NCT05012592|BEHAVIORAL|Health Awareness Program TO Reduce Malnutrition and Helminth Infestation among Primary School children|This interventional study period started from September 2021 up to September 2022 (13 months) by school nurses to implement HAPSC. After completing four to five months of the educational session the school nurse will collect midline follow-up data and the endline data will be collected at the end of the interventional study. In this period a total of nine months (except annual leave) will be considered an interventional education period. The intervention group will receive one educational session per week every month. School nurses will be assigned for each class to provide health education. Each session will be conducted for a maximum of 45 minutes. The community worker will be assigned to assist the school nurse and they will communicate with the child's parents about their child's healthy nutrition and good hygiene practice. The significance of healthy eating and hygiene behavior for the children will be shared with the child's parents or guardians properly.
41021015|NCT01151241|PROCEDURE|Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.|Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
41021016|NCT01151241|OTHER|Early Discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
40833544|NCT03755232|DIETARY_SUPPLEMENT|scFOS|Fossence™ (short chain Fructo-oligosaccharides (scFOS)
40833545|NCT03755232|OTHER|Control|water or dextrose or white bread
40833546|NCT00831701|DRUG|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
40833547|NCT00831701|DRUG|Placebo|One placebo pill per day for 21 days or until stone expulsion
40833548|NCT02534662|DEVICE|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
40833549|NCT03458702|BEHAVIORAL|YogaFit|For YogaFit Vinyasa Flow (referred to as YogaFit in this manuscript)\], participants followed, via digital versatile disc, a standardized YogaFit format choreographed by an American Council of Exercise Certified and Registered Yoga Teacher (RYT). YogaFit was performed in the same laboratory setting and lasted 30 min. YogaFit is a westernized version of yoga that does not use Sanskrit terms (Shaw 2009). Breath was an integral part of every movement with specific breath rates for each phase of the session. The objective was to move the body with intention and purpose and be present in the body.
41021017|NCT01151241|OTHER|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
41021018|NCT04120389|DEVICE|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)|wear an bandage contact lenses for a week after Complicated and Combined cataract surgery.
41352820|NCT02187133|DRUG|Carfilzomib|"Given IV; Dose Level (DL)~Twice Weekly:~DL -1 and DL 1: 15 mg/m\^2~Weekly:~DL 1.5: 20,27,27 mg/m\^2, DL 2: 20,36,36 mg/m\^2, DL 3: 20,56,56 mg/m\^2 DL 4: 20,70,70 mg/m\^2"
41352821|NCT02187133|DRUG|Bendamustine|"Given IV; Dose Level (DL)~DL -1: 75 mg/m\^2 DL 1,1.5, 2, 3, and 4: 90 mg/m\^2"
41352822|NCT02187133|DRUG|Rituximab|Given IV; 375 mg/m\^2
41352823|NCT00971191|DRUG|PF-00299804|Brief exposure (5- 11 days) to study drug prior to surgical resection
41352824|NCT06399068|DRUG|CKD-387|1 Tablet
41352825|NCT06399068|DRUG|D484|1 Tablet
40833550|NCT03458702|BEHAVIORAL|Quiet Rest|Participants completed 30 min of quiet rest
40833551|NCT00002762|BEHAVIORAL|patient interviewing to obtain menstrual history|
40833552|NCT00002762|PROCEDURE|blood sampling|
41352826|NCT06186089|DIETARY_SUPPLEMENT|probiotics|patients undergoing total gastrectomy take probiotics qd for 3 months
41352827|NCT00519571|DEVICE|ImplantLock device|dental implant
41352828|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
41352829|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
41352830|NCT03289494|OTHER|Balanced diet high in Slowly Digestible Starch|The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
41352831|NCT03289494|OTHER|Balanced diet low in Slowly Digestible Starch|The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
41352832|NCT04525911|DIAGNOSTIC_TEST|Diagnostic Test: serology test for COVID-19|a serology test will be performed at M3
40833553|NCT05157347|OTHER|Robot-assisted Training|The gait training in this study uses an exoskeletal wearable robot (Product name: ANGEL LEGS M20, Angel robotics, Co., Ltd.) consisting of a wearable part, a hip or knee joint gear providing the auxiliary force, and a controller backpack. This product is a powered orthopedic device for gait rehabilitation and treatment such as the lower limb muscle reconstruction and joint motion recovery in patients or handicapped individuals. The product consists of a power part, a controller part and a gear part, while the device is powered by an electric motor and the device motion induces the gait posture to support the lower limbs and allow the gait training to be performed.
41021019|NCT04120389|PROCEDURE|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
40833554|NCT05157347|OTHER|Conventional Therapy|The conventional gait rehabilitation has been performed as a 1:1 training session between the therapist and a stroke patient.
40833555|NCT02321891|DEVICE|NeuroConn DC Stimulator Plus, tDCS|transcranial electrical stimulation intervention with two experimental protocols
40833556|NCT04190004|DRUG|Vasopressins|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
40833557|NCT04190004|DRUG|Placebo|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
40833558|NCT05750433|DIETARY_SUPPLEMENT|PreforPro+B. subtilis DE111 probiotics|PreforPro is bacteriophage-based product which was used in combination with Bacillus subtilis probiotics.
40833559|NCT05750433|DIETARY_SUPPLEMENT|Placebo|Maltodextrin is rice based powder which was used as placebo.
40833560|NCT05750433|DIETARY_SUPPLEMENT|B. subtilis DE111|Bacillus subtilis probiotics.
40833561|NCT03302455|BEHAVIORAL|eCBTI|The brief eCBTI contains a one-week core course: sleep hygiene education, sleep restriction, stimulus control, relaxation audios, cognitive components, information about sleeping pills, and a brief overview. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
41021020|NCT06121882|DEVICE|Microfragmented Adipose Tissue derived using the Lipogems® System|Intra-articular knee injection of Microfragmented Adipose Tissue (MFat) derived using the Lipogems® System.
41493870|NCT00006216|BIOLOGICAL|PA-1-STK ovarian carcinoma vaccine|
41493871|NCT00006216|DRUG|ganciclovir|
41493872|NCT01983709|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10\^6 cells/kg or a maximum dose of 1 x 10\^8 total cells IV 4 days prior to undergoing a planned prostatectomy.~The remaining subjects will receive a single dose of 2 x 10\^6 cells/kg or a maximum dose of 2 x 10\^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy."
41493873|NCT02633488|DRUG|Placebos|A 12 week single blind placebos
40833562|NCT05019989|BEHAVIORAL|Intervention group on diet and physical activity|"The intervention wanted to increase physical activity, controlling weight, promoting healthy diet.~1. Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week~2. Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables~3. Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)"
40833563|NCT05019989|BEHAVIORAL|Control group: only public recommendation an lifestyle|"1. Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~2. Dissemination of the information on the study by media~3. Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
40833564|NCT01428336|PROCEDURE|1 ug ACTH stimulation test|1 ug cortrosyn dose
40833565|NCT01428336|PROCEDURE|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
41021021|NCT06121882|DRUG|Saline Injection|Intra-articular knee injection of saline
41021022|NCT00699881|DRUG|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
41021023|NCT06368583|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of vaginal delivery with neuraxial analgesia
41021024|NCT05691075|PROCEDURE|Arthrodesis of the metatarsophalangeal joint|Isolated surgery of the first ray of hallux valgus, hallux varus or hallux rigidus by percutaneous or conventional approach
41021025|NCT05438953|BIOLOGICAL|Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)|Participant of these arm will receive 2 doses of MVA vaccine spaced 28 days apart
41159712|NCT05393388|DRUG|[18F]AV-1451|\[18F\]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.
41159713|NCT02950870|DRUG|Ombitasvir-Paritaprevir-Ritonavir|The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose
41493874|NCT02633488|DRUG|metformin|A 12 week single blind metformin
41493875|NCT00568815|DRUG|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
41493876|NCT00426712|BIOLOGICAL|1018 ISS immunostimulatory oligonucleotide with HBV surface antigen|Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8
41493877|NCT00426712|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
41493878|NCT06033092|DRUG|Tamoxifen 10 mg Tablet|One tablet of Tamoxifen 10 mg every other day for 6 months
40833566|NCT01428336|PROCEDURE|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
41493879|NCT06033092|OTHER|Intermittent caloric restriction|"5:2 diet: 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)"
41493880|NCT06033092|BEHAVIORAL|Step counter Device|Participants will receive personal advice on healthy lifestyle and a step counter
41352833|NCT05619432|DEVICE|HMD: Immersive VR|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~STIMULATION:~One or more of the spheres is temporarily cued (target). Then all spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using a laser pointer, the initially cued target(s) among the eight spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
41352834|NCT01610414|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
41493881|NCT00737152|OTHER|RAS 130 with diet and exercise|Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
41493882|NCT00080314|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
41021026|NCT02443038|OTHER|Yoga|"16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.~The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups."
41021027|NCT04206163|DIAGNOSTIC_TEST|68Ga-DOTA-TOC PET/CT|Somatostatin receptor imaging
41352835|NCT01610414|BIOLOGICAL|Placebo|2 doses administered IM in deltoid region of non-dominant arm
41352836|NCT04995042|DRUG|SHR7280|Drug: SHR7280 All participants receive SHR7280 alone.
41352837|NCT03549585|OTHER|Criteria for Screening and Triaging to Appropriate aLternative care|CriSTAL Tool (Criteria for Screening and Treatment of Appropriate Long-Term Care) is a multidimensional geriatric tool that lists 18 elements of the literature, under construction and validation by an Australian retrospective study. This tool is a practical questionnaire and easy to use in current care, with items adapted to the geriatric dimension. The investigators chose to target hospitalized geriatric patients through emergencies.
41493883|NCT00080314|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
41493884|NCT00578669|DRUG|Fluoxetine|20mg once daily for 16 weeks
41021028|NCT04206163|BIOLOGICAL|Blood sample|Analysis of inflammatory biomarkers
41021029|NCT02811198|OTHER|No intervention|
41352838|NCT05944861|OTHER|Combined ultrasonography and flouroscopy guided injeciton|In the ultrasound+fluoroscopy group, the sacroiliac injection will be started under ultrasound guidance. With the help of ultrasound, when sacral 2 foramen is seen the needle will be advanced to the entrance of the sacroiliac joint under real-time in-plane view. After considering intra-articular placement, fluoroscopy guidance will be initiated. An anteroposterior image will be taken to confirm whether contrast material is within the joint. If intra-articular placement is not achieved after contrast medium infiltration, needle reposition will be performed under fluoroscopy for correct needle placement. After the intraarticular contrast pattern is seen, 1 ml of 40 mg methylprednisolone + 1 ml of 1% lidocaine mixture will be injected.
41352839|NCT05944861|OTHER|Flouroscopy guided injection|In the fluoroscopy group, the advancement of the needle into the sacroiliac joint will be performed by taking anteroposterior and lateral views. In the same way, the needle tip will be placed in the inferior of the sacroiliac joint, and contrast material distribution examination and injection of the drug will be performed as in the ultrasound + fluoroscopy group.
41352840|NCT01320033|DRUG|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
41493885|NCT00578669|DRUG|Dextrose|Once daily for 16 weeks
41493886|NCT04617054|DRUG|AB-106|600mg QD for each subjects.
41493887|NCT05185401|OTHER|Observational study|Retrospective data-analysis
41493888|NCT02835781|OTHER|Acellular dermal matrix implantation|Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
41493889|NCT03220061|BEHAVIORAL|music therapy|
41493890|NCT00144261|DRUG|nevirapine|
41493891|NCT03744663|DRUG|Suboxone® SL|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized to two groups one of which will be Suboxone® SL.
41021030|NCT03812718|DEVICE|Endotracheal tube (ETT)|After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
41021031|NCT03812718|DEVICE|ProSeal Laryngeal Mask Airway (PLMA)|After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
41352841|NCT01320033|DRUG|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
40833567|NCT01428336|PROCEDURE|Insulin tolerance test|subjects will undergo an insulin tolerance test
40833568|NCT01032317|DEVICE|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
40833569|NCT05014113|DEVICE|DELTA-ST cup in combination with MINIMA stem|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
40833570|NCT00487643|PROCEDURE|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
40833571|NCT05995041|BIOLOGICAL|CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells|Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
40833572|NCT03294629|DEVICE|SensAwake™ modification|SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
40833573|NCT02844283|DRUG|Ad-HGF|
40833574|NCT02844283|OTHER|0.9% NaCl|
40833575|NCT05532267|DRUG|Ciprofloxacin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
40833576|NCT05532267|DRUG|Ciproxin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
40833577|NCT04138719|DRUG|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
40833578|NCT04138719|DRUG|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and epirubicin given IV at 75 mg/m\^2 on days 1 every 21 days x 6 cycles；
41352842|NCT01320033|DRUG|Placebo|Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
40833579|NCT00287794|DRUG|diazepam, melatonin|Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
40833580|NCT03785587|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
41021032|NCT00585065|DEVICE|CRT device implant|The purpose of this study is to collect information on patients with chronic heart failure who have already been identified by their physician as candidates for CRT. All tests, including device implantation are standard of care for patients undergoing CRT. The only test involved in this study that is not standard of care is the quality of life questionnaire. Patients who undergo CRT system implant will be followed post-implant (up to 1 week), and at one month, three months, six months and twelve months. The only test involved in this study that is not standard of care is the quality of life questionnaire.
41021033|NCT00139997|DEVICE|Litebook treatment devices|Litebook LED phototherapy device used for 30 min before 8 am
41021034|NCT00139997|DEVICE|Inactivated negative ion generator|Equivalent exposure to inactivated negative ion generator
41352843|NCT02424890|OTHER|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
40833581|NCT02038660|DEVICE|Balloon angioplasty|
40833582|NCT01694277|DRUG|Masitinib|12 mg/kg/day
40833583|NCT01694277|DRUG|Sunitinib|50 mg/day
40833584|NCT00003825|DRUG|pentosan polysulfate sodium|
41021035|NCT00818441|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
41021036|NCT00818441|DRUG|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
41352844|NCT04839211|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the highest tolerable load and will be gradually increased.
40833585|NCT00003825|PROCEDURE|quality-of-life assessment|
40833586|NCT00206284|DRUG|AZD0865|
40833587|NCT02291393|DEVICE|80 lead ECG|
40833588|NCT03662659|BIOLOGICAL|BMS-986213|Relatlimab + Nivolumab specified dose on specified days
40833589|NCT03662659|BIOLOGICAL|Nivolumab|Specified dose on specified days
40833590|NCT03662659|DRUG|XELOX|Oxaliplatin + capecitabine
40833591|NCT03662659|DRUG|FOLFOX|Oxaliplatin + leucovorin + fluorouracil
40833592|NCT03662659|DRUG|SOX|Oxaliplatin + tegafur/gimeracil/oteracil potassium
40833593|NCT01024491|DRUG|paroxetine|daily dose of paroxetine 15mg for 12 weeks
40833594|NCT01024491|DRUG|paroxetine|active daily treatment with paroxetine 20 mg
40833595|NCT01024491|DRUG|placebo|active daily treatment with placebo
40833596|NCT05896852|BEHAVIORAL|physical activity|Participants will increase their physical activity through walking.
40833597|NCT01473095|DRUG|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
41493892|NCT03744663|DRUG|Sublocade®|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized, either Suboxone® SL or Sublocade®. Subjects with significant opioid craving (\> 20 mm on the Opioid Craving Visual Analog Scale) or withdrawal (a score of \> 12 on the Clinical Opiate Withdrawal Scale) after 14 days of treatment will be started on Sublocade® only at the consensus of the research team. Otherwise they will undergo an additional 7 day titration period. Study drug with Sublocade® group: Patients assigned to this group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. The location and specifications of its application will follow the recommendations by the FDA previously published.
41493893|NCT03360084|PROCEDURE|Percutaneous lung biopsy under CT guidance|Percutaneous lung biopsy under CT guidance
40833598|NCT02475616|DRUG|PCO371|
40833599|NCT02475616|DRUG|Placebo|
40833600|NCT01547312|DRUG|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
41021037|NCT01701466|OTHER|Aveeno cream|Twice a day
41021038|NCT01701466|OTHER|Flamazine cream|Twice a day, when there is dry desquamation
41021039|NCT01701466|OTHER|NeoVIDERM cream|Three times a day
41159714|NCT02950870|DRUG|Dasabuvir|The patient will be treated daily with Dasubavir 500 mg total dose
40833601|NCT01547312|PROCEDURE|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
40833602|NCT01547312|PROCEDURE|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
41352845|NCT04839211|DEVICE|Sham inspiratory muscle training|Sham inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the unloaded.
40833603|NCT01547312|PROCEDURE|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
41021040|NCT01700946|DRUG|dexamethasone|given intravenously or orally
41352846|NCT04087967|DRUG|Decitabine plus HAAG regimen|"Decitabine:20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~16,intravenous infusion; Aclarubicin:10mg/d, d3\~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
41021041|NCT01700946|DRUG|vincristine sulfate|given intravenously
41021042|NCT01700946|BIOLOGICAL|rituximab|given intravenously
41021043|NCT01700946|DRUG|clofarabine|given intravenously
41021044|NCT01700946|DRUG|cyclophosphamide|given intravenously
41352847|NCT04087967|DRUG|Idarubicine plus Cytarabine regimen|Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
40833604|NCT01547312|DRUG|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
40833605|NCT01547312|DRUG|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
40833606|NCT01547312|DRUG|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
40833607|NCT01547312|PROCEDURE|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
40833608|NCT04731207|DEVICE|Optovue®|Optical coherence tomography and optical coherece tomography angiography
41021045|NCT01700946|DRUG|etoposide|given intravenously
41021046|NCT01700946|BIOLOGICAL|aldesleukin|given subcutaneously
41021047|NCT01700946|DRUG|pegaspargase|given intravenously
41021048|NCT01700946|DRUG|methotrexate|given intrathecally or intravenously
41021049|NCT01700946|DRUG|mercaptopurine|given orally
41021050|NCT01700946|DRUG|cytarabine|given intrathecally or intravenously
41021051|NCT01700946|DRUG|mitoxantrone|given intravenously
41021052|NCT01700946|DRUG|teniposide|given intravenously
41021053|NCT01700946|DRUG|vinblastine|given intravenously
41021054|NCT01700946|BIOLOGICAL|natural killer cell infusion|undergo allogeneic natural killer cell infusion
41021055|NCT01700946|OTHER|laboratory biomarker analysis|correlative studies
41021056|NCT01700946|DRUG|therapeutic hydrocortisone|given intrathecally
41159715|NCT02950870|DRUG|Ribavirin|Patients will be treated with ribavirin if necessary.
41159716|NCT02030847|BIOLOGICAL|CART-19|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10\^8 transduced CAR T cells
41159717|NCT02030847|BIOLOGICAL|CART-19|As of June 2014, dose was reduced to a single dose of 1-5x10\^7 CART-19 cells.
41159718|NCT02030847|BIOLOGICAL|CART-19|In the protocol amendment in November 2014, the dose remained 1-5 x 10\^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
41159719|NCT02030847|BIOLOGICAL|CART-19|In the protocol amendment in May 2015, the dose was changed to 1-5 x 10\^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10\^7), 30% on Day 2 (3x10\^7-1.5x10\^8), 60% on Day 3 (6x10\^7-3x10\^8).
41493894|NCT01713452|PROCEDURE|Purse string closure|"1. An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.~2. Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.~3. Diameter of the skin defect should then be measured.~4. A postoperative photo will then be taken."
40833609|NCT03624088|BEHAVIORAL|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
40833610|NCT04036994|DEVICE|Photobiomodulation therapy|All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.
40833611|NCT03504566|DRUG|Linagliptin|Linagliptin
40833612|NCT03504566|DRUG|Empagliflozin|Empagliflozin
40833613|NCT03504566|DRUG|Telmisartan|Telmisartan
40833614|NCT03504566|DRUG|Sulodexide|Sulodexide
40833615|NCT02706028|DEVICE|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
40833616|NCT02706028|DEVICE|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
40833617|NCT01476280|DRUG|palonosetron|0.075mg immediately before induction of anesthesia
41021057|NCT01700946|PROCEDURE|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
41021058|NCT01700946|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
40833618|NCT01476280|DRUG|Ramosetron|0.3mg immediately before induction of anesthesia
40833619|NCT05371041|DEVICE|Medtronic Percept Neurostimulator|This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
41021059|NCT04067141|DEVICE|somofilcon A|Contact Lens
41159720|NCT06028399|OTHER|Concurrent Training|The patient in the Concurrent Training group will perform exercises for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR for 15 - 40 minutes, followed by resistance training (Quadriceps extension, leg curls, calf raise \& toe raise) using an elastic resistance band at an intensity of 60 - 80% of 1 RM, following appropriate rest intervals.
41159721|NCT06028399|OTHER|Aerobic Training|The patient in the Aerobic Training group will perform exercises on a treadmill for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR, following appropriate rest intervals.
41159722|NCT01145547|DEVICE|Dexcom Seven® Plus Continuous Glucose Monitoring sensor|A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.
41159723|NCT00627523|DRUG|Genotropin (PN-180,307) Somatropin|Injectable Genotropin
41352848|NCT01017991|OTHER|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
41352849|NCT01017991|OTHER|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
41352850|NCT02331316|OTHER|Daily extra water intake|"Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period"
41021060|NCT04067141|DEVICE|nelfilcon A|Contact Lens
41021061|NCT02939105|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform treatments.
41021062|NCT01662869|DRUG|5-Fluoruracil|Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
41021063|NCT01662869|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
41159724|NCT00627523|DRUG|Control-no treatment|Control-no treatment
41159725|NCT04027491|BEHAVIORAL|Virtual Reality|"The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period."
41159726|NCT05478720|DRUG|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-10 mg/kg per dose
41159727|NCT05478720|DRUG|Placebo|Single intravenous dose of saline
41352851|NCT03350724|DEVICE|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
40833620|NCT03696082|BEHAVIORAL|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
41493895|NCT01713452|PROCEDURE|Primary closure|"1. An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.~2. Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (\<1.5cm). No subcutaneous drains will be placed.~3. Length of the incision should be measured in centimeters.~4. A postoperative photo will then be taken."
41493896|NCT02242916|RADIATION|Photon therapy versus proton therapy|
40833621|NCT03696082|BEHAVIORAL|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
41493897|NCT02242916|RADIATION|Photon therapy versus C-ion therapy|
41493898|NCT00121472|DEVICE|Thoratec HeartMate II Left Ventricular Assist System (LVAS)|Implantation of ventricular assist device to provide hemodynamic support
41493899|NCT01054235|BEHAVIORAL|training|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
41493900|NCT02488330|DRUG|Onartuzumab|Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
41493901|NCT02488330|DRUG|Bevacizumab|All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
41493902|NCT02488330|DRUG|Erlotinib|All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
40833622|NCT03696082|BEHAVIORAL|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
40833623|NCT03696082|BEHAVIORAL|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
40833624|NCT01271257|DRUG|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
40833625|NCT03346551|BEHAVIORAL|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"
40833626|NCT03346551|BEHAVIORAL|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"
40833627|NCT06370234|RADIATION|Whole body 18F-FDG Positron Emission Tomography|The subjects enrolling and participating this study will have done PET/MR during pre-operation chemotherapy. But, in normal procedure, they will not have done.
40833628|NCT04857645|DRUG|ASTX727|Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation
40833629|NCT04857645|OTHER|Donor Lymphocyte Infusions|In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles
41021064|NCT01662869|DRUG|Onartuzumab|Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
41021065|NCT01662869|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
41352852|NCT03350724|DEVICE|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
41352853|NCT03638362|DIETARY_SUPPLEMENT|Placebo|Participants consumed placebo beverage for 4 weeks.
41352854|NCT03638362|DIETARY_SUPPLEMENT|Tart cherry juice|Participants consumed tart cherry juice (8 ounces; 240 mL) per day for four weeks.
41352855|NCT03128606|DRUG|GLPG3067 single dose|GLPG3067 oral suspension, single ascending doses, daily
41352856|NCT03128606|DRUG|Placebo single dose|Placebo, oral suspension, daily
41493903|NCT00899990|OTHER|Laboratory Biomarker Analysis|Correlative studies
41493904|NCT03441724|DIAGNOSTIC_TEST|Mechanocardiography|Mechanocardiographic recording
41352857|NCT03128606|DRUG|GLPG3067 multiple dose|GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
41352858|NCT03128606|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
41352859|NCT03128606|DRUG|GLPG3067 oral suspension|GLPG3067 oral suspension, single dose, daily
41352860|NCT03128606|DRUG|GLPG3067 oral tablet|GLPG3067 oral tablet, single dose, daily
41352861|NCT03128606|DRUG|GLPG3067/GLPG2222 multiple dose|GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
41021066|NCT01662869|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
41021067|NCT03280355|BEHAVIORAL|Singing training|"Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.~Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology."
41021068|NCT03280355|BEHAVIORAL|Physical Training|"Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.~The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.~Physical Training is conducted by the local physiotherapists in the local health centres."
41352862|NCT03128606|DRUG|GLPG3067/GLPG2222 Placebo multiple dose|GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
41352863|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 multiple dose|GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
41352864|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
41352865|NCT01566006|DRUG|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
41352866|NCT02417129|DRUG|Rituximab|BI 695500 375 mg/M2
41352867|NCT02417129|DRUG|BI 695500|BI 695500 375 mg/M2
41352868|NCT02773849|BIOLOGICAL|ADSTILADRIN|
41352869|NCT03899389|DIAGNOSTIC_TEST|plasma samples collection|Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
41352870|NCT02178592|DRUG|DTG 50 mg|DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
41352871|NCT02178592|DRUG|EFV 600 mg|EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
41352872|NCT02116192|BEHAVIORAL|Experimental: Low-fructose, reduced carbohydrate diet|"Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
41352873|NCT02116192|BEHAVIORAL|General Healthy Diet|Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
41352874|NCT03261739|BIOLOGICAL|RYI-018|Anti-CB1 monoclonal antibody
41352875|NCT03261739|BIOLOGICAL|Placebo|Placebo
41352876|NCT04545931|DEVICE|Posterior tibial nerve stimulation|34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator
41352877|NCT04545931|DRUG|Desmopressin Acetate|0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
41352878|NCT00329199|BEHAVIORAL|Attachment-Based Family Therapy|
41021069|NCT06133491|BIOLOGICAL|Daxibotulinumtonix A|SQ injections of 10u per site will be given over standard landmarks (18 sites) to patients who consent and are found eligible.
41021070|NCT01953484|OTHER|Change in extracorporeal carbon dioxide removal|
41493905|NCT03838510|BEHAVIORAL|REBOOT|The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.
41352879|NCT04241120|BEHAVIORAL|Device and app system designed for participant to self-administer Habit Reversal Training|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania.
41352880|NCT04241120|BEHAVIORAL|Reminder bracelet control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull.
41352881|NCT04519476|DRUG|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
41352882|NCT04519476|DRUG|Lenalidomide|Immunomodulatory drug
41352883|NCT04519476|DRUG|Methylprednisolone|Glucocorticoid, steroid
41159728|NCT05478720|DRUG|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-1.0 mg/kg per dose
41352884|NCT06504433|DIAGNOSTIC_TEST|Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain|This is a 10-year, longitudinal, non-randomised, retrospective and prospective, observational study that will be used to characterise the natural history of primary mitochondrial disease (MITO) in 400 participants and their asymptomatic family members (with no genetic risk), non-MITO healthy controls (100 participants) and form a biobank that can be used in future research using separate ethics approved protocols to identify biomarkers of disease onset and progression.
41493906|NCT03861481|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
41493907|NCT03861481|OTHER|Placebo|Subjects will receive placebo in a specified sequence during the treatment period.
40833630|NCT05301738|OTHER|Plyometric Exercises|The plyometric exercise group received a 12-week plyometric training program. Each session lasted 45 minutes and was repeated two times a week. The training was conducted in conformity with the National Strength and Conditioning Association guidelines and American Academy of Pediatrics safety standards. The plyometric exercise program consisted of ten unilateral and bilateral lower limb plyometrics in the form of hopping/bounding/jumping activities. The Iplyometric workout was proceeded by a 5-minute warm-up and ended up with a 5-minute cool-down
41352885|NCT00004654|DRUG|soy protein isolate|
41159729|NCT05149313|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
41159730|NCT05149313|DRUG|Lebrikizumab-matching Placebo|Matching Placebo solution for injection administered subcutaneously.
41159731|NCT05161143|DRUG|Donafenib|"Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,patients will receive TACE once."
41159732|NCT00003402|DRUG|carmustine|
41159733|NCT00003402|DRUG|cisplatin|
41159734|NCT00003402|DRUG|cyclophosphamide|
41159735|NCT00003402|DRUG|dexamethasone|
41159736|NCT00003402|DRUG|etoposide|
41159737|NCT00003402|DRUG|melphalan|
41159738|NCT00003402|DRUG|paclitaxel|
41159739|NCT00003402|PROCEDURE|bone marrow ablation with stem cell support|
41352886|NCT03427528|BEHAVIORAL|Fathers and Babies (FAB)|The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session.
41352887|NCT03427528|BEHAVIORAL|MB 1-on-1 plus TXT|Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT). After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
41493908|NCT02841813|OTHER|No intervention|No intervention
41493909|NCT03400085|OTHER|mHealth application|The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
41159740|NCT00003402|PROCEDURE|peripheral blood stem cell transplantation|
41159741|NCT03905213|DEVICE|dressing MEPORE|assignation to three different authorised and on label dressing: conventional dressing (MEPORE)
41352888|NCT02365740|OTHER|gastric emptying test|gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
41352889|NCT02365740|OTHER|gut hormones determination|blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
41352890|NCT02365740|OTHER|Continuous Glucose Monitoring|7 days Continuous Glucose Monitoring
41352891|NCT02365740|DRUG|Insulin single bolus|pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
41352892|NCT02365740|DRUG|Insulin double-wave bolus|pre-prandial insulin fractioned into a double-wave bolus
41493910|NCT02459548|OTHER|Follow up in Sleep Unit Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
41493911|NCT02459548|OTHER|Follow up in Primary Care Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
41493912|NCT02948153|OTHER|clinical study|It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
41493913|NCT00901992|BEHAVIORAL|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
40833631|NCT05301738|OTHER|Standard Physical Therapy|The control group received their usual physical rehabilitation program for 45 minutes, twice/week for 12 consecutive weeks. The program comprised advanced balance training, and gait training exercises, postural and flexibility exercises, strength training exercises.
40833632|NCT05908968|DIETARY_SUPPLEMENT|ELO water|Drinking 1.5 litres daily of ELO water for 12 weeks
41352893|NCT02630381|DEVICE|Unfocused extracoporeal shock wave therapy|"Shock waves are acoustical pulses that are characterized by high amplitude (\~500 bar) and short rise time (\~20 ns), which are followed by a longer low-magnitude negative wave (\~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.~Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed."
40833633|NCT05069207|OTHER|POWER breathe K5|Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
41352894|NCT01873196|BEHAVIORAL|Receive extra oil|
40833634|NCT05162053|DRUG|vicagrel Capsules|Oral administration for 7 days under fasting
40833635|NCT05162053|DRUG|Clopidogrel Tablets|Oral administration for 7 days under fasting
40833636|NCT04527523|DIAGNOSTIC_TEST|Optical Coherence Tomography|OCT is an imaging method that uses light waves to create images of the retina.
40833637|NCT05268744|DRUG|Micronutrient|Subject will take micronutrient supplement daily for 8 weeks
40833638|NCT05556629|OTHER|No Intervention|This is a non-interventional study.
41159742|NCT03905213|DEVICE|dressing MEPILEX|assignation to three different authorised and on label dressing: absorbent(MEPILEX)
41352895|NCT01873196|BEHAVIORAL|Receives behavior changed messages on CSB package|
41352896|NCT03087110|BIOLOGICAL|Matched sibling donor cord blood cell infusion|Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (\>1x10\^7 cells/kg)
41493914|NCT00901992|BEHAVIORAL|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
41352897|NCT02572869|OTHER|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
41352898|NCT02572869|BEHAVIORAL|questionnaires|"The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H\&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes."
41352899|NCT00679354|DRUG|cilengitide|Given IV
41352900|NCT00679354|OTHER|laboratory biomarker analysis|Correlative studies
41352901|NCT00679354|OTHER|pharmacological study|Correlative studies
41352902|NCT03838666|DRUG|Suspension of human autologous MSC 3P|Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
41352903|NCT02975206|DRUG|Serlopitant High Dose|serlopitant tablets - high dose
41352904|NCT02975206|DRUG|Placebo Oral Tablet|placebo tablet
41352905|NCT02975206|DRUG|Serlopitant Low Dose|serlopitant tablets - low dose
41352906|NCT04652102|BIOLOGICAL|CVnCoV|Intramuscular (IM) injection.
41352907|NCT04652102|BIOLOGICAL|Placebo|Intramuscular (IM) injection.
41352908|NCT04652102|BIOLOGICAL|Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program|Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
41352909|NCT00149006|PROCEDURE|Cell therapy|
41352910|NCT02382952|DEVICE|Differential Dissector|
41352911|NCT02382952|OTHER|Standard Dissection Method|
41493915|NCT03306524|DEVICE|SIPPV_VG_0_08|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.08 seconds, inspiratory time of 0.40 seconds for 15 minutes
41021071|NCT03527992|DEVICE|O2 automated|"In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates."
41021072|NCT03527992|DEVICE|O2 standard|"In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care"
41159743|NCT03905213|DEVICE|dressing PICCO|assignation to three different authorised and on label dressing:vacuum Therapy dressing(PICCO)
41352912|NCT06231927|BEHAVIORAL|The Skills for Life Adjustment and Resilience (SOLAR) program|The SOLAR program is a 5-session intervention program that aims to introduce participants necessary recovery skills after a traumatic event resulting in a subclinical distress. During the program, participants will be given workbooks including the topics for skill development for recovery and adjustment. At each session, they will discuss these topics with the study coaches.
41352913|NCT01738594|DRUG|carfilzomib|Given IV
41352914|NCT01738594|DRUG|romidepsin|Given IV
41352915|NCT01738594|OTHER|laboratory biomarker analysis|Correlative studies
41352916|NCT04330456|RADIATION|Preoperative stereotactic radiation therapy in hypofractionation mode|"At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues.~At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation.~GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy."
41352917|NCT04330456|PROCEDURE|Surgery|In 14-21 days after preoperative stereotactic radiation therapy radical surgery will be performed
41352918|NCT04330456|RADIATION|Postoperative conformal radiation therapy in normofractionation mode|"In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) СTV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm.~PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery."
41352919|NCT00395720|BIOLOGICAL|MVA85A (TB vaccine)|Intradermal vaccine
41352920|NCT00395720|BIOLOGICAL|MVA 85A|Intradermal vaccine
41352921|NCT02837549|OTHER|Occupational therapy treatment|This intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education
41352922|NCT01149044|PROCEDURE|Percutaneous Coronary Intervention with or without manual aspiration thrombectomy|
41352923|NCT00095134|DRUG|risperidone|
41493916|NCT03306524|DEVICE|SIPPV_VG_0_16|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.16seconds, inspiratory time of 0.40 seconds for 15 minutes
41493917|NCT03306524|DEVICE|SIPPV_VG_0_24|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.24 seconds, inspiratory time of 0.40 seconds for 15 minutes
41493918|NCT03306524|DEVICE|SIPPV_VG_0_32|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.32 seconds, inspiratory time of 0.40 seconds for 15 minutes
41493919|NCT03306524|DEVICE|SIPPV_VG_0_40|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.40 seconds, inspiratory time of 0.40 seconds for 15 minutes
41352924|NCT06331806|DIAGNOSTIC_TEST|Evaluation of myocardial fibrosis|echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent
41352925|NCT04549675|BEHAVIORAL|Sun Safe Partners Online|Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.
41352926|NCT04549675|BEHAVIORAL|Generic Online Sun Safety Information intervention|4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
41352927|NCT01979003|DRUG|Fluorescein|
41352928|NCT02683031|OTHER|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
41352929|NCT02816255|DEVICE|Full Face Mask with same CPAP Pressure|Full Face Mask with same CPAP Pressure
41352930|NCT02816255|DEVICE|Full Face Mask with new Pressure|New cpap pressure derived from our formula for the final two weeks.
40833639|NCT05122117|DEVICE|Methylene blue mediated Photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
40833640|NCT05122117|PROCEDURE|Non-surgical periodontal therapy|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
40833641|NCT04469231|DEVICE|Anterior Cervical Discectomy & Fusion|ACDF
40833642|NCT02813395|DEVICE|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
40833643|NCT02813395|DEVICE|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
40833644|NCT04504942|DRUG|Leronlimab|Drug: Leronlimab 525mg
40833645|NCT04700956|PROCEDURE|primary abdominal closure|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
40833646|NCT04700956|DEVICE|abdominal closure with prophylactic mesh|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
41021073|NCT00955877|DRUG|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
41021074|NCT00955877|DRUG|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
41352931|NCT05839899|DRUG|Mifepristone plus one dose Misoprostol|Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later
41352932|NCT05839899|DRUG|Mifepristone plus two doses Misoprostol|Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that
41352933|NCT05544214|DRUG|CKD-371|PO
41352934|NCT03552614|DEVICE|Upper limb robot-assisted rehabilitation|"Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames."
41352935|NCT03552614|OTHER|physiotherapy|Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
41352936|NCT03665129|BIOLOGICAL|IPH5401 and Durvalumab|IPH5401 and durvalumab
41352937|NCT04185792|DIAGNOSTIC_TEST|NBSS, Qualiveen and SF-Qualiveen|NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
41352938|NCT00886314|DRUG|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
41352939|NCT00886314|OTHER|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
41352940|NCT01191190|DRUG|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
41352941|NCT05032287|DRUG|Tamsulosin|Tamsulosin 0.4 mg once daily
41352942|NCT05032287|DRUG|Placebo|Placebo once daily
41352943|NCT00727350|RADIATION|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
41352944|NCT03990155|PROCEDURE|HFNCOT+ECCO2R|NIV will be discontinued, the ECCO2R setting will be unchanged (both sweep gas flow and blood flow through the artificial lung) and HFNCOT will be started, titrating the fraction of inspired Oxygen (FiO2) to obtain an oxygen saturation at periphery (SpO2) 88-92%; HFNCOT start temperature will be 31°C, the initial flow rate will be 60 L/min.
40833647|NCT00633789|DRUG|brivanib|Tablets, Oral, 800 mg, once daily, until progression
41352945|NCT04804072|DRUG|Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)|MOUD for OUD
40833648|NCT00633789|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, until progression
40833649|NCT04581382|BIOLOGICAL|Nivolumab|Given IV
40833650|NCT04581382|BIOLOGICAL|Pembrolizumab|Given IV
40833651|NCT04581382|RADIATION|Radiation Therapy|Undergo radiation therapy
40833652|NCT04581382|BIOLOGICAL|Therapeutic Exchange Plasma|Undergo therapeutic plasma exchange
40833653|NCT04581382|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40833654|NCT04581382|PROCEDURE|Computed Tomography|Undergo CT
40833655|NCT04581382|PROCEDURE|Positron Emission Tomography|Undergo PET
40833656|NCT04581382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41352946|NCT04804072|DIAGNOSTIC_TEST|HIV testing|HIV testing
41352947|NCT04804072|DRUG|HIV treatment for participants living with HIV not already in care|HIV treatment for participants living with HIV not already in care
41352948|NCT04804072|DRUG|PrEP for participants without HIV|PrEP for participants without HIV
41352949|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)|Testing and referral for vaccination or treatment for HAV and HBV
41352950|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for treatment for hepatitis C virus (HCV)|Testing and referral for treatment for HCV
41352951|NCT04804072|DIAGNOSTIC_TEST|Sexually transmitted infection (STI) testing and treatment|STI testing and treatment
41352952|NCT04804072|OTHER|Primary care|Primary care
41352953|NCT04804072|BEHAVIORAL|Harm reduction services|Harm reduction services
40833657|NCT02142881|OTHER|Antihypertensive medication intensification|Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of \<130 mmHg.
40833658|NCT02142881|OTHER|Usual care|Antihypertensive medications will be adjusted by the participants' providers (usual care).
40833659|NCT00085332|DRUG|docetaxel|
40833660|NCT02788201|DRUG|75 approved agents|One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
40833661|NCT02788201|OTHER|COXEN|The CO eXpression ExtrapolatioN (COXEN) algorithm will be used to determine the next best therapy from among 75 Food and Drug Administration (FDA) approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
40833662|NCT00097890|DRUG|Replagal (Agalsidase Alfa)|
40833663|NCT00097890|DRUG|Replagal|
40833664|NCT02922842|DEVICE|Transcutaneous Electrical Nerve Stimulation|
41352954|NCT04804072|BEHAVIORAL|Peer navigation|Peer navigation
41352955|NCT04804072|DIAGNOSTIC_TEST|COVID-19 testing and referral for further evaluation, care and/or treatment|COVID-19 testing and referral for further evaluation, care and/or treatment
41352956|NCT04093544|DEVICE|Deep brain stimulation|Steered stimulation using directional leads
41352957|NCT00934791|DRUG|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
41352958|NCT00934791|DRUG|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
41352959|NCT00934791|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
41352960|NCT00934791|DRUG|Prednisone|Prednisone tapered to 5 mg/day by day 92
41352961|NCT03347279|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
41352962|NCT03347279|OTHER|Placebo|Placebo subcutaneous injection
41352963|NCT02862028|BIOLOGICAL|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
41493920|NCT03306524|DEVICE|PSV_VG_0_08|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.08 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
41352964|NCT00135408|DRUG|Ipilimumab+ Placebo|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
41352965|NCT00135408|DRUG|Ipilimumab+ Budesonide|Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
41352966|NCT01126281|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
41352967|NCT05518994|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
41493921|NCT03306524|DEVICE|PSV_VG_0_16|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.16 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
41493922|NCT03306524|DEVICE|PSV_VG_0_24|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.24 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
41493923|NCT03306524|DEVICE|PSV_VG_0_32|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.32 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
41493924|NCT03306524|DEVICE|PSV_VG_0_40|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.40 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
40833665|NCT04179513|BIOLOGICAL|GB224 10mg|"10 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
40833666|NCT04179513|BIOLOGICAL|GB224 20mg|"20 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
40833667|NCT04581343|DRUG|Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine|Canakinumab 250 mg s.c. injection; Spartalizumab 400 mg IV infusion, nab-paclitaxel 125 mg/m2 IV infusion, gemcitabine 1000 mg/m2 IV infusion
40833668|NCT04976933|BEHAVIORAL|mHealth adherence app|The mHealth app is designed to remind caregivers to give medication in the outpatient setting, track adherence, and capture real time barriers to adherence if medication is missed.
41352968|NCT02065479|DRUG|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
41352969|NCT02065479|DRUG|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
40833669|NCT04353219|DEVICE|compression stocking|participants will continue their training program as prepared by their coach with compression stocking
40833670|NCT04353219|OTHER|control|participants will continue their training program as prepared by their coach without compression stocking
40833671|NCT00581828|DRUG|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
41493925|NCT00501501|PROCEDURE|Cesarean section|
41493926|NCT00501501|PROCEDURE|Vaginal delivery|
41493927|NCT03106649|DEVICE|Echocardiography|Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.
40833672|NCT02236416|BEHAVIORAL|Intervention group|Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
41021075|NCT00955877|DRUG|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
41021076|NCT00134108|BEHAVIORAL|Cognitive Behaviour Therapy|
41021077|NCT06572748|OTHER|10-week programme|"1. 2-week health education (4 sessions, 60 minutes per session) Social workers and occupational therapists will explain the cognitive training elements of the program and introduce the DementiAbility Methods to the participants. Nutritionist, speech therapists, and Chinese medicine practitioner will share insights from their perspectives to enhance participants' understanding of cognitive impairments.~2. 8-week cooking class (5 sessions, 120 minutes per session) The culinary instructor will teach participants to cook homemade dishes while integrating procedural memory into recipes. Older adults and their caregivers will cook together based on the procedural recipe designed by caregivers, aiming to enhance communication between them and create joyful memories. The cooking class will begin with 20-30 minutes an interactive nutrition-based session. The session themes will focus on healthy diet and food safety. Participants will be able to ask questions and make comments."
41021078|NCT06160024|BEHAVIORAL|Program to improve data quality of national quality indicators|"Interventions will be developed based on the findings from the first data collection period.~A bundle of interventions (Program to improve data quality of national quality indicators) will be offered to participating long-term care facilities to support changing behavior in data collection procedures via training and supporting material as implementation strategies with the goal to improve the data quality of the national quality indicators. The program will be tested in a separate pilot study. The second data collection period in the current study will be used to evaluate the effect of the implemented program."
41352970|NCT01633567|BEHAVIORAL|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
40833673|NCT02236416|BEHAVIORAL|Control group|Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
40833674|NCT02071186|DEVICE|Virtual Reality training|"Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.~To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis."
41021079|NCT03713294|DRUG|Dexamethasone|Given IV and PO
41021080|NCT03713294|BIOLOGICAL|Elotuzumab|Given IV
40833675|NCT02071186|OTHER|Computerized Cognitive Remediation|Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
40833676|NCT02071186|OTHER|Standard of care|
40833677|NCT01561547|BEHAVIORAL|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
41021081|NCT03713294|DRUG|Pomalidomide|Given PO
41352971|NCT01633567|BEHAVIORAL|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
40833678|NCT01561547|DIETARY_SUPPLEMENT|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
40833679|NCT05610046|DEVICE|Infrared sauna heating|Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.
40833680|NCT05610046|DEVICE|Sham sauna|Participants will sit in an inactive infrared sauna at room temperature (21° Celsius) for a total of 40 minutes.
40833681|NCT01969877|DRUG|cetuximab|
40833682|NCT01969877|DRUG|cisplatin|
40833683|NCT00506597|DRUG|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m\^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m\^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
40833684|NCT02809053|BIOLOGICAL|SAIT101|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
40833685|NCT02809053|BIOLOGICAL|MabThera®|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
40833686|NCT06461728|DEVICE|a new prototye device that heat and activate sodium hyochlorite (Aseptico)|endoactivator : it is a sonic activator device
40833687|NCT06020846|OTHER|Soleus Pushup Exercise|"Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.~4 sets of 15 minutes each,1hour total intervention time"
41021082|NCT05007873|DRUG|Dasatinib|Given PO
41021083|NCT05007873|DRUG|Decitabine and Cedazuridine|Given PO
41021084|NCT05600400|RADIATION|Stereotactic Ablative Body Radiation|2 Fraction
41352972|NCT06402240|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical behavior therapy (DBT) in its fully adherent form is a comprehensive intervention involving individual, group, and phone coaching sessions that addresses complex psychological conditions including suicidality, personality disorders, and post-traumatic stress disorder. Evidence for briefer formats incorporating the group skills training format have been successful for many types of conditions, which includes alcohol and substance use disorders. DBT skills training (DBT-ST) involves structured lessons for learning skills in 5 areas: mindfulness, emotion regulation, distress tolerance, interpersonal effectiveness, and addiction. The current intervention is an internet-delivered version of DBT-ST which aims to teach people the same 5 areas of skills in an online environment with a chatbot and interactive format.
41352973|NCT04884633|PROCEDURE|Pancreatic islet transplantation|New method of pancreatic islet transplantation into the omentum using a biodegradable scaffold
41352974|NCT04994886|PROCEDURE|Device implantation|The intervention involves the insertion of 2 lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) epidurally over the dorsal aspect of the spinal cord through 2 laminectomies and two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) in the abdomen of the participant.
41352975|NCT01520675|PROCEDURE|surgery|Drainage procedure
41352976|NCT01520675|PROCEDURE|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
40833688|NCT06020846|OTHER|treadmill walk group 2|The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time
40833689|NCT00139256|DRUG|Betamethasone|Betamethasone injection
40833690|NCT01612650|DEVICE|tomosynthesis|2 incidences 3D numeric mammography
40833691|NCT01612650|DEVICE|2D mammography|2 incidences 2D analogic mammography
40833692|NCT04407065|DRUG|Double trigger|Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
40833693|NCT04407065|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
40833694|NCT00886249|DEVICE|Acrysof IQ|Intraocular lens
40833695|NCT00886249|DEVICE|Acrysof Natural IOL|Intraocular Lens
40833696|NCT02146677|OTHER|Osteopathic manipulative treatment|
40833697|NCT02146677|OTHER|Sham therapy|
40833698|NCT02146677|OTHER|Usual care|
41021085|NCT01625052|DEVICE|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
41021086|NCT06460623|OTHER|external mobilization|two 5-minute sessions of external manipulation per week over a 5-week period.
41021087|NCT06460623|OTHER|rectal coccygeal mobilization|consisted of two 5-minute sessions of external manipulation per week over a 5-week period.
41021088|NCT06573801|DEVICE|Aktiia Bracelet|Wrist worn bracelet with an optical sensor that measures pulse wave characteristics at the wrist.
41021089|NCT06573801|DEVICE|Healthstats BPro Evo|Wrist worn watch that uses applanation tonometry to measure pulse wave characteristics at the wrist.
41021090|NCT06573801|DEVICE|Spacelabs OnTrak Ambulatory Blood Pressure monitor|Cuffed ambulatory BP monitor that will measure upper arm BP using oscillometry.
41159744|NCT00672763|DRUG|Colecalciferol D3 (Vigantol Oil)|"1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses)."
41159745|NCT00672763|DRUG|Medium chain triglycerides|"1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Migliol Oil 5ml oral fortnightly (2 doses)"
41352977|NCT02733276|OTHER|electroacupuncture|Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
40833699|NCT01628861|DEVICE|MyRestBreak 1.0|"Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
41352978|NCT02733276|OTHER|Sham: Electroacupuncture sham|Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
41352979|NCT01927640|DRUG|Dexmedetomidine|Dexmedetomidine (0.3-0.6 mcg/kg) infusion.
40833700|NCT01628861|BEHAVIORAL|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
40833701|NCT03509493|DIAGNOSTIC_TEST|FibriCheck|Digital health application
40833702|NCT03093636|DEVICE|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
40833703|NCT03093636|OTHER|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
40833704|NCT01710735|PROCEDURE|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
40833705|NCT04326764|DRUG|Panobinostat|"Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules."
40833706|NCT01888419|OTHER|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
41352980|NCT01927640|DRUG|Normal Saline|Normal saline infusion (10 cc)
41352981|NCT01927640|DRUG|Intranasal cocaine|Intranasal cocaine (2 mg/kg)
41352982|NCT01634087|DRUG|Itacitinib|Itacitinib administered orally
41352983|NCT01634087|DRUG|Placebo|Placebo administered orally
41352984|NCT02346955|BIOLOGICAL|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
41352985|NCT02346955|BIOLOGICAL|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
41352986|NCT03030092|OTHER|Maximal Strength Training|leg pres and abduction exercises
41352987|NCT05619939|DIETARY_SUPPLEMENT|Protein isolate|The indicated protein isolates will be given to subjects as their major protein source
40833707|NCT05997576|DRUG|TG103 22.5 mg|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
40833708|NCT05997576|DRUG|Placebo|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks.
41352988|NCT01579526|DRUG|FP01|comparison of different dosages
41352989|NCT00297284|DRUG|Modafinil|
40833709|NCT04560894|DRUG|SCT-I10A|Participants receive SCT-I10A intravenously，200mg，d1，Q3w
41352990|NCT00827112|DRUG|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
41352991|NCT00827112|DRUG|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
41352992|NCT05823376|DRUG|Avatrombopag|Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10\^9/L; Drug administration will be stopped when PLT≥100×10\^9/L.
41352993|NCT05544110|DEVICE|Active transcranial magnetic stimulation|The coil parallel to the scalp is placed on the target for real and effective stimulation.
40833710|NCT04560894|DRUG|SCT510|Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
41159746|NCT06405516|DEVICE|Autologous blood cell salvage with in-house device|In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
41159747|NCT06405516|DEVICE|Autologous cell salvage with i-Sep SAME device|In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
41159748|NCT04130958|DEVICE|Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)|iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
41159749|NCT04130958|DEVICE|Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)|The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
41352994|NCT05544110|DEVICE|Sham transcranial magnetic stimulation|The coil is placed perpendicular to the scalp above the target for ineffective stimulation.
40833711|NCT04560894|DRUG|Sorafenib 200mg|Participants receive sorafenib orally，400mg bid
40833712|NCT01100528|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously (SC) 3 times a week for 24 weeks
40833713|NCT01100528|DRUG|dacarbazine|Given IV on days 1 and 29
40833714|NCT01100528|OTHER|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
40833715|NCT01013779|DRUG|Carboplatin|"During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1."
40833716|NCT01013779|DRUG|Etoposide|After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
40833717|NCT01013779|RADIATION|Radiotherapy|"Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions~Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions"
41159750|NCT05942573|DRUG|Serplulimab+Paclitaxel+Apatinib|Immunotherapy+chemotherapy
41352995|NCT05924997|DRUG|adebrelimab, camrelizumab plus apatinib|adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle
41159751|NCT05942573|DRUG|Paclitaxel±Ramucirumab|chemotherapy±Targeted therapy
41159752|NCT04700397|DIAGNOSTIC_TEST|Nitroglycerine|We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
41159753|NCT02814097|DRUG|elamipretide|Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
41159754|NCT02814097|DRUG|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
41493928|NCT03106649|DEVICE|Treatment of spinal hypotension|For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.
41493929|NCT04558268|DRUG|Prednisone|"Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.~Prednisone is used as an anti-inflammatory or an immunosuppressant medication. Prednisone treats many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders."
41493930|NCT04558268|DRUG|Progesterone|"Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy."
41493931|NCT04558268|DIETARY_SUPPLEMENT|vit D|Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.
41493932|NCT04558268|DIETARY_SUPPLEMENT|Iron Supplement|Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.
41493933|NCT04558268|DIETARY_SUPPLEMENT|Folic Acid|"Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer."
41493934|NCT05053334|DRUG|Omalizumab Prefilled Syringe|150mg/ml of Omalizumab prefilled syringe
41493935|NCT01510548|BIOLOGICAL|Adalimumab injections for acute disc prolapse patients|see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
41493936|NCT00732576|DIETARY_SUPPLEMENT|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
41493937|NCT00732576|DIETARY_SUPPLEMENT|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
41493938|NCT00732576|DIETARY_SUPPLEMENT|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
41159755|NCT04346433|BEHAVIORAL|Restricted Sleep|During the restricted sleep condition adolescents will sleep 4 hours ±1 hour (0100-0500). This condition will last 1 night.
41493939|NCT05658978|OTHER|Neuromuscular training|Neuromuscular training Length: 12 weeks; Training duration: 90 minutes; Intensity: 70-95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.
41493940|NCT05658978|OTHER|Control group|The Control group continues previous regular exercises for 12 weeks with a duration of 90 minutes and three days per week.
41493941|NCT04245241|OTHER|High-flow nasal cannula (HFNC)|24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).
41159756|NCT04346433|BEHAVIORAL|Adequate Sleep|During the adequate sleep condition adolescents will sleep 9 hours ±1 hour (2100- 0800). This condition will last 1 night.
41159757|NCT00447629|DRUG|PPM-204|
40833718|NCT01471912|PROCEDURE|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
40833719|NCT02259140|PROCEDURE|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
40833720|NCT02259140|PROCEDURE|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
40833721|NCT04705415|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
40833722|NCT04705415|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
40833723|NCT06453603|DRUG|PRP injection|Receive pes anserinus PRP injection
40833724|NCT06453603|DRUG|corticosteroid injection|Receive pes anserinus corticosteroid injection
40833725|NCT03625232|DEVICE|CompuFlo® Epidural Computer Controlled System|"The CompuFlo® Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the HCP to perform epidural anesthesia and epidural injections using standard methods. Currently, HCPs rely on their subjective perception to feel a loss of resistance when inserting an epidural needle to identify the epidural space. The CompuFlo® Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
40833726|NCT04773041|PROCEDURE|Infinitome|All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.
40833727|NCT03353766|DEVICE|Early crossbite correction with Q-H Device|Crossbite treatment in deciduous dentition with Quad-Helix appliance
40833728|NCT05886530|OTHER|No intervention|Observational data collection only.
40833729|NCT02616393|DRUG|Tesevatinib|
40833730|NCT05977348|BEHAVIORAL|Healthy Eating Curriculum|The Healthy Eating (HE) curriculum is designed to provide children with skills needed to develop healthy eating habits. Each lesson builds upon the overall goal of creating a healthy restaurant. Children are taught to identify differences between GO and WHOA foods, recognize the five food groups, and learn to make healthy food choices.
41352996|NCT03756636|PROCEDURE|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
41352997|NCT04576390|DRUG|Ondansetron 4 mg|Antiemetic drug
41352998|NCT04576390|DRUG|Palonosetron 75 mcg|Antiemetic drug
40833731|NCT05977348|BEHAVIORAL|Improving the Classroom Food and Mealtime Environment|"HBP+ Classrooms will receive additional sensory activities for each lesson (e.g., posters, food models, games) designed to improve the classroom food environment and provide repeated exposure to activities and messages about fruits and vegetables. Teachers in HBP+ classrooms will be provided with additional training on strategies shown to increase food acceptance in preschool children (e.g., modeling, encouraging children to try foods without coercion). In addition, HBP+ classrooms will include tasting charts that children will stamp to indicate their liking for each food each week."
41159758|NCT02686671|OTHER|Shoulder clinical examination testing|Shoulder clinical examination including resistive shoulder abduction with and without a humeral traction (Pull Test). Functional status will be measured using the Shoulder Pain and Disability Index (SPADI).
41159759|NCT01705483|DRUG|ASP9853|oral
41352999|NCT01070186|DRUG|Sunitinib|50mg/day for 4 weeks
41353000|NCT01070186|OTHER|Tumor biopsy|Conducted prior to administration of sunitinib therapy
41353001|NCT01070186|PROCEDURE|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
41353002|NCT01070186|OTHER|Biomarkers|"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"
41353003|NCT03362723|DRUG|Idasanutlin|Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
41353004|NCT05968794|PROCEDURE|Vaginal cerclage|A vaginal cerclage is a short and minor surgical procedure performed under general or regional anesthesia. An unabsorbable suture is placed around/through the cervix to close the cervical canal and to increase its firmness, in order to reduce cervical insufficiency.
41353005|NCT06216054|DRUG|LPM3770164 sustained release tablet|administrated orally
41493942|NCT04106167|GENETIC|Allogeneic natural killer (NK) cell|No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy
41493943|NCT02444923|DEVICE|Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)|Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
41493944|NCT02444923|DEVICE|Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)|The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
40833732|NCT05977348|BEHAVIORAL|Parent Education|Parents in intervention classrooms will be given access to 8 web-based lessons on food parenting and responsive parenting. Topics include: establishing mealtime routines, shopping healthy on a budget; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; the division of responsibility in feeding, and portion control.
40833733|NCT05977348|BEHAVIORAL|ECE Food Acceptance Training|HBP+ early childhood educators (ECEs) will be asked to complete an online, self-paced course on increasing food acceptance in preschool children. Topics will include: repeated exposure to foods; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; and the division of responsibility in feeding.
40833734|NCT06239090|DEVICE|Rehacor-T|During each session of bio/neurofeedback IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.
41493945|NCT05797818|DEVICE|Methylene Blue Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene Blue (0.01%) + 4 minutes of light treatment"
40833735|NCT06239090|BEHAVIORAL|Sham Intervention|SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation and see only the scenarios
41159760|NCT01705483|DRUG|Docetaxel|intravenous (IV)
41159761|NCT01705483|DRUG|Paclitaxel|Taxol
41159762|NCT03771534|DRUG|Oxygen gas|Brief maternal administration of 65-70% O2 via a face mask during the last trimester
41353006|NCT06216054|DRUG|LPM3770164 sustained release tablet simulant|administrated orally
41159763|NCT01990378|DRUG|Rabeprazole sodium 20 mg Delayed Release tablet|
41353007|NCT06010836|BEHAVIORAL|Script guided conversation|Patients getting script guided intervention of 3 domains in the preoperative period
41353008|NCT03932292|DRUG|Ectoin Mouth Wash|According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
41353009|NCT03932292|DRUG|Supersaturated solution of calcium and phosphate ions|According to medical prescription of the instruction for use under consideration (4 times a day).
41353010|NCT03713242|DRUG|ACT-541468 25 mg|Administered as a tablet.
41353011|NCT03713242|DRUG|ACT-541468 25 mg (or 10 mg depending on interim results)|Administered as a tablet.
41353012|NCT00305266|DRUG|intravenous gammaglobulin|individual dose
41353013|NCT05467033|DRUG|Desmopressin|desmopressin 0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;
41353014|NCT05467033|DRUG|intravenous infusion NaCl|0,9% NaCl managed as intravenous infusion
41353015|NCT05913401|BEHAVIORAL|Aerobic Exercise|20 minutes of supervised aerobic exercise on a treadmill prior to each TMS session
41353016|NCT05913401|BEHAVIORAL|Video Watching|20 minutes of watching documentaries or educational videos prior to each TMS session
41159764|NCT03194854|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
41493946|NCT05797818|DEVICE|Chlorhexidine Gluconate Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
41493947|NCT05797818|DEVICE|Methylene Blue + Chlorhexidine Gluconate|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene blue (0.01%) + chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
41353017|NCT00066443|BIOLOGICAL|pegfilgrastim|Dose escalation schedule A\&B = 6mg fixed dose once per cycle on day 2
41493948|NCT05797818|DEVICE|Light Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- 4 minutes of light treatment only"
41493949|NCT00090363|DRUG|ZD4054 15 mg|15 mg oral tablet once daily
41493950|NCT00090363|DRUG|Placebo|
41493951|NCT00090363|DRUG|ZD4054 10 mg|10mg oral tablet once daily
41493952|NCT02092896|DRUG|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
41493953|NCT02092896|DRUG|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
41159765|NCT04451031|BEHAVIORAL|LiFT Program|
41159766|NCT00386997|DRUG|liposomal amphotericin B (AmBisome®)|
41353018|NCT00066443|DRUG|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
41353019|NCT00066443|DRUG|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
41493954|NCT02092896|DRUG|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
41493955|NCT02092896|DRUG|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
41493956|NCT04602715|DRUG|MET-2|Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.
41493957|NCT04602715|DRUG|Placebo|Placebo Control
41353020|NCT00639808|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
41353021|NCT00639808|DRUG|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
41353022|NCT00367627|DRUG|Albendazole|
41353023|NCT01271608|DEVICE|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
41353024|NCT03170765|BIOLOGICAL|Measles vaccine|Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
41493958|NCT03339167|DIETARY_SUPPLEMENT|Metabolic availability of lysine in millet|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from millet and 1 level from millet with lentils.
40833736|NCT03889548|OTHER|Mental Imagery|Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
40833737|NCT00226135|DRUG|lithium or lamotrigine|
40833738|NCT05117021|DRUG|Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg|Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
41353025|NCT04249466|OTHER|Questionnaire|"During this consult, several parameters will be measured :~* nutritional and physical activity parameters: Food Frequency Questionnaire (FFQ), International Physical Activity Questionnaire (IPAQ), Three-Factor Eating Questionnaire (TFEQ-R18), impedance test, anthropometric measurements, resting energy expenditure~* demographic and clinical parameters : Family history, date of birth (month and year), sex, genotype, best forced expiratory volume (FEV) (over the 12 months preceding inclusion), bacterial colonization~* patient treatment and biologic parameters: corticosteroid therapy (with dosage, over the 12 months preceding inclusion), antidiabetic treatment (oral or insulin), IV antibiotic treatment, corrective treatments, pancreatic enzymes, OGTT (blood glucose and insulin levels at three times), lipid balance, vitamin dosage."
41353026|NCT00577421|DRUG|risedronate|5 mg tablet of risedronate once a day for 2 years
41353027|NCT05238844|DRUG|ATI-2173 25mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
41493959|NCT06351475|OTHER|Intra-operative albumin administration|Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
41353028|NCT05238844|DRUG|Vebicorvir 300mg|Vebicorvir (formerly ABI-H0731) is an orally administered, potent and selective small molecule inhibitor of the HBV core protein
41353029|NCT05238844|DRUG|Viread 300Mg Tablet|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
41353030|NCT04831892|OTHER|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Study lotion containing 0.1% colloidal oatmeal along with 4% HydraSynol® DOI (Isosorbide Dicaprylate) and 4% HydraSynol® IDL/(Isosorbide Disunflowerseedate)
41353031|NCT04831892|OTHER|Moisturizer containing Colloidal Oatmeal only|Vehicle lotion containing 0.1% colloidal oatmeal.
40833739|NCT03224403|DRUG|Test acetaminophen|single dose of 2 Test acetaminophen 500 mg tablets
40833740|NCT03224403|DRUG|Commercial acetaminophen|single dose of 2 acetaminophen 500 mg caplets
40833741|NCT03224403|DRUG|Commercial ibuprofen|Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
40833742|NCT03224403|DRUG|Placebo|2 placebo caplets
40833743|NCT02554214|DEVICE|Glafkos drainage device|
41353032|NCT03979495|OTHER|mFOCUS|To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
41353033|NCT04090515|BEHAVIORAL|Project Health|This intervention involves a one-hour group meeting for six consecutive weeks.
41353034|NCT04090515|OTHER|Educational Video Control|This intervention involves a one-hour educational video control viewing for six consecutive weeks.
40833744|NCT05697666|OTHER|Modulation of the depth of the neuromuscular blockade|"Analysis of the respiratory mechanics at two times:~* Facial train of four = 0, indicating a deep neuromuscular blockade~* Facial train of four \> 0, indicating a intermediate to light neuromuscular blockade"
40833745|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
40833746|NCT04404270|BEHAVIORAL|Questionnaire|"Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3).~The questionnaire includes:~* medical data (height, weight, smoking, history of intense stress);~* socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.);~* clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19;~* use of care, hospitalization, work stoppage in the last 3 months;~* contact with people who are symptomatic or proven COVID-19."
41353035|NCT02894606|DRUG|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
40833747|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 serological controls and serum neutralization|Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.
40833748|NCT05278364|DRUG|SY-5007|a RET selective Inhibitor
40833749|NCT02654236|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
40833750|NCT02654236|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
41353036|NCT02894606|DRUG|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
41353037|NCT03543449|OTHER|Off-Pump Coronary Artery Bypass (OPCAB) surgery|Off-Pump Coronary Artery Bypass (OPCAB) surgery. This study is retrospective study
41353038|NCT04684706|DEVICE|intermittent Theta Burst Stimulation|The present study will utilize TMS dosage of iTBS of 18 000 pulses a day for 5 consecutive days.
40833751|NCT00459537|DRUG|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
40833752|NCT00459537|DRUG|amorolfine nail lacquer|5 % amorolfine nail lacquer
41353039|NCT00278486|BIOLOGICAL|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
41353040|NCT00490477|DEVICE|Polymyxin -B fiber hemoperfusion system|two hours treatment for two days
41353041|NCT01521494|DRUG|PA21|
41353042|NCT01521494|DRUG|PA21|
41353043|NCT01521494|DRUG|PA21|
41353044|NCT01521494|DRUG|PA21|
41353045|NCT01521494|DRUG|Placebo|
41353046|NCT00105833|BEHAVIORAL|Collaborative Care - Depression Decision Support (DDS)|Multifaceted collaborative intervention for depression based in primary care
41353047|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
41353048|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
41353049|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
41353050|NCT04470349|DEVICE|LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
41353051|NCT04470349|DEVICE|Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
40833753|NCT02921009|DEVICE|Crosslinking using UV light of two different fluence rates|The treatment of keratoconus involves the application of riboflavin followed by Ultraviolet light of differing intensities. This study will determine the effectiveness of a greater UV light fluence at a shorter treatment time than is currently utilized.
40833754|NCT02124772|DRUG|Trametinib|Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
40833755|NCT02124772|DRUG|Dabrafenib|Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
40833756|NCT05928845|DIAGNOSTIC_TEST|Muscle thickness measurement|Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission
40833757|NCT02360293|BEHAVIORAL|Stay Strong w/coaching|Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
40833758|NCT02360293|BEHAVIORAL|Stay Strong|Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
40833759|NCT00984607|PROCEDURE|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
40833760|NCT04679844|DEVICE|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 5cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.
40833761|NCT04679844|DEVICE|Demineralized Bone Matrix mixed with Autograft Bone|Demineralized Bone Matrix mixed with Autologous bone graft used in instrumented posterolateral fusion, 5cc-10cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.
40833762|NCT00612625|DRUG|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
40833763|NCT00612625|DRUG|Saline|continuous infusion of saline
40833764|NCT03990805|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection
40833765|NCT03990805|DRUG|saline|saline, 1 time injection
40833766|NCT03395561|DIETARY_SUPPLEMENT|green coffee|2 capsuls
40833767|NCT03395561|OTHER|control|2 capsuls
40833768|NCT05568030|BEHAVIORAL|Mindfulness|One session of a 20 minute mindfulness recording, based on standardised script, focused on stress management.
40833769|NCT05568030|BEHAVIORAL|Psycho-education|One session of a 20 minute recording, based on standardised script, focused on psychophysiological stress response description.
40833770|NCT05874492|OTHER|Thermal cure with a primary dermatological indication|The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)
41159767|NCT06479447|OTHER|PORTAL-PTSD|Patients will be eligible if they are 18+ years, have had a primary care visit in the last 2 years, and have not been screened for PTSD in the last year. The validated PC-PTSD-5 (Primary Care Post Traumatic Stress Disorder-5) screener will be used. Clinics will implement visit-based and population health screening for patients enrolled in the patient portal who have not been screened for PTSD in the last year and have had a clinic appointment in the last 2 years. The PCBH care manager or patient navigator will follow-up with patients every 2 weeks to ensure they have been connected to care and re-measure their PTSD symptoms. The follow-up calls will continue until symptom remission, after which follow-ups will occur quarterly for 6 months. Primary care clinicians will receive training on trauma-informed care and PTSD management, and will be surveyed at baseline, immediately after training, and 6 months-post intervention to evaluate changes in their knowledge of trauma-informed care.
40833771|NCT02972541|DEVICE|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will be given neoadjuvant chemotherapy. Surgery is performed after 3 cycles of mFOLFOX6 or 2 cycles of CapeOx. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 5-9 cycles of mFOLFOX6 or 4-6 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
40833772|NCT02972541|DEVICE|Stenting with immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days later. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 8-12 cycles of mFOLFOX6 or 6-8 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
40833773|NCT03191877|DIETARY_SUPPLEMENT|coffee|"Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811"
40833774|NCT01248871|DRUG|procedure:sevoflurane-remifentanil/sufentanil|Active Comparator
40833775|NCT01248871|DRUG|volatile agent only during reperfusion|Active Comparator
40833776|NCT01248871|DRUG|propofol-remifentanil/sufentanil|Active Comparator
40833777|NCT01842581|DRUG|Rifaximin|Rifaximin will be administered per the dose and schedule specified in the arms.
40833778|NCT01842581|DRUG|Lactulose|Laculose will be administered per the schedule specified in the respective arm.
40833779|NCT02099201|DRUG|ACT-389949 40 mg|
41159768|NCT00004403|DRUG|albendazole|
41353052|NCT00207636|BEHAVIORAL|Computer-based prostate cancer screening decision aid|
41493960|NCT06351475|OTHER|Control|Ringer lactate
41353053|NCT06032429|OTHER|Shared Medical Appointments|SMA is a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state, which involved both a person trained or skilled in delivering patient education or facilitating patient interaction.
41353054|NCT05605691|DEVICE|Renuvion APR System|"The Renuvion Generator (K192867) is indicated for delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The Renuvion APR Handpiece (K191542) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.~Together, the Renuvion Generator and Handpiece are referred to as the Renuvion APR System."
41353055|NCT02734472|OTHER|Incidence and risk factors of hypertension|During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
41353056|NCT06257615|BEHAVIORAL|Education provided via TeleNursing|"Online Video Call Online video interviews were conducted with the patients in the intervention group once in the first week (day 1-7), once in the second week (day 8-14) and once in the third week, using mobile phone programs and/or computer programs that provide video conversation opportunities. It was conducted in the form of remote online video calls, held three times in total, once within the 15-21st day.~Voice Phone Call After audio telephone interviews and online video interviews were completed within the first three weeks after the patients in the intervention group were discharged; It was carried out using a mobile phone 3 times in total: once in the fourth week (day 22-28), once in the fifth week (day 29-35) and once in the sixth week (day 36-42)."
41353057|NCT04815915|OTHER|Graston technique|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
41353058|NCT03258762|DRUG|Pyrimethamine|Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.
41353059|NCT03258762|DRUG|Calcium folinate|Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
41493961|NCT02195089|DRUG|BLS_ILS_E710c 500mg|- 2 capsules per day for 20 days (week 1,2,4 \& 8)
41493962|NCT02195089|DRUG|BLS_ILB_710c 1000mg|- 4 capsules per day for 20 days (week 1,2,4 \& 8)
41159769|NCT00004403|DRUG|dexamethasone|
41353060|NCT03808844|DRUG|HSK3486|Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
41353061|NCT03808844|DRUG|Propofol|Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
41353062|NCT00269685|DRUG|vasopressin|
41353063|NCT04170855|DRUG|Furosemide Injection|"We will measure kidney sodium content in patient with cardiorenal syndrome. we will inject within the week of this first measurement furosemide only in patient who will be resistant to diuretics (Based on these parameters, diuretic response will be defined as:~* A reduction in fractional spot urinary sodium~* An increase in urinary volume~* A \>1 kg reduction in body weight within 24 hours from diuretic administration (extrapolation of guidance on management of acute HF) and we will do another measurement of kidney sodium content after furosemide injection."
41353064|NCT04671576|OTHER|Control Infant Formula|Powder, standard commercial infant formula.
41353065|NCT04671576|OTHER|Organic Infant Formula|Powder, organic milk-based infant formula.
41353066|NCT01031108|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
41493963|NCT02195089|DRUG|BLS_ILS_E710c 1500mg|- 6 capsules per day for 8 weeks (week 1,2,4 \& 8)
41493964|NCT01913925|OTHER|Tyrosine-Containing Food Bar|
41493965|NCT01913925|OTHER|Placebo Bar|
41159770|NCT00004403|DRUG|phenytoin|
41493966|NCT02203422|DRUG|Cyclosporin A|given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
41493967|NCT02203422|DRUG|rhTPO|given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
41493968|NCT00019864|BIOLOGICAL|filgrastim|
41493969|NCT00019864|DRUG|cisplatin|
41493970|NCT00019864|DRUG|dexrazoxane hydrochloride|
41493971|NCT00019864|DRUG|doxorubicin hydrochloride|
41493972|NCT00019864|DRUG|leucovorin calcium|
41493973|NCT00019864|DRUG|methotrexate|
41493974|NCT00019864|PROCEDURE|adjuvant therapy|
41493975|NCT00019864|PROCEDURE|conventional surgery|
41493976|NCT00019864|PROCEDURE|neoadjuvant therapy|
41493977|NCT01206101|DRUG|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
41493978|NCT01206101|DRUG|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
41493979|NCT02737527|PROCEDURE|24G intravenous route for Lumbar Sympathetic Block (LSB):|Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
41493980|NCT02737527|DEVICE|15-cm Chiba needle for Lumbar Sympathetic Block (LSB)|The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
41493981|NCT02737527|DEVICE|Ultrasound for Lumbar Sympathetic Block (LSB)|Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra, the modified transverse scan through lumbar intertransverse space (ITS) is obtained with the transducer positioned 4-6 cm lateral to the mid-line at the L2-L3 intervertebral level. The needle is inserted from a lateral to medial direction using in-plane technique. The needle tip is inserted towards the anterior fascia of the psoas major muscle as close as paravertebral space.
40833780|NCT02099201|DRUG|ACT-389949 200 mg|Predicted dose
40833781|NCT02099201|DRUG|ACT-389949 800 mg|Predicted dose
40833782|NCT02099201|DRUG|ACT-389949 (Group C1 dose to be selected)|
40833783|NCT02099201|DRUG|ACT-389949 (Group C2 dose to be selected)|
40833784|NCT02099201|DRUG|Placebo|
40833785|NCT03287674|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
41353067|NCT01031108|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
41353068|NCT03684460|DEVICE|Daytime Bright Light|Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
41353069|NCT03684460|DEVICE|Usual Light|"Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2."
41353070|NCT02390362|DRUG|Rituximab|We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
41353071|NCT02390362|DRUG|MMF|Subjects randomized to MMF, will continue MMF as scheduled by the investigator
40833786|NCT03287674|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
40833787|NCT03287674|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
40833788|NCT03287674|DRUG|Interleukin-2|Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
40833789|NCT03287674|DRUG|Ipilimumab|One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
40833790|NCT03287674|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
40833791|NCT04825990|DRUG|Pembrolizumab|200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.
40833792|NCT05962034|DRUG|Aspirin|650 mg aspirin (Acetylsalicylic acid)
41353072|NCT03898856|DRUG|Crofelemer|125 mg tablets taken by mouth twice daily for 28 days
40833793|NCT05962034|OTHER|Placebo|placebo capsule
40833794|NCT02988999|DIETARY_SUPPLEMENT|D-allulose|D-allulose (psicose), a C-3 epimer of D-fructose, is defined one of the rare sugars since it is rarely found in nature. Rare sugars are monosaccharides which present in small quantities in commercial mixtures of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose (5). D-allulose (psicose) has been demonstrated to be a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Various physiological activities of D-allulose (psicose) have been revealed. Of those, its glucose suppressive effect has been proven by both animal and clinical studies.
40833795|NCT02988999|DIETARY_SUPPLEMENT|erythritol|non-calorie sweetener
41353073|NCT03898856|DIAGNOSTIC_TEST|Diagnostic tests for cause of chronic diarrhea|Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
41493982|NCT02737527|DEVICE|Fluoroscope for Lumbar Sympathetic Block (LSB)|Briefly, fluoroscopic guided LSBs are performed at the lower third of the L2 or the upper third of the L3 vertebra. A targeted lumbar vertebral is identified by AP fluoroscopic imaging and the fluoroscopic C-arm is adjusted 25-35° laterally to avoid the transverse process over the needle pathway. After the skin infiltration, the needle is advanced toward the anterolateral edge of the target lumbar vertebra under fluoroscopic guidance using the tunnel vision technique.
41493983|NCT02737527|DRUG|10 ml of 0.25% levobupivacaine injection for LSB|After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
40833796|NCT01287377|BEHAVIORAL|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
40833797|NCT01287377|DRUG|Nicotine Patches|"Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches."
41493984|NCT02737527|PROCEDURE|Temperature measurement for Lumbar Sympathetic Block (LSB)|Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
41493985|NCT02737527|PROCEDURE|Postprocedure care for LSB|Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
41493986|NCT00775905|DRUG|amlodipine 10 mg tablet|
41493987|NCT05910476|DRUG|a high dose of statin/ezetimib|"In randomization, 100 patients will proceed with Rosuvastatin/Ezetimib 20/10 mg and 100 patients will proceed with Atovastatin/Ezetimib 40/10 mg.~A new generation of drug elution stents can be inserted and later registered, and if the patient agrees to participate in the study, they are randomly assigned after stent implantation."
41493988|NCT05067530|DRUG|Palbociclib|CDK4/6 inhibitor
41493989|NCT05067530|DRUG|Paclitaxel|Chemotherapy
41493990|NCT05067530|DRUG|Carboplatin|Chemotherapy
41493991|NCT04060316|DRUG|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
41493992|NCT04060316|DRUG|Placebo|Placebo is given as a nasal spray using an atomizer
41493993|NCT00927394|DRUG|Aliskiren|Aliskiren 150 mg tablet
41493994|NCT00927394|DRUG|Valsartan|Valsartan 160 mg capsules
41493995|NCT00927394|DRUG|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
41493996|NCT00927394|DRUG|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
41353074|NCT05445869|DEVICE|ProSomnus® EVO Sleep and Snore Device|The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.
40833798|NCT03164850|DEVICE|Laparoscopic Tactile Imaging|Provides Tactile feedback during laparoscopic surgery
40833799|NCT05216055|COMBINATION_PRODUCT|Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline|Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg) Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug) Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg) Normal saline 0.9%, 18.5mL
40833800|NCT05216055|DRUG|Liposomal bupivacaine|Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg) Normal saline 0.9%, 40mL
40833801|NCT04821323|DRUG|Indomethacin|Indomethacin capsules will be administered orally.
40833802|NCT04821323|DIAGNOSTIC_TEST|Lactulose-mannitol|Lactulose-mannitol solution will be administered orally.
40833803|NCT03421743|DRUG|Inhaled molgramostim|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
41493997|NCT00072592|DRUG|Rituximab|
40833804|NCT03421743|DRUG|Antimycobacterial regimen|Multidrug NTM guideline-based antimycobacterial regimen
40833805|NCT02940782|PROCEDURE|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
40833806|NCT02940782|PROCEDURE|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
40833807|NCT02940782|DEVICE|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
40833808|NCT01203358|DRUG|Exosurf|Infants received up to four intratracheal doses of the surfactant.
40833809|NCT01203358|DRUG|Survanta|Infants received up to four intratracheal doses of the surfactant.
40833810|NCT00265070|DRUG|Gefitinib|250 mg tablet oral daily dose
40833811|NCT00419315|BEHAVIORAL|Alcohol Care Management|Care management for alcohol dependence with a focus on pharmacotherapy
40833812|NCT00419315|BEHAVIORAL|Usual Care|Usual care included a referral to a specialty addiction treatment program.
40833813|NCT00687609|DRUG|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
41353075|NCT03052699|PROCEDURE|vaginal Cesarean Section|follow-up to patients operated for vaginal Cesarean Section
40833814|NCT03741803|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds after birth
40833815|NCT03741803|PROCEDURE|Early cord clamping|The umbilical cord will be clamped as soon as feasible after birth, usually within the initial 15 seconds after birth.
40833816|NCT00605553|DRUG|Placebo|"Placebo oral capsules~Placebo for 7 days"
40833817|NCT00605553|DRUG|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
41353076|NCT00529152|DRUG|Deferiprone|Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
41353077|NCT02802735|DRUG|Apremilast|Tablet for oral administration
41493998|NCT00586352|OTHER|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
41493999|NCT04729309|DRUG|[12C] RO7049389|Participants will receive oral \[12C\] RO7049389.
41494000|NCT04729309|DRUG|[13C] RO7049389|Participants will receive IV \[13C\] RO7049389.
41494001|NCT04729309|DRUG|[14C] RO7049389|Participants will receive an oral suspension of \[14C\] RO7049389.
41494002|NCT01642459|OTHER|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
41494003|NCT01642459|OTHER|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
40833818|NCT03190694|DRUG|Dapagliflozin 10mg|Tablet
40833819|NCT03930875|OTHER|Aspirin Resistance testing|Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)
40833820|NCT05149131|DRUG|ADT (Eligard®*) with or without treatment intensification|"Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~\*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix"
40833821|NCT04037150|DIAGNOSTIC_TEST|Circulating tumor DNA|Circulating tumor DNA
41494004|NCT06431165|DRUG|Lidocaine IV|After confirming patient history, type of operation and patient group allocation, standard ASA monitoring will be attached to the patient then the I.V induction of anesthesia will be commenced using standard doses of Propofol \&Tracrium in addition to 1 μg/kg Fentanyl and 1 ml/10 kg from the bolus Lidocaine syringe followed after 3 minutes by endotracheal intubation, then the Lidocaine infusion Syringe will be attached to a separate I.V line at an infusion rate of 1 ml/10 kg/h. The patient will receive 1 gm of I.V paracetamol and the surgery will be allowed to proceed.
41494005|NCT00769990|DIETARY_SUPPLEMENT|genistein|Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
40833822|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
40833823|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
40833824|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
40833825|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
40833826|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
40833827|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
40833828|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
40833829|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
40833830|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
40833831|NCT00532792|BIOLOGICAL|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
40833832|NCT00002460|DRUG|goserelin acetate|
40833833|NCT00002460|DRUG|tamoxifen citrate|
40833834|NCT00002460|PROCEDURE|ablative endocrine surgery|
40833835|NCT00002460|PROCEDURE|oophorectomy|
40833836|NCT01787318|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
40833837|NCT01787318|DEVICE|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
40833838|NCT00320138|PROCEDURE|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
40833839|NCT03840525|BEHAVIORAL|The Qigong Intervention|Qigong is a low-impact, slow-movement, meditative form of exercise that has helped relieve mental and physical stressors.
40833840|NCT03840525|BEHAVIORAL|Sham Qigong|This intervention includes similar body movements to qigong; however, it does not have the meditative or breath work.
40833841|NCT04831099|DRUG|Testosterone gel|The route of administration is transdermal.
40833842|NCT04831099|DRUG|Placebo|The route of administration is transdermal
40833843|NCT06113224|PROCEDURE|Blood collection T0|2 blood samples will be taken in addition to the pre-operative check-up.
40833844|NCT06113224|PROCEDURE|Blood collection 6 months|1 blood sample will be taken 6 months after surgery.
40833845|NCT05601362|DEVICE|Gamified Attention Bias Modification|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT).
40833846|NCT05601362|DEVICE|Gamified Placebo Training|Placebo version of Gamified Attention Bias Modification. (Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias).
40833847|NCT05694715|DRUG|Niraparib|Given orally
40833848|NCT05694715|DRUG|Irinotecan|Given intravenously (IV)
40833849|NCT04628949|DEVICE|aScope™ Duodeno endoscope and aBox™ Duodeno|"The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.~The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope."
40833850|NCT00673881|DRUG|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
40833851|NCT00657150|DRUG|Enoxaparin|40 mg once daily
40833852|NCT00657150|DRUG|Dabigatran etexilate|220 mg once daily
40833853|NCT01993316|DEVICE|Mitsar 201 neurofeedback|
40833854|NCT01304329|DRUG|BI 10773|Medium dose oral administration
40833855|NCT01304329|DRUG|simvastatin|Medium dose oral administration
41353078|NCT02802735|DRUG|Placebo|Tablet for oral administration
40833856|NCT01304329|DRUG|simvastatin|Medium dose oral administration
40833857|NCT01304329|DRUG|BI 10773|Medium dose oral administration
40833858|NCT05835921|DEVICE|Virtual Reality|Both groups will receive a Virtual Reality Park experience, which is an empty park with no avatars. Only the experimental group will have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
40833859|NCT04254874|DRUG|Abidol hydrochloride|0.2g once, 3 times a day,two weeks
40833860|NCT04254874|DRUG|Abidol Hydrochloride combined with Interferon atomization|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
40833861|NCT04519047|BIOLOGICAL|PRP|Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
41353079|NCT00015015|DRUG|Dichloroacetate|
41494006|NCT00769990|RADIATION|radiation therapy|A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
40833862|NCT04866355|OTHER|Lumbar spine manipulation|Lumbar spine manipulation
40833863|NCT04866355|DRUG|Hyoscine and Ibuprofen|hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
41159771|NCT05459025|BEHAVIORAL|Aromatherapy yoga|The research assistant diluted the Lavandula angustifolia essential oil with distilled water (1:75) 10 min before the yoga session started. The solution was then atomized by three aroma diffusers, placed in the front, middle, and back of the classroom. The distance from each participant was less than 10 m to ensure that the aroma was absorbed com-pletely. The yoga course for the aromatherapy yoga group was the same as that of the yoga only group. The yoga group only took a yoga course, without aromatherapy.
41353080|NCT01816516|BEHAVIORAL|Healthy Babies|"Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects."
41353081|NCT01816516|BEHAVIORAL|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
41353082|NCT06378164|BEHAVIORAL|Exercise|For the combined step training group, the participants will receive training on both volitional and reactive stepping. The training will last for 1 hours per session, 2 session per week for 4 weeks.
41353083|NCT06378164|BEHAVIORAL|Active Control|An active control group will be used to minimise the placebo and history effect. The group will also receive a 4-week programme with the frequency and duration of the training and the instructor-to-participant ratio that match the combined step training group. During training, they will perform exercises not specific to reducing fall risk.
41353084|NCT05651412|OTHER|Dynamic gait index and 5 time sit to stand test|dynamic gait index and 5 time sit to stand test was administered to all sample size of 400
41353085|NCT05503966|BEHAVIORAL|Attentional Bias Modification|The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
41353086|NCT02176005|DEVICE|DAV132|DAV132 is associated to moxifloxacin or it is evaluated alone
41353087|NCT02176005|DRUG|Moxifloxacin|Moxifloxacin is used alone or associated to DAV132
41353088|NCT02176005|OTHER|Negative Control|Moxifloxacin is used alone
41353089|NCT02505009|DRUG|Engerix-B|The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.
41353090|NCT02505009|DRUG|Tenofovir|Both case and control will receive 300 mg Tenofovir for at least 3 years
41353091|NCT02505009|DRUG|Entecavir|Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
41494007|NCT06309654|BEHAVIORAL|12-week home-based circuit training (HBCT)|Participants in the exercise group performed HBCT three times per week on non-consecutive days for 12 weeks. The first session was conducted at USM Hospital and participants were instructed how to perform the prescribed exercises in a correct form. In each session, participants performed seven exercises (two aerobic- and five resistance-based) in a circuit fashion, using bodyweight movements and adjustable dumbbells for varied weights, activating all the major muscle groups. In weeks 1-6, participants executed 15 repetitions for 2 rounds with 1 min passive rest between exercises and rounds. In weeks 7-12, participants executed 30 repetitions for 4 rounds with the same rest as prescribed in weeks 1-6. Each round lasted 10-15 min and the total session duration was 20-60 min, aiming to help participants adapt gradually to increasing training volume.
41494008|NCT06309654|BEHAVIORAL|Standard of care (CONT)|"Providing education about the nature of OA, its progression, and strategies for symptom management.~Empowering individuals with self-management techniques, such as joint protection strategies, activity modification, and lifestyle changes (e.g., weight management, exercise)."
41494009|NCT05841303|DRUG|Vit C|Vit c is proven to be an anti-inflammatory and antioxidant agent. also play a great role in collagen biosynthesis (collagen type I), as it helps in fibroblasts proliferation. It reduces the potentiality of scaring via inhibiting cross-linking of collagen fibers and fibrosis. It acts as a cofactor in hydroxyproline synthesis to produce collagen type IV and improves endothelial cell vitality and function..
41494010|NCT05841303|OTHER|injectable PRF|5 ml of peripheral blood from each patient , blood will be transferred to a glass coated plastic vacutainer tube without anticoagulant. Then this tube will immediately centrifuged at 700 rpm for 3 mins \[Centrifuge Machine 5000rpm.After centrifugation, two fluid layers will formed, upper being yellow fluid layer (i-PRF) while lower layer containing red blood cells. Yellow fluid layer containing i-PRF will be immediately aspirated using micro needle to be injected for management of gingival phenotype
41494011|NCT00587015|DRUG|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60...μg/kg until toxicity supervenes.
41494012|NCT04566341|DEVICE|OCT - TCE|Participants will be asked to swallow the TCE. They may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE is past the pharynx. We will advance the TCE until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
41494013|NCT00244530|DRUG|Nifedipine|
41353092|NCT02733887|DEVICE|magnetic resonance imaging|MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
41353093|NCT02733887|DEVICE|positron emission tomography/computed tomography|18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
41353094|NCT02733887|RADIATION|fludeoxyglucose F 18|Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
41353095|NCT00336466|DRUG|Human recombinant erythropoietin|
41353096|NCT04045873|DEVICE|extracorporeal membrane oxygenation|The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.
41353097|NCT00543842|DRUG|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
41353098|NCT00543842|DRUG|Capecitabine|Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
41353099|NCT00543842|DRUG|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
41353100|NCT00543842|RADIATION|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
41353101|NCT00543842|PROCEDURE|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
41353102|NCT00312728|DRUG|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be \< 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
41353103|NCT00312728|DRUG|First-Line Chemotherapy Agents|"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
41494014|NCT04677296|OTHER|VS002A|Amino acid based ORS/Medical food
41494015|NCT04677296|OTHER|WHO-ORS|WHO Oral rehydration solution, which is glucose based
41494016|NCT06425497|OTHER|The dosage of dnDSA|Flow cytometric analysis using FlowPRA Screening Test and/or Luminex Single Antigen Beads class I and II- IgG (cut- positivity off = MFI\> 1000)
41494017|NCT03327792|DRUG|Mavoglurant|200 mg Mavoglurant
41494018|NCT03327792|DRUG|Placebo|Placebo
41494019|NCT06334965|OTHER|Simultaneous 18F-Choline PET-MRI|before first TARE administration (after work-up procedure) and one month after TARE administration
41159772|NCT05459025|BEHAVIORAL|Yoga|The design of the yoga lessons was based on a past study and a professional yoga instruction book. Yoga lessons were led by certified yoga tutors.
41159773|NCT02841085|GENETIC|Genetic sample|Blood sample or saliva collection
41494020|NCT04916002|DRUG|vidutolimod|Participants will receive vidutolimod for up to 2 years as follows: 10 mg IT weekly for 7 doses after which vidutolimod will be administered every 3 weeks (Q3W). The first dose of vidutolimod may be administered subcutaneously (SC) or IT at the discretion of Investigator. All subsequent doses will be IT. The initial 7 doses of vidutolimod, delivered on a weekly dosing schedule, must be completed before starting the Q3W vidutolimod dosing schedule.
41494021|NCT04916002|DRUG|cemiplimab|Participants will receive cemiplimab for up to 2 years as follows: 350 mg IV infusion over 30 minutes at week 1 dose 1 (W1D1) and Q3W thereafter.
41494022|NCT00936897|DRUG|Ibandronate|Ibandronate 150mg PO QM (tablet)
41494023|NCT00936897|DRUG|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
41494024|NCT02885597|DRUG|Juanbi pill|4g, twice a day, 3month, oral
41494025|NCT02885597|DRUG|Juanbi pill placebo|4g, twice a day, 3month, oral
41494026|NCT02885597|DRUG|Methotrexate|5mg, once a week, 3 month, oral
41494027|NCT03237949|BEHAVIORAL|Phone counseling|Four telephone counseling sessions using a motivational interviewing approach
41494028|NCT03237949|BEHAVIORAL|Text message|30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory. The messages follows the self efficacy theory.
41494029|NCT01432379|BIOLOGICAL|botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
41494030|NCT05082792|DIAGNOSTIC_TEST|doppler ultrasound|"Doppler ultrasound evaluation of AVF:~* pre-operative evaluation: venous system (patency of central veins and deep venous system, patency of superficial veins, the latter diameter, depth form skin surface, distance from nearby artery, any sizable adjacent tributaries), and arterial system including morphological evaluation (course, diameter, wall alterations, any stenoocclusive disorders) and functional evaluation (flow volume and ability to dilate)~* post-operative evaluation: anastomotic site (type of anastomosis, patency, diameter, PSV and any other morphologic alterations), inflow afferent artery (diameter, PSV and flow volume), outflow efferent vein (patency, diameter, color flow, spectral waveform)~* the first post-operative sonographic evaluation will be done after removal of stiches from the wound and periodic monitoring every one week up until completion of 6 weeks"
41494031|NCT05715983|PROCEDURE|Bascom II procedure|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide was injected in all orifices to visualize all tracts and sinuses. The proposal area of incision is marked nearby sinus tract openings and the skin with lateralization on one side of the cleft. A vertical-orientated incision of the skin and subcutaneous fat around the primary and secondary orifices is made using a scalpel or a monopolar electrocautery. The sinus tract is excised in en-block till unchanged subcutaneous tissue. The wound is irrigated with antiseptic solution. If postoperative wound is larger than 5 cm then a silicone draining tube is placed through the contraperature in the upper corner. The wound is closed by interrupted sutures Vicryl/Polysorb 2/0 3/0 layer by layer. Aseptic dressing is applied to the closed wound.
41494032|NCT05715983|PROCEDURE|SiLaC|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide is injected in all orifices to visualize all tracts and sinuses. All visible orifices are excised with a scalpel or dermo punch. After that hairs are removed from the sinus by Volkmann curette. A metallic stylet is used to determine the length and direction of the different tracts. Then laser destruction of the sinus is performed with FiberLase VT laser, wavelength 1460 or 1520 nm, the laser energy 10-12 Watts. The fiber delivers energy homogeneously in a continuous way. Hemostasis by electrocautery. The wound is washed with povidone-iodine solution. Aseptic dressing is applied.
41494033|NCT04468516|DEVICE|KKT|Vibroacoustic sound waves applied focally.
41494034|NCT04468516|DEVICE|sham KKT|sham KKT
41494035|NCT05379231|OTHER|BiCROS fitting|Each participant will be fitted with the experimental CROS device on the unaidable ear and with a compatible hearing aid on the other ear.
41494036|NCT05379231|OTHER|Monaural hearing aid fitting|"Each participant will be fitted with a hearing aid on the better hearing ear and no device on the unaidable ear.~Monaural hearing aid fitting acts as control intervention."
41159774|NCT04445519|DRUG|NCX 470 0.065% (initial phase of trial)|NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)
41494037|NCT05379231|OTHER|Unaided condition|"No treatment, i.e. the participants are not fitted with a CROS device and/ or hearing aid.~Unaided condition acts as control intervention."
41494038|NCT02740387|DRUG|OTO-104|
41494039|NCT00005809|PROCEDURE|computed tomography|
41494040|NCT00005809|PROCEDURE|diagnostic colonoscopy|
41494041|NCT02836496|DRUG|Mepolizumab 300 mg|Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
41494042|NCT02836496|DRUG|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution
41159775|NCT04445519|DRUG|Latanoprost 0.005% (initial phase of trial)|Latanoprost Ophthalmic Solution, 0.005%
41159776|NCT04445519|DRUG|NCX 470 0.1% (initial phase of trial)|NCX 470 Ophthalmic Solution, 0.1%
41159777|NCT04445519|DRUG|NCX 470 0.1% (remainder of trial)|NCX 470 Ophthalmic Solution, 0.1%
41159778|NCT04445519|DRUG|Latanoprost 0.005% (remainder of trial)|Latanoprost Ophthalmic Solution, 0.005%
41159779|NCT00288379|DRUG|formoterol|
41159780|NCT00288379|DRUG|budesonide/formoterol|
41159781|NCT00854152|DRUG|GDC-0980|Escalating repeating dose
41353104|NCT00312728|DRUG|Second-Line Chemotherapy Agents|"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
41353105|NCT03817424|DRUG|VIB7734|Participants will receive VIB7734 via injection.
41353106|NCT03817424|DRUG|Placebo|Participants will receive placebo matching to VIB7734 via injection.
41353107|NCT05046418|OTHER|Hypoallergenic formula containing synbiotics|An extensively hydrolysed formula containing synbiotics or an amino acid formula containing synbiotics.
41353108|NCT06372405|BEHAVIORAL|Cognitive reappraisal|Cognitive reappraisal is a psychotherapeutic strategy utilized to regulate emotions by reinterpreting the meaning of stimuli. Participants will receive instructions on generating and implementing cognitive reappraisal (distancing and reframing) in both misophonic and non-misophonic contexts and will be practicing it within psychotherapeutic sessions. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
41353109|NCT06372405|BEHAVIORAL|Schultz Autogenic Training|Schultz Autogenic Training is a relaxation technique aimed at promoting relaxation and reducing physiological arousal. It consists of six exercises focusing on sensations of heaviness, warmth, heartbeat, breathing, abdominal warmth, and coolness of the forehead. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
41353110|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 (25 ug ) Dose 1 administered once daily for 7 days
41353111|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 (50 ug ) administered once daily for 7 days
41353112|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 (100ug) administered once daily for 7 days
41353113|NCT01426009|DRUG|Placebo EP-101|Placebo EP-101 administered once daily for 7 days
41159782|NCT05211453|PROCEDURE|atrioventricular node ablation|atrioventricular node ablation
41159783|NCT01763034|PROCEDURE|limb ischemic preconditioning|use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
41353114|NCT01426009|DRUG|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
41353115|NCT01426009|DRUG|Ipratropium bromide Inhalation Solution via Handihaler® DPI|Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
41353116|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 (200) ug administered once daily for 7 days
41353117|NCT01444144|OTHER|Fracture union|Retrospective records review post-operatively until fracture resolved.
41353118|NCT03001726|PROCEDURE|Gastrectomy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
41353119|NCT03001726|DRUG|oxaliplatin|oxaliplatin 100 mg/m2
41353120|NCT03001726|DRUG|S1|S1 40mg/m2
41353121|NCT03001726|DRUG|Docetaxel|docetaxel 40 mg/m2
41353122|NCT05961592|DRUG|R-2487|Probiotic
41353123|NCT05305742|OTHER|Instrument Design|Research the effect of different instrument designs on root canal preparation by evaluating bacterial count reduction and post-operative pain
41353124|NCT03922919|DRUG|Cefotaxime Injection|Systematic use of cefotaxime.
41353125|NCT03922919|PROCEDURE|Rectal swab|Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
41353126|NCT03922919|DRUG|Cefotaxime/ceftriaxone|ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
41353127|NCT03568513|DIETARY_SUPPLEMENT|Curcumin|The curcumin food supplement will be administered in the form of capsules. Participants in the treatment arm will take 50 mg twice or three times a day, depending on their body weight. Participants will take the curcumin capsules for eight weeks.
41353128|NCT03568513|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered in the form of capsules. Participants in the placebo arm will take a capsule twice or three times a day, depending on their body weight. Participants will take the placebo capsules for eight weeks. The placebo capsule will be similar in size, shape and color to the curcumin capsule and they will contain inert food powder.
41353129|NCT01753843|PROCEDURE|early cord clamping|early ( \<20 seconds)
41353130|NCT01753843|PROCEDURE|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
41353131|NCT03446313|BEHAVIORAL|Movn Mobile App|The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
41353132|NCT02378610|OTHER|Observation|Observation of the gut bacterial flora in high- and low-stressed individuals
41353133|NCT06193837|DRUG|Augmentin|Use of prophylactic antibiotics in lap cholecystectomy
41159784|NCT03635775|DEVICE|Active tDCS|Low-level (1.5 milliampere) current delivered to the scalp using saline-soaked sponges.
41159785|NCT03635775|DEVICE|Sham tDCS|Sham-setting--no electrical current delivered.
41353134|NCT00006463|DRUG|ECTEINASCIDIN 743|
41353135|NCT01924260|DRUG|alisertib|Given PO
41353136|NCT01924260|DRUG|gemcitabine|Given IV
41353137|NCT05132140|DEVICE|adaptive optics system|the system consists of a wavefront sensor and a deformable mirror that measure and correct (or modify) the eye's optical imperfections (aberrations).
41353138|NCT03880123|DRUG|Selinexor|"Selinexor will be taken orally on Days 1, 8, 15, and 22 of each cycle at the following dose levels (DLs):~DL 1: 40 mg; DL 2: 60 mg; DL 3: 80 mg; DL 4: 100 mg~The selinexor product is provided as 20 mg tablets in wallet-sized blister packs. Selinexor should be taken together with ixazomib."
41353139|NCT03880123|DRUG|Ixazomib|"Ixazomib will be taken orally on Days 1, 8, and 15 of each cycle at the same dose level: 4 mg.~The ixazomib product is provided in strengths of 4.0, 3.0, and 2.3 mg capsules as the active boronic acid. Ixazomib should be taken on an empty stomach (no food or drink) at least 1 hour before or at least 2 hours after food."
41353140|NCT04121052|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 as oral tablet.
41353141|NCT01948791|DRUG|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
41353142|NCT02706535|DRUG|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
41353143|NCT02706535|DRUG|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
41353144|NCT02706535|DRUG|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
41353145|NCT02331927|BIOLOGICAL|Aflibercept|"Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression."
41353146|NCT03006276|DRUG|DFN-15 Active|
41353147|NCT03006276|OTHER|DFN-15 Placebo|
41353148|NCT00151528|DRUG|Pregabalin|
41353149|NCT00198406|PROCEDURE|diagnostic and therapeutic management|
41353150|NCT02251366|PROCEDURE|Physician-guided diagnostic|NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
41353151|NCT01594463|OTHER|ultrasound examination|ultrasound examination between week 30+1 weeks to 31+6 weeks
41353152|NCT01594463|OTHER|ultrasound examination|ultrasound examination between 34+1 weeks to 35+6 weeks
41353153|NCT04282967|BEHAVIORAL|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
41353154|NCT03262285|PROCEDURE|phacoemulsification|removal of cataract using ultrasound waves
41353155|NCT03262285|PROCEDURE|extracapsular cataract extraction|removal of cataract using surgical corneal incision
41353156|NCT04022304|BIOLOGICAL|Biocon Insulin N|Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).
41353157|NCT04022304|BIOLOGICAL|Humulin® N|Humulin® N (human insulin \[recombinant deoxyribonucleic acid origin\] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.
41353158|NCT00911326|DRUG|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
41353159|NCT00400868|BEHAVIORAL|psycho-educational Joint protection education|individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
41353160|NCT00826540|DRUG|sorafenib tosylate|Given orally
41353161|NCT00826540|BIOLOGICAL|bevacizumab|Given IV
41353162|NCT04772287|DRUG|Toripalimab|Toripalimab: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
41353163|NCT04772287|DRUG|Toripalimab mimetic (placebo)|Placebo: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
41353164|NCT06202677|DEVICE|Self-guided program on obsessive compulsive disorder|This is an 8-day program that provides psychoeducational on what obsessions and compulsions are, and how to identify them. Subsequently, through a series of content learning and daily exercises that increase in difficulty, participants are guided to conduct exposure exercises while tolerating distress and refraining from compulsions. Participants are also guided to set goals and type down the specific content of their intrusive thoughts and compulsive behaviours to keep track of their progress. Each session of the program is estimated to be approximately 5 minutes.
41159786|NCT03279536|COMBINATION_PRODUCT|Oral lactoferrin|Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
41353165|NCT06202677|DEVICE|Self-guided program on cooperation|This 8-day program on cooperation aims to improve participants' collaborative skills and interpersonal wellness through a series of content learning and practice exercises. The time and duration of this program is matched to the obsessive compulsive disorder program to ensure that participants spend a similar amount of time and effort across both the intervention and active control conditions.
41353166|NCT03603340|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
41353167|NCT03603340|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
41353168|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
41353169|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
41353170|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
41353171|NCT03097562|PROCEDURE|Femtosecond cataract surgery|Catalys create a circular opening for accessing and removing the cataract.
41353172|NCT04566523|OTHER|telerehabilitation|Patients undergo an online exercise training program via a certified host of health data website.
41353173|NCT05486689|OTHER|Pulmonary Rehabilitation|"The enrolled subjects will receivePR program. The 3 weeks inpatient PR will include education, exercise training, nutritional and psychological counselling.~Education: individualized session of 20 minutes each and group session of 45 minutes each. Endurance training: at least twelve 30-minute daily sessions of supervised incremental exercise training according to Maltais, continuous cycling at 50-70% of the maximal load calculated on the basis of the baseline 6MWT according to Hill. Strength training: twelve 30-minute daily sessions of peripheral limb muscle strength training: 2 set of 8 repetitions during the first week, increased at 12 from the second. The initial load will be set at 30/50% of maximal voluntary isometric strength (MVS). Psychological intervention: individual tailored intervention will be offered when the Hospital Anxiety and Depression Scale (HADS) score is \>10 or judged necessary by clinicians, after verifying the subject's motivation."
41353174|NCT02415582|OTHER|Aerobic exercise|Aerobic exercise on treadmill
41353175|NCT02415582|OTHER|Combined exercises|Combined resistance and aerobic exercise
41353176|NCT02415582|OTHER|Control|45 minutes resting sitting
41494043|NCT02836496|DRUG|Active OCS capsules (5 mg prednisolone or prednisone)|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
41494044|NCT02836496|DRUG|Placebo matching OCS capsules|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
40833864|NCT01335841|DEVICE|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
41159787|NCT03279536|COMBINATION_PRODUCT|TDI of LMW iron dextran|Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
41159788|NCT01468025|DRUG|Active Theramine and Active Naproxen|Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
41159789|NCT01468025|OTHER|Theramine and naproxen-like placebo|Theramine, a medical food, co-administered with naproxen-like placebo
41159790|NCT01468025|DRUG|Naproxen and Theramine-like placebo|naproxen co-administered with Theramine-like placebo.
41159791|NCT04292925|OTHER|New treatment protocol|The new treatment protocol focuses on training of executive processes using remedial strategies and on promoting the use of meta-cognitive strategies. Goal directed activities are used to improve the underlying cognitive process and transfer of the learned skill to everyday function will be encouraged.
41159792|NCT04292925|OTHER|Conventional therapy|conventional therapy
41159793|NCT01552668|DRUG|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
41159794|NCT01552668|DRUG|Placebo|Receive Placebo twice daily
41159795|NCT03788421|DEVICE|LIGASURE|Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.
41353177|NCT02726204|OTHER|Gravity Elimination Alone|CAREX will compensate for the gravity of the subject's arm, i.e. subject can move their arm to a specific position and relax all the arm muscles, CAREX will hold the arm in that configuration
40833865|NCT06430515|PROCEDURE|Intratumoral Injection of Chemotherapy|This project intends to investigate the clinical efficacy of intra-tumoural injection of chemotherapeutic agents (e.g. cisplatin, oxaliplatin, etc.)via fine needle aspiration guided by CT or ultrasound in patients with advanced solid cancers to validate the safety and efficacy.
40833866|NCT00164398|BEHAVIORAL|HIP: HIV Intervention for Providers|
40833867|NCT05291936|DEVICE|PRECISION1® for Astigmatism Contact Lenses|TEST
41353178|NCT02726204|OTHER|Path Assistance Alone|CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path
41353179|NCT02726204|OTHER|Path Assistance and Gravity Elimination|
40833868|NCT05291936|DEVICE|MyDay® Toric Soft Contact Lenses|CONTROL
41353180|NCT02901106|DRUG|Dimethyl fumarate|"Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate~Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate"
41353181|NCT03271944|DEVICE|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
41353182|NCT02394366|OTHER|Original Healing Salve (OHS)|Topical salve (Puremedy, Inc.)
41353183|NCT02394366|OTHER|OHS base only|Olive and beeswax salve base
40833869|NCT00117689|BIOLOGICAL|Thymoglobulin|Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
40833870|NCT00117689|DRUG|Corticosteroid|For a minimum of 3 months
40833871|NCT00117689|DRUG|Tacrolimus|Between Day 3 the last dose of Thymoglobulin
40833872|NCT00117689|DRUG|Mycophenolate Mofetil|for at least 1 month posttransplant
41353184|NCT05086640|OTHER|Lemon foot to prevent blister|The investigators make the hypothesis that the local application of Lemon allows a reduction of the number of blisters on ultra-trail.
40833873|NCT03894384|DIAGNOSTIC_TEST|Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)|Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
40833874|NCT00000916|DRUG|Indinavir sulfate|
40833875|NCT00000916|DRUG|Lamivudine/Zidovudine|
40833876|NCT00000916|DRUG|Hydroxyurea|
40833877|NCT00000916|DRUG|Lamivudine|
40833878|NCT00000916|DRUG|Stavudine|
40833879|NCT00000916|DRUG|Zidovudine|
40833880|NCT00000916|DRUG|Didanosine|
41353185|NCT02061540|DRUG|LUM001|LUM001 oral dose
41353186|NCT04882826|DRUG|Sildenafil film-coated tablet 100 mg|Sildenafil is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 100 mg of sildenafil.
41353187|NCT04882826|DRUG|Viagra® film-coated tablet 100 mg|Viagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil.
41353188|NCT04131127|DEVICE|Sentinel Device|Sentinel Device used during TAVI in a Low Risk Patient
41353189|NCT00538486|DRUG|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
41353190|NCT00538486|DRUG|Telmisartan|Telmisartan 80mg 1/d
41494045|NCT00999427|DRUG|Povidone-iodine|Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
41494046|NCT01557361|OTHER|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
40833881|NCT04887389|DRUG|Nano Silver Fluoride varnish|Nano Silver Fluoride(5%) is a new experimental formulation containing silver nanoparticles, chitosan and fluoride combines preventive and antimicrobial properties. It is a yellow solution and safe to be used in humans
40833882|NCT04887389|DRUG|nano-hydroxyapatite varnish|nano-hydroxyapatite (10%) has antibacterial effect, higher solubility, surface energy and bioactivity and its structure is similar to dental apatite.
40833883|NCT04887389|DRUG|sodium Fluoride Varnish|Fluoride varnish (5%) applied every six months is effective in preventing caries in the primary and permanent dentition of children and adolescents
41353191|NCT00538486|DRUG|Candesartan|Candesartan 8mg daily
41353192|NCT00538486|DRUG|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
41494047|NCT01557361|OTHER|Standard RRT initiation|"Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:~I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND~II. At least one of the following indications for RRT initiation:~1. Serum potassium ≥6.0 mmol/L, or~2. Serum bicarbonate ≤ 10 mmol/L, or~3. Evidence of severe respiratory failure, based on a PaO2/FiO2 \<200 and bilateral infiltrates on the chest x-ray, or~4. By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization"
41021091|NCT06535633|OTHER|Intervention arm: Exercise class|The exercise trainers, who are educated in chronic pain, will lead a set of classes, adapted to the needs of people with chronic pain. The investigators have conducted PPI activities with the members of Chronic Pain Ireland, to understand the barriers and facilitators for community-based exercise and their needs in relation to same. A forthcoming publication reports the results of a survey of a survey of (n=130) members of CPI highlightinged that key barriers to community-based exercise included fear of pain exacerbation, and not having skilled exercise instruction. The exercise modalities of choice have been informed by the survey results as well as alignment with the LSP class offerings and trainer competency. Classes on offer are focused on aquatic exercise, Activator pole walking, yoga or Pilates, and circuit-style fitness, for participants to choose their own preferred option. Classes will run weekly for 8 weeks, duration 1 hour.
41159796|NCT03788421|PROCEDURE|Clamping and suturing|Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.
40833884|NCT04462991|DIAGNOSTIC_TEST|corneal topography|In all patients, TCT will be measured first by WaveLight® Oculyzer™II Pentacam HR and second by The Optovue AS-OCT .
40833885|NCT06228638|OTHER|CognivAID (Sailuotong)|CognivAiD is 27.27 mg of panax ginseng standard extract, 27.27 mg of gingo biloba standard extract and 5.46 mg of crocus sativus standard extract which is equal to 60mg /capsule .CognivAiD is available at 60 mg /cap 2 caps twice a day.
40833886|NCT02154685|BEHAVIORAL|Retrieval-Extinction|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
41353193|NCT00538486|DRUG|Amlodipine|Amlodipine 5mg 1/d
41353194|NCT00538486|DRUG|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
41353195|NCT04656717|OTHER|Measure of the total cost of performing next-generation sequencing (NGS)|Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.
41353196|NCT02809391|DEVICE|Orthotics alone|The sole thin sport orthotic will be heat moulded to participants footwear. A top cover will be used of similar cushioning thickness and durometer properties as the orthotics+texture intervention.
41353197|NCT02809391|DEVICE|Orthotics+textured top cover|The sole thin sport orthotic will be heat moulded to participants footwear. A textured material will be used as the orthotic top cover in this intervention.
41353198|NCT02884440|DRUG|TAP block ropivacaine|
41353199|NCT02884440|DRUG|TAP block placebo|
41353200|NCT02884440|DRUG|General anesthesia|Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
41494048|NCT00700323|DIETARY_SUPPLEMENT|PS-Omega3 conjugate supplementation|
41494049|NCT00700323|DIETARY_SUPPLEMENT|placebo|
41494050|NCT00140426|DRUG|Risperidone|risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
41494051|NCT00140426|DRUG|Placebo|Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
40833887|NCT02154685|BEHAVIORAL|Non-Retrieval Extinction|Neutral cue exposure.
41159797|NCT00030303|BIOLOGICAL|recombinant 70-kD heat-shock protein|
41353201|NCT00058318|DRUG|capecitabine|Capecitabine will be given 625 mg/m\^2 (1250 mg/m\^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
41353202|NCT00058318|DRUG|gemcitabine hydrochloride|Gemcitabine will be given 900 mg/m\^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
41353203|NCT01038544|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
41353204|NCT01038544|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
41353205|NCT02363673|OTHER|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
41353206|NCT01402622|DRUG|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
41353207|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation|A non-invasive method of brain stimulation that emits a magnetic pulse.
41353208|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation (sham)|No brain stimulation will be administered.
41353209|NCT01886144|DEVICE|Knee OA Brace|
41353210|NCT03174392|OTHER|Resistance Based Training|Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
41353211|NCT03174392|OTHER|Speed Based Training|Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
41353212|NCT04265859|BEHAVIORAL|Cognitive Behavioral Training|The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.
41353213|NCT04265859|BEHAVIORAL|Mindfulness|The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
41353214|NCT05030662|OTHER|Walking stick exercise|"1. Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)~2. The video clip of walking stick exercise is available to the patients.~3. The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge."
41353215|NCT00908895|PROCEDURE|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
41353216|NCT00908895|PROCEDURE|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
41021092|NCT05708079|PROCEDURE|Endovascular thrombectomy|An endovascular thrombectomy is the removal of a thrombus (blood clot) under image guidance. A thrombectomy is most commonly performed for an arterial embolism, which is an arterial blockage often caused by atrial fibrillation, a heart rhythm disorder.
41353217|NCT06186895|DRUG|Dexmedetomidine|received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.
41353218|NCT06186895|DRUG|Fentanyl|fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
41353219|NCT04306770|OTHER|OPTIMUM programme|"OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content."
41353220|NCT00207493|BEHAVIORAL|Kit enhancement to referral|
41353221|NCT00207493|PROCEDURE|patient referral versus contract referral|
41353222|NCT00536094|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
40833888|NCT02506660|DRUG|Bupivacaine|
41494052|NCT00543608|DRUG|iclaprim|
41353223|NCT00536094|BEHAVIORAL|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
41353224|NCT03124524|DRUG|estradiol valerate/dienogest|oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
41353225|NCT03124524|DRUG|ethinylestradiol and drospirenone|oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
41353226|NCT01859884|BEHAVIORAL|Inform Me: web-based education tool|The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
41353227|NCT04904640|DEVICE|Hip stem|In every hip (with appropriate CT scan), 3 different stem designs will be positioned using a 3D Ct based software for surgical pre-operative planning.
41353228|NCT05703490|DIAGNOSTIC_TEST|IADLSys system|Subjects will receive IADLSys system which includes interactive tablet and 5 paired pTAGs (bluetooth sensors to attach to objects of interest at home). The pTAGs monitor activities of daily living to assess if they are being completed and communicate with the tablet to keep record of interactions. We anticipate IADLSys enables to distinguish between groups with and without cognitive impairment and determine the severity of cognitive impairment in the cognitive impaired group.
41021093|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
41353229|NCT01981096|BEHAVIORAL|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
41353230|NCT01981096|BEHAVIORAL|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
41353231|NCT04915937|OTHER|Study Infant Formula|RTF milk-based infant formula with oligosaccharides
41494053|NCT00543608|DRUG|vancomycin|
41494054|NCT02066948|OTHER|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
41494055|NCT02066948|OTHER|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
41494056|NCT02066948|OTHER|meal pattern|skew or even
41494057|NCT02066948|DIETARY_SUPPLEMENT|even|even amount of protein distributed between each meal
41494058|NCT02066948|DIETARY_SUPPLEMENT|skew|a skewed amount of protein is distributed between each meal
41494059|NCT01593514|BIOLOGICAL|MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
41494060|NCT01593514|BIOLOGICAL|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
41494061|NCT01593514|BIOLOGICAL|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
41494062|NCT01593514|BIOLOGICAL|1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
41494063|NCT01593514|BIOLOGICAL|Polysaccharide (subcutaneously)-conjugate|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
41021094|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
41021095|NCT02908269|BIOLOGICAL|Fluzone High-Dose, vaccine, 2016-2017 formulation|0.5 mL, Intramuscular
41021096|NCT04623801|PROCEDURE|Percutaneous Laser Ablation (PLA)|Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.
41021097|NCT04934670|DRUG|T-Guard|T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
41021098|NCT04934670|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
41159798|NCT02806596|DRUG|Sevoflurane|After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).
41353232|NCT04589832|DRUG|PAC-1|Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.
40833889|NCT02506660|DRUG|Perineural dexamethasone|Dexamethasone in nerve block
41021099|NCT05582863|OTHER|Virtual reality exercise intervention|The experimental group performed a 75-90-minute VR exercise routine twice a week for 12 weeks.
41021100|NCT00002181|DRUG|Cidofovir|
41021101|NCT06393361|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
41021102|NCT06393361|DRUG|Brentuximab Vedotin, anti-PD-1 antibody.|Brentuximab Vedotin 1.8mg/kg d1, anti-PD-1 antibody d1. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
41159799|NCT04031547|DEVICE|Transcranial Electrical Stimulation (tES)|In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
41159800|NCT06318364|OTHER|NO Intervention|NO Intervention
41353233|NCT04589832|DRUG|Entrectinib|Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
41353234|NCT03088410|DRUG|Zidovudine|neonatal 4 weeks prophylactic
41353235|NCT03088410|DRUG|Nevirapine|neonatal 4 weeks prophylactic
40833890|NCT02506660|DRUG|Intravenous dexamethasone|
40833891|NCT02506660|DRUG|Intravenous saline|
40833892|NCT02506660|DRUG|Perineural saline|Saline in nerve block
40833893|NCT02194322|DRUG|BIBN 4096 BS - in single rising doses|
40833894|NCT02194322|DRUG|Placebo|
41353236|NCT03996525|DEVICE|Electrical Stimulation|"Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~1. Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~2. Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision."
41353237|NCT03996525|DEVICE|Sham Treatment|"Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~1. Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~2. Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision."
41353238|NCT06482138|PROCEDURE|Biopsy and Cytobrush|Collection of olfactory cleft biopsies and cytobrushes
41353239|NCT01578525|OTHER|Pharmaceutical Care Service|Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
41353240|NCT03485404|DRUG|methylcobalamin|methylcobalamin tablets, 0.5mg/tablet, 3 tablets/day.
41353241|NCT03485404|DRUG|Folic Acid|folic acid tablets, 5mg/tablet, 1 tablet/day
41353242|NCT03485404|OTHER|Placebo for methylcobalamin|orange tablets that looks exactly like methylcobalamin
41494064|NCT03126617|BIOLOGICAL|Elotuzumab|Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
41494065|NCT00128830|DRUG|Etravirine (ETR)|Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
41494066|NCT00128830|DRUG|Nucleotide reverse transcriptase inhibitors (NRTIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
41494067|NCT00128830|DRUG|Protease inhibitors (PIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
41353243|NCT03485404|OTHER|Placebo for folic acid|yellow tablets that looks exactly like folic acid
41353244|NCT03485404|PROCEDURE|non-cardiac surgery|patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention
41353245|NCT03485404|BEHAVIORAL|NPB test|participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
41353246|NCT00377468|DRUG|Delta9-Tetrahydrocannabinol|
41494068|NCT00128830|DRUG|Enfuvirtide (ENF)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
41353247|NCT00675129|BEHAVIORAL|Dialectical behavioral therapy for adolescents (DBT-A)|"Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
41353248|NCT00675129|BEHAVIORAL|Treatment as usual|Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
41353249|NCT02869451|DRUG|bupropion|Prescribed one week prior to quit and continued until the 6 month follow-up visit.
41494069|NCT04100720|DEVICE|Cardiovalve Transfemoral Tricuspid Valve|The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
41494070|NCT02599038|DIETARY_SUPPLEMENT|Serine supplementation|Serine supplementation (200 mg/kg/day)
40833895|NCT02899923|OTHER|Data collection|
40833896|NCT01152515|DRUG|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
40833897|NCT03033563|PROCEDURE|Intracytoplasmic sperm injection|Intracytoplasmic sperm injection
40833898|NCT01557959|DRUG|cisplatin|Given IV
40833899|NCT01557959|BIOLOGICAL|pegfilgrastim|Given SC
41021103|NCT04736459|PROCEDURE|Pre-washed catheter vs. Unwashed catheter in the intrauterine insemination|The pre-washed catheter will be washed with culture medium before intrauterine insemination The unwashed catheter will not be washed with culture medium as a standard intrauterine insemination procedure
41353250|NCT02869451|DRUG|transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
40833900|NCT01557959|DRUG|erlotinib hydrochloride|Given PO
40833901|NCT01557959|OTHER|laboratory biomarker analysis|Optional correlative study
41021104|NCT05895006|DEVICE|alpha-frequency tACS|The investigators will apply a 2 mA sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup.
41353251|NCT02869451|DRUG|Nicotine polacrilex|Initiated at smoking quit date.
41353252|NCT02869451|DRUG|nicotine lozenge|Initiated at smoking quit date.
41353253|NCT02869451|BEHAVIORAL|counseling for marijuana and smoking cessation|5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
41353254|NCT02869451|BEHAVIORAL|mobile contingency management|treatment that provides money rewards for abstinence from smoking and marijuana
41353255|NCT05727527|PROCEDURE|Local Anesthesia 1|Local anesthesia injection after applying a candy flavor
41353256|NCT05727527|PROCEDURE|Local Anesthesia 2|Local anesthesia injection after applying sterile water
41353257|NCT02402049|DRUG|Natrum muriaticum 30C|3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
41353258|NCT02402049|DRUG|Lachesis 30C|3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
41353259|NCT02402049|DRUG|Sepia 30C|3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
41353260|NCT02402049|DRUG|Nux vomica 30C|3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
41494071|NCT03340363|BEHAVIORAL|environmental change|"1. Offer kid-friendly, low-cost recipes in a prominent, high-traffic location.~2. Offer healthy default ingredients (bundled ingredients promoted with recipes).~3. Promote recipe ingredients with prominently displayed signage and images.~4. Promote recipes in multiple locations throughout the store."
41494072|NCT03340363|BEHAVIORAL|messaging|Short, behavioral messages sent to participants via text message or email each week to promote the in-store environmental changes
40833902|NCT01557959|GENETIC|polymorphism analysis|Correlative study
40833903|NCT01557959|OTHER|pharmacogenomic studies|Correlative study
40833904|NCT01557959|GENETIC|genetic linkage analysis|Correlative study
40833905|NCT01557959|DRUG|docetaxel|Given IV
41021105|NCT05895006|DEVICE|Random noise stimulation|The investigators will apply a 2 mA sinusoid current oscillating at random frequency (1-200 Hz).
40833906|NCT05566262|DRUG|Bodewell Calming Cream|Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
41021106|NCT00204191|DRUG|tacrolimus|
41021107|NCT00509197|DRUG|Placebo (sham inhaler)|
41353261|NCT02402049|DRUG|Pulsatilla 30C|3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
41494073|NCT04127214|OTHER|ITA Integrated Treatment|The ITA Model combines outpatient intervention (mainly psychotherapy), day hospital care and hospitalization as a function of patients' characteristics. Case conceptualization of the psychological processes of patients is formulated and revised within a team including psychologists, psychotherapists, psychiatrists, nutritionists, physicians, nurses, and social workers. The major emphasis of the ITA model is on psychological interventions which include individual psychotherapy, family therapy and/or guidance, and group therapy of various formats and contents (e.g., drug abuse, mindfulness, emotion work) tailored to the needs of each patient. However, when required, drugs are prescribed adjusting type of medication and dosage to the need of the patient.
41353262|NCT02402049|DRUG|Folliculinum 30C|3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
41353263|NCT02402049|DRUG|Placebo Natrum muriaticum|3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
41353264|NCT02402049|DRUG|Placebo Lachesis|3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.
41494074|NCT02511821|OTHER|Computer-Assisted Intervention|Complete online surveys
41494075|NCT02511821|DEVICE|Vivofit watch|Wear Vivofit watch
41494076|NCT02511821|OTHER|Quality-of-Life Assessment|Ancillary studies
41494077|NCT02511821|OTHER|Questionnaire Administration|Ancillary studies
41021108|NCT00509197|DRUG|Fluticasone|Fluticasone 250mcg bid for one month
41353265|NCT02402049|DRUG|Placebo Sepia|3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
41353266|NCT02402049|DRUG|Placebo Nux vomica|3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
41353267|NCT02402049|DRUG|Placebo pulsatilla|3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
41353268|NCT02402049|DRUG|Placebo Folliculinum|3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
41353269|NCT02967172|DRUG|Ropivacaine|
41353270|NCT02967172|DRUG|Epinephrine|
41353271|NCT02967172|DRUG|Morphine|
41353272|NCT02967172|DRUG|0.9% sodium chloride solution|
41353273|NCT01889615|OTHER|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
41494078|NCT04428515|DEVICE|Photoacoustic Imaging System|Photoacoustic Imaging investigate changes of measured PA markers and compare these to radiological assessment of response of lymph node involvement to chemoradiation therapy for head and neck cancer
41494079|NCT06162130|DIAGNOSTIC_TEST|Eccentric quadriceps exercises|The activation of the vastus medialis, vastus lateralis, and rectus femoris muscles will be measured using surface electromyography (sEMG) during four distinct quadriceps eccentric exercises: Reverse Nordic, Pistol squat, Suspension-based Bulgarian split squat, and Bulgarian split squat. Participants will be instructed to perform three successful repetitions for each exercise. A 30-second break will be provided between each repetition, and there will be a minimum of 10 minutes of rest between each of the four exercises. Due to the belief that fatigue could impact exercise performance, the modified Borg scale will be used to ensure that fatigue does not occur before each exercise. Exercise recording will commence when scores reported using the modified Borg scale are 1 or lower.
40833907|NCT03772418|DRUG|Cream Base|The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
41021109|NCT00451620|DRUG|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
41021110|NCT00451620|DRUG|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
41353274|NCT02423733|OTHER|The Journal|"The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care."
41353275|NCT01113411|DEVICE|PHILOS™ locked plate system by Synthes Canada©|The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.
41353276|NCT01113411|OTHER|Early and intensive exercise program|"A thoraco brachial brace will be worn for 48 hours following the surgery and then removed for the remainder of treatment. Patients will then start the intensive rehabilitation program without physical therapy. The exercise program will be provided to the patient.~The exercises consist of active and active assisted movements of the shoulder for a period of six weeks, limiting external rotation to 0 °. Patients are encouraged to use their affected limb for daily activities. Strengthening exercises are started the 6th week following surgery and the full program will be completed three months after surgery. Patients who wish can then continue their rehabilitation with a physiotherapist.~The patient will complete a daily diary to validate the frequency and intensity of the exercises."
41021111|NCT06325995|RADIATION|Conventional radiation therapy|66-74 Gy in 33-37 daily fractions of 2 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
41021112|NCT06325995|RADIATION|Hypofractionated radiation therapy|57.5-65 Gy in 23-26 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
41021113|NCT00403091|BEHAVIORAL|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
41021114|NCT00403091|BEHAVIORAL|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
41021115|NCT01642797|DEVICE|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
41353277|NCT01113411|OTHER|Standard rehabilitation program|The patient will wear the thoraco brachial brace for a period of four weeks following the surgery. It may be taken off for hygiene purposes and dressing up. After the four weeks, the patient will take the brace off permanently and begins an exercise program, writing down the frequency and intensity of the exercises. Physiotherapy is allowed for the remaining part of the three months rehabilitation program.
41494080|NCT01567748|PROCEDURE|BP Measurements at aorta, radial and femoral locations|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
41494081|NCT02798432|PROCEDURE|Total knee arthroplasty|Use of an uncemented femoral component or a cemented femoral component randomly assigned.
41494082|NCT02798432|DEVICE|NEXGEN LPS total knee arthroplasty|Hybrid (non cemented femoral component, cemented tibial component) NEXGEN LPS total knee arthroplasty versus Cemented NEXGEN LPS total knee arthroplasty (both components are cemented).
41494083|NCT01804218|DRUG|Nadolol|
41494084|NCT01804218|DRUG|Placebo|
41494085|NCT00782821|DRUG|Rabbit Antithymocyte Globulin|rATG will be given 1.5mg/kg intravenous (IV) per dose.
41494086|NCT00782821|DRUG|Velcade|Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
41494087|NCT00782821|DRUG|Rituxan|Given via IV per group assignment.
41494088|NCT04758975|DRUG|Venetoclax|VENETOCLAX: Ramp-up than 400 mg QD
41021116|NCT01642797|DEVICE|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
41494089|NCT04758975|DRUG|Rituximab|RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2
41494090|NCT04758975|DRUG|Ibrutinib|IBRUTINIB 420 mg QD
41021117|NCT05395377|BEHAVIORAL|Registered Dietitian/Nutritionist|Participants received a FitBit Flex and Intensive Lifestyle Intervention coaching via telephone with Registered Dietitian/Nutritionist.
41494091|NCT02737982|PROCEDURE|percutaneous coronary intervention|coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion
41494092|NCT03096743|DIAGNOSTIC_TEST|MR elastography|MR elastography image acquisition will be conducted on the Compact 3T MRI scanner using a modified single-shot spin-echo echo-planar imaging pulse sequence.
41494093|NCT03096743|DIAGNOSTIC_TEST|MRI structural brain imaging|MRI structural brain imaging will be done on the Compact 3T MRI at the same time as MR elastography.
41021118|NCT05395377|BEHAVIORAL|Diabetes Prevention Program|Modified DPP group classes lead by a Registered Dietitian and Exercise Physiologist.
41494094|NCT03096743|PROCEDURE|Lumbar puncture|All patients with papilledema will get lumbar punctures with opening pressure as part of their work-up for papilledema. A small number of patients without increased intracranial pressure will receive a lumbar puncture.
41494095|NCT03096743|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) imaging|Optical Coherence Tomography (OCT) imaging will measure the peripapillary retinal nerve fiber layer (RNFL) thickness measurements The images with enhanced depth imaging will be obtained to measure the Bruch's membrane orientation.
41494096|NCT03096743|DIAGNOSTIC_TEST|Optic nerve B-scan ultrasound|Ultrasound will be used to measure the optic nerve sheath diameter 3 mm posterior to the posterior scleral surface.
41494097|NCT04030065|DRUG|Omega 3 fatty acid|10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
41494098|NCT02910063|DRUG|Blinatumomab|Blinatumomab monotherapy
41021119|NCT05395377|BEHAVIORAL|Weight Watchers, Reimagined|Participants in this group were provided with an online access code to enroll in WW and could choose the format of their choice- group, online, and/or smartphone app.
41021120|NCT05395377|BEHAVIORAL|DPP or RDN Counseling + Medication|Participants met with a weight management specialist to receive weight loss medications, as well as, receiving either the DPP or Registered Dietitian coaching. Medications utilized in this study were Phentermine and Metformin. Metformin was prescribed if the participant could not tolerate Phentermine.
41021121|NCT05395377|OTHER|Bariatric Surgery Evaluation|Participants (BMI \> 40) were offered a consultation with the bariatric surgical program that requires lifestyle weight management during the first 6 months. Participants were also able to choose to receive one of the other 4 intervention options in the first six months prior to consideration for bariatric surgery.
41021122|NCT00001100|DRUG|ganciclovir|
41353278|NCT01087229|DRUG|equimolar oxygen-nitrous oxide mixture|Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.
41353279|NCT01087229|DRUG|Placebo|Kinesitherapy is performed with a mask by which patient inhales a placebo.
41353280|NCT00069251|DRUG|Bupropion|
41353281|NCT05278884|BEHAVIORAL|Advanced Cardiac Life Support Training|Advanced Cardiovascular Life Support (ACLS) is a resuscitation course to teach recognition and treatment of cardiopulmonary arrest in patients.
41353282|NCT05278884|BEHAVIORAL|Vital Anesthesia Simulation Training|The Vital Anesthesia Simulation Training (VAST) Course focuses on core clinical practices and non-technical skills needed to respond to the most common urgent and emergent clinical challenges found in hospitals in resource-limited settings like Rwanda.
41494099|NCT05824247|DEVICE|68Ga-FAPI-PET-CT|a new technology that using Fibroblast activation protein （FAP）inhibitor as the tracer of PET-CT
41494100|NCT00476983|DRUG|saquinavir/ritonavir plus truvada|SQV/r 1500/100 mg OD + Truvada OD for 2 years
41353283|NCT03463044|DRUG|nangibotide|Continous i.v. infusion
41494101|NCT04129359|BEHAVIORAL|FamilieTrivsel|FamilieTrivsel is a modular internet-based low-cost and brief psychoeducation intervention based on the Robusthed (Resilience) programme (RP). Mentalisation approaches are used to increase resilience and ability to handle the challenges of life. The programme is licence free and can be used with low or high intensity and it can be combined with any other interventions. RP provides simple explanations and tools that can be used to discover, understand and regulate one's own thoughts and feelings by activating mental and physical resources and it provides examples and exercises that may promote communication about mental states between parents and the child. The content has been developed to include video-based training sessions based on different stages of pregnancy and early childrearing. RP appears suitable for use in general practice, where the GP sees young parents regularly and thus can direct patients towards components of the programme when need appears greatest.
41494102|NCT04129359|OTHER|enhanced care as usual|Structured assessments of maternal mental health, child neurodevelopment and parent-child interaction in routine preventive health care in general practice
41494103|NCT00021580|PROCEDURE|human cadaveric islet cell transplantation|
41494104|NCT05498402|DEVICE|i-gel ® device|Ventilations will be delivered through an i-gel ® device
40833908|NCT03772418|DRUG|Pomegrante and Ginkgo biloba group|The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
40833909|NCT04570683|DRUG|Nivolumab 10 MG/ML|Se previously
40833910|NCT04570683|DEVICE|Ablative fractionated laser|Se previously
40833911|NCT06516744|DIETARY_SUPPLEMENT|Bye Bye Bloat Capsules|Bye Bye Bloat Capsules contain the following ingredients: Organic Fenugreek Seed Powder, Organic Dandelion Root Powder, Organic Fennel Seed Powder, Organic Ginger Root Powder, Organic Parsley Leaf Powder, Amylase Complex, Protease Complex, Pepsin Complex, Lipase Complex, Bromelain Complex, Papain Complex. Other ingredients include Hypromellose Capsule, Maltodextrin, Microcrystalline Cellulose, and Magnesium Stearate. Participants will take 2 capsules immediately after eating at least 3 times a week and during times of hormonal bloating for 4 weeks.
40833912|NCT04413903|PROCEDURE|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
41159801|NCT03009877|DEVICE|Optiflow F&P 850™ System|"Optiflow™ (Fisher \& Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.~This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction."
41159802|NCT03009877|DEVICE|facemask|We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.
41353284|NCT03463044|DRUG|Placebo|Placebo
41353285|NCT03779828|DEVICE|HOME LINK|Telemonitoring system which include web platform and connected devices.
41353286|NCT03085342|DIAGNOSTIC_TEST|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
41353287|NCT03028532|DRUG|Clomid|Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
41353288|NCT02079506|DRUG|Candesartan|
41353289|NCT02079506|DRUG|Rosuvastatin|
41353290|NCT05116111|DRUG|SYHA1402 tablets|SYHA1402 tablets, oral, twice daily
41353291|NCT05116111|DRUG|Placebo|Placebo, oral, twice daily
41353292|NCT03088345|DRUG|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
41353293|NCT03088345|DRUG|Placebo|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
41353294|NCT05737004|DIAGNOSTIC_TEST|functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II|fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
41353295|NCT00645229|DRUG|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
41353296|NCT04727411|PROCEDURE|XEN45 Gel stent|XEN Gel stent implantation either combined or as a stand-alone procedure
41353297|NCT04727411|PROCEDURE|Trabeculectomy|XEN Gel stent implantation either combined or as a stand-alone procedure
41494105|NCT05498402|DEVICE|bag-valve-mask ventilation|Ventilations will be delivered using a bag-valve-mask
41159803|NCT03009877|DRUG|Rocuronium|Rocuronium will be administered after the ability to mask ventilate is determined.
41021123|NCT04894435|BIOLOGICAL|mRNA-1273 SARS-CoV-2 vaccine|Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.
41021124|NCT04894435|BIOLOGICAL|BNT162b2|A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.
41021125|NCT04894435|BIOLOGICAL|ChAdOx1-S [recombinant]|A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).
41021126|NCT04894435|OTHER|0, 28 day schedule|Second injection administered 28 days post first injection
41021127|NCT04894435|OTHER|0, 112 day schedule|Second injection administered 112 days post first injection
41021128|NCT04894435|BIOLOGICAL|Covifenz|COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration
41021129|NCT01611259|DRUG|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
41021130|NCT06387472|DEVICE|AI algorithm to evaluate photographs of skin test patch regions|Interpretation of skin test patch regions via artificial intelligence (AI)
41159804|NCT03009877|DRUG|Propofol|Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
41159805|NCT03009877|DRUG|Fentanyl|Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
41159806|NCT03009877|DRUG|Midazolam|midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
41353298|NCT01524809|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
41353299|NCT01524809|DRUG|biphasic insulin aspart 70|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
41353300|NCT04058795|BEHAVIORAL|Cancer Distress Coach (CaDC) App|an app that provides participants with tools to manage their stress in the moment they experience it.
41353301|NCT04058795|BEHAVIORAL|CaDC + mCoaching|The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.
41353302|NCT04058795|BEHAVIORAL|mCBT|8 mobile sessions with a therapist to receive cognitive behavioral therapy.
41353303|NCT06250933|OTHER|Postpartum Maternal Care and Premature Infant Care Training|"Intervention groups of women will receive a single-session intervention program in addition to their routine care.~The intervention, conducted in a single session, encompasses the provision of an educational program designed to enhance women's breastfeeding and maternal self-efficacy and mitigate the risk of postpartum depression.~During the educational phase, women will receive training on postpartum maternal care and premature infant care"
41353304|NCT04102410|OTHER|Sprints|"Two sprints of 8 seconds on a cycle ergometer will be performed for determine Force/Velocity Profile (FVP).~Realized at inclusion and 2 months after."
41353305|NCT04102410|OTHER|Vertical jumps|"Two vertical jumps will be performed. Height of theses vertical jumps will be measured by application My jump 2 to determine muscle power.~Realized at inclusion and 2 months after."
41353306|NCT04102410|OTHER|Questionary Short Form-12 (SF-12)|"Questionary Short Form-12 (SF-12) will be performed to evaluate quality of life. It is composed of 12 questions.~Realized at inclusion and 2 months after."
41353307|NCT04102410|DEVICE|activity actigraph|"Activity actigraph will be wearing by patient during 7 consecutive days. It measures the level of physical activity and the sedentary lifestyle of patients.~Realized at inclusion and 2 months after."
41353308|NCT04102410|OTHER|Program composed of two 2 training strategies|"Program composed of two 2 training strategies according to the initial Force/Velocity Profile (FVP) will be realized at the inclusion.~There are :~* Strategy experimental-speed: speed training strategy for subjects with a force-speed profile (PFV) in favour of force~* Strategy experimental-force: force training strategy for subjects with a force-speed profile (PFV) in favour of speed."
41353309|NCT04102410|OTHER|Program of usual practice|Program composed of training in force and speed independently of the initial Force/Velocity Profile (FVP).
41353310|NCT00003736|DRUG|motexafin gadolinium|
41353311|NCT00003736|PROCEDURE|biopsy|
41353312|NCT00003736|PROCEDURE|breast imaging study|
41353313|NCT00003736|PROCEDURE|comparison of screening methods|
41353314|NCT00003736|PROCEDURE|magnetic resonance imaging|
41353315|NCT00003736|PROCEDURE|study of high risk factors|
41353316|NCT04808492|DEVICE|CureWave High Intensity Laser|"* The participant will lie prone and the HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. The dose will include:~  * Power (44 Watts)~ * Mode (continues wave)~ * Time on (60000 ms)~ * Time off (1 ms)~ * Repeats (9)~* Distance of electrode from skin will begin 10 from skin surface. The participant may or may not feel mild warmth. Should the subject report excessive warmth or discomfort the probe distance will be increased in 2 intervals until it is comfortable. The entire process will take approximately 10 minutes.~* The participant will lie prone and the Placebo treatment will consist of positioning the HILT probe over the 9 symmetrical positions for 1 minutes each however the no laser will be admitted."
41353317|NCT04808492|OTHER|Placebo|"The participant will lie prone and the NON ACTIVE HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. THE LASER WILL NOT BE ACTIVE.~o Distance of electrode from skin will begin 10 from skin surface. The entire process will take approximately 10 minutes."
41353318|NCT00661362|DRUG|Saxagliptin|Oral tablet, once daily for 24 weeks
41353319|NCT00661362|DRUG|Placebo|oral tablet, once daily for 24 weeks
41353320|NCT00661362|DRUG|Metformin|oral tablet, once daily for 24 weeks
40833913|NCT00663299|DEVICE|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
40833914|NCT02054793|DRUG|Itraconazole|100 mg 200 mg 300 mg
40833915|NCT02054793|DRUG|Orteronel|300 mg
40833916|NCT02448888|OTHER|Adapted exercise|2 months, 3 times/week
40833917|NCT02448888|OTHER|General exercise recommendations|2 months, 3 times/week
40833918|NCT02725112|DRUG|Pregabalin ER|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
40833919|NCT02725112|DRUG|Pregabalin ER|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
41353321|NCT05989152|RADIATION|FDG-PET at the end of treatment for IE|FDG-PET at the end of treatment for IE in patients with a prosthetic valve
41353322|NCT00309361|DRUG|Phentolamine Mesylate (NV-101)|
41353323|NCT04331808|DRUG|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
40833920|NCT02725112|DRUG|Pregabalin ER|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
40833921|NCT02725112|DRUG|Pregabalin ER|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
40833922|NCT02725112|DRUG|Pregabalin ER|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
40833923|NCT02725112|DRUG|Pregabalin ER|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
40833924|NCT01046240|DRUG|Palonosetron|Palonosetron 3 mg administered SC or IV
40833925|NCT00350467|DRUG|ER OROS paliperidone and Olanzapine|
40833926|NCT05045677|OTHER|digital DBT skills intervention|The digital intervention consists of 6 modules that will be delivered over 6 to 10 days. The modules cover mindfulness skills, emotion regulation skills and distress tolerance skills.
40833927|NCT05045677|OTHER|Standard Care|Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).
40833928|NCT06182696|BIOLOGICAL|OriCAR-017|GPCRC5D-directed chimeric antigen receptor modified T cells
40833929|NCT00033540|DRUG|capecitabine|650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
40833930|NCT00033540|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
40833931|NCT02762747|PROCEDURE|preperitoneal suction drainage|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
40833932|NCT01407523|DRUG|Levetiracetam|"* Formulation: concentrate for solution for infusion~* Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~* Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~* Frequency: twice daily"
41021131|NCT06387472|DEVICE|Allergen Patch|Contains dime-sized disks which have different substance to which a person may be allergic.
41353324|NCT00805649|PROCEDURE|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
41353325|NCT00805649|PROCEDURE|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
41353326|NCT00805649|DRUG|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
41353327|NCT00805649|DRUG|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
41353328|NCT00805649|PROCEDURE|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
41353329|NCT00805649|DRUG|triamcincolone|intravitreal injection of 8 mg triamcincolone
41353330|NCT00952471|OTHER|Evidence Based Intervention to order set|The order set was altered to include evidence based care items
41353331|NCT00476190|DRUG|Doxorubicin|Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.
41353332|NCT00476190|DRUG|Cytarabine|Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
41353333|NCT00476190|DRUG|Methotrexate|"Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).~Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks."
41353334|NCT00476190|DRUG|Vincristine|Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.
41353335|NCT00476190|DRUG|Cyclophosphamide|Consolidation IB: Intravenously on day 1
41353336|NCT00476190|DRUG|Methylprednisone|Prophase: Intravenously on days 1-3
41353337|NCT00476190|DRUG|Hydrocortisone Sodium Succinate|Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.
41353338|NCT00476190|DRUG|Dexamethasone|Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.
41353339|NCT00476190|DRUG|6-MP|Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.
41353340|NCT00476190|DRUG|PEG-Asparaginase|"Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.~Consolidation II: Intravenously every 3 weeks."
40833933|NCT05782114|OTHER|Extracorporeal Shockwave therapy|The shockwave will be applied for the experimental group (Group A). The patients will be positioned on a chair, and the hand with the disorder will be placed on a surface with the radio ulnar joint will be in mid position and the thumb will be directed up. will be 1000 impulses with 2 bar pressure at a frequency of 15 Hz on the radial head and focused on the tissue surrounding the maximal pain point.
41159807|NCT03009877|DEVICE|C-MAC Premium Video Intubation Platform-KARL STORZ|After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
41353341|NCT00476190|DRUG|Imatinib|Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.
41353342|NCT00476190|DRUG|Etoposide|Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.
41353343|NCT00476190|PROCEDURE|Radiation Therapy|Given during CNS Therapy either 8 or 10 daily treatments, on days 1-8 or 1-10, depending upon leukemia involvement in the CSF
41353344|NCT00476190|DRUG|E. coli Asparaginase|Intramuscularly Day 7 of Induction.
41353345|NCT00369889|DRUG|bevacizumab|iv every 21 days
41353346|NCT00369889|DRUG|Erlotinib|oral daily
41353347|NCT01809327|DRUG|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
41353348|NCT01809327|DRUG|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
41353349|NCT01809327|DRUG|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
41353350|NCT00906555|PROCEDURE|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
41353351|NCT04399993|OTHER|Intervention Protocol in Diaphragm|"The protocol consists of three techniques. The two first techniques will be applied for 10 respiratory cycles.~Muscle Stretching Technique:~the researcher will perform a cephalic traction on the inferior costal border with the ulnar border during the inspiratory phase.~Phrenic-center inhibition technique:~the researcher, with a hand on the sternum to caudal and other hand on the umbilical region to cranial, will approach his hands on the horizontal plane, when the volunteer exales.~Functional diaphragm technique:~the researcher will perform a vertical pressure on the diaphragm for 5 minutes and will search for the facilitated parameters and maintain them until the release of all the periarticular elements."
41353352|NCT04399993|OTHER|Sham technique|In the sham group a manual contact without any therapeutic intention will be performed, in a distant region of the diaphragm (for example on the trapezius muscle). This contact will be maintained during the same amount of time as for the treatment group.
41353353|NCT02084316|BEHAVIORAL|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
41353354|NCT02084316|BEHAVIORAL|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
41353355|NCT01512849|DRUG|TA-7284 Low|Low
41353356|NCT01512849|DRUG|TA-7284 High|High
41159808|NCT06459037|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
41494106|NCT03267563|BEHAVIORAL|EIAU|Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
41494107|NCT03267563|BEHAVIORAL|LICF|"Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting."
41353357|NCT05314699|BEHAVIORAL|resistance-aerobic exercise, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
41353358|NCT05314699|BEHAVIORAL|aerobic-resistance exercise, AR|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cold down.
41353359|NCT00172003|DRUG|Zoledronic acid|
41353360|NCT05948722|BEHAVIORAL|Motivational Interview Group (MIG)|Brief MI intervention with the conventional treatment
41494108|NCT03267563|BEHAVIORAL|HICF|Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
41494109|NCT00049582|DRUG|decitabine|Given IV
41494110|NCT00049582|OTHER|laboratory biomarker analysis|Correlative studies
41494111|NCT00049582|OTHER|pharmacological study|Correlative studies
41494112|NCT05447000|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring anxiety levels with mindfulness program
41494113|NCT05447000|BEHAVIORAL|Deep Relaxation Exercises intervention|Deep Relaxation Exercises intervention: Monitoring anxiety levels with deep Relaxation Exercises intervention
41494114|NCT05447000|OTHER|No Intervention|No Intervention
41353361|NCT05948722|PROCEDURE|Conventional treatment group (CTG)|Conventional treatment
41353362|NCT00106496|DRUG|Protopic|topical
41353363|NCT00106496|DRUG|Corticosteroid|topical
41353364|NCT00106496|DRUG|placebo|topical
41353365|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 15 minutes (Intervention)|Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
41353366|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 30 minutes (Control)|Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
41353367|NCT03513432|DIETARY_SUPPLEMENT|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day during 4 weeks
41353368|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks
41494115|NCT01345435|PROCEDURE|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
40833934|NCT05782114|OTHER|Traditional physical therapy program|"1. Instruction to wear Thumb Spica splint:~   The Thumb Spica splint will be used for 4 weeks for both groups of patients.~2. Ultrasound Therapy:~   Therapeutic Ultrasound parameters will be mode: continuous, duration: 5 minutes, intensity: 1.2watt/cm2 and frequency: 1MHZ.~3. Stretching exercise:~1. Self-stretch of the thenar eminence: 2. Opposition stretches: 3. Wrist stretch:~4) Strengthening exercise:~1. Resisted exercise for thumb extension:~2. Resisted exercise for thumb abduction:~3. Resisted exercise for thumb opposition:~4. Wrist radial deviation strengthening:~5. Grip strengthening:~6. Finger spring:"
40833935|NCT05545865|OTHER|Low Flavanol Cocoa Powder|Measure the response 2 and 6 hours post low flavanol cocoa intake
40833936|NCT05545865|OTHER|High Flavanol Cocoa Powder|Measure the response 2 and 6 hours post high flavanol cocoa intake
40833937|NCT05545865|OTHER|Vine to Bar Chocolate - 2 servings|Measure the response 2 and 6 hours post chocolate intake
40833938|NCT05545865|OTHER|Vine to Bar Chocolate - 1 serving|Measure the response 2 and 6 hours post chocolate intake
41353369|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.00 % alcohol|330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
41353370|NCT00600639|DEVICE|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
41353371|NCT00600639|DRUG|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
41353372|NCT00600639|DRUG|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
41353373|NCT04893395|OTHER|Pharmacogenomic Screening|"First telehealth appointment:~1. Pharmacogenomics education and informed consent~2. Medical history~3. Sample collection~Second telehealth appointment:~1. Results of pharmacogenomic testing~2. Utility and limitations of pharmacogenomic testing~3. Patient-specific potential impacts on current or future medication therapies~4. Answering of patient questions~5. Referral to mental health provider(s) for treatment-specific recommendations"
41353374|NCT02366715|DEVICE|HeatedHumidifiedHighFlowNasalCannula|"We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. \[3\] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.~Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016."
41353375|NCT04889937|DEVICE|PointCheck|PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose
41353376|NCT04709276|DRUG|Nivolumab|360 mg intravenously every 3 weeks
41353377|NCT04709276|DRUG|Ipilimumab|1 mg/kg intravenously every 6 weeks
41353378|NCT04709276|DRUG|Carboplatin|"AUC 4 mg/ml per minute intravenously every 3 weeks for up to 10 cycles.~Subjects will also receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving carboplatin."
41353379|NCT04709276|DRUG|Cabazitaxel|"20 or 25 mg/m2 intravenously every 3 weeks for up to 10 cycles.~Subjects will also take prednisone by mouth at a dose of 10 mg daily and receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving cabazitaxel."
41353380|NCT01349491|DRUG|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
41159809|NCT02643953|BEHAVIORAL|Incentives|1) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
40833939|NCT05545865|OTHER|Vine to Bar Chocolate covered almonds|Measure the response 2 and 6 hours post chocolate covered almond intake
41353381|NCT01349491|DRUG|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
41353382|NCT03855358|DRUG|TQB2450 Injection and Anlotinib Hydrochioride Capsules|TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
41353383|NCT03210415|OTHER|Observational Study Model|There is no intervention for the study.
41494116|NCT01345435|PROCEDURE|Telemonitoring & Telemedicine|The Telemonitoring \& Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
41494117|NCT01345435|OTHER|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
41494118|NCT02378350|DEVICE|Hemodialysis treatment (no specific device is defined)|
41494119|NCT02378350|DRUG|Peritoneal Dialysis treatment (no specific drug is defined)|
41494120|NCT02036359|DRUG|erlotinib|150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
41494121|NCT02036359|DRUG|docetaxel|receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
41494122|NCT01521416|OTHER|Data collection|"Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.~All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated."
41494123|NCT03840616|DRUG|Oteseconazole (VT-1161) 150mg capsule|600mg administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14.
41494124|NCT03840616|DRUG|Fluconazole 150mg capsule|150mg administered every 72 hours in 3 sequential doses starting on Day 1.
41494125|NCT03840616|DRUG|Placebo|Administered once weekly starting on Day 14.
41494126|NCT04796753|OTHER|Basketball Injury Defense|To establish a specific evaluation protocol for youth basketball players.
41494127|NCT06031987|DEVICE|CareSens N (iSENS)|Control group is asked to perform SMBG (4 times or more per day).
40833940|NCT03503058|BIOLOGICAL|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
40833941|NCT03503058|BIOLOGICAL|PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|"Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
41353384|NCT05713331|BEHAVIORAL|CLS-R|CLS-R Training includes school provider training in CLS via web platform and videoconferencing for workshops, consultation and coaching.CLS is a 10-12 week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom and home.
41353385|NCT03290586|DEVICE|Flower Cube|single use, sterile disposable fixation construct
41353386|NCT06353529|DRUG|Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution|2mL injection bilateral (4mL total) of 0.5% bupivacaine with 1:200,000 epinephrine solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
41353387|NCT06353529|DRUG|Placebo|2mL injection bilateral (4mL total) 0.9% saline solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
41353388|NCT00004024|BIOLOGICAL|aldesleukin|
41353389|NCT00004024|BIOLOGICAL|autologous tumor cell vaccine|
41353390|NCT00004024|BIOLOGICAL|muromonab-CD3|
41494128|NCT06031987|DEVICE|Freestyle Libre (Abbott)|CGM group is asked to scan CGM (4 times or more per day).
41494129|NCT03494335|OTHER|Online surveys|The investigators are recruiting health care providers for these surveys that are involved in or use imaging.
41494130|NCT00730223|DRUG|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
41159810|NCT02643953|BEHAVIORAL|Community|1) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
41159811|NCT03628456|DEVICE|International Biophysics AffloVest|High-frequency chest wall oscillation vest
41353391|NCT00004024|BIOLOGICAL|sargramostim|
41353392|NCT00004024|BIOLOGICAL|therapeutic autologous lymphocytes|
41353393|NCT00004024|PROCEDURE|surgical procedure|
41353394|NCT00004024|RADIATION|radiation therapy|
41353395|NCT00656227|DRUG|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
41353396|NCT01008436|DRUG|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
41159812|NCT03628456|DEVICE|Hill-Rom Monarch|High-frequency chest wall oscillation vest
41353397|NCT01008436|DRUG|Control|Traditional surgical Hemostasis
41353398|NCT01271049|OTHER|Novel Food Product|Novel food product containing essential oil blend
41353399|NCT01271049|OTHER|Control Food Product|Control food product
41353400|NCT05433064|DEVICE|Epidural Stimulator|Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
41353401|NCT03138798|DEVICE|Laboraide TM dental support device|Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
41494131|NCT03206580|OTHER|Concentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
40833942|NCT03503058|OTHER|Normal Saline|0.9% Sodium chloride
41353402|NCT04828928|PROCEDURE|electromyogram|Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
41353403|NCT03574987|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
41494132|NCT03206580|OTHER|Concentric-Eccentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric-eccentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
41494133|NCT05795738|BEHAVIORAL|Chinese character-based visuomotor training program|this program includes visual-perceptual-motor play, paper-pencil activities, and ipad games using Chinese character as activity materials
41494134|NCT05795738|BEHAVIORAL|traditional visuomotor training program|this program includes play and paper-and-pencil activities, ipad games using commercial or self-designed stuffs as activity materials
40833943|NCT03503058|DRUG|Chloroquine chemoprophylaxis alone|"Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS."
40833944|NCT03481712|DIAGNOSTIC_TEST|Diagnostic tests|"Head-to-head comparison between:~* CADScor and Diamond-Foster score~* Rb PET and 3T CMRI~* QFR and ICA-FFR"
41494135|NCT01570803|DEVICE|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
40833945|NCT00054691|DRUG|Iressa|250 mg by mouth daily
40833946|NCT06385535|BEHAVIORAL|Habit Reversal Training (HRT)|Habit Reversal Training (HRT) is a multicomponent treatment package developed to treat a repetitive behaviors. HRT includes (1) increasing awareness of discrete occurrences of tics and associated premonitory urges (PMUs; i.e., awareness training), (2) teaching the patient to suppress tics by engaging in behaviors that are physically incompatible with target tics (i.e., competing response \[CR\] training), and (3) prompting and reinforcing between-session patient engagement with therapeutic techniques and homework (i.e., providing social support).
40833947|NCT05090514|BEHAVIORAL|Reading and Growth Mindset|Parents and students receive a packet of age-appropriate books and educational materials (flyer/handouts, link to educational video) on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
41353404|NCT02308709|RADIATION|Ventilation image-guided radiotherapy|Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
41353405|NCT01913509|DEVICE|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
41494136|NCT01570803|DEVICE|Complete SE Stent|same to SMART CONTROL Stent
41494137|NCT02368574|PROCEDURE|Class II hysterectomy|Class II hysterectomy
41494138|NCT00420459|DRUG|Aripiprazole|All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
41494139|NCT05680935|DIAGNOSTIC_TEST|blood microRNA|all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.
40833948|NCT05090514|BEHAVIORAL|Wait-list Control|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read or any information on growth mindset and reading.
40833949|NCT00518674|PROCEDURE|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
40833950|NCT02907853|BEHAVIORAL|Contingency Management|as described above
41494140|NCT05680935|DIAGNOSTIC_TEST|plaque and intima microRNA|The resulting surgical material will be sent for microRNA isolation.
41494141|NCT05680935|DIAGNOSTIC_TEST|histological examination of the plaque|The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.
41494142|NCT05680935|DIAGNOSTIC_TEST|blood level trimethyl N-oxide|all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.
40833951|NCT02226549|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
40833952|NCT02226549|DRUG|VDV|VDV 80 mg tablet administered orally once daily
40833953|NCT02226549|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
40833954|NCT01305603|DRUG|Bupivacaine|On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
41494143|NCT01383798|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
41494144|NCT01383798|DIETARY_SUPPLEMENT|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
41494145|NCT04500418|DRUG|Cenicriviroc (CVC)|Treatment with Cenicriviroc tablets of 150mg. (450g/300g on day 1 and 300mg/d on days 2-28).
41494146|NCT04500418|DRUG|Placebo|Optically identical pills without CVC.
41494147|NCT04711616|BEHAVIORAL|physical therapy intervention|physical therapy interventions include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
41159813|NCT04685317|DEVICE|Sentinel® Cerebral Protection System|A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures.
40833955|NCT01305603|PROCEDURE|Injection|Injection under ultrasound-guidance
40833956|NCT05330793|DIETARY_SUPPLEMENT|Oral probiotic|an oral probiotic intervention with or without a novel ADP1 toothpaste
40833957|NCT05330793|DIETARY_SUPPLEMENT|Placebo|placebo without Oral probiotic or toothpaste
40833958|NCT03474198|DRUG|Rifampicin|10mg/kg
40833959|NCT03474198|DRUG|Isoniazid|5mg/kg
40833960|NCT03474198|DRUG|Pyrazinamide|25mg/kg
40833961|NCT03474198|DRUG|Ethambutol|15mg/kg
40833962|NCT03474198|DRUG|Linezolid|600mg
40833963|NCT03474198|DRUG|Clofazimine|200mg
40833964|NCT03474198|DRUG|Rifapentine|1200mg
40833965|NCT03474198|DRUG|Levofloxacin|1000mg
41159814|NCT04685317|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
41353406|NCT01913509|DEVICE|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
41353407|NCT01706744|OTHER|Intermediate care unit|
41494148|NCT03050710|DEVICE|Princess® VOLUME Lidocaine|Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
41353408|NCT01706744|OTHER|Local health care 1|
41353409|NCT01706744|OTHER|Local health care 2|
41353410|NCT02087241|DRUG|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
41353411|NCT02087241|DRUG|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
41494149|NCT06182176|DRUG|Sulphadoxine-pyrimethamine and Amodiaquine|The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine), schistosomiasis (praziquantel) and soil-transmitted helminths (albendazole).
41494150|NCT05495958|DRUG|Topical Vitamin D eye drop|25 Microgram/cc or 1000 IU
41494151|NCT05495958|DRUG|Topical placebo eye drop|The same-shape packed drop without vitamin D
40833966|NCT03474198|DRUG|Bedaquiline|400mg once daily for 2 weeks then 200mg 3x a week
40833967|NCT03474198|DRUG|Rifampicin|35mg/kg
41353412|NCT02087241|DRUG|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
41494152|NCT02924636|BEHAVIORAL|ePPOP-ID program|This is a personalized and online program. The website will provide secure communication with dietician and lifestyle coaches.
41353413|NCT02087241|DRUG|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
41494153|NCT02167373|OTHER|Cogito Companion Intervention|
41494154|NCT02167373|DEVICE|mobile phone application|
41494155|NCT01406483|OTHER|Platelet reactivity assessment|Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
41494156|NCT03743792|DIETARY_SUPPLEMENT|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
41494157|NCT03743792|DIETARY_SUPPLEMENT|Control breakfast|Control drink + buttermilk biscuit sandwich
41494158|NCT02628743|DRUG|Olesoxime|Participants will receive homogeneous suspension of olesoxime.
40833968|NCT00138112|DRUG|Empirical Vancomycin|
40833969|NCT00138112|DRUG|Prophylactic Vancomycin|
40833970|NCT01586104|RADIATION|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
40833971|NCT01058135|OTHER|Hi-maize starch (Low dose)|resistant starch
40833972|NCT01058135|OTHER|Hi-maize starch (High-dose)|resistant starch
40833973|NCT01058135|OTHER|Control (starch)|rapidly digestible starch
41159815|NCT04998097|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|Investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
41159816|NCT04998097|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|no stimulation, Sham TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
41353414|NCT05858567|DRUG|Envafolimab|"Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Names:~KN053 Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure/Surgery: Biopsy, local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient."
41353415|NCT05441436|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Allogeneic hematopoietic stem cell transplantation
41353416|NCT05441436|PROCEDURE|Solid organ transplantation|Solid organ transplantation
41494159|NCT05808218|OTHER|Community-Led Total Sanitation|"The community-led total sanitation intervention is implemented across an entire Traditional Authority and includes the following village-level activities:~1. Triggering:~   * Village transect walks and open defecation site mapping~  * Demonstrations of food contamination and medical expense calculations~2. Development of a Community-Action Plan and identification of natural leaders~3. Post-triggering: routine follow-up by selected natural leaders to track and monitor progress against the Community Action Plan~In addition to the activities above, the WASH for Everyone team will:~* Train a cadre of local masons on sanitation construction~* Support the District Health office in the implementation of existing sanitation and hygiene promotion at village markets and other public spaces"
41494160|NCT05808218|OTHER|Care Groups|"* Orientation and training of village-level Care Group members on CLTS, latrine construction, and hygiene promotion~* Routine house-to-house follow-up of Care Group members to provide peer-to-peer counselling and support on sanitation and hygiene behaviours."
41494161|NCT01568060|OTHER|Infanrix-IPV data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
41353417|NCT04588909|PROCEDURE|Colorectal resections|All patients admitted with colorectal cancer were subjected to various types of colorectal resections
41353418|NCT04005885|DEVICE|comfilcon A|Contact Lens
41353419|NCT04005885|DEVICE|somofilcon A|daily disposable contact lens
41159817|NCT06479551|OTHER|high intensity-low volume resistance training|13 participants will be in experimental group giving them High intensity-low volume resistance training protocol of 4 reps and 2 sets comprising 90% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
40833974|NCT06254664|DRUG|Tiotropium 18 µg inhalation powder, hard capsule|Tiotropium 18 µg administered using Zephir inhaler
41021132|NCT06486545|DRUG|Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)|"Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1~DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first)."
41353420|NCT04005885|DEVICE|stenfilcon A|daily disposable contact lens
41353421|NCT05246644|DRUG|acetaminophen|we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
41353422|NCT05885373|DIETARY_SUPPLEMENT|SIM01|SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics
41494162|NCT01216696|DRUG|ipilimumab|Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
41353423|NCT00294528|DEVICE|Nexgen LPS-flex and AGC|
40833975|NCT06254664|DEVICE|Zephir inhaler|Tiotropium 18 µg administered using Zephir inhaler
40833976|NCT05840107|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously
40833977|NCT03458858|OTHER|Mixed Berry Diet|Mixed Berry Treatment
40833978|NCT03458858|OTHER|Carbohydrate Control Jello|Carbohydrate Control
40833979|NCT03458858|OTHER|Fiber Enriched Jello|Fiber Control
41353424|NCT02929875|BEHAVIORAL|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
41353425|NCT06261840|DRUG|Metronidazole 500 mg|Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men
41353426|NCT06261840|DRUG|Secnidazole 2000 MG|Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men
41159818|NCT06479551|OTHER|Moderate intensity-high volume resistance training|13 participants will be in control group giving them Moderate intensity-high volume resistance training of 8 reps and 3 sets comprising 80% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
41353427|NCT04328181|DEVICE|Spectral Photon Counting Computed Tomography (SPCCT)|"For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:~* Tube potential 120 kVp;~* Tube current time product of 150 mAs;~* Gantry revolution time 0.33 s;~* Automatic exposure control (angular and longitudinal) combined xyz-axis;~* Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;"
41353428|NCT04328181|DEVICE|DECT (Dual Energy CT)|"The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:~* Base platform : iCT scanner~* Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp~* Tube current (mA) : 10 - 300~* Spatial Resolution : \> 30 lp/cm, ≤ 250 µm~* Z-coverage isocenter (mm) : 20 mm~* FOV (mm) : 500~* Minimum rotation time : 0.33 s/rotation~* Acquisition modes : Axial, Helical, Step \& Shoot"
41353429|NCT00765830|DRUG|vildagliptin|50mg qd
41353430|NCT00765830|DRUG|Placebo|qd
41353431|NCT03261544|PROCEDURE|Proximal Femur Replacement|The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
41353432|NCT05490849|DRUG|68Ga-HX01|"For pharmacokinetics, healthy volunteer underwent 68Ga-HX01 PET imaging. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~Cancer patients,~1. Subjects should have 68Ga-HX01 and 18F-FDG PET scans two days apart.~2. Blood tests, liver and kidney function, tumor markers (CA125, CA199, CEA, etc.), and other biochemical markers must be performed one week prior to and after imaging.~3. Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
41353433|NCT02815072|OTHER|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
41353434|NCT05472051|OTHER|Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO|"In the framework of the current activities of the ARCAD Santé PLUS a team formed by a doctor, a nurse and laboratory assistant will provide prevention and medical activities during the community-based activities organized by the housekeepers ADDAD NGO. The medical consultation will propose:~* HIV screening, including pre- and post- counseling~* Hepatitis B and hepatitis C screening, including pré- and post- counseling. The HBV vaccine will be proposed to housekeepers with negative results to both HBV and HCV testing~* Tuberculosis screening will be proposed to housekeepers with symptoms suggesting the possibility of TB~* For housekeepers sexually active, the medical team will propose a gynecological test in order to screen for genital infections. Furthermore, a pregnancy test will be proposed.~Medicines for current diseases (headache, diarrhea, etc. will be provided by the medical staff)."
41353435|NCT04572464|OTHER|Mindfulness Based Guided Meditation|Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
41353436|NCT05750615|OTHER|Uncertain what intervention will be co-created|Uncertain what intervention will be co-created
41353437|NCT00053482|BIOLOGICAL|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
41353438|NCT00053482|BIOLOGICAL|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
41509147|NCT02208739|PROCEDURE|Nonsurgical periodontal therapy|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
41159819|NCT04156178|BIOLOGICAL|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
41159820|NCT01600235|DRUG|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
41159821|NCT01081730|BIOLOGICAL|anti-TNF biologics|as prescribed
41159822|NCT01081730|OTHER|general population|non-treated cohort
41353439|NCT04974411|OTHER|infection|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
41353440|NCT04974411|OTHER|sepsis|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
41021133|NCT03856229|DRUG|Conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
41353441|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
41353442|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
41353443|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
41021134|NCT03856229|DRUG|Shortened steroid regimen|"* Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~* Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
41021135|NCT01663636|BEHAVIORAL|SMS message reminding mothers to come for their scheduled vaccines|Reminder
41021136|NCT06316804|BEHAVIORAL|Video Intervention 1|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
40833980|NCT03458858|OTHER|Low Fiber Mixed Berry Juice|Anthocyanin Control
40833981|NCT03510871|DRUG|nivolumab, ipilimumab|All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
41021137|NCT06316804|BEHAVIORAL|Video Intervention 2|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
41021138|NCT06316804|BEHAVIORAL|Video Intervention 3|An experimental self-administered video-based mobile app with narratives on mental illness after the waitlist period has been completed. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
41021139|NCT00578773|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
41021140|NCT00578773|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
41159823|NCT01081730|BIOLOGICAL|non-anti-TNF biologics|as prescribed
41494163|NCT05830149|OTHER|Cryoinsufflation|In cryoinsufflation, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. A needle will be mounted on a liquid nitrogen cryosurgical unit. The needle will be inserted through the entire sinus tract and cryospray will be delivered to the length of the sinus tract as the needle is retracted with the intention to induce local tissue destruction. Each spray will be 5 seconds in duration and each tract will be sprayed 3 times per treatment session. This technique has been shown to be effective in sinus tract obliteration. This intervention may prevent local disease progression and prevent patients from undergoing more invasive surgeries. Overall, this would result in improved cosmesis, decreased pain, decreased bleeding and improved patient satisfaction.
40833982|NCT05792644|DRUG|crizotinib for rearrangement-negative, high phosphorylated ALK patients|Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
41353444|NCT05528068|BEHAVIORAL|supervised lifestyle intervention|Participants will receive personalized dietary and exercise prescription according to the assessment of nutritional status, physical fitness and physiological-biochemical indexes. The participants will use the digital application for the first 3 months with supervised lifestyle intervention. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. And then, participants will use the application by self-management for the next 6 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
41353445|NCT05528068|BEHAVIORAL|healthy lifestyle education|Participants will receive standard care and healthy lifestyle education for hypertension prevention and control. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. Participants will use the application by self-management for 9 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
40833983|NCT06176508|DRUG|HS-10374|Administered orally QD for 16 weeks
41021141|NCT00578773|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
41353446|NCT01873599|BEHAVIORAL|Positive Affect Journaling|
40833984|NCT06176508|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 16 weeks
41353447|NCT02992912|DRUG|Anti-PD-L1 antibody atezolizumab|1200 mg every 3 weeks
40833985|NCT06176508|DRUG|Tofacitinib 5Mg Tab,Oral|Administered orally BID for 16 weeks
41494164|NCT05830149|OTHER|Deroofing|Deroofing will serve as the control group as this is a minimally invasive procedure that is used for sinus tracts in HS. Studies have demonstrataed the efficacy of deroofing in treating the draining sinus tracts in HS. The control group should have decreased drainage, pain, recurrence, and scarring. In deroofing, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. The sinus tract is probed to clearly defined the sinus tract. The skin overlying the sinus tract is cut using an a scalpel. In this way, the top of the sinus tract is surgically removed. In this way, the top of the sinus tract is surgically removed. The floor of the sinus tract is exposed and left open to heal by secondary intention.
41494165|NCT06462859|OTHER|Sensory Integration Therapy Group|The experimental group received sensory integration therapy in addition to the NDT program. The NDT program is customized for each child, featuring a unique blend of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. Participants attended 45-minute NDT and sensory integration sessions three times a week for 8 weeks. Sensory integration therapy, visual perception activities (block design, shape recognition in pictures, puzzles, matching geometric shapes and letters, numbers and classification exercises), body awareness activities (showing body parts, drawing life-size drawings, turning left and right, recognizing body parts by touching ), tactile perception exercises (feeling and touching various textures and shapes) and visual-motor coordination training (eye tracking exercises, activities with moving objects and panel activities).
41353448|NCT02992912|PROCEDURE|SABR|Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
41353449|NCT00761033|BEHAVIORAL|music|
41353450|NCT02172326|DRUG|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
41494166|NCT06462859|OTHER|Neurodevelopmental Treatment Group|The NDT program is customized for each child, featuring a mix of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. He attended 45-minute NDT sessions three times a week for 8 weeks. There is no treatment or medication other than NDT.
41494167|NCT02498106|DIETARY_SUPPLEMENT|Orthica Soft Multi Mini and Orthica Fish EPA Mini|daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins \[B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene\] and minerals \[Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese\]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid \[EPA\] and docosahexaenic acid \[DHA\])
41494168|NCT02015429|DIETARY_SUPPLEMENT|Pasta meal with added fractions or control with no fractions|
41494169|NCT03163524|OTHER|e-Coupon Text Modification and Reminders|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
41494170|NCT03163524|OTHER|e-Coupon standard text|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
41494171|NCT02627248|DRUG|Huaier Granule|20g tid, orally
41159824|NCT01081730|BIOLOGICAL|ustekinumab|as prescribed
41159825|NCT01081730|DRUG|systemic non-biological treatments|as prescribed
41159826|NCT03441750|DRUG|metformin|Metformin tablets will be administrated in the experimental arm.
41353451|NCT05057377|DIAGNOSTIC_TEST|Standard Overground Assessment|The standard overground methods to assess three main components of walking are the 10 Meter Walk Test (meters/second, used to measure speed), 5x Sit-to-Stand (seconds, used to measure strength), and the 6-Minute Walk Test (meters, used to measure endurance).
41353452|NCT05057377|DIAGNOSTIC_TEST|Robotic Safety-Environment Assessment|The methods for assessment of the three main components of walking in the robotic environment will be the maximum walking speed tolerated (meters/second, to measure speed), deadband resistance (kilograms, to measure strength), and the 6-minute walk test (meters, to measure endurance).
41494172|NCT02627248|DRUG|Epirubicin|70 mg/m² ivdrip, d1 for both TEC and ET regimes
41494173|NCT02627248|DRUG|Docetaxel|75 mg/m² ivdrip, d2 for both TEC and ET regimes
41494174|NCT02627248|DRUG|Cyclophosphamide|600 mg/m² ivdrip, d2 for TEC regimes
40833986|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
41353453|NCT02136329|DRUG|Sildenafil|"The active study drug, Revatio®, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil citrate is designated chemically as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo \[4,3-d\] pyrimidin-5-yl)-4-ethoxyphenyl\] sulfonyl\]-4-methylpiperazine citrate.~The active study medication is supplied in single use glass vials and as a clear, colourless, sterile, ready-to-use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.~Sildenafil is manufactured under Good Manufacturing Practice (EU-GMP) by Pfizer Inc"
41353454|NCT03720106|OTHER|GOAL therapy plan|The GOAL algorithm designs a therapy plan based on the LIMOS assessment, patient goals and subject-specific treatment pathways. The adherence of this therapy plan is examined.
41353455|NCT05407376|OTHER|Produce prescription (weekly produce delivery)|Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.
41353456|NCT00812591|PROCEDURE|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):~Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.~Hyperinsulinemic euglycemic clamp (CLAMP):~Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
41353457|NCT04765839|OTHER|Educational, culturally appropriate COVID-19 messages|Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.
41353458|NCT05516316|DRUG|EP395|Capsule for oral use
40833987|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
40833988|NCT01101698|DRUG|Vitamin K2+10μg cholecalciferol|Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months
40833989|NCT01101698|DRUG|Vitamin D|Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months
40833990|NCT00199888|DRUG|124-Iodine-cG250 (124I-cG250)|
40833991|NCT02462408|PROCEDURE|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
40833992|NCT02462408|PROCEDURE|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
40833993|NCT02745717|DRUG|Thymoglobulin|administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
40833994|NCT02745717|PROCEDURE|Cord blood|transfusion of one unit of at least 4/6 HLA loci matched cord blood.
40833995|NCT02745717|DRUG|Cyclosporine Oral Product|administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
40833996|NCT03149003|DRUG|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
40833997|NCT03149003|DRUG|Bevacizumab|Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
40833998|NCT04240093|BEHAVIORAL|Behavioral Activation (BA) Therapy|8 sessions of behavioral activation therapy
40833999|NCT04240093|BEHAVIORAL|Substance Abuse and Health Navigation Counseling|2 standard substance abuse and health navigation counseling
41353459|NCT05516316|DRUG|Placebo|Capsule for oral use
41353460|NCT02296905|DRUG|ABT-493|Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
41353461|NCT02296905|DRUG|ABT-530|Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
41494175|NCT00315237|DRUG|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
41494176|NCT01890135|DRUG|Zibotentan (ZD4054)|10 mg
41494177|NCT01890135|DRUG|placebo|randomized double blind
40834000|NCT04240093|OTHER|Medications for Opioid Use Disorder|Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
40834001|NCT04825067|DEVICE|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
40834002|NCT05206071|BIOLOGICAL|CD19+22 CAR-T cells|Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
40834003|NCT02287753|OTHER|vascular occlusion test using Pediatric SomaSensor for INVOS 5100C|Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.
40834004|NCT05828472|DRUG|MY008211A tablets|MY008211A tablets, low/moderate/high dose orally, for 7 days
40834005|NCT05828472|DRUG|MY008211A tablets matched placebo|MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
40834006|NCT01556061|DEVICE|DMAC|The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
40834007|NCT01556061|DEVICE|CMAC|The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
40834008|NCT00378937|DRUG|acetaminophen|
40834009|NCT00378937|DRUG|codeine phosphate|
40834010|NCT00378937|DRUG|dextropropoxyphene hydrochloride|
40834011|NCT00378937|DRUG|morphine sulfate|
40834012|NCT00378937|DRUG|oxycodone hydrochloride|
40834013|NCT00378937|PROCEDURE|management of therapy complications|
40834014|NCT00378937|PROCEDURE|quality-of-life assessment|
40834015|NCT01485380|DRUG|dexmedetomidine|The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
40834016|NCT03765151|DEVICE|low-level laser therapy|LLLT will be performed by a diode gallium-aluminum-arsenide (Ga-Al-As) laser with a 940-nm wavelength (Ezlase; Biolase Technology Inc., Irvine, CA) and delivered by a quadrant-sized probe which cover the region from the central incisor to the first molar on the test side. The laser probe will be 1 cm from the soft tissue around the test tooth at the gingival margin and alveolar mucosa covering the root area using a setting of 800 milliwatt in a continuous wave. Each tooth will receive 30 seconds of exposure, with no more than 8.6 J/cm2 of energy delivered. In addition, a spot-size laser probe will be applied for 30 seconds 5 mm from the cervical dentin with an output power of 700 milliwatt to reduce tooth sensitivity.
40834017|NCT03765151|OTHER|orthodontic retention|All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
40834018|NCT03311984|DIAGNOSTIC_TEST|anti Xa level|monitoring the anti-Xa level according to LMWH emploing
40834019|NCT04921085|OTHER|Cross-sectional obeservational survey|Cross-sectional obeservational survey
40834020|NCT02285530|DRUG|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle.
40834021|NCT02285530|PROCEDURE|surgery group|Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
41159827|NCT03441750|OTHER|Standard lifestyle intervention|"Standard lifestyle advice will be united for all subjects by providing special booklet.~* All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes.~* The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction.~* Moderate intensity physical activity (150 minutes per week) is recommended.~* Smoking cessation is encouraged for the smoker.~* Excessive alcohol intake is encouraged to avoid."
41159828|NCT06201715|DRUG|Tofacitinib 5 MG|5mg tofacitinib tablet twice daily
40834022|NCT02285530|RADIATION|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
41159829|NCT06012305|OTHER|Taping|Taping has the effect of accelerating the flow in the tissue by increasing the epidermal dermal distance. The muscle technique used in the study will be applied to the trapezius muscle and aims to reduce the working level of the muscle. The EDF technique, which will be used in another group, aims to create a stronger base taping effect.
41353462|NCT05072834|PROCEDURE|Upper Gastrointestinal Endoscopy|"Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses.~For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken."
40834023|NCT01656629|DRUG|Teriparatide|20 mcg subq daily for 3 months
41159830|NCT02958475|BEHAVIORAL|Social Support Group (Facebook)|The breastfeeding social support group on Facebook will be moderated to facilitate posting of shared experiences. Short videos, photographs, and written blurbs on related topics are posted on the Facebook page to reinforce the messaging and content of the texts.
40834024|NCT01656629|DRUG|Alendronate|70 mg weekly for 3 months
41353463|NCT03391375|BIOLOGICAL|DNA-HIV-PT123 & AIDSVAX B/E|DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant
41353464|NCT04847167|PROCEDURE|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
40834025|NCT01656629|DIETARY_SUPPLEMENT|calcium and vitamin D|
40834026|NCT01350115|DRUG|LDE225|supplied as 100 mg capsules
40834027|NCT01350115|DRUG|Placebo|supplied in capsules
40834028|NCT05786365|DRUG|Ketalar 50 MG/ML Injectable Solution|Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
41353465|NCT05496855|OTHER|Conventional follow-up|Patients in the conventional/usual care arm will be treated according to current conventional follow-up regimen with PROs, blood tests, and face-to-face visits with an experienced nurse or a rheumatologist every 6 months. They can contact the hospital if they are experience worsening of their disease.
40834029|NCT00066547|BIOLOGICAL|monoclonal antibody HuHMFG1|
40834030|NCT02855944|DRUG|Chemotherapy|Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
40834031|NCT02855944|DRUG|Rucaparib|Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice a day
40834032|NCT05901805|OTHER|questionnaire application|"Participants will be asked to fill in the Occupational Sitting and Physical Activity Questionnaire adapted into Turkish. Correlation of the scale with the International Physical Activity Questionnaire-Short Form, VAS and YİBT-SF, Buss-Perry Aggression Scale will be tested. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
40834033|NCT04639817|DRUG|Levofloxacin|Levofloxacin administration
40834034|NCT04639817|DRUG|trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole administration
40834035|NCT06497335|DIAGNOSTIC_TEST|non invasive hemoglobin measure|non invasive hemoglobin measure
40834036|NCT02188498|PROCEDURE|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
40834037|NCT00096018|DRUG|fludarabine phosphate|Given IV
40834038|NCT00096018|DRUG|thalidomide|Orally
40834039|NCT04191135|BIOLOGICAL|Pembrolizumab|intravenous (IV) infusion
40834040|NCT04191135|DRUG|Olaparib|oral tablets
41494178|NCT02930967|BIOLOGICAL|autologous CSR T|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
40834041|NCT04191135|DRUG|Carboplatin|IV infusion
40834042|NCT04191135|DRUG|Gemcitabine|IV infusion
40834043|NCT00495924|PROCEDURE|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
40834044|NCT04804735|DEVICE|REV : local anesthesia and virtual reality|REV : local anesthesia and virtual reality in Implanted Venous Access Device (IVAD) procedure under local anesthesia
40834045|NCT04804735|DEVICE|MUS : local anesthesia and music therapy|MUS : local anesthesia and music therapy in Implanted Venous Access Device (IVAD) procedure under local anesthesia
40834046|NCT03761394|DEVICE|Testing Devices|Pulsewatch system testing application on smartphone with smartwatch.
40834047|NCT03761394|DEVICE|Cardea Solo by Cardiac Insight|Gold-standard cardiac monitor for comparison of testing devices.
40834048|NCT03761394|DEVICE|Kardia Mobile by AliveCor|Mobile ECG device for comparison of testing devices during the extended use period.
40834049|NCT05158985|OTHER|phonophoresis|treatment
40834050|NCT05158985|OTHER|exercises|treatment
40834051|NCT04902651|DEVICE|HM242-Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
40834052|NCT04902651|DEVICE|Intrasite Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
40834053|NCT03677479|PROCEDURE|socket preservation procedure|socket preservation of post extraction site using bone xenografts
40834054|NCT05760846|DEVICE|REAplan®|motor skill learning with the REAplan® rehabilitation robot, to be performed with both arms
40834055|NCT05760846|DEVICE|Dextrain Manipulandum®|motor skill learning with the Dextrain Manipulandum® dexterity tool to be performed with both hands
41021142|NCT01790750|DEVICE|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
41021143|NCT06573151|DRUG|Selinexor, anti-PD-1 antibody and P-GemOx|Selinexor, 40mg, qw, po; Pegaspargase, 2500U/m2, IM, d1; Gemcitabine, 1000mg/m2, i.v., d1, d8; Oxaliplatin, 130mg/m2, i.v., d1; anti-PD1 antibody, 200mg, d2, i.v. (21d cycle);
41021144|NCT05443984|DRUG|JP-1366 20mg|1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)
41494179|NCT05567263|PROCEDURE|Bulk-fill resin composite, (3M, ESPE)|Teeth will be restored with Bulk-fill resin composite, (3M, ESPE)
41494180|NCT05567263|PROCEDURE|Surefil one™ Self-Adhesive Composite Hybrid|teeth will be restored with Surefil one™ Self-Adhesive Composite Hybrid
41494181|NCT04053361|PROCEDURE|Catheter ablation|Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
41494182|NCT05251519|OTHER|Kinesio Taping|Derotation taping with Kinesio Tex is applied to the patients through a pediatric physiotherapist.
41494183|NCT05251519|OTHER|Conventional Rehabilitation|Conventional rehabilitation program is applied to the patients through a pediatric physiotherapist
41494184|NCT01194518|BEHAVIORAL|Lifestyle Intervention Program|
40834056|NCT02068118|DEVICE|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
40834057|NCT02067325|OTHER|Thai massage|
40834058|NCT01703065|DRUG|Cabozantinib|Given orally once a day
41353466|NCT05496855|OTHER|Remote monitoring|"The patients in the remote monitoring arm will use a web-app (Youwell) for self-reporting patient reported outcomes (PROs) and CRP/ESR, displaying results for PROs over time, and for synchronous (video) or asynchronous (chat) communication with healthcare providers. The patients will receive a SMS reminder for tasks (e.g., self-reporting PROs or registering results from blood tests) every month.~A study coordinator/nurse will monitor the PROs and blood test (CRP/ESR) results, and respond to chat messages. Based on the algorithm, a triaging functionality in the Youwell platform will aid healthcare providers in highlighting which patients needs attention."
41353467|NCT05335785|DEVICE|High-intensity lazer therapy|Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.
41353468|NCT05335785|OTHER|Exercises|Exercise program including Codman, Range of motion and streightening exercises three times in a week.
41353469|NCT01108263|DRUG|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
41494185|NCT04996550|DRUG|Carvedilol|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
41494186|NCT04996550|DRUG|Metoprolol Succinate|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
41494187|NCT04475835|DRUG|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
41494188|NCT04475835|DRUG|Heparin|Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
41494189|NCT02177656|BEHAVIORAL|Motivational Interviewing tailored intervention|MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
40834059|NCT03234296|DRUG|Ertapenem|Intravenous antibiotic followed by per oral antibiotics
40834060|NCT03234296|OTHER|Placebo|Intravenous placebo followed by per oral placebo
40834061|NCT05254496|BEHAVIORAL|Dietary Intervention Classes|Participants will attend classes once per week for 6 months and then bi-weekly for 6 months.
40834062|NCT00647660|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fasting
40834063|NCT00647660|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fasting
41021145|NCT05443984|DRUG|Esomeprazole 40mg|1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)
41021146|NCT00226941|DRUG|Cetuximab|Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m² (initial loading dose) or 250 mg/m² (weekly dose). Dosage is based on m² of body surface area (BSA)
41021147|NCT00226941|DRUG|Oxaliplatin|Oxaliplatin is a cancer medication used to treat colorectal cancer, and is administered on Days 2 and 23.
41021148|NCT00226941|DRUG|Capecitabine|Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
40834064|NCT03826823|DEVICE|HSG cannula|a thin catheter originally designed for IUI was introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum was loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye was injected slowly and the procedure was watched on the screen and x-ray films were taken.
40834065|NCT02459275|OTHER|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.
40834066|NCT02459275|DRUG|Metoclopramide|Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
40834067|NCT02805231|OTHER|Vitamin D receptor polymorphic analysis|
40834068|NCT00624416|DRUG|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
40834069|NCT02948907|OTHER|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA."
40834070|NCT05338203|OTHER|tandem breastfeedıng|mother mılk wıll collected from mothers and they wıll be analyzed in laboratuar.
40834071|NCT01709201|BEHAVIORAL|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
40834072|NCT00099294|DRUG|Glufosfamide|
40834073|NCT04825431|DRUG|TAS-205, [14C]TAS-205|single oral administration under fasted conditions on day 1
40834074|NCT04454593|OTHER|no intervention|This is an observation study,with no intervention
40834075|NCT00964301|OTHER|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
40834076|NCT00964301|OTHER|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
40834077|NCT05303688|DRUG|iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)|The primary predictor variable was preventive analgesia group. Patients were randomly divided in two groups. 50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey) were administrated 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15
40834078|NCT05303688|DRUG|Steril Salin (control)|30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15) and iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15).
40834079|NCT04035096|DRUG|Ascorbic Acid|"1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~2. The final dose will be kept for 12 weeks.~3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks"
40834080|NCT04035096|OTHER|Control group|"1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~2. Usual care"
40834081|NCT03449433|DRUG|LY900014|Administered SC
40834082|NCT03449433|DRUG|Insulin Lispro|Administered SC
40834083|NCT03449433|DRUG|Insulin Aspart|Administered SC
40834084|NCT03449433|DRUG|Insulin Aspart|Administered SC
40834085|NCT04423601|DRUG|SHR6390 tablet|single oral dose of SHR6390 or co-administered with itraconazole.
40834086|NCT04423601|DRUG|Itraconazole capsule|200 mg itraconazole was administered in the morning.
40834087|NCT01806064|DRUG|TRC105 and Axitinib|
40834088|NCT01806064|DRUG|Axitinib|
40834089|NCT00751283|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
41353470|NCT06319066|DEVICE|orthotic wedge|The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.
40834090|NCT00002363|DRUG|Peptide Construction 3, Synthetic|
40834091|NCT04830124|DRUG|Nemvaleukin Alfa Subcutaneous|Subcutaneous injection of nemvaleukin every 7 days
40834092|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days
40834093|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous Less Frequent Dosing|Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)
40834094|NCT04830124|DRUG|Pembrolizumab|Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle
41353471|NCT06319066|DEVICE|CFO|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
41494190|NCT00106067|BEHAVIORAL|coping and communication support (CCS) intervention|"Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.~The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families."
41494191|NCT00719030|DIETARY_SUPPLEMENT|Pomegranate pill|Pomegranate extract pill
41494192|NCT00719030|DIETARY_SUPPLEMENT|Pomegranate pill placebo|Pomegranate pill placebo
41494193|NCT04099550|DEVICE|RT-CGM|The group was monitored blood glucose initial 1-week with a RT-CGM.
40834095|NCT00231231|DEVICE|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
40834096|NCT00231231|DEVICE|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
40834097|NCT01376375|PROCEDURE|Acupuncture|
41159831|NCT02958475|BEHAVIORAL|Breastfeeding messages|The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
41494194|NCT04099550|OTHER|SMBG|The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
41494195|NCT03771248|DEVICE|peek telescopic partial denture|removable partial denture
41494196|NCT00002865|BIOLOGICAL|filgrastim|
41494197|NCT00002865|DRUG|cyclophosphamide|
40834098|NCT02124954|DRUG|TA-8995|
40834099|NCT02124954|DRUG|Midazolam|
40834100|NCT02124954|DRUG|Digoxin|
40834101|NCT04841603|DEVICE|Mindshift CBT|A tablet with the Mindshift CBT app installed. Mindshift CBT is a free, evidence based app developed by Anxiety Canada, designed to help users reduce symptoms of anxiety and distress.
40834102|NCT04841603|DEVICE|Treatment as Usual|Treatment as usual. A tablet identical to the intervention group, but without the Mindshift CBT app is available for patients to use during their inpatient stay.
40834103|NCT06390787|DRUG|Metoclopramide and Vitamin B6|We gave a combination of vitamin B6 (pyridoxine) and metoclopramide as a treatment for managing nausea and vomiting.
41494198|NCT00002865|DRUG|cytarabine|
41494199|NCT00002865|DRUG|dexamethasone|
41494200|NCT00002865|DRUG|doxorubicin hydrochloride|
40834104|NCT06390787|DRUG|Vitamin B6|We gave only vitamin B6 (pyridoxine) as a treatment for managing nausea and vomiting.
40834105|NCT06390787|DRUG|Ondansetron|We gave only Zofran as a treatment for managing nausea and vomiting.
40834106|NCT06390787|DRUG|Metoclopramide|We gave only Metoclopramide as a treatment for managing nausea and vomiting.
40834107|NCT04132635|DEVICE|artificial dermis|artificial dermis will be used after fully debridement of the wound
40834108|NCT04132635|OTHER|growth factor|growth factor
41353472|NCT05507086|OTHER|Antimicrobial therapy|Antimicrobial therapy
41353473|NCT04769986|BEHAVIORAL|Mobile Mindfulness-Relapse Prevention (mMBRP)|Mindfulness Coach 2.0 is a mobile application designed by the VA's National Center for PTSD. The app provides: (a) psychoeducational topics related to mindfulness; (b) audio-guided mindfulness exercises; (c) self-assessment using the Five Facet Mindfulness Questionnaire (d) a journal to track mindfulness practice sessions; (e) goal setting and tracking; (f) personal, customizable reminders; and (g) immediate access to support and crisis resources. We will enhance Mindfulness Coach with MBRP content by adding information about the triangle of awareness to understand connections among thoughts, sensations, and emotions, and specific meditations of sober breathing space and urge surfing to deal with cravings. We will add additional MBRP-specific modules. Participants will be asked to complete the intervention during 8 weeks, with two to three modules per week. After a beta test with 20 veterans, feedback will be used to refine the app for the national randomized clinical trial (RCT).
41353474|NCT04769986|BEHAVIORAL|Exercise/healthy eating mobile app|Participants in the control condition will be asked to download an exercise/healthy eating mobile app and use it for 8 weeks. Similar to Mindfulness Coach, the app will have specialized self-management guides that follow a guide-per-week format, educational videos that teach diet and exercise strategies, and a diary to track diet and exercise progress.
41353475|NCT02615808|OTHER|Oxygen saturation data visualization|The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
41494201|NCT00002865|DRUG|etoposide|
41494202|NCT00002865|DRUG|ifosfamide|
40834109|NCT05601661|DEVICE|Active VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0.8 mA)
40834110|NCT05601661|DEVICE|Sham VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0 mA)
40834111|NCT05601661|OTHER|Arm rehabilitation|. The rehabilitation therapy involves arm and hand exercises with objects. The therapist will select these exercises based on movement abilities. Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers. Approximately 30-50 repetitions will be performed in each category. On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
41159832|NCT02958475|BEHAVIORAL|Injury Prevention Messages|The Mother's Milk Messaging app will provide participants in the control group with genetic injury prevention message.
41159833|NCT02605772|DRUG|Acarbose|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
41159834|NCT02605772|DRUG|Metformin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
41494203|NCT00002865|DRUG|leucovorin calcium|
41494204|NCT00002865|DRUG|mesna|
41494205|NCT00002865|DRUG|methotrexate|
41494206|NCT00002865|DRUG|therapeutic hydrocortisone|
41494207|NCT00002865|DRUG|vincristine sulfate|
41494208|NCT00002865|RADIATION|low-LET cobalt-60 gamma ray therapy|
41494209|NCT00002865|RADIATION|low-LET photon therapy|
41494210|NCT03835676|DRUG|Treprostinil|"After inclusion and baseline measurements, patients will receive treprostinil in addition to background therapy for 24 months. Follow-up assessment will include:~* Clinical, echocardiographic, laboratory assessments will be repeated at 1, 3, 6, 12, 18, and 24 month (or when there is clinical indication)~* CMR will be performed at 6 monthly intervals for 2 years.~* Peak power output at 6,12, 18 and 24 month~* Right-side cardiac catheterization will be performed at 6, 12 , 18 and 24 months (or when there is clinical indication)"
41509148|NCT02208739|PROCEDURE|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
40834112|NCT03118830|DRUG|Triptorelin|daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
40834113|NCT03118830|DRUG|cetrorelix|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
40834114|NCT03118830|DRUG|Recombinant Follicle Stimulating Hormone|Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
41353476|NCT01731600|DRUG|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
41353477|NCT03700931|BEHAVIORAL|Eating recall condition|Recall of eating episodes would increase subsequent intake of fruit or vegetable items
41353478|NCT03700931|BEHAVIORAL|Non-eating recall condition|Recall of non-eating episodes would not influence subsequent intake of fruit or vegetable items
41353479|NCT00875966|DRUG|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
41353480|NCT00875966|DRUG|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
41353481|NCT02249351|DRUG|Talsaclidine|
41353482|NCT02249351|DRUG|Placebo|
41353483|NCT01597934|DRUG|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
41353484|NCT01597934|DRUG|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
40834115|NCT01051206|DRUG|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
41159835|NCT02605772|DRUG|Saxagliptin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
41353485|NCT02617199|DRUG|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
41353486|NCT02617199|DRUG|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
41353487|NCT00352170|DIETARY_SUPPLEMENT|calcium supplementation|calcium carbonate 1500 mg/day
41353488|NCT00352170|DIETARY_SUPPLEMENT|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
41353489|NCT00352170|DIETARY_SUPPLEMENT|Placebo|calcium and vitamin D3 placebo
41509149|NCT03310749|DRUG|Gemigliptin|A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
40834116|NCT05793034|DIAGNOSTIC_TEST|Biological biomarker assessment|IHC, PCR, NGS, methylome
40834117|NCT03842683|OTHER|CGM|This study seeks to assess CGM accuracy and develop prediction models for hypoglycemia detection and no intervention is therefore applied.
40834118|NCT01247363|DRUG|LY2608204|Administered orally.
40834119|NCT02447094|DRUG|Alteplase|Intravenous (i.v.) tPA per the standard of care
40834120|NCT00599456|DIETARY_SUPPLEMENT|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
40834121|NCT00599456|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
41021149|NCT00226941|RADIATION|Radiotherapy|"Radiotherapy is administered on weekdays in 180 centigray fractions (doses), for 28 total fractions delivering a total dose of 5040 centigray (cGy)"
41021150|NCT00226941|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
41021151|NCT06052384|OTHER|Standard pain management combined with sleep disorder management|Standard pain management combined with sleep disorder management at M3, M6, and M12
41021152|NCT02505516|OTHER|metformin|
41021153|NCT01795001|OTHER|No intervention|
41353490|NCT02639182|DRUG|AGS-16C3F|Intravenous (IV) infusion
41353491|NCT02639182|DRUG|Axitinib|Oral
41353492|NCT03268057|DRUG|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
41494211|NCT02546466|PROCEDURE|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
41494212|NCT02546466|PROCEDURE|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
41494213|NCT02546466|BEHAVIORAL|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
41509150|NCT03310749|DRUG|Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day|A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
41353493|NCT01836029|DRUG|VTX-2337|TLR8 Agonist
41353494|NCT01836029|DRUG|Carboplatin|
41353495|NCT01836029|DRUG|Cisplatin|
41353496|NCT01836029|DRUG|5-fluorouracil|
41353497|NCT01836029|DRUG|Placebo|
41353498|NCT00930501|BIOLOGICAL|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
41353499|NCT00003572|BIOLOGICAL|peripheral blood lymphocyte therapy|
41353500|NCT00003572|DRUG|mycophenolate mofetil|
41353501|NCT00003572|DRUG|tacrolimus|
41353502|NCT00003572|PROCEDURE|allogeneic bone marrow transplantation|
41353503|NCT00003572|RADIATION|radiation therapy|
41353504|NCT04143256|OTHER|JUUL ENDS 5% Virginia Tobacco|JUUL ENDS Virginia Tobacco 5% nicotine strength
41353505|NCT04143256|OTHER|JUUL 3% Virginia Tobacco ENDS|JUUL ENDS Virginia Tobacco 3% nicotine strength
41353506|NCT04143256|OTHER|JUUL 5% Mint ENDS|JUUL ENDS Mint 5% nicotine strength
41353507|NCT04143256|OTHER|JUUL 3% Mint ENDS|JUUL ENDS Mint 3% nicotine strength
41353508|NCT04143256|OTHER|JUUL 5% Menthol ENDS|JUUL ENDS Menthol 5% nicotine strength
41353509|NCT04143256|OTHER|JUUL 3% Menthol ENDS|JUUL ENDS Menthol 3% nicotine strength
41353510|NCT04143256|OTHER|JUUL 5% Mango ENDS|JUUL ENDS Mango 5% nicotine strength
41353511|NCT04143256|OTHER|JUUL 3% Mango ENDS|JUUL ENDS Mango 3% nicotine strength
41353512|NCT04143256|OTHER|US Cigarette, Non-menthol - Marlboro Gold King Size|US Cigarette, Non-menthol - Marlboro Gold King Size
41353513|NCT04143256|OTHER|US Cigarette, Menthol - Newport King Size|US Cigarette, Menthol - Newport King Size
41353514|NCT00780676|DRUG|Dasatinib|100 mg tablet by mouth daily
41353515|NCT00780676|DRUG|AZD6244|75 mg by mouth twice daily.
41353516|NCT03310879|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
41353517|NCT02177604|OTHER|Wingate HIT|"3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)"
41021154|NCT02238301|OTHER|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
41353518|NCT02177604|OTHER|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
41353519|NCT02177604|OTHER|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
41353520|NCT05745506|OTHER||Not applicable, there is no intervention description in this study.
41353521|NCT01185613|DEVICE|Therapy™ Cool Flex Ablation Catheter|"The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.~The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter~* IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.~* Cool Point™ Irrigation Pump~* Cool Point™ Tubing set~* Data Logger"
41353522|NCT05290441|PROCEDURE|None involvement|No EGFR involvement
41353523|NCT05191381|BIOLOGICAL|Application of exosomes in a whole blood assay|Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.
41353524|NCT05241756|DEVICE|FLACS using FEMTO LDV-Z8|Performance of femtosecond laser-assisted capsulotomy in the anterior capsule.
41353525|NCT04486404|OTHER|Online survey|Online survey including questions related to PPE availability, perceptions, emotions and EASE scale (Acute Stress Scale).
41353526|NCT05949528|OTHER|no intervention|no intervention
41353527|NCT02842333|OTHER|Additional biological samples|Blood samples
41353528|NCT00626795|DRUG|TD1414 2% cream|BID 7 days
41353529|NCT00626795|DRUG|TD1414 2% cream|TID 7 days
41353530|NCT00626795|DRUG|Bactroban® (mupirocin) 2% cream|BID 7 days
41353531|NCT04313309|OTHER|Integrative Yoga Therapy|Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
41353532|NCT04700891|DIAGNOSTIC_TEST|Olfactory identification test|"Burghart Sniffin' Sticks Screening 12 Test Olfactory function will be evaluated through the Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The short version of this test will be used and will consist solely of a test of odor identification function."
41494214|NCT02436967|OTHER|Carotid endarterectomy in clinical healthcare.|For the this study itself there is no intervention caused by the extra CT or MRI. The patients are scheduled for surgery as the routine intervention to reduce the risk of a new stroke in clinical practice. The performed extra diagnostic CT and MRI in this study before surgery will compare the vessel wall images with histology regardless of the patients status or medication.
41021155|NCT02238301|OTHER|Bold + ASL sequence|"A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation."
41021156|NCT01263873|DEVICE|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
41353533|NCT04700891|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
41353534|NCT04700891|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength is a simple and reliable measurement technique for the assessment of maximal voluntary hand force. Handgrip strength is used as a reflect of nutritional status and muscle mass, physical function and health status. Measurement will be realized using a digital handgrip dynamometer. Patients will be asked to grip the dynamometer with the second finger node at 90° angle to the handle and to grab the handle as strongly as they can. Maximal grip strength will be checked with the forearm away from the body in standing position.
41353535|NCT03316742|COMBINATION_PRODUCT|Intervention 1|Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.
41353536|NCT03316742|COMBINATION_PRODUCT|Intervention 2|Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
41353537|NCT04049344|DRUG|Decitabine; Oxaliplatin|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
41494215|NCT01761370|PROCEDURE|AHA diet plus exercise with BIB placement|AHA diet plus exercise with BIB placement for 6 months
41021157|NCT01263873|DEVICE|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
41021158|NCT06060405|DRUG|Durvalumab|Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.
41353538|NCT03058276|BEHAVIORAL|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
41353539|NCT03058276|OTHER|rTMS|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.
41353540|NCT03058276|OTHER|SAM|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
41353541|NCT06038968|DRUG|Methotrexate 25 MG/ML|Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division.
41353542|NCT06038968|PROCEDURE|parsplana vitrectomy|Pars plana vitrectomy (PPV) is a technique in vitreoretinal surgery that enables access to the posterior segment for treating tractional retinal detachment in advanced proliferative diabetic retinopathy, in a controlled, closed system.
41353543|NCT00728572|PROCEDURE|Logan Basic Technique and Surface EMG|Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
41353544|NCT00728572|OTHER|Surface EMG|Surface EMG only, no intervention
41353545|NCT00728572|PROCEDURE|Logan Basic Technique Sham|Participants will receive a sham Basic Technique treatment, not indicated by examination.
41353546|NCT05226572|DIAGNOSTIC_TEST|endoscopic ultrasound-guided fine needle biopsy|repeated endoscopic ultrasound-guided fine needle-biopsy after a previous non diagnostic or incoclusive endoscopic ultrasound-guided tissue aquisition for pancreatic solid lesions.
41353547|NCT03634852|DRUG|Moxifloxacin hydrochloride 0.5% eye drops|were prescribed four times a day for 1-month postoperatively
41353548|NCT03634852|DRUG|Dexamethasone 0.1% eye drops|were prescribed four times a day for 1-month postoperatively
41353549|NCT03634852|DRUG|Intracameral Moxifloxacin 0.1%|"Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient."
41494216|NCT01761370|PROCEDURE|AHA diet plus exercise with sham BIB placement|AHA diet plus exercise with sham BIB placement
41021159|NCT06060405|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.
41021160|NCT03144726|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
41021161|NCT03144726|OTHER|Standard dressing|A standard dressing will be applied to the amputations in this arm of the study
41353550|NCT03634852|DRUG|Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml|"Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure"
41353551|NCT02582619|OTHER|Focus groups, semistructured interviews and Delphi rounds|
41353552|NCT04030819|BEHAVIORAL|schema therapy|The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
41353553|NCT05466591|DIAGNOSTIC_TEST|Pre-hospital rule-out strategy|Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome
41353554|NCT00670813|DRUG|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
41353555|NCT00670813|DRUG|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
41021162|NCT03144570|OTHER|None, non-interventional study|Not applicable, non-interventional study
41353556|NCT05989815|OTHER|Muscle damage protocol training|The adopted protocol of muscle damage will follow the recommendations from American College of Sports Medicine (ACSM) in 2009 for trained individuals. It consists of 8-12 repetitions above 70% of 1 Repetition Maximum (1RM) with 1 minute of rest between sets and 2 minutes between exercises. The protocol will be composed as follows: 3 sets of 10 repetitions for each exercise, with an emphasis on producing microlesions in the muscle tissue (muscle damage protocol).
41353557|NCT05989815|DEVICE|Photobiomodulation therapy (PBMT)|PBMT will be administered using the Joovv Elite System, which has 6 panels of red LEDs (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 milliwatt (mW)/cm². The PBMT Sham dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm².
41353558|NCT02630459|DRUG|Placebo|placebo via subcutaneous injection
41353559|NCT02630459|DRUG|Erenumab|erenumab via subcutaneous injection
41353560|NCT02630459|DRUG|Erenumab|erenumab via autoinjector (AI)/pen
41494217|NCT06387602|PROCEDURE|Cryotherapy|Take an icepack and wrap it in a moisture-absorbing towel. The temperature of the icepack should be between 1˚ to 10˚. Any temperature below 0˚ can damage the skin. The icepack will be on strained adductors for 5-7 minutes. Patients will be advised to do cryotherapy at home for 24-42 hours after every 2 hours.
41494218|NCT06387602|PROCEDURE|Strengthening of adductors|"Both groups will perform the following strengthening of adductors which includes adductor isometrics, Side-lying adductor strengthening, and Adductor resistance with a stepper and will be done 10 repetitions, 3 times a week.~After the performance of the Adductor strengthening protocol, Group A will be given the Active release technique while Group B will be given post-isometric relaxation by the therapist."
41494219|NCT06387602|PROCEDURE|Active release technique|"Step 1: Place the body in a position (Dorsiflex ankle, flex the knee, extend the hip, flex the spine) so that the nerve is moved proximally. In this position, the nerve is relaxed on the distal side of the entrapment site and the nerve is tractioned on the proximal side.~Step 2: Place contact between the distal Gracilis and the Sartorius and push the muscle proximally. The contact should not compress the nerve.~Step 3: Move each joint so that the nerve moves distally past the muscle. The new position (Plantarflex and evert the ankle, extend the knee, flex the hip, extend the spine) will be achieved.~Step 4: Move the contact to the proximal side of the muscles and push the muscle distally.~Step 5: Move the nerve proximally again by pushing the muscle distally. This brings the position of the patient back to Step 1.~Contact will be held for a short time 5-20 seconds with repetitions 3-5 times to the injury site and 2 sessions per week."
40834122|NCT05592496|PROCEDURE|Bilateral retromuscular rectus sheath block catheters usage for early postoperative analgesia after laparotomic gastrectomy.|After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.
40834123|NCT05592496|DEVICE|Catheter insertion technique by using special tube t|By using special tube, it is possible to locate the catheters in retromuscular space, where they are close to cutaneous nervs
40834124|NCT05592496|PROCEDURE|"Connection of catheters bilateraly to easy pump system,"|"Connection of catheters, which are inserted in to retromuscular space, to ensure continuous receiving of Bupivacaine fluid for analgesia. Easy pump system provides continous receiving of bupivacaine fluid infusion speed - 5ml per hour"
40834125|NCT05592496|DIAGNOSTIC_TEST|VAS scale for pain control|By using Visual Analog scale of pains, the pain score is fixed
40834126|NCT05849818|DEVICE|full-immersive VRapeutic software gaming technology|"* Children of the study group will receive VR training sessions 3 times per week for 8 successive weeks.~* Viblio VRapeutic fully immersive game will be used.~* Manual instructions of the game will be followed and features of the game will be customized.~* The child instructed to put back a pile of books on the floor into their shelves.~* Level II of the game we will use audio visual distractors , repeated parrot sound and the child is required to order the books by colors~* Level III distracting tasks during book ordering~* The complexity of the game depend on task duration, number of books and the nature of distractors"
40834127|NCT05700253|DEVICE|Cooled Radiofrequency Ablation|Image-guided genicular nerve ablation will be performed with the Coolief System (COOLIEF\* CRFA; Avanos Medical).
40834128|NCT05700253|DEVICE|Hyaluronic Acid Injection|Synvisc-One (\[Hylan G-F 20\]; Sanofi) will be administered as a single intra-articular dose (6 mL).
40834129|NCT00460590|BIOLOGICAL|MVA 85A|ID vaccine
40834130|NCT02183129|DRUG|Diclofenac|
41494220|NCT06387602|PROCEDURE|Post-Isometric Relaxation|"Step 1: Position the patient's limb at a point with the highest resistance felt during abduction.~Step 2: The patient is asked to bring the leg back into adduction using only 20% of strength against firm resistance given by the therapist.~Step 3: The patient will contract the agonist (the muscle that needs to be released) while holding an inhaled breath. Contraction should be held between 7-10 seconds without any jerking, bouncing, or wobbling.~Step 4: The patient is asked to release their effort slowly and completely. As the patient relaxes, the limb is guided into a new resistance barrier where a bind is felt again.~Step 5: After PIR, a 10-20-second latency period exists and the muscle can be stretched more easily.~Contract adductor muscle for 7-10 seconds and relax the same for 7-10 seconds with repetitions 7 times and 2 sessions per week."
40834131|NCT02183129|DRUG|Meloxicam|
40834132|NCT05443282|DIAGNOSTIC_TEST|Prolidase Level|Measurement of venous blood serum level of prolidase enzyme level by ELISA method.
40834133|NCT05443282|DIAGNOSTIC_TEST|Follicle Stimulating Hormone Level|Measurement of venous blood serum level of follicle stimulating hormone level.
40834134|NCT05443282|DIAGNOSTIC_TEST|Estradiol Level|Measurement of venous blood serum level of estradiol hormone level.
40834135|NCT05443282|DIAGNOSTIC_TEST|Proline Level|Measurement of venous blood serum level of proline level.
40834136|NCT05443282|DIAGNOSTIC_TEST|Hydroxyproline Level|Measurement of venous blood serum level of hydroxyproline level.
40834137|NCT05443282|DIAGNOSTIC_TEST|Anti-mullerian Hormone Level|Measurement of venous blood serum level of anti-mullerian hormone level.
40834138|NCT05443282|DIAGNOSTIC_TEST|Antral Follicle Count|Ultrasonographic evaluation of antral follicle count to determine ovarian reserve.
40834139|NCT05443282|DIAGNOSTIC_TEST|Prolactine Level|Measurement of venous blood serum prolactine hormone level.
40834140|NCT05443282|DIAGNOSTIC_TEST|Thyroid Stimulating Hormone Level|Measurement of venous blood serum thyroid stimulating hormone level.
40834141|NCT00862472|DRUG|DuoTrav APS|DuoTrav APS QD AM
40834142|NCT00862472|DRUG|DuoTrav|DuoTrav QD AM
40834143|NCT05308524|DIAGNOSTIC_TEST|ICU scoring system in covid 19|The intensive care unit (ICU) at Assiut University Hospital, which is supervised by the staff members of the Chest Diseases Department and designated to deal with critically ill Covid 19 patients.
40834144|NCT05027984|DEVICE|Optical coherence tomography|OCT images will be acquired by means of the FD C7 XR system or the OPTIS system (both St. Jude Medical, St. Paul, MN, USA) with a non-occlusive technique.(33) The acquired OCT coronary images will be analyzed on-line using a proprietary OCT console (St Jude Medical, Inc., USA). Definitions and cut-offs for OCT vulnerability parameters derived from available consensus documents and from main IVUS/OCT studies.
40834145|NCT05027984|DEVICE|iFR/FFR/RFR|The iFR and FFR measurements will be obtained using a coronary-pressure guidewire (Pressure Wire / Certus or Aeris for FFR assessment and PressureWire™ X Guidewire/QUANTIEM™ for the RFR assessment by Abbott Vascular, Abbott Park, Illinois, U.S.A; Comet by Boston Scientific, Marlborough, MA, USA), OptoWire by Opsens, Quebec, Canada, or Verrata by Philips, San Diego, CA, USA.).
40834146|NCT01166061|BIOLOGICAL|Placebo|Solution resembling active solution but without peptides
41021163|NCT01747980|DRUG|PRX-112|Single dose level, four doses per cohort
41021164|NCT03394300|OTHER|iol power calculation|iol power calculation in high myopia
40834147|NCT01166061|BIOLOGICAL|ToleroMune Grass|1 x4 administrations 4 weeks apart
40834148|NCT01403376|DRUG|teriflunomide|"Film-coated tablet~Oral administration"
40834149|NCT01403376|DRUG|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
40834150|NCT01403376|BIOLOGICAL|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"
41353561|NCT02532075|OTHER|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
41353562|NCT02532075|OTHER|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
41353563|NCT02532075|OTHER|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
41021165|NCT04795505|BEHAVIORAL|Intervention|The subsequent visit was through WeChat-based online consultations. Follow-up, assessments and feedback were done at each visit. After follow-up, medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided.
41021166|NCT04795505|BEHAVIORAL|Control|The subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention
40834151|NCT02644902|OTHER|Avatar assisted cascade training|Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
40834152|NCT02644902|OTHER|Specialist led training in THP|Training and supervision of lady health workers by specialists as in original THP
40834153|NCT04346030|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
40834154|NCT04346030|DRUG|lidocaine hydrochloride|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
40834155|NCT04346030|DRUG|normal saline|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
41353564|NCT02532075|OTHER|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
40834156|NCT02120365|DRUG|Perampanel|Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
41353565|NCT04772651|OTHER|Mediterranean Diet|Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)
41353566|NCT04772651|OTHER|Normal hospital diet|Normal hospital diet
41353567|NCT04772651|OTHER|dietary coaching|dietary coaching
40834157|NCT02120365|DRUG|Placebo|Placebo given in place of perampanel during the pre-treatment period and lab session days.
40834158|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
41353568|NCT04772651|OTHER|Psychoeducation on depression|Psychoeducation on depression (50minutes once a week for 4 weeks)
41353569|NCT03030157|DRUG|pirarubicin(THP)|
40834159|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
40834160|NCT01289106|BIOLOGICAL|Hepavax-Gene|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
41353570|NCT00438724|BEHAVIORAL|Information, counseling and support|
41353571|NCT04563130|BEHAVIORAL|Cryocompression|Cryocompression will be administered using ice bags and compression socks/ surgical gloves
41353572|NCT00871468|PROCEDURE|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
41353573|NCT00871468|PROCEDURE|anterior-inferior plate|ORIF clavicle with anterior inferior plate
41353574|NCT05584072|DIAGNOSTIC_TEST|Active pedal plantarflexion (APP) test|Active pedal plantarflexion (APP) test
41353575|NCT02907801|BEHAVIORAL|Perception-Action Approach|Environmental set-up, gentle manual guidance, and caregiver education
41353576|NCT02074436|DRUG|EACA|EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.
41494221|NCT03275714|DEVICE|Smartphone APP|Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
41494222|NCT05608980|DRUG|0.01% hypochlorous acid|once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
41494223|NCT05608980|DRUG|Placebo|once daily eyelid wipes for 2 weeks
41494224|NCT06493851|DEVICE|hyperbaric oxygen therapy|"The HBOT protocol consists of 6 weeks protocol including 5 daily HBOT sessions per week (total of 30), each session lasts 90 minutes, of 100% oxygen at 2 atmosphere absolute (ATA) with 5-minute air breaks every 20 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux Starmed 2700, Germany) located at the Sagol center for hyperbaric medicine and research, Shamir (Assaf-Harofeh) Medical Center, Israel."
41494225|NCT04290273|DIAGNOSTIC_TEST|MED Test|Participant is irradiated with several doses of UV light on small areas of the outer thigh. 24 hours later this area is visually inspected for erythema, and the minimal erythemal dose (MED) is determined.
40834161|NCT02761577|DRUG|Sodium bicarbonate|3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
40834162|NCT02761577|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
40834163|NCT00744666|DRUG|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
40834164|NCT02916459|DEVICE|21G EBUS-TBNA needle|
40834165|NCT02916459|DEVICE|Flexible 19G EBUS-TBNA needle|
40834166|NCT05544630|DEVICE|computerized dynamic posturography (sensory orgnization test)|assess of an individual's ability to maintain static and dynamic stance. The assessment is composed of a battery of tests that are similar to everyday conditions of daily living. There are four main components to CDP that are used clinically: the Sensory Organization Test (SOT),
40834167|NCT05838014|OTHER|Sleep deprivation|Participants will undertake a period of 24 hours of total sleep deprivation prior to completing exercise
40834168|NCT05838014|OTHER|Normal sleep|Participants will undertake \~8 hours of normal sleep prior to completing exercise
40834169|NCT00114920|DRUG|Resiquimod|
40834170|NCT02662114|OTHER|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
40834171|NCT03077698|DRUG|Sodium Cridanimod|The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
40834172|NCT03077698|DRUG|progestin therapy|The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
40834173|NCT00702455|BEHAVIORAL|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
41353577|NCT02074436|OTHER|Platelet transfusion|Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
40834174|NCT00702455|BEHAVIORAL|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
41353578|NCT00534664|DEVICE|TheraBionic device|Daily outpatient treatment with theraBionic device
41353579|NCT03345849|DRUG|Upadacitinib|Oral; Tablet
41353580|NCT03345849|DRUG|Placebo for Upadacitinib|Oral; Tablet
41353581|NCT05092867|OTHER|Po Tra tool|Healthcare workers filled the 2 VAS of the tool but it did not impact or change the care of the patient. (observational)
41353582|NCT02027285|DIETARY_SUPPLEMENT|fortified milk|"FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml."
41353583|NCT01054339|DRUG|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
41353584|NCT02955446|DRUG|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
41353585|NCT05594667|DRUG|Psilocybin|25mg of psilocybin provided by Filament Health
41353586|NCT03422744|PROCEDURE|trans bronchial biopsy guided by echo-endoscopic miniprobes|We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.
41494226|NCT04290273|DEVICE|Wearing device|Participants wear a portable erythema measurement device for 48 hours. The device shines light on the skin at frequent intervals and measures skin 'redness'. The device is removed by a technician after the 48 hours.
41494227|NCT05311748|DIAGNOSTIC_TEST|Ultrasound and doppler|Penile echocolour doppler ultrasound
41494228|NCT00006239|DRUG|sodium phenylbutyrate|
41494229|NCT00006239|DRUG|tretinoin|
40834175|NCT06280534|DRUG|Test drug XT1061 capsules and placebo,Single dose group|Eight people took capsules of the test drug XT1061 and two people took a placebo.
40834176|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Multiple dosing group|D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.
41494230|NCT02606214|DRUG|TBA-354|
41494231|NCT02606214|DRUG|TBA-354 Placebo|
40834177|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Food Impact Group|Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.
40834178|NCT02119156|DRUG|Belimumab|Monthly intravenous infusions dosed as 10 mg/kg body weight
40834179|NCT01261169|DRUG|Myfortic|Myfortic in uveitis
40834180|NCT01049802|DEVICE|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
40834181|NCT00327574|BEHAVIORAL|Home heath education +/_ GP training|
40834182|NCT06519383|PROCEDURE|guided implant surgery|Surgical guide is fabricated and fitted onto the patient's arch and implant is placed with guide in place.
40834183|NCT00780481|DRUG|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
40834184|NCT01604655|PROCEDURE|Coronary CT Angiography|CCTA
40834185|NCT01604655|PROCEDURE|Stress Test|Stress Test
40834186|NCT04405271|DRUG|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks
40834187|NCT04405271|DRUG|Placebo|A dose of 1 tablet per day will be administered for a total of 12 weeks.
40834188|NCT02080260|DRUG|regorafenib|Single agent drug therapy with regorafenib
40834189|NCT06467669|OTHER|Wrist denervation procedure|To summarize, a Wagner incision is made starting over the junction of the glabrous and non-glabrous skin overlying the thumb CMC joint extending toward the distal wrist crease. The branches of the superficial radial nerve are identified as lying perpendicular to the plane overlying the fascia of the thenar muscles. The branches of the lateral antebrachial cutaneous nerve are identified and resected within the anatomic snuffbox deep to the first compartment. Finally, the thenar muscle fibers are divided at their proximal origin to identify the articular branches of the posterior cutaneous branch of the median nerve.
40834190|NCT00298493|PROCEDURE|Sedation management strategy|
40834191|NCT02395211|BEHAVIORAL|Usual Physiotherapy|"Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks"
40834192|NCT02395211|DEVICE|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
41353587|NCT03422744|PROCEDURE|if first one negative: samples under fluoroscopic control|If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control
41353588|NCT01321333|BIOLOGICAL|HuCNS-SC cells|single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
41353589|NCT04973722|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
41353590|NCT04973722|DRUG|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
41353591|NCT04604028|DRUG|Lenalidomide [Leavdo®]|Complete remission and partial remission rate
41353592|NCT00522652|DRUG|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
41494232|NCT00004553|PROCEDURE|Electromyography|
40834193|NCT03306641|DEVICE|Test Contact Lens|Daily disposable contact lens
40834194|NCT03306641|DEVICE|Nelfilcon A|Focus Dailies All Day Comfort contact lens (nelfilcon A)
40834195|NCT03287570|DEVICE|Cettum|The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
40834196|NCT03287570|PROCEDURE|Traditional indirect moxibustion|The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
40834197|NCT03287570|OTHER|Usual care|The patients in this group maintain the usual treatment and self-care.
40834198|NCT06107972|BEHAVIORAL|Launching! to Adulthood (¡Iniciando! la Adultez) program|The program includes cognitive behavioral and acceptance and commitment therapy, with a focus on developing goals during the transition to adulthood through a values framework. After a combined (parents and young adults) 90-minute introductory group meeting in-person, parents and the transition-aged young adults with ASD attend 9 separate, 90-minute weekly group telehealth meetings. Additionally, young adults have weekly personal coaching meetings for 30-minutes to discuss progress toward goals and barriers encountered. Leaders teach transition-aged young adult's skills through various social activities, as well as other skills (e.g., emotion regulation, cognitive diffusion) to help overcome barriers towards their goals. The treatment targets three core factors (i.e., mental health conditions, social skills, and coping with and adapting to stress). Leaders teach parents new parenting skills, knowledge of ASD, and readiness to support their young adult's transition to independent life.
40834199|NCT05769166|OTHER|thired domain of nordic orofcial test-screen|its a questionnaire which the parent will answer
40834200|NCT00784485|DRUG|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
40834201|NCT00630227|BIOLOGICAL|Biologic Lung Volume Reduction|20 mL Hydrogel
40834202|NCT00600769|DRUG|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
41353593|NCT01885962|BEHAVIORAL|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
41353594|NCT00421460|DRUG|Testosterone Undecanoate,1000mg|duration for 4 injections
41509151|NCT03310749|DRUG|Metformin|A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
40834203|NCT01377948|BEHAVIORAL|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
40834204|NCT04496375|OTHER|Survey|Self-completed questionnaires
40834205|NCT04072107|DRUG|sintilimab|Investigate whether capecitabine would be able to improve prognosis in patients at high risk groups
40834206|NCT04072107|DRUG|Capecitabine|Investigate whether capecitabine would be able to improve prognosis in patients at intermediate risk groups
40834207|NCT02204852|DRUG|Iloprost+eptifibatide|
40834208|NCT02204852|DRUG|Placebo|
40834209|NCT01838785|DRUG|18F-DTBZ AV-133|
40834210|NCT01112111|DRUG|mode of gonadotropin administration|Low dose step-up administration Step down administration sequential administration
40834211|NCT00869830|OTHER|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
40834212|NCT02857101|OTHER|dosage of calprotectin|
40834213|NCT03368014|BEHAVIORAL|Lyrics-writing and singing show|"Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony."
40834214|NCT02495688|PROCEDURE|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
40834215|NCT02495688|PROCEDURE|General anesthesia|Standard procedure.
40834216|NCT06466993|BEHAVIORAL|Intervention of standardized relaxing breathing|Relaxing breathing standardized to 6 respiratory cycles per minute that occur during rotation time before next station of OSCE start
40834217|NCT04738591|DEVICE|DIABE-TEXT|Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
40834218|NCT00236392|DRUG|rabeprazole|
40834219|NCT03288194|BEHAVIORAL|Problem-Solving Treatment|
40834220|NCT03288194|BEHAVIORAL|Time Management|
40834221|NCT03430271|OTHER|Physical Activity Intervention|Participants in this arm will complete exercise sessions 1 time per week for 24 weeks. An optional, second PA session will also be offered to PA participants. The exercise sessions will be multimodal and involve walking, lower extremity strengthening exercises, flexibility and balance training.
40834222|NCT03430271|OTHER|Healthy Aging Intervention|Participants will attend health education workshops on topics of relevance to older adults. Workshops will be offered weekly in a group setting, and participants will be required to attend biweekly.
40834223|NCT04479683|OTHER|FTH then DH support|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.~During this phase, all children are evaluated once a week on a somatic level."
41509152|NCT05736861|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
40834224|NCT04479683|OTHER|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
40834225|NCT00382915|DEVICE|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
40834226|NCT04932291|DRUG|vafidemstat|1.2mg capsule
40834227|NCT04932291|DRUG|Placebo|placebo capsule
40834228|NCT01904656|BEHAVIORAL|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
40834229|NCT01904656|BEHAVIORAL|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
40834230|NCT00494715|DRUG|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
40834231|NCT00494715|DRUG|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
41494233|NCT01525264|BEHAVIORAL|KIM-CHI|The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
40834232|NCT00494715|DRUG|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
40834233|NCT00581451|DRUG|bifeprunox|oral tablet once daily
41021167|NCT00969891|OTHER|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
41021168|NCT00557115|OTHER|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
40834234|NCT03322501|BEHAVIORAL|Provider Advice, Framed Messaging|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
41159836|NCT05371678|OTHER|Therapeutic motor control interventions|Treatment duration will be 8 weeks, two sessions a week. Each session will take approximately 60 minutes. This intervention includes education, dietary advices, core stabilization exercises and pelvic floor muscle training with surface Electromyographic-Biofeedback. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Core stabilization exercises will be performed 2 days a week with a physiotherapist and the session will be approximately 50 minutes. Diaphragmatic breathing will be taught to children in breathing exercises. The pelvic floor muscles exercises will be do by surface Electromyographic-Biofeedback. The Electromyographic-Biofeedback teaches the child how to relax the external anal sphincters with visual and auditory feedback techniques.The child will learn to relax the pelvic floor muscles during defecation by monitoring the recorded electromyographic activity.
41353595|NCT05012514|DEVICE|LLLT RED|"Participants received seven sessions of PBMT LED twice a week, the last session being about twenty minutes before the surgical procedure of bariatric surgery. The therapy was performed on the left side of the abdominal region following the linea alba of all research participants and the right side was considered as control, for application they will receive eye protection, using goggles for safety, the abdomen of the participants will be cleaned by using a neutral cleansing soap. A cluster applicator was used using the parameters described in table 1.~For therapy, the equipment Antares® was used, IBRAMED- Indústria Brasileira de Equipamentos Eletromédicos EIRELI \[EIRELI Brazilian Industry of Electromedical Equipment\], approved by Anvisa Nº 10360310037. Figure 1."
41353596|NCT03990324|PROCEDURE|Manual stretching|Manual stretching for the upper trapezius and levator scapulae muscle
41494234|NCT01525264|BEHAVIORAL|Healthy Wife Control Group|Intervention group of couples who received education about importance of Healthy diet
41353597|NCT01265940|DRUG|Pazopanib as add-on to vinflunine|"Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.~In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose."
40834235|NCT00283816|DRUG|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
40834236|NCT00283816|DRUG|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study"
41353598|NCT00887913|DEVICE|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
41353599|NCT03704090|BEHAVIORAL|Occupational therapy intervention|Prevention of postoperative delirium by occupational therapy intervention
40834237|NCT00283816|BEHAVIORAL|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise \& behavior modification skills on a regular weekly basis over the 24 week study
41494235|NCT00511095|BIOLOGICAL|HEPLISAV|Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
41494236|NCT05483725|BIOLOGICAL|Booster dose of mRNA vaccine|Administration of SARS-CoV-2 mRNA vaccine.
41494237|NCT02101593|DRUG|ADI-PEG 20|
41494238|NCT03148418|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
41159837|NCT05371678|OTHER|Conventional treatment|Treatment duration will be 8 weeks. This intervention includes education, dietary advices and laxative therapy. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Laxative therapy will be adjusted at different doses according to the child's age and weight. Laxative therapy will be administered to children by a specialist doctor.
40834238|NCT00283816|BEHAVIORAL|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
40834239|NCT00283816|PROCEDURE|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion"
41353600|NCT03704090|BEHAVIORAL|Standard non-pharmacological prevention intervention|Prevention of postoperative delirium using standard non-pharmacological prevention measures
41494239|NCT03148418|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
41353601|NCT06460935|BEHAVIORAL|sexual health training|The 20-hour sexual health training will be given online for 5 weeks. Case discussions using the Plissit Model will be held in the training content.
41494240|NCT03795766|PROCEDURE|Surgeries for gynecologic disease|All patients accept surgeries for gynecologic disease.
41494241|NCT03173638|PROCEDURE|intravitreal injection of MSV|A unique intravitreal injection of MSV in acute fase of NAION
41494242|NCT03123510|DIETARY_SUPPLEMENT|Bifidobacterium spp plus bimuno- galacto-oligosaccharides|Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.
40834240|NCT00283816|PROCEDURE|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
41159838|NCT05350514|DRUG|PI-2620 tracer|Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.
41159839|NCT04087798|BEHAVIORAL|Control-EDI|Patients in the control group will receive Control-EDI from their primary care provider during clinic visit. Subsequent patient CKD education and follow-up will be provider dependent. Patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).
41159840|NCT04087798|BEHAVIORAL|Intervention-EDI and health coaching|"Patients in the intervention group will receive a personalized Intervention-EDI from their primary care provider during visit, which will include their most recent BP, their urine protein level and most recent eGFR. There is also a space for their provider to type in a sentence about specific goals for the patient.~Health coaches will conduct a baseline call and 4-6 coaching calls, based on patient's needs, over an 11-month period. There are 4 topic areas related to blood pressure and CKD that will be the focus of the calls. Coaches will also have pre-determined and vetted educational resources to provide patients if needed. Additionally, patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only)."
41353602|NCT04896840|OTHER|Telerehabilitation İntervention, Motor learning|"Telerehabilitation İntervention:~Training videos will be sent to the families of the children in the tele-rehabilitation group before starting to work. With the training videos, it is aimed to teach the exercises to be done to the families. Treatment will be applied by their families for 8 weeks, 2 days a week, 40 minutes a day. Physiotherapist will attend the sessions by video conference method. Video conference calls will be made by phone over the WhatsApp application.~Motor learning:~The first 10 minutes will start with active stretching Functional lying in a sitting position, Functional lying with feet together in a standing position. rolling the pilates ball on the wall, walking on its side. Going up and down stairs at different heights. Walking across different surfaces and obstacles. Getting up from chairs of different heights, sitting and extending the object taken from the ground. Functional exercises suitable for the child's level."
41353603|NCT00878644|PROCEDURE|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
41353604|NCT00878644|OTHER|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
41353605|NCT04374149|PROCEDURE|Therapeutic Plasma Exchange|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy
41353606|NCT04374149|DRUG|Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
41353607|NCT00764322|DRUG|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
41353608|NCT00764322|GENETIC|gene expression analysis|Genetic analysis of blood sample.
41353609|NCT00764322|OTHER|pharmacogenomic studies|Genetic analysis of blood sample.
41353610|NCT00764322|OTHER|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
41353611|NCT00764322|PROCEDURE|quality-of-life assessment|Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
41353612|NCT05806099|DRUG|MBS303|"Phase I: The patients confirming to the eligibility criteria will be assigned to one of the 7 dose groups (0.05/0.15/0.45 mg \~ 1.5/6/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS303 as per the schedule specified in the respective arms. Based on the safety data of the previous dose groups, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subject should be given an IV infusion of MIL62 1000 mg single dose on the D-7.~Phase Ⅱ: One or two recommended doses will be selected based on the results of Phase I. Each patient will receive one of the two recommended doses MBS303 as step-up doses on D1 (low dose) and D8 (intermediate dose) of C1 and at the target dose on D1 of C2-17 (21-day cycles). Based on the previous safety data, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subjects should be given an IV infusion of MIL62 1000 mg single dose on the D-7"
41353613|NCT04337112|DRUG|viltolarsen|Intravenous (IV) infusions, weekly, at 80mg/kg, once weekly (approximately every 7 days).
41353614|NCT04173910|PROCEDURE|Ultrasound LPEC/Sellick|We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
41353615|NCT00421616|BEHAVIORAL|High protein diet study|
41353616|NCT06482801|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
41353617|NCT03039907|PROCEDURE|Total Knee Arthroplasty|Total knee arthroplasty
41353618|NCT05823428|PROCEDURE|Augmentation with subacromial bursa + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
41353619|NCT05823428|PROCEDURE|Rotator cuff debridement + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
41353620|NCT01433328|DRUG|Lidocaine|Lidocaine
41494243|NCT03123510|DIETARY_SUPPLEMENT|Placebo|Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
41494244|NCT03049605|DEVICE|Magnetic therapy|low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss . Magnetic device will be applied on each patient from a comfortable supine lying position. After the connection of appliance to electrical supply, the actions of PEMF will be directed and adjusted over lumbar spine, hip regions and calf muscles of both lower limbs.
41494245|NCT03049605|DEVICE|laser therapy|laser therapy of Helium neon infrared laser (850 nano-meter) was used in continuous wave mode from a comfortable prone lying position on the whole plantar surface of the foot and the lumbo-sacral area by four points, and two points laterally to the spine.
41494246|NCT03049605|DRUG|Only medical treatment|Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
41494247|NCT04844762|BEHAVIORAL|Menthol cigarettes substitutes|In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.
41494248|NCT04844762|BEHAVIORAL|Usual brand menthol cigarettes and substitutes|In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.
41494249|NCT04844762|BEHAVIORAL|Menthol cigarettes substitutes and menthol cigarettes|In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.
41494250|NCT03357835|OTHER|Trauma Decision System|At the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.
41494251|NCT02594085|OTHER|Patch 1|Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
41494252|NCT02594085|OTHER|Patch 2|Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
40834241|NCT00283816|PROCEDURE|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion"
41353621|NCT01433328|DRUG|Placebo|Placebo
41353622|NCT04322266|DRUG|HCP1701|Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
41353623|NCT04322266|DRUG|HCP1306|Ezetimibe /Rosuvastatin
41353624|NCT04322266|DRUG|HGP0904|Amlodipine
41353625|NCT04322266|DRUG|HGP0608|Losartan potassium
41353626|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels baseline|Measuring vitamin D plasma levels at baseline
41353627|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry at baseline|Measuring T-score and Z-score of the femur and lumbar spine at baseline
41494253|NCT02594085|OTHER|Patch 3|Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
41494254|NCT02594085|OTHER|Patch 4|Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
41494255|NCT02594085|OTHER|patch 5|Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
41353628|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials at baseline|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured.
41353629|NCT05322538|DIAGNOSTIC_TEST|Audiogram at baseline|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score.
41353630|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure at baseline|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test
41353631|NCT05322538|DIAGNOSTIC_TEST|cold pressor test at baseline|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function.
41353632|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels one year after recruitment|Measuring vitamin D plasma levels one year after recruitment
41353633|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels two years after recruitment|Measuring vitamin D plasma levels two years after recruitment
40834242|NCT00283816|PROCEDURE|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
40834243|NCT00283816|DRUG|placebo|placebo capsules, two capsules BID
40834244|NCT03454516|OTHER|telemonitoring|the follow-up of the patient will be performed with Telemonitoring
40834245|NCT05027620|OTHER|Motor-cognitive exercise therapy in the home|"Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.~Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period."
40834246|NCT04117763|DRUG|Empagliflozin 25 MG|Empagliflozin once daily, for three months
40834247|NCT00276614|DRUG|bortezomib|
40834248|NCT00690287|DRUG|AZD6370|Oral single doses a+b+c, o.d., suspension
40834249|NCT00690287|DRUG|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
40834250|NCT00690287|DRUG|Placebo|Placebo
40834251|NCT06161285|OTHER|Sampling|Single-time sampling of respiratory virus-infected children
41159841|NCT01730742|BEHAVIORAL|Neuroeconomics task|After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
40834252|NCT04672525|DRUG|Rifabutin|2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
41159842|NCT01730742|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
41159843|NCT01730742|PROCEDURE|Blood sample|After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
41159844|NCT03277417|OTHER|Echocardiography|Imaging of fetal heart and amniotic fluid
41159845|NCT05017025|DRUG|Aurora A Kinase Inhibitor LY3295668|Given PO
41353634|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry one year after recruitment|Measuring T-score and Z-score of the femur and lumbar spine one year after recruitment
41494256|NCT02594085|OTHER|Patch 6|Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
41494257|NCT05200897|DEVICE|Transdermal trigeminal electrical neuromodulation(Cefaly)|The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes
41494258|NCT01894035|DRUG|Iloprost (Ventavis, BAYQ 6256)|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
41494259|NCT05912439|BEHAVIORAL|SidekickHealth|Usage of mobile application called SidekickHealth.
41494260|NCT03775759|PROCEDURE|Tricuspid valve repair or replacement|Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.
41353635|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry two years after recruitment|Measuring T-score and Z-score of the femur and lumbar spine two years after recruitment
41353636|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials one year after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured one year after recruitment
41353637|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials two years after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured two years after recruitment
41353638|NCT05322538|DIAGNOSTIC_TEST|Audiogram one year after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed one year after recruitment
41353639|NCT05322538|DIAGNOSTIC_TEST|Audiogram two years after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed two years after recruitment
41353640|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure one year after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed one year after recruitment
41494261|NCT03775759|OTHER|Medical management of tricuspid regurgitation|The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.
41494262|NCT03885752|DRUG|chewed mint gum|In the preoperative waiting area before transferring to the operating room, patients in group G chewed mint gum for 2 minutes and then spit it out.
41494263|NCT03885752|OTHER|swallow twice|asked to swallow twice without any additional treatment.
41494264|NCT05783544|DIAGNOSTIC_TEST|Interleukin-1B|Level of serum interleukin-1B will be detected
41159846|NCT05017025|DRUG|Osimertinib|Given PO
41353641|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure two years after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed two year after recruitment.
41353642|NCT05322538|DIAGNOSTIC_TEST|cold pressor test one year after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed one year after recruitment.
41494265|NCT05783544|DIAGNOSTIC_TEST|Interleukin-4|Level of serum interleukin-4 will be detected
41494266|NCT05783544|DIAGNOSTIC_TEST|Interleukin-6|Level of serum interleukin-4 will be detected
41494267|NCT05783544|DIAGNOSTIC_TEST|tumor necrosis factor - a|Level of serum tumor necrosis factor - a will be detected
41494268|NCT05783544|DIAGNOSTIC_TEST|interferon- gamma|Level of serum interferon- gamma will be detected
41494269|NCT00521534|DEVICE|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
41494270|NCT00802594|DRUG|DB289|A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
41494271|NCT03472417|DEVICE|Active partial rebreathing device|
41494272|NCT03472417|DEVICE|Dummy partial rebreathing device|
41494273|NCT01639196|OTHER|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
40834253|NCT04672525|DRUG|Rifampicin|10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
40834254|NCT01035346|DRUG|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
40834255|NCT01035346|DRUG|Placebo|Single dose of a placebo
41494274|NCT01639196|OTHER|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
41159847|NCT00530049|OTHER|questionnaire administration|
40834256|NCT04350060|OTHER|Retro-fitted room with technological enhancements|Reconstructing and retrofitting a currently existing memory care room at Samaritan Bethany Arbor Terrace Senior Living with integrated technologies specifically to accommodate the needs of persons with dementia to enhance sensory stimulation in sight, sound and sleep.
41159848|NCT00530049|PROCEDURE|assessment of therapy complications|
41159849|NCT00530049|PROCEDURE|psychosocial assessment and care|
40834257|NCT03556098|DRUG|glucose-dependent insulinotropic peptide|Infusion of GIP
40834258|NCT03556098|DRUG|Glucose-Dependent Insulin-Releasing Hormone[3-30]|Infusion of GIP antagonist GIP\[3-30\]
40834259|NCT03556098|DRUG|Saline Solution|Infusion of Saline
40834260|NCT01349062|DRUG|"Kallunk oxide (Immunotherapy) "|"The study is assigned Arm 1 above 450 cu/mm\^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum."
41159850|NCT00530049|PROCEDURE|quality-of-life assessment|
41159851|NCT02852811|OTHER|Group education|Intervention involving two education session with topics common in menopause transition.
41159852|NCT03696602|DIAGNOSTIC_TEST|bronchial provocation test|
41494275|NCT04732624|DRUG|Oral Rehydration Solution|Feasibility study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
41494276|NCT04732624|DRUG|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
40834261|NCT01110798|OTHER|intraoperative complication management/prevention|
40834262|NCT01110798|PROCEDURE|assessment of therapy complications|
40834263|NCT01110798|PROCEDURE|gastrointestinal complications management/prevention|
40834264|NCT01110798|PROCEDURE|quality-of-life assessment|
40834265|NCT01110798|PROCEDURE|therapeutic conventional surgery|
40834266|NCT04526470|DRUG|Alpelisib|Dose level -2: 200 mg PO once daily / Dose level -1: 200 mg PO once daily / Dose level 0: 250 mg PO once daily / Dose level 1: 300 mg PO once daily
41159853|NCT06035003|BEHAVIORAL|Internet-based Mindfulness Intervention for Emotional Distress (iMIED)|Internet-based Mindfulness Intervention for Emotional Distress (iMIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
41159854|NCT02245464|DRUG|Telmisartan|
41159855|NCT02895750|DRUG|Metformin|Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)
41353643|NCT05322538|DIAGNOSTIC_TEST|cold pressor test two years after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed two years after recruitment.
41353644|NCT00850135|DEVICE|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
41353645|NCT02299128|OTHER|Physical Therapy Treatment|
41353646|NCT01830322|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
41353647|NCT01830322|DRUG|Gemcitabine|
41353648|NCT01830322|DRUG|Any non-gemcitabine chemotherapies or best supportive care|
41353649|NCT00722735|DRUG|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
41353650|NCT00722735|DRUG|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
41353651|NCT04139629|DIAGNOSTIC_TEST|antichlamydial antibody test|At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.
41353652|NCT04139629|DRUG|treatment of infertility with ART|COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
41353653|NCT02946008|RADIATION|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
40834267|NCT04526470|DRUG|Paclitaxel|Dose level -2: 60 mg/m2 IV on day 1, 8, and 15 / Dose level -1: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 0: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 1: 70 mg/m2 IV on day 1, 8, and 15
40834268|NCT05529342|BIOLOGICAL|Gene modified therapy|No investigational cell product will be administered
40834269|NCT05506488|DRUG|Dasatinib 100 MG + Quercetin (1000 MG)|The intervention group will receive intermittent orally administered dasatinib (100 mg/day) plus quercetin (1000 mg/day) on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
40834270|NCT05506488|OTHER|Placebo|The placebo group will receive intermittent orally administered placebo tablets on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
40834271|NCT00707746|DRUG|mipomersen|
41159856|NCT05326633|COMBINATION_PRODUCT|MRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|Mobility-based physical rehabilitation sessions performed 5 times/week by a study PT to provide strength and cardiopulmonary endurance training. High whey protein shakes prescribed to a total intake of 1.6-1.8 g/kg/d in 2 divided doses based on caloric needs. 2 x 30-minute lower extremity electric stimulation sessions/day, 5 times/wk performed by study PT.
41159857|NCT02679547|OTHER|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
41159858|NCT05764577|PROCEDURE|DIEP flap surgery|Removal off the DIEP flap followed by closure of the rectus sheath and abdominal skin.
41353654|NCT02946008|PROCEDURE|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
41353655|NCT02442375|RADIATION|standard dose prescription|"* standard elective dose~* no intermediate dose-level~* visual interpretation of FDG-PET-scan"
40834272|NCT00707746|DRUG|placebo|
40834273|NCT01451190|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
40834274|NCT02117635|BIOLOGICAL|CTX DP|20 million cell dose administered by surgery to the damaged area of the brain
41159859|NCT01959607|OTHER|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
40834275|NCT00369694|DRUG|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
40834276|NCT00369694|DRUG|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
40834277|NCT03129594|DIAGNOSTIC_TEST|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
40834278|NCT02581930|DRUG|Ibrutinib|Given PO
40834279|NCT02581930|OTHER|Laboratory Biomarker Analysis|Correlative studies
40834280|NCT02581930|OTHER|Pharmacogenomic Study|Correlative studies
40834281|NCT02581930|OTHER|Pharmacological Study|Correlative studies
40834282|NCT00226863|BEHAVIORAL|meditation plus education|
40834283|NCT00226863|BEHAVIORAL|group psychotherapy with hypnosis plus education|
40834284|NCT00226863|BEHAVIORAL|education|
41159860|NCT01959607|OTHER|CC|Single use of subject's own cigarette (CC)
41159861|NCT01959607|OTHER|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
41159862|NCT02461719|DRUG|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|1 drop twice/day for 12 weeks to both eyes.
41159863|NCT02461719|DRUG|Restasis|1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
41159864|NCT01532102|DRUG|AP611074|
41159865|NCT01532102|DRUG|Placebo|Placebo gel manufactured to appear identical to AP611074 5% gel
41353656|NCT02442375|RADIATION|FDG-PET guided gradient dose prescription|"* de-escalation of elective dose~* intermediate dose-level~* standardized methods to evaluate FDG-PET-scan"
41353657|NCT02586116|DEVICE|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
41353658|NCT02586116|DEVICE|C-Plus|C-Plus PEEK IBF Device with autograft
41353659|NCT00638989|BIOLOGICAL|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
41353660|NCT00638989|BIOLOGICAL|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
41353661|NCT00638989|BIOLOGICAL|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
41353662|NCT01815099|DEVICE|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
41353663|NCT04833049|DRUG|TAK-994 Oral Tablet|TAK-994 tablet.
41353664|NCT04833049|DRUG|[14C]TAK-994 Intravenous Infusion|\[14C\]TAK-994 intravenous infusion.
41353665|NCT04833049|DRUG|[14C]TAK-994 Oral Suspension|\[14C\]TAK-994 oral suspension.
41353666|NCT03792412|OTHER|Usability Questionnaire|Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
41353667|NCT05257915|DRUG|Perampanel|"For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients \<12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
41353668|NCT04115891|OTHER|Anxiety scale|Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.
41353669|NCT04115891|OTHER|Pain scale - 1|Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction
41353670|NCT04115891|OTHER|Pain scale - 2|Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction
41353671|NCT04115891|BEHAVIORAL|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to interventions
41353672|NCT03527290|BEHAVIORAL|Time Restricted Eating|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts related to circadian rhythms, metabolism and TRE; and the evidence demonstrating benefit of TRE in animal models and humans. The goal is provide rationale for the potential benefits of a TRE approach. In addition, the RD sessions focus on developing a plan for successfully implementing a TRE approach, identifying challenges for adherence, and a plan for dealing with real or potential challenges. The counseling is focused the TRE concept, with no specific direction or counseling related to modifying the content of the participant's diet or any prescription to reduce energy intake.
41353673|NCT03527290|BEHAVIORAL|Standard Cardiometabolic Health Diet|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts and known benefits related to eating a diet for cardiometabolic health and weight management recommended by the American Heart Association and the Academy of Nutrition and Dietetics as a standard of practice for dietitians in healthcare settings. The RD sessions focus on adopting a dietary pattern aligned with this approach, identifying challenges to adopting this dietary pattern, and education and plans for dealing with real or potential challenges. The counseling gives no direction related to modifying the timing of dietary intake or any prescription to reduce energy intake.
41353674|NCT03272009|DRUG|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
41353675|NCT03272009|DRUG|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
41353676|NCT03272009|DRUG|Entecavir|Tablets administered orally
41353677|NCT03272009|DRUG|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
41353678|NCT02203006|BIOLOGICAL|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
40834285|NCT05136898|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
41353679|NCT00117520|DRUG|Caffeine|
41353680|NCT05551234|OTHER|Regular exchanges|The seniors and childrens will meet once a week, for 7 months, over a period of one and a half hours, outside school hours (4:30 p.m. to 6:00 p.m.) and school holidays.
41353681|NCT02217046|PROCEDURE|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
41353682|NCT05639361|BEHAVIORAL|Repeated Exposure|Caregivers will be asked to offer a novel vegetable to their infant/toddler 10 times at home according to the schedule of repeated exposure to which they are randomized.
41494277|NCT05485701|DIAGNOSTIC_TEST|Screening tools for common mental disorders|A number of screening tools will be administered which will establish the likelihood of depression, anxiety, PTSD, somatisation and suicidality.
40834286|NCT02267304|DRUG|50 mL of sodium chloride (0,9%)|
40834287|NCT02267304|DRUG|Morphine 0,05mg/kg|
40834288|NCT02267304|DRUG|Naloxone 10mg|
41494278|NCT01760525|DRUG|CGM097|Patients treated with CGM097
40834289|NCT01658137|OTHER|Prudent Diet|This intervention lasts 2 weeks (14 days).
40834290|NCT01658137|OTHER|Typical Western Diet|This intervention lasts 2 weeks (14 days).
40834291|NCT03529110|DRUG|Trastuzumab deruxtecan (T-DXd)|T-DXd is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously.
41494279|NCT03619681|DRUG|KN026|Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
40834292|NCT03529110|DRUG|Ado-trastuzumab emtansine (T-DM1)|The treatment will be in accordance with the approved label.
41353683|NCT05739890|OTHER|Embryo genome sequencing|This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (\>depth of 30x per base).The remaining embryo tissue will be whole genome sequenced to validate the results of the biopsy.
40834293|NCT02792998|DRUG|IW-1701|IW-1701 Tablet
40834294|NCT02792998|DRUG|Placebo|Matching Placebo Tablet
40834295|NCT03042260|DRUG|Trimethoprim-Sulfamethoxazole|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
40834296|NCT03042260|DRUG|Placebo Oral Tablet|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
40834297|NCT04226976|DEVICE|Otoband|Participants with AUV will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
40834298|NCT04226976|DEVICE|Placebo Device|Participants with AUV will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
40834299|NCT06374186|BEHAVIORAL|Behavioral Intervention with financial rewards and coaching|Participants will receive variable financial incentives based on their engagement with the continuous glucose monitor and meeting diabetes treatment goals. In addition, they will participate in three motivational interviewing sessions focused on their diabetes management. Participants will continue to receive their diabetes treatment as usual.
40834300|NCT06374186|BEHAVIORAL|Control|Participants will only receive a continuous glucose monitor, which they may engage with as desired and no further intervention. Participants in the control group will continue to receive their diabetes treatment as usual.
40834301|NCT02044666|DEVICE|Micronized Small Intestinal Submucosa (SIS)|Micronized Small Intestinal Submucosa (SIS)
40834302|NCT03508323|DRUG|Teneligliptin|20mg/qd
40834303|NCT03508323|DRUG|Placebo|1T/qd
41353684|NCT05739890|OTHER|Parents genome sequencing|Analysis will be performed using trio testing of each embryo in addition to the DNA from the genetic parent to facilitate the derivation of de novo mutation rate.
41353685|NCT00942422|DIETARY_SUPPLEMENT|defined green tea catechin extract|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
41494280|NCT04642651|DRUG|Dexmedetomidine|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.
41494281|NCT04642651|DRUG|Placebo|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
41494282|NCT05140525|DRUG|Macitentan Tablets|10 mg oral once daily
41494283|NCT05140525|DRUG|Riociguat|1 mg to 2.5mg oral three times daily
40834304|NCT00901511|PROCEDURE|Baseline WLL|Scheduled bilateral WLL
40834305|NCT00901511|DRUG|Sargramostim|Inhaled GM-CSF
40834306|NCT00901511|PROCEDURE|Rescue WLL|Unscheduled bilateral WLL
40834307|NCT05036200|DEVICE|pulsed dye laser|four pulsed dye laser sessions were administered every eight weeks in the 21 patients
40834308|NCT00581867|DRUG|Insulin Aspart|40IU insulin aspart applied intranasally
40834309|NCT00581867|DRUG|Placebo|Placebo
40834310|NCT00663286|DRUG|IDP-110|Topical application for 12 weeks
40834311|NCT00663286|DRUG|Clindamycin|Topical application for 12 weeks
40834312|NCT00663286|DRUG|Benzoyl peroxide|Topical application for 12 weeks
40834313|NCT00663286|DRUG|Vehicle|Topical application for 12 weeks
41353686|NCT00942422|GENETIC|gene expression analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
40834314|NCT04218071|DRUG|Ruxolitinib|Ruxolitinib at protocol-specified doses for given platelet count
40834315|NCT04218071|DRUG|9-ING-41|9-
41159866|NCT01885377|OTHER|Specific exercise group|A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.
41353687|NCT00942422|GENETIC|protein analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
41353688|NCT00942422|OTHER|laboratory biomarker analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
41494284|NCT05140525|DEVICE|balloon pulmonary angioplasty|on hemodynamics and RV function (including advanced assessments of RV-PA coupling
41353689|NCT04450862|OTHER|Cognitive Behavioural therapy self help intervention for anxiety|"The intervention will involve five key components:~Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease.~Cognitions - Identify and challenge negative automatic thoughts associated with anxiety.~Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH.~Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure.~Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving."
41353690|NCT03770689|DRUG|Peposertib 50 mg|Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
41353691|NCT03770689|DRUG|Peposertib 100 mg|Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
41494285|NCT03802955|DRUG|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.
40834316|NCT02724735|DRUG|NSI-189|0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
41353692|NCT03770689|DRUG|Peposertib 150 mg|Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
41353693|NCT03770689|DRUG|Peposertib 250 mg|Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
41353694|NCT03770689|DRUG|Capecitabine|Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.
41353695|NCT03770689|RADIATION|Radiotherapy (RT)|Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
41353696|NCT06219876|DEVICE|low level laser treatment|The laser device from Mectronic Medicale was used for LLLT. LASER treatments were to be performed every other day for a total of 10 sessions.
41494286|NCT02909283|PROCEDURE|Physical exams and blood analyzes|Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
41353697|NCT06219876|DEVICE|High intensity laser treatment|The laser device from HIRO TT (ASA, Italy) was used for HILT. LASER treatments were to be performed every other day for a total of 10 sessions.
41353698|NCT06219876|OTHER|wrist splint|wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months
41494287|NCT00708773|DRUG|Irinotecan|"90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination."
40834317|NCT06385717|RADIATION|chemo-radiation|different Chemo-radiotherapy regimen
40834318|NCT01115335|PROCEDURE|Neonatal male circumcision|Circumcision performed on a male infant within the first month of life, using one of 3 devices
40834319|NCT02046694|DRUG|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight \>30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
40834320|NCT05549310|DEVICE|CPAP|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
41159867|NCT01885377|OTHER|Control exercise group|A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
41353699|NCT01430598|PROCEDURE|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
41494288|NCT04359511|DRUG|Prednisone|prednisone 0.7 mg/kg/d (PO)
41494289|NCT04359511|DRUG|Hydrocortisone|hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
41494290|NCT00996138|BIOLOGICAL|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
41494291|NCT05157906|BEHAVIORAL|Education based|The interventional materials will be provided digitally for 12 weeks, with the monthly theme featured from the educational Grow Happy book and related tips and videos that will be released weekly.
41021169|NCT06261697|OTHER|A web based survey|An online based questionnaire includes three screens, the first includes the consent form, the second includes the demographic data , and the third page includes questionnaires
41353700|NCT01430598|OTHER|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
40834321|NCT05549310|DEVICE|high-flow nasal canula oxygen therapy|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
40834322|NCT01038726|OTHER|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
40834323|NCT01038726|OTHER|Cognitive Training|Based on cognitive training program Brain Fitness®
40834324|NCT01038726|OTHER|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
40834325|NCT01038726|OTHER|Educational Sessions|DVD-based educational programs on history, art, and literature
40834326|NCT05410262|OTHER|Evaluation of CT images|A helicoidal CT scanner will be used (Aquilion CXL, Toshiba, Japan), with AIDR 3D technique (Adaptive Iterative Dose Reduction 3D) in order to minimize exposure to X-rays. Two complete thorax CT scans will be performed, one of them in expiratory pause (PEEP) and the other in inspiratory pause (PPlat). Esophageal pressure shall be measured (FluxMed GrT, Argentina) and transpulmonary pressure will be calculated at the end of inspiration (Ppl-insp) and expiration (Ppl-exp).
40834327|NCT03796754|BEHAVIORAL|YoBEKA|The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
40834328|NCT03554980|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush.
41353701|NCT01682759|DRUG|Omarigliptin|
41494292|NCT05157906|BEHAVIORAL|Control|At enrollment, subject will be provided with the Mother and Child booklet, which is the Indonesian standard of care for parenting guidance.
41494293|NCT00093873|DRUG|Anti-angiogenesis|Anti-angiogenesis
40834329|NCT03554980|DRUG|Sodium Fluoride varnish|NaF will be applied with a brush
40834330|NCT04147975|DIAGNOSTIC_TEST|RaPID/BSI Test|RaPID/BSI Test
41021170|NCT01915563|PROCEDURE|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
41021171|NCT06053658|DRUG|Tivozanib|Given by PO
41021172|NCT06053658|DRUG|Nivolumab|Given by IV (vein)
41021173|NCT06574087|DIAGNOSTIC_TEST|hrHPV test and cytology|Perfomance of hrHPV test and cytology
41021174|NCT03746535|DRUG|Elagolix|Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
41021175|NCT06033989|DRUG|Hyaluronic acid|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
41021176|NCT06033989|DRUG|sandblasted, and acid-etched|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
41021177|NCT06033989|PROCEDURE|Delayed dental implant|Surgical procedure of delayed dental implant in posterior maxilla after application of surface treatment to enhance Osseointegration and healing .
41021178|NCT05848739|DRUG|ST316|IV
41353702|NCT01682759|DRUG|Placebo to Omarigliptin|
41353703|NCT01682759|DRUG|Glimepiride|Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
41353704|NCT01682759|DRUG|Glimepiride Placebo|
41353705|NCT01682759|DRUG|Metformin|Participants will continue on their stable dose (\>=1500 mg/day) of open-label metformin throughout the trial.
41353706|NCT01682759|DRUG|Insulin Glargine|Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
41353707|NCT02593994|DEVICE|Onyx Drug Eluting Stent group|
41353708|NCT00298792|BEHAVIORAL|Cognitive Behavioral Treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.
41353709|NCT00298792|BEHAVIORAL|Cognitive-behavioral treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
41353710|NCT00850629|BEHAVIORAL|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
41353711|NCT00850629|BEHAVIORAL|placebo|no intervention, only follow up
41353712|NCT04184752|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
41353713|NCT04427904|DRUG|Bupivacaine 0.5% with 1:200 000 epinephrine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
41353714|NCT04427904|DRUG|Lidocaine 2% with 1:100 000 epinephrine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
41353715|NCT04885075|DRUG|IV diazepam|inj.diazepam 0.2mg/kg/dose stat
41353716|NCT04885075|DRUG|I/N Midazolam|intranasal midazolam 0.2mg/kg/dose stat
41494294|NCT00093873|DRUG|AMG 706|Anti-angiogenesis
41494295|NCT06370130|DRUG|Esketamine 0.2mg/kg|"Patients received 0.2 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points."
41494296|NCT06370130|DRUG|Esketamine 0.3mg/kg|"Patients received 0.3 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points."
41494297|NCT02845765|DEVICE|Dynamic Vessel Analyzer (DVA)|
40834331|NCT03166579|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
41353717|NCT04787276|DIETARY_SUPPLEMENT|E.coli Nissle 1917|Probiotic contains biomass of E.coli Nissle 1917, 2,5-25·109 colony forming units - CFU/g
41353718|NCT04787276|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
41353719|NCT04787276|DRUG|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
41494298|NCT02845765|DRUG|Phosphodiesterase type 5 Inhibitor (PDE5I)|
41353720|NCT03364114|DEVICE|EndoRotor Mucosal Resection System|The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
41353721|NCT03364114|DEVICE|Continued Ablation|Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
41353722|NCT06287944|BIOLOGICAL|Actinium Ac 225-DOTA-Daratumumab|Given IV
41353723|NCT06287944|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41353724|NCT06287944|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
41353725|NCT06287944|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
40834332|NCT05665049|BEHAVIORAL|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Using results from a qualitative study, we identified the following culturally grounded social transfer options that is responsive to the identified needs of new mothers. Based on the monthly Lao PDR minimum wage and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately $75 would fairly subsidize women's breastfeeding efforts. Therefore all social transfer options equate to approximately 75 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
40834333|NCT02177019|OTHER|Personalized health plan|
41021179|NCT05848739|DRUG|FOLFIRI regimen & bevacizumab|"FOLFIRI: Days 1 and 15 of each 28-day cycle:~* irinotecan 180 mg/m2 IV over 90 minutes concurrently with~* leucovorin 400 mg/m2 IV over 2 hours, and then~* 5-FU bolus 400mg/m2 (up to 15 min infusion)~* 5-FU 2400 mg/m2 IV over 46 hours~* bevacizumab should be administered as 5mg/kg."
41021180|NCT05848739|DRUG|Fruquintinib|5 mg once a day for the first 21 days of a 28-day cycle
40834334|NCT02525913|DEVICE|RFA Applicator|
40834335|NCT00475215|DRUG|Sugammadex|Sugammadex solution for injection.
40834336|NCT00475215|DRUG|Rocuronium|Rocuronium bromide solution for injection.
40834337|NCT02061046|DEVICE|CPAP therapy|8 weeks of CPAP therapy
40834338|NCT02744989|DEVICE|Neuroconn or Neuroelectric tDCS stimulator|Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental tDCS group will receive the ACTIVE stimulation with the following parameters: oscillatory Direct Current with high frequency random noise stimulation (hf-tRNS - 100 to 500 Hz), Intensity = 2 mA, offset = + 1 mA, seance duration = 20 minutes ramp up/ramp down 30 seconds. Total number of sessions = 10 (sessions twice daily for 5 days separated by at least 2 hours for 5 consecutive weekdays).
40834339|NCT02744989|DEVICE|Sham tDCS|The control group will receive the SHAM stimulation (placebo) following the same regimen (i.e., twice daily sessions separated by at least 2 hours for 5 consecutive weekdays). Sham stimulation consists of a 20 minutes session including 40 seconds of active stimulation (same parameters as in the ACTIVE arm) at the beginning of the sessions, whatever the stimulator
40834340|NCT04150692|BIOLOGICAL|Dara-SC|-Subcutaneous daratumumab and hyaluronidase-fihj
40834341|NCT04150692|PROCEDURE|Blood for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
41021181|NCT05848739|DRUG|Lonsurf & bevacizumab|Lonsurf 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 day bevacizumab 5 mg/kg on days 1 and 15. ST316
41021182|NCT00192179|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10\^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10\^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
41021183|NCT00192179|BIOLOGICAL|Placebo|The placebo consisted of physiologic normal saline.
41021184|NCT04089644|DEVICE|closed-loop system|"Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
41021185|NCT04089644|DEVICE|Manual adjustment|"Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
41021186|NCT02717793|OTHER|Strength testing|"isometric muscle strength~1RM measurement of muscle strength"
41021187|NCT00555438|DRUG|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
41021188|NCT01577394|OTHER|oculomotor measurements|"The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.~Mean reflexive saccades latency Percentage of express saccades"
40834342|NCT04150692|PROCEDURE|Bone marrow for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
40834343|NCT00424190|DRUG|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
40834344|NCT00424190|DRUG|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
40834345|NCT04808193|OTHER|Survey|Participants will fill in the survey
40834346|NCT02162212|OTHER|Optimized Shoulder Movement Program|"A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity."
41353726|NCT06287944|PROCEDURE|Computed Tomography|Undergo CT
41353727|NCT06287944|BIOLOGICAL|Daratumumab|Given IV
41353728|NCT06287944|PROCEDURE|Echocardiography|Undergo echocardiography
40834347|NCT02162212|OTHER|ADA Guideline Instructed|The ADA guideline instructions are to include: blood sugar control (goal is A1c \< 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is \<130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
40834348|NCT02964832|DEVICE|Grasp method|
40834349|NCT02964832|DEVICE|Armband-in-hand method|
40834350|NCT02964832|DEVICE|Armband-on-arm method|
40834351|NCT01536548|PROCEDURE|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
40834352|NCT01536548|PROCEDURE|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
40834353|NCT06031545|OTHER|Long peripheral venous catheters for use|Long peripheral venous catheters for use during the perioperative period in obese patients
40834354|NCT06031545|OTHER|Midline catheter|Midline catheters for use during the perioperative period in obese patients
40834355|NCT02499692|DEVICE|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
40834356|NCT01883011|DRUG|Piracetam|
41353729|NCT06287944|DRUG|Fludarabine|Given IV
41353730|NCT06287944|PROCEDURE|Hematopoietic Cell Transplantation|Undergo SCT
41353731|NCT06287944|BIOLOGICAL|Indium In 111-DOTA-Daratumumab|Given IV
41353732|NCT06287944|DRUG|Melphalan|Given IV
41353733|NCT06287944|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41353734|NCT06287944|PROCEDURE|Radionuclide Imaging|Undergo nuclear scan
40834357|NCT01883011|OTHER|Placebo|
41353735|NCT06287944|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT scan
41353736|NCT06287944|DRUG|Sirolimus|Given sirolimus
41353737|NCT06287944|DRUG|Tacrolimus|Given tacrolimus
41353738|NCT06287944|RADIATION|Total Marrow and Lymphoid Irradiation|Undergo TMLI
41353739|NCT03152175|DRUG|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride, oral capsule
41353740|NCT03152175|DRUG|Placebo|1mg / kg of matched placebo, oral capsule
41021189|NCT03769441|DRUG|Ferric carboxymaltose|Four intravenous dosages of ferric(III) carboxymaltose
41353741|NCT05143294|BEHAVIORAL|Conectar Jugando Classroom Program|Modern Board Games Intervention in Elementary Classrooms
41353742|NCT04428762|DEVICE|I-Port Advance use|participants will apply I-port advance for 4 weeks and will inject all insulin through the port. follow up 3 months with/ without i-port.
41353743|NCT00066716|DRUG|carboplatin|Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
41494299|NCT02714517|OTHER|hydrotherapy|30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
41021190|NCT03769441|DRUG|Sodium chloride|Four intravenous dosages of sodiumchloride
41021191|NCT03698682|DRUG|Levofloxacin 500mg|One tablet per day for 7 days.
41353744|NCT00066716|DRUG|celecoxib|400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
41353745|NCT00066716|DRUG|paclitaxel|200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
40834358|NCT06486272|OTHER|Financial Navigator|"Intervention: Access to a Financial Navigator We anticipate the Financial Navigator will meet at least 2 times and up to 2 additional visits, at a time convenient for the family. Examples of financial services that will likely be offered by the Financial Navigator are tax filing, applying for benefits and financial counseling. The program will be flexible and family centered. Families can choose if they would like to meet the Financial Navigator in person at the NNFU appointment, during another medical appointment, or at another time during a virtual visit. The Financial Navigator will be integrated into the existing SickKids Resource Navigation Service. At the 18-month NNFU visit the study will be completed."
41021192|NCT04629664|DRUG|FX-322|Active Comparator
41021193|NCT04629664|OTHER|Placebo|Placebo
41021194|NCT03511482|DEVICE|myAsthma Application|myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.
41353746|NCT00066716|PROCEDURE|adjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.~4. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year."
41494300|NCT02714517|OTHER|on land therapy|30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
41159868|NCT06479252|OTHER|Sit-to-Stand Test (STS)|The 30-s and 1-min STS tests are reliable, valid, and responsive tests for measuring functional exercise capacity in patients with lung disease. For the STS tests that are centre-based or supervised remotely, investigators will collect the total number of repetitions on the 30-s and 1-min STS tests, as well as the number and duration of rests within and between tests.
41159869|NCT00694564|DRUG|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
41353747|NCT00066716|PROCEDURE|conventional surgery|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
41353748|NCT00066716|PROCEDURE|neoadjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
40834359|NCT01048866|DRUG|placebo|Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
40834360|NCT01048866|DRUG|flurbiprofen|Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
40834361|NCT01048866|DRUG|acetaminophen 650mg|Rescue medication to be taken as needed. Rescue medication was not blinded.
40834362|NCT01531972|DRUG|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
41353749|NCT04102657|OTHER|Intermittent Fasting|Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.
41353750|NCT04102657|OTHER|Free-Living Diet|Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.
41353751|NCT04102657|OTHER|Left Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.
41353752|NCT04102657|OTHER|Right Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
41353753|NCT00757289|BIOLOGICAL|PRP Injection|PRP Injection
41353754|NCT00757289|BIOLOGICAL|Corticosteroid Injection|Corticosteroid Injection
40834363|NCT01531972|DRUG|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
41353755|NCT04610827|DRUG|Ferrous sulfate|Guideline-recommended 3 mg/kg/day dosing
41353756|NCT04604015|DIAGNOSTIC_TEST|NeuralBot Investigational System|The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.
41494301|NCT05280730|OTHER|No intervention|There is no intervention
41494302|NCT05727072|DRUG|LY3848575|Administered IV.
40834364|NCT00340379|DRUG|Ziprasidone|Target dosage 120-160mg/day based on tolerance
41353757|NCT04604015|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|A test that uses ultrasound to create a hemodynamic assessment for major cardiovascular events.
41353758|NCT00917878|DIETARY_SUPPLEMENT|Milk|500 mL low-fat milk added to high-fat meal
41353759|NCT00917878|DIETARY_SUPPLEMENT|Protein|Milk protein in 500 mL water added to high-fat meal
41353760|NCT00917878|DIETARY_SUPPLEMENT|Calcium|Milk calcium in 500 mL water added to high-fat meal
41353761|NCT00917878|DIETARY_SUPPLEMENT|Control|Lactose in 500 mL water added to high-fat meal
41353762|NCT06409975|BEHAVIORAL|Mindful Self-Compassion (MSC)|MSC is an 8-week virtual intervention with weekly 2.5-hour sessions and a 4-hour retreat (between sessions 5 and 6) which will take place online via HIPAA-compliant Zoom. Each weekly session includes an opening meditation, reflection on weekly practice, short teaching, a weekly core meditation or informal practice discussion, short break, brief centering practice, weekly core reflective activity and discussion, and self compassion skill of the week practice. The 4-hour retreat is focused on engaging with the formal practices that have been taught in weeks 1-5.
41353763|NCT02160639|OTHER|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
41353764|NCT05658328|BEHAVIORAL|SHARP - Physical and social activity|Technology-enabled neighborhood walking 3x/week for 16 weeks with conversational reminiscence
41159870|NCT01730118|BIOLOGICAL|Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine|autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
41353765|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
41353766|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
41353767|NCT01681537|DRUG|Lenalidomide|
41353768|NCT01681537|DRUG|Mitoxantrone|
41353769|NCT01681537|DRUG|Etoposide|
41353770|NCT01681537|DRUG|Cytarabine|
41353771|NCT01696708|OTHER|31-Phosphorus RMN Spectroscopy|
41353772|NCT03035058|DRUG|Vedolizumab|Vedolizumab intravenous infusion
41353773|NCT03035058|DRUG|Placebo|Placebo
41353774|NCT04101227|DRUG|AD04 (ondansetron)|AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
41353775|NCT04101227|DRUG|Matching placebo|Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
41353776|NCT04101227|DEVICE|Companion Diagnostic for Genetic Testing|Companion Diagnostic for Genetic Testing
41353777|NCT04101227|BEHAVIORAL|Brief Psychological Counseling|Brief Psychological Counseling
40834365|NCT00340379|DRUG|Sertraline|Target dosage 150-200mg/day based on tolerance.
41353778|NCT00171327|DRUG|valsartan, fluvastatin|
41353779|NCT00287976|DRUG|irinotecan hydrochloride|
41353780|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
41353781|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
40834366|NCT00340379|DRUG|Haloperidol|Target dosage 6-8mg/day based on tolerance.
40834367|NCT05356338|BEHAVIORAL|Pilot Intervention to reduce SSB consumption in children and families enrolled in WIC|"A 6-month intervention based on the use of 5 components: 2 educational videos, provision of a water-promotion toolkit, a mobile phone application (app), a series of 14 computerized interactive voice response (IVR) phone calls to parents and 2 counseling sessions by a WIC nutritionist to compare families' SSB's consumption behaviors"
40834368|NCT02554708|DEVICE|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
40834369|NCT04132492|OTHER|no intervention|there is no intervention
41353782|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
41353783|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
41353784|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
41353785|NCT00529113|DRUG|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
41353786|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
41353787|NCT00529113|DRUG|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
41353788|NCT00529113|DRUG|Placebo|Placebo capsules x 28 days
41353789|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
41353790|NCT00532987|BEHAVIORAL|Questionnaire|Questionnaire form to be completed by patient
41353791|NCT03289676|COMBINATION_PRODUCT|Storytelling Narrative Intervention|"In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection."
41494303|NCT05727072|DRUG|LY3848575|Administered SC.
41494304|NCT05727072|DRUG|Placebo|Administered IV.
41494305|NCT05727072|DRUG|Placebo|Administered SC.
41353792|NCT03952676|DEVICE|Moving cupping|"1. We use a black opaque eye mask to shield the patient's eyes and choose different sizes of cup according to the location of the treatment (There are three sizes of cups)~2. (1) First apply Vaseline to the skin lesions area; (2) Then hold the 95% ethanol cotton ball with tweezers, and hold the cup with the facing down, after the cotton ball is ignited, immediately sway down in the cup and then exit, and quickly buckle the cup to the skin lesions area. (3) After using the cup to absorb the skin lesions area, hold the cup body in one hand and push and pull the cup along the certain route with a little strength, so that the skin purple color of the treatment area is suitable. (4) Apply even force when pushing the cup to prevent the cup from falling off due to air leakage. (5) Acting on the skin lesions area 30 times, change cup 5 times per push and pull, the interval is not more than 10 seconds."
41494306|NCT03052296|DEVICE|Passeo-18 Lux DCB|The endovascular procedure is conducted as per the local standard practice and device instruction for use
41353793|NCT03952676|DEVICE|Moving cupping placebo|Using of special perforated cups, the manipulation method is the same as the intervention group.
40834370|NCT05506839|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
40834371|NCT03867019|DIAGNOSTIC_TEST|Heart rate variability parameters monitoring|"No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~1. Dizziness Handicap Inventory (DHI) - hebrew version.~2. Stait-Trait Anxiety Inventory (STAI)"
40834372|NCT00005056|DRUG|bryostatin 1|
41159871|NCT00747721|DRUG|Dexmedetomidine|2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
41159872|NCT01086878|DRUG|cotrimoxazole|"Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~* less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~* greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim"
41159873|NCT05926232|DRUG|Repotrectinib|Repotrectinib
41159874|NCT05784649|OTHER|health education|"The health education program will be conducted on the WeChat platform. The contents of health education include 1) knowledge about how to prevent anemia during pregnancy; 2) self-care education videos such as breastfeeding; 3) online courses on how to manage weight during pregnancy, and how to keep good emotions, etc.; 4) Nutrition and lifestyle guidance; 5) knowledge about recognition and prevention of risk factors or diseases: abortion, toxic substances, premature birth. The contents of health education will be totally shared 5 times from 12 weeks to 36 weeks in the pregnancy and once a month on the platform. Every participant should reply read after learning the contents. if they have any questions, they can reply for help for further connection with health professionals."
41266546|NCT04894799|OTHER|Vestibular stimulation|In Vestibular Stimulation (VS) group, all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
41494307|NCT03433898|DRUG|BI 754091|Solution for infusion
41494308|NCT03433898|DRUG|BI 754111|Solution for infusion
41494309|NCT01129687|PROCEDURE|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
41494310|NCT01129687|PROCEDURE|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
41494311|NCT00076076|DRUG|Roflumilast|
41353794|NCT03267004|DEVICE|Dietary Assessment of Meal A using images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich \[whole wheat bread 52g(female \& male), Turkey 70g(female) \& 133g(male), Provolone cheese 23g(female \& male), tomato 50g(female \& male), lettuce 45g(female \& male)\]; Chicken and wild rice \[chicken 98g(female \& male), wild rice 71g(female) \& 107g(male)\]; chocolate chips cookies \[44g(female) \& 60.5g(male)\]; potato chips \[39g(female) \& 52g(male)\]."
41353795|NCT03267004|DEVICE|Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham \& Cheddar cheese wrap \[Tortilla 45g(female \& male), Ham deli 76g(female) \& 103g(male), cheddar cheese 21g(female) \& 32g(male), Spring Mix 36g(female \& male), Fat Free ranch dressing 29g(female \& male)\]; Pasta with broccoli and Alfredo sauce \[Pasta 91g(female) \& 121g(male), Broccoli 66g(female \& male), Alfredo sauce 38g(female) \& 50g(male)\]; Chocolate Ice-cream \[107g(female), 138g(male)\]; Red seedless grapes \[365g (female), 471g(male)\]."
41353796|NCT05103540|BEHAVIORAL|Comprehensive SEM-Based Program|The SEM theorizes that there are multiple inter-related levels of influences on human behavior, and a successful preventive program should address factors at each stratum. My intervention addresses three levels; individual, interpersonal, and social. Firstly, the research will collaborate with relevant stakeholders to design and obtain a commitment from the schools to a suicidal behavior prevention policy and protocol document. Secondly, the intervention will train staff and students on best practices to improve students' connectedness thereby, creating a positive school environment. Thirdly, the study will identify and train gatekeepers on the proper response to suicidal thoughts and other suicidal behaviors; and serve as the link between the students and a school-linked mental health specialist. We will train the gatekeepers to use school-based screening tools. Lastly, this research will educate all students on suicidal behaviors.
41353797|NCT02940353|DEVICE|TREFOIL concept|
41353798|NCT01326481|DRUG|TRC105|IV
41494312|NCT02149290|DEVICE|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; heart rate measurements, activity data collection; ability to perform a health survey; ability to guide patients through a walk test
40834373|NCT02958306|BIOLOGICAL|platelet rich plasma|PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values
41159875|NCT05784649|BEHAVIORAL|individual counsel|The participants will receive the same health education as the control group. The pregnant women will have one routine checkup a month from 12 weeks to 36 weeks in the hospital. And they will receive counseling with a midwife and a doctor after every routine checkup. The counseling will have a total of 5 times and once a month, 45 minutes per time. The professionals will evaluate health-promoting behaviors such as nutrition and physical activity based on the procedure of the health promotion model. The model includes four continued parts: prior behaviors; personal influences; interpersonal Influences; commitment to a plan of action. Finally, the professionals will give person-centered advice to help the participants practice the content of health education, keep health-promoting behaviors, and achieve a healthy lifestyle.
40834374|NCT01821456|DRUG|Antiinfectives|To analyze to efficacy of (novel) drug therapies
41159876|NCT03421171|OTHER|no intervention|Qualitative research through semi-structured interviews
41159877|NCT01191450|DRUG|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
41159878|NCT01191450|DRUG|Higroton® Laboratório Novartis|Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
41159879|NCT06223100|DRUG|Eravacycline|There is no other intervention.
41159880|NCT03045302|DRUG|BIM23B065|Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
41159881|NCT03445507|OTHER|Chat bot|Patients in intervention arm will use an evidence-based chat bot as an aid for smoking cessation
41159882|NCT03445507|OTHER|Usual care|Usual care given by their usual general practitioners and nurses of primary care health centres, as defined in Public Health System Portfolio.
41159883|NCT00743223|OTHER|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
41159884|NCT03974789|DIAGNOSTIC_TEST|Blood test|Plasma cortisol level test
41159885|NCT03974789|DIAGNOSTIC_TEST|24-hour Urine test|Urinary free cortisol test
41353799|NCT01326481|DRUG|Capecitabine|oral
40834375|NCT05480449|BIOLOGICAL|Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)|The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
41353800|NCT03000413|DRUG|Ketamine|Active treatment
41353801|NCT03000413|DRUG|Fentanyl|
41353802|NCT04537156|BIOLOGICAL|Nonavalent HPV vaccine|Nonavalent HPV vaccine (270μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
41494313|NCT02449096|DEVICE|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
41494314|NCT02449096|OTHER|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
40834376|NCT04832945|DRUG|Ivermectin 6 Mg Oral Tablet|Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
40834377|NCT02816203|DEVICE|Hemostatic Intra-Uterine suction cup|The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
41494315|NCT01011179|BEHAVIORAL|Teens Taking Charge|The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
41494316|NCT01011179|BEHAVIORAL|Self-Management|"Adolescents' own best efforts at managing their JIA"
41494317|NCT06347601|OTHER|Without Intervention|Without Intervention
41494318|NCT03563651|PROCEDURE|Biopsy|Undergo biopsy
41494319|NCT03563651|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and stool
41494320|NCT03563651|OTHER|Laboratory Biomarker Analysis|Correlative studies
41494321|NCT03563651|OTHER|Questionnaire Administration|Ancillary studies
41494322|NCT00005727|BEHAVIORAL|Intervention|Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
41494323|NCT06075108|OTHER|P-KIDs CARE|The P-KIDs CARE intervention will include two components: 1) the World Health Organization (WHO) Basic Emergency Care Course for training on patient assessment and stabilization, and 2) a decision support tool which integrates adaptation of two evidence-based tools: a) the Pediatric Resuscitation and Trauma Outcome model for mortality risk assessment, and 3) the Field Triage Decision Scheme to assist with timely referral decisions. WHO Basic Emergency Care Course includes modules delivered via PowerPoint with hands-on training components. The decision support tool will be online with checkboxes that healthcare providers can cross as they fill it out in real time. The team will adapt the tool for use in Northern Tanzania, with particular attention to local contextual and cultural factors.
41353803|NCT04537156|BIOLOGICAL|Bivalent HPV vaccine|Bivalent HPV vaccine (60μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
41353804|NCT03698214|OTHER|reversed shock index < 1|Among patients with isolated TBI, those with an RSI \< 1 had higher mortality
41353805|NCT03698214|OTHER|reversed shock index ≥ 1|Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
41353806|NCT05402579|GENETIC|Genomic analysis|Genetic samples will be collected using a DNA saliva collection kit (Oragene: OG-510) and will be sent for genome-wide genotyping to The Centre for Applied Genomics in The Hospital for Sick Children (SickKids)
41494324|NCT04638335|BIOLOGICAL|Blood test|blood test for Anti-HAV antibodies
41494325|NCT01147263|OTHER|Evaluation of autonomic parameters|Physical examination, ECG, Loop recorder, Heart rate variability evaluation
41494326|NCT01943110|DEVICE|ID adapter (autodisable)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
41494327|NCT01943110|DEVICE|ID adapter (side load)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
41494328|NCT01955837|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
41494329|NCT01955837|DRUG|Placebo|Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
41494330|NCT00175188|DEVICE|Avanta (PIP joint implant with a titanium porous coating)|Implant is inserted at the time of surgery, after written consent
41159886|NCT03974789|DIAGNOSTIC_TEST|Saliva swab|salivette® for salivary cortisol quantification
40834378|NCT05999110|OTHER|Physical Exercise|The intervention includes a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. All participants also receive a nutritional advice session and a behavioral changes session.
41353807|NCT04834258|OTHER|Walking and respiratory training|"Walking and respiratory muscle training group ( W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged"
41353808|NCT04834258|OTHER|Respiratory muscle training|In the Respiratory muscle training group, Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged.
41353809|NCT06336694|PROCEDURE|surgery or diagnostic staging laparoscopy|diagnosis of PDAC with peritoneal examination based on the surgical (for tumors treated with surgery) or diagnostic staging laparoscopy findings (for tumors treated with radiotherapy/chemotherapy)
41353810|NCT01943266|DIETARY_SUPPLEMENT|protein intake|on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
41353811|NCT01938391|DEVICE|Stealth 360°® OAS|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
41353812|NCT01808911|DRUG|Steroid + cyclophosphamide|
41353813|NCT01808911|DRUG|Steroid + rituximab|
41353814|NCT05326932|PROCEDURE|Mechanical thrombectomy|Subjects in intervention group will receive MT as soon as possible. Investigators and clinicians should strive to reduce delays of pre-surgery procedure and follow the local standard guideline of MT during the operation and perioperative period. All CFDA approved devices are allowed in this trial. Angioplasty and stent placement can be performed at the discretion of the physicians. Base on site experience, the randomization-operation start period should be within 60 minutes.
41509153|NCT05736861|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
40834379|NCT01903889|OTHER|clinic based intervention|counseling C\&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
41159887|NCT03974789|DIAGNOSTIC_TEST|Dexamethasone test|Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
41159888|NCT03204045|DRUG|fentanyl|2 mL mixture of fentanyl with isotonic saline
41021195|NCT03511482|DEVICE|Lloyds Pharmacy Online Doctor|"Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare."
41494331|NCT05669963|DRUG|lactoferrin|"study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month."
41494332|NCT00198237|DRUG|docetaxel & capecitabine|
41494333|NCT05854394|BEHAVIORAL|Multimodal prehabilitation management Multimodal prehabilitation management|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including drug treatment recommendations for chronic disease, quit smoking and abstinence).
41494334|NCT06206200|OTHER|Cognitive dual task training (intervention group)|Simultaneously performing cognitive tasks and motor rehabilitative exercises.
41494335|NCT06206200|OTHER|Standard of care physiotherapy (control group)|The current best physical therapy treatment for patients with anterior cruciate ligament reconstruction based on existing scientific evidence.
41494336|NCT00394524|DEVICE|Glucommander|Glucommander is a Computer-guided Intravenous (IV) insulin infusion protocol used for glycemic control in inpatients. This algorithm directs the administration of IV insulin in response to Blood Glucose (BG) measurement at the patient's bedside. In this study, the Glucommander program was loaded into a PalmOne (Zire 31, Tungsten E2 by Palm Inc.) handheld personal digital assistant (PDA) device. During the infusion, the nurse entered BG levels into the system and the computer recommended the insulin infusion rate and a variable time to check the next glucose testing. An alarm prompted the scheduled glucose check. The insulin infusion followed the formula: Insulin/Hour = Multiplier × (BG- 60).
41494337|NCT00394524|OTHER|Standard insulin infusion algorithm|Standard insulin infusion Algorithm is a standard paper form insulin infusion algorithm. The algorithm is divided into four columns based on empirically determined insulin sensitivity. The first column was for the most insulin-sensitive patients, and the fourth column was for the most insulin resistant patients. The majority of patients are started in the algorithm 1 column. Insulin resistant patients, such as those receiving glucocorticoids or receiving \>80 units of insulin per day as outpatients, started in the algorithm 2 column. The insulin infusion rate was determined by the patient's BG level and was measured hourly until the patient was stable and within the target range. If BG targets were not achieved and the BG had not decreased by at least 60 mg/dL in the preceding hour, the patient was moved to the next column.
41494338|NCT00376038|DRUG|GSK189075 oral tablets|
41494339|NCT00376038|DRUG|metformin tablets|
41494340|NCT01049711|DRUG|erythropoietin|
41494341|NCT03822832|DRUG|BI 655130|Solution for infusion
41353815|NCT03153124|OTHER|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
41021196|NCT00499889|DRUG|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
41353816|NCT03686462|DEVICE|Virtual reality-based interactive treadmill training|During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
41353817|NCT03686462|DEVICE|Treadmill training without VR-based interaction|Treadmill training without VR-based interaction
41021197|NCT00499889|DRUG|Fludarabine (Fludara)|40 mg/m\^2 by vein daily for 4 Days
41494342|NCT03822832|DRUG|Placebo|Solution for infusion
41021198|NCT00499889|DRUG|Busulfan|130 mg/m\^2 by vein daily for 2 Days
41021199|NCT00499889|DRUG|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
41021200|NCT00499889|DRUG|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
41021201|NCT00499889|DRUG|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
41159889|NCT03204045|DRUG|Oxycodone|2 mL mixture of oxycodone with isotonic saline
41353818|NCT04541836|DIAGNOSTIC_TEST|18F-PMPBB3|single intravenous injection 5mCi 18F-PMPBB3 per scan
41494343|NCT04146116|DRUG|intranasal povidone-iodine|povidone-iodine USP, 10% w/w antiseptic
41494344|NCT00000591|PROCEDURE|lymphocyte depletion|
41494345|NCT03415061|DRUG|Regular Insulin, Human 100 UNT/ML|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
41494346|NCT03415061|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
41494347|NCT04024839|OTHER|Active Isolated Stretch|In supine position, participant was asked to lock the knee and slowly lift leg using the quadriceps muscles. gentle assistance was given by the rope at the end of the movement, as the quadriceps muscles continue to move the leg. strech was applied for 2 sec and then release to starting position. two sets of 10 repetitions were performed.
41353819|NCT02757768|DRUG|Mirabegron|Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
41353820|NCT02757768|DRUG|Placebo|Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
41353821|NCT02757768|DRUG|Tamsulosin Hydrochloride|Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
41353822|NCT05301140|DEVICE|Vivistim System|VNS Paired with rehabilitation movements
41353823|NCT02407236|DRUG|Placebo IV|Placebo will be administered as intravenous infusion.
41494348|NCT04024839|OTHER|Post Isometric Relaxation|In supine line, participant was asked to do SLR until resistance was met in hamstring muscles and then was asked to do isometric contraction (10-20% of maximum) for 5 - 10 sec and inhale. After this, patient was asked to exhale while doing so gentle stretch was applied till the new barrier. Starting from this new barrier, the procedure was repeated 2 - 3 times.
41494349|NCT05933863|DRUG|PD-(L)1 antibody immunotherapy|The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.
41494350|NCT00000114|DRUG|Vitamin E|
41494351|NCT00000114|DRUG|Vitamin A|
41494352|NCT03967171|OTHER|before uterine incision oxytocin|blood loss during elective cesarean section
41494353|NCT03967171|OTHER|after clamping the umbilical cord oxytocin|blood loss during elective cesarean section
41494354|NCT04604886|DIAGNOSTIC_TEST|Passive Leg Raising|Passive leg raising is induced by rasing the legs of patients to 45° from horizontal position.
41494355|NCT04604886|DIAGNOSTIC_TEST|Dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. hemodynamic data were recorded from PAC and LiDCO after 5-10 minutes of continuous infusion.
41494356|NCT05783830|DRUG|ACD856|IV injection 100 mcg
41494357|NCT01238380|OTHER|patient care pathway|"Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.~Stage 2: Pancreatic auto-antibodies measurement (GAD65 \& IA2); if negative progress to genetic testing.~Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.~Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change."
41494358|NCT06264401|OTHER|Alendronate|control group received (Alendronate) 70 mg 1 tab every week.
41494359|NCT06264401|OTHER|treatment exercises|the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program, each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 minutes.
41494360|NCT02445274|PROCEDURE|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
41494361|NCT03680066|OTHER|Oral food challenge to foods with traces|"Subjects will undergo an open food challenge to 3 processed foods labeled with may contain traces. The following foods (similar for all patients) will be given in one dose in the size of a regular serving:~* cookies, max 30 g;~* chocolate, max 30 g;~* breakfast cereals, max 50 g.~Each meal will be administered with a 1 hour observation period in between and at the end."
41494362|NCT05669183|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation|Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is mainly used for circulatory support in patients with severe cardiopulmonary failure. VA ECMO drains the blood from the venous system followed pumping the blood back into the arterial vascular compartment after oxygenation. It can be divided into two cannulation strategies for VA ECMO support, namely peripheral VA ECMO and central VA ECMO based on the arterial cannulation site. Peripheral VA ECMO is established via the femoral artery (FA), whereas axillary artery (AX) is an arterial cannulation site in central VA-ECMO.
41353824|NCT02407236|DRUG|Placebo SC|Placebo will be administered Subcutaneously.
41353825|NCT02407236|DRUG|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
41353826|NCT02407236|DRUG|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
41353827|NCT02961348|OTHER|Early start of NOAC|Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
41353828|NCT02961348|OTHER|Late start of NOAC|Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
41353829|NCT04035473|DRUG|HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules|"HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules"
41353830|NCT01140464|OTHER|Collaborative care|Provision of depression care management in the primary care setting to improve delivery of evidence based treatments
41353831|NCT01140464|OTHER|Enhanced Usual Care|Provision of screening results to provider, teen and parent with recommendation to seek further care
40834380|NCT01903889|OTHER|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
41494363|NCT02111928|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
41494364|NCT01527812|PROCEDURE|Femoral nerve block|We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
41494365|NCT00087620|DRUG|XELODA [capecitabine]|
41494366|NCT03151291|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate (HMB)|daily intake of 3 g HMB
41494367|NCT03151291|DIETARY_SUPPLEMENT|L-carnitine (LC)|daily intake of 4 g LC
41494368|NCT03151291|DIETARY_SUPPLEMENT|Eicosapentaenoic acid (EPA)|daily intake of 2.2 g EPA
41494369|NCT03151291|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
41494370|NCT04062656|DRUG|Nivolumab|Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes
41353832|NCT00184366|DRUG|efalizumab|efalizumab
41353833|NCT03479658|BEHAVIORAL|High intensity interval training|Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.
41353834|NCT03479658|BEHAVIORAL|Nutritional education|School-based nutritional education on healthy dietary habits
41353835|NCT06379672|OTHER|Resonance breathing|Resonant breathing was used on the subjects, using nasal inhalation and oral exhalation, for a total of 12 weeks.
41353836|NCT03996655|DRUG|Sugammadex Injection [Bridion]|Reversal of neuromuscular blockers
41353837|NCT03996655|DRUG|Neostigmine|Reversal of neuromuscular blockers
41494371|NCT04062656|DRUG|relatlimab|relatlimab (80mg flat dose) administered IV over 60 min
41494372|NCT04062656|DRUG|Oxaliplatin|Oxaliplatin 85mg/m² IV over 1 h
41494373|NCT04062656|DRUG|Docetaxel|Docetaxel 50mg/m² IV over 1 h
41494374|NCT04062656|DRUG|5-Fluorouracil (5-FU)|5-fluorouracil 2600mg/m² IV over 24h
41494375|NCT04062656|DRUG|Folic acid (FA)|Folic acid 200mg/m² IV over 30 min
41494376|NCT04431726|DRUG|Emicizumab|"Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.~At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.~During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first."
41494377|NCT02140411|DRUG|Ranibizumab Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
41494378|NCT04569708|OTHER|Auditory stimulation|Quiet auditory stimulation timed with sleep physiology
41494379|NCT04341857|DRUG|PD-1 Monoclonal Antibody(Sintilimab)|Sintilimab combined with FLOT regimen,Docetaxel#50mg/m2d1,iv infusion for 1 hour#,Oxaliplatin#80mg/m2d1#iv infusion for 2 hours#,Calcium,leucovate#200mg/m2d1#iv infusion# ,Fluorouracil#2600mg/m2,intravenous drip for 24h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
41494380|NCT05490485|DRUG|Camrelizumab|Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma
40834381|NCT00003787|BEHAVIORAL|educational/counseling intervention|
41159890|NCT03204045|DRUG|control|isotonic saline 2 mL
41159891|NCT05028283|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with atrophic acne scars on the cheeks
41159892|NCT02324088|DRUG|Docetaxel|
41159893|NCT02324088|DRUG|Cyclophosphamide|
41159894|NCT02324088|DRUG|Epirubicin|
40834382|NCT00003787|BEHAVIORAL|therapeutic dietary intervention|
40834383|NCT03653468|BEHAVIORAL|Concurrent training (CT)|The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
40834384|NCT01164332|OTHER|NRL972|Two-hour intravenous infusion of 5 and 15 mg per hour
40834385|NCT00001812|DRUG|Nystatin|
41021202|NCT00499889|PROCEDURE|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after \>4 weeks of imatinib.
41021203|NCT00499889|PROCEDURE|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
41021204|NCT01970332|PROCEDURE|Revascularization Surgery|
41353838|NCT01146691|OTHER|Alternative Intensivist staffing models|During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
41353839|NCT00790491|BEHAVIORAL|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
41353840|NCT06482957|OTHER|Surveys|Complete surveys
41353841|NCT06482957|OTHER|Blood Collection|Undergo blood collection
41353842|NCT06482957|OTHER|Saliva Collection|Undergo salvia collection
41353843|NCT06482957|OTHER|Urine Collection|Undergo urine collection
41353844|NCT06482957|OTHER|Stool Collection|Undergo stool collection
41353845|NCT06482957|OTHER|Tissue collection|Undergo tissue collection
41494381|NCT02226757|DRUG|Paclitaxel-trastzumab|"Trastuzumab~* Dose:~  * First dose: 4 mg/kg IV~ * Subsequent doses: 2 mg/kg every week IV.~* The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.~Paclitaxel~- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab"
41494382|NCT05182320|DEVICE|OrthoPath|unilateral TKA and THA patients using the BPMpathway rehabilitation sensor system
41494383|NCT05182320|DEVICE|Control|unilateral TKA and THA patients not using the BPMpathway rehabilitation sensor system
41021205|NCT01970332|OTHER|Supervised exercise therapy|
41021206|NCT02573324|DRUG|Temozolomide|Oral Capsule
41353846|NCT06482957|OTHER|Physical Activity Monitoring|FitBit will be worn to track physical activity
41353847|NCT02993133|DRUG|Cellcept® in autoimmune bullous dermatoses|The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
41353848|NCT05421416|DRUG|Loratadine|Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.
41353849|NCT05421416|DRUG|Placebo|Placebo sugar pill
41353850|NCT04239807|DEVICE|Group 1 GALILEO WBV|3 month home based WBV training
41353851|NCT04239807|OTHER|Group 2 Control|Training on the floor without WBV
41353852|NCT03091569|OTHER|Vitamin K Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
41494384|NCT05326321|OTHER|Study Group|The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure.
41494385|NCT03283761|DRUG|Nab-paclitaxel 150 mg/m^2|Stage I (N=12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
41494386|NCT03283761|DRUG|Oxaliplatin 85 mg/m^2|Stage I (N= 12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
41494387|NCT03283761|DRUG|5-FU 1200 mg/m^2 x 2 D|Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16
41494388|NCT03283761|DRUG|Leucovorin 400 mg/m^2|Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
41494389|NCT01696851|OTHER|tests and questionnaires|lung test, depression and self-efficacy questionnaires and Functional testing.
41159895|NCT02744898|DRUG|Carboplatin AUC|
41021207|NCT02573324|DRUG|Depatuxizumab mafodotin|Intravenous (IV) Infusion
41159896|NCT02744898|DRUG|Abraxane|100mg/m2
41021208|NCT02573324|RADIATION|Radiation|
41021209|NCT02573324|DRUG|Placebo for ABT-414|IV Infusion (IV)
41021210|NCT06004817|OTHER|evaluation of clinical severity|evaluation of clinical severity
41021211|NCT01253616|DEVICE|vagus nerve stimulation (VNS)|Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
41021212|NCT06410105|DEVICE|CLEAR ALIGNERS|The CA group included 13 patients treated with clear aligners Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm
41353853|NCT03091569|OTHER|Placebo Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
41159897|NCT01394783|DEVICE|Miller laryngoscope|Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
41353854|NCT05993455|DRUG|Oral sotorasib + IV Panitumumab|Oral sotorasib at a dose of 960 mg once daily with Panitumumab is administered intravenously (IV) at a dose of 6 mg/kg every 14 days, infused over 60 minutes (≤ 1,000 mg) or 90 minutes (\> 1,000 mg).
41353855|NCT05096442|DEVICE|GENOSS® DCB|Drug Coated Balloon
41353856|NCT05096442|DEVICE|SeQuent® Please NEO|Drug Coated Balloon
41353857|NCT05637294|DEVICE|splinting|neutral-positioned wrist orthosis
41353858|NCT05869240|DRUG|BPB-101|Subjects will receive an intravenous infusion of BPB-101 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
41353859|NCT00372905|DRUG|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
41353860|NCT00372905|DRUG|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
41353861|NCT00372905|DRUG|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
41353862|NCT01072656|DEVICE|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
41353863|NCT04591340|DIETARY_SUPPLEMENT|dietary advice, oral nutritional supplement, supplementary parenteral nutrition or total parenteral nutrition|All HSCT(hematopoietic stem cell transplantation) patients should be accepted dietary advice or oral nutritional supplement, if their energy intake will not reach 60% of the goal level during the transplanting, then supplementary parenteral nutrition or total parenteral nutrition.
41353864|NCT02906098|BEHAVIORAL|Patient centered oral health education|Procedure: The theory-based educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
41353865|NCT02906098|BEHAVIORAL|Standard educational intervention|Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
41353866|NCT03089489|DIAGNOSTIC_TEST|lung biomarkers in organ donor for PGD in lung recipient|Lung biopsies in organ donor before and after cold ischemia
41353867|NCT05344859|BEHAVIORAL|Weekly Automated Health Coaching|This intervention will involve health coaching delivered by Artificial intelligence (AI). The automated health coaching mechanism will be coupled with AI-based responses, and recent advancements have made the voices generated through the AI, almost human-like voices. Every week participants enrolled in automated health coaching intervention will receive a health coaching and goal-setting call that will help guide the participants in managing their Type 2 Diabetes Mellitus. This technology-driven study group will inform us whether trained human coaches are required or if the automated technologies are sufficient to create clinically meaningful HbA1c improvements.
41494390|NCT01502410|DRUG|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
41494391|NCT01502410|OTHER|pharmacological study|Optional correlative studies
41494392|NCT01502410|OTHER|laboratory biomarker analysis|Optional correlative studies
40834386|NCT05455177|OTHER|Digital first-line intervention for osteoarthritis including exercise and education|The digital OA management programme was delivered by a smartphone application, including education and exercises based on a face-to-face osteoarthritis self-management programme provided nationwide in Sweden and designed according to national and international guidelines. Over 12 weeks, which is the recommended minimum duration of a self-management intervention for OA, a total of 163 exercise sessions and 31 educational sessions are provided.
40834387|NCT00930969|DEVICE|ICD|Subjects implanted with an ICD.
41494393|NCT02761005|DRUG|Eradication of H. pylori|For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
40834388|NCT06190327|BEHAVIORAL|Blended indoor and outdoor multicomponent structured exercise|Participants will receive a 16-week blended indoor and outdoor multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Session 1/week will conduct in indoor setting, while session 2/week will conducted in outdoor setting (park). Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
40834389|NCT06190327|BEHAVIORAL|Indoor-only multicomponent structured exercise|Participants will receive a 16-week indoor-only multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Both two sessions will conducted in indoor setting. Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
40834390|NCT03036436|BEHAVIORAL|Intervention|A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
40834391|NCT01987219|DRUG|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
40834392|NCT01987219|DRUG|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
40834393|NCT01987219|OTHER|placebo|Saline solution 3 cc NA
41353868|NCT05344859|BEHAVIORAL|Weekly Human Health Coaching|Every week participants enrolled in human health coaching intervention will receive a health coaching call and goal-setting call from their respective health coaches to guide them in managing their Type 2 Diabetes Mellitus.
41353869|NCT05344859|BEHAVIORAL|Adapted Reward Level|In the adapted reward (gamified) variation, participants will receive 25 cents per day for the first week of daily-monitoring calls, 50 cents per day in the second week, 75 cents per day in the third week, and a dollar per day from the fourth week until the end of the study (Aim 2). In the adaptive variation, missing one day of monitoring (in the past seven days), drops the reward value by one level (example: 75 cents becomes 50 cents), two days of missed calls drop the reward level by two levels, and similarly for three days. In the adaptive variation, participants have to continue to daily monitor their behavior to again build up their reward levels.
41353870|NCT05344859|BEHAVIORAL|Fixed Gamified Reward Level|In our fixed-reward arm, participants will be awarded 25 cents per day for answering the daily monitoring call - this serves simply as a reward for answering the daily calls. It is important that the rewards are for answering the calls and not for the actual values of the responses provided.
41353871|NCT04825106|OTHER|Diagnostic context|A life-threatening situation occurs in 3 different contexts
41494394|NCT04292652|PROCEDURE|AAA surgery|EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.
41494395|NCT03218059|PROCEDURE|Methotrexate Combined With Transvaginal Surgery|The methods of treatment of CSP
41494396|NCT06421883|DIETARY_SUPPLEMENT|Lactobacillus containing probiotic|"Patients will be randomized into two groups each group includes 40 patients:~Control group: 40 patients will receive their standard therapy only. Intervention group (probiotic group): 40 patients will receive probiotic 5 billion unit per day with their standard therapy for 3 months."
41494397|NCT00925366|OTHER|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
41494398|NCT04349943|OTHER|nutrition therapy|With enteral nutrition as the preferred solution, the gradual transition from slow to fast, from lean to dense, from essential to whole protein type is conducted.
41494399|NCT01752686|DRUG|carboplatin|carboplatin as adjuvant chemotherapy
41494400|NCT02648100|OTHER|biomarker study|
41494401|NCT00007527|DRUG|naloxone|
41494402|NCT00007527|DRUG|buprenorphine|
41494403|NCT03552835|PROCEDURE|no caries removal|occlusal caries were treated with no caries removal and placement of stainless steel crown
41494404|NCT03552835|PROCEDURE|partial caries removal upto soft dentin|occlusal caries were treated by partial caries removal upto soft dentin followed by Glass Ionomer Cement placement as a base and composite restoration
41494405|NCT03552835|PROCEDURE|partial caries removal upto firm dentin|occlusal caries were treated by partial caries removal upto firm dentin followed by Glass Ionomer Cement placement as a base and composite restoration
41494406|NCT01348412|DRUG|oxaliplatin|130 mg/m²Every 21 days
41494407|NCT01348412|DRUG|raltitrexed|3 mg/m² with a maximum of 6 mg every 21 days
41494408|NCT01348412|DRUG|other intravenous chemotherapy drugs|
41494409|NCT00182247|PROCEDURE|venogram|
41494410|NCT02430831|DIETARY_SUPPLEMENT|Nidina|
41494411|NCT02430831|DIETARY_SUPPLEMENT|Placebo|
41494412|NCT00896480|BIOLOGICAL|Immunotherapeutic GSK2132231A|Administration by intramuscular injection
41494413|NCT02355483|DEVICE|Unenhanced abdominal Computed Tomography|Systematic Unenhanced abdominal Computed tomography
41494414|NCT01363024|DRUG|MFGR1877S|Intravenous escalating dose
41494415|NCT02085135|DRUG|ALKS 5461|Sublingual tablet taken once daily
41494416|NCT02716727|DEVICE|Aquasil Ultra Cordless, Dentsply|Cordless gingival displacement procedure
41494417|NCT02716727|DEVICE|Ultrapak, Ultradent cord|Cordless gingival displacement procedure
41494418|NCT01886196|DRUG|Non-steroidal anti-inflammatory drug (Ibuprofen)|400mg of ibuprofen administered after exercise training session 3 days per week
41494419|NCT01886196|OTHER|placebo|placebo designed to mimic experimental drug (ibuprofen)
41494420|NCT01886196|BEHAVIORAL|Resistance exercise|3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
41494421|NCT01886196|BEHAVIORAL|Flexibility training|3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
41494422|NCT01627353|PROCEDURE|Standard of care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
41494423|NCT01627353|PROCEDURE|Pre-emptive wound infiltration|"The Wound Infiltration Group will receive 100 mL 0.125% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.~The Anesthetic will be given as determined appropriate to the patient by the staff anesthetist with the addition of the following: 2 grams of Magnesium Sulphate, 10 mg of Dexamethasone, and 3 mg/kg of Lidocaine, half of which is given on induction and half of which is infused throughout the remainder of the case."
41494424|NCT06368115|OTHER|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
41494425|NCT00950963|BEHAVIORAL|Phone Counseling|Patient were contacted on a periodic basis via telephone to address there diabetes care.
41494426|NCT00950963|OTHER|Standard Clinical Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
41494427|NCT04849962|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
41494428|NCT04849962|OTHER|Pecan|Participants in this group received a muffin in which part of the butter was substituted out for pecans.
41494429|NCT00077857|DRUG|capecitabine (Xeloda®)|825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
41494430|NCT00077857|DRUG|docetaxel (Taxotere®)|75 mg/m\^2 intravenous on day 1 of each 3 week cycle
41494431|NCT01723579|DRUG|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
41353872|NCT05916794|OTHER|Modified Cervical Retraction Exercises (MCRE)|Group A includes Modified cervical retraction exercise The patient is in sitting OR standing position and faces the physical therapist. The MCRE program consisted of alternating head position( neutral, side bending and rotation) while pushing their chin backward patients maintained an upright posture and tried to pull back their shoulders while maintaining this retracted position patient side bend OR rotate their head respectively hold the position for 20 sec.subject performed 5 sets of 10 repetition for 3-4 days per week. Rest intervals of 30 seconds were provided after the completion of 10 repetitions for each pattern and between sets, respectively. The total duration of MCRE will be of approximately 15-20 minutes
41353873|NCT05916794|OTHER|Motor Control therapeutic exercise(MCTE)|Motor control therapeutic exercises will be guided for the retraining of cervical muscles.it include craniocervical flexor exercise,craniocervical extensor exercise, co-contraction of flexors and extensor, a synergy exercise for retraining the strength of the deep neck flexors. Each of these four exercises will be performed for 3 sets of 8 to 10 repetitions, taking an approximate total duration of 15-20 minutes for, 3 days a week
41353874|NCT05155540|DEVICE|Trevo and or Merci devices for stent retreival|FDA approved devices for stent retrieval during mechanical thrombectomy
41353875|NCT05155540|DEVICE|Penumbra system for stent aspiration|FDA approved devices for stent aspiration during mechanical thrombectomy
41353876|NCT05155540|DRUG|recombinant tissue plasminogen activator|FDA approved drug for treatment of acute ischemic stroke within 4.5 hours of strokeonset
41353877|NCT03701932|BEHAVIORAL|TMS and Lumosity®cognitive retraining|The Lumosity® training includes exercises for speed, memory, attention, flexibility, and problem solving. Subjects will complete this battery while receiving TMS treatment.
41353878|NCT03701932|BEHAVIORAL|TMS and non cognitive computer games|Subjects will play computer games while receiving TMS treatment.
41353879|NCT05734144|PROCEDURE|The intraoperative ERCP has been performed immediately before LC|combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy
41353880|NCT05734144|PROCEDURE|POES followed by LC|Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
41353881|NCT00267267|DRUG|torcetrapib/atorvastatin|
41353882|NCT00267267|DRUG|ezetimibe/simvastatin|
41353883|NCT01386749|PROCEDURE|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
41353884|NCT03840681|OTHER|Augmentation|non invasive technique to increase bone width and eliminate need for second surgery
41353885|NCT02295254|OTHER|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
41353886|NCT02971449|DEVICE|Amazon Fire Tablet|A generic amazon fire tablet with pre-loaded instructional videos
41353887|NCT02971449|OTHER|ICCM Traditional Trainins|Standard, Didactic VHT Training intervention as an active comparator
41353888|NCT06305169|DIAGNOSTIC_TEST|Gastropanel|Gastropanel is a commercially available blood test which given serum levels of pepsinogen I and II and gastrin 17 along with helicobacter pylori infection status
41353889|NCT01048164|PROCEDURE|Massage|Chair Massage
41021213|NCT05758025|PROCEDURE|"Resection based on thymus-vascular-inferior parathyroid complex"|"Before clearing the central lymph nodes, looking for the thyro-thymic ligament first, looking for the inferior parathyroid along the thyro-thymic ligament. Dissect and leave the thymus-vascular-inferior parathyroid complex laterally; the inner side of this layer is the tissue of the central area. Then remove the central lymph nodes. Check for parathyroids in the removed specimen, transplant the parathyroids which are removed by accident."
41353890|NCT06085768|BEHAVIORAL|VRE intervention|Virtual reality exposure therapy is a new treatment technology developed in recent years. This technology combines virtual reality technology with traditional exposure therapy, and uses virtual reality technology to present the exposure scenes required for exposure therapy. Therefore, it can break through the limitations of time and space and more intuitively display some things that are difficult to simulate in the treatment room. Scenes do not require the client to undergo treatment through imaginary exposure, thereby increasing the immersion and reality of the treatment. Over the past two decades, numerous studies have explored and proven the effectiveness of virtual exposure therapy.
41494432|NCT01723579|DRUG|Estradiol (E2)|Daily release of 1.5 mg
41494433|NCT04835623|DRUG|Cyclosporine 0.09% Ophthalmic Solution|one drop each eye twice daily
41494434|NCT03239912|DEVICE|Twin-block appliance|Functional treatment will be achieved using the Twin-block appliance
41494435|NCT03239912|OTHER|Low level laser|Functional treatment will be combined with low-level laser therapy on the TMG region
41494436|NCT01602718|OTHER|exercise training|Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
41494437|NCT02734654|PROCEDURE|remote ischemic preconditioning (RIPC)|Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
41509154|NCT05876637|OTHER|Left Nostril Breathing|The participants which will show cardiovascular hyper reactivity towards CPT will be divided into 2 groups having 30 participants in each group. Experimental group will receive Left Nostril Breathing(slow, deep breath taken through your left nostril while closing your right nostril with your right thumb. Then just as gently exhale long, slowly, and completely through the left nostril, just as gently. It will be done while sitting) for 10 minutes twice a day for the duration of 12 weeks. Follow up will be taken through administration Cold pressor test after every 4,8 and 12 weeks.
41021214|NCT04504227|DIETARY_SUPPLEMENT|Thin liquid swallows|Thin liquid swallows of formula or breastmilk or other liquid
41353891|NCT00934752|DEVICE|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
41353892|NCT05707520|DRUG|enteric-coated mycophenolate (MPAs)|Immunosuppression protocol with enteric-coated mycophenolate sodium
41353893|NCT05707520|DRUG|None MPA|Immunosuppression protocol without enteric-coated mycophenolate sodium
41353894|NCT04984811|DRUG|efineptakin alfa|1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
41353895|NCT04984811|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
41353896|NCT03082066|OTHER|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
41353897|NCT00394277|DRUG|peginterferon alfa-2a|180 µg sc weekly for 48 weeks
41353898|NCT00394277|DRUG|Ribavirin|1200 mg po daily for 48 weeks
41353899|NCT00394277|DRUG|peginterferon alfa-2a|360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
41353900|NCT00394277|DRUG|Ribavirin|1400-1600 mg po daily for 48 weeks
41353901|NCT05119244|OTHER|blood and hair sampling|3.5 ml blood sample Hair sample
41353902|NCT06502509|DIETARY_SUPPLEMENT|Commercial Kombucha tea (Brand name E-Ben Organic Kombucha Lemon)|Commercial lemon kombucha tea (Brand:E-Ben Organic Kombucha Lemon), which will be given to participants in opaque bottles for 8 weeks.
41353903|NCT06502509|DIETARY_SUPPLEMENT|Lemon tea|Diluted lemon juice with the same pH as the commercial kombucha tea as placebo, which will be given to participants in opaque bottles for 8 weeks.
41353904|NCT02705313|DRUG|177Lu-DOTA0-Tyr3-Octreotate|The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
41353905|NCT03167866|BEHAVIORAL|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
41353906|NCT03167866|BEHAVIORAL|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
41353907|NCT03042728|BEHAVIORAL|Dog Interaction|A therapy dog will visit the patients.
41353908|NCT03042728|BEHAVIORAL|Human Interaction|A human will visit the patients.
41353909|NCT04280185|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is a way of intraperitoneal chemotherapy
41353910|NCT06448299|PROCEDURE|TAPB|Patients will receive ultrasound guided bilateral oblique subcostal TAPB using 25 mL bupivacaine 0.25% in each side
41494438|NCT04800549|OTHER|Oral Mucositis|The data of the study were obtained by conducting six interviews with each child and the family. The first interview was conducted before starting to treatment on the first day of the treatment, the second interview was conducted on the 2nd day after the treatment and the following interviews were conducted on the 4th, 8th, 16th, and 21st days and in-mouth mucosa of the patient was evaluated by taking in-mouth pictures following interviewing with the child and the family. Oral care application was conducted four times a day with sodium bicarbonate solution and a lollipop made with black mulberry syrup (after meals and before going to the bed at night). Oral care was first conducted by the researcher, the oral care was then taught to the patient and patient's relatives and the application was evaluated. Figure 1 shows the study design.
41494439|NCT04530435|DEVICE|PEP flute|Participants are advised to use a PEP flute at least three times daily at an appropriate resistance. Ideally, each session consists of 15 breaths (for approximately 1 minute) repeated twice at an upright position.
41494440|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
41159898|NCT01394783|DEVICE|Storz videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
41353911|NCT06448299|BIOLOGICAL|ESPB|Patients will receive ultrasound guided bilateral ESPB at T8 level using 25 mL bupivacaine 0.25% in each side
41353912|NCT05299411|DRUG|iron (isomaltoside)|iron supplement through intravenous infusion
41353913|NCT05299411|DRUG|Dried Ferrous Sulfate|iron supplement through oral intake
41353914|NCT06325644|OTHER|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
41353915|NCT06325644|BIOLOGICAL|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
41494441|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
41494442|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
41494443|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
41494444|NCT04322110|OTHER|PronoKal Method|Multidisciplinary program of weight loss based on diet (initially ketogenic diet), physical activity and emotional support
41353916|NCT06325644|BIOLOGICAL|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
41353917|NCT06325644|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
41353918|NCT06325644|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
41353919|NCT06325644|OTHER|Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .|Changes in glomerular filtration rate will be assessed via magnetic resonance imagining conducted by trained professionals. MRI imaging analyses will determine cardiac function. Trained imaging professionals will analyze the images to determine overall change (mg/mmol).
41353920|NCT03919760|BEHAVIORAL|NAVIGATE|"NAVIGATE was developed in consultation with clinical and research experts, biostatisticians, health economists, consumers, family members, advocacy groups, and government officials. It is a form of coordinated specialty care for first episode psychosis consisting of 4 key intervention components:~1. individualized medication management using a decision support tool;~2. a package of psychoeducation and a blend of evidence-based psychotherapies called individual resiliency training (IRT);~3. supported employment and education (SEE);~4. a family education program"
41353921|NCT00062842|DRUG|Irinotecan|
41353922|NCT02411773|DRUG|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate \> 30).
41353923|NCT02411773|DRUG|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session.
41353924|NCT02411773|BEHAVIORAL|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
40834394|NCT05826223|OTHER|Implementation and evaluation of a sepsis sub-phenotyping algorithm|The algorithm will run silently in the background and continuously compute the subphenotypes of patients who are presenting to the emergency department (ED) with suspected infection.
40834395|NCT06508645|DRUG|DWP14012 injection|"1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)"
40834396|NCT05458453|DRUG|Esketamine|Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ esketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
40834397|NCT01012752|BIOLOGICAL|modified allergen extract|subcutaneous injections
40834398|NCT01012752|BIOLOGICAL|Placebo|subcutaneous injections
40834399|NCT05630976|DRUG|Isavuconazole|This is a single arm study, all enrolled participants will receive the study intervention.
40834400|NCT04094961|DRUG|Ixazomib|Oral, administered four times per cycle
41353925|NCT02411773|BEHAVIORAL|Control to Exercise (Stretching)|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
40834401|NCT04094961|DRUG|Pomalidomide|Oral, administered 14 times per cycle
40834402|NCT04094961|DRUG|Dexamethasone|Oral, fixed dose administered 8 times per cycle
40834403|NCT00004705|DRUG|amiloride|
40834404|NCT00004705|DRUG|uridine|
41353926|NCT02056249|OTHER|Norepinephrine Transporter (NET) ligand|Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
41353927|NCT01571973|PROCEDURE|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
41353928|NCT06039540|DRUG|Captopril Tablets|0.3mg/kg, tid
40834405|NCT04494724|DRUG|Clazakizumab|Infusion
40834406|NCT04494724|DRUG|Placebo|Infusion
41353929|NCT06039540|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
41353930|NCT06039540|DRUG|Spironolactone Tablets|2-4mg/kg, bid
41353931|NCT06039540|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
40834407|NCT06508372|DRUG|Topical thymoquinone Ointment|One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.
40834408|NCT06508372|DRUG|topical placebo ointment|In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
40834409|NCT00334282|DRUG|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
40834410|NCT00334282|DRUG|placebo|matching placebo (800 mg tablet) once daily
40834411|NCT00488124|DRUG|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
40834412|NCT05403697|PROCEDURE|Individualized MAP|Hemodynamic optimization beginning after general anesthesia induction, and ending at the 24th hour postoperatively, which consists in obtaining a mean arterial pressure (MAP) which is at least 90% of the usual MAP of the patient.
40834413|NCT04251975|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
40834414|NCT04534413|DEVICE|composite optical fiberscope (COF)|Fiber Technology
40834415|NCT02308488|RADIATION|Intensity-modulated radiation therapy (IMRT)|Patients will receive 15 daily radiation fractions of 2.7 Gy, Monday to Friday for three weeks, to the entire breast/chest wall and axillary level III and supraclavicular nodes with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7 Gy + 0.5 Gy). The overall dose will be 40.5 Gy to the breast/chest wall, axillary level III and supraclavicular nodes, and 48.0 Gy to the tumor bed.
40834416|NCT03008382|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
40834417|NCT03008382|DRUG|Placebo Oral Tablet|Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
40834418|NCT05525949|DEVICE|VIVID Brain|Participants receive visual perceptual training using the VIVID Brain software.
41159899|NCT06228742|OTHER|Unilateral leg immobilization|Participants will have one leg immobilized using a rigid knee brace. Participants will be expected to keep the knee brace on for 5 days and remain non-weight bearing on the immobilized leg. Participants will use crutches to remain non-weight bearing on the immobilized leg.
41159900|NCT06228742|OTHER|Contralateral active leg|One leg will remain non-immobilized and active during the study. Participants will use this leg to walk with crutches.
41159901|NCT06027697|DEVICE|AccuFill® Porous Bone Substitute Material (BSM)|The patient will undergo a minimally invasive surgery procedure (subchondroplasty) to receive the medical device AccuFill® Porous Bone Substitute Material (BSM).
41159902|NCT02801500|DEVICE|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
41159903|NCT02801500|PROCEDURE|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
41353932|NCT06039540|DRUG|Potassium citrate powder|0.06g/kg, tid
41353933|NCT01904760|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
41353934|NCT01904760|DRUG|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
41353935|NCT02678702|BEHAVIORAL|CBT-I|CBT-I
41353936|NCT02678702|BEHAVIORAL|Treatment as usual|Treatment as usual
41494445|NCT04322110|OTHER|Low calorie diet|Balanced hypocaloric diet (caloric intake 10% below basal metabolic rate) accompanied by physical exercise.
41494446|NCT03621501|DEVICE|Percutaneous coronary intervention|At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).
41494447|NCT02437435|OTHER|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
41494448|NCT02437435|OTHER|Placebo Intervention|Patient supine, legs in triple flexion, feet on table. Physical Therapist take contact with his right hand in patient's belly for 5 minutes, without any movement.
41494449|NCT04776538|BIOLOGICAL|Stem cells|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
41494450|NCT04776538|BIOLOGICAL|Placebo|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
41494451|NCT06460285|BEHAVIORAL|EmRes|There will be six, one hour, treatment sessions across nine weeks of emotional resolution therapy, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a licensed therapist.
41494452|NCT06460285|BEHAVIORAL|Mindfulness|There will be six, one hour, treatment sessions across nine weeks of a mindfulness intervention program, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a trained member of the study staff.
41494453|NCT03996135|DEVICE|Cannulation with AccuVein AV400|Cannulation using AccuVein AV400 device
41494454|NCT03516396|BEHAVIORAL|Training Plus|Training plus enhanced community development activities
41494455|NCT03516396|BEHAVIORAL|Training Only|Training Only (livestock management and child nutrition) for 24 months then add community development inputs
41494456|NCT03516396|BEHAVIORAL|No Inputs then Community development and training|No inputs for 24 months then add community development and training
41494457|NCT02944305|PROCEDURE|Endotracheal intubation|Endotracheal intubation under direct laryngoscopy using McIntosh blade
41494458|NCT05204836|DRUG|Zoledronic Acid Injection|5 mg / 100 mL intravenous infusion
41494459|NCT05204836|DRUG|Placebo|100 mL intravenous infusion
41494460|NCT01383213|OTHER|Oxygen therapy|patient in group oxygen therapy by Venturi Mask will be treated with oxygen until reaching clinical stability, or criteria of endotracheal intubation
41494461|NCT01383213|OTHER|Helmet CPAP|patient in group CPAP will be treated with CPAP until reaching clinical stability, or criteria of endotracheal intubation
41494462|NCT01383135|DRUG|F18-FPPRGD2|Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
41159904|NCT01889771|DRUG|Nicotine Patch|nicoderm patches are distributed in two different supplies through a telephone quitline
41159905|NCT00010842|DRUG|Ginkgo biloba|
41159906|NCT00010842|DRUG|Alpha-lipoic acid|
41159907|NCT00010842|DRUG|Vitamin E/Selenium|
41159908|NCT00010842|DRUG|Essential fatty acids|
41159909|NCT05225285|BIOLOGICAL|Inactivated Coronavac/Butantan vaccine|Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart
41159910|NCT05225285|BIOLOGICAL|BNT162b2 (Pfizer)|BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart
41159911|NCT00006578|DRUG|Ritonavir|
41159912|NCT00006578|DRUG|Abacavir sulfate|
41159913|NCT00006578|DRUG|Amprenavir|
41353937|NCT04081987|DEVICE|non-invasive monitoring|Comparing blood pressure (diastolic \& systolic), heart and respiration rates, blood oxygen level and body temperature measurement using the BiPS non-invasive monitor to an arterial line.
40834419|NCT05525949|OTHER|No-treatment Control|No-treatment is administered during control period.
40834420|NCT05942794|DEVICE|Screening examination|"After an initial clinical visit, all three operators will wear the tissue autofluorescence detection device (GOCCLES®), reporting both observations on their operator-module."
40834421|NCT00261508|DRUG|risperidone|
40834422|NCT01968577|DRUG|Rosuvastatin|Rosuvastatin 40 mg before percutaneous coronary intervention
40834423|NCT03299231|DEVICE|OPEP Aerobika|Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.
40834424|NCT03299231|DEVICE|OPEP Aerobika Sham device|The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
40834425|NCT04330781|DEVICE|Intraoral stent|Radiotherapy with intraoral stent
40834426|NCT04330781|OTHER|No intraoral stent|Radiotherapy without intraoral stent
40834427|NCT05478668|OTHER|visual analog scale|In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
40834428|NCT05513313|BIOLOGICAL|JYNNEOS|smallpox vaccine
41159914|NCT00006578|DRUG|Lamivudine|
40834429|NCT06098664|DIAGNOSTIC_TEST|AI-enabled ECG score for Atrial Fibrillation (DNN score)|"A 12-lead ECG, performed within 24 hours before the Pulmonary Vein Isolation (PVI) procedure, will be used to calculate the DNN score.~(DNN score details: https://doi.org/10.1016/j.jacep.2023.04.008)"
40834430|NCT06098664|DIAGNOSTIC_TEST|Atrial voltage map in sinus rhythm|An atrial voltage map will be constructed prior to the PVI procedure.
40834431|NCT03455439|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
40834432|NCT02971241|BEHAVIORAL|Intergenerational Mobile Technology Opportunities Program|The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
40834433|NCT03453866|PROCEDURE|Warmed Arthroscopic Fluids|Warmed Arthroscopic Fluids
40834434|NCT03453866|PROCEDURE|Room Temperature Arthroscopic Fluids|Room Temperature Arthroscopic Fluids
41159915|NCT00006578|DRUG|Filgrastim|
41159916|NCT03681002|BEHAVIORAL|structured lifestyle program|Intensive Lifestyle counseling during one year
41494463|NCT01894594|DRUG|Sodium Bicarbonate|"Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: \*\~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: \*\~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~\* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)"
40834435|NCT03578484|DIAGNOSTIC_TEST|Aesthetic assessment 3D breast scanning|Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
40834436|NCT00905086|OTHER|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
40834437|NCT00905086|PROCEDURE|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
40834438|NCT00905086|PROCEDURE|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
40834439|NCT00905086|PROCEDURE|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
40834440|NCT02747212|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
41494464|NCT06349252|PROCEDURE|Radical resection|Patients should undergo radical resection.
40834441|NCT04069923|OTHER|Magnesium-based Bone Void Filler|Given intraoperatively
40834442|NCT00478790|DEVICE|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
40834443|NCT02966015|DEVICE|Coloplast test catheter|This is a newly developed catheter
40834444|NCT00993733|PROCEDURE|Continuous veno-venous haemodiafiltration|Dialysis procedure administrated to the patients with acute renal failure
40834445|NCT04957758|DRUG|OC-01 (varenicline) nasal spray 1.2 mg/ml|OC-01
40834446|NCT04957758|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle)
40834447|NCT02332733|BIOLOGICAL|TV003|10\^3 plaque forming units (PFU) of rDEN1 delta 30, 10\^3 PFU of rDEN2/4 delta 30(ME), 10\^3 PFU of rDEN3 delta 30/31-7164, and 10\^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
40834448|NCT02332733|BIOLOGICAL|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
40834449|NCT04762524|OTHER|CVVH vs CVVHD|Patients are initiated on CRRT in either the CVVH or CVVHD modality
40834450|NCT01264614|BEHAVIORAL|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
40834451|NCT00002742|DRUG|amphotericin B deoxycholate|
40834452|NCT00002742|DRUG|nystatin|
41021215|NCT04504227|DIETARY_SUPPLEMENT|Slightly thickened liquid swallows|Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
40834453|NCT05267977|DRUG|Cephalosporin 1St Generation|
40834454|NCT05267977|DRUG|Aminoglycosides|
40834455|NCT06108843|OTHER|Myofascial Arm Pull and Active Release Technique|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
40834456|NCT06108843|OTHER|Myofacial Arm Pull|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
40834457|NCT05086055|BEHAVIORAL|Kinematic movement analysis|moving arm/leg while registration with electromyography, electroencephalogram, accelerometers, functional near infrared spectroscopy and 3 dimensional video registration of hand, arm, foot and leg movements.
40834458|NCT01973608|DRUG|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
40834459|NCT01973608|DRUG|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
40834460|NCT01973608|DRUG|MSB0010445 (1.8 mg/kg)|MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
40834461|NCT01973608|DRUG|MSB0010445 (2.4 mg/kg)|MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
40834462|NCT01973608|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
40834463|NCT05953948|OTHER|Intelligent Case Manage Platform (ICMP) and self-management program|This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.
40834464|NCT03928626|BEHAVIORAL|Regulation of craving|Participants in the ROC-T condition will be trained to use a strategy that instructs them to think of the negative outcomes associated with alcohol drinking while looking at alcohol-related images.
41021216|NCT04504227|DIETARY_SUPPLEMENT|Mildly thickened liquid swallows|Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
41021217|NCT04504227|DIETARY_SUPPLEMENT|Moderately thickened liquid swallows|Moderately thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
41021218|NCT01339650|DRUG|ABT-767|ABT-767 once or twice daily for a 28 day cycle
41021219|NCT03993418|DIETARY_SUPPLEMENT|stevia|This arm will be required to consume 5 stevia drops twice daily in habitual drinks
41353938|NCT05994664|OTHER|Heartmath Intervention|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. During the initial visit for the intervention group the same assessment will be included, however, they will also receive 10-15 of instruction on a basic Heartmath technique. Group participants will be asked to complete 5-10 minutes of HeartMath techniques 2x daily. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. However, each week the intervention group will receive an addition 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.
41353939|NCT05994664|OTHER|Control Group|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. The initial visit will include an HRV assessment using the HeartMath sensor via the 3-step Protocol developed by the HeartMath Institute. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.
41353940|NCT01314885|DRUG|PF-03715455|20mg, Inhaled, single dose
41353941|NCT01314885|DRUG|PH-797804|30mg, Oral, single dose
40834465|NCT03928626|BEHAVIORAL|Control (NO REGULATION)|In the CONTROL condition, participants would simply observe non-alcohol-related images and allow natural responses to come
40834466|NCT04512638|DRUG|Antibiotics|"Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed."
40834467|NCT04512638|DRUG|Chlorhexidine mouthwash|Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.
40834468|NCT04512638|PROCEDURE|Minimally invasive surgery with LPRF|Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
41021220|NCT02030691|DEVICE|Nasal continuous airway positive pressure (nCPAP)|
41353942|NCT01314885|DRUG|Placebo for PF-03715455|Single dose, inhaled, Placebo for PF-03715455
41021221|NCT02030691|DEVICE|Nasal high frequency percussive ventilation (nHFPV)|
41021222|NCT04018872|DRUG|Itraconazole|Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
41021223|NCT03156231|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
41021224|NCT03156231|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
41353943|NCT01314885|DRUG|Placebo for PH-797804|Single Dose, Oral, Placebo for PH-797804
41353944|NCT05883150|DRUG|Nebulized Midazolam|"All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child The sedative drug, the dosage will be diluted with an equal volume by adding distilled water.~The child will be seated in an upright position on the dental chair. Before placing the mask of the nebulizer, the child will be coached into proper breathing pattern"
41494465|NCT02021357|BEHAVIORAL|hyperbolid combined with tongue exercises on the palate|
41494466|NCT02021357|OTHER|hyperbolid|
41494467|NCT05673330|OTHER|Spinal Mobilizations|"1. Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~2. Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks"
41509155|NCT05876637|OTHER|Conventional|30 participants will be recruited in conventional group which will receive simple deep breathing exercises of 3 sessions per week for the duration of 12 weeks.Follow up will be taken after every 4,8 and 12 weeks.
41509156|NCT03834142|DEVICE|NSS-2 Bridge|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
41494468|NCT05673330|OTHER|Myofascial Release Technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
40834469|NCT04512638|PROCEDURE|Surgical resection|Primary surgical management consisting of the removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
40834470|NCT04149574|DRUG|nivolumab|Specified Dose on Specified Days
40834471|NCT04149574|OTHER|Placebo|Specified Dose on Specified Days
40834472|NCT04149574|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|Specified Dose on Specified Days
41494469|NCT02679235|DRUG|POST Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
40834473|NCT01443130|DRUG|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
40834474|NCT01443130|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
40834475|NCT02771626|DRUG|CB-839|Glutaminase inhibitor
40834476|NCT02771626|DRUG|Nivolumab|PD-1 inhibitor
40834477|NCT02800590|DRUG|ABP-700|
40834478|NCT05336825|DEVICE|CO2 laser|Mona Lisa CO2 laser
40834479|NCT05336825|DRUG|Lidocaine patch 5%|lidocaine
40834480|NCT05473013|BEHAVIORAL|Behavioral Therapy for Eating Disorders|Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
40834481|NCT05473013|BEHAVIORAL|Skills Monitoring On|Integrates behavioral treatment for eating disorders with a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
40834482|NCT05473013|BEHAVIORAL|Automated Reminder Messages|Integrates behavioral treatment for eating disorders with two randomly time automated push notifications from a smartphone application each week to remind participants about skills they have learned in session to encourage skill use.
40834483|NCT05473013|BEHAVIORAL|JITAIs|Integrates behavioral treatment for eating disorders with push notifications each week from a smartphone application to remind participants about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
40834484|NCT06318611|OTHER|sleep, chronotype|Our objectives were to compare sleep health composite dimensions, and chronotype in children and adolescents with and without T1D, and to explore relationship between sleep and glycemic variability in T1D.
40834485|NCT02757794|OTHER|computerized cognitive remediation program|a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
40834486|NCT02757794|OTHER|standard remediation|A speech therapy and / or academic support is realized.
40834487|NCT01389349|OTHER|Acupuncture|Battlefield acupuncture protocol
41159917|NCT03388021|PROCEDURE|completion angiography followed by endovascular treatment of residual or underlying lesions|completion angiography followed by endovascular treatment as thromboembolectomy under fluoroscopic guidance using Fogarty over the wire, angioplasty, stenting, or Intraarterial thrombolysis to treat residual or underlying lesions
40834488|NCT01389349|OTHER|Sham Control|Sham control acupuncture
41159918|NCT00993018|DRUG|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
41494470|NCT03323437|DRUG|Risperidone|Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
40834489|NCT02515201|DRUG|Taurolidine|taurolidine in central catheter lumen
40834490|NCT02515201|DRUG|Heparin|heparin in central venous catheter lumen
40834491|NCT00664326|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
40834492|NCT03635034|DEVICE|Insert bladder catheter|Bladder catheter will be inserted according to randomization schema
40834493|NCT03635034|DEVICE|No catheter|Subjects will not receive a bladder catheter during the ablation procedure
41159919|NCT00993018|DRUG|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
40834494|NCT04397965|DEVICE|Cascade Continuous Glucose Monitor|Continuous Glucose Monitoring
40834495|NCT02713529|BIOLOGICAL|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
40834496|NCT01877577|DIETARY_SUPPLEMENT|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
40834497|NCT00031460|DRUG|Acyclovir|Oral banana flavored acyclovir suspension: 300 mg/m\^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
40834498|NCT00031460|DRUG|Placebo|Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
40834499|NCT04069247|BEHAVIORAL|ECBT-I|The eCBT-I will be delivered through a mobile application (eSleep) with a personal password.
40834500|NCT04069247|BEHAVIORAL|HE|The HE will be delivered in control though a mobile application (eSleep) with a personal password.
41353945|NCT05883150|DRUG|Intranasal Midazolam|All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child, For children who will receive midazolam using the atomization device attached to a three-ml syringe, the child sitting reclined in knee-to-knee position. Half of the dose will be sprayed in the right nostril and the other half will be sprayed in the left nostril to double the absorptive surface area by short and quick puffs
40834501|NCT02223416|DRUG|RGB-10|
40834502|NCT02223416|DRUG|Teriparatide|
40834503|NCT03382067|DIETARY_SUPPLEMENT|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
40834504|NCT03382067|OTHER|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
40834505|NCT03908827|BIOLOGICAL|Bone Mineral Aspirate Concentrate (BMAC)|A single BMAC injection will be performed into the arthritic joint
41159920|NCT00993018|DRUG|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
41159921|NCT00993018|DRUG|Placebo|Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
41159922|NCT01971034|DRUG|Paclitaxel|80 mg/m2, IV, Day 1, Day 8 and Day 15.
41159923|NCT01971034|DRUG|Metformin|850mg, PO, every 8 hours, daily.
41159924|NCT01707498|PROCEDURE|Scanning device|Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.
40834506|NCT01762254|PROCEDURE|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
40834507|NCT01762254|PROCEDURE|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
41159925|NCT01707498|PROCEDURE|RoBIK Brain-Computer Interface|Patients will be asked to spell a text with the BCI
41159926|NCT00005797|DRUG|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
41159927|NCT00005797|DRUG|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
41159928|NCT00005797|DRUG|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is \>/= 150% of IBW, in which case adjusted body weight will be used.
41159929|NCT00005797|RADIATION|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
41353946|NCT03432208|PROCEDURE|GI consult|
41353947|NCT03052634|DRUG|RC48-ADC 1.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
41353948|NCT03052634|DRUG|RC48-ADC 2.0 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
41353949|NCT03052634|DRUG|RC48-ADC 2.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
41353950|NCT03052634|DRUG|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
41353951|NCT05022303|DRUG|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
41353952|NCT05022303|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
40834508|NCT05052060|OTHER|Group A|19 patients will be treated with pelvic tilt exercises
40834509|NCT05052060|OTHER|Group B|19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
40834510|NCT02484924|DRUG|Ticagrelor|No intervention- purely observational
41353953|NCT02382276|DRUG|Nalmefene hydrochloride|
41353954|NCT01915355|DEVICE|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
41494471|NCT01789723|DRUG|Fusilev|Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
41494472|NCT01789723|DRUG|Folotyn|A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
41494473|NCT03544489|BEHAVIORAL|E-ICD Intervention|Home walking 3 days/week x 12 weeks
41494474|NCT02516943|OTHER|Control|The patient's ABGs were test according to a 4 - hour routine
41494475|NCT02516943|OTHER|Guideline|The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
40834511|NCT06105658|BIOLOGICAL|Unrelated umbilical cord blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
40834512|NCT06105658|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
40834513|NCT06105658|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
40834514|NCT06105658|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
40834515|NCT02097342|DRUG|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
40834516|NCT02097342|DRUG|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
40834517|NCT02097342|DRUG|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
40834518|NCT04787380|DEVICE|Heartfelt device|"The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.~The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless.~In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition."
40834519|NCT06421402|OTHER|Air quality monitoring at patient's home|"Indoor Air Quality:~- MICA-INBIOT system: temperature (ºC), humidity (%), CO2 (ppm), total Volatile Organic Ccompounds (VOCs) (ppb), Formaldehyde (µg/m3); and Particulate Matter (PM) 1/2.5/4/10 (µg/m3)~Outdoor Air Quality:~- Aeris Weather platform: NO, NO2, NOx, SO2, SO3, CO, and PM10, all expressed in µg/m3"
40834520|NCT06421402|OTHER|Questionnaires: Baseline & every six months|"General surveys:~* PROMs: ICHOM Adult Set; encompassing Patient Reported Outcomes Measurement Information System (PROMIS 10), World Health Organization Wellbeing Index (WHO 5) and World Health Organization Disability Assessment Schedule (WHO-DAS 12) questionnaires.~* PREMs: Patient-Reported Indicator Survey (PaRIS)~Disease specific questionaires:~* COPD: COPD Assessment Test (CAT); modified Medical Research Council (mMRC) Dyspnea scale.~* Asthma: Asthma Control Test (ACT); Test of Adherence to Inhalers (TAI-12); Asthma Quality of Life Questionnaire (mini AQLQ); Sino-Nasal Outcome Test (SNOT-22)."
41353955|NCT04789564|DIAGNOSTIC_TEST|cardiovascular magnetic resonance (CMR)|Testing CMR on patients of 7 days and 6 months after myocardial infarction
41353956|NCT00281528|DRUG|ABI-007 (Abraxane)|30 minute infusions
41353957|NCT00281528|DRUG|bevacizumab|infusions
41353958|NCT04898036|DEVICE|Blue Light Therapy|This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.
41494476|NCT00820443|DEVICE|Ceramic on metal prosthesis|Ceramic femoral head with a metal acetabular component
41494477|NCT01250886|DRUG|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
41494478|NCT01250886|DRUG|Normal saline solution|Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
41494479|NCT01250886|DRUG|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
41494480|NCT02878941|PROCEDURE|Synovial Fluid Analysis|Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
41494481|NCT01363882|OTHER|Sleep study-guided adjustment of NIV|Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.
41353959|NCT04898036|DEVICE|Sham Light Therapy|To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.
41353960|NCT05830331|OTHER|ERASS Pathway|Enhanced Recovery After Spinal Surgery
41353961|NCT05633290|DIAGNOSTIC_TEST|CMR|CMR Imaging 6-10 weeks post hospital discharge.
41353962|NCT05633290|DIAGNOSTIC_TEST|hs-troponin|Biomarker of myocardial injury
41494482|NCT01363882|OTHER|Standard initiation of NIV|NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
41494483|NCT05635383|OTHER|PERIPHERAL NERVE BLOCK|Observation of rebound pain after peripheral nerve block application
41494484|NCT05277623|DRUG|Mannitol|During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg
41494485|NCT05277623|OTHER|0.9% normal saline|the same amount of 0.9% normal saline
41494486|NCT00255710|BIOLOGICAL|filgrastim|
41494487|NCT00255710|DRUG|cyclophosphamide|
41494488|NCT00255710|DRUG|fludarabine phosphate|
41494489|NCT00255710|DRUG|mycophenolate mofetil|
40834521|NCT06421402|DIAGNOSTIC_TEST|Lung function Testing: Baseline & every six months & during exacerbations|"* Forced Spirometry: Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1)~* Forced Oscillation Technique: Impedance, resistance and reactance.~Ancillary measurements: Systemic arterial pressure and pulse oximetry."
40834522|NCT06421402|OTHER|EMR & registry data|"Electronic Medical Records (EMRs): Updated every twelve months to track clinical events from Hospital and Primary Care databases.~Registry data: from the Catalan Health Surveillance System (CHSS)."
41021225|NCT04950608|DRUG|Psilocybin|Oral, single administration, dosage 25 mg orally
41021226|NCT04950608|BEHAVIORAL|Psychotherapy|The treatment regimen consists of a single administration of psilocybin orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions
41494490|NCT00255710|DRUG|tacrolimus|
41494491|NCT00255710|PROCEDURE|allogeneic bone marrow transplantation|
41494492|NCT00255710|PROCEDURE|peripheral blood stem cell transplantation|
41494493|NCT00255710|RADIATION|radiation therapy|
41494494|NCT00673153|DRUG|gemtuzumab ozogamicin|Given IV
41494495|NCT00673153|DRUG|vorinostat|Given orally
41494496|NCT00673153|OTHER|laboratory biomarker analysis|Correlative studies
41494497|NCT01517373|DRUG|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
41494498|NCT01517373|DRUG|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
41494499|NCT01517373|DRUG|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
41494500|NCT01517373|DRUG|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
41494501|NCT01517373|DRUG|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
41494502|NCT01329549|DRUG|BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
41021227|NCT05382325|BIOLOGICAL|MK-1484|Subcutaneous (SC) injection
41021228|NCT05382325|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
41021229|NCT05044741|PROCEDURE|Emergency surgical enterostomy|Emergency surgical enterostomy
41494503|NCT01329549|DRUG|BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
41494504|NCT01329549|DRUG|BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
41494505|NCT06490614|DRUG|Dexmedetomidine in superficial cervical plexus block|While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
41353963|NCT05633290|DIAGNOSTIC_TEST|NT-pro BNP|Biomarker for heart failure
41494506|NCT06490614|DRUG|Nalbuphine in superficial cervical plexus block|While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, 10 mg of Nalbuphine (nalufin 20mg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
41494507|NCT01339481|DRUG|abatacept|Intravenous Infusion
40834523|NCT06421402|DEVICE|Communication channel - Health Circuit Mobile App (Herranz C. JMIR 2023)|Health Circuit: chat, short questionnaires (Likert scale). As needed.
40834524|NCT06421402|DEVICE|Physiological data - Beat One Watch|Enhanced with real-time physiological data tracking (heart rate, steps walked and Heart Rate Variability (HRV))
41494508|NCT02618135|OTHER|Intervention Group|Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
40834525|NCT06421402|DEVICE|Patient Empowerment|Mobile App Health Circuit: follow-up of the personalized action plan agreed with the patient \& reference doctor
41494509|NCT02618135|OTHER|Control Group|"Participants will wait for 8 weeks before training intervention begins.~Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology."
40834526|NCT06421402|OTHER|Characteristics of exacerbations|Health Circuit: home-based oscillometry, daily disease-specific questionnaire during the acute episode and continuous assessment of physiological variables.
40834527|NCT02428413|DEVICE|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
40834528|NCT02428413|DEVICE|Standard oxygen mask|Provide supplemental oxygen
40834529|NCT01804166|DRUG|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
40834530|NCT01804166|DRUG|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
41021230|NCT01055392|DRUG|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
41021231|NCT01055392|DRUG|Placebo|Identical placebo tablets were administered twice-a-day for two years.
41021232|NCT05247918|BEHAVIORAL|Digital-physical care|Patients will get access to a digital communication platform. Two in person session and two digital contacts per year with possibility to chat with caregivers in between.
41021233|NCT05247918|BEHAVIORAL|Treatment as usual|Four in person session at the center in a year.
41021234|NCT03741959|PROCEDURE|Experimental group|"Active self-correction exercises (20 minutes) to achieve the best possible trunk alignment the patient can achieve in the three-dimensional planes using visual, proprioceptive and EMG feedbacks.~Passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint Functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015)."
41021235|NCT03741959|PROCEDURE|Control group|Training consisted of passive and active trunk mobilization (10 minutes) followed by muscle stretching, and strengthening exercises, and gait training (50 minutes)(Bartolo et. al., 2010).
41494510|NCT01323712|DIETARY_SUPPLEMENT|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
41021236|NCT02376426|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.
41494511|NCT03153761|OTHER|CSD170201AA|A moist snuff product
41494512|NCT03153761|OTHER|CSD170201AB|A moist snuff product
41494513|NCT00003920|BIOLOGICAL|filgrastim|
41494514|NCT00003920|DRUG|cyclosporine|
41494515|NCT00003920|PROCEDURE|peripheral blood stem cell transplantation|
41494516|NCT00003920|RADIATION|indium In 111 monoclonal antibody m170|
40834531|NCT05829863|BEHAVIORAL|educational message exposure|Exposing African American young adult vapers to persuasive anti-vaping public service announcements (PSAs) with the goal of reducing their subsequent e-cigarette use.
41021237|NCT02376426|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.
41021238|NCT02376426|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
41021239|NCT00723801|DRUG|Atenolol|Atenolol 50mg PO QD
41021240|NCT00723801|DRUG|Losartan|Losartan 100mg PO QD
41353964|NCT05633290|DIAGNOSTIC_TEST|CRP|Acute phase inflammatory marker
41353965|NCT05633290|DIAGNOSTIC_TEST|IL1-B|Inflammatory biomarker
41353966|NCT05633290|DIAGNOSTIC_TEST|IL-6|Inflammatory Biomarker
41353967|NCT05633290|DIAGNOSTIC_TEST|IL-10|Inflammatory Biomarker
41353968|NCT05633290|DIAGNOSTIC_TEST|TNF-alpha|Inflammatory Biomarker
41353969|NCT02750436|DEVICE|Ultrasound guided|This group will be treated using an ultrasound imaging device
41353970|NCT02750436|DEVICE|Fluoroscopy guided|This group will be treated using a fluoroscopy imaging device
41353971|NCT00741741|DRUG|TMC278|
40834532|NCT00843544|BEHAVIORAL|Integrative Medicine|"Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:~1. Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.~2. Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice~3. Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date."
40834533|NCT03577392|DRUG|oxaliplatin + capecitabine (XELOX chemotherapy)|Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
41353972|NCT05818215|OTHER|NO intervention|NO intervention
40834534|NCT03577392|DRUG|rebombniant human endostatin|Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
41353973|NCT03123549|DEVICE|Simplify Disc|Simplify Disc at two levels of the cervical spine
40834535|NCT02583321|DEVICE|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
40834536|NCT02583321|DEVICE|Endotracheal tubes allowing SSD|"In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
40834537|NCT05280249|OTHER|both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air.
40834538|NCT02614482|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
40834539|NCT06384664|DEVICE|Atricure's crysoSPHERE probe|Cryoablation is a procedure that is used to freeze and burn away tissue cells via a device called a cryosphere which emits a freezing gas.
40834540|NCT06384664|PROCEDURE|Standard of Care|An intercostal nerve block involves injecting anesthetic medications into nerves around the thoracic incision to provide temporary longer term pain relief after surgery.
41021241|NCT04352933|DRUG|Hydroxychloroquine - Daily dosing|"Active HCQ:~Days 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (\~3 months),~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
41159930|NCT02238691|PROCEDURE|Mask ventilation with PEEP via a face mask device|"15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.~15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask."
41353974|NCT03137524|DEVICE|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
41353975|NCT03620500|BEHAVIORAL|Gross motor and developmental balance testing|Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).
41353976|NCT04755751|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with a no resistance warm up lasting 1 to 3 minutes and followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment and ranging from no resistance (20 Rounds Per Minute (RPM)/minute) 5 to 20 Watts/minute on ramps or by successive stages
41353977|NCT02478658|OTHER|exercise training|high-intensity resistance training
41353978|NCT04383691|DRUG|Lurasidone HCl|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
41353979|NCT04383691|DRUG|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
41494517|NCT00003920|RADIATION|yttrium Y 90 monoclonal antibody m170|
41494518|NCT04645966|BIOLOGICAL|MenABCWY|Neisseria meningitis groups A, B, C W, and Y vaccine
41021242|NCT04352933|DRUG|Hydroxychloroquine - Weekly Dosing|"Active HCQ:~Days 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months)"
41021243|NCT04352933|OTHER|Matched Placebo Hydroxychloroquine|"Matched placebo HCQ - daily dosing:~Days 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
41353980|NCT01872273|OTHER|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
41021244|NCT04048460|DEVICE|Delivery of hearing healthcare through eAudiology application|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
41021245|NCT00503841|DRUG|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
41353981|NCT05569473|PROCEDURE|TEST GROUP: VCMX + OFD, CONTROL GROUP : OFD ONLY|A full-thickness mucoperiosteal flap will be raised, no bone recontouring would be performed, Thorough debridement of the surgical site would be performed. For the test group, VCMX would be placed according to the dimensions of the intrabony defect after open flap debridement (OFD). For the control group, OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
41353982|NCT05926011|DEVICE|RGn600|RGn600 with a 10 Hz-pulsed wave mode light emission
41353983|NCT05926011|DEVICE|RGn600 Sham|RGn600 inactivated
41353984|NCT00642824|DRUG|Standard chemotherapy|As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
41159931|NCT03440788|DRUG|Brentuximab Vedotin|Brentuximab vedotin (BV) will be prescribed to patients in accordance with indication for treatment as second or subsequent line therapy after failure of at least one type of first-line therapy for patients with relapsed or refractory HL who are not candidates for ASCT, or for patients with relapse after ASCT within routine hematological practice. Dose, preparation, administration etc - as in Instruction for use (Prescribing information).
41353985|NCT00642824|DRUG|bevacizumab [Avastin]|15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
41353986|NCT01599611|PROCEDURE|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
41494519|NCT04645966|BIOLOGICAL|Bivalent rLP2086 (60-µg Dose)|Trumenba (half dose) - Meningococcal Group B vaccine
41494520|NCT04645966|BIOLOGICAL|Bivalent rLP2086 (120-µg Dose)|Trumenba - Meningococcal Group B vaccine
41494521|NCT04645966|BIOLOGICAL|Bexsero|Bexsero - Meningococcal Group B vaccine
41494522|NCT04645966|DRUG|Prophylactic Liquid Paracetamol (PLP)|PLP administration during primary vaccinations 1 and 2
41494523|NCT04645966|BIOLOGICAL|Nimenrix|Nimenrix - Meningococcal Group A, C, W and Y vaccine
41494524|NCT04645966|OTHER|Placebo|Normal Saline
41494525|NCT04645966|DRUG|Scheduled Liquid Paracetamol (SLP)|SLP administration after primary vaccinations 1 and 2.
41494526|NCT04645966|DRUG|Therapeutic Liquid Paracetamol (TLP)|TLP administration after primary vaccinations 1 and 2
41509157|NCT06240195|OTHER|data collection|Collection of data relating to the effectiveness of sacituzumab govitecan and evaluation in a real-world context and planned research of predictive biomarkers of efficacy/tolerability
41021246|NCT00503841|OTHER|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
41021247|NCT00503841|OTHER|laboratory biomarker analysis|Correlative studies
41021248|NCT00503841|PROCEDURE|biopsy|14 days prior to surgery
41021249|NCT00503841|PROCEDURE|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
41021250|NCT00503841|PROCEDURE|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
41021251|NCT06040697|DEVICE|Thermal Anisotropy|Usability assessment observation.
41159932|NCT00095017|DRUG|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
40834541|NCT02867774|BEHAVIORAL|Physical Activity|"8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.~The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.~The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine."
40834542|NCT05883254|DIAGNOSTIC_TEST|RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR|"Quantatative Real -Time PCR for quantification of PUM1;~* The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~* The method of total RNA extraction: TRIzol and TRIzol LS.~* The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~* cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels"
40834543|NCT06365138|BEHAVIORAL|Bahaviour at the time of an aortic aneurysm rupture|Questionnaire and patient interview, diary for day of rupture and the three previous days
40834544|NCT05857904|DEVICE|CT-FFR|CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.
41021252|NCT05377320|OTHER|Clinical Decision Aid|The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
41021253|NCT05377320|OTHER|Standard Care|Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
41021254|NCT04174677|DRUG|Inebilizumab|Infusion of Inebilizumab
41021255|NCT04174677|DRUG|VIB4920|Infusion of VIB4920
41021256|NCT04174677|DRUG|Inebilzumab+VIB4920|Infusion of Inebilizumab and VIB4920
41159933|NCT05154539|DIAGNOSTIC_TEST|Remote digital assessment|Remote digital assessment of test group participants
41353987|NCT04542395|BEHAVIORAL|Increasing Willingness and Uptake of COVID-19 Testing and Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges and increase willingness and uptake in COVID-19 testing and vaccination.
41353988|NCT04637035|OTHER|Supportive Oncology Care at Home|Intervention entailing remote monitoring of patients' symptoms, vital signs, and body weight with home-based care.
41353989|NCT04763824|BEHAVIORAL|Telementoring with Practice Facilitation|We are attempting to provide education and encourage practice change
41509158|NCT02229461|DRUG|Naproxen Sodium (Aleve, BAY117031)|Naproxen sodium 220 mg qd or bid
41509159|NCT02229461|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|ASA 81 mg qd
41509160|NCT03140787|DRUG|Nasal Spray of Lidocaine HCL|This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
41509161|NCT03140787|DRUG|Infiltration injection of Lidocaine HCL|This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
41509162|NCT00725257|OTHER|Mediterranean diet|The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.
41021257|NCT06572709|DIAGNOSTIC_TEST|Parasternal intercostal muscle thickness with ultrasonography|Ultrasonographic measurements were performed of the bilateral parasternal intercostal muscle thickness in the supine position in the stroke patient group. Ultrasonographic measurements were performed of dominant side parasternal intercostal muscle thickness in the supine position in healthy individuals group. Spirometry evaluation was performed in both groups.
41021258|NCT00053131|BIOLOGICAL|filgrastim|
41021259|NCT00053131|BIOLOGICAL|sargramostim|
41021260|NCT00053131|DRUG|cytarabine|
41021261|NCT00053131|DRUG|mitoxantrone hydrochloride|
41021262|NCT05075876|DRUG|SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)|Single application for 6 days
41021263|NCT05075876|DRUG|SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)|Single application for 6 days
41021264|NCT03176394|DEVICE|BLASTX Gel|Foley Catheter lubricated with BLASTX Gel
41021265|NCT03176394|DEVICE|McKesson Jelly|Foley Catheter lubricated with McKesson Jelly
41021266|NCT05298605|BEHAVIORAL|Faith in Action! Church-based Navigation Model|Cancer screening education and navigation by identified trained navigators in faith based settings + American Cancer Society Screening Guidelines pamphlet
41021267|NCT05298605|OTHER|Control|Presentation on healthy behaviors (physical activity, nutrition) + American Cancer Society Screening Guidelines pamphlet
41021268|NCT00399152|DRUG|Perifosine|Perifosine Oral Dose
41021269|NCT00399152|DRUG|Sunitinib Malate|Sunitinib oral dose
41021270|NCT03634761|BEHAVIORAL|Competency based model|Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
41021271|NCT03634761|BEHAVIORAL|Comprehensive program|Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
41159934|NCT05154539|DIAGNOSTIC_TEST|Conventional physical assessment|Conventional physical assessment of control group participants
41509163|NCT00725257|OTHER|Low-fat diet|The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
41509164|NCT03886298|PROCEDURE|radiofrequency splanchnic denervation|the authors will denervate the splanchnic nerves via radiofrequency
40834545|NCT05857904|DEVICE|QFR|Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.
40834546|NCT04103463|OTHER|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
40834547|NCT04103463|OTHER|Home exercise|Home exercise
40834548|NCT01329913|DRUG|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
40834549|NCT01329913|DRUG|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
40834550|NCT01329913|DRUG|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
40834551|NCT01329913|DRUG|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
40834552|NCT01329913|DRUG|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
40834553|NCT01329913|DRUG|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
40834554|NCT02679365|PROCEDURE|lower segment cesarean section and double lock closure of rectus sheath|
41021272|NCT05036642|DEVICE|Compliant Passive Arm Support|The device is a mechanical device that consists of two linkages, elastic bands, a commercial posture brace, and a hook-and-loop fastener. The design of the device, with several compliant elements, ensures that one device fits many without joint alignment concerns. No motors or other actuators add energy into the system, meaning that it is stable.
40834555|NCT02679365|PROCEDURE|lower segment cesarean section and continuous non-locking closure of rectus sheath|
40834556|NCT02955680|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
40834557|NCT02955680|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
41021273|NCT00485108|DRUG|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
41021274|NCT00485108|DRUG|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
40834558|NCT04785625|COMBINATION_PRODUCT|Bupivacaine Hydrochloride|INL-001 (bupivacaine hydrochloride) implant
41021275|NCT00485108|DRUG|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
41021276|NCT00271336|DRUG|Pentoxifylline|
41509165|NCT03886298|PROCEDURE|retrocrural celiac denervation|the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol
40834559|NCT04785625|COMBINATION_PRODUCT|Placebo collagen-matrix implant|Placebo collagen-matrix implant
40834560|NCT02482402|DRUG|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
40834561|NCT02482402|DRUG|Placebo|inhalation solution placebo
40834562|NCT01005212|DRUG|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
40834563|NCT02103374|DRUG|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
40834564|NCT02103374|DRUG|Placebo|1 capsule lactose during 48 weeks
40834565|NCT04827797|DEVICE|balls|Birth balls to exercise
40834566|NCT03233295|DRUG|Vitamin D3 B.O.N. Injection|cholecalciferol 200,000IU
40834567|NCT00048750|DRUG|Micafungin|IV
40834568|NCT00048750|DRUG|Placebo|IV
40834569|NCT04292457|DRUG|Propofol|Anesthesia is maintained with a continuous infusion of Propofol. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
40834570|NCT04292457|DRUG|Sevoflurane|Anesthesia is maintained with a continuous inhalation of Sevoflurane. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
40834571|NCT03829345|DRUG|Olaparib|Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.
40834572|NCT03657147|BEHAVIORAL|Educational Video and Question Prompt List|A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
40834573|NCT01897649|DIETARY_SUPPLEMENT|NUTRIOSE FB06|15g/day NUTRIOSE FB06
41159935|NCT02231814|DIETARY_SUPPLEMENT|Crohns Disease Exclusion Diet + PEN|"Patients will use the CDED for a 24 week period, coupled with 1000 ml of polymeric formula (1 Kcal/mL) for the first 6 weeks. For weeks 7 to 24 patients will use the CDED coupled with 600 ml formula and a calcium supplement. The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase."
41159936|NCT02231814|OTHER|Crohns Disease Exclusion Diet|Crohn's Disease Exclusion Diet alone with a calcium supplement during the study (0-24). The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
40834574|NCT01897649|DIETARY_SUPPLEMENT|GLUCIDEX 21|15g/day GLUCIDEX 21
40834575|NCT01151761|PROCEDURE|Stereotactic Body Radiotherapy|Standard of care
40834576|NCT01151761|DRUG|Gemcitabine|100 mg/m2, IV
40834577|NCT01151761|DRUG|Cisplatin|25 mg/m2, IV
40834578|NCT01151761|DRUG|Carboplatin|AUC 2, based on Calvert formula, IV
40834579|NCT01151761|DRUG|Capecitabine|1000 mg/m2, PO
41494527|NCT03880786|DEVICE|pudendal PNE test lead|All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
41494528|NCT00006460|DRUG|hyperbaric oxygen|
40834580|NCT01151761|DRUG|5FU|200 mg/m2
40834581|NCT01151761|PROCEDURE|Liver transplantation|
40834582|NCT05164146|DRUG|propofol|during the induction, remimazolam dose was controlled according to sedline (Psi target 40)
40834583|NCT05164146|DRUG|remimazolam|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
40834584|NCT02198794|DRUG|SD-809|SD-809 will be administered per dose and schedule specified in the arm.
40834585|NCT02198794|DRUG|Placebo|Placebo matching to SD-809 will be administered per schedule specified in the arm.
40834586|NCT03814434|PROCEDURE|Non-Surgical treatment|Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation
40834587|NCT03814434|PROCEDURE|Surgical Treatment|Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture
40834588|NCT01722656|DRUG|Aflibercept|
40834589|NCT01303302|DEVICE|Tantalus System|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
40834590|NCT01303302|DEVICE|TANTALUS system|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
40834591|NCT06387199|DRUG|Semaglutide with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
40834592|NCT06387199|DRUG|Placebo with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
40834593|NCT03081676|DRUG|Glimepiride 1Mg Tablet|Glimepiride
40834594|NCT03081676|DRUG|Glucagon-like Peptide-1|GLP-1 infusion
40834595|NCT03081676|DRUG|Glucose-Dependent Insulinotropic Polypeptide|GIP-infusion
40834596|NCT03081676|DRUG|Placebo Oral Tablet|Placebo
40834597|NCT03081676|DRUG|Placebo infusion|Placebo (saline)
40834598|NCT05479123|DRUG|Propranolol three times a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided TID Week 2: 1 mg/kg/day divided TID Week 3: 2 mg/kg/day divided TID. Patients will stay on this dosage until their 3 month follow up visit."
40834599|NCT05479123|DRUG|Propranolol twice a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided BID Week 2: 1 mg/kg/day divided BID Week 3: 2 mg/kg/day divided BID. Patients will stay on this dosage until their 3 month follow up visit."
40834600|NCT05479123|DRUG|Timolol|Patients with a small (\<2cm) isolated infantile hemangioma are prescribed timolol 0.5% ophthalmic drops, a topical beta-blocker(1 drop BID directly onto the hemangioma).
40834601|NCT03848767|DEVICE|AID System|AID System
40834602|NCT03848767|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
40834603|NCT03241004|OTHER|Sleep Mask|sleep mask applied for two separate 60-minute periods during anesthesia
40834604|NCT02137187|PROCEDURE|AV junction ablation|AV junction ablation
40834605|NCT02137187|DEVICE|CRT|Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
41494529|NCT00006460|RADIATION|radiation therapy|
40834606|NCT02137187|DRUG|Optimized drug therapy|Optimized drug therapy for heart failure and atrial fibrillation rate control
40834607|NCT02137187|DEVICE|ICD|Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
41494530|NCT02598687|DRUG|TH-302|TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
41494531|NCT02598687|OTHER|HX4 scan|HX 4 scan day 1 and day 8
40834608|NCT03156959|BEHAVIORAL|EMDR|The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
40834609|NCT03156959|BEHAVIORAL|CBT-Eb|"The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself."
40834610|NCT02544256|PROCEDURE|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
41494532|NCT02598687|DRUG|Carboplatin|2mg/ml/min
41494533|NCT02598687|DRUG|Paclitaxel|50 mg/m2
41494534|NCT02598687|RADIATION|Radiotherapy|23 x 1.8 Gy
41509166|NCT05682612|OTHER|outcome|hospital survivors and nonsurvivors
40834611|NCT03855800|DIAGNOSTIC_TEST|Blood, stool, pancreatic juice and cyst fluid collection|Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
40834612|NCT03855800|PROCEDURE|Pancreatic Surgery|Surgical resection of pancreatic cyst
40834613|NCT03855800|PROCEDURE|Endoscopy Exam|Clinically indicated endoscopic ultrasound
40834614|NCT02839239|DIETARY_SUPPLEMENT|Drops with lactobacilli and vitamin D3|Oil suspension with lactobacilli and vitamin D3
40834615|NCT02839239|DIETARY_SUPPLEMENT|Drops with vitamin D3|Oil suspension with vitamin D3
41353990|NCT01333865|DRUG|Memantine|"Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.~During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated."
41353991|NCT04367649|OTHER|Hall technique|"* Orthodontic separators will be used to create space for fitting the stainless crown, then removed after 3-5 days~* Occlusion will be measured assessing the patient's occlusal-vertical dimensions (OVD) using a modified version of van der Zee and van Amerongen method with a millimeter probe measuring the distance from the lowest point of the gingiva, around the lower canine on the vestibular side up to the point where the tip of the upper canine ends in order to assess the degree of overbite after mounting of the crown.~* The correct crown size will be selected. The crown should cover all the cusps and approaches the contact points, with a slight feeling of spring back. till reaching the gingival margin. Cementation will be done using glass ionomer cement"
41353992|NCT04367649|OTHER|Atraumatic restorative treatment|Caries removal using excavators, then restoration using glass ionomer (GIC)
40834616|NCT05505188|OTHER|Questionnaire|"Self-questionnaires are completed by the patient at the time of this consultation:~* Neuropathic pain: NPSI in screening~* Anxiety/depression: HADS in screening~* Quality of life: EORTC (QLQC30 and H\&N43)~* Fatigue: MFI-20 hese self-questionnaires will be retrieved by the Clinical Research Associate (CRA) for verification.~Depending on the result of the NPSI questionnaire can be completed to better characterize neuropathic pain.~Depending on the result of the HADS, the MADRS questionnaire can be completed to quantify the degree of depression.~Individuals diagnosed with neuropathic pain or other depressive symptoms during the 6-month inclusion period will be referred to and managed by specialized practitioners. This assistance will be indicated in follow-up report"
40834617|NCT05231447|OTHER|Environmental survey|"Exposure to environmental factors, drugs or individual toxicity during the periconceptional period and at the beginning of the pregnancy will be investigated by means of a questionnaire administered to the parents. This questionnaire, drawn up by the Aquitaine Reproduction Enfance Maternité et Impact Santé-environnement (ARTEMIS) centre and completed by both members of the couple, will constitute an initial assessment that will make it possible to collect environmental exposures for the parents of cases identified by the register."
40834618|NCT02624336|OTHER|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
40834619|NCT02624336|OTHER|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
40834620|NCT02624336|OTHER|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
40834621|NCT05453695|DRUG|Intravenous DNase I|Dose-escalating intravenous infusion of DNase I
40834622|NCT02610244|OTHER|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
40834623|NCT00531583|DRUG|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
40834624|NCT05142345|OTHER|CONTINUUM Intervention|The intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consists of a video visit conducted by an oncology nurse practitioner within three business days of hospital discharge, to: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.
40834625|NCT05142345|OTHER|Usual Care|Patients assigned to the usual care group will have their post-discharge follow-up scheduled per hospital, outpatient oncology team, and patient preference.
40834626|NCT00384982|PROCEDURE|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
40834627|NCT05818514|DRUG|[11C]AZ14132516|Injection of radioligand for PET examinations
40834628|NCT05932264|DRUG|Apatinib + Fluzoparib|Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid
40834629|NCT05932264|DRUG|Apatinib + Fluzoparib + Adebrelimab|Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w\]
40834630|NCT04835168|DRUG|BT-11 low|Oral
40834631|NCT04835168|DRUG|BT-11 high|Oral
40834632|NCT04835168|DRUG|Placebo|Oral
40834633|NCT03395730|DRUG|Intraumbilical vein injection oxytocin|intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
40834634|NCT03395730|PROCEDURE|placental cord drainage|placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
40834635|NCT03395730|PROCEDURE|Expectant managment of 3rd stage of labour|Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
40834636|NCT01790555|DRUG|Namisol|
40834637|NCT01790555|DRUG|Diazepam/placebo|
40834638|NCT04015869|DRUG|Allopregnanolone|neurosteroid
40834639|NCT04015869|DRUG|Placebos|placebo
40834640|NCT00273845|BEHAVIORAL|Motivational interviewing|One session
40834641|NCT00273845|BEHAVIORAL|Strengths-Based Case Management|5 sessions
40834642|NCT00636012|PROCEDURE|verum acupuncture|acupuncture at St36 and Pe6
40834643|NCT00636012|PROCEDURE|sham acupuncture|superficial needling at sham points
40834644|NCT02077543|DEVICE|Brain Tissue Imprint - Medical Device (ProTool)|genomic, transcriptomic and proteomic studies.
40834645|NCT01528748|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
40834646|NCT06025734|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS) treatment|Spina Bifida pediatric patients with neurogenic bladder will be in Transcutaneous Tibial Nerve Stimulation (TTNS) treatment. Patient will complete 6 weeks of 30 minute treatment sessions (these can be done at home after the first teaching session)
40834647|NCT02575118|DEVICE|Restoration of dental caries with dental composite|
40834648|NCT02333890|DRUG|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
40834649|NCT02333890|DRUG|Placebo|
40834650|NCT06508879|COMBINATION_PRODUCT|Aquacel Ag Surgical®|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
41509167|NCT05682612|OTHER|Subtype of COVID-19|Different subtype of COVID-19
41353993|NCT04367649|OTHER|Conventional restorative treatment|Complete caries removal using high-speed hand piece, and an excavator to clear carious dentin from the pulpal wall. Then, stainless steel crown preparation, selection of the proper size with the smallest crown size that completely covers the preparation chosen. The correct occlusogingival crown length will be established. Cementation will be done using glass ionomer cement
41494535|NCT02598687|PROCEDURE|surgery|minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
41494536|NCT01046786|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
41494537|NCT01046786|DRUG|Methylprednisolone|30 mg/kg methylprednisolone
40834651|NCT06508879|OTHER|Standard Care (sterile gauze and adhesive tape)|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
40834652|NCT02406352|DEVICE|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change."
40834653|NCT04625868|OTHER|Educational video|Patients will watch a preoperative educational video on proper opioid use and disposal.
40834654|NCT00435526|BIOLOGICAL|anti-CFA/I bovine IgG, and anti-CfaE bovine IgG|
40834655|NCT01549795|PROCEDURE|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
40834656|NCT01549795|RADIATION|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
40834657|NCT01549795|RADIATION|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
40834658|NCT01549795|DRUG|Capecitabine|Capecitabine - administered till liver transplantation
40834659|NCT01549795|PROCEDURE|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
41494538|NCT01046786|DRUG|Lithium|oral lithium, titrated to maintain 0.6-1.0 mM serum level
41494539|NCT05259995|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
41494540|NCT05396235|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
41494541|NCT05396235|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
40834660|NCT00775112|DEVICE|pillow|use of pillow for lumbar punctures
40834661|NCT05348746|OTHER|Advanced Analysis of Polymorphism|Assessment of Plasmodium falciparum drug resistance. Target P. falciparum drug resistance genes: Pfk13 propeller, Pfdhfr and Pfdhps. The polymorphisms analysis of the propeller domain of the Pfk13 gene will be performed by PCR amplifications and subsequent sequencing. Analysis of Pfdhfr gene at codons 51, 59, 108 and Pfdhps gene at codon positions 436, 437, 540, 581, 613 will be done by means of amplifications and subsequent Sanger sequencing. Molecular studies will be performed only for research purposes and will have no impact on the clinical management of study patients.
41353994|NCT01902927|OTHER|Attentional distraction using IAPS protocol (standardized images)|Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
41353995|NCT02260791|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
41353996|NCT02260791|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
41353997|NCT03086044|DRUG|Sofosbuvir/velpatasvir|2 weeks of treatment beginning on the day of transplant
41494542|NCT06232798|OTHER|a dual energy catheter (RF and PFA) or PFA catheter only will be to treat PeAF,Cardiac Pulsed Electric Field Ablation Catheter|This study will be used two catheters, the contact force sensing catheter able to deliver both RF and PFA energy, this catheter provides both the radiofrequency (RF) energy and pulsed field ablation (PFA) energy to the catheter through the toggling of the two energy sources on the generator monitor. Another catheter is PFA catheter only.
41494543|NCT06232798|OTHER|catheter ablation|catheter ablation
41353998|NCT03086044|OTHER|Monitoring|Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
41494544|NCT02249130|DRUG|Tipranavir (TPV)|
41494545|NCT02249130|DRUG|Ritonavir (RTV)|
40834662|NCT05928832|OTHER|Follow-up by a case-manager and access to the internet platform|Patients in the intervention group receive an information letter on their discharge presenting the follow-up from which they benefit:call from the case-manager and access to the internet platform. The case-manager meets the patient and/or informal caregiver on the day of discharge from hospital. He recontacts the patient and/or informal caregiver within 7 days after returning home. A follow-up is offered to patients and caregivers following their return home, according to the objectives defined during the initial interview. The total duration of the support is 6 months maximum including at least 4 contacts with the case-manager,but this is refined and adapted with the patient, according to needs. Similarly, the frequency and methods (face-to-face or remote) of contact varies according to the needs of the patients and the stage of support, and is defined by the case-manager and patient. Patients and/or informal caregivers is also able to contact the case-manager 'on request'.
41353999|NCT04449614|PROCEDURE|Thoracoscopic CPAM resection|Surgical removal of lung lesion
41159937|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Adults Phase I|A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns \~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
41354000|NCT03642327|BEHAVIORAL|Experimental: Maintenance of Certification (MOC)|MOC training will lead to more positive attitudes, comfort level and competence in addressing risk factors for Child Maltreatment.
41354001|NCT03642327|OTHER|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
41354002|NCT04627233|DRUG|Human Ezrin Peptide 1 (HEP1)|"HEP-1 will be administrated s.c. into the lower abdominal wall~1. induction dosage: 2 mg Ezrin in 2 ml physiological saline applied s.c.,one injection every 12 hours until symptoms disappear followed by~2. maintenance dosage: 0.2 mg Ezrin in 1 ml physiological saline solution s.c 1/day for 10 days"
41354003|NCT04627233|DRUG|Placebo|placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
41354004|NCT06410729|OTHER|Observational study, no intervention|
41354005|NCT06127394|PROCEDURE|Sacral ESP Block|Sacral ESPB median approach, 40 ml %0,25 Bupivacaine
41354006|NCT06127394|PROCEDURE|Pudendal Block|Bilateral pudendal block, 10 ml %0,25 bupivacaine
41354007|NCT05696652|BEHAVIORAL|Acute exercise|40 minute moderate intensity exercise bout on a treadmill. This is similar to a single session of cardiac rehabilitation.
41354008|NCT05696652|BEHAVIORAL|Cardiac rehabilitation|12 week program of standard clinical cardiac rehabilitation for patients with symptomatic heart failure. Patients undergo 3-times weekly sessions of monitored exercise for 12 weeks. This is the same cardiac rehabilitation patients would get as part of clinical care.
41354009|NCT04316780|OTHER|Retrospective observational study- no intervention to occur.|Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.
41354010|NCT02853318|BIOLOGICAL|Bevacizumab|Given IV
41354011|NCT02853318|DRUG|Cyclophosphamide|Given PO
41354012|NCT02853318|OTHER|Laboratory Biomarker Analysis|Correlative studies
41354013|NCT02853318|BIOLOGICAL|Pembrolizumab|Given IV
41354014|NCT01854957|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
41354015|NCT01351415|DRUG|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
41354016|NCT01351415|DRUG|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m\^2) on Day 1 every 21 days.
41354017|NCT01351415|DRUG|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
41354018|NCT01351415|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 IV over 10 minutes on Day 1 every 21 days.
41354019|NCT02532816|DIETARY_SUPPLEMENT|Nutrient dense complementary foods|"Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements"
41354020|NCT02976194|DRUG|ranibizumab|Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
41354021|NCT03444831|DRUG|Buspirone|Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.
41354022|NCT03444831|DRUG|Placebo Oral Tablet|Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
41354023|NCT02009501|DEVICE|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
41354024|NCT02009501|DEVICE|VAC Ulta Therapy|VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
41354025|NCT03315416|OTHER|Speech Sound Assessment|Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
41494546|NCT02249130|DRUG|Delavirdine (DLV)|
41494547|NCT02249130|DRUG|Zidovudine (ZDV)|
41494548|NCT02249130|DRUG|Lamivudine (3TC)|
41494549|NCT02249130|DRUG|Stavudine (d4T)|
40834663|NCT04234087|OTHER|Additional balance and resistance training|Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
41494550|NCT03521466|BEHAVIORAL|Smoking Cessation Counseling|Trained medical students will visit patients inpatient while hospitalized and provide smoking cessation counseling and recommend Nicotine Replacement Therapy. They will continue to follow these patients for 2 months after discharge and provide telephone-based counseling.
41494551|NCT04594707|DRUG|PRM-151 (Zinpentraxin Alfa)|"Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.~Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo."
40834664|NCT03518268|DRUG|Vivomixx|The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
40834665|NCT03518268|DRUG|Placebo|The intervention consists of 2 sachets a day of placebo, for 6 months
41494552|NCT00777036|DRUG|Dasatinib|
40834666|NCT00567918|DRUG|FK506|Ophthalmic suspension
40834667|NCT03964753|DRUG|Nab-paclitaxel and Cisplatin|Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
40834668|NCT03964753|PROCEDURE|surgery|surgery
40834669|NCT01724424|DRUG|Melatonin|20 mg oral single dose
40834670|NCT01724424|DRUG|Melatonin|30 mg oral single dose
40834671|NCT01724424|DRUG|Melatonin|50mg oral single dose
40834672|NCT01724424|DRUG|Melatonin|100mg oral single dose
40834673|NCT04839848|DEVICE|Lichtenstein mesh repair|A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures
40834674|NCT03371953|DRUG|Vecuronium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
40834675|NCT03371953|DRUG|Atracurium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
40834676|NCT03371953|DRUG|Vecuronium + Atracurium|A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
41021277|NCT03765957|BIOLOGICAL|Mesenchymal Stem Cells|After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.
41494553|NCT02148289|DIETARY_SUPPLEMENT|Nitrate rich beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
41494554|NCT02148289|DIETARY_SUPPLEMENT|Nitrate free beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
41494555|NCT00620555|DRUG|gabapentin|Orally administered gabapentin
41494556|NCT04784754|DRUG|Melatonin|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
40834677|NCT04284813|BEHAVIORAL|CRAFT-FT|CRAFT-FT will be delivered via telemedicine. Topics include building motivation, self-care, communication, understanding patterns of behavior, positive reinforcement, and negative consequences. The intervention will be tailored to families of individuals experiencing psychosis and substance use who are enrolled in first episode psychosis outpatient services. Participants will be asked to completed assessments at pre-treatment, mid-treatment (approximately week 3), post-treatment, and a follow-up assessment approximately 3 month post-treatment.
40834678|NCT00203021|DRUG|Glatiramer acetate|Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.
40834679|NCT03189654|DEVICE|Non-invasive ventilation|Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
40834680|NCT00290875|BEHAVIORAL|Use of Xrays for diagnosis|
40834681|NCT02986932|DEVICE|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
40834682|NCT01760811|DRUG|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
41021278|NCT03160430|DRUG|apabetalone|RVX000222 oral (apabetalone), 100 mg capsule
41021279|NCT03160430|DRUG|Placebos|matching placebo capsule
40834683|NCT02611141|PROCEDURE|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|"To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack \& Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~1. Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~2. If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used."
40834684|NCT06406803|BEHAVIORAL|Dietary energy restriction|Patients enrolled in the dietary energy restriction group will reach an energy deficit of 40% only through reduced dietary intake.
40834685|NCT06406803|BEHAVIORAL|Daily exercise|Patients in the daily exercise group will reach an energy deficit of 40% through reduced dietary intake and increased physical activity (exercise).
40834686|NCT02916225|BEHAVIORAL|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
40834687|NCT02916225|BEHAVIORAL|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
41021280|NCT01455883|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
41021281|NCT01455883|DRUG|glimepiride|oral glimepiride does-escalated,if tolerated, to 8 mg/day
41021282|NCT05826821|DRUG|Pirfenidone|Intervention drug
41354026|NCT05569915|BEHAVIORAL|Trauma Expressive Writing|Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.
41021283|NCT00013312|PROCEDURE|Determine colonic tone|
41021284|NCT00861341|DRUG|Aspirin|81 mg
41354027|NCT05569915|BEHAVIORAL|Stigma Expressive Writing|Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.
41354028|NCT05569915|BEHAVIORAL|Control|Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.
41494557|NCT04784754|DRUG|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
41021285|NCT00861341|DRUG|Pioglitazone|30mg Pioglitazone x1
41354029|NCT00598884|BEHAVIORAL|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
41354030|NCT00680966|BEHAVIORAL|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
41354031|NCT00219310|DRUG|Famciclovir|
41354032|NCT00129376|DRUG|Doxorubicin|
41354033|NCT00129376|DRUG|Cyclophosphamide|
41354034|NCT00129376|DRUG|Docetaxel|
41354035|NCT02181335|DRUG|Respimat® Budesonide low dose|
41354036|NCT02181335|DRUG|Respimat® Budesonide high dose|
41354037|NCT02181335|DRUG|Turbohaler® Budesonide|
41354038|NCT02181335|DRUG|Placebo|
41494558|NCT01248013|BEHAVIORAL|gut focused hypnotherapy|7 session hypnotherapy protocol designed for irritable bowel syndrome
41494559|NCT04287335|DIAGNOSTIC_TEST|Multitarget stool FIT-DNA test - ColoClear|Multitarget stool FIT-DNA test
41354039|NCT05075434|OTHER|Conventional Treatment|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
41354040|NCT05075434|OTHER|Diacutaneous fibrolysis|"15 minutes of the treatment technique. The FD intervention will be carried out with the same duration and protocol for all participants.~The intervention protocol will be: Start with the point of maximum tension between the two muscle bellies of the calf and hamstring (reverse hook). Then work on the peroneus longus lateralis and soleus. Then the external calf muscle belly and soleus and the internal calf muscle belly and soleus. Then work on the tendon of the flexor hallucis proprio of the big toe and the inner edge of the Achilles tendon and peroneus longus. Then treatment of the peroneus longus with the peroneus brevis. Scraping of the insertion of the Achilles tendon, hooking of the internal and external part of the plantar fascia. Finally, longitudinal friction of the plantar fascia."
41354041|NCT00231972|BEHAVIORAL|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
41354042|NCT00231972|BEHAVIORAL|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
41354043|NCT00498927|DRUG|temozolomide|
41354044|NCT00498927|GENETIC|protein expression analysis|
41494560|NCT04287335|DIAGNOSTIC_TEST|FIT|fecal immunochemical test
41494561|NCT04287335|PROCEDURE|Colonoscopy|diagnostic colonoscopy
41494562|NCT04471974|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
41494563|NCT04471974|DRUG|Enzalutamide|Given PO
41354045|NCT00498927|GENETIC|reverse transcriptase-polymerase chain reaction|
41354046|NCT00498927|OTHER|diagnostic laboratory biomarker analysis|
41354047|NCT00498927|OTHER|immunoenzyme technique|
41354048|NCT04554394|DEVICE|CellFX Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
41354049|NCT01944254|PROCEDURE|Cardiac output measurement at random to respiration|Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)
41354050|NCT01944254|PROCEDURE|Cardiac output measurement synchronised at start of expiration|Cardiac output measurement obtained by PAC TD
41494564|NCT04471974|BIOLOGICAL|Pembrolizumab|Given IV
41494565|NCT00690976|BEHAVIORAL|Proyecto SOL|Group intervention
41494566|NCT00690976|BEHAVIORAL|HCT|Offer of HIV counseling and testing
41494567|NCT05231330|DRUG|silvernanoparticles|silvernanoparticles in fluoride varnish
41494568|NCT05231330|DRUG|SDF|silver diamine fluoride
41494569|NCT04504305|OTHER|NeuropAWAY|2 capsules thrice daily to be taken half an hour prior to meal.
41494570|NCT04504305|OTHER|Microcystalline cellulose|2 capsules thrice daily to be taken half an hour prior to meal.
40834688|NCT05579873|PROCEDURE|Clavicle plating|VariAx 2.0mm + 2.4 or 2.7mm vs any other single plate
41494571|NCT02857751|BEHAVIORAL|Surf therapy|The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
41354051|NCT01944254|PROCEDURE|Cardiac output measurement timed to instructed exhalation|Cardiac output measurement obtained by PAC TD
41354052|NCT00158275|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
41354053|NCT00158275|DRUG|Antidepressants|Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
41354054|NCT00158275|BEHAVIORAL|Problem solving therapy|Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
41354055|NCT05753124|OTHER|Observational|This is an observational study
41354056|NCT02289144|DRUG|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
41354057|NCT06439342|DRUG|Maribavir|Maribavir tablets
41354058|NCT06250712|DEVICE|Continous ECG Patch|Using a continuous patch ECG for 1 week during 1 month
41494572|NCT04101500|DRUG|Compound Ipratropium Bromide Solution(C1) for Inhalation|The patient's condition and basic condition were the same in the experimental group and the control group.
41494573|NCT04101500|DRUG|Compound Sodium Chlolate and Aminophylline Tablets(C2)|Applied only to the experimental group.
40834689|NCT00504140|DRUG|Etoposide|100 mg/m\^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
40834690|NCT00504140|DRUG|Interferon Alpha|5x10\^6 mu/m\^2 Subcutaneously Daily for 5 Days
41354059|NCT06250712|DEVICE|Intermittent handheld ECG|Using a handheld ECG twice daily and when symptoms are present during 1 month
41354060|NCT02670187|BIOLOGICAL|GLS-5300|
41354061|NCT00229242|DRUG|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
41354062|NCT00293319|BIOLOGICAL|filgrastim|
41354063|NCT00293319|RADIATION|iobenguane I 131|
41354064|NCT00901394|DRUG|B12-Folic Acid, nitrous oxide|"IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline."
40834691|NCT02425800|OTHER|Cytology Specimen Collection Procedure|Undergo collection of tissue samples
40834692|NCT02425800|OTHER|Laboratory Biomarker Analysis|Correlative studies
40834693|NCT01440517|DRUG|Tc99m-Maraciclatide|Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
40834694|NCT03463668|DEVICE|uncovered metal duodenal prosthesis|Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
40834695|NCT04911491|DEVICE|IMST|Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.
41354065|NCT00901394|DRUG|Nitrous oxide (NO) and placebo|60% nitrous oxide anesthesia plus saline
41354066|NCT00901394|OTHER|Placebo|Saline
41354067|NCT00901394|OTHER|oxygen nitrogen|60% air and oxygen mix.
41354068|NCT00243490|PROCEDURE|Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M|
41354069|NCT04615416|BEHAVIORAL|Emotion Regulation Training via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
41354070|NCT01279954|DRUG|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
41354071|NCT00439699|DRUG|Memantine|Mematine administration
40834696|NCT04911491|DEVICE|Sham Training|Repeated inhalations against a low resistance will be performed using a handheld device.
40834697|NCT06226168|OTHER|exercise and environmental conditions|Participants will perform endurance-strength training for 4 weeks in a variety of environmental conditions. Somatic indices and quantitative indicators of bone mass (bone mineral density) will be measured both before and after the training period. Before the first training day and the day after the last training day, blood will be drawn for biochemical analysis.
41354072|NCT05617872|DRUG|Vinegar 20ml|20ml vinegar infused into duodenum and suction for 5 minutes via EUS
41354073|NCT05617872|DRUG|Saline|20ml saline infused into duodenum and suction for 5 minutes via EUS
41494574|NCT04101500|DRUG|Placebo Tablets|Applied only to the control group.
41354074|NCT05617872|DRUG|Vinegar 40ml|40ml vinegar infused into duodenum and suction for 5 minutes via EUS
41354075|NCT05617872|DRUG|Vinegar 20ml, 3 phases|20ml vinegar infused into duodenum and pancreatic juice collected via EUS suction during the first 5 minutes, 5-10 minutes, and 10-15 minutes, separately.
41354076|NCT00536458|PROCEDURE|radiotherapy|mini chep+ radiotherapy
40834698|NCT06226168|OTHER|exercise and environmental conditions|Passive exposure to normobaric hypoxia conditions. No training intervention. There will be a measurement of selected somatic indices and a quantitative measurement of bone mass indices (bone mineral density). A blood draw for biochemical analysis will be performed.
40834699|NCT05373693|DEVICE|Single vision lens|Wear single vision lens
40834700|NCT05373693|DEVICE|+2D PDL|Wear Peripheral defocus lense with +2D
41354077|NCT00536458|DRUG|MINI CHEP|chemotherapy minichep 6 courses
41354078|NCT03810261|DIETARY_SUPPLEMENT|Oil-based vitamin D|Participants will receive oil-based VALENS vitamin D, 1000 IU/day for 8 weeks.
41494575|NCT02513511|PROCEDURE|laryngoscopy under hypnosis|patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
40834701|NCT05373693|DEVICE|+3D PDL|Wear Peripheral defocus lense with +3D
41494576|NCT02933268|DIETARY_SUPPLEMENT|High water intake|High water intake aimed at achieving an urine osmolality \< 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
40834702|NCT05373693|DEVICE|+4D PDL|Wear Peripheral defocus lense with +4D
41021286|NCT05101187|DRUG|Olorofim|Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
41354079|NCT03810261|DIETARY_SUPPLEMENT|Water-based vitamin D|Participants will receive water-based VALENS vitamin D, 1000 IU/day for 8 weeks.
41354080|NCT03810261|DIETARY_SUPPLEMENT|Vitamin D capsules|Participants will receive vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks.
41354081|NCT05890131|OTHER|Digital letter|A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
41354082|NCT05183594|DIETARY_SUPPLEMENT|TSupport (a Traditional Chinese Medicine)|TSupport is made up of 11 Chinese medicinal herbs.
41354083|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
40834703|NCT05400629|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
40834704|NCT02074072|DEVICE|15 degree left-lateral tilt wedges|The wedges are made of aluminium
41354084|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
41494577|NCT02933268|OTHER|Ad libitum water intake|Water intake guided by thirst
41494578|NCT06034002|DRUG|INCA033989|INCA033989 will be administered at protocol defined dose.
41509168|NCT06400030|PROCEDURE|Root canal treatment with AH Plus sealer|- AH Plus sealer Group: the base and accelerator of AH Plus Sealer was mixed, then the walls of the canal were coated with the AH Plus sealer using K-File, then lateral condensation was performed through a number of gutta-percha cones.
40834705|NCT02074072|DEVICE|30 degree left-lateral tilt wedges|The wedges are made of aluminium
41021287|NCT05101187|DRUG|AmBisome®|Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
41021288|NCT04255862|DRUG|Bimekizumab|Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
41354085|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
41354086|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
41354087|NCT01001884|OTHER|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
41354088|NCT03598140|DRUG|Sildenafil Citrate|Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
41354089|NCT03598140|DRUG|Placebo oral capsule|Placebo once (Group 1) or daily for 2 weeks (Group 2)
41354090|NCT03013335|DRUG|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
41354091|NCT01807676|DEVICE|ET View Double Lumen Tube|
41021289|NCT06463847|DRUG|UC-MSCs|"In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials."
40834706|NCT04595162|BIOLOGICAL|GC019F|GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.
40834707|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of normal protein liquid diet supplementation|group 1 (control group) who will get a hospital formula of normal protein liquid diet supplementation (40 grams per 1000 mL)
40834708|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of high protein liquid food supplementation|group 2 (intervention group) will get a hospital formula of high protein liquid food supplementation (60 grams per 1000 mL) as much as 2 bottles (each bottle contains 200 mL)
41021290|NCT02155439|DRUG|5-fluorouracil|antimitotic drug
41021291|NCT02155439|DRUG|Triamcinolone|
41021292|NCT05850533|BEHAVIORAL|Virtual Tai Chi Easy|Unique to other mind-body therapies, Tai Chi Easy (TCE) is multi-component mind-body therapy including: 1) Gentle movement, 2) Breath practice, 3) Self-massage, and 4) Meditation.
41021293|NCT03886038|BIOLOGICAL|Shingrix|immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
41021294|NCT04989816|DRUG|Trastuzumab Deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
41021295|NCT05153018|OTHER|Blood collection|a 4-mL blood sample collected in a dry tube
41354092|NCT01807676|DEVICE|conventional Double Lumen Tube|
41354093|NCT03094481|PROCEDURE|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
41354094|NCT03094481|PROCEDURE|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
41354095|NCT03094481|PROCEDURE|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
41354096|NCT03094481|DRUG|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
41354097|NCT02397980|BEHAVIORAL|Behavioral intervention|"* What the dementia is~* How to deal with behavioral problems in patients with dementia~* How to manage caregiver's stress~* How to care dementic patients as well as caregivers themselves"
41354098|NCT03687931|DRUG|Dexamethasone|Drop
41354099|NCT02700932|DEVICE|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
41354100|NCT05258565|DRUG|IV tPA (Activase)|Any patients eligible came with acute ischemic stroke with or without COVID-19 infection within the time window for thrombolytic therapy (within 4 hours of onset)
41354101|NCT01295632|DRUG|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
41354102|NCT01295632|DRUG|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
41354103|NCT01295632|DRUG|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
41354104|NCT02655315|DRUG|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
40834709|NCT00130923|DRUG|Risperidone Long Acting|Dose 25.00, 37.50 or 50.00 mg q two weeks
40834710|NCT00130923|DRUG|oral risperidone|0.50-6.00 mg oral risperidone daily
40834711|NCT05832736|PROCEDURE|Robotic hemi-prostatectomy with urethral preservation|Robotic hemi-prostatectomy with urethral preservation
40834712|NCT02574741|BEHAVIORAL|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
40834713|NCT02574741|DRUG|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
41354105|NCT02655315|DRUG|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
41354106|NCT04630561|BEHAVIORAL|Postural Intervention Program|Dynamic warmup program designed to target several areas of physical and mental wellbeing.
41354107|NCT04338542|GENETIC|Tumor biobsies analysis|Analysis on archived tumor biopsies
41354108|NCT05696613|DRUG|SNP-ACTH (1-39) Gel|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
41354109|NCT05696613|DRUG|Rituximab|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
41354110|NCT00519415|OTHER|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
41354111|NCT00519415|OTHER|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
41021296|NCT04162704|DEVICE|EpiCheck|If the EpiCheck test is positive at the time of inclusion, the test is repeated prior to the fourth and sixth instillation with Mitomycin as well as prior to the subsequent two cystoscopies. If the EpiCheck test is negative at the time of inclusion, no further tests will be performed.
41354112|NCT05376241|BEHAVIORAL|Decision aid|Mammography screening decision aid for women in their 40s with information about screening guidelines, breast cancer mortality reduction, false positives, overdiagnosis, and a personal breast cancer risk estimate.
41354113|NCT05729165|DEVICE|Novafon® Pro|Local vibration therapy. The target muscles were: the orbicularis muscles of the upper and lower lips, the masticatory muscles (masseter, temporalis, pterygoidis) and lingual muscles.
41354114|NCT05729165|OTHER|Conventional Therapy|maneuvers were performed for passive extra-oral and intra-oral thermal stimulation, passive extra-oral and intra-oral tactile stimulation, and elicitation of active movements of the bucco-lingual and pharyngo-laryngeal muscles.
41021297|NCT03398993|DRUG|Clomiphene Citrate|50 mg twice daily from3rd day of cycle till 7th day of cycle
41354115|NCT01930396|DRUG|Tinzaparin|
41354116|NCT01930396|DRUG|Unfractionated Heparin|
41354117|NCT01930396|DRUG|Placebo (for Tinzaparin)|0.9% Normal Saline
41354118|NCT01930396|DRUG|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
41354119|NCT04084873|BEHAVIORAL|PBrE|PbRE is a word reading task implementing through an App developed for smartphones. The patient will choose emotional positive and negative words related to personal and clinical characteristics.
41354120|NCT04084873|BEHAVIORAL|PBrE-Control|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
40834714|NCT02574741|DRUG|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
40834715|NCT01650714|OTHER|Full thickness gastric biopsy|
40834716|NCT01650714|PROCEDURE|Full thickness gastric biopsy|
40834717|NCT02266875|DRUG|hypertonic saline|
40834718|NCT02266875|DRUG|standard saline|
40834719|NCT04966000|BEHAVIORAL|Prism Adaptation Therapy|Participants wear goggles with built-in prisms (a 20-diopter lens) that shift the visual scene to the right. While wearing the googles they reach to and cross out 60 lines/circles, requiring them to learn to reach more leftward than the visual targets appear. Participants can only see the end of their movements.
40834720|NCT03691779|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet orally once daily in the morning.
40834721|NCT03691779|DRUG|IVA|IVA tablet orally once daily in the evening.
40834722|NCT05207163|BEHAVIORAL|Continuing medical education|Education section about knowledge of transmissions, severity of viral hepatitis B-C and update treatment strategy of the HBV-HCV
40834723|NCT05840692|DRUG|Escitalopram 20 mg|Antidepressant
40834724|NCT05840692|DRUG|Placebo|
40834725|NCT03675516|OTHER|No specific intervention|Usual care
41021298|NCT03398993|DRUG|Human chorionic gonadotropin|75 IU dail;y from 6th day of cycle till 8th of cycle once daily
41354121|NCT04084873|BEHAVIORAL|Control|Participants do not receive the intervention.
41354122|NCT03927703|DRUG|SB206 12%|Topically once daily
41354123|NCT03927703|DRUG|Placebo|Topically once daily
41354124|NCT01134328|DRUG|AC-150 Combo|1 drop in each eye for up to 14 days
41354125|NCT01134328|DRUG|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
41354126|NCT01134328|DRUG|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
41354127|NCT01134328|DRUG|Vehicle|1 drop in each eye once per day for up to 14 days
41354128|NCT06204133|OTHER|Artificial intelligence model building|Using non-image medical data of cervical lesions and clinical pathology results in different medical institutions, machine learning is adopted to establish multiple multi-modal cervical cancer intelligent screening prediction models. This method was used to analyze the prediction performance of the multi-modal cervical cancer intelligent screening prediction and risk triage model, and to evaluate and optimize the self-learning ability of the established multi-modal cervical cancer intelligent screening prediction model.
41354129|NCT00582764|OTHER|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
41494579|NCT06483347|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
41494580|NCT06223243|OTHER|Stingless bee honey mouthrinse|Three bottles of 90ml of stingless bee honey of 20% concentration was given to each subject. This mouthrinse preparation was instructed for subjects to be taken 30ml each, thrice daily for three days.
41494581|NCT06223243|OTHER|normal saline mouthrinse|Subjects were instructed to rinse with 30ml of normal saline (0.9% concentration) thrice daily for three days.
41494582|NCT06223243|OTHER|chlorhexidine mouthrinse|Subjects were instructed to rinse with 30ml of chlorhexidine mouthrinse thrice daily for three days.
41494583|NCT00849186|DRUG|sunitinib malate|oral
41494584|NCT00849186|PROCEDURE|neoadjuvant therapy|IV
41494585|NCT00849186|PROCEDURE|therapeutic conventional surgery|Surgery
41494586|NCT04122066|DRUG|sofosbuvir \daclatsvir|study the effect of the new oral antihepatitis C drugs on the respiratory system
41494587|NCT05379049|BIOLOGICAL|Infliximab: Adalimumab; Etanercept;|Therapeutic drug monitoring, evaluation of clinical outcomes and laboratory analysis of biomarkers
41494588|NCT03476733|OTHER|Detection of drug related problem in inpatient|Detection of drug related problem in inpatient
41494589|NCT05029830|COMBINATION_PRODUCT|investigations like MRI..|• Multiple Sclerosis Quality of Life-54 (MSQOL-54) Can be considered as the most known disease-specific instrument for the evaluation of quality of life in patients with multiple sclerosis (MS). It was developed to combine generic quality of life aspects of the SF-36 with MS-targeted dimensions and ratings for the overall quality of life. Therefore, 18 disease-specific items were added to the original 36 items of the SF-36. The 54 items are divided into 12 multi-item and 2 single-item scales. The MSQOL-54 items are transformed linearly to 0-100 scores and final scores are obtained by averaging items within the scales
40834726|NCT03730545|DIETARY_SUPPLEMENT|enteral immunonutrition|Enteral nutrition was started within 12h at an infusion rate of 20ml per hour for SEN group and 16ml per hour for EIN group in the first 24h. The rates of flow were gradually increasing with 50ml/h in SEN versus 40ml/h in EIN on day 2, 70ml/h versus 56ml/h on day 3 and 100ml/h versus 80ml/h until the 7th day depending on the feeding tolerance.
40834727|NCT03715192|BIOLOGICAL|LY3462817 IV|Administered IV
40834728|NCT03715192|BIOLOGICAL|LY3462817 SC|Administered SC
41494590|NCT04392583|DEVICE|ENTACT Septal Staple system|The ENTACT Septal Stapler delivers implantable septal staples which are intended to connect internal tissues to aid healing and for approximation of soft tissue during nasal septal surgery.
40834729|NCT03715192|DRUG|Placebo|Administered IV
41494591|NCT02623348|BEHAVIORAL|pedometer|pedometer-based physical activity recommendations
41494592|NCT01135186|DRUG|sapropterin dihydrochloride|sapropterin dihydrochloride: 10mg/kg/day
41494593|NCT02576912|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.036 mg/kg) given intravenously.
41494594|NCT02576912|DRUG|Active Pregnenolone|A dose given sublingually.
41494595|NCT02576912|DRUG|Placebo|A placebo dose given sublingually.
41494596|NCT02576912|DRUG|Placebo|Placebo dose given intravenously.
41509169|NCT06400030|PROCEDURE|Root canal treatment with BioCeramic sealer|- BioCeramic Sealer Group: the canals in this group were filled using BioCeramic-based sealer and a single gutta-percha cone, and gently insert it into the root canal to the preselected working length without applying pressure.
41509170|NCT03247179|OTHER|PTSD Coach mobile application|The PTSD Coach app is publicly available for free, and draws on cognitive behavioral therapy components to help participants learn, manage, and cope with their PTSD symptoms in real time.
40834730|NCT03002454|DRUG|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
40834731|NCT03502304|BEHAVIORAL|Endurance training plus resistant training|CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.
40834732|NCT02642146|DRUG|Calcium Channel Blockers|
40834733|NCT02642146|DRUG|Phosphodiesterase Inhibitors|
40834734|NCT02642146|DRUG|Endothelin receptor blocker|
40834735|NCT02642146|DRUG|Prostanoids|
40834736|NCT02642146|DRUG|Other vasodilator|
40834737|NCT04080323|DRUG|Dinoprostone 3 mg|1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
40834738|NCT04080323|DRUG|placebo|1 vaginal tablet of placebo 60 minutes before surgery
40834739|NCT03447093|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
40834740|NCT03447093|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
41494597|NCT05960812|PROCEDURE|skillful neglect Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear conservative treatment which is considered the standard technique.~* Semisetting position under GA.~* Standard shoulder arthroscopy with standard portals for RC repair.~* Inspection of articular surface of rotator cuff and biceps tendon.~* Bursectomy, visualization of all rotators.~* Mobilization is done for associated rotator tears by shaver and radiofrequency device.~* Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~* Skillful neglect to the tear.~* Rotator repair technique by RC anchors~* Biceps Tenotomy will be done in all cases by cutting of LHBT."
40834741|NCT06034756|OTHER|TMJ dysfunction|Fonseca's Anamnestic Questionnaire (FAQ) was used for TMJ dysfunction. The diagnostic accuracy of the FAQ was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
41494598|NCT05960812|PROCEDURE|arthroscopic repair Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear repair which is considered the standard technique.~* Semisetting position under GA.~* Standard shoulder arthroscopy with standard portals for RC repair.~* Inspection of articular surface of rotator cuff and biceps tendon.~* Bursectomy, visualization of all rotators.~* Mobilization is done for associated rotator tears by shaver and radiofrequency device.~* Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~* Skillful neglect to the tear.~* Rotator repair technique by RC anchors~* Biceps Tenotomy will be done in all cases by cutting of LHBT."
41494599|NCT03716414|PROCEDURE|SLN mapping|"Intra-operative SLN mapping with indocyanine green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and Arms Assigned Interventions another 1ml will be injected superficially (2mm-depth).~The time between the injection and the search for SLN must be as soon as possible."
40834742|NCT06034756|OTHER|Maximum pain-free mouth opening (MMO)|The maximum pain-free mouth opening was recorded using a 15 cm ruler
40834743|NCT06034756|OTHER|Forward head posture|Forward head posture was evaluated by CVA using a goniometer. CVA was measured in degrees as the angle between the horizontal plane, the seventh cervical vertebra and the ear hole
40834744|NCT06034756|OTHER|Tongue strength and endurance|Tongue strength and endurance were evaluated with IOPI (Medical LLC, Redmond, WA), which has been clinically validated and reliable
40834745|NCT06034756|OTHER|Static endurance evaluation of the trunk muscles|The Trunk Flexors Endurance Test and the Biering Sorenson Test were used. These static tests are measurements targeting the local core muscles.
41354130|NCT03160872|DIAGNOSTIC_TEST|Anti Mullerian Hormone Measurement|Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
41354131|NCT01970540|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
41354132|NCT01970540|DRUG|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
40834746|NCT06034756|OTHER|Dynamic endurance evaluation of the core muscles|The Sit-ups and the Modified Push-ups Tests were used. These dynamic tests are measurements targeting the global core muscles.
40834747|NCT06036329|DEVICE|Group A : provided with 1 Whitsundays Nasal mask without a spare mask cushion|Group A will be provided with 1 Whitsundays Nasal mask without a spare mask cushion (replacement cushions will only be provided when requested)
40834748|NCT06036329|DEVICE|Group B : provided with 1 Whitsundays Nasal mask with 2 spare mask cushions|Group B will be provided with 1 Whitsundays Nasal mask with 2 spare mask cushions
40834749|NCT05004506|DRUG|Adductor Canal Block|The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
40834750|NCT05004506|DRUG|Intra-articular Injection|receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
40834751|NCT01939132|DRUG|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
40834752|NCT03946865|OTHER|Reiki Therapy|Reiki is a healing practice that originated in Japan. Reiki practitioners place their hands lightly on or just above the person receiving treatment, with the goal of facilitating the person's own healing response.
40834753|NCT03924999|COMBINATION_PRODUCT|Combined decongestive treatment (CDT) & Combined exercise|Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 30 sessions.
40834754|NCT03924999|COMBINATION_PRODUCT|Intermittent pneumatic compression & Combined exercise|Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).
40834755|NCT03924999|COMBINATION_PRODUCT|Combined exercise|30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
41354133|NCT04728880|DRUG|Remdesivir|This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study we will analyze the data collected during treatment.
41354134|NCT05049122|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
41354135|NCT05617599|DEVICE|SUPRAFLEX CRUZ|Patients in whom treatment with SUPRAFLEX CRUZ has been attempted
40834756|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 1
41354136|NCT00125268|DEVICE|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm\^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
41354137|NCT00125268|DEVICE|Sham Device|The sham device is non-active but otherwise identical to the study device.
41354138|NCT01172795|BEHAVIORAL|Relaxation session|30 minutes relaxation session (audiotape)
41354139|NCT01172795|BEHAVIORAL|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
41354140|NCT02113644|OTHER|Lifestyle intervention|
41354141|NCT04765449|DRUG|Cytotoxic T Lymphocytes|Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
41354142|NCT03281356|BEHAVIORAL|Intervention Group|Participants will receive a total of 8 text messages during a 4 week period.
41354143|NCT00632372|DEVICE|Cardiac Resynchronization Therapy|Pacing of the left ventricle to resynchronize ventricular contraction.
40834757|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 2
40834758|NCT06506994|DRUG|Tolvaptan|Tolvaptan tablets
40834759|NCT01735669|DRUG|Remifentanil|
40834760|NCT01735669|DRUG|Nitrous Oxide|
40834761|NCT05559125|DRUG|STSA-1002 Injection|Intravenous injection
40834762|NCT05559125|DRUG|STSA-1005 Injection|Intravenous injection
40834763|NCT05021549|DEVICE|nasal prong|apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong during preintubation apnia
40834764|NCT01672866|BIOLOGICAL|Placebo|Placebo to match SIM via subcutaneous injection every week
41354144|NCT00632372|DEVICE|HeartPOD™ System|Left atrial pressure monitoring.
41354145|NCT04267939|DRUG|Elimusertib (BAY1895344)|Elimusertib will be administered in 28-day cycles.
41354146|NCT04267939|DRUG|Niraparib|Niraparib will be administered in 28-day cycles.
41354147|NCT00323804|BIOLOGICAL|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
41354148|NCT00323804|DRUG|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
40834765|NCT01672866|BIOLOGICAL|SIM|Subcutaneous injection every week
40834766|NCT02132273|OTHER|Educational Story|Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
40834767|NCT03503981|OTHER|Psychotherapy|There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.
40834768|NCT02739321|DEVICE|Sound to Sleep System|Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
40834769|NCT03362229|PROCEDURE|Fixation|A well reduced medial malleolus fracture will undergo internal fixation, guided by the surgeon's skill and expertise
40834770|NCT03362229|PROCEDURE|Non-fixation|A well reduced medial malleolus fracture will be left without fixation
41354149|NCT00323804|DRUG|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
41354150|NCT02825745|DIETARY_SUPPLEMENT|Betashot|Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
41354151|NCT01318291|BEHAVIORAL|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
41354152|NCT01318291|BEHAVIORAL|Control|Medical treatment alone
41354153|NCT03823963|COMBINATION_PRODUCT|Mepilex® Border dressing|Soft silicone self-adherent dressing (5-layers)
41354154|NCT03823963|OTHER|Standard care|The control group will receive pressure ulcer prevention standard care
40834771|NCT00895687|DRUG|Erlotinib Hydrochloride|Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
40834772|NCT00895687|DRUG|Bortezomib|Beginning dose of 1. mg/m\^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
40834773|NCT05978635|BEHAVIORAL|Group A Standard 4 deep breaths measured in milliliters from the ventilator.|Tidal volume breath measured in milliliters
40834774|NCT05978635|BEHAVIORAL|Group B Coached 4 deep breaths measured in milliliters from the ventilator|Coached tidal volume breath measured in milliliters
41354155|NCT00838968|DRUG|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
41354156|NCT06283615|DRUG|Vitamin D|Vitamin D2 injection
41354157|NCT06123962|PROCEDURE|Collect peripheral blood and bronchoalveolar lavage fluid|"Peripheral venous blood will be collected and stored from the study participants at a total of five time points: Day 0, Day 1, Day 2, Day 3 after admission to the ICU, and the day of ICU discharge/death. The collection will be conducted after assessing the patients' eligibility for ARDS diagnosis. Each time point will involve the collection of one tube of peripheral venous blood, totaling 5 mL per sample.~Within 24 hours after patients' admission to the ICU and meeting the assessment criteria for ARDS diagnosis, bronchoalveolar lavage fluid (BALF) will be collected and retained, totaling 10 mL."
41354158|NCT02853903|BIOLOGICAL|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
41354159|NCT05131815|BEHAVIORAL|Virtual group based physical activity (BurnAlong) and Social Media Discussion Board|Participants will engage in two to three virtual physical activity sessions a week through the BurnAlong app for three months with a chosen partner and participate at least twice a week in the research team-mediated social media message board. Additionally, participants will be asked to participate in one live physical activity session per month with an exercise physiologist.
41354160|NCT05608694|OTHER|Prostate MRI|Group placement is determined by GRS score, Family history, and germline testing
41354161|NCT06457529|DIAGNOSTIC_TEST|conventional treatment with Prolotherapy|"Group A got prolotherapy along with conven¬tional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Prolotherapy is an injection treatment used to relieve pain. Your healthcare provider will inject a small amount of an irritant into your body. Dextrose (sugar) solution is the most commonly injected irritant. Proponents of prolotherapy claim it relieves pain by jumpstarting your body's natural healing abilities."
41354162|NCT06457529|OTHER|Dry Needling and conventional treatment|"Group B Subjects in Group B will get Dry Needling along with conventional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle"
41494600|NCT03570671|DIAGNOSTIC_TEST|Spasm positive|"Investigators define the positive criteria for VSA on MDCTA as follows:~1. Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or~2. Diffuse small diameter (\< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT."
40834775|NCT04465565|PROCEDURE|9% Sodium Chloride (NaCl) IV|9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously
40834776|NCT04602767|DRUG|Vasopressin|Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP \< 65 mmHg
41494601|NCT03570671|DIAGNOSTIC_TEST|Spasm negative|Suspected vasospastic angina subjects with negative MDCTA-derived VSA are considered as reference modality.
41494602|NCT03074123|DIAGNOSTIC_TEST|low-dose cosyntropin stimulation test|Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
40834777|NCT04602767|DRUG|Phenylephrine|Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP \< 65 mmHg
41159938|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Infants Phase II|After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
41354163|NCT02616172|GENETIC|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
41354164|NCT05433233|BEHAVIORAL|Walking|Participants will perform 3,000 additional steps/day on 5 days/week.
41354165|NCT05433233|OTHER|HAPA Behavior Change Counseling|Structured dialogue for initiating behavior change.
41494603|NCT03659097|PROCEDURE|periodontally accelerated osteogenic orthodontics|Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement
41494604|NCT01545661|PROCEDURE|Sputum induction|Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
41494605|NCT01545661|PROCEDURE|standard routine expectorated sputum|Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
41494606|NCT03309995|DEVICE|Lozenges|The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.
41494607|NCT03309995|DEVICE|Placebo lozenges|Placebo lozenges
40834778|NCT00000120|DRUG|Erythromycin Ointment|
40834779|NCT00000120|DRUG|Silver Nitrate Drops|
40834780|NCT03233022|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
40834781|NCT02337699|DEVICE|Implantation with the commercially available Axium neurostimulator|
40834782|NCT02337699|PROCEDURE|QST Testing|
40834783|NCT04985539|DEVICE|Verily Study Watch|Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
41354166|NCT00045006|DRUG|vorinostat|
41494608|NCT02397408|DRUG|Carbon C 11 Choline|Given intravenously (IV) prior to imaging
41494609|NCT02397408|DRUG|Fluorine F 18 Choline|Given intravenously (IV) prior to imaging
41494610|NCT02397408|PROCEDURE|Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)|Undergo whole-body PET/MR imaging
41494611|NCT02459535|OTHER|oral stimulation glucose|oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion
41494612|NCT02459535|OTHER|oral stimulation saccharin|
41494613|NCT02459535|OTHER|oral stimulation aspartame|
41494614|NCT02459535|OTHER|oral stimulation sucralose|
41354167|NCT00215904|DRUG|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
41354168|NCT01636050|OTHER|squat exercise training|Intervention may include squat exercise for 8 weeks
40834784|NCT01127841|DRUG|Rituximab and Bendamustine|Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
40834785|NCT01282294|DEVICE|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
40834786|NCT04591743|DEVICE|Active TCS|TCS active at 1 Hz on the right DLPFC for 6 weeks
40834787|NCT04591743|DEVICE|Placebo TCS|Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks
40834788|NCT04591743|DRUG|nicotine treatment|at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
41159939|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Infants Phase III|Phase III (infants) to be determined upon completion of Phase II (infants).
41354169|NCT05978804|OTHER|Computerized Cognitive Training via BrainHQ|Computerized Cognitive training (BrainHQ)
41354170|NCT05978804|DEVICE|Active tDCS (tDCS) on DLPFC|Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
41354171|NCT03089008|OTHER|Eccentric exercises|
41354172|NCT03089008|OTHER|Stretching exercises|
41354173|NCT05934929|OTHER|Circulating tumor DNA detection|biological assessment on operating bed to detect residual circulating tumor DNA
41354174|NCT03844581|DEVICE|interferential current|Treatment was applied using four vacuum electrodes with wet sponge, two of them were put under the patient lumber region on a distance from lumber spinous process by five cm on each side and the other two were applied over the suprapubic region parallel to iliac crest.
40834789|NCT04591743|OTHER|Questionnaires|"EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART"
40834790|NCT02331979|DEVICE|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
40834791|NCT02782325|BIOLOGICAL|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
41159940|NCT03552237|DIETARY_SUPPLEMENT|dietary fiber|We will investigate in a 4 week intervention whether consumption of dietary fiber supplement affect the microbiota composition in schizophrenia patients with central obesity.
41159941|NCT03284593|DRUG|intensive chemotherapy|
41354175|NCT03844581|DRUG|Propiverine Hydrochloride|propiverine hydrochloride 20 mg/once per day in the morning
41354176|NCT05504811|DEVICE|FitMi AD|Exercise using the motion sensing devices and a tablet computer
41354177|NCT05504811|OTHER|Conventional exercise program|Exercise following printed sheets or booklet
41354178|NCT02067806|DRUG|2-chloroprocaine hydrochloride, 1%|Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.
41354179|NCT05297552|DRUG|RC48-ADC|Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
41354180|NCT05297552|DRUG|JS001|Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
40834792|NCT02782325|BIOLOGICAL|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
41354181|NCT01676428|RADIATION|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions \<5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
41354182|NCT02622802|DRUG|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
41354183|NCT02622802|DRUG|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
41354184|NCT02622802|DRUG|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
41354185|NCT04443205|OTHER|Data record|Data record
41354186|NCT04439266|DRUG|Crizotinib|Given PO
41354187|NCT05875194|DEVICE|active transcranial direct current stimulation (tDCS)|2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
41354188|NCT03474627|DEVICE|Non-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
41354189|NCT03474627|DEVICE|PLGA-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
41354190|NCT00605228|DRUG|MOVIPREP|2L Drug
41354191|NCT00605228|DRUG|COLOPEG|4L Drug
41354192|NCT05120375|DRUG|BAT6021|Ⅳ infusions
41354193|NCT04430036|DRUG|AGEN1884|A fully human monoclonal Anti-PD-1 Antibody
41354194|NCT04430036|DRUG|AGEN2034|A fully human monoclonal Anti-PD-1 Antibody
41354195|NCT04430036|DRUG|Cisplatin|Alkylating antineoplastic agent
41354196|NCT04430036|DRUG|Gemcitabine|Antimetabolite antineoplastic agent
41354197|NCT02458989|PROCEDURE|Scalpel|Use of a scalpel as a first incision during thyroid operation
41354198|NCT02458989|PROCEDURE|Electrocautery|Use of an electrocautery as a first incision during thyroid operation
41354199|NCT05609500|BEHAVIORAL|Warfarin dosage adjustment model|Warfarin dosage adjustment model use to predict the initiation and the maintenance dose of warfarin. Variation of warfarin dose during stable maintenance phase for the same patient might be influenced more by temporal factors such as modification of drug regimens that utilize the CYP450 pathway, or dietary vitamin K intake
41354200|NCT06419062|DEVICE|Frontier X2|Frontier X2 device will be used to measuring for physiological changes (breathing rate, heart rate, ECG, and heart rate variabilities) in people with COPD.
41354201|NCT04352049|PROCEDURE|Preoxygenation|
41159942|NCT03284593|DRUG|Azacitidine|
41354202|NCT02736942|PROCEDURE|Laparoscopic TME|Laparoscopic Total Mesorectal Excision
41354203|NCT02736942|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
41354204|NCT00025194|DRUG|estramustine phosphate sodium|
41354205|NCT00025194|DRUG|ixabepilone|
41354206|NCT01657149|PROCEDURE|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
41354207|NCT01657149|PROCEDURE|individual physiotherapy only|individual physiotherapy only
41354208|NCT01089933|PROCEDURE|Thoracic Paravertebral Block (TPVB)|The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
41354209|NCT01089933|PROCEDURE|Local Anesthetic|At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
41354210|NCT04806373|DRUG|Cathflo Activase|Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter
41354211|NCT04806373|DRUG|Talc Slurry Pleurodesis|Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter
41354212|NCT02646332|DRUG|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
41354213|NCT02646332|DRUG|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
41354214|NCT03438591|DEVICE|Medtronic 4196 lead|Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
41354215|NCT04574791|DRUG|TiZANidine 2 MG Oral Capsule|Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
41354216|NCT00600665|BEHAVIORAL|PAINReportIt|A pain assessment data collection tool
41354217|NCT00600665|BEHAVIORAL|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
41354218|NCT00600665|BEHAVIORAL|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
40834793|NCT01522430|PROCEDURE|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
41494615|NCT04113863|DRUG|all-trans retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
41494616|NCT04113863|DRUG|Anastrozole 1mg|Anastrozole will be administered orally at the dosage of 1 mg/die.
40834794|NCT01522430|PROCEDURE|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
40834795|NCT03559894|DIAGNOSTIC_TEST|Trans-thoracic echocardiography|Trans-thoracic echocardiography
41494617|NCT05491915|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the occipital nerves. The SPRINT System includes up to two leads (small wires) that are placed through your skin at the top of your neck. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
41494618|NCT05202730|PROCEDURE|New local anesthesia injection site and new local anesthetic drug formulation.|The traditional injection site is the posterior joint capsule and the popliteal artery space (iPACK) plus multiple layers of tissues around the knee joint (posterior joint capsule, ligaments and subcutaneous tissue). The traditional local anesthetic formulation is 1% ropivacaine 10ml+ normal saline 40ml+10mg Morphine + 5mg dexamethasone. The new local anesthesia injection site is iPACK+Knee Cutaneous Nerve Block. The new local anesthetic formula is 1% ropivacaine 10ml+ normal saline 40ml+10mg morphine+1ml triamcinolone acetonide.
41494619|NCT00328016|BEHAVIORAL|Guided Breathing|The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
41494620|NCT00328016|DEVICE|RESPeRATE|The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
41494621|NCT04159935|DEVICE|iLux® system|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
41494622|NCT02553031|DEVICE|The imaging biomarkers determined by MR-PET|This study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated MR-PET system and advanced MR techniques in patients with colorectal cancer.
41509171|NCT03835273|OTHER|3D motion capture system|Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
40834796|NCT02557113|PROCEDURE|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
40834797|NCT02557113|PROCEDURE|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
40834798|NCT03318224|OTHER|none (observational study)|only assessments via questionnaires, no interventions
40834799|NCT06222489|DRUG|89Zr-Patritumab deruxtecan|Day 1, day 3, day 6, day 11 and day 26 of first course
40834800|NCT02595697|BEHAVIORAL|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
41159943|NCT03329547|DRUG|Cefixime test capsule|"SKF101804/cefixime test capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as a dark purple head and off white body locking type capsule with GSK' printed on cap and 400MG printed on body of capsule."
41354219|NCT04952116|OTHER|Eyelid reconstruction|Assessment of differrent techniques in anterior and posterior lamella reconstruction after periocular defects
41354220|NCT00519558|DRUG|somatropin|
41354221|NCT05306860|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
41509172|NCT03835273|OTHER|Incentive spirometry|Incentive spirometry is a non-invasive device for assessment of pulmonary function.
41509173|NCT03835273|OTHER|Questionnaires|Two validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and one non-validated satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system \[7,8\]
40834801|NCT06218706|DEVICE|Low Intensity Focussed Ultrasound|The major objective of this study is to further test safety, tolerability, and feasibility of LIFU in this population as well as investigate the impact of LIFU on opioid and other substance use. The primary endpoint is 90 days (Post-LIFU Week 12) following Active/Sham LIFU. After the primary endpoint is reached, the blind will be broken and the group who received Sham LIFU will cross-over and receive Active LIFU
41494623|NCT06406270|OTHER|Fava|Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with fava bean food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
40834802|NCT00779961|PROCEDURE|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
40834803|NCT00779961|PROCEDURE|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
41494624|NCT06406270|OTHER|Buckwheat|Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with buckwheat food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
41494625|NCT02789618|OTHER|A01|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The gel will be applied in the evening of three consecutive days during the study time period
41494626|NCT02789618|OTHER|B99|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The bonding agent will be professional applied immediately prior to the clinical assessments.
40834804|NCT00003231|DRUG|cisplatin|
40834805|NCT00003231|DRUG|docetaxel|
40834806|NCT00003231|PROCEDURE|surgical procedure|
40834807|NCT00003231|RADIATION|radiation therapy|
40834808|NCT02314364|RADIATION|SBRT with protons or photons|
41494627|NCT02789618|OTHER|M89|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days.
40834809|NCT05207969|PROCEDURE|Instruction to urinate|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
40834810|NCT02275728|OTHER|Pelvic floor muscle training|assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
40834811|NCT02275728|OTHER|Eletromyography Biofeedback|
40834812|NCT00408590|BIOLOGICAL|carcinoembryonic antigen-expressing measles virus|
40834813|NCT00408590|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|
40834814|NCT00408590|GENETIC|reverse transcriptase-polymerase chain reaction|
41354222|NCT05193292|DRUG|Camrelizumab|200mg, iv, 21d for a treatment cycle
41494628|NCT06456983|DEVICE|maintenance electroconvulsive therapy (mECT)|see Arms
41494629|NCT04013321|DEVICE|SleepScore Max coaching feature|The SleepScore max is a non-contact sleep tracking device. The app has an integrated feedback coaching feature to improve sleep.
40834815|NCT00408590|OTHER|laboratory biomarker analysis|
40834816|NCT05305547|DRUG|S-217622|Administered as a round tablet.
40834817|NCT05305547|DRUG|Placebo|Administered as a round tablet.
40834818|NCT03821272|BIOLOGICAL|PepCan|50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities
41159944|NCT03329547|DRUG|Cefixime reference capsule|"Cefixime reference capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as red/orange hard gelatin size 0 capsule with Cefspan 400 mg printed on body of capsule."
41354223|NCT05193292|DRUG|Trastuzumab|8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle
40834819|NCT03821272|BIOLOGICAL|Placebo|0.9% Saline solution per dose administered intradermally in the extremities
40834820|NCT04970160|PROCEDURE|TSARP|We make four different surgical operations for female patients with rectovestibular fistula
40834821|NCT04970160|PROCEDURE|PSARP|Posterior sagittal anorectoplasty
40834822|NCT04970160|PROCEDURE|Classic ASARP|Anterior Sagittal anorectoplasty
40834823|NCT04970160|PROCEDURE|Modified ASARP|External anal sphincter preservation
41354224|NCT05193292|DRUG|XELOX regimen|Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w
41354225|NCT05193292|DRUG|mFOLFOX6 regimen|Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
41354226|NCT05193292|DRUG|FOLFIRI regimen|Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
41354227|NCT05193292|DRUG|mXELIRI regimen|Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w
40834824|NCT03023163|OTHER|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
40834825|NCT01288612|DEVICE|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
40834826|NCT01288612|DEVICE|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
40834827|NCT01183819|BEHAVIORAL|Space Fortress|Space Fortress sessions 3 times a week for 12 weeks
40834828|NCT01183819|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise 4 times a week for 12 weeks
40834829|NCT01183819|BEHAVIORAL|Stretching|Stretching/Toning exercise 4 times a week for 12 weeks.
40834830|NCT01183819|BEHAVIORAL|Control Games|Control games session 3 times a week for 12 weeks
40834831|NCT05451680|DEVICE|Negative pressure device|Negative-pressure therapy postoperatively on the full-thickness skin graft
40834832|NCT05451680|PROCEDURE|Conventional care|Conventional dressing postoperatively on the full-thickness skin graft
40834833|NCT01808885|DRUG|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
40834834|NCT01808885|DRUG|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
40834835|NCT06010381|OTHER|Muscle energy technique|It was applied on the shoulder flexion and the external rotation. An isometric contraction of the agonist muscle (the muscle which requires stretching) for 7 seconds with gentle muscle contraction to avoid the risk of increasing the muscle tone. This contraction started just short of the restrictive barrier. After that, the patient is asked to relax for 2-3 seconds and then the therapist stretches the contracted muscle in the opposite direction for 30 seconds. This is repeated three repetitions for each muscle.
40834836|NCT06010381|OTHER|Maitland mobilization|At the start of each session, the physical therapist examined the patient's ROM in all directions to obtain information about the end-range position and the end feel of the glenohumeral joint. Start with rhythmic mid-range mobilization with the patient in a supine position. The therapist's hands are placed close to the glenohumeral joint, and the humerus is brought into a position of maximal flexion in the sagittal plane. After 10 to 15 repetitions of intensive mobilization techniques in this end-range position, the direction of mobilization will be altered by varying the plane of elevation or by varying the degree of rotation. When alternating the direction of mobilization, other movements such as gliding techniques and distraction in that joint position were (inferior gliding, anterior gliding, and posterior gliding).
40834837|NCT06010381|OTHER|Traditional shoulder exercise|Traditional shoulder exercises in the form of shoulder range of motion exercises, stretching exercises and, scapular stabilization.
40834838|NCT04109833|DRUG|ABT|any antibiotic therapy in the first week of life
40834839|NCT03426631|DRUG|Placebo oral capsule|Placebo capsule 30 minutes before sleep
41021299|NCT03398993|DEVICE|Endometrial scratch|"The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle.~In the theatre, Patients put in a lithotomy position, sterilization was performed with the presence of good source of light., the procedure was carried out using a thin pipelle tube as follow :- A cuscoe's speculum was inserted into the vagina in order to visualize the cervix.~Cervix was grasped by vollselum upwards backwards, then pipelle tube passed through the cervix and uterine cavity, then moved up and down to make a single induced scratch two times in the lining endometrium of posterior wall of uterus.~The procedure took approximately 15minutes to complete"
41354228|NCT05193292|DRUG|mIRIS regimen|Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w
40834840|NCT03426631|DRUG|DAW1033B2 oral capsule|DAW1033B2 capsule 30 minutes before sleep
40834841|NCT01516567|DRUG|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
40834842|NCT01999075|DEVICE|Lung Volume Recruitment (LVR)|LVR will be used twice per day
40834843|NCT01999075|OTHER|Conventional Treatment|This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
40834844|NCT06105359|BEHAVIORAL|Dignity therapy|"Dignity therapy will be applied in the interview room that will be requested in the oncology clinic to protect the confidentiality of information.~The application is planned as five sessions and the sessions will last approximately 40 minutes. Two questions in the dignity therapy protocol will be discussed in each session."
40834845|NCT06105359|OTHER|standardize care|Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
41021300|NCT04819360|DRUG|VESIcare 10Mg Tablet|"Vesicare® 10 mg per day for 12 weeks~Vesicare 10mg 12 weeks"
41021301|NCT04819360|DRUG|Botox 100 UNT Injection|1 injection of Botox® 100 UNT
41021302|NCT01358981|DRUG|LY2881835|Administered orally
41021303|NCT01358981|DRUG|Placebo|Administered orally
41021304|NCT05480605|BEHAVIORAL|Occupational Therapy|Children with autism will receive 6 - 8 weeks of regularly scheduled occupational therapy at Nationwide Children's Hospital outpatient centers. The intervention consists of one-hour weekly sessions with a licensed occupational therapist.
41021305|NCT04223856|DRUG|Enfortumab vedotin|Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
41354229|NCT05007301|DEVICE|geko device|Neuromuscular electrostimulation of the peroneal nerve, 12h per day, for up to 12 weeks.
41354230|NCT06133790|GENETIC|PCR - Immunohistochemistry - Immunolabelling|Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
41354231|NCT05907083|RADIATION|cone beam computer tomography|Cone Beam CT Radiation
41354232|NCT00992615|PROCEDURE|prostate biopsy|prostate cores - 12 or 20
41494630|NCT04013321|BEHAVIORAL|Online CBTi|Online Cognitive Behavioral Therapy for insomnia is a user guided program to track sleep, receive sleep coaching, and initiate behavioral techniques such as tailored sleep scheduling and sleep hygiene to help improve sleep.
41494631|NCT03603548|DRUG|Envarsus|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
41494632|NCT03603548|DRUG|Advagraf|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
41494633|NCT02079779|OTHER|Robotic-assisted therapy|The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).
41494634|NCT02079779|OTHER|Classical therapy|Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
41494635|NCT02718508|BEHAVIORAL|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
41494636|NCT03256331|DRUG|BEL-X-HG|"This study will be carried out in 2 parts:~1. A sequential Dose Escalation Part of four doses following a 3 + 3 design where dose escalation will be made based on DLT, for a single cycle (28 days) of BEL-X-HG treatment~2. A Dose Extension Part of up to 5 cycles (28 days each) at the same dose level (starting dose) of BEL-X-HG treatment~Escalating dose levels of BEL-X-HG in 5 study cohorts and one modified dose will be as follows:~* Cohort 1: Dose level 1 - 0.5 g/day (0.25 g, bid)~* Cohort 2: Dose level 2 - 1.0 g/day (0.5 g, bid)~* Cohort 3: Dose level 3 - 2.0 g/day (1.0 g, bid)~* Cohort 4: Dose level 4 - 4.0 g/day (2.0 g, bid) Modified dose level Cohort 5: Dose level 5 - 1.5 g/day (0.75g bid) This re-escalation is allowed only when dose de-escalates from Dose level 3 to Dose level 2, and 1 DLT in 6 evaluable subjects of Dose level 2."
41494637|NCT05305612|OTHER|early anticoagulation|Anticoagulation prior to transseptal puncture
41494638|NCT05305612|OTHER|late anticoagulation|Anticoagulation after transseptal puncture
41494639|NCT04791514|DRUG|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
41494640|NCT05312320|OTHER|Information film|"* Sexual activity after MI does not increase risk of recurrence or death~* Sexual activity is associated with improved outcome after MI~* Resuming sexual activity as normal is recommended and completely safe"
41021306|NCT04223856|DRUG|Pembrolizumab|IV infusion on Day 1 of every 3-week cycle
41021307|NCT04223856|DRUG|Cisplatin|administered as IV infusion on Day 1 of each 3-week cycle
41354233|NCT05452187|DRUG|Assess the effectiveness and safety of DAAs in patients with IBD.|Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).
41354234|NCT05452187|DRUG|Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.|Variables evaluated: Interactions.
41494641|NCT02204306|GENETIC|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
41354235|NCT05452187|OTHER|Assessment of the impact of DAAs on the course of IBD.|Qualitative variables will be expressed as a percentage and 95% confidence interval and quantitative variables as median and interquartile range. A priori it is difficult to determine which statistical analysis should be performed. It is basically a descriptive study, and the subsequent statistical analysis will depend on the evolution that the patients have presented in relation to the DAA treatment. If the drugs have been well tolerated without adverse effects, further statistical analysis will not be necessary. Instead, if the DAAs trigger activity outbreaks, variables related to the appearance of these outbreaks will be evaluated (type of DAA, immunomodulator, ...). To compare whether there are differences between the established groups, Chi Square (in qualitative independent variables), a t-student or ANOVA or their corresponding non-parametric tests (in quantitative independent variables) will be used. Statistical significance has been set at a probability level of \<0.05.
41494642|NCT02013011|PROCEDURE|recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only|application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group
41354236|NCT01041586|DEVICE|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
41494643|NCT04044911|BEHAVIORAL|Task model (CogWatch)|
40834846|NCT02767739|BEHAVIORAL|Physical, social and cultural activities|This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.
41021308|NCT04223856|DRUG|Carboplatin|Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
41021309|NCT04223856|DRUG|Gemcitabine|IV infusion on Days 1 and 8 of every 3 week cycle
41021310|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received 10HZ rTMS protocol consisted of 5 sessions over 5 consecutive workdays
41494644|NCT03052127|DRUG|Light-activated AU-011|Study treatment
41494645|NCT03052127|DEVICE|Laser Activation|Study treatment
41494646|NCT00185445|DRUG|Fludarabine Phosphate (Fludara)|All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
41494647|NCT01830894|DEVICE|MRI|3 MRI on different times during the study for each arm.
41494648|NCT00770081|DRUG|vildagliptin|50mg qd
40834847|NCT06119295|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants. Depending on the condition participants are in, they will be served either a portion size which consists of the amount of food they consumed in the first test session, or a reduced portion size. Within these two reduced portion size conditions, one group of participants will be made aware that their portion size has been reduced, the other will not and instead will be told that this portion size is the same as the amount of food they consumed in the previous session.
40834848|NCT03624452|OTHER|rIPC + Exercise|The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
41494649|NCT00770081|DRUG|sitagliptin|25mg qd
40834849|NCT03624452|OTHER|rIPC only|Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
40834850|NCT00984815|DRUG|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
40834851|NCT04127799|OTHER|Hospital-Community-Family-Care Management Platform Online|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
40834852|NCT04127799|OTHER|Subjects with AF conventional treatment|Subjects with standardized treatment according to latest guidelines via conventional visit.
40834853|NCT03667846|DRUG|Topiramate|Generic topiramate, FDA-approve for clinical use, will be purchased in 25mg, 50mg, and 100mg strengths, and encapsulated.
40834854|NCT03667846|OTHER|Placebo|Placebo tablets will be encapsulated in identical capsules.
40834855|NCT02265315|OTHER|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
40834856|NCT02265315|BEHAVIORAL|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
40834857|NCT01189292|DRUG|Dexamethasone|8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
40834858|NCT01189292|OTHER|NaCl 0.9%|2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
40834859|NCT02538133|BIOLOGICAL|99mTc-Exametazime (HMPAO)-labeled leukocytes|Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
40834860|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
40834861|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
40834862|NCT02884375|OTHER|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :~* functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~* mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~* nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~* cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~* mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~* comorbidities (CIRS G)~* polypharmacy (number of medications)~* social environment (primary caregiver, support at home, friends , family, living alone)~* urinary and/or fecal incontinence"
40834863|NCT06135363|DRUG|SC1011|SC1011 tablet
40834864|NCT06135363|DRUG|Placebo tablet|SC1011-matching placebo tablet
40834865|NCT02064608|DRUG|AZD2014|mTOR inhibitor
41494650|NCT01043835|PROCEDURE|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
41494651|NCT01043835|PROCEDURE|Open gastrectomy|Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
41494652|NCT03525652|BIOLOGICAL|Therapeutic vaccine|The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.
41354237|NCT06311851|DRUG|Bevacizumab|Infusion of Bevacizumab-loaded hepaspher through transarterial chemoembolization.
41354238|NCT03220594|PROCEDURE|hypogastric artery ligation|hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
41494653|NCT03525652|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
41494654|NCT00510289|DRUG|Sorafenib|400 mg twice a day until progression or unacceptable toxicity develops.
41494655|NCT02255682|DRUG|Simvastatin|
41494656|NCT02255682|DIETARY_SUPPLEMENT|Q10|
40834866|NCT05044039|DRUG|Duvelisib|Patients should take duvelisib at approximately the same time every day, with or without food.
41494657|NCT01081834|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
40834867|NCT05647694|OTHER|V-NAV indoor navigation prototype|Users will use the V-NAV prototype as an augmentation to their indoor navigation activities.
40834868|NCT01608503|PROCEDURE|lung deflation|lung was deflated during respiration cycle
40834869|NCT01608503|PROCEDURE|lung inflation|lung was inflated during respiratory cycle
40834870|NCT01243528|OTHER|Laboratory values|Laboratory values which represent nutritional status
40834871|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on M1 and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The participants will be positioned in ventral decubitus position. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on C3 to stimulate the left primary motor cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
40834872|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on DLPFC and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on F3 to stimulate the left dorsolateral cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
41494658|NCT01081834|DRUG|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
41494659|NCT01081834|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
41494660|NCT01695863|DRUG|comparing 2 drugs on their effect on the bowel preparation for colonoscopy|the effects of the drug on the colon preparation for colonoscopy
41494661|NCT05070000|DIAGNOSTIC_TEST|Radiologic examination|Patients underwent US, CT or CT after US
41494662|NCT03825341|DRUG|Hydroxyurea|Drug: Hydroxyurea oral liquid dose administered will be 20mg/kg/day or infants's usual daily dose.
41494663|NCT03825341|DRUG|Hydroxyurea Oral Capsule|Drug: Hydroxyurea both a sprinkle formulation and capsules (Droxia 200mg) administered on 2 separate occasions.
41494664|NCT01857271|DRUG|Erlotinib Hydrochloride|Given PO
40834873|NCT04496661|DEVICE|Sham tDCS and PES|For sham tDCS and PES stimulation, patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes. The anodic electrode will be positioned on the left primary motor cortex, but the current will be turned off automatically after 30 seconds. The reference electrode will be positioned in the supra orbital contralateral region. For sham PES stimulations, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed), but the current will be turned off automatically after 30 seconds.
40834874|NCT00553007|PROCEDURE|Periodontal therapy|Normal periodontal therapy is performed.
41354239|NCT05507515|DRUG|ONO-2020|ONO-2020 tablets
41354240|NCT05507515|DRUG|Placebo|Placebo tablets matching ONO-2020 tablets
41354241|NCT03008928|BEHAVIORAL|Alcooquizz|
41354242|NCT00818636|BEHAVIORAL|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
41354243|NCT06282952|DIETARY_SUPPLEMENT|Fecal transplant|At delivery, the fecal transplant is thawed and 0.5 mL representing 3.5 mg of the mother's or donors' fecal sample is dissolved in 5 mL of the mother's own milk or when not available pasteurized bank milk. The sample is given orally to newborn infants as soon as possible but not later than 6 h of delivery and not later than two hours after defrosting.
41494665|NCT01857271|PROCEDURE|Therapeutic Conventional Surgery|Undergo thoracotomy
41494666|NCT01857271|OTHER|Laboratory Biomarker Analysis|Correlative studies
41494667|NCT00185666|PROCEDURE|Stereotactic radiosurgery|
41494668|NCT02078427|BIOLOGICAL|ADVATE|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
41494669|NCT02078427|BIOLOGICAL|ADYNOVI|Antihemophilic Factor (Recombinant) Pegylated
41494670|NCT04889287|DRUG|Elinzanetant (BAY3427080)|Once daily over 12 days
41494671|NCT04889287|DRUG|Rosuvastatin|Single doses on Day 1, Day 8, and Day 13
41354244|NCT06081946|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
41354245|NCT06081946|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
41354246|NCT05610670|OTHER|Questionnaire|The questionnaire will allow us to complete the information and to collect their experiences regarding the desire and/or achievement of a pregnancy, but also their gynecological follow-up in the broad sense, on the other hand.
41354247|NCT00545740|DRUG|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
41354248|NCT00545740|DRUG|SPD476 (2.4 g)|2.4g SPD476 QD orally
41354249|NCT00545740|DRUG|SPD476 (4.8 g)|4.8g SPD476 QD orally
41354250|NCT00545740|DRUG|Placebo|QD orally
41354251|NCT00806533|DRUG|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
41354252|NCT01582191|DRUG|Everolimus|Given PO
41354253|NCT01582191|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41494672|NCT03173326|PROCEDURE|General anesthesia|General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
41494673|NCT03173326|PROCEDURE|Subarachnoid block|Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
41494674|NCT01524679|DRUG|Pegylated interferon alfa-2a plus nucleos(t)ide(s)|Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
41494675|NCT00272051|DRUG|SR57746A|
41494676|NCT06084897|DRUG|TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.|"A maximum of six cycles was recommended for chemotherapy.~* Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin;~* Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin."
41494677|NCT06084897|BIOLOGICAL|PD-1 inhibitor|Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab
41494678|NCT06084897|RADIATION|Consolidation Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66Gy/19f or 40Gy/20f for organ metastasis patients. Radiation treatment is planned after chemotherapy completed.
41494679|NCT06084897|RADIATION|Salvage Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66\~49.22Gy/19f \~23f or 40\~50Gy/20\~25f for organ metastasis patients. Radiation treatment is planned after disease progression when recommended by multidisciplinary team.
41494680|NCT03862755|DRUG|Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)|Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
41494681|NCT02551432|DRUG|pembrolizumab, paclitaxel|pembrolizumab, paclitaxel
41494682|NCT04153383|DRUG|Milrinone Injection|giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV
41494683|NCT04012710|PROCEDURE|Laparoscopy|Conventional abdominal laparoscopy
41494684|NCT04012710|PROCEDURE|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
41494685|NCT04472793|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
41494686|NCT02458287|BIOLOGICAL|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
41354254|NCT01582191|OTHER|Pharmacological Study|Optional correlative studies
41354255|NCT01582191|DRUG|Vandetanib|Given PO
41354256|NCT01693666|BEHAVIORAL|Lifestyle intervention|"1. To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.~2. To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.~3. To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group."
41354257|NCT04525989|RADIATION|Radiation therapy|5 x 5 Gy external radiation therapy
41354258|NCT05505942|BEHAVIORAL|LPA Sessions|"A study interventionist will conduct phone/video sessions and provide information regarding the acute and long-term psychological and physical benefits of increasing PA. Participants will be introduced to the concept of utilizing brief bouts of PA as a coping strategy for managing emotions and urges to drink alcohol in-the-moment. Participants will also be given information on the public health guidelines for PA (and how these translate into step counts) as well as how to determine if their PA is moderate intensity (e.g., measuring heart rate and identifying rate of perceived exertion). Study clinicians will also orient participants to the proper use of the Fitbit activity tracker and tips for self-monitoring step counts with the tracker and on the app and/or website."
41354259|NCT05505942|OTHER|Fitbit Only|Interventionists will provide participants information about the proper use of the Fitbit activity tracker and offer tips for self-monitoring step counts with the tracker and on the app and/or website.
41494687|NCT02458287|BIOLOGICAL|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
40834875|NCT01669408|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
40834876|NCT02416700|PROCEDURE|immediate implant surgery|Surgery of dental implants in one side of the mouth.
41494688|NCT02458287|BIOLOGICAL|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
41494689|NCT02458287|BIOLOGICAL|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
41494690|NCT04297033|DRUG|Lovastatin|lovastatin 40mg/d 12m
40834877|NCT02416700|DEVICE|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
40834878|NCT05479929|OTHER|Canadian Triage Assessment Scale (CTAS)|The CTAS incorporates work of breathing into a subjective measurement in its assessment of patients and triaged.
41494691|NCT04297033|DRUG|Placebo|placebo
40834879|NCT00885768|PROCEDURE|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
40834880|NCT01727791|DRUG|pregabalin (Lyrica)|Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
41494692|NCT05148390|DEVICE|Cutimed® Gelling Fiber|application of dressing
41494693|NCT04328961|DRUG|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy
41494694|NCT04328961|DRUG|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.
41494695|NCT05842421|DEVICE|optical coherence tomography, in vivo reflectance confocal microscopy, 3D total body photography|each lesion is in addition to examination with dermoscopy examined with optical coherence tomography, in vivo reflectance confocal microscopy, each patient is photographed with 3D total body photography
41494696|NCT03558061|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
41494697|NCT02592083|DRUG|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
41494698|NCT02592083|DRUG|Palbociclib|
41494699|NCT00941148|DRUG|Insulin Glargin|
41494700|NCT00941148|DRUG|NPH insulin|
41494701|NCT00941148|DRUG|Insulin detemir|
40834881|NCT04234958|OTHER|Osteopathic manipulative treatment|Specific protocol including 4 osteopathic techniques targeting the pericardium
40834882|NCT04234958|OTHER|Sham therapy|Sham therapy mimicking the osteopathic techniques applied to experimental group
40834883|NCT02650271|DRUG|Entecavir|Patients will be received entecavir (10 mg/d) before liver resection.
40834884|NCT02650271|DRUG|Tenofovir|Patients will be received tenofovir before liver resection.
40834885|NCT00844805|DRUG|Infliximab|
40834886|NCT00844805|DRUG|Placebo|
41494702|NCT00941148|DRUG|metformin|metformin (2000 mg/day)
41494703|NCT02365870|DRUG|rotigotine transdermal patch|Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
41494704|NCT02365870|DRUG|placebo|Participants will receive a placebo transdermal patch to be worn daily
41494705|NCT02374489|DRUG|LDK378|LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
40834887|NCT00844805|DRUG|Naproxen|
40834888|NCT01895244|DRUG|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
40834889|NCT06243055|OTHER|questionnare|laval questionnare
40834890|NCT06243055|OTHER|questionnare|Obese-Specific Quality of Life
40834891|NCT06243055|OTHER|questionnare|SF-12 Quality of Life scale
40834892|NCT04459975|OTHER|Non interventional study|"Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient.~Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis"
40834893|NCT04180787|DIETARY_SUPPLEMENT|Beverage Consumption|Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
41494706|NCT05332028|DRUG|bupivacaine|Block applications
41494707|NCT05332028|DEVICE|22 gauge 100 mm needle|Block applications
41494708|NCT05332028|DRUG|Propofol|Routine general anesthesia protocol
41494709|NCT05332028|DRUG|fentanyl|patient-controlled analgesia
41494710|NCT02520063|DRUG|Letrozole|A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
41494711|NCT02520063|DRUG|Everolimus|The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
41494712|NCT02520063|DRUG|TRC105|The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
41494713|NCT03279211|OTHER|Whey Protein Isolate 894 Fonterra|30 g of protein powder diluted in water
41494714|NCT03279211|OTHER|Zein Sigma-Aldrich W555025|30 g of protein powder diluted in water
41494715|NCT03279211|OTHER|Protein-free test-meal|No protein included in the drink made of water and flavour/sugar
41494716|NCT05194137|OTHER|a proprioception protocol associated with vaginal palpation and feedback|A total of 13 previously established examples of voice commands can be used by the physiotherapists to help women understand how to perform a PFM contraction.
40834894|NCT02584361|PROCEDURE|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
40834895|NCT02584361|PROCEDURE|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
40834896|NCT00469963|PROCEDURE|quality-of-life assessment|quality-of-life assessment
40834897|NCT00469963|RADIATION|yttrium Y 90 resin microspheres|radiation therapy
40834898|NCT03443232|PROCEDURE|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
40834899|NCT03443232|PROCEDURE|Radiofrequency ablation|Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
40834900|NCT03281551|DRUG|PZ01 CAR-T cells|Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
40834901|NCT01862835|DRUG|Degarelix|
40834902|NCT01862835|DRUG|Testosterone|
40834903|NCT01862835|DRUG|Anastrozole|
40834904|NCT01862835|DRUG|Estrogen patch|
40834905|NCT03933176|PROCEDURE|Restoration of carious lesions|Selective carious tissue removal followed by restoration of the cavity using composite resin.
40834906|NCT06000306|DIAGNOSTIC_TEST|Digital Droplet PCR|Measurable residual disease Monitoring by Digital Droplet PCR in the Early Posttransplant Period
40834907|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
41354260|NCT01174602|BEHAVIORAL|Exposure Therapy for AN (AN-EX/RP)|12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
40834908|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
40834909|NCT01459367|DRUG|Lansoprazole|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks."
41021311|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received pcTBS protocol consisted of 5 sessions over 5 consecutive workdays
41021312|NCT05168319|DEVICE|Sham stimulation|Participants received Sham rTMS stimulations consisted of 5 sessions over 5 consecutive workdays
41021313|NCT06208709|DEVICE|carpal arch space augmentation (CASA)|A BOA brace with a balloon that is affixed internally. The device applies a small cyclic force of to the wrist. The cycles include a brief period of force applied, followed by a brief period of no force. The device is intended to be worn during hours of sleep.
41354261|NCT01174602|BEHAVIORAL|Cognitive Remediation Therapy|12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
41354262|NCT00816894|DRUG|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
41354263|NCT00816894|DRUG|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
41021314|NCT06208709|DEVICE|standard of care (SOC)|A BOA brace that can be adjusted to the arm of the participant.
41354264|NCT05246228|OTHER|Peripheral blood sampling in order to evaluate changes in the circulating immune population|Eveluation: circulating T cells CD3+CD8+ and CD3+CD4+, absolute lymphocyte count (ALC) and neutrophil counts (ANC) and neutrophil/lymphocyte ratio (NLR), Treg lymphocytes, Naïve/Memory T lymphocytes CD4+ and CD8+,myeloid-derived suppressor cells, Plasmacytoid Dendritic Cells NK cells dimension and bright, NKT cells, Myeloid Dendritic cells, Monocytes subsets, B lymphocytes ,Analysis of plasma cytokines (TNFalpha, TGFbeta, IL-6, IL-10) by ELISA,FN signature: real-time PCR on mRNA from peripheral blood mononuclear cells (PBMCs)
41354265|NCT00793715|PROCEDURE|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
41354266|NCT00793715|PROCEDURE|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
41354267|NCT04035356|DEVICE|Aortic valve repair|Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
41354268|NCT03903861|OTHER|Glucose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
41354269|NCT03903861|OTHER|Galactose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
41354270|NCT03903861|OTHER|Glucose and galactose|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
41354271|NCT05797727|DEVICE|LifeChamps Platform HCP|Healthcare professionals that will participate in the study will be introduced will have access to the LifeChamps Dashboard, which will display the data monitored from the patients, thus potentially facilitating patients' follow-up between clinical consultations. The LC Dashboard will provide pseudonymised information regarding the patients' physical activity and PROMs for the purpose of the pilot feasibility trial. They will not be able to view real time processed information, such as risk of frailty, QoL, risk of dependency and psychological condition, from the LIFECHAMPS analytics engine. They will be shown the anonymised outputs of the engine per patient and asked their opinions on the usability, acceptability and on whether such information would have helped better manage their patients' supportive care.
41354272|NCT05797727|DEVICE|LifeChamps Platform|Participants will be asked to provide 5 endpoints (PROMS) and will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors will be passively collecting information about their everyday living during these three months. At the end of the 3 month period, the participants will return the devices and will be asked to provide the 5 endpoints and their opinions regarding the usability and acceptability of the platform using structured questionnaires
41354273|NCT03212209|DEVICE|CPAP Fixed Pressure|Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
41354274|NCT06239649|PROCEDURE|Genicular nerve Radiofrequency Ablation block|Genicular nerve Radiofrequency Ablation block
41354275|NCT05857215|DRUG|amilo-5MER|amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).
41354276|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution Erector Spinae Plane Block|ultrasound guided ESPB - L4 level, unilateral
41354277|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution - PENG block|ultrasound guided PENG block
41354278|NCT06083428|DRUG|Control Test|Only spinal anesthesia
41354279|NCT01651676|OTHER|VQ11 validation|"Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug."
41494717|NCT05194137|OTHER|a proprioception protocol associated with biofeedback|The software has five different interfaces for visualize PFM contraction: sign itself and signal transformed into the movement of a balloon; an airplane; a fairy; or a bird. Positive reinforcements will be verbalized after each PFM contraction using one of 4 previously established examples of voice commands.
41494718|NCT02325518|DRUG|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
41494719|NCT02325518|DRUG|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
41494720|NCT02325518|DRUG|Subject's habitual PGA monotherapy|
41494721|NCT03594058|DRUG|Solabegron modified release tablets, low dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
41494722|NCT03594058|DRUG|Solabegron modified release tablets, high dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
41494723|NCT03594058|DRUG|Matching Placebo|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
41354280|NCT02883010|DEVICE|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
41354281|NCT02883010|OTHER|Standard Care|Care path normally used by the hospital
41494724|NCT06055530|DIAGNOSTIC_TEST|Artificial Intelligence Digital Pathology|School aged children will be asked to leave a stool sample. The samples will be prepared with the Kato-Katz method and scanned and processed by an artificial intelligence digital pathology system to determine the infection level of soil transmitted helminths and schistosomiasis. The samples will also be analyzed by a human microscopist for comparison.
41494725|NCT03624686|OTHER|peripheral blood|draw peripheral blood
41494726|NCT02076373|DRUG|recombinant human Erythropoietin|i.v. administration
41494727|NCT02076373|DRUG|Placebo|i.v. administration
41494728|NCT05353010|DRUG|Tacrolimus|Tacrolimus 5mg (1 mg \* 5 capsules)
41354282|NCT02283229|BEHAVIORAL|Newborns with preventive caring advices|Advices to prevent head molding
41354283|NCT02283229|OTHER|Newborns with normal caring advices|Normal handling
41494729|NCT05353010|DRUG|IN-A001(Tegoprazan)|IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)
41494730|NCT05353010|DRUG|IN-A001(Tegoprazan) + Tacrolimus|IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)
41494731|NCT00863395|PROCEDURE|skin biopsy|Lidocaine 1% c Epinephrine for local anesthesia
41494732|NCT01794026|PROCEDURE|diffusion weighted magnetic resonance imaging|for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
41494733|NCT02335918|DRUG|Combination of varlilumab and nivolumab|"Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
41494734|NCT06490445|DRUG|Medical Cannabis|Syqe cartridge containing medical cannabis (Bedrocan®) administered using Fixed-dose Syqe Inhaler.
41354284|NCT01512108|DRUG|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
41494735|NCT06490445|DRUG|Placebo|Placebo administered using Fixed-dose Syqe Inhaler.
41494736|NCT00006458|RADIATION|indium In 111 monoclonal antibody MN-14|
41494737|NCT00006458|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
41354285|NCT01512108|DRUG|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
41354286|NCT02186340|PROCEDURE|Inspiratory muscle training|
41494738|NCT05362838|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
41354287|NCT00137267|BEHAVIORAL|Time limited case management|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
41354288|NCT00137267|BEHAVIORAL|Health Education|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
41354289|NCT00427739|PROCEDURE|Cardiac CT|64 slice spiral computerized tomography
41021315|NCT00607841|DRUG|Ispinesib|10 mg/m2 dose as a 1-hour intravenous infusion.
41021316|NCT00607841|DRUG|Ispinesib|12 mg/m2 dose as a 1-hour intravenous infusion.
41354290|NCT02461342|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
41494739|NCT05362838|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
41494740|NCT04334694|DEVICE|Atrial flow regulator (Occlutech® AFR device)|Atrial septostomy followed by implantation of AFR.
41354291|NCT03970967|DEVICE|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
41494741|NCT00127218|DRUG|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
41354292|NCT02844322|DRUG|Bortezomib|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
41354293|NCT02844322|DRUG|Rituximab|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
41354294|NCT06212505|OTHER|blood test|blood test at the inclusion 10 tubes of 2.7mL blood
41354295|NCT01662752|DRUG|Indocyanine green|Please see arm description
41354296|NCT02557633|BIOLOGICAL|Grass MATA MPL 10200|
41354297|NCT02557633|BIOLOGICAL|Grass MATA MPL 18200|
41494742|NCT00127218|DRUG|niacin|long-acting niacin daily for 18 months
41494743|NCT00127218|DRUG|Placebo|matching placebo pill daily for 18 months
41494744|NCT03107312|PROCEDURE|Single blood sample collection|Collection of single blood sample of 10 ml volume by venepuncture
41494745|NCT02634359|DEVICE|EarlySense home device|Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
41354298|NCT02557633|BIOLOGICAL|Placebo|
41494746|NCT02634359|PROCEDURE|Vaginal ultrasound|Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
41021317|NCT00607841|DRUG|Ispinesib|14 mg/m2 dose as a 1-hour intravenous infusion.
41021318|NCT06567912|BEHAVIORAL|TEE simulation curriculum|The curriculum comprised of one-hour lecture and 3-hour hands-on training on a simulation model.
41021319|NCT02598726|DRUG|Curcumin|Given PO
41021320|NCT02598726|OTHER|Laboratory Biomarker Analysis|Correlative studies
41354299|NCT02020213|DRUG|Posaconazole|400 mg po bid for 8 weeks
41354300|NCT00026624|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
41354301|NCT00026624|DRUG|Keyhole-Limpet Hemocyanin|
41354302|NCT00002986|DRUG|carmustine|
41354303|NCT00002986|DRUG|topotecan hydrochloride|
41354304|NCT06054594|OTHER|Resistance exercise|After baseline testing, participants followed a progressive resistance training program 3 times a week for 4 months.
41021321|NCT02598726|DIETARY_SUPPLEMENT|Piperine Extract (Standardized)|Given PO
41021322|NCT02598726|OTHER|Quality-of-Life Assessment|Ancillary studies
41021323|NCT00945516|DEVICE|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
41021324|NCT00945516|DEVICE|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
41021325|NCT05580900|OTHER|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment.
41021326|NCT05580900|OTHER|Live Modality (control)|For this evaluation, the live or in-person modality is considered the control group.
41021327|NCT02792582|RADIATION|Proton Therapy|The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
41021328|NCT02792582|PROCEDURE|Surgery|When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
41021329|NCT02805192|DEVICE|Size Measurement by a Smart phone App|
41021330|NCT04816357|OTHER|Questionaire|only questionaire
41021331|NCT06444789|DEVICE|connected smartwatch|The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.
41159945|NCT03209297|OTHER|TMD treatment: physiotherapy and/or occlusal splints|The patient will receive the most appropriate TMD treatment, based on current literature.
41159946|NCT04021927|DEVICE|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
41494747|NCT02634359|PROCEDURE|Blood Test|Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
41494748|NCT00370812|PROCEDURE|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
41494749|NCT03368456|BEHAVIORAL|S4E|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs and a forthcoming module on tobacco prevention and cessation.
41494750|NCT03368456|BEHAVIORAL|Usual Care|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
40834910|NCT05996042|BEHAVIORAL|Time-restricted diet|"On Tuesdays, Thursdays and Saturdays, only eating is allowed between 7am and 3pm. The rest of the time, only drinking pure water is allowed, which is an eight-hour eating window and a 16-hour fasting period.~On Mondays, Wednesdays and Fridays, under the unified guidance of the physical education teachers of the Health Science Department from 6:00 PM to 7:00 PM, the venue is the gymnasium and sports field of Peking University Health Science Center. The exercise items include aerobics, yoga and comprehensive physical training."
41159947|NCT06197113|DEVICE|Magstim Rapid2 Magnetic Stimulator|For TMS, the Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device, available in our center, was used.
41494751|NCT03753763|DRUG|Safinamide Methanesulfonate|100 mg (free base)
41494752|NCT03753763|DRUG|Safinamide Methanesulfonate matching placebo|100 mg placebo
41494753|NCT03275116|DRUG|Tiotropium 'Respimat' 5 mcg|Once daily single bronchodilation
41494754|NCT03275116|DRUG|Aclidinium Bromide/Formoterol Fumarate 340/12 mcg|Twice daily dual bronchodilation
40834911|NCT04627285|DRUG|Lacosamide|"* Pharmaceutical form: Oral-solution~* Route of administration: Oral use~Subjects will receive lacosamide in a pre-specified sequence during the Treatment Period."
40834912|NCT00002447|DRUG|Ritonavir|
40834913|NCT00002447|DRUG|Efavirenz|
41159948|NCT02642159|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
41494755|NCT00977886|DRUG|Placebo|Oral, 10 days
41494756|NCT00977886|DRUG|ELB353|Oral, 10 days
41494757|NCT02107365|DRUG|Asunaprevir|Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24
40834914|NCT00002447|DRUG|Saquinavir|
41159949|NCT02642159|DRUG|Statins|Statins at stable dose without other LMT as clinically indicated.
41354305|NCT05610228|OTHER|NO intervention|No intervention
41494758|NCT02107365|DRUG|Daclatasvir|Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24
41354306|NCT05613491|DRUG|Intranasal insulin|Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
41354307|NCT05613491|DRUG|Intranasal saline|Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
41354308|NCT00286234|DRUG|omega-3 acid ethyl esters|4 q qd
41354309|NCT00286234|DRUG|extended release niacin|2 g qpm
41354310|NCT00286234|DRUG|placebo|omacor placebo plus niaspan placebo
41354311|NCT00286234|DRUG|omega-3 acid ethyl esters|4 g qd
41354312|NCT00286234|DRUG|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
41354313|NCT03490123|DRUG|R1-Total community treatment with azithromycin|At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
40834915|NCT00254683|DEVICE|PET/CT with FDG|PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
41159950|NCT02642159|DRUG|Ezetimibe|Pharmaceutical form: tablet Route of administration: oral
41159951|NCT02642159|DRUG|Fenofibrate|Pharmaceutical form: tablet Route of administration: oral
41159952|NCT02642159|DRUG|Nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
41354314|NCT03490123|DRUG|R2-Total community treatment with azithromycin|At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
41354315|NCT03490123|DRUG|R3-Total community treatment with azithromycin|At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
41354316|NCT03490123|DRUG|R2-Total targeted treatment with azithromycin|At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
41354317|NCT03490123|DRUG|R3-Total targeted treatment with azithromycin|At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
41354318|NCT05920655|DIAGNOSTIC_TEST|Optic coherence tomography|Eye examination of patients with optic coherence tomography test by an ophthalmologist
41494759|NCT02107365|DRUG|Ribavirin|Ribavirin tablets or capsules 200 mg, weight-based daily dose ( \<75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24
41494760|NCT02107365|DRUG|Pegylated Interferon alpha-2a|Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24
41494761|NCT03659292|OTHER|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
41494762|NCT03659292|OTHER|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine and 0.5ug/ml sufentanil infusion) will be provided after surgery.
41354319|NCT04890028|RADIATION|F-DOPA PET/CT|"All subjects will be imaged~1 time injection of 2 MBq/kg of 18F-DOPA"
41354320|NCT02924766|DRUG|Niraparib|Participants will start with niraparib 200 mg once daily.
41354321|NCT02924766|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4\*60 mg) once daily orally.
41494763|NCT03659292|OTHER|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
41354322|NCT02924766|DRUG|Abiraterone Acetate|Participants will receive 1000 mg (4\*250mg) once daily.
41494764|NCT03659292|OTHER|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
41494765|NCT06251492|RADIATION|Stereotactic body radiotherapy|8 Gray x 3 for 2 cycles
41494766|NCT06251492|DRUG|Adebrelimab|Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression
41494767|NCT02567643|RADIATION|Stereotactic Radiosurgery|
41494768|NCT06359626|DRUG|YHP2205|Test drug: YHP2205
41494769|NCT06359626|DRUG|YHR2401|comparator: YHR2401
41494770|NCT01743950|DRUG|Bevacizumab|10mg/kg every 2weeks.
40834916|NCT01293981|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
41159953|NCT02642159|DRUG|Omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
41354323|NCT02924766|DRUG|Prednisone|Participants will receive 10 mg (1\*5 mg twice daily).
41354324|NCT05393778|PROCEDURE|Measured Technique|Manual intra-operative checks and tools are used to aid in component placement during surgery.
41354325|NCT05393778|PROCEDURE|Navigated Technique|IntelliJoint® navigation is an imageless-based navigation system that utilizes a miniature infrared camera and microelectronics to measure hip center of rotation, acetabular inclination and version, leg length, and offset. The device provides accurate real-time data on implant positioning to aid in placement of the components during surgery.
40834917|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x1010 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
40834918|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x109 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
40834919|NCT02189707|OTHER|Placebo powder in capsules|Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
40834920|NCT04798469|DRUG|Testosterone Undecanoate 250 MG/ML|Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
40834921|NCT04798469|DRUG|Placebo|Intramuscular administration of placebo at baseline, weeks 4, and week 14.
40834922|NCT04152434|DRUG|Erenumab Auto-Injector|Assess synergy of add on medication to Erenumab
41159954|NCT02642159|DRUG|Antihyperglycemic Drug|Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
41354326|NCT03604094|PROCEDURE|Ultrasonographic evaluation|Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
41354327|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
41354328|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
41354329|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
41354330|NCT01023139|BEHAVIORAL|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
41354331|NCT00161720|DRUG|Protein C Concentrate (Human) Vapor Heated|Protein C Concentrate (Human) Vapor Heated
41354332|NCT05447559|DRUG|Cefazolin|Intravenous administration of 2 g cefazolin
41354333|NCT05447559|DRUG|Water for injection|Intravenous administration of 10mL sterile water for injection
41354334|NCT06103266|DRUG|Rivaroxaban|Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
41354335|NCT03348644|DIETARY_SUPPLEMENT|Phosphate tablets.|
41354336|NCT03348644|DIETARY_SUPPLEMENT|High cheese intake.|
41354337|NCT03348644|DIETARY_SUPPLEMENT|High milk intake.|
41354338|NCT02912793|DRUG|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
41354339|NCT02020564|BEHAVIORAL|Speed of Processing Training|
41354340|NCT02020564|BEHAVIORAL|Placebo Control|
41354341|NCT02624661|DRUG|Glycerol|
41354342|NCT05687266|DRUG|Datopotamab deruxtecan|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
41354343|NCT05687266|DRUG|Durvalumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
41354344|NCT05687266|DRUG|Carboplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
41354345|NCT05687266|DRUG|Pembrolizumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).
41354346|NCT05687266|DRUG|Cisplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
41354347|NCT05687266|DRUG|Pemetrexed|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
41354348|NCT05687266|DRUG|Paclitaxel|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
41354349|NCT02256150|DRUG|Mizoribine (MZR)|
41354350|NCT02256150|DRUG|Cyclophosphamide (CTX)|
41354351|NCT03186079|DRUG|Xiaojidaozhi Decoction|Mixture of twelve Chinese herbal medicines granule
41354352|NCT03186079|DRUG|Placebo|Mixture of 10% Chinese herbal medicines granule and 90% artificial gum
41354353|NCT03186079|DRUG|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
41354354|NCT03186079|BEHAVIORAL|Toilet training|Toilet training has been considered a routine method in treatment of constipation
41354355|NCT00442611|DRUG|Abatacept|
41354356|NCT00442611|DRUG|Placebo|
40834923|NCT04035746|OTHER|Observation of microcirculation and plasticity of the brain|Assessment of microcirculation, brain plasticity and clinical function
41159955|NCT03792789|DEVICE|mCIMT with real rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~rTMS will be provided using figure of eight shaped coil and TMS stimulator ((Magventure Denmark, X100 with mapoption) over contra-lesional primary motor cortex over 10 sessions of 20 minutes each spread over 4 weeks. Each session will comprise priming ( 10 minutes of 6Hz rTMS at 90% of resting motor threshold, delivered in two trains per minute with 5 seconds per train and 25-seconds intervals between trains (a total of 600 priming pulses)). Priming will be followed immediately by additional 10 minutes of 1Hz rTMS at 90% of resting motor threshold without interruption (a total of 600 low-frequency pulses)."
41159956|NCT03792789|DEVICE|mCIMT with sham rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~Sham rTMS will be given using a sham coil."
41159957|NCT06293014|DRUG|TAS-102+bevacizumab|TAS-102 35mg/m2, PO, D1-5, repeated every 14 days; Bevacizumab 5mg/kg, IV, D1, repeated every 14 days; Q4w.
41159958|NCT06293014|DRUG|Standard chemotherapy+bevacizumab|Standard chemotherapy (chemotherapy regimen based on investigator's choice, including FOLFIRI, FOLFOX, or CAPEOX); Bevacizumab
41159959|NCT03231761|OTHER|Service user testimonial videos|Service users describe their personal experiences receiving care for depression or psychosis and the impact of the treatment on their quality of life
41159960|NCT03231761|OTHER|mhGAP didactic video|Video with a narrated slide presentation describing diagnosis and treatment of depression and psychosis
41159961|NCT00355732|PROCEDURE|Weaning from mechanical ventilation|
41159962|NCT04850859|OTHER|measure various dimensions of the glenoid|measurement of Superior-Inferior glenoid diameter ,Anterior-Posterior glenoid diameter and study shape of the glenoid cavity .
41159963|NCT04850859|OTHER|measure various dimensions of the acetabulum|measurement of transverse diameter of the acetabulum ,vertical diameter of the acetabulum, depth of the acetabulum ,Width of acetabular notch and study shape of anterior acetabular ridge and ends of lunate surface .
41159964|NCT00074178|BIOLOGICAL|filgrastim|
41159965|NCT00074178|BIOLOGICAL|pegfilgrastim|
41159966|NCT00074178|DRUG|cyclophosphamide|
41159967|NCT00074178|DRUG|cytarabine|
41159968|NCT00074178|DRUG|dexamethasone|
41159969|NCT00074178|DRUG|etoposide phosphate|
41159970|NCT00074178|DRUG|methotrexate|
41159971|NCT05936905|OTHER|Acupuncture|Acupuncture 1 time per month
41159972|NCT05936905|OTHER|Chiropractic|Chiropractic 1 time per month
41159973|NCT01968083|BIOLOGICAL|RSV cps2 Vaccine|10\^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
41159974|NCT01968083|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
41159975|NCT05737797|PROCEDURE|cervical cytology during surgery.|Cervical cytology will be performed by the surgeon in the operating theatre before hysterectomy.
41159976|NCT06348498|DRUG|Jia Shen Tablet|Jia Shen Tablets contain 4 tablets (0.47 g per tablet), take orally, 2 times a day for 12 weeks
41159977|NCT01203956|DEVICE|SmartFlex|Device used with smartflex engaged.
41159978|NCT01203956|DEVICE|Standard|
41159979|NCT06390085|OTHER|Soft tissue manipulation|The clinician will perform a soft tissue massage intervention where she/he will use moderate massaging and compression. The amount of pressure is less than 5 N, the velocity is low at a controlled rate of 1 Hz, the duration of 30 seconds, angle 90 and 45 degrees.
41494771|NCT01743950|RADIATION|PRDR|Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
40834924|NCT04077294|OTHER|Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring|Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
41159980|NCT03357471|DRUG|e-Device|"* Active Substance: Certolizumab Pegol~* Pharmaceutical form: Solution for injection~* Route of administration: subcutaneous injection by e-Device"
41159981|NCT01116440|DRUG|BGS649|0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
41159982|NCT01116440|DRUG|Placebo|Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
40834925|NCT04077294|OTHER|Use of traditional perioperative cardiac risk stratification only|Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
41159983|NCT03074383|BEHAVIORAL|Workshop|A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.
41159984|NCT03074383|BEHAVIORAL|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
41159985|NCT03902145|OTHER|Egg|One egg per day for 6 months
41159986|NCT01184859|DRUG|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
41159987|NCT01184859|DRUG|Placebo|Placebo melt tablet for sublingual administration
41159988|NCT04106336|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict
41159989|NCT02636751|BEHAVIORAL|12-week prehabilitation program|stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
41159990|NCT02636751|DEVICE|Walking aid adjustment|Walking aid adjustment
41159991|NCT02636751|BEHAVIORAL|Information about pain control|General information about pain control, such as ice application and medication usage
41494772|NCT06117878|DRUG|NK510|NK510 will be administered through intravenous infusion.once a week，for a total of six times.
41494773|NCT06117878|DRUG|NK510|NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.
41354357|NCT00688649|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
41354358|NCT00688649|DIETARY_SUPPLEMENT|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
41354359|NCT01931189|BIOLOGICAL|NI-071|100mg/vial
41354360|NCT01931189|BIOLOGICAL|Infliximab|100mg/vial
41354361|NCT02504424|DEVICE|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
41354362|NCT02589873|BEHAVIORAL|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
41354363|NCT02589873|BEHAVIORAL|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
41494774|NCT00643136|DRUG|Pregabalin|Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
41021332|NCT01816620|DRUG|Lenalidomide, Dexamethasone|"12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle."
41021333|NCT04960813|BEHAVIORAL|Structured games|"Camp Kidpower - Structured Games is an interactive, child-friendly camp and is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 15 different exercises will be taught. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Playgroup intervention.~Parents will be asked to attend an approximately one-hour group meeting, during which information is presented regarding child anxiety, effortful control and the rationale for this treatment. Parents are asked to continue to utilize the intervention at home every day if possible with the child and will receive texts or emails to track the games that are played at home."
41159992|NCT01309633|DRUG|12.5mg sunitinib with Cisplatin and Gemcitabine|"1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
41159993|NCT01309633|DRUG|25mg Sunitinib alternating with Cisplatin and Gemcitabine|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
41354364|NCT05607849|OTHER|"Leaflet decidons ensemble (making a decision together)"|"At the beginning of the intervention, material i) informing women of the existence of the DA for participation or not in breast cancer screening and (ii) aiming to promote the implementation of shared medical decision will be sent or not sent to women and their GPs according to their allocation arm. This material will be sent at the same time as the breast cancer screening invitation letter.~For the secondary outcomes, questionnaires will be sent to a sample of women in each arm."
41354365|NCT01246024|DEVICE|ERG|scotopic and photopic ERG
41354366|NCT04765306|DEVICE|Traditional Direct Fascial Closure|Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.
41354367|NCT04765306|DEVICE|Fascial Closure Device|Fascial closure using a fascial closure device under direct laparoscopic guidance.
41354368|NCT01092572|DRUG|Simvastatin|simvastatin 40 mg per day orally for 12 weeks.
41354369|NCT01092572|DRUG|placebo|placebo 1 tablet once daily for 12 weeks
41494775|NCT00643136|DRUG|Placebo|Matching placebo capsules twice daily for 28 days
41354370|NCT05940051|DRUG|Zanubrutinib, Polatuzumab vedotin and Rituximab|Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1
41354371|NCT05416385|OTHER|Carotid Contrast Enhanced Ultrasound|Carotid Contrast-Enhanced Ultrasound (CEUS), a diagnostic ultrasound enhancing agent that opacifies the blood to delineate the vessel walls.
41354372|NCT02177942|OTHER|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
41354373|NCT02177942|OTHER|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
41354374|NCT04249791|PROCEDURE|Transplantation of the uterus from live donor.|Laparoscopic-robotic hysterectomy for uterine transplantation in live-donor patient.
41494776|NCT03463382|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block will be administered under general anesthesia before the surgery
41494777|NCT03463382|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block will be administered under general anesthesia before the surgery
41494778|NCT03463382|DRUG|Bupivacaine (Block Drug)|0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
41494779|NCT05880212|OTHER|Usual physiotherapy care|In Phase 1, physiotherapists will provide treatment for participants with chronic low back pain in accordance with their current standard physiotherapy practice. Physiotherapists will be free to choose the treatment approach they wish to.
40834926|NCT02880995|DEVICE|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
41354375|NCT04059354|BEHAVIORAL|Speech therapy addressing phonology and motor learning|Determine the efficacy of a newly devised intensive speech treatment plan (DS-DxTx) focusing on vowels that combines efficacious treatment approaches to use with individuals with Down syndrome. The phonological speech intervention, Phonological Cycles approach, is designed for use with children with highly unintelligible speech and the speech motor learning intervention, Script training is a functional treatment to promote phrase level productions. Both approaches are documented to be efficacious with other speech disorders. The proposed approach takes into account the multiple deficits commonly present in individuals with DS, and based on the acoustic and perceptual finding on vowels from our VTLab. Acoustic and perceptual measures will be used to assess treatment efficacy.
41354376|NCT01126528|DIETARY_SUPPLEMENT|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
41354377|NCT01126528|DIETARY_SUPPLEMENT|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
41354378|NCT05244421|OTHER|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
41494780|NCT05880212|OTHER|Individualized (STOPS) physiotherapy|In Phase 3, participants will receive individualized physiotherapy in accordance with the Specific Treatment of Problems of the Spine (STOPS) approach modified for chronic low back pain. Treatment will be individualized on the basis of biopsychosocial assessment findings including dominant pain type (nociceptive, neuropathic or nociplastic), pathoanatomical subgroups (if any), and other barriers to recovery (eg. inflammation, depression, anxiety, stress, catastrophising, pain self-efficacy, and unhelpful motor control strategies). Available treatment strategies will include individualized education/advice, exercise, manual therapy, activity modification/facilitation, goal setting, motor control optimisation, cognitive-behavioural strategies, inflammation management, pain management strategies, sleep management, work management, and relaxation approaches.
41494781|NCT00822406|DRUG|homeopathic medicine|individualized homeopathic medicine
41494782|NCT00822406|DRUG|placebo|placebo - 6 months
41494783|NCT03895671|DRUG|Ponatinib|"Induction phase (first three cycles)~- ponatinib: 45 mg/day orally continuously~Following the results of disease evaluation after 3 cycles:~* Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~* Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Maintenance therapy:~Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day"
41159994|NCT01309633|DRUG|7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
41159995|NCT01309633|DRUG|2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
41354379|NCT04719533|OTHER|Pre-marking of episiotomy location|A template marking the pre-determined correct location of episiotomy will be used to mark to women in the interventional group
41354380|NCT04121182|OTHER|On-line training|"Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia)."
41354381|NCT04121182|OTHER|Usual practice|Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
41354382|NCT06105502|BEHAVIORAL|Psychotherapy education|Psychotherapy education, including supervision, lectures, and workshops
41354383|NCT05613244|OTHER|Phone call|Patients will be asked to complete a questionnaire via a phone call
40834927|NCT02880995|BEHAVIORAL|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
41354384|NCT01021553|DRUG|GSK557296|50 mg GSK557296
41354385|NCT01021553|DRUG|GSK557296|150 mg GSK557296
41354386|NCT01021553|DRUG|placebo|placebo
41354387|NCT01029691|DEVICE|Positive Airway Pressure|Women will use positive airway pressure until delivery
41354388|NCT04467138|DRUG|Omegaven|Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
41354389|NCT00904436|DRUG|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
41354390|NCT02133144|BEHAVIORAL|overeating fat|
41354391|NCT02133144|BEHAVIORAL|overeating carbohydrate|
41354392|NCT01218061|OTHER|Pre-diabetes screening|The timing of the study is :- Screening of high metabolic risk patients based on a clinical score : Finnish Diabetes Risk Score ≥ 15- if Diabetes Risk Score ≥ 15 or if history of blood glucose between 1.10 and 1.26 g/l (impaired fasting glucose): measuring fasting glycaemia + HbA1C + lipids profile + creatinemia + liver enzymes- if fasting blood glucose between 1.10 and 1.26 g/l (=V0):\* OGTT (oral glucose tolerance test) to identify subjects with impaired glucose tolerance (optional)\* establishment of a serum bank to identify biomarkers (serum, genomic, proteomic) - to plan for 10 years annual follow-up (V1 to V10) with blood sample (fasting glycemia + HbA1C + lipids profile + creatinemia + liver enzymes + serum bank (not after V5)) Making a total of 11 visits (V0-V10) with 6 blood samples.
41354393|NCT06272279|DEVICE|spinal stimulation-DCS|transcutaneous spinal stimulation by direct current stimulation
41354394|NCT06272279|OTHER|spinal stimulation-sham DCS|sham transcutaneous spinal stimulation by direct current stimulation
41354395|NCT06272279|OTHER|spinal stimulation-EPS|transcutaneous spinal stimulation by electrical pulsed stimulation
41354396|NCT06272279|OTHER|sham spinal stimulation-EPS|sham transcutaneous spinal stimulation by electrical pulsed stimulation
41354397|NCT02367196|DRUG|CC-90002|
41354398|NCT02367196|DRUG|Rituximab|
41354399|NCT06459856|OTHER|Balloon blowing|Ask the patient to take in a deep breath; steadily and slowly blow up the huge balloon. See the balloon getting bigger, and bigger. Now ask the patient to close the eyes and imagine the balloon floating into the air. Let the patient continue blowing of balloons until he or she gets relaxed and calm.
41354400|NCT06459856|OTHER|Percussion|Percussion is a technique involving rhythmic tapping or clapping on the chest or back, serves as a means to move and loosen retained secretions within the airways. This mechanical intervention helps in removing mucus from the bronchial walls, and facilitates its expectoration and clearance
41354401|NCT01172561|BEHAVIORAL|Lay Health Advisor Education Intervention|The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.
41494784|NCT03895671|DRUG|Azacitidine|"Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:~- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks~No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%\<MR4≤0.01%;"
41494785|NCT02897583|PROCEDURE|YAG vitreolysis|
41494786|NCT01844739|DRUG|NVN1000 4% Gel|Applied topically twice daily
41494787|NCT01844739|DRUG|Vehicle Gel|Applied topically twice daily
41494788|NCT02658838|DRUG|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
41354402|NCT01172561|BEHAVIORAL|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
41354403|NCT05331144|DRUG|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) will be used to treat high blood pressure. Additional antihypertensive medications may be used if needed.
41354404|NCT05331144|OTHER|PCP|Participants will follow their PCP's recommendations for BP control.
41354405|NCT02918006|BIOLOGICAL|VXA-A1.1|Enteric coated oral vaccine tablet
41354406|NCT02918006|BIOLOGICAL|Fluzone®|Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection
41354407|NCT02918006|OTHER|Placebo Tablets|Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product
41354408|NCT02918006|OTHER|Saline Solution for Placebo IM Injection|
41354409|NCT03397199|DRUG|Apatinib + S-1|Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA \<1.4, 60mg bid BSA\>1.4），bid,from day1-day 14.
41354410|NCT04330794|OTHER|NMFACT|caries index
41354411|NCT04330794|OTHER|DMF index|caries index chart to collect data about decayed missed filled teeth
41354412|NCT06371326|DRUG|ZT002 Injection|Participants will receive ZT002 by subcutaneous (SC) injection.
41494789|NCT02658838|DRUG|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
41494790|NCT02658838|DRUG|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
41494791|NCT02658838|DRUG|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
41354413|NCT06371326|DRUG|Placebo|Participants will receive Placebo by subcutaneous (SC) injection.
41354414|NCT02429206|OTHER|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
41354415|NCT02429206|OTHER|standard moisturizing cream (Glaxal Base)|
41354416|NCT03432819|BEHAVIORAL|Siempre Seguiré|A culturally congruent CBT group intervention for HIV-positive LMSM, to include strategies for ART adherence and retention in HIV care.
41354417|NCT06315894|DEVICE|SuperCAP Program|"Distance program including tasks and exercises to improve cognitive, emotional, and functional status.~The intervention will be applied via cell phone and will have a duration of 3 months (12 weeks).~Tasks and exercises will be performed 5 days per week. Contents of the program will include daily exercises, daily games, daily videos, and weekly videos.~They will address cognitive functions, daily habits, and lifestyle factors in general.~Compliance will be monitored to control the adherence to the intervention. The program has been designed specifically for people with post-COVID syndrome."
41354418|NCT03630185|DEVICE|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
41354419|NCT03630185|DEVICE|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
41354420|NCT02297204|PROCEDURE|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
41354421|NCT02297204|DRUG|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
41354422|NCT03864029|DRUG|KUVAN|retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN
41354423|NCT02770872|OTHER|Observation of SAA on apoB containing lipoproteins|attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
41354424|NCT03234257|DEVICE|UF-ultrasound|the carotid plaque stability by UF in order to improve the stroke prediction in case of asymptomatic stenosis. A UF-ultrasound approach is a non-irradiating, easily accessible, and low cost technique
41354425|NCT05709587|OTHER|Virtual reality training|Virtual reality Training for 12 sessions, two to three times for one week, one training session last for 20 minutes
41354426|NCT01962909|DRUG|PTP-01|Dose level 1 is 10mCi (50ug of peptide)
41354427|NCT03436992|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C, Vitamin E, alpha lipoic acid
41354428|NCT03436992|DIETARY_SUPPLEMENT|Resveratrol|1500 mg trans-resveratrol
41494792|NCT03880916|DRUG|Duloxetine|"1. Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
41021334|NCT04960813|BEHAVIORAL|Playgroup|"Camp Kidpower - Playgroup includes structured play activities. This will include art activities, dramatic play props, and a story time. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Kidpower intervention.~During the first week parents will attend an approximately one-hour group meeting, during which information is presented regarding the positive benefits of child-led play and special time with caregivers.~Parents well be asked to complete homework with their children during the week between sessions, and are shown how to track time spent in this activity. Parents will receive a daily text (or email) to to measure frequency of homework practice between sessions."
41354429|NCT03436992|OTHER|Placebo|placebo
41354430|NCT03542292|DIAGNOSTIC_TEST|placental drainage|
41354431|NCT05612191|DRUG|AL3818|It inhibits VEGFR2-mediated downstream signal transduction, thereby inhibiting tumor angiogenesis. It also has high potency against FGFr as well as VEGFr, and as such acts as a mainly dual inhibitor.
41354432|NCT03011164|PROCEDURE|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
41354433|NCT00553904|DIETARY_SUPPLEMENT|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
41354434|NCT00208715|DRUG|Provigil|
41354435|NCT01181336|BIOLOGICAL|Influenza vaccine (FLU-v)|Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
41354436|NCT01181336|BIOLOGICAL|FLU-v Control|Adjuvant only or water for injection only Administration: a single subcutaneous injection
41354437|NCT05472506|DRUG|IK-175 + nivolumab|IK-175 + nivolumab
41354438|NCT02952430|PROCEDURE|Emergency laparotomy|Patients already undergoing emergency laparotomy - groups divided pre-operatively into frail and not frail based on modified Rockwood score. Then outcomes observed.
41354439|NCT00887094|BEHAVIORAL|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
41354440|NCT00887094|BEHAVIORAL|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
41021335|NCT04691479|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|"1. MEntA: Educational \& Training Program~2. Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~3. Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~4. Identification of Care plan and Schedule next visits~5. Follow-up D30-D60-D90-D180 depending of the care plan, through the channel that belong for each care plan"
41354441|NCT01551381|DRUG|EV-077|twice daily oral administration
41354442|NCT01551381|DRUG|Placebo|twice daily oral administration
41354443|NCT05832866|OTHER|Clinical Based Isometric contraction strengthening Exercises using Thera band|Patients did isometric contraction exercises using thera band in the clinic physically. They did not need to be monitored by telephone
41354444|NCT05832866|OTHER|Telemonitored Home based Isometric Cntraction strengthening exercises using Thera band|Patients did isometric contraction exercises using thera band at home, they were monitored by telephone three times in a week for 8 weeks
41354445|NCT00324454|BIOLOGICAL|Levetiracetam|Levetiracetam 1500 mg BID
41354446|NCT05284604|DRUG|Mesenchymal Stem Cells (MSCs)|The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.
41354447|NCT01943136|DRUG|papaya 1% extract ointment|
41354448|NCT01943136|DRUG|mupirocin 2% ointment|
41354449|NCT03419741|DEVICE|Transcranial Magnetic Stimulation Clinical Research System|Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
41354450|NCT01849549|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
41354451|NCT01849549|OTHER|MRI|Anatomical, diffusion, and/or functional MRI
41354452|NCT02783261|OTHER|CT volumetric measurement after Y90 radioembolization|Liver volume will be measure at 3 time points. All patients will undergo CT volumetry at baseline, 4-6 weeks and 8-12 weeks after SIRT. The images are then measured using a commercially available 3D software (Vital's Vitrea Advanced CT Liver Oncology package) and manually corrected, reviewed and resected by a single senior radiologist to ensure consistency in following the same anatomical landmarks.
41354453|NCT01675401|OTHER|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
41021336|NCT04691479|BEHAVIORAL|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
41021337|NCT02418260|PROCEDURE|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
41354454|NCT01675401|OTHER|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
41354455|NCT04327115|PROCEDURE|"Control strategy"|"Patients included in the control group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams."
41354456|NCT04327115|PROCEDURE|"Intervention strategy"|"Patients included in the intervention group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.~They will also get a physical activity program realized with a nurse or a nursing assistant, twice a day (morning and evening) for 5 days. The intervention consists of physical support with mimed instructions, the nature of which depends on the falling risk of the participant :~* High falling risk : out of bed exercise (on a chair for at least 30 min)~* Mild falling risk : out of bed exercise + in front of chair (The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes, on both feet or one foot)~* Low falling risk : out of bed exercise + in front of chair + FTSS exercise (The participant performs a transfer activity of sitting to standing repeated 5 times, with physical assistance or not)"
41021338|NCT02418260|PROCEDURE|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
41021339|NCT02418260|PROCEDURE|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
41021340|NCT03610490|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Given IV
41354457|NCT05293314|DIAGNOSTIC_TEST|an exhaled breath test|All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant.
41354458|NCT03076411|DRUG|Pepsin|
41494793|NCT03880916|DRUG|Placebo|Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
41494794|NCT02425163|DEVICE|Transrectal shear wave elastography of the prostate|Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
41354459|NCT01339845|BIOLOGICAL|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
41354460|NCT01339845|BEHAVIORAL|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
41354461|NCT02099292|DRUG|Rituximab and DexaBEAM|combination treatment
41354462|NCT03710343|DRUG|Metformin|Single case ABA study design. Phase B (intervention period) with metformin administered orally (or by gastrostomy tube) for 16 weeks.
41354463|NCT00397527|DRUG|lactoserum|
41354464|NCT01369667|DIETARY_SUPPLEMENT|Vitamin D3|
41354465|NCT01369667|OTHER|Placebo|
41354466|NCT02604628|BEHAVIORAL|Antibiotic Stewardship Intervention|The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.
41354467|NCT00060567|DRUG|E7070 + irinotecan combination|Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
41354468|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
41354469|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
41354470|NCT01802242|RADIATION|Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy|"Patients in this group will receive one of 2 treatment arms of their choice:~* Arm 1: VMAT delivery with integrated VMAT boost (IB-VMAT) GTV: 95Gy in 38fractions~* Arm 2: HDR-boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT"
41354471|NCT01802242|OTHER|No Active Treatment - completed Prior Radiation|Already had prior radiation treatment. MRI-guided prostate biopsy at 3 years and PSA per standard practice
41354472|NCT02109939|GENETIC|GeneSight Psychotropic|"The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented."
41354473|NCT01603628|BIOLOGICAL|botulinum toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.
41354474|NCT01603628|DRUG|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1.
41354475|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
41354476|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
41494795|NCT02425163|PROCEDURE|Transrectal random biopsy of the prostate|TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
41494796|NCT01292226|DRUG|mycophenolate mofetil|1 g PO BID for 24 weeks
41494797|NCT01292226|DRUG|antibody induction|According to manufacturer recommendation
41494798|NCT01292226|DRUG|Cyclosporine|According to manufacturer recommendation
41494799|NCT01292226|DRUG|corticosteroid|According to manufacturer recommendation
41494800|NCT01104792|DRUG|Cariprazine|Cariprazine was supplied in capsules.
41354477|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
40834928|NCT02880995|DRUG|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
41354478|NCT02411968|OTHER|111In-Girentuximab DOTA SPECT|
41354479|NCT03824704|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
41354480|NCT03824704|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
41354481|NCT04044625|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.
41354482|NCT04044625|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
41354483|NCT02659839|OTHER|Cancer patients admitted to the ICU|There will be no change in the standard ICU treatment.
41354484|NCT03883295|PROCEDURE|Control|The specimens will be root canal treated conventionally
41354485|NCT03883295|PROCEDURE|NeoMTA Plus|The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
41354486|NCT04597424|DRUG|Experimental: doxycycline|"2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days."
41354487|NCT04597424|BIOLOGICAL|Bexsero® vaccine|1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.
41354488|NCT05703789|PROCEDURE|Dental rehabilitation with either composite resin of crown therapy|Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
41354489|NCT05703789|OTHER|Waiting list|Waiting list. Patients randomized to this group will not receive any intervention but answer questionnaires after 4 months on waiting list
41354490|NCT01431794|DRUG|LDE225-600mg|"Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days."
41354491|NCT01431794|DRUG|Gemcitabine|Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
41354492|NCT01431794|DRUG|nab-paclitaxel|Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
41354493|NCT01431794|DRUG|LDE225-400mg|Phase I: oral LDE225 (Sonidegib), 400mg daily.
41354494|NCT01431794|DRUG|LDE225-800mg|Phase I: oral LDE225 (Sonidegib), 800mg daily.
41354495|NCT05248542|OTHER|Virtual Reality Usage on Oral Care Knowledge|Virtual Reality Usage on Oral Care Knowledge about independent older adults
41354496|NCT05353218|PROCEDURE|Intermediate cervical plexus block|Intermediate cervical plexus block will be applied in transverse plane using posterior approach at C4.
41354497|NCT05353218|PROCEDURE|Deep cervical plexus block|Deep cervical plexus block will be appliedin transverse plane using anterior approach at C2-3-4.
41494801|NCT03630250|BIOLOGICAL|N. lactamica|Genetically modified N. lactamica
41494802|NCT00004151|DRUG|acridine carboxamide|
41494803|NCT00635063|DRUG|AD 923|
41494804|NCT05569551|DEVICE|Adhesive pouch|Is a barrier dressing categorized under class C medical device. It is used to seal up the umbilical stump to prevent contamination until its cord detachment. It has an adhesive film that sticks to skin with a centrally located non-adhesive pouch ensuring that zero pressure is applied on the umbilicus. It is made of polyurethane, the same material as transparent intravenous cannula dressings making it hypoallergenic waterproof and breathable.
41354498|NCT05007236|DRUG|RP7214 + Standard of care (SOC)|RP7214 tablets will be administered orally twice a day for 14 days
41354499|NCT05007236|DRUG|Placebo + Standard of care (SOC)|Placebo will be administered orally twice a for 14 days
41354500|NCT00284258|DRUG|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
41354501|NCT00284258|DRUG|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
41354502|NCT02621281|DEVICE|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
41354503|NCT02621281|DEVICE|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
40834929|NCT00131456|DRUG|Venlafaxine|375mg/day
40834930|NCT00131456|DRUG|Placebo|Placebo
40834931|NCT01756443|DRUG|2% lidocaine/adrenaline and 0.5% bupivacaine|
40834932|NCT03132519|DRUG|Remifentanil|To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
40834933|NCT01008969|OTHER|SPECT-CT imaging|SPECT/CT for 3-dimensional mapping of 99mTc-sulfur nanocolloid in order to identify personalized lymphatic drainage patterns
41354504|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
41354505|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
41354506|NCT01567072|DRUG|Placebo|Only placebo treatment instead of NSAID painkillers
41354507|NCT03206606|DEVICE|SPIRO|Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
41494805|NCT06351436|BEHAVIORAL|Mindfulness|The mindfulness-based intervention will last for three months, with 6-8 weekly sessions lasting 1.5 hours each. Participants will attend the sessions in a group format, and the sessions will be administered by registered social worker who are specialized in counseling. The intervention is delivered using an immersive virtual reality cave system. The intervention content is designed by a registered clinical psychologist accredited for delivering mindfulness-based intervention and nurses who are experienced in mindfulness training. To ensure protocol adherence, the social workers administering the intervention will receive close supervision from the clinical psychologist. Weekly meetings will be held to discuss and resolve any difficulties or challenges encountered by the social workers.
41494806|NCT05445583|BEHAVIORAL|Motivational Enhancement System (MES)|MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
41494807|NCT05445583|BEHAVIORAL|Supportive Accountability (SA)|Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
41494808|NCT05445583|BEHAVIORAL|Text Messaging (SMS)|SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
41494809|NCT05445583|BEHAVIORAL|Physical Activity Tracking (PAT)|All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
41494810|NCT04903951|DEVICE|Adaptive Servoventilation (ASV) therapy|Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated
41494811|NCT04903951|OTHER|Best medical treatment|Best medical treatment for stroke, including rehabilitation
41494812|NCT05616962|DIETARY_SUPPLEMENT|Diosmiplex|diosmin glycoside in combination with alkaline granules known as alka4-complex
41494813|NCT04447339|PROCEDURE|Nipple Sparing Mastectomy|Prophylactic open NSM procedures
40834934|NCT05227599|OTHER|Online survey questionnaire|Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms
41354508|NCT01567254|BEHAVIORAL|guided imaginary|Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
41354509|NCT01567254|BEHAVIORAL|music ONLY|music. It will be equal in length to the auditory guided imagery disk
41354510|NCT03949816|OTHER|medical consultation: different doctor-patient-centered style of communication|Different doctor-patient communication
41354511|NCT03949816|OTHER|information letter / no medical consultation|In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
41354512|NCT01970436|OTHER|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
41354513|NCT02065635|PROCEDURE|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
41354514|NCT02065635|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
41354515|NCT04284033|DEVICE|Extended Wear Infusion Set|For two of the 4 weeks, the Extended Wear insulin infusion set will be used
41021341|NCT03610490|DRUG|Cyclophosphamide|Given IV
41021342|NCT03610490|DRUG|Fludarabine|Given IV
41021343|NCT03610490|BIOLOGICAL|Interleukin-2|Given IV
41021344|NCT03610490|OTHER|Quality-of-Life Assessment|Ancillary studies
41494814|NCT05104190|OTHER|Stabilization of teeth during debonding using fingure pressure and elastic wafer|To control pain during debonding in one group , teeth were stabilized with finger pressure with cotton between finger and teeth and then debonding using open mouth technique was done. In second group teeth were stabilized using a plastic wafer between maxillary and mandibular teeth and then debonding was done using closed mouth technique. In order to reduce biasness, all of the patients were debonded with same plier and with wires still ligated to brackets. With the help of VAS, pain score was measured after debonding. A single operator performed complete procedure of debonding and pain recording.
41494815|NCT03449004|OTHER|Validation of the OPSI questionnaire|A questionnaire to measure satisfaction with online information for patients with low back pain
41494816|NCT03044717|OTHER|Nutrition survey|Survey will be done prior to the initiation of the education
40834935|NCT05729906|OTHER|psychological and physical tests|"Once included (T0), participants will be reviewed at 6 (T1), and 12 (T2) months. At the three measurement times, research professionals (belonging to the PAVeA laboratory) will carry out, within the nursing home the physical and psychological measurements (classic standardized tests for the population). These measurements will be carried out in parallel with the routine biological explorations performed in the institution.~At each visit, the remaining blood sampled in routine will be frozen in 2 aliquots for metabolomic and spectrometric analyses at the end of the study by the iBrain and Research Center for Respiratory Diseases laboratories."
41354516|NCT04284033|DEVICE|Standard Infusion Set|For two of the 4 weeks, the standard insulin infusion set will be used
41354517|NCT00434876|DRUG|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
41354518|NCT00434876|DRUG|Placebo.|Inactive or inert pill which will be used as a comparator.
41354519|NCT00916994|DEVICE|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
41354520|NCT05853640|OTHER|Usual care|Usual care at the orthopedic department consists of a clinical examination, radiological imaging, and a diagnostic injection. A recommendation to get physical therapy treatment in primary care will be provided, but this intervention will not be controlled by the investigators in any capacity.
41354521|NCT05853640|OTHER|HIPSTER|"Patients will be provided with usual care at the orthopedic department, which consists of a clinical examination, radiological imaging, and a diagnostic injection.~In addition, participants in this group will be referred to physical therapists trained in administering a semi-structured, individualized, progressive treatment. This 16-week intervention targets known physical and psychological impairments in people with long-standing hip and groin pain, using exercise therapy and patient education."
41354522|NCT00207506|BEHAVIORAL|HoMBReS: A lay health advisor approach to STD prevention|
41354523|NCT02714894|DRUG|Clozapine|Patient participants will be starting clozapine as part of their clinical care.
41354524|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
41354525|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
41354526|NCT00090844|DRUG|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
41354527|NCT03586076|BIOLOGICAL|JHL1922|Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
41494817|NCT03044717|OTHER|Educational Conference|A prevention educational conference will be available to attend once every 5 weeks.
41494818|NCT03044717|OTHER|3-hour nutrition module|Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
41494819|NCT00918840|BIOLOGICAL|DermaVir|DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
41494820|NCT00918840|BIOLOGICAL|Placebo|Dextrose/glucose solution
40834936|NCT04366375|DIAGNOSTIC_TEST|PTX-3|Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.
41494821|NCT00918840|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
41494822|NCT02191631|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
41494823|NCT02994940|DRUG|Acetaminophen|already included in arm/group descriptions
40834937|NCT03349866|DRUG|apatinib|apatinib：250mg qd po
41354528|NCT03586076|BIOLOGICAL|dornase alfa|Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
41354529|NCT00570089|DRUG|Ranolazine|500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
40834938|NCT03349866|DRUG|Capecitabine|1000mg/m2 bid d1-14
40834939|NCT03349866|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
40834940|NCT03349866|RADIATION|Radiotherapy|45Gy/25f （1.8Gy/f/d，5 f/w）
40834941|NCT04592900|OTHER|balance exercising|selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
40834942|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
40834943|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
40834944|NCT02877498|OTHER|Adaptive support ventilation|Adaptive support ventilation during invasive mechanical ventilation
40834945|NCT02877498|OTHER|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
40834946|NCT01627444|PROCEDURE|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
40834947|NCT00148447|DRUG|escitalopram|
40834948|NCT05065567|DRUG|Droperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV
40834949|NCT05065567|DRUG|Haloperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM
40834950|NCT05065567|DRUG|Ondansetron 8mg|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
40834951|NCT02535299|DRUG|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
40834952|NCT02535299|DRUG|Metformin|Metformin(1500mg-2000mg/day) treatment for 6 months
40834953|NCT02254785|DRUG|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
40834954|NCT02254785|DRUG|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
40834955|NCT02254785|DRUG|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
40834956|NCT01805544|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
40834957|NCT00499655|DRUG|erlotinib hydrochloride|Given orally
40834958|NCT00499655|DRUG|celecoxib|Given orally
40834959|NCT00499655|OTHER|placebo|Given orally
40834960|NCT00499655|OTHER|laboratory biomarker analysis|Correlative studies
40834961|NCT00499655|OTHER|immunohistochemistry staining method|Correlative studies
40834962|NCT00499655|GENETIC|fluorescence in situ hybridization|Correlative studies
40834963|NCT00499655|GENETIC|mutation analysis|Correlative studies
40834964|NCT00499655|GENETIC|protein expression analysis|Correlative studies
40834965|NCT00499655|GENETIC|gene expression analysis|Correlative studies
40834966|NCT02148432|DRUG|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
40834967|NCT02148432|DRUG|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
40834968|NCT01272791|BIOLOGICAL|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
40834969|NCT01272791|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
40834970|NCT00461305|DRUG|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
40834971|NCT00461305|DRUG|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
40834972|NCT01533922|DRUG|Placebo|placebo matching tiotropium + olodaterol FDC
40834973|NCT01533922|DRUG|Tiotropium|Tiotropium 5 mcg once daily
40834974|NCT01533922|DRUG|Olodaterol|Olodaterol 5 mcg once daily
40834975|NCT01533922|DRUG|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
40834976|NCT01533922|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
40834977|NCT01533922|DEVICE|Respimat|Respimat inhaler
40834978|NCT02641522|DRUG|Siltuximab|Single infusion of siltuximab (11 mg/kg)
41021345|NCT04496609|DEVICE|Stimulation and automated rehabilitation / automated rehabilitation|Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
41021346|NCT04496609|DEVICE|Automated rehabilitation / Stimulation and automated rehabilitation|Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
41021347|NCT05943860|DIETARY_SUPPLEMENT|Pantovigar® vegan|Oral application of 1 capsule three times a day (morning, noon, evening) for 6 months
41494824|NCT02712333|BEHAVIORAL|Air Purifiers|The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.
41494825|NCT02712333|BEHAVIORAL|Sham Air Purifiers|The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
41494826|NCT01955083|DEVICE|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
41494827|NCT01955083|DEVICE|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
41494828|NCT06216223|PROCEDURE|treatment of anal diseases in inflammatory bowel patients|treatment of anal diseases in inflammatory bowel patients
41494829|NCT06216223|DEVICE|Laser|laser
41494830|NCT06216223|PROCEDURE|traditional surgery|traditional surgery
41494831|NCT04676659|DRUG|TNK-tPA|Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
41494832|NCT03190213|DRUG|Pembrolizumab Injection|Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
41494833|NCT05083130|BEHAVIORAL|a wake prone positioning|The team will give written and verbal advice and if necessary aid patients' positioning themselves in the prone position for at least 8 hours per day. The exact duration of prone sessions will be determined according to ward schedules to take account of nursing procedures, meal times and mitigation strategies. Other methods to encourage the maintenance of prone position includes phone calls to patients, carers or education of carers.
41494834|NCT00000259|DRUG|15 % Nitrous oxide|
41494835|NCT00000259|DRUG|0.3 % Sevoflurane|
41494836|NCT00000259|DRUG|30% Nitrous oxide|
41494837|NCT00000259|DRUG|0.6% Sevoflurane|
41494838|NCT00000259|OTHER|Placebo|
41494839|NCT03046407|BIOLOGICAL|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
41494840|NCT05578456|DRUG|Prednisone and Aspirin|prednisone 10 mg and aspirin 75-100mg per day per os
41494841|NCT05578456|DRUG|Placebo|placebo 2 starch tablets per day per os
41494842|NCT03244501|OTHER|Active tSMS|A cylindrical neodymium magnet is placed above the scalp.
41494843|NCT03244501|OTHER|Sham tSMS|A cylindrical piece of nonferrous metal (brass). This is not attracted to magnets, and is identical in weight and appearance to active magnets.
41494844|NCT03832101|BEHAVIORAL|MATB|MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
41494845|NCT04009512|DEVICE|Valiant Thoracoabdominal Stent Graft System|This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
41494846|NCT02653430|PROCEDURE|Sleeve gastrectomy|"After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate theSleeve gastrectomy laparoscopically by a group of experienced surgeons."
41494847|NCT04608435|OTHER|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
41354530|NCT00570089|DRUG|Placebo|Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
41494848|NCT04933968|BIOLOGICAL|ALVR106|Infusion, visually identical to placebo
41494849|NCT04933968|BIOLOGICAL|Placebo|Infusion, visually identical to ALVR106
41494850|NCT02480868|DEVICE|ARTEBONE|4,3 g Bone Void Filler
41494851|NCT01593696|BIOLOGICAL|Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)|Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)
41494852|NCT04865393|DRUG|SPR206|SPR206 100 mg single-dose IV infused over 1 hour
41494853|NCT01604590|RADIATION|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
41494854|NCT03460392|DRUG|Antibiotic therapy|To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
41354531|NCT04726436|OTHER|Dextrose 5% in water|One hour before operation, patients were given dexrose 5%100/hour only for 2 hours to end at about middle of surgery
41354532|NCT04726436|OTHER|Dextrose 10%|One hour before operation, patients were given dexrose 10 %100/hour only for 2 hours to end at about middle of surgery
41354533|NCT04726436|OTHER|Saline placebo|One hour before operation, patients were given normal saline100/hour only for 2 hours to end at about middle of surgery
41354534|NCT05286541|PROCEDURE|Lateralized buccal cortex with xenograft|the buccal cortex of the deficient ridge was separated and lateralized then fixed at the desired distance
41354535|NCT05286541|PROCEDURE|Lateralized buccal cortex with autogenous particulate|lateralized buccal cortex with autogenous particulate
41354536|NCT05825365|DRUG|Selumetinib|Selumetinib
41354537|NCT05825365|DRUG|Placebo|Placebo (Transfer to selumetinib on REiNS-defined PD)
41354538|NCT02672982|OTHER|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
41354539|NCT02672982|OTHER|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
41354540|NCT02003586|DIETARY_SUPPLEMENT|plant-based ingredient|
41354541|NCT02003586|DIETARY_SUPPLEMENT|No plant-based ingredient|
41354542|NCT04073472|DRUG|mesenchymal stem cells (MSCs)|Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
41354543|NCT05051306|OTHER|High-load resistance exercise|Subjects in high-load trial performed 4 sets per exercise, 8 repetitions with load of 85%-8RM with 90 sec of rest between sets.
41494855|NCT02748811|OTHER|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
41494856|NCT00222521|DRUG|Glargine insulin|
41494857|NCT04445363|DRUG|Jaktinib hydrochloride cream|Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks
41494858|NCT04445363|DRUG|Placebo|Dose extension: Placebo
41354544|NCT05051306|OTHER|Low-load resistance exercise|Subjects in low-load trial performed 4 sets per exercise, 15 repetitions with load of 45%-8RM with 90 sec of rest between sets.
41354545|NCT05281549|DRUG|Alteplase|Alteplase 0.9mg/kg are being used.
41354546|NCT05281549|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
41354547|NCT05281549|DRUG|Tenecteplase|Tenecteplase 0.4mg/kg are being used.
41494859|NCT03981419|BIOLOGICAL|GRF6021|for IV infusion
41494860|NCT03981419|OTHER|Placebo|for IV infusion
41494861|NCT01864850|RADIATION|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
41494862|NCT01864850|RADIATION|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
41354548|NCT01696396|DRUG|Abrilumab|Administered by subcutaneous injection.
41354549|NCT01696396|DRUG|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
41354550|NCT02255240|BEHAVIORAL|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
41494863|NCT02829294|DEVICE|E002 - cerumen removal aid|topical treatment
41494864|NCT03058588|GENETIC|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
41494865|NCT03143426|PROCEDURE|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualization as opposed to 2D visualization (conventional method). 3D supposedly provide sharper view with better depth perception and therefore might lead to reduce complication rates.
41509174|NCT04441151|BEHAVIORAL|Pulmonary rehabilitation therapy|Comprehensive interventions based on comprehensive evaluation and customization of patients, including, but not limited to, exercise training, education and behavioral changes, aimed at improving the physiological and psychological status of patients with chronic respiratory diseases, and urge patients to adhere to health promotion activities for a long time.
41354551|NCT05981872|BEHAVIORAL|rehacom|"Rehacom was carried out at the cognition laboratory at Faculty of physical therapy, Cairo University for training of figural memory, attention concentration.~1. Attention concentration training consists of 24 levels of difficulties .~2. Figural memory training consists of 9 levels of difficulties. In the training session, every patient was starting training from level one and when the patient successfully finished the level, the training then Progress to the level of difficulty."
41354552|NCT05091840|OTHER|oximetry monitoring|monitoring oximetry in both groups using the INVOS™ system 5100C Oximeter
41354553|NCT04210232|DEVICE|TECNIS® TORIC II Intraocular Lens (IOL)|Surgeons will perform standardized, small-incision, cataract surgery and implant in one or both eyes the study lenses.
41354554|NCT00065715|DIETARY_SUPPLEMENT|Echinacea|Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = \< 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet
41354555|NCT00065715|OTHER|Blinded placebo|Blinded placebo - Coated tablet
41354556|NCT02088736|DEVICE|Intraosseous|
41354557|NCT02088736|DEVICE|Intravenous|
41354558|NCT00411606|PROCEDURE|Thermography|Subjects will have a picture of their face taken with a thermal camera
41354559|NCT01143116|DEVICE|"Silver-nitrate coated catheter (Catheter A)"|Catheter A releases silver ions into the urethra and urinary bladder upon catheterization.
41354560|NCT01143116|DEVICE|"Degradable silver particle-coated catheter (Catheter B)"|Catheter B releases both silver ions and degradable silver particles into the urethra and urinary bladder upon catheterization.
41354561|NCT03943940|BIOLOGICAL|BM-MNC and UC-MSC|"Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.~UC-MSC: 1-2 x 10\^6 cells/kg"
41354562|NCT03943940|OTHER|Control|Standard medicine
41354563|NCT01547208|PROCEDURE|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
41354564|NCT01547208|PROCEDURE|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
41509175|NCT03216863|OTHER|Respiratory rehabilitation|It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
41354565|NCT02790450|DRUG|Benzbromarone|1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
41354566|NCT01327924|DRUG|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
41354567|NCT03408457|PROCEDURE|Blood sampling after antibiotic administration|Sampling of 6 x 8 mL (in sum 48 mL) via the central venous line (established for the surgical procedure) until postoperative day 2
41354568|NCT01351233|PROCEDURE|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
41354569|NCT00736385|DRUG|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
41354570|NCT00736385|DRUG|Placebo|placebo 2000 mg daily for 12 months
41509176|NCT04842292|DRUG|Heparin|Nebulized heparin 25,000 units every 6 hours
41354571|NCT02986425|OTHER|STRIP intervention|"The STRIP intervention consists of 9 steps:~1. structured history taking of medication~2. recording medication and diagnoses in STRIPA~3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~5. shared decision-making with the patient with possible adaptation of the recommendation~6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~7. generation of general practioner (GP) report~8. delivery of the report to the patient and to the GP (optional additional direct communication)~9. follow-up"
41494866|NCT04034563|PROCEDURE|1) Risk of metachronous advanced neoplasia at 3-year, beyond 3 years surveillance colonoscopy|"3-year group: High-risk subjects who have baseline colonoscopy done in 2014, 2015 and 2016 and will be eligible for 3-year surveillance colonoscopy in 2017-2019.~Beyond 3 years group: High-risk subjects who had screening colonoscopy prior 3 years, but not received or scheduled for a surveillance colonoscopy- either due to non-adherence or limited access to surveillance colonoscopy will be eligible for surveillance colonoscopy in 2017-2019.~For the surveillance interval beyond 3 years group, recruitment will be prioritizing to subjects who had the screening colonoscopy at the earliest date. This will in part ensure that subjects in this group will consist those with the longest surveillance interval, leading to an applicable estimation of the risk of metachronous advanced neoplasia beyond 3 years surveillance interval."
41494867|NCT05979363|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
41494868|NCT05979363|DRUG|VRD-based regimen|Bortezomib, Lenalidomide and Dexamethasone
41354572|NCT02986425|OTHER|Control|Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
41494869|NCT02792608|BEHAVIORAL|Mindfulness-based Therapy|MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
41494870|NCT00638027|DRUG|placebo|matched tablets bid
41494871|NCT00638027|DRUG|memantine|10 mg bid
41494872|NCT06190418|OTHER|Loaded sit to stand strengthening exercise|This Group will be given with the wieghted vest equal to that of 1RM for each child and Sit-to-Stand Strengthening Excerise will be given 3 times per week for 6 weeks
41494873|NCT06190418|OTHER|Unloaded sit to stand strengthening exercise|This Group will be given with the Sit-to-Stand Strengthening Excerise without any external load for 3 times per week for 6 weeks
41494874|NCT01399879|OTHER|Faraday cage, movement stabilization|The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
41494875|NCT05417035|DRUG|Nebido|To evaluate if traditional treatment induces puberty similary to newer treatment
41494876|NCT03365752|DRUG|Chloroprocaine|A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed
41494877|NCT03365752|DRUG|Mepivacaine|A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed
41494878|NCT03365752|DRUG|General Anesthetics|General anesthetics will be administered intravenously
41494879|NCT02032095|DRUG|GB-0998|
41494880|NCT02687529|DEVICE|CST001|
41494881|NCT01470495|OTHER|RFA + Sorafenib|combined RFA and Sorafenib to treat recurrent HCC
41494882|NCT01470495|OTHER|RFA|treat Recurrent HCC with RFA
41494883|NCT02067468|DEVICE|HPV test|QIAGEN - The Digene HPV test®
41494884|NCT02067468|PROCEDURE|COLPOSCOPY|Colposcopy routine health services
41494885|NCT02067468|DEVICE|cytology|Cytology routine health services
41494886|NCT02087189|DEVICE|First ICD/CRT-D implantation or upgrade from pacemaker|
40834979|NCT03645304|DRUG|Ropivacaine|"Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .~Ropivacaine is local analgesics."
41354573|NCT01195636|DRUG|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
41354574|NCT01195636|DRUG|Placebo|Twice daily application of Placebo ointment
41354575|NCT01576887|DRUG|Bardoxolone Methyl 20 mg|Oral, once daily
41354576|NCT01576887|DRUG|Placebo|Oral, once daily
41354577|NCT00462488|DRUG|Vicinium|Intravesical administration of Vicinium
41494887|NCT03944174|PROCEDURE|Fixation of unstable pelvic fractures|Percutaneous fixation of both iliac bones through the sacrum using one screw
41494888|NCT05189886|PROCEDURE|Double Balloon Valvuloplasty in TAVR|The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
41509177|NCT04842292|DRUG|Placebo|Sodium chloride 0.9% every 6 hours
41354578|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
40834980|NCT03645304|DRUG|0.9% saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
41354579|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
41354580|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
41354581|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
41354582|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
41494889|NCT01563835|DRUG|bupivacaine, fentanyl|10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.
41494890|NCT01563835|DRUG|fentanyl|fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
41494891|NCT00478426|DRUG|Sunitinib Malate|Given PO
41354583|NCT03099512|OTHER|SFE|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
41354584|NCT03099512|OTHER|Exercise|Exercises which improves muscle strength, ROM...
41354585|NCT01250899|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
41354586|NCT05718011|DRUG|Dexmedetomidine|0.5 micrograms/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
41354587|NCT05718011|DRUG|Ketamine|0.5 milligrams/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
41354588|NCT04016727|BIOLOGICAL|platelet rich plasma|Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
41494892|NCT01235195|DRUG|sertraline hydrochloride|50 mg capsule, single-dose
41354589|NCT03702452|OTHER|functional rehabilitation nursing program|According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.
41354590|NCT03702452|OTHER|control group|The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
41494893|NCT01235195|DRUG|sertraline hydrochloride|50 mg tablet, single-dose
40834981|NCT03645304|DEVICE|ON-Q Painbuster Silver Soaker|ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA)
40834982|NCT03031392|DIAGNOSTIC_TEST|Sensitivity test|Routine clinical and radiographic examination
41354591|NCT04840914|DRUG|LY3461767|Administered SC.
41494894|NCT03638778|DRUG|Semaglutide 3 mg|Semaglutide 3 mg will be administered once daily (OD) orally in the morning from day 1 to 5.
41494895|NCT03638778|DRUG|Semaglutide 7 mg|Semaglutide 7 mg will be administered OD orally in the morning from day 6 to 10.
41494896|NCT03638778|DRUG|Semaglutide B 3 mg|Semaglutide B 3 mg will be administered OD orally in the morning from day 1 to 5.
41494897|NCT03638778|DRUG|Semaglutide B 7 mg|Semaglutide B 7 mg will be administered OD orally in the morning from day 6 to 10.
41494898|NCT03638778|DRUG|Semaglutide C 3 mg|Semaglutide C 3 mg will be administered OD orally in the morning from day 1 to 5.
41494899|NCT03638778|DRUG|Semaglutide C 7 mg|Semaglutide C 7 mg will be administered OD orally in the morning from day 6 to 10.
41494900|NCT03638778|DRUG|Semaglutide D 3 mg|Semaglutide D 3 mg will be administered OD orally in the morning from day 1 to 5.
41494901|NCT03638778|DRUG|Semaglutide D 7 mg|Semaglutide D 7 mg will be administered OD orally in the morning from day 6 to 10.
41494902|NCT01119508|DRUG|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
41494903|NCT01119508|DRUG|Temozolomide|Induction Phase, 200 mg/m\^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
41354592|NCT04840914|DRUG|Placebo|Administered SC.
41354593|NCT01969604|BEHAVIORAL|Motivational Lifestyle Counselling|"The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.~The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.~Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:~• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand."
41354594|NCT01096615|DIETARY_SUPPLEMENT|Placebo|"Description:~- capsule size 3~Composition of the product:~* 45 mg of microcristalline cellulose,~* 132 mg of maltodextrin,~* 3 mg of magnesium stearate.~Composition of the capsule:~* 46 mg of hypromellose,~* 1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks."
41354595|NCT01096615|DIETARY_SUPPLEMENT|Lactobacillus paracasei LP-33|"Description:~* minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~* capsule size 3 1 capsule daily together with a meal, with a glass of water."
41354596|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy
41354597|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy
41354598|NCT03654638|OTHER|Questionnaire Administration|Ancillary studies
41494904|NCT02861079|DEVICE|Foley catheter|An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
41494905|NCT02861079|DRUG|PGE2|10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
41494906|NCT03102801|DRUG|Humulin S|Humulin S used to induce hypoglycaemia
41494907|NCT05614492|BEHAVIORAL|Individual PrEP Decision Aid|Participant engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV independently. They also enter data independently.
41494908|NCT05614492|BEHAVIORAL|CDC PrEP Video|A video from the Centers for Disease Control and Prevention that provides basic, general information on PrEP
41494909|NCT05614492|BEHAVIORAL|Shared PrEP Decision Aid|Domestic violence service advocate (DVA) engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV with the participant and enters data
40834983|NCT05184764|BIOLOGICAL|AP-SA02|Bacteriophage administered via intravenous bolus infusion
40834984|NCT05184764|OTHER|Placebo|Inactive Placebo administered via intravenous bolus infusion
40834985|NCT02698371|DEVICE|G1-Control: Futurabond®DC-SE (FBDC_SE)|Futurabond®DC (FBDC) adhesive by self-etch (SE) mode bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
41159996|NCT06042023|DEVICE|Lifesignals Wearable Sensor|"The participants will wear the patch for 3-5 days and be provided with the mobile device, which records data transmitted wirelessly directly from the biosensor patch. During the monitoring period, participants can continue their normal activities.~Remote monitoring will be undertaken using the CE-marked LifeSignals wearable biosensor. The biosensor communicates with a commercially available mobile device, which relays data to a secure Cloud server (GDPR compliant data transfer).~Participants will subsequently undergo their planned surgery in the usual way. Data captured from the remote monitoring will not be used or made accessible to inform decisions about clinical care.~There will be no clinical intervention from the researchers if abnormalities in vital signs are picked up by the monitoring patch, as all data will be analysed retrospectively after the participant's operation. Any clinical concerns about the device that arise will be reported to the relevant clinical team."
40834986|NCT02698371|DEVICE|G2-Control: Futurabond®DC_SE_EE|Futurabond®DC adhesive by self-etch mode with selective enamel etching (FBDC-SE-EE) bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
41159997|NCT01915992|OTHER|blood samples|
40834987|NCT02698371|DEVICE|G3: Futurabond® U - ER (FBU_ER)|FuturabondU® (FBU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
41159998|NCT03275402|BIOLOGICAL|131I-omburtamab|Murine IgG1 monoclonal antibody radiolabeled with iodine-131
41354599|NCT05044715|BEHAVIORAL|Treatment as Usual|"Treatment as usual-TAU groups include:~1. Mood Groups - General Process Groups~2. Anxiety Groups - Cognitive Behavioral Therapy~3. Body Image and Eating Concerns Groups~4. Reconciling Faith and Sexuality Groups"
41354600|NCT05044715|BEHAVIORAL|Compassion-Focused Therapy (CFT)|The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.
41354601|NCT05247515|DEVICE|Endoscopic mucosal resection with nexpowder|At the end of the EMR procedure, the patient will be randomized. In the treated group, Nexpowder will be sprayed thanks to a catheter inserted through the operating channel of the endoscope.
41354602|NCT00758316|OTHER|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
41159999|NCT05640947|DEVICE|The Hot AXIOS™ Stent and Electrocautery-Enhanced Delivery System|EUS-guided gastro-gastrostomy using the Hot Axios device: Using a therapeutic endoscopic ultrasound endoscope with a working channel of 3.7mm and under fluoroscopic control, the excluded stomach will be identified and punctured with a 19G needle. Contrast injection will confirm the good position of the needle in the excluded stomach. If needed, the excluded stomach will be filled with blue-stained aqua (5% indigocarmine) until a sufficient distension is obtained for placement of the lumen-apposing metal stent. A lumen-apposing metal stent with a diameter of 20mm will be used according to the manufacterers' instructions to create a gastrogastrostomy. Position will be checked with fluoroscopy.
41160000|NCT01732627|BIOLOGICAL|Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
41160001|NCT01732627|BIOLOGICAL|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous (SC)
41354603|NCT00758316|PROCEDURE|Thoracoscopy|Talc poudrage
41494910|NCT02202070|DRUG|onabotulinumtoxinA|
41354604|NCT03087474|OTHER|Non-Interventional|Non-Interventional
41354605|NCT04152538|OTHER|not intervention but investigation|possible differences in quadriceps muscular activity
41354606|NCT04176562|DEVICE|RTI Spine products|"* Interbody fusion devices - intended to help facilitate fusion by providing a platform for bone growth, while maintaining height and decompression.~* Supplemental fixation and/or stabilization devices - are intended to stabilize the spine to allow for fusion to occur, maintain current spinal movement, correct deformities or curvature, treat trauma, spinal stenosis, tumor and pseudarthrosis.~* Bone graft substitute - is intended to aid in fusion."
41354607|NCT05310006|OTHER|Exercise|Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.
41354608|NCT03070262|DRUG|CA|caffeic acid, 300mg, tid, po
41494911|NCT01631071|BIOLOGICAL|Virosomal influenza vaccine|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
41494912|NCT00227110|DRUG|Pioglitazone|30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.
41494913|NCT00227110|DRUG|Placebo|Placebo is given to match pioglitazone.
41494914|NCT05337371|DEVICE|ECG patch (Philips ePatch® 2.0)|The ECG patch will be put on the patients chest to monitor cardiac activity for a total time period of 14 days after cardiac arrest.
41494915|NCT02402114|DRUG|Hydrocortisone|120 mg Hydrocortisone given orally one time.
41494916|NCT03421730|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System|The VR647 Inhalation System consists of the VR647 Inhalation System 1 control unit, a VR647 nebulizer handset, a mouthpiece and VR647 Smart Cards designed specifically for this trial.
41494917|NCT03421730|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.
41494918|NCT00497861|PROCEDURE|Activator Methods Chiropractic Technique|
41494919|NCT05665114|DRUG|QN-030a|NK cell therapy
41494920|NCT05665114|DRUG|Cyclophosphamid|Lympho-conditioning Agent
41494921|NCT05665114|DRUG|Fludarabine|Lympho-conditioning Agent
41354609|NCT03070262|DRUG|placebo group|placebo tablet, 3 tablets, tid, po
41354610|NCT03839576|BEHAVIORAL|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
41354611|NCT03839576|BEHAVIORAL|Computerized training|Attention, memory, speed of processing, and executive functioning.
41354612|NCT02461576|DEVICE|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
41354613|NCT04125199|DIETARY_SUPPLEMENT|supplement consumption|"Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.~Placebo composition: Olive oil (each capsule is 700 mg).~Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.~Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days)."
41354614|NCT01646151|DRUG|Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
41354615|NCT01216644|DRUG|5-Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
41354616|NCT01216644|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
41354617|NCT01216644|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
41354618|NCT01216644|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
41354619|NCT01216644|DRUG|Epirubicin|50 mg/m2, d1, i.v., every 3 weeks
41354620|NCT01216644|DRUG|Cisplatin|60 mg/m², d1, i.v., every 3 weeks
41354621|NCT01216644|DRUG|5-fluorouracil|200 mg/m², d1-d21, i.v., every 3 weeks
41494922|NCT05665114|DRUG|Cytarabine|Lympho-conditioning Agent
41494923|NCT05665114|DRUG|VP-16|Lympho-conditioning Agent
41494924|NCT02909946|BEHAVIORAL|Multi-modal Infection Control Program|"1. Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).~2. Hand hygiene education to residents and families (resident-level intervention).~3. Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).~4. Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).~5. Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention)."
41494925|NCT04457336|DRUG|Tildacerfont/Placebo|Tablet, administered daily
41494926|NCT04899388|PROCEDURE|Pericapsular Nerve Block|regional anaesthia
41494927|NCT04899388|PROCEDURE|Lumbar Erector Spinae Plane Block|regional anaesthia
41494928|NCT04899388|DRUG|Fentanyl|intavenous
41494929|NCT00627315|PROCEDURE|Gastric bypass|NOTE: Surgery will not be paid by the study
41494930|NCT00627315|PROCEDURE|Gastric banding|NOTE: Surgery will not be paid by the study
41494931|NCT00788749|DRUG|Prednisolone|tablets 25 mg/day
41494932|NCT00788749|DRUG|Placebo|tablets once daily
41494933|NCT00788749|OTHER|fluticasone nasal drops|fluticasone nasal drops 800mcg/d
41494934|NCT00788749|OTHER|fluticasone nasal spray|fluticasone nasal spray 400 mcg/d
41160002|NCT05771558|DEVICE|Tailored Lighting Intervention (TLI)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
41494935|NCT04441710|OTHER|Questionnaire|Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
41494936|NCT06422312|DEVICE|Cystoscopy with RedPine flexible disposable cystoscope|Use of a disposable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents.
41494937|NCT06422312|DEVICE|Cystoscopy with standard of care flexible reusable scope|Use of a reusable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents
41494938|NCT01269333|DRUG|omeprazole|omeprazole 20mg for 7 days
41494939|NCT01269333|DRUG|fluvoxamine|fluvoxamine 50mg for 7 days
41494940|NCT01269333|DRUG|placebo|placebo for 7 days
41494941|NCT01707771|PROCEDURE|Roux-en-Y gastric bypass|Active Comparator: Roux-en-Y gastric bypass
41494942|NCT01707771|BEHAVIORAL|diet and lifestyle modifications|Active Comparator: diet and lifestyle modifications
41494943|NCT02514850|DRUG|Biochaperone Combo|Injection of BioChaperone Combo
41494944|NCT02514850|DRUG|Humalog Mix25|Injection of Humalog Mix25
41494945|NCT02514850|DRUG|Humalog|Injection of Humalog
41494946|NCT02514850|DRUG|Lantus|Injection of Lantus
41494947|NCT02514850|DRUG|Placebo|Injection of saline 0.9% solution
41494948|NCT04657796|DEVICE|High Flow Nasal Cannula|use of high flow nasal cannula as a weaning mode from invasive mechanical ventilation to deliver oxygen
41494949|NCT05169450|DRUG|Diterpene ginkgolides meglumine injection|Patients will receive intravenously administered diterpene ginkgolides meglumine injection, combined with guidelines-based standard care.
41494950|NCT05169450|DRUG|Ginaton|Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.
41494951|NCT01934335|DRUG|Vandetanib|
41494952|NCT01934335|OTHER|Placebo|
41494953|NCT02935153|BIOLOGICAL|Anti-CD22-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
41494954|NCT03673657|DIETARY_SUPPLEMENT|Early Nutrition Intervention from the start of CCRT|Nutrition counseling and oral nutritional supplements from the start of radiotherapy; weekly counseling sessions; daily energy intake of approximately 30 kcal/kg.
41494955|NCT03673657|RADIATION|Thoracic radiotherapy|Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy
41494956|NCT03673657|DRUG|Weekly DP chemotherapy concurrent with thoracic radiotherapy|Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
41494957|NCT02562339|BEHAVIORAL|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
41494958|NCT04819048|DEVICE|Low-Level Laser Therapy+acupuncture|"The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.~The needles using are disposable, sterile, individually packed, and made of stainless steel (Hua Tuo; Suzhou Medical Supplies Factory Co, Ltd,Suzhou, China), in sizes 0.25 mm ×40 mm.Asepsis of the skin will be performed with cotton wool and 75% alcohol."
41494959|NCT04819048|DEVICE|Low-Level Laser Therapy|The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.
41494960|NCT02186626|BIOLOGICAL|WN/DEN4Δ30 Vaccine|WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10\^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
41494961|NCT02186626|BIOLOGICAL|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm.
41509178|NCT04871256|PROCEDURE|Septorhinoplasty|This intervention will be performed by the same surgeon, after signing of patient inform consent.
41160003|NCT05771558|DEVICE|Actigraph|An actigraph is a wrist worn devices that measures rest and activity.
41160004|NCT02862652|OTHER|Blood sample|Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
41160005|NCT05250583|BIOLOGICAL|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
41160006|NCT02131155|DRUG|Placebo|Once daily
41160007|NCT02131155|DRUG|Afatinib|Once daily
41509179|NCT01255137|DRUG|Axitinib|5 mg tab orally twice a day with food every 28 days
41509180|NCT02418832|PROCEDURE|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
41509181|NCT02970448|PROCEDURE|LITT|MRI-guided laser interstitial thermal therapy uses a gas cooled side-firing (directional) laser and a variety of procedure specific tools to thermally ablate target tissue in-situ.
41354622|NCT03830463|DRUG|CTP-692|Single oral dose
41354623|NCT03830463|DRUG|Placebo|Single oral dose
41354624|NCT05902533|RADIATION|Radiation (reduced elective nodal dose (30.6 Gy)|28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54 Gy) which will occur over approximately 5.5 to 6 weeks.
41354625|NCT05902533|DRUG|Capecitabine|825 mg/m2 BID (Oral Twice daily on days with RT)
41354626|NCT05902533|DRUG|Mitomycin c|10 mg/m2 slow IV push Day 1 and 29
41354627|NCT04143828|BEHAVIORAL|mobile mindfulness programme|"The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience."
41354628|NCT03429166|BEHAVIORAL|Skills Training in Affective and Interpersonal Regulation|A non-trauma-focused treatment
41354629|NCT03429166|BEHAVIORAL|Present Centered Therapy|A non-trauma-focused treatment
41354630|NCT04503473|BEHAVIORAL|High Intensity Stepping Training|"The goals will be to maximize stepping activity at high intensities for 40 minutes per 1 hour session, with rest breaks as needed~Conventional Therapy: : Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions"
41354631|NCT04503473|BEHAVIORAL|Conventional Therapy|Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions
41354632|NCT01738568|BEHAVIORAL|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at \~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
41354633|NCT01738568|BEHAVIORAL|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
41354634|NCT02485405|OTHER|Trier social stress test|Volunteers perform Trier social stress test
41354635|NCT00303329|DRUG|Deferasirox|Deferasirox available as 125 mg, 250 mg or 500 mg tablets
41354636|NCT05297240|DRUG|Belantamab mafodotin|At least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021.
41354637|NCT01959269|DRUG|Regorafenib (Stivarga, BAY 73-4506)|As determined by the treating physician
41021348|NCT03360500|OTHER|EXERCISE PROTOCOL + CRYOTHERAPY|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field."
41354638|NCT01927276|OTHER|Gluten Free Flour|
41354639|NCT01927276|OTHER|Wheat Flour|
41354640|NCT05965999|DEVICE|EsoCheck|EsoCheck® (EC) is an FDA 510(k) cleared device that is indicated for use in the collection and retrieval of surface cells of the esophagus in the general population 12 years of age and older.
41354641|NCT05232344|DRUG|Estradiol / Progesterone|Treatment with estradiol (Provames®, 3 mg morning and evening, or 6 mg per day) will start on the 1st or 2nd day of her period. This treatment is continued until the end of the study (discontinuation treatment after the blood test taken on Day 7). After ten days of minimum estradiol treatment (and up to 7 days later to be working days), vaginal progesterone treatment will start in the evening on Day 0 (400 mg, Progestan®, evening and morning, ie 800 mg per day).
41354642|NCT05232344|BEHAVIORAL|Sexual event|A sexual intercourse (protected or not protected by condoms) will take place in a pre-defined order for each participant within one hour of the administration of the progesterone ovum on the evening of Day 2 and Day 6.
41354643|NCT03544385|DRUG|Ringers Solution|Treatment vs Placebo
41354644|NCT03544385|DRUG|Placebo - Concentrate|treatment vs placebo
41354645|NCT06000891|DRUG|ZP7570|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
41354646|NCT06000891|DRUG|Placebo|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
41354647|NCT01913652|DRUG|Cabazitaxel|
41354648|NCT03620292|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma
41354649|NCT03620292|DEVICE|near infrared (NIR) fluorescence imaging|Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens
41354650|NCT02807194|OTHER|spinal anesthesia|
41354651|NCT02807194|OTHER|general anesthesia|
41354652|NCT02807194|PROCEDURE|lumbar disc herniation|
41354653|NCT02258516|BEHAVIORAL|CHIME 3-M|behavioral intervention for self-management in heart failure
41354654|NCT02258516|BEHAVIORAL|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
41354655|NCT06102993|OTHER|Non-interventional study|The only intervention is to analyze serum molecules of patients with COPD and controls without COPD.
41354656|NCT00953784|PROCEDURE|standard operating management|As previously described
41354657|NCT02422160|OTHER|No interventions are planned|No interventions are planned
41354658|NCT02638363|BEHAVIORAL|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
41354659|NCT02406599|DEVICE|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
41354660|NCT02406599|OTHER|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
41354661|NCT03312075|OTHER|Sputum and blood samples|The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
41354662|NCT04844892|DEVICE|Lungpacer PROTECT Diaphragm Pacing Therapy|PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.
41354663|NCT05159063|DEVICE|Ultrasound imaging|"Patients scheduled to undergo right heart catheterization (RHC) as their standard of care will be included in the study.~The patient will be positioned supine at 0 degrees with normal restful breathing and patient looking straight up. After the right sternocleidomastoid muscle is identified, internal jugular vein (IJV) will be imaged at the apex of the triangle formed by the sternal and clavicular heads of the muscle. Similarly, the inferior vena cava (IVC) will be imaged at the caudal end of the sternum. The diameters of both the veins will be noted during normal respiration. The patients will then be asked to sniff and collapsibility of the veins will be noted. No pressure will be applied on the neck. The anticipated duration for image acquisition is between 5 to 10 minutes.~The patients will undergo the scheduled RHC within 1 hour as scheduled."
41354664|NCT05330806|PROCEDURE|Collagenase chemonucleolysis|"After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via safe entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months."
41494962|NCT00759850|DEVICE|Drug Eluting Stent (DES)|Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
41494963|NCT00963560|DEVICE|ReSTOR +3|Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.
41494964|NCT00963560|DEVICE|Crystalens HD|Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.
41494965|NCT00963560|DEVICE|Crystalens AO|Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
40834988|NCT02698371|DEVICE|G4: Futurabond® U - SE (FBU_SE)|FuturabondU® (FBU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
40834989|NCT02698371|DEVICE|G5: Adhese® Universal - ER (ADU_ER)|Adhese®Universal (ADU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
40834990|NCT02698371|DEVICE|G6: Adhese® Universal - SE (ADU_SE)|Adhese®Universal (ADU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
41160008|NCT00482417|DRUG|MK0359|
41354665|NCT05330806|PROCEDURE|Percutaneous endoscopic lumbar discectomy (PELD)|For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.
41354666|NCT05340816|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage will apply to the neck, abdominal, bilateral inguinal lymph nodes, bilateral anterior/posterior thighs, and lumbal area. Treatment duration will be approximately 30 minutes for 5 days.
41354667|NCT05340816|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation will be apply to abdominal and lumbal area as 100 Hz and 100 msn. Treatment duration will be approximately 20 minutes for 5 days.
41354668|NCT03453593|OTHER|No intervention|No intervention
41354669|NCT04083521|DIETARY_SUPPLEMENT|Bacillus subtilis DE111®|Subjects were administered a dose of Bacillus subtilis at levels of 1x10\^9 CFU once a day for 90-days.
41354670|NCT03870139|DEVICE|Cerebral stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
41354671|NCT03870139|DEVICE|Peripheral stimulation|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.
41354672|NCT05980390|DIAGNOSTIC_TEST|IL 35 in tissue biopsy|Elisa testing
41354673|NCT02717026|DEVICE|Optical coherence tomography|Sections including the retinal vasculature will be taken.
41354674|NCT02717026|DEVICE|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
41354675|NCT02717026|DEVICE|Fundus photography|30 and 50 degree fundus images
41354676|NCT01355094|DEVICE|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
41354677|NCT01355094|DEVICE|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
41354678|NCT05364658|DEVICE|Juvene IOL|Indicated for Implantation in the human eye after removal of a cataractous crystalline lens
41494966|NCT00000718|DRUG|Zidovudine|
41494967|NCT00000718|DRUG|Zalcitabine|
41494968|NCT01746459|OTHER|Paper-Based Reminder System|Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.
41494969|NCT01746459|OTHER|Peer-Based Reminder System|Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
41494970|NCT02589314|DEVICE|Mechanical periodontal therapy|
41494971|NCT02589314|PROCEDURE|nonsurgical periodontal therapy|
41494972|NCT01730066|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|"Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.~Patients randomized 1:1 between groups"
41494973|NCT00835965|DRUG|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
41494974|NCT00835965|DRUG|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
41494975|NCT00835965|DRUG|Placebo Dexamethasone|
41494976|NCT01004653|BIOLOGICAL|H1N1 influenza A Vaccine (Split virion), Inactivated|100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
41494977|NCT02009514|OTHER|Glucose-containing compared to glucose-free hemodialysate|Comparison of effects on glucose variation
41494978|NCT04713150|OTHER|No Intervention|No Intervention
41494979|NCT00227786|BEHAVIORAL|smoking cessation intervention|
41494980|NCT00227786|OTHER|counseling intervention|
41494981|NCT01036139|DRUG|BF2.649 (pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
41494982|NCT03084367|DIAGNOSTIC_TEST|iFR pullback|iFR pullback assessment post angiographically successful PCI
41494983|NCT02352818|OTHER|no study intervention|
41354679|NCT03112499|PROCEDURE|PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
41354680|NCT03112499|PROCEDURE|mini-PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
41354681|NCT03112499|PROCEDURE|RIRS|Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
41354682|NCT03132129|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
41354683|NCT03132129|DIAGNOSTIC_TEST|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
41354684|NCT03132129|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium scoring|Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
41354685|NCT03132129|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
41354686|NCT03132129|DIAGNOSTIC_TEST|Manganese-enhanced magnetic resonance imaging (MEMRI)|A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
41354687|NCT03132129|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring|A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.
41354688|NCT03132129|DIAGNOSTIC_TEST|Accelerometer watch|Watch worn to collect free living physical activity data for 7 days.
41354689|NCT03132129|DIAGNOSTIC_TEST|Blood tests|Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.
41021349|NCT03360500|OTHER|EXERCISE PROTOCOL|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises."
41354690|NCT05844592|DRUG|INV-101|subjects will be randomized 3:1 ratio
41354691|NCT03390127|OTHER|PEEP|After LMA Supreme™ insertion, it's proper position is confirmed. Then, PEEP of 7 cmH2O is applied during mechanical ventilation.
41354692|NCT00542425|DRUG|teriparatide|teriparatide 20 µg subcutaneous daily
41354693|NCT00542425|DRUG|Placebo|Placebo subcutaneous daily
41354694|NCT00542425|DRUG|BA058 20 µg|BA058 20 µg subcutaneous daily
41354695|NCT00542425|DRUG|BA058 40 µg|BA058 40 µg subcutaneous daily
41354696|NCT00542425|DRUG|BA058 80 µg|BA058 80 µg subcutaneous daily
41354697|NCT04302363|OTHER|Fecal microbiota detection and exfoliated cell gene detection|Fecal microbiota detection and exfoliated cell gene detection
41354698|NCT01739192|DRUG|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
40834991|NCT04391452|DIETARY_SUPPLEMENT|Stress Resist® (oral dietary supplement)|Stress Resist® (dietary supplement) is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg). Oral supplementation. All subjects in the MAGRITTE study will receive either a dietary supplement or a placebo for 28 days (morning intake). The effects on stress will be studied both with questionnaires, biological samples (blood, urine and stool), with a Heart Rate Variability test. 40 subjects (20 subjects per group) will have an fMRI exam.
40834992|NCT05221775|DRUG|Lenvatinib|XELOX regimen combined with GLS-010 and different doses of Lenvatinib
40834993|NCT00582738|DRUG|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
40834994|NCT00582738|DRUG|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
40834995|NCT00076518|DRUG|Fenofibrate|
41354699|NCT05064631|DRUG|Bacterial Lysate|Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system.
40834996|NCT00076518|DRUG|Fish Oil|
40834997|NCT02488642|DRUG|Isosorbide Dinitrate|
40834998|NCT02488642|DRUG|Misoprostol|
40834999|NCT02488642|DRUG|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
40835000|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
40835001|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
40835002|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10\^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
40835003|NCT06286826|PROCEDURE|Postero-lateral thoracotomy|this incision extends from the anterior axillary line, goes posteriorly behind the scapula and includes the division of the fibres of the latissimus dorsi muscle and the serratus anterior muscle. The latter approach presents the risk of numerous long-term musculoskeletal complications such as costal abnormalities (costal hypoplasia, costal fusion), winged scapula, scoliotic spine posture
40835004|NCT06286826|PROCEDURE|Minithoracotomy|Minithoracotomy aims to preserve the muscles of the rib cage by retracting or disconnecting them rather than sectioning them (muscle sparing technique)
41354700|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
41354701|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
40835005|NCT03522727|BEHAVIORAL|Single self-incentivising implementation intention|Participants are asked to form a single self-incentivising implementation intention (if-then plans)
40835006|NCT03522727|BEHAVIORAL|Multiple self-incentivising implementation intentions|Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
40835007|NCT03522727|BEHAVIORAL|Self-generated self-incentivising implementation intentions|Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
41160009|NCT02896439|DEVICE|Neurophysiological MONITORING|"The neurophysiology team perform:~* Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~* Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~* Establishment of a spacer or forceps in the greater or lesser sciatic notch~* Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~* At the end of the incision~* On the establishment of a spacer or forceps in the greater or lesser sciatic notch~* When towing layout~* At the end of the intervention"
41354702|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
41354703|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.
41354704|NCT00474552|DRUG|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
40835008|NCT01972685|PROCEDURE|Cryobiopsy biopsy|Cryobiopsy vs. Transbronchial vs. VATS biopsy
40835009|NCT01972685|PROCEDURE|Transbronchial Biopsy|
40835010|NCT01972685|PROCEDURE|VATS biopsy|
41354705|NCT00162799|DRUG|Triflusal (DCI)|
41354706|NCT06178835|DRUG|Erythropoietin|500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
41354707|NCT06178835|DRUG|normal saline|The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
41354708|NCT03926780|DRUG|Rivaroxaban 20 MG|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day
41354709|NCT03926780|DRUG|Warfarin Sodium|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3
40835011|NCT01913704|DEVICE|NatroxTM Device|"The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
40835012|NCT04679909|BIOLOGICAL|AdCOVID|Administered intranasally
40835013|NCT04679909|OTHER|Placebo|Administered intranasally
40835014|NCT02303899|DRUG|Gemcitabine|infusion drug
41160010|NCT02956915|PROCEDURE|Transfemoral Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI): The SAPIEN-3 prosthese are implanted without open heart surgery. The valve delivery system is inserted in the body via the femoral artery.
41354710|NCT02652286|DEVICE|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
41494984|NCT01498731|BEHAVIORAL|Discharge home|Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
41494985|NCT02077218|PROCEDURE|computed tomography|Undergo cardiac CT
41494986|NCT02077218|OTHER|cytology specimen collection procedure|Undergo collection of blood samples
41494987|NCT02077218|OTHER|laboratory biomarker analysis|Correlative studies
41494988|NCT02077218|OTHER|questionnaire administration|Ancillary studies
41494989|NCT03134118|DRUG|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
41160011|NCT01878253|DEVICE|Sidus Stem-Free Total Shoulder Arthroplasty System|
41160012|NCT02969629|DRUG|Apomorphine|
41160013|NCT02969629|DRUG|Normal Saline|
41494990|NCT01001988|OTHER|Blood sample|Blood sample for immunogenicity assessment
41494991|NCT01001988|BIOLOGICAL|JE-CV administered in Study JEC02|Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
41494992|NCT04342260|OTHER|Active Monitoring|The participants randomized to active symptom monitoring will have alerts sent to their clinicians when their PRO symptom scores exceed baseline postoperative scores (when discharge day scores are available) by 2 points or more, or when 'severe' or 'very severe' symptoms are reported.
41494993|NCT04342260|OTHER|Passive Monitoring|Participants randomized to the passive PRO monitoring arm will complete the same PROs as participants in the active monitoring arm, but will not have alerts sent to their clinician.
41494994|NCT03886740|PROCEDURE|Reducing symptoms of Eustachian tube dysfunction|One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
41494995|NCT03913819|DRUG|First line treatment: oral NSAID and anticholinergic agents|oral NSAID and anticholinergic agents
41494996|NCT03913819|DRUG|Second line treatment: additional treatment for pain control|Gabapentin, tramadol, Lyrica
40835015|NCT02303899|DRUG|Imatinib mesylate|oral drug
40835016|NCT05781360|DRUG|SIM0237|SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens
40835017|NCT01356732|DRUG|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
40835018|NCT02544334|PROCEDURE|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
40835019|NCT02544334|OTHER|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
40835020|NCT02544334|OTHER|Saliva Collection|All participants will have a saliva collection.
40835021|NCT04794660|DIAGNOSTIC_TEST|HPV DNA Test|Screening for HPV using a HPV DNA test
40835022|NCT04794660|DIAGNOSTIC_TEST|VIA triage test|"VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer"
40835023|NCT04794660|PROCEDURE|Treatment by ablative treatment|Cryotherapy or Thermal Ablation are performed on the cervix.
40835024|NCT04794660|PROCEDURE|Colposcopy|Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
41160014|NCT05283213|DIAGNOSTIC_TEST|Early biomarkers of acute kidney injury|"The biomarkers tested will be:~* creatinine levels \[pre-, post-CC, H6\],~* urinary TIMP2\*IGFBP7 \[H6\],~* Plasma NGAL \[Pre-, Post-CC, H6\].~* Urinary NGAL \[H6\]~* Plasma cystatin C \[Pre-CC, Post-CEC \& H6\],~* plasma HI \[pre-, post-CC, H6\],~* plasma IL-6 \[post-CC, H6\],~* uremia \[pre-, post-CC, H6\],~* urinary DKK3 \[pre-CC\], These biomarkers will, if necessary, be corrected for hemodilution or dilution of urine, if any, using \[pre-, post-CC, H6\] protein and \[pre-, post-CC, H6\] creatinine, respectively."
41494997|NCT03913819|DRUG|Third line treatment: A course of intravesical hyaluronate will be given.|A course of intravesical hyaluronate will be given.
41494998|NCT03913819|PROCEDURE|Fourth line treatment: surgical intervention|Consideration of hydrodistention and augmentation cystoplasty
41494999|NCT04280276|DIAGNOSTIC_TEST|TruGraf test|To obtain longitudinal TruGraf testing in patients with stable creatinine, high and normal IPV in tacrolimus levels, between 3 and 18 months post-transplant at the University of Maryland post-transplant clinic.
41509182|NCT02970448|RADIATION|Radiation therapy|One treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks. All portals shall be treated during each treatment session. Doses are specified such that at least 95% of the planning target volume (PTV) shall receive 100% of the prescribed dose.
40835025|NCT01883648|DRUG|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
40835026|NCT01883648|OTHER|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
40835027|NCT03612323|DRUG|Intra-ligamentary Piroxicam|Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
41354711|NCT03908268|BEHAVIORAL|Family Nurture Intervention (FNI)|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will attend eight group FNI sessions within sixteen weeks.
41354712|NCT03908268|BEHAVIORAL|Standard Children's Learning Center (CLC) Program|Typical, age-tailored CLC curriculum taught by CLC teachers. Children attend CLC as usual and parents do not take part in group sessions.
41354713|NCT05501002|DEVICE|eShunt® Implant|The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.
41354714|NCT02827331|OTHER|Exposition to hypnotics or anxiolytics benzodiazepines|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Benzodiazepine derivatives (N05BA)~* Benzodiazepine derivatives (N05CD)~* Benzodiazepine related drugs (N05CF)"
41354715|NCT02827331|OTHER|Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Antipsychotics (N05A)~* Antiepileptics with the exception of clonazepam (N03)~* Drugs used for alcohol dependance (N07BB)~* Drugs used for opioids dependance (N07BC)"
41354716|NCT02827331|OTHER|Medical consultation without prescription|Medical consultation without prescription of any drugs of interest
41354717|NCT02827331|OTHER|Administrative and medical data|"* Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)"
41495000|NCT05545358|OTHER|Questionnaires|Short-Form McGill Pain Questionnaire (SF-MPQ) Pain Disability Index (PDI) Prosthesis Evaluation Questionnaire (PEQ) Psychological Inflexibility to Pain Scale (PIPS) Chronic Pain Acceptance Questionnaire (CPAQ) Cognitive Difficulties Scale (CDS) Amputee Body Image Scale (ABIS) Trinity Amputation and Prosthesis Experience Scales (TAPES) Pain Catastrophizing Scale (PCS) Hospital Anxiety and Depression Scale (HAD) Credibility/Expectancy Questionnaire (CEQ) Short-Form Edinburgh Handedness Inventory (SF-EHI) Patient's Global Impression of Change (PGIC)
41495001|NCT05545358|DEVICE|Brain and Spinal Cord functional Magnetic Resonance Imaging|Brain and Spinal Cord functional Magnetic Resonance Imaging
40835028|NCT03612323|DRUG|Intra-ligamentary Articaine|Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
40835029|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
40835030|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
40835031|NCT00068094|DRUG|Probiotic-containing powder|
40835032|NCT00930436|DRUG|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
40835033|NCT05549375|DEVICE|MyHand System Hand Rehabilitation|15 1-hour patient specific sessions using the MyHand System to help improve Hand function in the affected hand of stroke survivors
40835034|NCT02645435|PROCEDURE|hip replacement|Total hip replacement
40835035|NCT05226611|OTHER|Counterstrain|Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
40835036|NCT03163368|RADIATION|Neoadjuvant stereotactic radiosurgery|Dose escalation of neoadjuvant stereotactic radiosurgery
40835037|NCT03163368|PROCEDURE|Neurosurgical resection|Surgical resection of newly diagnosed brain metastases
40835038|NCT05758285|OTHER|AI-Based Prediction of Treatment Engagement and Outcomes|AI-based algorithms and prediction models of treatment engagement and outcomes based on data from the Online Therapy Unit by Prof. Heather Hadjistavropoulos will be trained to predict symptom improvement of patients from pre- to post-digital psychotherapy intervention and to predict patients' engagement with the digital psychotherapy intervention and to predict patient drop out probability. For prediction model estimation, state of the art AI-based algorithms, such as XGBoost, is used . XGBoost is a machine learning method developed by refining previously established decision-tree-based methodologies. Data is split into training and testing sets (e.g., 80/20 split).
41354718|NCT05236257|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Pediatric patients with IFS harboring an NTRK gene fusion.
41354719|NCT05236257|DRUG|Standard of Care|Standard of care for the patients from the eligible external cohorts.
41495002|NCT05545358|OTHER|Proprioceptive training|Proprioceptive muscular training via a mechanical vibration of low amplitude and frequency between 60 and 80 Hz applied to the tendons.
41495003|NCT00213135|DRUG|Cladribine 5.25 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
41495004|NCT00213135|DRUG|Cladribine 3.5 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
41495005|NCT00213135|OTHER|Placebo|Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
41495006|NCT02166814|DRUG|Fimasartan and Rosuvastatin|
41495007|NCT02166814|DRUG|Fimasartan|
41495008|NCT02166814|DRUG|Rosuvastatin|
41495009|NCT00967655|BIOLOGICAL|panitumumab|
41495010|NCT00967655|DRUG|capecitabine|
41495011|NCT00967655|DRUG|irinotecan hydrochloride|
40835039|NCT00762996|DEVICE|etafilcon A|contact lens
40835040|NCT00762996|DEVICE|omafilcon A|contact lens
40835041|NCT00052312|DRUG|cisplatin|
40835042|NCT00052312|DRUG|doxorubicin hydrochloride|
41495012|NCT00967655|PROCEDURE|neoadjuvant therapy|
41495013|NCT00967655|PROCEDURE|therapeutic conventional surgery|
41495014|NCT00967655|RADIATION|radiation therapy|
41495015|NCT03759119|BEHAVIORAL|Tummy time and parent education|Participants will receive tummy time positioning while awake for 10 minutes two times a day. Physiological monitoring will be maintained throughout the entire intervention and the intervention will be adjusted if needed to maintain stability. Participants will also receive parent education on tummy time prior to the tummy time intervention. The primary investigator will perform the tummy time intervention. Participants will be encouraged to continue performing tummy time on their own and record their adherence via the PT Pal application.
41495016|NCT03759119|BEHAVIORAL|Parent education only|"Participants will receive the same tummy time education as those in the intervention group and will be asked to continue the intervention on their own and record their adherence via the PT Pal application.~Steps of the intervention for group 2 (standard care).~* Complete educational session with primary investigator.~* Adherence during the four-week intervention period will be measured remotely through the PT Pal® application."
40835043|NCT00052312|DRUG|paclitaxel|
40835044|NCT04474041|DEVICE|EyeQue Insight|The Insight will be used to measure visual acuity and compared with a standard ETDRS eye chart.
41495017|NCT02377427|DRUG|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
41495018|NCT00149812|BEHAVIORAL|Family Functioning Intervention|
41495019|NCT04132700|DEVICE|Q-NRG Metobolic Cart Device|ICU pateints will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
41495020|NCT02875015|DRUG|Liposomal Bupivacaine|20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
41495021|NCT02875015|DRUG|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
41495022|NCT02875015|PROCEDURE|Suburethral Sling|A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
40835045|NCT05703451|OTHER|laparoscopic surgery|"during laparoscopy Any adhesions will be noticed, the prevalence of adhesions will be calculated regarding the age, parity, previous history of miscarriage and past medical history.~The prevalence of adhesions will be calculated according to the indication of laparoscopy.~The prevalence of adhesions will be compared according to different items. Comparison between patients with no past surgical history and those who have past surgical history.~Comparison between patients who have history of ectopic pregnancy and those who have no history of ectopic pregnancy.~Comparison between patients with previous caesarean section and patients with previous other abdominopelvic surgery."
40835046|NCT02880527|OTHER|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :~1. medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~2. general practitioners~3. the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
40835047|NCT03689712|DRUG|GC4419 90mg|60 minute IV infusion
40835048|NCT03689712|DRUG|Placebo|60 minute IV infusion
40835049|NCT05943990|DRUG|GSK3845097|GSK3845097 was administered.
41021350|NCT03360500|OTHER|EXERCISE PROTOCOL + PLACEBO|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field."
41495023|NCT04311372|BEHAVIORAL|Educational Sesssion+Material+Videos|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
41495024|NCT04311372|BEHAVIORAL|Educational Sesssion+Material ONLY|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
41495025|NCT02884401|DEVICE|Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)|A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
40835050|NCT05943990|DRUG|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
40835051|NCT05943990|DRUG|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
41354720|NCT06314308|BEHAVIORAL|CATCHES|At the baseline visit (T0), informed consent will be obtained, and baseline questionnaires and measurements completed. A physical activity monitor will be provided. After discharge, Task Specific Training guided by Cognitive Behavioral Therapy with Exposure delivered over 7 one-hour sessions including two intake sessions by specialists and five follow up sessions delivered by CHWs individually at home over 3 months. After the final session at 12 weeks (about 3 months), participants will complete a study end visit (T1) which will include follow up questionnaires and measurements.
41354721|NCT00735072|DRUG|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
41354722|NCT00735072|DRUG|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
41354723|NCT01389076|DRUG|Bexxar|"Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body."
41354724|NCT01389076|DRUG|Low Dose Methotrexate|Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
41354725|NCT03865160|DRUG|Atropine eye drops, 0.01%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
41354726|NCT03865160|DRUG|Atropine eye drops, 0.02%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
41354727|NCT03865160|DRUG|Placebo (NaCl 0.9%) eye drops|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
41354728|NCT00174876|DRUG|Drug Abilify|
41354729|NCT03444246|DIETARY_SUPPLEMENT|Iodine free diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
41354730|NCT03444246|DIETARY_SUPPLEMENT|Normal iodine diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
41354731|NCT03223740|OTHER|Arm 1 pre-operative chemoradiation|"Chemotherapy 1:~First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.~2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29."
41354732|NCT03223740|OTHER|Arm 2 post operative chemoradiation|"Surgical resection, a D2 resection is encouraged.~Chemotherapy 1:~All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29"
41354733|NCT03377452|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Sleep Apnea (ACB-SA)|Six session manual-based program using acceptance-and commitment therapy (ACT) framework, behavior change strategies and sleep apnea/PAP education. Sessions delivered in individual format, either in-person or via telehealth.
41354734|NCT03377452|BEHAVIORAL|Non-directive sleep apnea education control|Six session sleep apnea and PAP education program. Sessions delivered in individual format, either in-person or via telehealth.
41354735|NCT02023892|DRUG|atorvastatin|
41495026|NCT00339092|BEHAVIORAL|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
41495027|NCT00339092|BEHAVIORAL|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
41160015|NCT02786290|DEVICE|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
41160016|NCT06277024|DRUG|Combination of Cardonizumab with Lenvatinib and SOX regimen|"Phase 1: Conduct a ramp up test on the dosage of lenvatinib according to the traditional 3+3 design; Phase 2: 6 cycles of treatment with candenizumab+lenvatinib+SOX regimen (Q3W); For patients who have not progressed, they will enter the third stage of maintenance treatment.~Phase 3: Maintenance therapy with candenizumab, lenvatinib, and tigio (Q3W)."
41160017|NCT00372255|BIOLOGICAL|Influsplit SSW® 2005/2006|Study influenza vaccine was administered intramuscularly in the non-dominant arm
41354736|NCT02023892|DRUG|placebo|
41354737|NCT02258841|BEHAVIORAL|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
41354738|NCT02258841|BEHAVIORAL|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
41354739|NCT02258841|BEHAVIORAL|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
41354740|NCT02258841|BEHAVIORAL|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
41354741|NCT02258841|BEHAVIORAL|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
41354742|NCT04671745|BEHAVIORAL|Music|patient receiving care with interactive music
41354743|NCT04671745|BEHAVIORAL|No music|patient receiving care without interactive music
41354744|NCT02908945|DRUG|Ketamine|Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
41354745|NCT02908945|DEVICE|NeuroSENSE monitor|NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
41354746|NCT03125902|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
41354747|NCT03125902|DRUG|Atezolizumab Placebo|Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
41354748|NCT03125902|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
41354749|NCT01725724|PROCEDURE|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
41354750|NCT01725724|PROCEDURE|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
41354751|NCT00457158|DEVICE|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
41354752|NCT01787435|DRUG|Risk of asthma in offspring|"Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy"
41354753|NCT06025656|DIAGNOSTIC_TEST|Leg Lateral Reach Test|"To conduct the leg reach test, participants began by positioning themselves with their arms hanging at their sides. They were then guided to raise the leg under assessment and extend it across the opposite leg to make contact with a wooden bar, employing trunk rotation in the process. During each trial, participants were consistently motivated to ensure that both shoulders remained in contact with the floor and to stretch their tested leg as far as they could along the length of the wooden bar. If a participant was unable to sustain contact between their foot and the wooden bar for a duration of 5 seconds at the point of maximal reach, or if both shoulders lifted off the floor, that specific trial was considered invalid and not included in the analysis.~Each participant completed three repetitions of this test for both the right and left sides, and the average of their reach distances was subsequently calculated for assessment."
41160018|NCT00354809|DRUG|GW679769|
41160019|NCT03606850|DEVICE|Measurements of markers of cortical excitability by TMS|"In the arm experimental treatment by citalopram, measurements of markers of cortical excitability by Transcranial Magnetic Stimulation will be applied. These measurements were: the cortical silent period CSP, the evoked potential MEP, the intra-cortical inhibition ICI and the intra-cortical facilitation ICF). Electromagnetic coil is placed upon the vertex, according to the International 10-20 EEG system. Gathering of the peripheral signal by a surface EMG electrode (non invasive device) placed regarding one of the first dorsal interosseous muscle."
41160020|NCT01251887|DIETARY_SUPPLEMENT|Linoleic Acid|
41160021|NCT01251887|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|
41160022|NCT01251887|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|
41160023|NCT04963998|DEVICE|Application of Wound Dressings with Copper Oxide|Application of Wound Dressings with Copper Oxide on chronic foot wounds in diabetic patients
41160024|NCT02668796|DRUG|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
41160025|NCT02668796|DRUG|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
41160026|NCT02668796|DRUG|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
41160027|NCT04612699|DRUG|Jaktinib|Administered orally
41160028|NCT04612699|DRUG|Placebo|Administered orally
41354754|NCT05840393|OTHER|Discharge training based on Roy adaptation model|The Roy Adaptation Model consists of four main areas of adaptation. In this study, the content of the discharge education given within the scope of the adaptation areas of the Roy Adaptation Model will be continued with information such as home nutrition process, pain, anxiety, fear, stress and coping methods, addressing changing roles and responsibilities, communication, problem solving and utilizing social support. A booklet will be prepared to increase the effectiveness of discharge training based on the Roy Adaptation Model and the booklet will be used as a guide in the training program.
41354755|NCT02301728|OTHER|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
41354756|NCT01700127|OTHER|Breastfeeding|breastfeeding encouraged versus withheld
41354757|NCT01126385|DEVICE|DensiProbe Spine|Intraoperative DensiProbe Spine measurements
41354758|NCT00173615|PROCEDURE|Extracorporeal membrane oxygenation|
41354759|NCT03615586|OTHER|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone.
41354760|NCT03615586|OTHER|Without Chaperone|Female patients examined by male physicians without the presence of a female (nurse) chaperone.
41354761|NCT02543801|DRUG|Liposomal Bupivacaine|Periarticular injection
40835052|NCT05735522|DEVICE|Extracorporeal magnetic stimulation|Extracorporeal magnetic stimulation is a technique based on Faraday's law of magnetic induction, approved by the United States Food and Drug Administration in 1998, for conservative treatment of urinary incontinence. It generates electrical activity, which induces controlled depolarization of the nerves, resulting in pelvic muscle contraction and sacral S2-S4 roots neuromodulation. The patient seats in the chair fully clothed.
40835053|NCT05735522|OTHER|Sham|The same chair as is used in the active group with the magnetic field density at the lower 2% resulting in negligible efficacy.
41160029|NCT00392314|OTHER|PET/CT post 2 cycles of chemotherapy|sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
40835054|NCT03071484|DEVICE|Transcranial Direct Current Stimulation|The tDCS is a non-invasive neuromodulatory technique that delivers low-intensity, direct current to cortical areas facilitating or inhibiting spontaneous neuronal activity.
41354762|NCT02543801|DRUG|Ropivacaine|Periarticular injection
41160030|NCT06217497|OTHER|Foot massage|Patients in the experimental group were subjected to a foot massage with baby oil for 10 minutes during HD treatment three times a week for four weeks, 12 times in total. At the end of the second and fourth weeks after the foot massage, the second and third readings were recorded by repeating the PFS and PSQI
41354763|NCT02543801|DRUG|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
41354764|NCT02543801|DRUG|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
41354765|NCT02543801|DRUG|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
41495028|NCT05320406|RADIATION|Radiation therapy|Undergo radiation therapy
41495029|NCT05320406|DRUG|Leuprolide|Given IM or SC
41495030|NCT05320406|DRUG|Relugolix|Given PO
41354766|NCT02543801|DRUG|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
41354767|NCT03782766|PROCEDURE|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
41354768|NCT05819424|DIETARY_SUPPLEMENT|Yeast Fermentate (EpiCor)|"Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding"
41354769|NCT00362297|DRUG|acyclovir|800 mg orally three times daily for 7 weeks
41495031|NCT03343652|DRUG|Nivolumab|3 mg/kg IV infusion on day 1,14 up to 3 cycles
41495032|NCT03343652|DRUG|Bendamustine Hydrochloride|90 mg/kg IV infusion on day 1 up to 3 cycles
41495033|NCT05939583|OTHER|Shock Wave Therapy|Receiving Shock wave therapy + US, TENS, IR and exercises.
41495034|NCT05939583|OTHER|US, TENS, IR and exercises.|Receiving US, TENS, IR and exercises only.
41495035|NCT00785460|DRUG|Benfotiamine|
41495036|NCT06410235|OTHER|Thoracic manipulation and exercise program|The group received exercises and manipulation with physiotherapist follow-up for eight weeks and thoracic manipulation was performed once a week.
41495037|NCT06410235|OTHER|exercise program|The group received exercise
41495038|NCT03751618|PROCEDURE|Hip arthroscopy|"Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure."
41495039|NCT05646420|OTHER|Blood sampling|A blood sample of 15 ml will be collected for each patient.
41495040|NCT03002571|DRUG|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
41160031|NCT01723332|BEHAVIORAL|Educational|"The first interaction will happen at study enrolment and will be educational in nature.~Following the session, the nurse will follow up with the participant to discuss any questions."
41354770|NCT00362297|DRUG|valacyclovir|500 mg orally once daily for 7 weeks
41354771|NCT04034342|OTHER|RaceRunning|RaceRunning (www.racerunning.org) is a growing disability sport that provides an opportunity for people with moderate-to-severe CP to participate in exercise in the community. It allows those who are unable to walk independently, to propel themselves using a RaceRunning bike, which has a breastplate for support but no pedals. Participants sit on the saddle and use their legs to propel themselves forward.
41160032|NCT01723332|BEHAVIORAL|Self management|"The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.~Following the session, the nurse will follow up with the participant to discuss any questions."
41354772|NCT04193228|DEVICE|Carbon Fibre Ankle Foot Orthosis|Off teh shelf carbon fibre ankle foot orthoses worn bilaterally
41354773|NCT04193228|BEHAVIORAL|Exercise|Ankle muscle strength training
41354774|NCT02176434|PROCEDURE|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
41354775|NCT02176434|BIOLOGICAL|hematopoietic stem cell|
41354776|NCT06089772|OTHER|Comparing to Manipulation and Myofascial Release Techniques|Randomized Controlled Trials
41354777|NCT06461195|OTHER|Monitoring of patients|Data from a spirometer and a stethoscope are captured to develop algorithms to detect and classify respiration sounds to support therapists and patients in future therapy.
41354778|NCT03125681|PROCEDURE|Remote ischemic conditioning|In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
41354779|NCT03125681|PROCEDURE|Control|In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
41354780|NCT04605341|DEVICE|miniplate|comparison between k wires and miniplate in metacarpal fractures
41354781|NCT06406829|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.
41354782|NCT06406829|DRUG|Normal saline|In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group
41354783|NCT06406829|OTHER|Local analgesic techniques|The 10ml 1% ropivacaine will be diluted into a 20ml syringe . As for scalp nerve block, each nerve will be blocked separately with 1-2 mL 0.5% ropivacaine.
41354784|NCT06406829|OTHER|no Local analgesic techniques|No Local analgesic techniques will be given.
41160033|NCT01026103|DEVICE|Tri Staple Technology stapler|This is a single arm study.
41160034|NCT06252909|BEHAVIORAL|Interpersonal Psychotherapy for Couples|"Interpersonal Psychotherapy for Couples (IPT-C) consists of 8 weekly conjoint sessions. The clinical goals are to promote resolution of the role dispute via renegotiation of role relations between the marriage partners and improve common mental disorders in the woman. Like Interpersonal Psychotherapy, IPT-C has an initiation phase (Session 1-2), middle phase (Sessions 3-6), and termination phase (Sessions 7-8)."
41160035|NCT06252909|BEHAVIORAL|Interpersonal Psychotherapy (Individual)|Interpersonal Psychotherapy (IPT) is an evidence-based treatment to reduce depression and other common mental disorders. It focuses on helping patients resolve interpersonal problems of disagreements, loneliness, life changes, and grief, and/or change their orientation to the problem.
41160036|NCT05106816|OTHER|skin surface vibration|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones.
41354785|NCT04297124|DRUG|CC-90009|0.6 mg \[ 14C\]-CC-90009 administered IV as a single dose
40835055|NCT06177470|DEVICE|Accelerated deep iTBS|Accelerated intermittant teta burst deep Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
41021351|NCT03395795|DEVICE|NAVA|"The study has 3 phases:~1. Phase 1:~   The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~2. Phase 2:~   Switch to NAVA mode (1h).~  * Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~  * NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~3. Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording."
41354786|NCT04297124|RADIATION|[14C]|A single dose of \[ 14C\]-CC-90009 will contain approximately 2 µCi of radioactivity.
41354787|NCT06366685|BEHAVIORAL|Exercise and Psychological Intervention|To address the symptoms and severity experienced by esophageal cancer patients after surgery, providing them with exercise or psychological interventions to improve their rehabilitation outcomes.
41354788|NCT00474539|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
41354789|NCT00474539|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
41354790|NCT04889950|DEVICE|Tixel C|Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
41021352|NCT02662712|DRUG|JNJ-56136379|JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
41354791|NCT04889950|DEVICE|LipiFlow|LipiFlow
41354792|NCT04793893|DEVICE|ReLex Smile|With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
41354793|NCT04978922|DEVICE|Machine Learning: ML (Artificial Intelligence System)|To applicate an artificial intelligence system (Machine Learning: ML) on an active telemonitoring programme of readmitted COPD patients (TelEPOC)
41354794|NCT02915133|PROCEDURE|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
41354795|NCT01183299|OTHER|Dietary salt intake|
41354796|NCT06375811|DRUG|Elagolix 200 MG|Elagolix tablet
41354797|NCT06375811|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
41354798|NCT03572699|OTHER|diabetic retinopathy|This is an observational study of patients with diabetes. Patients undergoing routine care will undergo retinal imaging using a nonmydriatic fundus camera. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the artificial intelligence algorithm will be compared to the image diagnosis given by the ophthalmologists. The ophthalmologists will be blinded to the diagnosis of the AI and vice versa. The data will be analyzed to evaluate the performance of the AI.
41354799|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
40835056|NCT06177470|DEVICE|Accelerated Sham iTBS|Sham accelerated intermittant teta burst Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
40835057|NCT02182674|DRUG|Placebo Combivent HFA|
41354800|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
41354801|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
41354802|NCT04383665|DEVICE|STN DBS 10Hz|Stimulation of existing DBS device at 100Hz, with other parameters at baseline
41354803|NCT04383665|DEVICE|STN DBS 130Hz|Stimulation of existing DBS device at 130Hz, with other parameters at baseline
41354804|NCT04383665|DEVICE|STN DBS off|Existing DBS device turned off
41354805|NCT04254575|OTHER|None, observational study only (no interventions)|None, observational study only (no interventions)
41354806|NCT03330106|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
41354807|NCT03330106|DRUG|Docetaxel|Docetaxel intravenous infusion.
41354808|NCT03330106|DRUG|Carboplatin|Carboplatin intravenous infusion.
41354809|NCT03330106|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
41354810|NCT00888316|PROCEDURE|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
41354811|NCT00888316|PROCEDURE|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
41495041|NCT03002571|DRUG|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
40835058|NCT02182674|DRUG|Combivent HFA|
40835059|NCT02182674|DRUG|Combivent (CFC)|
40835060|NCT02182674|DRUG|Placebo Combivent (CFC)|
40835061|NCT04979403|OTHER|Physiotherapy|Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
41021353|NCT02662712|DRUG|Placebo|Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
41021354|NCT00005787|BIOLOGICAL|epoetin alfa|
41021355|NCT00005787|BIOLOGICAL|filgrastim|
41021356|NCT00005787|BIOLOGICAL|recombinant flt3 ligand|
41509183|NCT02970448|DRUG|Temozolomide|Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days
41354812|NCT03582839|BEHAVIORAL|PROTECT+|The early intervention PROTECT+ consists of a cognitive-behavioral 4-session brief-protocol (100 minutes) and targets empirically identified risk factors of (I)GD/IUD, i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
41354813|NCT04828304|DEVICE|PLASOMA|Treatment with cold plasma device
41495042|NCT05056662|DIAGNOSTIC_TEST|Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR|Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.
41495043|NCT02748967|DRUG|ExPEC4V|Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
41495044|NCT02748967|DRUG|Placebo|Participant will receive single dose of Placebo on Day 1.
40835062|NCT04630717|OTHER|Medical hypnosis session|"the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient"
41354814|NCT04374526|BIOLOGICAL|COVID-19 Convalescent Plasma|ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
41354815|NCT02253173|DRUG|Estradiol|
41495045|NCT04935424|DEVICE|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.
41495046|NCT00001474|DRUG|Interleukin-2|
40835063|NCT04630717|OTHER|control groupe|the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
40835064|NCT01305655|DRUG|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is \>250 µM, 36 hour levels \>30 µM or 42 hours levels \>10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
40835065|NCT05501314|OTHER|Early discharge with remote home monitoring.|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. During home monitoring, heartrate, respiratory rate, posture and movement are monitored every 5 minutes for at least 4 days, using a wearable sensor. Core temperature is monitored using an ear thermometer. Patients are contacted once per day by a nurse from the Virtual Monitoring Centre (VMC) to assess pancreatitis related complaints, intake of fluids and food, pain and the use of analgesics. Patients are asked to provide information to the hospital using a smartphone app.
40835066|NCT01995552|DEVICE|External Loop Recorder|
40835067|NCT05020964|DRUG|Trastuzumab and Pyrotinib|"Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle.~Use until intolerable toxicity or disease progression occurs."
41021357|NCT00005787|BIOLOGICAL|recombinant interleukin-3|
41021358|NCT00005787|BIOLOGICAL|sargramostim|
41021359|NCT00005787|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
41021360|NCT05303805|DRUG|Sevoflurane|Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.
41021361|NCT05303805|COMBINATION_PRODUCT|Cyteal|Rinsing and cleaning of ulcer.
41021362|NCT06294314|PROCEDURE|Fertilized ACL|Fertilized ACL is an acl reconstruction with Bone marrow aspirate, demineralized bone matrix, and an internal brace.
41021363|NCT06043362|OTHER|0 mg nicotine pouch|Oral nicotine pouches that contain 0 mg of nicotine
41021364|NCT06043362|OTHER|3 mg nicotine pouch|Oral nicotine pouches that contain 3 mg of nicotine
41021365|NCT06043362|OTHER|6 mg nicotine pouch|Oral nicotine pouches that contain 6 mg of nicotine
41354816|NCT02253173|DRUG|Placebo|
41495047|NCT03474497|DRUG|IL-2|• A total of four interleukin-2 treatments will be delivered into the treatment lesion by intralesional injection biweekly (at least 48 hours apart) starting 24-96 hours after the completion of radiotherapy and to be completed during the second on-trial cycle of Pembrolizumab. Intralesional injections will be performed by direct visualization and/or palpation of the lesion or under ultrasound or CT guidance as indicated.
41495048|NCT03474497|DRUG|Pembrolizumab|Pembrolizumab will be delivered at 200 mg in three week cycles per standard protocol.
41495049|NCT03474497|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the second cycle of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1-2 of cycle 2 and will not be repeated in future cycles.
41021366|NCT06043362|OTHER|Smooth nicotine pouch|Non-flavored nicotine pouches that are characterized as smooth.
41021367|NCT06043362|OTHER|Wintergreen nicotine pouch|Menthol flavored nicotine pouches that are characterized as wintergreen.
41021368|NCT04959084|OTHER|Laser acupuncture therapy and pelvic floor training|The laser will be applied directly to the skin over acupuncture points and each point receive a shoot of 65 seconds followed by Pelvic floor exercises for 15 min.
41021369|NCT06497517|DRUG|GSK5464714- Camlipixant|GSK5464714- Camlipixant will be administered
40835068|NCT01972698|OTHER|Self-directed and simulation-assisted training|"All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).~Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.~* A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.~* Participant will have access to an ultrasound simulator.~* Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.~An investigator will supervise the sessions but will not interfere with the self-learning process.~- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm)."
40835069|NCT01972698|OTHER|Traditional apprenticeship training|"All participants will attend an half-day ultrasound introductory course.~* Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).~* Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer."
40835070|NCT00204867|OTHER|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
40835071|NCT06441292|PROCEDURE|AI-assisted|utilize advanced deep learning models that integrate multi-modal image fusion from multi-parameter ultrasound and MRI to guide the biopsy process
40835072|NCT06441292|PROCEDURE|Non-AI-assisted|undergo standard prostate biopsy procedures without additional technological assistance
40835073|NCT01142024|DRUG|Glutathione|NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
41354817|NCT01540110|DRUG|Neoadjuvant Docetaxel and Cyclophosphamide|"5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)"
41354818|NCT02002637|DEVICE|Latella Knee Implant System|
41354819|NCT01172054|BIOLOGICAL|VAX128|one IM injection
41354820|NCT01172054|BIOLOGICAL|Placebo|One IM injection
41354821|NCT04613687|DEVICE|Compression bandage|Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
41354822|NCT03008889|DRUG|N-acetylcysteine|"Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
41354823|NCT03008889|DRUG|Placebo|"Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
41354824|NCT02757651|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
41354825|NCT06355024|DRUG|Inosine|oral inosine 200mg tid
41354826|NCT06355024|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
41354827|NCT01327586|BEHAVIORAL|ATM|Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
41354828|NCT01327586|BEHAVIORAL|Individual Drug Counseling|Standard individualized drug counseling, modified from that described by Woody and colleagues
40835074|NCT01142024|DRUG|saline|NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
40835075|NCT01207245|OTHER|Tobramycin time of administration|Random allocation to time of day of administration of tobramycin
40835076|NCT04065633|DRUG|P3-Fast|200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
40835077|NCT04065633|DRUG|Comm-Fast|200 mg PF-04965842 commercial tablet formulation under fasted conditions
40835078|NCT04065633|DRUG|Vari-Fast|200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
40835079|NCT04065633|DRUG|Comm-Fed|200 mg PF-04965842 commercial tablet formulation under fed conditions
40835080|NCT03262116|DRUG|Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
41354829|NCT00078715|DRUG|Yohimbine hydrochloride|Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
41354830|NCT00078715|DRUG|Placebo|Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
41354831|NCT03474380|BEHAVIORAL|iHI-FIVES|Implementation of iHI-FIVES caregiver skills training
41354832|NCT05247736|DIAGNOSTIC_TEST|Infrared Thermography|Non-contact body thermometry
41354833|NCT01041885|DEVICE|INSTRUCT|INSTRUCT PolyActive scaffold implantation
41354834|NCT06012266|DRUG|Dapagliflozin tablet|"Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Dapagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose:~* participants ≤12 year old: 5mg once daily p.o. (commercially available tablet)~* participants \>12 year old: 10mg once daily p.o. (commercially available tablet)"
41354835|NCT06012266|DRUG|Empagliflozin Tablets|"Patients randomized to Group A will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Empagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose: Empagliflozin 10mg once daily p.o. (commercially available tablet)"
41354836|NCT00278213|BIOLOGICAL|alemtuzumab|
41354837|NCT00278213|DRUG|cyclophosphamide|
40835081|NCT03262116|DRUG|Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
41354838|NCT00278213|DRUG|fludarabine phosphate|
41354839|NCT00278213|DRUG|mitoxantrone hydrochloride|
41354840|NCT05042804|OTHER|Machine learning models predicting postoperative death and acute kidney injury|The machine learning display uses data from the electronic health record to predict the likelihood of postoperative death and postoperative acute kidney injury.
41354841|NCT03677440|BEHAVIORAL|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
41354842|NCT03677440|BEHAVIORAL|Stretching-and-Toning Exercise Training|12-weeks of supervised, progressive stretching-and-toning exercise training
41354843|NCT00136461|DRUG|All-trans retinoic acid|
41354844|NCT00136461|DRUG|Bryostatin 1|
41354845|NCT06503510|OTHER|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
41354846|NCT06503510|OTHER|Cowhage|Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.
41021370|NCT05169879|PROCEDURE|coronal flaring|early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
41021371|NCT05169879|PROCEDURE|Non coronal flaring|No coronal flaring will be performed
41354847|NCT06503510|OTHER|bovine adrenal medulla (BAM8-22)|A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
40835082|NCT03262116|DRUG|BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
40835083|NCT03262116|DEVICE|Bionic Pancreas|The insulin-only bionic pancreas will be used in all three arms of the study
40835084|NCT00667654|DRUG|CNTX-4975|Testing a range of dosing configurations to optimize patient tolerability
40835085|NCT04024423|OTHER|Epidemiologic investigation|Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
40835086|NCT02126072|DIETARY_SUPPLEMENT|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
40835087|NCT02126072|DIETARY_SUPPLEMENT|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
41354848|NCT01728454|DRUG|Placebo|Placebo matching capsules, orally, once daily for 18 weeks.
41354849|NCT01728454|DRUG|Telapristone acetate|Telapristone acetate capsules, orally once daily for 18 weeks.
41354850|NCT03216564|DRUG|Calcitriol|Active vitamin D (Calcitriol) 0.25 micrograms
41354851|NCT00204763|DEVICE|Air filled balloon catheter|The new air filled balloon catheter will be tested against the solid state catheter
41354852|NCT00204763|DEVICE|Solid state catheter|The standardly used solid state catheter will be tested against the new air filled balloon catheter
41354853|NCT02434250|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
40835088|NCT05644795|DIETARY_SUPPLEMENT|Wheat/milk free diet (W/MFD) group|Patients randomized to intervention diet group will have to follow a wheat and cow's milk products free diet and, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
40835089|NCT05644795|DIETARY_SUPPLEMENT|Rice/turkey free diet (R/TFD) group|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
40835090|NCT02973191|DRUG|JCAR015|
40835091|NCT02144831|DRUG|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
40835092|NCT00955604|DRUG|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
40835093|NCT00955604|DRUG|Group R Rasagiline|At least 2 months of rasagiline
40835094|NCT00955604|DRUG|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
40835095|NCT01479582|DRUG|Access to unlicensed cord blood units|
40835096|NCT03266172|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
41021372|NCT06446492|OTHER|ViDEO explaining study|The research team will introduce themselves and ask the parents to watch an informational video explaining the ViDES study on an iPad while they stay in the room with the parents. After viewing the video, the team will answer any questions and provide written consent and enough time to decide whether to participate in the study. The research team will also provide a QR code that grants parents/guardians access to the video on their own device at any time. This allows them to pause, rewind, and revisit the information.
41021373|NCT06446492|OTHER|Usual Care|The research team will present a detailed explanation of the ViDES study, answer questions, provide written consent, and provide enough time to decide on participation or not in the study.
41021374|NCT05464147|DEVICE|DynamX Drug-Eluting Coronary Bioadaptor System|DynamX Drug-Eluting Coronary Bioadaptor System Implantation in Coronary Artery Lesion
41021375|NCT05940285|DIAGNOSTIC_TEST|Dynamic 99mTc-Tetrofosmin CZT-SPECT|Patients included in the study will undergo subsequently at 1-month after acute coronary syndrome Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
41495050|NCT02376543|DEVICE|19 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.
40835097|NCT03266172|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
40835098|NCT02525094|BIOLOGICAL|MEDI9929|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
41021376|NCT03286140|PROCEDURE|Early endovenous ablation|
41021377|NCT03286140|PROCEDURE|Delayed endovenous intervention|
41495051|NCT02376543|DEVICE|22 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
41495052|NCT02928367|OTHER|rectal swab|rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)
41354854|NCT03411356|BEHAVIORAL|Daily Caloric Restriction (DCR)|Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
41495053|NCT02928367|OTHER|nasopharyngeal swab|nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)
41495054|NCT02928367|OTHER|blood draw|blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)
41495055|NCT03483246|DRUG|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum."
40835099|NCT02525094|BIOLOGICAL|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
40835100|NCT05690620|BEHAVIORAL|laughter yoga|Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
40835101|NCT05690620|OTHER|Control|"The students in the control group did not receive any intervention. Nursing students were followed for four weeks. Before the study, data collection tools were applied to the students. Again, after the start of the study and the end of the study, all other data collection tools except the Student Information Form were applied."
40835102|NCT00364052|DRUG|oral Valganciclovir vs oral Ganciclovir|
41495056|NCT03483246|DRUG|Sham-transplantation Placebo|"The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum."
41495057|NCT06455007|DRUG|Propolis|Propolis 3x10 drops (7 days)
41495058|NCT05692050|DRUG|Epcoritamab|Subcutaneous Injection
41495059|NCT03121378|OTHER|Blood sample 1|Blood taken before prosthesis implantation
41495060|NCT03121378|OTHER|Blood sample 2|Blood taken after prosthesis implantation
41495061|NCT00471289|DEVICE|PTA with placement of paclitaxel-eluting stent|PTA with placement of paclitaxel-eluting stent
41495062|NCT00471289|DEVICE|PTA|PTA
41495063|NCT00714896|BEHAVIORAL|Stepped-Care|"* stage-based expert system written intervention at baseline and 3 months~* in-person stage appropriate counseling at baseline and 3 months~* telephone counseling sessions at weeks 2,4 and 8,~* as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~* optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges"
40835103|NCT04489121|DRUG|Omalizumab|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
40835104|NCT01727011|RADIATION|IPAS|
40835105|NCT01617447|DRUG|Placebo of Aripiprazole|administered orally once daily
40835106|NCT01617447|DRUG|Aripiprazole|Flexibly dose administered orally once daily
41354855|NCT03411356|BEHAVIORAL|Intermittent Fasting (IMF)|Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
41354856|NCT06365957|OTHER|Ketone monoester supplementation|Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate, and acetone).
41354857|NCT06365957|OTHER|High-intensity interval exercise|High-intensity interval exercise is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high-intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of lower-intensity movements. The exercise will be conducted on a computer-monitored cycle ergometer.
41495064|NCT00714896|BEHAVIORAL|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
40835107|NCT05977452|DIAGNOSTIC_TEST|Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale|Patients with PICC placement will be assessed by the Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale（Chinese version） to predict the risk of PICC-related thrombosis. The time of evaluation are the day during PICC placement, 24-48h after PICC placement, and every time when patients receive PICC maintenance.
40835108|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
40835109|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
40835110|NCT01290900|DRUG|NXL104|IV Solution
40835111|NCT01290900|DRUG|Ceftaroline|IV Solution
40835112|NCT01290900|DRUG|Placebo Infusion|IV Saline
40835113|NCT01290900|DRUG|Ceftazidime|IV Solution
41354858|NCT06365957|OTHER|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise generally consists of 30-60 min of aerobic exercise at 64-76% peak heart rate, while interval training involves more intense bouts interspersed by recovery periods. The exercise will be conducted on a computer-monitored cycle ergometer.
41354859|NCT06365957|OTHER|Placebo|The placebo will be the taste-matched water.
41354860|NCT01593176|PROCEDURE|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
41354861|NCT02689089|DRUG|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
41354862|NCT00115622|DRUG|fluticasone furoate|
40835114|NCT01290900|DRUG|Moxifloxacin|Tablet (1)
41354863|NCT04581057|BIOLOGICAL|Specific blood sampling|"A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.~This sampling is carried out for :~* Search for CHIP-associated mutations in circulating leukocytes~* Plasma determination of IL-1β, IL-6, IL-10 and TNF-α"
41354864|NCT00477867|PROCEDURE|quality-of-life assessment|
41495065|NCT00313339|DRUG|Intra-coronary infusion|In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
41495066|NCT05674422|DRUG|total neoadjuvant therapy|All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
41495067|NCT00658021|DRUG|Placebo|Subcutaneous injection, twice a day
41495068|NCT00658021|DRUG|Exenatide|Subcutaneous injection, 5 µg, twice a day
41495069|NCT00658021|DRUG|Exenatide|Subcutaneous injection,10 µg, twice a day
41495070|NCT06169189|BEHAVIORAL|global warming-climate change based education|The experimental group will be given 8 weeks of global warming-climate change based training. No intervention will be applied to the control group.
41495071|NCT03525925|DRUG|Ibrutinib|Given PO
41495072|NCT03525925|OTHER|Laboratory Biomarker Analysis|Correlative studies
41495073|NCT03525925|BIOLOGICAL|Nivolumab|Given IV
40835115|NCT04872998|BEHAVIORAL|Step Count Reduction|Subjects reduce daily step counts by approximately 70% through monitoring and recording from step-count monitor
40835116|NCT01030185|DEVICE|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
40835117|NCT00689793|DRUG|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
40835118|NCT00689793|DRUG|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
40835119|NCT06477419|DRUG|Sacituzumab govitecan-hziy|After enrollment, participants will receive SG until disease progression or intolerable toxicity.
40835120|NCT02193113|DRUG|KVD001 Injection|A novel plasma kallikrein inhibitor
41160037|NCT05106816|OTHER|light skin surface vibration- SHAM|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones. Worn at the lowest frequency will simulate the active arms with no potential change in symptoms.
41160038|NCT04145089|DEVICE|Glidescope video laryngoscopy/ C-MAC video laryngoscopy|usage of said devices according to manual
41354865|NCT01234337|DRUG|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
41354866|NCT01234337|DRUG|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m\^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
41354867|NCT01234337|DRUG|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily,
41354868|NCT04806386|DIETARY_SUPPLEMENT|Psyllium|Psyllium fiber powder baked into a bar is commonly used as a first line of treatment for patients with fecal incontinence.
41354869|NCT00001343|DRUG|Humatrope|
40835121|NCT01038713|DEVICE|Biliary stent placement|Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
40835122|NCT04610736|DRUG|Temozolomide Oral Suspension|One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
40835123|NCT06077097|GENETIC|Biological samples|This project also includes an auxiliary exploratory biological study of subcellular mechanisms, using high-throughput sequencing (Next Generation Sequencing, NGS) to identify gene expression variations in order to determine the resilience/vulnerability of the variables studied with respect to the DC experience (cytogenetics and transcriptome).
40835124|NCT02805595|DRUG|23.4% Hypertonic saline|Saline Injections
40835125|NCT05671796|GENETIC|Mesenchymal stem cell transplantation|Patients will undergo two autologous bone marrow stem cell transplantation into the lesion area
40835126|NCT05671796|OTHER|Placebo|Patients will undergo two subcutaneous injections of 1 ml of glycophysiological solution into the lesion area by sham procedure
41160039|NCT03083093|DIAGNOSTIC_TEST|The initial CTPA will be reviewed|The initial CTPA will be reviewed
41354870|NCT00001343|DRUG|Oxandrolone|
41354871|NCT00979862|DRUG|Cediranib Maleate|Given PO
40835127|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
40835128|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
41354872|NCT00979862|DRUG|Cilengitide|Given IV
41354873|NCT00979862|OTHER|Laboratory Biomarker Analysis|Correlative studies
41495074|NCT01512706|BIOLOGICAL|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
40835129|NCT00413010|DRUG|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
41354874|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
41354875|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
41354876|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
41354877|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
41354878|NCT00004885|DRUG|FOLFIRI regimen|
41354879|NCT00004885|DRUG|fluorouracil|
41354880|NCT00004885|DRUG|irinotecan hydrochloride|
41354881|NCT00004885|DRUG|leucovorin calcium|
41354882|NCT01008098|DRUG|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
41354883|NCT03164213|DEVICE|experimental: tDCS|The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
41354884|NCT03164213|DEVICE|sham tDCS|"The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.~During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy."
41354885|NCT01719718|PROCEDURE|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
41354886|NCT01719718|PROCEDURE|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
41354887|NCT01488994|BIOLOGICAL|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
41354888|NCT02290951|DRUG|Odronextamab multiple dose levels|Administered by intravenous (IV) infusion
41354889|NCT02290951|DRUG|Odronextamab multiple dose levels|Administered by subcutaneous (SC) injection
41354890|NCT03058809|DEVICE|Oncopheresis|Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components.
41354891|NCT05288179|DRUG|Pirfenidone Capsules|After randomization, the experimental group took pirfenidone capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
41354892|NCT05288179|DRUG|placebo capsules|After randomization, the experimental group took placebo capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
40835130|NCT00413010|DRUG|placebo|placebo + concurrent GAD treatment from the open-label study period
41495075|NCT01512706|BIOLOGICAL|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
41495076|NCT01512706|BIOLOGICAL|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
41495077|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
41354893|NCT03428230|DRUG|30 mg Paracetamol 3% (1 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
41354894|NCT03428230|DRUG|60 mg Paracetamol 3% (2 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
41495078|NCT01512706|BIOLOGICAL|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
41495079|NCT01512706|BIOLOGICAL|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
41495080|NCT01512706|BIOLOGICAL|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
41495081|NCT01512706|BIOLOGICAL|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
41495082|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
41495083|NCT01512706|BIOLOGICAL|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
41495084|NCT01512706|BIOLOGICAL|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
40835131|NCT06225271|BEHAVIORAL|the combined intervention of exercise, fruit, and vitamin supplementation|"Group intervention~After each intervention, investigators will hold a 15-minute communication and discussion session for the participants. Besides, community health workers will organize at least one health education activity per week during the intervention for no less than 45 minutes.~Individual intervention~Physical activity~The participants will be gathered at the community activity center or day care center. The participants will be allowed to exercise in a way that interests them. The duration of exercise should be longer than 30 minutes.~Fruit supplementation~Consideration of seasonal supply situation and the participants' diabetic status, various types of fruit will be prepared. The fruit will be divided into 50g/100g servings. Participants will be required to eat on site.~Vitamin supplementation~During the intervention, the participants will be required to take 1 tablet of vitamin B complex plus 1 tablet of vitamin C every day."
41160040|NCT00841477|BIOLOGICAL|hepatitis B vaccine 3 dose schedule (0,1,2 month)|hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
41495085|NCT01512706|BIOLOGICAL|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
41495086|NCT01512706|BIOLOGICAL|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
41495087|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
41495088|NCT01512706|BIOLOGICAL|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
41495089|NCT00085930|BIOLOGICAL|EBV specific CTLs|CTLs: 2x10e7 cells/m2
41495090|NCT03581591|BIOLOGICAL|Burosumab|recombinant human IgG1 monoclonal antibody to fibroblast growth factor 23)
41495091|NCT05410132|OTHER|Internet-delivered Mindfulness Based Training (iMBT)|"The iMBT developed for this study will be adapted from our team's previous study and the manual of mindfulness based cognitive therapy. The program is designed to be brief in nature, for example, participants will be asked to practice meditations for 15 minutes a day instead of the original 45 minutes a day, and each module is shortened to approximately 1 hour instead of the original 2.5 hours.~This iMBT is comprised of six weekly modules on education about mindfulness, guidance on using mindfulness skills to manage symptoms, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and graphics are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice."
40835132|NCT05332808|OTHER|questionnare|collecting data about treatment and quality of life
41160041|NCT00841477|BEHAVIORAL|HBV Vaccination Self-Efficacy Intervention|HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
41495092|NCT05297695|DRUG|Triple therapy for H. pylori infection|Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks
40835133|NCT03207945|DRUG|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
41354895|NCT03428230|DRUG|90 mg Paracetamol 3% (3 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
41354896|NCT03428230|DRUG|Placebo, 0.9% saline solution|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
40835134|NCT03207945|OTHER|Placebo|Placebo
40835135|NCT01051401|DRUG|rosuvastatin|Given PO
40835136|NCT01051401|OTHER|placebo|Given PO
40835137|NCT01051401|OTHER|survey administration|Correlative study
40835138|NCT01051401|PROCEDURE|management of therapy complications|
40835139|NCT03105648|OTHER|computerized cytomorphometry|use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination
40835140|NCT02047097|DRUG|dimethyl fumarate|Provided under routine clinical care
40835141|NCT05340803|RADIATION|Ultrasonograghic optic nerve sheath diameter US-ONSD|To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD
41354897|NCT03428230|DRUG|NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection|Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
41354898|NCT02576652|OTHER|Tetracycline|Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
41495093|NCT03858543|DRUG|Poly-L Lactic Acid|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
41495094|NCT03858543|DEVICE|Fractional laser treatment|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
41495095|NCT02185053|DRUG|CPC-201|
41495096|NCT03407235|DEVICE|Computerized Laparoscopic Trainer|Gold standard laparoscopic trainer using simulated computerized equipment.
41495097|NCT03407235|DEVICE|Box trainer with eye patch|Simple, cost effective box trainer, with loss of dept perception achieved with use of eye patch
40835142|NCT05340803|DRUG|midazolam|midazolam
40835143|NCT05340803|DRUG|dexmedetomidine|dexmedetomidine
40835144|NCT05340803|DRUG|magnesium sulfate|magnesium sulfate
40835145|NCT06508242|DRUG|Cholecalciferol|cholecalciferol
40835146|NCT06508242|OTHER|Placebo|placebo
40835147|NCT01657708|OTHER|Shared Decision Making|
40835148|NCT00065806|DRUG|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
41354899|NCT02576652|OTHER|Demeclocycline|Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
41160042|NCT04787718|OTHER|Almond|2.0 oz of raw, shelled, unsalted almonds
41160043|NCT04787718|OTHER|Control group|an isocaloric amount of unsalted pretzels
41354900|NCT02576652|PROCEDURE|Total Hip Replacement|Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
41354901|NCT05967728|DEVICE|Remote ischemic conditioning (RIC) progammable device|RIC induces brief periods of ischemia-reperfusion in a limb. In our study, this is accomplished using a new device that can be remotely programmed to deliver either true RIC or a sham protocol, with remote monitoring capabilities to track completion of treatment sessions.
41354902|NCT06117644|DRUG|Furmonertinib|Furmonertinib 40 mg/tablet, 4 tablets, QD
41354903|NCT05650528|DRUG|QG101-23-0 capsules|Single and Multiple Dose for oral
41354904|NCT05650528|DRUG|Placebo|Single and Multiple Dose for oral
41354905|NCT03091920|DRUG|IW-1973|Oral Tablet
41354906|NCT03091920|DRUG|Placebo|Oral Tablet
41354907|NCT01176864|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy
41354908|NCT01176864|PROCEDURE|Single-balloon enteroscopy|Single-balloon enteroscopy
41495098|NCT02424110|PROCEDURE|argon beam coagulator ablation|The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
41495099|NCT02424110|PROCEDURE|bipolar radiofrequency ablation|The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
41495100|NCT02424110|DEVICE|argon beam coagulator （American，Valleylab）|Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
41495101|NCT02424110|DEVICE|bipolar radiofrequency (AtricuteTM)|The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
41495102|NCT02549027|DRUG|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
41354909|NCT05953129|DIAGNOSTIC_TEST|Right Jugular Vein Collapsibility Index|Ultrasonography will be used to evaluate the diameter of the jugular vein (minimum and maximum values) and carotid diameter. The jugular vein collapsibility index will be measured by the anesthesiologist using non-invasive ultrasonography. Jugular vein collapsibility index will be calculated using the measured diameters.
41354910|NCT00000894|DRUG|Cidofovir|
41495103|NCT02549027|DRUG|MK-6096|Oral MK-6096 tablets (5 mg strength)
41495104|NCT02549027|DRUG|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
41354911|NCT00000894|DRUG|Probenecid|
41354912|NCT00000894|DRUG|Ganciclovir|
41354913|NCT02155660|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
41354914|NCT02155660|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
41354915|NCT02155660|DRUG|Benralizumab Arm C|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
41354916|NCT02155660|DRUG|Placebo|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
41495105|NCT00971776|DEVICE|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
41495106|NCT04167293|RADIATION|stereotactic body radiotherapy|Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
41160044|NCT01764152|OTHER|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
40835149|NCT00065806|DRUG|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
41160045|NCT02315079|OTHER|Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
41160046|NCT02315079|OTHER|Without eye inflammation|This group will have a regular eye exam with the collection of tears.
41354917|NCT03678766|BEHAVIORAL|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
41495107|NCT04167293|DRUG|Sintilimab|Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
41495108|NCT00520286|DRUG|Modafinil|200 mg or 400 mg /daily
41160047|NCT02429752|OTHER|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
40835150|NCT06008483|DRUG|153-Sm-DOTMP (Samarium-153-DOTMP)|This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP, given as a tandemly administered pair of doses to subjects with solid tumors visible on bone scan.
40835151|NCT05469139|DIAGNOSTIC_TEST|Portable MRI acquisition|Patients on ECMO will undergo a portable MRI of the brain
41160048|NCT05432999|DEVICE|Extracorporeal Shockwave Therapy|Shockwaves are high pressure sound waves that interact with tissues to elicit a biological response. The shockwave probe will be placed on the skin with ultrasound gel and the muscle will be stimulated for a few minutes.
41160049|NCT03317678|DIETARY_SUPPLEMENT|BioKefir|BKP BioKefir (Lifeway Foods) is a lactose-free fermented milk product containing 12 different bacteria provided in a drink.
41160050|NCT03317678|DIETARY_SUPPLEMENT|Non-fermented milk|A non-fermented milk drink.
41354918|NCT03678766|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|"Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge."
41495109|NCT00520286|DRUG|Placebo|Placebo / daily
41495110|NCT00475150|DRUG|cediranib maleate|Given orally
41495111|NCT00475150|OTHER|laboratory biomarker analysis|Correlative studies
41495112|NCT01381666|DRUG|INS316 solution for inhalation|inhalation via nebulizer given for 2 doses for 60 minutes each
41160051|NCT02094547|DIETARY_SUPPLEMENT|New infant formula|New infant formula
41160052|NCT02094547|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
41160053|NCT02094547|DIETARY_SUPPLEMENT|Breastfeeding|Exclusive breastfeeding or less tan 25% formula intake
41160054|NCT00439348|BEHAVIORAL|Verbal advice|Patients receive verbal advice regarding specific over-the-counter medications.
41495113|NCT01381666|DRUG|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
41495114|NCT01505153|BIOLOGICAL|pbi-shRNA STMN1 LP|This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
41160055|NCT00439348|BEHAVIORAL|Prescription|Patients receive a prescription for a specific over-the-counter medication.
41495115|NCT04487938|OTHER|No intervention utilised|No intervention utilised
41354919|NCT02752178|OTHER|MA|Monoaminergic antidepressant use
41354920|NCT02752178|OTHER|DEP|Depression measured using the Hamilton Depression (HAM-D) questionnaire
41354921|NCT03822286|OTHER|e-training course|Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
41354922|NCT03822286|OTHER|Support group|A counseling master mix 8\~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40\~60 minutes each time.
41354923|NCT03822286|OTHER|traditional classroom teaching course programs|Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
41354924|NCT01310192|DEVICE|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
41354925|NCT02320591|OTHER|care management fee|for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
41354926|NCT02320591|OTHER|feedback reports|Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
41354927|NCT02320591|OTHER|technical assistance|CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
41354928|NCT01874587|RADIATION|adaptative radiotherapy|weekly replanning
41160056|NCT03268850|OTHER|Standard of Care|All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.
41354929|NCT02881918|OTHER|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
41354930|NCT03853057|OTHER|body positions|positive pressure ventilation at different body positions
41354931|NCT02223949|DEVICE|Cook double balloon catheter|
41354932|NCT02223949|DRUG|PGE1 tablet|
40835152|NCT02367404|DRUG|Duloxetine|Duloxetine 60mg OD for 3 months
41354933|NCT05926895|DRUG|Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space|Treatment method used in the treatment of subacromial impingement syndrome
41495116|NCT06405217|DRUG|Recombinant Human Thyroid Stimulating Hormone|Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days
41495117|NCT02192320|DRUG|Atorvastatin|20 mg (every evening orally) for 5 weeks
41495118|NCT02192320|DRUG|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
41354934|NCT00498706|BEHAVIORAL|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
41354935|NCT00498706|BEHAVIORAL|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
41354936|NCT00072215|DRUG|cisplatin|given IV
41354937|NCT00072215|DRUG|ifosfamide|given IV
41354938|NCT00072215|DRUG|paclitaxel|given IV
41354939|NCT00072215|DRUG|vinblastine|given IV
41354940|NCT05681169|OTHER|School-based HPV-counselling and HPV-vaccination.|"1. Scholl-based parental HPV-counselling~2. Scholl-based pupil HPV-counselling~3. Scholl-based HPVV"
41354941|NCT05095779|BEHAVIORAL|Coaching calls|OTH coaching calls
41354942|NCT05095779|DRUG|Nicotine replacement therapy|8 weeks of nicotine replacement therapy
40835153|NCT02367404|BEHAVIORAL|Pelvic Floor Muscle Training|PMFT weekly for 3 months
41354943|NCT05095779|BEHAVIORAL|Financial Incentives|Escalating financial incentives for completing up to 5 coaching calls
41354944|NCT02365311|PROCEDURE|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
41354945|NCT01309646|BIOLOGICAL|Infanrix™-IPV+Hib|Intramuscular, 3 doses
41495119|NCT03495349|OTHER|safety and effectiveness of the usual treatments of diabetic foot infections|clinical and biological follow-up necessary to assess the safety and effectiveness of the medical treatments, MOS-SF survey (36-Item Short Form Survey) to study the quality of life.
41495120|NCT00867503|DRUG|Bendamustine HCL|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
41495121|NCT00543946|DRUG|GAP-134|24-Hour IV infusion, SAD
41495122|NCT00992524|DRUG|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
41495123|NCT00992524|DRUG|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
41354946|NCT01309646|BIOLOGICAL|Infanrix™ IPV|Intramuscular, 3 doses
41354947|NCT01309646|BIOLOGICAL|Hiberix™|Intramuscular, 3 doses
41354948|NCT01309646|BIOLOGICAL|Synflorix™|Intramuscular, 3 doses
41354949|NCT01309646|BIOLOGICAL|Rotarix™|Oral, 2 doses
41354950|NCT00002625|DRUG|topotecan hydrochloride|
41354951|NCT00002625|RADIATION|low-LET electron therapy|
41354952|NCT00002625|RADIATION|low-LET photon therapy|
40835154|NCT06237556|OTHER|Placebo|Patients in the control group will receive placebo.
40835155|NCT06237556|DRUG|Melatonin 5 MG|Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
41354953|NCT04506073|DRUG|Mesenchymal Stem Cells|1 dose is 10 X 10\^6 MSC/kg
41354954|NCT04506073|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).
40835156|NCT05614921|OTHER|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 30 ml local anesthetic each side
41354955|NCT03961724|DEVICE|magnetic resonance image (MRI)|serum metabolomics
41354956|NCT01813630|DRUG|DA-3002|
41354957|NCT01813630|DRUG|Genotropin®|
41354958|NCT05838586|BEHAVIORAL|prolonged SB|4 hours of prolonged SB
40835157|NCT05614921|OTHER|Wound infiltration|5 ml local anesthetic for each trocar side
40835158|NCT03246490|OTHER|All Participants|all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
40835159|NCT05276895|DIETARY_SUPPLEMENT|Quercetin and Fisetin tab.|1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks over 15 weeks .
41354959|NCT05838586|BEHAVIORAL|SB broken 1|4 hours of SB broken up by 5 minutes of self-paced walking every hour
41354960|NCT05838586|BEHAVIORAL|SB broken 2|4 hours of SB with one 20-minute bout of self-paced walking
41354961|NCT04529525|DRUG|Ivermectin|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
41354962|NCT04529525|DRUG|Placebo|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
41354963|NCT00004842|DRUG|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
41354964|NCT02813681|PROCEDURE|US-epidural SVD|participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.
41354965|NCT02813681|PROCEDURE|US sham- epidural SVD|participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).
41354966|NCT02813681|PROCEDURE|Spontaneous vaginal delivery without an Epidural|Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
41354967|NCT00381706|BIOLOGICAL|cetuximab|given IV
41354968|NCT00381706|DRUG|ECF|epirubicin and 5-fluorouracil given IV
41354969|NCT00381706|DRUG|IC|cisplatin and irinotecan given IV
41495124|NCT01334983|BEHAVIORAL|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
41495125|NCT03735316|DRUG|Hydroxocobalamin|5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.
41495126|NCT03735316|PROCEDURE|Cardiopulmonary Bypass|Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.
41495127|NCT03735316|DRUG|Placebos|Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
41495128|NCT00140218|DRUG|R(+) pramipexole dihydrochloride monohydrate|10 mg tid oral
41495129|NCT02255825|GENETIC|Whole Genome Sequencing|Whole genome sequencing in a CLIA lab and return of results.
41495130|NCT02255825|PROCEDURE|Amniocentesis|Note: this is being performed on all subjects as a clinical (not research) procedure
41495131|NCT02255825|OTHER|Psychosocial assessment|Use of EPDS and STAI for assessment of maternal and paternal mood
41495132|NCT00810316|DRUG|Alprazolam|Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
41495133|NCT00810316|DRUG|Alprazolam XR|Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
41495134|NCT00810316|DRUG|Clonazepam|Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
41495135|NCT02378792|DEVICE|Vagus Nerve Stimulation|Vagus Nerve Stimulator
41495136|NCT02828306|OTHER|Patient Specific Implant|Implantation of Patient Specific Implant
41509184|NCT04603157|BEHAVIORAL|Hybrid Exercise Training|Personalized exercise program completing at least 3 aerobic exercise sessions a week and receive eight supervised training sessions over the 3-months
40835160|NCT05276895|DIETARY_SUPPLEMENT|Quercetin Cap/Tab,Fisetin Cap/tab and Glycyrrhizin capsules|quercetin + Fisetin for 3 consecutive days followed by 100mg/day glycyrrhizin for one week every 3 weeks over 15 weeks
41354970|NCT00381706|DRUG|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
41354971|NCT02129192|DRUG|Amlodipine 5mg capsule|Amlodipine 5mg capsule
41354972|NCT02129192|DRUG|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
41354973|NCT02129192|DRUG|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
41354974|NCT05166031|BIOLOGICAL|bOPV and nOPV2|Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
41354975|NCT05022693|DRUG|BIO89-100|Subcutaneous Injections
41509185|NCT02886780|BEHAVIORAL|Concentrated exposure treatment (cET)|Psychological cognitive behavioral treatment
41354976|NCT04335357|DRUG|TBR-760|TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.
41354977|NCT04335357|DRUG|Placebo|Placebo
41354978|NCT03294343|PROCEDURE|salpingo-oophorectomy only by laparoscopy|Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
41354979|NCT03294343|PROCEDURE|salpingo-oophorectomy with hysterectomy by laparoscopy|Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
41354980|NCT03294343|OTHER|Follow-up|Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
41354981|NCT00826787|DRUG|Levetiracetam|750 mg tablet
41354982|NCT02581852|OTHER|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
41354983|NCT01017211|OTHER|auricular acupuncture|"Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized."
41354984|NCT01860131|BEHAVIORAL|Weight Wise Community Modules|Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
41354985|NCT03960294|OTHER|DOZE Sleep App|DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
41354986|NCT05524259|DIETARY_SUPPLEMENT|Myo-inositol and routinely recommended folic acid|Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.
41354987|NCT05524259|DIETARY_SUPPLEMENT|Routinely recommended folic acid|The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
41495137|NCT04000763|DEVICE|superficial peroneal nerve stimulation|A commercially available FDA-approved transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes will be used to stimulate the foot. The electrodes will be attached to the dorsal surface of the foot and a sock will be placed over the foot to prevent detachment of the electrodes. Based on our animal studies, foot stimulation parameters of 2 Hz frequency and 0.2 ms pulse width will be used at the maximal intensity comfortable for each patient. It is expected that superficial peroneal nerve stimulation in patients can increase bladder sensation so that micturition can be initiated at a small bladder volume, or it can initiate bladder contraction at a small bladder volume and enhance the contraction or prolong the duration of contraction. Any of these excitatory effects, if occurs in human patients, will certainly improve the condition of non-obstructive urinary retention.
40835161|NCT05276895|OTHER|Placebo|Placebo capsule for one week every 3 weeks over 15 weeks
40835162|NCT06213285|DEVICE|Watchman FLX left atrial appendage occlusion|Early (30-120 days) CT follow-up after Watchman FLX LAAO
41354988|NCT06071533|DRUG|Dandshen|Dandshen injection 20ml /day
41354989|NCT01157585|DRUG|paliperidone ER|8 week prospective study
41354990|NCT02068391|BEHAVIORAL|Stretching Program|The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
41509186|NCT02886780|BEHAVIORAL|Self-help|
41509187|NCT03892499|DRUG|Olinciguat|Oral Tablet
40835163|NCT02131519|PROCEDURE|internal jugular vein catheter placement|
40835164|NCT03303612|DEVICE|Pacemaker implant|Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
41495138|NCT03546920|BEHAVIORAL|ALIGN Intervention Phase|"Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives."
40835165|NCT03303612|DEVICE|Transcutaneous cardiac monitor|"Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include:~Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval \>5 sec; Third-degree AV block or Mobitz 2 AV block;"
40835166|NCT00535821|DEVICE|Esophageal Doppler monitoring - CardioQ, Deltex Inc|6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
40835167|NCT00535821|DEVICE|Central line with CVP and continuous ScvO2 monitoring|6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
40835168|NCT04039867|DRUG|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
40835169|NCT01866033|DRUG|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
40835170|NCT01866033|DRUG|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
40835171|NCT01866033|DRUG|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
40835172|NCT01866033|DRUG|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
40835173|NCT00487123|DRUG|Valsartan+/- Hydrochlorothiazide|
40835174|NCT05141656|OTHER|No intervention will be considered in this study.|No intervention will be considered in this study.
40835175|NCT01930760|BEHAVIORAL|Standard Medical Training Educational|"Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour."
40835176|NCT01930760|BEHAVIORAL|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
40835177|NCT05014568|DRUG|tapinarof cream, 1%|applied topically once daily
40835178|NCT05014568|DRUG|Vehicle cream|applied topically once daily
40835179|NCT04928729|OTHER|Pursed Lip Breathing|PLB with frequency of three times daily for First 3 days of week for a duration of 5-10 mins is perform.
40835180|NCT04928729|OTHER|Pursed Lip Breathing +DB|PLB+DB with frequency of three times daily for Last three days of week for a duration of 10-15 mins is perform.
40835181|NCT04928729|OTHER|Conservative care|Participants will be having different dose as per tolerance 5 times daily.
40835182|NCT05640609|COMBINATION_PRODUCT|Capeox regimen combined with Sintilimab and Bevacizumab|Stage Ib：Oxaliplatin +Capecitabine Tablets +Sintilimab +Bevacizumab Stage II：Bevacizumab (the dose determined in phase Ib clinical study)，the dosage of other drugs was the same as before
41160057|NCT03268850|BEHAVIORAL|Wage Reimbursement A|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
40835183|NCT04878744|BEHAVIORAL|Shmapped|Novel app-based intervention to improve wellbeing in patients with common mental health problems.
40835184|NCT00189501|DRUG|Sensipar®|
40835185|NCT05605171|PROCEDURE|Posterior reconstruction urethrovesical anastomosis.|Rocco stitch.
40835186|NCT05605171|PROCEDURE|Conventional vesicourethral anastomosis.|Standard of care.
41509188|NCT03892499|DRUG|Itraconazole|Oral Capsule
41354991|NCT02068391|BEHAVIORAL|Exercise Program|The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
41354992|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
41354993|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
41354994|NCT03557801|OTHER|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
41354995|NCT05529030|BEHAVIORAL|Salience of Omicron variant|The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster
41354996|NCT05529030|BEHAVIORAL|Self-protection message|The message makes a reference to protecting one's self
41354997|NCT05529030|BEHAVIORAL|Other-protection message|The message makes a reference to protecting others (patients)
41354998|NCT05791357|DIAGNOSTIC_TEST|PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNA|Molecular diagnostic using a broad range PCR on obtained histological material (native valve/valve prosthesis/fragments of them)
41354999|NCT03230266|PROCEDURE|Collection of intra-peritoneal catheters for insulin infusion|Collection of intra-peritoneal catheters for insulin infusion
41355000|NCT02356042|OTHER|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
41355001|NCT02948244|DIETARY_SUPPLEMENT|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
41355002|NCT02948244|DIETARY_SUPPLEMENT|Placebo|Placebo
41355003|NCT01707940|DRUG|Ketoconazole|Ketoconazole 400 mg / day
41355004|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
41355005|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
41355006|NCT03384394|DEVICE|high-flow nasal cannula oxygen|high-flow nasal cannula oxygen
41355007|NCT03384394|DEVICE|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
41355008|NCT05084820|COMBINATION_PRODUCT|Action observation treatment|Participants will watch 5 videos of motor tasks; each video is of 30 sec and watch for 4 times (i.e. for 2 minutes). Then patient will execute the motor act, soon after the observation with an affected limb for 2 minutes, with total rest time of 5 minutes for this treatment. Conventional treatment of muscle stretching, strengthening and ROM exercises will be given for 15 minutes including rest. Total treatment time is 40 minutes.
41495139|NCT02205983|DRUG|2 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
41495140|NCT02205983|DRUG|1000 mg Acetaminophen|We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
41495141|NCT02205983|DRUG|4 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
41495142|NCT02205983|DRUG|dextrose|We are administering dextrose to healthy volunteers for our placebo group.
41160058|NCT03268850|BEHAVIORAL|Wage Reimbursement B|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount (different from LW-A), based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
41495143|NCT01912027|PROCEDURE|Open Latarjet technique|
41355009|NCT05084820|COMBINATION_PRODUCT|conventional treatment|conventional treatment of 40 minutes in total will be performed including Stretching (for 8-10 sec with set of 5 repetitions/ session on each side for 3 minutes total with rest), strengthening (weighted bicep curls, side arm raise and open arm movement exercises with set of 5 repetitions/ session for 9 minutes total with rest), Range of motion exercises active and passive with set of 5 repetitions/ session for 3 minutes total with rest and gripping,reaching, grasping exercises (on each side for total 25 minutes including rest) with assistance of physiotherapist
41355010|NCT03969589|BEHAVIORAL|Reproductive Life Planning-Mental Health (RLP-MH) Intervention|RLP-MH intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
41355011|NCT03969589|OTHER|Written Materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
41355012|NCT00018694|DRUG|Chenodeoxycholic Acid|
41355013|NCT00979004|DRUG|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
41495144|NCT01912027|PROCEDURE|Arthroscopic Latarjet techniques|
41495145|NCT02217787|DRUG|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
41495146|NCT02217787|DRUG|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
41495147|NCT05396378|DIETARY_SUPPLEMENT|Oral glucose in liquid form|A glucose containing drink that has a fixed dose of 25 g of glucose per can.
41495148|NCT03614897|BEHAVIORAL|Education|Education on guidelines for care of individuals at risk of falling
41160059|NCT00794911|BEHAVIORAL|Quality of Life Therapy|8 weekly individual counseling sessions
41495149|NCT00952211|DEVICE|CPAP|CPAP at therapeutic pressure during nighttime
41495150|NCT00952211|DEVICE|CPAP at sub-therapeutic pressure|CPAP delivered at sub-therapeutic pressure at nighttime
41495151|NCT06082895|BEHAVIORAL|Birth self-efficacy enhancement training based on motivational interviewing method|Birth self-efficacy enhancement training based on motivational interviewing method
41495152|NCT04877886|DIAGNOSTIC_TEST|Ultrasound with IV contrast|To compare the efficiency over the ultrasound scan within contrast
41495153|NCT04877886|DIAGNOSTIC_TEST|CT with IV contrast|CT with IV contrast
41495154|NCT04877886|DIAGNOSTIC_TEST|Ultrasound without IV contrast|Ultrasound without IV contrast
41495155|NCT04877886|DIAGNOSTIC_TEST|CT without IV contrast|CT without IV contrast
41495156|NCT01646138|BIOLOGICAL|Ca/04/2009/H1N1 Vero Grown Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
41495157|NCT02005263|PROCEDURE|Salpingography|Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
41495158|NCT06404164|PROCEDURE|Wedge resection under watershed analysis method|"* Compare the preoperative 3D reconstruction model, and use electrocautery to directionally separate and expose the target artery;~  * Auxiliary devices (unlimited) to block the target artery, but should not be severed; ③ Peripheral intravenous injection of ICG, electrocautery to mark the border of counter-staining; ④ Evaluate the actual incisal margin according to the preoperative planning, and use the cutting stapler to wedge resection of the pulmonary nodule"
41355014|NCT01664585|BEHAVIORAL|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
41355015|NCT01664585|BEHAVIORAL|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
41355016|NCT02180035|DIETARY_SUPPLEMENT|Symbiotic|6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
41355017|NCT02180035|DIETARY_SUPPLEMENT|Maltodextrin (placebo for symbiotic)|6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
41355018|NCT02180035|BEHAVIORAL|Nutritional intervention|Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
41495159|NCT06314880|BIOLOGICAL|Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)|Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
41355019|NCT01219166|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
41355020|NCT03307395|PROCEDURE|Middel Meningeal Artery Embolization|Blood supply to the subdural hematoma via the middle meningeal artery is interrupted.
41355021|NCT05643170|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
41355022|NCT02400593|BEHAVIORAL|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
41495160|NCT06314880|BIOLOGICAL|Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)|Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
41495161|NCT06314880|BIOLOGICAL|Placebo control|Placebo control. 20 people/group.
41495162|NCT02289235|DRUG|Ginger|Ginger powder capsule 1000 mg twice daily for 3 months
41495163|NCT02289235|DRUG|Placebo|Placebo powder 2 capsules twice daily for 3 months
41495164|NCT05212389|DRUG|Femicept|150 μg levonorgestrel +30 μg ethinylestradiol
41495165|NCT05212389|DRUG|Placebo|Placebo
41495166|NCT04755933|BEHAVIORAL|Raising Confident Children Course|An online learning tool consisting of 8 different modular components, designed to reduce the transmission of anxiety from parents to children. The modular components include: a core starter about anxiety, the role of avoidance, using play to develop childrens confidence, using Emotion Coaching with children, managing difficult behaviour, the role of sleep, exercise and diet, reducing overprotection, modelling confident behaviour and managing difficult behaviour.
41160060|NCT00794911|BEHAVIORAL|Supportive Therapy|8 weekly individual counseling sessions
41495167|NCT05638958|DEVICE|Immediate post-extractive Implant placement|Teeth scheduled for extraction will be used to study the effect of a customized healing abutment. All patients should receive prophylactic antibiotic therapy of 2g of amoxicillin (or clindamycin 600mg if allergic to penicillin) 1 hour before the surgery. Implant placed along the lingual/palatal bone plate and the implant platform should be placed at the level of the buccal bone plate. GUIDOR easy-graft CRYSTAL will be used to fill the defect between implant and buccal bone plate, subsequently, a standard healing abutment or a customized healing abutment will be screw-retained on the implants.
41495168|NCT01275430|DEVICE|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
41495169|NCT01275430|OTHER|Blind Placement|"PICCs will be placed blindly, without the use of any tip location/positioning device."
41495170|NCT04049110|DRUG|Forxiga 10mg|Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
41495171|NCT04049110|DRUG|Placebo|Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
41495172|NCT02087995|DEVICE|Continuous Glucose Monitoring|A prescribed clinic session day for participating subjects.
41495173|NCT02337959|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
41509189|NCT00704132|DRUG|Comparator: sitagliptin phosphate|Sitagliptin tablet 100 mg, administered once daily before the morning meal.
41160061|NCT01732926|DRUG|Idelalisib|150 mg tablet administered orally twice daily
41160062|NCT01732926|DRUG|Rituximab|375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
41160063|NCT01732926|DRUG|Bendamustine|90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
41355023|NCT05150171|OTHER|e-self-management intervention|The app is developed based on a combination of behavioural change techniques informed by Social cognitive theory and the EULAR recommendations on management of hand osteoarthritis. The 12-week intervention consists of 25 short informational videos addressing the themes prioritized by the patient research partners. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The informational videos and exercise program are delivered in a progressive order across the 12 weeks. Encouragement and motivational messages are provided each week to enhance continued adherence to the intervention.
41355024|NCT01365715|PROCEDURE|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
41495174|NCT04699851|BEHAVIORAL|Tailored recommendations|Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.
41495175|NCT04699851|BEHAVIORAL|General recommendation|The control group will receive general recommendations by email about health prevention in a pandemic.
41160064|NCT01732926|DRUG|Placebo|Tablet administered orally twice daily
41160065|NCT01716091|PROCEDURE|irrigation in the peritoneal cavity|irrigation in the peritoneal cavity after uterine wall closed at cesarean
41160066|NCT01547182|BEHAVIORAL|Caloric restriction|Caloric restriction
41160067|NCT01547182|BEHAVIORAL|Aerobic Training|Walking
41160068|NCT01547182|BEHAVIORAL|Resistance Training|Lifting weights
41160069|NCT06117761|OTHER|Attention Placebo|Telephone follow-up focused on information provision and brief counselling relating to their health conditions. They will also receive routine care from the healthcae system, including medical follow-ups with the clinical team, without structured out-patient rehabilitation services.
41355025|NCT01365715|PROCEDURE|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
41355026|NCT06183255|OTHER|Observation and evaluation of clinical parameters in the two cohorts|During medical history evaluation, all factors that could negatively affect male fertility, like prevalent comorbidities, previous testis surgery, and any disorder affecting testicular function will be investigated in fertile and infertile men. Moreover, family history will be deeply investigated, including fertility status and prevalence of malignant Non Communicables Diseases. A comprehensive physical examination will be performed on each infertile and fertile man.
41355027|NCT06436170|DIAGNOSTIC_TEST|OCTA|OCTA is a non invasive diagnostic technique to visualize RPC
41495176|NCT04728503|BEHAVIORAL|5-Minute Mindful Movement Video|5 minute video includes a brief verbal introduction to mindfulness and then guides participants through a mindful movement exercise to facilitate grounding in the present moment and activation of the parasympathetic nervous system.
41495177|NCT04728503|BEHAVIORAL|Written Educative Materials|1 page written educative material about the benefits of mindfulness to serve as a control.
41495178|NCT02816099|BIOLOGICAL|Prise de sang|
41355028|NCT00416572|BEHAVIORAL|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
41355029|NCT00416572|BEHAVIORAL|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
41355030|NCT00962416|DEVICE|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
41355031|NCT00962416|DEVICE|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
41355032|NCT03824444|DEVICE|PODS|Percutaneous Osseointegrated device for transhumeral patients
41355033|NCT03696498|PROCEDURE|Resin restoration (1 step)|Permanent resin restoration is placed on top of the partial removed caries.
41355034|NCT03696498|PROCEDURE|Resin restoration (2 steps)|A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
41355035|NCT02050672|DIETARY_SUPPLEMENT|Myo-inositol|
41355036|NCT02050672|OTHER|untreated|
41495179|NCT04333238|OTHER|New progress note template|Residents assigned to document with new progress note template
41495180|NCT04333238|OTHER|Standard progress note template|Residents assigned to document with standard progress note template
41495181|NCT00296231|OTHER|Nasal high frequency ventilation|use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.
41495182|NCT04300010|DRUG|5% Topical Benzoyl Peroxide Gel|Gel treatment used to treat acne
41495183|NCT04300010|DEVICE|Blue Light Therapy|Blue light therapy treatment for acne
41495184|NCT02028494|DRUG|Capecitabine|Two dosages comparison
41495185|NCT00077753|DRUG|enoxaparin sodium|
41509190|NCT00704132|DRUG|Comparator: placebo (unspecified)|Matching placebo tablet, administered once daily before the morning meal.
40835187|NCT05687006|PROCEDURE|Colour Doppler Ultrasound|The main perforators were examined using a LOGIQ S8/V1 CDU device (GE Healthcare, Chalfont St Giles, Great Britain) with a linear transducer of frequency 4-11 MHz. Measured parameters were: 1) calibre of artery and vein; 2) Peak systolic velocity (PSV) of blood in the artery \[cm/s\]; 3) blood velocity in the perforator vein \[cm/s\]; 2) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
40835188|NCT00416715|DRUG|letrozole|Given PO
40835189|NCT00416715|DIETARY_SUPPLEMENT|calcium carbonate|Given PO
40835190|NCT00416715|OTHER|laboratory biomarker analysis|Optional correlative studies
40835191|NCT00416715|DIETARY_SUPPLEMENT|calcium citrate|Given PO
40835192|NCT00416715|DIETARY_SUPPLEMENT|calcium glucarate|Given PO
40835193|NCT00416715|DRUG|calcium gluconate|Given PO
40835194|NCT00416715|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
41355037|NCT04950491|OTHER|Modified Dental Anxiety Score (MDAS) questionnaire|MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, \&Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
41355038|NCT04950491|OTHER|Pain questionnaire|Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
41495186|NCT05937984|DEVICE|Active Controlled Transcranial Magnetic Stimulation (cTMS)|cTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of cTMS requires 9 minutes in total.
41495187|NCT05937984|DEVICE|Sham Controlled Transcranial Magnetic Stimulation (cTMS)|A sham coil will be utilized for the sham cTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham cTMS will be identical to Active cTMS.
41495188|NCT00051987|DRUG|VELCADE TM (bortezomib) for Injection, or PS-341|
41495189|NCT05603377|DIAGNOSTIC_TEST|functional endoscopic evaluation of swallow|functional endoscopic evaluation of swallow
41495190|NCT02435095|DRUG|Maintenance treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
41355039|NCT04950491|OTHER|Oral Health-Related Quality of Life (OHRQoL) questionnaire|The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, \& Chaushu, 2004). Patients answered using a 5-category Likert scale.
41355040|NCT04735289|OTHER|EPIC-COS Food Frequency Questionnaire diet Evaluation|Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ
41355041|NCT04735289|OTHER|Metabolome, Microbiota, Lymphocytes subpopulations|"At diagnosis before any treatment for bone sarcoma will be obtained :~1. a blood sample for metabolomics analyses~2. a stool sample for microbiota analysis~3. Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples"
40835195|NCT00416715|PROCEDURE|assessment of therapy complications|Ancillary studies
40835196|NCT00416715|PROCEDURE|musculoskeletal complications management/prevention|Correlative studies
40835197|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
41355042|NCT00350610|OTHER|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
40835198|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
40835199|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
40835200|NCT02258529|DRUG|Idelalisib|150 tablets administered orally twice daily
40835201|NCT02258529|BIOLOGICAL|Rituximab|375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
41355043|NCT00350610|BEHAVIORAL|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
41021378|NCT05174975|BEHAVIORAL|App-based Positive Psychological Intervention|The PPI has included a 12-week PPI lessons. Each lesson has separated into 3 parts: introduction, activity, and feedback. Diabetes-related health education will include the basic knowledge of diabetes, diet, and exercise related videos. Physical records include record of daily blood sugar, blood pressure, HbA1c, diet, and exercise. In terms of dietary records, the amount of carbohydrates of each food will be calculate automatically after documented. Exercise records documents the burn of calories of each exercise (per 30 minutes). Both unit of dietary and exercise are based on Health Promotion Administration's criteria in Taiwan. Moreover, participants are available to have one-on-one instant online consultation with their diabetes educators via App.
41021379|NCT00293540|PROCEDURE|oophorectomy|Excision of an ovary
41160070|NCT06117761|OTHER|Home-based exercises combined with cognitive training|An 8-week, home-based, exercise with cognitive training intervention. 3 sessions per week, and 80 minutes per session.It comprises of 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.A blended training platform with supervised in-person home visits and a real-time supervised online and unsupervised selfpractice approach will be used to deliver the intervention, with the platform gradually shifted from home visits to unsupervised self-practice according to participants' physical functioning level. Family caregivers will be involved in the intervention, so that they can facilitate home-based training. Each intervention session will last for 80 minutes and comprise 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.
41160071|NCT06117761|OTHER|Home-based exercises|An 8-week, home-based, exercise-only intervention. Weeks 1 and 2 will be the induction phase, all sessions will be supervised with two home visit sessions and one online session in real-time. Weeks 3 to 6 will be the maintenance phase. For participants with a higher functional performance level (Level 3 or 4), the mode of delivery will change to one home visit and two online training sessions. Weeks 7 and 8 will be the consolidation phase, consisting of two online sessions and one unsupervised self-practice session. They will not receive any structured cognitive training.
41355044|NCT03068182|DEVICE|Arm crank|Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
41355045|NCT03068182|DEVICE|Treadmill|Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
41355046|NCT03068182|OTHER|Exercise|
40835202|NCT00438152|DRUG|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
40835203|NCT00438152|DRUG|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
40835204|NCT03825159|DEVICE|Spinal Orthosis with an Integrated System of Electric Surface Stimulation and Heat Sensing|The electrical stimulation technology integrated with the total contact spinal orthosis combines the external correction forces on the spinal skeleton from the passive orthosis with the muscle forces at the lateral trunk from the stimulation process.
41021380|NCT00293540|DRUG|Tamoxifen|20 mg orally every day
41021381|NCT03185624|DRUG|Rifaximin|Antibiotics
41495191|NCT02435095|DRUG|Intermittent treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
40835205|NCT03825159|DEVICE|spinal orthosis|The ventrally opened total contact spinal orthosis will be designed and made of Copolymer and Aliplast. Correcting pressure points have to use the pressure pads at relevant points.
40835206|NCT02827383|BEHAVIORAL|Stair Climbing Frequency|Includes 1 sedentary day prior to completing crossover phases.
40835207|NCT04323293|OTHER|Cold Water Bath|immersion of the hand for 2-5min in 2-10°C water
40835208|NCT04323293|OTHER|Neutral Water Bath|immersion of the hand for 2-5min in 32±2°C water
40835209|NCT01537055|DRUG|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
40835210|NCT01537055|DRUG|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
40835211|NCT00430937|DRUG|Daptomycin|4 mg/kg intravenous once daily
40835212|NCT00430937|DRUG|Vancomycin|1 g intravenous twice daily
40835213|NCT00430937|DRUG|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
40835214|NCT00002239|DRUG|Enfuvirtide|
40835215|NCT00002239|DRUG|Ritonavir|
40835216|NCT00002239|DRUG|Abacavir sulfate|
40835217|NCT00002239|DRUG|Amprenavir|
40835218|NCT00002239|DRUG|Efavirenz|
40835219|NCT04858685|OTHER|early mobilization|early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid.
41021382|NCT00451425|BEHAVIORAL|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
41021383|NCT00354926|BIOLOGICAL|AME-133v (LY2469298)|IV 4X weekly X 4
41021384|NCT06533605|DRUG|SSGJ-706|Bispecific antibody
41021385|NCT01478789|DIETARY_SUPPLEMENT|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
41021386|NCT01478789|DIETARY_SUPPLEMENT|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
41021387|NCT01478789|DIETARY_SUPPLEMENT|placebo|100g/d yogurt with no added plant sterol
41021388|NCT01702792|BIOLOGICAL|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
41021389|NCT03117335|DRUG|Placebos|"Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
41021390|NCT03117335|DRUG|Sulijia|"Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
41021391|NCT05117827|DEVICE|Power Wheelchair Standing Device|A power wheelchair standing device is a power wheelchair that allows a child to electronically move between sitting and standing. It can be driven in either position. The Permobil F5 Corpus VS is the specific power wheelchair standing device to be used in this study.
40835220|NCT03623178|OTHER|Assertive Community Treatment|The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
40835221|NCT03623178|OTHER|Treatment As Usual|The treatment as usual is the intervention given in our outpatient addictology unit. It consists of an individual treatment program at our outpatient unit with regular appointments with psychiatrists and nurses. The patient can also take part in therapeutic groups and receive help from a psychologist for a targeted program or psychotherapy. The multidisciplinary team also comprises a social worker and an occupational therapist.
40835222|NCT01960088|DRUG|HPV vaccine|
40835223|NCT05334420|BEHAVIORAL|Healthy Dads Healthy Kids|Group based lifestyle behavioral intervention for weight loss for fathers and increased physical activity for their child. The program meets weekly 90-minute sessions over 10 weeks. Mothers/partners are invited to one session (Week 4). Each meeting consisted of a brief review session with Dads and Kids together (15 minutes), separate break-out discussion for Dads (Dad's Club) and Kids (Kid's Club) (30 minutes); and a joint physical activity component for Dads and Kids (Sports Club) (45 minutes). Each week covers different topics for fathers and a corresponding session for kids. The program encourages fathers to be healthy, positive role models for their children, and teaching fathers weight loss strategies, authoritative parenting strategies and to encourage healthy behaviors in their kids. Fathers and kids are encouraged to eat healthy, reduce their screen time and be more active. If the COVID pandemic prevents in-person meetings, the program will be delivered virtually.
40835224|NCT05334420|OTHER|Standard of care control|Families will receive handouts on healthy eating, physical activity and screen media use to promote healthy weight status. Fathers will attend one group session with a focus on dietary changes and increased physical activity to promote healthy weight loss.
40835225|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel \[200 milligram/square meter (mg/m\^2)\] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram\*minute/milliliter (mg\*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
40835226|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
41021392|NCT00582582|DRUG|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
41021393|NCT00582582|DRUG|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
41021394|NCT04079933|OTHER|Oral tobacco-derived nicotine product (OTDN)|
41160072|NCT00220441|BEHAVIORAL|Aerobic exercise|
41495192|NCT02802449|DRUG|25 Hydroxy- Vitamin D3 [25 (OH) D3]|Two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
41495193|NCT02802449|DRUG|Placebo|
41355047|NCT05507190|OTHER|Self-management of post COVID-19 respiratory outcomes|Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred.
41355048|NCT00142818|DRUG|Naltrexone|150 mg daily for males; 100 mg daily for females
41355049|NCT00142818|DRUG|Modafinil|400 mg daily
41355050|NCT00142818|DRUG|Placebo|400 mg and/or 100-150 mg placebo pills
41355051|NCT03464461|DRUG|Ketorolac|IV drug
41355052|NCT00523172|PROCEDURE|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
41355053|NCT00523172|PROCEDURE|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
41355054|NCT00523172|PROCEDURE|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
41355055|NCT05542472|OTHER|Family Support Program Based on a Nurse-Led Case Management Model|A Family Support Program Based on the Nurse-Led Case Management Model create for the care givers in the intervention group. Case management is the process of planning an individual's care, coordinating it, managing it, implementing it and reviewing it. The aim in case management is to improve a person's quality of life by coordinating health care services and providing these services at a reasonable cost and in a productive way. The use of case management requires the cooperation of professionals from many different disciplines. Therefore, in areas where case management is applied, the case manager coordinates an individual's or patient's care by enabling this cooperation. In this way, in areas where health services are provided, the case manager may be a doctor, a nurse, a physiotherapist, a social services expert, or a speech therapist.
41355056|NCT04115605|DEVICE|Altis Single Incision Sling|Minimally invasive system including permanently implantable synthetic suburethral sling for the surgical treatment of female Stress Urinary Incontinence
41355057|NCT03646916|DRUG|Dexamethasone|Gluco-corticosteroid
41355058|NCT03646916|OTHER|No dexamethasone|Nothing
41355059|NCT03099018|DIAGNOSTIC_TEST|Sofia Strep A FIA|Patients who presented with sore throat will be performed throat swab for the new fluorescent immunoasssay (Sofia Strep A FIA), for a standard RADT (Alere Testpack Strep A) and for culture and backup PCR in case of discrepant results.
41355060|NCT01416259|DRUG|Withdraw treatment|
41355061|NCT04912297|BIOLOGICAL|10-valent pneumococcal conjugate vaccine, PCV10|10-valent pneumococcal conjugate vaccine, PCV10
41355062|NCT00171691|DRUG|Diclofenac Topical Sodium Gel 1%|
41355063|NCT00675844|DRUG|Elvucitabine|10 milligrams (mg) elvucitabine daily as part of an ART regimen
41355064|NCT04771936|OTHER|Physiotherapy Exercises|All patients shall be randomly assigned to 3 groups: the control group who shall be awaiting surgery and not receiving a regular physiotherapy, the exercise group who shall be subject to a set of conventional exercises and a core exercise group who shall be performing the conventional exercises plus exercises aimed at the activation of core muscles. These exercises shall be carried out 3 times weekly for a period of 3 months. During the first 4 weeks, all sessions shall be supervised by a physiotherapist. From the 5th to the 8th week, patients shall attend 2 supervised sessions and complete the 3rd one at home. Between the 9th and the 12th week, patients shall then attend 1 supervised intervention and complete 2 sessions at home.Patients assigned to the control group shall be given a chance to enrol into the program upon completion of the study if they wish to do so.
41355065|NCT03103464|OTHER|Standard-of-Care Therapy + Sit-to-Stand Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time + sit-to-stand training using the Movi chair 3x/wk for approximately 10 minutes each time.
40835227|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
41021395|NCT05038488|DRUG|MIB-626|Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.
41355066|NCT03103464|OTHER|Standard-of-Care Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time.
41355067|NCT01566981|PROCEDURE|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
41355068|NCT01215877|DRUG|Tesetaxel|"Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months~In Cycle 1, a dose of 27 mg/m2 will be administered. In subsequent cycles,~* the dose will be increased to 35 mg/m2 in Cycle 2 for subjects who did not have an ANC \< 1,500/mm3, a platelet count \< 100,000/mm3, or a Grade 3 (or higher grade) nonhematologic adverse event considered by the Investigator to be related to protocol therapy (excluding alopecia, nausea, and vomiting) in Cycle 1. The dose is not to exceed the dose of 35 mg/m2 in any cycle subsequent to Cycle 2.~* for all other subjects, the dose administered in Cycle 1 (27 mg/m2) will be administered in all subsequent cycles."
41355069|NCT02237573|OTHER|Written medical report and standardized medical advices|"The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:~1. a detailed report of the consultation (motive, case history, clinical examination, conclusion)~2. written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients."
41355070|NCT02237573|OTHER|Control|"Other:~Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator."
41355071|NCT04375007|OTHER|Routine care|Physiotherapy intervention in routine care
41355072|NCT00554424|DRUG|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
41355073|NCT00554424|DRUG|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
41355074|NCT06264336|BEHAVIORAL|treadmill training|Participants will undergo 12 sessions (4 weeks, 3 sessions/week) of treadmill training. During each session, participants will walk for 40 min. with 5 min. of warmup and cooldown at 50% of maximal walking speed (tested each week) with 30 min. of training interposed. The type of training will be determined by the assigned treatment arm.
41021396|NCT05038488|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.
41021397|NCT05038488|OTHER|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
41355075|NCT02629887|DEVICE|Non-inflatable supraglottic airway|at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
41495194|NCT02529215|BEHAVIORAL|Just-in-time training (JITT)|The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
41495195|NCT05637164|DRUG|norepinephrine bitartrate|The treatment group will receive a continuous infusion of norepinephrine at the beginning of anesthesia induction until 15 minutes after intubation. The dosage of norepinephrine was decided by the up-and-down sequential allocation method with an initial dose of 0.05 µg/kg/min and a 0.005 µg/kg/min gradient.
40835228|NCT00454649|DRUG|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m\^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
40835229|NCT00454649|DRUG|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m\^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
40835230|NCT00454649|DRUG|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m\^2) 60-minute infusion on Day 1 of each cycle.
40835231|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
40835232|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
40835233|NCT00454649|DRUG|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m\^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m\^2) infusion on Day 1 of each cycle.
40835234|NCT00454649|DRUG|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m\^2) 10-minute infusion followed by cisplatin (75 mg/m\^2) infusion on Day 1 of each cycle.
40835235|NCT06179316|PROCEDURE|Robot Assisted Radical Prostatectomy|Performing radical prostatectomy operation using robotic equipment while preserving bilateral nerve bundles
40835236|NCT03123042|PROCEDURE|Sentinel basin dissection|Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
40835237|NCT02074813|OTHER|Inspiratory muscle training|Inspiratory muscle training
40835238|NCT02178046|DEVICE|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
40835239|NCT02003937|BEHAVIORAL|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
40835240|NCT02753686|DRUG|Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|
40835241|NCT02753686|DRUG|Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy|
40835242|NCT05630638|DRUG|Doravirine|Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil
41495196|NCT02701270|DIETARY_SUPPLEMENT|Experimental Dietary Fibre 1|22.17 g of product diluted in 250 ml of water taken once orally.
41495197|NCT02701270|DIETARY_SUPPLEMENT|Experimental Dietary Fibre 2|21.84 g of product diluted in 250 ml of water taken once orally.
41495198|NCT02701270|DIETARY_SUPPLEMENT|Polydextrose|21.48 g of product diluted in 250 ml of water taken once orally.
41495199|NCT02701270|DIETARY_SUPPLEMENT|Dextrose|23.89 g of dextrose diluted in 250 ml of water taken once orally.
41495200|NCT00711438|BEHAVIORAL|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
41355076|NCT02629887|DEVICE|Face Mask|at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
40835243|NCT05630638|DRUG|Dolutegravir|Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil
40835244|NCT02818114|BEHAVIORAL|Peer Enhanced Prolonged Exposure|Peer support interventions as adjunct to prolonged exposure
40835245|NCT04941404|DRUG|TQ05105 tablets|Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
40835246|NCT00865085|DRUG|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
40835247|NCT00865085|DRUG|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
40835248|NCT04320511|DEVICE|CT-V|CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
40835249|NCT00832494|DRUG|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
40835250|NCT02674425|DEVICE|Dark Adaptometer|
40835251|NCT00539929|DRUG|E6201 0.005%|
41160073|NCT05671133|DIAGNOSTIC_TEST|Clinician Decision Support Tool|Clinician Decision Support Tool that provides information about patient's statistical probability of suicide attempt in next 1 month
40835252|NCT00539929|DRUG|E6201 0.01%|
40835253|NCT00539929|DRUG|E6201 0.03%|
40835254|NCT00539929|DRUG|Placebo|
41355077|NCT02629887|DEVICE|T-Piece Resuscitator|T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
41355078|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 1|
40835255|NCT05755555|BEHAVIORAL|Visit a doctor|Test messages based on concepts from behavioural economics that aim to make information on screening more salient by using the concept of social proof (person like you) and an authoritative source (a diabetes specialist)
40835256|NCT00613080|DRUG|capecitabine|1650 mg/m\^2/day orally 5 days/week during radiotherapy.
40835257|NCT00613080|DRUG|oxaliplatin|
40835258|NCT00613080|PROCEDURE|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
40835259|NCT00613080|RADIATION|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
40835260|NCT00613080|DRUG|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m\^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m\^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m\^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m\^2, IV continuous infusion over 46 hours, day 1."
40835261|NCT05995197|OTHER|action observation|cartoon observation
40835262|NCT04475484|OTHER|Online questionnaire|"Parents will receive a link to an online questionnaire through computing services of Lyon's Academy. They have to give their consent to allow their child to participate in the study. Then, children can complete the online questionnaire.~The questionnaire starts with few explanations on the context of the study, and ends with psycho-education advices and what to do in the event of psychological distress."
40835263|NCT06206811|DRUG|OD-07656|innate immune modulator
40835264|NCT03166072|OTHER|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
40835265|NCT03166072|OTHER|No Intervention|Participants will continue to receive treatment as usual
40835266|NCT02047201|RADIATION|IMRT|IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).
40835267|NCT02047201|RADIATION|PET/CT|Assessing tumor response using FDG-PET/CT.
40835268|NCT02047201|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
41160074|NCT00004740|DRUG|isoniazid|
41160075|NCT04502888|DRUG|Drug: SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
41160076|NCT02864147|DRUG|9-valent HPV vaccine|All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
41160077|NCT02864147|DRUG|Imiquimod|At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
41355079|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 2|
41355080|NCT00425594|DRUG|NuLYTELY|
40835269|NCT02047201|DRUG|Fluorouracil|750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
40835270|NCT02047201|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
40835271|NCT00693654|DRUG|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (\&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
40835272|NCT00693654|DRUG|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
40835273|NCT04419441|DRUG|Immune checkpoint inhibitor|concomitant administration of radiotherapy and immune checkpoint inhibitor
41355081|NCT04635111|DRUG|TURALIO™|This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.
41355082|NCT01145833|OTHER|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
41355083|NCT01145833|OTHER|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
40835274|NCT05918627|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
40835275|NCT05918627|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
40835276|NCT02633553|RADIATION|adjuvant radiotherapy|50Gy/25Fx
40835277|NCT06265623|OTHER|No active intervention, but observational follow-up|Patients remain in usual care by their pulmonary medicine specialists and are being observed during annual follow-up investigations during up to 3 years
40835278|NCT06257836|OTHER|MPFL-reconstruction|Children with patella dislocations are operated from 2016-2022 with a quadriceps knee cap stabilization technique.
40835279|NCT00221975|DRUG|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
40835280|NCT00221975|DRUG|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
40835281|NCT00221975|DRUG|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (\<2 months versus ≥2 months).
41355084|NCT00343161|DRUG|esomeprazole|
41355085|NCT00343161|DRUG|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
41355086|NCT06218290|DRUG|Oxylanthanum Carbonate|Phosphate Binder to Reduce Hyperphosphatemia
41495201|NCT00711438|BEHAVIORAL|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
40835282|NCT05826977|BEHAVIORAL|CASI-Plus|See arm description
40835283|NCT00566865|DRUG|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
40835284|NCT00566865|DRUG|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
40835285|NCT06508723|PROCEDURE|Dental implant placement|The same routine implant placement protocol will be applied to both study groups with different surfaces and will be placed in the bone. After local anesthesia, a full-thickness flap will be raised. The implant socket will be created according to the protocol recommended by the company and all implants will be placed in the socket with a torque force of 35 N and the implants will be placed. Once bleeding control is achieved, the flap will be closed primarily. Healing caps will be installed after 3 months. After waiting for wound healing, prosthetic restoration will be performed.
41355087|NCT02169466|DRUG|BIA 9-1067|OPC, Opicapone
41495202|NCT01516307|BIOLOGICAL|OPT-822/OPT-821(30 μg/100 μg)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.
41495203|NCT01516307|BIOLOGICAL|Phosphate Buffer Saline (PBS)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
41355088|NCT02169466|DRUG|Placebo|PLC, Placebo
41160078|NCT05958147|BIOLOGICAL|C-PRF|thorough scaling and root planing is performed followed by withdraw of 5ml of blood from antecubital vein of patient with consent . Following C-PRF protocol of 3000rpm for 8 min centrifugation is performed. 1ml of plasma is drawn from the test tube just above the red blood cell layer and allowed to clot and the formed clot is placed in the periodontal pocket after scaling and root planing
41355089|NCT02169466|DRUG|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
41355090|NCT01844414|BEHAVIORAL|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
41355091|NCT01844414|BEHAVIORAL|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
41355092|NCT01844414|BEHAVIORAL|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
41355093|NCT05758116|DRUG|Tislelizumab|Tislelizumab: 200mg d1,q21d\*17
41495204|NCT01516307|DRUG|Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
41495205|NCT06000943|OTHER|Low vs Intermediate vs High surgical risk stratified according with SAPT/DAPT/OAC and OAC+SAPT|"All patients undergoing TAVR will be stratified according with surgical risk level and all combination of antithrombotic therapy at discharge~Low risk (SAPT vs DAPT and OAC vs OAC+SAPT) Intermediate risk (SAPT vs DAPT and OAC vs OAC+SAPT) High risk (SAPT vs DAPT and OAC vs OAC+SAPT)"
41495206|NCT00935610|DIETARY_SUPPLEMENT|Immunocal|20 grams per day of Immunocal for 135 days.
40835286|NCT02282904|DRUG|Sirolimus|"For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum)."
40835287|NCT02282904|BIOLOGICAL|Donor peripheral blood stem cells.|Infuse donor graft.
40835288|NCT02282904|DRUG|Cyclophosphamide post transplant|50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
40835289|NCT02282904|RADIATION|Total body 200cGy|Day -1
40835290|NCT02282904|DRUG|Cyclophosphamide|14.5 mg/kg IV over one hour Day -6 and -5
40835291|NCT02282904|DRUG|Fludarabine|30 mg/m2 over 30 minutes Day -6 through Day -2
40835292|NCT02282904|DRUG|Busulfan|Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
41160079|NCT02538718|DRUG|MgSO4|
41160080|NCT02538718|DRUG|YTP(Ritodrine)|
41160081|NCT01215032|DRUG|Metformin|Taken orally twice daily each 28-day cycle, for 12 cycles
41355094|NCT01790633|OTHER|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
41355095|NCT01790633|OTHER|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
41355096|NCT02204267|OTHER|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
41355097|NCT02204267|DEVICE|ECG|
41355098|NCT04251949|PROCEDURE|LED photobiomodulation|1 PLED session before each radiotherapy session, until the end of the radio or radio-chemotherapy treatment. Each session will last 7 minutes. The light delivered will be preset on the lamp which will deliver a red light of a wavelength of 630nm, at a fluence of 37J/cm².
41355099|NCT02994927|DRUG|Avacopan|"Avacopan 30 mg twice daily orally for 52 weeks (364 days):~- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days):~* Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day."
41495207|NCT00935610|DIETARY_SUPPLEMENT|Casein|20 grams per day for 135 days
41495208|NCT05986253|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
41495209|NCT05986253|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin solution
41495210|NCT01152619|DRUG|Placebo|Subcutaneous repeated dose
41495211|NCT01152619|DRUG|RO4989991|Subcutaneous repeated dose
41495212|NCT03788304|DEVICE|non-invasive ventilation|conventional NIV
41495213|NCT03788304|DEVICE|high flow nasal cannula|HFNC ventilation
41495214|NCT02657265|DEVICE|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
40835293|NCT02091284|DEVICE|transcranial Direct Current Stimulation|Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
40835294|NCT00001724|DRUG|Flurbiprofen|
40835295|NCT04123223|BEHAVIORAL|Cognitive Remediation|Cognitive remediation (CR) is a behavioral treatment designed to address neurocognitive deficits through task practice and/or strategy acquisition.
40835296|NCT04123223|BEHAVIORAL|Computer Games|Sham placebo treatment
40835297|NCT00783913|OTHER|Visumotor Upper Extremity Training|Control
40835298|NCT00783913|OTHER|Anodal/Sham tDCS|Condition
40835299|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
40835300|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
40835301|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
40835302|NCT01278589|DIETARY_SUPPLEMENT|Placebo|Liquid (80g) without Plantago asiatica L. extract
40835303|NCT04022018|RADIATION|Adaptive radiotherapy|CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
40835304|NCT04022018|RADIATION|no adaptive radiotherapy|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
40835305|NCT01767272|DRUG|fexofenadine|fexofenadine brand name
40835306|NCT01363583|DRUG|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
40835307|NCT01363583|DRUG|normal saline|0.5-1.5 ml/hour during 4 days
40835308|NCT00680758|DRUG|cisplatin|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 25mg/m2/week 3-6 patients~* Dose Level: 1 25mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 25mg/m2/week 3-6 patients"
40835309|NCT00680758|DRUG|everolimus|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 20mg/m2/week 3-6 patients~* Dose Level: 1 20mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 30mg/m2/week 3-6 patients"
40835310|NCT00680758|DRUG|paclitaxel|"* Dose Level: -3 65mg/m2/week 3-6 patients~* Dose Level: -2 70mg/m2/week 3-6 patients~* Dose Level: -1 70mg/m2/week 3-6 patients~* Dose Level: 1 80mg/m2/week 3-6 patients~* Dose Level: 2 80mg/m2/week 3-6 patients~* Dose Level: 3 80mg/m2/week 3-6 patients"
41355100|NCT02994927|DRUG|Prednisone|"Avacopan-matching placebo twice daily orally for 52 weeks (364 days):~- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone tapering regimen over 20 weeks (140 days):~* Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day."
40835311|NCT02603445|DRUG|BCL201|
40835312|NCT02603445|DRUG|Idelalisib|
41355101|NCT02994927|DRUG|Cyclophosphamide|Orally or intravenously administered
41355102|NCT02994927|BIOLOGICAL|Rituximab|Intravenously administered
41495215|NCT02657265|DEVICE|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
40835313|NCT05867537|DIETARY_SUPPLEMENT|Gluten-free diet|Implementation a 78-week dietary intervention to patients with ulcerative colitis, crohn´s disease and UC patients with associated PSC (PSC-IBD).
40835314|NCT04218396|DEVICE|Virtual Reality use during painful bedside procedure|Virtual reality (VR) will be used in addition to standard analgesic practices during painful bedside procedures. A head mounted display (HMD, Oculus Go Model #1KWPH812PN8354) and noise-cancelling headphones (Sony Model #MDRZ110B) will be provided to the patient during the procedure. This unit involves the patient wearing VR goggles, noise-cancelling headphones, and using a smartphone-based program with various applications the patient can choose from for analgesia/relaxation (eg: calming imagery/scenery of nature, activities involving mindfulness, interactive games or guided imagery, music and imagery, exercise imagery...etc). There are numerous, standard applications available for the patient to choose from, and the choice of most optimal application for analgesia, distraction, or anxiolysis will be left to the decision of the patient prior to their procedure.
40835315|NCT04218396|DRUG|Standard Treatment during painful bedside procedure|Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)
40835316|NCT06506539|DRUG|Placental Extract|add placental extract gel as a local delivery drug in periodontal pocket
41355103|NCT02994927|DRUG|Azathioprine|Orally administered
41355104|NCT03818399|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
41495216|NCT04471337|DRUG|BAY1817080|BAY1817080 will be administered orally as tablet.
41495217|NCT00398255|BEHAVIORAL|self-management program|
41355105|NCT04997564|DRUG|Tenofovir Alafenamide 25 MG|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 1 patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment .
41355106|NCT04997564|DRUG|Sofosbuvir / Velpatasvir|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 2 patients will be received TAF once daily for 64 weeks. In this study, after week 64.
41495218|NCT02418481|BIOLOGICAL|DC-CIK|DC-CIK cells will be used against tumor cells.
41495219|NCT02418481|BIOLOGICAL|γδ T Cell|γδ T cells will be used against breast tumor.
41495220|NCT02418481|BIOLOGICAL|Combination|γδ T/DC-CIK cells will be used against breast tumor.
41495221|NCT00867997|OTHER|Chemoactive (remineralizing, neuroactive) dentifrice treatment|Chemoactive (remineralizing, neuroactive) dentifrice treatment
41355107|NCT04312061|DRUG|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
41495222|NCT00867997|OTHER|Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F|Self-etch DBA followed by a hydrophobic resin layer
41495223|NCT00867997|OTHER|Clearfil S3 Bond; Premise Flowable resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
41495224|NCT01616342|DEVICE|Spinal cord stimulator|Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
41495225|NCT01685411|DRUG|Allopurinol|Day -8 (prior to transplant): Per institutional guidelines
41495226|NCT01685411|DRUG|Keppra|Day -8 (prior to transplant): Per institutional guidelines
41495227|NCT01685411|DRUG|Busulfan|Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.
41495228|NCT01685411|DRUG|Cyclophosphamide|Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
41495229|NCT01685411|DRUG|Tacrolimus|All patients (regardless of allograft source) will receive tacrolimus therapy beginning on day -3. Dosing will be monitored and altered as clinically appropriate per institutional pharmacy guidelines. Dose adjustments will be made on the basis of toxicity and/or low tacrolimus levels. Taper at day +100 for matched sibling donor (MSD) recipients, and day +180 for non-MSD recipients. Taper to zero by 10% weekly dose reduction over approximately 10 weeks.
41495230|NCT01685411|DRUG|Mycophenolate mofetil|Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (\> or = 40 kg) or 15 mg/kg 3 times per day (\< 40 kg) for up to 30 days unless no engraftment.
41495231|NCT01685411|BIOLOGICAL|Allogeneic hematopoietic stem cell transplant|Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.
41495232|NCT01685411|BIOLOGICAL|Filgrastim|Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is \>2500 x 10\^9/L or per institutional guidelines.
41495233|NCT01685411|BIOLOGICAL|antithymocyte globulin|Administered per institutional guidelines for recipients of umbilical cord blood transplant.
41495234|NCT02064114|PROCEDURE|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
41495235|NCT02064114|PROCEDURE|control group|Followed for a period of 3,6 and 12 months after the procedure.
41495236|NCT01467414|DRUG|insulin degludec|Injected s.c. (under the skin) once daily for 6 days
41495237|NCT05075720|DIETARY_SUPPLEMENT|Meat with added nitrate|"The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat."
41495238|NCT05075720|DIETARY_SUPPLEMENT|Meat without added nitrate|"The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat."
41495239|NCT05075720|DIETARY_SUPPLEMENT|Control|The control comprises low nitrate vegetable protein burger on white bread. Protein content matched to interventions 1 and 2.
41495240|NCT00678197|OTHER|Access Intervention|
41495241|NCT00678197|OTHER|Bonus/Pay-for-Performance Intervention|
41495242|NCT02702661|PROCEDURE|Fascia Iliaca Compartment Block (FICB)|Fascia Iliaca Compartment Block
41495243|NCT02702661|PROCEDURE|Local Anaesthetic Infiltration (LAI)|Local Anaesthetic Infiltration (LAI) of the portal tracts
41495244|NCT02702661|DRUG|Levobupivacaine|Levobupivacaine 0.125% - 40ml
41495245|NCT04682730|BEHAVIORAL|Deliberative Loop|"The investigators will give background information to the stakeholders before they engage in the Deliberative session.~Stakeholders from a given clinic will come together for a Deliberative session (i.e., facilitated conversation), enabling them to hear the full range of perspectives held by their fellow colleagues and to share their own perspective regarding how best to implement the guideline in small-group discussions.~Following the Deliberative session, each stakeholder will have the opportunity to record their opinions regarding possible implementation interventions. The investigators will share these opinions with the clinic's decision-makers to help guide their decision-making about which implementation interventions to deploy. If a stakeholder happens to be absent the day of their clinic's Deliberative session, they will still have the opportunity to complete the survey."
41495246|NCT00858143|OTHER|Non Interventional Observation|Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
41495247|NCT02971735|OTHER|mobile technology of e-learning (M-TEL)|UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
41495248|NCT06457165|DEVICE|Difficult Intubation|Noted for each patient.
41495249|NCT06457165|DEVICE|Not Difficult Intubation|Noted for each patient.
41495250|NCT00331240|DRUG|travoprost/timolol fixed combination|
41495251|NCT00331240|DRUG|placebo (artificial tears)|
41495252|NCT02011113|DRUG|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
41495253|NCT02011113|DRUG|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
41495254|NCT01889212|OTHER|11C-erlotinib PET/CT|
41495255|NCT02885181|DRUG|GS-9876|One tablet administered orally once daily
41495256|NCT02885181|DRUG|Filgotinib|Two tablets administered orally once daily
41495257|NCT02885181|DRUG|GS-9876 placebo|One tablet administered orally once daily
41495258|NCT02885181|DRUG|Filgotinib placebo|Two tablets administered orally once daily
41495259|NCT02885181|DRUG|Methotrexate|Background therapy with methotrexate administered orally or parenterally once weekly
41495260|NCT00896909|GENETIC|gene expression analysis|
41495261|NCT00896909|GENETIC|mutation analysis|
41495262|NCT00896909|GENETIC|polymerase chain reaction|
40835317|NCT05130476|PROCEDURE|Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
41495263|NCT00896909|OTHER|diagnostic laboratory biomarker analysis|
40835318|NCT04250597|DRUG|GNX102|Dose Escalation
40835319|NCT04250597|DRUG|GNX102|Expansion Phase
40835320|NCT04375176|DIAGNOSTIC_TEST|Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2|Phenotypic and functional analysis of monocytes and NK cells
41495264|NCT06024889|DRUG|Furosemide Injection|Intravenous administration of 80 mg furosemide is followed by assessing blood pressure, peripheral oxygen saturation, pulmonary fluid content by ReDS\*, and ultrasound examination of heart and lungs, including assessment of filling pressures with doppler and strain analysis. These measurements are repeated at multiple time points until 6 hours have elapsed.
41495265|NCT02006693|DEVICE|XEN® Gel Stent|The XEN® Gel Stent (XEN45 implant) was placed in the study eye.
40835321|NCT06508606|DRUG|AK117|AK117: 45mg/kg (D1, IVGTT, Q3W maintained for one year or until progression or intolerable toxicity occurred
40835322|NCT06508606|DRUG|anti-EGFR|anti-EGFR:initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained for one year or until progression or intolerable toxicity occurred
40835323|NCT01689350|GENETIC|Genotype Detection|To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
41355108|NCT04312061|DRUG|Placebo oral tablet|oral placebo tablet given 1 hour before LNG-IUD insertion
41355109|NCT00409149|BEHAVIORAL|CALM Approache|
41495266|NCT02006693|PROCEDURE|Cataract Surgery|Participants diagnosed with a cataract elected to have cataract surgery.
41495267|NCT02132637|DRUG|Insulin Peglispro|Administered SQ
41355110|NCT00409149|BEHAVIORAL|DASH approach|standard dietary DASH approach in hypertensive patients
41355111|NCT01933399|OTHER|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
41355112|NCT01933399|OTHER|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
41355113|NCT01933399|OTHER|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
41355114|NCT04651699|DEVICE|Active Transcranial Direct Current Stimulation|The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.
41495268|NCT02132637|DRUG|Insulin Glargine|Administered SQ
41495269|NCT05858502|BIOLOGICAL|Blood sample collection|Blood sample collection between inclusion and 3 months max 55 ml at each visit
41495270|NCT05858502|OTHER|Saliva sample collection|Saliva sample collection between inclusion and 3 months
41495271|NCT05858502|OTHER|Nasopharyngeal and nasal sample collection|Nasopharyngeal and nasal sample collection between inclusion and 3 months
41355115|NCT04651699|DEVICE|Sham Transcranial Direct Current Stimulation|The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
41495272|NCT05858502|OTHER|Exhaled Breath Condensate (EBC)|Exhaled Breath Condensate (EBC) between inclusion and 3 months
41355116|NCT00122824|DRUG|duloxetine hydrochloride|
41495273|NCT05009914|PROCEDURE|cardiac denervation|Excision of Marshall ligament and Waterstone fat pad during CABG.
41495274|NCT02658825|DRUG|JNJ-63623872 2400 milligram (mg)|Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
41495275|NCT02658825|DRUG|JNJ-63623872 3000 mg|Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
40835324|NCT03211013|DRUG|Oxytocin|single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
40835325|NCT03211013|DRUG|Placebos|single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
41495276|NCT02658825|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
41495277|NCT02658825|DRUG|Moxifloxacin|Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
40835326|NCT05208775|PROCEDURE|PDT|"Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V.~Laser irradiation:~48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts."
40835327|NCT05208775|PROCEDURE|ESD|The patients received standard endoscopic submucosal dissection after enrollment.
40835328|NCT06349135|PROCEDURE|Open Reduction & Internal Fixation|Open Reduction \& Internal Fixation of Mandibular fracture either through intraoral or extraoral approaches.
40835329|NCT02537405|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
40835330|NCT02537405|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
40835331|NCT06301295|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject suspected of early-stage, resectable lung cancer will undergo bronchooscopic procedure. Ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Subsequently, intratumoral washing is performed. After undergoing surgery for suspected early-stage lung cancer, the analysis of next generation sequencing is conducted on intratumoral washing, tissue from surgical specimen, and blood.
41495278|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 2400 mg)|Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
41495279|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 3000 mg)|Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
41495280|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 Dose)|Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
40835332|NCT04828005|DRUG|Nalmefene hydrochloride|3mg Nasal spray
40835333|NCT04828005|DRUG|Naloxone hydrochloride|4mg Nasal Spray
41160082|NCT06283563|OTHER|Physical activity tracking|At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in MS will be given. Participants in the intervention group will be asked to join one of two groups created by the researchers via messaging app. Reminders will be arranged on Monday-Wednesday-Thursday in one of the groups, and on Tuesday-Thursday-Saturday in the other group. In this regard, it will be emphasized that he/she should exercise at least 3 days a week. In this regard, they will be encouraged to walk for at least 30 minutes, 3 days a week, on the days they determine. The total intervention period will be 8 weeks. Reminders to exercise will be given by the researchers in the created messaging app group. Patients will be reminded to take their mobile phones with them during physical activity and to record their daily exercise minutes.
41495281|NCT02658825|DRUG|Placebo (Matching with Moxifloxacin)|Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
41495282|NCT02592135|OTHER|hsTnT level|hsTnT and NTproBNP levels at baseline and baseline plus 3 hours.
41495283|NCT05452135|OTHER|Observation of visual, audotory and motor reaction time|Visual, auditory and motor reaction time will be measured as a result of the measurements made during the dual task evaluation.
40835334|NCT05915624|OTHER|telephone counseiling|One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
40835335|NCT03474081|DRUG|FF/UMEC/VI|A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.
40835336|NCT03474081|DRUG|Tiotropium|Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.
40835337|NCT03474081|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.
41355117|NCT00122824|DRUG|placebo|
41355118|NCT03165799|BEHAVIORAL|Mindfulness Education|Mindfulness Education
41355119|NCT02616328|OTHER|No intervention|No intervention administered in this study
41495284|NCT04651894|DEVICE|reactive hyperaemia index measurement|"reactive hyperaemia index with EndoPAT®~Pulse wave velocity measurement with Sphygmocor®"
40835338|NCT03474081|DRUG|Placebo to match FF/UMEC/VI|Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
41355120|NCT05704140|OTHER|Catheter based Dialysis|We will conduct a cross-section analysis regarding patients with catheter-based VA in Vienna.
41495285|NCT03767335|DRUG|MEN1611|MEN1611 oral dose administered twice daily for a continuous 28-day cycle
41495286|NCT03767335|DRUG|Trastuzumab|Trastuzumab solution for infusion administered weekly via IV
41495287|NCT03767335|DRUG|Fulvestrant|Fulvestrant solution for injection administered monthly via IM (only for HR-positive postmenopausal women)
41495288|NCT01996683|DRUG|desferal, ferriprox, blood transfusion|"Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation"
41355121|NCT03080506|DEVICE|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
41495289|NCT03904589|DIAGNOSTIC_TEST|Quality of Life assessment|Quality of life will be assessed by means of the Seattle Angina Questionnaire and the Patient Health Questionnaire.
40835339|NCT03474081|DRUG|Placebo to match tiotropium|Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.
40835340|NCT03474081|DEVICE|ELLIPTA inhaler|ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.
40835341|NCT03474081|DEVICE|HANDIHALER|Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.
40835342|NCT03474081|DEVICE|MDI|Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.
40835343|NCT02482857|DRUG|Acetylsalicylic acid|To compare BID dosing with OD dosing with clinically used aspirin dosages.
40835344|NCT03658070|DRUG|XY0206|Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
40835345|NCT03275948|OTHER|whole grain|whole grain rye
40835346|NCT03275948|OTHER|reference|white wheat bread
40835347|NCT06414161|DIETARY_SUPPLEMENT|mix of (green tea and peppermint)|"Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out \[27\].~The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben \[28\].~Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract."
40835348|NCT01968057|DRUG|Baricitinib|Administered orally
40835349|NCT01968057|DRUG|Ciclosporin|Administered orally
40835350|NCT01557881|DEVICE|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center \[SCC\] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
40835351|NCT02606266|DRUG|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
40835352|NCT00113750|BIOLOGICAL|TreeMATA MPL|
40835353|NCT02410265|BEHAVIORAL|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
40835354|NCT02410265|BEHAVIORAL|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
40835355|NCT02120703|DRUG|Pregabalin|Pregablin 75 mg per oral two times a day
40835356|NCT02120703|DRUG|Gabapentin|Gabapentin 200 mg twice daily per oral
40835357|NCT03303118|OTHER|Hypoxia|No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
40835358|NCT02398695|OTHER|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
40835359|NCT04388852|BIOLOGICAL|Ipilimumab|Given IV
40835360|NCT04388852|DRUG|Valemetostat|Given PO
41355122|NCT04310267|DEVICE|Petit typeface mask|(Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
41355123|NCT01884155|PROCEDURE|Allogeneic umbilical cord blood therapy|
41495290|NCT03639454|PROCEDURE|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
41355124|NCT06000826|DEVICE|Celsi Warmer|During the study, research participants will receive thermal care via the Celsi Warmer. Aside from thermal treatment, research participants will receive the standard of care from the neonatal unit, and will also be closely monitored by study personnel throughout the study. The results from this study will allow the research team to determine if the Celsi Warmer is an effective tool for warming and monitoring newborns in wards of low-resource hospitals. The research team hopes to demonstrate that the Celsi Warmer is effective for the appropriate treatment of newborn hypothermia in hospitals in low-resource settings.
41355125|NCT03421236|BIOLOGICAL|Ty21a|intravesical administration of Ty21a
41355126|NCT04491292|OTHER|Questionnaire Administration|Complete questionnaires
41355127|NCT02798809|OTHER|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
41495291|NCT03639454|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
41495292|NCT01666197|DRUG|diclofenac potassium 25 mg tablet|diclofenac potassium 25 mg tablet
41495293|NCT01666197|DRUG|placebo|placebo
41495294|NCT02985190|DRUG|Azacitidine|Azacitidine at 75mg/m²/j for 7 days.
40835361|NCT05885737|DRUG|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
40835362|NCT05885737|DRUG|Placebo Injection|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
40835363|NCT04033094|DRUG|MorphaBond ER|This was a retrospective, non-interventional study. Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).
40835364|NCT04033094|DRUG|Comparator Drug|This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
40835365|NCT04695028|OTHER|Data collection|"The following data will be collected by the physician: sociodemographic profile, clinical manifestations, comorbidities, laboratory tests,etc.~Diagnostic performance of different imagery techniques, performance of crystal deposit quantification in ultrasound and Dual-energy computed tomography (DECT), link between co-morbidities and volume of baseline crystal deposits then during monitoring, link between co-morbidities (including cardiovascular events and new diagnoses of co-morbidity) and vascular baseline crystal deposits and during follow-up, link between microcrystalline rheumatism activity and the quantity of crystal deposits in baseline imaging and during follow-up, link between co-morbidities and the evolution of microcrystalline baseline rheumatism and then during follow-up, link between co-morbidities and the evolution of crystal deposition volumes, the concordance of the evaluation of uratic stocks and their evolution between the imagery means."
40835366|NCT04175067|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
40835367|NCT04175067|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
40835368|NCT01179061|DRUG|Apelin|"Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.~Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.~Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine."
40835369|NCT01179061|DRUG|Placebo|As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
41355128|NCT00928499|DEVICE|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
41355129|NCT04013633|OTHER|Lifesaver virtual reality training|CPR training using the Lifesaver virtual reality application
41355130|NCT04013633|OTHER|Face-to-face training|Short face-to-face CPR training
40835370|NCT04109976|DRUG|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
41160083|NCT06283563|OTHER|No physical activity tracking|At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in multiple sclerosis will be given. Participants will be encouraged to continue their routine lives and no reminders will be given.
41355131|NCT02158000|OTHER|group A|one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
41355132|NCT03118713|DRUG|metformin|oral
41355133|NCT03118713|DRUG|ipragliflozin|oral
41495295|NCT02018783|PROCEDURE|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
41495296|NCT02018783|PROCEDURE|Sensodyne|Digital application for 60 seconds.
41495297|NCT02018783|PROCEDURE|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
41495298|NCT02018783|PROCEDURE|Cocorico|Digital application for 60 seconds
41495299|NCT00926224|DEVICE|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
41355134|NCT03118713|DRUG|glimepiride|oral
41355135|NCT03962413|PROCEDURE|Endoscopic Approaches To Maxillary Sinus|"The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach."
41355136|NCT01962272|BEHAVIORAL|Weekly nutritional counseling|The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
41495300|NCT02256527|OTHER|Observational|compare data
41495301|NCT03482700|BEHAVIORAL|Intervention Arm|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
41495302|NCT03482700|BEHAVIORAL|Control Arm|Usual standard of care
41495303|NCT03107143|DEVICE|Q2 System|
41495304|NCT05006768|DRUG|Barcimiant|1 tablet contains 4 mg Barcitinib
41495305|NCT05006768|DRUG|Olumiant (first dose)|1 tablet contains 4 mg Barcitinib
41495306|NCT05006768|DRUG|Olumiant (second dose)|1 tablet contains 4 mg Barcitinib
41495307|NCT03898089|OTHER|Core Stability Exercise|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks. Traditional physiotherapy methods will be applied to all participants. Traditional physiotherapy will include heat modality (a hot pack for 15 minutes), electrotherapy (transcutaneous electrical nerve stimulation (TENS), a 50 Hz conventional TENS with a pulse duration \<150 microseconds).Each training session will be lasted 60 min, starting with a 10-min warm up program mainly consisting of core strength exercises and ending with a 5-min cool-down program (stretching). Progression of exercises will be tailored to individual patients' ability, fatigue and pain. Exercises will be designed from 1 set to 3 sets, from 8 to 15 repetitions and contractions from 5 seconds to 10 seconds.
41021398|NCT03887481|DEVICE|"High-definition active tDCS (HD-tDCS) + Repeat After Me (RAM) Treatment"|"Device: Active HD-tDCS \& Repeat After Me (RAM) Treatment~Stimulation will be delivered by a battery-driven constant current stimulator. Electrical current will be administered to left supramarginal gyrus (L_SMG). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
41160084|NCT04656860|DIETARY_SUPPLEMENT|Juice Plus+|Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
41160085|NCT00705042|DRUG|Etanercept|
41160086|NCT03472976|OTHER|Aqueous Cream B.P.|Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
41355137|NCT01962272|DIETARY_SUPPLEMENT|Forticare®.|
41355138|NCT00539825|DRUG|GSK704838|
41355139|NCT00847249|DRUG|AZD9164|Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
41495308|NCT03898089|OTHER|Core Stability Exercise plus Myofascial Release Technique Group|In addition to the core stabilization exercise group myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks. The myofascial relaxation technique will be performed along the superficial back line (plantar fascia gastrocnemius muscles, hamstring muscles, sacrolumbar fascia, erector spinae muscles) bilaterally. Myofascial relaxation will be done to the anatomical structures indicated by roller massage technique. Applications will be made in 3 sets of 30sec for each zone (1 min rest between sets) and 7/10 according to VAS.
41495309|NCT04270318|OTHER|CH Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
41495310|NCT04270318|OTHER|CH pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
41495311|NCT04270318|OTHER|MTA Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
41495312|NCT04270318|OTHER|MTA pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
41495313|NCT00336245|DEVICE|Copper T Intrauterine Contraceptive Device|
41495314|NCT00336245|DRUG|Hormonal Contraception|
41495315|NCT01020955|DRUG|NutropinAq (GH) and Increlex (IGF-I)|NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
41495316|NCT01020955|DRUG|NutropinAq and placebo|NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
41495317|NCT04873765|BIOLOGICAL|Pegfilgastrim Megalabs|Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose
41495318|NCT04873765|BIOLOGICAL|Pegfilgastim Amgen|Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
41495319|NCT02261350|DIETARY_SUPPLEMENT|Food fortification|
41495320|NCT02261350|DIETARY_SUPPLEMENT|Oral Nutritional Supplements|
41495321|NCT05928286|DRUG|Remaxol|The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
41495322|NCT00416650|DRUG|erlotinib hydrochloride|All patients will receive 150 mg orally daily
41495323|NCT02689050|DEVICE|Needle based confocal laser endomicroscopy (nCLE)|During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
41355140|NCT00847249|DRUG|Placebo|Each subject will receive a single-dose.
41355141|NCT02053597|DRUG|Doxorubicin|All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
41355142|NCT02053597|DRUG|paclitaxel|All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
41355143|NCT02605889|OTHER|Laser acupuncture|Laser acupuncture
41355144|NCT01815866|PROCEDURE|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
41355145|NCT01223560|DRUG|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
41355146|NCT01223560|OTHER|Exercise|Exercise on tread mill
41495324|NCT01288144|OTHER|Quality improvement initiative|In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
41495325|NCT01466010|PROCEDURE|surgical removal of osteoid osteoma|surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
40835371|NCT05553275|PROCEDURE|Usual Care|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely managed with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor. Blood sugars of more than 110 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour. If blood sugar 111-140, insulin drip at 1 unit/hour will be given and continued if blood sugar is 111-140.If blood sugar is 141-180, then drip will be changed to to 1.5 unit/hour and if blood sugar is 181-220, drip will be changed to 2.0 units/hour and MD will be called if blood sugar is more than 221 mg/dl"
40835372|NCT05553275|PROCEDURE|Permissive intrapartum glucose control|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely management with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor.Blood sugars of more than 180 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour.If blood sugar is 181-200, insulin drip at 1 unit/hour will be given. If blood sugar is 201-220, then drip will be changed to 1.5 units/hour. If blood sugar is 221 - 250, then drip will be changed to 2.0 units/hour and if blood sugar is more than 251 MD will be called."
40835373|NCT01915823|DRUG|azelastine hydrochloride and fluticasone propionate|
40835374|NCT01915823|DRUG|Dymista vehicle|
41355147|NCT01223560|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate intake
41355148|NCT02358863|DRUG|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
41355149|NCT02358863|DRUG|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
41495326|NCT03560986|DRUG|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
40835375|NCT03276949|DEVICE|Blood glucose measurement|Device used to measure blood glucose levels
40835376|NCT03396510|OTHER|IMPROVED intervention|Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the investigators will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the investigators will not provide guidance about what actions to take in response to patients' symptoms.
40835377|NCT06507397|DRUG|hyperbaric bupivacaine and fentanyl|Patients received 3ml hyperbaric bupivacaine 0.5% combined with 25 microg of fentanyl.
40835378|NCT06507397|DRUG|plain bupivacaine and fentanyl|Patients received 15 mL mixture of (0.25% plain bupivacaine and 50 µg fentanyl) over 5 minutes, injected in the epidural space by epidural catheter at L3-L4 interspace, a dural puncture was created by the spinal needle. Braun's Espocan® combined spinal epidural kit before insertion of epidural catheter (needle-through-needle technique) but intrathecal medication administration was withheld.
41160087|NCT03472976|DRUG|Imiquimod|Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
41160088|NCT03472976|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04|Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04
41160089|NCT02812628|PROCEDURE|LAPR|Patients undergoing conventional LAPR, the common surgical procedure to treat low rectal cancer ≤5m from anal verge.
41160090|NCT02812628|PROCEDURE|LAPR-TILT|Patients undergoing LAPR-TILT, a modified APR procedure that is supposed to be safer and less invasive as compared to the LAPR.
41160091|NCT00658983|OTHER|Autologous Platelet Enriched Gel|Treatment with Autologous Platelet Enriched Gel
41355150|NCT02358863|DRUG|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
41355151|NCT02358863|DRUG|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
41355152|NCT02358863|DRUG|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
41355153|NCT02358863|DRUG|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
41355154|NCT02358863|DRUG|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
41355155|NCT02358863|DRUG|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
41355156|NCT00004236|DRUG|pegylated liposomal doxorubicin hydrochloride|
41495327|NCT03560986|DRUG|Placebo|Glass vials with matching placebo.
41495328|NCT02969265|DRUG|Amlodipine|Amlodipine Capsules
41495329|NCT02969265|DRUG|TCV-116CCB|TCV-116CCB Tablets
41495330|NCT02969265|DRUG|Amlodipine Placebo|Amlodipine placebo-matching capsules
41495331|NCT02969265|DRUG|TCV-116CCB Placebo|TCV-116CCB 8/5 mg placebo-matching tablets
41495332|NCT03090607|DEVICE|Aluvra™|Endoscopic injection of bulking agent to the lower esophageal sphincter
41495333|NCT03090607|DRUG|Saline|Endoscopic injection of saline
41355157|NCT03592693|DRUG|Combined Vitamin C and Stress-Dose Hydrocortisone|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
41355158|NCT03592693|DRUG|Placebo plus placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
41355159|NCT04966806|PROCEDURE|LASIK refractive surgery|laser vision correction for myopic eyes
41355160|NCT04522193|DEVICE|Glycemic Holter|Continuous glycaemia monitoring,
41495334|NCT00346463|DRUG|Allopurinol|
40835379|NCT00629473|DRUG|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
40835380|NCT00629473|DRUG|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
40835381|NCT00629473|DRUG|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
40835382|NCT02270723|DRUG|"5% Human Albumin  Behring"|Intravenous infusion of 5% Human Albumin during major surgery
40835383|NCT02270723|DRUG|Lactated Ringer|Intravenous infusion of Lactated Ringer during major surgery
40835384|NCT00475865|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
40835385|NCT00475865|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
41021399|NCT03887481|DEVICE|"Sham + Repeat After Me (RAM) Treatment"|"Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
41021400|NCT04298255|OTHER|Round Spermatid Injection (ROSI)|In Vitro Fertilization using Round Spermatid Injection (ROSI)
41160092|NCT00658983|OTHER|Metalloproteinase Inhibitor|Treatment with Metalloproteinase Inhibitor (Promogran)
41160093|NCT02206464|BIOLOGICAL|A/Shanghai/02/2013 (H7N9) MIV|Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
41160094|NCT02206464|BIOLOGICAL|VRC-FLUDNA071-00-VP|H7 DNA Vaccine
41160095|NCT00000904|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
41160096|NCT00000904|BIOLOGICAL|gp160 MN/LAI-2|
41355161|NCT04522193|RADIATION|gastric emptying scintigraphy|Fasting administration of a Technecium-labelled milk bottle and quantification of the remaining radioactivity by a camera every 30 minutes for 4 hours.
41355162|NCT04522193|DEVICE|Holter ECG|continuous cardiac monitoring
40835386|NCT00475865|DRUG|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
40835387|NCT02406443|DRUG|Sitaglitpin|Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
41160097|NCT00000904|BIOLOGICAL|ALVAC(1)120(B,MN)GNP (vCP1433)|
41355163|NCT01726504|DEVICE|electro-acupuncture|Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
41495335|NCT00106340|DRUG|vildagliptin|
41495336|NCT00106340|DRUG|glimepiride|
41495337|NCT00106340|DRUG|Metformin|
40835388|NCT02406443|OTHER|Placebo|Oral tablet (no medicinal ingredients) administered once daily for 28 days
40835389|NCT05996809|DEVICE|Coseal|Adhesion reduction
40835390|NCT06506929|OTHER|Task specific physical therapy|Physical Therapy based specifically on tasks that the participant os having difficulty with
40835391|NCT02203955|DRUG|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally for 12 months
40835392|NCT02203955|DRUG|Maltodextrin|4 chews (maltodextrin) daily for 12 months
40835393|NCT06357468|OTHER|midwife-led births in low risk women in pregnancy|Pregnant women in the low-risk collective are cared for in a midwife-led delivery room if they wish to have a natural birth
40835394|NCT05792592|DIAGNOSTIC_TEST|IOS (Impulse Oscillometry)|Small Airways Disease Assessment
40835395|NCT03168100|DRUG|Elotuzumab|administered via IV infusion
40835396|NCT03168100|DRUG|Lenalidomide|taken by mouth
40835397|NCT03168100|DRUG|Dexamethasone|taken by mouth
40835398|NCT03168100|DRUG|Bortezomib|administered as a subcutaneous injection
41160098|NCT00000904|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
41160099|NCT00000904|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
41160100|NCT05834361|DRUG|early vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is 20 minutes before the surgery.
41160101|NCT05834361|DRUG|delayed vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is usually 110-120 minutes before the surgery.
41160102|NCT05469763|OTHER|Circuit training|"Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~* Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~* Duration: 25 to 30 minutes of continuous aerobic activity.~* Frequency: three to five days per week."
41495338|NCT00106340|DRUG|Vildagliptin matching placebo|
41495339|NCT00106340|DRUG|Glimepiride matching placebo|
41495340|NCT01214915|DRUG|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
41495341|NCT00090181|DRUG|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
41495342|NCT00090181|DRUG|Comparator: diclofenac / Duration of Treatment: 4 weeks|
41495343|NCT00735605|OTHER|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
41355164|NCT01726504|DEVICE|sham electro-acupuncture|Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
41355165|NCT02021864|DRUG|vitamin D3 50,000 unit|vitamin D3 50,000 unit/week for 8 weeks
41355166|NCT02021864|DRUG|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
41355167|NCT01197976|DEVICE|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
41355168|NCT01197976|DEVICE|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
41355169|NCT02489656|DEVICE|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
41355170|NCT00065351|DRUG|CC-5013|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
41355171|NCT01011764|BEHAVIORAL|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
41355172|NCT00868738|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
41355173|NCT03665233|DEVICE|VR|People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
41355174|NCT02036983|PROCEDURE|Transversus abdominis plane block (TAP BLOCK)|Ultrasound guided TAP block with local anesthetics and dexamethasone.
41355175|NCT02036983|PROCEDURE|Instillation of surgical site with local anesthetic.|Instillation of surgical site with local anesthetics and dexamethasone.
41355176|NCT02036983|PROCEDURE|Opioid IV medications (Control)|Standard anesthetic technique.
41355177|NCT06409442|OTHER|Standard Physiotherapy Program|Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.
41355178|NCT06409442|OTHER|Kinesio Taping|In addition to the standard physiotherapy program, kinesio taping (device) will be applied.
41355179|NCT06409442|OTHER|Local Vibration Therapy|In addition to the standard physiotherapy program, local vibration (device) will be applied.
41355180|NCT04775485|DRUG|DAY101|DAY101 is an oral pan-RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL).
41355181|NCT04446494|PROCEDURE|Identification and preservation of arm lymphatics (DEPART)|Indocyanine green was utilized to identify arm sentinel nodes, and 0.1 ml MB was injected into the arm sentinel nodes to reveal the subsequent-echelon nodes and lymphatics. Gross arm lymph nodes were examined by intraoperative partial frozen section and were removed if positive.
41355182|NCT05746572|DRUG|MDMA|Participants will receive MDMA HCl (100 mg, 84 mg MDMA) in combination with massed exposure therapy for PTSD.
41021401|NCT04298255|OTHER|Half ROSI-half Sperm Donor Fertilization|Half ROSI-half Sperm Donor Fertilization
41021402|NCT02877485|DRUG|Triamcinolone Acetonide|2 sprays sprayed to both nostrils daily for 42 days.
41355183|NCT06318000|OTHER|Balance test, bilateral coordination test, fundamental motor skills test|Functional assessment
41355184|NCT00198042|PROCEDURE|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
41355185|NCT00069654|PROCEDURE|Forearm blood flow study|
41355186|NCT00069654|PROCEDURE|Brachial artery reactivity study|
41355187|NCT00069654|PROCEDURE|Treadmill exercise test|
41355188|NCT06376812|BEHAVIORAL|Physical activity intervention|Physical activity
41355189|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
41355190|NCT00983242|DRUG|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
41355191|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
41021403|NCT02877485|DRUG|Ayr saline nasal mist|110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
41355192|NCT00000151|DRUG|Aspirin|
41355193|NCT00000151|PROCEDURE|Argon Laser Photocoagulation|
41355194|NCT04108598|OTHER|Quality of life questionnaire|No intervention will be administered, select sites will administer a quality of life questionnaire
41355195|NCT04389931|OTHER|Lactose tab|Two tablets containing lactose Procedure: Periodontal treatment Scaling and root planning
41355196|NCT04389931|DRUG|Omega 3|Two tablets containing 1g Omega 3. Procedure:Periodontal treatment Scaling and root planning
41021404|NCT05893160|DRUG|JAN101 SR|The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.
40835399|NCT04721522|DIAGNOSTIC_TEST|blood sampling & ultrasound|"Blood sampling:~Serum P4 \& estradiol will be performed on the day of triggering and on the day of embryo transfer. Progesterone/ Estradiol (P4/E2) ratio will be calculated Ultrasound: On triggering day, at time of ovum pick up and on ET day, we will measure~1. Endometrial thickness~2. Endometrial pattern~3. Endometrial compaction: the difference in measurement of endometrial thickness between the day of embryo transfer and the day of triggering.~4. Junctional zone thickness~5. Uterine contraction (peristalsis).~6. Blood flow of uterine vessels: PI of the uterine arteries will be calculated also Endometrial - sub endometrial blood flow"
41355197|NCT00620672|DIETARY_SUPPLEMENT|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
40835400|NCT00002465|DRUG|megestrol acetate|
40835401|NCT04863196|OTHER|Laser therapy Treatment Group|laser in gastric mucosa lesion
40835402|NCT04863196|OTHER|Barrier Dust Treatment Group|barrier powder in gastric mucosa lesion
40835403|NCT03374202|GENETIC|VRC-HIVAAV070-00-GT (AAV8-VRC07)|AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07
40835404|NCT01737294|DRUG|Qutenza exposure|Cutaneous patch
40835405|NCT00081133|DRUG|arsenic trioxide|
40835406|NCT00081133|DRUG|imatinib mesylate|
41021405|NCT05893160|OTHER|Placebo|Inert placebo formulation
41021406|NCT05191706|DRUG|Dexamethasone|single anterior chamber injection
41021407|NCT05191706|DRUG|Prednisolone Acetate Ophthalmic|topical administration four times a day for 28 days, followed by treatment taper
41021408|NCT03380468|DRUG|cisplatin plus pemetrexed|cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
41021409|NCT04363606|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
41021410|NCT04363606|BIOLOGICAL|blood test|complete blood count and cytokine concentration, TNF-alpha, LDL oxidized, AOPP, SOD, GPX, catalase, albumin, transthyretin, RBP, transferin, α-1 glycoprotein acide, ferritine, selenium, zinc, magnesium
41021411|NCT04363606|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
41021412|NCT04363606|DEVICE|actigraphy|assessment of sleep quality
41021413|NCT04363606|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging"
41355198|NCT00620672|DIETARY_SUPPLEMENT|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
40835407|NCT05693454|DRUG|Infiltration with NaCl|Local wound infiltration at the end of spine surgery with NaCl
40835408|NCT05693454|DRUG|Infiltration with Ropivacain|Local wound infiltration at the end of spine surgery with Ropivacain
40835409|NCT05693454|DRUG|Infiltration with a combination of Levobupivacaine and Tramadol|Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
40835410|NCT00409344|DRUG|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
40835411|NCT00409344|OTHER|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
40835412|NCT06230978|BEHAVIORAL|Habit workup|The patient and pharmacist will work together to specify a cue to help them take their medicine every day (e.g. brushing teeth, getting dressed, eating breakfast, making coffee, alarms, visual reminders etc).
40835413|NCT06230978|BEHAVIORAL|Standard Medication Counseling|The pharmacist provides standard counseling on the new medication
41021414|NCT04363606|OTHER|stool analysis|analyze the composition of the intestinal microbiote. concerns only the patients of Saint Etienne
41021415|NCT04363606|OTHER|food diary|3 days of information to determine nutrient intakes. concerns only the patients of Saint Etienne
41021416|NCT00515476|BEHAVIORAL|physical exercise|8 weeks of regular exercise training
41021417|NCT04596878|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to Alhydrogel as an adjuvant.
41021418|NCT04596878|BIOLOGICAL|Placebo|Normal Saline 0.9%
41021419|NCT00054899|BIOLOGICAL|EP2101|
41021420|NCT03021759|BEHAVIORAL|Active choice|Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin
41021421|NCT03021759|BEHAVIORAL|Social comparison feedback|Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
41021422|NCT06123039|DIAGNOSTIC_TEST|Tidal Volume Challenge|The tidal volume challenge is a fluid response test that consists of increasing the tidal volume from 6 ml/kg to 8 ml/kg for 1 minute and evaluating PPV. If PPV increases by more than 2%, it is considered positive, otherwise it will be negative.
41021423|NCT06123039|PROCEDURE|Recruitment maneuver obtaining individualised PEEP|The alveolar recruitment maneuver is a well-studied procedure to open the lung during invasive mechanical ventilation, allowing us to achieve the best PEEP for that lung, which is individualised PEEP.
40835414|NCT04994418|DIETARY_SUPPLEMENT|Recommended sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily recommended sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
40835415|NCT04994418|DIETARY_SUPPLEMENT|High sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily high sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
40835416|NCT04994418|DIETARY_SUPPLEMENT|High sodium and high fructose diet|Upon completion of a 7 day dietary intervention of consuming the high sodium and high fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
40835417|NCT00109356|DRUG|AQ4N (Chemotherapy)|
40835418|NCT06508268|BEHAVIORAL|GAITRite walkway system OR 4-meter walking speed test|Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test
40835419|NCT06508268|BEHAVIORAL|Jamar hand dynamometer|Hand grip strength will be assessed by a Jamar hand dynamometer
40835420|NCT06508268|BEHAVIORAL|Picture description task|Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)
40835421|NCT06508268|BEHAVIORAL|Autobiographical semi-structured conversation|Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation
40835422|NCT06508268|BEHAVIORAL|Verbal fluency|The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency
40835423|NCT03832608|OTHER|No intervention|There is not intervention to be administered, only collection of data through various tests and questionnaires.
41021424|NCT01097226|OTHER|Apple extract delivering 70 mg epicatechin|Delivered as a flavoured water based beverage
41021425|NCT01097226|OTHER|Apple extract delivering 140 mg epicatechin|Delivered as a flavoured water based beverage
40835424|NCT06089941|OTHER|circulating tumoral DNA detection|blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse
40835425|NCT04254029|DIETARY_SUPPLEMENT|MOROLSTEVER1|The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days.
40835426|NCT00225342|DRUG|Rosiglitazone|
40835427|NCT00225342|DRUG|Gliclazide (Comparison drug)|
41021426|NCT01097226|OTHER|Apple granules delivering 70 mg epicatechin|Delivered as a puree
41021427|NCT01097226|OTHER|Water delivering no epicatechin|Delivered as flavoured water
41021428|NCT06262087|BEHAVIORAL|Change of direction training|The experimental group is implemented FIFA 11+ program combined with COD training
41021429|NCT06262087|BEHAVIORAL|FIFA 11+ program|The experimental group is implemented FIFA 11+ program.
41021430|NCT05262361|BEHAVIORAL|Office-based Vergence and Accommodative Therapy|Office-based Vergence and Accommodative Therapy has four phases which start with gross vergence and accommodation. Disparity vergence is isolated using instruments such as vectograms and accommodation is isolated using near far charts and accommodative rock. The final phase includes the integration of vergence and accommodation to increase range and visual comfort which performing activities close to the person.
41160103|NCT04089345|DRUG|Ustekinumab|All patients will receive intravenously (IV) ustekinumab \~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
41160104|NCT00453934|DEVICE|h-Patch|
41160105|NCT02110225|DRUG|rhNGF 60 µg/ml eye drops solution|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
41160106|NCT02110225|DRUG|rhNGF 180 µg/ml eye drops solution|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
41355199|NCT02205177|DEVICE|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
41355200|NCT02114359|DRUG|Capecitabine/cisplatin|Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
41355201|NCT02114359|DRUG|S-1/cisplatin|S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
41355202|NCT02114359|DRUG|Capecitabine/oxaliplatin|Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
41355203|NCT02114359|DRUG|5-fluorouracil/oxaliplatin|5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
40835428|NCT05115747|OTHER|weight off-loading aerobic exercise training.|"Mild to moderate intensity weight off-loading aerobic exercise training on the anti-gravity Alter-G treadmill. (speed 8-12 mph, 50%-70% heart rate reserve HRR, 12-16 score on the Borg's scale)"
41160107|NCT02110225|DRUG|Placebo|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
41355204|NCT02114359|DRUG|Capecitabine|Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 1000mg/m2 po bid)
41355205|NCT02114359|DRUG|S-1|S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 30mg/m2 po bid)
41355206|NCT02114359|DRUG|5-fluorouracil|5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
41495344|NCT00735605|PROCEDURE|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
41495345|NCT00735605|OTHER|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
41495346|NCT05857137|DEVICE|Active TMS|Continuous theta burst stimulation (cTBS) will be administered over the left inferior parietal lobule for approximately 3 minutes at 120% of the resting motor threshold.
41495347|NCT05857137|DEVICE|Placebo TMS|Placebo TMS will be applied over the left inferior parietal lobule for approximately 3 minutes.
40835429|NCT04297969|DIAGNOSTIC_TEST|"objective pediatric vision screen GCK glow fixation"|2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
40835430|NCT00766974|DEVICE|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
40835431|NCT00766974|DEVICE|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
40835432|NCT02901652|DEVICE|noninvasive respiratory support devices|
40835433|NCT03328858|OTHER|Ketogenic Diet|Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
40835434|NCT04761484|PROCEDURE|Vascular access on admission|PIVC insertion
41355207|NCT03280186|PROCEDURE|surgery|The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
41495348|NCT03512132|BIOLOGICAL|Blood samples|5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
41495349|NCT03512132|BIOLOGICAL|Urine sample|Urine sample on an empty stomach
41495350|NCT03194841|OTHER|Heart failure application|A mobile phone application that allowed for input of physiologic data, qualitative question input and education retrieval along with SMS use.
40835435|NCT01951313|OTHER|Egg consumption|Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (\< 2g) and low carotenoid (\< 2000µg) meal as the 2nd meal.
40835436|NCT03698175|BEHAVIORAL|Three good things exercise|Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
40835437|NCT03698175|BEHAVIORAL|Placebo exercise|Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
40835438|NCT02035956|BIOLOGICAL|IVAC MUTANOME, RBL001/RBL002|Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
40835439|NCT02982499|DEVICE|magnetic resonance image (MRI)|Radiographic imaging that takes about 30-45 minutes
40835440|NCT02982499|DEVICE|Optical Coherence Tomography (OCT)|Images taken from the back of the eye (retina)
41160108|NCT03824353|BEHAVIORAL|Social Intelligence Training|The social intelligence training consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that social intelligence training is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
41355208|NCT03706144|OTHER|Prodigy Math Training|https://www.prodigygame.com/
41355209|NCT02018276|DRUG|Lidocaine|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
40835441|NCT03344263|DIAGNOSTIC_TEST|tests of attentional performance|tests of attentional performance before and after 6 months of continuous positive airways pressure
40835442|NCT00003252|DRUG|amifostine trihydrate|
41160109|NCT03824353|BEHAVIORAL|The Healthy Living Program|A placebo condition delivered online which presents health-related information only.
41160110|NCT02671864|OTHER|1: incretin-based therapy|
41495351|NCT05268068|DRUG|Risankizumab|Intravenous (IV) Infusion
41495352|NCT05268068|DRUG|Risankizumab|Subcutaneous (SC) Injection
41495353|NCT02845141|PROCEDURE|Actifuse|bone tunnel filled with Actifuse
41495354|NCT02845141|PROCEDURE|bone graft|bone graft to fill bone tunnel
41495355|NCT04505748|DEVICE|Self-transfusion device|The Transfusion filter set for salvaged blood (Summit Medical Ltd, Gloucestershire, UK) has been randomly used in 20 patients postoperatively. Patients, who received autologous blood, transfused with the collected amount of blood, only once, 6h postoperatively
41355210|NCT02018276|DRUG|Magnesium|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
41355211|NCT02785861|BEHAVIORAL|supervision of physical activity|
41355212|NCT02785861|BEHAVIORAL|distance supervised physical activity|
41355213|NCT00859144|BEHAVIORAL|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
40835443|NCT03951909|BEHAVIORAL|Physiotherapy activity and awareness intervention: PAAI|10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.
41355214|NCT00859144|BEHAVIORAL|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
41355215|NCT00859144|BEHAVIORAL|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
41355216|NCT02306291|DRUG|GMI-1271|E-selectin antagonist
41355217|NCT02306291|DRUG|Mitoxantrone|induction chemotherapy
40835444|NCT03951909|BEHAVIORAL|Psychological intervention: Teaching recovery techniques (TRT)|TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
40835445|NCT03112304|BEHAVIORAL|MATCH-ADTC|MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita \& Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
41160111|NCT02671864|OTHER|2: other antidiabetic|
41160112|NCT01414725|OTHER|Standard Physiotherapy Exercises|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al \[2009\]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
41160113|NCT01414725|OTHER|Core Stability Training|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
41355218|NCT02306291|DRUG|Etoposide|induction chemotherapy
41355219|NCT02306291|DRUG|Cytarabine|induction chemotherapy
41355220|NCT02306291|DRUG|Idarubicin|induction chemotherapy
41355221|NCT02023515|BEHAVIORAL|Emotional brain training|Stress management based program
41495356|NCT00963781|DEVICE|Medtronic Endeavor Stent|The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
41495357|NCT00963781|DRUG|Reduced duration (6 months) DAPT|
41495358|NCT04006483|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
41495359|NCT04006483|DRUG|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
41355222|NCT02023515|BEHAVIORAL|Behavioral weight loss|Standard behavioral weight loss
41355223|NCT05454631|DEVICE|surgical mask (5 different types)|All the participants will wear 5 different types of surgical mask, in random order.
41495360|NCT04006483|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
41495361|NCT04635826|DRUG|Adderall 10Mg Tablet|Participants will be administered Adderall
41495362|NCT04635826|DRUG|Placebo|Participants will be administered placebo
41495363|NCT00611273|DEVICE|GFX|The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
40835446|NCT03112304|OTHER|TRAC|"TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard."
41355224|NCT05312359|DEVICE|Transcranial alternating current stimulation-true stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. Before the intervention, the individual alpha frequency (IAF) of the subjects was measured according to the average peak value of α waves at dorsolateral prefrontal cortex in the closed state. Then an alternating current at θ frequency (θ = IAF - 5Hz) was applied to each subject based on its IAF value. The amplitude of stimulation was increased with a step of 20μA starting from 0. When the subjects had a slight prickling sensation or optical illusion, the stimulation current was decreased with a step of 20μA until the sensation disappeared. The current value at this time was used as the stimulation current of the subjects.
41355225|NCT05312359|DEVICE|Transcranial alternating current stimulation-sham stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. The actual stimulation waveform was just implemented in the first 60 s (or more longer) and then faded out.
41355226|NCT01308151|OTHER|Other|No interventions other than the culturally adapted manualised cognitive behavioral therapy
40835447|NCT06424340|BIOLOGICAL|MB-dNPM1-TCR.1|T Cell Receptor (TCR) T cell therapy
40835448|NCT03283397|DRUG|EK-12|10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
40835449|NCT03283397|DRUG|INF beta-1a|Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
40835450|NCT01910870|DRUG|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
40835451|NCT01910870|DRUG|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
40835452|NCT01983124|DRUG|Fotemustine + Vemurafenib|"Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity."
40835453|NCT05740319|OTHER|FMT|FMT refers to transplanting healthy donor-derived microbiota to participants via oral capsule or injection of fecal suspension via nasojejunal tube.
40835454|NCT03630744|OTHER|Fluid therapy|"* Analyze the type of fluid administered:~  * crystalloids:~    * Saline serum 0.9% ....... ml~   * Ringer Lactate ........ ml~   * Isofundin ® ........ ml~   * Plasmalyte® ... ... ml~   * Glucose Serum 5% ....... ml~   * Glucose serum 10% ........ ml~ * Glucosaline serum ........ ml~ * colloids:~    * Hydroxyethyl starch 130 / 0.4 ... ... ml~   * Hydroxyethyl alimdon 130 / 0.42 ... .... ml~   * Gelatins ... ....... ml~   * Albumin 5% .......... ml~ * Albumin 20% .......... ml.~* Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~* Analyze the form of administration:~  * Standard~ * Standard with dosimeters~ * on pump"
40835455|NCT02471781|DEVICE|Zenith TX2 Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.
40835456|NCT00768482|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
40835457|NCT00768482|DRUG|Sublingual Buprenorphine|16 mg/day, QD
40835458|NCT04874090|OTHER|Acupuncture|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program
40835459|NCT04874090|OTHER|Exercises|Patient will perform neck exercises
40835460|NCT04454541|PROCEDURE|Ultrasound-guided nerve block for headache management|The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
40835461|NCT02479776|BIOLOGICAL|stem cell injection|Injection of autologous bone marrow derived stem cells
40835462|NCT03412604|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
40835463|NCT03315377|PROCEDURE|Lunate-Capitate Fusion (LCF)|Operation with lunate-capitate-fusion (LCF)
40835464|NCT03315377|PROCEDURE|Four Corner Fusion (4CF)|Operation with four-corner-fusion (4CF)
41355227|NCT02029885|DEVICE|Investigational Therapy (Surround Sound)|
41355228|NCT02029885|DEVICE|Sham Control|
40835465|NCT04452773|DIETARY_SUPPLEMENT|Manremyc|Manremyc is composed by 10E5 heat-inactivated Mycobacterium s. manresensis bacilli
40835466|NCT04452773|DIETARY_SUPPLEMENT|Placebo|Same excipients than active arm without bacilli.
40835467|NCT03150784|OTHER|EPIC Club|Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
40835468|NCT02090790|DRUG|iv dexamethasone|2 ml 8 mg iv dexamethasone
40835469|NCT02090790|DRUG|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
40835470|NCT02090790|DRUG|serum physiologic|2 ml iv serum physiologic
41355229|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization"
41355230|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization."
41355231|NCT02220660|DRUG|BI 1744 CL|
41495364|NCT03573778|BEHAVIORAL|iHEAL|Women work with a Registered Nurse in 10-18 visits (over 6 months) that focus on 6 inter-related 6 components (areas): Safeguarding, Managing Symptoms, Getting Basics, Cautiously Connecting, Regenerating Family, Renewing Self. Using a standard 3 phase process, and guided by 5 principles, the nurse discusses each of these components with the woman in order to identify the woman's needs, experiences and priorities. The nurse then provides personalized support to assist the woman in address the concerns that she sees as most important for her health and well-being; this support includes linking women to existing services if she chooses.
41495365|NCT03573778|BEHAVIORAL|Information about Community Services|Women are provided with information about community services appropriate for women experiencing intimate partner violence and consistent with what service providers might recommend (usual care). Women are encouraged to use this information as they see fit.
40835471|NCT02210832|BEHAVIORAL|Best practices|
40835472|NCT02210832|BEHAVIORAL|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
40835473|NCT01057485|PROCEDURE|AF ablation and AV node ablation|AF ablation and AV node ablation
40835474|NCT01057485|PROCEDURE|AV node ablation|AV node ablation
40835475|NCT04419480|DEVICE|CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization|Implantation of CardioMEMS Device in patients following admission for Cardiogenic shock, with regular ambulatory pulmonary artery pressure monitoring and medication optimization for the treatment of heart failure.
40835476|NCT03546335|DRUG|89Zr-DFO-CZP|89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
40835477|NCT03489512|DRUG|A (Chloraprep)|Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
40835478|NCT03489512|DRUG|B (Clorhexidine 2%)|Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
40835479|NCT03135210|OTHER|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
40835480|NCT03135210|DEVICE|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
40835481|NCT03386734|PROCEDURE|SLN biopsy only|In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
40835482|NCT03386734|PROCEDURE|SLN biopsy + PLN dissection|In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
40835483|NCT03296631|OTHER|collection of diapers with fresh stools|collection of diapers with fresh stools
40835484|NCT04485260|DRUG|KRT-232|administered by mouth
40835485|NCT04485260|DRUG|Ruxolitinib|administered by mouth
40835486|NCT00391001|DRUG|Taurine|double-blind, placebo-controlled, adjunctive medication
40835487|NCT06237803|OTHER|storage of biological samples|collect and store biological samples
40835488|NCT01027260|DRUG|Itopride HCI 50 mg|Variable dosing
40835489|NCT01027260|DRUG|Itopride HCI 100 mg|Variable dosing
40835490|NCT01027260|DRUG|Placebo|Variable dosing
40835491|NCT05490589|OTHER|EQUIPE Program|"EQUIPE is a manualised group community-based parent education programme. Groups consist of 15 parents who meet with one or two trained group leaders for weekly 2-hour sessions over 10 weeks.~This program promotes skill development in parents, strengthens relationships with children, increases cooperation, and helps solve problems in the home."
40835492|NCT03517995|DRUG|Sulforaphane Administration|1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
40835493|NCT03517995|OTHER|Placebo Administration|1 capsule (placebo) taken two times per day (2 capsules total).
40835494|NCT03517995|PROCEDURE|Standard of Care Surgery|The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
40835495|NCT03883113|BIOLOGICAL|MVA-NP+M1|Trial Vaccine
41355232|NCT02220660|DRUG|BI 54903 XX|
41355233|NCT02220660|DRUG|BI 1744 CL + BI 54903 XX FDC|
41355234|NCT02220660|DRUG|Placebo|
41355235|NCT04615429|BIOLOGICAL|Mesenchymal stromal cells|Administration of one single dose of allogenic Mesenchymal stromal cells
40835496|NCT03883113|BIOLOGICAL|Saline|Sodium Chloride Placebo
40835497|NCT03883113|BIOLOGICAL|H3N2 (A/Belgium/2417/2015)|Challenge Agent
40835498|NCT00625612|DRUG|Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
40835499|NCT00625612|DRUG|Placebo|Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
40835500|NCT00393341|PROCEDURE|Blood Draw|Blood sample will be drawn from a vein in the arm.
40835501|NCT04304885|DIAGNOSTIC_TEST|Sonication method|Sonication dislodges adherent bacteria from explanted prosthetics by ultrasound and may improve the diagnosis of periprosthetic joint infection.
41355236|NCT04615429|OTHER|Placebo|Administration of placebo (solution identical to experimental treatment, without the MSC)
41355237|NCT05230992|DEVICE|Cryoprobes First|In this experimental group, the Cryoprobe is used in first and the classic biopsy forceps in a second time. This medical device under study is the flexible, single-use Cryoprobe, supplied in sterile condition, 1.1 mm in diameter, 1150 mm long, with extraction tube, 817 mm long (reference 20402-401), or 757 mm long (reference 20402-402) marketed. These cryoprobes are covered by a CE marking. Cryoprobes must be used in conjunction with the Erbecryo®2 device and its accessories.
41495366|NCT05824416|DEVICE|Experimental: ALBA|"Device: Improve Upper Limb Mobility~The patients will undergo treatment with the conventional therapy, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise. In addition to training with the ALBA® device, Shoulder flexion, abduction, and external rotation, elbow flexion and extension."
41495367|NCT05824416|BEHAVIORAL|Conventional Therapy|The conventionl therapy will receive conventional treatment, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise
41495368|NCT02906761|DRUG|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
41495369|NCT02906761|DRUG|Placebo|Placebo (2 tablets) twice daily for 6 months
41495370|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): No maintenance treatment."
40835502|NCT02413411|BEHAVIORAL|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
41160114|NCT01414725|OTHER|Relaxation|Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
41355238|NCT05230992|DEVICE|Cryoprobes Second|In this second experimental group, the same medical devices are used but in the other order.
41355239|NCT00238160|DRUG|cisplatin|
41495371|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab."
41495372|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy."
41495373|NCT03761264|DRUG|Odontopaste®|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Odontopaste® will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
40835503|NCT02413411|BEHAVIORAL|an educational program (an NIH-developed booklet)|
40835504|NCT02968381|BEHAVIORAL|Imagery Intervention|Telephone coaching sessions, use of guided imagery and website.
41355240|NCT00238160|DRUG|fluorouracil|
41495374|NCT03761264|DRUG|Pulpdent|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Pulpdent paste will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
41495375|NCT03761264|DRUG|Amoxicillin|Teeth with abscess will be opened from the crown to allow cleaning of the canals . A sterile cotton pellet will be placed in the pulp chamber and cavity sealed with capsulated Glass ionomer cement. The patient will be prescribed oral amoxicillin at 15mg/kg body weight tds for 5 days
41355241|NCT00238160|PROCEDURE|adjuvant therapy|
41495376|NCT03082287|DEVICE|Fecal Calprotectin Level|Measurement of calprotectin in feces
40835505|NCT02968381|BEHAVIORAL|Control Condition|Telephone coaching using standard cognitive behavioral methods
41160115|NCT04141722|BEHAVIORAL|Overnight sleep|Participant sent home to sleep overnight wearing PSG.
41160116|NCT04141722|BEHAVIORAL|Wake|Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
41355242|NCT00238160|PROCEDURE|chemotherapy|
41355243|NCT00238160|PROCEDURE|conventional surgery|
41355244|NCT00238160|PROCEDURE|hepatic arterial infusion|
41355245|NCT00238160|PROCEDURE|surgery|
40835506|NCT06436586|OTHER|No intervention|No intervention
40835507|NCT00237380|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
40835508|NCT04213170|DRUG|sintilimab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d
41160117|NCT05218421|DIAGNOSTIC_TEST|Carotid ultrasound|Carotid ultrasound with flow and elastography (strain and shear wave) measurements will be performed maximally 2 weeks prior to the CEA. Ultrasound-based flow imaging will be repeated six weeks after the CEA to assess the hemodynamic consequences of the CEA procedure.
41355246|NCT02571829|DRUG|ribociclib|Oral, 600 mg x 1 a day, duration - according to response
41355247|NCT01408862|OTHER|venous puncture|Blood for in vitro studies will be drawn
41355248|NCT00126386|DRUG|Zoledronic acid (Zometa)|
41355249|NCT04799340|BEHAVIORAL|cognitive training|training to improve encoding and recognition of faces
41355250|NCT02261311|OTHER|Quality of Life|All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
41355251|NCT01006915|PROCEDURE|Surgery|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
41355252|NCT00413231|DEVICE|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
41355253|NCT00779233|DRUG|Zidovudine tablets 300 mg|
40835509|NCT04905355|DEVICE|Virtual reality|The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
40835510|NCT01384032|DIETARY_SUPPLEMENT|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
41160118|NCT05218421|OTHER|Biospecimen collection and examination|The plaque excised during CEA will be histologically examined to assess the plaque composition, and therefore plaque vulnerability.
40835511|NCT01384032|DIETARY_SUPPLEMENT|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
41160119|NCT05218421|OTHER|Blood sample collection|In the first 20 included patients in the Radboudumc, a 10 mL blood sample will be collected during surgery via the arterial line that is applied for regular care.
41355254|NCT00984919|OTHER|high performance liquid chromatography|
41355255|NCT00984919|OTHER|laboratory biomarker analysis|
41355256|NCT00984919|OTHER|mass spectrometry|
41355257|NCT03117686|DIAGNOSTIC_TEST|lung ultrasound|"lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro"
41355258|NCT00171964|DRUG|Zoledronic acid in combination with therapy|
41355259|NCT01273506|DRUG|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
41355260|NCT01273506|DRUG|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
41355261|NCT04343612|DEVICE|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
41355262|NCT04098029|BIOLOGICAL|Low HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 3 or fewer by A, B, DRB1 loci.
41355263|NCT04098029|BIOLOGICAL|High HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 4 or more by A, B, DRB1 loci.
41021431|NCT03555669|OTHER|Depression Treatment|The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
41355264|NCT04098029|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training, etc.
41355265|NCT02331173|DRUG|Dorzolamide 2% TID or brinzolamide 1% TID|"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~* Topical dorzolamide 2% three times per day~* Topical brinzolamide 1% three times per day"
41355266|NCT05754372|DIAGNOSTIC_TEST|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia, based on kinetic modelling
41355267|NCT03011424|DEVICE|Extracorporeal liver support therapy (ELS)|ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
41355268|NCT03395704|DRUG|LJPC-401|LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
41021432|NCT02237105|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
41021433|NCT01982916|DRUG|AGR tablet|
41021434|NCT01982916|DRUG|Placebo (for AGR tablet and/or Active Comparator)|
41355269|NCT03395704|DRUG|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
41355270|NCT02607735|DRUG|SOF/VEL/VOX|400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food
41355271|NCT02607735|DRUG|Placebo|Tablet administered orally once daily with food
41495377|NCT05073952|PROCEDURE|Connective tissue graft|Implants will be placed with a flap and a connective tissue graft.
41495378|NCT05073952|PROCEDURE|Flapless|Implants will be placed with a flapless approach
41021435|NCT01982916|DRUG|Active Comparator|
41355272|NCT05326672|DRUG|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
41355273|NCT05326672|DRUG|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
41495379|NCT04364659|BEHAVIORAL|Food-Specific Inhibitory Control Training (FoodT App)|FoodTrainer (FoodT) is a simple game that aims to train individuals to 'stop' to certain unhealthy foods. Repeatedly playing this game is hypothesised to help build associations between certain foods (such as chocolate) and stopping, putting the brakes on unhelpful eating behaviour.
41495380|NCT03397771|DRUG|Litoxetine|oral study medication provided in a dose titration manner
41021436|NCT05053386|DRUG|Idarubicin Hydrochloride for Injection|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
41495381|NCT03397771|DRUG|placebo|placebo medication provided in a dose titration manner
41495382|NCT03384082|PROCEDURE|hysteroscopic treatment|treatment
41495383|NCT00422578|DRUG|tadalafil|
41495384|NCT06273826|DIAGNOSTIC_TEST|"Colorectal Leakage App"|"The Colorectal Leakage App is a mobile application designed to aid in the early detection of anastomotic insufficiency after colorectal surgeries. The app is based on the Dutch Leakage Score (DLS) algorithm, which is a standardized protocol for postoperative monitoring."
41495385|NCT04400032|BIOLOGICAL|Mesenchymal Stromal Cells|The Mesenchymal Stromal Cells will be administered intravenously
41495386|NCT00060138|BIOLOGICAL|monoclonal antibody CAL|
41495387|NCT00060138|DRUG|zoledronic acid|
41495388|NCT01630967|DRUG|Degarelix|Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
41495389|NCT03410251|PROCEDURE|Socket preservation|"Teeth were extracted atraumatically and without flap release in patients who have received prophylactic antibiotherapy and local anaesthesia. After checking the integrity of the buccal and palatal bone plate, biomaterial (Bio-Oss®) was introduced into the socket. A connective tissue graft harvested from the palate was inserted and sutured in buccal and palatal pouches in order to cover the socket.~chlorhexidine spray (0.12%) twice a day and Ibuprofen 600 mg three times/ day were prescribed whereas antibiotics were continued for 5 days. Tooth brushing was banned at the extraction site for 10 days and sutures were removed 10 days after surgery."
41495390|NCT01906450|DRUG|Scaling and root planing plus Azithromycin|Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
41495391|NCT01906450|DRUG|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
41495392|NCT00182468|OTHER|Screening for intimate partner violence|Women are screened for intimate partner violence prior to seeing a health care provider.
41495393|NCT03911050|DIETARY_SUPPLEMENT|Apple consumption|Apple blends (600 g) One single dose
41495394|NCT03911050|DIETARY_SUPPLEMENT|Control group|Breakfast without any apple-related products
41495395|NCT00813527|DRUG|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
41495396|NCT00813527|DRUG|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
41021437|NCT05053386|DRUG|Epirubicin|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
41021438|NCT03383588|DRUG|Bupivacaine|20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
41021439|NCT03383588|DRUG|Morphine|intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
41021440|NCT03383588|DRUG|Fentanyl|intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
41160120|NCT00001077|DIETARY_SUPPLEMENT|Multivitamin and mineral supplements|Oral tablets taken daily
41160121|NCT00001077|DIETARY_SUPPLEMENT|Peptamen|Solution received daily
41160122|NCT00001077|DIETARY_SUPPLEMENT|NuBasics|Solution or dietary bar received daily
41160123|NCT03609671|BEHAVIORAL|Standard of Care + Experimental Individualized Therapy|Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.
41160124|NCT03609671|OTHER|Control: Standard of Care|Participants will undergo standard of care only (no Intervention/no individualized therapy) .
41495397|NCT01691924|DRUG|PBF-509|
41495398|NCT01691924|DRUG|Placebo|
41495399|NCT04319016|OTHER|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
41495400|NCT05284487|DEVICE|Jalosome® soothing gel|Jalosome® Soothing gel is a phospholipid based vesicular system based on hyaluronic acid (HA). HA supports the process of formation of extracellular matrix and collagen synthesis by fibroblasts, favoring the formation of a well-vascularized granulation tissue and thus accelerating the healing process. Jalosome® Soothing gel contains other active ingredients: Acetyl-L-carnitine which plays an important role as shuttle for energy production and is involved in cellular metabolism. It is an effective cytoprotective, anti-inflammatory, neuroprotective, metal chelator, anti-apoptotic and anti-oxidant agent. Allantoin is a key constituent of comfrey (Symphytum officinale L), it has moisturizing and keratolytic effect, increasing the water content of the extracellular matrix and enhancing desquamation of upper layers of dead skin cells. Hydrogenated phosphatidylcholine is a permeation enhancers, which increases the solubilization of active ingredients, improving their skin permeation ability.
41495401|NCT05284487|DEVICE|Placebo|The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
41495402|NCT02497651|DIETARY_SUPPLEMENT|Liquid mixed meal|The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
41495403|NCT02497651|OTHER|Skin Biopsy|All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
41495404|NCT03341819|PROCEDURE|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
41495405|NCT03341819|PROCEDURE|Urinary Catheterization|Urinary catheterization is a latex, polyurethane, or silicone tube known as a urinary catheter is inserted into a patient's bladder via the urethra. Catheterization allows the patient's urine to drain freely from the bladder for collection.
41495406|NCT01229709|BEHAVIORAL|Mindfulness Based Tinnitus Reduction|The Mindfulness Based Tinnitus Reduction (MBTR) program will be held for two-and-a-half hours one evening per week over 8 consecutive weeks. Participants will also complete a day-long Sunday retreat between the 6th and 7th sessions. Each participant will take part in a 30-minute private interview with the course instructor prior to beginning the program.
41495407|NCT04158700|DRUG|LY3200882|LY3200882 administered orally
41495408|NCT04158700|DRUG|Pembrolizumab|Pembrolizumab administered IV
41495409|NCT03591393|DIAGNOSTIC_TEST|questionnaire|"Validated self-administered questionnaires with five domains: Wexner questionnaire for anal incontinence, PAC-SYM for constipation, International Consultation on Incontinence Questionnaire Short Form for urinary incontinence, the Pelvic Organ Prolapse Distress Inventory for pelvic organ prolapse, POP/UI Sexual Questionnaire - IUGA revised for sexual function.~The body image perception will be assessed using the Dutch-validated version of the self-administered Body Image Disturbance Questionnaire."
41495410|NCT03544619|OTHER|Neuropathic Pain Symptom Inventory|Investigators will use the Neuropathic Pain Symptom Inventory for assessing neuropathic symptoms
41495411|NCT03918694|DIETARY_SUPPLEMENT|Vitamin C|Daily use of Vit C tablets
41495412|NCT03918694|DIETARY_SUPPLEMENT|Placebo|Daily use of placebo tablets
41495413|NCT05613296|DRUG|Fostamatinib|Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
41495414|NCT00151138|DRUG|Atenolol (drug), Lisinopril (drug)|
41495415|NCT02636543|OTHER|Questionnaire after the reading of letter B.|Oral questionnaire after the reading of letter B.
41495416|NCT02636543|OTHER|Questionnaire after the reading of letters A and B|Oral questionnaire after the reading of letters A and B during individual interview.
41495417|NCT02566356|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
41495418|NCT02566356|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
41495419|NCT04530708|RADIATION|Thoracic radiotherapy|36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.
41495420|NCT00027248|DRUG|MBI 226|
41495421|NCT01418963|DRUG|RO5285119|single and multiple ascending oral doses
40835512|NCT01384032|DIETARY_SUPPLEMENT|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
40835513|NCT01778920|DRUG|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
40835514|NCT00514228|DRUG|sunitinib malate|"* Starting dose: 37.5 mg 3 x 12.5 mg capsule~* Reduced dose: 25 mg 2 x 12.5 mg capsule"
40835515|NCT04743960|DIETARY_SUPPLEMENT|Time-of-day of parenteral nutrition provision|Parenteral nutrition will be provided during the nighttime followed by daytime.
40835516|NCT06507839|DRUG|THRV-1268|THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
40835517|NCT06507839|OTHER|Placebo|Matching placebo
40835518|NCT06476158|DEVICE|Kaiku Health|Digital follow-up with Kaiku Health as medical device
40835519|NCT00424411|DRUG|Inhaled human insulin (EXUBERA™)|
40835520|NCT05577546|OTHER|Moor S brace treatment|The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.
40835521|NCT05577546|OTHER|Schroth Three-Dimensional Scoliosis Exercise Treatment|Schroth Three-Dimensional Scoliosis Exercise Treatment has the main features of physiotherapeutic scoliosis-specific exercises: 1) Three-dimensional self-correction, 2) Training activities of daily living (ADL), and 3) Stabilization of the corrected posture. The basic principles of the Schroth method are autoelongation, deflection, derotation, rotational angular breathing and stabilization. Exercise therapy will be carried out at the brace center once a week with the researcher, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
40835522|NCT03552588|DIAGNOSTIC_TEST|Continuous Electrocardiogram|A high-sensitivity, 14-day continuous ECG monitor.
40835523|NCT01519739|DEVICE|MediGuide™|MediGuide™ system will be used to guide CRT implants
40835524|NCT02680470|DEVICE|Virtual observed therapy|Virtual Observation of participants taking their medication
41495422|NCT01418963|DRUG|placebo|single and multiple oral doses
41495423|NCT03408535|OTHER|Eriksholm Guide to Better Hearing|Online rehabilitation program.
41495424|NCT04710316|DIAGNOSTIC_TEST|SARS-CoV-2 screening by molecular biology|SARS-CoV-2 RT-PCR in nasopharyngeal swab targeting 2 regions of the viral genome
41495425|NCT04710316|DIAGNOSTIC_TEST|Serological screening|Serological screening of caregivers at D0, M1, M2, M3 (anti-nucleocapsid antibodies).
40835525|NCT00002039|DRUG|Foscarnet sodium|
40835526|NCT00576576|DRUG|Atorvastatin|Atorvastatin 80 mg a day
40835527|NCT05362474|DRUG|Montelukast|10mg orally once a day
40835528|NCT04476394|DRUG|[14C]-Anaprazole Sodium enteric-coated capsule|\[14C\]-Anaprazole Sodium enteric-coated capsule
40835529|NCT01300988|DRUG|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
40835530|NCT01300988|DRUG|Aprepitant placebo|Aprepitant(Emend®) placebo for 14 days
40835531|NCT02489812|BEHAVIORAL|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
41495426|NCT02135835|DRUG|Shenfu Zhusheye|
41495427|NCT02135835|DRUG|5% glucose injection|
41495428|NCT02476240|BEHAVIORAL|Parkinson's disease Sensory Attention Focused Exercise|The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
41495429|NCT04940260|DIAGNOSTIC_TEST|Renal function|measure eGFR at one year post partum
41495430|NCT04940260|DIAGNOSTIC_TEST|proteinuria|measure urine protein creatinine ratio at one year postpartum
41495431|NCT05160233|BEHAVIORAL|Standard implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
41160125|NCT00437619|DRUG|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a \>50% response to Daivobet from weeks 0-4.
41495432|NCT05160233|BEHAVIORAL|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
41160126|NCT00465478|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|
41160127|NCT03785210|DRUG|nivolumab|480 mg intravenous (IV) every 4 weeks
41495433|NCT05160233|BEHAVIORAL|Practice Facilitation|A trained facilitator provides support for implementation by delivering the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
41495434|NCT03080415|DRUG|Combined Therapy SOF and DCV|"1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients"
40835532|NCT05275790|DEVICE|Vestal device|Battery powered non-invasive neurostimulation device
41160128|NCT03785210|DRUG|tadalafil|10 mg by mouth (PO) daily
41160129|NCT03785210|DRUG|oral vancomycin|125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.
41160130|NCT03016364|DEVICE|APP software|A software used to by physicians to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain
40835533|NCT05275790|BEHAVIORAL|Lifestyle intervention|All subjects will be prescribed a diet plan and instructed to follow it for the duration of the 12-week study. The diet plan will be designed by the P.I. who is a qualified, obesity management coach.
40835534|NCT01066351|DRUG|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
41355274|NCT04238286|PROCEDURE|Dry needling|All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray \[Skin-des. Agupunt ®\]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
41495435|NCT01470911|DRUG|SB010|"Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.~Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL."
41495436|NCT01470911|DRUG|Placebo|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
40835535|NCT01066351|DRUG|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
41355275|NCT03884803|BEHAVIORAL|E-health website|Access to the e-health intervention (website)
41021441|NCT03383588|DRUG|Epinephrine|Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
41355276|NCT03884803|OTHER|Standard Care|Control group to continue with standard care
41355277|NCT04352686|DRUG|Buspirone|Administration of buspirone to assess esophageal sensitivity
40835536|NCT06397508|DRUG|AGMB-129|Each participant will receive 3 study interventions, 1 in each intervention period
41355278|NCT04352686|DRUG|Placebo|Administration of placebo to assess differences in esophageal sensitivity
41355279|NCT02286336|OTHER|brachial plexus block|brachial plexus block with ropivacaine 40ml
40835537|NCT04142190|DRUG|ELONVA|Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
40835538|NCT04142190|DRUG|PUREGON|Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
41355280|NCT02804386|DRUG|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
40835539|NCT00343382|DRUG|pilocarpine hydrochloride|Given orally
40835540|NCT00343382|OTHER|placebo|Given orally
41021442|NCT03383588|OTHER|Saline solution|20 ml subcutaneous NACL 0.9% - saline solution is the placebo
41021443|NCT05720624|DRUG|Anhydrous Enol-oxaloacetate|Given PO
41021444|NCT05720624|OTHER|Best Practice|Receive standard of care therapy
41021445|NCT05720624|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood
41021446|NCT05720624|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRS imaging
40835541|NCT04943562|DIAGNOSTIC_TEST|ACT+EEG|Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
41021447|NCT05720624|OTHER|Questionnaire Administration|Ancillary studies
41021448|NCT03105050|OTHER|Access to bariatric surgery|All countries representatives will be interviewed on their Healthcare systems
41355281|NCT05000866|BEHAVIORAL|Communication skills training video|The communication skills training video component is designed to be self-delivered. Four couples are depicted in separate scenes discussing HIV testing, drug use, sexual agreements, and drug use during sex. Each scene is viewed twice. In the initial viewing, the couple in the video makes one or more communication errors. The scene is subsequently viewed a second time and the couple utilizes more effective communication skills, resulting in a more adaptive resolution. Each scene is introduced by a narrator who points out communication errors and orients viewers to skills utilized in adaptive versions of each scene.
41021449|NCT06281496|BEHAVIORAL|AlloCare|Survivorship supportive care
41355282|NCT05000866|BEHAVIORAL|Drug use module|The substance use module is administered after step 5 of CHTC and prior to the delivery of rapid HIV-test results. The couple was first asked to fill in a calendar for the past 30 days, indicating each day on which either member used drugs or consumed alcohol. Completion of the calendar is done through an ACCESS database to facilitate remote intervention delivery. After completion of the calendar, the HIV tester asked a series of debriefing questions designed to elicit the couples' perspective on their use, establish the couple's goals and limits for drug use, and make plans to achieve these goals.
41355283|NCT04899752|BEHAVIORAL|Motivational Interviewing|Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.
41355284|NCT02581501|DRUG|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
41355285|NCT00482209|DRUG|Mifepristone, misoprostol|200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
41355286|NCT00482209|DRUG|mifepristone, misoprostol|200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
41355287|NCT02176226|BEHAVIORAL|IntelliCare|Behavioral interventions for depression and anxiety via a mobile phone application, IntelliCare.
41355288|NCT02532998|DRUG|AZD9977 oral suspension|AZD9977 oral suspension, single dose
41355289|NCT02532998|DRUG|AZD9977 placebo oral suspension|oral suspension, single dose
41355290|NCT02532998|DRUG|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
41355291|NCT02532998|DRUG|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
41355292|NCT04619563|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
41355293|NCT00250094|DRUG|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is \>1,500 and platelets \> 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
41355294|NCT02178215|OTHER|Placebo shower gel|Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks
41355295|NCT02178215|OTHER|Holly Mangrove Shower Gel|Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
41355296|NCT00269958|DRUG|epoetin alfa|
41355297|NCT02458742|DRUG|Morphine|0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
41355298|NCT02458742|DRUG|Placebo|0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
41355299|NCT05513456|BEHAVIORAL|Randomization to a different factors in the case descriptions|The case descriptions will include factors like age, co-morbid status and acute physiological parameters; but the factor of sex/gender will be randomized. Moreover, randomization to case description of typical vs non-typical national name will be done.
41355300|NCT05027711|RADIATION|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)
41355301|NCT05027711|RADIATION|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)
41355302|NCT04678973|BEHAVIORAL|Self-compassion mindfulness practice|"Guided Mindfulness Practice: Participants in the intervention group will receive compassion-based guided meditation audio recordings. Recordings will target self-compassion and body concerns simultaneously.~Psychoeducation: Participants in the intervention group will receive psychoeducation delivered via daily PDF over days 1-6. Psychoeducation will orient users to their upcoming experience, provide education about internalized weight bias, the chronic stress system, the utility of self-compassion practice to regulate physiological and psychological targets, and guidance on establishing, maintaining, and generalizing a mindfulness practice.~Daily prompts: Participants will receive a text message every morning indicating their task for that day.~Weekly prompts: Participants will receive a text message at the end of every week (Days 7, 14, 21, and 28) with a link to a brief adherence survey."
41355303|NCT02182856|DRUG|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
41355304|NCT02182856|DRUG|Ipratropium 500 µg|
41355305|NCT02182856|DRUG|Salbutamol sulphate 3 mg|
41355306|NCT02182856|DRUG|Salbutamol sulphate 6 mg|
41355307|NCT01292733|OTHER|Laboratory Tumor Marker Analysis|Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker. Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.
41355308|NCT01292733|OTHER|Transvaginal Ultrasound|Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
41355309|NCT01292733|OTHER|Health Status Questionnaire|Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
41021450|NCT04979221|DRUG|Cyproheptadine|Cyproheptadine 8mg three times a day during 10 days
41021451|NCT01049555|OTHER|Actigraphy and video recording signal|Actigraphy and video recording signal during 1 hour
41021452|NCT04394351|DRUG|Dupilumab|Single-use, prefilled syringe
41021453|NCT04394351|DRUG|Matching Placebo|Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
41355310|NCT02742155|BEHAVIORAL|Play2Sleep|Behavioral: Video self-modelling
41355311|NCT02742155|BEHAVIORAL|Comparison|Behavioral: Information only
41355312|NCT02638753|OTHER|education|Patients will be educated about pain neurophysiology.
41355313|NCT02638753|OTHER|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
41355314|NCT04093401|OTHER|individualized risk assessment|Individualized risk assessment of developing a second basal cell carcinoma
41355315|NCT05846542|OTHER|Video-game based therapy|Video-game based therapy will be designed for the individual basis for the upper extremity.
41355316|NCT05846542|OTHER|Conventional physiotherapy|Conventional physiotherapy within a specific program
41355317|NCT02146885|OTHER|Weight Control|Weight Control
41355318|NCT02995018|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-174)
41355319|NCT02995018|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
41355320|NCT03188003|OTHER|Exercise Movement Techniques based on mobilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
41355321|NCT03188003|OTHER|Exercise Movement Techniques based on stabilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
41355322|NCT03312127|DEVICE|ILIAC ENDOPROSTHESIS GORE EXCLUDER|Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
41355323|NCT03196206|DRUG|BMS-986177|Oral Suspension
41355324|NCT00333242|DRUG|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
41355325|NCT05750901|DEVICE|Fractional ablative laser|Fractional ablative laser used for treatment for skin laxity and tightening
41355326|NCT05212467|BEHAVIORAL|AIR-program|This is a guided self management program that is added on the treatment as usual.
41355327|NCT05212467|BEHAVIORAL|HUS Internet therapy|This is a guided self management program that is added on the treatment as usual.
41355328|NCT05212467|BEHAVIORAL|Treatment as usual|The patients receive routine care from their physician which may include drugs, visits or rehabilitation
41355329|NCT00883792|PROCEDURE|Colonoscopy|Once-only colonoscopy screening
41355330|NCT05790499|DRUG|Atorvastatin|Patients are treated with atorvastatin for 2 weeks (40 mg/day), atorvastatin free for 2 weeks, atorvastatin treatment for 2 weeks, atorvastatin free for 2 weeks, a 4-week washout period (no treatment), and atorvastatin treatment for the last 4 weeks.
41355331|NCT00145379|DRUG|Tablet Metformin 500 mg|
41355332|NCT00145379|DRUG|Placebo|
41355333|NCT00561028|OTHER|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
41355334|NCT01012700|DRUG|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
41355335|NCT05798286|OTHER|Quantra|The study plans to collect 2 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts.
41355336|NCT05798286|OTHER|Control|The study plans to collect 1 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts at each time.
41355337|NCT05528965|PROCEDURE|Perpendicular Group|Radiofrequency ablation was applied to the perpendicular group by placing the tip of electrode perpendicularly to contact the genicular nerves.
41355338|NCT05528965|PROCEDURE|Parallel Group|Radiofrequency ablation was applied to the parallel group by placing the electrode lay parallel to contact the genicular nerves.
41355339|NCT01388114|DEVICE|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
41355340|NCT05541159|DRUG|TNO155|Single oral dose of TNO155 on Day 1
41355341|NCT05754736|DRUG|Ametinib combined with bevacizumab|Ametinib 110mg po qd bevacizumab 15mg/kg ivdrip q3w
41355342|NCT04729699|OTHER|Aerobic exercise and exercise for TMJ|Aerobic exercise
41355343|NCT04729699|OTHER|Aerobic exercise at home|Aerobic exercise
41355344|NCT04184466|DRUG|Insulin Aspart|insulin aspart in doses 0.3 IU/kg
41495437|NCT00283023|PROCEDURE|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
41495438|NCT00273390|DRUG|Remicade (infliximab)|
41495439|NCT01840865|DEVICE|brain stimulation|oscillating direct current brain stimulation
41355345|NCT04184466|DRUG|NovoRapid® Penfill®|insulin aspart in doses 0.3 IU/kg
41355346|NCT03268395|DIAGNOSTIC_TEST|Arterial Blood Gas and Transcutaneous CO2 Monitor|Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
41355347|NCT03717727|OTHER|Exergame|16-week home-based exercise intervention with exergaming system and usual treatment.
41355348|NCT03717727|OTHER|Control|16-week home-based exercise by standard protocol and usual treatment.
41355349|NCT03276494|DEVICE|Intraosseous|Intraosseous administration of hypertonic saline
41355350|NCT03276494|DRUG|Hypertonic saline|Intraosseous administration of hypertonic saline
41355351|NCT05972668|DEVICE|Smartphone Apps|The intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits
41355352|NCT04717154|BIOLOGICAL|Ipilimumab|4 courses of 1mg/kg q3w
41355353|NCT04717154|BIOLOGICAL|Nivolumab|4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)
41355354|NCT01371799|DRUG|Drug|Placebo
41355355|NCT01371799|DRUG|Drug|4mg and 8mg Study drug
41355356|NCT05471453|DIETARY_SUPPLEMENT|DHEA|75 mg DHEA supplementation per day for 3 months before IVF
41495440|NCT01840865|DEVICE|no stimulation|sham Stimulation
41495441|NCT00396435|DRUG|Neorecormon|Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B
41495442|NCT02826837|DRUG|LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab|"The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
41495443|NCT03724214|COMBINATION_PRODUCT|Pre-hospital interventional care bundle|"The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment.~Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres.~Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol."
41509191|NCT06158919|DRUG|Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine|"Combined treatment period: A total of 6 cycles of combined treatment Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w SOX : Oxaliplatin 130mg/m2 iv.gtt d1, Teysuno 40mg/m2 p.o.b.i.d. d1\~ 14q3w. Or XELOX regimen: oxaliplatin 130mg/m2 iv.gtt d1 Capecitabine 1000mg/m2 p.o. b.i.d. d1\~ 14q3w.~Maintenance treatment period:~Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w Teysuno 40mg/m2 p.o.b.i.d. d1\~14 q3w or Capecitabine 1000mg/m2 p.o.b.i.d. d1\~14 q3w.~Maintenance of treatment until disease progression or toxicity becomes intolerable."
41355357|NCT05471453|DIETARY_SUPPLEMENT|DHEA+CoQ10+Tocotrienol|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
41355358|NCT00652964|DEVICE|CPAP|CPAP treatment for patients with congenital central hypoventilation syndrome
41355359|NCT00253422|DRUG|anastrozole|
41355360|NCT00253422|DRUG|exemestane|
41355361|NCT00253422|DRUG|fulvestrant|
41355362|NCT04474210|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 tablets orally.
41355363|NCT05237713|DRUG|Canakinumab Injection|Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years
41355364|NCT02650804|DRUG|BPM31510 Nanosuspension Injection|
41355365|NCT02650804|DRUG|Gemcitabine|
41355366|NCT04205604|DRUG|18F-Fluoro Dopa Imaging|Imaging with 18F-Fluoro Dopa PET Imaging
41355367|NCT04303247|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
41355368|NCT04360291|OTHER|Eye tracker|In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
41355369|NCT04440306|PROCEDURE|Mini-Gastric Bypass - Original Technique|Mini-Gastric Bypass - Original Technique is widely used form of bariatric surgery and includes a tailored BPLL
41355370|NCT00329992|BEHAVIORAL|Brief Eclectic Psychotherapy for PTSD|16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
41355371|NCT01213342|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|"Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:~* EPA (Eicosapentaenoic Acid) 1300mg~* DHA (Docosahexaenoic Acid) 900 mg~* Other Omega-3's 360mg~* Total Omega 3's 2560 mg"
41355372|NCT01213342|DIETARY_SUPPLEMENT|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
41355373|NCT04109066|BIOLOGICAL|nivolumab|Specified Dose on Specified days
41355374|NCT04109066|DRUG|paclitaxel (PTX)|Specified dose on Specified days
41355375|NCT04109066|OTHER|nivolumab placebo|Specified dose on Specified days
40835542|NCT03002311|DEVICE|Epharmix/CareSignal eHealth|The self-scheduling text and phone messaging system was built by Epharmix/CareSignal. Participants in the intervention group began receiving text or voice messages (for landlines) starting 1 hour following ED discharge if during normal business hours, or at 1000 the next business morning. Automated messages were sent up to 3 days in a row or until the participant responded or opted out. The phone system would ultimately connect them directly to their referral provider or clinic to schedule an appointment. Once participants hung up with the referral clinic, the intervention texted or called back to solicit the appointment date. If a date was entered, the system sent reminders at 14 days, 7 days, 3 days, and 1 day before the appointment. After the appointment, the intervention texted or called participants to confirm if they attended.
40835543|NCT01846559|BIOLOGICAL|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
40835544|NCT01846559|DRUG|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
40835545|NCT01846559|DRUG|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
40835546|NCT06147921|DRUG|Verasone|Administered by sinonasal irrigation.
40835547|NCT03396055|OTHER|specific rehabilitation exercise|specific rehabilitation exercise for patients with cervical myelopathy
40835548|NCT01827332|DRUG|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
40835549|NCT01827332|DRUG|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
40835550|NCT00238459|DRUG|Patients elected to take licensed drugs. The vaccine was not provided for evaluation|Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
40835551|NCT00238459|DRUG|multiple licensed drugs not randomized|
40835552|NCT00238459|DRUG|multiple licensed antiretroviral drugs; not randomized|
40835553|NCT00238459|OTHER|Intended vaccine not provided, Licensed drugs provided, but were not investigated|
40835554|NCT04109846|OTHER|Non-euploid embryo transfer|Other than choice of embryo for transfer, all other medical interventions will be at discretion of treating provider
40835555|NCT04109846|OTHER|Euploid Transfer|Standard of Care Protocol
40835556|NCT01605942|DRUG|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
40835557|NCT01605942|DRUG|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
40835558|NCT03409510|RADIATION|UVB radiation|"UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week"
40835559|NCT05920772|BEHAVIORAL|KickAsh! intervention|The general aim of the KickAsh! intervention is to prevent smoking initiation in adolescents living in vulnerable socioeconomic situations. The intervention exists of different components concerning smoking prevention. Most components have a direct influence on smoking initiation by affecting several determinants of the adolescents. These components include smoke-free games, mood boards, a smoke-free camp, the Kick some Ash!-challenge and exercises concerning self-efficacy and skills. Yet, some of the components target adolescents by influencing their environment, i.e. smoking policy in the organisation and youth workers as role models. All components are developed using a combination of theoretical methods to change or influence these determinants or environmental factors.
40835560|NCT01113034|DRUG|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
40835561|NCT01113034|DRUG|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
40835562|NCT05116605|OTHER|Photobiomodulation (PBM)|Photobiomodulation (PBM) is light therapy in both the visible and near-infrared range (non-UV). This light is absorbed through the skin and functions at the cellular level, providing a lowering of inflammation and oxidative stress. Participants will undergo 20 minute sessions three times a week for 4 weeks using the NovoTHOR as the only intervention.
40835563|NCT01584635|PROCEDURE|Peroral Endoscopic Myotomy a less invasive treatment for Achalasia|In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
40835564|NCT00348114|PROCEDURE|Transplantation of cultivated limbal epithelium|
40835565|NCT06486688|BEHAVIORAL|Centralized Virtual SBIRT|Brief interventions are delivered virtually by video or telephone by a centralized behavioral health clinician
41355376|NCT04109066|DRUG|anthracycline|Specified dose on Specified days
41355377|NCT04109066|DRUG|cyclophosphamide|Specified dose on Specified days
41355378|NCT04109066|DRUG|Endocrine Therapy|Variable endocrine therapy of investigators choice
41355379|NCT04109066|PROCEDURE|Surgery|Surgery for breast cancer
41355380|NCT05604131|DRUG|Deferiprone Tablets|Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
41355381|NCT05604131|DRUG|Placebo|Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
41509192|NCT05311579|COMBINATION_PRODUCT|Niraparib plus anlotinib|"Niraparib QD D1-21 plus Anlotinib 10mg QD D1-14 until disease progression or intolerable toxicity~21days/cycle"
41509193|NCT01806571|DRUG|Cytarabine|Given IV
40835566|NCT03576105|COMBINATION_PRODUCT|irrigation /sterile saline|mechanical removal of bacteria with sterile saline
41509194|NCT01806571|DRUG|Daunorubicin Hydrochloride|Given IV
41495444|NCT03724214|COMBINATION_PRODUCT|In-hospital interventional care bundle|"In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme.~In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available."
41495445|NCT04470687|DEVICE|contrast enhanced ultrafast ultrasound imaging|"Ultrasound contrast medium: SonoVue 8µL/mL (Bracco International BV) Ultrasound scanner: Aixplorer® device marketed by SuperSonic Imagine©, CE Doppler UltraFast™Doppler, contrast ultrasound (CEUS), color Doppler and ultra-sensitive energy Doppler, high-performance directional energy Doppler, Elastography ShearWave™ UF-Doppler (UltraFast-Doppler) and microbubble injection (SonoVue) Apparatus for performing the UF Doppler sequence: Aixplorer, manufacturer : Supersonic Imagine, Aix-en-Provence, France, CE Marking.~3D RCA dedicated vascular probe with dedicated Doppler sequences"
41495446|NCT03401359|GENETIC|tissue biopsy, blood sample|At baseline, 100 tumor/blood samples will be banked. Only \~60 will be profiled if the paired samples are acquired post-progression or on-treatment. On-treatment blood samples will be serially collected and banked from all consenting patients.
41495447|NCT06407986|DIAGNOSTIC_TEST|pulmonary function test|Whether the estimated value of FEV1 and FVC is greater than 80%.
41495448|NCT01987973|PROCEDURE|Partial Rotator Cuff Repair|This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.
41495449|NCT01987973|PROCEDURE|Partial Rotator Cuff Repair with Allograft Augmentation|Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
41495450|NCT04918498|BEHAVIORAL|early physiotherapy programs|establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy
40835567|NCT03576105|COMBINATION_PRODUCT|Conventional methylene blue as photosensitizer|Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
40835568|NCT03576105|COMBINATION_PRODUCT|Methylene blue for oral use as photosensitizer|Irrigation with 0,04mL of photosensitizer(0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
40835569|NCT03576105|COMBINATION_PRODUCT|Photodynamic therapy|Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
40835570|NCT05113667|OTHER|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program|Clinical pharmacist provided medication reconciliation and medication review during the hospital stay.
40835571|NCT04042376|DRUG|Ibrutinib|Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg\*3 capsules taken together at one time).
40835572|NCT05895903|DEVICE|Screw expander|threadform screw expanders with special condensing burs for lateralization and compaction of bone
40835573|NCT05895903|DEVICE|Osseodensification drills|special drills to expand narrow alveolar ridges.
40835574|NCT02048410|DIETARY_SUPPLEMENT|Lactobacillus paracasei B21060|combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
41495451|NCT04918498|BEHAVIORAL|routine treatment|provide routine nursing and rehabilitation program
41495452|NCT05590832|BEHAVIORAL|Activity of Whatsapp messages|Informative messages will be sent to the initiative group on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks.
41495453|NCT02287909|DRUG|Clopidogrel|Swiching from ticagrelor to clopidogrel
41495454|NCT02287909|DRUG|Ticagrelor|Continue treatment with ticagrelor
41495455|NCT02489253|OTHER|CT coronary angiogram and carotid ultrasound|Scans in addition to routine clinical care
41495456|NCT05729516|BEHAVIORAL|Hope App immersive learning and telehealth platform|As part of the Hope App intervention, participants attend 10 skills sessions related to diabetes self-management. ITG participants will also receive monthly health coaching calls. After 6 months of active participation, participants enter a maintenance period, during which programming concludes but continued access to the program materials remains.
41495457|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|15 IU/kg rAHF-PFM
41495458|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|30 IU/kg rAHF-PFM
41495459|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|50 IU/kg rAHF-PFM
41495460|NCT05291039|DRUG|Infliximab|group 1 (n=20): patients will receive IFX
41495461|NCT05291039|DRUG|Adalimumab|group 2 (n=20): patients will receive ADA
41495462|NCT03294720|PROCEDURE|Bio-ACL|ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.
41495463|NCT03294720|DEVICE|amnion wrap and BMAC|amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
41509195|NCT01806571|OTHER|Laboratory Biomarker Analysis|Correlative studies
40835575|NCT02048410|OTHER|low satured diet|
40835576|NCT00044824|DRUG|Fexofenadine|
40835577|NCT04202198|BIOLOGICAL|A-PRF|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla.previously prepared PRF membranes are placed through the access hole and the flap is advanced. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
41495464|NCT06483568|BEHAVIORAL|Pathways to Happiness Intervention|Four weeks of activities including a gratitude journal, random acts of kindness, self-compassionate letter, and capitalizing on positive events activities.
41495465|NCT06483568|BEHAVIORAL|Personal Organization Activities|"Four weeks of activities including a completed tasks journal, weekly task burst, productivity letter, and talking to others about task activities."
41495466|NCT01085721|DRUG|Dexchlorpheniramine, pseudoephedrine, guaifenesin|5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days
41495467|NCT01085721|DRUG|Dexchlorpheniramine|5 mL (2 mg dexchlorpheniramine) qid for 5 days
41495468|NCT02822495|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
41495469|NCT00685672|DRUG|adrenalin|adrenalin 2 microgram pr ml placebo
41355382|NCT05684315|PROCEDURE|soft tissue flossing therapy|BFRT and tissue threading is a therapy that involves applying external pressure below or above a joint or muscle of a selected limb, usually with a circumferential elastic band. The pressure provided by the rolled band securely maintains arterial blood supply but reduces or blocks venous outflow distal to the site.
41355383|NCT01306240|PROCEDURE|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
41495470|NCT00685672|DRUG|placebo|Saline instead of adrenaline in the epidural mixture
41495471|NCT02620644|DEVICE|OCT Retinal GCC|measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
41495472|NCT04669691|BIOLOGICAL|H5N1 antigen combined with MF59 adjuvant|Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
41495473|NCT02578030|DRUG|SHP465 12.5mg|
41495474|NCT02578030|DRUG|SHP465 25mg|
41495475|NCT00067899|DRUG|Vitamin E with and without Vitamin C|
41495476|NCT02329938|PROCEDURE|Lichtenstein tension free reair|a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.
41355384|NCT01306240|PROCEDURE|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
41355385|NCT06481605|DEVICE|C-REX|The C-REX is a CE-marked class IIa device consisting of an invasive surgical part, including two anastomotic rings, intended for short-term use, and surgical instruments LapAid and RectoAid for assisting the placement of the anastomotic ring to intestine. The device is supplemented with a catheter to monitor the anastomosis.
41495477|NCT02329938|PROCEDURE|Desarda's repair|the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
41495478|NCT03865368|OTHER|Whole Body Vibration Training|Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body
41495479|NCT00070096|DRUG|ixabepilone|
41495480|NCT00090610|DRUG|Docetaxel|"For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin"
41495481|NCT00090610|DRUG|Carboplatin|"Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel"
41495482|NCT06071169|OTHER|progressive relaxation exercise|Nurses will be asked to perform relaxation exercises 3 days a week for 5 weeks, 20 minutes in each practice.
41495483|NCT05875792|DEVICE|EvolvRehab - MoveWell|The Intervention has been developed and has a CE mark and has medical device level 1 approvals in the UK. It will be developed with patients in Phase 1 and will consist of initial staff training \[training package\]. Exercise prescription will be encouraged, in line with usual care, for the either one week (stage 1, phase 2) or six weeks (stage 2, phase 2). Individuals will be able to continue using the EvolvRehab - MoveWell system beyond 6 weeks from stage 2, phase 2, and technical support will continue until the end of the study completion, participants will not be limited in the additional activity that can be performed during this time, and encouraged to do as much as they wish, except if needed for clinical reasons. The intervention will be supported by the clinical team in keeping with routine care. The research therapist will attend clinical visits and support as required. The number of visits will be recorded, and will hopefully reduce to zero over the study.
41355386|NCT05690581|DRUG|CM369|Specified dose on specified days.
41495484|NCT00499421|PROCEDURE|Computed Tomography (CT) Scan|CT scan of the prostate three times a week, just before the delivery of radiation.
41495485|NCT00467935|DRUG|intravitreal injection Lucentis (ranibizumab)|intravitreal injection Lucentis (ranibizumab)
41495486|NCT00416702|DRUG|QAB149|
41509196|NCT01806571|DRUG|Nilotinib|Given PO
41509197|NCT01806571|OTHER|Pharmacological Study|Correlative studies
41509198|NCT04080544|DRUG|[18F]AV-1451|The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.
41355387|NCT03529162|PROCEDURE|Long head of Biceps Tenodesis|Patients will be randomized into two different groups to compare biceps tenodesis techniques
41355388|NCT00271362|BEHAVIORAL|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
41355389|NCT00271362|PROCEDURE|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
41355390|NCT01984359|OTHER|Obtaining Human tissue|
41355391|NCT05248776|DRUG|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
41355392|NCT05248776|DRUG|Placebo|Matching placebo tablet.
41355393|NCT00199368|DRUG|Istradefylline ( KW-6002)|
41355394|NCT01807494|DEVICE|Total hip replacement components|All patients will receive the same implants
40835578|NCT04202198|PROCEDURE|pinhole surgical technique only|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla followed by advancement of the flap. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
40835579|NCT03490149|DEVICE|Electroconvulsive Therapy|Series of electroconvulsive therapy for major depressive disorder
41355395|NCT06204003|DRUG|Cannabis/Hemp Isolate Extract|Formulation: CBD (99%; 0.1% THC isolate)
41355396|NCT02444611|DRUG|BCG Vaccine|intradermal vaccination
41160131|NCT02996097|DEVICE|The Lutronic electronic carbon dioxide (eCO2) Plus laser system|CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
40835580|NCT03490149|DRUG|Medication - Treatment as usual|Medication only sample - Treatment as usual
40835581|NCT02984059|GENETIC|Genomic DNA|blood draw
40835582|NCT02984059|GENETIC|RNA analysis|Mucosal Biopsy via colonoscopy
41355397|NCT02444611|DRUG|Hepatitis B Vaccine|intramuscular vaccination
41355398|NCT04079322|OTHER|Meal|Participants will consume a meal containing a stable iron isotope following exercise or rest.
41355399|NCT00045019|OTHER|quality-of-life assessment|QLQ-C30 SAT32
41495487|NCT02984085|DRUG|Genetically corrected cultured epidermal autograft (ATMP)|"Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent regeneration of a healthy, functional and renewing epidermis sustained by the engraftment of transduced epidermal stem cells.~By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery."
40835583|NCT02984059|GENETIC|Microbiome|Stool microbiome
40835584|NCT02984059|OTHER|Calprotectin|stool or blood analysis for calprotectin
40835585|NCT02984059|OTHER|Pain questionnaires|PSDS PCS-C/P PBI APPT
41160132|NCT02996097|DRUG|Intralesional Triamcinolone Acetonide|
41160133|NCT00692445|DRUG|TC-5214 + citalopram|TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
41495488|NCT01340326|DRUG|high dose of valsartan|comparison of different dosages of drug
41495489|NCT01340326|DRUG|usual dose of valsartan|comparison of different dosages of drug
41495490|NCT04941118|DRUG|Injection of dextrose, local anesthetic and saline to the myofascial trigger point|An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group from at least 10 trigger points.
41495491|NCT04941118|DRUG|Local anesthetic and saline injection to the myofascial trigger point|A total of 5 ml of solution created by using 4 ml of 0.9% saline and 1 ml of 2% local anesthetic (lidocaine) will be administered to the control group, with at least 10 trigger points.
41355400|NCT04027842|DEVICE|Prewarming|In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
41355401|NCT00050440|DRUG|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
41355402|NCT00050440|DRUG|Dexamethasone|Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
41495492|NCT01906892|OTHER|Group drumming (participatory)|Active participation in group drumming workshops
40835586|NCT02984059|OTHER|Anxiety/Depression Questionnaires|RCADS-25 CSI-24 ARCS
40835587|NCT05732961|DRUG|Luspatercept|Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
40835588|NCT03670784|OTHER|No intervention|No intervention, epidemiological investigation
40835589|NCT00000572|PROCEDURE|positive-pressure ventilation|Detailed computer protocol controlled positive pressure ventilation
40835590|NCT00000572|PROCEDURE|extracorporeal membrane oxygenation (CO2 removal)|Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
41160134|NCT00692445|DRUG|Placebo + citalopram|Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
41355403|NCT01678794|DRUG|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
41355404|NCT01678794|DRUG|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
41355405|NCT03639064|DRUG|Cannabis Oil|"Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil."
41355406|NCT01796795|DRUG|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
40835591|NCT04758520|DEVICE|FLOAT upper limb exoskeleton|The FLOAT device is composed by a wearable exoskeleton assembled on a poly-articulated arm that, in turn, is mounted on a support base with unlockable wheels. The exoskeleton includes 5 motors arranged in a way that, when generating movement, ensures the optimal involvement of all the articulations of the shoulder complex, particularly the glenohumeral and the scapulothoracic joints. According to the chosen modality of use of the exoskeleton, the device allows patient's passive or active-assisted mobilization. The poly-articulated arm supporting the exoskeleton is capable to compensate exoskeleton weight in every configuration and, if configured appropriately, permits exoskeleton use both in seated and standing positions. The support base of the device has unlockable wheels that, if unlocked, permit the free movement of the patient in the workspace, enabling the performance of more complex functional activities while assisted by the exoskeleton.
40835592|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
40835593|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
40835594|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
40835595|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
40835596|NCT04018313|BIOLOGICAL|US-licensed Xolair|150 mg/mL, Solution for injection in PFS
40835597|NCT02714881|DRUG|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
40835598|NCT02714881|RADIATION|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
40835599|NCT05291559|DIETARY_SUPPLEMENT|Enterade|Enterade is a glucose-free, amino acid-based medical food containing specific amino acids (aspartic acid, valine, serine, threonine and tyrosine) in addition to electrolytes and a non-sugar sweetener.
40835600|NCT05291559|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical product to Enterade except without added amino acids.
40835601|NCT02704611|DEVICE|Real tDCS|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
41355407|NCT01796795|DRUG|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
41355408|NCT01796795|DRUG|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
41355409|NCT01235767|OTHER|Food|Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
41355410|NCT01833299|PROCEDURE|TACE-Sorafenib group|"Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.~Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination."
41355411|NCT01833299|PROCEDURE|TACE|
41355412|NCT01230489|BIOLOGICAL|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
41495493|NCT01906892|OTHER|Group drumming (live)|Listening to live performances of group drumming
41495494|NCT01906892|OTHER|Group drumming (recorded)|Listening to recorded performances of group drumming
41495495|NCT01906892|OTHER|Comparative activity|Taking part in a literary-based activity
40835602|NCT02704611|DEVICE|Sham tDCS|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
40835603|NCT00388284|DEVICE|Arterial Sealing|
41355413|NCT06137235|OTHER|cows milk infant formula and follow-on formula with bioactive ingredients|infant formula and follow-on formula with bioactive ingredients
41355414|NCT06137235|OTHER|standard cows milk infant formula and follow-on formula|standard cows milk infant formula and follow-on formula
41495496|NCT02208986|DRUG|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
41509199|NCT04080544|PROCEDURE|Positron Emission Tomography|Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
41355415|NCT05290389|OTHER|SMART AMI APPLICATION|"SMART AMI allows real-time sharing and review of patient history and ECG between Emergency Department physicians and Interventional Cardiologists to allow for immediate decision-making regarding the need for percutaneous coronary intervention.~Participant physicians will use a smartphone application to communicate, transmit the ECG, and activate the STEMI team. This application enables calling and transmission of up to three images of ECGs, which can be reviewed immediately by the Interventional Cardiologist when communicating with the referring physician."
40835604|NCT03554135|OTHER|Personalization of palliative radiotherapy|Observe the rates of pain control and the need to retreat patient, when applied to personalization of indications and maximum technological support for palliative radiotherapy to patients with \< 6 months prognostic score attendance
41021454|NCT05546606|DEVICE|ECCO2R|ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.
41021455|NCT04899063|DEVICE|ELIOS Procedure|Treatment with the ELIOS System
41021456|NCT04436094|PROCEDURE|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
41021457|NCT04436094|PROCEDURE|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
40835605|NCT00214929|BEHAVIORAL|treatment at home|
40835606|NCT05302622|OTHER|There is no intervention planning|There is no intervention planning
40835607|NCT04118790|OTHER|Clinical Assessment|"1. Medical history and details of the vascular incident will be collected from the patient and the medical journal. (Duration: 1hr)~2. Neuropsychological measures collected using test measures and questionaries (duration approx 45-60 min)."
40835608|NCT04118790|PROCEDURE|MRI scan|1. MRI scan session, which includes Structural, Quantitative, Functional and Diffusion MRI sequences. (maximum duration: 90 min).
41021458|NCT00585897|BEHAVIORAL|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
41021459|NCT01112085|DRUG|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
41355416|NCT04087824|DEVICE|AI assisted recognition of colonic segments|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. The whole withdrawal process is monitored by AI associated recognition system. Key colonic segments include ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. When typical anatomic sites are detected, the AI device will automatically captured relevant images and report the name of each segment on the screen. The operating endoscopy expert will give the final answer and judge the performance of AI, which is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
41355417|NCT03244189|BEHAVIORAL|Fluid prescription|The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
41495497|NCT05789693|BEHAVIORAL|Physical activity changes|Previously an initial measure (qualitative and qualitative) will be made to know the little active adolescents. At the end of the physical activity program a retention measure will be carried out to know the scope and persistence of the variables analyzed. The intervention will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where there will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all.
41495498|NCT05546463|BEHAVIORAL|Digital games|"A digital game was played via iPad Air 2 32GB 9.7-inch wi-fi model tablet. The researcher created a folder with a range of selected games to appeal to different preferences. Children could choose from the following games: Word Travel, Talking Tom Candy Run, 384 Puzzles for Kids, Masha and The Bear, Subway Surfers, Head Ball 2 and Dream League Soccer."
41495499|NCT04483635|DIETARY_SUPPLEMENT|Placebo|Weekly oral dose of placebo
41495500|NCT04483635|DIETARY_SUPPLEMENT|Vitamin D|Weekly oral dose of Vitamin D
41495501|NCT05347381|DRUG|Selinexol and Dexamethasone|"Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;"
41021460|NCT01112085|DRUG|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
41021461|NCT00099476|BEHAVIORAL|Effects of dark chocolate|
41021462|NCT02556008|DRUG|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
41355418|NCT03244189|BEHAVIORAL|Financial incentive|Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
41355419|NCT03244189|BEHAVIORAL|Structured Problem Solving|Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
41355420|NCT02026193|PROCEDURE|oocyte vitrification|
41355421|NCT02026193|PROCEDURE|embryo freezing|
41021463|NCT00477711|DRUG|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
41021464|NCT04798586|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
41021465|NCT06571123|OTHER|İnteractive floor|Interactive floor The interactive floor system includes a computer, camera and projection. With the projection, videos that are ready on the computer are projected on the floor, image processing is done with the camera and it detects whether there is an object on the floor or not and creates effects on the video. For example, on the floor containing colored balloons, the balloons burst with the movement of the child. With this visual mobility, it is aimed to draw the child's attention to another direction.
41355422|NCT03459794|DRUG|Ivermectin|150 mcg/kg ivermectin, by mouth.
41355423|NCT03459794|OTHER|Placebo|An oral placebo will be administered, once
41355424|NCT04104893|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
41355425|NCT04098172|DEVICE|Pressure Guidewire|Fractional Flow Reserve measurement
41355426|NCT05156697|DIETARY_SUPPLEMENT|Capsinoids + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + supplementation with 12 mg of dihydrocapsiate (7 min before starting the aerobic exercise)
41355427|NCT05156697|OTHER|Placebo + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + placebo pills (7 min before starting the aerobic exercise)
41355428|NCT02959736|BEHAVIORAL|MATADOC and CRS-R|Behavioural assessments for Disorders of Consciousness
41355429|NCT04631757|DRUG|Camrelizumab + SOX + Radiotherapy|Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
41355430|NCT04586322|OTHER|No intervention, (observational study).|"From every participant the following information was recorded for further analysis:~* BEWE score- Basic erosive tooth wear examination (from 2 calibrated examiners) to diagnose the presence of erosive tooth wear.~* Their answer to a validated questionnaire assessing the dietary habits based in the frequency of acidic diet.~* 2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (in Volume loss per mm3) using Wearcompare software."
41355431|NCT01853397|DEVICE|Liposonix System (Model 2)|
41355432|NCT04864197|BIOLOGICAL|platelet rich fibrin|prf membrane placement over implant site for gingival thickening
41355433|NCT03637504|BEHAVIORAL|MedActionPlan®|web-based, mobile medication management application \[MedActionPlan® (MAP)\]
41355434|NCT02576171|BEHAVIORAL|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
41355435|NCT01294761|DRUG|Raltegravir, Darunavir/r|"An arm to change the regimen to: raltegravir and darunavir/ritonavir~Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID~from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD"
41355436|NCT03968523|PROCEDURE|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
41355437|NCT03968523|PROCEDURE|TAP block|TAP block technique
41355438|NCT04915209|OTHER|Narrative interviews|During the workshop, the participants will collectively create a common representation of the patient journey and co-design the envisioning care delivery model that support both social care and medical care.
41355439|NCT03944811|PROCEDURE|piezoelectric device|crestal approach will be used to augment the maxillary sinus with simultaneous implant placement
41355440|NCT03944811|PROCEDURE|Summers technique|Summers technique
41355441|NCT01211067|PROCEDURE|Lichtenstein hernioplasty|"* Mesh hernioplasty~* Ultrapro mesh (Ethicon, Johnson \& Johnson)"
41355442|NCT03606889|DIAGNOSTIC_TEST|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
41355443|NCT03606889|DIAGNOSTIC_TEST|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
41355444|NCT03606889|DRUG|Bupivacaine|0.2 ml/kg bupivicaine
41355445|NCT04736966|DRUG|Guselkumab 30mg|30mg of Guselkumab administered by subcutaneous injection
41355446|NCT04736966|DRUG|Guselkumab 70mg|70mg of Guselkumab administered by subcutaneous injection
41495502|NCT00619112|DRUG|temozolomide|single arm study
41495503|NCT05953090|DEVICE|7-0940|A non-hormonal and non-steroidal gel that supports vulvovaginal mucosal conditions and speeds up recovery post vaginal rejuvenation. It is a suitable alternative to vaginally administered estrogen and topical corticosteroids, that promotes a moist healing environment leading to faster re-epithelialization. The gel relieves symptoms such as itchiness, tenderness, dryness, burning sensation, painful intercourse (dyspareunia), painful urination (dysuria), rectal and defecating pain. It improves erythema, mucosal tissue thinning, erosions, fissures, ulcerations, scarring/adhesions and swelling. It is indicated for long-term use to maintain the health of the vaginal mucosa without the side effects of vaginally administered hormonal therapy and topical corticosteroids.
41355447|NCT04736966|DRUG|Guselkumab 100mg|100mg of Guselkumab administered by subcutaneous injection
41355448|NCT01077193|PROCEDURE|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
41495504|NCT02553083|DRUG|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
41495505|NCT02553083|DRUG|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
41495506|NCT02553083|DRUG|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
41495507|NCT02553083|DRUG|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
41495508|NCT02553083|DRUG|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
41355449|NCT01931020|DRUG|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
41355450|NCT01931020|DRUG|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
40835609|NCT03056963|BEHAVIORAL|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
40835610|NCT03056963|BEHAVIORAL|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
40835611|NCT03889210|OTHER|HVMN Ketone|Water-based, flavoured sport beverage
40835612|NCT03889210|OTHER|Placebo|Water, stevia, malic acid, and thickening agent
40835613|NCT00024011|DRUG|bortezomib|Given IV
40835614|NCT00024011|OTHER|laboratory biomarker analysis|Correlative studies
41355451|NCT02089191|DEVICE|Nelfilcon A contact lenses|
41355452|NCT02089191|DEVICE|Stenfilcon A contact lenses|
41355453|NCT06366035|DEVICE|LoVE4MUM mobile application|LoVE4MUM is an innovative mobile application developed based on cognitive behavioral therapy and psychoeducation. The mobile application consist of 5 main modules which delivers information pertaining self-care, postpartum depression, handling negative thoughts, mood tracking and information for seeking help. The module consist of short notes, videos and worksheets for the participants to conduct.
41355454|NCT03466528|DRUG|Magnesium Sulfate|Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes
41355455|NCT03466528|DRUG|Pabrinex|standard treatment
41355456|NCT03576456|DRUG|Alprazolam 0.5 mg|receive alprazolam prior to angio
41355457|NCT03576456|DRUG|Placebo Oral Tablet|receive placebo prior to angio
41355458|NCT00962780|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
40835615|NCT03506919|DRUG|Allopurinol|Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems
41021466|NCT05955560|DEVICE|PureWick Male External Catheter|The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.
41355459|NCT00962780|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
41355460|NCT00962780|PROCEDURE|Blood draw|Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
41355461|NCT00962780|PROCEDURE|Blood draw|1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
41355462|NCT01302535|OTHER|Yoga group with supervision (trainer)|The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.
41355463|NCT01302535|OTHER|Yoga at home|The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
40835616|NCT05440448|DEVICE|Patch-free occlusion therapy|Use of filters in glasses to provide occlusion therapy
40835617|NCT05440448|DEVICE|Adhesive patch|Standard-of-care occlusion therapy with an adhesive patch
40835618|NCT06282965|DRUG|Angiotensin (1-7)|The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.
40835619|NCT06282965|DRUG|Sterile saline|Sterile solution of 0.9% NaCl in water.
40835620|NCT03610139|DIETARY_SUPPLEMENT|Vitamin D3|At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
40835621|NCT05323071|OTHER|Sucrose 24%|"According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, \>37 weeks : 1 mL"
40835622|NCT01556321|DIETARY_SUPPLEMENT|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
40835623|NCT01556321|DIETARY_SUPPLEMENT|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule \[84.5 mg EGCG + 2.1 mg caffeine \], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
41355464|NCT01064622|DRUG|vismodegib|Given PO
41355465|NCT01064622|DRUG|gemcitabine hydrochloride|Given IV
41355466|NCT01064622|OTHER|hydrocortisone/placebo|Given PO
41355467|NCT05068726|DRUG|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
40835624|NCT04744012|PROCEDURE|Modified Periostal Pocket Flap Technique|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
41355468|NCT01143818|DRUG|AndroGel (testosterone gel) 1%|AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
41355469|NCT05254964|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hour on every working 20 days (4 weeks) during the subacute stroke phase
40835625|NCT01860898|OTHER|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
40835626|NCT03463395|DEVICE|Reza band|Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
40835627|NCT03851419|DIAGNOSTIC_TEST|Diagnosis of (Neuro)cysticercosis|"* Serological tests for cysticercosis~* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~* Stool testing for T. solium"
40835628|NCT02794389|DRUG|N-acetyl cysteine|
40835629|NCT02794389|DRUG|Placebo|
41160135|NCT03113214|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
41355470|NCT05849740|DRUG|Daratumumab and corticosteroid treatment|Daratumumab and corticosteroid treatment
41355471|NCT02443311|DRUG|Pimecrolimus 1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
41160136|NCT03113214|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
40835630|NCT06403878|DRUG|Carboplatin|neoadjuvant chemotherapy，2cycles.
41160137|NCT03113214|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
41160138|NCT03113214|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
41355472|NCT02443311|DRUG|Betamethasone 17-valerate 0.1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
41355473|NCT04901286|BEHAVIORAL|Exercise Only|Cycling in a lab environment
41355474|NCT04901286|BEHAVIORAL|Exercise + Non-Immersive Virtual Reality|Cycling with an environment simulated by non-immersive virtual reality
41355475|NCT04901286|BEHAVIORAL|Exercise + Immersive Virtual Reality|Cycling with an environment simulated by immersive virtual reality
41495509|NCT02553083|DRUG|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
41495510|NCT06048965|OTHER|No intervention to be performed|No intervention to be performed. Anonymous survey only.
41495511|NCT00003224|BIOLOGICAL|QS21|vaccine adjuvant
41495512|NCT00003224|BIOLOGICAL|IFA (incomplete Freund's adjuvant)|Peptides emulsified in IFA.
41495513|NCT00003224|BIOLOGICAL|p946|This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
41495514|NCT00003224|BIOLOGICAL|p946/tet-p|This peptide is a longer version of p946 (gp100 \[280-288\]) sythesized colinearly with the tetanus helper peptide (Tet-p)
40835631|NCT06403878|DRUG|Nab paclitaxel|neoadjuvant chemotherapy，2cycles.
40835632|NCT06403878|DRUG|Sintilimab|neoadjuvant immunotherapy，2cycles.
40835633|NCT00099060|DRUG|lapatinib ditosylate|"For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):~* Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).~* Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.~For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):~• Phase II: 750 mg GW572016 po b.i.d.~For all patients:~• Dose reductions as required based on adverse events."
41355476|NCT04810429|DRUG|Incobotulinumoxin A|"XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage. Xeomin is indicated for the symptomatic treatment of blepharospasm and hemifacial spasm, cervical dystonia of a predominantly rotational type (spasmodic torticollis), spasticity of the upper limbs and chronic sialorrhea due to neurological changes. Xeomin comes as a white powder for solution for injection. When dissolved Xeomin is a clear, colorless solution that does not contain particles. Xeomin is reconstituted before use with sterile sodium chloride 9 mg / ml (0.9%) solution, without preservatives, for injections.~The active substance is Clostridium botulinum type A neurotoxin (150 kD), without complexing proteins. The other components are human albumin and sucrose."
41355477|NCT04810429|PROCEDURE|TMJ surgical arthroscopy|TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.
41355478|NCT03049891|OTHER|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
41355479|NCT03049891|OTHER|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
41355480|NCT03049891|OTHER|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
41355481|NCT04450394|DRUG|LY3209590|Administered SC
41355482|NCT04450394|DRUG|Insulin Degludec|Administered SC
41021467|NCT05955560|DEVICE|Sage PrimoFit|The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.
41355483|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
41355484|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
41355485|NCT00068549|DRUG|Gemcitabine Hydrochloride|Given IV
41355486|NCT00068549|DRUG|Cisplatin|Given IV
41355487|NCT00068549|RADIATION|Radiation Therapy|Undergo whole pelvis radiotherapy
41355488|NCT00068549|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
41355489|NCT00307736|DRUG|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
41355490|NCT00307736|DRUG|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
41355491|NCT00307736|DRUG|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
41355492|NCT00307736|PROCEDURE|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
41355493|NCT01281592|DRUG|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
41355494|NCT04998344|BIOLOGICAL|Inactivated influenza vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
41355495|NCT04998344|BIOLOGICAL|Inactivated polio vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
41355496|NCT04770701|DRUG|Ahah Drug|"- Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
41355497|NCT04770701|DEVICE|Ahah Placebo|"- Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
41355498|NCT01738672|DRUG|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
41355499|NCT00959192|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
41355500|NCT00959192|OTHER|QS-21|IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
40835634|NCT04445376|OTHER|Physical Exercises|Aerobic Training and Breathing Exercises.
40835635|NCT03532217|BIOLOGICAL|PROSTVAC-V|-Replication-competent vaccinia virus which has been engineered to encode the sequences for a modified human prostate-specific antigen (PSA) and a triad of co-stimulatory molecules (TRICOM)
40835636|NCT03532217|BIOLOGICAL|PROSTVAC-F|-Fowlpox virus which does not replicate in human cells and has been engineered to encode the same sequences present in PROSTVAC-V.
41021468|NCT01747681|PROCEDURE|Microfracture|
41021469|NCT03111992|DRUG|PDR001|Anti-PD1 antibody
41021470|NCT03111992|DRUG|CJM112|Anti-IL-17A antibody
41355501|NCT00959192|OTHER|QS-21|IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
41355502|NCT02094339|PROCEDURE|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
41355503|NCT02094339|PROCEDURE|Nerve Block|Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
41355504|NCT02094339|PROCEDURE|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
41495515|NCT00003224|BIOLOGICAL|Tet-p|modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
41495516|NCT03908515|DEVICE|Foldable Capsular Vitreous Body (FCVB)|FCVB can be regarded as an artificial vitreous and consists of a thin vitreous-shaped capsule, a drain tube, and a valve. After foldable implantation into the eye, then silicone oil is injected into the capsule which inflated to support the retina. The capsular material of FCVB is silicone rubber. The capsule was fabricated a computer simulation of the human and rabbit vitreous cavities. The control of the intraocular pressure is achieved with adjusting the amount of injected medium through the tube-valve system. After the medium was injected into the capsule through the tube-valve system, the valve was subsequently fixed onto the sclera surface similar to the glaucoma valve.
41495517|NCT00300508|DRUG|Anastrozole|
41495518|NCT02546401|DRUG|Insulin Aspart|Injection of Insulin Aspart before or after meals
41495519|NCT02029586|DRUG|MB12066 200mg|oral administration, 100mg bid
41495520|NCT02029586|DRUG|Placebo|oral administration, 100mg bid
41495521|NCT00164151|DRUG|HalfLytely|
41495522|NCT00164151|DRUG|Visicol|
41495523|NCT05439876|DRUG|Melatonin|Melatonin 2 mg daily for 4 weeks
40835637|NCT03532217|DRUG|Nivolumab|-Nivolumab is a human monoclonal antibody (mAb)
41355505|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
40835638|NCT03532217|DRUG|Ipilimumab|-Ipilimumab is a mAb blocking the inhibitory signal mediated by cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that downregulates the immune system.
41355506|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
41355507|NCT02094339|DRUG|opioid|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
41355508|NCT02727452|OTHER|Skin-to-skin contact|
40835639|NCT03532217|BIOLOGICAL|Neoantigen DNA vaccine|Each DNA vaccination will be 1 mL vaccine administered intramuscularly. At each vaccination time point, patients will receive two injections at separate sites.
41355509|NCT05200468|OTHER|Ketogenic diet|Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
41355510|NCT05200468|OTHER|Caloric restriction diet|Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
41355511|NCT05200468|OTHER|Intermittent fasting 16/8|Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
41355512|NCT01985035|BEHAVIORAL|Diet|Reduction of energy intake in order to weight loss
41355513|NCT01683058|DRUG|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
41355514|NCT04354701|OTHER|Web-based REDCap survey|The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
41495524|NCT05439876|DRUG|Placebo|Placebo daily for 4 weeks
41495525|NCT04053049|OTHER|Diet|Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
41495526|NCT04317183|DRUG|chamomile topical oral gel|Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.
41495527|NCT04317183|DRUG|Miconazole Topical Gel|topical anti fungal agent
41495528|NCT04317183|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
40835640|NCT03532217|DEVICE|TriGrid Delivery System|-Electroporation device
40835641|NCT03532217|PROCEDURE|Tumor biopsy|-Pre-treatment, post-treatment A (optional), and end of treatment
41495529|NCT04317183|DRUG|Oracure gel|Topical analgesic gel
41495530|NCT04619095|DIETARY_SUPPLEMENT|Psyllium|See the information already included in the arm descriptions.
41495531|NCT04619095|DIETARY_SUPPLEMENT|Placebo|See the information already included in the arm descriptions.
41495532|NCT03321838|BEHAVIORAL|accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
41495533|NCT05919316|DEVICE|Rhinophototherapy|Intranasal rhinophotometer to be used at home for 4.5 minutes three times daily for 14 days
41495534|NCT05919316|DRUG|Nasonex Nasal Spray|50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
41021471|NCT03111992|DRUG|LCL161|Oral small molecule SMAC-mimetic
41495535|NCT04186351|BEHAVIORAL|Encounter notification service|The caring support and services provided by SCHSA will consist of multiple components, including standard call \& care center support, medical appointment reminder, assistance to reschedule appointment, follow-up calls with either nurse or health workers to monitor health situation of service recipients, assessing needs of service recipient for elderly home care and/or rehabilitation services, providing elderly home care and/or rehabilitation services based on assessment, assessing needs of service recipient for emotional and community support, providing additional emotional support via either social calls by volunteers or counseling by social workers, and making referrals for community support services.
41495536|NCT03885479|DIAGNOSTIC_TEST|ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
40835642|NCT03532217|PROCEDURE|Peripheral blood|-At the time of pre-treatment biopsy, mid-treatment of chemo-ADT, at time of enrollment (prior to POSTVAC administration), mid-treatment A, mid-treatment B (multiple)
40835643|NCT03532217|PROCEDURE|Fecal samples|-Post chemo/pre-treatment A, post-treatment A, pre-treatment B, post-treatment B
40835644|NCT03532217|PROCEDURE|Leukapheresis|"* Post-treatment A/pre-treatment B~* Mid-Treatment B, after Cycle 9 Day 1 and prior to Cycle 10 Day 1~* End of treatment"
40835645|NCT05449275|OTHER|Faradic current|The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.
40835646|NCT05449275|OTHER|Ankle foot orthosis|AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
40835647|NCT01848470|DRUG|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
40835648|NCT01848470|DRUG|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
40835649|NCT01848470|DRUG|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
40835650|NCT01848470|DRUG|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
40835651|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
40835652|NCT01848470|DRUG|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
40835653|NCT01848470|DRUG|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
40835654|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
40835655|NCT00299780|DRUG|Stem cell mobilization|
40835656|NCT03968783|OTHER|Monofilament suture|1.0 monofilament synthetic absorbable suture for closure of the low transverse uterine incision
40835657|NCT03968783|OTHER|Multifilament suture|1.0 multifilament synthetic absorbable suture for closure of the low transverse uterine incision
40835658|NCT03601559|DIETARY_SUPPLEMENT|Lactobacillus paracasei Lpc-37|Live probiotic bacteria
40835659|NCT03601559|DIETARY_SUPPLEMENT|Placebo|Inert placebo matched for taste and appearance
41355515|NCT03481296|BEHAVIORAL|Advanced Control|Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.
40835660|NCT02089113|DRUG|Dexamethasone|
40835661|NCT02089113|PROCEDURE|Placebo Vehicle|
40835662|NCT06036953|DEVICE|electrical muscle stimulation|The electric muscle stimulator (EMS) used in this study was from Funcare (Funcare Co., Ltd, Taichung, Taiwan). EMS electrodes were attached to the biceps of both hands, the abdomen, and the quadriceps of both legs sequentially. Each part was stimulated once a day for 30 minutes.
40835663|NCT04221191|DRUG|Dimethyl Fumarate|DMF as prescribed as standard of care.
40835664|NCT04221191|OTHER|PSP|PSPs is to support patient care.
40835665|NCT00864851|BIOLOGICAL|Replagal|Intravenous (IV) infusion for 12 months
40835666|NCT02763436|PROCEDURE|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
40835667|NCT01855152|OTHER|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
40835668|NCT01855152|OTHER|Treatment as usual|Treatment delivered as usual in the care home
41355516|NCT03481296|BEHAVIORAL|Culturally-Adapted Decision Support Navigation Intervention|Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
41021472|NCT06296342|BEHAVIORAL|Exposure to information framing message|The information framing message presents the objective of the front-of-package labeling policy as providing nutritional information.
41495537|NCT01751932|DEVICE|CGM Monitoring|All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
41495538|NCT00872482|DRUG|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
41021473|NCT06296342|BEHAVIORAL|Exposure to healthier choices framing message|The healthier choices framing message presents the objective of the front-of-package labeling policy as encouraging consumers to make healthier choices.
41021474|NCT06296342|BEHAVIORAL|Exposure to industry framing message|The industry framing message presents the objective of the front-of-package labeling policy as encouraging the food industry to make healthier products.
41355517|NCT03797391|DRUG|EMB-01|"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met."
41355518|NCT06358261|BEHAVIORAL|Diabetes Prevention Patient Activation Clinical Decision Support Tool|Diabetes Prevention Patient Activation Clinical Decision Support Tool will be used by the doctor during the visit to discuss lifestyle management
41355519|NCT00006025|DRUG|irinotecan hydrochloride|
41355520|NCT00006025|DRUG|temozolomide|
41355521|NCT02943577|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
41355522|NCT02943577|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
41355523|NCT03140150|DEVICE|Follow-up by Carelink express|Followed by the cardiologist exclusively using Carelink Express during the study period: a single visit 1 to 3 months after implantation, then followed by the cardiologist and interrogation of the stimulator by Carelink Express
41355524|NCT03140150|OTHER|Follow-up according to the usual recommendations|According to follow-up recommendations for pacemakers, a visit is planned every 6 months if the patient is dependent on the stimulator (either visits to M6, M12, M18 and M24) or annually if the patient is not dependent on the stimulator (visits to M12 and M24).
41355525|NCT04858516|DRUG|palbociclib and exemestane plus trastuzumab and pyrotinib|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib in ER-positive, HER2-positive breast cancer
41355526|NCT03459105|PROCEDURE|Ultrasound-assisted paramedian spinal anesthesia|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
41355527|NCT03459105|PROCEDURE|Landmark-guided spinal anesthesia|Spinal anesthesia will be done using conventional landmark-guided technique.
41355528|NCT03459105|DRUG|0.5% heavy bupivacaine|0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
41355529|NCT03962127|OTHER|no intervention|no intervention
41355530|NCT03433391|DEVICE|Oxiplex|Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.
41355531|NCT03433391|OTHER|Surgery Only|Single level partial discectomy as per standard of care procedures.
41495539|NCT02141425|DRUG|ASP015K|oral
41355532|NCT04906733|PROCEDURE|Tumor biopsy|Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.
41495540|NCT02141425|DRUG|Placebo|oral
41160139|NCT03113214|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
41160140|NCT03113214|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
41160141|NCT01961453|DRUG|Isosorbide Mononitrate, sustained release|60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
41355533|NCT03132038|DRUG|Nivolumab|3 mg/kg, every two weeks, during a maximum of one year
41355534|NCT06154460|PROCEDURE|Laterjet Surgery|The laterjet procedure is an operation in which the coracoid process is transferred to the glenoid rim with a screw.
41355535|NCT06154460|PROCEDURE|Reimplissage Surgery|"Reimplissagge operation, which means to fill, is an open procedure designed to limit the engagement of Hill-Sachs deformity by passing the infraspinatus into the Hill-Sachs defect."
41355536|NCT06154460|PROCEDURE|Capsular Reconstruction|Allografts or autografts are used for capsular reconstruction. In the procedure performed with capsular repair and grafts, the capsule is strengthened and stabilization is attempted
41355537|NCT02599740|OTHER|Natural fruit extract|Natural fruit extract consumed with rice
41495541|NCT03869086|OTHER|Freeze dried blueberry powder|36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
41495542|NCT03869086|OTHER|Anthocyanin free, sugar-matched placebo|36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.
41509200|NCT03543215|OTHER|Radiomics: Analysis of textural features of imaging (MRI and Ultrasound)|All patients with confirmed endometrial cancer will have received Ultrasound and MRI as part of routine standard of care. Textural features from this will be analysed to see if can predict prognosis.
40835669|NCT05086510|PROCEDURE|Radiofrequency ablation|Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.
41355538|NCT02599740|OTHER|Assumed active|Assumed key active consumed with rice
41495543|NCT05193643|DEVICE|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue within the focal area. The process is then repeated in a stepwise fashion to destroy the targeted tissues.
41495544|NCT06041152|DRUG|Psilocybin|2 macrodoses of 25mg separated by one week.
41495545|NCT06041152|DRUG|Placebo|2 doses of placebo separated by one week.
40835670|NCT04187742|BEHAVIORAL|Social Comparison Email vs. Standard Email|Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
40835671|NCT04187742|BEHAVIORAL|Maintenance Certification Email vs. Standard Email|Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
40835672|NCT04187742|BEHAVIORAL|Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)|Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
41021475|NCT04135131|OTHER|pilates mat exercises and home exercises|Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
41355539|NCT02599740|OTHER|Placebo|Rice only
41355540|NCT00040911|PROCEDURE|electroacupuncture therapy|
41355541|NCT00040911|PROCEDURE|sham intervention|Undergo electroacupuncture therapy to sham points
41355542|NCT00040911|PROCEDURE|quality-of-life assessment|Ancillary studies
41355543|NCT05314530|BEHAVIORAL|ReTA-model|Validating the rehabilitation model ReTA
41355544|NCT03928990|DEVICE|ActiGraph accelerometer|ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
41355545|NCT00138892|PROCEDURE|Waiting time (access time to Total joint replacement)|See Detailed Description.
41355546|NCT01492660|DEVICE|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
41495546|NCT00399256|DRUG|Acetylcysteine|
41495547|NCT00399256|DRUG|Zinc|
41495548|NCT02116608|DRUG|Betadine|Apply locally as needed.
41495549|NCT02116608|DRUG|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
41495550|NCT02116608|DRUG|Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
40835673|NCT03817294|OTHER|Comparison of exercise training modalities|As above
41495551|NCT03043976|DEVICE|Actigraph GT9X Link device|"Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased"
41495552|NCT06426615|DEVICE|Intracranial electrodes|Placement of intracranial electrodes in the cortico-subcortical system
41495553|NCT04286711|DRUG|Albumin-paclitaxel, Apatinib, Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8, Repeat the therapeutic schedule every 3 weeks; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day, Q3W;
40835674|NCT05320198|DRUG|DISC-0974|DISC-0974 is administered subcutaneously.
41355547|NCT01492660|DEVICE|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
41355548|NCT01497899|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
41355549|NCT01497899|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
41355550|NCT01497899|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
41355551|NCT01497899|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
41355552|NCT04851769|DRUG|PCSK9 inhibitor plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
41355553|NCT04851769|DRUG|standard statin therapy|Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
41355554|NCT04851769|PROCEDURE|Coronary imaging follow-up|coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
41355555|NCT02469506|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
41495554|NCT02996214|DRUG|Paclitaxel Liposome|Paclitaxel liposome injection 175 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
40835675|NCT04557787|DEVICE|SpeediCath® Standard female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.
40835676|NCT04557787|DEVICE|New intermittent Variant 1 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
41021476|NCT04362358|BEHAVIORAL|Online cognitive behavioral therapy (CBT)|7 sessions of Cognitive Behavioural Therapy (CBT) online + possibility to contact the psychological hotline
41021477|NCT04362358|BEHAVIORAL|Online bibliotherapy programme|online bibliotherapy programme on the Ma Santé website Also with explanatory sheets and tools to improve stress management and the possibility of contacting the Psychological Hotline
41021478|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
41021479|NCT03834194|BEHAVIORAL|Lottery + Overall Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
41021480|NCT03834194|BEHAVIORAL|Lottery + Overall Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
41021481|NCT03834194|BEHAVIORAL|Loss + Overall Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
41021482|NCT03834194|BEHAVIORAL|Loss + Overall Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
41021483|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
40835677|NCT04557787|DEVICE|New intermittent Variant 2 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
40835678|NCT01595191|OTHER|Bach music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
40835679|NCT01595191|OTHER|Mozart music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
40835680|NCT01595581|DRUG|Testosterone|8 weeks of testosterone administration beginning 2 weeks before ACL surgery
40835681|NCT01595581|DRUG|Placebo|8 weeks of saline administration beginning 2 weeks before ACL surgery
41160142|NCT01961453|DRUG|Placebo capsule|One capsule of placebo administered once daily at 8 am.
40835682|NCT02476474|PROCEDURE|3 cm start of resection|Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
40835683|NCT02476474|PROCEDURE|6 cm start of resection|Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
40835684|NCT04730427|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
40835685|NCT04730427|DRUG|GX-I7 vehicle|Formulation buffer of recombinant human interleukin-7 hybrid Fc
40835686|NCT05970094|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
40835687|NCT03675542|DRUG|CUDC-305|Dose-selection treatment with HSP90 inhibitor (CUDU-305)
40835688|NCT03468972|DRUG|Immunosuppressive treatment|At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria \< 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
40835689|NCT03468972|OTHER|intensive supportive care|During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of \<130/80 mmHg, and protein restriction diet. If proteinuria does not decrease \< 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids.
40835690|NCT05004974|DRUG|Sintilimab|Sintilimab is administered every 3 weeks (200mg, IV).
40835691|NCT05004974|DRUG|Pemigatinib|Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
40835692|NCT04536038|BEHAVIORAL|Opt-out|A study coordinator will call the patient unless they opt-out. See arm description for more details.
40835693|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
40835694|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 alone
40835695|NCT06252441|DRUG|Rectal Diclofenac|100 mg Rectal Diclofenac Before ERCP
41021484|NCT03834194|BEHAVIORAL|Loss + Monthly Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
41021485|NCT03834194|BEHAVIORAL|Loss + Monthly Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
41355556|NCT06282081|DIAGNOSTIC_TEST|Serum Neurofilament Light|The purpose of this research is to investigate a biomarker, called serum neurofilament light (sNfL), which is measured in blood. This study will attempt to investigate whether or not sNfL is a useful tool for clinicians in patients diagnosed with relapsing remitting multiple sclerosis.
41355557|NCT04791241|OTHER|check-list including lung ultrasound|"The investigator will follow the checklist which includes the collection of anamnestic data and clinical signs, the performance of a pulmonary embolism clinical probability score and a cardiopulmonary ultrasound with count -standardized rendering. After completing this checklist, the investigator will note their diagnosis (list of proposals on the data collection sheet), the treatments started (closed list of therapeutic classes). If he orders other tests, he will write them down and then note the diagnosis made and the treatments prescribed after obtaining the results of these tests.~The therapeutic management of patients compared to the usual care in the respective departments may be modified depending on the results of the cardiopulmonary ultrasound . The emergency physician may initiate therapy before the results of additional examinations that he would have usually performed without cardiopulmonary ultrasound."
41355558|NCT04130854|DRUG|APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days|"1. APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX~2. Short course radiation therapy 5 Gy x 5 days~3. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~4. Leucovorin 400mg/m2 IV Day 1 of each cycle~5. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
41355559|NCT04130854|DRUG|mFOLFOX and Radiation Therapy 5Gy x 5 days|"1. Short course radiation therapy 5 Gy x 5 days~2. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~3. Leucovorin 400mg/m2 IV Day 1 of each cycle~4. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
41355560|NCT03732040|OTHER|miswak stick|miswak stick use as preventive hygiene measures
41355561|NCT03732040|OTHER|Miswak plus tooth brushing and tooth paste|use of miswak stick with tooth brushing and fluoride toothpaste for oral hygiene measures
41495555|NCT02996214|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.
41495556|NCT02996214|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
41495557|NCT02552056|OTHER|CAMH training|Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
41495558|NCT04158388|OTHER|Mediterranean-diet enriched with a higher dose of tryptophan and magnesium|That gruop eaten at both breakfast and dinner from walnuts (3-5 units), as food with high values of tryptophan and magnesium
40835696|NCT06252441|DRUG|Oral N-acetyl cysteine|1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
40835697|NCT04308551|DRUG|Indobufen|Indobufen Tablets
40835698|NCT04308551|DRUG|Aspirin|Aspirin Tablets
40835699|NCT04148612|DIAGNOSTIC_TEST|Opti-Me|Opti-Me algorithm provides the likelihood of response to the 3 treatment options: SSRIs, SNRIs or TMS in MDD patients.
40835700|NCT00766246|DRUG|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
40835701|NCT00766246|DRUG|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
40835702|NCT00766246|DRUG|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
41160143|NCT04723888|DIETARY_SUPPLEMENT|alpha-ketoglutarate|alpha-ketoglutarate supplements
41160144|NCT00020709|DRUG|cisplatin|Given IV
41160145|NCT00020709|DRUG|docetaxel|Given IV
41160146|NCT00020709|DRUG|etoposide|Given IV
41160147|NCT00020709|DRUG|gefitinib|Given orally
41355562|NCT03732040|OTHER|Standard preventive measures (tooth brushing , interdental cleaning and mouth rinse use containing CHX and Fluoride)|use toothbrush with fluoride toothpaste and interdental cleaning by dental flossing and use mouth wash containing chlorohexadine
41355563|NCT04744311|OTHER|ObsQoR-11T Questionnaire|The ObsQoR-11T questionnaire consists of 11 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
41355564|NCT03164031|DEVICE|Close-fitting orthotic shorts|The orthotic shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. They will provide both pairs of shorts for each participant, both constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the compression and fit of the shorts, such as whether support for the lower trunk is required. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
41355565|NCT03164031|DEVICE|Looser fitting shorts|Looser fitting shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. Shorts will be constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the fit of the shorts. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
41355566|NCT06371989|PROCEDURE|Image guided vacuum assisted biopsy|Image guided VAB of tumor site. A needle is inserted into the affected tumor bed area using an US or stereotactic method to collect cells or tissue from a tumor mass.
41355567|NCT03472339|DRUG|Diclofenac Sodium|Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
41355568|NCT03397095|COMBINATION_PRODUCT|CSWT+BMMSCs|All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.
41355569|NCT03397095|DEVICE|CSWT+Sham operation|Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
41355570|NCT00992706|DRUG|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
41355571|NCT00992706|DRUG|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
41355572|NCT02394028|DRUG|Etrolizumab|Etrolizumab will be administered as per regimen specified in individual arms.
41355573|NCT02394028|DRUG|Placebo|Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
41355574|NCT00925522|DEVICE|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
41355575|NCT04247724|BEHAVIORAL|Recreational handball|
41355576|NCT04247724|BEHAVIORAL|Control|
41355577|NCT06095999|BEHAVIORAL|Perfect Fit intervention: virtual coaching intervention to quit smoking and increase physical activity|The intervention, delivered through a virtual coach, has a personalized duration and intensity, but will last on average 16 weeks. The intervention has three phases: preparation, execution (including \[re\]lapse) and closing. By having chat conversations with the Perfect Fit virtual coach (using the mobile application 'NiceDay'), the user will be guided through the different phases of the intervention. In each phase, the user has chat conversations with the virtual coach (e.g. about goal setting, weekly reflection) and, in addition, receives exercises and educational video material to support smoking cessation and PA promotion. Additionally, a smartwatch is used to objectively assess PA. It allows participants to monitor their PA and the data (on the number of steps) is used to give automatic, personalized PA advice to the user.
41355578|NCT06430736|DRUG|Tocilizumab before CAR-T cell infusion|"Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, with completion of the infusion 1 hour prior to infusion of CAR-T cells.~Treatment of eventual subsequent CRS/ICANS will be identical as in patients in the standard arm."
41355579|NCT06430736|DRUG|Tocilizumab at emerging CRS|Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS.
41355580|NCT03698370|DRUG|Gallium Ga 68 DOTA-NeoBOMB1|Administered intravenously (IV)
41160148|NCT00020709|RADIATION|radiation therapy|Undergo radiation therapy
41160149|NCT00020709|OTHER|placebo|Given orally
41355581|NCT03698370|DEVICE|Gallium Ga 68 PSMA-R2|Administered intravenously (IV)
41355582|NCT05910489|OTHER|Biomonitoring of MNPLs in biological samples of greenhouse workers and controls|Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces
41355583|NCT00997906|DRUG|carboplatin,|Given IV
41355584|NCT00997906|DRUG|cisplatin|Given IV
41355585|NCT00997906|DRUG|gemcitabine hydrochloride|Given IV
41355586|NCT00997906|DRUG|paclitaxel|Given IV
40835703|NCT04118907|DEVICE|multiple sensory stimulation|The patients were recruited to record their medical history, and the hearing level, tinnitus indicators, vestibular function and tinnitus disability indicators were tested. Then the patients were randomly divided into six groups. They received the corresponding stimulation 20 minutes a day, 5 days a week for 3 weeks. After the last stimulation, the above tests were repeated immediately, one week later and three months later.
40835704|NCT00012363|DRUG|gemcitabine hydrochloride|1,000mg/m2, IV over 30 min, days 1 \& 8, q 21 days
40835705|NCT00012363|DRUG|irinotecan hydrochloride|100 mg/m2, IV over 90 min, days 1 \& 8, q 21days
40835706|NCT06232551|OTHER|EHR (electronic health record) alert|Pop-up alert that informs the discharging clinician that the patient meets criteria to be considered for extended duration thromboprophylaxis
41355587|NCT00997906|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
40835707|NCT06232551|OTHER|No EHR (electronic health record) alert|During the baseline phase while risk is assessed and stored, no alerting occurs
40835708|NCT05991765|OTHER|Digit Tip Wound|Digit Tip Wound Exudate Sample Collected while Dressing Change
40835709|NCT05991765|OTHER|Split Skin Donor Site Wound|Split Skin Donor Site Wound Exudate Sample while Dressing Change
40835710|NCT01359462|DRUG|tolvaptan|"Drug: tolvaptan~tablet, 15mg, Qd, for 7 days."
40835711|NCT05570890|DEVICE|electrical noise stimulation|The intensity of electrical noise stimulation will be set at 90% of the sensory threshold of each participant.
40835712|NCT05570890|DEVICE|Sham stimulation|Participants will not receive stimulation.
40835713|NCT05570890|DEVICE|Foam|The foam will be used to make an unstable surface.
40835714|NCT03032445|OTHER|Alcoholic Beer|Subject will be asked to consume alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
40835715|NCT03032445|OTHER|Non alcoholic beer|Subject will be asked to consume non alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
41355588|NCT03812224|DRUG|Erenumab|Administered by subcutaneous injection once a month
40835716|NCT02917720|OTHER|TKI discontinuation|2nd or 3rd TKI stop after pre-treatment with nilotinib.
40835717|NCT02917720|DRUG|nilotinib|Pre-treatment with nilotinib 300 mg/bid for 2 years
40835718|NCT03765203|DIAGNOSTIC_TEST|Natera KidneyScan|Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients
40835719|NCT03765203|OTHER|Clinical Performance and Value Vignettes|Online renal allograft simulated patients
40835720|NCT03434314|PROCEDURE|Minimally-Invasive Segmental Artery Coil-Embolization|During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.
40835721|NCT04713033|DIAGNOSTIC_TEST|surface electromyogram (sEMG)|A device that measures electrical signals from your skin will be connected to those stickers and will make a graph that is characteristic to your vocal function.
40835722|NCT04713033|DIAGNOSTIC_TEST|flexible laryngoscopy|"A device that examines the throat and nasal passages. The flexible laryngoscope or scope consists of an eyepiece and a fiber-optic light enclosed in a thin, flexible tube. The scope looks like a strand of black spaghetti with a tiny light on the end of it. The scope is inserted through the nose, and can be moved around to help the doctor see all areas of the nasal passages and throat."
40835723|NCT03463954|DEVICE|Novilase Laser ablation|Image-guided, percutaneous laser ablation of breast tumors
40835724|NCT00544622|PROCEDURE|structured therapeutic chain of stroke treatment|
41355589|NCT03812224|DRUG|Placebo|Administered by subcutaneous injection once a month
41355590|NCT02436915|OTHER|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
41495559|NCT04158388|OTHER|Isocaloric diet|That group eaten isocaloric diet plan based on Mediterranean diet.
41495560|NCT04158388|OTHER|Manual therapy|That group received moderate pressure digital manual therapy.
41495561|NCT04158388|OTHER|Placebo therapy|That group was treated with a US (in off mode) without conductive gel.
41495562|NCT00044967|GENETIC|microsatellite instability analysis|
40835725|NCT05477199|OTHER|Cognitive behavioral principles-based treatment program|The treatment protocol had a total duration of 6 weeks. Two sessions were conducted each week, the first being a group session lasting 1.5 hours and the second an individual session lasting 45 minutes. During the group sessions, emotional disclosure and sharing of the experiences of patients with post COVID-19 syndrome were encouraged. During the individual sessions, a strong relationship was developed between the patient and the healthcare professional, with the healthcare professional helping the patient develop self-efficacy, thought monitoring, helpful self-talk, and reflection on changes in activity levels throughout the program.
41160150|NCT02508779|BEHAVIORAL|Bump2be|Bump2be is an internet intervention focusing on six topics (called cores) psycho-educational in nature with the goals of improving individuals' ability to: a) anticipate extreme BG levels, b) detect the presence of extreme BG levels, c) address current extreme BG levels, and d) prevent future extreme BG levels. The program includes didactic information, self-assessment tools, and active learning exercises.
40835726|NCT05477199|OTHER|Control intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
40835727|NCT02636946|DRUG|Bimatoprost SR|Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
40835728|NCT02636946|DRUG|Sham Bimatoprost SR|Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
40835729|NCT02636946|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
40835730|NCT02636946|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
40835731|NCT00513396|DRUG|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
40835732|NCT00513396|DRUG|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
40835733|NCT03697044|PROCEDURE|Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation|Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.
40835734|NCT02418988|DRUG|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
40835735|NCT02418988|DRUG|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
40835736|NCT03490604|DEVICE|wrist-worn accelerometer|accelerometer worn on the patient's wrist, changed every 15 ± 7 days for 6 months when the patient comes for a chemotherapy session
40835737|NCT03490604|OTHER|Auto-questionnaires|Questionnaire regarding physical activity over the previous 7 days, questionnaires EORTC QLQ-C30 and EORTC QLQ-PAN26
40835738|NCT06547892|DRUG|Vasopressin|"To dilute vasopressin, an ampoule containing 20 IU/ml (1 ml) of vasopressin will be used, which will be mixed with 100 ml of 0.9% physiological solution, resulting in a solution with a concentration of 0.2 IU/ ml. In this study, both central and peripheral vein infusion will be permitted.~The vasopressin administration protocol will consist of an initial dose of 0.02 IU/min (equivalent to 6 ml/h), which can be increased to 0.03 IU/min (9 ml/h) if the mean arterial pressure (MAP) is less than or equal to 65 mmHg. On the other hand, if MAP exceeds 90 mmHg, the dose can be reduced to 0.01 IU/min (3 ml/h). The minimum period for adjusting the drug dosage should be one hour."
40835739|NCT06547892|OTHER|0,9% saline solution|Similar to the intervention protocol, but using a placebo composed of 0.9% saline solution.
40835740|NCT05933629|BEHAVIORAL|Online EmReg|A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop
40835741|NCT05933629|BEHAVIORAL|Consultation Sessions|3 months of bi-weekly consultation sessions
41160151|NCT02508779|OTHER|Routine Care|Participants will continue to receive care from their clinician.
41160152|NCT04044352|BIOLOGICAL|Influenza A/Bethesda/MM2/H1N1 Challenge|Reverse-genetics derived live A/California/04/2009/H1N1-like influenza virus passaged six times in Vero cells.
41160153|NCT04473118|OTHER|Survey|An online-based questionnaire sent to participants via email
41160154|NCT02997397|PROCEDURE|tourniquet(+)|A novel atraumatic tourniquet technique, applied via placing a vascular clamp widely on both the infundibulopelvic ligament and uterine arteries.
41160155|NCT02997397|PROCEDURE|tourniquet(-)|
41355591|NCT02436915|OTHER|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
41495563|NCT01557738|DIETARY_SUPPLEMENT|High Flavanol Trial|The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
40835742|NCT04634942|DEVICE|Cryos REF 0971 Cold Spray|Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
40835743|NCT04634942|DEVICE|ShotBlocker BIONIX Press Firmly USA|ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
40835744|NCT01634529|DRUG|V158866|Single ascending oral doses of V158866 and Placebo
40835745|NCT01634529|DRUG|V158866|Multiple ascending oral doses of V158866 and Placebo
40835746|NCT04663334|OTHER|inverse myocardial remodeling|a myocardial reverse remodeling is described, generating a decrease in hypertrophy, interstitial oedema, and inflammation. Its effect on coronary microcirculatory reserve is not known. Some studies have shown improvement in coronary reserve immediately after TAVI and this effect seemed to last long after treatment
40835747|NCT05314933|DRUG|2-Deoxyglucose|Intranasal administration
40835748|NCT05314933|OTHER|Placebo|Intranasal administration
41021486|NCT05205772|DEVICE|transcranial magnetic stimulation|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. This device is FDA approved for treatment of depression and other neuropsychiatric disorders, and is regularly used in neurologic and psychiatric research.~iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes."
40835749|NCT05219669|DRUG|Nalmefene Hydrochloride|30 mg/mL solution
40835750|NCT00748709|DRUG|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
40835751|NCT01333995|BEHAVIORAL|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
40835752|NCT01194622|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
40835753|NCT01194622|DRUG|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
40835754|NCT01194622|DRUG|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
40835755|NCT00689754|PROCEDURE|nasogastric tube placement|standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
40835756|NCT04191785|DIAGNOSTIC_TEST|plasmatic NGAl and MRI|Determination of plasma NGAL protein during routine blood test Realization of a reno vesical MRI at 48 hours of inclusion
41021487|NCT02461589|DRUG|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
41021488|NCT02461589|DRUG|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
41021489|NCT02461589|DRUG|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
41355592|NCT01643889|DRUG|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
41355593|NCT01643889|DRUG|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
40835757|NCT01487993|DRUG|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
41021490|NCT03587259|DIAGNOSTIC_TEST|Tomosynthesis|DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
40835758|NCT01487993|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
41355594|NCT01643889|DRUG|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
40835759|NCT05992194|OTHER|multimodal oculomotor measurements|"* Visual assessment to ensure that the subject meets the inclusion and non-inclusion criteria, including anamnesis and the following visual tests: Lang stereotest, H-test ocular motility, convergence, masking and accommodative rock.~* Evaluation by experimenter A (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR headset~* Evaluation by experimenter B (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR helmet The sequence of experimenters A-B or B-A will be randomized."
41355595|NCT01643889|DRUG|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
41355596|NCT03789864|DIAGNOSTIC_TEST|Biodynamic imaging (BDI) of mycosis fungoides|Skin punch biopsy samples from cutaneous lesions will be profiled for sensitivity to gemcitabine using ex vivo Biodynamic imaging (BDI). A biodynamic profile, of either phenotypic responder or phenotypic non-responder, will be assigned.
41355597|NCT06194721|PROCEDURE|Cold intrapulpal anesthesia|Intrapulpal cold local anesthesia at 4-5 c temperature
41355598|NCT06194721|PROCEDURE|Room temperature intrapulpal anesthesia|Intrapulpal cold local anesthesia at room temperature
41355599|NCT04051944|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
41355600|NCT04849429|BIOLOGICAL|Platelet rich plasma (PRP) with exosomes|Autologous Platelet rich plasma (PRP) with exosomes Following skin disinfection of the back 2 ml from the total PRPex procured will be injected as soon as possible by an fluoroscopy guided lateral approach.
41355601|NCT04849429|DRUG|Normal Saline|placebo : 2 ml normal saline para discal administration
41355602|NCT04107935|BEHAVIORAL|TREAT-ON|"TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes."
41355603|NCT04107935|BEHAVIORAL|Usual Care|"A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE."
41355604|NCT03513835|DIAGNOSTIC_TEST|Diagnostic screenings tests|Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.
41355605|NCT05223478|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
41355606|NCT05223478|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
40835760|NCT05616585|OTHER|Pharmacokinetic (PK)- Controlled Feeding Diet|Pharmacokinetic- single-day isocaloric meals of beef, potatoes, chicken, whole wheat bread, corn, cheese, yogurt, and oats with blood and urine samples taken at Time Zero and every hour (blood) or two hours (urine) after eating, over 10 hours; and at 24 hr.
41021491|NCT03587259|DIAGNOSTIC_TEST|2D mammography|2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
41021492|NCT04889092|OTHER|Blood Flow Restriction exercise|Exercise training will consist of blood flow restriction exercise. Specifically blood pressure cuff will be wrapped around the most proximal portion of the thigh and inflated to a pressure that is 80% of the pressure required to completely occlude femoral blood flow. With the cuff inflated the subject will perform a series of knee extension/flexion exercise protocol. This consists of 30 reps, 15 reps, 15 reps and 15 reps all separated by 1 minute of recovery. All reps will be performed at 30% of the subjects 1 repetition max. This will be preformed 20 times over 8 weeks.
41021493|NCT04889092|OTHER|Traditional resistance exercise|Traditional knee extension/flexion exercise will be performed. This will consist of a series of 13 reps, 12 reps, 12 reps with 1 minute recovery between each set. The resistance will be set at 60% of their 1 repetition max. This will be performed 20 times across 8 weeks.
41355607|NCT02469662|DEVICE|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
41495564|NCT01557738|DIETARY_SUPPLEMENT|Low Flavanol Trial|The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
41355608|NCT03010358|DRUG|Entospletinib|Given PO
41355609|NCT03010358|OTHER|Laboratory Biomarker Analysis|Correlative studies
41355610|NCT03010358|BIOLOGICAL|Obinutuzumab|Given IV
41355611|NCT03010358|OTHER|Pharmacological Study|Correlative studies
41355612|NCT04045314|OTHER|Topical moisturizer|The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
41355613|NCT03245372|PROCEDURE|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
41355614|NCT03245372|PROCEDURE|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
41355615|NCT00034697|DRUG|temozolomide|
41355616|NCT04296344|OTHER|Acupuncture Therapy Treatments|10 consecutive weekly group acupuncture therapy treatments
41021494|NCT05944263|BEHAVIORAL|weRISE; The gratitude, kindness and hope (GKH) program|weRISE is an arts based train the trainer intervention that promotes positive mental health through cultivating gratitude, kindness and hope among youth in schools and informal settlements in India and Kenya
41355617|NCT04296344|OTHER|Yoga Therapy Sessions|8 consecutive yoga therapy sessions that occur immediately following in a room adjacent to acupuncture therapy.
41355618|NCT06381752|DEVICE|Continuous passive motion|Daily application of continuous passive motion
41355619|NCT06381752|OTHER|standard rehabilitation|standard rehabilitation program with group physiotherapy
41355620|NCT02331706|DRUG|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
41355621|NCT03297554|BEHAVIORAL|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
41355622|NCT00276224|DRUG|ferrous sulphate (drug)|
41355623|NCT04461899|BIOLOGICAL|Blood test|additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
41495565|NCT01557738|DIETARY_SUPPLEMENT|High Flavanol Trial; long-term|The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
41495566|NCT01557738|DIETARY_SUPPLEMENT|Low Flavanol Trial; long-term effects|The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
41355624|NCT02196389|DEVICE|Nasal dilator Nasanita|Nasal Dilator
41355625|NCT02196389|DEVICE|Nasal dilator Nozovent|
41160156|NCT05732922|DEVICE|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants in the intervention arm to use during their telemedicine consultations with health care providers.
41355626|NCT02196389|DEVICE|Nasal dilator Breath Right|
41495567|NCT05623306|DEVICE|PMT Stereoencephalography (SEEG)|For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.
41495568|NCT05623306|DEVICE|Vercise Genus™ Deep Brain Stimulation (DBS) System|For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.
41495569|NCT00388076|DRUG|Pazopanib|pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
41495570|NCT00388076|DRUG|Lapatinib|Lapatinib in combination with pazopanib and paclitaxel in Part 3
41495571|NCT00388076|DRUG|paclitaxel|in combination with pazopanib
41495572|NCT00388076|DRUG|carboplatin|in combination with pazopanib
41495573|NCT03946553|OTHER||No intervention
41495574|NCT05226546|DRUG|Platelet rich plasma (PRP)|PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
41495575|NCT05226546|OTHER|olfactory training|"The investigators compare the result of the PRP group to a control group how underwent simple olfactive training for one month.~The control group matched for age, gender and olfactory score at baseline. The patients had a sniffing stick test at the beginning and also after one month of olfactory training."
41495576|NCT03582748|PROCEDURE|sleeve gastrectomy|removal of most of stomach as a bariatric surgical procedure
41495577|NCT03582748|PROCEDURE|No sleeve gastrectomy|Non-receipt of sleeve gastrectomy procedure
41495578|NCT02509299|OTHER|Physiotherapy program 1|The standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises.
41495579|NCT02509299|OTHER|Physiotherapy program 2|COPD patients included in this group will receive the standard medical treatment and additionally, they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included neuromuscular stimulation therapy on quadriceps accompanied by lower limbs exercises
41160157|NCT02243436|DRUG|Brentuximab Vedotin|Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
41160158|NCT02243436|DRUG|Etoposide|Intravenose use, 40mg/m2/day, on days 1 to 4
41355627|NCT02196389|DEVICE|Nasal dilator Airmax|
41355628|NCT05724641|DIAGNOSTIC_TEST|MRI perfusion imaging using ASL's non-invasive technique|Patients will undergo through an MRI-scan using the ASL MRI sequence, as described per protocol.
41355629|NCT04263129|PROCEDURE|Tracheal, carinal or bronchial transplantation using a stented cryopreserved aortic|Radical resection of the lesions was performed using standard surgical techniques. After resection, airway reconstruction was performed using a human cryopreserved (-80°C) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. To prevent airway collapse, a custom-made stent was inserted into the allograft. In patients with proximal lung tumors, the lung-sparing intervention of bronchial transplantation was used.
41355630|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ machined bone allograft|Participant will undergo primary, elective one-level to four-level ACDF using machined bone allograft
41355631|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ Iliac Crest Bone Graft|Participant will undergo primary, elective one-level to four-level ACDF using iliac crest bone allograft
41355632|NCT01926366|DRUG|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
41355633|NCT01926366|DRUG|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
41355634|NCT02141854|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
41495580|NCT02509299|DRUG|Standard medical treatment|"The standard medical treatment consists on:~* Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~* Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
41495581|NCT06476951|BEHAVIORAL|Parent-Child Physical Activity Program|The program includes online education, parent-child games, parent-child dancing, and other parent-child physical activity activities.
41160159|NCT02243436|DRUG|Soludomerin|Intravenous use, 250mg/day, on days 1 to 4
41160160|NCT02243436|DRUG|Cisplatin|Intravenous use, 25mg/m2/day, on days 1 to 4
41355635|NCT02141854|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
41355636|NCT02141854|DRUG|Placebo MDPI|The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
41355637|NCT02141854|DRUG|Albuterol/salmeterol HFA MDI|Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
41495582|NCT05773833|BEHAVIORAL|"Go Healthy program"|Weekly food boxes of fresh fruits and vegetables for 16 weeks; healthy eating and traditional foods curriculum available inside the box; monthly in-person healthy eating and traditional Indigenous foods cooking workshop; Indigenous cooking demonstration video website links to accompany recipes; and a kitchen starter kit with kitchen cooking supplies
41495583|NCT04763564|DRUG|Liraglutide Pen Injector|Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.
41495584|NCT04763564|DRUG|Placebo Pen Injector|Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
41495585|NCT04201886|OTHER|serum calprotectin|serum calcium binding leucocyte protein
41495586|NCT03240835|DRUG|cisplatin and docetaxel|"NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles."
41495587|NCT03240835|RADIATION|IMRT|intensity modulation radiation therapy
41355638|NCT03671642|DEVICE|Q-ICG|Quantitative perfusion assessment with indocyanine green on a touch screen tablet
41160161|NCT02243436|DRUG|Ara C|Intravenous use, 2g/m2, day 5
41160162|NCT03806218|DEVICE|Bipolar RFA|Bipolar RFA in which RF currents flow between two electrodes
41355639|NCT03671642|PROCEDURE|White light perfusion assessment|Traditional visual perfusion assessment in white light
41355640|NCT03671642|PROCEDURE|Fluorescence angiography|Perfusion assessment with fluorescence angiography - without quantification
41355641|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played with a facilitator.
41355642|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played alone.
41495588|NCT04405830|PROCEDURE|Renal replacement therapy|Renal replacement therapy (RRT) refers to modalities of treatment that are used to replace the waste filtering functions of a normal kidney.
41495589|NCT02584400|DRUG|Injection with the hypoxia tracer [18F]HX4,|The \[18F\]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) \[18F\]HX4 via a bolus IV injection.
41495590|NCT02235090|OTHER|Direct current stimulation of cervical spinal cord|10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
41495591|NCT00400816|DRUG|temozolomide|Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\]
41495592|NCT01333774|DRUG|Glucobay (Acarbose, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
41355643|NCT01968629|DRUG|Eovist|
41355644|NCT00684073|DRUG|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
41355645|NCT00684073|DRUG|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
41355646|NCT01888367|DRUG|DFA-02 Antibiotic Gel|
41355647|NCT01888367|DRUG|DFA-02 Placebo Gel|
41355648|NCT00519220|OTHER|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
40835761|NCT05616585|OTHER|Dose Response (DR)- Controlled Feeding Diet|Dose Response-3 level, six days controlled feeding study with assignment to either beef/whole wheat bread, chicken/potato, salmon/corn, cheese/soybeans, or yogurt/oats within a standard diet at zero, medium, and high doses for 6 days.
40835762|NCT02301481|RADIATION|SIB-IMRT|45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
41021495|NCT05944263|BEHAVIORAL|The [adapted] Stan Kutcher Teen Mental Health (TMH) program|The 'Teen Mental Health' curriculum developed by Dr. Stan Kutcher, aims to increase mental health literacy among young people ;will be used in the control group (active comparator group). The control intervention consists of eight sessions (45 minutes each) delivered by older groups of young people (ages 18-24) in schools and community settings through a didactic approach.
40835763|NCT02301481|DRUG|S-1|40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
40835764|NCT02301481|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
40835765|NCT02301481|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
41355649|NCT03397966|DRUG|recombinant human BNP(1-32)|Subjects will receive an IV infusion of recombinant human BNP(1-32) for 240 minutes at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
41355650|NCT03397966|DRUG|placebo (control, normal saline)|Subjects will receive an IV infusion of placebo (normal saline) at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
41495593|NCT01837524|BEHAVIORAL|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
41495594|NCT01837524|BEHAVIORAL|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
40835766|NCT02461316|OTHER|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
41495595|NCT03033082|OTHER|Questionnaire sheets|"A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used."
41495596|NCT05527574|OTHER|Resistance Exercise|Participants are enrolled in 30-40 minutes of resistance exercise training using elastic bands for 30-40 minutes/session three times per week over six months
41495597|NCT02290301|DRUG|gemigliptin|
40835767|NCT05021692|BEHAVIORAL|Web-based support program for pregnant women with preeclampsia based on the Health Promotion Model|support program
40835768|NCT04054999|DRUG|Hydroxocobalamin|Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
41021496|NCT03333746|OTHER|Laboratory Biomarker Analysis|Correlative studies
41021497|NCT03333746|DRUG|Lenalidomide|Given PO
41355651|NCT01444989|OTHER|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
41509201|NCT02770378|DRUG|Temozolomide|Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
41509202|NCT02770378|DRUG|Aprepitant|Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
41355652|NCT01444989|OTHER|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
41355653|NCT04787042|BIOLOGICAL|ST-067|ST-067 is an engineered variant of human interleukin-18.
41495598|NCT02518516|DRUG|Rosuvastatin (≥10 mg)|"Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed \>120 days of the index date (i.e. no exposure within 120 days of the index date)."
41021498|NCT03333746|BIOLOGICAL|Nivolumab|Given IV
41021499|NCT03333746|OTHER|Pharmacological Study|Correlative studies
41355654|NCT04787042|BIOLOGICAL|Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]|Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.
41355655|NCT04787042|BIOLOGICAL|pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
41355656|NCT02130635|DRUG|GSK2269557 100 MCG|100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
41355657|NCT02130635|DRUG|GSK2269557 500 MCG|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
41355658|NCT02130635|DRUG|PLACEBO|Lactose administered using a matching dry powder inhaler device
41509203|NCT02770378|DRUG|Minocycline|Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
41021500|NCT06068205|DIAGNOSTIC_TEST|Blood test - atomic force microscopy in the force spectroscopy mode|A single blood test to be analysed through atomic force microscopy in the force spectroscopy mode
41021501|NCT01825551|DRUG|Granulocyte Colony Stimulating Factor|
41021502|NCT01825551|DRUG|Placebo|
41160163|NCT03806218|DEVICE|SM-RFA|Monopolar RFA using multiple electrodes with switching mode
41355659|NCT06092411|BEHAVIORAL|Cognitive Behavioural Therapy for Depression|Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
41355660|NCT06092411|DEVICE|Bright Light Therapy|Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
41355661|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Normal Aging|Using software developed for this purpose, a current photograph of the subject will be aged and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
41355662|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Smoking Consequences Aging|Using software developed for this purpose, a current photograph of the participant will be aged showing the results of continued smoking and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
41355663|NCT04754867|BEHAVIORAL|Current Self Virtual Reality Image|Using software developed for this purpose, a current photograph of the participant will be rendered as a 3D virtual reality avatar.
41355664|NCT04754867|BEHAVIORAL|Letter - 20 years|"Participants will write a 200-300 word letter to the self they see in that image in 20 years' time. The instructions will read: Think about who you will be in 20 years from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
41355665|NCT04754867|BEHAVIORAL|Letter - 3 months|"Participants will write a 200-300 word letter to the self they see in that image. The instructions will read: Think about who you will be in 3 months from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
41355666|NCT04611204|OTHER|Descriptive cohort|NT-proBNP assay, electrocardiogram and transthoracic echocardiography before CTS surgery release. Pathological analysis for amyloid deposits of transverse carpal ligament of patients included.
41355667|NCT02527031|OTHER|ECMO Insertion on pre hospital setting|ECMO Insertion on pre hospital setting
41355668|NCT02527031|OTHER|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
41355669|NCT02404909|OTHER|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
41355670|NCT03319329|DEVICE|Indirect Calorimetry|REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein \& Coulter, 2014);(P. Singer \& Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
41355671|NCT01160458|DRUG|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
41355672|NCT03146195|OTHER|Dynamic Magnetic resonance imaging|
41355673|NCT01688362|BIOLOGICAL|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
41355674|NCT01688362|DRUG|Corticosteroid|"Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site."
41355675|NCT00315692|DEVICE|Biomarker Assay (CA125 and HE4)|
41355676|NCT01156246|DRUG|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
41495599|NCT02518516|DRUG|Atorvastatin (≥20 mg)|"Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
41495600|NCT02518516|DRUG|Simvastatin (≥40 mg)|"Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
41509204|NCT02770378|DRUG|Disulfiram|Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
41355677|NCT00000368|BEHAVIORAL|Cognitive behavior therapy|
41355678|NCT00000368|DRUG|Paroxetine or other medication - algorithm used|
41355679|NCT00301236|DRUG|Dexmethylphenidate HCl extended-release capsules|
41355680|NCT01908335|DRUG|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
41355681|NCT01908335|DRUG|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
41355682|NCT01908335|DRUG|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
41355683|NCT01908335|DRUG|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
41495601|NCT02518516|DRUG|Fluvastatin|"Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
41495602|NCT02518516|DRUG|Pravastatin|"Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
41495603|NCT02518516|DRUG|Lovastatin|"Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
41495604|NCT02518516|DRUG|Atorvastatin (<20mg)|"Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
41495605|NCT02518516|DRUG|Simvastatin (<40 mg)|"Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
41021503|NCT02788175|BIOLOGICAL|Entyvio (Vedolizumab)|A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
41021504|NCT02210299|OTHER|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
41021505|NCT04472351|BEHAVIORAL|ASCEND-I|"The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties."
41021506|NCT02527057|DEVICE|DW-MRI|Participants will perform four DW-MRI scanning as follows,before chemoradiation , at 2 weeks , 4 weeks after the start of radiotherapy and before the surgery.If participants can not receive surgery,the last scanning time will replaced at the end of radiotherapy.
41021507|NCT05212636|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|A total of 12 sessions of rTMS (5 sessions per week for 2 weeks, follow by 1 session per week for next 2 weeks) .
41021508|NCT04198623|DRUG|Montelukast 10 Mg Oral Tablet|Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment
41021509|NCT01513291|DRUG|MK-6096|MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
41021510|NCT01513291|DRUG|Placebo|Placebo, 2 tablets, orally, once daily
41021511|NCT06202989|DRUG|Multiprofen-CC™ plus standard treatment|Multiprofen-CC™ \[ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)\] Dose: 1.0g, 3 times per day for 6 weeks after surgery
41355684|NCT00740116|DRUG|Tranexamic acid|Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery
41355685|NCT00740116|DRUG|0.9% NaCl solution|0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
41355686|NCT03778424|DRUG|Rufinamide|Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
41355687|NCT04090827|OTHER|Nurse-led transition intervention and access to the iHeartChange website|"Elements of the transition interventions include: (i) introduction to transition and its importance, (ii) creation of a MyHealth Passport, (iii) review diagram of participant's cardiac anatomy, (iv) discussion of 3 potential future cardiac complications (v) iHeartChange website (vi) discussion of the concept of self-management (vii) discussion and promotion of communication skills by the adolescent with their healthcare team via the GLADD technique (Give, Listen, Ask, Decide, Do) (viii) a 3-sentence summary about their CHD (ix) ongoing text/email support from RN"
41355688|NCT03515499|BEHAVIORAL|Incentives|Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.
41355689|NCT03515499|BEHAVIORAL|Medication device monitoring and reminders|Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
41355690|NCT05956080|DIAGNOSTIC_TEST|Allergy testing|University Medicine Greifswald
41355691|NCT00590031|DRUG|Cisplatin|pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
41355692|NCT00590031|DRUG|Irinotecan|Irinotecan will be given 65 mg/m2
41355693|NCT00590031|RADIATION|External Beam Radiation Therapy|will be delivered with multiple (\>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
41355694|NCT04613791|BIOLOGICAL|Blood test|Collection of epidemio-clinical, biological, radiological and therapeutic patient data. Study samples collected from 154 patients to determine whether a particular immune profile could identify individuals prone to insulin resistance
41355695|NCT04454281|DRUG|Naloxone Hydrochloride 0.4 MG/ML|Drug will be topically applied to the corneal surface then study evaluations will ensue.
41355696|NCT06404476|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
41355697|NCT06477523|DRUG|AK104|IV infusion
41355698|NCT06477523|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
41021512|NCT06202989|OTHER|Placebo plus standard treatment|The placebo is the base cream with no medicinal ingredients to be applied 3 times per day for 6 weeks after surgery
41021513|NCT04626674|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
41021514|NCT06572371|PROCEDURE|Laparoscopic pyeloplasty|The first trocar was inserted under vision through the same supraumbilical incision and the intraperitoneal cavity was inspected The second 5 mm trocar was placed in the midclavicular line 2 inches below the costal margin. The third 10 mm trocar was placed lateral to the rectus muscle at the level of the anterior superior iliac spine. In right-sided pyeloplasty, a fourth trocar was inserted below the xiphistemum for liver retraction. Incision of the line of Toldt and mobilization of the colon was the first step of the transperitoneal approach. A 4/0 polysorbe stay suture was taken in the lateral aspect of the ureter distal to uretero-pelvic junction obstruction to identify the correct orientation after dismembering the ureter. A full thickness anastomosis was started from the angle of V shape spatulation to the lower pole of the renal pelvis.
41160164|NCT03806218|DEVICE|Twin internally cooled-wet electrodes|Saline-enhanced twin internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity
41160165|NCT03806218|DEVICE|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
41160166|NCT01103141|DEVICE|Micropuncture needle set|Groin access for vascular intervention
40835769|NCT04054999|DRUG|Methylene Blue|Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
41355699|NCT06477523|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
41355700|NCT06477523|RADIATION|low-dose radiotherapy|"The subjects will receive LDRT, from C1D1-C1D5, once a day for 3Gy, until the target dose of 15Gy is achieved (Cycles 1).~LDRT treatment for primary/mediastinal positive lymph nodes/metastatic lesions during maintenance therapy (C1D1-C1D5, 15Gy)."
41355701|NCT01038635|DRUG|5-Azacytidine|75 mg/m\^2 IV daily x 5 days on days 1 to 5.
41355702|NCT01038635|DRUG|Lenalidomide|Starting dose 10 mg orally daily x 5 days on days 6 to 10.
41160167|NCT01103141|DEVICE|Standard gauge-18 needle set|Groin access for vascular intervention
41355703|NCT03267576|DRUG|Canagliflozin 300 mg|Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
41355704|NCT03267576|DRUG|Sitagliptin 100 mg|Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
41355705|NCT03267576|DRUG|Metformin|Participants will receive metformin at a stable dose of \>= 1500 mg/day throughout the study including the washout period between each intervention.
41355706|NCT05538689|DRUG|Myfembree Oral Product|The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.
41355707|NCT06334237|OTHER|personalized treatment|According to the condition of each individuals, the study continues their routine clinical care. The study does not offer anything more than a routine clinical care. It is named personalized treatment because the condition of each individual varies, so the doctor may prescribe or offer clinical advice accordingly. .
40835770|NCT04040842|DIAGNOSTIC_TEST|Patients undergoing low anterior resection|Patients before the surgery and one year after the surgery will be assessed with questionnaire.
40835771|NCT05804149|DEVICE|acupuncture|study group take acupuncture Acupuncture was applied with a total duration of 35-45 minutes, 2 sessions per week for 4 months.
40835772|NCT05804149|DRUG|Thyroxine|Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine
40835773|NCT05804149|DIETARY_SUPPLEMENT|low caloric diet|Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
41021515|NCT06572371|PROCEDURE|Open pyeloplasty|"A flank incision with the patient in lateral position was undertaken in open pyeloplasty. After accessing the retro- peritoneum, the ureter was identified and traced cranially till the PUJ segment.~Traction sutures was placed on the renal pelvis followed by excision of the narrowing segment. The ureter was spatulated by approximately 2 cm and a reduction pyeloplasty was performed, where necessary. Anastomosis was undertaken using vicryl 4-0 sutures. The primary anastomotic site was sutured in interrupted fashion followed by a continuous running suture of the posterior wall. Next, antegrade DJ stenting was performed and the anterior wall was anastomosed. After haemostatic control a 22 Fr drain was placed in the surgical bed."
41021516|NCT03621267|OTHER|Interactive Stepping Exercise|Interactive Stepping Exercise will perform on a thin mat, stepping pattern will display through a monitor screen, immediate auditory feedback will give for adjustment
41021517|NCT03621267|OTHER|Home exercise program|Home exercise program includes stretching exercise, general strengthening exercise on lower extremity muscles, posture control and balance exercise.
40835774|NCT01064687|DRUG|LY2189265|
40835775|NCT01064687|DRUG|Exenatide|
40835776|NCT01064687|DRUG|Placebo|
40835777|NCT01064687|DRUG|Metformin|
41021518|NCT03243734|DEVICE|trūFreeze® System spray cryotherapy|Subjects where trūFreeze® System spray cryotherapy is performed
41355708|NCT05040867|OTHER|Physical exercise program|"The physical exercise programme will last 16 weeks where participants will do three weekly sessions of 60 minutes, approximately. In these training sessions, cardiovascular and strength components will be worked out, planned from moderate to high intensity in the TEG and unique high intensity in the HRVG. The training programme will be divided into three mesocycles from neuromuscular adaptation to reach, in last period, the highest loads and cardiovascular levels. Each session will include a warm-up, a main part and a cool-down with stretching and mobility exercises.~The difference between the interventions of the HRVG and TEG will be in the planning of the intensity of the cardiovascular exercises and the weight to be lifted in the strength exercises. The first session of both programmes will have the same intensity but depending on how the heart rate variability of the HRVG patients reacts to, the weight and the intensity will be individualised each day."
41355709|NCT03191604|OTHER|Video intervention|Video clips of endoscopy footage with just HD-WLE and clips with NBI will be shown to endoscopists.
41355710|NCT06337942|PROCEDURE|Bladder Transplantation|A bladder transplantation will be performed. The bladder will be recovered from a brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the recipient's ureter(s) to the new bladder.
41355711|NCT06337942|PROCEDURE|Combined Kidney and Bladder Transplantation|For patients who qualify for a combined kidney and bladder transplant, both a kidney and a bladder transplant will be performed. Both kidney and bladder allografts will be recovered from the same brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the kidney transplant ureter to the transplanted bladder. If the recipient has continued urine output, new connections between the native ureters and the transplanted bladder will also be made.
41355712|NCT04659447|DRUG|Platelet-Rich Plasma|36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
41021519|NCT03903107|PROCEDURE|Conventional fluoroscopy guided Conduction System Pacing(CSP)|conventional standard approach Conduction System Pacing(CSP) using fluoroscopy
41021520|NCT03903107|PROCEDURE|Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)|Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy
41021521|NCT06573099|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
41021522|NCT01646671|DRUG|LCZ696|LCZ696 200 mg tablet once daily
41021523|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
41021524|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
40835778|NCT01064687|DRUG|Pioglitazone|
40835779|NCT03384914|BIOLOGICAL|DC1 Vaccine|"Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
40835780|NCT03384914|BIOLOGICAL|WOKVAC Vaccine|"Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
41355713|NCT02716532|DIETARY_SUPPLEMENT|Peptamen AF|Each patient will receive Peptamen AF throughout the trial.
41355714|NCT05357586|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders is a manualized, evidence-based form of cognitive behavioral therapy aimed at targeting emotion regulation processes that underlie common forms of emotional disorders such as anxiety, depression, and commonly co-occurring mental health challenges.
41355715|NCT05365984|DIAGNOSTIC_TEST|end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）|The measurement of end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）is conducted in the process of risk evaluation.
41355716|NCT05365984|OTHER|Internet Plus technology|The Internet Plus technology is applied in the process of follow-up management.
40835781|NCT02728414|DIETARY_SUPPLEMENT|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
40835782|NCT02728414|DIETARY_SUPPLEMENT|placebo|the patients in this arm will receive placebo intervention
40835783|NCT01448005|DEVICE|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
40835784|NCT00969436|BIOLOGICAL|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
40835785|NCT00969436|BIOLOGICAL|Priorix™|Subcutaneous injection
40835786|NCT00969436|BIOLOGICAL|Varilrix™|Subcutaneous injection
40835787|NCT00238914|DRUG|Naltrexone|50mg of oral naltrexone daily
41021525|NCT00514306|DRUG|OSI-906|Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
41021526|NCT04049994|DRUG|Uro-Vaxom|Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
41021527|NCT04049994|DRUG|Placebo oral tablet|Placebo oral tablet
41021528|NCT00259753|DRUG|Bevasiranib|
41021529|NCT05209191|BEHAVIORAL|Student Athlete Wellness Portal|A web-based design that illustrates various opioid misuse and diversion resistance strategies.
41021530|NCT02804607|OTHER|questionnaire|
41021531|NCT04603430|OTHER|Participation in a community wellness program|Participation in the STEPS program, a physical therapy student-run community wellness program for local seniors.
41355717|NCT02008981|DRUG|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
41355718|NCT02008981|DRUG|Angelica sinensis|Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
41495606|NCT01330459|DRUG|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
41355719|NCT02008981|DRUG|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
41355720|NCT02008981|DRUG|Aspirin|Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
40835788|NCT00238914|BEHAVIORAL|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
40835789|NCT00238914|BEHAVIORAL|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
40835790|NCT02784015|DRUG|Cisplatin|
40835791|NCT02784015|DRUG|Etoposide|
40835792|NCT02784015|DRUG|Doxorubicin|
40835793|NCT02784015|DRUG|Cyclophosphamide|
40835794|NCT02784015|DRUG|Ifosfamide|
40835795|NCT02784015|DRUG|Carboplatin|
40835796|NCT02784015|RADIATION|Radiotherapy|
40835797|NCT02784015|DRUG|Thiotepa|
40835798|NCT02784015|DRUG|Melphalan|
41160168|NCT01954771|BEHAVIORAL|SMBG|"Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively."
41355721|NCT03098667|DEVICE|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated.
40835799|NCT01439126|DRUG|clonidine hydrochloride|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
40835800|NCT01439126|DRUG|Placebo|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
40835801|NCT03689075|DRUG|Envarsus Oral Product|Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
40835802|NCT03984487|BEHAVIORAL|Surviving and Thriving in the Real World|The STRW intervention consists of 14 weekly concurrent adolescent and parent group sessions. The DLS to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning DLS and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
40835803|NCT03984487|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|PEERS is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning get-togethers with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
40835804|NCT01109771|DEVICE|permanent mesh fixation|Permanent mesh fixation will be used.
40835805|NCT01109771|DEVICE|absorbable mesh fixation|Absorbable mesh fixation will be used.
40835806|NCT04687423|DRUG|FCN-011|FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
40835807|NCT01908166|PROCEDURE|ultrasound elasticity imaging|Undergo ultrasound elastography
40835808|NCT04279145|DEVICE|swan ganze catheter /echocardiography|"Right heart catheterization and mixed venous blood samples will be obtained for ABG, biomarkers (troponin , uric acid and micro RNA).~Each subject will have echocardiography, 6 MWD, clinical functional class and blood sample at the day of right heart catheterization or at least less than week of right heart catheterization"
41021532|NCT02516059|DRUG|oxycodone/naloxone|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
41021533|NCT02516059|DRUG|Oxycodone|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
41021534|NCT02516059|DRUG|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
41021535|NCT02516059|DEVICE|epidural catheter|
41495607|NCT01330459|DRUG|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
41495608|NCT01330459|DRUG|Ibuprofen|800 mg oral ibuprofen
41355722|NCT03098667|DEVICE|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
41495609|NCT01330459|DRUG|Lorazepam|2 mg oral lorazepam
41355723|NCT00863031|BEHAVIORAL|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
41355724|NCT00863031|BEHAVIORAL|Video-viewing|Three sessions of viewing health educational videos.
41355725|NCT04252560|PROCEDURE|Colectomy, CRS+HIPEC|No special interventions are going to be performed. Fecal samples are going to be taken and analysed
41355726|NCT03701373|DRUG|S-1 maintenance|S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
41355727|NCT03701373|OTHER|Observation|Observation without anti-tumor treatment
41355728|NCT00763373|OTHER|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
41355729|NCT00001116|DRUG|Tumor Necrosis Factor soluble receptor-immunoadhesin complex|
41355730|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Experiential|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
41355731|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Psychoeducational|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
41021536|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 1|The performance of behavioral locomotion tasks is performed on 4 visits on pilot phase (2 in real condition and 2 in virtual reality in D1 and M1)
41021537|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 2|The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)
41355732|NCT05378893|DRUG|DR10624 for injection|administered via subcutaneous injection
41355733|NCT05378893|DRUG|Placebo|administered via subcutaneous injection
41355734|NCT00397644|BEHAVIORAL|Prompting (survey instrument/resources list) (behavior)|
41495610|NCT01330459|DRUG|Lidocaine|20 ml 1% buffered lidocaine, injected
41495611|NCT01206049|DRUG|Gemcitabine|1,000 mg/m2 on day 1 of a 2 weeks cycle
41021538|NCT05720832|OTHER|WINGS-IP1 Smartphone Application|"The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content."
41495612|NCT01206049|DRUG|Oxaliplatin|60 mg/m2 on day 1 of a 2 weeks cycle
41495613|NCT01206049|DRUG|Capecitabine|1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
41495614|NCT01206049|DRUG|Panitumumab|6 mg/kg on day 1 of a 2 weeks cycle
41021539|NCT01117311|DEVICE|VNB on|The implanted Vagal Nerve Blocker will be on at the time of study.
41021540|NCT01117311|DEVICE|VNB off|The implanted Vagal Nerve Blocker will be off at the time of study.
41495615|NCT01206049|DRUG|Bevacizumab|10 mg/kg on day 1 of a 2 weeks cycle
41495616|NCT05551819|DIETARY_SUPPLEMENT|MDF then RUTF/RUSF|Children randomized to feeding order 1: children will be provided MDF for the first two weeks then crossover to consume RUTF/RUSF for a second two weeks.
41495617|NCT05551819|DIETARY_SUPPLEMENT|RUTF/RUSF then MDF|Children randomized to feeding order 2: children will be provided RUTF/RUSF for the first two weeks then crossover to consume MDF for a second two weeks.
41495618|NCT06049979|OTHER|Acute gastrointestinal injury|AGIUS score\>2
41495619|NCT05177718|DRUG|Natalizumab 300 MG in 15 ML Injection|Disease modifying agent
41495620|NCT02472535|OTHER|Run-In Period: Placebo|2 capsules, once a day for two weeks
41495621|NCT02472535|DRUG|MBX-8025 50 mg (Dose Escalation Period 1)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg capsule)"
41495622|NCT02472535|DRUG|MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg or 100 mg capsule)"
41355735|NCT02939456|OTHER|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
41495623|NCT02472535|DRUG|MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)|"1 or 2 capsules once a day for 4 weeks~(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)"
40835809|NCT03917550|BEHAVIORAL|Recovery (Transdiagnostic & self)|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.
40835810|NCT03917550|BEHAVIORAL|Transdiagnostic|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
41495624|NCT00460538|DIETARY_SUPPLEMENT|Lectranal|"Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks"
41495625|NCT00460538|DIETARY_SUPPLEMENT|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
41495626|NCT03783273|DIETARY_SUPPLEMENT|Vitamin D3|Single dose vitamin D3
41021541|NCT04828759|BEHAVIORAL|VR-treatment|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
41355736|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1|Patients will receive Lemborexant 5 mg per day on the first day of sleep test
41355737|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2|Patients will receive Lemborexant 5 mg per day on the second day of sleep test
41355738|NCT05763329|DRUG|Placebo Day 1|Patients will receive placebo on the first day of sleep test
41355739|NCT05763329|DRUG|Placebo Day 2|Patients will receive placebo on the second day of sleep test
41355740|NCT03433599|OTHER|Repeated exposure to acute Intermittent Hypoxia (rAIH)|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of lower oxygen (tubing attached, 9-10% oxygen level), alternating with 60-90 sec of normal room air (no tubing attached).
41495627|NCT03783273|COMBINATION_PRODUCT|Whey protein-complex|Whey protein complex-bound vitamin D3
41495628|NCT03783273|OTHER|Water|500 mL water
41495629|NCT03783273|OTHER|Milk|500 mL milk
41495630|NCT03783273|OTHER|Juice|500 mL juice
41495631|NCT01032018|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
41495632|NCT01032018|DRUG|Sertraline, citalopram, or bupropion|"Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam"
41495633|NCT01032018|OTHER|Standard care|Participants will receive standard of care from the current physicians
41495634|NCT05016193|DEVICE|Axem Home Prototype Device|The Axem Home prototype device is a rehabilitation system designed to be used independently by a stroke survivor to facilitate physical rehabilitation exercises in their home environment. The device uses a functional near-infrared spectroscopy (fNIRS) headband that measures the hemodynamic response to rehabilitation exercises and displays this brain activity information to the user.
41355741|NCT03433599|OTHER|Normal Room Air|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of normal room air (with tubing attached to the mask) and 60-90 sec of normal room air (without the tubing attached to the mask).
41495635|NCT05016193|BEHAVIORAL|Rehabilitation Exercise Program|Individual exercise program prescribed by a therapist in the Early Supported Discharge Program.
41495636|NCT02052050|OTHER|core stability|
41495637|NCT05876767|DRUG|SAR444336|Single or repeated dose subcutaneous injection
41495638|NCT05876767|DRUG|Placebo|Single or repeated dose subcutaneous injection
41495639|NCT02040779|DRUG|Beclomethasone dipropionate breath-actuated inhaler|Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
41495640|NCT02040779|DRUG|Placebo breath-actuated inhaler|Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
41495641|NCT02040779|DRUG|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
41509205|NCT02770378|DRUG|Celecoxib|Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
41509206|NCT02770378|DRUG|Sertraline|Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
41495642|NCT05272748|OTHER|Conventional Exercise + Core Stabilization Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. In addition to the exercises in the conventional exercise group, patients will perform pelvic tilt, lateral bridge, single leg bridge, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, superman exercise. Exercises will be applied 3 times a week.
41355742|NCT03433599|OTHER|Upper-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, gross grasping, fine grasping, and hand cycle using an arm ergometer. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
40835811|NCT04112979|BEHAVIORAL|Music|45 dB SL, normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
41160169|NCT01954771|OTHER|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
41355743|NCT03433599|OTHER|Lower-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general leg/foot movement, over-ground walking, treadmill walking, stair climbing training, leg cycling, standing frame, and NuStep. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
41355744|NCT02699047|DIETARY_SUPPLEMENT|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
41355745|NCT02699047|DIETARY_SUPPLEMENT|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
41355746|NCT06202313|BIOLOGICAL|Cadonilimab|Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
41355747|NCT06202313|DRUG|Eribulin|Participants receive Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
41355748|NCT04795752|DEVICE|TearCare System|TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
41355749|NCT04795752|DRUG|Restasis|Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
41355750|NCT03115164|OTHER|To study the characteristics of patients with DIA / DIG|Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
41355751|NCT01558206|OTHER|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
41355752|NCT01558206|OTHER|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
41355753|NCT05832008|BEHAVIORAL|Patient Nudge|Brief persuasive messaging to increase awareness about the importance of annual lung cancer screening and completion of recommended follow-up sent to patients via text message.
41509207|NCT02770378|DRUG|Captopril|Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
40835812|NCT04112979|BEHAVIORAL|Mother's lap|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
40835813|NCT04112979|BEHAVIORAL|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 dB
40835814|NCT03974672|PROCEDURE|Re-laparotomy|
41495643|NCT05272748|OTHER|Conventional Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. Terminal knee extension, straight leg raise, heel slide, adductor isometric, bridge, mini squat, heel raise, lunge, range of motion and stretching exercises for lower extremities will be performed by the patients. Exercises will be applied 3 times a week.
41495644|NCT02119923|BEHAVIORAL|Working memory training|The WM consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. The Number-letter task trains the ability to shift between task relevant stimuli. Participants need to shift between four categories. In the Updating task participants receive a set of three words in which they have to compare the two consecutive words on emotional valence (positive or negative) to train their updating skills. Participants executed the training three times a week during four weeks.
41495645|NCT02119923|BEHAVIORAL|Placebo training|Both the WM and the placebo training consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. To prevent training WM the placebo training was a simplified version of the Number-letter task in which shifting was not required. In the Updating task the placebo group only had to count the number of positive or negative words. Participants executed the training three times a week during four weeks.
41495646|NCT05408936|DRUG|SGLT2 inhibitor|Patients receive an SGLT2 inhibitor as part of theirn routine care.
40835815|NCT01299571|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
40835816|NCT01494519|PROCEDURE|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
40835817|NCT01494519|PROCEDURE|Definitive fixation with a locked IM nail or plate|"Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.~Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used."
40835818|NCT02519868|DEVICE|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
41355754|NCT05832008|BEHAVIORAL|Clinician Nudge|EHR-based Prompts - an pended order and message that alerts a clinician if a patient is due for screening or diagnostic follow-up.
41355755|NCT03702023|DRUG|Acetaminophen|Intervention group will receive 1000 mg of acetaminophen
41355756|NCT03702023|DRUG|Placebo Oral Tablet|Control group will be given a placebo capsule.
41355757|NCT06322940|OTHER|250 mL serving size, 3.25% fat content|Milk
41355758|NCT06322940|OTHER|175 g serving size, ≥2% fat content|Yogurt
41355759|NCT06322940|OTHER|50 g serving size, ≥28% fat content|Cheese
41495647|NCT04645836|BEHAVIORAL|New management mode|"New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use"
41495648|NCT02555748|DRUG|Pazopanib|
41495649|NCT02555748|DRUG|Sunitinib|
41495650|NCT05874583|DRUG|Combined route administration of Tranexamic acid|tranexamic acid in topical route administration
41495651|NCT05874583|DRUG|Intravenous route Tranexamic acid injection|Intra venous route administration
41495652|NCT04140435|DEVICE|EUS-guided through-the-needle microbiopsy forceps (Moray)|"EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through-the-needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two bites per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology."
41495653|NCT02271139|DRUG|Alectinib|Alectinib 600 mg administered orally with food.
41495654|NCT04917289|DRUG|Chemotherapy|Started chemotherapy or change the current adjuvant therapy
41495655|NCT03684967|DRUG|Fruquintinib|Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
41160170|NCT01196247|DRUG|Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank|FDA approved drugs as indicated by molecular profiling
41160171|NCT04171258|DRUG|Botulinum toxin type A injection|Experimental
41160172|NCT04171258|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
41160173|NCT02212197|DRUG|leuprolide acetate FluidCrystal® injection depot|
41160174|NCT02212197|DRUG|leuprolide acetate|
41495656|NCT00097903|DRUG|Karenitecin (BNP1350)|Phase 1 study,dose-escalation design
41495657|NCT02469259|DRUG|Oxytocin|
41495658|NCT02469259|OTHER|Placebo|
41160175|NCT03716583|DRUG|Melatonin|25 mg
41160176|NCT03716583|DRUG|Dimethyl Sulfoxide|150 mg
41160177|NCT03716583|DRUG|Placebos|1 g
41160178|NCT02112578|DRUG|Meclizine|25 mg, 3 times per day up to 30 days
41160179|NCT02112578|DRUG|Dimenhydrinate|50 mg, 3 times per day up to 30 days
41160180|NCT04581356|DRUG|Voxelotor|daily voxelotor 1500mg oral medication
41160181|NCT01095601|DRUG|Avanafil|"* Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~* Treatment B: 2x100 mg Formulation II avanafil tablet, fed~* Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~* Treatment D: 1x50 mg Formulation II avanafil tablet, fasted"
41160182|NCT06038578|BIOLOGICAL|TRK-950|5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle
41160183|NCT06038578|DRUG|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
41160184|NCT06038578|DRUG|Paclitaxel|80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
41160185|NCT00988897|DRUG|OXALIPLATIN (SR96669)|Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
41495659|NCT03215186|OTHER|observational study|
41495660|NCT00556777|PROCEDURE|axillary lymph node dissection|
41495661|NCT00556777|PROCEDURE|conventional surgery|
41495662|NCT00556777|PROCEDURE|sentinel lymph node biopsy|
41495663|NCT00556777|RADIATION|intraoperative radiation therapy|
41355760|NCT03700424|DRUG|Trehalose|"Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes."
41355761|NCT03700424|DRUG|Normal saline|A solution of 0.90% w/v of sodium chloride (NaCl) in water
41355762|NCT04734249|DRUG|Surufatinib(HMPL-012)|"1. Cohort 1:Surufatinib(250mg ,qd,po)+mFOLFOX6/FOLFIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~   Cohort 2:Surufatinib(250mg ,qd,po)+FOLFOXIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~2. if the first-line chemotherapy was used FoLFOX ,the second-line is FOLFIRI,or the first-line chemotherapy was used FOLFIRI ,the second-line is FoLFOX.~3. Second-line Surufatinib Combined With Chemotherapy in Advanced CRC."
41355763|NCT02150785|DRUG|Streptokinase|
41355764|NCT02106845|DRUG|Digoxin|Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
41355765|NCT02106845|DRUG|Rosuvastatin|Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
41355766|NCT02106845|DRUG|Regorafenib (Stivarga, BAY73-4506)|Once daily orally 160 mg (4 tablets 40 mg)
41355767|NCT01207336|DEVICE|combined transcranial direct current stimulation and electrical peripheral nerve stimulation|tDCS: 1,2 mA 13 minutes rEPNS (radial nerve): 5 Hz, 0,7 x MT
41355768|NCT01531244|BIOLOGICAL|dactinomycin|Given via ILI
41160186|NCT00988897|DRUG|5-FLUOROURACIL (5-FU)|Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
41355769|NCT01531244|DRUG|melphalan|Given via ILI
41355770|NCT01531244|BIOLOGICAL|Conditionally replicative adenovirus 3/5-delta|Given via ILI
41355771|NCT01568957|BEHAVIORAL|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
41355772|NCT02424708|DRUG|Reduced Glutathione 100mg|100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
41021542|NCT04828759|BEHAVIORAL|Treatment as usual|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
41021543|NCT03795844|PROCEDURE|liver retraction Nathanson retractor|liver retractor will be used for the retraction of left lobe of liver
41355773|NCT02424708|DRUG|Reduced Glutathione 200mg|200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
41355774|NCT02424708|DRUG|Placebo|Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
41355775|NCT00718887|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
41355776|NCT00718887|DRUG|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
41355777|NCT00554229|DRUG|ZD4054|ZD4054 10 mg oral tablet once daily
41355778|NCT00554229|DRUG|Placebo|Matching placebo oral tablet once daily
41355779|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
41495664|NCT01171118|DRUG|Physostigmine|Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.
41495665|NCT01171118|DRUG|Oxygen|The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.
41021544|NCT03795844|PROCEDURE|liver retraction snake retractor|liver retractor will be used for the retraction of left lobe of liver
41021545|NCT03795844|PROCEDURE|liver retraction fan retractor|liver retractor will be used for the retraction of left lobe of liver
41355780|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
41355781|NCT02051257|OTHER|Laboratory Biomarker Analysis|Correlative studies
41355782|NCT06309368|DRUG|Primary Ostomy Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation|An elliptical transverse incision will be made extending 1-2 cm lateral and medial to the mucocutaneous junction. The mobilization, anastomosis and fascial closure will be performed as in the pursestring closure group. The incision will then be irrigated using direct stream into the wound with 350cc of Prontosan. After one minute the wound will be suctioned dry. The subcutaneous fat will be mobilized and approximated with interrupted 2-0 Vicryl. The skin will be approximated with deep dermal 3-0 Vicryl and a running subcuticular 4-0 Monocryl suture and Dermabond will be applied.
41495666|NCT01171118|DRUG|Placebo|The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
41495667|NCT04263402|DRUG|Methylprednisolone|Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(\<40mg/d intravenous drip for 7 days).
41495668|NCT04263402|DRUG|Methylprednisolone|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40\~80mg/d intravenous drip for 7 days).
41355783|NCT06309368|PROCEDURE|Pursestring Closure|A circular incision will be made at the mucocutaneous junction of the ileostomy. After complete mobilization of the ileal limbs off the fascia and a stapled side to side functional end to end anastomosis, the fascia including the external and posterior rectus sheath will be closed with two running #0 PDS (Polydioxanone) suture. The wound will then be irrigated with saline and partially closed in the subcuticular plane with a 2-0 Monocryl suture in a pursestring fashion and packed in the middle with plain packing.
41355784|NCT03524664|BEHAVIORAL|Tuning In to kids intervention|"The Tuning Into Kids Program involves:~* Meeting in a small group with other caregivers raising children with FASD.~* 8-week program that meets weekly for 2 hours at Mt. Hope Family Center or other community location.~* Learn and practice an approach of responding to children's emotions and behavior."
41355785|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
41495669|NCT03170427|DEVICE|Impedance cardiography|hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine
40835819|NCT02519868|DEVICE|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
40835820|NCT05269225|OTHER|Organic diet|Organically produced foods.
40835821|NCT05269225|OTHER|Conventional diet|Conventionally produced foods.
40835822|NCT04478032|DEVICE|deep transcranial magnetic stimulation with H7 coil|low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
40835823|NCT00607854|DRUG|Ibritumomab Tiuxetan (Zevalin)|"Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)"
40835824|NCT03375372|PROCEDURE|Scaling and Root Planing (S&RP)|dental Scaling and Root Planing and oral hygiene regimen
40835825|NCT03864393|OTHER|Multimodal overground locomotor training|Locomotor training sessions use various movement drills emphasizing power, stability, and stepping in a specific direction: forward, backward, lateral, rotational. Sessions also have an additional focus on gait initiation or steady-state walking. After circuit-style warm up exercises, participants perform overground movement drills that are specific to the emphasis of the individual training session, culminating in practicing everyday overground walking. Participants wear a heart rate monitor to ensure that the majority of the training session is performed at an aerobic intensity greater than 60% age predicted heart rate maximum (220-age +/- 5 bpm).
40835826|NCT06384690|DIETARY_SUPPLEMENT|Micro-vegetable blend|The intervention in this study is 6 weeks with a daily proprietary blend micro-vegetables that has been freeze-dried
40835827|NCT06384690|DIETARY_SUPPLEMENT|Placebo|The intervention in this study is 6 weeks with a placebo supplement
40835828|NCT01278316|BEHAVIORAL|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
40835829|NCT01278316|BEHAVIORAL|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
40835830|NCT02994368|OTHER|Observation|
40835831|NCT05953012|DRUG|PMC-403|PMC-403 will be administered Intravitreal.
40835832|NCT02032342|DEVICE|Endobronchial double lumen tube|Endobronchial double lumen tube for one lug ventilation
40835833|NCT02032342|DEVICE|Arndt® blocker|Arndt® blocker for selective lobar deflation
40835834|NCT02032342|DEVICE|Cohen blocker|Cohen blocker for selective lobar deflation
40835835|NCT02032342|DEVICE|Fuji Uni-blocker|Fuji Uni-blocker foe selective lobar deflation
40835836|NCT06458231|DEVICE|Blood Catheters|Central line as a predisposing factor for Blood stream infection
40835837|NCT05164588|OTHER|Statistics|Study and analyze the medicolegal aspects of different eye trauma cases ( patterns of injuries, mechanisms, causes, site of trauma and outcome)
41160187|NCT00988897|DRUG|LEUCOVORIN (LV)|Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
41355786|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
41495670|NCT03170427|DIAGNOSTIC_TEST|Sensory levels|Sensory levels are checked using ice test cold
41495671|NCT03170427|DIAGNOSTIC_TEST|Motor block|motor block is measured by modified Bromage scale
41495672|NCT03170427|DIAGNOSTIC_TEST|Sensory level|Sensory levels are checked using touch with alcohol puffs
41495673|NCT02207712|DEVICE|Noctura 400 Eye Mask|The intervention is the wearing of the eye mask
40835838|NCT02062983|DRUG|Herceptin|"Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.~Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression."
40835839|NCT03095820|BEHAVIORAL|Supportive therapy|
40835840|NCT03095820|BEHAVIORAL|Multidomain intervention|
41021546|NCT03795844|PROCEDURE|liver retraction laparoscopic grasper|laparoscopic grasper without any special tools
41021547|NCT00501891|DRUG|Bevacizumab|Bevacizumab administered intravenously 10mg/kg every other week.
41021548|NCT00501891|DRUG|Metronomic Temozolomide|Temozolomide 50mg/m2 given orally on a daily basis.
41021549|NCT05181605|DRUG|Folfirinox and Stereotactic Body Radiotherapy|Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
41021550|NCT02838017|DEVICE|Tissue Adhesive|
41021551|NCT02838017|DEVICE|Sterile strips|
41495674|NCT02207712|DRUG|Ranibizumab|Standard ranibizumab treatment only
41495675|NCT03361475|BEHAVIORAL|SME App|"The features in the App could be used in the future by linking with some platforms / existing services so that more SME messages can be sent to the students for sharing. One school workshop will be held to promote SME and introduce the function of SME App for students to download and use immediately to connect family members.~SME App promotes SME via:~* Express gratitude to family members (sharing)~* Deliver positive messages regularly (mind)~* Record physical and other joyful activities (enjoyment)~* Increase knowledge and understanding of adolescent mental health problem (in particular the anxiety disorders)"
41495676|NCT01963286|DEVICE|ICD with enhanced SVT discriminators|ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
41021552|NCT04258813|BEHAVIORAL|iGuide Intervention (Self-guided)|The iGuide Intervention consists of two patient-level and four PCP-level components. These components include: (1) the patient-level brief video vignettes with a written summary; and (2) patient-facing webinars. The investigators will not use any institutional branding in the videos, printed materials, or recorded webinars so that these deliverables can be used in other settings.
41021553|NCT04258813|BEHAVIORAL|iGuide 2 Intervention (Tailored/Targeted)|"The iGuide2 patient-level intervention will use a stage-based, tailored approach to four monthly 5-minute video vignettes that incorporates a pre-video worksheet. The investigators will send the worksheets and video vignettes in the method preferred by the patient.~The targeted iGuide 2 PCP-level intervention will include a cancer specialist-facing dashboard that includes the specialists's patients who are enrolled in the study and are in the intervention arm. The HEDIS quality measures for our three CVD comorbidities will be used. The dashboard will be populated with data available in Epic for the specific patient. If some information is missing (i.e., there is no lipid profile in the laboratory tab), the dashboard will query the PCP via an e-consult, asking to supply the information. Bimonthly, starting with the second randomization, an asynchronous specialist-to-PCP e-consult will be sent to PCPs whose patient(s) do not meet all three of the HEDIS quality metrics."
41021554|NCT04258813|BEHAVIORAL|Control|Participants randomized to the control group (n=400) will receive current guideline-concordant cancer care. The investigators will also provide information for healthy living during and after cancer and for preparing for transition from cancer therapy to follow-up care. Monthly, patient education material on healthy living will be sent to the participants via the patient portal or by mail, based on participant preference. At the completion of therapy, they will be provided the NCI Facing Forward:Life After Cancer booklet. Note, this approach is not fully equivalent to an attention control as there will be touch points in the iGuide and iGuide2 interventions that the investigators cannot match for the control group. Also, the research team will not engage the PCPs in clinics randomized to the control group.
41021555|NCT02272998|DRUG|ponatinib hydrochloride|Given PO
41021556|NCT02272998|OTHER|laboratory biomarker analysis|Correlative studies
41021557|NCT05561686|DRUG|Pyrotinib|This study adopted a prospective, multicenter, observational design. From October 1, 2022, 100 patients with HER2-positive breast cancer scheduled to receive neoadjuvant therapy with pyrotinib were enrolled. The treatment regimen was determined according to the patient 's condition, physician' s treatment experience, evidence-based evidence and other factors to assess the clinical benefit (pCR, ORR) and safety of different neoadjuvant therapy modalities containing pyrotinib. Exploratory analysis was performed to investigate the correlation between the level of TMB and the pCR rate of neoadjuvant therapy in HER2-positive breast cancer patients, and the effect of pyrotinib on intestinal flora.
41021558|NCT01014494|DEVICE|Adaprev|Class III Medical Device
41021559|NCT06194903|DEVICE|isopropyl alcohol wipes|cellphones will be sanitised with isopropyl alcohol wipes and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
41021560|NCT06194903|DEVICE|UVC box|cellphones will be sanitised in a UVC box and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
41355787|NCT02290990|BEHAVIORAL|"Imaginative Distention technique"|ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
41355788|NCT03313752|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
41355789|NCT03313752|OTHER|Placebo|placebo
41495677|NCT04722822|BEHAVIORAL|(Intervention) Recommending HPV vaccine for patients 9-10 years of age|Providers within intervention practices will receive training which includes both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.
41021561|NCT04177524|DEVICE|Background Mode|The LifeSaver app tracks the date, time, and global positioning system (GPS) location of each trip that the participant takes in a moving vehicle, along with a list of apps used during the trip, but does not contain any anti-distracted driving features.
41355790|NCT05669144|BIOLOGICAL|mitochondria and MSC-derived exosomes|autologous mitochondria and MSC-derived exosomes
41355791|NCT02079311|DEVICE|Active self warming blanket|BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.
41355792|NCT02079311|DEVICE|Forced air warming device|Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
41495678|NCT04722822|BEHAVIORAL|(Control) Recommending HPV vaccine for patients 11-12 years of age|Providers within control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).
41355793|NCT02893332|RADIATION|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
41355794|NCT02893332|DRUG|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
41355795|NCT03099811|BEHAVIORAL|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
41355796|NCT03099811|BEHAVIORAL|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
41355797|NCT05330429|DRUG|Magrolimab|Administered intravenously
41355798|NCT05330429|DRUG|Bevacizumab|Administered intravenously
41355799|NCT05330429|DRUG|Irinotecan|Administered intravenously
41355800|NCT05330429|DRUG|Fluorouracil|Administered intravenously
41355801|NCT05330429|DRUG|Leucovorin|Administered intravenously
41355802|NCT02094781|DIETARY_SUPPLEMENT|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
41355803|NCT02094781|DIETARY_SUPPLEMENT|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
41355804|NCT02094781|DIETARY_SUPPLEMENT|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
41495679|NCT06187090|DIETARY_SUPPLEMENT|Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form|Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.
41495680|NCT03993782|OTHER|A19010-R|A snus product
41495681|NCT03993782|OTHER|B19010-O|A snus product
41495682|NCT05926271|DRUG|Clopidogrel|See arm description earlier.
41021562|NCT04177524|DEVICE|Manual Mode|"In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button."
41355805|NCT02236013|DRUG|Gilteritinib|Oral
41495683|NCT06406218|BEHAVIORAL|Phase I Cardiac Rehabilitation Exercise Training|"A) In the morning, take a supine position and perform straight leg raises with each leg individually, lifting to a height of 30° and holding for 3-5 seconds. Raise both arms to the side of the head to a 90° angle and hold for 5-10 seconds. Inhale deeply when exerting force and exhale slowly when lowering. Alternate between leg lifts and arm raises, performing 5 sets per session. Adjust intensity based on individual condition and may be repeated. In the afternoon, sit beside the bed for 5 minutes. B) After transitioning to secondary care according to the patient's condition, stand beside the bed for 5 minutes in the morning; in the afternoon, march in place beside the bed for 5 minutes. C) Walk beside the bed for 10 minutes per session, twice a day. D) Move around and doing activities under supervision inside the ward, 10 minutes per session, twice a day.~Spend approximately one day at each level, gradually progressing the exercise to the patient's tolerance level."
41021563|NCT04177524|DEVICE|Auto-Detect Mode|"In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle."
41355806|NCT02236013|DRUG|Idarubicin|lyophilized powder administered intravenously
41355807|NCT02236013|DRUG|Cytarabine|solution administered intravenously
41355808|NCT02236013|DRUG|Daunorubicin|solution administered intravenously
41355809|NCT06077682|DRUG|Cyclopentolate|Well-known eye drop used for cycloplegic refraction among children.
41355810|NCT06077682|DRUG|Tropicamide|Well-known eye drop used for cycloplegic refraction among children.
41355811|NCT01728194|DRUG|Escitalopram|20 mg target dose for 12 weeks
41355812|NCT01728194|OTHER|Magnetic Resonance Imaging|Structural and functional MRI of the brain for research purposes.
41355813|NCT02795182|DRUG|Zanubrutinib|
41355814|NCT02795182|DRUG|Tislelizumab|
41355815|NCT01521637|PROCEDURE|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
41355816|NCT01521637|PROCEDURE|Sham-treatment: no NMES|Sham comparator
41355817|NCT00540228|BIOLOGICAL|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
41355818|NCT00540228|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
41355819|NCT04494087|OTHER|Explanatory video|Links to explanatory videos handed out to patients to be watched at home after standard informed consent giving
41355820|NCT04494087|OTHER|Informed consent form|Links to a digital version of the informed consent form already discussed during the process of informed consent giving.
41355821|NCT04984252|BEHAVIORAL|Self-compassion comprising compassionate body scan-1, compassion body scan-2 and short noticing practice|This intervention includes 3 short meditations that are identified as the active component in the previous study (ID: NCT04665167)
41495684|NCT04243083|DRUG|TLL018 tablet, placebo|Oral QD
41355822|NCT04984252|BEHAVIORAL|Self-compassion comprising self-compassion break, loving kindness meditation, and breathing exercise.|This intervention includes 3 short meditations that are identified as the inactive component in the previous study (ID: NCT04665167)
41355823|NCT04984252|BEHAVIORAL|Distraction group|Participants will be asked to listen recording on irrelevant topic.
41355824|NCT03720067|DRUG|Propranolol|40mg to 320mg / day
41355825|NCT03720067|DRUG|Carvedilol|6.25mg to 25mg / day
41355826|NCT03720067|DRUG|Rosuvastatin|20mg / day
41355827|NCT03720067|DRUG|Placebo|Placebo of rosuvastatin
41355828|NCT02409966|PROCEDURE|Quadrant-wise scaling|"Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
41355829|NCT02409966|PROCEDURE|Full-mouth 24-hour scaling|"Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
41355830|NCT02249377|OTHER|Platelets-Rich-Plasma|Platelet-Rich Plasma
41355831|NCT02249377|DRUG|Corticosteroid|Corticosteroid
41355832|NCT05659459|DRUG|KIN001|Oral tablet
41355833|NCT05659459|DRUG|KIN001-Placebo|Comparator - Oral tablet with same appearance of KIN001
41355834|NCT02297620|DRUG|Suglat®|oral
41355835|NCT02367157|PROCEDURE|Kenzo Kase Method|
41355836|NCT02367157|DEVICE|Kinesio Taping|
41355837|NCT00758394|DRUG|Fluoride|Brush two times a day for 4 days.
41355838|NCT00758394|DRUG|Triclosan/Fluoride|Brush two times daily for 4 days
41355839|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
41355840|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
41355841|NCT04277429|DIAGNOSTIC_TEST|Cardiac function assessment|Echocardiography, cardiac enzymes analysis
41355842|NCT00799370|PROCEDURE|Early weight bearing|Weight bearing performed immediately after surgery
41355843|NCT00799370|PROCEDURE|Delayed weight bearing|Weight bearing performed 2 months after surgery
41355844|NCT05605184|OTHER|Survey|Survey
41355845|NCT04822389|DEVICE|Telerehablitation using heart rate monitor|Eligible participants will undergo 12 weeks of physical exercise using a heart rate monitor and internet platform at home. The participants will regularly (minimum once per week) upload the exercise data from the heart rate monitor into the internet platform. An exercise telerehabilitation session consists of the warm-up phase, aerobic phase (30 - 50 minutes gradually increasing exercise duration; heart rate zone based on baseline cardiopulmonary exercise test) and cool-down phase. The exercise training period is set to 3 times a week for 12 weeks. Study participants will receive user guides developed by research team with detailed instructions regarding equipment set-up, training protocol, and contact information. Also, participants will receive weekly phone calls from week 0 to week 12 to monitor adverse events, encourage compliance and adherence to the study protocol, address any subject questions or concerns, and collect information regarding participants' current symptomatology.
41355846|NCT01329991|DRUG|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
41355847|NCT01329991|DRUG|Placebo|Matching placebo for PLX5622
41355848|NCT04766944|OTHER|No intervention|No intervention
41355849|NCT04693091|DEVICE|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
41355850|NCT05140486|PROCEDURE|Rehabilitation: shortwave diathermy and perceptual training|All subjects in the rehabilitation group received shortwave diathermy therapy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks.
41355851|NCT05284383|BEHAVIORAL|Closed-label nocebo conditioning|"Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials)."
41495685|NCT05296135|DIAGNOSTIC_TEST|OncoPrism-HNSCC™|OncoPrism-HNSCC™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
41495686|NCT03580083|GENETIC|RGX-111|Recombinant adeno-associated virus serotype 9 capsid containing α-L-iduronidase expression cassette
41355852|NCT05284383|BEHAVIORAL|Closed-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the counterconditioning procedure (i.e. activation of the device will reduce their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
41355853|NCT05284383|BEHAVIORAL|Open-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a open-label verbal suggestions in line with the counterconditioning procedure (i.e. they are told counterconditioning will be used to reduce nocebo effects and they are told the device is sham, but that their pain will still be influenced because of the placebo effect). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
41021564|NCT03726359|RADIATION|Fractionated Stereotactic Radiation Therapy|Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the SBRT schedule is completed within 1.5-2 weeks.
41495687|NCT02662283|DRUG|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
41495688|NCT02662283|DRUG|Reh-acteoside|Oral take and reh-acteoside (0.4g bid) for 8 weeks
41495689|NCT05896930|DRUG|Meropenem 6g IV over 6 hours|Meropenem 6g intravenously over 6 hours once daily on days 1-14.
41495690|NCT05896930|DRUG|Ertapenem 1g IM|Ertapenem 1g intramuscularly once daily on days 1-14.
41495691|NCT05896930|DRUG|Meropenem 3g IV|Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
41495692|NCT05896930|DRUG|Ertapenem 1g IV|Ertapenem 1g intravenously once daily on days 1-14.
41495693|NCT05896930|DRUG|Amoxicillin/CA twice daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
41495694|NCT05896930|DRUG|Rifampicin 35 mg/kg|Rifampicin 35 mg/kg once daily on days 1-14.
41495695|NCT05896930|DRUG|Meropenem 6g IV over 60 minutes|Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
41495696|NCT05896930|DRUG|Rifafour e-275|Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
41495697|NCT05896930|DRUG|Meropenem 4g IV|Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
41495698|NCT05896930|DRUG|Amoxicillin/CA once daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
41495699|NCT01708148|DIETARY_SUPPLEMENT|Probiotics|lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
41495700|NCT01708148|OTHER|Placebo|control group would receive a oral lactose placebo
41021565|NCT02164682|PROCEDURE|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
41021566|NCT02164682|PROCEDURE|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
41021567|NCT03713567|BEHAVIORAL|Experimentally induced plaque|Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
41021568|NCT00079352|DRUG|alvocidib|Given IV
41021569|NCT00079352|DRUG|gemcitabine hydrochloride|Given IV
41495701|NCT04776837|BEHAVIORAL|Observational Cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessment
41160188|NCT00988897|DRUG|BEVACIZUMAB|Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
41495702|NCT02943928|DEVICE|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
41495703|NCT02943928|DEVICE|traditional method by experience|Operator inserted the double lumen tube by experience
41495704|NCT05344248|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|Subcutaneous injection
41495705|NCT05344248|BIOLOGICAL|JS005 placebo|Subcutaneous injection
41495706|NCT00237913|DRUG|Aripiprazole|Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.
41495707|NCT00237913|DRUG|Olanzapine or Quetiapine or Risperidone|Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
41021570|NCT00079352|DRUG|irinotecan hydrochloride|Given IV
41160189|NCT05570578|DEVICE|HD-tDCS|The anode electrode will be placed over Broca's area, 4 cathode electrodes will be placed at about 2 cm distance each from the anode in 4 directions.
41160190|NCT02108483|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
41160191|NCT02108483|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
41160192|NCT05858047|DRUG|Placebo|Administered orally, once daily (QD)
41160193|NCT05858047|DRUG|SYHX1901|Administered orally, once daily (QD)
41495708|NCT04229173|DIAGNOSTIC_TEST|MRI acquisition|MRI acquisition
41495709|NCT04229173|DIAGNOSTIC_TEST|DAT-SPECT|Imaging with DAT SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography)
41495710|NCT04229173|DIAGNOSTIC_TEST|blood sample, cerebrospinal fluid (optional)|blood sample, cerebrospinal fluid
41495711|NCT04229173|BEHAVIORAL|Evaluations about motor abilities, depression, cognition and lifestyle|Evaluations about motor abilities (UMSAR scale), depression (BDI scale), cognition (MoCA scale) and lifestyle (MSA- QoL)
41495712|NCT04229173|BEHAVIORAL|Evaluation about depression cognition|Evaluations about depression (BDI scale), cognition (MoCA scale)
41495713|NCT05190809|PROCEDURE|Goldilocks mastectomy and fat transfer|Skin sparing mastectomy (Goldilocks mastectomy), then autologous fat grafting in the medial and lateral breast pillars as well as the inferior dermal flap
41495714|NCT02908035|DRUG|Temsirolimus|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
41495715|NCT02908035|DRUG|Saline|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
41495716|NCT05167227|OTHER|Extension for Community Healthcare Outcomes|ECHO is a technology enabled multi-disciplinary team-based care model centered on case-consultation and peer-to-peer sharing of emerging best practices (i.e., teleECHO) to support management of complex cases associated with Long COVID, ME/CFS, and other PIFI.
40835841|NCT02721108|BEHAVIORAL|Mindfulness meditation|The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
40835842|NCT02721108|BEHAVIORAL|Relaxation app|The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
40835843|NCT01328340|OTHER|High-speed power training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength
41355854|NCT05284383|BEHAVIORAL|Closed-label extinction|"Extinction consists of a learning and test phase. In the learning phase, slightly painful stimuli are used for all trials. During the testing phase, again a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials)."
41021571|NCT05859347|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.
41021572|NCT02736162|OTHER|No treatment (intervention) was administered|
41355855|NCT05895422|PROCEDURE|pyeloplasty|repair of the uPJO
41355856|NCT02559830|GENETIC|transduced CD34+ hematopoietic stem cell|Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10\^6 transduced CD34+ cells/Kg (maximum 20x10\^6) at bedside for infusion.
41495717|NCT06355791|DEVICE|Minuteman G5|The Minuteman G5 MIS Fusion Plate consists of spinous process plates and surgical instruments. Implants are made of Titanium alloy
40835844|NCT01328340|OTHER|Slow-speed strength training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
40835845|NCT02501564|DRUG|Naproxen Sodium Codeine|One tablet twice a day
41021573|NCT02120339|DRUG|Carvedilol|
41021574|NCT01485601|BIOLOGICAL|MT10109|Single dose intramuscular injection MT10109 vs Botox®
41021575|NCT00215293|DEVICE|Cervical I/F Cage|
41021576|NCT00215293|DEVICE|Autograft or allograft with a plate, or autograft alone.|
41021577|NCT02863354|DRUG|Aflibercept|Intravitreal injection
41021578|NCT03205696|DRUG|Antiretrovirals|The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
41021579|NCT06573892|DIETARY_SUPPLEMENT|Probiotic|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
41355857|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine, HBIG|Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG
41355858|NCT01183611|BIOLOGICAL|Active Comparator hepatitis B vaccine|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG
41355859|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine|Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine
41355860|NCT01183611|BIOLOGICAL|Active Comparator recombinant hepatitis B vaccine.|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
41355861|NCT01183611|BIOLOGICAL|Placebo Comparator recombinant hepatitis B vaccine|Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
41355862|NCT05523648|DRUG|Chronic Hepatitis B|92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.
41495718|NCT05004584|OTHER|Wheat home-based appetite assessment|Home-based appetite assessment with diet based on wheat cereal products.
41495719|NCT05004584|OTHER|Rye home-based appetite assessment|Home-based appetite assessment with diet based on rye cereal products.
41495720|NCT05004584|OTHER|Wheat clinic-based appetite assessment|Clinic-based appetite assessment with diet based on wheat cereal products.
41021580|NCT06573892|DIETARY_SUPPLEMENT|Placebo|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
41355863|NCT05282667|PROCEDURE|Reconstructive therapy of peri-implantitis by means of bone graft (and barrier membrane in the test group)|"A full-thickness flap was raised to ensure sufficient access. Debridement of granulation tissue was subsequently conducted using a mini-five curette (Hu-Friedy) and site-specific Gracey curettes (Hu-Friedy). The surgical approach was tailored to the clinical scenario. Specifically, resective therapy by means of implantoplasty was performed for supracrestal defects (Meisinger LLC, Nauss, Germany). Surface detoxification was performed with 3% hydrogen peroxide during 2 minutes and irrigation with 0.12% chlorhexidine. The intraosseous compartment was grafted using mineralized and demineralized bone graft (LifeNet Health, Virginia, USA). The graft was compartmentalized in the test group with a collagen porcine resorbable membrane (RTM, Cytoplast, California, USA) adapted to the defect morphology. Nylon 5.0 (Resorba Sutures, Osteogenics Biomedical, Lubbock, Texas) was used for suturing, ensuring primary wound closure"
41355864|NCT05784558|DEVICE|UroLift System|The UroLift System is a procedure that utilizes tiny implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra.
41355865|NCT05784558|OTHER|Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
41355866|NCT05784558|DEVICE|Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
41355867|NCT02079701|BIOLOGICAL|23-valent pneumococcal vaccine|randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
41021581|NCT01163682|DEVICE|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
41021582|NCT01163682|DEVICE|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The electro-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
41160194|NCT06116942|DEVICE|Active rTMS|"The Transcranial Magnetic Stimulation will consist of placing a figure-of-eight shape coil of wire over the head of the participants. Then, a brief electric current will pass through the coil, inducing a magnetic field capable of stimulating neurons located beneath the coil. For the active coil, the maximal stimulation intensity is reached beneath the center of the coil.~In the present study, the intermittent theta-burst protocol will be implemented. This protocol is expected to modulate the excitability of the brain, priming it for a stronger activation of the motor-related brain areas engaged during brain-computer interface-based training. The structural MRI of each participant will be used to guide neuronavigation towards ipsilesional motor areas."
41355868|NCT02079701|BIOLOGICAL|Placebo|
41355869|NCT00601510|DRUG|capecitabine|
41355870|NCT00601510|DRUG|cisplatin|
41355871|NCT00601510|DRUG|imatinib mesylate|
40835846|NCT02501564|DRUG|Placebo|One tablet twice a day
41355872|NCT02447393|DRUG|levocetirizine|levocetirizine
41355873|NCT02447393|DRUG|cetirizine|cetiridine
41355874|NCT02447393|DRUG|placebo|placebo
41355875|NCT05450133|OTHER|Systemic inflammatory index|neutrophil count x platelet count/lymphocyte count
41355876|NCT05450133|OTHER|BASDAI|Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.
41495721|NCT05004584|OTHER|Rye clinic-based appetite assessment|Clinic-based appetite assessment with diet based on rye cereal products.
41495722|NCT05004584|OTHER|Rye/Wheat clinic-based appetite assessment with blood sampling|Clinic-based appetite assessment with diet based on rye or wheat cereal products and continuous blood sampling.
40835847|NCT05902481|OTHER|Education|education about breastfeeding with mixed reality technology.
40835848|NCT04787068|BEHAVIORAL|Occupational Therapy support|Intervention include (a) didactic education about diseases; (b) the use of errorless techniques to improve assistance for CR's Activities of Daily Living (ADL), Instrumental ADL, and communication tasks; (c) the use of incentives (e.g., providing a favorite scented shampoo); (e) use of a schedule/calendar on a computer, cell phone and/or blackboard in CR's home to coordinate caregiving tasks for family members; (f) suggesting more frequent PACE daycare visits or use of a nearby PACE, having a snack or short game to prevent going to bed right after dinner); (d) use of the Buffalo Functional Exercise for strengthening ( a home-based exercise developed for PACE by the PI and shown to be effective in preventing falls)
40835849|NCT05323123|BEHAVIORAL|PrEP Romania|Enrolled participants will receive PrEP education and adherence counseling from trained counselors, and have a medical evaluation from a physician, who will prescribe PrEP.
40835850|NCT01406496|DRUG|insulin|Three different timings of insulin delivered by a pump
40835851|NCT05054543|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
40835852|NCT05054543|DRUG|Placebo|0.9% Sodium Chloride
41355877|NCT05450133|OTHER|ASDAS-ESR|The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).
41355878|NCT05450133|OTHER|ASDAS-CRP|The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).
41355879|NCT05450133|OTHER|MASES|It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.
41355880|NCT04669106|OTHER|laboratory clinical trial study|The research stage consisted of two stages, the first stage was the initial screening of the primary data of the research subjects, namely by analyzing food intake including mineral intake data, the diet of the research subjects, mineral and enzyme levels, and data on soil conditions in the area. The second stage was to analyze the relationship between the existing variables so that the most significant relationship was seen between the differences in diet, mineral content, enzyme levels, and soil content between the two groups.
41355881|NCT05060003|DRUG|Atezolizumab|Atezolizumab is provided by Genentech.
41355882|NCT05060003|DRUG|Tiragolumab|Tiragolumab is provided by Genentech.
41355883|NCT05060003|DEVICE|Signatera Assay|"* To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)"
41355884|NCT02993640|DRUG|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
41355885|NCT03578211|BEHAVIORAL|Shared decision making with decision aids|For obese patients, we use shared decision making with decision aids to help them choose the suitable types of bariatric surgery.
41355886|NCT00743639|PROCEDURE|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10\[7\] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
41355887|NCT05381194|DRUG|BPaL(M) regimen|"Patients diagnosed with MDR/RR-TB are initially assigned to the BPaLM regimen as a single-arm for treatment initiation. Afterward, if MDR/RR-TB is confirmed to be fluoroquinolone-resistant by molecular or phenotypic DST, the treatment is switched to the BPaL regimen (for 24 weeks). On the other hand, if MDR/RR-TB is confirmed to be fluoroquinolone-susceptible, treatment for MDR/RR-TB is maintained with the BPaLM regimen (for 26 weeks).~The dosage of each medication is as follows:~* Bedaquiline 400mg/day for the 2 weeks, 200mg/TIW afterward~* Pretomanid 200mg/day~* Linezolid 600mg/day for the 9weeks, 300mg/day afterward~* Moxifloxacin 400mg/day"
41355888|NCT05093842|BEHAVIORAL|Sedentary Behavior Reduction|Participants receive bimonthly behavioral health coaching, a sit-stand desk attachment or table, and an activity prompter if they do not already have one (e.g., fitbit, as needed).
41355889|NCT05093842|BEHAVIORAL|Information on Physical Activity Recommendations during Pregnancy|Participants in the study will receive educational materials provided one time by email about the currently recommended physical activity during pregnancy.
41495723|NCT06400277|OTHER|Edentulous maxilla final impression for complete denture|Final impressions of edentulous maxilla separated in two groups. In physical impression group stock and individual trays and physical impression materials used.
41355890|NCT01985152|DRUG|Azilsartan Trimethylethanolamine|
41495724|NCT05693207|DEVICE|EMG|wearables EMG
41495725|NCT03180463|DRUG|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2\*10\^7 cells,
41495726|NCT03180463|PROCEDURE|core decompression|The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
41495727|NCT04352387|BEHAVIORAL|Montessori Method for Dementia|The Montessori Method highlights the importance of considering the past experiences, identifying interests and maximizing spared capacity and abilities of each individual.
41495728|NCT04352387|BEHAVIORAL|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
41495729|NCT03666650|DRUG|Edoxaban 60 MG|Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
41495730|NCT04311788|DEVICE|Prophylactic self gripping mesh|Prophylactic self gripping mesh, Propgrip by Medtronic.
41495731|NCT04311788|DEVICE|Slowly absorbable continuous monofilament suture|Fascial closure by continuous slowly absorbable 4:1 suture
41495732|NCT02083718|BIOLOGICAL|PBSC|
41495733|NCT02083718|BIOLOGICAL|MSCs|
41355891|NCT01985152|DRUG|Placebo|
41495734|NCT04131777|DEVICE|Radiofrequency (RF) catheter|A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation
41509208|NCT02770378|DRUG|Itraconazole|Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
41509209|NCT02770378|DRUG|Ritonavir|Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
41355892|NCT03264027|DRUG|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
41355893|NCT03264027|DRUG|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
41355894|NCT03264027|DRUG|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
41355895|NCT04203290|DRUG|Bupivacaine|%0.25 bupivacaine solution
41355896|NCT04203290|DRUG|Sevoflurane|End tidal sevoflurane concentration
41355897|NCT00648544|DRUG|Pravastatin|Single-dose 80 mg oral immediate-release tablet
41355898|NCT00648544|DRUG|Pravastatin|Single-dose 80 mg oral immediate-release tablets
41355899|NCT01875731|BEHAVIORAL|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
41355900|NCT01875731|BEHAVIORAL|Guideline|Strategy based on enforced guideline guided antibiotic use
41355901|NCT01909635|BEHAVIORAL|Food Feelings|
41355902|NCT01909635|BEHAVIORAL|Other Feelings|
41355903|NCT03748654|DIAGNOSTIC_TEST|Visual Field Testing|Visual field test using the protocol 24-2 Threshold Test
41495735|NCT03092063|BEHAVIORAL|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
41495736|NCT03092063|BEHAVIORAL|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
41495737|NCT03092063|BEHAVIORAL|Enhanced engagement|The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
41495738|NCT03092063|BEHAVIORAL|Multifamily Group|"The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
41495739|NCT04600102|DEVICE|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Sensor scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
41495740|NCT05918406|COMBINATION_PRODUCT|Nasal Guide|Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
41495741|NCT00570895|DIETARY_SUPPLEMENT|Vitamin C|"Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2."
41355904|NCT02879435|DRUG|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
41021583|NCT06487039|DRUG|EB-203|Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.
41355905|NCT02879435|OTHER|Placebo|pre-operative wound infiltration with 10 ml of sterile water
41355906|NCT01432236|DRUG|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
41355907|NCT01432236|DRUG|placebo|placebo capsules twice a day for 14 weeks
41355908|NCT03500419|DEVICE|RestoreX|PTT - Penile traction therapy in the straight position.
41355909|NCT03500419|OTHER|No treatment|Control group. No treatment will be given for the 6 months post-prostatectomy
41021584|NCT05662241|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
41021585|NCT05662241|OTHER|Placebo|Placebo
41355910|NCT03315676|DRUG|Oral Bonoprazan|To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers
41355911|NCT03315676|DRUG|Oral Esomeprazol|To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
41355912|NCT05713344|OTHER|Clinical history|Detailed clinical history including demographic details, pain details (character, pattern, location, change in character, involvement of new areas), duration of disease, co-morbidities, family history, adverse life events, sleep details, details of stress/anxiety.
41355913|NCT05713344|OTHER|Clinical examination|Thorough clinical examination, anthropometric measurement, assessment of pain (Izbicki score, Visual analog scale, modified brief pain inventory, pain catastrophising score, painDetect)
41355914|NCT05713344|OTHER|Evaluation of quality of life|Use of the EORTC QLQ c30 with PAN 28 to evaluate quality of life
41355915|NCT05713344|OTHER|Evaluation of mental state|Use of Beck depression inventory and Hospital Anxiety Depression score to evaluate depression and anxiety
41355916|NCT05713344|DIAGNOSTIC_TEST|Pancreatic quantitative sensory testing|Pancreatic quantitative sensory testing will be performed to evaluate temporal summation, pain detection threshold, pain tolerance threshold, and conditioned pain modulation.
41355917|NCT00003899|BIOLOGICAL|filgrastim|
41355918|NCT00003899|DRUG|cyclophosphamide|
41355919|NCT00003899|DRUG|melphalan|
41355920|NCT00003899|DRUG|paclitaxel|
41355921|NCT00003899|DRUG|thiotepa|
41355922|NCT00003899|PROCEDURE|autologous bone marrow transplantation|
41355923|NCT00003899|PROCEDURE|peripheral blood stem cell transplantation|
41355924|NCT04704206|OTHER|Children will perform activities on interactive tablet|"The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions."
41355925|NCT05807646|OTHER|Vein ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.
41355926|NCT05807646|OTHER|Artery ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
41355927|NCT03724799|DEVICE|Intravascular laser irradiation of blood for the patients with cerebral infarction|Intravenous low level therapy has been a variety of applications in many different areas of medicine with a growing interest. It possesses laser specific biomodulation, analgesic, spasmolytic and even sedative effects among many other.
41355928|NCT05488873|DRUG|WST-057 Active|WST-057 Topical Solution
41355929|NCT05488873|DRUG|Placebo|Matching Placebo Topical Solution
41355930|NCT04842942|PROCEDURE|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
41355931|NCT04327245|OTHER|Intervention ingest a 5000 mg of D-tagatose|"Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids."
41355932|NCT04327245|OTHER|Intervention ingest a 15,3 mg of stevia|"Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
41355933|NCT00079157|BIOLOGICAL|incomplete Freund's adjuvant|
41355934|NCT00079157|BIOLOGICAL|sargramostim|
41355935|NCT00079157|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
41355936|NCT04030806|OTHER|Mirror therapy intervention and control intervention|"The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation."
41355937|NCT03357328|OTHER|Therapy light room|See group description
41355938|NCT03357328|OTHER|Standard light|See group description
41355939|NCT03637959|DEVICE|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.
41355940|NCT00951912|DIETARY_SUPPLEMENT|Placebo|10g soy protein isolated per day
41355941|NCT00951912|DIETARY_SUPPLEMENT|Daidzein|50mg daidzein +10g soy protein isolated per day
41021586|NCT06204159|DEVICE|TACE Catheters|"End Hole and TriNav catheters are FDA approved. This study is comparing the two for chemotherapy delivery during the TACE procedure.~This study will randomize which catheter is used for the first TACE procedure and the other catheter will be used for the second TACE procedure"
41355942|NCT00951912|DIETARY_SUPPLEMENT|Genistein|50mg genistein +10g soy protein isolated per day
41355943|NCT01196065|DRUG|RO5313534|single oral dose
41355944|NCT01196065|DRUG|memantine|multiple doses to steady state
41355945|NCT01982942|DRUG|ibudilast|Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
41355946|NCT01982942|DRUG|Placebo oral capsule|Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
41355947|NCT02245295|PROCEDURE|Moderate Sedation for EBUS/TBNA|EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
41021587|NCT04748380|OTHER|CRC decision aid pamphlet|A newly developed 8-10 page decision aid pamphlet that discusses:1. Information on CRC; 2. Information about risk and benefits including the 10-year lag-time to benefitting from CRC screening; 3. Information to help patients evaluate CRC screening options (colonoscopy or stool testing); 4. Possible outcomes relevant to LE and health status. In addition, there will be a values clarification exercise
41021588|NCT04748380|OTHER|Home Safety Pamphlet|The home safety information pamphlet is a 2-page fact sheet on home safety tips for older adults, and was designed by the AGS Health in Aging Foundation. It includes information in seven areas to help older adults stay safe in their homes. Areas include but are not limited to fall prevention and safety proofing homes. It has been used successfully in prior studies of DAs as a control intervention
41021589|NCT00546143|DRUG|Omalizumab|
41021590|NCT00546143|DRUG|Omalizumab|
41021591|NCT00546143|DRUG|Omalizumab|
41021592|NCT03913117|BIOLOGICAL|pNGVL4aCRTE6E7L2|Naked pNGVL4aCRTE6E7L2 DNA plasmid
40835853|NCT06027346|BIOLOGICAL|Bio-008|The subjects in each dose group received the corresponding dose of BIO-008 monotherapy, administered intravenously (ivd) for a duration of 0.5 to 3 hours (the researchers can adjust the administration time according to the patient's tolerance). If there is an infusion reaction, the infusion can be suspended and completed within 12 hours. Administer on the first day of each cycle, once every 3 weeks (1 cycle, i.e. 21 days) (Q3W) until the criteria for termination of treatment or withdrawal from the study are met, whichever occurs first.
40835854|NCT01561963|DRUG|Apremilast|Tablets for oral administration
40835855|NCT01561963|DRUG|Rifampin Oral Capsules|Capsules for oral administration
40835856|NCT01561963|DRUG|Rifampin IV Solution|Intravenous (IV) solution
41355948|NCT02245295|PROCEDURE|General anesthesia for EBUS/TBNA|EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
41355949|NCT04885205|BEHAVIORAL|cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I program is a 6-week, 1x/week, one-on-one program. The delivery of CBT-I will be done remotely over a secure teleconference service (Zoom) or phone. Participants will maintain a sleep diary during the course of the program to aid in tailoring the intervention. Each session lasts about 45-60min:
41355950|NCT02608099|DRUG|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
40835857|NCT03926962|DRUG|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
40835858|NCT03926962|DRUG|Placebo Oral Tablet|Visually matching placebo
41355951|NCT02608099|DRUG|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
41355952|NCT04120025|BEHAVIORAL|Diaphragm Training|training on isolated abdominal breathing with proper effort and hold time to promote strengthening
41355953|NCT00001126|DRUG|Cidofovir|
41355954|NCT04155190|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
40835859|NCT01747252|DIETARY_SUPPLEMENT|RGC|
40835860|NCT01747252|DIETARY_SUPPLEMENT|RGC|
41355955|NCT04155190|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
41355956|NCT03043300|OTHER|Screening Criteria Review|"The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.~This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States."
41355957|NCT03043300|OTHER|Pre-Travel Questionnaire|"The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.~This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States."
41355958|NCT03043300|OTHER|Pre-Travel Stool Specimen Collection|"The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
41355959|NCT03043300|OTHER|Short-Term Post-Travel Questionnaire|"The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.~This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel."
41355960|NCT03043300|OTHER|Short-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
40835861|NCT01747252|DIETARY_SUPPLEMENT|Resveratrol|The equivalent of 150 mg resveratrol
40835862|NCT02534116|PROCEDURE|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
40835863|NCT02534116|PROCEDURE|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
40835864|NCT03406416|DEVICE|44Ch Bionic Eye Device|Prototype wide view suprachoroidal retinal prosthesis
40835865|NCT04378296|OTHER|Teledermatology|The experimental group will be made up of dermatological patients monitored asynchronously.
41021593|NCT03913117|BIOLOGICAL|TA-CIN|TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
40835866|NCT01922375|DRUG|Naftopidil|
41021594|NCT06532331|DRUG|ONO-7475|Specified dose on specified days
41021595|NCT06532331|DRUG|ONO-4538|Specified dose on specified days
41021596|NCT06532331|DRUG|Nab-paclitaxel|Specified dose on specified days
41021597|NCT06532331|DRUG|Gemcitabine|Specified dose on specified days
41021598|NCT02096835|DEVICE|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
41355961|NCT03043300|OTHER|Long-Term Post-Travel Questionnaire|"The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.~This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel."
41355962|NCT03043300|OTHER|Long-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
41495742|NCT03868150|DRUG|Amiodarone Injection|Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
41495743|NCT03868150|DEVICE|Intraoperative Rapid Atrial Pacing|Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
41495744|NCT04542616|DEVICE|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
41495745|NCT04661683|OTHER|Combustible Hookah Smoke|Exposure to combustible hookah smoke for a duration of 60 minutes.
41495746|NCT04661683|OTHER|Electronic Hookah Aerosol|Exposure to electronic hookah aerosol for a duration of 60 minutes.
41495747|NCT04661683|OTHER|Clean Room Air|Exposure to room air for a duration of 60 minutes.
41495748|NCT05301153|DIAGNOSTIC_TEST|real time PCR , ELISA|Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39. Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA
41495749|NCT02068235|DRUG|Ponesimod 5mg i.v.|
41495750|NCT02068235|DRUG|Ponesimod i.v.|Dose and infusion rate will be adjusted according to the results of the pilot phase
41495751|NCT02068235|DRUG|Ponesimod 10 mg tablet|
41495752|NCT00002785|BIOLOGICAL|filgrastim|
41495753|NCT00002785|DRUG|asparaginase|
41021599|NCT02096835|DEVICE|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
41495754|NCT00002785|DRUG|cyclophosphamide|
41495755|NCT00002785|DRUG|cyclosporine|
41495756|NCT00002785|DRUG|cytarabine|
41495757|NCT00002785|DRUG|daunorubicin hydrochloride|
41495758|NCT00002785|DRUG|dexamethasone|
41495759|NCT00002785|DRUG|etoposide|
41021600|NCT02096835|DRUG|Tropisetron|will be given at the start of skin closure
41021601|NCT02096835|DRUG|Dexamethasone|will be given after induction
41495760|NCT00002785|DRUG|leucovorin calcium|
41495761|NCT00002785|DRUG|mercaptopurine|
41495762|NCT00002785|DRUG|mesna|
41495763|NCT00002785|DRUG|methotrexate|
41495764|NCT00002785|DRUG|methylprednisolone|
41021602|NCT02896231|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
41021603|NCT05410912|PROCEDURE|Great saphenous vein stripping and ambulatory phlebectomy|All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.
41355963|NCT03059576|OTHER|Chronobiological status of the subjects|"Participation was completely voluntary and not remunerated. The subjects were organized into groups of 5 pairs, and were given an appointment at a university facility located in the city center, where informed consent was signed prior to the procedures indicated below. An informational letter was sent to pre-selected individuals. Later a phone call confirmed their availability.~* Temperature rhythm was assessed continuously for 7 days using a temperature sensor and programmed to collect information every 10 min.~* Body position and rest-activity rhythm were assessed over the same 7 days using a Acceleration Data Logger that record data every min and placed on the non-dominant arm by means of an elastic band, with its X axis parallel to the humerus bone.~* Diet and sleep record were completed over the same week, their sleep schedules and their nutritional status."
41355964|NCT05434728|OTHER|20 ml venous blood collection|participant blood sample will be divided between sample EDTA sample tubes for thrombin generation testing and viscoelastic (ROTEM) testing of impaired hemostasis
41355965|NCT00041119|DRUG|AC regimen|Given IV
41355966|NCT00041119|DRUG|cyclophosphamide|Given IV
41355967|NCT00041119|DRUG|doxorubicin hydrochloride|Given IV
41495765|NCT00002785|DRUG|pegaspargase|
41495766|NCT00002785|DRUG|prednisone|
41495767|NCT00002785|DRUG|therapeutic hydrocortisone|
41021604|NCT04854200|DEVICE|Medtronic HeartWare ™ HVAD™ System|The Medtronic HeartWare™ HVAD™ System includes a ventricular assist device (VAD) that helps the heart pump and increases the amount of blood that flows through the body in patients with advanced heart failure.
41021605|NCT06280352|DEVICE|Custom made Total Knee Arthroplasty|Total knee replacement, patient specific custom made total knee Origin (Symbios, Symbios Orthopédie SA, Avenue des Sciences 1, 1400 Yverdon-les-Bains, Switzerland)
41021606|NCT06280352|DEVICE|Functionally aligned robotically assisted total knee arthroplasty|Total knee replacement, Total Knee Implant Triathlon (Stryker, Kalamazoo, Michigan, U.S.) implanted using MAKO Rio Robotic Arm (Stryker), using functional alignment strategy
41021607|NCT04670679|DRUG|ERAS-601|Administered orally
41355968|NCT00041119|DRUG|paclitaxel|Given IV
41355969|NCT00095836|DRUG|Gefitinib|Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
41021608|NCT04670679|DRUG|Cetuximab|Administered via intravenous infusion
41021609|NCT04670679|DRUG|Pembrolizumab|Administered via intravenous infusion
41021610|NCT03480555|DIETARY_SUPPLEMENT|Replenish Protein|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
41021611|NCT03480555|DIETARY_SUPPLEMENT|Standard protein|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
41021612|NCT02565381|DRUG|Transdermal nicotine patch|"* ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks"
41021613|NCT02565381|BEHAVIORAL|In-person smoking cessation counseling|- One-on-one 15-minute counseling sessions once per week for 8 weeks
41021614|NCT02565381|BEHAVIORAL|Contingent financial rewards for smoking abstinence|- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide \<8ppm
41021615|NCT02565381|BEHAVIORAL|Text messages to support smoking abstinence|- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
41021616|NCT04406805|DIAGNOSTIC_TEST|Measurement of plasma and urine trimethylamine-N-oxide concentration|Information already included in arm/group descriptions.
41021617|NCT01714700|BEHAVIORAL|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
41355970|NCT01278966|OTHER|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
41355971|NCT05032131|BIOLOGICAL|ADSVF|Group 1 and 2 : Escalating dose of ADSVF injection (5 millions of cells, 10 millions of cells and 20 millions of cells).
41495768|NCT00002785|DRUG|vincristine sulfate|
41495769|NCT00002785|PROCEDURE|allogeneic bone marrow transplantation|
41495770|NCT00002785|RADIATION|low-LET cobalt-60 gamma ray therapy|
41495771|NCT00002785|RADIATION|low-LET photon therapy|
41495772|NCT02283294|DRUG|Apixaban|
41495773|NCT02283294|DRUG|Warfarin|
41509210|NCT02770378|DRUG|Auranofin|Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
41021618|NCT01714700|BEHAVIORAL|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
41021619|NCT02127008|PROCEDURE|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
41355972|NCT02460120|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
41355973|NCT04168775|DEVICE|Home PIFR monitoring with InCheck Dial|The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
41355974|NCT04880642|DRUG|C21|C21
41355975|NCT04880642|DRUG|Placebo|Placebo
41509211|NCT05435690|DEVICE|Computer-assisted arthroplasty|Computer-assisted arthroplasty
41355976|NCT00552006|BEHAVIORAL|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
41355977|NCT00552006|BEHAVIORAL|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
41355978|NCT01671176|DEVICE|Wide diameter bone anchored implant|4.5 mm wide diameter bone anchored implant
41509212|NCT00003643|BIOLOGICAL|bleomycin sulfate|
41509213|NCT00003643|BIOLOGICAL|filgrastim|
41509214|NCT00003643|DRUG|cisplatin|
41509215|NCT00003643|DRUG|etoposide|
41021620|NCT02127008|PROCEDURE|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
41021621|NCT04475445|OTHER|Ultrasound-guided transforaminal epidural steroid injection|Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
41509216|NCT00003643|DRUG|paclitaxel|
41509217|NCT02407639|OTHER|CO2|gas
41509218|NCT02407639|OTHER|air|air
41355979|NCT03041493|BEHAVIORAL|Electronic cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
41160195|NCT06116942|DEVICE|Sham rTMS|To implement a placebo stimulation, a sham coil will be used to deliver the same stimulation protocol. The sham coil is identical in dimensions and weight to the active coil but produces a diminished magnetic field. For the sham coil, the stimulation intensity is minimal beneath the center of the coil, the same area with the highest intensity during stimulation with an active coil. The structural MRI scan of each participant will be used to guide neuronavigation towards the same area where the active stimulation was applied.
41495774|NCT01675466|PROCEDURE|early laparoscopy|Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.
41495775|NCT01675466|PROCEDURE|General anaesthesia|
40835867|NCT05474534|DEVICE|Neurofeedback (MUSE 2)|During each at-home treatment session, mothers will place the MUSE 2 on their heads and connect it to the app on their personal device. Their brain activity is monitored by the MUSE 2 and is represented on the app through audio-based feedback (e.g., birds chirping, sounds of waves lapping on the beach) that mothers will listen to with earbuds as they direct their focus on maintaining a calm state of mind during the session; when a calm state is maintained, they are rewarded with calming sounds. The goal is to gain increased conscious control over their own brain activity. The audio feedback, primarily composed of nature-based sounds, is meant to guide their brain activity into a calm state. The session will begin, and the MUSE 2 will provide audio feedback in real time to guide their brainwave activity into an optimal frequency bandwidth range (e.g., as their brain activity reaches the target state, sounds of wind would subside to peaceful waves or other rewarding audio feedback).
40835868|NCT05154604|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
40835869|NCT00721721|BEHAVIORAL|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
41355980|NCT03041493|BEHAVIORAL|traditional cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
41355981|NCT03041493|BEHAVIORAL|(sham cigarette) - no actual exposure to cigarettes|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
41355982|NCT06421363|DRUG|Inclisiran|Implementation of a follow-up program that incorporates Inclisiran treatment in patients with a history of chronic coronary syndrome
41355983|NCT04681742|BEHAVIORAL|CO-OP Group|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
41355984|NCT06019351|DEVICE|OrthoAnalyzer™ software|OrthoAnalyzer™ software module from 3Shape Software
41355985|NCT05748366|PROCEDURE|Serratus Anterior Plane Block (SAPB)|The ultrasound-guided serratus anterior plane block (SAPB) will be performed in a manner previously described in published medical literature. Patients will be consented and monitored. Bupivacaine 0.5% (5 mg/ml) diluted to 30-40 ml will be used in a dose not to exceed 2 mg/kg. The serratus anterior fascial plane will be identified in the 4th/5th intercostal space. The needle will be advanced under real-time ultrasound guidance targeting the superficial serratus anterior fascial plane. The procedure assistant will inject small volumes to hydrodissect the muscle bellies evenly under direct visualization, indicating local anesthetic spread within the fascial plane. Anesthetic will then be injected in 5 ml increments and the needle will be removed. Patient will be continuously monitored on telemetry and pulse-oximetry. Reassessment of the patient will continue for 30 minutes to monitor for signs of local anesthetic systemic toxicity.
41355986|NCT05748366|DRUG|Standard Analgesic Medications|Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
41355987|NCT05643287|PROCEDURE|Periodontal treatment|Non-surgical periodontal treatment
41355988|NCT05535452|DEVICE|Photobiomodulation through LED board|The applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physiotherapists and physiotherapy students, through the sportllux LED plate equipment, medium size, which combines light emitters in two wavelengths: red (660nm) and infrared (850nm).
41355989|NCT01005875|DRUG|Sorafenib|Nexavar in bottles of 120 tables
41355990|NCT01005875|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT
41355991|NCT03283813|DIETARY_SUPPLEMENT|Zinc|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
41355992|NCT03283813|DRUG|Placebos|In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
41495776|NCT01675466|DEVICE|Laparoscopic instruments|
40835870|NCT00721721|BEHAVIORAL|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
40835871|NCT00721721|DIETARY_SUPPLEMENT|Potassium Supplementation|60 mmol potassium supplement
41355993|NCT03283813|DRUG|Myoinositol|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
41355994|NCT02807376|DEVICE|Surgeon's 'standard of care' stapler|
41355995|NCT02807376|DEVICE|Ethicon Powered Vascular Stapler|
41355996|NCT01641029|OTHER|No intervention|There is no intervention
41355997|NCT04500626|DRUG|Oxygen|Hyperbaric oxygen therapy delivered in a monoplace or multi-place chamber. Supervised by a hyperbaric oxygen therapy physician and a chamber operator.
41495777|NCT04603235|BEHAVIORAL|Manual-based Art Therapy|This is a manual-based treatment and consists of 10 one-hour weekly sessions. The treatment consist of detailed guidelines based on phenomenological art therapy. The sessions follow the same structure: Introduction, short relaxation, art-making, reflections about the image, and conclusions. Examples of comprised art tasks; lifeline, emotional scribbles, and different roles. The art tasks served as a prompt for painting.
41495778|NCT02968849|BIOLOGICAL|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a dose \> 10\^6 cell culture infectious dose 50% (CCIDv50) and \< 1 × 10\^8 CCIDv50 (nominal dose of 10\^7 CCIDv50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%) delivered IM
40835872|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
40835873|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
40835874|NCT02817347|DRUG|piperacillin 2% + tazobactam 0.25%|
40835875|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5%|
40835876|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0%|
40835877|NCT06507670|DIAGNOSTIC_TEST|Point of care ultrasound|"Point of care medical ultrasound machines will be used to sonographically visualize the esophagus and following sonographic data will be collected:~* Presence/absence of suspected foreign body~* Sonographic esophageal measurements (diameters, area)~* Other relevant secondary sonographic findings"
41355998|NCT00444639|DRUG|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
41355999|NCT02084940|DRUG|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
41356000|NCT05522972|BEHAVIORAL|Video Game Vision Training|A new approach for improving amblyopic vision using video games
41495779|NCT02968849|BIOLOGICAL|Bivalent Subtype C gp120/MF59|Subtype C TV1.C gp120 Env and 1086.C gp120 Env proteins, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion) and delivered IM
41495780|NCT02968849|BIOLOGICAL|Placebo|Sodium Chloride for injection, 0.9% delivered IM
41495781|NCT00593905|DRUG|Sitaxsentan|Sitaxsentan sodium 100 mg tablet every morning
41495782|NCT00593905|DRUG|Bosentan, Ambrisentan|Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
41495783|NCT05404607|OTHER|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive FDM with INIT followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
41495784|NCT05404607|OTHER|Fascial distortion method|27 participants will receive FDM followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
41495785|NCT01442428|DRUG|Dexamethasone|Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
41495786|NCT01442428|DRUG|Atorvastatin|Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
40835878|NCT00915655|DRUG|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
40835879|NCT00915655|DRUG|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
40835880|NCT00915655|DRUG|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
40835881|NCT00915655|DRUG|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
40835882|NCT00915655|DRUG|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
40835883|NCT06516263|PROCEDURE|Leukocyte and platelet rich fibrin|Formation of an Leukocyte and platelet rich fibrin clot and placement into the osteotomy site prior to implant placement
40835884|NCT06516263|PROCEDURE|Standard implant placement|Standard implant placement without Leukocyte and platelet rich fibrin
40835885|NCT05570071|DEVICE|physical therapy|medical treatment of pelvic floor
40835886|NCT02514005|OTHER|Manual therapy|- Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
41356001|NCT05522972|BEHAVIORAL|Perceptual Learning|A new approach for improving amblyopic vision with perceptual learning
41356002|NCT05522972|BEHAVIORAL|Occlusion Therapy|Conventional treatment for amblyopia
41356003|NCT03119428|DRUG|OMP-313M32|OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
41356004|NCT03119428|DRUG|Nivolumab|Human IgG4 anti-PD-1 monoclonal antibody
41356005|NCT02073149|DIETARY_SUPPLEMENT|Low-dose iron as NaFeEDTA|Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
41356006|NCT02073149|DIETARY_SUPPLEMENT|Conventional dose iron as ferrous salt|Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
41356007|NCT02073149|DIETARY_SUPPLEMENT|Placebo|Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
41495787|NCT01442428|DRUG|Naproxen|Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
41495788|NCT01442428|DRUG|Placebo|Atorvastatin placebo
40835887|NCT02514005|DEVICE|Dry needling|"* Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.~* Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps."
41021622|NCT04475445|OTHER|Interlaminar epidural steroid injection|Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
41160196|NCT00952016|DRUG|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
41356008|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
41356009|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
41356010|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
41356011|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
41356012|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
41356013|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
41356014|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
41356015|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
41495789|NCT04175210|RADIATION|Radiation therapy - 3 weeks|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
40835888|NCT06233994|BIOLOGICAL|ZG005 Powder for Injection|ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).
41356016|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
41356017|NCT04465240|OTHER|Virtual reality|Participants are immersed in a neighborhood environment in virtual reality
41356018|NCT04225104|BEHAVIORAL|Yogic breathing intervention|Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.
41356019|NCT00111176|DEVICE|Endovascular repair|Endovascular repair.
41356020|NCT00111176|PROCEDURE|Surgical|Surgical endovascular repair
41356021|NCT01684085|BEHAVIORAL|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
41356022|NCT01684085|BEHAVIORAL|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
41356023|NCT01684085|DRUG|Lorazepam|Lorazepam 1 mg
41356024|NCT01070628|DRUG|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
41356025|NCT01070628|DRUG|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
41495790|NCT04175210|RADIATION|Radiation therapy - 2 weeks|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
41495791|NCT01021059|BIOLOGICAL|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
41495792|NCT01019928|DRUG|AZD1386|95 mg, oral solution, single dose
41495793|NCT01019928|DRUG|Placebo to AZD1386|Placebo, oral solution, single dose
41021623|NCT06513624|DRUG|ETC-159|ETC-159 will be administered orally.
41021624|NCT06513624|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously.
41021625|NCT06513624|DRUG|Denosumab / Zoledronic Acid|Denosumab will be administrated subcutaneously. Zoledronic Acid will be administered intravenously if denosumab has no response.
41021626|NCT04801524|BEHAVIORAL|Self-benefit|Participants will be reminded that the vaccine helps protect themselves from COVID.
41021627|NCT04801524|BEHAVIORAL|Prosocial-benefit|Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID
41021628|NCT04801524|BEHAVIORAL|Early access|Participants will be reminded that they have early access to COVID-19 vaccine.
41021629|NCT04801524|BEHAVIORAL|Fresh start|Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.
41021630|NCT04379011|DRUG|Brivaracetam|Escalating brivaracetam dose to 150 mg twice daily for 3 months
41160197|NCT02364505|BEHAVIORAL|Telemedicine mindfulness-based intervention|Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
41356026|NCT03287726|DIETARY_SUPPLEMENT|probiotics|NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
41356027|NCT03287726|DIETARY_SUPPLEMENT|placebo|Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
41356028|NCT00004166|DRUG|amifostine trihydrate|
41356029|NCT00004166|PROCEDURE|quality-of-life assessment|
41356030|NCT01729806|BIOLOGICAL|Ipilimumab|Given IV
41509219|NCT04934046|OTHER|Additional acquisition|Additional SPECT acquisition (30min added time approximately), with no added radiation
41356031|NCT01729806|OTHER|Laboratory Biomarker Analysis|Correlative studies
40835889|NCT06233994|DRUG|Donafenib Tosilate Tablets|Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).
40835890|NCT06233994|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).
40835891|NCT04129710|DRUG|Ibrutinib|Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
40835892|NCT04129710|DRUG|Lenalidomide|Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
40835893|NCT04129710|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
40835894|NCT04129710|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day 1
40835895|NCT04129710|DRUG|Etoposide|Etoposide 250 mg/m2 over 3 hours on day3
40835896|NCT04129710|DRUG|PEGylated recombinant human granulocyte colony|PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
40835897|NCT01224444|OTHER|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
40835898|NCT02525991|DEVICE|Staccato® Delivery System Loxapine (ADASUVE®)|one dose Loxapine Staccato 9.1 mg
40835899|NCT01295684|OTHER|Cranberry juice|base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
40835900|NCT01295684|OTHER|Placebo|base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
40835901|NCT05833451|OTHER|Reiki|Reiki, one of integrative practices, is an energy therapy involving the use of energy that flows naturally from the hands of the practitioner to strengthen the body's ability to heal itself in order to increase well-being. Reiki improves well-being in many areas, ensures that blood and lymph circulation is maintained properly, regulates blood pressure and pulse rate by stimulating the autonomic nervous system, increases comfort, reduces depression and anxiety levels. In this way, Reiki facilitates physical and mental relaxation and promotes health
40835902|NCT01052961|DRUG|Oseltamivir|oseltamivir 150 mg bd for 5 days
40835903|NCT03161860|BEHAVIORAL|Personalised citizen assistance for social participation(APIC)|The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
40835904|NCT00106600|DRUG|Pixantrone IV infusion|
40835905|NCT05896787|DRUG|AK104, nab-paclitaxel, carboplatin|AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy，and AK104 as adjuvant therapy for those who do not achieve pCR;
41356032|NCT01729806|BIOLOGICAL|Rituximab|Given IV
41356033|NCT03955211|DRUG|HTX-011|300 mg
40835906|NCT06197087|OTHER|cross-sectional observational survey study|Patients' pain intensity (with VAS), quality of life (with SF-12), sleep quality (with Pittsburgh sleep quality scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspect of pain (with Pain Catastrophizing Scale), presence of central sensitization (with the central sensitization scale), functional status (with the Fibromyalgia impact questionnaire), and chronotype preferences will be evaluated with the Morningness and Eveningness Questionnaire.
41356034|NCT03955211|DRUG|HTX-011|400 mg
41356035|NCT03955211|DEVICE|Luer Lock Applicator|Applicator for instillation.
41356036|NCT03955211|DRUG|Ibuprofen|400 mg
40835907|NCT05718193|DIAGNOSTIC_TEST|DeFrame|The DeFrame system is applicated during colonoscopy. The DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, notifying the endoscopists of the presence of the lesion.
41356037|NCT03955211|DRUG|Acetaminophen|975 mg to 1 g
41356038|NCT02243189|DRUG|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
41356039|NCT02243189|DRUG|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
41356040|NCT02243189|DRUG|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
41356041|NCT01592942|DEVICE|Histoacryl|cyanoacrylate glue fixation of mesh 1 ml
41495794|NCT00483483|BEHAVIORAL|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
41495795|NCT00483483|BEHAVIORAL|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
40835908|NCT05718193|DIAGNOSTIC_TEST|Classified DeFrame|The Classified DeFrame system is applicated during colonoscopy. The Classified DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, the color of the rectangle box will turn blue when the polyp is considered as an adenoma, notifying the endoscopists of the presence of the lesion.
40835909|NCT05718193|DIAGNOSTIC_TEST|conventional colonoscopy|conventional colonoscopy
40835910|NCT02970526|DRUG|Oxaliplatin|Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
41021631|NCT04379011|OTHER|Placebo|Placebo twice daily for 3 months
41021632|NCT02866617|DEVICE|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
41021633|NCT06040749|OTHER|Virtual group-based handcycling|Virtual group-based handcycling
41021634|NCT05195996|DRUG|Propranolol|intravenous propranolol for case patients
41021635|NCT05195996|DRUG|Saline|intravenous saline for placebo
41021636|NCT03345563|BEHAVIORAL|Body Mind Training (BMT)|"Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period."
41356042|NCT01592942|DEVICE|Progrip|self-gripping mesh
41356043|NCT01592942|DEVICE|sutures (prolene 3-0)|non-absorbable suture fixation 3-0
41356044|NCT01907750|DEVICE|biliary drainage tube|
40835911|NCT03730766|DRUG|Esomeprazole|Proton pump inhibitor
40835912|NCT03730766|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
40835913|NCT03730766|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
40835914|NCT00841932|PROCEDURE|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
40835915|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
40835916|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or Sham cPAP
40835917|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
40835918|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
40835919|NCT06298981|DEVICE|noninvasive and investigational NuraLogix AMC-SDK|The NuraLogix AMC-SDK is a noninvasive device that allows for real-time, remote measuring using facial recordings.
41160198|NCT02364505|BEHAVIORAL|Psycho-education intervention|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
41495796|NCT04304040|DRUG|Orelabrutinib|BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
41509220|NCT04653025|DEVICE|Implant placement|After tooth extraction implants were placed either immediate or delayed approach
40835920|NCT01930890|BIOLOGICAL|BIIB023|
41356045|NCT03894501|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
41356046|NCT03894501|BEHAVIORAL|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
41495797|NCT04304040|DRUG|Recombinant humanized monoclonal antibody MIL62 injection|Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
41495798|NCT00723723|DRUG|Statin|Statin
41495799|NCT04428216|OTHER|Group RIB|In group RIB, RIB block will be performed. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
41495800|NCT00601562|DRUG|Zidovudine|
41495801|NCT00866736|DRUG|dasatinib|100mg QD
41495802|NCT06032650|OTHER|Calisthenics exercise and High intensity interval training|"1. The calisthenics exercise focuses on big muscles and can be combined with breathing exercises and applied rhythmically,10-15 for each exercise,1-3 sets,3 days/week for 8 weeks. It will be progressed gradually by increasing the number of sets, repetitions and by using elastic bands and weighted vest progression.~2. High intensity interval training will be on treadmill for eight weeks, three times/week based on the following program:-Warming up period for 5 min at intensity corresponding to 65-75% of heart rate maximum (HRmax).Training phase for 30 min divided into four sets of 4-min length each at intensity equals 85- 90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.Cooling down period for 5 min of at 50-60% of the HRmax"
41495803|NCT03860662|DIAGNOSTIC_TEST|Nociceptor flexor reflex|The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
41495804|NCT03860662|DRUG|Botox|botox
41495805|NCT03860662|DRUG|Baclofen|baclofen
41495806|NCT05802732|DIAGNOSTIC_TEST|Stool Antigen test|Correlation between the result of endoscopic biopsy and stool antigen test
41495807|NCT03903809|DRUG|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
41495808|NCT03903809|DRUG|ESPO|Participants received ESPO by subcutaneous injection weekly. The starting dose was 6000 IU and was adjusted according to the instruction to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
41356047|NCT03792126|OTHER|Implicit Learning Approach|"All mobility focussed rehabilitation sessions will utilise the Implicit Learning Approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual - and primarily involves changing the quantity and focus of attention of instructions and feedback.~As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA."
41356048|NCT03369925|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
41356049|NCT03369925|DIETARY_SUPPLEMENT|Citicoline supplement|Cognizin
41356050|NCT01917799|DRUG|Aspirin|75mg tab of LDA once daily for 7 months
41356051|NCT01917799|DRUG|Heparin|0.4 mL/day of the Enoxaparin
41356052|NCT00271076|PROCEDURE|IVUS|
41356053|NCT00271076|DEVICE|CAS|
41356054|NCT00271076|PROCEDURE|CEA|
41356055|NCT05064449|DRUG|Soticlestat|Soticlestat tablets.
41356056|NCT05064449|DRUG|Itraconazole|Itraconazole oral solution.
41495809|NCT00135863|DRUG|tinzaparin|
41495810|NCT05243953|DRUG|Levcromakalim|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
41495811|NCT05243953|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
41495812|NCT01356264|BEHAVIORAL|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
41495813|NCT01356264|BEHAVIORAL|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
41495814|NCT03542955|DEVICE|ActiPatch|A Pulsed Shortwave Therapy Device
41495815|NCT03542955|DRUG|Etoricoxib 60 mg|nonsteroidal anti-inflammatory drug used as standard therapy
41356057|NCT05064449|DRUG|Mefenamic acid|Mefenamic acid capsule.
41356058|NCT00144456|DRUG|ED-71|0.75μg/day(p.o.)for 144 weeks
41356059|NCT00144456|DRUG|Alfacalcidol|1.0μg/day(p.o.)for 144 weeks
41356060|NCT00144456|DRUG|ED-71 placebo|0 μg/day(p.o.)for 144 weeks
41356061|NCT00144456|DRUG|Alfacalcidol placebo|0 μg/day(p.o.)for 144 weeks
41356062|NCT00615420|DIETARY_SUPPLEMENT|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
41356063|NCT00615420|DIETARY_SUPPLEMENT|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
41356064|NCT01412333|DRUG|Interferon beta-1a|
41356065|NCT01412333|DRUG|Ocrelizumab-matching placebo|
41356066|NCT01412333|DRUG|Ocrelizumab|
41356067|NCT01412333|DRUG|Interferon beta-1a-matching placebo|
41356068|NCT00982267|DRUG|SU014813|Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
41356069|NCT02136264|OTHER|PCFA interventional dietary counselling|
41356070|NCT02136264|OTHER|conventional DASH diet counselling|
41356071|NCT00504595|DRUG|ACZ885 (investigational)|The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
41356072|NCT00504595|DRUG|Placebo|Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
41495816|NCT03190330|DRUG|Ibrutinib 420 mg|Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
41495817|NCT03190330|DRUG|Ibrutinib 560 mg|Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
41495818|NCT00229983|BEHAVIORAL|Motivational Enhancement Therapy|Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
41495819|NCT04751929|DRUG|Abemaciclib|Taken orally 2x daily
41495820|NCT04751929|DRUG|Atezolizumab|Intravenously Day 1 of 21 day cycle
41495821|NCT03702361|DRUG|VPRIV|VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
41495822|NCT02656511|DRUG|Dolutegravir|Dolutegravir 50 mg PO daily
41495823|NCT02656511|DRUG|Emtricitabine/Tenofovir|Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily
41495824|NCT04220931|DRUG|botulinum toxin injection|injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
41495825|NCT02517463|DRUG|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
41495826|NCT04325763|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
41495827|NCT04325763|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
41495828|NCT04325763|DRUG|TQB2450(blank)|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
41495829|NCT04325763|DRUG|Anlotinib(blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
41495830|NCT00788320|DRUG|Vitamin D3|Vitamin D3 50,000 IU three times a week for 8 weeks
41495831|NCT00788320|DRUG|Placebo|Placebo three times a week for 8 weeks
41495832|NCT02263950|DRUG|Artemether|Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
41495833|NCT06171724|DIETARY_SUPPLEMENT|Shoden 240 mg|Participants will receive a single dose of 240 mg Shoden at pharmacokinetics visit 1 or 2 depending on their sequence group. Forty-eight hours later, participants will receive a 35-day supply of Shoden at a dose of 240 mg per day.
41495834|NCT06171724|DIETARY_SUPPLEMENT|Shoden 480 mg|Participants will receive a single dose of 480 mg Shoden at pharmacokinetics visit 1 or 2 depending on their sequence group. Forty-eight hours later, participants will receive a 35-day supply of Shoden at a dose of 480 mg per day.
41356073|NCT01594489|DRUG|Aminophylline|"* 200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration~* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
41495835|NCT04851938|DEVICE|transcutaneous electrical nerve stimulation device|The application of transcutaneous electrical nerve stimulation is a nonpharmacological method that midwives can apply and determining the effect on these factors will be a guide for the future applications.
41495836|NCT00421980|DRUG|Etanercept|
41495837|NCT03844217|DRUG|Macimorelin 0.5mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin
41495838|NCT03844217|DRUG|Macimorelin 0.75mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin
41495839|NCT01051219|DRUG|Losartan|50 milligrams to be taken orally, daily
41495840|NCT00355953|DRUG|Genistein|
41495841|NCT06552143|OTHER|Stone needle therapy follows the Belt channel|Stone needle therapy follows the Belt channel involves the use of stones by the intervener to follow the path of the Belt channel by pushing and rubbing the abdomen of patients with postpartum diastasis rectus abdominis.
41495842|NCT06303479|OTHER|Non-Instrumental breathing exercise group|Before starting the exercises, participants will be told about diaphragmatic breathing exercises, maximum inspiratory holding technique and thoracic expansion exercises through the Zoom program by telerehabilitation method, and people will be checked by the physiotherapist who manages the program during the practice. The program will last for 8 weeks and will be planned to be implemented 5 days a week in total, including 2 days of telerehabilitation, 3 days of home program. The participant will be asked to start the exercises in a reclining position with his back to the chair. He will be asked to place his right hand on his upper abdomen and his left hand on the upper side of his chest. In each session, the exercises will be performed with 1 set of 10 repetitions for each of the diaphragmatic breathing and thoracic expansion exercises and will progress with progression.
41495843|NCT06303479|OTHER|Instrumental breathing exercise group|The volume-oriented spirometer works with pressure and its indicator changes during breathing. When the participants breathe, the pressure in the tube decreases and the piston of the spirometer rises. The inhaled breath volume is seen at the top of the piston. In our study, participants will be told about the exercises through the Zoom program using the telerehabilitation method, and people will be checked by the responsible physiotherapist who manages the program during the application. The program will last for 8 weeks, 2 days of telerehabilitation, 3 days of home program will be planned to be implemented 5 days a week in total. Participants will be instructed to breathe up to their total lung capacity and maintain continuous inspiration for at least 3 seconds. The exercises will start with 1 set of 15 repetitions and the program will progress with progression.
41495844|NCT00593736|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
41495845|NCT00593736|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
41495846|NCT00593736|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
41495847|NCT00593736|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
41495848|NCT00000535|BEHAVIORAL|diet, reducing|
41495849|NCT00000535|BEHAVIORAL|diet, sodium-restricted|
41495850|NCT02044796|DRUG|Cladribine|Given IV
41495851|NCT02044796|DRUG|Cytarabine|Given IV
41495852|NCT02044796|BIOLOGICAL|Filgrastim|Given SC
41495853|NCT02044796|OTHER|Laboratory Biomarker Analysis|Correlative studies
41495854|NCT02044796|DRUG|Mitoxantrone Hydrochloride|Given IV
41495855|NCT03097510|BEHAVIORAL|Transcendental meditation|The TM technique was taught as a standard 7 step course over 4 consecutive days. Thereafter, subjects attended bimonthly group meetings for more advanced knowledge over the four month intervention period.
40835921|NCT01930890|DRUG|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
41160199|NCT04693650|DEVICE|NeuroBlock UHF stimulation|NeuroBlock ultrahigh frequency (UHF) stimulation with 500kHz intra-pulse
41495856|NCT05395455|PROCEDURE|Non-surgical periodontal treatment|Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
41495857|NCT06195280|RADIATION|Magnetic resonance imaging, 3DT1 sequence|The patient will have an exploration pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product.
41160200|NCT00614536|DRUG|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
41495858|NCT06195280|PROCEDURE|Laparoscopy|After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.
41495859|NCT00086827|DRUG|romidepsin|Given IV
41495860|NCT00086827|OTHER|laboratory biomarker analysis|Correlative studies
41495861|NCT06273930|DRUG|5% CALCIUM SODIUM PHOSPHOSILICATE|Calcium sodium phosphosilicate is a particulate, bioactive glass material that degrades in the aqueous oral environment to release calcium and phosphate ions, leading to formation of hydroxycarbonate apatite on the dentine surface result in reduction in dentine hypersenstivity
41495862|NCT06273930|DRUG|8% Arginine|Arginine contributes to Whole Mouth Health. It also plays a role with respect to dental caries, helping to maintain a pH-neutral environment, and is proven to rapidly help relieve dentin sensitivity. Arginine is truly a remarkable ingredient now being used in oral care products.
41495863|NCT03262038|DRUG|Ondansetron|This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
41495864|NCT03262038|DRUG|Placebo Comparator|This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
41495865|NCT01909063|DIETARY_SUPPLEMENT|Vitamin D|Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
41495866|NCT01909063|DIETARY_SUPPLEMENT|Vitamin D, Vitamin E, and Vitamin A|Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
41495867|NCT01909063|DIETARY_SUPPLEMENT|Control, 700 mg Calcium|Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
41495868|NCT05288712|OTHER|Training protocol with the device cervical for treatment (CDAT)|Training protocol with the cervical device for treatment (CDAT)
41495869|NCT05288712|OTHER|Conventional training protocol|Conventional training protocol
41495870|NCT03361774|DRUG|Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).|"Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to."
41160201|NCT00985621|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
41160202|NCT00985621|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
41160203|NCT00985621|DRUG|oxycodone|oxycodone CR, 10-40 mg q12h
41160204|NCT00985621|OTHER|placebo|placebo
41160205|NCT00729885|DEVICE|Goggle with 20 degree error|The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
41356074|NCT01594489|DRUG|Hydration plus N-acetylcisteine|"* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
41356075|NCT01164267|DRUG|Everolimus|Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. Patients with CR or PR may continue treatment until PD if well tolerated
41356076|NCT01813136|DRUG|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
41356077|NCT01813136|DRUG|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
41356078|NCT02315794|DEVICE|SPI®ART|implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
41356079|NCT02315794|DEVICE|SPI®EASY|implant prosthetic restoration using a commercially pure titanium grade 4 abutment
41356080|NCT05275140|OTHER|Physical activity|Combat sports and exercise
41356081|NCT02723474|DEVICE|MRI at baseline and over time|Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
41356082|NCT03026764|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
41356083|NCT03026764|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
41356084|NCT05146531|DEVICE|McCoy laryngoscope|Patients scheduled for general anesthesia were intubated with McCoy laryngoscope.
41356085|NCT05146531|DEVICE|C-MAC D-blade video laryngoscope|Patients scheduled for general anesthesia were intubated with C-MAC D-blade video laryngoscope.
41495871|NCT03361774|DRUG|Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).|Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.
41495872|NCT03590912|DRUG|Mometasone 50 Mcg/Inh Nasal Spray|One spray in each nostril once daily for one month
40835922|NCT01930890|DRUG|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
40835923|NCT04913701|OTHER|Observation group 1|Subjects will be followed with 3 swabs and serological test
41160206|NCT00729885|DEVICE|Optimized Goggle|The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
41160207|NCT00236483|DRUG|tramadol hydrochloride + acetaminophen|
41356086|NCT05074160|DEVICE|OCS Liver|Multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.
41356087|NCT04306692|DRUG|Myo-inositol|2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged).
41495873|NCT03590912|DRUG|Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%)|Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week, plus antihistamine and nasal decongestants. Oral levocetirizine (Syrup levocet 2.5 mg/5ml) 1.25 mg once daily for age up to six years, 2.5 mg once daily for elder children for a month, plus oxymetazoline (Nasivion) 0.025%, 4 drops twice daily for two weeks
41495874|NCT03590912|DRUG|Steroid Drug (prednisolone)|This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.
41495875|NCT04832893|DIAGNOSTIC_TEST|steady intensity aerobic test of 30 minutes long|the use of different type of masks during an aerobic exercise
41495876|NCT04299906|DEVICE|Solaris Vascular Stent Graft|Solaris Vascular Stent Graft for treatment of Iliac Lesions
40835924|NCT00215865|DRUG|PEGIntron plus ribavirin|
41160208|NCT04120064|DRUG|Cholecalciferol|Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol
40835925|NCT00117793|DEVICE|Total Surface Bearing Suction Socket|Current clinical practice
40835926|NCT00117793|DEVICE|Vacuum assisted socket system|Novel socket system
40835927|NCT03230292|DRUG|Bimekizumab|Bimekizumab will be administered subcutaneously in 2 different doses.
40835928|NCT05728073|PROCEDURE|ERCP|Patients separated to two groups according to having a ERCP history before the operation
41021637|NCT03345563|BEHAVIORAL|Body Training (BT):|Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
41021638|NCT03345563|BEHAVIORAL|Usual Care (UC)|Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
41356088|NCT04306692|DRUG|Clomiphene Citrate|"Each tablet contains 50 mg of clomiphene citrate which means 33,9 mg of clomiphene. Other constituents are sucrose, lactose monohydrate, corn starch, pregelatinized starch, yellow iron oxide (E172) and magnesium stearate (E470b).~Dosing: 1 tablet per day from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days."
41356089|NCT03577028|BIOLOGICAL|HPN424 Fixed IV 1.3 to 150 ng/kg|Fixed dose IV cohorts at doses from 1.3 to 150 ng/kg
41356090|NCT03577028|BIOLOGICAL|HPN424 Prime Step IV 36 ng/kg Target|Step-dosing IV cohort at a single Prime Dose followed by the Target Dose (12/36 ng/kg)
41356091|NCT03577028|BIOLOGICAL|HPN424 1 Prime Step IV 225-300 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
41356092|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 300 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
41356093|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 450 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
41356094|NCT03577028|BIOLOGICAL|HPN424 Fixed SC|Fixed subcutaneous dose 120 ng/kg
41356095|NCT06354920|BEHAVIORAL|Bonding Bundle|Doctors in the intervention arm will be asked to use suggested approaches while meeting with their hospitalized patients. The goal of these strategies is to improve the relationship and interactions between patients and physicians.
41495877|NCT00271154|DEVICE|Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT|All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
41495878|NCT05357118|BEHAVIORAL|Suppress Stigma, Support Services|Women living with HIV/AIDS (WLHA) will attend an initial group preparation session in Month 1 to form a network with peers and prepare for the following online support groups. During Month 2-4, study investigators will teach cognitive, emotional, and behavioral strategies to cope with stigma and utilize social support to seek healthcare services through online group activities. During Month 4-6, WLHA will self-administer the online support groups without the intervention of study investigators
41495879|NCT04740814|DRUG|Certolizumab pegol|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study."
41495880|NCT02788786|DRUG|Chlorhexidine|non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
41160209|NCT05720702|DIETARY_SUPPLEMENT|homocysteine (Hcy) lowering supplements|NAFLD participants will take homocysteine (Hcy) lowering supplements daily for 12 weeks.
41160210|NCT03030053|DIETARY_SUPPLEMENT|Cocoa-Flavanol Supplements|3 capsules each containing 300mg cocoa flavanols (total daily dose of 900mg cocoa-flavanols).
41356096|NCT01899729|DRUG|IMO-8400 Regimen 1|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
41356097|NCT01899729|DRUG|IMO-8400 Regimen 2|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
41356098|NCT01899729|DRUG|IMO-8400 Regimen 3|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
41356099|NCT01899729|DRUG|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
41356100|NCT01899729|DRUG|IMO-8400 Regimen 4|IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
41356101|NCT03010059|DRUG|JNJ-64041575 (oral suspension formulation)|Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
41356102|NCT03010059|DRUG|JNJ-64041575 (oral tablet formulation )|Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
41356103|NCT02962973|DEVICE|CARMAT TAH|
41356104|NCT02962973|PROCEDURE|Surgical intervention|
41356105|NCT03815201|DIETARY_SUPPLEMENT|Group 2|leucine-enriched protein supplementation during the first 1/2 hour post-training
41495881|NCT02788786|DRUG|Cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
41495882|NCT02788786|DRUG|Salt and Water|salt and water mix oral rinse
41495883|NCT03779737|BEHAVIORAL|Muscular Resistance training|
41495884|NCT03779737|BEHAVIORAL|Cardiorespiratory training|
41495885|NCT03779737|BEHAVIORAL|Habitual training|
41495886|NCT05323331|OTHER|Circuit Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
41495887|NCT05323331|OTHER|Aerobic Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
41495888|NCT02906566|DRUG|Retinol|Retinol in the form of vitamin A lotion
41495889|NCT02906566|DRUG|Placebo|Placebo of Retinol
41495890|NCT05179538|BEHAVIORAL|Cued picture-naming therapy|The proposed study will administer Cued Picture-Naming Treatment (CPNT) four days per week for four weeks (i.e. 16 sessions). During therapy, participants will attempt to name eight consecutive presentations of the same black and white picture, for each of the 20 pictures, with cueing from the administrator. Trials will include (1) independent naming, (2) orthographic cueing (i.e. the written word beneath the picture.), (3) repeating, (4) naming after a short delay (i.e. approximately three seconds), (5)semantic cueing (i.e. three cues providing semantic information about the target will be spoken to the participant by the clinician), (6) phonological cueing (i.e. the first sound and letter will be spoken by the clinician), (7) repeating, and (8) naming after a short delay. The administrator will provide the correct response for each incorrect participant response and will ask the participant to repeat it.
41495891|NCT01709253|RADIATION|proton beam therapy|hypofractionation study using proton beam therapy for prostate adenocarcinoma
41495892|NCT01750489|DEVICE|non-invasive ventilation (NIV)|
41495893|NCT04576481|BEHAVIORAL|Text Messaging|Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.
41356106|NCT03815201|OTHER|Group 1|placebo, an energy-matched mixture, during the first 1/2 hour post-training
41356107|NCT04097925|DRUG|Doravirine|Doravirine 100 mg tablet
41356108|NCT04097925|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
40835929|NCT02541136|BEHAVIORAL|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, \< 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
40835930|NCT01730404|DRUG|CHF6001 DPI|
40835931|NCT01730404|DRUG|Roflumilast|
40835932|NCT01730404|DRUG|Placebo|
40835933|NCT06423560|RADIATION|Computed tomography|Follow-up computed tomography at 3-6 months and 12 months
41495894|NCT04576481|BEHAVIORAL|Coaching|Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.
41495895|NCT04576481|BEHAVIORAL|Lottery|Participants who reply to a text message that they read on a particular day will be entered into daily and weekly drawings to receive cash payments.
41495896|NCT05410782|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm)
41495897|NCT00727870|DEVICE|Shapes by PolyMem dressing|Shapes by PolyMem dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
41495898|NCT00727870|DEVICE|Shapes by PolyMem Silver Dressing|Shapes by PolyMem Silver dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
41495899|NCT00727870|DEVICE|Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site|Shapes by PolyMem dressing on one site. Shapes by PolyMem Silver dressing on other site.
41495900|NCT02403453|DEVICE|Rhine Cervical Disc|RHINE Cervical Disc
41495901|NCT05668078|DIAGNOSTIC_TEST|Rapid Antigen Testing (RAT) for COVID-19|COVID-19 RAT intervention done among the school students to see if RAT test can play a role in reducing absenteeism. School type-1-only for symptomatic participants, School type-2-Serial testing at three days interval for all participants and School type-3 got no testing.
41495902|NCT05016895|DRUG|Single-dose azithromycin|Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.
41495903|NCT00604123|DRUG|JNJ-17166864|JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.
41495904|NCT00604123|DRUG|Placebo|Placebo nasal spray twice daily for 2 weeks.
41495905|NCT03934411|DRUG|Tramadol|The subjects will orally ingest 100 mg tramadol retard actavis
40835934|NCT04809974|DRUG|Niagen|The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
40835935|NCT00411190|DRUG|Relacatib|Subjects will administer 60 or 120 mg tablets in Session 2
41356109|NCT04849260|BIOLOGICAL|Pexa-Vec combined with ZKAB001|"1. Intratumoral injection of low dose Pexa-Vec (3×10\^8pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle.~2. Intratumoral injection of high dose Pexa-Vec (1×10\^9pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle."
41356110|NCT04849260|BIOLOGICAL|ZKAB001 monotherapy|ZKAB001 monotherapy
41356111|NCT01948089|BEHAVIORAL|Variable Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
41495906|NCT03934411|OTHER|Placebo|The subjects will orally ingest 100 mg calcium powder
41495907|NCT01664130|RADIATION|stereotactic body radiation therapy|Undergo SBRT
41495908|NCT01664130|PROCEDURE|quality-of-life assessment|Ancillary studies
41495909|NCT01664130|OTHER|laboratory biomarker analysis|Correlative studies
41495910|NCT00823108|DRUG|GIK|12 hour infusion of GIK solution
41495911|NCT06414720|DRUG|Dienogest 2 MG|The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.
41495912|NCT05653310|DRUG|Tradipitant|Tradipitant Capsule
41495913|NCT05653310|DRUG|Placebo|Placebo Capsule
41495914|NCT05357755|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as delayed release tablets.
41356112|NCT01948089|BEHAVIORAL|Constant Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
41495915|NCT05357755|DRUG|Placebo|Matching placebo will be administered orally as delayed release tablets.
41356113|NCT01063114|RADIATION|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
41495916|NCT00125840|DRUG|clofarabine (IV formulation)|
41495917|NCT03728634|DRUG|ION-682884|ION-682884 administered SC
41495918|NCT03728634|DRUG|Placebo|Placebo comparator calculated volume to match ION-682884 administered SC
41495919|NCT03728634|DIETARY_SUPPLEMENT|Vitamin A|Oral supplement
41495920|NCT04773301|DRUG|Levobupivacaine|Local anaesthetic drug belonging to the amino amide group. It is the S-enantiomer of bupivacaine
41495921|NCT04773301|DRUG|Ropivacaine|Local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer.
41495922|NCT00159627|DRUG|KW-3902IV|
41495923|NCT04202809|DRUG|Durvalumab|Durvalumab is given earlier as registered, during chemotherapy and radiotherapy in treatment Arm A
41160211|NCT03030053|DIETARY_SUPPLEMENT|Control Supplements|3 capsules each containing 0mg cocoa-flavanols
41160212|NCT05114902|DIAGNOSTIC_TEST|Nasopharyngeal swab|A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage
41495924|NCT02472028|OTHER|blood pressure lowering algorithm|"The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study."
41495925|NCT02472028|OTHER|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
41495926|NCT01799525|PROCEDURE|Hypercapnia by reduction of respiratory volume|By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
41495927|NCT05358470|OTHER|Exercise therapy and adapted physical activity-based program|Exercise therapy and adapted physical activity program based on racket sports
41495928|NCT00469911|PROCEDURE|Magnetic Resonance Spectroscopy|Magnetic Resonance Spectroscopy is a noninvasive procedure that provides detailed body images on any plane.
41495929|NCT00469911|PROCEDURE|Ex vivo heart biopsy|Heart transplant patients will have their normal clinical routine heart biopsy
41356114|NCT03281239|DIAGNOSTIC_TEST|Laser doppler, blood tests, and holter ECG|"Diagnostic tests :~* laser doppler~* blood tests~* Holter ECG. No drug and no placebo were used in this arm."
41495930|NCT03636412|OTHER|Ambulation|An ambulator will walk with a patient three times a day, based on physical therapy recommendations.
41495931|NCT05998512|OTHER|Observational register|This is a non-interventional observational registry on patients
40835936|NCT00411190|DRUG|Acetaminophen|Acetaminophen will be administered orally
40835937|NCT00411190|DRUG|Ibuprofen|Ibuprofen will be administered orally
40835938|NCT00411190|DRUG|Atorvastatin|Atorvastatin will be administered orally
40835939|NCT03233035|DRUG|Ketamine|25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
40835940|NCT03233035|DRUG|Placebo|0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
41160213|NCT00141336|DRUG|Pregabalin|
41160214|NCT00273351|DRUG|[123I]B-CIT|Subjects will receive up to 6 mCi of \[123I\] B-CIT injected intravenously
41495932|NCT02365558|DRUG|Evacetrapib|Administered orally
41495933|NCT02365558|DRUG|Omeprazole|Administered orally
41495934|NCT05937828|OTHER|data collection|description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.
41495935|NCT03183648|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
41495936|NCT02398773|PROCEDURE|Computed Tomography|Undergo PET/CT
41495937|NCT02398773|DRUG|F-18 16 Alpha-Fluoroestradiol|Given IV
41495938|NCT02398773|OTHER|Laboratory Biomarker Analysis|Correlative studies
41495939|NCT02398773|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40835941|NCT05686096|DRUG|MYK-224|Specified dose on specified days
40835942|NCT05077358|PROCEDURE|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
40835943|NCT05077358|PROCEDURE|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
40835944|NCT02082106|OTHER|Alpine skiing|
41356115|NCT01917136|DRUG|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
41356116|NCT01917136|DRUG|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
41356117|NCT01917136|OTHER|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
41356118|NCT06228365|DEVICE|use of a device incorporating virtual reality software|use of a device incorporating virtual reality software
41356119|NCT06228365|DRUG|Neuroleptanalgesia|Usual neuroleptanalgesic treatment
41356120|NCT04948840|BIOLOGICAL|Blood sampling|Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
41356121|NCT01485003|BIOLOGICAL|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
41356122|NCT03961529|DRUG|0.3% OPA-15406 ointment|Twice daily
41356123|NCT03961529|DRUG|1% OPA-15406 ointment|Twice daily
41356124|NCT03338699|DEVICE|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
41356125|NCT03338699|DEVICE|Mogen clamp|Mogen clamp circumcision
41356126|NCT01018069|DRUG|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
41160215|NCT04133259|DRUG|Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody|Treatment of CHB patient with HLX10
41356127|NCT02454140|RADIATION|SBRT|Fixed five-fraction stereotactic radiotherapy
41356128|NCT01455064|DEVICE|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
41356129|NCT00485121|DRUG|Ezetimibe|
41356130|NCT02147431|DRUG|semaglutide|"2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp"
41356131|NCT02147431|DRUG|placebo|"2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp."
40835945|NCT02082106|OTHER|cross country skiing|
40835946|NCT02082106|OTHER|Indoor training (cycling)|
40835947|NCT00846989|DRUG|RKI983A|RKI983 0.05 % twice daily
41160216|NCT04133259|DRUG|Nucleoside/nucleotide analogues|Treatment NAs for chronic hepatitis B subject to achieve adequate HBV viral suppression
41160217|NCT06477757|PROCEDURE|Minimally Invasive Extracorporeal Circulation|Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with minimally invasive extracorporeal circulation.
41160218|NCT06477757|PROCEDURE|Conventional Extracorporeal Circulation|Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with either conventional extracorporeal circulation.
41356132|NCT00412295|DEVICE|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
41356133|NCT01822912|OTHER|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
41356134|NCT01822912|OTHER|Heart Failure Usual Care|Subjects will receive standard of care.
41356135|NCT02487901|DEVICE|ultrasonic osteotome|making gutter with ultrasonic osteotome
41356136|NCT02487901|DEVICE|drill|making gutter with drill
41356137|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A."
41356138|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2A)|"10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A."
41356139|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3A)|"20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A."
41356140|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 4A)|"30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle."
41356141|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B."
40835948|NCT00846989|DRUG|RKI983A|RKI983 0.1 % twice daily
40835949|NCT00846989|DRUG|Latanoprost|Latanoprost 0.005 % once a day
40835950|NCT03559699|DRUG|AG-348|"Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1."
40835951|NCT02125565|OTHER|Injected subcutaneous local (lidocaine) anaesthesia|Trial of technique
40835952|NCT04386499|DIETARY_SUPPLEMENT|Resveratrol|mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6
40835953|NCT04386499|DIETARY_SUPPLEMENT|Folic acid|400 mcg of folic acid
41356142|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2B)|"20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B."
41356143|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3B)|"30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle."
40835954|NCT03119389|BEHAVIORAL|Donning Non-Sterile Gloves without HH|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
40835955|NCT01369680|DRUG|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
40835956|NCT02675335|DRUG|Sitagliptin|
40835957|NCT02675335|DRUG|Placebo|
40835958|NCT03530085|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -9 to -7.
40835959|NCT03530085|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.
40835960|NCT03530085|DRUG|Fludarabine(Flu)|Fludarabine(Flu) was administered at 30mg/m2/day on days -6 to -3.
40835961|NCT02604758|BEHAVIORAL|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
40835962|NCT03128190|OTHER|Pulse pressure variation monitoring|fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
41021639|NCT02744924|BEHAVIORAL|Physical activity intervention|"The intervention is comprised of 5 steps:~1. Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals~2. Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails~3. Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.~4. Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.~5. Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project"
41021640|NCT01340989|PROCEDURE|alteration of the insufflation gas|addition of 4% oxygen
41021641|NCT01340989|PROCEDURE|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum~* humidification~* set temperature of 32°C"
41021642|NCT01340989|PROCEDURE|standard pneumoperitoneum|no intervention besides the use of CO2
41160219|NCT00768209|DRUG|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
41160220|NCT06170229|BEHAVIORAL|eHIIT|"Education and High intensity Interval Training (Aerobic Exercise)~The focus of the one educational session is rationale for aerobic exercise, expected physiological effects of aerobic exercise, diet when performing an exercise program, how the knee accommodates to exercise (including potential experience of muscle soreness and how that is different from joint pain), and management of potential knee OA symptom flares.~HIIT is an aerobic exercise form. The eHITT protocol consist of eight 2-minute intervals of high intensity training (with the goal to train at a heart rate of at least 80% of HRmax) followed by 2 minutes of moderate training intensity (with the goal to train at a heart rate of at least 60% of HRmax).~There will be several types of exercise modalities for aerobic exercise available (treadmills, cross-trainers, row- and cycle ergometers) and participants may choose whichever they prefer."
41356144|NCT03796923|OTHER|Early follow-up visit after discharge|Early follow-up visit and different degrees of specialized care after discharge
41356145|NCT03796923|OTHER|Comprehensive geriatric assessment (CGA)|Comprehensive geriatric assessment (CGA) during admission
41356146|NCT03796923|OTHER|Continued geriatric care|Continued specialized geriatric care after discharge
40835963|NCT05883358|DRUG|Clonidine, Buprenorphine|Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
41356147|NCT03796923|OTHER|Possible follow-up visit from GP|Usual care: follow up visit from GP within one week after discharge
41356148|NCT03096691|DEVICE|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
41356149|NCT02058186|DRUG|oral vitamin D|
41356150|NCT02058186|DRUG|Placebo|
41356151|NCT00155246|DRUG|pentoxifylline (drug)|
41356152|NCT03527927|DRUG|Any LABA/LAMA|Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
41021643|NCT02733497|PROCEDURE|Sympathectomy|Resection of ganglia at T3 level
41021644|NCT02733497|PROCEDURE|Sympathicotomy|Cutting of symptahetic chain at T3 level without ganglia excision
41356153|NCT03154918|DRUG|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
41356154|NCT01766401|DRUG|Placebo|
41356155|NCT01766401|DRUG|Vilazadone|Viibryd
41356156|NCT06123676|DEVICE|Y90-PET-CT scan|40 min extra PET-CT scan - no extra injection of radiotracer. We image the Y90-microspheres administered to these patients during the therapy
41356157|NCT00396344|OTHER|Çontrol|Intravenous saline
41356158|NCT00396344|DRUG|Hydrocortisone|Intravenous stress dose of hydrocortisone
41356159|NCT00396344|DRUG|Hydrocortisone|Intravenous pharmacologic hydrocortisone
41509221|NCT01244503|DRUG|Sodium Octanoate Breath Test|100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
41509222|NCT04936165|PROCEDURE|Low-Level Laser Therapy|Use 810-nm-photosource to irradiate the participants' brain and forearm for 10 minutes with a water-cooling radiator to keep it at 25 ± 0.5 ℃.
41495940|NCT01615237|BEHAVIORAL|Audit and performance feedback (PF)|Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
40835964|NCT01124877|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
40835965|NCT01304810|BIOLOGICAL|NicVAX vaccine|Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
40835966|NCT01304810|BIOLOGICAL|Placebo|Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
40835967|NCT01307293|BEHAVIORAL|Cognitive behavior therapy|6 or 12 sessions of cognitive behavior therapy.
40835968|NCT04822246|PROCEDURE|Control: Hand instrumentation for caries excavation|"An enamel hatchet will be used to create access to the carious lesion and then removal of soft carious tissue will be undertaken with excavators. Excavation will be stopped when some resistance to excavation will be felt and the cavity will be then conditioned with polyacrylic acid for 20 s, washed and dried with cotton pellets. A high-viscosity glass-ionomer cement will be used to restore the cavity. Moisture control will be achieved with the use of cotton wool rolls. A chair-side assistant will hand-mix the glass-ionomer according to manufacturers' instructions and it will be placed in the cavity using the press-finger technique whenever the type of cavity allows it. In the case of root restorations, a glove coated with petroleum jelly will be used similarly to the press-finger technique to better condense the material into the cavity. Excess material will be removed; the restoration will be coated with petroleum jelly. No local anaesthetic will be used to provide ART treatment."
40835969|NCT04822246|PROCEDURE|Intervention 1: EMS Airflow device for caries excavation|An enamel hatchet will first be used to gain access into the cavity. Then the powder-water prophylaxis device will be used for the removal of soft carious tissue with the sodium bicarbonate powder-water jet. Excavation will be stopped when the colour of the lesion begins to darken and all the soft deposits are evacuated. The excavation will be done intermittently allowing sufficient time to check with hand instrument the surface hardness of the lesion. If the lesion is still soft excavation will be continued until the surface is hard suitable for restoring. The cavity will be then rinsed with copious water spray to evacuate all the powder-water material. The restoration procedure with a glass-ionomer cement will be done following the same procedures as in the control group.
40835970|NCT04822246|PROCEDURE|Intervention 2: Hand excavation + EMS Airflow device for caries excavation|The participants allocated to this group will have the caries excavated as described for the control group. Then prior to filling the excavated cavity, the procedure of sodium bicarbonate powder-water jet irrigation as described for the intervention group #1 will be performed to condition the prepared excavated cavity. Then the restorative procedure will be completed with the restorative material and procedures as described for the previous groups.
41356160|NCT02311634|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
41356161|NCT02311634|DEVICE|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
41356162|NCT03163121|BIOLOGICAL|PfSPZ-GA1 Vaccine|Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
41356163|NCT03163121|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
41356164|NCT03163121|OTHER|Normal Saline|0.9% sodium chloride
41356165|NCT03163121|BIOLOGICAL|Mosquito-bite CHMI|Bites of 5 infected mosquitoes of NF54 strain
41356166|NCT00516217|BIOLOGICAL|galiximab|
41495941|NCT01615237|BEHAVIORAL|Financial Incentive (P4P)|We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
40835971|NCT00004864|DRUG|GEM 231|
40835972|NCT00004864|DRUG|docetaxel|
40835973|NCT05302362|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea)
40835974|NCT04199819|DRUG|entecavir|Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis.
40835975|NCT00165542|OTHER|A PROTEIN level|
40835976|NCT01207089|DRUG|AZD8329|AZD8329 Oral Solution 20mg/ml
41356167|NCT04718883|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 will be administered at dose level: 1 x 10\^8 CAR+T cells
41356168|NCT05939336|DIETARY_SUPPLEMENT|Mannooligosaccharides yeast extract|15 g per day of mannooligosaccharide yeast extract.
41356169|NCT00384969|DRUG|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
41495942|NCT01615237|BEHAVIORAL|Current Best Practices (CBP)|CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
41495943|NCT04674865|OTHER|Standardized Physical therapy protocol|Standardized Phase 1 protocol without for 7 days without ANB sessions.
41495944|NCT04674865|OTHER|Alternate nostrils breathing|Alternate nostrils breathing 2 sessions per day
40835977|NCT01207089|DRUG|Placebo|Placebo AZD8329 Oral Solution
40835978|NCT02498574|DEVICE|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
41356170|NCT03958409|DIAGNOSTIC_TEST|measurements to evaluate metabolic bone disease|The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.
41356171|NCT03958409|DIAGNOSTIC_TEST|standard care|Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.
41495945|NCT02552212|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"
41495946|NCT02552212|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection"
41495947|NCT02936011|DEVICE|CTO PCI using Absorb Bioresorbable Vascular Scaffolds|CTO PCI
41495948|NCT01310270|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega, 4.4gm/day x 1 month
41495949|NCT01310270|DIETARY_SUPPLEMENT|Omega 3 Fatty Acid|4.4 gm/day for 1 month
41495950|NCT00658515|DRUG|Dalcetrapib (RO4607381)|600mg po daily
41495951|NCT00658515|DRUG|Evidence-based medical care for Acute Coronary Syndrome|As prescribed
41495952|NCT00658515|DRUG|Placebo|po daily
41495953|NCT05445661|DEVICE|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
41495954|NCT05445661|OTHER|Normal Saline|Sham Comparator
41495955|NCT05532124|BIOLOGICAL|LAENNEC (Human Placenta Hydrolysate)|Intravenous Injection
41495956|NCT05532124|OTHER|normal saline|Intravenous Injection
40835979|NCT02498574|BEHAVIORAL|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
40835980|NCT03980717|DEVICE|Goldbal Detachable Balloon and delivery microcatheter|Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
40835981|NCT04411537|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.
40835982|NCT04411537|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
40835983|NCT04411537|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
40835984|NCT04411537|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
40835985|NCT03300297|OTHER|Cervical Spine Thrust Joint Manipulation|High velocity, short amplitude thrust to the cervical spine
40835986|NCT03300297|OTHER|Cervical Spine Sham Manipulation|Manipulative hold position shy of end range without a thrust
40835987|NCT03300297|OTHER|Home Program|therapeutic exercise program and education
41495957|NCT02058550|OTHER|survey administration|Receive reminder email survey
41495958|NCT02058550|OTHER|computer-assisted intervention|Receive reminder email survey
41495959|NCT02058550|BEHAVIORAL|telephone-based intervention|Receive reminder phone call
41495960|NCT04549753|DEVICE|Transcranial direct current simulation|Four sessions of stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system
41495961|NCT02733926|OTHER|Adding of vegetation into the backyards of kindergarten|Living plants are transferred into the backyards of kindergartens. This is assumed to affect the measured variables of children.
41495962|NCT02212288|OTHER|Blood sample|Blood samples are for metabolic and genetic and biological investigation
41495963|NCT02212288|OTHER|Urine sample|Urine sample for biological investigation
41495964|NCT02051400|DEVICE|the McGrath® MAC video laryngoscope|
41495965|NCT02051400|DEVICE|the GlidesScope® Ranger video laryngoscope|
41495966|NCT02051400|DEVICE|the Macintosh laryngoscope|
41495967|NCT04312386|OTHER|OPTIMAT|Baseline menue, not optimized
41495968|NCT06341829|OTHER|Prismatic adaptation|Participants will fit with prismatic goggles that deviate their visual field by 13° either leftward or rightward. They will seat in front of a white horizontal board on which three target dots (5 mm diameter) were positioned at 0, -10 and +10° from their body midline at a distance of 57 cm from their eyes. They will perform a total of 150 verbally instructed pointing movements with their right index finger towards the right (+10°) and left (-10°) targets in a pseudorandom order.
41495969|NCT02777073|DRUG|Victoza|Single dose of Liraglutide
41495970|NCT02777073|DRUG|Placebo|Single dose of generic placebo
41495971|NCT02777073|DRUG|Dapagliflozin 10mg Tab|single dose of 10 mg dapagliflozin
41356172|NCT05892302|BEHAVIORAL|Access to Asma Guardian website/app|The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
41356173|NCT05892302|BEHAVIORAL|Delayed Access to Asma Guardian website/app|Delayed access to the website/app. The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
41356174|NCT04824118|DIAGNOSTIC_TEST|Thromboelastometry|Point of Care Test for clotting parameters (ClotPro device)
41356175|NCT04824118|DIAGNOSTIC_TEST|Clotting Studies|"Standard laboratory tests for clotting:~* International normalised ratio (INR)~* Prothrombin time (PT)~* adjusted partial thromboplastin time (aPTT)~* fibrinogen"
41495972|NCT03259438|BEHAVIORAL|Qigong|Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.
41495973|NCT03259438|BEHAVIORAL|Healthy Living (CHIP + Pre-Train)|The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
40835988|NCT03300297|OTHER|Suboccipital Release|suboccipital soft tissue mobilization
40835989|NCT06045572|DEVICE|VTM examination and breast biopsy|VTM examination performed by a radiologist, at the MART (Metabolic Activity in Real-Time) station, using the SaMD Mart 2.0, according to the inspection protocol to identify breast alterations and/or suspicious images to be biopsied for validation by genetic tests and histology / immunohistochemistry.
40835990|NCT04485195|DRUG|Vernakalant|an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
41356176|NCT04824118|DIAGNOSTIC_TEST|Full Blood Count|For platelet count
41356177|NCT04824118|DIAGNOSTIC_TEST|Quantitative hCG|Serum human chorionic gonadotrophin
41356178|NCT04824118|DIAGNOSTIC_TEST|Pregnancy Test|Point of care urinary pregnancy test
41356179|NCT01641523|DEVICE|CustomBone Service|customized hydroxyapatite cranial prosthesis
41356180|NCT00748449|PROCEDURE|Colonoscopy|1 Colonoscopy
41356181|NCT00748449|PROCEDURE|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
41356182|NCT02940158|OTHER|1/4 cup- Small red lentil|
41356183|NCT02940158|OTHER|1/4 cup- Small green lentil|
41356184|NCT02940158|OTHER|1/4 cup- corn|
41356185|NCT02940158|OTHER|1/4 cup- macaroni|
41356186|NCT02940158|OTHER|1/4 cup- white potato|
41356187|NCT02940158|OTHER|1/4 cup- white rice|
41356188|NCT02940158|OTHER|1/2 cup- small red lentil|
41356189|NCT02940158|OTHER|1/2 cup- small green lentil|
41356190|NCT02940158|OTHER|1/2 cup- corn|
41356191|NCT02940158|OTHER|1/2 cup- macaroni|
41495974|NCT01114100|DRUG|sertraline|starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
41495975|NCT01114100|DRUG|placebo|patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
41495976|NCT05938608|DRUG|Regimen 1 (Oral primaquine)|Primaquine 15 mg base orally once
41495977|NCT05938608|DRUG|Regimen 2 (IV primaquine phosphate)|Primaquine 7.5 mg base in normal saline 500 mL infused over 30 minutes intravenously
41495978|NCT05938608|DRUG|Regimen 3 (IV carboxyprimaquine)|Carboxyprimaquine 7.93 mg base in normal saline 500 mL infused over 30 minutes intravenously
41495979|NCT00485420|OTHER|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
41495980|NCT03311035|PROCEDURE|Seton|The identification of the primary tract of the fistula and the placement of the thread can be performed in one single step. a non-absorbable, braided thread is inserted . After excision of the external opening and the extrasphincteric parts of the fistula, the thread is grasped and is pulled out of the anus .The thread is cut in two parts. The mucosa is incised over the muscular bridge . One thread is tied snugly around the muscle; the other is tied loosely .The snugly tied seton has to be replaced after 14 days to provide appropriate tension to cut slowly trough the muscle. This can easily be achieved with the second loosely tied seton . A new thread is folded in the middle and connected to the opened sling of the loose seton using a special knot shown in.The old thread is removed and in the same maneuver two new setons are placed. Again, one thread is tied snugly around the remaining portion of the sphincter muscle; the other is tied loosely .
40835991|NCT04485195|DRUG|Procainamide|15 mg/kg in 500 mL of normal saline given over 60 minutes
41495981|NCT03311035|PROCEDURE|LIFT technique|The internal opening was identified . The intersphincteric plane was entered via a curvilinear incision corresponding to the site of the internal opening at the intersphincteric groove. The intersphincteric plane was developed by meticulous scissor and diathermy dissection up to the tract. Once identified, a small, right-angled clamp was hooked underneath or a tape passed round it. the tract was then transfixed close to the internal sphincter with 2/0 polyglactin suture . Saline was gently injected through the external opening to confirm that the tract was no longer patent and it was then divided distal to the point of ligation . After light traction, a segment of the distal tract was excised and, if needed, any defect in the external sphincter was closed. The intersphincteric incision wound was re-approximated loosely with interrupted 2/0 Vicryl. Partial core-out of the fistula tract was performed from the external opening to the external sphincter.
41495982|NCT00593151|OTHER|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
41021645|NCT05760092|COMBINATION_PRODUCT|Institutional standard treatment for xerostomia and Long Covid|(Medical follow-up at the general outpatient clinic for prescription and control of medications, underlying diseases, clinical status and routine short, medium and long-term care follow-up, standard guidelines for the use of aerobic physical activity in those who do not have contraindications, stretching exercises, ergonomics, home adaptation to maximize functionality and energy savings, emotional cognitive support psychotherapy, socio-educational measures, sleep hygiene, Nutritional follow-up and monitoring, dentistry follow-up at the University's odontological team, guidance on proper oral hygiene, use of low-sugar diets, daily topical use of fluoride and antimicrobial mouthwash to prevent dental caries, oral hydration, guidance on avoiding cigarette use or intake of caffeine-containing beverages . When necessary, measures such as oral lubricants, artificial saliva, measures to prevent aspirations, as well as the careful use of liquids during meals, can be instituted ) +
41021646|NCT05760092|RADIATION|Photobiomodulation Therapy|Application of Red LED in the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, for 36 seconds, twice a week for 06 weeks.
41021647|NCT05760092|RADIATION|Placebo Photobiomodulation Therapy|All parameters as the number of points, dose and place of application of the PBM will be the same as described in the item PBM therapy Intervention Group, however in the placebo PBM equipment will be turned off. The device activation noise will be recorded and used to mimic the irradiation.
41021648|NCT01775137|DRUG|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
41356192|NCT02940158|OTHER|1/2 cup- white potato|
41356193|NCT02940158|OTHER|1/2 cup- white rice|
41356194|NCT00544193|DRUG|gemcitabine hydrochloride|
41356195|NCT00544193|GENETIC|polymerase chain reaction|
41356196|NCT00544193|OTHER|immunohistochemistry staining method|
41356197|NCT00544193|PROCEDURE|conventional surgery|
41356198|NCT00544193|RADIATION|intraoperative radiation therapy|
41356199|NCT00544193|RADIATION|radiation therapy|
41356200|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a high total daily dose
41356201|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
41356202|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a low total daily dose
41356203|NCT00779181|DRUG|Placebo|Placebo taken three times a day
41356204|NCT01678469|OTHER|blood sample|
41495983|NCT00593151|BIOLOGICAL|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
41495984|NCT01788618|OTHER|Cognitive exams|"Psychopathological assessment (T0 and T3):~* Scale of Spielberger~* The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)"
41495985|NCT01788618|OTHER|standardized cognitive rehabilitation|Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
41356205|NCT05860166|OTHER|Test Scale|Developing an Neurodevelopment Test for evaluating infants in their neonatal period.
41356206|NCT04747028|DIAGNOSTIC_TEST|Dmf score|A chart to calculate the caries index
41356207|NCT03730870|DIAGNOSTIC_TEST|Pharmacogenomics report|Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
41356208|NCT00311012|DRUG|Aliskiren|
41356209|NCT01650610|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
41356210|NCT00356434|DEVICE|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
41356211|NCT00356434|DEVICE|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
41356212|NCT04151654|OTHER|Footwear Assessment Score|It was assessed using the Sharpened Romberg test and Single Leg Stance test for static balance. It was assessed Berg Balance Scale for dynamic balance, and Timed Up and Go test for functional performance. Balance and performance tests were done with and without footwear in all individuals.
41356213|NCT06011889|DRUG|Etanercept|treatment with etanercept in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
41356214|NCT06011889|DRUG|Placebo|treatment with placebo in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
41356215|NCT00863135|DEVICE|CPAP|continuous positive airways pressure
41021649|NCT06573047|OTHER|kinesotape|a- Kinesio-tape: cure tape (made in Korea) made from 100% gentle cotton fibre and 100% medical grade acrylic adhesive. its Hypoallergenic, water-resistant and does not limit range of motion (ROM), it is come with different colours and sizes. Kinesio Tape is safe enough for a baby's sensitive skin, and gentle enough for aging individuals, flexible enough for rehabilitation, durable enough to support working muscle, joint or ligament and strong enough for athletes at any level.
41021650|NCT06573047|BEHAVIORAL|Chest physiotherapy exercises|selected chest physiotherapy exercise three times per week for two weeks, each session will be about 20 minute which will include the following exercise ( huffing , coughing , percussion,and postural drainage)
41021651|NCT04011475|DRUG|Tiotropium + Olodaterol|Spiolto®
41021652|NCT04011475|DRUG|Other LABA/LAMA|tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
41021653|NCT04011475|DRUG|LAMA|aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
41021654|NCT02443298|DRUG|placebo|Matching placebo for risankizumab
41021655|NCT02443298|DRUG|risankizumab|Monoclonal IgG antibody
41021656|NCT01384539|DRUG|Cholecalciferol|
41021657|NCT01384539|DRUG|Calcitriol|
41021658|NCT03505658|BEHAVIORAL|Education and Behavior|Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
41356216|NCT00863135|DEVICE|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
41356217|NCT05573204|DRUG|Obeticholic Acid Oral Tablet|Obeticholic acid used as 10 mg tablet once daily for 6 months
41356218|NCT05573204|DRUG|Vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
41356219|NCT03493204|OTHER|Meal delivery|The food will be pre-packaged for storage and patient will prepare these meals at home
41356220|NCT03493204|OTHER|Standard pamphlet with Dietary Advice|Explains how to maintain a low-sodium diet
41356221|NCT01402206|BEHAVIORAL|Structured patient-centered follow up of depression|"All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention)."
41356222|NCT05860595|GENETIC|KL003 cell injection Drug Product|Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.
41356223|NCT06166394|DRUG|Spinal hypobaric Mepivacaine Local Anesthetic Injection|• Administration of a hypobaric spinal mixture for Day-Surgery patients: 3.4ml of 1.5% mepivacaine created by 3ml 2% mepivacaine with 1ml sterile water, and then discarding 0.6ml
41356224|NCT06166394|DRUG|Spinal hypobaric Bupivacaine Local Anesthetic Injection|"Administration of a hypobaric spinal mixture for In-patients:~3ml of 0.33% bupivacaine created by 2ml 0.5% bupivacaine with 1ml sterile water"
41356225|NCT03866824|DRUG|injection of Platelet Enhanced Plasma(PRP)|intra-articular injection
41356226|NCT03866824|DRUG|injection of corticosteroids|intra-articular injection
41356227|NCT03866824|DEVICE|RMI|A CONTROL RMI at 1 year follow-up.
41356228|NCT02683330|BEHAVIORAL|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
41356229|NCT00650975|DEVICE|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
41356230|NCT00650975|DEVICE|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
41356231|NCT01959594|DRUG|3 mg PF-06412562|oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
41356232|NCT01959594|DRUG|10 mg PF-06412562|oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
41356233|NCT01959594|DRUG|25 mg PF-06412562|oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
41356234|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
41356235|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
41356236|NCT03765554|DRUG|PF-06700841 Immediate release tablets|Small molecule tablets in immediate release form
41356237|NCT03765554|DRUG|PF-06700841 Modified release tablets|Small molecule tablets in modified release form
41356238|NCT03740516|DRUG|CC-10004|CC-10004 will be administered orally
41356239|NCT03735186|BEHAVIORAL|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
41356240|NCT00523744|DRUG|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
41356241|NCT00523744|DRUG|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
41356242|NCT00523744|DRUG|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
41356243|NCT00523744|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
41356244|NCT04422951|BEHAVIORAL|Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment|Addition of two wise wise social psychological interventions-growth mindset and self-affirmation-to a 6-month usual care behavioral intervention for weight control in children with obesity
41356245|NCT04422951|BEHAVIORAL|Education plus usual care behavioral treatment|6-month health education plus usual care behavioral intervention for weight control in children with obesity
41356246|NCT05713513|OTHER|Leukapheresis|Leukapheresis to isolate 1x10e9 cells, examined for purity and specificity under Good Manufacturing Practice (GMP)
41356247|NCT00003016|DRUG|tamoxifen citrate|
41356248|NCT00003016|PROCEDURE|adjuvant therapy|
40835992|NCT05140551|DEVICE|COMPASS: digital CBT|COMPASS is an evidence based digital CBT intervention with guided therapist support, tailored to treat anxiety and/or depression in long term conditions (LTCs). The intervention consists of eleven modules/sessions in which CBT techniques are taught. Users of COMPASS receive guided therapist support from a trained therapist. The guided support aims to help patients identify and apply the CBT skills outlined in COMPASS to meet their individual needs and experiences of living with LTC(s). The support can occur through in-site messaging or via the telephone.
40835993|NCT01643876|BEHAVIORAL|Palatal brushing|Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
41356249|NCT03917576|OTHER|Behavioral|The resting heart rate (HRrest), maximum HR (HRmax), HR recovery (HRRTEST), delta HR recovery (ΔHRRTEST) were measured by continuous telemetric heart rate sensor (Polar FT4, PolarTM, Finland) during an incremental exercise test designed to obtain maximum oxygen consumption (VO2max) on a cycle ergometer (Lode Corival, Groningen, The Netherlands) similar with previous studies using similar cohort. An indirect calorimetry/ergospirometry system (Ultima CPXTM metabolic system, Medgraphics, Minnesota, USA) was used to measure VO2max until volitional exhaustion. Thus, the modified Astrand volitional protocol was applied in the participants of all NG, Pre-T2D and T2D groups increasing the load (i.e., Watts) 25 W each 2 min to women, and 50 W each 2 min to men.
40835994|NCT00499408|DIETARY_SUPPLEMENT|Vitamin D|Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)
41356250|NCT03917576|OTHER|Exercise training intervention|Subjects also participated in a single HIIT session composed of 10-cycling intervals, using a Lode Corival cycle ergometer. The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at \~80-100 % maximal power achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively).
41356251|NCT02985385|OTHER|Palliative management|Diagnostic studies for abnormal fetal ultrasounds
41356252|NCT05979727|DRUG|RE02|Low, medium or high dose of RE02
41356253|NCT05979727|DRUG|Manitol|Placebo Comparator
41495986|NCT01788618|OTHER|Standardized home exercise|These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
41495987|NCT01788618|OTHER|Follow up by phone|These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
41509223|NCT01598194|DEVICE|Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle|Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
41509224|NCT03784027|DEVICE|CamAPS FX|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
40835995|NCT00499408|DIETARY_SUPPLEMENT|soy|Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
40835996|NCT01760473|DRUG|Intranasal challenge drug|Each of the experimental challenge drugs were administered intranasally to all participants in random order.
40835997|NCT04376827|DRUG|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 via IV administration.
40835998|NCT04376827|DRUG|Placebo|Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.
40835999|NCT04376827|DRUG|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 via SC route.
40836000|NCT04376827|DRUG|Standard-of-care treatment|Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.
40836001|NCT00915668|DRUG|JNJ-31001074|
41021659|NCT01312961|DRUG|Dupilumab|Solution for injection, one subcutaneous injection.
41021660|NCT01312961|DRUG|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
41021661|NCT01312961|DRUG|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
41021662|NCT01312961|DRUG|Fluticasone monotherapy|Oral inhalation twice daily.
41021663|NCT01312961|DRUG|Albuterol|Oral inhalation as needed.
41021664|NCT01312961|DRUG|Levalbuterol|Oral inhalation as needed.
41021665|NCT04463901|PROCEDURE|Pterygium excision|Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.
41021666|NCT04463901|PROCEDURE|Intraoperative mitomycin C|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.
41021667|NCT04463901|PROCEDURE|Conjunctival autograft|A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
41021668|NCT04463901|PROCEDURE|Limbal conjunctival autograft|A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
41021669|NCT04177355|BIOLOGICAL|BG505 SOSIP.664 gp140|Administered by IM injection
41356254|NCT00626327|BIOLOGICAL|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
41356255|NCT00626327|BIOLOGICAL|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
41356256|NCT00626327|BIOLOGICAL|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
41356257|NCT05875909|PROCEDURE|corneal flap transplantation|Patients with macular holes underwent a 25-gauge, 3-port pars plana vitrectomy . Fluid-air exchange was performed in patients with pathologic myopia suffering from macular holes with retinal detachment. We used a flute needle to drain the subretinal fluid. A corneal flap was obtained by small incision lenticule extraction (SMILE). Stripping pliers were applied to spread corneal flap over the macular hole. A drop of fresh autologous whole blood was dripped over the corneal flap to immobilise it. The vitreous cavity was filled with 14% perfluoropropane (C3F8) for macular holes with retinal detachment . The surgical incision was self-closed or sutured with a 6-0 polyglactin 910 suture . The patients were instructed to maintain a prone position for 2 weeks postoperatively.
41356258|NCT00558961|DRUG|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
41356259|NCT00006082|DRUG|rubitecan|
40836002|NCT04317326|PROCEDURE|"Lifestyle modifications group (Control)"|It will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 \<55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88). The treatment period will be three months.
40836003|NCT04317326|PROCEDURE|Automatic NIV|In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 18 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight, being able to be modified according to tolerance.The treatment period will be three months.
40836004|NCT04317326|PROCEDURE|CPAP treatment group|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines for CPAP titration (SEPAR guideline or AASM guideline).In addition to lifestyle modification and oxygen (if require), a home titrated CPAP therapy will be initiated.The treatment period will be three years.
40836005|NCT04317326|PROCEDURE|NIV treatment groups|In-laboratory polysomnographic NIV titration will be performed according to published guidelines In addition to lifestyle modification and oxygen (if required) home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel pressure in S/T mode. The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG. The treatment period will be three years.
41356260|NCT03082768|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two \[18F\]MNI-968 injections and PET scans.
41356261|NCT02055872|DRUG|Intravenous albumin|
41356262|NCT02055872|DRUG|Normal saline|
41356263|NCT02307331|DEVICE|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
41356264|NCT02307331|DEVICE|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
41356265|NCT02307331|DEVICE|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
41356266|NCT02307331|DEVICE|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
41356267|NCT02307331|DEVICE|Sirius stem|A polished tapered stem
41356268|NCT03309215|OTHER|Experimental stimulation with nickel discs|"All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of \>99 wt.% nickel one consist of \>99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.~One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy"
41356269|NCT01825811|BIOLOGICAL|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10\^6 cells mixed with fibrin-glue
41356270|NCT01825811|BIOLOGICAL|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10\^6 cells mixed with fibrin-glue
41356271|NCT03793010|DRUG|FX006|Single Intra-articular injection
41356272|NCT03793010|DRUG|Normal saline|Single Intra-articular injection
41356273|NCT05713929|OTHER|Recruitment maneuver (RM)|performance of a recruitment maneuver of 30 cm H20 for 30 seconds and measurement of electrical impedance
41356274|NCT05713929|OTHER|Reverse Trend (REV TREND)|Place the patient in the reverse trendelenburg position and measuring the electrical impedance after 5 minutes
41356275|NCT01913275|PROCEDURE|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
41356276|NCT01913275|PROCEDURE|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
41356277|NCT04314258|DIETARY_SUPPLEMENT|Moringa oleifera tea|4 grams of Moringa oleifera tea twice daily
41356278|NCT01721668|BEHAVIORAL|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
41356279|NCT01721668|BEHAVIORAL|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
41356280|NCT05814107|DRUG|CT-996|Capsule of CT-996
41356281|NCT05814107|DRUG|Placebo|Capsule of Placebo
40836006|NCT01009190|DRUG|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
40836007|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
40836008|NCT01009190|DRUG|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
40836009|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
41021670|NCT04177355|BIOLOGICAL|Placebo|Administered by IM injection
41356282|NCT01266811|DRUG|Placebo, Velcade and dexamethasone|Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
41356283|NCT01266811|BIOLOGICAL|Siltuximab, Velcade and dexamethasone|Given in 21-day treatment cycles
41356284|NCT00579527|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
41356285|NCT00579527|OTHER|Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation|For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
41509225|NCT03784027|OTHER|Sensor augmented therapy|Study insulin pump and study CGM.
41509226|NCT01233895|DRUG|AVE1642|For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg
41509227|NCT01233895|DRUG|Velcade|For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
40836010|NCT05453994|DRUG|H. pylori eradication|PPIs-based Antimicrobial agents for H. pylori eradication
40836011|NCT02334488|DRUG|Everolimus|Active Comparator
40836012|NCT02334488|DRUG|Tacrolimus|Active Comparator
40836013|NCT02334488|DRUG|Mycophenolate sodium|Experimental Arm
40836014|NCT06158230|DRUG|Pizotifen|Pizotifen will be given only at night time to avoid daytime somnolence. Starting dose will be 0.5mg then gradually increased to 1.5 mg
41021671|NCT04177355|BIOLOGICAL|3M-052-AF|Administered by IM injection
41021672|NCT04177355|BIOLOGICAL|CpG 1018|Administered by IM injection
41021673|NCT04177355|BIOLOGICAL|GLA-LSQ|Administered by IM injection
41021674|NCT04177355|BIOLOGICAL|Alum (Aluminum Hydroxide Suspension)|Administered by IM injection
41021675|NCT04177355|BIOLOGICAL|Trimer 4571|Administered by IM injection
41021676|NCT00323739|DRUG|bevacizumab|Bevacizumab 10mg/kg, IV infusion, every 2 weeks
41021677|NCT00323739|DRUG|RAD001|RAD001 10 mg by mouth daily
41495988|NCT03756506|DEVICE|Novel Microbicidal Liquid Polymer|The polymer is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
41495989|NCT04961463|BEHAVIORAL|psychoeducation|
41021678|NCT04345146|COMBINATION_PRODUCT|FSRT combined with Bevacizumab|"Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT.~Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases."
40836015|NCT06158230|DRUG|Amitriptyline-propranolol|"Amitriptyline will be given at bedtime only, starting at 10 mg daily and gradually increasing to 25 mg daily.~Propranolol will be started in 40 mg daily in divided doses, which gradually increases to 80 mg daily in divided doses"
41021679|NCT04111341|DRUG|TCM (Gan-Lu-Yin)GLY|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
41021680|NCT04111341|DRUG|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
41021681|NCT05910775|BEHAVIORAL|Pre and Post Treatment Presentations|A short presentation provided to the participants within 72 hours prior to the first treatment of the acute course. The presentation will emphasize the effectiveness of the treatment, and provide notable encouragement and reassurance. The intervention group will additionally receive a follow up session within 24 hours after the first treatment to provide encouragement and reassurance
41495990|NCT04380129|OTHER|Music therapy-conversation sessions|"The intervention will be performed four times per patient at a frequency once weekly. An effort shall be made to ensure that each treatment is exactly seven days from the previous one within ± one day. Each session is expected to last approximately seventy minutes (75'). The musical hearing will include Helen Bonny's short program Caring short version, which is proposed by the author of this Music therapy model as the most suitable for patients with chronic and severe pain. The program is as follows:~* Haydn - Cello Konzert in C, Adagio with duration 9:42~* Dvorak - Serenade in E-Dur, Larghetto with duration 6:49~* Warlock - Capriol Suite, Pieds en I'air with duration 2:21"
41495991|NCT04380129|OTHER|Discussion sessions|Discussion sessions without the application of music therapy
41021682|NCT06449911|PROCEDURE|HIFU|300 lines and 10,200 dots will be performed to each half lower two-thirds of the face and submental area of every participant.
41021683|NCT00559897|OTHER|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
40836016|NCT02609945|DRUG|zolmitriptan|Oral Tablet and Nasal Spray
40836017|NCT02609945|DRUG|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
40836018|NCT04093336|BIOLOGICAL|human umbilical cord mesenchymal stem cells|The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.
40836019|NCT04093336|BIOLOGICAL|Placebo|Placebo
40836020|NCT04093336|OTHER|standardized treatment|standardized treatment
41021684|NCT00559897|PROCEDURE|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
41021685|NCT06481150|DRUG|Tenapanor|Each tablet 30 mg
41021686|NCT06481150|OTHER|Placebo|Placebo
41356286|NCT00579527|PROCEDURE|Blood Draw|Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done.
41356287|NCT00579527|DRUG|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
41356288|NCT00579527|DRUG|Cyclosporine|"In addition to RATGAM, subjects with typical cDGA with PHA responses \>50,000 cpm, or atypical cDGA with PHA response \<75,000cpm (when not on immunosuppression) or \<40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.~Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol."
41356289|NCT00579527|DRUG|Tacrolimus|If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.
41356290|NCT00579527|DRUG|Methylprednisolone or Prednisolone|Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells \>4,000cumm. Steroids are weaned as per protocol.
41495992|NCT04777149|OTHER|transcranial Random Noise Stimulation (tRNS)|Two electrodes will be placed over the targeted areas on participant's head. A current of random frequency and intensity will be delivered. TRNS will be applied during the first 20 min of functional task practice.
41495993|NCT04777149|OTHER|transcranial Direct Current Stimulation (tDCS)|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered. TDCS will be applied during the first 20 min of functional task practice.
41495994|NCT04777149|OTHER|sham-stimulation|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered for 1- 2 min.
41495995|NCT01782430|PROCEDURE|- standard oxygenation|
41495996|NCT01147107|DRUG|Raltegravir|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
41495997|NCT01147107|DRUG|Efavirenz|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
40836021|NCT05093920|DRUG|Doxorubicin-Eluting Beads|"* The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~* After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter."
40836022|NCT04050267|DRUG|Nitrous Oxide|Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
40836023|NCT04050267|OTHER|Placebo - air|Breathing air with 21 % oxygen, no nitrous oxide.
41356291|NCT00579527|DRUG|Daclizumab|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.
41356292|NCT00579527|DRUG|Mycophenolate mofetil|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.
41356293|NCT04501991|OTHER|antidiabetic treatment|Every kind of antidiabetic treatment, oral or injective, were considered including patients treated only with diet
41356294|NCT01701531|DRUG|RBCPF|
41356295|NCT05151549|DRUG|Camrelizumab|200mg/3weeks
41356296|NCT05151549|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
41356297|NCT01657903|DRUG|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
41356298|NCT01657903|DRUG|Potassium nitrate|All study treatments contain 5% w/w KNO3.
41356299|NCT03783221|OTHER|High-fat diet|The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..
41509228|NCT02108184|DRUG|Sequential therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
40836024|NCT02930408|PROCEDURE|electrocardiogram|
40836025|NCT02930408|PROCEDURE|Echocardiography|
40836026|NCT00093886|DRUG|clevidipine|
41021687|NCT06573645|DRUG|Rituximab|Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).
41021688|NCT02703844|DEVICE|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
41495998|NCT02895607|PROCEDURE|Ambulatory care among eligible patients|"The management of Anterior Cruciate Ligament (ACL) Reconstruction reconstruction in outpatient will be proposed in consultation with the surgeon.~After an explanation of the course of treatment a fact sheet on the protocol will be provided to the patient and his doctor to the patient to decide its support in CA (ambulatory surgery) or HC (conventional hospitalization)."
41495999|NCT02418663|DRUG|Fluid challenge (250 ml Lactated Ringer's solution)|"When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above"
41496000|NCT00978263|DRUG|metformin-based Oral Antidiabetic Drugs|
41496001|NCT00978263|DRUG|Glargine|
41021689|NCT02703844|DEVICE|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
41021690|NCT06034080|OTHER|Changes to the electronic health record (EHR)|"EHR changes will include minor changes to prescription fields to make it easier for clinicians to order wait and see antibiotics to be filled only if the child worsens or does not improve rather than antibiotics to take immediately."
41496002|NCT06231056|DIETARY_SUPPLEMENT|Probiotic iNatal®|iNatal® (Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactococcus lactis SP38, Lacticaseibacillus casei R0215)
41496003|NCT02952898|DRUG|GDC 695|GDC 695 is a topical gel.
40836027|NCT00093886|DRUG|nitroglycerin|
40836028|NCT00314301|DEVICE|loaded sit-to-stand training|
40836029|NCT06203067|BEHAVIORAL|Standard of Care|Quarterly clinic visits with endocrinology provider.
41021691|NCT06034080|OTHER|Individualized audit and feedback reporting for clinicians|Automated audit and feedback reports detailing participating clinicians' antibiotic prescribing habits for AOM both individually and in comparison to their peers will be shared with clinicians on a quarterly basis throughout the intervention period.
41021692|NCT06034080|OTHER|Clinician education sessions|Virtual education sessions will be held for clinicians to learn more about national guidelines for antibiotic prescribing for AOM, etc. The sessions will be recorded and distributed to clinicians who were unable to attend. Attendance of these sessions will apply toward continuing medical education credits for participants.
41496004|NCT02952898|DRUG|Diclofenac Sodium Gel, 3%|Diclofenac sodium gel, 3% is an FDA-approved drug.
41496005|NCT02952898|DRUG|Vehicle gel|Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
41496006|NCT01783249|OTHER|Stationary Exercise cycling|Stationary exercise cycling
41496007|NCT06422910|OTHER|Telerehabilitation|"Home exercises will be delivered through a video mobile application. In this application, exercises for knee osteoarthritis will be presented according to their types (stretching, strengthening, etc.). Videos deemed appropriate by the physiotherapist will be added to the exercise prescription and sent to the patients via message. Patients will have the opportunity to remotely access their own exercise prescription with visual, auditory and written commands.~Translated with DeepL.com (free version)"
41496008|NCT06126068|DRUG|Use of magnesium sulfate to prevent and stop fits in pre-eclampsia and Eclampsia|Loading dose magnesium sulfate versus the Pritchard regimen
41496009|NCT00124761|PROCEDURE|Surgery + WBRT|Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks
41496010|NCT00124761|RADIATION|Radiosurgery + WBRT|Radiosurgery - Marginal dose based on maximum tumour diameter
41496011|NCT02029573|DRUG|Atorvastatin|80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
41356300|NCT03783221|OTHER|High-residue diet|The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
41356301|NCT05167955|BEHAVIORAL|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy|An online mindfulness-based cognitive intervention is used as a proposed treatment intervention for erectile dysfunction among African- Caribbean men based in the United Kingdom.
40836030|NCT06203067|BEHAVIORAL|Type 1 Together|In Type 1 Together, families will work with other families who have experience using CGM (Peer Mentors) to overcome common barriers to CGM use. Families in the Type 1 Together program will also have access to CGM-specific educational materials, a digital journal to facilitate patient-provider communication around issues with CGM, and social determinant of health screening and intervention with a diabetes community health worker.
41356302|NCT02876315|DIETARY_SUPPLEMENT|Redoxon VI|"Each tablet contains:~Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)~Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc"
41356303|NCT02876315|DIETARY_SUPPLEMENT|placebo|Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
41356304|NCT00510406|DRUG|tamsulosin hydrochloride|Alphablocker
40836031|NCT02634021|DRUG|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
40836032|NCT02634021|DRUG|midazolam group|intravenous loading of midazolam for 0.1 mg/kg
41021693|NCT06034080|OTHER|Use of a shared decision-making (SDM) aide|A previously validated SDM aide for AOM will be used by clinicians during visits with children with AOM. The aide will be available online and in paper form.
41021694|NCT06034080|OTHER|Shared decision-making (SDM) education|Clinicians will receive education on SDM and how to use the aid via virtual, recorded sessions.
41021695|NCT05580575|DEVICE|Daily disposable toric soft contact lens|Daily disposable toric soft contact lens
40836033|NCT00437450|DRUG|Epoetin/Atra|
40836034|NCT02822378|DIETARY_SUPPLEMENT|Dried Plum|Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
40836035|NCT02822378|DIETARY_SUPPLEMENT|Calcium supplement|All participants will consume calcium supplements for the duration of baseline and intervention.
40836036|NCT02822378|DIETARY_SUPPLEMENT|Vitamin D supplement|All participants will consume vitamin D supplements for the duration of baseline and intervention.
40836037|NCT04838704|DRUG|Ruxolitinib+Calcineurin +Methotrexate|low-dose ruxolitinib combine with calcineurin and short course of methotrexate.
41021696|NCT05580575|DEVICE|Monthly replacement toric daily wear soft contact lens|Monthly replacement toric daily wear soft contact lens
41021697|NCT00434720|DEVICE|GlideScope Specific Stylet|
41021698|NCT02203019|DRUG|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
41356305|NCT00510406|DRUG|solifenacin succinate|antimuscarinic
41356306|NCT00510406|DRUG|Placebo|Placebo
41356307|NCT03943602|DRUG|Cabozantinib|Cabozantinib 60 mg/day orally
40836038|NCT04838704|DRUG|Calcineurin +Methotrexate+Mycophenolate mofetil|calcineurin and short course of methotrexate and mycophenolate mofetil
40836039|NCT03226977|DEVICE|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
40836040|NCT03226977|DEVICE|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
40836041|NCT00489736|DRUG|dronedarone (SR33589)|oral administration
41356308|NCT03802201|DRUG|PTG-300|Subcutaneous (SC)
41356309|NCT00890201|PROCEDURE|Gallbladder bile sampling and intraoperative cholangiography|"Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished"
41356310|NCT04848129|BEHAVIORAL|Feeding clinic|These children have all attended a multidisciplinary feeding clinic with severe food refusal and were commonly receiving tube feeding or supplement drinks. The clinic helps children progress onto a normal oral diet
40836042|NCT00489736|DRUG|amiodarone|oral administration
40836043|NCT01167868|DRUG|FosD|oral tablet
40836044|NCT01167868|DRUG|Placebo|oral tablet
40836045|NCT01107782|DRUG|sildenafil|50 mg TDS orally until birth
40836046|NCT01107782|DRUG|placebo|50mg tid
41021699|NCT02203019|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
41021700|NCT02203019|DRUG|Fentanyl|"Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest."
41021701|NCT00950638|DRUG|ARC1905|intravitreal injection
41021702|NCT05430386|DRUG|HS-10241|"Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy."
41021703|NCT05969353|OTHER|accupunture|BFA
41021704|NCT05270213|DRUG|RBS2418|RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
41356311|NCT00483067|DRUG|2-CdA|12 mg/m\^2/day by vein (IV) Continuous Infusion x 5 Days
41021705|NCT02588118|DRUG|propofol|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
41356312|NCT00483067|DRUG|Ara-C|1 gm/m\^2/day IV Over 2 Hours x 5 Days
41356313|NCT00483067|DRUG|G-CSF (Granulocyte colony-stimulating factor)|5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
41356314|NCT03049189|DRUG|177Lu-edotreotide PRRT|PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
41021706|NCT02588118|DRUG|Cisatracurium|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
41356315|NCT03049189|DRUG|Everolimus|Everolimus will be adminstered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
41021707|NCT01375296|DEVICE|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
41356316|NCT03049189|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
41356317|NCT04084444|DRUG|T8 tablet 0.5mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
41356318|NCT04084444|DRUG|T8 tablet 1mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
41356319|NCT04084444|DRUG|Placebo|Blank control.
41356320|NCT05109728|DRUG|[177Lu]Lu-DOTA-TATE|"Group 1: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed."
41356321|NCT05109728|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
41356322|NCT05109728|OTHER|Temozolomide|"Concomitant Phase: Temozolomide 75mg/m2/d p.o until last day of EBRT.~Maintenance Phase: Temozolomide p.o 150 mg/m2/d during cycle 1 then 200 mg/m2/d for the following cycles if tolerated well in Cycle 1. 6 cycles total (1 cycle = every 28 days)"
41356323|NCT05109728|OTHER|Radiotherapy|2 Gy/day, 5 days per week followed by 2 days of rest, for 6 consecutive weeks
41496012|NCT02029573|DRUG|Temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
41021708|NCT01375296|OTHER|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
41021709|NCT05352139|PROCEDURE|Resection (removal) of the degenerative tissue using the Hydrocision TenJet system|During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.
41496013|NCT02029573|RADIATION|Radiotherapy|60 Gy in 30 fractions
41496014|NCT05914935|DRUG|Recombinant L-IFN adenovirus injection|The Ommaya reservoir was surgically implanted, and multiple intracapsular injections were given medicine. On the second day after Ommaya reservoir implantation, CT examination confirmed that the implantation was successful, and the experimental drug injection was started.
41021710|NCT05352139|DEVICE|Hydrocision Tenjet System|The TenJet system will be used during surgery to remove the damaged tissue from the joint
41021711|NCT02629146|DRUG|Midazolam|
41021712|NCT02629146|DRUG|Fentanyl|
41356324|NCT05891301|OTHER|Questionnaires set|The contents of the questionnaire included gender, age, BMI, previous operation history, previous medication history, smoking history,patient mobility in the hospital, etc.Questionnaire was completed on the first postoperative day.From the third day to the end of the seventh day, patients were evaluated daily for gastrointestinal dysfunction.Postoperative mobility was assessed daily.
41356325|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube
41356326|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube with rubber suction catheter
41496015|NCT00991419|DRUG|[18F]AZD4694|\[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
41496016|NCT03328195|DEVICE|Neuro RX Gamma synchronous|Twenty minute treatment, six days per week for 12 weeks
41021713|NCT02629146|DRUG|Isotonic saline|
41356327|NCT04695444|DEVICE|nasotracheal tube (portex)|different materials for nasotracheal intubation velvet soft PVC tube.
41496017|NCT03328195|DEVICE|Sham|Twenty minutes, six days per week for 12 weeks with sham device
41496018|NCT03328195|DEVICE|Neuro RX Gamma asynchronous|Twenty minutes, six days per week for 12 weeks with sham device
41496019|NCT03251339|DRUG|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
41021714|NCT04237298|DEVICE|Modified vacuum-formed retainer covering the palete|The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
41356328|NCT05644639|DEVICE|StimRouter Neuromodulation System|The StimRouter device is indicated for pain management in adults who have severe, intractable chronic pain of peripheral nerve origin and as an adjunct to other modes of therapy (e.g., medications). The StimRouter device is not intended to treat pain of craniofacial nerve origin.
41356329|NCT04171752|DRUG|elafibranor|elafibranor 120mg is a coated tablet for oral administration
41356330|NCT03549637|DIAGNOSTIC_TEST|Psychiatric population|Genetic and biological analysis of patients
41496020|NCT03251339|DRUG|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
41496021|NCT06016491|BEHAVIORAL|acupressure|Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each woman, and then the person were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks.
41496022|NCT06016491|BEHAVIORAL|Sham acupressure|Compression was applied on the bone region where the meridians did not pass, parallel to the KD1 and SP6 points (approximately 1-1.5 cm away). Similar to the acupressure group, the sham group was treated with symmetrical extremities and for similar durati
41496023|NCT01600430|DIETARY_SUPPLEMENT|Cholecalciferol|200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days
41496024|NCT01600430|DIETARY_SUPPLEMENT|Cholecalciferol|800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days
41496025|NCT01600430|DIETARY_SUPPLEMENT|Placebo|Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
41496026|NCT00763061|DRUG|Travoprost 0.004% Ophthalmic Solution (Travatan)|Travoprost at 9 AM + Placebo \& 9 PM
41496027|NCT00763061|DRUG|Timolol 0.5% Ophthalmic Solution (Timoptic)|Timolol in each eye, twice daily at 9 AM \& 9 PM
41496028|NCT01708551|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
41021715|NCT04237298|DEVICE|Hawley retainer|Standard retention regime for patients with arch expansion. Patients will be instructed to wear the retainer 24 hours during the study period.
41021716|NCT04221295|BEHAVIORAL|Exercise Group|Previously described in the arm/group descriptions.
41021717|NCT04151862|DEVICE|tight eye bandage|sterile eye pad made of 100% cotton
41496029|NCT05493137|OTHER|No intervention will be provided|No intervention will be provided, this is an observational study
41496030|NCT05749250|DEVICE|Acoustic cavitation of ultrasound enhancing agents|Cavitation therapy
41021718|NCT04151862|DEVICE|Soflex Soft Contact Lens|Therapeutic contact lenses (TCL)
41021719|NCT04407897|RADIATION|Stereotactic radiotherapy|Three different dose fractionation schemes will be available: 45 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 8 fractions.
41021720|NCT04401124|OTHER|no intervention|no intervention
41021721|NCT03062800|DRUG|Thalidomide|100-200mg/d,oral ,qn
41021722|NCT03062800|DRUG|pemetrexed|(500mg/m\^2) on day 1 of 21-days cycle,ivgtt
41021723|NCT03062800|DRUG|cisplatin|(75mg/m\^2) on day 1 of 21-days cycle, ivgtt
41021724|NCT03062800|DRUG|carboplatin|(AUC=5) on day 1 of 21-days cycle, ivgtt
41356331|NCT01017289|DEVICE|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
41356332|NCT02117024|DRUG|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
41356333|NCT02117024|DRUG|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
41356334|NCT02117024|DRUG|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed"
41356335|NCT03820518|DRUG|Calcitriol|
41356336|NCT02346799|BEHAVIORAL|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
41356337|NCT02346799|BEHAVIORAL|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
41356338|NCT02346799|BEHAVIORAL|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
41496031|NCT04963543|OTHER|FID123238|Lubricant applied to the ocular surface
41496032|NCT04713553|BIOLOGICAL|BNT162b2|Intramuscular injection
41496033|NCT04713553|BIOLOGICAL|BNT162b2.B.1.351|Intramuscular injection
40836047|NCT03100214|OTHER|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
41356339|NCT02346799|BEHAVIORAL|Partner Assignment|"Participants will be required to have same workout window as partners."
41356340|NCT03170635|BEHAVIORAL|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
40836048|NCT03100214|OTHER|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
40836049|NCT02421926|DRUG|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
40836050|NCT03580824|BIOLOGICAL|R21 in Matrix- M adjuvant vaccine|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
40836051|NCT05957614|PROCEDURE|Traditional rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture, including immobilization, early weightbearing ankle motion exercise and isolated early ankle motion exercises.
41496034|NCT05600465|BEHAVIORAL|Behavioral Activation + Occupational Therapy|In the BA-OT Approach, the PI will use an evidence-based 4-step process (Goal-Plan-Do-Check) to assist the older adults to develop strategies to plan and execute daily health self-management activities. BA-OT teaches older adults with MCC and functional limitations to 1) set achievable and meaningful activity goals, 2) engage in action planning that includes brainstorming strategies to overcome barriers, 3) evaluate the results after performing the activity, and 4) to modify the plan or choose a new goal, then generalize strategies to new problems. By assisting participants to develop daily routines and integrate safe health self-management activities into these routines, occupational therapists are providing strategies that support adaptation in the face of stressful situations.. Goal examples may include adapting and scheduling exercise plans, or exploring assistive devices and strategies for safe and healthy meal preparation.
41496035|NCT05600465|BEHAVIORAL|Enhanced Usual Care|Fitbit, 1 hour training, handout on managing chronic conditions
41496036|NCT06008626|DEVICE|Cryosa Procedure|Cryotherapy
41496037|NCT05149677|BEHAVIORAL|Music therapy|Music therapy intervention + Standard of Care for labor pain
41496038|NCT05739279|DIAGNOSTIC_TEST|STAR-Sonographic Thigh Adjustment Ratio|With ultrasonography, anterior thigh muscle thickness on the dominant extremity side will be measured at a 50% level between the anterior superior iliac spine and the upper pole of the patella in the supine position. The STAR-sonographic thigh adjustment ratio will be calculated by dividing the anterior thigh muscle thickness (mm) by the body mass index.
41356341|NCT00805142|DRUG|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
41356342|NCT05201924|BEHAVIORAL|Bedtime routine|a regular routine conducted around bedtime includes brush, book reading and regular bedtime
41356343|NCT05201924|BEHAVIORAL|Control|a healthy control checklist
41356344|NCT02330640|DRUG|ticagrelor|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
41356345|NCT02330640|DRUG|clopidogrel|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
41356346|NCT02330640|DRUG|asprin|All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
41356347|NCT00750867|DRUG|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
41356348|NCT02462200|PROCEDURE|Breast-conserving surgery (BCS)|
41496039|NCT05739279|DIAGNOSTIC_TEST|Hand Grip Strength|Hand grip strength will be measured with a Jamar dynamometer used in the second grip position, in a sitting position with shoulders adducted and neutrally rotated, elbows flexed to 90°, and forearms/wrists in the neutral position. Three repetitive measurements will be made from the dominant side and the maximum value obtained for analysis will be taken.
41356349|NCT02462200|PROCEDURE|Cavity shave margins (CSM)|
41356350|NCT02462200|BEHAVIORAL|BREAST-Q Questionnaire|
41356351|NCT02462200|DEVICE|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
41356352|NCT02462200|OTHER|Indocyanine green|
41356353|NCT02462200|DEVICE|Intraoperative imaging device|The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field
41356354|NCT02462200|PROCEDURE|Peripheral blood draw|-Time of surgery if coordinator is available
41356355|NCT02648867|DEVICE|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
41356356|NCT06178107|DIETARY_SUPPLEMENT|LP-LDL Probiotic|LP-LDL a dietary food supplement probiotic
41496040|NCT05739279|DIAGNOSTIC_TEST|Chair Stand Test|For the 5-repeat stand-up test, patients will be asked to get up from a chair without an armrest and sit (at the start) five times as fast as possible with their arms crossed over their chest.
41021725|NCT01858194|DEVICE|Renal sympathetic denervation|"* The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~* After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
41356357|NCT06178107|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo comparator Maltodextrin
41496041|NCT05739279|DIAGNOSTIC_TEST|6 Meter Gait Speed|For walking speed measurements, patients will be asked to stand with both feet touching the starting line and walk at their normal speed on a 6-meter track after the command. The time between the start and end will be measured with a stopwatch and converted to meters/second. Three consecutive measurements will be made for both and average values will be taken for the analyses.
41496042|NCT06358235|OTHER|Music Therapy|30-minute music therapy session.
41496043|NCT06358235|OTHER|No Music therapy|The practice where patients are simply fitted with headphones and rest quietly without listening to music.
41021726|NCT01858194|DEVICE|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
40836052|NCT05957614|PROCEDURE|Acupuncture-assisted Rehabilitation Protocol|Add acupuncture treatment on the basis of traditional rehabilitation protocol.The acupuncture procedure is as follows, acupuncture treatment is carried out for half an hour every day in two weeks after surgery. The acupoints on the affected side are ST36(ZuSanLi), GB34(YangLingQuan) and SP9(YinLingQuan), and the acupoints on the healthy side are Ki3(TaiXi), bl60(KunLun) and PC7(DaLing).
41021727|NCT06573255|OTHER|Healthy group|Cardiopulmonary exercise test, respiratory function tests, respiratory muscle strength and physical activity assessment will be performed in this group.
41021728|NCT06573697|OTHER|low-frequency continuous wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.
41356358|NCT01059955|DRUG|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
41356359|NCT01059955|DRUG|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
41356360|NCT00837889|DRUG|diuretics, inotropica|
41356361|NCT05734040|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1
41356362|NCT05734040|BIOLOGICAL|Fluarix Tetra|One single administration intramuscularly at Day 1
41356363|NCT05734040|BIOLOGICAL|Afluria Quad|One single administration intramuscularly at Day 1
41356364|NCT05734040|BIOLOGICAL|Placebo|One single administration intramuscularly at Day 1
41356365|NCT03225027|BEHAVIORAL|Emotional judgment task|Participants had to indicate on a computer the emotional intensity of audio recordings.
41496044|NCT05584592|OTHER|Intergrate early palliatuve care + Conventional chemotherapy|Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
41496045|NCT05584592|OTHER|Conventional chemotherapy|patients to receive routine palliative care when they want it or when it is needed by health care providers. In other words, if a patient assigned to the control group desires palliative care, they can receive conventional palliative care.
41356366|NCT03225027|BEHAVIORAL|Post-experimental questionnaire|Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
41356367|NCT03225027|BEHAVIORAL|Recognition task|Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
41356368|NCT03225027|BEHAVIORAL|Detection task|Participants indicate every time they heard a given sound in order to verify their audition level.
41356369|NCT03225027|OTHER|CAPE-42|This questionnaire allows evaluating the nature of psychotic experiences.
41356370|NCT03225027|DIAGNOSTIC_TEST|Trait Emotional Intelligence Questionnaire|To evaluate their emotional intelligence.
41356371|NCT03225027|DIAGNOSTIC_TEST|Positive And Negative Syndrome Scale|Evaluating the clinical status of patients with schizophrenia.
41356372|NCT03225027|OTHER|Mini International Neuropsychiatric Interview|Evaluating the exclusion criteria in healthy participants.
41356373|NCT06481410|DRUG|Methylene Blue Intervention Group|In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.
41356374|NCT06481410|DRUG|Normal Saline Control Group|In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group.
41356375|NCT06110091|BEHAVIORAL|Integrated Behavioral Therapy Program|Integrated Behavioral Therapy is a behavioral program that includes education, lifestyle habits management, cognitive, relaxation, and behavioral conditioning for nocturia and insomnia
41356376|NCT06110091|BEHAVIORAL|Health Education Program|Health Education Program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment.
41356377|NCT04180475|DEVICE|MedRem application|Medication adherence smartwatch application
41356378|NCT06164418|PROCEDURE|Dental restoration|Each patient will receive a cervical restoration using the corresponding group adhesive and restorative material
41356379|NCT03718728|BEHAVIORAL|Mind&Life|Acceptance and mindfulness-based group intervention program.
41356380|NCT03718728|BEHAVIORAL|Standard|Personalized diet and physical exercise recommendations.
41021729|NCT06573697|OTHER|discontinuous wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz discontinuous wave will be used for 20 min.
41021730|NCT06573697|OTHER|dilatational wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2/100Hz dilatational wave will be used for 20 min.
41160221|NCT06170229|BEHAVIORAL|NEMEX-e|"Education and Neuromuscular Exercise~The focus of the two educational sessions is on providing knowledge of OA and treatment options to the participants, with a special focus on knee OA, diet, and exercise and its benefits. Furthermore, advice about self-management is given.~The exercises are based on neuromuscular principles to improve sensorimotor control and achieve compensatory functional stability. Sensorimotor control is the ability to coordinate muscle activity and maintain functional stability during movement allowing for joint stability during physical activity. Various positions (sitting, lying, standing) are used to achieve the desired postural activity. The overall goal is to obtain muscle control and stability in situations resembling daily life and/or more strenuous activities. The focus is on achieving good quality of the performance in each exercise with appropriate postural orientation (e.g., joint positioned appropriately in relation to each other)."
41356381|NCT04778696|PROCEDURE|PASO Pacemapping|Using the PASO pacemapping visualisation module of CARTO3
41356382|NCT04778696|PROCEDURE|Conventional Pacemapping|without visualisation in 3D mapping
41356383|NCT00581724|BEHAVIORAL|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
41356384|NCT00782756|OTHER|radiotherapy (RT) in combination with temozolomide and bevacizumab|"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
41021731|NCT04243824|DRUG|Gallium 68 Macro-aggregated albumin|The radiotracer, Ga-68 MAA, will be administered prior to PET/MRI scan.
41021732|NCT06573528|DRUG|CS060380|Tablets administered orally
41160222|NCT05212597|DRUG|Sacubitril-valsartan|50mg\~100mg twice daily
41356385|NCT04063059|BEHAVIORAL|PRIDE counseling intervention|Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
41356386|NCT05113849|BIOLOGICAL|IN-B009 (Low-dose)|Two doses, intramuscular injection
41356387|NCT05113849|BIOLOGICAL|IN-B009 (High-dose)|Two doses, intramuscular injection
40836053|NCT03362697|DIETARY_SUPPLEMENT|Probiotics|The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day
40836054|NCT03362697|DRUG|Antibiotics|Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
40836055|NCT00143377|DRUG|tolterodine SR, overactive bladder|
41021733|NCT03264625|DRUG|Cholecalciferol (2000iu qd)|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
41021734|NCT03264625|OTHER|Routine therapy for PD|Patients randomized to the placebo group will receive routine therapy for PD.
41021735|NCT01076725|DEVICE|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
41021736|NCT01076725|DEVICE|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
41021737|NCT03487913|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
41356388|NCT03589794|OTHER|AP10-602|Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
41356389|NCT03589794|OTHER|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
41356390|NCT03589794|BIOLOGICAL|rCSP|The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
41356391|NCT04651647|PROCEDURE|Revision surgery with / without open bone graft|Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
41356392|NCT01442961|PROCEDURE|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
41021738|NCT04751916|DIETARY_SUPPLEMENT|Essential Amino Acid Protein Supplement|Proprietary essential amino acid protein supplement
41356393|NCT01442961|PROCEDURE|vaginal : vaginal hysterectomy|Vaginal hysterectomy
41356394|NCT02808273|DRUG|Bemiparine|Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
41356395|NCT03381144|DRUG|GDC-0334|Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
41356396|NCT03381144|DRUG|Placebo|Participants will receive GDC-0334-matching placebo.
41356397|NCT02399189|DRUG|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
41356398|NCT05189535|DRUG|Pentoxifylline|Pentoxifylline 400 mg oral tablet twice daily for 12 weeks.
41356399|NCT05189535|DRUG|Paclitaxel|Paclitaxel I.V 80 mg/m2 weekly
41496046|NCT03577418|BEHAVIORAL|Clinician-facilitated educational intervention|People with dementia (PWD) will complete the Preferences for Everyday Living (PELI). Care partners will complete the PELI from the perspective of the PWD (i.e., as if acting as surrogate decision-makers). Research staff will then review these assessments, highlighting areas of discrepancy in the importance of various preferences. A 30-minute preferences-based discussion will then be facilitated by the research clinician. This discussion will include review of the discrepancies identified in the assessments. The PWD and the care partners will then be encouraged to identify one area of discrepancy and to come together with a concrete action plan to resolve that area of discrepancy. A standardized document describing neuropsychiatric symptoms and reviewing the unmet needs hypothesis will be discussed with PWD and the care partners.
40836056|NCT00457223|PROCEDURE|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
41021739|NCT04751916|DIETARY_SUPPLEMENT|Beneprotein®|Whey protein supplement
40836057|NCT04662372|OTHER|Description|description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
40836058|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg untrained|We are looking at the untrained used of Handihaler
40836059|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg trained|We are looking at the trained use of Handihaler after 14 days treatment
41021740|NCT00088218|DRUG|Clofarabine|1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)
41160223|NCT05212597|DRUG|Amlodipine-losartan|amlodipine/losartan 2.5/25mg \~ 5/100mg once daily
41356400|NCT05189535|DRUG|Placebo|placebo
41356401|NCT00004333|DRUG|NTBC|
41356402|NCT05422027|DRUG|Selinexor|"Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles"
40836060|NCT02683668|COMBINATION_PRODUCT|Respimat-Tiotropium 5 mcg trained|we are looking at the trained use of Respimat after 14 days treatment
41021741|NCT00088218|DRUG|Ara-C|20 mg/m\^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
41021742|NCT02660359|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
41021743|NCT02660359|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
41356403|NCT05422027|DRUG|Bortezomib|"The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone"
41356404|NCT05422027|DRUG|Lenalidomide|"The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
41356405|NCT05422027|DRUG|Dexamethasone|"The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
41021744|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
41021745|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
41021746|NCT04901559|PROCEDURE|Graft type at ACLR|The choice of graft at primary ACL Reconstruction
41021747|NCT01578434|DRUG|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
41021748|NCT01578434|DRUG|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
41160224|NCT04773054|DIAGNOSTIC_TEST|Microbiological analysis of periprosthetic tissue|Microbiological culture of tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
41496047|NCT03577418|BEHAVIORAL|Enhanced usual care|In addition to the usual clinical care, the standardized document describing NPS and reviewing the unmet needs hypothesis will be given to the PWD and the care partner to review.
41021749|NCT01578434|DRUG|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
41021750|NCT03181516|BIOLOGICAL|Bifidobacterium animalis subsp. lactis BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
41021751|NCT03181516|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
41021752|NCT01813019|DRUG|AFQ056|mGluR5 antagonist
41021753|NCT01813019|DRUG|Placebo|Matched placebo
41021754|NCT03336008|OTHER|no intervention|No intervention but clinical assessement for all recruited subjects
41496048|NCT04314648|BEHAVIORAL|Substance Use Treatment and Recovery Team (START)|Embedding of a collaborative care team, called the Substance Use Treatment and Recovery Team (START), for inpatients with OAUDs within an existing hospital consultation liaison psychiatry service.
41496049|NCT03223792|OTHER|Control|Routine cow's milk-based infant formula
41496050|NCT03223792|OTHER|Investigational|Partially-hydrolyzed cow's milk protein infant formula
41496051|NCT02065856|BIOLOGICAL|AVANZ Salsola|AVANZ Salsola
41496052|NCT01476592|DIETARY_SUPPLEMENT|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
41496053|NCT01276301|DRUG|Verapamil|single dose verapamil
41021755|NCT03846024|DEVICE|RibFx Orthosis Belt|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
41021756|NCT02160873|OTHER|chocolate milk|12 oz, 7-8 hours prior to exercise trial (night before)
41021757|NCT02160873|OTHER|flavor-matched placebo|12 oz, non-caloric flavor-matched placebo
41021758|NCT02019719|DRUG|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
41021759|NCT02019719|DRUG|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
41021760|NCT05497908|PROCEDURE|TAP block via lateral approach|TAP block via lateral approach
41496054|NCT01276301|DRUG|BI 10773|single dose BI 10773
41496055|NCT01276301|DRUG|BI 10773|single dose BI 10773
41496056|NCT05256524|DRUG|The effect of LMWH|Quantified by aFXa-levels
41496057|NCT05256524|DIAGNOSTIC_TEST|Monitoring frequency of aFXa-levels|The frequency of aFXa-levels being sampled, analysed and integrated as a possible part of the basis for clinical decisionmaking
41021761|NCT05497908|PROCEDURE|TAP block via posterior approach|TAP block via posterior approach
41496058|NCT00000326|DRUG|Heroin Dependence|
41496059|NCT02164474|BEHAVIORAL|High-Intensity Interval Training|Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at \~85-90% peak oxygen uptake \[VO2peak\] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at \~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.
41496060|NCT01008982|DRUG|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
41496061|NCT05532371|OTHER|Aerobic exercise training combined with lower limb strengthening|The participants performed aerobic exercise training and lower limb strengthening during this intervention.
41496062|NCT05532371|OTHER|Dual-task training combined with lower limb strengthening group (DG)|The participants performed dual-task training combined with lower limb strengthening during this intervention.
41021762|NCT03173222|PROCEDURE|Electroacupuncture|A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
41021763|NCT01429545|DRUG|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
41021764|NCT01429545|DRUG|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (\<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
41021765|NCT02678611|DIETARY_SUPPLEMENT|Basis 250|
41021766|NCT02678611|DIETARY_SUPPLEMENT|Basis 500|
41021767|NCT02678611|DIETARY_SUPPLEMENT|Placebo|
41021768|NCT03285373|DRUG|NOAC|New Oral Anticoagulant
41021769|NCT04354831|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|"* SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~* Study drug will be administered as a single intravenous infusion"
41021770|NCT03813303|DRUG|Midazolam|Administration of midazolam by anesthesiologist for sedation.
41496063|NCT05532371|OTHER|Aerobic exercise training combined with dual-task training and lower limb strengthening|The participants performed aerobic exercise training combined with dual-task training and lower limb strengthening during this intervention.
41496064|NCT05532371|OTHER|Only lower limb strengthening group (CG)|The participants performed only lower limb strengthening group during this intervention.
41496065|NCT04626453|BEHAVIORAL|2-month home moderate-intensity exercise|The 2-month exercise will be conducted at the participants' homes. Participants will be recommended to perform the combined exercise, which consists of the resistance exercise and walking at a faster speed than leisure walking at a moderate-intensity, for 6 days/week. They can decide which day they won't perform the exercise. Participants will be encouraged to do progressive resistance exercise and walking twice a day, once in the morning and the other time in the afternoon. Resistance exercise will be suggested to perform every other day for three days/week and walking as the aerobic exercise will be on alternate days for three days/week.
40836061|NCT03654001|BIOLOGICAL|Albumin|Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
40836062|NCT03654001|OTHER|Balanced|Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
40836063|NCT04333342|DEVICE|heart rate monitoring using wearable devices|Using Fitbit (TM) wearable devices, heart rate, activity data are collected. Based on these data, resting heart rate is monitored daily basis. If resting heart rate increase beyond set range, users are notified to visit the hospital.
40836064|NCT00447473|DRUG|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
40836065|NCT00447473|DRUG|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
40836066|NCT00447473|DRUG|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
40836067|NCT04356794|OTHER|Acupuncture needle with electrical stimulation|EA is treated for 4 weeks, 3 times per week.
40836068|NCT04356794|OTHER|Sham electroacupuncture|Sham EA is treated for 4 weeks, 3 times per week.
40836069|NCT02418104|DRUG|CHS-1701|
40836070|NCT02418104|DRUG|Pegfilgrastim (Neulasta)|
40836071|NCT05214391|DRUG|Zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the investigator will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
40836072|NCT03037541|DRUG|Carac Cream|Carac Cream will be used once daily for seven consecutive days
40836073|NCT03037541|DRUG|Placebo Cetaphil cream|Placebo Cetaphil Cream will be used once daily for seven consecutive days
40836074|NCT00530920|DRUG|tipranavir|
40836075|NCT00530920|DRUG|ritonavir|
40836076|NCT00068510|BIOLOGICAL|therapeutic autologous dendritic cells|
40836077|NCT04139681|DRUG|A. Vogels Sore Throat lozenges|5 times 1 A. Vogels sore throat lozenges daily for 4 days
40836078|NCT05759468|DRUG|Investigational Product - MIB 626|The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
41021771|NCT03813303|DRUG|Fentanyl|Administration of fentanyl by anesthesiologist for sedation.
41160225|NCT04773054|DIAGNOSTIC_TEST|Histological analysis of periprosthetic tissue|Histological assessment of cellular reactivity associated with the infection on tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
40836079|NCT05759468|DRUG|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
41021772|NCT03813303|DRUG|Propofol|Administration of propofol by anesthesiologist for sedation.
41021773|NCT04387162|BEHAVIORAL|Prism Adaptation Treatment|Spatial retraining treatment
41021774|NCT01903447|DRUG|SSRI|
41021775|NCT01903447|BEHAVIORAL|CBT|
41021776|NCT00096941|DRUG|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
41021777|NCT04027686|DEVICE|Laser Therapy|Adjunctive application of laser therapy in the periodontal pocket
41160226|NCT04773054|OTHER|Characterization of tissue microbiota|"Assessment of tissue microbiome composition using the next-generation sequencing of DNA extracted from samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone."
41160227|NCT04773054|OTHER|Characterization of gut microbiota|"Assessment of gut microbiome composition using the next-generation sequencing of DNA extracted from stool samples."
40836080|NCT02259985|DRUG|Itasetron tablet|
40836081|NCT02259985|DRUG|Itasetron infusion|
40836082|NCT02259985|OTHER|high fat breakfast|
40836083|NCT04054492|BIOLOGICAL|Sabin-IPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
40836084|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
40836085|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+Sabin-IPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
40836086|NCT04772144|BEHAVIORAL|behavioural and cessation aids|information, motivational interview, refferal to healty life-centers, free cessation aids
40836087|NCT04208087|DRUG|SI-722|SI-722 will be intravesically instilled.
40836088|NCT04208087|DRUG|Placebo|Placebo will be intravesically instilled.
40836089|NCT02995044|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-180)
41021778|NCT04027686|PROCEDURE|Non-surgical Scaling and Root Planing|Scaling to remove calculus deposits and root planing to smooth root surfaces
41021779|NCT03653429|DRUG|Tranexamic Acid|administered prior to surgical incision
41021780|NCT03653429|DRUG|Normal saline|administered prior to surgical incision
41021781|NCT06238505|OTHER|Virtual|application will be made with virtual reality device
41021782|NCT06238505|OTHER|biodex|application will be made with biodex device
41496066|NCT02868645|BIOLOGICAL|Blood sampling|Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
40836090|NCT02995044|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
40836091|NCT06507033|DEVICE|Mobile application and an arm volume measurement device|The intervention consists mainly of two steps; (a) development of a mobile application with an arm volume measurement device (b) evaluation of the effectiveness of the products. Five components will be involved in the development of the mobile application. These components are; (I) exercise, (II) education, (III) coping mechanisms, (IV) arm volume measurement/recording and (V) appointment, exercise and measurement reminder panel. Exercise videos will include stretching exercises for the shoulder and arm as recommended in the guidelines
40836092|NCT06289816|PROCEDURE|Minimally Invasive Surgery|Minimally Invasive Surgery : Laparoscopic partial splenectomy, cystectomy, and cyst deroofing.
40836093|NCT05809804|DRUG|Esketamine|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
40836094|NCT06428812|OTHER|Experimental: perineal package application group|This group includes those in the 2nd stage of labor upright position spontaneous pushing Hot application will be made
40836095|NCT02059954|PROCEDURE|Hysterectomy|
41021783|NCT00194012|DRUG|Aripiprazole|Addressed in arm description.
41021784|NCT00194012|DRUG|Placebo|Addressed in arm description.
41021785|NCT06570096|DRUG|Lidocaine 2% then bupivacaine 0.5%|Patients will receive 10 ml of lidocaine 2% then 10 ml of bupivacaine 0.5% with a delay of 120s between injections.
41021786|NCT06570096|DRUG|Lidocaine 2% and bupivacaine 0.5%|Patients will receive 20 ml of freshly prepared mixtures of 10 ml of lidocaine 2% and 10 ml of bupivacaine 0.5%.
41021787|NCT02621164|BIOLOGICAL|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
41021788|NCT02621164|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
41021789|NCT02635438|DRUG|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
41021790|NCT02635438|DRUG|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
41021791|NCT05550129|DRUG|AMG 510|Oral tablet
41021792|NCT05550129|DRUG|Metformin|Oral tablet
41356406|NCT01568983|DIETARY_SUPPLEMENT|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
41356407|NCT01568983|DIETARY_SUPPLEMENT|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
41356408|NCT01568983|DIETARY_SUPPLEMENT|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
41496067|NCT04495283|DRUG|Pregabalin|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
41496068|NCT04495283|DRUG|Acetaminophen|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
41496069|NCT04495283|OTHER|Placebo 1|Placebo for APAP
41496070|NCT04495283|OTHER|Placebo 2|Placebo for combination
40836096|NCT02644356|BEHAVIORAL|Online CE/CME course|Educational modules of a proposed online CE/CME course, module topics consisting of acupuncture, massage, and music-related interventions
40836097|NCT05393739|DEVICE|Theta burst transcranial magnetic stimulation (TBS) procedure|The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
40836098|NCT06129929|BEHAVIORAL|Hospital Jujutsu Group, HJJ Group|The aim of this study, procedures, methodology, and the subject's rights were well explained to the eligible nursing staff according to the informed consent form. Written informed consent was obtained from each participant before data collection.
40836099|NCT03597282|BIOLOGICAL|NEO-PV-01|Personal Cancer Vaccine
41021793|NCT04335877|OTHER|Private sector component + modified BCC|Intervention group will be exposed to the private sector component + modified BCC and will receive current standard care
41021794|NCT06493370|DRUG|Intravenous ascorbic acid/vitamin C|A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles
41021795|NCT06572800|DEVICE|DiviTum-TKa|Analyze blood samples by DiviTum-TKa
41021796|NCT01699399|PROCEDURE|water immersion|
41160228|NCT04773054|OTHER|Characterization of oral microbiota|"Assessment of oral microbiome composition using the next-generation sequencing of DNA extracted from a buccal swab obtained by rubbing the mucosa of cheeks, gingivae, and palate."
41496071|NCT04460508|DRUG|Pegylated rhG-CSF|Pegylated rhG-CSF:6mg
41496072|NCT04460508|DRUG|rhG-CSF|rhG-CSF:5ug/kg/d
40836100|NCT03597282|BIOLOGICAL|Nivolumab|monoclonal antibody against PD-1
40836101|NCT03597282|OTHER|Adjuvant|immune adjuvant
41021797|NCT01699399|PROCEDURE|water exchange|
41021798|NCT01699399|PROCEDURE|air insufflation|
41021799|NCT03548610|OTHER|Nanofat-seeded biological scaffold on surgical defect|Nanofat-seeded biological scaffold in healing larger surgical defects (\>1.5cm) involving the lower limbs
41021800|NCT05660109|DRUG|TPM502|TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
41021801|NCT05660109|OTHER|Placebo|Placebo
41160229|NCT05532683|BEHAVIORAL|Health Behaviors Group|The proposed intervention will include eight modules across nine weekly group sessions targeting psychoeducation of CHR-P symptoms, goal setting, physical activity, sleep, substance use, nutrition, and evidence-based strategies for stress management. Intervention facilitators will utilize motivational interviewing (MI; Miller \& Rollnick, 2012) strategies to engage youth in goal setting to target change in health promotion behaviors. Caregivers will be invited to join at the end of each session for a 10-minute check-out where an outline of content covered and patient goals for the week will be shared.
41356409|NCT02183792|DRUG|Tolvaptan|
41356410|NCT02183792|DRUG|Furosemide|
41356411|NCT02215915|PROCEDURE|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
41356412|NCT02215915|PROCEDURE|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
41356413|NCT02215915|PROCEDURE|DES implantation|
41496073|NCT03683030|DEVICE|Multi-Electrode RF Balloon Catheter|Multi-Electrode RF Balloon Catheter will be inserted
41496074|NCT00517556|DRUG|CCOCP|(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
40836102|NCT03597282|BIOLOGICAL|APX005M|monoclonal agonist antibody against CD40
41496075|NCT00517556|DRUG|Traditional OCP|(traditional OCP) (21 active days/7 inactive days) treatment regimen
41496076|NCT01166165|DRUG|Cholecalciferol|3 tablets of 1000 IU daily for 20 weeks
41496077|NCT01166165|DRUG|Placebo|3 placebo tablets daily for 20 weeks
41496078|NCT02201212|DRUG|Everolimus|
41496079|NCT06388967|DIAGNOSTIC_TEST|PANcreatic cancer Exosome Early detectiON (PANXEON)|This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it
41496080|NCT04111393|PROCEDURE|transoral specimen extraction|transoral specimen extraction during laparoscopic gastric resection
41356414|NCT00460499|DRUG|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
41021802|NCT04944823|OTHER|Clinical follow-up for 24 months|Sampling and clinical follow-up for 24 months
41356415|NCT00460499|DRUG|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
40836103|NCT03597282|BIOLOGICAL|ipilimumab|monoclonal antibody against CTLA4
41021803|NCT04274517|OTHER|Sterile Water|1L of sterile water used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
41021804|NCT04274517|OTHER|3.5% Betadine|1L of 3.5% betadine used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
41160230|NCT01020942|PROCEDURE|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
40836104|NCT04644913|BEHAVIORAL|Quality of life questionnaire|Sending of 2 questionnaires (SF 36 and TESS)
41356416|NCT00460499|DRUG|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
41356417|NCT05560412|DIETARY_SUPPLEMENT|Zein nanocapsules|1 g of Zein nanoencapsulated daily
41496081|NCT02771535|BEHAVIORAL|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
40836105|NCT02989129|BEHAVIORAL|Questionnaires|Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
41356418|NCT05560412|DIETARY_SUPPLEMENT|control|1 g of Zein non-encapsulated daily
41496082|NCT02771535|BEHAVIORAL|Health Training|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
40836106|NCT02989129|DRUG|Quercetin|500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
41160231|NCT01020942|PROCEDURE|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
41160232|NCT00871143|BEHAVIORAL|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
41356419|NCT05453929|DRUG|Rocuronium for deep NMB|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
41356420|NCT05453929|DRUG|Rocuronium for moderate NMB|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
41356421|NCT05011110|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
41356422|NCT03399331|DIETARY_SUPPLEMENT|Manuka honey|5 for children or 10cc of honey for adults was ordered directly from a New Zealand company
41356423|NCT03399331|DIETARY_SUPPLEMENT|olive oil|5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.
41496083|NCT00976911|DRUG|Bevacizumab|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
41496084|NCT00976911|DRUG|liposomal doxorubicin|40mg/m2 iv every 4 weeks
41496085|NCT00976911|DRUG|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
41496086|NCT00976911|DRUG|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
41021805|NCT04274517|OTHER|0.05% Chlorhexidine Gluconate|1L of clorhexidine gluconate used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
41496087|NCT02288156|DRUG|Capsaicin|via nasal spray
41021806|NCT06155045|PROCEDURE|Modified Carbo-dissection Technique|This technique comes the C02 blower with electrocautery. Thereby, producing vasodilatation due to the gas and dissection aided by the electrocautery.
41356424|NCT03399331|COMBINATION_PRODUCT|Control group|Control at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine).
41356425|NCT02424136|OTHER|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
41356426|NCT02424136|OTHER|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
41356427|NCT02424136|OTHER|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
41356428|NCT02424136|OTHER|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
41496088|NCT02288156|DRUG|placebo|via nasal spray
40836107|NCT02915185|PROCEDURE|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
40836108|NCT02915185|DEVICE|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
40836109|NCT03770247|PROCEDURE|Intraoperative celiac plexus neurolysis|neurolysis of celiac plexus by intraoperative techniques
40836110|NCT03770247|PROCEDURE|CT guided celiac plexus neurolysis|Neurolysis of celiac plexus percutaneously by CT guidance
40836111|NCT00533650|DRUG|MK0429|
41356429|NCT02424136|OTHER|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
41356430|NCT02424136|OTHER|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
41356431|NCT02424136|OTHER|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
41356432|NCT01784900|DRUG|Catumaxomab 100µg|
41356433|NCT01784900|DRUG|Catumaxomab 140µg|
41356434|NCT04720027|DIAGNOSTIC_TEST|Duplex imaging|Completion of AVVQ and EQ5D questionnairs
41356435|NCT00304681|DRUG|OROS*-Methylphenidate|
41356436|NCT02897011|DRUG|Methotrexate|
41356437|NCT05815576|BEHAVIORAL|Intrinsic foot muscle fatigue|"Electrostimulation will be delivered through electrodes placed on the abductor hallucis (NOT invasive).~The investigators plan 4 sets of 4 minutes of repeated contractions (electrostimulation + voluntary contraction)."
41356438|NCT04934475|DRUG|Isatuximab|treatment with Isa-KRD during induction and consolidation , with revlimid or Iberdomide +isatuximab during maintenance phase
41356439|NCT04934475|PROCEDURE|ASCT|ASCT for ams B, C and D during consolidation
41356440|NCT05502276|PROCEDURE|Endoscopic Full-Thickness Resection (EFTR)|Full Thickness Endoscopic Resection using the FTRD Ovesco Device
40836112|NCT03935555|DRUG|PU-H71|PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
40836113|NCT04652674|BEHAVIORAL|Telemedicine visit|A postoperative visit with the patient's surgeon conducted remotely via audio/video smartphone app
40836114|NCT04652674|BEHAVIORAL|In-person postoperative visit|A standard-of-care in-person postoperatively visit with the patient's surgeon
41496089|NCT03322930|DIAGNOSTIC_TEST|Rod sensitivity|diagnostic test for rod loss in central retina
40836115|NCT00490022|DRUG|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
40836116|NCT00490022|DRUG|Placebo gel|Placebo gel for one month
40836117|NCT03724656|DEVICE|acupuncture treatment|"TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
41021807|NCT06155045|PROCEDURE|Conventional Arm|This technique uses only the electrocautery as conventional model
41021808|NCT00338351|BIOLOGICAL|Pneumococcal (vaccine)|
41356441|NCT05502276|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
41496090|NCT00754715|DRUG|AZD2516|Solution administered once orally
41496091|NCT00754715|DRUG|Placebo|Solution administered only once
41496092|NCT01286935|DRUG|Safinamide|
41496093|NCT01286935|DRUG|Safinamide|
41496094|NCT01286935|DRUG|Placebo|
41496095|NCT03828786|PROCEDURE|Endometrial scratching|Endometrial Biopsy by aspiration with a pipelle
41496096|NCT05890495|DRUG|Lidocaine topical|4% aqueous solution
41496097|NCT05890495|DEVICE|Tampon|Tampon with plastic applicator provided
41496098|NCT00661011|PROCEDURE|Lobectomy followed by concomitant mediastinal chemoradiotherapy|Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
41021809|NCT04274738|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
41021810|NCT04274738|DRUG|Ibrutinib|Ibrutinib capsules will be administered per dose and schedule specified in the arm.
40836118|NCT03724656|DEVICE|sham acupuncture treatment|"Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
40836119|NCT05729139|DRUG|Cemiplimab-Rwlc|350 mg via IV infusion over 30 minutes every 3 weeks for up to two years
40836120|NCT05729139|DRUG|PEG-IFN alfa-2a|"Self-administered by the participant via subcutaneous injection in the abdomen or thigh weekly for up to one year. Participants will receive one of three doses:~Dose level 0: 45 mcg~Dose level 1: 90 mcg~Dose level 2: 135 mcg~Dose level 0 is considered the starting dose and sequential cohorts of three participants will be treated with escalated doses until the maximum tolerated dose is established."
40836121|NCT04691856|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
41160233|NCT00871143|BEHAVIORAL|Non specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
41160234|NCT00733577|DRUG|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
41356442|NCT03884868|OTHER|Iconographies to communicate risks|Use of iconographies to communicate the risks of the different possible diagnosis after a positive FIT during the screening program nurse visit.
40836122|NCT04691856|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
40836123|NCT04691856|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
41160235|NCT03907254|OTHER|Service Dog Training Program|Participants will spend one hour, two times a week working with professional service dog trainers in order to shape the dog's behavior for it's future role as a service dog for service members with mobility impairments.
41160236|NCT03597542|OTHER|Eggs and Carbohydrates|Participants are asked to consume both egg based powder or maltodextrin dissolved in 500mL of water at two different time points at least one week apart. Participants will then submit to a venous blood draw to assess levels of cellular inflammation.
41356443|NCT00352833|DRUG|catumaxomab|
41356444|NCT02667262|OTHER|Algorithm to identify patients experiencing opioid abuse/addiction|
41356445|NCT00304421|DRUG|rabeprazole|
41356446|NCT00304421|DRUG|pantoprazole|
41356447|NCT06447935|OTHER|No intervention|not applicable - no intervention required
41356448|NCT04129138|OTHER|Survey Administration|Complete survey
41496099|NCT00678886|BIOLOGICAL|otelixizumab infusion plus physician determined standard of care|infusion
41021811|NCT05456035|BEHAVIORAL|Cognitive behavioral therapy plus social cognitive training (CBTSCT)|The study has two intervention arms to which depressed adolescents will be randomized: (1) CBTSCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking), and (2) CBT only is cognitive behavioral therapy without the additional social cognitive training component.
41160237|NCT00400959|PROCEDURE|cd133+cell intracoronary administration|
41356449|NCT05572489|DIAGNOSTIC_TEST|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale|evaluation of pain, fatigue, mood, quality of life, cognitive status
41021812|NCT04331327|DRUG|allogenic lyophilized growth factors|Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
41021813|NCT06057012|DRUG|BRII-296|2 intramuscular injections 300 mg each of BRII-296 admixed with Depo Medrol 40 mg/mL per injection, will be administered in participants with PPD.
41160238|NCT00223743|DRUG|Zonisamide|study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
41160239|NCT04968015|DRUG|Cytarabine-Venetoclax Association|Consolidation treatment with cytarabine + venetoclax
41160240|NCT04968015|DRUG|Cytarabine-Idarubicin Association|Consolidation treatment with cytarabine + idarubicin
41356450|NCT03683238|DIETARY_SUPPLEMENT|Mediterranean Diet|We aim to determine the effects of the traditional Mediterranean Diet on Hidradenitis suppurativa
41356451|NCT00856336|DRUG|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
41356452|NCT00861627|BIOLOGICAL|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
41356453|NCT00861627|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
40836124|NCT04691856|DRUG|Morphine|All patients were instructed to use intravenous patient-controlled analgesia (IV PCA). All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
41021814|NCT05005546|BEHAVIORAL|Yoga|Yoga will be applied to mothers in the yoga group
41356454|NCT00861627|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
40836125|NCT06075992|OTHER|experimental group|An experimental application will not be made to premature babies in this group.
41356455|NCT00170846|DRUG|Everolimus (RAD001)|
41356456|NCT00170846|DRUG|Calcineurin Inhibitors (CNI)|
41356457|NCT00170846|DRUG|Mycophenolate acid (MPA)/Azathioprine (AZA)|
41356458|NCT00170846|DRUG|Steroids|
41356459|NCT02842255|DEVICE|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
41356460|NCT04313894|BIOLOGICAL|Wharton Jelly Originated Mesencimal Stem Cell|In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.
41356461|NCT03759444|OTHER|Questionnaires|The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.
40836126|NCT03876600|PROCEDURE|Replacement of permanent pacemakers for elective wear.|"START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day."
41356462|NCT01625364|BEHAVIORAL|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
41356463|NCT01625364|BEHAVIORAL|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
41356464|NCT04922814|DRUG|muscle relaxation|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
41496100|NCT00678886|BIOLOGICAL|placebo infusion plus physician determined standard of care|infusion
40836127|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
40836128|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
40836129|NCT05793606|PROCEDURE|Deltoid ligament repair|Surgical repair for the deltoid ligament
41021815|NCT05005546|BEHAVIORAL|Laughter Yoga|Laughter Yoga will be applied to mothers in the yoga group
41021816|NCT04701268|OTHER|Device: Hemiverse|Implantation of the hemiverse shoulder prothesis
41021817|NCT01683591|PROCEDURE|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
41021818|NCT05167838|PROCEDURE|fresh embryo transfer|55 patients undergoing fresh embryo transfer after ovarian stimulation followed by luteal phase support
41356465|NCT00346294|DRUG|Etanercept|Intervention type was to study the drug delivery method.
41356466|NCT01969227|DRUG|Subanesthetic ketamine|Ketamine drip at a subanesthetic infusion rate (low dose ketamine 5 - 10 mcg/kg/min)
41496101|NCT03202524|BIOLOGICAL|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin for the prevention of post-paracentesis circulatory dysfunction.
41496102|NCT03202524|BIOLOGICAL|Albumin|Albumin will be used for the prevention of post-paracentesis circulatory dysfunction, as is the standard of care
41496103|NCT05668130|PROCEDURE|Sacrospinous ligament fixation|Women with stage II or higher pelvic organ prolapse with apical compartment involvement planned for surgical management will be randomised to either sacrospinous ligament fixation arm or uterosacral ligament suspension arm. those raandomized to sacrospinous ligament fixation arm will undergo unilateral (right) sided sacrospinous ligament fixation of apex as a part of pelvic organ prolapse surgery.
41356467|NCT03443921|PROCEDURE|Artery Divestment Technique|Tunica adventitia was pick up by forceps and opened by electrocoagulation at 1 cm distal from tumor-artery contact. Space between tunica adventitia and external elastic lamina (EEL) were blunt lifting tumor-invaded adventitia by angled clamp. Adventitia was then sectioned to show EEL. Loose dissect space could be achieve along long the plane between EEL and adventitia as long as tumor invasion outside EEL. Tumor and invaded adventitia were further cut open by electrocoagulation proximally. Circumferentially, separation could be done by blunt dissection around EEL. Nourishing blood vessels of the artery would be secured by electrocoagulation or ultrasonic scalpel while major branch would be ligated or transfixed.
41021819|NCT05167838|PROCEDURE|Frozen embryo transfer|55 patients undergoing frozen embryo transfer after ovarian stimulation followed by cryopreservation of all embryos and transfer in another cycle.
41356468|NCT03443921|DRUG|Nab-paclitaxel|After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
40836130|NCT05641987|BEHAVIORAL|Healthy Workplace Participatory Program|The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems. The Total Teacher Health Project adapted the HWPP for educators and refer to it as the Educator Well-being Program.
40836131|NCT02084238|DRUG|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
40836132|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves ( superior medial genicular, superior lateral genicular and the inferior medial genicular nerves ) .~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radiofrequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view separated by 0,5 cm to ensure successful targeting. Then remove the needles."
40836133|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency plus alcohol neurolysis|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves of the knee.~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radio-frequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view. After the radiofrequency is done at each level a 1 ml of 70% alcohol will be injected making a total of 3 ml injection to each nerve Then remove the needles."
40836134|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
40836135|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
40836136|NCT01719003|DRUG|Empagliflozin low dose qd|Empagliflozin low dose once daily
40836137|NCT01719003|DRUG|Empagliflozin high dose qd|Empagliflozin high dose once daily
40836138|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
40836139|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
40836140|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
41021820|NCT00126048|DRUG|Atorvastatin|40mg tablet
41496104|NCT05668130|PROCEDURE|Uterosacral Ligament Suspension|Similarly women randomised to uterosacral ligament suspension arm will undergo modified high uterosacral ligament suspension of apex. Both arms will be followed up in 6 months and 12 months for anatomical and functional outcome.
40836141|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
41021821|NCT00126048|DRUG|Placebo|Placebo tablet
41021822|NCT00673452|DRUG|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
41021823|NCT00673452|DRUG|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
41021824|NCT00824317|DRUG|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
41021825|NCT00824317|DRUG|Placebo|
41021826|NCT02319239|RADIATION|Fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
41496105|NCT04731337|DEVICE|Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the tip of the upper and lower canine teeth.
40836142|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
41496106|NCT05269979|BEHAVIORAL|Prevention of hip fractures|Physical exercise and lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
40836143|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
40836144|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
40836145|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
40836146|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
40836147|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
40836148|NCT02302235|OTHER|Ketogenic Diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction.
40836149|NCT02302235|OTHER|Standardized Diet|Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
41356469|NCT03928249|DIETARY_SUPPLEMENT|Eriocitrin|"A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio."
41356470|NCT01173874|DRUG|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
41356471|NCT01070511|DRUG|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.
41356472|NCT01070511|DRUG|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
41356473|NCT04834375|DRUG|Weight-based dexamethasone dose|Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
41356474|NCT00979264|BEHAVIORAL|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
41356475|NCT05600556|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41496107|NCT01104467|DRUG|Desmoteplase|1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
41496108|NCT01104467|DRUG|Desmoteplase|1 bolus injection of desmoteplase 90 µg/kg (IV)
40836150|NCT06464094|OTHER|User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Single group enrollment to examine user-acceptance and user experiences, while soliciting user feedback on wearability compliance (patient) and proposed clinical workflows using the most recent Vitaliti™ CVSM device.
40836151|NCT06129110|BEHAVIORAL|Diet Weight Loss|Low calorie diet of meal replacement shakes
41160241|NCT05918289|BEHAVIORAL|Blended& integrated happy aging active aging program(BIHAAAP)|12 Weeks intervention devided in to two phases( face to face and home based)
40836152|NCT05620784|DRUG|Furosemide|20mg of IV furosemide injection during the morcellation phase of HoLEP
40836153|NCT04170387|OTHER|Relaxometer|Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
40836154|NCT04100434|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
40836155|NCT03546218|DEVICE|Smartphone Application (SPSRS)|"Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli."
40836156|NCT03546218|DEVICE|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
40836157|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for MIP-1 alpha
41356476|NCT05600556|PROCEDURE|Computed Tomography|Undergo CT
41356477|NCT05600556|OTHER|Best Practice|Review imaging on standard computer screen
41356478|NCT05600556|OTHER|Questionnaire Administration|Complete questionnaire
41356479|NCT05600556|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41356480|NCT05600556|PROCEDURE|Computed Tomography|Undergo CT
41356481|NCT05600556|OTHER|Virtual Technology Intervention|Review virtual reality images
40836158|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for IL-6
40836159|NCT01453517|BEHAVIORAL|Behavioral intervention for regain after bariatric surgery|6 week intervention targeting dietary behavioral adherence, stress management, and distress tolerance skills to prevent weight regain
40836160|NCT05720091|DRUG|ZX-7101A 80mg|a drug to treatment influenza in Chinese adults
40836161|NCT04108728|DIAGNOSTIC_TEST|BRIEF SCORE AT INCLUSION|BRIEF SCALE evaluation
40836162|NCT03464422|BEHAVIORAL|ESTEEM conneCT|"The intervention adapts the ESTEEM (Pachankis et al, 2015) intervention to address the multiple-stigma stressors faced by MSM of color, including sexual orientation and racial stigma in a manualized, CBT-based intervention. Approximately thirty participants (divided between two cohorts) will complete ten group sessions will take place at regular times once per week over the course of three months. The groups will be closed, in that no new members will be allowed to join after the first week in order to promote open self-disclosure and trust among group members."
40836163|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
40836164|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
41356482|NCT05600556|OTHER|Questionnaire Administration|Complete questionnaire
40836165|NCT03634267|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
41021827|NCT02319239|RADIATION|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months
41021828|NCT02319239|RADIATION|stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
41021829|NCT04401228|OTHER|predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?|"patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact \< one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded"
41021830|NCT05988203|BIOLOGICAL|BNT166a|Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.
41021831|NCT02778529|DEVICE|Bilateral assessment robots (BiAS)|The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
41021832|NCT05494125|OTHER|Ropivacaine|Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters
41021833|NCT05494125|OTHER|Placebo|Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
41021834|NCT06402500|DRUG|Icon Infiltrant|White spot lesions are treated with the resin ICON (DMG, NJ, US) for masking their color. The mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
41356483|NCT00036816|BIOLOGICAL|MART-1 antigen|
41356484|NCT00036816|BIOLOGICAL|NA17-A antigen|
40836166|NCT03634267|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
40836167|NCT05577949|OTHER|Structured aerobics exercise|A 12 week structured aerobics exercise program will be offered. The patient has to perform exercise five times a week , 30 minutes a day
40836168|NCT05107583|BEHAVIORAL|Low-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a low-carbohydrate lunch meal (\<10% carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
40836169|NCT05107583|BEHAVIORAL|High-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a high-carbohydrate lunch meal (\~2.2 g/kg carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
40836170|NCT05107583|BEHAVIORAL|Fasted Exercise|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having skipped lunch, and having consumed nothing other than plain water since breakfast (08:00; 25% estimated energy requirements). Exercise will therefore commence after an 8 hour period of fasting.
40836171|NCT02822300|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-74_R84-086)
41021835|NCT06402500|DRUG|Bioactive infiltrant|White spot lesions are treated with HI-Bond universal bioactive resin (MEDICLUS, south Korea) for masking their color. Mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
41160242|NCT04557332|BEHAVIORAL|On the Dot Mobile app|On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
40836172|NCT05002842|BEHAVIORAL|LovingKindess Meditation|Participants will have access to a recording of a script to guide them through meditation
41356485|NCT00036816|BIOLOGICAL|gp100 antigen|
41356486|NCT00036816|BIOLOGICAL|tyrosinase peptide|
41356487|NCT01807442|OTHER|Qualitative Interview and Adherence|All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
41356488|NCT04598100|BEHAVIORAL|FOCUS-EC|
41356489|NCT01797302|DIETARY_SUPPLEMENT|Vitamin D3|Tablet form
40836173|NCT03560466|DRUG|Dupilumab (SAR231893/REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)"
40836174|NCT03560466|DRUG|Asthma controller therapies (incl. prednisone/prednisolone)|"Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral"
40836175|NCT03560466|DRUG|Asthma reliever therapies|"Pharmaceutical form: powder or solution~Route of administration: inhaled"
40836176|NCT03885050|OTHER|Ross score|modified score used for evaluation of heart failure in children, as a diagnostic tool for severity of heart failure
40836177|NCT05883046|OTHER|Performance-Enhancing Substances|All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
40836178|NCT05883046|OTHER|Placebo|20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)
40836179|NCT05883046|OTHER|Baseline (Control)|No supplement conditions
40836180|NCT04798209|DRUG|ACT-777991 (SAD)|ACT-777991 administered as hard capsules for oral use.
41356490|NCT04768439|DRUG|Low Dose Vitamin D|Patients will receive a 200 IU/d vitamin D since they tolerate full enteral nutrition.
41356491|NCT04768439|DRUG|High Dose Vitamin D|Patients will receive 1600 IU/d vitamin D since they tolerate full enteral nutrition.
40836181|NCT04798209|DRUG|ACT-777991 (MAD)|ACT-777991 administered as hard capsules for oral use, once daily.
40836182|NCT04798209|DRUG|Placebo (SAD)|ACT-777991 matching placebo administered as hard capsules for oral use.
41356492|NCT01584427|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet vs. Western Style Diet|Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
41356493|NCT03206190|OTHER|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
41356494|NCT03206190|BEHAVIORAL|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
41356495|NCT03206190|DIAGNOSTIC_TEST|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
41496109|NCT01104467|OTHER|Placebo|1 bolus injection of placebo IV
41496110|NCT02113553|DRUG|Triptorelin|Triptorelin administered once every 28 days in addition to chemotherapy
40836183|NCT04798209|DRUG|Placebo (MAD)|Matching placebo administered as hard capsules for oral use, once daily.
40836184|NCT04798209|DRUG|14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer, administered intravenously.
40836185|NCT04798209|DRUG|Microtracer matching placebo (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
40836186|NCT04798209|DRUG|14C-ACT-777991 microtracer (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer, oral solution..
40836187|NCT04798209|DRUG|Microtracer matching placebo (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
40836188|NCT02283307|OTHER|Reduced contrast DECT scan|Subjects will undergo a dual energy CT scan with reduced contrast
40836189|NCT02283307|OTHER|Standard contrast SECT scan|Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
40836190|NCT00599690|PROCEDURE|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
40836191|NCT05080634|OTHER|Patients who underwent POEM|chalasia patients were recruited from a single center. The pre- and postoperative assessments included Eckardt scores, GerdQ questionnaire, high-resolution esophageal manometry, esophagogastroscopy and pH monitoring.
40836192|NCT01195688|DRUG|BI 638683 or placebo|oral doses given to 6 subjects per dose group
40836193|NCT01195688|DRUG|Placebo solution|oral doses given to 2 subjects per dose group
40836194|NCT06051409|DRUG|Olverembatinib|Orally, once every other day (QOD).
40836195|NCT06051409|DRUG|Imatinib|Orally, once daily (QD).
40836196|NCT05883618|OTHER|Exposure|Human Development Index of Country
40836197|NCT04301180|DEVICE|Education food|The intervention consisted of the presentation of food education content while conducting an orchard with seasonal vegetables
40836198|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
40836199|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
41160243|NCT05600036|DRUG|ESK-001|Oral tablet
41160244|NCT05600036|DRUG|Placebo|Oral tablet
41160245|NCT02453516|PROCEDURE|Serratus Block|Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
41356496|NCT03206190|DIAGNOSTIC_TEST|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
41356497|NCT03206190|DIAGNOSTIC_TEST|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
41356498|NCT03206190|DIAGNOSTIC_TEST|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
41496111|NCT04488835|OTHER|Electromagnetic field therapy and transcutaneous electrical nerve stimulation|Both groups received conventional physical therapy treatment protocol. Moreover, group (A) has an additional TENS application and group (B) had PEMFS application. TENS and the PEMFT were applied once daily, three times per week for 20 minutes for each session. Assessment performed pre and post intervention using visual analogue scale (VAS) and estimation of the carbamazepine intake (CMI).
40836200|NCT05500300|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
40836201|NCT05500300|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
40836202|NCT05500300|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
40836203|NCT05500300|DEVICE|RBS-IPI|"Subjects will receive RBS-IPI electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
40836204|NCT05500300|DEVICE|HIFEM|"Subjects will receive HIFEM electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
40836205|NCT02037490|BEHAVIORAL|Grow2Gether|"Participants in this intervention will:~Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~1. View educational videos addressing topics related to healthy infant growth~2. Create photos/videos modeling healthy behaviors and post them to the group~3. Provide and receive feedback on posts~4. Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person."
41356499|NCT03206190|DIAGNOSTIC_TEST|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
40836206|NCT02017522|DEVICE|11C-PBR PET|"Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes."
40836207|NCT04689152|BIOLOGICAL|Cellgram-LC|Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.
41021836|NCT06464835|DEVICE|Transcranial magnetic stimulation|The treatment parameter for iTBS was 80% stimulus intensity. The stimulation frequency was 50Hz in the plexus and 5Hz in the interplexus. Each burst stimulus consisted of 3 consecutive pulses, 2s stimulus, 8s interval, and repeated 20 times, a total of 600 pulses, and the duration of stimulation was 189s. NMES treatment parameters for output waveform for two-way square wave, wave width 700 ms, positive and negative half wave (300 ms) between 100 ms intermittent, stimulating frequency 50 hz, treatment when the output intensity range of 0 \~ 25 ma, stimulating electrodes pasted in bilateral mandibular hyoid muscle movement points, output intensity in patients with tongue bone muscle group it is advisable to have a sense of fashion, extrusion. Each treatment lasted 30 minutes, once a day, 5 times a week for 2 weeks.
41021837|NCT03882619|BEHAVIORAL|Calligraphy|Participants will (1) detect the emotion him or herself; (2) do the calligraphy activity by writing positive terms (e.g., peace, life); (3) detect emotion again; (4) share the experience with group members.
41021838|NCT01896895|DRUG|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
41021839|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
41356500|NCT00852124|BIOLOGICAL|VSL#3|VSL#3 2 times daily
41356501|NCT00852124|BIOLOGICAL|VSL#3 or placebo|1 packet 2 x daily of placebo
41356502|NCT04953663|BIOLOGICAL|it-hMSC|Different doses of it-hMSC
41356503|NCT01778140|OTHER|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
41356504|NCT01778140|OTHER|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
41356505|NCT05275309|OTHER|Exploration of optimal PEEP in supine and prone position|"1. General anesthesia is done in routine manner~2. A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~3. In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~4. One hour after prone position, optimal PEEP is determined again."
41356506|NCT00459680|DEVICE|Laser acupoint treatment|Laser
41356507|NCT00459680|PROCEDURE|Acupuncture|Needle acupuncture on ST36 and LI11.
41356508|NCT04252872|DRUG|HCP0605|
41356509|NCT04252872|DRUG|HGP1405|
40836208|NCT02008409|DEVICE|EndoLift Liver Retractor|"During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
40836209|NCT01020903|PROCEDURE|Aprepitant|40 mg po pre-op
40836210|NCT01020903|DRUG|Placebo|Orally, pre-op
40836211|NCT03551665|BEHAVIORAL|Protective step training|Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
40836212|NCT05212844|PROCEDURE|Musculoskeletal Physical Therapy|Therapeutic exercise and manual physical therapy based on the individual response to end range repeated movements.
40836213|NCT04439994|OTHER|hypertonic saline|The participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution
40836214|NCT04439994|OTHER|Saline injection|The participant will be given i.d. in 0.1 mL volumes of a saline solution
41021840|NCT01896895|DRUG|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
41021841|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye."
40836215|NCT04439994|PROCEDURE|Blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
40836216|NCT00496132|DRUG|PRO131921|Escalating doses by IV infusion
40836217|NCT04373473|DRUG|PRIM-DJ2727|Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.
41021842|NCT00099697|DRUG|DHEA|
41356510|NCT04252872|DRUG|HCP1401|
40836218|NCT04373473|DRUG|Placebos|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
40836219|NCT01685983|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
40836220|NCT01685983|DRUG|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
40836221|NCT02437409|DEVICE|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
40836222|NCT00446186|DRUG|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
40836223|NCT00446186|DRUG|Comparator: placebo / Duration of Treatment: 2 Weeks|
41160246|NCT02453516|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
41160247|NCT02453516|DRUG|ropivacaine|Drug indicated for regional anesthesia
41160248|NCT02453516|DRUG|epinephrine|Drug indicated to prolong the action of regional anesthesia
41496112|NCT00565617|DEVICE|Synergy, Epidural cortical stimulation|Epidural cortical stimulation
40836224|NCT04834024|DRUG|Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide|The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.
40836225|NCT04834024|DRUG|lenalinomide|The patients confirming to the eligibility criteria will receive lenalidomide for 18 cycles, unless either rapid disease progression or unacceptable toxicity was observed.
40836226|NCT02555605|DRUG|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg-1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg-1•h-1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg-1•h-1. In addition, propofol 0.5 mg.kg-1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
40836227|NCT01407796|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|
40836228|NCT01407796|DRUG|[18F](+/-)NOS|
40836229|NCT02263261|OTHER|Flex HD Pliable Perforated HADM|Human Acellular Dermal Matrix
40836230|NCT01840254|DRUG|dexmedetomidine|
40836231|NCT01840254|DRUG|normal saline|
40836232|NCT02072525|BIOLOGICAL|Menveo®|One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
40836233|NCT02072525|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
40836234|NCT02072525|BIOLOGICAL|Pneumovax 23®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
40836235|NCT02072525|BIOLOGICAL|Prevnar 13®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
40836236|NCT05330858|DRUG|ESK-001|Oral tablet or liquid
40836237|NCT05330858|DRUG|Rabeprazole|Oral Tablet
41160249|NCT02453516|OTHER|sterile saline|Neutral injection (no drug involved)
41160250|NCT03549988|OTHER|Fecal Calprotectin (FC) measurements with IBDocTM|"Each IBDocTM kit measure one fecal calprotectin value. The IBDoc® is an in-vitro diagnostic immunoassay analyzed by a downloadable smartphone application (CalApp®). A patient is able to process their stool at home using a test cassette.~The IBDocTM test results are displayed in a light signal system as three titre categories; normal \<100 µg/g (green), 100-300 µg/g (yellow), \>300 µg/g (high). Patients' results will be sent directly to the central research coordinator through the IBDoc® Web Portal. If the FC is \>250 µg/g a second FC will be performed within 2 weeks. If this result is \<250 µg/g patients will continue to monitor their FC every 2 months. If the second result is \>250 µg/g, the attending physician will review the patient either by telephone or in the office within 7 days."
40836238|NCT01472211|DEVICE|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
40836239|NCT01472211|DEVICE|placebo filter|filter purifies water
40836240|NCT01472211|OTHER|disinfection tablets|government promoted tablets disinfect water
40836241|NCT03958708|DRUG|Rifaximin 550 MG|Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
41160251|NCT01074437|DRUG|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
41160252|NCT01074437|DRUG|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
41160253|NCT01074437|DRUG|Placebo|Liquid placebo will be given during the two month treatment trial.
41160254|NCT03168009|PROCEDURE|Bariatric Surgery|Patients will undergo bariatric surgery as routinely scheduled. The type of bariatric procedure will be suggested by the surgeon based on clinical considerations.
41509229|NCT02108184|DRUG|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
41160255|NCT00803335|DRUG|Vaginal conjugated estrogen cream 0.5gm|Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
41160256|NCT00803335|DRUG|Vaginal conjugated estrogen cream 1.0gm|Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
40836242|NCT00618605|BIOLOGICAL|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
40836243|NCT01756118|DRUG|BEZ235|A minimum of 3 dose levels
40836244|NCT01650415|DRUG|Erythropoietin|twice a week for 1 month
40836245|NCT01650415|DRUG|Placebo erythropoietin|twice a week for 1 month
40836246|NCT02705274|DRUG|Bevacizumab|"Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met."
40836247|NCT02705274|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation (full session completed within 42 days).
40836248|NCT03802539|DEVICE|Glass Liner|restoration of root caries according to two different protocols
40836249|NCT01345383|PROCEDURE|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
40836250|NCT00487474|DEVICE|DL6049 (injectable poly-L-lactic acid)|Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
40836251|NCT02492256|DEVICE|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
41496113|NCT03786718|OTHER|Patient-facing Diabetes Dashboard|The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.
41021843|NCT01607905|DRUG|Selinexor|Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m\^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
41021844|NCT01607905|DRUG|Acetaminophen|Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
41021845|NCT01259986|PROCEDURE|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm\^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
41021846|NCT02515019|DEVICE|Bispectral index Monitoring|In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
41160257|NCT02453802|DRUG|Tranexamic Acid 5%,5ml/amp|Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
41160258|NCT02453802|DRUG|Tranexamic Acid 5%,5ml/amp|IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
41160259|NCT02453802|DRUG|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
41356511|NCT00794235|DRUG|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
41356512|NCT05179291|OTHER|Buzzy Group|The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.
41356513|NCT05179291|OTHER|Virtual Realitiy-VR Group|VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
41356514|NCT04062513|OTHER|Olfactive stimulation intervention with familiarization|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.
41356515|NCT04062513|OTHER|Olfactive stimulation intervention|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.
41356516|NCT04062513|OTHER|Standard care|Preterm infants will receive sucrose during heel prick.
41356517|NCT00131131|BEHAVIORAL|Exercise|
41496114|NCT01366950|BEHAVIORAL|Intelligent physical activity|30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
40836252|NCT02492256|DEVICE|GP ablation guided by SUMO technology|"CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia."
41021847|NCT01744730|DRUG|Clindamycin|Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
41021848|NCT03272100|PROCEDURE|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
41160260|NCT02453802|DRUG|0.9% Normal Saline|Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
41160261|NCT02453802|DRUG|0.9% Normal Saline|Topical 160 ml normal saline application after closure of joint capsule.
41356518|NCT00671411|DRUG|Ultrasound with intravenous microbubble contrast injection|"Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings \& Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 \& 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings \& energy w/i FDA guidelines. This will only be performed while imaging the kidney."
41356519|NCT05859776|DRUG|AXT107 Low Dose|Single suprachoroidal injection of AXT107 (0.125 mg/eye)
41496115|NCT03058432|RADIATION|Radiotherapy alone|
41496116|NCT03058432|RADIATION|Concurrent chemoradiotherapy|
41356520|NCT05859776|DRUG|AXT107 Mid Dose|Single suprachoroidal injection of AXT107 (0.250 mg/eye)
41356521|NCT05859776|DRUG|AXT107 High Dose|Single suprachoroidal injection of AXT107 (0.500 mg/eye)
41356522|NCT02826083|DIETARY_SUPPLEMENT|XXS|
41356523|NCT02826083|DIETARY_SUPPLEMENT|non-XXS|
41356524|NCT03770663|DRUG|Cyclophosphamide and azathioprine|European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
41356525|NCT03770663|DRUG|Tacrolimus|American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
41356526|NCT03316599|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
41356527|NCT03316599|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
41356528|NCT03316599|DRUG|Ficlatuzumab|It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
41356529|NCT02565303|PROCEDURE|Intervertebral space|
41356530|NCT02565303|DRUG|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
41356531|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
41356532|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery using rigide instrumentation|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
41356533|NCT02509663|DEVICE|Sinuplasty balloon|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
41356534|NCT02509663|DEVICE|Endoscope|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
41356535|NCT05580107|DRUG|MDPK67b|24 mg or 48 mg
41496117|NCT05502081|DRUG|Casirivimab and Imdevimab Drug Combination|antiviral Monoclonal Antibodies
41356536|NCT04288713|DRUG|Eculizumab|A distal complement inhibitor.
41356537|NCT06217926|BEHAVIORAL|Experimental Group (Educational content; ChatGPT and Google Bard training)|"Educational content; ChatGPT and Google Bard training for senior students of the Faculty of Health Sciences who volunteered to participate in the study was provided by Dr. Lecturer It will be given by member Yasemin Özyer Güvener. After the training is completed, students will be asked to use generative artificial intelligence for educational purposes.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
41356538|NCT01297764|DRUG|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~1. 15 15 300 40~2. 20 15 300 40~3. 20 25 300 40~4. 20/27\* 25 300 40~5. 20/27\* 25 400 40"
41496118|NCT05502081|DRUG|Remdesivir|antiviral drug
41496119|NCT05502081|DRUG|Favipiravir|antiviral drug
41496120|NCT01296282|DEVICE|Medronics CRT Optivol Impedance Measurement|Pacemaker
41496121|NCT01296282|DEVICE|External Thoracic Impedance Measurement|
41496122|NCT03462849|OTHER|increase in positive end expiratory pressure|increase in positive end expiratory pressure from 5 to 10 then 15 cmH2O then at the value for trans pulmonary end expiratory pressure amounting to 3 cmH2O
41160262|NCT03585621|RADIATION|SBRT|Each radiation treatment plan will be customized to the patient and tumour in order to deliver highly conformal, conebeam CT guided SBRT radiotherapy in 4 fractions delivered over 2-4 weeks.
41356539|NCT00158301|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
41356540|NCT00158301|DRUG|Drug therapy|All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
41356541|NCT01056601|DRUG|Bortezomib|1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
41496123|NCT02992418|BIOLOGICAL|CYD Dengue Vaccine|0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively
41496124|NCT02992418|BIOLOGICAL|Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed|0.5 mL, intramuscularly (IM) at Month 1.
41496125|NCT02992418|BIOLOGICAL|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Day 0.
41496126|NCT02951975|DRUG|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
41160263|NCT05823805|OTHER|Community Health Worker|"Physicians will work with a Community Health Worker (CHW) to review the data presented in their Quality Improvement reports, and triage patients for proactive outreach (e.g. No action necessary, Call patient to check-in, Arrange BP, weight and labs, Book for phone appointment, Book for in-person appointment)."
40836253|NCT02492256|DEVICE|ILR implantation|Implantation the ECG loop recorder according to standard procedure
41160264|NCT01537120|DRUG|Vildagliptin|
41160265|NCT01537120|DRUG|Placebo|
41160266|NCT03630783|BEHAVIORAL|Combined Cognitive Bias Modification|
41160267|NCT04538534|DRUG|Nicardipine|To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm
40836254|NCT02577185|DRUG|Botulinum Toxin Type A|
41160268|NCT01547689|BIOLOGICAL|Human Umbilical Cord Derived MSC|20 million cells per subject（0.5×10\^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
41356542|NCT01056601|DRUG|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
41356543|NCT04498585|OTHER|VR Stimulation|Participants in the intervention group will be provided with 30 minutes of relaxing, 360-degree virtual reality stimulation and corresponding sounds, three times a day (morning, midday, evening) everyday during their stay in the ICU, up to a maximum of 14 days.
41356544|NCT02425813|DRUG|Budesonide|Given PO
41356545|NCT02425813|DRUG|Methylprednisolone Sodium Succinate|Given IA and IV
41356546|NCT00722410|DIETARY_SUPPLEMENT|VSL#3|A probiotic preparation.
41356547|NCT00722410|DRUG|Polyethylene glycol|Oral ingestion of 3 liters of polyethylene glycol solution.
41356548|NCT00845533|DRUG|Dihydroartemisinin-Piperaquine|
41356549|NCT06337656|DEVICE|Galileo WBV|Side-Alternating Whole-Body Vibration Training
41356550|NCT04779294|DIAGNOSTIC_TEST|STAN ( St wave analysis) and fetal blood sample-lactate|The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
41356551|NCT01773616|DRUG|Oral prednisolone|
41356552|NCT01773616|DRUG|Rituximab|
41356553|NCT01773616|DRUG|Mycophenolate mofetil|
40836255|NCT02577185|DRUG|Sodium chloride 9 mg/ml|
41356554|NCT01773616|DRUG|Methyl prednisolone|
40836256|NCT02008422|DRUG|Oxaliplatin|130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
40836257|NCT02008422|DRUG|Gimeracil and Oteracil Potassium Capsule|40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
40836258|NCT02008422|DRUG|Endostar injection|7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
40836259|NCT00324441|DEVICE|Iratherm® 1000|
40836260|NCT05042960|OTHER|Brightness|Changing the colors or brightness on the device (computer screen) for one month
40836261|NCT05661396|BEHAVIORAL|Serious game rehabilitation|Three patients received therapeutic serious game rehabilitation in addition to conventional rehabilitation. The serious game was proposed to be played three times per week for four weeks, for a total of 12 sessions, with 15 min per session (= 45 minutes per week).
40836262|NCT05639881|BEHAVIORAL|Enhancing Your Immune Health|In addition to routine mental health care, subjects receive an intervention to improve their immune health literacy and self-management behaviors.
41160269|NCT05358964|BEHAVIORAL|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
41160270|NCT03650244|DEVICE|REMEEX implantation|Device implantation
41160271|NCT01501747|DRUG|Caffeine, paracetamol, cephalexin, or ibuprofen|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
41160272|NCT01501747|DRUG|Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
41160273|NCT05531734|DEVICE|NaoX Intra-Auricular Device (IAD) monitoring EEG data|Intrauaricular measurement tool developed by NaoX Technology to retrieve EEG type data.
41160274|NCT05531734|BEHAVIORAL|Simple psychometric tests|Associated with simple and self-managed psychometric tests.
41160275|NCT04127578|BIOLOGICAL|LY3884961|Participants will receive a single dose of LY3884961, administered intra-cisterna magna
41160276|NCT04127578|DRUG|Methylprednisolone|6 IV pulses administered as concomitant medication over 3 months
41160277|NCT04127578|DRUG|Sirolimus|Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
41160278|NCT05908305|DRUG|articaine@ (4% 1:100000 epinephrine) dental anesthesia|Administration, calculation and adjustment of dental local anesthesia doses.
41356555|NCT01761682|OTHER|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
41356556|NCT01978548|DRUG|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
41356557|NCT01978548|DRUG|JNJ-54861911 50 mg|JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
41356558|NCT01978548|DRUG|Placebo|Matching placebo will be administered as 2 oral tablets once daily.
41356559|NCT04923958|DIAGNOSTIC_TEST|Novel mycobacterial culture techniques|We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
41356560|NCT04923958|DIAGNOSTIC_TEST|Novel sputum smear microscopy techniques|We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.
41356561|NCT04923958|DIAGNOSTIC_TEST|Sputum-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
41356562|NCT04923958|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
41356563|NCT04923958|DIAGNOSTIC_TEST|Urine LAM assays|We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.
41356564|NCT04923958|DIAGNOSTIC_TEST|Blood-based host immune response assays|We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.
41356565|NCT04923958|DIAGNOSTIC_TEST|Breath-based assays|We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
41356566|NCT04923958|DIAGNOSTIC_TEST|Artificial intelligence-based digital health tools|We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
40836263|NCT05484570|OTHER|Interval History|"The study coordinator or another team member will review standard health questions relevant to DNA repair disorders. The control group will not undergo an interval history. These questions will include:~1. How the participant's appetite and general weight trajectory has been since the last assessment~2. Any episodes of unexplained bleeding or bruising~3. Any jaundice~4. General level of alertness and interaction with family and others~5. Any changes in cognitive function such as speech, following commands, comprehension~6. Any changes in motor function, including the development of tremors and stiffness in movements"
41356567|NCT04923958|DIAGNOSTIC_TEST|Phage-based assays|We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.
41356568|NCT04923958|DIAGNOSTIC_TEST|Cartridge-based molecular assays for detecting drug resistance|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
41356569|NCT04923958|DIAGNOSTIC_TEST|Sequencing-based assays for detecting drug resistance|We will evaluate targeted and whole genome sequencing assays.
41356570|NCT00075634|DRUG|decitabine|Given IV
41160279|NCT01589380|DRUG|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP \< 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
41356571|NCT00075634|DRUG|doxorubicin hydrochloride|Given IV
41356572|NCT00075634|DRUG|cyclophosphamide|Given IV
41356573|NCT00075634|BIOLOGICAL|filgrastim|Given SC
41356574|NCT00075634|BIOLOGICAL|pegfilgrastim|Given SC
41356575|NCT00075634|OTHER|laboratory biomarker analysis|Correlative studies
41356576|NCT00075634|OTHER|pharmacological study|Correlative studies
41356577|NCT02365324|BEHAVIORAL|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
41356578|NCT02365324|BEHAVIORAL|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
41356579|NCT06405256|RADIATION|magnetic resonance imaging-guided adaptive radiotherapy|Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)
41356580|NCT00640900|BEHAVIORAL|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
41356581|NCT00640900|BEHAVIORAL|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
41356582|NCT00758420|DRUG|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
41356583|NCT00758420|DRUG|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
41356584|NCT02774863|OTHER|Home passages|Three home passages between the 2nd and 3rd months of follow up.
41356585|NCT03856879|BEHAVIORAL|Proactive E-consult|E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.
41356586|NCT00155324|DEVICE|Extracorporeal Shock Wave Therapy (Device)|
41356587|NCT02067546|DEVICE|Experimental toilet seat|
41356588|NCT02067546|DEVICE|Standard toilet seat|
41356589|NCT02197351|PROCEDURE|White light biopsy|Endoscopy with biopsies guided by high definition white light
41356590|NCT02197351|PROCEDURE|Protocolled|Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)
41356591|NCT02197351|PROCEDURE|Narrow Band Imaging Guided Biopsy|Upper Endoscopy with biopsy guided by narrow and imaging
41356592|NCT02481440|BIOLOGICAL|human umbilical cord mesenchymal stem cells (hUC-MSCs)|Four times of intrathecal administrations of hUC-MSCs
41356593|NCT06402149|OTHER|dexamethasone|Use of dexamethasone in infraclavicular block
41356594|NCT00430924|DRUG|Eplerenone|Once daily administration for 8 weeks and 8 weeks control.
41356595|NCT00636116|BIOLOGICAL|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Anavip Maintenance Therapy
41356596|NCT00636116|BIOLOGICAL|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Placebo Maintenance Therapy
41356597|NCT00636116|BIOLOGICAL|Crotalidae Polyvalent Immune Fab, ovine|CroFab with CroFab Maintenance Therapy
41356598|NCT02983240|DEVICE|Electrical Uterine Pacemaker|The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
41356599|NCT05950828|BEHAVIORAL|SkillTalk|A subscription-based microskills video training library designed to enhance the skills of high school sex educators to implement the frequently used core components of sexual and reproductive health (SRH) curricula.
41356600|NCT03277651|DIAGNOSTIC_TEST|hemodynamics tests|Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound
41356601|NCT00369564|DRUG|glutamic acid|Given orally 3 times daily
41356602|NCT00369564|OTHER|placebo|Given orally 3 times daily
41356603|NCT05194007|DRUG|Frondanol|Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings
41356604|NCT05194007|DRUG|Placebo|Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
41356605|NCT04515849|DRUG|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
41356606|NCT04515849|DRUG|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
41356607|NCT04515849|DRUG|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
41356608|NCT04515849|DRUG|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
41356609|NCT04515849|DRUG|Placebo|Placebo administered subcutaneously
41356610|NCT00043199|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
41356611|NCT01064973|DRUG|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
41356612|NCT03065166|OTHER|Raisin Treatment|Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
41356613|NCT03065166|OTHER|Bagel Control|Subjects will consume 95g of whole wheat bagel during a single intervention time point.
41496127|NCT02834676|DRUG|Gelified Ethanol|Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
41160280|NCT01589380|DRUG|Placebo|Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
41356614|NCT02886442|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
41160281|NCT01811628|BEHAVIORAL|Questionnaire|Questionnaire completion taking about 10-15 minutes.
41160282|NCT01811628|BEHAVIORAL|Interview|Audio-recorded interview that will last about 1 hour.
41356615|NCT02886442|OTHER|New adhesive strip|This is a newly developed adhesive strip
41356616|NCT04075240|DRUG|Rivaroxaban 10 MG and acetylsalicylic acid 81 mg|Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
41356617|NCT04075240|DRUG|acetylsalicylic acid 81 mg|Starting post op, aspirin for 9 days for TKA and 30 days for THA
41356618|NCT00305773|DRUG|vorinostat|Given orally once daily
41356619|NCT00305773|DRUG|vorinostat|Given orally three times daily
41356620|NCT03862781|PROCEDURE|Right Hemicolectomy|Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
41356621|NCT01496781|PROCEDURE|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
41356622|NCT01496781|PROCEDURE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
41356623|NCT04089228|OTHER|Kinesiotaping|Total of 4 sessions on upper trapezius trigger points on alternate days.
41356624|NCT04089228|OTHER|Integrated Neuromuscular Inhibition Technique|Sustain Pressure. Strain Counter-strain (for 90 sec) Passive Isometric Relaxation (PIR) (6-10 sec hold, 4 reps)
41356625|NCT00836199|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
41356626|NCT00836199|BIOLOGICAL|Placebo vaccine|Placebo vaccine given 6 times over 6 months
41496128|NCT04283500|DRUG|Buprenorphine Naloxone|Participants will receive the BUP SL 32mg in divided doses rather than all at once. If after the initial 8mg dose a participant experiences over-sedation or another adverse event that would preclude further dosing, such as an allergic reaction, the subsequent dose will not be administered and the patient will be withdrawn from the study. The participant will be reassessed for other possible etiologies for these symptoms.
41356627|NCT01697371|RADIATION|Proton|"All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments"
41356628|NCT01697371|RADIATION|Proton Radiation|
41356629|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (\~5 minutes)
41356630|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
41356631|NCT01064986|BIOLOGICAL|Placebo|Saline vehicle (placebo)
40836264|NCT05484570|OTHER|Physical Examination|A board-certified neurologist (the principal investigator) will perform a general physical examination and a neurological examination and complete a standard CRF to document relevant findings. The control group will not undergo a physical examination.
41356632|NCT01064986|BIOLOGICAL|Hydrocortisone|Hydrocortisone
41356633|NCT01562327|DRUG|Tocilizumab|Participants received tocilizumab according to individualized physician-prescribed regimens.
41356634|NCT06303362|OTHER|Elastic band excercise|experimenatal group was given elastic band excercises along with stretching (pectoralis major, minor, trapezius, rhomboids and neck flexors) and conventional therapy. Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
41356635|NCT06303362|OTHER|strengthening with conventional physical therapy|control group was given strengthening excercises and stretching (pectoralis major, minor, trapezius, rhomboids (Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
41356636|NCT06341738|BEHAVIORAL|Video education about HPV and HPV vaccine|video animation in 8 minutes to promote about HPV and HPV vaccine. the video is played in front of class using LCD projector.
41496129|NCT04318223|DRUG|Palbociclib|Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
41496130|NCT00642278|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
41496131|NCT00642278|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
41496132|NCT00642278|DRUG|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
40836265|NCT05484570|OTHER|ECAB Assessment|"An Early Clinical Assessment of Balance (ECAB) will be performed by the physical therapist. Part I can be assessed in all affected individuals, and Part II requires ambulation. For non-ambulatory individuals, only Part I will be applied. The items in the ECAB are summarized as follows:~Part I. Head and trunk postural control (maximum 36 points) Head righting - lateral (right and left) Head righting - extension Head righting - flexion Rotation in trunk (right and left) Equilibrium reactions in sitting (right and left) Protective extension - side Protection extension - backward Part II. Sitting and standing postural control (maximum 64 points) Sitting with back unsupported but feet supported on floor or on a stool Sitting to standing Standing unsupported with eyes closed Standing unsupported with feet together Turns 360 degrees Placing alternate foot on the step while standing unsupported"
41356637|NCT06341738|BEHAVIORAL|Electronic reminder messages|Reseachers send reminder messages twice per vaccination event (e.g., 7 days and 1 day before vaccination event), with a total of four times sending reminder messages using the app on the smartphone.
41356638|NCT06341738|BEHAVIORAL|Usual Information Service|this usual information (e.g., the HPV vaccination event) was delivered face-to-face by staff in front of class
41356639|NCT03995979|OTHER|4 Day Protein Restricted Diet|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided. They may also drink water. No food, other beverages, or alcohol may be consumed. The amount of diet to be consumed will be calculated for each patient based upon resting energy expenditures plus additional energy needs. These will be consumed by the study subjects at home in an unrestricted manner, in that they may be consumed at any point of time in the day.
41356640|NCT00842504|DRUG|Micafungin|3 mg/kg IV once over 1 hour
41356641|NCT05228236|DIETARY_SUPPLEMENT|Plant based protein|A single dose of \~30 g of a plant-based protein blend was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
41356642|NCT05228236|DIETARY_SUPPLEMENT|Whey protein|A single dose of \~30 g of whey protein was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
41356643|NCT01048736|BEHAVIORAL|Exercise Only|4 d/wk of aerobic exercise
41356644|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; \~4.5 kg weight loss).
41356645|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; \~10.9 kg weight loss)
41356646|NCT06046872|BEHAVIORAL|Report-back training|Researchers participate in a report-back training program to evaluate potential impacts on knowledge and future behaviors with respect to sharing personal exposure results with study participants.
41356647|NCT01207921|DRUG|Lenalidomide|
41356648|NCT03459976|DIAGNOSTIC_TEST|evaluate serum level HE4 in endometrial cancer|"1. HE4 in beignin endometrial diseases~2. HE4 in endometrial cancer"
41496133|NCT01672216|DEVICE|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
41496134|NCT01672216|DEVICE|EMG-biofeedback alone|
41496135|NCT01427530|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation
41496136|NCT00537303|DRUG|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
41496137|NCT00537303|DRUG|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
41496138|NCT00537303|DRUG|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
41496139|NCT02470533|RADIATION|Radiation therapy|6 fractions of 8-9Gy
41496140|NCT02470533|DEVICE|chemoembolization|Up to 4 sessions
41356649|NCT04205513|DEVICE|Medly|Medly is a mobile phone-based telemonitoring system that enables patients with heart failure to take clinically relevant physiological measurements with wireless home medical devices and answer symptom questions on the mobile phone. The measurements are automatically and wirelessly transmitted to the mobile phone and then to a data server.
41356650|NCT02098733|DRUG|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
41356651|NCT00153452|BEHAVIORAL|perpetration of intimate partner violence|
41356652|NCT05606549|BEHAVIORAL|Marital self disclosure|Intervention time during hospitalization is the first day after chemotherapy, and intervene once per chemotherapy, a total of 4 times, 40-60 min each time. Interventions included verbal and written disclosure. The researcher will preside over the MSD process and introduce of MSD for gastric patients and their spouse，both patient and their spouse will receive a training or review on MSD skills, 5-10 minutes each time. Couples practice MSD skills through 4 revealing themes. Couples are encouraged to express their FCR, and when one partner disclosure, supporters should allow the speaker to fully express their feelings and respond positively to the speaker's message, showing empathy for them, and acknowledging their point of view.
41356653|NCT00653198|OTHER|No intervention|
41356654|NCT02455596|DRUG|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
41356655|NCT06330649|DIETARY_SUPPLEMENT|Energy Drink|This is a commercially available energy drink
41356656|NCT06330649|OTHER|Water Control|This is a commercially available bottled water
41356657|NCT02139709|DIETARY_SUPPLEMENT|Ganglioside|
41356658|NCT02139709|DIETARY_SUPPLEMENT|Placebo|
41356659|NCT05198284|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
41356660|NCT05431231|DIAGNOSTIC_TEST|Outcome Questionnaire-45|a questionnaire that evaluates the patient's level of distress. The questionnaire was developed by Lambert et al. in 1996 and was translated to Hebrew by Gross, Glasser, Elisha et al. in 2015. The questionnaire is composed of 45 statements that describe emotional states, assessing three main components: subjective discomfort, interpersonal relationships and performance of social roles. The participants are asked to rate how often they have felt the states described by each statement using a five-level Likert scale (0 - never, 4 - almost always). This questionnaire has been used extensively and has showed good internal consistence of 0.93 for its English version and 0.91 for its Hebrew version.
41356661|NCT05431231|DIAGNOSTIC_TEST|Hopkins symptoms checklist - short form|a questionnaire for assessing symptomatic distress. The questionnaire was developed by Lutz, Tholen, Schürch, and Berking in 2006. It is a short version of the SCL-90-R, that was developed by Derogatis in 1992. The checklist includes 11 items that describe negative feelings and thoughts. Participants are asked to rate the extent to which a given feeling or thought has troubled them in the past week using a four-level Likert scale (1 - not at all, 4 - very much). This tool is highly correlated with the Global Severity Index (r=.91) and has shown high internal consistency.
41356662|NCT05431231|DIAGNOSTIC_TEST|Prodromal Questionnaire - Brief Version|a patient questionnaire that assesses the existence of a prodromal state or fully developed psychosis. It was developed by Ising et al. in 2012 and was translated to Hebrew by Koren et al. in 2016. The tool is based on a more extensive questionnaire - PQ-92 - that was developed by Loewy et al. in 2005 - and constitutes an attempt to create an improved shorter version. The PQ-16 includes 16 items that refer to thoughts, feelings and experiences that describe various symptoms, including abnormal perception (9 items), unconventional thinking and paranoia (5 items) and negative symptoms (2 items). For each item, first, the participant is asked to indicate whether he had experienced that phenomenon in the past month, and if he had, he is asked to describe the extent to which the phenomenon had caused him distress, using a four-level Likert scale (0 - no distress, 3 - severe distress). Ising et al. found that Kronbach's α was 0.774 for the whole questionnaire.
41356663|NCT05431231|DIAGNOSTIC_TEST|Manchester Short Assessment of Quality|a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
41356664|NCT05431231|DIAGNOSTIC_TEST|Self-Stigma of Mental Illness Scale|a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.
41496141|NCT05159167|OTHER|Baduanjin, a type of Qigong|Baduanjin is very popular in China. There is increasing evidence to support its positive effects on health outcomes in various groups of people with physical and mental disorders.
41496142|NCT00486941|BEHAVIORAL|Exercise and diet - based on DPS and DPP|
41509230|NCT02108184|DRUG|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
40836266|NCT05484570|OTHER|Gait Assessment|"For ambulatory participants, the physical therapist will also assess standardized gait outcome measures, including:~1. Gait Speed: may be measured over a 10 meter distance, assessing both comfortable walking speed and fast walking speed~2. 10-meter walk/run: timed assessment at fastest gait attainable. This assessment would be omitted for those participants who are determined to have a high fall risk.~3. Timed Up and Go (TUG): time to stand from a chair, walk 3 meters, go around a cone, and return to the chair (with or without an assistive device)~4. Dynamic Gait Index (DGI): assesses 8 balance challenges while walking"
40836267|NCT05484570|OTHER|Specimen Sample Collection|"Total blood volumes collected at each visit will be limited to 5mL/kg body weight, with a maximum of 18mL.~Saliva samples may be obtained if research is taking place where blood samples cannot be drawn or transferred."
40836268|NCT01281228|DRUG|exenatide|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
40836269|NCT01281228|DRUG|exenatide + exendin (9-39)|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
40836270|NCT01281228|DRUG|placebo|saline infusion
40836271|NCT03130426|DRUG|iGlarLixi|Dose is titrated to achieve fasting normoglycemia
40836272|NCT03130426|DRUG|Insulin Glargine|In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.
40836273|NCT03130426|DRUG|Metformin|Dose is titrated to 2000 mg daily or maximal tolerated dose
40836274|NCT03130426|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
40836275|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection|9MW1411 injection
40836276|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection placebo|9MW1411 injection placebo
40836277|NCT00823277|OTHER|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after \~ 1 Year.
40836278|NCT01458834|BEHAVIORAL|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
40836279|NCT01458834|BEHAVIORAL|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
40836280|NCT05736939|OTHER|Out-patient Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both \<4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.
40836281|NCT04041427|DRUG|Albendazole Pill|Albendazole 400mg po
40836282|NCT04041427|OTHER|High fat content diet|High fat content diet
40836283|NCT04041427|OTHER|Moderate fat content die|Moderate fat content die
40836284|NCT04252495|DRUG|Aprocitentan|A single oral dose of 25 mg.
40836285|NCT05620953|DIAGNOSTIC_TEST|respiratory specimen|nasopharyngeal swab or nasal aspiration or broncho-alveolar lavage
40836286|NCT02699372|DRUG|Placebo|
40836287|NCT02699372|DRUG|RO6889450|
40836288|NCT05547165|DEVICE|Percutaneous Patent Ductus Arteriosus Closure (PPC)|Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.
40836289|NCT05547165|COMBINATION_PRODUCT|Responsive Management Intervention|"Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.~Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP)."
40836290|NCT05547165|DIAGNOSTIC_TEST|Echocardiogram, cardiac|"An echocardiogram, also known as ECHO, is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions."
41160283|NCT06328725|DRUG|EN001|"Phase 1~* Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~* Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~Phase 2~* Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals.~* Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals."
41356665|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for patient|this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
41356666|NCT05431231|OTHER|Quality of service/satisfaction questionnaire|measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.
40836291|NCT05077098|DRUG|ADXS-504|ADXS-504 will be administered as monotherapy at 2 dose levels. Subjects who are assigned to receive Dose Level 1 (DL1) will be administered ADXS-504 at a dose of 1×107 CFU q4 weeks (±3 days) from Week 1 to Week 21. Subjects who are assigned to receive Dose Level 2 (DL2) will be administered ADXS-504 at a dose of 1×108 CFU q4 weeks (±3 days; Week 1 to Week 21). All 3-6 subjects must be enrolled in DL1, and DL1 must be confirmed safe, before enrollment for DL2 may begin. For both dose levels, these doses are followed by maintenance dosing at each respective dose level given every 12 (q12) weeks (±3 days) for 4 doses for overall total of 10 doses of the study treatment. If DL1 is deemed to exceed the MTD, dose reduction of ADXS-504 to DL-1 (1×106 CFU) may proceed. Dose level -1, intermediate dose levels or expansion of a cohort may also be further evaluated if recommended by the Investigator and Advaxis in future amendments.
40836292|NCT04533230|BEHAVIORAL|Educational intervention with prescription feedback|Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
41160284|NCT00609323|DRUG|lidocaine and tetracaine cream 7%/7%|One treatment of up to 400 cm2 Cream applied for 60 minutes.
41496143|NCT01735955|DRUG|Nilotinib|Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
41496144|NCT03106454|DRUG|Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate|Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
40836293|NCT04533230|BEHAVIORAL|Information on treatment guidelines|Written information on treatment guidelines.
40836294|NCT03300778|BEHAVIORAL|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
40836295|NCT03300778|BEHAVIORAL|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
41160285|NCT00609323|DRUG|Placebo|One treatment of up to 400 cm2 Cream applied for 60 minutes.
41356667|NCT05431231|DIAGNOSTIC_TEST|Clinical decision-making style|a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, \& Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.
40836296|NCT04021524|DRUG|Benzoyl Peroxide 10% Bar|Patients will wash with Benzoyl Peroxide 10% Bar
40836297|NCT04021524|DRUG|Chlorhexidine Gluconate|Patients will wash with Chlorhexidine Gluconate
40836298|NCT04385225|OTHER|Longitudinal follow-up|Longitudinal hearing, vestibular and cognitive follow-up
40836299|NCT04073160|DRUG|Tremelimumab|Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
41160286|NCT03199495|OTHER|electroacupuncture|acupuncture needle with TENS device
41496145|NCT03106454|DRUG|Norethindrone|Norethindrone 1.05mg
41496146|NCT00237640|DRUG|Cinnamon or placebo 500 mg capsule twice daily|Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
41356668|NCT05431231|DIAGNOSTIC_TEST|Global Assessment of Functioning Scale|a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, \& Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
40836300|NCT04073160|DRUG|Durvalumab|"Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle."
40836301|NCT04073160|RADIATION|Bladder radiation|During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
41356669|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for therapist|a questionnaire that has two - patient and therapist - versions, meant to assess the therapist-patient relationship (therapeutic alliance). It was developed by Falkenstrom, Hatcher, Skjulsvik, Larsson, \& Holmqvist in 2014. Each questionnaire (patient/therapist) is composed of 6 statements that refer to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). Falkenstrom et al reported that Kronbach's α coefficient ranged from 0.89 to 0.94 for their three tested samples. In the current study, patients will define who their main therapist is.
40836302|NCT04073160|DRUG|Intravesicular Therapy|Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
40836303|NCT05079633|BIOLOGICAL|Homologous boost schedule|1st dose mRNA 1273 , 2nd dose mRNA 1273
40836304|NCT05079633|BIOLOGICAL|Heterologous boost schedule|1st dose mRNA 1273 , 2nd dose MVC COV1901
40836305|NCT01534949|BIOLOGICAL|rituximab|375 mg/m2 by intravenous \[IV\] infusion
41021849|NCT05850897|OTHER|Masaj|Appropriate position is given to the patients. Thumb and finger movements, patting, rubbing and squeezing techniques are used in foot massage. During training, the active hand applies pressure, while the passive hand uses both hands to support the foot. The intervention begins with rubbing and warming the feet. The duration of the foot warming process is approximately 5 minutes, and after the foot warming maneuvers, the methods of moving the thumbs of both hands towards the soles of the feet and spinning the laundry are used. The inner and outer parts of the foot are patted in a balanced way. This caressing movement on both feet is done with these movements in a light and rhythmic way and the massage is completed. Data will be obtained with Patient Descriptive Information Form, Vital Signs Follow-up Form, Surgical Anxiety Scale for Adult Patients, Perianesthesia Comfort Scale, Numerical Pain Scale.
41021850|NCT00000153|PROCEDURE|Blue-Green Argon Laser Treatment|
41021851|NCT00000153|PROCEDURE|Red Krypton Laser Treatment|
41021852|NCT06570772|BIOLOGICAL|AVT16|AVT16 will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
41021853|NCT06570772|BIOLOGICAL|Vedolizumab|Entyvio (vedolizumab) will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
41021854|NCT01686087|BEHAVIORAL|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
41021855|NCT01686087|PROCEDURE|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
41356670|NCT04728789|DRUG|Avatrombopag 20 MG|Avatrombopag 20mg/week to 60mg/day, starting at 20mg/day and increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
41356671|NCT03700866|PROCEDURE|Functional splinting time|Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
41021856|NCT03563040|DRUG|Methoxsalen|"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"
41021857|NCT03563040|DEVICE|THERAKOS CELLEX Photopheresis System|Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
41021858|NCT04749264|BEHAVIORAL|Mindfulness meditation retreat|6 to 7-days mindfulness retreat (Vipassana/insight meditation). The retreats are held in silence and led by senior teachers with many years of experience in teaching meditation. The focus of the retreat is the practice of mindfulness meditation while sitting and walking. Retreats include focused attention and open monitoring mindfulness meditation practices. Each retreat has a similar practice schedule thus the amount and nature of formal practice is mostly the same.
41021859|NCT06271096|DRUG|Intra muscular Midazolam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
40836306|NCT03109691|DRUG|bupivacaine|group 1
40836307|NCT03109691|DRUG|Dexamethasone|group 2
41021860|NCT06271096|DRUG|Intravascular Diazepam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
41021861|NCT00962429|DRUG|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
40836308|NCT03109691|DEVICE|ultrasound|in all groups
41356672|NCT04319861|PROCEDURE|Anal fistula plug procedure|A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
41496147|NCT02730117|DEVICE|Dialysis with continuous renal replacement therapy|Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
41021862|NCT05874934|DEVICE|Intrahepatic biliary stent with retrieval string|Plastic biliary stent with 3-0 nylon (ethilon) thread tied to the distal end of the stent through the existing sidehole.
41021863|NCT02466945|DEVICE|V063B-DP3003|The medical device V063B-DP3003 has been developed to relieve and decrease dentinal hypersensitivity in patients by creating a film around the sensitive tooth in order to prevent pain. Application modalities: apply a pea size amount of product (around 0.5g) onto each of the sensitive teeth, 3 times a day, by gentle massage with clean finger after each brushing of teeth. Do not rinse
41021864|NCT03983590|OTHER|Visual Analogic Scale|VAS are collected in the first 24 hours after inclusion, 15 minutes, during and 15 minutes after the bed bath. Each time of collection are noted.
41021865|NCT06171152|DRUG|Liraglutide Pen Injector [Saxenda]|A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.
41021866|NCT06171152|OTHER|Medication Diary|Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.
41021867|NCT02972099|DEVICE|TcPRF|Transcutaneous Pulsed Radiofrequency is a method that is widely used for control of pain. There are no known complications. In this study a Radiofrequency generator will be used that has a separate outlet for transcutaneous use. It is used in the daily clinical practice in the Pain Center of the Swiss Paraplegic Center.
41021868|NCT02972099|DEVICE|Placebo|In the Placebo Treatment, no current will be delivered. Since no sensations are produced by TcPRF treatment the patients won't recognize the difference.
41021869|NCT01003249|DRUG|Baclofen|"Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
41021870|NCT01003249|DRUG|Placebo|"Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
41021871|NCT02936076|OTHER|Exercise intervention|
41021872|NCT02936076|OTHER|Delayed exercise intervention|
41021873|NCT03853707|DRUG|Atezolizumab|Given IV
41021874|NCT03853707|DRUG|Capecitabine|Given PO
41021875|NCT03853707|DRUG|Carboplatin|Given IV
41021876|NCT03853707|DRUG|Ipatasertib|Given PO
41021877|NCT03853707|DRUG|Paclitaxel|Given IV
41021878|NCT03853707|OTHER|Quality-of-Life Assessment|Ancillary studies
41021879|NCT03853707|OTHER|Questionnaire Administration|Ancillary studies
41021880|NCT05297994|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
41021881|NCT05297994|BIOLOGICAL|Inactivated influenza split vaccine|solution for intramuscular injection, 0.5 ml
41021882|NCT02012946|DRUG|Levosimendan|patient receiving levosimendan
41021883|NCT02012946|DRUG|Dobutamine|patient receiving dobutamine
41021884|NCT01805297|DRUG|Intravitreal Aflibercept Injection|One time 2.0mg aflibercept injection, following pars plana vitrectomy.
41021885|NCT01805297|OTHER|Standard Vitrectomy|Surgical intervention
41021886|NCT03204942|DEVICE|PRF on DRG|RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
41496148|NCT02730117|DEVICE|Mechanical ventilator|Invasive or noninvasive form of respiratory support
41496149|NCT02730117|DRUG|Anti-Bacterial Agents|Antibacterial agents deemed appropriate by physicians in the ICU
41496150|NCT02730117|DRUG|Vasopressors|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
41509231|NCT02108184|DRUG|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
41021887|NCT03204942|DEVICE|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
40836309|NCT04430647|PROCEDURE|combined phacoemulsification and ultrasound ciliary plasty (Phaco-UCP)|performing ultrasound ciliary plasty then performing standard phacoemulsification
40836310|NCT04430647|PROCEDURE|Phacoemulsification alone|standard phacoemulsification for catarct extraction
40836311|NCT06522685|DEVICE|transcranial direct current stimulation Soterix REMOTE 1x1 miniCT|Soterix Medical REMOTE Neuromodulation is the only system with device, accessories, and software designed for deployed use. Safe transcranial Electrical Stimulation requires advanced systems designed for consistency and control. REMOTE Neuromodulation is the only system designed from the ground up to allow translation of clinical tES, including tDCS protocols, to diverse deployed environments, while maintaining medical standards.
40836312|NCT05754060|OTHER|Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
40836313|NCT00721175|DEVICE|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
40836314|NCT00721175|DEVICE|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
41021888|NCT03204942|DRUG|Corticosteroid injection|Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
41021889|NCT04536844|DEVICE|Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)|An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.
41021890|NCT04536844|OTHER|Conventional prescheduled follow-up|Patients will be followed in the outpatient clinic by prescheduled follow-up
41021891|NCT02520245|DRUG|REGN2810|Patients will receive REGN2810 by intravenous (IV) infusion
41021892|NCT03943368|DEVICE|Ceevra Reveal|3D Digital models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source MR image.
41021893|NCT03919175|DRUG|Umbralisib|Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
41021894|NCT03919175|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
41021895|NCT01713803|DRUG|Buprenorphine and naloxone|
41356673|NCT04244773|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
41356674|NCT04244773|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
41356675|NCT05031494|DRUG|YH003|YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
41356676|NCT05031494|DRUG|Toripalimab|Toripalimab will be administered at a dose of 240 mg every 3 weeks.
41356677|NCT05031494|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
41356678|NCT05031494|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
41356679|NCT01537458|PROCEDURE|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
41356680|NCT04194086|DRUG|posaconazole oral suspensions|posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
41356681|NCT03322592|DIAGNOSTIC_TEST|Rapid on-site evaluation (ROSE)|On-site evaluation of the acquired samples will be performed by pathologist
41356682|NCT03322592|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
41356683|NCT02828202|OTHER|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
41356684|NCT02828202|OTHER|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
41356685|NCT02828202|OTHER|Quality of life|Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
41356686|NCT04228666|BIOLOGICAL|HB-adMSCs|Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
41356687|NCT01309581|DRUG|Ketamine|Ketamine 1-2 mg/kg IV as indicated for ECT
41356688|NCT01309581|DRUG|Methohexital|Methohexital 1 mg/kg IV as indicated for ECT
40836315|NCT05226585|BEHAVIORAL|In-Person Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi). CBTi contains the following well-validated components of cognitive behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
40836316|NCT05226585|BEHAVIORAL|Telehealth Cognitive Behavioral Therapy for Insomnia|Telehealth cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi) conducted via audio-video communication. tCBTi contains the following well-validated components of cognitive-behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
40836317|NCT05226585|BEHAVIORAL|Internet Cognitive Behavioral Therapy for Insomnia|Sleep Healthy Using The Internet (SHUTi; aka iCBTi) is a self-guided, fully automated, online CBTi program that includes interactive features: personalized goal setting, graphical feedback based on inputted data, animations/illustrations to enhance comprehension, patient vignettes, and video-based expert explanations.
40836318|NCT05614284|DEVICE|Virtuos|Use of autograft or Virtuous Lyograft as an adjunct to spinal fusion in TLIF.
40836319|NCT03759041|DRUG|Vancomycin Pre-Treatment|Four times per day dosing of vancomycin pre-treatment
40836320|NCT03759041|DRUG|Placebo for Vancomycin Pre-Treatment|Four times per day dosing of placebo pre-treatment
40836321|NCT03759041|DRUG|SER-287|Once-daily dosing of SER-287
40836322|NCT03759041|DRUG|Placebo for SER-287|Once-daily dosing of Placebo for SER-287
40836323|NCT05023148|PROCEDURE|Electroacupuncture|Stimulating acupoints using electric stimulator
40836324|NCT05023148|PROCEDURE|Thread embedded acupuncture|Stimulating acupoints using thread embedded
40836325|NCT01167907|DEVICE|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
40836326|NCT01167907|DRUG|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
40836327|NCT06380894|DEVICE|Virtual Reality Cognitive Training|"Participants who were assigned to the VRCT intervention group underwent 60 minutes of weekly VRCT sessions over a 10-week intervention period. The program consisted of two components: (1) psychoeducation on cognitive functioning and ways to maintain cognitive health, (2) VR multi-domain cognitive training tasks that target cognitive domains of attention, memory, and executive functioning.~The VR experiences were administered through a head-mounted Oculus Go Screen V7. The VR system runs on a software developed by Dancing Mind Pte Ltd. The software specifications and service provided by Dancing Mind Pte Ltd include: MindGym System Functions: System Setup (Processor Setup, Password Changing etc) and Data Centre (Memory Care Therapy Data Analytics Report Querying and Printing Functions). The MindGym cognitive training content was developed based on the Singaporean culture, with visual stimuli reflecting familiar local environments."
40836328|NCT06380894|BEHAVIORAL|Active Control|Participants who were assigned to the active control group were provided treatment-as-usual, which included: (1) psychoeducation on MCI, cognitive functioning, and compensatory strategies, and (2) brain training cognitive stimulation booklet which consisted of weekly homework activities focusing on attention, memory, and executive functioning. Control participants were reviewed for 3 sessions monthly to follow up on their progress on the cognitive stimulation activity booklet.
41356689|NCT01070654|PROCEDURE|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
41356690|NCT01070654|DEVICE|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
41356691|NCT05662488|DIAGNOSTIC_TEST|[68Ga]FAPI PET/CT and [18F]FDG PET/CT|To perform \[68Ga\]FAPI PET/CT and \[18F\]FDG PET/CT in patients with advanced liver and biliary cancer before and after treatment with PD-1 Based Combination Therapy
41356692|NCT00028015|DRUG|SarCNU|
41496151|NCT06506214|OTHER|Questionnaires|"Responses to questionnaires:~* Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)~* Medical Adherence Self-Report Inventory (MASRI)~* Morisky Medication Adherence Scale (MMAS4)~* Visual analog scale (VAS) on the perception of disease control~* Belief on Medicine Questionnaire (BMQ)~* Care patient Feedback measure~* Hospital Anxiety and Depression Scale (HAD)~* Dermatology Life Quality Index (DLQI)"
41496152|NCT04675619|DRUG|Oral pirfenidone|Treatment
41496153|NCT04675619|DRUG|Standard care|Treatment
40836329|NCT03542435|DRUG|SXC-2023|Oral capsule
40836330|NCT03542435|DRUG|Placebo|Placebo
40836331|NCT03505736|BIOLOGICAL|Adenosine|Given IV
40836332|NCT03505736|PROCEDURE|Magnetic Resonance Imaging|Undergo CMR imaging
40836333|NCT03505736|DRUG|Regadenoson|Given IV
40836334|NCT03505736|PROCEDURE|Stress Management Therapy|Undergo stress test
40836335|NCT00979849|DRUG|AZD8683|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
41356693|NCT04451369|OTHER|Prehabilitation program|physical, nutritional and psycho-social supports before surgery
41356694|NCT00656799|DRUG|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
41356695|NCT00656799|DRUG|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
41356696|NCT05850429|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
41356697|NCT05079724|PROCEDURE|Cardiac Surgery|About 3.5-31.0% of Patients undergoing cardiac surgery Complains from Postoperative Acute renal injury (AKI) that is a severe complication increasing the risk factor for mortality about 8-folds, The occurrence of AKI in patients undergoing cardiac surgery raises the mortality rate from 0.4-4.4% to 1.3-22.3%; when those same patients require dialysis.
41356698|NCT00935701|DEVICE|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
41496154|NCT04655430|OTHER|3-second SDF application|Dosage: 3-second 38% SDF solution application
41496155|NCT04655430|OTHER|5-second SDF application|Dosage: 5-second 38% SDF solution application
40836336|NCT00979849|DRUG|Placebo|Solution for nebulisation, inhaled
40836337|NCT01522404|DRUG|Atomoxetine|Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
41021896|NCT03147105|BEHAVIORAL|arm ergometry|home based arm ergometry, at least 4-5 sessions/week for 12 weeks
41021897|NCT05973487|BIOLOGICAL|TSC-204-A0201|Escalating doses of TSC-204-A0201 as a monotherapy
41021898|NCT05973487|BIOLOGICAL|TSC-204-C0702|Escalating doses of TSC-204-C0702 as a monotherapy
41356699|NCT04429828|OTHER|COVID-19 e-package: Psychological wellbeing for healthcare workers|All healthcare students have access to a COVID-19 educational learning package around psychological wellbeing (usual practice). In this study the investigators will conduct semi-structured qualitative interviews with healthcare students about their mental wellbeing, and use of this e-package.
41021899|NCT05973487|BIOLOGICAL|TSC-200-A0201|Escalating doses of TSC-200-A0201 as a monotherapy
41021900|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-C0702|Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702
41021901|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-200-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201
41356700|NCT02545686|BEHAVIORAL|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
40836338|NCT01522404|DRUG|Placebo|Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
40836339|NCT06473935|OTHER|Questionnaires and focus groups|"Participation in the research involves completing a test battery composed of self-administered questionnaires, all validated in the Italian language.~Additionally, qualitative data will be collected through semi-structured interviews (conducted in person or online, based on individual preferences) and focus groups, both lasting between 90 and 120 minutes."
41021902|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-200-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-200-A0201
41021903|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-203-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-203-A0201
41021904|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-203-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-203-A0201
41021905|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-203-A0201|Escalating doses of TSC-200-A0201 in combination with TSC-203-A0201
41021906|NCT05973487|BIOLOGICAL|TSC-203-A0201|Escalating doses of TSC-203-A0201 as a monotherapy
41356701|NCT02545686|BEHAVIORAL|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
41021907|NCT05973487|BIOLOGICAL|TSC-204-A0101|Escalating doses of TSC-204-A0101 as a monotherapy
41021908|NCT05973487|BIOLOGICAL|TSC-201-B0702|Escalating doses of TSC-201-B0702 as a monotherapy
41021909|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-A0101|Escalating doses of TSC-204-A0201 in combination with TSC-204-A0101
41021910|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-201-B0702|Escalating doses of TSC-204-A0201 in combination with TSC-201-B0702
41021911|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-204-A0101|Escalating doses of TSC-204-C0702 in combination with TSC-204-A0101
41021912|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-201-B0702|Escalating doses of TSC-204-C0702 in combination with TSC-201-B0702
41021913|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-204-A0101|Escalating doses of TSC-200-A0201 in combination with TSC-204-A0101
41021914|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-201-B0702|Escalating doses of TSC-200-A0201 in combination with TSC-201-B0702
41021915|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-204-A0101|Escalating doses of TSC-203-A0201 in combination with TSC-204-A0101
41356702|NCT02545686|PROCEDURE|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
41356703|NCT02545686|PROCEDURE|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
41356704|NCT04954976|OTHER|Orthodontic retention procedures survey|The survey was composed of eight parts, about sociodemographic status, retention system selection, choice of fixed and removable retention system, retention period, supervision, given instruction and needs for practice guidelines.
41496156|NCT04655430|OTHER|10-second SDF application|Dosage: 10-second 38% SDF solution application
41496157|NCT04655430|OTHER|15-second SDF application|Dosage: 15-second 38% SDF solution application
40836340|NCT01442805|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
40836341|NCT01442805|BEHAVIORAL|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
40836342|NCT02279836|DEVICE|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
40836343|NCT01123824|DRUG|CLOPIDOGREL|"Pharmaceutical form: tablets~Route of administration: oral"
40836344|NCT01123824|DRUG|placebo|"Pharmaceutical form: matching tablets~Route of administration: oral"
40836345|NCT04075409|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
40836346|NCT04366557|OTHER|Manual therapy, exercises and education program|a six week body posture therapy consisted of manual therapy (once per week) and home exercises; education about pelvic floor
41021916|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-201-B0702|Escalating doses of TSC-203-A0201 in combination with TSC-201-B0702
41021917|NCT02478892|OTHER|surveillance endoscopic ultrasound or MRI of the abdomen|The patients will be followed up clinically with routine surveillance endoscopic ultrasound or MRI surveillance every 12 months for a duration of 10 years
41021918|NCT05660525|DRUG|4 weeks of Nicotine lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
41021919|NCT05660525|DRUG|8 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
40836347|NCT04366557|OTHER|Education program|education about pelvic floor
40836348|NCT05956509|BIOLOGICAL|ABBV-950|Intramuscular (IM) Injection
40836349|NCT05956509|BIOLOGICAL|BOTOX|Intramuscular (IM) Injection
40836350|NCT05956509|DRUG|Placebo for ABBV-950|Intramuscular (IM) Injection
40836351|NCT00403533|DRUG|20 mg of atorvastatin daily|
40836352|NCT01295736|DRUG|Sildenafil|Sildenafil 20 mg TID per os during 90 days
41356705|NCT02646891|BIOLOGICAL|Trivalent P2-VP8 Subunit Rotavirus Vaccine|Manufactured and supplied by the Walter Reed Army Institute of Research (WRAIR) Pilot Bioproduction Facility (BPF). The trivalent P2-VP8 vaccine was formulated as a sterile suspension containing a total of 360 µg of protein (120 µg of each P type) per mL adsorbed to aluminum hydroxide (1.125 mg of aluminum per mL in a phosphate buffer, pH 7).
41356706|NCT02646891|BIOLOGICAL|Placebo|Sodium Chloride 0.9%, USP for Injection
41356707|NCT03696576|DEVICE|EMST|Training of the respiratory system muscles using the EMST device.
40836353|NCT01295736|DRUG|placebo|Placebo pills TID per os during 90 days
40836354|NCT03602885|BEHAVIORAL|Usual chemotherapy education (CE)|Standard chemo education will given per hospital guideline
40836355|NCT03602885|BEHAVIORAL|Chemotherapy education intervention (CEI)|Video, booklet, and website educational materials
40836356|NCT03101007|DEVICE|ATTUNE Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
40836357|NCT03101007|DEVICE|LCS Knee Prosthesis by DePuy|Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
40836358|NCT00006268|BIOLOGICAL|cintredekin besudotox|
40836359|NCT00006268|DRUG|isolated perfusion|
40836360|NCT00006268|PROCEDURE|conventional surgery|
41021920|NCT05660525|BEHAVIORAL|QuitAid|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
41021921|NCT05660525|BEHAVIORAL|Smokefree TXT|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.
41021922|NCT05660525|BEHAVIORAL|Tobacco Quitline|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.
41021923|NCT05660525|DRUG|4 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch.
41021924|NCT05660525|DRUG|8 Weeks Nicotine Lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
41021925|NCT00984841|OTHER|Tailored letter|
41021926|NCT02571894|OTHER|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
41021927|NCT01696630|DRUG|Xenon|
41356708|NCT03696576|BEHAVIORAL|PhoRTE|Completing of PhoRTE voice therapy.
41356709|NCT05977569|OTHER|Prolonged Fasting|Participants are asked to refrain from caloric intake for 3 days following a period of habitual lifestyle assessment and metabolic assessment.
40836361|NCT01243489|OTHER|compliance supporting measures|"Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary"
40836362|NCT01521910|DIETARY_SUPPLEMENT|low protein diet|"An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses \>= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet."
40836363|NCT01521910|DIETARY_SUPPLEMENT|normal protein diet|"The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period."
41021928|NCT01696630|DRUG|Desflurane|
41356710|NCT00805194|DRUG|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
41356711|NCT00805194|DRUG|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
41356712|NCT04072796|BEHAVIORAL|Questionnaires|Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
41356713|NCT03161015|DRUG|GBT440|Oral
41356714|NCT05763836|DRUG|Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]|Intravenous ibuprofen infusion
41356715|NCT05763836|PROCEDURE|Scalp nerve block|Scalp nerves blocked by using local anesthetics
41356716|NCT00006037|DRUG|fluorouracil|
41356717|NCT00006037|DRUG|irinotecan hydrochloride|
41496158|NCT04655430|OTHER|30-second SDF application|Dosage: 30-second 38% SDF solution application
40836364|NCT04543240|DEVICE|Integra™ dermal regeneration template|Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
40836365|NCT05275530|BEHAVIORAL|Active FIT Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a FIT, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
41021929|NCT03238001|DEVICE|DCTclock|DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
41021930|NCT05063734|DRUG|THR-687 dose level 1|3 intravitreal injections of THR-687 dose level 1, 1 month apart
41021931|NCT05063734|DRUG|THR-687 dose level 2|3 intravitreal injections of THR-687 dose level 2, 1 month apart
41021932|NCT05063734|DRUG|THR-687 selected dose level|3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
41021933|NCT05063734|DRUG|Aflibercept|3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
41021934|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
41021935|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
41021936|NCT01694706|DRUG|omeprazole|medium dose of omeprazole
41021937|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
41021938|NCT02940470|OTHER|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
41356718|NCT00006037|DRUG|oglufanide disodium|
41356719|NCT00574340|OTHER|Hyperinsulinemic Hypoglycemic Clamp|all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
41021939|NCT02940470|OTHER|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
41021940|NCT01458171|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).
41021941|NCT05351216|OTHER||No intervention
41021942|NCT01202838|DEVICE|Composite Implant|Subjects receiving composite implants
41021943|NCT06259344|BEHAVIORAL|Fractioned Pain Science Education (FPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 2 sessions of 45 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
41021944|NCT06259344|BEHAVIORAL|Full Dosage Mode Pain Science Education (FDPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 6 sessions of 15 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
41356720|NCT04873895|DRUG|Axitinib 5 MG|axitinib 5 mg po BID until progression or intolerance
41356721|NCT04873895|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 600 mg po BID until progression or intolerance
41356722|NCT04873895|PROCEDURE|trans arterial chemoembolization|segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
41356723|NCT00003874|BIOLOGICAL|monoclonal antibody CD19|
41356724|NCT00003874|BIOLOGICAL|monoclonal antibody CD20|
41356725|NCT00003874|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
41021945|NCT06259344|OTHER|Manual Therapy|Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
41356726|NCT00642122|DRUG|Budesonide|0.5mg once daily
41356727|NCT00642122|DRUG|Budesonide|1mg once daily
41356728|NCT00642122|DRUG|Budesonide|1mg twice daily
41496159|NCT04655430|OTHER|45-second SDF application|Dosage: 45-second 38% SDF solution application
41496160|NCT04655430|OTHER|60-second SDF application|Dosage: 60-second 38% SDF solution application
41021946|NCT06259344|OTHER|Orofacial and Neck Exercises (ONE)|"Orofacial Exercises: Mandibular body-condylar cross-pressure chewing technique; Post-isometric relaxation stretches-laterotrusion and opening (10 times/session; 10 seconds).~Neck Motor Control Exercises: Bracing exercises (6 hierarchical levels - HL). Extreme range of motion exercises (stable spine). Cervical isometric exercises (5 HL) directly forward, obliquely, toward right and left, and directly backward (stable spine - elastic resistive bands). Functional training with elastic resistance and exercise balls on unstable surfaces (8 HJ). The progress in each exercise domain will happen when sustaining the contraction for 10 seconds, 10 times."
41021947|NCT03772405|DRUG|Nascum Plus|nasal application of nascum plus
41021948|NCT03772405|OTHER|ACC|4 hours challenge to grass pollen in the allergen challenge chamber (ACC)
41021949|NCT00766415|DRUG|AZD1981|Oral tablet, twice daily, 4 weeks treatment
41021950|NCT00766415|DRUG|Placebo|Placebo
41021951|NCT02239458|DRUG|Saxagliptin|
41021952|NCT06467318|DRUG|Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
41021953|NCT06467318|DRUG|NSAID, Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
41356729|NCT00642122|DRUG|Budesonide|2mg once daily
41356730|NCT00642122|DRUG|Budesonide|4.00mcg twice daily
41356731|NCT03831607|DRUG|KHK7791|KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
41356732|NCT05488028|PROCEDURE|Piezo-electric surgery of impacted lower third molars|"During lower third molar surgery, osteotomy is performed using piezoelectric instrumentation.~When necessary, tooth sectioning was performed with a high-speed tungsten carbide slit drill under saline irrigation and the tooth removed in single or multiple segments."
41356733|NCT05488028|PROCEDURE|Rotary bur surgery of impacted lower third molars|During lower third molar surgery, osteotomy is performed using rotary instruments
41356734|NCT04717856|OTHER|screening: HCV RNA test and risk factors questionaire|Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
41496161|NCT04655430|OTHER|120-second SDF application|Dosage: 120-second 38% SDF solution application
41496162|NCT04655430|OTHER|180-second SDF application|Dosage: 180-second 38% SDF solution application
41496163|NCT04689555|PROCEDURE|Novel method without manual compression|Novel method for femoral artery hemostasis without manual compression. After sheath removal, four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
41496164|NCT04689555|PROCEDURE|Standard method with manual compression.|Standard method for femoral artery hemostasis with manual compression.After sheath removal, manual compression was continued for at least 10 minutes or until hemostasis. After that four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
41496165|NCT05665829|PROCEDURE|Awake transnasal laser-assisted surgery (TNLS)|The experimental intervention would be awake transnasal laser-assisted surgery under local anesthesia, carried out in minor operation theater as a day-case basis in ENT ambulatory center.
41496166|NCT05665829|PROCEDURE|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, laryngeal lesions are visualized and removed with under microscopic or endoscopic approach.
41496167|NCT04876365|OTHER|Non-Interventional|This is a Non-Interventional Study.
41356735|NCT04601779|BEHAVIORAL|VIPP-PUF|The VIPP-PUF Intervention is developed as an add-on to the existing PUF-program to address infants with major cognitive and regulatory vulnerabilities identified at age 9-10 months and adapted to the settings of community health nurses. The intervention (VIPP-PUF) will be created from an evidence-based method, the Video-based Intervention to Promote Positive Parenting (VIPP), to comprise six therapeutic sessions delivered by the community health nurse during home visits over a three months period. The VIPP -PUF builds on teaching the health nurses to promote parents' sensitivity to meet infants' cognitive and regulatory vulnerabilities, while taking in account the particular needs of families of psycho-social disadvantage.
40836366|NCT05275530|BEHAVIORAL|Active Colonoscopy Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about colonoscopy as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
40836367|NCT05275530|BEHAVIORAL|Active Dual Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT Kit and Colonoscopy screening. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with either a FIT or Colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
41021954|NCT00472914|DEVICE|portable surface electromyography|
41021955|NCT01771276|DEVICE|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
41356736|NCT04802928|DRUG|Isoniazid 300 milligram|Tablets 150 milligram b.i.d.
41356737|NCT04802928|DRUG|Placebo|Placebo
41356738|NCT04433936|DIAGNOSTIC_TEST|Pentacam tomography|The Pentacam maps were analyzed. The following anterior and posterior corneal surface parameters were evaluated by the Scheimpflug system: Kf, Ks, Kmax. The pachymetric map was analyzed, including CCT at the apex of the geometric center and CTmin. PPIavg, PPI min and PPI max were calculated . The Ambrósio relational thickness (ART) was calculated The posterior corneal elevation maps were evaluated and the posterior corneal elevation values relative to this reference were recorded. The back difference elevation and multimetric D index values were extrapolated from the difference map of the Belin/Ambrósio-enhanced ectasia display of the Pentacam system.
41356739|NCT04808167|DEVICE|autoRIC®|The autoRIC device will be modified by the company from the standard cuff inflation of 200 mmHg to 180 mmHg for the purposes of this study. Three cuff sizes are available from the company: small, medium, and large, correlating to standard adult cuff sizes. The remote ischemic preconditioning cycles will be performed daily by trained research personnel during the preparative regimen through day 0 (see Figure 1), defined as transplantation of stem cells (last preconditioning cycle on day -1). A control group will undergo a similar procedure, however, the cuff will not be inflated.
41356740|NCT04146870|OTHER|not have|not have
41356741|NCT00215228|DRUG|duloxetine vs. escitalopram|
41356742|NCT02353806|DRUG|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
41356743|NCT05200351|BEHAVIORAL|Equine assisted Therapy (EAT)|15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.
41356744|NCT06128642|DEVICE|Toe separator orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after the participants use the toe separation orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
41356745|NCT06128642|DEVICE|Dynamic orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after participants use the dynamic orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
41356746|NCT00031109|BIOLOGICAL|gp160 MN/LAI-2|
41496168|NCT03239743|DEVICE|Virtual Reality|Child will wear and interact with virtual reality headset while waiting for surgery.
41021956|NCT04468048|OTHER|"Music: Nada Himalaya performed by S. G. Sachchidananda"|"Music: Nada Himalaya performed by S. G. Sachchidananda"
41021957|NCT02805257|DRUG|Mitomycin-C|Intraoperative and postoperative injections of mitomycin-c/Mitosol
41496169|NCT03239743|DRUG|Midazolam|Child will receive Midazolam to help with pre-operative anxiety prior to surgery
41496170|NCT01123135|DRUG|Vaginal ERT|1gm of estrogen vaginal cream \[EVC\] at bed time 3 times a week
41496171|NCT01123135|DRUG|Placebo|Placebo
41496172|NCT03506906|DIAGNOSTIC_TEST|Sleep studies under noninvasive ventilation therapy|Polysomnography Transcutaneous capnography
41021958|NCT02805257|OTHER|Balanced Salt Solution|Intraoperative and postoperative injections of BSS
41021959|NCT02805257|PROCEDURE|Ahmed Glaucoma Valve Implant|Implantation of Ahmed Valve in study eye
41356747|NCT00031109|BIOLOGICAL|Aluminum hydroxide|
41356748|NCT01833793|DRUG|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
41356749|NCT01743066|DIETARY_SUPPLEMENT|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
41021960|NCT01465334|DRUG|Ofatumumab|
41021961|NCT01465334|DRUG|High-Dose Methylprednisolone|
41021962|NCT01465334|DRUG|Alemtuzumab|
41021963|NCT06531473|PROCEDURE|HoLEP|Patients will be randomized to one of the laser energy groups day of surgery.
41021964|NCT03213093|OTHER|Measure of cutaneous microcirculation|Measure of cutaneous microcirculation in response to a local application of pressure, to local heating and to the iontophoretic administration of acetylcholine
41021965|NCT06423833|DIAGNOSTIC_TEST|Trendelenburg maneuver (TM)|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Trendelenburg maneuver (TM) in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
41021966|NCT06423833|DIAGNOSTIC_TEST|Passive leg raising test|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Passive leg raising (PLR) test in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
41021967|NCT04381104|DRUG|Paracetamol|The intervention arm will receive 2 capsules of paracetamols of 500mg.
41021968|NCT00030797|DRUG|Irinotecan 70 mg/m2|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
41021969|NCT00030797|DRUG|Irinotecan 240 mg/m2|Irinotecan i.v. 240 mg/m2 day 1 and day 22
41021970|NCT00801684|DRUG|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
41356750|NCT04399434|OTHER|test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity|test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
41356751|NCT01786499|BEHAVIORAL|Relaxation Response Training|
41021971|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
41021972|NCT00801684|DRUG|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
41356752|NCT01364948|OTHER|Coconut oil application|Four ml coconut oil application twice daily for first week
41021973|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
41356753|NCT01364948|OTHER|No oil application|Oil application was not done
41356754|NCT03241485|DRUG|Intrathecal morphine|5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg
41021974|NCT00801684|DRUG|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
41021975|NCT01336465|DRUG|placebo|Repeating subcutaneous injection
41021976|NCT01336465|DRUG|rhuMAb Beta7|Repeating subcutaneous injection
41021977|NCT01196871|DRUG|Migalastat HCl|Oral capsules, single dose
41021978|NCT01196871|BIOLOGICAL|Agalsidase Beta|IV infusion, single dose
41021979|NCT01196871|BIOLOGICAL|Agalsidase Alfa|IV infusion, single dose
41021980|NCT03766646|DEVICE|Optiflow|45l.min oxygen
41356755|NCT03241485|DRUG|Placebo|Saline intrathecal given in the same manner as the intervention groups.
41356756|NCT00209755|PROCEDURE|therapeutic drug monitoring of ribavirin and dose adaptation|
41356757|NCT06016595|DIAGNOSTIC_TEST|Chronic prostatitis/chronic pelvic pain syndrome|Chronic prostatitis/chronic pelvic pain syndrome UPOINT
41356758|NCT06253624|PROCEDURE|All Arthroscopic ATFL Repair Surgery|The patients undergo surgery with spinal block, general anesthesia, or a combination of both. During the diagnostic arthroscopy, the anterior compartment is examined with a 4 mm 30-degree camera, and lateral ankle instability is diagnosed arthroscopically
41356759|NCT02827773|OTHER|Talking Pill Bottle|Made by Talking Rx
41356760|NCT06356649|PROCEDURE|extubation|Complications after extubation
41021981|NCT03436979|DEVICE|NeuGuide™ System|The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
41021982|NCT01727531|DRUG|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
41021983|NCT05206968|RADIATION|pelvic radiograph|Patients with hip involvement underwent a pelvic radiograph
41021984|NCT06443190|OTHER|Indigenous Patient Navigator Support|See Arm Description
41021985|NCT06573983|OTHER|Strengthening (Physical Therapy, Gerofit)|Individuals with physical fall risk will be referred to strengthening interventions available within the VHA. These may include Physical Therapy or Gerofit (a supervised exercise program).
41021986|NCT06573983|OTHER|Cognitive Behavioral Therapy (Clinical Psychology, Occupational Therapy)|Individuals with psychological fall risk will be referred psychological interventions such as cognitive behavioral therapy, which focuses on guided talking. This can be performed by VHA occupational therapists and clinical psychologists.
41021987|NCT06573983|OTHER|Medication Reconciliation (Clinical Pharmacology)|Individuals with pharmacological fall risk will be referred to clinical pharmacology for medication reconciliation. This includes examining the current medication list and deprescribing medications, if appropriate.
41496173|NCT03506906|DIAGNOSTIC_TEST|Routine tests|Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
41021988|NCT06573983|OTHER|Home Safety Modification (Occupational Therapy)|Individuals with environmental fall risk will be referred to occupational therapy for home safety assessments and modifications. This will involve modifying components within the home to reduce potential fall risk factors.
41356761|NCT06225830|DEVICE|Eksobionics Eksoskeleton NR|During treatment sessions, the therapist will guide the participant's progress using a specific plan. The therapist will set a trajectory for each leg, determining the appropriate step height and length, and program it into the Ekso device. The Ekso will then assist the participant by following this trajectory, with varying levels of assistance for each step. As the participant improves, the therapist will gradually reduce the assistance provided until the participant reaches a point where they no longer require assistance or reach a plateau. In the final phase, the trajectory will be removed, and the participant will walk using their own movements. The therapist may add resistance or assistance based on the participant's needs, but it will be in line with their self-generated movements rather than a predetermined path.
41496174|NCT00049530|BIOLOGICAL|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
41356762|NCT02579525|OTHER|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
41356763|NCT02579525|OTHER|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
41356764|NCT05030506|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg
41496175|NCT00299026|DEVICE|NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System|
40836368|NCT02030288|BEHAVIORAL|Relational Agent Intervention|"Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
40836369|NCT00272324|DRUG|Aspirin|
40836370|NCT00272324|DRUG|Folate|
41356765|NCT05030506|BIOLOGICAL|Pembrolizumab|25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
41496176|NCT01687478|DRUG|Olanzapine|Administered Orally
41356766|NCT05030506|DRUG|Lenvatinib|10 mg capsule administered orally at a dose of 20 mg
41356767|NCT00688194|DRUG|anastrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
41496177|NCT01687478|DRUG|Fluoxetine|Administered Orally
41496178|NCT01687478|DRUG|Placebo|Administered Orally
40836371|NCT06267638|DRUG|Ketamine group|Participants will receive intraoperative ketamine during total knee arthroplasty
40836372|NCT06267638|DRUG|Placebo group|Participants will receive intraoperative normal saline during total knee arthroplasty
40836373|NCT02383433|DRUG|Regorafenib|Given PO
40836374|NCT02383433|DRUG|Gemcitabine Hydrochloride|Given IV
41021989|NCT00636454|BEHAVIORAL|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
41356768|NCT00688194|DRUG|exemestane|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
40836375|NCT03344198|BEHAVIORAL|Circuit Training exercise & Modified Mediterranean diet|Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.
40836376|NCT00111904|DRUG|paclitaxel-loaded polymeric micelle|
41356769|NCT00688194|DRUG|fulvestrant|Given intramuscularly
41356770|NCT00688194|DRUG|lapatinib ditosylate|Given orally
41356771|NCT00688194|DRUG|letrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
41356772|NCT00688194|OTHER|placebo|Given orally
41356773|NCT01849289|DRUG|Insulin Degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
41356774|NCT01849289|DRUG|Insulin Glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
41496179|NCT01823835|DRUG|GDC-0810|GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
41496180|NCT01823835|DRUG|LHRH Agonist|LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
41496181|NCT01823835|DRUG|Palbociclib|Palbociclib administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
41021990|NCT00636454|OTHER|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
41021991|NCT01198184|DRUG|temsirolimus|Given IV or PO
41356775|NCT04303091|BEHAVIORAL|Physical Activity for Advanced Cancer Treatment (PAACT)|12-week physical activity intervention. 60 minute group-based exercise classes held once per week. Home-based exercise recommendations provided weekly along with basic take-home exercise equipment. Optional palliative care consultations offered.
41496182|NCT02001220|PROCEDURE|Once daily screening|"In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.~The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre."
41496183|NCT02001220|PROCEDURE|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
41496184|NCT06110910|DRUG|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
41356776|NCT04021706|DRUG|Anamorelin Hydrochloride|Ghrelin receptor agonist
41496185|NCT04857502|DRUG|99mTc-based PSMA Imaging and Surgery Agent|Given via IV injection
41496186|NCT04857502|PROCEDURE|Computed Tomography|Undergo SPECT/CT
41021992|NCT01198184|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
41021993|NCT01198184|OTHER|laboratory biomarker analysis|Correlative studies
41021994|NCT01198184|OTHER|pharmacological study|Correlative studies
41021995|NCT00969852|DRUG|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
41021996|NCT01169389|PROCEDURE|Intraarticular injection|Durolane, one vial
41021997|NCT01169389|PROCEDURE|Intra-articular injection of 0.5% Bupivacaine|
41021998|NCT02439086|DEVICE|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
41021999|NCT02929810|BEHAVIORAL|sleep extension|
41356777|NCT04021706|DRUG|Placebo|placebo is a inert substance
41356778|NCT04286724|BEHAVIORAL|"Brief behavioural procedure including a computerized visuospatial task (computer game Tetris)"|"Brief behavioural procedure including a computerized visuospatial task (the computer game Tetris) preceded by a reactivation of the traumatic memory of childbirth"
41022000|NCT02929810|BEHAVIORAL|sleep maintenance|
41022001|NCT06269614|DIETARY_SUPPLEMENT|Probiotic|Consumption of probiotic with parent- as tolerated for 4 weeks.
41022002|NCT05372198|DRUG|Chohort 1: Surufatinib|Surufatinib 300mg, qd, every 3 weeks as a cycle
41022003|NCT05372198|DRUG|Chohort 2: Immunotherapy|Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
41022004|NCT05372198|DRUG|Chohort 2: Surufatinib|Surufatinib 250mg, qd, every 3 weeks as a cycle
41022005|NCT04788147|DEVICE|RMRS IDE Device|Participants will be injected with FDG at the studied dose and will undergo imaging sessions using the RMRS IDE device and a third-party Positron Emission Tomography (PET)/CT imaging device.
41356779|NCT01864629|BEHAVIORAL|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
41356780|NCT00862329|DIETARY_SUPPLEMENT|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
41356781|NCT00862329|DIETARY_SUPPLEMENT|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
41022006|NCT01677195|DRUG|ACCS100|ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
41022007|NCT01677195|DRUG|Placebo|Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
41022008|NCT05573295|OTHER|Diagnostic Test: Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
41022009|NCT05573295|OTHER|Diagnostic Test: Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
41022010|NCT05573295|OTHER|Diagnostic Test: London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
40836377|NCT04534348|DEVICE|70% isopropyl alcohol-impregnated catheter caps|Implementation of 70% isopropyl alcohol-impregnated catheter caps in order to assess the number of CLABSI diagnosed during 1 Year
40836378|NCT01330654|DRUG|metoprolol|50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
40836379|NCT05339282|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
41356782|NCT00862329|DIETARY_SUPPLEMENT|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
41356783|NCT00862329|DIETARY_SUPPLEMENT|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
41356784|NCT04560179|DRUG|Tobramycin solution for inhalation 78mg dose|Inhaled tobramycin - 78mg administered every 12 hours for 14 days.
41356785|NCT04560179|DRUG|Tobramycin solution for inhalation 150mg dose|Inhaled tobramycin - 150mg administered every 12 hours for 14 days.
41496187|NCT04857502|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
41496188|NCT05523024|DIETARY_SUPPLEMENT|Probiotic|The probiotic group will receive one capsule of the probiotic mixture (dose:1x109 colony forming units (CFU) per day in one dose (before breakfast). The PRO preparation will contain the following bacterial strains: 50% Lactococcus lactis Rosell® - 1058, 25% Lactobacillus casei Rosell® - 215, 12,5% Lactobacillus helveticus Rosell® - 52, 12,5% Bifidobacterium bifidum Rosell® - 71). Probiotics will be administered orally.
41496189|NCT05523024|DIETARY_SUPPLEMENT|Berberine|The berberine group will receive 1500 mg of Berberine (Berberine hydrochloride 97% extract of Berberis aristata) per day in 3 doses. Berberine will be administered orally, before breakfast, dinner, and before supper.
40836380|NCT03897036|DRUG|CX-4945|API powder-in-capsule in 200 mg strength
40836381|NCT02064972|OTHER|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
40836382|NCT01566578|DRUG|Human recombinant epidermal growth factor|topical
40836383|NCT01566578|OTHER|Placebo cream|Dermal cream without EGF
40836384|NCT00002299|DRUG|Interferon beta-1b|
40836385|NCT00002299|DRUG|Ganciclovir|
41022011|NCT05927402|OTHER|Laughter Therapy Based on Kolcaba Comfort Theory|The laughter yoga will be applied to experimanetal group. Every laughter yoga practice is 45 minutes long and is planned 3 times a week for a total of 6 sessions. Control group patients will take only routine nursing care.
41356786|NCT04560179|DRUG|Tobramycin solution for inhalation 216mg dose|Inhaled tobramycin - 216mg administered every 12 hours for 14 days.
41356787|NCT04560179|DRUG|Tobramycin solution for inhalation 300mg dose|Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
41356788|NCT02409628|DEVICE|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
41356789|NCT00413777|DRUG|Tolvaptan|Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
41356790|NCT02184520|DEVICE|TRANSITION|
41356791|NCT02184520|DEVICE|REVERE|
41356792|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care + CARDIO|Combination of dietary supplement with clinical care
41356793|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care|Combination of placebo with clinical care
41356794|NCT01951976|OTHER|Questionnaires|Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
41356795|NCT01951976|OTHER|Yoga Classes|Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
41356796|NCT04065464|DEVICE|Ava Fertility Tracker|All women aged 18 to 40 years using Ava Fertility Tracker to track their cycles.
41356797|NCT00958230|DEVICE|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
41356798|NCT02381795|DRUG|Nasal Carbon Dioxide|
41496190|NCT05523024|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive a placebo. Placebo will contain only the excipients and will be administered orally for 24 weeks. Placebo in no way: color, taste, smell, form of taking, the dosage will not differ from the preparations tested. However, it will not contain probiotcs or berberine. Placebo will be orally administered three times a day: before breakfast, dinner, and supper (6.00-7.00 p.m.). To meet the GCP conditions, subjects from all groups will receive the same number of capsules (six) per day.
41496191|NCT05523024|DIETARY_SUPPLEMENT|Probiotc and Berberine|Probiotics and Berberine groupwill receive both: a probiotics mixture (as in PRO group: 1x109 CFU/day; in one dose) and 1500 mg/day of Berberine (Berberine hydrochloride 97% extract of Berberis aristata; in 3 doses). Probiotcs and berberine will be administered orally before breakfast, before dinner, and before supper.
41496192|NCT00561418|DRUG|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
41496193|NCT00561418|OTHER|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
41496194|NCT02950818|BEHAVIORAL|Take Heart|Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
40836386|NCT05135611|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with sleep apnea,. 4-channel NMES is the protocol that provides sequential electrical stimulation to Rt. suprahyoid m (channel 1), Lt.suprahyoid m (channel 2), bilateral thyrohyoid m (channel 3), and biltateral sternothyroid m (channel 4). At this time, channels 1 and 2 start to contract first and stimulate for 1200ms, and channel 3 starts stimulation 150ms after channels 1 and 2, and applies stimulation for 1050ms. Channel 4 starts stimulation 250ms after stimulation of channels 1 and 2 and stimulates it for 950 ms.
40836387|NCT02700165|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform the treatments.
40836388|NCT03751514|BIOLOGICAL|Bordetella Pertussis B1917|"The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Prn, PT and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.~Providing there are no safety concerns the standard inoculum (SI) will be identified in a dose escalating or de-escalating experiment commencing at 103 colony forming units administered intranasally."
40836389|NCT03751514|DRUG|Azithromycin 500 mg|To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.
41022012|NCT04202159|DRUG|Perampanel|Perampanel tablets.
41022013|NCT04202159|DRUG|Perampanel|Perampanel oral suspension.
41022014|NCT04079855|OTHER|Diet composition 1|A diet with a specified macronutrient composition different from arms 2 and 3.
41496195|NCT03821181|DEVICE|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
41496196|NCT03821181|DEVICE|Sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
41496197|NCT00111826|DEVICE|Celacade™ system|
41496198|NCT01022944|PROCEDURE|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
41496199|NCT01022944|PROCEDURE|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
41356799|NCT04778228|DEVICE|mechanical ventilation|"critically ill patients requiring mechanical ventilation (MV) were ventilated using high tidal volumes (Vt) and high airway pressures, until the pivotal ARDS net randomized controlled trial (RCT) demonstrated that a lung-protective MV strategy using a Vt of 4-8 mL/kg predicted body weight (PBW) and moderate levels of positive end-expiratory pressure (PEEP) improved survival (2). Since then, limitation of Vt to 4-8 mL/kg PBW, plateau pressures (Pplat) to a maximum of 30 cm H2O, and application of PEEP 10 -16 cm H2O represent the standard for MV in ARDS patients."
41356800|NCT01799291|BEHAVIORAL|Decision Making Tutorial|"A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches)."
41356801|NCT06110962|DEVICE|Sleeptracker-AI|The Sleeptracker-AI Monitor (Fullpower Technologies, California, USA) is a commercially available, unobtrusive, and non-wearable home sleep monitoring device. It is either pre-installed in a mattress or can be purchased separately by consumers where it is placed under the mattress. The device uses piezo-electric sensors that register the forces exerted through the mattress by features such as the subject's motion, respiration, heartbeats, and snoring vibrations.
40836390|NCT03751514|OTHER|Sterile Saline|To compare against B. pertussis, some volunteers will be enrolled onto the Sham arm. These volunteers will not receive B. pertussis but instead be given sterile saline
40836391|NCT03633669|DIAGNOSTIC_TEST|Fecal calprotectin|Testing every 3 months
40836392|NCT03633669|OTHER|Routine care|As per treating gastroenterologist
40836393|NCT00187070|DRUG|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
40836394|NCT00187070|PROCEDURE|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
40836395|NCT00187070|RADIATION|Radiation Therapy|See Detailed Description section for details of treatment interventions.
40836396|NCT00170989|DRUG|valsartan plus hydrochlorothiazide|
40836397|NCT03333148|DRUG|Nestle IMPACT Immunonutrition|Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
40836398|NCT03333148|OTHER|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
40836399|NCT03242018|DRUG|Placebo|Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
40836400|NCT03242018|DRUG|Sotagliflozin|Sotagliflozin 200 mg, tablet, orally, once daily.
40836401|NCT01713556|DRUG|Propranolol|
41356802|NCT04961125|GENETIC|germline variants|Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
41356803|NCT03299621|DEVICE|PLE (Phase Lag Entropy)|Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.
40836402|NCT01713556|OTHER|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
40836403|NCT01713556|DRUG|placebo|
40836404|NCT00810940|DRUG|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours
40836405|NCT00810940|DRUG|mannitol|mannitol plus standard treatment
40836406|NCT04596085|DIETARY_SUPPLEMENT|Investigational Product - ViraCide|Viracide
40836407|NCT04596085|OTHER|Placebo - Starch Powder Soft gels|Starch Powder Soft gels
40836408|NCT05625373|DRUG|Vancomycin|The powder will be placed within the surgical wound prior to skin closure.
41022015|NCT04079855|OTHER|Diet composition 2|A diet with a specified macronutrient composition different from arms 1 and 3.
41022016|NCT04079855|OTHER|Diet composition 3|A diet with a specified macronutrient composition different from arms 1 and 2, based on the current information about the US macronutrient composition.
41356804|NCT03299621|DRUG|Muscle Relaxant|Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
41356805|NCT03062605|DRUG|Iodine (Betadine)|
41356806|NCT03062605|BIOLOGICAL|NaOCL|
40836409|NCT04340440|PROCEDURE|D1 lymphadenectomy|Radical gastrectomy with D1 lymphadenectomy
40836410|NCT04340440|PROCEDURE|D2 lymphadenectomy|Radical gastrectomy with D2 lymphadenectomy
40836411|NCT02446873|OTHER|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
40836412|NCT05300841|DRUG|dydrogesterone 20 mg /d (Duphaston, Abott Healthcare , Egypt)|Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses
40836413|NCT05300841|DRUG|estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Shering, Germany)|will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
40836414|NCT03984630|BEHAVIORAL|Dietary Fiber Intervention|Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
41160287|NCT06339814|OTHER|Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol|An Eye Movement Desensitization and Reprocessing psychotherapist will hold the Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol sessions, dedicated to psychoeducation, imagery exercises, stabilization techniques and the reprocessing of traumatic events. The Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol will be composed of 4 sessions of 120 minutes each.
40836416|NCT01075971|DRUG|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
41356807|NCT00890851|PROCEDURE|Transurethral Needle Ablation (TUNA)|Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
40836417|NCT01075971|DRUG|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
41022017|NCT04689984|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
41022018|NCT04689984|DRUG|Astaxanthin|Astaxanthin 6 mg tablet once daily
41496200|NCT05453565|OTHER|Vasopressors|A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
41496201|NCT05453565|OTHER|Fluids|A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
40836418|NCT06450613|DEVICE|radiofrequency ablation|HCC Radiofrequency ablation
40836419|NCT06450613|OTHER|percutaneous ethanol injection|HCC percutaneous ethanol injection
40836420|NCT01800318|DEVICE|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
40836421|NCT01800318|BEHAVIORAL|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
40836422|NCT01800318|DEVICE|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
40836423|NCT01800318|BEHAVIORAL|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
40836424|NCT00142623|BEHAVIORAL|Tailored DVDs|Five DVDs aimed at reducing exposure to ETS
40836425|NCT03033953|DIETARY_SUPPLEMENT|Native whey|
40836426|NCT03033953|DIETARY_SUPPLEMENT|Milk|
40836427|NCT03033953|OTHER|Strength training|
40836428|NCT05504668|DIETARY_SUPPLEMENT|Turmeric Brainwave|A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.
40836429|NCT02179541|OTHER|RGB|When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
40836430|NCT04188652|OTHER|Detailed symptomregistration|Information on symptoms, specialized ultrasound in accordance to IOTA, and HE4 is registered in women with ovarian cysts. Participation in the study including symptom registration, description of the cyst using IOTA terminology, and HE4 determination will not affect further diagnostics or treatment. HE4 will not be informed to the patient or clinician.
40836431|NCT01029444|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
40836432|NCT05197582|OTHER|tele-monitoring|The symptoms of the patients were evaluated by calling the patients on the 1st, 5th, and 9th days of the quarantine by the researchers.
40836433|NCT00329615|DRUG|Insulatard, flexpen|
40836434|NCT05018741|PROCEDURE|liver transplantation|liver transplantation for chronic liver disease or acute liver failure
40836435|NCT01176955|BEHAVIORAL|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
40836436|NCT01176955|DRUG|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
40836437|NCT03445910|DRUG|Human chorionic gonadotropin|intrauterine injected of 500 IU of hCG on the day of ovum pick-up and
40836438|NCT02122809|DRUG|Chiauranib|Take orally
40836439|NCT03924921|OTHER|autogenic training|autogenic training
40836440|NCT04507165|PROCEDURE|Paravertebral block+Anterior serratus plane block|"Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure."
41022019|NCT03823651|BEHAVIORAL|Interval training|Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
41496202|NCT02067273|DEVICE|Transcranial Magnetic Stimulation (TMS)|
41496203|NCT00851318|DRUG|Certolizumab pegol|Subcutaneous (SC) injection
41496204|NCT00851318|DRUG|Methotrexate|Methotrexate dose between 6 to 8 mg/week.
41496205|NCT04407208|BIOLOGICAL|Convalescent plasma|The minimum titer of specific antibody is 1/80
41496206|NCT03521843|DEVICE|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
41496207|NCT03521843|DEVICE|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
41496208|NCT04954027|BEHAVIORAL|Questionnaires|"5 visits are planned during the study :~* the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online~* 4 telephone interviews for follow-up by investigator"
41496209|NCT00264368|DRUG|intravenous (IV) ganciclovir|
41496210|NCT03638414|OTHER|ePainQ questionnaire|This is a questionnaire which will be given to the intervention group about their perceptions of treatment. It will be online.
41496211|NCT05101681|DIAGNOSTIC_TEST|Teledentistry|Teledentistry using mobile photographs
41356808|NCT03753867|DRUG|Acitretin|Acitretin will be provided to participants in the formulation Soriatane. Soriatane doses are oral tablets taken daily by the participant. Participants will then receive 35mg of oral acitretin (Soriatane) daily for 8 weeks during the intervention phase. Participants will be asked to return two months after completion of the acitretin course for clinical follow-up and additional phlebotomy for laboratory testing.
41356809|NCT05978063|DRUG|difelikefalin 2.0 mg tablets|Oral difelikefalin 2.0 mg administered twice daily
40836441|NCT04507165|DRUG|opioid free anesthesia|"Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h)."
40836442|NCT04507165|DRUG|opioid based anesthesia|"Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively."
40836443|NCT02257723|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
41356810|NCT05978063|DRUG|difelikefalin 1.0 mg tablets|Oral difelikefalin 1.0 mg administered twice daily
40836444|NCT02257723|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
41496212|NCT03866902|BEHAVIORAL|Nutrition and Physical Activity Intervention|"Mothers. Twelve weekly classes for one hour focused on nutrition and exercise education and coping skills training followed by a forty five minute exercise class for mothers. Then they will return for one hour for continued support and a forty-five minute exercise class.~Children. Twelve weekly classes for one hour focused on Color Me Healthy and one hour of free play. Then 6 monthly continued support classes where a Color Me Healthy class will be reviewed and they will have one hour of free play."
41496213|NCT03866902|OTHER|English for Second Language Intervention|"Mothers. Control group mothers will receive 12 weekly English for Second Language classes for one hour and forty-five minutes. Then 6 monthly one hour and forty minute follow-up classes receiving English for Second Language material.~Children. Control group children will receive 12 weekly one hour and forty five minutes of having books read to them. Followed by 6 monthly meetings for one hour and 45 minutes being read to and coloring with crayons."
41496214|NCT03271723|OTHER|Observational study|No intervention
40836445|NCT02257723|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
40836446|NCT02257723|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
41022020|NCT03823651|BEHAVIORAL|Psychiatric consult|Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
41022021|NCT03823651|BEHAVIORAL|Nutrition/diet evaluation|PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
41022022|NCT03823651|BEHAVIORAL|Referral to Social Worker|Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
41022023|NCT04840745|DRUG|CKD-841 A-1 3.75mg|Single injection, subcutaneous injection
41022024|NCT04840745|DRUG|CKD-841 A-1 1.88mg|Single injection, subcutaneous injection
41022025|NCT04840745|DRUG|CKD-841 D 2.92mg|Single injection, subcutaneous injection
41022026|NCT04840745|DRUG|Leuplin Inj. 3.75 mg|Single injection, subcutaneous injection
41022027|NCT00685815|DRUG|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc NS IV over one hour, once on Day 3, once on Day 4
41022028|NCT00685815|DRUG|Placebo|250cc NS IV over one hour, once on Day 3, once on Day 4
41356811|NCT05978063|DRUG|difelikefalin 0.25 mg tablets|Oral difelikefalin 0.25 mg administered twice daily
41496215|NCT06314789|DIAGNOSTIC_TEST|doing lung ultrasonography|In the study, both LUS imaging and scoring will be performed in the delivery room within the first 30 minutes and LUS score evaluation will be performed at postnatal 2nd, 6th and 24th hours in the intensive care unit for inpatients and in the maternal ward for maternal patients.
41356812|NCT05978063|DRUG|Placebo tablets|Oral Placebo administered twice daily
41356813|NCT03943004|DRUG|DFP-14927|DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.
40836447|NCT02257723|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
41022029|NCT00796029|DRUG|14C-paliperidone|
41022030|NCT01353339|DRUG|Levofloxacin|500mg, PO, once daily for 3 months
41022031|NCT05694364|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
41022032|NCT05694364|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
41022033|NCT05694364|BIOLOGICAL|PRGN-3007|PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
41022034|NCT06205628|DRUG|ADX-850|siRNA duplex oligonucleotide
41022035|NCT06205628|DRUG|Placebo|Saline
41022036|NCT06205628|DRUG|Angiotensin Receptor Blockers|Angiotensin receptor blocker
41022037|NCT06532695|OTHER|No intervention will be provided.|no intervention will be provided.
41022038|NCT06084585|DIETARY_SUPPLEMENT|Study Product A (High-dose 2X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
41022039|NCT06084585|DIETARY_SUPPLEMENT|Study Product B (Low-dose X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
41022040|NCT06084585|DIETARY_SUPPLEMENT|Placebo|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
41022041|NCT05163860|OTHER|Survey|Participants will complete an online survey.
41022042|NCT01248117|DRUG|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
41022043|NCT03532789|DRUG|herbal patch|One patch with medicine should be applied to the skin every other day within two weeks
41022044|NCT03532789|DRUG|placebo patch|One patch without medicine should be applied to the skin every other day within two weeks
41356814|NCT06119828|BEHAVIORAL|breastfeeding education for family members|The first breastfeeding skills of mothers who gave birth in the delivery room and the first breastfeeding skills after birth were evaluated using BEDÖ. After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. After the mothers' 1-hour breastfeeding was evaluated in the delivery room, the training phase of family members began. CBT was administered to family members in the waiting room before the training, which lasted approximately 7-8 minutes. Then, breastfeeding training was given to family members for 20-25 minutes. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. On the 15th postpartum day, the family member was called by phone and reminded about breastfeeding education. At the first month postpartum,Checklist were administered to the mother via telephone conversation
41356815|NCT06119828|OTHER|receiving routine breastfeeding training|After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. Mothers' breastfeeding was evaluated at the 1st hour in the delivery room. CBT was administered to family members in the waiting room. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. At the first month postpartum, BBTÖ was administered to the family member, and BBTÖ and EÖY scale and Breastfeeding Checklist were administered to the mother over the phone.
41496216|NCT05721118|DIAGNOSTIC_TEST|CBCT and DXA exams performed in current practice in Nantes University Hospital|40 patients will be enrolled in order to study DXA/CBCT acquisitions of 16 osteoporotic women vs 34 osteopenic/healthy women (Estimated osteoporotic rate = 20%)
41496217|NCT03792295|DRUG|acetominophen, ibuprofen, oxycodone|Multimodal pain treatment group
41496218|NCT03792295|DRUG|Oxycodone|Classic opiod pain treatment group
41022045|NCT02477384|PROCEDURE|8mm-TIPS|
41496219|NCT00746876|DEVICE|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
41496220|NCT00746876|DEVICE|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
41496221|NCT03318731|OTHER|Sugar Pill|Taken orally in capsule form
41496222|NCT03318731|DIETARY_SUPPLEMENT|Fenugreek Extract, Low Dose|Taken orally in capsule form
41022046|NCT02477384|PROCEDURE|Endoscopic variceal ligation|
41022047|NCT02477384|DRUG|Propranolol|
41022048|NCT02477384|DEVICE|8mm ePTFE-covered stent|
41022049|NCT05944900|PROCEDURE|Cyanoacrylate glue application|"The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.~Cyanoacrylate glue should be applied in accordance with the instructions for use.~Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly."
41022050|NCT00720616|DRUG|Norditropin|Norditropin 0.1 mg/day self-administered once a day subcutaneously
41022051|NCT03264157|DRUG|HRIG|A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
41022052|NCT03264157|DRUG|HyperRAB|A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.
41022053|NCT03264157|BIOLOGICAL|RabAvert|A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
41022054|NCT06030193|DRUG|QLS-111 ophthalmic solution, (0.015%)|QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
41160288|NCT06339814|OTHER|Treatment As Usual|Treatment As Usual condition will receive only standard support.
41356816|NCT03941327|DEVICE|AxoGuard Nerve Cuff|A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
41356817|NCT01383551|BEHAVIORAL|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
41496223|NCT03318731|DIETARY_SUPPLEMENT|Fenugreek Extract, High Dose|Taken orally in capsule form
41496224|NCT00940316|BIOLOGICAL|panitumumab|Given intravenously 6mg/kg every 2 weeks
41496225|NCT00940316|DRUG|erlotinib hydrochloride|Given orally 150mg daily
41496226|NCT00940316|DRUG|irinotecan hydrochloride|Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
41496227|NCT03388489|BEHAVIORAL|Mind-Body Walking|walking, breathing, and mindfulness
41496228|NCT01899443|OTHER|Observation|This is an observational study observing relationship between routine care and outcomes after total hip or knee arthroplasty.
41496229|NCT02377050|OTHER|Higher Volume Feeding Goal|feeding volume goal of 180-200 ml/kg/day
41496230|NCT01966588|OTHER|Blood samples for whole genomic/transcriptomic sequencing|Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
41496231|NCT01966588|OTHER|UKU Side Effect Rating Scale|Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
41496232|NCT03872934|BEHAVIORAL|implant anxiety|to determine the type of music that reduces anxiety in patients undergoing implant surgery.
41496233|NCT05345743|PROCEDURE|Surgery|All types of surgery requiring general anesthesia
40836448|NCT04596865|PROCEDURE|Pancreaticoduodenectomy|Date of surgery 01/06/2010 - 31/05/2015
40836449|NCT05473286|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
40836450|NCT05292937|DIAGNOSTIC_TEST|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
40836451|NCT04506515|DIAGNOSTIC_TEST|Psychological stress and adaptation at work score (PSAS)|completing a survey based on PSAS
41356818|NCT01920516|DRUG|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
41356819|NCT04930627|DRUG|Empagliflozin|dosis depending on body weight: \<20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; \>40 kg 2 x 10 mg
41356820|NCT04333628|DRUG|chloroquine|oral treatment of chloroquine
41496234|NCT05980663|DIETARY_SUPPLEMENT|Meal replacement product- STANDARD PRODUCT|standard product line contains common ingredients and this type of product already exists on world markets
41356821|NCT04333628|OTHER|standard care|Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
41356822|NCT06389994|DEVICE|Esophageal String Test|The EnteroTracker® capsule is supplied in pouches, each pouch containing a single capsule. The device is comprised of an ingestible capsule that contains a weighted ball and a highly absorbent nylon string. The looped portion of the string is secured externally to the patient's cheek and the rest of the capsule is swallowed by the patient.
40836452|NCT04408768|OTHER|standard protocol for stroke patients|Standard protocol for stroke patients
40836453|NCT05901324|RADIATION|intensity-modulated radiotherapy (IMRT)|1.8 Gy of 4-6 MV X-ray to a total dose of 23.4 Gy (13 fractions) will be delivered.
40836454|NCT03579212|DEVICE|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
41356823|NCT03860181|PROCEDURE|Subcuticular Sutures - Surgeon 1|This intervention closes incisions after shoulder arthroplasty using subcuticular sutures with Dermabond.The deep layer closure will require interrupted sutures.
41356824|NCT03860181|PROCEDURE|Metal Staples - Surgeon 2|This intervention closes incisions after shoulder arthroplasty with metal staples. The deep layer closure will require interrupted sutures,
41356825|NCT03860181|DEVICE|PRINEO - Surgeon 1|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
41356826|NCT03860181|DEVICE|PRINEO - Surgeon 2|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
41356827|NCT00327210|BEHAVIORAL|Blood Glucose Awareness Training|
41356828|NCT02127970|DRUG|Dalbavancin|Dalbavancin IV infusion over 30 minutes.
41496235|NCT05980663|DIETARY_SUPPLEMENT|Meal replacement product- INNOVATIVE PRODUCT|innovative product line contains raw materials that are considered better sources of potentially bioactive components
41496236|NCT05231538|OTHER|Neurodevelopmental therapy|NDT is a hands-on, 'problem solving approach'. It is used in the management and treatment of children who have disorders of function, movement or postural control because of damage in their central nervous system.
41496237|NCT05231538|OTHER|Routine physical therapy|stretching, passive range of motion, and active range of motion).
41496238|NCT04339283|DIETARY_SUPPLEMENT|Standardized Hibiscus sabdariffa tea|Daily consumption of Standardized Hibiscus sabdariffa tea
41496239|NCT03929276|DEVICE|high-intensity laser therapy & exercises|A total of 15 sessions of high-dose laser treatment- i Lux Laser (Mectronic Medicale, Italy)- (in the first phase, 8 Watt for the analgesic effect; in the second phase, 12 Watt in burst mode for the biostimulation effect; and finally in the third phase with 8 Watt) will be applied.
41496240|NCT03929276|DEVICE|Shame laser & exercises|Sham laser treatment (the same device to be used, 0 watts) will be given.
41496241|NCT03929276|OTHER|exercise|Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.
41496242|NCT02747550|PROCEDURE|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
41496243|NCT02747550|PROCEDURE|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy
41496244|NCT01445210|PROCEDURE|Continuous saphenous nerve block|0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
41496245|NCT01445210|PROCEDURE|Placebo|Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
41496246|NCT02455037|OTHER|Neck Strengthening|Targeted neck strengthening exercises
41496247|NCT00424918|BEHAVIORAL|Physical Activity, reduced sedentary behavior|
41496248|NCT06450795|BEHAVIORAL|Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.|HIFEM treatment for 6 weeks, 2 days a week for 28 minutes. The evaluations will be repeated at the end of the treatment.
41496249|NCT03593018|DRUG|Oral azacitidine|Azacitidine tablets
41496250|NCT03593018|DRUG|Romidepsin|Romidepsin injection
41496251|NCT03593018|DRUG|Bendamustine|Bendamustine injection
41496252|NCT03593018|DRUG|Gemcitabine|Gemcitabine injection
40836455|NCT01762267|OTHER|nutrition intervention|DASH diet control diet
41496253|NCT00684489|DRUG|clinical hypertension specialist-no specific med. Any anti-hypertension meds.|assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
41496254|NCT00684489|DRUG|renin guided therapeutics-no specific med. Any anti-hypertensive med.|renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
41496255|NCT01344278|BEHAVIORAL|Lifestyle Counseling|A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
41496256|NCT05543408|BEHAVIORAL|EXERCISE|individualized, progressive, exercise program
41496257|NCT00928707|DRUG|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
41496258|NCT00928707|DRUG|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
41496259|NCT01510626|DIETARY_SUPPLEMENT|Food proteins|Food proteins
41356829|NCT02127970|DRUG|Dalbavancin-matching Placebo|Dalbavancin-matching placebo IV infusion over 30 minutes.
41496260|NCT01510626|DRUG|Omalizumab|Drug
41496261|NCT02934659|DEVICE|Atlas(TM) Knee System|The Atlas System is an extra-capsular knee implant designed to unload the medial knee.
40836456|NCT03052140|DEVICE|Lamelleye Dry Eye Drops|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
41356830|NCT02312375|DRUG|Fimasartan|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
41356831|NCT02312375|DRUG|Amlodipine|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
41356832|NCT05371249|DRUG|Vonoprazan-based triple therapy|vonoprazan 20mg+amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days
41356833|NCT05371249|DRUG|Extended sequential therapy|Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days
41356834|NCT04016506|OTHER|nutritional questionnaire|nutritional questionnaire is given to the patient after the injury
41022055|NCT06030193|DRUG|QLS-111 ophthalmic solution, (0.03%)|QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
41022056|NCT06030193|OTHER|QLS-111 ophthalmic vehicle solution|Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
41496262|NCT01283594|DRUG|Tozadenant (SYN115) 60 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID."
41496263|NCT01283594|DRUG|Placebo|White-coated, modified-oval placebo tablets.
41496264|NCT01283594|DRUG|Levodopa (L-dopa)|One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
41496265|NCT01283594|DRUG|Tozadenant (SYN115) 120 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID."
41496266|NCT01283594|DRUG|Tozadenant (SYN115) 180 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID."
40836457|NCT03052140|DEVICE|Optive Plus|Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye
40836458|NCT03444454|BEHAVIORAL|VRRS Khymeia|"Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes.~Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
40836459|NCT03444454|BEHAVIORAL|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
40836460|NCT03444454|BEHAVIORAL|VRRS Khymeia plus active tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
41022057|NCT06573749|DIETARY_SUPPLEMENT|Bioactive whey protein concentrate|Every day for 12 weeks, participants will mix 1 pre-packaged sachet with \~350ml of water and consume the resultant drink alongside their breakfast.
41160289|NCT03551197|DRUG|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
41160290|NCT04149587|DRUG|Brodalumab|Brodalumab will be administered per dose and schedule specified in the arm.
41160291|NCT02724163|DRUG|Gemtuzumab ozogamicin|Antibody-conjugated chemotherapy agent.
41160292|NCT02724163|DRUG|Liposomal daunorubicin|"Anthracycline~(Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug."
41160293|NCT02724163|DRUG|Mitoxantrone|DNA-reactive agent
41160294|NCT02724163|DRUG|Fludarabine|A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
41356835|NCT01643109|OTHER|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
41356836|NCT04553796|DEVICE|fibroscan|Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
41496267|NCT01283594|DRUG|Tozadenant (SYN115) 240 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID."
41496268|NCT06355011|DEVICE|Total Elbow Replacement|Total elbow replacement is a procedure that involves replacing the elbow joint with an implanted device to alleviate pain and improve function.
41496269|NCT05318274|RADIATION|Hypofractionated radiotherapy|Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.
41496270|NCT06085118|OTHER|Pepticate® Syneo®|Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).
41496271|NCT04181073|DEVICE|Jet Nebuliser|Jet Nebuliser
41496272|NCT04181073|DEVICE|Vibrating Mesh Nebuliser|Aerogen Device
41496273|NCT00034008|BEHAVIORAL|Healing Touch|
41496274|NCT06009627|DRUG|Dalcelli、Exemestane、Gosserine|"Dalcelli: once a day, 125 mg each time, taken for 3 weeks, stopped for 1 week, 1 for 4 weeks~Period. It is recommended to take the medication at approximately the same time every day, delivered in warm water, on an empty stomach, at least before taking the medication~Fasting for 1 hour before and after.~Exemestane: 25mg, oral, once a day, continuous administration.~Gosserine: 3.6mg, subcutaneous injection, once every four weeks, continuous administration"
40836461|NCT03444454|BEHAVIORAL|VRRS Khymeia plus placebo tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
40836462|NCT04973462|DRUG|standard treatment COVID-19 + Triazavirin|to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019
40836463|NCT04860622|DIAGNOSTIC_TEST|Serum thyroid function tests|At the first hospital visit, the blood tests will be made for TSH, FT4, FT3, and beta HCG concentration measurement
41356837|NCT00597129|BIOLOGICAL|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
41356838|NCT04441658|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
41356839|NCT04441658|BIOLOGICAL|saline|saline containing human albumin will be infused to the control group
41356840|NCT00298766|DRUG|VELCADE|"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"
41356841|NCT06401538|DRUG|BMB-101|BMB-101 liquid administered orally twice a day for 3 months
41356842|NCT04131504|DRUG|Infliximab|No standard dosing regimen will be used and the dose will be determined by the treating physician
41496275|NCT06009627|DRUG|Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection|"Docetaxel for injection: 75mg/m2, intravenous drip, approximately 30 minutes. Dose reduction and delayed administration are allowed every three weeks, with a maximum of three weeks of delayed administration allowed since the last administration time~Calculate, otherwise terminate treatment.~5. Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction~And delayed administration, with a maximum allowable delay of 3 weeks, calculated from the last administration time. Otherwise~Stop treatment.~6. Cyclophosphamide for injection: 500mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction and~Delayed administration, allowed up to 3 weeks, calculated from the last administration time, otherwise terminated treat"
41356843|NCT04131504|DRUG|Adalimumab|No standard dosing regimen will be used and the dose will be determined by the treating physician
41356844|NCT04395924|DIAGNOSTIC_TEST|Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta|"During labor and delivery~1. Sample of amniotic fluid~2. 2 samples of blood cord after the birth of the new born~3. 2 samples of placenta~These samples will be tested with A RT-PCR COVID-19 test and / or serology's A sample of blood cord and placenta will be frozen at -80 degree C and studied for PCR and viral proteome, cytokines , D-dimers and others inflammatory markers in the PRIMMO Laboratory (Prof. TOUMI and LESPESSAILLES) and after in the Centre of molecular biophysics of CNRS of Orleans (Prof. PICHON)"
41496276|NCT05000879|BEHAVIORAL|MMB for Moms|12-week program that emphasizes mindfulness and cognitive behavioral skills
41496277|NCT02711735|BIOLOGICAL|RUTI® Therapeutic vaccine|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
40836464|NCT00563823|DRUG|vatalanib|
40836465|NCT01386268|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
40836466|NCT00027586|DRUG|Imatinib mesylate (STI571)|400 mg twice a day orally
41356845|NCT05810415|DIAGNOSTIC_TEST|Renin levels and lactic acid levels|Sampling of blood for measuring renin and lactate
41356846|NCT00152997|DRUG|Pramipexole 0.125 mg tablets|
41356847|NCT00152997|DRUG|Pramipexole 0.125 mg tablets Placebo|
41356848|NCT00983944|BIOLOGICAL|bleomycin sulfate|Given IV
41356849|NCT00983944|BIOLOGICAL|rituximab|Given IV
41496278|NCT02711735|BIOLOGICAL|Matching RUTI® Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
41496279|NCT02293369|PROCEDURE|Cuff closure via vaginal route|Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
41496280|NCT02293369|PROCEDURE|Cuff closure via laparoscopic route|Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
41496281|NCT01724489|DRUG|Growth hormone|
41496282|NCT01724489|DRUG|Placebo|
41496283|NCT02216786|DRUG|AZD2014|Oral tablet
41496284|NCT02216786|DRUG|Everolimus|Oral tablet
40836467|NCT05451251|DEVICE|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine demyelinating lesion
40836468|NCT05105113|PROCEDURE|Zirconia dental implant installation surgery|Dental implant installation surgery using zirconia one-piece implant (Tav-dental)
40836469|NCT01441011|BEHAVIORAL|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
40836470|NCT01441011|BEHAVIORAL|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
41356850|NCT00983944|DRUG|EPOCH regimen|Given IV or orally
41356851|NCT00983944|DRUG|cyclophosphamide|Given IV or orally
41356852|NCT00983944|DRUG|doxorubicin hydrochloride|Given IV or orally
41356853|NCT00983944|DRUG|etoposide|Given IV or orally
41356854|NCT00983944|DRUG|prednisone|Given IV or orally
41356855|NCT00983944|DRUG|vincristine sulfate|Given IV or orally
41356856|NCT04657406|DRUG|Zofin|Subjects will receive standard of care plus 1 mL of Zofin on day 0, day 4 and day 8, containing 1-5 x 10\^11 particles/mL.
41356857|NCT00354627|DRUG|TMC125|200 mg b.i.d. till commercially available.
41356858|NCT02939326|DRUG|EB-001 injection|
41356859|NCT02939326|DRUG|Placebo injection|
41356860|NCT02839512|DEVICE|Jejunal to Ileal Diversion|The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
41496285|NCT02216786|DRUG|Fulvestrant|Im injection
41496286|NCT03051932|DRUG|Ofiramev® (IV Acetaminophen)|Post -op pain medication
41356861|NCT05761769|OTHER|no intervention|no intervention
41356862|NCT01393561|DRUG|Group 1|Brompheniramine + phenylephrine
41496287|NCT03051932|DRUG|Placebo IV administration|Post -op pain
41496288|NCT05217719|DRUG|recombinant human thrombopoietin|The dose of rhTPO is 15,000 U per day. The subcutaneous injection will be terminated when PCs are increased to normal. The duration of rhTPO will be 7 days.
41496289|NCT05217719|DRUG|normal saline|Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
41496290|NCT02535871|DRUG|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
41496291|NCT02535871|DRUG|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
41496292|NCT01333371|PROCEDURE|Surgical Repair of Distal Radius Fracture|2 surgical methods to treat Distal Radius Fracture
41496293|NCT04111055|DEVICE|Closed-loop system|the CLV system will correct hypotension by automated adjustment of norepinephrine.
41496294|NCT03251235|BEHAVIORAL|Cognitive Behaviour Therapy|
41496295|NCT04590638|OTHER|tumescent with adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.
41496296|NCT04590638|OTHER|tumescent without adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.
41496297|NCT02564211|DRUG|Ipragliflozin|one 50 mg tablet QD
41022058|NCT06573749|DIETARY_SUPPLEMENT|Pea-based protein supplement|Every day for 12 weeks, participants will mix 1 pre-packaged sachet with \~350ml of water and consume the resultant drink alongside their breakfast.
41160295|NCT02724163|DRUG|Cytarabine|Pyrimidine nucleoside analogue, an antineoplastic agent.
41160296|NCT02724163|DRUG|Busulfan|Alkylsulfonate
40836471|NCT06194500|DRUG|[14C]-LY3549492|Administered as oral solution.
40836472|NCT06194500|DRUG|LY3549492|Administered orally.
40836473|NCT06194500|DRUG|[14C]-LY3549492|Administered as IV infusion.
40836474|NCT03705910|OTHER|Perceptive Rehabilitation|"In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas."
41160297|NCT02724163|DRUG|Cyclophosphamide|A nitrogen mustard alkylating agent from the oxazaphosphorine group
41160298|NCT05814679|OTHER|Relaxation with virtual reality|In this research, a virtual reality relaxation video will be used in which the natural wonders are presented to the audience in an immersive environment.
41160299|NCT05814679|OTHER|Attention match|kidney function instruction
41356863|NCT01393561|DRUG|Group 2|Placebo
41356864|NCT00829010|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
41496298|NCT02564211|DRUG|Sitagliptin|one 50 mg tablet QD
41496299|NCT05131243|PROCEDURE|Chemotherapy time|6 months of chemotherapy
41496300|NCT05131243|PROCEDURE|Chemotherapy time|3 months of chemotherapy
41496301|NCT05988853|OTHER|follow-up of patients|Follow-up of evidence of nosocomial infections of patients in music therapy
41496302|NCT04849065|DRUG|MNC (Mononuclear cells)|"* Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side)~* Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)"
41356865|NCT00829010|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
41356866|NCT00829010|BIOLOGICAL|measles|Intramuscular injection, 2 doses
41356867|NCT00829010|BIOLOGICAL|Rotarix|Oral, 2 doses
41356868|NCT00829010|BIOLOGICAL|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
41496303|NCT04849065|DRUG|Placebo / Saline|- Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
41496304|NCT04461561|GENETIC|end-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
41496305|NCT04380363|DEVICE|Honda Walk Assist (HWA) device|Use of HWA for 2 months in the home setting
41496306|NCT04380363|OTHER|SRALab fitness center membership|Membership to Shirley Ryan AbilityLab fitness center for 2 months
41496307|NCT01910974|PROCEDURE|endoscopic sub-mucosal dissection|endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
41496308|NCT05865730|OTHER|Live Bacterial Product - Akkermansia muciniphila|Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.
40836475|NCT03705910|OTHER|Mobilisation Techniques|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
40836476|NCT00181610|DRUG|Recombinant Human Prolactin|60 mcg/kg every 12 hours
41496309|NCT05817682|OTHER|Interprofessional education|"The study will be conducted among students of the Krakow Academy. The experimental group will consist of 35 students participating in the Interdisciplinary Circle of Medical Simulation from the following faculties: medicine, nursing and medical rescue.~Students will be divided into 7 interprofessional teams, in which they will take classes planned for small groups."
40836477|NCT00181610|BIOLOGICAL|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
40836478|NCT00181610|BIOLOGICAL|Normal Saline|twice per day
40836479|NCT02745847|RADIATION|Re-irradiation with SBRT|Patients previously treated with SBRT with relapsed pancreatic cancer will be re-irradiated with SBRT.
40836480|NCT04014621|DEVICE|SPG stimulation|The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
40836481|NCT03823950|DRUG|Granulocyte Colony-Stimulating Factor|Begin G-CSF 72 hours following chemotherapy
40836482|NCT03255759|DIAGNOSTIC_TEST|Multiplex molecular diagnostic assay|To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
40836483|NCT02230371|DRUG|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
40836484|NCT02230371|DRUG|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
40836485|NCT01638559|DRUG|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
41160300|NCT00804414|DRUG|SBG|Solution for topical use
41160301|NCT00804414|DRUG|Placebo Comparator|Solutin for topical use
41356869|NCT02354690|DRUG|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
41356870|NCT02354690|DRUG|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
40836486|NCT05218226|DRUG|Avatrombopag|The subjects will initiate treatment with 60 mg/d Avatrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 60 mg daily. Subjects whose platelet count ≤100×109/L，the Avatrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Avatrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Avatrombopag to 20mg once every other day or lower frequency during the treatment period, Avatrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Avatrombopag if the platelet is greater than 50×109/L.
40836487|NCT00106574|DRUG|Placebo|iv every 4 weeks
40836488|NCT00106574|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
40836489|NCT04624334|OTHER|Elektro-Entero-Graphy procedure|Fasting, after which pre- and postprandial EEnG measurements are performed.
40836490|NCT04624334|OTHER|EEnG Questionnaire|Filling out questionnaire about EEnG procedure.
40836491|NCT04624334|OTHER|Gold Standard Questionnaire|Filling out questionnaire about Gold Standard diagnostic used to diagnose colonic motility disorder.
40836492|NCT00739466|DRUG|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
40836493|NCT00739466|DRUG|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
40836494|NCT00739466|DRUG|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
40836495|NCT01415804|DEVICE|endoprosthesis|Thoracic aortic stentgraft
40836496|NCT00914550|OTHER|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
40836497|NCT02953665|DRUG|Liraglutide|Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
40836498|NCT02953665|DRUG|Placebo|Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
40836499|NCT05052619|DRUG|Preventive use of advanced antibiotics|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
40836500|NCT05052619|OTHER|Routine|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
40836501|NCT01638104|DRUG|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
40836502|NCT01638104|DRUG|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
40836503|NCT02017561|BEHAVIORAL|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
40836504|NCT02017561|DRUG|Metformin|Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
40836505|NCT03217032|BIOLOGICAL|YUVA-GT-F801|Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
40836506|NCT02686476|DRUG|Empagliflozin|group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
40836507|NCT04836988|OTHER|Three months of digitally delivered osteoarthritis treatment|Digitally delivered osteoarthritis management including education and exercise and weight control if needed
40836508|NCT04836988|OTHER|Three months of face-to-face delivered osteoarthritis treatment|Face-toface delivered osteoarthritis management including education and exercise and weight control if needed
40836509|NCT00473603|DRUG|lipid/heparin infusion|to perform an i.v. lipid heparin infusion infusion for 4 h
41356871|NCT02354690|DRUG|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
40836510|NCT05810285|DEVICE|GKS Prime Flex Mobile knee|Total knee arthroplasty with a cemented mobile bearing bicompartmental knee prosthesis
40836511|NCT05173961|OTHER|Internet-Based Intervention|Use oncpatient mobile application
40836512|NCT05173961|OTHER|Survey Administration|Complete survey
40836513|NCT01965223|RADIATION|Multi-fraction SABR|Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
40836514|NCT01965223|RADIATION|Single Fraction SABR|Single fraction SABR; 28Gy delivered in 1 fraction
41356872|NCT02354690|DRUG|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
41496310|NCT05093361|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty for the treatment of hip arthritis.
41496311|NCT05093361|PROCEDURE|Physical Therapy|Self-driven training according to the training plan instructed by physical therapist.
40836515|NCT06025799|BEHAVIORAL|Mindfulness-based stress reduction intervention|The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
40836516|NCT05343234|DRUG|Placebo|tree different placebo drugs with tree different names and scheduled will be given
41022059|NCT01771133|BEHAVIORAL|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
41022060|NCT00377663|BEHAVIORAL|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
41022061|NCT02664038|BEHAVIORAL|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
41022062|NCT06567691|PROCEDURE|EUS Gastrojejunostomy|Endoscopic Ultrasound (EUS) Gastrojejunostomy. Under live real-time EUS visualization, a solution of normal saline or water and dilute methylene blue will be infused through the nasobiliary drainage catheter to mechanically distend the small intestine and create a suitable, expanded fluid-filled target for transgastric access. Once a suitable target has been identified, a lumen apposing metal stent (LAMS) will then be deployed securely across the newly created gastroenterostomy tract. Appropriate stent placement will be confirmed.
41022063|NCT06567691|PROCEDURE|Surgical Gastrojejunostomy|Gastrojejunostomy will be performed via an open technique using an upper midline or left sub-costal incision (at the discretion of the surgeon). An antecolic, pro-peristaltic, gastrojejunostomy will be performed using one of two standard techniques: 1) hand-sewn: 2-layer anastomosis using absorbable suture or 2) stapled: single-layer anastomosis using a surgical stapler with closed staple height ranging from 1.0 - 1.5 mm and suture closure of the common enterotomy. Feeding tube placement will be at the discretion of the operating surgeon and if performed, will be performed via a Stamm technique. Abdominal fascial closure will be performed with absorbable, monofilament, suture and skin will be closed using staples or suture at the discretion of the surgeon.
41022064|NCT06567691|OTHER|Gastric Outlet Obstruction Scoring System (GOOSS)|A previously validated instrument for assessing tolerance of oral intake.
41022065|NCT00124150|DRUG|Intravenous magnesium sulfate infusion|80mg per day
41022066|NCT05077267|BIOLOGICAL|ABNCoV2 100ug|IM injection 100ug dose
41022067|NCT05077267|BIOLOGICAL|ABNCoV2 50ug|IM injection 50ug dose
41022068|NCT01946308|OTHER|Conformational positioning system|The conformational positioning system will be compared to the standard infant crib mattress.
41022069|NCT00030589|DRUG|bexarotene|
41022070|NCT00030589|DRUG|methoxsalen|
41356873|NCT03175822|BEHAVIORAL|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements \[e.g., colour and line\] and principles \[e.g., proportion and balance\] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
41356874|NCT06091202|BEHAVIORAL|CORPs Intervention|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
40836517|NCT04400578|DEVICE|Trichloroacetic acid 85% (TCA)|Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
41022071|NCT00030589|PROCEDURE|UV light therapy|
41356875|NCT06091202|BEHAVIORAL|Minimally Enhanced Usual Care (MEUC)|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
41356876|NCT05932329|BEHAVIORAL|Dietary Advice|Dietary Advice provided
41356877|NCT01017640|OTHER|Laboratory Biomarker Analysis|Correlative studies
41356878|NCT01017640|DRUG|Mitomycin|Given IV
41356879|NCT01017640|DRUG|Veliparib|Given PO
40836518|NCT02679820|DEVICE|Copper T intrauterine device|
40836519|NCT02476123|BIOLOGICAL|Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)|i.v. administration
40836520|NCT05714943|BEHAVIORAL|DigiKnowIt News: Teen|Participants will interact with a multimedia educational website that will teach them about pediatric clinical trials, including topics such as participant rights and safety and different types of procedures used in trials, and will provide strategies for parent-teen shared decision-making about clinical trials.
41022072|NCT01480115|OTHER|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
41356880|NCT03435328|DEVICE|TENS|"* Duration of stimulation: 5 minutes.~* Frequency: will be fixed at 50 Hertz.~* Pulse duration: 250 µs.~* Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it).~* Sessions: only one session"
41356881|NCT05570747|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
41356882|NCT05570747|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
41356883|NCT05285397|DRUG|Liraglutide Pen Injector [Saxenda]|Subcutaneous injection of GLP-1 agonist
41356884|NCT01476033|DIETARY_SUPPLEMENT|nutraceutical group|6 capsules of supplement or placebo for 8wk
41356885|NCT00779597|BEHAVIORAL|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
41356886|NCT03187795|DRUG|Oxybutynin Chloride IR|Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
41356887|NCT03187795|DRUG|Mirabegron|Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
41356888|NCT04229186|DIETARY_SUPPLEMENT|EVOO-C|Each patient will consume 10 mg total daily amount EVOO-C
41356889|NCT04229186|DIETARY_SUPPLEMENT|ROO|Each patient will consume 10 mg total daily amount ROO
41356890|NCT00497939|DRUG|Saw palmetto and sanmiaoshan capsule|
41356891|NCT03240666|OTHER|non applicable|non applicable
41356892|NCT02142075|DRUG|Daptomycin|
41356893|NCT01183728|OTHER|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
41356894|NCT02200549|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
41356895|NCT02200549|DEVICE|calibrated cycle ergometer|The most common device to proform cycle training is calibrated cycle ergometer.
41356896|NCT02200549|DEVICE|calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
41356897|NCT05677906|OTHER|Walking only (Step It Up!)|Participants will meet weekly for 60 minutes and walk together as a group. Participants will progressively build up to walking for 45 minutes at a brisk pace. Walks will start with a check-in and end with stretching as a group.
41356898|NCT05677906|OTHER|Combined (Step It Up! plus Civic Engagement)|Participants in the combined groups will meet weekly for 90 minutes with group members. They will participate in a group walk for 60 minutes followed by 30 minutes of civic engagement aimed at improving walkability in the community
41356899|NCT00090324|DRUG|quetiapine fumarate tablets|
41356900|NCT02223533|DEVICE|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
41356901|NCT02223533|DRUG|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
41356902|NCT03345875|DIAGNOSTIC_TEST|HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment|Women who test HPV positive are offered visual assessment for treatment, with treatment method (cryotherapy, LEEP, or biopsy) based on visual assessment findings.
41356903|NCT05972343|DEVICE|Cryoablation|Takes place at single time point.
41356904|NCT03769792|DIAGNOSTIC_TEST|Blood and faeces tests|During V0 - Laboratory tests, particularly for calprotectin concentration assessment
41356905|NCT03769792|DEVICE|Impedance spectroscopy test|During V1 - the electrical impedance of pelvic floor muscles will be measured
41356906|NCT03769792|DIAGNOSTIC_TEST|Full gynecological and proctological examination|During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
40836521|NCT04602026|OTHER|Best Practice|Receive standard of care
40836522|NCT04602026|BEHAVIORAL|Exercise Intervention|Complete home exercise intervention
40836523|NCT04602026|PROCEDURE|Physical Therapy|Undergo physical therapy
40836524|NCT04602026|OTHER|Questionnaire Administration|Ancillary studies
41356907|NCT03769792|DIAGNOSTIC_TEST|Transanal ultrasonography|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
41356908|NCT03769792|DIAGNOSTIC_TEST|Anorectal manometry|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
41496312|NCT06046040|DRUG|TmPSMA-02 CAR T Cells|TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
41496313|NCT02913092|BEHAVIORAL|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
41496314|NCT03536533|OTHER|Exergame|Each of the 8 exercise sessions will last at least 42 minutes, with an actual training duration of 21 minutes. The participants will be accustomed gradually to the game. On one hand this will be achieved by increasing the difficulty in subsequent levels within the exergame.
41496315|NCT05594264|BEHAVIORAL|HBPStories|The objective of this arm was to pilot test the web-based storytelling program to determine the preliminary impact on blood pressure and medication adherence, and if the web-based approach was an engaging approach for individuals managing hypertension.
41496316|NCT06165250|DRUG|BR1018A|One tablet administered alone
41022073|NCT03922529|BEHAVIORAL|MACRO-I|MACRO-I coaches engage with patients regularly while they are still inpatients, and then by telephone once they are discharged. Coaching incorporates innovative techniques for holistic risk assessment (medical, functional, psychosocial), guidance to initiate CR in a format aligned with each patient's risks and preferences (i.e., CR as either site-based, home-based, or in a hybrid format \[site transitioning to home\]), behavioral prompts based on their personal goals of care, and de-prescribing of sedating medications.
41022074|NCT03922529|OTHER|Usual Care|Participants will receive usual care that is recommended by their providers. MACRO study personnel will follow the participant for the course of the study to assess endpoints in comparison to the MACRO-I arm.
41022075|NCT06317792|OTHER|online exergaming-based physiotherapy programs|The online exergaming-based physiotherapy programs focus on training in shoulder, hip, and knee ROM balance, weight-bearing, strength, weight shifting, and walking based on RF in machine learning to the features selection in patients with PIGD. The training tasks consist of a set of 10 pieces of training (20 min per session, five sessions every week, for 8 weeks). Five exergaming programs were used for training, designed to incorporate an appropriate level of challenge to match the ability and fitness of patients with PD.
41022076|NCT01160107|DRUG|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR \> 50%; 2. The study stop (if PR \<40% and grade 3-4 adverse events \>25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are \< 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are \> 50% and PR rate \> 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
41022077|NCT00753441|PROCEDURE|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
41022078|NCT00753441|PROCEDURE|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
41496317|NCT06165250|DRUG|BR1018A-1|One tablet administered alone
41496318|NCT06165250|DRUG|BR1018B|One tablet administered alone
41022079|NCT02940990|RADIATION|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
41022080|NCT02940990|DRUG|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
41022081|NCT00192725|OTHER|rapid tryptophan depletion|Amino-acid mixture without tryptophan
41496319|NCT06165250|DRUG|BR1018B-1|One tablet administered alone
40836525|NCT02340390|DEVICE|G7|The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
41496320|NCT06165250|DRUG|BR1018C|One tablet administered alone
41496321|NCT06165250|DRUG|BR1018C-1|One tablet administered alone
41496322|NCT00422500|BEHAVIORAL|Questionnaire|Surveys about symptoms, mood, and quality of life.
41496323|NCT00422500|BEHAVIORAL|Telephone Interactive System|Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
41496324|NCT00422500|OTHER|Blood Samples|For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
41496325|NCT01031030|DRUG|cyclophosphamide|
41496326|NCT01031030|DRUG|epirubicin hydrochloride|
41022082|NCT03944122|DEVICE|ultrasound|therapeutical ultrasound were applied to the patients
41356909|NCT04929314|BEHAVIORAL|Systematic Interactive Communication Model to Strengthen Self-Care Regardless of Health Literacy Level|The central element of the intervention is the interactive communication model. A website that contains easy-to-understand knowledge and material about various chronic diseases such as chronic obstructive pulmonary disease, diabetes, heart failure, as well as knowledge and material about wound care, compression treatment and prevention of infections has been developed. Information within each topic is given based on the interactive communication model. The idea is that community nurses should not themselves assess what characterizes an easy-to-understand level or the amount of information for each individual citizen, which seeks to ensure a systematic and uniformity in the work with self-care and more self-sufficient citizens. At the same time, the model makes it possible to take into account the individual citizen's knowledge and competencies (level of HL). Further, the nurses receive specialised education regarding HL to complement their use of the interactive communication model.
41356910|NCT00468273|DRUG|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
41356911|NCT04678349|DIETARY_SUPPLEMENT|PHGG|Subjects will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar, once allowed orally.
41356912|NCT04678349|OTHER|conventional care|follow low fibre diet and anti-diarrhea drugs
41356913|NCT01435564|BEHAVIORAL|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
41496327|NCT01031030|DRUG|fluorouracil|
41496328|NCT01031030|DRUG|methotrexate|
41496329|NCT01031030|OTHER|laboratory biomarker analysis|
41496330|NCT01031030|PROCEDURE|adjuvant therapy|
41496331|NCT03320200|OTHER|CNS-focused treatment|The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.
41496332|NCT03320200|OTHER|Standard Care Treatment|The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
41496333|NCT06423443|BEHAVIORAL|Digital Cognitive Behavioral Therapy|digital cognitive behavioral therapy app
40836526|NCT02340390|DEVICE|Exceed ABT|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
40836527|NCT00025623|DRUG|carboplatin|
41356914|NCT01435564|BEHAVIORAL|pedometer only|Participants in this group will receive only a pedometer.
41356915|NCT03104686|OTHER|Short pasta (dry)|50g available carbohydrate of penne pasta
41356916|NCT03104686|OTHER|Long pasta (dry)|50g available carbohydrate of spaghetti pasta
41496334|NCT06423443|BEHAVIORAL|Health Education|traditional on-line health education app
41496335|NCT06423443|DRUG|TAU|treatment as usual
40836528|NCT00025623|DRUG|cyclophosphamide|
40836529|NCT00025623|DRUG|doxorubicin hydrochloride|
40836530|NCT00025623|DRUG|etoposide|
40836531|NCT00025623|DRUG|vincristine sulfate|
40836532|NCT00025623|PROCEDURE|conventional surgery|
40836533|NCT01994993|DRUG|ampicillin and metronidazole and gentamicin|IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
41022083|NCT05626192|OTHER|Anatomical dissection and Immunohistochemical techniques|Anatomical dissection and description
41022084|NCT02992899|DEVICE|GammaCore/electroCore non-invasive VNS device|Vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) is adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery is 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan is conducted; following an additional 8 minutes, a second VNS delivery is administered, after which another scan is obtained.
41496336|NCT06455098|DEVICE|OMNYPULSE™ Catheter with the TRUPULSE Generator|OMNYPULSE™ Catheter and TRUPULSE™ Generator will be used for PF ablation.
41496337|NCT02752906|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
41496338|NCT02752906|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
41496339|NCT03047434|OTHER||
41496340|NCT00819637|DRUG|arformoterol (RR formoterol)|"Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.~Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses."
41496341|NCT00819637|DRUG|placebo|Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
41496342|NCT00819637|DRUG|levalbuterol|Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.
41496343|NCT05884294|DEVICE|PowerGlide Pro Midline catheter.|The Intervention Group will be represented by hospitalized adult clinical patients who have been identified with difficult intravenous access. These patients will receive an ultrasound-guided insertion of the PowerGlide ProTM Midline 20G (10 cm).
41496344|NCT05755776|DRUG|TMF|switch ETV to TMF
41496345|NCT00566007|PROCEDURE|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
41496346|NCT00566007|DRUG|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
40836534|NCT01994993|DRUG|ampicillin and gentamicin and clindamycin|IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
40836535|NCT01994993|DRUG|gentamicin and Piperacillin- tazobactam|IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
40836536|NCT01994993|DRUG|standard of care antibiotics and metronidazole|IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
40836537|NCT01994993|DRUG|metronidazole, clindamycin, or piperacillin-tazobactam|IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
40836538|NCT00077844|DRUG|Enoxaparin sodium|
40836539|NCT00078065|DRUG|Xcellerated T Cells|
40836540|NCT02170766|DRUG|BIBR 1048 low1|
40836541|NCT02170766|DRUG|BIBR 1048 low2|
40836542|NCT02170766|DRUG|BIBR 1048 medium|
40836543|NCT02170766|DRUG|BIBR 1048 high|
40836544|NCT02170766|DRUG|Pantoprazole|
41356917|NCT03104686|OTHER|Bread|50g available carbohydrate of bread
41356918|NCT03104686|OTHER|Glucose|50g available carbohydrate of glucose monohydrate
41356919|NCT04423224|OTHER|GDFM|Stroke volume variation fluid management
41356920|NCT04423224|OTHER|USUAL CARE - CONTROL|Usual care fluid management
41356921|NCT03011606|PROCEDURE|Robotic Surgery|Robotic Surgery after Focal Ablation Therapy
41356922|NCT03663361|OTHER|SMART Intervention|Ankle rehabilitation with the addition of sensorimotor components
41356923|NCT03663361|OTHER|Standard of Care Intervention|Ankle rehabilitation focused on restoring range of motion, strength and balance
41356924|NCT06135506|PROCEDURE|free-hand ridge splitting|Midcrestal incision will be followed by reflection of full thickness flap. Midcrestal cut without vertical osteotomy will be done using piezosurgery unit, and then the cut will be extended deep to the implant length. The ridge will be expanded progressively using bone wedges. Dental implant fixtures will be placed stably with 1 mm minimal thickness of buccal bone plate. Surgical site will be completely closed, and wound edges will be sutured in a tension-free way.
41496347|NCT00566007|DRUG|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
41496348|NCT01404832|DRUG|Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms|Treat with lansoprazole 30 mg BID for 2 weeks, perform endoscopic examination with esophageal biopsy
41496349|NCT00599963|DRUG|paricalcitol|paricalcitol 1 mg/day
40836545|NCT01818440|OTHER|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
41022085|NCT02992899|DEVICE|Sham gammaCore/electroCore|Sham vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The device is programmed such that no actual stimulation is given to the vagus nerve. The duration of delivery is 2 minutes, one minute into which the HR-PET scan is conducted; following an additional 8 minutes, a second sham VNS delivery is administered, after which another scan is obtained.
40836546|NCT01818440|OTHER|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
40836547|NCT01117935|RADIATION|intensity modulated external beam radiation therapy|"Low risk - 69.6 Gy in 2.4 Gy fractions to prostate~Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes~High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes"
40836548|NCT05025722|OTHER|Non Interventional|This is an observational study.
40836549|NCT06307236|BEHAVIORAL|Emotional Freedom Techniques|Emotional Freedom Technique (EFT), which is included in the energy psychotherapy similar to the cognitive behavioral therapy method, is an easily applicable method that is used to relieve mental problems such as anxiety and stress and has positive results, which has just started to be used in the world and in our country. EFT can be applied safely to all ages and groups.
40836550|NCT03233126|DRUG|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
40836551|NCT04983797|DEVICE|OPTRELL Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).
40836552|NCT05585515|BEHAVIORAL|Sleep deprivation|Total sleep deficit of consecutive 8 hours
41022086|NCT02992899|DRUG|O-15 water|Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
41496350|NCT00942435|DRUG|YM150|oral
41496351|NCT00942435|PROCEDURE|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
40836553|NCT05585515|BEHAVIORAL|Sleep restriction|Total sleep deficit of cumulative 8 hours
40836554|NCT06354374|DIAGNOSTIC_TEST|volume survey|All subjects will receive oral hygiene instructions and, if needed. A dental cleaning of plaque and calculus. After calibration using digital photographs and digital intraoral scans, CBCT scans will be taken as a prerequisite for dental implant treatment protocol. one dentist who will not be involved in the screening phase will obtain all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width) to avoid any bias. After finishing data collection, a customized treatment plan for each patient will be performed and dental implant treatment will be completed for each patient.
41356925|NCT06135506|PROCEDURE|AI/guided ridge splitting|"The patient specific guides will be placed and fixed by monocortical osteosynthesis screws at the pre-planned positions at the labial buccal mucosa.~A midcrestal cut will be performed on the crest of alveolar ridge guided by the guide slits. The cuts will be expanded progressively using bone wedges through the guide slits gradually lateralize and expand the labial alveolar plate of bone, so the labial cortex will move through the intentionally created micro gap till it touches the fitting aspect of the patient specific guide. Implant drills will be inserted through the guiding holes in the surgical guide and the implant osteotomy sites will be prepared. Finally, implants will be inserted in the osteotomy sites using torque-wrench in a self-tapping fashion engaging palatal and basal bone for primary stability."
41356926|NCT05675202|DRUG|TQ-B3525|TQ-B3525 is a new PI3K α/δ Kinase inhibitor
41356927|NCT05826431|DEVICE|Cubii elliptical|Low impact, portable, and compact elliptical for seated use.
41356928|NCT05909618|DRUG|Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]|5 mg/kg solution for injection
40836555|NCT03715296|DRUG|Lenalidomide 25mg|Lenalidomide 25mg/d PO d1-10 Plus Rituximab 375 mg/m2 IV d1, Cyclophosphamide 750mg/m2 IV d2, Doxorubicin 50mg/m2 IV d2, Vincristine 1.4 mg/m2 IV d2, Prednisone 60 mg/m2 PO d2-6 OR Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5\*\[GFR(ml/min)+25\]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3,
40836556|NCT03678233|DRUG|AndroGel 16.2 mg/L|Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
40836557|NCT04031872|DRUG|LY3200882|Combination treatment with LY3200882 and capecitabine
41496352|NCT06408948|DRUG|[14C]SHR7280|Patients will receive single dose of orally \[14C\]SHR7280 on Day 1.
41496353|NCT03263975|OTHER|Gatorade or Enterade|Commercially available oral rehydration therapies
40836558|NCT02180477|DRUG|UHAC 62 XX - TF1 tablet|
40836559|NCT02180477|DRUG|UHAC 62 XX - TF2 tablet|
40836560|NCT02180477|DRUG|UHAC 62 XX - capsules|
40836561|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
40836562|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
40836563|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
40836564|NCT05653440|BEHAVIORAL|Accuracy-maximized condition|Naming treatment condition in which the target will be immediately provided for repetition at picture onset.
40836565|NCT05653440|BEHAVIORAL|Effort-maximized condition|Naming treatment condition in which participants will have up to 10 seconds to respond before the target is provided for repetition.
40836566|NCT05653440|BEHAVIORAL|Effort-accuracy balanced condition|Naming treatment condition in which naming deadlines will be determined based on the balanced effort-to-accuracy benefit ratio formalized above, calculated on clinician-provided accuracy and response time ratings. Deadlines will be recalculated session-by-session to adjust to participant-specific treatment gains over time.
41356929|NCT05909618|DRUG|Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]|3 mg/mL solution for injection
41356930|NCT01485185|DRUG|Gabapentin lower dose|Repeat, oral dose
41356931|NCT01485185|DRUG|Donepezil|Repeat, oral dose
41496354|NCT02336724|DRUG|Famitinib|
41496355|NCT02465294|DIETARY_SUPPLEMENT|Probiotic|This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
41496356|NCT02465294|BEHAVIORAL|Behavioral lifestyle intervention|All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
41496357|NCT02465294|OTHER|Placebo|This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.
40836567|NCT05521633|DRUG|Metformin and Pioglitazone|Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
40836568|NCT06066073|DRUG|Lavender Oil|Twenty drops of lavender oil was added the distal water which fill the vaporizer which were placed in the waiting room. The patients inhaled the vapors of the lavender oil 20 minutes before starting the dental procedures
40836569|NCT06066073|DRUG|Distal Water|The patients inhaled vapors of the distal water in the waiting room 20 minutes before starting dental procedures
40836570|NCT02128945|OTHER|[18F] - Fludarabine PET/CT|\[18F\] - Fludarabine PET/CT before treatment
40836571|NCT00740623|DRUG|Carisbamate|800 mg/day for 14 weeks
40836572|NCT00740623|DRUG|placebo|placebo for 14 weeks
40836573|NCT00740623|DRUG|Carisbamate|1,200 mg/day for 14 weeks
40836574|NCT06438796|DRUG|Blinatumomab|Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation
40836575|NCT01345565|DRUG|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
41022087|NCT04097067|RADIATION|Radiation Therapy|Low dose radiotherapy with 20 Gy (10x2Gy)
41022088|NCT04980638|BIOLOGICAL|ER004|Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26
41356932|NCT01485185|OTHER|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
41356933|NCT01485185|OTHER|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
41496358|NCT02465294|OTHER|Blood Test|All subjects will have blood tests performed.
41496359|NCT02465294|DIETARY_SUPPLEMENT|Probiotic|This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
41496360|NCT04500093|PROCEDURE|Capsulotomy with Repair|Capsulotomy with Repair
41496361|NCT04500093|PROCEDURE|Capsuloectomy|Capsuloectomy
41496362|NCT04620928|BEHAVIORAL|Concepts|Images and sounds that are characteristic of various common objects.
41496363|NCT03146962|DRUG|Vitamin C|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
41496364|NCT04051463|DRUG|Netarsudil Ophthalmic Solution|Netarsudil eye drops instilled once daily
40836576|NCT01186640|DRUG|Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|"I. First treatment phase: Chemoimmunotherapy A-FMC~Alemtuzumab:~Cycle 1+2:~10 mg s.c., days 1-3~Cycle 3+4:~CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13."
41022089|NCT01624545|OTHER|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
41022090|NCT02554773|DRUG|Fitusiran (SAR439774)|Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
41022091|NCT05549674|OTHER|The COPAIN study is observational. There is no intervention.|The COPAIN study is observational. There is no intervention.
41022092|NCT02209324|DRUG|ASP2151|
41022093|NCT02188823|BEHAVIORAL|Low carbohydrate diet|
41022094|NCT02323464|PROCEDURE|Surgery for colorectal cancer|Includes open and minimally invasive surgery for colon- and rectal cancer
41356934|NCT01485185|DRUG|Gabapentin higher dose|Repeat, oral dose
41356935|NCT02137902|BEHAVIORAL|Tobacco/Physical Activity Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.
41356936|NCT02137902|BEHAVIORAL|Diet plus BP/CHOL Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
41356937|NCT05992051|BEHAVIORAL|Exercise Therapy|Exercise therapy is considered as the integral component of interventions for chronic non-specific neck pain. It includes different type resistance training, range of motion exercises and stretching exercises to improve neck condition and release symptoms.
41356938|NCT00073541|DRUG|EMD 72000|
41356939|NCT05162495|DEVICE|BioStation T101 and TeraTube|Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.
41356940|NCT05512195|RADIATION|New delineation approach|New delineation approach
41356941|NCT01888380|PROCEDURE|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
41356942|NCT01888380|PROCEDURE|Conventional autopsy|
41356943|NCT04925466|DEVICE|CPAP at pressure of 10 cmH2O|Patients used CPAP with the pressure of 10 cmH2O during overnight polysomnography
41356944|NCT04925466|DEVICE|CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
41022095|NCT02323464|OTHER|No Interventions|This is a control group from the population. They are not scheduled for surgery
41356945|NCT05170516|PROCEDURE|4 °C colled saline irrigation|In Experimental Group A , 4 °C colled saline irrigation was used during impacted third molar surgery
41356946|NCT05170516|PROCEDURE|10 °C cooled saline irrigation|Experimental Group B, 10°C colled saline irrigation was used during impacted third molar surgery.
41356947|NCT05170516|PROCEDURE|Room temperature saline irrigation|In Control Group A and B, salin irrigation at room temperature was used during impacted third molar surgery.
41356948|NCT03480529|DRUG|drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom|Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
41356949|NCT04623281|DEVICE|Sixty device|Prototype wearable hydration monitor to be worn by patient during dialysis and at night
41356950|NCT02681094|DRUG|Dapagliflozin|5mg, orally, Green, plain, diamond-shaped, film-coated tablet
41496365|NCT04051463|DRUG|Placebo|Placebo eye drops instilled once daily
41496366|NCT02684630|DEVICE|Trima Accel System|Platelet Apheresis Procedure
41496367|NCT04472091|DEVICE|Genicular artery embolization (GAE)|Participants will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ).
41496368|NCT01234922|DRUG|lisinopril|Given orally
41496369|NCT01234922|DRUG|losartan potassium|Given orally
41496370|NCT01234922|OTHER|laboratory biomarker analysis|Correlative studies
41496371|NCT01234922|DRUG|benazepril hydrochloride|Given orally
41496372|NCT01234922|DRUG|ramipril|Given orally
41496373|NCT04335786|DRUG|Valsartan (Diovan)|"At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.~Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d."
41496374|NCT04335786|DRUG|Placebo oral tablet|At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
41496375|NCT02074917|PROCEDURE|Anatomical ACL reconstruction|Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.
41356951|NCT02681094|DRUG|Placebo for Dapagliflozin|Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
40836577|NCT01186640|DRUG|Alemtuzumab|maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
40836578|NCT06507475|DRUG|Semaglutide|Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
40836579|NCT01739803|BEHAVIORAL|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
40836580|NCT01498016|DRUG|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
40836581|NCT03871660|DEVICE|FreeStyle Libre Pro|Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
40836582|NCT05099159|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
40836583|NCT05099159|DRUG|Placebo|Matching placebo orally once daily
40836584|NCT06334614|DEVICE|iReach|The iReach Device group will take part in playful multisensory motor and spatial activities for one month both at the clinic and at home with the medical device iReach.
40836585|NCT03062241|PROCEDURE|Cryoablation|After left atrial appendage (LAA) thrombus exclusion, the transseptal puncture will be performed and intravenous heparin will be administered to achieve Activated Clotting Time (ACT) ≥300 seconds.The pulmonary vein (PV) isolation will be performed. Optimal cryoballoon positioning will be confirmed by PVs angiography. Pulmonary veins isolation will be confirmed by entrance/exit block using appropriate catheter. During cryoablation of the right PVs, high-output right phrenic nerve stimulation will be performed using a diagnostic catheter placed in the superior vena cava. Whenever decrease/loss of pacing capture will be observed, cryoablation will be immediately terminated.
40836586|NCT02759991|DRUG|Hecolin|0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
40836587|NCT02759991|DRUG|Hepa-B|1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
41022096|NCT01427712|DRUG|Pancrelipase|
41356952|NCT02681094|DRUG|Saxagliptin|5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
41356953|NCT02681094|DRUG|Placebo for Saxagliptin|Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
41356954|NCT03356327|DRUG|Actitan F|A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children
41356955|NCT03356327|DRUG|Standard Oral Rehydration|Standard oral rehydration as suggested by ESPGHAN guidelines
41496376|NCT03535389|DIAGNOSTIC_TEST|Knee 4DCT|Dynamic knee 4DCT
41496377|NCT05394649|DEVICE|Intravascular Lithotripsy|"A new device has been designed by Shockwave Medical Inc. for the treatment of calcified vascular lesions to support stent delivery: the C2 Shockwave Medical® (IVL), Inc. coronary lithotripsy system. The system is based on lithotripsy to induce microfractures in the calcified plaque before low-pressure balloon dilation. The C2 Shockwave Medical® coronary lithotripsy (IVL) system consists of an IVL Catheter with two lithotripsy emitters enclosed within an integrated balloon, an IVL Generator, and an IVL Connector Cable."
41496378|NCT05394649|DEVICE|Rotational Atherectomy|Rotational Atherectomy is a technique of calcic coronary plaque preparation based on the debulking of superficial calcium by a high-speed burr in order to improve vessel compliance and immediate vessel lumen gain before stenting.
41496379|NCT01841476|DRUG|POL6326|
41496380|NCT02766374|BEHAVIORAL|Heart rate variability biofeedback|"Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA)."
41022097|NCT06569043|OTHER|Breakfast Bar|Packaged breakfast bar product available in retail stores
41022098|NCT00600821|DRUG|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
41022099|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
41022100|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
41356956|NCT02216539|BEHAVIORAL|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
41356957|NCT02216539|PROCEDURE|Lung transplantation|
41356958|NCT02216539|OTHER|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
41356959|NCT05954273|PROCEDURE|Osseodensification crestal sinsus graft|Osseodensification Mediated Maxillary Sinus Crestal Grafting
41356960|NCT00387621|DRUG|Nesiritide|The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
40836588|NCT05558215|OTHER|Otago Exercise Program|"The Otago Exercise Program (OEP) is a CDC endorsed evidence-based falls prevention program for older adults. It has not been well studied with individuals with dementia. It is comprised of a brief warm up/flexibility series, lower extremity strengthening, and balance exercises. The same menu of exercises is used for all participants, but exercises are progressed based upon individual performance. For the purposes of this study, three 25-minute video recorded versions of OEP will be rotated for use, all of which include brief flexibility activities, strengthening, and balance exercises. Strengthening exercises will be limited to body weight resistance for ease of instruction, safety, and consistency. Balance exercises involve changes in base of support in static and dynamic contexts, with challenge progressively increased by decreasing arm support during training (from 2-hands, to 1-hand, to no hands)."
40836589|NCT04903145|DIAGNOSTIC_TEST|REOM|To compare data generated by the REOM device with data from the tremoflo C-100 device
40836590|NCT02975752|GENETIC|LC-RT-PCR and NGS|highly sensitive PCR vs. multiplex targeted-resequencing
40836591|NCT04941937|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
40836592|NCT04941937|DRUG|Thalidomide|100mg/d, Po. on day1-28
40836593|NCT04941937|DRUG|Lenalidomide|PO,Lenalidomide 25mg once daily from D1-21
40836594|NCT04941937|DRUG|Pomalidomide|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
40836595|NCT04941937|DRUG|Dexamethasone|Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
40836596|NCT03879421|PROCEDURE|Accelerated corneal collagen cross linking|This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.
40836597|NCT00563043|PROCEDURE|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
40836598|NCT00635089|DRUG|reslizumab|
40836599|NCT01816555|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
40836600|NCT03345576|DEVICE|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
40836601|NCT03345576|DRUG|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
40836602|NCT04093804|DEVICE|Glenosphere size for Reverse Shoulder Arthroplasty|Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
40836603|NCT01958892|PROCEDURE|TURP, TUERP|
40836604|NCT00899158|OTHER|immunologic technique|
40836605|NCT00899158|OTHER|laboratory biomarker analysis|
40836606|NCT00899158|PROCEDURE|biopsy|
40836607|NCT00046930|BIOLOGICAL|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
40836608|NCT00046930|BIOLOGICAL|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
40836609|NCT00046930|DRUG|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
40836610|NCT00046930|DRUG|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
41160302|NCT03261713|DEVICE|Virtual reality|Virtual reality training is provided using Jintronix Rehabilitation software. A Kinect camera captures the movements of the participant using infrared technology and allows them to control an avatar, which interacts with an activity. Several games and activities are available to train standing balance (ex. slalom skiing), reaching (ex. planting seeds/harvesting tomatoes), stepping (ex. whack-a-mole), gentle strengthening (ex. knee extensions) and aerobic exercises (ex. marching on the spot). Game and activity difficulty can be increased by requiring more repetitions, or greater speed, distance and/or accuracy. Specific games and activities, and their parameters are customized for each participant. The exercise plan is performed 5 times a week for 6 weeks for 30 minutes at each session.
40836611|NCT00046930|DRUG|zosuquidar trihydrochloride|"Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3."
40836612|NCT00046930|DRUG|Placebo|"Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored."
40836613|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Lower Back Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 8 weeks with specific exercises to target low back pain.
41022101|NCT00600821|DRUG|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
41022102|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
41022103|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
40836614|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Persistent Post Mastectomy Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 4 weeks with specific exercises to mitigate persistent post mastectomy pain ahead of the surgery.
40836615|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Migraine|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 6 weeks with specific exercises to target migraine pain.
40836616|NCT04806360|PROCEDURE|ACRF surgery|A new surgical procedure that previously proposed by our team.
41356961|NCT00387621|DRUG|Placebo|The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
41496381|NCT02766374|BEHAVIORAL|Placebo|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
41496382|NCT03023176|BIOLOGICAL|Fluzone® standard IIV3|Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection
40836617|NCT04806360|PROCEDURE|conventional anterior surgery|Anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
40836618|NCT04806360|PROCEDURE|conventional posterior surgery|Laminectomy and fusion surgery or laminoplasty surgery.
40836619|NCT02274259|DRUG|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
40836620|NCT02274259|DRUG|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
41022104|NCT05696197|BEHAVIORAL|Targeted touchscreen training|Participants will practice the Swipe Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants form different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 minutes per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14 seconds. Instruction and answers are also included. Feedback will be provided by means of knowledge of performance. On each training day, participants will receive a reminder on the training tablet.
41356962|NCT00387621|DRUG|Saline|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
41356963|NCT05124327|OTHER|QI project- usage of RPM|close monitoring through RPM to analyze feasibility and compare readmission rates
41356964|NCT02931955|OTHER|Blood draw, stool collection.|Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.
41356965|NCT02860676|DRUG|cirmtuzumab|cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.
41496383|NCT03023176|BIOLOGICAL|Fluzone® standard IIV3 Pediatric Dose|Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
41496384|NCT02430285|PROCEDURE|Endoscopic Ultrasound|Endoscopic Ultrasound
41496385|NCT02430285|DEVICE|Olympus 180 series echoendoscope|
40836621|NCT01926769|DRUG|Metformin|
40836622|NCT00955149|DRUG|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
40836623|NCT05948618|BEHAVIORAL|Embodied Conversational Agent|The ECA- PRO measures will included PROMIS Profile measures, which include depression, anxiety, fatigue, pain intensity, and interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. In order to reduce boredom and confusion, equivalent forms of different items will be selected from the items pools. In this way, participants are not answering the same questions twice within one session.
40836624|NCT05948618|BEHAVIORAL|REDCap Survey|An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
40836625|NCT03764267|DRUG|Remifentanil|"Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain"
40836626|NCT03764267|DRUG|general anesthetic|general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
40836627|NCT05996029|COMBINATION_PRODUCT|Digital Smoking Cessation|The core technology of the study is a smoking cessation assistance practice service driven by a machine learning algorithm. The small programs used by the intervention group in this study included smoking cessation service packages based on cognitive behavioral therapy and online guidance from medical staff on staff, and more digital smoking cessation tools.
40836628|NCT05363540|PROCEDURE|pre-incisional parasternal intercostal block|LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used
41496386|NCT04340609|BIOLOGICAL|Mesenchymal Stem Cells|The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.
41356966|NCT02368158|OTHER|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors|During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
41356967|NCT06326073|PROCEDURE|Non Surgical Periodontal Treatment|Phase 1 periodontal (full mouth debridement) treatment was applied to groups with periodontitis in one session.
41496387|NCT00195637|DRUG|Immune Globulin|
41496388|NCT01997216|DEVICE|Delefilcon A multifocal contact lens|Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
41496389|NCT01997216|DEVICE|Lotrafilcon B multifocal contact lens|Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
41496390|NCT02965963|DRUG|Dopamine|
41496391|NCT02965963|DRUG|Metoclopramide|
41496392|NCT02965963|DRUG|Placebos|
41496393|NCT02965963|OTHER|Rest|
41496394|NCT02965963|OTHER|Exercise - 60%|60% of VO2max
40836629|NCT05363540|PROCEDURE|post-incisional parasternal intercostal block|LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
40836630|NCT03626545|DRUG|Canakinumab|Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)
40836631|NCT03626545|DRUG|Docetaxel|Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle
40836632|NCT03626545|OTHER|Placebo|Placebo, sub-cutaneous, admnistered at the RP3R defined in Part 1-safety run-in.
40836633|NCT01818492|BIOLOGICAL|NI-0501|
41022105|NCT05254379|DEVICE|tDCS|"tDCS is a painless brain stimulation treatment that uses direct electrical currents (at a constant, low-intensity level) to stimulate specific parts of the brain and help modulate neuronal activity. Participants will receive a series of tDCS treatments during the Intensive Outpatient Program (IOP) coupled with blood and saliva collections.~Participants will administer a stimulation session via the Soterix 1x1 tDCS mini-CT Stimulator, after being provided a single-use code to unlock the device by the research staff once proper contact quality is achieved. After the participant enters the unlock code, the screen on the device will show a timer that counts down the minutes until the end of the session. After 20 min, the device will turn off automatically and the study staff will instruct the participant to remove the headset and discard the sponges and to store safely all materials for the next session."
41022106|NCT04726865|OTHER|Naser Al-Husban|voluntary completion of an online questionnaire
41022107|NCT00764075|DEVICE|Beutel TM|application of BeutelTM
41022108|NCT00764075|OTHER|standard|standard procedure will be applied but no Beutel TM software
41022109|NCT00764075|DEVICE|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
41022110|NCT00704145|DEVICE|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
41022111|NCT00253526|DRUG|bevacizumab|
41022112|NCT00253526|DRUG|gemcitabine hydrochloride|
41022113|NCT00253526|PROCEDURE|adjuvant therapy|
41022114|NCT00253526|PROCEDURE|anti-cytokine therapy|
41022115|NCT00253526|PROCEDURE|antiangiogenesis therapy|
41022116|NCT00253526|PROCEDURE|antibody therapy|
41022117|NCT00253526|PROCEDURE|biological therapy|
41022118|NCT00253526|PROCEDURE|chemotherapy|
41022119|NCT00253526|PROCEDURE|conventional surgery|
41022120|NCT00253526|PROCEDURE|growth factor antagonist therapy|
41022121|NCT00253526|PROCEDURE|monoclonal antibody therapy|
41022122|NCT00253526|PROCEDURE|surgery|
41022123|NCT02181868|OTHER|Biodegradable and titanium fixation used in mandibular fractures.|
41160303|NCT03261713|DEVICE|Control|Participants in the control group are provided with an iPad which contains a selection of apps suited for memory (ex. memory card game), cognition (Sudoku, cross-word), visual tracking (word search) and fine motor skills (ex. writing, whack-a-mole). Participants are instructed to perform their exercise plan 5 times a week for 6 weeks for 30 minutes at each session.
41022124|NCT00151801|DRUG|estroprogestins|
41022125|NCT00151801|DRUG|interferon-beta 1a|
41496395|NCT02965963|OTHER|Exercise - 85%|85% of VO2max
41496396|NCT03709823|DRUG|Cytisine|film coated tablet containing 1.5 mg cytisine in a single tablet
41496397|NCT03709823|DRUG|Placebo Comparator|1.5 mg cellulose powder to match final weight of the cytisine tablet
41496398|NCT03709823|BEHAVIORAL|Behavioral support|12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
41496399|NCT04399486|OTHER|Physical Therapy|Physical Therapy is a therapeutic exercise, education and functional activities provided on a one to one basis with a licensed Physical Therapist to meet functional goals.
41496400|NCT04298060|DRUG|DAS181|SD (4.5mg/day), HD (9mg/day)
41496401|NCT04298060|DRUG|Placebo|Placebo 0mg/day
41496402|NCT02781870|PROCEDURE|LiquiBand Fix8 glue fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
41496403|NCT02781870|PROCEDURE|No-fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
41160304|NCT04893785|DRUG|Cabozantinib and Temozolomide|"Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.~Patients will be required to attend clinic on Day 1, Day 8, Day 14 and Day 22 of every 4 week cycle.~Patients will return to clinic at 30 days (+/- 5 days) of their last dose of cabozantinib or temozolomide (whichever is discontinued last), for an end of treatment visit.~Following their end of treatment visit patients will be followed-up 3-monthly during routine clinic appointments to collect data on further anti-cancer treatment and survival. Follow-up will continue until 6 months after the last patient stops study treatment or up to 18 months after the last patient is randomised, whichever is sooner."
41160305|NCT02269683|PROCEDURE|Robot-assisted distal pancreatectomy|
41160306|NCT02269683|PROCEDURE|Laparoscopic distal pancreatectomy|
41356968|NCT04241627|BEHAVIORAL|Cell Phone Support|Cell Phone Support includes short phone calls (\<5 minutes) made each weekday by a human AF to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services. Cell Phone Support calls focus on assisting AYAs in identifying and accessing resources and support from their natural environments, such as finding ways they can receive needed help from their families, peers, medical teams, and communities. Live Text Support will deliver the same intervention, by text message.
41356969|NCT00000642|DRUG|CD4-IgG|
40836634|NCT05042609|DRUG|TRS01|TRS01 eye drops Dosed four times a day (QID)
41356970|NCT05758493|DIAGNOSTIC_TEST|124I-Evuzamitide|Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
41356971|NCT02092142|BIOLOGICAL|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
41022126|NCT05024695|DEVICE|MINIject™ Implant|The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.
41022127|NCT06332794|DEVICE|KOKU4PD|Exercise at home using the KOKU app for 4 weeks.
41022128|NCT03529630|OTHER|Inverted syringe|Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
41356972|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)|"Phase 1 comprises the dose-escalation part of the study and is designed to determine the recommended phase 2a dose regimen (RP2D-R) and/or the maximum tolerated dose-regimen (MTD-R) for MP0533 monotherapy.~Once the RP2D-R or MTD-R has been selected based on the dose escalation part, the study will proceed into the phase 2 expansion part and up to 30 additional patients will be treated."
41356973|NCT06212518|OTHER|GENPOP ad libitum fluid intake|Unrestricted fluid intake.
41356974|NCT06212518|OTHER|GENPOP fluid restriction|In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).
41356975|NCT06212518|OTHER|ATHLETE ad libitum fluid intake|No restriction on fluid intake
40836635|NCT05042609|DRUG|FDA approved steroid eye drop (masked)|FDA approved steroid eye drop Dosed four times a day (QID)
41160307|NCT01870414|OTHER|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes \[2, 17\], temperature of 4º C \[22, 24\], water level at 20 cm
41160308|NCT00321529|DEVICE|motion analysis by durometer|
41160309|NCT03314233|PROCEDURE|DING|"Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol."
41160310|NCT06023134|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.
41160311|NCT06023134|DIAGNOSTIC_TEST|Right heart catheterization|"Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload."
40836636|NCT01859845|OTHER|Smartphone|"Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research."
41022129|NCT00684580|OTHER|Data Collection|Continuing review of outcomes and late toxicities
41022130|NCT03146702|OTHER|Quality of Life|Patients self administor quality of life questionnaires such as Minnesota Living with Heart Failure Questionnaire and EmPHasis-10 questionnaire
41160312|NCT06439147|PROCEDURE|U shaped capsular incision during capsulorrhaphy|Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip,Incision is done with its base proximally. The transverse limb is 1 cm proximal to femoral neck base
41356976|NCT06212518|OTHER|ATHLETE restricted fluid intake|Not permitted to drink during training session.
41356977|NCT02712008|DRUG|REGN910-3|Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
41356978|NCT02712008|DRUG|Intravitreal Aflibercept Injection (IAI)|
41356979|NCT02271620|PROCEDURE|nasal allergen provocation test|nasal allergen provocation test
41356980|NCT00564135|PROCEDURE|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
41356981|NCT01072500|BEHAVIORAL|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
40836637|NCT05781646|DIAGNOSTIC_TEST|Xpert MTB/RIF|CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).
40836638|NCT02914561|DRUG|Filgotinib|Filgotinib tablets administered orally once daily.
40836639|NCT02914561|OTHER|Placebo|Placebo administered orally once daily.
40836640|NCT05623111|DRUG|Incobotulinumtoxin-A 100 UNIT Injection|Perineural injection
40836641|NCT05623111|DRUG|Saline|Placebo containing trace amounts of human albumin and sucrose, diluted with 5ml of sterile saline.
40836642|NCT00318331|DRUG|Glutamine|Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
40836643|NCT00421642|DRUG|Adalimumab|The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.
40836644|NCT05579769|DRUG|Ruxolitinib|Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
40836645|NCT05579769|DRUG|Mesna|Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.
40836646|NCT05579769|DRUG|Anti-thymocyte globulin (ATG)|Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
40836647|NCT05579769|DRUG|Cyclosporine|Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
40836648|NCT05579769|DRUG|Cyclophosphamide|Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
40836649|NCT05579769|DRUG|Fludarabine|Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous
40836650|NCT05579769|DRUG|Methotrexate|Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
41022131|NCT05539950|OTHER|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation helps patients maximize functional potential due to progressive deconditioning or acute decompensation following an acute medical event. This intervention is medically supervised and individualized according to their results of the cardiopulmonary Exercise Testing (CPET).
41022132|NCT05539950|OTHER|Health education|Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.
41022133|NCT05087940|DRUG|Add-on therapy|Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
41022134|NCT05383677|DRUG|Anifrolumab|Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
41160313|NCT06439147|PROCEDURE|T-shaped capsular incision diuring capsulorraphy|Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip done by two incisions: Vertical limb parallel to femoral neck axis and a transverse one parallel to the inguinal ligament resulting into two flabs.
41160314|NCT00462202|DRUG|sulodexide|
41160315|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of SOCS3 gene|Detection of expression of SOCS3, in each samples using Real-Time PCR
41160316|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of IFN-α gene|Detection of expression of IFN-α gene in each samples using Real-Time PCR
41160317|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of IFN-β gene|Detection of expression of IFN-β gene in each samples using Real-Time PCR
41160318|NCT02264418|DRUG|ODM 203|ODM 203
41160319|NCT02264418|DRUG|ODM 203|ODM 203
41356982|NCT01072500|BEHAVIORAL|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
40836651|NCT05579769|RADIATION|Total Body Irradiation (radiation treatment)|"Days -7, -6, -5 and -4 6.2.3 Target Dose 1200 cGy total dose delivered 150 cGy per treatment fraction delivered BID over 4 days with 6 MV photons.~Dose rate should be \< 10 cGy/min in patients treated at extended SSD (450-500 cm) in the TBI couch and will be less than 15 cGy/min in young children and infants treated at extended SSD (200-220 cm) on the floor.~Intra-fraction interval should be 6 hours. Custom posteriorly placed (PA only) partial transmission lung shields (blocks) will be used to reduce the average dose to the lung to approximately 1000 cGy total dose.~An additional 400 cGy supplemental testicular radiation delivered in 2 fractions of 200 cGy delivered for males with lymphoid lineage leukemia."
40836652|NCT05579769|DRUG|Bone marrow infusion|Day 0
40836653|NCT05579769|DRUG|Busulfan|Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.
40836654|NCT05579769|DRUG|Thiotepa|Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous
40836655|NCT00906958|DEVICE|Nexus Flow Generator|The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.
40836656|NCT00906958|DEVICE|VPAP Flow Generator 25|Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
40836657|NCT05490966|OTHER|isometric trunk extensor muscles fatigue|Participants will perform three sets of intermittent isometric efforts between 50 and 60 percents of their maximal isometric strength. A padded force sensor will be placed approximately at the level of the 7th thoracic vertebrae. The first two sets will last six minutes each, while the third set will last three minutes. Between each set participants will rest for two minutes.
40836658|NCT04316156|DEVICE|Uincare Homeplus|Interactive digital healthcare system
40836659|NCT04316156|OTHER|Brochure|Brochure
40836660|NCT06506890|OTHER|Use of C-Polar coated HVAC Filter versus conventional HVAC Filter|comparing the difference in reduction of bioaerosols between HVAC filters.
41022135|NCT05383677|DRUG|Placebo|Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
41022136|NCT04788992|OTHER|Intervention group|Dementia care training consists of dementia care e-books, dementia virtual reality activity and peer support program.
41022137|NCT04788992|OTHER|Control group|Dementia care training consists of dementia care e-books and peer support program without dementia virtual reality activity
41022138|NCT03598998|BIOLOGICAL|Pembrolizumab|Given IV
41160320|NCT06162806|PROCEDURE|ultrasound guided caudal epidural block using 1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl|injection of local anesthetic mixture(Bupivacaine +Fentanyl ) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
40836661|NCT02804750|DRUG|CORT125134|
40836662|NCT06464861|BIOLOGICAL|CD19-CAR-NK/T|Cord blood derived CD19 CARNK sequential Treatment with 7x19 CAR-T
40836663|NCT02845076|OTHER|Protocol for weaning of noninvasive ventilation|3 protocols for weaning of noninvasive ventilation will be compared
40836664|NCT04391166|OTHER|Non invasive visual acuity testing|This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.
40836665|NCT03481491|OTHER|transcranial magnetic stimulation of the cerebellum|The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.
40836666|NCT04659694|OTHER|Wellness programme provided by Oomph! Wellness company|The Oomph! wellness programme empowers older adults to lead a full life for life. It focuses on building an individual-centred programme that consists of a varied exercise and activity plans including days out. All of these, aims in improving the physical and psychosocial wellness in older adults. This intervention is a three day training session for care home staff to understand and learn how to facilitate care activities within their care home.
40836667|NCT01771614|BEHAVIORAL|Exercise|
40836668|NCT01771614|PROCEDURE|Hyperglycemia|
40836669|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with in person meetings.
40836670|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with emails.
40836671|NCT05531721|OTHER|Observation|Observation and retrospective data collection
40836672|NCT02790814|DEVICE|Moyo strap-on|Continous measurements
40836673|NCT02790814|DEVICE|Hand-held fetoscope|Intermittent measurements
40836674|NCT00846716|DRUG|Pioglitazone add on to SU or biguanide|As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
40836675|NCT00846716|DRUG|SU or Biguanide|As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
41022139|NCT03598998|DRUG|Pralatrexate|Given IV
41022140|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fed condition
41022141|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fasted condition
41022142|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fed condition
41022143|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fasted condition
40836676|NCT03645317|DIAGNOSTIC_TEST|Blood tests & cardiac imaging|Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
40836677|NCT04356482|BIOLOGICAL|convalescent plasma|"In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case.~In phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated."
40836678|NCT04087161|OTHER|Nephrocheck bed side testing of AKI|Usage of Nephrocheck system to assess AKI after open TAAA repair
40836679|NCT06481085|DRUG|HDM1002 50 mg|HDM1002 tablets, 50 mg once daily, 12 weeks
40836680|NCT06481085|DRUG|HDM1002 100 mg|HDM1002 tablets, 100 mg once daily, 12 weeks
40836681|NCT06481085|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily, 12 weeks
40836682|NCT06481085|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily, 12 weeks
40836683|NCT06481085|DRUG|HDM1002 200 mg BID|HDM1002 tablets, 200 mg twice daily, 12 weeks
40836684|NCT06481085|DRUG|Placebo|Matching placebo will be provided
40836685|NCT02496923|DEVICE|High flow nasal oxygen therapy (Optiflow™)|
40836686|NCT02496923|DEVICE|Standard oxygen therapy (Hudson Type face mask or nasal prongs)|
40836687|NCT02559414|DRUG|Aspirin|
40836688|NCT02559414|DRUG|Clopidogrel|
40836689|NCT05545644|BEHAVIORAL|Brief Family-Involved Treatment for Alcohol Use Disorder|Up to 3 sessions of counseling involving a patient with alcohol use disorder and a concerned family member
40836690|NCT05365737|OTHER|Oral rinse|Participants use mouthwasher for a given time.
40836691|NCT05365737|OTHER|Saliva harvest|Non-stimulated saliva harvesting
41022144|NCT01788540|DRUG|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
41022145|NCT00764348|OTHER|no treatment|
41022146|NCT03412643|DRUG|Doxorubicin|60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
41022147|NCT03412643|DRUG|Cyclophosphamide|600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
41022148|NCT03412643|DRUG|Weekly Paclitaxel|80 mg/m2 IV weekly for 12 doses
41022149|NCT03412643|DRUG|Trastuzumab|loading dose of 8 mg/kg IV; then 6 mg/kg IV every 3 weeks for Cycles 2-4
41022150|NCT03412643|DRUG|Pertuzumab|loading dose of 840 mg IV; then 420 mg IV every 3 weeks for Cycles 2-4
41022151|NCT03412643|DIAGNOSTIC_TEST|Celcuity CELx HSF|Prior to drug interventions 3, 4,and 5, the Celcuity CELx HSF diagnostic test will be conducted to assess HER2 signaling activity
41022152|NCT06431763|DRUG|Inclisiran sodium|300 mg s.c. administered at day 1 and day 90
41022153|NCT06431763|DRUG|BPA|180 mg daily per oral
41356983|NCT03820804|OTHER|Diet|A specific dietary treatment for patients with Phenylketonuria.
41356984|NCT03820804|DRUG|Sapropterin|A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
41356985|NCT01110889|DRUG|Agomelatine (AGO178C)|
40836692|NCT00697294|DIETARY_SUPPLEMENT|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
41022154|NCT03732638|DRUG|Rimegepant|Rimegepant 75 mg tablet EOD
41356986|NCT01110889|DRUG|Agomelatine (AGO178C)|
41356987|NCT01110889|DRUG|Placebo|
41022155|NCT03732638|DRUG|Placebo|Placebo tablet to match rimegepant tablet EOD
41022156|NCT02170727|DRUG|DCV/ASV/BMS-791325|
41022157|NCT02109588|BEHAVIORAL|A supervised physical exercise program|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
41356988|NCT02142673|DEVICE|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
41356989|NCT02142673|DEVICE|Filling pressure 60|The hysteroscope filling pressure will be reduced to 50mm Hg
41356990|NCT02142673|DEVICE|Filling pressure 40|The hysteroscope filling pressure will be 40mm Hg
41356991|NCT01522599|OTHER|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
41356992|NCT01522599|OTHER|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
41356993|NCT02768636|DIETARY_SUPPLEMENT|Omega-3|Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
41356994|NCT06218238|OTHER|Powered prosthetic knee joint|Subjects will be fitted and trained on the Ossur Power Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
40836693|NCT05564195|DIAGNOSTIC_TEST|Postoperative cognitive function|"Digital cognitive tests - Mindmore-P, will be used to assess neurocognitive capacity and includes tests of verbal episodic memory, executive functions, visuospatial function and attention. The cognitive tests are self-administered on a touch screen tablet (10.1 20-30 min Windows). The Mindmore-P is a web-application running on a full-screen Chrome browser. The test is administered by using a capacitive touchscreen with features that record detailed information such as timing, pauses, and lifting of finger from the touchscreen. Speech recognition is used in the screening of verbal memory and language."
40836694|NCT04771325|BEHAVIORAL|Support from a trained companion|Birth companions trained on how to effectively support women during labor
40836695|NCT03208439|DEVICE|lower-limb cycling system|patients will receive 30-minute cycling exercise
40836696|NCT05874349|BEHAVIORAL|General variables|Variables evaluated: age, sex, location, extent, and phenotype of IBD according to the Montreal classification, smoking habit, therapeutic requirements (immunosuppressants, biologics, steroids, salicylates, drugs that cause enteropathy such as olmesartan, valsartan, non-steroidal anti-inflammatory drugs, etc, ...).
40836697|NCT05874349|BEHAVIORAL|Clinical activity|Clinical activity was evaluated using the Harvey-Bradshaw index (HBI) (cut-off values: \<5, remission; 5-7, mild activity; 8-16, moderate activity; and \>16, severe activity).
40836698|NCT05874349|PROCEDURE|Laboratory data|Laboratory data: blood count, renal function and C-reactive protein, anti-transglutaminase antibodies, genetic study of celiac disease DQ2.5, DQ8, and DQ2.2, study of parasites, fecal calprotectin.
40836699|NCT05874349|PROCEDURE|Endoscopic and histology data|"Endoscopic signs suggestive of CD in UDT (presence of canker sores, ulcers, ...) and colon inflammatory activity was evaluated when available in patients with active disease using the Simple Endoscopic Score for CD (SES-CD: 0-2, remission; 3-6, mild endoscopic activity; 7-15, moderate endoscopic activity; and \>15, severe endoscopic activity).~Duodenal biopsies were assessed by 2 pathologists and were evaluated according to Marsh classification modified by Ensari \[Marsh 0, 1, 2 or 3\], the limit of normality for intraepithelial lymphocytes (IELs) per 100 enterocytes is set at 25, gastric biopsies (determination of H. Pylori by immunohistochemistry) and esophageal biopsies was recorded too.~Percentage of lymphocyte subpopulations are assessed by flow cytometry."
40836700|NCT00875173|DRUG|Selenium|selenium as a drug according to Brazilian regulation laws
40836701|NCT00875173|DRUG|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
40836702|NCT00721539|DEVICE|da Vinci Surgical Robot Platform|daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
40836703|NCT00721539|PROCEDURE|Transoral Robotic Surgery|Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
40836704|NCT05367141|OTHER|"CDSS (MedicBK)"|"Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care."
40836705|NCT00342706|PROCEDURE|Community based intervention|
40836706|NCT03886155|PROCEDURE|Biopsy|During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.
40836707|NCT02231268|DRUG|Gladem|
40836708|NCT04225819|DIETARY_SUPPLEMENT|Vitamin D3|Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water
40836709|NCT04225819|OTHER|Placebo|Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
41356995|NCT06218238|OTHER|Conventional prosthetic knee joint|Subjects will be fitted and trained on the Ossur Rheo XC Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
40836710|NCT01583660|DRUG|celecoxib|200mg, PO.Bid, last from admission to hospital to one week after operation.
40836711|NCT01583660|DRUG|Acetaminophen oxycodone|1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
40836712|NCT05565768|DRUG|HZN-457|HZN-457 will be given in one subcutaneous administration
40836713|NCT05565768|DRUG|Placebo|Placebo will be given in one subcutaneous administration
40836714|NCT02758301|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
40836715|NCT01329744|DRUG|mecasermin|a subcutaneous injection twice a day
40836716|NCT01329744|DRUG|Placebo control|Subcutaneous injection given twice per day of placebo compound, for 24 weeks
40836717|NCT06475040|DEVICE|transcranial magnetic stimulation|non-invasive form of brain stimulation accelerated intermittent theta burst stimulation (aiTBS)
40836718|NCT02408523|DRUG|Lacosamide Tablet|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
40836719|NCT02408523|DRUG|Lasosamide Oral Solution|"* Active Substance: Lacosamide~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
40836720|NCT02408523|OTHER|Placebo Tablet|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
40836721|NCT02408523|OTHER|Placebo Oral Solution|"* Active Substance: Placebo~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
40836722|NCT03435562|OTHER|JUUL electronic cigarette|Effects of JUUL electronic cigarette use.
40836723|NCT03435562|OTHER|IQOS electronic cigarette|Effects of IQOS electronic cigarette use.
40836724|NCT03435562|OTHER|Own Brand cigarette|Effects of own brand cigarette use.
40836725|NCT04454736|BEHAVIORAL|"Amateur Group Singing"|45-minute singing session led by a professional choirmaster without a therapeutic background once a week
41356996|NCT05786404|DRUG|PRIM-DJ2727 - FROZEN|Patients with active UC will receive induction dose of 100 grams of stool via frozen retention enema, Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-FROZEN administered in clinic. This consists of microbiota suspension from well-screened donors. Twice filtered fecal microbiota product diluted in saline to 500 mL containing 100g of study drug will be administered as frozen enema induction dose
41356997|NCT05786404|DRUG|PRIM-DJ2727 - CAPSULES|Patients with active UC will receive induction dose of 100 grams of stool in orally administered enteric-coated capsules Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-CAPSULES.These capsules consists of microbiota from well-screened donors. The induction dose of enteric-coated capsules will be derived from 100 grams stool.
41496404|NCT02129244|OTHER|NCM-Plus|"The NCM will follow the domains of the chronic care model by:~1. Assuring effective, efficient clinical care and self-management support~2. Promoting clinical care consistent with scientific evidence and patient preferences~3. Organizing data to facilitate efficient, effective care~4. Empowering and preparing patients to manage their health and health-care needs~5. Mobilizing community resources to meet the needs of patients"
41496405|NCT05908630|OTHER|Hypothermia|"Accidental hypothermia is defined as: an involuntary drop in core body temperature \<35C"
41496406|NCT02293863|DRUG|MHAA4549A|Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
41496407|NCT02293863|DRUG|Oseltamivir|Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
41496408|NCT02293863|DRUG|Placebo|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
41496409|NCT05375526|DEVICE|Magtrace|"In the proper ovarian ligament (or its remnants), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle.~If a hysterectomy has been conducted, this step can be omitted. In the infundibulopelvic ligament (suspensory ligament of the ovary), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle."
41356998|NCT00864539|DIETARY_SUPPLEMENT|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
41496410|NCT01948713|OTHER|Strengthening of pelvic floor muscles.|Kegel exercises kinesiotherapy
41356999|NCT00864539|DIETARY_SUPPLEMENT|plain milk|daily intake of 200 ml plain milk
41357000|NCT00864539|DIETARY_SUPPLEMENT|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
41496411|NCT01948713|OTHER|Strengthening of hip muscles.|Kegel exercises and strengthening of hip muscles as Gluteus Maximus and Medius and adductor muscles
41496412|NCT03705130|DEVICE|Single Vision Contact Lens|Spherical Contact Lens worn on non-dispensing basis
41357001|NCT00864539|DIETARY_SUPPLEMENT|plain orange juice|daily intake of 250 ml plain orange juice
41496413|NCT03705130|DEVICE|Multifocal Contact Lens 1|Multifocal Contact Lens worn on non-dispensing basis
41496414|NCT03705130|DEVICE|Multifocal Contact Lens 2|Multifocal Contact Lens worn on non-dispensing basis
41496415|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 1|Free mobile mental health application that focuses on meditation
41496416|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 2|Free mobile mental health application that assists with coping with COVID-19
41357002|NCT00864539|DIETARY_SUPPLEMENT|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
41496417|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 3|Free mobile mental health application that focuses on positive psychology.
41496418|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 4|Free mobile application that addresses mental health issues through mood tracking
41357003|NCT00864539|DIETARY_SUPPLEMENT|Placebo|daily placebo
41496419|NCT04670276|PROCEDURE|injection of emulsified adipose tissue stromal vascular fraction|Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
41496420|NCT03816852|BIOLOGICAL|hucMSCs|Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
41357004|NCT01378156|BIOLOGICAL|JS7 plasmid DNA and MVA62B vaccine|JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
41357005|NCT03137433|DIETARY_SUPPLEMENT|Meal-replacement Therapy|We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.
41357006|NCT00003716|BIOLOGICAL|rituximab|
41357007|NCT01713569|DEVICE|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
41357008|NCT00187148|BIOLOGICAL|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
41496421|NCT02217254|PROCEDURE|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
41357009|NCT01524094|DRUG|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
41357010|NCT01524094|PROCEDURE|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
41357011|NCT05734703|DRUG|Nutraceutical Topical|Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
41160321|NCT06162806|PROCEDURE|ultrasound guided caudal epidural block using 50 mg of Magnesium sulfate added to(1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl)|injection of local anesthetic mixture(Bupivacaine +Fentanyl +magnesium sulfate) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
41357012|NCT00004937|DRUG|acridine carboxamide|
41357013|NCT04547127|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT Plasma|Intravenous infusion.
41357014|NCT04547127|DRUG|Standard Medical Treatment|SMT
41357015|NCT02449694|DEVICE|OCS Liver|OCS Liver will be used to preserve the donor liver
41357016|NCT03588949|DIETARY_SUPPLEMENT|Dietary Supplement with L-carnitine (FertilHom)|1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
41357017|NCT03588949|DIETARY_SUPPLEMENT|Control Dietary Supplement|1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
41496422|NCT02664714|OTHER|PFMT|Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
41496423|NCT03260985|OTHER|Feedback Report|A report of the data from the comprehensive neuroscience assessment is provided to the patient's care team.
41496424|NCT04497948|DRUG|Acalabrutinib|Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor
41496425|NCT01535092|DRUG|Silibinin|20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
41496426|NCT01535092|DRUG|Placebo|Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
41496427|NCT04270136|PROCEDURE|total mastectomy|breast cancer non conserving surgery
41496428|NCT03207737|BEHAVIORAL|MENTOR + Telehealth|Participants will live on campus for one week and complete the MENTOR program, which is a course about resilience and how nutrition, exercise and mindfulness help with resilience for individuals with a spinal cord injury. Different experts will cover the three main topics with lectures and application of knowledge through related activities. Participants will then begin a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
41357018|NCT04565535|BEHAVIORAL|Novel donor lifestyle optimisation protocol|Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
41357019|NCT05276024|DEVICE|iFuse Bedrock technique|Lumbosacral arthrodesis on 2 or more spinal segments (including at least L4, L5 and S1 vertebrae) associated with a sacroiliac fusion procedure according to the Bedrock technique using the iFuse 3D system and iliac fixation.
41496429|NCT03207737|BEHAVIORAL|Telehealth Only|Participants will complete a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
41496430|NCT06059443|BEHAVIORAL|mLab App Plus|Participants will use the mLab Plus app to test for Syphilis and HIV using the DPP HIV/Syphilis Test
41496431|NCT00006043|DRUG|temozolomide|
41496432|NCT03467139|OTHER|Abdominal breathing exercise|Deep Breathing Exercise
41496433|NCT00358410|DRUG|GW679769 oral tablets|2x GW679769 60mg tablets
41496434|NCT00358410|DRUG|Placebo|Placebo oral tablets to match experimental intervention
41496435|NCT02422589|DRUG|ceritinib|
40836726|NCT04454736|BEHAVIORAL|"Professional Group Singing"|120-minute singing session led by a professional choirmaster without a therapeutic background three times a week. Assessments take place twice a week.
40836727|NCT02210091|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
40836728|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
41496436|NCT02422589|DRUG|warfarin|
41496437|NCT02422589|DRUG|midazolam|
40836729|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
40836730|NCT05670509|DRUG|administration of Nasal midazolam in home group as a rescue medication for seizure control.|Children from home group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
40836731|NCT05670509|DRUG|administration of Buccal midazolam in home group as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
41496438|NCT00134667|DRUG|Photodynamic Therapy (PDT) with Visudyne (verteporfin)|
41496439|NCT00134667|DRUG|Macugen (pegaptanib sodium)|
40836732|NCT05670509|DRUG|administration of intramuscular midazolam in homegroup as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
41496440|NCT05726903|DRUG|Depo-subQ Provera Injectable Product|SC Injection at Home
40836733|NCT05670509|DRUG|administration of Nasal midazolam in ER group as a rescue medication for seizure control.|Children from the ER group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
41496441|NCT03768518|DIAGNOSTIC_TEST|68Ga-exendin-4 PET/CT|68Ga-exendin-4 PET/CT
40836734|NCT05670509|DRUG|administration of Buccal midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
40836735|NCT05670509|DRUG|administration of intramuscular midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
40836736|NCT00434356|DRUG|bevacizumab|Intravenous repeating dose
40836737|NCT00434356|DRUG|sunitinib|Oral repeating dose
40836738|NCT00434356|DRUG|paclitaxel|Intravenous repeating dose
40836739|NCT03823846|DRUG|Routine Dezocine injection|Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
40836740|NCT03823846|DRUG|Adjusted Dezocine injection|Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
41022158|NCT03799575|BEHAVIORAL|Transmission Electron Microscopy analysis|Morphology of two vitreal side of Internal Limiting Membrane in contact
41022159|NCT05623709|DEVICE|Positive airway pressure with continuous positive airway pressure or noninvasive ventilation|CPAP or NIV prescribed by the treating respirologist for long-term use at home
40836741|NCT03823846|DRUG|Routine Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
40836742|NCT03823846|DRUG|Adjusted Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
40836743|NCT03823846|OTHER|postoperative rehabilitation|Rehabilitation was conducted at 8:00am and 2:00pm.
41022160|NCT03393598|DEVICE|pre-expansion using Kiwi® VAC-6000M.|The pre-expansion will be performed with Kiwi® VAC-6000M with the PalmPumpTM.
41022161|NCT03393598|DEVICE|pre-heating using Hilotherm Calido®.|The pre-heating will be performed with Hilotherm Calido®.
41496442|NCT01932723|BEHAVIORAL|Lumbar stabilization exercises|The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
41509232|NCT06487793|BEHAVIORAL|Enhanced Insomnia Coach|The intervention combines the Insomnia Coach app with additional brief alcohol intervention to facilitate behavior change for both drinking behavior and insomnia symptoms. Insomnia Coach contains multiple components of CBT-I (e.g., stimulus control, cognitive restructuring, relaxation training, sleep hygiene/psychoeducation, monitoring of sleep via journals). The brief alcohol intervention content added to the CBT-I app is based on CBT skills for moderate drinking, delivered in a motivational enhancement style, and has demonstrated efficacy among young adults and veterans (e.g., correcting perceived norms, use of protective behavioral strategies, challenging expectancies).
41357020|NCT03343990|PROCEDURE|Interlocking multi-twisted wires in sternal closure|One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried
41357021|NCT03343990|PROCEDURE|Eight Figure techniqe in sternal closure|The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
41357022|NCT01078974|DRUG|pomalidomide|Taken orally once a day
41357023|NCT01078974|DRUG|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
41357024|NCT01078974|DRUG|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
41496443|NCT05591586|BEHAVIORAL|Web based educational modules|This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 6 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and 6) solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be \<15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (\<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
41496444|NCT05591586|BEHAVIORAL|mobile video interpreting (mVI) access|This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
41496445|NCT04527445|PROCEDURE|Reduced radiation fluoroscopy|See previous information about each arm
40836744|NCT03823846|DRUG|normal analgesia pump administration|Dose of analgesia pump was added if needed.
40836745|NCT03823846|DRUG|adjusted analgesia pump administration|Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
40836746|NCT04251780|PROCEDURE|Surgical Treatment of Hyperaldosteronism|Surgery of an Aldosterone-producing adenoma
40836747|NCT04251780|DRUG|Drug treatment of Hyperaldosteronism|Treatment of Hyperaldosteronism with Spironolactone or Eplerenone.
40836748|NCT02801890|BIOLOGICAL|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
40836749|NCT00239954|DRUG|Escitalopram|
41022162|NCT03393598|DEVICE|pre-expansion-heating|Both preconditioning methods - Kiwi® VAC-6000M and additionally Hilotherm Calido® - will be applied.
41357025|NCT06201585|DEVICE|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
41357026|NCT02885506|DRUG|Oral administration of P218 capsules|Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
41357027|NCT02885506|DRUG|Oral administration of P218 matching placebo|Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
40836750|NCT04791059|DRUG|S-ketamine|S-ketamine 50 mg is included in the mixture for patient-controlled analgesia.
40836751|NCT04791059|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
40836752|NCT04791059|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
40836753|NCT03048838|BEHAVIORAL|Risk reduction behavioral intervention|
40836754|NCT03048838|BEHAVIORAL|Wellness Promotion Intervention|
40836755|NCT05463068|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
40836756|NCT03945019|BIOLOGICAL|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
40836757|NCT03945019|OTHER|Placebo SC|Subcutaneous injection of Placebo SC
40836758|NCT01632644|OTHER|Survey/Interview|Each group will be surveyed and interviewed.
40836759|NCT04997525|DRUG|Estradiol Tablets|Combined with progesterone
40836760|NCT04997525|DRUG|Progesterone|Combined with estradiol
40836761|NCT04997525|DRUG|Follitropin Alfa|Combined with hCG
40836762|NCT04997525|DRUG|Chorionic Gonadotropin, Alpha|In either natural cycle or combined with Follitropin Alfa
40836763|NCT02365571|DRUG|LY3154207|Administered orally
40836764|NCT02365571|DRUG|Placebo|Administered orally
40836765|NCT02365571|DRUG|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
40836766|NCT05329207|BEHAVIORAL|Experimental group|Web Based Adolescent Health Promotion Education Program
40836767|NCT06267066|DRUG|Betamethasone Valerate 0.1% Cream|Moderate potency
40836768|NCT06267066|DEVICE|SmartXide® fractional carbon dioxide laser|Ablative
40836769|NCT06267066|DRUG|Vaseline Topical Product|Emollient
41496446|NCT04527445|PROCEDURE|Conventional fluoroscopy|See previous information about each arm
41496447|NCT03562559|OTHER|Measurements Using Ultrasound|Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.
41496448|NCT03679182|DRUG|Olanzapine|Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours
41496449|NCT05265637|DEVICE|Visian|Visian implantable collamer lens (ICL)
41496450|NCT03343444|DRUG|12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks
41496451|NCT03343444|DRUG|8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 8 weeks
41496452|NCT04651413|DIAGNOSTIC_TEST|PCR Value|Data collection and interpretation
41496453|NCT03183336|PROCEDURE|ridge split interpositional block graft|
41496454|NCT03183336|PROCEDURE|decortication Onlay block graft|
41496455|NCT06186934|DRUG|the standard-dose group (4 g/day)|Patients with chronic kidney disease undergoing hemodialysis and controlling hyperphosphatemia
41496456|NCT03598868|DRUG|Vortioxetine|Augmentation : Vortioxetine 10 mg p.o. for week 1, Vortioxetine 5-20 mg p.o. for week 2,4,6.
41496457|NCT03598868|DRUG|Placebo|Augmentation : Placebo for week 1,2,4,6
41496458|NCT04300283|BEHAVIORAL|Hypnosis|See previous description
41496459|NCT02331329|DEVICE|NICOM cardiac output measurement|
41496460|NCT02331329|DEVICE|Cardiac MRT cardiac output measurement|
41496461|NCT04100863|OTHER|No Intervention|There is no intervention for this study.
41496462|NCT06362668|DEVICE|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
41496463|NCT06362668|DRUG|Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
41496464|NCT04067427|OTHER|Mental training|App-based mental training
41496465|NCT05123183|OTHER|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36 and CV17 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to CV17 point (single point) and ST36 point (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
41496466|NCT05123183|OTHER|back massage group|The mother sits in the chair and leans forward, placing her arms on the table at her level and resting her head on her arms. The mother's breasts are naked and freely released. The researcher massages the mother from top to bottom on both sides of the spine between the scapula bones. At this time, his fists are clenched and the thumb is open. While pressing firmly with his fists, small circular friction movements are made with his thumb. From the neck to the scapula, both sides of the spine are rubbed at the same time for 3 minutes. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
41496467|NCT05123183|OTHER|control group|No application will be made to the mothers in this group, and the amount of milk will be measured by weighing the baby before and after breastfeeding.
41496468|NCT02475330|DIETARY_SUPPLEMENT|Flaxseed|Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
41022163|NCT06570967|DRUG|Methimazole(MMI)|The initial dose of methimazole was 0.2-0.8 mg/(kg▪d). This dose was subsequently reduced by 25% to 50% and adjusted to maintain euthyroidism, based on the results of serum thyroid hormone testing during follow-up.
41022164|NCT03294434|OTHER|Diffusion tensor Imaging (DTI)|Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
41496469|NCT00634881|BIOLOGICAL|Alemtuzumab i.v.|"Alemtuzumab will be administered once per week as a 2 h infusion~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
41496470|NCT00634881|BIOLOGICAL|Alemtuzumab s.c.|"Alemtuzumab will be administered once per week subcutaneously~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
41496471|NCT05546112|DEVICE|Transcutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B|A device that improves insomnia symptoms by transcutaneously applying electrical stimulation including a pulse (10 kHz) burst waveform (10 Hz) to the forehead area to the trigeminal nerve
41022165|NCT03970135|OTHER|Fasting|Fasting for 24 hours or until hypoglycemia (blood glucose \< 3mmol/L) or symptoms of hypoglycemia
41496472|NCT05546112|DEVICE|Sham Stimulation using YPS-401B|A device that is attached in the same way as a real medical device, but actually applies a shum stimulus
41496473|NCT03741712|DRUG|SHR3680|Tablet. Specifications of 80mg
41496474|NCT03741712|DRUG|SHR2554|Tablet. Specifications of 50mg and 200mg
41496475|NCT06452667|PROCEDURE|platelet-rich fibin|Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich fibin therapy on one side of the face. The other side of the face was treated with platelet-rich palsma.
41022166|NCT02230657|PROCEDURE|Same day discharge|
41022167|NCT02230657|PROCEDURE|Next day discharge|
41022168|NCT02541721|DEVICE|LabiaStick#01|"This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.~The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area."
41022169|NCT01162629|DEVICE|Osteon bone graft|Osteon bone substitute placed to a height of 2 mm above the top of the dental implant
41022170|NCT05482347|OTHER|Educational video|The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.
41022171|NCT02278497|OTHER|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
41022172|NCT03494010|OTHER|Observation|There is no intervention. Patients will receive the HCL system as part of their clinical care.
41022173|NCT05876078|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in ADHF patients
41022174|NCT03859232|OTHER|Delta Dry® Waterproof Pantaloon|Cast with newer waterproof material developed to reduce the skin complications associated with traditional cotton liners.
41022175|NCT03859232|OTHER|Cotton Padding|Cast with traditional cotton liner.
41022176|NCT06573710|DEVICE|sonic activator|Polyamide EDDY tips 28mm long is inserted in the canal 2mm short of the working length operated at 6,000 Hz. Activation is done for three cycles each for 20sec. The tip is moved vertically in up and down motion, 1ml is used for each activation cycle followed by 2ml 17% EDTA20
41022177|NCT06573710|DEVICE|LASER activation|Diode laser 980nm is used to activate the irrigant using fiber optic tip of (200micrometer) and power of 1.5w continuous mode. The tip is placed 2 mm shorter than the working length. Laser irradiation is done for each canal for 20 secs repeated over three cycles for total time of 60 secs and 10 secs pauses between each cycle
41022178|NCT06573710|DEVICE|Ultrasonic activation|ED60tip is used with ultrasonic device operated on mode E and inserted in the canal 2mm short of the working. Activation is done for three cycles each for 20 sec. The tip is moved vertically in up and down motion,1ml is used for each activation cycle followed by 2ml 17% EDTA
41022179|NCT06573710|DEVICE|passive irrigation with Endodontic needle|Each canal is irrigated with side vented endodontic needle 30G Placed 2mm short of the working length with total time of 60 secs followed by 2ml 17% EDTA
41022180|NCT00654849|PROCEDURE|Plasmakinetic bipolar energy forceps|Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy
41022181|NCT00654849|PROCEDURE|Abdominal Hysterectomy with traditional suture technique|The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
41496476|NCT06452667|PROCEDURE|platelet-rich palsma|Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich palsma therapy on one side of the face. The other side of the face was treated with platelet-rich fibin.
41496477|NCT05119153|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo designed to mimic coffee color.
41496478|NCT05119153|DIETARY_SUPPLEMENT|Light Roasted Coffee|12 oz light roast coffee
41496479|NCT05119153|DIETARY_SUPPLEMENT|Medium Roasted Coffee|12 oz medium roast coffee
40836770|NCT00346840|DRUG|Misoprostol vaginal insert 25 mcg|One hydrogel polymer vaginal insert for up to 24h
40836771|NCT00346840|DRUG|Misoprostol vaginal insert 50 mcg|One hydrogel polymer vaginal insert for up to 24h
41022182|NCT03205085|RADIATION|magnetic resonance imaging|assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.
41022183|NCT03205085|PROCEDURE|2D and 3D trans-thoracic echocardiography|assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography
41160322|NCT02908412|DRUG|Digital nerve block with bupivacaine|The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
41496480|NCT05119153|DIETARY_SUPPLEMENT|Dark Roasted Coffee|12 oz dark roast coffee
41496481|NCT05840237|OTHER|"Anhydrous Enol-Oxaloacetate, a Medical Food"|"Treatment with the medical food Oxaloacetate CFS, 2 - 500 mg capsules BID with food"
41496482|NCT05840237|OTHER|White Rice Flour|"Treatment with the food White Rice Flour, 2- 500 mg capsules BID with food"
41496483|NCT05795556|OTHER|Assessing sarcopenia and potential biomarkers of sarcopenia in fall patients|Blood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles (ultrasound), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)
41496484|NCT06112496|DEVICE|EMG|Neuro-EMG-Micro, Neurosoft, Ivanovo, Russia, will be used for the assessment of muscle activity for muscles.
41496485|NCT01119794|DRUG|Ofatumumab and Bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
41496486|NCT06414317|PROCEDURE|Assessment of Distress|Undergo psychological distress screening
41496487|NCT06414317|OTHER|Consultation Visit|Attend consultations
41496488|NCT06414317|OTHER|Nutritional Assessment|Undergo malnutrition screening
41022184|NCT03205085|OTHER|Blood samples|Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
41022185|NCT04898231|DRUG|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
41496489|NCT06414317|OTHER|Questionnaire Administration|Ancillary studies
41496490|NCT06414317|OTHER|Supportive Care|Receive access to bladder cancer ENST
41496491|NCT06414317|OTHER|Supportive Care|Attend virtual support group meetings
41496492|NCT03303183|DEVICE|Standard Impression technique|Silicone impression technique
41496493|NCT03303183|DEVICE|Direct Ear Scanner|Direct Ear Scanner to scan the ear anatomy
41496494|NCT01716689|DRUG|oral cyclophosphamide|50mg daily
40836772|NCT00346840|DRUG|Misoprostol vaginal insert 100 mcg|One hydrogel polymer vaginal insert for up to 24h
41357028|NCT02907866|DEVICE|Ultrasound with EBUS scope and with linear ultrasound probe|All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
41357029|NCT05902611|BEHAVIORAL|BMI determination, Eruption Time Assessment, Caries Assessment|BMI determination, Eruption Time Assessment, Caries Assessment
41496495|NCT02974179|BIOLOGICAL|Subjects from Study AG-CLI-0206 who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
40836773|NCT00346840|DRUG|Misoprostol vaginal insert 200 mcg|One hydrogel polymer vaginal insert for up to 24h
40836774|NCT05824936|BEHAVIORAL|Pilot study arm for technology-enhanced asthma intervention|Participants will be enrolled in a remote monitoring program using monthly remote study visits which will include the use of a mobile spirometer (device for testing lung function). Participants will complete monthly remote study visits visits using telehealth platform and will complete lung function testing during the visit using a mobile spirometer as well as remote study measures.
40836775|NCT06336655|DEVICE|IABP|LV unloading via intra-aortic balloon pump (IABP)
40836776|NCT03143998|DRUG|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
40836777|NCT02215928|GENETIC|mutation analysis|Correlative studies
40836778|NCT02215928|OTHER|cytology specimen collection procedure|Correlative studies
40836779|NCT02215928|OTHER|laboratory biomarker analysis|Correlative studies
40836780|NCT01762813|PROCEDURE|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
40836781|NCT04714021|OTHER|CO2|to insufflate CO2 into the stomach instead of air during the PEG
40836782|NCT04714021|OTHER|air|to insufflate air into the stomach instead of CO2 during the PEG
40836783|NCT03187808|OTHER|Single thoracic manipulation|The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
40836784|NCT03187808|OTHER|Special massage technique (RT technique)|The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
40836785|NCT06507384|OTHER|AI-Based Risk Assessment Model|Bukret AI Risk Assessment Model is a sophisticated decision support system that evaluates clinical data and patient history to generate personalized risk scores and classify patients into risk group categories for those undergoing plastic surgery. This AI model analyzes various risk factors, including BMI, age, smoking habits, and medical history, to identify potential complications. Based on the AI-generated risk group and specific risk factors, the model provides tailored recommendations for preoperative management, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to minimize surgical risks and improve outcomes. This intervention aims to enhance surgical planning and patient safety by offering personalized, actionable recommendations.
40836786|NCT05960084|OTHER|screening|screening for colistin resistant E. coli
41357030|NCT03263169|BEHAVIORAL|Community-based personalized care|volunteer support, health technology, interprofessional care, social network linkage
41496496|NCT00985712|DRUG|Insulin Lispro|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
41496497|NCT00985712|DRUG|Huminsulin Regular|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
41496498|NCT00985712|DEVICE|HumaPen Memoir|subcutaneously, daily for 24 weeks
41496499|NCT00985712|DEVICE|HumaPen Luxura|subcutaneously, daily for 24 weeks
41496500|NCT03363386|PROCEDURE|Proprioceptive Exercises|Patients trained for proprioceptive exercises
41496501|NCT03363386|PROCEDURE|Resistive Exercises|Patients trained for resistive exercises
40836787|NCT04689971|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
40836788|NCT04689971|DRUG|Vitamin B combination|Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
41022186|NCT04898231|DRUG|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
41022187|NCT04898231|DRUG|Methylprednisolone|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
41496502|NCT03363386|PROCEDURE|Aerobic Exercise|Patients were educated with treadmill walking for 30 minutes of each exercise session
41022188|NCT05868694|DIAGNOSTIC_TEST|polysomnography|Polysomnography is mainly used to diagnose sleep breathing disorders, including sleep apnea syndrome, snoring, upper airway resistance syndrome, and also used for the auxiliary diagnosis of other sleep disorders, such as: narcolepsy, restless legs syndrome, insomnia classification, etc.
41022189|NCT06129292|BEHAVIORAL|EFT group|"Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held."
41022190|NCT04611997|DRUG|Indocyanine Green|Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
41022191|NCT04375423|BEHAVIORAL|Ecological momentary assessment and intervention: Behaviorally-dependent messaging|In response to behavioral data submitted intervention arm participants receive messages on their phones reinforcing healthy behaviors or encouraging alternative behaviors to limit risks
41022192|NCT04375423|BEHAVIORAL|Ecological momentary assessment only|Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
41022193|NCT06448429|OTHER|Usual care|Participants will have the usual diabetes care at the Grady Diabetes Clinic.
41022194|NCT06448429|OTHER|Collaborative care model (CoCM)|"Collaborative care will include:~* Care with a behavioral health consultant (BHC)~* Measurement-based mental health care~* Systematic caseload reviews~* Medical management of depression~The BHC will monitor depression and anxiety severity, promote behavioral change with patients through Behavioral Activation, and support the medical management of depression through participation in caseload reviews (I.e., Mental health care plans for individual patients will be reviewed monthly by a multi-disciplinary T1D clinical team and BHC). Depression treatment initiation (if warranted) by a clinician and engagement in mental health care."
41357031|NCT04493736|BEHAVIORAL|MHSAFE app recording|Participants are asked a series of questions to elicit their feelings and emotions as part of an audio recorded interview along with their normal therapy session.
41357032|NCT02499172|BIOLOGICAL|Shanchol|
41357033|NCT03646955|RADIATION|No partial breast irradiation|Omission of radiation therapy
41496503|NCT05400408|DIAGNOSTIC_TEST|VOX|Breath Biopsy Analysis
41496504|NCT06634342|DIAGNOSTIC_TEST|HCV RNA Rapid testing|Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.
41022195|NCT03828305|OTHER|Training and creation of the Network-CPR|Training and creation of the Network-CPR that will cover the city. This network will be created with certain population groups that are routinely in contact with susceptible persons of OHCA (police, firemen, teaching staff, health personnel, merchants, pharmacists, university students, etc.), in addition, relatives of people with heart disease will be included. In the case of elderly people who are alone, they will include their neighbors or caregivers. In the city, there are 2,105 people with heart disease susceptible to OHCA. The research team and the health personnel of the participating primary care centers (PCC) will offer training courses on basic CPR maneuvers and use of the AED, following the protocol of the Center Català de Ressucitació (CCR). The training is aimed at training 430 people (20% of the relatives of people with heart disease) and will be made by trainers accredited by the CCR. There will be a total of 30 sessions with groups of approximately 15 people.
41022196|NCT03828305|OTHER|Control Group|No intervention
41022197|NCT04590547|DRUG|GLS-1027|GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.
41496505|NCT04225910|DRUG|225Ac-PSMA|all the patients will receive 225Ac-PSMA RLT for 2 cycles. The dosage will be calculated according to 100KBq/kg body weight. The drug will be administered by vein injection.
41022198|NCT04590547|DRUG|Placebo|Placebo looks like GLS-1027
41357034|NCT04778215|OTHER|A progressive specific lumbar stabilization program|The aim of these programs is to optimize the stabilization and control of segmental motion of the lumbar spine. It is based on the draw-in action, hereafter called the abdominal hollowing, presented by Richardson and Jull (1995). The training program consists of three levels. Level 1 introduces the abdominal hollowing exercise in the prone and four-point kneeling position. Level 2 is a progression of these exercises and the gymnasts are also instructed to perform the abdominal hollowing standing on a balance board with slightly flexed knees while slowly moving the arms. Level 3 takes the training into sports specificity and the abdominal hollowing are to be held during three different basic trampette jumps with emphasis on good trunk and body control during jumping and landing.
41022199|NCT03899116|OTHER|deflation of pneumatic tourniquet|gradual deflation with variable degrees
41496506|NCT00946686|DRUG|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
41496507|NCT00946686|DRUG|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
41496508|NCT03040557|DEVICE|Flexible footwear|- Arm Flexible footwear: The intervention will be with flexible shoes in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
41022200|NCT05569785|OTHER|Resistance Exercise Therapy|"4 weeks of Resistance Exercise Therapy. This is a 4 week resistance exercise training programme that can be completed at home. The programme is designed to be progressive. It was designed by a bariatric physiotherapist and an exercise physiologist. This exercise programme will be discussed at the screening visit, educational material will be provided to the participants who are randomised to the intervention RET group.~Safety advice will be given to each eligible participant to ensure that if they feel unwell, develop chest pain/tightness, then they must seek advice from GP/urgent care if necessary. The exercises will need to be performed at least three times a week. Compliance will be monitored with Fitbit downloads at each visit. Fitbits will be worn during exercise sessions only."
41022201|NCT05035979|DRUG|BaidI Quzhi granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
40836789|NCT03529279|DRUG|CNG Chemotherapy|"CNG I, IMRT plus oral adjuvant chemotherapy, if EBV-DNA \> 0,according to CNG II. CNG II, IMRT + concurrent chemotherapy + oral adjuvant chemotherapy. CNG III, systemic chemotherapy, plus IMRT.~Chemotherapy strategy: Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1. Systemic chemotherapy, 5-Fu + nedaplatin (cisplatin), every 60 days; 5-Fu (100 - 200 mg/m2. D) civ for 30 days, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1,D28. Aim to achieve CR in imaging.Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID). Oral 10 days and stop 20 days, 3 months/course. After 6 courses, oral 10 days and stop 50 days, half year/course, 6-7 courses, lasted for 5 years."
41022202|NCT05035979|DRUG|Ju Yin cream|Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
41022203|NCT05035979|DRUG|Baidi Quzhi placebo granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
41022204|NCT05035979|DRUG|Ju Yin placebo cream|Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
41022205|NCT01266239|PROCEDURE|kissing balloon inflation|Kissing balloon inflation following the MV stenting
41022206|NCT01266239|DEVICE|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
41022207|NCT04830826|PROCEDURE|Surgeries|Surgeries
41022208|NCT05233072|OTHER|Blood sample|Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0
41022209|NCT02664428|DIETARY_SUPPLEMENT|PreBIOil|A daily dose of about 90 gram will be given for 8 weeks
41022210|NCT02664428|DIETARY_SUPPLEMENT|Control|A daily dose of about 90 gram will be given for 8 weeks
41357035|NCT06169449|BEHAVIORAL|Weight management--diet|The diet structure adopts an energy-limited balanced diet. In this structure, the total daily energy intake is reduced by 500\~1000 kcal based on the target energy intake; however, the balance is maintained for the energy supply ratio of the three major nutrients (with carbohydrate, protein, and fat accounting for 55\~60%, 10\~20%, and 15\~30% of the total daily energy, respectively). Combined with the patient's eating habits, the food exchange portion method is used as a guide; each portion providing 90 kcal is considered as one portion. Specific recipes are formulated after calculating the ideal weight and the total daily calorie intake based on activity intensity, determining the number of six food exchange portions and the distribution of three meals according to the total calorie and diet structure, and combining the equivalent food exchange table based on individual tastes and preferences; this ensures patient acceptability and implementation.
41357036|NCT06169449|BEHAVIORAL|Weight management--exercise|Exercise goals are divided into four levels based on individual health conditions and personal preferences; these include: cultivating exercise habits, improving cardiopulmonary function, enhancing muscle strength, and improving flexibility. Individualized exercise prescriptions that specify the exercise type, intensity, time, and frequency are formulated.
41357037|NCT06169449|BEHAVIORAL|Weight management--accompany|This component involves the inclusion of patients in online management. Online groups are established, daily feedback is obtained regarding weight management implementation, self-sharing is encouraged, and peer support is established; a total of 6 sessions of online health education are provided once every 4 weeks for 20-60 minutes at each session. This includes information regarding the risks associated with overweightness and obesity; weight management benefits; knowledge regarding diet and nutrition, exercise and sports, and behavioral styles; and problem exchange and sharing, among others. Professional support is provided by weekly communication with patients one-on one via WeChat or telephonic conversations. The patient's diet and exercise record sheet are checked, patients are asked questions regarding implementation of the current program and any discomfort or difficulties; corresponding guidance is provided as appropriate.
41496509|NCT03040557|DEVICE|Orthopedic insole|- Arm Orthopedic insole: The intervention will be with orthopedic insole in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
41496510|NCT04928716|OTHER|voiding phase evaluation|Assessment of voiding phase in multiple sclerosis patients
41496511|NCT01004003|DRUG|Sorafenib|
41496512|NCT01004003|DRUG|BIBF 1120|Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
41022211|NCT05360095|BEHAVIORAL|Meaning of Screening|The Meaning of Screening game is a decision making tool that is accessible through the most common web platforms. Users have the ability to explore learn about prenatal screening through multiple approaches, including presentation of facts, personal stories, and values clarification. Users will access the game from their personal phone or computer prior to completing prenatal screening.
41022212|NCT05360095|BEHAVIORAL|Genetic Counseling|This intervention consists of a 45-minute prenatal screening genetic counseling session (in person or online) completed after confirmation of pregnancy and before actual screening.
41022213|NCT05360095|BEHAVIORAL|Usual Care|Participants in the Usual Care group will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format so they can read it before they complete prenatal screening.
41022214|NCT06016634|DRUG|Alendronate Sodium|Administer oral alendronate 70 mg once a week x 24 weeks to all study participants
41022215|NCT05344105|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.
41160323|NCT04872842|OTHER|Obervation|This study is an observational study without any intervention
41160324|NCT03644524|BEHAVIORAL|Heat therapy|Regular hot tub use
41160325|NCT04672499|DRUG|Miricorilant 300 mg tablets|Miricorilant 300 mg tablets for oral administration
41022216|NCT02791048|BEHAVIORAL|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
41022217|NCT02144675|DRUG|choline magnesium trisalicylate|Given PO
41022218|NCT02144675|DRUG|idarubicin|Given IV
41022219|NCT02144675|DRUG|cytarabine|Given IV
41022220|NCT02144675|OTHER|laboratory biomarker analysis|Correlative studies
41022221|NCT00678600|OTHER|Standard (static) Computer Alerts|Static Computer Alerts on Patient's EMR webpage.
41022222|NCT00678600|OTHER|Enhanced Computer Alerts|Population level and asynchronous alerts with enhanced functionality
41022223|NCT03272191|PROCEDURE|Liposuction and stem cell implantation|The adipose tissue specimen will be collected mainly from the patient's abdomen using a liposuction cannula. The adipose tissue may be collected from other areas if necessary The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred to an injection/infusion catheter for delivery into the akinetic myocardial scar in the region of a previous infarct
41022224|NCT00633035|DRUG|esomeprazole 40 mg|esomeprazole 40 mg po given for 7 days
41022225|NCT00633035|DRUG|famotidine 20 mg|famotidine 20 mg intravenous bolus q12h for 7 days
41022226|NCT04339335|PROCEDURE|Pulsed radiofrequency of the occipital nerves|pulsed radiofrequency of the greater and lesser occipital nerves bilaterally
41022227|NCT00014534|BIOLOGICAL|filgrastim|6 mg sub Q
41022228|NCT00014534|DRUG|cisplatin|60 mg/sq m IV
41022229|NCT00014534|DRUG|doxorubicin hydrochloride|50 mg/ sq m IV
41022230|NCT00014534|DRUG|gemcitabine hydrochloride|1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
41022231|NCT06014658|DRUG|Antibody-Drug Conjugate|MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE
41022232|NCT05148494|DRUG|Fleet Enema|standard pre-op application, see arm description
41022233|NCT05148494|DRUG|Pico-Salax|standard pre-op application, see arm description
41022234|NCT01697384|DRUG|histrelin acetate|52 week implant
41022235|NCT03112044|DRUG|Sofosbuvir-velpatasvir (400 mg/100 mg)|Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
41022236|NCT03112044|DEVICE|Ex Vivo Lung Perfusion (EVLP)|Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
41022237|NCT02990663|OTHER|Use of blood pressure lowering medication at bedtime|Blood pressure lowering medications will be switched (one at a time as tolerated) to bedtime, or maintained at bedtime if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
41022238|NCT02990663|OTHER|Use of blood pressure lowering medication in the morning|Blood pressure lowering medications will be switched (one at a time as tolerated) to morning, or maintained in the morning if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
41022239|NCT04689113|BEHAVIORAL|Incontinence Health Belief Development Program|After the applied interventions, it is desired to develop kegel exercise behavior in women.
41022240|NCT05953194|BEHAVIORAL|Exposure to counter-marketing messages|Counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.
41022241|NCT05953194|BEHAVIORAL|Exposure to traditional health messages|Traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
41022242|NCT05953194|BEHAVIORAL|Exposure to control (neutral) messages|Control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
41496513|NCT03559400|DRUG|local gentamicin injection|Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
41496514|NCT03559400|DRUG|placebo saline injection|Treatment includes debridement and administration of the local antibiotic which will consist of 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
41496515|NCT04084093|DEVICE|Surfactant Gel|This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.
41496516|NCT04732910|DRUG|Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor|observational
40836790|NCT03529279|DRUG|NCCN Chemotherapy|"UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy."
40836791|NCT03529279|RADIATION|CNG Radiation|"IMRT technique. GTV was given to 6810cGy, CTV1 was given to 6000cGy, and CTV2 was given to 4800-5400cGy. 30 fractions, daily, QW1-5.~CT-SIM or MR-CIM was evaluated every 10 fractions. If CR for CNG I and II patients at 10 fractions, radiotherapy were given 25 fractions, that was, GTV was given to 5675cGy, CTV1 was given 5000cGy, and CTV2 was given 4000-4500cGy, 25 fractions, daily, QW1-5.~If tumor reduced less than 50% at 20 fractions, GTV was modified according to tumor size at 20 fractions. The modified GTV was given 300cGy/F×5 after 25 fractions; the original CTV1 and CTV2 were unchanged, that is, GTV was given to 5675cGy/25Fr+1500cGy/5Fr and CTV1 was given to 6000cGy/30Fr, CTV2 was given 4800-5400cGy/30Fr."
40836792|NCT03529279|RADIATION|NCCN Radiation|"IMRT technique. When IMRT alone, GTV were given (1) 66Gy (2.2Gy/Fr) to 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 6-7 weeks; (2) 69.96 Gy (2.12 Gy/Fr), 6-7 weeks; CTV1-2 were given 44-50 (2.0 Gy/Fr) to 54-63 (1.8 Gy/Fr).~When combined with chemotherapy, GTV were given 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 7 weeks; CTV1-2 were given 44-50 Gy (2 Gy/Fr) to 54-63 Gy (1.8 Gy/Fr).~When palliative radiotherapy, 50Gy/20Fr; 37.5 Gy/15Fr (if tolerable, increases 5 fractions to 50Gy); 30Gy/10Fr, 30Gy/5Fr, 2 fractions per week, interval more than 3 days; 44.4Gy/12Fr was divided into 3 cycles, 2 fractions a day, 6 hours of interval, 2 consecutive days and 3-4 weeks between two cycles. After second cycles, the treatment plan must completely avoid the irradiation of the spinal cord."
40836793|NCT02613169|DRUG|Isoniazid|HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
41496517|NCT00235209|DEVICE|Collagen ORC Antimicrobial Matrix (CAM)|
40836794|NCT02239146|DRUG|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
40836795|NCT02239146|DRUG|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
40836796|NCT03436823|OTHER|nurse semi-structured interview|The first session of rTMS is D1. From the first meeting to D14 semi -structured interviews are set up
40836797|NCT03436823|OTHER|Music & Relaxation with eyes closed|The first session of rTMS is D1. From the first meeting to D14 music \& relaxation with eyes closed sessions are set up
40836798|NCT02545816|DEVICE|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
40836799|NCT04608162|OTHER|Pulsed Electromagnetic Field (PEMF)|PEMF was administered to the whole body using a 1.8×0.6m mat
40836800|NCT04608162|OTHER|Exercise Program|Exercise program to facilitate bone health
40836801|NCT04608162|OTHER|Placebo PEMF|Patients received placebo PEMF
40836802|NCT00073463|GENETIC|tgAAVCF|
41022243|NCT01030224|DRUG|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
41022244|NCT01030224|DRUG|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
41022245|NCT06142279|BIOLOGICAL|Sampling|At baseline, nasal, salivary and blood sampling will be taken for the participants.
41022246|NCT06142279|BIOLOGICAL|PCR (polymerase chain reaction) SARS-CoV-2|At baseline, this PCR SARS-CoV-2 will be taken for the participants.
41357038|NCT06169449|BEHAVIORAL|Weight management--refresh|According to the dietary nutrition guidelines for Chinese residents, patients are advised to drink 2500 ml or more of water daily; they are also advised to work and rest regularly to ensure sufficient sleep time, ensure smooth bowel movements, take deep breaths when waking up in the morning, pay attention to the work-rest balance, avoid being sedentary, and stand up and move around at least once every 50 minutes, maintain physical vitality by adjusting daily living habits.
41357039|NCT06169449|BEHAVIORAL|Control group|The relationship between overweightness and obesity and endometrial cancer risk was explained to patients in the control group and their willingness for self-weight management was respected. Communication was maintained with patients from treatment initiation to 3 and 6 months after treatment; patients' questions regarding weight reduction were answered and suggestions were provided regarding nutrition, exercise, and lifestyle management.
41496518|NCT04440670|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 28 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) within 24 hours after birth
41496519|NCT04440670|BIOLOGICAL|normal saline|preterm neonates less than 28 weeks are assigned to receive normal saline within 24 hours after birth
41496520|NCT05657392|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment. Last few decades, it has been revealed that rTMS accelerates motor recovery and may reduce stroke-related symptoms.
41357040|NCT02611037|DRUG|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
41022247|NCT05647824|DEVICE|Capillary Testing|Testing Contour Fit BGMS with capillary blood
41022248|NCT05647824|DEVICE|Alternative Site Testing (AST)|Testing Contour Fit BGMS using blood from alternative site
41022249|NCT05647824|DEVICE|Venous Testing|Testing Contour Fit BGMS with venous blood
41022250|NCT02039531|BIOLOGICAL|Plasma rich in growth factors|
41022251|NCT02039531|DRUG|Hyaluronic Acid|
41357041|NCT02611037|DRUG|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\^2).
41357042|NCT02611037|DRUG|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
41357043|NCT02611037|OTHER|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
41357044|NCT00968929|DRUG|Recombinant Streptokinase|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
41357045|NCT00968929|DRUG|Urokinase|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
41357046|NCT00004569|PROCEDURE|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
41357047|NCT03708029|OTHER|Revita Allograft|Human placental allograft
41357048|NCT00299091|DRUG|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
41357049|NCT02909504|DRUG|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels \> 0.6 mEq/L
41357050|NCT06075251|BEHAVIORAL|I-InTERACT-North|I-InTERACT-North is a virtual stepped-care positive parenting program. It comprises online psychoeducational modules as well as live therapy and coaching sessions. The program lasts anywhere from 1 to 16 weeks depending on parents' progress.
41022252|NCT05257993|DRUG|JPI-547|"* Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split."
41022253|NCT05257993|DRUG|modified FOLFIRINOX|"* After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~* After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~* Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~* Repeated administration every 2 weeks on a 14-day cycle"
41496521|NCT05657392|OTHER|32 electrode electroencephalography (EEG)|32-electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting
41496522|NCT05851625|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
41496523|NCT05851625|DEVICE|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
41496524|NCT00002393|DRUG|Indinavir sulfate|
41496525|NCT00002393|DRUG|Efavirenz|
41496526|NCT02131961|DRUG|Collagenase ointment|250 collagenase units/g
41496527|NCT02131961|DEVICE|Modified Contact Cast System|1 Unit
41496528|NCT03292159|DEVICE|Active RAVANS concurrent with arm motor training|Patient receives non-painful, sensory-level stimulation to the skin of left outer ear, where nerve endings of the auricular branch of the vagus nerve reside, while participating in arm motor training
41496529|NCT03292159|DEVICE|Inactive RAVANS concurrent with arm motor training|Patient does not receive stimulation delivered to the skin of left outer ear while participating in arm motor training
41496530|NCT05778487|DIETARY_SUPPLEMENT|Gatorade Thirst Quencher|Gatorade Thirst Quencher, 710ml (45g of carbohydrates, 6.3% carbohydrates, 25.4kcal/100ml)
41496531|NCT00176423|DRUG|galantamine|see arm/group description
41496532|NCT03168581|DRUG|CN-105|Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
41496533|NCT06270212|DEVICE|STAIRWAY|Evaluation of STAIRWAY (new airway device) during sedation.
41496534|NCT06270212|DEVICE|NO DEVICE|Evaluation of NO DEVICE during sedation
41496535|NCT00906386|DRUG|Varenicline|oral, 1 mg twice daily, 12 weeks
41022254|NCT05257993|DRUG|Gemcitabine-nab-paclitaxel|"* After IV administration of nab-paclitaxel 100 mg/m2 for 30 minutes~* IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~* Administration on Days 1, 8, and 15 on a 28-day cycle"
41022255|NCT06452615|DEVICE|Extracorporeal shockwave|The patients will receive 3000 to 6000 pulses every session by a radius of 15 mm probe (R15) at a frequency of 10 Hz, with energy gradually increasing from 1.4 to 1.5 bar
41022256|NCT01947803|DRUG|Paliperidone Palmitate|Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
41022257|NCT01204892|PROCEDURE|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
41022258|NCT01204892|PROCEDURE|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
41022259|NCT03367533|DRUG|Ketamine|Intravenous ketamine
41022260|NCT03367533|DRUG|Perampanel|Oral perampanel (6 mg)
41022261|NCT03367533|DRUG|Placebo|Oral placebo
41022262|NCT00358241|PROCEDURE|Nerve block|
41022263|NCT01369290|DRUG|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
41022264|NCT01369290|DRUG|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
41022265|NCT01369290|DRUG|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
41357051|NCT02014285|PROCEDURE|Muscle Ultrasound and Muscle Sample|The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
41357052|NCT02619461|OTHER|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
41357053|NCT02766309|OTHER|Sf12-v2|structured questioner Sf-12v2, developed by Ware.et al (Ware, Kosinski, Turner-Bowker \& Gandeck, 2002).
41357054|NCT00755521|DRUG|etoricoxib|"Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg"
41357055|NCT02394457|DRUG|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
41357056|NCT02394457|PROCEDURE|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
41357057|NCT01729065|OTHER|Physical therapy intervention|Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
41357058|NCT00663533|DEVICE|Vas-X|mechanical vasectomy device
41357059|NCT00592644|PROCEDURE|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
41357060|NCT00592644|PROCEDURE|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
41357061|NCT01835964|PROCEDURE|Glucose Variability Observation|On the morning of \~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
41357062|NCT00645736|OTHER|No intervention|No intervention
41357063|NCT01256957|DEVICE|HEPA filter|
41357064|NCT06230003|DRUG|Ropivacaine|Ultrasound guided ESP block either with the local anesthetic of 0.5% of Ropivicane 20 mL bilaterally (intervention group) or normal saline (control group) before surgery which will take 5-10 minutes in a 1:1 ratio.
41496536|NCT00906386|DRUG|placebo|oral, 1 mg twice daily, 12 weeks
41509233|NCT06487793|BEHAVIORAL|Sleep hygiene comparator|Content is based on sleep hygiene practices, but without additional CBT-I content featured in the experimental condition. There is also not brief alcohol intervention content in the control condition.
40836803|NCT02618668|DRUG|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
41022266|NCT01369290|OTHER|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
41022267|NCT01369290|DRUG|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
41022268|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
41357065|NCT06230003|DRUG|normal saline|Ultrasound guided bilateral ESP block either with normal saline
41357066|NCT00143728|DRUG|Lamivudine|See Detailed Description.
41357067|NCT03055806|DRUG|IX-01 400 mg|IX-01 400 mg caplet
41357068|NCT03055806|DRUG|Placebo|Placebo caplet(s)
41357069|NCT03055806|DRUG|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
41357070|NCT03055806|DRUG|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
41357071|NCT04173169|DRUG|Elagolix 200 MG|Elagolix tablet
41357072|NCT04173169|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
41357073|NCT02610894|OTHER|mHealth application (PoCAH)|Participants will have unlimited access to the mHealth app via iPad Mini for 5 days post-operatively to aid in pain management
41357074|NCT02610894|OTHER|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
41509234|NCT01959373|PROCEDURE|electroencephalograms (EEG)|
41509235|NCT01959373|PROCEDURE|electro-myography (EMG)|
41509236|NCT05416788|OTHER|cervical manipulation|high-velocity, low-amplitude cervical manipulation
41022269|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
40836804|NCT02618668|DRUG|Propofol|2 mg/kg I.V
41022270|NCT03797027|DEVICE|Percutaneous Nephrolithotomy without an abdominal cushion|patients undergo prone PNCL without an abdominal cushion
41022271|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 5 cm abdominal cushion
41022272|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 10 cm abdominal cushion
41022273|NCT06574009|BEHAVIORAL|Multimodal pain care|Behavioral therapy (as below), physical therapy, assistive devices (e.g. TENS, bracing), referrals to VA specialists (e.g. interventional pain), and complementary and integrative therapies (e.g. acupuncture or massage
41022274|NCT06574009|DRUG|Medication optimization|Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.
41022275|NCT06574009|DEVICE|Buprenorphine rotation|Subjects randomized to this arm at 6 months will be offered the chance to rotate from their full mu agonist opioid to buprenorphine using a standardized protocol
41022276|NCT06574009|OTHER|Opioid tapering|Subjects randomized to tapering will receive recommendations based upon the VA PBM's opioid tapering reference guide
41022277|NCT02113020|DRUG|TAK-233|Oral administration of TAK-233
41022278|NCT02113020|DRUG|Placebo|Oral admininstration of Placebo
41022279|NCT06364566|RADIATION|Neoadjuvant chemradiotherapy|Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage
41022280|NCT06364566|PROCEDURE|Minimally invasive esophagectomy|The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes
41022281|NCT02663128|DRUG|Lanabecestat|Administered orally
41022282|NCT02436382|OTHER|change in temperature|increase in ambient room temperature
41022283|NCT00650533|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fed
41022284|NCT00650533|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fed
41022285|NCT01092195|BIOLOGICAL|Gardasil|3 separate 0.5 ml intramuscular
41022286|NCT00928148|DRUG|SPD465|50 or 75 mg once daily for 7 days
41022287|NCT00928148|DRUG|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
41022288|NCT00928148|DRUG|Placebo|Once daily for 7 days
41022289|NCT02866578|PROCEDURE|Open lung protective ventilation strategy|
41022290|NCT05866003|DEVICE|Active conventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, an electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
41022291|NCT05866003|DEVICE|Active unconventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
41022292|NCT05866003|DEVICE|Sham tDCS plus CCFES|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator.
41160326|NCT04672499|DRUG|Miricorilant 150 mg tablets|Miricorilant 150 mg tablets for oral administration
41160327|NCT04672499|DRUG|Placebo 150 mg tablets|Placebo to match miricorilant 150 mg tablets for oral administration
41357075|NCT05862675|DIAGNOSTIC_TEST|RNA sequencing of blood samples|Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
41357076|NCT03975816|DEVICE|Analgesia nociception index|Monitor the maternity with Analgesia nociception index
41357077|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
41357078|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
41357079|NCT01795313|BIOLOGICAL|HLA-A2 restricted synthetic tumor antigen|
41357080|NCT01795313|DRUG|Imiquimod|
41357081|NCT01795313|OTHER|enzyme-linked immunosorbent assay|
41357082|NCT01795313|OTHER|flow cytometry|
41357083|NCT01795313|OTHER|immunohistochemistry staining method|
41357084|NCT01795313|OTHER|laboratory biomarker analysis|
41357085|NCT03198884|DRUG|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
41357086|NCT02498340|DIETARY_SUPPLEMENT|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
41022293|NCT05866003|BEHAVIORAL|CCFES with Occupational Therapy|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator. During the lab visits, all participants will use CCFES to assist hand opening during occupational therapy task practice.
41357087|NCT01299636|DRUG|PM060184|PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
40836805|NCT05589883|BEHAVIORAL|EMPOWER-Latinx|EMPOWER-Latinx will be delivered in Spanish by videoconferencing (i.e., Zoom, WebEx) with a trained study interventionist. Intervention modules will be audio- and video-recorded (videorecording optional).
41496537|NCT05812443|OTHER|Shabad Kriya Meditation|The Shabad Krya meditation technique, used in Kundalini Yoga, will be performed by the participants of this intervention group for 8 consecutive weeks, for 30 minutes, before going to sleep. This group will be trained by a Kundalini Yoga teacher with extensive experience in Shabad Krya meditation. The evaluation of Sleep Quality, Mental Health and Spirituality parameters will be measured through specific questionnaires, shortly after the end of the eighth week of intervention, and also one month and three months after the end of the intervention.
41496538|NCT05812443|OTHER|Relaxing reading|Relaxing reading will be performed by the participants of this control group for 8 consecutive weeks, for 30 minutes, before going to sleep. The evaluation of Sleep Quality, Mental Health and Spirituality parameters will be measured through specific questionnaires, shortly after the end of the eighth week of intervention, and also one month and three months after the end of the intervention.
41496539|NCT01058772|OTHER|INDUCTION of LABOUR|Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score \< 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
41357088|NCT00002494|DRUG|cyclophosphamide|
41357089|NCT00002494|DRUG|cytarabine|
41357090|NCT00002494|DRUG|dexamethasone|
41357091|NCT00002494|DRUG|doxorubicin hydrochloride|
41496540|NCT01774552|DEVICE|Photo Acoustic Microscopy and Optical Coherence tomography|Photo Acoustic Microscopy and Optical Coherence tomography
40836806|NCT04701203|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
40836807|NCT04701203|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
40836808|NCT06290193|BIOLOGICAL|Acute Normovolemic Hemodilution/ANH|For participants randomized to ANH, the volume of blood to be removed will be calculated using an established formula, based on preoperative hemoglobin, target hemoglobin after hemodilution, and the patient's estimated blood volume.
40836809|NCT03445390|DRUG|Acetaminophen|Acetaminophen 1 g intravenous given at the beginning and end of surgery.
40836810|NCT03445390|DRUG|Placebo|Placebo to match acetaminophen given at the beginning and end of surgery.
40836811|NCT03987386|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
40836812|NCT03987386|OTHER|Quality-of-Life Assessment|Ancillary studies
40836813|NCT03987386|OTHER|Questionnaire Administration|Ancillary studies
40836814|NCT03987386|RADIATION|Radiation Therapy|Undergo conventional radiation therapy
41496541|NCT04127630|PROCEDURE|mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
41022294|NCT02772016|DRUG|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
41022295|NCT04006158|DEVICE|LED bed|Low risk FDA cleared full body LED bed
41022296|NCT06105476|OTHER|Alcohol|Test drink with 12 g alcohol (30 g vodka 40%) in water
41022297|NCT06105476|OTHER|Alcohol+protein|Test drink with 12 g alcohol (30 g vodka 40%) and 25 g whey protein in water
41022298|NCT06105476|OTHER|Alcohol+retinol|Test drink with 12 g alcohol (30 g vodka 40%) and 1000 μg retinol in water
41022299|NCT06105476|OTHER|Retinol|Test drink with 1000 μg retinol in water
41357092|NCT00002494|DRUG|etoposide|
41357093|NCT00002494|DRUG|ifosfamide|
41357094|NCT00002494|DRUG|leucovorin calcium|
41357095|NCT00002494|DRUG|mesna|
41357096|NCT00002494|DRUG|methotrexate|
41357097|NCT00002494|DRUG|prednisone|
41357098|NCT00002494|DRUG|therapeutic hydrocortisone|
41357099|NCT00002494|DRUG|vincristine sulfate|
41357100|NCT00002494|RADIATION|low-LET cobalt-60 gamma ray therapy|
41357101|NCT00002494|RADIATION|low-LET photon therapy|
41496542|NCT05987319|DEVICE|RadioFrequency Microneedling Device|RadioFrequency device will be used for the treatment of dermatologic conditions.
41160328|NCT05465486|DEVICE|Brain-Computer Interface control of robotic arms with augmented reality|"The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions~Device: robotic arms MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics \& Digital Innovation Lab."
41160329|NCT05465486|DEVICE|Serious game with augmented reality|"The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game wiil be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions~Device: Wearable robotics The NeuroSuitUp wearable robotics jacket \& gloves are non-commercial wearable devices, equiped with inertial motion units, electromyography and electrical muscle stimulation, built and developed by the Medical Physics \& Digital Innovation Lab"
41496543|NCT01377987|DRUG|Acetazolamide|4 mg/kg, once daily before bed, for 7 days
40836815|NCT03825237|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
40836816|NCT02446470|PROCEDURE|Sinus Tarsi approach|A straight incision is made on the lateral side of the foot from the tip of the fibula to the base of the fourth metatarsal which centers the incision over the sinus tarsi. Then careful dissection is made through the subcutaneous tissues to prevent damage to the sural nerve, peroneal tendons, and extensor digitorum brevis (EDB). The origin of EDB is identified and the muscle is released distal enough to fully visualize the fracture and articular surface of the calcaneus. Following exposure of the fracture and articular surface of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
41496544|NCT01377987|DRUG|Placebo|4 mg/kg, once daily before bed, for 7 days
41160330|NCT01654445|DRUG|Tenecteplase|Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
41160331|NCT02146300|BIOLOGICAL|1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure|Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
41357102|NCT03265431|DRUG|18F-TPP|Imaging with 18-F-TPP (18F-BFPET)
41496545|NCT02394704|OTHER|Sensory attention training|"Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks."
41509237|NCT05416788|OTHER|Sham intervention|lateral flexion and cervical rotation without manipulation
41509238|NCT02473198|DRUG|Exparel|Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
41357103|NCT04528433|BEHAVIORAL|Medical-education-community Collaborated Intervention|The Medical-education-community Collaborated Intervention adds an additional part in comparison with the control group of classroom management guidance for teachers, review and practice organizational skills based on school daily activities in the school, teacher rewards and encouragement of students.
41357104|NCT04528433|BEHAVIORAL|routine clinical care|Routine clinical care includes a structured family behavioral intervention for ADHD symptom management and organizational skill training, the medication will be used if necessary.
41357105|NCT03845504|DEVICE|Intermittent Theta Burst Stimulation|Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
41496546|NCT04245956|PROCEDURE|Measure of hemodynamic indices in a stenosed coronary artery using a pressure wire|The intervention consists of measuring a series of hemodynamic indices in a stenosed coronary using a pressure wire, immediately before and after transcatheter mitral valve repair using the percutaneous edge-to-edge MitraClip system in patients with severe mitral insufficiency and concomitant intermediate coronary artery stenosis.
41496547|NCT02188173|DRUG|dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
40836817|NCT02446470|PROCEDURE|Extensile Lateral approach|An L-shaped incision overlying the lateral wall of the calcaneus will be made, followed by sharp dissection of soft tissues in line with the skin incision down to the periosteum. Effort will be made to identify and protect the sural nerve, as it commonly crosses the surgical field with this approach. The soft tissue flap is retracted as a single unit as subperiosteal dissection is performed. Following exposure of the lateral wall of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
40836818|NCT06088160|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty is a common surgical procedure performed in people with advanced hip osteoarthritis
40836819|NCT01120925|BIOLOGICAL|MNC|2-3 X 109 cells in 20ML suspension IPV in 4 min
40836820|NCT01120925|BIOLOGICAL|CD133|5-15 X 106 cells in 20ML suspension IPV
40836821|NCT01120925|BIOLOGICAL|Control|Injection of 20 ml Normal saline via IPV
40836822|NCT05485883|DRUG|Tislelizumab Lenvatinib|Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
40836823|NCT02558400|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
40836824|NCT02558400|DRUG|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
40836825|NCT02558400|DRUG|Latanoprost Ophthalmic Solution 0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
40836826|NCT02366767|DEVICE|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
40836827|NCT02366767|DEVICE|Control|Threshold suspend
40836828|NCT00569868|DRUG|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."
40836829|NCT02451891|BIOLOGICAL|MVA-EBO Z|
40836830|NCT02451891|BIOLOGICAL|ChAd3-EBO Z|
40836831|NCT06262256|BEHAVIORAL|High-intensity interval training|supervised exercise conducted on stationary bikes after individualized intensity prescription.
41496548|NCT06105827|DRUG|Control group|Give antibiotics or diclofenac sodium suppository as needed.
41496549|NCT06105827|DRUG|Ningmitai capsule|Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.
40836832|NCT02927275|BEHAVIORAL|Experimental: Standing Modality|Cognitive performance when standing
40836833|NCT02927275|BEHAVIORAL|Experimental: Biking Modality|Cognitive performance when biking slowly
40836834|NCT02927275|BEHAVIORAL|Experimental: Walking Modality|Cognitive performance when walking at 1mph
40836835|NCT02927275|BEHAVIORAL|No Intervention: Seated Modality|Cognitive performance when sitting.
40836836|NCT04029571|DRUG|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
40836837|NCT04029571|OTHER|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
40836838|NCT06326684|DRUG|Alcohol|The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.
40836839|NCT06326684|DRUG|Placebo|The effects of placebo will be determined.
41357106|NCT01272245|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
40836840|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 1 will be determined.
40836841|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 2 will be determined.
40836842|NCT05597332|OTHER|Care bundle for AKI|To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
40836843|NCT06470750|OTHER|Non-Interventional Study|Non-interventional study
41022300|NCT03329352|DEVICE|F&P Full-Face Mask|The F\&P full-face mask will serve as the participant's primary PAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial full-face mask as their primary PAP therapy mask for 6 months after Visit 3.
41357107|NCT01272245|DRUG|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
41357108|NCT00003368|DRUG|irinotecan hydrochloride|
41357109|NCT01930487|DIETARY_SUPPLEMENT|dietary supplement with antioxidants|Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
41357110|NCT01930487|DIETARY_SUPPLEMENT|Placebo|Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
41357111|NCT02402920|DRUG|Carboplatin|Given IV
41357112|NCT02402920|DRUG|Cisplatin|Given IV
41357113|NCT02402920|DRUG|Etoposide|Given IV
41357114|NCT02402920|OTHER|Laboratory Biomarker Analysis|Correlative studies
41022301|NCT03006328|BEHAVIORAL|GEM|Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.
41022302|NCT03006328|BEHAVIORAL|Enhanced Usual Care|Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
41022303|NCT01519518|DRUG|unfractionated heparin|70 units/kg body weight intravenous
41357115|NCT02402920|BIOLOGICAL|Pembrolizumab|Given IV
41357116|NCT02402920|PROCEDURE|Radiation Therapy|Undergo radiation therapy
41357117|NCT05577351|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System paired with a single-use, disposable tubing set specific for use with the RapidPulseTM Aspiration System
41357118|NCT00440232|DRUG|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
41357119|NCT00440232|DRUG|Placebo|Inert tab identical in appearance to Frovatriptan
41357120|NCT03181672|PROCEDURE|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
41022304|NCT01519518|DRUG|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
41022305|NCT05272852|DEVICE|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
41022308|NCT02455908|DRUG|Proleukin®|
41022309|NCT02563041|DRUG|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
41022310|NCT02563041|DRUG|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
41022311|NCT01326520|DIETARY_SUPPLEMENT|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
41022312|NCT01326520|DIETARY_SUPPLEMENT|diary product|The patients will consume daily 250 mL of a common dairy product.
41357121|NCT03181672|PROCEDURE|control group|Deltoid muscle injection with 1% lidocaine 10ml
41357122|NCT00278044|PROCEDURE|blood sampling and medical records|
41357123|NCT00764530|DEVICE|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
41357124|NCT00764530|DEVICE|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
41357125|NCT01199913|OTHER|The intervention will be Mini-Mental Status Examination (MMSE)|A questionnaire given to the study patient before and after the anesthetic at 1, 6 and 24 hours.
41357126|NCT02485340|DRUG|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
41357127|NCT02485340|DRUG|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
41357128|NCT02485340|DRUG|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
41357129|NCT03303131|OTHER|Discharge from community-based management|Comparison of patient characteristics and treatment outcomes between two groups
41357130|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
41357131|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
41357132|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
41357133|NCT00214942|DRUG|ORAVESCENT Fentanyl Citrate|
40836844|NCT05303675|OTHER|exercise and training|"Preoperative: An introductory information form will be filled out, and a lymphedema self-care and exercise booklet will be given.~Postoperative: Patients will be applied Progressive Upper Limb Exercises and Muscle Relaxation Training (PULE-MRT), lymphedema upper extremity circumference measurement, and symptom alert model until discharge, and Muscle Relaxation Training will continue until discharge.~Post-Discharge: They will be asked to record a diary at home. PULE-MRT will continue until day 15. The 15-day exercise program will continue for up to 3 months. Follow-up will be made by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
40836845|NCT05613582|DEVICE|Transcranial Direct Current Stimulation|The flow of DC electric current 1 mA for 20 minutes. The position of the electrode placement follows the international EEG 10/20 system.
40836846|NCT01238978|DRUG|Vildagliptin|
40836847|NCT01238978|DRUG|"Usual Care"|
40836848|NCT01665989|BEHAVIORAL|Group Lifestyle Program|
40836849|NCT01665989|BEHAVIORAL|Usual Care|Visits with a dietitian at nutrition services at MGH
40836850|NCT02565810|DRUG|Adalimumab PFS and Pen|
40836851|NCT02159378|OTHER|Fructosamines|
40836852|NCT02062203|DRUG|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
40836853|NCT02062203|DRUG|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
41022313|NCT02932631|OTHER|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
41022314|NCT03030833|DEVICE|Pulse Oximeter|Comparison of pulse oximetry to blood gas analyzer.
41022315|NCT06105489|PROCEDURE|Lateral Sinus Lift using tunnel flap technique|"The surgical procedure will involve the following steps:~* A single vertical anterior incision will be made, at least 10 mm mesially to the expected outline of the bony window.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
41022316|NCT06105489|PROCEDURE|Lateral Sinus Lift using crestal incision flap|"The surgical procedure will involve the following steps:~* A horizontal incision is made on the top of the alveolar ridge, along with two additional releasing incisions in the mesial and distal regions.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
40836854|NCT02062203|DRUG|Placebo|Single oral dose of placebo
40836855|NCT02062203|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
40836856|NCT00937989|OTHER|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
40836857|NCT00937989|OTHER|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
40836858|NCT00937989|OTHER|medical chart review|Baseline, 3, 6 and 9 months after starting the study
40836859|NCT00937989|OTHER|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
40836860|NCT00937989|OTHER|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
40836861|NCT00937989|PROCEDURE|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
41022317|NCT05629026|PROCEDURE|Micro-biopsies|Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.
40836862|NCT04960566|OTHER|Cognitive Behavioral Therapy|The CBT intervention is based on the theoretical framework that under stress (reflux symptoms) a person makes a rapid cognitive appraisal of the potential threat (automatic thoughts), leading to both emotional and physical responses in the body, thereby reacting behaviorally (avoidance, increased HCU) in an attempt to mitigate unpleasantness. CBT is a collaborative, present-focused treatment that utilizes a skills-based approach with home practice exercises. CBT targets automatic thoughts and appraisals of threat via education, self-monitoring of stressors and symptoms, and strategies to reframe problematic thinking patterns to more adaptive ones. Resonance frequency breathing (RFB) is achieved when a person breathes at a pace, typically 4 to 6 breaths per minute, that engages the body's baroreflex to modulate arousal. Prior research demonstrates 4 to 6 weeks of RFB training is sufficient to significantly increase baseline HRV with enduring effects for up to 6 months.
40836863|NCT04960566|OTHER|Sham-SOC Lifestyle Coaching|Sham-SOC Lifestyle Coaching
41022318|NCT01264861|DRUG|Safinamide|"Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food."
40836864|NCT06198088|OTHER|PNF techniques|The patient in the experiment group will PNF techniques (hold relax) the participants who were assigned for post traumatic stiffness of the elbow with baseline treatment (heating pad), stretching applied for 30 sec then relaxation time 10 sec, 5 repetition were given in a session for 5 days a week for 4 weeks.
40836865|NCT06198088|OTHER|Exercise therapy|exercise therapy range of motion, stretching and strengthening were applied with heating pad as baseline treatment. 5 repetition were given in a session for 5 days a week for 4 week.
40836866|NCT05478291|OTHER|Vitamin D supplementation|Appropriate diet and physical activity counselling to both groups. Supplementation with Vitamin D and oral Calcium-Doses of cholecalciferol (commercial name, Calcirol) 60,000 IU (sachets, dissolved in half glass milk) once per week for eight weeks for the intervention group and placebo (Lactose granules) to the placebo group according to the random numbers generated by the computer. After every 24 weeks blood 25 (OH) D levels will be assessed. If the subjects are found to be still deficient then supplementation of cholecalciferol 60,000 IU per week for eight weeks will be repeated.If the 25 (OH) D levels are normal, then cholecalciferol supplementation in doses of 200 IU per day will be given as a maintenance dose. Equal doses of calcium carbonate (1gm per day, commercial name Calcal) will be given to both the groups.
40836867|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
40836868|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
40836869|NCT04773990|DEVICE|Biodex Balance System|Subjects will receive several unique training modules using biodex
40836870|NCT04773990|OTHER|specific physical therapy exercise program|Subjects will receive recommended PT program
40836871|NCT03028987|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
40836872|NCT03028987|BIOLOGICAL|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
40836873|NCT00888641|PROCEDURE|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
40836874|NCT03286179|OTHER|modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS)|Provision of estimated risk for major cardiac events at 60 days based on the modified HEART and/or EDACS, using KPNC specific estimates derived from an internal validation study
40836875|NCT05764915|DRUG|RGT-264 phosphate tablets|RGT-264 phosphate tablets will be administered orally once daily (QD).
40836876|NCT03762798|DEVICE|The Bridge|The Bridge (Also known as NSS-2) is a percutaneous, auricular field stimulator developed to alleviate pain through stimulation of peripheral cranial neurovascular bundles in the external ear that could potentially gain access to brain areas involved in fear, pain and nociception. After five days, the subject will return to the clinic for device removal and disposal.
40836877|NCT01484379|PROCEDURE|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
41022319|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
41022320|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
41022321|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
41022322|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
41022323|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
41022324|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
41022325|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
41022326|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
41022327|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
41022328|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
41022329|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
41022330|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
41022331|NCT05505708|DRUG|hydroxyethyl starch in sodium chloride injection Brand Name: Voluven|"(6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5."
41022332|NCT05505708|DRUG|saline solution|Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
41022333|NCT05979805|OTHER|Conventional Educational interventions|Conventional educational methods can be verbal, written or visual and can be combined for greater understanding and effectiveness in oral health and dietary routines. The education are imparted in the first appointment of the appliances cementation by a video and oral health instruction booklet and each patient receive an oral hygiene kit. This education is repeated in month 1 and 3 after appliances cementation.
41022334|NCT05979805|BEHAVIORAL|Motivational intervention|In addition to the conventional educational method, a motivational interviewing (MI) by Miller and Rollnick of 30 minutes will be used, with an initial script according to the stage of change in each patient in T0. The reinforcements of motivational interviewing are in month one and three after the installation of the braces, they will have the same methodology but will be focused on the aspects that in the previous session or in the clinical assessment were detected as the most important deficiencies or risk factors for the patient.
41022335|NCT03565406|DRUG|Mocetinostat Induction Phase + Ipilimumab + Nivolumab|"Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles."
41022336|NCT03565406|DRUG|Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab|"De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period"
41022337|NCT01010984|DEVICE|LC beads loaded with Doxorubicin|During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicin will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
41357134|NCT01796106|DEVICE|Resin infiltration|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth, the study lesions will be treated using the resin infiltrant Icon (DMG, Germany) according to manufactures´ instructions. Essentially, the treatment consists of the following parts: 1) isolating the tooth with a rubber dam and cleaning its surface; 2) removing/ conditioning the surface layer of the lesion (using Icon-Etch) to open the lesion body; 3) drying of the exposed porous enamel; 4) infiltrating the existing pore volume with the resin infiltrant (Icon Infiltrant); 5) light curing of the resin infiltrant; 6) repeating the infiltration step including light curing; followed by 7) finalizing using interproximal finishing/polishing strips.
41357135|NCT01796106|DEVICE|Fluoride varnish & Oral hygiene instruction|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth oral hygiene instruction and topical fluoridation therapy will be provided. For topical fluoridation Duraphat Fluoride Varnish (Colgate, USA) will be used according to manufactures´ instructions.
41357136|NCT04340804|BEHAVIORAL|Kcal labelling|Real-time kcal counter synchronised with the food amount changes
41357137|NCT04340804|BEHAVIORAL|PACE labelling|Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
40836878|NCT04527627|BEHAVIORAL|Nursing Empowerment Intervention|"Nursing empowerment intervention The intervention will be carried out during the ICU discharge planning. A Patient Information Guide for Intensive Care Unit patients will be developed.~The guide will be based on the findings obtained in a previous qualitative study and on previous studies on patient empowerment and education. Its structure will take into account the dimensions of empowerment: bio-physiological, functional, social, experience, ethics and the financial aspect. The guide will be reviewed by experts in the development of information guides for patients and family members and will be evaluated by the participating ICUs before use.~EG patients will receive the intervention verbally and in booklet format from the study nurses at each ICU."
40836879|NCT04788771|PROCEDURE|Tracheal intubation in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
41496550|NCT06105827|DRUG|Combined group (Ningmitai plus tamsulosin)|Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.
40836880|NCT06507683|RADIATION|simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib|"A cumulative radiation dose of 50 to 70 Gy is administered in 25-30 fractions, 5 fractions per week, to the target lesion(s).~ripretinib: oral 150mg QD"
41022338|NCT04341922|BEHAVIORAL|Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic|The intervention focuses on 1) teaching participants how to discriminate between functional and dysfunctional worry (what are solvable problems vs. what is worry, i.e. unsolvable thoughts?) 2) providing participants with skills to solve functional worry topics (e.g. set time and make a workable plan to be prepared for possible negative outcomes \[e.g. becoming unemployed\]), 3) helping participants to reduce unhelpful behaviors that may reinforce worry (e.g., limit excessive news consumption, refrain from assurance seeking behaviors), 4) providing participants with skills to approach dysfunctional worry (e.g., not engage in worrisome thoughts, just leave them), and 5) increase the behavioral repertoire (take walks, engage in activities that promote health without putting oneself at risk to become infected).
41357138|NCT01161433|BEHAVIORAL|Virtually delivered spirometry quality improvement program|"Sites in the intervention arm receive the virtually delivered QI program.~The program includes:~1. Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;~2. Case-based, interactive webinars; and~3. an Internet-based spirometry quality feedback reporting system."
41357139|NCT00702949|DRUG|pregabalin|Given orally
41357140|NCT00702949|OTHER|placebo|Given orally
41357141|NCT04067076|OTHER|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
41357142|NCT02364999|DRUG|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
41022339|NCT06315491|DRUG|CBX-12|CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
41022340|NCT01320163|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
41022341|NCT01320163|DEVICE|Laryngeal Mask Airway|supra-glottic airway device
41496551|NCT00792935|DRUG|MK-0941|MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
41496552|NCT00792935|DRUG|Glimepiride|Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
41022342|NCT05797779|PROCEDURE|Skin biopsy|Punch biopsy of the skin
41022343|NCT00779246|OTHER|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
41022344|NCT00779246|DRUG|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
41022345|NCT00779246|OTHER|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
41022346|NCT06043414|DEVICE|triclosan-coated barbed suture|STRATAFIX™ Symmetric PDS™ (Johnson \& Johnson) triclosan-coated polydioxanone barbed suture caliber 0 or 1 will be the standardized suture used for abdominal fascial closure in patients randomized to the treatment group. STRATAFIX™ Symmetric PDS™ is an FDA approved sterile, synthetic, absorbable, barbed triclosan-coated polydioxanone suture. Its indications for use include soft tissue approximation where absorbable suture is appropriate.
41357143|NCT02364999|DRUG|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
41496553|NCT00792935|DRUG|Metformin|The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin \[(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\], the participant should remain on the same metformin dose throughout the study.
41496554|NCT06201429|DEVICE|Mechanical Tissue Resuscitation (MTR™)|Mechanical Tissue Resuscitation (MTR™) to externally drain excess fluid volume from the site of surgery in patients who have undergone a surgical procedure (craniotomy/craniectomy) for which a portion of the skull has been removed resulting in exposure of the dura/brain and require drainage of fluid.
41496555|NCT05021718|OTHER|Strengthening exercises|Back and hip strengthening exercises. The intensity of exercises was based on the exercise tolerance and pain thresholds of the individual subjects.
41496556|NCT05021718|DRUG|Pharmacological therapy|Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks
41496557|NCT05021718|OTHER|Hot compression|Hot moist compression from week 4 to week 6.
41022347|NCT06043414|DEVICE|triclosan-coated non-barbed suture|PDS™ Plus (Johnson \& Johnson) non-barbed triclosan-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ Plus is an FDA approved sterile, synthetic, absorbable, triclosan-coated surgical monofilament suture prepared from the polyester, poly(p-dioxanone). Its indications for use include soft tissue approximation where absorbable suture is appropriate.
41022348|NCT06043414|DEVICE|Non-coated non-barbed suture|PDS™ II (Johnson \& Johnson) non-barbed non-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ II is a FDA approved sterile, synthetic, absorbable, surgical monofilament suture prepared from the polyester, polyester, poly(p-dioxanone) indicated for use in soft tissue approximation where absorbable suture is appropriate.
41022349|NCT01706510|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
41022350|NCT01706510|DRUG|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
41022351|NCT05323383|BEHAVIORAL|Mindfulness Meditation|Participants in the mindfulness meditation condition will listen to a 20minute guided mindfulness meditation practice that holds the breath and body as the object of meditation.
41022352|NCT05323383|BEHAVIORAL|Self-hypnosis|Participants in self-hypnosis will listen to a 20-minute audio-guided hypnosis practice with an induction phase, followed by suggestions tailored towards shifts in affect and decentering, and then a re-alerting with post-hypnotic suggestions phase.
41022353|NCT05323383|OTHER|Attention Control|Control participants will listen to a 20-minute natural history recording which was chosen as past research has found that individuals who listen to it report this to be a neutral, but relaxing passage, and it has been used as an effective control condition in previous research.
41022354|NCT02758236|OTHER|No Intervention|No Intervention
41022355|NCT04424368|DEVICE|The remote monitoring system|Usage of remote monitoring system
41022356|NCT05194410|BEHAVIORAL|First 3 months of virtual, team-based exercise|Participants will be randomized onto mixed teams of medical students, residents, fellows, and attendings and registered for the virtual, team-based exercise intervention on FitRankings.com. All exercise (including walking, biking, lifting, yoga, and 40+ exercises) will be tracked via user's smartwatches (ie Apple, Garmin), smartphone fitness apps (ie MapMyRun), or manual upload, converted into Metabolic Equivalent of a Task (MET) minutes, and displayed on online leaderboards. Group activities will be encouraged by awarding raffle tickets for prizes to those who submit pictures with their teammates.
41022357|NCT05194410|BEHAVIORAL|Second 3 months of virtual, team-based exercise|Same as above
41022358|NCT03526913|PROCEDURE|PRP|PRP: autologous platelet-rich plasma
41022359|NCT03526913|PROCEDURE|STSG|skin graft: Split Thickness Skin Grafting (STSG)
41022360|NCT00797784|DRUG|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
41022361|NCT00968617|DRUG|MK2578|MK2578 1.0 mcg/kg/month
41022362|NCT00968617|DRUG|MK2578|MK2578 2.0 mcg/kg/month
41022363|NCT00968617|DRUG|MK2578|MK2578 3.6 mcg/kg/month
41022364|NCT00968617|DRUG|Comparator: darbepoetin alfa|darbepoetin alfa
41022365|NCT06534294|OTHER|reflexology|Reflex therapy was done for each patient for 30 minutes, first for the right foot and then for the left foot (15 minutes each) and breathing exercises in 3 stages
41022366|NCT06534294|OTHER|breathing exercise|breathing exercise done as 3 stages,stage one for 5 minutes, stage two for 10 minutes end stage ; Close eyes and focus your present feelings, Then Relax the whole body for 5 minutes.
41022367|NCT06534294|OTHER|standard care|standard medical care no other treatment
41022368|NCT01959581|DEVICE|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
41022369|NCT05702957|DRUG|letrozole 2.5mg-7.5mg|Tab letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
41022370|NCT05702957|DRUG|Clomiphene Citrate 50mg-150mg|Tab clomiphene citrate 50-150mg per day for 5 days started from 2nd day of menses.
41357144|NCT02364999|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
41496558|NCT05021718|BEHAVIORAL|Activities to daily living instructions|"* Avoid forward bending.~* Avoid heavy weightlifting.~* Avoid prolong standing.~* Avoid prolong sitting.~* Use a plain firm bed.~* Lie down in a supine position."
41022371|NCT00789217|PROCEDURE|Immediate skin test|Intradermal test with immediate reading
41357145|NCT02364999|DRUG|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
41022372|NCT03830502|PROCEDURE|Surgical sterilization|Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
41022373|NCT04632940|DRUG|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
41022374|NCT04632940|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
41022375|NCT04632940|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
41022376|NCT03740217|DRUG|GKT137831|oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
41022377|NCT02376049|DRUG|Pimecrolimus cream|
41022378|NCT02376049|DRUG|Betamethasone dipropionate cream|
41022379|NCT02376049|DRUG|Clobetasol propionate cream|
41022380|NCT02376049|DRUG|Glaxal Base cream vehicle|
41022381|NCT00821626|DEVICE|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
41022382|NCT00821626|OTHER|Control|No rapid flu test
41357146|NCT03719716|OTHER|Anticipatory care planning letter|Patient letter to take to GP and GP literature
41357147|NCT06227689|OTHER|Vaccine chatbot that offering HPV vaccine-related information|The intervention group will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get previously validated answers from the chatbot immediately. All the answers will be drawn from a database, whose content were obtained from official websites of Chinese government, HPV vaccine enterprises, and International organizations like WHO, and had been validated by experts. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
40836881|NCT01373320|BEHAVIORAL|Lay health advisor interactions|"For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.~For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening."
40836882|NCT04591249|BEHAVIORAL|Physical activity intervention|Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is \<8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.
41357148|NCT00295152|BEHAVIORAL|community occupational therapy in dementia|
41357149|NCT04951479|DEVICE|Gel-Bead embolization|OptiSphere is FDA approved for the embolization of hypervascular tumors. The product is crosslinked with glutaraldehyde, which improves the mechanical strength of the spheres and provides controlled degradation after implant. The spherical shape provides smooth embolic delivery and even, predictable distribution. In this study the Optispheres will be used for Geniculate artery embolization (GAE) which is a minimally-invasive procedure that has historically been performed for treatment of patients with recurrent knee hemarthrosis. Embolization is a procedure in which material is used to block small blood vessels. Angiogenesis, or growth of new vessels, has been implicated in the initiation and maintenance of joint inflammation. GAE has been applied to patients with moderate osteoarthritis-related pain refractory to maximal medical management with preliminary studies demonstrating a reduction in patient pain.
41357150|NCT01861158|BEHAVIORAL|Parenting Wisely|Computer-based, online, interactive parenting intervention
41357151|NCT00382044|DRUG|Eprex; Neorecormon; Aranesp|
40836883|NCT04591249|OTHER|Usual care|Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
40836884|NCT01348555|DRUG|Bronchodilatator|
40836885|NCT01348555|DRUG|Bronchodilatator|
40836886|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
40836887|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
40836888|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
40836889|NCT06373783|PROCEDURE|subepithelial connective tissue graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of the canine and the mesial of the first molar in the palate. Connective tissue dimensions were approximately 10x5x2 mm. The graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and an electronic caliper during surgery.
41022383|NCT03290716|OTHER|SS|Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.
41022384|NCT03290716|OTHER|SSSC|A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
41022385|NCT00213174|BEHAVIORAL|school playgrounds|
41022386|NCT06535698|DIETARY_SUPPLEMENT|Perelel Health Hormonal Balance Support|The supplement contains Myo-inositol (1000 mcg), Metabolic balance blend (200 mcg) including Berberine HCl, Alpha lipoic acid, DIM (33'-Diindolylmethane), and D-chiro-inositol (25 mg). Other ingredients include Vegetable cellulose (capsule), plant cellulose, and L-leucine.
41022387|NCT01369628|DRUG|Atacicept|"1. Regimen 1: Atacicept 25 mg weekly for 12 weeks~2. Regimen 2: Atacicept 75 mg weekly for 12 weeks~3. Regimen 3: Atacicept 150 mg weekly for 12 weeks"
41022388|NCT06460194|DRUG|Botuinum toxin|Injection of botulinum toxin in the palm of the hand
41022389|NCT00258986|PROCEDURE|Living donornephrectomy|
41022390|NCT04739748|DIAGNOSTIC_TEST|complete blood picture|Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).
41357152|NCT01494909|DIETARY_SUPPLEMENT|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
41357153|NCT02220608|BIOLOGICAL|Bortezomib|
41357154|NCT02220608|DRUG|G-CSF|
41022391|NCT06532006|DRUG|HLX22|HLX22 15mg/kg Q3w
41022392|NCT06532006|DRUG|Pembrolizumab|Pembrolizumab 200mg q3w
41022393|NCT06532006|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W
41022394|NCT06532006|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 ,Q3W
41022395|NCT06532006|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
41022396|NCT00134277|PROCEDURE|Infragenual dilatation|Infragenual dilatation
41496559|NCT01026987|DRUG|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
41022397|NCT00134277|PROCEDURE|Infragenual dilatation with stenting|Infragenual dilatation with stenting
41357155|NCT00436085|BEHAVIORAL|Cognitive behavioral stress management training|
41357156|NCT05779410|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks
41357157|NCT05779410|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily for 4 weeks
41357158|NCT01229592|DRUG|Ethanol|Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
41022398|NCT00134277|PROCEDURE|Infragenual dilatation with cutting balloon|Infragenual dilatation with cutting balloon
41022399|NCT00134277|PROCEDURE|Laser therapy|Laser therapy
41357159|NCT01229592|DRUG|Heparine|Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
41496560|NCT01026987|DRUG|AMD3100|
41496561|NCT01026987|PROCEDURE|Leukapheresis|
41496562|NCT01026987|PROCEDURE|Stem Cell Infusion|
41496563|NCT00995280|DEVICE|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
41496564|NCT00995280|DEVICE|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
41496565|NCT00163488|DRUG|Ciclesonide|
41509239|NCT02473198|DRUG|Femoral Nerve Block Bupivacaine|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
41496566|NCT04922320|BEHAVIORAL|Patient Priorities Care|A facilitator will schedule a PPC facilitation encounter 2-3 weeks before an upcoming PCP visit. The facilitator conducts a structured assessment using a written conversation guide that begins with general questions establishing what is most important to Veterans about their health and moves toward establishing specific goals (actionable outcomes), and what patients are willing/not willing to do to achieve these goals (care preferences). The result is a structured patient priorities report delivered to PCPs designed to facilitate changes in the patient's care plan to align it with his/her priorities. In the subsequent visit, the PCP will use one or more of the established PPC decisional strategies to align care with patients' priorities. Education for PCPs about the facilitation process, the patient priorities report, and the decisional strategies occurs prior to the PCP seeing any intervention patients. The PCP will document changes in care made to achieve the identified priorities.
41496567|NCT04922320|OTHER|Usual Care|PCPs will not be alerted when an encounter involves a UC group participant. UC participant visits will appear the same as all other unenrolled patient encounters. PCPs will be trained to address the needs of UC participants based on their typical approach without the use of a facilitator or explicit process for identifying patient priorities. UC participants will not receive any additional preparation
41496568|NCT00148005|PROCEDURE|Questionnaire and micturition and drinking diaries|
40836890|NCT06373783|PROCEDURE|de- epithelize gingival graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. A shallow horizontal incision was made at ≈3 mm apical from the gingival margin of the maxillary molar teeth using a number 15 scalpel blade. Subsequently, a parallel horizontal incision, at ≈ 4 mm apical from the first horizontal incision, was traced in conjunction with two vertical releasing incisions to delineate a rectangular area. Then, the uppermost epithelial layer was scraped off using a size 11 scalpel tip. The connective tissue graft to be taken from the palate area was 10x5x2 mm in size, and the graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and electronic caliper during surgery.
41357160|NCT01002196|BEHAVIORAL|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
41357161|NCT01002196|BEHAVIORAL|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
41357162|NCT03803176|PROCEDURE|Open Flap Debridement|Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
41357163|NCT03437811|DEVICE|Electro Flo Percussor, Model 5000|FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
41496569|NCT00148005|PROCEDURE|Clinical and functional examination (uroflowmetry, bladder scan and video-urodynamic examination)|
41496570|NCT00148005|BEHAVIORAL|Adaptation of the drinking scheme|
41496571|NCT00148005|DRUG|Anticholinergic therapy|
41496572|NCT00148005|BEHAVIORAL|Micturition clock|
41357164|NCT04390217|DRUG|LB1148|LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
41357165|NCT04390217|DRUG|Placebo|Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
41357166|NCT03556644|RADIATION|CTCA imaging|All the studied patients will have CTCA before percutaneous coronary intervention and 3 vessel NIRS-IVUS imaging during percutaneous coronary intervention
41496573|NCT04717765|DEVICE|Preventive, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
41496574|NCT04717765|DEVICE|Curative, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
41357167|NCT01468389|DRUG|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
41496575|NCT04717765|DEVICE|Preventive, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
40836891|NCT06373783|DIAGNOSTIC_TEST|ultrasonography|"Clinical parameter measurements (probing depth (PD), clinical attachment level (CAL), gingival recession depth and width, keratinized tissue width and height) were taken on the day of surgery, the 3rd days, the 14th days, the 1st month, the 3rd months and the 6th months.~Ultrasonography measurements A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the receiver site in the buccal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit pulsatility index (PI) = (Vmax-Vmin) (Vmean) (Vmax is peak systolic flow velocity. Vmin is diastolic flow velocity and Vmean is mean flow velocity.) The mean PI values of each patient were measured."
41357168|NCT01468389|DRUG|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
41357169|NCT02802527|PROCEDURE|Percutaneous Tracheostomy|
41357170|NCT02293200|DEVICE|Standard BLS|basic life support without any feedback device
41357171|NCT02293200|DEVICE|TrueCPR|CPR with feedback device
41357172|NCT02265575|DRUG|Hyaluronic Acid|rehydration using hyaluronidase-assisted subcutaneous infusion
41357173|NCT00606021|DRUG|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
41160332|NCT05394883|BEHAVIORAL|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week. Each session will consist of: 5-min flexibility warm-up and cool-down; 40 min of moderate intensity calculated as 40-59% Heart Rate Reserve (HRR) along with Rating of Perceived Exertion (RPE) between 13-14; and 20 minutes of resistance with an additional 30 minutes of unsupervised home aerobic activity per week. The women will be given their choice of aerobic equipment or walking either track/ treadmill to achieve a total of 40 minutes of moderate intensity exercise. The Supervised Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
41160333|NCT05394883|BEHAVIORAL|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking program including tips for walking indoors and outdoors, exercise handouts for warm-up/cool-down activities, demonstrations for resistance training activities and an exercise log. Women assigned to Home Exercise group will be contacted once per week to discuss their progress, barriers/challenges faced, ask questions, and strategies to achieve the exercise guidelines. The Home Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
41160334|NCT01421797|DRUG|Dexamethasone|1 mg PO
41022400|NCT05229679|DIAGNOSTIC_TEST|HPV testing|All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
41022401|NCT06057415|PROCEDURE|HAPTOS (Handling Adapted to Postnatal age with Tactile-kinaesthetic and Oral sensorimotor Stimulation|Tactile-kinaesthetic and Oral sensorimotor Stimulation
41160335|NCT01421797|DRUG|Cortrosyn|single IV bolus of 0.25 mg will be administered
41160336|NCT00308841|DRUG|Lidocaine (drug)|
41160337|NCT05335577|DIAGNOSTIC_TEST|Urinary Claudin-2|A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
41496576|NCT04717765|DEVICE|Curative, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
40836892|NCT00758641|DEVICE|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
41022402|NCT04596163|PROCEDURE|Transversus thoracis muscle plane block|After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.
41160338|NCT05335577|DIAGNOSTIC_TEST|Urinary Caveolin-1|A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
41160339|NCT05335577|DIAGNOSTIC_TEST|Urinary EGF|A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.
41160340|NCT02703402|OTHER|Exercise protocol|Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.
41160341|NCT02703402|OTHER|Manual of exercises|Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
41496577|NCT04499092|BEHAVIORAL|Neuropsychological treatment|Neuropsychological treatment
41496578|NCT06442189|DIETARY_SUPPLEMENT|Mediterranean Diet|The aim was to evaluate the effects of the application of a Mediterranean diet on the reproductive and metabolic parameters in the 3rd month of patients with a body mass index of 25 and more who were treated in our clinic due to a diagnosis of PCOS.
41022403|NCT05423262|BIOLOGICAL|TRK-950|5 or 10 mg/kg administered intravenously over 60 minutes (weekly)
41022404|NCT05423262|BIOLOGICAL|TRK-950|10 mg/kg administered intravenously over 60 minutes (weekly)
41357174|NCT00606021|DRUG|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
41357175|NCT05370560|OTHER|Plasma transthyretin concentration|Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
41357176|NCT04293081|DRUG|Preemptive chlorepheniramine maleate intravenous injection|Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
41357177|NCT04293081|DRUG|normal saline|participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
41357178|NCT01417949|OTHER|Time of starting antiretroviral therapy|"Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit."
41357179|NCT00935766|DRUG|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
41357180|NCT00935766|DRUG|Placebo|
41357181|NCT00952133|DRUG|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
41357182|NCT00952133|DRUG|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
41357183|NCT05541380|OTHER|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
41357184|NCT02292615|OTHER|Medical Imaging|
41496579|NCT05191017|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
41496580|NCT05191017|DRUG|Enzalutamide|Enzalutamide
41496581|NCT05850806|DEVICE|The KmAsthma self-management smart phone app intervention|KmAsthma is a free app which enables users to track their symptoms, access their action plan, learn about asthma and set goals to make change
41496582|NCT03856112|DRUG|Dexamethasone|Given PO
41357185|NCT01682694|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
41357186|NCT01682694|DIETARY_SUPPLEMENT|placebo|
41357187|NCT00133640|DRUG|cholecalciferol|
41357188|NCT00133640|BEHAVIORAL|Physiotherapy|
40836893|NCT00758641|DRUG|Corticosteroid Injection|kenacort 40 mg/ml triamcinolon acetonide
40836894|NCT02365285|DRUG|Galantamine|16 mg po prior to the infusion of intralipid
40836895|NCT02365285|DRUG|Placebo Oral Capsule|Placebo oral capsule prior to the infusion of intralipid/heparin
41022405|NCT05423262|BIOLOGICAL|TRK-950|20 mg/kg administered intravenously over 60 minutes (bi-weekly)
41022406|NCT05423262|DRUG|Nivolumab|240 mg administered intravenously over 30 minutes (bi-weekly)
41022407|NCT02823925|DRUG|Pamidronate or Zoledronate|
41022408|NCT00334815|BIOLOGICAL|Bevacizumab|Given IV
41022409|NCT00334815|DRUG|Cisplatin|Given IV
41022410|NCT00334815|DRUG|Docetaxel|Given IV
41022411|NCT00334815|DRUG|Etoposide|Given IV
41022412|NCT00334815|BIOLOGICAL|Filgrastim|Given SC
41022413|NCT00334815|BIOLOGICAL|Pegfilgrastim|Given SC
41357189|NCT03313440|OTHER|High wheat fiber|Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
41357190|NCT03313440|OTHER|Low fiber|Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
41496583|NCT03856112|DRUG|Ixazomib|Given PO
41496584|NCT03856112|DRUG|Ixazomib Citrate|Given PO
41496585|NCT03856112|DRUG|Venetoclax|Given PO
41496586|NCT03730818|OTHER|Water-based Exercise Group|The intervention consist will of a water-based exercise protocol
41496587|NCT03730818|OTHER|Land-based Exercise Group|The intervention will consist of a land-based exercise protocol
41496588|NCT00616798|DRUG|RO4917838|10mg po daily
41496589|NCT00616798|DRUG|RO4917838|30mg po daily
41496590|NCT00616798|DRUG|RO4917838|60mg po daily
41022414|NCT00334815|RADIATION|Radiation Therapy|Undergo thoracic radiotherapy
41160342|NCT04103905|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
41160343|NCT01878188|DRUG|BC-819/PEI|Intravesical instillation
40836896|NCT02365285|DRUG|Intralipid|Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
41022415|NCT03991741|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|Autologous TILs
41022416|NCT03991741|BIOLOGICAL|High-Dose Interleukin 2|720,000 IU/kg every 8 hours for up to 15 doses
41022417|NCT01148810|DRUG|BAF312|
41022418|NCT01148810|DRUG|Placebo|
41160344|NCT01878188|DRUG|BCG Vaccine|intravesical instillations
41160345|NCT05141071|DRUG|Ivabradine 5mg Tab|Ivabradine will be administrated enterally
41496591|NCT00616798|DRUG|Placebo|po daily
41022419|NCT00497926|BIOLOGICAL|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
41022420|NCT00476424|DRUG|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
41022421|NCT01732835|DEVICE|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
41022422|NCT01963624|DEVICE|Ultrasonography|Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
41022423|NCT01326780|DRUG|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
41022424|NCT01326780|DRUG|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
41022425|NCT01326780|DRUG|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
41022426|NCT01326780|OTHER|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
41160346|NCT05141071|DRUG|Placebo|50 ml of saline will be administrated enterally
41160347|NCT01187147|DIETARY_SUPPLEMENT|green tea extract|Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
41160348|NCT04750577|DRUG|Placebo matching BI 685509|film-coated tablet
41160349|NCT04750577|DRUG|BI 685509|film-coated tablet
41160350|NCT04180397|DRUG|Furosemide|Furosemide 10 mg/ml for injection/infusion
41160351|NCT04180397|DRUG|Isotonic saline|Isotonic saline used as placebo (injection/infusion)
41496592|NCT00616798|DRUG|Standard antipsychotic therapy|As prescribed
41496593|NCT00326963|DRUG|Background ARVs|As prescribed
41357191|NCT02996175|BEHAVIORAL|Behavioral Sleep Treatment|"1. Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~2. Information on healthy sleep hygiene, preventative techniques, and use of visual supports~3. Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~4. Information on procedures for delayed sleep onset and problematic sleep associations~5. Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
41357192|NCT02996175|BEHAVIORAL|Standard of care sleep treatment enhanced with psychoeducation|"1. Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome~2. Introduction to understanding and interpreting results from clinical evaluations~3. Introduction to educational planning, expectations, and transition planning~4. Introduction to lifespan development and advocacy and support services available~5. Feedback on current concerns and methods for obtaining services to manage concerns"
41357193|NCT00000970|DRUG|Foscarnet sodium|
40836897|NCT02365285|DRUG|Heparin|heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
40836898|NCT01056120|DEVICE|Pro Kinetic Energy bare metal stent|PCI
40836899|NCT04731532|PROCEDURE|classical respiratory physiotherapy with thoracic vibration|Classical respiratory physiotherapy application: Patient is positioned, postural drainage application is operated by tapping and trifled .
40836900|NCT04826016|DRUG|POL6326|POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
40836901|NCT04826016|DRUG|Eribulin|Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
40836902|NCT04826016|DRUG|Nab paclitaxel|Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
41357194|NCT00000970|DRUG|Ganciclovir|
41357195|NCT02728804|OTHER|Quality-of-Life Assessment|Complete questionnaire
41357196|NCT02728804|OTHER|Questionnaire Administration|Complete questionnaires
41357197|NCT04216628|OTHER|Amniotomy|Artificial rupturing of membranes and IV infusion of Oxytocin
41357198|NCT00352794|DRUG|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
40836903|NCT04670783|PROCEDURE|Surgery|Orthopedic surgery (i.e. tenotomy, tendon transfer) or percutaneous neuroablative procedures (i.e. cryoneurotomy) which will be done for upper limb refractory spasticity after being triaged by DNB.
40836904|NCT03654287|OTHER|Treatment|The CELS way to intervene severe sepsis and refractory shock
40836905|NCT00180167|DRUG|randomization between two established Chemotherapies|
40836906|NCT02096263|BIOLOGICAL|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
40836907|NCT02096263|BIOLOGICAL|Pediarix|3 doses administered intramuscularly in the right thigh
40836908|NCT02096263|BIOLOGICAL|ActHIB|4 doses administered intramuscularly in the upper left thigh
40836909|NCT02096263|BIOLOGICAL|Pentacel|4 doses administered intramuscularly in the right thigh
40836910|NCT02096263|BIOLOGICAL|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
40836911|NCT02096263|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the right thigh
40836912|NCT02096263|BIOLOGICAL|Hiberix|1 dose administered intramuscularly in the left thigh
40836913|NCT02096263|BIOLOGICAL|Prevnar13|3 doses administered intramuscularly in the lower left thigh
40836914|NCT02096263|BIOLOGICAL|Rotarix|2 doses administered orally
40836915|NCT02184832|DRUG|Metformin|2 doses of 500 mg metformin given approximately 12 hrs apart
40836916|NCT02184832|OTHER|Low tryptophan diet|
40836917|NCT02184832|OTHER|High tryptophan diet|
40836918|NCT03547934|DEVICE|High Intensity Focused ElectroMagnetic system.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
41357199|NCT00352794|DRUG|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
41357200|NCT06308289|OTHER|Global Posture Re-education|Focusing on postural correction and movement patterns
41357201|NCT06308289|OTHER|Active Cycle of Breathing Technique|Emphasizing breathing control, thoracic expansion, and mucus clearance techniques
41496594|NCT00326963|DRUG|PI|As prescribed
41496595|NCT00326963|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
41357202|NCT01550315|PROCEDURE|Pulsitile Arterial Tonometry (PAT) Protocol|"* A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~* RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~* Continuous recording of pulsatile blood volume responses from both hands will be initiated.~* After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
41357203|NCT01550315|DEVICE|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (\~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
41496596|NCT04959591|DRUG|intravenous acetaminophen|experimental(pre): administration of IV acetaminophen
41357204|NCT01550315|DEVICE|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
40836919|NCT03947970|DRUG|[14C] CR845|Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
41357205|NCT06376201|DRUG|Amphotericin B cholesterol-sulfate complex for injection|"Patients were eligible for enrollment on antifungal therapy with injectable amphotericin B cholesterol-sulfate complex (ABCD) at the same time as a treatment for underlying disease.~Dosage: According to the patient's condition and the investigator's judgment, the initial dose of ABCD can be 0.5-1.0mg/kg/d, and the dose can be increased daily according to the situation, and the therapeutic dose can be increased to 3.0-4.0mg/kg/d on the third day.~Course of treatment: ≥ 14 days (whether to continue to receive trial drug treatment after 14 days is decided by the investigator according to the patient's condition)."
41357206|NCT03021707|DEVICE|WaveLight® Ultraviolet Femtosecond (FS) Laser System|Utilizes ultraviolet (UV) light with a wavelength of 347 nanometers (nm) for refractive error correction
41357207|NCT03021707|PROCEDURE|Laser Assisted Lenticular Extraction|Used for refractive error correction
41357208|NCT04047342|BEHAVIORAL|Welcome email|Email
41357209|NCT04047342|BEHAVIORAL|Loss frame|Email
41357210|NCT03596307|DIETARY_SUPPLEMENT|Ashwagandha extract|Shoden 180 mg capsule.
41357211|NCT03596307|DIETARY_SUPPLEMENT|Placebo|Placebo 180 mg (Sucrose) capsule.
41357212|NCT04301492|DRUG|Vortioxetine|16 weeks for each participant. During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day. At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
41496597|NCT04959591|DRUG|intravenous acetaminophen|experimental(post): administration of IV acetaminophen
41496598|NCT04959591|DRUG|Placebo|placebo comparator: administration of normal saline
41496599|NCT02675569|PROCEDURE|Catheter|A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
41496600|NCT02675569|PROCEDURE|Fistula|A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
41496601|NCT00468260|DRUG|Patupilone|
41496602|NCT06345365|DRUG|mitoxantrone liposome, Ara-Cytarabine and azacitidine|Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7
40836920|NCT03738007|DEVICE|HA IDF II|Treatment with HA IDF II (YVOIRE volume)
40836921|NCT03738007|DEVICE|Perlane|Treatment with Perlane
40836922|NCT03191370|OTHER|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
40836923|NCT03191370|DRUG|Local Anesthetics,Topical|Anesthetic spray
40836924|NCT00946907|DRUG|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
40836925|NCT00946907|DRUG|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
40836926|NCT03075124|DEVICE|External Counter Pulsation|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
41357213|NCT03986671|DEVICE|Transmembrane EMG Oropharynx Probe|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
41496603|NCT06345365|DRUG|Daunorubicin,Ara-Cytarabine, azacitidine|Daunorubicin 60 mg/m2, intravenously, once daily, days 1 to 3; Ara-Cytarabine 100 mg/m2, IV drip, every 12h, days 1 to 7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;
41496604|NCT00087282|DRUG|alvocidib|
41496605|NCT00087282|DRUG|irinotecan hydrochloride|
41496606|NCT06354452|OTHER|Person-level linkage of the database looking for relationship with sepsis survival and previous intake of certain drug families and previous dependence on health services.|"A descriptive analysis of the baseline demographics, risk factors, health status, comorbidities, frailty, and previous dependence on health services of all patients admitted to hospitals in the region will be carried out.~Both the overall data of patients admitted to hospitals in any ward and those admitted to ICU will be analysed. The survival data of patients will be compared with their previous individual drug consumption, trying to find out the relationship between chronic consumption of certain families of drugs and inhospital survival to sepsis. In addition, drug dependence and dependence on health services of sepsis survivors will be studied in comparison with their situation prior to sepsis."
41496607|NCT04709367|OTHER|3D optical scan|The clinical protocol consisted of four test sessions in four different days for an overall duration of 3 weeks. During the 1st session, amputees' residual limb volume was measured 7 times at intervals of 10 minutes after the prosthesis removal. During the subsequent sessions, the residual limb volume was measured immediately after the prosthesis doffing and after the amputee's stabilization time, before and after 15-min of walking on a treadmill, both in the morning and in the afternoon.
41496608|NCT02283008|BEHAVIORAL|Assessment of inhaler technique pre and 6 weeks post training|Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
41357214|NCT03602209|PROCEDURE|Removal of infected implant|
41357215|NCT03602209|DRUG|Antibiotic durations|
41496609|NCT02360176|PROCEDURE|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
41496610|NCT02360176|PROCEDURE|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
41496611|NCT03250559|PROCEDURE|Percutaneous nephrolithotomy|Endoscopic kidney stone extraction technique.
41496612|NCT06453629|DEVICE|Floreo VR|12 week VR program to help children with ASD to reduce the core symptoms of Autism
41496613|NCT06453629|DEVICE|VR Control|12 week program administered in VR
41496614|NCT06453629|DEVICE|VR Control Crossover|If opt in, this group will crossover at the end of 12 weeks to the Floreo VR program
40836927|NCT05202821|DRUG|PRG Barrier Coat|3 arm randomized single blind clinical trial comparing 3 groups. first group will be receiving fluoride varnish, second group will be receiving PRG Barrier Coat and the third group will be receiving MI paste
40836928|NCT05202821|DRUG|Fluoride varnish|First group will be receiving Fluoride varnish every 3 months
40836929|NCT05202821|DRUG|MI paste|Third group will be receiving MI paste
40836930|NCT03256435|BEHAVIORAL|RAMP PrEP initiation, adherence, and retention intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
40836931|NCT01522261|OTHER|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
41357216|NCT05327868|OTHER|Low Fat Diet (LFD)|Subjects will be asked to adhere to a low fat diet (assigned in random order) and be counseled by a dietitian using 5 days of sample menus, monitored online using a shared nutrient analysis program, and supplied with low fat foods to increase compliance
41357217|NCT05327868|OTHER|High Fat Diet (HFD)|Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance
41357218|NCT02054572|DRUG|[¹⁴C]Etelcalcetide|750 nCi of \[¹⁴C\]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
41357219|NCT00149227|DRUG|Valsartan|Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.
41496615|NCT03107247|DRUG|Imaging Time|Participants will be asked to be imaged at an additional time point.
40836932|NCT01522261|OTHER|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
40836933|NCT00875940|OTHER|Diagnostic imaging procedures.|
40836934|NCT00351273|DRUG|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
40836935|NCT00351273|DRUG|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
40836936|NCT00351273|DRUG|Placebo|Methylcellulose
40836937|NCT00140959|DRUG|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
41357220|NCT00149227|DRUG|Non-ARB|'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
40836938|NCT00140959|DRUG|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
40836939|NCT01232153|DEVICE|Non invasive ventilation|Non invasive ventilation
40836940|NCT02033213|OTHER|Restrictive group|"A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
40836941|NCT02033213|OTHER|Liberal group|"A group of patients who received \> 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
41357221|NCT03188133|OTHER|behavioral task : emotional priming|emotional priming task on ambiguous visual stimuli
41357222|NCT04193137|DIAGNOSTIC_TEST|Oral sodium loading test,Seated saline infusion test and Captopril challenge test|"Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.~Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge."
41357223|NCT02543879|DRUG|FT-1101|FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
41357224|NCT02543879|DRUG|Azacitidine|Azacitidine will be administered per site's standard of care
41357225|NCT02993731|DRUG|Napabucasin|Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
41357226|NCT02993731|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
41357227|NCT02993731|DRUG|Gemcitabine|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
41357228|NCT05243199|DRUG|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).
41357229|NCT05243199|DRUG|Irbesartan|The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
41357230|NCT02670395|DRUG|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
41357231|NCT02670395|DRUG|Placebo|Placebo solution will be administered orally.
41357232|NCT01738724|DRUG|Dienogest|Dienogest 2mg pills daily during 6 months
40836942|NCT03364413|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
41357233|NCT01738724|DRUG|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
40836943|NCT00427882|DRUG|ALFUZOSIN|
40836944|NCT03819452|DIAGNOSTIC_TEST|Vitamin D Level|Vitamin D level is measured upon the presentation of the case with ischemic stroke
41357234|NCT01738724|DRUG|Desogestrel|Desogestrel 75mcg pills daily during six months
41357235|NCT05170581|DRUG|Sintilimab Combined with Platinum-containing Chemotherapy|Admininster Sintilimab and platinum-containing chemotherapy in neoadjuvant treatment of resectable stage ⅡB～ⅢA Non-small Cell Lung Cancer
41357236|NCT01259388|DRUG|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
41357237|NCT00963742|DEVICE|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
41509240|NCT02473198|DRUG|Toradol|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
41357238|NCT06261268|PROCEDURE|Strip graft with Mucograft|"An apically repositioned flap is made in the vestibular region. The flap is then elevated with a split-thickness preparation, and the mucogingival junction will be repositioned apically and fixed with periosteal-anchored sutures. Then, a free epithelialized gingival strip graft will be harvested from the molar area of the palate. The Strip graft is sutured to the apical end of the recipient bed. The remaining uncovered part of the periosteal bed will be covered with a xenogeneic collagen matrix (Mucograft®. Geistlich Pharma AG, Wolhusen, Switzerland) fixed with simple interrupted and crossed sutures. The edges of the palatal wound (donor area) will be approximated with crossed sutures."
41357239|NCT06261268|PROCEDURE|Free gingival graft|The preparation of the apically repositioned flap and the recipient bed with its apico-coronal design and dimension is performed as in the test group. Subsequently, an epithelialized free gingival graft with the size of the entire recipient area with a thickness of 2 mm will be harvested from the molar area of the palate. The graft is sutured to the recipient periosteal bed using simple interrupted and crossed sutures. In the donor area, a collagen sponge is sutured to the wound by means of crossed sutures.
41022427|NCT04411290|PROCEDURE|Total thyroidectomy (TT)|Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)
41022428|NCT03099382|BIOLOGICAL|camrelizumab|Subjects receive camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks
41022429|NCT03099382|DRUG|Docetaxel|Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks
41022430|NCT03099382|DRUG|Irinotecan|Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks
41022431|NCT01018849|DIETARY_SUPPLEMENT|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
41357240|NCT02949544|OTHER|water immersion|warm water immersion
41357241|NCT04418752|OTHER|Psychological therapy|"The National Institute for Health and Care Excellence (2018) specifies NET as a psychological intervention for the treatment of PTSD or prominent symptoms of PTSD in adults. NET is a short-term treatment which incorporates elements of CBT exposure therapy and testimonial therapy. In exposure therapy, clients are encouraged to repeatedly discuss traumatic experiences in detail, including emotions and sensory experiences (Schauer, Elbert, \& Neuner, 2011).Testimonial therapy involves the construction of a detailed and coherent report of the survivor's biography including an explicit description of the traumatic events (Neuner, Schauer, Roth \& Elbert, 2002, pp.5-6). Therefore, NET aims to embed the traumatic experience within the context of the person's life and the mechanisms of change are theorised to be exposure and habituation to the traumatic experience and the reconstruction of autobiographical memory."
41357242|NCT06127108|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Panel is a visual lateral flow in vitro immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B in anterior nasal swab samples from individuals with symptoms and suspected of COVID-19 or Flu infection by their healthcare provider.
41357243|NCT00372944|DRUG|AZD6244|oral capsule
41357244|NCT00372944|DRUG|capecitabine|oral tablet
41022432|NCT01018849|DIETARY_SUPPLEMENT|Placebo|placebo by mouth every 2 months for 1 year
41022433|NCT04981041|DRUG|Prasugrel or Ticagrelor|Escalated antiplatelet therapy with a potent P2Y12- inhibitor for one month in patients with atrial fibrillation and indication for treatment non-vitamin K antagonist oral anticoagulants (NOACs)
41022434|NCT04981041|DRUG|Clopidogrel|Clopidogrel and NOAC
41496616|NCT05063435|DIAGNOSTIC_TEST|Carotid ultrasonography|"1. Study takes 10 - 15 minutes to complete~2. Subject will be asked to lay still and quietly during procedure~3. The ultrasound probe will be placed on one side of the neck to capture images of the carotid artery. When images from one side have been captured, the probe will be moved to the other side of the neck to capture images from the other carotid artery.~4. Blood pressure and heart rate will be obtained during the study~5. Results will be anonymized, digitized and stored on CD with unique identifier"
41496617|NCT05063435|DIAGNOSTIC_TEST|Echocardiography, transthoracic|"1. Study takes 15 - 20 minutes to complete~2. Subject will be asked to lay still and quietly during procedure~3. The technician will apply an ultrasound probe to the chest. Images and movies will be acquired.~4. Results will be digitized and stored on CD"
41357245|NCT03027180|DEVICE|Noninvasive positive airway pressure with different levels|
41357246|NCT04652466|DEVICE|farukcicekci2|To compare the incidence of for I-Gel malposition between USG and FOB, and to find the correlation between I-Gel's USG and FOB-detected malposition
41357247|NCT04123340|DIAGNOSTIC_TEST|Additional intraprocedural pre-ablation CT-scan|In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
41357248|NCT03163290|OTHER|Posterolateral Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise
41357249|NCT03163290|OTHER|Anteromedial Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
41357250|NCT01716585|DRUG|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
41357251|NCT01716585|DRUG|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
41357252|NCT01716585|DRUG|Placebo for ABT-450/r/ABT-267|Tablet
41357253|NCT01716585|DRUG|Placebo for ABT-333|Tablet
41357254|NCT01716585|DRUG|Placebo for ribavirin|Capsule
41357255|NCT03486951|PROCEDURE|Orthognathic Surgery:|maxillary/mandibular osteotomies for orthognathic purposes for the treatment of a dento-maxillary dysharmony The choice between outpatient procedure or hospitalization is decided by the surgeon on a case-by-case basis according to data relating to the general state of the patient, the type of surgery, the social context, the distance from the patient's home. a medical center in accordance with the usual and legal standards of outpatient surgery
41357256|NCT02068261|BEHAVIORAL|Computerized Cogmed working memory training|Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
41357257|NCT02068261|BEHAVIORAL|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
41357258|NCT01734967|DEVICE|needle based CLE|"EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis."
41357259|NCT01734967|PROCEDURE|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
41357260|NCT06403358|DIETARY_SUPPLEMENT|YOVIS BIMBI|42 male and female subjects, aged between 3 and 14 years with acute diarrhea will be treated with Yovis BAMBINI. The 42 subjects will be recruited with a competitive enrolment at the involved study sites.
41357261|NCT06214039|BEHAVIORAL|Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety|A 3-hour one session exposure therapy for public speaking anxiety
41357262|NCT04981236|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.3% will be injected.
41357263|NCT04981236|PROCEDURE|Periarticular block|The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
41357264|NCT02401945|DRUG|DE-120|
41357265|NCT02401945|DRUG|Aflibercept|
41357266|NCT05215106|DRUG|Durvalumab|Following preparation of durvalumab, the entire contents of the IV bag should be administered as an IV infusion over approximately 60 minutes (±5 minutes), using a 0.2μm in-line filter (or add-on filter).
41357267|NCT05837429|BEHAVIORAL|Low Volume High Intensity Exercise Training|Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
41357268|NCT05837429|BEHAVIORAL|Aerobic Exercise Training|Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
41357269|NCT05330195|OTHER|Bicycle Ergometer Training|Bicycle ergometer training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group.
41357270|NCT05330195|OTHER|Home-based exercise group|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
41357271|NCT04555876|DEVICE|high tone external muscle stimulation- stationary bicycle|high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
41357272|NCT01359865|PROCEDURE|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at \<0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
41357273|NCT06131294|DEVICE|Fluoride Application (Experimental Fluoride Application)|Fluoride containing applications are applied on white spot lesions. First solution was air-dried before the second application with the other component was done.
41357274|NCT06131294|DEVICE|Fluor Protector S|Fluor Protector S is applied on white spot lesions.
41357275|NCT00917553|DRUG|doxycycline monohydrate|50 mg
41357276|NCT00917553|DRUG|Placebo|Cellulose Placebo Capsule
41357277|NCT03894111|OTHER|decesased patients|mortality ratio
41357278|NCT03458468|DRUG|Tranexamic Acid|1g Tranexamic acid prior to skin incision
41357279|NCT03458468|DRUG|Saline|Equivalent volume of saline prior to skin incision
41357280|NCT03029494|DEVICE|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
41357281|NCT03029494|DRUG|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
41357282|NCT03029494|DEVICE|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
41357283|NCT03029494|DIETARY_SUPPLEMENT|Vitamin C|1000 mg
41357284|NCT02118493|DEVICE|Benign Biliary Stenosis, Laser|Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
40836945|NCT06172400|DRUG|Mepivacaine, Combinations|Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.
41357285|NCT00126763|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
41357286|NCT04312737|DEVICE|Self-Collecting Devices|FLOQSwab (Copan) Colli-Pee (Novosanis)
41357287|NCT04312737|DIAGNOSTIC_TEST|In Vitro Diagnostic Assays|Papilloplex (GeneFirst) HPV Oncopredict DNA (Hiantis) HPV Oncopredict RNA (GeneFirst)
41357288|NCT02865278|OTHER|Standard meal|The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
41357289|NCT04290000|OTHER|additional biological samples during CAR-T CELL treatment|"Blood samples (additional tubes) and marrow (quantity taken in addition from the same aspiration) will be collected in addition to those useful for the follow up of the patients (progress of their disease after treatment with CAR-T Cells) at specific points in his treatment journey.~The following samples will also be collected during Apheresis and at Car-T Cells reinjection :~* Apheresis sampling~* CAR-T Cells collected from bag rinsate~In case of invasion, a skin biopsy will be made, 2 days and 8 days after the beginning of the CAR T Cell Treatment, during the patient's hospitalization and during a consultation visit in case of therapeutic progression or failure."
41496618|NCT05063435|PROCEDURE|Venipuncture|"1. 10 mL of blood total will be drawn (5 mL in a blue top citrate tube, 5 mL in a purple top EDTA tube). Measurements of cytokines, clusterin, lipidomics, cathepsin S protease, and elastin (previously identified potential biomarker candidates) will be performed.~2. Blood will preferably be drawn via venipuncture, but if patient has a port-a-cath already implanted and is having blood drawn via port-a-cath for clinically required reasons, then study-related blood draw via port-a-cath can take place concurrently with clinically required blood draws."
41496619|NCT00872794|DEVICE|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
41496620|NCT01303770|BEHAVIORAL|Self-management cognitive rehabilitation group intervention|8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
41496621|NCT01303770|BEHAVIORAL|Control intervention|8-week group program that is not specifically directed to management of cognitive impairments.
41496622|NCT05729685|OTHER|Interval training|"The interval training group trained using the interval method. During the exercise sessions the participants ran each bout at an intensity corresponding to 90% of PTV. PTV was used to prescribe the exercise intensity at the INT group. The duration of the running-bouts was equal to ¼ of the individual time to exhaustion at 90% of PTV (determined during the CV testing) followed by passive rest equal to 2/3 of exercise duration. The duration of the exercise-bouts was individualized based on the time to exhaustion at 90% of PTV to reduce the between subject's variability. The participants terminated each exercise session when an RPE value of 17 was reached. Running bout duration and intensity were adjusted after 7 training sessions (during the 3rd week) following a reassessment of the time to exhaustion at 90% of the new PTV achieved during mid-testing as a result of training."
41496623|NCT05729685|OTHER|Continuous training|The continuous group trained using the continuous method. During the training sessions the participants ran with an intensity corresponding to -2,5% of CV until they reported a rating of 17 at the 6-20 Borg's scale. Running velocity was adjusted after 7 training sessions (during the 3rd week) after reassessment of CV. CV was used to determine the exercise intensity in the CONT group to ensure that all individuals would ran at the heavy intensity domain and be able to complete at least 15 min of continuous running, and to minimize the high inter-individual variations in endurance time at intensities near the upper limit of the heavy intensity domain. Using PTV to determine the intensity in the CONT group, would increase the possibility for trainees to exercise at different exercise intensity domains.
41496624|NCT03748030|RADIATION|Confirmed Left-Sided Breast Cancer|Left-Sided Patients will receive standard radiation therapy, including 42.5 Gy in 16 fractions or 50 Gy in 25 fractions.
41357290|NCT04882930|PROCEDURE|Functional Near-Infrared Spectroscopy (fNIRS)|All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
41357291|NCT02776904|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|Computerized assessment that provides information related to visual reaction time and visual memory.
41357292|NCT02776904|OTHER|Gait with single and dual task|Walking alone and then walking while performing a memory task on a tablet.
41357293|NCT02776904|OTHER|Y-Balance test|Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
41357294|NCT02776904|OTHER|Psychomotor Vigilance Task|Assessment measuring reaction time based on auditory cues.
41357295|NCT01609361|OTHER|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
41357296|NCT03097666|DEVICE|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
41496625|NCT00004025|BIOLOGICAL|aldesleukin|
41496626|NCT00004025|BIOLOGICAL|dendritic cell-gp100-MART-1 antigen vaccine|
40836946|NCT02915913|BEHAVIORAL|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
40836947|NCT02915913|BEHAVIORAL|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
41357297|NCT00182364|DRUG|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
41357298|NCT01212627|DRUG|Ridaforolimus|Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
40836948|NCT02915913|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
41357299|NCT05409742|DIAGNOSTIC_TEST|Modified Hall technique|The standard Hall technique was later modified with several modifications including occasional/rare use of anesthetic and about 1 mm proximal slice that the preformed metal crown fits without separation, and minimal occlusal reduction of the cusps
41357300|NCT04586920|DRUG|LY3509754|Administered orally
41357301|NCT04586920|DRUG|Placebo|Administered orally
41357302|NCT04586920|DRUG|Itraconazole|Administered orally
40836949|NCT02915913|OTHER|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
40836950|NCT00346645|DRUG|Bortezomid (VELCADE®)|
41357303|NCT04586920|DRUG|Midazolam|Administered orally
41357304|NCT00417235|DEVICE|Chlorhexidine Sponge (Biopatch TM)|dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
41357305|NCT00417235|BEHAVIORAL|7-day catheter dressing frequency|dressing changes every 7 days versus every classical change every 3 days
41357306|NCT00656981|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
41357307|NCT00656981|DRUG|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
41357308|NCT02141529|PROCEDURE|Unipolar pulsed radiofrequency thermocoagulation|Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
41357309|NCT02141529|PROCEDURE|Bipolar pulsed radiofrequency thermocoagulation|Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
41357310|NCT00086164|DRUG|edifoligide (E2F Decoy)|
41357311|NCT01756482|DRUG|GS-5806|GS-5806, powder for oral solution
41357312|NCT01756482|DRUG|Placebo|
41496627|NCT04565925|DRUG|Sildenafil Citrate|Sildenafil 20mg TID for 4 weeks
41496628|NCT04565925|DRUG|Placebo|Placebo (Lactose) TID for 4 weeks
41509241|NCT02473198|DRUG|Morphine Sulfate|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
41357313|NCT06116474|BEHAVIORAL|Web-Based Physical Fitness Intervention|The exercise program has been designed according to the progressive overload method. Therefore, the volume of the exercise program increased as the weeks progressed. Exercise videos were uploaded to YouTube on Mondays, Wednesdays and Fridays send to participants via a message group to follow the program. The videos featured the experts' explanations of the movements for each exercise.. The equipment that the participants should use in the training sessions was selected from the materials available at home (eg., use of water bottles instead of weight dumbbells). The exercise sessions is divided into 3 parts: warm-up (2-4 min. average), main part (14-19 min. average), cool-down (3-5 min. average). The warm-up includes movements to increase the heart rate and warm up the muscles to be worked on for that session. The main part of the exercise program also included rest breaks when the participants were asked to move and stretch.
41357314|NCT00551200|DRUG|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
41357315|NCT00551200|DRUG|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
41357316|NCT00312390|PROCEDURE|Flicker|
41357317|NCT00312390|PROCEDURE|Retinal Vessel Diameter|
41496629|NCT04581369|OTHER|Care Coordinator Intervention for Direct Intervention Group|"The First Visit: The care coordinator will conduct a visit within 72 hours of hospital discharge to assess the patient's physical, cognitive, and psychological status, and will complete a needs assessment for both the patient and family caregiver. These measures will be used to guide the use of care protocols and development of the individualized care plan. The care plan will be developed with an emphasis on coordinating services with the patient's providers.~The Second Visit: During the second visit, the coordinator will review the individualized care plan with both the patient and the family caregiver and will make revisions to the plan based on assessment outcomes.~The 6-month Interaction Period: Approximately every 2 weeks, the coordinator will meet with the participant to revisit the care plan and to facilitate care.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians."
41496630|NCT04581369|OTHER|Care Coordinator Intervention for Standard of Care Group|For participants randomized to this arm, a consultation with the care team will be arranged prior to hospital discharge. Outcome measures will be obtained by blinded research staff from all enrolled subjects at baseline, 3 months, and 6 months. This is the extent of interventions received for participants in this arm.
41496631|NCT04581369|OTHER|Caregiver Intervention|Caregivers of the participants will be assessed for caregiver burden at 3 time points.
41496632|NCT00104143|DRUG|A4I Antagonist|
41496633|NCT04100785|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|The iCBT programme comprised on 6 online modules. Module 1 provided an introduction to the symptoms of depression, its causes and information on CBT. Module 2 covered problem-solving strategies. Module 3 provided information on problematic thought patterns and beliefs in depression. Module 4 entailed identifying problematic thought patterns and using various techniques to counter problematic thoughts. Module 5 covered pleasurable activities scheduling to help increase activity levels.
40836951|NCT05400421|DEVICE|System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure|Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
40836952|NCT01852279|DEVICE|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
40836953|NCT01852279|DEVICE|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
40836954|NCT02887547|PROCEDURE|micro-osteoperforation|
40836955|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)|vaccination
41357318|NCT00312390|PROCEDURE|Retinal Blood Flow|
41357319|NCT00455780|BEHAVIORAL|Weight Loss Phase|Weight loss using CBT and meal replacements
41357320|NCT00455780|BEHAVIORAL|Continued CBT|Using CBT during weight loss maintenance
41357321|NCT00455780|BEHAVIORAL|reduced energy density education|Additional nutritional learning
41357322|NCT00455780|BEHAVIORAL|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
41357323|NCT02102776|PROCEDURE|MMC|Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
41496634|NCT01602536|BEHAVIORAL|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
41496635|NCT01602536|BEHAVIORAL|Twitter|Twitter quit-smoking group
41496636|NCT05710692|DRUG|PRX-102 1 mg/kg every 2 weeks|PRX-102 1 mg/kg every 2 weeks
41496637|NCT05710692|DRUG|PRX-102 2 mg/kg every 4 weeks|PRX-102 2 mg/kg every 4 weeks
41496638|NCT04808427|DEVICE|TULSA-PRO|Transurethral MR-Thermometry Guided Ultrasound Ablation of the Prostate
41496639|NCT01385449|PROCEDURE|interscalene catheter|interscalene catheter
41496640|NCT01385449|PROCEDURE|interscalene block|interscalene block
41496641|NCT03726853|DRUG|CKD-497 200mg|CKD-497 200mg
41496642|NCT03726853|DRUG|CKD-497 300mg|CKD-497 300mg
41496643|NCT03726853|DRUG|CKD-497 placebo|Placebo of CKD-497
41496644|NCT03726853|DRUG|Comparator|Comparator
41496645|NCT03726853|DRUG|Comparator placebo|Comparator placebo
40836956|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)|vaccination
41496646|NCT05001217|DRUG|Conventional medication|Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
40836957|NCT01788579|BEHAVIORAL|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
40836958|NCT01788579|BEHAVIORAL|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
41496647|NCT05001217|DRUG|Chinese herbal medicine treatment|"1. Huanglian Wendan Decoction~2. Jin Gui Shen Qi Pill~3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~4. Bu Yang Huan Wu Decoction"
41496648|NCT00609518|DRUG|pemetrexed|500 mg/m\^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
41496649|NCT00609518|DIETARY_SUPPLEMENT|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
41496650|NCT00609518|DIETARY_SUPPLEMENT|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
41496651|NCT00609518|DIETARY_SUPPLEMENT|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
40836959|NCT03361189|DEVICE|Closed loop stimulation|Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.
41496652|NCT00609518|DRUG|dexamethasone|4 mg taken orally \[or equivalent\] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
41496653|NCT00609518|DRUG|dexamethasone|4 mg taken orally \[or equivalent\] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
41496654|NCT00237965|BEHAVIORAL|Mole Mapping Diagram|
41496655|NCT06498635|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41496656|NCT06498635|PROCEDURE|Computed Tomography|Undergo CT
41496657|NCT06498635|BIOLOGICAL|Durvalumab|Given IV
41496658|NCT06498635|OTHER|Patient Observation|Undergo active surveillance
41496659|NCT06498635|OTHER|Questionnaire Administration|Ancillary studies
41496660|NCT06159777|DRUG|Polyethylene Glycol 3350|\*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
41496661|NCT02527538|DEVICE|Pleth|apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
41496662|NCT02854592|DRUG|rtPA|intravenous thrombolysis with rtPa
41496663|NCT02854592|DRUG|urokinase|intravenous thrombolysis with urokinase
41496664|NCT04644822|DIAGNOSTIC_TEST|[18F] PSMA-1007 Injection|a novel \[18F\] PSMA radiotracer that is highly selective for PSMA.
41496665|NCT01140503|DRUG|Apremilast|Apremilast 20mg PO BID
41496666|NCT04831463|BEHAVIORAL|Increasising Health Awareness Program for Immigrant Men|The IHAPIM program is a health promotion intervention. The aim of intervention improve health perception and responsibilitiy
41496667|NCT00818688|PROCEDURE|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
41496668|NCT04937114|PROCEDURE|Barbed suture|Experimental: Wound will be closed using unidirectional barbed sutures in muco-gingival surgeries Active Comparator: Wound will be closed using conventional sutures in muco-gingival surgeries
41496669|NCT05209594|BEHAVIORAL|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|The Healthy Relationships Program (HRP) for Two-Spirit, Lesbian, Gay, Bisexual, Trans, Queer, Intersex, and Asexual + (2SLGBTQIA+) Youth is a small group positive mental health promotion program for gender, sexual, and romantic minority youth. It helps build resiliency and promote well-being among 2SLGBTQIA+ youth. It affirms, validates, and celebrates sexual and gender diversity, cultivates a caring and supportive community, and helps 2SLGBTQIA+ youth develop skills and strategies that promote healthy relationships. This trauma-informed, strengths-focused program explores stressors unique to 2SLGBTQIA+ youth, including identity and expression invalidation, stigma, prejudice and discrimination, internalized oppression, coming out, safety, and microaggressions. This program includes 17 sessions, each lasting approximately 45 minutes. It may be delivered in school-based Genders and Sexualities Alliances/Gay-Straight Alliances (GSA) or 2SLGBTQIA+ youth group settings.
41509242|NCT00002225|DRUG|Efavirenz|
41509243|NCT00002225|DRUG|Stavudine|
41509244|NCT00002225|DRUG|Didanosine|
41357324|NCT02102776|PROCEDURE|AMT|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
41357325|NCT02102776|PROCEDURE|CAG|A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
41357326|NCT02102776|PROCEDURE|Pterygium excision|Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
41357327|NCT05384873|DIETARY_SUPPLEMENT|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs
41357328|NCT05384873|OTHER|Control dietary intervention|Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
41357329|NCT02523742|DEVICE|IMRf|
41357330|NCT02523742|OTHER|language task and a reference task (rest and Tamil)|
41357331|NCT01450566|DRUG|Lidocaine|Use of lidocaine
41357332|NCT01450566|DRUG|Saline|Saline
41496670|NCT05209594|BEHAVIORAL|Standard GSA Programming|Students at comparison sites will participate in standard GSA programming, a safe space for 2SLGBTQIA+ youth and their allies to meet, develop relationships, support each other, socialize, and learn about sexuality and gender-related topics, and lobby for social change.
41496671|NCT03669939|OTHER|Communication Strategy|Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.
41496672|NCT03669939|OTHER|Standard of Care|The standard information about the CDC Guidelines and no other information that is available through the study.
41496673|NCT01069276|OTHER|No intervention in this study|No intervention in this study
41496674|NCT02123082|DEVICE|Storz single Lumen Ureteroscope|Single lumen, flexible scope for ureteroscopies
41357333|NCT01747928|OTHER|dual-chamber syringe|dual-chamber syringe for mock injection
41357334|NCT01277666|DRUG|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
41357335|NCT01277666|DRUG|GSK1605786A|500 mg once daily, administered orally for 12 weeks
41357336|NCT01277666|DRUG|Placebo|Placebo capsules, administered orally for 12 weeks
40836960|NCT03361189|DEVICE|Standard rate response|Standard rate response is an algorithm to increase heartrate based on movement
40836961|NCT03973905|OTHER|Not applicable / dataset analysis|Not applicable / dataset analysis
41357337|NCT02363322|DRUG|B/Current Standard of Care Plus ZMapp|Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
41357338|NCT02363322|OTHER|A/Current Standard of Care Alone|Optimized standard of care for Ebola virus infection
41357339|NCT01083615|DRUG|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
41496675|NCT02123082|DEVICE|Dual Lumen Ureteroscope|Dual lumen, flexible scope for ureteroscopies
41496676|NCT03888950|DIAGNOSTIC_TEST|FDG PET-CT|FDG PET/CT for oncological imaging of adult patients
41496677|NCT01178216|BIOLOGICAL|Rituxan|Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
41496678|NCT02968836|DIETARY_SUPPLEMENT|Blend of amino acids|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
41357340|NCT01083615|DRUG|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
41357341|NCT01083615|DRUG|docetaxel|
41357342|NCT01083615|DRUG|cabazitaxel|
41357343|NCT01083615|DRUG|prednisone|
41357344|NCT01063699|PROCEDURE|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
41496679|NCT02968836|DIETARY_SUPPLEMENT|Maltodextrin only|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
41509245|NCT05133934|OTHER|Observational|A cohort study will be used to collect patient data, analyze the clinical characteristics, TCM syndromes, and treatment of knee osteoarthritis in China
41022435|NCT06358924|OTHER|Potassium nitrate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of the desensitizing agent recommended by the manufacturer (After Whitening Mousse), once for 10 minutes.
41022436|NCT06358924|OTHER|Casein phosphopeptide-amorphous calcium phosphate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Mi Paste Plus once for 3 minutes.
41496680|NCT06130098|OTHER|control group|"Training by the clinical nurse before discharge. Prepare an educational brochure and give it to patients. Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale During the routine check-up in the first week, evaluates the development of complications without knowing which group the patient is in.~Within the first week and at the end of the fourth week, the wound site is evaluated by the physician for the development of complications, . Patients who cannot come for a check-up should send a photo of the wound area to the researcher via WhatsApp application, and the photo will be forwarded to the clinician who performed the surgery and the physician will record the complication situation. It is planned to receive complication development and wound site evaluation results from the physician system.~At the end of the fourth and sixth weeks after discharge, the EQ-5D-5L and OKS scale must be filled in again by the patients."
41509246|NCT01573104|OTHER|Proteomic assay|Urine will be taken for proteomic assay at baseline, day 1 and day 2
40836962|NCT06427694|DRUG|Aldesleukin|IL2 antagonist
41022437|NCT06358924|OTHER|Hydroxyapatite with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Hydroxyapatite and Fluoride (ReminPro) once for 3 minutes.
41022438|NCT06358924|OTHER|PAMAM-carboxylic acid dendrimer|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of PAMAM once for 30 minutes.
41509247|NCT01573104|OTHER|Blood sampling|Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
41509248|NCT01573104|OTHER|Biomarker sampling|Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
41509249|NCT01811329|DIETARY_SUPPLEMENT|Dairy fat|
41022439|NCT00286143|DRUG|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
41022440|NCT00506935|DRUG|GVG|5 grams GVG
40836963|NCT06427694|DRUG|Dextrose 5% in water|matched placebo to active
41022441|NCT00506935|DRUG|placebo|placebo
41022442|NCT06572969|OTHER|Elastic-Resistance Kick Training|Athletes used tailored Elastic Resistance training
41022443|NCT06572969|OTHER|No Elastic-Resistance Kick Training|Regular Taekwondo regimen without Elastic Resistance training
41022444|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
41509250|NCT01811329|DIETARY_SUPPLEMENT|Dairy fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
41509251|NCT01811329|DIETARY_SUPPLEMENT|Palm fat|
41496681|NCT06130098|OTHER|experimental group|"Providing training before discharge Prepare an educational brochure and give it to patients. You will be contacted by phone at the end of the first, second, third and fourth weeks after discharge.~Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale Evaluating the wound site in terms of complications within the first week and at the end of the fourth week. It is planned to receive complication development and wound site evaluation results from the system.~After the first check-up, calling the patients in the study group at the end of the first week after discharge.~Providing training on the subjects included in the training brochure in the first phone call and recording any existing problems.~In the fourth meeting, tele-nursing service will be provided through the Telephone Counseling Protocol.~EQ-5D-5L and OKS forms must be filled out again by patients at the routine check-up at the end of the fourth and sixth weeks after discharge."
41496682|NCT05519319|PROCEDURE|RFA|RFA will be performed
41496683|NCT05519319|PROCEDURE|PDT|PDT will be performed
41496684|NCT05519319|PROCEDURE|RFA combined with PDT|RFA and PDT will be performed
41496685|NCT04645264|DEVICE|Foley Catheter|The patient is catheterized during surgery.
41496686|NCT02904824|BIOLOGICAL|adipose derived regenerative cells|Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
40836964|NCT01977690|DEVICE|Clavicle Brace|
40836965|NCT02286323|DEVICE|Bonfils|Bonfils Intubation Fiberoscope
40836966|NCT02286323|DEVICE|Macintosh|Direct laryngoscopy using Macintosh Laryngoscope
40836967|NCT05377736|GENETIC|Molecular analyses|Collect thyroid tissue for molecular analysis from the histological specimen collected by routine surgery
40836968|NCT02089152|OTHER|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
40836969|NCT03582813|BEHAVIORAL|Self-directed care|Traditional and non-traditional behavioral health services are chosen from within and outside the public mental health system
40836970|NCT03582813|BEHAVIORAL|Services as usual|Traditional behavioral health services are chosen from along those delivered at the patient's community mental health agency
40836971|NCT03619135|DEVICE|Buzzy|The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
40836972|NCT03619135|OTHER|Placebo|No use of the Buzzy (standard IV access techniques)
40836973|NCT03399656|DIETARY_SUPPLEMENT|Avmacol tablets|The active components of Avmacol® are ground broccoli seeds that provide glucoraphanin and freeze-dried broccoli sprouts that provide a stabilized form of the enzyme myrosinase, which converts glucoraphanin to sulforaphane.
41496687|NCT02904824|BIOLOGICAL|centrifuged autologous fat|centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
40836974|NCT03399656|DIETARY_SUPPLEMENT|Placebo tablets|MCC 90M Emcocel
40836975|NCT02018874|DRUG|LY2780301|"LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D."
40836976|NCT02018874|DRUG|Gemcitabine|The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
41022445|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support (Wait-list)|Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
41022446|NCT04508049|DEVICE|qMT-MRI to detect fibrosis.|The hypothesis underlying this proposal is that qMT would reliably detect development of renal fibrosis at both 1.5T and 3.0T in subjects with RVD. Patients will be studied with MRI (for fibrosis) and CT (for renal function).
41496688|NCT04423029|DRUG|DF6002|Specified dose on specified days
41496689|NCT04423029|DRUG|Nivolumab|Specified dose on specified days
41496690|NCT02106897|DRUG|BIIB059 (litifilimab)|See Arm Descriptions
40836977|NCT03792152|DRUG|Rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd (15mg If creatinine clearance is between 30-49 ml/min).
41022447|NCT02984176|DRUG|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
41022448|NCT02984176|DRUG|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
41496691|NCT02106897|DRUG|Placebo|See Arm Descriptions
41496692|NCT04675814|OTHER|Adapted Physical Activity (APA)|Adapted Physical Activity (APA)
41496693|NCT02092467|DRUG|tofacitinib|Oral tablet, 5 mg BID
41496694|NCT02092467|DRUG|tofacitinib|Oral tablet, 10 mg BID
41496695|NCT02092467|BIOLOGICAL|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
41357345|NCT02683135|BEHAVIORAL|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
41357346|NCT02683135|BEHAVIORAL|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
41022449|NCT00829621|OTHER|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
41357347|NCT02683135|BEHAVIORAL|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning \~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
41022450|NCT00829621|OTHER|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
41022451|NCT05552703|PROCEDURE|surgical evacuation of extradural hematoma|evacuation of extradural hematoma by craniotomy
41357348|NCT00496145|BEHAVIORAL|Spanish Diabetes Self-Management Program|small-group self management education program
41357349|NCT02530281|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
41022452|NCT03347994|DRUG|Minnelide|Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
41160352|NCT03998501|BEHAVIORAL|Cognitive Behavioral Therapy with Mindfulness Class|The CBTm classes are five, 90-minute sessions focused on strategies to reduce symptoms of anxiety and depression.
41160353|NCT00466622|DRUG|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
41160354|NCT00466622|DRUG|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
41357350|NCT02530281|OTHER|Vehicle|Vehicle (placebo) topical wipes
41357351|NCT04927611|PROCEDURE|Biopsy, open or laparoscopic surgery|Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.
41357352|NCT05327309|DRUG|Bleomycin|
41357353|NCT01817218|DRUG|Platelet Rich Plasma|
41022453|NCT02081794|OTHER|Tailored education intervention|Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
41022454|NCT02081794|OTHER|Standard fall care|Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
41357354|NCT01817218|DEVICE|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
41357355|NCT03579862|OTHER|Blood Draw|
41357356|NCT02967042|DEVICE|18F-PET-TT|can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
41357357|NCT03757026|OTHER|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
41022455|NCT03948074|DRUG|Cannabis|Medicinal Cannabis Oil
41022456|NCT01503489|DRUG|Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.|Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
41022457|NCT01319734|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C supplementation 500mg
41022458|NCT01319734|DRUG|glyburide|this group receiving glyburide 5 mg alone
41022459|NCT02609126|DRUG|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
41022460|NCT02609126|DRUG|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
41160355|NCT04063878|DEVICE|Conometric Abutment and Conometric Final Cap|Conometric concept developed by Dentsply Sirona Implants for implant systems Ankylos, Astra Tech Implant System and Xive.
41160356|NCT03910296|BEHAVIORAL|Acceptance & Commitment Therapy|ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.
41496696|NCT02092467|BIOLOGICAL|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
40836978|NCT03792152|DRUG|Warfarin|After the diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin (4000iu q12h) and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
40836979|NCT02437786|DRUG|GRAZAX|GRAZAX
40836980|NCT03033342|DRUG|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
40836981|NCT03033342|DRUG|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
40836982|NCT03033342|DRUG|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
40836983|NCT03033342|DRUG|Oral single doses of placebo|Single doses of placebo to match MRX-4
40836984|NCT03033342|DRUG|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
40836985|NCT03033342|DRUG|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
40836986|NCT04548362|OTHER|Meat arm|Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination
40836987|NCT04548362|OTHER|Starchy foods arm|Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
40836988|NCT04021173|DRUG|Anfibatide|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
40836989|NCT04021173|DRUG|Placebos|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
40836990|NCT00424268|DRUG|Roflumilast|500 µg, once daily, oral administration in the morning
40836991|NCT00424268|DRUG|Placebo|once daily
40836992|NCT05792566|OTHER|Atomic app|Using the Atomic app to improve physical activity
40836993|NCT00071448|DRUG|insulin human|
40836994|NCT00071448|DRUG|insulin lispro|
40836995|NCT00071448|DRUG|insulin aspart|
40836996|NCT02760810|DEVICE|Marketed Contact Lens|Narafilcon A
40836997|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen|Patient will be asked to lie down flat on the plinth with legs elevated from 45 degrees until the skin turns pale, it will take approximately 2 minutes to occur. Then the patient turns to sit at the edge of the plinth with feet hanging and doing the following exercises; dorsiflexion, plantar flexion, inversion, eversion, and flexion the extension of toes, this phase may also be maintained for 2 minutes. Finally, the patient lies flat with his leg rested in a horizontal position and covered with a warm blanket for about 5 minutes
40836998|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises|The intervention will be repeated 3 times per day and the posttest will be conducted 5th day using KOOS, NPRS and goniometer.
40836999|NCT03079856|BEHAVIORAL|Brief Intervention|"Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a \~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment."
40837000|NCT03494218|DIAGNOSTIC_TEST|Nociception Coma Scale (NCS)|Patients have been assessed with both the Nociception Coma Scale (NCS) and the FLACC.
40837001|NCT04148430|DRUG|Anakinra|100mg subcutaneous
41496697|NCT05436067|DEVICE|Vestibular rehabilitation app|Delivery of vestibular rehabilitation through an app on a tablet or other portable device. The app takes patients through their rehabilitation session that has been prescribed by a clinician. Exercises are presented in the forms of games that are controlled by head or torso motion via a motion sensor that is placed on that body part. Data on the motion of the patient are calculated from sensor data and sent over the cloud for the clinician to access remotely.
41496698|NCT02451332|BIOLOGICAL|inactivated seasonal flu vaccine|Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
40837002|NCT04597671|DRUG|Durvalumab|Durvalumab is used as standard of care
40837003|NCT04597671|RADIATION|low-dose PCI|PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
40837004|NCT03038893|DIAGNOSTIC_TEST|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
40837005|NCT03038893|DIAGNOSTIC_TEST|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
40837006|NCT04343014|DEVICE|Tongue Root Retractor|Fibroptic endutracheal intubation will be performed with tongue root retractor.
40837007|NCT04343014|DEVICE|Conventional Fibroscope|Fibroptic endutracheal intubation will be performed in conventional way.
40837008|NCT03972410|BEHAVIORAL|EMDR|2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol
40837009|NCT03972410|BEHAVIORAL|SEDP|2-4 sessions individual 60-min-long treatment sessions of SEDP
40837010|NCT02196428|OTHER|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
40837011|NCT05837104|DRUG|Magnesium vitamin B6|Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
40837012|NCT05837104|DRUG|Placebo|Placebo tablet, three times daily for four weeks.
41496699|NCT01874067|DEVICE|Arthritis glove|Isotoner three-quarter finger arthritis glove
40837013|NCT04897607|BEHAVIORAL|Standard Care|Participants will be advised to quit smoking and offered a choice of nicotine replacement patches or varenicline. Participants are free to decline medication.
40837014|NCT04897607|BEHAVIORAL|Precision pharmacotherapy|Participants will be advised to quit smoking and provided a medication recommendation on the basis of their nicotine metabolite ratio (NMR) test (i.e., nicotine replacement patches for slower metabolizers, varenicline for faster metabolizers). Participants are free to choose either medication or decline any medication.
40837015|NCT03411564|OTHER|Filming Together to See Ourselves in a New 'Present'|"PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process."
40837016|NCT03562793|BEHAVIORAL|Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)|. COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
40837017|NCT01013415|DRUG|HAART|
40837018|NCT01013415|BIOLOGICAL|T cells|
40837019|NCT00480259|BEHAVIORAL|hyperproteic nutrition|
40837020|NCT05297526|BEHAVIORAL|Culturally adapted children's book|Tribe-specific children's book celebrating tribal culture with an embedded oral health message
40837021|NCT05297526|BEHAVIORAL|Standard informational brochure on children's oral health|Informational brochure about children's oral health designed by the NIH for American Indian/Alaska Native parents.
40837022|NCT02098811|DEVICE|1064nm Laser|Patient will be treated with 1064nm Laser prior to abdominoplasty
40837023|NCT02098811|DEVICE|940nm Laser|Patient will be treated with 940nm Laser prior to abdominoplasty
40837024|NCT02725281|OTHER|Stress ball|The patients in this group were given stress ball into their both palms 5 min before the lithotripsy and told to squeeze the ball whenever they would like until end of the process. This ball was medium hard and has been made of high quality silicon.
41357358|NCT03757026|OTHER|Slip Training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine interventional sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
41357359|NCT03757026|OTHER|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
41357360|NCT03704233|PROCEDURE|Transbronchial cryobiopsy|Transbronchial cryobiopsy procedure
41357361|NCT01825759|DRUG|danshen dripping pill|
41496700|NCT03214029|DIAGNOSTIC_TEST|Cardiac troponin testing|Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
41496701|NCT02454127|BEHAVIORAL|Atkins Diet|Dietary counseling for 1 year
41496702|NCT02454127|BEHAVIORAL|Zone Diet|Dietary counseling for 1 year
41496703|NCT02454127|BEHAVIORAL|Weight Watchers Diet|Dietary counseling for 1 year
41357362|NCT04854603|OTHER|Food|Dairy products with regular and reduced sugar content and water control.
41496704|NCT02454127|BEHAVIORAL|Ornish Diet|Dietary counseling for 1 year
40837025|NCT02725281|OTHER|Music|The patients in this group were also listened to the music chosen by them with a headset from 5 min before until the end of lithotripsy. Types of music played for the patients were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
40837026|NCT04453176|OTHER|Patient Satisfaction|Patient satisfaction evaluated with EVAN G questionnaire
40837027|NCT06295705|BEHAVIORAL|Hip-Hop Dance|"I. Week 1 - Session 1~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Hip-Hop~4. Cool-Down: Deep Breathing~5. Debrief Check-In~II. Week 2 - Session 2~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Locking~4. Cool-Down: Instructed Yoga~5. Debrief Check-In~III. Week 3 - Session 3~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Breaking~4. Cool-Down: Sensory Time~5. Debrief Check-In~IV. Week 4 - Session 4~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Popping~4. Cool-Down: Animal Deep Breathing~5. Debrief Check-In~V. Week 5 - Session 5~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Learn Showcase Routine~4. Cool-Down: Animal Instructed Yoga~5. Debrief Check-In~VI. Week 6 - Session 6~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Review Showcase Routine~4. Cool-Down: Sensory Time~5. Debrief Check-In~VII. Week 7 - Dance Showcase"
40837028|NCT04955418|DEVICE|Epi-No®|evaluation, 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device and revaluation six months after delivery.
40837029|NCT04955418|DIAGNOSTIC_TEST|Evaluation|evaluation (anamnesis, childbirth data, perineometry, International Consultation on Incontinence Questionnaire - Short Form, Female Sexual Function Index) six months after vaginal delivery.
40837030|NCT02976103|DEVICE|Jacki Recovery jacket|An outer jacket that holds surgical drains and allows access for blood draws
41357363|NCT03163277|DRUG|emtricitabine, darunavir/cobicistat, maraviroc|Treatment change
40837031|NCT02976103|OTHER|Standard Care Pain medicine/management|Standard care pain medicine and management in hospitals where the study enrolls
40837032|NCT01439178|DRUG|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
40837033|NCT04407104|DIAGNOSTIC_TEST|skin prick-test|retrospective study on data already collected
40837034|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 2.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)"
40837035|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 1.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))"
40837036|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 4.0 μg once a day, in the morning~(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)"
40837037|NCT00605891|DRUG|salmeterol|Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
40837038|NCT00605891|DRUG|placebo|Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
40837039|NCT05389215|DRUG|DWN12088|DWN12088 Xmg Tablet (BID)
40837040|NCT05389215|DRUG|Placebo|Placebo 0mg Tablet (BID)
40837041|NCT05749653|DRUG|Bi-annual CDTI|Bi-annual CDTI
40837042|NCT00758589|DRUG|AZD1981|Oral tablet, 50 mg twice daily
40837043|NCT00758589|DRUG|AZD1981|Oral tablet, 400 mg twice daily
40837044|NCT00758589|DRUG|AZD1981|Oral tablet, 1000 mg twice daily
40837045|NCT00758589|DRUG|Placebo|
41357364|NCT02699515|DRUG|MSB0011359C|Subjects with metastatic or locally advanced solid tumors will receive intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
41357365|NCT01265511|DRUG|Placebo|Oral tablets given bid for 28 days
41357366|NCT01265511|DRUG|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
41509252|NCT01811329|DIETARY_SUPPLEMENT|Palm fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
41509253|NCT04322058|OTHER|The Dads' Club|The core intervention is Core 24/7 workshop attendance
40837046|NCT04294550|OTHER|Naloxegol|28 days of therapy with 25 mg/day of Naloxegol on cancer patients using opioids and suffering for opioids induced constipation not relieved by first-line laxatives.
40837047|NCT03147638|DRUG|Warfarin, NOAC|duration of treatment
40837048|NCT00491920|DRUG|cholecalciferol (Vitamin D3)|"20 000 Iu x2/week~+ calcium 500 mg/cholecalciferol 400 IU x2/d"
40837049|NCT00491920|DRUG|placebo|Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
40837050|NCT00724412|OTHER|Systane|Dry Eye relief eye drops
40837051|NCT00724412|OTHER|Optive|Dry Eye relief eye drops
40837052|NCT02973776|DRUG|LEO 90100 aerosol foam|
40837053|NCT02973776|DRUG|Dermoval®/Dermovate®|
40837054|NCT02973776|DRUG|Diprosone|
40837055|NCT02973776|DRUG|Elocon|
41357367|NCT01265511|DRUG|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
41357368|NCT01265511|DRUG|Copegus|tablets given bid for up to 48 weeks
41357369|NCT04754568|OTHER|Virtual reality instructional design|60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
41357370|NCT04754568|OTHER|Role-playing instructional design|60 minute traditional role-playing with standardized patient
40837056|NCT02973776|DRUG|Locoid|
40837057|NCT02973776|OTHER|LEO 90100 foam vehicle|
40837058|NCT03009643|DRUG|Inhaled Nitric Oxide|Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
40837059|NCT03009643|DEVICE|lung protective mechanical ventilation|Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
40837060|NCT03009643|DEVICE|Hemodynamic monitoring|Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
40837061|NCT00053807|BIOLOGICAL|aldesleukin|
40837062|NCT00053807|BIOLOGICAL|recombinant interferon alfa|
40837063|NCT00053807|DRUG|fluorouracil|
40837064|NCT00053807|PROCEDURE|adjuvant therapy|
40837065|NCT00131651|DRUG|ATN-161|
40837066|NCT02514668|DRUG|Isatuximab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
40837067|NCT00286221|DRUG|PCA fentanyl|"PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted"
40837068|NCT00286221|DRUG|PRN fentanyl|IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
41357371|NCT04498949|BEHAVIORAL|UP|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
41357372|NCT04498949|OTHER|Treatment as usual|Diagnostic test. Psychoeducation Supoortive care
41357373|NCT00591786|DRUG|Sugammadex|After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
41357374|NCT00808184|DRUG|CPT-11, Raltegravir (Isentress®), Midazolam|
41357375|NCT01511549|DRUG|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
41357376|NCT01511549|DRUG|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
41357377|NCT02522091|DEVICE|functional brain MRI|
41357378|NCT02522091|OTHER|Neuropsychology tests|
40837069|NCT05643586|DRUG|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
40837070|NCT05643586|DRUG|Prasugrel|Patient treated with 60 mg prasugrel 12 hours before the procedure
40837071|NCT02273713|DRUG|Nab-paclitaxel|Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
40837072|NCT04576078|DRUG|Oral nefopam|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
40837073|NCT04576078|DRUG|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
40837074|NCT02434328|DRUG|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
41357379|NCT03699501|OTHER|Questionnaires|"* A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~* A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~* A validated depression scale: the Beck scale~* A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~* A validated self-assessment questionnaire for coping: The Brief cope)"
41357380|NCT03699501|PROCEDURE|Oral examination|"* An evaluation of dental health using the CAO index~* An evaluation of oral hygiene with the IHO-S index"
40837075|NCT02434328|DRUG|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
40837076|NCT04395287|BEHAVIORAL|Leisure screen time|Questionnaire-based assessment of typical amount of time per week spent using screen-based media devices during leisure, assessed at two time points. Continuously scaled in main analyses; a difference is computed (18-month follow-up value minus baseline value). Additionally, screen time amount at the two time points will be scaled categorically, according to being classified as low or high according to WHO criteria for preschool children (Low (recommended): \<=1 hour/day, high: \>1 hour/day): High-high, high-low, low-high, and low-low.
40837077|NCT00645905|DRUG|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
41357381|NCT03699501|OTHER|questionnaires (test-retest)|SCOOHP and SOHP questionnaires
41357382|NCT03958695|DEVICE|Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)|A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period
41357383|NCT03958695|DEVICE|Transobturator mid-urethral tape, Urosling (Lintex, LLC)|A transobturator tension-free mid-urethral sling
41357384|NCT02841254|OTHER|Non interventional study|
41357385|NCT03110172|DRUG|Duloxetine Hydrochloride|The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
41357386|NCT06234891|DRUG|Nsaid|Medical treatment
41357387|NCT06234891|OTHER|Phsiotheraphy|Nsaid and phsiotheraphy (hotpack-ultrasound therapy- tens)
41357388|NCT01488227|DIETARY_SUPPLEMENT|Vitamin D|4000 IU of Vitamin D daily for 6 months
41357389|NCT01488227|DIETARY_SUPPLEMENT|Placebo|Acts as a control for the Vitamin D intervention
41357390|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
41357391|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
41357392|NCT00668876|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition
40837078|NCT00645905|DRUG|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
40837079|NCT00001136|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
40837080|NCT03951090|OTHER|Results of the brief geriatric assessment|Providers will receive results of the brief geriatric assessment with recommendations for address deficits identified through the results of the brief geriatric assessment
40837081|NCT03951090|OTHER|No results of brief geriatric assessments|Providers will not receive results of the brief geriatric assessment. Participants will receive standard of care treatment
40837082|NCT03572790|DRUG|Prucalopride|1mg prucalopride capsule, once daily for seven days
40837083|NCT03572790|OTHER|Placebo|Lactose placebo capsule, once daily for seven days
40837084|NCT03743064|DRUG|anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
40837085|NCT03743064|DRUG|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
40837086|NCT00053547|DRUG|paricalcitol injection|
41266547|NCT04894799|OTHER|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
41357393|NCT00514241|DEVICE|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
41357394|NCT01986166|DRUG|Cobimetinib|In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.
41357395|NCT01986166|DRUG|MEHD7945A|MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
41357396|NCT03716206|DEVICE|Exergame|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
41357397|NCT03716206|OTHER|Physical therapy|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
41357398|NCT02216227|DRUG|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
41357399|NCT02216227|DRUG|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
41357400|NCT02216227|DRUG|Cefazolin|All patients will receive Cefazolin during surgery
41357401|NCT02216227|DRUG|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
40837087|NCT00606398|PROCEDURE|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
40837088|NCT00002112|DRUG|Nystatin|
40837089|NCT00002112|DRUG|Fluconazole|
40837090|NCT01492413|BEHAVIORAL|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
40837091|NCT05135962|DEVICE|orthodontic - rapid maxillary expansion|Rapid expansion: when RME was in situ, patients started the screw activation of one-quarter turn a day until overcorrection was achieved and RME was kept on teeth as a passive retainer and removed after one year from its application.
40837092|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with leaf expander|Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.
40837093|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with self leaf expander|Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.
40837094|NCT04512508|DIAGNOSTIC_TEST|Self test sample|Self test sample, DNA analysis, Biopsy and Anoscopy
40837095|NCT06140459|DEVICE|Conventional Toothbrushes|Oral-B Stages 3
41266548|NCT02969902|DEVICE|Buzzy® device|
41357402|NCT02216227|DRUG|Nasal Povidone Iodine|The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
41357403|NCT05964296|OTHER|The MAURISSE application use|"* Exchanges with the care team via the messaging system,~* Postponement of consumption,~* Monitoring of consumption,~* Access to information on the To Do List,~* Access to personal content to help with management (Socio-professional situation, type of life, personal history..).~* Postponement of a feeling of boredom,~* Access to proposals to fight against this feeling."
40837096|NCT06140459|DEVICE|Pulsating Toothbrushes|Oral-B Pulsar, Colgate 360º Micro Sonic Power
40837097|NCT02578342|DEVICE|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
40837098|NCT02753634|BEHAVIORAL|Square-stepping exercise|Participants are asked to remember and repeat stepping patterns across a gridded mat as shown to them by an instructor.
40837099|NCT00514020|DRUG|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
40837100|NCT00514020|DRUG|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
40837101|NCT00514020|DRUG|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
40837102|NCT00514020|GENETIC|gene expression analysis|Blood collection
40837103|NCT00514020|GENETIC|polymorphism analysis|Blood collection
40837104|NCT00514020|GENETIC|protein expression analysis|Blood collection
40837105|NCT00514020|OTHER|pharmacological study|Blood collection
41357404|NCT05964296|OTHER|Usual care|The usual care within the center will consist of appointments with doctors; regular follow-up meetings with nurses, psychologists, social workers, therapeutic groups depending on the evaluation.
41357405|NCT01117428|DRUG|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
41357406|NCT05466604|DRUG|Hyaluronidase Injection mesomedica|injection of 150 IU hyaluronidase to perioperative region, submucosally.
41357407|NCT05466604|DRUG|Dexamethasone dekort|injection of 8 mg dexamethasone to perioperative region, submucosally.
41357408|NCT00073515|DRUG|Alfimeprase|
40837106|NCT00332865|BEHAVIORAL|Swallowing Exercises|Daily exercises
40837107|NCT02678884|DRUG|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
40837108|NCT03009318|OTHER|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
40837109|NCT00003719|DRUG|irinotecan hydrochloride|
40837110|NCT05153707|BEHAVIORAL|Discharge Education Program|medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on Health Belief Model by using written material and video, and verbally \[by using Teach back method especially for patients with low health literacy\]) and counseling (using behavior change techniques based on The Capability, Opportunity, and Motivation Behavior model).
40837111|NCT05811117|DIAGNOSTIC_TEST|There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.|We will study patients that undergo autopsy after CAR T cell infusion.
40837112|NCT01726673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
41357409|NCT00495794|BEHAVIORAL|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
41357410|NCT04643769|DRUG|ORIN1001|Oral tablet - ORIN1001
41357411|NCT04643769|DRUG|Placebo|Oral tablet - placebo
41357412|NCT04312815|DRUG|SM03|SM03: 600 mg intravenous (IV)
41357413|NCT04312815|DRUG|Placebo|Placebo: 600 mg intravenous (IV)
40837113|NCT01726673|DEVICE|Placebo sham|
40837114|NCT01806649|DRUG|BKM120|
40837115|NCT06054854|BIOLOGICAL|Extra blood sampling, Non-invasive or leftover samples or medical waste|"Extra blood sampling, Urine, Saliva, Stool, Superficial nasal swamp sampling. Bronchoalveolar lavage fluid, Mediastinal node or mass, Peripheral nodule aspiration supernatant, Pleural fluid, Cerebrospinal fluid collection (leftover samples or medical waste).~Blood will be collected in larger quantity during a blood test planned as part of the patient's care.~Non-invasive or leftover samples or medical waste will be collected on top of the usual diagnosis and during follow-up, depending on the case."
40837116|NCT05002387|DEVICE|NanoScope™ Operative Arthroscopy (Arthrex, Inc)|Needle arthroscopy will be performed in the operating room to visual the medial, lateral, and patellofemoral compartments prior to undergoing either unicompartmental or total knee arthroplasty
41266549|NCT02969902|DEVICE|Hand-held computer|
41266550|NCT05963503|OTHER|Assessments|Health literacy Anxiety and depression Physical activity Adherence to airway clearance techniques
41266551|NCT01818726|DRUG|ICL670|ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
41266552|NCT01818726|DRUG|Chelation|Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
40837117|NCT04176120|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
40837118|NCT04176120|OTHER|Standard Care|"Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics."
40837119|NCT01929538|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
40837120|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 12mm in diameter|
41022461|NCT06261749|OTHER|Voluntary Abdominal Contractions|Abdominal contraction will be taught before exercise. They will be instructed to tighten their abdomen as if they were wearing tight pants and not to hold their breath. The visual biofeedback unit will be placed between the therapy table and the participant's abdominal area and will be used to monitor the contraction of the abdominal muscles. The visual biofeedback inelastic bag will be inflated to 70 mmHg and the participant will be instructed to draw the abdomen in and maintain the position. The participant will be asked to maintain a pressure of 60 mmHg during scapular retraction with visual feedback from an analog pressure gauge. Pressure changes of ± 5 mmHg due to breathing will be allowed. During exercise, the patient will be asked to perform the exercises while maintaining the pressure on the visual biofeedback.
41022462|NCT06261749|OTHER|Exercise|"Exercises;~1. Scapular retraction with arms next to the trunk~2. Scapular retraction with arms abducted at 45 degrees,~3. Scapular retraction with arms 90 degrees abducted,~4. Scapular retraction exercises with arms 120 degrees abducted The exercises will be performed with the shoulder head off the bed. The exercises will be repeated 3 times with 5 seconds rest between repetitions. To reduce the effect of fatigue, 2 minutes rest will be given between exercises. Each exercise will be performed with 3 seconds of concentric, 3 seconds of isometric and 3 seconds of eccentric contraction and muscle activation of UT-LT and SA muscles will be measured during these phases."
41022463|NCT04736784|OTHER|Food-based - beetroot juice|Beetroot juice containing approximately 340 mg nitrate daily
41022464|NCT04736784|OTHER|Food-based - leafy green vegetable juice|Leafy green vegetable juice containing approximately 340 mg nitrate daily
41022465|NCT04978246|BEHAVIORAL|Neuropsychometric Test|Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
41022466|NCT01390558|PROCEDURE|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
41022467|NCT03985319|DRUG|YYD601 20mg|Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)
41357414|NCT04312815|DRUG|MTX|Methotrexate: 7.5-20 mg/wk oral
41357415|NCT04464876|DEVICE|SATURN TA System|SATURN TA TMVR Device implanted
40837121|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 10mm in diameter|
40837122|NCT03859921|DRUG|Dydrogesterone|Progesterone
40837123|NCT03859921|DRUG|Placebo|Placebo with appearance similar to Dydrogesterone
40837124|NCT00162266|DRUG|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
40837125|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
40837126|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
40837127|NCT00162266|DRUG|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
40837128|NCT01399268|DRUG|Hydrocortisone|Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
40837129|NCT01399268|DRUG|Saline|Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
40837130|NCT02060032|DRUG|1.2% Atorvastatin local drug delivery|
40837131|NCT02060032|DRUG|1.2% simvastatin local drug delivery|
40837132|NCT02060032|DRUG|Placebo local drug delivery|
41357416|NCT02195895|DRUG|Alendronate|Weekly oral alendronate 70 mg for 12 months
41357417|NCT02195895|DIETARY_SUPPLEMENT|Calcium|Daily oral 1000 mg Calcium
41357418|NCT02195895|DIETARY_SUPPLEMENT|Vitamin D|Daily oral 1000 IU
41357419|NCT04983004|BEHAVIORAL|tele-rehabilitation|According to the pre-arranged case service schedule, the researcher is asked to push the computer and cart to the case ward for installation, and use the communication software to interact with each other in real time. The intervention method directly plays the recorded video to demonstrate the action according to the action needs of the case. The therapist can observe the video demonstration and the actual action execution of the case at the same time from the screen.
41357420|NCT04983004|BEHAVIORAL|bedside rehabilitation|The bedside therapist and the case work together to set an activity schedule. The case is asked to establish and record daily routine activities, provide basic exercise and activity schedules to avoid degradation and reduce the lack of active participation in activities. The protection is to wear personal protective equipment, including protective clothing, gloves, masks, and face shields, and wash hands and disinfect before and after treatment.
41357421|NCT01548729|PROCEDURE|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
41357422|NCT03500315|OTHER|HIV D+/R+|Kidney from an HIV-infected deceased donor
41357423|NCT05309785|DRUG|Invokana 300 mg and 100 mg tablet|"Substudy 1 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 12+2 weeks (phase 1). For participants who have tolerated the drug, canagliflozin will be increased to 300 mg po daily for an additional 12+2 weeks (phase 2) and then stopped. If not tolerated, the dose will be reduced to 100 mg until the end of follow-up.~Each phase of 12 weeks is followed by a 2-week window to ascertain surrogate efficacy outcomes.~Substudy 2 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 9 days."
41357424|NCT04006431|OTHER|embolization|Retrospective, observational collection with division of patients into two groups according to unilateral or bilateral embolization of the porstatic arteries.
41357425|NCT03862729|PROCEDURE|Minimally invasive surgery|Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
41357426|NCT03862729|PROCEDURE|conventional treatment|Conventional treatment includes medical treatment and conventional craniotomy.
41357427|NCT02058966|DRUG|Entacapone|Entacapone 200 mg oral dose
41357428|NCT02058966|DRUG|Methamphetamine|Methamphetamine 20 mg oral dose
41357429|NCT02058966|DRUG|Placebo|capsules compounded to be of similar appearance to the active drugs
41357430|NCT00963820|DRUG|Ixazomib citrate|Ixazomib citrate capsules
41357431|NCT02929836|PROCEDURE|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
40837133|NCT03766269|DRUG|Dronabinol|Dronabinol coadministered with patient's existing Baseline Opioid.
40837134|NCT04104880|DEVICE|Continuous positive airway pressure (CPAP)|Adults previously diagnosed with obstructive sleep apnoea will receive a three-month CPAP intervention
40837135|NCT03166644|DEVICE|Analgesia Nociception Index (ANI)-guided sufentanil administration|One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
40837136|NCT02560298|DRUG|Capecitabine|
40837137|NCT02560298|DRUG|Carboplatin|Given IV
40837138|NCT02560298|DRUG|Cisplatin|Given IV
40837139|NCT02560298|DRUG|Fluorouracil|Given IV
40837140|NCT02560298|OTHER|Laboratory Biomarker Analysis|Correlative studies
40837141|NCT02560298|DRUG|Paclitaxel|Given IV
40837142|NCT02560298|OTHER|Quality-of-Life Assessment|Ancillary studies
40837143|NCT01878994|BEHAVIORAL|Counselling group|
40837144|NCT01878994|BEHAVIORAL|Nereu group|
41357432|NCT02929836|PROCEDURE|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
40837145|NCT05287048|DIAGNOSTIC_TEST|MCM5 ELISA|ADXGYNAE is a non-invasive ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the detection of endometrial cancer in women with postmenopausal bleeding who are suspected of having endometrial cancer. Participants will be asked to provide a urine specimen, which will be centrifuged before the sediment is lysed. The lysed sample will then be tested with the MCM5 ELISA.
40837146|NCT04569994|DRUG|NNC0363-0845|A single dose administered s.c. (subcutaneously, under the skin)
41357433|NCT02929836|PROCEDURE|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
41357434|NCT02929836|PROCEDURE|linear ablation|Right atrial CTI ablation was performed during SR.
41357435|NCT02929836|DEVICE|CARTO|3 dimensional mapping system
41357436|NCT05430230|DRUG|Naproxen 500 Mg|naproxen tablets
41357437|NCT05430230|DRUG|Placebo|lactose NF
41357438|NCT00002362|DRUG|Abacavir sulfate|
41357439|NCT00002362|DRUG|Efavirenz|
41357440|NCT00002362|DRUG|Emtricitabine|
41357441|NCT00002362|DRUG|Stavudine|
41357442|NCT00374764|DRUG|Risperidone|
41357443|NCT00374764|BEHAVIORAL|ABA|
41357444|NCT05213689|BEHAVIORAL|Educational comic book|An educational comic book was developed with qualitative data collected from an earlier study phase involving focus groups with youth from Bidi Bidi. The comic book is focused on HIV testing information and decision making as it follows the story of youth in Bidi Bidi who are seeking out HIV testing. Each youth in the appropriate arm with receive a copy of the comic book and together with 5-10 other youth will meet with a PN to read through and discuss the comic book. The comic will also include blank pages so that the youth can participate in the dialogue of the comic book. The comic will be available in English, Bari and Juba Arabic.
41357445|NCT05213689|DIAGNOSTIC_TEST|HIV Self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
41357446|NCT04166136|OTHER|Transition from the Rearfoot to the Forefoot and Midfoot|Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
41357447|NCT04166136|OTHER|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
41357448|NCT04166136|OTHER|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
41496705|NCT06255158|BEHAVIORAL|INSIGHT Program|"INSIGHT Program:~the program targets the reduction of EMSs' interference in social information processing, which may otherwise lead to the use of deviant behavior to fulfill emotional and sexual needs. Furthermore, the program has specific goals: (1) developing insight about the offense cycle; (2) fostering empathy for victims; (3) enhancing intimate and social/ interpersonal skills; (4) increasing emotional regulation skills."
41496706|NCT06255158|OTHER|Treatment As Usual (TAU)|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
41496707|NCT01898650|OTHER|MR scan|
40837147|NCT04569994|DRUG|Placebo (NNC0363-0845)|A single dose administered s.c.
40837148|NCT04569994|DRUG|Insulin degludec|A single dose administered s.c.
40837149|NCT05378295|DIETARY_SUPPLEMENT|Fermentable oligosaccharide|Supplementation period 12 weeks
41357449|NCT01901679|DRUG|Celebrex|200 mg PO BID
41357450|NCT03180268|OTHER|Clinical Observation|Undergo observation
41357451|NCT03180268|RADIATION|Radiation Therapy|Undergo radiation therapy
41357452|NCT00101790|DRUG|pamidronate|There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
41357453|NCT03378284|DRUG|Tegoprazan|Tegoprazan QD for 7 days
41357454|NCT03378284|DRUG|Revaprazan|Revaprazan QD for 7 days
41357455|NCT04557696|OTHER|REFLECT Curriculum|Annual quarterly workshops will consist of guest lecturers, role playing, patient panels, coaching, knowledge assessments, Standardized Patient (SP) simulations and debriefing/feedback sessions.
41496708|NCT05404945|DRUG|Pembrolizumab|Pembrolizumab 400 mg IV
41496709|NCT05404945|DRUG|Doxorubicin|Doxorubicin 25mg/m2 IV
41496710|NCT05404945|DRUG|Vinblastine|Vinblastine 6mg/m2 IV
41496711|NCT05404945|DRUG|Dacarbazine|Dacarbazine 375mg/m2 IV
41496712|NCT05404945|DRUG|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg IV
40837150|NCT05378295|DIETARY_SUPPLEMENT|Personalized fiber mixture|Supplementation period 12 weeks
41496713|NCT05224310|PROCEDURE|PECS block, SAP block|performing either PECS block or SAP block
41496714|NCT05944601|BEHAVIORAL|Virtual and computer-based cognitive remediation training|Amyloid-positive MCI patients, and individuals carrying the ApoE- ε4 allele will undergo a combined intervention of computer-based sessions of a spatial memory task by the Erica software (Giunti, Florence, Italy) and VR navigation sessions by the NeuroVirtual 3D software (Serino et al., 2010), in order to improve spatial memory for landmarks location and mental frame syncing for supporting spatial scenarios, respectively. The intervention will last one month for a total of 12 sessions (3 days a week, 50 minutes per session).
41496715|NCT04048044|DEVICE|Exposure to GHz electromagnetic energy (RejuvaMatrix)|75 decibels of 54 to 78 GHz daily for 60 minutes
41496716|NCT00069511|DRUG|UT-231B|
41496717|NCT05739253|PROCEDURE|Transcatheter aortic valve replacement|All patients undergo transfemoral transcatheter aortic valve replacement for aortic stenosis
41496718|NCT04516135|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
41496719|NCT04516135|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41496720|NCT04516135|OTHER|Quality-of-Life Assessment|Ancillary studies
41496721|NCT04516135|OTHER|Questionnaire Administration|Ancillary studies
41496722|NCT04516135|RADIATION|Volume Modulated Arc Therapy|Undergo VMAT
40837151|NCT05039658|DRUG|IBI110 plus sintilimab|Sintilimab is a NMPA approved high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
40837152|NCT05039658|DRUG|IBI110|BI110 is a high-affinity, ligand-blocking, humanized anti- Lymphocyte Activation Gene-3 (LAG-3) IgG4 antibody that blocks the binding of LAG-3 to MHCII.
41022468|NCT03985319|DRUG|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg Effecacy and Effects: GERD and Antibiotics combined therapy to eradicate the Helicobacter pylori
41496723|NCT04471025|PROCEDURE|USG guided infraclavicular block|USG guided infraclavicular block was applied to patients either by conventional two-person technique or by one person Jedi technique according to the allocated group. On Group I single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm. On Group II, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic.
41496724|NCT03483727|DEVICE|SIMMAXMARCHERYAN|Digital cognitive aid during the management of simulated combat wounded.
41496725|NCT05149157|OTHER|Symptomatic malaria|This observational study will be recruiting patients who have symptomatic malaria (confirmed by presence of asexual stage parasitaemia of any Plasmodium species on blood film)
41496726|NCT03776838|DRUG|Intravenous Fentanyl guided by SoC+NOL|Predeterminated bolus of IV Fentanyl will be given at the induction of anesthesia (2 mcg/kg), at the time of incision (1 mcg/kg). During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administred following a pre determinated algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
41496727|NCT03776838|DRUG|Intravenous Fentanyl guided by SoC|Bolus of IV Fentanyl at the discretion of a physician will be given at the induction of anesthesia, and at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
41496728|NCT02495623|DRUG|SYN-010 21 mg|
41496729|NCT02495623|DRUG|SYN-010 42 mg|
41496730|NCT02495623|DRUG|Placebo|
41496731|NCT00390559|DRUG|nicotine transdermal system|21 mg nicotine transdermal system
41496732|NCT00390559|DRUG|Nicotine transdermal system|Placebo nicotine patch
41496733|NCT00390559|OTHER|Nicotine containing cigarette|Nicotine containing cigarette
41496734|NCT00390559|OTHER|Placebo cigarette|Non nicotine containing cigarette
41496735|NCT01531543|DEVICE|V.A.C.- Vacuum assisted closure laparostomy (KCI)|Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
41496736|NCT04332887|BEHAVIORAL|Multidimensional Exercise Program|Patients in the experimental group will receive a 12-week multidimensional exercise program; patients in the control group will maintain their usual life activities.
41496737|NCT04810286|PROCEDURE|3d-Printing Myofunctional Appliance|To evaluate soft- and hard-tissue changes Class II division 1 tchildren with a prefabricated myofunctional appliance versus a 3D-printed myofunctional appliance.
41496738|NCT04795830|COMBINATION_PRODUCT|Bioceramic root repair material as pulp dressing in pulpotomy in primary molars|BC RRM-F, a novel premixed bioceramic-based putty, can be used as a pulp dressing to promote pulp healing and repair with an added convenience for the pediatric patient. The aim of the present study is to evaluate the efficacy of a bioceramic root repair material as pulp dressing in pulpotomy in primary molars. The success of this material as pulpotomy dressing in primary molars will be evaluated clinically and radiographically in comparison to mineral trioxide aggregate pulpotomy. Both materials will be compared in terms of ease of handling, time to perform procedure and convenience of application. Each material's success will be evaluated by comparing its performance with or without the added peripheral seal of a stainless steel crown.
41496739|NCT04795830|COMBINATION_PRODUCT|Mineral Trioxide Aggregate as pulp dressing in primary molars (MTA)|MTA's sealing ability, biocompatibility, ability to stimulate hard tissue formation and its regenerative ability when used in contact with pulp tissues has made MTA pulpotomy the new gold standard as opposed to formocresol pulpotomy in treating the amputated pulp stumps of primary molars.
41496740|NCT02985671|DRUG|orphenadrine, acetaminophen, caffeine and diclofenac sodium|orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
41496741|NCT02985671|DRUG|Diclofenac Sodium 50 MG|Voltaren (diclofenac sodium 50mg) tablet
41496742|NCT02985671|DRUG|Placebo (for experimental drug)|tablet without active substances, manufactured to mimic experimental product tablet
41496743|NCT02985671|DRUG|Placebo (for Voltaren)|tablet without active substances, manufactured to mimic Voltaren 50mg tablet
41496744|NCT04555720|BEHAVIORAL|Interdisciplinary Visit|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participants doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
41496745|NCT03413293|DIAGNOSTIC_TEST|Diagnosis of bacterial infections|Cultures
41496746|NCT05607979|DRUG|Lavior Diabetic Wound Gel|Daily application of hydrogel treatment for 60 days.
41496747|NCT05607979|DRUG|Smith & Nephew Solosite Gel Hydrogel Wound Dressing|Daily application of hydrogel treatment for 60 days.
41022469|NCT03654677|BIOLOGICAL|inactivated hepatitis A vaccine|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
41022470|NCT03654677|BIOLOGICAL|Havrix Inj|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
41022471|NCT06078397|DEVICE|remote programming|Remote programming (RP) is a new type of patient management method after DBS surgery, which allows physicians to understand the patient's movement symptoms and adjust parameters through video conferencing. At the same time, the RP system also includes device checks, medication adjustments, psychological counseling, and other contents. Compared to standard programming that requires going to the hospital, the application of RP can save the burden on patients and their caregivers.
41357456|NCT03385629|BEHAVIORAL|CSM theory-based didactic education and skills training|Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.
41357457|NCT03385629|OTHER|AAP-based didactic education|American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.
41357458|NCT03385629|OTHER|Practice EMR changes|Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
41357459|NCT02216630|DRUG|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
41357460|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
41357461|NCT00833066|BIOLOGICAL|Placebo|placebo entero-coated capsules
41357462|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
41357463|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
41357464|NCT05841615|OTHER|Renal Denervation operation|RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W\~12W for 40 seconds
41357465|NCT05841615|OTHER|Pulmonary vein isolation|PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
40837153|NCT05771038|PROCEDURE|socket preservation using sodium alendronate gel|"sockets will be preserved by sodium alendronate gel before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
40837154|NCT05771038|PROCEDURE|socket preservation using sticky bone|"sockets will be preserved by sticky bone as mentioned before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
40837155|NCT01497613|BEHAVIORAL|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
40837156|NCT01497613|BEHAVIORAL|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
40837157|NCT03623061|DIAGNOSTIC_TEST|F-Point|F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
41357466|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
41357467|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
41357468|NCT03108989|DRUG|Sugammadex|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
41357469|NCT03108989|DRUG|Neostigmine|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
41357470|NCT05070208|OTHER|NOT PROVIDED|NOT PROVIDED
41357471|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
41357472|NCT00315640|DRUG|Anecortave Acetate Suspension Depot, 30 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
41357473|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
41357474|NCT00315640|OTHER|Anecortave Acetate Vehicle|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
41496748|NCT02340052|DRUG|Pain treatment|Registration af actual analgesic treatment and outcomes
41496749|NCT02208635|OTHER|Biofortified Maize|Participant in this arm were fed zinc biofortified maize (\~30 µg Zn/g).
41496750|NCT02208635|OTHER|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of \~60 µg Zn/g).
40837158|NCT02772978|DRUG|Tolcapone|Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
40837159|NCT02772978|DRUG|Placebo|A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
41357475|NCT04328142|OTHER|Qigong group|Traditional Chinese Medicine exercise programme
41357476|NCT04328142|OTHER|Physiotherapy|Physiotherapy exercise programme
41496751|NCT02208635|OTHER|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (\~15 µg Zn/g maize).
40837160|NCT03445221|DIETARY_SUPPLEMENT|IV Immunonutrition|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
41022472|NCT06078397|DEVICE|standard programming|Programming refers to a series of methods that set the parameters of the IPG after the implantation of DBS, and adjust the device parameters based on the patient's symptoms during subsequent follow-up to maintain the efficacy of electrical stimulation.
41022473|NCT06535204|DIETARY_SUPPLEMENT|Aqueous extract of A. sylvestris leaves|Provided functional food made from Aqueous extract of A. sylvestris leaves
41022474|NCT06535204|DIETARY_SUPPLEMENT|microcrystalline cellulose|Provided placebo composed of microcrystalline cellulose instead of A. sylvestris leaf extract.
41357477|NCT03434860|DIETARY_SUPPLEMENT|probiotic|"The multiprobiotic Symbiter which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day."
41357478|NCT03434860|DIETARY_SUPPLEMENT|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
41357479|NCT01211366|OTHER|Cell Saver RBCs|Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
41357480|NCT01211366|OTHER|Conventional volume infusion|Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
41357481|NCT04250142|DEVICE|Self-etching Adhesive|A Self-etching adhesive will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
41022475|NCT02685163|OTHER|Antioxidant ice-cream|Narutal Antioxidant ice-cream
41022476|NCT02685163|OTHER|Control Ice-cream|Natural Control Ice-cream
41022477|NCT00809289|DRUG|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
41022478|NCT00809289|DRUG|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
41357482|NCT04250142|DEVICE|Glass Ionomer|A conventional glass ionomer will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
41357483|NCT03757299|DIAGNOSTIC_TEST|HPV Test|Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
41357484|NCT00183027|BEHAVIORAL|Dietary composition and energy intake|
41357485|NCT05814406|DRUG|JW0201|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
41496752|NCT06451055|BEHAVIORAL|Low-calorie diet|LCD diet is designed to provide \~1300 kcal/day with a macronutrient composition of 55% carbohydrate, 13% fat, 25% protein, and 2% fiber.
41496753|NCT06451055|BEHAVIORAL|Routine dietary and physical activity habits|Participants will be asked to maintain their habitual dietary and physical activity habits.
41496754|NCT04380090|DRUG|Propylene Glycol|Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
41496755|NCT04380090|DRUG|Docusate Sodium|Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
41496756|NCT04001127|OTHER|High Intensity Functional Training|"The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing)."
41496757|NCT00811356|DRUG|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
41496758|NCT01910779|PROCEDURE|100 joule as first biphasic shock energy|
41496759|NCT01910779|PROCEDURE|120 joule as first biphasic shock energy|
41496760|NCT01648660|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
41496761|NCT05320601|DEVICE|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at trigger point of upper trapezius muscle
41496762|NCT05320601|PROCEDURE|Dry needling|Dry needling at trigger point of upper trapezius muscle
41496763|NCT01410643|OTHER|Macronutrient Modification|reduced carbohydrate versus standard carbohydrate diet
40837161|NCT03445221|DIETARY_SUPPLEMENT|Conventional Diet|patients will continue preoperative oral conventional diet.
40837162|NCT04464525|DRUG|Omecamtiv mecarbil|Film-coated tablet administered orally.
40837163|NCT00973882|DRUG|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
40837164|NCT00973882|DRUG|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
41022479|NCT00809289|DRUG|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
41022480|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
41022481|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
41022482|NCT04928352|OTHER|0.9% saline|Preoperative nebulized same volume of saline placebo
41022483|NCT01955876|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931)|Patients treated with Fosrenol in daily clinical practice.
41022484|NCT06526507|OTHER|Implementation strategy package|Package includes a Community of Practice, a quality improvement (QI) practice, and a training \& delivery toolkit.
41022485|NCT05864027|BEHAVIORAL|Peer-led Oral Health Recovery Group|"The interactive Oral Health Recovery group will be centered around the tailored materials previously developed, with topics such as it's never too late to make a change, oral health and whole health, taking care of your teeth, and going to the dentist."
41022486|NCT05864027|BEHAVIORAL|Educational Video about Oral Health|The video comparison will be pulled from Toothflix 2.0 Patient Education DVD Series, which are patient education videos developed by the American Dental Association.
41022487|NCT06538532|OTHER|Zamzam water|Zamzam water
41022488|NCT06148597|PROCEDURE|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA)|application local anesthetic between internal oblique and transversus abdominis muscle at the level of 10th costal cartilage
41022489|NCT03959501|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10mg daily for 24 weeks
41022490|NCT03959501|DRUG|Sitagliptin 100mg|Sitagliptin 100mg daily for 24 weeks
41022491|NCT06317181|DEVICE|Collection of elastography data|patients who are scheduled for an elastography for clinical reasons usually receive an ultrasound scan in which the b-mode images of the liver tissue are collected. In this study additional radiofrequency data is collected through a software access.
41022492|NCT06317181|DEVICE|Collection of ultrasonic raw data|Patients who are transferred to the ultrasound departement due to suspicious focal lesions receive an ultrasonic investigation including the acquisition of raw data and extracting a definitive diagnose from the following clinical routine investigation, depending on the standards of the participating center
41022493|NCT01513317|DRUG|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
41022494|NCT01513317|DRUG|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
41022495|NCT01513317|DRUG|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
41022496|NCT05086458|DIETARY_SUPPLEMENT|probiotics|probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis
41357486|NCT05814406|DRUG|Placebo|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
41022497|NCT04143347|OTHER|No Intervention|
41022498|NCT00165438|PROCEDURE|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
41160357|NCT05571553|OTHER|Recommendations and reorientation towards healthcare resources|"Phase 1~* After completing the CARE© questionnaire, participants will be given recommendations.~* After the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments made.~Phase 2~* After completing the CARE© questionnaire, participants will be given recommendations.~* If their health status is judged fragile by the CARE© score, and after the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments.~For both phases, after 3 (6) months, the participants of the Control group will benefit from the recommendations following the CARE© assessment done at M3 (M6), and if necessary from the ESOGER© assessment and the Red Cross intervention. Throughout the study, they will continue to receive their conventional care."
41357487|NCT04477668|DEVICE|Helmet non-invasive ventilation|Patients will be allocated to helmet non-invasive ventilation
41496764|NCT02532725|PROCEDURE|Cardiopulmonary Exercise Stress Test|Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.
41160358|NCT06244030|OTHER|core stabilization group|The athletes in the training group will be applied 15-20 repetitions of core stabilization exercise program 3 days a week for 6 weeks by the researcher.
41357488|NCT00969735|DEVICE|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
41496765|NCT02532725|PROCEDURE|Climatic-Controlled Cardiopulmonary Exercise Stress Test|Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.
41022499|NCT00165438|PROCEDURE|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
41022500|NCT05290129|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
41022501|NCT04986618|OTHER|One-way Nordic Exercise|Participants in this group will be given the standard Nordic Hamstring exercise.
41022502|NCT04986618|OTHER|Two-way Nordic Exercise|In addition to the standard Nordic Hamstring exercise, participants in this group will do the same exercise backwards for the quadriceps.
41022503|NCT01645475|DRUG|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
41022504|NCT02104557|OTHER|Non intervention|Non intervention
41022505|NCT02104557|OTHER|Non intervention|Non intervention
41022506|NCT00309933|PROCEDURE|cognitive assessment|
41022507|NCT00309933|PROCEDURE|psychosocial assessment and care|
41022508|NCT00309933|PROCEDURE|quality-of-life assessment|
41496766|NCT02532725|PROCEDURE|Body Composition Evaluation|Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.
41496767|NCT02532725|PROCEDURE|Pre-Exercise Risk Assessment|Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.
41496768|NCT06315595|OTHER|Non-Interventional Study|Non-interventional study
41357489|NCT00969735|DEVICE|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter \> 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
40837165|NCT03911466|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
40837166|NCT03911466|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
40837167|NCT03829956|DEVICE|Intraoral tongue stimulator (Snoozeal)|Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
40837168|NCT00858663|RADIATION|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
41160359|NCT05144438|DIAGNOSTIC_TEST|Toxseek test|Hair taking
41266553|NCT01818726|DRUG|No chelation|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
41357490|NCT02306928|OTHER|Blood draw|
41357491|NCT04437524|OTHER|therapeutic exercises|Treatment that will continue 3 days a week for 6 weeks in female patients with fibromyalgia.
41357492|NCT06356441|DIAGNOSTIC_TEST|AI|An artificial intelligence model predicts the risk and contours of local recurrence for MR images and triages them before radiologists interpret them.
41496769|NCT01399567|BEHAVIORAL|Algorithm|The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
41496770|NCT04384835|BIOLOGICAL|Blood sample collection (one tube)|Collection of one tube of 7.5 ml blood in addition to a blood sample made in clinical practice
41496771|NCT04384835|BIOLOGICAL|Blood sample collection (five tubes)|Collection of five tubes of 7.5 ml blood in addition to a blood sample made in clinical practice
41496772|NCT04013984|OTHER|Accupuncture|In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons
41496773|NCT04759053|PROCEDURE|FNB|Fine needle aspiration from the nodules
41496774|NCT04759053|PROCEDURE|Core biopsy|Core biopsy from thyroid nodules
41496775|NCT05524961|DEVICE|Bright light therapy|Regularly-timed exposure to 10,000lux bright light therapy for 60minutes a day for six weeks
41496776|NCT05524961|DEVICE|Inactivated negative ion generator|Regularly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
41022509|NCT03028376|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
41022510|NCT04558346|DRUG|Ghrelin (OXE-103)|40ug/kg twice daily by self-injection
41496777|NCT05524961|DEVICE|Inactivated negative ion generator|Randomly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
41496778|NCT00635232|DRUG|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
41496779|NCT00635232|DRUG|placebo|placebo capsules once daily for 12 weeks
41496780|NCT00635232|DRUG|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
41022511|NCT04558346|DRUG|Placebo|40ug/kg twice daily by self-injection
41022512|NCT05158062|BIOLOGICAL|pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
41022513|NCT05158062|DRUG|olaparib|olaparib 300 mg twice daily (BID) during maintenance period
41022514|NCT05158062|BIOLOGICAL|bevacizumab|bevacizumab 15 mg/kg Q3W
41022515|NCT05158062|DRUG|carboplatin|carboplatin AUC=5 or 6 Q3W during treatment period
41022516|NCT05158062|DRUG|paclitaxel|paclitaxel 175 mg/m2 Q3W during treatment period
41022517|NCT05158062|DRUG|docetaxel|docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
41496781|NCT00635232|DRUG|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
41496782|NCT00635232|DRUG|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
41496783|NCT03761563|DEVICE|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
41022518|NCT04262258|DIETARY_SUPPLEMENT|Blueberry enriched diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
41022519|NCT02139852|DIETARY_SUPPLEMENT|Capsaicin|
41022520|NCT06161376|OTHER|S1P level|Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.
41022521|NCT06419127|DIAGNOSTIC_TEST|Timelapse incubation and PGT|Patients will have their embryos cultured in a timelapse incubator and their PGT results will be compared to the data collected during timelapse incubation.
41022522|NCT04964934|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
41022523|NCT04964934|DRUG|AZD9833 Placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
41357493|NCT01880489|BEHAVIORAL|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
41357494|NCT03470506|OTHER|Stool Samples|Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups
41357495|NCT05240573|OTHER|SKI App|"The intervention for the SKI App digital service will include the visualization of real-time kidney data, the kidney care recommendation, and innovative artificial intelligence-based services for kidney health prediction and suggestion.~The intervention for the CMUH Dialysis Care App digital service will include simple records of blood pressure, medication records, and routine health education information."
41357496|NCT04787744|PROCEDURE|PET-directed Local Therapy using Surgery|Surgery will be used to treat metastases.
41357497|NCT04787744|RADIATION|PET-directed Local Therapy using Radiation|"Radiation therapy will be used to treat metastases.~Radiation options include:~1. Stereotactic body radiotherapy (SBRT) using 1-10 fractions~2. Conventionally fractionated radiotherapy using elective nodal radiotherapy and a simultaneous integrated boost to involved nodes~The selection of the form of metastasis-directed radiotherapy for each metastasis will be determined using shared decision-making between the treating physician and the Veteran."
41357498|NCT04787744|OTHER|Salvage Local Therapy for locally recurrent disease|For Veterans who have a local recurrence in addition to oligorecurrent metastatic lesions, they will undergo salvage local therapy using brachytherapy, SBRT, surgery, cryotherapy or HIFU. The selection of modality of salvage local therapy will be determined using shared decision-making between the treating physician and Veteran.
41357499|NCT04787744|DRUG|Goserelin, Histrelin, Leuprolide & Triptorelin|Androgen deprivation therapy (ADT) using an LHRH agonist
41357500|NCT04787744|DRUG|ADT + Nilutamide, Flutamide, & Bicalutamide|ADT adding anti-androgen therapy to an LHRH agonist
41357501|NCT04787744|DRUG|Degarelix & Relugolix|ADT using an LHRH Antagonist.
41357502|NCT04787744|DRUG|ADT + Docetaxel +/- prednisone|Enhanced SST using chemohormonal therapy
41357503|NCT04787744|DRUG|ADT + Abiraterone + Prednisone|Enhanced SST using Abiraterone + Prednisone
41022524|NCT04964934|DRUG|Anastrozole|Dosage formulation: anastrozole tablets will be administered orally.
41022525|NCT04964934|DRUG|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
41022526|NCT04964934|DRUG|Letrozole|Dosage formulation: letrozole tablets will be administered orally.
41022527|NCT04964934|DRUG|Letrozole placebo|Dosage formulation: letrozole placebo tablets will be administered orally.
41022528|NCT04964934|DRUG|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
41022529|NCT04964934|DRUG|Abemaciclib|Dosage formulation: abemaciclib tablets will be administered orally
41022530|NCT04964934|DRUG|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
41357504|NCT04787744|DRUG|ADT + Abiraterone + Methylprednisolone|Enhanced SST using Abiraterone + Methylprednisolone
41357505|NCT04787744|DRUG|ADT + Apalutamide|Enhanced SST using ADT + Apalutamide
41357506|NCT04787744|DRUG|ADT + Enzalutamide|Enhanced SST using ADT + Enzalutamide
41496784|NCT03127683|OTHER|Neutral position|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
41022531|NCT04964934|DRUG|Ribociclib|Dosage formulation: ribociclib tablets will be administered orally
41022532|NCT05627440|DIETARY_SUPPLEMENT|Ensure Max Protein|Ensure Max Protein, 1 bottle daily (330 mL), 30 grams protein
41022533|NCT05627440|DIETARY_SUPPLEMENT|Ensure Original|Ensure Original, 1 bottle daily (237 mL), 9 grams protein
41022534|NCT03267238|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
41022535|NCT06227780|OTHER|Alpha Auditory Entrainment|"Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers"
41022536|NCT06227780|OTHER|Sham|"Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers"
41266554|NCT00854646|DRUG|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
41266555|NCT03607279|PROCEDURE|NGAL|
41496785|NCT03127683|OTHER|Extension|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
41496786|NCT03127683|OTHER|Flexion|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
41496787|NCT03127683|OTHER|Rotation|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
41357507|NCT04787744|RADIATION|Prostate-directed Radiation for De novo oligometastatic prostate cancer|"Veterans in ARM 1 will receive prostate-directed RT only and NO treatment to any nodal or distant metastatic sites.~Acceptable dose/fractionations include 55 Gy in 20 fractions and 36 Gy in 6 fractions.~Veterans in ARM 2 should receive prostate-directed local therapy using radiotherapy or radical prostatectomy in addition to PET-directed local therapy to metastases."
41496788|NCT03127683|DEVICE|Ambu AuraGain TM|Single Use Laryngeal Mask Sterile
41496789|NCT00853463|BEHAVIORAL|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
41357508|NCT05998603|DIETARY_SUPPLEMENT|High protein intake|The participants received a 60g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
41357509|NCT05998603|DIETARY_SUPPLEMENT|Moderate protein intake|The participants received a 20g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
41357510|NCT05998603|DIETARY_SUPPLEMENT|Carbohydrate maltodextrin placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep pre and post a military load carriage test.
41357511|NCT05998603|OTHER|Control no supplementation|Control group, no supplementation, only basic training
41357512|NCT01722552|BEHAVIORAL|adherence feedback|
41357513|NCT01722552|BEHAVIORAL|standard of care|
41357514|NCT01024946|DRUG|everolimus|Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
41357515|NCT05147194|DRUG|Trimetazidine|Oral，35mg bid
41357516|NCT03960164|COMBINATION_PRODUCT|Dermal regeneration photosynthetic matrix (DRPM)|"Primary Procedure: DRPM implantation~1. Wound bed preparation and cleaning.~2. DRPM implantation.~3. Illumination with LED device.~Secondary Procedure: Autologous partial skin graft"
41357517|NCT01749228|DRUG|Etodolac Capsules USP 300 mg|300 mg capsule once a day
41357518|NCT01749228|DRUG|Etodolac|500 mg tablet once a day
41357519|NCT00202267|DEVICE|Four-layer Bandage (Elastomeric)|Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
41357520|NCT00202267|DEVICE|Short-stretch Bandage (Non-elastomeric)|These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
41357521|NCT02897830|DRUG|Ixazomib|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21)."
41496790|NCT05168683|DRUG|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal|Dosing or radiolabelled ALLN-346 fast or slow release tablets or capsules. Scintigraphic images will be taken
41022537|NCT04127032|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly support, or monitored optional support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their access to therapist support by an additional 8 weeks (i.e., up to 16 weeks in total).
41496791|NCT05168683|DRUG|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state|Selected dosing of Part One treatments in fasted and/or fed states
41496792|NCT06438809|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|MSC suspension single does injection.
41496793|NCT01796938|DRUG|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
41496794|NCT00521469|DEVICE|Pro Adjuster|
41496795|NCT00898235|GENETIC|clonality analysis|analyze clonality
41496796|NCT00898235|GENETIC|polymerase chain reaction|analyze polymerase chain reaction
41496797|NCT00898235|GENETIC|protein analysis|analyze protein
41496798|NCT00898235|OTHER|biologic sample preservation procedure|preserve biologic samples
41496799|NCT00898235|OTHER|laboratory biomarker analysis|analyze laboratory biomarkers
41496800|NCT00898235|PROCEDURE|fluorescence spectroscopy|perform fluorescence spectroscopy on specimens
41496801|NCT00898235|PROCEDURE|quality-of-life assessment|assess quality of life at each follow-up for life
41496802|NCT05413616|BEHAVIORAL|FITFOOD lifestyle intervention|Lifestyle intervention with a nutritional and exercise component.
41357522|NCT02897830|DRUG|Lenalidomide|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles"
41496803|NCT00799448|DRUG|repaglinide|
41496804|NCT00799448|DRUG|biphasic human insulin 30|
41496805|NCT00799448|DRUG|insulin NPH|
41496806|NCT04365218|DRUG|MEDI8367|Subjects will receive subcutaneous (SC) single dose of MEDI8367, depending upon dose escalation strategy and Safety Review Committee results. The maximum dose will not exceed 600 mg. The dose will be administered as a single injection or multiple injections in the abdomen region.
41496807|NCT04365218|DRUG|Placebo|Saline solution for injection and the placebo volume to be administered will be equivalent to the MEDI8367 volume administered for each dosing cohort.
40837169|NCT00858663|DRUG|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
40837170|NCT01212614|PROCEDURE|MRI, non invasive 13C-breath test, 24h-intragastric / esophageal pH monitoring|MRI, non invasive 13C-breath test, 24h-intragastric/esophageal pH monitoring
40837171|NCT00186277|DRUG|Oxaliplatin|Calculated per patient
40837172|NCT00186277|DRUG|Taxotere|Calculated per patient
40837173|NCT04082013|OTHER|Hamstring Flexibility|"The active knee extension test has been proposed as the gold standard for assessment of hamstring flexibility, as it utilizes readily available equipment and offers a quick, reliable, and low-cost alternative for measurement of hamstring flexibility (Connor et al; 2015).~* The subject will be instructed to maintain 90° hip flexion in the supine position.~* Then asked to actively extend the knee joint.~* The degree of achieving active knee extension will be measured using a universal goniometer.~* The average of three active knee extension measurements will be used as the hamstring muscle length for the data analysis (Dong-Kyu Lee, et al; 2018).~  * the procedures will be done with opposite-leg flexed, then repeated with opposite-leg extended."
40837174|NCT00514345|GENETIC|gene expression analysis|
40837175|NCT00514345|GENETIC|polymorphism analysis|
40837176|NCT00514345|PROCEDURE|management of therapy complications|
40837177|NCT03082352|DRUG|BF-Metoprolol Tablet 100mg|BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
40837178|NCT03082352|DRUG|Betaloc Tablet 100mg|Betaloc Tablet 100mg will be used as a comparator drug for the BE study
41496808|NCT02008435|BEHAVIORAL|Enriched GLB|Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
41496809|NCT02008435|BEHAVIORAL|Standard GLB|This arm is the standard Group Lifestyle Balance program
41496810|NCT04504253|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate loose powder
40837179|NCT06221748|DRUG|Disitamab Vedotin Injection|Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks
40837180|NCT06221748|DRUG|Cadonilimab Injection|Phase II and III study ：6.0mg/kg, intravenous infusion，D1, every 2 weeks.
41357523|NCT02897830|DRUG|Dexamethasone|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week)."
41496811|NCT04504253|DRUG|Placebo|Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
41496812|NCT05990153|OTHER|Myofascial Release (MR)|Myofascial release therapy is a type of gentle, constant massage that releases tightness and pain throughout myofascial tissues.
41496813|NCT05990153|DRUG|clinical practice drug treatment|drug treatment according to the medical indications of clinical practice
41496814|NCT05990153|OTHER|Manual therapy (MT)|The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
41496815|NCT05990153|OTHER|Therapeutic exercise (TE)|The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).
41496816|NCT06394700|BEHAVIORAL|written exposure therapy|Written Exposure Therapy (WET) is a manualized exposure-based therapy involving five sequential weekly individual sessions. Each session lasts approximately 40 minutes except the first, which is one hour. In the initial session, the therapist explains the treatment rationale and guides the participant to write about their traumatic experience uninterrupted for 30 minutes. Subsequent sessions start with a brief discussion about the previous session's writing, followed by another 30-minute writing session, concluding with a short check-in. There is no homework between sessions.
41160360|NCT05869149|BEHAVIORAL|Multilevel restaurant intervention to improve the food environment|FRESH is a restaurant-based intervention in low-income neighborhoods in Baltimore, MD and the Washington, District of Columbia metro area that aims to improve the healthy prepared-food environment for consumers, informed by community members and other stakeholders. FRESH intervention components include food preparation, food access and procurement, and consumer nutrition environment. Activities will take place over 16 months, and include training restaurant chefs to use healthier cooking methods, partnering with restaurant suppliers to offer healthier ingredients, and offering point-of-purchase promotions to educate customers on the healthier promoted food options. Intervention staff will form strong relationships with restaurant owners and chefs via in-person visits at least twice a month. Data from the intervention trial will inform the development of a system dynamics simulation model that will allow stakeholders to test new policy ideas prior to implementation.
41160361|NCT05194813|OTHER|Aqua alvim CM, neodent implant (Test)|Acqua, Hydrophilic sandblasted, and acid-etched dental implants
41357524|NCT04845581|PROCEDURE|Diagnostic tests: Determination of the gingival phenotype, measure gingival thickness and width of keratinized tissue|Gingival thickness was measured using UGTM method and CBCT/ CAD with PDIP technology at upper incisors and canines in three points localized midbucally : Free gingival thickness (FGT), supracrestal ( SGT) and crestal (CGT). Width of keratinized tissue was measured using periodontal probe calibrated for 1 mm. The gingival phenotype was determined by both methods according to the following criteria: GT ≤ 0,7 mm - thin gingival phenotype, GT \&gt; 0,7 mm ≤ 1,0 mm - medium gingival phenotype, GT \&gt; 1,0 mm - thick gingival phenotype. Toincrease the repeatability of the results, two researchers tested the same values twice on 2days interval between sessions.
41357525|NCT04102696|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
41357526|NCT04102696|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
40837181|NCT06221748|DRUG|Paclitaxel Injection|Phase II and III study ：Calculate dosage based on body surface are,160mg/m2,intravenous infusion，D1,D8 every 3 weeks
40837182|NCT02022241|DRUG|triptorelin|0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
41160362|NCT05194813|OTHER|Neoporous alvim CM, neodent implant (Control)|Neoporous, Hydrophilic sandblasted, and acid-etched dental implants
41357527|NCT03841708|DEVICE|Pleth variability index|The utility of a early goal directed therapy will be evaluate by the pleth variability index (PVI). If above\>13% in a well sedated patients perfectly synchronized with the ventilator providing at least 6ml/kg of ideal body weight, a fluid challeng with 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
41496817|NCT06394700|BEHAVIORAL|Written Exposure Therapy plus Mindfulness-Based App (WET + MBA)|"WET + MBA combines the standard WET protocol with the addition of a mindfulness practice facilitated through a mobile app called Now Meditation. This app is among the most downloaded mindfulness apps in China, used to help manage symptoms of insomnia commonly comorbid with PTSD. Participants are instructed to engage in daily mindfulness exercises according to the app's 7-Day Basic Meditation program and continue practicing mindfulness throughout the duration of the therapy. This is intended to supplement the therapeutic effects of WET by providing tools to manage insomnia and potentially enhancing the therapeutic process by fostering greater mindfulness and relaxation."
41496818|NCT06394700|BEHAVIORAL|Minimal Contact Control (MCC)|MCC contains weekly phone calls from a study therapist to monitor their status and provide support as needed, without introducing any specific therapeutic interventions. These calls are brief, generally lasting between 10 to 15 minutes, and are strictly for the purpose of engagement and safety monitoring rather than therapeutic intervention.
41160363|NCT04919044|OTHER|Motor Imagery Training|The number of imagined contractions were 34 trials, each trial was 10 seconds with 5seconds rest between each trial and 2 minutes' rest was given after first 17 trials.
40837183|NCT03493789|DRUG|Fludeoxyglucose F-18|Given IV
40837184|NCT03493789|PROCEDURE|Positron Emission Tomography (PET)|Undergo FDG-PET
40837185|NCT03493789|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
40837186|NCT00220207|BEHAVIORAL|Internet co-management module|
41496819|NCT02076490|OTHER|Physical/Occupational therapy|At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
41496820|NCT02049450|DRUG|ruxolitinib|Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
40837187|NCT05087719|COMBINATION_PRODUCT|experimental group|patients will receive the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints,stereognosis will be of 15 minutes. For motor training patients will practice 15 mints motor tasks
40837188|NCT05087719|COMBINATION_PRODUCT|conventional treatment|patients will receive the baseline treatment of hot pack for 15 minutes. The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
40837189|NCT04542720|PROCEDURE|Observational: Decompression|Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
41357528|NCT03841708|DEVICE|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG. If deemed necessary by the treating physician a fluid challenge of 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
41357529|NCT00268658|DEVICE|SmartStep(tm) biofeedback device|
41357530|NCT05761405|COMBINATION_PRODUCT|mannitol-enhanced aminoglycoside|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics (± mannitol) will be delivered in a single infusion that will be administered within 30 minutes."
41496821|NCT01080664|DRUG|AS703569|"Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops"
41496822|NCT01080664|DRUG|AS703569|"Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops."
41357531|NCT05761405|DRUG|Ceftriaxon|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes."
41357532|NCT05761405|DRUG|Amikacin|Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
41357533|NCT00382382|OTHER|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
41357534|NCT01798433|DEVICE|One stent technique alone|One stent technique alone with drug-eluting stent
41496823|NCT03891030|OTHER|Checklist Based Box system intervention|The intervention has both behavioural change and service utilization drop out tracing mechanism. Special type of boxes designed to schedule health educations and continued service utilization monitoring boxes will be placed at health posts and health centers respectively. Community level survey will be conducted to identify suspected pregnant mothers using stanback et al, 1999 checklist, and mothers are linked to health centers. Then, they will be followed for their subsequent attendance of consecutive maternal health services (ANC 2nd-third PNC). Mothers who fail to utilize the service will be traced; will get person-centered health education to continue the service.
41496824|NCT00935688|OTHER|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
41496825|NCT03261960|DRUG|BLI4700|Oral bowel preparation
41496826|NCT03261960|DRUG|Magnesium bowel preparation|Oral bowel preparation
41496827|NCT02988024|DRUG|LY03005|LY03005
41496828|NCT02988024|DRUG|Pristiq|
41496829|NCT01550627|OTHER|extra fluid/iv fluid supplementation during phototherapy|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.
41496830|NCT01550627|OTHER|Non extra fluid|Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
41496831|NCT01242995|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
41496832|NCT06110624|OTHER|Survey|A survey study will be conducted to evaluate if GHCPs have the Intention to Use (IU) MuSt-PC in daily practice.
41496833|NCT05363514|DRUG|Low Dose Naltrexone|Participant takes Low Dose Naltrexone 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
41357535|NCT01798433|DEVICE|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
41160364|NCT05934084|BEHAVIORAL|Lifestyles Implemented-Survivorship Care Plan (LS-SCP)|Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (LS-SCP, Lifestyles implemented-Survivorship Care Plan) will be performed.
41357536|NCT01798433|PROCEDURE|Provisional approach|Provisional approach with drung-eluting stents
41357537|NCT01798433|DEVICE|Elective 2-stent|Elective 2-stent with drug-eluting stents
41357538|NCT00381810|DRUG|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
41357539|NCT00381810|DRUG|Methylprednisolone|
41357540|NCT00381810|DRUG|Acetaminophen|
41357541|NCT00381810|DRUG|Diphenhydramine|
41357542|NCT04286737|OTHER|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
41357543|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
41357544|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
41357545|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
41357546|NCT01138605|DRUG|Darunavir|Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
41357547|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
41357548|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
41496834|NCT05363514|DRUG|Microcrystalline cellulose|Participant takes microcrystalline cellulose 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
41509254|NCT04628091|OTHER|Sampling on surgery day|"In the morning, the day of the surgery (the patient will be fasting):~* Occipital hair sample (without roots)~* Venous blood sample (3 tubes of 7mL)~During the surgery:~* Sample of 0.5 to 1 cm3 of subcutaneous adipose tissue during laparoscopic umbilical access~* Collection of a portion of Ampulla proximal part and Isthmus distal part in order to obtain a piece of approximately 4 cm long (2cm of ampulla and 2 cm of isthmus) for each tube."
40837190|NCT04542720|PROCEDURE|Observational: Extension Fusion|Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
40837191|NCT00378248|BEHAVIORAL|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
40837192|NCT00378248|BEHAVIORAL|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
41509255|NCT06582940|RADIATION|MRI-guided adaptive SRT|MRI-guided online adaptive SRT (without PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. MRI will be acquired.
41509256|NCT06582940|RADIATION|Conventional SRT|Conventional SRT (with PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. CBCT will be acquired.
41357549|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
41357550|NCT01138605|DRUG|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
41357551|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
41357552|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
41357553|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
41357554|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
41357555|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
41357556|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
41357557|NCT01138605|DRUG|Ritonavir|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
41357558|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
41357559|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
41357560|NCT01193361|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
41357561|NCT01193361|DRUG|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
41357562|NCT01193361|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
41357563|NCT05512039|DRUG|Botox 50 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
41357564|NCT05512039|DRUG|Botox 100 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat injection up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
41357565|NCT03906006|DRUG|ABP-671|Drug: ABP-671, single oral dose
41357566|NCT03906006|OTHER|Placebo|Other: Placebo, single oral dose
41357567|NCT00109239|DRUG|rhuMAb VEGF (Bevacizumab)|
41509257|NCT05892744|DRUG|Sertraline|50-200mg/day
41022538|NCT04407663|OTHER|Telemedicine to remote outpatient visit in bariatric patient|Patients that referred for the first time to our bariatric center were investigated for anthropometric, psychological and instrumental data in order to evaluate the eligibility for a future bariatric procedure. In established patients, eligibility for tele-consultation was evaluated by three experienced physicians, consulting the stored patients' data. All included patients provided oral informed consent. Patients approached the virtual visit with their personal smart devices, desktop or laptop computer. Medical counselling was performed using a desktop or laptop computer from the Hospital or home in a smart working modality. The video call was carried out using Skype platform by Microsoft®; any document drawn up by the physician was saved as pdf using the Cute Professional™ PDF software, that allows to add passwords and set security options to protect the patients' data.
41357568|NCT01344213|DRUG|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
41509258|NCT04261101|OTHER|Test-enhanced learning|Test-enhanced learning with short answers of questions regarding diabetes and adrenal
41357569|NCT01344213|DRUG|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
41357570|NCT01344213|DRUG|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
41357571|NCT01344213|DRUG|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
41357572|NCT00760994|BEHAVIORAL|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert \& Forsyth, 2005; Hayes, Strosahl, \& Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, \& Barlow, 2004).
41357573|NCT00760994|BEHAVIORAL|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
41357574|NCT00760994|OTHER|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
41022539|NCT01905982|PROCEDURE|reflectory breathing therapy|duration:2x60 minutes
41022540|NCT01905982|PROCEDURE|conventional breathing therapy|duration:4x30 minutes
41022541|NCT03268811|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
41022542|NCT01892475|BEHAVIORAL|Incentive-based physical activity program|"Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:~1. Accurately predicting step target attainment the following months (SGD10)~2. Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)"
41022543|NCT01892475|BEHAVIORAL|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
41357575|NCT03775733|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
41357576|NCT03775733|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
41496835|NCT04858035|BEHAVIORAL|Perceptual training|"Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program.~Stimuli are organized into three separate tasks:~Tasks 1 and 3 will train category goodness judgment: Participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels.~Task 2: Participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline."
41022544|NCT04159831|DRUG|LTI-01|single-chain urokinase plasminogen activator, scuPA
41160365|NCT02580214|DIETARY_SUPPLEMENT|Impact|600 ml of Impact, Nestle for 5 days prior to surgery
41266556|NCT05852639|DEVICE|Ultrasound|Routine obstetric ultrasound will be done at term (at 37 weeks gestation): to confirm gestational age, assess fetal weight and amniotic fluid index and to exclude fetal anomalies.Doppler study and cerebroplacental ratio assessment will be done at 37 weeks gestation and repeated every two weeks
41357577|NCT05578040|PROCEDURE|Auricular acupressure|To conduct this intervention, we used adhesive patches without Vaccaria seed to sham auricular acupressure at the cervical vertebra acupoint in the first trial phase and auricular acupressure at the cervical vertebra acupoint in the other two trial phases in 2 groups of auricular acupressure acupoints of the left and right cervical vertebra.
41357578|NCT00212667|DRUG|ONO-5920|
41266557|NCT02653950|PROCEDURE|Endoscopic septoplasty|Endoscopic surgery; septoplasty with or without middle turbenectomy
41266558|NCT02653950|PROCEDURE|Traditional septoplasty|septoplasty under direct vision
41357579|NCT06449794|DIAGNOSTIC_TEST|Anti Phospholipid antibodies|diagnosis of SLE
40837193|NCT00002807|RADIATION|radiation therapy|45 Gy in 25 fractions over 5 weeks
41357580|NCT06449794|RADIATION|EEG|EEG for Cases with seizures.
41357581|NCT05013476|COMBINATION_PRODUCT|Butterfly handheld ultrasound machine|Both arms of study will utilize the Butterfly ultrasound machine. Only the virtual learners will utilize zoom for their virtual education
41357582|NCT00651911|DRUG|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
41022545|NCT04159831|DRUG|Placebo|normal saline
41496836|NCT04858035|BEHAVIORAL|Production training|"Instruction: Discuss tongue shapes for /r/. Pre-practice: relatively unstructured, highly interactive elicitation; provide models and placement cue and KP on every trial.~Structured syllable practice: Practice will occur in blocks of 10 consecutive trials on the same syllable (e.g., 10 /ra/), after which a new syllable will be addressed (e.g., 10 /re/--but note that in the fully blocked condition, the same syllable should occur in two consecutive blocks of 10)."
41022546|NCT02284828|DRUG|BIA 2-093|
41022547|NCT03215355|DRUG|Primovist|"Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.~Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety."
41357583|NCT05460793|DEVICE|Minimally invasive endoscopy-guided surgery|The devices allowed into the trial, are minimally invasive neuronavigation integrated endoscopy-guided devices that are CE approved and admissible by the steering committee. Currently, only the Artemis Neuro Evacuation Device (Penumbra Inc, Alameda, California, USA) is available and CE approved.
41496837|NCT05563376|DIAGNOSTIC_TEST|Univentricular Hearts|Prevention when factors are recognized
41496838|NCT00009815|DRUG|etoposide|
41496839|NCT00009815|DRUG|leucovorin calcium|
41496840|NCT00009815|DRUG|tegafur-uracil|
41496841|NCT04140305|DRUG|RPC-1063|Oral capsule
41496842|NCT03058094|DRUG|Pemetrexed|Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.
41496843|NCT03058094|DRUG|Cisplatin 75mg/m2|Cisplatin will be administered as an intravenous infusion.
40837194|NCT03273660|DEVICE|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
40837195|NCT02182271|DRUG|BI 201335 ZW - single rising dose|
40837196|NCT02182271|DRUG|Placebo|
40837197|NCT00850941|BEHAVIORAL|Questionnaire|Information collection.
40837198|NCT04124614|DRUG|Brexpiprazole|Up to 3 mg pill
40837199|NCT04124614|DRUG|Sertraline|Up to 150 mg pill
41496844|NCT03058094|DRUG|AC0010|300mg, orally, BID
40837200|NCT04124614|OTHER|Placebo|Pill
41022548|NCT03603964|DRUG|Guadecitabine|Guadecitabine
41022549|NCT06573138|DRUG|Selinexor, anti-PD-1 antibody plus Golidocitinib|Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.
41022550|NCT03063541|DRUG|Acetylsalicylic acid|100 mg daily as one tablet
41022551|NCT03063541|OTHER|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
41022552|NCT02791334|DRUG|LY3300054|Administered IV
40837201|NCT01367392|DEVICE|biopsy or ablation|biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
40837202|NCT00313547|DRUG|Quinapril 40 mg|
40837203|NCT00313547|DRUG|Quinapril 10 mg and amlodipine 5 mg|
40837204|NCT05258084|BEHAVIORAL|sexual minority awareness training|sexual minority awareness training is planned as 4 interviews (1 interview per week) for a total of 4 hours. Gender and sexuality-related terminologies and concepts will be discussed in the 1st meeting. Expression of sexual identity and gender transition processes will be examined in the 2nd meeting. In the 3rd meeting, the determining factors in the inadequate utilization of health services by LGBT individuals will be discussed. In the 4th meeting, what can be done to create a safe and health-friendly environment for LGBT individuals and healthcare professionals will be discussed.
40837205|NCT00885482|DRUG|Lamiduvine (Epivir)|Epivir 300 mg
40837206|NCT00885482|DRUG|Atazanavir (Reyataz)|Reyataz 300 mg
40837207|NCT00885482|DRUG|Ritonavir (Norvir)|Norvir 100 mg
40837208|NCT00780273|DEVICE|Ankylos Implants|ANKYLOS Implant System vs Certain PREVAIL Implant
40837209|NCT00780273|DEVICE|Biomet 3i Prevail Implants|
41022553|NCT02791334|DRUG|Ramucirumab|Administered IV
41022554|NCT02791334|DRUG|Abemaciclib|Administered orally
41022555|NCT02791334|DRUG|Merestinib|Administered orally
41022556|NCT02791334|DRUG|LY3321367|Administered IV
41022557|NCT02041429|DRUG|Ruxolitinib|
41022558|NCT02041429|DRUG|Paclitaxel|
41357584|NCT01359813|DRUG|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
41357585|NCT03309722|OTHER|biomarker study|
41496845|NCT06353568|DEVICE|Photobiomodulation|The PBM Group will use a boot with 1344 LEDs, including 504 LEDs of 660 nm located on the sides of the boot (28.5 mW, 10 J per LED); 504 LEDs of 850 nm also located on the sides of the boot (23 mW, 8 J per LED); 168 LEDs of 660 nm located at the base of the boot (28.5 mW, 10 J per LED); and 168 LEDs of 850 nm also located at the base of the boot (23 mW, 8 J per LED) once daily for 6 minutes, over 60 days.
41496846|NCT06353568|DEVICE|Simulation of Photobiomodulation|The Control Group will use a non-therapeutic LED boot (sham procedure) for 6 minutes once daily for 60 days. The boot used is identical to the active boot, but there is no light emission.
41496847|NCT06353568|BEHAVIORAL|Therapeutic education|Participants will receive therapeutic education regarding nutrition, foot examination, self-care, and guidance on physical activity.
41496848|NCT06000774|OTHER|Therapeutic Ketogenic Diet|therapeutic ketogenic diet
41496849|NCT03801889|DRUG|SP-420|Self-administered by mouth
41496850|NCT01885026|BEHAVIORAL|eScreen|Access to the eScreen platform offering assessment of alcohol and drug use, with automated feedback on problematic or non-problematic use. Follow-up over time based on user needs.
41496851|NCT01885026|BEHAVIORAL|Assessment only of alcohol and drug use.|Assessment of alcohol and drug use at baseline and follow-up.
41496852|NCT01885026|BEHAVIORAL|Internet-based treatment for depression or anxiety|Internet-based treatment for primary diagnoses of depression, panic anxiety or social phobia.
41496853|NCT00912912|DRUG|Sunitinib Malate|50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
41496854|NCT05643053|OTHER|thomas fixation|Use of the thomas tube holder for endotracheal tube fixation in patients operated in the prone position
40837210|NCT05479045|BIOLOGICAL|NY-ESO-1 Peptide vaccine|300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 3 weeks.
41022559|NCT00471601|BEHAVIORAL|counseling intervention|
41022560|NCT00471601|BEHAVIORAL|questionnaire administration|
41496855|NCT05643053|OTHER|elastic band|Use of the elastic band for endotracheal tube fixation in patients operated in the prone position
41496856|NCT05643053|OTHER|normal fixation adhesive tape|Use of the adhesive tape for endotracheal tube fixation in patients operated in the prone position
41496857|NCT05643053|OTHER|reinforced adhesive tape fixation|Use of the reinforced adhesive tape fixation for endotracheal tube fixation in patients operated in the prone position
41496858|NCT04643561|OTHER|Travelan OTC|5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention
41496859|NCT05980195|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy for 30 times within 50 days
41496860|NCT05980195|DRUG|Standard medical treatment|"Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months"
41496861|NCT05980195|BEHAVIORAL|Risk factor management|Management of risk factors including hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise
41496862|NCT00668161|BEHAVIORAL|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
41496863|NCT04395014|DIAGNOSTIC_TEST|2D Echocardiography|In this echocardiographic imaging acquisition protocol, the pregnancy patients, are colocated in the left lateral decubitus position on a clinical bed with the left arm flex and the hand behind the head. All the echocardiographic measurements are taken by the examiner in this position.
41496864|NCT04631952|BEHAVIORAL|Online exercise|SMS messeages on encouraging active lifestyle and online exercise video will be sent to the participant weekly for 8 weeks.
41496865|NCT04631952|BEHAVIORAL|SMS message|SMS messeages on encouraging active lifestyle will be sent to the participant weekly for 8 weeks.
41496866|NCT03504397|DRUG|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
41357586|NCT01990339|DRUG|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
41496867|NCT03504397|DRUG|placebo|Placebo will be administered as a minimum 2-hour IV infusion.
41496868|NCT03504397|DRUG|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion
41496869|NCT03504397|DRUG|folinic acid|Folinic acid will be administered as a 2-hour IV infusion.
41496870|NCT03504397|DRUG|fluorouracil|Fluorouracil will be administered as IV bolus over 5-15 minutes and continuous IV infusion over 46-48 hours.
40837211|NCT05479045|DRUG|Toripalimab-tpzi|240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine
40837212|NCT00554658|DRUG|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
40837213|NCT02900755|DRUG|Perampanel|The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
41022561|NCT00471601|BEHAVIORAL|psychosocial assessment and care|
41022562|NCT00471601|BEHAVIORAL|quality-of-life assessment|
41022563|NCT04638608|OTHER|EMBRACE (relatives)|Online support program for both relatives
41022564|NCT04638608|OTHER|EMBRACE (Health care providers)|Online support program for health care providers
41022565|NCT05737641|OTHER|water ingestion|ingestion of water after an 8h-fasting period
41022566|NCT05737641|DIETARY_SUPPLEMENT|jelly ingestion|ingestion of jelly after an 8h-fasting period
41357587|NCT06286735|DIETARY_SUPPLEMENT|cinnamomum|60 capsules of 500 mg of powdered cinnamomum bark (Cinnamomum verum; 40% polyphenols). Participants in this group will be instructed to consume two capsules per day, one after lunch and one after dinner for 3 months.
41496871|NCT01593033|DIETARY_SUPPLEMENT|Fish oil and Micronutrient Supplementation|"0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months~1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months"
41496872|NCT01593033|DIETARY_SUPPLEMENT|Micronutrient Supplement|1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
41496873|NCT01593033|DRUG|Placebo|10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
41496874|NCT01539018|DRUG|Sorafenib|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
41022567|NCT05295290|DIAGNOSTIC_TEST|Cardiac Imaging|ECG, echocardiogram, ambulatory monitor, exercise stress test
41022568|NCT02897843|DEVICE|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
41496875|NCT01539018|DRUG|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
41357588|NCT06286735|OTHER|Placebo|60 capsules with 500 mg of corn starch per month, until the end of the three months of intervention. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
41357589|NCT04679896|DEVICE|MagnetOs Putty|Procedure: Instrumented posterolateral spine fusion
40837214|NCT03255564|OTHER|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.~Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
40837215|NCT06264284|PROCEDURE|epidural anesthesia|Emergency cesarean section (red code) with epidural anesthesia
40837216|NCT06264284|PROCEDURE|general anesthesia|Emergency cesarean section (red code) with general anesthesia
40837217|NCT01237782|DRUG|Denture soaking solution|Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
40837218|NCT01237782|DRUG|Saline solution|Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
40837219|NCT01073878|DEVICE|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
40837220|NCT03833713|BEHAVIORAL|SMS Dialogue|Once-weekly SMS dialogue sessions or micro-interventions and use behavior change techniques (BCTs) including self-monitoring with performance feedback and goal support
40837221|NCT03833713|BEHAVIORAL|SMS Assessments|Once-weekly SMS assessments of motor vehicle risks
40837222|NCT06120101|BEHAVIORAL|Reflexology Massage|The researcher washed his hands with an antibacterial soap before cleaning the patient's feet. The feet were cleaned according to the patient's preference; To wash feet with water or use disposable wet cloth. The patients were placed in a supine position on the bed in the room and their joint points were supported. The researcher stood at the end of the patient's bed during treatment. Unscented sesame oil at room temperature was used to provide lubrication during reflexology. The application started with the patient's right foot. The foot was first relaxed by applying effleurage, shaking, rotation and stretching methods. During the application, the researcher used the fingers of the other hand while supporting the patient's foot with one hand, and the thumb and caterpillar technique was mostly used. In other applications, the index finger and other fingers were used. The training ended by applying solar plexus pressure to both feet.
40837223|NCT02789410|DRUG|Morphine|Morphine is administered as part of spinal anesthesia for post-operative pain relief.
40837224|NCT02789410|DRUG|Hydromorphone|Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
40837225|NCT05451355|BEHAVIORAL|Family Safety Check-In|Prototype decision aid to support within-family communication and decision making about firearm storage.
40837226|NCT05451355|BEHAVIORAL|AAP Firearm Storage Web Page|Educational web page that discusses safe firearm storage practices.
41022569|NCT02897843|DEVICE|sham tDCS|sham tDCS
41496876|NCT05907629|OTHER|MRI|Additional MRI to the CAPTIVA study at baseline and 12 months follow-up
41496877|NCT05971303|OTHER|Questionnaire|Questionnaires will be given to patients, interpreters and cancer car professionals with aims of delineating the attitudes and experiences of patients, interpreters and cancer care professionals involved in the care of oncology patients with gynecologic malignancies
40837227|NCT04476927|DEVICE|DiaNose|"DiaNose system is an electronic nose device that can smell diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases.~The DiaNose prototype system consists the following elements:~* A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.~* Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B).~* Laptop - Laptop is used to activate and save the test measurements."
41022570|NCT01697306|DRUG|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
41022571|NCT01697306|DRUG|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
41357590|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
41496878|NCT00527553|DIETARY_SUPPLEMENT|not enriched egg|daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin
41357591|NCT05459519|DRUG|Placebo|Placebo, 4 capsules each time, twice daily
41357592|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
41357593|NCT02041533|BIOLOGICAL|Nivolumab|
41357594|NCT02041533|DRUG|Gemcitabine|
41357595|NCT02041533|DRUG|Cisplatin|
41357596|NCT02041533|DRUG|Carboplatin|
41357597|NCT02041533|DRUG|Paclitaxel|
41022572|NCT04384536|PROCEDURE|Neural therapy application|Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
41022573|NCT04088981|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet and a portion-controlled diet
41357598|NCT02041533|DRUG|Pemetrexed|
41357599|NCT02583828|DRUG|Cyclophosphamide 50mg|
41496879|NCT00527553|DIETARY_SUPPLEMENT|lutein|daily lutein enriched egg
41496880|NCT00527553|DIETARY_SUPPLEMENT|zeaxanthin|daily zeaxanthin enriched egg
41022574|NCT03891212|BEHAVIORAL|Placed in prone position for at least 16 consecutive hours a day.|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
41357600|NCT02583828|DRUG|Letrozole 2.5 mg|
41496881|NCT00527553|DIETARY_SUPPLEMENT|egg product from enriched eggs|daily egg product from lutein enriched eggs
41496882|NCT05325073|DRUG|Erythropoietin|Erythropoietin
41496883|NCT00800007|DRUG|ANZ-521|3x10\^7 cfu or 3x10\^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
41496884|NCT00800007|DRUG|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
41496885|NCT01235832|OTHER|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (\~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
41357601|NCT06421194|OTHER|Investigational meal 1 - Commercial animal-based protein foods [Siew mai (6 pieces) and Ngoh hiang (2 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
41357602|NCT06421194|OTHER|Investigational meal 2- Commercial animal-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Gyoza and oven-baked Luncheon meat) in a fasted state.
41496886|NCT01235832|OTHER|Lower-Fat Diet|The Lower-Fat diet will provide \~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
41496887|NCT01235832|OTHER|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
41496888|NCT06399848|OTHER|Skip one day of peritoneal dialysis treatment|Skip one day of peritoneal dialysis treatment
41022575|NCT02893722|DRUG|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
41357603|NCT06421194|OTHER|Investigational meal 3- Formulated plant-based protein foods [Siew mai (6 pieces) and Ngoh hiang (1 piece cut into 2)]|Participants consume a meal consisting of formulated plant-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
41496889|NCT02212613|DRUG|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
41496890|NCT05483595|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 10ml
41496891|NCT04483206|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
41496892|NCT04483206|DRUG|Melphalan|Given IV
41496893|NCT04483206|OTHER|Questionnaire Administration|Ancillary studies
41509259|NCT03997773|BEHAVIORAL|Face-it Intervention|The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
41022576|NCT02893722|DRUG|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
41022577|NCT05264805|DRUG|0.25% Bupivacaine|20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
40837228|NCT01655147|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
41357604|NCT06421194|OTHER|Investigational meal 4- Formulated plant-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of formulated plant-based protein foods (Gyoza and Luncheon meat) in a fasted state.
40837229|NCT01655147|DRUG|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
40837230|NCT01836081|OTHER|Volume expansion|
40837231|NCT00882739|DRUG|Clopidogrel 300 mg|Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
40837232|NCT00882739|DRUG|Clopidogrel 600 mg|Patients will receive a 600 mg clopidogrel loading dose at first medical contact
41022578|NCT06572566|OTHER|Non-invasive examination and assessment.|1) Test the blood and urine components of all subjects to evaluate the damage to kidney function caused by excessive cadmium. 2) Conduct MRI examinations on all subjects to evaluate changes in brain functional connectivity, metabolism, and structure after excessive cadmium exposure. 3) Conduct bone density examinations on all subjects to evaluate changes in bone density after excessive cadmium exposure. (3) Clinical psychiatric assessment: All subjects will be assessed on their mental and psychological conditions such as pain, cognitive function, depression, anxiety, mania, sleep quality, and suicide risk.
41022579|NCT04402333|PROCEDURE|Robotic Interval Debulking Surgery|Interval debulking surgery carried out in a minimally invasive manner using the Da Vinci Robot.
41022580|NCT04713748|DEVICE|Tasso-SST on Demand|Participants will collect a small blood sample using the Tasso-SST OnDemand device during a serology blood draw visit already scheduled for the MURDOCK C3PI Study (Pro00105703). Participants will be provided a kit that includes written, step-by-step instructions that include pictures. Participants will also have the option to watch a brief video on using the device, available online, prior to collection. Both blood samples will be spun and processed for serum. Serum will be frozen and shipped to the lab at Duke for antibody testing. Antibody results will be compared between the two methods.
41022581|NCT04713748|OTHER|Regular Phlebotomy|Participants will have a small blood sample collected via regular venipuncture.
41022582|NCT00022516|DRUG|Cyclophosphamide|50 mg/day orally continuously for 1 year
41022583|NCT00022516|DRUG|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
41022584|NCT04906200|OTHER|Best Practice|Receive usual care
41022585|NCT04906200|OTHER|Internet-Based Intervention|Receive access to YES portal
41022586|NCT04906200|OTHER|Survey Administration|Complete survey
41022587|NCT03330834|BIOLOGICAL|CAR-T cells to treat advanced lung cancer|"Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells."
41022588|NCT05913297|DIAGNOSTIC_TEST|Magnetic Resonance|Magnetic Resonance
41022589|NCT05913297|DIAGNOSTIC_TEST|Polysomnographic evaluation|Polysomnographic evaluation
41022590|NCT05252559|PROCEDURE|ultrafiltration|In cardiac surgery patients, ultrafiltration is usually applied to reduce free water and concentrate all blood components before weaning from cardiopulmonary bypass
41022591|NCT05252559|DIAGNOSTIC_TEST|maximal clot firmness in EXTEM assay of ROTEM test|before and after applying ultrafiltration, arterial blood sample underwent EXTEM and FIBTEM assays of rotational thromboelastometry
41022592|NCT06384677|OTHER|M-Tapa Block|M-TAPA block was performed bilaterally with 20 mL of 0.2% bupivacaine under ultrasound guidance at the end of surgery
41022593|NCT05169294|OTHER|Telerehabilitation Program|Telerehabilitation program: Intervention will be applied by video interview for eight weeks, 3 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on fine motor skills, handwriting skills and activities of daily life of the individuals.
41022594|NCT05169294|OTHER|Written Home Program|Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
41022595|NCT05928325|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessments
41022596|NCT05928325|BEHAVIORAL|Health Education|Receive survivorship care education
41022597|NCT05928325|OTHER|Medical Device Usage and Evaluation|Wear activity tracking device
41022598|NCT05928325|OTHER|Supportive Care|Receive geriatric assessment-guided interventions
41022599|NCT03731494|BIOLOGICAL|Nickel oral hyposensitization treatment|Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
41022600|NCT05852444|DEVICE|Passive Ultrasonic Activation|Agitation of root canal irrigation solution with an ultrasonic activation device (Ultra X).
41022601|NCT05852444|DEVICE|Manual Dynamic Agitation|Agitation of root canal irrigation solution with master gutta percha cone
41509260|NCT04548765|BEHAVIORAL|Letter|Recipients receive a letter promoting CRC screening.
41509261|NCT04548765|BEHAVIORAL|Loss Frame and Fear Appeals|The letter is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
40837233|NCT00882739|DRUG|Clopidogrel 900 mg|Patients will receive a 900 mg clopidogrel loading dose at first medical contact
40837234|NCT05252221|OTHER|ATC Intervention|The ATC intervention offers convenient access to specialty consultation for PCPs and offers patients direct access to addiction treatment in a non-stigmatized primary care setting
40837235|NCT05683873|PROCEDURE|Electrocardiogram|Inclusion visit, V1, V2 and V3
40837236|NCT05683873|PROCEDURE|transthoracic echocardiography|V1, V2 and V3
40837237|NCT05683873|BIOLOGICAL|standard biology|Inclusion visit
41022602|NCT05900024|OTHER|Funk It Cycle Bites|The intervention product contains: Organic Pumpkin Seed Butter, Prebiotic Agave Inulin, Organic Flax Seed, Organic Oat Flour, Organic Ginger, Quinoa Sprouts, Crispy Red Rice, Organic Cacao Nibs, Sunflower Seed Butter, Organic Reishi Mushroom, Organic Amaranth Seeds, Dates, Organic Button Mushroom, Acai Berry, Amla Fruit, Goji Berry, Pomegranate, Cranberry, Acerola (Cherry Juice), Rosemary Extract, Vitamin E (Mixed Tocopherols), Organic Vanilla Extract, Sea Salt, Cinnamon, Naturally Sourced Potassium Sorbate.
41022603|NCT05372484|DEVICE|Multimodal optical imaging|Women referred for colposcopy due to abnormal cervical screening will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
41022604|NCT06568939|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
41022605|NCT00815126|PROCEDURE|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
40837238|NCT05683873|BIOLOGICAL|determination of serum GDF-15, osteoprotegerin and ST-2|Inclusion visit, V1, V2 and V3
40837239|NCT05683873|BIOLOGICAL|Ultrasensitive Troponin-Ic|Inclusion visit, V1, V2 and V3
40837240|NCT05683873|OTHER|Collection of clinical and radiological data|Inclusion visit, V1 and V3: clinical data only V2: clinical and radiological data
40837241|NCT05683873|OTHER|72-hour continuous Holter-ECG recording|V1
40837242|NCT02488460|BEHAVIORAL|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
41509262|NCT04548765|BEHAVIORAL|Transparency|The letter explains why the kit was sent, which makes the purposes of the mailing clear to the recipient.
40837243|NCT03850002|OTHER|Early detection of CLAD by Lung Clearance Index (LCI)|Lung transplant candidates without prior CLAD (evaluated in study part I) will be followed over a period of 3 years to evaluate the potential of LCI to detect early CLAD
41357605|NCT05706376|BEHAVIORAL|Promoting Positive Family Futures|Promoting Positive Family Futures is a group-based program that aims to help parents and their adolescent children (13-16 yrs) cope with chronic violence by developing emotional and cognitive awareness, learning constructive conflict resolution strategies, and developing family-wide emotional security and positive family relationships. Emotional Security Theory is the foundational conceptual model for the program, and as such, the PPFF focuses on promoting family-wide communication and establishing emotional security in both the family and community across multiple sessions.Firmly grounded the cultural context of Palestine, the intervention also incorporates intervention elements derived from social ecological theories of resilience, and cognitive behavioral approaches to coping. In total, the program includes 8 sessions lasting approximately 1.5 hours each.
40837244|NCT05986617|DEVICE|InBody Band 2|Wearable bioimpediance monitor similar to a fitness watch.
41022606|NCT02498665|DRUG|DSP-7888 Dosing Emulsion|"Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks."
41022607|NCT04183933|OTHER|Pilates Exercise|Pilates exercises will be given for 6 weeks, 3 days in a week.
41022608|NCT04183933|OTHER|Combined Exercise|Combined exercise will be given for 6 weeks, 3 days in a week.
40837245|NCT03288363|DEVICE|tDCS|20 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus DC-Stimulator Plus (Neuroconn)
41022609|NCT02074735|DRUG|Placebo|Inactive ingredient matching the active comparator in appearance
41022610|NCT02074735|DRUG|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
41022611|NCT03821428|PROCEDURE|Acupuncture|Needling of P6 and CV24 points
41022612|NCT03821428|PROCEDURE|Placebo|Application of placebo acupuncture needles to the areas, where the acupoints are situated
41022613|NCT06534866|OTHER|Traditional Physical Therapy|"1. TENS+cold pack (For 10 mins on plantar ascpect of foot)~2. Stretching exercises (5 repetition 2 sets/day) Standing calf stretch Seated plantar fascia stretch Plantar fascia massage Achilles stretch Frozen can roll Towel stretch"
41022614|NCT06534866|OTHER|Kinesiotaping|In the first step, after the metatarsophalangeal joints is dorsiflexed, the first strap will be adhered firmly to the posterior heel at its proximal end. The other end of the strap is cut into four slices of equal width. Each slice is applied with a 50% stretch (50% tensile strain) and attached to the plantar forefoot. In the second step, another strap is applied with gentle compression across the bases of the four slices beneath the foot and wrapped around the rearfoot
40837246|NCT00933894|DRUG|Telaprevir; Escitalopram|
41022615|NCT06347185|PROCEDURE|Early palliative care, integrated with the standard oncologic care (proactive approach)|Besides the Oncology visit, patient will have the palliative care expert visit and follow up (proactive approach). The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to the Liverpool Head and Neck Patient Concern Inventory (PCI-H\&N) and patient priority questionnaire's results.
41022616|NCT06347185|PROCEDURE|Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)|The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise (reactive approach). The oncologist will base the choices also upon the results of the PCI-H\&N and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.
41357606|NCT05706376|BEHAVIORAL|Treatment as Usual|Families assigned to the TAU condition will participate in a common service offered by both PCC and CRS - a weekly adolescent-only support group. Both CRS and PCC conduct extended group programs for children and adolescents (24 sessions at PCC; 25 sessions at CRS).
41357607|NCT01315873|DRUG|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
41357608|NCT01315873|DRUG|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
40837247|NCT01665352|DRUG|TTP054|Administered orally once daily for 12 weeks.
40837248|NCT01665352|DRUG|Placebo|Administered orally once daily for 12 weeks.
40837249|NCT01180608|OTHER|MR Spectroscopy|"During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~* gamma-aminobutyric acid (GABA)~* glutamate (Glu)~* glutamine (Gln)~* N-acetylaspartate (NAA)~* Choline-containing compounds (Cho)~* Creatine plus phophocreatine (total creatine: Cr)~* Myo-inositiol (Ins)~* Choline (Cho)~* Glucose (Glc)~* Lactate (Lac)"
40837250|NCT04240314|BIOLOGICAL|scAAV9.U7.ACCA|A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.
40837251|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
40837252|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
40837253|NCT00069992|RADIATION|Total Body Irradiation|Total body irradiation of 450cGy as a single dose, day -6
41357609|NCT04852484|DRUG|local anesthetic-morphine|Before the operation, 19 mL of 0.5% Ropivacaine + 2 mg of morphine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 6 mg of morphine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
41357610|NCT04852484|DRUG|local anesthetic-ketamine|Before the operation, 19 mL of 0.5% Ropivacaine + 50 mg of ketamine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 200 mg of ketamine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
41357611|NCT04852484|DRUG|local anesthetic|Before the operation, 19 mL of 0.5% Ropivacaine + 1 mL of normal saline (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
41496894|NCT05394779|DEVICE|DTXO APP|DTXO is an investigational therapeutic intervention (Digital Therapeutics - DTx) for obese patients, under clinical validation with a randomized and placebo-controlled clinical trial for confirmatory purposes. It is intended to improve weight loss, weight-loss maintenance, and overall health in patients with obesity by increasing their self-engagement, self-monitoring and adherence to dietary/exercise and behavioral programs. The App integrates different non-pharmacological approaches, engaging the patient through monitoring of her/his non-vital parameters, monitoring of patient diet and exercise, monitoring of patient psychological status, prescription of exercise and diet in a weight-loss program.
40837254|NCT00069992|DRUG|Fludarabine|Fludarabine 30mg/m2 Day -5 to -2
40837255|NCT00069992|DRUG|Campath 1H|Campath 1H dosing as per institutional SOPs Day -5 to -2
41022617|NCT06057896|DIETARY_SUPPLEMENT|inositol, phytoestrogens, cocoa polyphenols|myo-inositol, soy isoflavones and cocoa polyphenols
41496895|NCT05394779|DEVICE|PLACEBO APP - Control group|The placebo App will include only the non-medical modules of the digital therapy and has been introduced to make the experience of subjects in the control arm more similar to that of subjects in the experimental arm; moreover, data collection through the placebo app (questionnaires) will streamline the data collection process, avoiding manual data entry and reducing the possibility of entry errors.
41496896|NCT03958253|OTHER|Toolbox for Lung Cancer Screening|"-Toolbox of evidence-based elements that a primary care or referral site could implement to address known barriers to screening and referral, as well as required elements for screening. These elements will be designed to be adaptable to the unique needs and screening processes of the participating practices.~* Patient education materials~* Primary care practice educational materials~* Pack-years/eligibility calculator~* Local referral process guide~* Smoking cessation materials and support~* Shared decision-making guide~* LDCT best practice guidelines"
41496897|NCT04020757|DEVICE|variation in dialysis bicarbonate|35 mEq/L dialysate bicarbonate for one week, followed by 30 mEq/L for one week, followed by 35mEq/L for one week with nutritional supplement during dialysis
41496898|NCT04020757|DIETARY_SUPPLEMENT|Zone Perfect bar|16g protein supplement given during first 30 mins of dialysis on last testing day
41496899|NCT05367583|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
41496900|NCT02728843|DRUG|Deferiprone|600 mg tablets
41496901|NCT02728843|DRUG|Placebo|Tablets that match the deferiprone tablets in appearance
41496902|NCT01830634|BEHAVIORAL|Theraband with strengthening and stretching exercise|"Using the theraband for strengthening and stretching the upper and lower extremity muscles.~All exercises were performed by using a Theraband in the following movements: shoulder elevating and abducting, horizontal and oblique direction, plantar flexion, dorsi-flexion, inversion and eversion of ankle, knee extension and hip abduction. The stretching exercises were focused on the hamstring muscle and heel cord. Each movement was held for 5 seconds. The participants were instructed to perform 5-10 repetitions of each movements twice per day."
41496903|NCT00554606|DRUG|Canakinumab|Canakinumab
41496904|NCT01005277|OTHER|Laboratory Biomarker Analysis|Correlative studies
41496905|NCT02174380|OTHER|Active Household Contact Evaluation|Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
41022618|NCT00244244|DRUG|arimoclomol|
41022619|NCT06532903|OTHER|Selective muscle electrostimulation with exponential current|An electroevaluation will be performed, with an exponential current generator equipment, using Meditea® brand Neuromatic 700 equipment, which consists of a first application of the current, the pulse width (in milliseconds) in which a contraction is achieved will be sought. frank, visible and selective of the facial muscle that is being stimulated. The purpose is to identify the pulse width and the lowest intensity to obtain a frank, visible and selective contraction, understood as the best quality.
41357612|NCT01098435|DRUG|RDC-0313 (ALKS 33)|Capsules for daily oral administration
41357613|NCT01098435|DRUG|Placebo|Capsules containing lactose and no active drug for daily oral administration
41357614|NCT05178563|PROCEDURE|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
41357615|NCT05178563|PROCEDURE|IPT+Placebo|IPT+Placebo
41357616|NCT04264260|DRUG|Colchicine Tablets|three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
41357617|NCT05977777|DIAGNOSTIC_TEST|Contrast- enhanced ultrasound|Contrast- enahnched ultrasound is performed on target pancreatic lesion
41357618|NCT00000980|DRUG|Spiramycin|
41357619|NCT04637113|OTHER|This is a non-interventional study|This is a non-interventional study.
41357620|NCT03808194|OTHER|Conditional lottery incentive|Participants in the lottery incentive arm must fulfill the following criteria to be entered into the lottery. Participants must visit the clinic by month 1, initiate ART by month 3 and achieve viral suppression by month 6. Participants in this arm will be eligible to win the lottery.
41357621|NCT03808194|OTHER|Optimized ART linkage package|Optimized ART linkage package
41357622|NCT03813576|DIAGNOSTIC_TEST|Self-collected HPV vaginal swab|Patients will be instructed on how to collect a vaginal swab on themselves which will then be processed for presence of HPV DNA.
41022620|NCT06532903|OTHER|Facial muscle reeducation in front of the mirror|"Muscle re-education: Symmetrical facial movements will be requested, activating the muscles of the affected side, avoiding the participation of the unaffected side. We will work with the patient sitting in front of a mirror, asking him to perform the following actions or gestures: raise his eyebrows, frown, close his eyes (tightly and blink), smell an unpleasant odor, show his fangs, blow a kiss, blow , fake smile (lip corner pulled back horizontally), frank smile (lip corner pulled back and up, showing teeth), kiss and pout. The functional capacity of the mouth will be trained, inflating the cheekbones and moving the air from one side to the other, avoiding compensations. Depending on the degree of facial dysfunction and its condition, the kinesiologist will perform a stretch reflex, facilitation of movement and/or inhibition of it. Three series of five repetitions of each gesture described will be done."
41022621|NCT05640934|DRUG|Melatonin|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
41022622|NCT05640934|DRUG|Placebo|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
41022623|NCT03860389|OTHER|Exercise|An exercise programme will be delivered in the school for a period of up to 16 weeks. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
41022624|NCT00614939|DRUG|Saxagliptin|2.5 mg once daily oral dose
41022625|NCT00614939|DRUG|Placebo|Placebo
41022626|NCT00690547|OTHER|muscle activation|activation of the muscle quadriceps femoris
41022627|NCT06025721|BEHAVIORAL|Cardiovascular Risk Homeless Support|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve cardiovascular health behaviors. The coach will encourage a focus on smoking\>medication\>sleep\>physical activity\>healthy eating to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief cardiovascular health education as needed in participants' preferred format (handout, video, audio, etc.).
41022628|NCT06097039|DEVICE|abdominal U/S|A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.
41022629|NCT06097039|DEVICE|Fibroscan with Controlled Attenuated Parameter (CAP scan):|"Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m)."
41022630|NCT05634681|RADIATION|Plan of the day|Several treatment plans are prepared and the appropriate plan is used at each treatment session.
41022631|NCT05634681|RADIATION|Standard plan|One treatment plan
41022632|NCT06573658|BEHAVIORAL|Perturbation-based balance training (PBT)|It will be a two-session training with each session lasting for approximately half an hour. Perturbations will be induced during treadmill walking. Participants will be instructed to recover their balance and continue walking after the perturbations.
41022633|NCT06573658|BEHAVIORAL|Active control (control)|It will be a two-session training with each session lasting for approximately half an hour. The same training duration and format will be used as the PBT group, except no perturbations will be induced during the treadmill walking.
41022634|NCT03292757|DRUG|Indocyanine Green|Fluorescent dye - indocyanine green
41022635|NCT06314698|DRUG|Narlumosbart|Administered by subcutaneous injection once every 4 weeks.
41022636|NCT06314698|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks.
41022637|NCT04935697|DEVICE|nVNS|3x daily treatment of nVNS + SOC
41022638|NCT04935697|OTHER|SOC|Standard of care patient management.
41496906|NCT05819203|DEVICE|Healsea Babykids|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
41022639|NCT03966404|DIAGNOSTIC_TEST|EyeBOX device|The EyeBOX medical device tracks a patient's eye movement and calculates a BOX Score ranging from 0-20. The BOX score is interpreted as a binary classification for eye movement abnormalities, where anything equal to or greater than 10 is a positive result for the initial evaluation of concussion and everything below 10 is negative.
41022640|NCT06441513|OTHER|Chinese traditional medicine nursing combined with case tracking management|First, we set up a team for the prevention of hand foot syndrome, including 1 head nurse of the tumor chemotherapy department, 2 doctors, 16 nurses (16 nurses were divided into 4 groups, each group designated a team leader) and the researchers of this experiment. Doctors are responsible for the diagnosis of HFS and the determination of traditional Chinese medicine prescriptions, head nurses and team leaders are responsible for quality control, and nurses are responsible for the assessment, intervention and evaluation of patients.
41022641|NCT06441513|OTHER|Health Education|elaborating the symptoms, mechanism and corresponding treatment measures of HFS for patients, reducing the fear of patients, helping them relax and adjust their mentality, and cooperating with observation.
41022642|NCT05027191|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin (NGAL)|The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.
41022643|NCT05027191|DRUG|Desflurane|Desflurane
41022644|NCT05027191|DRUG|Sevoflurane|Sevoflurane
41022645|NCT00388518|DRUG|Actos|45mg po daily
41022646|NCT00388518|DRUG|Placebo|po daily
41022647|NCT00388518|DRUG|aleglitazar|Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
41022648|NCT00209313|DRUG|Acyclovir|Acyclovir 800 mg twice daily or placebo
41022649|NCT06227494|BEHAVIORAL|Fiber Intervention|Group education and phone-based motivational interviewing to gradually increase dietary fiber consumption to 30-35 grams per day.
41022650|NCT06227494|BEHAVIORAL|Standard Weight Loss Education|Group education and phone-based motivational interviewing to promote current evidence-based behaviors to promote weight loss via achieving a negative energy balance.
41022651|NCT03095300|PROCEDURE|Prone position|Patients are rotated from the supine to the prone position for a period of 2 hours.
41022652|NCT01859455|DRUG|LGT209 50 mg|Active experimental drug
41022653|NCT01859455|DRUG|LGT209 300 mg|Active experimental drug
41022654|NCT01859455|DRUG|Placebo|Placebo comparator
41022655|NCT01859455|DRUG|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
41022656|NCT02791139|OTHER|Cardiovascular Magnetic Resonance Imaging (MRI)|Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.
41022657|NCT02791139|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
41022658|NCT02791139|OTHER|Tonometry|Tonometry is a noninvasive method to obtain arterial pressure waveform
41022659|NCT02791139|OTHER|Genetic Testing (Blood)|The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.
41022660|NCT02791139|OTHER|Hand-Grip Strength Measurement|We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.
41496907|NCT05819203|DEVICE|Placebo|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
41022661|NCT02791139|OTHER|Body Fat Mass Analysis|Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
41496908|NCT00764686|OTHER|Exercise and Education|One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
41496909|NCT00764686|OTHER|Exercise and Education|Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
41022662|NCT05565612|DIETARY_SUPPLEMENT|Normodigest Classic|Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
41022663|NCT05565612|DIETARY_SUPPLEMENT|Placebo|Compound based on maltodextrin and other excipients
41022664|NCT02829034|DRUG|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
41022665|NCT02829034|DRUG|Placebo|Placebo by mouth twice per day for a total of 26 weeks
41022666|NCT01110291|DRUG|docetaxel + CEF|"Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.~Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times."
41022667|NCT02262429|OTHER|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
41022668|NCT02262429|OTHER|ONS Standard Feeding|Standard of care
41022669|NCT01462734|PROCEDURE|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
41022670|NCT00951067|OTHER|Exercise, Elevation, and Compression Garment|"Patients will be asked to daily:~* exercise~* elevate arm~* wear an arm compression garment"
41022671|NCT00951067|DEVICE|E0650 PCD with non-sequential waveform|Use of an E0650 PCD with non-sequential waveform for two hours every day.
41022672|NCT00951067|DEVICE|E0651 PCD with sequential, non-gradient waveform|Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
41022673|NCT00951067|DEVICE|E0652 PCD with sequential, gradient waveform|Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
41022674|NCT00951067|DEVICE|E0652 PCD with peristaltic pulse waveform|Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
41022675|NCT04317612|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
41022676|NCT04317612|OTHER|Reference product|Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.
41022677|NCT04795271|OTHER|Orthopedic intervention|"In each custom insole, modifications can be included in the following aspects according to the requirements of each participant :~1. Forefoot specifications: a) Retrocapital bar, b) Retrocapital support, c) Claw toe correction element, d) Pronating wedge, e) Supinator wedge, f) Metatarsal head pad, g) Selective perforations in the insole, h) Others.~2. Midfoot specifications: a) Internal arch, b) External arch, c) Full support, d) Excavations, e) Others.~3. Hindfoot specifications: a) Heel cup, b) Supinator wedge, c) Pronating wedge, d) Lifter, e) Cup, f) Others.~4. Insole type and lining material~5. Materials of the added corrections~6. Insole base: a) soft ethylene vinyl acetate (eva), b) semi-soft eva, c) hard eva, d) rubber, e) cuerolite."
41022678|NCT01480765|DRUG|Pregabalin|150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
41022679|NCT01480765|DRUG|Ketamine infusion|0.1mg/kg/hr for 48 hours post operatively
41022680|NCT01480765|DRUG|Placebo capsules|Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
40837256|NCT06308250|OTHER|MIME THERAPY|"Mime therapy consist of:~Self massage: patients will be taught to massage their face and neck daily for about 10 minutes which includes effleurage and kneading of both sides of face.~Breathing exercises: patient will be taught to recognize tension and feel the difference between tension and relaxation in facial musculature for 5 minutes. Expiration exercises will be used to induce relaxation.~Articulation: vowels such as a,e,i,o,u and consonants such as p and b will be used to teach position of the lips for 5 minutes.~Facial expression exercises: forehead wrinkle, smiling, eye closure, frowning, disgust, surprise, anger, sadness will be performed for 10 minutes"
40837257|NCT06308250|OTHER|ACTION OBSERVATION THERAPY|"Function of each of the muscle is observed for 3 minutes and then executed for 2 minutes.~Frontalis (Raising eyebrows and forehead wrinkling). Corrugator Supercili (Moving the eyebrow down and inward toward the nose and inner eye).~Orbicularis oculi (Closing the eyelids). Buccinator (Blowing air in and out of the mouth). Zygomaticus major (Smiling). Orbicularis oris (Lip pursing or puckering)."
40837258|NCT02999152|OTHER|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
41022681|NCT01480765|DRUG|Placebo infusion|Normal saline placebo intravenous infusion for 48 hours
40837259|NCT03569839|DRUG|Propofol|Patients undergoing surgery, TIVA (total intravenous anaesthesia)
40837260|NCT02355951|OTHER|blood draw|
40837261|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Preperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
40837262|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Intraperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
41022682|NCT04790045|DRUG|Venetoclax|Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens
41022683|NCT00843791|DRUG|placebo|treatment with placebo for 3 months
41022684|NCT00843791|DRUG|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
41022685|NCT06572761|DRUG|Combination of antibiotics|Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally
41022686|NCT06572761|DEVICE|Emergency cerclage|Emergency cerclage
41022687|NCT06572761|DRUG|Vaginal progesterone|Vaginal progesterone
41022688|NCT04494919|DEVICE|Ultrafine Endoscope|The reversal of the normal colonoscope (CV-260SL; Olympus, Tokyo, Japan) along the guidewire to replace the UFE (GIF-XP260NS; Olympus, Tokyo, Japan).
41022689|NCT00974428|DIETARY_SUPPLEMENT|Wobenzym® N|4 tablets TID, 6 weeks
41022690|NCT00974428|DIETARY_SUPPLEMENT|Placebo|4 tablets TID
41022691|NCT01746823|DRUG|Cyclosporins|
41022692|NCT04175262|DRUG|sunitinib|Patients to receive sunitinib as second line therapy for mRCC
41357623|NCT06496698|PROCEDURE|Simple Interrupted Suture|In the control group, simple interrupted sutures will be used for wound closure after surgical repair of ankle fractures.
41357624|NCT06496698|PROCEDURE|Subcuticular Suture|In the experimental group, subcuticular sutures will be used for wound closure after surgical repair of ankle fractures.
41357625|NCT03177473|DEVICE|CervicalStim bone growth stimulator|Orthofix CervicalStim bone growth stimulator
41357626|NCT00155428|PROCEDURE|rapid prototyping|
41357627|NCT00155428|PROCEDURE|computed tomography|
41357628|NCT02371980|DRUG|Vortioxetine|Vortioxetine capsules
41496910|NCT04516993|DRUG|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
41496911|NCT04516993|DRUG|The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)|Best treatment arm
40837263|NCT04361890|DIAGNOSTIC_TEST|perineal ultrasound|all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
40837264|NCT00299247|DRUG|sulfadoxine/pyrimethamine|
40837265|NCT01954316|DRUG|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
40837266|NCT03947528|DRUG|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fed condition
41496912|NCT01763190|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
40837267|NCT02831790|OTHER|Fontan Education Videos|"The intervention will consist of three brief (\~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~1. Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~2. Anticoagulation~3. Prolonged pleural drainage"
40837268|NCT04004403|OTHER|Alternate day fasting|"The diet involves consuming 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
40837269|NCT04004403|OTHER|Exercise|The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
40837270|NCT04302064|DRUG|Eplontersen|Eplontersen administered SC
40837271|NCT04302064|DRUG|Placebo|Eplontersen-matching placebo administered SC
40837272|NCT02072187|DIETARY_SUPPLEMENT|Active|
41160366|NCT03115229|BEHAVIORAL|Protective Nursing Interventions for Reduction Obesity Risk|"Applications for the experimental group for 11 weeks are grouped under three headings.~These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.~Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.~Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks."
41357629|NCT02371980|DRUG|Placebo|Vortioxetine placebo-matching capsules
41357630|NCT04930133|DRUG|Gilotrif|This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
41496913|NCT06017479|DRUG|Fosfomycin 3000 MG|Fosfomycin 3 g single dosage 1 hour before the urodynamic examination
41496914|NCT06017479|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
41357631|NCT00212615|DRUG|Oxaliplatin (Eloxatin)|
41357632|NCT00212615|DRUG|Capecitabine (Xeloda)|
41357633|NCT04885660|DRUG|compound lisinopril tablet|The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)
41496915|NCT04541316|DEVICE|ProFlor inguinal hernia device|Inguinal hernia repair
41496916|NCT05039138|OTHER|NEUROMUSCULAR TRAINING EXERCISE|patients will receive neuromuscular training exercises in group II
41496917|NCT05039138|OTHER|traditional training exerises|traditional strength training exercises in group I
41496918|NCT05982288|OTHER|Virtual Reality Software|Training of intensive care nurses with virtual reality software
41496919|NCT04864405|OTHER|Morning administration of endocrine therapy|Endocrine therapy administered within one hour of patient wake up time
41496920|NCT04864405|OTHER|Evening administration of endocrine therapy|Endocrine therapy administered within one hour of the patient bed time
40837273|NCT02072187|DIETARY_SUPPLEMENT|Placebo|
40837274|NCT00440310|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
41496921|NCT01400919|DEVICE|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
41496922|NCT01497808|DRUG|Ipilimumab|
41496923|NCT01497808|RADIATION|Stereotactic Body Radiation Therapy|
41496924|NCT04384653|DRUG|Furosemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution for subcutaneous administration (80 mg)
41496925|NCT04384653|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration
41496926|NCT04384653|DEVICE|Medfusion 3500 (v6) precision infusion pump|Furosemide Injection Solution for subcutaneous administration (80 mg)
41496927|NCT05268835|DRUG|Dalacin C|The objective of the intervention is to determine the effect of antibiotic prophylaxis with three different doses of clindamycin on preventing infection and other complications after surgical extraction of impacted mandibular third molars
41496928|NCT00224380|BEHAVIORAL|Using Medications Effectively|
41496929|NCT04029753|BEHAVIORAL|Walk out from operating room|After the surgery of laparoscopic radical gastrectomy, patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb.
41496930|NCT04885153|DRUG|Fenofibrate|Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.
41496931|NCT04885153|DRUG|Placebo|Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
41022693|NCT00659165|DRUG|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
41357634|NCT04885660|DRUG|compound lisinopril tablet(Lisonorm®)|The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)
41357635|NCT03195231|DRUG|Wuling Powder|Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
41022694|NCT00659165|DRUG|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
41022695|NCT02076464|BEHAVIORAL|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
41022696|NCT06532045|DEVICE|Transcutaneous electrical nerve stimulation|TENS applied for 30 min for each time, five times a week, for 2 weeks and deep breathing relaxation exercise given to the intervention group twice a day (10min/exercise) for two weeks.
41022697|NCT01993719|DRUG|Aldesleukin|720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
41022698|NCT01993719|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days
41022699|NCT01993719|DRUG|Fludarabine|30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.
41022700|NCT01993719|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV)
41022701|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
41160367|NCT02935777|DIETARY_SUPPLEMENT|Pomegranate Extract|The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
41160368|NCT02935777|DIETARY_SUPPLEMENT|Placebo capsule|One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
41357636|NCT03195231|DRUG|Placebo|Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
41022702|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm): 300 mg/m\^2 IV over 60 minutes.
41022703|NCT01993719|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV)
41357637|NCT06370065|DRUG|HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）|PD-1 inhibitor
41357638|NCT02638285|DRUG|LH|
41357639|NCT02638285|DRUG|HCG|
41357640|NCT02638285|DRUG|Clomiphene|
41357641|NCT06439251|COMBINATION_PRODUCT|Group 1|The treatment included TENS therapy, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques. Participants in Group A also received Phonophoresis as an experimental technique.
41357642|NCT06439251|COMBINATION_PRODUCT|Group 2|The treatment included routine physiotherapy with TENS, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques.
41022704|NCT01993719|DRUG|Pembrolizumab|2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
41022705|NCT05257889|DIAGNOSTIC_TEST|blood and CSF studies + neuroimaging studies|blood and CSF studies + neuroimaging studies
41022706|NCT04705077|DRUG|SR419|2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
41022707|NCT00062244|BIOLOGICAL|oblimersen sodium|Given IV
41160369|NCT05699369|OTHER|Digital health interventions|Described in arm descriptions.
41160370|NCT02166047|DRUG|Vesatolimod|Vesatolimod tablet administered orally
41160371|NCT02166047|DRUG|Placebo|Placebo to match vesatolimod tablet administered orally
41160372|NCT01027247|DEVICE|Ologen TM|
41357643|NCT04026633|BEHAVIORAL|CAA|Participants will write about the use of PBS and alcohol use.
41357644|NCT04026633|BEHAVIORAL|Control|Participants will write about eating and exercise.
40837275|NCT00440310|PROCEDURE|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
41357645|NCT03561844|OTHER|aromatherapy|Each of participants in the aromatherapy (inhalation) group will receive inhalation aromatherapy and those in the aromatherapy (massage) group will receive aromatherapeutic massage. As to the waiting control group, participants will be given either one of these two interventions after the implementation phase is completed.
41496932|NCT05189834|DIETARY_SUPPLEMENT|Gelsectan|Xyloglucan, vegetable protein and xylooligosaccharides
40837276|NCT00440310|DEVICE|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
40837277|NCT00440310|DRUG|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
40837278|NCT00440310|DRUG|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
40837279|NCT00848341|DEVICE|GUIDANT ICD SYSTEM|
40837280|NCT01092962|DRUG|Cyclophosphamide|2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
40837281|NCT01092962|DRUG|Mycophenolate mofetil|1200mg/m²/jour in two divided doses during 18 months
40837282|NCT01394887|DRUG|Metformin|850 mg of metformin twice daily over 12 weeks
40837283|NCT01394887|DRUG|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
40837284|NCT01171586|BEHAVIORAL|mDiet|"The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics."
40837285|NCT01571869|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
40837286|NCT01571869|OTHER|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
40837287|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
40837288|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
40837289|NCT06234215|DEVICE|functional electrical stimulation|electrical stimulation during function
40837290|NCT06234215|OTHER|functional task training|functional exercise
40837291|NCT02078648|DRUG|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated)."
40837292|NCT02078648|DRUG|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
40837293|NCT02078648|DRUG|SL-701 + GM-CSF|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~150 μg GM-CSF should be administered as a SC injection immediately after SL-701 emulsion administration and within 1 cm from the center of the SL-701 emulsion injection site."
40837294|NCT02078648|DRUG|Imiquimod|Within 5 minutes following the administration of the SL-701 emulsion, approximately 125 mg of imiquimod cream will be applied topically on the injection site. The imiquimod cream should be rubbed in until the cream is no longer visible.
40837295|NCT04098978|OTHER|Pharmacist Drug Therapy Management|Patients will be seen by pharmacist for collaborative drug therapy management.
40837296|NCT03901404|PROCEDURE|Myomectomy Operation|Patients undergoing myomectomy for myoma uteri
40837297|NCT04702113|DIAGNOSTIC_TEST|Cipherome Lighthouse Pilot|Preemptive pharmacogenomic testing
40837298|NCT03103035|OTHER|Blog|Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
41160373|NCT02542085|PROCEDURE|Laparoscopic repair|operative method
41160374|NCT02542085|PROCEDURE|Hybrid repair|operative method
41160375|NCT01093690|DRUG|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
41160376|NCT01093690|DRUG|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
41357646|NCT05488327|DRUG|Lenalidomide|All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
41357647|NCT02416466|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells.
41496933|NCT03648853|DEVICE|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
41496934|NCT01133886|DRUG|Decitabine|Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
41496935|NCT01589965|BEHAVIORAL|Financial incentive through lotteries|Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
41496936|NCT03424018|DRUG|BMN 111|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
41160377|NCT04297839|DRUG|Citrate Anticoagulation Solution|Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)
41160378|NCT04297839|DRUG|Control Group (heparin or continuous saline)|Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
41496937|NCT03040700|OTHER|Myocardial Perfusion Scan|Myocardial perfusion scan will be performed at rest and during pharmacological stress with dipyridamole (99mTc-Sestamibi)
41496938|NCT03040700|OTHER|Coronary CTA|Coronary CTA will be performed using a 320-detector scanner, 0.5 mm slice thickness, with gantry rotation of 350ms. Prior to each scan, the patient's blood pressure and heart rate will be assessed, and if the heart rate is above 70bpm, beta-blockers will be given orally. Following oral beta blocker administration, if the heart rate is still greater than 64bpm, intravenous metoprolol will be administered. A total of 70-100 mL of iodinated contrast will be administered via an automated injector at a rate of 5mL/s. All coronary CTA images will be transferred to a workstation (Vitrea FX-Vital Image) and analyzed by two experienced cardiac imagers who are blinded to all other data using a standard 18-segment coronary tree model.
41496939|NCT05644600|DRUG|Nintedanib|The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.
41496940|NCT05644600|DRUG|AZD5055|The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.
40837299|NCT06446154|DRUG|FOLFOX systemic chemotherapy plus fruquintinib and sintilimab|"The current PICC catheterization was unified for patients undergoing FOLFOX systemic chemotherapy. After catheterization, the catheter was connected to the injection pump in the ward and was continuously pumped into the following chemotherapeutic drugs. The chemotherapy was repeated every 3 weeks for a total of 8 courses.~Oxaliplatin, 85mg/m2，IV (intra venous)，Day 1. Calcium folinate, 400mg/m2，IV，Day1. 5FU, 400mg/m2, IV, Day1, sequentially 2400mg/m2, IV, lasting for 46 hours. Fruquintinib was given orally for 5mg/ days. After 3 weeks, the drug was stopped for 1 week.~Sintilimab was infused intravenously 200mg each time, repeated every three weeks."
41160379|NCT01270217|BEHAVIORAL|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
41357648|NCT02416466|DEVICE|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
41357649|NCT04005924|OTHER|arabinogalactan|Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
41357650|NCT00566475|OTHER|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
40837300|NCT00969072|DRUG|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
40837301|NCT00969072|DRUG|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
40837302|NCT00969072|DRUG|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
41160380|NCT02003664|DRUG|Baclofen ER|Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
41357651|NCT05597189|DIETARY_SUPPLEMENT|Experimental product|Botanical extract
41357652|NCT05597189|OTHER|Control product consumption|Product with identical characteristics to the experimental product.
41357653|NCT05661500|OTHER|Creative Darama Group|Postmortem care training given by creative drama method
41357654|NCT05661500|OTHER|Classical Education Group|Postmortem care training given by classical education method
41357655|NCT02367859|DRUG|Dabrafenib|Given PO
41357656|NCT02367859|DRUG|Trametinib|Given PO
41357657|NCT04390334|DRUG|Daridorexant|Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.
41357658|NCT04390334|DRUG|Famotidine|Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.
41357659|NCT04390334|DRUG|Efavirenz|Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.
41357660|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single dose orally
41357661|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
41357662|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
41357663|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
41357664|NCT05263895|DRUG|PF-07321332|PF-07321332 will be administered as single oral dose orally.
41357665|NCT00743613|BEHAVIORAL|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
41160381|NCT02003664|DRUG|Placebo|Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
41160382|NCT01329419|DRUG|adefovir dipivoxil|Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
40837303|NCT01122108|DRUG|Cholestyramine|Cholestyramine 12 grams, one time dose
40837304|NCT01122108|DRUG|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
40837305|NCT03802045|PROCEDURE|Electroacupuncture|"The interventions will be performed by acupuncture specialists with at least 3 years of clinical experience, who will receive prior training to ensure that they rigorously follow the study protocol and are familiar with the types of treatments, including details such as acupuncture points and manipulation of electroacupuncture parameters.~After the randomization, the acupuncturist will sequentially open the envelopes, and the individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF), high frequency EA (HF), alternating frequency EA (AF), control group (C) and placebo group (P), each containing 25 participants. The acupuncture points will be located and described according to the WHO Standard Acupuncture Locations. Based on the beneficial effects of previous clinical trials, the acupoints selected for this study will be: BL23, BL25, BL40, SP6 and KI3."
40837306|NCT03802045|DEVICE|Needle|Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
40837307|NCT03802045|DEVICE|Adhesive Moxa|In the placebo group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it.
40837308|NCT05850923|OTHER|speech competition training|Speech competition training include voice competition training twice a day in adjunction with drug treatment, and the patients will be required to perform voice-related tasks according to the instruction.
40837309|NCT05850923|OTHER|the soothing music|the soothing music
41160383|NCT01872156|OTHER|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
41160384|NCT01872156|OTHER|Control Group|The group control will act according to usual management.
41160385|NCT02886234|BEHAVIORAL|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
41357666|NCT00743613|PROCEDURE|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
41357667|NCT04778995|OTHER|Structured online training program for effective management of nursing services|"An online structured training program was prepared to reach out to manager nurses for increasing their knowledge regarding the effective management of nursing services in crisis periods. A web page was structured with the support of a professional computer engineer.~Participant manager nurses could log into the system via a personal username and password on the main login screen of the site. In this page, there is an Informed Consent Form.~In the Download Training Documents link; the educational content prepared in sections was presented. Educational content consisted of the issues such as: Management of Crises and Emergency Situations, Leadership in Crisis, Planning and Managing Nurse Human Power in Crisis, Supervision and Management of Patient Care, Logistics and Support Services, Communication in Extraordinary Situations, Motivation Tools Used in Extraordinary Situations, Stress Management During Crisis and Employee Adaptation and Training in Crisis."
41357668|NCT05734586|OTHER|EAT-10 (Eating assessment Tool) screening questionnaire|After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team
41357669|NCT05734586|PROCEDURE|Protective measures for the upper airways|"In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures"
41496941|NCT00095797|DRUG|R(+)XK469|Given IV
40837310|NCT03734029|DRUG|Trastuzumab deruxtecan (DS-8201a)|DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
41496942|NCT00095797|OTHER|pharmacological study|Correlative studies
41496943|NCT00095797|OTHER|laboratory biomarker analysis|Optional correlative studies
40837311|NCT03734029|DRUG|Capecitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
40837312|NCT03734029|DRUG|Eribulin|Administered according to label, as one option for Physician's Choice (determined before randomization)
40837313|NCT03734029|DRUG|Gemcitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
40837314|NCT03734029|DRUG|Paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
41357670|NCT04335227|OTHER|Structured yoga therapy program|Structured yoga therapy prepared according to traditional yoga scriptures of Patanjali yoga sutras will be administered to 32 females with PCOS. The structured yoga therapy which includes, Surya Namaskara (Sun Salutation) and asanas performed in four positions, standing, sitting, supine and prone for total duration of 60 minutes. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
41357671|NCT04335227|OTHER|Aerobic exercise training program|Thirty two females with PCOS in aerobic exercise (AE) group will be subjected to aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks, in the light of guidelines framed by American College of Sports Medicine (ACSM). Aerobic exercise volume for each female recruited will be set at greater than 500 and up to 1000 MET-min/week, which will be approximately equal to 1000 kcal/week. They will be made sure that they exercise for minimum duration of 150 min/week and thereby covering 5400 to 7900 steps/day in pedometer readings. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
41496944|NCT03437226|DRUG|Levosimendan 2.5 MG/ML|Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
40837315|NCT03734029|DRUG|Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
40837316|NCT00974285|DRUG|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
40837317|NCT00974285|DRUG|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
40837318|NCT02981966|DRUG|Dapagliflozin|dapagliflozin, 10mg tablet
40837319|NCT02981966|DRUG|Placebo|Placebo for dapagliflozin
40837320|NCT01948232|DRUG|Perindopril|Angiotensin converting enzyme inhibitor
40837321|NCT02371200|DEVICE|Brain Sentinel Seizure Detection and Warning System|The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
40837322|NCT03379142|BEHAVIORAL|Faith-Based messages|We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
41022708|NCT04244474|DRUG|A single one ml injection|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
41022709|NCT00153101|DRUG|Telmisartan|
41022710|NCT00153101|DRUG|Combination of Telmisartan and Ramipril|
41357672|NCT04335227|OTHER|Combined yoga and aerobic training program|Thirty two females with PCOS in combined yoga therapy and aerobic exercise (cYTAE) group will be subjected to three days of structured yoga therapy and three days of aerobic training of vigorous intensity. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
41022711|NCT00153101|DRUG|Ramipril|
41022712|NCT03120975|OTHER|Computerized decision support and audit & feedback|"* suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system~* mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment~* suggestion of standard antimicrobial treatment duration according to indication"
41022713|NCT03120975|OTHER|Audit & Feedback|\* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)
41022714|NCT03120975|OTHER|Standard antibiotic stewardship|"* Infectious diseases consultation on demand~* Review of positive blood cultures~* Availability of a antibiotic use guidelines (on paper and as PDF)"
40837323|NCT03052556|PROCEDURE|Pap smear test and HPV test|"Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).~This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).~Patients with an initial abnormal pap smear or a positive HPV test will be monitored:~* In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period~* In case of an abnormal smear:~ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed"
40837324|NCT03960723|OTHER|Questionnaire|A questionnaire asking the patients for several questions related to the Informed Consent Form they have signed before surgery, will be administered.
41357673|NCT04335227|OTHER|Nutritional management|Thirty two females with PCOS will be asked to undergo only nutritional management uniquely prepared by dietitian
41357674|NCT03799523|OTHER|Temporary skin markings|To use temporary markings in lieu of localization tattoos.
41357675|NCT03799523|OTHER|Surface imaging|To use light-based surface imaging for patient positioning during radiation treatment.
41357676|NCT00089206|BIOLOGICAL|incomplete Freund's adjuvant|
41496945|NCT03437226|DRUG|Placebos|Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
41496946|NCT00509366|DRUG|Cisplatin & Gemcitabine|"Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
41496947|NCT00509366|DRUG|Cisplatin & Pemetrexed|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
40837325|NCT02248740|PROCEDURE|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
40837326|NCT03836677|COMBINATION_PRODUCT|BGF|Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
40837327|NCT03836677|COMBINATION_PRODUCT|GFF|Treatment with Glycopyrronium/Formoterol Fumarate
40837328|NCT00877721|DEVICE|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
41022715|NCT00744536|DRUG|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
41496948|NCT00509366|DRUG|Docetaxel & Gemcitabine|"Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
41496949|NCT00509366|DRUG|Pemetrexed & Gemcitabine|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
41022716|NCT03650426|PROCEDURE|Total knee with onlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone
41496950|NCT00509795|BIOLOGICAL|ranibizumab|Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
41357677|NCT00089206|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
41496951|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
41496952|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
40837329|NCT04906057|BEHAVIORAL|Forced Aerobic Exercise (FE)|High-rate aerobic exercise on a semi-recumbent custom-designed stationary cycle ergometer
40837330|NCT04906057|BEHAVIORAL|Voluntary Aerobic Exercise (VE)|Voluntary-rate aerobic exercise on a semi-recumbent stationary cycle ergometer
40837331|NCT04845139|DRUG|Nivolumab|Nivolumab given intraventricularly
40837332|NCT03854539|OTHER|Transdermal Vagus Nerve Stimulation|intermittent transdermal stimulation of the aurical vagus
41357678|NCT00089206|BIOLOGICAL|sargramostim|
41357679|NCT02827084|DEVICE|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
41357680|NCT02827084|DEVICE|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
41357681|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
41357682|NCT00984009|OTHER|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
41357683|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
41496953|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
41496954|NCT03512418|BEHAVIORAL|PrEPsteps|Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).
41496955|NCT03512418|DEVICE|Digital pill|The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
41022717|NCT03650426|PROCEDURE|Total knee with inlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
41160386|NCT02886234|BEHAVIORAL|Health Coaching (HC)|The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
41496956|NCT03512418|DRUG|Truvada|Participants receive once daily Truvada as PrEP to prevent HIV.
41496957|NCT06362694|DRUG|Dabrafenib + Trametinib|Dabrafenib is an inhibitor of some mutated forms of BRAF kinases. Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. Dabrafenib and trametinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib 623 and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumors.
41496958|NCT00850434|DEVICE|Modified AutoSet Algorithm|"The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm"
41496959|NCT00850434|DEVICE|Standard AutoSet Algorithm|The standard AutoSet used for treatment of OSA
41496960|NCT03422939|OTHER|there was no intervention, only separate analyses|We only conducted separate analyses to see if responses differed according to level of experience.
41496961|NCT02337296|BEHAVIORAL|ADHERE|"ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.~All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence."
41496962|NCT02053935|DRUG|Dopamine|Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
41496963|NCT01030653|DRUG|Voriconazole low dose|Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses
41022718|NCT04419636|DRUG|Lu AG06466|capsules, orally
41022719|NCT01587183|BEHAVIORAL|Educational material control|Participants will be given educational materials on starting a running program using a run/walk approach.
41022720|NCT01587183|BEHAVIORAL|Group running style B|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
41022721|NCT01587183|BEHAVIORAL|Group running style A|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
41160387|NCT04096157|DRUG|Isavuconazonium sulfate IV|Intravenous (IV) via nasogastric (NG) tube
41496964|NCT01030653|DRUG|Voriconazole high dose|Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
41160388|NCT04096157|DRUG|Isavuconazonium sulfate capsules|Oral
41160389|NCT02722122|DRUG|AIR DNase™|
41496965|NCT04570462|OTHER|Hypothermia Via Cooling Machine- Arctic Sun 5000|"Initiate hypothermia using the Arctic Sun.The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.~Duration of hypothermia will be 48 hours after which the subject will be rewarmed. Metabolic rate, or indirect Calorimetry, will be assessed at baseline, day 1 of hypothermia, day 2 of hypothermia before rewarming, and after full rewarming. CBC, basic metabolic profile, magnesium, phosphorus, coagulation profile, ABG, inflammatory markers would be drawn every 12 hours during hypothermia until subject has achieved full rewarming and once after full rewarming.~The entire hypothermia procedure will last 48 hours. Acceptable rewarming range is a temperature of 36.5C to 37.5C. The subject body temperature rewarming is typically set over 6-8 hours. Therefore, the final 6-8 hours of the 48 hour time period is set to rewarm the subject."
41496966|NCT05893810|DRUG|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares
41496967|NCT03460314|DRUG|Buprenorphine|Patients are tested for their normal prescription buprenorphine medication
41496968|NCT04878848|OTHER|Proprioceptive Neuromuscular Facilitation Exercises|Within the scope of proprioceptive neuromuscular facilitation exercises, rhythmic initiation, repeated stretch and hold-relax techniques in the upper extremity flexion-abduction-external rotation pattern and scapular patterns of anterior elevation, posterior depression, anterior depression and posterior elevation will be applied to the participants. In addition to these exercises, functional activities in the flexion-abduction-external rotation pattern such as hair combing, turning over from side lying, wearing a jacket, reaching on the shelf will be performed.
41160390|NCT02254681|DRUG|Gemcitabine|
41160391|NCT02254681|DRUG|Cisplatin|
41160392|NCT02254681|RADIATION|low dose radiotherapy|Whole liver and portal lymph node basin low dose radiotherapy
41160393|NCT02026505|DRUG|Bortezomib|
41160394|NCT01894256|DRUG|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
41022722|NCT01621373|DRUG|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
41022723|NCT04533841|DRUG|Misoprostol|Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
41022724|NCT04533841|DRUG|Placebo|placebo
41022725|NCT04533841|DRUG|Propranolol|Propranolol
41022726|NCT00688805|DRUG|Propranolol|40 mg given as a single oral administration in an opaque capsule
41022727|NCT00688805|DRUG|Placebo|matching capsule containing no active medication
41022728|NCT00652457|DRUG|Memantine|10 mg BID x 3 months
41022729|NCT04907240|DEVICE|GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)|Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.
41022730|NCT06052969|DEVICE|Pulse NanoMED System|The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.
41022731|NCT01040611|BEHAVIORAL|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
41022732|NCT06398704|OTHER|Standart of care|No additional intervention was made. An evaluation was made.
41160395|NCT01509937|DEVICE|body bioimpedance spectroscopy device|Name of the device is BCM from Fresenius Medical Care D GmbH
41160396|NCT01509937|DEVICE|Device|participants in control arm will not receive BCM measurement.
41357684|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate and vitamin C|28 mg iron; 240 mg vitamin C
41160397|NCT04365738|OTHER|Rehabilitation|Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
41357685|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate|28 mg iron only
41357686|NCT04477018|DIETARY_SUPPLEMENT|Placebo|Matched placebo
41357687|NCT00273715|PROCEDURE|Surgical wound closure techniques|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
41357688|NCT00273715|PROCEDURE|Surgical wound closure techniques (Comparator)|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
41357689|NCT01365468|DRUG|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
41357690|NCT04383743|DRUG|Cisplatin|Given IV
41357691|NCT04383743|DRUG|Doxorubicin|Given IV
41357692|NCT04383743|DRUG|Methotrexate|Given IV
41357693|NCT04383743|BIOLOGICAL|Pegfilgrastim|Given SC
41022733|NCT06198439|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Therapy System
41022734|NCT02293005|DRUG|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
41022735|NCT03991195|DIETARY_SUPPLEMENT|Probiotic supplemented intervention|In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
41022736|NCT03991195|DIETARY_SUPPLEMENT|Placebo|In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
41022737|NCT01210768|DRUG|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
41022738|NCT01210768|DRUG|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
41022739|NCT05003921|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41022740|NCT02947347|DRUG|ibrutinib|ibrutinib 560mg administered orally
41022741|NCT02947347|DRUG|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
41022742|NCT02947347|DRUG|rituximab|rituximab 375mg/m\^2 IV
41022743|NCT06572735|OTHER|QoL surveys|2 quality of life surveys (OV28 and ELD14) will be completed by patients every 3 months during a 12-month period
41022744|NCT06572735|OTHER|Geriatric assessment (G-CODE)|A geriatric assessment (G-CODE) will be performed by the research staff every 3 months during a 12-month period
41022745|NCT06572735|BIOLOGICAL|Blood sampling|A supplementary volume of blood will be collected from a routine blood sample (8 mL) at 3 different time points : one at inclusion, one 6 and 12 months after the beginning of PARP inhibitors treatment. Genetic lab test will be performed to assess whether there is a specific genetic signature for PARP inhibitors toxicity.
41160398|NCT05925114|DRUG|S-309309|Administered as oral capsules
41160399|NCT05925114|DRUG|Placebo|Administered as an oral capsule that looks identical to S-309309 capsule
41160400|NCT03058237|DRUG|Arbaclofen Placarbil SR|One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
41160401|NCT03058237|DRUG|Arbaclofen Placarbil MR Prototype A|One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
41357694|NCT04383743|BIOLOGICAL|Pembrolizumab|Given IV
41357695|NCT04383743|PROCEDURE|Radical Cystectomy|Undergo standard of care radical cystectomy
41357696|NCT04383743|DRUG|Vinblastine Sulfate|Given IV
41357697|NCT03112343|DEVICE|Algorithm-based feedback messages|ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
41357698|NCT03112343|DEVICE|Personal Health Record|Subjects will save and send their health information to the server via the personal health record app
41160402|NCT03058237|DRUG|Arbaclofen Placarbil MR Prototype B|One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
41357699|NCT02375529|PROCEDURE|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
41357700|NCT02375529|PROCEDURE|Four Ports Laparoscopic Cholecystectomy (4PLC)|"An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation ."
41160403|NCT03058237|DRUG|Arbaclofen Placarbil IR|One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
41160404|NCT01040403|DRUG|olodaterol (BI 1744) low|olodaterol (BI 1744) low
41160405|NCT01040403|DRUG|low tiotropium bromide|low tiotropium bromide
41160406|NCT01040403|DRUG|olodaterol (BI 1744) high|olodaterol (BI 1744) high
41160407|NCT01040403|DRUG|medium tiotropium bromide|medium tiotropium bromide
41160408|NCT01040403|DRUG|high tiotropium bromide|high tiotropium bromide
41160409|NCT01040403|DRUG|Placebo|Placebo
41160410|NCT01040403|DEVICE|Respimat|Respimat inhaler
41357701|NCT02510885|DEVICE|AngioVue SD-OCT|OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
41357702|NCT03672721|DRUG|IA Carbo+ Radiation|combination of intraarterial carboplatin + radiation in dose escalation
41357703|NCT00842829|DRUG|Fentanyl Buccal Tablet (FBT)|FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
41357704|NCT00665249|BEHAVIORAL|Motivational Interviewing|See MotivationalInterviewing.org
41357705|NCT00665249|BEHAVIORAL|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
41357706|NCT00665249|OTHER|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
41357707|NCT00000175|DRUG|Estrogen|
41357708|NCT00000175|DRUG|Testosterone|
41357709|NCT05362825|DRUG|Neo-adjuvant Chemotherapy FOLFOXIRI Regimen|Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.
40837333|NCT03556020|DRUG|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
40837334|NCT02733653|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
40837335|NCT03189966|PROCEDURE|transversalis fascia plane block|With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
40837336|NCT03189966|PROCEDURE|quadratus lumborum block|The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
40837337|NCT01979939|DRUG|DCV/ASV/BMS-791325|
40837338|NCT06522399|PROCEDURE|TAMIS mucosectomy|internal Delorme's procedure using TAMIS
40837339|NCT00368121|DRUG|Cetuximab +/- Dexamethasone|"Cetuximab dosing schedule:~• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion~Dexamethasone dosing schedule:~• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.~Mode of administration: orally"
41022746|NCT06535087|DRUG|Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis|"1. Subcutaneous Allergen-Specific Immunotherapy:~   * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~  * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~   * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~  * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation."
41357710|NCT05362825|PROCEDURE|synchronous resection surgery|Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
41357711|NCT00556309|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
41357712|NCT05122442|OTHER|Patients with inherited retinal disease|Patients with inherited retinal disease
41357713|NCT03550976|BEHAVIORAL|The low-GI diet and muscle training|During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
41357714|NCT06282731|DRUG|Silodosin|Indications:Benign prostate hyperplasia
41357715|NCT05956223|DEVICE|Virtual Reality measurement of essential tremor and dystonia|"1. The virtual reality (VR) platform, which detects whole-of-body movements. The VR environment is a series of sensors in a room that detect whole body motion and a series of sensors worn by the participant. As well the participant dons VR goggles that allows them to see a virtual environment in which they can perform the TETRAS.~   Within the VR platform, an avatar (an electronic image that represents the participant) is produced in the VR environment, and this will be used to review the participant.~2. Sensors for the detection of wrist, head and voice tremor. The sensors are small devices worn on the wrists and head of the participant and are similar to those used in the VR system. A microphone is attached to the participants to detect voice tremor."
41496969|NCT04878848|OTHER|Conventional Rehabilitation Group|Active assisted / active range of motion exercises and Wand exercises will be applied to the participants in the conventional rehabilitation group for flexion, abduction and external rotation movements. Exercises will be applied as 5 repetitions in the first 2 weeks and 10 repetitions in the last 2 weeks. Strengthening exercises will be performed with an elastic band and free weights. Strengthening exercises will be started as 2 sets of 5 repetitions and at the end of the second week, it will be applied as 2 sets of 10 repetitions. In addition to these exercises, glenohumeral distraction, glenohumeral posterior and caudal glide will be applied for joint mobilization and it will show progression at the end of the second week.
41160411|NCT05095714|OTHER|Liver ultrasound and fast-MRI|Half-yearly liver ultrasound and fast-MRI
41357716|NCT03040180|DRUG|Electrochemotherapy with bleomycin|Systemic injection, once only treatment
41357717|NCT03040180|DEVICE|EndoVE|Electroporation using an endoscopic electroporation device
41357718|NCT05002049|BEHAVIORAL|Intervention Group|Teenagers with leadership skills from intervention schools (called ambassadors) and stakeholders will participate in focus groups to gain insights on the barriers and facilitators for healthy lifestyles of teenagers, and how science could help address these. Building on the information of the focus groups, ambassadors, stakeholders and other peers will participate in a collaborative competition event where the SEEDS intervention(s) will be designed. The intervention(s) will be implemented at intervention high-schools during 6 months. Outcomes in health behaviours and science literacy will be assessed by validated questionnaires at the start and end of the project.
41357719|NCT01049789|BEHAVIORAL|COMB - Combination Cognitive Behavioral Therapy and Medication Management|"Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.~Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48."
41496970|NCT02320760|BEHAVIORAL|Physical activity on prescription|
41496971|NCT02187692|BEHAVIORAL|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
41496972|NCT05076695|DRUG|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles)
41496973|NCT05076695|DRUG|trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks for a total of 6 administrations.
41496974|NCT05076695|DRUG|pyrotinib|Pyrotinib 400mg, PO daily, continuously
41160412|NCT05095714|OTHER|Liver ultrasound|Half-yearly liver ultrasound
41160413|NCT02686983|DRUG|Betamethasone and local anesthetic|Infiltration of the greater occipital nerve .
41160414|NCT04034914|OTHER|Questionnaire administration|Ancillary studies
41160415|NCT00685425|DRUG|Levalbuterol HFA MDI|"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
41357720|NCT01049789|BEHAVIORAL|TAU - Treatment as Usual|"Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.~Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48."
41357721|NCT03594422|DRUG|HQP1351|HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
41160416|NCT00685425|DRUG|Racemic Albuterol|"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
41357722|NCT06268366|OTHER|Exercise|Three exercises consisting of stretching and strengthening specific to the movement pattern dysfunction scored by Symmio will be prescribed to the participants. The exercises are standardized and assigned within the Symmio application with video instruction and guidance.
41357723|NCT04306835|BEHAVIORAL|Cognitive behavioural therapy for insomnia|a technique for treating insomnia without medications
41357724|NCT04129931|DRUG|MCT|Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily
41357725|NCT04129931|DRUG|Clazakizumab|12.5 mg subcutaneous injection given once every 4 weeks for 16 weeks. Lab driven dose reductions will be made based on safety lab data. If criteria are met for dose reduction, the participant will be reduced to a 6.25 mg dose.
41357726|NCT04129931|DRUG|Broncho-Vaxom|7 mg taken orally once a day, on an empty stomach, for 16 weeks
41357727|NCT04129931|DRUG|Imatinib Mesylate|Two 100 mg tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. If the drug is well tolerated, participants will titrate up to four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Safety labs will be collected at each study visit to monitor the tolerability of each participant.
41357728|NCT04129931|DRUG|Cavosonstat|50 mg capsule orally twice a day for 16 weeks.
41357729|NCT04129931|OTHER|Placebo|"MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks."
41357730|NCT03814876|BEHAVIORAL|Group session psycho-education|Active comparator - control group
41496975|NCT05076695|DRUG|fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intramuscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose.
41496976|NCT02482961|DRUG|colistimethate sodium|At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
41357731|NCT03814876|BEHAVIORAL|FITS|Manualized family intervention
41496977|NCT06322173|DIAGNOSTIC_TEST|NGS Analysis|An analytical pipeline with NGS technology developed in the GENRES study will be used for the identification of infecting microorganisms and the drug resistance they carry. For this purpose, a sequencing method will be identified and adopted that can obtain gene sequences of approximately 75 bp in length and on the Illumina MiSeq platform. Furthermore, IT software and bioinformatics analyzes with specific quality control parameters (pre- and post-alignment of reads) will be identified and adopted in order to develop an IVD system that includes a complete package of sequencing kits and software.
41160417|NCT00051103|DRUG|Investigational Cancer Drug|
41160418|NCT02777242|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|SC injections of QST 50 mg or 75 mg or 100 mg
41357732|NCT05507294|DRUG|Glumetinib|"Fasting: Subjects are fasted overnight (at least 10 hours before administration) and receive Glumetinib tablets with 240 mL warm water the next morning.~Fed (high-fat meal/low-fat meal): Following an overnight fast for at least 10 hours, subjects finished a high-fat meal, or a low-fat meal within 30 minutes the next morning (eat up all meals). Glumetinib tablets are orally administered by subjects with 240 mL warm water on 30 minutes after starting the meal. Water is allowed as desired except for 1 hour before and 2 hours after administration (including the meal), and no more than 500 mL of water will be consumed including the water intake during the high-fat meals or low-fat meals, and the water for administration. The subjects will be fasted for at least 4 hours after administration, and then have dinner approximately 9 hours after administration."
41357733|NCT01428479|DRUG|GR121167 Solution|GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
40837340|NCT05390541|BEHAVIORAL|Empowered to Test Yourself|There will be 5 sessions of the intervention, all of which will follow the same format. Participants will be sent push notifications for each session. Each session will begin with using relevant constructs from sIMB (i.e., information and behavioral skills). Next, participants will choose positive outcomes resulting from the behavior, barriers to performing the behavior (mental contrasting), select situational cues and action plans to overcome selected barriers (implementation intentions), and practice typing in implementation intentions and positive outcomes from memory (memory practice). To ensure participants retain the implementation intentions, the investigators will use memory practice. Participants will be asked to self-code if the participant is correct or incorrect. Lastly, participants will learn behavioral skills to engage in each of the 5 actions to increase self-efficacy.
40837341|NCT05390541|OTHER|Educational Control|Participants will receive the HIV/STI home testing kit, instructions to mail in the kit, notification when results are ready to check online, treatment from a provider at Kind Clinic for positive results, and referral to Kind Clinic for PrEP. Each session and assessment will occur every 3 days. Session 1: Basic information about STIs. Session 2: HIV and stigma, basic information about HIV, and HIV transmission facts and myths. Session 3: Four stories about different people who are HIV-positive, how HIV was contracted, and one story about a woman who contracted herpes and how to all cope and live healthy lives. Session 4: How to disclose positive STI status. Session 5: Basic information about PrEP, and information on how to correctly use a male condom, female condom, and dental dam.
40837342|NCT00456599|DRUG|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
40837343|NCT00456599|DRUG|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
40837344|NCT00456599|PROCEDURE|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
41357734|NCT01428479|DRUG|Placebo|Placebo solution will be administered intravenously.
40837345|NCT01560299|DRUG|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
40837346|NCT01560299|DRUG|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
40837347|NCT01560299|DRUG|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
40837348|NCT03436485|DRUG|ODM-208|co-administered with glucocorticoid and fludrocortisone, orally daily
40837349|NCT03436485|DRUG|Midazolam|orally
40837350|NCT01837667|DRUG|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
41357735|NCT05421676|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
41496978|NCT05596565|OTHER|Supervised Exercise by a physiotherapist via face to face|"Participants in group-1 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face.~Participants in group-2 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference"
41496979|NCT05833698|DIAGNOSTIC_TEST|Elevation of NLR|Blood test
41496980|NCT05354635|OTHER|Antibiotics Dosing|Dosing concerns the main antibiotics used in the unit: b-lactams, linezolid, vancomycin and aminosides
41496981|NCT03371459|DRUG|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
40837351|NCT01837667|DRUG|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
40837352|NCT03931915|DRUG|TAK-385|TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
40837353|NCT03931915|DRUG|Leuprorelin acetate|TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
40837354|NCT03090347|OTHER|Overconsumption of specific dietary nutrient|Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
40837355|NCT05386212|DEVICE|web app healthcare instructions for relieving back pain|This study designed web-based dynamic pain relief instructions for women with spinal compression fractures.
40837356|NCT00201123|DRUG|Aerosol Interferon-Gamma|Participants will receive aerosol interferon-gamma.
41357736|NCT00535236|BIOLOGICAL|V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
40837357|NCT00201123|DRUG|Subcutaneous interferon-gamma|Patients will receive subcutaneous interferon-gamma
40837358|NCT00201123|OTHER|Placebo|
40837359|NCT04515329|DRUG|Cyclosporine|Eye drops taken twice daily.
40837360|NCT04515329|DRUG|Artificial tear|Preservative-free artificial tear drops 4 times a day.
40837361|NCT01378429|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
40837362|NCT01378429|DRUG|Placebo|Placebo
41022747|NCT03374124|DIAGNOSTIC_TEST|sinonasal outcome test-22|Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
41357737|NCT00535236|BIOLOGICAL|Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
41496982|NCT03371459|DRUG|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
40837363|NCT04066634|DEVICE|Vivio System|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
40837364|NCT05722041|PROCEDURE|Immediate dental implant placement|Placement of one dental implant immediately after tooth extraction.
40837365|NCT03536026|PROCEDURE|Conventional bronchoscopy|-Standard of care
40837366|NCT03536026|DEVICE|VIDA Pulmonary Workstation 2|-Virtual bronchoscopic navigation system
40837367|NCT03536026|PROCEDURE|Biopsy|-Standard of care
40837368|NCT06098118|BEHAVIORAL|MyMammogram decision aid|An online breast cancer screening decision aid that includes personalized risk assessment, information on benefits and risks of mammography screening, values clarification, outcome expectancies, and a summative document with participant responses.
40837369|NCT05772078|OTHER|Assess compliance rate and demographics|Records to evaluate attendance rate
40837370|NCT05275322|BEHAVIORAL|Unified Protocol|The Unified Protocol for transdiagnostic treatment of EDs (hereinafter UP) is a transdiagnostic treatment based on emotional regulation published in 2011 by David H. Barlow et al. (Barlow et al., 2011). It consists of eight treatment modules, with five of them being central (mindfulness, cognitive flexibility, countering emotional behaviors, tolerating physical sensations, and emotional exposure).
40837371|NCT03204890|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation|Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
40837372|NCT04279158|BEHAVIORAL|"experience 1 The negative priming task"|The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.
40837373|NCT04279158|BEHAVIORAL|"experience 2 Stop signal task"|The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
40837374|NCT04279158|BEHAVIORAL|"experience 3 Anti-saccades"|The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target
40837375|NCT04207918|RADIATION|Radiotherapy|44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
40837376|NCT04207918|DRUG|Nimotuzumab|400mg, by intravenous infusion once a week in 4-6 weeks.
40837377|NCT04207918|DRUG|S-1|40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
40837378|NCT02653716|BEHAVIORAL|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
40837379|NCT02653716|BEHAVIORAL|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
40837380|NCT00005048|DRUG|estramustine phosphate sodium|
40837381|NCT00005048|DRUG|paclitaxel|
40837382|NCT04063787|DEVICE|Fist Assist|"The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12."
40837383|NCT03462953|PROCEDURE|Gingival tissue samples will be harvested|"Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls and during periodontal surgery or extraction of hopeless teeth with periodontal disease ..~The dissected gingival samples will be washed in saline solution and fixed in 4% buffered formalin for 48 hours, dehydrated in ascending grades of ethyl alcohol, cleared in xylene and embedded in paraffin and will be subjected to the following:.~1. Sections of 4-5 µm in thickness will be obtained, deparaffinized, rehydrated and subjected to histological staining and histomorphometric analysis.~2. Real time- PCR for TGF-B1 ,Vimenten , E-Cadherin ."
40837384|NCT05562960|PROCEDURE|Plasmapheresis|Regular plasmapheresis to remove anti-NRIP autoantibody
40837385|NCT02365415|DRUG|Sirolimus|8 weeks oral sirolimus, following drug levels
40837386|NCT04049929|DRUG|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
40837387|NCT03298841|DEVICE|Zeiss|"This study proposal will highlight the advanced technology features of the Zeiss Lumera surgical operating microscope which include but are not limited to:~Stereo Coaxial Illumination for improved visualization High resolution video screen/co-observation tool to help OR staff anticipate next steps Integrated toric alignment tool Surgical microscope touch screen Cordless foot control for faster turnover between cases"
40837388|NCT03147794|DEVICE|MyndMove|A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
41022748|NCT00922610|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
41022749|NCT01478698|DRUG|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
41357738|NCT03653039|DEVICE|Tritube|The ultra thin tribute is used used for the ventilation of the patients in this arm
41357739|NCT03653039|DEVICE|Standard enditracheal tube|A standard endotracheal tube is used used for the ventilation of the patients in this arm
41357740|NCT02095444|DRUG|Menstrual blood stem cells|10\*7 cells/kg, intravenous injection for 4 times during two weeks
41357741|NCT04046666|DEVICE|Functional near infrared spectroscopy|Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
41022750|NCT01478698|DRUG|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
41357742|NCT04046666|PROCEDURE|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm."
40837389|NCT06137872|OTHER|Music Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. In the music group, the pregnant woman, who was assigned to the next group according to randomization during the non-stress test, was allowed to listen to music with disposable headphones for at least 20 minutes until the procedure was completed. At the same time, the mother will be asked to close her eyes and be relaxed. Headphones used to prevent infection were given to the pregnant woman as a gift at the end of the procedure.
41357743|NCT05312528|PROCEDURE|endometriosis surgery|Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.
41357744|NCT05312528|PROCEDURE|other benign condition surgeries|ovarian cystectomy, bilateral tubal ligation, myomectomy etc.
41357745|NCT05940324|DRUG|Ketamine|Ketamine is an FDA-approved dissociative anesthetic.
41357746|NCT05940324|DRUG|Naltrexone Pill|Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)
41357747|NCT05940324|OTHER|Placebo pill|An oral inactive placebo pill will be administered to preserve the blinded nature of the study.
41357748|NCT02119780|DEVICE|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
41022751|NCT06533709|DIAGNOSTIC_TEST|Radio-score|A score based on the LASSO regression model predicting the R0 resection of the primary debulking surgery of advanced ovarian cancer.
41357749|NCT02119780|DEVICE|Restylane SubQ™|Restylane SubQ™ injection into the anteromedial malar region
41357750|NCT01440231|DRUG|Placebo|Matching placebo administered by subcutaneous injection, once weekly
41357751|NCT01440231|DRUG|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
41022752|NCT02526134|DEVICE|radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)|
41022753|NCT03231371|DRUG|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
41022754|NCT01778192|DRUG|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
41022755|NCT01778192|DRUG|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
41022756|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
41022757|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
41022758|NCT03474159|DEVICE|Magnetic Resonance Imaging|Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
41357752|NCT01440231|DRUG|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
41357753|NCT01440231|DRUG|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
41357754|NCT01440231|DRUG|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
41357755|NCT05476094|DRUG|Polyene Phosphatidylcholine|AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
41022759|NCT03474159|DEVICE|Transthoracic echocardiography|Aortic distensibility measured in TTE of the same segments in TM and in B mode
41022760|NCT03474159|DEVICE|Echography UltraFast|Carotid pulse rate measured on carotid arteries by UF
41022761|NCT02732847|OTHER|A delayed prescription dated 2 days after clinical office visit|
41022762|NCT02732847|DRUG|Usual Dated|
41022763|NCT02323724|GENETIC|BRAF V600E mutation by pyrosequencing technique|
41022764|NCT05311033|OTHER|Exacyl|Healthy males with at risk of post-inflammatory hyperpigmentation have a skin samples for evaluate the activity of tranexamic acid.
41022765|NCT02013323|DRUG|Scaling and root planing, and Septilin for 7 days|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
41022766|NCT02013323|DRUG|Scaling and root planing, and Placebo drug for 7 days|Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
41022767|NCT03095989|BEHAVIORAL|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
41022768|NCT01252251|DRUG|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
41022769|NCT03632356|BEHAVIORAL|Stepped Care Intervention (STEP)|A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.
41022770|NCT03632356|DIAGNOSTIC_TEST|Screening only|Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
41022771|NCT00001631|PROCEDURE|Magnetic resonance imaging|
41022772|NCT01903278|DRUG|PEG-IFN-SA /RBV|
41022773|NCT01903278|DRUG|Pegasys /RBV|
41022774|NCT04588077|BIOLOGICAL|Heplisav-B Injectable Product, 2-dose regimen|Investigators will randomly assign patients into a 2-dose regimen.
41022775|NCT04588077|BIOLOGICAL|Heplisav-B Injectable Product, 3-dose regimen|Investigators will randomly assign patients into a 3-dose regimen.
41022776|NCT04049526|BEHAVIORAL|The influence of different music genres on Heart Rate Variability (HRV) in preterm infants|Neonates undergo a daily randomized music listening program (25 minutes, every day, for 3 days) based on different music genres listening (soft pop-rap, pop-rock and classical music). Music programs is followed by 1 day of no music monitoring (25 minutes). An electrocardiogram is performed to evaluate HRV parameters in each neonate with and without music exposure
41022777|NCT03464682|DRUG|HS-25 10mg|HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
41022778|NCT03464682|DRUG|HS-25 10mg combination with Atorvastatin|HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
41357756|NCT03427762|OTHER|Rehabilitation|"Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups."
40837390|NCT06137872|OTHER|Control Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. During the non-stress test, routine non-stress test was performed on the pregnant control group, which was assigned to the next group according to randomization.
40837391|NCT05521438|DRUG|QRX003-2% Lotion|QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
40837392|NCT05521438|DRUG|QRX003-4% Lotion QAM|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
40837393|NCT05521438|DRUG|Vehicle|Vehicle Lotion
40837394|NCT05521438|DRUG|QRX003-4% Lotion BID|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
40837395|NCT03120377|OTHER|Platform|Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.
40837396|NCT03120377|OTHER|Platform sham|will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
40837397|NCT01657760|DRUG|citalopram|citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
40837398|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/CT|Imaging scan
40837399|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/MR|Imaging scan
40837400|NCT04943692|DRUG|Metformin glycinate|1050 mg, tablets Administered orally, twice a day, for 12 months.
40837401|NCT04943692|DRUG|Metformin Hydrochloride|850 mg, tablets. Administered orally, twice a day, for 12 months.
40837402|NCT04268550|DRUG|Selpercatinib|Given PO
40837403|NCT02177409|DRUG|Telmisartan|
41357757|NCT02046213|DRUG|E2006|Single oral 10mg dose of 100 uCi \[14C\]E2006
41357758|NCT05614362|DIETARY_SUPPLEMENT|Channa Striatus extract|Channa Striatus extract given with a dose of 500 mg three-times-daily for each patient
41357759|NCT05614362|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin given three-times-daily for each patient
40837404|NCT02177409|DEVICE|Amlodipine|
40837405|NCT02177409|DRUG|Placebo|
40837406|NCT00398203|DEVICE|NaviAid™ BGE Device|NaviAid™ Balloon Guided Endoscopy Device
40837407|NCT01694719|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|
40837408|NCT01694719|BEHAVIORAL|Cognitive Control Training|
40837409|NCT03943849|OTHER|Particulate bone graft|Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
40837410|NCT03943849|OTHER|Autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside, mixed with hydrated particulate bone graft, and then placed in the extraction socket.
40837411|NCT03943849|OTHER|Resorbable collagen membrane|After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured.
40837412|NCT03943849|OTHER|Suture|Resorbable or non-resorbable suture material
40837413|NCT06273046|BEHAVIORAL|Biofeedback|Three visits will be made throughout the study. The first visit (Day -14) will consist of an evaluation of the inclusion criteria. A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient. The second visit will take place 14 days later (Day 0). During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria. Patients who meet the criteria will be randomized 2:1 to active treatment or placebo. Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home. A final visit will be performed at the end of the study (3 months in incontinence studies and 4 weeks in dyssynergic defecation studies). In incontinence study a final phone call will be performed at 6 months.
40837414|NCT06273046|BEHAVIORAL|Placebo|Three visits will be made throughout the study following the same procedure as patients in the active arm. Patients randomized to placebo treatment will receive instructions to take a pill of placebo containing 0.3 g glucose daily at home. A final visit will be performed at the end of the study alike the active treatment group.
40837415|NCT02881619|DRUG|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
40837416|NCT02881619|DRUG|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
40837417|NCT01469403|BEHAVIORAL|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
40837418|NCT02973568|OTHER|Observational Study|
40837419|NCT06287307|OTHER|Placebo|The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
40837420|NCT06287307|DRUG|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
41022779|NCT03464682|DRUG|HS-25 20mg combination with Atorvastatin|HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
41022780|NCT03464682|DRUG|Atorvastatin 10mg|Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
41357760|NCT03018028|DRUG|Semaglutide|Oral administration once daily
41357761|NCT03018028|DRUG|Placebo|Oral administration once daily
41357762|NCT03018028|DRUG|Liraglutide|Subcutaneous (s.c., under the skin) injection once daily
41357763|NCT00721136|DRUG|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
41022781|NCT03464682|DRUG|HS-25 20mg|HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
40837421|NCT03897530|BEHAVIORAL|Smoking Cessation Intervention|View and purchase hypothetical tobacco products during four distinctly different ETM
40837422|NCT03897530|OTHER|Functional Assessment|Visual attention is evaluated via eye-tracking equipment
40837423|NCT03897530|OTHER|Questionnaire Administration|Ancillary studies
40837424|NCT03974412|DIAGNOSTIC_TEST|Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]"
40837425|NCT03974412|DEVICE|Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
40837426|NCT03974737|DEVICE|CRI device (non-invasive vitals sign measurement)|Survey administration, Orthostatic vital measurements
41022782|NCT03464682|DRUG|Placebe of HS-25 and Atorvastatin|Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
41022783|NCT02530619|DRUG|Alisertib|Given PO
41022784|NCT02530619|OTHER|Laboratory Biomarker Analysis|Correlative studies
41357764|NCT00721136|DRUG|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
41357765|NCT00721136|DRUG|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
41357766|NCT02992054|OTHER|stimulating activities|
41357767|NCT05042531|DRUG|Azacitidine|Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days
41357768|NCT05042531|DRUG|Dasatinib|dasatinib,20mg,po,qd,treatment cycles every 28 days
41357769|NCT06333535|OTHER|foot massage|foot massage
41496983|NCT04605003|DEVICE|Novel rig-S|A new device created to hold the high level disinfectant and automatically indicate when sterilisation process has been completed
41496984|NCT04605003|DEVICE|Conventional Autoclave machine|The gold standard device to clean all medical instruments
40837427|NCT03256747|DEVICE|NMES|NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.
40837428|NCT03256747|DEVICE|NMES-placebo|NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
41022785|NCT02530619|OTHER|Pharmacological Study|Correlative studies
41022786|NCT00273611|BEHAVIORAL|Pharmacist Education about Vitamin D|
41022787|NCT05296616|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
41357770|NCT06333535|OTHER|abdominal massage|abdominal massage
41022788|NCT01657201|DRUG|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
41022789|NCT01657201|DRUG|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
41357771|NCT06333535|OTHER|foot and abdominal massage|foot and abdominal massage
41496985|NCT06195488|PROCEDURE|Gastric ultrasound|performing gastric ultrasound to determine gastric contents
41496986|NCT00437840|DRUG|GSK598809|GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
41496987|NCT00437840|DRUG|Placebo|Subjects will receive single oral dose of matching placebo tablet to GSK598809.
41496988|NCT02391480|DRUG|ABBV-075|ABBV-075 Oral tablets
41496989|NCT02391480|DRUG|Venetoclax|Venetoclax tablets, film-coated
40837429|NCT04133714|DEVICE|multi-channel tDCS|multi-channel transcranial direct current stimulation, tDCS
40837430|NCT04133714|DEVICE|single-channel tDCS|single-channel transcranial direct current stimulation
40837431|NCT04516551|BIOLOGICAL|anti-CD19 allo-CAR-T cells|The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.
40837432|NCT05055882|OTHER|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|Comparison of Adult-Onset Still's disease phenotypes
41022790|NCT05117606|DEVICE|LYNG by Ably Medical|Comparing LYNG to traditional, standard equipment for heart rate, respiration, movement, and blood pressure.
41022791|NCT03639155|DRUG|vadadustat reference tablets|oral tablet
41022792|NCT03639155|DRUG|vadadustat test tablets|oral tablet
41022793|NCT01936961|DRUG|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
41022794|NCT01936961|RADIATION|Hypofractionated Radiotherapy|
41022795|NCT05268796|BEHAVIORAL|Behavior therapy|Caregivers will be coached either in-person or via telehealth to implement function-based behavioral treatment in 1-hour sessions each week with their child over 12 weeks.
41022796|NCT05268796|OTHER|Psychoeducation|Caregivers will complete online education modules in 1-hour sessions each week over 12 weeks.
41022797|NCT00452634|DRUG|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
41357772|NCT02943863|DEVICE|HFNC followed by conventional nasal cannula|
41357773|NCT02943863|DEVICE|Conventional nasal cannula followed by HFNC|
41357774|NCT05879380|DIAGNOSTIC_TEST|MRPA|patients will receive an extra MRPA, on top of the standard CTPA
41357775|NCT05879380|DIAGNOSTIC_TEST|CPTA|patients will receive an extra MRPA, on top of the standard CTPA
41357776|NCT06095349|OTHER|inhalatory treatment with sulfureous aerosol|osteopenic patients are subject to a 12-days cycle of 30 minutes-long inhalatory treatment with sulfureous aerosol
41357777|NCT04121637|OTHER|Aerobic Exercise|"Each exercise session;~* 5 min warm-up = 30% of VO2 max~* 20 min exercise = 50-60% of VO2 max~* 5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS."
41357778|NCT04121637|OTHER|Frenkel coordination exercises|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
41357779|NCT00682409|OTHER|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
41496990|NCT00642681|DRUG|Technosphere Insulin|Technosphere® Insulin (TI) Inhalation Powder, prandial
41496991|NCT01830205|DRUG|Daclatasvir|
41496992|NCT03876418|DIAGNOSTIC_TEST|Intra-abdominal Pressure|Aggressive screening, prevention and treatment of intra-abdominal hypertension
41496993|NCT00120679|DRUG|darbepoetin alfa|
41496994|NCT00120679|DRUG|recombinant human erythropoietin (rHuEPO)|
40837433|NCT04615325|DRUG|RO7303359|RO730359 will be administered as a single intravitreal injection.
41357780|NCT02809872|OTHER|Diagnostic Thoracic Ultrasound|
41357781|NCT03016520|DRUG|DWJ1392|
40837434|NCT01107938|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
41357782|NCT03016520|DRUG|DWC20164|
41496995|NCT01413490|DRUG|rimantadine|12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
41357783|NCT05485779|DRUG|AQ280|"Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral"
41496996|NCT06168279|PROCEDURE|hand occlusal articulation|The upper and lower cast will be scanning separately then will be articulated manually in the final occlusion then scanned after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
40837435|NCT01107938|DRUG|15 mg ilaprazole|Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
40837436|NCT01107938|DRUG|40 mg esomeprazole|One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
40837437|NCT02391961|DRUG|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
40837438|NCT02391961|DRUG|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
40837439|NCT00757692|DRUG|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
40837440|NCT00757692|DRUG|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
41357784|NCT05485779|DRUG|Placebo|"Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral"
41357785|NCT03621111|BEHAVIORAL|Patient-counseling|After one month from the hospital discharge, the pharmacist will give to the patient general advices and suggestions regarding disease, therapy and drugs.
41357786|NCT03621111|BEHAVIORAL|Patient self-administered questionnaire|The pharmacist will submit the questionnaire to the patient for the evaluation of drug adherence, life style, feelings and approach to therapies, at 30 days, 3, 6, 9 and 12 months from the enrollment. This self-questionnaire of 13 questions contains the 8 multiple choice questions of the Morisky medication adherence scale (MMAS-8-Item, Italian version).
41496997|NCT06168279|PROCEDURE|digital occlusal articulation|Both upper and lower casts will be scanning separately, then the 3D casts will be articulating by using 3d virtual program to obtained the final occlusion after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
41496998|NCT06505941|DRUG|umbilical cord mesenchymal stem cell|umbilical cord mesenchymal stem cell
41496999|NCT06505941|DRUG|Placebo|non-cell-containing placebo
41497000|NCT04913948|OTHER|No intervention|No intervention
41497001|NCT01247883|DRUG|PF-04634817|single dose, 20mg, tablet
41497002|NCT01247883|DRUG|PF-04634817|single dose, 20mg, solution
41022798|NCT00452634|DRUG|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
41022799|NCT00452634|DRUG|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
41022800|NCT00963664|DRUG|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
41022801|NCT00963664|DRUG|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
41022802|NCT00248222|BEHAVIORAL|Supervised aerobic training|
41022803|NCT04233814|DRUG|Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)|LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.
41022804|NCT04233814|DRUG|Placebo|Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
41022805|NCT01569334|BIOLOGICAL|blood samples|
41022806|NCT05829408|BEHAVIORAL|KOPPeling|KOPPeling lasts ten to twelve weeks and will be administered by health care professionals.
41357787|NCT03621111|BEHAVIORAL|Pills counts|At the time of the monthly drug re-supply at the community pharmacy, the patient will bring the boxes of the drugs taken in the previous month (empty or not), for the pill counts. The pharmacist will verify the correct assumption of the pharmacological therapies.
41357788|NCT02815475|DIETARY_SUPPLEMENT|Placebo comparator|
41357789|NCT02815475|DIETARY_SUPPLEMENT|Curcumin|
41357790|NCT02815475|DIETARY_SUPPLEMENT|Turmeric powder|
41357791|NCT01607996|PROCEDURE|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
41357792|NCT01607996|DRUG|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
41357793|NCT00006242|DRUG|BMS-214662|Given IV
41357794|NCT00006242|OTHER|laboratory biomarker analysis|Correlative studies
41022807|NCT03545126|OTHER|13C6 Leucine|Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
41022808|NCT00161928|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)|
40837441|NCT00806923|DRUG|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
40837442|NCT00806923|DRUG|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
41022809|NCT04120896|BEHAVIORAL|Karate group|Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
41022810|NCT04120896|BEHAVIORAL|Kung fu group|Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
41022811|NCT05740930|OTHER|Partition defocus myopia management spectacle lens|Participants in the intervention group will receive the partition defocus myopia management spectacles lens and receive follow-up checks.
41022812|NCT05740930|OTHER|Spectacle lenses with aspherical lenslets|Participants in the control group will receive the spectacle lenses with aspherical lenslets and receive follow-up checks.
41022813|NCT00285753|BEHAVIORAL|support groups|cognitive behavioral intervention with psychoeducation
41022814|NCT06573034|BEHAVIORAL|Daoist Zhanzhuang|Each session of practice will last 30 minutes, and participants are expected to participate every day for 3 months. During the initial 3 weeks, participants will engage in in-person sessions 3 times a week. On non-session days, they can choose to either attend a Zoom practice session with the coach or submit a recording of their individual practice for fidelity check. In Week 4, participants will attend an in-person session for both practice and assessment. Over the subsequent 8 weeks, participants will either attend in-person or Zoom sessions, with a total of 3 check-in sessions.
41357795|NCT00006242|OTHER|pharmacological study|Correlative studies
41357796|NCT04383041|OTHER|No intervention|Completing questionnaires via ePRO app from their own mobile devices
41357797|NCT00193856|DRUG|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
41357798|NCT00193856|DRUG|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
41357799|NCT00193856|RADIATION|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.
41357800|NCT03110757|BIOLOGICAL|GLA-AF|Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
41357801|NCT03110757|BIOLOGICAL|Hepatitis B Virus Vaccine (Recombinant)|A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.
41509263|NCT04548765|BEHAVIORAL|Default Effect and Presentation of Alternatives|The pros and cons for screening with FIT kits and colonoscopy are presented. By showing an additional option, the table frames the FIT kit as the default option (since they are included in the mailer). In this situation, inaction is no longer the default option. Changing the default option increases the chance that the FIT kit is used. In addition, another viable alternative is provided (colonoscopy), which still contributes to the goal of the project (getting screened).
40837443|NCT00806923|DRUG|Placebo|iv on day 1 of each 3 week cycle until disease progression
40837444|NCT00806923|DRUG|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
40837445|NCT00806923|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
41022815|NCT06573034|BEHAVIORAL|Sham Wall Squat|Same as the Zhanzhuang group.
41022816|NCT02360917|OTHER|Emerging from the Haze|A 6 week psycho-educational class
41022817|NCT02344186|DRUG|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
41022818|NCT03565718|BEHAVIORAL|Dietary Intervention: Restaurant|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
41160419|NCT05715502|RADIATION|brachytherapy|Radiation: focal low dose rate or high dose rate brachytherapy for the lesion with appropriate margin, defined in magnetic resonance or positron emission tomography All recruited participants will be treated with interstitial brachytherapy for local recurrence of prostate cancer. The low dose rate of brachytherapy is used with a total dose of 145 Gy in the clinical target volume for participants after hypofractionated radiotherapy, a high dose rate brachytherapy as monotherapy or boost with external beam radiotherapy The high dose rate brachytherapy with two fractions of 13 Gy in the clinical target volume with a 3 to 14 days break is used after primary low dose rate brachytherapy or external beam radiotherapy alone.
41357802|NCT03110757|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel
41357803|NCT02798172|DRUG|Alogliptin and Metformin|The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
41357804|NCT02997111|DEVICE|PFA-100|The PFA-100 will be used to assess platelet function before and after energy drink consumption.
41357805|NCT01228084|DRUG|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
41357806|NCT01228084|OTHER|Laboratory biomarker analysis|Correlative studies
41357807|NCT01228084|OTHER|Pharmacological study|Correlative studies
41357808|NCT03516227|BEHAVIORAL|heart rate variability biofeedback|The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
41357809|NCT00004728|DRUG|Warfarin|
41357810|NCT00004728|DRUG|Aspirin|
41357811|NCT04337203|BEHAVIORAL|SHARE-S Implementation Program|The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).
41357812|NCT06193733|BIOLOGICAL|Autologous Dendritic Cell|Biological: Immunotherapy with dendritic cells
41357813|NCT06107387|BEHAVIORAL|Binge Eating Self-help for Teens|Guided self-help intervention
40837446|NCT00003847|DRUG|biricodar dicitrate|
40837447|NCT00003847|DRUG|doxorubicin hydrochloride|
41022819|NCT03565718|BEHAVIORAL|Dietary Intervention: Standard/Grocery|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
41022820|NCT06045624|DRUG|OR-101 (Single ascending dose)|SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.
41160420|NCT03303521|DRUG|Placebo|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days."
41357814|NCT04896606|OTHER|Standard of Care|Patients will receive standard of care for COVID-19.
40837448|NCT00003847|DRUG|vincristine sulfate|
40837449|NCT00512291|DRUG|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
41357815|NCT04896606|BIOLOGICAL|SARS-CoV2-CTLS|Patients may receive up to 5 CTL infusions to treat SARA-CoV-2 in combination with standard of care.
41357816|NCT05465785|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
41357817|NCT01878786|DRUG|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
40837450|NCT06013436|DRUG|Autologous serum tears combined with 0.05% cyclosporin eye drop|All patients administrated autologous serum tears twelve times daily（per hour） and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.
41022821|NCT06045624|DRUG|OR-101 (Food effect)|Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group
40837451|NCT03758690|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
40837452|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
41357818|NCT01878786|DRUG|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
40837453|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
40837454|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
40837455|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
40837456|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
41022822|NCT06045624|DRUG|OR-101 (Multiple ascending dose)|MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days
41022823|NCT06045624|DRUG|Placebo|Participants will receive matching placebo across Part A and C of the study
41357819|NCT01878786|DRUG|Mycophenolate mofetil (MMF/MPA)|Control Drug
41497003|NCT05576883|BEHAVIORAL|Transdiagnostic emotion regulation intervention|"The intervention under study includes 5 therapeutic approaches, namely: Positive psychology \[PP\], Mindfulness, Acceptance and Commitment Therapy \[ACT\], Breathing and relaxation, and Self-compassion \[SC\].~The intervention consists of 4 core features:~(i) monitoring through filling in EMAs assessing participants emotional states~(ii) feedback through visualization of participant emotional states upon every completion of the EMAs~(iii) exercises targeting different emotion regulation skills \[i.e., upregulation of positive affect, mindfulness, cognitive defusion, breathing and relaxation, self-compassion) and health facts (i.e., control intervention) describing health information including nutrition, exercise, sleeping habits.~(iv) psychoeducative articles describing the 5 therapeutic approaches (PP, ACT, Mindfulness, Breathing and Relaxation, SC)"
40837457|NCT04438460|BIOLOGICAL|Blood test|"For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery."
40837458|NCT03957941|BEHAVIORAL|FamilyLink Pumping|Viewing baby via FamilyLink while pumping
40837459|NCT03957941|BEHAVIORAL|Standard Pumping|Not viewing baby via FamilyLink while pumping
41022824|NCT00022776|PROCEDURE|Surgical decompression|Simple decompression not requiring fusion.
41022825|NCT00022776|PROCEDURE|Physical therapy|2 physical therapy sessions per week for 6 weeks Followed by home program.
41022826|NCT00005619|GENETIC|polymerase chain reaction|
41022827|NCT00005619|OTHER|flow cytometry|
41022828|NCT00005619|OTHER|immunohistochemistry staining method|
41022829|NCT06531668|DIETARY_SUPPLEMENT|Beyond Hormone|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
41022830|NCT06531668|OTHER|Placebo|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
41022831|NCT06219655|PROCEDURE|thoracoscopic sympathectomy|sympathectomy
41497004|NCT02623283|OTHER|No intervention given|Participants will have a full dental examination but no operative intervention
41497005|NCT00351533|DRUG|Fish oil (eicosapentaenoic acid and docosahexanoic acid)|Liquid fish oil 7.5cc enterally every 6 hours
41022832|NCT00529945|DEVICE|PFx Closure System|
41022833|NCT06454513|PROCEDURE|general anesthesia|Different anesthesia methods
41022834|NCT05547932|PROCEDURE|RIB+SAP blocks|RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
41022835|NCT04183400|BEHAVIORAL|Safety Awareness For Empowerment (SAFE)|SAFE is a mindfulness-based cognitive-behavioral intervention that aims to build risk-related attention skills.
41022836|NCT06494735|BEHAVIORAL|MyMCT|Using the french version of the metagognitive bibliotherapy MyMCT
41357820|NCT05553886|DRUG|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug
41357821|NCT01073384|DRUG|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
41357822|NCT00993694|DRUG|chemotherapy|
40837460|NCT03843801|DEVICE|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of transmural anterior-posterior sutures in the stomach in order to achieve a gastric remodelling. Patient will be kept overnight after the procedure.
40837461|NCT03177096|BEHAVIORAL|Peds QL questionnaire and diabetes modulate|Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)
40837462|NCT03177096|BEHAVIORAL|WHO-5 questionnaire|WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children
40837463|NCT03177096|BEHAVIORAL|Felt questionnaire|Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
41022837|NCT02886845|GENETIC|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
41022838|NCT00961974|BEHAVIORAL|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
41509264|NCT04548765|BEHAVIORAL|Enhanced Fear Appeals and Decoy Effect|Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed. Inaction is presented as a decoy, which has worse outcomes than either of the screening options. Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
41022839|NCT00961974|BEHAVIORAL|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
40837464|NCT04485572|DIAGNOSTIC_TEST|Straight Leg Raise test (SLR) and Bragard test (B)|The following neurodynamic and/or orthopedic tension tests were done: the Straight Leg Raise test (SLR), the Bragard test (B) and another test which was the combined test of both (SLR+B)
41022840|NCT06572722|DRUG|Atezolizumab|atezolizumab adjuvant therapy
41022841|NCT06572722|DRUG|Nivolumab|nivolumab neoadjuvant therapy
41022842|NCT06572722|DRUG|Pembrolizumab|pembrolizumab neoadjuvant+adjuvant therapy
41509265|NCT03745079|OTHER|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
41509266|NCT03745079|OTHER|Spoton Temporal|Mesuring temperature on skin near to temporal artery using Spoton
40837465|NCT04485572|DIAGNOSTIC_TEST|Fajersztajn test (F) and Sicard test (S)|The following neurodynamic and/or orthopedic tension tests were done: the Fajersztajn test (F), the Sicard test (S) and another test which was the combination of both (F+S)
40837466|NCT04485572|DIAGNOSTIC_TEST|Passive Neck Flexion test (PNF)and Kernig test (K)|The following neurodynamic and/or orthopedic tension tests were done: the Passive Neck Flexion test (PNF), the Kernig test (K) and another test which was the combination of both (PNF+K)
40837467|NCT04485572|DIAGNOSTIC_TEST|Slump test (ST) and Dejerine triad (DT)|The following neurodynamic and/or orthopedic tension tests were done: the Slump test (ST), the Dejerine triad (DT) and another test which was the combination of both (ST+DT)
41357823|NCT00993694|DRUG|dapsone|
41357824|NCT00993694|OTHER|medical chart review|
41357825|NCT00993694|PROCEDURE|assessment of therapy complications|
41357826|NCT05824611|OTHER|collect movement data from epileptic seizures|non-invasive recording of movement data during care as usual
41357827|NCT03890029|BEHAVIORAL|Intervention Training|After pre-testing and randomization, intervention participants will meet in small groups for 60 minutes/week over eight weeks for resilience training. Participants needing extra help will receive it at the end of each session. Controls will be on a minimal attention list, not being trained. After eight weeks, all participants will be post-tested.
41357828|NCT03890029|BEHAVIORAL|Control Condition|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training.
41497006|NCT03797716|DEVICE|Little Journey app|"The Little Journey app allows children to explore 360-degree hospital environments familiarising and desensitising them to areas and staff they'll see on the day of surgery. Children can visit the day case ward, anaesthetic and recovery rooms where their operation will occur -all while feeling safe in their own home. As the child explores the three areas, they are introduced to animated characters of staff who explain what will happen, the equipment that will be used and how they might feel. Using head tracking technology, the child triggers the animated characters by looking at them; meaning they control the pace of learning and speed at which they progress. The preparatory tool follows a pre-set story-line reflecting what happens from admission to discharge on the day of surgery."
41497007|NCT02128061|DRUG|Lenalidomide|
40837468|NCT04485572|DIAGNOSTIC_TEST|MRI scan|All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard
40837469|NCT02338375|BIOLOGICAL|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
40837470|NCT04039152|OTHER|locally adapted neonatal sepsis treatment protocol|the neonatal sepsis treatment protocol was modified according to the local antibiotics susceptibility patterns
40837471|NCT01259453|BIOLOGICAL|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
40837472|NCT05335902|DIAGNOSTIC_TEST|ultrasound measurement of the optic nerve sheath diameter|ultrasound measurement of the optic nerve sheath diameter
40837473|NCT05335902|DIAGNOSTIC_TEST|MoCA test|MoCA test is a short bedside test for measuring cognitive disfunction
40837474|NCT04852510|DRUG|Metformin Versus a combination of Metformin and Thymoquinone (TQ)|Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
40837475|NCT00034879|DRUG|ZD1839 (Gefitinib)|
40837476|NCT03783494|DRUG|Target control infusion with propofol|Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
40837477|NCT04425785|OTHER|Physical Exercise Program|A structured exercise program
40837478|NCT04425785|BEHAVIORAL|Cognitive Behavioural Therapy|A structured cognitive behavioural therapy program
41357829|NCT01279421|BEHAVIORAL|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
41357830|NCT01279421|BEHAVIORAL|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
41357831|NCT00121459|DEVICE|Ortho All-Flex diaphragm and Replens lubricant gel|
41357832|NCT05613933|OTHER|Improved practices|A package of tools including: antibiotic prophylaxis guidelines reminders, periodic reminders, the Infectious Endocarditis Prevention Card for patients at risk, practical information targeting both dentists and patients, etc...
41357833|NCT02218346|DRUG|AG221|AG221 in fed and fasted conditions
41357834|NCT04568629|OTHER|Advice from the PiPS-B14 prognostic tool|"Participants were informed that prognostic advice came from the PiPS-B14 prognostic tool. PiPS-B14 is a validated prognostic algorithm that has been shown to be as accurate as an agreed multi-professional survival estimate.~Participants were further informed that in a previous study the PiPS-B14 risk categories for predicting two-week survival were as accurate as a doctor's or a nurse's prediction."
41357835|NCT04568629|OTHER|Advice from another clinician|"Participants were informed that prognostic advice came from another clinician.~Doctors were told that advice was from a nurse, whereas nurses or other types of HCPs were told that advice was from a doctor."
41497008|NCT02128061|DRUG|Rituximab|
41497009|NCT03745716|DRUG|APR-246 + azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
41497010|NCT03745716|DRUG|Azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
41509267|NCT03745079|OTHER|Spoton Carotid|Mesuring temperature on skin near to carotidl artery using Spoton
40837479|NCT04326686|OTHER|Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet|30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet
41357836|NCT01491711|DRUG|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
41357837|NCT01491711|DRUG|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
41357838|NCT05780099|OTHER|Inpatient or Outpatient visit|Patients will be seen and treated at the clinics like in the usual care
41357839|NCT04258761|DRUG|10XB-101 Solution for Injection|Active test article
41357840|NCT02206958|BEHAVIORAL|Defeating Urinary Incontinence with Exercise Training|"12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor."
41357841|NCT00000610|DRUG|magnesium|
41357842|NCT04688827|OTHER|Exercise therapy|15 weeks of resistance training (additional to endurance training)
41357843|NCT05670028|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
41022843|NCT03574389|BIOLOGICAL|13vPnC|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
41022844|NCT03574389|BIOLOGICAL|Hib|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
41509268|NCT02318212|DEVICE|Dilapan-S|Synthetic osmotic dilators Dilapan-S or Dilasoft for cervical priming prior to induced abortion
40837480|NCT05077462|DRUG|C52R1M Tab. and C52R2 Tab.|Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
40837481|NCT05077462|DRUG|AJU-C52H|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
40837482|NCT03130452|DRUG|Lansoprazole 30mg|lansoprazole 30 mg tablet
41022845|NCT05060224|DEVICE|EasyLaser: Low Level Laser therapy|
40837483|NCT03130452|DRUG|Amoxicillin 1.0g Tab|Amoxicillin 1.0g tablet
41022846|NCT00119444|PROCEDURE|Periacetabular osteotomy|osteotomy of the pelvis to increase acetabular coverage
40837484|NCT03130452|DRUG|Clarithromycin 500mg|Clarithromycin 500mg tablet
40837485|NCT03130452|DRUG|Metronidazole 500 mg|Metronidazole 500 mg tablet
41022847|NCT05333445|BEHAVIORAL|educational program|"Education for the management of AF is carried out in a structured way, following the Bowyer model using the following pre-specified subtitles: How the heart works; Causes and risk factors of AF; Symptoms of AF; Goals of treatment in atrial fibrillation ; ''preparation for the ablation procedure''; and Lifestyle Modification. The technique consists of discussing the main subtitles and adapting the visit line to the needs of each patient"
41022848|NCT05333445|BEHAVIORAL|risk factors management|identify risk factors and offer guidance based on management strategies for the specific risk factor in each case
41022849|NCT05333445|BEHAVIORAL|telephone and e-mail contact|patients will also be provided with a phone number and email to contact the nurse for any concerns outside the designated times within the twelve-month follow-up.
41022850|NCT05333445|OTHER|usual care|standard care
41160421|NCT03303521|DRUG|Sodium Zirconium Cyclosilicate (ZS)|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days."
41160422|NCT03078751|DRUG|Ribociclib|"Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib was supplied in the form of 200 mg film-coated tablets taken by mouth."
41022851|NCT05582538|DRUG|Ceralasertib|240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
41022852|NCT05582538|DRUG|Durvalumab|1500 mg i.v. day 1 (q28)
41022853|NCT05582538|DRUG|Nab-paclitaxel|100mg/m2 i.v. day 1,8,15 (q28)
41022854|NCT03394924|DRUG|EDP-305 1 mg|Two tablets daily for 12 weeks
41022855|NCT03394924|DRUG|EDP-305 2.5 mg|Two tablets daily for 12 weeks
41022856|NCT03394924|DRUG|Placebo|Two tablets daily for 12 weeks
41022857|NCT05497843|DRUG|Chiauranib|50mg, orally once daily
41022858|NCT04108039|DRUG|GnRh antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles \>14mm or E2 levels \>400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS
41022859|NCT04108039|DRUG|Micronized progesterone|Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
41022860|NCT03128749|BEHAVIORAL|Mindfulness Based Intervention|"The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams \& Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013)."
41022861|NCT03128749|DRUG|Treatment as Usual|The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
41022862|NCT05638360|DRUG|Ru Yi Jin Huang Powder|Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.
41022863|NCT05638360|DRUG|Placebo|Each patch contains 13g starch and 10c.c. water.
41022864|NCT05427149|DRUG|25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)|It will be evaluated whether there is postpinal shivering in the cases.
41022865|NCT04602520|BEHAVIORAL|3 Wishes Project|Behavioral: Focused conversations at end-of-life to promote the connections between patients, family members, and clinicians.
41022866|NCT04585334|DRUG|Tricortin 1000|Tricortin 1000 \[2 mL ampoules containing 12 mg of phospholipids and 1 mg of Vitamin B12 (Cyanocobalamin)\] will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
41022867|NCT04585334|DRUG|Itami|Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications plus Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2).
40837486|NCT00443781|PROCEDURE|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
40837487|NCT00443781|PROCEDURE|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
40837488|NCT00547040|OTHER|no intervention|no intervention
40837489|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive a second cycle of vaccination
41022868|NCT04585334|DRUG|Placebo|Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
41022869|NCT06362291|PROCEDURE|MRI-AI guided cognitive prostate targeted biopsy|Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
41022870|NCT06362291|PROCEDURE|Routine cognitive prostate targeted biopsy|Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
41022871|NCT00646958|DRUG|Radezolid|450mg PO QD
41022872|NCT00646958|DRUG|Radezolid|450mg PO BID
40837490|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive vaccination according to the guidelines.
40837491|NCT00994994|DRUG|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
41022873|NCT00646958|DRUG|Linezolid|600mg PO BID
41022874|NCT01312116|BEHAVIORAL|iCBT|Internet-delivered cognitive behavior therapy, 8 weeks
41022875|NCT01312116|BEHAVIORAL|iPDT|Internet-delivered psychodynamic therapy, 8 weeks
41022876|NCT01793857|OTHER|Data collection|Paper questionnaire
41160423|NCT03078751|DRUG|Adjuvant endocrine therapy|Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
41022877|NCT03055234|DRUG|Oral Treprostinil|Extended-release oral tablet for TID administration
41022878|NCT03055234|DRUG|Placebo|Matching placebo for TID administration
41022879|NCT00587145|DRUG|S-1,Docetaxel|"* S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~* Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
41022880|NCT06414291|OTHER|Plain Water|Plain water without calories, sweetener, or electolytes
41022881|NCT06414291|OTHER|Liquid IV Hydration Multiplier|Drink with 22 grams of carbohydrate, 1020 milligrams of sodium, and 760 milligrams of potassium per liter. Hydration multiplier liquid IV
41022882|NCT06414291|OTHER|Liquid IV Sugar Free|10 grams of carbohydrate, 1060 milligrams of sodium, and 760 milligrams of potassium per liter. Sugar free Liquid IV
41022883|NCT06563323|DRUG|Guselkumab|Subjects with PG will be treated with 100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks.
41022884|NCT04870151|PROCEDURE|Anterolateral approach|Cemented hemiarthroplasty using an anterolateral approach.
41497011|NCT03555331|BEHAVIORAL|Child Safety Control Intervention|In the study period which spanned from early infancy through age 3 years, the child safety intervention group was given an educational program with messages focused on child and home safety, guided by the American Academy of Pediatrics and the Academy's guide for health supervision, Bright Futures. The observation-only study extension will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
41497012|NCT03555331|BEHAVIORAL|Responsive Parenting Intervention|During infancy, the Responsive Parenting group was given an educational program containing messages providing developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle aimed at preventing rapid weight gain in infancy and overweight at age 3 years. The new study period will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
41497013|NCT00944619|DEVICE|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
41497014|NCT00944619|DEVICE|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
41497015|NCT06632522|DRUG|radiotherapy combined with Camrelizumab and Apatinib|Camrelizumab is administered intravenously (without preventive medication), with a fixed dose of 200mg, with an infusion of 30 min (not less than 20 min and not more than 60 min) every three weeks. Apatinib, 250 mg, taken orally within half an hour after meals, QD, continuously.
41497016|NCT05775952|BIOLOGICAL|HRV-39|We will use a US Food and Drug Administration (FDA) approved Good Manufacturing Practices (GMP)-grade HRV-39 for our proposed study. Use of this GMP-grade HRV-39 viral stock ensures compliance with recent regulatory agency requirements which, beginning in 2001, have mandated that HRV preparations used for human inoculation be made under Good Manufacturing Practices (GMP). This proposed clinical study will allow us to address fundamental questions regarding the nature, kinetics and potential mechanisms of upper and lower airway inflammatory responses in subjects with well-controlled mild-moderate asthma and in healthy, non-asthmatic control subjects; a better understanding of these mechanisms may lead to new paradigms in the treatment of virally-induced airway remodeling and asthma exacerbations.
41497017|NCT05640336|PROCEDURE|Single Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint. The polyethylene (plastic) insert, which acts as the articulating surface (modular component) of the prosthesis, will be removed and the exposed surfaces scrubbed, sterilized, and soaked. A new modular component will be placed with additional irrigation and antiseptic soak. Tissue cultures will be sent to the lab for further evaluation and antibiotic guidance. After the operation subjects will continue six weeks of IV antibiotics followed by oral antibiotic suppression for the life of the implant or at least two years after operation.
41497018|NCT05640336|PROCEDURE|Planned Double Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint with an additional irrigation and debridement scheduled for approximately 5 days after the initial DAIR. During the first washout, antibiotic cement beads will be placed in the joint and these will remain in the interim until they are removed during the second washout. During the second DAIR, the antibiotic beads are removed, and the modular components are once again removed and replaced with new components. Exposed surfaces are again irrigated and debrided following a standardized protocol. A six-week course of IV antibiotics will follow the DAIR with additional oral antibiotics for the life of the component (standard of care) or at least a minimum of two years.
40837492|NCT04552327|DEVICE|Solcera|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
41357844|NCT03815955|BEHAVIORAL|Non-Sedentary Behaviour Modelling|Consistent with social learning theory, the primary care provider and the DIGMA support team will model, demonstrate, and verbalize aspects of increased confidence to perform the 1-hour appointment in a standing position and offer a variety of strategies to cope and overcome any feelings of discomfort. Emphasis will be placed on the strategies the primary care team uses to break sitting with standing and light, incidental movements. It will be anticipated that the participant will observe cues and relevant information specific to their behaviour change and engage in minimal sedentary behaviour.
40837493|NCT04552327|DEVICE|Placebo|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
41357845|NCT03515265|OTHER|Fiber reinforced resin composite restoration|a type of resin composite with improved strength due to the fiber's action
41357846|NCT03515265|OTHER|Microhybrid resin composite restoration|a type of conventional resin composite
41357847|NCT03917394|DRUG|rHuEPO|rHuEPO was administrated daily with 10000 IU or 20000 IU
41357848|NCT03917394|DRUG|Iron sucrose|Iron sucrose was administrated daily with 100mg or 200mg
40837494|NCT04552327|DRUG|Solaraze|Twice daily application for a duration of 60 days
40837495|NCT01256021|DRUG|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
41022885|NCT04870151|PROCEDURE|Direct lateral approach|Cemented hemiarthroplasty using a direct lateral approach.
41022886|NCT03022357|OTHER|Patient assessment|Clinical examination, Examination, Questionnaires
41022887|NCT03022357|RADIATION|DATScan|In small subgroup
41022888|NCT03022357|RADIATION|Orbital X-Ray|If foreign body in eye needs exclusion
41022889|NCT03022357|OTHER|Magnetic Resonance Imaging (MRI)|MRI scanning of all subjects
41022890|NCT02242786|RADIATION|External beam radiation therapy|
40837496|NCT05732636|OTHER|Validation study|"The whole protocol is divided into two stages: Urdu Translation and validation. Following steps were involved.~1. First version (Forward Translation): Forward translation from the English to Urdu by two bilingual translators (Version 1)~2. Second Version: Three experts compared the original FADI with urdu version of FADI.~3. Backward translation: Version 2 was translated Back in English by an independent translator.~4. Third Version: was finalized after tracking differences in forward and backward translation.~5. Final Version: of Urdu FADI was used on Chronic Ankle Instability patients.~Foot and Ankle Disability Index(FADI) Urdu version was introduced and the patients were asked to fill FADI Urdu version. The questionnaire was filled again by the same participants after one week to assess the test retest reliability."
40837497|NCT04980365|BEHAVIORAL|Mindfulness|Participants will be asked to use the app Mindfulness Coach daily for 10 minutes. Participants will follow app instructions for brief guided meditation sessions for 14 days.
40837498|NCT04980365|BEHAVIORAL|Gratitude|Participants will be asked to use the app Grateful daily for 10 minutes. Participants will follow app instructions and will be answering to prompts related to gratitude provided by the app daily, for 10 minutes for 14 days.
40837499|NCT04980365|BEHAVIORAL|Food Journal|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
40837500|NCT03143751|DRUG|NaCl20% (Continuous hyperosmolar therapy)|"Early intravenous administration (\<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ \< 145 mmol/L; 7.5 g if 145 \< Na+ \< 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+\< 150 mmol/L, reduced to 0.5 g/L if 150 \< Na+ \< 155 mmol/L, Discontinuation when 155 mmol/L\<Na+"
40837501|NCT00876785|OTHER|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
40837502|NCT00876785|OTHER|wheat bread based breakfast|Reference wheat bread breakfast
40837503|NCT00233012|DRUG|Topiramate|
40837504|NCT02903394|DEVICE|mLCI Device|imaging of cervical epithelium using mLCI device
40837505|NCT02605317|OTHER|WhatsApp|Consultations used WhatsApp Messenger
41357849|NCT04001699|OTHER|Preoperative geriatric assessment|In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.
41357850|NCT05043194|DRUG|Ursodeoxycholic Acid 250 Mg Oral Capsule|prevention
40837506|NCT01274611|DRUG|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
40837507|NCT01274611|DEVICE|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
40837508|NCT00319241|BEHAVIORAL|Parenting Intervention|
40837509|NCT04649047|BEHAVIORAL|Goal-oriented episodic future thinking|All participants will receive a 3-week web-based intervention plus individual health coaching. The intervention topics include stress management, healthy eating, and physical activity
40837510|NCT03510325|DRUG|Olanzapine|Commonly used oral antipsychotics intervention therapy.
40837511|NCT03510325|DRUG|Risperidone|Commonly used oral antipsychotics intervention therapy.
40837512|NCT03510325|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
40837513|NCT03510325|DRUG|Amisulpride|Commonly used oral antipsychotics intervention therapy.
40837514|NCT03510325|DRUG|Paliperidone long-acting injection|long-acting injection
40837515|NCT02237482|DEVICE|Trilogy cup|
40837516|NCT02237482|DEVICE|Trabecular metal cup (TM)|
41357851|NCT03763292|BEHAVIORAL|Specific information brochure|A purpose-designed brochure about anesthesia and surgery in the ear in children is developed by the investigators. This brochure has photos and describes the procedures the child is going through.
41357852|NCT00424736|PROCEDURE|whole body CT scan|
40837517|NCT02237482|DEVICE|ZCA cup|
40837518|NCT05607329|PROCEDURE|Secondary cytoreduction|Open surgery is conducted by senior clinicians in gynecological oncology. Operation time，location and number of relapsed lesions, location and number of excised lesions, Whether achieved R0 or not, and other information are recorded.
40837519|NCT05607329|DRUG|Chemotherapy|chemotherapy
41357853|NCT03670056|DRUG|Combination immunotherapy with Ipilimumab and Nivolumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
40837520|NCT05738720|DEVICE|Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer)|Pulmonary Function Test (PFT): Pulmonary function test will be performed with a Teknikel Spirobank home pulmonary function test device. In the study group, the patient will make weekly measurements at home and send it to the physiotherapist. In the control group, evaluation will be made with the device only at the beginning and end of the treatment.
40837521|NCT05738720|OTHER|Exercise Programme|"Exercise Program~* Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~* Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~* Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test."
41497019|NCT01246063|DRUG|carfilzomib|
40837522|NCT04014387|DRUG|Suvorexant|Suvorexant (Belsomra) is an FDA approved, dual orexin receptor antagonist. It is prescribed for insomnia, reducing time to sleep onset, and to maintain nighttime sleep.
40837523|NCT04014387|DRUG|Zolpidem|Zolpidem (Ambien) is an FDA approved, Benzodiazepine Receptor agonist that has been extensively studied for the treatment of insomnia in older adults. It acts as a sedative and is typically prescribed to treat insomnia, reducing time to sleep onset, but may not alter the ability to maintain sleep.
40837524|NCT04014387|DRUG|Placebo oral capsule|Placebo (microcrystalline cellulose) capsules will be used.
40837525|NCT02303106|DRUG|Lamotrigine|
40837526|NCT00439452|OTHER|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
40837527|NCT00439452|OTHER|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
41022891|NCT01200121|DRUG|Bevacizumab|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
41022892|NCT01200121|OTHER|Placebo|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
41022893|NCT04064697|DRUG|Valganciclovir|The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
41022894|NCT06208527|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of 2000 mg NR is administered daily for 1 year.
41022895|NCT06208527|OTHER|Placebo|Placebo tablet identical in taste, shape and appearance to NR tablets.
41022896|NCT02200042|RADIATION|Image Guided Radiation Therapy|Patients undergo 15 fractions of image-guided radiation therapy delivered over 19-26 or 27-34 days.
41022897|NCT04408443|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 + Vitamine D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
41022898|NCT04408443|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
41022899|NCT04564352|DIETARY_SUPPLEMENT|Adansonia digitata|Juice of AD fruit
41160424|NCT03078751|DRUG|Placebo|"Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth."
41160425|NCT02444884|DRUG|MLN8237|
41160426|NCT00953342|BEHAVIORAL|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
41160427|NCT00953342|BEHAVIORAL|Usual care|Standard medical care
41160428|NCT01974661|BIOLOGICAL|COMBIG-DC (ilixadencel)|Allogenic dendrite-cell based therapeutic vaccine
41160429|NCT01249599|PROCEDURE|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
40837528|NCT00444977|BEHAVIORAL|Case-management linkage intervention|dental care
41357854|NCT03145857|DRUG|[68]Ga-HA-DOTATATE|All participants will be injected with \[68\]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
40837529|NCT05119140|DRUG|Hydroxychloroquine|400mg of hydroxychloroquine per oral daily
41357855|NCT02500706|DRUG|Faster-acting insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
41357856|NCT02500706|DRUG|insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
40837530|NCT05119140|DRUG|Mesalamine|the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
40837531|NCT04208048|DEVICE|FLXfit 15TM device|In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
40837532|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (English)|completing the English version of the AGPM and validated health literacy and numeracy instruments
41160430|NCT01703988|DRUG|Nusinersen|Single IT injection for each dose
41160431|NCT03121729|PROCEDURE|enhanced recovery after surgery|Undergo an enhanced recovery after surgery program
41160432|NCT05818137|BIOLOGICAL|Sotatercept|SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.
41160433|NCT03986983|DEVICE|Shockwave therapy|Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.
41160434|NCT03986983|OTHER|Aerobic exercise|Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
41160435|NCT05029349|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
41160436|NCT02953028|DEVICE|CPAP|Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
41160437|NCT02953028|DEVICE|Mandibular Advancing Splint|Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
41022900|NCT04578314|BEHAVIORAL|Relating Therapy|Relating Therapy (RT) is a symptom-specific behaviourally oriented intervention that targets interpersonal relating as a key mechanism associated with auditory hallucination distress. The aim is that patients learn to relate more assertively within the difficult relationships they have with both the auditory hallucinations and other people. The RT will follow a treatment manual consisting of three phases: 1. Socialization to relating therapy and its implications; 2. Exploration of themes within the relational history of the participant and their experience of relationships with AH, and interpersonal relating within the family and social environment (identifying any prominent themes, such as abuse, disempowerment, or rivalry); 3. Exploration and development of assertive approaches to relating to AH and other people.
41022901|NCT04578314|OTHER|Treatment as usual|TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.
41022902|NCT01546493|RADIATION|MRI|MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.
41022903|NCT01546493|RADIATION|qCT|Quantitative computed tomography(QCT) scans using a CT phantom
41497020|NCT01246063|DRUG|pegylated liposomal doxorubicin (PLD)|
41497021|NCT01246063|DRUG|Dexamethasone|
41497022|NCT01679639|DRUG|aleglitazar|Single dose of aleglitazar in Periods 1, 2, 3
41497023|NCT01679639|DRUG|rifampicin|Single dose in Periods 1 and 2; multiple doses in Period 3
41497024|NCT05962203|DIAGNOSTIC_TEST|Multi-factorial geriatric assessment, monitoring & management systems|Multi-factorial geriatric assessment, monitoring \& management systems, e.g. community-based and home-based exercise programs, polypharmacy
41497025|NCT03509805|DIAGNOSTIC_TEST|polysomnography|
41497026|NCT01759732|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -4
41497027|NCT01759732|DRUG|Cyclophosphamide|60 mg/kg IV on day-3 and -2
41497028|NCT01759732|BIOLOGICAL|anti-thymocyte globulin|
41497029|NCT01759732|BIOLOGICAL|filgrastim|
41497030|NCT01759732|RADIATION|Total body irradiation|200 cGy per day on D-5 \& -4
40837533|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (Spanish)|completing the Spanish version of the AGPM and validated health literacy and numeracy instruments
40837534|NCT02974894|DIETARY_SUPPLEMENT|Probiotic (Lactobacillus Plantarum)|
41022904|NCT01546493|OTHER|Motion Analysis|3D motion analysis to assess hip function.
41022905|NCT01546493|RADIATION|PET-MRI|Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that will help us examine bone and cartilage at the molecular level.
41022906|NCT06574022|DRUG|Bupivacain|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 30 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
41497031|NCT01759732|PROCEDURE|CD3-depleted hematopoietic cell transplantation|Immunogenetic depletion on CliniMACS
41497032|NCT01844466|PROCEDURE|Physiotherapy and speech therapy|
41497033|NCT03200912|DRUG|Ingenol Mebutate (Picato®)|Brand product
41497034|NCT03200912|DRUG|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
41497035|NCT03200912|DRUG|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
41497036|NCT04405167|DRUG|Tasquinimod|Tasquinimod will be supplied as oral capsules.
41497037|NCT04405167|DRUG|IRd chemotherapy|IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
41497038|NCT06340763|DEVICE|JETi Hydrodynamic Thrombectomy System|The JETi Hydrodynamic Thrombectomy System is a hydro-mechanical aspiration system intended for the removal of intravascular thrombus. The system is comprised of the JETi Catheter, JETi Pump Set, and JETi Saline Drive Unit (SDU), accessory cart, suction tubing, and non-sterile canister set. The JETi System is designed to simultaneously deliver a stream of high-pressure saline via a displacement pump to the distal tip of the JETi Catheter, while aspirating thrombotic material macerated by the saline stream.
40837535|NCT02974894|DIETARY_SUPPLEMENT|Placebo|
40837536|NCT03255538|OTHER|DFM: Mean pressure|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.
41357857|NCT02500706|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
40837537|NCT03255538|OTHER|DFM: Mean pressure - 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.
40837538|NCT03255538|OTHER|DFM: Mean pressure + 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
41357858|NCT00002276|DRUG|Ibuprofen|
41497039|NCT06633211|PROCEDURE|Alveolar ridge preservation using DBBM + Regenfast + collagen matrix|Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland) mixed with polynucleotide and hyaluronic acid-based gel (Regenfast®). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
41022907|NCT06574022|DRUG|Exparel|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 20 cc of Exparel mixed with 10 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
41022908|NCT06574022|PROCEDURE|Intraoperative Pecs II block (IOB) & superior AT (EX or BP)|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle with superior anesthetic as determined by stage I, after mastectomy completion and prior to reconstruction, if performed, or wound closure.
41022909|NCT06574022|PROCEDURE|Preoperative Pecs II block (POB) & superior AT (EX or BP)|Preoperative Pecs II block to be administered by 1 of 6 acute pain specialized anesthesiologists in same day surgery. Patient will be lightly sedated with midazolam, at the discretion of the anesthesiologist. The pecs II block will be performed under ultrasound guidance using a 21-gauge, 80 mm length needle to administer the superior anesthetic as determined in stage I.
41022910|NCT04932174|OTHER|High-intensity Interval Training|"Consisting of the following program:~* Warming up period for 10 minutes at 60-70% of HR max.~* Training phase 4x4 min intervals at 85-90% of HRmax with a 3 min active recovery at 70% of HRmax between each interval.~* Duration of HIIT 4 minute~* Number of interval per session 4~* Duration of rest interval 3 minute 3-10 min cool-down period, giving a total of 60 min."
41497040|NCT06633211|PROCEDURE|Alveolar ridge preservation using DBBM + collagen matrix|Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
41357859|NCT00002276|DRUG|Zidovudine|
41357860|NCT00996385|DRUG|Velcade (bortezomib) plus Eloxatin (oxaliplatin)|One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
41497041|NCT00555386|DIETARY_SUPPLEMENT|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
41509269|NCT01277159|DRUG|A. Control Nerve Block. IV Dexamethasone (4 mg).|A. Control Nerve Block. IV Dexamethasone (4 mg).
40837539|NCT02967939|DRUG|DA-2802|DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.
40837540|NCT02967939|DRUG|Viread®|Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
41022911|NCT04932174|OTHER|Low-intensity Continuous Training|"Consisting of the following program:~* Warming up period for 10 minutes.~* Training phase for 60-minute walking on a treadmill at intensity 40-50% HRR (1- 6) weeks then 60-70% HRR (7-12) weeks.~* cooling down period for 10 minutes."
41022912|NCT05515432|DRUG|Single oral dose of BAY3283142 IR (immediate release) tablet|Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design
41357861|NCT01446744|RADIATION|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
41509270|NCT01277159|DRUG|B. Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
40837541|NCT00560495|DRUG|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
40837542|NCT00560495|OTHER|immunoenzyme technique|
41509271|NCT01277159|DRUG|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
41509272|NCT01277159|DRUG|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
40837543|NCT00560495|OTHER|laboratory biomarker analysis|
40837544|NCT00560495|RADIATION|Tc 99m sestamibi|
40837545|NCT00560495|RADIATION|radiation therapy|once daily, 5 days a week, for 6-7 weeks
40837546|NCT03690180|DIAGNOSTIC_TEST|serum magnesium|assessment of serum magnesium in all patients
40837547|NCT03837288|PROCEDURE|Cerclage|Cervical cerclage under effect of spinal anaesthesia
41022913|NCT02259530|BEHAVIORAL|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
41022914|NCT00501150|DRUG|linezolid|Linezolid is an antimicrobial with activity against MRSA that can be given orally.
41022915|NCT03676049|DRUG|Cannabidiol|CBD will be administered as an adjunct to all current antiepileptic drugs. A dosing titration period will start with 100 mg/day, with 50mg BID dosing, and will be titrated monthly as tolerated based on clinical response, up to 300mg/day. This is based on a targeted dosing of 2.5 ---5---7.5 mg/kg/d.
41022916|NCT04181034|BEHAVIORAL|Adolescent Family Life Program Positive Youth Development (PYD) program|Home visiting program for pregnant and parenting teens with PYD component
41022917|NCT04181034|BEHAVIORAL|Adolescent Family Life Program (AFLP)|Home visiting program for pregnant and parenting teens
41022918|NCT03112772|OTHER|Puros® Allograft|It is a type of bone grafting materials used for enhancing bone formation
40837548|NCT04515368|BIOLOGICAL|Immunization|Immunisation with one of four licensed vaccines
40837549|NCT04064346|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
40837550|NCT04064346|DRUG|Placebo|Matching placebo
40837551|NCT03132025|DRUG|"Apatinib and Capecitabine"|"Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
40837552|NCT03132025|DRUG|"Capecitabine"|"Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
41022919|NCT03112772|OTHER|CopiOs® Cancellous Particulate|It is a type of bone grafting materials used for enhancing bone formation
41022920|NCT00006411|OTHER|corneas assigned by donor age group|A web-based computer program was used to select and assign a cornea by donor age group from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors \>=66 and \<66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
41022921|NCT06573489|DRUG|Fospropofol|Use fospropofol for general anesthesia maintenance
41022922|NCT06573489|DRUG|Propofol|Use propofol for general anesthesia maintenance
41357862|NCT01446744|RADIATION|palliative radiotherapy|"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice"
41357863|NCT02327182|DRUG|MT-4666|
41357864|NCT02212249|BIOLOGICAL|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
40837553|NCT01518504|OTHER|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
40837554|NCT01518504|OTHER|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
40837555|NCT02621073|DRUG|VeraFlo with Prontosan|VeraFlo device with Prontosan instillation (n=10).
40837556|NCT02621073|DEVICE|V.A.C Ulta System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
40837557|NCT00096330|DIETARY_SUPPLEMENT|dietary intervention|oral folic acid supplementation once daily on days 57-84
40837558|NCT00096330|DIETARY_SUPPLEMENT|folic acid|oral folic acid supplementation once daily on days 1-56.
40837559|NCT06302894|BEHAVIORAL|Self-sufficiency|Rewarding positive behavior and developing alternative behaviors towards obstacles such as feeling restless, depressed or angry if internet use is reduced or controlled.
40837560|NCT02850900|BEHAVIORAL|Internet Survey|Weekly survey will be emailed, subjects should complete them
40837561|NCT03289949|DRUG|Psilocybine|Oral dose of psilocybine.
41357865|NCT01342627|DRUG|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued."
41357866|NCT00191438|DRUG|gemcitabine|
41357867|NCT00191438|DRUG|capecitabine|
41357868|NCT00191438|DRUG|docetaxel|
41357869|NCT05603481|DEVICE|Continuous Glucose Monitor|Patients will wear a CGM device on their arm for 10 days, while receiving standard of care blood draws and finger stick sugar checks.
40837562|NCT03289949|DRUG|Ketanserin|Oral dose of ketanserin.
40837563|NCT02400944|BEHAVIORAL|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
40837564|NCT02400944|OTHER|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
40837565|NCT05037084|OTHER|no intervention|no intervention
40837566|NCT05205655|BEHAVIORAL|collection of odour samples|Odours will be collected by participants by putting sterile compresses under the armpits for at least 4 h.
40837567|NCT03759964|DRUG|Ferric carboxymaltose|1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
40837568|NCT03759964|DRUG|Placebo|100 mL of IV isotonic serum saline at day 1 following surgery
41357870|NCT04887012|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR
41357871|NCT02552537|DRUG|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
40837569|NCT01573481|OTHER|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
40837570|NCT01573481|OTHER|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate \> or equal to 12 breath per min).
40837571|NCT02299076|BEHAVIORAL|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
41022923|NCT03127124|DRUG|NANT-008|Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI)
41022924|NCT03127124|DRUG|Fluorouracil Injectable Product|5-fluoro-2,4 (1H,3H)-pyrimidinedione.
41022925|NCT03127124|DRUG|Avastin Injectable Product|Recombinant humanized monoclonal IgG1 antibody
41357872|NCT02552537|DRUG|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
41357873|NCT02288793|OTHER|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
41357874|NCT04361695|PROCEDURE|Hemorrhoidectomy|The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.
41357875|NCT04361695|DRUG|Ketoprophenum|Ketoprophenum
41357876|NCT04361695|DRUG|Placebo|Placebo
41357877|NCT06006676|OTHER|Near Apnoeic ventilation|Near Apnoeic ventilation (with a respiratory rate of 2 breaths per minute, plateau pressure of 30cmH20 and PEEP set according to the mean airway pressure being delivered during mechanical ventilation prior to randomisation) for a 72 hour period following randomisation
41357878|NCT06006676|OTHER|Crossover standardised ECMO weaning trials|"When all patients are eligible for a trial of ECMO weaning, they will have standardised ECMO weaning trials lasting up to 1 hour with 0 sweep gas flow. 1) One-stage weaning- sweep gas flow rate sequentially decreased to zero 2) Two-stage weaning- fraction of oxygen of sweep gas flow decreased to 0.21 sequentially. Then the sweep gas flow rate decreased to 0 sequentially"
41357879|NCT02275949|DEVICE|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
41357880|NCT02275949|DEVICE|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
41357881|NCT02275949|DEVICE|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
41357882|NCT02275949|DEVICE|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
41357883|NCT02275949|DEVICE|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
41357884|NCT01773057|OTHER|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
41357885|NCT06220227|PROCEDURE|vitrification and thawing procedures|"Vitrification and thawing are crucial steps in infertility treatment. Vitrification solutions are aqueous cryoprotectant solutions that undergo solidification (and not freezing) when cooled at high rates to very low temperatures, thanks to an increase in viscosity.~Thawing consists in remove the cryoprotectants, warm and dilute the blastocyst."
40837572|NCT02299076|OTHER|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
41357886|NCT06241144|DEVICE|Information and communication technology -based health behavior change support system|Information and communication technology -based health behavior change support system addition to conventional postpartum lifestyle education
41357887|NCT03273868|OTHER|High velocity low amplitude manipulation|The researcher manually applies a preload force on the T5/T6 level followed by a single posterior to anterior thrust.
41357888|NCT03273868|OTHER|Sham manipulation|The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
41497042|NCT03213730|OTHER|3D-MOT Neurotracker|"A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks."
41509273|NCT01277159|DRUG|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
41357889|NCT03651011|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.
41357890|NCT03651011|PROCEDURE|Navigated laser photocoagulation|Navigated laser photocoagulation planned from flourscein angiography.
41357891|NCT05834673|DRUG|Inclisiran Prefilled Syringe|Inclisiran, 284 mg, 1.5 ml Liquid in a single-use prefilled syringe (PFS) for s.c. administration and any standard medications to be used within registered indication and at the treating physician's discretion.
41357892|NCT05834673|OTHER|SMS messages|Participants will receive monthly SMS messages regarding cardiovascular health (low touch engagement nudges)
41357893|NCT05834673|OTHER|Telephone-based support calls|Participants will receive telephone-based support calls from a study nurse trained in motivational interviewing. These telephone calls will cover diet, exercise, medication, and where necessary smoking cessation. A summary of any recommendations will then be sent to the primary care physician via email or letter.
41357894|NCT02612558|DRUG|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
41357895|NCT02963194|DRUG|Oxytocin|
40837573|NCT06487728|DIAGNOSTIC_TEST|Urinary titin|Urinary titin and skeletal muscle index as predictor of muscle wasting in critically ill patient
40837574|NCT00199667|DRUG|Mycophenolate Mofetil|
40837575|NCT03927079|BIOLOGICAL|measure of intra-alveolar antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
40837576|NCT03927079|PROCEDURE|broncho-alveolar lavage (BAL)|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
40837577|NCT03927079|BIOLOGICAL|blood test to measure plasmatic antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
41357896|NCT02963194|DRUG|Placebo|
41357897|NCT05779280|OTHER|THDA + Acetyl Zingerone Topical Product|A skin care product with Acetyl Zingerone (Synoxyl® AZ) and THDA (VitaSynol® C) used twice daily
41357898|NCT05779280|OTHER|THDA|A skin care product with THDA (VitaSynol® C) used twice daily
41357899|NCT00082628|DRUG|Placebo|Placebo matched to serostim® as subcutaneous injection.
41357900|NCT00082628|DRUG|Serostim® 4 mg|Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
41357901|NCT00082628|DRUG|Serostim® 2 mg|Serostim® 2 mg as subcutaneous injection on alternate days.
41357902|NCT04417166|DRUG|Pembrolizumab|50 mg powder for concentrate for solution for infusion
40837578|NCT01317511|DIETARY_SUPPLEMENT|Protein|Protein drink
40837579|NCT01256762|DRUG|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
40837580|NCT01256762|DRUG|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
40837581|NCT01256762|DRUG|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
40837582|NCT02238015|PROCEDURE|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
41022926|NCT03127124|DRUG|Leucovorin Calcium Injection|Calcium N -\[p -\[\[\[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1).
41022927|NCT03127124|DRUG|Eloxatin Injectable Product|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum.
41022928|NCT01807130|OTHER|Automated HF/EP Referral|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
41022929|NCT01807130|OTHER|Placebo (Registry Arm)|Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
41022930|NCT02703935|BEHAVIORAL|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included an associate professor, an assistant professor and a research student at a local university, a pediatric oncologist and oncology nurse and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.
41022931|NCT02703935|BEHAVIORAL|Placebo Control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museums and theme parks and galleries
41160438|NCT06446024|DEVICE|Mechanical aspiration thrombectomy|Mechanical thrombectomy is an endovascular technique for removing blood clots from vessels. Penumbra's Indigo system actively extracts thrombus using a continuous vacuum pump, enabling aspiration of thrombus of various sizes and lengths.
41160439|NCT00912275|DRUG|lapatinib plus oral vinorelbine|Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
41357903|NCT04417166|RADIATION|Involved Field Radiation Therapy|"50-54 Gy Involved Field Radiation Therapy (IFRT) as proposed by the International Lymphoma Radiation Oncology Group (ILROG) guidelines. 50 Gy is recommended in patients without primary tumor invasiveness (invasion to adjacent tissue and/or organs), 54 Gy in locally advanced cases (invasion to adjacent tissue and/or organs) or with other risk factors (age \> 60 years, stage II, elevated serum LDH levels).~Intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended but not mandatory; 3-dimensional conformal RT (3D-CRT) is allowed."
40837583|NCT02098889|DRUG|hyoscine-N-butyl bromide(HBB)|A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
40837584|NCT02098889|DRUG|Saline|placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
40837585|NCT06337591|PROCEDURE|VI-RADS|Patients with suspected bladder cancer underwent multiparametric magnetic resonance imaging (mMRI) and vescical imaging reporting and data system (VI-RADS) score calculation. After trans-urethral resection of bladder (TURB), the results of biopsy were compared to the VI-RADS score to verify their concordance.
40837586|NCT03636607|DIAGNOSTIC_TEST|PET/CT dynamic scan|The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
40837587|NCT04353882|OTHER|Assess the difference in MOR-1 expression between healthy and tumor tissue|Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
40837588|NCT00412074|DRUG|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
40837589|NCT00412074|DRUG|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
40837590|NCT00412074|DRUG|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
40837591|NCT00947414|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
40837592|NCT00947414|DEVICE|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
40837593|NCT02744417|BEHAVIORAL|Smoking cessation counseling|Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques
41357904|NCT01053806|DRUG|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
41357905|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 5µg|
40837594|NCT02744417|PROCEDURE|Non-surgical periodontal therapy|Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
40837595|NCT02744417|DRUG|Nicotine replacement therapy|Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)
40837596|NCT02744417|DRUG|bupropion hydrochloride|bupropion hydrochloride 150mg
40837597|NCT02744417|DRUG|Varenicline|Varenicline 0,5mg
40837598|NCT02189408|BIOLOGICAL|Platelet rich plasma|
40837599|NCT03963089|PROCEDURE|Tidal volume_6mL/kg|Set tidal volume to 6mL/kg for 1 minute
40837600|NCT03963089|PROCEDURE|Tidal volume_10mL/kg|Set tidal volume to 10mL/kg for 1 minute
40837601|NCT03963089|PROCEDURE|Tidal volume_14mL/kg|Set tidal volume to 10mL/kg for 1 minute
41022932|NCT06532422|PROCEDURE|Partial or total laparoscopic nephrectomy|Nephrectomy is currently the primary indication for localised kidney cancer. All patients consulting a surgeon at the Clinique de la Sauvegarde for localised kidney cancer, for which surgical excision has been validated by the multidisciplinary consultation meeting and who are eligible for outpatient treatment, will be offered the opportunity to take part in this study during the preoperative consultation.
41357906|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 10µg|
41022933|NCT02067013|DRUG|Ranibizumab|Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.
41022934|NCT02067013|OTHER|No Ranibizumab|Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
40837602|NCT03963089|PROCEDURE|Fluid loading|Administer 10mL/kg of crystalloid for 5 minutes
41160440|NCT02212301|DEVICE|senofilcon A|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
41357907|NCT04421105|DRUG|Lysergic acid diethylamide (LSD)20 µg|
41357908|NCT04421105|DRUG|Placebo|
41357909|NCT04657003|DRUG|Tirzepatide|Administered SC
41357910|NCT04657003|OTHER|Placebo|Administered SC
41357911|NCT02838186|PROCEDURE|retroflexion|examination of the right colon with scope retroflexion
40837603|NCT03530332|DIAGNOSTIC_TEST|PreTRM test|Blood test to determine risk of preterm birth
40837604|NCT03631212|BEHAVIORAL|Flexiquit|Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
40837605|NCT03158350|OTHER|Instructed Brushing Method|Stationary Bristle Technique
41357912|NCT02838186|PROCEDURE|forward view|examination of the right colon in forward view
41357913|NCT02499380|DEVICE|PneumRx Coil System|
40837606|NCT00819494|PROCEDURE|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
40837607|NCT04190797|DEVICE|Photobiomodulation + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
40837608|NCT04190797|DEVICE|Placebo + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
40837609|NCT05147103|DEVICE|Low-Intensity Focused Ultrasound|LIFU application using various durations, responses of neuromodulation recorded using TMS and EMG.
40837610|NCT04940936|BEHAVIORAL|A Patient Decision Aid|The Patient Decision Aid informs about the pros and cons of each option
40837611|NCT04593459|DIETARY_SUPPLEMENT|Probiotic|See Arm description
40837612|NCT04593459|DRUG|Metformin Hydrochloride|See Arm description
41160441|NCT02212301|DEVICE|lotrafilcon B|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
41357914|NCT00981266|DEVICE|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
41022935|NCT05401123|DEVICE|milking pump|"n the study, all mothers who come to the Lactation/Relactation outpatient clinic will be informed about the study, and mothers who accept the study will have to fill out the Conformity to Criteria Form created by the researcher. Between the ages of 20-35, postpartum 1-5. Participants who gave birth after the 37th week of pregnancy, did not have literacy problems, mental disabilities and communication problems, did not have chronic diseases, did not use any medication, and volunteered to participate in the study will be included in the study. by milking, 2 ml of first milk will be taken from the participants in the control group (via the milking pump). The collected milk will be taken to the laboratory for analysis by the researcher."
41022936|NCT04170647|DRUG|Plasminogen Activators|standard dosage of 0.9 mg/kg or reduced dosage of 0.6 mg/kg, divided into a 15% bolus and an 85% venous infusion
41022937|NCT00013897|DRUG|Atazanavir|
41022938|NCT00013897|DRUG|Lamivudine/Zidovudine|
41160442|NCT02772445|BEHAVIORAL|STROKE-CARE|In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
41160443|NCT01298219|DRUG|Lubiprostone|24 mcg administered orally twice daily (BID)
41357915|NCT04706715|OTHER|89Zr-DFO-REGN3767|Anti-LAG-3 PET imaging tracer
41357916|NCT04706715|DRUG|Cemiplimab|Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
41160444|NCT01298219|DRUG|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
41160445|NCT01909947|OTHER|Cardiorespiratory signal acquisition|"Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:~1. A 60-minute period while the infant receives any mode of conventional mechanical ventilation~2. A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant"
40837613|NCT04593459|DIETARY_SUPPLEMENT|Probiotic Placebo|See Arm description
40837614|NCT02221154|DIETARY_SUPPLEMENT|Inofolic®|
40837615|NCT02221154|OTHER|Gonadotropins; Folic Acid|standard ovarian stimulation
40837616|NCT01360177|PROCEDURE|124 PET/CT imaging|Standard of Care
41022939|NCT00013897|DRUG|Efavirenz|
41022940|NCT01099995|OTHER|Hyperbaric oxygen therapy|one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
41022941|NCT01099995|OTHER|hyperbaric oxygen therapy|two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
41022942|NCT00291382|DRUG|Salmeterol/fluticasone propionate combination|
41022943|NCT06569342|PROCEDURE|Intradetrusor BoNT-A|For intravesical injections, BoNT-A (Allergan, Irvine, CA, USA) was diluted in 0.9% saline to 10 93 international units/ml. Multiple injections were distributed throughout the detrusor, using a 94 transurethral 23-gauge injection needle under rigid cystoscopic guidance (9.8 Fr paediatric 95 cystoscope) at 10 units/kg to a maximum of 300 units. All injections were performed under general 96 anaesthesia with antibiotic prophylaxis given intra-operative as single dose intravenously.
41022944|NCT03421613|DRUG|3VM1001|Self treatment 3 times daily for 10 days
41022945|NCT03421613|OTHER|Placebo|Cream without investigational drug. Self treatment 3 times daily for 10 days
41022946|NCT05335356|BIOLOGICAL|Stelara|45 mg , 90 mg at Week 0, 4, 16, 28 and 40; Before dosing at Week 16, patients in the Stelara group were randomly assigned in a 1:1 ratio to receive either Bmab 1200 or Stelara
41022947|NCT05335356|BIOLOGICAL|Bmab1200|45 mg , 90 mg at Week 0, 4, 16, 28 and 40
41022948|NCT01125423|DRUG|Milnacipran|Subject with Fibromyalgia will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
41022949|NCT01125423|PROCEDURE|Skin biopsy|Subjects with Fibromyalgia will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
41022950|NCT01125423|PROCEDURE|Skin Biopsy|Control Subjects will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
41022951|NCT05457881|DIETARY_SUPPLEMENT|Scandi-Shake|Scandi-Shake \[any of 4 flavors - vanilla, strawberry, banana cream, and caramel\] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk), calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on ideal body weight. The Mifflin St. Jeor equation will be used to calculate the total 24-hour energy needs based on gender, age, height, weight, and activity factor for the PCR diet. Daily physical activity will be assessed by questionnaire to determine the activity factor for accurate calorie restriction calculations. Nutritionists will use this equation to create a unique shake for each individual patient. The shakes will be separated into 4 equal portions per day, for a total of 16 portions across the 4 pre-operative days. Patients can consume the 4 daily portions at whichever time of day they choose. The shakes are frozen 24 hours before distribution.
41022952|NCT00902200|DRUG|AR-12286|See arms
41022953|NCT00902200|DRUG|AR-12286 vehicle|See arms
41022954|NCT02338362|DRUG|Fluticasone propionate inhaler|fluticasone propionate 250 µg metered-dose inhaler
41022955|NCT02338362|DRUG|Saline placebo inhaler|saline metered dose inhaler
41022956|NCT00710333|DRUG|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
40837617|NCT01360177|DRUG|Na134I|25 to 150 mCi
40837618|NCT01360177|DRUG|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
41022957|NCT00710333|DRUG|placebo|placebo
41022958|NCT06299202|DIAGNOSTIC_TEST|Diagnostic test|"* Inclusion visit (V1) Initial baseline CESM (V2) 15 days after inclusion~* First chemotherapy treatment (V3) 28 days after V2.~* Unilateral follow-up CESM (V4) 4 to 6 weeks after the first course of chemotherapy.~* Surgery (V5):~  3 to 6 weeks later at the end of the complete treatment with primary chemotherapy~* End of research visit (V6) It corresponds to the histological analysis on the surgical specimen after the complete treatment with neoadjuvant or primary chemotherapy."
41022959|NCT04522947|OTHER|Milkshake fMRI|While in the MRI scanner, the participant is shown a cue indicating the impending delivery of either milkshake or tasteless solution, followed by a brief blank screen, then delivery of the sip, and then a swallow cue. This procedure is repeated throughout the task.
41022960|NCT03065387|DRUG|Everolimus|Given PO
41022961|NCT03065387|DRUG|Neratinib|Given PO
41022962|NCT03065387|DRUG|Palbociclib|Given PO
41022963|NCT03065387|DRUG|Trametinib|Given PO
40837619|NCT01360177|DRUG|Tri-iodothyronine|20 mg/day x 2
41022964|NCT05349669|DRUG|Jafron use during CPB|Use of filter Jafron during CPB
41022965|NCT04527263|DIAGNOSTIC_TEST|measurement of urinary 5-HIAA|urinary assessment of 5-HIAA
41160446|NCT05463445|OTHER|Only observation|No intervention is needed.
40837620|NCT02117349|DRUG|Raplixa|Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
40837621|NCT02117349|DEVICE|Gelfoam|Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.
40837622|NCT02117349|DRUG|Rescue treatment|Thrombin-containing hemostats included in standard care at the site
40837623|NCT04229355|DRUG|DEB-TACE plus Sorafenib|Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)
40837624|NCT04229355|DRUG|DEB-TACE plus Lenvatinib|Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)
40837625|NCT04229355|DRUG|DEB-TACE plus PD-1 inhibitor|Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor
41022966|NCT01359735|BIOLOGICAL|HP802-247|High dose HP 802-247, applied at each visit (Week 1-13) or until healed
40837626|NCT00381875|BIOLOGICAL|E1M184V peptide vaccine|
40837627|NCT00381875|BIOLOGICAL|incomplete Freund's adjuvant|
40837628|NCT00381875|BIOLOGICAL|sargramostim|
41357917|NCT02030795|OTHER|Disconnection group|The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
40837629|NCT00381875|OTHER|immunoenzyme technique|
40837630|NCT06320548|DIETARY_SUPPLEMENT|Low-residue diet|Patients received clear explanations, practical schemes, and a list of allowed foods, tailored to fit individual needs.
41022967|NCT01359735|BIOLOGICAL|Bacitracin Ointment|One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).
40837631|NCT06320548|DIETARY_SUPPLEMENT|Free diet|Patients had free diet.
40837632|NCT03181295|BEHAVIORAL|Personalized exercise Rx and resources|Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
40837633|NCT00295932|BIOLOGICAL|rituximab|Given IV
40837634|NCT00295932|DRUG|bortezomib|Given IV
41022968|NCT03173196|DEVICE|Non-invasive Multispectral Sonography|We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
41022969|NCT04641468|PROCEDURE|DCB|OCT technical guidance: if B-type or C-type dissection can be seen, Oct should be used for further evaluation, and des treatment should be conducted if necessary
41022970|NCT04770714|DIAGNOSTIC_TEST|Breast MRI|Standard of Care Breast MRI
41022971|NCT04770714|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|Standard of Care Contrast Enhanced Mammography
41022972|NCT00548782|OTHER|Paleolithic diet|diet
41022973|NCT00548782|OTHER|ADA ( American Diabetes Association) recommended diet|diet
41022974|NCT02813031|OTHER|Functional meat products|
41022975|NCT02813031|OTHER|Traditional meat products|
40837635|NCT00295932|DRUG|cyclophosphamide|Given IV
41022976|NCT02205619|DEVICE|Air Flow Master Piezon®, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
41022977|NCT02205619|DEVICE|Gracey curettes, American Eagle, Missoula, MT, USA|comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
41022978|NCT02205619|DEVICE|Air-flow® Powder Perio, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
41160447|NCT05499247|OTHER|SkinQ Glow Bright Wonder Mask|"Mode of Usage:~Cleanse and dry face. Apply 1 tsp or 5g of the product. Apply with clean finger or brush to full face. Leave to dry for 15 minutes. Wipe with wet cotton or rinse with cool water.~Route of Administration: Topical"
41357918|NCT02030795|OTHER|Bronchial Suction group|The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
40837636|NCT00295932|DRUG|prednisone|Given orally
40837637|NCT00775333|PROCEDURE|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
40837638|NCT00038779|PROCEDURE|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation|
40837639|NCT01167166|DRUG|rigosertib|The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
40837640|NCT04517838|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor tissue samples
40837641|NCT04102722|DEVICE|MUST device|Imaging with MUST device
40837642|NCT02261233|PROCEDURE|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
40837643|NCT00003447|DRUG|gemcitabine hydrochloride|
40837644|NCT00003447|DRUG|vinorelbine tartrate|
40837645|NCT01073124|PROCEDURE|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
41357919|NCT01097057|DRUG|Carboplatin|Given IV
41357920|NCT01097057|DRUG|Etoposide|Given IV
41022979|NCT05201157|OTHER|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36, LI4 and SP6 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to points (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch
41022980|NCT05201157|OTHER|Control Group|No application will be made. The mothers in this group will fill in the Visual Similarity Scale for Fatigue twice, once between 8-12 hours post-op and once on the post-op 2nd day.
41022981|NCT00616967|DRUG|carboplatin|Given IV
41022982|NCT00616967|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
41022983|NCT00616967|DRUG|vorinostat|Given orally
41022984|NCT00616967|OTHER|placebo|Given orally
41022985|NCT06573957|DRUG|Dexmedetomidine|Patient in experimental arms will received intravenous dexmedetomidine at a dose of 0.5 µg/kg body weight 10 minutes before general anesthesia induction
41022986|NCT06573957|DRUG|Lidocain|Patient in experimental arms will receive intravenous lidocaine at 1.5 mg/kg body weight in a 5cc syringe 90 seconds before intubation
41022987|NCT04757012|DEVICE|calinange|calinange
41022988|NCT04475003|OTHER|Teaching|Teaching session about anaphylaxis
41022989|NCT03223818|OTHER|Fast-track peri-operative program|"Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.~All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia."
41022990|NCT01422759|DRUG|Spironolactone|50-100 mg PO BID (X 12 weeks)
40837646|NCT01908088|BIOLOGICAL|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
41022991|NCT01991834|PROCEDURE|gynecologic laparoscopy|Gynecological laparoscopy without opening hollow viscera.
41022992|NCT01991834|DRUG|Cefazolin|Intravenous administration of 1 g of cefazolin
41022993|NCT01991834|DRUG|Placebo|Intravenous administration of saline sterile solution
41022994|NCT02184468|OTHER|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
41022995|NCT03773744|DRUG|Ad-MAGEA3|Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
40837647|NCT04738253|DIAGNOSTIC_TEST|Ultrasonography|The ultrasound measurement s of the axillary recess capsule thickness.
41022996|NCT03773744|DRUG|MG1-MAGEA3|MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
41022997|NCT03773744|DRUG|Pembrolizumab|monoclonal antibody; checkpoint inhibitor of PD1
41022998|NCT03773744|DRUG|Cyclophosphamide|low-dose chemotherapy
41022999|NCT05290259|OTHER|Ballroom Dance|The Ballroom Basics for Balance Program is a dance focused exercise program developed by a Physical Therapist in the Madison area.
41023000|NCT06131918|DRUG|Resveratrol, Alpha lipoic acid, Super oxide dismutase|Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD
41023001|NCT06131918|DRUG|Resveratrol|Tab Resveratrol 1500 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
40837648|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
41023002|NCT06131918|DRUG|Alpha lipoic acid|Tab Alpha lipoic acid 600 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
41023003|NCT06131918|DRUG|Super Oxide Dismutase|Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
40837649|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
40837650|NCT03203733|DEVICE|Cooral™|An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
40837651|NCT03203733|OTHER|cryotherapy|Oral cooling by ice chips or crushed ice or ice pop
41023004|NCT05204524|DRUG|Temozolomide for injection combined with epirubicin|Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months.
41023005|NCT01411189|DRUG|Menthol|20 mL NPO-11 in prefilled syringe
41023006|NCT06294002|OTHER|Dynamic neuromuscular stabilisation group|DNS group protocol involved 5 min a moderate intensity warm-up, 40 minutes of DNS movements according to the DNS approach, different diaphragmatic breathing, mobility and controlled movement exercises and 5 minutes of cool-down. Exercises gradually increased in complexity and difﬁculty level regarding DNS training principles. The participants were instructed to refrain from engaging in high-intensity anaerobic or anaerobic resistance training throughout the study period to prevent potential disruptions in the study results.
41357921|NCT01097057|BIOLOGICAL|Filgrastim|Given SC
41357922|NCT01097057|DRUG|Ifosfamide|Given IV
41357923|NCT01097057|PROCEDURE|Leukapheresis|Given through catheter
41357924|NCT01097057|DRUG|Plerixafor|Given SC
41357925|NCT01097057|BIOLOGICAL|Rituximab|Given IV
41357926|NCT06382428|OTHER|Pelvic floor muscle training|The PFMT program was carried out for 45-50 minutes, 2 days a week for 8 weeks, by two physiotherapists specialized experienced in the pelvic floor. The program consisted of education, diaphragm breathing exercises, pelvic mobility exercises, exercises to strengthen and stretch the pelvic floor muscles and other muscles related to the pelvis. In addition, the participants were expected to do the same exercises at home 2 days a week.
41357927|NCT02143336|PROCEDURE|subcuticular suture|
41497043|NCT03213730|OTHER|Visual Attention Intervention|The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
41497044|NCT06172244|OTHER|Applying with whole body vibration device|A total of 5 sets of vibration will be given at 30 Hz, 2 mm amplitude, 1 minute of application and 1 minute of rest.
40837652|NCT04878536|DIETARY_SUPPLEMENT|Collagen drink|Testing product
40837653|NCT04878536|DIETARY_SUPPLEMENT|Blank|Placebo drink
40837654|NCT03198364|BEHAVIORAL|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
40837655|NCT03198364|BEHAVIORAL|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
40837656|NCT04211870|RADIATION|Low-level laser therapy|Sessions will be held twice a week for six weeks (total: 12 session). A potentiometer will be used to measure the mean power of the equipment and therapeutic dose, ensuring safety to the participant and operator. Laser will be administered at a wavelength of 786.94 nm using an energy density of 2 J/cm², intensity of 1.675 mW/cm² and power of 70 mW (0.070 W) for 20 seconds per point. The point application method will be used with a conventional tip in contact with the skin (spot area: 0.04 cm²) following the protocol suggested by Venezian et al.59 and Carvalho et al.60.
40837657|NCT04211870|RADIATION|Sham treatment|Sessions will be held twice a week for six weeks (total: 12 session). During sham treatment the device will emit a guide light and sound, but no energy.
40837658|NCT03689244|DRUG|Selexipag|oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration
40837659|NCT03689244|DRUG|Placebo|Oral tablets without active compound
40837660|NCT04065594|PROCEDURE|PRP dressing|PRP dressing gel dressings for treatment of chronic ulcer
40837661|NCT04065594|PROCEDURE|conventional ordinary dressing|conventional ordinary dressing for treatment of chronic ulcer
40837662|NCT01267175|DEVICE|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
40837663|NCT00084656|BIOLOGICAL|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
40837664|NCT00084656|BIOLOGICAL|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A\*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
41497045|NCT00416884|DRUG|Campath|30 mg on day -8 over 5-6 hours
41497046|NCT00416884|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 on day -4 through day -2
41497047|NCT00416884|RADIATION|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
41497048|NCT00416884|OTHER|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
41497049|NCT05549323|DRUG|PF-07054894|Oral
41497050|NCT05549323|DRUG|Placebo|Placebo
40837665|NCT00005976|DRUG|carboplatin|
40837666|NCT00005976|DRUG|pyrazoloacridine|
40837667|NCT05489900|DRUG|Dexmedetomidine Hydrochloride|"Dexmedetomidine is a specific and potent α2-adrenergic agonist. By acting directly on the sympathetic nervous system, they can exert beneficial effects on the immune system through neuroimmune interactions. Its administration can induce an anti-inflammatory response due to different central (increase parasympathetic tone, promoting control of the inflammatory condition) and peripheral effects (stimulating innate immunity).(MILLER, 2015).~Venous blood samples were collected at three times (T1, T2 and T3): Before anesthetic induction with collection in the preoperative environment on the day of surgery or during venoclysis before anesthetic induction (sample 1, T1); 6 hours after starting orifice closure and completion of drug or placebo infusion (sample 2, T2); and the last blood sample will be collected by me on the morning after the postoperative period, close to hospital discharge - 24h (sample 3, T3)."
40837668|NCT04810611|DRUG|MBG453|Anti-TIM3 monoclonal antibody
40837669|NCT04810611|DRUG|NIS793|Anti-TGF-β monoclonal antibody
40837670|NCT04810611|DRUG|canakinumab|Anti-IL-1β monoclonal antibody
40837671|NCT04498377|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
40837672|NCT04498377|BIOLOGICAL|Placebo|Placebo administered intravenously
41357928|NCT02143336|PROCEDURE|Skin staples|
41357929|NCT00180349|DEVICE|Endotak Reliance|Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
41357930|NCT03202641|PROCEDURE|PEEP ARDSnet|PEEP settings based on the low PEEP/high FiO2 table
41357931|NCT03202641|PROCEDURE|PEEP LRM|A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
41497051|NCT01468818|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
41357932|NCT01691937|PROCEDURE|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
41357933|NCT01691937|PROCEDURE|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
41357934|NCT01691937|PROCEDURE|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
41357935|NCT04310995|DRUG|Nicorandil 5mg tid|oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
40837673|NCT02483390|OTHER|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
40837674|NCT02971150|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|
41357936|NCT04310995|DRUG|Diltiazem 180mg qd|oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
41357937|NCT04310995|DRUG|Isosorbide Mononitrate 50mg qd|oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
41357938|NCT03024944|DRUG|18F-THK-5351|Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
41357939|NCT00000529|DRUG|tamoxifen|
41357940|NCT03901742|OTHER|Protein-enriched nutrition|Protein-enriched enteral nutrition with a polymeric infant formula
41357941|NCT03901742|DIETARY_SUPPLEMENT|High Protein-enriched Nutrition|High protein-enriched enteral nutrition with a polymeric infant formula plus a protein supplement
40837675|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
40837676|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
40837677|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
41357942|NCT03901742|OTHER|Standard Enteral Nutrition|Cow's milk based infant formula.
40837678|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
41357943|NCT04636333|BIOLOGICAL|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
41497052|NCT01468818|DRUG|Fludarabine|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
41497053|NCT01468818|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
40837679|NCT00351962|PROCEDURE|Fractionated Stereotactic Radiotherapy|
40837680|NCT01872442|DRUG|Dasatinib|"Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes \> 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study"
41357944|NCT04636333|BIOLOGICAL|Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
41497054|NCT04444674|BIOLOGICAL|ChAdOx1 nCoV-19|Dose of 5-7.5x10\^10vp of ChAdOx1 nCoV-19
41497055|NCT04444674|BIOLOGICAL|Normal saline 0.9%|Normal saline 0.9% as placebo
41497056|NCT02879734|OTHER|Prophylactic laparoscopic omentopexy|Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
40837681|NCT01872442|DRUG|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
40837682|NCT04480034|PROCEDURE|Bariatric procedures|All standard, laparoscopic bariatric procedures endorsed by SICOB (Società Italiana della Chirurgia dell'Obesità, Italian Society of Obesity Surgery) and by IFSO (International Federation of the Societies of Obesity Surgery), will be considered: sleeve gastrectomy, R-en-Y gastric bypass, one anastomosis gastric bypass, single anastomosis duodeno-ileal bypass with sleeve. The selection criteria for the surgery candidates will comply to the latest guidelines for bariatric surgery endorsed by SICOB, IFSO and EAES (European Association of Endoscopic Surgery). All the participating centers will follow the usual recruitment protocol. Restart of the bariatric elective surgery is based on the guidelines of SICOB for the bariatric surgery restart in Italy during the COVID-19 phase 2-3 of endemics.
40837683|NCT06174909|DRUG|Calcium Hydroxide|After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement
41160448|NCT04707456|OTHER|Training operator|"After recruitment, the participants were divided into two groups to perform first-trimester ultrasound scan by two different levels of proficiency.~First group : operator has experience more than 3 years in NT scan and second trimester ultrasound scan Second group : operator has experience less than 3 years in NT scan and second trimester ultrasound scan"
41357945|NCT04636333|BIOLOGICAL|Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
41357946|NCT04636333|BIOLOGICAL|Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
40837684|NCT06174909|DRUG|Triple Antibiotic paste|After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
40837685|NCT04877769|DRUG|AT-527|administered twice daily (BID) for 2.5 days (5 doses in total)
40837686|NCT02035722|BEHAVIORAL|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
40837687|NCT02035722|BEHAVIORAL|Video|AMD-related information is presented as in the form of a video
40837688|NCT04867694|BEHAVIORAL|BCC|Behavior change communication on Nutrition, Health \& Hygiene, including (but not limited to) awareness of dietary diversification from 6 months of age and adequate complementary feeding; and raising awareness of good water and hygiene practices.
40837689|NCT04867694|DIETARY_SUPPLEMENT|Preventive supplement|Monthly delivery of a nutritional supplement: enriched flour (CSB++), at a dose of 3 kg/month/beneficiary child. The nutritional supplement is limited to \[6-11\] months old children diagnosed as non-wasted (green MUAC); or children \[12-59\] months old for 6 months after discharge from a CMAM treatment or consolidation program.
40837690|NCT04867694|DIETARY_SUPPLEMENT|MNP|Delivery of micronutrient powders to \[12-23\] months old children (30 sachets per month for 2 months, every 6 months, according to international recommendations).
40837691|NCT04867694|OTHER|Water purification input|Monthly delivery of a water purification input: bleach or flocculant/decontamination sachets for the potabilization of the water of the whole household. The water treatment input is limited to households with \[6-11\] months old children, or children \[12-59\] months old enrolled in a CMAM treatment program and for 6 months after discharge.
40837692|NCT04867694|BEHAVIORAL|Family MUAC|"One-time delivery of a mid-upper arm circumference (MUAC) measuring tape and training of families in its use, and actions to be taken based on the results. This will involve distributing Shakir bands to all households with \[6-59\] months old children and training mothers/guardians, or any other family members who express an interest, in screening for wasting using the MUAC criteria, and explaining the procedure to follow if the child tests positive in the family.~Formative supervision of MUAC measurement in families. The training will be carried out by the members of the care groups and at each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary."
40837693|NCT04867694|BEHAVIORAL|Screening by care group|"Monthly screening by the care group volunteers of the children they follow, using the MUAC.~Referral to the health center of \[6-59\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled"
40837694|NCT04867694|BEHAVIORAL|CMAM compliance|"Weekly follow-up of \[6-59\] months old children under treatment and for 6 months after discharge from the national treatment and consolidation program : care group volunteers follow children under treatment until they recover and for the whole duration of their consolidation (for children cured of severe emaciation) through weekly home visits.~They monitor treatment adherence (i.e., families follow the planned schedule of visits and receive inputs for treatment or consolidation) and treatment compliance (i.e., the malnourished or consolidating child receives the planned dose of therapeutic or supplementary food each day)."
40837695|NCT05364762|DRUG|Cyclophosphamide|Given IV
40837696|NCT05364762|DRUG|Itacitinib|Given PO
41160449|NCT02556918|DRUG|Sitagliptin|Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
41160450|NCT02556918|DRUG|Placebo|One pill daily starting one day prior to surgery until discharge from the hospital.
41357947|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
41357948|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
41357949|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
41357950|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
41357951|NCT04287673|OTHER|Rehabilitation involving strongly the trunk|The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
41357952|NCT00695318|DRUG|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
41357953|NCT00695318|DRUG|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
41497057|NCT02744118|OTHER|5A's Model|"The adapted 5A's model will include the following elements:~1. Ask the patient about their marijuana use~2. Advise every patient to quit/reduce marijuana use using clear, specific personalized advice~3. Assess factors affecting choice of behavior and behavior change~4. Assist abstinence/reduction in in marijuana use using behavior change techniques to aid the patient~5. Arrange follow-up for ongoing assistance and support, and to adjust treatment plans"
41023007|NCT06294002|OTHER|Whole body vibration group|WBV was performed on the Power Plate Next Generation vibration platform (Power Plate North America, Chicago, IL). All training routines were approximately 50 minutes long, commencing with 5 minutes of moderate-intensity warm-up and concluding with a cool-down period. The program consisted of 8-10 static and dynamic exercises for PS that progressively increased in difficulty and complexity. During the training process, the frequency increased from 20 to 35 Hz in the last week of the experiment; the exercise duration was from 20 - 60 seconds (in the previous week), followed by 1-minute seated rest. Moreover, the complexity and difficulty of exercise increased over the experimental period. The resting period between sets was constant from the start to the end of the training process. During the experiment, the WBV intervention group performed three weekly training sessions.
41023008|NCT06294002|OTHER|Dynamic neuromuscular stabilisation with whole body vibration group|The MIX group underwent a two-month training program consisting of three weekly sessions, including a 50-minute exercise program with a 5-minute warm-up and cool-down period. The training included 20 minutes of WBV and 20 minutes of DNS training, following previous research and training recommendations. VIBRO exercises were performed on the Power Plate Next Generation vibration platform, with 6-8 exercises for balance and PS. Participants were advised not to engage in high-intensity anaerobic or anaerobic resistance training. The training protocol was adapted from previous research.
41023009|NCT03934229|DIETARY_SUPPLEMENT|Daily intake of study product|Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
41023010|NCT04577144|OTHER|Online survey only|There are no interventions planned for this study. This is an observational study only.
41023011|NCT02819726|BIOLOGICAL|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
41357954|NCT02481986|BEHAVIORAL|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
41497058|NCT02744118|OTHER|Healthy Internet Use Model|"The Healthy Internet Use Model provides a framework for conversations between pediatric practitioners and their adolescent patients. It focuses on 3 key areas of social media behavior:~1. Balance~2. Boundaries~3. Communication"
41497059|NCT04067986|DRUG|Camrelizumab|"Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w~One course will last 28 days. Oral administration at a dose of 250 mg/d"
40837697|NCT05364762|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell infusion
40837698|NCT05364762|OTHER|Quality-of-Life Assessment|Ancillary studies
40837699|NCT05364762|DRUG|Tacrolimus|Given IV or PO
40837700|NCT04094584|DRUG|Vivitrol (Extended Release Naltrexone)|Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
40837701|NCT02135978|OTHER|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
40837702|NCT00230152|DEVICE|Imaging|
41023012|NCT02819726|BIOLOGICAL|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
41023013|NCT02819726|BIOLOGICAL|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
41023014|NCT04755660|BEHAVIORAL|Exercise behavior change for resistance exercise|The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.
41023015|NCT03872050|DIAGNOSTIC_TEST|No intervention apart from tests, including interview|No interventions
41357955|NCT02481986|BEHAVIORAL|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
41023016|NCT06069154|DEVICE|Cryoneurolysis|Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.
41023017|NCT06069154|PROCEDURE|Local anesthetic peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks. The injectate through the introducer will depend on the treatment group: for participants of the control group, ropivacaine 0.5% or bupivacaine 0.375% (both with epinephrine 1:400,000) will be injected (volume determined by institutional standard-of-care). This will provide a peripheral nerve block for the control group.
41023018|NCT06069154|DEVICE|Sham Cryoneurolysis|Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). However, for the sham comparator, the gas will NOT be deployed to the tip, there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
41023019|NCT06069154|PROCEDURE|Sham peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks: for participants allocated to the cryoneurolysis group (experimental group), normal saline will be injected for the peripheral nerve block. This will result in a sham/placebo nerve block for the experimental group.
41023020|NCT02040597|DRUG|Beclometasone/Formoterol/Glycopyrrolate|
41023021|NCT06164912|OTHER|Transcranial Magnetic Simulation with Pseudofeedback|Participants will receive TMS with bogus feedback that will be displayed on a screen as they imagine movement.
41023022|NCT06164912|OTHER|Transcranial Magnetic Simulation with Neurofeedback|Participants will receive TMS with live Neurofeedback that will be displayed on a screen for them as they are imagining movement
41023023|NCT03221257|DRUG|Pirfenidone (PFD)|Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
41023024|NCT03221257|DRUG|Placebo (Plac)|Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
41023025|NCT03221257|DRUG|Mycophenolate Mofetil (MMF)|Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
41023026|NCT03219528|DRUG|Rifaximin 550 MG|Rifaximin 550 mg three times daily for 14 days
41023027|NCT03219528|OTHER|Low FODMAP Diet|Low FODMAP dietary intervention for 4 weeks
41023028|NCT06532110|OTHER|Endoscopy/Colonoscopy|Esophagogastroduodenoscopy and colonoscopy with video recording and biopsy collection
41357956|NCT03316898|DRUG|AGN-242071|AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
41497060|NCT04067986|DRUG|Apatinib|Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd
41023029|NCT06192511|BEHAVIORAL|Educational Website and Video|The website offers users the opportunity to choose to watch a 4-minute video or read relevant information about Newborn Screening and the Michigan BioTrust. If they choose to read, the website is designed to present information in an engaging manner, while providing optional voiceover. The video uses a mixture of live action shots and animation, all with voiceover. All materials are available in English, Spanish and Arabic.
41023030|NCT01224496|DRUG|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
41497061|NCT06010537|DRUG|polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection is a magnetic resonance contrast agent.
41023031|NCT01266759|DRUG|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
41023032|NCT01266759|DRUG|Norethisterone Acetate tablets - 5mg|Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
41497062|NCT05888623|DEVICE|Computer Assisted Detection|Computer-aided polyp detection system that utilizes artificial intelligence (AI) during colonoscopy
41497063|NCT06388759|DRUG|TQ05105 Tablets|TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 （JAK2） Inhibitor
41023033|NCT03062826|DRUG|dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)|Patients who met the inclusion criteria will be treated with dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel).
41497064|NCT06548308|DIAGNOSTIC_TEST|Corneal Incision|Astigmatism will be assessed by objective and subjective refraction by using the Autorefrectometer and retinoscop.Autorefrectometer uses to acsess the refracive state of eye by which we measure the astigmatim in patients eyes .Then after ctaract surgry in the next followup we will again use autorefrectometer to take readings and these both will be compared on visits among patients undergoing two procedures.
41023034|NCT03251703|PROCEDURE|Ultrasound-Guided Suprascapular Pulsed Radiofrequency .|The ultrasound-Guided Suprascapular Pulsed Radiofrequency was administered under operating room conditions while the patient was monitored in a sitting position.An ultrasound-guided 22 G 5-mm active-tip 100-mm radiofrequency needle (SC-K; Top Neuropole, Tokyo, Japan) was pushed forward towards the suprascapular notch until it passed the transverse scapular ligament using an in-plane approach.
41497065|NCT06548308|OTHER|Toric Intraocular|Two cataract surgery techniques will be used .1 : Toric IOL lenses designed with a unique shape to help provide clear vision at all distances for individuals with astigmatism compared to give better results specially in astigmatic patients.2: Corneal Inscion is which eye surgeon makes a very small opening on the eye, next to the outer corner. to remove the catract during surgry .
41023035|NCT04590755|BEHAVIORAL|Interactive father-child sessions and website|The Run Daddy Run intervention will consist of 5 (inter)active sessions for fathers and their children + 1 follow-up session, each session lasting 90 minutes. These sessions will be given to 8 groups of +- 13 families (fathers and their children), guided by 2 facilitators and will take place every 2 weeks, at a location in the neighborhood of fathers and children (e.g. school of the children). Additionally, a website will be available for the fathers and their children, with additional information about the project, tips and information about being active together (e.g. movement breaks, fundamental movement skills, etc.) and limiting screen time. In addition, fathers and their children will also log their goals on this website, and between two sessions (= a period of 2 weeks) they will be asked to keep track of their co-PA on this website, aiming to reach their goal.
41023036|NCT01699425|DEVICE|Ajust sling|
41023037|NCT01699425|DEVICE|Classical transobturator sling|Control group
41023038|NCT03345459|OTHER|ICare Prevent (internet-based treatment for depression in college students)|ICare Prevent (internet-based treatment for depression in college students): 7 weekly sessions and 1 booster session. Each session requires about 30-45 minutes to complete. All sessions are accessed online, and it is a guided treatment (i.e., each patient provided an eCoach).
41023039|NCT04813341|OTHER|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles. The participant will be instructed to perform 3-5 repetitions of these movements at the start, and to add two more repetitions for each movement every week until the end of the intervention.
41023040|NCT04813341|OTHER|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
41023041|NCT06336135|OTHER|autologous hair follicle derived secretome|aHFS is a cosmetic topical intended to be applied to the human body after skin resurfacing cosmetic procedures. aHFS is produced from the plucked hair follicles of each individual, making it autologous.
41497066|NCT00889369|DRUG|Duloxetine|Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
41497067|NCT04492657|OTHER|no intervention|Natural exposure of iodine.
41497068|NCT05206292|DIAGNOSTIC_TEST|Sulfitest|Urine strip to detect the presence of sulfites in urine. Immediate result.
41497069|NCT04142892|DRUG|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
41497070|NCT03062423|DRUG|Sofodelevier|1 tablet contains 400 mg sofosbuvir
41497071|NCT03062423|DRUG|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
41497072|NCT03062423|DRUG|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
41357957|NCT03316898|DRUG|Placebo|Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
40837703|NCT05094830|PROCEDURE|Stomach Intestinal Pylorus-Sparing (SIPS) Procedure|The SIPS procedure will be performed as an investigational bariatric surgery. The SIPS procedure involves the creation of a standard sleeve gastrectomy over a 36-40 bougie. Division of the duodenum post-pylorus is performed, followed by the creation of a common channel 300 cm from the ileo-cecal valve. A hand-sewn anti-side duodenoileostomy is performed and the anastomosis tested for leaks through use of endoscopic insufflation and under water air leak test. Incisions are then closed in standard fashion. The SIPS procedure itself is not a separate surgery but rather a modification to the standard of care surgery.
40837704|NCT03308149|DRUG|infiltration with triamcinolone and bupivacaine|facet joint infiltration
41357958|NCT03316898|DRUG|Donepezil|Donepezil 10 mg as prescribed by the physician as per standard of care.
41357959|NCT03316898|DRUG|Memantine|Memantine as prescribed by the physician as per standard of care.
41357960|NCT02059174|DRUG|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
41357961|NCT02059174|DRUG|EU-Lantus™|EU-Lantus™ 0.4 units/kg administered subcutaneously
40837705|NCT05678452|PROCEDURE|HOLEP for treating BPH|HoLEP will be performed using 100W Versapulse, Luminis Inc., with 2J/25Hz for LP-HoLEP and 2J/50Hz for HP-HoLEP.
40837706|NCT00958737|DRUG|FOLFOX regimen|6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))
40837707|NCT00958737|DRUG|CAPOX|4 or 8 cycles
41023042|NCT00460512|DRUG|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
41023043|NCT00058890|DRUG|Gabapentin|Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
41023044|NCT00058890|DRUG|Placebo|
41357962|NCT02059174|DRUG|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
41357963|NCT04030351|OTHER|food - dried fruit|raisins, apricots, figs, and pineapple
41023045|NCT04994366|OTHER|Thank you card|A card thanking the patient for choosing NYU and entrusting us with their care. The card notifies the patient that they may receive a patient satisfaction survey after discharge.
41357964|NCT05190406|PROCEDURE|Pulpotomy|After achieving hemostasis, in pulpotomy group bioceramic material will be placed and then permanent restoration will be done.
41357965|NCT05190406|PROCEDURE|root canal treatment|Single visit root canal treatment will be done according to standard protocol.
40837708|NCT04932213|DRUG|Tropicamide Ophthalmic|Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.
40837709|NCT03528005|BEHAVIORAL|Multi-domain intervention|60 minutes cognitive training, 45 minutes physical exercise, 15 diet nutrition and intermittent disease management consultation
40837710|NCT02190890|PROCEDURE|Dry needling|
40837711|NCT02190890|PROCEDURE|Control|
40837712|NCT01058941|DRUG|Lipoic acid and fish oil concentrate|Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
40837713|NCT01058941|DRUG|Placebo|Placebo LA and placebo oil capsules for 18 months
40837714|NCT02526251|OTHER|observational|No intervention
41023046|NCT00836641|BIOLOGICAL|prevenar|7-valent pneumococcal conjugate vaccine
41023047|NCT00836641|BIOLOGICAL|pneumovax|23 valent pneumococcal polysaccharide vaccine
41023048|NCT00404157|DRUG|Rituximab|
41357966|NCT01617356|OTHER|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
41357967|NCT01617356|OTHER|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
41357968|NCT03845842|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding cannabis use.
41357969|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
41357970|NCT00659009|OTHER|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
41357971|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
41357972|NCT00286156|DRUG|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
41357973|NCT03660566|PROCEDURE|Test - Implant with L-PRF|The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
41357974|NCT03660566|PROCEDURE|Control - Implant without L-PRF|Single implant installation surgery in maxillary esthetic area.
41357975|NCT03671811|DRUG|Megestrol Acetate|Given PO
41357976|NCT03671811|BIOLOGICAL|Pterostilbene|Given PO
40837715|NCT03106467|PROCEDURE|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.
40837716|NCT03106467|PROCEDURE|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
40837717|NCT02142036|DRUG|EMA-approved ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
40837718|NCT00554762|DRUG|GW842166X|Administer
40837719|NCT02517632|BEHAVIORAL|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
40837720|NCT02517632|BEHAVIORAL|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
40837721|NCT02752464|BEHAVIORAL|Counseling|Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.
40837722|NCT02752464|BEHAVIORAL|feedback report|All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
40837723|NCT04402541|DRUG|CB-5339|25mg and 75mg capsules
40837724|NCT05266560|DRUG|ciprofol|A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-\[(1R)-1-cyclopropylethyl\]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.
40837725|NCT05266560|DRUG|Propofol|Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
40837726|NCT01815632|OTHER|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
40837727|NCT01815632|OTHER|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
40837728|NCT01945684|DRUG|Botulinum toxin type A|Maximum dose 360 U
40837729|NCT02535416|DRUG|ARC-520|
40837730|NCT02535416|DRUG|cetirizine|
41023049|NCT02248584|DIETARY_SUPPLEMENT|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
41497073|NCT04502212|DEVICE|Hepatic Ultrasound Insonification|Hepatic ultrasound insonification will be performed after an overnight fast (no food or drinks except for water for at least 10 hours) at approximately the same time on each day for three days.
41497074|NCT03715361|DIAGNOSTIC_TEST|SL-ECG|additional SL-ECG measurement
40837731|NCT02535416|DRUG|diphenhydramine|
40837732|NCT01137019|DEVICE|Biolimus-eluting stent|The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.
40837733|NCT01137019|DEVICE|Everolimus-eluting coronary stent|The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
41023050|NCT03582306|BEHAVIORAL|High chlorophyll diet - intervention 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
40837734|NCT02598128|DEVICE|RELiZORB|Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
40837735|NCT02598128|DEVICE|Placebo|Sham device
41023051|NCT03582306|BEHAVIORAL|High chlorophyll diet - control 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
41023052|NCT00793910|DRUG|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
41023053|NCT00793910|DRUG|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
41357977|NCT01574118|BEHAVIORAL|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
41497075|NCT04431583|PROCEDURE|Bariatric surgery- single surgeon service|
41497076|NCT04431583|PROCEDURE|Bariatric surgery- multiple surgeon + multidisciplinary team approach|
41497077|NCT04431583|PROCEDURE|Bariatric surgery: formalized streamlined multiple surgeon + multidisciplinary team approach|
41497078|NCT06369597|PROCEDURE|Robotic telesurgery|Telesurgery by domestic surgical robot
40837736|NCT00468403|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
40837737|NCT00468403|BIOLOGICAL|Belatacept|Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
40837738|NCT00468403|BIOLOGICAL|Basiliximab|Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
40837739|NCT00468403|DRUG|Mycophenolate Mofetil|Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
40837740|NCT00468403|DRUG|Tacrolimus|Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
40837741|NCT00468403|PROCEDURE|Intraportal infusion of islet cells|The infusion of allogeneic pancreatic islet cells (islet transplant\[s\]) will occur intraportally.
40837742|NCT00457444|DRUG|Pollen|
40837743|NCT00774020|DRUG|Zoledronic acid|5mg, i.v. single dose
40837744|NCT06416293|OTHER|Questionnaire patients|Completion of a two-part questionnaire with a special focus on communication around the breast cancer diagnosis. Tumor stage and therapies received are also surveyed. The questionnaire can be answered online via a secure tool (REDCap) or in paper form.
40837745|NCT06416293|OTHER|Questionnaire physicians|Completion of a questionnaire with a special focus on communication around the breast cancer diagnosis
40837746|NCT02920957|DEVICE|comfilcon A|contact lens
40837747|NCT02920957|DEVICE|senofilcon C|contact lens
40837748|NCT01146964|PROCEDURE|MSSICS|Manual super small incision cataract surgery
41023054|NCT02929576|DRUG|Enzalutamide|Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
41023055|NCT02929576|DRUG|Placebo|
40837749|NCT01146964|PROCEDURE|Phacoemulsification|cataract surgery with Phacoemulsification
40837750|NCT00558532|PROCEDURE|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
40837751|NCT01918449|OTHER|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
41160451|NCT02556918|DRUG|Regular Human Insulin|Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
40837752|NCT04029818|BIOLOGICAL|Bifidobacterium BSL_PS404|Each participant will consume 1 capsule daily at lunch for 8 weeks.
40837753|NCT04029818|BIOLOGICAL|Placebo|Each participant will consume 1 capsule daily at lunch for 8 weeks.
40837754|NCT03693547|DRUG|utidelone injection|utidelone monotherapy in patients with advanced NSCLC by utidelone
40837755|NCT06147687|DIAGNOSTIC_TEST|Self reported data collection|ML assessement of colleceted data
41357978|NCT01574118|BEHAVIORAL|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
41357979|NCT01574118|BEHAVIORAL|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
41357980|NCT01574118|BEHAVIORAL|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
41357981|NCT01574118|BEHAVIORAL|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
41357982|NCT01574118|BEHAVIORAL|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
41023056|NCT02929576|DRUG|Paclitaxel|Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
41023057|NCT06114797|OTHER|Chamomile|"* Chamomile was topically applied to the oral mucosa as oral rinse.~* Based on this protocol, patients had oral rinses 3 times per day.~* Patients were instructed to perform chamomile rinses in the oral mucosa.~* Patients were instructed not to swallow the chamomile oral rinse."
41023058|NCT06114797|OTHER|Saline mouthwash|Saline mouthwash was used by elderly patients in the control arm.
41023059|NCT02942160|BIOLOGICAL|Collagenase Clostridium Histolyticum|
41023060|NCT00982319|DRUG|Broccoli sprout extract|100 µmols of sulforaphane (dissolvable)
41023061|NCT00982319|DRUG|Mango juice|150 mL of mango juice
41497079|NCT06369597|PROCEDURE|Laparoscopic surgery|Local laparoscopic surgery
41497080|NCT06262802|DEVICE|Active decompression|Intracystic active negative pressure
40837756|NCT00521222|DRUG|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
40837757|NCT00521222|DRUG|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
40837758|NCT00521222|DRUG|Ipratropium HFA|Primary as-needed rescue medication in all treatment groups
40837759|NCT00521222|DRUG|Albuterol HFA|Secondary as-needed rescue medication in all treatment groups
41023062|NCT06428201|DIAGNOSTIC_TEST|Control Group|The control group receives standard care, which includes routine medical management and general physical rehabilitation exercises. This involves regular consultations with healthcare providers and exercises aimed at maintaining mobility and physical function. The control group also follows a schedule of three 45-minute sessions per week for 12 weeks, ensuring a consistent comparison with the experimental group.
41023063|NCT06428201|COMBINATION_PRODUCT|Experimental Group|The experimental intervention involves tele-rehabilitation-based task-specific training to enhance cognitive functions in multiple sclerosis (MS) patients. This program includes cognitive exercises targeting memory, attention, executive function, and processing speed, conducted remotely via a tele-rehabilitation platform. Patients participate in three 45-minute sessions per week for 12 weeks. Each session is guided by a trained therapist, ensuring personalized support and real-time feedback.
41023064|NCT06573203|DEVICE|Non-contact heart rate and respiratory rate monitoring system|Each neonate enrolled underwent four sleep and vital signs monitoring procedures after admission.
41023065|NCT06573203|DEVICE|Mindray ECG monitor|Heart rate and respiratory rate of each enrolled child were monitored after admission.
41023066|NCT06573203|DEVICE|aEEG|Each enrolled child underwent a 6-hour sleep-wake cycle, quiet sleep, and active sleep monitoring after admission.
41023067|NCT06573203|OTHER|Neonatal Sleep-Wake Assessment Tool (NSWAT) included four dimensions: eye movement, respiratory rate, facial expression and muscle activity.|The study nurses observed and scored the children's sleep-wake status 10 minutes after two meals during the mattress test period, each time for 5 minutes.
41023068|NCT03957122|DEVICE|repetitive transcranial magnetic stimulation|"Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6"
41023069|NCT03207750|BIOLOGICAL|Rotarix|Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
41023070|NCT03207750|BIOLOGICAL|Pediarix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
41023071|NCT03207750|BIOLOGICAL|Hiberix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
41023072|NCT03207750|BIOLOGICAL|Prevenar 13|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
41023073|NCT01609556|DRUG|Mirvetuximab soravtansine|Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
41023074|NCT01661660|OTHER|observationnal|Observation during a physical exercise
41023075|NCT02736084|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
41023076|NCT00055328|BEHAVIORAL|Problem-Solving Treatment for Primary Care|
41160452|NCT02556918|DRUG|Insulin glargine|"Patients that required continuous insulin infusion (CII) at a rate \>1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between \>180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG \>241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG \<100 mg/dl: stop basal"
41023077|NCT03448549|DRUG|Oxaliplatin|adjuvant chemotherapy
41023078|NCT03448549|DRUG|Tegafur，gimeracil and oteracil potassium|adjuvant chemotherapy
40837760|NCT02478580|DRUG|Nuvigil|Patients will receive Nuvigil before the surgery
40837761|NCT02478580|DRUG|Placebo|Placebo will be given before surgery
40837762|NCT02310997|OTHER|Umbilical Cord Blood Transplant|
40837763|NCT02310997|DRUG|Cyclophosphamide|
40837764|NCT02310997|RADIATION|Total body irradiation|
40837765|NCT02310997|DRUG|Busulfan|
40837766|NCT02310997|DRUG|Melphalan|
40837767|NCT02310997|DRUG|Fludarabine|
40837768|NCT04989647|RADIATION|No adjuvant therapy|Patients will not receive any type of adjuvant therapy.
40837769|NCT04989647|RADIATION|Adjuvant radiotherapy|Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).
40837770|NCT02796885|OTHER|no intervention - observational study|
40837771|NCT00494910|BEHAVIORAL|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
40837772|NCT00494910|BEHAVIORAL|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
40837773|NCT01824706|PROCEDURE|craniectomy|craniectomy
40837774|NCT01242566|DRUG|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
40837775|NCT02290938|BEHAVIORAL|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
41023079|NCT03448549|DRUG|Xeloda|adjuvant chemotherapy
40837776|NCT02290938|OTHER|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
40837777|NCT02388542|BEHAVIORAL|Educational Intervention|Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
40837778|NCT02212158|BEHAVIORAL|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
40837779|NCT00005875|DRUG|rubitecan|
40837780|NCT02707393|DRUG|Fludarabine|infusion
40837781|NCT02707393|DRUG|Thiotepa|infusion
40837782|NCT02707393|DRUG|Melphalan|infusion
40837783|NCT02707393|DRUG|ATG|infusion
40837784|NCT02707393|DRUG|Cyclosporine A|infusion, orally if possible
40837785|NCT02707393|DRUG|Mycophenolate mofetil|infusion
40837786|NCT02707393|BIOLOGICAL|bone marrow or peripheral blood stem cells|infusion
41023080|NCT06531525|DRUG|Enoxaparin|Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
40837787|NCT00036101|DRUG|aripiprazole|
40837788|NCT03721809|BIOLOGICAL|Blood samples|"There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient."
40837789|NCT06177093|RADIATION|MR Linac delivered Radiotherapy|All radiotherapy will be delivered on the MR-linac. The whole prostate will receive 30 Gy in 5 fractions and the dominant lesion plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.
40837790|NCT06301139|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Infant formula based on goat milk for 4 weeks at volume depending on the infant
40837791|NCT06301139|DIETARY_SUPPLEMENT|Cow's milk-based infant formula with probiotic drops|Infant formula based on cow's milk with probiotic Lactobacillus reuteri drops for 4 weeks at volume depending on the infant
40837792|NCT05205369|BEHAVIORAL|10-week home-based Yi Jin Bang exercise program|Each participant in this group will do a home-based Yi Jin Bang exercise program four times a week for ten consecutive weeks, which consists of ten minutes of warm-up, 18 minutes of Yi Jin Bang exercise (ten exercises), and ten minutes of cool-down. To learn how to conduct the home-based exercise session, each participant will be invited to one introductory session before starting the prescribed exercise program. Two experienced Yi Jin Bang instructors will lead the introductory session. Besides, in order to monitor participants' adherence and help them to conduct self-training, we will use the Zoom Meeting application. Zoom can capture and record participants' movements through the webcam. During the introduction sessions, we will teach participants how to use Zoom. Furthermore, we will provide support for adherence to the home exercise sessions through telephone calls or e-mail every two weeks.
40837793|NCT05205369|BEHAVIORAL|10-week home-based usual exercise therapy program|Among exercise therapy in the treatment of SAPS, stretching and strengthening protocols are often used . Therefore, participants in this group will do a standardized home-based stretching and strengthening exercise program four times per week for ten weeks, which is set up according to a previous study. This program has been demonstrated that can be effective in reducing pain and improving function in patients with SAPS. For strengthening exercises, elastic bands will be used. To learn how to conduct the self-training program, each participant in this group will also be invited to one introductory session before starting the prescribed exercise training. Two certificated physiotherapists will lead the introductory session. In addition, a video demonstration clip will be given to each participant to provide a home reference, and the Zoom Meeting application will be used to help monitor the exercise.
40837794|NCT00370513|DRUG|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
40837795|NCT05094817|OTHER|Brain Health Assessment|BHA is a free, self-administered online cognitive screening test developed in Toronto at Baycrest (www.cogniciti.com). BHA has been validated against a gold standard neuropsychological assessment for detecting amnestic MCI (aMCI) - the most common type of MCI - in community dwelling older adults. BHA has high sensitivity (.78), specificity (.78), PPV (.82), NPV (.74), and was better than MoCA for identifying aMCI. ROC curves showed an AUC of 0.75 for detecting aMCI from normal subjects. BHA measures memory and executive attention processes sensitive to subtle cognitive changes associated with normal aging and MCI. BHA can be completed from a patient's home or can be self-administered in hospital.
40837796|NCT05094817|OTHER|Demographics questionnaire|To compare the sociodemographic characteristics of patients completing Cogniciti's BHA vs. those who are not able to complete the BHA.
41023081|NCT06531525|DRUG|Aspirin|Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
41023082|NCT06531525|DRUG|Enoxaparin|Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.
41023083|NCT02825394|OTHER|anti-Xa activity point-of-care testing (aXa-POCT)|
41023084|NCT02825394|OTHER|ecarin clotting time point-of-care testing (ECT-POCT)|
41023085|NCT01914848|OTHER|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
41023086|NCT01914848|OTHER|Control Group|A routine care discharge planning with the social service
41023087|NCT01022034|PROCEDURE|sacral rectopexy with sutures or meshes|
41023088|NCT01022034|PROCEDURE|full rectal mobilization from the sacrum without sacral rectopexy|
41023089|NCT04332744|DRUG|Enzalutamide|Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)
41023090|NCT04332744|DRUG|Talazoparib|Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)
41023091|NCT02879838|OTHER|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
40837797|NCT05094817|OTHER|PHQ-2|PHQ-2 is a shortened version of PHQ-9 which is originally a component of the longer Patient Health Questionnaire. The tool incorporates DSM-IV depression criteria and other leading major depressive symptoms into brief self-reported instruments. PHQ-2 inquires about the degree to which an individual experiences depression and anhedonia (inability to feel pleasure) over the past two weeks. The tool is not for final diagnosis of depression or monitoring its severity but only for the purpose of screening for the condition.The questionnaire comprises of the first two questions from PHQ-9, each item is scored 0-3. Therefore, the PHQ-2 score ranges from 0-6.
41023092|NCT03127397|BEHAVIORAL|Praise message phone call|Praise message phone calls after each completed ART appointment, up to two calls per month.
41023093|NCT03108534|DRUG|CHF1535 NEXThaler|Rescue treatment
41023094|NCT03108534|DRUG|CHF1535 pMDI|Rescue treatment
41023095|NCT03108534|DRUG|Placebo|Rescue treatment
41023096|NCT06110546|DRUG|Methadone group|Participants will be started on Methadone 5mg, 10mg or 15mg every 8 hours depending on Fentanyl drip rate (0-100mcg/hr, 100-200mcg/hr or \>200mcg/hr) or hydromorphone drip rate (0-1.5mg/hr, 1.5-3mg/hr, or \>3mg/hr).
41023097|NCT06110546|DRUG|Usual care|Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols
41023098|NCT03751904|DEVICE|AcoustiCare|Electronic stethoscope
41023099|NCT04170192|PROCEDURE|Cord Blood Stem Cell Transplantation|Unrelated cord blood stem cell selection; Reduced intensity conditioning regime; GVHD prevention; Infection prevention.
41023100|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
41023101|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
41023102|NCT04787666|PROCEDURE|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure
41023103|NCT05881941|DEVICE|using a soundproof nebulizer with a music and a funny mask added|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
41023104|NCT05881941|DEVICE|using a silent nebulizer with no extra attachments|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
41023105|NCT05881941|DEVICE|using a routinely employed nebulizer|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
40837798|NCT05094817|OTHER|AFT|AFT is a free, rapid cognitive assessment commonly used to assess semantic language ability. Language is one of the earliest functions affected by AD and naming and semantical knowledge seems to be particularly affected. The identification of language deficits may pick up signs of neurological decline preceding the appearance of clinical symptoms. Milder forms of cognitive impairment such as MCI may also show language deficits if language is one of the domains affected.
41023106|NCT02613481|DRUG|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
41023107|NCT02731131|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
41023108|NCT02731131|DRUG|Ribavirin|Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
41023109|NCT04614428|BEHAVIORAL|RESILIENCE Program|"In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective."
41023110|NCT04695691|DEVICE|Cutera Laser System|Subjects will receive laser treatments
41023111|NCT05924646|DIETARY_SUPPLEMENT|Sodium Chloride Capsules|Table salt in slow release capsules.
41023112|NCT05924646|OTHER|Microcystalline Cellulose Capsules|Microcrystalline Cellulose Capsules (Placebo)
40837799|NCT05094817|OTHER|GAI-SF|GAI-SF is a 5-item questionnaire derived from the original 20-item Geriatric Anxiety Inventory (GAI).In the population of community dwelling older women GAI-SF was developed in, a cut-off score of 3 yields a specificity of 87% and sensitivity of 75%. This highly accessible questionnaire is suitable for everyday use in a range of health-care settings. It has been employed amongst older adults in primary care settings, nursing homes, geriatric psychiatry patients and amongst clinical geriatric participants with co-morbid anxiety and unipolar mood disorder and their controls.
40837800|NCT05094817|OTHER|pain VAS|The VAS is a unidimensional measure of pain intensity. The VAS tries to measure a continuous characteristic or attitude signifying the intensity or frequency of symptoms. The scale ranges from 0-10, with 0 = no pain to 10 = worst pain.
41023113|NCT06572189|GENETIC|Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)|Receive administration of 100μg of CD-801 via hepatic arterial injection every 14 ± 3 days (the dosing interval will be adjusted based on the tolerability, safety, and therapeutic effect of the subjects), for one treatment cycle. Treatment will continue until the occurrence of disease progression, death, intolerable toxicity, voluntary withdrawal of informed consent, loss to follow-up, initiation of new antitumor treatment, or termination of the study by the investigator (whichever comes first), and completion of the final follow-up and assessment 14 days after the last administration.
41023114|NCT02899728|DRUG|Carboplatin|Given IV
41023115|NCT02899728|DRUG|Cediranib|Given PO
41497081|NCT06226012|DEVICE|pulsed magnetic field|Children in this group received pulsed magnetic therapy in addition to traditional exercise program
41497082|NCT06226012|DEVICE|Low level laser|Children in this group received low level laser therapy in addition to traditional exercise program
41497083|NCT04413331|OTHER|Data collection|Medical data collection at M0, M3, M6, M9 and M12 then every 6 months until M60 and at each vascularitis relapse
40837801|NCT05094817|OTHER|IADL|Instrumental activities such as preparing meals or managing finances allow individuals to maintain their health while living on their own. The IADL measures the ability of older adults to manage their daily activities, as well as the impact, if any, cognitive decline would have on these activities. Scores range from 0-5 for men, and 0-8 for women, with higher sores being more independent and higher functioning.
40837802|NCT05094817|OTHER|FAM CAM|FAM-CAM was derived from the CAM instrument in order to screen for delirium by interviewing family members or caregivers of the patient. They are asked specific questions about any new or sudden changes in the patient's activity, behavioural or cognitive status. FAM-CAM showed good sensitivity and specificity in the original study where caregivers of elderly patients with pre-existing cognitive impairment were interviewed.
40837803|NCT05094817|OTHER|4AT|The 4AT is a rapid tool for delirium detection that has previously been used in a surgical setting. The 4Ats test for the patient's alertness, mental state, attention, and signs of acute change. Across 17 studies, the pooled sensitivity and specificity of 4AT was 0.86 and 0.89. The 4AT will be administered after the patient has completed surgery, prior to discharge.
40837804|NCT05094817|OTHER|BHA Usability Survey|The survey aims to assess system usability and acceptability based on standard questions adapted from the validated System Usability Scale. The questions evaluate satisfaction, experience with technology, and comfort level, as well as questions targeting usability concerns typically experienced by older adults, such as typeface and font size, consistent navigation, and writing style.
40837805|NCT05094817|OTHER|Clinical Frailty Scale|CFS is a 9-item scale that uses clinical descriptors and pictographs and is an easily applicable tool to stratify older adults according to level of vulnerability. The CFS divides patients into 9 classes from very fit (CFS = 1) to terminally ill (CFS = 9). It is easy to use and may readily be administered in a clinical setting, an advantage over the tools previously developed. The scale helps in objective early identification of older adults with frailty in acute care units and helps to target interventions to prevent complications and to implement effective discharge planning.
40837806|NCT04253457|DRUG|1ml of triamcinolone (40mg/1ml)|Single injection of 1ml of triamcinolone (40mg/1ml)
41023116|NCT02899728|DRUG|Cediranib Maleate|Given PO
41023117|NCT02899728|DRUG|Cisplatin|Given IV
41023118|NCT02899728|DRUG|Etoposide|Given IV
41023119|NCT02899728|DRUG|Olaparib|Given PO
41023120|NCT03084328|DIETARY_SUPPLEMENT|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
41023121|NCT03188640|PROCEDURE|Laparoscopic gastric-bypass surgery|Female participants with BMI \>30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
41023122|NCT01376752|PROCEDURE|Maximal cytoreductive surgery|Maximal cytoreductive surgery
41497084|NCT04413331|OTHER|Biological samples and data collection|Biological samples at M0, M6, M12, M24 and at each relapse until M60
40837807|NCT05261581|PROCEDURE|Erector Spinae Plane Block|Erector spinae block (ESB) is an ultrasound-guided interfascial plane block. The local anesthetic is injected using ultrasound guidance superficial to transverse process and deep to erector spinae muscle group
40837808|NCT05261581|DRUG|NSAID|Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to relieve pain, reduce inflammation.
41357983|NCT01574118|BEHAVIORAL|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
41357984|NCT01574118|BEHAVIORAL|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
40837809|NCT05261581|BEHAVIORAL|Home Exercise Programme|Home exercise programme will include some stretches that aid in pain relief by helping take stress off the low back and hips, core stabilization exercises and postural exercises.
40837810|NCT02495493|DRUG|Induction DCS chemotherapy|docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
40837811|NCT03386409|BEHAVIORAL|Free safe firearm storage device distribution|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
40837812|NCT03386409|BEHAVIORAL|Low cost safe firearm storage device|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
40837813|NCT06383104|OTHER|Intervention|Three myofascial release techniques will be performed with low load and long duration stretching to the myofascial complex to restore optimal length, decrease pain and improve function. In the development of the deep myofascial techniques, respiratory synchronisation with the patient will be performed. Proprioceptive neuromuscular facilitation techniques will be performed by executing diagonal spiral movements against resistance, several times, through a full range of motion. Three sets of three repetitions with 6-second contractions and a 30-second rest between sets shall be performed.
40837814|NCT01940393|DRUG|Cetirizine|Drug administration
40837815|NCT01940393|DRUG|Desloratadine|Drug Administration
40837816|NCT01940393|DRUG|Fexofenadine|Drug administration
41023123|NCT01376752|DRUG|HIPEC|HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
41023124|NCT02464501|OTHER|Paclitaxel administration using the OPC|
41023125|NCT01003418|BIOLOGICAL|GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine|Two doses; intramuscular administration
41023126|NCT01003418|BIOLOGICAL|Infanrix™-IPV/Hib|Routine infant immunisation vaccine, three doses administered intramuscularly
41023127|NCT01003418|BIOLOGICAL|Prevenar|Routine infant immunisation vaccine, three doses administered intramuscularly
41023128|NCT05683340|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
41357985|NCT05289999|DEVICE|Virtual reality headset for first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
41357986|NCT05289999|DEVICE|Virtual reality headset for second injection|Performing the second ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
41357987|NCT03770936|DRUG|Candesartan|Candesartan 8 mg/day
41497085|NCT05456555|PROCEDURE|Flapless with Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. In the test group, the roots will be conditioned with 24% ethylenediaminetetraacetic acid (EDTA) for 2 minutes. After rinsing with sterile saline, enamel matrix derivatives (EMD) will be applied on the dried root surface.
41023129|NCT05683340|DRUG|Placebo|placebo, tablet, once daily, for 12 weeks
41023130|NCT02033889|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
41357988|NCT03770936|DRUG|Ramipril|ramipril 1.25 mg/day
41357989|NCT00499161|BEHAVIORAL|New model of nursing care|
41357990|NCT00928642|DRUG|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
40837817|NCT01940393|DRUG|Ebastine|Drug administration
41357991|NCT00928642|DRUG|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
41357992|NCT05492994|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test
41357993|NCT05492994|DIAGNOSTIC_TEST|Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Pulmonary function test
41357994|NCT05492994|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging
40837818|NCT01940393|DRUG|Bilastine|Drug administration
40837819|NCT04462939|DIETARY_SUPPLEMENT|Elevit Breastfeeding & Postnatal Care|Multi-micronutrients, lutein and DHA soft gel capsules; one capsule daily, oral
41357995|NCT05492994|DIAGNOSTIC_TEST|Chest Computer Tomography|Chest Computer Tomography
41357996|NCT05492994|DIAGNOSTIC_TEST|Blood biomarker analysis|Blood biomarker analysis
41023131|NCT02033889|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
41160453|NCT02556918|DRUG|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG greater than 400 mg/dL; 7-9 units of insulin lispro"
41357997|NCT05585801|DEVICE|Dexcom G6 continuous glucose monitor|"Continuous glucose monitor will be used to measure interstitial glucose and aid in guiding the insulin therapy to achieve target blood glucose range of 6-10 mmol/l.~In the control group, blood glucose will be measured according to standards of care and a blinded continuous monitor will be used to compare the time i range between the arms."
41357998|NCT05585801|DIAGNOSTIC_TEST|Blood glucose measurements according to standards of care|Blood glucose will be measured using point of care glucose meter and standard biochemistry methods. Blinded CGM will be applied to obtain continuous glucose values for post-hoc comparison.
41357999|NCT00039546|DRUG|cyclophosphamide|
40837820|NCT04462939|DRUG|Placebo|No active ingredients except of 225 μg iodine; One capsule daily, oral
40837821|NCT02557984|DRUG|Placebo|Placebo Pill
40837822|NCT02557984|DRUG|Amisulpride|400 mg Amisulpride
40837823|NCT02557984|DRUG|Naltrexone|50 mg Naltrexone
40837824|NCT04764344|DRUG|Haloperidol|2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
40837825|NCT04764344|DRUG|Ondansetron|Ondansetron
40837826|NCT05574465|DEVICE|High resolution solid state manometry|The use of esophageal manometry device during removal of endotracheal tube by anesthesia
40837827|NCT03063190|DRUG|Vitamin D|patients will receive vitamin D supplementation according to guidelines
40837828|NCT03063190|DRUG|Placebo Oral Tablet|patients will receive placebo oral tablets
40837829|NCT03460548|DEVICE|Remogen|instil 1 drop of the product in each eye, 4 times per day
40837830|NCT03460548|DEVICE|Cationorm|instil 1 drop of the product in each eye, 4 times per day
40837831|NCT00636259|DRUG|Bicalutamide (Casodex)|150mg
40837832|NCT03710304|DRUG|Oxytocin|20 IU oxytocin or placebo ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal plus 110 ml saline by slow infusion
40837833|NCT03710304|DRUG|Tranexamic acid plus misoprostol|1 gm TA or separate placebo will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision,
40837834|NCT03710304|DRUG|misoprostol|400 μg misoprostol (2 tablets of 200 μg) will be give buccally after spinal anesthesia and few minutes before skin incision;
40837835|NCT05988190|BEHAVIORAL|Contextual Word Learning Intervention|Metalinguistic intervention consisting of meaning generation, explanation and feedback, with semantic diversity varying (no, medium, high).
40837836|NCT02938273|DRUG|avelumab|Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
40837837|NCT02938273|RADIATION|radiotherapy|5 times a week, 7 weeks, total dose 70 Gy
40837838|NCT02938273|DRUG|cetuximab|loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
41023132|NCT02033889|DRUG|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
41023133|NCT02033889|OTHER|Glimepiride|Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
41023134|NCT02033889|DRUG|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
41358000|NCT00039546|DRUG|epirubicin hydrochloride|
41358001|NCT00039546|DRUG|gemcitabine hydrochloride|
41358002|NCT00039546|DRUG|paclitaxel|
41358003|NCT00039546|PROCEDURE|adjuvant therapy|
40837839|NCT06164288|DRUG|Human Amniotic Epithelial Stem Cell Injection|"The dose escalation is carried out according to the 3+3 ascending principle, and a total of 3 dose levels are set:~1. Dose Level 1: 1×106 cells/kg;~2. Dose Level 2: 2×106 cells/kg;~3. Dose Level 3: 3×106 cells/kg; Note: In this study, if the maximum tolerated dose (MTD) is not explored at dose level 3 (3×106 cells/kg), it will be discussed by the Safety Review Committee (SRC) to decide whether to proceed with further dose escalation or expansion to 6 patients."
40837840|NCT04274803|DRUG|Intralipid, 20% Intravenous Emulsion|intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
40837841|NCT04274803|DRUG|Conventional therapy of antiphospholipis syndrome|the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
40837842|NCT02712424|BIOLOGICAL|DAR-901|
40837843|NCT02712424|BIOLOGICAL|Sterile saline placebo|
40837844|NCT00002177|DRUG|Hydroxyurea|
40837845|NCT00002177|DRUG|Nelfinavir mesylate|
40837846|NCT00002177|DRUG|Stavudine|
40837847|NCT00002177|DRUG|Didanosine|
40837848|NCT04113460|OTHER|Yoga|Yoga@work program included physical movements, yoga posture, breathing exercise, pranayama and yoga chants. Session with trainer was conducted on worksite once a week for an hour.
40837849|NCT02391532|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
40837850|NCT02391532|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
40837851|NCT05869500|DEVICE|Left Bundle Branch Area Pacemaker|Implantation of Medtronic 3830 lead for left bundle branch area pacing
40837852|NCT05869500|DEVICE|Right Ventricular Pacemaker|Implantation of a conventional right ventricular pacemaker lead
40837853|NCT05998135|DRUG|Atovaquone|Given PO
40837854|NCT05998135|PROCEDURE|Biopsy|Undergo biopsy
41358004|NCT05202106|BEHAVIORAL|Home visits|Home visits entail a visit a children's home every two weeks. During this visit, trained child development agents will engage parents in activities with the child and provide basic toys and learning materials.
40837855|NCT05998135|PROCEDURE|Computed Tomography|Undergo CT
40837856|NCT05998135|PROCEDURE|Paracentesis|Undergo paracentesis
40837857|NCT03568955|DIAGNOSTIC_TEST|International Prolonged Grief Disorder Scale (IPGDS)|Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items
40837858|NCT00499902|DRUG|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
40837859|NCT05361642|DRUG|Bupivacaine HCl 0.5% Injectable Solution|using nasal block including sphenopalatine ganglion block with general anesthesia to optimize surgical field
40837860|NCT05361642|DRUG|Dexmedetomidine|using dexmedetomidine with induction of general anesthesia to optimize surgical field
40837861|NCT01133015|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
40837862|NCT01133015|DEVICE|IVUS|intravascular ultrasound
40837863|NCT06495866|RADIATION|ultrasound|Ultrasound finding of entheseal sites of upper \& lower limbs of all groups and scoring according to enthesitis scoring system
40837864|NCT02904655|OTHER|healthy diet|Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
40837865|NCT00819455|BEHAVIORAL|Experimental|Active Life style modification-motivation by I.T technology
40837866|NCT00819455|BEHAVIORAL|Control arm (usual care/standard care arm)|Life style modification only once
40837867|NCT04464824|OTHER|no intervention|no intervention
40837868|NCT00182897|BEHAVIORAL|Skills Building for Caregiver Health and Care-recipient|
40837869|NCT05108805|PROCEDURE|Telemedicine Visit|A remote telemedicine visit with audio and video, using the internet with a nurse practitioner located elsewhere. The participant and NP will activate the telemedicine App in their electronic device. Family will obtain vital signs (BP, HR, RR, SPO2) and provide NP with the information. NP will also review the previous vital signs. Review of system questions are asked, and the answers given by subject recorded. Neurological assessment done, and ICE score calculated.
40837870|NCT05108805|PROCEDURE|Vital sign measurements|Participant and their family will record and measure vital signs using a wearable device and will place a call to the covering nurse practitioner to report the vital signs prior to reporting to the out patient visit.
40837871|NCT05108805|PROCEDURE|Out-Patient Clinic Visit|Physical exam and review of all available data
40837872|NCT05108805|PROCEDURE|Blood pressure and pulse oximeter|Participant and their family take their blood pressure and pulse oximeter
40837873|NCT02133807|PROCEDURE|Specific Lp(a) apheresis|"Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol"
40837874|NCT00702494|BIOLOGICAL|TB-403|Multiple IV
40837875|NCT00915148|OTHER|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
40837876|NCT03050762|OTHER|Data Collection|Participant information collected from either source document or direct participant response.
40837877|NCT03050762|BEHAVIORAL|Follow Up|Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
40837878|NCT03127423|PROCEDURE|Hybrid ablation|This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
40837879|NCT03127423|PROCEDURE|Thoracoscopic surgical ablation|This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
40837880|NCT06050798|DIAGNOSTIC_TEST|Von willebrand antigen|Von willebrand antigen change and hematological disorder in patients with angiodysplasia
40837881|NCT04273022|OTHER|Exercise|A single bout of standardized, moderate exercise
40837882|NCT04300803|BIOLOGICAL|Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression|Expanded Access Program, Non-Interventional Study
40837883|NCT04588090|PROCEDURE|The concurrent 3 weeks TP regimen|paclitaxel + cisplatin regimen (TP-TAX: 150mg/m\^2, DDP: 70mg/m\^2 (35mg/m\^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
40837884|NCT04588090|PROCEDURE|The concurrent weekly TP regimen|paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m\^2, DDP: 25mg/m\^2) 6 cycles of chemotherapy
40837885|NCT04588090|RADIATION|External radiation plus intraluminal after-loading irradiation|External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
40837886|NCT00006455|DRUG|cyclophosphamide|
40837887|NCT00006455|DRUG|cytarabine|
40837888|NCT00006455|DRUG|dexamethasone|
40837889|NCT00006455|DRUG|doxorubicin hydrochloride|
40837890|NCT00006455|DRUG|etoposide|
40837891|NCT00006455|DRUG|ifosfamide|
40837892|NCT00006455|DRUG|leucovorin calcium|
40837893|NCT00006455|DRUG|methotrexate|
40837894|NCT00006455|DRUG|therapeutic hydrocortisone|
40837895|NCT00006455|DRUG|vinblastine sulfate|
40837896|NCT00308074|DRUG|Aripiprazole|open-label, flexible-dosing
40837897|NCT06077370|DEVICE|deep TMS|Deep Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
40837898|NCT06077370|DEVICE|Sham TMS|Sham Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
40837899|NCT03606772|OTHER|Questionanniare|Filling printed questionnaire + Pelvic examination
40837900|NCT02544997|DRUG|Poziotinib|12mg P.O. for 2wks q21days
40837901|NCT05389189|BEHAVIORAL|Intervention Arm|"The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour)."
40837902|NCT04371341|PROCEDURE|erector spinae block by 0.25% bupivacaine|A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.
40837903|NCT04033874|OTHER|kangaroo care|kangaroo care
40837904|NCT04033874|OTHER|holding on the mother's lap|holding on the mother's lap
40837905|NCT04033874|OTHER|white noise listening|white noise listening
40837906|NCT04033874|OTHER|ambient sound listening|ambient sound listening
40837907|NCT06543927|DIAGNOSTIC_TEST|serum creatinine|Detection of renal impairment in patients receiving anticoagulants
40837908|NCT06543927|DIAGNOSTIC_TEST|INR|Detection of bleeding in patients with choronic kidney disease receiving anticoagulants
40837909|NCT00402493|DRUG|ibuprofen, latanoprost, brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
40837910|NCT00402493|DRUG|Ibuprofen, brimonidine, latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
40837911|NCT00402493|DRUG|Ibuprofen|ibuprofen 200mg
40837912|NCT01742065|OTHER|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
40837913|NCT03266913|DRUG|Probiotic|Probiotics drop
41497086|NCT05456555|PROCEDURE|Flapless without Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. No adjunct will be administered.
40837914|NCT03047291|DRUG|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
40837915|NCT03047291|DEVICE|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
40837916|NCT06103994|DIETARY_SUPPLEMENT|Multistrain probiotic|Multistrain Probiotic
40837917|NCT06103994|OTHER|Placebo|Placebo
40837918|NCT01711866|DRUG|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
40837919|NCT04807803|DIAGNOSTIC_TEST|Assessment of Minimal hepatic encephalopathy (MHE)|Assessment of MHE at the inclusion and 6 months after treatment if diagnosed with MHE: Serum ammonia analysis, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT) and evaluation of abdominal imaging, liver and splenic transient elastography, gastroscopy
40837920|NCT06508736|BEHAVIORAL|Storytelling|It is aimed that adolescents gain behavioral change through stories.
40837921|NCT06508736|BEHAVIORAL|Training|Participants will be trained on cyberbullying in 4 sessions.
40837922|NCT00788580|DRUG|pazopanib hydrochloride|
40837923|NCT00788580|DRUG|temsirolimus|
41160454|NCT02556918|DRUG|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG greater than 400 mg/dL; 7-9 units of insulin aspart"
40837924|NCT00788580|PROCEDURE|immunoenzyme technique|
40837925|NCT00788580|PROCEDURE|laboratory biomarker analysis|
40837926|NCT00788580|PROCEDURE|pharmacological study|
40837927|NCT00468988|DRUG|Travatan® Z|
40837928|NCT00468988|DRUG|Xalatan®|
41160455|NCT05501483|DRUG|Pioglitazone 45 mg|Starts with 45 mg
40837929|NCT00798317|DRUG|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
40837930|NCT00798317|DRUG|Placebo|Intravitreal injection placebo.
40837931|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term \[ST\], 42 months long term \[LT\])
41160456|NCT05501483|DRUG|Empagliflozin 25 MG|Starts with 25 mg
41160457|NCT05501483|DRUG|Semaglutide 7 MG|Starts with 3 mg daily for the first 2 weeks
40837932|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
41497087|NCT00886405|DRUG|Transdermal nitroglycerin|Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
41497088|NCT01902368|OTHER|gluten free diet|
41497089|NCT01531829|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Low dose (50mg/2h) rt-PA plus LMWH
40837933|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
40837934|NCT00121641|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
40837935|NCT00121641|DRUG|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
40837936|NCT00121641|DRUG|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
40837937|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
40837938|NCT00121641|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
40837939|NCT06203977|DRUG|Colchicine|0.3mg and 0.6mg tablets
40837940|NCT01270152|DRUG|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
40837941|NCT04284566|BEHAVIORAL|TAU + multicomponent treatment FIBROWALK|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30min.)~* Mindfulness techniques (30 min.)~* Physical exercise(30 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
40837942|NCT04284566|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option.
40837943|NCT01576185|OTHER|laboratory biomarker analysis|Correlative studies
40837944|NCT01576185|DRUG|quizartinib|Via gavage
40837945|NCT01576185|DRUG|sorafenib tosylate|Via gavage
40837946|NCT01547091|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
41023135|NCT02033889|BIOLOGICAL|Basal Insulin|Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
40837947|NCT01547091|DRUG|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
40837948|NCT01547091|BIOLOGICAL|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
40837949|NCT02170909|DRUG|BIBR 1048 MS low dose|
40837950|NCT02170909|DRUG|BIBR 1048 MS medium dose|
40837951|NCT02170909|DRUG|BIBR 1048 MS high dose|
40837952|NCT03469024|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
40837953|NCT03469024|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
40837954|NCT02273570|DRUG|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
40837955|NCT02273570|DRUG|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
40837956|NCT06510621|PROCEDURE|Socket-Shield Technique|A high-speed turbine was used to cut the tooth crown 1.5-2 mm from the buccal gingival margin. The tooth was then divided along the long axis, approximately 2 mm from the buccal side(Figure 1c, 1d). The palatal roots were removed using minimally invasive elevation and extraction forceps. Next, the buccal socket-shield was trimmed to approximately 4-6 mm in height (1 mm from the buccal gingival margin)\[18\], 3-4 mm in width, and 1-1.5 mm in thickness\[19,20\]. The trimming process required with clear visualization of the shield and calibration by periodontal probe. Finally, the socket-shield was removed by minimally invasive forceps when the adjacent tooth moved proximate to the shield during the process of closing orthodontic gap.
40837957|NCT05616884|PROCEDURE|Cementless fixation|Three dimensional printed porous metal, a biomaterial with morphological and mechanical properties that resemble those of native trabecular bone, is now being used for fixation of the tibial component in unicondylar knee arthroplasty. This can reliably achieve osseointegration into the tibia and could lead to a lower risk of aseptic loosening which is the leading cause of revision in partial knee replacements.
40837958|NCT05058846|PROCEDURE|Biospecimen Collection|Undergo blood, tissue, and saliva collection
40837959|NCT05058846|PROCEDURE|Magnetic Resonance Cholangiopancreatography|Undergo MRCP
40837960|NCT05058846|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40837961|NCT05058846|PROCEDURE|Endoscopic ultrasound|Undergo endoscopic ultrasound
40837962|NCT05058846|OTHER|Questionnaires|Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire
41160458|NCT03282877|BEHAVIORAL|iCST web-application|The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
41160459|NCT02380885|BEHAVIORAL|SCIT|psychosocial group intervention
40837963|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
40837964|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
40837965|NCT01519674|DRUG|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
40837966|NCT01519674|DRUG|metformin|Subjects will continue on their pre-trial metformin treatment.
40837967|NCT06175351|DRUG|9MW1911|Participants will receive IV 9MW1911 every 4 weeks.
40837968|NCT06175351|DRUG|Placebo|Participants will receive IV placebo every 4 weeks.
41023136|NCT02033889|DRUG|Metformin|Metformin \>=1500 mg/day, orally, once a day
41160460|NCT02380885|BEHAVIORAL|TAFT|psychosocial group intervention
41023137|NCT00110240|DRUG|vildagliptin|
41023138|NCT03007316|PROCEDURE|VIP graft|surgical soft tissue grafting concomitant to implant placement
41160461|NCT04208815|OTHER|Milk Polar Lipids|Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.
41160462|NCT04208815|OTHER|Milk Fat|Effects of the addition of 20 g milk fat.
40837969|NCT03888677|DRUG|5-FU, epirubicin and cyclophosphamide|Tailored dose escalation of epirubicin and cyclophosphamide.
40837970|NCT03199521|OTHER|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)|Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
41497090|NCT01531829|DRUG|Low Molecular Weight Heparin|0.1ml/10kg,q12h,5-7 days
40837971|NCT02358915|DEVICE|FastStart neuromuscular electrical stimulator|
40837972|NCT04226040|BEHAVIORAL|DOW and illness perception|Acutely ill patients are exposed to a survey regarding their degree of worry and illness perception
40837973|NCT01563016|DIETARY_SUPPLEMENT|glucose drink|participants will receive a drink rich in glucose
40837974|NCT02519569|OTHER|Internet-based cognitive-behavioral therapy|The intervention consists of ten writing assignments
40837975|NCT00957333|OTHER|ketamine|
40837976|NCT04059107|DEVICE|3D Printed Myoelectric Prosthetic Device|3D Printed Myoelectric Prosthetic Device
40837977|NCT06172920|DRUG|Tramadol hydrochloride|Patients are receiving tramadol hydrochloride under thoracic surgery
40837978|NCT06172920|DRUG|Aldolan|Patients are receiving meperidine under thoracic surgery
40837979|NCT06172920|DRUG|Morphine hydrochloride|Patients are receiving Morphine hydrochloride under thoracic surgery
40837980|NCT02279498|DRUG|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
40837981|NCT02279498|DRUG|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
40837982|NCT02530736|OTHER|4 metre gait speed|Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
40837983|NCT03613467|PROCEDURE|VATS lobectomy|Patients who received lobectomy by video-assisted thoracoscopic surgery
40837984|NCT03613467|PROCEDURE|Thoracotomy lobectomy|Patients who received lobectomy by thoracotomy
40837985|NCT02499042|DRUG|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
40837986|NCT03364972|DEVICE|Cataract surgery|Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
40837987|NCT02610933|DRUG|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
40837988|NCT02610933|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2 supplementation
41497091|NCT06400134|OTHER|Cognitive Function|The Standardized Mini Mental Test (SMMT) was used to evaluate the cognitive status of the geriatric individuals'. In the test, which has a total score of 30, those with a score of 24 or less are recommended to be evaluated for dementia.
40837989|NCT01608373|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
41023139|NCT06533202|BEHAVIORAL|Psychoeducational Programme|The objective of this type of programme is to equip individuals with the knowledge and skills required to navigate the challenges and capitalise on the opportunities presented by retirement. In particular, the programme strives to enhance the quality of life and attitudes towards retirement, elevate levels of life satisfaction, psychological flexibility, perceived social support and general health, self-efficacy and self-regulation, and mitigate stereotypes associated with ageing.
40837990|NCT01608373|DRUG|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
40837991|NCT01608373|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
40837992|NCT05788133|OTHER|treatment and screening by neuropsychological tests on humanoid robot|treatment and screening by neuropsychological tests on humanoid robot
40837993|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 80-110 mg/dL
40837994|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 150-180 mg/dL
41023140|NCT06533202|BEHAVIORAL|Education Programme|At the end of the baseline assessment, participants will receive instructions and recommendations to facilitate a positive and healthy transition to retirement, as part of an education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow.
40837995|NCT05059977|BIOLOGICAL|TAK-881|Participants will receive subcutaneous infusion of TAK-881 on Day 1.
41023141|NCT01330940|DIETARY_SUPPLEMENT|Orange soda|32 ounces per day
41358005|NCT05202106|OTHER|Afini App|Afini is an app designed to help parents provide nurturing environments and stimulation to their young children. Most caregivers currently connect to the platform via Facebook Messenger; once they sign up, the platforms start engaging the caregiver by recommending age-specific health- and development-promoting activities. Rather than just hoping that caregivers will later engage in these activities, the virtual assistant directly observes whether caregivers access the materials for the recommended activity, and asks caregivers to provide feedback on each task.
41497092|NCT06400134|OTHER|Physical Performance|The Brief Physical Performance Battery (BPPB) was used to assess the physical performance of geriatric individuals. All three physical performance measures (balance, walking speed, getting up from the chair) were scored between 0-4 according to the duration of the activity, these scores were summed and the total score was determined between 0 (poor) and 12 (very good).
40837996|NCT04023617|DRUG|Nivolumab|Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
41358006|NCT02779621|PROCEDURE|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
41358007|NCT02779621|PROCEDURE|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
41497093|NCT06400134|OTHER|Grip Strength|Muscle strength was assessed with a hand grip dynamometer. In the geriatric individuals, less than 30 kg for men and less than 20 kg for women was considered as low hand grip strength.
41497094|NCT06400134|OTHER|Walking speed|Walking speed was assessed with the 6-metre walk test. Speed was calculated by dividing each known distance by the time it took for each individual, on each trial, to walk from the start to the end points marked on the floor and then converting to m/s.
41497095|NCT06400134|OTHER|Mobility|The Time up Go test (TUG) was used for mobility. The risk of falling increases with increasing duration.
40837997|NCT01319721|PROCEDURE|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
40837998|NCT01319721|PROCEDURE|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
40837999|NCT01319721|PROCEDURE|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
40838000|NCT02916147|DRUG|Sevoflurane|
41023142|NCT02555410|DEVICE|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
41023143|NCT02839291|OTHER|quality of life questionaries|
41023144|NCT02839291|DRUG|intravenous or oral bone antiresorptive treatments|
41023145|NCT03071406|DRUG|Nivolumab|Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.
41023146|NCT03071406|DRUG|Ipilimumab|Ipilimumab 1 mg/kg/dose IV q6 weeks.
41023147|NCT03071406|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
40838001|NCT02916147|DRUG|Propofol|
40838002|NCT04869033|OTHER|Farinelli's Breathing Exercise|after 1 minute of normal breathing, follow this instruction; inhale 2 seconds, suspend 2 seconds, exhale 2 seconds. inhale 3 seconds, suspend 3 seconds, exhale 3 seconds. inhale 4 seconds, suspend 4 seconds, exhale 4 seconds. inhale 5 seconds, suspend 5 seconds, exhale 5 seconds. inhale 6 seconds, suspend 6 seconds, exhale 6 seconds. This cycle lasted 1 minute (60 seconds), called Farinelli's breathing (FB). When participants finished these cycle, repeated it again 4 times. 1 minute of NB + 4 minutes of FB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
40838003|NCT04869033|OTHER|Diaphragmatic Breathing Exercise|after 1 minute of normal breathing, inhale 2 seconds and exhale 2 seconds with nasal airway. Continued breathing this pattern until 4 minutes, then back to normal breathing 1 minute . 1 minute of NB + 4 minute of DB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
40838004|NCT01095354|DRUG|Sodium Chloride Inhalation|"Spirometry: all subjects Plethysmography and exhaled nitric oxide: \>6 years Multiple Breath Washout: Tidal breathing using a facemask \<9 years or mouthpiece \>9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches \<0.1%.~Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.~Induced sputum in asthma subjects \>10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum."
40838005|NCT01198509|DRUG|doxycycline|doxycycline - 100 mg twice per day, for 2 months
40838006|NCT01198509|DRUG|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
40838007|NCT04082780|DRUG|Rifamycin SV MMX|Intervention arm
40838008|NCT04082780|OTHER|Placebo|Placebo arm
40838009|NCT00861718|DRUG|AZD7268|Capsule, Oral, QD
40838010|NCT00861718|DRUG|AZD7268|Capsule, Oral, BID
40838011|NCT00861718|DRUG|Placebo|Capsule, Oral BID
40838012|NCT06171074|BIOLOGICAL|CM310|CM310 injection
40838013|NCT00568113|DRUG|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
41023148|NCT00123240|BEHAVIORAL|Low calorie high carbohydrate diet|65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
41023149|NCT00123240|BEHAVIORAL|Low calorie high fat/protein diet|High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
41023150|NCT00672880|BEHAVIORAL|Self-System Therapy|12 sessions of structured Self-System Therapy
41160463|NCT02130271|DRUG|Radioactive dye|The radioactive dye \[11C\]PBR28 will be administered through an intravenous line (IV).
40838014|NCT04248335|DRUG|Pantoprazole|single-dose administration
41023151|NCT00672880|BEHAVIORAL|Education|12 sessions of spine and muscle education including life style changes and medical treatments.
41023152|NCT00672880|OTHER|Standard Care|Study participants continue with their usual medical care, no changes.
41160464|NCT02130271|RADIATION|PET/MRI|All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
40838015|NCT04248335|DRUG|Midazolam injection|single-dose administration
40838016|NCT02851823|DEVICE|Periodontal curettes|
40838017|NCT02851823|DEVICE|Er-YAG+Nd-YAG lasers|
40838018|NCT06198855|DEVICE|QMon-20 device|Automatic Blood pressure measurement with QMon-20 device in the waiting room for 20 minutes every 5 minutes.
40838019|NCT02625870|DRUG|Omega-3-Acid Ethyl Esters 90 Soft Capsules|Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
40838020|NCT02625870|DRUG|Corn Oil|Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
40838021|NCT05391308|OTHER|Pre-polysomnography mesurement|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner), time spent sitting down (self-reporting)
40838022|NCT05391308|OTHER|Polysomnography measure|Apnea-Hypopnea Index
41023153|NCT01401530|BIOLOGICAL|denileukin diftitox (E7777)|E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
41023154|NCT03348904|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
41160465|NCT02130271|OTHER|Blood draw|Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
41160466|NCT01408875|DEVICE|Low electrical myostimulation|The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
41023155|NCT03348904|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
41023156|NCT03348904|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
41023157|NCT03348904|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
41023158|NCT03348904|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
41160467|NCT00982540|DRUG|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
41160468|NCT03139383|OTHER|dextrose solution|The patients received 5%D/N/2 during surgery
41358008|NCT00963469|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
41358009|NCT00963469|DRUG|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
41358010|NCT00963469|DRUG|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
40838023|NCT05391308|OTHER|Post-polysomnography measurements|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner)
40838024|NCT00262990|DRUG|EPO906 (Patupilone)|
40838025|NCT00262990|DRUG|doxorubicin|
40838026|NCT03609476|PROCEDURE|Room temperature saline instillation|Saline is used as room temperature
40838027|NCT03609476|PROCEDURE|Warmed saline instillation|Saline is warmed to 37Celcius prior to instillation
40838028|NCT03609476|PROCEDURE|No saline instillation|No saline is used prior to catheter removal
40838029|NCT04172168|DIAGNOSTIC_TEST|Heart rupture|Left ventricular free-wall ruptrue after AMI
41023159|NCT03348904|DRUG|Gemcitabine|Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
41023160|NCT03348904|DRUG|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
41023161|NCT03348904|DRUG|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
41023162|NCT05853094|PROCEDURE|Ileostomy|Protective loop ileostomy after low anterior resection
41023163|NCT05853094|PROCEDURE|Transverse colostomy|Protective loop transverse colostomy after low anterior resection
41023164|NCT04526808|OTHER|FODMAP diet|low FODMAP diet
41023165|NCT03498534|DRUG|Isoniazid 300Mg Tab|-TST tests will receive isoniazid 300Mg Tab for 6 months
41160469|NCT03139383|OTHER|saline solution|The patients received NSS during surgery
41358011|NCT06037499|DIAGNOSTIC_TEST|Glucometer Test|measurement of blood glucose concentration using different BGM and Reference Method
41497096|NCT06400134|OTHER|Fraility|Frailty assessment was performed using the FRAIL scale.The scale was scored by giving 0 or 1 point according to the answer given. The higher the score, the greater the fraility.
41497097|NCT04883619|OTHER|Placebo|Placebo will be administered intravenously.
41497098|NCT04883619|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
41497099|NCT04883619|DRUG|Standard-of-care treatment|Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
41497100|NCT01683292|DRUG|Inhaled VR040|
40838030|NCT05654688|OTHER|graston and muscle energy technique|"Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles."
40838031|NCT05650671|DEVICE|instrumented wheelchair|Measurements of pressure, temperature and humidity at the subject/cushion interface
41358012|NCT01429376|OTHER|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
41358013|NCT01429376|OTHER|Blood tests|"First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).~Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.~Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR."
41358014|NCT01429376|OTHER|Questionnaires|"Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.~All questionnaires were completed on the day of initial pulmonary function tests and three months later."
41358015|NCT01429376|OTHER|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
41358016|NCT06443281|DIAGNOSTIC_TEST|Neurophysiology|Pain-related evoked potentials and nerve conduction studies
41358017|NCT06443281|DIAGNOSTIC_TEST|Cardiovascular test|Blood pressure control, orthostatic intolerance test, baro-reflex sensitivity, heart-rate variability
41358018|NCT06443281|DIAGNOSTIC_TEST|Experimental pain paradigms|Temporal summation of pain, conditioned pain modulation
41358019|NCT06443281|DIAGNOSTIC_TEST|Quantitative sensory testing|Thermal and mechanical sensory testing
41358020|NCT06443281|DIAGNOSTIC_TEST|Clinical pain phenotype|Pain drawings, plus and minus signs of pain
41358021|NCT05950373|OTHER|Education video|six minute long education video focusing on protein and energy meals for older adults.
41358022|NCT02952027|BEHAVIORAL|Use-recording, patient-reminder alarm for incentive spirometry|
41497101|NCT01683292|DRUG|Placebo for VR040|Placebo arm
41497102|NCT01682486|DEVICE|BIP ETT (Bactiguard)|Ventilation of surgery patients during anesthesia using BIP ETT
41497103|NCT01682486|PROCEDURE|Standard ETT|Ventilation of surgery patients during anesthesia using standard ETT
41497104|NCT05484219|DEVICE|Functional navigation|Surgeon removes brain tumor or vascular malformation and assesses location of motor areas with functional navigation and intraoperative neuromonitoring
41497105|NCT05561543|DIETARY_SUPPLEMENT|Peppermint oil|Peppermint oil
41497106|NCT05561543|OTHER|Placebo|Placebo
41497107|NCT04587063|BEHAVIORAL|Fear Appeals|Email
41497108|NCT04587063|BEHAVIORAL|Message about Future Healthcare Costs|Email
41497109|NCT04587063|BEHAVIORAL|Endorsement from a Doctor|Email
41497110|NCT04587063|BEHAVIORAL|Comparison Table|Email
41497111|NCT04587063|BEHAVIORAL|Highlighting Cost Savings and Convenience|Email
41497112|NCT05743205|BEHAVIORAL|voluntary consultative wellness session|Professional wellness counseling sessions provided to health care professionals through voluntary enrollment. Consultative sessions will conducted throughout the course of 1 year and number of subsequent sessions will be determined by the participant.
41497113|NCT04199871|OTHER|dichoptic 3D movies|dichoptic movies presented on a Nintendo 3DS
41497114|NCT04244123|COMBINATION_PRODUCT|integrated information and nurse led telephone clinic|combining web-based information from easypod connect with nurse led telephone clinic
41497115|NCT04305587|DRUG|PF-07081532|Investigational Drug once daily for up to 42 days; multiple ascending dose design.
41497116|NCT04305587|OTHER|Placebo|Placebo once daily for up to 42 days.
40838032|NCT06459882|BEHAVIORAL|progressive relaxation exercises|Patients in the intervention group received 30-minute progressive relaxation exercises for 6 weeks
40838033|NCT02643823|BIOLOGICAL|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
40838034|NCT02643823|DRUG|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
40838035|NCT06182163|BEHAVIORAL|Sedentary time intervention|Tests the effect of a multi-component mobile health (mHealth) intervention on reducing sedentary behavior among adolescents with ALL during maintenance therapy. The intervention includes an app-based peer support group for study participants via WhatsApp, individualized coaching sessions with study staff, and prompts to move delivered via a Fitbit wearable fitness tracker.
41358023|NCT04524013|OTHER|There is no intervention. It is an observational study.|There is not intervention
41358024|NCT01494727|DRUG|CJ Amlodipine/Valsartan 10/160mg|single dose
41497117|NCT04305587|DRUG|Clopidogrel|Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
41497118|NCT00630929|DRUG|Ibuprofen|800 mg oral tablet 3 times daily with meals for 6 weeks
41497119|NCT00630929|DRUG|Placebo|Matched placebo orally for 6 weeks
41497120|NCT00630929|DRUG|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
41497121|NCT02099682|DRUG|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
41497122|NCT01151228|OTHER|Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.|Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
41497123|NCT00403637|DRUG|indacaterol maleate|
41497124|NCT05407324|DRUG|Dazucorilant 300 mg|300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.
41497125|NCT05407324|DRUG|Dazucorilant 150 mg|Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.
41497126|NCT05407324|OTHER|Placebo|Placebo will be administered once daily in 4 softgel capsules of placebo equivalent.
41497127|NCT03450174|DIETARY_SUPPLEMENT|Placebo|In control group, participants will receive only a placebo product
41497128|NCT03450174|BEHAVIORAL|Formative messgaes|In this group, participants will only receive daily formative messages
40838036|NCT05547789|DRUG|non steroidal anti inflammatory drugs|effect of non steroidal anti inflammatory drugs on macular changes
40838037|NCT00667290|BEHAVIORAL|Treadmill exercise|Graded treadmill walking 3 times per week for 3 months
40838038|NCT02933840|DEVICE|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
40838039|NCT03139799|BEHAVIORAL|Experimental - Puzzle Video Game Intervention|The psychological intervention consists of two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC; Bejeweled, PopCap Games). The puzzle games are delivered on tablet-computers computer (12.9-inch tablet computer iPad Pro, Apple Inc., Cupertino, CA, USA).
40838040|NCT03139799|BEHAVIORAL|Control - Tablet Newspaper Reading Intervention|The control intervention uses a newspaper/ magazine reading task that will be delivered to participants using the same device (iPad Pro) as in the experimental intervention. The newspaper/ magazine reading task will be running on the built-in Apple Newsstand application. Participants will be offered subscriptions for two newspapers and/or magazines that they are instructed to read following the same regime as in the experimental condition.
40838041|NCT06508034|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
40838042|NCT06508034|DIETARY_SUPPLEMENT|Live Freeze-Dried Lactic Acid Bacteria Probiotic|Given PO
40838043|NCT06508034|OTHER|Questionnaire Administration|Ancillary studies
40838044|NCT06256718|OTHER|Educational Intervention|Evidence-based strategy (PC TEACH)
40838045|NCT00167661|DRUG|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
40838046|NCT00587847|DRUG|Campath|Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
41023166|NCT03498534|DRUG|Isoniazid 300 MG|+ TST test will receive isoniazid 300MG Tab for 6 months
41023167|NCT03498534|DRUG|Isoniazid 300 MG|HIV positive patient will receive isoniazid 300MGTab for 6 months
41023168|NCT02447731|DEVICE|"Induction of sound waves in lungs by sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
41023169|NCT00608829|DEVICE|GORE TAG® Thoracic Endoprosthesis|Implant
41023170|NCT03224468|DRUG|Medical Marijuana|Patients in this group can choose when, where, and how much medical marijuana to use.
41358025|NCT01494727|DRUG|Novartis Exforge 10/160mg|single dose
41358026|NCT04629235|OTHER|wonder around|wonder around after 8 hours of bedrest
41358027|NCT04629235|BEHAVIORAL|bedrest|24 hours of bedrest
41358028|NCT05188560|OTHER|Action observation therapy|Subject is asked to observe videos with motor contents
41358029|NCT05188560|OTHER|motor imagery|mental simulation of a motor task
41358030|NCT01679964|DRUG|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
41358031|NCT03581032|DEVICE|Active reprogam|Reprogram Changes in AV/PV delays
41358032|NCT03953794|DEVICE|Fitbit Charge 3|Smart watch monitoring activity and movement, heart rate, sleep, and more
41358033|NCT05456516|BEHAVIORAL|Food Rating|Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants
41358034|NCT05135637|OTHER|Mobile health services|Mobile health services (MHS) will be deployed with one team per UC. MHS will focus on underserved areas to provide basic health services, immunization, \& health and nutrition counseling for under-five children \& WRAs.
41358035|NCT05135637|OTHER|Private practitioner engagement for immunization|Private healthcare providers (HCPs) will be taken on board to increase coverage of immunization. HCPs will offer routine vaccination to all under-five children visiting their clinics. Project team will liaison with EPI to arrange vaccines for them.
41358036|NCT05135637|OTHER|Community engagement and mobilization|Community engagement \& mobilization will focus on immunization, breastfeeding practices, \& optimal care-seeking for both pregnant women and young children. Opinion leaders will be engaged to gain support for activities.
41358037|NCT05135637|OTHER|Sehat Nishani - a health, nutrition and immunization app|Sehat Nishani App will be launched to assess feasibility of a health, \& immunization app to capture information on birth, nutrition, immunization \& growth records. Lady health workers (LHWs), lady health visitors (LHVs) in government health facilities, EPI vaccinators \& HCPs will be engaged to use app.
41358038|NCT01250236|DRUG|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
41358039|NCT01250236|DRUG|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
41358040|NCT03988465|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
41358041|NCT04830293|PROCEDURE|Carotis Doppler Ultrasound|Neck was rotated about 30-45 ° to the opposite side of the image. The common carotid artery and internal jugular vein were viewed transversely on the B Mode USG image. Then, the probe was rotated approximately 90 ° and the carotid artery was visualized in the longitudinal plane. The probe and guide line were adjusted so that the Doppler angle was 60 °. The image was created with the guiding line parallel to the blood flow. After imaging of the carotid artery bifurcation, measurements were made 1 cm distal to this level.
41358042|NCT00298285|DRUG|enoxaparin|
41358043|NCT03181776|OTHER|left lateral tilting in 15 degrees|The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge
41358044|NCT03181776|OTHER|left lateral tilting in 30 degrees|The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge
41358045|NCT03181776|OTHER|supine position|The mother will be placed in standard supine position
41358046|NCT03026556|DRUG|Dabigatran vs. Rivaroxaban|observed for 6 years
41358047|NCT03026556|DRUG|Dabigatran vs. Apixaban|Observed for 6 years
41358048|NCT04812821|OTHER|questionnaire|questionnaire post delivery
41358049|NCT03552172|OTHER|Physical activity|PHYSICAL ACTIVITY: Rhythm of meetings, number of meetings, place of meetings
41358050|NCT03552172|OTHER|Absence of or suspended physical activity|the brakes responsible for a stop or lack of practice
41358051|NCT05482958|DEVICE|HOP watch|Prospective observational study
41497129|NCT03450174|DIETARY_SUPPLEMENT|Fortified product|In this group, participants will receive fortified product on alternate day up till 8 months
41497130|NCT03450174|COMBINATION_PRODUCT|Fortified product plus|In this group participants will receive fortified product on alternate day and formative messages up till 8 months
41023171|NCT04521010|OTHER|COVID-19 pandemic|The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.
41023172|NCT00125554|DRUG|Metyrapone|
41497131|NCT05508841|OTHER|tDCS and Cognitive Training|Participants will receive mild stimulation or no stimulation along with cognitive training
41497132|NCT05141331|DEVICE|piezoelectric|Comparing Piezoelectric split-crest technique versus expansion using Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
41497133|NCT05913778|DEVICE|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
41023173|NCT00064805|BEHAVIORAL|Cognitive Therapy to Improve Reading|
41023174|NCT03223558|BEHAVIORAL|timing of initiation of cardiac rehabilitation|earlier timing of cardiac rehabilitation
41358052|NCT02337075|BEHAVIORAL|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
41358053|NCT02337075|DEVICE|Activity Mentor|
41358054|NCT06030531|OTHER|Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation|We will test for presence of biological markers in blood that may correlate with levels of spasticity or neurological recovery and functional improvement, including the presence or absence of neuroplastic genetic polymorphisms (e.g. BDNF Val66Met polymorphism), as well as circulating levels of neuroplastic(e.g. BDNF) or inflammatory factors (e.g. interleukins, TNF) that may affect neuronal growth and functional restoration.
41358055|NCT06030531|OTHER|Analysis of biomarkers|We will test for the presence of biological markers in the blood to compare the distribution of polymorphisms and biomarkers with the spinal cord injury patient population.
41358056|NCT03272672|OTHER|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment."
41358057|NCT03169842|DEVICE|pancreatic cyst fluid glucose analysis using a bedside glucometer|Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
41358058|NCT02918136|BIOLOGICAL|Adipose derived regenerative cells|
41358059|NCT02918136|DRUG|Cortisone Injectable|
41358060|NCT01212666|PROCEDURE|Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
41358061|NCT01212666|PROCEDURE|Saline|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
41358062|NCT04187586|OTHER|Extracorporeal shock wave therapy|ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
41497134|NCT02923986|DRUG|BP1001 (varying dose)|BP1001 (varying dose)
41497135|NCT02923986|DRUG|BP1001 (fixed dose)|BP1001 (fixed dose)
41497136|NCT02923986|DRUG|Dasatinib|Dasatinib
41497137|NCT03574948|DRUG|5-HTP|8 weeks active substance 5-HTP (2 x 100mg per day)
41497138|NCT03574948|DRUG|Placebo oral capsule|8 weeks placebo (2 x 1 caps per day)
41497139|NCT02312908|DRUG|Clonazepam|For experimental treatment of RBD
41497140|NCT02312908|DRUG|Placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
41497141|NCT03828916|OTHER|NuShield|SOC surgery with the addition of NuShield
41497142|NCT00430820|PROCEDURE|per intervention|per intervention
41023175|NCT06531733|DEVICE|Sleep Promoting (pink noise)|Participants will be provided with comfortable headphones to wear throughout their daytime sleep opportunity. The headphones will deliver a continuous pink noise sound no greater than 50 decibels. Participants will be allowed to turn down the sound of the pink noise if they find it too loud. Participants will wear the headphones with no noise during the placebo condition.
41358063|NCT05419596|PROCEDURE|Urologic Surgery|Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).
41358064|NCT06354075|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (explanatory video, information form, etc.).
41358065|NCT06045936|DRUG|Lidocaine|2 teaspoons of 2% lidocaine injection
41358066|NCT06045936|DRUG|Placebo|Saline injection
41358067|NCT05855382|OTHER|Persistent COVID-19|To determine the prevalence of persistent COVID-19 diagnosis in the current study, we will identify adults between 18 and 100 years of age who have had at least one positive SARS-CoV-2 RT-qPCR test from the COVID-19 database maintained by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.
41358068|NCT01244971|DRUG|Acarbose|100mg, 3 times daily
41358069|NCT01244971|BEHAVIORAL|Exercise|Moderate combined exercise, 50 minutes 3 times per week
41358070|NCT01244971|OTHER|Exercise + Acarbose|See respective monotherapy description
41358071|NCT05733468|DRUG|Theracal LC|After hemorrhage control , 1-1.5mm of TheraCal LC will be placed on the radicular pulp stumps followed by light curing, followed by the placement of IRM and composite restorative material after 2 weeks
41358072|NCT05733468|DRUG|MTA|After hemorrhage control , a small ball like consistency of 2-3mm of MTA will be placed on the radicular pulp stumps, followed by the placement of IRM and composite restorative material after 2 weeks
41358073|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
41358074|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
41358075|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
41358076|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
41358077|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
41497143|NCT00003960|DRUG|busulfan|
41497144|NCT00003960|DRUG|cyclophosphamide|
41160470|NCT05666141|DEVICE|Pharyngeal Electrical Stimulation|"A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters."
41358078|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
41358079|NCT01091116|DRUG|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
41358080|NCT01091116|DRUG|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
41358081|NCT01091116|DRUG|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
41358082|NCT01091116|DRUG|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
41358083|NCT01091116|DRUG|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
41358084|NCT01811693|DRUG|Glycerly Trinitrate|5mg/24hour (0.2mg/hour) transdermal
41358085|NCT01811693|DRUG|Glycerly Trinitrate|10mg/24hour (0.4mg/hour) transdermal
41358086|NCT01811693|DRUG|Glycerly Trinitrate|0.4 mg sublingual single metered spray
41358087|NCT02489994|DEVICE|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
41358088|NCT05979857|DRUG|SP-3164|SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
41497145|NCT00003960|DRUG|methylprednisolone|
41497146|NCT00003960|PROCEDURE|allogeneic bone marrow transplantation|
41497147|NCT00003960|PROCEDURE|in vitro-treated bone marrow transplantation|
41497148|NCT02043587|DRUG|DNR|Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
41497149|NCT02043587|DRUG|VCR|1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages \>50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
41497150|NCT02043587|DRUG|PEG-asp|2,000 IU/m2 IV for ages \</= 50, age \> 50, 1000 IU/m2 IV Day 16, Courses 1A \& 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
41358089|NCT04914091|OTHER|Semi-structured interviews and self-administered questionnaires|Interviews and questionnaires will be performed before administration of CAR-T cells, 3 month after and 6 month after, and will last 60 minutes each time. Semi-structured interview using pre-established questionnaires will be completed with a hospital pharmacist, concerning the patient's perception of his family, socio-professional environment, his knowledge of his illness and his treatment, the consumption of prescribed drugs outside the hospital, self-medication, complementary alternative therapies including herbal medicine. Seven self-administered questionnaires will be completed, concerning quality of life, Assessment of Cancer Treatment-Lymphoma, Beliefs about Medicines, Brief Illness Perception, satisfaction with medication, perceived social support scale, and on Health Literacy.
41023176|NCT06531733|DEVICE|Wake Promoting (blue enriched light plus a nap)|Participants randomized to the blue-enriched light and nap condition will have the blue-enriched light turned on during their nighttime stay in the lab. The light will be turned off for up to one hour during the nap. During the placebo condition, participants will have an overhead room light of \~150 lux illuminated throughout their nighttime stay in the lab. This light level reflects an older NASA standard which was used in the design of some Artemis vehicles. During the placebo condition, participants will be asked to engage in quiet activities such as reading for one hour.
41023177|NCT05778981|DIAGNOSTIC_TEST|FMD - Troponin measurement|Echographic FMD evaluation. Pre and post-operative troponin measurements.
41023178|NCT00592449|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
41023179|NCT00592449|BEHAVIORAL|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
41023180|NCT02031276|DRUG|risankizumab IV|risankizumab administered by IV infusion
41023181|NCT02031276|DRUG|risankizumab SC|risankizumab administered by SC injection
41023182|NCT02031276|DRUG|Placebo|Placebo for risankizumab administered by IV infusion
41023183|NCT06173791|DEVICE|DFDBA fibers|Bone Allograft fibers used in dental sinus reconstruction surgery
41023184|NCT06173791|DEVICE|DFDBA particles|Bone Allograft particles used in dental sinus reconstruction surgery
41023185|NCT06173791|DEVICE|DBBM|DBBM is routinely used in sinus augmentation to support dental implant placement and restoration of missing teeth.
41023186|NCT06207578|PROCEDURE|implant placement using crestal sinus approach|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision. After flap reflection, the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
41023187|NCT06207578|PROCEDURE|Implant placement using osseodensification|The implant motor will be adjusted on reverse mode with 800 to 1200 rpm. According to the desired implant dimension, Densah bur diameter will be used and then implant placement.
41023188|NCT02029443|DRUG|Acalabrutinib|Participants will receive acalabrutinib as stated in the arms' description.
41023189|NCT02682654|DEVICE|Dr. Scholl's Prototype Ankle Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
41160471|NCT05666141|OTHER|Sham treatment|In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
41358090|NCT02179216|OTHER|Hydration|Hydratation the first day in the arm 1 Hydration the second day in the arm 2
41358091|NCT02179216|OTHER|Venous contention|Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
41358092|NCT04134949|BEHAVIORAL|Cognitive Behavior Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
41358093|NCT04134949|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
41358094|NCT01598831|DRUG|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
41023190|NCT02682654|DEVICE|Dr. Scholl's Prototype Knee Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
41023191|NCT01713777|DRUG|"Lamotrigine Generic A"|
41023192|NCT01713777|DRUG|"Lamotrigine generic B"|
41160472|NCT04646135|DRUG|Lorazepam 4 mg/ml|Lorazepam will be administered intravenously according to the scheduled sequences.
41023193|NCT04260191|DRUG|AMG 910|IV Infusion
41023194|NCT03702465|OTHER|DNA-based dietary intervention|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the intervention arm, will be provided with a hard-copy of a genetic report, which will explain how their SNPs influence their dietary habits.
41023195|NCT03702465|OTHER|DNA-based dietary intervention using an app|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the exploratory arm, will be given personalised DNA-based dietary advice via the DnaNudge App.
41023196|NCT03702465|OTHER|Control arm|Standard care for pre-diabetic individuals: dietary advice as per the NICE guidelines for individuals who have pre-diabetes.
41023197|NCT00234884|BIOLOGICAL|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
41023198|NCT01595516|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
41023199|NCT01595516|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
41023200|NCT01595516|DRUG|Placebo|Gelatin capsule to be taken by mouth once per day for 12 weeks
41023201|NCT01595516|OTHER|Bradykinin|Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.
41023202|NCT01595516|OTHER|Saline|Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.
41023203|NCT01595516|OTHER|Vitamin C|The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (\~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.
40838047|NCT06256991|DRUG|Patiromer 8400 MG [Veltassa]|Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
41160473|NCT02937051|OTHER|Tobacco product administration and assessment|two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
41358095|NCT01598831|DRUG|Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
41358096|NCT03861832|DIETARY_SUPPLEMENT|KB220Z|Acts to enhance dopamine
41358097|NCT03861832|DIETARY_SUPPLEMENT|Placebo|A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
41358098|NCT03558503|DRUG|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
41358099|NCT00544674|DRUG|PR104|administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks
41358100|NCT00544674|OTHER|F-18-fluoromisonidazole|administered intravenously prior to PET scan
41358101|NCT03362827|OTHER|Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
41358102|NCT03362827|OTHER|Subjects without chronic low back pain|These participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
41358103|NCT00153699|DRUG|Topiramate|
41358104|NCT00999882|DRUG|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
41358105|NCT00412360|BIOLOGICAL|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
41358106|NCT00412360|BIOLOGICAL|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
41358107|NCT00412360|RADIATION|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
41358108|NCT00412360|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
41358109|NCT00412360|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
41358110|NCT00412360|DRUG|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
40838048|NCT06256991|DRUG|Placebo|Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
40838049|NCT05190861|DIAGNOSTIC_TEST|droplet digital PCR method|The droplet digital PCR method can detect nucleic acids from the most common pathogens (approximately 90%) responsible for BSIs according to Chinet2020 and takes about 4 hours to perform, reporting within the first 24h of suspected sepsis/septic shock.
40838050|NCT05190861|DIAGNOSTIC_TEST|blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling.
40838051|NCT02076906|DEVICE|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
40838052|NCT01170078|DRUG|Epoetin Hospira|IV dose 3 times a week.
40838053|NCT01170078|DRUG|Epogen|IV dose 3 times a week
40838054|NCT00160654|DRUG|Levetiracetam|"* Pharmaceutical form: oral tablets~* Concentration: 500 mg~* Route of administration: Oral use"
40838055|NCT02925169|DEVICE|CT Scan|CT imaging
40838056|NCT05141955|OTHER|Group Erector Spinae Plane Block (ESPB)|"Patients will receive general anesthesia initially then bilateral ESPB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed (not exceeding toxic dose) 150 mg "
40838057|NCT05141955|OTHER|Group Quadratus Lumborum Block (QLB)|"Patients will receive general anesthesia initially then bilateral QLB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed not exceeding toxic dose150 mg "
40838058|NCT05141955|OTHER|Group (C) (Control group)|Where patients will be operated under general anesthesia.
40838059|NCT01092793|DIETARY_SUPPLEMENT|Krill|Encapsulated oil from the antarctic crustacean Krill
40838060|NCT01092793|DIETARY_SUPPLEMENT|Fish oil|Encapsulated, raffined cod-oil
40838061|NCT03693911|BEHAVIORAL|Acceptance and Commitment Therapy|6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
40838062|NCT03656081|DRUG|inhaled Ambisome®|inhaled liposomal amphotericin B = inhaled LAmB
40838063|NCT03656081|DRUG|inhaled placebo|inhaled isotonic saline
40838064|NCT03656081|DRUG|Itraconazole|Itraconazole tablet
40838065|NCT04527939|PROCEDURE|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
40838066|NCT00870194|DRUG|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
40838067|NCT00870194|DRUG|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
40838068|NCT05827601|DIAGNOSTIC_TEST|respiratory specimen|participants will perform self-sampling with a nasopharyngeal swab
40838069|NCT05827601|DIAGNOSTIC_TEST|serum|participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood
40838070|NCT04058548|DIAGNOSTIC_TEST|Sit to stand test|Participants will complete a sit to stand test in addition to a 6 minute walk test
41358111|NCT00412360|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if \> 50 kg or 15 mg/kg IV q 8 hours if \< 50 kg beginning the morning of Day -3.
40838071|NCT02544373|DEVICE|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
40838072|NCT00328250|BEHAVIORAL|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
40838073|NCT02845531|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator and Optimal Medical Therapy
40838074|NCT02845531|DRUG|Optimal Medical Therapy|
40838075|NCT01831817|DRUG|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
40838076|NCT01831817|DRUG|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
40838077|NCT01831817|DRUG|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
40838078|NCT01831817|DRUG|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
40838079|NCT04876612|PROCEDURE|Transforaminal epidural steroid injection (TFESI)|Well trained pain physician performs all the fluoroscopy-guided transforaminal epidural steroid injection (TFESI), who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For TFESI, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under fluoroscopy guidance at the patient's symptom complaining level. After confirming with a contrast medium, 3 ml of 0.1875% ropivacaine and 5 mg of dexamethasone are administered.
40838080|NCT04761744|DRUG|Nivolumab|Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
40838081|NCT04392921|DRUG|Amiodarone|"Patients will undergo one of the two regimens of amiodarone, based on their ability to tolerate po (per os) intake in the post-operative period:~• All patient will receive 1050mg of amiodarone in 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~* If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* If unable to tolerate po intake: daily infusion of 1050mg in 100mL of 5% dextrose for postoperative days 1 to 5 or until the day of discharge (whichever occurs first)."
41358112|NCT06160531|DRUG|CC-42344|Anti-influenza A agent
41358113|NCT06160531|DRUG|Placebo|Matching placebo
41358114|NCT00508001|DRUG|Vandetanib|ZD6474 300mg
41358115|NCT00508001|DRUG|Vandetanib|ZD6474 100 mg
41358116|NCT00508001|DRUG|Best Supportive Care|Placebo + Best Supportive Care
41358117|NCT02293265|DRUG|Short Acting Beta Agonist (SABA)|Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
41358118|NCT01990001|OTHER|enrollment in online reminder system|Study personnel enrolled members in the online reminder system during their office visit.
41023204|NCT01428492|DRUG|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
41160474|NCT02368691|DRUG|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
41160475|NCT04148521|BEHAVIORAL|Behavioral Health - Virtual Patient Navigation|Patients are identified by a clinician in the ED as needing psychiatric evaluation and a referral is made to a tele-psych provider for a virtual consult. Patients can be enrolled to the intervention arm based on a randomization scheme that randomly allocates days that navigators are available. The psychiatrist will make a recommendation to admit or discharge the patient. For patients that have a discharge recommendation on days that BH-VPN is available, patients will be offered the BH-VPN program. Enrolled patients are followed for up to 45 days. On days where the navigator is available, all patients who meet eligibility criteria will be considered exposed to the intervention.
40838082|NCT04392921|DRUG|Placebo|"Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:~* All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~  o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first)."
40838083|NCT06507514|COMBINATION_PRODUCT|"blinatumomab and auto-HSCT sandwich  strategy"|The patients received sequential infusion of blinatumomab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after infusion. Following successful stem cell collection, autologous stem cell transplantation was conducted. Starting from the third month after autologous stem cell transplantation, the second maintenance treatment with brentuximab vedotin was administered, with one cycle every three months, for a total of four cycles. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
40838084|NCT00002254|DRUG|Alovudine|
40838085|NCT06066918|DRUG|Pregabalin 75mg|Pregabalin 75 mg twice a day
40838086|NCT03545997|DRUG|Montelukast 10mg|The capsules will be presented in box of 95 capsules packaged in unit blister
40838087|NCT03545997|DRUG|Placebo|Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
40838088|NCT05012007|OTHER|Reminder Phone|Standard reminder via phone (audiocare)
40838089|NCT05012007|OTHER|Reminder Text|reminder via text (VEText)
40838090|NCT05511350|DRUG|TJ210001|
40838091|NCT04375397|DRUG|Ibrutinib|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
40838092|NCT04375397|DRUG|Placebo|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
40838093|NCT06119438|OTHER|Aromatherapy|Aromatherapy is a TAT (Tapas Acupressure technique) method in which essential oils created from fragrant parts of plants are absorbed from the body and show their effects. The therapeutic, disease-relieving or preventive properties of essential oils are utilized
41358119|NCT03710460|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
41358120|NCT03710460|DRUG|Dapagliflozin plus Metformin XR|10/1000 mg, one per day before breakfast during 12 weeks.
41160476|NCT00786721|DEVICE|Diffuse Optical Spectroscopy|muscle properties scanning
41160477|NCT04748471|BIOLOGICAL|mRNA-1273|SARS-CoV-2 vaccine
40838094|NCT06038994|OTHER|No intervention|This is an obvertional study, and there is no intervention.
40838095|NCT04566653|DRUG|Calcium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
40838096|NCT04566653|DRUG|Lokelma® 5 g/45mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
40838097|NCT04566653|DRUG|Lokelma® 10 g/45 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
40838098|NCT04566653|DRUG|Veltassa® 8,4 g/80mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
40838099|NCT04566653|DRUG|Sodium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
41023205|NCT01428492|DRUG|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
41023206|NCT01428492|DRUG|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
41023207|NCT01384344|OTHER|observational|Observation during a physical exercise
41023208|NCT01639898|DRUG|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
41023209|NCT01639898|DRUG|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
41358121|NCT03710460|DRUG|Metformin XR|1000 mg, one per day before breakfast during 12 weeks.
41358122|NCT03157752|BEHAVIORAL|Quality of life questionnaire|Quality of life questionnaire
41497151|NCT02043587|DRUG|CTX|750 mg/m2 IV, days 1 \&15 for subjects \<40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 \& 16 for subjects \< 40 years of age if day 14 bone marrow M2 or M3; Courses 1A \& 2A
41497152|NCT02043587|DRUG|Prednisone|60 mg/m2 orally once daily on days 1-28 during Courses 1A \& 2A; Maintenance: Monthly, days 1-5
41497153|NCT02043587|DRUG|Liposomal AraC|25 mg intrathecal (IT), on days 1 \& 15 during Courses 1A \& 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
41497154|NCT02043587|DRUG|MTX|220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B \& 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
41497155|NCT02043587|DRUG|LCV|50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B \& 2B
41497156|NCT02043587|DRUG|AraC|2,000 mg/m2 IV, days 1-4 during Courses 1C \& 2C
41497157|NCT02043587|DRUG|Etoposide|500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C \& 2C
40838100|NCT06046690|DEVICE|Mechanical Ventilation Device|"During the first week of training, ventilator trigger sensitivity will be initiated at 20% of the patient's baseline MIP (NIF). Patients will train for 5 minutes twice a day for the first days. As the training progresses, the triggering sensitivity will be gradually increased to 30% and 40% of the initial MIP and the duration will be increased up to 30 minutes. During the training sessions, participants will be elevated to a position similar to the Semi-Fowler position at an angle of approximately 45°. Vital signs will be monitored regularly.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
41497158|NCT02043587|DRUG|Dasatinib|140 mg orally daily if BCR/ABL positive and/or Ph+
40838101|NCT06046690|DEVICE|External Device|"The IMT (Inspiratory Muscle Training) with device will commence at 20% of the value obtained from the NIF (Negative Inspiratory Force) measurement or the lowest pressure setting, depending on the patient's tolerance. The duration and intensity will be gradually increased. Once the participants are disconnected from the mechanical ventilator, the IMT device will be connected to the T-tube via a catheter mount with a Catheter Mount. Patients will be instructed to breathe against the resistance set on the IMT device. After completing 8 repetitions, the patient will be allowed to rest for a few minutes. This routine will be repeated for a total of 3 sets of 8 repetitions.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
40838102|NCT05674110|BEHAVIORAL|DSMES Intervention|This study will provide participants with on-line education, plus weekly text messaging that will contain messages of support or encouragement sent to participants in the individual's preferred language (English or Spanish). Participants will be encouraged to attend monthly group support meetings to review the content and address any questions. Group meetings will occur at 3-time intervals (end of months: 1, 2, and 3). Group support meetings will be held in-person at a food pantry and moderated by peer mentors, nursing students, registered dietitian nutritionist (RDN), and/or a diabetes care and education specialist (DCES). Group support meetings will be held in Spanish and/or English, with no more than 10 participants in a group at one time, and will last approximately 50 minutes. For the duration of the study, participants will continue to receive monthly food items from the food pantry.
40838103|NCT00869401|DRUG|dasatinib|Given orally
40838104|NCT00869401|DRUG|temozolomide|Given orally
40838105|NCT00869401|OTHER|placebo|Given orally
40838106|NCT00869401|RADIATION|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
41160478|NCT05051124|BEHAVIORAL|Peer Delivery of Medications|The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities
41160479|NCT05051124|BEHAVIORAL|Health Information Technology (HIT) Platform|To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.
41497159|NCT02043587|DRUG|Rituximab|375 mg/m2 IV once daily on days 1 \& 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C \& 2A
41497160|NCT02043587|DRUG|Hydrocortisone|Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
41497161|NCT01085123|DRUG|Rapimelt|oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
41497162|NCT01085123|DRUG|[11C]AZ10419369|solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
41497163|NCT01683838|DRUG|Fampridine-SR|25mg bid (twice daily)
41497164|NCT01683838|DRUG|Placebo|Placebo
41497165|NCT05700370|DIAGNOSTIC_TEST|MyProstateScore|MyProstateScore is a urine-based biomarker test used to predict the risk of clinically significant prostate cancer
41497166|NCT05489237|DRUG|IDRX-42|IDRX-42 will be administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.
41160480|NCT03408821|OTHER|Problem Solving Therapy (PST)|Participants will attend 8 weekly session of Case Manager (CM) implemented PST, a form of group talk therapy.
41160481|NCT05051696|DRUG|H101|Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
41160482|NCT04823117|OTHER|music therapy|music includes nature sounds recommended by the Turkish Psychological Association
41160483|NCT01362283|OTHER|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
41160484|NCT03732950|BIOLOGICAL|Pembrolizumab|Given IV
40838107|NCT03420105|OTHER|Neuropsychological, psycho-pathological and quality of life assessments|Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
40838108|NCT03420105|DRUG|Hormonotherapy|Adjuvant hormone therapy
40838109|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
41160485|NCT02676440|OTHER|Treatment|F13/T38
41160486|NCT02676440|OTHER|Comparator|M26
41160487|NCT05545319|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours
41160488|NCT05545319|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
41160489|NCT05545319|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
41160490|NCT01857362|DRUG|Nitisinone 20 mg|Nitisinone 20 mg capsules
41160491|NCT01857362|DRUG|Nitisinone 10 mg|Nitisinone 10 mg capsules
41160492|NCT02269917|DRUG|D/C/F/TAF|Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
41160493|NCT02269917|DRUG|Boosted Protease Inhibitor (bPI)|Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
41160494|NCT02269917|DRUG|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
41160495|NCT06127485|PROCEDURE|Neuropilates+occupational therapy and physiotherapy conventional|Participants assigned to the experimental group received 60 minutes of conventional rehabilitation combined with the Pilates Method, divided into 20 minutes of physical therapy, 20 minutes of occupational therapy and 20 minutes of Pilates Method. Pilates routines will be performed on a mat through the practice of Pilates activation exercises. Each participant will be given the necessary adaptations of each exercise according to their difficulties/disabilities.
41160496|NCT06127485|PROCEDURE|Occupational Therapy and Physiotherapy conventional|Conventional physical therapy in both groups will include stretching techniques and muscle activation of the lower limb and gait reeducation. Conventional occupational therapy will include stretching techniques and muscle activation in the upper limb as well as training in activities of daily living and functional activities of the upper limb.
41497167|NCT05489237|DRUG|IDRX-42|IDRX-42 will be administered at RP1bD(s) once or twice daily in continuous cycles of 28 days each.
40838110|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
40838111|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
40838112|NCT05920408|DRUG|EXS21546|EXS21546 Granule in Capsule
40838113|NCT05274360|BEHAVIORAL|Mobile evidence-based aphasia therapy|Use of mobile application to practice language for 2 weeks with a recommendation of 2 sessions per day of 20 minutes. The Android application, which is a Unity-based 2D game, will be installed on the patient's own phone, and they will play individually with the support of a family member if needed. The patients are free to start and stop using the application at any time. The application is safe to use, and it consists of therapeutic training methods such as object-matching, word search, writing, and manual voice recordings.
40838114|NCT05274360|BEHAVIORAL|Conventional aphasia rehabilitation|Control Group (conventional aphasia rehabilitation). No therapy as patients are in the chronic stage, where they do not receive healthcare rehabilitation training.
40838115|NCT06380010|OTHER|Mediterranean diet group|Females who met the inclusion and exclusion criteria were allocated in groups of one to either the Control group or the Intervention (MD) group using a random assignment method applied by an independent statistician. During the trial, every participant in both groups had two individual sessions with the assigned researchers. These sessions took place at the beginning of the trial and three months later, and involved anthropometry measurements, evaluation of dietary habits, assessment of psychological well-being, and collection of blood samples. Treatment allocation was not revealed to the appointed statistician until the end of the study and release of the final outcomes.
40838116|NCT02337725|DRUG|TVP-1012|TVP-1012 1mg Tablets
40838117|NCT02337725|DRUG|Placebo|Placebo tablets
40838118|NCT05108597|DRUG|Misoprostol|400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
40838119|NCT03765827|DRUG|Vitamine E Acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
40838120|NCT03765827|DRUG|No application of vitamin E acetate|Vitamin E acetate ointment will not be applied in this group
40838121|NCT02349490|DEVICE|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
40838122|NCT00509171|DEVICE|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
40838123|NCT04494308|OTHER|biomarker identification|flow cytometric analysis of eosinophils membrane molecules
40838124|NCT06027398|DIAGNOSTIC_TEST|SARS-CoV-2 RNA detection|SARS-CoV-2 RNA detection in used mask filters
40838125|NCT00548717|DRUG|Sirolimus|
40838126|NCT00548717|DRUG|Mycophenolate mofetil|
40838127|NCT00548717|DRUG|Bortezomib|
41497168|NCT03916510|BIOLOGICAL|Enadenotucirev|Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.
41497169|NCT03916510|DRUG|Capecitabine|Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
41497170|NCT03916510|RADIATION|Radiotherapy|50 Gy/25#
41497171|NCT06549114|DRUG|Leniolisib|The doses selected will range from 10 to 70 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 140 mg per day).
41497172|NCT02102516|DRUG|SPRIX(intranasal ketorolac tromethamine)|"Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing \>=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug."
40838128|NCT04942990|OTHER|calisthenic exercises|these exercises are a kind of exercise for increasing cardiovascular endurance
40838129|NCT02714361|DIETARY_SUPPLEMENT|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
40838130|NCT02714361|OTHER|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
40838131|NCT05272176|BEHAVIORAL|Coping Long Term with Active Suicide Program (CLASP)|Telehealth-based case management intervention designed to reduce suicidal behavior among individuals at high risk for suicide across the transition from inpatient hospitalization to the community.
40838132|NCT03631277|DEVICE|photo-activated oral disinfection|Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
40838133|NCT03631277|DRUG|Calcium Hydroxide|calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
40838134|NCT00697437|DRUG|Docetaxel|70mg q3wx 1 dose
41497173|NCT03151811|DRUG|Melflufen|Intravenous infusion
41497174|NCT03151811|DRUG|Pomalidomide|Oral capsules
41497175|NCT03151811|DRUG|Dexamethasone|Oral tablets
41497176|NCT00620100|DRUG|Docetaxel|
40838135|NCT00697437|DRUG|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
41358123|NCT03943394|OTHER|fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene|"Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris \[pH 8.0\], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with \~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope."
40838136|NCT04147936|DIETARY_SUPPLEMENT|AXA1665|Dietary supplement: AXA1665
40838137|NCT04147936|DIETARY_SUPPLEMENT|Placebo|Placebo
40838138|NCT06304506|OTHER|Cross sectional study|Physiological testing, Sampling of blood and abdominal adipose tissue and respiratory measurements at rest and during exercise
40838139|NCT05529966|DEVICE|NGENUITY|Device for 3-D viewing during placement of micro-stent placement.
40838140|NCT05529966|DEVICE|Conventional microscope|Device for stereoscopic viewing during placement of micro-stent placement.
40838141|NCT00050674|DRUG|Filgrastim-SD/01|6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
40838142|NCT04871594|DRUG|Nivolumab|On day 1, 22, and 43 240mg
40838143|NCT03754829|BEHAVIORAL|Her Sey Kontrol Altinda (HSKA)|HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.
40838144|NCT06339138|OTHER|Non-Interventional Study|Non-interventional study
41160497|NCT05269147|PROCEDURE|Sphenopalatine Ganglion Block (SPGB)|"The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop."
41160498|NCT01516502|OTHER|low-level laser therapy|An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
41358124|NCT04517825|DIAGNOSTIC_TEST|Cepheid Xpert HIV-1 Viral Load Assay|Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
41358125|NCT02287363|OTHER|No intervention involved|No interventions will be involved since it is an observational study
40838145|NCT01410708|DRUG|Dasatinib|
40838146|NCT06113575|DEVICE|NeuroStar TMS|NeuroStar TMS treatment - 90-120% of Observed MT, 3 pulses/burst, 5 bursts/sec, 2 sec stimulation, 20 msec interval, 20 trains, 600 total pulses/session for 36 treatments in 5 days. 6 treatments on day 1, 8 treatments on days 2, 3, and 4, 6 treatments on day 5.
40838147|NCT00733057|DRUG|Minocycline|Minocycline as an add-on drug (200 mg/day)
40838148|NCT00733057|DRUG|Placebo (200 mg/day)|
40838149|NCT05707481|OTHER|Clinical Pharmacist-Led Educational Intervention|Non Pharmacological management strategies include information related to life style modification, healthy dietary habits, physical activity and stress management techniques. In contrast, pharmacological educational intervention involves disease -related information ( diabetes/hypertension sign and symptoms, risk factor, complications, self-monitoring of blood pressure/glucose, symptoms and management of hypoglycemia/hypotension etc. ) and drug related information ( prescribed drug name, indication, contraindication, adverse effects etc.) as well as importance of adherence to prescribed medication and strategies to minimize DRPs issues. These teaching sessions will be carried out with the help of verbal communication, audio visual demonstration (including charts,pictorial etc) and information leaflets. Furthermore, a copy of educational package would be given to each participant for reference and guidance.
40838150|NCT05937594|GENETIC|Buccal swab saliva for further genetic testing|Genetic testing. Whole saliva RNA will be isolated for downstream microRNA quantification.
40838151|NCT00710242|DRUG|DF01|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
40838152|NCT00710242|DRUG|Placebo|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
40838153|NCT02649192|BIOLOGICAL|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
40838154|NCT02649192|DIETARY_SUPPLEMENT|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
41160499|NCT03835403|OTHER|Activation of HeartRunners|Activation of volunteer citizen first-responders to respond to nearby cardiac arrests
41160500|NCT02735798|DRUG|MM-302|
41160501|NCT02735798|DRUG|Trastuzumab|
41160502|NCT04117256|DEVICE|Direct Current Stimulation|20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm
41497177|NCT04277143|DRUG|Daptomycin|"Adult patients are given the recommended dose of daptomycin for injection. Patients with creatinine clearance (CLCR) ≥ 30 mL / min: 6 mg / kg every 24 hours.~Patients with creatinine clearance (CLCR) \<30mL / min (including hemodialysis or peritoneal dialysis): 6mg / kg every 48 hours. Dissolve 6mg / kg of this drug in 0.9% sodium chloride injection and instill it over a 30-minute time course once every 24 or 48 hours."
41497178|NCT01119183|BEHAVIORAL|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
41023210|NCT03356002|DEVICE|C-Scan System|"Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
40838155|NCT02649192|OTHER|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
40838156|NCT03106285|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938|5 drops of active oil drops. The active dose consists of 10\^8 CFU L retueri DSM17938
41023211|NCT01358526|DRUG|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
41023212|NCT01358526|DRUG|Placebo|Placebo tablets to match OXN taken orally every 12 hours
41358126|NCT02473380|DEVICE|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
41023213|NCT01584284|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.
41023214|NCT01313572|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
41497179|NCT01119183|BEHAVIORAL|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
41497180|NCT05499949|DIAGNOSTIC_TEST|NASH screening|Evaluate liver steatosis and elasticity using transient elastography in the FONS group
40838157|NCT03106285|DIETARY_SUPPLEMENT|Placebo|5 drops of placebo drops
40838158|NCT01495520|DRUG|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
40838159|NCT01495520|DRUG|Placebo|os, pill, b.i.d., 30 days
40838160|NCT06376071|DIAGNOSTIC_TEST|functional endoscopic sinus surgery|functional endoscopic sinus surgery for diagnosis the disease
40838161|NCT00901810|DEVICE|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
41023215|NCT01313572|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
41023216|NCT04363905|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
41023217|NCT04363905|DIETARY_SUPPLEMENT|Ferrous sulfate|20 mg per day of elemental iron for 6 weeks
41023218|NCT02480621|DRUG|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
41023219|NCT04279574|DEVICE|Lithium disilicate onlays (IPS emaxCAD/Ivoclar)|Restoration of posterior teeth
41497181|NCT05499949|DIAGNOSTIC_TEST|Cardiac dysfunction screening|Evaluate cardiac dysfunction in 60 patients from the FONS group with transthoracic echocardiography
41497182|NCT05499949|DIAGNOSTIC_TEST|Liver biopsy|For participants from the FONS group with an elevated liver fibrosis measurement (≥F2) with TE, a laparoscopic liver biopsy will be performed during the bariatric procedure.
40838162|NCT00901810|DEVICE|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
40838163|NCT02235103|OTHER|Sperm Chromatin Dispersion Test|
40838164|NCT05900570|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
40838165|NCT02335060|DRUG|Delta-9-THC|Active Delta-9-THC (0.036mg/Kg) given intravenously.
40838166|NCT02335060|DRUG|N-acetylcysteine|A pill given orally.
40838167|NCT02335060|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
40838168|NCT02335060|DRUG|Placebo|"Placebo sugar pill given orally with no N-acetylcysteine."
40838169|NCT02455076|DRUG|Exenatide|Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
40838170|NCT02455076|DRUG|Glargine|"Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.~1. FBG \>180 mg/dL, no hypoglycemia; glargine increased by 4 IU.~2. FBG \>140 mg/dL, no hypoglycemia; glargine increased by 2 IU.~3. FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.~4. FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.~5. FBG or RBG \< 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.~6. FBG or RBG \< 40 mg/dl, decrease dose of glargine by 30%."
40838171|NCT02455076|DRUG|Rapid-acting insulin analogs|"If the BG levels are \>140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG\> 400 mg/dL, the insulin will be 8,12 or 16 units."
40838172|NCT01735071|DRUG|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
40838173|NCT01735071|DRUG|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
40838174|NCT00815828|OTHER|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
40838175|NCT00185601|BEHAVIORAL|Internet Diabetes Self-Management Program|
40838176|NCT04334564|DRUG|Ginkgo biloba capsule|Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
40838177|NCT04334564|DRUG|Placebos|Placebos were controls.
41023220|NCT04279574|DEVICE|Chairside zirconia crowns (3M)|Restoration of posterior teeth
41160503|NCT04117256|DEVICE|Sham DCS|20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.
40838178|NCT06546072|OTHER|MRI|
40838179|NCT06324695|BEHAVIORAL|HautKompass|The HautKompass program is a structured self-guided online psychosocial intervention designed to reduce self-stigma in people with visible chronic skin diseases. It combines educational content and practical exercises based on cognitive-behavioral therapy (CBT), namely cognitive restructuring of negative automatic thoughts and cultivating self-compassionate thinking and behavior. The program consists of eight skin-generic modules (on average, 15-20 minutes per module, one module per week).
40838180|NCT02406729|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
40838181|NCT02406729|OTHER|Placebo|Route:subcutaneous
41160504|NCT05693480|DEVICE|Balance sensor|Participants will engage in the device test, clinical assessment tests, and related user experience surveys to uncover problems in the effectiveness, efficiency, and acceptance of the device prototype. The whole test will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the validity and reliability of the device, user experiences, and the accuracy of the device's fall prediction.
41160505|NCT01716923|BIOLOGICAL|S-303 Red Blood Cells (RBCs) - Test|
41160506|NCT01716923|BIOLOGICAL|Conventional, untreated red blood cells (RBCs) - Control|
41497183|NCT02024113|OTHER|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
41497184|NCT01401556|OTHER|case management|
41497185|NCT01401556|OTHER|Multifaceted quality improvement intervention|
41497186|NCT00046241|DRUG|Extended-release bupropion hydrochloride|
41497187|NCT01724086|DRUG|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
41497188|NCT01724086|DRUG|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
40838182|NCT02491424|DEVICE|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
41023221|NCT03881462|PROCEDURE|Axillary nerve block for artificial deltoid muscle palsy|"Axillary nerve block block (AXNB):~The ultrasound probe is placed transversally in the infraclavicular region with the arm in 90° abduction. The brachial plexus and its cords are identified l lateral to the brachial artery. The posterior cord is identified by ultrasound and is blocked - or, if the axillary nerve visible too - the axillary nerve is selectively blocked when it leaves the posterior cord and lies on the subscapular muscle accompanied by the posterior circumflex humeral artery. Using an in-plane technique, a short bevel connected to a nerve stimulator with the setting 0.5 mA current intensity, 0.1 ms impulse duration and 2 Hz impulse frequency for dual guidance, will be advanced until its tip is positioned near the nerve without eliciting motor contractions. After careful negative (for blood) aspiration local anesthetic will be applied until the targeted neuronal structure is surrounded by the injected fluid."
41023222|NCT04632667|BEHAVIORAL|Comparison School Group|All control schools will receive training and materials for the CATCH sun safety curriculum. Ray and the Sunbeatables®: A Sun Safety Curriculum is an evidence-based curriculum educates children, parents and teachers about sun protection and promotes sun safety behaviors in an effort to reduce children's lifetime risk of developing skin cancer. Training will be conducted with booster trainings yearly.
40838183|NCT02502162|DRUG|LDN|
41023223|NCT04632667|BEHAVIORAL|Intervention School Group|"This intervention includes toothbrushing which will be implemented as a daily activity to develop skills and technique,classroom curriculum, which includes theory-based interactive lessons on oral health care,the physical education component consisting of an activity box containing different structured physical activities that will integrate the nutrition and oral health education messages, all cafeteria-based intervention materials including the tooth friendly Eat Smart guide, signage, nutrition labeling, menu planning and labeling using the tooth-friendly Go-Slow-Whoa CATCH terminology will be provided to the food service staff that is displayed across the cafeteria and sent home to parents and parents will be provided with tools and tips for maintaining oral health with website resources,parent-child homework activities, send-home infographics on dental care, parent-monitored tracking of child oral health,family fun nights in schools, and social media."
41023224|NCT06234605|DRUG|HC-7366|HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.
41023225|NCT06234605|DRUG|Belzutifan|Belzutifan is a potent and selective HIF-2α inhibitor
41023227|NCT01307501|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
40838184|NCT02502162|DRUG|Placebo|Sugar pill
40838185|NCT05105867|BIOLOGICAL|Anti-CD19 Universal CAR-T Cells injection|Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion.
40838186|NCT05503888|DRUG|Almonertinib combined with SHR-1701|"Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral"
40838187|NCT05503888|DRUG|Almonertinib|"Phase Ⅱ:~Almonertinib: tablets, oral"
41497189|NCT01724086|DRUG|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
40838188|NCT02272179|BEHAVIORAL|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, Brite); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
40838189|NCT02272179|BEHAVIORAL|Brite|Brite is a HIPAA-compliant mobile application designed to provide the participants with emotion regulation and distress tolerance skills, social support, and convenient access to safety plan resources via the patients' phone.
40838190|NCT02272179|BEHAVIORAL|Treatment as Usual|Participants received usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which included a paper safety plan.
40838191|NCT04365933|DRUG|EYP001a|Oral tablets
40838192|NCT04365933|DRUG|Entecavir|Oral tablets
40838193|NCT04365933|DRUG|Pegylated interferon alpha2a|Subcutaneous
41358127|NCT02352181|PROCEDURE|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if fibrinogen \<1gram per liter~Platelet concentrate :~* if platelets \<50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~* if platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~* if prothrombin\<40% before transfusion at anhepatic phase or in case of bleeding.~* if prothrombin\<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
40838194|NCT04836676|DEVICE|C-REX Device|"The investigational devices are C-REX LapAid Cath or C-REX RectoAid Cath. C-REX LapAid Cath consists of an invasive surgical part, i.e. anastomotic ring comprised of two LapAn coupled by DMC/DM, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX RectoAid Cath consists of an invasive surgical part, i.e. an anastomotic ring comprised of RectoAn and LapAn, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX LapAid Cath and C-REX RectoAid Cath are easy to use, with unique possibility to control and validate the integrity of the anastomosis during and after surgery."
40838195|NCT00771121|DRUG|urea/lactic acid|new emulsion type
40838196|NCT00771121|DRUG|Placebo|only emulsion base
40838197|NCT06414330|BIOLOGICAL|Ringer acetate based Del Nido cardioplegia|All patients will receive hypothermia 29 - 32 ℃ and cardioplegia will be injected between the aortic valve and aortic cross clamp in a pressure not less than 50 mmHg above systolic pressure. After removal of aortic cross clamping, the heart will be monitored for ventricular arrhythmias, early recovery, and postoperative 24 hours serum troponin and new changes in echocardiography.
40838198|NCT06414330|BIOLOGICAL|HTK|Giving HTK instead of Del Nido
40838199|NCT03055390|DRUG|hyoscine butylbromide|Intravenous administration of hyoscine butylbromide during first stage of labor
40838200|NCT03055390|DRUG|placebo|2ml of saline intravenous
40838201|NCT01019837|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
40838202|NCT05546671|DIAGNOSTIC_TEST|Hand grip strength measurement|"Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI \>28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI \>29: hand grip strength ≤21 kg"
41023228|NCT03029208|DRUG|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
40838203|NCT05428813|BEHAVIORAL|art therapy techniques|Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
40838204|NCT02616770|DRUG|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
40838205|NCT02616770|DRUG|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
40838206|NCT02616770|DRUG|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
40838207|NCT02616770|DRUG|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
40838208|NCT02616770|DRUG|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
40838209|NCT02616770|DRUG|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
40838210|NCT02672592|DRUG|Anakinra|Anakinra 100mg s.c. bid
40838211|NCT02672592|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% s.c. bid
40838212|NCT00581360|DRUG|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
40838213|NCT04806802|DEVICE|APIOC Sphere and APIOC Astigmatism|Single Vision Contact Lenses
40838214|NCT01300455|DRUG|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
40838215|NCT01300455|DRUG|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
40838216|NCT00257972|DRUG|aripiprazole|
40838217|NCT03703323|OTHER|Rotative thromboelastometry analysis|Obtaining blood sample (one tube of blood)
40838218|NCT00575874|DRUG|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
40838219|NCT00575874|DRUG|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
40838220|NCT00575874|DRUG|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
40838221|NCT00575874|DRUG|pioglitazone HCl|30 mg capsules once daily for 12 weeks
40838222|NCT00575874|DRUG|placebo|matching tablets or capsule once daily for 12 weeks
40838223|NCT03410342|OTHER|LFV|1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day
40838224|NCT03410342|OTHER|HFV|4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
40838225|NCT03410342|OTHER|CC|4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
40838226|NCT01314560|OTHER|Blood sample|Blood sample
40838227|NCT02438345|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCr5
40838228|NCT02952560|OTHER|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
40838229|NCT06054256|BEHAVIORAL|Group CBT-I|The group-based intervention will consist of 6 weekly sessions (90-min, 5-8 pregnant women in each group). The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia with the followings: psycho-education about sleep and sleep hygiene (e.g., psychoeducation about sleep during pregnancy and normal development and patterns of infant sleep, psychoeducation on ways of improving infant sleep, strategies to limit the development of unwanted sleep associations, etc.), stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
40838230|NCT06054256|BEHAVIORAL|App-based CBT-I|The smartphone app-based intervention will consist of 6 weekly sessions. The app-based intervention will involve a self-paced, fully automated digital programme with interactive components. The structure of the app involves six sequential modules (comparable to the six treatment sessions delivered in groups) with different elements to engage the users, such as animated videos, case vignettes, narration, quizzes, and homework assignment. Each module will be unlocked and released to the participants every week after the previous module has been completed. Personalised feedback will be provided by the app following the completion of sleep diary each week. Automated messages will be sent to the participants regularly via phone to remind them of implementing learned strategies after each module, as well as timely completing the treatment modules and sleep diaries.
40838231|NCT06054256|OTHER|Health related psychoeducation|The control group will receive 6 sessions of group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components.
40838232|NCT06540989|BEHAVIORAL|Immediate treatment|Participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
40838233|NCT06540989|BEHAVIORAL|Deferred treatment|This group of participants will receive the same treatment as those in the immediate treatment group. The only difference is the timeline of treatment onset. Therefore, participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
40838234|NCT06201351|DEVICE|adaptive radiotherapy|MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
41023229|NCT03029208|DRUG|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
40838235|NCT03094559|DEVICE|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
40838236|NCT05007977|DRUG|ZT-01 low dose|Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
40838237|NCT05007977|DRUG|ZT-01 high dose|Single SC injection of ZT-01 20 mg during hypoglycemic clamp
40838238|NCT05007977|DRUG|Placebo|Single SC injection of placebo during hypoglycemic clamp
41023230|NCT03029208|DRUG|Iron therapy|Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
40838239|NCT00275756|DRUG|Timolol (drug)|Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp \& Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
41497190|NCT01724086|DRUG|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
40838240|NCT00275756|DRUG|dorzolamide (drug)|Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp \& Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
40838241|NCT00275756|DRUG|brimonidine (drug)|Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
40838242|NCT00275756|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
41497191|NCT01724086|DRUG|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
41497192|NCT01724086|DRUG|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
41497193|NCT03489109|BEHAVIORAL|Intermittent fasting|Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet
41497194|NCT03489109|OTHER|Standard of Care|Subject will receive standard of care recommendations for healthy diet and lifestyle
40838243|NCT00275756|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements, in total 2x 5 measurements on two study days
40838244|NCT00275756|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
41160507|NCT06333496|DIETARY_SUPPLEMENT|GLP1 Booster (GB)|GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, White kidney bean (Phaseolus vulgaris) extract, berberine (from Berberis aristata bark extract), and chromium (III) an essential trace mineral. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
41160508|NCT04841811|DRUG|Almonertinib|ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
41160509|NCT05319002|BEHAVIORAL|Group EMDR|The eight phases of the adapted group EMDR protocol was administered during each session: 1. Meeting: Explaining the nature of trauma, group rules, name tags, filling in the scales. 2. Preparation: Exploring children's support system, explaining EMDR, safe place, resource exercise, and installation with bilateral stimulation (BLS, butterfly hug or knee tapping). 3. Assessment: Drawing the worst image on a small separate sheet of paper, SUD level, (negative cognition, emotions, body sensations - if possible). 4. Desensitization: It is done with drawing on 4 separate papers with BLS (butterfly hug or knee tapping). 5. Installation: With the healing story written according to the adaptive information processing (AIP) model, the installation is accompanied BLS. 6. Body scan: A positive body state is installed with the relaxation technique. 7. Closure \& future template: Strong closure with artwork. 8. Re-evaluation: if possible.
41160510|NCT02089984|BEHAVIORAL|Internet Based CBT Training|
40838245|NCT06259682|BEHAVIORAL|Paradoxical Intention|Paradoxical intention (PI). PI is described as instructing patients with sleep onset insomnia to try to remain awake for as long as possible rather than to focus on trying to fall asleep
41497195|NCT03963986|DEVICE|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
40838246|NCT04022980|DRUG|Nivolumab|HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
40838247|NCT02858752|OTHER|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
40838248|NCT02858752|OTHER|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, ...). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
40838249|NCT02858752|OTHER|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
40838250|NCT02858752|OTHER|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
40838251|NCT02858752|OTHER|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
40838252|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
40838253|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
40838254|NCT00300365|DRUG|Pioglitazone|Pioglitazone, initially 30 mg, then titrated to 45 mg/day
40838255|NCT00300365|OTHER|Placebo|Pioglitazone placebo
40838256|NCT00300365|DRUG|Niacin ER|Niacin ER 2.0 g/day
41358128|NCT02352181|PROCEDURE|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM \<8 mm~Platelet concentrate :~* If MCF EXTEM \<40mm or A10\<35 mm and MCF or A10 FIBTEM \>8mm.~* If platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~  2 Fresh frozen plasma if CT EXTEM \>100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~* if fibrinolysis in EXTEM~* Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes \>15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
41358129|NCT06208410|DRUG|JS105|JS105 is administered once daily, orally
41497196|NCT02113189|OTHER|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
40838257|NCT00300365|DRUG|Aspirin|asprin 325 mg/day
40838258|NCT00129467|DRUG|Methylphenidate|"Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.~If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.~Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is \> 10 at day 18, the dose may be increased to 15 mg bid."
41160511|NCT05036499|BEHAVIORAL|Personalized Feedback Intervention|Providing corrective normative feedback on alcohol use, psychoeducation on the interplay between pain and alcohol use, and providing exercises to target pain-related anxiety
41160512|NCT05245084|DRUG|CKD-386(3)|QD, PO
41160513|NCT05245084|DRUG|D013, D326, D337|QD, PO
41497197|NCT02113189|OTHER|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
41497198|NCT02113189|OTHER|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
41160514|NCT03228654|PROCEDURE|Unipolar Electrocautery sealing of vessels|"1. Vaginal walls are incised by monoplar current (40 W)~2. A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.~3. uterine vessels are individually secured.~4. Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements."
41497199|NCT04610372|RADIATION|Hypofractionated external beam radiotherapy|5500 cGy/20 fractions delivered 5 days per week over 4 weeks
41497200|NCT04610372|RADIATION|High dose rate brachytherapy|A single fraction of 19 Gy is delivered from an automated afterloading Iridium-192 source via interstitial catheters placed under ultrasound guidance
41497201|NCT04610372|RADIATION|Permanent seed implant|Iodine-125 radioactive seeds are implanted permanently in the prostate in a single procedure under transrectal ultrasound guidance
41497202|NCT04610372|RADIATION|Stereotactic body radiotherapy|External radiation using SABR technology delivers 36.25 Gy to the prostate in 5 fractions given either once weekly for 5 weeks or every second day over 2 weeks.
41497203|NCT04216667|PROCEDURE|Catheter ablation|Catheter ablation
41497204|NCT02863783|DEVICE|EUS with Fiducial|EUS will be used to place fiducial into pancreas tumor at time of biopsy
41497205|NCT01783548|DRUG|BDP Nasal Aerosol|
41497206|NCT01783548|DRUG|Placebo|
41497207|NCT05818618|DRUG|Clobetasol Topical Gel|Topic Clobetasol gel applied locally on OLP lesions.
41497208|NCT05818618|DRUG|Placebo|Placebo oral gel applied locally on OLP lesions.
41497209|NCT00054574|BIOLOGICAL|panitumumab|
40838259|NCT00129467|DRUG|Placebo|"Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention."
40838260|NCT00129467|DRUG|Selective Serotonin Uptake Inhibitor (SSRI)|"Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.~A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion"
40838261|NCT06141837|OTHER|Observation|No intervention: observational study
41358130|NCT06208410|DRUG|Fulvestrant injection|Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle
41358131|NCT06208410|DRUG|Dalpiciclib Isetionate Tablets|Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle
41358132|NCT06208410|DRUG|Toripalimab Injection|Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle
41358133|NCT06208410|DRUG|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle
41497210|NCT03844958|OTHER|Red Furu|"50 g red furu was consumed with 2 slices of plain bread for one-day~50 g Fresh tofu was consumed with 2 slices of plain bread for one-day"
41358134|NCT06208410|DRUG|Fluzoparib Capsules|Fluzoparib Capsules is administered once daily, orally
41497211|NCT03844958|OTHER|Tofu|"50 g Fresh tofu was consumed with 2 slices of plain bread for one-day~50 g red furu was consumed with 2 slices of plain bread for one-day"
41497212|NCT03703869|DRUG|Insulin glargine (U300)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
41497213|NCT03915028|OTHER|Spa therapy|"The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.~Each day, the patient receives at least four treatments, among which:~* Cure of Drink (in addition to 4 daily cares)~* Bath in running water: Bath~* Bath in running water: Pool at 32 ° C~* Bath with aerobain~* Immersion shower bath~* Shower of high pressure under immersion in swimming pool~* General penetrating shower~* General jet shower~* Local jet shower~* Local mud bath at the feet~* Single poultice~* Multiple poultice~* Compress~* Mobilization pool~* Massages under water"
41497214|NCT00734396|PROCEDURE|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
41497215|NCT05646043|BEHAVIORAL|Physical training|Physical training consists of endurance walking and strength training. The basis for determining the number of steps per day is the baseline value of each patient. This will increase by 10-15% every week until the surgery date. The assumption of a total load increase is 120-180% compared to the baseline.
41497216|NCT05646043|BEHAVIORAL|Muscle strength training|Muscle strength training will take place using exercises to strengthen the upper and lower limbs and to strengthen the trunk. There will be a set of 5 exercises in two difficulty variants. The study subjects will perform this set 7 days a week, and will repeat the assembly a total of two times. The total time of strength training is 10 min.
40838262|NCT04903366|DRUG|Timolol Maleate|timolol maleate 0.5% gel-forming solution
40838263|NCT01030614|DRUG|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
40838264|NCT01030614|DRUG|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
40838265|NCT04186247|DRUG|Azithromycin|Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks
40838266|NCT04186247|DRUG|Metronidazole|Weeks 4-12: 20 mg/kg/day of metronidazole (10 mg/kg twice daily to a maximum of 1000 mg/day) for 8 weeks
41358135|NCT06208410|DRUG|Pyrotinib Maleate Tablets|Pyrotinib Maleate Tablets is administered once daily, orally
41358136|NCT06208410|DRUG|Capecitabine Tablets|Capecitabine Tablets is administered once daily, orally
41358137|NCT03714451|DIETARY_SUPPLEMENT|onyx sorghum|The diet intervention will last a total of 28 days. Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat. In the Onyx Group, 25% of carbohydrate will come from the onyx sorghum, and at least three foods per day (including cereals, bread, muffins, pasta, and smoothie boosters) will contain this.
41358138|NCT03714451|DIETARY_SUPPLEMENT|whole wheat flour|Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat.
41358139|NCT00983827|DEVICE|Aquatic treadmill training|HydroWorx aquatic therapy pool with an underwater, integrated and adjustable speed treadmill
41358140|NCT03575975|DEVICE|Total Ankle Replacement Prosthesis|Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
41358141|NCT05626959|DRUG|NTI164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
41358142|NCT03244111|BEHAVIORAL|simple memory tool|The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
41358143|NCT00498784|DRUG|Mirena|Mirena 52mg during 1 year
41358144|NCT06139978|BEHAVIORAL|ultrasound observation|The relationship between the anteroposterior diameter of the CM and the gestational age and gender
41358145|NCT00059267|DRUG|HBIG, Epivir, Hepsera|
41497217|NCT04451681|OTHER|Cardiopulmonary exercise test|Data such as oxygen consumption, cardiac parameters and speed of the patient are analyzed numerically on the treadmill in the KPET; Objective performance values such as maximum oxygen use (VO2max), maximum heart rate, respiratory capacity, and maximum rate will be obtained.
41497218|NCT01635218|DRUG|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
41497219|NCT01635218|DRUG|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
41497220|NCT01635218|DRUG|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
41497221|NCT02870179|DEVICE|Pulse Oximeter|Measurement of physiological parameters
41497222|NCT06314347|DIAGNOSTIC_TEST|Figure of 8 walk test|clinical measurement
41497223|NCT00562237|BIOLOGICAL|S205 placebo|2 i.m. injections per subject (0.5 mL each)
41497224|NCT00562237|BIOLOGICAL|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
41497225|NCT00562237|BIOLOGICAL|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
41497226|NCT00562237|BIOLOGICAL|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
41497227|NCT00562237|BIOLOGICAL|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
41497228|NCT00562237|BIOLOGICAL|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
41497229|NCT00562237|BIOLOGICAL|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
41497230|NCT01900561|BEHAVIORAL|Interactive Voice Response Symptom Management|The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
40838267|NCT04186247|OTHER|Standard of Care|SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.
40838268|NCT00213096|DRUG|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
41160515|NCT03228654|PROCEDURE|Purohit technique for vaginal hysterectomy|using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
41358146|NCT02389868|DRUG|Lovastatin|
41358147|NCT02400281|DRUG|Crenolanib besylate|
41358148|NCT02400281|DRUG|Idarubicin|
41358149|NCT02400281|DRUG|Cytarabine|
41358150|NCT02400281|DRUG|Azacytidine|
41358151|NCT02400281|DRUG|Mitoxantrone|
41358152|NCT02400281|DRUG|Etoposide|
41358153|NCT02400281|DRUG|Fludarabine|
41358154|NCT02400281|DRUG|G-CSF|
41358155|NCT00154895|DRUG|intrapleural minocycline instillation|
41358156|NCT04998058|PROCEDURE|Maxillary sinus floor elevation grafting with synthetic bone substitute.|Bone augmentation at the floor of the maxillary sinus with bone substitutes.
41358157|NCT00000322|BEHAVIORAL|Tyrosine|
41358158|NCT01064518|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) applied topically at Baseline (Day 0) to the lateral canthal lines
41358159|NCT01064518|DRUG|Placebo (Dose B)|Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
41497231|NCT01900561|BEHAVIORAL|Tailored Newsletters|Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
41497232|NCT00922272|DRUG|SPD489 (lisdexamfetamine dimesylate)|oral, 20, 30, 40, 50, 60, or 70 mg once daily
41497233|NCT00922272|DRUG|Placebo matching SPD489 (lisdexamfetamine dimesylate)|oral, once daily
41497234|NCT05386030|COMBINATION_PRODUCT|saypha® VOLUME Lidocaine|Crosslinked hyaluronic acid (HA) 23 mg/mL + 0.3% lidocaine hydrochloride.
41497235|NCT05386030|COMBINATION_PRODUCT|Juvéderm® Voluma™ XC|Crosslinked HA 20 mg/mL + 0.3% lidocaine hydrochloride
41497236|NCT04683744|OTHER|Semi-structured interviews-Patients|The interview guide will consist of questions to elicit the patients thoughts about getting preventive healthcare during the COVID-19 pandemic, including perception of risk, barriers to getting healthcare, and information needed for decision making.
41497237|NCT04683744|OTHER|Semi-structured interviews-Health system|The interview guide will consist of questions to elicit thoughts from health system leadership, providers, and staff about implementing decision aids, provider notifications, and cancer risk assessments in their health center or healthcare system. The questions may be specific to colorectal cancer screening or more generally about other cancer screenings. The investigators may also ask questions about cancer screening initiatives their health center or healthcare system engaged in during the COVID-19 pandemic.
40838269|NCT03970616|DRUG|Tivozanib|Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day
41497238|NCT00236912|DRUG|levofloxacin; metronidazole|
41497239|NCT00205244|BEHAVIORAL|Healing images, relaxation and distraction materials|
41497240|NCT02548130|OTHER|MELD score|introduction of MELD score
41497241|NCT06008782|DEVICE|HEARS-SLP device|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
41497242|NCT06008782|BEHAVIORAL|HEARS-SLP program|Tailored aural rehabilitation for participant and communication partner
41497243|NCT04458792|OTHER|Paraffin tissue samples|Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue
41497244|NCT04458792|OTHER|blood sample|MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery radiotherapy toxicity : Blood samples collected before the radiotherapy
41497245|NCT03828513|DEVICE|High flow nasal cannula oxygen is applied|Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.
41497246|NCT03828513|DEVICE|High flow nasal cannula oxygen is not applied|Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2\> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
41497247|NCT00525798|DRUG|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
41497248|NCT00525798|DRUG|SMC021 Placebo|SMC021 - Placebo, once daily
41497249|NCT00169481|BIOLOGICAL|Pneumococcal (vaccine)|
41497250|NCT00205803|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
41497251|NCT00205803|BIOLOGICAL|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)|
41497252|NCT05328934|DEVICE|SoftHand Pro|Performance assessments utilizing the SoftHand Pro over an 8-week period.
41497253|NCT05328934|DEVICE|Ossur i-Limb|Performance assessments utilizing the i-Limb over an 8-week period.
41497254|NCT04008628|DRUG|Nitrous Oxide|Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
41160516|NCT03668041|DRUG|Trazodone|Trazodone is approved by the Food and Drug Administration (FDA) for treating major depression in adults but not for PTSD. Although trazodone has not been approved by the FDA to treat insomnia or PTSD, some doctors have tried it for these purposes. The doses in this study will be lower than the doses used to treat depression.
41497255|NCT03069950|DRUG|Floxuridine (FUDR)|5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
41497256|NCT03069950|DRUG|Irinotecan (CPT-11)|Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
41497257|NCT03069950|DRUG|FLUOROURACIL|5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
41160517|NCT03668041|DRUG|Eszopiclone|Eszopiclone is approved by the FDA for treating insomnia, but it's unknown if eszopiclone can help treat insomnia when it's related to PTSD. Some doctors have tried it for this purpose. The doses in this study will be the same as the doses used to treat insomnia. A small study found it to be helpful for treating patients with PTSD.
41160518|NCT03668041|OTHER|Placebo|The active study medications listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it.
41160519|NCT03134274|DEVICE|Dip HBDA|Participant receive Dip HBDA semiquantitative urinalyiss kit to be used at home one day after routine prenatal consultation. Dip HBDA consists of a testing kit containing calibration color board, 10 parameter urine dipstick and a urine cup as well as a smartphone application. Application guides participant through the test flow. Dipstick is immersed in urine cup, placed on color board and scanned with smartphone.
41160520|NCT04725617|DRUG|Varenicline|Standard smoking cessation treatment.
41497258|NCT03069950|DRUG|PANITUMUMAB|Panitumumab (6 mg/kg IV over 60 min)
41497259|NCT03069950|DRUG|DEXAMETHASONE|flat dose of 25 mg on Day 1
41160521|NCT04725617|BEHAVIORAL|Smoking Cessation Counseling|Standard smoking cessation treatment
41497260|NCT03069950|DRUG|Leucovorin|Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
41497261|NCT03718312|PROCEDURE|clamping with pre-conditioning (PCl)|"PCI procedure: clamping of the supracellular thoracic aorta for 5 minutes followed by a 5-minutes de-clamping period.~PCI procedure is repeated twice."
41497262|NCT02929524|DRUG|Ketamine|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
41497263|NCT02929524|DRUG|Placebo|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
40838270|NCT03970616|DRUG|Durvalumab|1500mg every 28 days
40838271|NCT05661266|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
41160522|NCT04725617|BEHAVIORAL|Health Approach 1 to Reduce Smoking|Behavioral health intervention option 1
40838272|NCT01119677|DRUG|Avonex|Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
40838273|NCT02663141|DRUG|Losartan|
41160523|NCT04725617|OTHER|Health Approach 2 to Reduce Smoking|Behavioral health intervention option 2
41358160|NCT01180829|BEHAVIORAL|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
41358161|NCT01180829|BEHAVIORAL|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
41358162|NCT05730049|DEVICE|Transcutaneous auricular vagus nerve stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).
41358163|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
41358164|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
41358165|NCT01434498|DRUG|GS-5885 tablet|GS-5885 tablet, 90 mg, QD
41358166|NCT01434498|DRUG|GS-9451 tablet|GS-9451 tablet, 200 mg QD
41358167|NCT01434498|DRUG|tegobuvir capsule|tegobuvir capsule, 30 mg BID
41358168|NCT01434498|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
41358169|NCT01434498|DRUG|placebo matching ribavirin tablet|placebo matching ribavirin tablet, BID
41358170|NCT01434498|DEVICE|placebo matching tegobuvir capsule|placebo matching tegobuvir capsule, BID
41358171|NCT00208572|DRUG|Citalopram|
41358172|NCT03501394|OTHER|Magnetic Resonance Imaging|Patients will undergo 4 MRI sessions during NACT treatment. The first scan will take place at treatment baseline before their first cycle of NACT treatment. The second scan will take place following the first treatment cycle prior to the second treatment cycle. Likewise, the third and last scan will take place after the third treatment cycle and sixth (final) treatment cycle prior to surgery. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
41358173|NCT03501394|OTHER|Histopathological Analysis|Study specific analysis will be performed on the core biopsy and tissue removed in surgery following the completion of NACT treatment. Standard routine histological analysis will be performed, as well as study specific analysis for immunostaining, grading and slide scan imaging for measurement of cellularity markers.
41358174|NCT03501394|OTHER|Health Questionnaire|Health and demographic information will be collected.
41358175|NCT04343937|PROCEDURE|retrolaminar block|local anesthetic injection on the between the lamina of the vertebra and the paraspinous muscle
41358176|NCT04372173|DIAGNOSTIC_TEST|analysis of the concentration of the clotting factors in patients who underwent primary hip arthroplasty|"Blood samples were taken before surgery, 6 hours, two, four, and six days after the procedure. Venous blood samples were taken from peripheral veins.~All analyzed parameters (fibrinogen, factor II, factor VIII, factor X, D-dimer) were determined using an ACL TOP 500 CTS automated coagulation analyzer.~All patients were operated on by a single surgical team, with cementless hip replacements implanted, and without tranexamic acid administered in the perioperative period. All patients underwent venous thromboembolic complications prophylaxis.~The following data were collected: age, body mass index, gender, perioperative risk assessment scale according to the American Society of Anesthesiologists score, blood transfusions, hemoglobin levels before surgery and two days post-surgery, instances of thromboembolic complications. Because of the observational nature of this study no changes in the treatment of patients were made."
41358177|NCT01513824|BEHAVIORAL|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
41358178|NCT00039104|DRUG|rebimastat|Given PO
41497264|NCT05416697|DRUG|CBD oil|The subjects will receive cannabis 2.7 mg THC 2.5 mg CBD twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study.
40838274|NCT02663141|DRUG|Intravitreal bevacizumab|
40838275|NCT02663141|DRUG|Placebo|
40838276|NCT04738630|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
40838277|NCT00903331|DRUG|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
40838278|NCT00903331|DRUG|Placebo|matching placebo, once daily
40838279|NCT04052776|DRUG|Buspirone|40mg
40838280|NCT04052776|DRUG|Levodopa-Carbidopa|400mg/100mg
40838281|NCT04052776|DRUG|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
40838282|NCT04052776|DRUG|Placebo oral tablet|Non-active metabolite
40838283|NCT01669213|DRUG|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
40838284|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
40838285|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
40838286|NCT01669213|DRUG|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
40838287|NCT03353103|DRUG|Sodium fluoride F-18 PET imaging|prior to surgical endarterectomy each patient will undergo sodium fluoride F-18 PET imaging
40838288|NCT01551524|BIOLOGICAL|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
40838289|NCT05933590|DIAGNOSTIC_TEST|Cervical Joint Repositioning Error Assessment|The cervical joint repositioning error assessment is a non-invasive diagnostic test used to measure the ability of an individual to accurately reproduce a specific head position in different orientations (flexion, neutral position, 50% range of motion of left rotation, and 50% range of motion of right rotation). Participants in both the chronic migraine group and the control group will undergo this assessment using a digital inclinometer. The primary outcome of this study is the difference between the initial and repositioned cervical joint angles, measured in degrees.
41497265|NCT05416697|DRUG|Placebo|The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
41023231|NCT05315388|OTHER|Immersion therapy in nature - Vitamin N|"Usual therapy group The first saliva sample will be taken upon awakening to determine cortisol concentration. At their workplace, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~Group 2A and Group 2B In the natural environment, a saliva sample will be taken upon awakening to determine cortisol concentration. After arrival at the site, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~The first phase is a session of observation of the site for 15 minutes. A slow, unhurried walk will be performed for 1 hour and 45 minutes. The order of activities (sitting and walking) will be established to ensure reliability of physiological measurements."
41497266|NCT06246214|DEVICE|Blue Light Therapy|The BlueLT device is equipped with a narrow band short wavelength Light Emitting Diode (LED) - wavelength peak(λp) of \~470 nm (blue).
40838290|NCT05876247|OTHER|Electromagnetic Articulography|Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
40838291|NCT03677297|DRUG|Rosuvastatin|Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
40838292|NCT02447809|DRUG|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)\* 12 month.
40838293|NCT02447809|DRUG|acetylsalicylic acid (ASA)|
41497267|NCT06246214|DEVICE|ControlLT|The ControlLT (placebo) device is equipped with a dim long-wavelength enriched LED.
41023232|NCT05576467|BEHAVIORAL|MBCT-Telephone|Classes follow MBCT protocol delivered via telephone by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
41160524|NCT03298555|BEHAVIORAL|Mobile phone based intervention|Participants in the intervention group will receive a 6-month mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to promote healthy gestational weight gain.
41160525|NCT00796497|DRUG|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
41497268|NCT05176795|OTHER|Stool sample|Comparaison of the gut microbiota composition
41497269|NCT01798355|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
40838294|NCT01395277|DIETARY_SUPPLEMENT|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
40838295|NCT01395277|DIETARY_SUPPLEMENT|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
40838296|NCT02291926|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
40838297|NCT01606033|OTHER|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
40838298|NCT01606033|OTHER|questionnaire|understanding of the implications of participating in a clinical trial
41023233|NCT05576467|BEHAVIORAL|MBCT-Video|Classes follow MBCT protocol delivered via video by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
41160526|NCT01626677|BIOLOGICAL|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
41160527|NCT01626677|PROCEDURE|Microfracture|Active control
41160528|NCT00012636|PROCEDURE|Computer generated statements about guideline concordance of drug therapy deliver to clinicians|
41358179|NCT00039104|DRUG|zoledronic acid|Given IV
41497270|NCT01798355|BEHAVIORAL|Treatment As Usual|Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
41497271|NCT05682859|DRUG|Roflumilast 500 Mcg Oral Tablet|Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.
41497272|NCT05682859|DRUG|Placebo|Placebo tablets
41497273|NCT01684397|BIOLOGICAL|Bevacizumab|Given IV
41497274|NCT01684397|OTHER|Laboratory Biomarker Analysis|Correlative studies
41497275|NCT01684397|DRUG|Pazopanib Hydrochloride|Given PO
41497276|NCT01684397|OTHER|Pharmacological Study|Correlative studies
40838299|NCT03075995|OTHER|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
41023234|NCT05576467|BEHAVIORAL|Enhanced Usual Care (EUC)|Weekly online modules follow migraine and behavior principles delivered via web portal developed by a team of licensed clinical psychologists, neurologists, and mental health providers.
41160529|NCT03067610|RADIATION|Intensity Modulated Radiation Therapy|The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
41023235|NCT05019586|DRUG|levofloxacin, amoxicillin, clarithromycin|Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
40838300|NCT05718037|BIOLOGICAL|Recombinant Zoster Vaccine|0.5mL, Intramuscular
40838301|NCT05718037|BIOLOGICAL|Placebo|0.5mL, Intramuscular
40838302|NCT05718037|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted|0.5mL, Intramuscular
40838303|NCT02869698|PROCEDURE|Spectral Dynamic Imaging|
40838304|NCT02869698|DEVICE|Hybride electrode|
40838305|NCT02869698|DEVICE|Macro electrode|
40838306|NCT04886700|DRUG|SG001|Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
41023236|NCT05769452|DEVICE|closed IV catheter system (BD Nexiva™)|There is a high-pressure extension set and a Q-syte split septum needle-free intervention device at the tip of the catheter. It creates a closed integrated system with this apparatus, reducing the risk of catheter-related bloodstream infection.
41023237|NCT05769452|DEVICE|open IV catheter (BD Insyte™ Autoguard™)|BD Instaflash™ needle technology improves initial entry success by confirming vascular access through the needle noch. It has flexible wings for secure cannula fixation.
41160530|NCT03067610|DRUG|chemotherapy|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
41358180|NCT00039104|OTHER|laboratory biomarker analysis|Correlative studies
40838307|NCT05462808|DRUG|High viscosity glass ionomer cement|High viscosity glass ionomer cement
40838308|NCT05462808|DEVICE|Stainless steel crown|Stainless steel crown
40838309|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
40838310|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
41023238|NCT02048761|DRUG|Placebo gel|After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
41023239|NCT02048761|DRUG|1 % Metformin gel|After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
41023240|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
40838311|NCT05774652|BEHAVIORAL|Lifestyle intervention Dietary advise and/or advise on physical activity|Lifestyle intervention Dietary advise and/or advise on physical activity
41023241|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
41023242|NCT01047683|DRUG|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
41358181|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib \<900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
40838312|NCT05304312|DEVICE|Kegel Exercises guidebook|The Kegel exercises book is consisted of basic explanation about stress urinary incontinence and Kegel exercises, how to do Kegel exercises, table for them to write how many session they did in a day, and lastly their report progress (UDI-6, IIQ-7, periineometer, and 1-hour pad test) that we updated every four weeks
40838313|NCT02795312|BEHAVIORAL|Smoking Cessation Program|Participants will take part in a 9-week Smoking Cessation Program
40838314|NCT04212013|DRUG|Ibrutinib|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.
40838315|NCT04212013|DRUG|Rituximab|Will receive rituximab: 375 mg/m\^2 on days 1, 8, 15 and 22 of cycle 1
40838316|NCT04212013|OTHER|Placebo|Placebo capsules will be similarly dosed at 4 capsules daily.
41358182|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
41358183|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily"
41358184|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily"
41358185|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily"
41358186|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily"
41358187|NCT01654224|BIOLOGICAL|High Dose Inactivated Influenza Vaccine|0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
41358188|NCT01654224|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine|0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
41358189|NCT05425537|OTHER|Drowning incident|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
41358190|NCT02519777|DRUG|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
41358191|NCT02519777|DRUG|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
41358192|NCT02519777|DRUG|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
40838317|NCT05241925|OTHER|Rehabilitation, exercise|"Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
41160531|NCT06268600|RADIATION|Modified neck target volume delineation|Modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
41160532|NCT02077153|BEHAVIORAL|Reminiscence therapy|
41160533|NCT02077153|BEHAVIORAL|Active participation in group setting|
41160534|NCT02534129|DRUG|Difinsa53|Difinsa53 cream is applied to one half of radiation field
41160535|NCT02534129|DRUG|Aquaphor|Aquaphor is applied to one half of radiation field
41160536|NCT00404547|DRUG|Ciclesonide|Asthma Care with Alvesco
41160537|NCT00404547|DRUG|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
41160538|NCT00404508|DRUG|Hydralazine and magnesium valproate|
41160539|NCT03377283|BIOLOGICAL|organ perfusion with rabbit anti-thymocyte globulin (rATG)|
41358193|NCT02519777|DRUG|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
41358194|NCT04854122|BEHAVIORAL|Combined exercise intervention|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week. Aerobic exercise will be part of all three sessions, with resistance exercise during two out of three sessions. Training sessions will be supervised by personal trainers to ensure the safe use of the equipment and the correct form when performing each exercise. The first 3 weeks of the intervention will be familiarization with the exercises and the program. After a warm-up, the participant will perform 30 min of aerobic exercise at a heart rate of 65% of the participant's maximum heart rate \[43\], which increases to 65-85% during weeks 4-12 of the intervention. The resistance exercise part will include all major muscle groups, both upper and lower body.
41358195|NCT04854122|BEHAVIORAL|Usual care / Sham intervention|The control condition consists of usual activities.
41358196|NCT02558595|DIETARY_SUPPLEMENT|Niacinamide|
41358197|NCT02558595|OTHER|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
41358198|NCT04360889|DRUG|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
41358199|NCT04360889|DRUG|Tocopherol|patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
41358200|NCT04360889|OTHER|Elastic compression|patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
41358201|NCT05121129|DEVICE|iTBS|25 active iTBS sessions (5 sessions of 9.5 minutes/day, 1,800 pulses per session, 90% of resting motor threshold, placed over the left DLPFC)
41023243|NCT06574256|OTHER|Chemotherapy symptom Management Online Education|"Randomization was achieved and data collection began. Patients were given the Chemotherapy Symptom Management Education Booklet and were informed that they would be contacted by phone.~In the second and third stages of data collection, they were called by phone on the 7th day after receiving chemotherapy treatment. The symptoms experienced by the patient were evaluated with the N-SDS and the quality of life was evaluated with the EORTC QLQ-C30. Online nursing education videos were sent to the women in the intervention group regarding the symptoms they experienced. The practices they performed from the suggestions in the education videos and education booklets sent were recorded on the nurse follow-up form.~In the fourth stage, the practices specified in the third stage were repeated on the 7th day after the third chemotherapy course, and at this stage, the satisfaction of the women in the intervention group with the online education was evaluated."
41023244|NCT01513772|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
41023245|NCT01513772|DRUG|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
41023246|NCT02174094|DRUG|Clobazam|
41023247|NCT02174094|DRUG|Placebo|
41023248|NCT06173817|DEVICE|isocapnic hyperventilation|isocapnic hyperventilation (iHV) increases the elimination of methanol to the extent that it could replace haemodialysis for elimination purposes when haemodialysis is not required for the correction of acidosis, and alcohol dehydrogenase (ADH) is completely blocked by an antidote.
41023249|NCT06168643|OTHER|Core stability|Physical therapy interventions will include core stability exercises which will be demonstrated and will be checked if they are being performed correctly. The exercises guided shall be performed 3 times daily and logbook will be provided to keep the record of exercise program.
41023250|NCT06168643|OTHER|Core stability with pregnancy support belt|Participants will receive same information and exercises as those in Group A. they will also receive pregnancy support belt. The logbook will be provided to keep the record of hours the belt has been worn along with exercise record.
40838318|NCT01660100|PROCEDURE|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
40838319|NCT01660100|PROCEDURE|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
41023251|NCT01429896|OTHER|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
41023252|NCT03893227|OTHER|Questionnaire|Patients and healthy controls will fill out a questionnaire
41023253|NCT02091804|BEHAVIORAL|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
41160540|NCT03377283|OTHER|organ perfusion with saline|
41358202|NCT03347461|DRUG|Otiprio|Otiprio is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery. Otoprio (6% ciprofloxacin, 60 mg/mL) will be administered through the tube lumen by the otolaryngologist immediately after tympanostomy surgery.
41358203|NCT03347461|DRUG|Ciprodex|Ciprodex is a combined antibiotic and steroid ear drop used to treat otitis media with tympanostomy tubes. Four drops of Ciprodex (0.14mL) instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery. Each mL of Ciprodex contains ciprofloxacin hydrochloride 0.3 % (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1 % equivalent to 1 mg dexamethasone
40838320|NCT06505538|DEVICE|NL-Mapp|Mobile applicaiton
40838321|NCT00708734|BEHAVIORAL|functional exercise training|twice weekly group sessions for 5 weeks
40838322|NCT01969721|DRUG|fluticasone propionate|low dose
40838323|NCT01969721|DRUG|salmeterol|
40838324|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
40838325|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
40838326|NCT01969721|DRUG|tiotropium|tiotropium high dose
40838327|NCT01969721|DRUG|olodaterol|
40838328|NCT01969721|DRUG|olodaterol|
40838329|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
40838330|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
40838331|NCT01969721|DRUG|tiotropium|tiotropium low dose
40838332|NCT01969721|DRUG|fluticasone propionate|low dose
40838333|NCT01969721|DRUG|salmeterol|
40838334|NCT00967759|DRUG|Bronpheniramine and fenilefrine (Decongex Plus)|Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
40838335|NCT00967759|DRUG|Bronpheniramine isolated|Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
41023254|NCT02091804|BEHAVIORAL|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
41358204|NCT05871008|OTHER|Assessment tool IA3-CP with SDoH|Each patient randomly assigned to IA3-CP with SDoH study arm will complete a pre-visit assessment tool including SDoH. Feedback is provided to provider and patient.
41358205|NCT05871008|OTHER|Assessment tool IA3-CP without SDoH|Each patient randomly assigned to IA3-CP only study arm will complete a pre-visit assessment tool excluding SDoH. Feedback is provided to provider and patient.
40838336|NCT00967759|DRUG|Fenilefrine isolated|Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
40838337|NCT03429543|DRUG|Metformin|At least 1000 mg/day or up to a maximal tolerated dose.
40838338|NCT03429543|DRUG|Insulin|Basal or multiple dose injection.
40838339|NCT03429543|DRUG|Placebo|1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.
40838340|NCT03429543|DRUG|Linagliptin|1 film-coated tablet Linagliptin once daily, until end of treatment.
40838341|NCT03429543|DRUG|Empagliflozin|1 film-coated tablet of Empagliflozin once daily, until end of treatment.
40838342|NCT00895661|DRUG|rituximab|Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
40838343|NCT01985763|DRUG|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
40838344|NCT02318290|DRUG|Opiates|Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
40838345|NCT04918355|OTHER|Clinical Decision Support (CDS) alerts|CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.
40838346|NCT05004129|DRUG|Tideglusib|All subjects will receive weight-adjusted 1000 mg tideglusib following a titration period of 2 weeks at a weight-adjusted dose of 400 mg and 2 weeks at a weight-adjusted dose of 600 mg tideglusib.
40838347|NCT03514563|DIAGNOSTIC_TEST|MRI imaging|MRI recordings of the craniofacial region
40838348|NCT03514563|DIAGNOSTIC_TEST|Optical scan|Optical intraoral scans
40838349|NCT03514563|DIAGNOSTIC_TEST|3D photography|Facial stereophotogrammetry
40838350|NCT04499911|DRUG|Isotonic dextrose 5% in water solution|The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
40838351|NCT00102713|DRUG|Divalproex Sodium (Depakote Sprinkle Capsules)|
40838352|NCT00872729|DRUG|Cystagon®|"Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H."
40838353|NCT00872729|DRUG|RP103|"Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product."
40838354|NCT02539511|DRUG|CI-581a|
40838355|NCT02539511|DRUG|CI-581b|
40838356|NCT02539511|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
40838357|NCT03233438|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
40838358|NCT03233438|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
40838359|NCT03380767|PROCEDURE|Trauma-induced coagulopathy treatment|Transfusion as needed according to the assay methodology
40838360|NCT01364701|DRUG|Sildenafil 100 mg|4 tablets for on demand use
40838361|NCT01364701|DRUG|Tadalafil 20 mg|4 tablets on demand
40838362|NCT01364701|DRUG|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
40838363|NCT00924404|DRUG|Xylitol|5% solution for sinus rinse
40838364|NCT00924404|DRUG|Saline|saline for sinus rinse
40838365|NCT05825625|DRUG|Atezolizumab|Atezolizumab 1,200 mg by IV infusion Q3W.
40838366|NCT05825625|DRUG|Tiragolumab|Tiragolumab by IV infusion Q3W.
41023255|NCT06446193|DEVICE|NDTx-01|NDTx-01 intervention: Run 'NDTx-01' application on a smartphone 5 times a week, for 6 weeks, 30 sessions in total.
41023256|NCT06446193|BEHAVIORAL|TAU|TAU: Autism Spectrum Disorders(ASD) or Social Communication Disorders(SCD)-related treatment/rehabilitation/education
41023257|NCT01702883|OTHER|Internet Survey|prompt to complete internet survey
41023258|NCT03752164|BEHAVIORAL|Yoga and Mindfulness Skills|Single brief session in which children are taught yoga and skills in mindfulness
41358206|NCT05908422|DEVICE|Alvision™ Interventional Cardiology Diagnostic Catheter|The Alvision™ Interventional Cardiology Diagnostic Catheter is a single use only, thin, flexible single lumen tube, with a proximal hub, sterilized with ethylene oxide (EO) gas, non-pyrogenic. The product is defined as a catheter to inject a contrast medium into selected blood vessels.
40838367|NCT01530607|DRUG|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
40838368|NCT01530607|DRUG|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
40838369|NCT05661045|PROCEDURE|low-flow anesthesia|Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
40838370|NCT06104956|DRUG|HFNO weaning protocol|Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done
40838371|NCT06104956|DRUG|Standard of care|Weaning methods will be left to the free choice of the practitioner.
40838372|NCT06256146|OTHER|Food allergy desensitization / Oral Immunotherapy|"Participants consume increasing doses of allergenic food daily until they reach a maintenance dose. In the case of the High Dose Arm, participants will progress to a daily dose of either 1200 mg, 300 mg or 200 ml of egg, peanut or milk respectively.~Participants randomized to the Low Dose Arm also begin by consuming small amounts of the allergenic food, gradually increasing the daily dose. However, participants in this group only progress to 300 ml, 30 mg or 50 ml daily dose of egg, peanut or milk respectively.~The Cooked/Transformed Allergen Arm begins the desensitization with a cooked or transformed form of the allergen - muffins in the case of egg or milk, Bamba puffs in the case of peanut. Participants take increasing amounts of these products (one muffin for egg and milk and four Bamba puffs for peanut) then transition to egg, milk or peanut. Participants then continue their dose progression, getting to 1200 mg, 200 ml or 300 mg for egg, milk and peanut respectively."
40838373|NCT05110313|BIOLOGICAL|TILDRAKIZUMAB|"ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.~ILUMYA injection for subcutaneous use is a sterile, clear to slightly opalescent, colorless to slightly yellow solution supplied in 1mL single-dose prefilled syringe which contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle."
40838374|NCT03769311|DRUG|Cetuximab|Monoclonal antibody against epidermal growth factor receptor (EGFR)
41358207|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy super-selective clamping|The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
41358208|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy with renal artery clamping|Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
40838375|NCT04167072|PROCEDURE|Stent removal|This is a procedural intervention in which the stent will be removed via endoscopy.
40838376|NCT05327764|OTHER|Work to rest cycles of 40:20 minutes|Walking in a hot environment for 2 hours with repeated 40 minutes of work and 20 minutes of rest
40838377|NCT05327764|OTHER|Work to rest cycles of 20:10 minutes|Walking in a hot environment for 2 hours with repeated 20 minutes of work and 10 minutes of rest
40838378|NCT04081272|DRUG|Sodium Chromate Cr51|Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
40838379|NCT00161525|PROCEDURE|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
40838380|NCT04151277|DRUG|FOLFOX-A|Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle
40838381|NCT04151277|DRUG|Gemcitabe and Abraxane|Patients will receive gemcitabine and nab-paclitaxel 3 weeks out of 4
40838382|NCT04151277|DRUG|G-CSF|Patients in the FOLFOX-A arm will also receive daily G-CSF as primary prophylaxis for all cycles. This will be given as per local site policy for 14 day chemotherapy regimens
41160541|NCT05056129|BEHAVIORAL|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
41160542|NCT05056129|BEHAVIORAL|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
41358209|NCT00519597|DEVICE|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
41358210|NCT05910242|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
41497277|NCT03940131|DRUG|Panitumumab|FOLFOX6 regimen consists of 2-hour infusion of oxaliplatin (85 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFOX6 regimen will be repeated at 2-week intervals. FOLFIRI regimen consists of 2-hour infusion of irinotecan (180 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFIRI regimen will be repeated at 2-week intervals.
41358211|NCT05910242|PROCEDURE|Sham remote ischemic conditioning|Sham-RIC is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
41358212|NCT04803656|OTHER|Assessment of COPD patients|Assessments explained in the arm section were made as described in one session.
41358213|NCT02398643|OTHER|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
41497278|NCT03516110|OTHER|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.
41497279|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44
41497280|NCT06049810|DRUG|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection
41497281|NCT06049810|DRUG|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44
41497282|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44
41497283|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44
41497284|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection
41497285|NCT01043666|DRUG|YM178|oral
41497286|NCT01043666|DRUG|Placebo|oral
41497287|NCT01043666|DRUG|tolterodine ER|oral
41497288|NCT01422629|DEVICE|Ultrasonic ablation device|High Intensity focused ultrasound treatment
41497289|NCT02853370|DRUG|Bendamustine and Rituximab|
41497290|NCT02912169|PROCEDURE|Liposuction under local anesthesia|Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
41497291|NCT02912169|BIOLOGICAL|Infusion of AD-SVF via IV and Intranasal|IV and Intranasal Infusion of isolated AD-SVF
41497292|NCT02826772|DRUG|GT0918|anti-tumor activity
41160543|NCT01621321|DRUG|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
41160544|NCT01621321|DRUG|Voriconazole|Voriconazole 200 mg BD for 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
41358214|NCT02398643|OTHER|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
41358215|NCT01226134|DRUG|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
41358216|NCT01226134|DRUG|Placebo|placebo capsules,thrice a day for four weeks
41358217|NCT06035666|OTHER|Your World|Your World consists of a vitality session and use of the Your World app
41358218|NCT06035666|OTHER|Control app|Control app, no effect on stress/vitality
41358219|NCT06482086|DRUG|Anlotinib|8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.
41358220|NCT06482086|DRUG|Lenvatinib|8/12 mg qd, po.
41358221|NCT06482086|DRUG|Sorafenib|0.4 g bid, po.
41358222|NCT06482086|DRUG|Donafenib|0.3 g bid, po.
41358223|NCT06482086|DRUG|Everolimus|10 mg qd, po.
41358224|NCT06482086|DRUG|Apatinib|500 mg qd, po.
41358225|NCT06482086|DRUG|Dabrafenib + Trametinib|Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.
41497293|NCT03441932|PROCEDURE|Fiberoptic endoscopic evaluation of swallowing (FEES)|"Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree."
41497294|NCT04981730|BEHAVIORAL|Web-based intervention|The web-based intervention participants will follow the website's orientation, the curriculum of modules, and professional feedback to complete the intervention.
41497295|NCT06634199|DRUG|Durvalumab|Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital
41497296|NCT03288701|DEVICE|Seca medical Body Composition Analyser 515|Comparison of reduction of whole body water and body weight in patients with decompensated heart failure under forced diuretic treatment
41358226|NCT06482086|DRUG|Cabozantinib|Cabozantinib 60mg qd, po.
41358227|NCT06482086|DRUG|Vandetanib|Vandetanib 300mg qd, po.
41358228|NCT06482086|DRUG|Entrectinib|Entrectinib 600mg qd，po.
41358229|NCT06482086|DRUG|Pralsetinib|400mg qd, po.
41358230|NCT06482086|DRUG|Larotrectinib|100mg qd，po
41358231|NCT01944462|BEHAVIORAL|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
41358232|NCT01756209|DRUG|Magnesium 400Mg|magnesium 400 mg + conventional treatment
41358233|NCT01756209|DRUG|Ibuprofen 10 mg/kg|ibuprofen 10 mg/kg oral single dose
41358234|NCT01756209|DRUG|acetaminophen 15 mg/kg|Acetaminophen 15 mg/kg oral single dose
41358235|NCT03654963|PROCEDURE|Medication reconciliation|Medication reconciliation is the systematic process described above.
41497297|NCT03186781|BIOLOGICAL|VRC-FLUNPF081-00-VP (HA-F A/Sing)|VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.
41497298|NCT03186781|BIOLOGICAL|VRC-FLUDNA082-00-VP (DNA A/Sing)|VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.
41497299|NCT03421795|OTHER|Let's Talk About Pain Training|See arm/group descriptions.
41497300|NCT03421795|OTHER|Family Centered Care Training|See arm/group descriptions.
41160545|NCT02295852|DIETARY_SUPPLEMENT|LOW-SODIUM LOW LIPID CALCIUM RICH DIET|1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
41358236|NCT03499496|DIAGNOSTIC_TEST|ultrasound guided detection of atherosclerotic plaques|screening by ultrasound of atherosclerotic plaques
41497301|NCT06419595|BEHAVIORAL|Behavioral: Screening and Support for Youth (SASY) Multi-component Platform: includes screening, feedback, single session intervention, and resource information|Description: Description: Participants who interact with a QR code and express interest in participating will be randomized to receive either: 1) recruitment from a Research Coordinator (standard research staff approach) or 2) recruitment from an EYE for Prevention Youth Researcher. The process of consent, screening, providing feedback, and offering access to a Single Session Intervention and information on additional resources (per scoring on the screening into Tier 1 (low risk/normal), 2 (moderate/at risk), or 3 (high/clinical risk): Tier 1 = screening+feedback; Tier 2=screening+feedback+SSI; Tier 3=screening+feedback+SSI+resource information) will be the same in each group. The randomization is simply changing who provides the process and platform to the participant.
41497302|NCT06419595|BEHAVIORAL|Behavioral: Screening and Support for Youth (SASY) Multi-component Platform: includes screening, feedback, single session intervention, and resource information|Description: Description: Participants who interact with a QR code and express interest in participating will be randomized to receive either: 1) recruitment from a Research Coordinator (standard research staff approach) or 2) recruitment from an EYE for Prevention Youth Researcher. The process of consent, screening, providing feedback, and offering access to a Single Session Intervention and information on additional resources (per scoring on the screening into Tier 1 (low risk/normal), 2 (moderate/at risk), or 3 (high/clinical risk): Tier 1 = screening+feedback; Tier 2=screening+feedback+SSI; Tier 3=screening+feedback+SSI+resource information) will be the same in each group. The randomization is simply changing who provides the process and platform to the participant.
41497303|NCT03916783|BEHAVIORAL|Combination intervention|"The FDA will be a matched savings account held in the child's name with the parent or caregiver as the co-signer, in a financial institution registered by the Central Bank (Bank of Uganda). The account opened will be matched with money from the program up to a match cap of 72,000 Uganda shillings (an equivalent of $20) a month per family for the 9-month intervention period.~The FDAs will be complemented with four sessions of Financial Literacy and Management (FL\&M) and two sessions of cancer education conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use."
41497304|NCT05900258|DRUG|Tirbanibulin|Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.
41497305|NCT03074773|DRUG|Dexamethasone|"Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action"
41497306|NCT03074773|DEVICE|ultrasound|The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
41497307|NCT03074773|PROCEDURE|paravertebral block|paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
41497308|NCT03074773|DRUG|Bupivacaine|it is an amino amide local anesthetic drug
41497309|NCT03074773|OTHER|isotonic saline|sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
41497310|NCT04237337|OTHER|Exposure to MS drugs|Exposure in ICSRs to MS drugs (dichotomous, exposed/not exposed), for each individual MS drug
41497311|NCT06122376|DEVICE|U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
41497312|NCT06122376|DEVICE|Soft Manual Toothbrush|Twice daily brushing for two minutes with fluoride toothpaste
41497313|NCT05869903|DRUG|Orforglipron|Administered orally.
41497314|NCT05869903|DRUG|Placebo|Administered orally.
41497315|NCT04459507|OTHER|No intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
41497316|NCT05561647|OTHER|No Intervention|This is non-interventional study.
41497317|NCT04312529|OTHER|Isokinetic test + EMG|Isokinetic test:The isokinetic device is used to evaluate the strength of a subject. The test will be performed in two positions. This will determine the best position to activate shoulder muscles EMG (electromyography):it's a device that measures the electrical activity of muscles. This will allow us to record the maximum activity of the shoulder muscles during force tests.
41497318|NCT06403124|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation by reconstruction plate and screws
41497319|NCT00463697|DRUG|GW642444H (100mcg)|H salt
41160546|NCT02295852|DIETARY_SUPPLEMENT|LOW-SODIUM LOW LIPID DIET|2. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
41160547|NCT04435405|OTHER|Observational|video footage analysis of group and individual behavioral processes.
41160548|NCT00224809|DRUG|Angiotensin-Converting Enzyme Inhibitors|
41160549|NCT00224809|PROCEDURE|Coronary Artery Bypass Graft|
41358237|NCT05725837|DRUG|Paroxetine|Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
41358238|NCT01484522|BIOLOGICAL|FluMist|Administered at the manufacture's recommended dose
41358239|NCT01484522|BIOLOGICAL|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
41358240|NCT01484522|BIOLOGICAL|Fluzone|Vaccine administered at manufacturer's recommended dose
41358241|NCT03243981|DEVICE|Sciton SkinTyte (800-1800 nm) with Broadband Light Technology|This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
41358242|NCT04312958|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
41358243|NCT04647929|DEVICE|Santen PRESERFLO MicroShunt|the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
41358244|NCT04647929|PROCEDURE|Trabeculectomy|a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
41358245|NCT05343403|OTHER|Family Integrated Care|The intervention will consist of FICare, including parental participation in medical rounds (FCR). Parents and healthcare professionals will be educated and supported by the four pillars of FICare: parent education, education of healthcare professionals, psychosocial support and a supportive environment of the neonatal ward.
41358246|NCT03136809|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
41358247|NCT05815004|DRUG|Gene therapy|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)
41358248|NCT05815004|DRUG|Enzyme Replacement Agent|A hydrolytic lysosomal glucocerebrosidase-specific enzyme
41358249|NCT04613804|DRUG|Toripalimab Injection|"Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle."
41358250|NCT03020797|DRUG|Perampanel|
41358251|NCT03020797|DRUG|Placebo Oral Tablet|
41358252|NCT04256642|PROCEDURE|Erector Spinae Plane Block|A nerve block that injects local anesthetic in the Erector Spinae Plane
41358253|NCT04256642|DRUG|Intrathecal morphine|Intrathecal morphine at the time of spinal anesthesia
41358254|NCT04005781|DRUG|Hydroxychloroquine sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
41358255|NCT04005781|DRUG|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
41358256|NCT02808299|OTHER|HBV infection history|HBV infection history or HBV carriers
41358257|NCT00892879|DEVICE|Laparoscopic cholecystectomy surgery|Single port laparoscopic cholecystectomy surgery versus a standard four port device.
41358258|NCT03976882|DRUG|Hetrombopag|Hetrombopag
41358259|NCT03976882|DRUG|Placebo|Placebo
41358260|NCT04114266|OTHER|Questionnaires on Urinary Incontinence-, Sex Function- and Quality of Life (ICIQ-UI-SF, ICIQ-FLUTSsex, ICIQ-LUTSqol, PGI-I)|"Artificial Urinary Sphincter Surgery (Robot-assisted, Laparoscopic, Open, or other) for Female Stress Urinary Incontinence due to intrinsic sphincter deficiency is according to standard practice. Patients scheduled for this type of surgery will be asked to participate in this Registry.~At baseline and follow-up, the patients will be required to fill in Questionnaires, i.e. ICIQ -Urinary Incontinence - Short Form (ICIQ-UI-SF), ICIQ Female Sexual Matters associated with Lower Urinary Tract Symptoms ( ICIQ-FLUTSsex), ICIQ Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol), Patient Global Impression of Improvement-I (PGI-I) which are commonly used in daily practice to assess urinary incontinence, sexual function and quality of life. During the yearly visits, patients will not be required to come for a clinical visit as the questionnaires and a Follow-up form can be completed by post, e-mail or phone call."
41358261|NCT03636009|OTHER|concurrent traction and neuromobilization technique|participant will be on a mechanical traction machine with an on:off cycle. During the on cycle, the primary researcher will be performing a neuromobilization technique on the symptomatic arm. Patients will also receive exercise and manual therapy
41358262|NCT03636009|OTHER|sequential traction and neuromobilization technique|Participants will receive neuromobilzation techniques followed by supine cervical traction
41497320|NCT00463697|DRUG|placebo|placebo
41497321|NCT00463697|DRUG|GW642444M (25, 100 & 400 mcg)|M salt
41497322|NCT03806712|OTHER|multi method questionary (developped by De Rosa, in 1995 and 2014)|questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
41160550|NCT00224809|DRUG|Angiotensin Receptor Blockers|
41160551|NCT00224809|DRUG|Spironolactone|
41160552|NCT00224809|DRUG|Aspirin|
41358263|NCT03636009|OTHER|active exercise program|Participants will have 4-5 exercises to perform at each session
41497323|NCT01161407|DIETARY_SUPPLEMENT|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
41497324|NCT01161407|DIETARY_SUPPLEMENT|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
41497325|NCT00107289|DRUG|iobenguane I 131|"Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) IV over 30 minutes to 4 hours on day 0. Patients undergo radiation dosimetry following the first dose of \^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.~After completion of study treatment, patients are followed at 4-6 weeks after \^131I-MIBG administration and then every 3 months for up to 1 year."
41358264|NCT03636009|OTHER|manual therapy to cervical and thoracic spine|Lateral glides to cervical spine and thoracic manipulations
41358265|NCT00472823|DIETARY_SUPPLEMENT|Vitamin D3|Orally for one year
41358266|NCT00472823|DIETARY_SUPPLEMENT|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
41358267|NCT02709889|DRUG|Rovalpituzumab tesirine|
41358268|NCT02709889|DRUG|Dexamethasone|Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
41160553|NCT00224809|DRUG|Clopidogrel|
41358269|NCT00757159|DEVICE|Ostim|Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.
41358270|NCT00757159|DEVICE|Emdogain|Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
41358271|NCT04056962|DRUG|Tacrolimus ointment|topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
41358272|NCT01265628|PROCEDURE|perimetry|automated static perimetry with adapted GATE strategy
41358273|NCT02466906|DRUG|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC\>20.0X109/L.
41497326|NCT00096603|DRUG|Raptiva (efalizumab)|
41497327|NCT04889144|OTHER|Communication Intervention|Participate in PLAN intervention
41160554|NCT00224809|PROCEDURE|Surgical Ventricular Restoration|
41160555|NCT04265742|RADIATION|bone densitometry|Bone Mineral Density (BMD), body composition, vertebral fractures
41023259|NCT02358486|DEVICE|Acupuncture|"1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 \~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
41023260|NCT02358486|DEVICE|Sham acupuncture|The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
41023261|NCT04565977|OTHER|Observational|Retrospective chart review
41023262|NCT04552873|DRUG|Urea|"the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered."
41023263|NCT04552873|OTHER|PLACEBO|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
41023264|NCT01343056|BEHAVIORAL|Office Staff Support|The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
41023265|NCT01343056|BEHAVIORAL|Peer Support|Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
41160556|NCT04265742|RADIATION|High resolution peripheral QCT|High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength
41160557|NCT04265742|DIAGNOSTIC_TEST|Collection of biological samples|Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition
41160558|NCT04265742|OTHER|questionnaires|Epidemiologic and nutritional questionnaire and physical activity scale
41160559|NCT04265742|OTHER|clinical tests|physical performance tests and grip strenght measurement
41160560|NCT04531371|DRUG|Dexmedetomidine injection|post surgical agitation prophylaxis
41160561|NCT05983068|DRUG|dupilumab|solution for injection; by subcutaneous (SC) injection
41160562|NCT00248079|DEVICE|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
41358274|NCT02466906|DRUG|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
41358275|NCT01157962|PROCEDURE|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
40838383|NCT00812903|BEHAVIORAL|Exercise|Training exercises chosen with background in knowledge of intelligent training
40838384|NCT00647114|BIOLOGICAL|V930|V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
40838385|NCT00647114|BIOLOGICAL|V932|V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
41160563|NCT01134718|DRUG|TMC435 (G006)|one morning dose of 150 mg
41160564|NCT01134718|DRUG|TMC435 (F021)|one morning dose of 150 mg
41358276|NCT05241470|DRUG|ST-100 Ophthalmic Solution|One drop in each eye twice a day
41358277|NCT05241470|DRUG|Placebo Ophthalmic Solution|One drop in each eye twice a day
41358278|NCT04352244|PROCEDURE|Fat biopsy|"The fat biopsy is performed during a scheduled procedure at the Beth Israel Deaconess Medical Center (BIDMC). Routine preoperative procedures will be followed, including local anesthesia (numbing a particular region of the body) or general anesthesia (being put to sleep).~Adipose tissue will be sampled from different depots depending on the procedure. For example, the surgeon will collect adipose tissue from the neck and supraclavicular depots from cervical spine, thyroid, and parathyroid procedures; perinephric fat from adrenalectomies, omental fat from abdominal procedures, and paraspinal fat from lumbar spine procedures. Up to 5 pieces of fat tissue weighing about three to six grams will be removed. All other aspects of the surgical procedure will proceed as planned. Samples will be prepared for subsequent laboratory analysis."
41497328|NCT04889144|OTHER|Best Practice|Receive usual care
41160565|NCT01134718|DRUG|TMC435 (G007)|one morning dose of 150 mg
41160566|NCT03697070|OTHER|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
41497329|NCT04889144|OTHER|Questionnaire Administration|Ancillary studies
41023266|NCT01343056|BEHAVIORAL|Usual Care Support|Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
41023267|NCT01343056|BEHAVIORAL|Educator Support|Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
41023268|NCT04779957|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg before or immediately after graft nephrectomy.
41023269|NCT00129415|PROCEDURE|UVA1 Irradiation|The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
41023270|NCT00129415|PROCEDURE|UVB Irradiation|The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
41023271|NCT04808609|DEVICE|Lumme mobile phone application|Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors
41023272|NCT04808609|BEHAVIORAL|Standard of Care|Smoking cessation counseling and nicotine replacement therapy
41023273|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
41023274|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
41023275|NCT01040130|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
41023276|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose
41023277|NCT01040130|DRUG|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
41023278|NCT00664144|DRUG|Rasburicase (SR29142)|
41023279|NCT03977324|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
41023280|NCT03977324|PROCEDURE|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
41023281|NCT01311830|BEHAVIORAL|Telephone Counseling|
41023282|NCT01311830|BEHAVIORAL|Written Materials|
41023283|NCT01072487|PROCEDURE|Capnography|Monitoring of the capnography curve for early detection of apnea
41023284|NCT02715765|DEVICE|Transcranial Direct Current Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
41023285|NCT02715765|DEVICE|Transcranial Random Noise Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
41023286|NCT02715765|DEVICE|Transcranial Sham Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
41160567|NCT03697070|OTHER|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
41023287|NCT02479425|PROCEDURE|patient positioning|positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
41023288|NCT04249843|DRUG|BGB-3245|administered orally (PO)
41023289|NCT01136837|OTHER|primary pcı|
41023290|NCT03755765|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
41023291|NCT03755765|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
41023292|NCT03755765|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
41023293|NCT02560129|OTHER|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
41023294|NCT02098343|DRUG|APR-246|Intravenous infusion.
41023295|NCT02098343|DRUG|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion.
41023296|NCT03593083|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
41023297|NCT03593083|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
41023298|NCT04136938|OTHER|Social marketing campaign|A social marketing campaign of prevention workshop sessions will be performed.
41023299|NCT06532747|BEHAVIORAL|Integrated Lifestyle Intervention (ILI)|ILI participants will receive training in empirically supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with BWL content adapted to meet the needs of EAs.
41023300|NCT06532747|BEHAVIORAL|Monitoring with digital tools|All participants will receive digital tools to facilitate self-monitoring-the initial 4-month program will consist of group sessions via Zoom (8 weekly, 4 bi-weekly) with weekly tailored e-coaching, followed by monthly boosters through 12 months.
41023301|NCT04465994|PROCEDURE|gastrocnemius turn-down flaps|We classified the patients with acute achilles tendon rupture by type of surgery. The group who received the gastrocnemius turn-down flaps is the intervention group.
41023302|NCT02149589|PROCEDURE|Mechanical ventilation|
41023303|NCT06068894|DIETARY_SUPPLEMENT|"Humanized galacto-oligosaccharides (hGOS)"|10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage
41023304|NCT06068894|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage.
41023305|NCT06068894|OTHER|Matching Placebo|10-15 g/day powdered corn syrup comprised of fructose, glucose, and an inert cellulose material that matches the consistency, color sweetness, and taste of the prebiotics, that can be added to any non-alcoholic beverage.
41023306|NCT04589559|BEHAVIORAL|Heart Rate Variability Biofeedback Training|First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
41023307|NCT03599427|DRUG|systemic lidocaine|Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
41023308|NCT03599427|DRUG|Placebo|Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
41023309|NCT04620317|DIETARY_SUPPLEMENT|Synbiotic|10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
41023310|NCT04620317|DIETARY_SUPPLEMENT|Placebo|Non-active ingredients - Maltodextrins
41023311|NCT02782481|DRUG|ND0612|
41023312|NCT02782481|DRUG|Placebo|
41023313|NCT05743985|OTHER|Cannabigerol|Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.
41023314|NCT05812027|DIAGNOSTIC_TEST|Tumor and HLA Profiling|HLA genotyping and tumor tissue profiling for certain TAA and LOH.
41023315|NCT00982189|DRUG|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
41023316|NCT00982189|DRUG|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
41023317|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 1 to day 14
41023318|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 8 to day 14
41023319|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 8 to day 14
41023320|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 1 to day 14
41023321|NCT04654689|DIETARY_SUPPLEMENT|Liposomed polyphenols resveratrol and curcumin|Combination of resveratrol (75mg) and curcumin (200mg) liposomed
41023322|NCT04654689|OTHER|Placebo for liposomed resveratrol and curcumin|Water with sucrose replacing the liposomed polyphenols
41023323|NCT04654689|DIETARY_SUPPLEMENT|Isocaloric Diet|40% carbohydrates, 40% lipids and 20% proteins
41023324|NCT04654689|DRUG|G04CB02|G04CB02, in a single daily dose for 4 months
41023325|NCT04654689|OTHER|Placebo microcrystalline methylcellulose|Placebo replacing G04CB02
41023326|NCT01692197|DRUG|E7070|400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
41023327|NCT01692197|DRUG|Idarubicin|8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
41023328|NCT01692197|DRUG|Cytarabine|1.0 g/m2 by vein daily on Days 9 - 12 (age \<60 years) or Days 9 - 11 (age \> 60 years).
41023329|NCT01692197|DRUG|Dexamethasone|10 mg by vein daily for 3 - 4 days with cytarabine.
41023330|NCT00054002|PROCEDURE|adjuvant therapy|Lung surgery
41023331|NCT00054002|PROCEDURE|conventional surgery|Lung surgery
40838386|NCT06344260|PROCEDURE|human Neural Stem Cells (hNSC)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
40838387|NCT06344260|PROCEDURE|Saline (Placebo)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
40838388|NCT01813123|BEHAVIORAL|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
40838389|NCT01431885|PROCEDURE|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
40838390|NCT01431885|PROCEDURE|Cervical change|Diagnosis will be made by digital examination of cervical change
40838391|NCT03467672|OTHER|Diagnosis of bacterial infection|use of eosinopenia in the diagnosis of bacterial infection
40838392|NCT02920723|OTHER|Training|
40838393|NCT02920723|OTHER|Control|
40838394|NCT01993563|OTHER|Graded Motor Imagery|"GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).~IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15 screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.~EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.~MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror."
40838395|NCT01993563|OTHER|Standard treatment|Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
40838396|NCT05962359|BEHAVIORAL|Parent-Implemented Communication Treatment|The intervention will be taught by a qualified professional online and/or in-person for about 6 months. Parents will learn strategies to enhance their children's social communication and will receive coaching and feedback.
40838397|NCT04170829|BIOLOGICAL|ChAdOx1 MERS|a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
41023332|NCT00054002|DRUG|porfimer sodium|iv
41023333|NCT03969810|BEHAVIORAL|Rounding Summary|Written summary of rounds
41023334|NCT01264302|DRUG|Finasteride|Finasteride Tablets 5 mg
41023335|NCT02479984|PROCEDURE|Staging Laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
41358279|NCT04352244|DIAGNOSTIC_TEST|Blood sampling|A blood sample will be collected in the fasting state either during preoperative testing or in the preoperative area on the day of planned procedure for measurement of adipose functional markers (leptin, adiponectin) and insulin resistance (insulin, C-peptide), and measures of glycemia (glucose, hemoglobin A1c).
40838398|NCT02471638|DEVICE|PQ Bypass System for Femoropopliteal Bypass|To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
40838399|NCT01877889|DRUG|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).
41023336|NCT02479984|DEVICE|Laparoscopic ultrasound|
41358280|NCT04352244|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with adipose phenotypes will be performed.
41358281|NCT02350660|DIETARY_SUPPLEMENT|cow's milk|daily consumption of cow's milk
41358282|NCT02350660|DIETARY_SUPPLEMENT|peanut powder|peanut oral immunotherapy
41358283|NCT04022109|DEVICE|Breath sampling for VOC detection|Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
41497330|NCT05794360|BEHAVIORAL|ACtive Children Enhance LEaRning and AttenTION (ACCELERATION)|A diverse group of key informants (i.e., PE teachers, school athletic department director) and community stakeholders (i.e., professional soccer coaches, Houston Dynamo Academy director) were engaged to help the research team design, modify, and implement the ACCELERATION curriculum to ensure program relevance and appeal. There are several components that described below make our program design both comprehensive and highly adaptable for optimal reach and effectiveness. These include staff development training, parent workshops, on-site and virtual developmental programs, delivery and implementation support from community stakeholders, online resources, family engagement events, equipment donations to improve activity, and on-going support and mentoring services for parents and school-based educators.
41497331|NCT02521376|DRUG|Entospletinib|Entospletinib 100 mg tablet administered orally
41497332|NCT00191971|DRUG|Gemcitabine|
41497333|NCT02075177|DRUG|Fenretinide Lym-X-Sorb Oral Powder|Fenretinide Lym-X-Sorb 1500 mg/m2/day, daily for 7 days every 3 weeks
41497334|NCT02075177|DRUG|Ketoconazole|Ketoconazole 6 mg/kg/day, daily for 7 days every 3 weeks.
41497335|NCT00062400|PROCEDURE|psychosocial assessment and care|
41497336|NCT01612299|DRUG|Zortress® /Everolimus|"Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml \>6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 \&2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml \>6 mo post transplant 4-7 ng/ml."
41497337|NCT01224665|PROCEDURE|therapeutic conventional surgery|Patients undergo radical cystectomy
41497338|NCT01224665|PROCEDURE|therapeutic standard lymphadenectomy|Patients undergo standard pelvic lymphadenectomy.
41497339|NCT01224665|PROCEDURE|therapeutic extended lymphadenectomy|Patients undergo extended pelvic lymphadenectomy
41497340|NCT05568901|BEHAVIORAL|Lethal means counseling|"Lethal means counseling is a type of safety education that advises securement or removal of potentially hazardous household items such as medications, knives, and firearms. Counseling provided by study team was derived from the Suicide Prevention Resource Center's Counseling on Access to Lethal Means training module and the Store It Safe campaign from the Ohio Chapter of the American Academy of Pediatrics (AAP). Guidance focused on securement of dangerous items in the household, such as medications and firearms, with locking devices-or more preferably removing these items from the home, even if temporarily."
41023337|NCT03949725|BEHAVIORAL|Hans Kai Program|In Hans Kai, first, participants attend a 2-month Health School to develop the skills necessary to improve their health and wellbeing. The Health School includes sessions on health indicators; nutrition, grocery shopping and meal planning; physical activity; stress, coping, and health (sleep); and primary care through the years. After participants complete the Health School, they form Hans Kai groups (of 3 or more adults) and begin to meet regularly (at least once a month) independently of facilitators, in a self-sustaining model.
41023338|NCT03934268|GENETIC|KCNQ2|The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
41023339|NCT03492307|OTHER|Weight-Based Flow for High Flow Nasal Cannula (HFNC) (2L/kg/minute)|A weight-based flow for HFNC.
41023340|NCT03492307|OTHER|Standard Flow for HFNC (Maximum 8L/minute)|Maximum flow of 8L/minute.
41023341|NCT02731001|RADIATION|Proton therapy|
41023342|NCT02731001|RADIATION|Photon therapy|
41023343|NCT04681521|OTHER|Hot and Cold compress, nursing interventions|using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
41023344|NCT05813834|PROCEDURE|Genicular Nerves Block|US guided genicular nerves block
41023345|NCT03663413|DEVICE|non-invasive monitor|cutaneous EEG monitor
41358284|NCT04022109|PROCEDURE|Surgery material collection for VOC headspace analysis|Only for gastric cancer patients undergoing surgery (Group 1)
41358285|NCT04022109|DIAGNOSTIC_TEST|Upper endoscopy|Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
41497341|NCT05568901|BEHAVIORAL|Provision of Cable-style gun locks|Caregivers were provided 2 (two) SnapSafe Cable Padlock (Item No. 75281), advised on how to use these devices to store firearms safely (including instructions from within the package of the provided gun locks) and were advised to store keys away from the firearm in a location that children would not have access
41497342|NCT00991705|DRUG|Atorvastatin|
41358286|NCT04022109|DIAGNOSTIC_TEST|Microbiota testing|Faecal and gastric contents and biopsy samples for microbiota testing
41358287|NCT06292026|DEVICE|ProgenaMatrix Keratin graft|place ProgenaMatrix graft on the wound
41358288|NCT06292026|OTHER|standard of care|apply non adherent dressing
41358289|NCT05150925|OTHER|Cast treatment|Dorsal cast placed in OR
41358290|NCT05150925|OTHER|Immediate mobilization|Immediate mobilization postoperatively without casting
41497343|NCT00991705|DRUG|Fimasartan|
41358291|NCT05150925|PROCEDURE|Volar plating|Volar plating of distal radius fracture
41023346|NCT04831125|OTHER|Data collection|Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use.
41023347|NCT04112849|DIAGNOSTIC_TEST|Measurement of S3 heart sound|S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
41023348|NCT02637934|DRUG|[18F]FluorThanatrace|
41023349|NCT02637934|RADIATION|PET/CT imaging sessions|
41023350|NCT05040217|GENETIC|AAV2-BDNF Gene Therapy|AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
41023351|NCT05040217|BIOLOGICAL|AAV2-BDNF Gene Therapy|Gene therapy is a biological therapy delivering the BDNF gene to the brain
41023352|NCT00618020|DEVICE|CiTop(tm) Guidewire|CiTop(tm)6 Guidewire
41497344|NCT04055038|DRUG|Platinum-Based Drug|Reintroduction of platinum-based chemotherapy
41497345|NCT04055038|DRUG|Conventional chemotherapy|Conventional chemotherapy
41497346|NCT02662660|DRUG|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
41497347|NCT02662660|DRUG|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
41497348|NCT02662660|DRUG|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
41497349|NCT04810130|OTHER|Soccer Kicking|Subjects assigned to the soccer kicking arm will complete 10 soccer kicks in 10 minutes.
41497350|NCT04810130|OTHER|Soccer Heading (Frontal)|Subjects assigned to the soccer heading (frontal) arm will complete 10 frontal soccer headers (ball headed directly back to launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
41497351|NCT04810130|OTHER|Soccer Heading (Oblique)|Subjects assigned to the soccer heading (oblique) arm will complete 10 oblique soccer headers (ball headed 90° to the right from ball launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
41497352|NCT02086903|DRUG|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
41497353|NCT02086903|DRUG|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
41497354|NCT05522985|DRUG|Triprilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
41497355|NCT01879930|DRUG|doxycycline|"Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100"
41497356|NCT01879930|DRUG|placebo|"Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group"
41497357|NCT04326465|DEVICE|Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage|Fractional Carbon Dioxide Laser Therapy is an ablative therapy where abnormal collagen in scarred tissue is destroyed to permit the formation of more organized collagen. Previous studies have demonstrated its efficacy in treating medical conditions (ex. hypertrophic scars) similar to Peyronies Disease. There is evidence that Fractional Carbon Dioxide Laser Therapy has the ability to target and alter the molecular pathways that are similar to the ones that lead to Peyronie's Disease.
41497358|NCT01343316|DEVICE|Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)|To determine the benefits of utilizing one type of transpyloric tube over another.
41497359|NCT01062867|DRUG|ORG25435|Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
41497360|NCT04034537|DIAGNOSTIC_TEST|cPSTA|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
41497361|NCT03665441|DRUG|eryaspase|L-asparaginase encapsulated in erythrocytes (red blood cells)
41497362|NCT03665441|DRUG|Gemcitabine plus Abraxane|gemcitabine, Abraxane
41497363|NCT03665441|DRUG|Irinotecan plus 5-FU plus leucovorin|irinotecan, 5-FU, leucovorin
41497364|NCT03667209|OTHER|Pain neuroscience education (PNE) and traditional exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
41023353|NCT01871298|OTHER|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
40838400|NCT01877889|DRUG|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).
40838401|NCT01189305|BEHAVIORAL|Behavioral Couples Therapy|Behavioral Couples Therapy
40838402|NCT01189305|BEHAVIORAL|Individual Drug Counseling|Individual Drug Counseling
41023354|NCT03586635|OTHER|neurological exam|"Patients participating in the study are recruited from the investigator's tertiary multiple sclerosis management centre. They are systematically examined neurologically as part of their routine follow-up.~the patient will be exceptionally examined by two distinct persons, a senior doctor and a junior doctor (internal or external) independently.~At the end of the neurological examination, each examiner will evaluate the EDSS score in a classical way (using paper definitions) then using the smartphone application"
41160568|NCT01940523|DRUG|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
41160569|NCT01940523|DRUG|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
41358292|NCT03184805|DRUG|Continuing aspirin|Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.
41160570|NCT06276114|DEVICE|Stent Underexpansion|Stent underexpansion was diagnosed as stent expansion of \<80% assessed with intravascular imaging.
41160571|NCT04225637|DEVICE|Miniscrew-Supported Maxillary Expander- Slow activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated slowly by turning the expansion screw once every other day to correct the transverse maxillary deficiency.
41358293|NCT03184805|DRUG|Stopping aspirin|Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
41497365|NCT03667209|OTHER|Pain neuroscience education (PNE) and suspension exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises. delivered in suspension.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
41497366|NCT00912925|BIOLOGICAL|rhIDU (recombinant human-Alpha-L-Iduronidase)|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
41497367|NCT00912925|BIOLOGICAL|Placebo|Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
41497368|NCT00151112|PROCEDURE|Positioning and plexus anesthesia|positioning during plexus anesthesia
41497369|NCT00005399|OTHER|No interventions|No interventions
41160572|NCT04225637|DEVICE|Miniscrew-Supported Maxillary Expander- Rapid activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated rapidly by turning the expansion screw twice per day to correct the transverse maxillary deficiency.
41160573|NCT03128788|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain
41160574|NCT02737670|DRUG|Sulodexide|25 mg morning and evening for 40 days
41358294|NCT05998902|PROCEDURE|Trophic enteral feeding combined with supplemental parenteral nutrition|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Patients will receive the trophic enteral feeding with a caloric target of 500kcal/d (20-35ml/h), and the remaining calories are supplemented by parenteral nutrition. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
41160575|NCT02737670|DRUG|Placebo|1 tablet morning and evening for 40 days
41358295|NCT05998902|PROCEDURE|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day. Enteral nutrition is given through nasogastric tube or nasointestinal tube.
41160576|NCT00196378|DRUG|Synthetic Conjugated estrogens, B|1 (0.3mg) tablet daily
41160577|NCT00196378|OTHER|Placebo|1 tablet daily
41358296|NCT00303290|DRUG|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
41160578|NCT00710814|DRUG|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
41358297|NCT00303290|DRUG|Ara-C (cytosine arabinoside)|10 mg under the skin daily
41358298|NCT06457373|PROCEDURE|Demineralized Dentin Allograft|20 sockets are randomly allocated to receive the Demineralized Dentin Allograft (split-mouth study)
41358299|NCT06457373|PROCEDURE|Demineralized Dentin Autograft|20 sockets are randomly allocated to receive the Demineralized Dentin Autograft (split-mouth study)
40838403|NCT03433534|OTHER|Pharmacokinetic of Nivolumab|Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
40838404|NCT01986959|PROCEDURE|With Periodontal dressing|After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
41160579|NCT00710814|OTHER|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
41160580|NCT03594266|DEVICE|Therapy A spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy A stimulation patterns
41160581|NCT03594266|DEVICE|Therapy B spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy B stimulation patterns
40838405|NCT01986959|PROCEDURE|Without Periodontal dressing|The dressing was not inserted.
40838406|NCT05035589|DRUG|Tocilizumab|Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
41497370|NCT03052010|OTHER|Integrated PrEP as a bridge to ART HIV-1 prevention strategy|The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services
41497371|NCT03052010|DRUG|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
41023355|NCT06572462|DRUG|individualized ATG dosing strategy|Investigators quantified active ATG exposure in 106 haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) recipients, who received a conventional fixed dose of 10 mg/kg ATG during conditioning, the optimal concentration range of active ATG-AUC was determined through the application of machine learning methods, was found to be 100-148.5 × 10\^3 UE·d/L. This concentration range was associated with a reduction in CMV/EBV reactivation, without an increase in acute GVHD or malignant disease relapse. Mathematical function was then exploited to determine the total targeted ATG dose on -3days to -2days based on concentrations of active ATG on -5daysto -4days. Based on this function, investigators established a dosing strategy that aimed to maintain the active ATG-AUC within the optimal range.
41160582|NCT05930132|PROCEDURE|submucosal conchoplasty|Regarding the submucosal conchoplasty technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000. The mucosa was incised by blade 15 starting from the axilla posteriorly up to the attachment with the basal lamella. The mucosa covering the lateral lamella was dissected using the freer dissector. The lateral lamella was removed using a through cut forceps then the mucosa was repositioned. The bony skeleton of the medial lamella was preserved
41497372|NCT03052010|DRUG|ART|ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
40838407|NCT06194071|OTHER|Completion of questionnaires and on-site visits during an 18 months follow-up after TBI|"We will evaluate the same outcomes and use the same questionnaires at 6, 12 and 18 months post-TBI.~For patients we will evaluate:~* Functional Outcome (GOS-Extended)~* Health-related Quality of Life (QOLIBRI)~* Neurocognitive tests (MoCA)~* Independence (Barthel Index)~* Daily issues (BICOQ)~* Anxiety and depression symptoms (HADS)~* Medico-economic evaluation (EQ5D-5L)~For Relatives we will evaluate:~* Symptoms of anxiety and depression (HADS)~* The appreciation of the patient's daily issues from their point of view (dedicated Bicoq for relatives)~* Burden of care (ZARIT)~Throughout the follow-up we will nest a qualitative research programs which will focus on several aspects:~* feasibility of such follow-up (6 months is the primary endpoint) defined as the drop-out rate, complete or incomplete completion of scales and their reasons~* factors that may lead to drop-out or the contrary that solidifies the follow-up"
40838408|NCT01028170|DRUG|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
40838409|NCT01028170|DRUG|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
41358300|NCT03539900|DRUG|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination|NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.
41358301|NCT03539900|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
41358302|NCT02612194|DRUG|Crizotinib|Crizotinib was administered orally at 250mg twice daily
41358303|NCT05763472|GENETIC|Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).|Next-generation sequencing (NGS) analysis with TruSight Oncology 500 (TSO 500) is performed on tumor samples from breast and ovarian cancer of the enrolled patients.
41358304|NCT04785781|OTHER|without masks|apply a bicycle ergometer test protocol to individuals without a mask
41358305|NCT04785781|OTHER|Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)|apply a bicycle ergometer test protocol to individuals with a surgical mask
41497373|NCT01907126|BEHAVIORAL|Nutrition Program (NP)|Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
41358306|NCT04785781|OTHER|FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)|apply a bicycle ergometer test protocol to individuals with a FFP2\\N95 mask
41358307|NCT04835389|BIOLOGICAL|AlloGen Liquid|Amniotic fluid
40838410|NCT06120894|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using Snellen optotype chart.
40838411|NCT06120894|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
40838412|NCT06120894|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
41358308|NCT04835389|DRUG|Placebo|0.9% normal saline
41358309|NCT03599284|DRUG|Vicagrel 5mg|Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
41358310|NCT03599284|DRUG|Vicagrel 6mg|Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
41358311|NCT03599284|DRUG|Vicagrel 7.5mg|Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
41497374|NCT01907126|BEHAVIORAL|Women's Prison CoOp (WPC)|Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
41497375|NCT00810576|DRUG|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
41497376|NCT00810576|DRUG|Bortezomib|Dose of 1.3 mg/m\^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
41497377|NCT01142479|DRUG|Chinese herbal medicine decoction|100 ml /Qd for 6 weeks(42 days)
41497378|NCT01345916|DRUG|CHF 1535 100/6 NEXT DPI® 2 months|CHF 1535 100/6 NEXT DPI® 2 months
40838413|NCT06120894|DIAGNOSTIC_TEST|Refraction and keratometry|Measurement of refraction and keratometry using refractometer Nidek ARK-1a.
40838414|NCT06120894|DIAGNOSTIC_TEST|Optical biometry|Measurement of optical biometry using biometer Argos (Barrett or SRK/T formula).
40838415|NCT06120894|DIAGNOSTIC_TEST|Strip meniscometry (SM)|Strip meniscometry examination using strip meniscometry tube.
40838416|NCT06120894|DIAGNOSTIC_TEST|Lid Parallel Conjunctival Folds test (LIPCOF)|Evaluation of lid parallel conjunctival folds using slit lamp examination.
40838417|NCT06120894|DIAGNOSTIC_TEST|Staining of the ocular surface with fluorescein|Evaluation of ocular surface fluorescein staining using Oxford scheme.
40838418|NCT06120894|DIAGNOSTIC_TEST|Tear break up time test (TBUT)|Evaluation of tear break up time using slit lamp examination.
40838419|NCT06120894|OTHER|Ocular Surface Disease Index questionnaire (OSDI)|Evaluation of Ocular Surface Disease Index using Ocular Surface Disease Index questionnaire.
41497379|NCT01345916|DRUG|CHF 1535 100/6 pMDI 2 months|CHF 1535 100/6 pMDI 2 months
41497380|NCT01345916|DRUG|BDP DPI 2 months|BDP DPI 2 months
41497381|NCT05486793|BEHAVIORAL|Written Exposure Therapy (WET)|5 individual sessions that cover psychoeducation about PTSD, the rationale for exposure treatment, and directing patients to write in session for 30 minutes about their traumatic experience using scripted instructions. Each session includes unique writing instructions. Earlier sessions focus on describing the details of a traumatic stressor linked to their symptoms, with particular attention to felt emotions and thoughts. Later writing sessions focus on writing about the meaning of the traumatic event and how the event has changed their life and how they relate to other people. After writing, therapists spend \~10 minutes processing the patient's experience with the writing. WET does not include between session assignments.
40838420|NCT01998191|OTHER|Explicit case note review checklist (nurse)|"A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
40838421|NCT01998191|OTHER|Explicit case note review checklist (physician)|"A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
40838422|NCT01998191|OTHER|Explicit case note review checklist (MDT)|"A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
40838423|NCT03408210|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
41160583|NCT05930132|PROCEDURE|classic lateral lamellectomy|"Regarding the lateral lamellectomy technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000; the sickle knife was used to open the concha then the scissor was used to remove the lateral lamella with its covering mucosa in one block.~No middle meatus packing was applied. Systemic antibiotics and steroids (0.5 mg / kg prednisolone) were given for two weeks after the surgery. The patients were instructed to use local nasal irrigations (2 ml of budesonide 0.5 mg / ml mixed with 250 ml of normal saline) two times daily for a month postoperatively. Patients were followed up at the end of each month throughout the six months follow-up period."
41358312|NCT03599284|DRUG|Clopidogrel 75mg|Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
41497382|NCT05486793|BEHAVIORAL|Emotion Focused Supportive Therapy (EFST)|5 individual sessions where patients choose what problems to discuss in each session. Therapists validate and clarify patients' emotions and engage in problem solving during sessions.
41497383|NCT02707445|DRUG|Clopidogrel|Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
41497384|NCT06483321|DIETARY_SUPPLEMENT|Creatine Supplementation|"Normocaloric vegan diet supplemented with 0.1 g/kg/day of creatine monohydrate~Normocaloric diet based solely on foods of plant sources with creatine supplementatio (0.1 g/kg/day)"
41497385|NCT06483321|DIETARY_SUPPLEMENT|Placebo|Normocaloric vegan diet supplemented with 0.1 g/kg/day of placebo (maltodextrin)
41497386|NCT02150135|OTHER|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
41497387|NCT05023837|DRUG|Pembrolizumab 100 MG Injection|Pembrolizumab iv 200mg q21d
41497388|NCT03383237|DRUG|Apatinib|500mg/d,q.d.,p.o.
41497389|NCT00519688|DRUG|Thalidomide|100 mg, BID
41497390|NCT00519688|DRUG|Tegafur/Uracil|125 mg/m2, based on tegafur, BID
41497391|NCT04932057|OTHER|Action observation Training|Action observation training is a relatively new rehabilitation approach in which the subject is asked to carefully observe the actions presented through a video clip or performed by an operator.
41497392|NCT04932057|OTHER|Action Practice|Participants perform an upper extremity functionality test a couple of times.
41497393|NCT04932057|OTHER|Observation|Participants will watch a slide show of landscape
41497394|NCT06050889|OTHER|Positive Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention known to be effective for some people with shoulder pain. We expect this will make you less sensitive to the pressure applied to your shoulder and thigh and you will require more pressure than what was previously necessary to experience pain."
41497395|NCT06050889|OTHER|Negative Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention which is not effective for some people with shoulder pain. We expect this will make you more sensitive to the pressure applied to your shoulder and thigh and you will require less pressure than what was previously necessary to experience pain."
41023356|NCT01478945|DEVICE|311 nm NB-UVB light|"Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp."
41160584|NCT00497198|DRUG|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
41497396|NCT00041626|GENETIC|INGN 201|
41497397|NCT04105140|DRUG|Oxytocin|intranasal administration of oxytocin (24 IU)
41497398|NCT04105140|DRUG|Placebo|intranasal administration of placebo (24 IU)
41497399|NCT03466437|DEVICE|Glass-fiber post and composite resin restoration|Patients will receive a glass-fiber and composite resin restoration followed by removable partial denture fabrication
41497400|NCT03466437|DEVICE|Glass-fiber post and metalceramic crown|Patients will receive a glass-fiber and metalceramic crown followed by removable partial denture fabrication
41023357|NCT03246009|DRUG|rHSA/GCSF|single injection-1.8mg
41023358|NCT03246009|DRUG|rHSA/GCSF|single injection-2.1mg
41023359|NCT03246009|DRUG|rHSA/GCSF|single injection-2.4mg
41160585|NCT00497198|DRUG|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
41160586|NCT02878421|DEVICE|electronic cigarette + 16mg nicotine & flavor|comparison of different strengths of nicotine
41160587|NCT02878421|OTHER|electronic cigarette + 0mg nicotine & flavor|comparison of different strengths of nicotine
41160588|NCT02878421|OTHER|Tobacco cigarette|Participant to remain on traditional cigarettes for 28 days
41160589|NCT05359705|DEVICE|DJO 456|Data will be recorded while subjects wear a 456 back brace manufactured by DJO Global
41160590|NCT05359705|DEVICE|Aspen 456|Data will be recorded while subjects wear a 456 back brace manufactured by Aspen Medical Products
41160591|NCT05359705|DEVICE|DJO 464|Data will be recorded while subjects wear a 464 back brace manufactured by DJO Global
41497401|NCT03466437|DEVICE|Cast-metal post and metalceramic crown|Patients will receive a cast-metal post and metalceramic crown followed by removable partial denture fabrication
41497402|NCT02933255|BIOLOGICAL|PROSTVAC-V/F|PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10\^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10\^9 infectious units.
40838424|NCT03408210|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
40838425|NCT06507917|DIAGNOSTIC_TEST|anal swabbing|anal swabbing
40838426|NCT02570880|OTHER|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products - Determination of the glycaemic index (GI) and recommendation for food classification
40838427|NCT06102772|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
40838428|NCT00663845|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
40838429|NCT00663845|DRUG|Placebo|Matching placebo
40838430|NCT01454349|DRUG|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
40838431|NCT01454349|DRUG|Placebo|Single intraprostatic injection of matching placebo
41160592|NCT05359705|DEVICE|Aspen 464|Data will be recorded while subjects wear a 464 back brace manufactured by Aspen Medical Products
40838432|NCT05124379|DEVICE|Hemoclin Gel|Non sterile gel for intra-rectal use
40838433|NCT02460341|DRUG|ondansetron|Ondansetron 8mg, 16mg, 24mg
40838434|NCT02460341|DRUG|placebo|placebo pill
40838435|NCT06368934|PROCEDURE|sub-lobectomy|Combined with previous research and our team's precise neurosurgery concept, we define the surgical strategy based on lobectomy and further preserving the brain parenchyma in functional areas according to anatomical landmarks and electrophysiological boundaries as sub-lobectomy.
40838436|NCT06368934|PROCEDURE|imaging total resection|Imaging total resection (T1-enhanced borders) will met the RANO criteria
41160593|NCT02078947|BEHAVIORAL|High Intensity Exercise|
41160594|NCT02078947|BEHAVIORAL|Moderate Continuous Exercise|
41160595|NCT02078947|BEHAVIORAL|Usual Care|
41358313|NCT01397331|DRUG|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
41358314|NCT01397331|DRUG|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
41358315|NCT01523613|DEVICE|Chemfil ROCK Glassionomer restoration|High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.
41497403|NCT02933255|DRUG|Nivolumab|Nivolumab is to be administered as a flat dose over approximately 30-minutes via intravenous (IV) infusion.
41497404|NCT02933255|PROCEDURE|Prostatectomy|Participants in the neoadjuvant cohort will undergo a radical prostatectomy in week 9. (If surgery is scheduled earlier than 9 weeks after initial dosing, the 6 and 8 week dosing may be skipped, and surgery may be done as early as week 5.)
41497405|NCT02933255|PROCEDURE|Biopsy|A baseline biopsy is performed for participants in the neoadjuvant cohort that do not have a previous collection of biopsy material.
41497406|NCT02933255|DRUG|Tylenol|Participants who experience aches or fever after vaccination may take Tylenol as directed.
41497407|NCT03908762|DEVICE|iSage App with connected glucometer|Providers prescribe an insulin dosing plan to patients and provide them with a connected glucometer. The patient's plan is administered through a mobile application. In addition, patients receive education and guidance on insulin administration.
41497408|NCT03908762|BEHAVIORAL|Magnet|Patients are given a refrigerator magnet with an insulin titration algorithm and are asked to follow the instructions on the magnet.
41497409|NCT06284603|DEVICE|Hyperbaric Oxygen Therapy - HBOT|Each session includes exposure of 60 minutes to 100% oxygen at 2.5 atmosphere absolute (ATA), with 5-minute air breaks every 20 minutes
41497410|NCT02031458|DRUG|Atezolizumab|1200 mg IV every 3 weeks
41497411|NCT05915975|BEHAVIORAL|Behavioral Care Coordinated with Medical Care Intervention|Participants will be meeting with a behavioral health provider during their clinic visit. Subsequent visits can be held either via telehealth or in-person. Participants should expect weekly visits during the first two months and less frequent visits (biweekly or monthly) for the last two months. Some sessions that are provided via telehealth might be video recorded and later reviewed to ensure that the program is being delivered as intended.
41497412|NCT05915975|BEHAVIORAL|Behavioral Care Not Coordinated with Medical Care Intervention|Participants will meet with a study team member during their in-person visit and will receive a list of clinics that are panelled with their insurance. The participants will be responsible for calling the clinics to set up their appointments. Services might be provided in person or via telehealth based on the participant's preference and the clinics' availability.
41497413|NCT04709835|DRUG|AT-527|Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.
41497414|NCT04709835|DRUG|Placebo|The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.
41497415|NCT02410980|DRUG|Tretinoin cream 0.1%|Assessment of the skin change
40838437|NCT00612508|DRUG|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
40838438|NCT00612508|DRUG|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
40838439|NCT02412059|DRUG|Prednisolone acetate|
40838440|NCT01798030|OTHER|Vitamin D|N/A, frozen specimen study
40838441|NCT02644382|OTHER|qualitative data collection|qualitative data collection
40838442|NCT02644382|OTHER|survey|survey pre and post-surgical consult
40838443|NCT02644382|OTHER|decision aid|web-based decision aid post-surgical consult
41023360|NCT03246009|DRUG|rHSA/GCSF|multiple injection-1.8mg
41023361|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.1mg
41023362|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.4mg
41023363|NCT01083550|OTHER|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
41358316|NCT01523613|DEVICE|Fuji IX GP Extra Glassionomer restoration|High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.
41023364|NCT03702829|DRUG|Inotersen|Open Label Study
41023365|NCT02262845|DEVICE|The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers|Used to drain pancreatic ducts
41358317|NCT01768039|DRUG|Vitamin D|
41358318|NCT01768039|DRUG|Placebo|
41497416|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
41497417|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
41497418|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
41497419|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
41497420|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
41497421|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
41497422|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
41497423|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
41497424|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
41497425|NCT02036775|DRUG|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
41497426|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
41497427|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
41497428|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
41497429|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
41497430|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
41497431|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
41023366|NCT05871164|PROCEDURE|Pancreatic radiofrequency|Pancreatic radiofrequency is similar to a puncture under echoendoscopy. The lesion is located then punctured by transgastric or transduodenal route either using a 19 gauge needle with exchange of the stylet for a probe, or using a 19 gauge needle whose distal end of 5-10 mm corresponds to the active part, connected to a generator with an integrated cooling system.
41023367|NCT02783586|PROCEDURE|Quadratus Lumborum Block type II|Local anaesthetic injection on the posterior border of the quadratus lumborum muscle
41023368|NCT02783586|PROCEDURE|Transversus Abdominalis Plane Block|Local anaesthetic injection between internal oblique and transversus abdominis muscle
41497432|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
41497433|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
41497434|NCT03240237|DEVICE|Optimizer SMART|Cardiac Contractility Modulation
41023369|NCT02783586|DRUG|Bupivacaine|20 ml of bupivacaine with adrenaline
41023370|NCT02783586|DEVICE|Ultraplex|A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
41023371|NCT02182544|DRUG|WAL801CL dry syrup|
41023372|NCT02182544|DRUG|Ketotifen fumarate dry syrup|
41023373|NCT02182544|DRUG|Ketotifen fumarate dry syrup placebo|
41023374|NCT02182544|DRUG|WAL 801 CL dry syrup placebo|
41023375|NCT02606136|DRUG|Pamrevlumab|Pamrevlumab, 10 milligrams (mg)/milliliter (mL), single dose vials
41023376|NCT03110159|DRUG|Levulan® Kerastick®|Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
41023377|NCT03110159|DRUG|BLU-U Blue Light Photodynamic Therapy|3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
41160596|NCT01780545|DRUG|OGX-427|"Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity."
41160597|NCT01780545|DRUG|Docetaxel|"For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles."
41160598|NCT02251756|DEVICE|Actinica, 0.8 mg/cm2, 1 application|
41160599|NCT02251756|DEVICE|Actinica, 0.8 mg/cm2, 2 applications|
41497435|NCT02955823|DRUG|Rituximab-Dexamethasone-Lenalidomide|"1. st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~2. nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~   * if \<PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~  * if \<PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity."
41497436|NCT06232473|BEHAVIORAL|Patient Education|Please see arm desciption
41497437|NCT06232473|DRUG|Duloxetine|Please see arm description
41497438|NCT06232473|DRUG|Benztropine Mesylate 0.5 MG and passive placebo RAP|Please see arm description
41160600|NCT02251756|DEVICE|Actinica, 2 mg/cm2, 1 application|
41160601|NCT02251756|DEVICE|Actinica, 2 mg/cm2, 2 applications|
41160602|NCT05388149|DRUG|Neratinib|Neratinib administered as 40mg tablets
41160603|NCT03900884|DRUG|Venetoclax|At commencement of study: Venetoclax will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 100 and 800 mg/day depending on dose escalation results and recommendation of the safety committee.
41358319|NCT00609089|BEHAVIORAL|CRAFT-T|The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).
41358320|NCT00609089|BEHAVIORAL|Treatment as usual|Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
41358321|NCT01736176|DRUG|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
41358322|NCT01736176|PROCEDURE|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
41358323|NCT01736176|DRUG|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
41358324|NCT03613766|OTHER|Physical activity program|
41358325|NCT01591044|DRUG|Placebo|1 puff bid or 2 puffs bid
41358326|NCT01591044|DRUG|R940343 1mg|R343 1mg, 1 puff bid
41358327|NCT01591044|DRUG|R940343 2mg|R343 2mg, 2 puffs bid
41358328|NCT00531310|DRUG|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
41358329|NCT00747942|BEHAVIORAL|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
41358330|NCT05594966|DIAGNOSTIC_TEST|multimodal MRI|patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI
41358331|NCT04461457|COMBINATION_PRODUCT|211-astatine MX35 F(ab')2|Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).
41358332|NCT04390360|PROCEDURE|Protective ventilation implementation|In this condition, we will implement the protective ventilation related with gender and height . A blood gas will be performed at before protective ventilation implementation and at the end of this condition.Time condition 30 minutes
41358333|NCT04390360|PROCEDURE|Protective ventilation with HME|In this condition, the patient will received protective ventilation with a Heat Moisture Exchanger (HME). A blood gas will be performed at the end of this condition.Time condition 30 minutes
41358334|NCT04390360|PROCEDURE|Protective ventilation with Heated humidifier|In this condition, the patient will received protective ventilation with a Heated humidifier. A blood gas will be performed at the end of this condition.Time condition 30 minutes
41358335|NCT04390360|PROCEDURE|Tidal Volume reduction|n this condition, we will reduce Tidal volume (with smartphone application calculation) to obtain the same alveolar ventilation (PaCO2) obtained on the HME condition
41358336|NCT01335659|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
41358337|NCT01335659|DEVICE|IVUS|"intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
41358338|NCT01108068|DRUG|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
41358339|NCT02833727|OTHER|Smoking|Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
41358340|NCT03925493|BEHAVIORAL|Graded Exercise Stress test (GXT) with Target Heart Rate Range|Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.
41497439|NCT06232473|BEHAVIORAL|Enhanced usual care|Please see arm description
41497440|NCT01087489|DRUG|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
41358341|NCT03925493|BEHAVIORAL|Heart rate monitors|Heart rate monitors (HRM) will be given to half of the patients randomly assigned to exercise stress testing group. Patients will receive a polar heart rate chest strap and polar watch. Patients will be asked to wear both, the chest strap and the watch during cardiac rehabilitation. Ultimately, we hope that the use of HRM is not necessary, but it may be needed to assure that patients in the THHR are able to consistently know their HR and adjust their exercise prescription. This will also increase the likelihood that there is a difference in heart rates between the THRR group from the RPE group.
41358342|NCT00375596|DRUG|Ketotifen/vasoconstrictor|
41497441|NCT01087489|DRUG|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
41497442|NCT00056394|BEHAVIORAL|Comprehensive Coping Skills Training|10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.
41358343|NCT02439424|DEVICE|Reactive ATP|"Reactive ATP turned to on"
40838444|NCT03567018|DEVICE|MRI Scan|Study participants will be scanned with a 3.0 Tesla Phillips Ingenia CX whole body clinical MRI system located at the Wright Center of Innovation at The Ohio State University Medical Center. Anatomical and angiographic MR images will be acquired for one of the most commonly used flap surgery donor perforators including but not limited to: the deep inferior epigastric perforators (DIEP); the superior gluteal arter perforators (SGAP); the inferior gluteal artery perforators (IGAP); the thoracodorsal artery perforators (TDAP); the anterolateral thigh perforators (ATL).
40838445|NCT01381536|DRUG|GSK1550188 1mg/kg or 10mg/kg|IV one shot
41358344|NCT01071772|DRUG|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
41358345|NCT03287830|BEHAVIORAL|Text message influenza vaccine reminders|Text message reminders for second dose of influenza vaccination
41497443|NCT00056394|BEHAVIORAL|Arthritis Education Sessions|10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.
41497444|NCT00056394|BEHAVIORAL|Standard Care|Usual care from participants' rheumatologists but no treatment sessions.
41497445|NCT02819050|DEVICE|NCPAP|Nasal Continuous Positive Airway Pressure
41497446|NCT00307437|DRUG|Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
41497447|NCT00307437|DRUG|Ustekinumab (CNTO 1275) 45 mg|Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
41497448|NCT00307437|DRUG|Ustekinumab (CNTO 1275) 90 mg|Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
40838446|NCT00845065|DRUG|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
40838447|NCT00845065|OTHER|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
41358346|NCT06051305|BEHAVIORAL|Sensory Training|Participants will use gamified sensory training technology once daily for 8 weeks. This will involve participants completing a 15 minute sensory training session using the provided technology. The tool used in this study has two components. The first is a game that can be downloaded onto any smartphone device. The second component is two tactile devices that can be attached to the body.
41358347|NCT02539680|PROCEDURE|endoscopy|duodenal biopsies
41358348|NCT06021028|PROCEDURE|complex proximal carious cavities in posterior teeth.|Selective enamel etching with 37% phosphoric acid for 30 second will be done then the bonding agent will be applied following the manufacturer's instructions.
41358349|NCT04900714|PROCEDURE|Decremental PEEP|High PEEP to low PEEP.
41358350|NCT04900714|DIAGNOSTIC_TEST|Lung ultrasound score|lung ultrasound to determine the extend of atelectasis. Uses validated lung ultrasound score.
41358351|NCT04900714|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analysis to determine arterial oxygen tension
41358352|NCT04900714|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
41497449|NCT05614427|DIAGNOSTIC_TEST|Innova Lateral Flow Test|Lateral flow test performed on anterior nasal or buccal swabs
41497450|NCT04854889|DRUG|Decitabine|Demethylating agents
41497451|NCT00986518|BIOLOGICAL|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
41497452|NCT04892017|DRUG|DCC-3116|Oral Tablet Formulation
41497453|NCT04892017|DRUG|Trametinib|Oral Tablet Formulation
41497454|NCT04892017|DRUG|Binimetinib|Oral Tablet Formulation
41497455|NCT04892017|DRUG|Sotorasib|Oral Tablet Formulation
41497456|NCT05372640|DRUG|Abemaciclib|Given PO
41497457|NCT05372640|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
41358353|NCT04900714|DIAGNOSTIC_TEST|Evaluation of dead space|Dead space will be measured non-invasively using volumetric capnography on the FluxMed respiratory monitor (MBMED, Argentina)
40838448|NCT00845065|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
40838449|NCT00845065|DRUG|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing~* \<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~* \>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks"
40838450|NCT00442325|DRUG|Atorvastatin (Lipitor)|
41023378|NCT05352074|PROCEDURE|subtotal colectomy with cecal-rectal anastomosis|The intervention involves, after a complete mobilization of the colon, a resection 2-3 cm distal to the ileocecal junction and at the upper part of the rectal ampulla; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. In the laparoscopic approach we use 5 trocars (trocar 1 periumbilical, trocars 2-3-4-5 drawing a 15-cm side square around trocar 1), using a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
41023379|NCT05352074|PROCEDURE|total colectomy with ileorectal anastomosis|After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis (end to end) is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
41023380|NCT03156023|DRUG|Rozibafusp Alfa|Administered by subcutaneous injection once every 2 weeks.
40838451|NCT00054028|DRUG|suramin|Given IV
41023381|NCT03156023|DRUG|Placebo|Administered by subcutaneous injection once every 2 weeks.
41023382|NCT01394861|DEVICE|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
41160604|NCT03900884|DRUG|Palbociclib|At commencement of study: Palbociclib will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 75 and 125 mg/day depending on dose escalation results and recommendation of the safety committee.
41358354|NCT01611558|BIOLOGICAL|Ipilimumab|
41023383|NCT01898195|DRUG|Varenicline|Varenicline will be provided for three months.
41023384|NCT01898195|BEHAVIORAL|Text Message|Text messages will be developed twice daily for three months
41023385|NCT01898195|BEHAVIORAL|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
41023386|NCT04589065|DEVICE|Selective Cytopheretic Device|SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.
41023387|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
41160605|NCT03900884|DRUG|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
41160606|NCT03820570|PROCEDURE|hernia repair|inguinal hernia repair
41358355|NCT06000462|DRUG|Dapagliflozin 10mg Tab|Mentioned in detailed description.
41358356|NCT03523390|DRUG|Avelumab 3 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks (Q2W) until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
41358357|NCT03523390|DRUG|Avelumab 10 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
41023388|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
41497458|NCT05372640|PROCEDURE|Biopsy|Undergo biopsy
41497459|NCT05372640|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40838452|NCT00054028|DRUG|paclitaxel|Given IV
40838453|NCT00054028|OTHER|pharmacological study|Correlative studies
40838454|NCT00422994|DRUG|ropinirole dosing for up to 28 days|
40838455|NCT05683015|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of tildrakizumab.
40838456|NCT05683015|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
40838457|NCT00348894|DRUG|[S,S]-Reboxetine|\[S,S\]-reboxetine
40838458|NCT00348894|DRUG|Any|Any standard of care treatment for DPN
41023389|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
41023390|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
41023391|NCT00206674|DRUG|Sargramostim (Leukine)|6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
41023392|NCT00206674|DRUG|Placebo|Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
41023393|NCT02006030|DRUG|ADI-PEG 20|
41023394|NCT02006030|DRUG|Transarterial chemoembolization|
41023395|NCT05981651|OTHER|non-intervention|non-intervention
41160607|NCT01143298|DRUG|LEO 27847 oral solution|
41160608|NCT00560807|PROCEDURE|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
40838459|NCT05404581|DEVICE|neuromodulation|"During the inpatient phase of the study, insular mapping will be performed with electrical stimulation to implanted SEEG electrodes in order to optimize the region for trial stimulation.~Subjects who respond favorably to trial stimulation in the hospital, will progress to the outpatient clinical trial phase where a DBS system will be implanted. All subjects will be blindly randomized to 3 months of stimulation and 3 months of sham stimulation."
40838460|NCT06064123|DIAGNOSTIC_TEST|Cell-free DNA|Donor-derived cell-free DNA relation to recipient-derived cell-free DNA is compared to histopathological rejection grade from the same time frame.
40838461|NCT03864913|DRUG|Testosterone injection|SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
40838462|NCT03864913|BEHAVIORAL|PedsQL questionnarie|Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.
40838463|NCT03864913|OTHER|Masculinizing effects questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
41023396|NCT06528301|GENETIC|UB-VV111|UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.
41023397|NCT06528301|DRUG|rapamycin|Rapamycin is an FDA-approved drug.
41023398|NCT01566136|BEHAVIORAL|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
41023399|NCT05173519|DEVICE|Omnibond Topical Skin Adhesive|Application of Omnibond topical skin adhesive to close incision following surgery
41023400|NCT05173519|DEVICE|Dermabond Advanced Topical Skin Adhesive|Application of Dermabond topical skin adhesive to close incision following surgery
41023401|NCT00750945|OTHER|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
41023402|NCT00750945|OTHER|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
41023403|NCT00750945|OTHER|Home program|Home walking program 6 days/wk x 4 weeks
41023404|NCT03041610|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
41358358|NCT03523390|DRUG|Avelumab 20 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
40838464|NCT03864913|OTHER|Medication experience questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
40838465|NCT05514249|DRUG|CRD-TMH-001|Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.
40838466|NCT02033239|DRUG|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
40838467|NCT02033239|DRUG|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
40838468|NCT01936493|GENETIC|DNA analysis|At a future time DNA analysis will be performed
40838469|NCT01936493|OTHER|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
41023405|NCT05819086|BEHAVIORAL|Rate Emotional Response|Participants will view their assigned video package, and will be asked to rate their emotional response to the message
41358359|NCT03523390|DRUG|Avelumab 10 mg/kg QW|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg every week (QW) for the first 12 weeks followed by once every 2 weeks, started at Week 13 until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
40838470|NCT00595933|OTHER|sugar-free chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
40838471|NCT00595933|OTHER|chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
40838472|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire
40838473|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
40838474|NCT00595933|DRUG|mouth spray|Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
40838475|NCT00595933|DRUG|mouth spray|Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
41023406|NCT05819086|BEHAVIORAL|Rate Impact of Message|Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.
41023407|NCT02412267|DRUG|O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)|Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
41023408|NCT01681082|BEHAVIORAL|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
41160609|NCT01157377|DRUG|AGN-214868|AGN-214868 injected into the bladder.
41160610|NCT01157377|DRUG|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
41358360|NCT01013636|PROCEDURE|Blood sampling|"* Anaplasma diagnosis test : serology and PCR~* If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
40838476|NCT00724906|DRUG|123 I - ALTROPANE®|8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
40838477|NCT00227513|DRUG|bortezomib|Given IV
40838478|NCT00227513|DRUG|vorinostat|Given orally
40838479|NCT00086645|DRUG|citalopram hydrobromide|10mg/5ml solution
41023409|NCT00734526|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
41497460|NCT05372640|PROCEDURE|Diagnostic Imaging|Undergo imaging evaluation
41023410|NCT00734526|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
41160611|NCT03652870|DRUG|Nortriptyline|A medication used to treat conditions such as depression
41160612|NCT03652870|DRUG|Escitalopram|A medication used to treat conditions such as depression
41497461|NCT05133791|DRUG|Annexin A5|Annexin A5 coupled to IRDye800CW as a potential treatment for RVO
40838480|NCT00086645|OTHER|placebo|up to equivalent of 20 mg of active comparator daily
40838481|NCT01864161|DRUG|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
41160613|NCT03652870|DRUG|Placebo|Lactose and magnesium stearate tablet to be used as a placebo.
41497462|NCT04855149|OTHER|Patient satisfaction|Patient satisfaction evaluated with EVAN LR questionnaire
41497463|NCT00229320|BEHAVIORAL|Group therapy|
41497464|NCT00534807|DRUG|Vinflunine|
40838482|NCT01864161|DRUG|Liposomal iron|Sideral forte 30 mg/die
40838483|NCT04844086|BIOLOGICAL|RPM CD19-mbIL15-CAR-T cells|"Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
40838484|NCT01978626|BEHAVIORAL|App modules|
40838485|NCT01978626|BEHAVIORAL|Traditional CBT-I|
41497465|NCT00534807|DRUG|Rifampin|
41497466|NCT02266537|DRUG|Tamsulosin|
41497467|NCT02266537|DRUG|Alfuzosin|
41497468|NCT02266537|DRUG|Doxazosin|
41497469|NCT02266537|DRUG|Placebo|
41497470|NCT02903030|DRUG|Maltose (placebo)|Maltose with a trace amount of silicon dioxide
40838486|NCT04313491|OTHER|Yoga|Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
40838487|NCT00062608|BEHAVIORAL|Written self-disclosure|
41497471|NCT02903030|DRUG|Visbiome Extra Strength|It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
41497472|NCT06300320|DRUG|TQ05105 tablets|Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.
40838488|NCT00797680|OTHER|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
40838489|NCT00797680|OTHER|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
40838490|NCT03987906|BEHAVIORAL|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
40838491|NCT03877653|DEVICE|Wireless neuromodulation|A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.
40838492|NCT03571165|BEHAVIORAL|My Tools 4 Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
40838493|NCT04222855|DRUG|Diltiazem|Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
41497473|NCT00760851|OTHER|probiotic strain Bb-12|10\^9 CFU Bb-12 per 4 oz yogurt
41497474|NCT00760851|OTHER|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
41497475|NCT04164225|BEHAVIORAL|Qigong Exercise|"Participants with chronic low back pain will follow the free 5 elements Qigong healing class (estimate of 6 hours) at the Spring Forest Qigong center and then practice the 5 elements healing Qigong at home 3 times a week for 40 minutes with a freely available online video, for 12 weeks. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed."
41023411|NCT00734526|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
41023412|NCT04725994|DRUG|IDX-1197+XELOX|The dose levels will be escalated following a 3+3 dose escalation scheme.
41023413|NCT04725994|DRUG|IDX-1197+Irinotecan|The dose levels will be escalated following a 3+3 dose escalation scheme.
41023414|NCT02121145|BIOLOGICAL|Vivotif|3 oral doses
41023415|NCT02121145|BIOLOGICAL|Typherix|one intramuscular dose
40838494|NCT03332160|DEVICE|Flexitouch head and neck lymphedema treatment system|Pneumatic compression device cleared for use by medical professionals and patients who are under medical supervision, for the treatment of many conditions such as: lymphedema; primary lymphedema; post mastectomy edema; edema following trauma and sports injuries; post immobilization edema; venous insufficiency; reducing wound healing time; treatment and assistance in healing stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers. The Flexitouch system and garments for head and neck are intended for use by medical professionals and patients who are under medical supervision for the treatment of head and neck lymphedema.
40838495|NCT03332160|OTHER|Standard home lymphedema care|May include daily self manual lymphatic drainage, exercise, skin care, compression garments (as appropriate).
40838496|NCT03976999|OTHER|Biological collection|"* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~* Tissue samples (tumor tissue and healthy tissue) collected during the surgery"
41023416|NCT06572813|DRUG|Bortezomib Injection|Bortezomib Injection, a kind of chemotherapy drug
41497476|NCT04164225|BEHAVIORAL|P.Volve Exercises|P.Volve exercise focuses on low impact core strengthening, core stabilization, and stretching. The program is similar in delivery as Qigong (i.e., online videos). An introductory class (estimate of 2.5h) will be given by the P.Volve team, the principal investigator, and a physical therapist who has experience with P.Volve exercises. Participants will access online videos for individual home practice in 40min/session, 3x/week for 12 weeks. Participants will receive a P.ball for some exercises, while other exercises are done with no equipment. Tailored videos will be available for those with cLBP. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed.
41497477|NCT00397059|DRUG|Escitalopram|
41023417|NCT06572813|DRUG|Sintilimab|PD-1 antibody
40838497|NCT04856254|PROCEDURE|Trial of labor after cesarean section|The pregnant females with history of previous cesarean section will be classified according to clinical and ultrasound score as patient suitable to undergo trial of labor after CS \[TOLAC\]or not suitable for \[TOLAC\] so undergo from the beginning to elective repeated cesarean section.
40838498|NCT01777945|DRUG|capecitabine|Participants received capecitabine according to individualized physician-prescribed regimen.
40838499|NCT01777945|DRUG|docetaxel|Participants received docetaxel according to individualized physician-prescribed regimens.
41023418|NCT06572813|DRUG|mFOLFIRINOX|Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium
41160614|NCT04697641|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg twice a day for two weeks
41160615|NCT04697641|DRUG|Amoxicillin 1000 MG|Amoxicillin 1000mg twice a day for two weeks
41358361|NCT01432756|BEHAVIORAL|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
41358362|NCT01694667|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).
41358363|NCT01694667|OTHER|Placebo|Placebo packets will have same orange-flavored pudding as active Omega-3 fatty acids comparator with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
41358364|NCT04974853|COMBINATION_PRODUCT|Cardio-complement|Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
41358365|NCT03909724|DRUG|Sunitinib Malate|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
41358366|NCT03909724|DRUG|TAS 102|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
41358367|NCT04337879|DRUG|AL2846|AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
41358368|NCT04337879|DRUG|Calcium folate|Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
41358369|NCT04337879|DRUG|5-FU|5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
41358370|NCT04337879|DRUG|Oxaliplatin|Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.
41358371|NCT04337879|DRUG|Irinotecan|Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.
41497478|NCT02450955|OTHER|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading, five minutes prone and five minutes supine with a focus on cervical and suboccipital muscles in order to induce a global relaxation of the cervical and suboccipital region. Resting position. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
40838500|NCT05583149|DRUG|ACALABRUTINIB|Oral, twice daily, timing and dosage per protocol
40838501|NCT05583149|DRUG|LISOCABTAGENE MARALEUCEL|via IV timings and dosage per protocol
40838502|NCT05583149|DRUG|Lymphodepleting chemotherapy|lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.
40838503|NCT06216249|PROCEDURE|Computed Tomography|Undergo PSMA PET/CT, SPECT/CT, PET/CT and CT
40838504|NCT06216249|OTHER|Gallium Ga 68 Gozetotide|Given IV
40838505|NCT06216249|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
40838506|NCT06216249|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40838507|NCT06216249|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT
41358372|NCT03958149|DEVICE|spinal collar|cervical collar to immobilise the cervical spine
41497479|NCT02450955|OTHER|Occiput-Atlas-Axis Technique|This technique was applied as described previously and is used with the aim of restoring joint mobility between the occiput, atlas and axis. It is a structural technique applied bilaterally, performed on a vertical axis passing through the dens process of the axis without extension or flexion and very little side-bending. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
40838508|NCT06216249|OTHER|Questionnaire Administration|Ancillary studies
40838509|NCT06216249|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
40838510|NCT03354390|BIOLOGICAL|cell infusion|This is a single-arm, phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A\*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.
40838511|NCT04664582|PROCEDURE|Sentinel Lymph Node Biopsy|see intervention group description
41358373|NCT02067104|DRUG|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
41358374|NCT02067104|DRUG|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
41358375|NCT01741285|DRUG|Beclomethasone (QVAR)|Small particle treatment
41358376|NCT01741285|DRUG|Beclomethasone (Clenil)|Course particle beclomethasone
41358377|NCT01741285|DRUG|Fluticasone|Course particle treatment
40838512|NCT02599623|PROCEDURE|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
40838513|NCT02599623|PROCEDURE|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
40838514|NCT02886559|DRUG|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
41023419|NCT05289102|OTHER|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks and one later at 7 weeks postpartum.
41358378|NCT02804581|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
41358379|NCT00331058|PROCEDURE|Bronchoscopsy|Healthy and Asthmatic Volunteers
41358380|NCT00331058|PROCEDURE|Prednisolone|Asthmatic Volunteers
41497480|NCT02932306|DRUG|IDP-121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
41497481|NCT02932306|DRUG|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
40838515|NCT04294446|DEVICE|Biodesign Hernia Graft|The Biodesign Hernia Graft is comprised of 8 layers of decellularized porcine small intestinal submucosa (SIS) that has been pressed-lyophilized (i.e., freeze-dried under vacuum pressure) to laminate the component sheets (i.e., layers) together. In addition, it is perforated and sewn with 4-0 Trisorb suture (polyglycolic acid (PGA); Samyang Corporation, Seoul, South Korea). The suture is distributed in a diamond pattern across the graft and along the periphery and is intended to mitigate delamination of the layers upon rehydration and/or manipulation during implantation. Being a completely biologic device, the Biodesign Hernia Graft is considered MR safe.
40838516|NCT00559130|DEVICE|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
40838517|NCT05184933|OTHER|At-home Polysomnography|Participants will complete one night of unattended polysomnography in their home environment (SOMNOtouch RESP, SOMNOmedics America Inc., FL, USA).
41023420|NCT05289102|OTHER|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
41023421|NCT00143858|DEVICE|Pulse Volume Measurement|patients will wear a newly designed calf monitor that will be hooked up to a computer that will monitor leg peripheral pulse volumes which will then be correlated to pressures obtained with Swan Ganz monitoring. The calf monitor is gut two bands with sensors that are wrapped around the ankle and below the knww
41497482|NCT03897803|DIAGNOSTIC_TEST|strain elastography|strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.
41358381|NCT00650715|DEVICE|Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
41358382|NCT00650715|DEVICE|Placebo Whole-body vibration exercise|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
41497483|NCT01037296|PROCEDURE|catheter ablation|ablation procedure performed with Hansen robotic navigation system
41497484|NCT01037296|PROCEDURE|catheter ablation|Ablation will be performed as normal treatment
41023422|NCT01175655|OTHER|MSC|mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
41358383|NCT03061617|OTHER|VCV mode|set fixed 6ml/kg tide volume
41358384|NCT03061617|OTHER|PCV mode|adjust pressure to achieve tide volume of 6ml/kg
41358385|NCT00087594|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
41358386|NCT00087594|DRUG|ribavirin|1000/1200mg (\< or \>= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
41358387|NCT00124384|BEHAVIORAL|CBT-I|
41358388|NCT00124384|DRUG|modafinil|
41358389|NCT02769689|DRUG|Methylprednisolone|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
41497485|NCT00933348|DRUG|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
40838518|NCT05184933|OTHER|Circadian Protocol|Participants will spend 4 days/3 nights in the laboratory to uncover circadian rhythms. After 2 nights for acclimatization and baseline measurements, participants will stay awake for 28 hours in dim light, constant temperature, and semi-recumbent posture. Participants will be provided with standardized snacks regularly. Polysomnography, core body temperature, sleep, finger oximetry, electrocardiogram (ECG), and beat-to-beat BP will (except microneurography) be measured throughout. Blood will be drawn every 2-4h to analyze catecholamines, renin activity, and aldosterone. All other measurements, including BP, heart rate (HR), and flow-mediated dilation will be performed regularly. Salivary samples will be collected every 2hrs (when awake) to analyze melatonin levels. A recovery sleep period will be provided and baseline testing procedures will be performed. Investigators may acquire direct recordings of sympathetic activity using microneurography.
40838519|NCT05184933|OTHER|Rested Wakefulness Trial|Participants will start wearing an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm. Participants will receive a standardized snack, and dinner \~4 hours before the start of the trial. Participants will be instrumented for microneurography. Participants will be awake in bed in dim light (\<8 lux). An investigator will constantly be present in the control room to monitor and ensure constant supine posture and wakefulness. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Flow-mediated dilation will be conducted before bed and after bed. The two trials will be conducted \~one month apart to accommodate the menstrual cycle phase in pre-menopausal females.
40838520|NCT05184933|OTHER|Overnight Sleep Trial|Participants will wear an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm, and then participants will receive a standardized snack, and dinner 4 hours before the start of the trial. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Participants will be instrumented for microneurography. Participants will begin an 8-hour sleep opportunity (\<0.1 lux) at their chosen sleep time. At the end of the sleep episode, participants will be gently awoken in a standardized fashion by use of a mild auditory stimulus. Flow-mediated dilation will be conducted before bed and after sleep. The two trials will be conducted one month apart to accommodate the menstrual cycle.
40838521|NCT05184933|BEHAVIORAL|Regularized Sleep Schedule|All participants will be asked to maintain a self-selected bedtime (sleep duration not controlled) for two weeks as an intervention after the completion of the constant routine and both the resting wakefulness and overnight sleep trials. During this time, participants will be asked to call a time-stamped voicemail box upon waking and going to bed, as well as complete a daily sleep diary and wear an Actigraph device on their wrist. Ambulatory blood pressure will be measured at home before and at the end of the two-week intervention.
40838522|NCT05052593|OTHER|compressive myofascial release|Patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. With pressure directed from distal to proximal.
40838523|NCT05052593|OTHER|conventional treatment group|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
40838524|NCT02718014|OTHER|scaling and root planing (srp)|
40838525|NCT01086852|BIOLOGICAL|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
41023423|NCT00780572|BEHAVIORAL|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
41358390|NCT02769689|DRUG|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
41358391|NCT02769689|DRUG|natalizumab (NTZ)|Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
41358392|NCT02769689|DRUG|fingolimob (FTY)|Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
41358393|NCT00547729|DEVICE|HeartPOD™ System|HeartPOD™ device with DynamicRx® automatically measures left heart pressures throughout the day.
41358394|NCT05455723|PROCEDURE|Tracheal Intubation|Inflation-Deflation Technique Versus Magill Forceps Technique for Nasal Intubation by Video-assisted Laryngoscope
41358395|NCT05399823|OTHER|Exercise|Strecthing exercises will given for 15-20 minutes everyday for four weeks
41358396|NCT04265027|DRUG|50 mg BIA 9 1067|Hard Capsule; Oral
41358397|NCT04265027|DRUG|25 mg BIA9 1067|Hard Capsule; Oral
41358398|NCT04265027|DRUG|50 mg Ongentys|Hard Capsule; Oral
41358399|NCT04265027|DRUG|25 mg Ongentys|Hard Capsule; Oral
41358400|NCT04176016|DRUG|OTSA101-DTPA-111In|single IV injection, 185MBq/body
41358401|NCT04176016|DRUG|OTSA101-DTPA-90Y|IV injection (max. 3 injections per patient), 1110MBq/body
41358402|NCT04927585|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid
41497486|NCT00933348|DRUG|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
41497487|NCT04858256|DRUG|Pacritinib|Pacritinib will be dosed at 200mg twice daily.
41497488|NCT04426812|OTHER|No intervention; just data collection|No intervention; just data collection
41497489|NCT02820649|OTHER|Sleep deprivation|40 hours of continuous wakefullness
41497490|NCT03558386|BEHAVIORAL|ePRO survey|An electronic patient reported outcomes survey will be completed by the patient.
41497491|NCT00128271|DRUG|Bavituximab|
41497492|NCT01882972|BEHAVIORAL|Exercise|
41358403|NCT04927585|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid
41497493|NCT01882972|BEHAVIORAL|Meditation|
41497494|NCT05947110|OTHER|Plyometric-based hydro-kinesio therapy|The plyometric-based hydro-kinesio therapy was conducted for 45 minutes, twice weekly, for 8 successive weeks. The training was geared toward the lower body and was conducted under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
41497495|NCT05947110|OTHER|Standard exercise therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for 8 successive weeks.
41497496|NCT03004287|DRUG|Carfilzomib|Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
41497497|NCT03004287|DRUG|Thalidomide|Given by mouth at bedtime: days 1-4 of Induction
41497498|NCT03004287|DRUG|Dexamethasone|Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
41497499|NCT03004287|DRUG|Daratumumab|Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
40838526|NCT00881504|DRUG|"Bevacizumab in combination with modified FOLFOX6."|Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay \> 4 weeks
40838527|NCT05848765|DRUG|Epcoritamab|Bispecific antibody
40838528|NCT05848765|DRUG|Lenalidomide|Immunomodulatory agent
41497500|NCT03004287|DRUG|Cisplatin|Given by vein: days 1-4 (continuous infusion) of Induction
41497501|NCT03004287|DRUG|Adriamycin|Given by vein: days 1-4 (continuous infusion) of Induction
41497502|NCT03004287|DRUG|Cyclophosphamide|Given by vein: days 1-4 (continuous infusion) of Induction
41497503|NCT03004287|DRUG|Etoposide|Given by vein: days 1-4 (continuous infusion) of Induction
41497504|NCT03004287|DRUG|Melphalan|Given by vein: days -4 - -1 of Transplant(s)
41497505|NCT03004287|PROCEDURE|ASCT|day 0 of Transplant(s)
41497506|NCT03004287|DRUG|Lenalidomide|Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
41497507|NCT03004287|DRUG|Bortezomib|Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
40838529|NCT05848765|DRUG|Rituximab|Monoclonal antibody
40838530|NCT05848765|DRUG|Obinutuzumab|Monoclonal antibody
40838531|NCT05848765|DRUG|Bendamustine|Alkylating agent (chemotherapy drug)
40838532|NCT05848765|DRUG|Vincristine|Antineoplastic, Vinca Alkaloid
40838533|NCT05848765|DRUG|Doxorubicin|Anthracycline
40838534|NCT05848765|DRUG|Cyclophosphamide|Alkylating agent (chemotherapy drug)
40838535|NCT05848765|DRUG|Prednisone|Corticosteroid
40838536|NCT05848765|DRUG|Investigation agent 2|The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
41160616|NCT04697641|DRUG|Pantoprazole 40mg|Pantoprazole 40 mg or equivalent for eight weeks
41358404|NCT04927585|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
41358405|NCT04927585|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
41358406|NCT00266604|DRUG|Topiramate|
41358407|NCT01475227|DRUG|1 Solvazinc tablet, day 2 to day 15|Zinc sulphate 125mg, day 2 to day 15
41358408|NCT01475227|DRUG|1 Solvazinc tablet, day 15 to day 28|Zinc sulphate 125mg, day 15 to day 28
41358409|NCT04385667|DEVICE|levonorgestrel intrauterine system (LNG-IUD)|progestin delivery for regression of atypical endometrial hyperplasia
41497508|NCT04383223|BEHAVIORAL|iTransition|Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.
41497509|NCT06202378|DRUG|3 ampoules of SHPL-49 Injection|3 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
40838537|NCT05848765|DRUG|Investigation agent 3|The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
41023424|NCT03937375|BEHAVIORAL|High PEEP|Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia
41497510|NCT06202378|DRUG|6 ampoules of SHPL-49 Injection|6 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
41497511|NCT06202378|DRUG|0.9% Sodium Chloride Injection|100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
41497512|NCT05478512|DRUG|VenObi+Ven or VenObi+VenZan|"Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~* if uMRD = Venetoclax 400 mg/d orally until cycle 13.~* if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~* if uMRD = stop treatment~* if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression"
41497513|NCT01243775|DRUG|Belotaxel|60 mg/m2 3 weekly (day 1)
40838538|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of beef|Beef patty will replace one of the participants protein servings each day for 30 days. Each serving is 114 grams of 90% lean ground sirloin given to participants as an uncooked frozen patty.
41497514|NCT01243775|DRUG|Belloxa|70 mg/m2 3 weekly (day 2)
41023425|NCT03937375|BEHAVIORAL|Low PEEP|Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
41358410|NCT04385667|DRUG|Oral Megesterol 160 mg daily|progestin delivery for regression of atypical endometrial hyperplasia
41497515|NCT02512653|BIOLOGICAL|Cupressus arizonica|Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
40838539|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of the vegatable protein source|Veggie patty will replace one of the participants protein servings each day for 30 days. No beef will be consumed during this period. The veggie patty is commercially available Morningstar veggie burger and is given to participants in commercial packaging as a frozen precooked patty.
40838540|NCT01009086|DRUG|Placebo|SC injections
40838541|NCT01009086|DRUG|Ustekinumab 45 mg|SC injections
40838542|NCT01009086|DRUG|Ustekinumab 90 mg|SC injections
40838543|NCT05037513|BEHAVIORAL|SBCM-PrEP|Multi-session SBCM intervention adapted for PrEP initiation focus
40838544|NCT05037513|BEHAVIORAL|CDC-PrEP|1 session PrEP education following CDC guidelines
40838545|NCT06081192|PROCEDURE|Implant placement surgery|Placement of six mini implants in the edentulous maxilla using a partially-guided protocol
40838546|NCT01188057|DRUG|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions
40838547|NCT01188057|DRUG|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
40838548|NCT04215432|DEVICE|Gel containing propolis extract, nanovitamin C and nanovitamin E|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.
40838549|NCT04215432|DEVICE|Placebo|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.
41023426|NCT03594994|BEHAVIORAL|Sleep extension|Extend time-in-bed by one hour
41160617|NCT04697641|DRUG|Levosulpiride|Levosulpiride 25 mg as and when required before meals
41160618|NCT04697641|DRUG|Acotiamide|Acotiamide 100mg as when required before meals
41160619|NCT04697641|DRUG|Itopride|Itopride 50mg as when required before meals
41358411|NCT02694562|DEVICE|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
41358412|NCT02260609|OTHER|Grafix®|"The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.~Patients will be treated for up to 16 weeks.~Patients will be evaluated at screening and then weekly throughout the study or until wound closure."
41358413|NCT04325490|DRUG|Liquid powder|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
41358414|NCT04325490|DRUG|Hydrocortisone cream 1%|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
41358415|NCT02033824|OTHER|dHACM|A piece of dHACM placed over any dural defect or dural closure during craniectomy.
41358416|NCT02033824|PROCEDURE|Craniectomy|Removal of the skull flap followed by closure techniques per current SOC.
41358417|NCT04038437|DRUG|CPX-351|CPX-351 will be administered on Days 1 and 3 of each cycle
41358418|NCT04038437|DRUG|Venetoclax|Venetoclax will be adminstered on Days 2 to 21 of each cycle
41497516|NCT01796912|OTHER|Lipoprotein Apheresis|Weekly lipoprotein apheresis for 3 months
40838550|NCT05332093|DIAGNOSTIC_TEST|skin biopsy|4mm skin biopsy
41497517|NCT01796912|OTHER|Sham Apheresis|Weekly sham (placebo) apheresis for 3 months
41497518|NCT06060379|OTHER|GiochiAMO a 626|The subjects of the intervention group will play three different games: a role-playing game, a card game and a board game.
41497519|NCT01181362|PROCEDURE|Endoscopy|All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
41497520|NCT01831453|DRUG|omega-3|polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
41497521|NCT01831453|DRUG|placebo|soft gelatinous capsules filled with isopropylmyristate oil
41497522|NCT04047186|DRUG|Nivolumab Injection|Nivolumab 3mg/kg on day-28 and day-14 prior to planned surgical resection
40838551|NCT05332093|DIAGNOSTIC_TEST|venous blood sample (plasma, PBMC, WB)|venous blood sample to acquire plasma, PBMCs and whole blood
40838552|NCT05332093|GENETIC|venous blood sample (HLA)|venous blood sample used for HLA typing
40838553|NCT05332093|GENETIC|skin slit|genome sequencing of parasite DNA that is extracted from the skin slit
40838554|NCT01640665|DRUG|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
41358419|NCT00751335|DEVICE|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
40838555|NCT01640665|DRUG|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
40838556|NCT03700814|DRUG|Co-amoxiclav|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
40838557|NCT04433013|DRUG|Lianhua Qingwen|The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
40838558|NCT04433013|DRUG|Placebo|The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
40838559|NCT02963701|DRUG|Ibuprofen|Fixed dose combination
40838560|NCT02963701|DRUG|Pseudoephedrine-HCl|Fixed dose combination
40838561|NCT04566146|OTHER|scapular muscle training, serratus anterior strength, scapular stabilization exercises|patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
40838562|NCT00771615|BIOLOGICAL|GSK A/turkey H5N1 Influenza vaccine|One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
40838563|NCT04764110|DIETARY_SUPPLEMENT|Cyplexinol|partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)
40838564|NCT04764110|OTHER|Placebo|Maltodextrin
40838565|NCT04316000|OTHER|Initial Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.
40838566|NCT04316000|PROCEDURE|Endoscopic band ligation without resection of the subpetihelial tumour.|Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.
40838567|NCT04316000|OTHER|1-2 Months Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.
40838568|NCT04316000|OTHER|1 Year Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.
40838569|NCT05622214|DIETARY_SUPPLEMENT|Else nutrition formula|Plant based nutrition from almond and buckwheat
40838570|NCT05607706|BEHAVIORAL|Exposure to maternal odor|Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
41497523|NCT00548470|DRUG|Varenicline|Varenicline 1-2 mg/day
41497524|NCT04360096|DRUG|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
41497525|NCT04360096|DRUG|Placebo|Normal Saline Inhalation
41497526|NCT04360096|DEVICE|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
41497527|NCT00435812|BIOLOGICAL|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24
40838571|NCT02434965|DRUG|HPDSC|Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
40838572|NCT02434965|DRUG|Cord blood|Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
40838573|NCT02198690|OTHER|Mammography decision aid|
40838574|NCT02198690|OTHER|Home safety pamphlet|
40838575|NCT05277038|DRUG|Clonidine 0.1mg pill|Routine prescription for insomnia
40838576|NCT05277038|DRUG|Clonidine 0.2mg pill|Routine prescription for insomnia
40838577|NCT05277038|DRUG|Zopiclone 3.75mg pill|Routine prescription for insomnia
40838578|NCT05277038|DRUG|Zopiclone 7.5mg pill|Routine prescription for insomnia
40838579|NCT04246814|DEVICE|LG1|Application of LASER AsGa 904nm 10 J/cm².
40838580|NCT04246814|DEVICE|LG2|Application of LASER AsGa 904nm 8 J/cm².
40838581|NCT04246814|DEVICE|LG3|Application of LASER AsGa 904nm 4 J/cm².
40838582|NCT04246814|DEVICE|CC|Application of placebo LASER.
41358420|NCT00751335|DEVICE|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
41358421|NCT06317298|DRUG|Fruquintinib and Everolimus|Fruquintinib and Everolimus
41358422|NCT03563807|OTHER|Golf Instruction|Subjects will participate in two weekly hour-long golf classes. Classes will be led by professional golf instructors that will work with individuals to teach participants how to play golf. This will include stretching, individual coaching, and working with participants to maximize their golf swing.
41358423|NCT03563807|OTHER|Tai Chi Class|Tai Chi is an ancient martial art that uses meditative movement to improve strength, flexibility, and balance. Subjects will participate in two weekly hour-long Tai Chi classes.The class will be led by a certified Tai Chi instructor and consist of approximately 12 people.
41358424|NCT01842334|BEHAVIORAL|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
41358425|NCT01842334|DRUG|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
40838583|NCT04246814|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
40838584|NCT05414955|DEVICE|Neuromodulation|Neuromodulation
40838585|NCT05747417|OTHER|prismatic glasses|prism glasses ranging from 4-10 prism diopters
41358426|NCT06042179|BEHAVIORAL|Frequent PT|Physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
40838586|NCT03437707|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
40838587|NCT03437707|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
41358427|NCT06042179|BEHAVIORAL|Intense PT|Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
41497528|NCT00435812|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4, and Week 24
40838588|NCT03437707|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
40838589|NCT00327990|DRUG|Ibandronate|
40838590|NCT00327990|DRUG|Alendronate|
40838591|NCT03519061|DRUG|Budesonide|Nasal saline irrigations with budesonide
40838592|NCT06026501|DRUG|PE0116,PE0105|"1. PE0116: 4-1BB Agonist Antibody Drug~2. PE0105: PD-1 Monoclonal Antibody Drug"
40838593|NCT00607399|DRUG|SGX523 Capsules|This is a dose escalation study
40838594|NCT02498990|BEHAVIORAL|Low calorie diet followed by life style intervention|"1. Low calorie diet of 800 kcal/day for 7 weeks.~2. Life style intervention for the remaining study period"
40838595|NCT00773890|DRUG|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
40838596|NCT00773890|DRUG|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
40838597|NCT01389999|OTHER|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
40838598|NCT03596450|DRUG|Semaglutide|Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
40838599|NCT03596450|DRUG|Standard of care|Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
40838600|NCT03468582|COMBINATION_PRODUCT|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
40838601|NCT04539860|DEVICE|Transdermal Optical Imaging|Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
40838602|NCT05546073|OTHER|Advanced point-of-care technology|"The intervention consists of:~* focused lung ultrasound scan(FLUS)~* venous blood samples for leucocytes with 5-part differential count, creatinin, sodium, potassium, urea"
40838603|NCT05701046|PROCEDURE|Interbody fusion surgery|Interbody fusion surgery
40838604|NCT06506799|OTHER|Training Given to Intensive Care Nurses on the Use of Physical Fixation|"Data will be collected with the 'Participant Information Form' and the 'Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale', prepared by the researcher in line with the literature and containing the demographic characteristics of the participants.~Intensive care nurses who will participate in the research will be asked to fill out the survey forms with individual consent.~Participant Information Form and Nurses' Knowledge, Attitude and Practice Levels Regarding Physical Restraint Scale will be used as pre-tests. After the pre-test, nurses will be given physical restraint training. The training content was created using the ADDIE model as reference. After the training, the Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale will be used as the final test."
40838605|NCT00316420|DRUG|Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
40838606|NCT00316420|DRUG|Gemcitabine|750 mg/m2 IV Days 1 \& 8 q 21 days
40838607|NCT06515314|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|"AFP Specific T Cell Receptor T Cells On day 1, the TCR-T cells will be administered intravenously.~Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days"
40838608|NCT06242223|OTHER|Multimodal HIIT|multimodal HIIT protocol followed by sprinting followed by 2 minutes of rest, burpees with 3 minutes rest between sets and push ups 4-5 rep at 80-100% of HR max with a total of 20 minutes exercise per session a day 3 times a week followed by 6 weeks.
40838609|NCT06242223|OTHER|conventional HIIT|conve protocol with 4-5 repetitions of 40 seconds maximum running at 80-100% HR max followed by 20 seconds of walking for 20 minutes exercise per session 3 times a week followed by 6 weeks.
40838610|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Premeal Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for daily water intake timing and volume.
40838611|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Total Daily Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for total daily water intake.
40838612|NCT05843318|BEHAVIORAL|Water Intake and weight control in older adults - hypocaloric diet alone|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive instructions in the hypocaloric diet, without specific fluid intake recommendations.
40838613|NCT03858504|OTHER|Exercise|The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.
41023427|NCT05058911|BEHAVIORAL|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
41023428|NCT05058911|BEHAVIORAL|Internet-delivered traditional cognitive behavior therapy|This treatment is based on components typical of T-CBT for FM, such as relaxation, activity planning or pacing, cognitive restructuring techniques and stress management strategies.
41023429|NCT06326372|PROCEDURE|control|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation
41023430|NCT06326372|PROCEDURE|ORi+SpO2|"Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
41023431|NCT00217906|BEHAVIORAL|A+ Asthma early intervention program|
41023432|NCT02533843|PROCEDURE|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
41358428|NCT05853289|OTHER|Maternal Opioid use Disorder Management and Care Resources (MOM CARE) in Custody|MOM CARE is a web-based implementation resource designed for jail staff to help the staff provide evidence-based, trauma-informed and patient-centered care and support to pregnant people with opioid use disorder in and leaving custody. MOM CARE's content will include medical guidance and best-practices from intake to discharge, reentry steps and recommendations, and implementation 'how to' content. There will be specific content for jail administrators, medical and custody staff. Content will be curated from existing resources regarding this topic with new original tools specific to pregnant people with OUD in jail.
40838614|NCT03217799|DEVICE|Measurement of coagulability of blood|A small pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
41023433|NCT05029648|OTHER|Cohort|Cohort
41023434|NCT00023452|DRUG|RPT + INH once weekly for 3 months given by DOT|"Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons \> 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if \> 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT)."
41023435|NCT00023452|DRUG|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
41023436|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules (CALM)|CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.
41023437|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules--Relaxation (CALM-R)|CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
41023438|NCT01079221|BEHAVIORAL|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at \< 90 % of peak power, 3 days/week for 6 weeks
41023439|NCT04278326|PROCEDURE|Vaginal Biopsy|"1. Vaginal biopsies~2. Additional cervical and vaginal biopsies~3. Non invasive cervico-vaginal swab like a smear"
41023440|NCT05868798|DRUG|Ammonia Inhalant|For all AI trials, a capsule containing 0.3 mL of AI (composed of 15% of ammonia and 35% of alcohol) was used according to the manufacturer's instructions (Dynarex Corporation, Orangeburg, NY). When the ammonia fumes were released, researcher immediately held the capsule under the participant's nose to inhale until a voluntary withdrawal reflex was observed.
41023441|NCT00883571|PROCEDURE|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
41023442|NCT00883571|PROCEDURE|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
41358429|NCT00417248|DRUG|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
41358430|NCT00417248|DRUG|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
41358431|NCT00417248|PROCEDURE|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
41023443|NCT00883571|PROCEDURE|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
41023444|NCT06544408|DEVICE|Cool B70 AP Coil - Active (dl-PFC)|One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
41023445|NCT06544408|DEVICE|Cool B70 AP Coil- Sham (dl-PFC)|One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
41023446|NCT06544408|DEVICE|Cool D-B80 AP Coil - Active (dm-PFC)|One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
41358432|NCT00417248|DRUG|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
41358433|NCT03763942|BEHAVIORAL|HealthMindr App|Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.
41358434|NCT03763942|BEHAVIORAL|Control App|Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
40838615|NCT05530889|DEVICE|TEST Lens|ACUVUE® Theravision® with Ketotifen
41023447|NCT06544408|DEVICE|Cool D-B80 AP Coil - Sham (dm-PFC)|One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
41023448|NCT06544408|DEVICE|Cool B70 Treatment Coil - Active Only|The treatment will be the same as the left dl-PFC accel-TMS dl-PFC except that the Cool B70 Treatment coil only has an active treatment coil.
41358435|NCT04279509|PROCEDURE|Tumor Core Biopsy|"Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses."
41358436|NCT04279509|PROCEDURE|Blood sampling|Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
41358437|NCT05743439|BEHAVIORAL|Early Augmentative and Alternative Communication (AAC) Intervention|Caregivers will receive 24, 50 min intervention sessions twice a week for three months. During each intervention session, the therapist provides instruction and coaching on using AAC and a set of evidence-based language support strategies. Strategies are taught sequentially in three phases: (1) Responding to all Communication, (2) Teaching Words, and (3) Creating Communication Opportunities. Caregivers practice using the AAC intervention strategies during three, five-minute routines with their children. Therapists coach the caregiver on using the targeted strategies during these routines, encouraging caregivers to reflect on their implementation, and developing a plan to use the AAC strategies during activities not practiced during the intervention session. The AAC intervention is provided to families using an evidence-based service delivery model, Family Guided Routines Based Intervention.
41358438|NCT04126187|DEVICE|Panoptix|Panoptix trifocal intraocular lens (IOL)
41358439|NCT03908723|OTHER|Panretinal photocoagulation|Intravitreal Aflibercept with PRP to the peripheral vascular lesions
41358440|NCT05116904|OTHER|Assessment|Pupil reflex and melatonin profile, circadian profile assessment
41358441|NCT03647059|DIAGNOSTIC_TEST|LSCM examination|Cut a piece of donor liver and conduct the LSCM examination after staining fluorescein
41358442|NCT03187951|BEHAVIORAL|Questionnaires|Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.
40838616|NCT05530889|DEVICE|CONTROL Lens|1-DAY ACUVUE® MOIST.
41023449|NCT00642304|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
41023450|NCT04408963|BIOLOGICAL|VRC-HIVMAB0102-00-AB|The VRC-HIVMAB0102-00-AB (CAP256V2LS) broadly neutralizing monoclonal antibody (bNAb) targets the V1V2 region of the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
41023451|NCT03649126|BEHAVIORAL|Implementation tools|Implementation tools developed by experts in order to increase the use of SSR in pathology
41023452|NCT02061631|DRUG|Cisplatin|Pharmaceutical form:solution Route of administration: intravenous
41023453|NCT02061631|DRUG|DOCETAXEL XRP6976|Pharmaceutical form:solution Route of administration: intravenous
41023454|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:tablet Route of administration: oral
41023455|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
41023456|NCT02120924|DRUG|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
41023457|NCT02120924|DRUG|Vehicle|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
41023458|NCT02120924|DRUG|Finacea|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
41023459|NCT00634647|DRUG|Satraplatin|80 mg/m\^2 days 1-5 of every 35 day cycle
41023460|NCT00634647|DRUG|prednisone|5 mg twice daily every 35 days
41023461|NCT05456295|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.
41023462|NCT03808285|OTHER|mandibular osteomylitis|
41023463|NCT00591812|DEVICE|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
41023464|NCT02341248|OTHER|Exclusive Enteral Nutrition (EEN)|8 week standard course of treatment with EEN
41358443|NCT03187951|BEHAVIORAL|Nutritional Questionnaire and Nutritional Counseling|Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.
41023465|NCT02406144|DRUG|MLN9708|
41023466|NCT02406144|DRUG|Lenalidomide|
41023467|NCT02406144|DRUG|Dexamethasone|
41023468|NCT04293159|DIETARY_SUPPLEMENT|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
41023469|NCT03386617|DRUG|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
41023470|NCT02612012|RADIATION|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
41023471|NCT02908438|DRUG|Gonadotrophin releasing hormone agonist(GnRHa)|GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
41023472|NCT01274637|DRUG|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
41023473|NCT00217698|DRUG|cisplatin|
41023474|NCT00217698|DRUG|gefitinib|
41023475|NCT00217698|DRUG|gemcitabine hydrochloride|
41023476|NCT03609801|BEHAVIORAL|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
41358444|NCT03187951|OTHER|Booklet|Participants receive a booklet that contains a stretching guide with full-body stretches and safety.
41358445|NCT03187951|BEHAVIORAL|Aerobic Exercise and Strength Training Exercises|Participants complete up to 30 minutes of moderate-intensity aerobic exercise (such as brisk walking, stationary cycling, and/or elliptical or stair stepping machines) for at least 5 days each week. Participants complete strength training exercises at least 2 times per week.
41023477|NCT03609801|BEHAVIORAL|The Duluth Model|The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
41023478|NCT01734746|PROCEDURE|Tracerinjection|The intervention concerns the tracerinjection for detection of the sentinel node.
41023479|NCT02670590|BEHAVIORAL|diet|diet
41023480|NCT04779645|DRUG|REMD-477|12-Week, once weekly subcutaneous injection with 70mg REMD-477
41358446|NCT03187951|BEHAVIORAL|Phone Calls|Participants contacted by phone by member of study staff one (1) time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing. These calls should last about 15 minutes.
41023481|NCT04779645|DRUG|Placebo|12-Week, once weekly subcutaneous injection with placebo
41023482|NCT02377986|BEHAVIORAL|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
41358447|NCT03187951|BEHAVIORAL|Physical Assessments|After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participant's hand grip strength measured using a hand-held machine. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes.
41358448|NCT00188162|DEVICE|CT|
41358449|NCT06323629|BEHAVIORAL|Adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. It adapts the complexity of the treatment tasks.
41358450|NCT06323629|BEHAVIORAL|Non-adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. However, it does not adapt the complexity of the treatment tasks.
40838617|NCT03144869|BEHAVIORAL|physical activity monitor and feedback|Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
40838618|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
41358451|NCT03673631|DEVICE|NIV|NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)
41497529|NCT04040608|OTHER|Influence of screen sizes on responses to visual analog scales of stress|"An open questionnaire will be created by the Clinical Research Direction. The questionnaire will be opened by the examinator who will fulfill the anonymized identification of participants and the type of screens. In a dedicated room at the LaPSCo, the participants will answer the same VAS on four different sizes/types of screens (24-inch screen, laptop, tablet, smartphone) and on paper. Saliva will be collected after answering questionnaires. Heart rate variability and skin conductance will be measured with the use of a wrist watch during 15 minutes, from the entrance in the room to the completion of questionnaires.~The participant will undergo the same examination within a week (15 minutes)."
41497530|NCT04641585|DIAGNOSTIC_TEST|Patients affected by Brugada Syndrome 1|ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
41358452|NCT03673631|DEVICE|NFHC-O2|NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
41358453|NCT01371721|DRUG|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
41358454|NCT06150352|DEVICE|Continuous Positive Airway Pressure or other management for OSA per clinical indications.|PAP therapy or other management will be advised for subjects with OSA per usual clinical criteria
40838619|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with posterior wall box isolation.
40838620|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
41358455|NCT03822689|DEVICE|Ventilator breathing tube F2220|M: Folding D: 22mm; L: 2.0M
41358456|NCT03822689|DEVICE|Ventilator breathing tube F2216|M: Folding; D: 22mm; L:1.6M
41358457|NCT03822689|DEVICE|Ventilator breathing tube F1520|M: Folding; D: 15mm; L:2.0M
41358458|NCT03822689|DEVICE|Ventilator breathing tube F1516|M: Folding; D: 15mm; L:1.6M
41358459|NCT03822689|DEVICE|Ventilator breathing tube U1016|M: Unfolding; D: 10mm; L:1.6M
41358460|NCT03822689|DEVICE|Ventilator breathing tube U1516|M: Unfolding; D: 15mm; L:1.6M
41497531|NCT05623072|DEVICE|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in vmPFC
41497532|NCT05623072|DEVICE|Sham tDCS|20 min, vmPFC Sham tDCS
41497533|NCT00644852|OTHER|Retrospective chart review study|Retrospective study chart review long acting risperidone
41497534|NCT04535544|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a SC injection.
41497535|NCT04535544|DRUG|Placebo|Matching placebo to JNJ-73763989 will be administered as a SC injection.
41358461|NCT03822689|DEVICE|Ventilator breathing tube CA20|M: Co-axis; L:2.0M
41358462|NCT03822689|DEVICE|Ventilator breathing tube CA16|M: Co-axis; L:1.6M
41358463|NCT02590627|DRUG|Artemether-lumefantrine|Artemether-lumefantrine
41358464|NCT02590627|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine
41358465|NCT03870646|COMBINATION_PRODUCT|Hypertonic saline of NaCl (7%) in combination with hyaluronic acid|Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.
40838621|NCT03082014|DRUG|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
41358466|NCT03870646|COMBINATION_PRODUCT|Isotonic saline of NaCl (0,9%)|Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
40838622|NCT03082014|DRUG|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
40838623|NCT03082014|DRUG|Atenolol|blood pressure lowering agent - beta-blocker
40838624|NCT04147533|DRUG|Imatinib withdrawal|withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial
40838625|NCT04147533|DRUG|Dasatinib|withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial
40838626|NCT04147533|DRUG|Nilotinib|withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
40838627|NCT04870541|DRUG|Ondansetron 8mg|Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
40838628|NCT04870541|DRUG|Nefopam Injectable Solution|Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
40838629|NCT00946673|DRUG|Vorinostat|Orally up to 400 mg
41023483|NCT02377986|BEHAVIORAL|In-Home Decluttering|In-home decluttering practice
40838630|NCT00946673|PROCEDURE|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
40838631|NCT03394690|DIETARY_SUPPLEMENT|green coffee|2 capsuls
40838632|NCT03394690|OTHER|control|2 capsuls
40838633|NCT01932255|PROCEDURE|prophylactic spinal tap|
40838634|NCT01932255|PROCEDURE|no prophylactic spinal tap|
41358467|NCT04491045|OTHER|Workshop Training on Multicomponent Collaborative Care for Depression|Hybrid Workshop Trainings on Stepped collaborative care model for depression that involves using a team-based approach to integrating depression care components (screening, psychoeducation, Behavior Activation therapy, and antidepressant medications) into primary care settings. This integration involves task-shifting mental health tasks from mental health specialist to community providers at the commune health stations.
41358468|NCT04491045|OTHER|Supervision|Ongoing supervision and coaching is provided to community health providers by local mental health specialist from the provincial psychiatric hospital for 6-9 months
40838635|NCT05741047|OTHER|a2Milk skim milk powder|a2Milk skim milk powder (1L) containing A2 β-casein only
40838636|NCT05741047|OTHER|Yili skim milk powder|Yili skim milk powder (1L) containing A1 and A2 β-caseins
41023484|NCT02769143|OTHER|Whole-Body Vibration|Will be performed six months of WBV exercises
41023485|NCT02769143|OTHER|Pilates|Will be performed six months of Pilates exercises
41023486|NCT06270303|PROCEDURE|Access flap & surgical debridement|Following surgical exposure, roots are carefully debrided.
41358469|NCT04491045|OTHER|Community-Engaged Learning Collaborative|The CELC group will receive support for continuous quality improvement using a province-wide learning collaborative that will meet monthly for 3 months, followed by bi-monthly meetings for 12 months.
41358470|NCT01542632|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
41358471|NCT01542632|BIOLOGICAL|TDV New Formulation|TDV New Formulation subcutaneous injection
41497536|NCT04535544|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film coated tablet will be administered orally.
41497537|NCT04535544|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
41497538|NCT04535544|DRUG|Tenofovir alafenamide (TAF)|TAF film coated tablet will be administered orally.
41497539|NCT02600689|BEHAVIORAL|Physical exercise training|
41497540|NCT02600689|BEHAVIORAL|Cognitive exercise training|
41497541|NCT04330716|BEHAVIORAL|Standard Genetic Counseling|Standard of care genetic counseling
41023487|NCT06270303|PROCEDURE|Application of bone substitute material (BioOss Collagen)|Following surgical debridement, the bone substitute material is applied to the furcation defect.
41023488|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic|
41023489|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isotonic|
41160620|NCT05304221|OTHER|Shamir Resistance Calculator|"An on-line calculator which is free and accessible from all devices, which may predict the risk of MDRO infection upon admission, and the risk of nosocomial XDRO infection during the hospitalization.~The calculator contains only parameters that could be extracted bedside, at the first presentation of a septic patient, including the ability to conduct a complete assessment also among patients with reduced consciousness and/or cognition."
41358472|NCT01542632|DRUG|Placebo|Placebo subcutaneous injection
41497542|NCT04330716|BEHAVIORAL|Educational Video|Video tutorial about genetic testing
41358473|NCT01542632|DRUG|New Formulation Placebo|New Formulation placebo subcutaneous injection
41497543|NCT00004378|PROCEDURE|Stem Cell Transplantation|
40838637|NCT06253169|DIAGNOSTIC_TEST|HPV DNA self-test|HPV DNA swab from the cervix performed by the patient herself.
40838638|NCT03254355|PROCEDURE|Multimodal physiotherapy|12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback
40838639|NCT02438813|DRUG|Deoxycholic acid|Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.
40838640|NCT02438813|PROCEDURE|Surgical Procedures|Surgical procedures for treatment of SMF as per standard of care in clinical practice.
40838641|NCT02438813|PROCEDURE|Laser Liposuction|Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..
40838642|NCT02438813|DEVICE|Energy Devices|Energy Devices for the treatment of SMF as per standard of care in clinical practice.
40838643|NCT02438813|OTHER|Other Treatments|Other treatments for SMF as per standard of care in clinical practice.
41023490|NCT02795286|DEVICE|Artis Haemodialysis Machine w/o ASIST Software|
41023491|NCT01100463|DRUG|Cream|Twice daily lotion to prevent HFS
41023492|NCT01100463|DRUG|0.1% Uracil Cream|Twice daily lotion to prevent HFS
41023493|NCT06563089|OTHER|blood sampling|Albumin level in blood
41358474|NCT05331547|DEVICE|BioFreedom BA9 (SS) Ultra DCS|BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
41497544|NCT05372653|DRUG|OPA-15406|0.3% or 1% ointment, topical, twice daily, for 52 weeks
41497545|NCT01624792|DIETARY_SUPPLEMENT|Olive oil|Dose: 7.0 g/day (= 7 capsules/day).
41497546|NCT01624792|DIETARY_SUPPLEMENT|Fish oil|Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
41497547|NCT01624792|DIETARY_SUPPLEMENT|Fish oil and placebo|Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
41497548|NCT04880863|DRUG|NAP (Naptumomab estafenatox)|Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4. NAP will be administered in a dose of 10 μg/kg/day by IV bolus on Days 1 - 4 of treatment cycles 1-6. Starting cycle 7, NAP at a higher dose of 15 μg/kg will be administered on Day 1.
41497549|NCT04880863|DRUG|Docetaxel|Docetaxel is administered in combination with the study drug, NAP, on Day 5 of the treatment cycles 1-6. Starting cycle 7, Docetaxel will be administered in combination with the study drug, NAP, on Day 2.
41497550|NCT04880863|DRUG|Obinutuzumab|Obinutuzumab is administered as pre-medication on Day -13 and -12 of the first treatment cycle.
41497551|NCT02171494|DRUG|IVAX Warfarin|
41497552|NCT02171494|DRUG|BMS Coumadin|
41497553|NCT00987389|PROCEDURE|Plasma Exchange|Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
41497554|NCT00987389|OTHER|No Plasma Exchange|No plasma exchange.
40838644|NCT02698722|OTHER|End-stage renal disease treatment options|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
40838645|NCT06518616|BEHAVIORAL|10-day meditation intervention|prerecorded meditation units delivered by smartphone app
40838646|NCT06518616|BEHAVIORAL|10-day health education intervention|prerecorded health education units delivered by smartphone app
40838647|NCT05932602|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention is required in this study.
40838648|NCT05932602|DEVICE|Dual Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a dual-chamber transvenous pacemaker as a comparator to the Aveir DR LP system study arm. No device intervention is required in this study.
40838649|NCT01943006|DRUG|Hirudoid cream 0.3 % Mucopolysaccharide polysulfate|Hirudoid cream
40838650|NCT01943006|DRUG|Placebo cream without active substance|
40838651|NCT05269030|DRUG|Ivermectin Topical|Ivermectin 1% in a dose of two drops per nostril twice daily.
40838652|NCT05269030|DRUG|Budesonide Nasal|64 µg per puff in a dose of 1 puff for each nostril twice daily.
40838653|NCT02296450|BEHAVIORAL|Quality of Life (QoL) Assessment|Per physician's discretion, the patient (or, if applicable, patient's family member/ spouse/ caregiver for FDLQI) will complete one or more of the following dermatology-specific QoL instruments: Skindex-16, Skindex-29 DLQI (Dermatology Life Quality Index), FDLQI (Family DLQI) - for patient's family member/spouse/caregiver ONLY, CDLQI (Children's DLQI;Cartoon version) - for patient's under the age of 18 ONLY-written, CDLQI (Children's DLQI; Cartoon version) - for patients under the age of 18 ONLY - cartoon version, FACT-G (Functional Assessment of Cancer Thearpy-General), FACT-Melanoma (Functional Assessment of Cancer Therapy-Melanoma), SCI (Skin Cancer Index) FACT-EGFRI-18 (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18), HFS-14 (Hand-Foot Syndrome) OMWQ (Oral Mucositis Weekly Questionnaire), ESTEEM, Hairdex , Skindex-29 modified for hair loss, Itchy QoL,CADS (Chemotherapy-induced alopecia distress scale)
40838654|NCT03329716|OTHER|Brace weaning|For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed
41497555|NCT00987389|DRUG|Glucocorticoids [Standard Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
40838655|NCT00596583|DRUG|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
40838656|NCT00596583|DRUG|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
40838657|NCT04752345|OTHER|Pharmacoinvasive strategy|Pharmacoinvasive treatment \[full-dose fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI (3 to 24 hours, in case of successful fibrinolysis)
41023494|NCT00653224|DRUG|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
41023495|NCT00653224|DRUG|placebo|0 mg daily (matching oral tablet) for 14 days
41023496|NCT05205603|DRUG|Infliximab|Infliximab, 5mg/kg at week 0,2,6 and schedule administration at every 8 weeks
41497556|NCT00987389|DRUG|Glucocorticoids [Reduced Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
41497557|NCT06399809|DRUG|Fisetin|Fisetin is a flavanol, present in strawberries, apples, and persimmons, that destroys senescent cells (i.e. a senolytic therapy). Of three senolytic therapies being tested in clinical trials, fisetin has the best safety profile.
41497558|NCT06399809|DRUG|Placebo|The placebo will be matched to the Fisetin intervention
41497559|NCT01120704|DRUG|Short Term Combination Nicotine Replacement Therapy (patch + gum)|"IF participant smokes \>10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.~IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment."
40838658|NCT04752345|OTHER|Reduced-dose facilitated PCI strategy|Reduced-dose facilitated PCI\[reduced-dose fibrinolysis,simultaneously transfer,immediate coronary angiography and andioplasty when arrived at PCI center(\<3 hours)\]
40838659|NCT06522971|BEHAVIORAL|High-intensiy interval training|All participants undergo physical capacity tests before the onset of NAC and after the last course of NAC but before the breast cancer surgery. A treadmill protocol consisting of twenty-one 1-minute stages, with speed and/or grade increments at each stage, is used to obtain VO2 peak (the highest amount of oxygen consumed at peak exercise) data. The HIIT intervention consists of 2 to 3 exercise sessions per week for 6 months. The HIIT session starts with a 6-minute warm-up period at about 65-70% of maximal heart rate (HRmax) followed by 4 X 4-min high-intensity intervals (85%-95% of HRmax) combined with 3 min period of active recovery (55-70% of HRmax).
40838660|NCT05569694|OTHER|Movement-based pelvic health education|A single virtual education session led by a physical therapist trained in pelvic health. The virtual course was approximately one hour and included movement-based education through various positions, exercises, and movements with explanations for each pose as it relates to pelvic health.
41023497|NCT05205603|DRUG|Vedolizumab|Vedolizumab, 300mg at week 0,2,6 and schedule administration at every 8 weeks
41023498|NCT05205603|DRUG|Mesalazine|Mesalazine, 4-6g/d, systemic and/or topical administration
41023499|NCT05906693|OTHER|Quality of life|Parkinson's Disease Quality of Life Questionnaire (PDQ-39)
41023500|NCT05906693|OTHER|Upper limb functionality|Nine-Hole Peg Test
41023501|NCT05906693|OTHER|Grip and pinch strength|Dynamometer
41023502|NCT05906693|OTHER|Tremor amplitude|Electromyography
41023503|NCT05906693|OTHER|Depression and anxiety levels|Hospital Anxiety and Depression Scale
41023504|NCT05906693|OTHER|Clinical manifestations|The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale
41023505|NCT03869229|BIOLOGICAL|Intra-articular injection of ADMSC|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million
41023506|NCT01389219|OTHER|Intervention|"A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~1. Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron \& vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~2. Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~3. Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections."
41023507|NCT03271437|BEHAVIORAL|PC-based Flash|Progressive counting with Flash technique
41023508|NCT03271437|BEHAVIORAL|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
41023509|NCT04260581|DRUG|Determination of drug effects through amantadine cessation|Patients will discontinue amantadine, which has been taken since beginning of diagnosis.
41358475|NCT05186220|PROCEDURE|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx, Carto), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
41023510|NCT02731092|DIETARY_SUPPLEMENT|Lactoferrin|Bovine Lactoferrin 100 mg/ml dissolved in sterile water
41358476|NCT05186220|DEVICE|Permanent dual chamber pacemaker implantation|Under local anesthesia and using a subclavian or cephalic vein approach a dual chamber pacemaker implantation with a lead in the right atrium and a lead in the right ventricle will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
41358477|NCT05774886|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Small, implantable device with 30 reservoirs for drug and drug combinations.~* Placement of 2 microdevices into tumor will be performed via needle, percutaneously, and guided by interventional radiologic techniques.~* Drugs include all or a subset of the following: Doxorubicin, Paclitaxel, Carboplatin, Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat, Panobinostat, Olaparib, Capecitabine, Sacituzumab govitecan, Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin (combination), Carboplatin + paclitaxel (combination), Doxorubicin + cyclophosphamide + pembrolizumab (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin + Pembrolizumab (combination), Paclitaxel + atezolizumab (combination), Paclitaxel + pembrolizumab (combination), Carboplatin + gemcitabine + pembrolizumab (combination), Carboplatin + paclitaxel + pembrolizumab (combination), Trastuzumab deruxtecan"
41023511|NCT06428188|BIOLOGICAL|BCMA/CD19 CAR-T cells|"The intervention in this clinical trial involves a novel approach using BCMA/CD19 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/CD19 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, BCMA/CD19 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial BCMA/CD19 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
41023512|NCT03324061|DRUG|Fulvestrant for Injectable Suspension|Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
41023513|NCT03324061|DRUG|Faslodex (Reference)|Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
41358478|NCT05791487|OTHER|Ulcerative colitis Exclusion Diet|a limited whole food diet (UCED)
41358479|NCT05791487|OTHER|Partial enteral nutrition (PEN)|"The diet will be supplemented by 3 glasses a day (750 ml) of the formula developed for UC using the UCED principles."
41358480|NCT05791487|OTHER|free diet|oral Budeosnide for 6 weeks + free diet
41358481|NCT05791487|DRUG|Oral Budesonide|Oral Budesonide 9 mg
41358482|NCT00005089|BIOLOGICAL|rituximab|375 mg/m\^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
41358483|NCT00005089|DRUG|cyclophosphamide|750 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
41023514|NCT00176098|PROCEDURE|Hypnoanalgesia; Hypnotic shielding|
41160621|NCT01797133|PROCEDURE|ID fellow-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.
41358484|NCT00005089|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
41358485|NCT00005089|DRUG|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
41358486|NCT00005089|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
41358487|NCT00005089|RADIATION|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
41358488|NCT06033495|DEVICE|Coronary sinus reduction stent|Percutaneous stent implantation to reduce the dimension of the coronary sinus
41358489|NCT00219531|BEHAVIORAL|perception of rectal balloon distention|functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
41358490|NCT02189239|DRUG|Zeller Entspannung film coated tablet|
41358491|NCT02189239|DRUG|Placebo|
41358492|NCT02189239|OTHER|No Treatment|
41358493|NCT04645628|OTHER|MRI examination|All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
41358494|NCT02118272|DEVICE|Physica KR|
41358495|NCT04193982|DRUG|Saroglitazar|Patient receives Saraglitazar 4mg once daily
41358496|NCT04193982|DRUG|Vitamin E|Patient receive Vitamin E 400mg twice daily after food for 6 months
41023515|NCT05711550|DEVICE|Real Neurofeedback|Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min
41023516|NCT05711550|DEVICE|Sham Neurofeedback|The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
41358497|NCT04193982|DRUG|Combination drug|Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
41358498|NCT04193982|BEHAVIORAL|Lifestyle Changes|Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months
41358499|NCT06186674|DIAGNOSTIC_TEST|sorensen test for back endurance|• Biering-Sorensen test will be utilized to gauge the trunk extensor muscles' isometric endurance. The patient will be lying on a treatment couch, prone. The top half of the body will be permitted to rest on a chair prior to the test starting. The patient will be told to elevate their upper trunks off of the chair at the start of the test. the examiner determined how long the individual could hold this position.
41023517|NCT05337501|OTHER|Collecting data|Anamnesis, clinical examination, Quantitative Sensory Testing (following DFNS, German Research Network on Neuropathic Pain, protocol), visual TOJ (Temporal Order Judgement) task
41023518|NCT02719405|DIETARY_SUPPLEMENT|Lactobacillus GG|Lactobacillus GG
41023519|NCT02719405|DIETARY_SUPPLEMENT|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
41023520|NCT02719405|DIETARY_SUPPLEMENT|Amino Acid Formula|Amino Acid Formula
41023521|NCT04227483|DRUG|Deflazacort|Deflazacort for 4 months
41023522|NCT04227483|DRUG|Prednisolone|Prednisolone for 4 months
40838661|NCT06312241|BEHAVIORAL|Metacognitive Training-Silver BeWell|Metacognitive Training- Silver BeWell is a cognitive behavioral based group intervention, which focuses on helping participants gain (metacognitive) distance from thought and behavioral patterns as well as behaviors and ER-strategies that are implicated in the onset of depression and reduced overall mental well-being. In 10 modules, MCT-Silver addresses issues specific to later life such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life, acceptance of negative feelings and resilience. In the training participants are made aware of information processing biases that have been shown to contribute to the onset of depression through engaging exercises using examples from daily life. Groups are comprised of up to 10 participants. Each session is 90 minutes.
40838662|NCT01762995|DRUG|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
40838663|NCT01762995|DRUG|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
40838664|NCT01762995|DRUG|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
40838665|NCT05629910|DEVICE|O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
40838666|NCT04845191|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|hAd5-S-Fusion+N-ETSD is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen S fusion protein and N with an enhanced T-cell stimulation domain.
40838667|NCT02195804|DRUG|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
40838668|NCT02195804|DRUG|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
40838669|NCT02195804|DRUG|Ranitidine hydrochloride|
40838670|NCT01131741|DRUG|Epinephrine|This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
40838671|NCT01131741|DRUG|Control|This group receives 3 mL of saline IV during operation.
40838672|NCT03927404|DEVICE|Active vacuum test prosthesis|The adaptive vacuum prosthesis is sold as a commercial device by the company Willow Wood with suggested U.S. L-Code L5781. The device is designated as a Class 1 Medical Device and 510(K) Exempt. This category is part of a low or moderate risk to patient safety and health. The Prosthetic socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
40838673|NCT03030339|OTHER|High VA intake, recent VAS|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.
40838674|NCT03030339|OTHER|High VA intake|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
40838675|NCT03030339|OTHER|Low/adequate VA intake|Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
40838676|NCT05527886|OTHER|AAROM|AAROM with knee to wall exercise, 3x30 reps
40838677|NCT05527886|OTHER|Slow Load|Single leg heel raise, 3x10 reps
40838678|NCT05527886|OTHER|Plyometric|Double leg 5 inch wall hops, 3x10 sec
40838679|NCT02739516|DRUG|Human chorionic gonadotropin|In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
41023523|NCT04574362|DRUG|Rimegepant|One 75mg orally disintegrating tablet
41023524|NCT04574362|DRUG|Placebo|Matching placebo
41023525|NCT04879472|PROCEDURE|Osteosynthesis|The elderly are mainly treated by arthroplasty (total hip replacement or hemiarthroplasty) while the younger age groups, by osteosynthesis either using pins, screws or nails
41023526|NCT03927885|OTHER|Placebo Administration|Given open labeled placebo PO
41023527|NCT03927885|OTHER|Quality-of-Life Assessment|Ancillary studies
41023528|NCT03927885|OTHER|Questionnaire Administration|Ancillary studies
41023529|NCT03927885|OTHER|Waiting List|Assigned to a waiting list
40838680|NCT02739516|DRUG|FSH co-trigger|In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
40838681|NCT02739516|DRUG|Letrozole|Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.
41358500|NCT06186674|DIAGNOSTIC_TEST|6 minute walk test|"It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace.~It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace."
41358501|NCT06186674|DIAGNOSTIC_TEST|c7-s1 SVA|Subjects will obtain standardized lateral views radiographs in a neutral standing position for the whole spine. The C7- S1 SVA will be measured as the distance from the plumb line dropped from the center of the C7 vertebral body to the most posterior edge of the upper sacral endplate surface.
41358502|NCT02967965|OTHER|Imagery|MRI at year 3
41358503|NCT04999319|PROCEDURE|PVB|Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
41358504|NCT04999319|PROCEDURE|ESPB|Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
41358505|NCT03996993|DRUG|Casodex, Axumin|Patients will receive hormone therapy if Axumin positive area appears.
41358506|NCT03996993|RADIATION|Salvage Radiation, Axumin|Patients will receive salvage radiation therapy if Axumin positive area appears.
41358507|NCT04438642|PROCEDURE|shoulder finishline|tooth will be prepared having shoulder finishline.
41358508|NCT04438642|PROCEDURE|butt joint with bevel|tooth will be prepared having butt joint with bevel finishline.
41358509|NCT03984643|DEVICE|Vim-Deep Brain Stimulation|This study consists of testing additional model-derived DBS settings during initial and regular follow-up clinical visits every 6 months for up to 2 years in which individuals with DBS implants are re-evaluated by a clinician to make sure that the stimulation settings employed during the previous clinical visit remain therapeutic. It is important to note that this study is post-surgical and all procedures (i.e. stimulation settings that will be tested in the clinic) are within the FDA-approved range of stimulation settings available on the implanted pulse generator.
41358510|NCT01767844|DIETARY_SUPPLEMENT|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
41358511|NCT01767844|DIETARY_SUPPLEMENT|Placebo|
41358512|NCT00203294|DRUG|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
40838682|NCT05956834|DEVICE|PAMSys|Wearable accelerometer and gyroscope for measuring movement
40838683|NCT05956834|DEVICE|LEGSys|Wearable accelerometer and gyroscope for measuring movement
41023530|NCT01842828|OTHER|Standard care plus electronic cigarettes|
41023531|NCT01842828|BEHAVIORAL|Standard care|
41358513|NCT00203294|DRUG|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
41358514|NCT06235281|DRUG|Mogamulizumab-Kpkc|Participants will receive 8 total cycles of Mogamulizumab-Kpkc over approximately 224 days.
41358515|NCT06235281|DEVICE|Phototherapy|Participants will begin receiving Phototherapy on day 56 and will continue until day 224. Participants with Complete response (CR) or Partial response (PR) to therapy at day 224 will remain on phototherapy maintenance.
41358516|NCT04778722|DIETARY_SUPPLEMENT|Oral probiotics|containing four Lactobacillus strains (Lactobacillus crispatus -Lbv88, Lactobacillus rhamnosus -Lbv96, Lactobacillus jensenii -Lbv116, and Lactobacillus gasseri -Lbv150)
41358517|NCT06323863|PROCEDURE|stapedectomy|stapes removal and replacement by a prosthesis
41358518|NCT06323863|RADIATION|ultra high resolution CT|imaging study
41358519|NCT05386979|PROCEDURE|Opioid free anesthesia technology|We have adopted a variety of methods to replace the use of opioids in the process of balanced anesthesia.
41358520|NCT03973775|DRUG|Permethrin Cream 5%|Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
41358521|NCT04501419|PROCEDURE|US-guided breast biopsy|During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
40838684|NCT00149019|DRUG|Cell therapy with bispecific antibodies|
40838685|NCT02553408|DEVICE|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
40838686|NCT01779505|BIOLOGICAL|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
40838687|NCT00778895|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
40838688|NCT00778895|BIOLOGICAL|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
40838689|NCT05435066|DIAGNOSTIC_TEST|Harbinger Health Test|This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched non-cancer controls. The non-cancer controls will be followed for up to 1 year
40838690|NCT00684827|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, Pirbuterol HFA MDI"
41160622|NCT01797133|PROCEDURE|Pharmacist-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.
41358522|NCT04501419|OTHER|Ultrasound-guided breast biopsy training program|This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients
41358523|NCT02987205|DEVICE|Revanesse Ultra|NLF correction
41358524|NCT02987205|DEVICE|Restylane|NLF Correction
41358525|NCT06477432|DEVICE|mesofiller® mesotox|The investigated product mesofiller® mesotox was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14-day intervals.
41358526|NCT04955236|DRUG|Partial scalp block|"Partial scalp blocks will be performed bilaterally after assuming the prone position.The Greater occipital will be blocked by injecting 3ml of local anaesthetic at a point half way between the mastoid process the external occipital protuberance along the superior nuchal line, medial to the occipital artery. The Lesser occipital nerve will be blocked by injecting 3ml of local anaesthetic infiltration along the superior nuchal line, 2.5 cm lateral to the greater occipital nerve block. The greater occipital nerve block also will cover the third occipital nerve due to the close location of the two nerves.~A placebo infusion (normal saline) will be administered at the same rate as fentanyl infusion in the active comparator arm(1 µg/kg/hr.)."
41358527|NCT04955236|DRUG|Fentanyl|1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
41358528|NCT01729481|DRUG|Gemcitabine|1000 mg/m² iv weekly
40838691|NCT00684827|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. Pirbuterol HFA MDI, Xopenex HFA MDI"
40838692|NCT03511469|OTHER|Control Group|Control Group: Standart rehabilitation
40838693|NCT03511469|OTHER|Isokinetic Group|Concentric group: Standart rehabilitation + isokinetic training
40838694|NCT04369508|RADIATION|permanent brachytherapy|"Briefly, the patient had a general anesthesia and PPB was performed by using the real-time intraoperative planning method guided by TRUS. The radioactive seeds were inserted transperineally according to a modified peripherally loaded Seattle technique 17. I-125 was used for all implants with a mean seed activity of 0.45 mCi per seed. All procedures were completed by a single surgeon."
40838695|NCT02830620|OTHER|Dosage of chimiokines|
40838696|NCT05839704|PROCEDURE|Bilateral Erector Spinae Plane Block|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the erector spinae plane at the level of T8.
41358529|NCT01729481|DRUG|Erlotinib|100mg, once per day
40838697|NCT05839704|PROCEDURE|Abdominal Wall Blocks|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the subcostal transversus abdominus plane bilaterally and the serratus plane on the left side
40838698|NCT06334757|DRUG|Serplulimab|300 mg，IV，Q3W
40838699|NCT06334757|DRUG|Bevacizumab Biosimilar HLX04|7.5 mg/kg，Q3W
40838700|NCT06334757|DRUG|Pemetrexed|500 mg/m2，IV，Q3W
40838701|NCT06334757|DRUG|Carboplatin|AUC=5，IV，Q3W
40838702|NCT06036316|BEHAVIORAL|Language assessment|"The proposed speech and language therapy assessment will consist of a battery of standardized tests that speech and language therapists can use to assess the language skills in reception and expression of adult patients.~Concerning the assessment of the interactions between working memory and semantic abilities, a complete protocol has been developed."
41358530|NCT01729481|DRUG|Oxaliplatin|85mg/m², q2weeks
40838703|NCT06036316|BEHAVIORAL|TLC - Scale for the Assessment of Thought, Language, and Communication|This scale is frequently used in psychiatry and is used to measure formal thought disorders in patients suffering from psychosis. As part of this study, it will be intended for patients suffering from schizophrenia
41358531|NCT01729481|DRUG|Folinic Acid|400 mg/m², q2weeks
41358532|NCT01729481|DRUG|Irinotecan|180 mg/m², q2weeks
41358533|NCT01729481|DRUG|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
41358534|NCT04748159|OTHER|Prone position/ Abdominal position|Standardized positioning of the infant in the prone position respectively abdominal position. Depending on age and size, one or two rolled towels are placed lengthwise under the baby. Both arms are placed cranially in U-position towards the head. Since the position of the head has no significant influence on lung ventilation, the head is placed according to the infant's tolerance.
40838704|NCT06036316|BEHAVIORAL|MINI - Mini International Neuropsychiatric Interview|This scale corresponds to a rapid assessment of the psychiatric and psychological state of patients. It helps detect any psychiatric disorders. Here, it will be offered to volunteers who are part of the control group.
40838705|NCT06036316|COMBINATION_PRODUCT|CAST - Cannabis Abuse Screening Test|The purpose of this questionnaire is to approximate participants' cannabis consumption and to assess any disorders associated with cannabis consumption. It will be offered to all participants, patients and healthy controls
41358535|NCT05976711|DEVICE|Magnetic resonance imaging (with PROUD software)|Philips Ingenia 3.0T MR system with in-house developed PROUD software
41358536|NCT04980300|BEHAVIORAL|Expanded Intervention|Participants in the Expanded Intervention arm will receive five virtual consultation sessions, delivered by a physical therapist over 12 weeks (at Weeks 1, 2, 4, 7, and 10) and lasting approximately 45-60 minutes each. Each session will focus on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis. Participants will be provided with an exercise manual, tracking log, educational manual, and a step counter. Participants will be prescribed up to 6 exercises (quadriceps, hip abductor/gluteal, hamstrings/gluteal, calf, balance) and daily walking step goals. Progression will be a joint decision by the participant and physical therapist. Education will include information on knee osteoarthritis, managing pain, being active, weight loss, dealing with setbacks, and progressing activity. The physical therapist will also discuss barriers and facilitators to meeting and progressing goals as appropriate.
41358537|NCT04980300|BEHAVIORAL|Brief Intervention|Participants in the Brief Intervention arm will receive access to a study-specific website that navigates them to a variety of web-based resources on knee osteoarthritis. Topics for the various resources include an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis. Sessions range from 20 - 70+ minutes.
40838706|NCT06182241|BEHAVIORAL|Retention in cervical cancer care intervention|Aim 1 data will inform this intervention, however the participant intervention will likely be one or two sessions, conducted in-person, coupled with text- or phone-based client navigation with women who received abnormal high-risk Pap smear results. We anticipate that the intervention may integrate (1) information to improve awareness of cervical cancer susceptibility and treatment, (2) motivational interviewing to assess pros and cons of attending a follow-up appointment and completing treatment; (3) brief cognitive behavioral therapy (CBT) skills to reduce individual-level barriers, (4) problem-solving to increase social support, and (5) patient navigation tools to mitigate clinic-level challenges.
40838707|NCT03679455|DRUG|Obinutuzumab 25 MG/ML|Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
40838708|NCT05668663|DIAGNOSTIC_TEST|Plasmatic Vitamin C concentrations (known as ascorbemia) on a single blood sample|"If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.~The blood sample will be collected up to 3 days after admission"
41358538|NCT05474885|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
41358539|NCT03677661|OTHER|Conventional approach|The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
40838709|NCT06507800|OTHER|Observational cohort|Cancer incidence after AHSCT for an autoimmune indication.
40838710|NCT03100110|DEVICE|NeuroCognitive Communicator|Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
40838711|NCT03756831|DIAGNOSTIC_TEST|Core Stability Assessment|Core Stability Assessment will be consisted of bilateral static balance with open and close eye, right foot balance test, and dynamic balance test.
40838712|NCT06349304|DIETARY_SUPPLEMENT|Freeze-dried table grape powder|Consumption of grape powder as part of daily diet
40838713|NCT06349304|DIETARY_SUPPLEMENT|Placebo grape powder|Consumption of placebo grape powder as part of daily diet
40838714|NCT06004375|DIETARY_SUPPLEMENT|Neomune|Neomune containing 4.8 g arginine and 2 g glutamine
41358540|NCT03677661|OTHER|Personalized rehabilitation program|The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
41497560|NCT01120704|DRUG|Long Term Combination Nicotine Replacement Therapy (patch + gum)|"IF the participant smokes \>10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.~IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment."
40838715|NCT05250791|DRUG|Lidocaine hydrochloride 2% for injection|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
40838716|NCT05250791|DRUG|0.9% sterile Sodium Chloride solution for injection|Administered as lidocaine
40838717|NCT04713332|DIETARY_SUPPLEMENT|Vitamin E|Members of the vitamin E family are hydrophobic fat-soluble compounds found in a variety of food sources such as vegetable oils, fruits, and vegetables consumed through diet. Vitamin E exists in 8 isoforms, a, b, g, d-tocopherol, and a, b, g, d-tocotrienol. The recommended daily allowance for adults is 15 mg per day for alpha-tocopherol, an amount which is easily met by dietary sources, and 30 mg per day for synthetic all-rac-alpha-tocopherol. The upper limit for intake is 1,000 mg per day. Very often, the dosage of vitamin E is given in international units (IU) as capsules, with a typical dose being 400 IU per day, which is above the recommended daily allowance. The health benefits of consuming vitamin E through diet or supplementation are believed to be for its antioxidant properties as a peroxyl radical scavenger. Vitamin E protects cells from cell damage caused by free radicals that damage cell membranes through lipid oxidation leading to DNA damage and cancer development.
40838718|NCT04713332|DIETARY_SUPPLEMENT|Hydrogen rich water|Molecular hydrogen is a new medical gas that can be dissolved in water and administered through drinking, inhalation, baths, intravenous drip. A growing body of evidence indicates that hydrogen, as a novel antioxidant, scavenges hydroxyl radical and peroxynitrite. In contrast to other antioxidants, gaseous molecular hydrogen efficiently penetrates cytoplasmic membranes and targets intracellular organelles, largely owing to its small size and neutral electricity. Thus, hydrogen has been suggested as a suitable candidate for the therapeutic strategies for various diseases, including certain types of cancer. Hydrogen has emerged as a promising cancer remedy as a preventative agent or in combined therapy with anticancer drugs. Hydrogen water consumption might mitigate the side effects of anticancer drugs by decreasing oxidative stress and ameliorating metamorphosis due to decreased apoptosis.
40838719|NCT04713332|DIETARY_SUPPLEMENT|placebo|Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
40838720|NCT02947399|RADIATION|Radioactive Iodine 124|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
40838721|NCT00436254|BIOLOGICAL|pNGVL3-hICD vaccine|Plasmid-based DNA vaccine, given intradermally
40838722|NCT00436254|BIOLOGICAL|sargramostim|Given intradermally
40838723|NCT00436254|OTHER|flow cytometry|Correlative studies
40838724|NCT00436254|OTHER|immunologic technique|Correlative studies
40838725|NCT00436254|OTHER|immunoenzyme technique|Undergo ELIspot (correlative studies)
41358541|NCT02254694|OTHER|high heeled shoes|see detailed study description
40838726|NCT00436254|GENETIC|protein expression analysis|Undergo ELISA (correlative studies)
40838727|NCT00436254|PROCEDURE|biopsy|Undergo punch biopsy (correlative studies)
40838728|NCT04379778|OTHER|Aerobic exercise|Progressive moderate to high intensity aerobic exercise.
40838729|NCT01833234|OTHER|Interviews and questionnaires|
40838730|NCT01177969|BEHAVIORAL|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
41358542|NCT05818202|OTHER|Questionannire|The questionannaires for both physiotherapists and stroke patients were formed in this study. The perspectives of the participants were recorded.
40838731|NCT01177969|BEHAVIORAL|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
41358543|NCT03114709|OTHER|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
41358544|NCT03114709|OTHER|10 Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
41358545|NCT03494946|PROCEDURE|Liver transplantation|
40838732|NCT03874039|DEVICE|Gas sensor|The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
40838733|NCT03874039|DEVICE|Sweat Sensor|The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
40838734|NCT01581008|OTHER|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
40838735|NCT01581008|BEHAVIORAL|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
40838736|NCT03731260|DRUG|Avapritinib|Avapritinib tablet
40838737|NCT03731260|DRUG|Placebo|Placebo tablet
40838738|NCT05173701|DIETARY_SUPPLEMENT|Probiotics|Selected probiotics mixture, in powder form, will be administered once daily for three months in the morning.
40838739|NCT05173701|DIETARY_SUPPLEMENT|Placebo|A placebo (2,7g maltodextrin) will be administered once daily for three months in the morning.
40838740|NCT06358404|BEHAVIORAL|PeersCOG|. The intervention will consist of 8 weekly video chats focused on emotional, appraisal, and informational support delivered by community-based older adult peer coaches to adults 60 years of age and older with subthreshold depression and SCD.
40838741|NCT01927042|BEHAVIORAL|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
40838742|NCT01927042|BEHAVIORAL|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
40838743|NCT01274910|DIETARY_SUPPLEMENT|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day"
40838744|NCT01274910|DIETARY_SUPPLEMENT|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day"
40838745|NCT04934436|OTHER|sleeping glasses and earplug|In this study, the effect of the chronotype-appropriate nursing care on the intervention group will be examined.
40838746|NCT01070108|DRUG|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
40838747|NCT01070108|DRUG|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
40838748|NCT01070108|DRUG|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
41358546|NCT03494946|DRUG|Chemotherapy|May include chemotherapy, TACE, SIRT or other available treatment options.
40838749|NCT01076621|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
41358547|NCT00027404|DRUG|Fluoxetine|
40838750|NCT04684992|DEVICE|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
40838751|NCT04358159|DEVICE|Ventralex|Repair of the hernia by a Ventralex patch in sublay position
40838752|NCT04358159|DEVICE|Progrip|Repair of the hernia by a Progrip mesh in onlay position
40838753|NCT02435706|PROCEDURE|Flapless immediate implant placement|Experimental group: No elevation of flap prior to immediate implant placement
40838754|NCT02435706|PROCEDURE|Flap assisted immediate implant placement|Control group: Flap will be elevated prior to immediate implant placement
40838755|NCT02435706|DEVICE|Implant and temporary crown|Both groups receive this intervention
40838756|NCT00777699|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
40838757|NCT00777699|DRUG|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
40838758|NCT03444012|DRUG|ticagrelor 90 mg|persistence and adherence on ticagrelor in ACS patients
40838759|NCT00001909|DRUG|Soluble recombinantly produced IL-4R|
41358548|NCT04065516|PROCEDURE|ARAT technique|After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
41358549|NCT03040479|DRUG|lasmiditan 200 mg|single dose
41358550|NCT05458674|DRUG|Tucatinib|taken orally
41358551|NCT05458674|DRUG|Eribulin|taknen intravenously
41358552|NCT05458674|DRUG|Trastuzumab|taken intravenously
41358553|NCT05270876|DEVICE|Cochlear Implant and sound processor device fitting paradigm or diagnostic/measurement technique|Experimental: The investigational device will be a new device fitting paradigm or diagnostic/measurement technique implemented for use with the commercially available sound processor and implant.
41358554|NCT05270876|DEVICE|Standard of care fitting or diagnostic measurement of Cochlear Implant and sound processor|The comparator will be the standard of care fitting or diagnostic or measurement approach.
41358555|NCT05389865|PROCEDURE|Surgery on the proximal aorta (aortic root +/- ascending aorta)|Surgery involving replacing, repairing or reinforcing the proximal aorta (root and ascending aorta)
41023532|NCT02766491|OTHER|Strengthening and stretching|"Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
41023533|NCT02766491|OTHER|conventional stretching|"This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
41023534|NCT06071000|BEHAVIORAL|Neuro-developmental stimulation (Neuro-vývojová stimulace).|Neuro-developmental stimulation is exercise based intervention program that is focused on repeating reflex movements and thus inhibiting reflexive response.
41023535|NCT02578524|OTHER|Survey|
41023536|NCT04999592|DRUG|Standard of care without prophylaxis|Administer antibiotics in response to infection
41023537|NCT04999592|DRUG|Antibiotic prophylaxis|Ceftriaxone 2 gm IV q12h for 3 days
41023538|NCT04013451|BEHAVIORAL|Acts of kindness|Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
41023539|NCT05734859|DEVICE|Electrolyzed Alkaline Ionizer|Patients will drink EHARW calculated by 20 mL/kg body weight/day which can be divided into several times a day for drinking. The patient is recommended to drink water in an empty stomach and to drink water generated from the device as soon as possible.
41023540|NCT01682291|BEHAVIORAL|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
41023541|NCT01682291|DIETARY_SUPPLEMENT|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
41023542|NCT01962974|BIOLOGICAL|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
41023543|NCT03175640|BEHAVIORAL|Implementation intervention|The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
41023544|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 1|Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
41023545|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 2|Dose level 2 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 2 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
41023546|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 3|Dose level 3 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 3 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
41023547|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 4|Dose level 4 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 4 and OA GSK4382276A Dose level 4 groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
41023548|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 6|Dose level 6 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 6 group, at Day 1.
41023549|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 7|Dose level 7 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 7 group, at Day 1.
41358556|NCT05389865|OTHER|Patients diagnosed with thoracic aortopathy but not operated upon|Radiological size criteria or Genetic mutations associated with aortopathies
40838760|NCT06356688|DRUG|paclitaxel polymer micelles and cisplatin combined with Cadonilimab|Paclitaxel polymer micelles:Cycle 1: 230mg/m2, IV ≥3 hours; Cycles 2-4: If the patient has a neutrophil nadir ≥1.0 x 109/L along with a platelet nadir ≥80 x 109/L after Cycle 1 dosing and has not experienced grade II-IV non-hematologic toxicity, then give 260mg/m2, IV ≥3 hours, d1, q3w; Cisplatin: 25mg/m2/d x d1-3, IV drip, q3w; Cadonilimab: 375mg, IV drip, d3, q3w;
40838761|NCT05768984|OTHER|Empowerment program|It is planned to conduct the empowerment program online (zoom session). For this, to protect each individual's privacy, a quiet, bright and ventilated, spacious physical environment and technological elements such as computers, headphones, microphones and internet connection are needed. The empowerment program was planned as a total of 10 sessions, one session per week. In the program, goals and objectives have been established for each session. These aims and objectives will be shared with the participants before each session. The application time of each session is planned as an average of 90 minutes.
40838762|NCT00110461|DRUG|Aripiprazole|Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
40838763|NCT00110461|DRUG|Aripiprazole|Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
40838764|NCT00110461|DRUG|placebo|Placebo tablet
40838765|NCT05635474|DIETARY_SUPPLEMENT|Bacillus Coagulans|Bacillus coagulans is a Gram-positive bacterium belonging to the genus Bacillus and does not exist in the intestinal microbiota, because it has the characteristics of spore production and lactobacillus lactic acid production, and has the ability to maintain the health of intestinal bacteria, acid and alkali resistance, With the advantages of high temperature resistance and high stability, it is currently one of the commonly used probiotic strains.
40838766|NCT05635474|DIETARY_SUPPLEMENT|Placebo|The placebo was also administered in the form of capsules consisting of maltodextrin, silicon dioxide, and magnesium stearate.
40838767|NCT05156268|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
40838768|NCT05156268|DRUG|Olaparib|Olaparib will be administered orally at 300 mg every 12 hours.
40838769|NCT01030874|OTHER|Medication review|Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
41023550|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 8|Dose level 8 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 8 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
41023551|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 9|Dose level 9 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 9 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
41023552|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 10|Dose level 10 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 10 group, at Day 1.
41023553|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 11|Dose level 11 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 11 group, at Day 1.
41023554|NCT05446740|COMBINATION_PRODUCT|FDQ21A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.
41023555|NCT05446740|COMBINATION_PRODUCT|FDQ22A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 2, at Day 1.
41023556|NCT06532825|DIAGNOSTIC_TEST|heart monitoring|individual comparison of heart rate variability at admission with a repeated measurement before discharge
41023557|NCT05684484|DRUG|Roflumilast 500 Ug ORAL TABLET [Daliresp]|Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
41023558|NCT05684484|DRUG|corticosteroids +immune suppressive +amino salicylic acid|conventional treatment
41358557|NCT01934166|DRUG|Nalmefene 18 mg|One single oral dose of 18 mg
41023559|NCT03905759|DRUG|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
41358558|NCT01496924|OTHER|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
41358559|NCT03821142|DEVICE|Transvaginal mesh for anterior pelvic organ prolapse repair|synthetic mesh for anterior pelvic organ prolapse with or without apical vaginal wall involvement via the vaginal route in a highly selected patient population
41358560|NCT00462657|GENETIC|polymerase chain reaction|
41358561|NCT00462657|OTHER|bronchoalveolar lavage|
41358562|NCT00462657|OTHER|immunoenzyme technique|
41358563|NCT00462657|OTHER|laboratory biomarker analysis|
41358564|NCT00462657|PROCEDURE|bronchoscopy|
41358565|NCT00462657|PROCEDURE|management of therapy complications|
41023560|NCT03905759|DRUG|Amiodarone|Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
41023561|NCT03905759|DRUG|Colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
41023562|NCT02815111|DRUG|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
41023563|NCT02815111|DRUG|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
41023564|NCT02815111|DRUG|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
41023565|NCT02815111|DRUG|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
41358566|NCT02476903|DRUG|Monovisc|
41497561|NCT01120704|BEHAVIORAL|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 \& 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
41497562|NCT01120704|BEHAVIORAL|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
41497563|NCT01120704|BEHAVIORAL|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
41497564|NCT01120704|BEHAVIORAL|Automated Adherence Prompting Phone Calls|"Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.~Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 \& 23."
41497565|NCT04709770|DRUG|2-liters polyethylene glycol with citrate and simethicone|Low-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
41497566|NCT04709770|DRUG|4-liters polyethylene glycol with simethicone|High-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
40838770|NCT01030874|OTHER|Nutrition/Salt intake|Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
40838771|NCT01030874|OTHER|Education|The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
41358567|NCT05489276|DRUG|TQB2825 injection|TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
41358568|NCT03131258|PROCEDURE|Donor Nephrectomy|48 Donor Nephrectomy Patients
41358569|NCT00840931|DRUG|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
41358570|NCT00840931|BIOLOGICAL|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
41358571|NCT06207864|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, saliva, and stool samples
41358572|NCT06207864|PROCEDURE|Return of Results|Receive results
41023566|NCT03798691|BIOLOGICAL|Shingrix|"Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
41358573|NCT06207864|OTHER|Survey Administration|Surveys and Interviews
41358574|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride|Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
41358575|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
41358576|NCT03851315|DEVICE|permanent left bundle branch area pacing|Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
41358577|NCT05649046|DEVICE|thoracic scan Low dose|within 3 months after the V0 visit
41358578|NCT05649046|BIOLOGICAL|BLOOD SAMPLE|within 3 months after the V0 visit
41358579|NCT05649046|BIOLOGICAL|FECES SAMPLE|within 3 months after the V0 visit
41358580|NCT04470960|BEHAVIORAL|Training course for the community center health coordinators|"These community centers who have volunteered to join the project will receive a 12 week training session which includes the values and principles of health promotion and the principles of building a health promotion project.~The participants will be requested to build a health promotion project within their community. Building and implementing the project will be assisted by a health promotion specialist. Each health promotion project will be evaluated according to the principles of health promotion."
41358581|NCT03005691|RADIATION|Spectroscopy|"Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data."
40838772|NCT01030874|OTHER|Exercise|The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
41358582|NCT03005691|OTHER|Questionnaires|Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.
41358583|NCT03005691|PROCEDURE|Conditioned Pain Modulation|Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)
41358584|NCT02083822|PROCEDURE|term MRI, executive EF functions testing|An MRI will be realized at term born between 25 and 32 weeks GA
41358585|NCT04145310|DRUG|BOL-DP-o-04 + SCO|sublingual drops
41023567|NCT00934193|DRUG|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
41358586|NCT04145310|DRUG|Placebo + SCO|sublingual drops
41358587|NCT03819023|DIAGNOSTIC_TEST|Respilife monitor|Respilife monitor
41497567|NCT04709770|DIETARY_SUPPLEMENT|Low-residue diet|Diet before colonoscopy.
41497568|NCT03376230|OTHER|Collect of blood, urines, and intestinal biopsies|
41497569|NCT06506162|OTHER|Flavor|The study will compare sweet vs. cool flavors
41497570|NCT06506162|OTHER|Nicotine concentration|The study will compare low vs. high strength Oral Nicotine Products
41497571|NCT01110135|DRUG|bendamustine hydrochloride|Given IV
41497572|NCT01110135|DRUG|dexamethasone|Given PO
41497573|NCT01110135|BIOLOGICAL|filgrastim|Given SC
41497574|NCT01110135|PROCEDURE|leukapheresis|Given IV
41497575|NCT01110135|OTHER|laboratory biomarker analysis|Correlative studies
41497576|NCT01110135|OTHER|flow cytometry|Correlative studies
41497577|NCT01110135|DRUG|etoposide|Given IV
41497578|NCT00154271|DRUG|Valsartan, Valsartan HCT|
41023568|NCT00934193|DRUG|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
41358588|NCT03363126|PROCEDURE|Endonasal transsphenoidal pituitary tumor removal|Removal of pituitary tumor by transsphenoidal endonasal surgery
41358589|NCT03691649|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
41358590|NCT03691649|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
41358591|NCT04252924|OTHER|lifestyle characteristics|Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
41358592|NCT03933254|DIAGNOSTIC_TEST|Intraocular pressure measurement via ocular tonometry|Intraocular pressure and optic nerve sheath diameter changes of the patients undergoing laparoscopic cholecystectomy will be measured throughout the surgery at different times using ocular tonometry and ultrasound, respectively.
41358593|NCT06479577|OTHER|ultrasound|ultrasound 1 MHZ continuous for 20 minute with routine physical therapy 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
41358594|NCT06479577|OTHER|high intensity laser therapy|905 nm super pulsed laser 40 minute session 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
41358595|NCT01924793|DRUG|DAS181-F02 Dry Powder in Bulk|Administered via DPI
41358596|NCT01924793|DRUG|DAS181-F02 Nebulized Formulation Inhaled Dose|Administered via Nebulizer
41358597|NCT03003429|OTHER|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
41358598|NCT01694459|DRUG|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
41358599|NCT01694459|DRUG|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
41358600|NCT03431467|DEVICE|Impella-CP LV Vent|Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
41358601|NCT00693524|DRUG|tacrolimus|oral
41497579|NCT05338606|DRUG|Bimatoprost Sustained Release Implant|Intraocular Implant
41497580|NCT02686138|DRUG|Tenapanor|
41497581|NCT02686138|DRUG|Placebo|
41497582|NCT05475886|DRUG|Hydroxyethyl starch 130/0.4|An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.
41497583|NCT01341782|DRUG|paricalcitol|
41497584|NCT01341782|DRUG|maxacalcitol|
41497585|NCT01341782|DRUG|paricalcitol placebo|
41497586|NCT01341782|DRUG|maxacalcitol placebo|
41497587|NCT04523935|OTHER|Placebo|Fructose powder identical with the drugs was used
41497588|NCT04523935|DRUG|Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.|Drugs were used either singly or in combination guided by clinical findings and investigations.
41497589|NCT01865240|DEVICE|Renal Denervation|Renal Denervation Catheter
41497590|NCT01195792|DRUG|GSK1521498|GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
41497591|NCT01195792|DRUG|Placebo|Placebo will be given for up to 35 days and subjects will be assessed weekly
41497592|NCT06181708|OTHER|N/A - Questionnaire based study|Questionnaire based study
41023569|NCT04334603|OTHER|Exercise Training Program|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
41023570|NCT05616130|OTHER|Data Collection|Researcher will collect data from subject's medical records: information regarding your medical history, trauma injury, heart rate, blood pressure, temperature (vital signs), use of antibiotics (medications used to treat infection) and other medications, development of infection, and treatment results will be recorded and kept with your research records. Demographic information (such as name, address, phone number, gender, race, height and weight, age and birth date), medical record notes (including but not limited to history and physical exam notes, progress notes, consultation reports, laboratory test results, operative reports, information relating to acquired immunodeficiency virus (HIV) infection, radiologic (x-ray studies) results, and blood samples)
41023571|NCT05616130|PROCEDURE|Bone marrow collection and blood collection|At time of scheduled surgery, researcher will collect a 20ml (approximately 4 teaspoons) sample of bone marrow while you are in the operating room receiving surgery for your orthopedic (bone) injuries or elective hip repair. Blood collection will occur at time of surgery, day 14 on study or discharge from hospital and at 3 and 6 months. Up to 58 ml (about 4 tablespoons) sample of blood will be collected from an existing intravenous line or peripheral needle stick.
41023572|NCT05616130|OTHER|Serial interviews to complete surveys and questionnaires|Participants will be asked to complete questionnaires and surveys that assess your health, quality of life, daily living activities, and mobility. These activities occur at enrollment, day 14 in hospital or discharge, and at the 3, 6, and 12-month visits.
41023573|NCT05616130|OTHER|Telephone follow up call|The study team will contact you at 12 months to complete a telephone interview to learn about your health and well being.
41023574|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
41023575|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
41023576|NCT00961259|DRUG|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
41023577|NCT00029835|DRUG|Rimonabant (SR141716)|
41023578|NCT01316627|BEHAVIORAL|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
41023579|NCT01316627|BEHAVIORAL|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
41023580|NCT03539380|DRUG|TRx0237|Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)
41023581|NCT03178071|DRUG|Lorlatinib|oral tablets, administered daily, continuously
41023582|NCT00093145|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
41023583|NCT00093145|DRUG|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
41023584|NCT00093145|DRUG|Herceptin®|Administered by IV infusion
41023585|NCT04989998|DEVICE|Hip7 Software on Kick/ CORI platforms|Total hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants.
41023586|NCT04989998|DEVICE|Conventional surgical procedures|THA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants.
41023587|NCT02578485|DEVICE|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
41023588|NCT02578485|DEVICE|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
41023589|NCT02578485|DEVICE|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
41023590|NCT02578485|DEVICE|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
41023591|NCT02578485|DEVICE|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
41358602|NCT00693524|DRUG|Anti-IL2R AB|i.v.
41023592|NCT00242034|PROCEDURE|CT and MRI with contrast|
41358603|NCT00693524|DRUG|Mycophenolate mofetil|oral
41358604|NCT00693524|DRUG|prednisone|oral
41023593|NCT00667784|BEHAVIORAL|Questionnaire|Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
41023594|NCT02048956|OTHER|Hydrotherapy intervention|Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.
41358605|NCT02168816|DRUG|Intravenous Antibacterial Agent|Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
41358606|NCT02168816|DRUG|Oral Antibacterial Agent|Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
41358607|NCT02159911|DRUG|Misoprostol administered orally one hour before surgery|"Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient."
41358608|NCT00809627|DRUG|Caffeine|Caffeine 500 mg IV
41358609|NCT00809627|DRUG|saline|Normal saline
41023595|NCT02048956|OTHER|Control group|Standard exercises of hydrotherapy
41023596|NCT02737566|BEHAVIORAL|Standard Care + Financial Incentives|Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
41023597|NCT02737566|OTHER|Standard Care|Tobacco cessation counseling plus pharmacotherapy.
41023598|NCT04574895|OTHER|Hematology Review|VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
41023599|NCT02881281|OTHER|educational program for Development of problem-solving skills|
41023600|NCT02881281|OTHER|no education program|no education program
41023601|NCT01301963|DRUG|plerixafor|Given SC
41023602|NCT01301963|BIOLOGICAL|filgrastim|Given SC
41023603|NCT01842009|DEVICE|High Definition transcranial Direct Current Stimulation|
41023604|NCT01605045|OTHER|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
41023605|NCT01605045|OTHER|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
41023606|NCT00759967|PROCEDURE|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
41023607|NCT00759967|PROCEDURE|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
41023608|NCT00165724|DRUG|Donepezil Hydrochloride|
41023609|NCT01506245|BEHAVIORAL|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
41023610|NCT05915065|DEVICE|Coapt Phantom Limb Pain Management System|The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
41023611|NCT05133648|PROCEDURE|Hip Fracture Surgery|Hip fracture surgery
41023612|NCT05133648|OTHER|COVID-19 infection|COVID-19 infection
41023613|NCT04306224|BIOLOGICAL|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
41358614|NCT05529927|DRUG|Sustained-release Dexamphetamine|"During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period."
41358615|NCT05529927|DRUG|Placebo|"Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group."
41358616|NCT01100203|DRUG|Eplerenone|25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
41358617|NCT01353976|DRUG|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
41358618|NCT01353976|OTHER|Vehicle Foam|Vehicle foam applied once a day for 4 weeks
41358619|NCT05231551|PROCEDURE|Placental tissues|Placental tissues are collected after aspiration of abortion products. They are treated immediately in order to isolate placental stem cells. Organoid culture is established and the obtained embryoids are cultured in monophasic or biphasic oxygen conditions. Extra organoids are cryopreserved in liquid nitrogen
41358620|NCT03136029|DIETARY_SUPPLEMENT|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
41358621|NCT03136029|DIETARY_SUPPLEMENT|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
41358622|NCT03136029|OTHER|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
41023614|NCT05955638|DEVICE|MiSight contact lenses|Contact lens for myopia management.
41023615|NCT05955638|DEVICE|Proclear contact lenses|Single vision contact lens as control
41023616|NCT05025293|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|100ml Zoledronic acid (5mg/100ml) administered intravenously
41023617|NCT05025293|DRUG|sodium chloride|100ml NaCl 9mg/ml administered intravenously
41023618|NCT02972697|RADIATION|11C-acetate ligand|
41023619|NCT02972697|RADIATION|FDG ligand|
41160623|NCT06170502|DEVICE|Using the mobile application and applying the survey|"In the study, The Form for Determining the Educational Needs of Parents Administering Medicines at Home, Introductory Information Form, Parental Drug Preparation Information Evaluation Form, Parent Evaluation Form in Suspension Drug Administration, Capsule Drug Application Parent Evaluation Form, developed by the researchers in line with the literature, Tablet Pharmaceutical Application Parent Evaluation Form, Mobile Application Usability Questionnaire, AkilMobil Expert Opinion Evaluation Form and STAI State Anxiety Inventory developed by Spielberger et al. will be used."
41160624|NCT04494243|DRUG|AD-214 10/600mg|1 tablet administered before the breakfast during 7 days
41160625|NCT04494243|DRUG|Rabeprazole 10mg|1 tablet administered before the breakfast during 7 days
41358623|NCT02017366|OTHER|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
41358624|NCT02438111|GENETIC|metagenome|metagenome
41358625|NCT02603380|OTHER|No intervention|This is an observational study. No intervention will be given.
41358626|NCT00986817|DRUG|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
41023620|NCT05476003|PROCEDURE|Ultrasound-guided Bilateral superficial cervical plexus block|"This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus."
41358627|NCT00986817|DRUG|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
41358628|NCT01489332|DRUG|intensified preoperative chemotherapy|"capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).~Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery"
41023621|NCT05476003|DRUG|Midazolam|All patients will be premedicated with Midazolam (0.02mg/Kg).
41023622|NCT02415816|PROCEDURE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
41358629|NCT03081494|DRUG|spartalizumab (PDR001)|100 mg lyophilisate in vial received 400 mg every 4 weeks
41358630|NCT03081494|DRUG|regorafenib|120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
41358631|NCT05836428|OTHER|no intervention|no intervention
41358632|NCT04313595|DEVICE|RespirHó|"The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject ."
41358633|NCT01062516|DRUG|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
41358634|NCT01062516|DRUG|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
41358635|NCT02998931|DRUG|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
41358636|NCT02998931|OTHER|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours
41358637|NCT03770078|DEVICE|Test Product A|The test product is a newly developed ostomy product
41358638|NCT03406806|OTHER|Gaitbox|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
41358639|NCT03406806|OTHER|SprintSystem device|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
41023623|NCT05171569|DEVICE|Virtual care with remote automated monitoring (RAM)|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
41023624|NCT02109055|OTHER|Pilates|The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
40838773|NCT01030874|OTHER|Drug Recommendations|The protocol permits the study physician to recommend medications for orthostatic hypotension. The patient's clinical team can implement, ignore, or modify these recommendations and only the clinical team can write orders for them. Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily \[Mukai 2002; Grubb 2003\]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily \[Low, 1997\]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
40838774|NCT03168360|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
40838775|NCT01107223|OTHER|Experimental: Training to antibiotic prescription|GPs assigned to the intervention group attended a two days didactic educational meeting on evidence-based guidelines for diagnosis and treatment of acute respiratory tract infection.
40838776|NCT01107223|OTHER|No education on antibiotic prescription rules.|GPs assigned to control group received no specific recommendations on antibiotic prescription.
40838777|NCT04172467|OTHER|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
40838778|NCT01934309|BEHAVIORAL|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
41023625|NCT02109055|OTHER|Conventional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
41023626|NCT05447169|DIAGNOSTIC_TEST|EBV antibodies test|ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma
41023627|NCT05447169|DIAGNOSTIC_TEST|EBV DNA test|quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma
41023628|NCT03542227|OTHER|First-void urine collection|Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.
41023629|NCT03542227|OTHER|Blood draw|Blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
41358640|NCT03406806|OTHER|NIH toolbox 4 meter walk|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
41358641|NCT03670927|OTHER|Environmental, occupational and lifestyle-related exposures|A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
41358642|NCT06205459|PROCEDURE|deep marginal acquisition using thermacut bur|thermacut bur is a tool which doesn't contain any abrasives so it is much safer on the root surface of both prepared and adjacent teeth, and yields better treatment outcome in cases when exposing deep margins is needed.
41023630|NCT02983955|DEVICE|UPnRIDE Powered Wheelchair|The UPnRIDE Powered Wheelchair device is a product which changes people position from sitting to standing and standing to sitting. The product provides indoor and outdoor mobility.
41358643|NCT05709470|OTHER|No-intervention|Observational cross-sectional study design with no intervention
41023631|NCT02256046|DEVICE|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
41358644|NCT00526227|DEVICE|Secura ICD|Secura Implantable Cardioverter Defibrillator (ICD) will be implanted
41358645|NCT00515866|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
41358646|NCT00515866|DRUG|Gemcitabine|intravenous injection
41358647|NCT01287403|OTHER|Refined wheat flour|A treated cereal flour mixed with milk.
41358648|NCT01287403|OTHER|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
41358649|NCT01287403|OTHER|Wholegrain wheat flour|A treated cereal flour mixed with milk.
41358650|NCT01287403|OTHER|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
41358651|NCT01287403|OTHER|Wholegrain barley flour|A treated cereal flour mixed with milk.
41358652|NCT01287403|OTHER|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
41358653|NCT01674868|DRUG|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
41358654|NCT01674868|DRUG|placebo|subjects will take one pill po daily for 90 days.
41358655|NCT04997291|DRUG|Dexrazoxane|Twelve enrollees will be consecutively assigned to a dosing regimen of 400 mg/m2/dose. The medication will be administered in the operating room 30 minutes prior to starting cardiopulmonary bypass (dose #1), prior to aortic cross clamp removal (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3).
41358656|NCT04201444|DIAGNOSTIC_TEST|Patient group|Patients with Cushing Disease (CD) receiving a medical treatment: n = 30 Plasmatic cortisol UFC Urine biocollection Salive biocollection
41358657|NCT04201444|DIAGNOSTIC_TEST|Remission control group|Patients in remission of CD and having recovered a normal pituitary function for at least 12 months following pituitary surgery (normal UFC associated to: cortisol suppression following dexamethasone suppression test, or normal LNSC, or midnight serum cortisol \< 200 nmol/L) n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
41358658|NCT04201444|DIAGNOSTIC_TEST|Bilateral surrenalectomy control group|Patients with previous CD, treated with bilateral adrenalectomy and receiving weight adjusted doses of hydrocortisone for at least 6 months. Last daily dose of Hydrocortisone should be administered no later than 5 pm. n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
41358659|NCT01782976|DRUG|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
41358660|NCT01782976|DRUG|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
41358661|NCT01782976|BEHAVIORAL|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
41358662|NCT04600115|DRUG|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
41358663|NCT04600115|DRUG|Regadenoson|0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
41358664|NCT04600115|DRUG|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
41358665|NCT04600115|DEVICE|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
41023632|NCT04453592|OTHER|No intervention assigned as part of this study.|"The intervention included in this study is part of routine medical care, and not assigned as a result of study participation. This study includes only the addition of a measurement; the bent knee fall out test. Therefore, we believe this study design is observational, and in line with the provided observation study design definition: Observational: studies in human beings in which biomedical and/or health outcomes are assessed in predefined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.~See uploaded study protocol for further details."
41023633|NCT03634579|DEVICE|MRI Guided Focal Laser Interstitial Thermal Ablation|"The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps."
41023634|NCT00931021|DRUG|Varenicline (Chantix)|2 mg
41023635|NCT00931021|DRUG|Nicotine Patch|21 mg
41023636|NCT01038921|DRUG|Melatonin|8 mg dose of Melatonin
41023637|NCT01038921|DRUG|Placebo|Placebo
41358666|NCT04600115|DEVICE|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
40838779|NCT02396394|BEHAVIORAL|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is \<95%.
41358667|NCT02132312|DRUG|OMS302|
41358668|NCT02132312|DRUG|Phenylephrine HCl|
41358669|NCT02572492|DRUG|Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|"All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 \> 2.0 m CD34+ stem cells/kg body weight on day 0"
40838780|NCT05515289|DRUG|SHR6390|SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.
40838781|NCT04589143|DRUG|Agomelatine|Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks
40838782|NCT04589143|DRUG|Placebos|Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
40838783|NCT04325230|DEVICE|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
41358670|NCT02572492|DRUG|Carfilzomib/dexamethasone maintenance|Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
41358671|NCT02572492|DRUG|Observation without carfilzomib/dexamethasone maintenance|Observation without carfilzomib/dexamethasone maintenance
40838784|NCT02049619|DEVICE|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
41023638|NCT03440632|DEVICE|FES|Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
40838785|NCT04367597|DEVICE|Home-based Neuromuscular Electrical Stimulation (NMES) therapy|A home-based NMES treatment applied by the subjects daily
40838786|NCT01401699|DEVICE|Optical Frequency Domain Imaging (OFDI)|Optical Frequency Domain (OFDI) imaging of esophagus
40838787|NCT01725243|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
41023639|NCT03985813|BEHAVIORAL|Screening Wizard|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
41023640|NCT05825287|OTHER|Trained by teaching back method|in chemotherapy symptom management training, 2 groups will be created and a group will be given normal symptom management training, and the other group will be trained by teaching back method to assess the symptom control and quality of life after the chemotherapy training that patients have received and evaluate the effect of the teaching back method
41023641|NCT05825287|OTHER|Management training|Management training
41023642|NCT03294447|BEHAVIORAL|Fall Prevention by the Occupational Therapist|The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
41023643|NCT01646034|DRUG|carboplatin, thiotepa, and cyclophosphamide|tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
41023644|NCT01646034|DRUG|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)|"* chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~* chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~* previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~* previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
41023645|NCT02973451|DRUG|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
41023646|NCT02973451|DRUG|local Bupivacaine|Bupivacaine Trocar Site Infiltration
41023647|NCT05658692|DEVICE|protective ventilation|Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.
41023648|NCT05658692|BEHAVIORAL|prone position ventilation|patients with moderate to severe ARDS who don't have contraindications were given prone ventilation for over 12 hours.
41023649|NCT05658692|DRUG|glucocorticoid therapy|"Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.~Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours)."
41358672|NCT01497002|DRUG|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
41358673|NCT01497002|BIOLOGICAL|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
40838788|NCT00921310|DRUG|Pemetrexed|
40838789|NCT00921310|DRUG|Temsirolimus|
40838790|NCT00944463|DRUG|Gemcitabine+simvastatin|Gemcitabine and simvastatin
40838791|NCT00944463|DRUG|Gemcitabine+Placebo|Gemcitabine plus Placebo
40838792|NCT00026377|DRUG|bicalutamide|50 mg daily for 1 month
40838793|NCT00026377|DRUG|flutamide|250 mg 3 times daily for 1 month
41023650|NCT05658692|OTHER|restrictive fluid resuscitation|"1. without other organ dysfunction patients: Minimize fluid was given;~2. other ARDS patients: In the resuscitation phase, controlled fluid replacement combined with vasoactive drugs was given; multiple measures were taken, like lactate and so on, to utilizedto guide fluid resuscitation therapy; diuretics or diuretics in combination with albumin to achieve fluid balance."
41023651|NCT05658692|BIOLOGICAL|Thymosin Alpha|People received thymosin Alpha subcutaneous injections, twice a week.
41023652|NCT05658692|DRUG|Muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
40838794|NCT00026377|DRUG|goserelin acetate|3.6 mg once a month for 4 months
40838795|NCT00026377|DRUG|leuprolide acetate|7.5 mg once a month for 4 months
41023653|NCT05658692|OTHER|Integrated Chinese and Western Medicine Treatment|"1. ventilation;~2. conventional western medicine treatment；~3. Chinese herbal medicine（Determining medication based on syndrome differentiation）"
41023654|NCT05658692|DRUG|statin therapy|"1. Simvastatin: 80mg qd po for not more than 28days;~2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died."
41023655|NCT05658692|COMBINATION_PRODUCT|anti-infective treatment|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
40838796|NCT00026377|DRUG|SU5416|IV infusion at assigned dose
40838797|NCT00026377|RADIATION|radiation therapy|daily for 5 days each week
40838798|NCT03757754|DRUG|HPPH 2.5 mg/m2|HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
40838799|NCT03757754|DRUG|HPPH 3 mg/m2|HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
40838800|NCT03757754|DRUG|HPPH 3.5 mg/m2|HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
40838801|NCT03757754|DRUG|HPPH 4 mg/m2|HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
41023656|NCT05658692|DEVICE|Extracorporeal Membrane Oxygenation（ECMO）|"1. For severe ARDS patients with refractory hypoxemia within 7 days of onset;~2. (Inspiratory oxygen concentration) ≥ 0.80, tidal volume 6ml/kg (PBW), positive end-expiratory pressure \[PEEP\] ≥ 10 cmH2O;~3. V-V Model."
41023657|NCT05658692|GENETIC|stem cell therapy|A single injection of bone marrow stem cells, doses of 1, 5, 10\*106 cells/kg was taken according to the previous clinical studies.
41023658|NCT05658692|DRUG|Sedative analgesia/muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
41023659|NCT05658692|DRUG|inotropes therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
41023660|NCT05658692|DRUG|Vasoactive drug therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
41023661|NCT00058305|DRUG|bryostatin 1|Given IV
41023662|NCT00058305|DRUG|vincristine sulfate|Given IV
41023663|NCT00058305|OTHER|laboratory biomarker analysis|Correlative studies
40838802|NCT03757754|DRUG|HPPH 5 mg/m2|HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
40838803|NCT03757754|DRUG|HPPH 6 mg/m2|HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
40838804|NCT02083887|BIOLOGICAL|ChAd63 ME-TRAP / MVA ME-TRAP|Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu
41023664|NCT03981406|BEHAVIORAL|Palliative Care|The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
41023665|NCT03981406|BEHAVIORAL|Standard of Care|Control group will receive standard of care treatment for IPF.
41023666|NCT00111943|DRUG|1% tenofovir gel|
41023667|NCT01176591|DRUG|Placebo session 1, Aprepitant session 2|placebo in session 1, Aprepitant 80 mg in session 2, oral administration.
41023668|NCT01176591|DRUG|Placebo session 1, Placebo session 2|Placebo, one per session, oral administration
41023669|NCT02566837|PROCEDURE|Ultrasound|ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
41023670|NCT02566837|PROCEDURE|electrical stimulation|electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
40838805|NCT01610986|DIETARY_SUPPLEMENT|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
40838806|NCT01610986|DIETARY_SUPPLEMENT|Water|Only water intake during training
40838807|NCT02002572|OTHER|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
40838808|NCT00208520|DRUG|Carbamazepine|
40838809|NCT00208520|DRUG|Lamotrigine|
41358674|NCT00623753|BIOLOGICAL|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
41358675|NCT03607435|DEVICE|Spectroscopy for Analyte Quantification|Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
41358676|NCT00327834|DRUG|atomoxetine|
41358677|NCT01353521|PROCEDURE|Contrast-enhanced ultrasound|A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
41358678|NCT06162429|PROCEDURE|Flexible Bronchoscopy|Subjects with pleural effusion who underwent medical thoracoscopy using flexible bronchoscopy
41358679|NCT06162429|PROCEDURE|Semi-Rigid Pleuroscopy|Subjects with pleural effusion who underwent medical thorascopy using semi-rigid pleuroscopy
41358680|NCT00347685|DRUG|tramadol ER|
41358681|NCT03223649|OTHER|Walking Bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
41358682|NCT03223649|OTHER|Sedentary|(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
40838810|NCT00208520|DRUG|Levetiracetam|
41497593|NCT04559737|OTHER|Case Management|"Population management platforms capable of automatically risk stratifying patients (eg, automatically identifying poor users) may be another cost-effective technology-based tool by enabling a management by exception (MBE) follow-up intervention. This intervention concentrates provider effort on patients most at need by allowing providers to passively observe successful users and actively intervene only in CPAP strugglers. Therefore, in addition to Usual Care we will implement this population management process by identifying CPAP strugglers only and further follow-up encounters will be triggered for these select patients for troubleshooting. Additionally, throughout the 1-year period, Q1 window of \<70% nights \>4 hours will trigger a phone call and at the discretion of the sleep provider convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year."
41497594|NCT03045991|BEHAVIORAL|aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
40838811|NCT00676910|DRUG|JNJ-26854165|
41497595|NCT03045991|BEHAVIORAL|control training|The control training program will receive 30 minutes non-aerobic exercise training, including stretching muscle skills, joint mobility exercises; in addition to one 30-minute session of unstructured mental activities, such as reading books or reading educational films.
41497596|NCT03045991|BEHAVIORAL|cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
41497597|NCT01350583|DRUG|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
41497598|NCT05062213|OTHER|Moisturizer Body Lotion|Moisturizer Body Lotion
40838812|NCT04166760|DIETARY_SUPPLEMENT|speWHE|25 gram of a specific whey fraction (confidential)
40838813|NCT04166760|DIETARY_SUPPLEMENT|WHE|25 gram protein of a regular whey compound
41497599|NCT05180357|OTHER|FASENRA(benralizumab)|This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
41497600|NCT05419609|PROCEDURE|Limited facelift|A limited procedure under local anesthesia that addresses signs of aging in the lower face and neck
41497601|NCT05419609|PROCEDURE|Full facelift|A full face and neck lift that addresses signs of aging in the face and neck
40838814|NCT02454153|DEVICE|REMStar Positive Airway Pressure|Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
40838815|NCT02454153|BEHAVIORAL|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
40838816|NCT05910567|DIAGNOSTIC_TEST|Focused Assessment with Sonography for Trauma (FAST) Examination|A bedside Focused Assessment with Sonography for Trauma (FAST) Examination will be conducted on those participants who are randomized to the FAST arm.
40838817|NCT05910567|OTHER|No Intervention: Standard of Care - Without the FAST Examination|Participants randomized to usual care will be evaluated per the standard operating procedures of the institution/site for the condition under study without the FAST exam.
40838818|NCT05322330|DRUG|Selinexor|40-60mg QW,w-3～d-3,PO
40838819|NCT05322330|DRUG|Flu|25-30 mg/m2，d-5 ～d-3，qd，ivgtt
40838820|NCT05322330|DRUG|CTX|250-500 mg/m2，d-5 ～d-3，qd，ivgtt
40838821|NCT05322330|DRUG|CAR-T|2-5×10\^6 CAR-T/kg，ivgtt。
41358683|NCT05707104|OTHER|Pilates Exercises|"NO. Exercises Targeted muscles Repetitions~1. Pelvic curl Abdominals, Hamstrings \& Quadriceps Femoris, Gluteus Maximums. 05~2. Chest lift Rectus Abdominus, Internal \& External Oblique Muscles 10~3. Leg lift supine Quadriceps Femoris, Internal \& External Oblique Muscles 10~4. Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal \& External Oblique Muscle 10~5. Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~6. Spine twist supine Abdominals,Quadriceps \& Hamstring group of Muscles 10~7. Chest lift with rotation Internal \& External Oblique, Rectus \& Transverses Abdominus Muscles 5 on each side~8. Back extension BACK EXTENSION Abdominal group, Gluteus Maximus \& Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds"
41358684|NCT05707104|OTHER|plyometrics exercises|"1. SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~2. SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~3. DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~4. DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~5. LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~6. DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6"
41358685|NCT05650827|BEHAVIORAL|Resistance training|10 weeks of resistance training 3 times pr. week.
41358686|NCT05650827|DIETARY_SUPPLEMENT|Protein supplement|A daily supplement of protein to ensure a daily intake of 1,6g protein/kg bodyweight
41358687|NCT05671029|DRUG|Pritelivir and moxifloxacin placebo|oral administration
41358688|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin and moxifloxacin placebo|oral administration
40838822|NCT04556318|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
40838823|NCT01113346|DRUG|Filtrum-STI (lignin hydrolytic)|"For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days."
40838824|NCT01113346|DRUG|Placebo|"For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days."
41023671|NCT05718908|DIETARY_SUPPLEMENT|Food supplement|FibrofixPlus® is an authorized food supplement.
41023672|NCT04541381|OTHER|Availability of clinical decision support based on pharmacogenomic results.|Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
41358689|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin placebo and moxifloxacin|oral administration
41358690|NCT05870891|OTHER|Food|Food
41358691|NCT03920046|BEHAVIORAL|Control Group|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents no smoking.
41358692|NCT00730665|DRUG|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
41358693|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
41358694|NCT00730665|DRUG|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
41358695|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
41358696|NCT00730665|DRUG|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
41358697|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
40838825|NCT04463849|DIAGNOSTIC_TEST|Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection|"All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.~The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols."
40838826|NCT03027232|OTHER|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
41023673|NCT01383941|DRUG|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
41358698|NCT00730665|DRUG|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
41358699|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
41023674|NCT06275100|OTHER|Prehabilitation|"Participants will be exposed to exercise and psychoeducation. Aerobic exercise will be on a cycle ergometer tailored to their capability and will aim for a low to moderate intensity.The patients will be exercised using the intermittent protocol of alternating 1 minute moderate and 1 minute low intensity aerobic exercise. This duration can be gradually increased during subsequent sessions depending on the patient's ability. Aerobic exercise will be conducted 2- 3 times per week depending on patient's ability.~In addition, participants are expected to do strength and inspiratory muscle training in their own time.~The psychoeducation booklet and audio are designed with input from in-house clinical psychologist. The aim of the booklet is to explain the emotions they may feel whilst being in hospital, symptoms of anxiety, suggest how to manage anxiety, behavioural strategies that may help and signposting if they require further support."
41023675|NCT05339685|DRUG|BL-M02D1|Administration by intravenous infusion
41023676|NCT06211582|DEVICE|Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)|The Alkasite-Based Tooth-Colored Material
41023677|NCT06211582|DEVICE|Equia Forte HT ( GC, Tokyo, Japan)|Glass Hybrid Restorative Material
41358700|NCT00730665|OTHER|Placebo|Capsule, Placebo, every 12 hours (twice a day)
41358701|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
41358702|NCT03102073|DIAGNOSTIC_TEST|Radner test|"* The A5 reading booklet is held by the subject~* The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~* The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~* One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~* Stop criterion: reading time longer than 20 seconds or severe errors."
41358703|NCT01896596|BIOLOGICAL|Menjugate|Administered with routine vaccinations at 3 months of age
41497602|NCT05419609|OTHER|"FACE-Q | Aesthetics - Satisfaction With Lower Face and Jawline"|"Completed by patients. The FACE-Q \| Aesthetics - Satisfaction With Lower Face and Jawline is a 5-item questionnaire. Each item is rated 1-4, with 1 being Very Dissatisfied and 4 being Very Satisfied. Lower scores suggest the person may be less pleased with the appearance of their lower face and jawline."
41497603|NCT05419609|OTHER|"FACE-Q | Aesthetics - Recovery Early Symptoms"|"Completed by patients. The FACE-Q \| Aesthetics - Recovery Early Symptoms is a 17-item questionnaire. Each item is rated 1-4, with 1 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms early in their recovery following an aesthetic facial procedure."
41023678|NCT06211582|DEVICE|Gradia Direct Posterior ( GC, Tokyo, Japan)|Conventional Composite Resin
41023679|NCT02304237|DRUG|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
41358704|NCT01896596|BIOLOGICAL|Menitorix|Administered with routine vaccinations at 3 months
41358705|NCT01896596|BIOLOGICAL|NeisVac-C|Administered with routine vaccinations at 3 months
41358706|NCT01749930|DRUG|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
41358707|NCT01749930|DRUG|Timolol|Timolol will be administered BID once in the morning and once in the evening.
41358708|NCT01749930|DRUG|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
41358709|NCT02677506|PROCEDURE|Supraclavicular|Brachial plexus block with supraclavicular approach
41358710|NCT02677506|PROCEDURE|Infraclavicular|Brachial plexus block with infraclavicular approach
41358711|NCT03042663|PROCEDURE|USG stellate ganglion block|After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
41358712|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
41358713|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
41023680|NCT02304237|DRUG|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
41023681|NCT06574139|BEHAVIORAL|Unstained|Unstained is an individual-level, virtual intervention that involves three \~60-minute sessions delivered over a 3-6 week period. Each session includes watching two videos (six videos total), followed by a discussion facilitated by study coordinators.
41023682|NCT06574139|BEHAVIORAL|Like|Like is an hour-long film that discusses the impact of social media on the brain. Participants will receive a link to the film and will be asked to watch it independently. The film does not include information related to the outcomes of interest for the study.
40838827|NCT05046691|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
40838828|NCT00507273|OTHER|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
40838829|NCT02909855|OTHER|No intervention|Participants in this study will not receive any interventions as part of the study.
40838830|NCT04469348|DIAGNOSTIC_TEST|nasal swab|nasal swab will be performed to analysis biological markers at every visit.
40838831|NCT05978102|DRUG|STI-7349|Administered by intravenous infusion (IV)
40838832|NCT05978102|DRUG|Pembrolizumab|Administered by intravenous infusion (IV)
40838833|NCT05978102|DRUG|Standard treatment（SoC）|Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines.
40838834|NCT00792532|PROCEDURE|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
40838835|NCT00792532|DEVICE|DBS electrodes|Deep brain stimulation (DBS) electrodes
40838836|NCT03235219|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
41023683|NCT05806762|DEVICE|BioIntellisense|Enrolled patients will have a Fitbit placed on their wrist. There is no comparator group enrolled.
41023684|NCT05442411|DRUG|Ropivacaine 0.75% Injectable Solution|comparison of scalp block vs conventional post operative parecoxib
41023685|NCT03634592|PROCEDURE|Catheter ablation|Radiofrequency catheter pulmonary vein isolation
41023686|NCT01023126|BEHAVIORAL|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
41358714|NCT01248923|DRUG|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
41358715|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
40838837|NCT03235219|DRUG|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
40838838|NCT02671565|DRUG|Hyaluronic Acid injections|
40838839|NCT02759315|DRUG|Uprifosbuvir 450 mg|450 mg administered as 3 x 150 mg oral tablets
40838840|NCT02759315|DRUG|Ruzasvir 60 mg|60 mg administered as 6 x 10 mg oral capsules
40838841|NCT01699711|DIETARY_SUPPLEMENT|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
40838842|NCT04025177|DRUG|Indomethacin Injection|The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.
41358716|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
41358717|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
41358718|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
41358719|NCT00564759|DRUG|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
41358720|NCT01442545|DRUG|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
41358721|NCT01503567|OTHER|No treatment given|Subject will only fill out a questionaire
41358722|NCT03757936|DRUG|HLX04|Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
41358723|NCT03757936|DRUG|HLX10|Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
41023687|NCT06420635|BEHAVIORAL|Interdisciplinary intervention program on maternal self-efficacy and the motor development of premature children|The experimental group will receive an intervention about maternal self-efficacy and motor stimulation strategies for premature children applied by mothers. There will be two face-to-face meetings: the first with a theoretical session on motor development, a practical workshop on stimulation skills using a baby simulator and strengthening of maternal self-efficacy. The second meeting seeks for mothers to reflect on self-efficacy and carry out practical simulation of strategies with their children. At home (for four weeks), self-efficacy will be strengthened through 4 strategies twice a week, for 8 sessions. Mothers will put into practice with the baby the 10 stimulation strategies explained in the face-to-face sessions, must complete 14 sessions per week, 2 times a day, for a total of 56 sessions. The initial measurement will be carried out before the intervention, the second at 4 weeks and the third at 8 weeks after the intervention began.
41023688|NCT06420635|BEHAVIORAL|Traditional kangaroo program|The control group will receive the conventional family-centered care plan, including kangaroo position, exclusive breastfeeding, and outpatient follow-up. The traditional intervention for the control group is based on the Kangaroo Mother Method (KMC) program, proposed according to technical guidelines, which promotes skin-to-skin contact between mother and premature baby. In periodic outpatient consultations, clinical assessments are carried out focused on optimal growth (goal 15-20g/kg/day), neurological and psychomotor development, and timely detection of pathologies that require specialized care according to findings. Compliance with the vaccination schedule and medical indications, and assurance of breastfeeding, are monitored. The frequency of check-ups is daily initially, then weekly until 40 weeks and then monthly. The approach includes early stimulation and follow-up until 12 months of corrected age.
41023689|NCT00191321|DRUG|Teriparatide|
41023690|NCT01911533|PROCEDURE|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
41023691|NCT01911533|PROCEDURE|No extracorporeal CO2-removal|Patients are their own control group.
41023692|NCT01306552|BEHAVIORAL|Student-Intervention only group|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.~The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
41023693|NCT01306552|BEHAVIORAL|Multi-component Intervention|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail"
41023694|NCT01306552|BEHAVIORAL|Control Group|"One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).~(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)"
41023695|NCT05407545|DEVICE|Current prosthesis|A unilateral transfemoral amputee will conduct experiments with the current prosthesis
41358724|NCT04879511|DRUG|metformin|Oral hypoglycemic drug metformin
41358725|NCT04879511|DRUG|Basal/bolus insulin|Basal/bolus insulin
41358726|NCT02475564|DRUG|Placebo|40mg of starch
41358727|NCT02475564|DRUG|Resveratrol|40mg of resveratrol (powder)
41358728|NCT01397409|DRUG|AGN-150998|AGN-150998 Intravitreal injection.
41358729|NCT01397409|DRUG|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
41358730|NCT01397409|OTHER|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
41358731|NCT02561273|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
41358732|NCT02561273|DRUG|Cyclophosphamide|Given IV
41358733|NCT02561273|DRUG|Doxorubicin Hydrochloride|Given IV
41358734|NCT02561273|DRUG|Etoposide|Given IV
41358735|NCT02561273|OTHER|Laboratory Biomarker Analysis|Correlative studies
41358736|NCT02561273|DRUG|Lenalidomide|Given PO
41358737|NCT02561273|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
41358738|NCT02561273|DRUG|Prednisone|Given PO
41358739|NCT02561273|DRUG|Vincristine Sulfate|Given IV
41358740|NCT02195349|BIOLOGICAL|GSK2831781|GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
41358741|NCT02195349|BIOLOGICAL|Placebo|Commercial saline solution administered by IV over approximately 2 hours
41358742|NCT02931357|DEVICE|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
41358743|NCT02931357|DRUG|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
41358744|NCT01619436|DRUG|Clonidine|bolus, clonidine 2 mg/kg IV
41023696|NCT05407545|DEVICE|Active Prosthesis (PowerKnee)|A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
40838843|NCT06282601|OTHER|Audiogram|Tonal and vocal free-field without lip-reading
40838844|NCT06282601|OTHER|Musical priming for the syntax test|Listening to music with a regular or irregular rhythm, then judging the grammaticality of 2x6 blocks of French sentences interrupted by a pause, each block presenting 4 sentences including 2 grammatically correct sentences and 2 grammatically incorrect sentences. The sentences are pronounced by a French female voice at a natural rhythm and comfortable volume.
41023697|NCT01164059|DRUG|Olanzapine|Olanzapine 10, 15, or 20 mg / day
41358745|NCT01619436|DRUG|Ringer lactato|1 ML ringer lactato IV, as placebo
41358746|NCT04542525|DEVICE|ACRYSOF IQ PanOptix Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism
41358747|NCT04542525|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
41358748|NCT06082011|DEVICE|da Vinci SP Surgical System|Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
41358749|NCT00596622|DRUG|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
41358750|NCT03929614|OTHER|MOBI validation|Final version will be distributed to 176 French speaking subjects, 30 of whom are randomly selected and will fill it a second time, at after 72 hrs. To consider of its kind, Moreover, the Bem Inventory for Children will be completed by everyone as well as the SF-12 and SRS-22.
41358751|NCT01500538|DRUG|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
41358752|NCT04524130|DRUG|Lidocaine Hydrochloride|lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.
41358753|NCT04524130|DRUG|Ketamine|Ketamine will be given 0.35 mg/kg bolus at induction then 0.2 mg/kg/hr until the end of surgery.
41358754|NCT04524130|DRUG|Placebo|Normal saline will be given with the same rate of lidocaine or ketamine.
41358755|NCT06154044|BIOLOGICAL|CD34+ stem cell therapy|After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
41497604|NCT05419609|OTHER|"FACE-Q | Aesthetics - Satisfaction with Outcome"|"Completed by patients. The FACE-Q \| Aesthetics - Satisfaction with Outcome is a 6-item questionnaire. Each item is rated 1-4, with 1 being Definitely disagree and 4 being Definitely agree. Lower scores suggest the person may be less pleased with their final appearance following surgery and the decision to have an aesthetic facial procedure."
41497605|NCT05419609|OTHER|"FACE-Q | Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck"|"Completed by patients. The FACE-Q \| Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck is a 15-item questionnaire. Each item is rated 1-3, with 1 being Not at all and 3 being A lot. Lower scores suggest the person may be experiencing fewer chronic symptoms following an aesthetic facial procedure."
40838845|NCT06282601|OTHER|Test MMSE|test to assess a person's cognitive functions and memory capacity.
41497606|NCT00969540|DEVICE|Active Mattress Cover|Active Mattress Cover
40838846|NCT06282601|OTHER|Barcelona Music Reward Questionnaire|"20 questions exploring 5 main facets of the musical reward experience, with 4 items for each of the 5 facets, for which participants indicate the level of agreement using a 5-level scale, ranging from strongly disagree to strongly agree."
41358756|NCT03979131|COMBINATION_PRODUCT|Avelumab addition to perioperative chemotherapy in GC and GEJC|Avelumab addition to perioperative chemotherapy in GC and GEJC. Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year. There will be be a follow-up of 5 years.
40838847|NCT00469326|DRUG|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
41497607|NCT00969540|DEVICE|Placebo Mattress Cover|Placebo Mattress Cover
40838848|NCT05200689|DEVICE|Kinesiotaping (KT)|"Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin."
40838849|NCT04784468|OTHER|No intervention|Case-control design, one single investigation
40838850|NCT02004977|BEHAVIORAL|Improve access to the school breakfast program|Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
41023698|NCT01164059|DRUG|Flupentixol|Flupentixol 6, 9, or 12 mg / day
41023699|NCT01164059|DRUG|Quetiapine|Quetiapine 400, 600, or 800 mg / day
41023700|NCT01164059|DRUG|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
41023701|NCT01164059|DRUG|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
41358757|NCT01858675|OTHER|Biomarkers, red blood cells and plasma assessment|
41358758|NCT02738073|DRUG|Control: Saline|
41358759|NCT02738073|DRUG|Tranexamic Acid|
41497608|NCT04007991|DRUG|Ecopipam|Ecopipam HCI tablets administered PO to establish 2 mg/kg/day
41023702|NCT01920295|DEVICE|Cryoballoon ablation|
41023703|NCT02908568|DEVICE|Spring device|Brisk dilatation of fhe mouth.
41497609|NCT04007991|DRUG|Placebo|Matching Placebo
41497610|NCT01034254|BIOLOGICAL|influenza vaccine|Pregnant women will receive FDA approved influenza vaccine.
41497611|NCT01034254|BIOLOGICAL|saline placebo|Vaccination of pregnant women with saline placebo.
41497612|NCT05637619|DEVICE|Monolithic Zirconia|Maxillary or/and mandibular screw retained zirconia monolithic prostheses supported by at least 4 implants
41023704|NCT02908568|DEVICE|Mandible stimulator|Stimulation of fhe mouth.
41023705|NCT04471259|OTHER|Classification statistics|We classified patients by gender, age, recovery time,etc
41023706|NCT00002526|BIOLOGICAL|filgrastim|
41023707|NCT00002526|DRUG|doxorubicin hydrochloride|
41023708|NCT00002526|DRUG|ifosfamide|
41023709|NCT03195413|PROCEDURE|Ultrasound-guided forearm nerve block|An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
40838851|NCT05104541|OTHER|Weight loss|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
40838852|NCT02878044|OTHER|Thyroid Decision Aid|The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
41358760|NCT01343940|BEHAVIORAL|Project dulce|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation."
41023710|NCT03195413|DRUG|1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine|This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
41358761|NCT01343940|BEHAVIORAL|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
40838853|NCT05342337|OTHER|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management.~Telerehabilitation group participate in the sessions that last for one and a half hours, 3 days a week for 12 weeks, video conference over the Zoom program. The investigator, who provides supervision during the sessions, also participates in the exercises simultaneously."
41023711|NCT03195413|DEVICE|Bedside ultrasound machine|This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
41023712|NCT00439140|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
41023713|NCT00439140|DRUG|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
41023714|NCT02449824|OTHER|magnetic resonance imaging|early MRI
41358762|NCT00000721|DRUG|CD4 Antigens|
41358763|NCT04415931|PROCEDURE|Local infiltration analgesia|"Local infiltration injection intraoperatively prior to closing during the procedure. A standardized dose of 100 mL of infiltration will be utilized according to the following formula. The mixture will be injected into the deltoid and pectoralis major muscles and fasciae, and subcutaneous tissues using an 18-guage needle.~Total dose 100mL~Ropivacaine 0.5% 40mL Epinephrine 1mg/mL 0.1mL Ketorolac 30mg/mL 1mL Morphine 10mg/mL 0.5mL Normal saline 0.9% 58.4mL"
41023715|NCT01100177|DRUG|Sunitinib|Sunitinib 37.5mg/m2/d
41358764|NCT04415931|PROCEDURE|Interscalene block|Standard interscalene brachial plexus regional block
41358765|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil|20 g of coconut oil
41358766|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + MCT|10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)
41358767|NCT02679222|DIETARY_SUPPLEMENT|MCT|20 g of MCT (60 of C8+40 of C10)
41023716|NCT01100177|RADIATION|Radiation|Radiation therapy (60Gy) 2 Gy per day during 30 days
41023717|NCT06317805|DRUG|Generic treprostinil sodium + Standard of Care (Double Oral)|Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.
41023718|NCT06317805|DRUG|Standard of Care - Double Oral|All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
41023719|NCT06321705|DRUG|CS1|CS1 delayed release capsules will be supplied with 160 mg active pharmaceutical ingredient (API) per capsule. Three dose levels will be administered in this expanded access study at the same dose the patient received in the parent study (CS1-003) of 480 mg, 960 mg, or 1920 mg. All patients will later have the option to be titrated to the most efficacious and safe dose determined from the ongoing CS1-003 study when completed.
41358768|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + tricaprylin|10 g coconut oil + 10 g tricaprylin
41358769|NCT02679222|DIETARY_SUPPLEMENT|Tricaprylin|20 g tricaprylin
41358770|NCT02679222|DIETARY_SUPPLEMENT|Tricaprin|20 g tricaprin
41358771|NCT02679222|DIETARY_SUPPLEMENT|Control|No supplement taken on this visit
41358772|NCT03494140|DEVICE|Viscontour® Serum Med|Viscontour® Serum Med is a CE-certified preservative-free isotonic solution containing 5.0 mg sodium hyaluronate.
41358773|NCT02840760|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the primary motor cortex for 2 weeks.
41358774|NCT03942029|DRUG|LY3154207 Capsule|Administered orally as capsule
41358775|NCT03942029|DRUG|LY3154207 Tablet|Administered orally as tablet
41358776|NCT03942029|DRUG|Placebo|Administered orally as tablet
41358777|NCT03942029|DRUG|Fluconazole Tablet|Administered orally as tablet
40838854|NCT05342337|OTHER|Control group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
41358778|NCT00497744|DRUG|Intraperitoneal Cefepime|
41358779|NCT03682471|DRUG|Deoxycholic acid Injection|Solution for subcutaneous injection.
41358780|NCT03682471|DRUG|Placebo|Placebo, 10 mM sodium phosphate, 0.9% \[w/v\] sodium chloride in water for subcutaneous injection.
41358781|NCT03435289|DRUG|CPI 613 in Combination With Gemcitabine and Nab-paclitaxel|"Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min"
41358782|NCT02200510|BEHAVIORAL|Self-management intervention for Adolescents with SCD|Chronic Disease Self-Management Program
41358783|NCT02200510|BEHAVIORAL|Patient Portal Intervention for Adolescents with SCD|MyChart for SCD intervention
41497613|NCT05637619|DEVICE|Hybrid-Acrylic|Maxillary or/and mandibular screw retained hybrid prostheses supported by at least 4 implants;
41497614|NCT05637619|BEHAVIORAL|Dentate Patients|Dentate Patients with natural dentition or tooth supported crowns
41023720|NCT04368598|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)
40838855|NCT01893359|DRUG|riboflavin ophthalmic solution, 0% dextran|
40838856|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
40838857|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
40838858|NCT01893359|PROCEDURE|Laser-assisted in situ keratomileusis|
40838859|NCT02481713|BEHAVIORAL|motivational interviewing|motivational interviewing
40838860|NCT02481713|BEHAVIORAL|learning style interviews|interview and feedback about learning style
40838861|NCT06256653|DIETARY_SUPPLEMENT|Freeze-dried blueberries|"* Participants will be supplied with an 8-week supply of Study Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Study Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Study Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
40838862|NCT06256653|DIETARY_SUPPLEMENT|Placebo|"* Participants will be supplied with an 8-week supply of Placebo Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Placebo Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Placebo Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
40838863|NCT03976323|BIOLOGICAL|Pembrolizumab|IV infusion
41358784|NCT02422537|DIETARY_SUPPLEMENT|Unmodified wheat bran|
41358785|NCT02422537|DIETARY_SUPPLEMENT|Wheat bran with reduced particle size|
41023721|NCT04368598|DRUG|Acetylcysteine|Acetylcysteine, po, 400mg tid, for 4 weeks
40838864|NCT03976323|DRUG|Pemetrexed|IV infusion
40838865|NCT03976323|DRUG|Carboplatin|IV infusion
40838866|NCT03976323|DRUG|Cisplatin|IV infusion
40838867|NCT03976323|DRUG|Olaparib|Tablets
40838868|NCT01181024|DRUG|Placebo|matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
40838869|NCT01181024|DRUG|RO5303253|Cohorts receiving single ascending doses
40838870|NCT01181024|DRUG|RO5303253|Single dose
40838871|NCT01181024|DRUG|RO5303253|Multiple doses
40838872|NCT02325674|DRUG|Metreleptin|
40838873|NCT05204056|DRUG|iced normal saline|Iced normal saline (20ml) was given intraoperative joint cavity infusion therapy
40838874|NCT05204056|DRUG|Tranexamic acid injection|20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.
40838875|NCT05204056|OTHER|Cocktail (composing by Ropivacaine, Morphine and Epinephrine) perfusion|Cocktail was formulated during the operation by mixing Ropivacaine 150mg, Morphine 10mg and Epinephrine 1mg, then normal saline was used to dilute the mixture to 60ml. Then the cocktail mixture was applied for the joint cavity perfusion.
41497615|NCT06499857|DRUG|Semaglutide|3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.
41497616|NCT06499857|DRUG|Placebo|3ml pen-injector containing placebo solution for subcutaneous use.
41497617|NCT02586246|DRUG|CDP870|Self-injection
41497618|NCT05151783|OTHER|conventional physiotherapy|"Control group receivewill routine physical therapy including modalities like ultrasound (3 MHz continuous type; duration 10 minutes), heat modalities (apply to the involved region of shoulder joint shoulder for 10 minutes), shoulder ROM exercises, capsular stretching, and joint mobilization 5 times per week for four weeks. Duration of session will be 40 minutes.~All Maitland mobilization will be given in supine position. After giving glenohumeral (GH) joint distraction, GH caudal glide, GH dorsal glide, and GH ventral glide were given at a rate of 2-3/second oscillations for 1-2 minutes to patients. Grade I or II rhythmic oscillations will be applied in pain free movement."
40838876|NCT01081639|DRUG|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
41358786|NCT02422537|DIETARY_SUPPLEMENT|Destarched pericarp-enriched wheat bran|
40838877|NCT01081639|DRUG|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
41358787|NCT02422537|DIETARY_SUPPLEMENT|No wheat bran fraction|
40838878|NCT06064773|DIAGNOSTIC_TEST|thoracic USG|the confirmation of double lumen tube placement with thoracic USG in thoracic surgery operations with one lung ventilation.
41358788|NCT04854226|DIETARY_SUPPLEMENT|Macronutrients_CARB|Breast milk 150 to 170 mL/d; Target fortification: 9.0 g/100mL COH, 3.0 g/100mL protein, 4.0 g/100mL fat, 86.4 kcal/100mL
41358789|NCT04854226|DIETARY_SUPPLEMENT|Macronutrient_FAT|Breast milk 150 to 170 mL/d; Target fortification: 5.5 g/100mL COH, 3.0 g/100mL protein, 5.5 g/100mL fat, 86 kcal/100mL
41023722|NCT01963689|OTHER|Intervention Group 2|Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
41023723|NCT01963689|OTHER|Intervention Group 1|Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
41023724|NCT01963689|OTHER|Intervention Group 3|Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
41023725|NCT05446415|OTHER|Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.|Preoperative and postoperative
41023726|NCT02912351|OTHER|Patient record review, Radiographs, and questionaires.|KSS-Objective Knee Scores, KSS Subsets, Radiographs and Patient Satisfaction
41023727|NCT03701477|BEHAVIORAL|Trans-diagnostic cognitive-behavioral therapy|10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination
40838879|NCT06419816|OTHER|"Physician-managed WellCheck use"|"Physician-managed WellCheck use"
40838880|NCT06419816|OTHER|"self-managed WellCheck use"|"self-managed WellCheck use"
40838881|NCT00786539|DEVICE|Diffuse Optical Spectroscopy|mitochondria
40838882|NCT00671437|PROCEDURE|FDG-PET/CT|
41023728|NCT03701477|BEHAVIORAL|General relaxation/stress management therapeutic session|Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
41023729|NCT03054909|BIOLOGICAL|ALT-803 Subcutaneous|Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
41023730|NCT03054909|BIOLOGICAL|ALT-803 Intraperitoneal|Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
40838883|NCT00671437|DRUG|Cetuximab|
41023731|NCT04337567|PROCEDURE|radiofrequency ablation|ablative treatment as allocated to radiofrequency ablation
41023732|NCT04337567|PROCEDURE|ballon cryoablation|ablative treatment as allocated to ballon cryoablation
41023733|NCT01973829|OTHER|Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
41358790|NCT05511636|OTHER|Oxygen therapy|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
41358791|NCT03377985|PROCEDURE|brachial plexus block|
41358792|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma|Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.
41358793|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma_M|Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.
41358794|NCT03984916|DIETARY_SUPPLEMENT|Cardiose|Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.
41358795|NCT03185637|PROCEDURE|Various interventions for each of the conditions.|"This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair."
41358796|NCT03918356|DEVICE|electrical impedance myography|Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.
41358797|NCT03918356|OTHER|healthy control group|healthy control
41358798|NCT00216346|DRUG|Paromomycin sulfate|
41358799|NCT00216346|DRUG|Amphotericin B|
41358800|NCT05231291|OTHER|hand grip strength|Observational study
41358801|NCT03656315|OTHER|Airway Assessment|All patients recruited to this study will have an ultrasound of their cricothyroid membrane
41358802|NCT05761158|OTHER|questionnaire|patients are asked to complete a questionnaire
41023734|NCT05622773|OTHER|Mat use application|In the research, repeated measurements will be made by using mats and foot baths in a single group and the data will be recorded.
41358803|NCT05505487|OTHER|integrated care model|The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
40838884|NCT05716243|DEVICE|The nociception level index monitorization|The nociception level index (NOL) is one of the nociception monitors and stands out from the others with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives).
41023735|NCT04951310|BEHAVIORAL|Philly Vax Sweepstakes|"The Philly Vax Sweepstakes is a citywide sweepstakes designed to motivate Philadelphians to get vaccinated against COVID-19. A total of 36 vaccinated Philadelphians will win among three cash prize packages, distributed from the total cash pool. These 36 will be chosen over three drawings, with 12 residents chosen in each drawing."
41023736|NCT05067075|DEVICE|Blinded CGM|CGM that records blood glucose but is not visible to patient or provider in real-time
41023737|NCT01347021|PROCEDURE|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
41358804|NCT04144257|DRUG|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
41358805|NCT04144257|DRUG|[C-11]Methylreboxetine|PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
41358806|NCT03212872|DIAGNOSTIC_TEST|Endoscopy|
41358807|NCT06330727|DIETARY_SUPPLEMENT|Coffee capsule|Take 12 coffee capsules containing 3.6 g instant black coffee powder per day (take 6 coffee capsules twice daily with breakfast and lunch).
41358808|NCT06330727|DIETARY_SUPPLEMENT|Corn starch capsule|Take 12 placebo capsules containing 3.6 g corn starch per day (take 6 placebo capsules twice daily with breakfast and lunch).
41358809|NCT01711359|DRUG|Baricitinib|Administered orally
41358810|NCT01711359|DRUG|Methotrexate|Administered orally
41358811|NCT01711359|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
41358812|NCT01711359|DRUG|MTX Placebo|MTX placebo administered orally once weekly.
41358813|NCT01711359|DRUG|Folic Acid|Administered orally every day
41358814|NCT02242305|DRUG|Hyoscine Butylbromide - Tablet|
41358815|NCT02242305|DRUG|Hyoscine Butylbromide - Capsule|
41358816|NCT02242305|DRUG|Placebo|
41497619|NCT05151783|OTHER|PNF technique|Group will receive scapular PNF techniques with routine physical therapy explained above For PNF techniques, patients will be lying on unaffected shoulder. In this group, 20 repetitions of diagonal scapular Pattern (Anterior Elevation and Posterior Depression and Posterior Elevation and Anterior Depression) with 20 sec rest period will be given to patients. Preparatory instructions for the desired movement will be given to patients at the start of procedure. PNF facilitation techniques of RI (Rhythmic initiation) \& repeated contractions will be used in all patterns
40838885|NCT05716243|DEVICE|The nociception level index measurement;postoperative|The nociception level index (NOL) will be used postoperatively
40838886|NCT04400929|DRUG|Sargramostim|Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
40838887|NCT04400929|OTHER|Normal Saline 0.9%|IV normal saline 0.9% for 5 days
40838888|NCT00228865|PROCEDURE|Pulsatile IV insulin therapy|Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
40838889|NCT00228865|PROCEDURE|Effects of Pulsatile IV Insulin on Cognitive functions|Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
40838890|NCT01606787|DRUG|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
40838891|NCT01606787|OTHER|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
40838892|NCT01401712|PROCEDURE|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
40838893|NCT01401712|PROCEDURE|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
40838894|NCT02703688|BEHAVIORAL|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
40838895|NCT02703688|OTHER|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
40838896|NCT00269204|DRUG|niacin (+) laropiprant|Duration of Treatment - 24 weeks
40838897|NCT00269204|DRUG|ER-niacin|Duration of Treatment - 24 weeks
41023738|NCT01070927|DRUG|RO4929097|80mg po daily, 3 days on 4 days off schedule
41023739|NCT01070927|DRUG|RO4929097|recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
41023740|NCT03952884|BEHAVIORAL|Resistance Exercise|Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
41023741|NCT03952884|BEHAVIORAL|No Resistance Exercise|Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.
41023742|NCT03952884|DIETARY_SUPPLEMENT|Leucine|Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
41023743|NCT03952884|DIETARY_SUPPLEMENT|Dileucine|Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
41358817|NCT03338335|DRUG|prolonged DAPT|Dual antiplatelet therapy will be prescribed for more than 12 months
41497620|NCT03470168|DEVICE|Hyperbaric Oxygenation Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
41497621|NCT03470168|DEVICE|Normobaric Oxygenation therapy|Received the Normobaric Oxygen therapy treatment at 1 ATA for 90 minutes each day.
41023744|NCT03132116|DRUG|gentamicin|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
41358818|NCT00754273|OTHER|etest susceptability testing|E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
41023745|NCT03132116|DRUG|placebo|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
41023746|NCT05894200|OTHER|Glass Ionomer cement pit and fissure sealant, Silver Diamine Fluoride|GC Fuji 7, e-SDF
41358819|NCT01766024|DRUG|Interferon beta-1a|Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
41023747|NCT01764334|DEVICE|Fractional flow reserve|"Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed."
41023748|NCT05187455|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg at reappearance of the second twitch of the train-of-four (TOF).
41358820|NCT00422955|DRUG|rosiglitazone|
41358821|NCT00210067|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
41497622|NCT04063423|PROCEDURE|blood sample|Blood sample at start and at the end of the dialysis session; membrane scoring after dialysis; total cell volume measurement of dialyzer after dialysis; micro-CT of dialyzer after dialysis.
41497623|NCT01085201|DRUG|Lexiscan|Given as an infusion
41497624|NCT04496284|OTHER|Vitrification via slush nitrogen|blastocyst stage embryos will be vitrified via slush nitrogen
41497625|NCT00752648|DRUG|TMC435350|
41497626|NCT04305951|PROCEDURE|Comprehensive acupuncture therapy (CAT)|"CAT will be conducted for 2 sessions per week for 12 consecutive weeks.~The following 14 body acupoints with only manual stimulation will be used: HT7 (Shenmen), LI4 (Hegu), TH5 (Waiguan), ST36 (Zusanli), ST40 (Fenglong) and SP6 (Sanyinjiao) in two sides, and CV12 (Zhongwan) and CV4 (Guanyuan) in midline. Electrical stimulation will be conducted on the following frontal acupoints: GV20 (Baihui), EX-HN3 (Yintang), GB15 (Toulinqi), GB8 (Shuaigu), EX-HN5 (Taiyang), and ST8 (Touwei) on two sides, and left and right EX-HN1 (Sishencong).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation is additionally delivered on the 6 pairs of the frontal acupoints. Each session of treatment will last 30 minutes."
41497627|NCT04305951|PROCEDURE|Comfy Acupressure for the Elderly (CAE)|"CAE intervention will be conducted for 3 times per week for 12 consecutive weeks.~CAE consists of 12 steps which need about 15 minutes to complete and mainly concentrates on the acupoints on face, head, neck, and shoulder. The detailed CAE Operation Guide will be provided for the provider and the video demonstration is accessible at https://www.youtube.com/watch?v=pAqNIZPKmnM."
41023749|NCT06075511|DIAGNOSTIC_TEST|6 minutes walk distance|Subjects walk as far as possible for 6 minutes at a self-selected pace, and the total distance walked will be recorded
41023750|NCT06075511|BEHAVIORAL|Activity Monitor|Subjects will wear an Actigraph on their wrist like a watch for up to 10 days at home to monitor activity.
41023751|NCT06075511|BEHAVIORAL|Continuous Glucose Monitor|Subjects will collect glucose values in the fluid under their skin for up to 10 days at home.
41023752|NCT06075511|BEHAVIORAL|Blood Pressure Monitoring|Subjects will monitor their blood pressure at home for 10 consecutive days 3 times a day
40838898|NCT02713516|OTHER|Virtual Reality|Use of virtual reality to deliver exposure therapy
41023753|NCT06075511|DIAGNOSTIC_TEST|Blood Pressure Monitoring|24-hour ambulatory blood pressure monitoring
41358822|NCT03604159|DRUG|Buprenorphine Extended Release|XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
41358823|NCT03604159|DRUG|Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)|SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
41023754|NCT06075511|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
41023755|NCT06075511|DIAGNOSTIC_TEST|Mixed meal testing|Subjects will consume 6 ml/kg body weight of Boost, up to maximum of 360 ml, within 5 min
41358824|NCT02777294|BEHAVIORAL|Online intervention|Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD
41358825|NCT02777294|BEHAVIORAL|Psycho-educational website|Psycho-educational self-help website about rape-related PTSD
41358826|NCT01632345|DRUG|Doravirine|Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
41358827|NCT01632345|DRUG|Efavirenz|Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
41358828|NCT01632345|DRUG|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
41358829|NCT01632345|DRUG|Placebo for Doravirine|Placebo tablets matching doravirine
41358830|NCT01632345|DRUG|Placebo for Efavirenz|Placebo tablets matching efavirenz
41358831|NCT03693391|DRUG|JNJ-64140284|Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
41023756|NCT06075511|DIAGNOSTIC_TEST|Quality of Life|Subject will complete Quality of Life Questionnaire
41358832|NCT03693391|DRUG|Fluorine-18 Labeled [18F]-JNJ-64511070|An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.
41358833|NCT05238324|BIOLOGICAL|Genetic HMI-203|HMI-203 delivered intravenously
41358834|NCT02372539|OTHER|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
41023757|NCT06038682|DRUG|Argatroban Injection|Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.
41023758|NCT06038682|DRUG|Heparin|Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
41023759|NCT01807585|DEVICE|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
41023760|NCT01807585|DEVICE|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
41023761|NCT01807585|DEVICE|Roll-in (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
41023762|NCT02906007|DRUG|Bedaquiline|100 mg oral tablets. In Cohorts 2 and 3 only under protocol Version 2.0, 20 mg oral dispersible tablet may alternatively be used. Doses will vary based on the participant's age and weight.
41023763|NCT03732248|DRUG|Rapamycin|Immunosuppressive drug
41023764|NCT03732248|DRUG|Placebo|Inert drug
41023765|NCT05085340|DRUG|Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP)|IPTi will be administered as full therapeutic courses of SP alongside routine EPI immunisations at defined intervals corresponding to vaccination schedules - usually at 10 weeks, 14 weeks, and 9 months of age - to infants living in project districts. Additional doses of IPTi will be administered at 6, 12, and 15 or 18 months of age, coinciding with vitamin A administration and measles booster immunisation. The number of doses of IPTi a child will receive will depend of the EPI schedule in the country, with a maximum of six doses in the first two years of life.
41023766|NCT06127420|OTHER|coronary physiological indices|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Resting full-cycle ratio, Coronary Flow Reserve, Microvascular resistance
41358835|NCT02372539|OTHER|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
41358836|NCT05510999|OTHER|Placebo|One capsule of placebo will be taken twice daily for 24 weeks.
41358837|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction|Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.
41358838|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.
41358839|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction|Each capsule contains 9 mg of lipid soluble pollen extract fraction. One capsule of will be taken twice daily (18 mg/day) for 24 weeks.
41358840|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction + cranberry powder|Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder. One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
41358841|NCT01790451|PROCEDURE|Irreversible Electroporation|
41358842|NCT02705339|DRUG|Rociletinib|
41358843|NCT02705339|PROCEDURE|Biopsy|Standard of care biopsies will be taken at diagnosis and at the time of disease progression
41358844|NCT02705339|PROCEDURE|Blood draw|-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
41358845|NCT02514629|DRUG|Placebo|
41358846|NCT02514629|DRUG|Metformin|
41358847|NCT02514629|DRUG|Testosterone Undecanoate|
41358848|NCT02514629|DRUG|Metformin + Testosterone Undecanoate|
41358849|NCT05785949|PROCEDURE|Microfracture|Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3\~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3\~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5\~7 mm.
41358850|NCT05785949|DEVICE|Chondro-Gide bilayer collagen membrane|After the Microfracture, the porous layer of the bilayer collagen membrane faces the bone surface. The already trimmed, cut and wetted membrane is insert into the defect and fixed symmetrically with absorbable surgical suture with needle. Knots are put on the pinhole of collagen membrane to avoid tearing of surrounding cartilage or collagen membrane during knotting.
41358851|NCT05441124|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
40838899|NCT06544031|BEHAVIORAL|Healthy Nutrition Education Program|The program consists of two sessions totaling 2 hours. The first session includes a traditional presentation on healthy nutrition, and the second session involves an interactive question and answer segment. The intervention aims to improve nutritional knowledge and attitudes towards healthy eating among elderly residents.
41023767|NCT01183793|RADIATION|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
41023768|NCT00102791|DRUG|ICA-17043|
41358852|NCT01388205|BEHAVIORAL|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
41358853|NCT01844310|DRUG|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
41358854|NCT01844310|DRUG|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
41358855|NCT03689114|DRUG|Low dose carbamazepine|Carbamazepine, 300 mg/die
41358856|NCT03689114|DRUG|Standard dose carbamazepine|Carbamazepine 600 mg/die
41358857|NCT03689114|DRUG|Low dose levetiracetam|Levetiracetam 500 mg/die
41358858|NCT03689114|DRUG|Standard dose levetiracetam|Levetiracetam 1000 mg/die
41358859|NCT03689114|DRUG|Low dose valproate|Valproate 300 mg/die
40838900|NCT05898230|DEVICE|Mitral Valve Replacement|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
40838901|NCT01055483|DRUG|panobinostat/LBH589B|
40838902|NCT01480011|DRUG|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
40838903|NCT00987701|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
40838904|NCT00987701|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
41358860|NCT03689114|DRUG|Standard dose valproate|Valproate 600 mg/die
41358861|NCT03689114|DRUG|Low dose zonisamide|Zonisamide 150 mg/die
40838905|NCT01077180|DEVICE|Implantation of the Rheos System|Open label
40838906|NCT01077180|OTHER|Standard of care medical management|Patients will continue with medical therapy for standard of care of their hypertension.
40838907|NCT02342379|DRUG|Bevacizumab|10mg/kg
40838908|NCT02342379|DRUG|TH-302|670mg/m2
41023769|NCT03361410|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 12 months
41023770|NCT03361410|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 12 months
41358862|NCT03689114|DRUG|Standard dose zonisamide|Zonisamide 300 mg/die
41358863|NCT03689114|DRUG|Low dose oxcarbazepine|Oxcarbazepine 600 mg/die
41358864|NCT03689114|DRUG|Standard dose oxcarbazepine|Oxcarbazepine 1200 mg/die
41358865|NCT03689114|DRUG|Low dose topiramate|Topiramate 100 mg/die
41358866|NCT03689114|DRUG|Standard dose topiramate|Topiramate 200 mg/die
41358867|NCT03689114|DRUG|Low dose lamotrigine|Lamotrigine 100 mg/die
41358868|NCT03689114|DRUG|Standard dose lamotrigine|Lamotrigine 200 mg/die
41358869|NCT03689114|DRUG|Low dose gabapentin|Gabapentin 450 mg/die
41358870|NCT03689114|DRUG|Standard dose gabapentin|Gabapentin 900 mg/die
41358871|NCT00266331|DRUG|Reduced glutathione|
41358872|NCT00186121|DRUG|Anastrozole (Arimidex)|Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
41358873|NCT00186121|DRUG|Goserelin (Zoladex)|Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
41358874|NCT04152109|OTHER|Without laying on of hands subgroup|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, around 8 weeks.
41358875|NCT04152109|OTHER|Laying on of hands without Spiritual connection|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, around 8 weeks.
41358876|NCT04152109|OTHER|"Laying on of hands by Spiritual Passe"|"The participants will be subjected application of the laying on of hands by the volunteer who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks."
41358877|NCT05862740|PROCEDURE|Laparoscopic Debulking Surgery in advanced ovarian cancer|Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparotomy.
41358878|NCT05862740|PROCEDURE|Standard laparotomic Debulking Surgery in advanced ovarian cancer|Debulking by laparotomy in patients when debulking could not be accomplished by laparoscopy.
41358879|NCT00405795|DEVICE|Envision® Patient Support System|
41358880|NCT01409642|BEHAVIORAL|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
41358881|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
41497628|NCT05928598|BEHAVIORAL|Survey questionnaires|Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.
41497629|NCT05928598|BEHAVIORAL|Epilepsy Visit Planner|"Participants will be identified before a scheduled clinic appointment. Prior to the clinic visit (at the site) the participants will meet with a research staff to obtain written informed consent and then present the Epilepsy Visit Planner to the patient. Participants will be encouraged to use the Planner and share the Planner's output with the provider during the clinic visit. In some cases, there could be an option for the participants to consent prior to the visit and have a virtual presentation of the Planner.~Following the clinic visit, the research staff will ask the participants to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record."
41023771|NCT02691858|DRUG|Hydrocortisone|10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
41023772|NCT02691858|DRUG|Saline|100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
41023773|NCT05101252|DEVICE|senofilcon A C3|TEST Lens
41023774|NCT05101252|DEVICE|Dailies Total 1 Multifocal Contact Lenses|CONTROL Lens
41023775|NCT02760394|DEVICE|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
41023776|NCT05417711|DEVICE|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.
41358882|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
41358883|NCT00784160|DRUG|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
41358884|NCT05205161|DRUG|AZD0466|All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
41358885|NCT03036891|DRUG|Naloxegol 25 MG Oral Tablet [Movantik]|Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
41358886|NCT03036891|DRUG|Placebo Oral Tablet|Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
41358887|NCT00396266|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
41358888|NCT02948452|OTHER|fMRI|fMRI: reward task, anxiety provocation
41358889|NCT00146458|PROCEDURE|18F-fluorodeoxyglucose positron emission tomography|
41358890|NCT02186548|PROCEDURE|Closed surgical technique|"* Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~* The bone covering the canine is being removed~* Attachment with a chain is bonded to the exposed tooth~* The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~* The canine is orthodontically moved beneath the palatal mucosa"
41358891|NCT02186548|PROCEDURE|Open surgical technique|"* Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~* Pack/filling material is applied on the tooth~* Spontaneous eruption of the palatally impacted canine is allowed expected~* The canine is orthodontically moved above the mucosa"
40838909|NCT04921332|DEVICE|Bright Light Therapy (BLT) Lamp|With its built in automatic timer shut-off function, the bedside registered nurse (RN) would not need to return to the room to turn off this lamp after 30 minutes because the lamp will automatically shut off on its own.
40838910|NCT01389323|DRUG|Daclatasvir|Tablet, Oral, 60 mg, once daily, 24 weeks
40838911|NCT01389323|DRUG|Peg-Interferon Alfa-2a|Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
41358892|NCT05872243|DEVICE|active rTMS|Each participant will receive two 1800 pulse active rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
41358893|NCT05872243|DEVICE|sham rTMS|Each participant will receive two 1800 pulse sham rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
41358894|NCT01297621|PROCEDURE|reduction mammaplasty|conventional reduction mammaplasty
41358895|NCT01297621|OTHER|control|follow up, questionnaire responses
41358896|NCT01028131|BEHAVIORAL|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
41358897|NCT01028131|BEHAVIORAL|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
41358898|NCT03452059|DEVICE|AiLegs, AiWalker and HKAFO|5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
41358899|NCT02961049|PROCEDURE|Gingival displacement|Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.
41358900|NCT02961049|PROCEDURE|Enamel and dentin etched|Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
41358901|NCT02961049|PROCEDURE|Selective enamel etched|Selective enamel etched with 35% phosphoric acid for 15 seconds.
41358902|NCT02961049|PROCEDURE|Wash and dry|Wash and dry with absorbent paper.
41358903|NCT02961049|DEVICE|Total-etch adhesive system|Two layers of pirmer/bond on enamel and dentin with a brush.
41358904|NCT02961049|DEVICE|self-conditioning adhesive system|One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
41358905|NCT02961049|PROCEDURE|Photoactivated|Photoactivated for 20 seconds
41358906|NCT06234995|DRUG|Levodopa|Participants will take levodopa in dosages prescribed by their care provider. Patients will be instructed to not take their regularly prescribed PD medications for 12 hours prior to the study assessment, as is typical for clinical evaluations in patients with PD. Participants will be tested in both levodopa-off (after 12 hours of not having medication) and levodopa-on states.
41358907|NCT06234995|DEVICE|Clinical DBS Setting|Deep brain stimulation performed with the patients' optimized clinical setting.
41358908|NCT06234995|DEVICE|Sham DBS|Deep brain stimulation performed with sham stimulation.
41358909|NCT06234995|DEVICE|DBS Setting Maximizing Prefrontal Activation|Deep brain stimulation performed to maximize the activation of the prefrontal cortico-STN projections.
41358910|NCT06234995|DEVICE|DBS Setting Minimizing Prefrontal Activation|Deep brain stimulation performed to minimize the activation of the prefrontal cortico-STN projections.
41358911|NCT04343027|BEHAVIORAL|Review|Physicians will review patient-reported outcome measurements with their patients during office visits.
41358912|NCT04021342|DIETARY_SUPPLEMENT|Montmorency tart cherry concentrate|Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
41358913|NCT04021342|DIETARY_SUPPLEMENT|Placebo|Placebo beverage matched for calorie content and visual properties of the cherry concentrate
41358914|NCT00464126|OTHER|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
41358915|NCT00464126|OTHER|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
41358916|NCT06376942|DRUG|Glycopyrronium|Nebulized glycopyrronium 50 mcg
41358917|NCT06376942|DRUG|Ipratropium|Nebulized iptratropium 500 mcg
41023777|NCT05417711|DEVICE|Tailor-made Notched Music Training|Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.
41358918|NCT06376942|OTHER|Saline|0.9% saline 2 ml
41358919|NCT03232151|DIAGNOSTIC_TEST|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
41497630|NCT05928598|BEHAVIORAL|Questionnaires for Providers|Providers will be asked to complete a survey after the clinic visit for the intervention group.
41497631|NCT00462124|DEVICE|Absorbable perirectal spacer|biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
41497632|NCT02816008|BEHAVIORAL|Cognitive rehabilitation training with RGS in the clinic|Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
41023778|NCT04420026|RADIATION|Interact Active Tracker|Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
41358920|NCT00464841|PROCEDURE|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
41358921|NCT00464841|PROCEDURE|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
41358922|NCT05138731|OTHER|treatments according guidelines|different group intervened with different treatment following guidelines/consensuses accordingly
41358923|NCT02793531|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
41497633|NCT02816008|BEHAVIORAL|Passive/conventional cognitive training at home.|Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
40838912|NCT01389323|DRUG|Ribavirin|Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
41497634|NCT03874286|DIAGNOSTIC_TEST|Liver Transplant|Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsies are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.
41497635|NCT05540028|BIOLOGICAL|IVT PCV-25|25 valent pneumococcal conjugate vaccine
41023779|NCT02709070|PROCEDURE|resection|hepatectomy for HCC
41023780|NCT02709070|PROCEDURE|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
41358924|NCT01208376|OTHER|Fibroscan|Fibroscan and Serum Fibrose-marker
41358925|NCT04126876|DRUG|Tilsotolimod|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
41358926|NCT04126876|DRUG|Saline (0.9% sodium chloride)|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
41358927|NCT05047601|DRUG|PF-07321332|PF-07321332
41497636|NCT05540028|BIOLOGICAL|PCV 20|20 valent pneumococcal conjugate vaccine
41497637|NCT06279559|BEHAVIORAL|Music-therapy|10 sessions of online music therapy held by expert music therapists
41497638|NCT01852500|OTHER|Sham Osteopathic Manipulative Treatment|Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
41497639|NCT01852500|OTHER|Standard care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
40838913|NCT01781351|OTHER|Taping the ankle|
40838914|NCT06026995|DRUG|PEG-rhG-CSF|Subcutaneous injection with a fixed dose of 12 mg
40838915|NCT06026995|DRUG|RhG-CSF|Inject rhG-CSF 5-10 μg/kg subcutaneously every day
40838916|NCT01800656|PROCEDURE|"Endoloop-assisted ligate and let go colorectal polypectomy"|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
40838917|NCT01800656|PROCEDURE|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
41023781|NCT05433883|PROCEDURE|sleep surgery|Thirty severe OSA patients (AHI\>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.
41023782|NCT05081661|OTHER|Motor Imagery Program|The intervention group of the study will undergo standard postoperative physical therapy treatment at their therapist. Beginning on the third day after surgery, the participant will begin an motor imagery program to be performed three times a week for four weeks. A session lasts between fifteen and twenty minutes. It begins with a body awareness phase followed by a series of three to five one-minute exercises to be repeated three times, with a one-minute break between each exercise. The program is performed independently at home using a standardized audio tape.
41023783|NCT05081661|OTHER|Placebo program|"The control group of the study will undergo standard postoperative physiotherapy treatment at their therapist. On the third day after surgery, the participant will begin a relaxation program inspired by the mindfulness tool called Bodyscan that acts as a placebo mental imagery program. Nevertheless, the program created for this technique does not follow the Bodyscan guidelines (Jon Kabat-Zinn, 2005), as we do not want there to be any effects in favor of improved body perception on the participants, which could bring an additional biai to the study. For the sake of understanding, we have used the term body visualization in the various documents distributed to the participants. The program is to be performed three times a week for four weeks. A session lasts between ten and fifteen minutes. The program is performed independently at home using a standardized audio tape."
41497640|NCT03072979|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy
41497641|NCT05434429|OTHER|mobile application|Participants in the intervention group are able to access the intervention materials 5 days after enrollment. Two main self-guided intervention modules are available. Short-term self-guided intervention module include mainly audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation. Moreover, there based on breath relaxation exercises, craving management, and motivation to change. Long-term self-guided intervention module include CBT-based interventions, meditations, mindfulness, and journaling.
41497642|NCT00174954|PROCEDURE|MRI|Subjects underwent MRI to evaluate tophi.
41023784|NCT05873192|DRUG|ADT|Given by PO
41023785|NCT05873192|DRUG|Enzalutamide|Given by PO
41023786|NCT05873192|DRUG|Talazoparib|Given by PO
41023787|NCT05873192|DRUG|Degarelix|Given PO or given INJ
41358928|NCT05047601|DRUG|Placebo for PF-07321332|Placebo
41497643|NCT00888056|PROCEDURE|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
41497644|NCT02651259|DRUG|Rifapentine (RPT)|900 mg of RPT
41023788|NCT05873192|DRUG|Luprolide|Given PO or given INJ
41023789|NCT04315311|DRUG|CREON|Capsule: Oral
41358929|NCT05047601|DRUG|Placebo for Ritonavir|Placebo
41358930|NCT05047601|DRUG|Ritonavir|Ritonavir
41023790|NCT01820130|DEVICE|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
40838918|NCT02567045|PROCEDURE|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
40838919|NCT02567045|PROCEDURE|colonoscopy with sedation|One-time Colonoscopy with sedation.
40838920|NCT01875042|DEVICE|TENS|Transcutaneous electrical nerve stimulation
40838921|NCT01875042|DEVICE|Sham TENS|Sham Transcutaneous electrical nerve stimulation
40838922|NCT03959982|DEVICE|HHHFA Device|Participants will be instructed to use the HHHFA for at least 4 hours during their sleep but will be allowed to use it as long as they want during sleep.
40838923|NCT03959982|DIAGNOSTIC_TEST|Spirometry|Pre and post spirometry using albuterol.
41358931|NCT02493075|BEHAVIORAL|The operator blinded to the contact force data or not.|"CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I."
41358932|NCT03224442|PROCEDURE|PRF|soft tissue augmentation by prf
41358933|NCT03224442|PROCEDURE|Palatal Pedicle|soft tissue augmentation by palatal pedicle
41358934|NCT03138707|OTHER|patients who die|
41358935|NCT01480193|OTHER|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
40838924|NCT03959982|DIAGNOSTIC_TEST|6-minute walk|6-minute walk
40838925|NCT03959982|DIAGNOSTIC_TEST|CT scan|CT scan
41358936|NCT01480193|OTHER|Integrative Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
40838926|NCT03959982|OTHER|Medical Research Council dyspnea scale (MRC)|MRC questionnaire
40838927|NCT03959982|OTHER|St. George's Respiratory Questionnaire (SGRQ)|SGRQ questionnaire
41497645|NCT02651259|DRUG|Isoniazid (INH)|900 mg of INH
40838928|NCT03959982|OTHER|COPD Assessment Test (CAT)|CAT questionnaire
40838929|NCT03959982|OTHER|Pittsburgh Sleep Quality Index (PSQI)|PSQI questionnaire
40838930|NCT03959982|OTHER|CASA-Q|CASA-Q questionnaire
40838931|NCT03959982|OTHER|Spirehealth Tag Device|Subjects will wear the Spirehealth Tag Device to measure heart rate, respiratory rate, sleep time, physical activity (movement), and calories burned with activity.
40838932|NCT03066167|OTHER|Validation of different dysphagia scores|
40838933|NCT00190047|DRUG|DP-b99|
40838934|NCT03706300|DRUG|Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg|
40838935|NCT00380419|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
40838936|NCT00508612|BEHAVIORAL|Williams LifeSkills Stress and Anger Management Workshop|Williams LifeSkills Stress and Anger Management Workshop
40838937|NCT00508612|BEHAVIORAL|High school classes|The control group will attend regular high school classes.
40838938|NCT00005053|DRUG|glufosfamide|
40838939|NCT04896372|OTHER|ACT comprehensive of standard care|"The proposed intervention was designed by the authors of the study. It was developed following the main ACT-based manuals, with adjustments according to the users and the context of the study implementation.~Specifically, we developed a practical and interactive intervention, which comprises practical activities such as roleplay and writing activities and imaginative activities supported by metaphors. The sessions are based on the use of age-appropriate language to convey the most complex therapeutic processes easily. According to Strosahl and colleagues' model, sessions will respectively target the components of openness, awareness, and engagement."
41023791|NCT05693922|DEVICE|Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Delta-beta stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
41358937|NCT04841928|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
41358938|NCT04841928|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
41358939|NCT04841928|BEHAVIORAL|Value-based action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
41358940|NCT04568382|OTHER|CI-PVP (context-informed pre-visit planning)|may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit
41358941|NCT04568382|OTHER|Standard PVP (pre-visit planning)|standard clinic staff chart review, email and/or phone call prior to diabetes office visit
41358942|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage with added sugar|10 oz daily for three weeks
41358943|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi &Lemonade Flavored Beverage with added sugar|10 oz daily for three weeks
41358944|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage no added sugar|10 oz daily for three weeks
41358945|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi & Lemonade Flavored Beverage no added sugar|10 oz daily for three weeks
41358946|NCT03490734|OTHER|Water|Three mL administered per associated logo presentation only during MRI procedure.
41358947|NCT02369575|OTHER|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
41358948|NCT04851041|OTHER|Potato|Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health
41358949|NCT04851041|OTHER|Pasta/rice|Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.
40838940|NCT04896372|OTHER|TAU only|adolescents will be assessed by a staff dietician and placed on an individualized hy-pocaloric balanced Mediterranean diet. They will also follow a nutritional counselling aimed at promoting the adoption of a healthy lifestyle. Moreover, they will attend a physical activity program consisting of five training sessions per week lasting one hour each with trainers; In addition, they will be involved in psychological counselling pro-vided once a week by a clinical psychologist, aimed to address psychological factors related to dysfunctional lifestyle habits.
40838941|NCT05512013|DRUG|Ibuprofen 800 mg|Ibuprofen taken orally 2 hours prior to exercise
41358950|NCT03755037|DRUG|Clomid, Respatio and Ethinyl estradiol|Drugs were received during the menstrual cycle.
41358951|NCT06015269|DRUG|DC cells|At a single arm, 1x107cells dose
41358952|NCT01200251|DRUG|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
41358953|NCT03459963|DEVICE|indwelling urinary catheter|85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
41358954|NCT06207786|OTHER|Povidone-Iodine Swabs|Undergo nasal swab of both nostrils for 30 seconds into each nostril, allowing two minutes to dry, immediately (e.g. within 30 minutes) prior to performing skin reconstruction.
41358955|NCT06207786|DIAGNOSTIC_TEST|Staphylococcus nasal swab|Undergo a nasal swab to identify patients with preoperative nasal Staphylococcus aureus colonization
41358956|NCT06207786|DRUG|Antibiotic|Receive an oral anti-staphylococcal antibiotic (e.g. oral cephalexin) with standard dosing only if indicated for antibiotic prophylaxis per the Mayo Clinic Dermatologic Surgery Antibiotic Prophylaxis protocol that is currently standard practice for patients undergoing Mohs micrographic surgery (MMS)
41358957|NCT06381310|DEVICE|asus-handheld-ultrasound LU710L|Ultrasound-guided group:The nurse uses ultrasound-guide injection. control group: After physical assessment by the nurse, the injection will be carried out according to the conventional injection plan.
41358958|NCT00245726|DEVICE|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
41358959|NCT00245726|DEVICE|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
41358960|NCT00245726|DEVICE|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
41358961|NCT02545465|DRUG|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
40838942|NCT05512013|DRUG|Celecoxib 200mg|Celebrex taken orally 2 hours prior to exercise
40838943|NCT05512013|DRUG|Flurbiprofen 100 mg|Flurbiprofen taken orally 2 hours prior to exercise
40838944|NCT05512013|DRUG|Placebo|Inert placebo taken orally 2 hours prior to exercise
40838945|NCT00002020|DRUG|Zidovudine|
40838946|NCT02211313|DEVICE|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
40838947|NCT01659255|DRUG|Tirabrutinib|Capsules administered orally
41358962|NCT00671190|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally once daily for up to 5 days
41358963|NCT00671190|DRUG|Ramelteon|Ramelteon 2 mg, tablets, orally once daily for up to 5 days
41358964|NCT00671190|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally once daily for up to 5 days
41358965|NCT00671190|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally once daily for up to 5 days
41358966|NCT00671190|DRUG|Placebo|Ramelteon placebo-matching tablets, orally once daily for up to 5 days
41497646|NCT02651259|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
41497647|NCT00252200|DRUG|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
41358967|NCT03727685|BEHAVIORAL|Our Care Wishes|A flyer describing the Our Care Wishes platform will be added to the back pocket of admission packets for patients being admitted via the Silverstein 1 Admission Office and the Emergency Department and for patients being seen in the Pre Admission Testing office. Registration reps in these locations will inform all patients seen that Penn has created a free, online resource called Our Care Wishes to help patients with Advance Care Planning and ask if they would like to be sent a link to Our Care Wishes by email or text. For those patients who respond affirmatively, the rep will then complete the necessary fields to refer on www.ourcarewishes.org/refer.
41023792|NCT05693922|BEHAVIORAL|Single-session behavioral activation|"Participants will take part in a single-session behavioral activation (BA) intervention. This intervention was adapted from standard BA protocols for the treatment of depression to be completed in a single, 90-minute session. This intervention will have 4 main components based on prior protocols:~* Treatment overview and rationale~* Tracking of daily activities~* Exploration of values~* Planning/scheduling activities"
41497648|NCT03782909|BEHAVIORAL|Behaviour change intervention|"The behaviour change intervention consists of;~1. Feedback via an app based food diary~2. Coaching with problem solving and implementation plans~The intensive phase consists of 2 home visits and 4 phone calls and the use of the app The maintenance phase consists of use of the app if the PWCF wishes to continue using it"
41358968|NCT04561739|DEVICE|Paclitaxel coated balloon|"The Paclitaxel coated balloon is a paclitaxel-eluting rapid exchange balloon catheter for PTCA. Paclitaxel is the pharmacologically active substance for anti-neointima, whereas iopromide, a well-tolerated nonionic x-ray contrast agent, acts as a release-supporting additive.~The active drug coating is located on the surface of the balloon, which contains 3 μg Paclitaxel per 1 mm2. The spray coating of the mixture of paclitaxel and iopromide of the Swide is via ultrasound, with the crystal size\<2um."
41358969|NCT04561739|DEVICE|Sirolimus eluting stents|The device has a backbone of L605 cobalt chromium. The stent has a open cell, in-phase, peak-to-valley design. The strut thickness is 86 μm and has a stent profile less than 1.12mm. The polymer coating of the stent is a styrene-butadiene block copolymer. The antiproliferative drug concentration is at 9 ug/mm, which 80% of the drug is released by 30 days.
41497649|NCT00357123|DRUG|Rosuvastatin|20 mg 10 days daily since abdominal sepsis diagnosis
41497650|NCT00252239|DRUG|tenecteplase|This study will compare 3 different doses of tenecteplase to tPA.
41497651|NCT00252239|DRUG|tissue plasminogen activator, tPA|To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
41497652|NCT02293889|DIETARY_SUPPLEMENT|Vitamin D3 2000IU/daily 3 months|Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (\>50nmol/L) by 3 months.
41497653|NCT02293889|BEHAVIORAL|PA intervention People with Osteoarthritis Walking Programme|The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).
41497654|NCT02293889|OTHER|Placebo capsule (Vitamin D): edible oil|Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
41497655|NCT05241028|DRUG|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
41497656|NCT03995186|BEHAVIORAL|Behavioural activation|4-week programme based on the behavioural activation treatment provided in the NHS IAPT services. The programme includes psychoeducation on the relationship between activity and depression, examining the depressed person's level of activity, helping them identify activities they would like to increase and supporting them in the planning and conduct of those activities.
41497657|NCT03995186|BEHAVIORAL|Activity monitoring|4-week programme where participants simply monitor their general daily activities in a diary.
41497658|NCT05963867|DRUG|BI 764532|BI 764532
41023793|NCT05693922|DEVICE|Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Active sham stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
41023794|NCT05561998|DEVICE|TalkingMats|TalkingMats is a low-technology communication framework, to help people with communication difficulties to express their views. It uses a simple system of picture symbols, placed on a textured mat, that allow people to indicate their feelings about various options within a topic by placing the relevant image below a visual scale. Three sets of symbols are used, one set for the topics of the conversation, one set for the options within each topic and one set consisting of the value scale under which the options are placed.
41358970|NCT00515021|DRUG|Eplerenone (Morning)|"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."
41358971|NCT00515021|DRUG|Eplerenone (Night-time)|Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
41497659|NCT05963867|DRUG|[89Zr]Zr-BI 764532|\[89Zr\]Zr-BI 764532
41023795|NCT05561998|OTHER|Usual conversation method|The standard procedure during needs-assessment conversation and conversations planning the provision of home care services.
41497660|NCT05487300|DRUG|Autonomic testing on and off levodopa|"Participants with Parkinson's disease with and without orthostatic hypotension will undergo standardized autonomic testing on two separate days on levodopa and off levodopa."
41497661|NCT00681590|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|400 IU daily (low dose)
41497662|NCT00681590|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|2000 IU daily (high dose)
41497663|NCT04485832|DEVICE|Telehealth care|Patients in the intervention group daily answer 6 questions, which are focused on the recognition of AECOPD, using the electronic healthcare platform Evita by Swisscom, which has been and continuously is developed by the study team and Swisscom. The study team daily analyses all patients online and reacts according to a pre-specified action plan.
41497664|NCT04485832|DIAGNOSTIC_TEST|Weekly CAT measurement|
41497665|NCT03660826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41358972|NCT03586063|OTHER|Data collection|"This is a non-interventional (observational) national multicentre prospective study.~Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days.~The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study."
41358973|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
41358974|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
41358975|NCT01201902|BIOLOGICAL|un-adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
41358976|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
41358977|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
41358978|NCT01914042|DRUG|Morphine|
41358979|NCT01914042|DRUG|Milnacipran|
41358980|NCT02709239|DIETARY_SUPPLEMENT|DHA 200mg|4 50mg capsules of DHA to be taken by mouth daily
41358981|NCT02709239|DIETARY_SUPPLEMENT|DHA 800mg|4 200mg capsules of DHA to be taken by mouth daily
41358982|NCT05038306|DRUG|Chinese medicine WT|The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
41497666|NCT03660826|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspiration and biopsy
41497667|NCT03660826|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
40838948|NCT02300597|OTHER|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
40838949|NCT05442177|PROCEDURE|Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment|
40838950|NCT06285994|PROCEDURE|High frequency jet ventilation|Use of high frequency jet ventilation during bronchoscopy
40838951|NCT02896270|DRUG|Valproic Acid|The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
40838952|NCT05632276|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
40838953|NCT03400631|DRUG|Dextrose 0|Dextrose injection at time 0
41023796|NCT02948985|OTHER|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
41358983|NCT04537364|DIAGNOSTIC_TEST|combined diagnosis of renal parenchymal damage|"This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~1. This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~   MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~   Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity \>1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~2. The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time."
41358984|NCT00300794|DRUG|Ketamine|
41358985|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System|Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
41358986|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System with sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
40838954|NCT03400631|DRUG|Aspiration 0|Aspiration only at time 0
40838955|NCT03400631|DRUG|Dextrose 1|Dextrose injection at week 1
41358987|NCT03266653|DRUG|cytotoxic t-lymphocytes|EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
41358988|NCT06106399|PROCEDURE|WALLANT|Comparison between (WALLANT) and (CPB) as a sole anesthesia in clavicle surgery
41497668|NCT03660826|DRUG|Capivasertib|Given PO
41497669|NCT03660826|DRUG|Cediranib|Given PO
41497670|NCT03660826|DRUG|Cediranib Maleate|Given PO
41497671|NCT03660826|PROCEDURE|Computed Tomography|Undergo CT scan
41497672|NCT03660826|BIOLOGICAL|Durvalumab|Given IV
41497673|NCT03660826|PROCEDURE|Echocardiography|Undergo Echo
41497674|NCT03660826|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40838956|NCT03400631|DRUG|Aspiration 1|Aspiration only at week 1
41023797|NCT04487977|OTHER|Survey|Answering a survey on airway management in COVID-19 patients
41023798|NCT03637751|BEHAVIORAL|Behavioral|Trier Social Stress Test
41497675|NCT03660826|DRUG|Olaparib|Given PO
41497676|NCT04896411|OTHER|Alternative phrasing for no code|This intervention will use the alternative phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
41023799|NCT03637751|BEHAVIORAL|Control condition|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
41023800|NCT00519805|DRUG|dalteparin|
41023801|NCT00519805|PROCEDURE|quality-of-life assessment|
41023802|NCT00734838|DEVICE|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
40838957|NCT04622904|DRUG|lidocaine-magnesium infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of ketamine of 0.35 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 0.2 mg/kg/h of ketamine will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
41023803|NCT00975975|DRUG|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
41023804|NCT01266772|DRUG|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
41023805|NCT01266772|DRUG|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
41023806|NCT02543541|BEHAVIORAL|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
41023807|NCT02543541|BEHAVIORAL|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
41023808|NCT05494398|DRUG|N-acetylcysteine|12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.
41023809|NCT04700423|DRUG|moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
41023810|NCT04700423|DRUG|ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
41023811|NCT04700423|DRUG|ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]|Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
41023812|NCT04700423|DRUG|ivermectin (200 µg/kg)|Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
41023813|NCT04700423|DRUG|moxidectin (8 mg)|Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
41023814|NCT03674424|DRUG|Avelumab|Chemotherapy with or without avelumab followed by surgery
41358989|NCT04436042|DEVICE|MyHand Device|These subjects may be asked to attend 1-40 sessions (approximately 90 mins) to trial a variety of device controls and/or components.
41023815|NCT03674424|PROCEDURE|cystectomy|Cystectomy 3 to 6 weeks after last administration of chemotherapy
41023816|NCT03674424|COMBINATION_PRODUCT|CG|Chemotherapy 4 cycles of 3 weeks
41023817|NCT03674424|COMBINATION_PRODUCT|DD-MVAC|Chemotherapy 4 cycles of 2 weeks
41023818|NCT03674424|COMBINATION_PRODUCT|PG|Chemotherapy 2 cycles of 4 weeks
41023819|NCT02279810|BEHAVIORAL|survey|Survey
41023820|NCT00393445|DRUG|GLP-1 control|intravenous infusion of GLP-1
41023821|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 300|intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
41023822|NCT00393445|DRUG|saline control|intravenous infusion of saline
41023823|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 600|intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
41358990|NCT01960036|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|
41358991|NCT01960036|BEHAVIORAL|Womens Health Education|
41358992|NCT05043493|PROCEDURE|Injection in the intraarticular space of glenohumeral joint|U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)
41023824|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 900|intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
41023825|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 1200|intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
41023826|NCT02671123|PROCEDURE|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
41023827|NCT02671123|PROCEDURE|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
41023828|NCT00541047|DRUG|bicalutamide|
41023829|NCT00541047|DRUG|goserelin acetate|
41023830|NCT00541047|DRUG|leuprolide acetate|
41023831|NCT00541047|PROCEDURE|adjuvant therapy|
41358993|NCT01449604|RADIATION|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
41358994|NCT01449604|RADIATION|stereotactic radiosurgery|Radio surgery 12 Gy
41358995|NCT03725709|PROCEDURE|spinal anesthesia|Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
41358996|NCT01060150|DRUG|OROS Methylphenidate HCl|Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
40838958|NCT04622904|DRUG|lidocaine-ketamine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of magnesium of 50 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
41358997|NCT04277286|BEHAVIORAL|survey|"Behavioral study of patients who are in the Transend Program (compliance in follow-up visits after transfert from pediatric to adult care in the 24 months)"
40838959|NCT04622904|DRUG|lidocaine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of normal saline 100 mL will be administered preoperatively within 10 minutes. Followingly, normal saline will be administered intraoperatively at a rate of 20 mL/h
41023832|NCT00541047|PROCEDURE|quality-of-life assessment|
41023833|NCT00541047|RADIATION|radiation therapy|
41023834|NCT05889624|BEHAVIORAL|CBT|"During an 8-week active treatment, participants will receive 6 telehealth CBT sessions, followed by a maintenance phase (16 weeks) when participants will receive 3 booster CBT sessions. The sessions will be conducted by teletherapists from the Clinical Coordinating Center at Cincinnati Children's using a standardized treatment manual. A parent/legal guardian will be included in 2 sessions teaching ways to be active coaches, encouraging use of effective coping skills and refraining from reinforcement of maladaptive coping. Each session will be about 45 minutes."
41023835|NCT05889624|DRUG|Amitriptyline|During an 8-week active treatment, participants will begin taking a daily pill (amitriptyline) prescribed and managed clinically by the site headache provider. Amitriptyline will be taken once a day before bedtime. The weight based dosage will gradually be increased based on tolerability and a standardized titration protocol during the 8 week active treatment. The participant will remain on a maximum tolerated dose for the final 16 weeks (maintenance).
41023836|NCT02430077|DRUG|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
41023837|NCT02430077|DRUG|Placebo|Identical to Obeticholic Acid - placebo drug
41023838|NCT02023385|DEVICE|BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
41023839|NCT02023385|DEVICE|sham BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
41023840|NCT05935826|DRUG|Essential Amino Acid Supplement by Amino Co|2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA
41023841|NCT05935826|OTHER|Placebo|2 months of twice daily consumption of Placebo, followed by 10 months open label extension of EAA
41023842|NCT04679129|DRUG|ASC42|Oral tablets
41023843|NCT04679129|DRUG|Placebo|Oral tablets
41023844|NCT03632161|DRUG|Dexmedetomidine|isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
40838960|NCT01571232|DRUG|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
40838961|NCT01571232|DRUG|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
40838962|NCT00821912|DRUG|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
41023845|NCT03632161|DRUG|Bupivacaine|isobaric bupivacaine 0.5% (0.3ml/kg)
41023846|NCT03738150|BIOLOGICAL|Sotatercept|Sotatercept injection
41023847|NCT03738150|OTHER|SOC|SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
41023848|NCT04193202|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
41023849|NCT04193202|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
41023850|NCT05595798|DIAGNOSTIC_TEST|Airmod breathing sound monitoring|Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
41023851|NCT06532487|OTHER|Critical Time Medical-Legal Partnership Intervention|Utilizing a hybrid type II effectiveness-implementation trial with a cluster randomized design in six predominantly Latino-serving federally qualified health centers (FQHCs) in three major urban settings, we are examining whether integrating legal services into existing health clinics that serve Latinx and recent migrant communities can improve engagement in care and improve the health of Latinx/Hispanic and recent migrants.
41023852|NCT02172209|DRUG|BI 10773|
41023853|NCT02809976|DRUG|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
41023854|NCT03455283|DRUG|Clariscan|Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
41023855|NCT03455283|OTHER|Gadolinium-Based Contrast Agents|All GBCAs will be selected by the sites and recorded as by the brand names.
41023856|NCT00287911|DRUG|cisplatin|intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
41023857|NCT00287911|DRUG|topotecan hydrochloride|intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
41358998|NCT04403074|PROCEDURE|Celiac Plexus Neurolysis|When CPBs are not effective (less than one month of relief) then a Celiac Plexus Neurolysis may be completed to manage pain associated with Chronic Pancreatitis.
41358999|NCT04476706|DRUG|canakinumab|canakinumab
40838963|NCT00821912|DRUG|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
40838964|NCT00119821|BEHAVIORAL|Weight Reducing Diet|Behavioral intervention
40838965|NCT00119821|BEHAVIORAL|Exercise|Moderate exercise implemented plus behavioral intervention.
40838966|NCT00119821|BEHAVIORAL|Smoking Cessation|"Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.~NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant."
40838967|NCT01295970|PROCEDURE|Surgery|Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
41023858|NCT00287911|RADIATION|brachytherapy|Some patients may also undergo brachytherapy
41023859|NCT00287911|RADIATION|radiation therapy|once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
41023860|NCT05464628|DRUG|Atorvastatin|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
41023861|NCT05464628|DRUG|ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
41359000|NCT05136326|RADIATION|External-beam radiation|External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)
41359001|NCT05136326|DRUG|Capecitabine|825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
41359002|NCT05136326|DRUG|Temozolomide|75 mg/sqm p.o. 5 days/week for 5 weeks
41359003|NCT01493024|DRUG|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.
41359004|NCT01493024|DRUG|Placebo|Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
41359005|NCT05224856|BIOLOGICAL|CT-P63 and CT-P66 / Placebo|Inhalation
41359006|NCT01768624|PROCEDURE|dialysis, kidney transplant|
41359007|NCT03088995|DIAGNOSTIC_TEST|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
41359008|NCT06077409|OTHER|Skin To Skin|"Skin to Skin Contact Group The temperature of the environment where kangaroo care will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and kangaroo care will continue until 5 minutes after the procedure."
41359009|NCT06077409|BEHAVIORAL|Gentle Human Touch|Experimental Group (Gentle Touch/Gentle Human Touch-GHT); After the mother is dressed in a clean apron, her hands are washed and disinfected, and it is safe to warm the hand temperature with a non-contact thermometer device until the measured value is 34 ºC. The mother, who was previously informed about the method, will be placed on the eyebrow line with the crown piece that will separate the fingertips and tuft of one hand, while the other hand will be placed on the lower abdomen, which will mark the waist and hips (Figure 1). The blood collection amount of GHT application will be started 5 minutes before, make sure that the blood collection is done and the blood collection will continue until 5 minutes later.
41359010|NCT05911893|DIETARY_SUPPLEMENT|high caloric oral nutritional supplements|High caloric oral nutritional supplements (which can supplement 30% of the energy requirement) is given daily, and the recommended amount of energy and protein is referred to the 2013 Chinese Dietary Nutrient Reference Intake Table. At 6 months of enrollment, participants will be asked to evaluate whether to continue feeding according to the experimental group protocol or to stop to ensure proper nutritional intake.
41497677|NCT04896411|OTHER|Standard of care for no code|This intervention will use the standard of care phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
41497678|NCT02936453|PROCEDURE|Device implantation|"* Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~* Implantation of Activa RC neurostimulator"
41359011|NCT05911893|BEHAVIORAL|nutritional education|After enrollment,health education information is pushed approximately every 4 weeks through the WeChat platform or/and short text messages to parents.
41497679|NCT02457663|PROCEDURE|Blood Draw|Blood is to be collected at admission, prior to the 1st operating procedure, once daily for the following 7 consecutive days, at day 15, and at discharge (11 blood draws total). Blood will be taken from IV catheter or routine venipuncture if the catheter is not in place. The blood draw will occur prior to the induction of anesthesia or operating surgical procedure.
41497680|NCT05387850|OTHER|no intervention|no intervention
41497681|NCT03712514|OTHER|Destabilization of the upper cervical spine by Cervistab|Simulate a situation of destabilization of the cervical spine with Cervistab
41497682|NCT01221363|BEHAVIORAL|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
41497683|NCT01577589|DRUG|600 mg ceftaroline fosamil in 50 ml infusion volume|IV infusion
41497684|NCT01577589|DRUG|Placebo in 50 ml infusion volume|IV infusion
41497685|NCT01577589|DRUG|600 ceftaroline fosamil in 250 ml infusion volume|IV infusion
41497686|NCT01577589|DRUG|Placebo in 250 ml infusion volume|IV infusion
41497687|NCT01577589|DRUG|600 mg ceftaroline in 100 ml infusion volume|IV infusion
41497688|NCT01577589|DRUG|Placebo in 100 ml infusion volume|IV infusion
41497689|NCT00529282|DRUG|Ceftobiprole Medocaril|500 mg every 8 hours
41497690|NCT00529282|DRUG|Cefepime with or without vancomycin|120-minute infusion \[250 mL\]
41497691|NCT06568055|OTHER|No Intervention|This is non-interventional study.
41497692|NCT01616108|DRUG|Bupivacaine|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
41497693|NCT00699283|DRUG|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
41497694|NCT00699283|DRUG|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
41036555|NCT05255016|COMBINATION_PRODUCT|PXL Platinum 330 system + Riboflavin 0.25% TE Solution|"Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition CXL + Riboflavin 0.25% TE solution.~After topical anesthesia, the surgeon or trained designee will apply topical riboflavin (1 drop every 2 min for 40 min with PESCHKE TE solution \[0.25%\], or longer as needed to assure adequate corneal penetration). At the end of this pre-treatment period, the eye will be examined at the slit lamp with the blue filter for the presence of riboflavin throughout the stroma. When sufficient corneal riboflavin penetration is confirmed, the eye will be aligned under the PXL Platinum 330 light. The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min)."
41359012|NCT05911893|BEHAVIORAL|dietary guidance|At follow-up visits at 0, 1, 2, 3, 6,and 12 months after enrollment, a professionally trained pediatrician give the participant's guardian dietary instructions appropriate to the age stage and physical condition of the child. Each session lasts approximately 10 minutes.
41359013|NCT01757821|DEVICE|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
41359014|NCT01757821|DEVICE|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
41359015|NCT01757821|DEVICE|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
41359016|NCT02347124|BEHAVIORAL|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
41359017|NCT02347124|BEHAVIORAL|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
41359018|NCT01207427|DRUG|Placebo|
41359019|NCT01207427|DRUG|ADL5945 0.1 mg|
41359020|NCT01207427|DRUG|ADL5945 0.25 mg|
41359021|NCT02384629|DEVICE|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
41359022|NCT02384629|DEVICE|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
41359023|NCT02384629|DEVICE|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
41359024|NCT02384629|DEVICE|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
41359025|NCT00104299|DRUG|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m\^2 infusions once weekly for 4 week
41023862|NCT06560268|DRUG|Sevoflurane; In our study, the effects of sevoflurane in different FGFs administered in children undergoing strabismus surgery on EA and anesthetic agent consumption will be investigated.|Low-flow anaesthesia is generally adminstered as nitrogen wash-out, a period of higher flow rate in combination with a high vaporizer setting for initial saturation, and subsequent reduction of fresh gas flow and adjustment of the vaporizer to maintain the desired end-tidal anesthetic agent concentration (Etaa).In the initial wash-in phase, the vaporizer setting is adjusted to 6% for desflurane and 2.5-3% for sevoflurane, with FGF=4 L/min, until the Etaa concentration is 1-1.3 MAC. In another method, the vaporizer setting is adjusted to 12-18% for desflurane and 6-8% for sevoflurane, with FGA=1 L/min. Reducing the FGF during the wash-in period prevents unnecessary depth of anesthesia and reduces the consumption of inhalational anesthetics. In LFA using minimal FGF (250-500 mL/min), if the vaporizer is turned off 10-15 min before the end of the operation and the FGF is not changed, the inhaled anesthetic agent concentration gradually and slowly decreases to zero.
41023863|NCT05673694|DRUG|EG017|According to the dosage group of the program, once a day.
41359026|NCT00104299|DRUG|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
41497695|NCT06200324|OTHER|Ready-to-Use Parenteral Nutrition|"In newborns weighing less than 1000 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum volume of 128 ml/kg/day, with a provision of 4 grams/kg/day of protein and a metabolic rate of 12 mg/kg/minute.~For newborns weighing between 1001-1500 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum of 110 ml/kg/day.~When enteral intake exceeds 70 ml/kg/day, a gradual decrease in the volume of parenteral nutrition is initiated. We discontinue parenteral nutrition in newborns weighing less than 1000 grams with enteral volume of 120 ml/kg/day, and for those between 1000 grams and 1500 grams, enteral nutrition volume of 100 ml/kg/day."
41497696|NCT03967535|DEVICE|MRI Brain Imaging|Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
41497697|NCT03967535|BEHAVIORAL|Mental Health Assessment and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
41497698|NCT06358430|DRUG|Fludarabine Phosphate|Given by IV
41497699|NCT06358430|DRUG|Cyclophosphamide|Given by IV
41497700|NCT06358430|DRUG|Cetuximab|Given by IV
41023864|NCT00812812|DRUG|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
41023865|NCT00812812|DRUG|paroxetine 20mg tablet|1 tablet once a day
41359027|NCT00104299|DRUG|Azathioprine|2 mg/kg/day orally for months 4-6
41359028|NCT00104299|DRUG|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
41359029|NCT00104299|DRUG|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
41359030|NCT04506606|PROCEDURE|Afferent block|Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
41359031|NCT05119998|DRUG|IBI325 + sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 and sintilimab until progressive disease, intolerability, or other reasons leading to treatment discontinuation
41359032|NCT05119998|DRUG|IBI325|IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation
41359033|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
41359034|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
41359035|NCT00195702|DRUG|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
41359036|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
41497701|NCT06358430|DRUG|TROP2-CAR-NK Cells|Given by IV
41497702|NCT06358430|DRUG|Rimiducid (AP1903)|Given by IV
41497703|NCT06358430|PROCEDURE|Lymphodepleting Chemotherapy|Given by Chemotherapy
41497704|NCT05670574|PROCEDURE|Surgery with extended (D3) mesenterectomy for small bowel tumors|
41497705|NCT04830059|BEHAVIORAL|Exercise|Two types of exercise intervention and control group
41497706|NCT04830059|BEHAVIORAL|Air purification|Air purification in order to reduce the PM2.5 and PM10
41497707|NCT05248035|OTHER|Adult patient hospitalized in ICU|acquisition of dynamic parameters in addition to pupillary diameter, such as . pupillary diameter, variation of the pupillary diameter, pupillary constriction speed, pupillary dilatation speed, photomotor reflex latency, NPi and symmetry of pupillary responses after a standardized light stimulus
41497708|NCT03477903|DRUG|TAK-954|TAK-954 infusion
41497709|NCT03477903|DRUG|Metoclopramide|Metoclopramide infusion
41497710|NCT03477903|DRUG|Normal Saline|0.9% sodium chloride for injection
41497711|NCT01192763|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
41497712|NCT01192763|OTHER|laboratory biomarker analysis|Correlative studies
41497713|NCT01192763|OTHER|pharmacological study|Correlative studies
41497714|NCT01192763|PROCEDURE|neoadjuvant therapy|
41497715|NCT01192763|PROCEDURE|therapeutic conventional surgery|
41023866|NCT00812812|DRUG|matched placebo to paroxetine 10mg|2 tablets once a day
41023867|NCT00812812|DRUG|matched placebo to paroxetine 20mg|1 tablet once a day
41023868|NCT04794582|DEVICE|ProGrip™ Self-Gripping Polyester Mesh|Supra-aponeurotic placement of ProGrip® macroporous polyester mesh in the supra-aponeurotic position
41023869|NCT03503968|DRUG|MDG1011|PRAME-T-Cell Receptor Gene Modified Autologous T Cells
41023870|NCT03503968|OTHER|Investigator Choice therapy|Any intervention/therapy chosen by the investigator
41023871|NCT05159752|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
41023872|NCT05324137|DRUG|CM326|CM326 injection
41023873|NCT05324137|OTHER|Placebo|Placebo
41023874|NCT06533774|DEVICE|Phonak Audéo Lumity 90-R|This study will be using the Audeo L90-R devices, which are programmed by the hearing care professional (HCP) using Target fitting software version 8.1.
41023875|NCT02527720|BEHAVIORAL|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at \~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
41023876|NCT03430466|DRUG|Durvalmab&Tremelimumab&Fulvestrant|Durvalumab and Tremelimumab once in 4 weeks Durvalumab for 13 months Tremelimumab for initial 4 months Fulvestrant : At baseline, then week 2, week 4 and after that every 4 weeks
41359037|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
41359038|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
40838968|NCT01295970|PROCEDURE|Stereotactic Radiosurgery|This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
41359039|NCT04484610|DRUG|Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain|Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
41359040|NCT00948389|DRUG|Dasatinib|Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
41359041|NCT00948389|DRUG|Lomustine|Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
41359042|NCT04686396|DEVICE|Demineralized bone matrix|Demineralized bone matrix
41359043|NCT02777008|DRUG|CTP-543|
41359044|NCT02777008|DRUG|Placebo for CTP-543|
41359045|NCT05931575|DRUG|Fasudil hydrochloride|Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.
41023877|NCT00847574|BEHAVIORAL|Moderate-fat|35% of calories from fat
41023878|NCT00847574|BEHAVIORAL|Lower-fat|20% of calories from fat
41359046|NCT05931575|DRUG|Placebo|0.05 ml Quinine dihydrochloride solution (from Quinina Labesfal) in screw flask supplemented with 30 ml Glucose 40% solution from miniplasco directly before use
41023879|NCT05005611|DIETARY_SUPPLEMENT|Placebo|"A pack of powder without probiotics.~1 pack / day"
41359047|NCT05356637|DEVICE|Werewolf Fastseal 6.0|bi-polar hemostatic wand
41359048|NCT02883894|OTHER|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
41359049|NCT05963581|BEHAVIORAL|Salsa Dancing|Participants will complete salsa dancing classes in central Oxford with instructor(s) from the Oxford University Salsa Society
41359050|NCT02087085|DRUG|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
41359051|NCT02087085|OTHER|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
41023880|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus salivarius AP-32|"A pack of powder with probiotics Lactobacillus salivarius AP-32~1 pack / day"
41023881|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Bifidobacterium animalis subsp. lactis CP-9|"A pack of powder with probiotics Bifidobacterium animalis subsp. lactis CP-9~1 pack / day"
41023882|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus rhamnosus LGG|"A pack of powder with probiotics Lactobacillus rhamnosus LGG~1 pack / day"
40838969|NCT04487171|OTHER|Questionnaire|The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.
40838970|NCT01477008|DEVICE|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
40838971|NCT01477008|PROCEDURE|Marrow Stimulation|Microfracture or Subchondral Drilling
40838972|NCT00002580|DRUG|cyclophosphamide|
40838973|NCT00002580|DRUG|fluorouracil|
41023883|NCT01449305|DEVICE|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
41023884|NCT02131298|DRUG|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
41160626|NCT00541840|DRUG|Sorafenib|"Phase I:~Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .~Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Phase II:~Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity."
41160627|NCT05188547|DEVICE|Video education|Participants will be shown a video educating them on anesthesia and perioperative instructions.
40838974|NCT00002580|DRUG|goserelin acetate|
40838975|NCT00002580|DRUG|leuprolide acetate|
40838976|NCT00002580|DRUG|methotrexate|
41023885|NCT02131298|DRUG|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
41023886|NCT05285982|DRUG|Nintedanib (Ofev®)|Nintedanib (Ofev®) soft capsules
41023887|NCT05746338|DEVICE|Ring-type wearable device|The ring-type wearable device is a slim, lightweight smart ring that continuously tracks blood oxygen saturation and heart rate throughout the day.
41023888|NCT05746338|DEVICE|Overnight polysomnography|Overnight polysomnography is the gold standard for diagnosing OSAS.
41023889|NCT04536896|OTHER|Smartphone breastfeeding application|This intervention consists of a smartphone application which contains relevant information and topics regarding proper breastfeeding knowledge for medical students.
40838977|NCT00002580|DRUG|tamoxifen citrate|
40838978|NCT00002580|PROCEDURE|conventional surgery|
40838979|NCT00002580|PROCEDURE|laparoscopic surgery|
40838980|NCT00002580|PROCEDURE|oophorectomy|
40838981|NCT00002580|RADIATION|radiation therapy|
40838982|NCT05225259|DRUG|LOXO-260|Oral
40838983|NCT03358940|OTHER|urine collection|For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
40838984|NCT03134183|DRUG|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D\&E
40838985|NCT03134183|DRUG|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D\&E
40838986|NCT02178267|DIETARY_SUPPLEMENT|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
40838987|NCT00290498|DRUG|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
40838988|NCT00290498|DRUG|Cyclophosphamide|"Arm A: Cyclophosphamide 300 mg/m\^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1"
40838989|NCT00290498|DRUG|Doxorubicin|Arm A: Doxorubicin 50 mg/m\^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
41359052|NCT05947968|OTHER|Scapular PNF|"Scapular proprioceptive neuromuscular facilitation exercise: will be applied in two diagonals:~1. anterior elevation and posterior depression~2. posterior elevation and anterior depression for 3 sets of 10 repetitions, The rest interval between sets will be 20 seconds.~Patients will lay on the unaffected side while the therapist stands in the line of desired motion. Firstly, the therapist will give preparatory instructions. In the beginning of the pattern, the therapist pulls the scapula to the elongated position and then gives instructions for the desired movement."
41359053|NCT05947968|OTHER|Shoulder strengthening exercises|"Shoulder strengthening exercises:~The following four exercises will focus on shoulder and scapular strengthening. Before starting the program, the patients will be thoroughly instructed in the four exercises, and illustrations with specific exercise instructions will be provided. All subjects will perform the exercises with the affected side for three sets of 10 repetitions for each exercise, with a 1-minute rest between sets.~1. Standing shoulder external rotation with elastic resistance.~2. Bilateral external rotation with scapular retraction exercise.~3. Resisted scapular retraction with shoulder external rotation (Middle trapezius muscle).~4. Weighted scapular retraction and downward rotation Y-shape (lower trapezius muscle)."
41497716|NCT03696238|DIETARY_SUPPLEMENT|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
41497717|NCT03696238|OTHER|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
41497718|NCT01504958|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS."
41023890|NCT04536896|OTHER|Traditional face-to-face breastfeeding lecture|This intervention consists of the impartition of a face-to-face breastfeeding course
41359054|NCT04197999|DRUG|GMI-1359|Injection 10 mg/mL
41359055|NCT00000829|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
41359056|NCT00000829|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
41359057|NCT00000829|BIOLOGICAL|Placebo|Administered at 0, 2, 4, and 15 months of age
41359058|NCT02871024|DEVICE|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
41359059|NCT06119061|DRUG|Telavancin Injection|Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).
41359060|NCT04449185|DRUG|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days
41359061|NCT01935622|DRUG|Doxycycline|Doxycycline 1 tablet every 12 hours for 14 days
41359062|NCT01935622|DRUG|placebo|Placebo 1 tablet every 12 hours for 14 days
41497719|NCT01504958|BEHAVIORAL|NICE Cognitive Training|"12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group."
41023891|NCT02002767|DRUG|Velpatasvir|Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
41160628|NCT03011554|DEVICE|Implantable Miniature Telescope (IMT)|Monocular implantation of the IMT.
41160629|NCT03321656|DRUG|Tacrolimus|0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally
41160630|NCT03321656|DRUG|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
41359063|NCT00998933|DRUG|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
41359064|NCT02517502|DRUG|DHA|4 capsules of 400 mg DHA daily
41359065|NCT02517502|DRUG|Placebo|Matched, blinded placebo
41359066|NCT03729128|DRUG|dextromethorphan and memantine (DM+MM)|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.
41359067|NCT03729128|DRUG|Placebos|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
41359068|NCT04815226|DEVICE|Peristeen Transanal Irrigation|Using Peristeen Transanal Irrigation twice per week for 12 weeks
41359069|NCT04801615|OTHER|Surgery|All patients in the database undergo surgery due to a suspicion of necrotizing soft tissue infections
41359070|NCT00443794|DRUG|Thiazides|Capsule (blinded) oral administration once daily for 12 weeks
41359071|NCT00443794|DRUG|Ramipril with Thiazide|Capsule (blinded) oral administration 12 weeks
41359072|NCT00443794|DRUG|Thiazide plus atenolol|Caspule (blinded) for oral administration once daily for 12 weeks
41359073|NCT00443794|DRUG|Ramipril plus atenolol|Capsule ( blinded) for oral administration once daily for 12 weeks
41359074|NCT00443794|DRUG|Ramipril plus atenolol plus thiazide|Capsule (blinded) for oral administration once daily for 12 weeeks
41359075|NCT00443794|DRUG|POLYCAP|Capsule for Oral Administration once daily for 12 weeks
41359076|NCT00443794|DRUG|Thiazide + Ramipril+Atenolol+Aspirin|Capsule (Blinded) for oral administration once daily for 12 weeks
41359077|NCT00443794|DRUG|Simvastatin|Capsule (Blinded) for oral administration once daily for 12 weeks
41359078|NCT00443794|DRUG|aspirin|capsule (Blinded) for oral administration once daily for 12 weeks
41359079|NCT02781662|BEHAVIORAL|Pharmacist Home-Visit|
41359080|NCT02768428|OTHER|Video-Audio Media|each arm spends 15 mins for watching the video or study the handbooks
41359081|NCT00672464|DRUG|Olanzapine|Olanzapine zydis 15 mg QHS for 28 days
41497720|NCT05734430|GENETIC|Genetic profiling|Whole exome sequencing
41497721|NCT05734430|OTHER|Retrospective tissue procurement|Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed
41497722|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
41497723|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
41497724|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
41497725|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
41497726|NCT04020289|BEHAVIORAL|"Psychoeducational Program BalancingMySwing"|"Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy"
41497727|NCT01595763|OTHER|D Dimer and ultrasonography|clinical history, Dimer D, ultrasonography
41497728|NCT04460482|DEVICE|Near-infrared spectroscopy (NIRS)|NIRS-guided PCI
41497729|NCT04460482|DEVICE|Angiography|Angiography guided PCI
40838990|NCT00290498|DRUG|Vincristine|"Arm A: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle."
41160631|NCT04765813|BEHAVIORAL|Cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a smartphone App with therapeutic components during the intervention (8 weeks) and follow-up period (time frame: one year)."
41359082|NCT00672464|DRUG|Metformin|Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
41359083|NCT00672464|DRUG|Simvastatin|Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
41359084|NCT01293123|DRUG|Raltegravir|raltegravir 400 mg PO twice daily
41359085|NCT01293123|DRUG|Efavirenz|efavirenz 600 mg PO once daily
41359086|NCT01602627|DRUG|Hsp90 inhibitor AUY922|Given IV
41359087|NCT01602627|OTHER|pharmacological study|Correlative studies
41359088|NCT01602627|OTHER|laboratory biomarker analysis|Correlative studies
41359089|NCT00469443|DRUG|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
41359090|NCT00469443|DRUG|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
41359091|NCT00469443|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
41359092|NCT00469443|DRUG|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
41497730|NCT05209152|DRUG|AMG 176|Administered as an intravenous (IV) infusion.
41497731|NCT05209152|DRUG|Azacitidine|Administered as an IV infusion or subcutaneous (SC) injection.
41497732|NCT00798148|DRUG|131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation|131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
41497733|NCT04810949|DIETARY_SUPPLEMENT|Vitamine D3 supplementation|1. The supplementation treatment will consist of prescribing vitamin D3 consumption of 4000 U 13 single dose tablets each month (52,000 IU).
41497734|NCT04810949|DIETARY_SUPPLEMENT|Diet and sun exposure|"2. Hygienic-dietary recommendations will consist of 2 steps~1. Sun exposure at least 10 minutes a day from 10: 00-6: 00 pm~2. Consumption of foods rich in vitamin D: milk, fish, almonds, mushrooms"
41497735|NCT01044264|DRUG|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Topical Gel
41497736|NCT01044264|DRUG|Placebo|Placebo
41497737|NCT04824157|OTHER|Non|Follow up
41497738|NCT05160857|DRUG|Herombopag Olamine|The initial dose of hetropapa is recommended to be 7.5mg, once a day, oral on an empty stomach, and can only be eaten after oral administration for 2 hours, so as to avoid taking it with meals.
41497739|NCT03463473|DRUG|3 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 3 mg/kg (Q3W)
41497740|NCT03463473|DRUG|10 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q3W)
41497741|NCT03463473|DRUG|20 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 20 mg/kg (Q3W)
41497742|NCT03463473|DRUG|10 mg/kg Q2W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q2W)
41497743|NCT05310162|BEHAVIORAL|Food, fun and family|"The intervention consists of a series of change of habits in the way children eat, the reduction of the recreational time of screens and healthy habits of physical activity. This intervention, which is called Food, Fun \& Family (FFF), is aimed at parents and has been shown to be effective in reducing the consumption of empty calories by children. It teaches parents skills to reduce their daily energy intake of added sugars and saturated fats, it also seeks to reduce screen time.~The intervention contains information and recommendations, through guides, in which precise instructions are given about how to maintain a healthy environment at home."
40838991|NCT00290498|DRUG|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
41023892|NCT06536218|BEHAVIORAL|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION Conscious Awareness Based Stress Reduction (BFTSA) intervention consists of seven sessions in total and is planned to be completed in a total of seven weeks, with one session per week and each session being 45 minutes. After the results of the PSG patients are determined according to the randomization criteria, they receive certain points from the sleep scale, it is planned to call the patients by phone and explain the meaning and importance of the study, the applications to be performed in the study and its duration. It is planned to hold online individual interviews with patients who agree to participate in this study.
41023893|NCT06431620|DRUG|Recombinant Human Thyroid Stimulating Hormone|recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.
41036556|NCT05255016|OTHER|Sham CXL + Artificial Tears|Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition, for subjects in the sham group, artificial tears (1 drop every 2 min for 40 min) will be administered. after instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
41359093|NCT00469443|DRUG|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
40838992|NCT00290498|DRUG|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
41359094|NCT00469443|DRUG|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
41359095|NCT00469443|DRUG|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
41359096|NCT03365531|OTHER|Alternate Daily Fasting (ADF)|See ADF arm for details
41359097|NCT03365531|OTHER|Caloric Restriction (CR)|See CR arm for details
41359098|NCT03479424|OTHER|Observational|The MYIA in-home suite of devices.
40838993|NCT00290498|DRUG|Cytarabine|Arm B: Cytarabine 3 g/m\^2 by vein over 2 hours every 12 hours X 4 doses on days 3 \& 4, cycle 2 and alternating cycles.
40838994|NCT00290498|DRUG|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
40838995|NCT02288988|PROCEDURE|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
40838996|NCT00875862|PROCEDURE|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
40838997|NCT02780973|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
41359099|NCT06462079|DRUG|Sacituzumab Govitecan|Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity.
41359100|NCT06462079|RADIATION|Radiotherapy|Radiotherapy was administered after the second infusion of Sacituzumab Govitecan, on day 9 after the start of this regimen. The radiotherapy regimen was: brain metastases at a dose of 60 Gy/20 doses. For lesions located adjacent to the brainstem and optic nerve, 54 Gy/20 doses were given. For patients with ≥5 lesions, whole-brain radiotherapy at 40 Gy/20 doses was synchronized with radiotherapy to localized brain metastases.
41023894|NCT05236790|DIAGNOSTIC_TEST|Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye|Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
41359101|NCT03458351|DEVICE|Remote ischemic preconditioning|Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
41359102|NCT03458351|DEVICE|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
41359103|NCT01287858|DRUG|AC430|Healthy volunteers will either receive AC430 or placebo.
41359104|NCT00389909|DRUG|Doxapram|"Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender."
41359105|NCT01612494|DRUG|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
41359106|NCT01612494|OTHER|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
41359107|NCT04812236|DRUG|Wulingsan single decoction granules|Wulingsan single decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
40838998|NCT01805388|DRUG|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
40838999|NCT01805388|PROCEDURE|Control Non-Study Drug Group|Endodontic RTC with no study drug
40839000|NCT02196480|BIOLOGICAL|anti-TNF|Anti-tumor necrosis factor therapy
41359108|NCT04812236|DRUG|Wulingsan co-decoction granules|Wulingsan co-decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
41359109|NCT04812236|DRUG|Wuling Powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. 2 times a day, 5g each time, take it with warm water
41359110|NCT04812236|DRUG|Wulingsan granule simulant|Wulingsan granule simulant, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
41023895|NCT05501509|PROCEDURE|Coracoclavicular fixation with acromioclavicular stabilization for the management of an unstable acromiclavicular luxation|Using a 3-hole third plate and high resistance sutures across the acromioclavicular joint to achieve horizontal and vertical stability of the joint
40839001|NCT02726945|DEVICE|GID SVF-2|The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
40839002|NCT02726945|OTHER|Placebo|Placebo Control
41023896|NCT05501509|PROCEDURE|Coracoclavicular fixation for the management of an unstable acromiclavicular luxation|Isolated coracoclavicular repair using a 3 hole third plate.
41023897|NCT06502457|DRUG|painkiller|The control group will receive a painkiller adapted to the service protocol after the fetal heart rate has been recorded.
41023898|NCT06502457|OTHER|hypnosis group|"The hypnosis group will receive a hypnosis session after the fetal heart rate has been recorded. Automated measurement of blood pressure and maternal heart rate will take place during the session in order to objectively assess the impact of the session on the mother.~Patients in the hypnosis group will then have access to the virtual reality headset on request throughout the latency or maturation phase, and will also be able to benefit from a painkiller in accordance with the service protocol if they so request."
41023899|NCT04734379|DRUG|Fasudil|Oral fasudil 180 mg/day
41023900|NCT01626976|DRUG|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
41023901|NCT01626976|DRUG|Placebo|Solution, single dose
41023902|NCT01626976|DRUG|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
41023903|NCT01626976|DRUG|Placebo|suspension, single dose
41023904|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
41023905|NCT01626976|DRUG|Placebo|suspension, single dose
40839003|NCT05612360|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
40839004|NCT03228485|DEVICE|MyBPH Care mobile app|The application that will give daily medication reminders and via which the questionnaires can be filled out.
40839005|NCT05158790|OTHER|Questionnaire|Administration of a questionnaire
41023906|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
41023907|NCT01626976|DRUG|Placebo|suspension, single dose
41023908|NCT01626976|DRUG|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
41023909|NCT01626976|DRUG|Placebo|suspension, single dose
41023910|NCT06024954|OTHER|aromatherapy|"Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated."
41359111|NCT03524560|OTHER|Comprehensive geriatric assesment|Comprehensive Geriatric Assesment (CGA) consisting of detailed history and examination, drug consumption information, Body Mass Index (BMI), Waist Circumference (WC), Timed Up \& Go test (TUG), Clock Drawing Test (CD), Activities of Daily Living and Instrumental Activities of Daily Living scales (ADL \& IADL), Mini Mental State Examination (MMSE), Tinetti Gait and Tinetti Balance scores (TG \&TB), 30 items Geriatric Depression Scale (GDS) was performed for each subject
40839006|NCT02870088|BEHAVIORAL|Prolonged Sitting|After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
41023911|NCT06024954|OTHER|music therapy|"The relaxing music group listened to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and sound elements from nature (eg rain, bird, forest sound). Listened with headphones for 20 minutes."
41023912|NCT06024954|OTHER|aromatherapy and music therapy|Inpatients will be given music with a loudspeaker with the effect of aromatherapy inhaler for three consecutive days. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again, pain, anxiety, blood pressure, pulse, respiratory rate were evaluated.
41359112|NCT00282373|DEVICE|mild hypothermia|
41359113|NCT06248515|DRUG|Sacituzumab govitecan-hziy|10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles
41359114|NCT02935010|DRUG|Esomeprazole|proton pump inhibitor
41359115|NCT02935010|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
40839007|NCT02870088|BEHAVIORAL|Breaking Sitting|After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
41497744|NCT05310162|BEHAVIORAL|Counseling|"Simple verbal instructions will be given in the consultation to reduce the time of use of screens and refined sugar.~For refined sugar reduction, parents will be told to avoid sugary drinks, add sugar to drinks (juices, milk, etc.), and avoid snacks and sweets. It will also be indicated that the screen time should be less than two hours a day and in no case use them two hours before sleeping."
40839008|NCT04966923|OTHER|No intervention in this study|Analyses of pathogenic variant TP53 and variants in genetic test
41023913|NCT01256905|DRUG|Armodafinil|Armodafinil 150 mg
41359116|NCT02935010|DRUG|Amoxicillin|antibiotic for H. pylori eradication
41359117|NCT02935010|DRUG|Clarithromycin|antibiotic for H. pylori eradication
41359118|NCT02935010|DRUG|Metronidazole|antibiotic for H. pylori eradication
41497745|NCT05917600|OTHER|APN intervention|"Advanced Practice Nurses (APN) intervention between the ambulatory hospitalization (AH) and the MD consultation~APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
41497746|NCT06332729|DEVICE|universal exercis unit|Universal exercise unit (UEU) consists of system of pulleys, suspensions, belts for supporting and elastic cords. UEU is based on the concept of unloading the body against gravity and to perform movement of weak part of the body. Therapist's hands are free to provide adequate support as required by the patient during exercise training Universal exercise unit, therapy sessions extended are from three to four hours Children and adults have neurological conditions can used. Spider cage is made of metal could be depending on population pediatric or adults. Elastic resistance of cords used to increase strengthen of muscle
41023914|NCT06572930|DRUG|Gonal-f (gonadotropin)|Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.
41359119|NCT02935010|DRUG|Levofloxacin|antibiotic for H. pylori eradication
41359120|NCT02306525|PROCEDURE|Arthroscopic surgery of the hip joint|Arthroscopic treatment of Femoroacetabular Impingement
40839009|NCT00328471|BEHAVIORAL|care management|
40839010|NCT06507527|OTHER|Collection of variables|This is an observational study, so no interventions that are not routine clinical practice are performed. It is only about collecting information on variables that are already collected in normal clinical practice.
40839011|NCT03465553|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with advanced thoracic cancer
40839012|NCT00536887|DRUG|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
40839013|NCT04043832|DIAGNOSTIC_TEST|quantitative ultrasonic technique|Collection of all quantitative ultrasonic data was performed by one ultrasound physician
40839014|NCT00619489|DRUG|vedolizumab|Vedolizumab for intravenous (IV) infusion
40839015|NCT06412952|DRUG|68Ga-RM26|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.
40839016|NCT01583816|DRUG|Resiquimod 0.03%|topical application
40839017|NCT01583816|DRUG|Resiquimod 0.01%|topical application
41359121|NCT03427203|DEVICE|SenSura Mio|SenSura Mio is a marked ostomy device which is used as the comparator in this study
41359122|NCT03427203|DEVICE|Coloplast Ostomy device 1|Coloplast Ostomy device 1 a newly developed ostomy device
41359123|NCT03427203|DEVICE|Coloplast Ostomy device|Coloplast Ostomy device 2 a newly developed ostomy device
41359124|NCT03427203|DEVICE|Coloplast Ostomy device 3|Coloplast Ostomy device 3 a newly developed ostomy device
41359125|NCT03933553|OTHER|Aromatherapy with essential oil|the aromatherapy by fragrance inhalation
40839018|NCT01583816|DRUG|placebo|topical application
40839019|NCT01636349|OTHER|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
40839020|NCT06382935|OTHER|Probin Pocket Depth reduction|Probin Pocket Depth reduction in millimetres before and after treatment
40839021|NCT03107988|DRUG|Lorlatinib|Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.
40839022|NCT03107988|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2/day will be administered as a 30 minute IV infusion on days 1-5 of each cycle
40839023|NCT03107988|DRUG|Topotecan|Topotecan 0.75mg/m2/day will be administered as a 30 minute IV infusion immediately following cyclophosphamide on days 1-5 of each cycle
41359126|NCT02698176|DRUG|Birabresib|Administered as an oral capsule in a fasted state
41359127|NCT02134340|DRUG|[I-124]-CPD-1028 Injection|A single intravenous dose of \[I-124\]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
41359128|NCT02134340|BIOLOGICAL|CPD-1061|\[Optional\] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of \[I-124\]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
40839024|NCT03107988|DRUG|Filgrastim/pegfilgrastim|"Filgrastim is to be given with each course beginning 24-48 hours following completion of cyclophosphamide and topotecan and continued through post-nadir count recovery with an ANC \> 2000/mm\^3 at 5mcg/kg/day. Filgrastim must be discontinued at least 24 hours prior to the start of the next course of therapy.~Pegfilgrastim (100mcg/kg; 6mg maximum dose) may be substituted and is given one time at 24-48 hours from completion of cyclophosphamide and topotecan."
40839025|NCT01287195|DRUG|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
41359129|NCT02369757|BEHAVIORAL|Navigator intervention|peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
40839026|NCT01287195|DRUG|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
40839027|NCT04946123|DIETARY_SUPPLEMENT|L-carnitine+Selenium|Supplementation with L-carnitine and Selenium
40839028|NCT00785174|DEVICE|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
40839029|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
40839030|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
40839031|NCT03700437|OTHER|Fasting-Mimicking Diet|Chemo-immunotherapy + FMD (fast-mimicking diet)
40839032|NCT03813381|BEHAVIORAL|Calorie and protein restriction diet|"Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention."
40839033|NCT02751528|BIOLOGICAL|ETBX-021|ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
40839034|NCT05296031|DEVICE|Treatment with Zilver PTX Drug Eluting Stent (DES) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
40839035|NCT05296031|DEVICE|Treatment with Zilver Flex Bare Metal Stent (BMS) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
40839036|NCT05571956|OTHER|Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group|Pancreatic masses were sampled using a 22-gauge FNB needle. If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs
40839037|NCT00724113|PROCEDURE|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
40839038|NCT00724113|PROCEDURE|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
41023915|NCT05609097|OTHER|PRIME|PRIME is a a 'hybrid' aerobic-resistance (cardio and weights) program designed to target all major muscle groups and address the muscle limitations responsible for reduced fitness in the elderly. This occurs by minimizing the central limitations to more traditional exercise by delivering an ideal exercise stimulus to muscles in a way in which the heart is not a limiting factor. Each exercise involves contractions of specific isolated muscle groups with a moderate load, defined as 40%-50% of their maximal voluntary capacity.
41359130|NCT06464276|OTHER|No intervention|No intervention
41359131|NCT01266876|DRUG|Alirocumab|Alirocumab two SC injections in the abdomen only.
41359132|NCT01266876|DRUG|Placebo|Placebo two SC injections in the abdomen only.
41359133|NCT03562728|DEVICE|MRP and NMES(neuromuscular electric stimulation)|nutrition supplementation includes addition of essential amino acids 3 times a day to feeding
41359134|NCT03562728|OTHER|Standard of Care|Patients in the control group are going to receive standard of care
41497747|NCT06332729|DEVICE|functional electrical stimulation|Functional electrical stimulation (FES) is defined as the electrical stimulation of muscles that have impaired motor control to produce a contraction to obtain functional useful movement
41497748|NCT05127512|OTHER|Education Video|A 6.47-minute education video was created by the research group based on American Urogynecology Society (AUGS) and International Urogynecologic Association (IUGA) patient education pamphlets. Participants in the intervention group will be asked to watch this video after completing a baseline knowledge questionnaire of pelvic floor disorders.
41497749|NCT05930457|DRUG|2.5-3.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2.5-3.5mCi 64Cu-FAPI-XT117 injection.
41497750|NCT05930457|DRUG|3.5-4.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 3.5-4.5mCi 64Cu-FAPI-XT117 injection.
41497751|NCT05930457|DRUG|4.5-5.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4.5-5.5mCi 64Cu-FAPI-XT117 injection.
40839039|NCT05629507|DEVICE|Virtual Reality|"The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.~The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios)."
40839040|NCT01114360|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
40839041|NCT01114360|DRUG|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
40839042|NCT01062061|BIOLOGICAL|VARIVAX™|Attenuated live varicella vaccine
40839043|NCT00495755|DRUG|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
40839044|NCT00434798|BIOLOGICAL|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10\^6-10\^9 CFU
40839045|NCT02506686|DRUG|Meropenem|Meropenem i.v.
40839046|NCT04591925|DEVICE|Control Device insulin infusion devcie|Control Device - Commercially available insulin infusion device using a soft Teflon indwelling cannula
40839047|NCT04591925|DEVICE|Investigative insulin infusion devcie|Investigative insulin infusion device with coil-reinforced soft polymer indwelling cannula
40839048|NCT05490108|BIOLOGICAL|ZR202-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype)
41036557|NCT05735951|DRUG|STIRIPENTOL oral administration|"Oral administration of:~* Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~* Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~* Day 15: 1000 mg of stiripentol (single dose at the end of breakfast)."
41359135|NCT03950505|DRUG|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks|All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5\~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
41359136|NCT02557269|DRUG|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
41359137|NCT02557269|DRUG|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
41359138|NCT02557269|DRUG|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
41359139|NCT02557269|DRUG|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
41359140|NCT02557269|OTHER|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
41497752|NCT05423795|OTHER|Telemedicine-based intervention|Telemedicine-based intervention Multifaceted intervention including daily videoconferences with audit and feedback, educational interventions, and dissemination of published works
41497753|NCT05423795|OTHER|Standard of care arm|Classic expertise (as routinely performed in the participating ICU)
41497754|NCT02338804|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
41497755|NCT02338804|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
41497756|NCT05377892|OTHER|Dietary protein|High protein followed by reduced protein diet
40839049|NCT05490108|BIOLOGICAL|ZR202a-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (variant)
40839050|NCT05490108|BIOLOGICAL|Comirnaty®|Comirnaty® (Pfizer-BioNTech)
40839051|NCT05628207|OTHER|Observational|There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.
40839052|NCT05628207|OTHER|Observational-control|There is no intervention, the hospitals will not use the CDS system.
40839053|NCT02488746|DEVICE|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
41359141|NCT02557269|DRUG|Bilastine 20 mg|1 tablet per os - as needed
41023916|NCT05609097|OTHER|COMBO|"COMBO training includes both aerobic (cardio) and resistance (weightlifting) exercises. The aerobic component will be done on the stationary bicycle at 10-15 min duration at a target exercise intensity of 40-50% of VO2peak. This will feel like an intensity that is fairly light to somewhat hard, progressing gradually according to tolerance up to 20 mins. Intensity will be adjusted so that the difficulty remains in the target zone. The resistance component involves eight exercises, two sets of 10 repetitions, initially prescribed at 50-60% 1 repetition max. Subject will lift about half of their predicted maximal strength, 10 times, on 2 separate occasions with a rest between. Thereafter, the difficulty will be increased by approximately 10% when difficulty drops below the target range."
41359142|NCT02557269|DRUG|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
41359143|NCT00129220|DRUG|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
41359144|NCT00129220|DRUG|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
41359145|NCT00129220|DRUG|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
41023917|NCT00849342|DRUG|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
41023918|NCT04431102|OTHER|PILATES METHOD|"It is intended that the Pilates program have a duration of four weeks and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule. In this sense the sessions of Pilates is adjusted to these assumptions and the Pilates monitor offers several schedules on diferent days of week.~The pregnant women assigned to the intervention group will be supervised by the midwifery of reference and trained by a Pilates monitor who will explain the training program and resolve the doubts raised by the women.~The therapeutic control will be carried out by telephone call and clinical history review between the eighth and tenth day."
41497757|NCT05142280|OTHER|Decision-aid for cardiovascular disease risk|The active choice intervention aims to promote an active choice regarding coping with an increased risk of cardiovascular disease. This means that individuals should (a) become aware of a discrepancy between the current and desired situation; (b) understand what the CVD risk means, and what its causes and consequences are; (c) evaluate the pros and cons of the different options to cope with the risk; and (d) are clear about their values regarding the choice.
40839054|NCT04942223|DEVICE|guided bone regeneration|After local anesthesia, the surgery started with a mid-crestal incision with vertical releasing cuts followed by the full-thickness buccal and lingual/palatal flaps raising to expose the bone defect completely. The flaps were coronally extended to assure a complete closure with a passive suture above the titanium. Subsequently, an intra-oral mandibular ramus bone cortical block was harvested in the molar zone. The bone block was milled and mixed with freeze-dried. The particulate graft was put to fill the deficit above the mesh until its perfect stability and unity with the defect's borders. Two or three titanium mini-screws were used to stabilize the device , and the flaps were carefully sutured. Ceftriaxone was administered intravenously at a loading dose of 2 g; together with a non-steroidal analgesic, it was continued at two g/die per os beginning the day after surgery and continuing for six days.
40839055|NCT05821725|DEVICE|Hyaluronic acid|Hyaluronic acid and hemostatic sponge
41359146|NCT01539720|DRUG|Ulipristal acetate|30 mg tablet
40839056|NCT05821725|DEVICE|Control|Hemostatic sponge
41023919|NCT03678181|BEHAVIORAL|Information Resources|The investigators will provide a HIV-related content as the attention-control condition.
40839057|NCT00149175|OTHER|Blood sampling, skin biopsy|Blood sampling, skin biopsy in the field of the medical follow-up
40839058|NCT02717130|DRUG|Aripiprazole|
41023920|NCT03678181|BEHAVIORAL|Social Support|The investigators will provide evidence-based answers to users' health questions, including linkage to care.
41023921|NCT03678181|BEHAVIORAL|HIV Testing|The investigators will provide opportunities for participants to get tested through HIV home test kits.
41023922|NCT02251535|DEVICE|ATTUNE® Knee System|
41023923|NCT02251535|DEVICE|PFC® SIGMA® Knee System|
41023924|NCT02376413|PROCEDURE|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
41359147|NCT01539720|DEVICE|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
41497758|NCT05142280|OTHER|Control|The control condition contains information that resembles usual care by a GP regarding CVD prevention
41497759|NCT03510780|PROCEDURE|Periodontal surgery with Enamel Matrix Derivative|Patients will be treated by periodontal surgical flaps with the addition of EMD + bone graft
41497760|NCT03510780|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
40839059|NCT00112177|DRUG|Itopride Hydrochloride|
40839060|NCT03481140|DEVICE|TissuGlu Surgical Adhesive|lysine-derived urethane adhesive
40839061|NCT05529004|DRUG|Oral Capsule pregapalin|oral cap of pregapalin has been administration to patient before surgery to prvent PONV
40839062|NCT05529004|DEVICE|laparoscope device|general anesthesia with complete relaxation under laparoscopic cholecystectomy
41023925|NCT02376413|DRUG|Chemotherapy or endocrine therapy or Trastuzumab therapy|
41023926|NCT02376413|RADIATION|Radiation therapy|
41023927|NCT01854554|RADIATION|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
41023928|NCT01854554|RADIATION|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
41023929|NCT01854554|BEHAVIORAL|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
41023930|NCT01854554|BEHAVIORAL|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
41023931|NCT06239116|DRUG|Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)|Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)
41023932|NCT06239116|DRUG|Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)|Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)
41497761|NCT05888194|DEVICE|Mucogyne® gel|In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
41359148|NCT03914924|BEHAVIORAL|Exercise Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session lasts approximately 60 minutes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the exercise intervention through a website specific to the Ex program. Participants will receive weekly WhatsApp messages to remind them about the exercise routine.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
41359149|NCT03914924|BEHAVIORAL|Lifestyle Education Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session will last approximately 60 minutes. Participants will receive a printed version of the Diabetes College Guide containing twenty chapters and they will attend eighteen thirty-minute education classes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the interventions (exercise and education) through a website specific to the ExLE program. Participants will receive a printed version of the Diabetes College Guide, as well as, guidance on accessing the educational content on the website and weekly WhatsApp messages with reminders about educational content scheduled for that week.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
41497762|NCT05543343|DRUG|High dose or normal dose staphylococcus albicans|8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
41497763|NCT05543343|DRUG|Placebo|8 placebo tablets 3 times daily
40839063|NCT05749354|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through."
40839064|NCT04445623|DRUG|Prasugrel Hydrochloride 10 MG Oral Tablet|administration of prasugrel daily for 15 days
40839065|NCT04445623|DRUG|Placebo|administration of placebo daily for 15 days
41359150|NCT00889031|OTHER|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
41497764|NCT05479656|OTHER|Training program|8-week rehabilitation program aimed at increasing trunk and lower limb motor control on balance and walking abilities, and accomplishment of activities of daily living.
41497765|NCT01844856|DRUG|Eravacycline|
41497766|NCT01844856|DRUG|Ertapenem|
41497767|NCT01844856|DRUG|Placebo|Administered IV to maintain the blind.
41497768|NCT02895152|BEHAVIORAL|Feedback|Will receive feedback on the amount of activity that has been undertaken in the last week, will specialist advice on steps taken, active minutes each day, how much device has been worn and tailored advice on how to improve activity levels
41497769|NCT04767191|DRUG|artemether lumefantrine|The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
41497770|NCT04767191|DRUG|dihydroartemisinin piperaquine|Antimalarial Combinations
41497771|NCT01685450|DEVICE|Echodia® hand-held equipment|
41497772|NCT06633341|BIOLOGICAL|CD5 CAR T-cells|Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion
41497773|NCT05509738|BEHAVIORAL|SMS Text Messaging|"The text message-based healthcare assistance includes 1) message reminders and 2) a daily achievement reflection. The delivery schedule is as below.~1. Message reminders:~   The investigators will send participants two text reminders per day, one in the morning and one in the afternoon, from Monday to Friday, with the information on helping their child achieve healthy bladder goals.~2. Daily achievement reflection:~The investigators will send participants a text message with a survey link to reflect their and their children's daily goal achievement Monday to Friday evenings. Timely feedback (e.g., inspirational and compliment messages) will be provided based on participants' responses."
41497774|NCT03696030|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given HER2-CAR T cells via intraventricular administration
41497775|NCT02400853|DEVICE|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
41497776|NCT02400853|PROCEDURE|Cord blood analysis|Cord blood will be collected during deliverance and analysed
41497777|NCT00985179|BEHAVIORAL|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
41497778|NCT05080426|BEHAVIORAL|Family Supportive Supervisor Training 2.0|FSST 2.0 is a workplace intervention package designed to increase supervisors' family and leave supportive behaviors and leave supportive behaviors. The package includes Workplace Assessment tool, 2 45-60 minute online training modules (family-supportive supervisor training and supervisors' leave supportive behavior training), a webinar, behavior training, and individualized feedback reports.
41497779|NCT02940808|DIETARY_SUPPLEMENT|Caffeine (200mg)|Oral consumption of capsule containing 200mg caffeine.
41497780|NCT02940808|OTHER|Placebo|Oral consumption of capsule containing a placebo substance.
41497781|NCT04590040|OTHER|Placebo|0% nano-HAP toothpaste
41497782|NCT04590040|DEVICE|15% nano-HAP toothpaste|Toothpaste with identical base formulation as the placebo containing 15% nano-HAP
41497783|NCT04590040|DEVICE|5% KNO3 toothpaste|Toothpaste with identical base formulation as the placebo containing 5% KNO3
40839066|NCT02025439|DEVICE|rTMS|
40839067|NCT02025439|DRUG|Amantadine|
40839068|NCT06508359|DRUG|Norepinephrine|Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension
41497784|NCT02907255|DEVICE|Oximetry monitor|Wireless respiratory monitoring system
41497785|NCT04778085|BEHAVIORAL|Illness management and recovery|Treatment given in groups, weekly for 10-12 months.
41497786|NCT04778085|OTHER|Semi-structured interviews|Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.
40839069|NCT06508359|DRUG|Phenylephrine|Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension
41023933|NCT06239116|DRUG|Part C: RM-718|Multiple ascending doses of RM-718 (specific to Part C dose cohorts)
41359151|NCT01066624|DRUG|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
41497787|NCT00000116|DIETARY_SUPPLEMENT|Vitamin A|15000 IU/d as retinyl palmitate
41497788|NCT00000116|DIETARY_SUPPLEMENT|Docosahexaenoic acid|1200 mg/d
41497789|NCT00000116|DIETARY_SUPPLEMENT|Control fatty acid|
41497790|NCT04172116|DEVICE|Continuous glucose monitoring|see arm/group descriptions
41497791|NCT06390995|DRUG|TAK-853|TAK-853 intravenous injection
41497792|NCT04868994|DIAGNOSTIC_TEST|Whole Body MRI and ENMG|Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
41497793|NCT05477095|BIOLOGICAL|UB-313|A synthetic peptide-based immunotherapy
41497794|NCT05477095|BIOLOGICAL|Placebo|Normal saline
41497795|NCT02332837|BEHAVIORAL|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
41497796|NCT02332837|BEHAVIORAL|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
41497797|NCT02332837|BEHAVIORAL|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
41497798|NCT05691088|DEVICE|Paracetamol injection|"Patients were randomized to receive either paracetamol during mechanical ventilation. When patients were randomized to receive paracetamol (40 mg/kg per day in 4 doses), a placebo infusion of normal saline was administered continuously at the same rate as an equivalent infusion. Placebos could not be distinguished from the active study drug in color, odor, or viscosity.~In both study groups, IMV was maintained with sufentanil (0-0.2 mcg/kg/h), propofol (0-4 mg/kg/h), and dexmedetomidine (0-1 mcg/kg/h). Assessment of sedation levels by the bedside nurse using the FLACC pain scale to determine if the child is adequately comfortable or in need of more or less medication to maintain adequate ventilation. Assessment of sedation levels by the bedside nurse using the FLACC pain scale (every 6 hours as a minimum time interval)."
41497799|NCT02040506|DRUG|IGN523|Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
41497800|NCT02986867|RADIATION|SAbR Treatment of Lesions|"SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions."
41497801|NCT04715932|DRUG|Hesperidin|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
41497802|NCT04715932|DRUG|Placebo|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
41497803|NCT06262932|DRUG|Amiodarone|Assess the effectiveness of repeated bolus dosing strategies of amiodarone.
41497804|NCT04070235|DRUG|SH229 tablets|SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
41497805|NCT04070235|DRUG|Daclatasvir dihydrochloride|Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
41497806|NCT00700297|DRUG|Colchicine|100 mg Colchicine per day for 4 months
41497807|NCT00700297|DRUG|Placebo|One tablet placebo per day for 4 months
40839070|NCT04001595|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
40839071|NCT02452203|BEHAVIORAL|Floating|Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
41359152|NCT01066624|OTHER|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
41359153|NCT01066624|DEVICE|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
41497808|NCT05899491|PROCEDURE|ARMA|Patients will be instructed to fast for 6 hours pre-ARMA, the Procedure will be performed under propofol-based sedation. Patients will be in the left lateral decubitus position. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.
41497809|NCT05899491|PROCEDURE|UGI Endoscopy|"UGI Endoscopy will be performed under propofol based sedation with scope kept inside for atleast 5 minutes.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry, reflux questionnaire."
41497810|NCT04973930|BEHAVIORAL|Interpersonal Psychotherapy|Time-limited, affect-focused, empirically supported psychotherapy
41497811|NCT04973930|DRUG|Venlafaxine HCl ER|FDA-approved antidepressant medications
41497812|NCT02790515|DRUG|Anti-thymocyte globulin (rabbit)|Given intravenous (IV) prior to transplant on Days -14, -13, -12.
41497813|NCT02790515|DRUG|Blinatumomab|Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
41497814|NCT02790515|DRUG|Cyclophosphamide|Given by IV infusion prior to transplant on Day -9.
41497815|NCT02790515|DRUG|Fludarabine|Given IV prior to transplant on Days -8, -7, -6, -5, and -4.
41497816|NCT02790515|DRUG|G-CSF|Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.
41497817|NCT02790515|DRUG|Melphalan|Given IV prior to transplant on Days -2 and -1.
41497818|NCT02790515|DRUG|Mesna|Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
41497819|NCT02790515|DRUG|Rituximab|Given IV prior to transplant on Day -1.
40839072|NCT06546176|OTHER|End to end with Omega suture|After the rectum was divided with a linear stapler, the circular stapler was placed allowing the anvil rod to penetrate the rectal stump near the linear stapler line. An omega suture including both ends of the linear stapler line was placed. The linear stapler line was approximated around the anvil rod of the circular stapler in an omega shape fashion as the omega suture was tied. This technique resulted in a complete resection of linear stapler line by the circular stapler.
41359154|NCT03264976|DIAGNOSTIC_TEST|hematological examination, ophthalmic examination|Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
41359155|NCT04589260|DRUG|TD-1058|Study drug to be administered by oral inhalation
41359156|NCT04589260|DRUG|Placebo|Placebo to be administered by oral inhalation
40839073|NCT06546176|OTHER|End to anterior rectal wall|"A burse string suture was applied over the anvil of the circular stapler at the transection point of the descending colon using prolene 2/0.~The circular stapler introduced though the anus and its rod directed toward the anterior rectal wall and colorectal anastomosis was performed."
41359157|NCT03584399|OTHER|PICS in critically ill pediatric population|Collection of additional blood sample from those subjects meeting criteria for the study.
41359158|NCT02828982|DEVICE|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
41359159|NCT02828982|DEVICE|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
41359160|NCT00001151|DRUG|1,25-Dihydroxycholecalciferol|Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
41359161|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin|Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
41359162|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin hydrogel|Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.
41359163|NCT03731065|DIETARY_SUPPLEMENT|Glucose-maltodextrin|Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
41359164|NCT04420390|RADIATION|Radiotherapy|Low-dose radiotherapy
41359165|NCT01809158|DRUG|minocycline|
41359166|NCT01809158|DRUG|placebo|
41359167|NCT02471625|DEVICE|ClearView Scanning|
41359168|NCT04818034|DRUG|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes.
41359169|NCT00560872|DEVICE|remote magnetic catheter navigation|use of the Stereotaxis system
41359170|NCT00560872|PROCEDURE|cavotricuspid isthmus ablation|conventional (manual) approach
41359171|NCT01852591|BIOLOGICAL|PCV 13|
41359172|NCT01957904|DEVICE|ArterX Surgical Sealant|
40839074|NCT00885781|DRUG|lipid emulsion for TPN|1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
41359173|NCT02337855|OTHER|Placebo|Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
41359174|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
41359175|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel/GLA-AF|Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
41359176|NCT02465957|BIOLOGICAL|aNK (NK-92)|A natural killer cell line recovered from a patient with large granular lymphoma
41359177|NCT02465957|BIOLOGICAL|aNK (NK-92) + N-803|aNK - A natural killer cell line recovered from a patient with large granular lymphoma and N-803 - Recombinant human super agonist interleukin-15 (IL-15) complex
41359178|NCT00743041|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
41359179|NCT02373176|DRUG|[14C]PRC 4016 (Icosabutate)|Single oral dose
41359180|NCT05117580|DEVICE|telemedicine lifestyle guidance|Telemedicine lifestyle advices are given during 3 months, based on telemonitoring system data.
41359181|NCT06201936|BEHAVIORAL|Preliminary information on neuroaxial procedures|Pre-existing information of pregnant women on neuroaxial pain-relieving procedures for childbirth and their informative sources
41359182|NCT06135558|DIAGNOSTIC_TEST|MAI detection|to detect the presence of marginal acute inflammation
41359183|NCT00402376|DRUG|Pravastatin, Carvedilol, Perindopril|
41359184|NCT00402376|DEVICE|Biventricular assist device (Thoratec paracorporeal assist device)|
41359185|NCT04851522|DRUG|Di-Dak-Sol|Topical solution applied externally.
41359186|NCT04851522|OTHER|White Petrolatum|Topical ointment applied externally
41359187|NCT02477215|DRUG|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
41359188|NCT02477215|DRUG|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
40839075|NCT05831995|DRUG|ABM-168|Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
40839076|NCT00001696|DRUG|Genistein|
40839077|NCT00537407|DRUG|Debio 025|Debio 025 supplied as a 100 mg/mL oral solution
41359189|NCT02477215|DRUG|Bendamustine (multiple dose levels)|70 mg/m\^2, 80 mg/m\^2, or 90 mg/m\^2 on days 1 and 2
41359190|NCT02477215|DRUG|Bendamustine (MTD)|80 mg/m\^2 on days 1 and 2
41359191|NCT02268942|DEVICE|HeartWare HVAD|Implant of HeartWare HVAD via thoracotomy implant technique
41359192|NCT02268942|PROCEDURE|Thoracotomy|Thoracotomy implant technique
40839078|NCT00537407|DRUG|Peg-IFNα2a|Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
40839079|NCT00537407|DRUG|Ribavirin|Ribavirin supplied as 200 mg tablets
40839080|NCT05910333|OTHER|observation|To compare the effect of the mandibular implant retained OVD using quadrilateral distribution (QD) versus linear distribution (LD) on posterior mandibular ridge resorption (PMandRR), anterior maxillary ridge resorption (AMaxRR), and changes to the crestal bone level around implants after 10 years of function.
40839081|NCT01965899|DEVICE|Insertable Cardiac Monitor Implant|The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
40839082|NCT00754091|DEVICE|Polymer based lubricating liquid|three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
40839083|NCT02557022|OTHER|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
40839084|NCT04214639|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
40839085|NCT04214639|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
40839086|NCT02134678|BEHAVIORAL|self-system therapy|
41497820|NCT02790515|DRUG|Tacrolimus|Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.
41497821|NCT02790515|DRUG|Thiotepa|Given IV prior to transplant on Day -3.
41497822|NCT02790515|BIOLOGICAL|HPC,A Infusion|Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
41497823|NCT02790515|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
41497824|NCT02790515|DRUG|Sirolimus|Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.
41497825|NCT04808336|OTHER|PRP injection.|Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
41497826|NCT04808336|PROCEDURE|fixation surgical procedure|Group 2: thirty patients underwent surgery
41497827|NCT04339218|DEVICE|Cryoablation|"Cryoablation will be performed by a specialized radiologist, percutaneously, ie through the skin. The operation is performed under general anesthesia, under the guidance of the scanner. The images from the scanner make it possible to precisely insert and place a needle at the level of the tumor to be treated. Intense cold will be produced by the needle and will destroy the cancer cells by freezing (temperatures of -40 °C). Freezing is localized to the tumor, the rest of the organ will not suffer from the cold.~The aftermath of the intervention causes only minimal pain and in most cases does not require pain treatment. As the operation is minimally traumatic, the risk of complications is low. Hospitalization is around twenty-four hours and usual or professional activities can be resumed very quickly."
41497828|NCT04339218|DRUG|Pembrolizumab|Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.
41497829|NCT04339218|DRUG|Pemetrexed|Pemetrexed will be prescribed and administered at the dose recommended by market authorization.
41497830|NCT04339218|DRUG|Carboplatin|Carboplatin will be prescribed and administered at the dose recommended by market authorization.
41497831|NCT04960579|BIOLOGICAL|P-BCMA-ALLO1 CAR-T cells|Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
41497832|NCT04960579|DRUG|Rimiducid|Safety switch activator
41497833|NCT03581409|DRUG|Aspirin|Aspirin protect tablet
41497834|NCT03581409|DRUG|Prasugrel|Prasugrel tablet
41497835|NCT03581409|DRUG|Clopidogrel|Clopidogrel 75mg tablet
41497836|NCT03581409|DRUG|Cilostazol|Cilostazol tablet
41497837|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
41497838|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg , i.v. single dose usage.
41497839|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
41497840|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
41497841|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
41497842|NCT05256719|BIOLOGICAL|Placebo-1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
40839087|NCT02134678|BEHAVIORAL|cognitive therapy|
40839088|NCT04185415|DRUG|bepranemab|"bepranemab will be administered in a predefined dosage.~* Pharmaceutical Form: Solution for infusion~* Route of Administration: Intravenous"
41497843|NCT05256719|BIOLOGICAL|Placebo-2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg
41497844|NCT05256719|BIOLOGICAL|Placebo-5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
41497845|NCT05256719|BIOLOGICAL|Placebo-7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg
41497846|NCT05256719|BIOLOGICAL|Placebo-10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
41497847|NCT02299115|DRUG|Prednisolone|Corticosteroid
41497848|NCT02299115|DRUG|Vigabatrin|Antiepileptic
40839089|NCT04185415|DRUG|Placebo|"* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9% w/v sodium chloride aqueous solution~* Route of Administration: Intravenous"
40839090|NCT00541346|DRUG|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
40839091|NCT05735756|DRUG|Citalopram 20mg|Citalopram 20mg once a day for 12 weeks
41359193|NCT02303730|DRUG|Exenatide|The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose\<2.9 mmol/l or \< 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
40839092|NCT05735756|DRUG|Placebo|Placebo once a day for 12 weeks
40839093|NCT00516035|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
40839094|NCT00829491|BEHAVIORAL|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
40839095|NCT05006508|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
40839096|NCT04763187|PROCEDURE|Tooth extraction|Tooth extraction and alveolus regeneration with autologous blood concentrate.
40839097|NCT02861911|OTHER|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
40839098|NCT02861911|DEVICE|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
40839099|NCT04354272|OTHER|Questionnaire|Questionnaire for the satisfaction of patients consulting the odontological emergencies of the GHPS during COVID 19.
40839100|NCT00156169|DRUG|Dunaliella|
41359194|NCT02303730|DRUG|insulin glargine|"The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c \<8% use 0.1 -0.2 U/kg per day;HbA1c \>8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) \> 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose \<70mg/dl（3.9mmol/l）: 10%-20%; blood glucose \<40mg/dl（2.2mmol/l）: 20%-40%."
41359195|NCT03428490|BEHAVIORAL|Fully integrated treatment|Clinicians will be delivering CBT for Social Anxiety Disorder directly into the context of the Matrix's evidence-based treatment for substance use disorders (i.e., The Matrix Model).
41359196|NCT03428490|BEHAVIORAL|Stand-alone Intensive Outpatient Program|Evidence-based treatment for substance use disorders (i.e., The Matrix Model).
41359197|NCT00107536|DRUG|lapatinib ditosylate|
41497849|NCT00948727|BEHAVIORAL|Dose adaptation according to CN activity monitoring|The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.
41497850|NCT00948727|DRUG|Cyclosporine (CsA)|Cyclosporine (CsA)
41497851|NCT01438996|BIOLOGICAL|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
41497852|NCT06152406|PROCEDURE|Ablation and Pacemaker Implantation|All patients will be implanted with a pacemaker device with one lead positioned in right ventricle (control arm only) and an additional lead will be positioned on the distal (ventricular) HIS bundle if in intervention arm. All patients will undergo ablation.
40839101|NCT04524455|DRUG|Blinatumomab|Blinatumomab will be administered as a continuous intravenous infusion (cIV).
40839102|NCT04524455|DRUG|AMG 404|AMG 404 will be administered as an intravenous infusion (IV).
40839103|NCT04524455|DRUG|Dexamethasone Premedication|Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
40839104|NCT06335355|DRUG|Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin|Adebrelimab,1200mg; SHR-8068, 1.0 mg/kg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
40839105|NCT06335355|DRUG|Camrelizumab + Pemetrexed + Carboplatin|Camrelizumab,200mg;Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
40839106|NCT06335355|DRUG|Adebrelimab + Pemetrexed + Carboplatin|Adebrelimab,1200mg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
40839107|NCT00594594|OTHER|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
40839108|NCT01793259|DRUG|methotrexate prefilled pen|
40839109|NCT01793259|DRUG|methotrexate prefilled syringe|
40839110|NCT06312033|DRUG|Estradiol Valerate|To elevate estradiol levels each woman has received 6mg on two consecutive days (total 12mg) of estradiol valerate (Progynova21©)
40839111|NCT06312033|DRUG|Placebo|Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)
40839112|NCT01498185|DRUG|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
40839113|NCT01498185|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
40839114|NCT04847557|DRUG|Tirzepatide|Administered SC
40839115|NCT04847557|OTHER|Placebo|Administered SC
40839116|NCT01853072|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
40839117|NCT01853072|OTHER|Nepafenac vehicle|Inactive ingredients used as placebo comparator
41359198|NCT00107536|OTHER|laboratory biomarker analysis|Correlative studies
41497853|NCT03555006|OTHER|"Dual ultrasound reading local vs remote"|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation and a posteriori by a third radiologist.
41023934|NCT04118218|OTHER|Rhizolysis pain analysis|"Definition of the subgroup of good clinical outcome after rhizolysis (called effective rhizolysis) by lumbar VAS or lower extremity pain VAS or Oswestry index decreased at 6 weeks after rhizolysis.~The efficiency criterion based on the decrease in the dolorimeter or the Oswestry index corresponds to a decrease of at least 50% \[1, 2, 3, 4\]."
41023935|NCT03217136|DRUG|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg (maximum 1 g) and tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.
41023936|NCT03217136|DRUG|Metronidazole|Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants ≤ 28 days old, start with a loading dose of 15 mg/kg; then if ≤ 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if \> 2 kg are dosed 10 mg/kg every 8 hours.
41023937|NCT03217136|DRUG|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days.
41359199|NCT00921973|BIOLOGICAL|VAX102|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
41359200|NCT00921973|BIOLOGICAL|Placebo|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
41023938|NCT03217136|DRUG|Placebo for Metronidazole|Placebo for metronidazole administered IV every 8 hours for between 5 to 14 days.
41023939|NCT01459796|DRUG|Rilonacept|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.
41023940|NCT01459796|DRUG|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
41023941|NCT01459796|DRUG|Allopurinol|Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
41359201|NCT04039295|PROCEDURE|ultrasound guided caudal epidural block|dynamic ultrasound imaging of the spread of local anesthetics
41497854|NCT03555006|OTHER|"Dual ultrasound reading local vs local"|The examination will be interpreted by two department's radiologists and a posteriori by a third radiologist.
41497855|NCT05784532|DEVICE|STERN FIX|Sternotomy closure with STERN FIX and supplemented with wires
40839118|NCT01853072|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
40839119|NCT03333317|DRUG|Lumicitabine|Participants will receive oral administration of lumicitabine.
40839120|NCT03333317|DRUG|Placebo|Participants will receive oral administration of matching placebo.
41023942|NCT04537091|PROCEDURE|rESWT|rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel
41359202|NCT00314028|BEHAVIORAL|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
41359203|NCT00314028|OTHER|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
41359204|NCT02027324|DRUG|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
41023943|NCT04537091|PROCEDURE|PRP injection|PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
41359205|NCT02027324|DRUG|Povidone-Iodine Group|10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
41359206|NCT03718624|DRUG|apatinib|apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.
41359207|NCT03718624|DRUG|paclitaxel|Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.
41359208|NCT03718624|DRUG|S-1|S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.
41023944|NCT03783559|DRUG|TACE|TACE
41497856|NCT03834454|DRUG|Bupivacaine|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
41497857|NCT03834454|DRUG|Bupivacaine|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
41497858|NCT05944614|OTHER|Magnetic Resonance imaging (MRI) examination|3D CINE and 4 dimensional (4D) flow MRI sequence
41023945|NCT03783559|DRUG|chemotherapy±target therapy|chemotherapy±target therapy
41359209|NCT02164890|OTHER|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
41359210|NCT01903096|BEHAVIORAL|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
41497859|NCT01607307|DRUG|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
40839121|NCT00483041|OTHER|PLACEBO|Placebo administered as a single intravenous infusion
40839122|NCT00483041|BIOLOGICAL|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
40839123|NCT02437604|DRUG|Treatment A: Fp MDPI|Fp MDPI 200 mcg, 1 inhalation
41023946|NCT05625204|BEHAVIORAL|Center based attention control|Center based attention control
41023947|NCT05625204|BEHAVIORAL|Center based HIIT|Center based HIIT
41497860|NCT01607307|DRUG|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
41497861|NCT06633484|OTHER|functional magnetic resonance imaging|non-diagnostic, non-invasive, passive measurement of the brain\&#39;s structure and function
41497862|NCT03812549|DRUG|Sintilimab|Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.
41497863|NCT03812549|RADIATION|stereotactic body radiation therapy|Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f
41359211|NCT01903096|DRUG|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
41359212|NCT00712608|OTHER|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
41359213|NCT00712608|OTHER|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
41359214|NCT00712608|OTHER|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
41359215|NCT00752518|DRUG|bortezomib|
41359216|NCT04509206|BEHAVIORAL|Nutritional education|The curriculum for the four classes include understanding MyPlate guidelines, learn basic knife skills, meal prep, and plan, home farming and no-cook cooking.
41359217|NCT06172205|DRUG|intravenous FOLFOX7 plus Camrelizumab and apatinib|"Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
41497864|NCT03812549|RADIATION|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.
41497865|NCT01045538|DRUG|Vorinostat, capecitabine, and cisplatin|Vorinostat 200\~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
40839124|NCT02437604|DRUG|Treatment B: FS MDPI|FS MDPI 200/12.5 mcg, 1 inhalation
41023948|NCT05625204|BEHAVIORAL|Home based HIIT|Home based HIIT
41359218|NCT06172205|DRUG|HAIC-FOLFOX plus Camrelizumab and apatinib|"2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
41497866|NCT04283968|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
41497867|NCT04283968|BIOLOGICAL|placebo fecal transplantation|placebo fecal transplantation
41497868|NCT03968978|BIOLOGICAL|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
41497869|NCT03968978|BIOLOGICAL|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
41497870|NCT04553016|BIOLOGICAL|Vaccine|IM vaccination with ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4
41023949|NCT05419206|DIAGNOSTIC_TEST|CMV DNA analysis|CMV DNA quantitative viral load levels were studied
41359219|NCT03873259|DEVICE|Burst Wave Lithotripsy|Fragment upper urinary tract stones
41359220|NCT02830295|OTHER|Basic Body Awareness Therapy|Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
41497871|NCT04553016|BIOLOGICAL|Placebo|IM administration of 0.9% sterile sodium chloride solution
41497872|NCT03988283|BIOLOGICAL|Personalized neoantigen DNA vaccine|At each vaccination time point, patients will receive one injection of the neoantigen DNA vaccine, one injection into the vastus lateralis.
41497873|NCT03988283|DEVICE|Papivax Biotech TDS-IM v2.0|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM v2.0 device - Papivax Biotech).
40839125|NCT02437604|DRUG|Treatment C Flovent|FLOVENT DISKUS 250 mcg, 2 inhalations
41023950|NCT03037944|DRUG|Yasmin|(ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets
41023951|NCT03037944|DEVICE|Metraplant-E|"Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD Metraplant, modified by Azzam 2013"
41023952|NCT02669186|DRUG|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
41023953|NCT02669186|DRUG|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
41497874|NCT03988283|PROCEDURE|Peripheral blood draw|-After trial enrollment and up to 7 days after the first vaccine dose (baseline); no more than 2 weeks after the 3rd vaccine dose; no more than 2 weeks after the 6th vaccine dose; two weeks after the last dose; time of progression or discontinuation (optional)
40839126|NCT02437604|DRUG|Treatment D: Advair|ADVAIR DISKUS 500/50 mcg, 1 inhalation
40839127|NCT00549770|DRUG|LCZ696|
41359221|NCT01384513|DRUG|Fludarabine|Given IV
41359222|NCT01384513|DRUG|Busulfan|Given IV
40839128|NCT00549770|DRUG|Valsartan|
41359223|NCT01384513|RADIATION|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
41359224|NCT01384513|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
41497875|NCT05289297|PROCEDURE|Karydakis Flap Procedure|Pilonidal sinus surgery will be performed with the Karydakis Flap procedure.
41497876|NCT05289297|PROCEDURE|Burow's Triangle Advancement Flap Procedure|Pilonidal sinus surgery will be performed with the Burow's Triangle Advancement Flap procedure.
41497877|NCT00206323|DRUG|Topiramate (drug)|Topiramate 25 mg titrated to 200 mg
41497878|NCT00206323|DRUG|placebo/sugar pill|placebo
41497879|NCT04485039|DRUG|Tecovirimat|oral antiviral
41497880|NCT04485039|DRUG|sevelamer carbonate oral tablet|phosphate binder
40839129|NCT00549770|DRUG|AHU377|
40839130|NCT00549770|DRUG|Placebo|
41359225|NCT01384513|DRUG|Cyclophosphamide (CY)|Given IV
41359226|NCT01384513|DRUG|Tacrolimus|Given IV or PO
41359227|NCT01384513|DRUG|Mycophenolate mofetil|Given IV
41359228|NCT01384513|DEVICE|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
41359229|NCT01384513|PROCEDURE|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
41359230|NCT04689399|DIAGNOSTIC_TEST|Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.|Alle Danish citizens tested for infection with SARS-CoV-2 by swabs in the oropharynx, and subsequently analysis of the specimens by RT-PCR test at Testcenter Danmark's test centers will be included in the study. Participants will, in addition to the oropharyngeal swab they are already schedule for, be examined by a rapid antigen test.
41359231|NCT05744466|DRUG|Deucravacitinib|As prescribed by treating clinician
41359232|NCT05744466|DRUG|Apremilast|As prescribed by treating clinician
41497881|NCT04485039|DRUG|sucroferric oxyhydroxide chewable tablet|phosphate binder
40839131|NCT00158912|DEVICE|Implantable Cardioverter Defibrillator|
40839132|NCT00016965|DRUG|ixabepilone|
40839133|NCT04683458|DEVICE|Drug-coated device|The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
40839134|NCT02723955|DRUG|feladilimab (GSK3359609)|
40839135|NCT02723955|DRUG|GSK3174998|
40839136|NCT02723955|DRUG|Pembrolizumab|
40839137|NCT02723955|DRUG|Docetaxel|
40839138|NCT02723955|DRUG|Pemetrexed|
40839139|NCT02723955|DRUG|Paclitaxel plus Carboplatin|
40839140|NCT02723955|DRUG|Gemcitabine plus Carboplatin|
41497882|NCT04485039|DRUG|calcium acetate oral tablet|phosphate binder
41497883|NCT04485039|DRUG|Lanthanum Carbonate Chewable Tablet|phosphate binder
41359233|NCT05588076|OTHER|no intervention|no intervention
41359234|NCT03580902|BEHAVIORAL|CBT4CBT-Buprenorphine|Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
41359235|NCT03580902|DRUG|Buprenorphine/naloxone|Standard outpatient buprenorphine maintenance
41359236|NCT05485194|OTHER|Reducing dimensional changes following tooth extraction|Use of a titanium bone screw for ridge preservation following tooth extraction
41359237|NCT06043895|DEVICE|EpiFaith CV|The conducting physician will localize the central vein using EpiFaith CV and assess if there is arterial puncture.
41359238|NCT06043895|DEVICE|Conventional|The conducting physician will localize the central vein using Raulerson syringe and assess if there is arterial puncture.
41359239|NCT04115020|DRUG|Naltrexone|Naltrexone 4.5 mg oral suspension
40839141|NCT02723955|DRUG|Fluorouracil (5-FU) plus carboplatin or cisplatin|
40839142|NCT02723955|DRUG|Dostarlimab|
40839143|NCT02723955|DRUG|Cobolimab|
40839144|NCT02723955|DRUG|Bintrafusp alfa|
40839145|NCT05847413|DRUG|Verapamil|Subjects will receive oral verapamil for 12 weeks
41359240|NCT04115020|DRUG|Placebo|Placebo oral suspension
41359241|NCT05157009|PROCEDURE|implant placement|autogenous bone reconstruction of damaged socket \& simultaneous implant placement
40839146|NCT03327064|DRUG|UAB30|9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.
41359242|NCT01742013|DRUG|GCJBP Laennec Inj.|Test drug
41359243|NCT01742013|DRUG|Placebo|Comparator
41359244|NCT00003089|DRUG|amifostine trihydrate|
41359245|NCT00003089|DRUG|carboplatin|
41359246|NCT00003089|DRUG|paclitaxel|
41359247|NCT00003089|RADIATION|radiation therapy|
41497884|NCT00405444|DRUG|Fentanyl|The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
40839147|NCT03327064|DRUG|Placebo|This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
40839148|NCT00337792|DRUG|oxycodone + lorazepam versus fentanyl + midazolam|
40839149|NCT02303860|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
40839150|NCT02303860|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
40839151|NCT02303860|DRUG|ORM-12741 IR|Immediately release formulation of ORM-12741
40839152|NCT00552760|DRUG|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
40839153|NCT00552760|DRUG|Placebo|one tablet at bedtime for up to 6 months
41359248|NCT04342572|DRUG|Melphalan|-The drug is commerically available
41359249|NCT04013906|DIAGNOSTIC_TEST|Rotational atherectomy|Rotational atherectomy
41359250|NCT06070831|DEVICE|Inspiratory muscle training|"Respiratory training, performed through IMT, was carried out with a pressure threshold device (Treshold IMT, Philips-Respironics, Pittsburg, PA, USA). Threshold IMT offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the inspiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
41497885|NCT00405444|DRUG|Sterile water|The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
41497886|NCT00021827|DRUG|Parathyroid hormone-related protein or ''PTHrP''|
41497887|NCT02542553|PROCEDURE|Bilateral BAL|
41497888|NCT04290975|OTHER|Task-shifting of follow-up care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be shifted to be performed primarily by Community Health Workers (CHWs) with specialized epilepsy training
41497889|NCT04290975|OTHER|Enhanced usual care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be performed primarily by physicians, with CHWs serving to collect standardized data regarding outcomes
41497890|NCT01925300|DRUG|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab|
41160632|NCT04765813|BEHAVIORAL|Cognitive-behavioral treatment to quit smoking along with a control App|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a control smartphone App (only to access session materials) during the intervention period (8 weeks)."
41359251|NCT06070831|DEVICE|Expiratory muscle training|"Respiratory training, performed through PEP, was carried out with a pressure threshold device (Treshold PEP, Philips-Respironics, Pittsburg, PA, USA). Threshold PEP offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the expiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
40839154|NCT05082727|DIETARY_SUPPLEMENT|KOVIR (TD0068) oral softgel|KOVIR (TD0068) is a softgel containing Allium sativum extract 270mg, Colostrum156.4 mg, fine powder mixed herbs 43.6mg
40839155|NCT05082727|DIETARY_SUPPLEMENT|Placebo oral softgel|Placebo
40839156|NCT02790021|PROCEDURE|Lymphaticovenous anastomosis (LVA)|LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
41160633|NCT00019019|DRUG|carboxyamidotriazole|
41160634|NCT00019019|DRUG|paclitaxel|
41497891|NCT01925300|DRUG|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab|
41497892|NCT01925300|DRUG|Concor 5mg 2T and Crestor 20 mg 1Tab|
41497893|NCT04200898|DEVICE|Cheetah System|For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
41497894|NCT03210714|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41497895|NCT03210714|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
41023954|NCT00753324|DRUG|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
41023955|NCT05932316|DIAGNOSTIC_TEST|spirometry|participants will undertake spirometry testing before and after bronchodilators and placebo
41023956|NCT05932316|DRUG|Salbutamol|Salbutamol inhalation to determine bronchodilator response
41023957|NCT05932316|DRUG|placebo|placebo inhalation prior to repeating spirometry
41023958|NCT05891249|BIOLOGICAL|Luspatercept|Specified dose on specified days
41023959|NCT02966080|DRUG|HEP-IV|
41023960|NCT02864017|PROCEDURE|Enteral nutrition|
41023961|NCT02864017|DIETARY_SUPPLEMENT|L-Citrulline|
41023962|NCT02864017|DIETARY_SUPPLEMENT|Placebo|
41023963|NCT04965779|DEVICE|Abdominal Binder|Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.
41023964|NCT04965779|OTHER|Postpartum nursing care|Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
41023965|NCT02507102|DEVICE|Voyager|Non-invasive RFE therapy
41023966|NCT05322603|DRUG|Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)|A decrease in the pain severity (VAS);opioid-sparing effect
41023967|NCT05322603|DRUG|Analgesics|A decrease in the pain severity (VAS)
41023968|NCT04167397|OTHER|Collaborative learning|Participants will be allocated to either single, dyad, triad or tetrad practice during initials skills training on an ultrasound simulator. Afterwards their competencies will be assessed with an individual transfer test on another simulator.
41023969|NCT00003457|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
41023970|NCT06573632|DIETARY_SUPPLEMENT|TPN-N7 Baxter|providing TPN to all malnutrition patients preoperatively as well as postoperatively.
41023971|NCT01391377|DRUG|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
41023972|NCT01391377|DRUG|Sugar pill|Placebo
41023973|NCT01284400|OTHER|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
41023974|NCT02445235|OTHER|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
41023975|NCT05390489|DRUG|Cascara pulp arabica gayo coffee cream|extract of cascara pulp arabica gayo coffee
41023976|NCT04455386|DIAGNOSTIC_TEST|Stress radiography,Anterior drawer test,Stress ultrasound,Computed tomography, Magnetic resonance imaging,Arthroscopy|All patients suspected chronic ankle instability, will perform an anterior drawer test, stress ultrasound, computed tomography, magnetic resonance imaging of ankle. Patients with chronic ankle instability will be recommended to perform an arthroscopic repair if non-operative treatment failed.
41359252|NCT05223374|DEVICE|Canvas Dx|Canvas Dx is intended for use by healthcare providers as an aid in the diagnosis of autism spectrum disorder (ASD) for patients ages 18 months through 72 months who are at risk for developmental delay based on concerns of a parent, caregiver, or healthcare provider. The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process. The device is for prescription use only (Rx only)
41023977|NCT01474135|DRUG|0.25% AR-12286 / 0.004% travoprost|
41023978|NCT01474135|DRUG|0.5% AR-12286, 0.004% travoprost|
41023979|NCT01474135|DRUG|0.004% Travoprost|
41023980|NCT01668095|OTHER|Laboratory Biomarker Analysis|Correlative studies
41023981|NCT03212586|DRUG|BAY1902607|Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
41497896|NCT03210714|PROCEDURE|Bone Scan|Undergo a bone scan
41023982|NCT03212586|DRUG|Placebo|Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
41023983|NCT03483623|OTHER|NATO WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
41023984|NCT03483623|OTHER|NATO FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
41160635|NCT05748678|DEVICE|Compression pants|"Patients will have 3D photos taken each week of each buttock and thigh separately. A lymph scanner will also be used for each section to provide a percentage of water content. Weight will also be taken for each visit.~The first 2 weeks the patients will wear their regular pants, and from weeks 3-7 wear the compression pants provided. Weeks 8-9 the patients will be asked to resume to regular pants again"
41160636|NCT00001083|DRUG|Indinavir sulfate|
41023985|NCT03483623|OTHER|RAVEN WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
41359253|NCT01208025|OTHER|Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)|3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
41359254|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
40839157|NCT02741037|BEHAVIORAL|Dyadic lifestyle intervention|Dyadic lifestyle intervention: The dyadic behavioral lifestyle intervention was modeled after the Diabetes Prevention Program (DPP), and was adapted to make it more easily accessible to low-income Latinas. In addition, this intervention arm has a dyadic component to examine the effectiveness of mothers and daughters engaging in the lifestyle intervention together as partners. Participants also will receive usual care.
40839158|NCT02741037|BEHAVIORAL|Individual lifestyle intervention|Individual lifestyle intervention: The individual behavioral lifestyle intervention was modeled after the Diabetes Prevention Program, and was adapted to make it more easily accessible to low-income Latinas. Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers. Participants also will receive usual care.
41023986|NCT03483623|OTHER|RAVEN FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
41160637|NCT00001083|DRUG|Ritonavir|
41359255|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
41359256|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
40839159|NCT02741037|OTHER|Usual Care|Usual Care: Mother and daughter participants will receive Usual Care.
40839160|NCT04057885|DEVICE|Orthosensor™ VERASENSE™ Knee System|A group of patients will receive a total knee arthroplasty using the Orthosensor device
41023987|NCT03750136|DRUG|Hypertonic saline|high dose furosemide with hypertonic saline 3x daily
41023988|NCT03750136|DRUG|Furosemide Injection|high dose furosemide
40839161|NCT02520739|DIETARY_SUPPLEMENT|Virgin Olive Oil (VOO)|VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
40839162|NCT02520739|DIETARY_SUPPLEMENT|Optimized High Phenolic Content Oil (OHPCO)|OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
41160638|NCT00001083|DRUG|Nevirapine|
40839163|NCT02520739|DIETARY_SUPPLEMENT|Functional Olive Oil (FOO)|FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
40839164|NCT04654260|BEHAVIORAL|Behavioral Therapy for Irritability in Autism|The child-focused components of BTIA are organized in modules dedicated to emotion regulation, problem solving and practice of planned steps to prevent or resolve conflicts. Each session contains a set of six to seven goals, and each goal contains a menu of techniques and activities that can be used to attain this goal. In order to administer the treatment in a flexible yet reliable manner, the therapist works collaboratively with the child and his or her parents to select activities that are perceived as relevant for attaining the session's goal. The parent-focused components of BTIA include include education about the effects of antecedents and consequences on disruptive behavior, developing strategies for reducing or altering antecedent events that may lead to disruptive reactions and helping parents to use reinforcement of competent and calm responses in potentially frustrating situations.
40839165|NCT04654260|BEHAVIORAL|Psychoeducation and Supportive Therapy (PST)|Each PST session will start with a review of events of the past week and include queries of topics such as school, interests, hobbies, and family with an overarching goal of enhancing subjective well-being. A major objective is to enables the participant to discuss his or her concerns with a therapist toward a goal of enhancing overall psychological wellbeing. Education about autism diagnosis and services is also provided to families as part of PST.
40839166|NCT05831254|OTHER|Health education:Interactive group training|"1. To introduce e-pulse software, which is a personal health record system, to show its use, to provide training materials such as video-brochures about e-pulse. This program will be done as interactive group training~2. Six modular interactive group training, each of which includes the steps of the European Health Literacy Scale of 90 minutes."
41023989|NCT01187589|DEVICE|Pulsehaler|
41023990|NCT01187589|DRUG|Nebulizer & Albuterol 0.5ml|Albuterol aerosolized by a nebulizer
41023991|NCT02569697|OTHER|HEC Placebo gel|
41023992|NCT02569697|OTHER|Placebo Intravaginal Ring|
41023993|NCT02569697|OTHER|Placebo Vaginal Film|
41023994|NCT02569697|OTHER|Placebo Vaginal Insert|
41023995|NCT00147147|PROCEDURE|Gastrectomy with D2 or greater lymph node dissection|
41023996|NCT00147147|DRUG|Gastrectomy+ chemotherapy|
41160639|NCT00001083|DRUG|Lamivudine|
41160640|NCT00001083|DRUG|Stavudine|
41160641|NCT00001083|DRUG|Zidovudine|
41160642|NCT03496337|OTHER|Assessment of motor and process skills test|At baseline and follow-up (after 8-10 weeks) all patients are assessed with AMPS in addition to the standard test of Canadian Occupational Performance Measure (COPM) hand grip strength and joint range of motion.
41359257|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
41359258|NCT05157178|BIOLOGICAL|Covid-19 (recombinante) vaccine|Administration of the Covid-19 (recombinante) vaccine
41359259|NCT00247962|DRUG|etanercept|50 mg
41359260|NCT00247962|DRUG|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
41359261|NCT02468076|DEVICE|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
41359262|NCT03033290|DRUG|Bu-Zhong-Yi-Qi-Tang|Qi-tonifying regimen of traditional Chinese herbal medicine
41359263|NCT03033290|DRUG|placebo|placebo control
41359264|NCT00493909|PROCEDURE|intrathecal opioids and thoracic paravertebral analgesia|
41359265|NCT00493909|PROCEDURE|thoracic epidural analgesia|
41359266|NCT04427306|DRUG|T-Vec|(talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
41359267|NCT03273933|DEVICE|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
40839167|NCT05831254|OTHER|Health education: Individually training|To introduce e-pulse software, which is a personal health record system, to provide training materials such as video-brochures about e-pulse. This education will be done individually.
41023997|NCT05108493|OTHER|Dry needling|Three sessions dry needling of lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).
40839168|NCT01997190|BIOLOGICAL|AdV-tk + valacyclovir|AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
41160643|NCT04022603|DEVICE|Cyclometer Ergometer|The measurements are carried out on a max effort of 12 minutes on a cyclometer ergometer with a constant load (Motomed viva2 light). A first effort is made with a Venturi type mask whose Inspired Fraction in Oxygen (FiO2) is set for a pulsated oxygen saturation (SpO2) greater than or equal to 85%, and then a second at 2h interval with high-throughput googles (Optiflow) with the corresponding FiO2.
40839169|NCT04466527|DEVICE|Laser Intervention|Subjects with undergo laser exposure of their active acne vulgaris.
40839170|NCT01629472|BEHAVIORAL|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
40839171|NCT02715726|DRUG|Alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
40839172|NCT02715726|DRUG|Placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
40839173|NCT02715726|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
40839174|NCT02715726|DRUG|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
40839175|NCT02715726|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
40839176|NCT02715726|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
40839177|NCT02715726|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
40839178|NCT01856621|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
41359268|NCT03273933|DEVICE|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
41359269|NCT00741624|OTHER|Bandage|one application for one week
41359270|NCT02230644|OTHER|Enhanced clinical environment|Surgical booths containing artwork and calming background music.
40839179|NCT01856621|DRUG|Seretide Diskus|2 inhalations as a single dose
41036558|NCT04992767|BEHAVIORAL|Sunnyside|The Sunnyside intervention is an online intervention(an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
41359271|NCT02230644|OTHER|Other distraction|Such as newspaper, magazine or the news on television
41359272|NCT06444724|PROCEDURE|APP|Patients in the application group communicated via Line applications (APP group) with guidance on preparation before colonoscopy through video media.
41359273|NCT00551681|DEVICE|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
41359274|NCT00551681|DEVICE|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
41359275|NCT01680835|DEVICE|EverFlex™ Self-Expanding Peripheral Stent System|Using the EverFlex™ Self-Expanding Peripheral Stent System to treat atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions 4-18 cm long in subjects with Rutherford Clinical Categories 2-4.
41359276|NCT04076280|BEHAVIORAL|Sodium Watcher Program-Hypertension|The Sodium Watcher Program -Hypertension intervention consists of 14 weeks of education \[4 weekly education sessions (45 minutes)followed by 5 bi-weekly sessions 5-20 minutes\] that will be held at the dyads' preferred time delivered to their homes using a video conferencing program through an iPad.
41497897|NCT03210714|PROCEDURE|Computed Tomography|Undergo a CT scan
41497898|NCT03210714|DRUG|Erdafitinib|Given PO
41359277|NCT04076280|BEHAVIORAL|Usual Care|Participants in the usual care group receive their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium restricted diet and take medications as ordered. Usual care consists of recommendations to follow a sodium restricted diet, but without explicit skills training including instructions on gradual adaptation to sodium restricted diet, follow-up of progress or provision of monitoring.
41497899|NCT03210714|OTHER|Laboratory Biomarker Analysis|Correlative studies
41497900|NCT03210714|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40839180|NCT01856621|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
40839181|NCT01856621|DRUG|SF Easyhaler|2 inhalations as a single dose
40839182|NCT03464916|BIOLOGICAL|CAR2 Anti-CD38 A2 CAR-T Cells|Autologous IV infusion; dose-escalation
40839183|NCT04734587|DIAGNOSTIC_TEST|Blood serum Neuron-specific Enolase measurement|The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
40839184|NCT03544307|BEHAVIORAL|Taekwondo training|Exercise group
40839185|NCT06377891|OTHER|Emotional Resilience training|Primiparous pregnant women in the experimental group will be given emotional resilience training in the last trimester.
41359278|NCT03973827|DRUG|ProTrans|Single infusion of 25, 100 or 200 million cells per patient.
40839186|NCT01513681|DRUG|Lamotrigine|Lamotrigine Tablets 200 mg
40839187|NCT01513681|DRUG|Lamictal®|Lamictal® 200 mg Tablets
40839188|NCT03281889|RADIATION|Proton Beam|precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
40839189|NCT04432805|DEVICE|Performing of lung ultrasound|Performing of lung ultrasound at bedside in labor ward or in COVID unit
40839190|NCT06506877|BEHAVIORAL|Implementation of Cognitive Risk Calculator (RC) and Brief Assessment of Cognitive Health (BACH)|Enrolled providers will have access to two cognitive screening tools during the active phase. The first tool is a Cognitive Risk-Calculator (RC), integrated into the Electronic Health Record, to help providers identify patients who are at high risk of exhibiting cognitive decline. The second tool is a computerized cognitive screening tool, the Brief Assessment of Cognitive Health (BACH), which patients complete independently. Results are automatically entered into the patient's medical record, along with patient-specific flags for concerns about depression and/or sleep disorder. The purpose of these tools is to facilitate cognitive screening and treatment for factors that may be contributing to cognitive decline.
40839191|NCT03974295|BEHAVIORAL|Vaginal unprotected intercourse|Patients will allowed to engage in vaginal unprotected intercourse as many times as desired after 24 hours of pelvic rest after a frozen embryo transfer.
41359279|NCT03973827|DRUG|Placebo|Placebo Comparator: Sham transplantation (placebo) Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)
41497901|NCT03210714|OTHER|Pharmacological Study|Correlative studies
41497902|NCT03210714|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
40839192|NCT01063088|BIOLOGICAL|Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)|Single 0.5 mL intramuscular injection
40839193|NCT03930992|DRUG|Colaren in HIV positive|1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
40839194|NCT03930992|DRUG|standard treatment in HIV positive|2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
41359280|NCT04488406|OTHER|No Intervention|Not applicable to these subjects. There is no study-related intervention
41359281|NCT02324426|DRUG|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
41497903|NCT03210714|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
41497904|NCT03210714|PROCEDURE|X-Ray Imaging|Undergo an x-ray
41497905|NCT02616965|DRUG|Romidepsin|Romidepsin at the dosage 10mg/m2 or 14mg/m2 will be given ONCE 14 days prior to cycle one and then on days 1,8,15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
41497906|NCT02616965|DRUG|Brentuximab vedotin|Brentuximab vedotin at the dosage 0.9mg/kg or 1.2 mg/kg will be given on days 1 and 15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
41497907|NCT03769714|DRUG|Saline Solution for Injection|Injection of 20mL of 0.9%Normal Saline
41023998|NCT05108493|OTHER|Home exercise program|All participants will start the home exercise program during the study period consisting of range of motion exercises for wrist flexion, extension, ulnar and radial deviation, elbow flexion and extensor; forearm supinator, and pronator muscles; stretching exercises. Eccentric strengthening of the wrist flexor extensors, ulnar and radial deviation, forearm pronation, supination, and strengthening exercise training will be given to the elbow extensors and flexors. Progressive strengthening exercises will be added to the program. The exercise program will be terminated with stretching exercises. The exercises will be performed for 10 repetitions 2 times a day, stay in each position for 10 seconds, and rest for 30 seconds between periods. Both groups will be advised to continue the exercise program for 12 weeks.
41023999|NCT03370341|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks to assess IA
41024000|NCT03370341|DEVICE|sham tDCS|sham tDCS with behavioral tasks to assess IA
41024001|NCT01464918|DEVICE|Endoscopic submucosal dissection (ESD) using device, MASTER|Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
41024002|NCT02784314|PROCEDURE|Robotic-Assisted Radical Prostatectomy|
41024003|NCT02784314|PROCEDURE|Laparoscopic Radical Prostatectomy|
41024004|NCT02205892|DRUG|Lupeol|Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
41024005|NCT02205892|DRUG|Placebo vehicle|Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
41024006|NCT05971212|BEHAVIORAL|Behavioural sleep clinic access|Access to behavioural Sleep Clinic
41024007|NCT05535192|BEHAVIORAL|THRIVE|"The THRIVE Intervention will involve:~1) one in-person exercise sessions, followed by twice-weekly, home-based exercise sessions, supervised remotely through telehealth, and 2) a remotely delivered dietary assessment and recommendations to support protein intake throughout the study"
41024008|NCT05535192|BEHAVIORAL|Health Education Support Program|Participants will receive a tablet with information and resources regarding mediation, stretching and gentle movement, relaxation and creative arts during chemotherapy
41024009|NCT01368458|OTHER|Conversion to Antipsychotic Monotherapy|Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
41024010|NCT03169153|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
41359282|NCT00848172|DRUG|Octanoic Acid|4mg/kg
41359283|NCT00848172|DRUG|Placebo|identical capsules
41359284|NCT02343991|DEVICE|Transcranial ExABlate|MR Guided Focused Ultrasound
41024011|NCT03169153|DEVICE|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
41024012|NCT01037309|DRUG|PRO044 SC|Subcutaneous injection, once a week, for five weeks
41024013|NCT01037309|DRUG|PRO044 IV|Intravenous injection, once a week, for five weeks
41024014|NCT02476565|DEVICE|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
41024015|NCT02476565|DEVICE|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
41359285|NCT06083376|OTHER|Spinal Stabilization Exercise|Spinal stability exercises are commonly used isometric and isotonic exercises. A spinal stabilization exercise training program will be applied to the exercise group participants using the telerehabilitation method (simultaneous connection) 3 days a week for 8 weeks and a total of 24 sessions.
41359286|NCT06083376|OTHER|physical activity counseling|Control group participants will first be given initial evaluations and verbal physical activity recommendations will be given. Patients will be contacted by phone at the 2nd, 4th and 6th weeks and reminded about the importance of physical activity.
41359287|NCT01694966|DRUG|Methylene Blue MMX®|
41359288|NCT01694966|DRUG|Placebo|Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
41359289|NCT01996956|OTHER|volume expansion|fluid loading of 10 ml/kg colloid or blood product
41359290|NCT00377273|DRUG|fluorouracil cream 0.5%|
40839195|NCT03930992|DRUG|Colaren in HIV negative|3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
40839196|NCT03930992|DRUG|standard treatment in HIV negative|4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
40839197|NCT02049138|DRUG|Upadacitinib|Tablet taken orally
41024016|NCT06574334|PROCEDURE|Proprioceptive exercise|"* The first session was included an orientation to the exercises and its purpose to geriatric participants in the first week. Also, pretest was done in the first session before implementing exercises to assess geriatric KOA pain and QOL, each session started by revision about what was given during the previous session and the objectives of the next session.~* The 2nd session about exercises.~* The 3rd session for repetition of exercises to ensure that the patient has learned it well in the second week.~* The 4th session after six weeks later (from wk. (3) to wk. (8) to make posttest after implementation session.~* The 5th session after two-month later (from wk. (9) to wk. (16) to do follow up test."
41024017|NCT02425631|DEVICE|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
41024018|NCT04604522|PROCEDURE|Biospecimen Collection|Undergo collection of blood, airway brushings.
41024019|NCT04604522|OTHER|Medical Chart Review|Patients' medical records are reviewed
41497908|NCT03769714|DRUG|Exparel|Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
41497909|NCT02912585|BIOLOGICAL|Oropharyngeal administration of own mother's colostrum|
41497910|NCT02912585|OTHER|Oropharyngeal administration of sterile water (placebo)|
41024020|NCT04988165|DRUG|Traditional Chinese Medicine|It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
41024021|NCT03030612|DRUG|ARGX-110|ARGX-110 will be administered intravenously.
41359291|NCT02229513|PROCEDURE|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
41024022|NCT03030612|DRUG|AZA|AZA will be administered subcutaneously/intravenously.
41024023|NCT00000463|DRUG|lovastatin|
41024024|NCT00000463|DRUG|cholestyramine|
41359292|NCT02185040|DRUG|CC-220|0.3 mg oral capsules once every other day with or without food
41359293|NCT02185040|DRUG|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
41359294|NCT02185040|DRUG|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
40839198|NCT02049138|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine (PCV-13)|Administered by intramuscular injection
40839199|NCT01013363|OTHER|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
41359295|NCT02185040|DRUG|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
41359296|NCT02185040|DRUG|Placebo|Matching oral placebo daily
41359297|NCT01709240|DEVICE|BioWeld1 System|External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
40839200|NCT00288314|PROCEDURE|Magnetic Resonance Imaging, Functional|Structural and functional MRI
40839201|NCT03125694|DRUG|Sitagliptin 100mg|Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
41024025|NCT00000463|DRUG|warfarin|
41359298|NCT06065787|DEVICE|NeuroGlove|The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development.
41359299|NCT03422731|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow and blood samples
41359300|NCT03422731|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT
40839202|NCT03125694|DRUG|Pioglitazone 30 mg|Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
40839203|NCT01932775|DEVICE|GlucoTab System|
40839204|NCT02582047|BIOLOGICAL|Influenza vaccination with PPV23|GCflu and Pneumovax-23
40839205|NCT02582047|BIOLOGICAL|Influenza vaccination with PCV13|GCflu and Prevenar-13
41024026|NCT01554046|DRUG|Methylphenidate- Ritalin IR (Immediate Release)|"Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~* Ages 6-12, up to 25Kg - 35mg maximum per day.~* Ages 6-12, above 25Kg - 50mg maximum per day.~* Ages 12-65, above 25Kg - 80mg maximum per day."
41024027|NCT01351740|DRUG|atazanavir|switch to unboosted atazanavir 400 mg daily
41024028|NCT01351740|DRUG|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
41024029|NCT06440668|BEHAVIORAL|Chronic Pain Management Workshop with Non-Pharmacological Therapies|"1st Session: Welcome. Expectations. Pathophysiological mechanism of pain. Influence of emotions on pain intensity. Activities: My limiting beliefs; Affirmations in front of the mirror; Mental analgesia. / 2nd: Pain and its impact on the patient's life. Forgiveness and self-forgiveness. Ho'oponopono technique. Self-esteem. Activities: Labels that limit us; Reading When I Loved Myself for Real; Self-healing meditation; Life purpose. / 3rd: Tips to slow down aging. Promotion of healthy habits; Metta meditation; Motivation for change. / 4th: Active participation in my own healing. How to face illness. Creative visualization. Activity:Energy wheel. / 5th: Review of the tools. Resolving doubts. Workshop evaluation and scales. Guide with the tools presented. Activities: Final farewell. / At the end of each session, the homework assignments are explained, and at the beginning of the next, they are reviewed. Sessions 2, 3, 4 5: Experience of a previous workshop patient."
41024030|NCT02804165|GENETIC|Enterovirus vaccination|Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
41024031|NCT05649722|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a capsule-based dry powder inhaler device.
41024032|NCT05649722|DRUG|Placebo|Oral placebo inhalation using a capsule-based dry powder inhaler device.
41359301|NCT03422731|DRUG|Fluorothymidine F-18|Undergo FLT PET
41359302|NCT03422731|OTHER|Laboratory Biomarker Analysis|Correlative studies
41359303|NCT03422731|PROCEDURE|Magnetic Resonance Imaging|Undergo water-fat MRI
41359304|NCT03422731|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
41359305|NCT00720291|DRUG|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
41359306|NCT00720291|DRUG|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
41359307|NCT05515653|GENETIC|Exposure to genetics (polygenic)|The polygenic risk score (PRS) aggregates the effects of genetic variants into a single number that predicts the genetic predisposition to a phenotype. PRS are typically composed of hundreds to millions of genetic variants, usually Single Nucleotide Polymorphisms (SNPs). For each individual, the number of risk alleles computed in each variant is summed and weighted by the estimated value of the obtained effects (log odds ratio for traits with binary values or Beta coefficients for traits with continuous value) obtained from large-scale genomic studies ( GWAS)
41024033|NCT01739322|BIOLOGICAL|Prick test Platanus acerifolia allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
41359308|NCT02349841|DRUG|Meropenem|To administer 2g daily 8 hourly for 14 days
41359309|NCT02349841|DRUG|Faropenem|To adminster 600mg 8 hourly daily for 14 days
41359310|NCT02349841|DRUG|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
41359311|NCT02349841|DRUG|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
41359312|NCT04416074|BEHAVIORAL|An online 5-week professional identity group psychotherapy|This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.
41359313|NCT04416074|OTHER|Message push|Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
41024034|NCT01060384|DRUG|Lenalidomide|"Dose Cohort -1\^ 10mg daily on Days 1-21 every 28 days~Dose Cohort +1\^\^ 15mg daily on Days 1-21, every 28 days~Dose Cohort +2 20 mg daily on Days 1-21, every 28 days~Dose Cohort #3 25 mg daily on Days 1-21, every 28 days~\^Used only if Dose Cohort +1 requires further reduction~\^\^Starting Dose Cohort in Phase I"
41024035|NCT01060384|DRUG|ofatumumab|8 weekly infusions of ofatumumab 1000mg.
41024036|NCT01841749|PROCEDURE|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
41024037|NCT02793492|DEVICE|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
41024038|NCT05038059|DRUG|ethanolic extract of sapindus mukorossi|ethanolic extract will be used as final endodontic irrigant during root canal procedures in extracted teeth.
41024039|NCT05038059|DRUG|ethylene diamine tetra acetic acid|used as final endodontic irrigant in root canal therapy
41024040|NCT06146244|PROCEDURE|sinus lift|Implant placement on grafted sinus vs antral autogenous bone
41024041|NCT06146244|DEVICE|resonance frequency analysis|analysis of the ISQ evolution and its changes after 3 months of placing the implant in native or regenerated bone, always in the antral area
41359314|NCT04509024|BEHAVIORAL|Incidental training|Training involving non-speech sounds embedded in a video-game.
41359315|NCT04509024|BEHAVIORAL|Explicit training|Training involving explicit sound and category information
41359316|NCT04509024|BEHAVIORAL|Classroom training|Structured adult classroom language training.
41359317|NCT04509024|BEHAVIORAL|Classroom and incidental training|Both classroom and incidental training.
40839206|NCT05705661|DEVICE|HIGH FREQUENCY CHEST WALL OSCILLATION|The HFCWO device used a triangular wave form which increases the airflow velocity more than other devices. Therefore, clearing sticky airway mucus and alveolar exudates and maintaining airway patency has become currently the most urgent issue in the ventilatory management of patients with severe COVID-19.
41024042|NCT05897359|BEHAVIORAL|bCBTMI|This experimental group involves 4 weekly 30-45 minute sessions using the brief CBT and the brief MI models by trained nursing students.
41024043|NCT05897359|BEHAVIORAL|Control|The control group will receive health talks about internet addiction consequences and impacts on young people by nursing students who are not involved in the intervention group to mimic the time and attention spent on the intervention group. These health talks are considered routine care for IA health promotion.
41024044|NCT05577052|RADIATION|Metastatic vertebrae treated with SBRT|High-dose SBRT treatment
41024045|NCT02490813|DIETARY_SUPPLEMENT|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
41359318|NCT04509024|BEHAVIORAL|Classroom and explicit training|Both classroom and explicit training.
41497911|NCT02912585|BIOLOGICAL|Oropharyngeal administration of donor human milk|
41497912|NCT03664492|OTHER|Educational whiteboard video|Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
41497913|NCT01773837|DRUG|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
41497914|NCT01773837|DRUG|placebo|placebo (pill) p.o.
41359319|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency and transcutaneous tibial nerve stimulation|The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies. 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side. Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a transdiscal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds. Two 50x50 mm electrode pads were placed on the posterior-superior aspect of the medial malleolus for posterior tibial nerve stimulation. Stimulation was delivered in continuous mode at a frequency of 20 Hz and a pulsed width of 200 ms. It was applied once a week for 30 min for 4 weeks.
41497915|NCT05971940|DRUG|Orforglipron|Administered orally.
41497916|NCT05971940|DRUG|Placebo|Administered orally
41497917|NCT05162014|DRUG|empagliflozin|empagliflozin
40839207|NCT02522442|DEVICE|CPAP|Continuous positive airway pressure
40839208|NCT02522442|DEVICE|Auto BiLevel|Auto Bilevel positive airway pressure with Flex
40839209|NCT03890328|PROCEDURE|radiofrequency ablation|apply RF therapy to the treatment of splenic trauma
40839210|NCT04969198|DRUG|Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)|Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
40839211|NCT00336557|PROCEDURE|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
40839212|NCT03323671|DRUG|preemptive mefenamic acid|preemptive analgesia before menstrual pain
40839213|NCT03323671|DRUG|mefenamic acid|mefenamic acid given only during menstruation
40839214|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - ALS|"ALS patients will be administered the following TBCS tests:~* ALS Cognitive Behavioral Screen-Phone Version;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~This group will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Caregiver Behavioral Questionnaire;~* ECAS-Carer Interview."
40839215|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD|"AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory."
40839216|NCT06337578|BEHAVIORAL|Telephone-based and in-person cognitive screening - NIs|"NIs will undergo the Telephone Interview for Cognitive Status over the telephone and will be additionally administered, in person, the following cognitive screeners:~* Mini-Mental State Examination~* Montreal Cognitive Assessment~* In-Person Telephone Interview for Cognitive Status in person."
40839217|NCT04912752|GENETIC|Migraine CNV|Copy number variation effect on migraine disease
40839218|NCT00007020|DRUG|Cholic Acids|10-15 mg/kg body weight/day taken orally.
40839219|NCT00625638|BEHAVIORAL|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
40839220|NCT00625638|OTHER|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
40839221|NCT05941260|DIAGNOSTIC_TEST|Computational fluid dynamics (CFD)|"- Video recording starts in an antegrade manner starting from the bladder neck through the prostatic urethra and ends after the verumontanum at the external sphincter. Videos were taken with a very slow movement of the endoscope to ensure the sharpness of the data and to prevent complications in post-processing.~The focal length and zoom of the endoscope camera were set at the beginning and maintained throughout the capturing, while the angle of the lens changes to capture the widest field possible for each targeted area.~* Computational fluid dynamics (CFD) can then be used to numerically model the behavior of the flow inside the urethra by solving the governing equations of the flow using the finite volume method.~* Through which we can develop a urodynamic computer model to simulate the bladder-urethral passage and predict the success of the resection undertaken by the surgeon. No extra intervention will be provided to our patients apart from their routine surgery."
40839222|NCT05948046|BEHAVIORAL|Visual training in hospital|Completion of 1 session of standardized visual training
41497918|NCT05162014|DRUG|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
41497919|NCT04260555|DRUG|DW1601|Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
40839223|NCT05833724|DRUG|Chidamide|Subjects will receive a single dose of 30 mg chidamide. Twice a week.
41024046|NCT02490813|DIETARY_SUPPLEMENT|Placebo|Placebo will be starch with colorings
41024047|NCT04295941|DRUG|TraZODone Hydrochloride 300 MG|Oral administration of Trazodone once-a-day.
41024048|NCT02602288|BEHAVIORAL|Ask, Advise, Refer|WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
41024049|NCT02602288|BEHAVIORAL|Telebased tobacco counseling|Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
41024050|NCT02602288|BEHAVIORAL|Telebased nutrition counseling|Telephone counseling to promote nutritious eating practices in the family.
41359320|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency|"The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies.~After negative aspiration of blood, 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side.~Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a trans discal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds."
41024051|NCT02602288|DEVICE|Mobile phone smoking cessation application|Smartphone based application to support smoking cessation efforts
41024052|NCT02602288|DEVICE|Mobile phone nutrition application|Smartphone based application to support healthy eating habits
41024053|NCT02602288|DRUG|Nicotine polacrilex|Over the counter nicotine replacement therapy in gum or lozenge form.
41024054|NCT03915548|BEHAVIORAL|The Behavioral Activation/ Problem Solving Intervention|The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.
41497920|NCT04260555|DRUG|DW16011|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
41024055|NCT03915548|BEHAVIORAL|Attention Control Condition|The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
41024056|NCT06531499|DRUG|AAA617|\[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for up to 12 cycles.
41359321|NCT02269709|DEVICE|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
41359322|NCT01833351|DRUG|IV Vitamin C|"We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks."
41497921|NCT04260555|DRUG|DW16012|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
41497922|NCT01293539|DRUG|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (\>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle."
41497923|NCT03957252|DIAGNOSTIC_TEST|Blood test: ClarityDX Prostate|PSA on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.
41024057|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) analogues|Anatomical Therapeutic Chemical \[ATC\] code L02AE
41024058|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) antagonists|Degarelix, Relugolix
41024059|NCT05905965|DRUG|Empagliflozin 20 mg|Patients receiving empagliflozin 20 mg daily - experimental arm
41024060|NCT05905965|DRUG|Empagliflozin 10 mg|Patients receiving empagliflozin 10 mg daily - control arm
41497924|NCT01808820|BIOLOGICAL|Dendritic Cell Vaccine|Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.
41024061|NCT06536010|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；|VAG in the induction phase of the ND-AML treatment protocol
41359323|NCT01833351|DRUG|IV Vitamin C|"There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits."
41359324|NCT04826315|BEHAVIORAL|COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
41359325|NCT01711190|PROCEDURE|trabeculectomy|Filtering surgery to reduce the intra-ocular pressure.
41359326|NCT05464849|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
41359327|NCT01763099|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
41359328|NCT01763099|BIOLOGICAL|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10\^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
41359329|NCT05521828|DRUG|Follitropin delta (Rekovelle)|12 mcg/day will be used for ovarian stimulation in both arms
41359330|NCT05521828|DRUG|Duphaston|20 mg/day will be used for pituitary suppression in both arms
41359331|NCT05521828|DRUG|GnRH agonist (Gonapeptyl)|(2 ampules:0.2 mg) will be used for ovulation triggering in both arms
41359332|NCT00902473|DRUG|Topiramate|25mg tablets
41359333|NCT04862689|DEVICE|Ringer Perfusion Balloon Catheter|Non-emergent Percutaneous Coronary Intervention (PCI) for treatment of a coronary artery lesion with Ringer Perfusion Balloon Catheter.
41359334|NCT04412226|DEVICE|aerosol box|The aerosol box is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cube that covers the patient's head during the endotracheal intubation. Operator can intubate the patient through the two holes for arms.
41359335|NCT04412226|DEVICE|transparent sheet|The transparent sheet is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cover that covers the patient's head and body during the endotracheal intubation. Operator can intubate the patient through the space under the cover
41359336|NCT05429528|BEHAVIORAL|Implicit Tax|This will be levied only on certain beverage categories: a 50% tax on the sales prices of carbonated drinks and sugar-sweetened beverages (SSBs) and 100% tax on the sales prices of energy drinks (milk, milk-based products, and natural fruit juice are excluded).
41359337|NCT05429528|BEHAVIORAL|Explicit Tiered Tax|This is an explicit tiered tax based on (underlying) Nutri-Score (NS) grades which will be levied on all food and beverages. In this arm, the investigators implement a 20% sales tax on the retail price for NS D beverages and 10% for NS D foods along with a 50% sales tax on NS E beverages and 20% on NS E foods. The NS labels will not be displayed.
41359338|NCT03832712|PROCEDURE|Deep Brain Stimulation|Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator
41359339|NCT03832712|DRUG|Best Medical Treatment|Unselective β-blockers such as Propanolol
41359340|NCT02363699|DRUG|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
41359341|NCT02363699|DRUG|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
41024062|NCT06222723|DRUG|Dexamethasone|Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
41359342|NCT01362062|DRUG|Tocilizumab|
41359343|NCT03236935|DRUG|L-NMMA|pan-nitric oxide synthase inhibitor
41359344|NCT03236935|DRUG|Pembrolizumab|PD-1 inhibitor
41359345|NCT00483600|DRUG|fondaparinux|injections of 2.5mg every other day for 4 weeks
41359346|NCT05004363|DRUG|Lokelma Oral Product|Potassium binder
41359347|NCT00673140|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
41359348|NCT00673140|RADIATION|Far infrared radiation|Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
41359349|NCT01520727|DRUG|BIA 9-1067|single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
41497925|NCT01808820|BIOLOGICAL|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
41497926|NCT01808820|DRUG|Imiquimod|5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
41024063|NCT06222723|DRUG|Ribavirin|Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
41024064|NCT02956629|DRUG|Uprifosbuvir|Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
41497927|NCT01808820|PROCEDURE|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
41024065|NCT02956629|DRUG|Ruzasvir|Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
41359350|NCT01520727|DRUG|Placebo|single-dose
41497928|NCT00556400|DRUG|Lo-Ovral Oral Contraceptive Pills|
41024066|NCT02956629|DRUG|Ribavirin|RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
41024067|NCT04212507|DIAGNOSTIC_TEST|The serum level of Claudin-3 and intestinal Fatty acid binding protein|The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.
41024068|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
41024069|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
41497929|NCT00556400|DRUG|Placebo - sugar pill|
41497930|NCT00002070|DRUG|Sargramostim|
41497931|NCT00002070|DRUG|Ganciclovir|
41024070|NCT03893448|BIOLOGICAL|V114|V114 15-valent pneumococcal conjugate vaccine containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration.
41024071|NCT03893448|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
41024072|NCT03893448|BIOLOGICAL|RotaTeq™|A total of 3 RotaTeq™ 2 mL oral dosings at \~2, \~4, and \~6 months of age.
41024073|NCT03893448|BIOLOGICAL|Pentacel™|A total of 3 Pentacel™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
41497932|NCT00381914|DRUG|Vitamin D|400 IU vitamin D / day
41497933|NCT00381914|DRUG|Vitamin D|800 IU vitamin D / day
41497934|NCT00381914|DRUG|Vitamin D|1200 IU vitamin D / day
41024074|NCT03893448|BIOLOGICAL|RECOMBIVAX HB™|A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
41024075|NCT03893448|BIOLOGICAL|VAQTA™|One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.
41024076|NCT03893448|BIOLOGICAL|MMR II™|One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
41024077|NCT03893448|BIOLOGICAL|VARIVAX™|One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.
41024078|NCT03893448|BIOLOGICAL|HIBERIX™|One HIBERIX™ 0.5 mL IM dosing at Visit 5.
41024079|NCT04946513|OTHER|Muscle volumes were measured on pre- and postoperative MRI scans.|Muscle volumes were measured on pre- and postoperative MRI scans.
41024080|NCT03619694|DEVICE|MRI Spectroscopy|Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology
41024081|NCT00984269|PROCEDURE|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
41024082|NCT05984394|DIAGNOSTIC_TEST|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT
41497935|NCT02712580|DEVICE|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
41497936|NCT02712580|DEVICE|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
41497937|NCT02712580|DEVICE|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
41497938|NCT02712580|DEVICE|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
41024083|NCT01111500|DEVICE|Donjoy ER brace|Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
41024084|NCT01111500|DEVICE|Thoraco brachial brace|Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
41024085|NCT04879238|BEHAVIORAL|BEING|60 minute yoga session that blends mindfulness techniques
41160644|NCT00616486|DEVICE|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
41160645|NCT00616486|DEVICE|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
41359351|NCT01102816|OTHER|Individualized acupuncture treatment|"Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.~Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.~Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)"
41497939|NCT05583305|DIAGNOSTIC_TEST|Imaging assessment|Investigators shall perform cranial MRI examinations. The scanning protocol will employ an MRI scan protocol with T1-weighted, T2-weighted, FLAIR, susceptibility weighted imaging, diffusion weighted imaging, and time-of-flight magnetic resonance angiography (MRA) sequences. In addition, high-resolution magnetic resonance vessel wall imaging (HRMRI) allows assessment of the vessel wall using specific the SPACE sequence and the MATCH sequence. Assessors of the HRMRI images shall be blinded to the group allocation and clinical information.
41497940|NCT05583305|DIAGNOSTIC_TEST|Neurosonology assessment|Investigators shall perform carotid duplex ultrasonography (CD) assessment, focusing on the peak systolic (PSV) and end diastolic velocity (EDV) of bilateral extracranial internal carotid arteries (ICA) Brightness mode imaging shall gauge the intimal thickness and plaque characteristics (if any) of bilateral ICAs.
41497941|NCT05583305|DIAGNOSTIC_TEST|Blood Test|Nine milliliters of EDTA blood will be drawn during the research clinic visit for evaluation of the degree of neurovascular inflammation. Serum plasminogen activator inhibitor-1 (PAI-1) and high-sensitive C-reactive protein (hsCRP) are markers of vascular inflammation, atherosclerosis, and thrombotic risk. Serum neurofilament light chain (NfL) is a biomarker for neuroaxonal injury that correlates with small vessel disease.
41160646|NCT04717713|DRUG|steroid injection|steroid injection at surgical location
41024086|NCT06574178|BEHAVIORAL|Dietary Counseling|A Registered Dietitian or Nutritionist will provide nutrition education either in person, over the phone, or via Zoom. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant.
41160647|NCT04717713|DRUG|placebo|saline injection at surgical location
41160648|NCT00647998|DRUG|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
41160649|NCT00647998|OTHER|Standard care|
41160650|NCT04636021|DIAGNOSTIC_TEST|COVID-19 testing|Pre and post procedure COVID-19 testing for patients undergoing outpatient cardiac procedures.
41160651|NCT06197685|BEHAVIORAL|The Kessler Foundation modified Story Memory Technique® (KF-mSMT®)|KF-mSMT is a memory retraining technique that consists of two-related skills: (1) imagery and (2) context/organization. The proposed KF-mSMT intervention includes 10 total sessions with 2 sessions per week for 5 weeks. Each session will last 45-60 minutes.
41024087|NCT02229097|DRUG|Normal bolus|"During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period"
41024088|NCT02229097|DRUG|Coordinated bolus|The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
41024089|NCT00638547|DRUG|IRT Laronidase|"Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture"
41024090|NCT00803023|DRUG|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
41024091|NCT00803023|DRUG|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
41024092|NCT00803023|DRUG|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
41024093|NCT00803023|DRUG|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
41359352|NCT01102816|OTHER|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
41497942|NCT03713619|DRUG|secukinumab|Secukinumab 300mg every 2 or every 4 weeks
41024094|NCT05908240|OTHER|Care Coordinator Model|A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
41497943|NCT03713619|DRUG|Placebo|Placebo 300mg every 2 or every 4 weeks
41024095|NCT00144118|DRUG|sevoflurane or isoflurane|
41024096|NCT00268125|DEVICE|Acupression's bracelet|
41024097|NCT00268125|BEHAVIORAL|Hygiene and dietetic advices|
41024098|NCT06237426|DRUG|Methylone|"A course of methylone treatment includes weekly oral methylone administrations for up to 4 weeks.~Participants may be eligible to receive up to two courses of methylone treatment in this study. After a course of methylone treatment is complete, participants will return to observational study visits."
41024099|NCT04898010|DEVICE|Selective Cytopheretic Device|The Selective Cytopheretic Device (SCD) treatment will be delivered using a two-cartridge system using a type of dialysis equipment commonly used for conventional hemodialysis therapy. The SCD cartridge will be added immediately post-hemofilter to the circuit of a standard hemodialysis system, and treatment will be delivered for 24 hours. Blood exchange will occur using a dialysis catheter.
41024100|NCT00501605|DRUG|AZD2171|
41024101|NCT01794949|DEVICE|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
41024102|NCT04612491|BEHAVIORAL|Pre-operative Consultation|Pre-operative consultation will be given before Mohs surgery
41024103|NCT00028834|DRUG|gemcitabine hydrochloride|Given IV
41024104|NCT00028834|BIOLOGICAL|bevacizumab|Given IV
41024105|NCT00028834|OTHER|laboratory biomarker analysis|Correlative studies
41036559|NCT04992767|BEHAVIORAL|SunnysideFlex|SunnysideFlex consists of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. SunnysideFlex has adapted the original Sunnyside intervention with revised, trauma-focused content that covers the impact of PTSD symptoms on the perinatal period and daily functioning, more broadly
41359353|NCT02288416|OTHER|educational intervention|Undergo video-based intervention
41359354|NCT02288416|OTHER|questionnaire administration|Ancillary studies
41359355|NCT02288416|OTHER|quality-of-life assessment|Ancillary studies
41359356|NCT02288416|OTHER|Best Practice|
41359357|NCT04282499|PROCEDURE|combined exercise|Patients will be undergone to aerobic exercises in addition to the resistance training.
41359358|NCT04282499|PROCEDURE|aerobic exercise|Patients will be trained through the aerobic exercises only.
41359359|NCT03356301|DEVICE|Cardiac MRI|Non injected cardiac MRI exam
41359360|NCT03356301|DEVICE|Applanation tonometry|Applanation tonometry and ECG
41359361|NCT00919828|DEVICE|Avivo System|Non invasive external monitoring device
41359362|NCT06284772|OTHER|Questionnaire and fecal sampling|The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.
41497944|NCT02317289|DEVICE|Detection of freezing|single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
41497945|NCT03172494|DRUG|Insulin degludec/liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
41497946|NCT03172494|DRUG|Insulin degludec|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
41024106|NCT05567991|BEHAVIORAL|Comprehensive Mindulness-Based Intervention (C-MBI)|C-MBI, was administer online via Zoom and included: 10 Integral Meditation classes lasting approximately 35 minutes each, given twice a week (Monday and Wednesday); 10 minutes of yoga exercises focused on breathing and posture before each IM class; and dietary advice. Regarding this latter, the participants received via email a document which entailed non-mandatory dietary suggestions to promote healthy nutrition, sleep and stress-relief. An online lecture held by the nutritionist with a question-and-answer format was also organized. The degree to which to follow this advice was left to the discretion of each participant. The core of our intervention was represented by the IM training, that is a MBI intervention, that simultaneously uses breathing, focusing attention, releasing of physical tensions, thoughts and feeling sensations through internal senses and imagery, allowing a quick relaxation and more deeply a physical, energetic, and spiritual well-being.
41497947|NCT03172494|DRUG|Liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
41024107|NCT04849975|OTHER|Pelvimetric measurements|The patients in this group are pregnant women after failure of external manual version (EMV) in case of breech fetal presentation. The participants will successively perform MRI pelvimetry (conventional management) and EOS imaging.
41024108|NCT03486041|BEHAVIORAL|Comprehensive Behavior Modification|Behavior therapy approach to BFRBs involving targeted intervention tactics chosen in accordance with the modality of functioning (ex: Sensory, Cognitive.....) seeming to cause the most frequent and problematic urges to engage in the BFRB. Therapist and client work together, using careful assessments including detailed self-monitoring, to determine what behavioral methods will suffice for lasting change.
41024109|NCT03486041|BEHAVIORAL|Attention|Weekly brief calls from therapist to check on safety and clinical status. No focus on TTM.
41359363|NCT06284772|OTHER|Health examination|This examination will include measurements for anthropometrics, cognition (MoCA, Stroop, DSST), and blood pressure. The participants will undergo blood draw for laboratory analyses of CMD risk factors, such as blood lipids, glucose metabolism (fasting glucose, HbA1c, and fasting insulin), liver enzymes (GGT, ALT, and AST), inflammation (hs-CRP), and cardiac markers (proBNP and hs-TnI). We will perform ultrasound imaging for hepatic fibrosis.
41359364|NCT05901142|BEHAVIORAL|Exercise-based multi-phasic, multi-modal intervention|"Pre-op: 2\*60min supervised; 1\*30min unsupervised walking sessions per week Supervised session: Aerobic: 8\*60secs star jump, squat thrust, high knees with 90sec rest. Elastic resistance: 2\*10-12reps of chest press, seated row, leg press, 'lat' pulldown, and either abdominal flexion or lumbar extension-alternated, with 60-90sec rest. Targeted physiotherapy: general breathing exercises, active-assisted range of motion (RoM) exercises, and active-resisted RoM exercises~Postop: 1\*60min supervised exercise; unsupervised walking \[2\*30min weeks 1-2; 3\*30min week 3; 4\*30min weeks 4-6\] session per week Supervised session: Aerobic: As above using full body extension, squat jump, static sprint in week 1-4. Progressed to those performed preoperatively from week 5. Elastic resistance: As above from week 4, performed 3\*week. Targeted physiotherapy: As above, with active-assisted RoM progressing from 1\*10reps in week 1, to 2\*10reps in weeks 2-4, and 3\*10reps in weeks 4-6"
41497948|NCT05528471|OTHER|Dietary intervention|To compare an iso-caloric, low fructose diet (\~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) to an iso-caloric, higher fructose diet (\~10% of TEI; HFCS max 20-30% of total fructose intake) in adolescents with NAFLD. The 10% higher fructose diet is part of standard of care and is NOT the intervention.
41497949|NCT03713632|DRUG|Secukinumab|Secukinumab 300mg every 2 or every 4 weeks
41497950|NCT03713632|DRUG|Placebo|Placebo 300mg every 2 or every 4 weeks
41497951|NCT06139406|DRUG|JNJ-87801493|JNJ-87801493 will be administered subcutaneously.
41497952|NCT06139406|DRUG|JNJ-80948543|JNJ-80948543 will be administered subcutaneously.
41497953|NCT06139406|DRUG|JNJ-75348780|JNJ-75348780 will be administered subcutaneously.
41497954|NCT06132113|DRUG|BI 764532|BI 764532
41497955|NCT06132113|DRUG|Carboplatin|Standard of care
41497956|NCT06132113|DRUG|Etoposide|Standard of care
41497957|NCT06132113|DRUG|Cisplatin|Standard of care
41497958|NCT06148142|BEHAVIORAL|Pharmacy based health promotion|This project will consist of three phases: baseline survey with first time intervention implementation; second intervention at 6 months; and third, end-line survey at 12 months. As part of the intervention within the randomized selected groups, the CP will conduct two 15-30 minute sessions throughout the intervention period, once at the baseline or first visit (T0) and once at the sixth month (T1). Patients will attend the two sessions at the pharmacies where they collect their prescription medication. Face-to-face counselling sessions will be held about hypertension and its management, including lifestyle changes and drug compliance.
41497959|NCT06350916|BEHAVIORAL|SeamlessMD® Mobile Application|Mobile cloud-based applications (apps), such as SeamlessMD®, are readily accessible on smart phones and offer an innovative strategy to encourage and track patient adherence to recommended ERAS components pre- and postoperatively.
41497960|NCT00247780|PROCEDURE|Pulmonary vein isolation and cavotricuspid ishtmusblock|
41497961|NCT05158088|DEVICE|Borescope|Endotracheal intubation using borescope
41497962|NCT05158088|DEVICE|Video laryngoscope|Endotracheal intubation using video laryngoscope
41497963|NCT05655221|DRUG|B1344|multi-site abdominal s.c. injections (maximum 2 mL at each site)
41497964|NCT05655221|OTHER|Placebo|multi-site abdominal s.c. injections (maximum 2 mL at each site)
41497965|NCT03379389|DRUG|Methenamine + Methylthioninium|Methenamine + Methylthioninium
41497966|NCT03379389|DRUG|Methenamine + Methylthioninium + Acriflavine + Atropa belladona|Methenamine + Methylthioninium + Acriflavine + Atropa belladona
41359365|NCT04759391|OTHER|Exercise|Pelvic floor muscle training program planned under the supervision of a physiotherapist was applied and followed to the exercise group, using the digital application.
41359366|NCT04759391|OTHER|Lifestyle recommendations|Information was given within the scope of lifestyle recommendations (fluid intake, diet, constipation, weight control, smoking related to lower urinary system symptoms
41359367|NCT03946592|DRUG|Normal saline|Inject the Drug into submental fat via subcutaneous
41359368|NCT03946592|DRUG|DWJ211|Inject the Drug into submental fat via subcutaneous
41359369|NCT00612456|DRUG|Pazopanib|Pazopanib eye drops formulation
41359370|NCT03310476|OTHER|Potatoes|Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
41359371|NCT01905241|DEVICE|Anatomic TSA using RTI|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Real Time Instrumentation (RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
41024110|NCT04116229|PROCEDURE|Oral glucose tolerance test|After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
41024111|NCT04116229|BEHAVIORAL|Cognitive testing|For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
41036560|NCT02863562|OTHER|Kinesio taping|Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training. This procedure was repeated each week for one month.
41359372|NCT01905241|PROCEDURE|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same with the exception of the instrumentation used to place the guide pin for placement of the glenoid implant.
41359373|NCT03802799|DRUG|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
41359374|NCT04306627|DRUG|Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment|comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
41497967|NCT03379389|DRUG|Antibiotics|Antibiotics based on individual subjects urine culture / antibiogram
41497968|NCT05014412|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
41497969|NCT01413516|BEHAVIORAL|Smoking cessation counseling|Counseling sessions provided by a trained smoking counselor
41359375|NCT05751915|DEVICE|CardioFlux|CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.
41024112|NCT04116229|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
41024113|NCT05544877|BEHAVIORAL|Integrated 5-day Gratitude Exercise and Behavioral Activation Program|The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
41024114|NCT04594512|OTHER|Fresh corneal lenticule and autologous serum in advanced keratoconus using ReLex Smile surgery|A 19-year-old female patient with keratoconus and chronic hydrops cornea referred to the cornea department of our clinic with thin cornea and hydrops in chronic stage and minimal dry eye symptoms. Minimum corneal pachymetry in the right eye was 378 µm as measured by optical coherence tomography(AS-OCT-Zeiss). Atlas corneal topography showed steep K-values 82.60 ax.37 and flat K 75.15 D ax 127 with -7.45 corneal astigmatism. Her best corrected visual acuity was 0.0.5 in right eye and 1.0 in the left eye. Slit lamp examination showed intense punctate epitheliopathy (Figure 1), tear film break-up time (TBUT) was measured as 7-8 sec and Schirmer test was 10 mm in right eye, and the other eye examinations were determined normally
41024115|NCT02305940|DRUG|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
41024116|NCT02305940|DRUG|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
41024117|NCT06573827|DIAGNOSTIC_TEST|Blood and urine sample evaluation|Blood and urine sample evaluation will be performed in healthy female volunteers.
41024118|NCT01079520|PROCEDURE|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
41024119|NCT01079520|PROCEDURE|Mediastinoscopy|Traditional surgical method to stage lung cancers
41024120|NCT02462395|DEVICE|tDCS|"Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.~A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.~Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software."
41024121|NCT06346977|DRUG|Pemetrexed|Intrathecal injection of pemetrexed
41024122|NCT05059392|BEHAVIORAL|Training for Awareness, Resilience and Action (TARA)|See arm description
41024123|NCT01229228|DRUG|Naproxen Test|200-mg single dose
41024124|NCT01229228|DRUG|Naproxen Test|400-mg (2 x 200-mg)
41024125|NCT01229228|DRUG|Naprosyn|single dose
41024126|NCT01229228|DRUG|Naprosyn|single dose
41024127|NCT01229228|DRUG|Placebo|single dose
41024128|NCT06535009|DRUG|ONO-7914|Specified dose on specified days
41024129|NCT06535009|DRUG|ONO-4538|Specified dose on specified days
41024130|NCT05247944|PROCEDURE|Fenestrated and branched endovascular aortic repair (F-BEVAR)|Fenestrated and branched endovascular aortic repair (F-BEVAR)
41024131|NCT05247944|PROCEDURE|Open repair|Open surgery for complex abdominal aortic aneurysm
41024132|NCT03701659|PROCEDURE|Surgery combinate with Endocrine therapy|TUPKRP is abbreviation of transurethral plasma kinetic resection of prostate, which is an effective treatment of bladder outlet obstruction for benign prostate hyperplasia. MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrinotherapy for advanced prostate cancer.
41024133|NCT03701659|DRUG|Endocrine therapy|MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
41024134|NCT01709058|DRUG|Intramuscular/paravertebral injections of Oxygen-Ozone|"Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL"
41024135|NCT01709058|OTHER|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
41024136|NCT06161363|OTHER|The Morisky Medication Adherence Scale|The Morisky Medication Adherence Scale will be completed bu the patients
41359376|NCT00784836|DRUG|BG9418 (interferon beta 1-a)|
41024137|NCT05632952|DEVICE|Intraperitoneal Onlay Mesh positioning Plus|"Intraperitoneal Onlay Mesh (IPOM) Plus with closure of the hernia defect will be performed according to the common recommendations.~The closure of the wall defect will be decided according to the surgeon evaluations: hernia size and choice of technique will be recorded in the database. The mesh will have an overlap of at least 5 cm on all sides of the defect. Dimension of the mesh will be sized to overlap the hernia orifice by at least five centimetres and placed in the intraperitoneal position. Using non-articulating laparoscopic fixation devices, 5.1-mm non-absorbable or absorbable tacks will be then positioned around the circumference of the prosthesis in a 3-row manner or 2-row manner based on the intraoperative findings, the patient's specific situation and the operating surgeon's decision."
41024138|NCT00226434|PROCEDURE|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
41024139|NCT00226434|PROCEDURE|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
41024140|NCT05787769|DRUG|P shot arm ( Autologous Platelet Rich Plasma)|Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum
41024141|NCT05787769|DRUG|PDE5i arm|Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
41024142|NCT03322306|GENETIC|Genechip screening kit|10 ml blood for genetic screening by specific genetic screening kit
41024143|NCT00879294|DEVICE|Motion sickness wristband|No drugs are involved.
41024144|NCT00879294|DIETARY_SUPPLEMENT|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
41024145|NCT00956150|PROCEDURE|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
41024146|NCT00956150|DRUG|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
41024147|NCT00956150|DRUG|Placebo|Placebo TID PO x 10 days
41024148|NCT01085318|DRUG|Rebif|44 mcg tiw
41024149|NCT06573788|BEHAVIORAL|Internet + wearble device multimodal prehabilitation|Use the Prehabilitation Learning Platform to learn what to do and follow along with the videos for follow up exercises
41024150|NCT06573788|BEHAVIORAL|traditional multimodal prehabilitation|The researchers used a prehabilitation manual to explain to subjects what they needed to do, and the patients went home and practiced on their own, recording the exercises daily
41024151|NCT04136106|DRUG|IL-2|IL-2 is a medicine which can use in autoimmune disease, infection or cancer with different dose. Low-dose IL-2 preferentially used in autoimmune disease, such as SLE. Our enrolled SLE patients will divided into two groups depend on whether use IL-2 or not, combined with corticosteroid and immunosuppressor.
41024152|NCT02804919|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
41024153|NCT05706259|DIETARY_SUPPLEMENT|Soft gelatin 200000 IU vitamin D3 capsule|Weekly single dose for 3-weeks
41024154|NCT05706259|DIETARY_SUPPLEMENT|Orodispersible (sachet) 200000 IU vitamin D3|Weekly single dose for 3-weeks
41024155|NCT04462796|DIETARY_SUPPLEMENT|Magnesium Citrate|Magnesium Citrate 200 mg daily
41024156|NCT04055129|OTHER|No interventions|Observational. Data will be gathered and analyzed on ligament laxity, EMG, kinetics and kinematics during a landing and jumping activity
41024157|NCT02172313|DRUG|semaglutide|For oral administration.
41024158|NCT04031339|PROCEDURE|Standard treatment|e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance
41024159|NCT06572553|DRUG|Faricimab|Faricimab (faricimab-svoa; Vabysmo), a bispecific antibody that inhibits both VEGF-A and Ang-2, was developed by Roche/Genentech, and dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease relative to anti-VEGF therapy alone.
41024160|NCT00185133|DRUG|Olmesartan medoxomil|
41024161|NCT00185133|DRUG|Amlodipine|
41160652|NCT06197685|BEHAVIORAL|Aerobic Exercise Training (AET) plus Virtual Reality (IDEAL)|The AET condition includes 12 weeks of supervised, progressive, moderate intensity cycle ergometry. The AET will include semi-immersive, interactive VR such the cycling speed on the bike will translate directly to perceived speed through the virtual environment.
41160653|NCT06197685|BEHAVIORAL|Stretching and Toning (S/T)|The S/T condition will include 12 weeks of supervised S/T activities that target the head/neck. shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
41160654|NCT02028234|DRUG|Pantoprazole,|os, 20 mg, once per day, for 30 days
41024162|NCT00130884|DRUG|levosimendan|
41024163|NCT04010617|DEVICE|Pharyngeal Electrical Stimulation (PES)|PES will be delivered by a commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK), which comprises a nasogastric feeding catheter that houses stimulation ring-electrodes and a computerised base station that delivers stimulation in the range 1-50 mA at 5 Hz.
41024164|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Norway|
41024165|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Sweden|Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden
41024166|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Denmark|Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
41024167|NCT03176108|BEHAVIORAL|Cognitive Behavorial Therapy (CBT)|Cognitive Behaviorial Therapy (CBT)
41024168|NCT03176108|BEHAVIORAL|Body mediation|Body mediation (theatre)
41024169|NCT05052359|DIAGNOSTIC_TEST|Lectin-histochemistry retrospectively performed|Lectin-histochemistry was performed on 37 archival paraffin wax-embedded specimens of various follicular thyroid tumours (10 follicular adenomas (FA), 10 minimally invasive follicular carcinomas (miFTC), 13 widely invasive follicular cancers (wiFTC) and 4 metastatic follicular thyroid cancers (metFTC)).
41024170|NCT02692989|PROCEDURE|Hip fracture surgery and anesthesia|any operative fixation for hip fracture whether under General Anesthesia or Regional anesthesia
41024171|NCT06205290|BIOLOGICAL|Liso-cel|Specified dose on specified days
40839224|NCT04070066|OTHER|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
41024172|NCT06205290|DRUG|Idelalisib|Specified dose on specified days
41024173|NCT06205290|DRUG|Rituximab|Specified dose on specified days
40839225|NCT04070066|OTHER|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
40839226|NCT00488904|DIETARY_SUPPLEMENT|supportan|2 sip feed pr. day
40839227|NCT00488904|DIETARY_SUPPLEMENT|supportan placebo|2 sip feed pr. day
40839228|NCT03963102|DRUG|Ameluz|Leaving on the gel for 4 hours rather than the standard 3 hours.
40839229|NCT01665534|BEHAVIORAL|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
40839230|NCT00861016|DRUG|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
40839231|NCT01621867|DRUG|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
40839232|NCT01621867|DRUG|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
40839233|NCT04336527|BEHAVIORAL|Home Treatment with Peer Support|After allocation participants receive a combination of Home Treatment by a multiprofessional team and Peer Support.
40839234|NCT04336527|BEHAVIORAL|Home Treatment without Peer Support|After allocation participants receive professional-led Home Treatment by a multiprofessional team without Peer Support (treatment as usual).
40839235|NCT03550768|OTHER|MDP|evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP
41024174|NCT06205290|DRUG|Bendamustine|Specified dose on specified days
41024175|NCT06205290|DRUG|Fludarabine|Specified dose on specified days
41024176|NCT06205290|DRUG|Cyclophosphamide|Specified dose on specified days
41024177|NCT01679119|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
41024178|NCT01679119|DRUG|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
41024179|NCT01679119|DRUG|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
41024180|NCT01679119|DRUG|Rituximab|Rituximab 375mg/m2 IV given day 1
41024181|NCT01679119|DRUG|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
40839236|NCT01277315|DRUG|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
40839237|NCT05192213|DRUG|Vitamin C|Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days
40839238|NCT05192213|OTHER|Placebo|Patients will receive 2 placebos (every 6 hours and every 12 hours) + Hydrocortisone (50 mg every 6 hours) for 7 days.
41024182|NCT01679119|DRUG|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
40839239|NCT04370379|DRUG|IBI302 (the first dose level)|q4week (3 injections) followed by PRN dosing
41024183|NCT01172938|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
41024184|NCT01172938|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
41024185|NCT01172938|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
41024186|NCT01172938|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
41024187|NCT05889559|DEVICE|Tissue Ultrafiltration Catheters|patients randomized to the experimental arm will have three TUF catheters placed in the anterior muscle compartment of the injured limb. The TUF catheters will be connected to a closed suction drain and will remove interstitial fluid from the muscle.
41024188|NCT00928317|DRUG|ART621|3.0mg/kg s.c.
41160655|NCT02028234|DRUG|Omeprazole|os, 20 mg, once per day, for 30 days
41160656|NCT02775214|DEVICE|Video Laryngoscopy|
40839240|NCT04370379|DRUG|IBI302 (the second dose level)|q4week (3 injections) followed by PRN dosing
40839241|NCT04370379|DRUG|Aflibercept|2mg, q4week (3 injections) followed by q8week
40839242|NCT01916850|DRUG|LX4211 400 mg|
40839243|NCT01916850|DRUG|LX4211 800 mg|
41024189|NCT00928317|DRUG|ART621|1.5mg/kg s.c.
41024190|NCT00928317|DRUG|ART621|0.75mg/kg s.c.
41024191|NCT00928317|DRUG|Placebo|Placebo s.c.
41024192|NCT02356016|BEHAVIORAL|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
41024193|NCT02356016|BEHAVIORAL|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
41024194|NCT02356016|OTHER|control (dietary counseling)|Monthly dietary counseling only
41160657|NCT00105521|DRUG|Sarizotan|Sarizotan will be administered twice daily.
41160658|NCT00105521|DRUG|Placebo|Placebo matching to sarizotan will be administered twice daily.
41497970|NCT01413516|DRUG|Placebo|Sugar pill without any active medication
41359377|NCT05286034|BEHAVIORAL|Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms|"Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms.~ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels."
41359378|NCT00867061|DRUG|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
41359379|NCT02811367|DEVICE|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
41359380|NCT04401488|BIOLOGICAL|Prevenar 7 and Prevenar 13|pneumococcal conjugate vaccines
41359381|NCT01577446|PROCEDURE|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
41359382|NCT00537251|DRUG|Insulin glargine|
41359383|NCT05867849|DRUG|Cannabidiol|Cannabinoid
41359384|NCT05867849|OTHER|Placebo|Inactive substance
41359385|NCT01560013|DRUG|Naltrexone|Naltrexone, oral 50 mg per day.
41024195|NCT03488381|DEVICE|Soccer Heading|"Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals."
41024196|NCT03120104|OTHER|pelvic floor muscle exercise before stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just one month before the stoma closure
41024197|NCT03120104|OTHER|pelvic floor muscle exercise after stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just two weeks after the stoma closure
41160659|NCT04881396|BIOLOGICAL|Evaluation of the immunogenicity of the vaccine in haemodialysis patients|The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)
41160660|NCT00729053|DRUG|IMO-2055|immunostimulatory oligonucleotide
41160661|NCT02584218|PROCEDURE|Non-invasive resin based caries sealing|The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
41160662|NCT02584218|PROCEDURE|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
41160663|NCT02864199|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
41160664|NCT02864199|DRUG|Ribavirin|Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
41160665|NCT00078858|DRUG|fludarabine phosphate|Given IV
41359386|NCT00627991|DRUG|Valsartan|
40839244|NCT01916850|DRUG|LX4211 Placebo|
40839245|NCT05892640|OTHER|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
40839246|NCT02030990|DRUG|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
40839247|NCT02030990|DRUG|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
40839248|NCT02858921|DRUG|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
40839249|NCT02858921|DRUG|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
41359387|NCT00266149|DRUG|Oral contraception|
41359388|NCT00266149|DRUG|Lamotrigine|
41359389|NCT00464854|DRUG|Glargine and insulin aspart or lispro|
40839250|NCT02858921|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
40839251|NCT04496453|OTHER|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
41359390|NCT03595072|OTHER|observation of VNS stimulation effects|ECOGs will be recorded during VNS stimulation and inter stimulation periods
41359391|NCT03263767|DRUG|Fludarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
41359392|NCT03263767|DRUG|Clofarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
41359393|NCT03263767|RADIATION|Full body irradiation|2 grays at Day-1
41359394|NCT03263767|DRUG|Cyclophosphamide|14 mg/kg intravenous 2 days at Day - 6 and day -5
41359395|NCT03263767|DRUG|Cyclophosphamide|50 mg/kg intravenous 2 days at day +3 and day +4
41359396|NCT03263767|OTHER|stem cell transplantation|at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
41359397|NCT03263767|OTHER|nuclear cells|CD3+ cells if needed after transplantation
41359398|NCT03263767|DRUG|Thymoglobulin Injectable Product|At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
41359399|NCT03180320|BEHAVIORAL|BESMILE-HF program|"The following activities will be conducted as part of the BESMILE-HF program:~1. Baduanjin exercise;~2. evaluations of exercise capacity and clinical conditions;~3. consultations on exercise prescription and management of symptoms/signs during exercise;~4. education covering topics related to the CHF and exercise; and~5. a series of adherence strategies."
41359400|NCT03180320|DRUG|Usual medications|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
41359401|NCT03302923|BEHAVIORAL|Brisk walking|Prospective randomized clinical trial with 2 intervention groups and 1 control group.
41497971|NCT01413516|DRUG|Varenicline|Varenicline (an approved medication for smoking cessation)
41497972|NCT05187130|OTHER|Mindfulness|60 patients in the mindfulness-based breathing and music therapy group were divided into subgroups of 5 participants each. Each 6-person group started by having participants complete the pretest State Anxiety Inventory, Beck Depression Inventory, and Psychological Well-Being Scale via Survey Monkey. Mindfulness-based breathing and music therapy was applied to each patient group in approximately 45-minute sessions per day. At the end of the session, participants re-filled the posttest State Anxiety Inventory, Work-Related Tension Scale, and Psychological Well-Being Scale. A total of 3 sessions were completed with an interval of two days.
40839252|NCT06288971|OTHER|Self-adaption web-based software for the rehabilitation of EF and visuo-spatial abilities|- Self-adaption web-based software integrated with neuropsychomotor activities in small groups to strengthen EF. The training will take place bi-weekly, for 3 months, for approximately 60 minutes per meeting. For the intervention will be used the Bee-bot, a robot to be programmed to achieve objectives set in space, allows to stimulate navigation, visuospatial working memory and planning skills (the activities will be taken from those already used in our previous studies in children with typical development and BES (Di Lieto et al., 2020)).
40839253|NCT06288971|OTHER|Tele-rehabilitation of EF and specific cognitive processes underlying academic skills|- Tele-rehabilitation intervention on FE (RuntheRAN and MemoRAN). The training will be conducted at home, with periodic meetings with the clinician, for 3 months, for approximately 4/5 days a week for approximately 30/40 minutes per day. An adult (e.g. a family member) will support the child in the treatment and ensure that the exercises are carried out adequately at home. One of the following tele-rehabilitation software will be used: RuntheRAN (RidiNet, Coopertiva Sociale Anastasis), a software that aims to strengthen the prerequisites of reading by requiring the timed and progressively faster naming of colour matrices or black and white figures. MemoRAN (RidiNet, Cooperativa Sociale Anastasis), which involves rapid naming exercises of stimuli (figures and colors) presented in matrices, within tasks that require inhibition, cognitive flexibility and updating in working memory.
41024198|NCT03032692|DEVICE|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
41024199|NCT03032692|OTHER|Exercise with biofeedback|
41024200|NCT03032692|OTHER|exercise without biofeedback|
41024201|NCT03957174|DRUG|Reboxetine|Single dose used to increase central norepinepherine
41024202|NCT03957174|DRUG|Rivastigmine|Single dose to increase central acetylcholine
41024203|NCT03957174|DRUG|Placebo oral tablet|Single dose as control condition
41024204|NCT04868201|DEVICE|0-anxiety|0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
41024205|NCT01984398|DRUG|12.5 mg Androxal Formulation A|Single dose of 12.5 mg Androxal formulation A
41024206|NCT01984398|DRUG|12.5 mg Androxal Formulation B|Single dose of 12.5 mg Androxal Formulation B
41160666|NCT00078858|RADIATION|total-body irradiation|Undergo TBI
41359402|NCT05071742|GENETIC|2ml peripheral venous blood was collected to detect genetic genes|"Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use.~(2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection"
41497973|NCT05121792|BEHAVIORAL|Web Based Therapist Tutorial on Prolonged Grief Disorder Therapy|The tutorial consists of 10 online modules following the main procedures of the Prolonged Grief Disorder Therapy (formerly known as Complicated Grief Treatment). Each module includes didactic information and interactive activities and videos, and takes approximately 30 minutes to review. Participants can study the material at their own pace.
41497974|NCT05512637|DIAGNOSTIC_TEST|Step 1 - Screening ; Step 2 - Clinical interview|"Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview.~Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process."
41497975|NCT06467110|DEVICE|transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)|The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.
41497976|NCT06319963|DRUG|Two IM injections Lenti-HPV-07|two Lenti-HPV-07 intramuscular injections one month apart
41359403|NCT05568966|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to draw up to 24mL of venous blood.
40839254|NCT06288971|OTHER|Game-based tools for the rehabilitation of EF and motor planning|- MondoELLI intervention (Cooperativa Sociale Anastasis) integrated with neuropsychomotor activities. The game-based app involves activities in small groups to strengthen various components of EF (interference control, inhibition, working memory, flexibility). The activities are organized with increasing difficulty, according to the self-adaptive algorithm, and within a narrative context.
40839255|NCT00988481|DRUG|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
41359404|NCT05568966|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
41024207|NCT01984398|DRUG|25 mg Androxal Formulation A|Single dose of 25 mg Androxal formulation A
41359405|NCT04657302|DRUG|Obinutuzumab|Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.
41359406|NCT04657302|DRUG|Glofitamab|Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
41024208|NCT01984398|DRUG|25 mg Androxal Formulation B|Single dose of 25 mg Androxal formulation B
41024209|NCT03208972|DRUG|low dose hCG|
41024210|NCT03208972|DRUG|hp-FSH|
40839256|NCT02580513|BEHAVIORAL|Circadian Misalignment|
40839257|NCT03828474|DRUG|Acetazolamide Pill|Acetazolamide pill
41024211|NCT03208972|DRUG|Corifollitropin Alfa|"Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG"
40839258|NCT05375864|OTHER|Absorption test|Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.
40839259|NCT01085032|DRUG|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
40839260|NCT01085032|DRUG|Placebo nicotine patch|"Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used."
41024212|NCT05450289|DRUG|Nigella Sativa Oil|In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.
41024213|NCT05450289|DRUG|Allergen Specific Immunotherapy|In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.
41024214|NCT05450289|DRUG|Standard pharmacotherapy|Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
41024215|NCT05522036|COMBINATION_PRODUCT|Metvix + Dermaris|Photodynamic Therapy
41359407|NCT04657302|DRUG|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
40839261|NCT00637572|DRUG|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
40839262|NCT00637572|DRUG|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
41359408|NCT01116661|DRUG|5-Aminolevuline Acid (ALA)|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
41359409|NCT05611281|DRUG|GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication|The dosage was calculated according to body weight and dose group once a day according to the assigned group.
41359410|NCT04382209|PROCEDURE|Erector spinae plane block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. Bilateral ultrasound guided erector spinae plane block with 20 mL of 0.375% bupivacaine each using an in-plane, cranial-to-caudad approach to contact the bony shadow of the transverse process (TP) with the tip deep to the fascial plane of the erector spinae muscle. The correct location of the needle tip was confirmed by injecting 0.5-1 cc of normal saline 0.9% and observing linear fluid spread lifting the erector spinae muscle off the tip of the TP.
41359411|NCT04382209|DEVICE|Intravenous meperidine patient controlled analgesia device|Intravenous meperidine patient controlled analgesia device will be given to the patients postoperatively and 24 hour meperidine consumption will be recorded
40839263|NCT05307432|BEHAVIORAL|SPI+ Delivered by ED Staff|ED staff will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
41024216|NCT00002312|DRUG|Delavirdine mesylate|
41024217|NCT00002312|DRUG|Zidovudine|
41024218|NCT04756219|OTHER|Contact Video|No additional information necessary.
41024219|NCT04756219|OTHER|Contact Text|No additional information necessary.
41024220|NCT04756219|OTHER|Education Video|No additional information necessary.
41024221|NCT04756219|OTHER|Education Text|No additional information necessary.
41024222|NCT03892889|COMBINATION_PRODUCT|Abilify MyCite®|Combination product of aripiprazole tablet embedded with sensor and wearable patch.
41024223|NCT04482062|DEVICE|Edwards EVOQUE System|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT
41160667|NCT00078858|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBMC transplantation
41359412|NCT03963076|OTHER|nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)|One spray of nasal hypertonic spray morning and evening every day during 30 days
41359413|NCT00252798|DRUG|Gefitinib|
41359414|NCT00252798|DRUG|Carboplatin|
41359415|NCT00252798|DRUG|Paclitaxel|
41359416|NCT00252798|PROCEDURE|Radiation|
41024224|NCT04482062|DRUG|Optimal Medical Therapy|Optimal Medical Therapy
41160668|NCT00078858|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBMC transplantation
40839264|NCT05307432|BEHAVIORAL|SPI+ Delivered by SPCC Clinicians|The Suicide Prevention Consultation Center (SPCC) will be located external to the Emergency Department (ED). ED staff will be able to refer patients at risk for suicide to the SPCC. Licensed and credentialed mental health clinicians will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) via telehealth to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
41359417|NCT00465894|DRUG|Extended Release Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
41359418|NCT00465894|DRUG|Intra Vaginal Estradiol Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
41359419|NCT01332006|PROCEDURE|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
40839265|NCT02404649|DEVICE|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
40839266|NCT02404649|DEVICE|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
40839267|NCT00840060|BEHAVIORAL|AMALS|Addressing multiple aspects of language simultaneously
40839268|NCT00840060|BEHAVIORAL|DTA|Discrete Trial Approach
40839269|NCT06484517|DEVICE|Hugemed Videolaryngoscope|After general anesthesia induction, the first group of patients (Group M, n=20) was intubated with the McGrath videolaryngoscope. For the second group (Group H, n=20), the Hugemed videolaryngoscope was used. Patients were intubated using one of the appropriate blades numbered 1, 2, or 3 based on their height, weight, and age.
40839270|NCT03465787|DRUG|Lurasidone HCL 160 mg|Lurasidone HCL 2 80mg tablets, QD
40839271|NCT03465787|DRUG|Quetiapine XR 600 mg|Quetiapine XR 2 300 mg tablets, QD
41359420|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|
40839272|NCT01927055|DRUG|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
40839273|NCT01927055|DRUG|Placebo|Placebo to match droxidopa capsules and strength designations
40839274|NCT02965690|PROCEDURE|Zimmer Biomet NexGen CR|Total Knee Replacement
40839275|NCT02965690|PROCEDURE|Medacta International GMK Sphere|Total Knee Replacement
40839276|NCT01410812|BEHAVIORAL|Control|Receive weekly emails asking participants about their exercise and receive cash.
40839277|NCT01410812|BEHAVIORAL|Suggested Tying Intervention|Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
40839278|NCT01410812|BEHAVIORAL|Forced Tying Intervention|Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
40839279|NCT03218579|DIETARY_SUPPLEMENT|Probiotic treatment|4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
40839280|NCT03218579|BIOLOGICAL|Bacteriotherapy|Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
40839281|NCT00905203|OTHER|exercise|exercise training
40839282|NCT01022359|DEVICE|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
40839283|NCT01022359|DEVICE|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
41160669|NCT00078858|DRUG|cyclosporine|Given PO
41160670|NCT00078858|DRUG|mycophenolate mofetil|Given PO or IV
41359421|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
41359422|NCT00352027|DRUG|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
41359423|NCT00352027|DRUG|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
41497977|NCT06319963|DRUG|One IM injection Lenti-HPV-07|a single intramuscular injection prior to receiving a standard of care 28 days at least after the injection.
41497978|NCT02138058|DRUG|Topiramate|
41497979|NCT02138058|BEHAVIORAL|Cognitive restructuring intervention|4 sessions of a manualized cognitive restructuring intervention for compulsive buying
41497980|NCT05248165|DEVICE|PCI|Percutaneous coronary intervention
40839284|NCT03576313|DRUG|dihydroartemisinin-piperaquine (DP)|DP will be available as tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food
41497981|NCT01015937|DRUG|Turmeric extract|turmeric 500 mg TID for 45 days
41497982|NCT01015937|DRUG|Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker|maximum dosage as patient tolerated for 45 days
41497983|NCT04617522|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
41497984|NCT04345601|BIOLOGICAL|Mesenchymal Stromal Cells|Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10\^8 MSCs.
40839285|NCT03576313|DRUG|ivermectin (IVM)|IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water
41497985|NCT04345601|OTHER|Supportive Care|Patients will receive supportive care per their treating physician
41497986|NCT00979914|OTHER|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
41497987|NCT02283983|OTHER|mittens and booties|
41497988|NCT02283983|OTHER|cooling helmet|
40839286|NCT03576313|OTHER|standard malaria control interventions only|this is the standard malaria control interventions in the Gambia
41160671|NCT00078858|OTHER|laboratory biomarker analysis|Correlative studies
41359424|NCT00352027|DRUG|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
41359425|NCT00352027|DRUG|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
41359426|NCT00352027|DRUG|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
41497989|NCT03749083|OTHER|The Functional Assessment of Cancer Therapy- Colorectal|The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses.
41497990|NCT03953989|DRUG|Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die|Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
41359427|NCT00352027|DRUG|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
41359428|NCT00352027|DRUG|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
41359429|NCT00352027|DRUG|Prednisone|Given PO every other day of weeks 1-12.
41359430|NCT00352027|BIOLOGICAL|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
41359431|NCT00352027|PROCEDURE|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
41359432|NCT05879302|BEHAVIORAL|Kidney Offer Shared Decision Making|The intervention consists of receiving the Donor Offer Plan (DOP), reviewing a web-based educational module about donor offers including practice offer videos, followed by a discussion about the DOP with a transplant nurse coordinator.
41497991|NCT01685840|OTHER|Usual Care|Usual Care
41497992|NCT01685840|DEVICE|Biomarker-guided care NT-proBNP|Device: NT-proBNP
41497993|NCT03853148|BEHAVIORAL|Otago|Exercise program for strength and balance
41497994|NCT03853148|BEHAVIORAL|Gentle yogic breathing|yogic breathing
41497995|NCT03853148|BEHAVIORAL|Behavioral Activation|Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.
41497996|NCT03853148|BEHAVIORAL|Caregiver Gentle yogic breathing|yogic breathing
41497997|NCT03391414|DRUG|hypertonic bicarbonate|8.4% sodium bicarbonate inhaled
41497998|NCT03391414|DRUG|sodium chloride|7% sodium chloride inhaled
41497999|NCT00457483|DRUG|hydrochlorothiazide|12.5 mg once-a-day
41498000|NCT00457483|DRUG|valsartan, 80 mg once-a-day|80 mg once-a-day
41498001|NCT02862561|DRUG|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
41498002|NCT02862561|BIOLOGICAL|Precision Cells|DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
41498003|NCT02388360|DRUG|topical prostaglandin analogs|
41498004|NCT04386486|OTHER|Bathe anamnesis method|BATHE anamnesis (BA) is applied to first group and preoperative examinations are completed.
41498005|NCT04386486|OTHER|standart anamnesis|standart anamnesis is applied to second group and preoperative examinations are completed.
41498006|NCT01716715|DRUG|Cabozantinib S-malate|Given PO
41498007|NCT01716715|OTHER|Laboratory Biomarker Analysis|Correlative studies
41498008|NCT01716715|DRUG|Paclitaxel|Given IV
41498009|NCT05393518|BEHAVIORAL|Anxiety-induced task|Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.
41498010|NCT05393518|BEHAVIORAL|Neuropsychiatric assessment|Screening for depression and anxiety
41359433|NCT03715036|DIAGNOSTIC_TEST|Point-of-care US|The intervention includes reassuring the AC and DVP
40839287|NCT03492931|DRUG|Ticagrelor|Patients will receive a single dose of ticagrelor
40839288|NCT05117203|DEVICE|WB-EMS (Whole body electrostimulation)|Application of physical exercise and electrical stimulation on the abdominal muscles through the WB-EMS during 20 minutes training session with specific exercise (CORE)
41359434|NCT05423847|DIAGNOSTIC_TEST|POCUS|POCUS of lungs, pericardium and abdomen
41359435|NCT03188991|DRUG|NanoPac®|NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
41359436|NCT06381336|DEVICE|TRAK-SILVER platform|"The Experimental Group used TRAK-SILVER, a cross-platform web application that empowers healthcare professionals and patients. It facilitates the management of a patient's condition by providing therapeutic exercises, monitoring activity, and administering clinical assessment scales and questionnaires. The platform's advanced artificial vision algorithm, known for its precision, enhances patient engagement with real-time measurements and corrections during exercise.~Physiotherapists monitored the sessions through the TRAK-SILVER platform's monitoring system and weekly phone calls. The TRAK-SILVER platform had an alert notification system.~The program's second part involved weekly uploads of health-promoting information pills to the platform."
41359437|NCT03440606|BEHAVIORAL|Mindful-Compassion Art Therapy Supervision|"Each Mindful-Compassion Art Therapy Supervision group will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific structure include: (1) Self-care and Stress Management in Week 1 and 2 (i.e., concept of mindfulness and art, the symbol of the mandala and its use in self-care, mindfulness practice and art); (2) Sharing of Clinical Expertise and Experiences in Week 3 and 4 (i.e., Create mindful art about one meaningful and one challenging patient/client interaction with small group discussion); and (3) Understanding Grief and Meaning-Making in Week 5 and 6 (i.e., Create mindful art representing a clinical encounter of mortality, and meaning-making from reflection on grief)."
41498011|NCT06197373|PROCEDURE|Laparoscopic cholecystectomy|Doing laparoscopic cholecystectomy after ERCP at different intervals
40839289|NCT05117203|DEVICE|EMS|Application of physical exercise and electrical stimulation on the abdominal muscles through the EMS during 20 minutes training session with specific exercise (CORE)
40839290|NCT05117203|DEVICE|WB-EMS off|Application of physical exercise without electrical stimulation on the abdominal muscles through the WB-EMS off during a 20 minutes training session with specific exercise (CORE).
41024225|NCT05838222|BEHAVIORAL|Solution Focused Intervention|A short term, goal focused, therapeutic approach which helps patients address problems contributing to health and mental health challenges
41498012|NCT02419144|BEHAVIORAL|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
41024226|NCT05838222|OTHER|Treatment as Usual|The patient receives standardized care from primary care team without the SFBT intervention
41160672|NCT02149732|BIOLOGICAL|cultivated oral mucosal epithelial sheet transplantation|Autologous cultivated oral mucosal epithelial cell sheet transplantation using oral mucosal adult stem cells in the patients with intractable corneal limbal deficiency
41160673|NCT04892602|DIAGNOSTIC_TEST|Serum vitaminDlevel|Investigate about fibromyalgia in psoiaritic and rheumatiod arthritis patients ...and assesment of seum vitamin D level
41160674|NCT01829828|BEHAVIORAL|No intervention|This is an observational study with no investigational drug administered.
41498013|NCT04428333|DRUG|Feladilimab|Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
41498014|NCT04428333|DRUG|Pembrolizumab|Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
40839291|NCT02208349|DEVICE|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
41498015|NCT04428333|DRUG|Placebo|Sterile normal saline
41498016|NCT04428333|DRUG|Platinum based chemotherapy|Cisplatin/carboplatin
41498017|NCT04428333|DRUG|Fluorouracil (5FU)|5-fluorouracil
41498018|NCT03317834|DEVICE|Navio ™ Robotic-assisted Surgical System|Total Knee Replacement
41498019|NCT04628793|DRUG|PF-07258669|PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
40839292|NCT02208349|DEVICE|traditional direct laryngoscopy (DL)|
40839293|NCT05178784|DEVICE|External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation|Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.
41024227|NCT00367263|DRUG|Alvesco (Ciclesonide) 160 ug/day|
41024228|NCT06535256|DRUG|bupivacaine with dexamethasone|intra-peritoneal instillation of bupivacaine with dexamethasone (received 40 mL of 0.25% bupivacaine + 16 mg dexamethasone with 5 ml normal saline).
41160675|NCT00866918|DRUG|Arsenic Trioxide|Given IV
41160676|NCT00866918|DRUG|Cytarabine|Given IT or IV
41160677|NCT00866918|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
41160678|NCT00866918|DRUG|Idarubicin|Given IV
41160679|NCT00866918|DRUG|Mercaptopurine|Given orally
41160680|NCT00866918|DRUG|Methotrexate|Given orally
41160681|NCT00866918|DRUG|Mitoxantrone Hydrochloride|Given IV
41160682|NCT00866918|DRUG|Tretinoin|Given orally
41160683|NCT05959811|OTHER|yoga|60 minutes yoga practice ,twice a week for 8 weeks
41359438|NCT03671434|BEHAVIORAL|Research-to-Policy Collaboration|The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.
41498020|NCT04628793|DRUG|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
41498021|NCT02185716|DRUG|Levobupivacaine 0.25 %|
41498022|NCT02185716|DRUG|Levobupivacaine 0.5%|
41498023|NCT04028193|DIETARY_SUPPLEMENT|Calogen|Polyunsaturated liquid fat supplement
41498024|NCT04028193|DIETARY_SUPPLEMENT|Resource Energy|Carbohydrate Supplement
41498025|NCT01402635|DEVICE|point-of-care chemistry test(POCT) (Piccolo)|comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
41498026|NCT05349643|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
41498027|NCT05240170|DEVICE|RIRS|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
41498028|NCT05240170|DEVICE|SWL|Patients who underwent SWL at our institution in the past five years. According to (a) the type of renal anomaly (rotation, position, or rotation/position anomaly), (b) the size of the stone (±5 mm), (c) location of the stone (lower polar or non-lower polar), and (d) density of the stone (\>800 HU or ≤800 HU), matched cases will be selected for comparison.
41498029|NCT05438914|DEVICE|Repair of the subscapularis|"The subscapularis will be repaired using the suture through bone and prosthesis holes surgical technique."
41498030|NCT06449651|DRUG|Nipocalimab|Nipocalimab will be administrated intravenously.
41498031|NCT06449651|DRUG|Placebo|Placebo will be administrated intravenously.
41498032|NCT03290703|DRUG|GDC-0853|Participants will receive different formulations of GDC-0853 tablet.
40839294|NCT04341688|DRUG|Gargle/Mouthwash|"There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period."
40839295|NCT04167865|OTHER|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
40839296|NCT01545973|OTHER|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
40839297|NCT05556213|PROCEDURE|laparoscopic examination|laparoscopic examination for staging of endometriosis
41498033|NCT03290703|DRUG|Rabeprazole|Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
41498034|NCT05046964|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Radical-7 Pulse CO-Oximeter uses photospectroscopy to non-invasively measure the total hemoglobin (SpHb) in a patient's blood throughout their C-section.
41498035|NCT03002129|OTHER|fluid challenge|At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
41498036|NCT06202612|DRUG|SHR0302 quick release tablets|SHR0302 quick release tablets 8 mg
41498037|NCT06202612|DRUG|SHR0302 sustained-release tablets|SHR0302 sustained-release tablets 10 mg
41498038|NCT04702243|DIAGNOSTIC_TEST|Genetic Testing for PCD or PID|Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes.
41498039|NCT04702243|OTHER|Unaffected Family Member Genetic Testing|Unaffected family members will undergo genetic testing if genetic findings are identified in their affected family member.
41498040|NCT04869215|OTHER|EverVita Pro|EverVita Pro is composed of barley and corn, grown and mechanically processed in Europe, with non-GMO grains.
41498041|NCT04869215|OTHER|Control bread|Bread baked with normal Bakers flour
41498042|NCT06632717|DRUG|Cisplatin|"Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity"
41498043|NCT06632717|DRUG|5-fluorouracil|"Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity"
41498044|NCT06632717|PROCEDURE|Lipiodol embolization|"Lipiodol embolization protocol~* Lipiodol embolization will be performed on day 3 after completion of 5-FU infusion, up to 4 cycles. Fixed dose lipiodol of 10mL will be given on day 3 followed by 30mL normal saline flush.~* The administration of lipiodol is mandatory on cycle 1. The administration of lipiodol on cycle 2 to cycle 4 will depend on the discretion of the treating physician and the presence of adverse effects from lipiodol embolization."
40839298|NCT05556213|DIAGNOSTIC_TEST|Blood sampling|Blood sample to detect endometriosis
41498045|NCT02374138|BEHAVIORAL|Parental stress management|"The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches."
41359439|NCT03671434|BEHAVIORAL|Light Touch Policy Training|Control Researchers are provided information on policy engagement via email.
41498046|NCT02374138|OTHER|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
41498047|NCT04774848|DEVICE|High Frequency Jet Ventilator|HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.
41498048|NCT04774848|DEVICE|High Frequency Oscillatory Ventilator|HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.
40839299|NCT00895960|DRUG|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
40839300|NCT00895960|RADIATION|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
40839301|NCT00895960|DRUG|TMZ (Temozolomide)|75 mg/m\^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m\^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles.
41498049|NCT05999058|PROCEDURE|Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation|The dacryoendoscopy was inserted into the lacrimal duct through the upper or lower lacrimal punctum. When the dacryoendoscopy reached the postsaccal obstruction, laser dacryoplasty (FOX diode laser, A.R.C. Laser, Nürnberg, Germany) was performed by widening the stenotic or obstructed section. After removing the dacryoendoscopy, a silicone tube inserted into lacrimal passage. Double bicanalicular silicone intubation was performed as previously described.
40839302|NCT00307554|BIOLOGICAL|Pneumococcal (vaccine)|
40839303|NCT03922178|DEVICE|Pressure/Volume Combination Catheter|Hemodynamic data routinely collected and data collected by means of the placement of a Pressure/Volume Combination Catheter (Pressure/Volume Combination Catheter,Leycom,The Netherlands) will be collected simultaneously. The catheter will be placed and held in place as long as the patient is in a position to be assisted by extracorporeal circulation. This means that the placement of the catheter will follow the heparinization of the patient and the placement of the cannulas necessary for the realization of extracorporal circulation. It will be removed from the left ventricular cavity before removal of extra-corporal cannulas.
40839304|NCT03922178|DEVICE|Transthoracic echocardiography|A complete transthoracic echocardiography will be performed the day before the surgical procedure, as per standard of care. It will establish the presence of the inclusion and exclusion criteria and evaluate the contractile function of the left ventricle. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).
40839305|NCT03922178|DEVICE|Transesophageal echocardiogram|A transesophageal echocardiogram will be performed during the cardiac surgery, as per standard of care, using an Acuson Sequoia system (Siemens AG, Germany). It will facilitate the placement of the pressure/volume combination catheter and collect echographic data.
40839306|NCT02107872|DRUG|REGN1500|
40839307|NCT02107872|DRUG|placebo|
40839308|NCT05879575|BEHAVIORAL|weight training|Pregnant women assigned to the intervention group will receive online weight training sessions twice a week, for 60 minutes per session, from the 16th to the 36th week of pregnancy. The Pelvic Girdle Questionnaire will be used to assess the condition of pelvic girdle pain during pregnancy, and to analyze whether weight training can improve this problem. Pelvic floor muscle structure will also be analyzed by pelvic ultrasound to determine whether it has been altered by weight training, leading to an improvement in pain.
40839309|NCT03713541|OTHER|No intervention|Survey during normal supply.
41359440|NCT02238509|DRUG|Lapatinib|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
41359441|NCT02238509|DRUG|Trastuzumab|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
41359442|NCT03349957|DRUG|Transarterial chemoembolization using TANDEM and idarubicin|Transarterial chemoembolization using TANDEM and idarubicin
40839310|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
41359443|NCT00745004|DRUG|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
41359444|NCT00745004|DRUG|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
41359445|NCT00216112|DRUG|Imatinib Mesylate|Imatinib mesylate 600 mg po qd
41359446|NCT00216112|DRUG|Docetaxel|Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
41498050|NCT03324295|DIAGNOSTIC_TEST|cortical cataract|Blood urea
41024229|NCT06535256|DRUG|bupivacaine with dexmedetomidine|intra-peritoneal instillation of bupivacaine with dexmedetomidine (received 40 mL of 0.25% bupivacaine + dexmedetomidine 1 μg/kg with normal saline 5 ml).
41359447|NCT04166721|DRUG|Atezolizumab|Immunotherapy
41359448|NCT02238392|PROCEDURE|Adenosine test|Testing dormant conduction after PVI
41024230|NCT02839434|PROCEDURE|Blood sample|This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
41024231|NCT06215638|DRUG|Bortezomib|Bortezomib 2 mg per week subcutaneously, for twelve weeks in total
41024232|NCT01984723|DRUG|Experimental: EVP-6124|
41024233|NCT01769794|DRUG|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
41024234|NCT01769794|DRUG|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
41359449|NCT02238392|PROCEDURE|Termination of AF|Testing AF iducibility and ermination of
41359450|NCT02063958|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
41359451|NCT00165256|OTHER|Observation|Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
40839311|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
40839312|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide|High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
40839313|NCT03369431|DIETARY_SUPPLEMENT|Vivomixx|Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.
40839314|NCT03369431|DIETARY_SUPPLEMENT|Placebo|4.4 grams of maltose and silicon dioxide per sachet
40839315|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg)
40839316|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg)
40839317|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.05 mmol/kg BW (0.05 mL/kg) for stress MRI and 0.05 mmol/kg BW (0.05 mL/kg) for rest MRI (total dose 0.1 mmol/kg)
40839318|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.1 mmol/kg BW (0.1 mL/kg) for stress MRI and 0.1 mmol/kg BW (0.1 mL/kg) for rest MRI (total dose 0.2 mmol/kg)
40839319|NCT00675896|DRUG|Quetiapine Fumarate Sustained Release|50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
40839320|NCT00675896|DRUG|Placebo|1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
40839321|NCT02163213|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
40839322|NCT01274520|DEVICE|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
40839323|NCT05178862|DRUG|SCY-078|Oral ibrexafungerp (SCY-078) as step-down therapy.
40839324|NCT05178862|DRUG|Fluconazole|Oral fluconazole (SCY-078) as step-down therapy.
40839325|NCT05178862|DRUG|Echinocandin|Intravenous echinocandin
40839326|NCT03861156|DRUG|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
40839327|NCT02108691|DIETARY_SUPPLEMENT|Glycin max(L.) Merr. peel extract|Glycin max(L.) Merr. peel extract (2.5g/day)
41359452|NCT02122302|DEVICE|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
41359453|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 0.3 mg, once daily, 1 day
41359454|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 1.0 mg, once daily, 1 day
41498051|NCT01145508|DRUG|Docetaxel|Given IV
41359455|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 3 mg, once daily, 1 day
41359456|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 10 mg, once daily, 1 day
41359457|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 30 mg, once daily, 1 day
41359458|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral , 75 mg, once daily, 1 day
41359459|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 150 mg, once daily, 1 day
41498052|NCT01145508|OTHER|Laboratory Biomarker Analysis|Correlative studies
41498053|NCT01145508|DRUG|Prednisone|Given PO
41498054|NCT01145508|BIOLOGICAL|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
40839328|NCT02108691|DIETARY_SUPPLEMENT|Placebo|Placebo (2.5g/day)
40839329|NCT05875974|DRUG|JZP258 (XYWAV)|Initiate dosage per study protocol and titrate to variable dosage.
40839330|NCT04476875|OTHER|Open Outpatient Clinic Programme|
40839331|NCT03475329|OTHER|adenotonsillectomy|adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
40839332|NCT00828789|DRUG|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
40839333|NCT04729231|PROCEDURE|Nasalis Sling Flap|The nasalis sling flap involves alteration of the nasalis muscle to create a myocutaneous pedicle flap that will be used to fill in the wound.
40839334|NCT04729231|PROCEDURE|Lobed Transposition Flap|Lobed flap reconstruction involves the use of cutaneous tissue located adjacent to the nasal tip to fill in the wound. The flap will undergo a 90-degree arc to approximate the desired position.
40839335|NCT03580928|DRUG|Venetoclax|Venetoclax is an oral drug that blocks the function of a protein called BCL-2. CLL cancer cells are thought to depend on the BCL-2 protein for their survival. By blocking BCL-2, venetoclax may kill cancer cells or stop them from growing.
41359460|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 300 mg, once daily, 1 day
41498055|NCT01145508|BIOLOGICAL|Rilimogene Galvacirepvec|Given SC
41498056|NCT05926960|DRUG|encorafenib|encorafenib
41498057|NCT05926960|DRUG|binimetinib|binimetinib
41498058|NCT05926960|DRUG|pembrolizumab|pembrolizumab
41498059|NCT05926960|DRUG|ipilimumab|ipilimumab
41498060|NCT05926960|DRUG|nivolumab|nivolumab
40839336|NCT03580928|DRUG|Obinutuzumab|Obinutuzumab is a type of drug called a monoclonal antibody. It targets a protein CD20 on the surface of the CLL cell, causing it to die
40839337|NCT03580928|DRUG|Acalabrutinib|Acalabrutinib is a type of drug called a kinase inhibitor. It blocks a type of protein called Bruton Tyrosine Kinase (BTK) that helps CLL cells live and grow
40839338|NCT00552409|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU by mouth daily for one year
40839339|NCT00552409|DIETARY_SUPPLEMENT|Placebo|One softgel daily for one year
40839340|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)|programmed intermittent bolus 5ml each one hour.
40839341|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode)|continuous infusion 6ml/h
40839342|NCT02504931|DRUG|Sertraline|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
40839343|NCT02504931|DRUG|Placebo|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
40839344|NCT00490620|DRUG|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
40839345|NCT00490620|DRUG|Placebo|placebo BID for 6 months
40839346|NCT04170270|DRUG|Omeprazole|"Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours."
41024235|NCT01769794|DRUG|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
41024236|NCT05654506|DRUG|Daratumumab|1800 mg subcutaneous (SC) injection (total amount 15 mL) into the right/left abdominal area once weekly for 8 doses followed by once every 2 weeks for an additional 8 doses
41024237|NCT00893490|DEVICE|Ahmed Glaucoma Valve (AGV)|AGV implantation
41024238|NCT00893490|DRUG|Mitomycin C (MMC)|3 minute MMC application
41024239|NCT00893490|PROCEDURE|amniotic membrane coverage|single layer coverage of amniotic membrane
41024240|NCT03684798|OTHER|MCII|In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.
41024241|NCT03684798|OTHER|Treatment as usual|The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
41359461|NCT01105429|DRUG|BMS-820132|Capsule, Oral, (TBD), once daily, 2 days
41024242|NCT03544034|BEHAVIORAL|HomeTeam Toolkit|"A multi-component intervention (8S's)~1. Safety at home through partnership.~2. Safety risk assessment at the admission~3. Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~4. Safety tools. Cognitive tools to support patient/family after discharge~5. Safety education. Enhanced Patient/ family medication safety education~6. Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~7. Safety through learning routines across the care continuum~8. Safety assessment after discharge"
40839347|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Two MSC infusions of 2.5x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
40839348|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose|Two MSC infusions of 5.0x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
40839349|NCT03254550|OTHER|PrEP Promotion Package|A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
40839350|NCT05041569|OTHER|MRI sequences|perform additional sequences added by research
40839351|NCT01541917|BEHAVIORAL|Web-based coping skills training|This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
41024243|NCT04622358|DRUG|AD-214-02|1 tablet administered before the breakfast during 7 days
41024244|NCT04622358|DRUG|Rabeprazole|1 tablet administered before the breakfast during 7 days
41024245|NCT02219932|DRUG|fampridine|
41024246|NCT02219932|DRUG|Placebo|Matched placebo
41024247|NCT01787604|PROCEDURE|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
41024248|NCT01787604|PROCEDURE|Aortic Valve Reimplantation Procedure|David I
41359462|NCT01105429|DRUG|Placebo|Oral Solution, Oral, 0mg, once daily, 1 day
41359463|NCT01105429|DRUG|Placebo|Capsule, Oral, (TBD), once daily, 2 days
41359464|NCT05322759|OTHER|aquatic exercises|aquatic polymetric exercises for 30 min including hip abduction/adduction, knee flexion/extension, hip flexion/extension, holding pool from sides, bending forward and picking up objects, shoulder flexion/extension kangroo jumpes, jumping to sides.
41359465|NCT05322759|OTHER|halliwick exercise programme|Halliwick exercise programme for 30 min include sagittal rotations, transversal rotations, longitudnal rotations and combined rotations.
41359466|NCT00087685|DRUG|RAD001|10 mg by mouth Daily
41359467|NCT06496399|BEHAVIORAL|psychoeducation|"-The elderly's preferences for art therapy (art activities such as wood painting, creating shapes with mud) will be taken into account.~2-Expression of emotions through motivational interviewing 3-Conscious Awareness therapy, staying in the moment here and now 4- Hobbies (growing flowers, gardening, handicraft knitting, puzzle solving, card games, chess game, etc., organizing trips, cinema, movie events and so on)"
40839352|NCT01541917|BEHAVIORAL|Online disease education|"The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease."
40839353|NCT00837603|BEHAVIORAL|Training|Controlled home ergometer training
40839354|NCT03695952|DRUG|Nivolumab or pembrolizumab|Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
40839355|NCT02092402|OTHER|Fecal transplantation|
40839356|NCT04195386|PROCEDURE|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
40839357|NCT04195386|PROCEDURE|Dental Restoration with Resin-Modified Glass ionomer Cement|Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
40839358|NCT01760590|PROCEDURE|Manual Manipulation|A grade 5 thrust to the thoracic spine
40839359|NCT01760590|PROCEDURE|Mobilization|A grade 1-4 mobilization directed at thoracic spine
40839360|NCT05348486|RADIATION|Dose escalation|Dose escalation 75,9 - 79,2 Gy in 33 fractions for GTV hypoxic or any hypoxic LN \> 2cm
40839361|NCT00963768|DRUG|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
40839362|NCT00963768|DRUG|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
41160684|NCT05031468|BIOLOGICAL|Licensed or EUA SARS-CoV-2 vaccine|Several SARS-CoV-2 vaccines utilizing different platforms (e.g., mRNA, viral vector, etc.), are available under EUA (and soon to be licensed) and are being administered to individuals who are pregnant or postpartum who belong to high-risk priority groups for vaccination. Participants will receive the SARS-CoV-2 vaccine of their choice or the type that is available to them. The researchers anticipate including up to 3 vaccines, whether given as part of the primary series or additional doses, as part of this non-interventional study.
40839363|NCT02280447|BIOLOGICAL|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
40839364|NCT02280447|BIOLOGICAL|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
40839365|NCT02280447|BIOLOGICAL|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
40839366|NCT02280447|BIOLOGICAL|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
40839367|NCT01221194|BEHAVIORAL|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
40839368|NCT01221194|DEVICE|PFC Stockings|A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
41359468|NCT04241705|OTHER|Treatment of positive individuals per national treatment guidelines|"Treatment for everyone except children \<6 months of age, pregnant women, women breastfeeding children \<6 months of age, and women 12-49 years of age with an unknown pregnancy status:~* P. falciparum cases: artemether-lumefantrine (AL) plus single dose primaquine (PQ) (0.25mg/kg daily)~* P. vivax cases: chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily)~* Mixed infections: AL plus 14 days of PQ (0.25mg/kg daily)~Treatment for pregnant women and women breastfeeding children \<6 months of age:~* P. falciparum cases or mixed infections: Quinine (1st trimester); AL (2nd \& 3rd trimesters or breastfeeding)~* P. vivax cases: Chloroquine (CQ)"
40839369|NCT03615014|OTHER|Filling questionnaires|Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
40839370|NCT02782026|DEVICE|Exhaled Breath Olfactory Signature (Artificial Nose)|
40839371|NCT05996614|PROCEDURE|PRP in skin grafts|topical application of platelet rich plasma before resurfacing with STSG in Post burn raw areas
40839372|NCT05996614|PROCEDURE|conventional methods in skin grafts|fixation of the graft with stitches and staplers
41024249|NCT05378711|DRUG|Fluoxetine|Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.
41024250|NCT00917345|DRUG|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
41359469|NCT04241705|OTHER|Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)|"Everyone who is eligible for the study except pregnant women and women breastfeeding children \<6 months of age AND who are confirmed to have normal G6PD status will be treated presumptively with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ). Treatment will be given without RDT for malaria.~* Women in the first trimester of pregnancy will be treated presumptively with quinine.~* Women in the second and third trimesters or women who are breastfeeding will receive artemether-lumefantrine (AL).~Again, treatment will be given without RDT for malaria."
41359470|NCT04241705|OTHER|Optimized malaria control interventions|Optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services including follow-up, and social and behavior change communication to seek prompt treatment and use long lasting insecticidal nets (LLINs). Case management includes passive detection of malaria cases and treatment with artemether-lumefantrine (AL) plus single low dose primaquine (PQ) (0.25mg/kg once) for Plasmodium falciparum (Pf) cases and chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily) for Plasmodium vivax (Pv) cases, and AL plus 14 days of PQ (0.25mg/kg daily) for mixed infections as well as follow-up at the health post or health center on days 3, 7, and 13 for those receiving 14 days of PQ to assess for adverse events and adherence as per the national treatment guidelines.
41359471|NCT02517606|OTHER|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
41359472|NCT02517606|OTHER|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
41359473|NCT00060333|RADIATION|radiation therapy|
41359474|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
41359475|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
41359476|NCT00808132|DRUG|bazedoxifene 20 mg|One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
41359477|NCT00808132|DRUG|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
41359478|NCT00808132|DRUG|Placebo|One capsule, placebo (over-encapsulated), once a day for one year.
41359479|NCT01957033|BEHAVIORAL|Exercise and education once/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
41359480|NCT01957033|BEHAVIORAL|Exercise and education twice/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
41024251|NCT01764100|GENETIC|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
41024252|NCT00006508|PROCEDURE|Controlled hypoglycemia using insulin|
41024253|NCT00006508|PROCEDURE|formula meal|
41160685|NCT04739189|BEHAVIORAL|Con : control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
41359481|NCT01957033|BEHAVIORAL|Exercise and education 3 times/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
41359482|NCT01957033|OTHER|Manual therapy once/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
41359483|NCT01957033|OTHER|Manual therapy twice/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
41024254|NCT03892824|DEVICE|Vine™ Embolic Protection System|"The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button."
41024255|NCT05085457|DIAGNOSTIC_TEST|ExPreS Protocol|Prof, aqui explicamos o que é o ExPreS????? Já que ele fala para não repetir informação
41024256|NCT03832946|DRUG|GB0139|GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
41359484|NCT01957033|OTHER|Manual therapy 3 times/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
41359485|NCT01957033|OTHER|Manual therapy once/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
41359486|NCT01957033|OTHER|Manual therapy twice/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
41359487|NCT01957033|OTHER|Manual therapy 3 times/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
41359488|NCT01710215|OTHER|FIT Screening Strategy|"* Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~* Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
41359489|NCT01710215|OTHER|Colon Screening Strategy|"* Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~* Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
41359490|NCT05280223|DRUG|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection
41359491|NCT05280223|DRUG|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
41359492|NCT01483378|OTHER|Choosing to receive the vaccine|
41359493|NCT02763605|OTHER|no intervention|
41359494|NCT00270816|DRUG|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
41359495|NCT00270816|DRUG|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
41359496|NCT00796172|BEHAVIORAL|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
41359497|NCT00796172|BEHAVIORAL|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
41359498|NCT02795871|BEHAVIORAL|Neuropsychological and cognitive assessment|
41359499|NCT05246735|DIAGNOSTIC_TEST|MR-guided Near Infrared optical tomography|
41359500|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg I.V.
41359501|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
41359502|NCT05916534|BEHAVIORAL|WeCAB Intervention|The WeCAB intervention will use a dedicated WeCAB community health worker who will administer a social determinants of health (SDOH) tool and use digital care navigation to monitor closed loop referrals.
41359503|NCT06187519|DEVICE|Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch|The intervention tested is the system (patch and mobile device/phone for reporting) that provides patients with better knowledge (test results) about the impact of their daily dietary choices on their uric acid levels.
41359504|NCT03367091|OTHER|Ekso GT gait training with high swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance"
41359505|NCT03367091|OTHER|Ekso GT gait training with neutral swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral"
41359506|NCT03367091|OTHER|Ekso GT gait training with high swing resistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance"
41359507|NCT01013116|BIOLOGICAL|modified allergen extract of house dust mites|subcutaneous injections
41359508|NCT01013116|BIOLOGICAL|placebo|subcutaneous injections
41359509|NCT00426842|DRUG|Midodrine Hydrochloride|Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
41359510|NCT04539444|BIOLOGICAL|CD19/22 CART|CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10\*107 CART cells per kilogram of body weight.
41359511|NCT04539444|DRUG|Tislelizumab|Patients will receive Tislelizumab 200mg/dose every 3 weeks.
41359512|NCT05340179|PROCEDURE|Interlaminar cervical epidural injection|Fluoroscopy-guided interlaminar cervical epidural injection
41359513|NCT05340179|PROCEDURE|Cervical selective nerve root block|Ultrasound-guided cervical selective nerve root block
41359514|NCT03380806|DRUG|LHRH agonist|Standard LHRH agonist for 3 years
41359515|NCT03380806|RADIATION|Pelvic Radiation|Pelvic Radiation
41024257|NCT03832946|DRUG|Placebo|Placebo is administered as inhalation once a day
41024258|NCT01283269|BEHAVIORAL|Memory Support System|Training in use of a memory notebook system
41024259|NCT01283269|BEHAVIORAL|Computer Training|Computer brain fitness training
41024260|NCT05230329|PROCEDURE|right sided hemicolectomy, laparoscopy|Comparison of CME
41024261|NCT00883389|DEVICE|Medical Alert Bracelet|Medical Alert Bracelet alerting health care providers to consider the patient's chronic kidney disease condition when planning care. It also provides a link to a website about safe kidney care (safekidneycare.org)
41024262|NCT01992536|BIOLOGICAL|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
41024263|NCT01992536|BIOLOGICAL|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
41024264|NCT01992536|BIOLOGICAL|Placebo|Saline solution for injection (0.5mL)
41359516|NCT03380806|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT: 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days)
41024265|NCT00038493|DRUG|Temozolomide and SCH66336|
41024266|NCT05063201|DRUG|Cariprazine 1.5 MG|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
41359517|NCT03380806|RADIATION|Conventional Radiotherapy (CRT) Prostate Boost|CRT: 33 - 35 Gy in 16 fractions (5 days per week - over 22 days)
41359518|NCT01365104|DRUG|desferrioxamine|intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
41359519|NCT03515031|DEVICE|High Flow Nasal Cannula Oxygenation|Delivery of humidified and heated (37ºC) high flow oxygen
41359520|NCT03515031|DEVICE|Venturi Mask Oxygenation|delivery of high flow oxygen
41359521|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 300mg
41359522|NCT01719627|DRUG|TVD 300/200 QD|TVD 300/200 QD during 7 days
41359523|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 600mg
41359524|NCT06067373|OTHER|questionnaire|"After agreeing to participate, the patients receive a questionnaire in paper form.~This consists of a total of 12 higher-level self-compiled questions as well validated survey instruments. The free questions relate, among other things, to to the surgery postponement, the associated burden, complications occurred, Effects on the employment situation, as well as the current state. The following validated survey instruments are used in the questionnaire: the NCCN Distress Thermometer to record the mental stress, a Severity Symptom Scale to record the symptom burden and the PROMIS-10 for recording the health-related life quality."
41359525|NCT01190280|PROCEDURE|Cholecystectomy operation|Cholecystectomy after randomization
41359526|NCT03307408|OTHER|blood collection|Standard routine practice clinico-biological data will be collected
41024267|NCT05063201|DRUG|Placebo|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
41359527|NCT01071902|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
41359528|NCT01071902|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
41359529|NCT01071902|OTHER|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
41359530|NCT01071902|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
41359531|NCT01332422|DRUG|Salmeterol and Fluticasone|Collection of safety data
41359532|NCT04810806|PROCEDURE|Immediate coronary angiography within 2 hours after randomization|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Immediate CAG group will receive CAG within 2 hours after randomization. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
41359533|NCT04810806|PROCEDURE|Delayed coronary angiography after stabilization of heart failure|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Delayed CAG group will receive CAG after stabilization of ADHF; improvement of symptoms and signs of heart failure. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
41359534|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Histoacryl|"Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:~0.5 ml of cyanoacrylate glue is used for mesh fixation"
41359535|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
41359536|NCT04157907|BEHAVIORAL|Mentalization based therapy|Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation
41359537|NCT02020811|DEVICE|Sentinel|
41498061|NCT00103610|DRUG|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
41498062|NCT00103610|DRUG|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
41498063|NCT01609712|PROCEDURE|Radiofrequency Kyphoplasty|"Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved."
41498064|NCT04842773|DIAGNOSTIC_TEST|Ultrasound measurement|Ultrasound measurement of sarcopenia in an elderly population
41498065|NCT05886010|DEVICE|prototypes 1 everyday|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
41498066|NCT05886010|DEVICE|prototypes 1 every week|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
41498067|NCT05886010|DEVICE|prototypes 1 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
40839373|NCT00428207|DRUG|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
41359538|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
41024268|NCT04141293|PROCEDURE|alveolar recruitment|Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
41359539|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
40839374|NCT00428207|DRUG|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
40839375|NCT03369613|DEVICE|transcranial electrical stimulation|The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
41024269|NCT06207565|PROCEDURE|Vestibular Flap Group|Achieving the vestibular flap, a 1-cm long horizontal vestibular access incision using a 15c blade 3-4mm apical to the mucogingival junction of the hopeless tooth, exposing the alveolar bone. Flap dissection in a coronal direction to detach the periosteum is completed, forming a sub-periosteal tunnel.
41160686|NCT04739189|BEHAVIORAL|Def-EX : Condition with an exercise-induced energy deficit|Condition with an exercise-induced energy deficit The adolescents will be asked to complete an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 400 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
41359540|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
41359541|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
41359542|NCT04514705|OTHER|Exercise|Exercise with treadmil and weight training station
41359543|NCT05007912|PROCEDURE|Esophagojejunostomy type|Use of either circular or linear stapler
41024270|NCT06207565|PROCEDURE|Single Flap Approach group|A modified envelope flap originally reported as an access flap for single implant insertion in areas of esthetic relevance will be performed. A sulcular incision on the labial aspect extending at least one tooth mesial and distal to the implant site (permitting enough accessibility for bone augmentation) is done. The flap is reflected by performing a split-thickness flap elevation starting from the interproximal incisions, leaving the anatomical papillae in situ. While the full-thickness flap elevation is performed on the labial aspect of the included surgical area, starting at the sulcus, and reaching at least 3 mm apical to the bone crest.
41160687|NCT04739189|BEHAVIORAL|Def-EI : Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will be asked to remain quiet during the whole day (no physical activity). They will receive a calibrated breakfast reduced from 400 kcal compare to their CON and Def-EX conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
41359544|NCT00072098|BIOLOGICAL|adenovirus vector|
41024271|NCT01491243|DRUG|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
41024272|NCT01491243|DRUG|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
41160688|NCT02279992|DRUG|Vardenafil|
41160689|NCT02279992|DRUG|Carboplatin|
41359545|NCT00072098|BIOLOGICAL|interleukin-12 gene|
41359546|NCT01227694|OTHER|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
41359549|NCT04723342|DRUG|Blinatumomab|"Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment"
41359550|NCT04342858|DRUG|Fluoride Varnish|Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK
41359551|NCT04342858|DRUG|Fluoride Varnish with tricalcium phosphate|Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA
41359552|NCT04342858|OTHER|Oral health education|Standard oral hygiene instructions every 3 months
41359553|NCT03480620|OTHER|Online Telerehabilitation Platform Access|Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.
41359554|NCT03480620|OTHER|Usual care|Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.
41498068|NCT05886010|DEVICE|prototypes 2 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
41498069|NCT05886010|DEVICE|prototypes 3 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
41498070|NCT04129073|OTHER|Intensive care treatment|Intensive care treatment; Utilization of neuroprognostication tools
41498071|NCT02549586|DRUG|Autologous Hematopoietic Stem Cell Transplant|"Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.~Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT."
41024273|NCT04878705|DRUG|TWP-201|a single subcutaneous injection
41359555|NCT03646812|OTHER|Glucose Reference 1|Glucose contains 50g of available carbohydrates
41359556|NCT03646812|OTHER|Glucose Reference 2|Glucose contains 50g of available carbohydrates
41359557|NCT03646812|OTHER|Glucose Reference 3|Glucose contains 50g of available carbohydrates
41359558|NCT03646812|OTHER|Semolina Penne|Semolina Penne contains 50g of available carbohydrates
41359559|NCT03646812|OTHER|Wholegrain Penne|Wholegrain Penne contains 50g of available carbohydrates
41359560|NCT03646812|OTHER|Semolina Spaghetti|Semolina Spaghetti contains 50g of available carbohydrates
41498072|NCT00752011|DRUG|TAS-106|Starting dose 2.0 mg/m\^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
41498073|NCT00752011|DRUG|Carboplatin|Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
41498074|NCT04258319|DIAGNOSTIC_TEST|Ultrasound Procedure|Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
41498075|NCT04680858|OTHER|DECT|Use of a digital enhanced telecommunication headset for team communication
41498076|NCT06484478|OTHER|Wearable technology monitoring|Observational study (no intervention delivered)
41024274|NCT04878705|DRUG|placebo|a single subcutaneous injection
41024275|NCT02322697|DRUG|Intravenous administration of L-carnitine|Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
41024276|NCT04051892|DEVICE|FixNip™ NRI|The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition
41359561|NCT03646812|OTHER|Wholegrain Spaghetti|Wholegrain Spaghetti contains 50g of available carbohydrates
41359562|NCT03646812|OTHER|Jasmine Rice|Jasmine Rice contains 50g of available carbohydrates
41359563|NCT03646812|OTHER|Asian Noodles|Asian Noodles contains 50g of available carbohydrates
41359564|NCT03721406|DRUG|Ropivacaine|ropivacaine administerd via thoracic paraveretebral catheter
41359565|NCT03896334|BEHAVIORAL|Supervised Isometric Handgrip Training|The participants randomized to the experimental group will perform 24 weeks of isometric handgrip exercise training, three times/week for 16 minutes with time to rest.
41359566|NCT03896334|BEHAVIORAL|Sham comparator - stretching and relaxation exercises|The participants randomized to the control group (active comparator) will perform 24 weeks of stretching and relaxation exercise training, three times/week for 16 minutes with time to rest.
41359567|NCT01201291|OTHER|Normobaric oxygen|Fraction of inspired oxygen
41359568|NCT03506464|PROCEDURE|Myofascial Release Technique|The same described in the arm description
41359569|NCT03688841|DEVICE|Bridged V.A.C.® with compression therapy|Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.
41359570|NCT03688841|DEVICE|Conventional Compression Therapy|Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
41024277|NCT03788486|DEVICE|2-3 Joule LED blue light device|application of blue light LED light device for 2 minutes in the central lower lids, temporal lower lids and upper temporal lids twice weekly under observation for one month
41024278|NCT06535815|OTHER|Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts.
41024279|NCT06191705|DIAGNOSTIC_TEST|QuickDASH|Participants will be administered Urdu version of QuickDASH to collect data regarding Disabilities of Arm, Shoulder \& Hand twice with a time interval of 72 hours to determine validity and reliability.
41024280|NCT06497257|OTHER|Evaluating wrist flexor and extensor peak torque|Evaluation of wrist flexor and extensor peak torque
41024281|NCT06497257|OTHER|Evaluating functional disability|Evaluation of functional disability
41024282|NCT06497257|OTHER|Evaluating hand grip strength|Evaluation of hand grip strength
41024283|NCT03889717|DIETARY_SUPPLEMENT|vitamin D|vitamin d drops will be given daily to the 2 groups of neonates ( 1st group will be given 400 iu /day and 2nd group will be given 1000 iu per day ) when they reach 100 cc per kg enteral feeding .. until they reach 40 weeks gestational age
41024284|NCT05869812|DRUG|CaHMB (Dietary supplement, not Drug)|The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
41024285|NCT05869812|DIETARY_SUPPLEMENT|CaLa|Comparative placebo
41024286|NCT05831098|DEVICE|Reveal TP (Syphilis) Antibody Test|All subjects tested with both investigational devices and conventional syphilis serology tests.
41359571|NCT02671786|OTHER|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories \& 15-17 gms of proteins.
41359572|NCT04169126|DRUG|F-18 PMPBB3|The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
41359573|NCT00380601|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks
41359574|NCT02662374|DRUG|.02% Chlorohexidine Gluconate|5ml of the drug in mouthwash form to be swished four times a day
41498077|NCT00371397|BEHAVIORAL|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
41024287|NCT05430412|DEVICE|Adacolumn|The study will consist of 10 sessions of Adacolumn® treatment (once per week) and a follow-up period (from week 12 to week 40 since study inclusion).
41024288|NCT01924936|BEHAVIORAL|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
41024289|NCT02088996|DEVICE|longwave diathermy on high power and interferential therapy|
41024290|NCT02088996|DEVICE|longwave diathermy on low power|
41024291|NCT03550963|OTHER|rice-richen meal|Participants in group one will be provided with rice-richen meal. All participants will be required to test and record blood glucose.
41024292|NCT03550963|OTHER|wheaten-richen meal|Participants in group two will be provided with wheaten-richen meal.All participants will be required to test and record blood glucose.
41359575|NCT02662374|DRUG|3% Sodium Bicarbonate|5ml of the drug in the form of a prepared solution to be swished four times a day
41359576|NCT02662374|DRUG|Nystatin 10000U/ml|5ml of the drug in mouthwash form to be swished and swallowed four times a day
41359577|NCT02662374|DEVICE|Extra Soft Toothbrush|To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
41359578|NCT02662374|DRUG|Supersaturated Calcium Phosphate|5ml of the solution to be swished four times a day
41359579|NCT02074059|DRUG|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
41359580|NCT02074059|DEVICE|nCPAP alone|nCPAP therapy
41024293|NCT04168749|COMBINATION_PRODUCT|Numeta G13|10 days
41359581|NCT01916733|DRUG|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
41024294|NCT02889549|DRUG|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
41024295|NCT02889549|DRUG|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
41160690|NCT05736302|OTHER|Doubly-Labeled Water|All eligible participants will receive a dose of doubly-labeled water.
41498078|NCT00371397|BEHAVIORAL|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
41498079|NCT05352165|DRUG|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
41359582|NCT01209299|GENETIC|DNA methylation analysis|
41359583|NCT01209299|GENETIC|gene expression analysis|
41359584|NCT01209299|OTHER|laboratory biomarker analysis|
41359585|NCT01475981|DRUG|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
41359586|NCT03281694|DRUG|Placebo|placebo skin patch and placebo oral solution
41024296|NCT02820987|DRUG|MEROPENEM|Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
41024297|NCT02820987|DRUG|PIPERACILLIN-TAZOBACTAM|Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
41359587|NCT03281694|DRUG|Nicotine|nicotine skin patch (7 mg/24 hrs) and placebo oral solution
41359588|NCT03281694|DRUG|AVL-3288|placebo skin patch and AVL-3288 oral solution (3 mg)
41359589|NCT03281694|DRUG|Nicotine + AVL-3288|nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
41498080|NCT05352165|DRUG|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
41498081|NCT05352165|DRUG|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
41498082|NCT05352165|DRUG|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
41498083|NCT05352165|DRUG|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
41498084|NCT05352165|DRUG|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
41498085|NCT00015873|DRUG|asparaginase|
41498086|NCT00015873|DRUG|cytarabine|
41498087|NCT00015873|DRUG|mercaptopurine|
41498088|NCT00015873|DRUG|methotrexate|
41498089|NCT00015873|DRUG|prednisolone|
41498090|NCT00015873|DRUG|vincristine sulfate|
41498091|NCT05911880|BEHAVIORAL|Plant-based diet for 14 days in patients with rheumatoid arthritis.|Patients with low to moderate disease activity of rheumatoid arthritis (2.6-5.1 DAS28-CRP) underwent a dietary intervention consisting of an individualized, isocaloric, and plant-based diet with 57% carbohydrates, 25% lipids, and 18% proteins (80% of plant origin) for 14 days, without any modification of their medication regimen and with restricted consumption of processed foods.
41024298|NCT02820987|DRUG|CEFEPIME|Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
41024299|NCT02946736|BEHAVIORAL|FSSB/Sleep Leadership Training|Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
41024300|NCT02946736|BEHAVIORAL|Actigraphy Feedback|Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
41024301|NCT00020410|BIOLOGICAL|filgrastim|
41024302|NCT00020410|PROCEDURE|peripheral blood stem cell transplantation|
41024303|NCT00020410|RADIATION|yttrium Y 90 monoclonal antibody B3|
41024304|NCT03953027|OTHER|Survey Administration|Ancillary studies
41024305|NCT05492318|DRUG|ITF2357 Givinostat 10mg/mL|Dose: 10 mg/mL; Dosage form: oral suspension
41160691|NCT04299724|BIOLOGICAL|Pathogen-specific aAPC|The subjects will receive three injections of 5x10\^6 each Covid-19/aAPC vaccine via subcutaneous injections.
41498092|NCT03610516|DRUG|CFZ533|Multiple doses of 10 mg/kg CFZ533 intravenous (IV) infusion. CFZ533 was administered every 4 weeks (Q4W; from Day 1 to Day 141), plus an additional dose of 10 mg/kg IV at Day 15, resulting in a Q2W loading regimen up to the third dose on Day 29.
41498093|NCT03610516|DRUG|Placebo|multiple doses of placebo intravenous infusion
41498094|NCT06209541|BEHAVIORAL|Internet-based cognitive behavioral therapy (ICBT)|All participants get treatment and are thus included in experimental groups, no matter the randomization result. It consists of eight treatment weeks with weekly support. The treatment format will differ between the four groups, depending on type of treatment content and type of support.
41498095|NCT00951496|BIOLOGICAL|Bevacizumab|Given IV
41498096|NCT00951496|DRUG|Carboplatin|Given IV
41359590|NCT01591577|OTHER|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
41498097|NCT00951496|DRUG|Carboplatin|Given IP
41359591|NCT00572858|PROCEDURE|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
41359592|NCT00572858|GENETIC|Blood test|Blood test for genetic testing
41359593|NCT00572858|PROCEDURE|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
41498098|NCT00951496|DRUG|Cisplatin|Given IP
41498099|NCT00951496|OTHER|Laboratory Biomarker Analysis|Correlative studies
41498100|NCT00951496|DRUG|Paclitaxel|Given IV
41498101|NCT00951496|DRUG|Paclitaxel|Given IP
41498102|NCT00951496|OTHER|Quality-of-Life Assessment|Ancillary studies
41160692|NCT01641627|PROCEDURE|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
41359594|NCT00572858|PROCEDURE|Saliva test|Saliva test for cotisol levels
41498103|NCT04605224|BEHAVIORAL|Culinary class|This hands-on, optional course teaches students how to measure and weigh ingredients, read and follow recipes, apply various food preparation, cooking and assembly techniques, as well as prepare meals, as per the provincial curriculum
41498104|NCT04720118|OTHER|No Intervention|There is no intervention for this study.
41498105|NCT03253055|RADIATION|DEXA|Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are \~8uSv and \~4uSv respectively.
41498106|NCT03253055|RADIATION|pQCT|A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.
41498107|NCT03253055|OTHER|Lifestyle Questionnaire|Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.
41498108|NCT03253055|OTHER|Aerobic Fitness|Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.
41498109|NCT03253055|OTHER|Muscular Strength|Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.
41024306|NCT05492318|DRUG|Midazolam 1Mg/Ml (Pf) Inj Syringe 5Ml|Dose: 1 mg/ml; Dosage form: solution for injection/infusion or rectal administration
41024307|NCT05492318|DRUG|Midazolam Oral Liquid Product|Dose: 2.5 mg; Dosage form: oromucosal solution
41498110|NCT03253055|BIOLOGICAL|Blood draw and finger prick test|15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count
41498111|NCT03253055|OTHER|Muscular Power|Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.
41498112|NCT04102280|DEVICE|Dialyser|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
41498113|NCT03787134|BEHAVIORAL|working memory and attention|Behavioral tests of working memory and attention
41024308|NCT05492318|DRUG|Dabigatran Etexilate 75 MG [Pradaxa]|Dose: 75 mg; Dosage form: hard capsules
41024309|NCT05492318|DRUG|Clarithromycin 500Mg Tab|Dose: 500 mg; Dosage form: immediate-release film-coated tablets
41024310|NCT00618657|DRUG|Carboplatin|Given IV
41024311|NCT00618657|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
41024312|NCT00618657|DRUG|bevacizumab|Given IV
41024313|NCT00618657|DRUG|trastuzumab|Given IV
41024314|NCT00618657|PROCEDURE|magnetic resonance imaging|Optional correlative studies
41024315|NCT00618657|PROCEDURE|therapeutic conventional surgery|Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
41024316|NCT04939259|DEVICE|New Music Program|A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
40839376|NCT05484323|OTHER|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
41498114|NCT01596309|DIETARY_SUPPLEMENT|Cocoa extract|Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
40839377|NCT05484323|OTHER|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
40839378|NCT05484323|DIAGNOSTIC_TEST|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
40839379|NCT05484323|OTHER|Cookie containing 2.5 g spirulina|TThirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
40839380|NCT01071616|DRUG|Cannabis Cigarette|
40839381|NCT02107157|DEVICE|755nm Laser with Cap Array|
40839382|NCT02619721|DEVICE|PINS SNS|
40839383|NCT04911179|OTHER|Vivfrail-Cog combined multicomponent physical exercise and cognitive stimulation.|"The areas to be worked on are: Attentional system: selective attention and concentration; alternating attention / dual attention; Processing speed; perceptual organization; working memory and cognitive flexibility; comprehension, abstraction and verbal reasoning, planning, execution, and problem solving.~Four programs have been developed stimulation different difficulty levels to adapt to the capabilities of each participant."
40839384|NCT03562416|DRUG|Nintedanib|Nintedanib (BIBF 1120, Ofev)
41024317|NCT04939259|DEVICE|Standard Listening Program|A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
41024318|NCT01772992|BEHAVIORAL|CVCTPLUS|For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
41359595|NCT01118039|DRUG|sunitinib malate|
41359596|NCT01118039|OTHER|immunohistochemistry staining method|
41359597|NCT01118039|OTHER|laboratory biomarker analysis|
40839385|NCT03562416|DRUG|Placebo Oral Tablet|Placebo
40839386|NCT06260969|DEVICE|balloon dilatation|Direct balloon dilation vs stenting vs embolectomy + tirofiban vs embolectomy + balloon dilation vs embolectomy + balloon dilation + intracranial stenting
41024319|NCT03762226|DRUG|Anti-VEGF|Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.
40839387|NCT00235950|DRUG|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
41024320|NCT05987267|OTHER|multidisciplinary precision care|The experimental group received precision nursing based on a multidisciplinary collaborative team in addition to standard treatment and care
41024321|NCT04823845|DRUG|Topical Adapalene Gel 0.1%|applying Adapalene Gel 0.1% to plantar warts topically
41024322|NCT00510666|DRUG|Saline|Saline infusion adjunct to morphine PCA pump
41024323|NCT00510666|DRUG|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
41024324|NCT00510666|DRUG|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
41024325|NCT00510666|DRUG|Saline|Preemptive saline as a control group to tramadol one
41359598|NCT01118039|OTHER|pharmacological study|
41359599|NCT01118039|PROCEDURE|quality-of-life assessment|
41359600|NCT05547828|DRUG|Tislelizumab combined with chemoradiotherapy|"Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)"
41359601|NCT03366935|OTHER|EPL and CEI|"Procedure: Standard epidural placement(EPL)~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
41498115|NCT00143923|BEHAVIORAL|Nutrition, Exercise, Stress Management Counseling|Individualized advice
41498116|NCT00143923|OTHER|usual care|usual care
41498117|NCT03037437|DRUG|Sorafenib (SOR)|Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
41498118|NCT03037437|DRUG|Hydroxychloroquine (HCQ)|400mg by mouth daily
40839388|NCT02274545|BIOLOGICAL|H7N9 Anhui 2013/AA ca|10\^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
40839389|NCT02274545|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|30 mcg
40839390|NCT05772910|BEHAVIORAL|EDUcation|The education intervention will consist of an individualized educative program based on intrinsic capacity optimization through lifestyle changes. To develop the program, the program creation team will be multidisciplinary (psychologists, medical doctor, dietitian...) and will discuss goal setting, the education strategy, and retention of motivation. The experts are required to create the education program such that the participants can manage their health by themselves. The goal will be self-management of dietary habits and increases in physical activity levels for each individual case. The education program will be in Spanish or in English; as it will consist in personal counselling, even with a low level of the language the communication will be possible. The nutritional education program will be conducted every 2 weeks for 10 consecutive weeks, with 20-min counselling sessions by an expert.
40839391|NCT05772910|OTHER|EXERcise|The intervention period will have 10 weeks, in which the EXER group will carry out 2-3 sessions a week (total of 20-30 sessions). In this concurrent program, exercises of the lower extremities (leg press, abduction and plantar flexion) will be performed mainly on weight training machines. Intensity in each exercise will be individualized for each participant through a test to determine muscle power. In addition, in the last part of each session the participants will perform an endurance training type high insensitive interval training on a cycle ergometer (60-80 rpm). The intensity will be individualized to each patient through an incremental stress test until volitional exhaustion, and the subjects will alternate intervals of 30 seconds at 90% of the maximum workload, with intervals of 90 seconds at 40% of the maximum. Each session is estimated to have a total duration of 30-50 minutes.
40839392|NCT05772910|OTHER|EDU-EXER|This group will carry out the same two previous interventions together.
40839393|NCT05772910|OTHER|CONtrol|CONtrol group will continue the usual clinical treatment and their normal life
40839394|NCT00987493|BIOLOGICAL|rituximab|day 1 at a fixed dose of 375mg/m2
40839395|NCT00987493|DRUG|bendamustine hydrochloride|Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
40839396|NCT00987493|DRUG|lenalidomide|Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
40839397|NCT03418558|DRUG|Trastuzumab emtansine|
40839398|NCT04921059|DIAGNOSTIC_TEST|Active Stand|The participant is asked to lie down for 10 mins without moving or speaking. A heart rate monitor is attached while the participant is lying down. They are then asked to stand up as quickly as possible and to remain standing unassisted for 3 minutes. The participant will be asked to describe any symptoms at 1 and 3 minutes after standing. Blood pressure and heart rate will be monitored constantly throughout the test.
40839399|NCT00651963|DRUG|ezetimibe|"Ezetimibe 10 mg daily was added during 4 weeks.~The patients continued taking their usual Statin without titrating the dose."
40839400|NCT05922241|OTHER|Costophrenic assisted cough|Therapist places the hands on the costophrenic angles of the patient's rib cage. During the patient's inspiration, the therapist applies a series of three repeated quick-stretch contractions down and in to encourage maximal inspiration. At the end of expiration, the therapist applies a quick stretch down and in on the patient's lower chest to facilitate a stronger diaphragmatic and intercostal muscle contraction. While instructing the patient to cough, the therapist applies strong pressure through the hands in toward the central tendon of the patient's diaphragm
40839401|NCT05922241|OTHER|Anterior chest compression|The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process
41024326|NCT00002684|DRUG|cisplatin|
41024327|NCT00002684|DRUG|ifosfamide|
41498119|NCT05709535|DIAGNOSTIC_TEST|[18F]-PSMA-1007|\[18F\]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of \[18F\]PSMA-1007 for PET scan.
41498120|NCT05767320|PROCEDURE|open repair(exploration)|repair of defect of perforated peptic ulcer and peritoneal decontamination by exploration
40839402|NCT04971252|DIAGNOSTIC_TEST|Hematologic tests for patients with diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among diabetic patients with chronic kidney disease
40839403|NCT04161781|DRUG|18F-BMS-986229 Injection|Single injection prior to scan
40839404|NCT04161781|DRUG|IV 18F-BMS-986229|370 MBq administered intravenously prior to scan
40839405|NCT04161781|DIAGNOSTIC_TEST|PET/CT Scan|Whole-body PET/CT (80 mA)
40839406|NCT01986972|OTHER|Toothbrushing With Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
41024328|NCT00002684|DRUG|paclitaxel|
41024329|NCT05156125|DRUG|VTX002|Dose A tablet administered orally once daily
41024330|NCT05156125|DRUG|VTX002|Dose B Tablet administered orally once daily
41024331|NCT05156125|DRUG|Placebo|Placebo Tablet for VTX002 administered orally once daily
41036561|NCT02863562|OTHER|Proprioceptive exercises|Proprioceptive exercises were performed twice a week for one month. They were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed.
41036562|NCT02863562|OTHER|Placebo Kinesio taping|
41036563|NCT00472095|OTHER|Fotonovela|
41036564|NCT00472095|OTHER|Placebo Fotonovela|
41498121|NCT05767320|PROCEDURE|abdominal laparoscopy|repair of defect of perforated peptic ulcer and peritoneal decontamination by laparoscopy
41498122|NCT00892996|DRUG|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
41498123|NCT00892996|DRUG|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
40839407|NCT01986972|OTHER|Toothbrushing Without Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
40839408|NCT03133312|DRUG|Chlorhexidine Gluconate|Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
41498124|NCT03523078|PROCEDURE|Breast reconstructive surgery|All sorts of breast reconstructive surgery are allowed in this study in terms of timing, autologous/prosthetic and so forth.
40839409|NCT03133312|DRUG|Povidone-Iodine Scrub and Paint|Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
40839410|NCT03782922|OTHER|Exercise Training Program|10min of coordination and strength training (2-3x per week) during 2-6 weeks
40839411|NCT01943019|DRUG|Linagliptin|
40839412|NCT03481426|OTHER|Workplace intervention|The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.
40839413|NCT03234231|BEHAVIORAL|3-month supervised tooth brushing programme|One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.
40839414|NCT03234231|BEHAVIORAL|oral health education talk|It is conducted by a dentist, while written materials will be delivered to the students and their carers.
40839415|NCT02606357|DRUG|INSULIN GLARGINE|"Pharmaceutical form:Solution~Route of administration: Subcutaneous"
40839416|NCT06095167|DRUG|without concurrent cisplatin chemotherapy|IMRT without concurrent cisplatin chemotherapy
40839417|NCT06095167|DRUG|with concurrent cisplatin chemotherapy|IMRT with concurrent cisplatin chemotherapy
40839418|NCT02412709|DEVICE|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
41160693|NCT02399982|OTHER|CBT-GSH|The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
41160694|NCT02399982|OTHER|Noom Monitor|This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
41160695|NCT01437813|DRUG|Glimepiride/ Extended release Metformin|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
41160696|NCT03336073|DRUG|Carfilzomib|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15
41160697|NCT03336073|DRUG|Dexamethasone|dexamethasone oral at a dose of 20 mg (10 mg for patients \>75 years) days 1, 2, 8, 9, 15 and 16
41498125|NCT01801631|OTHER|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
40839419|NCT06448819|OTHER|Diet|Patients received Crohn's disease exclusion diet or Mediterranean diet
40839420|NCT00238368|BIOLOGICAL|filgrastim|
40839421|NCT00238368|BIOLOGICAL|rituximab|
40839422|NCT00238368|DRUG|busulfan|
40839423|NCT00238368|DRUG|cisplatin|
40839424|NCT00238368|DRUG|cyclophosphamide|
40839425|NCT00238368|DRUG|cytarabine|
40839426|NCT00238368|DRUG|doxorubicin hydrochloride|
40839427|NCT00238368|DRUG|etoposide|
40839428|NCT00238368|DRUG|methylprednisolone|
40839429|NCT00238368|DRUG|prednisone|
40839430|NCT00238368|DRUG|vincristine sulfate|
40839431|NCT00238368|PROCEDURE|autologous bone marrow transplantation|
40839432|NCT00238368|PROCEDURE|peripheral blood stem cell transplantation|
40839433|NCT00238368|PROCEDURE|positron emission tomography|
40839434|NCT00238368|RADIATION|fludeoxyglucose F 18|
40839435|NCT00238368|RADIATION|radiation therapy|
40839436|NCT01801852|BIOLOGICAL|NKT cells|
41160698|NCT03336073|DRUG|cyclophosphamide|cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15
41160699|NCT02224352|DEVICE|Functional neuromuscular electrical stimulation|
41160700|NCT04151771|OTHER|Low-load blood flow restriction training|The intervention group will perform the exercises of the lower limbs using LL-BFRT with an occlusion pressure of 70% of arterial occlusion pressure with low training loads (30% of the 1 repetition maximum).
41160701|NCT04151771|OTHER|Usual outpatient pulmonary rehabilitation|The control group will perform outpatient pulmonary rehabilitation as established.
41160702|NCT03809286|DEVICE|active rTMS|rTMS delivers magnetic stimulation to the brain by using an electromagnet to generate a current that can penetrate the scalp and skull.
41498126|NCT01801631|OTHER|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
41498127|NCT00581087|DRUG|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
40839437|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
40839438|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
40839439|NCT04314219|DRUG|Cyclophosphamide 50mg|Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5
40839440|NCT04314219|DRUG|Methotrexate|Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6
41359602|NCT03366935|OTHER|DPE and CEI|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
41359603|NCT03366935|OTHER|DPE and PIEB|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA)."
40839441|NCT00304005|DRUG|laromustine|
40839442|NCT03891914|DRUG|Positron Emission Tomography using 18F-FCH|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
41024332|NCT03246360|DRUG|Modification for administration mode of cloxacillin antibiotic|"For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms"
41024333|NCT00004327|DRUG|octreotide|
41359604|NCT01921842|BEHAVIORAL|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
40839443|NCT03891914|DRUG|Positron Emission Tomography using 18F-FDG|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
40839444|NCT01048450|RADIATION|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
40839445|NCT01048450|PROCEDURE|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
40839446|NCT01048450|PROCEDURE|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
40839447|NCT04001972|BEHAVIORAL|Brief advice (AWARD model)|"Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention."
40839448|NCT04001972|DRUG|NRT-S|One-week free NRT (gum or patch) will be provided with dosage based on time to first cigarette smoking after waking up in the morning and previous NRT use (standard practice and according to specific NRT product instructions). Subjects who have first cigarette \<30 minutes in the morning or have previously used NRT, will receive 4mg nicotine gum or 21mg nicotine patch. Those who have first cigarette \>30 minutes after waking up and have not previously used NRT will receive 2mg nicotine gum or 14mg nicotine patch. NRT use and potential side effects will be briefly explained orally based on standardized script according to the product instructions. An NRT use card containing reminders of NRT use and potential side effects will be given.
41024334|NCT02809495|OTHER|use of app in smartphone|
41024335|NCT03512340|DRUG|SRF231|SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
41024336|NCT05734482|BIOLOGICAL|Secukinumab|for subcutaneous injection only
41024337|NCT02453113|OTHER|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
41024338|NCT03384758|DEVICE|Compression Therapy|Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
41160703|NCT03809286|BEHAVIORAL|Inpatient admission|All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.
41359605|NCT04524507|BIOLOGICAL|High-titer Convalescent COVID-19 Plasma (CCP1)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
41498128|NCT00581087|DRUG|Placebo|Treatment : 200 mg/day hard gelatine capsule
41498129|NCT03288181|DEVICE|Muscle Stretch|The splint will be applied to the affected leg as per the protocol for 30 minutes per day, 5 days per week for 4 weeks.
40839449|NCT04001972|BEHAVIORAL|IM Apps and Chatbot|Twelve-week personalized behavioral support will be delivered using interactive communication technologies using (1) regular tailored messages on abstinence, and (2) synchronous IM Apps conversation with trained SC advisors, and (3) a Chatbot: A Chatbot will be built using open source NLP and machine intelligence platforms. The unstructured text data from our previous study (ClinicalTrials.gov ID: NCT03182790) will be used to train the proposed Chatbot. We will draft responses for each identified question. The final version will be incorporated with Application Programming Interface (API) integration into user-friendly apps (iOS/Android/web app) with a backend server support and continuous data collection for potential bigdata analysis.
40839450|NCT04001972|BEHAVIORAL|Regular SMS message|Regular SMS messages focus on general health and remind the importance of participating in the follow-up surveys and biochemical validation for quitting
40839451|NCT00081211|BIOLOGICAL|PV701|Given intratumorally
40839452|NCT02955459|DRUG|VNRX-5133|
40839453|NCT02955459|DRUG|Placebo|
41024339|NCT03736200|OTHER|Exergaming group|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (1/day)
41024340|NCT03736200|OTHER|Physiotherapy|Physiotherapy 4-week-long.
41359606|NCT04524507|BIOLOGICAL|Standard-titer Convalescent COVID-19 plasma (CCP2)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
41359607|NCT03270631|OTHER|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
41498130|NCT03337243|PROCEDURE|HAM and HUMCWJ Injections|SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.
41359608|NCT03270631|OTHER|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
41498131|NCT06049927|BIOLOGICAL|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
41498132|NCT06049927|BIOLOGICAL|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
41498133|NCT06049927|BIOLOGICAL|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region. And the immunization schedule is two doses on day 0, 28.
40839454|NCT05088668|OTHER|Augmented reality|"The subjects will perform scapular repositioning exercise using glasses of augmented reality to see their scapular movement simultaneously. Furthermore, they will also see at the same time a video record of an ideal scapular movement, and will me encouraged to simulate that ideal scapular movement."
41024341|NCT03736200|OTHER|Exergaming group 2/day|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/day)
41024342|NCT02129686|PROCEDURE|Immediate Acupuncture Group|
41024343|NCT02129686|PROCEDURE|Delayed Acupuncture Group|
41024344|NCT02448784|DRUG|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
41024345|NCT00994916|DRUG|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
40839455|NCT05088668|OTHER|Scapular repositioning exercise|Subjects will perform scapular repositioning exercises for improving scapular movement.
41024346|NCT00125632|PROCEDURE|Eccentric Viewing Training for Reading|
41024347|NCT02973958|DRUG|Bupivacaine|See active comparator description
41024348|NCT02973958|DRUG|Sevoflurane|See active comparator description
41024349|NCT02973958|DRUG|Acetaminophen|See active comparator description
41024350|NCT02973958|DRUG|Ibuprofen|See active comparator description
41024351|NCT02973958|DRUG|Ketorolac|See experimental arm description
41359609|NCT03270631|OTHER|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
41359610|NCT03270631|OTHER|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
41024352|NCT03239652|DEVICE|Taiwan ACE Beads|Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
41024353|NCT04744363|DRUG|Stelara PFS|Pre filled syringes filled with AVT04 and Stelara
41498134|NCT06049927|BIOLOGICAL|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses vaccine on day 0, 28.
41024354|NCT06372093|DEVICE|Picterus Jaundice Pro|Picterus Jaundice Pro is a smartphone based screening tool for neonatal jaundice that takes images of the skin of the newborn chest where the Picterus Calibration Card is placed.
41024355|NCT01143259|DRUG|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
41024356|NCT01143259|DRUG|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
41024357|NCT02497664|OTHER|Active Breathing Control|
41160704|NCT03809286|DEVICE|sham rTMS|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
41160705|NCT01644825|DRUG|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
41160706|NCT01644825|DRUG|pazopanib|orally, 800 mg orally daily
41359611|NCT04960332|DEVICE|Prevena|RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
41160707|NCT03667599|OTHER|home care|This is the interventional arm where patients receive the transplant care in their homes.
40839456|NCT01919736|BEHAVIORAL|Gait Retraining|
40839457|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
40839458|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
40839459|NCT00658307|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|"The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
40839460|NCT03223623|DEVICE|TMS|Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)
41160708|NCT01503437|DRUG|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
41160709|NCT04929054|DIAGNOSTIC_TEST|imaging|ultrasound and contrast enhanced ultrasound for BI RADS4A breast modules
41160710|NCT02753764|DRUG|AZD7624|
41359612|NCT01540006|OTHER|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
40839461|NCT03223623|DEVICE|MRI|High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.
40839462|NCT03223623|DEVICE|VASO Imaging|The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
40839463|NCT01475162|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
41024358|NCT03270761|OTHER||
41024359|NCT00194922|DIETARY_SUPPLEMENT|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
41024360|NCT03291444|BIOLOGICAL|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
41024361|NCT03291444|BIOLOGICAL|peptide specific dendritic cell|After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
41160711|NCT02753764|DRUG|prednisone|oral prednisone 20 mg bid for one week
41160712|NCT02753764|DRUG|Placebo|
41160713|NCT05335239|OTHER|Professional dental cleaning|The dental nurse will visit at home and delivers professional dental cleaning, a reminder to use the fluoridated toothpaste (\> 4000 ppm ) and oral hygiene instruction to participants accompanied by home care aides, with manual toothbrush, fluoridated toothpaste (\> 4000 ppm) and relevant interproximal aids.
41160714|NCT04189341|DRUG|Erector spinae plane block (Group E)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
41160715|NCT04189341|DRUG|Modified-thoracolumbar interfascial plane block|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
41160716|NCT00945763|DRUG|N1539|30 mg
41160717|NCT00945763|DRUG|placebo|tablets
41160718|NCT00945763|DRUG|N1539|15 mg
41160719|NCT00945763|DRUG|N1539|60 mg
41160720|NCT00945763|DRUG|Motrin|400 mg
41160721|NCT01204593|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
41359613|NCT00738322|DRUG|AZD1305|Solution for iv infusion, single dose
41359614|NCT00738322|DRUG|Placebo|NaCl solution for iv infusion, single dose
41359615|NCT00183976|DRUG|Pegylated Liposomal Doxorubicin (Doxil) and Rituximab|
41359616|NCT03225833|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
40839464|NCT04487561|DEVICE|hemopatch|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
40839465|NCT04487561|PROCEDURE|Aspirative drainage|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
40839466|NCT01447303|OTHER|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
40839467|NCT01569386|BEHAVIORAL|Daily low intensity physical activity by the half squat|They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.
41160722|NCT01204593|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
41160723|NCT04255654|OTHER|Brief Intervention for Food Insecurity|2 item screening tool (brief intervention)
41160724|NCT00640523|DRUG|forodesine HCl|2 x 100mg capsules daily
41359617|NCT03225833|DRUG|Placebo|0.9% Sodium Chloride
41359618|NCT01486992|DRUG|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
41359619|NCT04622878|PROCEDURE|thrombectomy and PTA|open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
41359620|NCT01640704|BEHAVIORAL|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
41359621|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
41359622|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|FEIBA NF dose and dosing interval as prescribed by the treating physician
41359623|NCT03843567|OTHER|Endoscopic characterisation training|"Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour."
41359624|NCT01515813|DRUG|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
41359625|NCT01515813|DRUG|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
41160725|NCT00572351|OTHER|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
41359626|NCT01515813|DRUG|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
41359627|NCT01231620|DRUG|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
41359628|NCT01231620|DRUG|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
41359629|NCT01231620|DRUG|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
41359630|NCT01231620|DRUG|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
41359631|NCT04371757|DRUG|α1-adrenergic block|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
41359632|NCT04371757|OTHER|Placebo|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
41359633|NCT02412826|DEVICE|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
41359634|NCT02759939|OTHER|Video + Prompt Card|"1. A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~2. A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video."
41359635|NCT02759939|OTHER|Decision Aids + Training|"1. Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~2. A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit."
41359636|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
41359637|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
41359638|NCT00498069|DEVICE|Harvest Smartprep2 BMAC System|injection of 40cc bmac
41359639|NCT00498069|DEVICE|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
41359640|NCT00498069|BIOLOGICAL|placebo|injection of placebo into ischemic tissue of the lower extremity
41359641|NCT03733704|DIAGNOSTIC_TEST|Heart rate variability analysis|Heart rate variability analysis extracted from ECG during normal and obstructed breathing
41359642|NCT00750360|BIOLOGICAL|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
41359643|NCT02109731|OTHER|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
41359644|NCT04568265|DRUG|APG-1387|Weekly intravenous infusion for 30 minutes
41359645|NCT04568265|DRUG|Entecavir 0.5 mg|Taken daily by mouth
41359646|NCT03464162|BEHAVIORAL|Social Network Meetings|Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
41359647|NCT04346368|BIOLOGICAL|BM-MSCs|Participants will receive conventional treatment plus BM-MSCs(1\*10E6 /kg body weight intravenously at Day 1).
41359648|NCT04346368|BIOLOGICAL|Placebo|Placebo
40839468|NCT01569386|BEHAVIORAL|stretch exercise and usual activity|They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
41160726|NCT00572351|OTHER|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
41160727|NCT01314638|OTHER|Workshop balances|one workshop per week for 20 weeks. Evaluation before and after.
41160728|NCT05590806|OTHER|Direct composite build-ups|Direct composite build-ups application
41359649|NCT00931515|DEVICE|NuBac|NuBac device implanted at the L4/5 level.
41359650|NCT00931515|DEVICE|Prodisc-L|Prodisc-L implanted at the L4/5 level.
41359651|NCT04993144|DEVICE|continuous theta burst stimulation|stimulatory protocol
41359652|NCT02114099|DRUG|Atorvastatin|10 mg qd x1 year
41359653|NCT05685537|DRUG|Levosimendan|Initiation of levosimendan 48 hours before surgery
41359654|NCT02390323|PROCEDURE|Lumbar Sympathetic Block|"A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The lumbar sympathetic nerves are a small bundle of nerves that carries sympathetic nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system."
41498135|NCT03529825|DRUG|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
40839469|NCT01820312|RADIATION|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
40839470|NCT00280345|PROCEDURE|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
40839471|NCT00280345|PROCEDURE|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
40839472|NCT00280345|PROCEDURE|Cataract surgery|Removal of the cataract from the eye
40839473|NCT00119665|DRUG|MF101|
40839474|NCT01589913|BEHAVIORAL|ICD-Forum|"The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~1. Introduction to participants and online system~2. Knowledge regarding ICDs~3. Strategies for behavior change~4. Psychological models for anxiety and depression~5. Strategies to cope with avoidance, anxiety and depression~6. Resume, evaluation, resolution of open questions, goal setting, good bye"
40839475|NCT05135481|PROCEDURE|phrenectomy|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
40839476|NCT05135481|OTHER|Increased lactation support|Management in group 2 will include increased lactation care both during hospital stay and post discharge.
41024362|NCT02575599|BEHAVIORAL|Guided self-determination programme (GSD)|The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
41024363|NCT05527028|OTHER|Occupational Therapy Services|Investigators will complete an initial assessment based on a thorough chart review and observation of the participants activities of daily living during week one. The resident will receive approximately 30 minutes a day of direct student OT service delivery. Additional intervention may be delivered through an indirect, collaborative, or consultative service delivery model. Students will use a workload measurement tool to track the amount of time and types of intervention provided to these residents. The intervention will be delivered by two pairs of OT students under the direction of a registered OT. Student OTs will have access to Point Click Care and will document daily and will be required to document indirect and non-direct time for each resident.
41024364|NCT00637546|OTHER|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
41024365|NCT06298006|OTHER|Follow-up|Follow-up of neurocognitive and psychiatric symptoms in Post COVID patients (baseline, 12 months, 24 months) in correlation with biomarkers using MRI, fMRI, neuropsychological testing, lab samples (blood, CSF, microbiota).
41024366|NCT00380640|DRUG|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
41024367|NCT00380640|DRUG|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
41160729|NCT05985083|DRUG|IMM47|IMM47 is humanized mAb targeting CD24 to be administered via intravenous infusion every 2 weeks in 28-day treatment cycles.
41160730|NCT04440930|OTHER|White tea|Mouthwash with white tea five to six times a day for nine weeks
41160731|NCT04440930|OTHER|Salt water with soda|Mouthwash with salt water and soda eight to ten times a day for nine weeks
41160732|NCT00006099|BIOLOGICAL|Monoclonal antibody hu3S193|Hu3S193 was to be administered intraperitoneally or intravenously at a dose of 5mg. Doses of hu3S193 were radiolabeled with 5 mCi of 111In.
41160733|NCT04851171|PROCEDURE|Flexible Ureteroscopy|Flexible ureteroscopy is the use of flexible ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
41160734|NCT04851171|PROCEDURE|Semi-rigid Ureteroscopy|Semi-rigid ureteroscopy is the use of the semi-rigid ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
41160735|NCT05131711|COMBINATION_PRODUCT|Combined stereotactic radiosurgery and enhanced immunotherapy|Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.
40839477|NCT00918554|DRUG|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
40839478|NCT00918554|DRUG|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
40839479|NCT02359214|DIETARY_SUPPLEMENT|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
40839480|NCT02359214|OTHER|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
40839481|NCT01989611|DRUG|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
40839482|NCT01468636|DRUG|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
41359655|NCT02390323|DEVICE|Skin conductance algesimeter|The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
41359656|NCT04862351|BEHAVIORAL|exercise training for TechCR|3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
40839483|NCT01468636|DRUG|Placebo|200mg BID x 8 weeks
41498136|NCT06160193|BEHAVIORAL|Brief behavioral parent training with optional care as usual|A brief behavioral parent training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of 120 minutes, and a third session of 60 minutes, in which the training will be evaluated and maintenance training will be provided.
41359657|NCT04862351|BEHAVIORAL|audio/video conference|weekly audio/video conference
41359658|NCT04862351|BEHAVIORAL|educational video|weekly for 6 weeks, duration of video about 10-15 minutes
41359659|NCT04862351|BEHAVIORAL|Daily log|daily dietary and exercise log
41359660|NCT04862351|BEHAVIORAL|exercise training for centre-based|6 times of supervised exercise training
40839484|NCT05170789|DRUG|Elotuzumab, Selinexor, and Dexamethasone (ESd)|This is a single-arm, interventional, phase II clinical trial, in which the anticipated 18 enrolled patients will receive the trial drug, a combination of Elotuzumab, Selinexor, and Dexamethasone in monthly cycles. The study tests the theory of synergy between these drugs, as detailed in the study description above.
41160736|NCT02552693|OTHER|Enhanced training, supervision and support|"The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities."
40839485|NCT00049595|BIOLOGICAL|bleomycin sulfate|
41024368|NCT03908684|DEVICE|Ultrasound Imaging|Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
41160737|NCT02476708|DIETARY_SUPPLEMENT|curcumin 1800mg|Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
41359661|NCT03804476|DRUG|AER-271|AER-271, the test article for this study.
41359662|NCT03804476|DRUG|Placebo|Placebo control for this study.
40839486|NCT00049595|BIOLOGICAL|filgrastim|
40839487|NCT00049595|BIOLOGICAL|pegfilgrastim|
40839488|NCT00049595|DRUG|ABVD regimen|
41359663|NCT04424589|OTHER|Myofascial release|Myofascial release or induction (IMF) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. The experimental group will receive 1 examination session and 6 myofascial induction sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for spinal at the level of the lumbar square, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks.
41359664|NCT04424589|OTHER|Sham therapy|The control group will receive 1 examination session and 6 simulated myofascial induction sessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial induction, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
41359665|NCT02956408|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)
41359666|NCT03045497|DRUG|Perflutren Lipid Microspheres|Given IV
40839489|NCT00049595|DRUG|BEACOPP regimen|
40839490|NCT00049595|DRUG|cyclophosphamide|
40839491|NCT00049595|DRUG|dacarbazine|
40839492|NCT00049595|DRUG|doxorubicin hydrochloride|
40839493|NCT00049595|DRUG|etoposide|
40839494|NCT00049595|DRUG|prednisone|
40839495|NCT00049595|DRUG|procarbazine hydrochloride|
40839496|NCT00049595|DRUG|vinblastine sulfate|
40839497|NCT00049595|DRUG|vincristine sulfate|
41160738|NCT02476708|DIETARY_SUPPLEMENT|Placebo|oral placebo capsule
41160739|NCT00030745|DRUG|cisplatin|
41160740|NCT00030745|DRUG|gemcitabine hydrochloride|
41160741|NCT00030745|PROCEDURE|conventional surgery|
41160742|NCT00399997|BEHAVIORAL|Exercise on Prescription|
40839498|NCT03867682|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
40839499|NCT03867682|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
40839500|NCT03867682|DRUG|Spironolactone|25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
40839501|NCT00951756|OTHER|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
40839502|NCT04754230|DRUG|Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)|Medication administered 15 minutes prior to end of surgery.
40839503|NCT06158113|DRUG|Baricitinib 4 milligram Oral Tablet|4 milligrams once daily
41024369|NCT06262620|PROCEDURE|EBUS-TBNA|A 22G biopsy needle was insert into the lesion through tracheal-bronchial wall under real-time EBUS guided by bronchoscopist. Needle punctures were performed by using the jabbing method. Once it is confirmed that the puncture needle is within the target lesion, the puncture needle is moved back and forth while suction (An empty 50 ml syringe was connected to the port at the end of the puncture needle and aspirated to 20 ml maintained for 20 seconds.) is applied. Each lymph node was operated 5 times.
41024370|NCT06262620|PROCEDURE|EBUS-TBMC via a tunnel|First a tunnel between airway wall and mediastinal and/or hilar lesion was made by a puncture dilation catheter (BroncTruTM AK-91-55, Bronchus Inc. Hangzhou, China). The 1.1mm cryoprobe (Erbe 20402-401, ERBE, Tübingen, Germany) entered the target lymph node through the tunnel under direct monitoring of EBUS, and the distance between the tip of the cryoprobe and the border of target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue. Samples were retrieved by thawing in saline and then fixed in formalin. The same lymph node was operated for 3 times.
41024371|NCT06262620|PROCEDURE|EBUS-TBFB via a tunnel|Firstly, a tunnel to reach the lymph node is established by making use of a puncture dilation catheter, and a 1.5mm biopsy forceps is pushed into the lymph node through the working channel of the ultrasound bronchoscope. After entering the lymph node, the biopsy forceps were opened proximally to the lymph node, the biopsy forceps were advanced, and then the biopsy forceps were closed distally to the lymph node for each specimen. Each lymph node was operated 5 times.
41024372|NCT06403592|OTHER|optic nerve sheath diamater|Measurement of optic nerve sheath diameter
41024373|NCT04209582|DEVICE|measurement of TcPO2 with skin electrode|measurement of TcPO2 with skin electrode
41024374|NCT04529577|DEVICE|His-bundle pacing|"A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup."
41024375|NCT04642105|DEVICE|Sensor-Dot and Plug 'n Patch system|We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)
41359667|NCT03045497|DEVICE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
41359668|NCT03045497|DEVICE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
41359669|NCT06188403|PROCEDURE|Orthognathic surgery (lefort1)|Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate
41359670|NCT06210828|BEHAVIORAL|Telerehabilitation|Two weekly exercise sessions over a 12-week period at home via LINE Video call with physical therapist. Focusing on lower extremity strengthening and balance exercises. In addition to the guided sessions, participants are encouraged to perform self-directed exercises one day per week.
40839504|NCT02456857|BIOLOGICAL|Bevacizumab|Given IV
40839505|NCT02456857|DRUG|Everolimus|Given PO
40839506|NCT02456857|OTHER|Laboratory Biomarker Analysis|Correlative studies
40839507|NCT02456857|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
40839508|NCT01102894|DEVICE|SmartPill|SmartPill
40839509|NCT01280578|DEVICE|Transcatheter PFO Closure|Transcatheter PFO Closure
40839510|NCT05216276|PROCEDURE|TEP|Laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair
40839511|NCT05216276|PROCEDURE|rTAPP|robotic transabdominal preperitoneal (TAPP) inguinal hernia repair
40839512|NCT05742165|BEHAVIORAL|Time Restricted Eating (TRE)|TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.
40839513|NCT00031564|BIOLOGICAL|Interleukin-2|
40839514|NCT00031564|BIOLOGICAL|B7-1|
40839515|NCT05262686|DRUG|Belimumab|Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
40839516|NCT05262686|DRUG|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
40839517|NCT01918514|DRUG|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
41359671|NCT06210828|BEHAVIORAL|Control|Receive fall prevention exercise brochure
41359672|NCT03965234|DRUG|Cisplatin|Given via infusion
41359673|NCT03965234|PROCEDURE|Isolated Chemotherapeutic Lung Perfusion|Undergo pulmonary suffusion
40839518|NCT06106269|DEVICE|Rectal Artery Embolization|Subjects will undergo planned rectal artery embolization (RAE) in Vascular and Interventional Radiology per standard clinical protocol.
40839519|NCT06362122|OTHER|identification anatomo-clinico-biological profiles|to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature
40839520|NCT03969017|DRUG|pegylated interferon (Peg IFN)α-2b|Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg \<0.05IU/ml, with a maximum duration of 48 weeks.
41024376|NCT01620463|DRUG|liraglutide|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
41024377|NCT01620463|DRUG|placebo|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
41024378|NCT03210506|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
41359674|NCT03965234|PROCEDURE|Metastasectomy|Undergo metastasectomy
41359675|NCT01422395|PROCEDURE|Freezing|Vitrification
41359676|NCT00391911|DRUG|N-Acetylcysteine|Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
41359677|NCT00391911|OTHER|N-Acetylcystine and Non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
41359678|NCT00391911|OTHER|Placebo and CRRT|Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
41359679|NCT00391911|OTHER|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
41359680|NCT02557828|PROCEDURE|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
41498137|NCT06160193|OTHER|Care as usual|Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
40839521|NCT03969017|DRUG|Nucleoside （acid）analogue (NAs)|Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
40839522|NCT06316973|DRUG|CS-1103|CS-1103 for infusion
40839523|NCT06316973|DRUG|Sterile Saline|Sterile Saline for Injection
40839524|NCT05332418|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise, Educational postural correction, and Home neck exercise program for patient
40839525|NCT05332418|DEVICE|Electromagenetic Field therapy|Magnetotherapy application the device will be adjusted around the neck and shoulder area at low frequency (50 Hz), with intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60) , and the application time (10 minutes)
40839526|NCT04590209|OTHER|Blood sampling|Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis
40839527|NCT04590209|OTHER|Skin biopsy|Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
40839528|NCT00795288|DRUG|Simvastatin, 80 mg/day for 21 days|Active treatment group
40839529|NCT00795288|DRUG|placebo|Control group
40839530|NCT00803972|DRUG|rHuPH20|recombinant human hyaluronidase PH20
40839531|NCT00803972|DRUG|Insulin Human Injection|injection
40839532|NCT00803972|DRUG|Insulin Lispro Injection|injection
40839533|NCT04246723|DRUG|Narlaprevir|100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
40839534|NCT04246723|DRUG|Ritonavir|100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle
41359681|NCT01085149|DRUG|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
41359682|NCT02534181|DRUG|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
41359683|NCT04833972|OTHER|Survey questionnaire|Each version of the questionnaire has the same questions about perceived norms about substance use in the community but differs in how the response options are offered.
41359684|NCT05852964|GENETIC|Molecular Immunology , gene expressions|Expression levels of inflammatory and anti-inflammatory genes
41359685|NCT02699489|PROCEDURE|Laparoscopic donor nephrectomy|Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
41359686|NCT02699489|PROCEDURE|Open donor nephrectomy|Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
41359687|NCT04843527|DEVICE|FreeStyle Libre System|FreeStyle Libre Flash Glucose Monitoring System
41359688|NCT04843527|DEVICE|FreeStyle Libre System plus food app|FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application
40839535|NCT04246723|DRUG|Sofosbuvir|"400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle."
40839536|NCT02776592|OTHER|Cow's milk-based formula with added nutrients|
41359689|NCT00002715|BIOLOGICAL|Bleomycin sulfate|A component of the Stanford V regimen.
41359690|NCT00002715|DRUG|Stanford V regimen|
41359691|NCT00002715|DRUG|Doxorubicin hydrochloride|A component of the Stanford V regimen.
41359692|NCT00002715|DRUG|Etoposide|A component of the Stanford V regimen.
41359693|NCT00002715|DRUG|Mechlorethamine hydrochloride|A component of the Stanford V regimen.
41359694|NCT00002715|DRUG|Prednisone|A component of the Stanford V regimen.
41359695|NCT00002715|DRUG|Vinblastine|A component of the Stanford V regimen.
41498138|NCT06633315|OTHER|low dos dexmedetomidine|received dexmedetomidine 2.5 μ g/kg nasal drops
41498139|NCT06633315|OTHER|high dos dexmedetomidine|received dexmedetomidine 3 μ g/kg nasal drops
41498140|NCT06633315|OTHER|dexmedetomidine and esketamine|received dexmedetomidine 2 μ g/kg nasal drops plus ketamine 0.5 mg/kg nasal drops
40839537|NCT02776592|OTHER|Cow's milk-based formula|
40839538|NCT02723175|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.
41359696|NCT00002715|DRUG|Vincristine sulfate|A component of the Stanford V regimen.
41359697|NCT01203566|PROCEDURE|LESS appendectomy|See under arms description
41359698|NCT01203566|PROCEDURE|Conventional 3-port laparoscopic appendectomy|See under arms description
41359699|NCT02086760|OTHER|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
41359700|NCT02086760|RADIATION|Scintigraphy|
41359701|NCT00417898|DRUG|Aspirin|
41359702|NCT02698917|OTHER|Low normal PaCO2|4.5-4.7 kPa
41498141|NCT04149093|DIAGNOSTIC_TEST|Calretinin staining|"A paraffin-embedded hematoxylinphloxin-safran sections will be performed on tissue specimens of proximal resection margins to evaluate the presence or absence of ganglion cells.~Immunohistochemistry (IHC) will then be done on paraffin-embedded sections for calretinin staining."
41498142|NCT01930565|OTHER|LFCO application|Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
41498143|NCT01930565|OTHER|TTO application|Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
41498144|NCT03490760|DRUG|Durvalumab|Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks
41498145|NCT03490760|RADIATION|Radiation Therapy|24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
40839539|NCT06137768|DRUG|HRS-5965|HRS-5965
40839540|NCT06137768|DRUG|Placebo|Placebo.
40839541|NCT00565799|PROCEDURE|Omentectomy|Removing the omentum
40839542|NCT00565799|OTHER|No intervention|Only LAGB without Omentectomy
41024379|NCT02782819|DRUG|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
41024380|NCT02782819|DRUG|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
41024381|NCT06266221|DRUG|Prednisone 20 Mg|Oral corticosteriods
41024382|NCT06266221|DRUG|Oral Placebo|Oral placebo
41024383|NCT06266221|DRUG|Methylprednisolone 120 Mg|IV corticosteriods
41024384|NCT06266221|DRUG|IV Placebo|IV placebo
41024385|NCT02657850|OTHER|non- head and neck self reporting|non- head and neck patient self reports dysphagia symptoms
41024386|NCT02657850|OTHER|head neck self reporting|head and neck patient self reports dysphagia symptoms
41024387|NCT02657850|OTHER|provider reporting|provider reports on head and neck cancer patients' dysphagia symptoms
41024388|NCT00803894|DRUG|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
41024389|NCT00803894|DRUG|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
41359703|NCT02698917|OTHER|High normal PaCO2|5.8-6.0 kPa
41359704|NCT02698917|OTHER|Low normal PaO2|10-15 kPa
41359705|NCT02698917|OTHER|High normal PaO2|20-25 kPa
41359706|NCT02698917|OTHER|Low normal MAP|65-75 mmHg
41359707|NCT02698917|OTHER|High normal MAP|80-100 mmHg
41359708|NCT02327949|DEVICE|W-Shaped Angular Plate|Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
41359709|NCT02327949|DEVICE|Reconstruction Plate|Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
41359710|NCT01834040|OTHER|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
41359711|NCT01329822|BEHAVIORAL|Caloric restriction|Caloric restriction
41359712|NCT03402308|DIETARY_SUPPLEMENT|Schisandra chinensis extract|Schisandra chinensis extract 1,000 mg/day for 12 weeks
41359713|NCT03402308|DIETARY_SUPPLEMENT|Placebo|Starch placebo 1,000 mg/day for 12 weeks
40839543|NCT04491760|OTHER|Inspiratory Muscle Training|The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
40839544|NCT06422364|DEVICE|Weighted Wearable Blanket provided by Dreamland Baby Co.|All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete a nap polysomnogram.
40839545|NCT02458547|DRUG|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8\~1.0
40839546|NCT02458547|DRUG|Propofol|Total intravenous anesthesia with propofol target controlled infusion
40839547|NCT02458547|DRUG|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
40839548|NCT05484284|PROCEDURE|two-stage primary total knee arthroplasty with low-dose antibiotics|Briefly, investigators completely debrided all necrotic soft tissue in the first stage of the operation. The surgical site was flushed twice with hydrogen peroxide, iodine, and saline solutions. Then, the antibiotic-loaded cement spacer was inserted. After surgery, a 10-day course of intravenous organism-specific antibiotics or vancomycin was administered, followed by oral antibiotic therapy. Second-stage reimplantation was performed once there was no sign of infection. The spacer was removed and the new prosthesis was implanted without the use of antibiotic-containing bone cement.
41359714|NCT03703609|BEHAVIORAL|Tele-yoga|Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
41359715|NCT02935023|RADIATION|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
40839549|NCT02566733|DRUG|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
40839550|NCT02566733|DRUG|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
40839551|NCT05200572|BEHAVIORAL|Dyadic Life Review (DLR)|DLR will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes. Each session will facilitate a recall of each phase of life: childhood, adolescence, young adulthood, mid-life, earlier later life, and later life. While together, the patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life.
40839552|NCT04788862|BIOLOGICAL|P. falciparum infected erythrocytes|Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.
40839553|NCT05093803|BEHAVIORAL|CONTROL GROUP|Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.
40839554|NCT05093803|BEHAVIORAL|HEALTH APP GROUP|"Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators."
40839555|NCT01906112|PROCEDURE|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
41359716|NCT02192190|DRUG|LY2951742|Administered subcutaneously (SC)
41359717|NCT02192190|OTHER|Placebo- oral|Administered orally
41359718|NCT02192190|OTHER|Placebo - SC|Administered SC
41359719|NCT02192190|DRUG|Celecoxib|Administered orally
40839556|NCT03755583|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|a complete liquid diet of formula for 8 weeks were adminstered in Crohn's Diseas patients ,Nutritional intake was based on the child's estimated energy requirements, no regular table food during 8 weeks treament.
40839557|NCT04350307|DEVICE|22-gauge needle|22-gauge Quincke needle used for epidural injection
40839558|NCT04350307|DEVICE|25-gauge needle|25-gauge Quincke needle used for epidural injection
40839559|NCT00747409|DRUG|insulin aspart and detemir (NovoRapid, Levemir)|use of basal-bolus therapy with insulin aspart and detemir
41359720|NCT00735163|OTHER|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
41359721|NCT03846466|DRUG|KHK4323 IV/S|IV / Single administration
41359722|NCT03846466|DRUG|KHK4323 SC/S|SC / Single administration
41359723|NCT03846466|DRUG|KHK4323 IV/M|IV / Multiple administration
40839560|NCT00747409|DRUG|human regular insulin and NPH insulin (Actrapid, Protaphne)|basal-bolus therapy with human regular and NPH insulin
40839561|NCT02704689|DEVICE|AccuLIF expandable TLIF cage|AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
40839562|NCT06507124|OTHER|This is observational with no intervention|This is observational with no intervention
40839563|NCT03535285|PROCEDURE|Periodontal ligament distraction|decrease the bony resistant during canine retration
40839564|NCT03204422|OTHER|No intervention|no any other intervention
41024390|NCT00803894|DRUG|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
41024391|NCT04575779|DRUG|Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h|To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.
41359724|NCT03846466|DRUG|Placebo IV/S|IV / Single administration
41359725|NCT03846466|DRUG|Placebo IV/M|IV / Multiple administration
40839565|NCT05597072|BEHAVIORAL|Intervention|Less people within the OR but longer waiting time.
40839566|NCT05597072|BEHAVIORAL|Control|More people in the OR but shorter waiting time
40839567|NCT05245214|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Muscle analysis by Magnetic Resonance Imaging
40839568|NCT02182765|DRUG|Nevirapine|
40839569|NCT02182765|DRUG|Amprenavir|
40839570|NCT02182765|DRUG|Abacavir|
41359726|NCT03846466|DRUG|Placebo SC/S|SC / Single administration
41359727|NCT01533285|BIOLOGICAL|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
41359728|NCT01533285|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
41359729|NCT02945072|PROCEDURE|TIVA|TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
41359730|NCT02945072|PROCEDURE|Sevoflurane|Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
41359731|NCT01906489|DRUG|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
41359732|NCT01906489|DRUG|Placebo|Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
41359733|NCT00518167|BEHAVIORAL|Intensive lifestyle counselling|"Individualized dietary and physical activity counselling aiming at~1. weight reduction~2. dietary fibre 15 g /1000 kcal or more~3. energy proportion of dietary fat less than 30%~4. energy proportion of saturated fat less than 10%~5. moderate physical activity \>30 minutes per day or 4 hours per week"
41359734|NCT01719042|DRUG|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
41359735|NCT01719042|DIETARY_SUPPLEMENT|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
40839571|NCT00001307|DRUG|Oxygen-15 Water|
40839572|NCT00001307|DRUG|Capsaicin|
40839573|NCT01123473|DRUG|capecitabine|
40839574|NCT01123473|DRUG|cisplatin|
41359736|NCT00779506|DRUG|Quetiapine Fumarate XR|oral, once daily, flexible dose
41359737|NCT04601194|BEHAVIORAL|Coaching and Virtual Provider Program Practice|4 weekly goal setting/coaching sessions, coupled with Virtual Provider program training and practice
40839575|NCT01123473|DRUG|epirubicin hydrochloride|
40839576|NCT01123473|DRUG|fluorouracil|
40839577|NCT01123473|DRUG|lapatinib ditosylate|
40839578|NCT00127335|DRUG|cellulose placebo vs. atorvastatin|drug
40839579|NCT06377709|OTHER|ProACTive™|ProACTive™ intervention, a talking therapy utilising acceptance and commitment therapy (ACT) techniques.
40839580|NCT04667416|BIOLOGICAL|PalinGen Flow Amniotic Tissue Allograft|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
40839581|NCT03420404|OTHER|TCM physician involved collaborative care model (TCMCMC)|"TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total."
40839582|NCT05856097|OTHER|kinesio taping with diaphragmatic breathing|.kinesio tape was applied on1st day of intervention with the 20 minutes session of diaphragmatic breathing 3 sessions were given
40839583|NCT05856097|OTHER|kinesio taping without diaphragmatic breathing|kinesio tape was applied day 1st of intervention. 3 sessions were given
40839584|NCT00474461|BIOLOGICAL|Treatment group|Intracoronary injection of cardiac stem cells
40839585|NCT04055454|BIOLOGICAL|MV-LASV|The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.
40839586|NCT04055454|OTHER|Placebo|A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
41024392|NCT04455100|DRUG|SHR1459/Itraconazole|SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
41024393|NCT05927441|DEVICE|DragonFly Transcatheter Mitral Valve Repair System|Edge-to-edge repair with DragonFly System
41024394|NCT04153370|DEVICE|Airtraq|airtraq video laryngoscope was used for intubation of the infant
41024395|NCT04153370|DEVICE|glidescope|glidescope video laryngoscope was used for intubation of the infant
40839587|NCT02191605|BEHAVIORAL|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
40839588|NCT02191605|BEHAVIORAL|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
40839589|NCT04956588|COMBINATION_PRODUCT|surgical robot|The surgical robot completed the screw placement according to the surgical plan, and the researchers closely monitored the screw placement process.
40839590|NCT04956588|COMBINATION_PRODUCT|controlled approach|The screw placement was performed using a controlled approach according to the surgical plan.
40839591|NCT01342614|DRUG|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
40839592|NCT01342614|DRUG|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
40839593|NCT01150643|GENETIC|gene expression analysis|
40839594|NCT01150643|GENETIC|microarray analysis|
40839595|NCT01150643|GENETIC|polymerase chain reaction|
40839596|NCT01150643|GENETIC|polymorphism analysis|
40839597|NCT01150643|OTHER|immunohistochemistry staining method|
40839598|NCT01150643|OTHER|laboratory biomarker analysis|
40839599|NCT00906269|DRUG|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
40839600|NCT00906269|DRUG|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
40839601|NCT02297165|BEHAVIORAL|olfactory stimulation program|"8 individual sessions of olfactory stimulation at the rate of 2 sessions per week. 3 semi-directed interviews will be help (one at the beginning of the trial, the second 5 weeks later and the third at 6 month).~For each session, patients have to smell two different odors (previously selected from a panel presented to the patient during first visits) and then they are invited to evoke memories and feelings related to each odor."
41024396|NCT04153370|DEVICE|c-mac|c-mac video laryngoscope was used for intubation of the infant
40839602|NCT05903859|DRUG|Probenecid 500 Milligrams (mg)|Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.
40839603|NCT05903859|DRUG|probenecid 250 Milligrams (mg)|Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.
40839604|NCT05903859|DRUG|Placebo|Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
40839605|NCT00982202|DRUG|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for \~18months
40839606|NCT00982202|DRUG|Placebo|1 to 3 tablets daily for \~18 months
40839607|NCT04833959|DRUG|89Zr-panitumumab|Imaging Agent
40839608|NCT00897390|DRUG|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
40839609|NCT00897390|DRUG|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
40839610|NCT00897390|DRUG|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
40839611|NCT00214084|DRUG|Allopurinol|
40839612|NCT02994693|DEVICE|OFDI capsule imaging|Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
40839613|NCT02986113|BEHAVIORAL|MAPS tailored multimedia patient activation program|
40839614|NCT02986113|BEHAVIORAL|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
41024397|NCT03136068|DRUG|Digoxin|Trans-abdominal injection
41024398|NCT03136068|DRUG|Placebo|Trans-abdominal injection
40839615|NCT02986113|BEHAVIORAL|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
40839616|NCT02986113|BEHAVIORAL|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
40839617|NCT00257660|BIOLOGICAL|Botulinum toxin type A|500 units
41024399|NCT05431855|BEHAVIORAL|eWrapper-Engagement strategies to facilitate alcohol biosensor wearing|We will conduct a 30-day micro-randomized trial (MRT)--a clinical trial design for developing and optimizing mHealth interventions to test which engagement strategy works better, for who, and under what condition. A subset of the participants will be micro-randomized in the morning and in the evening, to either a prompt delivering non-contingent small reward (reciprocity); or a prompt containing feedback on self-monitoring progress based on dynamic self-regulation theories (personalized feedback); or no prompt.
41359738|NCT00157157|BIOLOGICAL|Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.~For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.~Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.~rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion."
41359739|NCT00134199|DRUG|CP-945,598|
41359740|NCT00134199|DRUG|sibutramine|
41498146|NCT06141967|DEVICE|WITHINGS Sleep Analyzer|"Potentially eligible patients will be offered to participate in the study, the information leaflet will be given to them and the informed consent form will be signed if the patient agrees to participate in the study.~In hospitalization in Endocrinology:~* Realization of the current care report~* Including systematic achievement of EPWORTH and BERLIN scores~* Activation of the WSA throughout the duration of the hospitalization~* Completion of a feasibility questionnaire for the team~* Quantification of the non-usable screening technique~* Completion of a patient experience questionnaire at the end of the stay~* In the event of published positive criteria either for the BERLIN questionnaires, EPWORTH questionnaires or WSA, the patient will be referred to the VISAS center for definitive diagnostic evaluation by polygraphy or polysomnography."
40839618|NCT00257660|DRUG|Placebo|500 units
40839619|NCT01744314|DRUG|Indomethacin and Pantoprazole|
40839620|NCT01744314|DRUG|microcrystalline cellulose powder tablets|
40839621|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low carbohydrate diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
41024400|NCT06479174|BEHAVIORAL|CHAMPS-TR|Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).
40839622|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low low fat diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
40839623|NCT05351268|RADIATION|Radioactive seed brachytherapy|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
40839624|NCT01008124|OTHER|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
40839625|NCT01008124|OTHER|Placebo maneuver|3 cycles placebo maneuver initial session.
40839626|NCT00491881|BEHAVIORAL|no added salt diet|
40839627|NCT05538390|OTHER||
40839628|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with normal saline|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with normal saline and to compared with those smeared with exosomes after laser treatment.
41024401|NCT06200805|BEHAVIORAL|tai ji quan|24-Style Taijiquan as an Intervention for College Students with Insomnia
40839629|NCT06221787|PROCEDURE|microneedles combined with hUCMSC-Exos|the hUCMSC-Exos were applied while rolling a microneedle roller and to compared with those used 1565 nm non-ablative fractional laser or PBASM combined with hUCMSC-Exos.
40839630|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with hUCMSC-Exos|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with hUCMSC-Exos and to compared with those smeared with normal saline after laser treatment.What's more,compared with those used microneedles or PBASM combined with hUCMSC-Exos.
40839631|NCT06221787|PROCEDURE|PBASM combined with hUCMSC-Exos|a plasma named Peninsula Blue Aurora Shumin Master (PBASM) rolling each area for 8-10 min before applying the hUCMSC-Exos in the entire face. And to compared with those used 1565 nm non-ablative fractional laser or microneedles combined with hUCMSC-Exos.
41024402|NCT01687517|DRUG|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
41024403|NCT01698060|BIOLOGICAL|ND1.1|
41359741|NCT01226316|DRUG|AZD5363|Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
41498147|NCT02531750|OTHER|Immobilization due to an Achilles tendon rupture|
41024404|NCT01061294|PROCEDURE|Advanced CustomVue™ iLASIK procedure|
41024405|NCT01061294|DEVICE|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
40839632|NCT04363047|OTHER|40ml blood sample|We'll be collecting cells, DNA and serum.
40839633|NCT05118490|DRUG|Daily rifapentine and isoniazid for 4 weeks|Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)
41024406|NCT05163145|OTHER|TPN|early detection of comlications of prolonged TPN on neonatal liver
41024407|NCT05861115|DEVICE|"Chang Gung Ventricular Systolic Dysfunction Screening Software"|This software is suitable for 12-lead ECG signals of adults over 20 years old, and assists doctors in screening patients for left ventricular systolic dysfunction.
40839634|NCT05118490|DRUG|Weekly rifapentine and isoniazid for 12 weeks|Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)
40839635|NCT04382417|OTHER|Observational study|Not required
41024408|NCT01381055|DRUG|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
41024409|NCT01381055|DRUG|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
41024410|NCT04886167|DRUG|AbobotulinumtoxinA|Injection of platysmal bands.
41359742|NCT01226316|DRUG|AZD5363|Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
40839636|NCT01378611|DEVICE|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
41024411|NCT05841745|DEVICE|Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. The CorPath GRX System is composed of two units; the first is a bedside unit which consists of the extended robotic arm, robotic drive, and single-use loading cassette, and the second is the remote workstation, which consists of the interventional cockpit and the control console. A key innovation of the CorPath GRX System is the software-based automation of common maneuvers, called technIQ automated movements with the potential to increase procedural success, reduce procedure time, and generally increase user comfort with robotic assistance during PCI.
41359743|NCT01226316|DRUG|AZD5363|Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
41498148|NCT00460135|BEHAVIORAL|resistance training|2 times a week resistance training
41498149|NCT00084032|BEHAVIORAL|Structured treatment interruption|Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2
41024412|NCT01672151|DRUG|rapamycin|4mg oral administration on the first day, 2 mg/d oral administration for 3 months
41024413|NCT04480294|DRUG|HRS5091|"Single dose in group 1-5~Multiple doses in group 6-9"
41024414|NCT04002752|DRUG|JNJ-73763989|Participants will receive JNJ-73763989 as single subcutaneous injection.
41024415|NCT04002752|DRUG|Placebo|Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
40839637|NCT01493856|DRUG|Cresto|tablet, rosuvastatin 20mg
40839638|NCT01493856|DRUG|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
40839639|NCT01493856|DRUG|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
40839640|NCT02006069|DEVICE|MPP|"All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.~The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming)."
40839641|NCT00311116|DRUG|Vitamin E|
40839642|NCT00016549|BIOLOGICAL|Bevacizumab|
41024416|NCT06415201|OTHER|Interactive Artificial Intelligence|scenario based AI to assess, classify, explain and conduct supportive interviews
41024417|NCT00861939|DRUG|Bupropion HCI 300 mg Extended-Release Tablets EON|
41024418|NCT00861939|DRUG|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
41024419|NCT02459067|BIOLOGICAL|ImmuniCell®|Autologous γδ T Lymphocytes
41024420|NCT04102501|DRUG|RT001|RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
41359744|NCT01226316|DRUG|AZD5363|Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
41359745|NCT00495274|DRUG|Formulation A|Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
41498150|NCT00084032|DRUG|Antiretroviral regimen|Participants will take any combination of FDA-approved ARV medications prescribed by their physician
41024421|NCT04102501|DRUG|Placebo|The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
41024422|NCT00127673|DRUG|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
41024423|NCT00127673|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
41498151|NCT03783039|DEVICE|SURGICEL Powder|Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Powder, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
41024424|NCT02318329|DRUG|FPA144|FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
41498152|NCT03783039|DEVICE|SURGICEL Original|Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Original, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
41024425|NCT04603989|DRUG|HNC042 for Injection|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
41024426|NCT04603989|DRUG|Placebo Comparator|Placebo , Intravenous route , multiple ascending doses
41024427|NCT03855215|DIAGNOSTIC_TEST|ACTIM CRP Rapid Test (Medix, Biochemica)|The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
41359746|NCT00495274|DRUG|Formulation B|Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
41359747|NCT00495274|DRUG|Formulation C|Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
41359748|NCT00495274|DRUG|Formulation D|Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
40839643|NCT03048591|DEVICE|electroacupuncture|Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
40839644|NCT05816213|DEVICE|Portable low-field MRI|"Three FDA-approved low-field (LF) portable MRI commercialized by Hyperfine Research Inc. (www.hyperfine.io) will be employed. Patients will undergo LF-MRI in the CT suite during the downtime of preparation which usually occurs after urgent imaging in the CT suite (mean time, as calculated basing on the current door to imaging time: \~20-25 minutes), thus not delaying the conventional diagnostic processes and treatment administration. LF-MRI will be also repeated by the study staff at predefined time-points: 24 h, 72 h, at the discharge and 4 weeks after the event.~A prespecified acquisition of Fast-Spin Echo (Fast-SE) essential stroke sequences will be performed, starting with diffusion weighted imaging (DWI) + apparent diffusion coefficient (ADC) mapping and fluid attenuated inversion recovery (FLAIR)."
40839645|NCT03088553|DRUG|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
41024428|NCT05316857|DRUG|Orelabrutinib + Rifampin|Orelabrutinib + Rifampin
41024429|NCT05316857|DRUG|Orelabrutinib + Itraconazole|Orelabrutinib + Itraconazole
41024430|NCT01851057|BEHAVIORAL|STAR|Problem-solving and education intervention (8 total sessions)
41024431|NCT01851057|BEHAVIORAL|Education Only|Education around epilepsy (8 total sessions)
41024432|NCT01806337|DRUG|Alemtuzumab|Consolidation after CHOP induction
41024433|NCT02445079|OTHER|This is an observational study only|Observational study only
41359749|NCT00495274|DRUG|Formulation E|Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
41359750|NCT00495274|DRUG|Formulation F|Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
40839646|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
40839647|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
40839648|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
40839649|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
40839650|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
40839651|NCT05618093|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds. If two finger probes are available, measurements will alternate between fingers.
40839652|NCT02584920|DRUG|HLX01|
40839653|NCT02584920|DRUG|Rituximab|
40839654|NCT03328416|DEVICE|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
40839655|NCT04547361|DRUG|E2511|E2511 tablets.
41359751|NCT00495274|DRUG|Formulation G|Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
41359752|NCT05233956|DEVICE|LNG IUS|Avibela®: Levonorgestrel intrauterine system (LNG IUS) containing 52mg of LNG, released in the uterine cavity at approximately 19mcg per day.
41359753|NCT05233956|DRUG|COCs|FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
41359754|NCT00531466|DRUG|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
41359755|NCT00531466|DRUG|Placebo|One tablet orally three times a day for 28 days
40839656|NCT04547361|DRUG|E2511 Matched Placebo|Placebo tablets matching E2511 tablets.
40839657|NCT02266212|PROCEDURE|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
40839658|NCT00115895|DRUG|Radioactive iodine|Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
40839659|NCT03403309|DRUG|1) Inosine 5'-monophosphate|1) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
40839660|NCT03403309|DRUG|Placebo|2) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
40839661|NCT06316440|DEVICE|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
40839662|NCT06116695|DRUG|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
41359756|NCT01531764|DRUG|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 \& 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
41024434|NCT05842057|BIOLOGICAL|BioDFence G3 Placental Tissue Membrane|The BioDFence G3 Placental Tissue Membrane is a three-layer tissue allograft consisting of amnion-chorion-amnion. Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP. The membrane will be cut into two longitudinal pieces and placed over each neurovascular bundle separately.
41359757|NCT05153252|BEHAVIORAL|Morning Exercise|Morning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
41359758|NCT05153252|BEHAVIORAL|Evening Exercise|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
40839663|NCT06116695|DRUG|Mineral Tri-Oxide Aggregate|mineral trioxide aggregate was used as control
40839664|NCT03570346|DRUG|Hemay005|Subjects will be randomized into 3 dose groups orally twice daily.
40839665|NCT03570346|DRUG|Placebo|Subjects will be randomized into 3 dose groups orally twice daily.
41359759|NCT02801487|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
40839666|NCT01370759|OTHER|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
40839667|NCT02974569|DEVICE|Computer Symptom Capture Tool|"C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience."
40839668|NCT01839656|DRUG|nusinersen|Administered by intrathecal (IT) injection
40839669|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccinations (high dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)"
40839670|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccination (low dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)"
40839671|NCT04033068|BIOLOGICAL|One MV-ZIKA-RSP vaccination (high dose) and one placebo|"In this arm of the study, 12 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo"
40839672|NCT04033068|OTHER|Two placebo injection|"In this arm of the study, 8 participants will receive:~1. V1= day 0; placebo treatment~2. V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo"
40839673|NCT02313883|DRUG|PerioSept(r)|Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
41024435|NCT05842057|PROCEDURE|Robot-Assisted Radical Prostatectomy|Robot-assisted surgical removal of the prostate, administered standard of care.
41024436|NCT04112147|DRUG|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
41024437|NCT04112147|DRUG|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
41024438|NCT04112147|DRUG|Placebo oral capsule|Patients will receive 12-week of 100mg BID Antroquinonol placebo
41024439|NCT00013793|BEHAVIORAL|Motivational enhancement and ultrasound|
41359760|NCT02801487|DRUG|Cisplatin|Cisplatin (40mg/m\^2) monotherapy will be given weekly along with radiotherapy.
41359761|NCT00211692|DRUG|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
40839674|NCT04640974|DEVICE|Cingal|Single injection into the ankle joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
40839675|NCT03551756|OTHER|Biomarker Assessment|Exploratory Biomarker Analysis for cardiac patients versus healthy adults
40839676|NCT03199391|DEVICE|BioWick SureLock Implant|The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
40839677|NCT00240604|DRUG|Rosiglitazone|4 mg rosiglitazone per day
40839678|NCT04140981|DEVICE|ultrasounography|in preoperative period, airway ultrasounagraphy for all patients will be made
40839679|NCT01238965|DRUG|panobinostat|Given orally
40839680|NCT01238965|DRUG|fluorouracil|Given IV
40839681|NCT01238965|DRUG|leucovorin calcium|Given IV
40839682|NCT01238965|PROCEDURE|biopsy|Correlative studies
40839683|NCT01238965|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
40839684|NCT01238965|GENETIC|western blotting|Correlative studies
40839685|NCT01238965|OTHER|laboratory biomarker analysis|Correlative studies
40839686|NCT01238965|GENETIC|gene expression analysis|Correlative studies
40839687|NCT01238965|GENETIC|RNA analysis|Correlative studies
40839688|NCT01238965|GENETIC|polymorphism analysis|Correlative studies
40839689|NCT06024785|PROCEDURE|Vertebropexy|microsurgical (i.e., the use of a microscope or magnifying glasses during decompression) lumbar laminotomy with partial removal of the medial facet joint by preserving the midline structures (supraspinous-interspinous ligament complex); approach: bilateral or ipsilateral with cross-over to the contralateral side. Additional stabilization of the spine with a ligament (for instance semitendinosus donor allograft), which connect the postoprior structures (Proc. Spinosus and/or Lamina) of the vertebrae . Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia)
40839690|NCT04454645|BEHAVIORAL|mABC|Intervention targets parenting sensitivity and nurturance.
40839691|NCT04454645|BEHAVIORAL|mDEF|Intervention targets parenting enhancing infant cognitive development
40839692|NCT03197909|OTHER|Determination of pro-inflammatory plasma factors|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
40839693|NCT02177838|BIOLOGICAL|cetuximab|Given IV
40839694|NCT02177838|DRUG|cisplatin|Given IV
40839695|NCT02177838|RADIATION|external beam radiation therapy|Undergo EBRT
40839696|NCT02177838|OTHER|laboratory biomarker analysis|Correlative studies
40839697|NCT04732104|DRUG|Lidocaine topical|intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia
40839698|NCT04732104|DRUG|Lidocaine Hydrochloride|injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth
40839699|NCT02774655|DEVICE|Pai APP|prescribed 100 PAI weekly
40839700|NCT02774655|DEVICE|FitBit APP|prescribed 10000 steps daily
40839701|NCT05147714|DEVICE|Surgical Pleth Index (SPI)|SPI data were recorded at one-minute intervals during the last five minutes (6 times in total) until the entropy value reached 60
41024440|NCT02917109|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
40839702|NCT02982083|DRUG|Raloxifene hydrochloride|20 patients consume raloxifene hydrochloride oral tablet daily for one year.
40839703|NCT02982083|DRUG|Placebo Oral Tablet|20 patients consume placebo oral tablets daily for one year.
40839704|NCT04084821|OTHER|none - observation only|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
40839705|NCT02564328|GENETIC|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
40839706|NCT00733941|BEHAVIORAL|High frequency training|24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
40839707|NCT00733941|BEHAVIORAL|normal frequence training|24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
40839708|NCT02990507|OTHER|AVEED: Arm rotation, video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
40839709|NCT02990507|OTHER|AVEED: Arm rotation, without video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
40839710|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
40839711|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, without video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
40839712|NCT02618551|PROCEDURE|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
40839713|NCT02533726|OTHER|Optimal Turning|Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
40839714|NCT02533726|OTHER|Standard Care Practices|Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
41359762|NCT00211692|DRUG|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
41498153|NCT06632899|BEHAVIORAL|combined physical and cognitive training and 1 hour of risk factor prevention and healthy lifestyle development|"Dosage: a 2-hour session once a week for 12 weeks. Each multidomain intervention session includes 1 hour of combined physical (balance, strength and aerobic exercises) and cognitive (attention, memory, calculation, visual-spatial ability, processing speed and executive function) training and 1 hour of risk factor prevention (nutrition, chronic disease management, oral health, fall prevention and transportation safety, psychosocial factors and sleep) and healthy lifestyle development (Discussion and sharing on topics such as self-health management, goal setting, and the health journal.)"
41498154|NCT04636164|DIAGNOSTIC_TEST|Model Dermatology (deep neural networks; Build 2020)|Physicians in the DNN group take pictures of the skin lesion and use the algorithm by uploading pictures.
40839715|NCT02533726|OTHER|Patient Sensor|A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
40839716|NCT03169257|BEHAVIORAL|diet plus physical activity|OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
40839717|NCT00678548|BEHAVIORAL|Pleasant guided imagery|CD with pleasant guided imagery
40839718|NCT00678548|BEHAVIORAL|Pain diary|Filling out a pain diary
41024441|NCT02447991|DRUG|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
41024442|NCT02447991|DRUG|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
41024443|NCT01071395|DRUG|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
41024444|NCT01071395|DRUG|Placebo|Sugar pill given 3 times daily
41024445|NCT06509373|BEHAVIORAL|Advance Care Planning Tool - ACPVoice|Eligible patients will be sent a secure MyChart message with a motivational message asking them to complete the advance care planning tool (ACPVoice) with their care partner/surrogate decision-maker or loved one before their upcoming primary care visit. The ACPVoice tool will be attached electronically to the mychart message. A reminder message will be sent to an non-responders with a different motivational message.
41359763|NCT01813149|DRUG|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
41359764|NCT01813149|OTHER|punch biopsy|
41359765|NCT06028763|PROCEDURE|Injection of biocomposite hydrogel into ankle's cartilage lesion under arthroscopic control|Surgical treatment involves the use of an injectable biocomposite hydrogel containing autologous mesenchymal stem cells (MSCs), adipose tissue-derived cells, and chondroinductive growth factors (TGF-β1 and BMP-4) under arthroscopic control
41498155|NCT06628947|OTHER|Placebo (Sterile Saline)|A control 50 μl injection of clear sterile saline liquid
41498156|NCT06628947|DRUG|100 μg KIO-301|KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
41498157|NCT06628947|DRUG|50 μg KIO-301|KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
41498158|NCT01308905|DEVICE|FLT-PET|PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
41498159|NCT06486805|DRUG|N acetyl cysteine|N-acetylcysteine (NAC) is a small molecule containing a thiol (sulfhydryl-containing) group, which has antioxidant properties and is freely filterable, thus making it readily accessible to the intracellular compartment
41498160|NCT06486805|OTHER|normal saline|the same volume of normal saline
40839719|NCT01325714|BEHAVIORAL|PAVeD Intervention|In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
40839720|NCT01325714|BEHAVIORAL|Enhanced Usual Care|"In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.~Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain."
40839721|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
41024446|NCT06509373|BEHAVIORAL|Standard of Care for Advance Care Planning|Patients will have access to the standardized advance care planning questionnaires readily available already within their mychart account which is part of standard of care.
41024447|NCT03540901|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
41024448|NCT03540901|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
41024449|NCT06534138|BEHAVIORAL|Physical exercise|The CP-exercise group was categorized based on patients' self-reported daily exercise time into four levels: 15 minutes/day, 30 minutes/day, 45 minutes/day, and ≥60 minutes/day. Additionally, resistance exercise and endurance exercise were distinguished based on patients' self-reported exercise modalities, including swimming, jogging, brisk walking, practicing Tai Chi, and dumbbell training.
41024450|NCT01542528|BEHAVIORAL|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
41024451|NCT06293937|BEHAVIORAL|Numerical label|Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
41024452|NCT06293937|BEHAVIORAL|Interpretive text-only label|Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
40839722|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
40839723|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
40839724|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
40839725|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
40839726|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
40839727|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
40839728|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
40839729|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
41024453|NCT06293937|BEHAVIORAL|Interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
41024454|NCT06293937|BEHAVIORAL|Separated interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
41024455|NCT01487330|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
40839730|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
40839731|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
40839732|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
41024456|NCT00001402|DEVICE|PET scan|
40839733|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
41024457|NCT05658081|PROCEDURE|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
41024458|NCT05658081|PROCEDURE|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
41024459|NCT05929014|DEVICE|Bilateral-Transcranial direct current stimulation (bilateral-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal and anodal electrodes will be applied over the right and left primary motor areas, respectively.
41024460|NCT05929014|DEVICE|Cathodal-Transcranial direct current stimulation (cathodal-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal electrode will be attached over the left primary motor area while the anodal will be applied over the right supraorbital.
41024461|NCT05929014|DEVICE|Sham bilateral-tDCS|Sham bilateral-tDCS
41024462|NCT05929014|DEVICE|Sham cathodal-tDCS|Sham cathodal-tDCS
41498161|NCT05109338|DEVICE|Ben-Guard Garment|Wearable device designed to secure CVCs and gastrointestinal feeding tubes. The Ben-Guard Catheter Securement Device was designed specifically to better secure and conceal CVC tubing, protecting the patient by keeping tubing closer to the body.
41498162|NCT06633445|PROCEDURE|botulinum toxin type A injection in lateral pterygoid muscle|"* Needle insertion guide will be placed on upper teeth.~* Needle will be inserted from needle insertion sleeve and 25-30 units of botulinum toxin type A will be injected.~* Aspiration will be done before injection, and then, the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle."
40839734|NCT00517569|GENETIC|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
40839735|NCT00517569|DRUG|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
40839736|NCT06060860|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules:~1. emotion awareness,~2. cognitive appraisal \& reappraisal,~3. emotion avoidance \& emotion-driven behaviors,~4. awareness and tolerance of emotion-related physical sensations, \&~5. interoceptive and situational emotion-focused exposures.~There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth."
40839737|NCT06060860|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.
41024463|NCT00364481|DRUG|omeprazole|
41024464|NCT00364481|BEHAVIORAL|Tongue exercises|
41024465|NCT04173533|DRUG|Oral azacitidine|Oral azacitidine (CC-486) 200 mg tablet
41024466|NCT04173533|DRUG|Matched placebo|Oral azacitidine (CC-486) matched placebo tablet
41024467|NCT02429063|OTHER|Bright White Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
41024468|NCT02429063|OTHER|Dim Red Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
41024469|NCT02010385|DRUG|Octreotide|
41359766|NCT06028763|PROCEDURE|Microfracture of ankle's cartilage lesion under arthroscopic control|Microfracture involves creating tiny perforations in the damaged cartilage, exposing the underlying bone. This encourages the formation of a healing response, where blood and bone marrow cells fill the holes, forming a repair tissue known as fibrocartilage. This newly formed tissue aims to improve joint function and alleviate symptoms associated with cartilage damage. The procedure is performed under arthroscopic guidance, allowing for precise targeting of the lesion while minimizing trauma to the surrounding tissues.
41359767|NCT00159146|DRUG|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
41359768|NCT06048627|DRUG|Amine/zinc lactate/fluoride system|Amine/zinc lactate/fluoride system (250 ppm F), meridol®, Colgate-Palmolive
41024470|NCT02010385|DRUG|Saline|
41024471|NCT00889122|BEHAVIORAL|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
41024472|NCT01804959|DIETARY_SUPPLEMENT|Vivomixx probiotics|
41024473|NCT02573987|DRUG|Oxygen/nitrous oxide equimolar mix|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
41024474|NCT02573987|DRUG|Lidocaine|standard strategy by local injection anesthesia of lidocaine
41359769|NCT06048627|DRUG|negative control|Sodium fluoride mouthwash 250 ppm
41359770|NCT01871428|DRUG|aleglitazar|150 mcg orally daily
41359771|NCT01871428|DRUG|placebo|matching aleglitazar placebo orally daily
41359772|NCT00508118|DRUG|Nicardipine|on bypass
41359773|NCT00508118|DRUG|0.9% saline|on bypass
41359774|NCT04602468|DRUG|Kaftrio|The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
41359775|NCT00719693|DRUG|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
41498163|NCT06633445|PROCEDURE|botox injection in lateral pterygoid muscle|"* A 27- gauge needle electrode will be inserted lateral to the maxillary tuberosity, just above the maxillary molars to inject 25-30 units of botulinum toxin type A under electromyographic guidance.~* Aspiration will be done before injection, and then the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle.~* The intramuscular injection will be confirmed when the electromyographic device produces a distinct loud sound."
41498164|NCT06447129|OTHER|Exercise|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The patients will do exercises under the control of the physiotherapist in the clinic.~The patient will perform the exercises with the verbal and visual commands of the physiotherapist."
40839738|NCT05792306|DEVICE|The novel electrolyzed water spray|The researcher use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
41024475|NCT01665235|DRUG|Amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
41024476|NCT01665235|DRUG|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
41024477|NCT01665235|DRUG|Aspirin or Clopidogrel|aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
41024478|NCT01665235|DRUG|Atorvastatin|Atorvastatin 10 - 40mg / d ( statin therapy)
41024479|NCT05239026|BEHAVIORAL|Advanced treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. The cadence will be progressively reduced for the first 3 Blocks. Speed will progressively increase during Blocks 4-6 while cadence from Block 3 is maintained.
41024480|NCT05239026|BEHAVIORAL|Traditional treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. Participants will walk at self-selected cadence during Blocks 1-3. Speed will progressively increase during Blocks 4-6.
41359776|NCT00719693|DRUG|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
41024481|NCT02762409|OTHER|experimental|corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015
41359777|NCT06212349|OTHER|therapeutic-educational physiotherapy and pain education program|The EG will carry out a total of 24 sessions, at a rate of 3 weekly sessions of 30 minutes each. The first session of each month will be in person and the rest will be done at home following video tutorials with an App (https://fisiotrack.com). The face-to-face sessions will be conducted by a women's health physiotherapist, and will consist on therapeutic exercises based on body awareness, motor control and respiratory awareness.They will also receive a pain education program with indications on pain education, as well as basic information and general advice on the positive effects of physical activity and a healthy lifestyle for endometriosis. In addition, biweekly supervision will be carried out via telephone or video conference by a specialized physiotherapist.
41359778|NCT06212349|OTHER|pain education program|They will receive instructions on pain education, as well as basic information and general advice about the positive effects of physical activity and a healthy lifestyle for your endometriosis, in writing via email. In addition, they will receive biweekly supervision via telephone or video conference by a specialized physical therapist.
41359779|NCT05267327|OTHER|Verzenios|Study drug is Verzenios, it is an observational study.
40839739|NCT05792306|DEVICE|The saline spray|The researcher use saline to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
41359780|NCT01287507|DIETARY_SUPPLEMENT|Lactoferrin (bovine origin)|Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
41359781|NCT03046329|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
41359782|NCT03023436|PROCEDURE|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
41359783|NCT03023436|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
41359784|NCT03023436|DRUG|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
41359785|NCT03023436|DRUG|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
41359786|NCT03708042|COMBINATION_PRODUCT|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
41359787|NCT03708042|COMBINATION_PRODUCT|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
41359788|NCT01552408|DRUG|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
41498165|NCT06447129|OTHER|Neuromuscular electrical stimulation|The Neuromuscular Electrical Stimulation (NMES) will be applied for 20 minutes. The patient will be seated with hips and knees flexed at 90°. Electrodes will be placed on the proximal and distal ends of the vastus medialis obliquus and vastus lateralis muscles. The intensity will be increased as much as the patient can tolerate, and the patient will be asked to relax and not make voluntary muscle contractions.
40839740|NCT00462748|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
40839741|NCT00462748|DRUG|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
40839742|NCT00462748|DRUG|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
41359789|NCT01552408|PROCEDURE|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
41359790|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
41359791|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
41359792|NCT01049360|DRUG|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
40839743|NCT01137253|DRUG|Trimethaphan|Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
40839744|NCT01137253|DRUG|Placebo|Response to intrabrachial vasodilators during IV saline infusion
40839745|NCT01252524|DRUG|Placebo|Placebo tablet po TID before each meal with 8 oz of water for 6 months
40839746|NCT01252524|DRUG|Calcium polycarbophil|calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
40839747|NCT04515108|OTHER|Clinical assessment|Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.
40839748|NCT00025155|DRUG|ixabepilone|Given IV
40839749|NCT04280874|DRUG|Dinoprostone 0.5 MG|0.5mg dinoprostone applied intracervically
40839750|NCT04280874|DRUG|Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly|2mg dinoprostone applied intravaginally
41024482|NCT02762409|OTHER|control|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015"
41024483|NCT04798300|PROCEDURE|Newly Introduced Gradient Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Newly Introduced Gradient Monolithic Zirconia to measure wear
41024484|NCT04798300|PROCEDURE|Full Strength Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Full Strength Monolithic Zirconia to measure wear
41498166|NCT02302053|DIETARY_SUPPLEMENT|New Viviscal Professional Supplement|The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
40839751|NCT02378207|BIOLOGICAL|H4:IC31|H4 contains Mtb antigens Ag85B and TB10.4
41024485|NCT05040412|DEVICE|difficult laryngoscopy|Patients will be intubated with the direct laryngoscope.
41024486|NCT06458010|DRUG|YOLT-101|The IP is administered intravenously at the predetermined dose.
41498167|NCT02302053|DIETARY_SUPPLEMENT|Placebo tablets|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
41498168|NCT01086397|PROCEDURE|Urine sample collection|All subjects have non-invasive urine sample collection performed
40839752|NCT02378207|BIOLOGICAL|H56:IC31|H56 contains Mtb antigens ESAT-6, and Rv2660c
40839753|NCT02378207|BIOLOGICAL|BCG|
41498169|NCT04437459|OTHER|High-fat shake|Participant consumes a high-fat test shake. Blood is drawn before and 4 hours after this shake to measure triglycerides.
40839754|NCT02378207|BIOLOGICAL|Control Sodium Chloride 0.9%|
41024487|NCT03335657|OTHER|CBPT|The CBPT program focuses on a patient-oriented cognitive-behavioral self-management approach to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy.
41024488|NCT03335657|OTHER|Education Treatment|Participants receiving the education control arm are receiving a placebo intervention to control for the attention of the interventionist. They will receive standardized educational material addressing recovery from orthopaedic trauma.
41024489|NCT04718246|OTHER|Dental Implants Placed In hyperlipidemia patients|"A preoperative cone beam CT (CBCT) will be performed for each patient prior to the surgery.~Surgical phase (T0):~After local anesthetics, all osteotomies will be prepared by the same operator, using a drilling speed of 1200 rpm, under copious irrigation with normal saline.~* Penetration of cortical bone will be achieved with no. 6 round burs.~* The osteotomies will be widened, using a drill 1 mm larger than the final drill provided by the manufacturer. The final size of the control osteotomies were same diameter of the implant.~* Periotest® will measure initial implant stability. Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks"
41498170|NCT04437459|OTHER|Pure glucose solution|Participant consumes 75 grams of pure glucose. Blood is drawn before and 2 hours after this drink to measure glucose.
41498171|NCT05719688|DEVICE|Mechanical thrombectomy|Treatment of ischemic stroke patients with Mechanical thrombectomy
41024490|NCT05413538|BEHAVIORAL|Mindfulness training|The intervention recordings will teach the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording has the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
41024491|NCT02348138|OTHER|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
40839755|NCT04772508|PROCEDURE|Scaling and root planing|15 sites with periodontal pockets ≥ 5mm received only SRP
40839756|NCT04772508|BIOLOGICAL|Amnion membrane|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.
40839757|NCT04772508|DRUG|Taurine|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
40839758|NCT01230138|DRUG|Placebo|Placebo tablets
40839759|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 250mg TID
40839760|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 375mg BID
40839761|NCT01230138|DRUG|FP187|Low daily dose of 500mg FP187 administered as 250mg BID
40839762|NCT01230138|DRUG|FP187|Oral tablets, up to 3 times daily for 20 weeks.
40839763|NCT04294771|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)
40839764|NCT00491374|DRUG|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
40839765|NCT00491374|DRUG|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
40839766|NCT05464264|DRUG|Ketamine|Participants suffering from TRD will receive their ketamine treatment intravenously twice weekly for two weeks (4 treatments in total). A dose of 0.5 mg/kg is infused over 40 minutes, with dose adjustments made at the psychiatrist's discretion.
40839767|NCT02185989|OTHER|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
40839768|NCT01014455|BEHAVIORAL|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
41359793|NCT01049360|DRUG|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
41359794|NCT01049360|DRUG|Placebo|Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
40839769|NCT01014455|BEHAVIORAL|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
41024492|NCT00614029|DEVICE|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
40839770|NCT00444067|DEVICE|Spinal Sealant|Spinal Sealant System
41024493|NCT01884350|DRUG|Apixaban|
41359795|NCT00788801|DRUG|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
41359796|NCT05110495|DRUG|Xentuzumab|The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
41359797|NCT05231694|DRUG|Nerver growth factor (NGF) injection|The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
41359798|NCT05231694|DRUG|Placebo injection|The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
41359799|NCT05231694|DEVICE|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
41359800|NCT05231694|DEVICE|sham EA intervention|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
41359801|NCT00830479|PROCEDURE|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
40839771|NCT00444067|OTHER|Standard of Care|Standard of Care
41359802|NCT00830479|PROCEDURE|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
41359803|NCT05230693|BEHAVIORAL|Sarcoidosis Patient Assessment and Resource Companion App|"The first group, called the SPARC group will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day"
41498172|NCT05358249|DRUG|JDQ443|KRAS G12C inhibitor, oral
40839772|NCT00089947|DRUG|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|
40839773|NCT00975143|DRUG|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
40839774|NCT00975143|DRUG|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
40839775|NCT00521664|BIOLOGICAL|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
40839776|NCT00521664|BIOLOGICAL|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
40839777|NCT06181370|DRUG|AGMB-447|AGMB-447 inhaled drug
40839778|NCT06181370|OTHER|placebo|placebo inhaled drug
40839779|NCT00211952|DRUG|celecoxib|
40839780|NCT03790800|DRUG|urapidil|A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.
40839781|NCT01395407|RADIATION|Radiosurgery dose escalation|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume \> 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume \> 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~1. 21 18 15~2. 23 20 17~3. 25 22 19"
40839782|NCT01848847|PROCEDURE|Hysteroscopy|
40839783|NCT00278330|DRUG|alvocidib|Given by infusion
40839784|NCT00278330|DRUG|vorinostat|Given orally
40839785|NCT04415996|OTHER|HVLA L3/4|"The participant will be lateral decubitus and the investigator will locate the third lumbar vertebra. Then with one hand the investigator will contact the interspinous space underlying L3 and with the other hand he will take the top leg into flexion until the investigator feels tension in L3/L4 joint. Then he puls the tables´s arm until felling tension in the region to be manipulated. Afterwards the investigator will globally rotate the participant in the horizontal plane and will approach to the L3/L4 joint. With one arm the investigator will contact the deltopectoral groove and with the other one will contact the external iliac fossa. Finally, the investigator will compress and rotate the pelvis and will apply an impulse in a rapid rotation, without losing the parameters with a body drop allowed by the flexion of the knees and the contraction of the large pectorals."
40839786|NCT04415996|OTHER|Sham|The participant will be in lateral decubitus and the top leg and knee will be flexed until the foot reaches the popliteal region of the other leg. There won't be applied any tension in no structure. This intervention will be applied during 20 seconds each side.
41359804|NCT05230693|BEHAVIORAL|Enhanced Standard Care|Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.
41359805|NCT03491501|OTHER|Ergonomic evaluation using questionnaires|Employees will be provided with questionnaires such as the 'Rapid Entire Body Assessment' and NIOSH to obtain information regarding ergonomic working situations
41359806|NCT01116895|DRUG|LEO 22811|Oral solution
41359807|NCT01116895|DRUG|Placebo|Placebo
41359808|NCT02609529|OTHER|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
40839787|NCT04287686|DRUG|Recombinant human angiotensin-converting enzyme 2 (rhACE2)|In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.
40839788|NCT02526108|OTHER|HIFT|Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
40839789|NCT02995551|PROCEDURE|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
40839790|NCT02995551|BEHAVIORAL|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
40839791|NCT06547060|OTHER|Exercise leggings|The participants will wear two types of leggings (i.e., control leggings vs. leggings with shortened resistance bands) while performing the same exercise on two different days, respectively.
40839792|NCT02342262|DIETARY_SUPPLEMENT|EcologicBarrier|multispecies probiotic product, 2x10-9 cfu/gram
40839793|NCT02342262|OTHER|Placebo|similar appearance as the probiotic product, but without bacteria
40839794|NCT01073917|OTHER|Spontaneous Breathing|
40839795|NCT01073917|OTHER|Pressure Controlled Ventilation|
40839796|NCT01073917|OTHER|Pressure Support Ventilation|
40839797|NCT02145871|OTHER|standard fluid management|
41359809|NCT02609529|OTHER|Placebo|
41359810|NCT04369742|DRUG|Hydroxychloroquine (HCQ)|HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)
41359811|NCT04369742|DRUG|Placebo: Calcium citrate|Calcium citrate 2 tablets (400mg) BID on day 1, 1 tablet (200mg) on days 2-5
41359812|NCT03445780|DRUG|Ethyl chloride spray|Skin cooling with ethyl chloride spray 5 seconds prior to injection
41359813|NCT03445780|PROCEDURE|Pinching|Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection
41359814|NCT03445780|PROCEDURE|No Site of Procedure|Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure
40839798|NCT02145871|OTHER|fluid management guided by the EV1000|
40839799|NCT04523090|DRUG|Nitazoxanide|Nitazoxanide (NTZ) is licensed in the USA for treatment of diarrhoea caused by Cryptosporidium parvum and Giardia lamblia. NTZ is a pro-drug for tizoxanide, which also has broad spectrum antiviral properties, has many viral indications and shows promising pharmacodynamics against Coronaviridae. NTZ was identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. In vitro studies evaluating tizoxanide, the active circulating metabolite of NTZ, inhibits the replication of broad range of influenza A and B, HIN1, H3N2, H3N2V, H3N8, H5N9, H7N1 and oseltamivir resistant strain and coronaviruses . It has been shown to have anti-viral activity against several viruses including Ebola, hepatitis B and C, rotavirus and norovirus.
40839800|NCT04523090|DRUG|Placebo|Placebo pills with no active ingredient.
41359815|NCT05564364|DEVICE|Recumbent Bike|The first group will exercise with a recumbent bike for 20 minutes, 3 sessions/week for 6 weeks.
40839801|NCT03678831|PROCEDURE|tissue|Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
40839802|NCT04114799|PROCEDURE|Hemodynamic management based on invasive fluid responsiveness parameters|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)
40839803|NCT04114799|PROCEDURE|Hemodynamic management based on noninvasive cardiac output and SVV measurement|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
40839804|NCT02168985|BEHAVIORAL|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
40839805|NCT00909597|DRUG|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
40839806|NCT00909597|DRUG|taspoglutide|10mg sc once weekly
40839807|NCT00909597|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
40839808|NCT01756859|PROCEDURE|MRI Scan|
40839809|NCT04451473|PROCEDURE|Enhanced Recovery After Surgery (ERAS )|the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
40839810|NCT04451473|PROCEDURE|Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )|the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
40839811|NCT00498121|DEVICE|PROCALCITONIN LEVEL|measuring PROCALCITONIN LEVEL
41359816|NCT05564364|DEVICE|Upright Bike|The first group will exercise with a upright bike for 20 minutes, 3 sessions/week for 6 weeks.
41498173|NCT05358249|DRUG|trametinib|MEK inhibitor, oral
41498174|NCT05358249|DRUG|Ribociclib|CDK4/6 inhibitor, oral
41498175|NCT05358249|BIOLOGICAL|cetuximab|EGFR inhibitor, intravenous
41498176|NCT05444530|BIOLOGICAL|VAC85135|Participants will receive VAC85135 as IM injection.
41359817|NCT04531436|OTHER|Brief mindful eating intervention|Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
41359818|NCT03755401|OTHER|TFPP|Trauma-Focused Psychodynamic Psychotherapy
41359819|NCT03755401|OTHER|TAU|treatment as usual at the VA for PTSD
40839812|NCT03274804|BIOLOGICAL|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
41359820|NCT00807768|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
40839813|NCT03274804|DRUG|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
41359821|NCT00807768|DRUG|Carboplatin|Given IV
40839814|NCT03605290|DIAGNOSTIC_TEST|REHAGAIT ANYLIZER|Gait analysis instrumentation
40839815|NCT02478450|BIOLOGICAL|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
40839816|NCT00219960|DRUG|North American Ginseng (Panax Quinquefolius)|
40839817|NCT00871923|DRUG|Tarceva (Erlotinib hydrochloride)|150 mg by mouth every day beginning Day 1.
40839818|NCT00871923|RADIATION|Radiation Therapy|Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
40839819|NCT05822050|DRUG|Selinexor|XPO1 inhibitor
40839820|NCT04569812|PROCEDURE|Cardiopulmonary Resuscitation|flowchart-assisted standard resuscitation or chest compressions-only resuscitation for 5min
40839821|NCT06347250|PROCEDURE|Nerve Block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40839822|NCT06347250|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
40839823|NCT06347250|BEHAVIORAL|routine therapy|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
40839824|NCT06347250|PROCEDURE|placebo block|the patients were provided with normal saline. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40839825|NCT04881747|DRUG|Lasmiditan|Administered orally.
40839826|NCT01297400|DRUG|Investigational Drug, MW-III|Topical application, twice a day
41359822|NCT00807768|RADIATION|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
40839827|NCT01297400|DRUG|Silvadene® Cream 1% [Silver Sulfadiazine]|Topical application, twice a day
40839828|NCT02520921|DRUG|Novel strategy Aspirin|Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
40839829|NCT02520921|DRUG|Conventional strategy Aspirin|Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
40839830|NCT00397007|BEHAVIORAL|Biofeedback-based cognitive-behavioural intervention|
41359823|NCT00807768|RADIATION|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
41359824|NCT00807768|OTHER|Laboratory Biomarker Analysis|Correlative studies
41359825|NCT00807768|DRUG|Paclitaxel|Given IV
41359826|NCT00807768|OTHER|Quality-of-Life Assessment|Ancillary studies
41359827|NCT00807768|OTHER|Questionnaire Administration|Ancillary studies
41359828|NCT06004882|OTHER|PNS therapy|PNS therapy-NS is a 60-day therapy targeting chronic pain. The procedure involves implanting a small piece of wire next to the nerve causing pain, and the wire is connected to an external device that is then used to apply electric pulses to the nerve, blocking pain signals, for 60 days
41359829|NCT06004882|DRUG|Triamcinolone|Given by Injection
41359830|NCT06004882|DRUG|Bupivacaine|Given by Injection
41498177|NCT05444530|DRUG|Ipilimumab|Participants will receive Ipilimumab as IV infusion.
41498178|NCT02752087|DRUG|LY900014|Administered SC
40839831|NCT04240626|DRUG|Neurontin|600 mg on-call prior to surgery, post surgery 100 mg liquid q 8-12 hours post surgery with Tylenol every 6 hours
40839832|NCT04240626|DRUG|Dilaudid Injectable Product|.5-1 mg IV Q3 hours and IV Tylenol 1000mg every 6 hours post surgery transitioning to oral pain control medications (Hycet 7.5/325mg/5 ml, 5-10 ml every 4 hours
41359831|NCT06004882|OTHER|Placebo|Given by Injection
41359832|NCT01633398|GENETIC|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
41359833|NCT02619942|PROCEDURE|D2 radical operation|In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
41359834|NCT02619942|PROCEDURE|Complete mesocolic excision (CME)|In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
40839833|NCT04240626|DRUG|Marcaine Injectable Product|0.25% local injectable anesthetic agent infiltrated at all laparoscopic incision sites for both groups.
40839834|NCT04240626|DRUG|Oxycodone Hydrochloride|1 mg/ml oral solution, dosage 5-10mg q4h prn for pain control
40839835|NCT04240626|DRUG|Hycet 7.5Mg-325Mg/15Ml Solution|Dosage: 10-15ml q4h prn for pain control
40839836|NCT04240626|DRUG|Zofran Injection|4 mg IV for nausea control while inpatient, prn
41359835|NCT06062108|OTHER|Pain evaluation|All included patients will have an evaluation of their pain, if they have no pain, the assessment stop with one date (pain or no pain), if they have pain, an assessment is done (localization of the pain, pain intensity), if they have a pain duration over 3 months, a DN4 questionnaire, HAD scale, ISI scale and SF-1 questionnaire is evaluated.
41359836|NCT03893994|OTHER|Stretching exercises|Stretching exercises will be applied 6 days a week, 30sec / 5 reps
40839837|NCT04240626|DRUG|Scopolamine patch|Topical application patch for nausea control, used with/without Ativan.
41359837|NCT04796454|DRUG|Cisplatin|Cisplatin IV 25 mg/m² on d1 and d8 - always combined with Gemcitabine; maximum treatment 2 years
41359838|NCT04796454|DRUG|Gemcitabine|Gemcitabine IV 1000 mg/m² on d1 and d8 if in combination with Cisplatin; Gemcitabine IV 1000 mg/m² on d1 and d15 if in combination with Oxaliplatin; maximum treatment 2 years
41359839|NCT04796454|DRUG|Oxaliplatin|Oxaliplatin IV 100 mg/m² on d1 and d15 - always combined with Gemcitabine; maximum treatment 2 years
41359840|NCT04796454|DRUG|Pamiparib|Pamiparib 60 mg PO twice a day from d1 to day28 in a 4-week cycle - always combined with Temozolomide; until progression or maximum treatment 2 years
41359841|NCT04796454|DRUG|Temozolomide|Temozolomide 60 mg PO once a day from d1 to d7 in a 4-week cycle - always combined with Pamiparib; until progression or maximum treatment 2 years
41359842|NCT01919749|OTHER|treated recommended|Treatment will be recommended after reviewing the profiling analysis
41498179|NCT06118606|OTHER|Case-manager led multidisciplinary follow-up after intensive care|Early in-hospital follow-up in survivors of intensive care with an increased risk of psychological/physical sequelae. The follow-up is led by a case-manager reassessing the patient after ICU discharge for psychological/physical rehabilitation needs. The CM will discuss patient needs with concerned specialists in a multidisciplinary team, leading to the establishment of a personal rehabilitation plan, communicated to the patient and next-of-kin. The CM will keep track of the patient during hospital stay and ensure primary care rehabilitation (if needed) is established once the patient is discharged from the hospital. The CM will contact the patient weekly to follow up on well-being and primary care activities until 12 weeks after discharge.
41498180|NCT03901963|DRUG|Daratumumab|Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
41498181|NCT03901963|DRUG|Lenalidomide|Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
40839838|NCT04240626|DRUG|Ativan|0.5mg IV as needed in conjunction with/without Scopolamine and Zofran for Nausea control
40839839|NCT04240626|DRUG|Flexeril Oral Product|5 mg orally q8h prn for muscle spasms.
40839840|NCT04240626|DRUG|Tylenol Suspension|1000 mg q6h PRN for pain control.
40839841|NCT05248503|BEHAVIORAL|Complex Care Training of Hereditary Epidermolysis Bullosa|Training in the care of epidermolysis bullosa by combining theoretical content on the disease and practical workshops.
40839842|NCT03153488|RADIATION|MRI|All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
40839843|NCT05071430|DRUG|HB-01|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
40839844|NCT05071430|DRUG|Placebo|HB-1 matched placebo
40839845|NCT04083755|DRUG|Ferric Carboxymaltose Injection [Injectafer]|1000mg intravenous
40839846|NCT04083755|OTHER|no treatment or oral iron supplementation|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
40839847|NCT02469415|DRUG|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
40839848|NCT02469415|DRUG|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
40839849|NCT02469415|DRUG|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
41359843|NCT06163144|OTHER|lab investigation|"Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.~\*Automated cell counters~* Advia 2120 8 difference~* PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected."
40839850|NCT05327504|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a 5 session treatment in which individuals write about their trauma event in a specified manner.
40839851|NCT05327504|BEHAVIORAL|Neutral Topic Writing|Treatment as Usual augmented by 5 sessions of Neutral Topic Writing which involves writing about specific objects (e.g., what they have eaten over the past week) or events (e.g., what they did since yesterday) in detail without discussing thoughts or feelings.
40839852|NCT03201159|DRUG|VLX103|150mg tablets
40839853|NCT03159104|DRUG|Tenoten for children|Tablet for oral use.
40839854|NCT03159104|DRUG|Placebo|Tablet for oral use.
40839855|NCT05053607|BEHAVIORAL|Digital Health Coaching Program|consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
40839856|NCT05053607|DEVICE|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
40839857|NCT05977166|DEVICE|hyperbaric oxygen therapy|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
40839858|NCT05977166|DEVICE|breathing exercise|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
40839859|NCT05977166|DRUG|medical treatment|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
40839860|NCT05265507|DRUG|Glycopyrronium|Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
40839861|NCT05265507|DRUG|Ondansetron|Glycopyrronium (4mg) was intravenously given at the ending of the surgery.
41359844|NCT01999205|BEHAVIORAL|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
40839862|NCT04578925|BEHAVIORAL|Happy, Healthy, Loved|A text message based, mobile-device delivered intervention that provides educational information to primiparous mothers and their partners about breast-feeding and coping with stress.
40839863|NCT05011799|BEHAVIORAL|Cancer Educational Materials|Receive prostate cancer educational materials
40839864|NCT05011799|OTHER|Questionnaire Administration|Ancillary studies
40839865|NCT05011799|OTHER|Educational Intervention|Attend peer-led education sessions
40839866|NCT04345094|OTHER|Hexylresourcinol|Emulsion containing hexylresorcinol as an active
40839867|NCT04345094|OTHER|Hydroquinone|Emulsions containing hydroquinone as an active
40839868|NCT03778463|OTHER|Synovectomy|Removal of the synovium during total knee arthroplasty
40839869|NCT01650740|DRUG|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
40839870|NCT01650740|DRUG|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
40839871|NCT01650740|OTHER|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
40839872|NCT04538313|DRUG|Tumor infiltrating lymphocyte|Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.
40839873|NCT00651365|DRUG|JNJ-38877605|
40839874|NCT03256253|DRUG|Pregabalin|pregabalin up to 600 mg/day
40839875|NCT05074420|DRUG|Baricitinib|Given Orally
40839876|NCT00716742|DRUG|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
40839877|NCT06228690|OTHER|Gold Fish exercises|Specific exercise for the flexibility of TMJ that will target the Jaw muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Gold Fish exercises for jaw flexibility, pain and maximum mouth opening.
41498182|NCT06007911|DRUG|Navitoclax Dose Level -1|25 mg by mouth on days 1-7.
41498183|NCT06007911|DRUG|Navitoclax Dose Level 0|50 mg by mouth on days 1-10.
40839878|NCT06228690|OTHER|Cervico-thoracic postural correction training|"Cervico-thoracic postural correction training for upper thoracic and neck muscles.~Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Muscle energy technique to improve range of motion, pain and maximum mouth opening."
40839879|NCT06228690|OTHER|Conventional PT treatment|"Conventional PT including Hot Pack for 10mins, Active-Passive neck Stretching Exercise + jaw Isometric Exercises.~* Frequency: hold followed by 5secs rest. 2-3times for 3 times/week for 4 weeks, Intensity: moderate-high intensity (depending on pain tolerance) Time: 30-45 mins for Active-Passive neck Stretching.~* Frequency: 3secs hold, 6 times repetitions for Isometric Exercises. Type: conventional treatment for pain, ROM, MMO."
40839880|NCT03477058|OTHER|WO 3308 cosmetic product for topical use|Application on the entire body at least once a day over two weeks
40839881|NCT00454584|DRUG|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
40839882|NCT00454584|DRUG|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
40839883|NCT00454584|DRUG|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
40839884|NCT01900288|BEHAVIORAL|HPN Group Clinic Appointments using Mobile Devices (experimental)|Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).
40839885|NCT01900288|BEHAVIORAL|Mobile Device Access (placebo)|Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
40839886|NCT05792267|DEVICE|artificial intelligence system|Patients will undergo EUS examination with the assistance of artificial intelligence(AI) system.
40839887|NCT06020755|DRUG|Toripalimab|200mg q2w intravenous
40839888|NCT06020755|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
41024494|NCT00277017|DRUG|5-Flourouracil, Interferon-a, IL-2 and Thalidomide|"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated."
41024495|NCT02393313|PROCEDURE|Cataract surgery|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
41024496|NCT02393313|DEVICE|Rayner T-flex Toric IOLs|
41024497|NCT04966104|BEHAVIORAL|ODYSSEE-vCHAT|Automated digital counselling program with social network support
40839889|NCT03566121|OTHER|Pelvic ultrasound / Urodynamic ultrasound|Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
40839890|NCT04515524|OTHER|Non-Interventional|No study treatment will be administered in this study
41359845|NCT03640962|OTHER|Evaluation|This cross-sectional study was conducted in 368 postmenopausal women aged between 40 and 65 years. This study was carried out in family health centers in Istanbul. Data were collected via face-to-face interviews by the researchers.
40839891|NCT06085313|BEHAVIORAL|CAI|Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality
40839892|NCT06085313|BEHAVIORAL|CAPA|Web App-based information and coaching/support program for cancer pain management
40839893|NCT05726890|BEHAVIORAL|bedtime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime. These changes are expected to foster the infant's ability to fall asleep independently at bedtime. It is also expected that after 1-2 weeks, these changes would lead to self-soothing also during the night.
41359846|NCT05917002|DEVICE|Real TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system).
40839894|NCT05726890|BEHAVIORAL|bedtime and nighttime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime and during the night. These changes are expected to foster the infant's ability to fall asleep independently at bedtime and to resume sleep independently during the night.
41024498|NCT05353829|DRUG|Methotrexate|When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration
41024499|NCT01591681|DEVICE|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
41024500|NCT04071873|DIAGNOSTIC_TEST|Point-of-care HIV testing|Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.
41024501|NCT04071873|BEHAVIORAL|HIV testing education|Participants will be provided with education on community based HIV resources.
41498184|NCT06007911|DRUG|Navitoclax Dose Level 1|75 mg by mouth on days 1-10.
41498185|NCT06007911|DRUG|Navitoclax Dose Level 2|100 mg by mouth on days 1-10.
40839895|NCT00330668|DRUG|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
40839896|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort -1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day."
41359847|NCT05917002|DEVICE|Sham TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system). The Magventure MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
41359848|NCT00686894|PROCEDURE|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
41359849|NCT00686894|DRUG|Infliximab|"* 5 mg/kg~* IV~* Frequency : weeks 0,2,6"
41359850|NCT04850066|BEHAVIORAL|Equine-assisted intervention|Usual care including an equine-assisted intervention carried out on foot, next to the horse, in 3 sessions of 3 hours each, spread over 4 weeks. This program is based on self-awareness, communication, assertiveness and adaptability.
41359851|NCT00847951|PROCEDURE|3D Ultrasound Imaging|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
41359852|NCT00006358|DRUG|temozolomide|
41359853|NCT00006358|DRUG|thalidomide|
41359854|NCT05217017|DIAGNOSTIC_TEST|FACS|Diagnostic Test: Assessment of disability and behavior (by questionnaires)
41359855|NCT00732199|OTHER|1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia|1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
41359856|NCT05732740|BEHAVIORAL|Empower@Home:Connected|Cognitive behavioral therapy
41359857|NCT03238209|DIAGNOSTIC_TEST|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
40839897|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 0|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort."
41359858|NCT06221722|DIAGNOSTIC_TEST|BOLD-fMRI|Blood-Oxygen-Level Dependent Functional Magnetic Resonance Imaging
41359859|NCT06221722|DRUG|Regular treatment of functional constipation|at least 3 months of continuous regular treatment. This treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.
41359860|NCT06221722|DRUG|fluoxetine|Fluoxetine oral treatment for 4 weeks.
41359861|NCT05984914|BEHAVIORAL|PSAI|The 8 sessions included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention, introduction to the Pythagorean Self-Awareness Intervention, instructions for the implementation of the technique, analysis of the Golden Verses,and their connection with lifestyle medicine as well as active involvement of the participants with group conversation and sharing of experiences.
41359862|NCT05984914|BEHAVIORAL|One day seminar|The one day seminar included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention.
41359863|NCT02554916|BEHAVIORAL|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
41359864|NCT02554916|BEHAVIORAL|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
41359865|NCT02554916|OTHER|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
41359866|NCT02554916|DEVICE|Dual-Belt Treadmill|
41498186|NCT06007911|DRUG|Venetoclax Dose Level -1|400 mg by mouth on days 1-7.
41498187|NCT06007911|DRUG|Venetoclax Dose Levels 0 to 2|400 mg by mouth on days 1-14.
41498188|NCT06007911|DRUG|Cladribine|5 mg/m\^2 intravenously days 1-5.
41498189|NCT06007911|DRUG|Cytarabine (Cladribine Low Dose Cytarabine Backbone)|20 mg/m\^2 subcutaneous days 1-10.
41498190|NCT06007911|DRUG|Cytarabine (CLAG-M Backbone)|1.5 g/m\^2 intravenously days 1-5.
41498191|NCT06007911|DRUG|Mitoxantrone|10 mg/m\^2 intravenously days 1-3.
41498192|NCT06007911|DRUG|Granulocyte Colony-Stimulating Factor|300 mcg subcutaneously days 1-5.
41498193|NCT05971693|DEVICE|OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator|Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping \[stimulating and recording\] and, when used with a Generator, for cardiac ablation).
41498194|NCT04709211|PROCEDURE|Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca block using 50 ml 0f Bupivacaine 0.25%
41498195|NCT04709211|PROCEDURE|Anterior Quadratus Lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using 50 ml 0f Bupivacaine 0.25%
41498196|NCT04709211|DRUG|bupivacaine|bupivacaine
41024502|NCT05343312|DRUG|AL (Coartem)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
41359867|NCT04921111|DRUG|SCT1000|Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)
41359868|NCT04921111|DRUG|Gardasil®9|Recombinant 9 or 4 valent human papillomavirus vaccine
41359869|NCT04921111|DRUG|placebo|aluminium phosphate
40839898|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort."
40839899|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 2|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day."
40839900|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 3|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day."
40839901|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 4|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day."
40839902|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 5|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day."
40839903|NCT00024375|DRUG|DHA-paclitaxel|
41359870|NCT04921111|DRUG|Gardasil®|Recombinant 4 valent human papillomavirus vaccine
40839904|NCT01631916|DRUG|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
41359871|NCT02625610|DRUG|Avelumab|Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
41359872|NCT02625610|DRUG|Oxaliplatin|"Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
41359873|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
41498197|NCT06522633|DRUG|The intervention involves the discontinuation of the opioid.|Patients with dysphagia and esophageal manometry indicating opioid-induced esophageal dysfunction (OIED) will have the opioid discontinued, and esophageal manometry will be repeated.
41498198|NCT04227847|DRUG|SEA-CD70|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
40839905|NCT02551029|OTHER|Capsaicin|
40839906|NCT02551029|OTHER|Placebo|
40839907|NCT03584555|PROCEDURE|SMILE using 120μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
40839908|NCT03584555|PROCEDURE|SMILE using 140μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
40839909|NCT00387647|DRUG|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
40839910|NCT02995798|OTHER|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
41359874|NCT02625610|DRUG|Leucovorin|"Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
41359875|NCT02625610|DRUG|Capecitabine|"Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
41359876|NCT02625610|OTHER|Best supportive care|Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.
41498199|NCT04227847|DRUG|azacitidine|75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
41498200|NCT06096922|OTHER|No intervention|No intervention
41498201|NCT05918861|DRUG|Dalcetrapib|Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets
41498202|NCT05918861|DRUG|Placebo|matching placebo tablets
41498203|NCT03302026|BEHAVIORAL|Realtime biofeedback using fMRI|Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
41498204|NCT05156398|DRUG|Rimegepant|Rimegepant 75mg or 50mg (2 X 25mg) ODT
40839911|NCT04454944|BEHAVIORAL|LPG subsidy|Different subsidy rates, ranging between 0% and 100% (listed below) will be written on cards. Individuals will randomly select a card to display the subsidy rate for each household. The card will be concealed with a scratch-off sticker, with a higher likelihood of drawing a high price (low subsidy) than a low price (high subsidy) given that take up will be higher in the latter group.
41498205|NCT05156398|DRUG|Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
40839912|NCT04454944|BEHAVIORAL|Distance allocation|We will set up fuel supply depots to increase the convenience and lower costs and hassle associated with traveling to an established filling station. The supply depots will mirror a recirculation model of LPG distribution currently being piloted by the National Petroleum Authority of Ghana. Households will be randomly assigned to one of the supply depots in advance or to continue refilling their cylinder at the filling station.
40839913|NCT05243589|OTHER|Proprioceptive training|"Proprioceptive training included exercises on different floor textures composed of 10 stations of exercises with the objective of stimulating the sole of the foot where participants had to coordinate gait by stepping with alternate feet on markers placed on the ground and the progression was manipulated through modifications of speed and direction.~Sequence of materials was 10 cm-thick foam, wood box with beans, two-cm thick mat with a density lower than the foam, wood box with cotton, two-cm thick mat volunteers sat on a bench and trained feet flexors by grasping with the toes a towel put on the floor, Two proprioception balls was used with an eight cm diameter with external projections resting on the floor a box with grains and sandpaper. After that joint Positional Sense Exercises were performed."
40839914|NCT05243589|OTHER|routine physical therapy|Routine physical therapy included range of motion exercises for bilateral ankle joints (5 min.), functional balance training (15 min.) involving sit to stand (5 times); standing weight shift (5 times each); functional reach- sideway and anterior for touching targets set by the therapist (5 times each); bipedal heel rise for 20 seconds (5 times); unipedal standing for 15 seconds (5 times each) and unipedal standing with knee bending for 15 second (5 times each). Other exercises was practiced as wobble board training (6 min).
40839915|NCT05023278|DRUG|Venlafaxine 37.5 MG|venlafaxine 37.5mg daily for 7 consecutive days.
40839916|NCT05023278|DRUG|Placebo|placebo filled pill daily for 7 consecutive days.
41498206|NCT01581866|DRUG|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
41498207|NCT04956432|DRUG|SHR4640|SHR4640 Dose 1 ,tablets, QD
41498208|NCT04956432|DRUG|Allopurinol|Allopurinol 300mg, tablets, QD
41498209|NCT03877991|DRUG|CBD-sesame oil capsule|A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
41498210|NCT03877991|DRUG|CBD-LNL capsule|A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
41498211|NCT03877991|DRUG|CBD powder form capsule|Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
41498212|NCT00520819|DRUG|Antioxidant-rich food items|
41498213|NCT06527638|BEHAVIORAL|Experimental Group: eHealth intervention for UI symptoms improvement|"The intervention was theoretically based on the HAPA model (including effective strategies in behaviour change, for example, action planning and coping with obstacles) and Common Sense Model of Self Regulation (beliefs, coping and appraisal), focusing on risk perception, planning, and self-efficacy.~The intervention consisted of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, were led by the psychologist responsible for the study, except the second session that was led by a physiotherapist. WhatsApp groups were created, to share experiences, knowledge, doubts and fears, and to create a sense of belonging, understanding and cohesion.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
41498214|NCT06527638|BEHAVIORAL|Control Group: Delivery of a Health Literacy single-leaflet|"A health literacy single-leaflet was delivered, by e-mail in the first week of the intervention. Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
41498215|NCT01729455|BIOLOGICAL|BENLYSTA|"As prescribed.~Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus."
40839917|NCT01440881|DRUG|Nesiritide|infuses at 0.01MCG/KG/min for 48 hours
40839918|NCT01440881|DRUG|Placebo|infuses at 0.01MCG/KG/min for 48 hours
40839919|NCT00584129|OTHER|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
40839920|NCT00584129|OTHER|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
41359877|NCT02625610|DRUG|Oxaliplatin|Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
41359878|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
40839921|NCT00317408|BIOLOGICAL|anti-thymocyte globulin|
40839922|NCT00317408|DRUG|busulfan|
40839923|NCT00317408|DRUG|carboplatin|
40839924|NCT00317408|DRUG|carmustine|
40839925|NCT00317408|DRUG|cyclosporine|
41024503|NCT05343312|DRUG|AS-AQ (Carsucam)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, and 28 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
41160743|NCT03358303|DEVICE|Medly|Medly will enable patients with HF to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
40839926|NCT00317408|DRUG|cytarabine|
40839927|NCT00317408|DRUG|dexamethasone|
40839928|NCT00317408|DRUG|etoposide phosphate|
40839929|NCT00317408|DRUG|idarubicin|
40839930|NCT00317408|DRUG|ifosfamide|
40839931|NCT00317408|DRUG|leucovorin calcium|
40839932|NCT00317408|DRUG|lomustine|
40839933|NCT00317408|DRUG|melphalan|
40839934|NCT00317408|DRUG|methotrexate|
40839935|NCT00317408|DRUG|mitoxantrone hydrochloride|
40839936|NCT00317408|DRUG|prednisolone|
40839937|NCT00317408|DRUG|thiotepa|
40839938|NCT00317408|DRUG|vinblastine sulfate|
40839939|NCT00317408|DRUG|vindesine|
40839940|NCT00317408|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40839941|NCT00317408|PROCEDURE|autologous hematopoietic stem cell transplantation|
40839942|NCT00317408|PROCEDURE|peripheral blood stem cell transplantation|
40839943|NCT00317408|RADIATION|total-body irradiation|
40839944|NCT02326766|DIETARY_SUPPLEMENT|KRG|5g Korea red ginseng (KRG)
40839945|NCT02326766|DIETARY_SUPPLEMENT|Placebo|5g placebo
40839946|NCT05407415|OTHER|Kardia Mobile 6L Device|"The KardiaAL is a software analysis library intended to assess ambulatory electrocardiogram (ECG) rhythms from adult subjects. The device supports analyzing data recorded in compatible fonnats from any ambulatory ECG devices such as event recorders, or other similar devices. The library is intended to be integrated into other device software. The library is not intended for use in life supporting, or sustaining systems, or ECG monitors, or cardiac alarm, or OTC use only devices.~The KardiaAI library provides the following capabilities:~* ECG noise filtering,~* heart rate measurement from ECGs,~* detection of noisy ECGs, and~* ECG rhythm analysis for detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia (when prescribed or used under the care of a physician)."
40839947|NCT00599508|DIETARY_SUPPLEMENT|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
40839948|NCT00599508|DIETARY_SUPPLEMENT|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
40839949|NCT00599508|DIETARY_SUPPLEMENT|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
41024504|NCT05343312|DRUG|DHP|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
41024505|NCT05343312|DRUG|PA|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
41024506|NCT06532227|OTHER|No intervention|No intervention excepted data collection
41024507|NCT00262834|DRUG|vorinostat|Given orally, conventional surgery to follow.
41024508|NCT00262834|OTHER|conventional surgery|Undergo conventional surgery
41160744|NCT00688077|DRUG|Calcitonin|Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
41160745|NCT00688077|DRUG|Placebo|NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
41359879|NCT02625610|DRUG|Leucovorin|Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
41359880|NCT02625610|DRUG|Capecitabine|Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
41359881|NCT01443039|DRUG|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =\>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
41359882|NCT06148181|DRUG|ABBV-141|Infusion; intravenous (IV)
41359883|NCT06148181|DRUG|Placebo for ABBV-141|Infusion; IV
41359884|NCT06148181|DRUG|ABBV-141|Injection; subcutaneous (SC)
41359885|NCT06148181|DRUG|Placebo for ABBV-141|Injection; SC
41359886|NCT03270527|OTHER|High SFA diet (Diet 1)|'Diet 1' will contain \~18% of its total energy as SFA .
41359887|NCT03270527|OTHER|Low SFA diet (Diet 2)|'Diet 2' will contain \~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
41359888|NCT05032196|DRUG|WVE-003|WVE-003 is a stereopure antisense oligonucleotide (ASO)
41359889|NCT03092141|OTHER|Physical training|
41359890|NCT04467216|DEVICE|Computerised cognitive training using virtual reality|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong.The VR systems available in the market for older people are only for non-interactive activities (e.g., watching movies) to provide unusual experiences for disabled older people who cannot travel too far from home.
40839950|NCT00599508|DIETARY_SUPPLEMENT|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
40839951|NCT00599508|DIETARY_SUPPLEMENT|berry placebo powder|berry placebo powder administered daily for 16 weeks
40839952|NCT00003027|BIOLOGICAL|aldesleukin|
40839953|NCT00003027|BIOLOGICAL|filgrastim|
40839954|NCT00003027|BIOLOGICAL|recombinant interferon alfa|
41024509|NCT01057212|DRUG|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
41359891|NCT01684930|DRUG|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
41359892|NCT01684930|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
41359893|NCT04737551|OTHER|Follow-up only|Only routine follow-up but no treatment
41359894|NCT04737551|DRUG|Adjuvant chemotherapy|Chemotherapy regimens will be decided by physicians or MDT teams, basing on patients' physical status, income status, and/or desire. Toxicity was evaluated every cycle and efficacy was evaluated every two cycles. The treatment course of adjuvant chemotherapy was followed the recommendation of NCCN guideline.
41359895|NCT04737551|RADIATION|Adjuvant chemoradiotherapy|"Adjuvant CRT could be delivered before or simultaneously with adjuvant chemotherapy. Radiation used 6 MV or 15 MVX-ray beams delivering daily fractions of 180-200cGy to a total dose of 45-55Gy in 25-28 fractions using CT-based, three-dimensional conformal radiation therapy (3DRT), intensity-modulated radiation therapy (IMRT) or tomotherapy (TOMO).~S-1 was administered orally at a dose of 40mg twice a day during radiation day as radiosensitizer through radiotherapy. Antiemetic medications and proton pump inhibitor were prophylactic used to reduce the occurrence of nausea and inhibit gastric acid secretion."
41359896|NCT04737551|RADIATION|Adjuvant chemoradiotherapy + Adjuvant chemotherapy|See as above (adjuvant chemotherapy and adjuvant chemoradiotherapy).
40839955|NCT00003027|DRUG|cisplatin|
41359897|NCT03756805|DEVICE|upper airway stimulation|One group of patients with UAS
41359898|NCT03756805|DEVICE|continuous positive airway pressure|One group of patients with CPAP
41359899|NCT04694079|PROCEDURE|Group 1, CMR-guided/aided VT ablation|"Ablation of the anatomical channels of heterogeneous tissue within the scar"
40839956|NCT00003027|DRUG|dacarbazine|
40839957|NCT00003027|DRUG|vinblastine|
40839958|NCT01268215|DRUG|Infasurf|Endotracheal instillation of Infasurf once per week for three weeks
40839959|NCT01268215|DRUG|Pulmicort|Endotracheal instillation, once per week for three weeks
40839960|NCT01268215|OTHER|Sham|None instilled through the endotracheal tube
40839961|NCT04394936|DRUG|Guselkumab|100 mg guselkumab administered subcutaneously
40839962|NCT04394936|DRUG|Placebos|Sodiumchloride 0,9% solution for injection
40839963|NCT01141478|RADIATION|Proton Beam Radiotherapy|Fifteen consecutive sessions
41024510|NCT01057212|DRUG|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
41024511|NCT04884126|PROCEDURE|dental implant placement|The time of dental implant surgery
40839964|NCT01141478|DRUG|Sorafenib|400 mg po bid
40839965|NCT03480009|DRUG|Dextromethorphan Hydrobromide|Dextromethorphan capsule
40839966|NCT03480009|DRUG|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding|Placebo capsule
40839967|NCT03480009|DRUG|Oxycodone|Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
40839968|NCT00634790|DRUG|alprazolam XR|Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
41024512|NCT05835726|DRUG|Daratumumab|NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
41160746|NCT06423859|DRUG|Articaine|supraclavicular brachial plexus block with articaine 2%
41359900|NCT04694079|PROCEDURE|Group 2, CMR-aided VT ablation|"Ablation of the electrical conduction channels within the scar"
41359901|NCT04694079|PROCEDURE|Group 3, Electroanatomical guided ablation|Ablation guided by an electro-anatomical system without the aid of CMR
41359902|NCT04749303|PROCEDURE|Large Screen|Large screen size is 4x larger than standard screen, we hope that the colonoscopies carried out with large screens will confer to better lesion detection
41359903|NCT01135368|DRUG|Lansoprazole|Lansoprazole capsules
41359904|NCT00004580|DRUG|Lopinavir/Ritonavir|
41359905|NCT00004580|DRUG|Nevirapine|
41160747|NCT06423859|DRUG|Dexmedetomidine|supraclavicular brachial plexus block with articaine 2% in addition with Dexmedetomidine
41160748|NCT03834207|DEVICE|Use of the C3-Cloud IT system|Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
41359906|NCT02718131|DEVICE|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
41359907|NCT02718131|PROCEDURE|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
41359908|NCT03021733|PROCEDURE|Operative management|Rotator cuff surgery
40839969|NCT02745535|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|
41160749|NCT05113212|DEVICE|Macular surgery with NGENUITY surgical display system|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon
41160750|NCT05113212|DEVICE|Macular surgery with standard operating microscope|Patient undergoes VR surgery with visualization using standard operating microscope
41160751|NCT01256372|DRUG|AP214|AP214
41160752|NCT01256372|DRUG|Placebo|Placebo; intravenous infusion
41359909|NCT04076865|DRUG|EMLA (lidocaine) +Itch (Histamine and cowhage)|"Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain."
41359910|NCT04794491|DRUG|JZP-258|Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose \> 6 g
41359911|NCT00946829|DRUG|telmisartan|
41359912|NCT00724243|DRUG|Infliximab|Infliximab given in accordance with the local summary of product characteristics
41359913|NCT03919032|OTHER|This is an observational study without intervention|This is an observational study without intervention
41359914|NCT04972097|DEVICE|Irreversible Electroporation|IRE of the prostate is typically performed with the subject in the lithotomy position, with 2-6 monopolar probes placed through the perineum using a brachytherapy grid and ultrasound or CT guidance. IRE supplies the targeted tissue with high voltage (2-3 kV) direct current pulses lasting up to 100 microseconds through the electrode probes.
41359915|NCT02561026|BIOLOGICAL|Frozen plasma|patients randomized to receive frozen plasma transfusions
41359916|NCT06281171|OTHER|SkillTalk for Autistic Young Adults|A Microskills video training library on communication skills for autistic young adults.
41359917|NCT06281171|OTHER|Flyer Library|A collection of existing online resources on relationship skills
41359918|NCT05811143|DEVICE|Spinal Cord Stimulator|SOC Implantation of Spinal Cord Stimulator for Lipomatosis and Low Back Pain.
41359919|NCT00795717|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
41359920|NCT00795717|DRUG|Placebo|2 capsules given twice daily
41359921|NCT04210141|BIOLOGICAL|lyophilized BPI viper antivenom|Antivenom
41359922|NCT04455958|DRUG|Lopinavir/Ritonavir|Given PO
41359923|NCT04455958|DRUG|Placebo Administration|Given PO
41359924|NCT04455958|OTHER|Questionnaire Administration|Ancillary studies
41359925|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
41359926|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
41359927|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
41359928|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
41359929|NCT01054794|DEVICE|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
41359930|NCT00006493|DRUG|Rosiglitazone|
41359931|NCT04313660|DRUG|Anlotinib In Combination With PD-1/L1 Inhibitor|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
41359932|NCT06300866|DRUG|Test|test toothpaste containing 0.45% stannous fluoride
41359933|NCT06300866|DRUG|Control|toothpaste containing 0.76% sodium monofluorophosphate
41359934|NCT03878420|DEVICE|Valeda PBM treatment|The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.
41024513|NCT05087043|DEVICE|Oral motor stimulation (OMS) and The supplemental nursing system (SNS)|OMS and an SNS were applied to preterm infants in the experimental group. Oral stimulation intervention provides assisted movement to activate muscle contraction and provides movement against resistance to build strength. The cheeks (internal and external), lips, gums, tongue, and palate were stimulated by finger-stroking following the protocol. OMS consisted of intra (oral region) and peri-oral stimulation (around the oral region). The OMS was administered three times a day by a nurse, from the day of initiation of oral feeding to the day of independent oral feeding 15 minutes before the feeding schedule. A bottle/container was filled with breast milk before the process and given to the baby via SNS while the baby was holding the mother's breast. The SNS consists of a syringe/container and a feeding catheter. One end of the feeding probe is inside the syringe/container, while the other end of it is fixed to the mother's nipple using plaster.
41359935|NCT03878420|DEVICE|Valeda Sham treatment|The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.
41359936|NCT02574429|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions \& 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
41359937|NCT03767309|PROCEDURE|coronally advanced flap with abrasive de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur
41359938|NCT03767309|PROCEDURE|coronally advanced flap with de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
41359939|NCT00617994|DRUG|Ruxolitinib|Ruxolitinib 1.5% cream BID for 28 days
41359940|NCT05376163|OTHER|Survey Study|Headache Disabilty Index (HDI) will be applied.
41359941|NCT03907072|DRUG|WVE-210201 (suvodirsen)|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
41024514|NCT05586867|PROCEDURE|Blood test|15 mL of blood to follow the evolution of hepcidin and erythroferrone levels
41024515|NCT01323439|DEVICE|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
41024516|NCT00296101|BEHAVIORAL|Physical Activity|
41024517|NCT01390246|DRUG|Bupropion SR|Bupropion SR 150 mg tablet
41024518|NCT01390246|BEHAVIORAL|Smoking Cessation Counseling|35-min counseling by trained research nurse
41024519|NCT01390246|DRUG|Placebo|Matching Bupropion SR placebo tablet
41024520|NCT05422118|DIAGNOSTIC_TEST|ascitic fluid calprotectin|ascitic fluid calprotectin
41024521|NCT04849234|BEHAVIORAL|newborn cries|"Their cries will be longitudinally registered from the age of birth until the first 15 minutes of birth using an automatic record device: Recorder ZOOM H4N.~The wav-sized files obtained from each recording will then be analyzed indiscriminately via an acoustic processing script created for the PRAAT software® by the post-doctoral fellows of the ENES laboratory (Sensory NeuroEthology Team) on the site of the Faculty of Sciences of Saint-Etienne."
41024522|NCT06535269|PROCEDURE|Monopolar Hemorroidecotmy|Hemorrhoidectomy with monopolar diathermy
41024523|NCT06535269|PROCEDURE|Caiman Hemorroidectomy|Hemorrhoidectomy with Caiman® bipolar energy
41024524|NCT06222476|DRUG|Dorzagliatin|Dorzagliatin will be initiated and maintained at 75mg twice a day
41024525|NCT06222476|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg once a day
41024526|NCT00289796|BIOLOGICAL|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
41024527|NCT04931849|DRUG|Avatrombopag|Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
41024528|NCT05106868|DEVICE|acupuncture|Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.
41024529|NCT03529526|DRUG|KN046|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg."
41024530|NCT06328699|PROCEDURE|Spiritual Therapy|Undergo chaplain led compassionate centered spiritual health sessions
41359942|NCT03907072|DRUG|Placebo|Buffered saline solution
41024531|NCT06328699|OTHER|Best Practice|Receive a traditional chaplain consultation and will receive care upon request
41024532|NCT02546245|BEHAVIORAL|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
41024533|NCT02546245|BEHAVIORAL|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
41024534|NCT00322062|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
41024535|NCT00322062|DRUG|Sodium Phosphate Solution|1 x 45ml solution, BID
41024536|NCT00698958|PROCEDURE|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
41359943|NCT02113891|DRUG|Eculizumab|"Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant)."
41359944|NCT00561964|DRUG|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
41359945|NCT00561964|DRUG|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
41359946|NCT00408031|DRUG|D-cycloserine|D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
40839970|NCT03238924|DRUG|Oxytocin|40 IU oxytocin nasal spray, self-administered
40839971|NCT03238924|DRUG|Placebos|Saline nasal spray, self-administered
40839972|NCT03514433|OTHER|TRIP Patient Navigation Intervention|The TRIP intervention will replace the current standard of care at the 5 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.
41024537|NCT00698958|PROCEDURE|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
41024538|NCT06097052|DEVICE|Hypotension Predictive Index|Introduction of Hypotension Predictive index and transition from a reactive to a proactive approach of intraoperative hypotension treatment.
41024539|NCT01084044|DRUG|ulinastatin, saline solution|the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
41359947|NCT03474991|DRUG|Celestamine®|Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
41024540|NCT00745927|OTHER|CO2 insufflations|CO2 insufflations during whole procedure of colonoscopy
41359948|NCT01503528|PROCEDURE|Motor Sparing Nerve Block|Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.
41359949|NCT01503528|PROCEDURE|Peri-articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
41359950|NCT03077399|DEVICE|SCALA|All items of SCALA are applied
41359951|NCT05262842|DRUG|JS001+IMP4297|"Phase I: Dose Escalation The primary endpoints are the safety and tolerability of the combination, including the incidence and nature of DLTs and the determination of the MTD and RP2D. A 3 + 3 dose-escalation (60mg,80mg,100mg)design will be used. Patient in each dose level will be treated with toripalimab 240mg in combination with senaparib.~Phase Ib: Dose Expansion This part will commence after the RP2D is determined and will further evaluate the safety and anti-tumor activity of toripalimab and senaparib in patients with specific types of advanced solid tumors. Patients will be enrolled concurrently into 5 exploratory cohorts with approximately 20 patients each cohort."
41359952|NCT01491828|DEVICE|Kai Strap|Medical device component that vibrates on a subject's neck.
41359953|NCT01442142|BEHAVIORAL|CAAT: Appetite Awareness|"Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks."
41359954|NCT01442142|BEHAVIORAL|CRST: Volcravo|"Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause."
41359955|NCT01442142|BEHAVIORAL|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
41024541|NCT02325882|DRUG|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
40839973|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 1"
40839974|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 2"
40839975|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 3"
40839976|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 4"
40839977|NCT00697281|DRUG|Placebo|"Tablets twice daily for 8 days~Dose level 5"
40839978|NCT04356079|DIAGNOSTIC_TEST|International Headache Society Test|Thorough History of Patients and families
40839979|NCT03716752|PROCEDURE|Modified connective tissue graft wall with wing technique|the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth
40839980|NCT02445573|OTHER|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
40839981|NCT02445573|OTHER|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
40839982|NCT01156168|GENETIC|DNA analysis|
40839983|NCT01156168|GENETIC|gene expression analysis|
40839984|NCT01156168|GENETIC|polymorphism analysis|
40839985|NCT01156168|GENETIC|protein expression analysis|
41024542|NCT02325882|DRUG|Fentanyl 1|conventional fentanyl-based epidural PCA
40839986|NCT01156168|OTHER|immunohistochemistry staining method|
40839987|NCT01156168|OTHER|laboratory biomarker analysis|
40839988|NCT04787185|RADIATION|Valutation of toxicity|"Observation of toxicity~All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy"
40839989|NCT06271330|DRUG|Faricimab|switch from previous anti-VEGF agents to faricimab
40839990|NCT06017934|BEHAVIORAL|Volunteer-led physical activity|Participants will be assessed by the therapy team who will prescribe tailored activity and then liaise with the mobility volunteers, who will deliver the intervention. Participants who can mobilise independently will be encouraged to perform walking exercises, progressing their walking distance over set markers in the hospital (e.g., to the end of the bed and back; to the doorway and back; to the toilet and back). Participants who require assistance in mobility will perform bed (e.g., hip abduction, static quads), or chair exercises (e.g., ankle pumps, knee extension, arm raise), and will be progressed to performing walking exercises when their physical function improves. Volunteers will check with nursing staff that participants are safe to exercise before each activity session. Participants will receive the mobility sessions twice daily, starting upon recruitment and continuing until the day of discharge from hospital.
41024543|NCT02325882|DRUG|Fentanyl 2|conventional fentanyl based intravenous PCA
41359956|NCT00141297|DRUG|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
41359957|NCT00723060|DRUG|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
41359958|NCT02772042|OTHER|Intervention Group|
41359959|NCT02772042|OTHER|Control Group|
41359960|NCT06428175|BEHAVIORAL|Focused Dose Hospital-to-Home Transitional Care Interventions|Focused dose H2H-TCIs will consist of a one-time post-discharge phone call completed within 72 hours post-hospital discharge by a clinical interventionist (e.g., nurse care coordinator or care manager). Calls will follow a structured template that provides empirically supported core H2H-TCI functions (follow-up care access, contingency planning, medication review, family education). The interventionist will also conduct a pre-hospital discharge clinical needs assessment with the parent.
41359961|NCT06428175|BEHAVIORAL|Extended Dose Hospital-to-Home Transitional Care Interventions|Extended dose H2H-TCIs will include a pre-discharge clinical needs assessment and initial phone call within 72 hours post-discharge, similar to the focused arm. After the initial contact, the dose of the extended H2H-TCI will increase as subjects receive high-intensity support during weekly post-discharge phone contacts through 30 days post-discharge. All contacts in the extended dose arm will be completed by a transition coach interventionist (e.g., nurse care coordinator or care manager) who will be formally trained on pillars of the Care Transitions Intervention© (CTI), a multi-faceted H2H-TCI that is the basis for the extended dose arm.
41359962|NCT03804138|OTHER|Anti-influenza and DTp pertussis vaccinations|Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
41359963|NCT03863964|DIAGNOSTIC_TEST|blood test|13 blood samples will be drawn: at 3 min, 7 min, 15 min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, and 5h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.
41359964|NCT01772017|DEVICE|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
40839991|NCT03289117|DEVICE|Novel gel installation device procedure|Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device
40839992|NCT03289117|DEVICE|Standard procedure|Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
40839993|NCT02882100|BIOLOGICAL|adjuvanted trivalent influenza vaccine|Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).
40839994|NCT02882100|BIOLOGICAL|trivalent influenza vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
40839995|NCT00491608|BIOLOGICAL|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
40839996|NCT01885910|DRUG|Doxycycline 100mg|Doxycycline 100mg by mouth once daily
40839997|NCT01885910|DRUG|Aczone 5% gel|Aczone 5% gel twice daily
40839998|NCT00188006|DEVICE|heparin-coated cardiopulmonary bypass|
41024544|NCT00621439|DRUG|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
41359965|NCT06093321|DEVICE|SYB PDO Thread|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
41359966|NCT06093321|DEVICE|MINT lift®|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
41359967|NCT00526760|DRUG|Dexmedetomidine|
41359968|NCT02303535|PROCEDURE|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
41359969|NCT02303535|PROCEDURE|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
41024545|NCT00621439|DRUG|Placebo|Patients will receive placebo.
41024546|NCT01979926|DRUG|Combination of Broussonetia spp and Lonicera spp|600 mg/ day or 1200 mg/ day for 7 days
41024547|NCT03357042|OTHER|Aerobic exercise and balance retraining|Aerobic and balance exercises that gradually progress in intensity over the course of 8 weeks.
41359970|NCT04981886|DRUG|Netarsudil Ophthalmic|Subjects will be randomly assigned to this group
41359971|NCT04981886|DRUG|Bimatoprost Ophthalmic|Subjects will be randomly assigned to this group
41359972|NCT05342376|DRUG|Dexmedetomidine Hydrochloride|The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
41359973|NCT05342376|DRUG|Normal Saline|The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
41359974|NCT05776381|OTHER|Shared Decision Making using a Patient Decision Aid.|The intervention comprises the surgeon actively using the tailored PtDA and SDM with the patient when deciding on the management of an unexpected malignant colorectal polyp.
40839999|NCT06517056|DEVICE|Emovi Knee Kinesiography|All participants will receive a KneeKG exam. This device will capture three-dimensional knee kinematics for a participant's knee, using the KneeKG system. Therapists will use these reports and suggested exercises to guide their care for participants in the Intervention group.
41024548|NCT03357042|OTHER|Standard of care|Normal concussion treatment; physical and cognitive rest
41359975|NCT02835391|DEVICE|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
41359976|NCT02835391|DEVICE|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
40840000|NCT01723540|PROCEDURE|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
41359977|NCT02835391|PROCEDURE|Electrocautery/Diatermy|Procedure for the control of bleeding
41359978|NCT02812602|DRUG|Lidocaine patch|Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
40840001|NCT05245877|DRUG|enoxaparin/tinzaparin/dalteparin|Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
40840002|NCT05188495|DRUG|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
40840003|NCT01331291|DRUG|bosutinib|Taken orally
41359979|NCT02812602|DRUG|placebo|Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
41359980|NCT03061864|BEHAVIORAL|Periviable Birth Plan|
41359981|NCT00507312|DEVICE|HD medical device (ViScope)|Device
41359982|NCT00507312|DEVICE|CSIRO device|device
40840004|NCT03597594|DRUG|Anti-thymocyte globulin (rabbit)|given intravenously
40840005|NCT03597594|DRUG|Busulfan|given intravenously
40840006|NCT03597594|DRUG|Fludarabine|given intravenously
40840007|NCT03597594|DRUG|Thiotepa|given intravenous infusion
40840008|NCT03597594|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
40840009|NCT03597594|OTHER|Donor Lymphocyte Infusion|given intravenous infusion
41359983|NCT05129618|DIETARY_SUPPLEMENT|MHS 1031|prebiotic syrup in individual sachets containing 1g (1.4 ml) of panosyl-isomaltooligosaccharides
41359984|NCT05129618|OTHER|placebo|liquid combination formulation of Neotame 7.92 mcg/g, phosphoric acid, and sterile water, designed to have the same degree of sweetness as the test material, provided in individual sachets containing 1.4 ml.
41024549|NCT06365736|BEHAVIORAL|Contemplating in nature|"Participants will spend 30 minutes in nature per day for 10 times over 14 days.~Each time, participants will walk for 10 minutes and then choose a nice spot to sit for 10 minutes. During these minutes they will be asked to be silently present and observe trees, plants, flowers or other aspects of nature and contemplate their connectedness to nature and their own awareness. Then walk back 10 minutes."
41024550|NCT06365736|BEHAVIORAL|Walking in nature|Participants will be asked to walk for 30 minutes in nature per day for 10 times over 14 days without further instruction.
41024551|NCT01847508|DEVICE|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
41359985|NCT04715958|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
41359986|NCT04715958|DRUG|Perflutren Lipid Microspheres|Given IV
41359987|NCT04715958|PROCEDURE|Ultrasound|Undergo unenhanced baseline ultrasound
41359988|NCT00000799|DRUG|Cidofovir|
41359989|NCT00000799|DRUG|Probenecid|
41498216|NCT01729455|OTHER|SLE treatment|"As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated."
41359990|NCT06188039|DIAGNOSTIC_TEST|Superior vena cava collapsibility index|"After induction of general anaesthesia following interventions will be performed.~1. Insertion of a tranesophageal echocardiography probe~2. Measurement of SVC-CI~3. Measurement of LVOT-VTI prior to fluid bolus~4. Fluid bolus (250ml of crystalloid)~5. Measurement of LVOT-VTI after fluid bolus~Several volume trials per patient will be allowed, until safety criteria are met. In such cases further testing will be stopped."
40840010|NCT02266576|BEHAVIORAL|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the San Jose State Timpany Center is the Group Lifestyle Balance™ DPP, which has previously been tailored for urban American Indians and Alaska Natives by the Indian Health Service. Standard DPP components consist of 16 group classes, 4 visits with a lifestyle coach and access to a therapeutic swimming pool and gym.
40840011|NCT02266576|BEHAVIORAL|Enhanced DPP|Enhanced DPP components consist of access to a mental health counselor, active referrals to mental health services, and traditional healing workshops such as the use of talking circles, a modified photo voice and digital storytelling to address specific psychosocial issues that are a result of historical trauma, stress, and grief.
40840012|NCT03249103|DRUG|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
41359991|NCT06188039|OTHER|PEEP elevation|"A transient elevation of positive end-expiratory pressure (PEEP) will be applied, in order to validate SVC-CI in the setting of elevated PEEP.~A PEEP level of 8-10cmH2O will be applied for 1 minute prior to every measurement of SVC-CI. Then the previous PEEP level will be reinstated."
41359992|NCT04414150|DRUG|SHR-1802|This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available.
41359993|NCT01094821|DRUG|ATI-7505|3 mg three times daily for 9 days
40840013|NCT03249103|DRUG|Placebo oral capsule|Matching placebo capsules.
40840014|NCT05754593|BIOLOGICAL|Anti-Mullerian hormone (AMH) level|Measure of Anti-Mullerian hormone (AMH) level by blood sample
40840015|NCT05754593|OTHER|Antral follicle count (AFC)|Measure of Antral follicle count (AFC) by ultrasound imaging
40840016|NCT05754593|OTHER|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
40840017|NCT03895255|PROCEDURE|Paraaortic lymph node dissection, IMA high ligation, TME, routine splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized. Side-to-end sigmoido-rectal anastomosis is created.
40840018|NCT03895255|PROCEDURE|Paraaortic lymph node dissection, IMA low ligation, TME, selective splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. Then inferior mesenteric artery is skeletonized down to the origin of left colic artery and divided below it. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized only if sigmoid colon is unsuitable for anastomosis or doesn't reach the rectal stump. Then descending-rectal side-to-end anastomosis is created.
40840019|NCT06061029|BEHAVIORAL|Brief Yoga- and Mindfulness-Based Psychoeducation Program|A unique mindfulness psychoeducation program incorporating features of Hatha yoga and mindfulness-based cognitive therapy, plus the main concepts of self-compassion
40840020|NCT02134288|DRUG|Belatacept|
40840021|NCT02134288|DRUG|Everolimus|
40840022|NCT05976009|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
40840023|NCT00296153|DRUG|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
40840024|NCT01423734|OTHER|magnetic resonance imaging (MRI)|"Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.~During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center."
40840025|NCT04106102|DEVICE|Transcramial Direct current stimulation|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder
40840026|NCT04106102|DEVICE|Placebo|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder without direct current. They xwill just wear electrodes.
41359994|NCT01094821|DRUG|Placebo|Placebo capsule three times daily for 9 days
41359995|NCT01094821|DRUG|ATI-7505|10 mg ATI-7505 three times daily for 9 days
41359996|NCT01094821|DRUG|ATI-7505|20 mg ATI-7505 three times daily for 9 days
41359997|NCT01901809|DRUG|Furosemide|
41359998|NCT01901809|DRUG|Dopamine|
41359999|NCT01114191|DRUG|ABT-869|2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\]
41360000|NCT01114191|DRUG|ketoconazole|400 mg days 6-11
41360001|NCT01276795|DIETARY_SUPPLEMENT|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
41360002|NCT04334876|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody Testing Kit|A, finger prick, at home test for SARS-CoV-2 IgG Antibodies.
41360003|NCT06076863|OTHER|Pharmacist Care|Management of Paxlovid e-visits per regional protocol
40840027|NCT04232436|OTHER|Survival at discharge|Survival at discharge
40840028|NCT04232436|OTHER|Survival without severe morbidity|Survival without severe morbidity (IVH, severe BPD, NEC, ROP)
40840029|NCT03903939|DRUG|Iloprost|continuously infusion for 72 hours 1 ng/kg/min
41360004|NCT06076863|OTHER|AFM Pool Care|Management of Paxlovid e-visits per regional and local protocols
41360005|NCT04974931|DEVICE|PREVENA Incision Management System|Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
41360006|NCT00224952|OTHER|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
41360007|NCT05049915|DEVICE|bioglass (S53P4)|surgical procedure: Masquelet defect augmentation with bioglass
41360008|NCT05049915|DEVICE|RIA and TCP|surgical procedure: Masquelet defect augmentation with RIA and TCP
41360009|NCT04057313|DIETARY_SUPPLEMENT|Coffee|Coffee used will be the boiled unfiltered Arabica coffee
41498217|NCT04012151|OTHER|Physical measurement|Parturients of gestational week \>= 32 weeks will have their arms and fingers measured to generate the conicity index.
41498218|NCT04012151|OTHER|Cuff size fitting|Fit on arm cuff and finger cuff as selected by investigators based on the measurement.
40840030|NCT03903939|DRUG|Isotonic saline|continuously infusion for 72 hours equal volume to Iloprost
40840031|NCT06371534|DRUG|QL2109|subcutaneous injection 3-5 min D1 (Day 1, single dose)
40840032|NCT06371534|DRUG|DARZALEX FASPRO®|subcutaneous injection 3-5 min D1 (Day 1, single dose)
40840033|NCT02133976|BEHAVIORAL|cognitive therapy|
40840034|NCT02133976|BEHAVIORAL|mindfulness training|
40840035|NCT02133976|BEHAVIORAL|behavioral therapy|
40840036|NCT02133976|OTHER|treatment as usual|
40840037|NCT03936751|DEVICE|CPAP|This is the standard treatment for OSA.
40840038|NCT03936751|DEVICE|Nasal Strips|Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo.
40840039|NCT00958932|BEHAVIORAL|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
40840040|NCT03455608|BEHAVIORAL|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified
40840041|NCT03455608|BEHAVIORAL|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
40840042|NCT03455608|BEHAVIORAL|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
40840043|NCT02198235|DRUG|Dexamethasone|
40840044|NCT02198235|DRUG|Buprenorphine|
41024552|NCT01847508|DEVICE|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
41024553|NCT00693992|OTHER|Laboratory Biomarker Analysis|Correlative studies
41360010|NCT02357394|DEVICE|Arabin Pessary|Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
41360011|NCT00977366|OTHER|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
41360012|NCT00977366|OTHER|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
41360013|NCT05620160|DRUG|RAY1216|RAY1216（tablet）
41360014|NCT05620160|DRUG|Placebo|placebo （tablet）
41360015|NCT04794530|DRUG|cocoa flavanols|The cocoa flavanols intervention is manufactured by Mars Inc. Participants randomized to cocoa flavanols will take two capsules daily of cocoa flavanols. The two capsules of cocoa flavanols will contain approximately 500 mg of cocoa flavanols and appoximately 80 mg of (-)-epicatechin.
41360016|NCT04794530|DRUG|placebo|The placebo intervention will be manufactured by Mars Inc. and will appear identical to the cocoa flavanols intervention. Participants will take two capsules daily of placebo. The placebo will be a cellulose based capsule and will not contain cocoa flavanols or (-)-epicatechin.
41360017|NCT03489460|BEHAVIORAL|Specialized sleep-related message interventions|Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.
41498219|NCT06397417|OTHER|Data collection|The data from hospital treatment will be used for research as well as subsequently, that is to say after discharge from the intensive care units, medical reports and correspondence with the attending physician will be used for the study.
41498220|NCT00829803|DEVICE|SNAP monitor; Bispectral Index Monitor (BIS Monitor)|Intended to monitor the state of the brain by data acquisition of EEG signals.
41498221|NCT06627491|BEHAVIORAL|Imagined muscle contractions|The intervention involved imagining, with no physical movement, of muscle contractions.
41498222|NCT00576108|DRUG|KD7040 Topical Gel|KD7040 topical gel
41498223|NCT00576108|DRUG|Placebo gel|Placebo gel
41498224|NCT04362748|DRUG|AMG 256|AMG 256 administered as an intravenous (IV) infusion.
41498225|NCT05469555|PROCEDURE|High Resolution Oesophageal Manometry|High Resolution Oesophageal manometry assesses how well the muscles of the oesophagus are working when you swallow. It also checks the relaxation of the valves at the top and bottom of the oesophagus.
41498226|NCT03286335|RADIATION|Proton Radiation|Radiation treatment
41360018|NCT03489460|BEHAVIORAL|GAD|Survey responses will be merged with objective GAD data (sleep time, time in deep sleep, physical activity) which will assist in developing message design formats for message testing.
40840045|NCT06269237|DEVICE|M22|"Participants in the group with 3 sessions of IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.~Other Names:~• IPL"
40840046|NCT06269237|DEVICE|sham M22|Participants in the group with 2 sessions of IPL, 1 session of sham IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
40840047|NCT04777266|BEHAVIORAL|Music therapy and treatment as usual|The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy \[37\], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence \[38\]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
40840048|NCT02528682|BIOLOGICAL|MiHA-loaded PD-L-silenced DC Vaccination|Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
40840049|NCT05498116|DRUG|Montelukast|10mg daily
40840050|NCT05498116|OTHER|Placebo|1 capsule daily
40840051|NCT03957876|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
40840052|NCT06088836|DRUG|Retrolaminar block group|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency linear ultrasound probe (6-11 MHz) was placed into a longitudinal orientation in the paraspinous line 1 cm from the midline. Lamina appeared as a continuous line interrupted by the intra laminar spaces.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done Then, an 18-gauge Tuohy needle was inserted in plane 1 cm lateral to the spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina."
41024554|NCT00693992|OTHER|Placebo|Given PO
41360019|NCT00694265|PROCEDURE|Decompression|Surgical decompression of the median nerve
41360020|NCT00694265|PROCEDURE|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
41360021|NCT05359575|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application
41360022|NCT05359575|BEHAVIORAL|Instructional flashcard (version 1)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.
41360023|NCT05359575|BEHAVIORAL|In-person training|10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).
41360024|NCT05359575|BEHAVIORAL|Instructional flashcard (version 2)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.
41360025|NCT01407068|BIOLOGICAL|AA4500 collagenase clostridium histolyticum|2 concurrent injections (0.58 mg) into 2 cords on the same hand
41360026|NCT00496574|BIOLOGICAL|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
41360027|NCT02610231|DRUG|Istradefylline 20 mg or 40 mg|Istradefylline 20 or 40 mg
41360028|NCT00000528|BEHAVIORAL|diet, sodium-restricted (Phase III) diet, sodium-restricted|
41360029|NCT00000528|BEHAVIORAL|diet, reducing (Phase III)|
41360030|NCT02330731|PROCEDURE|injection sclerotherapy for gastric varices|The intravariceal technique of injection
41360031|NCT05875272|PROCEDURE|interchangeability of arterial or venous hemostasis|Paired arterial and venous blood sampling respectively on the radial arterial catheter and on the central venous catheter before the extracorporeal circulation, and on the sampling ramp during the extracorporeal circulation. Point of care biology exams are performed on two HSE devices simultaneously. Controls carried out, routinely, every 20 minutes according to the service protocol, before the CPB (starting ACT without heparin), during the CPB (ACT objective ≥400 seconds), after protamine reversal of heparin. On average, 10 samples are taken during heart surgery.
41360032|NCT04149210|DRUG|Fluorometholone 0.1% Oph Susp|fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
41360033|NCT04149210|DRUG|Artificial Tears|Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
41024555|NCT00693992|OTHER|Quality-of-Life Assessment|Ancillary studies
41024556|NCT00693992|DRUG|Sunitinib Malate|Given PO
41024557|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type A mouldable adhesive|
41024558|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type B mouldable adhesive|
41360034|NCT02695758|PROCEDURE|Interscalene brachial plexus block|
41360035|NCT02695758|PROCEDURE|bupivacaine extended-release liposome injection|
41360036|NCT03110497|RADIATION|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
41360037|NCT01048827|DRUG|Busulfan|"1. 1250 uMol\*min (AUC to time 6 hrs)\^~2. 1400 uMol\*min (AUC to time 6 hrs~3. 1550 uMol\*min (AUC to time 6 hrs)\^"
41360038|NCT03379324|BIOLOGICAL|Superiority of augmented repairs|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
41360039|NCT03379324|BIOLOGICAL|Fat degeneration of supraspinatus muscle|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
41360040|NCT03049839|BEHAVIORAL|Intervention_ S|One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
41360041|NCT03049839|BEHAVIORAL|Intervention_ I|One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)
41360042|NCT03049839|BEHAVIORAL|Intervention_ C|One year, Intervention program at Community level. People with a FINDRISC less than 12 points
41360043|NCT04135599|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
41360044|NCT00336986|DRUG|recombinant interleukin-21|
41360045|NCT02941861|OTHER|Recurrence Rate of HCC after surgery|Recurrence Rate of HCC after surgery
41360046|NCT02941861|OTHER|Recurrence Rate of CCA after surgery|Recurrence Rate of CCA after surgery
41360047|NCT03487562|DRUG|DWP14012 Amg|DWP14012 Amg
41360048|NCT03487562|DRUG|DWP14012 Bmg|DWP14012 Bmg
41360049|NCT03487562|DRUG|Clarithromycin|Clarithromycin 500 mg
41360050|NCT03487562|DRUG|Amoxicillin|Amoxicillin 1 g
40840053|NCT06088836|DRUG|Erector spinae plane block group.|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the midline midway between the uppermost and the lowest fractured rib to identify counting of ribs using ultrasound three muscles were identified as superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. However, when the rhomboid major muscle disappears this indicates that we are at the level of the seventh thoracic vertebra.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done. Then, an 18-gauge Tuohy needle was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles"
40840054|NCT05006144|OTHER|sequenced trunk co-activation exercises|"* Sequenced trunk co-activation exercises were basically used for facilitation of functional activities through trunk musculature dynamic co-activation of in the lateral plane which is required for basic developmental milestones. In the frontal plane, encourage the child to actively shift his/her weight to maintain the weight-bearing side straight while keeping proper active co-activation of trunk musculature. Efficient trunk rotation is essential for acquiring of equilibrium reactions and balance. Enhancement of efficient active trunk rotation as the child could achieve active trunk musculature co-activation while maintaining the weight-bearing side straight (Arndt et al., 2008).~* Righting and protective reactions~* Functional stretching exercises."
41024560|NCT06126562|DRUG|Lanifibranor|Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
41024561|NCT01415505|DRUG|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
41360051|NCT03487562|DRUG|Lansoprazole|Lansoprazole 30 mg
41360052|NCT03286114|DRUG|Pembrolizumab|200mg IV every 21 days
41360053|NCT05032391|BIOLOGICAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Three times orally in a volume of 2.5 ml (1 dose)
41360054|NCT05032391|DRUG|Placebo|Three times orally in a volume of 2.5 ml (1 dose)
41360055|NCT05182034|BIOLOGICAL|SMUP-IA-01(low dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
41360056|NCT05182034|BIOLOGICAL|SMUP-IA-01(mid dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
41360057|NCT05182034|DRUG|Active Control Group Sodium chloride|A single knee administration of Sodium chloride
41498227|NCT05871723|OTHER|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|o measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
41360058|NCT02505945|DRUG|Omeprazole|
41360059|NCT02505945|DEVICE|LINX Reflux Management System|
41360060|NCT05502120|DEVICE|Laryngoscopy with Vie-Scope laryngoscope|Evaluation of laryngeal view using Vie-Scope laryngoscope, intubation efficacy, complications
41360061|NCT05502120|DEVICE|Laryngoscopy with Macintosh blade laryngoscope|Evaluation of laryngeal view using stnadard Macintosh blade laryngoscope
41360062|NCT02045615|PROCEDURE|Proposed technique for removal of the Wichita Fusion Nail|
41360063|NCT04882579|DIAGNOSTIC_TEST|Point-of-care-ultrasound examination|"The intervention consists of three ultrasound modalities:~1. Cardiac ultrasound assessing signs of right ventricular strain or other obvious pathology.~2. Deep venous ultrasound assessing presence of a deep venous thrombus~3. Lung ultrasound assessing presence of pulmonary infarctions, pleural effusion, pneumothorax or interstitial syndrome."
41360064|NCT01567046|OTHER|laboratory biomarker analysis|Correlative studies
41360065|NCT04994015|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
41360066|NCT06089226|OTHER|Assessment Group|In our prospectively planned study, patients who meet the inclusion criteria will be evaluated by the researcher via face-to-face interview method and the evaluations specified in the outcome measurements. Patients participating in the study will first be given a general explanation about the purpose of the study and evaluation methods, and their written consent will be obtained.
41360067|NCT02555722|DEVICE|fanfilcon A (test)|silicone hydrogel lens
41498228|NCT05871723|OTHER|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56. The Berg Balance Scale is commonly used in clinical and research settings to assess balance impairment and monitor changes in balance over time, particularly in individuals with neurological conditions such as stroke. The test has good reliability and validity and is considered a gold standard for assessing balance in these populations.
41360068|NCT02555722|DEVICE|enfilcon A (control)|silicone hydrogel lens
41360069|NCT02071342|PROCEDURE|angioplasty|patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
41360070|NCT03726099|DRUG|esomeprazole, amoxicillin, furazolidone，tetracycline|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day concomitant therapy containing esomeprazole 40mg bid, amoxicillin 1000mg bid , furazolidone 100mg bid and tetracycline 500mg qid.
41360071|NCT02605720|DRUG|Dihydroartemisinin-piperaquine|DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
41360072|NCT04804111|DRUG|arm 0|placebo group
41360073|NCT04804111|DRUG|arm 1|3 mg of the URC102 group
41360074|NCT04804111|DRUG|arm 2|6 mg of the URC102 group
41360075|NCT04804111|DRUG|arm 3|9 mg of the URC102 group
41360076|NCT04804111|DRUG|arm 4|Febuxostat 80 mg
41498229|NCT00887055|DEVICE|CRT device|
41498230|NCT02530658|OTHER|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
41498231|NCT02530658|OTHER|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
41498232|NCT02530658|OTHER|Informed Consent Follow-Up Visit|At or after enrollment but before the release of the gerline results, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
41024562|NCT03890302|DRUG|FB704A|Administered by IV infusion
41024563|NCT03890302|DRUG|Placebo|Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
41024564|NCT01467323|DRUG|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
41360077|NCT06152367|BIOLOGICAL|TAPCells vaccine|Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
41360078|NCT04362527|DRUG|Milrinone 1 Mg/mL Solution for Injection|Blinding procedure will be set up for the administration of the treatment
41360079|NCT04362527|DRUG|Saline solution for injection|Blinding procedure will be set up for the administration of the treatment
41360080|NCT00681772|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
41024565|NCT01467323|DRUG|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
41024566|NCT05360238|BIOLOGICAL|MB-106|T-cells derived from autologous leukapheresis that are genetically modified.
41360081|NCT03861442|DEVICE|Audio processor SONNET|AI - N/A, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
41360082|NCT03861442|DEVICE|SONNET 2: Configuration 1|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Mild, TNR - Mild
41360083|NCT03861442|DEVICE|SONNET 2: Configuration 2|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Strong, TNR - Strong
41360084|NCT03861442|DEVICE|SONNET 2: Configuration 3|AI - Mild, WNR - Mild, Beam-former - Auto (NAT), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Mild), TNR - Auto (Off-Mild)
41024567|NCT05080582|BEHAVIORAL|Mother-Scented Simulated Hand|Preterm neonates wrapped with a warm Mother-Scented Simulated Hand during the invasive procedures
41024568|NCT05080582|BEHAVIORAL|NICU Standard Care|Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture.
41360085|NCT03861442|DEVICE|SONNET 2: Configuration 4|AI - Strong, WNR - Strong, Beam-former - Auto (OMNI-ABF), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Strong), TNR - Auto (Off-Strong)
41360086|NCT03861442|DEVICE|SONNET 2: OPUS 2 configuration|AI - Off, WNR - Off, Beam-former - OMNI, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
41360087|NCT03861442|DEVICE|SONNET 2: SONNET configuration|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
41498233|NCT02530658|OTHER|Return of Results Conversation|Participants will complete the assessment questionnaires.
41024569|NCT04297878|DIETARY_SUPPLEMENT|probiotic supplement Streptococcus salivarius K12 (Bactoblis®)|Probiotic food supplement
41498234|NCT02530658|OTHER|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 28 ± 4 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
41360088|NCT05776706|DIAGNOSTIC_TEST|AR-based navigation|"The surgeon will perform all surgical planning and operations with reference to the existing navigation. In this process, the errors of the existing navigation and the newly developed navigation are measured and compared in 3D at several points, and the points are as follows.~1. Fiducial markers~2. Nasion~3. Tumor's margin (anterior, posterior, superior, inferior)"
41360089|NCT01317264|OTHER|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
41360090|NCT01317264|OTHER|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
41360091|NCT01317264|OTHER|barley β-glucan|"daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days"
41360092|NCT01317264|OTHER|mutant-barley β-glucan|"daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days"
41360093|NCT04907942|DEVICE|EMA + Automated Text Message Intervention|Intervention includes 3 weeks of EMA (2 daily surveys per day delivered during waking hours to evaluate momentary affects) plus 2 weeks of automated text messages delivered twice a day, which content follows constructs from The Transactional Model of Stress and Coping.
41360094|NCT04907942|BEHAVIORAL|EMA Alone|Three weeks of EMA consisting of 2 daily surveys per day delivered during waking hours to evaluate momentary affects.
41360095|NCT03289442|PROCEDURE|supine position|patients were positioned on their supine position to receive colonoscopy insertion
41360096|NCT04549766|OTHER|calculate PRECISE DAPT score using clinical data|calculate PRECISE DAPT score using clinical data in STEMI patients after PPCI
41360097|NCT01333020|OTHER|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
41360098|NCT03369340|OTHER|P3P 1|2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
41360099|NCT03369340|OTHER|P3P 2|2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
41360100|NCT03369340|OTHER|P3P 3|1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
41360101|NCT03369340|OTHER|P3P 4|2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
41360102|NCT05510401|OTHER|SECURIDRAP® SELFIA®|Use of SECURIDRAP® SELFIA® for 15 night
41360103|NCT00114400|DRUG|folic acid|
41360104|NCT00114400|DRUG|vitamin B12|
41360105|NCT00114400|DRUG|vitamin B6|
41360106|NCT02583399|DRUG|Ibuprofen|Ibuprofen, 10 mg/kg
40840055|NCT05006144|OTHER|Standard Orthotic Management|A custom-made articulating ankle foot orthosis with a hinge at the level of the medial malleolus of the ankle is fabricated for each child from the same copolymer thermoplastic mold after casting with the subtalar joint in neutral position. The orthosis extended distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured to the foot by three straps across the forefoot, the front of the ankle, and to the anterior upper tibial portion. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day in the third and fourth months to accommodate children to the orthosis.
41360107|NCT06017349|DEVICE|Non-invasive glucose meter|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Place your index finger into the non-invasive blood glucose meter and wait for the instrument to display the reading.
41360108|NCT06017349|DEVICE|EKF analyzer|Blood glucose levels were measured while fasting, after breakfast, and after lunch，After collecting venous blood and separating plasma, blood glucose detection is performed using the EKF analyzer with the hexokinase method.
41360109|NCT06017349|DEVICE|Accu-Chek Guide|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Use Accu-Chek Guide blood glucose meter to prick the finger and obtain blood for glucose measurement
41360110|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 300mg for 12 weeks
41360111|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 400mg for 12 weeks
41360112|NCT05442827|DRUG|PlaceboSHR7280 tablets blank preparation|Placebo group: SHR7280 tablets blank preparation for 12 weeks
41498235|NCT02530658|PROCEDURE|Blood Sample|For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
41360113|NCT00056472|DRUG|Olanzapine|10-20mg/day
41360114|NCT00056472|DRUG|Sertraline|150-200mg/day
41360115|NCT00056472|OTHER|placebo|tablet that ressembles sertraline but contains no medication
41360116|NCT01832753|DRUG|Levothyroxine|
41360117|NCT02917161|DEVICE|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
41360118|NCT04459858|OTHER|data analysis|"Data is extracted from the existing medical records and from the Rotator Cuff Repair Database (RCR_USB). The GTA (determined as the angle between a line parallel to the humerus diaphysis passing through the humeral head center of rotation and a line connecting the upper border of the humeral head to the most superolateral edge of the greater tuberosity) is determined."
41360119|NCT03117192|DRUG|Zinc Sulfate|Zinc supplementation in syrup form
41360120|NCT03117192|DRUG|Sucrose Syrup|Sucrose as placebo, with same taste and consistency as zinc
41360121|NCT03629834|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Maintenance Wakefulness Test
41360122|NCT01599585|BEHAVIORAL|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
41360123|NCT02764931|OTHER|Gluten free oats and gastrointestinal health|Subjects will be served 3 different test meals in a randomized order in the cross-over design
41360124|NCT04322799|PROCEDURE|Device: Randomization between prosthetic components|Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
41360125|NCT04384952|OTHER|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.
41360126|NCT04384952|OTHER|Dyslexic's Holiday Workbook|Use of a special Dyslexic's holiday book, no parent-guided training.
41360129|NCT04036214|DEVICE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty Laser
41360130|NCT05215327|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
41360131|NCT05215327|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
41360132|NCT04806334|DIAGNOSTIC_TEST|MRI imaging of the pelvis/bladder|The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI).
41360133|NCT04806334|DIAGNOSTIC_TEST|genomic analysis of tumor|Single cell RNA sequencing of transurethral resection of bladder tumor (TURBT)
41360134|NCT05798299|BEHAVIORAL|Arm 1: Transdiagnostic intervention|The UP-C/C consists of 15 weekly sessions for children, each lasting 90 minutes. It is also composed by three sessions for parents and a meeting with the family prior to the exposure sessions. Parents have access to weekly psychoeducational material (in written and in video format) and help the children with homework completion.
41360135|NCT05798299|BEHAVIORAL|Arm 2: Anxiety-focused intervention|The Coping Cat in group format is a cognitive-behavioral evidence-based intervention for anxiety problems. It is composed by 16 90-minute sessions for children and two parenting sessions.
41360136|NCT03508206|DIETARY_SUPPLEMENT|SBRP|SBRP capsules
41498236|NCT02530658|PROCEDURE|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
41498237|NCT01851200|DRUG|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
40840056|NCT05006144|OTHER|selective dorsal rhizotomy|All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact. After opening the dura, the posterior nerve roots of L2 to S1 were identified and divided into 3 to 6 rootlets. At L2, from 30% to 50% of the posterior nerve rootlets were sectioned without selective stimulation. Selective electric stimulation of each nerve rootlet was performed from L3 to S1. The percentage of rootlets sectioned at each level (table 3) was determined by the surgical team based on the electromyographic results obtained intrasurgically and knowledge of the presurgical assessment results. The laminae were replaced on the completion of the rootlet stimulation and secured with sutures in the yellow ligament and the supraspinous ligament.
40840057|NCT03238248|DRUG|Azacitidine Subcutaneous Injection or Intravenous Infusion|75 mg/m2
40840058|NCT03238248|DRUG|Pevonedistat Infusion|20 mg/m2
40840059|NCT03238248|PROCEDURE|Bone Marrow Biopsy & Aspirate|Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
40840060|NCT05024136|DEVICE|Limon essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of Limon essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
40840061|NCT05024136|DEVICE|Vetiver essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of vetiver essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
40840062|NCT04496024|DRUG|ofloxacin|ofloxacin treatment in patients with bone and joint infections
40840063|NCT04496024|OTHER|questionnaire|questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42
40840064|NCT04496024|BIOLOGICAL|Ofloxacin Serum concentration|Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).
40840065|NCT06464965|BIOLOGICAL|CB CAR-NK182|To study the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of cord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2 in patients with advanced gastric cancer and advanced pancreatic cancer
40840066|NCT06065592|DRUG|Palbociclib|Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.
40840067|NCT06065592|DRUG|Rivaroxaban|Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.
40840068|NCT06065592|GENETIC|SNP|diagnostics of patients' carriers or not of the risk allele(s)
40840069|NCT01992562|DRUG|Ziconotide|
40840070|NCT01992562|DRUG|placebo|
41360137|NCT03508206|DIETARY_SUPPLEMENT|PLACEBO|Placebo capsules
41360138|NCT02856295|DRUG|clexane (LMWH)|to compare tow doses of clexane for preventing VTE in postpartum women
41360139|NCT01376765|DRUG|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
41360140|NCT01376765|OTHER|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
41360141|NCT01376765|BIOLOGICAL|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
41360142|NCT03178591|DRUG|vildagliptin|
41360143|NCT03178591|DRUG|Dapagliflozin|
41360144|NCT01712763|DRUG|degarelix|180 women will be treated with degarlix 120 mg, in only one administration covering three months
41024570|NCT03050476|DRUG|RESCAP®|intravenous application before, during, and for 24 or 96 hours after heart surgery
40840071|NCT01181258|DRUG|Rituximab|375 mg/m\^2 administered intravenously (IV) weekly \* 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
40840072|NCT01181258|BIOLOGICAL|Interleukin-2|subcutaneously administered 9 million international units (IU) every other day \* 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight \< 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
40840073|NCT01181258|BIOLOGICAL|Natural killer cells|administered intravenously 1.5 to 8 \* 10\^7 cells/kg on Day 0 (day of NK cell infusion)
40840074|NCT01181258|DRUG|Cyclophosphamide|60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
40840075|NCT01181258|DRUG|Methylprednisolone|1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
40840076|NCT01181258|DRUG|Fludarabine|25 mg/m\^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
40840077|NCT05352763|DRUG|simufilam|simufilam 100 mg oral tablets
40840078|NCT06079151|DEVICE|Nasal high-flow|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen if necessary
40840079|NCT04545463|DIETARY_SUPPLEMENT|FIBRACEP|A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months
40840080|NCT04545463|DIETARY_SUPPLEMENT|INSOLUBLE|A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months
40840081|NCT04545463|DIETARY_SUPPLEMENT|SOLUBLE|A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
40840082|NCT02283203|DRUG|APOTEL max|The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
40840083|NCT02283203|DRUG|Placebo|Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
40840084|NCT03404856|DRUG|ORL-1G - D-galactose|Oral ORL-1G - D-galactose
40840085|NCT03125460|DEVICE|Xpert Bladder Cancer Monitor|in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
40840086|NCT04799691|PROCEDURE|Invasive ventilation strategy|Use of an invasive ventilatory support strategy
40840087|NCT04799691|PROCEDURE|Non-invasive ventilation strategies|Use of non-invasive ventilatory support strategies
40840088|NCT01171209|DRUG|Interferon-beta and human leukocyte Interferon-α|One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up.
40840089|NCT05429073|DRUG|RGLS8429|solution for subcutaneous injection
40840090|NCT05429073|DRUG|Placebo volume-matching RGLS8429 dose|solution for subcutaneous injection
40840091|NCT05777239|PROCEDURE|Dental Implant Approach for Crestal Sinus Elevation|Crestal Sinus Elevation by elevating the sinus membrane with a blunt ended dental implant approach
40840092|NCT01124981|DRUG|Haemocomplettan® P|Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
40840093|NCT01124981|DRUG|Human albumin (Placebo)|Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
41024571|NCT03050476|DRUG|placebo|intravenous application before, during, and for 24 or 96 hours after heart surgery
41024572|NCT00917046|BEHAVIORAL|high-intensity interval training|3 weekly sessions of high-intensity interval training in 12 weeks
41360145|NCT01712763|DRUG|Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)|180 women will be treated with leuprolide acetate11.25 only once covering three months
41360146|NCT02825589|DEVICE|BIA|BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
41360147|NCT01298661|OTHER|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
41360148|NCT00250042|DRUG|Gleevec and Arsenic Trioxide|Pts. who fit the inclusion criteria, \& were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) \& then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
41360149|NCT00281359|DEVICE|With heat|heat pad followed by dynamic splinting
41360150|NCT00281359|DEVICE|No heat|No heat added to tissue prior to dynamic splinting
41360151|NCT06428929|OTHER|The musical and lighted baby crib mobile:|The musical and lighted baby crib mobile: It measures 43.5x33x9.5 cm and is made of plastic. It is recommended for use in infants 0-12 months. It has music that makes it easier for babies to fall asleep by reducing stress. This baby mobile has a projection and music function. In addition, the mobile has a 360° flexible swivel bracket that can be adjusted as desired. The surface of the apparatus of the mobile, which is designed to be environmentally and baby friendly, is smooth. There are four rattles on the mobile
41360152|NCT01952041|BEHAVIORAL|Device: Smartphone|
41360153|NCT01952041|BEHAVIORAL|Treatment as usual|
41360154|NCT02548091|OTHER|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
41360155|NCT02548091|PROCEDURE|Non invasive ventilation|
41360156|NCT02548091|PROCEDURE|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
41360157|NCT02548091|PROCEDURE|Computed tomography (CT)|
41360158|NCT04118127|DRUG|2mg conventional tablet, once-weekly tablets|In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
41360159|NCT01681004|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
41360160|NCT01681004|OTHER|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
41360161|NCT04418908|DRUG|Cetrorelix acetate, 0.25 mg/day|All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).
41360162|NCT04418908|DRUG|Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release|Active estradiol transdermal patch.
41360163|NCT04418908|DRUG|Placebo patch|Placebo patch designed to match active Climara patches.
41360164|NCT01787123|DRUG|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
41360165|NCT01787123|DRUG|Normal Saline|14-day course of intravenous normal saline started within 4 days of ictus
41360166|NCT00967343|BIOLOGICAL|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
41360167|NCT04018391|BEHAVIORAL|Stepped care for nonadherence and depression|"* Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~* Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence."
41360168|NCT04018391|OTHER|Enhanced Usual Care|Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
41360169|NCT01008228|PROCEDURE|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
41360170|NCT01008228|PROCEDURE|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
41360171|NCT04675437|OTHER|Aerobic exercise|12-weeks aerobic exercise program
41360172|NCT00723515|DRUG|sodium fluoride|sodium fluoride 5%
41360173|NCT00723515|DRUG|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
41360174|NCT00114894|OTHER|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
41360175|NCT00114894|OTHER|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
40840094|NCT05499624|DEVICE|MicroTrend System|The hands-free device measures oral mucosal carbon dioxide pressure (POMCO2) and functions outside of the body and does not require a surgical procedure or any significant deviation from standard practice to operate.
40840095|NCT01300260|BIOLOGICAL|LY2189265|Administered subcutaneously
40840096|NCT01300260|DRUG|Placebo|Administered subcutaneously
40840097|NCT01300260|DRUG|Insulin|Administered intravenously
41360176|NCT01632527|DRUG|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
41360177|NCT00365872|BIOLOGICAL|Dendritic Cell (DC) Injections|"* DCs (10\^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~* One additional DC injection was given before surgery to assess DC migration~* Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
41360178|NCT00365872|PROCEDURE|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
41360179|NCT00365872|PROCEDURE|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
41360180|NCT03942991|DRUG|articaine|infiltration injection of 4%artpharmadent
41360181|NCT03942991|DRUG|Mepivacaine 2% Injection|infiltration injection of 2% Mepecaine-L
41360182|NCT05067387|DRUG|Placebo|Oral placebo
41498238|NCT04122144|BEHAVIORAL|ENHANCED -SPS intervention|a) Enhanced VL counseling: Explanation of VL \& Importance of VL suppression,assessment of adherence, counseling based on VL result and schedule for next VL testing and the role of VL and the MTCT risk; b).Standardized peer mother support: includes training of peer mothers on mandatory enhanced VL counseling during the routine peer counseling and education, follow up of mothers and continued adherence counseling and disclosure support and bi-weekly phone calls to mothers to provide VL counseling and follow up
41498239|NCT06077383|DIETARY_SUPPLEMENT|Weizmania Coagulans BC99|Probiotics group subjects take probiotics every day for 8 weeks.
41360183|NCT05067387|DRUG|THC|Oral THC (20 mg)
41360184|NCT05067387|DRUG|CBD|Oral CBD (20 mg)
41498240|NCT05389631|OTHER|no intervention|no intervention
41360185|NCT05067387|DRUG|THC + CBD|Oral THC (20 mg) + CBD (20 mg)
41360186|NCT00005066|DRUG|O6-benzylguanine|
41360187|NCT00005066|DRUG|carmustine|
41360188|NCT06261216|OTHER|Interview|"* International Physical Activity Questionnaire (IPAQ-SF)~* interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form"
40840098|NCT01300260|DRUG|Glucose|Administered intravenously
41360189|NCT00557362|DRUG|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
40840099|NCT01300260|DRUG|Glucagon|Administered intravenously
41360190|NCT00557362|DRUG|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
41498241|NCT05808920|GENETIC|Molecular Analyses|Nucleic acid extraction, protein analysis. Tumour tissue, blood and saliva samples collected.
41498242|NCT00772421|DEVICE|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
41498243|NCT01753297|DRUG|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
41498244|NCT00397774|BEHAVIORAL|Physical exercise|Physical exercise twice a week for 8 weeks, and best supportive care
40840100|NCT01958853|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
41360191|NCT00557362|PROCEDURE|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
41360192|NCT01226186|BEHAVIORAL|Nurse dispensed oral morphine.|Nurse will dispense oral morphine on request from the patient.
41360193|NCT01226186|BEHAVIORAL|Patient self medication of oral morphine.|Patients will self medicate their oral morphine pain control solution following surgery.
41360194|NCT02812550|PROCEDURE|colonoscopy procedure|endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
41498245|NCT00397774|OTHER|best supportive care|
41498246|NCT02704403|DRUG|Elafibranor|
41498247|NCT02704403|DRUG|Placebo|
41498248|NCT01507363|DRUG|Gabapentin|Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
40840101|NCT00028886|BIOLOGICAL|filgrastim|
40840102|NCT00028886|BIOLOGICAL|recombinant interferon alfa|
40840103|NCT00028886|DRUG|cyclophosphamide|
41498249|NCT01507363|DRUG|Gabapentin|Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
41498250|NCT01507363|DRUG|Placebo|Placebo tablets for 7 days, starting on the day of surgery
41498251|NCT05183152|DEVICE|NMES Feedback|Electroencephalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to trigger electrical stimulation on the flexors/extensors of the targeted arm contingent to the detection of a subject-specific flexion/extension EEG patterns.
40840104|NCT00028886|DRUG|dexamethasone|
40840105|NCT00028886|DRUG|doxorubicin hydrochloride|
40840106|NCT00028886|DRUG|melphalan|
40840107|NCT00028886|DRUG|thalidomide|
40840108|NCT00028886|DRUG|vincristine sulfate|
40840109|NCT00028886|PROCEDURE|bone marrow ablation with stem cell support|
40840110|NCT00028886|PROCEDURE|peripheral blood stem cell transplantation|
40840111|NCT05199961|BEHAVIORAL|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
40840112|NCT00309062|BIOLOGICAL|Recombinant birch pollen|
41360195|NCT00424463|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
41360196|NCT00424463|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
41360197|NCT01513460|DRUG|NVA237 50µg once daily|NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
41360198|NCT01513460|DRUG|Tiotropium 18µg once daily|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
41360199|NCT01513460|DRUG|Flu/Sal|Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
41360200|NCT01513460|DRUG|NVA237 placebo + Tiotropium placebo.|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
41360201|NCT00694239|BEHAVIORAL|Knowledge of Cardiovascular Risk Assessment|Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
41360202|NCT04419558|DRUG|Pamrevlumab|Sterile solution for injection
41360203|NCT04419558|DRUG|Placebo|Sterile solution for injection
41360204|NCT00475579|PROCEDURE|tube with subglottic drainage and polyurethane cuff|
41360205|NCT00461851|DRUG|Gemcitabine|Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
41360206|NCT00461851|DRUG|Carboplatin|Carboplatin will be given on day 1 to an AUC of 5.
41360207|NCT00461851|DRUG|Sorafenib|Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
41360208|NCT00845299|DRUG|Latanoprost punctal plug|Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.
41360209|NCT00845299|DRUG|artificial tears preserved with Benzalkonium Chloride|
41360210|NCT02404324|OTHER|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
41360211|NCT04846543|OTHER|MRI Scan|MRI scan
41360212|NCT04378049|PROCEDURE|Total knee arthroplasty|Surgeon will perform a total knee arthroplasty procedure according to local standard of care
41360213|NCT04378049|PROCEDURE|Robot-assisted partial knee arthroplasty|Surgeon will perform a robot-assisted unicompartmental or bicompartmental knee arthroplasty procedure
41360214|NCT02600715|DRUG|Onabotulinumtoxin A (BoNT)|
41360215|NCT02600715|DRUG|belladonna|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
41360216|NCT02600715|DRUG|Morphine|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
40840113|NCT00651625|DEVICE|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
40840114|NCT00651625|DEVICE|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
41360217|NCT02600715|DRUG|Placebo|matching placebo to B\&O suppository
41360218|NCT02600715|DRUG|Active B&O suppository of belladonna|belladonna 16.2mg and morphine 7.5mg
41360219|NCT01404689|DRUG|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
41360220|NCT01404689|OTHER|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
41360221|NCT02587845|DRUG|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
41360222|NCT02587845|DRUG|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
41360223|NCT00361504|DRUG|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
41360224|NCT00361504|DRUG|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
41360225|NCT02430298|DRUG|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
41360226|NCT02430298|DRUG|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
40840115|NCT06508229|DRUG|Adebrelimab|adebrelimab, IV
40840116|NCT06508229|DRUG|albumin paclitaxel|albumin paclitaxel, iv
40840117|NCT06508229|DRUG|Nedaplatin|Nedaplatin，IV
40840118|NCT05713539|OTHER|Metal block|Small sheet of copper will be used when cooled to the designated temperature
40840119|NCT00828152|BEHAVIORAL|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
41360227|NCT01724021|DRUG|Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Standard chemotherapy
41360228|NCT01724021|DRUG|Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Standard chemotherapy
41360229|NCT01724021|DRUG|Bendamustine|Standard chemotherapy
41360230|NCT01724021|DRUG|Rituximab|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
41360231|NCT01724021|DRUG|Rituximab|375 mg/m2 IV, Day 1 Cycles 1-4
41360232|NCT01724021|DRUG|Rituximab|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
41360233|NCT01724021|DRUG|Rituximab|1400 mg SC, Day 1 Cycles 5-8
41360234|NCT00266799|DRUG|Pegylated liposomal doxorubicin (SCH 200746)|pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
41360235|NCT00266799|DRUG|Capecitabine|capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
41360236|NCT02561572|OTHER|Acupuncture|Yintang point acupuncture
41360237|NCT06203028|BEHAVIORAL|Cyberbullying Awareness Training|The 'Cyberbullying Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours. The training program will be implemented in line with the headings 'Definition of cyberbullying, Cyberbullying tools and practices, Case studies on cyberbullying, Causes of cyberbullying, Academic, social, psychological and physical effects of cyberbullying, Coping strategies with cyberbullying'.
41360238|NCT01392079|DRUG|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
41360239|NCT03907085|OTHER|HILT + exercise|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
41360240|NCT03907085|OTHER|Placebo HILT + exercise|Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
41360241|NCT00702637|DRUG|Modafinil|
41498252|NCT05183152|DEVICE|Visual Feedback|Electroencephalography (EEG) - recorded from subjects as they perform cued motor imagery (MI) tasks - are classified in real-time using a subject-specific BCI decoder,. The output classification probability of the decoder is accumulated using exponential smoothing and translated into continuous visual feedback by means of a bar - on a computer screen - that moves to the right or left in response to classification of one or the other MI task.
41498253|NCT05183152|DEVICE|TESS|Transcutaneous Electrical Spinal Stimulation (TESS) is applied over the C5-C6 spinal segment for 20 minutes at 30Hz with 5kHz carrier frequency.
41024573|NCT00917046|BEHAVIORAL|Moderate continuous training|3 weekly sessions of moderate continuous training for 12 weeks
41360242|NCT00062972|DRUG|donepezil|
41360243|NCT00062972|DRUG|glucose|
41360244|NCT03218943|DEVICE|APRV ventilation mode|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours
41360245|NCT03218943|DEVICE|BIPAP ventilation moood|start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours
40840120|NCT00828152|BEHAVIORAL|On line discussion group|Placebo. On line discussion group.
40840121|NCT01722292|DRUG|LY2940680|Administered orally
40840122|NCT01722292|DRUG|Carboplatin|Administered IV
40840123|NCT01722292|DRUG|Etoposide|Administered IV
40840124|NCT01722292|DRUG|Placebo|Administered orally
41024574|NCT00917046|BEHAVIORAL|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
40840125|NCT00708760|BEHAVIORAL|paper based training|read selected material, test skills learned in simulator lab
41024575|NCT01717235|DRUG|Ropinirole hydrochloride CR Tablets 2mg|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
41024576|NCT04848285|OTHER|Early Mobilization|Additional 2 or more sessions of out-of-bed activity to the standard stroke care, focused in active sitting, standing and walking assisted by physiotherapists
41360246|NCT04054050|OTHER|Light therapy|Bright light (10,000 lux) therapy will be administered via a light box.
41360247|NCT00696774|DRUG|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
41360248|NCT04536181|DRUG|Prednisolone|12 weeks prednisolone treatment
41360249|NCT04536181|DRUG|Placebo|12 weeks simulated tablets
41360250|NCT00034606|DRUG|Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)|
41498254|NCT04856410|OTHER|Spaceflight|Exposure to the spaceflight environment on the International Space Station for 2, 6, or 12 months.
41498255|NCT04856410|OTHER|Controls|No intervention
41498256|NCT03612557|DRUG|penicillin G benzathine|2.4 million units (IM) of benzathine benzylpenicillin
41498257|NCT03552068|DRUG|placebo|"Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.~Medication: placebo twice a day (in the morning and evening)."
41498258|NCT03552068|DRUG|Clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).
40840126|NCT00708760|BEHAVIORAL|web based training|read and view selected web based material, test skills learned in simulator lab
40840127|NCT02265796|DRUG|Ranolazine|"Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
40840128|NCT02265796|DRUG|Sugar pill|"1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
40840129|NCT04403243|DRUG|Colchicine|0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight \< 86 kg or 0.5mg twice a day per os if weight \> 85kg for seven days.
40840130|NCT04403243|DRUG|Ruxolitinib 5 MG|Ruxolitinib - 5mg twice a day per os for ten days
41360251|NCT05914480|OTHER|PCR for legionella ,blood ,urine cultures and from catheters or source of infection|Investigations to detect cause of sepsis as blood cultures ,urine cultures and from catheters .also PCR for legionella will be done
40840131|NCT04403243|DRUG|Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Secukinumab - 300mg subcutaneously singly
41024577|NCT04848285|OTHER|Standard care|Standard protocol of mobilization in acute stroke patients admitted to the Stroke Unit at the discretion of the nursing and physiotherapy staff
41024578|NCT00210652|DRUG|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
41024579|NCT03468439|OTHER|Femoral nerve block with phenol|
41360252|NCT03039699|DRUG|Ergoferon|
41024580|NCT06534073|DEVICE|Socks|Plantar orthotic elements will be designed, according to the participants' previous baropodometric pattern, to alleviate pathological plantar pressure. These elements will be integrated into commonly worn items by patients, such as stockings or socks.
41024581|NCT06534073|DEVICE|Standard device|Removable device of digital alignment to stabilize and unload the affected metatarsophalangeal joint. They do not require frequent replacement as they are washable and reusable elements.
41024582|NCT06534073|DEVICE|Foot orthoses|Custom-made foot orthoses.
41024583|NCT06535282|OTHER|surgery|Surgical treatment of conductive hearing loss with tinnitus
41024584|NCT00297453|BEHAVIORAL|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
41360253|NCT03039699|DRUG|Placebo|
41360254|NCT04105231|DRUG|Cannabidiol|Cannabidiol oral suspension
41024585|NCT00297453|BEHAVIORAL|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
41024586|NCT00297453|BEHAVIORAL|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
41024587|NCT02649686|DRUG|Durvalumab|
41024588|NCT02649686|DRUG|Trastuzumab|
41024589|NCT06346561|DRUG|Dexmedetomidine|the reduction of controlled hypotension and the control of hemodynamic responses of the body
41024590|NCT06346561|DRUG|Labetalol|the reduction of controlled hypotension and the control of hemodynamic responses of the body
41360255|NCT04105231|DRUG|Risperidone|Risperidone, encapsulated tablet.
41360256|NCT00967811|DRUG|Formulation E1 of L-PPDS|Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
41360257|NCT00967811|DRUG|Formulation E2 of L-PPDS|Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
41360258|NCT05804344|DEVICE|Anodal speech motor tDCS|tDCS montage set for Anode: C5; Cathode: Fp2
40840132|NCT04403243|OTHER|standard therapy|standard therapy for COVID 19
40840133|NCT02659319|BEHAVIORAL|Family Lifestyle (FL)|12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
41024591|NCT03049059|DEVICE|Fractional Picosecond 1,064 nm laser|Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
41024592|NCT03049059|DRUG|4% hydroquinone cream|
41024593|NCT01343706|DRUG|Placebo|Solution for oral administration
41024594|NCT01343706|DRUG|Placebo|Immediate release solid oral dosage (film-coated tablet)
41024595|NCT01343706|DRUG|BI 409306|Immediate release solid oral dosage (film-coated tablet)
41024596|NCT01343706|DRUG|BI 409306|solution for oral administration
41024597|NCT01462344|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
41024598|NCT01462344|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
41360259|NCT05804344|DEVICE|Cathodal speech motor tDCS|tDCS montage set for Anode: Fp2; Cathode: C5
41360260|NCT05804344|DEVICE|Anodal IFG tDCS|tDCS montage set for Anode: F3; Cathode: Fp2
41360261|NCT05804344|DEVICE|Cathodal IFG tDCS|tDCS montage set for Anode: Fp2; Cathode: F3
41360262|NCT05804344|DEVICE|Sham tDCS|tDCS device set in Sham mode
41360263|NCT00499733|DRUG|cyclophosphamide|500 mg/m\^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
40840134|NCT02659319|BEHAVIORAL|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
40840135|NCT02659319|BEHAVIORAL|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
40840136|NCT00701805|DRUG|Paricalcitol|Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
40840137|NCT02411929|DRUG|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
41024599|NCT01462344|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
41024600|NCT01462344|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
41024601|NCT02421991|BEHAVIORAL|Telephone Delivered Intervention|
41360264|NCT00499733|DEVICE|Cryoablation|Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
41360265|NCT02275559|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
41360266|NCT02275559|BEHAVIORAL|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
41360267|NCT03144596|DRUG|Alfuzosin Hydrochloride 10 MG|Alfuzosin hydrochloride Tablet
41360268|NCT03144596|DRUG|Tamsulosin Hydrochloride 0.4 MG|Tamsulosin Hydrochloride Tablet
41360269|NCT02896972|PROCEDURE|Vitrectomy|Vitrectomy with inverted ILM technique or ILM peeling
41360270|NCT02791841|BEHAVIORAL|Rhythmic Reading Training|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
41360271|NCT02791841|BEHAVIORAL|Visual Hemispheric-Specific Stimulation + Action Video Games|"This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).~AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used."
41360272|NCT02791841|BEHAVIORAL|Action Video Games|AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
41360273|NCT00709813|BEHAVIORAL|Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))|Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
41360274|NCT05321264|BEHAVIORAL|Educational nursing intervention|Four weekly individualized intervention sessions, with a duration of 40 minutes.
41360275|NCT03389490|DRUG|Insulin Glargine 300 UNT/ML|Self titration of insulin glargine U300
41360276|NCT03389490|DRUG|Neutral protamine hagedorn insulin|Self titration of NPH insulin
41024602|NCT02810535|OTHER|Observation|"Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE"
41024603|NCT04861649|BIOLOGICAL|fecal microbiota transplantation|"The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
41024604|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain Plus dexamethasone|Bupivacain 0.1%, 35 ml with dexmedetomidine 0.5 µG/kg on each side
41024605|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain|plain bupivacaine 0.25%, 25 ml bilaterally
41360277|NCT01385098|DIETARY_SUPPLEMENT|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
41360278|NCT03919682|OTHER|Experimental: Training, Phase 1|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
40840138|NCT02411929|DRUG|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
40840139|NCT02411929|DRUG|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
40840140|NCT02424045|DRUG|BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)|All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
41024606|NCT03728582|DEVICE|Active tDCS plus Speech-Language Therapy|1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
41360279|NCT03919682|OTHER|Experimental: Training, Phase 2|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
41360280|NCT01156857|DRUG|PGL4001, placebo|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
41360281|NCT01156857|DRUG|PGL4001, progestin|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
41360282|NCT04179266|DRUG|Ketamine|One Cluster headache attack is treated with intranasal ketamine
40840141|NCT05807685|BEHAVIORAL|laughter therapy|Description: Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researchers who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
40840142|NCT02984449|BEHAVIORAL|Pre+post-operative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
40840143|NCT02984449|BEHAVIORAL|Postoperative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
41360283|NCT00551629|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
41360284|NCT00551629|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
41360285|NCT00551629|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
41360286|NCT00551629|BIOLOGICAL|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
41360287|NCT01922466|PROCEDURE|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol~- Increment Protocol as~* 1st week - SC 0.2cc/day, 2 days/week~* 2nd week - SC 0.4cc/day, 2 days/week~* 3nd week - SC 0.8cc/day, 2 days/week"
41360288|NCT01922466|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
41360289|NCT05365256|BEHAVIORAL|Standard distraction during chemotherapy treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care
41360290|NCT05365256|BEHAVIORAL|Virtual distraction during chemotherapy treatment period|A virtual reality headset will be worn for 15 minutes per hour of treatment
41360291|NCT05411705|DRUG|rhTPO|rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10\^9/L or when the platelet count rises to ≥250×10\^9/L.
41360292|NCT05411705|DRUG|Control|Non-rhTPO treatment
41360293|NCT03513575|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink without any intervention.
41360294|NCT03513575|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
41360295|NCT03513575|OTHER|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
41360296|NCT03513575|OTHER|Group 4: Fluoridated tooth paste|The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
41360297|NCT03513575|OTHER|Group 5: Polyol containing gum|The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.
41360298|NCT03513575|OTHER|Group 6: 1% sodium bicarbonate solution|The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
41360299|NCT01238757|OTHER|Non-invasive Ventilation under Pressure Support|"Non-invasive Ventilation under Pressure Support:~15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order"
41360300|NCT01238757|OTHER|Non-Invasive ventilation under NAVA|20 min session under non-invasive ventilation with NAVA
41360301|NCT01373294|DRUG|Bacille Calmette-Guerrin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
40840144|NCT02800265|DIETARY_SUPPLEMENT|Avmacol|Avmacol is an over-the-counter mixture of broccoli seed and sprout extracts in tablet form to promote detoxification. These tablets contain natural substances that stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke.
40840145|NCT05553418|DEVICE|In-clinic wear first|Participant will remain in clinic and wear devices adhered on abdomen or arm approximately 27hrs prior to injection
41498259|NCT02064985|DRUG|"Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)"|To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
41498260|NCT03103139|PROCEDURE|Transpapillary Stent|ERCP with placement of short stent
41498261|NCT03103139|PROCEDURE|Stent across bile leak|ERCP with long stent
41498262|NCT04608123|OTHER|none (observational study)|DBS
41498263|NCT02281292|BIOLOGICAL|LKA651 ophthalmic solution|
41498264|NCT02281292|BIOLOGICAL|Ranibizumab ophthalmic solution|
41498265|NCT02281292|BIOLOGICAL|Sham injection|Mock injection administered as an empty hub without needle
41498266|NCT04591951|BEHAVIORAL|I2-ART|Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
41360302|NCT01373294|DRUG|Lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
41360303|NCT05563441|PROCEDURE|laparoscopic surgery|Patients over 70 years old underwent laparoscopic or laparotomic colorectal resection were enrolled.
41360304|NCT00491062|PROCEDURE|Biopsies|
41360305|NCT00027846|BIOLOGICAL|filgrastim|Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC \>1500/μl given subcutaneously or intravenously.
41360306|NCT00027846|DRUG|carboplatin|Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA \<0.45m2 the dose is 12.5 mg/kg/day.
40840146|NCT05553418|DEVICE|Home wear first|Device will be applied to the abdomen or arm to deliver placebo subcutaneously. After device application, participant will go home and return to clinic before delivery.
40840147|NCT05737719|BEHAVIORAL|Rehabilitation before knee surgery (prehab)|Physiotherapy strategies for preparing the patient awaiting the surgical procedure
41360307|NCT00027846|DRUG|cyclophosphamide|Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA\<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
41360308|NCT00027846|DRUG|etoposide|Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA \< 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
41360309|NCT00027846|DRUG|vincristine sulfate|Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA\<0.45m2 the dose is 0.05mg/kg.
41360310|NCT00027846|RADIATION|radiation therapy|Given once daily 5 days a week for 6-6½ weeks
41498267|NCT04591951|OTHER|Usual care|Care as usual
41498268|NCT06227572|BEHAVIORAL|CATNAP MI|"Three motivational interviewing (MI) sessions will be facilitated by trained MI staff and will focus on improving participants' knowledge about their OSA diagnosis, understanding of sleep health, and increasing PAP use. Sessions will also provide information about health benefits associated with good sleep and will help participants create an action plan regarding their PAP use and indicators of success, when appropriate.~Electronic messaging will be standardized for frequency and content but personalized to participants' preferred mode of delivery. Messages will focus on PAP adherence or non-adherence."
41498269|NCT00001049|DRUG|Zidovudine|
41498270|NCT00001049|DRUG|Didanosine|
41498271|NCT04934410|DRUG|Etomidate|Use of etomidate during induction as decided by attending anesthesiologist
41498272|NCT04934410|DRUG|Midazolam|Use of midazolam during induction as decided by attending anesthesiologist
41498273|NCT04934410|DRUG|Sevoflurane|Use of sevoflurane during induction as decided by attending anesthesiologist
41498274|NCT05328635|DRUG|Candesartan|Multdisciplinary approach
41498275|NCT05984979|OTHER|Standardized meal|The participants will receive a standardized meal for breakfast
41498276|NCT04423185|DRUG|Almonertinib 110 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.
41498277|NCT04423185|DRUG|Dacomitinib 45 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.
41498278|NCT04423185|DRUG|Alectinib 150 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.
40840148|NCT05737719|BEHAVIORAL|Post-surgery rehabilitation|Physiotherapy strategies to manage post-surgery recovery
41498279|NCT04423185|DRUG|Crizotinib 250 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
41498280|NCT04423185|DRUG|Pyrotinib 160/80 MG|Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.
41498281|NCT04423185|DRUG|Imatinib 400 MG|Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.
40840149|NCT01110382|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
40840150|NCT01110382|DRUG|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
40840151|NCT01110382|DRUG|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
41498282|NCT04423185|DRUG|Niraparib 200/300 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.
41024607|NCT03728582|DEVICE|Sham tDCS plus Speech-Language Therapy|Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
41024608|NCT02453789|DRUG|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
41024609|NCT02453789|DRUG|Placebo|
41024610|NCT03111498|OTHER|practice-based training programme (one-to-one teaching)|practice-based training programme (one-to-one teaching) for conducting VAD
41360311|NCT00027846|DRUG|Mesna|Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA\<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
41360312|NCT00027846|PROCEDURE|therapeutic conventional surgery|
41360313|NCT02746276|DRUG|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
40840152|NCT01110382|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
40840153|NCT01110382|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
40840154|NCT01716104|DRUG|Afalaza|Safety and Efficacy
40840155|NCT01716104|DRUG|Placebo|Safety and Efficacy
41498283|NCT04423185|DRUG|Palbociclib 125mg|Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
41498284|NCT04423185|DRUG|Vemurafenib 240 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.
41498285|NCT04423185|DRUG|Sintilimab 100MG|Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
40840156|NCT01152177|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
40840157|NCT02530996|DRUG|BH4|BH4 10 mg/kg/day given once to a total of 12 SSc patients
40840158|NCT02530996|DIAGNOSTIC_TEST|Vasculopathy assessment|Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
41024611|NCT03111498|OTHER|theory-based training programme|theory-based training programme for conducting VAD
41024612|NCT04689828|DRUG|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
40840159|NCT02530996|DRUG|Placebo|On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.
41360314|NCT02746276|DRUG|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
41360315|NCT03040063|PROCEDURE|Combined endovascular approach (EVAR)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Heparin 70-80 IU/kg i.a.~5. implantation of peripheral stent graft VIABAHN~6. implantation of peripheral stent SUPERA into stent graft~7. insertion of strait flush catheter for local thrombolysis~8. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~9. control angiography in 12 hrs or earlier according to clinical status and symptoms~10. repeated angiography in 24 hrs"
41498286|NCT04423185|DRUG|Atezolizumab 1680 MG|Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
41498287|NCT06632561|DRUG|Empagliflozin 10 mg|Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months
41498288|NCT06632561|DRUG|Placebo|Sugar pills one tablet daily for 6 months
41498289|NCT04075591|DEVICE|iDesign Refractive Studio with STAR S4 IR® Excimer laser System|Surgeons will perform wavefront-guided monovision LASIK for the treatment of myopic subjects with presbyopia based upon measurements obtained with an iDesign Refractive Studio.
41498290|NCT01704794|DIETARY_SUPPLEMENT|Folic Acid + Paludrine + Jobelyn (500mg)|Combination of routine drugs + Jobelyn
41498291|NCT01704794|DRUG|Folic Acid + Paludrine + Jobelyn (250mg)|Standard routine drugs for treatment of SCD with 250mg Jobelyn
40840160|NCT06040281|BEHAVIORAL|intensive individual support in nutrition and exercise|"Intensive care for nutrition and exercise adapted to the social context. Individualised exercise and nutrition recommendations.~three weeks of inpatient rehabilitation with an individual plan of treatment, which includes medical care, sports therapy, physiotherapy, ergotherapy, nutritional education and psychological care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)"
40840161|NCT06040281|BEHAVIORAL|Usual Care|Usual care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)
41498292|NCT01704794|DIETARY_SUPPLEMENT|Folic Acid + Paludrine + Jobelyn (2mg)|Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
41498293|NCT00301093|BIOLOGICAL|GM-K562 cell vaccine|Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations
40840162|NCT06394453|OTHER|enteral feeding with mother milk or human donor breast milk|The experimental group will start enteral feeding with mother milk or human donor breast milk if mother milk is not accesible during the first day of therapeutic hypothermia.
40840163|NCT03048760|OTHER|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans \& 1 after approx. 2 weeks of radiotherapy treatment.
41360316|NCT03040063|PROCEDURE|Standard optimal therapy (OPT)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Unfractionated heparin 70-80 IU/kg i.a.~5. insertion of strait flush catheter for local thrombolysis~6. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~7. control angiography in 12 hrs or according to clinical status and symptoms~8. repeated angiography in24 hrs~9. Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
41360317|NCT00003855|PROCEDURE|axillary lymph node dissection|
41360318|NCT00003855|RADIATION|whole breast irradiation|
41360319|NCT04282343|BEHAVIORAL|The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
41360320|NCT04282343|BEHAVIORAL|Usual Care|Patients randomized to this arm will receive usual care.
41360321|NCT01335360|DRUG|Nevirapine|200mg twice daily of nevirapine
41360322|NCT03537417|PROCEDURE|for thoracoscopic ablation of cervical sympathetic chain|bilateral thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
41360323|NCT06183060|PROCEDURE|endotracheal intubation|all patients will receive laryngoscopy and endotracheal intubation
41360324|NCT06201884|DEVICE|Early rehabilitation through Adapted Physical Activity|From the day after surgery, 1 to 2 walking sessions with walking platform, lasting 6 to 30 minutes (min-max), will be proposed daily until the day of discharge.
41498294|NCT00301093|DRUG|imatinib mesylate|Participants will continue on current dose
41498295|NCT02114476|DEVICE|progestin implant|two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix
40840164|NCT03729245|BIOLOGICAL|bempegaldesleukin|Specified dose on specified days
40840165|NCT03729245|DRUG|sunitinib|Specified dose on specified days
40840166|NCT03729245|BIOLOGICAL|nivolumab|Specified dose on specified days
40840167|NCT03729245|DRUG|cabozantinib|Specified dose on specified days
40840168|NCT05633329|PROCEDURE|single level|injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)
40840169|NCT05633329|PROCEDURE|dual level|injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)
40840170|NCT02048371|DRUG|Regorafenib|Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
40840171|NCT02048371|DRUG|Placebo|21 days on and 7 days off
40840172|NCT04631653|DEVICE|VeriSee®|Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®
40840173|NCT05941832|DEVICE|ANNE Chest Sensor|Wearing ANNE Chest Sensor for 6 weeks
41024613|NCT04689828|DRUG|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
41024614|NCT04689828|DRUG|ARDT|administered orally on a continuous basis, as per package insert and guidelines
41024615|NCT04689828|OTHER|Best supportive care|Best supportive/best standard of care as defined by the local investigator
41498296|NCT02114476|DEVICE|Placebo|
41498297|NCT00372151|DIETARY_SUPPLEMENT|L-Theanine|400 mg/day, caps.
41498298|NCT00372151|OTHER|Placebo|caps.
41498299|NCT06173778|DRUG|semaglutide 2.4mg|Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
41360325|NCT04071028|PROCEDURE|warm-water footbath|"All the participants in the intervention group were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
40840174|NCT04780789|PROCEDURE|Transarterial Chemoembolization|A contrast agent (Xenetix350, Guerbet, France) was applied under local anaesthesia via the common femoral artery using a 5F sheath. Selective catheterization of the coeliac trunk and other arteries supplying the liver was then performed under fluoroscopic control. A pathological vascularization pattern was identified and chemoembolization material consisting of DC beads (BTG International Ltd) was injected by the treating angiographist using micro instrumentation. Follow-up CT or MRI was performed after 1-3 TACE sessions according to the extent of the lesion, 3 weeks following the last procedure. Patients with completed treatments were scheduled for an imaging follow-up every 3 months, allowing evaluation of the effect of treatment. In case of a positive response to the treatment another session of TACE was indicated. Chemoembolization sessions were performed as inpatient procedures with the mean hospitalization time of 4 days.
40840175|NCT04677153|OTHER|Test and treat plus peer mentors|Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.
40840176|NCT04677153|OTHER|Usual care|Participants are referred to another location for HCV treatment.
40840177|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
40840178|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
41360326|NCT05034029|DRUG|Metformin hydrochloride sustained release tablets|Oral
41360327|NCT05034029|DRUG|Placebo|Placebo
41360328|NCT00372580|PROCEDURE|blood test|
41360329|NCT01866839|DEVICE|Graft Manipulation (CD34+ Selection)|
41360330|NCT03187626|DRUG|botulinum toxin A|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
41360331|NCT03187626|DRUG|saline|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
41360332|NCT00784680|DRUG|Anastrozole|1mg, orally, once daily
41360333|NCT00784680|DRUG|Tamoxifen|20mg, orally, once daily
41498300|NCT06173778|DRUG|Placebo|Non-active medication, self-administered
40840179|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
40840180|NCT01143194|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo twice a day
40840181|NCT04893499|BEHAVIORAL|Chios mastic water|Participants randomized to this intervention arm will be provided with a sparkling water enriched with the natural mastic aqueous extract (0.06%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
40840182|NCT04893499|BEHAVIORAL|Placebo water|Participants randomized to this intervention arm will be provided with a standard sparkling water and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
40840183|NCT04893499|BEHAVIORAL|Chios mastic fruit juice|Participants randomized to this intervention arm will be provided with a sparkling fruit juice enriched with the natural mastic aqueous extract (0.55%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
40840184|NCT04893499|BEHAVIORAL|Placebo fruit juice|Participants randomized to this intervention arm will be provided with a standard sparkling fruit juice and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
41360334|NCT00411229|DRUG|Capecitabine|1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
41360335|NCT00411229|DRUG|Oxaliplatin|IV infusion, 130mg/m²
41360336|NCT04917536|PROCEDURE|Humeral neailling in humeral fractures|Humeral neailling in humeral fractures
41360337|NCT03942536|OTHER|Focus Group Discussion|At 12-month follow-up, a purposeful, convenience sample of study participants and their significant others, Community Health Workers trained as Health Navigators, and local program staff, will be invited by research staff to participate in focus group discussions to collect qualitative data on pregnancy care, experience of navigating obstetrical emergencies, financial hardships, and Health Navigation program feasibility/acceptability. Particular attention will be paid to recruiting study subjects involved in complex obstetrical emergencies, cases that involved significant delays in transfer of care, cases resulting in significant morbidity/mortality, as well as cases that involved efficient/successful care coordination, referral, and transportation.
41360338|NCT00724594|DRUG|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
41360339|NCT00724594|DRUG|Control|Saline was given in the same volume, at the same timing as NAC infusions
41498301|NCT06173778|DRUG|Nicotine Replacement Therapy (NRT, nicotine patch)|Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
41498302|NCT06173778|BEHAVIORAL|Brief Smoking Cessation Counseling|Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
40840185|NCT00249613|BEHAVIORAL|Women-Only|Gender-responsive treatment for women only
41498303|NCT03881423|DRUG|Rocuronium Bromide|DEEP block to PTC 1-3
40840186|NCT01096511|DRUG|Moxifloxacin (Avelox, BAY12-8039)|The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
40840187|NCT05190055|DEVICE|bone graft delivery system/wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. In the case of the device group, a novel filler tube with an integrated threaded rod, which can be connected to a surgical drill, A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
40840188|NCT05190055|DEVICE|wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. For the control group, the bone substitutes were filled in the disc space manually using a bone grafting funnel. A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
40840189|NCT06546488|BEHAVIORAL|Assessments|A standardized assessment battery will be administered. It will consist of cognitive, functional and motor assessments.
40840190|NCT02228096|BIOLOGICAL|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10\^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10\^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg).
40840191|NCT00849862|DRUG|Levetiracetam|750 mg Tablet
40840192|NCT00849862|DRUG|Keppra®|750 mg Tablet
40840193|NCT03442296|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner (if applicable)
40840194|NCT03442296|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
40840195|NCT03113604|OTHER|Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma|"Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib"
40840196|NCT03234491|DEVICE|DiAS|Diabetes Assistant (DiAS) hybrid closed loop system.
40840197|NCT03234491|DRUG|Afrezza low dose|Afrezza inhaled insulin low dose.
40840198|NCT03234491|DRUG|Afrezza high dose|Afrezza inhaled insulin high dose.
40840199|NCT05406609|OTHER|Cost|Costs of operating room, drugs and equipments which are used by anesthesia
40840200|NCT05406609|OTHER|Time|Time of using operating room
40840201|NCT03035682|OTHER|Augmented Media Group|The intervention group will receive traditional PT services deemed clinically appropriate via examination plus home exercise prescription augmented via a mobile health application. The augmented media group will receive digital exercise prescription via a mobile health application source (Physitrack) that includes: high definition video and pictures, education material and written instruction, reminder notification and in-app logging of completion.
40840202|NCT03035682|OTHER|Traditional Group|The Traditional Group will receive traditional PT services deemed clinically appropriate via examination plus traditional home exercise prescription.
40840203|NCT04506203|DIAGNOSTIC_TEST|Air test|Patients will breathe 0.21 \< FiO2 \< 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.
40840204|NCT04953624|DIAGNOSTIC_TEST|Appetite rating scale CNAQ|Chinese version of Appetite rating scale CNAQ
40840205|NCT03474783|BEHAVIORAL|Health education|Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
40840206|NCT02325297|OTHER|Letter of condolence|
40840207|NCT02186704|DEVICE|ICD with DX system|Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
40840208|NCT03712111|DRUG|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
40840209|NCT03712111|DRUG|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
41498304|NCT04544410|DRUG|Tildacerfont/Placebo|Tablet, administered daily
41360340|NCT04218942|DEVICE|Exime is the name of the single use temporary prostatic stent used instead of the Foley catheter|"Insertion after instillation of a local lubricant anesthetic gel in the urethra like for Foley insertion. Calibration of the urethral meatus with a 22F Bougie. Insertion of the Bougie until abutment against the posterior wall of the bulbous urethra just below the striated sphincter. Note depth of abutment on the scale of the Bougie. Retrieve the Bougie and glide the device to the same depth until abutment against the posterior wall of the bulbous urethra. At this stage the stent is correctly positioned. Stent release: unlock the Luer connection between pusher tube and stylet . Retrieve pusher tube, stylet and flattener tube.~Control of correct positioning: ask patient to stand up to verify the absence of any urine leak. Ask patient to void immediately to control clear urine output."
40840210|NCT03712111|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
40840211|NCT03712111|DRUG|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block
40840212|NCT01387724|GENETIC|RNA analysis|
40840213|NCT01387724|GENETIC|polymerase chain reaction|
40840214|NCT01387724|GENETIC|protein expression analysis|
40840215|NCT01387724|GENETIC|proteomic profiling|
40840216|NCT01387724|GENETIC|western blotting|
40840217|NCT01387724|OTHER|enzyme-linked immunosorbent assay|
41024616|NCT02596724|OTHER|Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue
41360341|NCT03474172|DEVICE|Cloak Shape Device for Sham Tuina|The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated
41360342|NCT03474172|DEVICE|Cloak Shape Device for Genuine Tuina|The Cloak Shape Device for Genuine Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a genuine Tuina will be manipulated.
41360343|NCT01222767|DRUG|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
41360344|NCT02405676|DRUG|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
41360345|NCT02405676|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
41360346|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
41360347|NCT02405676|DRUG|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
41360348|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
41360349|NCT02405676|DRUG|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
41360350|NCT06170359|PROCEDURE|robotic surgery under general anaesthesia|During robotic surgery, the standard 45-degree upright Trendelenburg position and for postoperative analgesia, 0.06 mg/kg morphine, 1 gram (g) paracetomol and 8 mg onasetron are administered iv to all patients 30 minutes before the end of the operation. At the end of surgery and after extubation, patients are taken from the recovery unit to the service. In the service, all patients are given paracetamol 1g every 8 hours and tenoxicam 20 mg every 24 hours for pain treatment. Tramadol 1 mg/kg iv is administered as rescue analgesic to patients with a VAS score \>4.
40840218|NCT01387724|OTHER|immunohistochemistry staining method|
40840219|NCT01387724|OTHER|laboratory biomarker analysis|
40840220|NCT01387724|OTHER|liquid chromatography|
40840221|NCT01387724|OTHER|mass spectrometry|
40840222|NCT01676623|BEHAVIORAL|Standard government health services|This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.
40840223|NCT01676623|BEHAVIORAL|Alive & Thrive IYCF franchise services|This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.
40840224|NCT01676623|BEHAVIORAL|Mass media campaign|Alive \& Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
40840225|NCT00007267|BEHAVIORAL|Cognitive behavioral therapy|
40840226|NCT00007267|BEHAVIORAL|Disease/health education|
40840227|NCT00007267|BEHAVIORAL|Self-help cognitive behavioral intervention facilitated by a psychologist|
41024617|NCT04457648|DEVICE|manuka honey 16% eye drops ( Optimel )|16% manuka honey eye drops, australian FDA approved
41024618|NCT04457648|DEVICE|systane eye drops|systane lubricant eye drops
41024619|NCT06341244|DEVICE|Air Stacking Technique|To perform the air stacking technique, an air manual breathing unit (AMBU) was used, attached to a unidirectional valve and nasal/oral mask. For each AMBU manual compression (three in the total), the patient was instructed to breathe in deeply and hold the air inside the lungs.
41024620|NCT01621360|PROCEDURE|Arthroscopic hip surgery|Hip arthroscopy
41360351|NCT01731951|DRUG|Imetelstat|Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
41360352|NCT03080389|PROCEDURE|Extended Urine Culture|"Extended Urine Culture Standard cultures will include 0.001 ml of specimen plated on sheep blood agar and MacConkey agar. Plates were inoculated and incubated at 35 degrees Celsius for 24 hours. Samples were considered positive if there were 10\^3 cfu or greater. The extended urine culture will be spun down by centrifuge (3000 rpm for 5 min) and 0.1 ml of the sediment will be cultured for 48 hours.~The participants will fill out the Bother, UDI-6, and PUF questionnaires before the cultures. If a patient has a positive urine culture, the patient will be asked to repeat the questionnaires 7-30 days post treatment with antibiotics. A comparison will be made between the standard and extended urine cultures to assess for a difference in identification and treatment of uropathogens."
41360353|NCT04036006|BEHAVIORAL|Group-Based Program|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
40840228|NCT03377933|OTHER|Compound Lactobacillus acidophilus|Compound Lactobacillus acidophilus Tablet
40840229|NCT03307031|OTHER|High Volume Group|Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.
40840230|NCT03307031|OTHER|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
40840231|NCT03307031|OTHER|Control Group|Did not exercise, during 10 weeks.
40840232|NCT05308927|DRUG|Norditropin|Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.
40840233|NCT04123613|DRUG|DM199|A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
40840234|NCT02036762|OTHER|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
40840235|NCT05776628|DEVICE|Plenum® Tissue ortho membrane (polydioxanone membrane)|Membrane addition after flavectomy and spinal nerve and dura mater manipulation.
40840236|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^3 dose of rDEN3-3'D4delta30 vaccine.
40840237|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^5 dose of rDEN3-3'D4delta30 vaccine.
40840238|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^1 dose of rDEN3-3'D4delta30 vaccine.
40840239|NCT00884832|DRUG|Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
40840240|NCT00884832|DRUG|Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
40840241|NCT05011721|DEVICE|Activity tracker|"Participants will receive a Withings Steel HR activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the NeoFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure NeoFit space."
40840242|NCT04346121|OTHER|GPs reports of potential patient safety incidents, non-COVID-19 related|GPs reports of potential patient safety incidents, non-COVID-19 related
40840243|NCT02334397|BEHAVIORAL|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
40840244|NCT04243928|OTHER|kinesio taping|apply kinesio taping on dorsi flexors muscles
40840245|NCT00034736|DRUG|Levofloxacin|
40840246|NCT06198335|OTHER|Modified Perichondral Approach Thoracoabdominal Nerve block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
41360354|NCT04036006|BEHAVIORAL|Self-Directed Program|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
41498305|NCT03275818|DRUG|nab paclitaxel|Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
40840247|NCT06198335|OTHER|Transversus Abdominal Plane block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
41024621|NCT01621360|OTHER|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
41360355|NCT01721213|DRUG|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
41360356|NCT00495508|DRUG|Quinine|
41360357|NCT00495508|DRUG|artemether / lumefantrine|
41360358|NCT01711931|DEVICE|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
41360359|NCT01711931|DEVICE|Implantation of everolimus-eluting stents|
41360360|NCT01711931|DEVICE|Implantation of biolimus-eluting stents|
41360361|NCT01040494|DRUG|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
41360362|NCT01040494|DRUG|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
41360363|NCT04052906|OTHER|Training|Planned Inhaler Medication Trainning
41360364|NCT01482338|DRUG|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
41360365|NCT01482338|DRUG|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
41360366|NCT01791088|DRUG|sirolimus|Given PO
41360367|NCT01791088|OTHER|pharmacological study|Correlative studies
41498306|NCT06050161|DEVICE|Articulating laparoscopic instrument|The Artisential articulating laparoscopic instrument will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
41360368|NCT01791088|OTHER|laboratory biomarker analysis|Correlative studies
41498307|NCT06050161|DEVICE|Conventional laparoscopic instrument|Conventional laparoscopic instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
40840248|NCT03583827|OTHER|Virtual reality|Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
40840249|NCT03583827|OTHER|Conventional physical therapy|Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
40840250|NCT00604617|PROCEDURE|Interferon-Gamma Release Assay|IGRAs
40840251|NCT00604617|DRUG|RT-23|TST - tuberculin skin test
40840252|NCT02207257|DRUG|PER977|Reversal of edoxaban-induced anticoagulation
40840253|NCT02207257|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
40840254|NCT02207257|DRUG|Edoxaban|
40840255|NCT06491810|OTHER|Arm crank exercise|The arm ergometer exercise will be the only intervention implemented during the study.
40840256|NCT03031067|DEVICE|Machine perfusion|"The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer."
40840257|NCT04519580|DIAGNOSTIC_TEST|PET/CT|FDG-PET/CT at baseline, week 8 and week 10.
41024622|NCT03395535|PROCEDURE|Primary Selective Laser Trabeculoplasty Treatment Pathway|"Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
41024623|NCT03395535|DRUG|Primary Medical Treatment Pathway|"Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
41024624|NCT00039767|DRUG|Lepirudin|
41498308|NCT06050161|DEVICE|Robotic surgical instrument|Robotic surgical instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
41498309|NCT04494880|DRUG|Bupivacaine Injection|Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.
41498310|NCT04697836|PROCEDURE|ST|"After a computer-generated randomization list with a 1:1 intergroup ratio, ensuring equal distribution in the two groups, 30 opaque sealed envelopes numbered 1-30 were prepared. The patients were randomly divided into the Group with bilateral CPB with 15 ml 0.5% bupivacaine or the patients with translaryngeal block with 5 ml 2% lidocaine in addition to bilateral CPB.~Following inclusion, two research assistants, with no further involvement in the study, prepared 15mL syringes and 5 ml syringes according to the envelope's specifications. The syringes were marked with the patient's randomization number. All other investigators, staff, and patients were blinded to group allocations. Before surgery, the patients were transferred to the specified block room area monitored with 3-lead electrocardiography, pulse oximetry, and non-invasive blood pressure. All patients had two intravenous cannula lines, and then bilateral CPB block procedures were performed in awake non-sedated patients."
41498311|NCT04011163|DEVICE|VPIA pump|The pump is a specially designed and manufactured infusion syringe pump for intravenous analgesia. It incorporates the VPIA study regimen to meet the specific requirements of the clinical trial. It is intended to be used only for delivering drugs intravenously.
41498312|NCT04011163|DRUG|Morphine|Intravenous medication used is morphine diluted in normal saline to a concentration of 1mg/ml. This is a standard dilution and are routine drugs used as standard of care.
41498313|NCT00229723|DRUG|gefitinib (Iressa)|250 mg oral tablet
40840258|NCT00752726|DRUG|Orlistat|Weight loss treatment
41498314|NCT00229723|DRUG|cisplatin|intravenous infusion
41498315|NCT00229723|RADIATION|radiotherapy|radiation therapy
41498316|NCT00229723|DRUG|Gefitinib (Iressa)|500 mg oral tablet
41498317|NCT02399319|PROCEDURE|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
41498318|NCT02399319|PROCEDURE|Symphyseal Plate|A plate that spans across the symphysis to maintain reduction and stability.
41498319|NCT04139759|OTHER|hand massage|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
41498320|NCT04139759|OTHER|foot massage|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
41498321|NCT01337258|DRUG|Dutasteride|dutasteride 0.5mg daily.
41498322|NCT01337258|DRUG|Placebo|Men taking placebo daily
40840259|NCT00752726|DRUG|Placebo|Inactive
40840260|NCT02410577|DRUG|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
40840261|NCT02410577|DEVICE|PET/CT Scan|
40840262|NCT02410577|DEVICE|MRI|
41498323|NCT04917042|DRUG|Tazemetostat|Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.
40840263|NCT02410577|OTHER|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
40840264|NCT01375465|DEVICE|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
40840265|NCT02749383|DRUG|PAC-14028 cream 0.3%|Topical application
40840266|NCT02749383|DRUG|PAC-14028 cream 1.0%|Topical application
40840267|NCT02749383|DRUG|PAC-14028 cream vehicle|Topical application
41024625|NCT04704414|DEVICE|Exophthalmos measurement|Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
41024626|NCT03937167|OTHER|Psychotherapy group|Added to standard treatment patients will participate in a standardized group of psychological intervention. 21 sessions with 10 to 12 members closed-ended groups.
41498324|NCT03902886|DIAGNOSTIC_TEST|gait analysis|gait analysis using an optoelectronic system and a surface EMG
41498325|NCT01123967|OTHER|proactive outreach (PRO)|a mailed invitation letter followed by telephone outreach
41498326|NCT01123967|OTHER|telephone counseling (TC)|free telephone counseling
40840268|NCT00226070|PROCEDURE|interview and advising|
40840269|NCT00226070|BEHAVIORAL|3 follow up interviews and personal advising|
41024627|NCT01016834|DEVICE|Sumavel DosePro|Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
41024628|NCT01016834|DRUG|Sumatriptan|subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
41024629|NCT00671281|DRUG|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
41498327|NCT01123967|OTHER|Nicotine replacement therapy (NRT)|free nicotine replacement therapy (NRT)
40840270|NCT00226070|PROCEDURE|interview SF-36 self rated health|
40840271|NCT03407833|OTHER|Endoscopy biopsy|Tissue samples will be collected from the jejunum, duodenum, and colon during the subject's standard of care procedure.
40840272|NCT03407833|OTHER|Surgical biopsy|Biopsy of the liver is standard of care for diagnosing NAFLD. Biopsy of omentum, skeletal muscle and subcutaneous adipose (the latter two tissues taken at the site of trocar placement) will be collected intraoperatively at the time of Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).
40840273|NCT03407833|OTHER|Mixed-meal tolerance test|The mixed meal tolerance test (MMTT) shows how much insulin your body is making after drinking a liquid meal beverage that contains fats, protein and carbohydrates (sugar). Glucose, C-peptide, free fatty acids, triglycerides, incretins, pancreatic polypertide, bile aceis, and fatty acid amides can also be measured. A total of 9 tablespoons of blood is taken over a 255 minute period.
41024630|NCT00671281|DRUG|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
41024631|NCT02073045|OTHER|educational intervention|Receive educational handouts
41024632|NCT02073045|OTHER|lymphedema survey|Ancillary studies
41024633|NCT06024447|PROCEDURE|Subgingival Instrumentation|Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.
41360369|NCT02114736|PROCEDURE|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
41498328|NCT01123967|OTHER|Usual care (UC)|nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
41498329|NCT05375071|OTHER|Blood Flow Restriction (BFR) Therapy|BFR Cuff will be applied to the most proximal portion of the affected arm or leg, immediately before performing exercises during physical therapy. The cuff will remain on for the entire time while an exercise is performed and will be removed in between exercises while the subject rests.
40840274|NCT03407833|OTHER|Excised Liver Tissue Sampling|Tissue will be collected from the excised liver for research after the diseased liver has been removed as part of the standard of care procedure.
40840275|NCT02191839|DRUG|Alpha 1-Antitrypsin|
40840276|NCT02893124|DRUG|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
40840277|NCT01999218|DRUG|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
40840278|NCT01999218|DRUG|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
41360370|NCT02114736|DRUG|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
41360371|NCT04012866|BEHAVIORAL|Aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
41498330|NCT05375071|OTHER|Physical Therapy|Standard of care physical therapy consisting of a structured program progressing from range of motion to strength training and then functional tests
41498331|NCT03523442|DRUG|Apalutamide|The participants will receive apalutamide 240 mg once daily orally.
40840279|NCT01999218|DRUG|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
40840280|NCT01999218|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
40840281|NCT01999218|DRUG|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
41498332|NCT04278950|DRUG|Povidone-Iodine|For the PVP-I group, the final concentration of available iodine in the solution will be 0.01%, (from diluting 10% PVP-I solution), as previously demonstrated to be below ciliotoxic levels of 1.25% and greater than 0.01% which is the lower limit of active potency.
41498333|NCT04278950|DRUG|Placebos|The placebo will be 2.5mL of saline with brown food coloring.
41498334|NCT01405014|BEHAVIORAL|Hold Me Tight|Relationship enhancement group
41498335|NCT05994001|DRUG|cardonilizumab|cardonilizumab:PD1 and CTLA-4 bispecific antibody
41498336|NCT05994001|DRUG|LM-302|LM-302 :ClAUDIN 18.2-ADC
41498337|NCT04037774|DRUG|Dexmedetomidine|comparision of different doses of dexmedetomidine used intrathecally
40840282|NCT01999218|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
40840283|NCT01999218|DRUG|Sitagliptin|Open label, oral, once daily, rescue medication as required.
40840284|NCT01065831|BEHAVIORAL|Motivational interviewing (MINT-TLC)|The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
40840285|NCT05026853|BEHAVIORAL|PRO Integration into Clinical Practice|HCPs will document their discussion and recommendations/referrals in MiChart (Epic EMR)
40840286|NCT06507150|OTHER|AI-assisted migraine education (AIME)|AIME Group will undergo the established migraine education plus AI-assisted education.
40840287|NCT02591459|OTHER|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
40840288|NCT01304407|OTHER|Calcium stable isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
41360372|NCT04012866|BEHAVIORAL|Computerized cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
41360373|NCT04012866|BEHAVIORAL|Control training|The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
41360374|NCT02996162|DEVICE|Massimo Root Monitoring System|The Masimo Root system is a patient monitoring and connectivity platform; Root displays patient monitoring information from the connected modules. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
41498338|NCT04037774|OTHER|placebo|addition of placebo with local anesthetic to create a control group
41498339|NCT00749021|DRUG|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
41498340|NCT00749021|DRUG|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
41498341|NCT00749021|DRUG|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
41498342|NCT00749021|DRUG|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
41498343|NCT04938323|DRUG|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
41498344|NCT04938323|DRUG|Placebo|.1 mL of diluent (saline) given intradermally at baseline
41498345|NCT05151666|OTHER|Sunny Health & Fitness Magnetic Mini Exercise Pedal Cycle - SF-B020026 Gray|The intervention will be that the patient cycles in a sitting position within the first 2 hours of hemodialysis treatment for 15-60 minutes/as tolerated, either intermittent/continuous duration. - Graded duration will increase every 2 weeks. This will be supervised by a dialysis nurse as per the schedule of study assessments.
41498346|NCT01690741|DRUG|Nerofe|Nerofe administered intravenously 3x/week
41498347|NCT02529891|OTHER|Measurement of VOC in exhaled air|Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer
41360375|NCT02996162|DEVICE|ISA-Infrared Sidestream Gas Analyzer|The ISA-Infrared Sidestream Gas Analyzer displays end-tidal carbon dioxide waveforms and measurements and trends of end tidal CO2. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
40840289|NCT02342080|OTHER|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
40840290|NCT02342080|DEVICE|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
40840291|NCT02201836|OTHER|One time music therapy|
40840292|NCT02201836|OTHER|Group music therapy|
40840293|NCT04724395|OTHER|Hospitalization|Hospitalization in intensive care and non-intensive care units for COVID-19 followed by usual care
40840294|NCT00262847|BIOLOGICAL|Bevacizumab|Given IV
40840295|NCT00262847|DRUG|Carboplatin|Given IV
40840296|NCT00262847|OTHER|Laboratory Biomarker Analysis|Correlative studies
40840297|NCT00262847|DRUG|Paclitaxel|Given IV
40840298|NCT00262847|OTHER|Placebo|Given IV
40840299|NCT00262847|OTHER|Quality-of-Life Assessment|Ancillary studies
40840300|NCT03598751|DRUG|BCD-085|120 mg / 2 mL subcutaneously
41360376|NCT02243163|BEHAVIORAL|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
41360377|NCT04832633|DIAGNOSTIC_TEST|Different contrast media injection methods|Different contrast media injection methods
41360378|NCT03650387|DEVICE|RADIESSE® (+) Lidocaine|RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
40840301|NCT03598751|DRUG|Placebo|2 mL
40840302|NCT00946322|BEHAVIORAL|Couple-Based Treatment for Alcohol Use Disorders and PTSD|This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
40840303|NCT01345682|DRUG|Afatinib|Once daily
40840304|NCT01345682|DRUG|Methotrexate|Weekly
40840305|NCT05463991|DEVICE|Bioengineered collagen implant|Urethral stricture repair
40840306|NCT03537313|PROCEDURE|Vagina douching|Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery
40840307|NCT03537313|PROCEDURE|Vagina painting|Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml
40840308|NCT02728531|DRUG|Bendamustine|
41360379|NCT00807456|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
40840309|NCT02728531|DRUG|Rituximab|
40840310|NCT02728531|DRUG|Cytarabine|
40840311|NCT02728531|DRUG|Pegfilgrastim|
40840312|NCT02728531|PROCEDURE|Leukapheresis|
40840313|NCT02728531|DRUG|Filgrastim|
40840314|NCT02728531|PROCEDURE|Autologous stem cell transplant|
40840315|NCT04986280|DIAGNOSTIC_TEST|[18F]PSMA-1007|PSMA PET/CT using the intervention.
40840316|NCT03039894|OTHER|Gradebook Game|Students in the intervention group will spend time meeting as teams to review their scorecards, and do team-building activities, all of which will occur during non-content periods at school (Advisory and Enrichment).
40840317|NCT00759525|DRUG|Glycyrrhetic Acid|130 mg daily for fourteen days
40840318|NCT00759525|DRUG|Placebo|Placebo daily for fourteen days
40840319|NCT01802307|RADIATION|Brachytherapy|
40840320|NCT03759470|DIAGNOSTIC_TEST|CSF examination|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperature. Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with \~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit."
40840321|NCT05293678|DRUG|REGN15160 (IV)|Administered in single intravenous (IV) dose
40840322|NCT05293678|DRUG|Matching Placebo (IV)|Administered in single IV dose
40840323|NCT05293678|DRUG|REGN15160 (SC)|Administered in single subcutaneous (SC) dose
40840324|NCT05293678|DRUG|Matching Placebo (SC)|Administered in single SC dose
40840325|NCT02174744|OTHER|numeric pain rating scale|
40840326|NCT05285306|BEHAVIORAL|PEACE Program|This pilot will consist of 3 individual telemedicine sessions to teach cognitive behavioral coping skills and provide education related to gynecologic cancer surveillance and psychological distress.
40840327|NCT01985360|PROCEDURE|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
40840328|NCT01985360|PROCEDURE|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
41360380|NCT01365195|DRUG|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
41360381|NCT01365195|DRUG|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
41360382|NCT01365195|DRUG|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
41360383|NCT01688479|DRUG|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
41024634|NCT03910335|DIAGNOSTIC_TEST|LSS Screen|Patients will fill out a questionnaire with 13 questions related to presence or absence of clinical symptoms of lumbar spinal stenosis (neurogenic claudication)
41360384|NCT01688479|DRUG|Essex® cream (Schering-Plough), aqueous cream without parabens|
41360385|NCT03062631|DRUG|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
41360386|NCT03145428|DIAGNOSTIC_TEST|CBC-Diff Monocyte volume width distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients
41360387|NCT06143449|OTHER|Observational study - registry|Observational study - registry
41360388|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with FibriCheck®|Measurements are performed twice daily, starting 4 weeks before a pulmonary vein isolation procedure (PVI) and ending 4 weeks after the PVI.
41498348|NCT01816659|DRUG|Metformin ER|500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
41498349|NCT00794508|BIOLOGICAL|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
41498350|NCT04632511|DEVICE|MetaSAMP|Rectal Sampler
41360389|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with Kardia Mobile®|Measurements are performed immediately before and after every FibriCheck® measurement.
41360390|NCT06427616|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|"Participants will start soleus push-ups in sitting positions. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, feet will be placed flat on the ground. Participants will then move their heels up and down continuously.~Soleus push-ups will be performed with moderate intensity using weights which will be placed on their laps.~Participants will perform this activity till their 60-80% of their maximum heart rate is achieved and maintained"
41360391|NCT06427616|BEHAVIORAL|Sustained Soleus Push-ups|"Participants will start soleus push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and feet will be placed flat on the ground. Participants will then move their heels up and down continuously for.~Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum of 4 min break time after every 90 mins intervention. In the meantime, their blood sample will be collected"
41498351|NCT01192607|DEVICE|Endoscopic treatment during root canal treatment|Endoscopic treatment during root canal treatment
41498352|NCT06165601|PROCEDURE|Follow-up at D14|A blood test and urinary test will be performed at D14.
41498353|NCT06165601|PROCEDURE|Follow-up at M1|A blood test and urinary test will be performed at M1.
41498354|NCT00152737|PROCEDURE|Exercise test with Transcutaneous oxygene pressure|Ce marked devices
41498355|NCT00152737|PROCEDURE|Ankle and arm pressure values|one test before and one test after surgery
41360392|NCT02899026|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
41024635|NCT01650389|BIOLOGICAL|MVA85A|
41024636|NCT01650389|BIOLOGICAL|Candin|
41360393|NCT02899026|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
41360394|NCT02899026|DRUG|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
41360395|NCT05536934|DRUG|Nω-hydroxy-nor-arginine|
41360396|NCT00485615|DRUG|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
41498356|NCT01534130|DEVICE|Acupuncture|Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
41498357|NCT01534130|DEVICE|Sham acupuncture|Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
41498358|NCT00735306|DRUG|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
41498359|NCT00735306|DRUG|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
41498360|NCT00735306|RADIATION|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
41024637|NCT01650389|BIOLOGICAL|BCG Vaccine SSI|"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination."
41024638|NCT00175136|DEVICE|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
41024639|NCT00617240|DRUG|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
41498361|NCT02819700|BEHAVIORAL|prevalence of behavioural dysexecutive syndrome|Behavioural Dysexecutive Syndrome Inventory (ISDC)
41498362|NCT03038841|DEVICE|Mobile Health|Patients discharged from hospital will be equipped with a tracking bracelet and a smart phone
41498363|NCT05213455|BIOLOGICAL|booster vaccine for COVID 19|The effect of Booster vaccine will be seen in participants in terms of antibody response IgG
41498364|NCT05347212|DRUG|Nivolumab|Given by IV
41498365|NCT05347212|DRUG|Relatlimab|Given by IV
41498366|NCT05253963|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be used during the second night of polysomnography .
41024640|NCT00617240|DRUG|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
41360397|NCT01759095|DEVICE|Electronic multidrug blister pack|At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
41024641|NCT06535074|OTHER|Detecting changes in lung volume with hypoxemia episodes|"Electrical impedance tomography (EIT) will be used to assess changes in lung aeration prior and during hypoxemia episodes to classify them into four different subtypes.~FE subtype: Defined as HEs preceded by reduction in EELI below the baseline.~Apnea subtype: Defined as HEs not meeting the criteria for FE subtype and preceded by cessation of breathing.~Mixed subtype: Defined as HEs meeting the criteria for both FE and apnea subtypes.~Unclassified: Defined as HEs not categorized into any of the above parameters."
41360398|NCT04915742|BEHAVIORAL|exercises|The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.
41360399|NCT04915742|BEHAVIORAL|thetahealing and exercises|"The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.~The exercise and Thetahealing treatment group, on the other hand, is planned for 6 weeks , 1 session per week, 30 minutes per session, in addition to the exercise sessions, the first and last sessions to be individual and personalized .~Applications will be carried out on the online platform."
41360400|NCT00611351|BIOLOGICAL|anti-thymocyte globulin|
41360401|NCT00611351|DRUG|busulfan|
41360402|NCT00611351|DRUG|cyclophosphamide|
41360403|NCT00611351|DRUG|mycophenolate mofetil|
41360404|NCT00611351|DRUG|tacrolimus|
41360405|NCT00611351|GENETIC|polymerase chain reaction|
41360406|NCT00611351|GENETIC|polymorphism analysis|
41360407|NCT00611351|OTHER|flow cytometry|
41360408|NCT00611351|OTHER|laboratory biomarker analysis|
41360409|NCT00611351|OTHER|pharmacogenomic studies|
41360410|NCT00611351|OTHER|pharmacological study|
41360411|NCT00611351|PROCEDURE|allogeneic bone marrow transplantation|
41360412|NCT00611351|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41360413|NCT00611351|PROCEDURE|peripheral blood stem cell transplantation|
41360414|NCT02781246|DRUG|perineural dexmedetomidine|"Children scheduled for arm and forearm surgery underwent supraclavicle brachial plexus blocks with ropivacaine and dexmedetomidine guided by ultrasound visualisation were randomly assigned five groups: Group A (perineural ropivacaine), Group B (ropivacaine plus 0.5 mcg/kg dexmedetomidine), Group C (ropivacaine plus 1 mcg/kg dexmedetomidine), Group D (ropivacaine plus 1.5mcg/kg dexmedetomidine) and Group E (ropivacaine plus 2 mcg/kg dexmedetomidine). In each group, children received a certain concentration of ropivacaine which adjusted by the Dixon up-and-down method for supraclavicle brachial plexus. The first child received 0.2% ropivacaine , and the concentration of ropivacaine varied by 0.1% according to the up-and-down method. The primary endpoint was the minimum local anesthetic concentration (MLAC)."
41024642|NCT04410692|OTHER|Prediction Market|"Participants bet on likely future outcomes using a prediction market"
41360415|NCT02263924|DIETARY_SUPPLEMENT|Tocotrienol|Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
41360416|NCT02263924|DIETARY_SUPPLEMENT|Placebo capsules|Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
41360417|NCT04060589|OTHER|Tissue donation|Biopsies will be performed as part of standard of care, additional cores will be performed for research. Access to standard of care prostate biopsy tissue will also be requested after standard of care reporting is complete.
41360418|NCT04060589|OTHER|Blood Donation|Phlebotomy will be performed prior to tissue collection following trust standard operating procedures or drawn when cannula already in situ in preparation for the prostate biopsy.
41360419|NCT04060589|OTHER|Urine Donation|Urine will be collected prior to prostate biopsy
41360420|NCT04060589|OTHER|Healthcare data linkage|Men will consent to healthcare data linkage via national databases.
41360421|NCT00937703|DEVICE|placebo|paper support for glycaemia face to face visit at T4mounths
41360422|NCT00937703|DEVICE|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks."
41360423|NCT00937703|DEVICE|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
41360424|NCT02010489|OTHER|12 week Exercise Program|Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
41360425|NCT02515604|DRUG|Misoprostol|
41360426|NCT02081664|BEHAVIORAL|lifestyle intervention|
41024643|NCT02973659|DRUG|Oxybutynin|10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
41024644|NCT02973659|DRUG|Placebos|
41498367|NCT03602612|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
41360427|NCT00670098|PROCEDURE|Bariatric surgery|patients receive either gastric bypass or lap-band
41360428|NCT00670098|BEHAVIORAL|lifestyle intervention (behavioral weight loss)|participants attend biweekly weight loss counseling group sessions
41360429|NCT00757380|PROCEDURE|Trypan Blue|Membranepeeling with TB
41498368|NCT03602612|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3
41498369|NCT03602612|BIOLOGICAL|Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells|0.75x10\^6 - 12.0X10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
41498370|NCT02393248|DRUG|Pemigatinib|
41498371|NCT02393248|DRUG|Gemcitabine|
41360430|NCT00757380|PROCEDURE|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
41360431|NCT05892094|OTHER|Resistance and Aerobic Training|For aerobic exercise, participants will do brisk walking 30 minutes in the first two weeks, 3-6. weeks will be 35 minutes, 7th and 8th weeks will be 40 minutes.The first and last 10 minutes of each walk will be said to be done at a slow pace, for the warm-up and cool-down periods. Participants will be called regularly to monitor their participation in the aerobic exercise program, and their compliance with the exercise will be checked, and they will be motivated to continue the exercises by providing the necessary information. Resistance exercises sessions will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. The training load will be provided by progressively increasing the repetitions. The Borg Scale will be used to adjust the exercise intensity. Rest time between sets will be 60 seconds.
41360432|NCT04008160|DEVICE|ProTex|Non invasive measurement of pressure, temperature, humidity, perfusion, and oxygenation
41498372|NCT02393248|DRUG|Pembrolizumab|
41498373|NCT02393248|DRUG|Docetaxel|
41498374|NCT02393248|DRUG|Trastuzumab|
41498375|NCT02393248|DRUG|Retifanlimab|
41498376|NCT02393248|DRUG|Cisplatin|
41498377|NCT05055830|DRUG|The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.|The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws), this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care.
41498378|NCT05462171|DIAGNOSTIC_TEST|Questionnaires|Participants will be asked to complete validated questionnaires (the five-item International Index of Erectile Function - IIEF-5, Premature Ejaculation Diagnostic Tool - PEDT, International Prostate Symptom Score - IPSS, Overactive Bladder - Validated 8-question Screener - OAB-V8, Hospital Anxiety and Depression Scale - HADS, Athens Insomnia Scale - AIS).
41498379|NCT01667835|BEHAVIORAL|Yoga Intervention|12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
41498380|NCT03357965|OTHER|Questionnaire|Women who had gave birth in 6 weeks
41498381|NCT02936414|DRUG|Berberine|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
41498382|NCT02936414|DRUG|Placebo|Accept placebo(300 mg/tid)+SGAs monotherapy.
41498383|NCT03358186|PROCEDURE|surgically treated periprosthetic femur fracture|patients with surgically treated periprosthetic femur fracture
41498384|NCT04942743|DIAGNOSTIC_TEST|MRI|MRI OF TMJ
41498385|NCT01811316|OTHER|Probiotics|
41498386|NCT01220297|DRUG|Sirolimus|"Immunosuppressant administered orally to:~* Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.~* Children \< 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.~Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months."
41498387|NCT01220297|DRUG|Mycophenolate mofetil (MMF)|Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
41498388|NCT01220297|DRUG|Carmustine|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
41360433|NCT02409576|BIOLOGICAL|Expanded , Activated NK cells|"1. Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.~   Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days~2. Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy~3. Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses~4. NK cells - Expanded activated haploidentical NK cells will be infused on day 0."
41360434|NCT01663246|PROCEDURE|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
41360435|NCT03341728|BEHAVIORAL|Optical flow perturbations|Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.
41498389|NCT01220297|DRUG|Etoposide|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
41498390|NCT01220297|DRUG|Cyclophosphamide (Cyclo, CY)|"Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg"
41498391|NCT01220297|DRUG|FTBI|For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
41498392|NCT05748106|DEVICE|Ultrasound-based imaging|Ultrasound-based imaging
41498393|NCT04236323|DRUG|Not used remifentanil infusion|Remifentanil is not used during operation
41498394|NCT01043224|DRUG|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
41498395|NCT03850314|DIETARY_SUPPLEMENT|Glycine|Glycine powder to be dissolved in water.
41498396|NCT02871271|DIETARY_SUPPLEMENT|IQP-AS-121|
41498397|NCT02398383|OTHER|Oral Glucose Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Patients will drink 1.75 gm/kg glucose (Glucola) to a maximum of 75 gm. Venous samples for glucose and c-peptide will be drawn from the IV at 0, 30, 60, 90 and 120 minutes. Subjects will be instructed to eat at least 75 gm carbohydrates daily in the week prior to this test.
41498398|NCT02398383|OTHER|Mixed Meal Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Subjects will consume 6 kcal/kg (6 ml/kg) Boost High Protein Nutritional Energy Drink (Mead-Johnson) over five minutes to a maximum of 360 ml. Venous samples for glucose, glucagon, GLP-1, GIP, and c-peptide will be drawn at -10, 0, 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes.
41498399|NCT02398383|OTHER|Hypoglycemic Clamp|All subjects with CF and adult (but not pediatric) controls will undergo one-step hypoglycemic clamp. Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling and a second IV for infusion of insulin and dextrose.
41498400|NCT04987385|DIETARY_SUPPLEMENT|Protein supplementation|Patients will receive a box with 7 sealable of 90-gram protein containers that will be dissolved in maximal 1L liquid (i.e., water or milk) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake. A wash-out period of minimum 7 days between Protein supplementation and Oral urea will be performed.
41498401|NCT04987385|DIETARY_SUPPLEMENT|Oral urea|Patients will receive a box with 7 30-grams urea sealable containers. The total daily oral urea dosage of 30 grams that will be dissolved in maximal 1L of a liquid of choice (water, milk, juice, ...) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake.
41498402|NCT06224465|OTHER|aerobic exercises|"Antiaging diet instruction :Be aware of the amount of calories, Reduce overall fat and sugar intake, Drink at least 10 glasses of water every day in order to remain healthy.~d. Eat a variety of complex carbohydrates and vegetables instead of bread, rice, and corn."
41498403|NCT04066595|DRUG|Cabozantinib|60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
41498404|NCT05487534|OTHER|Observational|The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.
41498405|NCT06633042|DRUG|Universal BCMA-CD19 CART|1.0-4.0×10\^6 CAR-T cells/kg
41498406|NCT02242032|DRUG|P-321 Ophthalmic Solution|
41024645|NCT03265028|BEHAVIORAL|TRACE e-learning|The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
41360436|NCT03341728|BEHAVIORAL|Normal walking|Usual treadmill walking without optical flow perturbations
41498407|NCT02242032|DRUG|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
41498408|NCT00507130|BIOLOGICAL|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
41498409|NCT00507130|BIOLOGICAL|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
41498410|NCT00507130|BIOLOGICAL|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
41498411|NCT00507130|OTHER|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
41024646|NCT03313362|DEVICE|SPEAC System|Seizure Monitoring and Alerting System
41360437|NCT04823858|PROCEDURE|Lumbar Interbody Fusion|The TLIF/PLIF system includes a TLIF/PLIF interbody cage and a pedicle screw system (4 screws with 2 rods). Any FDA cleared TLIF/PLIF interbody cage and pedicle screw system is acceptable for this study (with the exception of PEEK rods) as long as it is implanted per the package insert. No subjects implanted with an off-label use of a device are permitted for this study.
41360438|NCT02264327|BEHAVIORAL|Motivational Interviewing Simulator (SIM)|The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
41498412|NCT03869034|COMBINATION_PRODUCT|HAIC+PD1|Sintilimab ( 200mg Q3W iv D1)+FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3), maximally 8 cycles Multi-disciplinary consultation was organized to decide the chance of surgery and subsequent treatment per 2 treatment cycles. Patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection. After recovery from operation , sintilimab monotherapy was given per three weeks for maximally 16 doses. Patients who were ineligible for resection would continue to receive the combination therapy.
41498413|NCT03869034|DRUG|HAIC|FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
41498414|NCT05735340|BEHAVIORAL|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
41498415|NCT05735340|BEHAVIORAL|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
41498416|NCT05597137|DIETARY_SUPPLEMENT|Zinc Gluconate|Each participant should receive a regular zinc diet for weeks 1-2 and take zinc supplements for weeks 3-4.
40840329|NCT01985360|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
40840330|NCT01985360|BEHAVIORAL|Lifestyle|Diet, physical activity, smoking cessation
41360439|NCT02264327|BEHAVIORAL|Motivational Interviewing eBook (eBook)|"The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills."
41498417|NCT03583684|BEHAVIORAL|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
41498418|NCT04202003|DRUG|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
41498419|NCT04773522|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
41498420|NCT05979441|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
41498421|NCT05287256|DRUG|Oral Delta-8-THC Cannabis|Delta-8-THC cannabis will be orally self-administered by study participants
41498422|NCT05287256|DRUG|Oral Delta-9-THC Cannabis|Delta-9-THC cannabis will be orally self-administered by study participants
40840331|NCT01985360|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
41498423|NCT05287256|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants
40840332|NCT00653081|PROCEDURE|Physical therapy method called Supervised Exercises|Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks
40840333|NCT00653081|PROCEDURE|Radial Extracorporeal Shockwave Therapy|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
41498424|NCT05287256|DRUG|Vaporized Delta-8-THC Cannabis|Delta-8-THC cannabis will be self-administered by study participants using a vaporizer
40840334|NCT00875342|DRUG|DCS|1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
40840335|NCT00875342|OTHER|Placebo|2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
40840336|NCT00760838|DRUG|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
40840337|NCT00760838|DRUG|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
40840338|NCT01944579|OTHER|Blackberries|Participants will receive blackberries as part of a controlled diet.
40840339|NCT01944579|OTHER|Control|Participants will receive a control food (jello) as part of a controlled diet.
40840340|NCT05298800|BIOLOGICAL|Vaccine|Different arms were administrated different vaccines
40840341|NCT00897624|GENETIC|gene expression analysis|
40840342|NCT00897624|GENETIC|reverse transcriptase-polymerase chain reaction|
40840343|NCT00897624|OTHER|laboratory biomarker analysis|
40840344|NCT06526156|DRUG|Bupivacaine injection|A 3 mL hypobaric (0.33%) solution of bupivacaine, prepared by mixing 2 mL of isobaric (0.5%) bupivacaine with 1 mL of sterile water. Dural puncture will be performed using a 25 or 27G (gauge) spinal needle at the L5-S1 intervertebral space, and the 3 mL of 0.33% bupivacaine will be injected into the intrathecal space.
40840345|NCT02263911|DRUG|Baricitinib|Administered orally
40840346|NCT06099873|DRUG|ZX-7101A|Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water
40840347|NCT06099873|DRUG|Placebo|Day1 Take one tablet of Placebo orally once with appropriate amount of warm water
40840348|NCT03562234|DIAGNOSTIC_TEST|MR|Liver fat (measured as a percentage - hepatic fat fraction) will be measured by Magnetic Resonance imaging
40840349|NCT03562234|DIAGNOSTIC_TEST|LiMAx|Liver function will be measured using the relatively new CE licenced non-invasive LiMAx (Liver Maximum Capacity) test device, manufactured by Humedics GmbH
40840350|NCT05296980|BEHAVIORAL|REMINDER|The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to stimulate cognitive reserve, socialization and personal development, to diminish the risk of cognitive decline.
40840351|NCT05296980|BEHAVIORAL|Brain health Psychoeducation|Delivery of psychoeducation sessions about dementia modifiable risk factors, brain health solutions and lifestyle change tips.
40840352|NCT01008462|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
40840353|NCT01008462|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
40840354|NCT01008462|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
40840355|NCT01008462|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
40840356|NCT01008462|DRUG|Carmustine|Given IV
40840357|NCT01008462|DRUG|Cyclophosphamide|Given IV
40840358|NCT01008462|DRUG|Cytarabine|Given IV
40840359|NCT01008462|DRUG|Etoposide|Given IV
40840360|NCT01008462|DRUG|Fludarabine Phosphate|Given IV
40840361|NCT01008462|OTHER|Laboratory Biomarker Analysis|Correlative study
40840362|NCT01008462|DRUG|Melphalan|Given IV
40840363|NCT01008462|DRUG|Mycophenolate Mofetil|Given PO
41498425|NCT05287256|DRUG|Vaporized Delta-9-THC Cannabis|Delta-9-THC cannabis will be self-administered by study participants using a vaporizer
41498426|NCT05287256|DRUG|Vaporized Placebo|Placebo will be self-administered by study participants using a vaporizer
41498427|NCT03555292|DRUG|11C-PiB|11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans
41498428|NCT04136457|OTHER|Endurance training|Subjects perform a period of endurance training
41498429|NCT04136457|OTHER|Resistance training|Subjects perform a period of resistance training
41498430|NCT04136457|OTHER|Sprint training|Subjects perform a period of sprint training
40840364|NCT01008462|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
40840365|NCT01008462|DRUG|Tacrolimus|Given IV or PO
40840366|NCT01008462|RADIATION|Total-Body Irradiation|Undergo TBI
40840367|NCT02918708|BIOLOGICAL|Synflorix|10-valent pneumococcal conjugate vaccine
40840368|NCT02918708|BIOLOGICAL|Prevenar13|13-valent pneumococcal conjugate vaccine
41024647|NCT03313362|DEVICE|video EEG|The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.
41024648|NCT05630716|DEVICE|NICOM|non-invasive monitor capable of measuring cardiac output (CO) and cardiac index (CI), and stroke volume (SV) and stroke volume index (SVI) based on heart rate. The NICOM technology will be implemented by the Rapid Response Team providers (Advanced Practice Providers) and ICU nurses at FSH, most of whom are already trained and familiar with its use.
40840369|NCT01528761|BEHAVIORAL|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
40840370|NCT01528761|OTHER|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
41498431|NCT03326713|BEHAVIORAL|Telephone Counseling & Navigation (TCN)|A health coach will conduct a 15-30 minute telephone counseling session with participants. Prior to the telephone session, participants will receive the same brochure that the TP arm receives. After the phone call, participants will receive a tailored follow-up letter which will include images tailored to the individual's age, self-identified ethnicity, and family composition.
41498432|NCT03326713|BEHAVIORAL|Mailed Targeted Print (TP)|Participants will be mailed an educational brochure within two weeks of completing the baseline survey that addresses important evidence-based theoretical targets: CGRA guideline (knowledge), threat appraisal (to validate or raise risk perceptions, HBOC seriousness), response efficacy (benefits and expectations about CGRA), self-efficacy messages (CGRA resources, insurance reimbursement, and assistance for those with financial challenges) and possible actions to take (make an appointment and discuss with provider). Both the targeted print and tailored intervention materials were developed using formative community engaged research methods.
40840371|NCT03472690|BIOLOGICAL|QBECO-SSI|Subcutaneous injection
40840372|NCT03472690|OTHER|Placebo|Subcutaneous injection
40840373|NCT05606991|OTHER|CPAP Withdrawal|Complete withdrawal of continuous positive airway pressure (CPAP) therapy for a 2-week period.
40840374|NCT05450627|DRUG|Pancreatic Enzyme|Registry of pancreatic enzyme therapy prescribed to included patients
40840375|NCT00437255|DRUG|Clobetasol Propionate, 0.05%|Topical, twice daily for 4 weeks
40840376|NCT00437255|DRUG|Calcipotriene and betamethasone dipropionate ointment|Topical, once daily
40840377|NCT03847909|DRUG|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
41498433|NCT03326713|OTHER|Usual Care (UC)|A usual care arm is included to assess CGRA uptake in the absence of intervention as well as priming from the surveys for the primary outcome analysis.
40840378|NCT03847909|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
40840379|NCT03744520|PROCEDURE|Erector spinae plane block|Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
41498434|NCT00482807|DRUG|bicalutamide|
41498435|NCT00482807|DRUG|docetaxel|
40840380|NCT04963907|DEVICE|Active Alpha-Stim CES|Active Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
40840381|NCT04963907|DEVICE|Sham Alpha-Stim CES|Sham Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
40840382|NCT05672355|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40840383|NCT05672355|BIOLOGICAL|mRNA COVID-19 Vaccine|Given IM
41498436|NCT00482807|DRUG|goserelin|
41498437|NCT00482807|RADIATION|intensity-modulated radiation therapy|
41498438|NCT04711902|DRUG|AIN457|Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
40840384|NCT05672355|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM
40840385|NCT01642758|DRUG|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
40840386|NCT04062097|DRUG|Dabigatran Etexilate Oral Capsule [Pradaxa]|Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
40840387|NCT04062097|DRUG|Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]|Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
40840388|NCT04062097|DRUG|Vitamin K antagonist|This drug group includes the active substances phenprocoumon and warfarin.
40840389|NCT05733728|OTHER|any therapy suitable|any therapy suitable
40840390|NCT05740865|PROCEDURE|open posterior instrumented thoracolumbar surgery|Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers
41360440|NCT02264327|BEHAVIORAL|Motivational Interviewing Training (MI Training)|The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
41360441|NCT00568399|DRUG|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
41360442|NCT04656769|PROCEDURE|Peridural analgesia|We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.
41360443|NCT02723539|DRUG|MBN-101|Topical application
41024649|NCT04660981|BEHAVIORAL|Antenatal education|Training Program on Fear of Childbirth Based on Motivational Interview Method
41360444|NCT02723539|DRUG|Placebo|Topical application
41360445|NCT04628754|OTHER|Exercise and protein|Home based exercise regime and dietary protein guidance
41360446|NCT03373006|DRUG|Axumin PET/CT|Synthetic amino acid uptake agent injection followed by imaging
41360447|NCT02816853|DRUG|Domperidone|Domperidone 10 mg or 20 mg tablets will be administered.
41360448|NCT02816853|DRUG|Placebo|Matching placebo will be administered.
41498439|NCT04711902|OTHER|Secukinumab Placebo|Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
41498440|NCT03671889|DEVICE|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
41498441|NCT04608110|DRUG|ASTX030|In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
41360449|NCT02816853|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet will be administered.
41360450|NCT03841500|DEVICE|Biocomposite intereference screw femoral tunnel fixation|ACL reconstruction using biocomposite intereference screw for femoral tunnel fixation
41360451|NCT03841500|DEVICE|Endobutton (Tightrope) femoral tunnel fixation|ACL reconstruction using endobutton (Tightrope) for femoral tunnel fixation
41498442|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 weeks
41024650|NCT04863950|DRUG|Lomustine|"For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks."
41360452|NCT06011551|DEVICE|The ReGelTec HYDRAFIL™ System|The ReGelTec HYDRAFIL System is designed to deliver an injectable hydrogel implant (the HYDRAFIL implant) for the treatment of a degenerative lumbar disc.
41360453|NCT06011551|OTHER|Conservative Care Management|Conservative care management (including physical therapy and/or pain medication)
41360454|NCT04185194|DRUG|Lidocaine|transmission of the drug molecules to the underlying muscles
41360455|NCT04185194|DEVICE|pulsed ultrasound|using thermogenic and cavitation effect of ultrasound to reduce tight muscles and relieve pain
41360456|NCT04185194|OTHER|especially designed physical therapy program|by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius
41498443|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 g once a day for 8 weeks
41360457|NCT03230240|DRUG|HIPEC|heated intraIP chemotherapy
41360458|NCT00151723|PROCEDURE|treatment with 131I|
41360459|NCT00005838|DRUG|shark cartilage extract AE-941|Given orally
41360460|NCT00005838|OTHER|placebo|Given orally
41360461|NCT00005838|DRUG|cisplatin|Given IV
41360462|NCT00005838|DRUG|vinorelbine tartrate|Given IV
41360463|NCT00005838|DRUG|carboplatin|Given IV
41360464|NCT00005838|DRUG|paclitaxel|Given IV
41498444|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 5 g + Maltodextrin 10 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 weeks
41498445|NCT04716868|DIETARY_SUPPLEMENT|Psyllium plantago|Psyllium plantago 15 g once a day for 8 weeks
41498446|NCT02699060|PROCEDURE|Upper gastrointestinal endoscopy with biopsy and collection of refluxate|we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.
41498447|NCT02699060|PROCEDURE|Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring|we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was \<4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.
41498448|NCT05908292|PROCEDURE|Pelvic Floor Scar Tissue Self-Scar Massage|Self scar-massage intervention of healed pelvic floor scar tissue for 5 minutes, 3x/week for 6 weeks.
41498449|NCT00625625|DRUG|isosulfan blue|
41498450|NCT00625625|GENETIC|polymerase chain reaction|
41498451|NCT00625625|OTHER|diagnostic laboratory biomarker analysis|
41360465|NCT00005838|RADIATION|radiation therapy|Undergo radiotherapy
41360466|NCT05986409|OTHER|light cover|10 wards were randomly selected as the intervention group (opaque black tape covering part of the light source), and another 10 wards were selected as the control group (no intervention).
41360467|NCT03389659|DRUG|vitamin D3|vitamin D3 400IU\*5pills po. qd continue to disease progression
41360468|NCT03389659|DRUG|Placebo|placebo 5 pills po. qd continue to disease progression
41498452|NCT00625625|OTHER|immunohistochemistry staining method|
40840391|NCT06033872|COMBINATION_PRODUCT|Focused education, medication adjustment and telemonitoring|"1. Focused diabetes education session for Ramadan fasting~   Participants will be taught to record~  1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia.~2. Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting.~3. Telemonitoring~Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software."
40840392|NCT00687102|DRUG|tamoxifen|oral tamoxifen plus placebo daily for 5 years
40840393|NCT00687102|DRUG|raloxifene|oral raloxifene plus placebo daily for 5 years
40840394|NCT03086902|DEVICE|Radiofrequency Ablation Catheter|Ablation of PVC with RF energy
40840395|NCT03086902|DEVICE|Cryo Ablation catheter|Ablation pf PVC with Cryo enerygy
41360469|NCT06497569|BEHAVIORAL|Dietitian Consultation|"Participants will meet with a dietitian who will provide individualized nutrition counseling and dietary goals for calorie and protein intake.~Bi-weekly, 30-minute dietitian telehealth visits will be conducted via ZOOM videoconferencing at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention."
41360470|NCT06497569|BEHAVIORAL|Survey|"Surveys will be conducted using the PG-SGA short form19-21 and a brief symptom assessment tool that captures additional nutrition-impact symptoms not captured by the PG-SGA (e.g., swallowing difficulty) measured by the FACT Esophageal and Gastric Cancer scales and the FAACT anorexia/cachexia scales 22,23 through REDCap.~Surveys are completed at the pre-intervention baseline visit and monthly during the intervention period prior to the dietitian visits (up to 90 days), and at the 4 and 6 month timepoints post-intervention."
41360471|NCT06497569|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietitian during the 30-minute dietitian telehealth visits at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention.
41360472|NCT06497569|BEHAVIORAL|Referral to Dietitian|Usual Care condition referral to a dietitian based on physician discretion.
41360473|NCT06497569|BEHAVIORAL|Social Determinants of Health Survey (SDOH)|"Participants will complete a SDOH Survey that captures individual-level factors (insurance type, preferred language, educational attainment, annual household income, digital health literacy, financial toxicity, and self-reported barriers to care \[e.g., transportation\]) and structural-level factors (neighborhood disadvantage, rural residence).~Digital health literacy will be measured using the validated eHEALS scale, an 8-item measure assessing confidence with finding, evaluating, and applying electronic information to inform health decision-making (score ≤ 30 indicates low literacy)."
41360474|NCT05551195|DEVICE|WB001|WB001 is a digital therapeutic for postpartum depression.
41360475|NCT05551195|DEVICE|ED001|ED001 is a digital therapeutic for postpartum depression.
41360476|NCT01454531|DRUG|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
41360477|NCT02036476|DRUG|Cabozantinib|oral administration
41360478|NCT04852809|OTHER|No intervention|This is an observational study
41360479|NCT01933542|DRUG|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
41360480|NCT01933542|DRUG|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
41360481|NCT01933542|DRUG|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
41360482|NCT01933542|DRUG|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
41360483|NCT00002075|DRUG|Flucytosine|
41360484|NCT00002075|DRUG|Fluconazole|
40840396|NCT02666794|DRUG|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
40840397|NCT02666794|DRUG|Epidural sufentanil|20 mcg
40840398|NCT02666794|PROCEDURE|Placement of the epidural catheter|Placement of the epidural catheter
40840399|NCT02666794|DRUG|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
40840400|NCT02666794|DRUG|Intrathecal morphine|60 mcg
40840401|NCT02666794|PROCEDURE|Placement of an epidural catheter to the catheter through technical needle|Placement of an epidural catheter to the catheter through technical needle
40840402|NCT02666794|DRUG|Intrathecal sufentanil|5 mcg
40840403|NCT03672786|DIETARY_SUPPLEMENT|Multicentrum|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
40840404|NCT05618418|OTHER|No intervention|No intervention
40840405|NCT05115513|DRUG|Medium THC|Marijuana flower with medium THC
40840406|NCT05115513|DRUG|Placebo THC|Marijuana flower with no THC
40840407|NCT01820052|DRUG|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
40840408|NCT01820052|DRUG|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
41360485|NCT00002075|DRUG|Amphotericin B|
41360486|NCT03687229|DIAGNOSTIC_TEST|A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)|measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction
41360487|NCT03687229|DIAGNOSTIC_TEST|A)fasting serum glucose, B)Fasting serum insulin|measure level of insulin resistance
41360488|NCT04899167|OTHER|MRI 1.5T and 3.0T|Magnetic Resonance Imaging for Renal Fibrosis
41360489|NCT05768360|DRUG|Savolitinib|The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
41360490|NCT05768360|DRUG|Digoxin|The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
41360491|NCT05768360|DRUG|Metformin Hydrochloride|The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
41360492|NCT05768360|DRUG|Rosuvastatin|The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
41498453|NCT00625625|PROCEDURE|diagnostic lymphadenectomy|
41498454|NCT00625625|PROCEDURE|therapeutic conventional surgery|
41360493|NCT05768360|DRUG|Furosemide|The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
40840409|NCT03256786|BEHAVIORAL|Prewarming using forced air warmer, warmed intravenous fluid|Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
40840410|NCT05246930|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
40840411|NCT04070495|DRUG|KW-6356|A single oral dose will be administered at Day 1 and 15
41360494|NCT05987709|DIAGNOSTIC_TEST|GuardantSHIELD Blood Test|The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC
41360495|NCT00031824|DRUG|cyclosporine|
40840412|NCT04070495|DRUG|Clarithromycin|400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
40840413|NCT04070495|DRUG|Rifampicin|600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
40840414|NCT05233345|BEHAVIORAL|Occupational Therapy|online occupational therapy sessions are based on the activity training
41266559|NCT00537433|OTHER|Pictogram|"The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.~Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home."
40840416|NCT05969132|PROCEDURE|Fully digital guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement.~3. Oral hygiene instructions (OHI)~4. Presurgical intraoral scanning using an intraoral scanner (IOS)~5. Fabrication of the Gingivectomy guide:~   * Convert (DICOM) file to STL file then merged to STL file corresponding oral soft tissues 3D data obtained by IOS using software of surgical planning.~  * Digital waxing up with new desired positions of gingival margins and zenith points performed.~  * Designing Gingivectomy guide then exported to a 3D printer and mill a transparent resin gingivectomy guide.~6. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~7. Postoperative care"
40840417|NCT05969132|PROCEDURE|Convectional guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement with OHI~3. Gingivectomy guide fabrication:~   * Impressions and casts obtained.~  * Waxing-up included new positions of gingival margins and zenith points.~  * Silicone index with condensation silicone impression materials made with pressure on the cast to reproduce the details of the wax, then filled after setting with resin material and placed in the patient's mouth.~  * Resin mock-up trimmed with blade to define the correct new gingival level.~  * After the patient accept the mock-up design will used as Gingivectomy guide.~4. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~5. Postoperative care"
40840418|NCT03930407|PROCEDURE|The Hayman uterine compression suture.|Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atony during cesarean section.
40840419|NCT00252772|DRUG|Tesaglitazar|
40840420|NCT00252772|BEHAVIORAL|Dietary and Lifestyle counseling|
40840421|NCT03051594|DEVICE|fluorescent camera|used too detect residual caries depending on the bacterial byproducts.
41360496|NCT00031824|DRUG|hydroxychloroquine|
41360497|NCT00031824|DRUG|prednisone|
41360498|NCT00031824|DRUG|tacrolimus|
41360499|NCT01876056|BEHAVIORAL|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
41498455|NCT00625625|PROCEDURE|therapeutic lymphadenectomy|
40840422|NCT03051594|OTHER|caries detector dye|dye used to detect the residual caries.
40840423|NCT03051594|DIAGNOSTIC_TEST|visual tactile assessment|method usually used to detect the residual caries.
40840424|NCT00889200|DRUG|eszopiclone|6 weeks standard oral therapy
40840425|NCT05109260|DIAGNOSTIC_TEST|Point-of-Care Immunoassay device|2 POC Immunoassay devices will be used. One will measure D-dimer levels in capillary blood, the other will measure venous.
41360500|NCT05135507|BEHAVIORAL|An integrated parenting intervention for families of children with developmental disabilities|Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
41360501|NCT06157970|PROCEDURE|Sphenopalatine Ganglion Block|For SPGB, the plastic part of the 16G angiogram is advanced transnasally into both nostrils, with the patient in the supine position and the head in 15-20° extension, until it contacts the posterior mucosa, and after contact, it is withdrawn 1 mm and 2 ml of 0.5% bupivacaine is dripped into the postnasal space within 1 minute. is applied.
41024651|NCT04863950|DRUG|Imipramine Hydrochloride|"For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days."
41024652|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training With Visual and Auditory Cues|Comparison of Effects of Treadmill Training With Visual and Auditory Cues
41024653|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training Without Visual and Auditory Cues|Comparison of Effects of Treadmill Training Without Visual and Auditory Cues
41360502|NCT00759551|DRUG|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
41024654|NCT06105307|BEHAVIORAL|RN-SLEEP|RN-SLEEP is a training program delivered via mobile application and designed to help improve the sleep of nurses who engage in shift work. RN-SLEEP aims to include training on strategies for sleeping while working shift work, basics of sleep science and physiology, behavior change components (i.e., goal setting), and components of cognitive behavioral therapy for insomnia (i.e., relaxation).
41024655|NCT06105307|BEHAVIORAL|Healthy Habit - Educational Control|Healthy habit app (i.e., exercise tracking) to act as a control arm for the RN-SLEEP intervention
41024656|NCT01471535|DRUG|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
41024657|NCT02805842|DRUG|Tacrolimus BID|Administration of Tacrolimus BID
41024658|NCT02805842|DRUG|Advagraf QD|administration of Advagraf QD
41024659|NCT03186898|RADIATION|Proton Therapy (Radiation Therapy)|Undergo proton therapy
41024660|NCT03186898|RADIATION|Photon Therapy (Radiation Therapy)|Undergo photon therapy
41024661|NCT01969838|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
41024662|NCT01969838|DRUG|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
41024663|NCT01969838|DRUG|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
41024664|NCT01969838|DRUG|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
41024665|NCT03129347|DRUG|Nalmefene|Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
41024666|NCT05914610|DRUG|Envolimab|Envolizumab 300mg, D1, ih, Q3W 4-6cycles
41266560|NCT00200850|BIOLOGICAL|House Dust Mite SLIT|low dose SLIT 143 Allergen Units(AU)/ml daily
41266561|NCT00200850|BIOLOGICAL|High dose SLIT|House Dust Mite SLIT- 10,000 Allergen units(AU)/ml daily
41266562|NCT00200850|BIOLOGICAL|Placebo SLIT|Placebo SLIT daily
41266563|NCT02834910|OTHER|collection of bacterial sample|
41266564|NCT02527356|BEHAVIORAL|Ride-On Cars with Standing Posture (ROC-Stand)|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
41266565|NCT02527356|BEHAVIORAL|Ride-On Cars with Standing Postures (ROC-Sit)|Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.
41266566|NCT02527356|BEHAVIORAL|Regular Therapy Program|The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. In addition, they will receive training program in a hospital for 2 hours/per session, 2 sessions/per week for a total of 12-week intervention. The participants will also experience the two 30-minute car driving sessions during the whole 2-hour training. The difference between the regular therapy group and the two ROC groups is the experience of car driving is controlled by the therapist, i.e. passive locomotion. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
41266567|NCT00859365|PROCEDURE|Real Acupuncture|Real acupuncture treatment in real acupuncture points
41266568|NCT00859365|PROCEDURE|Placebo Acupuncture|empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
41266569|NCT00859365|PROCEDURE|No intervention|Patients lay down for a period of 35 minutes without any treatment o intervention
41266570|NCT02664116|DRUG|Diclofenac postassium powder for oral solution and placebo injection|Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
41266571|NCT02664116|DRUG|Ketorolac intramuscular injection and placebo oral solution|ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
41266572|NCT02320487|DRUG|Bendamustine|Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m\^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
41266573|NCT02320487|DRUG|Obinutuzumab|Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
41266574|NCT01823068|DRUG|Vandetanib|Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
41266575|NCT00483327|DRUG|Megestrol Acetate|
41266576|NCT03881709|BEHAVIORAL|Using an E-Book|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
41360503|NCT00759551|DRUG|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
41360504|NCT00759551|DRUG|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
40840426|NCT05883722|PROCEDURE|Catheter ablation|The ablation approach includes: pulmonary vein isolation, left side linear ablation, left side driver ablation and right atrial driver ablation
40840427|NCT03414294|DRUG|K-755 Part A (SAD)|Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
40840428|NCT03414294|DRUG|Placebo Part A (SAD)|Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
40840429|NCT03414294|DRUG|K-755 Part B (MAD)|Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
40840430|NCT03414294|DRUG|Placebo Part B (MAD)|Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
40840431|NCT03414294|DRUG|K-755 Part C (FE)|Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
40840432|NCT03414294|DRUG|K-755 Part D (FE)|Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
41024667|NCT05914610|DRUG|Fruquintinib|Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
40840433|NCT03414294|DRUG|K-755 Part E (MAD)|Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
40840434|NCT03414294|DRUG|Placebo Part E (MAD)|Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
40840435|NCT05505604|PROCEDURE|PENG|patients will receive an ultrasound-guided Pericapsular Nerve Group Block with 20mL of 0.25% bupivacaine (not to exceed 2mg/kg)
40840436|NCT05505604|PROCEDURE|FICB|Patients will receive an ultrasound-guided Fascia Iliaca Compartment Block with 20 mL of 0.25% bupivacaine (not to exceed 2 mg/kg) diluted to total volume of 40 mL of injectate
40840437|NCT00000713|DRUG|Ampligen|
40840438|NCT00313859|DRUG|simvastatin|
40840439|NCT01874938|BIOLOGICAL|LY2875358|Administered IV
40840440|NCT04152213|BEHAVIORAL|Low GI diet|This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
40840441|NCT00844558|OTHER|Gait Training|Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
40840442|NCT00844558|OTHER|Control|There is no intervention associated with this arm of the study
40840443|NCT05644093|DRUG|SPL026 IV|IV dosing
40840444|NCT05644093|DRUG|SPL026 IM|IM dosing
41024668|NCT05914610|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
41024669|NCT05914610|DRUG|Tegafur|Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles
41266577|NCT02755402|DEVICE|Xpert HCV Viral load|HCV viral load testing
40840445|NCT00215514|DRUG|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
40840446|NCT00215514|DRUG|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
40840447|NCT00215514|DRUG|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
41024670|NCT00447863|DRUG|Levonorgestrel/Ethinyl Estradiol|
41024671|NCT05814341|DRUG|Citrate|Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets
41024672|NCT00426478|DRUG|Valsartan plus Hydrochlorothiazide (80mg/12.5mg)|
41266578|NCT02755402|DEVICE|Transient elastography|Evaluation of liver fibrosis
41266579|NCT00000191|DRUG|Carbamazepine|
41266580|NCT00421876|BEHAVIORAL|multifactorial continued educational - behavioural programme|
41266581|NCT03830216|DEVICE|Connected insulin pen and smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is paired with a smartphone app with dose calculator.
41266582|NCT03830216|DEVICE|Inactive connected insulin pen without smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is inactive and not paired with a smartphone app or dose calculator.
41266583|NCT01459978|OTHER|CUmulative SUM (CUSUM) Chart|"Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose"
41266584|NCT04026984|DRUG|Rifamycin SV-MMX|2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT
41266585|NCT04026984|DRUG|Placebo|Matching Placebo tablets
41024673|NCT00426478|DRUG|Amlodipine (5mg)|
41360505|NCT00759551|DRUG|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
41360506|NCT00759551|DRUG|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
41360507|NCT00759551|DRUG|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
40840448|NCT00215514|PROCEDURE|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
40840449|NCT02229526|DIETARY_SUPPLEMENT|Low dose fish oil|Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.
40840450|NCT02229526|DIETARY_SUPPLEMENT|Low dose olive oil|Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
40840451|NCT02229526|DIETARY_SUPPLEMENT|High dose fish oil|Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.
40840452|NCT02229526|DIETARY_SUPPLEMENT|High dose olive oil|Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
40840453|NCT01843270|DEVICE|actual body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
40840454|NCT01843270|DEVICE|ideal body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
41024674|NCT02504645|DRUG|IPP-201101|
41024675|NCT02504645|DRUG|Placebo|
41024676|NCT02504645|OTHER|Standard of Care|
41024677|NCT04751253|DEVICE|High Intensity Laser Therapy|different doses of energies of high-intensity LASER on pain and functional activity in patients with chronic knee OA.
40840455|NCT06102109|PROCEDURE|Pars plana vitrectomy|25gauge pars plana vitrectomy: to remove the vitreous if present
40840456|NCT06102109|PROCEDURE|IOL explantation|Removing if present a subluxated IOL from the anterior chamber or the vitreous cavity
40840457|NCT06102109|PROCEDURE|Scleral IOL fixation Yamane Technique|Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera using only its haptics, which are externalised 2.5mm behind the blue line. The haptic ends are flanged using a thermo cautery to prevent slipping back in.
41024678|NCT02175446|DRUG|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
41024679|NCT01083381|DRUG|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
41024680|NCT01083381|DRUG|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
41024681|NCT06283758|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
41024682|NCT06283758|DEVICE|Sham-control group|Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
41360508|NCT00759551|DRUG|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
41360509|NCT05507346|DEVICE|Cross over Device (PCD or Dayspring - alternate to first group)|Cross over after three month of use and a month of washout period
41360510|NCT04235673|DIETARY_SUPPLEMENT|melatonin|orally administered drops
41360511|NCT04235673|DRUG|placebo|orally administered drops
41360512|NCT04196010|DRUG|Cladribine|Given IV
40840458|NCT06102109|PROCEDURE|"Scleral IOL fixation 4-flanged Technique"|Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physical Micropure 123) gets fixated in the sclera using one 6.0 polypropylene suture per 2 haptic loops, which are put trough the loops in a W shape. The suture ends are externalised 2.5mm behind the blue line and its ends are flanged using a thermo cautery to prevent slipping back in.
40840459|NCT01009177|DRUG|Bosentan|Bosentan 500 mg bid
40840460|NCT01009177|DRUG|Placebo|Placebo
40840461|NCT01865383|BEHAVIORAL|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
40840462|NCT02968147|DEVICE|High frequency jet ventilation|General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system
40840463|NCT02968147|DEVICE|Conventional ventilation|General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
40840464|NCT00259207|PROCEDURE|Pulmonary valve insertion|Pulmonary valve insertion
40840465|NCT00259207|PROCEDURE|medical surgery hybride|medical surgery hybride
40840466|NCT04136626|DEVICE|Perspectives OCD|The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work) and behavioral skills (e.g., exposure and response prevention).
40840467|NCT04136626|DEVICE|The Health and Well-Being Program|The website includes 12 modules related to general health and well-being (e.g., sleep and nutrition). Each module contains educational information and questions about an indvidual's experience with the given topic.
40840468|NCT05492916|BEHAVIORAL|Diabetes Prevention Program (DPP)|Video-based intervention to prevent or delay Type 2 Diabetes. Includes both educational and social cognitive theory (SCT)-based behavioral content. Each video lasts about 5 minutes in duration.
40840469|NCT05492916|BEHAVIORAL|Community-Supported Agriculture (CSA)|Provides weekly and culturally appropriate fresh produce and in-language education on nutrition, healthy cooking demonstrations, and culturally tailored recipes for participants. Enables participants to socialize with other Chinese immigrants in the program as a way to enhance social cohesion and support.
40840470|NCT06284330|OTHER|Enhanced cascade testing|Direct mailed at-home genetic testing kit to probands' relatives.
40840471|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular
40840472|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular
40840473|NCT01178424|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
40840474|NCT01178424|BEHAVIORAL|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
40840475|NCT05010447|DEVICE|Virtual Coach App|The avatar-guided app aims to deepen the user's understanding of Acceptance and Commitment Therapy (ACT) and promote application of ACT skills in every-day-life. Event-Sampling-Methodology (ESM) is used to capture the user's progress as it unfolds.
40840476|NCT04097977|OTHER|An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work) targeting young people with mental health difficulties.|"An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work).~Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group.~Network meetings The RENEW-S network meetings is fundamental for this approach. First meeting between the young person and the facilitator is about what the young person can expect, and information about the principles and ideas behind RENEW-S. The RENEW-S process consists of 4 general phases: 1) a mapping process 2) the development of a team to support goal attainment 3) implementing the plans 4) preparation for exiting RENEW.~Youth group The group is structured around the same agenda each time, starting with a presentation round, followed by an activity within the topic of the day, and finishing with sharing experiences of the activity in plenum. The young people can find inspiration regarding themes and exercises in the RENEW manual."
40840477|NCT02264080|DRUG|WAL2014|
40840478|NCT02264080|DRUG|Placebo|
41024683|NCT05681884|DRUG|Faricimab|Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.
41360513|NCT04196010|DRUG|Cytarabine|Given IV
40840479|NCT03070821|OTHER|rtfMRI neurofeedback training|Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
40840480|NCT03070821|DEVICE|3T MRI|A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
40840481|NCT05115916|BEHAVIORAL|MyChart Priming Message|In addition to the standard FIT mailer protocol, we will send randomized participants a message via their personal health portal. Patients receive the primer approximately 1-2 weeks prior to arrival of the FIT kit, which informed patients about the incoming FIT Kit and instructed patients to complete and return the kit promptly.
40840482|NCT00624754|DRUG|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
40840483|NCT00624754|DRUG|lactose|Lactose 2 puffs b.i.d for 1 month
40840484|NCT06050486|BEHAVIORAL|Mentalization-based treatment for children (MBT-C)|MBT-C is a time-limited intervention designed to resolve the child's emotional or behavioral problems and to promote resilience, by promoting the child's and parent's mentalizing capacities. It is composed by 1) an assessment phase, composed of 3 to 4 sessions, with the family, the child and the parent(s), 2) an intervention phase, composed of a minimum block of 12 individual sessions with the child and parallel sessions for the parent(s), that can be repeated up to three times (i.e., maximum of 36 sessions), and 3) a booster session 3 to 12 months after the last session. In this clinical trial, MBT-C will be composed of: 3 assessment sessions; 12 individual sessions with the child, plus 6 parallel individual sessions with the parent with BPD; 1 booster family session, 3 months after the last session.
40840485|NCT04311463|DRUG|Paroxetine hydrochloride|Paroxetine hydrochloride will be administered.
40840486|NCT04311463|DRUG|PAXIL (Paroxetine hydrochloride )|PAXIL will be administered.
40840487|NCT00122044|DRUG|trihexyphenidyl|
41360514|NCT04196010|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
41024684|NCT04652193|PROCEDURE|Recovery profile from general anesthesia|It includes the phases during recovery from general anesthesia: Time to spontaneous ventilation, Laryngeal Mask Airway (LMA) removal time, open eyes, and Post-Anesthesia Care Unit (PACU) discharge.
41024685|NCT06153979|BIOLOGICAL|Verorab|Participants in each group will receive rabies vaccination (standard 3-dose series given as PrEP), with the first dose randomized to either Week 8 or Week 47 after enrollment.
41024686|NCT02283528|DEVICE|Stryker Hybrid|Place Hybrid arch bars
41024687|NCT02283528|DEVICE|Erich|Control group is Erich arch bars
41024688|NCT01978119|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
41024689|NCT01978119|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
41360515|NCT04196010|DRUG|Mitoxantrone|Given IV
41360516|NCT00386035|DRUG|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
41360517|NCT00386035|DRUG|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
41360518|NCT04087733|DRUG|OZODROP|3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
41024690|NCT04674345|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).
41024691|NCT06572527|BEHAVIORAL|Physical Activity Program|"Nurse-Led Coordinated Physical Activity Program for Child Health, developed as part of the Coordinated Approach to Child Health program for preschool children."
41024692|NCT00913159|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
41024693|NCT01076595|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
41024694|NCT03843359|DRUG|GSK3745417|GSK3745417 will be administered.
40840488|NCT00820404|DRUG|BLI-489|
40840489|NCT00820404|DRUG|Placebo|
40840490|NCT01410188|DRUG|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
41024695|NCT03843359|DRUG|Dostarlimab|Dostarlimab will be administered.
41024696|NCT04163276|DIAGNOSTIC_TEST|18F FDG PET exam|All patients have received 18F-FDG PET/CT in nuclear medicine
41024697|NCT04077008|PROCEDURE|unilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
41024698|NCT04077008|PROCEDURE|bilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
41024699|NCT06066112|DRUG|Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.|Randomly assign to TR or RT sequence groups based on a predetermined random table and receive the corresponding study drug according to the corresponding administration sequence.
41024700|NCT06197139|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose.
41024701|NCT03223103|DRUG|Poly-ICLC|Poly-ICLC 100mcg per peptide per dose
41024702|NCT03223103|DEVICE|Tumor Treating Fields|an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
41024703|NCT03223103|BIOLOGICAL|Peptides|synthetic long peptides (SLP) as vaccine substrate
41360519|NCT02698020|PROCEDURE|Room-air|Provision of room-air
40840491|NCT01410188|DRUG|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
40840492|NCT01410188|DRUG|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
40840493|NCT05674253|DRUG|Dexmedetomidine + Hydrocortisone|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
40840494|NCT00865839|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
40840495|NCT00865839|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
40840496|NCT02517320|DRUG|MT-3995 Low|
41360520|NCT04691518|OTHER|Acute Intermittent Hypoxia|30 minute session of Acute Intermittent Hypoxia
41360521|NCT04691518|OTHER|Sham Acute Intermittent Hypoxia|30 minute session of Sham Acute Intermittent Hypoxia
41360522|NCT01411059|BEHAVIORAL|yoga|yoga classes 2 times per week for 32 weeks
40840497|NCT02517320|DRUG|MT-3995 Middle|
40840498|NCT02517320|DRUG|MT-3995 High|
40840499|NCT02517320|DRUG|Placebo|
40840500|NCT04349956|DRUG|UBX0101 or placebo|This is an observational study. No intervention is administered.
40840501|NCT01984450|PROCEDURE|ACIC|"Autologous Collagen Induced Chondrogenesis (ACIC):~ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation."
40840502|NCT01984450|PROCEDURE|MCIC|"Mesenchymal Cell Induced Chondrogenesis (MCIC):~MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation."
40840503|NCT01984450|DEVICE|implant with a collagen + fibrin gel mixture|
40840504|NCT04122170|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
40840505|NCT04122170|DRUG|Aspirin (ASA) Oral Tablet - Pre-Treatment|Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
41024704|NCT05580913|BEHAVIORAL|Resistance training|12 weeks of resistance-training performed two times per week
40840506|NCT04122170|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion."
40840507|NCT04122170|DRUG|Placebo (0.9% Sodium chloride) infusion|0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
40840508|NCT00317590|DEVICE|Rapid Diagnostic Test for Malaria (Paracheck®)|
41024705|NCT03088384|DRUG|Ketamine|Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
41024706|NCT05009797|PROCEDURE|atrial fibrillation catheter ablation|The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.
41024707|NCT01543256|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|"Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell. (RMV in intervention name indicates removable)"
40840509|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
40840510|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
40840511|NCT00885794|DRUG|Ranibizumab|3 intravitreal injection every 5 weeks
40840512|NCT06421272|BEHAVIORAL|APP-based emotion recognition intervention|ASD children were asked to play emotion recognition-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
40840513|NCT06421272|BEHAVIORAL|APP-based memory intervention|ASD children were asked to play memory-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
40840514|NCT02647346|DEVICE|Daily use of podimetrics smart-foot mat|
41024708|NCT01543256|DEVICE|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
41024709|NCT02977377|OTHER|Exercise therapy|Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
41024710|NCT02977377|OTHER|Whole body vibration|4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
41360523|NCT05585099|OTHER|Exercise|Participants will stand on lower body positive pressure treadmill and participate in walking exercise.
41360524|NCT04143815|DRUG|MBA-P01 (Botulinum toxin A)|Intramuscular injection, dose varies by groups
41360525|NCT04143815|DRUG|Placebo|Intramuscular injection
40840515|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
40840516|NCT00853840|DRUG|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
40840517|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
40840518|NCT00853840|DRUG|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
40840519|NCT01276002|PROCEDURE|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
40840520|NCT01873690|DRUG|Ciprofloxacin|Once, 400 mg IV
40840521|NCT01873690|DRUG|Placebo|5% Dextrose in water
41360526|NCT03812614|BEHAVIORAL|FAM ACT|Patient and Support Person (dyad) will receive a Diabetes Complications Risk Assessment profile and introduction session, Support Person-focused information/skills training through 4-6 extended DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
40840522|NCT05485142|PROCEDURE|prolotherapy|5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.
40840523|NCT00060580|PROCEDURE|Raman scattering spectroscopy|
40840524|NCT00461461|PROCEDURE|meeting nurses / physicians, quality improvement sessions|"For each iatrogenic indicator, the interventions are:~1. Meeting with the ICU staff to discuss the epidemiology of patients on each theme.~2. Pocket card with guidelines on the theme and ICU protocol in each study ICU.~3. Feedback meeting twice a month on errors in the unit, preventability, and appropriate changes in procedures on the subject."
41024711|NCT06535997|OTHER|Questionnaire|For patients alive only at the time of inclusion, completion of a quality-of-life questionnaire and a medico-economic interview (prospective).
41360527|NCT03812614|BEHAVIORAL|I-DSMES|Patient only will receive a Diabetes Complications Risk Assessment profile and introduction session, 4-6 group DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
40840525|NCT03870425|OTHER|Distribution pattern of dietary proteins (minced meat)|Study effect of an even or skewed distribution pattern of dietary protein
40840526|NCT03668990|OTHER|IMUs (Xsens, MVN Studio)|It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
40840527|NCT06380127|BEHAVIORAL|Exercise training|The exercise intervention will take place at the nursing homes and consists of 12 weeks of supervised concurrent exercise training, performed thrice weekly on nonconsecutive days to avoid overtraining and fatigue. Each session will last 50-60 min and consist of a warm-up, resistance plus aerobic training, and a 5-min cool-down period. The resistance training will comprise 2-3 sets of 10 to 15 repetitions with a load equivalent to 40 to 70% of the 1-repetition maximum (1RM) for upper (i.e., bicep curl) and lower body exercises (i.e., seated knee extension). The sit-to-stand exercise will be performed as fast as possible according to each participant's capacity without external load. The recovery between sets is between 1 and 2 min. Afterwards, participants will perform walking exercises with changes in pace and direction. The duration of the aerobic training will progress from 5-10 min duration in the first weeks to 10-15 min. The sessions will end with stretching exercises.The exercise
41024712|NCT00491686|DRUG|AZD6765|intravenous infusion
41024713|NCT01621750|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
41024714|NCT06065696|PROCEDURE|Early mobilization|Patients who received early mobilization in postoperative period
41360528|NCT03730987|BEHAVIORAL|HoMBReS intervention|Adapted intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors, substance abuse and HIV among recently immigrated rural and urban men.
41360529|NCT03730987|BEHAVIORAL|Families Talking Together (FTT)|The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, reduce alcohol use, risky sexual behaviors and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
41360530|NCT03730987|BEHAVIORAL|Diabetes Prevention Intervention|Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
41360531|NCT02256956|DRUG|Amitriptyline|25 mg / day for 10 days
41360532|NCT02256956|DRUG|Tolterodine|Placebo 1 mg / day for 10 days
41360533|NCT05527418|DRUG|Dasatinib|Dasatinib monotherapy 70 mg/day, during 16 weeks.
41360534|NCT05527418|DRUG|Placebo|Placebo during 16 weeks.
41024715|NCT06065696|PROCEDURE|No early mobilization|Patients who did not receive early mobilization in postoperative period
41024716|NCT00659646|DRUG|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
41024717|NCT00659646|DRUG|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
41360535|NCT02822274|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-70_R84-064)
41360536|NCT01142960|DIETARY_SUPPLEMENT|Starch|1350mg/day
41360537|NCT01142960|DIETARY_SUPPLEMENT|Lycium Barbarum|1350mg/day
41360538|NCT04369599|DEVICE|V/Q System|With the patient supine, sedated, and hemodynamically stable, the Vest is placed upon the patient and secured by clinicians and staff. All chambers of the Vest will be inflated simultaneously. First inflation will be for one hour to a pressure of 0.4 psi. Subsequent inflations at 0.8 and finally 1.2 psi will be performed for one hour each. Participants will be treated for up to four hours and then will be observed for an additional hour.
41498456|NCT04660240|DEVICE|Abluminus Sirolimus Eluting Stent System (ASES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the ASES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
40840528|NCT03155308|DEVICE|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
41024718|NCT02676206|OTHER|Classical music|Classical music will be played over the headphones
41024719|NCT01242488|BIOLOGICAL|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
41360539|NCT03145207|DRUG|Lidocaine patch|lidocaine patch
41360540|NCT02500901|DRUG|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
41360541|NCT02500901|DRUG|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
41360542|NCT02003287|OTHER|VFSS|Videofluoroscopic Swallow Study
41360543|NCT02003287|OTHER|FEES|Fiberoptic Endoscopic Swallow Study
41024720|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
41024721|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
41024722|NCT01242488|BIOLOGICAL|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
41024723|NCT01242488|BIOLOGICAL|CDP6038|60 mg sc at Weeks 0, 4 and 8
41360544|NCT05207371|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)
41360545|NCT01869686|BIOLOGICAL|Denosumab|60 mg
41360546|NCT04588298|DRUG|AZD9833|AZD9833 tablets will be administered orally.
41360547|NCT04802226|OTHER|self exclusion procedure|self exclusion procedure( responsible gambling tool)
41024724|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 4 and 8
41024725|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 4 and 8
41024726|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
41360548|NCT02651038|DRUG|Micafungin|Measurement of PK
41360549|NCT02516605|DRUG|Part 1: LJN452|LJN452 capsules administered once daily for 28 days
41360550|NCT02516605|DRUG|Part 1: Placebo|Matching placebo capsules administered once daily for 28 days
41360551|NCT02516605|DRUG|Part 2: LJN452 Dose level 1|LJN452 capsules administered once a day for 12 weeks
41360552|NCT02516605|DRUG|Part 2: Placebo|Matching placebo to LJN452 administered once a day for 12 weeks
41360553|NCT02516605|DRUG|Part 2: LJN452 Dose level 2|LJN452
41360554|NCT05014945|PROCEDURE|(atelocollagen group)|Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
41360555|NCT02926690|DRUG|OTS167PO|Single arm, no competitor
41360556|NCT03046069|OTHER|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
41360557|NCT03046069|OTHER|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
41360558|NCT03046069|OTHER|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
40840529|NCT06124820|DEVICE|Deka SmartXide Touch C60 (MonaLisa Touch)|Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch)
40840530|NCT06124820|DEVICE|Sham|Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
40840531|NCT05978141|OTHER|Optional Blood Sample and Nail Sample|Participants may provide optional research blood and nail samples for biobanking and future use
40840532|NCT05592132|OTHER|Virtual reality headset|Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.
40840533|NCT01164553|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
40840534|NCT06285123|BEHAVIORAL|REP|"REP is a bundle of strategies designed to help hospitals implement an evidence-based clinical practice. REP's core components include 1) user-friendly packaging of the clinical guidance, 2) structured clinician training, 3) performance feedback, and 4) brief technical assistance."
40840535|NCT06285123|BEHAVIORAL|Facillitation|Facilitation is a process of interactive problem-solving via a supportive consultation relationship. Facilitation is delivered by an expert who meets regularly with site quality improvement leaders to support interactive problem-solving to address local barriers and unanticipated implementation challenges. In contrast to the group-based, brief technical assistance in REP, facilitation is individualized consultation with the site clinical champion that generates highly customized, local solutions that can potentially be sustained by the local providers and champions.
40840536|NCT01443663|BIOLOGICAL|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
40840537|NCT01826435|BEHAVIORAL|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
41360559|NCT03046069|OTHER|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
40840538|NCT05522569|DRUG|Allogeneic human mesenchymal stem cells (Allo-hMSCs)|Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.
40840539|NCT00659503|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
40840540|NCT00659503|DRUG|Placebo|placebo
40840541|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
40840542|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
40840543|NCT06492473|DEVICE|ECHO|type and size of ventricular septal defect
40840544|NCT02943616|DEVICE|Absorb BVS|"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~* Scaffold diameters: 2.5, 3.0, and 3.5 mm~* Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
40840545|NCT00991783|DRUG|Digoxin + Fimasartan|Digoxin (7 days), Digoxin + Fimasartan (7 days)
40840546|NCT00628147|DEVICE|Narrow band imaging colonoscope|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
40840547|NCT04082286|OTHER|Yttrium-90 labelled monoclonal antibody against CD66|
41360560|NCT03046069|OTHER|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
41498457|NCT04660240|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the OSES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
40840548|NCT04210115|BIOLOGICAL|pembrolizumab|IV infusion
40840549|NCT04210115|DRUG|placebo|IV infusion
40840550|NCT04210115|DRUG|cisplatin|IV infusion
40840551|NCT04210115|DRUG|5-FU|IV infusion
40840552|NCT04210115|RADIATION|radiotherapy|external radiation
40840553|NCT04210115|DRUG|leucovorin|IV infusion
40840554|NCT04210115|DRUG|levoleucovorin|IV infusion
40840555|NCT04210115|DRUG|oxaliplatin|IV infusion
41024727|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
41360561|NCT00002176|DRUG|Hydroxyurea|
41360562|NCT00002176|DRUG|Nelfinavir mesylate|
41360563|NCT00002176|DRUG|Stavudine|
41360564|NCT00002176|DRUG|Didanosine|
41360565|NCT01218477|DRUG|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)
41024728|NCT01242488|OTHER|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
40840556|NCT06175156|PROCEDURE|Controlled analgesia/sedation|During the pre anesthesia assessment, explain in detail to the patient the usage of the self-control pump and confirm that each patient can master it. Firstly, connect the self-control analgesic pump with a loading dose of 3 ml. Then, continuously pump in a mixture of propofol and remifentanil at a speed of 0.1 ml/kg/h. After the loading dose is completed, the examination can begin. During the operation, press the self-control handle according to the patient's sensation. Each press can quickly push 1ml of the medication, with a locking time of 1 minute
41360566|NCT01218477|DRUG|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
40840557|NCT06175156|PROCEDURE|Intravenous combined anesthesia|Intravenous slow infusion of fentanyl 1 μ G/kg, midazolam 0.02mg/kg, slowly administer propofol 0.8-1mg/kg after 2 minutes (time greater than 60 seconds), and start the examination when the patient's consciousness disappears and they do not respond. During the surgery, propofol is interrupted to maintain the auditory evoked potential index (AAI) between 30-40.
40840558|NCT04067778|DIAGNOSTIC_TEST|Intervention Group|Standard colonoscopy with targeted biopsies only
40840559|NCT04067778|DIAGNOSTIC_TEST|Control Group|Standard colonoscopy with random AND targeted biopsies
40840560|NCT03259685|OTHER|710 ml of regular soft drinks, taken daily for 10 weeks|Subjects will consume regular soft drinks to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatments (diet and stevia beverages).
40840561|NCT03259685|OTHER|710 ml of diet soft drinks, taken daily for 10 weeks|Subjects will consume diet soft drinks during 10 weeks to test the possible effects of aspartame/acesulfame-K sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
41024729|NCT00486343|DRUG|Zileuton CR|Zileuton CR tablets 2x600mg BID for 24 weeks
41024730|NCT00486343|DRUG|Placebo|Placebo tablets 2x600mg BID for 24 weeks
41024731|NCT05710068|DEVICE|RF Microneedle|Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
41360567|NCT03109418|DRUG|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
41360568|NCT03109418|PROCEDURE|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
41360569|NCT06227429|DRUG|Nitisinone|According to prescription
41360570|NCT05277805|OTHER|EMPOWER-UP questionnaire|Participants are asked to respond to the EMPOWER-UP questionnaire to test the psychometric properties of the questionnaire.
41024732|NCT05710068|DRUG|Combination cream|5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
41360571|NCT04937608|DIAGNOSTIC_TEST|Sperm analysis|Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.
41360572|NCT01000233|DIETARY_SUPPLEMENT|Phytine (phytate)|300 mg tid \* 24 months
41360573|NCT01000233|DIETARY_SUPPLEMENT|Placebo|Phytine (Phytate)
41360574|NCT02286622|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
41360575|NCT03936868|PROCEDURE|Tendon transfer|flexor carpi radialis transfer in most of patients and boye-transfer in very few
41360576|NCT02789761|DIETARY_SUPPLEMENT|High-flavanol milk choocolate|
41360577|NCT02789761|DIETARY_SUPPLEMENT|Low-flavanol milk chocolate|
41360578|NCT00453635|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m\^2 IV on day 1 every 3 weeks for 6 consecutive cycles
41360579|NCT00453635|DRUG|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
41360580|NCT00453635|DRUG|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
41360581|NCT00453635|DRUG|Vinorelbine|Vinorelbine at the dose of 60mg/m\^2 per os,weekly
41360582|NCT00841854|DRUG|pantoprazole|pantoprazole 40mg bid
41360583|NCT00841854|DRUG|bismuth|bismuth 300mg qid
41360584|NCT00841854|DRUG|metronidazole|metronidazole 500mg tid
41360585|NCT00841854|DRUG|tetracycline|tetracycline 500mg qid
41360586|NCT06137027|DRUG|Cannabidiol Oil|Cannabidiol oil will be administered sublingually 2-3 hours preoperatively
41360587|NCT06137027|DRUG|Placebo|Placebo will be administered sublingually 2-3 hours preoperatively
41498458|NCT04925479|DRUG|Asciminib Pediatric formulation group|"Asciminib Pediatric formulation group: Mini-tablets will be supplied as size 0 capsules containing 1 mg mini-tablets, taken orally:~10 mg (10x 1 mg tablets in capsule) 15 mg (15x 1 mg tablets in capsule) 20 mg (20x 1 mg tablets in capsule) 30 mg (30x 1 mg tablets in capsule)"
41360588|NCT03471143|DRUG|adrabetadex (2-Hydroxypropyl-Beta-Cyclodextrin)|"VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg"
41498459|NCT04925479|DRUG|Asciminib Adult formulation group|"Asciminib Adult formulation group:~40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally."
41498460|NCT06390267|DEVICE|Sparrow Hawk (Active)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of active (prophylactic or acute) therapy according to the participant's randomization group.
41498461|NCT06390267|DEVICE|Sparrow Hawk (Sham)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of sham (prophylactic or acute) therapy according to the participant's randomization group.
41024733|NCT01747759|OTHER|Kruskal-Wallis and qualitative parameters|
41024734|NCT02509689|BEHAVIORAL|Global Z-Score Neurofeedback Training|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
41360589|NCT06115343|BEHAVIORAL|Mindfulness|Conscious awareness practice was carried out in 6 sessions. Various inventories are used depending on the nature of the session. For example, in the leaf theme, participants are asked to close their eyes and put their thoughts from the past on a leaf and drop them into running water.
41360590|NCT01464073|BEHAVIORAL|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
41360591|NCT01464073|BEHAVIORAL|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
41024735|NCT02418546|BEHAVIORAL|In-Person Nutritional Counseling by a Registered Dietitian|
41360592|NCT01464073|BEHAVIORAL|Good Medical Practices|"Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise)."
41360593|NCT01464073|DIETARY_SUPPLEMENT|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
41360594|NCT01176422|GENETIC|Blood sample|Blood samples will be collected before and after treatment completion.
41360595|NCT00945945|DRUG|Duloxetine (DLX)|dose daily by mouth
41360596|NCT00945945|DRUG|Placebo (PLA)|Placebo Comparator daily by mouth
41360597|NCT02288663|OTHER|measurement of morphological parameters|measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
41360598|NCT02288663|BIOLOGICAL|a blood sample|One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
41360599|NCT02288663|BIOLOGICAL|albumin or blood in urine|dipstick analysis for albumin or blood in urine
41360600|NCT02288663|DEVICE|Dual X-ray absorptiometry (DXA)|measurement of lean body mass by whole-body DXA
41360601|NCT02288663|DEVICE|Bioelectric Impedance Spectroscopy (BIS)|measurement of lean body mass by BIS
41360602|NCT02288663|BIOLOGICAL|51Cr-EDTA plasma clearance|measurement of 51Cr-EDTA plasma clearance to determine GFR
41360603|NCT04868760|DRUG|Ipilimumab|Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
41360604|NCT04868760|DRUG|IBI310|Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
41360605|NCT06173726|BIOLOGICAL|BST02 Injection|"The TIL used for tumor tissue surgical sampling of qualified subjects was used to prepare BST02 injection, and the subjects who successfully received the surgical sampling were considered to be enrolled.~In the study process, cell transfusions were recorded as day 0 of the study. On the 3rd day (D-3) before infusion of BST02 injection, it is necessary to receive eluvial pretreatment. Considering that this product is unmodified autologous T lymphocytes, previous studies have shown that low-intensity cyclophosphamide can stimulate their proliferation in vivo. Therefore, the cyclophosphamide (Cy) single-drug regimen is recommended: Cy 250mg\~1.5g/m2, a single intravenous infusion"
41360606|NCT01626599|DEVICE|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~* is not implantable and no surgical procedure is required for a human subject to use the devices;~* is not for use in supporting or sustaining a human life; and~* is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~* Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
41360607|NCT00355251|DRUG|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
41360608|NCT05973825|PROCEDURE|Leucapheresis|leucapheresis is a procedure in which a large amount of blood cells are obtained by an apheresis procedure
40840562|NCT03259685|OTHER|710 ml of stevia-sweetened soft drinks, taken daily for 10 weeks|Subjects will consume soft drinks containing stevia during 10 weeks to test the possible effects of steviol glycosides sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
41024736|NCT02418546|BEHAVIORAL|Nutritional counseling using an e-Health Application|
41360610|NCT03187314|DRUG|Radiation|RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
41360611|NCT03187314|DRUG|SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
41360612|NCT05848128|DRUG|5% Tavilermide ophthalmic solution|Twice a day topicial dosing
41360613|NCT05848128|OTHER|Vehicle ophthalmic solution|Twice a day topical dosing
41498462|NCT06633679|BEHAVIORAL|Se Cuida Intervention|The intervention consist in an internet based cognitive behavioural therapy program delivered through a online platform. Intervention consist of 8 weeks with 8 weekly modules assigned to the participants. The program has been translated and adapted to the Brazilian and is based on CBT techniques focused on managing psychological symptoms of anxiety and depression in young people. Out of a total 14 modules adaptaded, 8 will be delivered in the treatment: 5 will be available to all participants and 3 will be tailored according to the initial assessment and interviews. The intervention is self-guided with support on demand, meaning that when participants need support, they could chat directly through the platform text message channel with a psychoteraphist responsible for them. Also, once a week each participants receive feedbacks regarding their work on the program\&#39;s exercises.
41498463|NCT04630158|OTHER|SAF312 Placebo|Topical ocular, suspension eye drops
41498464|NCT04630158|DRUG|SAF312|Topical ocular, suspension eye drops
41498465|NCT06066424|DRUG|Rimiducid|Given by (IV) vein
41360614|NCT02785588|DEVICE|3.0 T Neonatal MRI scanner|eligible subjects will undergo neonatal MRI scan procedure
41360615|NCT04537312|PROCEDURE|Robot-assisted Nipple Sparing Mastectomy|Under RNSM
41360616|NCT04537312|OTHER|Survey Administration|ancillary correlative
41360617|NCT04537312|DEVICE|RNSM|Robot-assisted Nipple Sparing Mastectomy
41360618|NCT02554721|DRUG|Cilostazol|
41360619|NCT02554721|DRUG|Acetylsalicylic acid|
41360620|NCT02554721|DRUG|Clopidogrel|
41498466|NCT06066424|DRUG|TROP2-CAR-NK Cells|Given by (IV) vein
41498467|NCT06066424|DRUG|Fludarabine phosphate|Given by (IV) vein
41498468|NCT06066424|DRUG|Cyclophosphamide|Given by (IV) vein
40840563|NCT04135846|DRUG|Doxazosin|16 mg or maximum tolerated dose (MTD)
40840564|NCT04135846|DRUG|Placebo|Matching placebo
40840565|NCT02859896|DRUG|Doxercalciferol (GZ427397)|"Pharmaceutical form: capsule~Route of administration: oral"
40840566|NCT02859896|DRUG|Calcitriol|"Pharmaceutical form: capsule~Route of administration: oral"
41024737|NCT00001663|DEVICE|Magstim Super Rapid Stimulator|
41498469|NCT03307616|BIOLOGICAL|Ipilimumab|Given IV
41498470|NCT03307616|BIOLOGICAL|Nivolumab|Given IV
41498471|NCT03307616|RADIATION|Radiation Therapy|Undergo radiation therapy
41498472|NCT03067597|DRUG|Dinoprostone|The DVI contains 10 mg dinoprostone
41498473|NCT05379816|PROCEDURE|5% DW perineural injection|5% DW perineural injection to intercostal nerve
41498474|NCT03983824|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41360621|NCT04301349|DRUG|vaginal dinoprostone|two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
41498475|NCT03983824|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41024738|NCT06123767|PROCEDURE|CAS + Intravascular measuring the pressure gradient|"Measurements taken during the procedure during CAS~* placement of a FFR- micro catheter on the neuroprotection wire and taking a measurement before the stenosis and in the internal carotid artery above the stenosis~* reading the pressure gradient after obtaining a stable value (a minimum of 5 cardiac cycles)~  * the study of intravascular pressure measurements will be performed using a special micro catheter"
41024739|NCT06123767|PROCEDURE|CAS (standard)|"Animation of blood pressure measurements on the FFR console without actual measurement in carotid artery (blinding of the study to the patient) during CAS procedure."
41024740|NCT06123767|DIAGNOSTIC_TEST|Doppler ultrasonound of cephalic arteries|non-invasive assessment of carotid stenosis before surgery and assessment of results after CAS (3 and 12 months after CAS)
41024741|NCT06123767|RADIATION|Angio-CT of the neck and head|Non-invasive pre-operative assessment and post-CAS result (3 months after)
41024742|NCT06123767|OTHER|Otolaryngological examination|Hearing and balance tests (before and after CAS) - prospective follow-up
41024743|NCT06123767|OTHER|Psychological examination|psychological examination with questionnaires (before and after CAS) - prospective follow-up
41024744|NCT06123767|OTHER|Neurological examination|neurological examination with questionnaires (before and after CAS) - prospective follow-up
41360622|NCT04301349|DRUG|vaginal misoprostol|two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
41360623|NCT04301349|DRUG|placebo|two tablets of placebo given 3 hours prior to IUD insertion
41360624|NCT02939508|OTHER|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
41360625|NCT02939508|OTHER|Non-colon originated: Neostigmin, Colonoscopy decompression|
41498476|NCT03983824|DRUG|Cytarabine|Given IV
41498477|NCT03983824|PROCEDURE|Echocardiogram Recording|Undergo ECHO
41498478|NCT03983824|DRUG|Etoposide Phosphate|Given IV
41498479|NCT03983824|DRUG|Mitoxantrone Hydrochloride|Given IV
41498480|NCT03983824|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41498481|NCT03983824|DRUG|Peposertib|Given PO
41498482|NCT04638075|DEVICE|Supplemental Nursing System|The SNS is a device designed to deliver supplemental milk by suckling at the mother's nipple. A specially designed bottle attaches to the mother's breast and serves as the reservoir for milk. Attached to the bottle is a small tube which runs down to and is placed on the tip of the mother's nipple. With an adequate latch the neonate obtains supplementation by suckling. Additionally, this suckling stimulates milk production (Lawrence \& Lawrence, 2016).
41498483|NCT03803982|PROCEDURE|Deep Neuromuscular Blockade|The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.
41498484|NCT03803982|DRUG|Sugammadex|Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
41498485|NCT01832779|OTHER|Achalasia subjects|Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
41360626|NCT04621825|DEVICE|ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over a four - six-week period (per AMS Product) or until the wound is healed to extent that the use of the ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings. is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
41498486|NCT06167863|DIAGNOSTIC_TEST|radiomics|extracted image features from CT or MRI
41498487|NCT06500624|DRUG|Pizotifen|Each subject will be given 0.5mg pizotifen with 10-20mg escitalopram in patients with depressive disorder
41498488|NCT05149859|OTHER|Observational|(no intervention)
41498489|NCT01064752|DRUG|Minocycline|100 mg po bid for 8 weeks
41360627|NCT01156636|DRUG|Sildenafil|50 mg 3 times/day for 1 year
41360628|NCT01156636|DRUG|Placebo|
41498490|NCT06168630|OTHER|Manual lymph drainage|It consists of patients who will receive manual lymph drainage everyday for 5 days. The subject's position will be supine with their knees bent. Every session will be of 45 minutes. Manual lymph drainage will with abdominal lymph drainage, after which central lymph stimulation will be performed. Then, by stimulating the bilateral axillary lymph nodes, the flow of fluid over the right and left breasts will be directed toward the axillary lymph nodes. While the patients in the prone position, bilateral axillary lymph nodes will be stimulated, and each manual lymph drainage will be performed from the dorsum to the axillary lymph node .
41498491|NCT06168630|OTHER|Control group|The other group will receive massage for 20 minutes every day for 5 days from first day of treatment. Massage will be done using the index and middle fingers in a spiral motion towards the nipples.
41498492|NCT04863599|OTHER|Questionnaire|Patients will be asked to complete the Bauer and Brice questionnaire at post-operative day 1.
41360629|NCT00990522|PROCEDURE|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
41360630|NCT00302731|DRUG|Estradiol , estriol , progesterone|
41024745|NCT06123767|DIAGNOSTIC_TEST|MR cerebral perfusion|"Assessment of the cerebral perfusion alterations using DSC (dynamic susceptibility contrast) MR perfusion, before and after CAS (after 3 months):~Parametric maps of cerebral blood flow (CBF), cerebral blood volume (CBV), time to peak (TTP), and mean transit time (MTT) will be generated and used for the qualitative and quantitative analyses of the following perfusion parameters:~* cerebral blood volume (CBV) value in ml/100ml;~* cerebral blood flow (CBF) value in ml/100ml/min;~* mean transit time (MTT) value in seconds~* time to peak (TTP) value in seconds"
41024746|NCT06057051|DEVICE|iStent Infinite|iStent Infinite Trabecular Micro-Bypass System
41024747|NCT00995449|BIOLOGICAL|KB003|KB003 IV x5 doses
41024748|NCT00995449|OTHER|Placebo Comparator|Placebo IV x5 doses
41024749|NCT02784418|PROCEDURE|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
41360631|NCT00302731|DRUG|estradiol, progesterone|
41360632|NCT00302731|DRUG|estriol, progesterone|
41360633|NCT00302731|DRUG|equine estrogens m-progesteroneacetate|
41498493|NCT04336943|BIOLOGICAL|Durvalumab|Given IV
41498494|NCT04336943|DRUG|Olaparib|Given PO
41498495|NCT04336943|OTHER|Quality-of-Life Assessment|Ancillary studies
41498496|NCT04336943|OTHER|Questionnaire Administration|Ancillary studies
41498497|NCT06200207|DRUG|Ziltivekimab|Zilitivekimab will be administered subcutaneously once-monthly.
41024750|NCT02784418|PROCEDURE|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
41360634|NCT02432924|BEHAVIORAL|Instant + Multidimensional Physical Activity Feedback|
41360635|NCT04799509|PROCEDURE|VATS lobectomy|VATS lobectomy
41498498|NCT06200207|DRUG|Placebo|Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
41498499|NCT06424015|OTHER|Intralipid and heparin|Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance
41498500|NCT06424015|OTHER|Saline|Saline will be infused
41498501|NCT06016036|DRUG|SAL-0951|"SAL-0951：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
41266586|NCT03450928|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|"Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~1. Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~2. Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~3. Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~4. After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips"
41360636|NCT04631835|DRUG|HS-10352|Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
41360637|NCT02176122|DRUG|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
41360638|NCT02176122|DRUG|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
41360639|NCT04919889|OTHER|Exercise prescription|All individuals referred to the community-based Exercise on Prescription program
41360640|NCT03796858|DRUG|Guselkumab 100 mg|Participants will receive guselkumab 100mg as SC injection.
41360641|NCT03796858|DRUG|Placebo|Participants will receive placebo as SC injection.
41360642|NCT02792387|OTHER|CVP measurement|CVP measurements had been performed with an electronic pressure transducer in spontaneously breathing non-ventilated patients. Central vein access was established trough the subclavian or internal jugular veins. Mean CVP was recorded for each patient, measured in mmHg.
41360643|NCT00001658|DRUG|Amoxicillin|
41360644|NCT03355001|DEVICE|Monosyn® Quick|"* Mucosal sutures in the facial and oral~* Dermal sutures, particularly in pediatrics~* Episiotomy~* Circumcision"
41360645|NCT04594213|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
41360646|NCT04594213|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
41360647|NCT00166803|DRUG|Rosiglitazone|Rosiglitazone , 4 mg daily
41360648|NCT01967082|BEHAVIORAL|APPSPIRE|Given APPSPIRE app
41360649|NCT01967082|BEHAVIORAL|Focus Group|Attend focus group
41360650|NCT01967082|OTHER|Survey Administration|Complete survey
41360651|NCT00298506|DRUG|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
41360652|NCT00207363|DRUG|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
41360653|NCT00207363|DRUG|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
41360654|NCT05472168|OTHER|Olfactory Stimulation|Participants are exposed to different odours and energy expenditure is assessed via indirect calorimetry.
41360655|NCT01265316|DEVICE|There is no intervention for this study.|There is no intervention for this study. The pre-NSR IDE for this study is simply a modification to allow for recording of data without intervention.
41360656|NCT00121485|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
41360657|NCT00391443|DRUG|Bosentan|Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight \< 40 kg)
41360658|NCT00391443|DRUG|Placebo|Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
41360659|NCT05273203|BEHAVIORAL|FIM-1|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
41360660|NCT05273203|BEHAVIORAL|FIM-2|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
41360661|NCT05273203|BEHAVIORAL|FIM-3|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
41360662|NCT05273203|BEHAVIORAL|Control|No football training will be performed during 6 months period. Participation only in measurements at baseline and at 6 months.
41498502|NCT06016036|DRUG|Placebo|"SAL-0951 placebo：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
41498503|NCT06633263|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Introduce self-recording with the sleep diary; Introduce basic notions of insomnia; Introduce basic notions of sleep hygiene; Introduce basic notions of sleep; Recreate a time and place dedicated to sleep; Limit time spent in bed to time slept; Promote attitudes and beliefs that favor sleep and manage worries; Relapse prevention. This intervention is empirically validated (Morin, 2022).
41498504|NCT06633263|BEHAVIORAL|Behavioral Activation Treatment for Depression|Introduce self-recording with daily activities; Introduce the basic concept of depression; Identify and increase activities associated with positive reinforcement; Reflect on life domains and values to identify reinforcing activities; Identify and decrease activities associated with negative reinforcement; Identify and decrease activities associated with negative reinforcement; Relapse prevention. This intervention is empirically validated (Ciharova et al., 2021)
41498505|NCT01959295|DRUG|ASP2151|200 mg once daily
41498506|NCT01959295|DRUG|ASP2151 placebo|once daily
41498507|NCT01635283|BIOLOGICAL|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
41498508|NCT01635283|OTHER|laboratory biomarker analysis|Correlative studies
41024751|NCT02015377|OTHER|High sugar versus low sugar meals|Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
41024752|NCT02116322|PROCEDURE|EUS-FNA with Corkscrew technique|
41498509|NCT03458260|DRUG|Pixantrone|6 cycles - dose = 80mg/m²
41498510|NCT03458260|OTHER|Ifosfamide|6 cycles - 1500 mg/m2
41498511|NCT03458260|OTHER|Etoposide|6 cycles - 150 mg/m2
41024753|NCT02116322|DEVICE|Expect 19 G Flex needle|
41024754|NCT01187238|DRUG|cisplatin|in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
41024755|NCT06535308|DRUG|BnH-015B 5 mg|Korean / 3 on BnH-015B, 1 on placebo
41024756|NCT06535308|DRUG|BnH-015B 10 mg|Korean / 6 on BnH-015B, 2 on placebo
41024757|NCT06535308|DRUG|BnH-015B 20 mg|Korean / 6 on BnH-015B, 2 on placebo
41024758|NCT06535308|DRUG|BnH-015B 40 mg (Dietary impact)|Korean / 6 on BnH-015B, 2 on placebo
41498512|NCT03458260|OTHER|Rituximab|6 cycles - 375 mg/m2
41024759|NCT06535308|DRUG|BnH-015B 40 mg|Caucasian / 6 on BnH-015B, 2 on placebo
41024760|NCT06535308|DRUG|BnH-015B 80 mg|Korean / 6 on BnH-015B, 2 on placebo
41024761|NCT06535308|DRUG|BnH-015B 160 mg|Korean / 6 on BnH-015B, 2 on placebo
41024762|NCT06535308|DRUG|BnH-015B 40 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
41024763|NCT06535308|DRUG|BnH-015B 80 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
41498513|NCT03458260|PROCEDURE|Transplant|after 2 or 6 cycles
41498514|NCT05452122|OTHER|Auditory and Electrical Stimulation|Electrical and auditory stimulation will be applied during sleep.
41498515|NCT01434082|BEHAVIORAL|comparison of types of sleep disordered breathing|comparison of types of sleep disordered breathing (primary snoring, upper airway resistance syndrome, obstructive sleep apnea) in children with and without arthritis.
41024764|NCT06535308|DRUG|BnH-015B 40 mg (Part II)|Korean / 9 subjects
41024765|NCT06535308|DRUG|BnH-015B 80 mg (Part II)|Korean / 9 subjects
41024766|NCT06535308|DRUG|BnH-015B Placebo (Part II)|Korean / 6 subjects
41024767|NCT01260441|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
41266587|NCT01961544|DRUG|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
41266588|NCT00003378|DRUG|carboplatin|
41266589|NCT00003378|DRUG|gemcitabine hydrochloride|
41498516|NCT02804022|DEVICE|VPIA analgesia|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line with an anti-reflux valve to ensure precise drug administration and no backflow.
41498517|NCT02804022|DRUG|Morphine|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line.
41498518|NCT02461160|DRUG|TAK-915 suspension|TAK-915 oral suspension
41498519|NCT02461160|DRUG|Midazolam|Midazolam oral solution
41498520|NCT02461160|DRUG|Placebo|Placebo-matching TAK-915 suspension
41498521|NCT02461160|DRUG|TAK-915 tablet|TAK-915 tablet
41498522|NCT03063840|DEVICE|Microwave ablation|Microwave ablation (MWA): Emprint Microwave Ablation system with 2.45 GHz microwave generator
41498523|NCT05549609|BIOLOGICAL|XSTEM-VLU|XSTEM-VLU is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of venous leg ulcers.
41498524|NCT05549609|OTHER|Vehicle|CryoStor CS10 cryomedium
41498525|NCT01120509|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
41360663|NCT00630942|DRUG|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
41360664|NCT00754312|DRUG|SNDX-275|
41360665|NCT01296321|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
41360666|NCT01296321|BEHAVIORAL|Waitlist|Passive waitlist during 8-10 weeks.
41360667|NCT01597076|DIETARY_SUPPLEMENT|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas \& Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
41498526|NCT06216574|OTHER|Internet-based Intervention|Receive access to SHINE modules
41498527|NCT02123758|DRUG|Abiraterone Acetate|Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
41498528|NCT02123758|DRUG|Prednisone|Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
41498529|NCT02123758|DRUG|JNJ-56021927|Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
41498530|NCT02504671|DRUG|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
41498531|NCT02504671|DRUG|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
41498532|NCT02504671|DRUG|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
41498533|NCT02504671|DRUG|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
41498534|NCT04799938|BEHAVIORAL|Exercise|180 minutes of moderate-intensity exercise per week
41498535|NCT06372327|BEHAVIORAL|Daily Exercise Snacks|Participants will be encouraged to break up prolonged sitting at work with brief, high-intensity exercise snacks of varying length / total number depending on condition assignment.
41498536|NCT06034197|DRUG|VGT-309|0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
41498537|NCT05279313|DRUG|Centanafadine Hydrochloride|Capsule
41498538|NCT00081536|DRUG|Aroplatin (Liposomal NDDP) in combination with capecitabine|
41024768|NCT05177809|OTHER|Clinical rating scale to measure ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
41024769|NCT00390390|DRUG|Lansoprazole|
41024770|NCT03923634|DEVICE|Princess® RICH|Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
41498539|NCT01203020|DRUG|Busulfan|Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
41498540|NCT01203020|DRUG|Fludarabine|Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
41266590|NCT00003378|DRUG|paclitaxel|
41360668|NCT03366649|PROCEDURE|Undersizing Mitral Annuloplasty|Participants will receive a commercially available annuloplasty ring of the surgeon's choice. Sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size.
41266591|NCT04428047|DRUG|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
41360669|NCT03366649|PROCEDURE|Papillary Muscle Approximation|One or two 4-0 pledgeted sutures are used to draw the two papillary muscle tips together to reduce the inter papillary muscle separation (IPMS) before undergoing undersizing mitral annuloplasty.
41360670|NCT01087944|DEVICE|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
41360671|NCT01087944|DEVICE|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
41360672|NCT01334008|BIOLOGICAL|Blood sampling|30ml of patient peripherical blood will be collected
41360673|NCT03775642|BEHAVIORAL|Intervention video|The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.
41360674|NCT03775642|BEHAVIORAL|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
41360675|NCT01005355|BIOLOGICAL|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
41360676|NCT01693640|DRUG|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
41360677|NCT05003687|DRUG|Lu AG06474|solution, orally (Parts A and B)
41360678|NCT05003687|DRUG|Placebo|solution, orally (Part A only)
41360679|NCT03449186|OTHER|Saliva collection|
41360680|NCT03449186|OTHER|GCF collection|
41360681|NCT05304078|BEHAVIORAL|Telehealth Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide (mailed hard copy, USB drive, eBook, and Website access) and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The TASK III nurse will train caregivers how to assess their needs and concerns, and how to use the TASK III Resource Guide containing content and skill-building tip sheets to address their needs and concerns. Caregivers will also receive an American Heart Association brochure about family caregiving, as well as information, support, and referral to community resources.
41360682|NCT05304078|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure about family caregiving and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The ISR nurse will provide information, support, and referral to community resources.
41360683|NCT00004795|DRUG|dehydroepiandrosterone|
41360684|NCT05272969|DIAGNOSTIC_TEST|Beck depression inventory fast screen (Questionnaire)|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
40840567|NCT04183088|DRUG|Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2.|"There will be no dose reduction for tislelizumab in this study. In the part 1(safety cohort), if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles (6 weeks) of treatment, the dosage of regorafenib may be escalated. For subjects who escalate the regorafenib dosage to Level 2, if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles of study drug treatment, the dosage of regorafenib may be further escalated to Level 3.~During study drug treatment, dose delay/ interruption of regorafenib will be done depending on the occurrence and severity of regorafenib-related adverse events. After dose reduction of regorafenib, if the subjects tolerate the reduced dose of regorafenib well, the investigators may consider re-escalation of regorafenib to the previous dose level, depending on the types and severity of adverse events that led to dose reduction."
40840568|NCT03628729|OTHER|Embrace™ WetBond™ Pit & Fissure Sealant|pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions
40840569|NCT03628729|OTHER|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Fluoride releasing resin based pits and fissures sealant
40840570|NCT05320159|DRUG|Secukinumab|Included all the patients treated with secukinumab
40840571|NCT06191575|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
40840572|NCT06191575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40840573|NCT06191575|PROCEDURE|Cognitive Assessment|Undergo cognitive assessment
40840574|NCT01380704|DRUG|ABT-436|QD Days 1-7
40840575|NCT01380704|DRUG|Matching Placebo|QD Days 1-7
40840576|NCT02694952|BIOLOGICAL|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
40840577|NCT02694952|BIOLOGICAL|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
41266592|NCT04880122|DIAGNOSTIC_TEST|Dried blood spot and venous blood collection|A paired venous blood and capillary blood sample (dried blood spot) were collected in every participant for validation purpose. Venous blood samples were analyzed using a chemiluminescent microparticle immunoassay ( the Architect i2000sr Plus system, Abbott), as a reference. Dried blood spots (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) or (Whatman™, GE Healthcare Sciences, Cardiff, UK) were analyzed by means of a SARS-CoV-2 IgG ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany).
41360685|NCT05272969|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI) (Questionnaire)|Validated questionnaire for pain.
41360686|NCT05272969|DIAGNOSTIC_TEST|German Pain Inventory (Questionnaire)|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
41360687|NCT05272969|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS) (Questionnaire)|Validated questionnaire for perceived fatigue
41360688|NCT05272969|DIAGNOSTIC_TEST|Rotterdam Handicap Scale (RHS) (Questionnaire)|validated questionnaire to assess a patient's functional ability and level of handicap
41360689|NCT05272969|DIAGNOSTIC_TEST|R-PAct (Questionnaire)|The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options.
41498541|NCT00645892|DRUG|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
41498542|NCT00645892|DRUG|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
41498543|NCT05722522|DRUG|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
41498544|NCT05722522|DRUG|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
41498545|NCT04971187|DRUG|Bintrafusp Alfa|Given IV
41498546|NCT04971187|DRUG|Pemetrexed|Given IV
41498547|NCT04971187|DRUG|Carboplatin|Given IV
41498548|NCT04971187|DRUG|Cisplatin|Given IV
41498549|NCT01802450|DRUG|Dasatinib|
41024771|NCT03626181|DEVICE|Theta Burst Stimulation ( Transcranial Magnetic Stimulation)|"Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval."
41024772|NCT03391843|DRUG|FOLFOXIRI+Cetuximab regimen|FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle
41024773|NCT00927446|PROCEDURE|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
41360690|NCT05272969|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
41360691|NCT05272969|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
41360692|NCT05272969|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once.
41360693|NCT05272969|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
41498550|NCT06149663|DRUG|LP352|LP352 will be administered as a liquid either orally or through a G-tube or PEG tube.
41498551|NCT06002581|DEVICE|rTMS real stimulation stage1|In the first stage, the early treatment group use low-frequency rTMS real stimulation,
41498552|NCT06002581|DEVICE|rTMS shame stimulation stage1|In the first stage, the control group (delayed treatment group) all use sham stimulation.
41498553|NCT06002581|DEVICE|rTMS real stimulation stage 2|In the second stage, both the early treatment group and the control group (delayed treatment group) will be treated with true stimulation low-frequency rTMS.
41498554|NCT01053000|DRUG|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
41498555|NCT00603837|DEVICE|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
41498556|NCT00603837|DEVICE|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
41498557|NCT04248218|BEHAVIORAL|Active Rehabilitation Group/Case|If the patient is in the active rehabilitation group, the patient will receive instructions based on the latest CDC concussion management guidelines that specify a symptom-limited progressive return to full activities. This group will be instructed to take at least 10,000 steps a day for five days on their pedometers. In addition, they will also watch a two-minute video by the PI and research team reinforcing the active rehabilitation instructions.
41498558|NCT03589040|DRUG|Etonogestrel 68Mg Implant|Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants
41498559|NCT03589040|DRUG|rilpivirine|Oral rilpvirine 25mg
41498560|NCT03589040|DRUG|darunavir|Oral darunavir+ritonavir 600/100mg
41498561|NCT02902367|OTHER|Outdoor walking and strength exercise|Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
41024774|NCT02658851|DEVICE|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
41024775|NCT02449759|BEHAVIORAL|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
41024776|NCT02575664|DRUG|Buprenorphine|Buprenorphine 5 microg/h/7 days
41024777|NCT02575664|DRUG|Placebo|Placebo patch
41024778|NCT01410838|OTHER|Broth|200 mL of sodium chloride containing broth, consumed three times per day
41024779|NCT01410838|OTHER|Broth|200 mL of MSG containing broth consumed three times per day
41360694|NCT05272969|DIAGNOSTIC_TEST|Muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes.
41360695|NCT05272969|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
41498562|NCT02902367|OTHER|control group|Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
41498563|NCT06359288|OTHER|Group receiving QR code supported training|During the training process, QR codes were integrated into the sections related to the care of the newborn in the guide to provide mothers with the opportunity to watch the video simultaneously while reading the guide in practices requiring skills related to hygienic care of the newborn and nutrition / communication / sleep, and to allow them to watch it repeatedly as long as they feel the need. In these videos, the application steps were shown one by one. When the code is scanned with a smartphone, it automatically redirects the user to the specified URL. The QR codes in the Implementation Guide on the Care of the Newborn consist of eight videos) that allow mothers to watch the hygienic care of the newborn in practice. After the end of this phase of the training, the questionnaires were re-administered to the mothers in both groups one month after discharge.
41498564|NCT06007833|BEHAVIORAL|Physical Therapy and Rehabilitation Modalities|In the experimental group, the subjects who were taken to the physical therapy modality in addition to conventional therapy. Total, each session was performed for 60 minutes, 8 weeks, 3 days a week, under the supervision of a physiotherapist, while the other days, the family member performed 3 times a day, each movement for 3 sets, 10-15 repetitions, for a total of 60 minutes. A rest interval of less than 2 minutes was given between each set. By making use of heat modalities before starting the exercises, the elongation ability of the warmed tense structure was increased and the risk of damage in stretching exercises was reduced. The cold application was applied to the soft tissues in the extended position for 1-2 minutes with a cold pack, as the application of cold immediately after the stretching would ensure the preservation of the range of motion. Progress in the exercise program; adjusted for strength, endurance, flexibility, balance and functionality parameters.
41498565|NCT06007833|BEHAVIORAL|Conventional Group|As a conservative treatment in the control group, post-surgical plastering followed by orthoses and positioning was applied.
41498566|NCT00030979|DRUG|Donepezil|
41498567|NCT04154774|DRUG|Apalutamide|Apalutamide will be administered orally.
41024780|NCT04790253|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer.
41024781|NCT02523534|PROCEDURE|MRI|MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
41024782|NCT02523534|PROCEDURE|ECG|ECG readings will be taken prior to the participants clinically indicated procedure.
41024783|NCT00745017|BEHAVIORAL|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
41024784|NCT00745017|BEHAVIORAL|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
41024785|NCT00745017|DRUG|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
41266593|NCT00412477|BIOLOGICAL|HIV LFn-p24|HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
41360696|NCT05272969|DIAGNOSTIC_TEST|Borg Scale|The Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
41360697|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Creatine kinase|CK-Level assessment in peripheral blood (peripheral venous blood draw)
41360698|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Vitamin D Level|Vitamin D Level in peripheral blood (peripheral venous blood draw)
41360699|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: calcium|calcium level in peripheral blood (peripheral venous blood draw)
41024786|NCT04690608|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
41024787|NCT02559986|OTHER|telephone interview|telephone interview about their care received during the first year of life and associated events
41024788|NCT01849367|DEVICE|Eldith Neuroconn tDCS device|
41024789|NCT03229551|DRUG|Xylitol|Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
41024790|NCT03229551|DRUG|Saline|Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
41498568|NCT03259659|OTHER|ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index|In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.
41498569|NCT05523310|OTHER|Daily questionnaire|All patients will be asked to complete a daily questionnaire regarding their migraine, medications, and prodromal symptoms during that day
41498570|NCT06379217|DRUG|[68Ga]Ga-PSMA-11|\[68Ga\]Ga-PSMA-11 will be administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and approximately 7 weeks after last RLT dose. Administered dose should not be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)
41498571|NCT06379217|DRUG|[68Ga]GA-DOTA-TATE|\[68Ga\]Ga-DOTA-TATE will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose, within a range of 100-200MBq (2.7-5.4 mCi)
41498572|NCT06379217|DRUG|[68Ga]Ga-NeoB|\[68Ga\]Ga-NeoB will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose.within a range of 150-250 MBq (4.1-6.8 mCi).
41498573|NCT06379217|DRUG|[177Lu]Lu-PSMA-617|\[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for 6 cycles.
41498574|NCT06379217|DRUG|[177Lu]Lu-DOTA-TATE|\[177Lu\]Lu-DOTA-TATE will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%) every 6 weeks for 6 cycles.
41498575|NCT06379217|DRUG|[177Lu]Lu-NeoB|\[177Lu\]Lu-NeoB will be administered as an intravenous infusion at a dose of 9.25 GBq (250mCi) every 6 weeks for 6 cycles
41498576|NCT06379217|DRUG|L-Lysine HCl-L-Arginine HCl, 2.5 %,|sterile solution for infusion Lysine HCl-Arginine HCl, 2.5 % (1L)
41498577|NCT06379217|DRUG|Gonadotropin-releasing hormone (GnRH) analogues|Anatomical Therapeutic Chemical \[ATC\] code L02AE
41024791|NCT00660010|DRUG|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
41024792|NCT05058274|DEVICE|Implant of the AT-TORBI 709 lens|Implant of the AT-TORBI 709 lens
41024793|NCT05804058|PROCEDURE|Revision surgery|Patients due to undergo prosthetic revision surgery for any reason (infection or aseptic)
41024794|NCT01105533|DRUG|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
41024795|NCT01105533|DRUG|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
41024796|NCT01105533|DRUG|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
41024797|NCT01105533|DRUG|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
41498578|NCT06379217|DRUG|GnRH antagonists|abarelix, degarelix, or relugolix
41498579|NCT06379217|DRUG|Antiemetics & antinauseants|ATC code A04A
41498580|NCT06379217|DRUG|Metoclopramide|ATC code A03FA01
41498581|NCT02444117|OTHER|functional rehabilitation of social communication|
41498582|NCT01814553|DRUG|afatinib|Daily treatment starting 40 mg per day
41498583|NCT01814553|DRUG|loperamide|Follow cohort assignment and diarrhea management guidelines
41024798|NCT01105533|DRUG|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
41024799|NCT01105533|DRUG|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
41360700|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: magnesium|magnesium level in peripheral blood (peripheral venous blood draw)
41498584|NCT02366429|BEHAVIORAL|ICBT for antenatal depression|Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
41498585|NCT02366429|OTHER|TAU|Treatment as usual provided at antenatal clinics and other health care instances
41024800|NCT01105533|DRUG|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
41024801|NCT01105533|DRUG|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
41024802|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
41024803|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
41024804|NCT03551652|DRUG|Pharmacokinetics of rocuronium induced neuromuscular block|Measurement of rocuronium induced neuromuscular block comparing patients aged \> 80 years with patients aged 18 to 50 years
41360701|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: phosphate|phosphate level in peripheral blood (peripheral venous blood draw)
41360702|NCT05272969|GENETIC|Genetic test: ACE polymorphism|peripheral venous blood draw for genetic analysis of ACE polymorphism
41498586|NCT05094089|DEVICE|Hernia repair with mesh|Hernia repair with GORE® SYNECOR Biomaterial; technical approach laparoscopic, robotic or open surgical / minimally invasive surgery
41498587|NCT00282919|DRUG|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
41024805|NCT02343341|BEHAVIORAL|Preschool Health Promotion Education Program|
41024806|NCT01745263|DRUG|Vitamin D3|2000 IU/d
41498588|NCT06533098|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
41498589|NCT06533098|DRUG|Intravenous immunoglobulins (IVIG)|IVIG will be administered intravenously.
41498590|NCT06533098|DRUG|Prednisone|Prednisone will be administered orally.
41360703|NCT05272969|GENETIC|Genetic test: ACTN3 polymorphism|peripheral venous blood draw for genetic analysis of ACTN3 polymorphism
41360704|NCT05272969|GENETIC|Blood draw for optional genetic exome sequencing|"Optionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms myalgia, muscle pain, chronic pain, musculoskeletal pain, pain, and nociceptive pain."
41360705|NCT06113276|RADIATION|Low dose computed tomography to evaluate biomechanical parameters in the lung|In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.
41360706|NCT04663646|OTHER|Optokinetic stimulation|"Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected.~The study will be carried out for 10 weeks with a frequency of two weekly sessions. During them, the participants will receive stimulation with OKS.~Stimulation will be performed at 1 cm/second, the vertical black bars will move to the left. The bars change color and the participants will be asked to detect the changes that will occur in the stimulus."
41498591|NCT02369991|PROCEDURE|Reconstructive surgery|Patients were treated with free latissimus dorsi flap and bone transport technique
41498592|NCT06470815|PROCEDURE|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
41498593|NCT04832126|GENETIC|Genetic analysis|Genomic DNA will be purified from peripheral blood or mouth swabs. Whole blood will be collected by peripheral phlebotomy in tubes containing K2EDTA as an anticoagulant. Blood samples will be stored at 4-8 oC for up to a week before DNA purification. Mouth swabs will be collected using the ORAcollect • DNA kit (OCR-100) (DNA Genotek Inc., Canada). Genomic DNA from whole blood or mouth swab samples will be purified using DNeasy Blood \& Tissue Kit (QIAGEN).
41498594|NCT02244814|BEHAVIORAL|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
41498595|NCT02244814|BEHAVIORAL|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
41024807|NCT01745263|DRUG|Omega 3 fatty acids|"Ratio EPA:DHA = 1:2~1 g/d"
41024808|NCT01745263|PROCEDURE|Strength Home Exercise|
41024809|NCT01745263|PROCEDURE|Flexibility Home Exercise|
41024810|NCT02873104|DEVICE|truSculpt rf device|radiofrequency device
41024811|NCT00786916|DRUG|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
41266594|NCT05607628|COMBINATION_PRODUCT|Low Calorie Animal Protein Meals|Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
41498596|NCT04422782|OTHER|For each routine sample, an additional tube will be collected to measure the osmotic pressure in the blood and urine|Interventional research protocol involving the human person category 2 at risk and minimal constraints
40840578|NCT02687516|BEHAVIORAL|Family-based behavioral social facilitation therapy|"Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the Traffic light diet in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities."
40840579|NCT02687516|BEHAVIORAL|TAU - Treatment as usual|"This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a contract is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic."
40840580|NCT03806075|BEHAVIORAL|Second generation sequencing|Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen
40840581|NCT03806075|BEHAVIORAL|16s rRNA gene sequencing|Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
40840582|NCT00386555|DRUG|docetaxel|
40840583|NCT00386555|DRUG|CP-868,596 + docetaxel|
40840584|NCT00386555|DRUG|AG-013736 + docetaxel|
40840585|NCT00386555|DRUG|CP-868,596 + AG-013736 + docetaxel|
40840586|NCT03809910|DEVICE|Reference MTB|Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
40840587|NCT03809910|DEVICE|Reference PTB|Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
40840588|NCT03809910|DEVICE|Prototype PTB (Gum line mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff."
40840589|NCT03809910|DEVICE|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff."
40840590|NCT03553082|DRUG|Sevoflurane|Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
40840591|NCT03553082|DRUG|Propofol|Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
40840592|NCT01423916|DRUG|OPC-34712 (4mg)|Arms assigned to this intervention receive 4mg.
41498597|NCT01008332|BIOLOGICAL|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
41498598|NCT01008332|BIOLOGICAL|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
41498599|NCT04159870|DRUG|Rifaximin|Rifaximin pills 400 mg x 3/day
41498600|NCT04159870|DRUG|Norfloxacin|Norlfloxacin 400 mg 1 pill/day
41498601|NCT03411135|OTHER|VES and VASI scores as assessment methods for vitiligo|compare VES and VASI scores as assessment methods for vitiligo
41498602|NCT05806294|BEHAVIORAL|Digital Metabolic Rehabilitation|Digital Metabolic Rehabilitation combines two programs: The Canadian Health Advanced by Nutrition and Graded Exercise Protocol (CHANGE) and My Viva Plan (MVP). All participants receive free access to MVP and attend group video conferencing sessions with health professionals. After the 60-minute initial assessments with the dietitian and the kinesiologist, each participant has an individualized diet and exercise plan based on the intervention protocol built in MVP. Participants are split into groups of 20 based on physical ability and stage of COPD. Intervention has 3 phases. In phase 1, weekly videoconferences with the kinesiologist and dietitian and monthly sessions with psychologist and respiratory therapist are held for the first 3 months. Phase 2 lasts from months 4 to 6 and has biweekly videoconferences with health professionals. Phase 3 starts in month 6 and has monthly group sessions with health professionals.
40840593|NCT01423916|DRUG|Moxifloxacin|Arms assigned to this intervention will receive 400mg.
40840594|NCT01423916|DRUG|OPC-34712 (12mg)|Arms assigned to this intervention receive 12mg.
40840595|NCT01423916|DRUG|Placebo|OPC-34712 placebo
40840596|NCT00483795|DRUG|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
40840597|NCT01511809|DRUG|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
40840598|NCT05650853|OTHER|Transrectal ultrasound|Examinations for observation of the pre, per and post-ejaculatory phases
40840599|NCT05650853|OTHER|Urethroscopy|Examinations for observation of the pre, per and post-ejaculatory phases
40840600|NCT02151331|BEHAVIORAL|External Facilitation|Non-responding sites randomized to receive external facilitation
40840601|NCT02151331|BEHAVIORAL|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
40840602|NCT03899792|DRUG|LOXO-292|Oral LOXO-292
40840603|NCT01597024|OTHER|Breakfast Study|Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
41360707|NCT04663646|OTHER|Placebo|Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected. In this group, stimulation consists of a video with static vertical bars that change their colour at a randon intervals, in the same way that in the intervention group. The difference between groups is that in control group, bars are not in movement, preventing from generating optokinetic stimulation.
41360708|NCT03838692|DRUG|Ponatinib|A daily oral dose at 30 mg.
41360709|NCT05779501|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program follows the theorized five stages of strengths use interventions: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation. To increase participant engagement and motivation, gamification components are embedded in several stages.~The intervention was previously tested through a feasibility and acceptability trial (NCT05474807).~The entire intervention will be delivered online via an LMS software solution."
41360710|NCT05779501|BEHAVIORAL|Waiting-list|"The waiting-list arm will serve as the control group, filling in only the outcome measure at the same time as the intervention group participants.~After the intervention group finishes participating in the intervention, the waiting-list participants will benefit from the same internet-delivered strengths use program."
41360711|NCT04682158|DRUG|Carboplatin|Given IV
41360712|NCT04682158|RADIATION|3 Dimensional Conformal Radiation Therapy|Undergo 3D CRT
41360713|NCT04682158|DRUG|Propranolol|Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks
41360714|NCT04682158|RADIATION|Intensity Modulated Radiation Therapy|Undergo IMRT
41360715|NCT04682158|DRUG|Paclitaxel|Given IV
41360716|NCT06016166|DEVICE|Eye mask|The 3D eye mask with the ability to adjust for different faces and eliminate light
41360717|NCT00026559|DEVICE|Shock Device|Shock Device
41360718|NCT00026559|DEVICE|Auditory Startle Device|Auditory Startle Device
41360719|NCT00625027|OTHER|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
41360720|NCT05931614|OTHER|Unlimited fluid restrictions|Patients are recommended unlimited fluid intake
41360721|NCT02140996|DRUG|Ad-sig-hMUC-1/ecdCD40L vector vaccine|
41360722|NCT04929782|DEVICE|Resin-based sealant|Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
41360723|NCT04929782|DEVICE|Giomer sealants|Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
41360724|NCT00085189|BIOLOGICAL|gp100 antigen|Given SC
41498603|NCT03399799|DRUG|Talquetamab|Participants will receive IV infusion or SC injection of Talquetamab.
41498604|NCT00368979|DRUG|Dutasteride|once daily
41498605|NCT00368979|DRUG|Placebo|once daily
40840604|NCT01597024|OTHER|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
40840605|NCT02843191|DRUG|Chemotherapy|5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
40840606|NCT01462877|DRUG|fenofibrate|Fenofibrate Capsule 200mg qd orally
40840607|NCT03216759|PROCEDURE|Ischemic preconditioning|After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.
40840608|NCT03216759|DRUG|Dexmedetomidine|At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.
40840609|NCT03216759|PROCEDURE|Patient-controlled epidural analgesia|Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
40840610|NCT01761773|DRUG|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
41360725|NCT00085189|BIOLOGICAL|tyrosinase peptide|Given SC
41360726|NCT00085189|BIOLOGICAL|recombinant MAGE-3.1 antigen|Given SC
41360727|NCT00085189|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given SC
41360728|NCT00085189|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
41360729|NCT00085189|DRUG|Montanide ISA 51 VG|Given SC
41360730|NCT00085189|DRUG|agatolimod sodium|Given SC
41360731|NCT00085189|OTHER|laboratory biomarker analysis|Correlative studies
41498606|NCT04372108|DRUG|Ustekinumab|Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
41498607|NCT04372108|DRUG|Other Biologic Therapies|Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
41360732|NCT05990257|PROCEDURE|HHB+TAPB+and LA|Hepatic Hilar Block (HHB), Transversus Abdominis Plane Block (TAPB), and Local Anesthesia (LA)
41360733|NCT05990257|PROCEDURE|HHB+LA|Hepatic Hilar Block (HHB) and Local Anesthesia (LA)
41360734|NCT05990257|PROCEDURE|TAPB+LA|Transversus Abdominis Plane Block (TAPB) and Local Anesthesia (LA)
41360735|NCT02201199|DRUG|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
41360736|NCT02201199|DRUG|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
41360737|NCT02201199|DRUG|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
41024812|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
41360738|NCT04605133|DEVICE|Electrical impedance tomography|Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
40840611|NCT03148015|OTHER|Biomarkers|Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
40840612|NCT03668405|DRUG|Lu AF20513|Injection
40840613|NCT04683120|DIAGNOSTIC_TEST|Zenith FLIM Diagnostics|In-vitro
40840614|NCT02066129|DRUG|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
40840615|NCT02066129|DRUG|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
41024813|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
41360739|NCT03602521|OTHER|Interpersonal stress|"Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~* 1) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~* 2) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?"
41360740|NCT01883362|DRUG|Midostaurin|Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
41360741|NCT01883362|OTHER|Standard of Care|Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
41360742|NCT02503956|DEVICE|Perforated Punctal plugs|Perforated punctal plugs
40840616|NCT04566692|BIOLOGICAL|IGSC 20%|SC infusion pump.
41024814|NCT05054023|DRUG|Soulagel®|topic gel
41024815|NCT05054023|DRUG|Arthrosyl®|topic gel
41024816|NCT05940233|DRUG|Letrozole|In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.
41360743|NCT02503956|PROCEDURE|Crawford tube insertion|
41360744|NCT02503956|DEVICE|Crawford lacrimal tube|
41360745|NCT04659356|OTHER|Patients admitted in Intensive Care Units|Data will be collected computerized patient records by the clinicians in charge of the patient.
41360746|NCT06111729|DEVICE|HabitAware group|A device that provides gentle vibration when the motion of nail biting is sensed will be provided to all participants. Participants will use an app that connects to the device to track the frequency of their nail biting over the study period.
41360747|NCT04846634|DRUG|Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
41360748|NCT04846634|DRUG|Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
41498608|NCT06633770|DIAGNOSTIC_TEST|proclcitonin and presepsin|"All included patients will be subjected to:~* laboratory investigations~  * Complete Blood Count (CBC),~ * Liver Function Test(LFT) ( ALT,AST, Billirubin, total protein and albumin)~ * Kidney function test (KFT) ( Urea and creatinine)~ * Random Blood Glucose (RBG).~ * Erythrocyte Sedimentation Rate(ESR )~ * Urine analysis -A special investigations include (blood culture, C Reactive protein (CRP), proclcitonin and presepsin)."
41024817|NCT05897645|OTHER|Registration|collect clinical date, assess the morphologic characteristics of plaque
41024818|NCT00844441|OTHER|medical chart review|
41024819|NCT00844441|OTHER|questionnaire administration|
41024820|NCT00844441|PROCEDURE|quality-of-life assessment|
41024821|NCT02710630|DRUG|Dabigatran etexilate tablet E1|
41024822|NCT02710630|DRUG|Dabigatran etexilate tablet D1|
41024823|NCT02710630|DRUG|Dabigatran etexilate tablet C1|
41024824|NCT02710630|DRUG|Dabigatran etexilate tablet B1|
41024825|NCT02710630|DRUG|Dabigatran etexilate tablet A1|
41498609|NCT00720252|DEVICE|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
41498610|NCT00767169|DEVICE|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
41024826|NCT02710630|DRUG|Dabigatran etexilate capsule|
41024827|NCT03526523|BEHAVIORAL|Mindfulness-based stress reduction|8 weekly 2.5-hour group sessions of mindfulness based stress reduction, led by a certified MBSR instructor
41024828|NCT01840592|DRUG|Sorafenib|
41024829|NCT01840592|DRUG|Doxorubicin|
41024830|NCT05958992|OTHER|E-cigarette|Participants will self-administer experimenter-provided e-cigarettes
41024831|NCT04624698|DEVICE|iStent Inject Implantation|Subjects will be implanted with the iStent Injection Micro-Bypass device
41024832|NCT05284045|OTHER|Detailed information|Subjects in this arm will receive usual information + detailed information on side effects
41024833|NCT01351805|DRUG|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
41024834|NCT01351805|DIETARY_SUPPLEMENT|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
41024835|NCT01351805|OTHER|placebo pill|placebo
41024836|NCT05073536|DEVICE|mini-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
41024837|NCT05073536|DEVICE|normal-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
41024838|NCT01899924|BEHAVIORAL|Event Related Potentials recording|
41024839|NCT01287585|DRUG|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
41024840|NCT01287585|DRUG|Placebo|weekly, intramuscular, until disease progression or toxicity.
41024841|NCT01287585|OTHER|Best Supportive Care|treatment of disease-related symptoms throughout the study.
41024842|NCT02233712|BIOLOGICAL|G17DT|
41024843|NCT00363714|DRUG|AGN211745|100microgram single intravitreal injection
41024844|NCT00363714|DRUG|AGN211745|200microgram single intravitreal injection
41024845|NCT00363714|DRUG|AGN211745|400microgram single intravitreal injection
41024846|NCT00363714|DRUG|AGN211745|800microgram single intravitreal injection
41024847|NCT00363714|DRUG|AGN211745|1200microgram single intravitreal injection
41498611|NCT03394365|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
41498612|NCT06413706|DRUG|Abemaciclib|Administered orally
41498613|NCT06413706|DRUG|Temozolomide|Administered orally or IV
41498614|NCT04688905|DIAGNOSTIC_TEST|Invasive hemodynamics of left ventricle via conductance catheter at rest, with exercise and with temporary vena cava occlusion|Invasive hemodynamics of left ventricle will be done by the conductance method. Left ventricular stiffness constant will be obtained by temporary vena cava occlusion. Right heart catherization will be done by pulmonary artery catherization and cardiac output will be estimated by thermodilution and Fick´s method.
41498615|NCT04269681|DEVICE|High Flow Nasal Cannula|"Experimental intervention (HFNC) The HFNC (AIRVO 2 - Fisher \& Paykel Healthcare, Auckland, New Zealand) consists of a device that allows FiO2 adjustable from 21 to 100% and that delivers a flow of humidified and heated gas up to 60 l / min and 37 degrees C of temperature.~The HFNC will be offered until resolution of the ARF or until decision by the assisting team and the patient and/or their legal guardian, for the suspension of the treatment due to intolerance, and/or worsening of the discomfort and / or dyspnea.~The HFNC should be offered to the patient in ARF as follows:~* Initial parameters: Flow 45 ml / L, FiO2 50%, AIRVO 37oC temperature;~* Titrate the flow up to 60ml / L or up to the maximum tolerated;~* Titrate FiO2 to maintain SatO2 between 92% to 98%, starting with 50%;~* Keep the AIRVO temperature at 37oC, if not possible, acceptable down to 34oC."
41498616|NCT04269681|OTHER|Standard respiratory support|The patient randomized to standard respiratory support will be placed on conventional low flow oxygen therapy according to the center's standard of care aiming at SpO2 90 - 98% and improvement of dyspnea. For cases refractory to oxygen therapy, keeping SpO2 below 90% or if dyspnea does not improve, non-invasive positive pressure ventilation (NIPPV) may be offered at the discretion of the assistant team. NIPPV will be performed with the patient in a supine position at 45 degrees. The mask will be facial (oronasal or full face) with an appropriate size for each patient and adapted in a way to minimize leakage. A hydrocolloid dressing can be placed over the nose in order to avoid ulcerations and increase comfort. The NIPPV will be performed with the help of a ventilator with inspiratory and expiratory circuits or with Bilevel devices with a single circuit and exhalation valve according to the availability of each center.
41360749|NCT04846634|DRUG|Penpulimab+Anlotinib|A cycle of treatment is defined as 21 days of once daily treatment.
41360750|NCT00420823|DRUG|Taurine 4g|
41498617|NCT05691504|PROCEDURE|Biopsy|Undergo biopsy
41498618|NCT05691504|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41498619|NCT05691504|DRUG|Cobimetinib|Given PO
41498620|NCT05691504|PROCEDURE|Computed Tomography|Undergo CT
41360751|NCT00724789|DRUG|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
41360752|NCT00724789|DRUG|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
41360753|NCT02382419|DRUG|carrageenan-containing gel|Applied vaginally
41360754|NCT02382419|OTHER|Placebo|Applied vaginally
41360755|NCT02382419|OTHER|Laboratory Biomarker Analysis|Correlative studies
41498621|NCT05691504|PROCEDURE|Echocardiography|Undergo ECHO
41024848|NCT00363714|DRUG|AGN211745|1600microgram single intravitreal injection
41024849|NCT01929356|PROCEDURE|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
41266595|NCT05607628|COMBINATION_PRODUCT|Low Calorie Plant Protein Meals|Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
41360756|NCT02382419|OTHER|Questionnaire Administration|Ancillary studies
41360757|NCT03795324|OTHER|Redlove Apple intervention|The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.
41360758|NCT03795324|OTHER|Green Apple intervention|It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.
41360759|NCT03795324|OTHER|Aronia drink intervention|The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink
41360760|NCT04329273|OTHER|Sliding leg curl|The exercise protocol consists of the following sets and repetitions Week 1- 2 sessions with 2 sets of 6 repetitions Week 2- 2 sessions with 3 sets of 6 repetitions Week 3- 2 sessions with 4 sets of 6 repetitions Week 4- 2 sessions with 4 sets of 8 repetitions Week 5- 2 sessions with 4 sets of 10 repetitions Week 6- 2 sessions with 4 sets of 10 repetitions Week 7- 2 sessions with 4 sets of 8 repetitions Week 8- 2 sessions with 4 sets of 8 repetitions
41360761|NCT04329273|OTHER|Balance training|"The exercise protocol consists of 2 sessions/week with 4 sets of 30'' single stance.~Week 1 and 2- 1 set of 30'' single leg stance and 3 sets of 30'' single leg stance and ball kicks with contralateral foot Week 3 and 4- 2 sets of 30'' single leg stance while moving the ball around the leg with the contralateral foot and 2 sets of 30'' single leg stance, moving a ball around the knee with hands and kicking a ball with contralateral foot Week 5 and 6- 2 sets of 30'' single leg stance while giving and receiving hand passes with medicine ball (in couples) and 2 sets of 30'' single leg stance with perturbations (in couples) Week 7 and 8- Same as week 5 and 6 with extra 15 in each repetition"
41498622|NCT05691504|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41498623|NCT05691504|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41498624|NCT05691504|DRUG|Pelcitoclax|Given IV
41498625|NCT01098630|OTHER|Medical Chart Review|Patients' medical record information is collected and staff complete the treatment review form
41498626|NCT01098630|OTHER|Questionnaire Administration|Ancillary studies
41498627|NCT05084716|BEHAVIORAL|Enhanced PrEP provision|At the intervention site during healthcare facility outreach events, all community members will be offered the opportunity to attend intervention workshops where they can learn basic facts about PrEP and be taught skills about how to advocate for PrEP in their community. Check-in reminder calls will be conducted systematically with PrEP users. Healthcare facility staff will encourage PrEP initiators to select an adherence supporter.
40840618|NCT06505759|DRUG|Bromelain gel|bromelain gel is prepared from bromelain capsules in laboratory
40840619|NCT06505759|DRUG|chlorhexidine gel|chlorhexidine gel is prepared from mouth wash
40840620|NCT06505759|PROCEDURE|SRP|Scaling and root planing was done with ultra sonic and hand scaling
41360762|NCT04329273|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions Week 1 and 2- 3 sets of 30'' front plank, 3 sets of 20'' side plank, 2 sets of 30'' superman, 2 sets of 30'' supine bridge and 2 sets of 10 repetitions leg lowering exercise Week 3 and 4- increasing difficulty in 2 of the sets Week 5 and 6- adding 1 more set at each exercise Week 7 and 8- adding 15 in each repetition"
41360763|NCT02874755|OTHER|Tuberculosis Program|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
41360764|NCT02173015|OTHER|Compensatory step training|The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
40840621|NCT05042973|DRUG|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
41360765|NCT04153799|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6 / kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
41360766|NCT00211536|DRUG|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
41360767|NCT00211536|DEVICE|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
41360768|NCT00211536|DRUG|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
41360769|NCT05943548|BEHAVIORAL|Omuyambi|HIV testing, referral, care linkage, and medication adherence support
41498628|NCT01172119|DEVICE|Biofreedom Drug Eluting Stent|Biofreedom DES with a standard dose of Biolimus A9TM
40840622|NCT05042973|DRUG|Placebo|Placebo matches the active drug in appearance, odor and labelling.
40840623|NCT06246071|DRUG|TYK-00540|TYK-00540 PO, BID
40840624|NCT05097300|OTHER|Suboccipital inhibition|The therapist will place his hands under the patient's head, making contact with the suboccipital muscles in the region of the posterior arch of the atlas, applying progressive and deep pressure. This pressure will be maintained for 10 minutes
40840625|NCT05097300|OTHER|Ischemic pressure|"Pressures will be made on the temporal, superior trapezius, masseter and sternocleidomastoid muscles. Physical therapist will apply gradual sustained finger pressure to the muscle's active trigger points for 5-15 seconds. The therapist will begin with light firm pressure and gradually increase the pressure until the patient feels a moderate but bearable level of pain (corresponding to a level 7 on a pain scale of 1 to 10 levels where 1 indicates no pain and 10 is excruciating pain). Pressure will remain at this level until pain levels decrease to level 3. The therapist will repeat this procedure approximately 3-4 times over a 90 second period."
41360770|NCT05943548|BEHAVIORAL|Control|HIV Testing and referral
41360771|NCT05291429|DEVICE|OVR Health's VR experience|Virtual reality experience
41360772|NCT02483715|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
41360773|NCT02483715|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
41360774|NCT04301557|DRUG|PD-1 Antibody|PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
41360775|NCT04301557|DRUG|Oxaliplatin|Oxiliplatin 130mg/m\^2 (100mg/m\^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
41498629|NCT01172119|DEVICE|Biofreedom Drug Eluting Stent|Biofreedom DES with a low dose of Biolimus A9TM
41498630|NCT01172119|DEVICE|Tuxus Liberte Drug Eluting Stent|Standard paclitaxel dose Taxus Liberte DES
41498631|NCT02554565|PROCEDURE|Tumor biopsy|Tumor biopsy before treatment
41498632|NCT02554565|PROCEDURE|Blood sampling|Blood sample before, during and after treatment
41360776|NCT04301557|DRUG|Capecitabine|Capecitabine 1000mg/m\^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
41360777|NCT04301557|RADIATION|External beam radiotherapy|Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV
40840626|NCT05097300|OTHER|Passive stretching|Passive stretches will be applied to each muscle 2 times for 30 seconds, they will be performed slowly at the rate of the patient's normal breathing and checking that no compensations appear.
41024850|NCT01785589|PROCEDURE|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
41360778|NCT04301557|PROCEDURE|Total mesorectal excision|Total mesorectal excision
41360779|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
41360780|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
41360781|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
41266596|NCT00358813|DRUG|Casopitant|Casopitant oral tablets will be available with a dose of 50 milligrams.
41266597|NCT03804541|DRUG|Ensartinib|A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
41360782|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
41360783|NCT01823991|DRUG|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
41024851|NCT02157740|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
41360784|NCT01823991|OTHER|Placebo|"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
41360785|NCT01823991|DRUG|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
41360786|NCT02743494|DRUG|Nivolumab|Specified dose on specified days
41498633|NCT01649401|DEVICE|Standard nebulizer|"Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
41498634|NCT01649401|DEVICE|PARI LC Sprint Sp nebulizer|"Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
41498635|NCT06619626|DEVICE|alveolar recruitment strategy applied group|the effect of alveolar recruitment strategy on the mechanical parameters of the patients
41498636|NCT06619626|DRUG|group without alveolar recruitment strategy|effect on mechanical parameters of patients without alveolar recruitment strategy
41266598|NCT00437216|DRUG|Clobetasol Propionate, 0.05%|Apply twice daily for 2 or 4 weeks as monotherapy
41266599|NCT00437216|DRUG|Clobetasol propionate, 0.05% Spray|Apply twice daily for 2 or 4 weeks as add-on therapy
41266600|NCT01051089|BEHAVIORAL|Lifestyle modification|Exercise and diet education
41266601|NCT06018649|COMBINATION_PRODUCT|Balneotherapy plus complex|The three groups of study (SAB, LAB, LIB) will get same balneotherapy intervention with the difference in duration and mode (outpatient/inpatient). Balneotherapy plus complex procedures: swimming pool with light exercises- 20 min (29-31°C), rest 15 min, wrapping/bath with peloids (peat mud, sapropel)- 20 min (38-40°C), rest 20 min, mineral water bath- 20 min (36-38°C), salt therapy- 25 min (humidity 35%, temperature about 22°).
41266602|NCT06018649|COMBINATION_PRODUCT|Combined nature resources treatment|"The participants of CNT group will be given combined treatment: nature therapy procedure (45 min) and balneotherapy plus complex intervention procedures.~The nature therapy procedure was created by researchers by combining the principles of nature therapy, mindfulness, wild nature therapy, kinesiology selecting actions suitable for the season. A procedure instructions with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest)."
41266603|NCT06018649|OTHER|Nature therapy procedure|The participants of NT group will be given nature therapy procedure (45 min) created by researchers by combining the principles of nature therapy, kinesiology, mindfulness, wild nature therapy, selecting actions suitable for the season. A procedure instruction with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest).
41266604|NCT00357773|DRUG|Azithromycin (T1225)|
41266605|NCT03097380|DRUG|AZD2115|AZD2115
41266606|NCT03097380|DRUG|SPIRIVA|Tiotropium
41266607|NCT03097380|RADIATION|[11C]AZ13754366|Radioligand
41266608|NCT00126165|PROCEDURE|radiotherapy|
41266609|NCT02777528|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
41266610|NCT02777528|PROCEDURE|Revascularization Procedure|Revascularization procedure of the great vessel
41266611|NCT01984021|DEVICE|Acupuncture|
41266612|NCT01984021|DEVICE|Sham acupuncture|
41266613|NCT05136274|DRUG|Medical treatment|The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
41266614|NCT04892563|PROCEDURE|Erector Spinae Plane Block|Nerve block with local anesthetic in the erector spinae plane
41266615|NCT04892563|DRUG|IV Analgesia|IV analgesia, typically Morphine/Opioid medications
41266616|NCT02700451|DRUG|Ketorolac|"Age 18-64: Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.~Age 65-75: Intravenous Ketorolac 15 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed."
41266617|NCT02700451|DRUG|Acetaminophen|Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
41266618|NCT02700451|DRUG|Placebo|Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
41266619|NCT02266173|DRUG|Pertuzumab|Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
41266620|NCT00313274|DRUG|Clevudine|
41266621|NCT03280251|DRUG|Methylphenidate|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
41266622|NCT03280251|DRUG|Placebo|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
41266623|NCT03280251|OTHER|CogniPlus software|Structured cognitive training with CogniPlus software, twice per week during 6 weeks
41266624|NCT03280251|OTHER|Pseudo cognitive training|Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
41266625|NCT00891995|DEVICE|Closed loop|Closed loop therapy for up to 4 to 6 days
41360787|NCT02743494|OTHER|Placebo|Specified dose on specified days
41498637|NCT01008189|BEHAVIORAL|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
40840627|NCT05097300|OTHER|Diaphragmatic breathing exercice|To perform diaphragmatic breaths, there will first be an education on how to do them. The patient will lie supine, with the hips and knees semi-flexed. The therapist will ask you to place one hand on your chest and one on your abdomen. Successively, it will ask you to take a few deep breaths, inhaling through your nose for 2 seconds and exhaling through your mouth, with your lips pursed (almost closed) for 4 seconds, helping you to maintain the rhythm of your breath by counting out loud. The patient should note that during inspiration his hand on top of the chest does not rise (the chest remains still) and during expiration that his hand on top of the abdomen goes down (the abdomen sinks).
40840628|NCT03369002|DRUG|seladelpar|Oral single dose 10 mg
41498638|NCT01008189|BEHAVIORAL|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
41498639|NCT01352780|BEHAVIORAL|Motivational interviewing|"Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.~Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client's perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening."
40840629|NCT03855852|PROCEDURE|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
40840630|NCT03855852|PROCEDURE|Xenograft and APRF|Placing the implant with APRF and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
41498640|NCT00598572|DRUG|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
40840631|NCT02251210|DRUG|BIIL 284 BS low dose|
41266626|NCT00891995|DEVICE|Home glucose monitoring|Standard diabetes management using a home glucose meter.
41266627|NCT00891995|DEVICE|Insulin pump|Insulin pump use for 2 years
41360788|NCT01667731|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
41360789|NCT01667731|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
41360790|NCT06370494|BEHAVIORAL|Living Healthier with Diabetes|Interventions are different aspects of digital health utilizing American Diabetes Association recognized diabetes programs/applications or a combined approach. All participants were randomly assigned to their education arm and received an A1c kit, glucometer, testing strips, and surveys.
41498641|NCT00471952|DRUG|Maxalt 10mg MLT plus Caffeine 75mg|One migraine attack will be treated
41498642|NCT00471952|DRUG|Maxalt 10mg MLT plus Placebo|One migraine attack will be treated with Maxalt 10mg plus placebo
41498643|NCT00471952|DRUG|Placebo + Placebo|One migraine attack will be treated with double placebo
41498644|NCT04990427|DRUG|CLBS201|1 x 10\^6 to 300 x 10\^6 autologous CD34+ cells
41498645|NCT06450210|DRUG|psilocybin trihydrate|Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).
41498646|NCT06450210|DRUG|Placebo|Participants will receive a capsule identical in appearance to the active drug that contains an inactive substance.
41498647|NCT02342639|DRUG|Rifaximin|550mg pills
41498648|NCT02342639|DRUG|Placebo|Placebo pill
41498649|NCT02757573|PROCEDURE|Hypercarbia|PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
40840632|NCT02251210|DRUG|BIIL 284 BS medium dose|
40840633|NCT02251210|DRUG|BIIL 284 BS high dose|
40840634|NCT02251210|DRUG|Placebo|
40840635|NCT04896593|BEHAVIORAL|Smartphone App|Smartphone app teaching suicide prevention skills.
41498650|NCT04322565|DRUG|Colchicine|Cochicine 1mg/day
40840636|NCT03726931|DIAGNOSTIC_TEST|18F-Fluorestradiol PET/CT scan|\[18F\]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.
40840637|NCT01107613|BEHAVIORAL|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.
40840638|NCT00542061|DEVICE|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
40840639|NCT04133194|DRUG|Mesalazine|1600 mg Asacol \[mesalazine\]
41266628|NCT00891995|DEVICE|Continuous glucose monitor|Continuous glucose monitor use for 2 years
41498651|NCT04576923|DIAGNOSTIC_TEST|Velacur by Sonic Incytes|liver stiffness measurement
40840640|NCT04133194|DRUG|Mesalazine|800 mg Asacol \[mesalazine\]
40840641|NCT01420666|DRUG|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
40840642|NCT01420666|DRUG|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
41498652|NCT06430359|DIAGNOSTIC_TEST|urine and blood test|3 urine collections of an 8h period. One blood sample for liver function test and copper assessment
41498653|NCT03330821|DRUG|Cytarabine|Given IV
41498654|NCT03330821|DRUG|Idarubicin|Given IV
41360791|NCT06221085|DIAGNOSTIC_TEST|Pain Pressure Threshold (PPT)|"Researchers measure pain pressure thresholds (PPTs) by applying a Pressure gauge algometer (PGA) over the myofascial trigger points (TrPs) on the body. PPT is defined as the lowest stimulus intensity at which a subject perceives pain.~The clinician applies it perpendicular to the long axis of the structure on which it is placed. The examiner increases the pressure at a rate of 1 kg/s until the subject feels pain or discomfort, and then the PPT values are measured three times for each muscle. Participants verbally report the first sensation of pain or discomfort, at which point the examiner stops the pressure."
41360792|NCT06092866|BEHAVIORAL|Digital triage|A registered nurse assesses the symptoms reported by the patient on the online platform and gives appropriate advice for further care using chat.
41360793|NCT03294798|BIOLOGICAL|Human Serum Albumin/interferon alpha2b fusion protein|In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
41498655|NCT03330821|OTHER|Laboratory Biomarker Analysis|Correlative studies
41498656|NCT03330821|DRUG|Pevonedistat|Given IV
41498657|NCT03330821|OTHER|Pharmacological Study|Correlative studies
41498658|NCT00237783|DRUG|dialysate sodium (140 mmol/L)|
41160753|NCT05666063|DIAGNOSTIC_TEST|Ambulatory Urodynamic Study|Ambulatory urodynamic study is started after spontaneous diuresis of the patients. Ambulatory monitoring time is limited to each patient's own voiding cycle. The patient and a family member are instructed on the use of the event buttons on the patient module to flag incontinence, urgency, physical activity, and water drinking. With the use of catheters attached to microcomputers attached to their shoulders, patients are free to move around and engage in activities that may cause urinary incontinence. After voiding, the residual urine volume is first measured and then urethral and rectal catheters are placed. Monitoring is terminated when the patient feels that he cannot delay the urination sensation.Questionnaires that are routinely applied in our clinic will be applied in order to objectively evaluate the symptoms. Before urodynamics, urinary tract infection, whether symptomatic or not, must be routinely excluded with a complete urinalysis and urine culture.
41360794|NCT03294798|BIOLOGICAL|Pegasys|In comparator group, each subject will recieve 180mcg once per week.
41498659|NCT00237783|DRUG|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
41498660|NCT03882528|BIOLOGICAL|Plasmodium falciparum malaria parasite|Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
41498661|NCT01023048|OTHER|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
41498662|NCT05420870|BEHAVIORAL|exercise|"Six weeks of exercise intervention~To meet weekly 150 min of moderate to vigorous physical activity and twice weekly strength exercise General description of the exercise program~Main goal of the supervised exercise (1 hour per session, twice a week) are three folds. 1) Instruct participants to correctly perform prescribed exercises. 2) Encourage participants to be compliant to exercise program. 3) Participants were encouraged to hand in their exercise diary~Main goal of the home-based exercise is to perform calisthenics exercise daily. Participants were encouraged to perform at least one set of exercise (8-12 different exercises) and stretching (At least 3 days per week, but preferably most of the days) daily~Basic 8 exercises which increase ROM and strength of shoulder, lower back, Hip, Knee and ankle Additional 4 exercise to increase core strength and stability"
41498663|NCT04749238|DEVICE|NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm
41498664|NCT03553953|DEVICE|BIS device|Recording data from BIS device from patients who undergo elective surgery under general anesthesia
41360795|NCT02452138|OTHER|Severe sepsis management|
41360796|NCT00490815|DRUG|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
41360797|NCT00490815|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
41360798|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
41360799|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
41360800|NCT04873609|BEHAVIORAL|Patient portal message|Direct-to-patient message via the electronic patient portal (MyHealth) with HCV antibody lab order directed to their preferred laboratory
41360801|NCT02008461|PROCEDURE|radiofrequency ablation|
41498665|NCT02936180|BIOLOGICAL|HD-TIV|
41498666|NCT02936180|BIOLOGICAL|SD-QIV|
41498667|NCT05160272|DRUG|AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
41498668|NCT05160272|DRUG|Placebo matching AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
41498669|NCT00128050|DRUG|rFactor VIIa (Eptacog alfa, NovoNordisk)|rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
41498670|NCT00128050|DRUG|rFVIIa|Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
41498671|NCT00128050|OTHER|Sodiun chloride 0.9%|Bolus injection of sodium chloride 0.9% after surgical hematoma removal
41498672|NCT03357653|DRUG|Losartan group|Losartan 50 mg daily
41498673|NCT03357653|DRUG|Placebo group|Placebo 1 pill daily
41498674|NCT00089024|DRUG|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 \& 2; Repeat one 3-week cycle starting day 22
41498675|NCT00089024|DRUG|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 \& 2; Repeat one 3-week cycle starting day 22
41498676|NCT00089024|DRUG|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
41498677|NCT00089024|DRUG|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
40840643|NCT01420666|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
40840644|NCT01420666|DRUG|Placebo|placebo, three tablets four times a day, orally, with food
40840645|NCT05833178|BEHAVIORAL|Drawn Blood Volume|Hemoglobine Changes
41160754|NCT03185585|OTHER|Mini Nutrition Assessment (MNA® )|MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.
41360802|NCT02008461|DRUG|botulinum toxin injection|
41360803|NCT00578331|DRUG|Olopatadine 0.6% nasal spray|2 sprays each nostril twice daily
41360804|NCT00578331|DRUG|Placebo Nasal Spray|2 sprays each nostril twice daily
41360805|NCT02251574|OTHER|Low Calorie Diet|Weight management program designed around a low calorie diet.
41360806|NCT02251574|OTHER|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
41360807|NCT02251574|OTHER|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
41360808|NCT01481259|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
41360809|NCT01481259|OTHER|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
41360810|NCT03251716|DRUG|berberine|berberine 300mg TID add-on for berberine adjunctive group
41360811|NCT05785559|PROCEDURE|uterine biopsies|uterine biopsies performed on the areas of cesarean section scars
41360812|NCT02054624|BEHAVIORAL|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
41360813|NCT02054624|BEHAVIORAL|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
41360814|NCT02054624|BEHAVIORAL|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
41360815|NCT02054624|BEHAVIORAL|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
40840646|NCT04465968|DRUG|Cisplatin|Cisplatin 60 mg/m2, IV, day 1
40840647|NCT04465968|DRUG|S1|80 - 120 mg/day, PO, day 1-14
40840648|NCT04465968|RADIATION|concurrent radiotherapy|66 Gy/33 Fr
41360816|NCT05411731|OTHER|Conventional physical therapy treatment|"The control group (group A) will receive the exercise program which focused on improving the arm function as well as shoulder abduction and external rotation for 10 week.~stretching Aeroplan positioning"
41360817|NCT05411731|OTHER|Constraint induced movement therapy|The study group (group B) who will receive Modified constraint induced movement therapy for 3 hrs. a day 12 hrs. a week in addition to the same exercise program given to the control group for 10 weeks.
41360818|NCT01354964|DRUG|Vitamin D|
41360819|NCT01354964|DRUG|Placebo|
41360820|NCT04902573|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
41360821|NCT04937127|BEHAVIORAL|I-LEARN training|Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part
41360822|NCT04937127|OTHER|usual care|usual care
41360823|NCT05359328|DEVICE|Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line|Measurement of physiological parameters
41360824|NCT05884606|DEVICE|Allurion Digital Behaviour Change Intervention|The Allurion DBCI adheres to current National Institute for Health and Care Excellence (NICE) guidance for obesity.
41360825|NCT04927858|DRUG|Empagliflozin|Empagliflozin
41360826|NCT00472628|PROCEDURE|Blood samples collected|
41498678|NCT00089024|PROCEDURE|adjuvant therapy|"Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy."
41360827|NCT06421727|OTHER|Rehabilitation by optokinetic stimulation and virtual reality exercises .|Rehabilitation by optokinetic stimulation and virtual reality exercises(by deviceVirtual reality system(Meta Quest 2_Advanced All-In-One Virtual Reality Headset_ 128 GB)).
41498679|NCT00089024|PROCEDURE|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 \[negative margins\] or R1 \[positive microscopic margins\]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
41498680|NCT00089024|PROCEDURE|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
41498681|NCT00089024|RADIATION|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
41498682|NCT06385561|DRUG|Tramadol|Tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200 mg)
41498683|NCT06385561|DRUG|Placebo|Placebo is administered orally twice daily.
41498684|NCT05631223|BEHAVIORAL|Telemedicine|The intervention will consist of two structured telemedicine visits delivered between two routine office visits and conducted by providers (nurse practitioners and clinical nurse specialists).
41360828|NCT06423118|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a pair of non-invasive, flexible sensors originally designed for vital signs monitoring in the paediatric intensive care unit.
41360829|NCT02131142|DEVICE|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
41498685|NCT04235361|DIAGNOSTIC_TEST|Differential RPA tests|The mobile diagnostic suitcases will be deployed at Ebola Treatment centres in DRC. Samples of patients refered for diagnostic testing will be tested by PCR by existing diagnostic teams, and will be additionally tested by the mobile suitcase laboratory using differential RPA tests for 6 parameters.
41498686|NCT03232632|DRUG|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl ®)
41498687|NCT06495489|OTHER|Detection of preload responders by a PLR test|Detection of preload dependency by using PLR test and echocardiography
41160755|NCT03185585|OTHER|Comprehensive Older Adult Screening Tool (COAST)|Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
41360830|NCT04778111|OTHER|Measurement of the actual and perceived maximum reachable distance|A device (a table) will present luminous targets (green circles) to the subjects. Subjects will be asked to determine whether or not they are able to reach this target with their upper limb.
41498688|NCT04478630|OTHER|Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract|Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).
41360831|NCT03782389|OTHER|Preseason Periodic Health Examination Completion|all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.
41498689|NCT05792696|BEHAVIORAL|PPI guided strategies|For targeted MAP or lower, if PPI\<1, more fluid therapy. if PPI\>3, vasoconstriction therapy. For MAP\<65mmHg and 1\<=PPI\<3, test bolus of 250 ml crystalloid fluid.
41498690|NCT05792696|BEHAVIORAL|Empirical strategies|Fluid therapy or vasoconstriction depended on experiences of anesthetic staffs.
40840649|NCT04465968|DRUG|Durvalumab|preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
41360832|NCT03514368|OTHER|Patients treated with immune checkpoint blockade|"Tumor biopsy specimens and blood samples will be collected at different time points:~* Baseline~* before the 3rd ICB administration (blood samples only)~* before the 5th ICB administration (blood samples only)~* at the time of treatment permanent discontinuation (blood samples only)~* at the time of progression (tumor biopsy specimens only)~* after the last dose of ICB treatment (blood samples only taken twice per year until study termination)"
41360833|NCT05720936|PROCEDURE|Percutaneous stellate ganglion block (PSGB)|"Both the two approaches present in literature and commonly used for this technique are allowed for the study:~* The anatomical approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion~* The echo-guided approach"
41360834|NCT03975881|OTHER|application on smartphone|The aim of this study is to test the feasibility of our approach of preventing suicide relapse with the use of a smartphone application.
41498691|NCT04702438|BEHAVIORAL|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
41498692|NCT03283462|DIETARY_SUPPLEMENT|Mitopure|Mitopure (Urolithin A) containing softgels
41498693|NCT03283462|DIETARY_SUPPLEMENT|Placebo|Placebo containing softgels
41498694|NCT03454178|DIAGNOSTIC_TEST|WatchBP Office (BP measurement machine)|BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
41498695|NCT04920500|DRUG|Daunorubicin Cytarabine liposome for injection|Induction 1: \[100 U/m²\] i.v. d1,3,5 Induction 2: \[100 U/m²\] i.v. d1,3
41498696|NCT04920500|DRUG|Vyxeos、Daunorubicin Cytarabine liposome for injection|Induction 1: \[100 U/m²\] i.v. Vyxeos（d1）,Daunorubicin Cytarabine liposome for injection（d3、d5） Induction 2: \[100 U/m²\] i.v. Daunorubicin Cytarabine liposome for injection（d1、d3 ）
41498697|NCT04237935|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg dispensing claim is used as the exposure group
41498698|NCT04237935|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
41498699|NCT02730026|DRUG|Ketoprofen|Clinical efficacy of the Ketoprofen 100 mg was study after lower third molar surgery.
41498700|NCT02730026|DRUG|Ketoprofen and Omeprazole|Clinical efficacy of the Ketoprofen 200 mg and Omeprazole 20 mg will be study after lower third molar surgery.
40840650|NCT04465968|PROCEDURE|Surgery|Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.
41266629|NCT00067756|DRUG|4-PBA|During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day
41266630|NCT01011348|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg/day for three months
41266631|NCT01011348|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg/day for three months
41266632|NCT01011348|DIETARY_SUPPLEMENT|Placebo|Three month period
41266633|NCT03411395|DIETARY_SUPPLEMENT|5AA+CrPic Water|Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate
41266634|NCT03411395|OTHER|Placebo drink|Placebo water with carbonation and aroma
41266635|NCT05146908|BIOLOGICAL|2 Blood samples from arterial and/or central venous catheters|5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
41266636|NCT05146908|OTHER|Echography|"In 3 steps:~* before initiation of enteral nutrition~* 4h after initiation of enteral nutrition~* After 24 hours of enteral nutrition"
41024852|NCT02984501|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by CTV with a safety margin of 1cm in all directions to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a 15-MV linear accelerator (Varian Medical System) with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied for all patients with periodical digital portal images to evaluate the precision of the set-up.
41024853|NCT02984501|DRUG|Chemotherapy|The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
41024854|NCT00036166|DRUG|FK463|
41024855|NCT02835014|BEHAVIORAL|Mental Health Symptoms|Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)
40840651|NCT04465968|DRUG|Durvalumab|"(For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1"
41024856|NCT02835014|BEHAVIORAL|Self-efficacy regarding self-care and diabetes management|Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management
41024857|NCT02835014|BEHAVIORAL|Parenting Styles|Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
41024858|NCT05211024|DRUG|Penicillin G Benzathine|Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care
41024859|NCT02256111|DRUG|Enzalutamide|
41024860|NCT02256111|DRUG|Androgen deprivation therapy|
41024861|NCT02256111|BEHAVIORAL|Supervised exercise training|
41024862|NCT04819997|OTHER|Educational Intervention|Participate in videoconference session
41024863|NCT02410681|DEVICE|Electromyographic recording of temporalis muscle activity during sleep|"Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.~1. 3 recordings after the baseline visit~2. 3 recordings 6 weeks after the baseline visit~3. 3 recordings one year after the baseline visit"
41024864|NCT02410681|RADIATION|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
41360835|NCT02741336|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Cognitive-behavioral therapy is a short-term, focused psychotherapy for a wide range of psychological and behavioral issues including depression, anxiety, anger, and non-compliance. The focus of the intervention is on how one thinks, behaves, and communicates in real time, as opposed to a focus on one's early childhood experiences. The therapist assists the patient in identifying specific distortions and biases in thinking and provides guidance on how to modify these beliefs. CBT helps the patient learn effective self-help skills that are used in homework assignments that ultimately help change the way one thinks, feels and behaves. The~￼ intervention is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training."
41024865|NCT02410681|OTHER|Collection of biofilm sample|"Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:~1. At the baseline visit~2. Three months after the baseline visit~3. One year after the baseline visit"
41024866|NCT06300645|PROCEDURE|SPLATT|split tibialis anterior tendon transfer to peroneus brevis total tibialis anterior tendon transfer to lateral cuneiform
41024867|NCT04121598|OTHER|Observational|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
41024868|NCT04621448|BEHAVIORAL|Moving Together|"Two-way livestreaming virtual group classes will be offered for 1 hour, 2 days/week for 12 weeks to all participants. Classes will be led by a trained instructor who will demonstrate all movements and will provide brief explanations for the goals of movements. Consistent with the in-person program, classes will focus on the 7 guiding principles of Moving Together:~1. repetition with variation (to promote procedural learning);~2. progressive, functional movements (to improve daily function);~3. slow pace and step-by-step instruction (to minimize cognitive demands);~4. participant-centered goal orientation (to enhance personal meaningfulness of movements);~5. body awareness, mindfulness and breathing (to encourage present-centeredness);~6. social interaction (to promote meaningful connection); and~7. positive emotions (to promote feelings of well-being."
41360836|NCT02741336|BEHAVIORAL|Self-Monitoring|
41498701|NCT05666245|BEHAVIORAL|Personal Protective Equipment (PPE) - Under High Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
41360837|NCT00285857|DRUG|Lovastatin|"Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent."
41498702|NCT05666245|BEHAVIORAL|No Intervention - Under High Air Hygiene|"No intervention~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
41498703|NCT05666245|BEHAVIORAL|Personal Protective Equipment (PPE) - Under Low Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~Low air hygiene is achieved with minimal ventilation."
41498704|NCT05666245|BEHAVIORAL|No Intervention - Under Low Air Hygiene|"No intervention~Low air hygiene is achieved with minimal ventilation."
40840652|NCT03959202|BEHAVIORAL|ELDERFITNESS|In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks \& 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps \& minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
41360838|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
40840653|NCT03959202|OTHER|Control|General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
41360839|NCT00960323|DRUG|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
41360840|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
40840654|NCT01950091|BEHAVIORAL|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
40840655|NCT01950091|OTHER|Alternative Website Control|Intervention is a Menu of links to 4 popular Websites offering back pain education
41360841|NCT00167713|DRUG|Ibuprofen|
40840656|NCT02399514|OTHER|Polysomnographic diagnostic|Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
40840657|NCT04726059|DEVICE|Transcutaneous Spinal Cord Stimulation|Therapeutic TSCS will be delivered during ABT using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). Stimulation will involve charge balanced monophasic rectangular waveforms with 1.0-ms pulses, administered at 30 Hz, with a carrier frequency of 10 kHz and a current ranging from 10 to 130 mA.
40840658|NCT04726059|DEVICE|SHAM (low-intensity) Transcutaneous Spinal Cord Stimulation|Ineffective stimulation will be administered at the same anatomical location as therapeutic TSCS.
40840659|NCT04726059|DEVICE|Activity-Based Therapy|"Using BWSTT, all participants (both arms) will train 3 times per week for 12 weeks with a target to reach 45 minutes of gait training in each session.~For gait training, the level of body weight support and speed of walking will be adjusted to allow the person to bear as much weight as possible while maintaining proper stance limb kinematics."
40840660|NCT02461888|DRUG|Ixazomib|Chemotherapy
40840661|NCT02461888|DRUG|Cyclophosphamide|Chemotherapy
40840662|NCT02461888|DRUG|Dexamethasone|Chemotherapy
41498705|NCT01987037|BEHAVIORAL|neuropsychomotor assessment|Children with autism spectrum disorders pass a specific battery test (NP-MOT) for a neuropsychomotor assessment. This neuropsychomotor assessment is administered in a half-day maximum. This battery aims to investigate passive muscle tone (shoulders, limbs, and trunk), standing and synkinesia, static and dynamic balance, tonic laterality (extensibility and dangling of hands and feet to identify the tonic dominant side), laterality of use, fine-digit movements, digital tactile gnosis, and body spatial integration (knowing left from right: for oneself and that of others, and with regard to objects).
41498706|NCT02654860|DRUG|Paracetamol 3%|Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
40840663|NCT04924478|BIOLOGICAL|Mepolizumab|Patients will be receiving this treatment as part of their standard clinical care
40840664|NCT03612050|BEHAVIORAL|Meaning Centered Psychotherapy|"Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life."
40840665|NCT05216627|DIAGNOSTIC_TEST|Self-administered saliva-based viral testing|Participants will be instructed on how to inactivate the virus and bring their sample to their laboratory's central PCR machine, where they will take an assay test. They will be instructed to collect saliva into a 1.5 milliliter (mL) collection tube containing inactivation buffer (TCEP and EDTA) using a small funnel and inactivate at 95°C for 10 minutes. Participants will then transfer 6ul of saliva into 2 PCR tubes containing amplification master mix and primers, put tubes in a heat block or PCR machine at 65°C for 45 minutes and assess fluorescence using a simple battery-powered fluorescence viewer. Once they assess their sample, they will be instructed to dispose of the saliva sample safely and in accordance with best laboratory practices. No saliva samples will be collected by the research team at any time as part of this study.
40840666|NCT00006094|DRUG|oxaliplatin|Given IV
40840667|NCT00006094|DRUG|fluorouracil|Given IV
40840668|NCT00006094|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
40840669|NCT03672630|DRUG|Azithromycin|Azithromycin 500 MG Oral Tablet \[ZITHROMAX\]
40840670|NCT03672630|DRUG|Ethambutol|Ethambutol 25 mg/kg \[MYAMBUTOL\]
40840671|NCT03672630|DRUG|Rifampin|Rifampin 600 MG \[RIFADIN\]
41360842|NCT03971968|PROCEDURE|Skin replacement with artificial skin|Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
41360843|NCT02114905|BEHAVIORAL|OTs Trained and Deliver CBIT|"CBIT is a highly structured therapy that typically takes place on a weekly basis. The patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This competing response helps to reduce, and in some cases, even eliminate the tic. The functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily."
41360844|NCT01840332|DRUG|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is \< 30 after 4 weeks the study continues up to 6 weeks.
41360845|NCT01693991|BEHAVIORAL|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
41360846|NCT01693991|BEHAVIORAL|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
41360847|NCT01475812|OTHER|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
41360848|NCT03854552|DRUG|BI 764198|capsule
41360849|NCT03854552|DRUG|Placebo|capsule
41360850|NCT04310852|DEVICE|BioCue Concentration Kit|The treatment will be carried out in the operating room under ordinary hospitalization and involves the application of 9 ml of autologous bone marrow concentrate in the knee affected by arthrosis. Specifically, 3 ml will be applied at the level of the bone-cartilage interface of the femur, 3 ml at the level of the bone-cartilage interface of the tibia, and 3 ml will be injected into the joint for a simultaneous action also at the level of the cartilage. To obtain the necessary amount of bone marrow concentrate, an aspirate of bone marrow will be taken from the iliac crest (60 ml) and homolateral tibia (30 ml) of the patient and concentrated by BioCue Concentration Kit, company Zimmer biomet, and centrifuge. This autologous bone marrow concentrate will be injected by means of the Perfuse at the level of the tibial and femoral bone-cartilage interface of the percutaneous arthrosis affected compartment under radiographic control.
41360851|NCT00270010|DRUG|epoetin alfa|
41360852|NCT06322511|BEHAVIORAL|Dialogical Family Guidance (DFG)|DFG is family intervention including six meetings with family members. The individual needs and questions of each family are discussed and issues parents bring up are seemed as important.
41360853|NCT01121224|DEVICE|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
41360854|NCT01121224|DEVICE|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
41360855|NCT01121224|DRUG|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
41360856|NCT01121224|DRUG|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
41360857|NCT01121224|DRUG|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
41360858|NCT00777439|DRUG|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
41360859|NCT06085690|BEHAVIORAL|evidence-based intervention Plan for the Prevention of CRBSI in ICU patients|"On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention."
41360860|NCT04533932|DIAGNOSTIC_TEST|Elastography|Endosonographic shear wave elastography
41360861|NCT02693405|OTHER|Executive functions|measures of executive functioning with tasks
41360862|NCT02693405|OTHER|social cognition|measures of socio-cognitive functioning with tasks
40840672|NCT04520724|DIETARY_SUPPLEMENT|plant fiber|The patients with NAFLD (study and control group) will receive low-processed rolls with an 12 g plant fiber content twice daily, which would be a convenient for easy replenishment of the amount of vegetable fiber (act as prebiotic) in the diet. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
40840673|NCT04520724|DIETARY_SUPPLEMENT|maltodextrin bar|The patients with NAFLD (placebo group) will receive maltodextrin bars twice daily, which would be a convenient and easy-to-eat snack replacing the second breakfast and afternoon tea. The bars must be eaten with 180 ml of water or unsweetened liquid. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
41360863|NCT02693405|OTHER|quality of life|measures of quality of life with questionnaires
41360864|NCT05539040|PROCEDURE|Right Atrial ganglionated plexus ablation|"A 3D electroanatomic map of the right atrium will be made. During sinus rhythm, the ablation catheter will be positioned at a spot to test with HFS. The right atrium will be paced at a fixed rate, for up to four beats to ensure that there is no ventricular capture then a short burst of HFS will be synchronized to each paced stimulus for up to 15 trains. This will be performed using a custom-built GP stimulator that has been validated for reproducibility against Grass Stimulator (AstroMed).~All Sites will be marked on the 3D map and the positive sites will be ablated at the end of the mapping. If the patient converts to AF, then DC cardioversion will be performed. If mapping in sinus rhythm is not feasible, HFS will be performed continuously for several seconds to identify atrioventricular dissociating GPs (AVD-GPs).~Every ablated GP site will be re-tested with HFS at the end of the procedure until they are all rendered non-functional."
41360865|NCT05539040|DIAGNOSTIC_TEST|Holter Monitor|"48 hour Holter monitors will be performed post procedure to monitor for recurrence of AF.~These will be performed at 3, 6, 9, 12 months"
41360866|NCT05539040|PROCEDURE|Pulmonary vein isolation|"Transseptal puncture for access into the left atrium will be guided by TOE and fluoroscopy.~ACT will be maintained at 300s with heparin. A 3D electroanatomic map of the left atrium will be created and all PVs will be identified. Touch-up radiofrequency ablation will be performed at electrical gaps around the reconnected PVs until complete PVI is achieved."
41360867|NCT05539040|PROCEDURE|Right cavo-tricuspid and left roof linear ablation|CONTROL ARM (Redo-PVI) only: If all Pulmonary veins are isolated at the start of the procedure, the operator will be allowed to perform a right cavo-tricuspid and left roof linear ablation.
41498707|NCT02654860|DRUG|Placebo injection containing Saline solution 0.9%|Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
41498708|NCT02654860|DRUG|Hyperbaric Bupivacaine HCl 0.5%|NIMP, spinal anaesthetic before the surgical procedure
41498709|NCT00403507|BEHAVIORAL|Participation in a monitored exercise program|No contact with control group during 20 weeks.
40840674|NCT00098306|DRUG|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
40840675|NCT00098306|DRUG|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
41498710|NCT00403507|BEHAVIORAL|Personalized aerobic and strength training.|Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
41498711|NCT00140348|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
41498712|NCT06522217|DEVICE|nasoalveolar molding appliance|making impression then make the conventional lab procedures for group A for the production of conventional appliances
41498713|NCT06522217|DEVICE|digital nasoalveolar molding appliance|group B scanning the model and designing the appliances on 3shap and 3d printing the appliances
41498714|NCT06093438|DRUG|Toripalimab|Patients enrolled in this arm would receive three cycles of induction treatment before receiving definitive chemoradiotherapy. The specific regimen is: Paclitaxel(135mg/m2,ivd, d1)+cisplatin(75mg/m2,ivd,d1-3)+Toripalimab (240mg,ivd,d1)±bevacizumab(ivd, d1)/q21d. Patients would receive pelvic MRI to evaluate the regression status of tumor after three cycles of induction treatment. Patients with satisfying tumor regression would receive definitive chemoradiotherapy afterwards. During chemoradiotherapy, patients would receive weekly cisplatin (40mg/m2) and 240mg toripalimab every three weeks. After chemoradiotherapy, patients would receive another three cycles of consolidated treatment (regimen identical to induction treatment).
41498715|NCT05436262|DEVICE|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~1. Overt finger tapping in time with a flashing cue.~2. Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
40840676|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
40840677|NCT00098306|DRUG|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
40840678|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
41024869|NCT04188041|OTHER|TB Infection ECHO|A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion
41498716|NCT05436262|BEHAVIORAL|At-home therapy|"Participants are assigned to groups where the participants will practice each day for 3 weeks at-home.~1. Group 1: Imagery only.~2. Group 2: Overt finger tapping only.~3. Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that the participants are finger tapping in time with the flashing cue, using the imagery strategies identified during participants' previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
41498717|NCT03323047|DRUG|Acetaminophen|Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
41498718|NCT03323047|DRUG|Low-dose Dexamethasone|Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
41498719|NCT03323047|DRUG|Placebo Oral Tablet|Oral placebo 1 hr pre-operatively
41498720|NCT03323047|DRUG|High-Dose Dexamethasone|Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
41498721|NCT01539135|DRUG|Methylene Blue|20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
41498722|NCT04837924|PROCEDURE|fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml)|Land mark technique will be used to perform FICB on the side of the hip fracture. The injection site is one centimetre caudal from the junction between medial 2/3 and lateral 1/3 in the imaginary line between anterior superior iliac spine and ipsilateral pubic tubercle. The goal is to administer local anesthetic in the fascia iliaca compartment.
41498723|NCT04837924|DRUG|paracetamol 1 gram IV|paracetamol 1 gram IV every six hours, 4 times in 24 hours
40840679|NCT00538993|BEHAVIORAL|Stage based counseling|
40840680|NCT01694108|BIOLOGICAL|BCG-vaccine (SSI)|
40840681|NCT00240383|DRUG|Muraglitazar|
40840682|NCT01158690|OTHER|resource card|the intervention group receives an envelop with resource card
41024870|NCT01706952|DRUG|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
41024871|NCT01706952|DRUG|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
41024872|NCT06235749|DRUG|Calcium Gluconate 10%|Administration of Calcium Gluconate 10% IV following umbilical cord clamping
41024873|NCT06235749|DRUG|sodium chloride 0.9%|Administration of sodium chloride 0.9% IV following umbilical cord clamping
41024874|NCT00001059|DRUG|Doxorubicin hydrochloride (liposomal)|
41024875|NCT00001059|DRUG|Filgrastim|
41024876|NCT00001059|DRUG|Bleomycin sulfate|
41024877|NCT00001059|DRUG|Vincristine sulfate|
41498724|NCT04837924|DRUG|Rescue analgesic tramadol 100 mg IV if needed|Rescue analgesic, if needed, tramadol 100 mg in 100 ml saline (0,9% Sodium chloride) IV, up to 4 times in 24 hours
41498725|NCT04837924|PROCEDURE|Sham injection|Sting with blunt needle, (without piercing the skin), same site as fascia iliaca compartment block
40840683|NCT01158690|OTHER|no resource card|the control group receives an envelop without resource card
40840684|NCT03025178|PROCEDURE|4Fr central venous catheter insertion|The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
40840685|NCT06393634|DRUG|Testosterone injection|A single injection of testosterone
40840686|NCT06393634|DRUG|Testosterone gel|A daily dose of testosterone gel
41024878|NCT04912505|DRUG|Aspirin|Run-in phase during one week with daily aspirin intake at 8 AM; visit 1: blood sampling at H24 and H2; intermediate phase (two weeks): daily aspirin intake at 8 PM; visit 2: blood sampling at H12; then daily intake of aspirin at the time preferred by the patient and study end visit 2 weeks after visit 2
40840687|NCT06393634|DRUG|Testosterone Oral|A twice-daily pill of testosterone pill to swallow
41498726|NCT06148168|DRUG|Bupivacaine plus normal saline|"Unlike specific peripheral nerve blocks, TAP block is a non-dermatomal field block. Even with the same US-guided technique, the extent of spread of local anesthetics can be variable due to individual anatomical variations (18). In order to perform the blocks, abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest .Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study."
40840688|NCT04259970|DRUG|Initiation of CFTR Modulator|Inhaled contrast for MRI occurring at each 4 visits.
40840689|NCT02871089|DEVICE|Closed-loop system (Florence M or CamAPS FX)|"The automated closed-loop system (FlorenceM) will consist of:~* Sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite/Guardian 3 real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.~The automated closed-loop system (CamAPS FX) will consist of:~* Dana R or RS insulin pump~* Dexcom G6 real-time CGM~* CamAPS FX App on an unlocked android smartphone.~Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue)."
40840690|NCT02871089|OTHER|Multiple Daily Injections|"Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes.~Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed."
40840691|NCT03443427|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.
40840692|NCT03443427|BIOLOGICAL|Placebo|One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.
40840693|NCT00056446|DRUG|Vatalanib|
40840694|NCT06219395|PROCEDURE|Endoscopy|Patients will be examined with gastroscopy, colonoscopy and WCE and the diagnostic yield of combined gastroscopy/colonoscopy will be compared to WCE
40840695|NCT01833000|DEVICE|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
40840696|NCT03914677|DRUG|Mecamylamine Oral Tablet|nicotinic antagonist (ganglionic blocker)
40840697|NCT03329261|DRUG|Clopidogrel|COPIGREL® - clopidogrel dosed at 75 mg per tablet
41498727|NCT06148168|DRUG|Bupivacaine plus normal saline containing MgSO4|Bupivacaine plus normal saline containing MgSO4
41498728|NCT02335983|DRUG|Carfilzomib|Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
40840698|NCT02014779|BEHAVIORAL|eChange|A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
40840699|NCT02014779|BEHAVIORAL|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
40840700|NCT05374187|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. Participants deemed to be positive responders to blinded active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
41024879|NCT06216626|DIETARY_SUPPLEMENT|myota's prebiotic fibre blend|"Each 10g daily serve of supplement contains the following fibres:~* Fructooligosaccharides~* Inulin~* Resistant dextrin~* Resistant maltodextrin~* Partially hydrolysed guar gum~* Guar gum"
40840701|NCT05374187|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. At conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open active eTNS treatment. Participants deemed to be positive responders to open active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
40840702|NCT05192889|DRUG|Venetoclax|Given oral (PO).
40840703|NCT05192889|DRUG|Navitoclax|Given oral (PO).
40840704|NCT05192889|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
40840705|NCT05192889|DRUG|Vincristine|Given intravenously (IV).
40840706|NCT05192889|DRUG|Calaspargase Pegol|Given intravenously (IV).
40840707|NCT05192889|DRUG|Dasatinib|Given oral (PO).
40840708|NCT05192889|DRUG|Cytarabine|Given intravenously (IV) or Intrathecal (IT).
40840709|NCT05192889|BIOLOGICAL|Blinatumomab|Given intravenously (IV).
40840710|NCT05192889|DRUG|Methotrexate|Given intravenously (IV), oral (PO), or Intrathecal (IT).
41024880|NCT05866757|OTHER|Discontinuation of maintenance treatment|The discontinuation of maintenance treatment in multiple myeloma. Classed as interventional due to treatment being taken away.
41160756|NCT05561296|PROCEDURE|Femtosecond laser assisted cataract surgery with astigmatism management|The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient. Patients will undergo femtosecond laser-assisted cataract surgery with Catalys femtosecond laser.
41360868|NCT05539040|DIAGNOSTIC_TEST|Personal ECG recordings|All patients will be provided with an AliveCor KardiaMobile-6L ECG recorder. The device will continue to be used within its CE-marked and NICE-approved purpose. Patients will be asked to take a daily recording from this, once the blanking period is over, in addition to taking a recording if symptomatic. Patients will submit this to the connected care team at Hammersmith Hospital via a secure NHS.net email address, who will assess the recordings both for the study and clinical purposes.
41360869|NCT05539040|OTHER|Quality of life questionnaire|A Quality of life questionnaire will be performed at baseline, 6 and 12 months to assess the effect of the procedures on patients quality of life.
41360870|NCT04335929|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
41498729|NCT02335983|DRUG|Lenalidomide|Administered orally once daily on days 1-21 of each 28-day cycle.
41498730|NCT02335983|DRUG|Dexamethasone|Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
41498731|NCT06374758|OTHER|The Accelerate model of care|"Contact is established by the study team~The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact~At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study~The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.~B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.~A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.~Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider."
41498732|NCT06374758|DRUG|bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg|Same as above, it is the same intervetion
41498733|NCT03269227|RADIATION|Accelerated hypofractionation with Tomotherapy|"Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription doses:~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.~Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment."
41498734|NCT02029014|DEVICE|LAA closure system|
41498735|NCT00552851|DRUG|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
40840711|NCT05192889|DRUG|Mercaptopurine|Given oral (PO).
41160757|NCT03439397|DEVICE|Ballon Technique|Ballon Technique
41498736|NCT00106964|BIOLOGICAL|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
40840712|NCT05192889|DRUG|Cyclophosphamide|Given intravenously (IV).
40840713|NCT05192889|DRUG|Etoposide|Given intravenously (IV).
41024881|NCT00701051|BEHAVIORAL|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
41024882|NCT00701051|BEHAVIORAL|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
41024883|NCT01527201|PROCEDURE|Arthroscopic debridement|Surgeon will debride, or remove, worn out cartilage.
41160758|NCT03439397|DEVICE|SOAI|SOAI
41360871|NCT01363232|DRUG|BKM120 + MEK162|
41024884|NCT05115162|OTHER|Exercise|The exercises consist of flexibility, strengthening exercises for the trunk and extremities, and walking indoors.The walking program was applied for at least 30 minutes. Eight different exercises were given for the trunk and extremities and these exercises were applied 3 times a week, 2 sets, each set with 10 repetitions.
41024885|NCT02610140|DRUG|Anetumab ravtansine (BAY94-9343)|Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
41024886|NCT02610140|DRUG|Vinorelbine|Starting dose: 30mg/m\^2 administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
40840714|NCT05192889|DRUG|Leucovorin|Given oral (PO) or intravenously (IV).
40840715|NCT05192889|DRUG|Intrathecal Triples|Given Intrathecal (IT).
41024887|NCT02855294|DRUG|COC containing 30 μg of EE and 3mg of drospirenone|treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
41024888|NCT01267071|DRUG|A|GSK962040 (50 mg, SD, oral)
41024889|NCT01267071|DRUG|B|14C GSK962040 (100 μg, SD, iv)
41024890|NCT01494285|DRUG|ARK-E021 5%|Topically applied once daily at bedtime
41024891|NCT01494285|DRUG|ARK-E021 10%|Topically applied once daily at bedtime
41024892|NCT01494285|DRUG|Placebo|Topically applied once daily at bedtime
41024893|NCT05009563|RADIATION|FDG-PET/CT|whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
41024894|NCT00151645|DRUG|activated lymphocytes|
41024895|NCT02998294|DEVICE|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
40840716|NCT05192889|DRUG|Pegaspargase|May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).
40840717|NCT05192889|DRUG|Erwinia asparaginase|To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).
40840718|NCT05192889|RADIATION|Radiation|See detailed description section.
40840719|NCT01502163|DEVICE|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
40840720|NCT01502163|DEVICE|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
41024896|NCT02998294|DEVICE|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
41024897|NCT06464055|DRUG|Dose Escalation|GQ1010
41024898|NCT06464055|DRUG|Dose Expansion1|GQ1010 dose1
41360872|NCT04555993|PROCEDURE|lower abdominal surgery|Patients will undergo lower abdominal surgery under general anesthesia.
41360873|NCT04555993|OTHER|Erector spinae plane block|patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).
40840721|NCT03016923|DEVICE|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
40840722|NCT01595594|DRUG|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
40840723|NCT01595594|DRUG|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
41024899|NCT06464055|DRUG|Dose Expansion2|Drug: GQ1010 dose2
41360874|NCT04555993|OTHER|Transversus abdominis plane block|patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
41360875|NCT04613076|BEHAVIORAL|"Me cuido y me siento mejor"|A multicomponent, collaborative, computer-assisted, psycho-educational intervention for the management of depressive symptoms in primary care patients with diabetes and/or hypertension.
41360876|NCT04613076|BEHAVIORAL|Enhanced Usual Treatment|Enhanced Usual Treatment
41360877|NCT06506526|PROCEDURE|Sodium hypochlorite irrigating solution|2 ml 1% NaOCl after each file
41360878|NCT06506526|PROCEDURE|one minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for one minute.
41360879|NCT06506526|PROCEDURE|Three minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for three minute.
41024900|NCT06464055|DRUG|phase II|Drug: GQ1010 RP2D
41024901|NCT04414644|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
41024902|NCT01469689|OTHER|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
41360880|NCT04769258|BIOLOGICAL|Pfizer Comirnaty vaccine|COVID 19 vaccines administered to the patients according to the times and modalities established by the Italian National Vaccination Plan. Further vaccines will be evaluated if and when they are available in Italy during the study period.
41160759|NCT05307237|DEVICE|Dexcom G6 Continous Glucose Monitoring Management|CGM data will be transmitted from the bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by the remote monitoring team) and (2) Clinical Optimization (via CLARITY, by which a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub.
41360881|NCT02301468|OTHER|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
40840724|NCT03841136|DRUG|anlotinib|anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1\~D3
40840725|NCT04753021|OTHER|Exercise|Progressively increasing training load
40840726|NCT06055660|GENETIC|Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma|Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.
40840727|NCT00075738|DRUG|cisplatin|
40840728|NCT00075738|DRUG|fluorouracil|
40840729|NCT00075738|DRUG|irinotecan hydrochloride|
40840730|NCT00075738|DRUG|leucovorin calcium|
40840731|NCT04054804|DIAGNOSTIC_TEST|D-Foot|A digital foot check i assessed by using the software D-Foot.
41024903|NCT01469689|OTHER|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
41024904|NCT01177501|DRUG|Topotecan|Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
41360882|NCT02301468|OTHER|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
41498737|NCT00106964|BIOLOGICAL|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
41498738|NCT00106964|BIOLOGICAL|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|"Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle."
41498739|NCT00054665|DRUG|PS-341|1.3 mg/m\^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
40840732|NCT04320108|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy 6 times during 2 weeks
41160760|NCT05307237|DEVICE|Usual Care - Blinded Continuous Glucose Monitoring Management|CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring.
40840733|NCT01355796|DRUG|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
41160761|NCT03726983|OTHER|Experimental group|Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
41160762|NCT01575483|DRUG|No Intervention (subjects were previously treated with Onglyza®)|No Intervention
41360883|NCT04164264|DRUG|Propofol|At T0, a propofol infusion at a rate of 1.5 mg/kg/min will be started until apnea is achieved. Loss of consciousness will be defined clinically using loss of eyelash reflex (TLOER) and tolerance of nasal cannulae (TNC), tested every 10 sec., and by a BIS \<60 for 30 sec. (TBIS). Apnea will be defined as absence of end-tidal CO2 for at least 20 seconds (TAPNEA). A saliva sample with be taken under anesthesia for genome-wide association study and principal component analysis.
41360884|NCT02255162|DRUG|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
41360885|NCT02255162|GENETIC|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
41360886|NCT02255162|DRUG|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
41360887|NCT02463097|DEVICE|Insulin Pump|Closed Loop Algorithm
41360888|NCT05232903|BIOLOGICAL|SVF therapy group|The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.
41360889|NCT00635804|DRUG|MK-3281|MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
41360890|NCT00635804|DRUG|Placebo to MK-3281|Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
41360891|NCT02094794|DRUG|etoposide|Given IV
41360892|NCT02094794|DRUG|cyclophosphamide|Given IV
41360893|NCT02094794|RADIATION|total marrow irradiation|Undergo TMLI
41360894|NCT02094794|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
41360895|NCT02094794|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
41360896|NCT00142207|DRUG|Intermittent preventive treatment:sulphadoxine-pyrimethamine|Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
41360897|NCT00142207|DEVICE|Insecticide-treated mosquito bed net|Insecticide-treated mosquito bed net
41360898|NCT05336045|PROCEDURE|trigger finger release|The A1 pulley and tendon sheath is divided in local anaestethic through a small incision in the palm
41360899|NCT00036660|DRUG|SarCNU|
41498740|NCT00054665|DRUG|Etoposide|50 mg/m\^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
41498741|NCT00054665|DRUG|Doxorubicin|10 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
41498742|NCT00054665|DRUG|Vincristine|0.4 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
41498743|NCT00054665|DRUG|Cyclophosphamide|750 mg/m\^2 day IV day 5 bolus. Repeat cycle every 21 days.
41498744|NCT00054665|DRUG|Prednisone|60 mg/m\^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
41498745|NCT00054665|DRUG|Filgrastim|300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm\^3. Repeat cycle every 21 days.
40840734|NCT01355796|DRUG|Hypertonic saline|4 ml of 7 % saline aerosolized twice a day for 2 weeks
40840735|NCT05583994|OTHER|Optim Park Intervention|For participants receiving the Optim-Park II intervention, the aim is to enhance the process of living with Parkinson's Disease for the person with PD and the family-carer by building a multisectoral care pathway, with a special focus on how to optimize the use of resources and systems of support in the community in disadvantaged populations in UK.
40840736|NCT05648682|OTHER|Salin|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use. SF solution was obtained from the medical company as 500 ml separately for each patient.
41360900|NCT05465200|PROCEDURE|Structured treatment of cardiogenic shock patients|"Creation of hub\&spoke structure which covers all Lower Silesian Voivodeship (Poland) for treatment of cardiogenic shock patients. Based on shared protocol patients are reported to hub by spoke and decision is made as for patient transfer or further treatment in the spoke facility. If decision on transfer is made, patient is further treated according to hub on site shock team protocol"
41360901|NCT04576585|BEHAVIORAL|Lexicon training|Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.
41360902|NCT03017066|DEVICE|Ultrasound|Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.
41360903|NCT03017066|OTHER|General anesthesia|Scheduled operation under general anesthesia
41360904|NCT02926833|BIOLOGICAL|KTE-C19|A single infusion of KTE-C19 CAR-T cells administered intravenously
41360905|NCT02926833|BIOLOGICAL|Atezolizumab|Administered intravenously
41360906|NCT02926833|DRUG|Cyclophosphamide|Administered intravenously
41360907|NCT02926833|DRUG|Fludarabine|Administered intravenously
41360908|NCT04681872|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
41360909|NCT04681872|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
41498746|NCT00522561|OTHER|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
41498747|NCT04646876|DRUG|Magnesium Sulfate|Prospective , comparative , double blind study
41498748|NCT04646876|DRUG|Placebo|Prospective , comparative , double blind study
41360910|NCT04681872|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus
41360911|NCT03648047|DEVICE|Digital kinematic biofeedback device|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.
41498749|NCT05410886|OTHER|Questionnaire|A questionnaire including up to 20 questions will be distributed to study participants. This questionnaire will be used to identify women with FHA.
41498750|NCT01709838|DRUG|deferasirox|Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
41498751|NCT00856375|DRUG|NKTR-102|IV every 3 weeks
41498752|NCT00856375|DRUG|irinotecan|IV every 3 weeks
41498753|NCT01094886|DRUG|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
41498754|NCT00719771|DEVICE|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
41498755|NCT03875859|DRUG|Remetinostat|Topical 1% remetinostat gel
41498756|NCT06483789|DRUG|HB-1|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
41498757|NCT06483789|DRUG|Telmisartan Only Product in Oral Dose Form|Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.
40840737|NCT05648682|OTHER|Sodium bicarbonate|Patients were told that they should gargle using approximately two tablespoons of the solution given for each use. The 500 ml distilled water bottle to be used for the SB solution was obtained from the medical company, separately for each patient.
40840738|NCT05648682|OTHER|Thyme honey|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use.
41360912|NCT03648047|OTHER|Conventional rehabilitation|Patients will receive conventional face-to-face sessions by a Physical Therapist.
41498758|NCT06483789|DRUG|Verapamil Only Product in Oral Dose Form|Verapamil will be supplied as a single active pharmaceutical ingredient tablet.
40840739|NCT05648682|OTHER|Control|The patients continued to use the antifungal solution containing the active ingredient nystatin, which was prescribed routinely in the clinical procedure, 3 times a day.
41024905|NCT04741425|OTHER|REST intervention|"The breastfeeding talk will be conducted by Zoom at the third trimester about breastfeeding benefits and other practical advices. There is also a sharing session by a successful breastfeeding mother and a group discussion with different breastfeeding scenarios.~Once the mothers return home after delivery, individualized breastfeeding coaching will be provided by PI through a daily Zoom videoconference within 24 hours upon hospital discharge till Day 7 after delivery.~During the last breastfeeding videoconference, mothers will be reminded to have weekly telephone follow-ups by PI from week 2 to 2 months postpartum.~Women who are randomised into the intervention group will receive REST in addition to the standard antenatal and postnatal care (described at below) by the Obstetrics Department of their delivery hospitals."
41360913|NCT03648047|OTHER|Additional face-to-face rehabilitation sessions|Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
41360914|NCT02906644|DRUG|lorcaserin|
41498759|NCT06483789|DRUG|Placebo|Matched Placebo will be supplied as a tablet.
41498760|NCT03139786|OTHER|Study the natural history of bicuspid|Study the natural history of bicuspid
41498761|NCT04762849|PROCEDURE|Laparoscopic one anastomosis gastric bypass|Laparoscopic one anastomosis gastric bypass include the creation of gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. For the creation of a gastric pouch and gastroenterostomy use a linear stapler.
40840740|NCT05479890|OTHER|ClientBot|ClientBot is an AI-based simulated client that supports skills improvement for providers learning and using Motivational Interviewing
40840741|NCT05523375|BEHAVIORAL|Intensive Lifestyle Intervention|"Trained health coaches deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
40840742|NCT02014584|DRUG|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
40840743|NCT02014584|DRUG|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
40840744|NCT04706000|GENETIC|Beclin 1 gene|The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.
41360915|NCT02906644|DRUG|nicotine patch|
41360916|NCT02906644|DRUG|placebo lorcaserin|
41498762|NCT04762849|DEVICE|A shape-memory ring for adjustable gastric banding|A shape-memory ring (SMR) use for adjustable gastric banding. SMR is placed around the gastric pouch above the gastro-entero-anastomosis.
41498763|NCT01838668|DRUG|Placebo|Two placebo capsules orally BID
41498764|NCT01838668|DRUG|dimethyl fumarate|Two dimethyl fumarate 120mg capsules orally BID
40840745|NCT00641082|DRUG|Clevudine|30mg for 48 weeks
40840746|NCT00641082|DRUG|Adefovir dipivoxil|10mg for 48 weeks
40840747|NCT00290667|BIOLOGICAL|pegfilgrastim|
40840748|NCT00290667|BIOLOGICAL|rituximab|
40840749|NCT00290667|DRUG|cyclophosphamide|
41024906|NCT03056846|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
41360917|NCT03490929|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|injection of Lumason (ultrasound contrast agent)
41360918|NCT03490929|DEVICE|contrast-enhanced ultrasound|ultrasound of the abdomen after injection of ultrasound contrast agent (Lumason)
41360919|NCT02155725|DRUG|Human Fibrinogen concentrate|Injection as soon as possible and within 30 min following the start of prostaglandin infusion
41360920|NCT02155725|DRUG|Placebo|As soon as possible and within 30 min following the start of prostaglandin infusion
40840750|NCT00290667|DRUG|doxorubicin hydrochloride|
40840751|NCT00290667|DRUG|prednisone|
41360921|NCT04603339|OTHER|Multidisciplinary rehabilitation programme delivered via telehealth|"12 week programme of;~1) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions"
40840752|NCT00290667|DRUG|vincristine sulfate|
40840753|NCT00290667|OTHER|pharmacological study|
40840754|NCT00290667|RADIATION|radiation therapy|
40840755|NCT02648217|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
40840756|NCT02648217|DRUG|biphasic insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
40840757|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
40840758|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
40840759|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
40840760|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
40840761|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
40840762|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
40840763|NCT00002140|DRUG|Ethambutol hydrochloride|
40840764|NCT00002140|DRUG|Clarithromycin|
40840765|NCT00002140|DRUG|Azithromycin|
40840766|NCT02345330|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
40840767|NCT02345330|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
40840768|NCT02643589|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
40840769|NCT04829253|BEHAVIORAL|Dialectical Behavior Therapy -3-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, phone check-ins, crisis management and individual initial assessment.
40840770|NCT04829253|BEHAVIORAL|Dialectical Behavior Therapy -6-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, individual psychotherapy, coaching calls and treatment-team consultation.
40840771|NCT00734071|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
40840772|NCT00734071|DRUG|Placebo|Vortioxetine placebo-matching capsules
40840773|NCT06531317|DEVICE|transcranial Direct Current Stimulation|The treatment follows an approved neuromodulation protocol at our center (approved on Nov. 4 2021, valid until Nov. 4 2024). tDCS will be administered with a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland), using saline-saturated circular electrodes with a diameter of 6 cm². The anode will be positioned over C3 to stimulate the primary motor cortex (M1), and the cathode over the contralateral supraorbital area (FP2). For asymmetric pain, stimulation targets the M1 contralateral to the more painful side, and for symmetric pain, the dominant hemisphere (C3) is stimulated. The maximum current is 2 mA (current density: 0.06 mA/cm²). Each session lasts 30 minutes, conducted daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation (Bikson et al., 2016).
40840774|NCT06531317|DIAGNOSTIC_TEST|Electroencephalography|64-channel active-electrode EEG with impedances kept \~5KOhm
40840775|NCT01803867|DRUG|rHIgM22|Administered via IV infusion
40840776|NCT02223481|DRUG|Terbogrel low dose|
40840777|NCT02223481|DRUG|Terbogrel high dose|
40840778|NCT02223481|DRUG|Placebo|
41160763|NCT05744791|BEHAVIORAL|Active Play planned movement program|Teachers will implement an addition two physical activity opportunities that incorporate active play each day for a potential dose of 20-30 minutes per day and 100-150 minutes per week.
41360922|NCT03374228|DRUG|BMS-986205|Specified Dose on Specified Days
41360923|NCT00139373|DRUG|donepezil|
41360924|NCT00250601|DRUG|Saredutant succinate (SR48968C)|
41360925|NCT00660829|DRUG|Placebo|Placebo
41360926|NCT00660829|DRUG|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
41360927|NCT00578006|BEHAVIORAL|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
41360928|NCT00578006|BEHAVIORAL|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
41360929|NCT05814744|DRUG|dexmedetomidine|adding dexmedetomidine as adjuvant with bupivacaine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy surgery.
41360930|NCT05814744|DRUG|bupivacaine 0.25%|patients will receive bilateral Intermediate Cervical plexus block with 20 ml bupivacaine 0.25%.
41360931|NCT05814744|PROCEDURE|Thyroidectomy Surgery|surgical removal of all or part of thyroid gland.
41360932|NCT05814744|PROCEDURE|Ultrasound-guided intermediate Cervical Plexus Block Technique|the injection of local anesthetic in intermediate cervical plexus nerve block is made between the investing layer of the deep cervical fascia and the prevertebral fascia. Following negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site.
41360933|NCT01547494|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
41360934|NCT01547494|DIETARY_SUPPLEMENT|mixture of omega3 and vitamins|mixture of omega3 and vitamins
41360935|NCT01381601|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
41360936|NCT05364203|DEVICE|DEEPSEN virtual reality mask|DEEPSEN virtual reality mask with 360 ° vision. The audio-visual content will be chosen by the patient.
41360937|NCT00755976|DRUG|epirubicin hydrochloride|
41360938|NCT00755976|DRUG|sulindac|
41360939|NCT00755976|OTHER|immunologic technique|
41360940|NCT04963738|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a single SC injection.
41360941|NCT00723489|BIOLOGICAL|Live Yellow Fever Vaccine (YFV-17D)|
41360942|NCT00723489|DRUG|YFV-17D Placebo|
41360943|NCT02751606|DRUG|ferumoxtran-10|ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
41360944|NCT02751606|DEVICE|7 Tesla MRI|Subjects undergo a 7 Tesla MRI scan
41360945|NCT02751606|DEVICE|3 Tesla MRI|Subjects undergo a 3 Tesla MRI scan
41360946|NCT00082238|OTHER|Stable isotopes|Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
41024907|NCT03056846|DIETARY_SUPPLEMENT|Probiotic Combination|A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
41024908|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium bifidum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
40840779|NCT00787501|DRUG|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI \< 2) and tolerability is adequate. Nonresponse at week 10 (CGI \< 2) will be cause for medication switch or augmentation.
41024909|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium longum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
41024910|NCT02567422|DRUG|Berzosertib|Given IV
41024911|NCT02567422|DRUG|Cisplatin|Given IV
41360947|NCT03683680|OTHER|MPT Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
41360948|NCT03683680|OTHER|CLDN15/VIM Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
41360949|NCT02690506|DRUG|Placebo|
41360950|NCT02690506|DRUG|Pregabalin|
41360951|NCT04556942|DIAGNOSTIC_TEST|Flow Mediated Dilation (FMD) measurement|FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or \> 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
41360952|NCT04556942|OTHER|Blood pressure, pulse and blood oxygen saturation measurement|"Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient."
41360953|NCT04556942|OTHER|ST George Respiratory Questionnaire|The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
41360954|NCT04556942|OTHER|Physical activity level (PAL) measurement|PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
41360955|NCT04556942|BIOLOGICAL|Withdrawal of a blood sample|5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
41360956|NCT04556942|PROCEDURE|Immediate Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
40840780|NCT00787501|BEHAVIORAL|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
40840781|NCT03913494|DEVICE|Transoral Neurostimulation Device (Snoozeal)|Use of the Transoral Neurostimulation Device for 20 minutes, morning and night, every day for at least 4 weeks.
41360957|NCT04556942|PROCEDURE|Delayed Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
41360958|NCT05768776|PROCEDURE|HoLEP patients without MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, without using MOSES technology
41360959|NCT05768776|PROCEDURE|HoLEP patients with MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, with the use of MOSES technology
41360960|NCT04101994|DEVICE|Virtual cycling training|Virtual cycling training is a convenient and easy approach for muscle strengthening.
41360961|NCT04101994|DEVICE|Repetitive transcranial magnetic stimulation|Intermittent theta burst stimulation produces short TBS trains intermittently to facilitate cortical excitability.
41498765|NCT02938559|BEHAVIORAL|Cognitive Therapy (CT) for depression|There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
41498766|NCT02938559|BEHAVIORAL|Cognitive Therapy (CT) for depression + Memory Support|The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
41498767|NCT02967796|DIETARY_SUPPLEMENT|Proteochoc|
41498768|NCT03990610|PROCEDURE|Mammoplasty|Undergo standard of care breast reconstructive surgery
41498769|NCT03990610|PROCEDURE|Vascularized Lymph Node Transfer|Undergo vascularized lymph node transfer
40840782|NCT02541786|DRUG|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
40840783|NCT02541786|DRUG|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
41360962|NCT04101994|DEVICE|Transcranial electric stimulation|TES is a constant current with low intensity delivered to the skull through surface electrodes.
40840784|NCT02821364|OTHER|Advanced Life Support|IV FLUIDS, INTUBATION
40840785|NCT04238169|DRUG|Bevacizumab|7.5mg/kg once every three weeks
41360963|NCT05534594|DRUG|18F-PSMA-1007|As explained under 'Arms'.
41360964|NCT05370235|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
40840786|NCT04238169|DRUG|Toripalimab|240 mg once every three weeks
40840787|NCT04238169|RADIATION|SBRT|30-50Gy/5F（2-4 lesions）
40840788|NCT00073281|PROCEDURE|Islet transplantation|
41024912|NCT02567422|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41024913|NCT02567422|OTHER|Laboratory Biomarker Analysis|Correlative studies
41024914|NCT02567422|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41024915|NCT02567422|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41360965|NCT00469391|DEVICE|GI Sleeve Implantable weight loss device (EndoBarrier)|device for weight loss
41360966|NCT00469391|PROCEDURE|Sham Procedure|Weight loss
41024916|NCT02567422|RADIATION|Radiation Therapy|Undergo radiation therapy
41024917|NCT04543734|DEVICE|HemoScreen hematology analyzer|The use of HemoScreen for self-testing of blood values
41024918|NCT01701375|DRUG|PD 0332991|• PD 0332991 will be given orally days 1,2,3
41360967|NCT03288558|OTHER|A comprehensive perioperative mechanical ventilation strategy|"1) Intervention group.~* Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~* Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~* Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~* Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~* For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass"
41360968|NCT03817814|BEHAVIORAL|web-based questionnaire|Participants will complete a web-based questionnaire examining the decisions patients made about fertility preservation before and after treatment, the factors that influenced their decisions, and the ways in which patients pursue family building after treatment.
41360969|NCT00631228|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
41498770|NCT04327739|OTHER|Intervention 1 Exercise|• Exercise programme Endurance and Resistant training exercise program (Duration: 45 minutes) • Muscle retraining of longus colli and endurance training of the deep cervical flexors. • Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM). • Active ROM exercises for the neck muscles • Upper limbs exercises with resistant bands • Stretching exercises for the neck and upper limbs muscles
41498771|NCT04327739|OTHER|Intervention 2 Exercise and INIT|"* Exercise programme same as Intervention Group 1 and~* Integrated Neuromuscular Inhibition Technique application. Integrated Neuromuscular Inhibition Technique application. (Duration: 15min) The protocol was applied to the following muscles: • Upper border of the trapezius muscle • sternocleidomastoid • levator scapulae muscle • splenius capitis muscle Integrated Neuromuscular Inhibition Technique includes the combination of the following technique: • Ischemic compression • Muscle energy technique • Straincounterstrain technique"
40840789|NCT05563467|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
40840790|NCT04117698|DRUG|Antitubercular treatment (RIFATER ©)|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group."
40840791|NCT04117698|DRUG|Ethambutol|Ethambutol
40840792|NCT04117698|DRUG|RIFINAH ©|RIFINAH ©
40840793|NCT05160818|RADIATION|Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiotherapy radiosurgery (SRS)|intervention description see above
40840794|NCT05751148|DRUG|Hyperbaric bupivacaïne|Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution
40840795|NCT05751148|DRUG|Hyperbaric prilocaïne|Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne
40840796|NCT00724529|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
40840797|NCT00859742|PROCEDURE|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
40840798|NCT00030277|PROCEDURE|high-intensity focused ultrasound ablation|
40840799|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
40840800|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet|Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)
41360970|NCT04614142|DRUG|Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]|The subject will begin an 8 week course of therapy with glecaprevir (100mg) / pibrentasvir (40mg) starting on day 3 (+/- 2 days) post-kidney transplantation from a hepatitis C positive donor.
41024919|NCT01444534|DEVICE|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
40840801|NCT01291277|DEVICE|Endoscopic Variceal Ligation|Ligation of esophageal varices
40840802|NCT06453317|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.
40840803|NCT06453317|BIOLOGICAL|Ustekinumab|Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.
41360971|NCT03519815|DEVICE|Ectoin® Eye Spray - Colloidal|eye spray to be applied to the closed eye lid
40840804|NCT01379300|DRUG|dabigatran etexilate|dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
40840805|NCT01379300|DRUG|rivaroxaban|rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
40840806|NCT03297125|DEVICE|Standard Magnetic Resonance Imaging (MRI)|Standard MRI.
40840807|NCT03297125|DEVICE|Advanced MRI.|Perfusion and diffusion MRI.
40840808|NCT00756951|DRUG|Placebo|Placebo
40840809|NCT00756951|DRUG|SCV-07|0.02 mg/kg
40840810|NCT00756951|DRUG|SCV-07|0.10 mg/kg
40840811|NCT04405245|DRUG|Latanoprost ophthalmic solution|Latanoprost opthalmic solution to be dosed once daily
40840812|NCT04405245|DRUG|AKB-9778 4%|Razuprotafib opthalmic solution
40840813|NCT04405245|DRUG|Placebo|placebo for razuprotafib opthalmic solution
41024920|NCT01444534|DEVICE|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
41024921|NCT06107218|OTHER|Bioactive Glass Air Abrasion Particles.|Finishing of cavity walls by AquaCare Air Abrasion Device using Bioactive Glass Air Abrasion Particles.
41360972|NCT03519815|DEVICE|Liposomal eye spray Tears Again®|eye spray to be applied to the closed eye lid
41360973|NCT05423600|PROCEDURE|BES + TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
41360974|NCT05423600|PROCEDURE|Experimental: BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
41498772|NCT04327739|OTHER|Intervention 3 Exercise and SMT|"* Exercise programme same as Intervention Group 1 and~* Manipulation Care. Participants allocated to this group received Spinal Manipulation Therapy after the therapeutic exercise programme. Treatment was delivered by 1 chiropractor with a minimum 5-year experience of clinical practice. Pain provocation and static/motion palpation findings were used to determine areas of treatment in the cervical spine. The Manipulation Therapy technique included joint motion using a diversified thrust technique, and mobilization, a low-velocity type of joint oscillation. The type and the force of the applied spinal manipulation were individualized according to the age and physical condition of each participant. Soft passive stretching, light massage and hot packs were applied to the cervical and upper thoracic area before manipulation in order to prepare each participant."
41498773|NCT04327739|OTHER|Control|Participants allocated to this group received general consulting istructions and a home based general exercise sheet
41498774|NCT01626443|DIETARY_SUPPLEMENT|Myo-inositol + D-chiro-inositol + Folic acid|Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
41498775|NCT01626443|DIETARY_SUPPLEMENT|Folic acid|Folic acid (200 mcg); 2 x die
41498776|NCT01562561|DRUG|repaglinide|2 mg at each main meal
41024922|NCT06107218|OTHER|Diamond Stone.|Finishing of cavity walls using Diamond Stone.
41498777|NCT01562561|DRUG|insulin NPH|Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
41498778|NCT01340768|DRUG|Sitagliptin|One 100 mg tablet taken orally once daily
41498779|NCT01340768|DRUG|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
41498780|NCT01340768|DRUG|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
41498781|NCT02593253|OTHER|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
41498782|NCT02593253|OTHER|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
41498783|NCT06012461|OTHER|Closed-loop DBS stimulation for 24 hours|Continuous closed-loop modulation for 24 hours
41024923|NCT01427244|DRUG|trastuzumab|monoclonal antibody
41024924|NCT03791398|DRUG|Dose level 1 ONC201 625mg|ONC201 625mg + Nivolumab 240mg IV flat dose
41024925|NCT03791398|DRUG|Dose level 2 ONC201 500mg|ONC201 500mg + Nivolumab 240mg IV flat dose
41024926|NCT03791398|DRUG|Dose level 3 ONC201 375mg|ONC201 375mg + Nivolumab 240mg IV flat dose
41024927|NCT01398605|OTHER|Exercise training|Different dose of exercise training
41498784|NCT06012461|OTHER|Open-loop DBS stimulation for 24 hours|Continuous open-loop modulation for 24 hours
41498785|NCT06012461|OTHER|Closed-loop DBS stimulation for 72 hours|Continuous closed-loop modulation for 72 hours
41498786|NCT06012461|OTHER|Open-loop DBS stimulation for 72 hours|Continuous open-loop modulation for 72 hours
41024928|NCT01206335|DRUG|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
41024929|NCT04954365|DRUG|Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)|Rescue Post-Operative Nausea and Vomiting (PONV) treatment
41498787|NCT06064851|DEVICE|Volta System|The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During Second Menstruation, participants will self-administer 2, 1-hour sessions of active tAN daily with the Volta System Device beginning Day 1 of second menstruation through the final day of second menstruation.
41498788|NCT00364936|PROCEDURE|Palliative care service|
41498789|NCT04484259|DRUG|Ticagrelor monotherapy|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
41498790|NCT04484259|DRUG|Ticagrelor plus aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
41498791|NCT04484259|DRUG|Clopidogrel with aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
41498792|NCT05458882|BEHAVIORAL|"living with food allergy educational booklet"|An educational booklet giving information on social and eating out habits as well as reaction rates in food allergy Irish children.
41498793|NCT05367050|BEHAVIORAL|Lucid Lane Therapy Program|This intervention is designed to aid participants with pre-surgery anxiety management and surgery prep and pain management post-surgery. Participants will be assigned a Lucid Lane pain coach who will utilize mindfulness, cognitive behavioral therapy, group therapy, and mind-body therapies, to accomplish those goals.
41498794|NCT05367050|BEHAVIORAL|Surgical Preparedness Course|This intervention is designed to help the participant prepare for their upcoming surgery. Classes will include discussions around managing chronic pain before surgery, building mental resilience, dealing with the uncertainty of a new diagnosis or treatment plan, questions to ask their anesthesiologist before and on the day of surgery, what to expect during their potential stay at the hospital, and how to optimize their recovery after surgery. Sessions will often include expert doctors who focus on surgery and medical management around it.
41498795|NCT04851535|DRUG|Jaktinib Hydrochloride Tablets|Jaktinib 100mg Bid
41360975|NCT02334813|DRUG|Prednisone|Continuous daily therapy
41498796|NCT03007238|BIOLOGICAL|Aldesleukin|Given SC
41498797|NCT03007238|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
41360976|NCT02334813|DRUG|Dexamethasone|4-day pulses every 3 weeks
41498798|NCT03007238|OTHER|Laboratory Biomarker Analysis|Correlative studies
41498799|NCT03007238|OTHER|Quality-of-Life Assessment|Ancillary studies
40840814|NCT00438594|BEHAVIORAL|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
41024930|NCT04954365|DRUG|Amisulpride|Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
41360977|NCT02298790|BEHAVIORAL|Meal schedule|
41360978|NCT05497570|DRUG|Tenoxicam Injectable Product|After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
41360979|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency|Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
41360980|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency*1.5|Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency\*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
40840815|NCT00003709|DRUG|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
41360981|NCT05152836|DEVICE|Vibrotactile stimulation at continuous stimulation|Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
41360982|NCT05152836|DEVICE|Vibrotactile stimulation 10% below and above step frequency|This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
41360983|NCT02429076|DRUG|IV methylphenidate|IV methylphenidate will be administered to induce emergence from general anesthesia.
41360984|NCT02429076|DRUG|Placebo|normal saline
41360985|NCT02429076|DRUG|Sevoflurane|Inhaled anesthetic
41360986|NCT02429076|DRUG|Propofol|IV anesthetic
41360987|NCT03710395|PROCEDURE|Blood and breast milk sampling|At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
41360988|NCT03710395|DRUG|Nifedipine|Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
41360989|NCT02388750|DRUG|Palonosetron|Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT
41360990|NCT02388750|RADIATION|Low or moderate risk radiotherapy|Low or moderately emetogenic radiotherapy will be given to all patients on study.
41360991|NCT00792324|DRUG|Etravirine|Four 100mg tablets daily for 12-24 weeks
41360992|NCT00792324|DRUG|Efavirenz|One 600mg tablet daily
41360993|NCT04809142|DRUG|TQB2450 Injection|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
41360994|NCT04809142|DRUG|Anlotinib hydrochloride|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
41360995|NCT04809142|DRUG|Oxaliplatin injection|Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;
41360996|NCT04809142|DRUG|Capecitabine tablets|Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
41360997|NCT04809142|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
41360998|NCT01031368|DRUG|cytarabine|Given IV
41360999|NCT01031368|DRUG|clofarabine|Given IV
41361000|NCT01031368|DRUG|filgrastim|Given SC
41361001|NCT01031368|BIOLOGICAL|Ex-vivo expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
41361002|NCT01031368|OTHER|laboratory biomarker analysis|Correlative studies
41361003|NCT00784316|DRUG|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
41361004|NCT02987166|RADIATION|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"
41361005|NCT02987166|DRUG|Pembrolizumab|200 mg
41498800|NCT00005983|RADIATION|radiation therapy|
41498801|NCT00005983|PROCEDURE|surgery|surgery
41498802|NCT03456583|DEVICE|Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
40840816|NCT05866016|BEHAVIORAL|Skill birth attendant training|It is an intervention targeted to enhance the competencies of Maternal Neonatal Health (MNH) service providers (skilled birth attendants) in Nepal. It is a capacity-building intervention that is expected to contribute to reducing maternal and neonatal morbidities and mortalities by improving the midwifery competencies (knowledge, attitudes, and skills) of MNH service providers.
41361006|NCT01854918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
41361007|NCT01854918|DRUG|Standard of Care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
41361008|NCT04998175|PROCEDURE|ventriculo-peritoneal shunt|A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
41498803|NCT02525237|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
41498804|NCT02525237|DRUG|S-1|S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
41361009|NCT00741910|DRUG|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
41361010|NCT03757702|OTHER|Evaluation|Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
41361011|NCT04703712|PROCEDURE|Lens extraction combined with goniosynechialysis|The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.
41361012|NCT04703712|PROCEDURE|Trabeculectomy surgery|The patients enrolled underwent trabeculectomy surgery
41361013|NCT06212960|BIOLOGICAL|DWP712|Clostridium botulinum Toxin
41361014|NCT06212960|BIOLOGICAL|BOTOX®|Clostridium botulinum Toxin
41498805|NCT00005827|DIETARY_SUPPLEMENT|genistein|
41498806|NCT00037024|PROCEDURE|fatigue assessment and management|
41498807|NCT00037024|PROCEDURE|nutritional support|
41498808|NCT00037024|PROCEDURE|physical therapy|
41498809|NCT00037024|PROCEDURE|psychosocial assessment and care|
41498810|NCT00037024|PROCEDURE|quality-of-life assessment|
40840817|NCT05654701|DRUG|Palopegteriparatide (TransCon PTH)|The investigational drug Palopegteriparatide (TransCon PTH) is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
41361015|NCT03481634|DRUG|Brolucizumab|Intravitreal injection
41361016|NCT03481634|DRUG|Aflibercept|Intravitreal injection
41361017|NCT01882036|PROCEDURE|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
41361018|NCT01882036|OTHER|Hypocaloric diet|Hypocaloric liquid diet for 10 days
41361019|NCT03111810|DRUG|AZD4017 and prednisolone|The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
41361020|NCT03111810|DRUG|Placebo Oral Tablet and prednisolone|Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
41361021|NCT05712174|DRUG|[18]F-PSMA-1007|\[18\]F-PSMA-1007 is a diagnostic radiopharmaceutical for use with PET/CT or PET/MRI scanning to diagnose prostate cancer.
41361022|NCT00097916|DRUG|memantine HCl|
41361023|NCT04065412|PROCEDURE|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.
41361024|NCT04065412|PROCEDURE|Modified laryngeal handshake technique|The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.
41361025|NCT03355872|DRUG|HLX01|Biosimilar of Rituximab
41361026|NCT06431139|OTHER|INSPIRE intervention protocol|2-week training program with daily sit-to-stand exercises. Each working day the participant's goals will be adjusted, until exercising a minimum of 100 repetitions using an exercise progression table. When participants complete one level, they will progress to the next level the following day. Participants who do not reach the goals at level one will continue to strive to reach the 100 repetitions. The number of repetitions can be split and performed throughout the day. As the participants' capacity for doing the exercises increases, so will the number of repetitions within each bout of sit-to-stand. Participants are allowed to do the number of repetitions from a higher exercise level if they can and will continue by progressing from that level on the next day. The repetitions will be done from a height that makes it possible to accomplish the sit-to-stand movement. Therefore, the height of the sitting surface will be adjusted according to the participant's abilities.
41361027|NCT00622310|BEHAVIORAL|Walking exercise|Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (\~6.8 kg) during the 6 month intervention.
41361028|NCT04369443|PROCEDURE|Large volume Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
41361029|NCT03602911|DRUG|The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT|All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging
41361030|NCT03534466|DEVICE|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
41361031|NCT03534466|BEHAVIORAL|Conventional physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
41361032|NCT03463980|BEHAVIORAL|Compassion meditation (CM)|CM session: 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants are also encouraged to meditate at least 30 minutes a day.
41498811|NCT05864963|PROCEDURE|Medial tab-type fasciocutaneous flap|"The flap can be taken in different ways depending on the defect. Once the base of the flap is identified, the posterior edge of the tibia is taken as reference; marking of the tab is performed considering that the posterior incision is located 5 cm from the posterior edge of the tibia, and the anterior incision is located longitudinally of the medial region of the tibial diaphysis, the length of the incision depends on the base of the flap and the defect's size.~The posterior incision is made first in the skin, subcutaneous cellular tissue until the fascia is identified; the subfascial flap is dissected to avoid injuring perforators, dissection is completed up to the anterior edge of the flap, if needed direct cutaneous perforators are ligated; once the subfascial plane has been identified and dissected, the tab is completed in its proximal or distal part according to the previous surgical planning. Later, the tab is rotated to the anterior region of the tibia to cover the defect."
41498812|NCT04626648|BEHAVIORAL|Pause with a sugar containing drink|Three-minute long intraoperative pause, including a sugar-containing drink
41361033|NCT03463980|BEHAVIORAL|Support group (SG)|SG session: 90 minutes to talk about current concerns and to receive support and guidance from other group members and the leaders.
41361034|NCT02138864|RADIATION|18F-FP-(+)-DTBZ|no available
41361035|NCT00052494|DRUG|cisplatin|
41361036|NCT00052494|DRUG|imatinib mesylate|
41361037|NCT00052494|DRUG|irinotecan hydrochloride|
41361038|NCT00284726|DEVICE|Celsior Cold Storage Solution|
40840818|NCT00763945|OTHER|data collection|The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
40840819|NCT04077931|OTHER|exercises|Walking on treadmill with fixed 0% grade inclination
40840820|NCT05501795|DEVICE|WaveLight® FS200 femtosecond laser|Flap creation with the WaveLight® FS200 femtosecond laser
40840821|NCT00852241|DRUG|Restalyne|one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
41361039|NCT06343259|PROCEDURE|General Anesthesia|After preoxygenation, intravenous fentanyl (1 μg/kg), propofol (2 mg/kg), and rocuronium (0.6 mg/kg) will be used for anesthesia induction. Intubation will be performed with a 7.0-8.0 sized tube, followed by the initiation of mechanical ventilation (tidal volume: 6-8 ml/kg, respiratory rate: 12 breaths/min). Sevoflurane will be used to maintain anesthesia (0.7-1 MAC), and remifentanil infusion will be administered for analgesia. Postoperatively, tramadol (1 mg/kg) and paracetamol (10 mg/kg) will be administered intravenously. Neuromuscular blockade will be reversed using sugammadex. Patients with an Aldrete Recovery Score ≥9 will be transferred to the post-anesthesia care unit after extubation.
41498813|NCT02098239|DRUG|G17DT|
40840822|NCT00852241|DRUG|Perlane|One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
40840823|NCT03696901|DRUG|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
40840824|NCT00209898|PROCEDURE|Fast initiation procedure|
40840825|NCT06437912|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
40840826|NCT02880813|OTHER|Infusion|infusion of nutrients
40840827|NCT01339117|OTHER|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
41498814|NCT00400595|DRUG|Mupirocin ointment|topical ointment (already in widespread clinical use)
41498815|NCT00400595|DRUG|Polysporin Triple|
41498816|NCT06359106|DRUG|80% Oxygen|After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 80%, and the total gas flow rate will be set at 2L/minute.
40840828|NCT01339117|OTHER|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
40840829|NCT03507075|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
40840830|NCT03507075|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
40840831|NCT03852979|DRUG|Paclitaxel|weekly paclitaxel 80 mg/m2 for 12 weeks
40840832|NCT03852979|DRUG|Carboplatin|weekly carboplatin AUC=2 for 12 weeks
40840833|NCT03852979|PROCEDURE|conisation|if tumor is reduced to \<2 cm, patients will be treated with a conisation
40840834|NCT05748314|OTHER|Questionnaire|KINDL-R; Morisky Medication Adherence Scale;
40840835|NCT01548742|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
40840836|NCT01548742|BEHAVIORAL|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
40840837|NCT05852821|OTHER|5STS remote assessment via videoconference|Patients will be asked to perform several times the 5STS test, from their home through videoconference, on 3 occasions (day 1, 24h later and 1month later).
40840838|NCT01427634|BEHAVIORAL|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
40840839|NCT01427634|OTHER|Usual Care|Receive usual care as provided by the VAD clinical team.
40840840|NCT00683969|DRUG|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
40840841|NCT00683969|DRUG|placebo|po bid for 36 weeks
40840842|NCT00383396|DRUG|Topical Cyclosporine|
40840843|NCT02483949|BEHAVIORAL|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|
40840844|NCT02427724|DRUG|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
40840845|NCT02427724|DRUG|lidocaine 7%/tetracaine 7% topical anesthetic|
41361040|NCT06343259|PROCEDURE|Spinal Anesthesia|Patients will be positioned laterally with the hip to be operated on the lower side, and skin asepsis will be ensured, followed by sterile draping. A dural puncture will be performed at the L3-4 spinal level using a 22-25 gauge Quincke-tip spinal needle. After the detection of cerebrospinal fluid, 7.5 mg of 0.5% hyperbaric bupivacaine will be slowly injected. Following a 10-minute interval, the sensory block level will be assessed using the pinprick test and modified Bromage scale, aiming for a T10 sensory block. Surgery will commence upon achieving adequate sensory block. Postoperatively, patients will be transferred to the recovery room. Patients failing to attain sufficient sensory block and experiencing pain will undergo transition to general anesthesia, terminating their cases.
41361041|NCT01636674|OTHER|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
41361042|NCT00430703|BEHAVIORAL|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
41361043|NCT01657994|OTHER|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
41361044|NCT01226758|BIOLOGICAL|Influenza vaccine (FLU-v)|FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.
41361045|NCT01226758|BIOLOGICAL|Placebo (adjuvant only)|Single subcutaneous injection of adjuvant
41361046|NCT02990325|DRUG|ABX464 150mg|ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)
41361047|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)
41361048|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)
41361049|NCT04806191|OTHER|Evidence based treatment strategy|Evidence-based clinical examination and treatment plan
41361050|NCT04806191|OTHER|Targeted patient information package|GPs will in cooperation with the patients tailor a information package targeted to the patients needs regarding their clinical shoulder diagnosis and individual implications and needs (Pain, sleep, exercises etc.).
41361051|NCT04806191|OTHER|Treatment as usual (TAU)|Usual care as provided by the GP
41361052|NCT03213106|DEVICE|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
41361053|NCT03213106|DEVICE|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
41361054|NCT04048434|DEVICE|Cytosorb|extracorporeal cytokine adsorption
41361055|NCT00865176|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
41361056|NCT00865176|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
41361057|NCT02857049|OTHER|Oral nutritional supplements (ONS) degustation|
41361058|NCT02827747|OTHER|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
41361059|NCT02827747|OTHER|Placebo|Placebo pill
41361060|NCT02827747|DIETARY_SUPPLEMENT|Centrum|Centrum
41361061|NCT02827747|COMBINATION_PRODUCT|Dietary Sources|From dietary sources of vitamins.
41361062|NCT02230501|DIETARY_SUPPLEMENT|stringent diet regimen|
41361063|NCT02230501|DIETARY_SUPPLEMENT|moderate diet regimen|
41361064|NCT03226743|OTHER|collaborative and stepped care model|"Including elements:~* collaborative and stepped care of patients with mental disorders~* treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities~* initial training of participating health care providers~* formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders~* formalized ICD-diagnostics~* guideline-oriented treatment recommendations~* bibliotherapy or internet-based self-help for patient with mild to moderate disorders~* online referral platform~* case management for patients with severe disorders~* systematic and regular monitoring~* regular quality circles for participating health care providers"
41361065|NCT00014560|BIOLOGICAL|bispecific antibody 4G7xH22|
41361066|NCT00014560|BIOLOGICAL|sargramostim|
41361067|NCT06420921|BEHAVIORAL|Speech in noise comprehension test|Speech in noise comprehension tests consisting of listening to a speech source and one or more competing sources (noise, speech or sound cues) simultaneously. The volunteers will have to repeat the speech source in order to assess intelligibility for each situation, as a function of the intensity ratio of the two sources (SNR).
41361068|NCT06420921|BEHAVIORAL|Objective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. The volunteers will have to identify sound cues in order to assess the ability to perceive the sound environment for each situation, depending on the intensity ratio of the different sources.
40840846|NCT02427724|DRUG|placebo vehicle|
41024931|NCT04083989|OTHER|Integrative medicine-based multimodal treatment|Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
41024932|NCT03540342|PROCEDURE|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
41361069|NCT06420921|BEHAVIORAL|Subjective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. Using a simple interface, the volunteers will have to identify the intensity ratio of the sources that they consider to be the best compromise between understanding speech and perceiving the sound environment.
41361070|NCT02792569|PROCEDURE|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
41361071|NCT00402662|DRUG|everolimus|
41498817|NCT06359106|DRUG|40% Oxygen|After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 40%, and the total gas flow rate will be set at 2L/minute.
41498818|NCT06286696|DIAGNOSTIC_TEST|Optic Nerve Sheath Diameter|Point of care ultrasonography of the optic nerve sheath diameter
41498819|NCT01521182|OTHER|1-Fermented Dairy Product (test)|1 = Intervention 1 (test product)
40840847|NCT02427724|DEVICE|Q-switched 532nm Laser|
41361072|NCT00402662|DRUG|Imatinib|
41498820|NCT01521182|OTHER|2-Milk-based non-fermented dairy product (control)|2 = Intervention 2 (control product)
41024933|NCT04895397|DEVICE|ultrasound guided Nerve Block procedure|"In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally.~the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected.~the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected.~Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane."
41498821|NCT05641090|OTHER|Nordic walking in water|Nordic walking in water will be based on nordic walking in water at temperature 34◦C. Nordic walking in water will be conducted at moderate intensity (40-60% heart rate reserve). The program was exercised 60 minutes include warm-up and cool down. At first 6 weeks, The exercise intensity was 40-50% heart rate reserve and it will be increased 50-60% heart rate reserve. The training program will be performed 3 times per week for 12 weeks.
41024934|NCT03334500|DEVICE|[18F]FluorThanatrace|Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.
41361073|NCT02122965|OTHER|Pharmacist-led medication review|Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
41498822|NCT05641090|OTHER|No exercise intervention|This group wasn't receive intervention program. The participants in this group will do following a physician who treat them. They can exercise according to the physician recommend.
41498823|NCT06552065|OTHER|collagen with silk fibroin membrane|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.~An immediate implant with collagen membrane ( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures"
41361074|NCT05521542|DEVICE|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter is a Drug-Coated Balloon to treat de novo lesions in patients with symptomatic stable angina, unstable angina, or NSTEMI
41361075|NCT00824759|OTHER|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
41361076|NCT02628262|PROCEDURE|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
41498824|NCT06552065|OTHER|cross linked collagen membrane|A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.
41498825|NCT00637767|DRUG|melphalan|
41498826|NCT00637767|PROCEDURE|autologous hematopoietic stem cell transplantation|
41498827|NCT00637767|RADIATION|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
41498828|NCT03850925|PROCEDURE|Laser therapy|4 consecutive sessions of laser therapy
41498829|NCT02743338|BEHAVIORAL|Sleep Restriction|Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
41498830|NCT02743338|BEHAVIORAL|Sleep Compression|Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
41498831|NCT02743338|BEHAVIORAL|Additional CBT-i components|After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
41361077|NCT05407168|OTHER|Best Practice|Receive standard of care
41361078|NCT05407168|OTHER|Health Promotion and Education|View decision aid
41361079|NCT05407168|OTHER|Questionnaire Administration|Ancillary studies
41361080|NCT00669240|DRUG|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
41361081|NCT00701181|PROCEDURE|Laser Treatment|Necessity of laser treatment is assessed every three months.
41361082|NCT00701181|DRUG|PF-04523655 high|3 mg intravitreal injection
41361083|NCT00701181|DRUG|PF-04523655 middle|1 mg intravitreal injection
41361084|NCT00701181|DRUG|PF-04523655 low|0.4 mg intravitreal injection
41361085|NCT05707403|DRUG|BI 1015550|Treatment T
40840848|NCT04054466|BEHAVIORAL|Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART|"It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly."
41024935|NCT03334500|DRUG|Poly(ADP Ribose) Polymerase 1|Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
41361086|NCT05707403|DRUG|BI 1015550 mixed with [C-14]-BI 1015550|Treatment R
41361087|NCT05439200|DEVICE|Asynchronous 3D movies|3D movies streamed at home for viewing on a handheld lenticular 3D screen
41498832|NCT02105558|DRUG|Epidural anesthesia|"￼An epidural involves injecting pain-blocking medication into a space between the vertebrae and the spinal fluid; it usually takes about 15 minutes to work.~Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered."
41498833|NCT02105558|DRUG|Combined spinal and epidural anesthesia|"A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr."
41498834|NCT01129843|DRUG|Directly observed home based daily iron therapy|Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
41498835|NCT05958888|BEHAVIORAL|Text only sodium label|"Warning: High in sodium. is shown in a black square label on the can of soup."
41498836|NCT05958888|BEHAVIORAL|Icon sodium label|"Warning: High in sodium. is shown beneath a yellow triangle icon with an exclamation mark all in a black square label on the can of soup."
41498837|NCT05958888|BEHAVIORAL|Pictorial sodium label|"Warning: High in sodium. is shown beneath an image of a spilled salt shaker, all in a black square label on the can of soup."
41498838|NCT05958888|BEHAVIORAL|Barcode label|Barcode is shown in white square label on the can of soup
41498839|NCT03201432|DEVICE|Drug eluting stent (DES)|Polymer-free paclitaxel eluting stents
41498840|NCT03201432|DEVICE|Bare metal stent (BES)|Bare metal stent
41498841|NCT05042544|DIAGNOSTIC_TEST|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
41498842|NCT04809051|OTHER|Stratified Transplant Survival Metric|"Both transplant metric conditions display the number of hearts offered to each center, the number of hearts accepted by each center, and the number of transplants performed at each center (in a year), in addition to the condition-specific metrics below. The stratified condition instead features a pair of values corresponding to each center's offers/acceptances/transplant survival rates for donor hearts of optimal or adequate quality."
41498843|NCT04809051|OTHER|SRTR Information Format|The information format varies based on how the transplant hospital statistics are organized when presented to participants on the choice screen. The SRTR conditions mimic the information format present on the SRTR public reporting website.
41498844|NCT00150761|DRUG|Levocetirizine (drug)|
41024936|NCT04491500|BEHAVIORAL|High attitude environment|The participants will go to 4000m altitude to work for two weeks.
41024937|NCT03103867|DEVICE|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
41024938|NCT03103867|DEVICE|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
41361088|NCT05439200|DEVICE|Patching|Adhesive patch to cover the fellow eye
41498845|NCT05316311|DEVICE|CERENOVUS ENTERPRISE 2 Intracranial Stent|CERENOVUS ENTERPRISE 2 Intracranial Stent will be used to treat severe symptomatic intracranial artery stenosis.
40840849|NCT04054466|BEHAVIORAL|Habitual Counseling|Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
41024939|NCT06311500|BEHAVIORAL|Sleep health enhancement intervention|4 weekly visits of education and strategies to enhance sleep health
41024940|NCT02500225|DRUG|Etomidate|0.2 mg/kg etomidate
41024941|NCT02500225|DRUG|Sevoflurane|8% Sevoflurane
41361089|NCT06098001|DIETARY_SUPPLEMENT|Low dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose esacalation design
41361090|NCT06098001|DIETARY_SUPPLEMENT|High dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose escalation design
41361091|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
41361092|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
41361093|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
41498846|NCT06116786|DRUG|JNJ-86974680|JNJ-86974680 will be administered.
41498847|NCT06116786|DRUG|Cetrelimab|Cetrelimab will be administered.
41024942|NCT05861544|DIETARY_SUPPLEMENT|Pomegranate juice|The pomegranate juice that will be used in the experiment is a 100% natural product without conservatives. It will kindly be donated from the company Rodi Hellas SA, Pella, Greece. The product is in line with the quality assurance certificates by the International Organization for Standardization (ISO 22000:2005), Global Gap, Grasp and Kosher.
41361094|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
41361095|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
41498848|NCT06116786|RADIATION|Radiation Therapy|Radiation therapy will be administered.
41498849|NCT06634394|DRUG|APVO436|Infusion drug administered as a 4 hour infusion.
40840850|NCT02458183|BIOLOGICAL|DTaP-IPV combination vaccine|0.5-mL IM
40840851|NCT02458183|BIOLOGICAL|DTaP vaccine and IPV vaccine|0.5-mL IM
40840852|NCT06499883|BEHAVIORAL|Pocket Ark|Pocket Ark (PA) is a mobile e-learning and assessment platform for use by flood remediation workers in the field. The purpose of this mobile application is to provide workers with real-time data to assist with making safe decisions during the planning phase in the flooded zone and provide a communications platform to improve logistics between operational bases and workers during and after the deployment to the flooded zone. Pocket Ark incorporates an action planner, scenario-based PPE training content, assessments (both knowledge and health-risk), personal security protection, and resource location features for workers involved in disaster rescue and recovery. Individual construction worker's readiness to be safely deployed to flooded and post-flood environments will be assessed.
41361096|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
41361097|NCT01619176|PROCEDURE|Acupuncture|"30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20."
41361098|NCT05836688|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
41498850|NCT06634394|DRUG|Venetoclax|Oral tablet given on days 1 through 22, of a 28 day cycle.
41498851|NCT06634394|DRUG|Azacitidine|Intravenous infusion given on days 1-8 of a 28 day cycle
41498852|NCT02776137|DRUG|Docetaxel|Docetaxel: 20mg/m2/w for 6 weeks
41498853|NCT02776137|RADIATION|Intensity-modulated radiotherapy|a total dose of 60Gy in 30 fractions over 6 weeks
41498854|NCT06237439|BEHAVIORAL|Move with HaRT|Move with HaRT is a group-based, manualized mind-body intervention.
40840853|NCT03688243|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
40840854|NCT01471210|DRUG|Urelumab (BMS-663513)|
40840855|NCT04608422|OTHER|Electrical stimulation|A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
40840856|NCT04969315|DRUG|TT-10|TT-10 orally administered BID starting at 10 mg and will be increased to 200 mg (additional dose levels maybe explored, if appropriate based on emerging safety, PK or PD data).
40840857|NCT00661947|OTHER|Dr Pepper sweetened with sucrose or high fructose corn syrup|Comparison of different formulations of fructose.
40840858|NCT00550901|DRUG|cisplatin|
40840859|NCT00550901|DRUG|dexrazoxane hydrochloride|
40840860|NCT00550901|OTHER|high performance liquid chromatography|
40840861|NCT00550901|OTHER|laboratory biomarker analysis|
40840862|NCT00550901|OTHER|mass spectrometry|
40840863|NCT00550901|OTHER|pharmacological study|
40840864|NCT06020443|PROCEDURE|Low Dose chest CT Scan for Lung Cancer Screening|Low dose CT scans will be performed for three years
40840865|NCT01554514|BIOLOGICAL|rituximab|rituximab intravenously 100 mg every week for four doses
41498855|NCT03017703|DRUG|Eplerenone|
41498856|NCT02141035|DRUG|Acetyl-l-carnitine|Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
41498857|NCT02141035|DRUG|placebo|The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
41498858|NCT03055650|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
41498859|NCT02466685|DRUG|JNJ-18038683|JNJ-18038683 10-20 mg/day tablet for 8 weeks
41498860|NCT02466685|DRUG|Placebo|placebo tablet daily
41160764|NCT03187041|OTHER|Sensation and Skin Surface Pressures Under Blood-Draw Tourniquets|"Phase 1: Skin surface pressures will be recorded by an investigator during each of the 10 applications of the tourniquet. All 10 tourniquet skin pressure measurements will take place in the Blood Draw clinic at the UCSD Medical Center in Hillcrest on the same day for a subject.~Phase 2: The same 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 70 minutes. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use. External skin pressures will not exceed 60mmHg. During this prolonged tourniquet application the investigators will monitor changes in hand sensation at 10-minute intervals using Semmes-Weinstein monofilaments on three peripheral nerves of the hand (median, radian, and ulnar)."
41160765|NCT02619279|OTHER|Livelihood intervention|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
41160766|NCT00536081|DRUG|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
40840866|NCT00459472|BEHAVIORAL|laparoscopic training curriculum|All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
40840867|NCT01609413|DIETARY_SUPPLEMENT|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
40840868|NCT01609413|DIETARY_SUPPLEMENT|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
40840869|NCT04345718|DRUG|Extended Release Buprenorphine|XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).
40840870|NCT04345718|DRUG|Treatment as Usual|Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
40840871|NCT02163785|PROCEDURE|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
40840872|NCT00109577|DRUG|MCN36 (nutritional supplement)|nutritional supplement
40840873|NCT00109577|DRUG|Placebo|nutritional supplement
40840874|NCT01754792|DIETARY_SUPPLEMENT|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
40840875|NCT05325294|DEVICE|MiniMed 780G System|MiniMed™ 780G Insulin Pump, Guardian™ 4 Glucose Sensor, and Guardian 4 Transmitter; used with Insulin Lyumjev® insulin lispro-aabc
40840876|NCT01472744|BEHAVIORAL|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
40840877|NCT01472744|BEHAVIORAL|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
40840878|NCT01472744|BEHAVIORAL|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
40840879|NCT01472744|BEHAVIORAL|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
40840880|NCT05004948|OTHER|Exercise training|The first group conducted a resistance exercise program (REP, 50-60% of 1RM, for 40-50 min) combined with metformin, the second group conducted an aerobic exercise program (AEP, 50-70% maxHR, for 40-50 min) combined with metformin, and the third group received only metformin without exercise intervention (Met group). The study program was conducted thrice weekly for consecutive twelve weeks.
40840881|NCT03423524|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per eye will be implanted"
41024943|NCT05134805|PROCEDURE|Bipolar hemiarthroplasty , proximal femoral nail|"* Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~* Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail)."
41160767|NCT00639236|OTHER|hypertonic saline|inhaled hypertonic saline (at a dose of 5 ml of a 3% solution) three times a week, combined with a program of physical exercises.
41160768|NCT05678010|DRUG|AZD1390|Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80
41024944|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on Planned Behavior Theory|On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.
41024945|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on standart|Standard training for gestational diabetes will be given once at 28 weeks of gestation.
41024946|NCT06137300|DRUG|Urinary kallidinogenase for injection|Urinary kallidinogenase 0.15PNA once daily for 7 days.
41024947|NCT06137300|OTHER|Guideline-prescribed medical therapy|Guideline-prescribed medical therapy
41024948|NCT02545712|OTHER|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
41024949|NCT02545712|OTHER|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
41361099|NCT05836688|BEHAVIORAL|Individual Supportive Listening|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
41361100|NCT04880499|DIETARY_SUPPLEMENT|Iron plus folic acid, vitamin B2, B6, B12, C, and E|A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.
41498861|NCT05292794|DEVICE|CereGate Software; BSN cDBS Programmer; BSN Burst Programmer|"CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD:~(i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced cueing stimulation-to mitigate FOG.~The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System."
41498862|NCT00555360|BEHAVIORAL|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
41498863|NCT00555360|BEHAVIORAL|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
41361101|NCT05015959|OTHER|observation|quality
41361102|NCT03776331|DIAGNOSTIC_TEST|Flow mediated dilation|Measurement of the change in the vasodilatative reserve of the brachial artery
41361103|NCT05741528|DRUG|SEP-363856|SEP-363856 tablet
41361104|NCT00004911|PROCEDURE|bowel obstruction management|
41361105|NCT00004911|PROCEDURE|quality-of-life assessment|
41361106|NCT04552340|OTHER|Patient with SAR-CoV-2 infection|Study population The study cohort will be enrolled among patients referred to our the Humanitas Research Hospital, the Hospital Cliniche Gavazzeni (Bergamo) hospitals for SARS-CoV-2 screening who will/will not be hospitalized in wards dedicated to COVID-19 patients or admitted to intensive care unit.
41498864|NCT03031886|OTHER|low glycaemic index intervention|Low GI sweetener would be added to the treatment meals. 30 grams of isomaltulose to dinner and breakfast and 20 grams of isomaltulose to lunch and snack.
41498865|NCT03031886|OTHER|high glycaemic index intervention|High GI sweetener would be added to the treatment meals. 30 grams of sucrose to dinner and breakfast and 20 grams of sucrose to lunch and snack.
41498866|NCT05923463|BEHAVIORAL|precision-enhanced feedback email messages|Providers receive customized messages prioritizing metrics in an optimal formatting.
41498867|NCT05923463|BEHAVIORAL|standard feedback email messages|Providers receive metrics in a common format.
41498868|NCT03924518|DRUG|Granisetron Hydrochloride|Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
41498869|NCT03924518|DRUG|Placebo（Normal saline）|therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
41498870|NCT01265433|BIOLOGICAL|Galinpepimut-S + Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self administered) subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
41498871|NCT01265433|BIOLOGICAL|Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self-administered)subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
41498872|NCT03411096|PROCEDURE|Quadratus lumborum block using ropivacaine|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with 0.75% ropivacaine (20cc) under ultrasound guidance.
41498873|NCT03411096|PROCEDURE|Quadratus lumborum block with normal saline|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with normal saline (20cc) under ultrasound guidance.
41498874|NCT06077838|BEHAVIORAL|RELAXaHEAD Smartphone App Version 1|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts.
41024950|NCT02545712|OTHER|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
41361107|NCT04511533|DRUG|Dacomitinib|Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
41498875|NCT06077838|BEHAVIORAL|RELAXaHEAD Smartphone App Version 2|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts. This version also contains audio materials.
41498876|NCT00898638|OTHER|biologic sample preservation procedure|
41498877|NCT00898638|OTHER|medical chart review|
41498878|NCT04917471|DIETARY_SUPPLEMENT|Beet root juice|70 ml bid
41024951|NCT02545712|OTHER|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
41024952|NCT02545712|OTHER|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
41024953|NCT02545712|OTHER|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
41024954|NCT02545712|OTHER|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
41024955|NCT02545712|OTHER|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
41024956|NCT02545712|OTHER|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
41024957|NCT02545712|OTHER|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
41024958|NCT03102099|PROCEDURE|contrast-enhanced ultrasound group|The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.
41024959|NCT03102099|PROCEDURE|conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
41361108|NCT02505789|OTHER|Determining the source of EBV in severe EBV infections|Blood units administered to patients with severe EBV infection will be traced back to the donors who in turn (with consent) will be serologically assessed for EBV, and all seropositive donors will have their EBV strain genotyped for comparison to the patient's strain.
41024960|NCT06534333|OTHER|Ultrasonography|musculoskeletal ultrasonography
41024961|NCT05310825|OTHER|Dry Wiping Bath with Single-Use Wipes|Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. These wipes are a product routinely used in patient hygiene procedures in the intensive care unit where the study is to be conducted. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850W for 50 seconds in a microwave oven which will be brought by the researcher The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated.
41361109|NCT03143855|DRUG|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
41498879|NCT04917471|DIETARY_SUPPLEMENT|Placebo juice|70 ml bid
40840882|NCT05454826|OTHER|Exercise|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
41160769|NCT05678010|RADIATION|Stereotactic Body Radiotherapy|Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.
41498880|NCT06551779|PROCEDURE|inyección perineural con solución de dextrosa tamponada|Application of perineural injection with buffered dextrose solution, adding 2.5 ml of 7.5% sodium bicarbonate to a 250 ml bottle of glucose solution at 5% concentration, applying 1cc of the solution at different points on the path of the facial nerve.
41160770|NCT05982028|PROCEDURE|Minimally invasive pit-picking surgery|Midline pits and secondary fistula openings were probed to determine the direction and length of any associated sinus tracts, followed by an excision with a 3 or 5 mm punch biopsy needle, depending on the size of the pit. A 2 cm lateral incision was made parallel to the pilonidal cyst. Hair and granulations within the sinus tracts were removed, and the cyst cavity was drained through the incision. Nonabsorbable monofilament sutures were used to close the excisional wounds of the pits and secondary fistula. Once haemostasis was achieved, the wound was covered with a sterile gauze with 10 % povidone-iodine solution.
41361110|NCT03143855|DRUG|Placebo|Placebo will be administered twice daily for for 5 days
41361111|NCT00527722|DEVICE|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
41361112|NCT00527722|OTHER|No lung plug|Standard lung biopsy without placement of the plug.
41498881|NCT05705765|OTHER|Suspension training|Training with suspension devices. 12 sessions of 40-45 min in four weeks.
41498882|NCT05705765|OTHER|Instability training|Training on unstable surfaces. 12 sessions of 40-45 min in four weeks.
41498883|NCT05801718|DIAGNOSTIC_TEST|Growth parameters & body mass index|measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.
41498884|NCT02740699|DRUG|Rosuvastatin|Participants will receive 20-40 mg once daily
41498885|NCT02740699|DRUG|Atorvastatin|Participants will receive 40-80 mg once daily.
41498886|NCT02740699|RADIATION|Cardiac Computed Tomography (CT)|Cardiac CT angiography (CCTA) provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Performed at baseline, 12 months 24 months, and 36 months.
41498887|NCT02740699|RADIATION|Cardiac Magnetic Resonance Image (MRI)|Provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Cardiac MRI may be performed at baseline, and 24 months (optional).
41498888|NCT00928161|DRUG|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
41361113|NCT05883566|BEHAVIORAL|experimental|During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
41498889|NCT00877162|BEHAVIORAL|Controlled crying and routines|Behavioural (teaching and support)
41361114|NCT06313658|PROCEDURE|Total brachial plexus exploration and reconstruction|In the adopted strategy, anatomical reconstruction was always performed when feasible and the lower trunk was considered the primary reinnervation target. Anatomical reconstruction of the plexus was attempted in the presence of at least three available roots; the best quality root stump (usually C5) was used for hand reanimation, while the lower ruptured roots were directed towards the upper and middle trunks. If one or more of the remaining root stumps were of doubtful quality, the compromised roots were grafted to the posterior divisions of the upper and middle trunks, while elbow flexion could be restored by transferring the intercostal nerves (T3-5) to the lateral cord. The lateral root of the median nerve was also included in the intercostal nerve transfer to restore hand sensations. In all cases, the spinal accessory nerve was directly sutured to the suprascapular nerve to restore rotator cuff function.
41361115|NCT05601271|DRUG|Allopurinol|Allopurinol 100 to 300 mg a day for 3 months
41361116|NCT06289543|DIETARY_SUPPLEMENT|Preoperative carbohydrate solution|water and solution will be given to patients to drink 2 hours before the operation
41361117|NCT02701933|DRUG|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
41361118|NCT02701933|DRUG|Saline|Saline, intravenous infusion
41361119|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
41361120|NCT02793115|BEHAVIORAL|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
41361121|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
41498890|NCT05612672|OTHER|GeoHAI|A Geographic healthcare-associated infection (HAI) visualization and assessment tool (GeoHAI) which uses spatio-temporal Bayesian models to identify clusters of National Healthcare Safety Network (NHSN)-defined hospital onset Clostridium difficile (CDI) and multidrug resistant organisms (MDRO), and predict potential high risk areas given hospital and patient risk factors.
41498891|NCT03484143|DEVICE|Active Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
41498892|NCT03484143|DEVICE|Sham Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
41498893|NCT01211938|RADIATION|single-fraction radiotherapy with concomitant 5FU and Hydrea|single-fraction radiotherapy with concomitant 5FU and Hydrea
41498894|NCT01211938|RADIATION|hyperfractionated radiotherapy with concomitant Cetuximab|hyperfractionated radiotherapy with concomitant Cetuximab
40840883|NCT05454826|OTHER|Cold Application|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
41498895|NCT00362544|DRUG|Ambisome|
41498896|NCT02474875|OTHER|Educational program|Patients in experimental groups will receive different educational sessions (contents and duration)
41498897|NCT04856423|DIAGNOSTIC_TEST|The us-qFIT and colonoscopy with pathological examination|Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
40840884|NCT01424228|DRUG|placebo|Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
40840885|NCT01424228|DRUG|prucalopride|"Prucalopride 2 mg daily before breakfast~1 mg for subjects \>65 years; in case of insufficient response 2 mg at week 2 or week 4"
41024962|NCT05310825|OTHER|Traditional Body Wiping Bath|"The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water. As soon as the bathing procedure is commenced, a chronometer will be started by another nurse who is independent of the study.~The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated"
41024963|NCT04628429|DRUG|Erenumab|anti-CGRP-receptor monoclonal anti-body
41024964|NCT04628429|DRUG|Galcanezumab|anti-CGRP-ligand monoclonal anti-body
41024965|NCT04628429|DRUG|Fremanezumab|anti-CGRP-ligand monoclonal anti-body
41024966|NCT06112236|OTHER|no intervention|no intervention
41024967|NCT00765167|DRUG|Fluoride|Brush half mouth twice daily for four days
41024968|NCT00765167|DRUG|Triclosan|Brush half mouth daily for four days
41024969|NCT00765167|DRUG|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
41024970|NCT00765167|DRUG|Fluoride|Brush half mouth daily for four days
41024971|NCT01025713|DRUG|GS-9411|Inhaled GS-9411
41024972|NCT01025713|DRUG|Placebo|Inhaled Placebo
41024973|NCT02873923|DRUG|undefined|Chemotherapy drug (meta-analyses of randomized trials)
41024974|NCT05974358|PROCEDURE|Kono-S anastomosis|Kono et al. described a new operative technique that could reduce the rate of post-operative recurrence: a termino-terminal ileocolonic anastomosis, anti-mesenteric, with a supporting column to prevent distortion and anastomotic stenosis (Kono-S anastomosis).
41024975|NCT05974358|PROCEDURE|Conventional anastomosis for ileocolonicresection of Crohn's disease|conventional anastomosis for ileocolonicresection of Crohn's disease
41024976|NCT01265953|DRUG|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
41024977|NCT01265953|DIETARY_SUPPLEMENT|Gelatin capsule containing microcrystalline cellulose.|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
41024978|NCT00529932|OTHER|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
41024979|NCT00529932|OTHER|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
41024980|NCT01798446|DRUG|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
41024981|NCT02722694|DRUG|Subcutaneous(SC) Abatacept|Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.
41024982|NCT02722694|OTHER|Placebo|Subjects received weekly SC placebo injections for 24 weeks
41024983|NCT02722694|DRUG|Methotrexate|All Subjects received backup Methotrexate treatment.
41024984|NCT00596765|BEHAVIORAL|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
41024985|NCT03787667|DIAGNOSTIC_TEST|CT or MRI based Radiomics|Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
41361122|NCT02793115|BEHAVIORAL|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
41024986|NCT00782613|DRUG|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
41024987|NCT00782613|DRUG|Placebo|Placebo in a cream formulation
41024988|NCT05219877|DRUG|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
41024989|NCT05219877|DRUG|Post-urodynamic Levofloxacin|Administering once daily Levofloxacin 500 mg for 3 days after urodynamic study
40840886|NCT00565136|DEVICE|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
41024990|NCT06129058|DEVICE|At-home transcranial direct current stimulation (tDCS)|30 minutes session 5 days/week for 3 weeks.
41024991|NCT06129058|DEVICE|Sham at-home tDCS|30 minutes session 5 days/week for 3 weeks.
41024992|NCT02211989|DRUG|BI 14332 CL|
41024993|NCT02211989|DRUG|Placebo|
41024994|NCT00351780|DEVICE|FFR measurement, side branch angioplasty|
41024995|NCT05872139|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
41024996|NCT05872139|DIETARY_SUPPLEMENT|Mitoquinone Mesylate|MitoQ was given once (single dose, 80 mg)
41498898|NCT03218124|OTHER|Remifentanil Effect site concentration|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
40840887|NCT06053736|DEVICE|REVIVE Contact Lens|REVIVE Contact Lens
40840888|NCT00712582|DRUG|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
41024997|NCT05699863|BEHAVIORAL|Lifestyle intervention|"Lifestyle intervention in the form of individualised dietitian consultation with the overall goal of weight loss.~Intervention includes one initial consultation with a dietician of 1 hour and 15 minutes where participants receive a personalised diet-plan customised to the participants everyday life. After the initial consultation, the participants attend 10 follow-ups of about 25 minutes that are spread out over 4-5 months."
41024998|NCT02057055|OTHER|Soap 300000027003|
41024999|NCT02057055|OTHER|Soap 300000029240|
41498899|NCT00186888|PROCEDURE|Enucleation|"Enucleation (possibly associated with all treatment strata/arms. For Stratum A, patients with bilateral disease will have surgery to remove the advanced eye before chemotherapy, or patients that have disease progression after chemotherapy may have surgery to remove the affected eye.~For Stratum B, Surgical removal of the affected eye may be required in cases of disease progression For Stratum C, first intervention is removal of the affected eye."
41025000|NCT02604589|DRUG|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
41025001|NCT02604589|PROCEDURE|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
41025002|NCT02604589|DRUG|bupivicaine 0.25%|Low Dose analgesia
41361123|NCT02793115|BEHAVIORAL|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
41361124|NCT02961153|OTHER|death|
41361125|NCT05931094|OTHER|Augmented Reality based games|Games of Wonder Tree Augmented Reality
41361126|NCT05931094|OTHER|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
41361127|NCT06219304|OTHER|Multimodal functional training|40 minutes of multimodal functional training: 20 minutes of aerobic training on treadmill, 10 minutes of dynamic balance training; 10 minutes of functional strength training.
41361128|NCT06219304|OTHER|Usual care|Exercises aimed at improving balance and mobility
41361129|NCT03941041|BEHAVIORAL|Prenatal Yoga Course|participation in a 12-week prenatal yoga course (optimally), 1 session in duration of 90 minutes per week
41361130|NCT06042764|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
41361131|NCT01314261|DRUG|ABT-267|5 mg or 25 mg tablets
41361132|NCT01314261|DRUG|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
40840889|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
41025003|NCT02604589|DRUG|bupivicaine 0.5%|High dose analgesia
41025004|NCT04777344|BEHAVIORAL|Tobacco Treatment Specialist (TTS) intervention|A trained Tobacco Treatment specialist (TTS) embedded in the multi-disciplinary CF care team will provide tobacco use counseling to smoking caregivers of children with CF.
41025005|NCT03103282|DEVICE|PuraStat®|Synthetic haemostatic material
41025006|NCT05794217|BEHAVIORAL|This is a non-interventional study|This is a non-interventional study
41025007|NCT01081977|PROCEDURE|Early Cord Clamping|Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)
41361133|NCT01314261|DRUG|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
41361134|NCT01314261|OTHER|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
41361135|NCT01645449|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
41361136|NCT00364351|DRUG|Vandetanib|once daily oral tablet
41361137|NCT00364351|DRUG|Erlotinib|oral dose
41025008|NCT01081977|PROCEDURE|Delayed Cord Clamping|Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
41025009|NCT03211936|PROCEDURE|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
41025010|NCT03211936|DEVICE|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
41025011|NCT03211936|DEVICE|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
41025012|NCT03211936|OTHER|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
41361138|NCT04589221|BEHAVIORAL|Ad libitum energy intake|Investigate ad libitum energy intake according to degree of food processing and eating behaviour
41361139|NCT01122992|PROCEDURE|Limbal relaxing incision|
41361140|NCT01403415|DRUG|Dexamethasone|Given PO or IV
41361141|NCT01403415|OTHER|Laboratory Biomarker Analysis|Correlative studies
41361142|NCT01403415|DRUG|Methotrexate|Given IT
41361143|NCT01403415|DRUG|Mitoxantrone Hydrochloride|Given IV
41361144|NCT01403415|DRUG|Pegaspargase|Given IV
41361145|NCT01403415|OTHER|Pharmacological Study|Correlative studies
41361146|NCT01403415|DRUG|Temsirolimus|Given IV
41361147|NCT01403415|DRUG|Vincristine Sulfate|Given IV
41361148|NCT04703959|OTHER|polysomnography|polysomnography is already done for all patients
41498900|NCT00186888|DRUG|Vincristine, Carboplatin|(Stratum A subjects receive 8 courses every 3-4 weeks, Stratum B subjects receive this combination for Courses 3, 4, 6, 7, 9, and 10 after the window, if they respond to window therapy) Vincristine dosage\< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1.
41498901|NCT00186888|PROCEDURE|Focal Therapies|Method will be at the discretion of the treating team, used after second course of chemotherapy. Cryotherapy- freezing of affected tissue, Laser photocoagulation- using lasers to destroy affected tissue, Thermotherapy and thermochemotherapy- using heat or heat/chemotherapy combination to destroy diseased tissue, and Episcleral plaque brachytherapy- radiation insertions in the diseased area to destroy affected tissue.
41498902|NCT00186888|RADIATION|External Beam Radiation|44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.
41498903|NCT00186888|DRUG|Vincristine and Topotecan|(Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml\*hr, daily for 5 consecutive days, infused over 30 minutes.
41498904|NCT00186888|DRUG|Vincristine + Carboplatin + Etoposide|"Stratum B patients that do not respond to window receive 6 courses of this combination.~Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3"
41025013|NCT03211936|OTHER|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
41025014|NCT00583492|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
41361149|NCT04046029|DRUG|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
41361150|NCT04046029|DRUG|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
41361151|NCT02174406|PROCEDURE|breast ultrasound|
41025015|NCT00583492|RADIATION|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
41025016|NCT04905680|DEVICE|CGM lifestyle tracking and coaching|"Participants in the experimental group will go through a total of 5 lifestyle tracking sessions (including baseline), of which 1 will include CGM tracking. For this CGM lifestyle tracking session, experimental group participants will receive real-time feedback through the study applications, which will display the CGM trace.~The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans."
41025017|NCT02983578|DRUG|Danvatirsen|Given IV
41025018|NCT02983578|BIOLOGICAL|Durvalumab|Given IV
41025019|NCT05570695|BEHAVIORAL|attention right training, ARTNF|In a first verum neurofeedback condition, participants will be instructed to focus attention on their right hand and the up-regulation of alpha oscillations in the right hemisphere relative to alpha oscillations in the left hemisphere will be incentivized through neurofeedback.
41025020|NCT05570695|BEHAVIORAL|attention left training, ALTNF|In a second verum neurofeedback condition, participants will be instructed to focus attention on their left hand and the down-regulation of right relative to left alpha oscillations will be incentivized.
41361152|NCT02174406|PROCEDURE|DBT (Full field digital mammography + tomosynthesis)|
41361153|NCT04627389|PROCEDURE|orbicularis oris muscle Z- plasty modification of modified millard technique|After orbicularis oris muscle had been released from the overlying skin, the previously marked points using methylene blue for designing the z-plasty were shown to be followed by back-cut incisions including the OOM and inner mucosa in both medial and lateral elements without involving the overlying skin. This procedure resulted in two triangular flaps in both segments
41361154|NCT04627389|PROCEDURE|modified millard technique|no z-plasty modification
41361155|NCT03511222|DRUG|Vorolanib|Patients should take vorolanib at approximately the same time every day with food.
41361156|NCT03511222|DRUG|Nivolumab|Standard of care
41025021|NCT05570695|BEHAVIORAL|sham attention right training, ARTsham|During the first sham neurofeedback condition, participants will be instructed to focus attention on their right hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ARTNF for ARTsham, will be replayed (yoked feedback).
41025022|NCT05570695|BEHAVIORAL|sham attention left training, ALTsham|During the second sham neurofeedback condition, participants will be instructed to focus attention on their left hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ALTNF for ALTsham, will be replayed (yoked feedback).
41025023|NCT02700646|BEHAVIORAL|Developmental recommendations|
41025024|NCT02700646|BEHAVIORAL|Standard care|standard care
41025025|NCT05741710|DRUG|Methylone|Methylone capsules, given orally, once a week for 4 weeks
41025026|NCT05741710|DRUG|Placebo|Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B
41025027|NCT00578370|DRUG|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
41025028|NCT00578370|DRUG|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
41025029|NCT00578370|DRUG|0.1% betamethasone|Solution 200µl once a day (26 days)
40840890|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."
41025030|NCT00578370|DRUG|0.005% calcipotriol|Solution 200µl once a day (26 days)
41025031|NCT00578370|DRUG|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
41025032|NCT05166252|BEHAVIORAL|Time out from smartphone use during meal time|"One parent will be instructed to install a study app. Further, he/she press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and the parent needs to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the parent is instructed to take a picture with their smartphone from the smartphone-free family meal table . The time-out is over as soon as the parent presses the stop button."
41025033|NCT05166252|BEHAVIORAL|Control condition|The same as the experimental condition but without a timeout from smartphone use.
41025034|NCT05404529|DRUG|Tavapadon|Oral tablets
41025035|NCT00824681|BEHAVIORAL|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
40840891|NCT03124212|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
41025036|NCT00824681|OTHER|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
41025037|NCT00647855|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
41025038|NCT00647855|DRUG|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
41025039|NCT06159894|OTHER|DAY HOSPITAL ARM|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
41361157|NCT03511222|DRUG|Pembrolizumab|Standard of care
41361158|NCT03420846|OTHER|OCT Mapped|Presurgical mapping of Basal Cell Carcinoma margins
41361159|NCT02366494|DRUG|Bicalutamide|ANDROGEN BLOCKADE
41361160|NCT02366494|DRUG|Leuprolide|ANDROGEN BLOCKADE
41361161|NCT02366494|DRUG|Goserelin|ANDROGEN BLOCKADE
41361162|NCT02366494|DRUG|Triptorelin|ANDROGEN BLOCKADE
41361163|NCT02366494|DRUG|Docetaxel|Chemo hormonal therapy
41361164|NCT02366494|DRUG|Abiraterone|Chemo hormonal therapy
41361165|NCT02366494|DRUG|Apalutamide|Nonsteroidal antiandrogen medication
41361166|NCT02366494|DRUG|Enzalutamide|Nonsteroidal antiandrogen medication
41361167|NCT02911324|DRUG|Nabilone|"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
41361168|NCT02911324|BEHAVIORAL|Exposure and Response Prevention Therapy|Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
41361169|NCT03495999|DIAGNOSTIC_TEST|hyperuricemia|serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
41361170|NCT05512273|PROCEDURE|Piezosurgery assisted osteotomy|Sequential osteotomy drilling was done using mectron piezosurgery implant drilling protocol
41361171|NCT05512273|PROCEDURE|Conventional drilling osteotomy|bone osteotomy for implant placement was done following the BEGO Semados RS/RSX TrayPlus conventional drilling
41361172|NCT00134563|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
41361173|NCT00134563|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
41361174|NCT04000412|DEVICE|CardioZ multifrequency impedance recording system|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
41361175|NCT02062385|BIOLOGICAL|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
41361176|NCT02062385|BIOLOGICAL|Placebo to V260|Placebo control
41361177|NCT02062385|BIOLOGICAL|OPV|Oral poliovirus vaccine administered according to the standard of care
41361178|NCT02062385|BIOLOGICAL|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
41361179|NCT05959876|OTHER|Training group|Face-to-face perineal care training
41361180|NCT05959876|OTHER|Control group|No intervention
41361181|NCT05191927|OTHER|male|Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
41361182|NCT00667381|DEVICE|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
41361183|NCT00143039|PROCEDURE|Tandem MS test for inborn errors of metabolism|Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
41361184|NCT04417816|OTHER|Exercise training intervention with ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
41361185|NCT04417816|OTHER|Exercise training intervention without ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
41361186|NCT01277757|DRUG|Akt Inhibitor MK2206|Given orally (PO) weekly, starting (dose 0) at 200 mg
41361187|NCT01277757|OTHER|Laboratory Biomarker Analysis|Correlative studies
41361188|NCT01277757|OTHER|Pharmacological Study|Correlative studies
41361189|NCT06279169|BEHAVIORAL|Heart Sound|In the Heart sound group, this sound will be played to the newborn 5 minutes before Hep B vaccine administration, during the procedure (at 1 minute) and 5 minutes after Hep B vaccine administration
41361190|NCT06279169|BEHAVIORAL|White Noise|"Musician Osman Orhan's song Bebeğiniz Ağlamasın from his album Kolik will be used for white noise. The volume will be set to 45 db."
41361191|NCT04330586|DRUG|Ciclesonide Metered Dose Inhaler [Alvesco]|Ciclesonide 320ug oral inhalation q12h for 14 days
41361192|NCT02527291|OTHER|Blood test|Blood test for CMV PCR and IL28
41361193|NCT03949894|DRUG|Tolvaptan|30mg and 15mg of Tolvaptan Tablet
41361194|NCT06151743|DRUG|three cycles (toripalimab + cetuximab + platinum)|Cetuximab 250 mg/m2 i.v. qw (first loading dose 400 mg/m2) for nine doses; Toripalimab 240 mg/m2 i.v. d1, q21d, three cycles; Cisplatin 25 mg/m2 i.v. d1-3, q21d, three cycles or Carboplatin AUC 5 i.v. d1, q21d, three cycles (patients with cisplatin contraindications or renal impairment after cisplatin use).
41361195|NCT06151743|PROCEDURE|Radical surgery|The attending physician should select the appropriate surgical treatment and try to perform radical laryngeal preservation surgery for patients with tumor retraction after induction therapy. Patients who cannot preserve laryngeal function due to tumor load need to undergo total laryngeal resection. According to the scope of pharyngectomy, the surgical treatments include partial laryngopharyngectomy, total laryngectomy and partial pharyngectomy, total laryngopharyngectomy, and total pharyngo-laryngo-esophagectomy. Cervical lymph node dissection was performed when necessary.
41361196|NCT06151743|RADIATION|Radiotherapy or chemoradiotherapy|"1. Using intensity-modulated radiotherapy (IMRT) technology, the dose of radiotherapy is determined according to whether there are adverse prognostic factors in the postoperative pathology, including positive margins, extracapsular invasion of lymph nodes, primary pT3 or T4, N2 lymph node lesions, peripheral nerve invasion, vascular/lymphatic infiltration.~   Primary site: residual GTV or tumor bed dose 60-70Gy: 1.8-2.12 Gy / fraction. Cervical lymph nodes or lymphatic drainage area: 56-70 Gy: 1.7-2.12 Gy / fraction.~2. Postoperative adjuvant concurrent chemotherapy regimen:~Cisplatin 25mg/m2 i.v. d1-3, d22-24 or Carboplatin AUC 5 i.v. d1, d22 (if cisplatin contraindications)."
41361197|NCT05937503|OTHER|manual therapy|The manual therapy group will receive a 4-week manual therapy plus conventionel physiotherapy.
41361198|NCT05937503|OTHER|conventional physiotherapy|Control group will only receive conventionel physiotherapy intervention.
41498905|NCT00186888|DRUG|vincristine, cyclophosphamide, and doxorubicin|(High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: \< 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin \< 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
41498906|NCT00186888|DRUG|Vincristine, Carboplatin and Etoposide|High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
41498907|NCT00186888|PROCEDURE|Periocular carboplatin|Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
40840892|NCT06321939|DIAGNOSTIC_TEST|EBV-DNA next generation sequencing|EBV-DNA next generation sequencing
40840893|NCT01205477|DRUG|EXPERIMENTAL|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
40840894|NCT01205477|DRUG|PLACEBO|Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
40840895|NCT05055310|DIAGNOSTIC_TEST|MicRNAs test|plasma micRNAs concentration
40840896|NCT02913768|DRUG|Ondansetron|
40840897|NCT02913768|DRUG|Normal saline|
40840898|NCT01278082|DRUG|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
40840899|NCT01278082|DRUG|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
40840900|NCT02112734|DRUG|Vitamin D|400 IU/daily until age 12 months
40840901|NCT02112734|DRUG|placebo|identical placebo daily
41498908|NCT00186888|OTHER|G-CSF|G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is \> 2,000/mL in one occasion after the expected nadir.
40840902|NCT02887755|DEVICE|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
40840903|NCT02108665|RADIATION|Radiographic hysterosalpingography|
40840904|NCT02108665|RADIATION|Magnetic resonance imaging hysterosalpingography|
40840905|NCT02068560|DRUG|dDAVP infusion|
40840906|NCT03753399|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.
40840907|NCT04124003|DRUG|rosuvastatin|Specified dose on specified days
40840908|NCT04124003|DRUG|BMS-963272|Specified dose on specified days
40840909|NCT03083184|DRUG|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
41498909|NCT04495881|DRUG|Sitagliptin 100mg|Sitagliptin 100mg Qd
41498910|NCT04440137|BEHAVIORAL|Bottle-feeding cessation program|Specific brochure and proper oral hygiene education emphasizing on the benefit of stopping bottle-feeding given to subject
40840910|NCT03083184|DRUG|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
41498911|NCT00256438|DEVICE|Transcranial Direct Current Stimulation|
41498912|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
41498913|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
41498914|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
41498915|NCT01739348|DRUG|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
40840911|NCT03913195|DRUG|ibalizumab-uiyk|Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
40840912|NCT03645109|DIETARY_SUPPLEMENT|Vitamin D3|Capsules with 5,000 IU of vitamin D3 once a day (one capsule)
40840913|NCT03645109|OTHER|Capsules with placebo (talcum food grade)|Capsules with placebo (talcum food grade)
40840914|NCT04018742|OTHER|Surgical puncture|Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
40840915|NCT02587546|PROCEDURE|laryngeal carcinoma|treatment of laryngeal carcinoma using thulium contact laser
40840916|NCT02587546|PROCEDURE|bilateral vocal cord paralysis|treatment of bilateral vocal cord paralysis using thulium contact laser
40840917|NCT02587546|PROCEDURE|subglottic stenosis|treatment of subglottic stenosis using thulium contact laser
41498916|NCT01739348|DRUG|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
41361199|NCT03554798|BIOLOGICAL|nOPV2 (monovalent oral polio vaccine)|"Cohort A: 150 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~Cohort B: 972 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2."
41361200|NCT06492421|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
41361201|NCT06085404|PROCEDURE|Blood sample|Patients will be enrolled starting right after Ethics Committee approval. Samples will be taken during surgery that will take place in the operating rooms of oncological gynecology.
41361202|NCT00154986|PROCEDURE|immunohistochemical staining, transfection, invasion assay|
41361203|NCT05217004|OTHER|Dementia Talk mobile application|The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
41361204|NCT05217004|OTHER|CLEAR Dementia Care mobile application|The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
41361205|NCT04135222|DIAGNOSTIC_TEST|Measurements of gingiva thickness|Measurements were performed at upper canines and incisors in thirty periodontally healthy patients. The CBCT/CAD technology along with the PDIP software were used to measure crestal (CGT in mm ), supracrestal (SGT in mm) and free gingival thickness (FGT in mm ) as well as alveolar crest-gingival margin (AC-GM) and cemento-enamel junction (AC-CEJ) distance and the TLPAC localized 2, 4 and 8mm apically than the edge of the AC. Width of keratinized tissue (WKT) were measured using a periodontal probe. For each patient, the periodontal phenotype was evaluated on the basis of coronal width/length (CW/CL in percentages) ratio of both upper central incisors. For each tooth, the gingival phenotype was assessed on the basis of the GT measurement( in mm).
41361206|NCT02887508|BEHAVIORAL|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
41361207|NCT02887508|BEHAVIORAL|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
41361208|NCT01795716|DRUG|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
41361209|NCT01795716|DRUG|Glivec|Single and multiple oral Glivec 400mg qd
41361210|NCT02665273|PROCEDURE|Greater occipital nerve block|Bilateral greater occipital nerve block
41361211|NCT02665273|DRUG|Bupivacaine|0.5 cc of 0.5% bupivacaine injected intradermally
41361212|NCT01822886|DRUG|Romidepsin + Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
41361213|NCT05689645|DRUG|F573 for injection|The first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg,2 mL,intramuscular injection (IM),once a day for 7 daysand. the subsequent 9 patients with CHB were given doses of 2 mL intramuscular injection (IM), once a day for 7 days, according to the results of the efficacy and safety trials of the first 16 patients. The dose of the second stage was determined according to the results of the efficacy and safety trials in the first stage. The dose volume was 2 mL, and was administered intramuscular injection (IM) once a day for 14 days. The dosage of the third stage was determined according to the results of the first and second stage efficacy and safety trials. The dosage volume was 2 mL and intramuscular injection (IM) was administered once a day for 28 consecutive days. The dosage of the above three stages of administration was calculated according to the weight of the most recent visit
41361214|NCT05689645|DRUG|Sterilizing water for injection|"The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days."
41361215|NCT00000291|DRUG|Labetalol|
41498917|NCT06020287|PROCEDURE|the robot-assisted laparoscopic radical prostatectomy|We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.
41498918|NCT00277173|BEHAVIORAL|Adoption of Crew Resource Management approach|
41498919|NCT05255848|DRUG|Unfractionated heparin|Patients will be given the same standard of care treatment plus nebulized heparin 5000IU every 8 hours started 24 hours after randomization, using a compressed air nebulizer, and will be continued for one week. In case of any complication, if the attending physician feels it necessary intervention treatment will be stopped
41498920|NCT05440123|OTHER|screening for bronchopulmonary cancer|The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
41498921|NCT06633224|PROCEDURE|Blood Specimen Collection|Blood samples will be obtained throughout the course of the study
41498922|NCT06633224|OTHER|Stool Specimen Collection|Stool samples will be obtained throughout the course of the study
41361216|NCT04776434|DEVICE|SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)|This study will capture data from the use of the SELUTION SLR according to its approved labelling.
41361217|NCT06099509|OTHER|Self-administered oral glucose tolerance test|Participants will be asked to self-administer the postpartum 75-gram oral glucose tolerance test. They will be provided the glucose solution and instructions. A 4 week virtual visit will be arranged where the test results will be reported to the provider and appropriate follow up arranged based on the results of their screen.
41361218|NCT04187612|DEVICE|Bioelectrical Impedance Analysis (BIA)|BIA will be used to determine total body water
41361219|NCT04853069|DRUG|Transdermal estradiol gel|Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
41361220|NCT02441387|DRUG|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
41361221|NCT02441387|OTHER|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
41361222|NCT02441387|OTHER|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
41361223|NCT04051320|DRUG|Leuprolide Acetate 3.75 MG/ML|3.75 mg/month leuprolide acetate intramuscular injection
41361224|NCT04051320|DRUG|Estradiol 2 Mg tablet|2 mg estradiol tablet
41361225|NCT04051320|DRUG|Micronized progesterone|200 mg micronized progesterone tablets
41361226|NCT03498911|PROCEDURE|Mucogingival surgery|The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
41361227|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
41361228|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
41361229|NCT01074086|DRUG|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
41361230|NCT02712892|GENETIC|Non Interventional Study|
41361231|NCT06198946|DEVICE|External diaphragm pacing（EDP）|After the skin is disinfected, place the small electrode pads on the lower 1/3 of the outer edges of the sternocleidomastoid muscles on the left and right sides, and place the large electrodes on the surface of the pectoralis major muscles on both sides, and fix them with medical tape. Adjust the pacing according to the patient's tolerance. Frequency and stimulation intensity, each treatment time is 20 minutes, treatment is once a day, 5 days a week, and the treatment course is 4 weeks.
41498923|NCT06633224|OTHER|Quality of Life (QOL) Questionnaires|Surveys will be given throughout the course of the study.
41498924|NCT00827632|DRUG|Low dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet."
41498925|NCT00827632|DRUG|High dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet."
41498926|NCT06086392|DRUG|Placebo|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the supraclavicular brachial plexus block
41498927|NCT06086392|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the supraclavicular brachial plexus block
41498928|NCT06086392|DRUG|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0,2% ropivacaine with 0.05mg/kg Dexamethasone for the supraclavicular brachial plexus block
41498929|NCT04696809|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
41498930|NCT04305353|OTHER|Diary (blank journal) plus PTSD psycho-education|A blank journal where a prospective account of a patient's ICU course (everyday events) can be documented by family members and healthcare providers
41498931|NCT04305353|OTHER|PTSD psycho-education alone|"We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015."
41498932|NCT01462812|DRUG|Sumatriptan|Sumatriptan 20mg
41498933|NCT01462812|DRUG|Placebo|Matching placebo
41498934|NCT04342715|DRUG|Sodium stibogluconate / paramomycin|Treatment with Sodium stibogluconate / paramomycin
40840918|NCT00638976|DRUG|eptifibatide|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
41361232|NCT06198946|OTHER|Routine rehabilitation treatment|Participants received comprehensive rehabilitation treatments such as muscle strength training, hemiplegic limb comprehensive training, balance function training, limb neuromuscular electrical stimulation, acupuncture and other comprehensive rehabilitation treatments. Each project was 30 minutes/time, once a day, 5 days a week, and the treatment course was 4 weeks.comprehensive rehabilitation treatments, each item is 30 minutes/time, once a day, 5 days a week, and the treatment course is 4 weeks.
41361233|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Endurance)|"* Faster application (using for Endurance) : 3 days in a week for 6 weeks,very season was 40 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
41361234|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Attention and Motivation)|"* Smile application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Gabarello application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
41361235|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Activity Timing)|"* High Flyer application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 20 min.~* Treasures application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Curve Pursuit application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
41361236|NCT05419791|OTHER|Conventional Physiotherapy|-Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.
41361237|NCT03826641|DRUG|HCP1805|Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
40840919|NCT00638976|DRUG|placebo|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
40840920|NCT02858557|BEHAVIORAL|Mediterranean diet|The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
40840921|NCT02858557|BEHAVIORAL|Specific Carbohydrate Diet|The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
41025040|NCT06159894|OTHER|Specialist-Care arm|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
41025041|NCT02323594|DRUG|Daclatasvir|Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
41025042|NCT02323594|DRUG|Daclatasvir|Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
41025043|NCT02323594|DRUG|Asunaprevir|Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
41025044|NCT02323594|DRUG|Daclatasvir|Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
41025045|NCT05457335|PROCEDURE|undergoing PGT|Preimplantation genetic testing for aneuploidy
41025046|NCT04241939|BEHAVIORAL|Numberless BDS|Participants perform daily weighing using a numberless BDS with feedback from app (color codes, challenges), in conjunction with modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
41361238|NCT03826641|DRUG|HCP1801|Dapagliflozin/Metformin 10/1000mg
41361239|NCT01087151|DRUG|ABT-263|Oral repeating dose
40840922|NCT01404455|OTHER|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
40840923|NCT04477057|DRUG|HS-10241|HS-10241 is a tablet in the form of 100 mg, oral, once daily.
41361240|NCT01087151|DRUG|rituximab|Intravenous repeating dose
41361241|NCT05308420|PROCEDURE|Pericapsular nerve group (PENG) block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and 20ml 0.5% levobupivacaine with 2mg (0.5ml) dexamethasone injected (total volume of injectate 20.5ml) between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
41361242|NCT05308420|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally
40840924|NCT04379999|DRUG|Atorvastatin 20mg|No history of colorectal cancer and no colorectal adenomas within 5 years.
41361243|NCT05308420|DRUG|Intrathecal morphine|100 micrograms of preservative free morphine diluted to a volume of 0.5ml is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
41498935|NCT00124124|DRUG|KLH; Peptides; Dendritic Cells|Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
41498936|NCT00124124|DRUG|KLH, peptides plus Montanide|Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
41498937|NCT02287818|DRUG|Placebo|Placebo twice daily from Day 1 to Week 12
41498938|NCT02287818|DRUG|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
41498939|NCT02287818|DRUG|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL
41498940|NCT04691154|COMBINATION_PRODUCT|L606 inhalation suspension|L606 inhalation suspension, twice daily dosing
41498941|NCT06632548|DEVICE|telescopic overdenture|two implant retained mandibular overdenture with telescopic attachment
41498942|NCT02553447|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
41498943|NCT02553447|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41498944|NCT04180631|DIAGNOSTIC_TEST|Quantitative ultrasound imaging parameter (QUS)|Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis
41498945|NCT04226950|DRUG|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers;
41498946|NCT04226950|DRUG|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area \< 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
41498947|NCT05357482|RADIATION|TBI|300 cGy total body irradiation (TBI, day -2)
41498948|NCT05357482|DRUG|Hydroxyurea|Optimized 4-12 weeks prior to planned transplant date
41498949|NCT05357482|BIOLOGICAL|briquilimab|briquilimab, anti-CD117 monoclonal antibody at 0.6mg/kg at day -11 prior to infusion of allogeneic HSCs
41498950|NCT05357482|DRUG|Filgrastim (G-CSF)|May be used to minimize the days of neutropenia, and may be administered beginning near day 10 post stem cell infusion at 5 mcg/kg (rounding to the nearest vial) at the discretion of investigator.
41498951|NCT05357482|DRUG|Sirolimus|For immune suppression (day -1)
41498952|NCT05357482|BIOLOGICAL|Alemtuzumab|Alemtuzumab 1 mg/kg of alemtuzumab divided over 5 days (-7 through -3),
41498953|NCT05357482|DRUG|Plerixafor|For autologous HSC collection; dose of plerixafor at 240 mcg/kg (capped at 20mg)
41498954|NCT02658799|DRUG|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
41498955|NCT02658799|DRUG|placebo|"Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly."
41498956|NCT04097873|OTHER|Diaphragm ultrasonography reeducation plus inspiratory training|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
41498957|NCT04097873|OTHER|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
41498958|NCT04067453|OTHER|Fatiguing contractions|10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
41498959|NCT00773630|DRUG|Cilostazol|100 mg Cilostazol
41498960|NCT00196924|BIOLOGICAL|HPV-16/18 L1/AS04|
41361244|NCT05308420|PROCEDURE|Sham PENG block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and a placebo solution consisting of 20.5ml 0.9%NaCl injected between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
41361245|NCT05308420|DRUG|Intrathecal placebo|0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
41361246|NCT06482905|BIOLOGICAL|Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103|3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells
41361247|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (12.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
41361248|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (18.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
41160771|NCT05982028|PROCEDURE|Radical surgical excision without suturing|Under the guidance of brilliant green, the cavity of the pilonidal cyst, along with the sinus tracts and fistulas, was marked. A symmetric elliptical incision was made to excise the pits and secondary fistula openings. The pilonidal cyst was removed from the healthy subcutaneous tissue and sacrococcygeal fascia using monopolar electrocautery. The wound was not sutured and was left open to heal by secondary intention. After haemostasis was achieved, the wound was covered with sterile gauze with 10 % povidone-iodine solution.
41160772|NCT00475735|DRUG|MK0249|MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
41361249|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
41361250|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (24.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
41361251|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
41361252|NCT01234142|DRUG|varenicline free base patch|2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
41361253|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
41361254|NCT03939858|PROCEDURE|Cognitive Assessment|Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
41498961|NCT06584422|BEHAVIORAL|Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression|Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
41361255|NCT03939858|DIAGNOSTIC_TEST|Blood Collection|16 ml of blood will be collected before 10 a.m. and after the participant has fasted for 8 hours. White blood cells and platelets will be used for respirometric analysis. Plasma will be additionally processed and saved in 500uL aliquots(x2) and the remainder in 1mL aliquots at -80°C.
41361256|NCT03939858|DIAGNOSTIC_TEST|Bioenergetic Profiling|Peripheral blood mononuclear cells (PBMCs) and platelets will be separated from the blood. Primary respirometric parameters will be measured with high-throughput respirometry using the Agilent Seahorse 24XFe. Additional parameters will be collected with high-resolution respirometry using the OROBOROS Oxygraph-2k. Both methods will report a variety of mitochondrial parameters resulting in 48 measures per participant, creating robust profiles of bioenergetic health. Additional analysis will include western blots to enumerate protein density for the five major mitochondrial complexes, mtDNA copy number analysis, and citrate synthase activity as these assays provide different but complementary data to respirometry for a more dynamic picture of mitochondrial metabolism.
40840925|NCT04379999|DRUG|Atorvastatin 20mg AND Aspirin 325 mg|History of colorectal cancer and/or history of colorectal adenomas within 5 years.
40840926|NCT01978444|PROCEDURE|Laparoscopic D2 lymphadenectomy plus CME|
40840927|NCT01978444|PROCEDURE|Laparoscopic D2 lymphadenectomy|
40840928|NCT00677755|DRUG|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
40840929|NCT00677755|DRUG|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
40840930|NCT02441556|DEVICE|endovascular treatment|The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
41025047|NCT04241939|BEHAVIORAL|Digital Scale|Participants perform daily weighing using a digital scale (number readout), in conjunction with standard adolescent weight loss program
41361257|NCT01623492|OTHER|Subjects with diagnosis of Eisenmenger Syndrome|"1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine~2. Contraception counseling, and recommendations regarding avoidance of pregnancy~3. Documentation and prescription of the specific medications:~   1. Oxygen~  2. Diuretic~  3. ASA, Anticoagulant~  4. CCB, BB, ACEI, ARB~  5. Iron Supplementation~  6. Allopurinol~  7. PAH specific therapy"
41361258|NCT04466592|BEHAVIORAL|Promotion of competences of participant involved in the management of the post operative period|The research psychologist will be in touch with the participants for 9 months after the surgery (weekly, biweekly or monthly) in order to help them recovering social and work activities, and dealing with the consequences of the surgery. Specifically, four competences will be promoted (future forethought; context evaluation; consequences of own actions forethought; use of available resources), each relevant to four areas (clinical; familiar; working; daily-activities).
41361259|NCT03677752|OTHER|GP_Posit|Mother-infant dyads allocated to this arm will receive the GP_Posit intervention. The intervention consists of a guided participation intervention to positioning. Mothers will meet with the intervention nurse twice a week for the two first weeks after birth and then one a week until the infant will reach 35 weeks of gestational age. During these encounters, mothers will learn how to interpret their infant's stress and stability cues and participate in his/her care and positioning while being guided by the intervention nurse.
41361260|NCT00638651|DEVICE|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
41361261|NCT00638651|DRUG|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
41361262|NCT02793024|BEHAVIORAL|Intervention|Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
41361263|NCT04971577|DRUG|Simvastatin 40mg|participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
41498962|NCT06584422|OTHER|Telephone friendly visits|Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
41160773|NCT00475735|DRUG|Concerta (methylphenidate)|Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
41160774|NCT00475735|DRUG|Placebo|For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
41498963|NCT01085734|DRUG|Avastin|1.25mg intravitreally
41498964|NCT01085734|DRUG|Osurdex|0.7mg intravitreally
41498965|NCT01085734|DRUG|Avastin|1.25mg intravitreally
41498966|NCT01216618|DEVICE|InsuPatch|the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
41025048|NCT04241939|BEHAVIORAL|Modified Motivational Interviewing|Modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
41361264|NCT01110603|DRUG|MK-4827|Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
41498967|NCT01239134|BIOLOGICAL|TRX518|Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
41498968|NCT03207867|DRUG|NIR178|"NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.~NIR178 was administered orally twice daily (BID) as a capsule (Part 1, Part 2 and Japanese safety run-in) and as a film-coated table (Part 3). There were up to 3 dose levels assessed: 80, 160 and 240 mg. Three alternative dosing schedules were evaluated: continuous (Part 1, Part 2, Part 3, Japanese safety run-in), 2 weeks on/2 weeks off (Part 2) and 1 week on/1 week off (Part 2).~Each cycle consisted of 28 days."
41498969|NCT03207867|DRUG|PDR001|PDR001 is a human monoclonal antibody (MAb) administered on Day 1 of each cycle. PDR001 400 mg was administered via intravenous (i.v.) infusion over 30 minutes every 4 weeks (Q4W).
41361265|NCT01110603|DRUG|carboplatin|Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
41498970|NCT03058289|DRUG|INT230-6|"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations."
41498971|NCT03058289|BIOLOGICAL|anti-PD-1 antibody|The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
41498972|NCT03058289|BIOLOGICAL|anti-CTLA-4 antibody|The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
40840931|NCT02441556|OTHER|standard medical therapy|If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
40840932|NCT00940784|DRUG|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
41025049|NCT01866436|OTHER|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
41025050|NCT01866436|OTHER|Study Day Group|"Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection"
40840933|NCT00940784|DRUG|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
41361266|NCT01110603|DRUG|paclitaxel|Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
41361267|NCT01110603|DRUG|liposomal doxorubicin|Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
41361268|NCT06399172|DEVICE|OncoSil|Intra-tumoural implantation
41361269|NCT04547452|RADIATION|Stereotactic body radiation therapy|Sintilimab Combined with SBRT
41361270|NCT04547452|DRUG|Anti-PD-1 antibody drug named Sintilimab|Sintilimab
41361271|NCT04271904|OTHER|Placebo Diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
41361272|NCT02944604|DRUG|PEG-rhG-CSF|
41361273|NCT02490111|DRUG|DWJ1319|
40840934|NCT00940784|DRUG|Aspirin|81-100 mg qd
40840935|NCT05136261|DEVICE|Ceradan ® Advanced Cream|Ceradan ® Advanced Cream
41025051|NCT03052985|PROCEDURE|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
41160775|NCT03565783|BIOLOGICAL|Cemiplimab|Given IV
41160776|NCT03441919|RADIATION|PET-CT (positron emission tomography - computer tomography)|PET-CT to determine vascular inflammation
41160777|NCT03441919|DIAGNOSTIC_TEST|Blood drawn|Blood drawn
41160778|NCT05317377|OTHER|Exercise Therapy|Structured exercises focused on hand functionality
41361274|NCT02490111|DRUG|Placebo|
41361275|NCT04527458|OTHER|Patient Characteristics|Characteristics of the patients
41361276|NCT04527458|OTHER|COVID-19 treatments|Specific treatments used on COVID-19 patients
41361277|NCT04527458|OTHER|Differences in triage|Triage criteria for treating COVID-19 patients
41361278|NCT04527458|OTHER|Surge capacity|Capacity of hospitals
41361279|NCT03764904|RADIATION|Airway Ultrasound|Laryngeal US will be performed with a 12 megahertz (MHz) linear probe attached to the ultrasound device. With the probe placed transversely on the midline of the anterior neck over the cricothyroid membrane.
41361280|NCT05408676|DEVICE|electric stimulation therapy|Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)
41498973|NCT01778686|DRUG|Citalopram and Pindolol|"Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist"
41498974|NCT01778686|OTHER|Placebo|On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
40840936|NCT05136261|DEVICE|Basic cream|Basic cream
40840937|NCT00513955|DRUG|bortezomib|
40840938|NCT00513955|DRUG|cyclophosphamide|
40840939|NCT00513955|DRUG|doxorubicin hydrochloride|
40840940|NCT00513955|DRUG|prednisolone|
40840941|NCT00513955|DRUG|vincristine sulfate|
40840942|NCT00513955|OTHER|questionnaire administration|
40840943|NCT00513955|PROCEDURE|quality-of-life assessment|
40840944|NCT01555489|DRUG|Ascorbic Acid|3x per week
40840945|NCT01364909|OTHER|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises"
41025052|NCT05872230|DEVICE|Massage Percussion Therapy device|Using massage percussion postoperatively.
41025053|NCT03196921|DRUG|Encochleated Amphotericin B|lipid-crystal nanoparticle formulation of amphotericin B; oral
41498975|NCT01778686|DIETARY_SUPPLEMENT|Acute tryptophan depletion|
41498976|NCT05545371|BIOLOGICAL|immunization procedures|The subjects were vaccinated with rabies vaccine according to different immunization procedures
41361281|NCT06205875|PROCEDURE|High dose serratus anterior plane block (2.4 mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% plus epinephrine solution will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% plus epinephrine solution will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound. In total a dose of 2.4mg/kg patient ideal body weight will be administered. There is a maximal dose of 200 mg adrenalized bupivacaine for patients with an ideal body weight of 83 kg or more.
41361282|NCT06205875|PROCEDURE|Low dose serratus anterior plane block (1.2mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound.
40840946|NCT01364909|OTHER|Usual practice|These patients will not receive exercise early in their intensive care admission
41361283|NCT06205875|DRUG|PCIA with morphine|A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
41361284|NCT04060706|RADIATION|Radical Image-Guided Radiotherapy|Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
41361285|NCT03336307|OTHER|Rehabilitation program|"all patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease and focus on:~* endurance, strength, flexibility and balance with functional practice for all H/Y stage~* endurance also for H/Y stage 1,~* motor learning principles and cue functional for H/Y stage 2-3~* external cues and self-instruction strategies and attention H/Y for stage 2-3 The rehabilitative program comprised 60-minute sessions a day (3d/wk)."
41361286|NCT01245296|PROCEDURE|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
41361287|NCT01226602|DRUG|AZD6140|P2Y12 receptor antagonist
41361288|NCT01226602|DRUG|Placebo|
41361289|NCT03458429|DRUG|GMFFP|Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
41361290|NCT06481046|BIOLOGICAL|Platelet Rich Plasma (PRP)|Platelet Rich Plasma (PRP) prepared from patient blood, spun twice to concentrate platelets. 45 cc of initial blood resulting in 4cc of injectable PRP.
41361291|NCT02061020|DRUG|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
41361292|NCT04632316|DRUG|Cyclophosphamide-Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
40840947|NCT05235919|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|30 minutes rTMS session 5 days/week for 3 weeks.
40840948|NCT05235919|OTHER|Sham stimulation|30 minutes sham stimulation 5 days/week for 3 weeks.
40840949|NCT04927793|DRUG|EDP-938|\[14C\]EDP-938
40840950|NCT05602077|DEVICE|POCUS|"POCUS: The ultrasound examination of the injured elbow includes seven standard settings. The probe is placed on the joint in four ventral and in three posterior positions. If hemarthrosis is detected, this is always suspicious of a possible intra-articular fracture. Even the smallest amounts of blood can be detected sonographically. The surfaces of the bones involved in the joint (humerus, ulna, radius) are accurately displayed in all seven sonography settings. Disrupted bone surface indicates a fracture.~XR: The conventional radiograph of the injured elbow consists of three standard views: ap, lateral and Norman oblique.~CBCT: The injured elbow is placed in an almost most extended position in the CBCT tube."
41361293|NCT04632316|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
41160779|NCT05317377|DEVICE|Leap Motion Based Exergame|Appropriate games from Leap Motion Based Exergame system focused on hand functionality
41361294|NCT00544154|DRUG|CDP870|
41361295|NCT01160029|DRUG|Nateglinide|Nateglinide Tablets 120 mg
41361296|NCT00422942|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
41361297|NCT00422942|DRUG|Methotrexate|10-25mg po weekly
41361298|NCT02377401|DRUG|Zanamivir|Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
41361299|NCT05277597|DIAGNOSTIC_TEST|The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.|Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.
41160780|NCT05502861|BEHAVIORAL|Generalist + Specialist palliative care|Clinicians are alerted in the EHR to make an active choice whether to provide generalist palliative care themselves, consult PC specialist, or to defer PC at that time.
41160781|NCT05502861|BEHAVIORAL|Pre-Intervention phase|Patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care.
41160782|NCT00495261|BEHAVIORAL|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
40840951|NCT00588094|DRUG|Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant|"ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.~Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.~For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is \> 100kg. Leukapheresis will continue."
40840952|NCT02001337|OTHER|medical chart review|baseline, quarterly follow-up for 24 months
41036565|NCT05057533|OTHER|a questionnaire based on Rome IV Diagnostic criteria of IBS|"The Rome IV criteria for the diagnosis of IBS require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following~1. Related to defecation (may be increased or unchanged by defecation)~2. Associated with a change in stool frequency~3. Associated with a change in stool form or appearance The Rome IV criteria (May 2016) only require abdominal pain in defining this condition; discomfort is no longer a requirement owing to its nonspecificity, and the recurrent abdominal pain. \[2\] Supporting symptoms include the following:Altered stool frequency Altered stool form Altered stool passage (straining and/or urgency) Mucorrhea Abdominal bloating or subjective distention."
41160783|NCT00495261|BEHAVIORAL|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
41160784|NCT04491006|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
40840953|NCT02001337|OTHER|survey administration|baseline
40840954|NCT02001337|OTHER|Specimen collection|baseline
40840955|NCT03716661|PROCEDURE|ORIF|Open Reduction Internal Fixation
40840956|NCT00578630|OTHER|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
40840957|NCT03966885|BEHAVIORAL|Brief Intervention|The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
41361300|NCT05277597|DIAGNOSTIC_TEST|The same exercise training program without the sauna treatments|The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
41361301|NCT04353739|BEHAVIORAL|Self-Management for HIV-positive Asian Pacific Americans|Developed upon the results of our prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program.
41361302|NCT05995548|OTHER|Interview|The interview will take place face-to-face. It will take place in a quiet room, with the door and windows closed. Only the participant and the investigator will be present. It will be recorded using a dedicated to this research. At the end of the interview, so as not to influence the participant's discourse, the participant will be asked to fill in the self-questionnaire 'EAI' (Exercise Addiction Inventory), which will confirm or refute the diagnosis, thus exploring a possible discrepancy between the participant's feelings and the diagnosis.
41361303|NCT05278611|DRUG|EP-9001A|The initial dose of the study was set as 1 mg, and the doses were escalated sequentially in the order of 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 25 mg
41361304|NCT05278611|DRUG|placebo|placebo
41361305|NCT02155712|DEVICE|Triathlon Tritanium Knee|Cementless
41361306|NCT02155712|DEVICE|Triathlon Knee|Cemented
41361307|NCT02254876|OTHER|Standard physical therapy program|Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
41361308|NCT02254876|OTHER|NeuroMuscular Taping (NMT)|"The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.~In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus."
41361309|NCT03635645|DEVICE|New visual processing unit (VPU) with asymmetric waveforms|A VPU will apply asymmetric and symmetric stimulation pulses.
41361310|NCT03635645|DEVICE|New VPU with bipolar stimulation|A VPU will apply bipolar stimulus pulses.
41361311|NCT04033328|DRUG|ORIC-101|ORIC-101 once daily in each 28-day cycle
41361312|NCT04033328|DRUG|enzalutamide 40 MG oral capsule [Xtandi]|160 mg once daily in each 28-day cycle
41361313|NCT04020224|DEVICE|Amustaline/GSH pathogen reduction technology|Whole blood treated with pathogen reduction technology
41361314|NCT04020224|DEVICE|Standard of Care|Red Blood Cell Component or whole blood
41361315|NCT03977376|OTHER|Guide of hosting|Guide of hosting with information about hospitalization to decrease anxiety
41361316|NCT04726943|PROCEDURE|Radiofrequency Energy Applications|RF energy applications to the atrial edge of a leak resulting from incomplete LAA occlusion
41361317|NCT05868629|OTHER|Non-investigational|Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
41361318|NCT01028599|OTHER|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
41361319|NCT03377218|DIETARY_SUPPLEMENT|Iodine|Receiving 150 μg iodine (as potassium iodide) daily
41361320|NCT03377218|DIETARY_SUPPLEMENT|Iodine + Selenium|Receiving a combination of 150 μg iodine (as potassium iodide) and 100 μg selenium daily
41361321|NCT00106626|DRUG|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
41361322|NCT06241495|OTHER|Placebo|Placebo oil will be applied to the individuals included in the study. During the semen sample giving process, coconut oil (placebo) will be applied with a diffuser.
41361323|NCT06241495|OTHER|Aromatherapy|Aromatherapy will be applied to the individuals included in the study. During the semen sample giving process, lavender oil will be applied with a diffuser.
41361324|NCT03506529|OTHER|questionnary|questionnary on predictif factors about physiological hypermetabolism of anal canal
41361325|NCT02501486|OTHER|ACTH stimulation test|An ACTH stimulation test will be done
41498977|NCT06399653|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
41498978|NCT06399653|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS devices look identical to active devices and participants will undergo identical training for self-administration on upper anterior cervical area (overlying carotid artery). Sham devices do not stimulate the vagus nerve.
41498979|NCT03634475|DRUG|PP-001|Drug - no placebo
41498980|NCT06457893|OTHER|The health belief model-based exercise training program and health belief model-based education|The health belief model-based exercise training program and education program will implement with the students in the experimental group for 5 weeks and follow-ups will be made at the 3rd and 6th months.
41498981|NCT02640092|DRUG|[18F]GTP1|Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description.
41160785|NCT04491006|DRUG|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
41361326|NCT05897996|DEVICE|creation of vascular access for hemodialysis|endo-AVfs created with Wavelinq
41361327|NCT01115205|BEHAVIORAL|Supervised walking|Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
41361328|NCT01115205|BEHAVIORAL|Standard counselling procedure|Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
41361329|NCT02624713|BEHAVIORAL|obesity treatment|"1. Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~2. Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~3. Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
41361330|NCT02160509|DEVICE|IPhone based realtime remote ultrasound interpretation|
41361331|NCT03876509|DIAGNOSTIC_TEST|Impedance Cardiography|"Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured."
41361332|NCT02908841|DEVICE|Surgicel Snow|
41361333|NCT02908841|OTHER|Standard of Care|
41361334|NCT05114031|OTHER|FB101|Microbial intervention using product FB101
41361335|NCT05114031|OTHER|Placebo|Saline water
41361336|NCT02748018|DEVICE|670G and 770G Insulin Pump|Medtronic 670G and 770G Hybrid Closed Loop Systems
41361337|NCT02748018|DEVICE|Subject's Current Diabetes Therapy|Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
41498982|NCT02675439|DRUG|ADU-S100|
41498983|NCT02675439|BIOLOGICAL|ipilimumab|
41498984|NCT01758588|DRUG|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
41498985|NCT03813810|OTHER|Non|There would be no interventions. Only measurements will be performed.
41498986|NCT05395390|BEHAVIORAL|Exercise (Resistance Training|Resistance Training done both at home and on site using either dumbells or keiser pneumatic exercise machines respectively
41036566|NCT03882476|DIAGNOSTIC_TEST|InSight|Clinical decision support (CDS) system for sepsis detection
41036567|NCT02105948|DRUG|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
41036568|NCT02105948|DRUG|Placebo|Sterile 0.9% sodium chloride solution
41036569|NCT00105326|DRUG|paliperidone ER|
41036570|NCT05013333|DEVICE|AED 3 with Uni-padz|Use of AED 3 with Uni-padz by lay rescuer
41036571|NCT01390012|DRUG|Dexamethasone tablet 6 mg|Dexamethasone tablet 6 mg
41036572|NCT01390012|DRUG|Dexamethasone injection 4 mg|Dexamethasone injection 4 mg
41036573|NCT02938000|DEVICE|Theraband with exercise video|Theraband exercise band for resistance training
41036574|NCT02938000|OTHER|usual care with advice to exercise|advice to exercise
41361338|NCT06393205|DEVICE|Naso-Esophageal Tube Feeding|During nasogastric tube feeding, a thin, flexible tube is carefully inserted through one nostril and passed down the throat into the stomach. Once in place, liquid nutrition, medication, or fluids can be administered through the tube, providing essential nutrients and hydration directly to the patient's digestive system. Nasogastric tube feeding may be used temporarily to support patients during acute illness or surgery, or it may be a long-term solution for individuals with chronic conditions that affect their ability to eat normally.
41361339|NCT06393205|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
41361340|NCT06393205|BEHAVIORAL|Routine treatment|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
41361341|NCT02774499|DRUG|Methadone|0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
41361342|NCT02774499|DRUG|Placebo|equivalent volume (5mL) of syrup given preoperatively
41361343|NCT00783822|OTHER|RGCT|rapid genetic counseling and testing
41361344|NCT01078181|PROCEDURE|gastric bypass|laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
41361345|NCT05658133|OTHER|Survey of sports nutrition knowledge|Questionnaire
40840958|NCT03966885|BEHAVIORAL|Common Elements Treatment Approach (CETA)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
41361346|NCT01897779|DRUG|RPX7009|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
41361347|NCT01897779|DRUG|RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
41361348|NCT01897779|DRUG|Placebo|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
41361349|NCT01897779|DRUG|Combination RPX7009 and RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
41361350|NCT01883596|DRUG|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
41361351|NCT01883596|DRUG|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
41361352|NCT06207708|OTHER|questionnaires QLQ-FA12, Mini Nutritional Assessment Short Form, Nutritional Risk Screening, diet questionnaire of frequency, ,body mass index measurement|the patient is administered with questionnaires focused on diet, fatigue, nutrition screening and on body mass index at the beginning and at the end pf particle therapy radiation treatment
40840959|NCT03139617|PROCEDURE|Fascia Iliaca Compartment Block (FICB)|"The FICB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block. Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel. Lignocaine 2% for local anaesthetic infiltration at punctured site.A blunted needle (Plexufix® 24G x 2, B Braun Melsungen AG 34209 Germany).A line was drawn from pubic tubercle to anterior superior iliac spine, the punctured point is 2-3cm distal to the point where medial 2/3rd and lateral 1/3rd of the line meet. Loss of resistance 2 times indicated the punctured of fascia lata and iliaca.A total volume of Ropivacaine 0.375% per body weight was given with repeated aspiration."
41036575|NCT05509972|DEVICE|total knee prosthesis implantation|Total Knee Arthroplasty (TKA) represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or comparable conditions even in young patients compromised by knee pain and limitations of daily living
41036576|NCT03278665|DRUG|4SC-202 in combination with Pembrolizumab|4SC-202 in combination with Pembrolizumab
41036577|NCT02529319|PROCEDURE|MRI-Guided Ablation|Catheter ablation of AF will be guided by a DE-MRI of the patient's heart prior to the procedure.
41361353|NCT06207708|DIAGNOSTIC_TEST|blood biomarkers|as per clinical routine, hemoglobin, lymphocytes, albumin and NLR will be collected
41361354|NCT02948998|DRUG|Spironolactone|The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
41361355|NCT01840566|DRUG|Carmustine|
41361356|NCT01840566|DRUG|Etoposide|
41361357|NCT01840566|DRUG|Cytarabine|
41361358|NCT01840566|DRUG|Melphalan|
41361359|NCT01840566|BIOLOGICAL|Pegfilgrastim|
41361360|NCT01840566|BIOLOGICAL|19-28z T CELLS|
41361361|NCT01840566|PROCEDURE|Autologous Stem Cell Transplantation|
41361362|NCT03794856|OTHER|Functional and Structural Magnetic Resonance Imaging (research grade)|Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.
41361363|NCT03794856|OTHER|Cognitive Function Testing (non-diagnostic)|Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.
41361364|NCT03794856|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Participants will fill out asthma and psychological questionnaires (non-diagnostic)
41361365|NCT03171142|DRUG|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
41361366|NCT03171142|DRUG|Air|Air 21% via nasal cannula 2 litter per minutes
41361367|NCT00242658|BEHAVIORAL|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
41498987|NCT04522817|BIOLOGICAL|CLBS119|Peripheral blood derived autologous CD34+ cells
41361368|NCT02033642|BEHAVIORAL|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.
41036578|NCT02529319|PROCEDURE|Conventional Ablation|Catheter ablation of AF using pulmonary vein isolation (PVI) will be performed using the HRS guidelines.
41361369|NCT02033642|BEHAVIORAL|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
41498988|NCT03473769|OTHER|Vital Signs at 2 Hours|Patients vital signs assessed at 2 hours of arrival at ICU
41498989|NCT03473769|OTHER|Confusion Assessment method for the ICU (CAM-ICU)|patient must have altered mental status/fluctuating course and inattention, and either disorganized thinking or altered level of consciousness to be CAM positive; these features are determined by observing the patient during bedside cognitive testing.
41498990|NCT01996449|DRUG|Eplerenone|The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
41498991|NCT01996449|DRUG|Amlodipine|The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
41498992|NCT01996449|PROCEDURE|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
41498993|NCT01996449|PROCEDURE|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
41498994|NCT01996449|PROCEDURE|Sustained hand grip|Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
41498995|NCT01996449|PROCEDURE|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
41036579|NCT00193700|DRUG|Testosterone Gel (1%)|
41036580|NCT02866253|DRUG|DHEA|Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
41036581|NCT05676476|DRUG|Antihypertensive treatment|Antihypertensive treatment to goal of less than 140/90 mmHg
41036582|NCT05099848|DRUG|Camrelizumab|"Procedure:~1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication.~2. On the 2nd day of treatment, intravenous infusion of Camrelizumab 200mg every 3 weeks.~3. On the 3rd to 4th day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX, oxaliplatin 85 mg/m2 in 0-2 hours, folinic acid 400 mg/m2 in 2-3 hours, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 8 times.~The cumulative maximum drug use period is up to 8 cycles. Patient will be administratied radical resection if possible during treatment. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
41036583|NCT06457750|BEHAVIORAL|Feeding, Lifestyle, Activity Goals (FLAGs) Digital Health Application|Feeding, lifestyle, activity goals (FLAGs) is a digital assessment and advisory tool developed by the investigators to facilitate early identification of lifestyle behaviour problems and abnormal feeding patterns in infants, with real-time feedback for caregivers. The FLAGs questionnaire examines the domains of energy regulation, timeliness and adequacy of weaning, dietary practices, and lifestyle habits. Tailored recommendations have been developed for each domain accordingly. The objective of FLAGs is shaping healthy lifestyle and feeding behaviours from birth, charting a trajectory to optimal metabolic health.
41036584|NCT01842139|BIOLOGICAL|basiliximab|Given IV
41036585|NCT01842139|BIOLOGICAL|WT1 126-134 peptide vaccine|Given SC
41036586|NCT01842139|DRUG|Montanide ISA 51 VG|Given SC
41036587|NCT01842139|DRUG|poly ICLC|Given SC
41036588|NCT01842139|OTHER|laboratory biomarker analysis|Correlative studies
41361370|NCT05891457|COMBINATION_PRODUCT|Nutritional Intervention|"* Severe acute malnourished children were provided with appropriate nutritional therapy/treatment that include supplementation of a high-calorie diet; i.e., F-100 milk and khichuri-halwa for nutritional rehabilitation.~* Egg milk and micronutrient supplementation for recovery from severe stunting following standard guidelines for facility based management and recently conducted community based nutrition intervention studies.~* Wasted children were treated with suitable local nutritional management (NM), such as infant and young child feeding practices (IYCF), providing MNP and nutrition education."
41361371|NCT01970384|DEVICE|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
40840960|NCT03139617|PROCEDURE|3 in 1 femoral block (FNB)|"The FNB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block.Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel.Lignocaine 2% for local anaesthetic infiltration at punctured site.An insulated stimulating needle (Stimuplex® D Plus 22g x 2, B Braun Melsungen AG 34209 Melsungen Germany). Ultrasound was used to locate the femoral vessel and nerve and by using 'in plane' technique, the skin was punctured with the insulated needle and advance in transverse plane at around 30 angle to the skin. Local anaesthetic solution as per ideal body weight given after negative aspiration of blood ."
41361372|NCT01970384|DEVICE|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
41160786|NCT03238456|BEHAVIORAL|Motivating Pacifika Against Cigarettes and Tobacco|"Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.~The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages."
41160787|NCT02261545|DIETARY_SUPPLEMENT|n-3 Fatty Acid|n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
41361373|NCT05686668|OTHER|assessment by scales|Assessment from many scales: AASP, HARS, HDRS, CORE, EES, CISS, SHAPS at V1 Assessment from many scales: AASP, HARS, HDRS, CORE, EES, SHAPS at V2
41361374|NCT01230021|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight
41361375|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
41361376|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
41160788|NCT02261545|DIETARY_SUPPLEMENT|Placebo|3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.
41160789|NCT02316392|DRUG|Hyperpolarized Helium-3 MRI|Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
41498996|NCT01996449|PROCEDURE|Arm cycling exercise|Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
41498997|NCT01996449|PROCEDURE|Cold Pressor test|Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
40840961|NCT01191346|OTHER|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
41361377|NCT04249076|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
41361378|NCT04249076|DRUG|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
41361379|NCT01510392|DEVICE|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
41361380|NCT03006549|BEHAVIORAL|Emergency Manual (Crisis Checklist)|participants will have an Emergency Manual available to them during the crisis simulation scenario.
41361381|NCT03336164|BEHAVIORAL|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
41361382|NCT01304576|BEHAVIORAL|Neuropsychological testing|Experimental test about orientation agnosia and standard neuropsychological tests.
41361383|NCT01304576|OTHER|MRI|Cerebral MRI
41498998|NCT03285100|DIAGNOSTIC_TEST|Venipuncture|"* Approximately 6 months after discontinuation of VKAs one additional venipuncture will be performed for determination of dp-ucMGP and desmosine.~* At baseline two additional blood collection tubes will be drawn for determination of dp-ucMGP, desmosine and VKORC1 polymorphisms. Since this is during one of the last regular International Normalized Ratio (INR) testing at the anticoagulation clinic, no additional venipuncture has to be performed at this moment."
41498999|NCT04990700|PROCEDURE|Partial rib resection|1 cm partial rib resection during thoracotomy opening
41499000|NCT06633354|BIOLOGICAL|CD5 CAR T-cells|Each subject receive CD5+ T-ALL Targeted CAR T-cells by intravenous infusion
41499001|NCT03165838|BEHAVIORAL|Postpartum Visit 3-4 Weeks|This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
40840962|NCT05024903|OTHER|Serious illness medical planning plus the novel e-health platform (PWG 2.0)|"PWG 2.0 consists of the following components:~1. A diagnostic questionnaire, Preparedness for the Future Questionnaire and bench-marked report that helps users assess their strengths, weaknesses and opportunities for improvement.~2. A comprehensive e-workbook that helps users understand the science behind personal behavior change.~3. Links to webpages with additional e-workbooks and curated content aimed to help users progress on the 30 different attitudes, behaviors, and activities that portend for a better future (topics listed in Appendix A).~4. E-messages delivered via emails (via text an option for those that prefer) with tailored content designed to provide multiple nudges to guide the user to progress through our content.~5. Monthly newsletter with current topics and issues related to the 30 topics and behavior change in general.~6. A virtual consultation with Dr. Heyland, creator of PWG and principal investigator."
40840963|NCT05024903|OTHER|Standard of care|Participants are not planning for their future (PWG 2.0) or using the e-health platform
41160790|NCT06330233|OTHER|Moxibustion|"The recruited patients all received diabetes mellitus education. Patients with combined hypertension and hyperlipidemia received daily treatment to lower their blood pressure and blood lipids. The medication was based on their current self-medication, to keep their conditions under normal control.~The conventional treatment group received mecobalamin tablets and epastat orally for four weeks along with their daily treatment.~Moxibustion 15 minutes group: The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11) and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.~Moxibustion 15 minutes group of Part Two will use the same intervention as above.~Moxibustion 30 minutes group: Except for the operating time others are the same as the Moxibustion 15 minutes group."
41160791|NCT04999683|DIETARY_SUPPLEMENT|ITIS diet|anti-inflammatory diet for 14 days
41160792|NCT03648684|BEHAVIORAL|Caffeine-Based Expectancy Challenge|Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)
41160793|NCT03648684|BEHAVIORAL|Placebo-Based Expectancy Challenge|Intervention to alter expectancies (expectancy modification only)
41160794|NCT02032420|BEHAVIORAL|STAR|
41160795|NCT02032420|BEHAVIORAL|ART|
41160796|NCT03942276|OTHER|High intensity interval training|Consists of 60 seconds sets of high-intensity exercises, characterized by heart rate\> 85% of maximal heart rate (HRmax), obtained through the formula (220-age), or by the Rated Perceived Exertion between 7 and 8 on the Borg scale, which ranges from 0 to 10. Of the 60 seconds of high intensity exercise, 30 seconds will be to get up and down a 16 cm step and 30 seconds of squats, with knee flexion greater than 90º, both at the highest possible speed. The recovery between sets is light walk for 60 seconds. If the volunteers do not reach the proposed intensity zone, they will be instructed to increase the number of squats and step ascents and descents.
41160797|NCT03942276|OTHER|Moderate intensity continuous training|Consist of performing a 30 minute walk at 50% of reserve heart rate (HRR), calculated by (HRmax - HRmax) x% + HRmax. HRmax being obtained by means of the formula (220 - age).
41160798|NCT03942276|OTHER|Control|Consist of performing no exercise training.
41499002|NCT03165838|BEHAVIORAL|Postpartum Visit 6-8 Weeks|This standard of care postpartum visit will be scheduled for the standard time interval.
41499003|NCT02796794|DIETARY_SUPPLEMENT|Genistein|Total 30 patients will be included into the study They will be divided into two groups each containing 15 patients. Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
41499004|NCT02796794|OTHER|enteral nutrition only|These are the patients receiving enteral nutrition
41499005|NCT06260709|DRUG|NNC6019-0001|Intravenous NNC6019-0001 every 4 weeks added to the standard of care until Week 140.
41499006|NCT06359964|PROCEDURE|Transperineal Biopsy without antibiotics prophylaxis|Transperineal Biopsy without antibiotics prophylaxis
41499007|NCT06359964|PROCEDURE|Transperineal Biopsy with antibiotics prophylaxis|Transperineal Biopsy with antibiotics prophylaxis
41499008|NCT01404130|DRUG|Isotretinoin|0.5-1mg/kg daily for 4-6 months
41499009|NCT04283201|OTHER|Physical activity|Moderate activity 150 min per week
41499010|NCT04283201|OTHER|Macronutrient modification|Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation
41499011|NCT05742763|COMBINATION_PRODUCT|Ibuprofen and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
41499012|NCT05742763|COMBINATION_PRODUCT|Acetaminophen and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
40840964|NCT00450073|DRUG|ergocalciferol (vitamin D2)|50,000 IU weekly
41361384|NCT04059328|PROCEDURE|Surgical training|This was a gyn laparoscopy training and simulation course
41361385|NCT03217565|DRUG|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
41361386|NCT03217565|DRUG|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension.
41361387|NCT02491593|DEVICE|fecal occult blood test|
41361388|NCT01845129|DEVICE|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
41361389|NCT01845129|DEVICE|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
41361390|NCT05654740|DEVICE|Virtual Reality Experiences|Virtual Reality experiences including stress reduction, distraction and entertainment
41361391|NCT02715115|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
41361392|NCT02715115|DRUG|Placebo|Strawberry flavored solution and Water for Injection
41361393|NCT04663386|DRUG|Budesonide-Formoterol|Dry powder inhaler
41361394|NCT00451776|DRUG|etomidate|patients who received etomidate
41361395|NCT00451776|DRUG|propofol|patients who received propofol
41361396|NCT01047215|DRUG|Aripiprazole; Quetiapine|Aripiprazole Quetiapine
41361397|NCT03293706|OTHER|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
41361398|NCT03293706|OTHER|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
41361399|NCT03293706|OTHER|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
41361400|NCT03293706|OTHER|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
40840965|NCT00450073|DEVICE|Sperti Del Sol Lamp|5 times a week for 12 weeks
41025054|NCT02802553|DEVICE|Smart Goggle|Smart Goggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The Smart Goggles is a non-invasive imaging system that does not require contact with patients.
41025055|NCT02802553|OTHER|Cardio-Green|Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
41025056|NCT02802553|DEVICE|SPY Elite Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
41025057|NCT02802553|DEVICE|Quest near-infrared (NIR) Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
41160799|NCT02639078|DRUG|TD-0714|One time dosing in capsule formulation
41160800|NCT02639078|DRUG|Placebo Comparator|One time dosing in capsule formulation
41361401|NCT03293706|OTHER|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
41361402|NCT01809028|PROCEDURE|EUS FNA with 2 passes|biopsy with 2 passes
41361403|NCT01809028|PROCEDURE|EUS FNA with 4 passes|biopsy with 4 passes
41160801|NCT03416335|DRUG|DSP-0509|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
41361404|NCT04495166|BEHAVIORAL|Motherly 1.0|A mobile app designed to promote life habits that have been shown to improve physical and mental health in pregnant women. The app consists of a package of specific and customized interventions defined by eight different modules: 1) Mental Health; 2) Sleep; 3) Nutrition; 4) Physical activity; 5) Social support; 6) Prenatal support; 7) Postnatal support, and 8) Library of pre and postnatal content. The app relies on extensive psychoeducational content delivered as tutorials, brief messages, and available as a library that can be read at the users' discretion; behavior monitoring using schedules, checklists, and notifications to help participants keep track of their health care visits, and schedule behavior activation activities; and gaming elements such as changes in background appearance to reflect participant's mood assessment and ratings of activities, and graphical and easy-to-use questionnaires for obtaining information (mood, nutrition habits).
41361405|NCT04495166|BEHAVIORAL|Brief Psychotherapy|Brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation (BA). Participants will be guided by psychotherapists to plan, schedule, and engage in positively reinforcing activities, and will be aided to develop problem-solving strategies for circumventing barriers to completing scheduled activities. Implementation of these techniques will be conducted with the aid of the Motherly 1.0 for participants in the experimental arm; for participants in the control arm, BA will be implemented without the aid of Motherly 1.0. Throughout the four sessions, psychotherapists will monitor participants' adherence, answering questions about the strategies and providing support for solving problems or CBT techniques, such as cognitive restructuring, relaxation techniques, sleep hygiene, stress and anxiety management, among other evidence-based techniques might be used if appropriate to the case.
41361406|NCT04495166|BEHAVIORAL|Educational app|A simplified version of the Motherly 1.0 app consisting of psychoeducational content about various aspects of pregnancy, maternal physical and mental health, and child development. Active intervention functionalities, such as behavioral activation, activity scheduling, sleep hygiene, among others, are NOT present in this simplified version of the app.
41361407|NCT00656136|DRUG|placebo|Patients receive placebo once daily
40840966|NCT00450073|DRUG|Vitamin D3|50,000 IU weekly
41361408|NCT00656136|DRUG|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
40840967|NCT00613093|DRUG|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
40840968|NCT01424566|DRUG|Nabiximols|
40840969|NCT01424566|DRUG|Placebo (GA-0034)|
40840970|NCT02839694|DRUG|decitabine (DAC)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
40840971|NCT02839694|DRUG|Tetrahydrouridine (THU)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
40840972|NCT02839694|DRUG|Celecoxib|400 mg orally twice a day every day for while on DAC-THU therapy
40840973|NCT00464659|DEVICE|Effective CPAP|Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
40840974|NCT00464659|DEVICE|Sham CPAP|Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
40840975|NCT01704456|BEHAVIORAL|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
40840976|NCT01704456|BEHAVIORAL|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
41361409|NCT04415749|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine
41361410|NCT04415749|OTHER|Placebo|Normal saline
40840977|NCT00952614|DEVICE|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
40840978|NCT01759823|BIOLOGICAL|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
40840979|NCT01759823|OTHER|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
41025058|NCT02802553|DEVICE|PDE Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
41361411|NCT04350034|OTHER|Xbox training|"patients in this group received routine physical therapy protocol plus Xbox training.~Before the intervention started, the Xbox group was given a 45 min introductory session on how to use the xbox adventure games and its tools. All sessions were led by a single experienced physiotherapist (different to the physiotherapist who performed the assessments tests) in order to provide instruction on how to perform each exercise."
41499013|NCT05742763|COMBINATION_PRODUCT|Placebo and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
41499014|NCT05856643|DRUG|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8, 2.0×10\^8and 5.0×10\^8 cells. The infusion is given every 2 weeks.
41499015|NCT04594317|DEVICE|low level laser therapy|buccal application of diode laser on non-contact mode
41499016|NCT00345943|OTHER|MRI|Magnetic Resonance Imaging scans
41499017|NCT00345943|BEHAVIORAL|Neuropsychological Testing|Neuropsychological tests
41499018|NCT03471000|OTHER|Short implants Treatment|Short implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
41499019|NCT03471000|OTHER|Regular implants Treatment|Sinus lift procedure is done and regular implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
41499020|NCT02669030|DRUG|suvorexant|an FDA-approved sleep aid
41499021|NCT02669030|DRUG|Placebo|control group
41499022|NCT01687244|DRUG|INSTILADRIN|The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
41499023|NCT00418002|DRUG|AQW051|
41499024|NCT03083080|PROCEDURE|VATS|VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
41499025|NCT03083080|DRUG|Ropivacaine|30 mL 0.5% ropivacaine is used to achieve VATS block
41499026|NCT03083080|DRUG|Epinephrine|1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
41499027|NCT05531292|DEVICE|Model C0002|Eligible subjects will be randomized in a 1:1 ratio to the investigational IOL Model C0002 in both eyes for the duration of the study.
41499028|NCT05531292|DEVICE|Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to the control IOL Model ZCB00 in both eyes for the duration of the study.
41499029|NCT01952210|BEHAVIORAL|nutritional consultation and exercise program|The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.
41499030|NCT01952210|BEHAVIORAL|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
40840980|NCT01759823|BIOLOGICAL|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
41499031|NCT02315430|DRUG|Cabozantinib S-malate|Given PO
41499032|NCT02315430|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41499033|NCT01663883|OTHER|Isometric exercise|use of a handgrip for 3x2 minutes
41499034|NCT00134004|DRUG|cyclophosphamide|
41499035|NCT00134004|DRUG|fludarabine phosphate|
41499036|NCT00134004|DRUG|mycophenolate mofetil|
41499037|NCT00134004|DRUG|tacrolimus|
41499038|NCT00134004|PROCEDURE|allogeneic bone marrow transplantation|
40840981|NCT01054521|PROCEDURE|Temperature-controlled RF|"The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF."
40840982|NCT01054521|DEVICE|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
40840983|NCT01283542|DRUG|Pasireotide LAR|20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
41025059|NCT02802553|DEVICE|Gamma probe|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
41499039|NCT00134004|RADIATION|radiation therapy|
41499040|NCT04487951|OTHER|Pro BNP , Vitamin D|This study is designed to assess the difference between level of NT-pro-BNP, and Vitamin D in moderate cases who progressed to severe or critically ill category compared to those who did not.
41361412|NCT04350034|OTHER|Control group|routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
41499041|NCT05750862|PROCEDURE|Marking of the intended axis of IOL-Implantation manually with an ink and marking device on the surface of the eye|The marking of the intended implantation axis of the interocular lens will be marked in all patients with topography guided in the corneal stroma with laser and in addition manually with a caliper and ink on the corneal surface
41499042|NCT02089035|DIETARY_SUPPLEMENT|MUFA-rich dairy products (UHT milk, cheese and butter)|
41499043|NCT02089035|DIETARY_SUPPLEMENT|Conventional dairy products (UHT milk, cheese, butter)|
41499044|NCT01775449|BEHAVIORAL|Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines|
41499045|NCT06196814|DRUG|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
41499046|NCT01152151|DEVICE|Postal reminder letters|Postal reminder letters if adherence is not obtained (up to four)
41499047|NCT01152151|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
41499048|NCT01152151|DEVICE|Reminder letters|up to four reminder letters in september - december 2010
41499049|NCT05119348|OTHER|STOPCOV|Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
41499050|NCT06633250|OTHER|Test Formula|Hydrolyzed rice protein formula
41499051|NCT06633250|OTHER|Control Formula|Commercially available extensively hydrolyzed cow's milk formula
41499052|NCT04260971|DEVICE|Abbott St Jude Medical Infinity 7 neurostimulator|The stimulator has the capability to deliver both continuous and cyclical modes of stimulation which is being investigated in this study
41499053|NCT03922776|PROCEDURE|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~* at diagnosis, before chemotherapy (pre-CT)~* after chemotherapy (post-ct) Collection of two blood samples (5mL),~* before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~* and then, after chemotherapy (post-CT), up to 3 months after enrollment"
41499054|NCT01833819|DRUG|Dexmedetomidine and lidocaine|
41499055|NCT01833819|DRUG|Remifentanil|
41499056|NCT02326441|DRUG|KX2-361|
41361413|NCT02538705|DRUG|Neovasculgen|
41361414|NCT01995396|PROCEDURE|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
41361415|NCT01995396|PROCEDURE|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
41361416|NCT04882839|COMBINATION_PRODUCT|psychotherapy assisted psilocybin|psychotherapy for patients while under the influence of psilocybin
41361417|NCT01347515|OTHER|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
41361418|NCT00850213|DEVICE|Endeavor Resolute Stent|Single implantation
41361419|NCT03852901|DRUG|empagliflozin (Jardiance) 25 mg|Oral empagliflozin 25 mg/day x 14 days
41361420|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab|Patients in Experimental group will be given ramucirumab (8mg/kg) by intravenous drip on the first day of each cycle, 3 weeks a cycle.
41361421|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1|Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time. Patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
41361422|NCT05460468|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
41361423|NCT04067804|BEHAVIORAL|Dynamic Adaptation Process|The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
41361424|NCT02297295|OTHER|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
41361425|NCT06022627|BEHAVIORAL|Pranayama Yoga|Doing practice of paranayam yoga which including breathing exercises yoga-life energy
41361426|NCT05102734|DRUG|Nitroglycerin Topical Product|Topical nitroglycerin solution
41361427|NCT01379911|OTHER|Yogurt|
41361428|NCT05158127|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41361429|NCT03103724|DRUG|Xtandi|Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
41499057|NCT06028321|DRUG|Part 1 Group 1 Regime A (ACM-001.1)|"Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.~Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B."
41361430|NCT05632705|OTHER|Closing pack|A closing pack, new sterile gloves and new sterile drapes will be used when commencing closure of the sheath and skin
41361431|NCT02434666|DRUG|CPC-201|
41361432|NCT00733096|DRUG|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
41361433|NCT00733096|DRUG|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
41361434|NCT00733096|DRUG|normal saline|Two transforaminal epidural saline injections, two weeks apart
41499058|NCT06028321|DRUG|Part 1 Group 2 Regimen C (Pindolol)|Drug: Pindolol tablets for oral use.
41499059|NCT06028321|DRUG|Part 2 Group D (Pindolol)|Drug: Pindolol tablets for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
41499060|NCT06028321|DRUG|Part 2 Group E (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
41025060|NCT02802553|OTHER|Blue Dyes|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
41361435|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
41361436|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
41361437|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
41361438|NCT02055976|DRUG|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
41361439|NCT02055976|DRUG|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
41361440|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
41361441|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
41361442|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
41361443|NCT02055976|DRUG|Placebo|Placebo Q14D SC for 16 week
41361444|NCT05006404|DEVICE|Pulmonary Valve Replacement Surgery|Pulmonary valve replacement surgery with the Autus Valve
41361445|NCT05204576|BEHAVIORAL|CBT4CBT COPES|Individuals will receive standard agonist treatment plus access to the CBT4CBT-COPES website plus daily IVR assessment calls
41361446|NCT05341609|DRUG|JT001|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
41361447|NCT05341609|DRUG|Paxlovid|Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
41361448|NCT02600195|BEHAVIORAL|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
41361449|NCT01414686|OTHER|Commercially-Available Interactive Video Games|"Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours."
41361450|NCT03334682|DRUG|spironolactone|Dispensation of spironolactone at each visit according to the arm description described above.
41361451|NCT03334682|DRUG|Doxycycline|Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
41361452|NCT03142958|DEVICE|Integra Cadence Total Ankle System|Primary or revision on total ankle replacement
41361453|NCT01289730|DRUG|Etanercept|Etanercept 25 mg subcutaneously twice a week
41361454|NCT01025739|DEVICE|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
41025061|NCT03611803|DEVICE|Physiotherapy + Robotic-device|Daily use of an exoskeleton (robotic-device) on 5 successive days as well as daily physiotherapy sessions
41361455|NCT03958461|PROCEDURE|Anti-infective treatment of periodontal pockets|Removing calculi from teeths' periodontal pockets
41361456|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
41499061|NCT06028321|DRUG|Part 2 Group F (ACM-001.1 )|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
41025062|NCT03611803|OTHER|Physiotherapy only|Participants will engage in daily physiotherapy sessions (without the exoskeleton) and/or home-based sit-to-stand exercises
41361457|NCT02427412|DRUG|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
41025063|NCT04488731|BEHAVIORAL|Normal BMI and moderate coffee consumption|Normal BMI and moderate coffee consumption
41499062|NCT06028321|DRUG|Part 2 Group G (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
41499063|NCT06028321|DRUG|Part 1 Group 1 Regimen B (Pindolol)|Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
41499064|NCT06028321|OTHER|Part 1 Group 1 Regimen A (Placebo)|Placebo for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
41025064|NCT04488731|BEHAVIORAL|Normal BMI and heavy coffee consumption|Normal BMI and heavy coffee consumption
41499065|NCT06028321|OTHER|Part 2 Group E (Placebo)|"Placebo for oral use. Subjects were dosed over a four day treatment period twice daily.~Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D."
41499066|NCT06028321|OTHER|Part 2 Group F (Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
41025065|NCT04488731|BEHAVIORAL|overweight and moderate coffee consumption|overweight and moderate coffee consumption
41025066|NCT04488731|BEHAVIORAL|overweight and heavy coffee consumption|overweight and heavy coffee consumption
41025067|NCT00338338|DRUG|Lacidipine 4 or 6 mg (oral)|
41025068|NCT00338338|DRUG|Amlodipine 5 or 10 mg(oral)|
41025069|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum|The therapist will coach parents in the context of clinic-based play activities and help parents identify contexts and activities at home where the parents could follow up on the program at home. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
41361458|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
41361459|NCT04642326|DEVICE|Test Group: experimental - UVC Therapy applied|in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
41361460|NCT03891199|PROCEDURE|Robotic-Arm Assisted THA|The study will examine the acetabular cup placement of THA patients and compare results for patients who undergo THA with robotic-arm assistance with those who undergo traditional THA.
41361461|NCT03859115|PROCEDURE|TENS (transcutaneous electrical nerve stimulation)|transcutaneous nerve stimulation with electrical pulse generation
41361462|NCT03859115|PROCEDURE|sham intervention|sham stimulation without electrical pulse generation
41361463|NCT03487120|PROCEDURE|facet joint denervation|Bipolar electrocautery
41361464|NCT01051414|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24 weeks
41361465|NCT01051414|DRUG|BMS-650032|Tablets, Oral, 1200 mg, daily, 24 weeks
41361466|NCT05463315|DEVICE|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
41361467|NCT04932915|DRUG|Niclosamide|Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
41361468|NCT04932915|DRUG|Placebo|The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
41361469|NCT01146158|PROCEDURE|Axillary dissection for breast carcinomas|surgery Axillary dissection
41361470|NCT04693481|OTHER|nature exposure|Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.
41361471|NCT00160147|DRUG|bifeprunox|One week titration with dose adjustments
41361472|NCT00160147|DRUG|Placebo|Placebo
41361473|NCT04209140|DRUG|lithium treatment|"Decisions relating to treatment are also considered the clinician's responsibility to be made according to bipolar treatment guidelines and international standards of care (e.g. discontinuation, co-prescriptions, and according to SmPC in force). After the clinician has confirmed the indication of Lithium treatment as well as the absence of contra-indicated concomintant medication (NSAIDs and Diuretics) and after pre-~Lithium evaluations confirm the absence of contra-indication, Lithium is initiated following standard of care:~progressive titration to reach therapeutic plasma levels. Clinicians will use the therapeutic range provided by the laboratory they use in their usual clinical practice and according to the type of Lithium they prescribe."
41361474|NCT06167031|OTHER|chatbot facilitate teaching|"The experimental group will use chatbot to facilitate teaching."
41361475|NCT06167031|OTHER|lecture-based teaching|The control group only receives lecture-based teaching.
41361476|NCT05610865|OTHER|Control; Standard-of-care management|Patients will undergo conventional wound care management.
41361477|NCT05610865|BIOLOGICAL|Only PRP injection|Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.
41361478|NCT05610865|BIOLOGICAL|PRP + SVF injection|Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
41361479|NCT05610865|BIOLOGICAL|PRP + ASCs injection|Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
41361480|NCT01791543|DEVICE|Intramural Needle Ablation Catheter|
41361481|NCT03585829|DRUG|Hydrocortisone|at a substitutive dosage
41361482|NCT03585829|DRUG|Prednisolone|at a substitutive dosage
41361483|NCT04824599|PROCEDURE|PECS II|Pectoral nerves block (PECS II) is performed with the help of ultrasound. Two injection are performed in two fascial planes. One between pectoralis major muscle and serratus anterior muscle. Second one between pectoralis major and minor muscles.
41361484|NCT04824599|PROCEDURE|Local anesthetic infiltration|Ropivacaine is administered by surgeon prior to scrubbing and following the removal of the tumor.
41361485|NCT04824599|PROCEDURE|Subcutaneus local anesthetic infiltration|Ropivacaine is administered by the surgeon at the end of surgery
41361486|NCT04824599|DRUG|Ropivacaine|Local anesthetic ropivacaine is administered in both study arms according to the study protocol
41361487|NCT04824599|DEVICE|bk medical Flex Focus 500 Ultrasound Machine|Ultrasound with linear probe is performed. Using in-plane technique a correct placement of the injection needle is secured.
40840984|NCT04752189|BEHAVIORAL|Enhanced Replicating Effective Programs (Enhanced REP)|Deploy Enhanced REP to optimize the delivery of a drug use prevention intervention in community schools and test its feasibility, acceptability, and appropriateness; Enhanced REP includes tailoring the curriculum, training, and providing ongoing provider consultation, or facilitation, to support implementation.
40840985|NCT04752189|BEHAVIORAL|Standard implementation|Standard implementation of the Michigan Model for Health is akin to Standard REP and includes the curriculum materials, standard training and as-needed technical assistance.
40840986|NCT05647668|PROCEDURE|Laparoscopic fundoplication|Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.
40840987|NCT03649204|BEHAVIORAL|HY-PAD|Hybrid intervention that includes supervised on-site and home-based components in people with PAD
40840988|NCT01896271|DRUG|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
41160802|NCT03416335|DRUG|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
41361488|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 1)|Comparator
41361489|NCT04874129|DRUG|YYC506 (phase 1)|Test
41361490|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 2)|Comparator
41361491|NCT04874129|DRUG|YYC506 (phase 2)|Test
40840989|NCT01896271|RADIATION|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
40840990|NCT05378074|DRUG|Maxipost|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.
40840991|NCT05378074|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
40840992|NCT03301467|DRUG|Avacopan|Orally administered
40840993|NCT03301467|DRUG|Avacopan Matching Placebo|avacopan matching placebo
40840994|NCT02473276|DRUG|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
40840995|NCT02473276|DRUG|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
40840996|NCT04576689|DRUG|IBE-814 70ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
40840997|NCT04576689|DRUG|IBE-814 140ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
40840998|NCT01260545|DRUG|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
41361492|NCT02622217|BEHAVIORAL|Sleep deprivation|
41361493|NCT03559595|BEHAVIORAL|Project Prevent|The Project Prevent intervention entails 1) a media campaign to raise PrEP awareness, 2) geographically targeted education initiatives with medical personnel to increase access to consumers, and 3) programming with AIDS service organizations to improve service delivery around PrEP.
41361494|NCT02934282|DRUG|HBOC-201|Hemoglobin Based Oxygen Carrier (HBOC)
41361495|NCT05233319|OTHER|There is no intervention|There is no intervention
41361496|NCT01026558|DRUG|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
41361497|NCT03104361|BIOLOGICAL|Platelet-Rich Plasma|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
41361498|NCT01129219|OTHER|Strength training|Strength training for 24 weeks
41361499|NCT04697199|DRUG|Lactobacillus Reuteri Oral Drops|Subgingival delivery of probiotic suspension
41361500|NCT04697199|PROCEDURE|Scaling and root planing|Scaling and root planing using hand and ultrasonic instruments
41361501|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
41025070|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum - Telerehabilitation|Parent-child interactions during activities at home will be observed through video conferencing. Parents will be encouraged to interact with their child using strategies aimed at increasing their child's attention and motivation, turn-taking routines, initiating and responding to joint attention, communication, etc. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
41025071|NCT03046680|OTHER|Health Coaching|
41025072|NCT03046680|OTHER|Multiprofessional Team|
41025073|NCT05759091|BEHAVIORAL|cognitive defusion techniques|"Defusing from your delusions helps to lessen their negative impact on your behaviour. So defusion is a vital step towards being able to act flexibly, in accordance with core values, instead of being dictated to by inflexible rules, reasons, judgments etc. There are numerous exercises in ACT Companion with a focus on identifying unhelpful thoughts which would benefit from defusion, or building defusion skills, most of which are found in the open up section of the app. Some of these are reading and writing exercises, and some are guided meditation audio recordings.~ACT Companion defusion exercises~1. Letting go~2. Not good enough~3. Thought defusion~4. Observing your thoughts~5. Labelling thoughts and feelings~6. I am having the thought that.....~7. milk.milk.milk exercise~8. silly voice exercise, passenger on the bus, tug of war with a monster"
41025074|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
41025075|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
41025076|NCT04897048|PROCEDURE|Incremental exercise test (IET)|Incremental cardio pulmonary exercise test until exhaustion
40840999|NCT05710276|OTHER|abdominal infrared radiation|In a specific room (controlled temperature and humidity) with a patient lying on his back, we will determine the abdominal infrared radiation with a FLIR® thermal camera (without contact) and quantify the thermal signal by spectral analysis (in degrees Celsius).
40841000|NCT03322813|DEVICE|ExAblate 4000 - Type 2|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma undergoing resection
40841001|NCT02593656|BEHAVIORAL|High Protein|Protein-pacing throughout the day and exercise training for 12 weeks
40841002|NCT02593656|BEHAVIORAL|Normal Protein|Normal protein intake throughout the day and exercise training for 12 weeks
40841003|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm1 (patients wearing the complete denture for the first time)|Tongue pressure recordings during speech production, wet and dry swallowing tasks planned in 3 sessions, when the complete denture is worn for the first time, after 3 weeks, then after 3 months in order to characterise the adaptation to this new prosthesis.
40841004|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm2 (patients used to wear the complete denture)|These measures provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during speech production in patients used to their prosthesis. They also provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during swallowing) in these patients. The measurement is made at once when the new denture which replaces the old one is placed in the mouth.
40841005|NCT05349383|DRUG|Antibody-Drug Conjugate|"Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin."
40841006|NCT05349383|DRUG|Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate|We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
40841007|NCT05772156|DRUG|Methylergonovine|Methylergonovine 200mcg Intramuscular (IM)
40841008|NCT05772156|DRUG|Placebo|Matching saline placebo
40841009|NCT03623009|BEHAVIORAL|An article meant to trigger certain psychosocial behaviors|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
41025077|NCT04897048|PROCEDURE|Constant work rate exercise test (CWRET)|constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
41025078|NCT00007800|BEHAVIORAL|Behavioral Group Weight Loss Intervention|
41025079|NCT00007800|BEHAVIORAL|Motivational Interviewing|
41025080|NCT01455649|DRUG|Everolimus|Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).
41025081|NCT01455649|DRUG|calcineurin inhibitor|Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
41025082|NCT02106338|OTHER|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
41499067|NCT06028321|OTHER|Part 2 Group G ( Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
41025083|NCT02106338|DRUG|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
41160803|NCT03416335|DRUG|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
41160804|NCT02739490|PROCEDURE|Core Training Group|Performs oriented exercise segmental stabilization lumbar-pelvic.
41160805|NCT04807283|DEVICE|Left Atrial Appendage Closure|Closure or occlusion of the left atrial appendage to reduce the risk of thromboembolism in patients with NVAF
41160806|NCT02926495|DEVICE|eCoin System|Median nerve neurostimulator.
41499068|NCT05707754|DRUG|Bupivacaine|Topically applied to sphenopalatine ganglion
41499069|NCT05707754|DEVICE|angiocatheter|Introduced into nose to reach sphenopalatine ganglion nerve
41499070|NCT00482781|BIOLOGICAL|Infanrix|
40841010|NCT03623009|BEHAVIORAL|a neutral article|The control arm will receive a neutral article prior to completing the assessment.
40841011|NCT02463864|OTHER|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
41025084|NCT04506450|PROCEDURE|Peripheral nerve block|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during hip surgery.~Lumbar plexus and sciatic nerve blocks will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle and plantar or dorsal flexion of the foot will be detected respectively. For both, a mixture of mepivacaine and levobupivacaine will be injected.~Lateral femoral cutaneous nerve block will be performed with the ultrasound technique. After identifying the nerve, a needle will be inserted with an in plane approach and will be injected.~Lateral branch of iliohypogastric nerve block will be executed with the De Visme approach. Along the iliac crest (range between 7 and 11 cm from the anterior superior iliac spine) a needle will be inserted until bone contact is found. Then a mixture of mepivacaine and levobupivacaine will be injected."
41025085|NCT04506450|PROCEDURE|Spinal anesthesia|"In this group, spinal anesthesia will be performed to ensure anesthesia during surgery, while lumbar plexus block will be performed to ensure postoperative analgesia Spinal anesthesia will be performed with a 25 G needle and 12 mg 0.5% levobupivacaine will be injected.~Lumbar plexus block will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle will be detected. 20 ml 0.5% levobupivacaine will be injected."
41025086|NCT00054535|BIOLOGICAL|aldesleukin|
41025087|NCT00054535|BIOLOGICAL|recombinant fowlpox-tyrosinase vaccine|
41025088|NCT00054535|BIOLOGICAL|vaccinia-tyrosinase vaccine|
41025089|NCT01640301|BIOLOGICAL|Aldesleukin|Given SC
41025090|NCT01640301|DRUG|Cyclophosphamide|Given IV
41025091|NCT01640301|DRUG|Fludarabine Phosphate|Given IV
41025092|NCT01640301|OTHER|Laboratory Biomarker Analysis|Correlative studies
41025093|NCT01640301|BIOLOGICAL|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
41025094|NCT05843968|DRUG|Rituximab|"2 doses of rituximab 375 mg/m\^2(maximum 500mg/day) at 6 months intervals.~Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection."
41025095|NCT05843968|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50μg.h/ml. Total duration:1year.~Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks"
41025096|NCT03019952|BEHAVIORAL|Care Coordination Visit|This is a longitudinal study. Adolescents or young adults with autism will participate in this study. Participants will be required to complete a baseline of assessment measures at enrollment and then monthly assessments (described in the study procedures below) during the first (approximately) 10-15 minutes of each visit with the t-CARE coordinator. The remainder of the visit will focus on care coordination and clinical treatment goals.
41025097|NCT03042806|BEHAVIORAL|questionnaire|all the COPD patients will be ask to complete the questionnaire
41025098|NCT06240026|DEVICE|taVNS|transauricular vagal nerve stimulation electrodes (NEMOS, CerboMed GmbH, Erlangen, Germany), attached to a digitimer.
40841012|NCT02463864|OTHER|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
40841013|NCT03762447|DRUG|INCB086550|INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
40841014|NCT02707796|PROCEDURE|Hemicolectomy|
40841015|NCT05223387|DEVICE|Axiom TL REG|"Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
40841016|NCT05223387|DEVICE|Axiom BL REG|"Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
40841017|NCT00439881|DRUG|SB-681323|
41025099|NCT06240026|DEVICE|Earlobe Stimulation|Standard electrodes (Ambu, Neuroline, Bordeaux, France) cut into 0.5cm and 1cm rounds, attached to a digitimer.
41025100|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position
41025101|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position
41025102|NCT04596072|COMBINATION_PRODUCT|Chinese traditional rehabilitation|Chinese traditional rehabilitation including acupuncture and herbs
41025103|NCT03735966|DRUG|Pyrotinib plus trastuzumab and docetaxel and carboplatin|pyrotinib: 320mg orally daily，6cycles; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6cycles; docetaxel:after the biological window, 100mg/m2 for a total of 6 cycles carboplatin:d1 ，AUC 6 iv 3-weekly for a total of 6 cycles
41025104|NCT01089140|DRUG|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
41025105|NCT01089140|DRUG|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
41025106|NCT01089140|DRUG|Saline solution|Saline placebo
41025107|NCT00235534|BEHAVIORAL|Immediate initiation of OCPs|
41025108|NCT00235534|BEHAVIORAL|Delayed initiation of OCPs|
41025109|NCT01942382|DRUG|Paliperidone palmitate|Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
41361502|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
41361503|NCT06278831|OTHER|Questionnaire|Patients will be approached three times throughout the study at the beforementioned interview dates to fill out a questionnaire. They will be contacted via e-mail, telephone and/or mobile app.
41361504|NCT05681533|PROCEDURE|CT scan|coronary calcium score measurement by CT scan
41361505|NCT05135494|OTHER|Inspiratory Muscle Training|"The Experimental Group will perform IMT which includes training of the inspiratory muscles with the PowerBreath Medic Plus regulated at 75% of the subjects' maximal inspiratory pressure (MIP) values, five times/week over five weeks 5 sets of 5 repetitions with 1 set increasing each week.~They will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA."
40841018|NCT01310478|DRUG|recombinant human endostatin (Endostat)|mFOLFOX6:Oxaliplatin 85 mg/m2 d1 Leucovorin 400 mg/m2 d1+5-FU 400 mg/m2 bolus d1+5-FU 2.4 CIV 46h Endostar 7.5mg/m2/d～45mg/m2/d continous intravenous d4～d14
40841019|NCT00167388|OTHER|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
40841020|NCT02161926|OTHER|dietary restrictions|Dietary restrictions during 8 weeks
40841021|NCT03407885|OTHER|Bundled payments for knee and hip replacement|"The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices."
40841022|NCT05113914|DIAGNOSTIC_TEST|Cardio-pulmonary exercise test|An incremental running test was conducted on the treadmill. Initially, the exercise protocol included standing still for 3 min and walking for 3 min at a constant speed of 4 km/h. After this introductory part, the speed was increased to 8 km/h and then every 3 min by 2 km/h until the volitional exhaustion was reached. During all procedure oxygen consumption was measured with the use of a portable breath-by-breath ergospirometer.
40841023|NCT03802903|DEVICE|Remo-Wax|topical treatment
40841024|NCT04712552|PROCEDURE|deep brain stimulation|"On the day of surgery, under general anesthesia, a Fischer ZD frame will be attached to the skull. A T1-weighted 3D MRI with gadolinium will be performed.~Investigators will plan on this MRI, anatomical targets and deep brain trajectories using the NeuroInspire surgical planning software.~The patient will be attached to the base of the robot through the frame. Registration will be performed using the Neurolocate method after the acquisition of 3D CT images using the O-arm. The Neurolocate recording is based on radiographic images.The 3D MRI will be merged with the 3D tomography images taken with the O-arm to co-register the trajectories planned on the MRI in the robot space The surgical procedure will be performed as usual by milling the bone at the entry point and inserting under robotic guidance an electrode through a guide tube to the intended target."
40841025|NCT05642507|DRUG|AC01|AC01 microtablets
41361506|NCT05135494|OTHER|Control|The control group will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA.
41361507|NCT04843189|PROCEDURE|Da Vinci Robotic Surgery|Da Vinci Robotic Surgery
41025110|NCT05626361|OTHER|Dysphagia training|Training using PowerPoint and simulation. Training includes anatomy physiology, screening and management sections. Simulation will be used for practice. Reading material will also be provided
41499071|NCT00482781|BIOLOGICAL|Pediatrix|
41499072|NCT01604135|DEVICE|Corneal Collagen Crosslinking|Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
41499073|NCT06549283|DEVICE|Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation|Researchers applied NIPPV treatment using binasal cannulas through a mechanical ventilator during intubation.
41499074|NCT04601610|DRUG|KN046 （PD-L1/CTLA4 BsAb）|KN046 5mg/kg Q3W
41499075|NCT04601610|DRUG|Ningetinib Tosylate（multi-target TKI）|ningtinib QD, dose will be decided by investigator
41499076|NCT00933361|DRUG|ghrelin|As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8μg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 μg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 μg/kg Dose level 2 = 48 μg/kg Dose level 3 = 72 μg/kg Dose level 4 = 108 μg/kg Dose level 5 = 135 μg/kg Dose level 6 = 169 μg/kg Dose level 7 = 211 μg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.
41499077|NCT01449448|DRUG|Ketorolac|Subacromial injection
41499078|NCT01449448|DRUG|Triamcinolone|Subacromial Injection
40841026|NCT00989781|RADIATION|3-D Ultrasound|One time pelvic ultrasound
40841027|NCT00989781|DRUG|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
40841028|NCT00989781|DRUG|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
41025111|NCT05626361|OTHER|Reading material|Reading material provided to nurses covering knowledge related to nursing evaluation and caring for dysphagia patients
41025112|NCT00771680|DRUG|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
41160807|NCT00357318|DRUG|sunitinib malate|Given PO
40841029|NCT00989781|DRUG|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
40841030|NCT00989781|DRUG|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
40841031|NCT00989781|DRUG|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
41025113|NCT00771680|DRUG|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
41025114|NCT00771680|DRUG|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
41025115|NCT03108339|OTHER|Guideline recommended physiotherapy care|The intervention will follow current care i.e. guideline informed intervention used by physiotherapists in the treatment of LBP in primary health care. The intervention will use a pragmatic approach and follow a framework of: 1) information of return to activity and to stay active 2) instruction on posture in loaded and unloaded positions 3) information on work and leisure based positions in activity and sitting 4) information on good sleeping position 4) instruction of an individualized exercise program based on findings from the examination enhancing core control 5) a choice of exercises as a home training program. Manual methods may if necessary be used. Choice of treatment, choice of exercises (loaded, unloaded) and also number of treatments is logged and noted.
41025116|NCT02264223|DIETARY_SUPPLEMENT|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
41025117|NCT02264223|DIETARY_SUPPLEMENT|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
41025118|NCT03153332|OTHER|surgical residents' comprehension of the hepatic anatomy|Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
41025119|NCT02569047|PROCEDURE|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
41025120|NCT02569047|PROCEDURE|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
41025121|NCT00003863|GENETIC|comparative genomic hybridization|
41025122|NCT00003863|GENETIC|cytogenetic analysis|
41025123|NCT00003863|GENETIC|fluorescence in situ hybridization|
41025124|NCT00003863|GENETIC|gene rearrangement analysis|
41025125|NCT01709227|DRUG|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output \>1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
41025126|NCT01709227|PROCEDURE|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
41160808|NCT00357318|BIOLOGICAL|bevacizumab|Given IV
41160809|NCT00357318|OTHER|pharmacological study|Correlative studies
41361508|NCT03607968|PROCEDURE|The novel anterior TVM surgeries|A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
40841032|NCT02894450|OTHER|blood test|bioassay xaban
40841033|NCT03952715|DRUG|Ibuprofen 400 mg|Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.
41160810|NCT00357318|OTHER|laboratory biomarker analysis|Correlative studies
41160811|NCT02018471|BEHAVIORAL|Psychoeducative training|The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
41160812|NCT06079424|OTHER|high-precision carotid echo-tracking|evaluation of vascular aging parameters and baroreflex sensitivity
41160813|NCT00359385|DRUG|Alendronate 70mg weekly|70mg weekly
41160814|NCT00629317|OTHER|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
41160815|NCT00629317|DRUG|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
40841034|NCT03952715|DRUG|Placebo oral tablet|Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
40841035|NCT05568550|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.
40841036|NCT05568550|DRUG|Olaparib|200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.
40841037|NCT05568550|DRUG|Androgen Deprivation Therapy|Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
40841038|NCT05568550|RADIATION|Radiation Therapy|Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.
40841039|NCT01106274|RADIATION|ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
40841040|NCT02380898|DRUG|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
40841041|NCT02380898|DRUG|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
40841042|NCT05951712|DRUG|Simethicone 150mg|Impact of simethicone on the mucosal visibility of stomach and duodenum
41160816|NCT02367664|BIOLOGICAL|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
41160817|NCT02367664|BIOLOGICAL|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
41361509|NCT04843228|BEHAVIORAL|Cognitive Bias Modification|There will be four sessions of CBM. Each session will consist of two different part. The first part of the intervention will be the training based on the ambiguous scenario paradigm for perfectionism developed by Dodd (2019). Participants will need to complete word fragments in the last part of the scenario to resolve the ambiguity of the scenario. Then, a comprehension question will be presented to them to underscore the interpretation condition. Feedback will be given after each question. For the second part of the intervention aimed to intervene intolerance to uncertainty, word sentence association paradigm for intolerance to uncertainty developed by Oglesby (2017) will be used. In this intervention, participants will be asked to judge the relatedness of words and sentences which will be presented to them. Feedback will be given after each word-sentence.
41499079|NCT05385965|BEHAVIORAL|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants reduce pain interference so that they can engage with what gives them a sense of meaning, purpose, and peace.
41499080|NCT03777618|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two differents well-known flaps for gluteal augmentation
40841043|NCT05951712|DRUG|N Acetyl cysteine 600mg|Impact of N Acetyl cysteine on the mucosal visibility of stomach and duodenum
40841044|NCT05951712|DRUG|Simethicone 150mg plus N Acetyl cysteine 600 mg|Impact of simethicone plus N Acetyl cysteine on the mucosal visibility of stomach and duodenum
40841045|NCT05951712|OTHER|Placebo|Impact of water on the mucosal visibility of stomach and duodenum
41499081|NCT00062985|BEHAVIORAL|Mail-based weight loss intervention|
41499082|NCT00062985|BEHAVIORAL|Phone-based weight loss intervention|
41499083|NCT05719792|PROCEDURE|Transforaminal Epidural Steroid Injection|In the TFESI group, all patients were positioned prone. The injection site was cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) was applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle was inserted just below the pedicle. It was advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position was confirmed through a lateral view. Using lateral views, the needle was placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized. Once the epidural distribution of the contrast agent was confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 2 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride was injected.
41499084|NCT05719792|PROCEDURE|Erector Spina Plane Block|Patients are placed in the prone position to determine the vertebrae in the middle of the involved area. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a high-frequency (8 MHz) linear ultrasound (USG) probe. The transverse process is, then, visualized approximately at the 3 cm lateral from the midline and the erector spinae muscle is visualized on it. The 22-gauge 50 mm block needle is advanced towards the in-plane section craniocaudally and the transverse process is touched. Then the needle is then withdrawn minimally to confirm that it is between the erector spinae muscle and the transverse process through hydrodissection. Following that, 5 mL from 0.5% bupivacaine hydrochloride, 8 mg dexamethasone and 3 ml saline is administered and local anesthetic spread is confirmed by USG.
41499085|NCT05776823|BEHAVIORAL|Pharmacist Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
41499086|NCT05776823|BEHAVIORAL|BIRT|BIRT participants will receive a 30-45-minute session delivered by the pharmacist to introduce and encourage treatment options, MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials), and a referral to treatment/linkage to service providers.
40841046|NCT04705948|DRUG|Magnesium sulfate versus ketamine|Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation
40841047|NCT00003658|BIOLOGICAL|filgrastim|
40841048|NCT00003658|BIOLOGICAL|rituximab|
40841049|NCT00003658|DRUG|cyclophosphamide|
40841050|NCT00003658|DRUG|pentostatin|
40841051|NCT02320344|BEHAVIORAL|Partners in Care|"The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications."
40841052|NCT04563013|DEVICE|Transcutaneous vagus nerve stimulation|the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
40841053|NCT03022981|DRUG|SOF/VEL|SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
40841054|NCT03022981|DRUG|SOF/VEL|SOF/VEL FDC 200/50 mg oral granules
41025127|NCT01159418|DRUG|Panobinostat (LBH589), Carboplatin and Paclitaxel|"1. Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~2. Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~3. Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression."
40841055|NCT00979225|OTHER|Medication Management report|Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.
40841056|NCT00979225|OTHER|Care manager email notices|Community-based care managers receive email notices if the patient has not seen his/her primary care provider in the past 6 months, has low adherence to medications, and has no scheduled appointment.
41025128|NCT06037759|DIAGNOSTIC_TEST|Cardiac Biomarkers|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
41025129|NCT06037759|DIAGNOSTIC_TEST|Lipidomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
41025130|NCT06037759|DIAGNOSTIC_TEST|Proteomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
41025131|NCT05520138|DRUG|Enzalutamide|As provided in real-world setting
41025132|NCT05520138|DRUG|Abiraterone acetate|As provided in real-world setting
41025133|NCT03296189|DRUG|Levobupivacaine|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
41025134|NCT03296189|DRUG|Dexamethasone Sodium Phosphate|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
41025135|NCT03296189|DRUG|Placebos|10 mls normal saline
41025136|NCT03407352|BEHAVIORAL|Active Video Game Play|60 minutes of active video game play at a moderate intensity
41025137|NCT03407352|BEHAVIORAL|Passive Video Game Play|60 minutes of passive video game play
41025138|NCT04599881|DRUG|PTR-01|IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
41160818|NCT02367664|BIOLOGICAL|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
41266699|NCT04323371|DIAGNOSTIC_TEST|ELISA|Blood and derived fluids will be collected from 26 ADHF CS patients admitted to intensive care at Niguarda Hospital and locally stored.Stocked samples will be shipped to the Central Laboratories at Milano Uni and MilaIFC-CNR for the metabolomic and biomarkers analysis,respectively.To evaluate interleukin-6 (marker of systemic inflammation),angiopoietin-2 (marker of endothelial permeability), syndecan-1 and heparan sulfate (markers of endothelial glycocalyx),2 aliquotes of serum samples will be used by IFC CNR.The biomarkers will be assessed through ELISA analytical techniques, based on the interactions inside a microplate between a primary pre-coated antibody and the specific protein contained in serum samples.A secondary antibody, link to a horseradish peroxidase (HRP) detection system, is able to recognize and bind the antigen, and to produce a colorimetric reaction after the addition of enzyme substrate which is proportional to the amount of the target protein bound
41361510|NCT04843228|BEHAVIORAL|Cognitive Bias Modification for Control Group|For the first part of the intervention, the control group will be presented with the same procedures as the active group; however, feedbacks will be given to resolve the scenarios in a neutral way. When it comes to the second part of the intervention, different word-sentence pairings will be presented to the control group.
41361511|NCT00389922|DRUG|lapatinib ditosylate|Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
40841057|NCT00803062|BIOLOGICAL|Bevacizumab|Given IV
40841058|NCT00803062|DRUG|Cisplatin|Given IV
41361512|NCT00389922|DRUG|vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
41361513|NCT00389922|GENETIC|comparative genomic hybridization|Molecular correlative study
41361514|NCT00389922|GENETIC|cytogenetic analysis|Molecular correlative study
41361515|NCT00389922|GENETIC|gene expression analysis|Molecular correlative study
40841059|NCT00803062|OTHER|Laboratory Biomarker Analysis|Correlative studies
40841060|NCT00803062|DRUG|Paclitaxel|Given IV
40841061|NCT00803062|OTHER|Quality-of-Life Assessment|Ancillary studies
40841062|NCT00803062|OTHER|Questionnaire Administration|Ancillary studies
40841063|NCT00803062|DRUG|Topotecan Hydrochloride|Given IV
40841064|NCT06533930|OTHER|Transorbital Sonography|OND and ONSD of participants in the MS patient group and healthy control group were measured by TOS.
40841065|NCT06533930|OTHER|Orbita Magnetic Resonance Imaging|OND and ONSD of participants in the MS patient group were measured by orbita MRI.
41361516|NCT00389922|GENETIC|mutation analysis|Molecular correlative study
41361517|NCT00389922|GENETIC|polymerase chain reaction|Molecular correlative study
41361518|NCT00389922|GENETIC|polymorphism analysis|Molecular correlative study
41361519|NCT00389922|GENETIC|proteomic profiling|Molecular correlative study
41361520|NCT00389922|GENETIC|reverse transcriptase-polymerase chain reaction|Molecular correlative study
41361521|NCT00389922|OTHER|immunohistochemistry staining method|Molecular correlative study
41361522|NCT00389922|OTHER|laboratory biomarker analysis|Molecular correlative study
41361523|NCT00389922|DRUG|lapatinib ditosylate|Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
41361524|NCT00389922|DRUG|Vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
41361525|NCT04628585|OTHER|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
41361526|NCT04812457|DRUG|Hialucic|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
41361527|NCT04812457|DRUG|Betadine gel|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the control group, Betadine Gel will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
41361528|NCT04126759|DEVICE|P0.3|Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.
41361529|NCT02744963|OTHER|Free and convenient medicine access|
41361530|NCT05237843|DRUG|Hydroxychloroquine|Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
41361531|NCT01102439|DRUG|Clopidogrel|300 mg loading dose, then 75 mg daily
41361532|NCT01102439|DRUG|Clopidogrel|600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
41361533|NCT01102439|DRUG|Aspirin|81 mg daily
41361534|NCT01102439|DRUG|Aspirin|325 mg daily
40841066|NCT06533930|OTHER|Visual Evoked Potentials|P100 amplitude and P100 latency values of participants in the MS patient group were measured by VEP.
40841067|NCT06533930|OTHER|Optical Coherence Tomography|pRNFL thickness of participants in the MS patient group were measured by OCT.
40841068|NCT02668029|DRUG|oxygen|information already included in arm/group descriptions.
41266700|NCT05943080|DRUG|PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|The application is made into the anatomical space between the posterior capsule and the popliteal artery before implantation.
41266701|NCT05943080|DRUG|IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|It is applied to the anatomical space between the posterior capsule and the popliteal artery with the help of USG.
41361535|NCT01177943|DRUG|Atomoxetine|Administered orally, once.
41361536|NCT00769821|OTHER|questionnaire administration|
41361537|NCT00769821|PROCEDURE|assessment of therapy complications|
41361538|NCT00769821|PROCEDURE|bioimpedance spectroscopy|
41499087|NCT05776823|BEHAVIORAL|SMC|SMS participants will receive a 5-10-minute counseling session delivered by the pharmacist providing MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials).
41499088|NCT05776823|BEHAVIORAL|Substance Use Counselor Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
40841069|NCT02668029|DRUG|medical air|Placebo
41361539|NCT00769821|PROCEDURE|quality-of-life assessment|
41361540|NCT03303144|DRUG|Triferic|ferric pyrophosphate citrate
41361541|NCT01974414|DRUG|orally administered cedar honey|
41361542|NCT01047631|BEHAVIORAL|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Exercise classes \& activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period."
40841070|NCT06530719|DRUG|Osimertinib mesylate|Osimertinib mesylate , 80mg QD，until the duration of treatment reaches 3 years, the disease progresses, or other treatment termination criteria are met
40841071|NCT01105585|DEVICE|Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
40841072|NCT01105585|DEVICE|AcrySof Natural IQ (SN60WF) IOL|AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
40841073|NCT00523497|DEVICE|Non invasive mechanical ventilation|
41266702|NCT05943080|DRUG|ACB ( 0.25% marcaine + %0.9 saline)|It is inserted into the adductor canal by simultaneous imaging of the needle, accompanied by ultrasonography, from the level just below the sartorius muscle.
41266703|NCT03079440|DRUG|TEMCAP|Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
41499089|NCT03207243|DRUG|GSK3772847|GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
40841074|NCT02662179|OTHER|Quality of life evaluation|Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
40841075|NCT02662179|OTHER|Functional decline assessment|Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
40841076|NCT02662179|OTHER|Physical decline assessment|Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
40841077|NCT02662179|OTHER|Cognitive decline assessment|Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
40841078|NCT03459053|BEHAVIORAL|CBART|Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
40841079|NCT02067494|OTHER|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
40841080|NCT02067494|OTHER|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
41025139|NCT06312098|OTHER|remote ischemic preconditioning (RIPC)|After induction of anesthesia, the paired RIPC group took the RIPC intervention on the upper arm in the lateral position. The RIPC intervention was applied using a manual cuff inflator, which consisted of three cycles of 5-min inflation of the blood pressure cuff (to 250 mmHg, or to 50 mmHg higher than the preoperative SBP), followed by 5-min deflation of the cuff. In the no-RIPC group, a blood pressure cuff was also applied on the upper arm but was not inflated.
41266704|NCT01016873|DEVICE|IRay|Low voltage stereotactic radiotherapy system
41361543|NCT01047631|BEHAVIORAL|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support"
41499090|NCT03207243|DRUG|Placebo|Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
41499091|NCT03207243|DRUG|Fluticasone propionate/salmeterol|FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.
40841081|NCT02477553|BEHAVIORAL|DA - Quantitative|
40841082|NCT02477553|BEHAVIORAL|DA - Verbal|
40841083|NCT04229836|DRUG|Tildrakizumab 100 mg Solution for Injection|Participants will be treated with tildrakizumab 100 mg.
40841084|NCT05383534|DRUG|Propofol Injection|propofol injections were used for the induction of anesthesia according to the body weight of the patients.
41499092|NCT03207243|DRUG|Fluticasone propionate|FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
41499093|NCT05404334|DIAGNOSTIC_TEST|Androgen receptor status and BRCA mutation|Androgen receptor status by IHC and germ line BRCA mutation
41499094|NCT05405348|BEHAVIORAL|Intervention|The patients did not eat anything during hemodialysis.
40841085|NCT01697943|PROCEDURE|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
40841086|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with or without a boost of 10 Gy in 5 fractions to the cavity.
40841087|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
41025140|NCT06183229|DRUG|Cycloferon|Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
41025141|NCT06183229|DRUG|Placebo|Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
41025142|NCT05387759|DRUG|Aticaprant Supratherapeutic Dose|Aticaprant supratherapeutic dose capsule will be administered orally.
41025143|NCT05387759|DRUG|Aticaprant Therapeutic Dose|Aticaprant therapeutic dose capsule will be administered orally.
41025144|NCT05387759|DRUG|Placebo|Placebo will be administered orally.
41025145|NCT05387759|DRUG|Moxifloxacin|Moxifloxacin capsule will be administered orally.
41266705|NCT00427362|DRUG|Adalimumab|
41266706|NCT03514082|DEVICE|Rigid Thermoplastic Spinal Brace|Custom made rigid thermoplastic brace with 23 hours daily wearing time.
41266707|NCT01227967|DRUG|Amantadine, Ribavirin, Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
41499095|NCT04320251|PROCEDURE|cochlear implant revision surgery|Observation during routine cochlear implant revision surgery
41499096|NCT06632418|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
41499097|NCT06323980|DEVICE|Reverse Total Shoulder|Uncemented Reverse Total Shoulder
41499098|NCT04241315|DRUG|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
41499099|NCT04241315|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
41499100|NCT05854810|PROCEDURE|fertilized embryo Insertion|insertion of single fertilized embryo through IVF
41499101|NCT05854810|PROCEDURE|fertilized embryo Insertion|insertion of double fertilized embryo through IVF
41025146|NCT01332305|DRUG|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
41025147|NCT01332305|DRUG|Placebo|Placebo orally once daily
41025148|NCT05209893|OTHER|Telerehabilitation|Application based video home exercise for the knee osteoarthritis
41499102|NCT06299917|OTHER|WORK-ON|The intervention includes three parts: 1) a coordinating occupational therapist, 2) four group sessions and 3) Individual consultations based on the agreed upon goals.
41499103|NCT00386633|BIOLOGICAL|MVA-mBN32|3 immunizations; first study group: 10E7_TCID50
41499104|NCT00386633|BIOLOGICAL|MVA-mBN32|3 immunizations; second study group: 10E8_TCID50
41499105|NCT04077918|DIETARY_SUPPLEMENT|protein diet|100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
41499106|NCT05943808|OTHER|Book reading|subjects are given an acupuncture textbook to read for 30 minutes
41499107|NCT05943808|OTHER|VR pre-recorded video watching|subjects are given an pre-recorded VR video to watch for 30 minutes
41499108|NCT00492024|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
41499109|NCT00492024|DRUG|Placebo|Placebo - 380 mg Microcrystalline Cellulose
41499110|NCT03335215|OTHER|cognitive remediation|The innovative nature of this program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains that may have an impact on the maintenance of the therapeutic contract will be offered to patients. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context. The different procedures of neuropsychological management (facilitation, use of preserved capacities and compensation) will help to integrate the concepts and addictological strategies necessary to maintain the therapeutic contract taking into account cognitive impairments.
41499111|NCT00824616|DRUG|MK-0941|MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
41499112|NCT00824616|DRUG|Placebo|Placebo tablets, taken 3 times daily.
41499113|NCT00824616|DRUG|Insulin|Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
41499114|NCT06633692|OTHER|Head down tilt (HDT)|In the head-down tilt intervention, a participant is positioned on a tilt table, initially in supine position and afterwards with their head inclined downward at a specific angle. This position causes a shift of body fluids towards the head, mimicking the fluid redistribution observed in microgravity conditions in space.
41499115|NCT04005014|OTHER|Myopia prediction algorithm|Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
41499116|NCT02373189|DEVICE|Bright light|The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
41499117|NCT03729817|DEVICE|Submaximal balloon angioplasty|An endovascular procedure involving inflation of a balloon catheter undersized to 50-75% of normal vessel diameter to perform angioplasty of a stenotic blood vessel segment, with the goal of increasing blood flow.
41499118|NCT01027338|OTHER|Tai chi exercise|
41499119|NCT05090488|BEHAVIORAL|Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
41499120|NCT03516253|DIETARY_SUPPLEMENT|Fish oil + EPO|Supplementation with both fish oil and EPO
41499121|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
41025149|NCT05209893|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the knee osteoarthritis
41025150|NCT06228092|DRUG|neostigmine/glycopyrrolate|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
41025151|NCT06228092|DRUG|Sugammadex|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
41025152|NCT05767970|BEHAVIORAL|Integrated Stress Toolbox for Healthcare Providers (ISTH)|The ISTH is a 12-week meditation-based well-being training. In weeks 1-8, participants engage in weekly 2-hour class sessions that are recorded and posted on a private Youtube channel for one week. There is a final two-hour session at week 12. In-class learning is augmented and extended through content in a special version of the Healthy Minds Program smartphone app that participants are asked to use on a daily basis throughout the intervention.
41025153|NCT03793101|PROCEDURE|BiMICS|Biaxial microincision cataract surgery implies performing of 2 corneal incisions under 1.8mm, removal of the crystalline lens with the use of ultrasounds and implantation of the artificial intraocular lens.
41025154|NCT04313153|DRUG|Vadadustat|oral tablets
41025155|NCT04313153|DRUG|Darbepoetin alfa|intravenous or subcutaneous solution
40841088|NCT00681993|OTHER|Standard Dose Dense Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
40841089|NCT00681993|OTHER|Standard Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
40841090|NCT00681993|OTHER|Standard Docetaxel, Carboplatin, and Herceptin|6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
40841091|NCT00681993|OTHER|Standard Docetaxel, Doxorubucin and Cyclophosphamide|3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
40841092|NCT00681993|OTHER|Standard Docetaxel and Cyclophosphamide|4 cycles of Standard Docetaxel and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
40841093|NCT06256705|OTHER|Simultaneous 68Ga-DOTATOC PET-MRI|on month before first cycle of 177Lu-DOTATATE, after second cycle and one year after first cycle
40841094|NCT01024192|DRUG|ZOLPIDEM SL800750|"Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)"
40841095|NCT01274429|DRUG|Peanut flour|Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
40841096|NCT06455748|DRUG|Daratumumab/daratumumab and hyaluronidase-fihj|Daratumumab/daratumumab and hyaluronidase-fihj: Dara SC 1800mg subcutaneous (IH) or Dara 16mg/kg intravenously (IV) administered weekly (qwk) x 4 every 2 weeks X 3 doses per month starting C7.
40841097|NCT06455748|DRUG|Pomalidomide|Pomalidomide: pom 2-4mg PO day (D) 1-21/28 (adjust dose for renal function).
40841098|NCT06455748|DRUG|Dexamethasone|Dexamethasone: dex C1: 20mg IV D1/8, 20mg PO D2/9 and 40mg PO C1D15 weekly up to C6, then 20mg IV monthly starting C7D1 and 20mg PO D8, 15, 22.
40841099|NCT05728281|OTHER|Recommended time after hysterectomy|Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.
40841100|NCT04969536|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Supplementation with 8 g Nutrex Research Amino Acid Drive BCAA in 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
40841101|NCT04969536|OTHER|Placebo|Supplementation with 2.0 milliliters of a sucralose-based drink mix with 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
40841102|NCT02008357|DRUG|Placebo|Administered IV
40841103|NCT02008357|DRUG|Solanezumab|Administered IV
41025156|NCT05075317|BEHAVIORAL|Standard cardiac rehabilitation|Standard, multi-dimensional cardiac rehabilitation program.
41499122|NCT01103830|DRUG|Riamet®|4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
40841104|NCT03948919|DRUG|Fecal microbiota|Lyophilized encapsulated fecal microbiota given daily for 8 weeks.
40841105|NCT03948919|OTHER|Placebo|Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.
41025157|NCT05075317|BEHAVIORAL|Time-Restricted Eating|Counselling to restrict their eating to between 11 am and 7 pm and to consume water-only for the remaining 16 hours per day
41025158|NCT01295606|DRUG|Cefazolin|iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
41025159|NCT01525082|DRUG|Capecitabine|Capecitabine by mouth twice daily on Days 1 to 14
41025160|NCT01525082|DRUG|Temozolomide|Temozolomide by mouth daily on Days 10 to 14
41025161|NCT01525082|BIOLOGICAL|Bevacizumab|Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15
41025162|NCT03434717|OTHER|Individualised rehabilitation|Patients will get access/support to individualised rehabilitation based on their needs identified through the distress thermometer
41025163|NCT03434717|OTHER|Care as usual|Patients will get care as usual
40841106|NCT04570189|DEVICE|Auscul-X|The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously
41499123|NCT01103830|OTHER|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning."
40841107|NCT01399008|DRUG|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
40841108|NCT01399008|DRUG|Allopurinol|Allopurinol 300 mg as active comparator
40841109|NCT01399008|DRUG|Colchicine|0.6 mg colchicine daily as flare prophylaxis
40841110|NCT01399008|DRUG|Placebo|Placebo
40841111|NCT00265018|DRUG|Adriamycin|
40841112|NCT00265018|DRUG|Bleomycin|
40841113|NCT00265018|DRUG|Vinblastine|
40841114|NCT00265018|DRUG|DTIC|
40841115|NCT00265018|RADIATION|30 Gy IF-RT|
40841116|NCT00265018|RADIATION|20 Gy IF-RT|
40841117|NCT04597840|PROCEDURE|Incisional hernia repair with reinforcement of biosynthetic mesh|The biosynthetic mesh (Phasix or Bio-A meshes) will be placed as a sublay in the retromuscular position to reinforce midline fascial closure. All the surgical procedure (including placement and fixation of the mesh) will be performed according to a standardized protocol.
40841118|NCT04597840|PROCEDURE|Incisional hernia repair with simple suture or synthetic mesh reinforcement.|Based on the discretion of the surgeon, the incisional hernia repair will be done by simple suture or by synthetic mesh reinforcement. All the surgical procedure (including placement and fixation of the mesh if applicable) will be performed according to a standardized protocol.
40841119|NCT04498351|DRUG|Control Test|"Spermatic cord block by18ml levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.~The procedure is repeated on the contralateral side."
40841120|NCT04498351|DRUG|Dexmedetomidine|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml The procedure is repeated on the contralateral side.
40841121|NCT04498351|DRUG|Dexmedetomidine and magnesium sulphate|"Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .~The procedure is repeated on the contralateral side."
41499124|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
40841122|NCT04498351|DRUG|magnesium sulphate|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 100 mg magnesium sulphate in 2 ml in total volume of 20 ml
41499125|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
41499126|NCT01103830|OTHER|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning."
40841123|NCT05047575|OTHER|REASSURE|REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.
40841124|NCT05575908|PROCEDURE|Digital expert team|A digital team will be appointed based on the participant's answers in the digital screening questionnaire. Members of the team can be specialists in Physical and rehabilitation medicine, psychologist, physiotherapist, social workers, and consultants in the labor- and welfare administration. The general practitioner will also be invited to the meeting.
40841125|NCT06299176|OTHER|Whole Heart Radiation Therapy|Radiation to the whole heart in one treatment with a prescribed dose of 5 Gy.
40841126|NCT03166111|DRUG|lidocaine gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
40841127|NCT03166111|DRUG|placebo gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
40841128|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
40841129|NCT01763294|DEVICE|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
41025164|NCT05341089|DRUG|LY3502970|Administered orally.
41499127|NCT01835054|OTHER|Blood biomarkers|Observational Study using Imaging and Biomarkers
41499128|NCT01835054|GENETIC|DNA collection|Observational Study using Imaging and Biomarkers
41499129|NCT01835054|OTHER|Echocardiography|Observational Study using Imaging and Biomarkers
41025165|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose1|Tablet,dose1,QD
41025166|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose2|Tablet,dose1, dose2 QD
41025167|NCT04180982|DRUG|SHR4640 dose2 plus Febuxostat dose3|Tablet,dose2, dose3 QD
41361544|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
41361545|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
41361546|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
41361547|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
41361548|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
41361549|NCT03448458|PROCEDURE|CT (Computed Tomography)|Undergo PET/CT
41361550|NCT03448458|DRUG|Gallium Ga 68-DOTATATE|Given IV
41361551|NCT03448458|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41361552|NCT01370499|DRUG|LY2216684|
41361553|NCT01370499|DRUG|SSRI|Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.
41361554|NCT04554888|DRUG|Doxepin Topical|Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
41361555|NCT04554888|DRUG|Papain|Papain will be applied by 1 SPT prick thought the skin
41361556|NCT04554888|DRUG|Histamine|Histamine will be applied by 1 SPT prick thought the skin
41361557|NCT04554888|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
41361558|NCT04335552|OTHER|Standard of care|Standard of care
41361559|NCT04335552|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5
41361560|NCT04335552|DRUG|Azithromycin|Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
41361561|NCT05261321|DRUG|Cannabis oil with a high ratio of THC to CBD|In the first active condition, cannabis oil with a high THC to CBD ratio will be administered to participants.
41361562|NCT05261321|DRUG|Cannabis oil with a high ratio of CBD to THC|In the second active condition, cannabis oil with a high CBD to THC ratio will be administered to participants.
41361563|NCT05261321|DRUG|Placebo|In the control condition, the placebo will be administered to participants.
41361564|NCT01531049|DRUG|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
41361565|NCT01531049|DRUG|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
41361566|NCT01531049|DRUG|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
41361567|NCT01531049|OTHER|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
41361568|NCT00003524|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41361569|NCT04244227|DEVICE|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
41361570|NCT03365401|PROCEDURE|decompression surgery|undertake decompression surgery
41361571|NCT03365401|PROCEDURE|nonsurgical treatment|complete on bed with prevention of complication
41361572|NCT03747497|DRUG|contezolid acefosamil|IV and oral contezolid acefosamil given twice a day for 10 to 14 days
41361573|NCT03747497|DRUG|linezolid 600 mg|IV and oral linezolid given twice a day for 10 to 14 days
41025168|NCT04806815|OTHER|A survey of 60 questions was created through the internet-based 'Google Forms surveys' site.|"The following tests will be used together with the survey;~* Menstrual Symptom Questionnaire~* Fatigue Severity Scale~* Short Form Of Coronavirus Anxiety Scale"
41025169|NCT02041455|DRUG|Melatonin and Placebo|
41025170|NCT02041455|DRUG|Amitriptyline and Placebo|
41025171|NCT02041455|DRUG|Melatonin and Amitriptylin|
41025172|NCT06532539|DRUG|Paclitaxel and Cisplatin|"Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Duration: 6-8 cycles, until disease progression or intolerable adverse effects as judged by the investigator.~Alternative: If contraindicated for cisplatin, or if there is an allergy to paclitaxel and/or cisplatin, alternative drugs such as different types of paclitaxel or carboplatin can be used."
41025173|NCT06532539|DRUG|Cadonilimab|Cadonilimab: 5-10 mg/kg, intravenous infusion, Day 1, every 3 weeks (Q3W). Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.
41025174|NCT06532539|RADIATION|Radiotherapy|"Site Selection: Original site, lymph nodes, lung metastasis, bone metastasis, adrenal metastasis, brain metastasis, and other relatively isolated, well-vascularized lesions. Select at least one suitable lesion for radiotherapy based on the impact of the recurrent or metastatic lesion on the body, prioritizing lesions that cause symptoms, are life-threatening, or are expected to cause symptoms.All tumor lesions will be irradiated, which can be done in phases.~Dosage and Fractionation: Conventional or hypofractionated radiotherapy, with a biologically effective dose (BED) of ≥ 72 Gy. Dose adjustments can be made for brain metastases.~Timing: After completing relevant baseline examinations, radiotherapy can be implemented generally after 2-6 cycles of systemic therapy, or after the first cycle for small, solitary metastatic lesions.~echnique: IMRT, TOMO, SBRT, 3D-BT, interstitial implantation therapy, or proton therapy."
41025175|NCT00141440|PROCEDURE|mechanical ventilation|evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
41025176|NCT00443547|DEVICE|Vectra-T|Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
40841130|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
41025177|NCT05363891|DRUG|Natrunix|Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.
41025178|NCT05363891|DRUG|Placebo|Placebo
41025179|NCT00359762|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
41025180|NCT00359762|DRUG|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
41025181|NCT01702129|DRUG|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
41025182|NCT04368936|GENETIC|Isolated DNA, Real Time PCR|"We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele."
41025183|NCT01993524|DIETARY_SUPPLEMENT|probiotic|antibiotic plus probiotic
41025184|NCT01993524|OTHER|placebo|antibiotic plus placebo
41025185|NCT04612270|OTHER|Venous blood collection|Two venous blood collections in within one week. No drug-related intervention in-vivo.
41266708|NCT01227967|DRUG|Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
41499130|NCT01835054|OTHER|Cardiopulmonary exercise testing|Observational Study using Imaging and Biomarkers
41499131|NCT01835054|OTHER|Magnetic resonance imaging (MRI)|Observational Study using Imaging and Biomarkers
41499132|NCT01835054|OTHER|Exercise stress doppler echocardiography|Observational Study using Imaging and Biomarkers
41499133|NCT01835054|OTHER|Holter ECG|Observational Study using Imaging and Biomarkers
41499134|NCT05199090|DRUG|MBL949|subcutaneous injections administered for 14 weeks
41499135|NCT05199090|DRUG|Placebo|Placebo Comparator to MLB949
41025186|NCT01438632|DEVICE|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
41025187|NCT03136601|OTHER|PTNS maintenance|The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
40841131|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
40841132|NCT01763294|DEVICE|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
40841133|NCT01375608|DRUG|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
40841134|NCT01948063|DRUG|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
40841135|NCT01948063|DIETARY_SUPPLEMENT|Placebo|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
40841136|NCT01416428|DRUG|oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
40841137|NCT05685056|BEHAVIORAL|Text messages|Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
40841138|NCT05065450|DEVICE|Intracranial Stimulation|Electrodes localized to the BLA will be stimulated with either active-BLAES (0.5-3.5 mA, theta-modulated gamma burst) electrical stimulation for a 1-sec duration immediately following item image presentation or sham-BLAES (zero-amplitude). At later stages of the project, stimulation parameters and timing will be varied and triggered not at random, but by real-time closed-loop analysis of memory biomarkers in the medial temporal lobe.
40841139|NCT03255876|DIETARY_SUPPLEMENT|Enriched pomegranate juice|Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
40841140|NCT03255876|DIETARY_SUPPLEMENT|Placebo beverage|Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
40841141|NCT05538351|DEVICE|Body Composition Monitor (BCM)|The hydration status of each participant from the clinical assessment and the patient reported signs and symptoms will be compared with the readings from bioimpedance (BCM machine).
40841142|NCT02576808|DRUG|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
40841143|NCT02576808|DRUG|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
40841144|NCT05231707|BEHAVIORAL|A couples-focused intervention for HIV prevention and care in South Africa|From a sample of 272 male-female couples (544 individuals, 272 men and 272 women) recruited from rural KaZulu-Natal, South Africa, couples will be randomized to receive either individual a package of dyadic counseling and testing (intervention arm) or an attention matched control.
41025188|NCT02316236|DRUG|dexmedetomidine|an alpha-2 receptor agonist
41025189|NCT02316236|OTHER|loading dose|0.8ug/kg of dexmedetomidine is given in 10 minutes
41025190|NCT02316236|OTHER|sustaining dose|0.4ug/kg/min of dexmedetomidine is given
41025191|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
41025192|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
41025193|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
41025194|NCT00828646|DRUG|Placebo|Capsules, Oral, once daily, 14 days
41025195|NCT04405024|DIAGNOSTIC_TEST|Hepatitis C testing|Hepatitis C Screening
41025196|NCT04876027|DRUG|GLP-1 RAs|GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
41025197|NCT04876027|OTHER|calorie restricted diet|Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
41025198|NCT04480645|DEVICE|CivaDerm|radioactive bandage
40841145|NCT00367276|DRUG|Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)|Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
40841146|NCT00825721|DRUG|LiquiTears|4 drops applied daily for 360 days
40841147|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
40841148|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
40841149|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
40841150|NCT05492981|BEHAVIORAL|Enhanced (intervention) education|See arm description
40841151|NCT01435837|DRUG|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
40841152|NCT01435837|DRUG|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
40841153|NCT01435837|DRUG|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
40841154|NCT01435837|DRUG|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
40841155|NCT05703594|DIAGNOSTIC_TEST|performance based balance test|Performance based balance test; 360° Turn Test, Alternative Step Test, Pen Pickup Test,5 Repetitive Stand Up and Sit Test, 10 Meter Walk Test Lower extremity strengthening exercises; Quadriceps femoris strengthening exercise Hamstring strengthening exercise Gluteus medius muscle strengthening exercise Strengthening exercise for hip adductor muscles Balance exercises; Standing tandem walk Standing side walks Standing cross walks Standing back walking
40841156|NCT02149017|RADIATION|SNUBH-NM-333(18F)|5-10 mCi
40841157|NCT01345552|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
40841158|NCT04913740|OTHER|Ointment and dressing for external use|"1. pay attention to the protection of exposed skin, so that it is local dry.~2. Do a good job of facial moisturizing work before work use moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~3. Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~4. After work, avoid using irritants to clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
40841159|NCT00997620|DRUG|Fluticasone furoate Nasal Spray 110 mcg|Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
41361574|NCT05330728|OTHER|Suggestions for lifestyle changes+ Abdominal massage|Suggestions for lifestyle changes+ abdominal massage will be applied. Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Abdominal massage will be applied 3 times a week for 4 weeks.
41025199|NCT00148343|DEVICE|Odstock Dropped-Foot Stimulator (ODFS)|Device implementation \& use for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
41025200|NCT00148343|OTHER|Conventional Standard of Care|Conventional standard of care (which may include implementation \& use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.
41025201|NCT00148343|PROCEDURE|Traditional Physical Therapy Treatment|Traditional physical therapy treatment for 12 weeks.
41361575|NCT05330728|OTHER|Suggestions for lifestyle changes+ Kinesio taping|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Kinesio taping will be applied 3 times a week for 4 weeks.
40841160|NCT00997620|DRUG|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
40841161|NCT04627935|BEHAVIORAL|The COPD Assessment Test|Used to assess symptoms in COPD patients.
40841162|NCT04627935|DIAGNOSTIC_TEST|Navicular Drop Test|It is the test used to measure the amount of pronation in the foot.
41025202|NCT06502314|BEHAVIORAL|Stress management training|"It is a psychoeducational program that includes seven modules (1. Stress and its components, 2. Stress Management, 3. Crisis and its components, 4. Crisis Management, 5. Anger and its components, 6. Anger Management, 7. Psychological resilience)~."
41025203|NCT06327126|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
40841163|NCT04627935|BEHAVIORAL|International Physical Activity Questionnaires (IPAQ)|The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.
40841164|NCT04627935|BEHAVIORAL|COPD and Asthma Fatigue Scale (CAFS)|CAFS is a comprehensive, brief, patient-centered questionnaire developed to capture fatigue experienced by patients with asthma or COPD.
40841165|NCT04627935|BEHAVIORAL|Saint George Respiratory Questionnaire|Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.
40841166|NCT02220114|DRUG|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"* first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~* second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision)."
40841167|NCT01130090|DEVICE|Adjustment of back-up respiratory rate on bi-level ventilator|"3 consecutive nights in randomized order, in either S (Spontaneous) mode, ST (Spontaneous/Timed) mode with a back-up rate under spontaneous respiratory rate of the patient, or in ST (Spontaneous/Timed) mode with a back-up rate at least 2 cycles/minute above spontaneous nocturnal respiratory rate. Each assessment will include complete polysomnographic recording (sleep study) as well as SpO2, PtcCO2, pneumotachograph (flow), mask pressure, quantitative assessment of patient-ventilator synchronisation, central or obstructive apnea and hypopnea, data of built-in software, and rating of patient comfort"
40841168|NCT05583032|DEVICE|ScanNav Anatomy PNB|AI-powered device that highlights anatomy of interest during ultrasound scans.
40841169|NCT01675362|DRUG|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
40841170|NCT01675362|DRUG|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
40841171|NCT01675362|DRUG|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
40841172|NCT01675362|DRUG|Placebo|They will receive placebo
40841173|NCT00541853|DRUG|Candesartan|Candesartan upto 8mg
40841174|NCT00541853|DRUG|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
40841175|NCT00541853|DRUG|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
40841176|NCT00870298|DRUG|Trimethoprim/Sulfamethoxazole and Warfarin|
41025204|NCT06327126|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
41499136|NCT06634121|DEVICE|Transcatheter mitral valve edge-to-edge repair (M-TEER)|M-TEER is performed via a transfemoral venous approach. After puncture of the interatrial septum the mitral valve is repaired using either the PASCAL or MitraClip device.
41499137|NCT03849183|DRUG|Nitroglycerin|Subcutaneous nitroglycerin injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
40841177|NCT01241071|OTHER|myofascial treatment|myofascial release techniques of different muscles implicated in low back pain
40841178|NCT01241071|OTHER|Placebo|A manual sham intervention will be applied to different muscles implicated in low back pain
40841179|NCT01313962|DRUG|Flufirvitide-3 0.05 mg single dose|Nasal Spray
40841180|NCT01313962|DRUG|Flufirvitide-3, 0.1 mg single dose|Nasal spray
40841181|NCT01313962|DRUG|Flufirvitide-3, 0.2 mg single dose|nasal spray
40841182|NCT01313962|DRUG|Flufirvitide-3, 0.4 mg single dose|Nasal spray
40841183|NCT01313962|OTHER|Placebo|Nasal spray
40841184|NCT03612310|PROCEDURE|Skin biopsy/Urine Collection/Blood Sample Collection|"Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. Clinician will collect a 5-7mm section of skin, the area may be numbed beforehand and stitches may be used to close the wound when required. The wound will be dressed if deemed necessary by medical professional.~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or phlebotomost will use a disposable needle to remove a blood sample (normally 50ml but could be up to 320ml for adults).~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or other nominated member of the clinical team will provide a sterile urine collection vessel and direct the volunteer to a suitable private toilet area to provide the sample."
41025205|NCT01778465|BEHAVIORAL|Low salicylate diet|Participants followed a 7 days period under a Low salicylate diet
41025206|NCT01778465|BEHAVIORAL|Normal Diet|Participants followed a 7 days period under a Normal Diet
41025207|NCT04273958|DEVICE|Virtual reality helmet|During a painful procedure, the patient will watch a virtual world in a virtual reality helmet, while wearing a noise-canceling headset with soothing music.
41499138|NCT03849183|DRUG|Normal saline|Subcutaneous normal saline injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
41499139|NCT03141866|OTHER|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
41499140|NCT03141866|OTHER|Exercise Intervention 2: Machine-based resistance training intervention|Specialised, chair-based, pneumatic resistance training equipment for older adults.
41499141|NCT06357806|DRUG|Sintilimab|100mg/10ml/1bottle
41499142|NCT06357806|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
41499143|NCT06357806|DRUG|NAs|tablets
41025208|NCT04273958|DEVICE|Computer screen|During a painful procedure, the patient will watch the same virtual world, while wearing a noise-canceling headset with the same soothing music.
41025209|NCT02398097|BIOLOGICAL|Agripal|2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
41361576|NCT05330728|OTHER|Suggestions for lifestyle changes|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once.
41361577|NCT03819504|PROCEDURE|4-D navigated stereotactic radio surgical ablation|4-D navigated stereotactic radio surgical ablation will be performed in patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias
41025210|NCT02398097|BIOLOGICAL|IDflu9μg|2011/2012 influenza season reduced-content intradermal split vaccine, single dose
41025211|NCT02398097|BIOLOGICAL|IDflu15μg|2011/2012 influenza season standard-content intradermal split vaccine, single dose
41025212|NCT05257538|OTHER|FMT|Fecal microbiota transfer from a healthy and tested volunteer
41025213|NCT05257538|OTHER|placebo enema|colored water enema
40841185|NCT03417986|DRUG|TEP|"For safety reasons the clinical trial will first enroll 14 subjects (7 patients and 7 healthy volunteers) for Group 1a receiving 26 mg TEP daily for 4 days with subsequent safety evaluation, based on adverse events and the safety parameters discussed in the protocol. A second set of patients (Group 1b), which will receive a higher dosage of 52 mg per day for 4 days will be enrolled optionally after recommendation to continue and subsequently treatment Group 2 with a treatment paradigm of 26 mg TEP daily for 54 days will start.~Subjects eligible for participation are subjects with newly diagnosed (within last 12 month) early-to-mild dementia due to AD and healthy volunteers who fulfill all inclusion criteria and have none of the exclusion criteria present at screening."
41025214|NCT05806697|PROCEDURE|Electroencephalogram (EEG)|The EEG will be uniquely performed during for the whole study if a given subject converts to symptomatic AD or in the occurrence of significant cognitive decline.
41025215|NCT05806697|PROCEDURE|Oculomotor tests|All participants in the INSIGHT-2 study are invited to perform the oculomotor test, excepting subjects reporting oculomotor disorders.
41361578|NCT06452680|PROCEDURE|Preserving IPL during surgery|IPL was preserved during surgery
41361579|NCT03762785|DRUG|nebulized Dexmedetomidine|inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
40841186|NCT03730415|PROCEDURE|Viscoelastic (VE) Guided Transfusion|A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
41361580|NCT04130633|DRUG|Placebo|Placebo vapor (distilled water)
41361581|NCT04130633|DRUG|THC|Pure THC vapor
41361582|NCT04130633|DRUG|Alpha-Pinene|Pure alpha-pinene vapor
41361583|NCT01192139|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
41361584|NCT01192139|DRUG|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
41361585|NCT01192139|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
41025216|NCT05806697|PROCEDURE|MRI|All INSIGHT-2 participants will undergo a baseline MRI (structural and resting state fMRI) a follow-up MRI at M12, M36 and M60.
41025217|NCT05806697|RADIATION|18-F amyloid PET Scan|The primary endpoint is conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir PET imaging. Participants will receive an injection of 18F-Florbetapir prior to undergoing amyloid PET scanning. Florbetapir (18F) is an experimental imaging compound labeled with \[18F\] fluorine that decays by positron (β+) emission and has a half-life of 109.77 min. This procedure will be done at baseline.
41025218|NCT05806697|RADIATION|18F-fluorodeoxyglucose (FDG) PET Scan|Participants will receive an injection of Fludeoxyglucose 18F prior to undergoing FDG-PET. The \[18F\]FDG is the most well-known radiopharmaceutical positron emitter, in both clinical and preclinical fields.
41025219|NCT05806697|BIOLOGICAL|Blood sampling|A total of 80 ml of whole blood will be collected for each participant in the INSIGHT-2 study for routine laboratory assessment and biobank sampling.
41025220|NCT05806697|BIOLOGICAL|Lumbar puncture|A lumbar puncture for cerebrospinal fluid (CSF) collection is proposed to all participants.
41025221|NCT00580905|DRUG|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
41025222|NCT00580905|DRUG|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
41266709|NCT05242770|OTHER|Control Arm|Participants randomized to this arm will only receive educational pamphlets with resources for sexual dysfunction and will not participate in physical therapy. Participants will be contacted at 3 months and 6 months to fill out two questionnaires about sexual function and quality of life. After 6months, if participants desire a referral to physical therapy, investigators will provide a referral.
41361586|NCT01645215|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
41361587|NCT01322711|DRUG|Atorvastatin|Atorvastatin 40 mg day
41361588|NCT01322711|DRUG|Placebo|Diet
41361589|NCT02950168|PROCEDURE|Edoxaban|Edoxaban according to Summary of Product Characteristic (SMPC)
41361590|NCT05905692|DRUG|L Carnitine|L carnitine will be given to group 1 (20 mg/kg/day) 3 times per week
41499144|NCT05649930|OTHER|Functional power training|The training consists of weighted running and walking exercises performed at high-velocity and is given three times a week for 12 weeks.
41361591|NCT03410641|BEHAVIORAL|Diet and antismoking advice|Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
40841187|NCT05059964|OTHER|Circuit Training program|"The 4 weeks Circuit Training program, it will be of 3 times per week. Each CT workout includes 6 stations per circuit Training. Before the training period, all participants underwent an exercise familiarization session to ensure proper execution of technique.~The 6 stations will be included as 40 lb. carry for 100 ft., 3-min stair climb, 45 s plank pose, 20 lb. carry with a fast walk for 100 ft., right and left single leg stands for as long as balance was maintained, and a 15 lb. carry up and down 30 stairs"
40841188|NCT05059964|OTHER|Continuous aerobic exercise Group|Continuous aerobic exercise Frequency 3 time per week Intensity 50% of Heart rate reserve Type continuous aerobic exercise Time 40 minutes
40841189|NCT00316524|BIOLOGICAL|MVA-BN® (IMVAMUNE)|1x 10E8_TCID50
41361592|NCT02033369|DRUG|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
40841190|NCT00316524|BIOLOGICAL|Placebo|Tris-Buffer
40841191|NCT00301288|PROCEDURE|Autologous stem cell transplant|
40841192|NCT00791596|OTHER|Ergonomic Intervention|The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
40841193|NCT04878692|DRUG|Application of Onco-Rash cream|"The cream Onco-Rash will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
40841194|NCT04878692|DRUG|Application of Onco-Neutre cream|"The cream Onco-Neutre will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
40841195|NCT00166491|DRUG|Insulin|
41025223|NCT00580905|DRUG|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
41361593|NCT06454227|PROCEDURE|Subcutaneous washing|subcutaneous washing with chlorhexidine gluconate prior to skin closure
41361594|NCT06454227|PROCEDURE|no subcutaneous washing|no washing
40841196|NCT01353911|DRUG|Grazoprevir|Orally once daily in AM. Blinded or open-label depending on treatment arm.
40841197|NCT01353911|DRUG|Boceprevir|Four 200 mg capsules orally three times daily.
40841198|NCT01353911|DRUG|Placebo for Grazoprevir|Orally once daily in AM.
40841199|NCT01353911|DRUG|Placebo for Boceprevir|Four capsules orally three times daily.
40841200|NCT01353911|DRUG|Peg-interferon alfa-2b|1.5 μg/kg/week subcutaneous injection.
40841201|NCT01353911|DRUG|Ribavirin|300 mg to 700 mg orally twice daily.
41025224|NCT03614026|BEHAVIORAL|Teachers and Parents as Partners|Family-school partnership intervention
41361595|NCT00612573|DRUG|Doxycycline 0.6 mg/kg/day|doxycycline 40 mg/day, oral, 12 weeks
41361596|NCT00612573|DRUG|Doxycycline 1.2 mg/kg/day|doxycycline 80 mg/day, 12 weeks
41361597|NCT00612573|DRUG|Doxycycline 2.4 mg/kg/day|doxycycline 160 mg/day, 12 weeks
41361598|NCT00612573|DRUG|Placebo|Placebo, 12 weeks
40841202|NCT01264419|DEVICE|Silk Road Embolic Protection System|System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
40841203|NCT03131596|PROCEDURE|IUB dilatation therapy|A Foley catheter (size 14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-4.5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
40841204|NCT03976284|BEHAVIORAL|Garden-fresh produce and exercise|The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
40841205|NCT00037154|DRUG|Saw Palmetto|
40841206|NCT01181674|DRUG|insulin glargine|sc injection
40841207|NCT01181674|DRUG|metformin|oral administration
40841208|NCT01181674|DRUG|acarbose|oral administration
40841209|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
40841210|NCT01181674|DRUG|insulin glargine|sc injection
40841211|NCT01181674|DRUG|metformin|oral administration
40841212|NCT01181674|DRUG|acarbose|oral administration
40841213|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
40841214|NCT01181674|OTHER|Standard glycemic care|as informed by the current clinical practice guidelines
40841215|NCT00558272|DRUG|AZD0530|Daily oral dose
40841216|NCT00558272|DRUG|Zoledronic Acid|
40841217|NCT03500588|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction was used to diagnose gene polymorphism.
40841218|NCT03500588|DEVICE|Doppler ultrasound|Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .
41361599|NCT04139161|PROCEDURE|Q-Factor Intervention|The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion \>12, indicating a transition to moderate physical activity, or 3) self-reported pain \>5.
41025225|NCT01366833|RADIATION|Brachytherapy|Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
41025226|NCT01366833|PROCEDURE|Stent insertion|After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
41361600|NCT04920305|DIETARY_SUPPLEMENT|Phosphatidylserine|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
41025227|NCT05877729|OTHER|Standard of Care|The SOC arm will include the current care delivery model: regularly scheduled visits with a healthcare provider and lab testing every 3-6 months or more/less frequently depending on the individual's HIV health outcomes (e.g., VL suppression). At each assessment, the investigators will review 149 SOC participant responses to examine acute need for referral for medical, psychological, or substance use services. In between assessments, the investigators will also do monthly check-ins to improve retention and check contact information.
41025228|NCT05877729|BEHAVIORAL|Video-counseling+app|"The intervention tailors the telehealth counseling according to the individual's needs. Tailoring occurs based on the participant's baseline MH, SU, and HIV knowledge/outcomes and assessment responses inform the sessions on these topics. Participants choose from a list identified in the menu sessions: HIV care, MH, SU, lifestyle, health, social support, family of origin, romantic and sexual relationships, self-identity and disclosure, subsistence needs, education and vocation, and a wildcard session.~WYZ contains 3 main features: My Health, My Team, and My Community. Tailoring is achieved based on the individual's needs at a given time (e.g., My Community may be used more if social isolation is a barrier)."
41025229|NCT05494879|BEHAVIORAL|microkinesitherapy treatment|"The therapeutic session of microkinesitherapy included a seeking of body scares both taking into account somatic dysfunctions as well as psychosomatic disorders. According to the creators of the method, Grosjean and Benini Everything that happens with us in a toxic level, either physically or emotionally, are stored by the brain which keeps memories and generates links that may harm the function of the cells generating a vast array of symptoms and dysfunctions."
41025230|NCT02765945|OTHER|Supervised exercise program|Subjects were enrolled in a hospital-based wellness center where, after analysis of their medical history and previous levels of physical activity ands documentation of a normal exercise stress test, they chose individually tailored exercise programs
41025231|NCT00993720|DRUG|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
41025232|NCT00993720|DRUG|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
41025233|NCT00993720|OTHER|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
41025234|NCT04695301|OTHER|Rehabilitation protocol through a digital platform|During 3 months the patients will participate in a rehabilitation program through a digital platform
41025235|NCT05490667|DRUG|Anlotinib|Anlotinib combined with chemotherapy for desmoid tumors
41025236|NCT06540456|DRUG|Qutenza® 8% Capsaicin Topical System|Treatment of patients with neuropathic LBP and painful lumbosacral radiculopathy using the Qutenza 8% capsaicin topical system.
41025237|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate|Zinc Picolinate (50 mg PO TID x 5 days)
41025238|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2 grams po BID x 5 days
41025239|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate Placebo|Zinc Picolinate Matched Placebo PO TID x 5 days
41361601|NCT04920305|DIETARY_SUPPLEMENT|Bean powder|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.).
41025240|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol Placebo|Resveratrol Matched Placebo PO BID x 5 days
41025241|NCT00949026|DRUG|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
41361602|NCT04718038|DRUG|Cetuximab combind mFOLFOX6/FOLFIRI|Cetuximab 500mg/m2 ivgtt 2h d1 ,q14d;mFOLFOX6: Oxaliplatin 85mg/m2 ivgtt 2h d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1, 5-Fu 2.4/m2 CIV 46h, q14d; FOLFIRI: CPT-11 180mg/m2 ivgtt 60-90mins d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1,5-Fu 2.4/m2 CIV 46-48h, q14d
41361603|NCT03162302|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
41361604|NCT02584660|DRUG|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
41361605|NCT02584660|DRUG|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
41361606|NCT04324983|OTHER|Blood sample|"Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination."
41361607|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
41361608|NCT02666118|PROCEDURE|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
41361609|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
41361610|NCT02666118|PROCEDURE|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
40841219|NCT04171232|OTHER|Balance It|Each patient in group 1 i.e. Balance It group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to balance the objects falling from above on the imaginary bar (and an actual bar at later stages) held with their both hands, and not let those objects fall by opening their arms wide open and by staying or moving according to the target spot for the set time. This session would be repeated three times a week for two months (total 12 sessions/month).
40841220|NCT04171232|OTHER|Bubble Pop|Each patient in group II i.e. Bubble Pop group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to reach for the balloons coming from random directions and pop them by moving their upper limbs and even their whole body if required. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
40841221|NCT04171232|OTHER|Scoop'd|Each patient in group III i.e. Scoop'd group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to hold an imaginary ice cream cone (and an actual basket designed similar to an ice cream cone in later stages) with their both hands and move to catch the ice cream scoops falling at random spots from above, one spot at a time. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
40841222|NCT01220180|DRUG|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
40841223|NCT01220180|DRUG|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
40841224|NCT01220180|DRUG|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
40841225|NCT03972956|OTHER|No intervention will be given to patients.|Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
40841226|NCT01158209|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
41025242|NCT05313243|DRUG|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.
41361611|NCT02477631|DRUG|Deferiprone|This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
41361612|NCT03284931|DRUG|SAGE-217 high dose|high dose
41361613|NCT03284931|DRUG|Placebo|placebo
41361614|NCT03284931|DRUG|SAGE-217 low dose|low dose
41361615|NCT00290329|BIOLOGICAL|Mencevax ACWY|1 subcutaneous injection.
41361616|NCT01144897|RADIATION|PET Acetate scan|PET Acetate scans will be done to detect prostate cancer lesions.
41361617|NCT01144897|DRUG|Carbon-11 labeled Acetate|C-11 Acetate is a radiotracer used in PET scanning
40841227|NCT01616979|PROCEDURE|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
41025243|NCT05313243|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
41025244|NCT05233891|PROCEDURE|Breast reconstruction|Breast reconstruction after breast cancer.
41025245|NCT05233891|PROCEDURE|Breast reduction|Breast reduction due to breast hypertrophy.
41025246|NCT02294292|DRUG|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.
41025247|NCT02294292|DRUG|Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
40841228|NCT05544149|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors
40841229|NCT06213181|OTHER|Mindfulness intervention|It consists of 8 weekly sessions with a duration of 2 hours each. A variety of mindfulness practices including mindful movement will be introduced in all sessions. Participants will approach meditation as something natural and everyday, with the possibility of directing attention in all the moments and activities of daily life. Body scanning practices and conscious breathing will also be included. We will work in the group, with reflections and readings, as well as carrying out meditation and mindfulness practices, during the week, so that they can be carried out in the daily life of each participant. The intervention based on mindfulness will focus on the areas of well-being and personal skills such as attention, communication, emotional regulation and decision making.
40841230|NCT00303888|DRUG|docetaxel|Given IV
41025248|NCT02294292|PROCEDURE|Endoscopic Variceal Ligation|
41025249|NCT04760470|OTHER|Technology-assisted upper extremity rehabilitation|Subjects get 6 weeks of technology-assisted upper extremity rehabilitation
41025250|NCT00090012|DRUG|Olanzapine|
41025251|NCT00090012|DRUG|Quetiapine|
41025252|NCT01954017|BIOLOGICAL|STP206|Live Biotherapeutic
41025253|NCT01954017|OTHER|Control|Sterile Water
41025254|NCT06298643|PROCEDURE|Red blood cell transfusion|≥2 units of red blood cell transfusion
41025255|NCT06298643|PROCEDURE|Red blood cell transfusion|0 units or \<2 units of red blood cell transfusion
41025256|NCT03142074|OTHER|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
41025257|NCT03142074|RADIATION|ECG-gated CT|Image analysis of ECG-gated CT.
41025258|NCT04882501|OTHER|QUEASEEase aromatherapy quick tab|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
41025259|NCT04882501|OTHER|Placebo product|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
40841231|NCT00303888|DRUG|idronoxil|Given orally
40841232|NCT00303888|OTHER|placebo|Given orally
41025260|NCT04158401|DEVICE|Pregnolia|The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
41025261|NCT00113516|DRUG|carboplatin|AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
41025262|NCT00113516|DRUG|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
41025263|NCT00113516|DRUG|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
41025264|NCT02270580|BEHAVIORAL|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
41025265|NCT02270580|BEHAVIORAL|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
41025266|NCT05946018|OTHER|Educational video on ergonomics|A 6-8 minute education video that includes information on why ergonomics is important and recommendations for how to arrange the operating room to reduce the risk of injury.
41025267|NCT05946018|OTHER|Verbal physical therapy coaching sessions|Physical therapy coaching sessions include a standard assessment with individualized instruction on range of motion, strength, endurance, and flexibility.
41025268|NCT01169857|DRUG|Velcade|Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
41025269|NCT04134897|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
41025270|NCT04134897|DRUG|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
41025271|NCT04134897|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
41025272|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
41025273|NCT04134897|PROCEDURE|Rectal cancer surgery|Laparoscopic or open total mesorectal excision
41025274|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
41025275|NCT03866174|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
40841233|NCT06503120|BEHAVIORAL|Mediterranean-diet intervention group|Dietitian-guided Nutritionist Education Process
41025276|NCT03866174|DRUG|Niacin|The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
41025277|NCT03866174|OTHER|Set and Setting (SaS) Protocol|The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
40841234|NCT06503120|BEHAVIORAL|Standard care|A 10-minute talk on the epidemiology of MASLD and balanced diet, resembling routine clinical practice.
40841235|NCT01714258|PROCEDURE|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
40841236|NCT03969511|PROCEDURE|direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CBCT in order to confirm ischemic stroke. Mechanical thrombectomy is the performed as well as intravenous thrombolysis when contraindications are excluded.
41160819|NCT03994341|DIAGNOSTIC_TEST|A FLIR Thermovision a320M thermal IR camera|"1. Clothing removed if necessary~2. ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~3. Axillary temperature prior to starting the thermographic imaging.~4. Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~5. After surface cooling, thermal imaging will be recorded for \~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~6. After \~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~7. Axillary temperature to ensure temperature stability, any clothes will be put back on."
40841237|NCT03969511|PROCEDURE|standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
40841238|NCT05301036|DEVICE|Diadem prototype|Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
40841239|NCT04122131|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical analysis of biomarker in post-surgical sample
40841240|NCT00114088|PROCEDURE|hysterectomy|
40841241|NCT00114088|PROCEDURE|endometrial ablation|
40841242|NCT00787215|OTHER|observational: no treatment involved|observational: no treatment involved
40841243|NCT00483002|DRUG|varenicline|As prescribed by physician in usual clinical practice.
41025278|NCT06308913|DRUG|INCB081776|INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus INCBMGA00012 (NCT03522142), which is 120 mg daily.
41160820|NCT03265847|BEHAVIORAL|Culturally-tailored Safety Planning|The intervention will provide safety planning/referrals tailored to the DA
40841244|NCT00259688|DEVICE|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
40841245|NCT02078388|DRUG|Doxorubicin|
40841246|NCT06166329|OTHER|chair lift test|repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute
40841247|NCT02355444|DIETARY_SUPPLEMENT|blackberry polyphenol enriched beverage|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
40841248|NCT02355444|DIETARY_SUPPLEMENT|blackberry beverage with minimal polyphenol concentrations|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
40841249|NCT02929082|RADIATION|IRM with a 5-minute- additional sequence to measure FRM|IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
40841250|NCT00348647|BEHAVIORAL|physical training program to prevent injuries|
41025279|NCT06308913|DRUG|Pembrolizumab|Immune checkpoint blockade with anti-PD-1 (Pembrolizumab) will be given as 200 mg IV on cycle 1 day 15 and cycle 1 day 36. Starting from cycle 2, pembrolizumab will be given on day 1 on each subsequent cycle.
41025280|NCT06308913|RADIATION|Palliative RT|Palliative RT will be given as either 24 Gy in 3 fractions (8 Gy per fraction) or 20 Gy in 5 fractions (4 Gy per fraction). The palliative radiation therapy dose will be determined based on the clinical judgment of the treating radiation oncology physician. Palliative RT must be completed between cycle 1 day 29 to cycle 1 day 33. After completion of palliative radiation therapy, patients will continue with additional cycles of INCB081776 and pembrolizumab until disease progression, intolerance to the combination regimen, or patient withdrawal.
41025281|NCT05961293|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand of a stroke victim during acute, subacute, or chronic phases of a stroke. NeuroGlove provides sensory stimulation in the forms of pneumatic puffs of air. There is some early evidence that early peripheral sensory stimulation may improve neurological outcomes following an ischemic stroke.
41025282|NCT02972580|GENETIC|Genetic characterization|Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
41025283|NCT01218646|BIOLOGICAL|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
41361618|NCT03436576|DRUG|Autologous Serum 20%|Instillation of 1 drop of Autologous Serum 20% four times a day
40841251|NCT01026740|DRUG|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
41025284|NCT01218646|BIOLOGICAL|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
41025285|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
41361619|NCT03436576|DRUG|Autologous Serum 50%|Instillation of 1 drop of Autologous Serum 50% four times a day
41361620|NCT04763460|DEVICE|Programming of CRT device settings|Reprogramming of CRT device to maximize the benefit derived from the electrocardiographic assessment.
41025286|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
41025287|NCT01032694|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
41025288|NCT01032694|DRUG|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
41025289|NCT05043077|DRUG|Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (6.5 μL) for 3 doses with 5-minute intervals
41025290|NCT05043077|DRUG|Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (28-34 μL) for 3 doses with 5-minute intervals
41025291|NCT04535037|BIOLOGICAL|DTPa-HBV-IPV/Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTPa-HBV-IPV/Hib vaccine administered by intramuscular injection into the right thigh
41025292|NCT04535037|BIOLOGICAL|DTaP5-HBV-IPV-Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTaP5-HBV-IPV-Hib vaccine administered by intramuscular injection into the right thigh
41025293|NCT04535037|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
41025294|NCT03457259|DEVICE|PVC and/or PICCline|Pt. will receive PVC and/or PICCline
41025295|NCT03457259|DEVICE|Midline|Pt. will receive midline
41025296|NCT03809845|DEVICE|High-density surface electromyography|High-density surface electromyography
41025297|NCT05723523|OTHER|CI-CDS|The CI-CDS system is a clinical decision support tool that assists clinicians in the diagnosis and management of cognitive impairment.
41025298|NCT05035082|DRUG|semaglutide|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
41025299|NCT05035082|DRUG|oral glucose-lowering medications (commercially available)|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
41025300|NCT00651989|OTHER|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
41160821|NCT06229236|BEHAVIORAL|Diabetes Navigator|Participants in the Diabetes Navigator (DN) arm will receive support from a trained navigator to help them improve progression (improving use/optimization) in use of advanced diabetes technology. The Diabetes Navigator will engage with participants immediately after randomization, throughout the duration of study, using a predefined toolkit, educational resources and interventions to assist them in optimizing use of advanced diabetes technology.
41160822|NCT05716152|DIAGNOSTIC_TEST|Morning blood sample and skin punch biopsy of 4 mm diameter.|"1. Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~2. Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody"
41160823|NCT04373642|DRUG|Pebrolizumab + QUADSHOT Radiotherapy|"Treatment will consist of QUAD SHOT radiotherapy combined with pembrolizumab."
41361621|NCT04001426|DEVICE|The FemPulse System|Non-invasive monitoring during activation of the FemPulse System
41361622|NCT04094662|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
41361623|NCT04094662|DRUG|Placebo|Matching placebo tablets for oral administration
41361624|NCT05776511|PROCEDURE|eVOG|video digital oculography
41361625|NCT05250999|OTHER|Skin stretch sensory stimuli|Skin stretch sensory stimuli will be exerted by a piece of kinesio tape that as applied above right and left lateral malleolus on posterior leg and on both side of spinous process of second thoracic vertebrae till 15cm below for 24 hours a day, 5 days/ week for 6 weeks along with conventional physiotherapy.
41025301|NCT02192268|OTHER|PEP|
41025302|NCT02192268|OTHER|HFOO|
41025303|NCT02192268|OTHER|Assisted Coughing|
41025304|NCT04726709|BEHAVIORAL|Poised for Parkinson's|Lecture, demonstration, activities, and supplemental materials designed to improve self-awareness, situational awareness, and ability to make good choices for physical and emotional self-care, moment-to-moment.
41025305|NCT00852397|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
41025306|NCT00852397|DRUG|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
41025307|NCT00852397|OTHER|Placebo|Placebo tablet for 24 weeks
41025308|NCT02770391|DRUG|Leuprolide acetate|Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3
41025309|NCT02770391|DRUG|Apalutamide|Apalutamide, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. Apalutamide will be initiated the same day patients receive their leuprolide acetate injection.
41025310|NCT02770391|PROCEDURE|Radical prostatectomy|
41025311|NCT02505932|PROCEDURE|Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
41025312|NCT02505932|PROCEDURE|Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
41499145|NCT05164887|PROCEDURE|Laparoscopic colorectal resection|the patients candidate to laparoscopic colorectal resection for cancer are perioperatively treated with mechanical bowel preparation, oral antibiotics and administration of probiotics
40841252|NCT03626857|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40\& of the contralateral MVIC.
40841253|NCT03626857|OTHER|Eccentric Exercise (ECC)|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum
40841254|NCT03626857|DEVICE|Neuromuscular Electrical Stimulation (NMES) placebo|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.
40841255|NCT03626857|OTHER|Eccentric Exercise (ECC) placebo|4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum
40841256|NCT05455801|DEVICE|negative preassure wound therapy|wound treated with negative pressure therapy dressing
40841257|NCT02998034|DEVICE|Uncemented Furlong Hemiarthroplasty|A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.
41160824|NCT04362072|DRUG|Lorlatinib|25 milligram (mg) tablet
41361626|NCT05250999|OTHER|Transcutaneous Electrical nerve stimulation|TENS will be applied to patient while in sitting position for 30 minutes, twice a week, and for 6 weeks (12 treatment sessions along with conventional physiotherapy). A maximum of 25 m amp electrical stimulation with a biphasic square-wave pattern and a pulse width of 0.5ms in a continuous duty cycle will be used. The intensity of the electrical stimulation will be regulated to the high tolerable level without initiating muscle contractions.
41499146|NCT04639492|DIETARY_SUPPLEMENT|MBS oral solution|Oral BIDAC, twice a day before breakfast and dinner times
41499147|NCT05092451|DRUG|Cyclophosphamide|Given by IV
40841258|NCT02998034|DEVICE|Cemented tapered stem hemiarthroplasty|A cemented double tapered stem hemiarthroplasty
40841259|NCT05986903|DRUG|Tumor necrosis factor (TNF)-alpha inhibitors|"Proactive drug monitoring was defined as the assessment of trough concentrations to optimize dosing during induction therapy and intermittently thereafter regardless of symptoms or inflammatory markers.~During induction, the following target concentrations are employed: 25-30 mcg/ml (week 2) and 20 mcg/ml (week 6) for Infliximab and \> 10 mcg/ml (week 2 and 4) for Adalimumab. Checks are performed systematically at week 2 and 6 (infliximab) and at week 4 (adalimumab).~During the maintenance, the targets are 5-10 mcg/ml for Infliximab and 8-12 mcg/ml for Adalimumab. In case of perianal disease, the targets are 7-20 mcg/ml."
40841260|NCT02391493|DEVICE|functional magnetic resonance imaging|"Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds)."
40841261|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea containing L-arabinose and indigestible dextrin|
40841262|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea (Placebo)|
40841263|NCT03180970|DRUG|1.2% Lugol's solution|1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
40841264|NCT03180970|DRUG|1.0% Lugol's solution|1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
40841265|NCT03180970|DRUG|0.8% Lugol's solution|0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
40841266|NCT03180970|DRUG|0.6% Lugol's solution|0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
40841267|NCT03180970|DRUG|0.4% Lugol's solution|0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
41160825|NCT02217241|OTHER|Handoff Workshop|
41499148|NCT05092451|DRUG|CAR.70/IL15-transduced CB-NK cells|Given by IV
41499149|NCT05092451|DRUG|Fludarabine phosphate|Given by IV
41499150|NCT05934409|PROCEDURE|Bariatric surgery|Laparoscopic Sleeve Gastrectomy
41499151|NCT05934409|DRUG|Nicotinic Acid|Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.
41499152|NCT02777814|DRUG|Entecavir|anti hepatitis B virus
41499153|NCT05832567|DEVICE|Active rTMS|Subjects will undergo repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
41499154|NCT05832567|DEVICE|Sham rTMS|Subjects will undergo sham repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
41499155|NCT05832567|DIETARY_SUPPLEMENT|Open Placebo|The open placebo will consist of an inactive substance pill commonly used in clinical trials and given to the subject in a regular pill dispenser.
41499156|NCT06345495|DRUG|Ruxolitinib|Given by PO
40841268|NCT05069753|PROCEDURE|Immediate sequential bilateral cataract surgery (ISBCS)|Surgery on both eyes will be performed on the same day as separate procedures: Once surgery on the first eye is completed, a new sterile procedure on the second eye will commence.
40841269|NCT05069753|PROCEDURE|Delayed sequential bilateral cataract surgery (DSBCS)|The group will undergo bilateral cataract surgery on two separate days with a time period of one week between the two procedures.
40841270|NCT02803996|DRUG|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
40841271|NCT02803996|DRUG|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
40841272|NCT00275977|PROCEDURE|Coronary catherization and stem cell infusion|
40841273|NCT01973556|OTHER|Pharmacist-Physician Collaborative Medication Therapy Management|
40841274|NCT03429257|OTHER|Exposures of interest: Maternal EED and Aflatoxin Exposure|Maternal EED, measured via lactulose: mannitol (L:M) ratios and serum concentrations of antibodies to the bacterial components flagellin and lipopolysaccharide (LPS); Maternal aflatoxin exposure, measured via serum concentration of AFB1-lysine adduct
40841275|NCT02160444|BEHAVIORAL|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
40841276|NCT05827315|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
40841277|NCT05827315|DIAGNOSTIC_TEST|T1 Cardiovascular Magnetic Resonance|T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
40841278|NCT05827315|DIAGNOSTIC_TEST|Right heart catheterisation and coronary sinus blood sampling|10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
40841279|NCT05294458|DRUG|cotadutide solution for injection|cotadutide solution for injection
40841280|NCT02105545|OTHER|Cancer Treatment Options|Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
41499157|NCT06345495|PROCEDURE|Allogeneic Stem Cell Transplantation|Given by Transplant
41499158|NCT06345495|DRUG|Levetiracetam|Given by PO
40841281|NCT00527319|DRUG|VT-122 low dose|VT-122 low dose, dose escalated
41499159|NCT06345495|DRUG|Eltrombopag|Given by PO
41499160|NCT06345495|DRUG|Busulfan|Given by IV
41499161|NCT06345495|DRUG|Romiplostim|Given by IV
41499162|NCT06345495|DRUG|Fludarabine phosphate|Given by IV
41499163|NCT06345495|DRUG|Cyclophosphamide|Given by IV
41499164|NCT06345495|DRUG|Mesna|Given by IV
41499165|NCT06345495|DRUG|Tacrolimus|Given by IV or PO
41499166|NCT05939635|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
40841282|NCT00527319|DRUG|VT-122 high dose|VT-122 high dose, dose escalated
40841283|NCT05732883|DRUG|Dexamethasone|Dexamethasone injection
40841284|NCT05732883|DRUG|Normal saline|Placebo
40841285|NCT01753401|DRUG|Acthar|Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
40841286|NCT01753401|DRUG|Placebo|Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
40841287|NCT01753401|DRUG|Steroid Drug|The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
40841288|NCT06137521|PROCEDURE|Coronary angiography|
40841289|NCT03328923|DIETARY_SUPPLEMENT|500mg brown seaweed powder|
40841290|NCT03328923|DIETARY_SUPPLEMENT|Placebo|
40841291|NCT05173935|PROCEDURE|Percutaneous endoscopic gastrostomy|Gastrostomy tube placement using an endoscopic camera inserted via the mouth into the stomach to place the tube.
40841292|NCT05173935|PROCEDURE|Radiologically-inserted gastrostomy|Gastrostomy tube placement using a temporary nasogastric tube placed from nose to stomach and fluoroscopy (x-rays).
40841293|NCT00576472|DRUG|Methylphenidate|Please see detailed description for dosing information and study design.
41499167|NCT05939635|PROCEDURE|Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block|"Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
41499168|NCT05939635|DRUG|IV morphine patient-controlled analgesia (PCA)|Morphine will be administered via PCA device for the first 24 hours after surgery
41361627|NCT05250999|OTHER|Control Group|This program include balance exercises performed twice a week for 6 weeks, which consists of balance, progressive strength, and functional mobility training. Static exercise consists of heel and toe raises, one-legged stance for each limb, weight shifting forward, backward, sideward and diagonally, and turning the head to the left and then to the right keeping the feet together. This exercise comprises two 10-min sessions each, with eyes opened and eyes closed, respectively. Dynamic exercise comprises of walking, step-ups, and bipedal jumps for 10 min. Progressive balance exercises comprises of narrow walking, walking backward, walking sideward, stepping over obstacles, passing, throwing and catching a ball.
40841294|NCT04468074|DEVICE|Virtual Reality Therapy for Chronic Pain|"1. A 1 1/2 PowerPoint-based education session on the science behind chronic pain and a basic overview of the VR therapy~2. Virtual Reality Therapy: a virtual reality therapy consisting of different psychological training exercises"
40841295|NCT02834286|DRUG|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
40841296|NCT02834286|DRUG|Eltrombopag|Eltrombopag 50 mg PO days 1-28
40841297|NCT02834286|DRUG|Dexamethasone|Dexamethasone 40 mg IV/PO days 1-4
40841298|NCT00940485|DRUG|entecavir|0.5mg po daily for 8 weeks
40841299|NCT00940485|DRUG|entecavir|0.5mg po daily for 48 weeks
40841300|NCT00940485|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
40841301|NCT04363450|DRUG|Hydroxychloroquine|Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly
40841302|NCT04363450|DRUG|Placebo|Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
40841303|NCT02102152|DRUG|Tobramycin|
40841304|NCT01029041|OTHER|Strengthening Exercises|Exercises that aim the improvement of muscular strength of arms and legs
40841305|NCT01029041|OTHER|Stretching exercises|Exercises that aim the improvement of muscular flexibility of arms, legs and spine
41361628|NCT01136759|DRUG|Tenofovir 1% gel|One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
41361629|NCT01136759|OTHER|Placebo gel|One applicator of placebo gel administered vaginally for 7 consecutive days
40841306|NCT06246812|BEHAVIORAL|Deans' Fit Family Challenge|An annual 8-week physical activity and weight loss competition between VCOM-Auburn, AU College of Nursing, and AU Harrison School of Pharmacy
40841307|NCT06246812|BEHAVIORAL|Text message|Three text messages per week to promote and motive physical activity
40841308|NCT03517566|DRUG|Placebo|once daily from baseline until week 16
40841309|NCT03517566|DRUG|ZPL389 3mg|ZPL389 3 mg oral powder; once daily from baseline to week 16
40841310|NCT03517566|DRUG|ZPL389 10mg|ZPL389 10 mg oral powder; once daily from baseline to week 16
40841311|NCT03517566|DRUG|ZPL389 30mg|ZPL389 30 mg oral powder; once daily from baseline to week 16
40841312|NCT03517566|DRUG|ZPL389 50mg|ZPL389 50 mg oral powder; once daily from baseline to week 16
40841313|NCT03346577|DEVICE|stent or balloon|Endovascular treatment with stent or balloon according to current practice
40841314|NCT03699137|OTHER|No interventions|No interventions
40841315|NCT02072395|PROCEDURE|Plication|Plication of the stomach will be performed in conjunction with placement of a gastric band.
40841316|NCT04809350|DIETARY_SUPPLEMENT|Adjustable Human Milk Fortification|"BUN and sodium concentrations will be measured every week in infants on full enteral feeds with fortified human milk.~Liquid protein will be added based on serum urea."
41361630|NCT03907943|PROCEDURE|carotid endarterectomy|Surgical treatment of ICA stenosis.
41361631|NCT00148980|DEVICE|DBM for creation of bone marrow microenvironment|
41361632|NCT03481933|DEVICE|Transcranial stimulation|"1. 10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~   * left-excitatory tDCS (N=20)~  * right-inhibitory tDCS (N=20)~  * sham tDCS (N=20)~2. 4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~3. 2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS"
41361633|NCT00786058|DRUG|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
40841317|NCT04809350|DIETARY_SUPPLEMENT|Targeted Human Milk Fortification|"Human milk will be analyzed twice weekly. Before the day of analysis, each mother will store fresh milk pumped from 10:00 AM until 8:00 AM of the previous day in a refrigerator and bring it to the hospital.~Protein, fat, and sodium supplementation will be added to the human milk to meet the recommended daily intakes."
40841318|NCT02145598|DRUG|Lenalidomide|after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
40841319|NCT02145598|DRUG|Placebo|after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
41361634|NCT01488175|PROCEDURE|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
41361635|NCT01488175|PROCEDURE|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
41361636|NCT01402999|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
41361637|NCT05280691|OTHER|Family Support Intervention (FSI)|In addition to usual care, families in the intervention group will receive (1) specialist nurse support along the patient pathway at defined time-points, from admission to discharge including follow-up care, and (2) nurse-coordinated liaison and structured, interprofessional communication by the ICU team. The intervention is grounded in a family systems approach and guideline-based strategies for family engagement in the ICU and has been pilot-tested in one ICU.
41361638|NCT05078268|BEHAVIORAL|HRV biofeedback training and self-help CBT-I|Participants will receive a booklet with content related to both self-help CBT-I and HRV biofeedback per week for 6 consecutive weeks. Participants are required to use around 1 hour to read through the content and perform the HRV biofeedback practice for around 20 minutes a day, 5-7 days a week and record their practice.
40841320|NCT02476136|DRUG|paroxetine, duloxetine, fluoxetine or venlafaxine|
40841321|NCT01420419|OTHER|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
41266710|NCT05242770|OTHER|Physical Therapy Arm|Participants will receive a referral to begin a pelvic physical therapy regimen. Participants will complete the sexual function and quality of life questionnaires after completion of the physical therapy regimen and again 3 months after. There will be a brief exit interview.
41266711|NCT05242770|OTHER|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)|Questionnaire designed to measure cancer patients' physical, psychological and social functions
41361639|NCT05078268|BEHAVIORAL|Self-help CBT-I only|Participants will receive a booklet with content related to self-help CBT-I only per week for 6 consecutive weeks. Participants are required to use 30 to 40 minutes to read through the content.
41361640|NCT01509651|DRUG|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
41025313|NCT05242614|BEHAVIORAL|The Hybrid Mindfulness-based Dementia caregiving program (MBDCP)|The hybrid MBDCP includes 6 weekly 90-minute group-based sessions delivered through a face-to-face (1st, 2nd, and 6th sessions) and online approach (3rd, 4th, and 5th sessions). The online session is designed for self-directed learning. The MBDCP includes different mindfulness practices (e.g., mindful eating, body scanning, and mindful walking), psychoeducation on caregiving, and group sharing, aimed at helping caregivers to develop mindfulness skills through the formal and informal practice of mindfulness, and to integrate these skills into their everyday life. The duration of each session is 90 minutes. Th MBDCP will be delivered by a qualified mindfulness therapist. In the MBDCP's online sessions, the caregivers will watch a teaching video (e.g., a video demonstrating mindfulness practices) through a website.
41266712|NCT05242770|OTHER|Female Sexual Function Index (FSFI)|19-item self-report inventory designed to assess female sexual function.
41266713|NCT05242770|OTHER|Exit Interview|11-item questionnaire for participants to give feedback to investigators about teir experience with the intervention.
41266714|NCT01348737|DRUG|AZD3839|Single Oral Dose
41361641|NCT02719028|DRUG|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
41361642|NCT02719028|DRUG|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
40841322|NCT01420419|OTHER|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
40841323|NCT05339230|DIETARY_SUPPLEMENT|Salovum and SPC-flakes active or placebo|Foods for specific medical purposes or corresponding placebo
40841324|NCT02103413|DEVICE|EUS-BD|When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
40841325|NCT02103413|DEVICE|PTBD|PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
40841326|NCT03157037|BIOLOGICAL|Imlifidase|One dose of 0.25 mg/kg body weight imlifidase on study day 1
40841327|NCT02163421|DRUG|Vedolizumab SC|Vedolizumab injection, for subcutaneous use (vedolizumab SC)
40841328|NCT02163421|DRUG|Vedolizumab IV|Vedolizumab injection, for intravenous use (vedolizumab IV)
40841329|NCT06030284|DEVICE|BurstDR-SCS|Spinal Cord Stimulation with a BurstDR-SCS system.
40841330|NCT06030284|DEVICE|BurstDR-SCS|BurstDR-SCS system turned off.
40841331|NCT05626608|DEVICE|Classical ring stimulation|Unilateral or bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
40841332|NCT05626608|DEVICE|Stimulation in directional mode|Directional stimulation of the subthalamic nucleus in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
40841333|NCT01304589|DRUG|Milnacipran|6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose) for 12 weeks - total treatment period is 18 weeks
40841334|NCT03688555|DRUG|ACT-774312|ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312
40841335|NCT03688555|DRUG|Placebo|Matching placebo hard gelatin capsules
40841336|NCT00003711|DRUG|irinotecan hydrochloride|
40841337|NCT00003711|DRUG|pemetrexed disodium|
41361643|NCT04307264|PROCEDURE|Esophagogasrtoduodendoscopy, liver stiffness measurement|Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
41499169|NCT02308566|PROCEDURE|Minimized Extracorporeal Circulation (MECC)|This group of patients receives surgical aortic valve replacement using MECC.
41499170|NCT02308566|PROCEDURE|Conventional Extracorporeal Circulation (CECC)|This group of patients receives surgical aortic valve replacement using CECC.
40841338|NCT04298424|OTHER|PLSM|The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
40841339|NCT00261703|DRUG|Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
40841340|NCT00261703|DRUG|Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
40841341|NCT00261703|OTHER|Cisplatin + radiotherapy|Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
40841342|NCT02472613|DEVICE|acupuncture|"Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).~The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
40841343|NCT02472613|DRUG|placebo|Placebo was given for 12 consecutive weeks.
40841344|NCT02472613|DEVICE|sham-acupoint acupuncture|"Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.~• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
41025314|NCT05242614|BEHAVIORAL|Psychoeducation educational program|This program serves as a control for the social effects of the MBDCP. The brief education program consists of 6 weekly 90-minutes group sessions in which the sessions (1st, 2nd, and 6th) and (3rd 4th 5th) will be delivered through the face-to-face and online approach respectively, with the similar group size of the MBDCP. The education contents include caregiving skills, education on mood, and group sharing. The program will be led by a nurse.
41025315|NCT06535113|OTHER|Clinical Practice|"All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines.~There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures."
41025316|NCT04544826|DRUG|JNJ-77474462|JNJ-77474462 will be administered as SC injection.
41025317|NCT04544826|DRUG|Placebo|Matching placebo to JNJ-77474462 will be administered as SC injection.
41025318|NCT02528214|DRUG|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
41025319|NCT02528214|DRUG|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
41499171|NCT03887793|OTHER|VACs|The VACs (Vaccinate Adolescents against Cancer) model for HPV vaccine quality improvement is a strategy developed by the American Cancer Society to improve HPV vaccination coverage in large integrated health care delivery systems. It includes the development of a quality improvement (QI) action plan, the formation of a QI team of health care providers, education for the QI team about HPV-related disease burden and vaccine efficacy, HPV vaccine coverage assessments at several time points that are shared with individual clinics within the health are system, and the adoption of specific QI strategies by participating clinics in the health care system.
41025320|NCT02528214|DRUG|Oral corticosteroid therapy (prednisone/prednisolone)|Oral administration.
41025321|NCT02528214|DRUG|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
41025322|NCT02528214|DRUG|Albuterol/Salbutamol|Oral inhalation as needed.
41499172|NCT03499210|DEVICE|ReWalk ReStore device|The ReWalk ReStore device is intended to be used to perform ambulatory functions in rehabilitation institutions under the supervision of a trained therapist for people with hemiplegia/hemiparesis due to stroke.
41499173|NCT06389539|OTHER|SBD111 medical food|SBD111 medical food is a defined microbial assemblage (DMA) consisting of oligofructose and dried berry powder (prebiotics), a Pseudomonas fluorescens, a Lactobacillus brevis, a Leuconostoc mesenteroides, a Lactobacillus plantarum, and a Pichia kudriavzevii (yeast).
41499174|NCT06389539|OTHER|Placebo|Placebo
41499175|NCT04032236|OTHER|caffeine|At room temperature (18-25 ° C) the same place and standard environment will be done. All involved cases will undergo a dental examination and within 30 minutes three samples of saliva will be taken, including first sample, after coffee drink and after drinking water. The pH of samples will be measured and the smoking cessation rate of the smoking cigarette smoker with simultaneous VAS (VISUAL ANALOG SCALA) will be measured. This data will be compared in-house and non-smoking control group
41499176|NCT05766514|DRUG|Cladribine|Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.
41499177|NCT05766514|DRUG|Cytarabine|Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.
41499178|NCT05766514|DRUG|Decitabine|Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16
41266715|NCT01348737|DRUG|AZD3839 Placebo|Single Oral Dose
40841345|NCT02472613|DRUG|Fluoxetine|Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
40841346|NCT05679063|OTHER|Physiotherapy|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group
41025323|NCT02528214|DRUG|Levalbuterol/Levosalbutamol|Oral inhalation as needed.
41025324|NCT01911364|DRUG|BDP/FF/GB|Superiority over Tiotropium
41025325|NCT01911364|DRUG|Tiotropium|Superiority of CHF5993 over Tiotropium
41025326|NCT01911364|DRUG|BDP/FF + Tiotropium|non inferiority vs CHF5993
41025327|NCT01361087|OTHER|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
41025328|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3 + K2-MK7|Combined supplementation
41025329|NCT05689632|DIETARY_SUPPLEMENT|Placebo|MCT
41025330|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 - 7000 IU
41025331|NCT04028375|OTHER|No intervention|No intervention
41025332|NCT01415791|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
41025333|NCT01722331|DRUG|Tildrakizumab 200 mg|Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
41361644|NCT00499395|PROCEDURE|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
41499179|NCT05766514|DRUG|azacitidine or decitabine|Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitidine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.
41499180|NCT05766514|DRUG|Venetoclax|Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
41499181|NCT01782300|BIOLOGICAL|TV003 Vaccine|TV003 will contain an admixture of the following monovalent dengue vaccines: 10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
41499182|NCT01782300|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
41499183|NCT06463002|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring and Montreal Cognitive Assessment|Noninvasive tests to assess blood pressure control and cognition
41499184|NCT03456297|OTHER|Web-based clinical pedagogy program (WCP)|The nurse preceptors in the experimental cluster will be given access to download the WCP on mobile devices. The unique interactive features provide continuous support and allow preceptors to discuss the clinical encounters with their peers and consult experts for advice.
41499185|NCT01173081|DRUG|Teriparatide|20mcg once daily for 16 weeks or until study endpoint is achieved.
40841347|NCT05679063|OTHER|Sham, Control|Talks about healthy habits
41025334|NCT01722331|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg/mL PFS
41025335|NCT01722331|DRUG|Matching Placebo|Matching placebo to tildrakizumab PFS
41025336|NCT04592692|DRUG|PEGylated Liposome (PEGLip)|Intravenous co-administration of PEGLip with Simoctocog alfa
41025337|NCT03280277|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
41025338|NCT03280277|DRUG|Ferumoxytol|Given IV
41025339|NCT03421197|DRUG|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg tablet once per day
41025340|NCT03421197|DRUG|PPC-06 400 mg BID|Tepilamide Fumarate tablets 400 mg twice per day
41025341|NCT03421197|DRUG|PPC-06 600 mg|Tepilamide Fumarate tablets 600 mg twice per day
41025342|NCT03421197|DRUG|Placebo|white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
41266716|NCT01290887|DRUG|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
41266717|NCT03283085|DRUG|25 mg Ontamalimab|Ontamalimab SC solution for injection
41361645|NCT00499395|PROCEDURE|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
41499186|NCT01173081|DRUG|Placebo|matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
41499187|NCT02412696|DEVICE|Positive Airway Pressure|Auto-titrating PAP + nasal dilator strips during sleep
41499188|NCT02412696|OTHER|Nasal Dilator Strips|Nasal dilator strips
41499189|NCT06633523|PROCEDURE|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM)|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM) After performing PVI, electrogram mapping of the posterior left atrial wall is conducted. Subsequently, PWI and EGM ablation are performed. In this group, multipolar mapping catheters are used for EGM mapping. Target EGMs include spatially discrete potentials (STPs), localized short cycle length potentials (SCLPs), and focal activities.
41499190|NCT06633523|PROCEDURE|PVI + Posterior Wall Isolation (PWI)|After performing PVI, the mapping catheter will be placed on the posterior wall to assess electrical activity and guide ablation. A bottom linear ablation (25-40W) will be performed, connecting the lowest points beneath the lower PVs. A top linear ablation (25-40W) will be conducted at the top of the left atrium, connecting the highest points above the upper PVs. If posterior wall isolation is not achieved after completing the bottom and top lines, mapping and localization of the earliest activation point within the box will be performed during pacing from the coronary sinus (CS). Posterior wall isolation will be completed by identifying and ablating local potentials at the entry and exit sites.
41499191|NCT06633523|PROCEDURE|Pulmonary Vein Isolation (PVI) alone|The distance between the ablation lines on the posterior wall after circumferential pulmonary vein isolation should be at least 2 centimeters to limit the portion of the posterior wall within the PVI ablation zone. PVI will be confirmed by verifying entrance and exit block at the PV orifices.
41025343|NCT05294640|DRUG|0.9% Bacteriostatic Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
41025344|NCT05294640|DRUG|1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
41025345|NCT05294640|PROCEDURE|Eyelid Lesion Removal|Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.
41025346|NCT00346034|DRUG|Pregabalin|150 to 600mg/day
41025347|NCT00483522|BEHAVIORAL|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
41025348|NCT00539526|DRUG|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
41025349|NCT00539526|DRUG|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
41025350|NCT00539526|DRUG|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
41025351|NCT02279303|BEHAVIORAL|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
41025352|NCT02279303|BEHAVIORAL|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
41025353|NCT04938037|PROCEDURE|US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine|nerve block
41025354|NCT02911402|OTHER|sea sickness questionnaires|
41266718|NCT03283085|DRUG|75 mg Ontamalimab|Ontamalimab SC solution for injection
41266719|NCT06076629|OTHER|Low temperature (16#) group|The exposure group will be exposed to low temperature (16#) in a chamber for about 2 hours, resting during the whole periods.
41499192|NCT01873183|OTHER|Goal directed fluid therapy|
41499193|NCT03803930|DEVICE|Using 22G FNB, the first pass is SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
41499194|NCT03803930|DEVICE|Using 22G FNB, the first pass is MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
41499195|NCT03803930|DEVICE|Using 20G FNB, the first pass is SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
41499196|NCT03803930|DEVICE|Using 20G FNB, the first pass is MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.technique-slow pull.
41499197|NCT04708548|OTHER|Health-related Quality of Life|Health-related quality of life (HRQOL) is an individual's or a group's perceived physical and mental health over time.
41499198|NCT04708548|OTHER|Psychological Distress|Measured of the distress experienced by patients
41499199|NCT04708548|OTHER|Fatigue|Measure of the extreme tiredness resulting from mental or physical exertion or illness
41499200|NCT04708548|OTHER|Cognitive Functioning|Cognitive functioning refers to multiple mental abilities, including learning, thinking, reasoning, remembering, problem solving, decision making, and attention. This will be measured through self-report and cognitive testing.
41499201|NCT05147324|BEHAVIORAL|"MyPlan - Individualized Planned Eating Pattern"|Sessions involve a structured behavior change counseling module derived from FLEX (NCT01286350), DASH-4-Teens (NCT00585832), and a Social Cognitive Theory and Transtheoretical Model informed conceptual framework, which uses education, motivation and self-efficacy enhancement, goal setting, and problem-solving skills training to initiate and sustain eating pattern adherence. Sessions support incremental progress towards meeting all five eating behavior goals by helping youth develop action plans, troubleshoot barriers to adherence, and refine action plans to improve adherence. Youth log in MyFitnessPal at least three days per week. Logs are used to assess and troubleshoot adherence, support youth in developing and refining action plans, and reward youth with points. Incentives are allocated using a point scheme designed to promote logging and goal achievement. Formal adjustment of the eating pattern is based on adherence according to logs and youth/guardian acceptability.
41499202|NCT04638530|OTHER|Education on breaking bad news to family members remotely|Participants will receive a combination of surveys, pre- and post-tests, lectures and didactics to increase their awareness of techniques to communicate difficult topics with patients remotely as well as skill building exercises.
41499203|NCT03994601|DRUG|BMS-986288|Specified dose on specified days
41499204|NCT03994601|DRUG|Nivolumab|Specified dose on specified days
41499205|NCT03994601|DRUG|Regorafenib|Specified dose on specified days
41499206|NCT03870282|BEHAVIORAL|Sleep Extension|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
41499207|NCT01279083|DRUG|DE-112|Topical ocular solution
41499208|NCT01279083|DRUG|DE-112|Topical ocular solution
41499209|NCT01279083|DRUG|DE-112|Topical ocular solution
41499210|NCT01279083|DRUG|DE-112|Topical ocular solution
41499211|NCT01279083|DRUG|DE-112 Vehicle Solution|Topical ocular solution
40841348|NCT01402648|DIETARY_SUPPLEMENT|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
41361646|NCT01302340|DRUG|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
40841349|NCT01402648|DIETARY_SUPPLEMENT|Maltodextrins|900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
40841350|NCT02315482|PROCEDURE|pneumoperitoneum insufflation and steep trendelenburg|the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
40841351|NCT01111279|BIOLOGICAL|gpASIT+TM|1 subcutaneous injection every 7 days, during 29 days.
40841352|NCT01111279|BIOLOGICAL|gpAST+TM/adjuvant|1 subcutaneous injection every 7 days, during 29 days
40841353|NCT01111279|BIOLOGICAL|Placebo solution|1 subcutaneous injection every 7 days, during 29 days
41499212|NCT01279083|DRUG|Timolol Maleate Solution|Topical ocular solution
41499213|NCT04005235|DEVICE|Thorasys Tremoflo C-100 Airwave Oscillometry System (FOT)|Ultrasonography will be used to confirm hemidiaphragm dysfunction after brachial plexus nerve block. In subjects with U/S confirmed hemidiaphragm dysfunction, FOT measurements will be taken before and after nerve block and post-operatively after upper extremity surgery.
41499214|NCT00152178|DRUG|UFT (uracil, tegafur) and tamoxifen|UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
40841354|NCT03020017|OTHER|Laboratory Biomarker Analysis|Correlative studies
40841355|NCT03020017|OTHER|Pharmacological Study|Correlative studies
40841356|NCT03020017|DRUG|Targeted Molecular Therapy|Given NU-0129 IV
40841357|NCT01836393|DRUG|Plavina cream|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of ...%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
40841358|NCT02174653|DRUG|EPs® 7630|20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
40841359|NCT02174653|DRUG|Placebo|Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
41025355|NCT03705039|OTHER|Pulsed Ultrasound Treatment|Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
41025356|NCT03705039|OTHER|Control group|Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
41025357|NCT02905526|BEHAVIORAL|Contraceptive instant messages|Contraceptive Instant messages
40841360|NCT03826199|DRUG|TDF-FTC|We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
40841361|NCT03826199|BEHAVIORAL|Counselling on PrEP in antenatal and postnatal care|Information about PrEP will be integrated into regular group education in ANC by existing health care providers during discussion about HIV testing and treatment. During every study visit, PrEP counseling (including adherence counseling for women already on PrEP) will be provided. For women not on PrEP, counselling will be provided on PrEP and HIV prevention.
40841362|NCT02920515|DRUG|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
40841363|NCT02920515|DRUG|Zhibo dihuang pills|Traditional Chinese Medicine
41025358|NCT02905526|OTHER|Mobile phone app|Mobile phone app
41025359|NCT02199847|DRUG|Pharmaton® Caplets|
41361647|NCT01302340|DRUG|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
41361648|NCT01302340|DRUG|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
41361649|NCT02934919|DRUG|Nalmefene|30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
40841364|NCT02920515|DRUG|Dabu ying pills|Traditional Chinese Medicine
40841365|NCT05044624|PROCEDURE|retroperitoneal mass excision|retroperitoneal mass excision
41025360|NCT02199847|DRUG|Placebo|
41025361|NCT02451748|OTHER|Lab Work|Lab work to measure IL-7 and IL-7R
41025362|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)|"Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
41025363|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)|"rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
41025364|NCT02451748|DRUG|Hydroxychloroquine|some patients are on 400mg/day of hydroxychloroquine.
41025365|NCT02451748|DRUG|Sulfasalazine|some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
41025366|NCT02451748|DRUG|Medrol|some patients are on 8mg/day of medrol
40841366|NCT00324233|DEVICE|Intermittent catheter|SpeediCath catherter (SC) for intermittent catherisation
40841367|NCT00324233|DEVICE|Compact intermittent catheter|SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
40841368|NCT02099305|OTHER|Adolescent Depression Awareness Program (ADAP)|Depression education curriculum delivered by trained school health education teachers or other school personnel
40841369|NCT05296993|DIETARY_SUPPLEMENT|Extracts found in the Extended Longevity supplements|Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.
41025367|NCT02451748|DRUG|Prednisone|some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone
41499215|NCT00152178|DRUG|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen|CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
41025368|NCT02451748|DRUG|Triamcinolone|some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly
41025369|NCT02451748|DRUG|Naproxen|some patients are on 1000 mg/day of naproxen
41025370|NCT02451748|DRUG|Leflunomide|some patients are on 20mg/day of leflunomide
41160826|NCT01111136|BEHAVIORAL|Stress intervention|To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
40841370|NCT04326816|PROCEDURE|Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)|
40841371|NCT02789891|PROCEDURE|D2 lymphadenectomy including No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
41160827|NCT05235997|DIETARY_SUPPLEMENT|Hydrolized Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
41160828|NCT05235997|OTHER|Placebo|Placebo look alike the experimental product
41361650|NCT04900961|OTHER|Resistance Exercise|The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
41499216|NCT05850585|DRUG|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
41025371|NCT02451748|DRUG|Methotrexate|some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
41025372|NCT02451748|DRUG|humira|some patients are on Humira 40mg q2weeks
41025373|NCT03650881|DRUG|Neutrogena ® Light Therapy Acne Mask (MASK)|Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
41025374|NCT03650881|DRUG|Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene|Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
41025375|NCT02992639|BEHAVIORAL|Control group|The participants who included in control group did not receive any treatment.
41025376|NCT02992639|BEHAVIORAL|Weight loss group|The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
41361651|NCT00876759|RADIATION|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
41361652|NCT00876759|RADIATION|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
41361653|NCT04434703|PROCEDURE|Platelet rich fibrin (PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound
41499217|NCT05850585|OTHER|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
41499218|NCT03122288|BEHAVIORAL|Individualized Cognitive Training|These are specific computerized exercises that are designed to improve performance in particular cognitive domains (e.g., attention, speed of processing, verbal learning/memory).
41499219|NCT03122288|OTHER|No-Contact Control|This is simply a no-contact control group. Participants in this group will receive no additional contact with the study beyond the baseline and posttest assessments.
41499220|NCT03725332|BEHAVIORAL|Telemedicine|Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with substance use counselor or perinatal nurse facilitator. Consultations will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months postpartum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
41499221|NCT03725332|BEHAVIORAL|Group Care|Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator or substance use counselor, with a peer support specialist. Small group care meetings will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
41499222|NCT01144507|PROCEDURE|Abdominal Ultrasound|To establish eligibility and/or markers regarding echo pattern types.
41499223|NCT01144507|OTHER|Sample collection procedures|Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects
41499224|NCT03814525|RADIATION|Photobiomodulation|PBM will be applied with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
41499225|NCT03814525|RADIATION|Placebo Photobiomodulation|The person responsible for applying the PBM will simulate the irradiation by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off
41499226|NCT01342900|DEVICE|connected to the InSpectra Monitor|
41499227|NCT03516279|DRUG|Dasatinib|Given PO
41025377|NCT02678546|OTHER|Other|case review of diagnosed disease
41025378|NCT04478097|DRUG|CKD-330 Tab. and D086 Tab.|1T
41025379|NCT04478097|DRUG|CKD-333 Tab.|1T
41025380|NCT00268749|DRUG|glycine|0.8 g/kg/day
41025381|NCT04144400|BEHAVIORAL|Direction Check App|Direction Check is a simple, inexpensive app that builds resilience through balanced values to target the everyday personal and occupational stressors faced by military populations.
41025382|NCT04144400|BEHAVIORAL|Direction Check App (Time Management Version)|Direction Check (Time Management Version) is a simple, inexpensive app that builds resilience through time management exercises to target the everyday personal and occupational stressors faced by military populations.
41499228|NCT03516279|DRUG|Imatinib Mesylate|Given PO
41499229|NCT03516279|OTHER|Laboratory Biomarker Analysis|Correlative studies
41499230|NCT03516279|DRUG|Nilotinib|Given PO
41499231|NCT03516279|BIOLOGICAL|Pembrolizumab|Given IV
41499232|NCT00834496|PROCEDURE|Liver biopsy|percutaneous liver biopsy
41499233|NCT03167723|DEVICE|Chest tube placement|Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
40841372|NCT02789891|PROCEDURE|lymphadenectomy excluding No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
41025383|NCT03666676|OTHER|Signal processing to improve intelligibility|Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.
41025384|NCT00964691|DRUG|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
41025385|NCT00964691|DRUG|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
41025386|NCT06139575|DRUG|Lutetium Lu 177 JH020002 Injection|Patients will receive Lutetium Lu 177 JH020002 Injection every 6 weeks for a maximum of 6 doses. Doses range between 1.85 and 8.88 GBq (50-240 mCi)
41025387|NCT00289341|BIOLOGICAL|vaccine vehicle only|Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
41025388|NCT00289341|BIOLOGICAL|DC/LNCaP|Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
41025389|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^6 TCID50/mL.
41499234|NCT05996562|PROCEDURE|Pulmonary Artery Denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55°C for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA."
41499235|NCT03784053|OTHER|Immersive virtual reality|At the start of every session, the participants' top five occupational problems will be reviewed, and a list of apps corresponding to the desired occupational problem will be offered through the immersive virtual reality device (Oculus Go). There will be eight 30-minute virtual reality sessions.
41025390|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^7 TCID50/mL.
41025391|NCT04039516|DRUG|Lutathera|A total of 4 infusions of Lutathera to be administered every 8 weeks.
41025392|NCT05665218|DIAGNOSTIC_TEST|right heart catheterization|Right heart catheterization (RHC) is an invasive hemodynamic procedure that allows direct measurement of right-sided cardiac pressures, calculation of cardiac output and pulmonary vascular resistance. It is the gold standard for the diagnosis of pulmonary arterial hypertension. Right heart catheterization is commonly performed by accessing the internal jugular vein (echo-guided access). Swan Ganz catheter with a dedicated thermistor is used to perform RHC; it is advanced through the right heart chambers to measure right atrial, right ventricle, pulmonary artery and pulmonary arterial wedge pressures. Cardiac output is measured using Fick direct, Fick indirect and thermodilution methods.
41361654|NCT04434703|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound
41361655|NCT04434703|PROCEDURE|blood clot|following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
41361656|NCT02730234|DEVICE|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
41499236|NCT03579927|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
41499237|NCT03579927|DRUG|Carmustine|Given IV
41499238|NCT03579927|DRUG|Cytarabine|Given IV
41499239|NCT03579927|DRUG|Etoposide|Given IV
41499240|NCT03579927|BIOLOGICAL|Filgrastim|Given SC
41499241|NCT03579927|DRUG|Melphalan|Given IV
41499242|NCT03579927|BIOLOGICAL|Rituximab|Given IV
41499243|NCT03579927|BIOLOGICAL|Umbilical Cord Blood-derived Natural Killer Cells|Given CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV
41499244|NCT06039189|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
41499245|NCT06039189|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
41499246|NCT00324727|DRUG|melphalan|Given throug isolated hepatic artery infusion
40841373|NCT00473525|DRUG|Placebo|Placebo QD
40841374|NCT00473525|DRUG|PF-00734200 10 mg QD|10 mg QD
40841375|NCT00473525|DRUG|PF-00734200 20 mg QD|20 mg QD
41361657|NCT00307658|DRUG|Intravenous immunoglobulins (human immunoglobulins G)|
41361658|NCT05580081|BEHAVIORAL|i-CAN|online support and consultation to providers
41361659|NCT02582008|DRUG|Bupropion Hydrochloride|Given PO
41361660|NCT02582008|OTHER|Laboratory Biomarker Analysis|Correlative studies
41361661|NCT02582008|DRUG|Nicotine Replacement|Given NRT
41499247|NCT00324727|DRUG|regional chemotherapy|Patients receive the best alternative therapy
41499248|NCT00324727|DRUG|systemic chemotherapy|Patients receive the best alternative therapy
41499249|NCT00324727|PROCEDURE|hepatic artery embolization|Patients receive the best alternative therapy
41499250|NCT04340596|BIOLOGICAL|N-803 (IL-15 Superagonist)|Administered by subcutaneous (SQ) injection
41499251|NCT04340596|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion
41499252|NCT04340596|BIOLOGICAL|10-1074|Administered by intravenous (IV) infusion
40841376|NCT00473525|DRUG|PF-00734200 5 mg QD|5 mg QD
41025393|NCT05191498|DEVICE|QuiremSpheres®|Intratumoral injection of QuiremSpheres® up to a dose of 150 Gy.
41025394|NCT01168934|DRUG|crizotinib|Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
41025395|NCT01168934|DRUG|crizotinib|Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
41025396|NCT01615445|DRUG|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
41025397|NCT01615445|DRUG|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
41025398|NCT01927445|OTHER|quality improvement toolkit|educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
41025399|NCT02721589|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
41025400|NCT01184014|DRUG|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
41025401|NCT01184014|DRUG|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
41025402|NCT01046643|DRUG|Estradiol (E2)|One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
41025403|NCT01046643|DRUG|Progesterone (P10) x90|One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
41025404|NCT01046643|DRUG|Progesterone (P10) x10|One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
41025405|NCT04532892|DIETARY_SUPPLEMENT|Meta 18.06 Day and Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
41025406|NCT04532892|DIETARY_SUPPLEMENT|Placebo Meta 18.06 Day and Placebo Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
41025407|NCT01690403|DRUG|rifapentine (M000473)|"Pharmaceutical form:tablet~Route of administration: oral"
41025408|NCT01690403|DRUG|EFZ EMT TDF|"Pharmaceutical form:tablet~Route of administration: oral"
41025409|NCT06421233|OTHER|massage|Endorphin massage will be given for 15 minutes every 2 hours.
41025410|NCT01972061|DEVICE|Foot stimulation|Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
41025411|NCT03901248|OTHER|No Intervention|Observational study
41025412|NCT03898245|DEVICE|apply tDCS|Intensity 2mA, 20minues, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
41025413|NCT03898245|DEVICE|Sham tDCS|Intensity 0mA, 40 seconds, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
41025414|NCT04382794|DRUG|Retrospective case-control analysis|Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
41025415|NCT02754167|BIOLOGICAL|PRS-080#022-DP|Hepcidin antagonism to mobilize iron and to treat anemia
41025416|NCT02754167|BIOLOGICAL|PRS-080-Placebo#001|Placebo comparator
41025417|NCT04800185|DRUG|Crisaborole 2% Top Oint|To analyze the skin microbiome of patients with atopic dermatitis before, during, and after treatment with crisaborole 2% ointment
41361662|NCT02582008|OTHER|Quality-of-Life Assessment|Ancillary studies
40841377|NCT00473525|DRUG|PF-00734200 2 mg QD|2 mg QD
41361663|NCT02582008|OTHER|Questionnaire Administration|Ancillary studies
40841378|NCT06087978|DRUG|14C RPT193|Radiolabelled RPT193
40841379|NCT02134730|BEHAVIORAL|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
40841380|NCT00043927|DRUG|topotecan/cisplatin|
40841381|NCT00043927|DRUG|etoposide/cisplatin|
40841382|NCT01416623|DRUG|henatinib|Henatinib Maleate Tablets
40841383|NCT01065311|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
41361664|NCT02582008|DRUG|Varenicline|Given PO
41160829|NCT02604342|DRUG|Alectinib|Participants will receive oral alectinib at a dose of 600 mg twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
41160830|NCT02604342|DRUG|Docetaxel|Participants will receive docetaxel at a dose of 75 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
41361665|NCT06440876|BEHAVIORAL|Music and Imagery|See music and imagery arm description.
41361666|NCT05431816|DIETARY_SUPPLEMENT|Dietary intervention|dietary fiber （Inulin 4g，Resistant Starch 4g，β-glucan 2g）
41361667|NCT04041648|DRUG|L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Single ascending dose
41361668|NCT04041648|DEVICE|L606 Inhalation System|Single ascending dose
41361669|NCT04041648|OTHER|Placebo Solution|Single ascending dose
41361670|NCT01420523|DRUG|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
41361671|NCT00307073|DEVICE|Implantable Pulse Generator|
41361672|NCT00987558|DRUG|Eslicarbazepine acetate|
41361673|NCT00987558|DRUG|Simvastatin|
41361674|NCT05179564|DIAGNOSTIC_TEST|iohexol administration|IV injection of weight-dependent low dose of iohexol at time 0
41361675|NCT05179564|DIAGNOSTIC_TEST|iohexol blood sampling|Blood sampling will be performed through an arterial (preferred) or venous line, other than the iohexol infusion line. In the first 30 minutes after iohexol injection, a blood sample of 2 ml will be obtained for iohexol concentration measurement and determination of renal biomarkers serum creatinine, cystatin C, betatrace protein. Subsequently, 2 up to 5 additional blood samples of 0,5 ml will be obtained for iohexol determination at 60,120 ,180, 240 and 360 minutes after iohexol injection to calculate iohexol plasma clearance from the plasma disappearance curve
41361676|NCT04084210|DEVICE|Juul Electronic cigarette|The juul e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.
41361677|NCT04084210|OTHER|Very Low Nicotine Cigarettes|These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from National Institute on Drug Abuse (NIDA's) Drug Supply Program (NOT-DA-14-004).
41361678|NCT04084210|DRUG|Active Nicotine Patch|Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).
41361679|NCT04084210|OTHER|Placebo Patch|Placebo patch containing no nicotine.
41361680|NCT04585789|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
41361681|NCT04585789|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
41361682|NCT04585789|DRUG|Entecavir (ETV)|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
41361683|NCT04585789|DRUG|Tenofovir disoproxil|Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
41361684|NCT04585789|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
41361685|NCT04585789|DRUG|PegIFN-alpha-2a (Optional)|PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
41361686|NCT05384509|DIAGNOSTIC_TEST|solid organ malignancies treatment|Major inclusion criteria for this cohort of the study included: (1) age above 20 years; (2) presence of solid organ malignancies treated with immunotherapy, chemotherapy, Target therapy irrespective of the treatment phase; and (3) eligibility for vaccination.
41361687|NCT05299112|DIETARY_SUPPLEMENT|Arginine|The intervention parenteral nutrition contains additional arginine (18% arginine content) as compared to standard parenteral nutrition (6.3% arginine content).
41361688|NCT01549327|OTHER|Oncology Interactive Navigator|
41361689|NCT01549327|OTHER|Routine Care|
41361690|NCT03345927|OTHER|no intervention|no intervention
41361691|NCT04561960|DRUG|Fluoride toothpaste|Fluoridated paste containing 1450ppm NaF
41361692|NCT04561960|DRUG|Toothpaste Product|Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
41361693|NCT04561960|DEVICE|Toothbrush|Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
41361694|NCT04561960|DEVICE|Miswak Stick|A miswak stick of 15 cm length
41361695|NCT05878340|BEHAVIORAL|Miffy|A method to stimulate children to try different fruits and vegetables using reward and role modelling
41361696|NCT05878340|BEHAVIORAL|Reward|Reference method to stimulate children to try fruits and vegetables using reward alone
41361697|NCT04694820|OTHER|Text Message-Based Navigation Intervention|Receive txt4TKI
41361698|NCT04694820|OTHER|Survey Administration|Ancillary studies
40841384|NCT01065311|BEHAVIORAL|The Cognitive Behavioral Analysis System of Psychotherapy|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
40841385|NCT01065311|BIOLOGICAL|Standard psychiatric care|"Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
40841386|NCT03225924|DRUG|Entospletinib|200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
40841387|NCT03225924|DRUG|Rituximab|cycles of 21 days - 375mg/m²
40841388|NCT03225924|DRUG|Cyclophosphamide|cycles of 21 days - 750 mg/m²
40841389|NCT03225924|DRUG|Doxorubicin|cycles of 21 days - 50mg/m²
40841390|NCT03225924|DRUG|Vincristine|cycles of 21 days - 1.4mg/m²
40841391|NCT03225924|DRUG|Prednisone|cycles of 21 days - 40mg/m²
40841392|NCT00455208|DRUG|Cura-100|
41025418|NCT04800185|GENETIC|Skin Microbiome Swabs|At the baseline visit the investigator will identify sites for swabbing the skin including one affected distinct crisaborole-treated AD lesion, and one untreated AD lesion. The lesions will both be sampled at baseline, 14 days into treatment, 28 days into treatment, 3 months into treatment, and 4 weeks after treatment completion. Photographs of each lesion will be taken for reference. Skin swabs will be obtained in a sterile fashion using a BD Culture SwabsTM EZ Collection and Transport System (or equivalent) and soaked with sterilized 0.15 M NaCl and 0.1% Tween-20. The samples will be frozen at -80 C, kept at this temperature, and stored until analysis may be completed.
41025419|NCT04440111|OTHER|One year training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015.~After that, they will make a practical workshop on BLS. Finally they will repeat the initial test. The second year, this group will only make the test, they won't receive any theory or practice."
41025420|NCT04440111|OTHER|Two years training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015. After that they will make a practical workshop on BLS.~Finally they will repeat the initial test. The second year, this group will repeat the same process."
41025421|NCT03956602|OTHER|Pretzels|To examine postprandial responses of pretzel consumption
41025422|NCT03956602|OTHER|Brazil nuts|To examine postprandial responses of Brazil nut consumption
41025423|NCT03956602|OTHER|Potato chips|To examine postprandial responses of potato chip consumption
41025424|NCT03956602|OTHER|Mixed nuts|To examine postprandial responses of mixed nut consumption
40841393|NCT03860467|OTHER|collection of patient data|Patient data will be collected using the in-house digital patient record systems and the local digital electroencephalogram (EEG)-database
40841394|NCT01581619|RADIATION|External Beam Partial-Breast Irradiation|40 Gy in ten daily fractions over two weeks
40841395|NCT02502981|DRUG|Spironolactone|25mg orally once a day for 40 weeks
41025425|NCT03956602|OTHER|White bread|To examine postprandial responses of white bread consumption
41025426|NCT03956602|OTHER|Dried mango|To examine postprandial responses of dried mango consumption
41025427|NCT03956602|OTHER|Mango fruit|To examine postprandial responses of fresh mango consumption
41025428|NCT02540239|DRUG|2L PEG|
41025429|NCT02540239|DRUG|2L PEG+simethicone|
40841396|NCT02502981|DRUG|Chlortalidone|25mg orally once a day for 40 weeks
40841397|NCT05676216|DRUG|Diphenhydramine|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
40841398|NCT05676216|DRUG|Sodium Bicarbonate|Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
40841399|NCT05676216|DRUG|Diphenhydramine + Sodium Bicarbonate|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push when vertigo patients visit Emergency Department
40841400|NCT00820222|DRUG|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
40841401|NCT00820222|DRUG|lapatinib|oral medication; daily dose taken once a day
41025430|NCT00743353|DRUG|F-18 RGD-K5|Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
41025431|NCT04696796|PROCEDURE|Mediolateral Episiotomy with BasIQ-4 Surgical Knife|Mediolateral episiotomy will be performed with BasIQ-4 Surgical Knife which cuts from distal to the center with inner knife.
41025432|NCT04696796|PROCEDURE|Mediolateral Episiotomy with Episiotomy Scissors|Mediolateral episiotomy will be made from the central to the distal with episiotomy scissors
41025433|NCT03169140|DEVICE|TheraBand Kinesiology Tape|A 20 cm strip of tape will be applied to each side of the low back directly over the erector spinae muscles at the site of pain. This tape will remain there, and be reapplied when necessary, for one week.
41025434|NCT03169140|DEVICE|Biofreeze|The topical analgesic will be sprayed directly on top of the erector spinae and site of pain low back directly, from inferior to superior to inferior 4 times a day for one week.
40841402|NCT00820222|DRUG|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
40841403|NCT01009866|BIOLOGICAL|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
40841404|NCT02270255|PROCEDURE|Superior hypogastric nerve block|21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
40841405|NCT02270255|DRUG|0.75% Ropivacaine|20 ml of 0.75% Ropivacaine
40841406|NCT02270255|PROCEDURE|Subcutaneous injection|Injection into subcutaneous tissues in periumbilical region
40841407|NCT02270255|DRUG|1% Xylocaine|5ml of 1% Xylocaine
40841408|NCT03672526|DEVICE|measure of injection pressure by compuflo|injection pressure mesured by Compuflo
40841409|NCT03173768|PROCEDURE|ID specialist approval|Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
40841410|NCT06249906|DEVICE|Commercial bone implant product Group|Commercial bone implant product Group with a smooth surface （without particular microstructures）.
40841411|NCT06249906|DEVICE|Mirco-structured Bioceramic Group|β-tri-Calcium phosphate with microstructures such as grooves, patterns and so on.
40841412|NCT01731067|DRUG|Cocktail probe drugs|
40841413|NCT00896649|OTHER|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
41025435|NCT03169140|BEHAVIORAL|Advice|An at-home pain management care sheet, outlining standard care advice will be followed for at home pain management for one week.
40841414|NCT00896649|PROCEDURE|digital mammography|standard screening mammogram
41025436|NCT03038373|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
40841415|NCT00896649|PROCEDURE|positron emission mammography|one-time positron emission mammography to compare recall rates with that of standard mammogram
40841416|NCT06027021|DIAGNOSTIC_TEST|18F-Fluoromisonidazole PET|Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.
40841417|NCT02408809|BEHAVIORAL|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
40841418|NCT02408809|BEHAVIORAL|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
40841419|NCT03695965|PROCEDURE|magnetic resonance imaging.|1.5 Tesla magnet system is going to be utilized for ankle imaging. A dedicated extremity surface coil (Foot/Ankle 16-Channel Coil; Siemens Medical Solution) is used to enhance spatial resolution.
41025437|NCT00000123|DEVICE|Polymethyl Methacrylate-Silicone Contact Lenses|
41025438|NCT00000123|DEVICE|Polymethyl Methacrylate Contact Lenses|
41361699|NCT05645939|OTHER|Diasgnosis of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
40841420|NCT02228447|BEHAVIORAL|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
40841421|NCT02720640|DEVICE|Implant 'on' vs implant 'off'|Single group assignment
40841422|NCT04267185|BEHAVIORAL|Physical Activity Together for PwMS and their CGs (PAT-MS)|A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
40841423|NCT04619147|OTHER|No intervention|This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.
40841424|NCT01365624|DRUG|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
41361700|NCT05215600|DEVICE|Anaverse Shoulder System|Reverse Shoulder Arthroplasty
40841425|NCT06508476|BIOLOGICAL|Amnion Chorion membrane|it is a placental allograft.
40841426|NCT06508476|PROCEDURE|connective tissue graft|it is an autograft
40841427|NCT05318196|BIOLOGICAL|Biological samples collection|"SOT patients: samples will be collected at the time of the protocol follow-up visit (registration on the transplant list, on the day of the transplantation, and then at day 15, month 1-3-6-9-12 and then annually, as well as if complications or therapeutic modifications).~Dialysis patients: at the start of the dialysis and then at M3, M12, and if complications or modification of the dialysis protocol.~Non-dialysis or cancer patients: the sampling frequency will be individualized according to the pathology studied (acute or chronic) and the purpose of the sampling (diagnostic, mechanistic, prediction, evaluation of the therapeutic response). Samples for diagnostic and mechanistic purposes will be taken only once. Samples for prognostic purposes will be taken at regular intervals, adapted to the natural history of the disease while respecting the maximum volume of blood samples defined by the French law. Samples will be collected during a sampling performed as part of routine care."
40841428|NCT03007095|BEHAVIORAL|Evaluation of the children's social cognitive development|standardized neuropsychological tests
41361701|NCT03449342|DRUG|turoctocog alfa|Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
41361702|NCT00051246|BEHAVIORAL|Mother-Infant Group Psychotherapy|Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
41361703|NCT00051246|BEHAVIORAL|Interpersonal Psychotherapy|Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
41361704|NCT04606810|OTHER|multidisciplinary educational intervention|At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
40841429|NCT04014127|DIAGNOSTIC_TEST|Coronary flow reserve assessment|Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.
40841430|NCT04014127|DIAGNOSTIC_TEST|Sphygmocor|Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device
40841431|NCT04014127|DIAGNOSTIC_TEST|Electrocardiogram|An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease
40841432|NCT04014127|OTHER|Blood test|Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury
41361705|NCT03467035|OTHER|Inflammasone|Serum level of cytokine and RT-PCR for PBMC
40841433|NCT04014127|OTHER|Urinary albumin/creatinine ratio|Urine will be analysed for albumin/creatinine ratio
40841434|NCT02831933|BIOLOGICAL|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
41361706|NCT05514093|DEVICE|Beyond Silence App|"The Beyond Silence app is designed to be a mental health coach in your pocket for healthcare workers. It provides opportunities to build mental health literacy and reduce barriers to seeking support, including access to peer support either within or outside the organization."
41361707|NCT02478736|OTHER|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
41361708|NCT01928758|DRUG|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
40841435|NCT02831933|DRUG|Valacyclovir|Prodrug of the antiviral drug acyclovir
41361709|NCT01928758|DRUG|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
41361710|NCT02853097|OTHER|Cytology Specimen Collection Procedure|Undergo blood collection
41361711|NCT02853097|OTHER|Laboratory Biomarker Analysis|Correlative studies
41499253|NCT05245318|OTHER|Standard Clinical care|The standard care treatment comprises 12 face-to-face individual physiotherapy sessions at a ratio of 1 session a week. Every patient in the control group will be treated in a tailored manner according to their results on the baseline measurements. The multimodal treatment program will consist of exercises to increase strength, endurance and coordination of the cervical spine and shoulder stabilising muscles, exercises to increase mobility and improve posture. In case of jaw complaints stretching exercises of the masticatory muscles are added to the program. In addition, manual mobilisations and manual techniques to decrease muscle tension in neck and jaw muscles can be added to the exercise program if necessary. Patients will receive counselling to learn about their neck/jaw complaints but no tinnitus counselling. Patients will be motivated to perform the exercise program at home on a daily basis. Patients will be evaluated weekly.
41499254|NCT05245318|DEVICE|Blended physiotherapy program|The experimental group will receive a blended physiotherapy program consisting of six physiotherapy treatments over a period of 12 weeks, meaning one treatment session every two weeks. In addition, a smartphone application will offer the patients a daily exercise program, based upon the standard physiotherapy treatment, and psychological counselling. Before the start of the program, the exercises will be tailored to the area, type and degree of the patient's dysfunctions. During the six physiotherapy treatment sessions patients will (if needed), receive additional manual mobilisations to increase mobility of the neck and/or temporomandibular joints or manual techniques to decrease muscle tension in neck and jaw muscles. Additional counselling on knowledge about neck and jaw pain and advice about good posture and movement habits will also be provided by the physiotherapist during these six treatment sessions.
41361712|NCT04250246|DRUG|Ipilimumab plus nivolumab plus guadecitabine|"Cohort A Melanoma ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 1 mg/Kg i.v.q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 480mg i.v. q4wks for 2 years"
41361713|NCT04250246|DRUG|Ipilimumab plus nivolumab|"Cohort A Melanoma ARM B Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM B Ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q6 wks plus nivolumab 480mg i.v. q4wks for 2 years."
41361714|NCT01402882|DRUG|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
41361715|NCT00337935|DRUG|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
41361716|NCT00337935|OTHER|Standard of care|
40841436|NCT02831933|RADIATION|SBRT|Low-dose SBRT
40841437|NCT02831933|DRUG|nivolumab|Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
40841438|NCT05423912|BEHAVIORAL|Couple in Control (CiC) Program|MCI dyads engaging in the pilot testing aim of the CiC Program meet in virtual intervention group meetings lasting 90 to 120 minutes over the course of 8-9 consecutive weeks. Participants are asked to take part in structured quantitative interviews at baseline and 4 and 8 weeks post-intervention. A subsample of participants will be interviewed virtually via videoconference for a 30 to 60 minute discussion on their experiences in and perceptions of the intervention.
41361717|NCT02335411|BIOLOGICAL|pembrolizumab|IV infusion
41361718|NCT02335411|DRUG|cisplatin|IV infusion
41361719|NCT02335411|DRUG|5-FU|IV infusion
41361720|NCT02335411|DRUG|capecitabine|oral tablets
40841439|NCT04598269|DRUG|ATI-1777|ATI-1777 topical solution 2.0% w/w
40841440|NCT04598269|DRUG|Vehicle|Vehicle topical solution containing no ATI-1777
41361721|NCT01116726|BEHAVIORAL|Motivational interviewing|MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
41361722|NCT01116726|BEHAVIORAL|Enhanced community services|Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
41361723|NCT04852601|OTHER|ToolboxDetect|The clinician or staff member will identify the patient by either scanning a barcode or entering his/her name, age and medical record number on an administrative screen (allowing for proper routing of test results). After completing the test, a 'submit' button will automatically generate a secure HL7 message, sharing 1) a binary classification of the results ('impaired cognition' or 'normal function'), 2) the quantitative ToolboxDetect score, and 3) brief clinical decision support to rule out any reversible causes. These results will be linked to a discrete, queriable, Epic SmartData element. As patients undergo multiple AWVs over time, ToolboxDetect quantitative scores will be displayed in Epic Synopsis Activity, a graphical display that can visualize trend data (e.g. patient vitals) and calculate a percentage change from the prior year. This will allow a clinician to establish a patient's own baseline (instead of using normative data only) for reference.
41361724|NCT05196074|OTHER|Acute hypoxemic respiratory failure patients on VV-ECMO|To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.
41361725|NCT03915782|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning (RIC): Four cycles of \[5 minutes of brachial cuff inflation at 200 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
41361726|NCT03915782|DEVICE|Patients with a sham procedure of remote ischemic conditioning|Sham procedure: Four cycles of \[5 minutes of brachial cuff inflation at 30 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
41361727|NCT06365840|DRUG|IMC-001|All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.
41361728|NCT01959087|PROCEDURE|single port surgery|Single port surgery can be converted in multiport surgery if necessary
41361729|NCT01959087|PROCEDURE|Multiport surgery|
41361730|NCT04759729|COMBINATION_PRODUCT|Probiotic and vitamin D|"Participants enrolled to PRO + D group will receive probiotics and vitamin D supplements as a intervention product.~Participants enrolled to probiotic group will receive probiotics as well as vitamin D supplements."
41361731|NCT04759729|DIETARY_SUPPLEMENT|placebo and vitamin D|Participants enrolled to PL+D group will receive vitamin D. Additionally they will get placebo instead of probiotics.
41361732|NCT00862927|OTHER|Breath Sample|Breathe into machine measuring carbon monoxide.
41361733|NCT00862927|OTHER|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
41361734|NCT00862927|BEHAVIORAL|Questionnaire|6 surveys, taking approximately 30 minutes total.
41361735|NCT00862927|BEHAVIORAL|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
41361736|NCT04870294|DEVICE|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material.
40841441|NCT01751139|PROCEDURE|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
40841442|NCT01751139|OTHER|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
40841443|NCT01729494|DRUG|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
41025439|NCT04103229|PROCEDURE|The use of different types and volumes of solutions to inflate the catheter balloon|In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
41361737|NCT04870294|DEVICE|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
41361738|NCT01718574|OTHER|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
41361739|NCT04323345|DIETARY_SUPPLEMENT|Natural Honey|Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.
41361740|NCT04323345|OTHER|Standard Care|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
41361741|NCT06080529|OTHER|Sandbag exercise|Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean
41361742|NCT05631873|OTHER|Assistance with implementing Epic Smartlist|A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
41499255|NCT01650701|DRUG|Rituximab|• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
41361743|NCT00459329|BEHAVIORAL|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).~PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.~Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.~After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
41361744|NCT03037489|DRUG|MIV-711|MIV-711 administered orally once daily
41361745|NCT00104429|DRUG|GW873140|
41025440|NCT06418971|BEHAVIORAL|CarePair|This study will pilot test the feasibility and acceptability of a digital self-assessment and referral tool using machine learning models to enhance service use and address unmet needs in ADRD caregivers.
41361746|NCT00104429|DRUG|Combivir|
41361747|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily in a predefined dose escalation scheme.
41025441|NCT03025620|DIETARY_SUPPLEMENT|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
41025442|NCT03025620|DIETARY_SUPPLEMENT|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
41361748|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
41361749|NCT06462391|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Group|Psychotherapy group (delivered virtually)
41361750|NCT03031873|DEVICE|MRI perfusion imaging|Evaluate the evolution of progressive obliteration of the AVM nidus
41361751|NCT00460642|DRUG|GnRH Antagonist (Cetrotide)|
41361752|NCT01398176|DIETARY_SUPPLEMENT|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
41361753|NCT01398176|DIETARY_SUPPLEMENT|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
41361754|NCT01376115|DRUG|Nelarabine|
41361755|NCT04701801|DIAGNOSTIC_TEST|MoCA test|Preoperative MoCA test and State-Trait Anxiety Inventory Test (STAI FORM ) questionnaire form will be filled in female patients between the ages of 18-65 by making a one-on-one interview with the patient and the MoCA test will be applied in the early postoperative period (1st week) to ensure its relationship with POCD will be checked.
41361756|NCT00852735|DIETARY_SUPPLEMENT|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
41361757|NCT01465984|DRUG|Paracetamol|paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
40841444|NCT01729494|DRUG|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
40841445|NCT01729494|DRUG|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
40841446|NCT01729494|DRUG|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
40841447|NCT01729494|DRUG|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
40841448|NCT01729494|DRUG|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
40841449|NCT02773654|OTHER|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
40841450|NCT02773654|OTHER|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
40841451|NCT00958217|BEHAVIORAL|Cognitive Processing Therapy-Modified (CPT-M)|Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
40841452|NCT00958217|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (ICBT)|Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
41025443|NCT02533882|BEHAVIORAL|Movement to Music|
41025444|NCT02533882|BEHAVIORAL|Adapted Yoga|
41025445|NCT04396886|DRUG|Bintrafusp Alfa|Bintrafusp alfa will be administered intravenously every 2 weeks
41025446|NCT03870230|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT
41025447|NCT03870230|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device
41025448|NCT03870230|DEVICE|Pattern Electroretinography (pERG)|to assess the neuronal function of the retina, pattern ERG will be performed
41025449|NCT03870230|DEVICE|Optical coherence tomography (OCT)|to assess the morphology of the retina, OCT will be performed
41025450|NCT03870230|DEVICE|Laser Speckle Flowgraphy (LSFG)|to assess retinal blood flow, LSFG will be performed
41025451|NCT03025165|OTHER|Community Adherence Clubs|Provision of ART care in the community to a club of 20-25 HIV+ patients
41025452|NCT03025165|OTHER|Home-Based ART Delivery|Provision of ART care to an individual at their home
41025453|NCT03025165|OTHER|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
41025454|NCT04012398|DIAGNOSTIC_TEST|Amsterdam IADL Questionnaire short, German version|Questionnaire to assess impairments in instrumental activities of daily living
41025455|NCT03208387|DIAGNOSTIC_TEST|Diffusion tensor imaging (DTI)|DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
41025456|NCT03208387|DIAGNOSTIC_TEST|Resting state functional connectivity MRI (rs-fcMRI)|rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement). Neuroimaging data will be collected as soon as possible (can be the same day), for up to 6 weeks.
41025457|NCT03208387|BEHAVIORAL|Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
41025458|NCT03208387|BEHAVIORAL|California Verbal Learning Test (CVLT-C)|Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.
41361758|NCT00120029|BEHAVIORAL|weight loss counseling|
40841453|NCT05220332|BEHAVIORAL|Heart to Heart|The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.
41025459|NCT03208387|BEHAVIORAL|Beery Test of Visual Motor Integration 6th edition|Measure designed to assess visual-motor functioning of subjects between the ages of 2-99 years old by copying designs using paper and pencil.
41025460|NCT03208387|BEHAVIORAL|Grooved Pegboard|This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.
41025461|NCT03208387|BEHAVIORAL|PedsQL Multidimensional Fatigue Scale|Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).
41025462|NCT03208387|DIAGNOSTIC_TEST|MRI|Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
41361759|NCT01337440|DRUG|UDCA|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
41361760|NCT01337440|DRUG|Sitagliptin|"UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
41361761|NCT04781127|DEVICE|Soterix Medical mini-CT tDCS stimulator|Stimulation will last 30 minutes per day, 5 days per week, for 5 weeks, then 3 days per week for 1 week and then 1 day per week for 4 weeks.
41025463|NCT00472667|PROCEDURE|Procalcitonin guided strategy|Procalcitonin guided strategy
41266720|NCT06076629|OTHER|Moderate temperature (22#) group|The exposure group will be exposed to thermoneutral temperature (22#) in a chamber for about 2 hours, resting during the whole periods.
41361762|NCT04306575|OTHER|Trans-venous lead extraction|Patients with a dysfunction or infection of a cardiac pacemaker or a defibrillator are indicated for extraction of these devices, so lead extraction is done transvenously to remove these leads
40841454|NCT05220332|BEHAVIORAL|Money Smart|The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.
40841455|NCT05856565|OTHER|Photo|Photography intake
40841456|NCT04367467|OTHER|Kidney Function Test|Cystatin-C measurement
41361763|NCT05879848|OTHER|VR|virtual reality scenario synchronized with the uterine contractions
41361764|NCT00241371|DRUG|Clofarabine|
41361765|NCT01248429|BIOLOGICAL|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
41361766|NCT01248429|OTHER|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
41361767|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
40841457|NCT04863690|BEHAVIORAL|Meditation|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations, as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks. If they also wish to use the Muse system more frequently (day or night), they will be encouraged to do so and will be able to choose between several styles of available meditation (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations). Participants will be asked to also wear their Muse device while they sleep, as often as they like in order to track their sleep.
40841458|NCT04863690|BEHAVIORAL|Digital Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
41361768|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
41361769|NCT00247052|DRUG|diclofenac|diclofenac 50 mg bid versus placebo bid
41361770|NCT00247052|DRUG|diclofenac|diclofenac 100 mg per day for 14 days
41361771|NCT00247052|DRUG|matching placebo|
41361772|NCT02180854|OTHER|Control group|
41361773|NCT02180854|OTHER|Increased monitoring frequency|
41361774|NCT01286766|DRUG|DCS (docetaxel with cisplatin with TS-1)|"1. S-1: 70 mg/m2 #2 bid PO, D1-14~2. Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8~3. Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks."
41361775|NCT01286766|DRUG|DCF (docetaxel with cisplatin with 5-FU)|"1. 5-FU: 1,000 mg/m2 CI, D1-3~2. Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by~3. Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.~   * Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)~  * treatment is repeated until 4 cycles"
41361776|NCT01130831|DRUG|Lanthanum carbonate|
41361777|NCT05222516|DRUG|Broncho-Vaxom|Daily administration of Broncho-Vaxom 3.5mg capsules
41025464|NCT02550613|DEVICE|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
41361778|NCT05222516|DRUG|Placebo|Daily administration of Placebo capsules
41361779|NCT04873323|DRUG|TS-142|Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
41361780|NCT04873323|DRUG|Moxifloxacin|Single dose of moxifloxacin 400 mg in the morning under fasting in each period
41361781|NCT04873323|DRUG|Placebo|Single dose of TS-142 placebo in the morning under fasting in each period
41361782|NCT01273012|DRUG|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
41361783|NCT00232531|DRUG|Niaspan|
41361784|NCT02362295|OTHER|qualitative interview|some patient are interviewed.
41361785|NCT03812198|DRUG|LEO 32731 modified release tablet|At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.
41361786|NCT03812198|DRUG|LEO 32731 blend, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
41361787|NCT03812198|DRUG|LEO 32731 API, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
41361788|NCT03812198|DRUG|LEO 32731 soft capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
41361789|NCT03812198|DRUG|LEO 32731 gastro-resistant capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
41025465|NCT04790149|OTHER|Conventional Rehabilitation|Motor Imagery Training combined with Active functional exercises
41025466|NCT04790149|OTHER|NEUROM + tDCS|NEUROM combined to tDCS
41361790|NCT03812198|DRUG|LEO 32731|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
41361791|NCT03812198|OTHER|Placebo|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
41025467|NCT04790149|OTHER|NEUROM|protocol to induce motor recovery
41025468|NCT03141502|DEVICE|Skin stretching device (SSD)|By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.
41025469|NCT03141502|PROCEDURE|Skin grafting|the standard technique of skin grafting after wound preparation.
41025470|NCT03917290|BEHAVIORAL|Neuromuscular training|Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants. Due to in-person restrictions that have resulted from COVID-19, participants may also complete the intervention via remote (virtual) training sessions.
41266721|NCT01330901|DRUG|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
41266722|NCT05527457|DRUG|BAY2586116|160 μg BAY2586116 nasal spray application
41266723|NCT05527457|DRUG|Placebo|Placebo (saline) nasal spray application
41266724|NCT01976949|BEHAVIORAL|online social-networking intervention|
41266725|NCT05876403|OTHER|Conventional|The participants of controlled group will be given the treatment protocol after baseline measurements controlled breathing techniques (3session per week 10mins for 6 weeks) \& Aerobic exercise(3 session per week for 6 weeks) with 10sec hold into 10reps.outcome measures will be recorded through a digital spirometer \& measurement of 6MWT \& chest expansion.
41266726|NCT05876403|OTHER|PNF|The participants of experimental group will be given the Intervention protocol after baseline measurements. Additionally these 30 participants will also receive PNF technique exercises consisting of Thoracic Vertebral pressure, Anterior Basal stretch, and Intercostal stretch for 20-25 minutes in 3 sessions per week, and outcomes Measures will be recorded through a digital spirometer and measurements of 6 minutes walk test and chest Expansion.
41266727|NCT05495347|OTHER|patients diagnosed with OSA|All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
41266728|NCT04870437|OTHER|Extracorporeal phototherapy|The principle of ECP is to collect mononucleated cells from the blood by centrifugation. After purification, the mononucleated cells are incubated ex-vivo with a photo-activatable DNA intercalating agent (8-methoxypsoralen, UVADEX®), then re-injected to the patient.
41266729|NCT03257189|DEVICE|Physiological signal monitor|Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.
41266730|NCT03257189|DEVICE|Heart rate and heart rate variability comparison device|FDA cleared reference device that monitors heart rate and heart rate variability in subjects
41266731|NCT03257189|DEVICE|Respiration rate comparison device|FDA cleared reference device that monitors respiration rate in subjects
41266732|NCT03257189|OTHER|Activity classification|Visual annotation of subject posture and other activities used for reference
41266733|NCT05124223|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI was performed as clinically indicated to assess cardiac pathology.
41266734|NCT00397722|DRUG|GW876008|
41266735|NCT00397722|DRUG|paroxetine|
41361792|NCT00193726|DRUG|Tab Premarin (Ethinyl estradiol)|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
41361793|NCT00193726|DRUG|Placebo|Placebo once a day for 5 days prior to each cycle of chemotherapy
41361794|NCT05530798|DEVICE|Definity Perflutren Lipid Microsphere Ultrasound Contrast|"1. Before the spinal decompression surgery has started, the study team will inject the ultrasound contrast to visualize the spinal cord prior to decompression of the spinal cord.~2. After the spinal cord has been decompressed, the study team will inject the ultrasound contrast to visualize the spinal cord directly after decompression of the spinal cord.~3. Prior to completion and closure of the incision, the study team will once more inject the ultrasound contrast to visualize the spinal cord.~4. A member of the research team will follow up with study participants within a week of the procedure by phone. The research staff will also review the participants' medical record for up to 360 days after your procedure to collect information on clinical outcomes and any additional treatments, tests or procedures the study participants may have had."
41361795|NCT03960476|BEHAVIORAL|PlanYourLifespan.org|The study intervention is a web-based planning tool, PlanYourLifespan.org
41361796|NCT03351660|DIAGNOSTIC_TEST|connected ECG|Cardiosecur allows the realization of a 15 or 22 leads ECG with only 4 electrodes connected to a tablet with an automatic interpretation function
41361797|NCT03378531|DRUG|AEB1102|modified human arginase I
41361798|NCT06078189|DEVICE|HORUS|"The trapezium-metacarpal arthroplasty consists of the installation of a bipolar prosthesis composed of a metacarpal implant and a trapezial implant articulated through a metacarpal head."
41499256|NCT01650701|DRUG|Lenalidomide|• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
41499257|NCT01650701|DRUG|Rituximab - CHOP|six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
40841459|NCT04863690|BEHAVIORAL|Digital Coaching plus Human Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation. All participants will also be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account.
41361799|NCT05717413|DEVICE|metatarsophalangeal joint endoprosthesis|arthroplasty of 1 metatarsophalangeal joint
41361800|NCT05129644|DRUG|P1101 (24 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.
41361801|NCT05129644|DRUG|P1101 (48 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.
41361802|NCT05129644|DRUG|P1101 (90 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.
41361803|NCT05129644|DRUG|P1101 (180 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.
41361804|NCT05129644|DRUG|P1101 (225 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.
41361805|NCT05129644|DRUG|P1101 (270 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.
41361806|NCT05129644|DRUG|Pegasys|Pegasys for injection, 180 mcg/mL, 1.0 mL/vial, Dose/subject: 180 mcg subcutaneously.
41361807|NCT05910606|BEHAVIORAL|Digital Exercise|Fall Prevention Program: Our fall- risk reduction program overs digitally delivered exercise with real time feedback from expert instructors.
41361808|NCT02206230|RADIATION|Hypofractionated radiation therapy|
41361809|NCT02206230|RADIATION|Standard radiation therapy|
41266736|NCT00249574|DRUG|Buprenorphine/naloxone|Human subjects HIV, HCV
41499258|NCT01650701|DRUG|Rituximab - CVP|eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
41499259|NCT01650701|DRUG|Rituximab - Bendamustine|six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
41499260|NCT00919854|DRUG|Darunavir|Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and \<20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
41499261|NCT00919854|DRUG|Ritonavir|Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
41499262|NCT05470283|DRUG|OBX-115|Given by IV
40841460|NCT02782767|OTHER|Wound catheter infusion|Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
41025471|NCT01679535|BEHAVIORAL|nutrition and hygiene education|Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
41361810|NCT05588622|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
41025472|NCT06535724|PROCEDURE|Chronic plantar fasciitis endoscopic debridement coupled with heel spur resection|"1. Preoperative Preparation: popliteal nerve block, patient positioning supine with the operated limb fully externally rotated, spinal anesthesia, tourniquet application.~2. Surgical Procedure:~   * Initial Marking from the heel bone arch to the calcaneal bone to locate the entry point.~  * First Incision and Portal Creation: an initial incision at the palpated site using a size 11 blade; blunt dissection to reveal the plantar fascia; arthroscope entry.~  * Secondary Entry: 3 cm distally from the initial incision; positioning of the arthroscope; additional blunt dissection and obturator insertion.~  * Operative Technique: continuous irrigation with sterile saline; 3.5-mm shaver introduced through the distal portal; meticulous debridement of inflamed and pathological tissue; removal of calcaneal spurs; thinning of the plantar fascia~3. Postoperative Care • Careful monitoring and guided rehabilitation to support optimal healing and recovery."
41025473|NCT00466193|DRUG|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
41025474|NCT00466193|DRUG|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
41025475|NCT02029924|DRUG|BioChaperone insulin lispro|Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
41025476|NCT02029924|DRUG|Humalog®|Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
41361811|NCT02924129|DEVICE|Evoke Spinal Cord Stimulator (SCS) System|Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
41361812|NCT00824746|DRUG|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
41361813|NCT01140646|DRUG|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
41361814|NCT01140646|OTHER|questionnaire administration|Ancillary studies
41361815|NCT01140646|PROCEDURE|quality-of-life assessment|Ancillary studies
41361816|NCT02981745|DRUG|CT-1530|Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma
41361817|NCT04944966|DRUG|Maytenus Senegalensis|"* Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg"
41361818|NCT01134458|BEHAVIORAL|Web-Based Intervention|"1. Health Dialog Cardiac Risk Calculator~2. Health Dialog's Living with Coronary Heart Disease~3. Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight"
41361819|NCT06299150|OTHER|IPS e.max CAD|CAD CAM Restoration
41361820|NCT05519891|OTHER|Custom 3D printed device|A 3D printed adaptation for a mobile device.
41361821|NCT04034225|DRUG|SNS-301|Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
41361822|NCT04034225|DRUG|Pembrolizumab|Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
41361823|NCT00003230|DRUG|paclitaxel|
41361824|NCT02136719|PROCEDURE|bimanual uterine compression|bimanual uterine compression immediately after delivery of placenta for 5 minutes
41361825|NCT04982276|BIOLOGICAL|AK109|Subjects will receive AK109 by intravenous administration.
41361826|NCT04982276|DRUG|paclitaxel|Subjects will receive AK109 in combination with paclitaxel.
41361827|NCT04982276|DRUG|paclitaxel|Subjects will receive AK104 and AK109 in combination with paclitaxel.
41361828|NCT04982276|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration.
41361829|NCT04550234|DRUG|Verinurad prolonged release HPMC capsule|Randomized subjects will receive oral dose of verinurad HPMC capsule.
41361830|NCT04550234|DRUG|Allopurinol Tablet|Randomized subjects will receive oral dose of allopurinol tablet.
41361831|NCT04550234|DRUG|Verinurad/Allopurinol FDC Capsule|Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.
41361832|NCT04550234|DRUG|Verinurad prolonged release gelatin Capsule|Randomized subjects will receive oral dose of Verinurad gelatin capsule.
40841461|NCT02782767|OTHER|Epidural infusion|Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
40841462|NCT01943552|DRUG|placebo|normal saline
40841463|NCT01943552|DRUG|ipratropium bromide|ipratropium bromide
40841464|NCT04129385|PROCEDURE|20 degree Trendelenburg position|The patients in the intervention group will be placed in trendelenburg position postoperatively.
40841465|NCT00751855|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
41025477|NCT00630877|DRUG|Niacin extended-release (NER)|Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
41025478|NCT00630877|DRUG|Niacin extended-release (NER) placebo|Tablets administered once daily for 6 weeks
40841466|NCT00751855|DRUG|Hydrocortisone|30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
41499263|NCT05470283|DRUG|Acetazolamide|Given by PO
41499264|NCT05470283|DRUG|Cyclophosphamide|Given by IV
40841467|NCT00751855|DRUG|placebo|placebo
40841468|NCT05749952|DEVICE|Symphonie Aqua Digital System|We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
41025479|NCT00630877|DRUG|Aspirin (ASA)|Tablets (325 mg) administered once daily for 6 weeks
41025480|NCT00630877|DRUG|Aspirin (ASA) placebo|Tablets administered once daily for 6 weeks
41025481|NCT01324024|DRUG|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
41499265|NCT05470283|DRUG|Furosemide|Given by IV
41499266|NCT05470283|DRUG|Mesna|Given by IV
41499267|NCT05470283|DRUG|Fludarabine Phosphate|Given by IV
41361833|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
41499268|NCT01421511|DRUG|TR-701 FA|"* TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~* TR-701 FA Tablets, 200 mg, orally once daily"
41499269|NCT01421511|DRUG|Linezolid|"* Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~* Linezolid Tablets, 600 mg, orally every 12 hours"
41499270|NCT05408234|OTHER|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
41499271|NCT06113016|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41499272|NCT06113016|OTHER|Educational Intervention|Receive handout on physical activity
41499273|NCT06113016|OTHER|Exercise Intervention|Receive individually tailored exercise intervention
41499274|NCT06113016|DRUG|Fisetin|Given PO
41361834|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
41361835|NCT00205010|PROCEDURE|Lymphoscintigraphy|
41361836|NCT03034746|OTHER|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
41361837|NCT03034746|OTHER|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
41361838|NCT04275024|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
41361839|NCT04275024|DRUG|PSORI-CM01 Granule|PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
41361840|NCT04275024|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg
41361841|NCT02984631|PROCEDURE|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
41361842|NCT04787146|OTHER|No intervention|Once the patient is included, a drug assessment is carried out as part of the treatment and then an compliance questionnaire is submitted to him.
41499275|NCT06113016|OTHER|Physical Performance Testing|Ancillary studies
41499276|NCT06113016|DRUG|Placebo Administration|Given PO
41361843|NCT05174013|DRUG|GSK3858279|GSK3858279 will be administered
41499277|NCT06113016|OTHER|Quality-of-Life Assessment|Ancillary studies
41499278|NCT06113016|OTHER|Questionnaire Administration|Ancillary studies
41499279|NCT06195072|DRUG|Amlitelimab|"IP will be administered subcutaneously by the Investigator or designee as follows:~* Amlitelimab or~* Matching placebo"
41499280|NCT06195072|DRUG|BI 1015550|Study participants will take the active investigational product BI 1015550 or matching placebo provided as film-coated tablets, administered orally BID.
41499281|NCT06195072|DRUG|Placebo|see Experimental Arm intervention description
41499282|NCT06494488|DRUG|EPA|Fish oil
41499283|NCT06494488|DRUG|DHA|Fish oil
41499284|NCT04886258|DRUG|DFV890|DFV890
41499285|NCT04886258|DRUG|Placebo|Placebo
41499286|NCT05828576|DIAGNOSTIC_TEST|MRI|Patients will be asked for two additional control visits in the hospital. Overview of measurements: Included subject will visit the UMCU at two occasions. The first MRI scan will be the baseline MRI, and the second MRI will take place after 2 years of follow-up. Additional follow-up data will be collected through medical records reporting on regular follow-up.
41499287|NCT01960712|DEVICE|Transpapillary plastic stent (7-10 Fr)|Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
41499288|NCT02175316|DEVICE|Enhanced External Counterpulsation|Enhanced External Counterpulsation
40841469|NCT05749952|DEVICE|Symphonie Aqua System (Non-Digital)|A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
41499289|NCT06168110|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment method widely used for pain control
41499290|NCT02390687|DRUG|Probiotic|Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
40841470|NCT04519060|DEVICE|phototherapy eye shield|Phototherapy eye shields will be applied to the eyes of infants dilated for scheduled eye exam. They will be worn until four (4) hours after the last dose of dilating eye drops.
40841471|NCT06508008|PROCEDURE|continuous negative pressure suction|(1) Open the mouth with a tongue depressor; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) Insert a suction tube into the mouth to aspirate phlegm.
41361844|NCT05174013|DRUG|Placebo|Placebo will be administered
41499291|NCT02390687|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
41499292|NCT04618640|BIOLOGICAL|DTaP-IPV combination vaccine|Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years
41499293|NCT06080854|DRUG|Toripalimab|Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks
41499294|NCT06080854|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks
41499295|NCT06080854|DRUG|Nab paclitaxel|Nab paclitaxel 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
40841472|NCT06508008|PROCEDURE|Intermittent negative pressure sputum suction through oral pharyngeal airway|(1) Insert the oropharyngeal airway parallel into the oral cavity; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) The suction tube is inserted into the deep oral cavity through the middle lumen of the oropharyngeal airway; (4) Intermittent negative pressure for suction and suction of sputum
40841473|NCT03518346|BEHAVIORAL|Virtual Reality|Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction
40841474|NCT03518346|BEHAVIORAL|Standard of Care|Books, movies, TV
40841475|NCT00665236|OTHER|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
40841476|NCT00665236|PROCEDURE|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
41361845|NCT01965691|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals-~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
41361846|NCT02449733|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
41361847|NCT02449733|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
41361848|NCT02449733|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
41361849|NCT02449733|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|"FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit."
41361850|NCT02449733|OTHER|HIV Testing|Rapid HIV testing at multiple time points
41361851|NCT02449733|OTHER|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
41361852|NCT02449733|PROCEDURE|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
41361853|NCT02449733|BEHAVIORAL|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
41361854|NCT05106101|DRUG|L-glutamine|L-glutamine oral powder in 5 gram packet
41361855|NCT04083287|OTHER|Erector spinae plane block (Group E)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
41499296|NCT06080854|OTHER|SBRT|SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions
40841477|NCT02423122|DRUG|VX-745|Orally-Active Selective P45 MAP Kinase inhibitor
40841478|NCT01586455|DRUG|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
40841479|NCT01272869|DEVICE|SenSura|The ostomy bag filter will be tested for a period of 14 days
40841480|NCT01272869|DEVICE|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
40841481|NCT02874027|OTHER|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
40841482|NCT00326248|DRUG|GW679769 (casopitant)|
41025482|NCT01324024|DRUG|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
41025483|NCT01446848|DIETARY_SUPPLEMENT|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
41025484|NCT05104398|DEVICE|Efferon CT|extracorporeal adsorbers containing mesoporous styrene-divinylbenzene copolymer to remove pro-inflammatory 6-60 kD molecules
41025485|NCT06429306|DRUG|Dexycu|5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
41025486|NCT06429306|DRUG|Placebo|Acetyl triethyl citrate
41361856|NCT04083287|OTHER|Interscalen brachial plexus block (Group I)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
41361857|NCT01379599|BEHAVIORAL|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
41361858|NCT04378855|OTHER|Questionnaire|Quality of life assessment
41361859|NCT05503043|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
41361860|NCT05503043|DRUG|Normal saline|Patients are received equal volumes of saline intravenously until the end of the surgery
41361861|NCT01614951|PROCEDURE|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
41361862|NCT01614951|DRUG|HTK Custodiol|Pulmoplegia before ECC.
41361863|NCT01614951|OTHER|Standard ECC|ECC after standard procedure
41361864|NCT03301272|DRUG|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
41361865|NCT03301272|OTHER|Placebo|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
41361866|NCT06041594|DEVICE|Laguna Thrombectomy System|Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism
41361867|NCT02924922|PROCEDURE|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
41361868|NCT02924922|PROCEDURE|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
41361869|NCT02924922|DEVICE|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
41361870|NCT02924922|DEVICE|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
41361871|NCT02924922|DRUG|Mannitol|
41361872|NCT00386152|DRUG|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
41361873|NCT00386152|DRUG|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
41361874|NCT02549261|DRUG|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
41361875|NCT02549261|DRUG|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
41361876|NCT02549261|DRUG|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
41025487|NCT04117932|DRUG|Ustekinumab|Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
41025488|NCT02574923|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
41025489|NCT01501318|BEHAVIORAL|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
41361877|NCT02549261|RADIATION|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
41361878|NCT02815982|BEHAVIORAL|NOURISH-T|Overweight/obesity family intervention
41361879|NCT02815982|BEHAVIORAL|Enhanced Usual Care|Publicly available overweight/obesity materials
41025490|NCT01501318|BEHAVIORAL|Personalized feedback report plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
41025491|NCT00548821|DRUG|Cisplatin|
41025492|NCT04955626|BIOLOGICAL|BNT162b2|Intramuscular Injection
41025493|NCT04955626|OTHER|Placebo|Intramuscular Injection
41025494|NCT04955626|BIOLOGICAL|BNT162b2 OMI|Intramuscular Injection
41025495|NCT04955626|BIOLOGICAL|Combination BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection"
41361880|NCT01296464|DRUG|Carbidopa|Capsules
41361881|NCT03909035|OTHER|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* A patient-pharmacist interview to collect comorbidities, medication, laboratory results, self-medication, adherence, medication patient's knowledge.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* Detailed feedback to the general practitioner.~* An appointment with the patient to explain the modifications made by the general practitioner (GP)"
41361882|NCT05627999|PROCEDURE|doppler endoanal ultrasound|The primary aim was to assess the reduction in the blood supply by comparing the hemorrhoidal arterial systolic peak (overall and sectorial) before and after Emborrhoid.
41025496|NCT04955626|BIOLOGICAL|Combination (Bivalent) BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection"
41025497|NCT04351152|BIOLOGICAL|Lenzilumab|Administered as an intravenous (IV) infusion
41025498|NCT04351152|DRUG|Standard of Care|Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
41025499|NCT00426023|DRUG|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
41025500|NCT00426023|DRUG|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
41025501|NCT02505646|OTHER|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
40841483|NCT03527719|OTHER|Village-doctor-led multifaceted intervention|"* Establishing a network including hypertension specialists at city/county hospitals, primary care physicians at township hospitals, and village doctors to collaboratively manage hypertension~* Using hypertension control rate as one of the metrics for incentive supplements to village doctors~* Providing discounted or free antihypertensive medications to patients with hypertension~* Training village doctors to measure blood pressure according to a standard protocol~* Training village doctors to use a simple stepwise protocol for hypertension treatment~* Training village doctors to conduct health coaching on lifestyle change (e.g., lowering sodium and alcohol intake) and medication adherence~* Providing free blood-pressure monitor and training to patients for home blood pressure measurement~* Encouraging lifestyle change and medication adherence~* Connecting patients through WeChat or telephone for group social support"
40841484|NCT04435990|BIOLOGICAL|10,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL
40841485|NCT04435990|BIOLOGICAL|30,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL
41361883|NCT04273620|BEHAVIORAL|Optokinetic stimulation and cueing-based reading therapy (OKS-READ)|"Each intervention session starts with an optokinetic stimulation (OKS) of at least 15 minutes duration. A pattern of squares, dots, triangles and stars will coherently and continuously move to the left on a computer screen in front of the patients. Patients are instructed to choose one stimulus and follow it with the eyes until it has reached the left side of the screen, then jump to the right edge of the screen and start again.~The second part of each intervention session is the cueing-based reading therapy (READ), which will also last at least 15 minutes. The task of the patient is to read out loud words or a text presented on a paper in front of them. We will use exogenous (e.g., the therapist highlights words when they were omitted) and endogenous cues (verbal instructions which require intrinsic action by the patient) to facilitate attentional shifts to the left. The intensity of cueing will be matched to the actual severity of neglect (adaptive therapy)."
41361884|NCT04273620|BEHAVIORAL|General neuropsychological treatment|As a control treatment the patients will receive neuropsychological treatment without targeting visuospatial attention. Examples for components implemented are supporting conversations, diagnostic assessments (e.g. memory diagnostics) and training of memory and executive functions.
40841486|NCT04435990|BIOLOGICAL|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
41361885|NCT03053466|DRUG|APL-501|"Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle."
40841487|NCT04330027|BIOLOGICAL|Growth factors|A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma
40841488|NCT04330027|OTHER|Saline|0.9% Sodium Chloride
41361886|NCT06026137|PROCEDURE|eFisioTrack Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity using the efisioTrack system without supervision by the physiotherapist.
41025502|NCT00724971|DRUG|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
41025503|NCT00724971|DRUG|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
41361887|NCT06026137|PROCEDURE|Excercises Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity supervised by the physical physiotherapist in a hospital room.
41025504|NCT04909697|DRUG|Sivelestat sodium|4.8mg/kg sivelestat sodium was given in 50ml normal saline, and was continuously pumped in the dark for 24h, equivalent to 0.2mg/kg/h.Applied for 5 consecutive days
41025505|NCT04909697|DRUG|Saline|50ml normal saline was continuously pumped in the dark for 24h. Applied for 5 consecutive days
41025506|NCT03072901|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
41025507|NCT03036514|DEVICE|Sublingual sufentanil tablet system|Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.
41025508|NCT03036514|DRUG|Patient-controlled intravenous analgesia|Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
41025509|NCT02060890|OTHER|specialized tumor board recommendation|feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
41025510|NCT00345579|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
41025511|NCT00345579|BIOLOGICAL|ActHIB|3-dose intramuscular injection
41361888|NCT03125421|PROCEDURE|standard preventive methods of pressure sores|"During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.~The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage."
41025512|NCT00345579|BIOLOGICAL|Pediarix/Infanrix Penta|3-dose intramuscular injection
41025513|NCT04696159|PROCEDURE|Pyloromyotomy|Endoscopic Per-Oral Pyloromyotomy (POP)
41361889|NCT03125421|PROCEDURE|experimental multifaceted preventive methods of pressure sores|"During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.~The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected."
41499297|NCT04890301|BEHAVIORAL|CT guided biopsy for pulmonary nodule|"The technical process of the experimental group: ① design of puncture path, positioning and fixation of patients; ② puncture point positioning; ③ installation of navigation frame and template; ④ percutaneous lung biopsy guided by PT combined with CT.~The technical process of the active comparator group: ① planning puncture path, positioning and fixation of patients; ② positioning puncture point; ③ CT guided percutaneous lung biopsy.~The operation related information, complications and postoperative pathological results were collected."
41499298|NCT01167101|DRUG|Rebamipide|Rebamipide 100mg Tid for 28days
41499299|NCT01167101|DRUG|pantoprazole|pantoprazole 40mg qd for 28days
41499300|NCT04829110|OTHER|ETOH|Participants will consume Vodka
41499301|NCT04829110|OTHER|Sucrose|Participants will consume sucrose in solution with water
41499302|NCT02826512|DRUG|Niraparib|niraparib 300 mg QD continuously
41499303|NCT05346536|OTHER|Detection of circulating tumor cells expressing Axl: CTC-AXL(+)|"Detection of CTC-AXL(+) using 2 techniques:~* CellSearch®, FDA-USA approved technology~* EPIDROP System~CellSearch® (Menarini Company) The current gold-standard CellSearch® technique requires the use of CellSave tubes. This technique allows the isolation of fixed CTCs. This technique uses a positive (CellSearch® Epithelial Cell Kit) enrichment method from total blood using magnetic beads coupled to an EpCAM capture antibody. CTCs are then detected (anti-panCK antibodies, DAPI, anti-CD45 and characterized (anti-AXL antibody) by immunofluorescence (IF).~EPIDROP It requires the use of EDTA tubes. This technique is based on a method of negative enrichment of CTCs from total blood using a cocktail of tetrameric antibodies to eliminate unwanted blood cells and to preserve only purified tumor cells (RosetteSep - StemCell Technology).Then, cells are loaded in a microfluidic chip. The detection and characterization is done by IF to the single cell in micro-droplets."
41499304|NCT03881020|DRUG|Silver diamine Fluoride 38%|In the intervention group 38% Silver Diamine Fluoride will be applied to the surface of the isolated lesion for a period of 1 minute followed by glass ionomer restoration at the same visit.
41361890|NCT01466972|DRUG|Pazopanib|Oral, 800mg tablet daily per cycle
41361891|NCT04019860|BEHAVIORAL|High Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.
41361892|NCT04019860|BEHAVIORAL|Time-Restricted Eating|Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
41499305|NCT03881020|PROCEDURE|Conventional atraumatic restorative treatment|In the active comparator group caries will be removed from primary molars using sharp excavators then teeth will be restored using glass ionomer filling material at the same visit.
41499306|NCT00186095|PROCEDURE|autologous followed by nonmyeloablative allogeneic transplant|
41499307|NCT05394311|OTHER|sports based mental health promotion program|sports related programs
41499308|NCT04131738|DRUG|Baricitinib|Baricitinib may be taken without regard to food. It should be taken at the same time every day.
41499309|NCT04276441|DEVICE|Heart healthy Engagement Program with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants without a diagnosis of AF will be enrolled and a heart healthy Engagement Program delivered via the Heartline app on the iPhone with the Apple Watch Series 5 or later.
41361893|NCT04089423|DEVICE|Fujifilm SILVAMP TB LAM|Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.
41361894|NCT05262946|BEHAVIORAL|sensorimotor training based on Feldenkrais method|8 weeks of balance and sensorimotor training twice a week
41025514|NCT06293963|BEHAVIORAL|Guideline Daily Amounts label|Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
41499310|NCT04276441|DEVICE|Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants with a diagnosis of AF (taking a DOAC for at least 30 days) will be enrolled and an Anti-Coagulation Adherence Module delivered via the Heartline app on the iPhone with an Apple Watch Series 5 or later.
41361895|NCT05262946|BEHAVIORAL|foot care education|Recommendations for preventing foot ulcers
41499311|NCT00729573|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tabletas a part of MTN-003
41499312|NCT00729573|DRUG|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
41499313|NCT00729573|DRUG|Tenofovir disoproxil fumarate|300 mg tablet as a part of MTN-003
41499314|NCT00729573|DRUG|Tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
41499315|NCT00927732|DRUG|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
41499316|NCT00927732|DRUG|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
41361896|NCT05262946|COMBINATION_PRODUCT|usual care|drugs and diet usual care
41499317|NCT00168818|DRUG|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
41499318|NCT00168818|DRUG|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
41499319|NCT00168818|DRUG|enoxaparin|40 mg once daily
41499320|NCT05180201|DIETARY_SUPPLEMENT|Synbiotic|Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide
41499321|NCT05180201|DIETARY_SUPPLEMENT|Probiotic|Lactiplantibacillus plantarum ATCC 202195
41499322|NCT05180201|OTHER|Placebo|Maltodextrin
41499323|NCT02180178|OTHER|observational only- no intervention|
41499324|NCT05535153|OTHER|functional movement screen|The volunteer subjects had to perform the FMS test at the request of the investigator, which is made up of seven movements: the squat, the crossing of the hurdle, the line lunge, the active elevation with the straight leg, a movement concerning the mobility of the shoulders, a rotational stability assessment movement and a core stability assessment movement.
41025515|NCT06293963|BEHAVIORAL|Interpretive text-only label|Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
41025516|NCT06293963|BEHAVIORAL|Interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
41025517|NCT06293963|BEHAVIORAL|Separated interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
41025518|NCT01575340|DIETARY_SUPPLEMENT|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
41025519|NCT06531447|DRUG|Cisplatin|Every 21 days 6 cycles
41025520|NCT06531447|DRUG|Gemcitabine|Every 21 days (First and 8th days) 6 cycles
41025521|NCT06531447|DRUG|Doxorubicin|Every 21 days 4 cycles
41025522|NCT06531447|DRUG|Cyclophosphamide|Every 21 days 4 cycles
41025523|NCT06531447|DRUG|Paclitaxel|Every 21 days 4 cycles or once a week for 12 weeks
41025524|NCT01175226|DRUG|BTA798|BTA798 twice daily
41025525|NCT01175226|DRUG|Placebo|Placebo twice daily
41025526|NCT01491477|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
41025527|NCT01491477|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
41025528|NCT02376452|DRUG|Raltitrexed|2mg/m2 iv gtt, d1
41025529|NCT02376452|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
41025530|NCT02376452|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
41025531|NCT02376452|DRUG|Leucovorin|400mg/m2 iv gtt,d1
41025532|NCT06535178|BEHAVIORAL|Sleep Regularity Group|Maintained consistent sleep onset time (±30 min self-selected sleep time) for 12-weeks.
41025533|NCT03923127|OTHER|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
41361897|NCT03699774|DRUG|DS-8500a|DS-8500a is provided as three 25-mg tablets for oral administration
41499325|NCT06628557|OTHER|The Effect of Mandala Art Therapy on Anxiety and Pain in Patients|The Effect of Mandala Art Therapy on Anxiety and Pain in Patients
41499326|NCT04123561|DRUG|TLC599|TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
41499327|NCT04123561|DRUG|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
41499328|NCT04123561|OTHER|Normal Saline|0.9% normal saline
41499329|NCT01090752|DRUG|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
41499330|NCT01090752|DRUG|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
40841489|NCT03171818|DRUG|Darbepoetin Alfa|Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
40841490|NCT03171818|DRUG|Saline|The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
41361898|NCT03699774|DRUG|Rosuvastatin|Rosuvastatin is provided as a 10-mg tablet for oral administration
41361899|NCT00743626|OTHER|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
41361900|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (whole virion, Vero cell-derived)|
41361901|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (egg derived) [licensed control vaccine]|
41361902|NCT00000649|DRUG|Nevirapine|
41361903|NCT00000649|DRUG|Zidovudine|
41361904|NCT05345431|DEVICE|endovascular denervation|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
41361905|NCT05345431|DEVICE|PTA|Treating with balloon dilation or stent implantation
41361906|NCT03384316|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
41361907|NCT03384316|BIOLOGICAL|ETBX-061; adenoviral Mucin-1 (MUC1) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
41361908|NCT03384316|BIOLOGICAL|ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
41361909|NCT01078389|DRUG|Febuxostat|Febuxostat capsules
41361910|NCT01078389|DRUG|Placebo for Febuxostat|Febuxostat placebo-matching capsules
41361911|NCT04470362|DEVICE|Isokinetic dynamometer|an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing the quadriceps power and strength.
41361912|NCT02902276|OTHER|additional blood sample|Two blood samples will be taken at ICU admission
41361913|NCT01066819|DRUG|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
41361914|NCT01066819|DRUG|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
41361915|NCT05638529|DRUG|Pregnyl (1,500) IU|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.
41361916|NCT05638529|DRUG|1.5 mL of normal saline|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
40841491|NCT00665769|OTHER|Hypercapnia|transcutaenous CO2 50-60 mm Hg
40841492|NCT00665769|OTHER|Normocapnia|transcutaneous CO2 35-45 mm Hg
40841493|NCT00086411|DRUG|nicotine transdermal system|starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
41025534|NCT04317300|DRUG|Varenicline|Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
41361917|NCT05653115|PROCEDURE|Bariatric surgery|Bariatric surgery
41361918|NCT00573352|RADIATION|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
41361919|NCT00466986|DRUG|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
41361920|NCT00800085|DRUG|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
41361921|NCT00950755|BIOLOGICAL|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
41361922|NCT04968327|OTHER|Micro-osteoperforations (MOPs)|MOPs included shallow perforations of the buccal cortical plate surrounding the tooth that requires orthodontic tooth movement, with no flap reflection was performed using a surgical bur using the special calibrated device called PROPEL
40841494|NCT00086411|DRUG|bupropion|150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
40841495|NCT00086411|BEHAVIORAL|Medication Management|Brief manual based therapy; four 15 minute session over 10 weeks.
40841496|NCT00086411|BEHAVIORAL|Mayo Counseling|Manual based therapy; Weekly 30 minute sessions for 10 weeks
40841497|NCT00086411|DRUG|placebo patch|placebo patch containing no nicotine
40841498|NCT00086411|DRUG|placebo bupropion|placebo pills
40841499|NCT05150210|DEVICE|Robotic-Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
40841500|NCT06175169|DEVICE|Information of Appendix (IA) model|Deep learning model
40841501|NCT03336385|DIETARY_SUPPLEMENT|Naxus|Non-digestible polysaccharides arabinoxylan (Naxus)
41025535|NCT04317300|OTHER|brief behavioral therapy|brief behavioral therapy
41025536|NCT05415228|DRUG|68Ga-PSMA-11|68Ga-PSMA-11 is a radiopharmaceutical for the detection of prostate cancer using PET/CT imaging
41025537|NCT06431750|OTHER|Secukinumab|This is an observational study, there is no treatment allocation.
41025538|NCT03531593|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound elastography is a new, noninvasive technique that can assess the stiffness of the liver by the evaluation of how sound waves propagate through the liver parenchyma.
41025539|NCT04204421|OTHER|Experience Sampling Method (ESM)|Experience Sampling Method (ESM) is a method for real time complaints assessment where people are asked to fill out a questionnaire 10 times per day at random moments. This will be done via a mobile phone application.
41361923|NCT04968327|OTHER|Conventional canine retraction|using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side
41025540|NCT02157311|DRUG|Four consecutive days on treatment and 3 days off|All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
41025541|NCT03855189|DRUG|Mometasone Furoate (MF)|Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
41025542|NCT03855189|DRUG|Beclomethasone Dipropionate (BDP)|Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.
41025543|NCT03855189|DRUG|Placebo|Placebo nasal spray administered for 4 weeks.
41025544|NCT02745626|DEVICE|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
41025545|NCT02310438|OTHER|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
41025546|NCT03771729|DRUG|LCZ 696|LCZ696 200mg twice daily
41025547|NCT05185024|DIETARY_SUPPLEMENT|Ferrous Sulfate Capsules|Once daily dose of one Ferrous Sulfate Capsule for 12 weeks in total.
41025548|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Capsules|Once daily dose of one \>Your\< Iron Forte Capsule for 12 weeks in total.
41025549|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Liquid|Once daily dose of 5 ml of \>Your\< Iron Forte Liquid for 12 weeks in total.
41025550|NCT05185024|OTHER|Blank Capsules|Once daily dose of one Blank Capsule (excipients only) for 12 weeks in total.
41025551|NCT05185024|OTHER|Blank Liquid|Once daily dose of 5 ml of Blank Liquid (excipients only) for 12 weeks in total.
41025552|NCT03789526|PROCEDURE|ultrasound guidance|ultrasound guidance of tendon injection
41025553|NCT03399760|BIOLOGICAL|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
41025554|NCT03399760|PROCEDURE|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
41025555|NCT05724199|DRUG|Rocatinlimab|Subcutaneous (SC) injection
41025556|NCT05724199|OTHER|Placebo|SC injection
41025557|NCT00000838|DRUG|Lamivudine|
41025558|NCT00000838|DRUG|Stavudine|
41025559|NCT00000838|DRUG|Zidovudine|
41025560|NCT00000838|DRUG|Didanosine|
41025561|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
41025562|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
41025563|NCT01577134|BEHAVIORAL|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
41025564|NCT03453333|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
41025565|NCT03453333|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
41025566|NCT01954706|OTHER|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
41361924|NCT00887601|DRUG|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
40841502|NCT03336385|DIETARY_SUPPLEMENT|Oatwell|Non-digestible polysaccharides oat beta-glucan (Oatwell)
41025567|NCT01954706|OTHER|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
41025568|NCT05145231|OTHER|observational|The scales will be filled by asking the family.
41361925|NCT00887601|DRUG|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
41361926|NCT00887601|DRUG|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
40841503|NCT03336385|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as placebo
40841504|NCT04185506|BEHAVIORAL|DBT+BWL|DBT skills include a focus on emotion regulation, distress tolerance, and mindfulness techniques. BWL includes a focus on monitoring of food intake, calorie reduction, and dietary and physical activity education.
41025569|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
41025570|NCT02199691|BIOLOGICAL|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, IM
41025571|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
41025572|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
41025573|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
41025574|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
41025575|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
41025576|NCT02497326|DRUG|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
41361927|NCT00887601|DRUG|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
41361928|NCT01869920|BEHAVIORAL|Intervention group|Education on breastfeeding
41361929|NCT01869920|BEHAVIORAL|Usual care|Usual care
40841505|NCT02725190|BEHAVIORAL|Sleepless night|Each subject will undergo 28 hours of sleep deprivation.
41361930|NCT03172026|DRUG|Maraviroc 300 mg|FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
41361931|NCT03172026|BEHAVIORAL|Rehabilitation therapy|"All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily."
41361932|NCT03172026|DRUG|Placebo 300 mg|Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
41361933|NCT01639807|DRUG|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
41025577|NCT02497326|DRUG|Topical Heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval"
41361934|NCT01639807|PROCEDURE|SLT|Selective Laser Trabeculoplasty
41361935|NCT05607927|PROCEDURE|Parks surgery|Parks surgery
41361936|NCT05607927|PROCEDURE|PE-Bacon surgery|PE-Bacon surgery
40841506|NCT02725190|BEHAVIORAL|Normal sleep night|Normal sleep at home before trial.
40841507|NCT01975610|DRUG|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
40841508|NCT01975610|DRUG|Placebo|Twice daily for 28 days
41025578|NCT02497326|DRUG|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score \>4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
40841509|NCT03530670|OTHER|oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before anesthesia induction
40841510|NCT03530670|OTHER|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|"Patients will be watched a short movie (at URL:~http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) 20 minutes before induction."
41361937|NCT02540811|DEVICE|dCELL® ACL Scaffold|
41361938|NCT04436406|DIAGNOSTIC_TEST|[99mTc]-NM-01 SPECT/CT|Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT
41361939|NCT06199791|DRUG|Lamotrigine 100 MG|tablets
41361940|NCT01621659|BEHAVIORAL|Multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
41361941|NCT05184062|DRUG|600 mg AZD7442 IV|Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
41361942|NCT05184062|DRUG|600mg placebo IV|Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
41361943|NCT03181139|OTHER|ERAS pathway for Total Mastectomy|Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
41361944|NCT01074060|DRUG|plerixafor|Given IV
40841511|NCT03530670|OTHER|Playing smartphone game|Patients will be played with smartphone (angry birds, subway surfers or snail Bob) 20 minutes before induction
40841512|NCT01310829|BEHAVIORAL|Questionnaires|Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
41361945|NCT01074060|BIOLOGICAL|filgrastim|Given SC
40841513|NCT01310829|BEHAVIORAL|Physiological Measurements|Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
40841514|NCT01310829|BEHAVIORAL|Virtual Reality Scene Viewing|Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
40841515|NCT02785419|BEHAVIORAL|Arm Training with Action Selection|Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
41361946|NCT01074060|DRUG|cyclophosphamide|Given IV
41361947|NCT01074060|PROCEDURE|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
41025579|NCT02177344|DRUG|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
41025580|NCT02177344|DRUG|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
41025581|NCT02177344|DRUG|Atrovent|Two puffs, 4 times daily by oral inhalation
41160831|NCT02604342|DRUG|Pemetrexed|Participants will receive pemetrexed at a dose of 500 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
41361948|NCT01074060|OTHER|laboratory biomarker analysis|Correlative studies
41361949|NCT05764694|OTHER|bullied children|A questionnaire will be answered by parent to measure the primary outcome of the study, which is Presence, duration, and frequency of Oral habits (Bruxism, Nail biting) in addition to a questionnaire answered by child to measure the secondary outcome which is Prevalence of Bullying and victimization.
41361950|NCT05950399|PROCEDURE|Echocardiography|Undergo resting echocardiography
41361951|NCT05950399|OTHER|Electronic Health Record Review|Ancillary studies
41361952|NCT05950399|OTHER|Questionnaire Administration|Ancillary studies
41361953|NCT05950399|PROCEDURE|Stress Echocardiography|Undergo stress echocardiography
41361954|NCT01361724|BEHAVIORAL|Physical therapy|Physical therapy program for people with PD--one on one with a PT
41361955|NCT01361724|BEHAVIORAL|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
41361956|NCT01361724|BEHAVIORAL|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
41361957|NCT04926129|OTHER|Other: Assessments|Administered as specified in the treatment arm.
41361958|NCT05722418|BIOLOGICAL|CB-011|CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
41361959|NCT00756223|DRUG|Arm A|Dose escalation Arm A (4 weeks)
41160832|NCT04331015|DIAGNOSTIC_TEST|Pure tone audiometry|pure tone audiometry
41160833|NCT01692132|DRUG|Prucalopride|Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (\>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
41361960|NCT00756223|DRUG|Arm B|Dose escalation Arm B (3 weeks)
41361961|NCT02275052|DRUG|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
41361962|NCT02275052|DRUG|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
41361963|NCT02275052|DRUG|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
41499331|NCT01025115|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
41025582|NCT02177344|DRUG|Placebo|
41025583|NCT05457270|DRUG|AZD4831|Participants will receive a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 of Period 2. Each period lasts for 8 days.
41025584|NCT00522210|DRUG|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
40841516|NCT03258060|PROCEDURE|Temporary pacing study|
40841517|NCT03258060|RADIATION|Body Surface Mapping|
41499332|NCT01025115|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
41499333|NCT04292665|BEHAVIORAL|Classical Massage|During the first interview, a booklet explaining the introduction, purpose, benefits and application steps of hand-foot massage will be given to the patients in the classical massage group. Hand and foot massage will be applied to the patients for 30 minutes in the form of right hand five minutes, left hand five minutes, right foot ten minutes, left foot ten minutes, using liquid vaseline in each session twice a day in the patient's own bed with individual applied sessions by the researcher. Patients will receive a total of 14 sessions of classical massage, twice a day, for seven days.
40841518|NCT02772770|OTHER|Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions|The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
40841519|NCT02772770|PROCEDURE|Surgical technique: Transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
40841520|NCT02772770|PROCEDURE|Surgical technique: Partial transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
41361964|NCT05363787|OTHER|therapeutic touch|Therapeutic Touch (TT) is an evidence-based holistic treatment method in which universal energy is used intentionally and with compassion for a specific purpose, in order to contribute to one's balance and recovery.In a world dominated by technology, one can lose touch with our inner self. We lose our intuitive abilities for beautiful everyday sensations of nature, the surrounding environment, and various visual and auditory elements. The Therapeutic Touch is an ancient Ayurvedic self-massage technique that connects your body to your soul.It is also used in therapeutic communication. Therapeutic communication is the process of influencing and being influenced by one another. It consists of individual-centered, purposeful, planned, effective and satisfying actions.
41499334|NCT04292665|BEHAVIORAL|Benson Relaxation Exercise|During the first interview, patients will be given a booklet explaining the description, purpose, benefits and application steps of the Benson relaxation exercise. With individual counseling sessions, a total of 14 sessions of Benson relaxation exercises will be performed in a quiet room, twice a day for seven days, each session lasting 20 minutes. At the beginning of the application, patients will focus on their breaths by taking slow and natural breaths with the researchers' commands and will quietly say to yourself the words of the focus, sound, sentence or prayer they choose, which are meaningful to them.
41499335|NCT04292665|OTHER|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
41361965|NCT00923806|BIOLOGICAL|PG13-CEA_TCR (Anti-CEA TCR PBL)|
41361966|NCT00923806|DRUG|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
41361967|NCT06008522|DRUG|Bevacizumab-800CW|Imaging of fluorescently labeled Bevacizumab-800CW using OCT.
41361968|NCT01310426|OTHER|3D transperineal Ultrasound|3D transperineal Ultrasound after vaginal delivery
41361969|NCT00000576|DRUG|beclomethasone|
41361970|NCT02443558|OTHER|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
41361971|NCT02443558|DEVICE|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
41361972|NCT06021912|DRUG|Immunotherapy|Sublingual immunotherapy
41361973|NCT03070054|DRUG|20ml 0.25% bupivacaine-epinephrine|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
41361974|NCT02357108|OTHER|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
41361975|NCT02357108|BEHAVIORAL|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
41361976|NCT00237146|DRUG|Zoledronic acid|
41361977|NCT05899127|DRUG|Lidocaine|1.5mg/kg induction，1.5 mg/kg/h maintenance
41361978|NCT05899127|DRUG|0.9%NaCl|2mg/kg induction，1.5 mg/kg/h maintenance
41361979|NCT00964470|DEVICE|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
41361980|NCT06332274|DRUG|Tislelizumab|"Formulation : 100 mg of antibody in 10 mL of isotonic solution (25 mM citrate buffer, 15 mM L-histidine/histidine hydrochloride, 190 mM trehalose-dihydrate, and 0.02% polysorbate 20 at pH 6.5) in a single-use vial.~Dose Regimen: Tislelizumab 400 mg every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
41361981|NCT06332274|OTHER|Blood sampling|Blood sampling for analyses of MRD (Molecular Residual Disease)
41499336|NCT05899751|DRUG|High-dose methotrexate|High-dose methotrexate
41499337|NCT05899751|DRUG|Glucarpidase|Glucarpidase
41499338|NCT00289120|DRUG|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
40841521|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Anderson method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
40841522|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
40841523|NCT04100941|DIAGNOSTIC_TEST|standard suction|After the needle is inserted in the mass, removing the stylet before performing EUS-FNA. Then attach a 10mL syringe to the end of needle. 20 times of for-backward Suction was applied after the lesion was punctured.
41361982|NCT06332274|DRUG|Placebo|"Pharmaceutical form : Solvent IV bags used for dilution of tislelizumab (for example: CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable) Dose Regimen: every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
41361983|NCT03474588|BEHAVIORAL|Standard treatment (ST) PLUS web-based CBT4CBT|Participants will have access to the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on
41361984|NCT03474588|BEHAVIORAL|Standard Treatment (ST)|ST includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks
41361985|NCT01341574|PROCEDURE|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
41361986|NCT01341574|PROCEDURE|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
41361987|NCT06373640|PROCEDURE|Insertion of drains|Insertion of lumbar drain and basal cistern drain
41361988|NCT06373640|DRUG|Vancomycin|Administration of vancomycin
41361989|NCT03331250|DRUG|Eribulin|It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
41361990|NCT03990168|DEVICE|Anodal tDCS|1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.
41361991|NCT03990168|BEHAVIORAL|fluency intervention/ Delayed Auditory Feedback|Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
41361992|NCT03990168|DEVICE|Sham tDCS|The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
41361993|NCT03387189|OTHER|Quality Improvement Project|Simulation education conducted at Regions Hospital for a Quality Improvement project on delivery of impacted fetal head at cesarean section. This is a department-wide, simulation-based educational training required for all Regions Hospital Birth Center staff physicians, residents, nursing staff, and surgical techs.
40841524|NCT04100941|DIAGNOSTIC_TEST|slow pull|After the needle is inserted in the mass, slowly pull the stylet out while performing EUS-FNA with 20 times for-backward.
41361994|NCT01169233|DEVICE|Bright Light Box|Increased lighting used during night shifts to prevent sleepiness.
41361995|NCT02101216|DRUG|Prurisol|Experimental Drug
41361996|NCT02101216|DRUG|Ziagen|Active comparator
41361997|NCT06371560|OTHER|Questionnaire|online based questionnaire
40841525|NCT04100941|DIAGNOSTIC_TEST|wet suction|After removing the stylet, the needle was flushed with 5mL of saline solution to replace the column of air with saline. A 10mL syringe was attached to the end of the needle. 20 times of for-backward Suction was applied after the lesion was punctured.
41266737|NCT00249574|DRUG|pegInterferon|intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.
40841526|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
40841527|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
40841528|NCT02953886|DEVICE|Silver Diamine Fluoride (SDF)|No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
40841529|NCT06089902|PROCEDURE|unroofing or other surgery if needed|unroofing of coronary artery
40841530|NCT02667756|OTHER|Non-interventional|
41266738|NCT04227756|DRUG|LSD|LSD 0.1 mg per os, single dose OR Psilocybin 20 mg per os, single dose OR Mescaline 300 mg per os, single dose OR Placebo
41266739|NCT04227756|DRUG|Psilocybin|Psilocybin 20 mg per os, single dose
41266740|NCT04227756|DRUG|Mescaline|Mescaline 300 mg or 500 mg per os, single dose
41266741|NCT04227756|OTHER|Placebo|Placebo (Mannitol)
41266742|NCT04323449|DEVICE|Compare two control methods for a wheelchair-mounted robotic manipulator|Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.
41266743|NCT02720757|DRUG|Spiolto Respimat|Tiotropium bromide + Olodaterol
41266744|NCT00650858|DRUG|tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)|0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
41266745|NCT01133145|PROCEDURE|knee joint transplantation|transplantation of a kne joint from a multi organ donor to a recipient with a severly injured knee joint
41266746|NCT04774939|PROCEDURE|Endovenous laser ablation|The aim is to combine the significance of for sclerotherapy at the primary EVLA treatment
41266747|NCT00892580|DRUG|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
41266748|NCT05512871|BEHAVIORAL|Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)|The study aim to conduct lifestyle intervention trials to examine the feasibility, efficacy, and cost-effectiveness of the mHealth approach in preventing them from developing Type 2 Diabetes in the future. This pilot study will primarily aim to determine the feasibility of our intervention approaches as well as enhance health literacy and promote healthy lifestyle in the study participants. In the longer term, we hope that the proposed mHealth intervention can be translated to include women from the community setting and involve wider healthcare setting to come together and reduce the burden of Type 2 Diabetes in Singapore.
41266749|NCT04351139|OTHER|modification of the planned therapeutic management|to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers
41266750|NCT04297358|DRUG|Hyperbaric oxygen|40 consecutive (5/7) sessions of hyperbaric oxygen
41266751|NCT05463081|DEVICE|Laser treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
41266752|NCT05463081|DIAGNOSTIC_TEST|Blood test|Taking blood from a vein for Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study) and clinical blood analysis (to include the participant in the study and evaluate procedure efficiency)
41266753|NCT05463081|DIAGNOSTIC_TEST|Clinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
41266754|NCT05463081|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study and evaluate procedure efficiency)
41266755|NCT05463081|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
41266756|NCT05463081|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
41361998|NCT04622163|OTHER|Secondary Mentor|Subjects will be matched with a secondary mentor from the Department of Medicine for 6 months. Mentors and mentees are expected to hold one-on-one meetings monthly for the first 3 months followed by at least once every 3 months thereafter.
41025585|NCT00522210|OTHER|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
41025586|NCT05244356|BEHAVIORAL|Health message exposure|Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
41025587|NCT04358926|DEVICE|Hyperbaric oxygen therapy|8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
41025588|NCT00423436|BEHAVIORAL|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
41025589|NCT00423436|BEHAVIORAL|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
41025590|NCT00423436|BEHAVIORAL|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
41025591|NCT00265057|DRUG|ADH -1 (Exherin™)|
41025592|NCT02250885|DRUG|Selinexor|Selective Inhibitor fo Nuclear Export (SINE)
41025593|NCT06267482|PROCEDURE|ROSA PSA Parapatellar Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be the same as the standard of care (medial parapatellar approach).
41025594|NCT06267482|PROCEDURE|ROSA PSA Subvastus Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be an alternative, quad-sparring, subvastus approach.
41025595|NCT04092634|DEVICE|Dual mobility implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
41025596|NCT04092634|DEVICE|Traditional, Single-bearing hip implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
41361999|NCT04622163|OTHER|Career Development Resources|Subjects will receive career development resources.
41362000|NCT00701064|OTHER|Bright Light Exposure|Administered via bright light box
41362001|NCT00701064|OTHER|Negative Ion Generator|Administered via Negative Ion Generatore
41362002|NCT04582695|BEHAVIORAL|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|Participants will receive 5 to 6 weeks of an integrated behavioral therapy that address posttraumatic stress disorder and alcohol use disorder. Sessions will be 60 minutes in length. It will include written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes. In addition, they will receive 20 minutes of intervention focused on cognitive behavioral therapy for alcohol use disorder which involves learning skills to cope with alcohol cravings and behavior (e.g., challenging thoughts, problem solving).
41362003|NCT04582695|BEHAVIORAL|Written Exposure Therapy|Participants will receive 5 to 6 weeks of written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
41362004|NCT02908815|DEVICE|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
41362005|NCT02908815|DEVICE|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
41362006|NCT02833142|DRUG|BIIB033 (opicinumab)|
41362007|NCT03390049|DEVICE|Fractional CO2 Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the fractional CO2 laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe with the following settings: dot power 26 Watts, dwell time 1000 μs, dot spacing 1000 μm, and smart stack parameter from 1 to 3. Stack 1 is used at baseline; stack 3 is used 6 and 12 weeks after.
41499339|NCT00289120|DRUG|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
41025597|NCT02939222|DEVICE|Implant placement|Routine implant placement in the ideal three dimensional implant position
41025598|NCT04494412|DRUG|Zanamivir|Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.
41499340|NCT04627987|DIAGNOSTIC_TEST|Cardiac MRI scan|Cardiac MRI scan pre- and post- aortic valve replacement to assess degree of left ventricular remodelling, fibrosis and myocardial blood flow.
41025599|NCT04824846|BEHAVIORAL|Integrated back pain module (IBPM)|All Ambulance drivers will be screening with the Proforma to determine their low back pain symptoms. Those workers who are diagnosed with mechanical back pain during the 12 months fulfill a self-report quality of life questionnaire (SF-36). Then Integrated back pain module (IBPM) will be delivered to them after the introduction course conducted for 1 day and then the intervention will last for 6 months. Research staff will explain how to operate and use the module. Subjects must comply with all the care and prevention guidelines of the research module so that it achieves the expected results. They also need to complete the checklist provided in the Edmodo software via their respective smartphones.
41362008|NCT03390049|DEVICE|Sham Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the sham laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe. However, these sham laser sessions will administer no fractional CO2 laser energy. To increase the likelihood that subjects assigned to sham laser remain blinded to treatment arm assignment during the study, MonaLisa Touch will provide a software package with settings that allow for reproduction of the sounds generated during a regular fractional CO2 laser session but using 0 Watts of power.
41362009|NCT03618433|OTHER|study group|The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .
41499341|NCT04627987|DIAGNOSTIC_TEST|Serum biomarkers (High sensitivity troponin, NT-proBNP|Blood tests looking evidence of cardiac structural remodelling and function.
40841531|NCT06341010|PROCEDURE|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis
40841532|NCT00885300|DRUG|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
41025600|NCT04824846|OTHER|Health Educational Pamphlet.|In Health Educational Pamphlet (HEP) sessions, Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
41025601|NCT05987891|DIAGNOSTIC_TEST|Treadmill exercise stress test|Ellestad protocol will be applied in all subjects up to fatigue and recovery will be monitored.
41160834|NCT04851145|DIAGNOSTIC_TEST|Mass spectrometry-based proteomics of FFPE biopsies and urine samples|"The biopsy and urine samples will be processed by the OncoProt platform (University of Bordeaux) for proteomic analysis by tandem mass spectrometry (label-free quantification) as follows:~* Biopsies: laser microdissection of the renal cortex, fixation reversion, protein extraction and electrophoretic migration, tryptic digestion.~* Urines: samples concentration by centrifugation/filtration and tryptic digestion according to a protocol adapted from the FASP method (Filter-Aided Sample Preparation)"
41362010|NCT03618433|OTHER|Control group|The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
41499342|NCT04627987|PROCEDURE|Implantable Loop Recorder|Determine post-AVR arrhythmia burden
41160835|NCT01302301|PROCEDURE|Per oral endolumenal myotomy|flexible endoscopic submucosal esophageal partial myotomy
41160836|NCT03363542|DIETARY_SUPPLEMENT|fruits, vegetables and/or whole grain high fiber rich diet|Dietary education to Increase fruits, vegetables and/or high fiber intake
41160837|NCT01582412|DRUG|Isavuconazole|oral
41160838|NCT01582412|DRUG|digoxin|oral
41362011|NCT00003649|BIOLOGICAL|Ad5CMV-p53 gene|
41499343|NCT04627987|DIAGNOSTIC_TEST|6 minute walk test|Validated assessment of functional capacity - distance walked over 6 minute time frame.
40841533|NCT00885300|DRUG|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
40841534|NCT03191253|OTHER|Medically-appropriate meals and groceries|Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
40841535|NCT00003842|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
40841536|NCT00003842|DRUG|isolated perfusion|
40841537|NCT00003842|PROCEDURE|surgical procedure|
40841538|NCT00506168|DRUG|Irinotecan, Capecitabine|
40841539|NCT03392870|OTHER|Integrative interventional programme|The active condition includes specialized, multidisciplinary and intensive individual (weekly to monthly) or group interventions (weekly). Only high-functioning subjects will be considered for group interventions.
41025602|NCT03965260|BIOLOGICAL|Bacterial samples from blood or peritoneal liquids|"For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance."
41025603|NCT03757559|DRUG|Cebranopadol 100 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
41025604|NCT03757559|DRUG|Cebranopadol 400 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
41025605|NCT03757559|DRUG|Hydromorphone hydrochloride 4 milligrams|Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
41025606|NCT03757559|DRUG|Placebo matching hydromorphone|Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
41160839|NCT04814615|DRUG|89Zr-daratumumab PET/CT|CD38-targeting imaging
41160840|NCT01602003|DRUG|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
41499344|NCT04627987|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound assessment of heart structure and function. Standard of care in valve surgery pathway.
41025607|NCT03757559|DRUG|Placebo matching cebranopadol|Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
41025608|NCT06017284|DRUG|Thalidomide|Thalidomide 100 mg/day, once a day, orally intake at night.
41025609|NCT06017284|DRUG|Nab paclitaxel|nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.
41025610|NCT06017284|DRUG|Gemcitabine|gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
41025611|NCT06017284|DRUG|Placebo|Placebo, 100 mg/day, once a day, orally intake at night.
41025612|NCT05158946|BEHAVIORAL|Future Oriented Group Training|This study's experimental condition consisted of a Future Oriented Group Training (FOGT), originally developed in 2008 by van Beek et al. (2009). Participants followed this training weekly, over a period of 9 weeks in groups of 6 to 10 participants. The sessions, which lasted one and a half hours each, were each led by one trainer.
41025613|NCT02709967|OTHER|Material support|Writing materials
41025614|NCT02709967|OTHER|Economic|Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
41025615|NCT02709967|BEHAVIORAL|Community dialogue|Community dialogue (youth club meetings, community and parent meetings)
41025616|NCT03788889|DRUG|Ketamine|Ketamine infusion
41025617|NCT03788889|DRUG|Phenobarbital|Phenobarbital intravenous injection
41025618|NCT03788889|DRUG|Lorazepam|Standard of Care
41025619|NCT03788889|DRUG|Placebo A|Placebo injection
41025620|NCT03788889|DRUG|Placebo B|Placebo infusion
41025621|NCT04397081|OTHER|HPV test results|The human papillomavirus (HPV) test detects the presence of the human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The procedure includes taking samples of your cervical cells using a soft brush and a flat scraping device called a spatula. This doesn't hurt, and you may not even feel the sample being taken.
41362012|NCT01867996|DRUG|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
41362013|NCT01867996|DRUG|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
41362014|NCT01824524|DRUG|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
41362015|NCT02896998|PROCEDURE|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
41362016|NCT02896998|PROCEDURE|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
40841540|NCT03392870|OTHER|As usual|The control group will follow treatment as usual, consisting in conventional general psychiatrist/psychologist clinical follow-up. The frequency varies between 3-6 months or 15-21 days if worsening of symptoms or comorbid conditions.
41266757|NCT05463081|OTHER|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
41266758|NCT05463081|OTHER|The Short Form Health Survey|The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
41362017|NCT00132405|DRUG|ALGRX 3268|
41362018|NCT02138552|DRUG|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
41362019|NCT02138552|DRUG|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
41499345|NCT05079581|OTHER|Pelvic floor exercises|"The participants in the intervention group will be taught exercises involving strengthening the muscles around the pelvic floor in sitting, standing and lying positions by a physiotherapist who has been trained in women's health for 4 years and will be asked to perform them as home exercises every day for 8 weeks. The exercises are as follows:~They will be asked to tighten the muscles around the urethra, vagina and rectum as hard as possible, upwards and inwards (from the bottom up) and hold it in this way for 8-10 seconds. It will be applied in different positions as in the table."
40841541|NCT02882386|OTHER|Strength Training|
40841542|NCT02882386|DIETARY_SUPPLEMENT|Milk 1%|
40841543|NCT02882386|DIETARY_SUPPLEMENT|Whey protein concentrate 80 (WPC-80)|
40841544|NCT02882386|DIETARY_SUPPLEMENT|Microparticulated whey|
40841545|NCT02882386|DIETARY_SUPPLEMENT|Hydrolyzed whey|
40841546|NCT02882386|DIETARY_SUPPLEMENT|Native whey|
40841547|NCT06387641|BEHAVIORAL|Life review|Life review is a process that involves a thorough examination and reflection on one's past experiences, memories, and life events. This process often involves the identification and examination of significant themes, patterns, and lessons learned throughout one's lifespan. Through life review, individuals can gain a deeper understanding of their own identity, values, and beliefs, and how these have shaped their present circumstances and future outlooks. It can serve as a tool for personal growth, self-discovery, and the promotion of a sense of meaning and purpose in life.
40841548|NCT06387641|BEHAVIORAL|Routine community health services|"Routine community health services refer to a comprehensive health care service system that is government-led, community-participated, and guided by superior health institutions. It focuses on grass-roots health institutions and is staffed with general practitioners as the backbone. By rationally utilizing community resources, it provides a series of comprehensive health care services to community residents. These services center on human health, target families as the unit, cover the entire community, and aim to meet the basic health service needs of community residents.~Specifically, routine community health services include the following aspects: Health Education, Prevention and Control, Health Care Services and so on."
40841549|NCT02440789|DRUG|Sirolimus|"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."
40841550|NCT00205816|DRUG|Tigecycline|
40841551|NCT00196053|DEVICE|Archimedes Constant Flow Implantable Pump|
40841552|NCT02797158|PROCEDURE|TAVI procedure|Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
40841553|NCT03555682|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
40841554|NCT03555682|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
41266759|NCT05463081|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
41362020|NCT00740766|BEHAVIORAL|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
41362021|NCT01206894|PROCEDURE|Transthoracic Ultrasound|1 transthoracic ultrasound will be performed the evening before the thoracic surgery
41499346|NCT02529644|BEHAVIORAL|Taking It to the Pews (Comparison)|Pastors and Health Action Team members will be trained and receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events. Comparison churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. The comparison churches will offer 3 HIV screening events and deliver 1-2 standard materials per month for the 12 month study period. All comparison churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
41499347|NCT02529644|BEHAVIORAL|Taking It to the Pews (Experimental)|Pastors and Health Action Team members will be trained in treatment implementation procedures using the scripted, study implementation manual. Intervention churches will receive the TIPS HIV Tool Kit, including a study manual. These churches will hold a Kick-off event, where tools will be distributed, and motivational strategies implemented. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities minimum of 24 tools over the 12 month study period. Two additional HIV screening events will be planned (one for community members) and will be open to all persons seeking screening, including study nonparticipants. Both groups will receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events.
41499348|NCT03813953|PROCEDURE|Liver resection|Resection of diseased liver
40841555|NCT03259815|PROCEDURE|P.I.O.S.|Physiologically-Guided Incremental Optimisation Strategy
41362022|NCT01663298|PROCEDURE|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
41362023|NCT06419023|BEHAVIORAL|supervised physical activity intervention using the Pilates Method (exercises on the mat)|"Each Pilates session was consisted of: a) introduction to the goal of training, familiarizing new skills (2-3 min); b) Pre-Pilates warm-up and respiratory exercises (5-10 min); c) mat Pilates exercises with the traditional Pilates repertoire: basic, beginner (40 min); d) cool down and endings exercises (5 min); e) session summary (2-3min). When required, exercises were adapted for breast cancer body needs and restrictions. Depending on the purpose of the exercise, different equipment was used (Pilates small ball 22 cm, Swiss ball, small massage balls, resistance band, towels, rollers, boxes, Magic Circle)."
41362024|NCT02985541|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
40841556|NCT03259815|DIAGNOSTIC_TEST|Pre and post-PCI coronary physiology measurements|Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
40841557|NCT02189681|PROCEDURE|Conventional landmark guided midline spinal anaesthesia|Spinal anaesthesia was administered based on conventional landmark based midline approach.
41025622|NCT04280211|OTHER|Respiratory Assessment|Spirometric measurement
41025623|NCT04280211|OTHER|Vestibular Assessment|Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction
41025624|NCT04280211|OTHER|Balance Assessment|Postural stability
41025625|NCT04812912|DIAGNOSTIC_TEST|Hormone biomarker analysis|For female patients, hormone biomarker analysis will be performed to measure: anti-Mullerian hormone (AMH), estradiol and FSH in the blood. In male patients, hormone biomarkers of testicular function and spermatogenesis will be monitored: testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH. Sperm analysis will also be performed in male patients to monitor changes in sperm count.
41025626|NCT04812912|BEHAVIORAL|QoL Questionnaires|All participants will respond to protocol questionnaires, which will include both validated questionnaires as well as non-validated ones. This design will allow for basic demographic, psychosocial and sexual-health-related data to be obtained.
41025627|NCT05267301|DIETARY_SUPPLEMENT|AlmegaPL (FDA NDIN # 826)|The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA). EPA is a type of omega-3 essential fatty acid known to play a beneficial role in protection against cardiovascular disease. Iwi/Cholesterol is the only source of long chain omega-3 that does not contain the DHA that is present in other omega-3 sources (fish oil, krill oil, other algal oils). Almega®PL was registered at the Food and Drug Administration (FDA) as a New Dietary Ingredient (NDIN) in 2014.
41025628|NCT04359836|OTHER|There is no intervention in this study|There is no intervention in this study
41025629|NCT04209660|DRUG|Lenvatinib|Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.
41362025|NCT04730739|DEVICE|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The FastFrame External Fixation Systems - Knee Spanning Kit and Damage Control Kit are single-use external fixators that are sterile packed with all required components for convenience of the end user.
41362026|NCT04371068|BIOLOGICAL|Culture of removed prosthesis using DTT|No specific or supplementary intervention is performed among patients. The included patients have scheduled surgery consisting of prosthesis removal or change. Instead of being discarded, the prosthesis which was removed during the surgery was sent to the laboratory using the MicroDTTect system and bacterial culture was performed with the fluid obtained. Results will be then compared to classical culture of periprosthetic tissues (PPT).
41362027|NCT04881682|DEVICE|Immunoadsorption|see arm/group description
40841558|NCT02189681|PROCEDURE|pre-procedure ultrasound guided L5S1 paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.
41025630|NCT04209660|DRUG|Pembrolizumab|Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.
41025631|NCT04153409|DRUG|LAT8881|Two 30 mg capsules of LAT8881
41266760|NCT05463081|DIAGNOSTIC_TEST|Vital signs determination|Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
41362028|NCT04881682|BIOLOGICAL|Immunoglobulins|see arm/group description
41362029|NCT06401902|PROCEDURE|carotid clamping|Occurrence of consciousness perturbations, language difficulties and/or contralateral motor deficit during the carotid-clamping test and requiring shunt placement.
41362030|NCT04387396|OTHER|Exercise|Exercise specific to knee osteoarthritis.
41362031|NCT00211133|DRUG|epoetin alfa|
41362032|NCT03658213|DRUG|ZOLADEX 10.8 mg|10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
41362033|NCT03658213|DRUG|ZOLADEX 3.6mg|3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
41362034|NCT02090140|PROCEDURE|ADSC Application|Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.
41362035|NCT02090140|PROCEDURE|Microfracture|Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).
41362036|NCT02194699|BIOLOGICAL|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
41362037|NCT02194699|OTHER|Placebo|Placebo subcutaneous injection
41362038|NCT03398187|DEVICE|cardiac catheterization|diagnostic and interventional cardiac catheterization
41499349|NCT05924854|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints). Equipment used in the trial included:~1. Huatuo brand copper filiform needle (diameter: 0.35×50mm), Suzhou Medical Supplies Factory, Food and Drug Administration firearms production: Suzhou Food and Drug Administration firearms production No. 20010020.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675"
40841559|NCT02189681|DEVICE|spinal anaesthesia|Spinal anaesthesia is administered with appropriate spinal needle
41025632|NCT04153409|DRUG|Placebo|Two capsules of placebo
41025633|NCT00159523|DIETARY_SUPPLEMENT|Probiotic|
41025634|NCT00159523|BIOLOGICAL|placebo|
41266761|NCT05463081|DIAGNOSTIC_TEST|pH of vagina determination|Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).
41266762|NCT05463081|DIAGNOSTIC_TEST|Physical parameters determination|Physical parameters determination (body weight, age, height, body mass index).
41362039|NCT02950428|DEVICE|ACURATE neo™TA Delivery System|ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
41362040|NCT01075022|DRUG|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
41362041|NCT01075022|DRUG|Placebo|Placebo Capsule, Single Dose
41362042|NCT05754242|DRUG|Ascorbic acid|1.5 gr of ascorbic acid
41362043|NCT05754242|DRUG|0.9% Saline solution|100 ml of 0.9% saline solution
41025635|NCT06535789|DRUG|Inhaled Technosphere Insulin|Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal
41362044|NCT02665039|DRUG|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged \>80 years and/or GFR 30-40 ml/min"
40841560|NCT03149029|DRUG|Pembrolizumab|Pembrolizumab is a type of antibody that inhibits the cancer cell growth
41499350|NCT04074629|DIAGNOSTIC_TEST|Diagnosis, skin volatile organic compounds (VOCs)|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\\or GC-MS analysis"
41362045|NCT02665039|DRUG|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
40841561|NCT03149029|DRUG|Dabrafenib|Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
41025636|NCT04702074|DRUG|Traditional Chinese medicine granules|"Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months."
41025637|NCT04702074|DRUG|Traditional Chinese medicine granules placebo|"Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules ."
41025638|NCT04278833|DRUG|Triamcinolone or Betamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
41362046|NCT02665039|DRUG|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
41025639|NCT04278833|DRUG|Dexamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
41025640|NCT00501384|DRUG|satavaptan (SR121463B)|
41499351|NCT02186834|DRUG|Selinexor|Selinexor orally as outlined in the study treatment arm.
41025641|NCT06074094|DRUG|Control Test|Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients
41499352|NCT02186834|DRUG|Liposomal doxorubicin|Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
41025642|NCT05668195|PROCEDURE|systematic aerobic exercise and intelligent monitoring system in executive skill training|This is a closed-loop training initially developed by the research team in conjunction with other teams, adding a systematic aerobic exercise and intelligent monitoring system to the typical executive skill training, and is being further explored in training.
41025643|NCT05668195|PROCEDURE|executive skill training|The training program, based on Dawson and Guare's (2010) training of executive skills for children, aimed to improve the everyday performance of executive skills among children with ADHD. Qian Y and her team added some culturally adapted information, following the theory of cognitive behavioral therapy, to ensure that the concepts were acceptable to Chinese children.
41362047|NCT06509139|DRUG|Drug: Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
41362048|NCT06509139|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
41362049|NCT06509139|DRUG|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
41362050|NCT06509139|DRUG|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
41499353|NCT02186834|DRUG|Dexamethasone|Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
40841562|NCT03149029|DRUG|Trametinib|Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
40841563|NCT04506333|DEVICE|A&D UA-651 Blood Pressure Monitor|Test device to be validated.
41025644|NCT00612066|DRUG|rosiglitazone maleate|
41499354|NCT05580965|OTHER|20 N pressure for 1 minute|After blood collection, 20 N pressure applied for 1 minute
41499355|NCT05580965|OTHER|20 N pressure for 3 minute|After blood collection, 20 N pressure applied for 3 minute
41499356|NCT05580965|OTHER|20 N pressure for 5 minute|After blood collection, 20 N pressure applied for 5 minute
40841564|NCT04506333|DEVICE|ADC 740-N Manual Sphygmomanometer|Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.
41025645|NCT00198640|PROCEDURE|Antibiotic use|
41025646|NCT06243913|PROCEDURE|IUI with vitrified sperm from donor:|"After signing the informed consent, the clinic's Matching team will assign a donor semen straw based on phenotypic characteristics, blood group, and genetic compatibility (if applicable), with the female partner.~On the day of the Intrauterine Insemination (IUI), the laboratory team will thaw the assigned donor semen straw and post-thaw sperm parameters will be analyzed, including the total number of sperm with progressive motility. Subsequently, the IUI will be performed following the standard protocol."
41025647|NCT00572572|DRUG|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
41362051|NCT02015858|PROCEDURE|Chest drain withdrawal|
41025648|NCT00572572|DRUG|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
41025649|NCT06360302|DIAGNOSTIC_TEST|Exercise test|"Metabolic effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes."
41025650|NCT06360302|DIAGNOSTIC_TEST|Blood sample|"A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.~Sampling times synchronized with stress test measurements"
41025651|NCT06360302|DIAGNOSTIC_TEST|Impedancemetry|measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
41025652|NCT06535581|PROCEDURE|surgery patient|patients with hypertension (group 2) and without (group 1) hypertension. The predictive ability of postoperative pain as a tool for measuring and assessing pain was examined by analysing the relative change in the Perfuston index.
40841565|NCT02383771|DRUG|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
41025653|NCT00857194|PROCEDURE|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
41025654|NCT00857194|PROCEDURE|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
41025655|NCT04833257|DRUG|GP combine with Tislelizumab neoadjuvant therapy+CCRT|chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy
40841566|NCT02383771|DRUG|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
41025656|NCT02529020|DEVICE|Mouthguard|Condition of wearing mouthguard
41025657|NCT02529020|DEVICE|No mouthguard|Condition without mouthguard
41362052|NCT02015858|DEVICE|Pain Monitor|
40841567|NCT02383771|DRUG|Control|No Anti-platelet Therapy
40841568|NCT02383771|DRUG|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
40841569|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
41025658|NCT01614210|DRUG|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
41025659|NCT01614210|PROCEDURE|Breast cancer surgery|Breast cancer surgery
41025660|NCT00014144|DRUG|gefitinib|
41025661|NCT03036566|DEVICE|Lithium disilicate ceramic (Ivoclar)|Three unit high strength ceramic bridges replacing a single tooth.
41362053|NCT04306003|OTHER|ERAS pathway|See ERAS pathway arm description.
41362054|NCT04306003|OTHER|Standard Perioperative Care|See control arm description.
41362055|NCT04160494|DRUG|D2C7-IT (6920 ng/mL via convection-enhanced delivery)|dual-specific mAB
41362056|NCT04160494|DRUG|Atezolizumab (1200 mg every three weeks)|programmed cell death ligand 1 (PD-L1) blocking antibody
41362057|NCT04160494|DRUG|D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)|dual-specific mAB
41499357|NCT03425695|DEVICE|CheseeTM Diode Laser|low level laser therapy was utilized adjunct with free gingival graft.
41025662|NCT03646422|OTHER|Registry of patients (exposure is Cutaneous Lymphoma)|
41025663|NCT05175352|DRUG|Cendakimab|Specified dose on specified days
41362058|NCT02246309|DEVICE|Embryoscope Time Lapse System|The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
41362059|NCT02246309|DEVICE|Standard Embryo Culture|Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
41362060|NCT04531345|DIAGNOSTIC_TEST|Flow cytometric analysis|IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
41362061|NCT00417495|BEHAVIORAL|Sentinel Lymph Node Technique|
41362062|NCT01920061|DRUG|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
41362063|NCT01920061|DRUG|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
41362064|NCT01920061|DRUG|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
41362065|NCT01920061|DRUG|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
41362066|NCT05379621|OTHER|COVID-19 infection|All persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
41362067|NCT06345287|RADIATION|radical radiotherapy (60Gy)|concurrent chemoradiotherapy (60Gy) after induction therapy
41362068|NCT06345287|RADIATION|radical radiotherapy (66Gy)|concurrent chemoradiotherapy (66Gy) after induction therapy
41362069|NCT06345287|RADIATION|radical radiotherapy (70Gy)|concurrent chemoradiotherapy (70Gy) after induction therapy
41362070|NCT06345287|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy
41362071|NCT05129917|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 14 day
41362072|NCT05129917|DIETARY_SUPPLEMENT|Gojinsen® drinks|consume 1 sachet per day for 14 day
41362073|NCT05507840|DEVICE|Valeda machine|Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.
41362074|NCT01829542|DIETARY_SUPPLEMENT|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
41362075|NCT01829542|DIETARY_SUPPLEMENT|Control|Macro- and micro-nutrient matched control in water
41362076|NCT05609682|DRUG|Gabapentin|Scheduled gabapentin given for two weeks after surgery
41025664|NCT05175352|DRUG|CYP substrates|Specified dose on specified days
41025665|NCT05453305|PROCEDURE|Control group: Traditional venipuncture, on the stretcher.|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial assessment of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child pain and stress using FLACC and Groningen scale and will record it. Next, the companion will place the child on the stretcher in supine position with the limb to be punctured in decline. During the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture and/or collecting samples. The observer will assess child's pain and stress and caregiver's STAI during the intervention with the same scales.
41362077|NCT05609682|DRUG|Placebo|Placebo given for two weeks after surgery
41362078|NCT02063932|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
41362079|NCT00556283|DEVICE|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
41362080|NCT00556283|BEHAVIORAL|Biofeedback|electromyographic-based treatment sessions
41362081|NCT01365182|BEHAVIORAL|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
41362082|NCT01365182|BEHAVIORAL|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
41362083|NCT02657109|OTHER|physical therapy procedure|physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
41362084|NCT00245869|PROCEDURE|Contrast-enhanced Ultrasound|
41362085|NCT05011240|BEHAVIORAL|Paediatric Autism Communication Therapy (PACT)|PACT is a parent-mediated therapy that aims to improve children's social-communication development. During PACT, a therapist uses video-feedback of parent-child play interactions to coach the parent in how to improve their sensitivity and responsiveness to their child's social-communication and interaction behaviours and to implement evidence-based strategies that facilitate social-communication development.
41362086|NCT05011240|BEHAVIORAL|Psychoeducation|Control participants will receive monthly psychoeducation sessions led by a developmental specialist
41362087|NCT01880320|DRUG|CD0271 0.3% / CD1579 2.5%|
41362088|NCT01880320|DRUG|CD0271 0.1% / CD1579 2.5%|
41499358|NCT03425695|OTHER|Clinical examination|"The shrinkage of the graft area was calculated according to the differences between the graft area at baseline, 1st, 3rd, and 6th months.~Epithelization was determined via bubbling test by using 3% hydrogen peroxide (H2O2) at 7, 14, 21, and 28 days after surgery."
41499359|NCT00839254|BIOLOGICAL|Pneumococcal conjugate vaccine Synflorix (GSK1024850A)|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
40841570|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
41160841|NCT01602003|DRUG|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
41362089|NCT01880320|DRUG|Topical Gel Vehicle|
41362090|NCT04205188|OTHER|therapeutic exercises|aerobic- balance -stretching and strengthening exercises
40841571|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
40841572|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
40841573|NCT05277428|DIETARY_SUPPLEMENT|GTB1|2 capsule/day
40841574|NCT05277428|DIETARY_SUPPLEMENT|Placebo|2 capsule/day
41362091|NCT03374059|OTHER|Exercise program|
41362092|NCT03374059|OTHER|Life modification|
41499360|NCT00839254|BIOLOGICAL|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children \< 12 months of age at the time of first study vaccination.
41499361|NCT00839254|BIOLOGICAL|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections only for children \>= 12 months of age at the time of first study vaccination.
41362093|NCT05076981|DRUG|human chorionic gonadotropin|once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously
41362094|NCT05810324|DRUG|18F-FAPI|Each patient receive a single intravenous injection of 18F-FAPI, and undergo PET/CT scan within specified time.
41362095|NCT04226365|DRUG|Nortriptyline|10mg capsule Nortryptyline
41362096|NCT04226365|DRUG|Placebo|10mg capsule Thick-It filler
41362097|NCT02359500|DRUG|68Ga-DOTATOC PET|68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
41499362|NCT06158256|OTHER|Voluntary apnoea|Series of static apneas at low lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds until completing the 6 minutes.
41499363|NCT02912949|DRUG|zenocutuzumab (MCLA-128)|full length IgG1 bispecific antibody targeting HER2 and HER3
41499364|NCT00177359|BEHAVIORAL|gait intervention|
41025666|NCT05453305|PROCEDURE|Intervention group: DAK method venipuncture, simulating a hug|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial evaluation of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child's pain and stress using the FLACC and Groningen scale and record it. Subsequently, the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture and collecting samples. The observer will assess the child's pain and stress during the intervention, and will deliver the STAI to the caregiver, to be completed with their perceived sensations during the technique.
41362098|NCT00528294|RADIATION|GRID radiotherapy|GRID-radiotherapy followed by biological imaging guided IMRT
41362099|NCT03114475|RADIATION|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
41362100|NCT03114475|OTHER|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
41362101|NCT03151928|DIAGNOSTIC_TEST|BDMax Vaginal Panel|The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
41362102|NCT04680273|DRUG|[14C]-GDC-9545|Participants will receive a single oral dose of \[14C\]-GDC-9545 capsule, 30 milligrams (mg) (not more than \[NMT\] 4.6 megabecquerel \[MBq\]; 124 microcurie \[μCi\]) with approximately 240 millilitres (mL) water in the fasted state.
41362103|NCT04680273|DRUG|GDC-9545 Solution for Infusion|Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
41362104|NCT04680273|DRUG|GDC-9545/F12 Capsule|Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.
41362105|NCT04680273|DRUG|GDC-9545/F18 Capsule|Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.
41362106|NCT05723211|BEHAVIORAL|Vinyasa yoga group|Participants will be instructed to perform a pre-recorded 60-minute vinyasa yoga session 3 times a week for 4 weeks.
41362107|NCT05723211|OTHER|Non-active control group|Participants will be instructed to sit quietly for 60 minutes and watch a nature documentary during this time. The participants will be asked to maintain their current lifestyle habits and refrain from starting a new exercise and/or yoga program.
41499365|NCT05267730|BEHAVIORAL|Conectar Jugando Game Program|Modern Board and Card Games as Cognitive Training in Rural Elementary Classrooms
41499366|NCT05102214|DRUG|HLX301|A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, HLX301 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
41362108|NCT00003389|DRUG|Doxorubicin|given IV
41362109|NCT00003389|DRUG|Bleomycin|given IV
41362110|NCT00003389|DRUG|Vinblastine|given IV
41499367|NCT02045589|GENETIC|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
41499368|NCT02045589|DRUG|Gemcitabine|1000 mg/m2 intravenous administration
41025667|NCT01010581|DRUG|SC12267 (4SC-101)|oral administration
41362111|NCT00003389|DRUG|Dacarbazine|given IV
41362112|NCT00003389|DRUG|Vincristine|given IV
41362113|NCT00003389|DRUG|Mechlorethamine|given IV
41362114|NCT00003389|DRUG|Etoposide|given IV
41362115|NCT00003389|DRUG|Prednisone|taken orally
41362116|NCT00003389|DRUG|Cyclophosphamide|given IV
41362117|NCT00003389|RADIATION|Radiotherapy|
41362118|NCT04035408|OTHER|Skin health assessment|Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
41362119|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
41362120|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
41362121|NCT03438773|DRUG|Envarsus|Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.
41362122|NCT03438773|DRUG|Tacrolimus|Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
41362123|NCT03494764|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts
41362124|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
41499369|NCT02045589|DRUG|Abraxane®|125 mg/m2 intravenous administration
41499370|NCT04061031|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|A trained clinician teaches the caregiver to deliver a number of behavior modification techniques for use with the child and coaches the caregiver in the delivery of those techniques.
41499371|NCT04061031|BEHAVIORAL|Child-Centered Therapy with Parent Education|A trained clinician delivers non-directive, child-centered treatment techniques with the child while providing education to the parent based on current recommendations from the Department of Health and Human Services' Child Welfare Information Gateway.
41499372|NCT01421173|DRUG|Vorinostat|Starting dose: 200 mg by mouth on Days -8 to -2.
41499373|NCT01421173|DRUG|Gemcitabine|Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.
41499374|NCT01421173|DRUG|Busulfan|"AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.~Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5."
41499375|NCT01421173|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
40841575|NCT01551277|OTHER|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
41499376|NCT01421173|PROCEDURE|Stem Cell Infusion|Infusion of stem cells by vein on Day 0.
41499377|NCT01421173|DRUG|Rituximab|375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.
41499378|NCT01421173|DRUG|G-CSF|5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
41499379|NCT01421173|DRUG|Palifermin|60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.
41499380|NCT01421173|DRUG|Dexamethasone acetate|8 mg by vein twice a day from day -8 AM to day -2 PM.
41499381|NCT03173430|DRUG|Blinatumomab|Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
40841576|NCT01551277|OTHER|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
40841577|NCT02846012|OTHER|CSCM2|
40841578|NCT01732913|DRUG|Placebo|Tablets administered orally twice daily
40841579|NCT01732913|DRUG|Rituximab|375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
41499382|NCT00284024|DRUG|domperidone|
41499383|NCT03510026|DEVICE|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
40841580|NCT01732913|DRUG|Idelalisib|150 mg tablets administered orally twice daily
40841581|NCT05855343|OTHER|BIDI Stick e-cigarette|The BIDI will be dispensed, and subjects will be instructed to use the BIDI as often as they like during the 12 week period, and to switch completely to the BIDI within 1 week. If, however, they do smoke any CC, they will also be instructed to use the BIDI immediately before each CC to relieve their craving as much as possible before smoking their usual brand. The BIDI will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute BIDI for CCs by the end of the first week of use.
40841582|NCT02754960|DRUG|Thalidomide|Interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
41499384|NCT01659086|BIOLOGICAL|Investigational H9N2 vaccine GSK2654911A|2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.
41499385|NCT01659086|BIOLOGICAL|Investigational H9N2 vaccine GSK2654909A|2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.
41499386|NCT01659086|BIOLOGICAL|Placebo|1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
41499387|NCT01485744|DRUG|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
40841583|NCT02754960|DRUG|Placebo|Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
40841584|NCT01105455|OTHER|Nutrition education|Group nutrition classes supplemented by handouts and provision of key study foods.
41025668|NCT01010581|DRUG|Placebo|oral administration
41025669|NCT01010581|DRUG|Methotrexate|oral administration
41499388|NCT04465695|DRUG|Interferon beta-1b|Subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) for 3 days
41499389|NCT04465695|DRUG|Clofazimine|Oral 100mg twice daily on day 1, then 100mg daily for 2 days
41499390|NCT06423092|OTHER|Music therapy songwriting|"Session 1: The goal of the first music therapy session is to know the parents musically and to provide information about song creation. This is achieved by exploring their favorite songs. Options for creating a song (original song or song parody) are presented and possibilities for creating lyrics are discussed.~Sessions 2-7: The structure of the song will be created and discussed with the parents. Parents will also be invited to include written messages from other family members in the lyrics if they wish. In each session, the developing welcome song is sung together with the parents, accompanied by the music therapist, who provides vocal or instrumental support.~The final sessions (Sessions 8-9) are dedicated to singing the final version of the song with the parents and their infant. Should the parents desire, a final recording of the song will also be made and the digital songbook will be created."
41499391|NCT03261011|BIOLOGICAL|AK-104|Subjects will receive AK104 by intravenous administration.
41499392|NCT04928092|PROCEDURE|Standard of care Ultra Low Contrast PCI|PCI using low amounts of contrast media which is standard of care at VCU Medical Center
41499393|NCT06633939|BEHAVIORAL|Behavioral Treatment|The theoretical framework for the Move \&amp; Eat 2 Live intervention is guided by the health belief model (HBM), socioecological model (SEM) and motivational interviewing (MI) approach. Tailoring to the target community will include a standard cultural adaptation that will replace curriculum content and examples with Native American relevant foods, physical activities, and representation in materials. For this study, the intervention will be piloted in the target population and will include the first 5 sessions of the original 12-session program.
41499394|NCT01371383|DIETARY_SUPPLEMENT|n-3 fatty acids|EPA 1680 mg/d + DHA 880 mg/d
41499395|NCT01371383|DIETARY_SUPPLEMENT|placebo|Soybean oil
41499396|NCT04653272|OTHER|Questionnaire|Patients will be evaluated identically to routine care with reference tests (Lysholm-Tegner, and Knee injury and Osteoarthritis Outcome Score (KOSS) and, IKDC (Evaluation of knee ligament injuries). This is filled in without any external help. The questionnaire includes the Lysholm-Tegner (young adult group), IKDC and KOOS scores (young and senior adult groups).
41499397|NCT03908879|PROCEDURE|Standard intraosseous (IO) catheter confirmation procedure|The physician will evaluate the ability or inability of the intraosseous (IO) catheter to stand upright unassisted, the ability or inability to aspirate blood or bone marrow from the IO catheter, and whether or not there is visible or palpable extravasation of infusate from the IO catheter insertion site or surrounding subcutaneous tissue during IO catheter use.
41499398|NCT03908879|PROCEDURE|Color flow Doppler intraosseous (IO) catheter confirmation procedure|The high frequency probe of a portable ultrasound with color flow Doppler is placed adjacent to the intraosseous (IO) catheter, visualizing the IO space in long or short axis. Color flow Doppler signal will be turned on during IO use and the physician will determine if the Doppler signal is in the intraosseous space or the extraosseous space. Saved data of the ultrasound image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
41025670|NCT01010581|DRUG|Folic Acid|oral administration
41362125|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
41362126|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)|In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
41362127|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
41362128|NCT00157638|BEHAVIORAL|integration of pharmacist into primary care|
41362129|NCT00157638|DRUG|optimizing therapeutic treatments|
41499399|NCT03908879|PROCEDURE|Pressure transduction intraosseous (IO) catheter confirmation procedure|The intraosseous (IO) catheter will be attached to a pressure transducer to demonstrate a waveform on the telemetry monitor. Physicians will evaluate for the presence of a pulsatile waveform with objective measurements of a systolic pressure, diastolic pressure and mean pressure. Saved data of the waveform image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
40841585|NCT01524081|DRUG|Metronidazole, Cefuroxime|"administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~1. - Cefuroxime in 100ml saline~2. - Metronidazole in 500ml saline"
41362130|NCT00157638|BEHAVIORAL|optimizing processes of care|
41362131|NCT03463720|OTHER|Infected|Extremity wound, infected
41362132|NCT03463720|OTHER|Not infected|Extremity wounds, non-infected
41362133|NCT01914900|DRUG|docetaxel, cisplatin, 5 fluorouracil|
41499400|NCT02465268|BIOLOGICAL|pp65-shLAMP DC with GM-CSF|
41499401|NCT02465268|BIOLOGICAL|unpulsed PBMC and saline|
41499402|NCT02465268|DRUG|Td|All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
41499403|NCT02465268|DRUG|Saline|
40841586|NCT01524081|DRUG|Amoxicillin (+ clavulanic acid) and Fluconazole|"Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~1. - 2x amoxicillin in 100ml saline~2. - Fluconazole in 500ml saline"
40841587|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 100ml saline solution~2. - 500ml saline solution"
41362134|NCT03233776|DRUG|Anakinra|Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
41499404|NCT02465268|BIOLOGICAL|pp65-flLAMP DC with GM-CSF|
40841588|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 2x 100ml saline solution~2. - 500ml saline solution"
40841589|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
40841590|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
41362135|NCT01633762|DRUG|meropenem, gentamicin, vancomycin (together)|"4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)"
41362136|NCT05212792|BIOLOGICAL|COVID-19 vaccines|Any licensing COVID-19 vaccine platform
41362137|NCT03497975|DRUG|Nalbuphine ER Tablets|Active Nalbuphine ER Tablets
41362138|NCT03497975|OTHER|Matching Placebo Tablets|Matching Tablets with no active substance
41362139|NCT03497975|DRUG|Nalbuphine ER Tablets|Open Label Extension
41362140|NCT02119559|OTHER|Blood analysis by EPISPOT and CellSearch®|
41362141|NCT02185638|OTHER|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
41362142|NCT02737514|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
41362143|NCT02737514|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
41362144|NCT02737514|PROCEDURE|water exchange|Water will infused and removed during insertion phase of colonoscopy
41362145|NCT04354870|DRUG|Hydroxychloroquine (HCQ)|Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
41499405|NCT00879957|DRUG|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
41499406|NCT00879957|DRUG|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
41499407|NCT05530187|DEVICE|Electronic Patient-reported Outcomes-based Model of Care|Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).
41499408|NCT04731753|DEVICE|mechanical debridement|The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.
41499409|NCT04293796|PROCEDURE|Vacuum-assisted biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, after neoadjuvant systemic treatment on patients with clinical complete response on primary breast cancer management we recommend to take at least 12 biopsies with 7-10G needle sizes with sentinel lymph node biopsy.
41499410|NCT02714426|BEHAVIORAL|Mindfulness-inspired treatment|Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) psychoeducation, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
41499411|NCT02714426|OTHER|Brain health|Eight weekly group brain health sessions lasting 90-120 minutes. The intervention is psychoeducational, and each week presents information from NIH regarding factors that may promote cognitive health in late life (e.g., sleep, physical activity, social engagement and leisure, cognitive training). Weekly sessions are supplemented with educational videos and group discussion. Weekly homework consists of readings about brain health.
41499412|NCT02252991|OTHER|physical activity|Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
41025671|NCT04856319|PROCEDURE|Dental implant placement|Insertion of not more than two dental implants at the same area
41499413|NCT03303196|DEVICE|Bihormonal Bionic Pancreas|A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.
41499414|NCT05369832|DRUG|Ozanimod|Specified dose on specified days
40841591|NCT06520007|DRUG|Doxycyclin|The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.
40841592|NCT01990456|DEVICE|PHASE 1: impact of tidal ventilation on VILI|PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
41025672|NCT04856319|DRUG|Antibiotic prophylaxis|Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
41025673|NCT04856319|OTHER|Placebo|Per-os placebo (inert polysaccharide) will be administered one hour prior to the surgery
41025674|NCT01853150|DEVICE|rTMS Motor cortex|
41362146|NCT00852358|DRUG|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
41362147|NCT05066906|DEVICE|Use of Identifor assessment tool and Companion app|"Identifor pinpoints what players excel at by using objective metrics and quantifiable data to collect information relevant to employment, including Multiple Intelligence, Executive Function, and personality themes.~Companion is a 24/7 personalized aide for teens and adults iwth special needs that uses and artificial intelligence avatar to have back-and-forth conversations with users in a meaningful way to support the user in different domains of their everyday lives including public transit, managing personal schedules, and money management."
41025675|NCT01853150|DEVICE|rTMS Supplementary motor area|
41025676|NCT03191344|BEHAVIORAL|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
40841593|NCT01990456|DEVICE|PHASE 2: impact of PEEP on VILI|PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
40841594|NCT01536808|OTHER|Cardiac RMI|Cardiac RMI
40841595|NCT01536808|OTHER|Analysis telomere|Analysis telomere
40841596|NCT01536808|OTHER|Stress test|Stress test
40841597|NCT01536808|OTHER|echocardiography|echocardiography
40841598|NCT01172574|OTHER|Motor control exercise|Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
40841599|NCT03770104|PROCEDURE|ETT insertion depth using Spanish recommendations|Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.
40841600|NCT03770104|PROCEDURE|ETT insertion depth using international recommendations|Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
40841601|NCT00504374|BEHAVIORAL|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
40841602|NCT01814670|BIOLOGICAL|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
40841603|NCT00359723|DRUG|methylphenidate|
40841604|NCT01897090|OTHER|Elimination Diet|
40841605|NCT01897090|OTHER|Dietary Guidelines for Americans|
40841606|NCT01286103|DRUG|Canagliflozin 300 mg once daily and 150 mg twice daily|Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
40841607|NCT01286103|DRUG|Canagliflozin 100 mg once daily and 50 mg twice daily|Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
40841608|NCT02945644|DRUG|Trazodone|take at bedtime for 14 days
41160842|NCT01602003|DRUG|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
41160843|NCT02396498|DRUG|HIPEC|Using cisplatin in HIPEC plus oral S-1
41362148|NCT05066906|OTHER|Referral to employment agencies|Standard referral to employment agencies based on an individual's background, skillset, and preferences
41499415|NCT04225624|BEHAVIORAL|Emotion Regulation Therapy - Attention Regulation (AR-ERT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based AR-ERT. This intervention aims to build attention regulation skills (i.e., the ability to flexibly shift and sustain attention) by teaching participants exercises for Orienting their attention and Allowing the presence of negative emotions. Participants are taught to apply these skills to counteract reactive perseverative thinking when negative emotions arise as well as proactively engage with emotion-laden situations that trigger repetitive negative thinking.
40841609|NCT02945644|DRUG|Placebo|take at bedtime for 14 days
40841610|NCT00225784|DRUG|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
40841611|NCT00225784|PROCEDURE|Radiotherapy|Daily radiotherapy for 28 days
40841612|NCT00042666|DRUG|LY317615|500 mg, oral, QD, up to six 28 day cycles
40841613|NCT05587166|OTHER|ultrasound guided adductor canal block|ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
40841614|NCT03262467|PROCEDURE|Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)|In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
40841615|NCT00953940|DRUG|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
40841616|NCT02722265|DRUG|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
40841617|NCT00536952|DRUG|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
40841618|NCT00536952|DRUG|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
40841619|NCT00536952|RADIATION|Radiation Therapy|5 days per week for 4 weeks
40841620|NCT02437370|DRUG|Pembrolizumab|Given IV
40841621|NCT02437370|DRUG|Docetaxel|Given IV
40841622|NCT02437370|DRUG|Gemcitabine Hydrochloride|Given IV
40841623|NCT02623504|DRUG|Carbamazepine|200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
40841624|NCT02623504|DRUG|Placebo|Dosage to match active treatment by mouth twice daily in the morning and in the evening.
40841625|NCT00243984|DRUG|topiramate|
40841626|NCT00000802|DRUG|Atovaquone|
40841627|NCT00000802|DRUG|Dapsone|
41160844|NCT01910740|OTHER|Enhanced Physical Activity|Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
41160845|NCT01910740|OTHER|Usual Care|Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
41499416|NCT04225624|BEHAVIORAL|Supportive Psychotherapy (SPT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based SPT. This intervention addresses factors that may affect participants' repetitive negative thinking symptoms (for example, relationships, work, stress), and teaches skills for managing challenges by improving self-esteem and positive coping skills.
41362149|NCT03540602|DIETARY_SUPPLEMENT|Tart Cherry|NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
41362150|NCT03540602|OTHER|Placebo Oral Capsule [CEBOCAP]|Rice flour
41362151|NCT05991401|DRUG|DA-8010 5mg|\[Period 1\] DA-8010 5mg \[Period 2\] DA-8010 5mg, Clarithromycin 500mg \[Period 3\] DA-8010 5mg, Rifampicin 600mg
41362152|NCT05991401|DRUG|Clarithromycin 500mg|\[Period 2\] DA-8010 5mg, Clarithromycin 500mg
41362153|NCT05991401|DRUG|Rifampicin 600mg|\[Period 3\] DA-8010 5mg, Rifampicin 600mg
41362154|NCT01953419|DRUG|Pemetrexed disodium|Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
41499417|NCT03243058|BIOLOGICAL|ILT-101 (Aldesleukin; IL-2)|Administration of Low-Dose Interleukin-2 (ILT-101) for two years
41499418|NCT03243058|OTHER|Treatment-Placebo Arm|Administration of Low-Dose Interleukin-2 (ILT-101) for one year, and then placebo for the second year.
41499419|NCT03243058|OTHER|Placebo Arm|Participants in this group will receive a placebo injection for two years.
41499420|NCT03249792|DRUG|MK-2118 (IT)|IT injection
41499421|NCT03249792|DRUG|MK-2118 (SC)|SC injection
41499422|NCT03249792|BIOLOGICAL|Pembrolizumab|IV infusion
41499423|NCT01693510|BEHAVIORAL|Exercise and Nutrition Intervention|Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
41362155|NCT02240901|DEVICE|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
41362156|NCT02240901|DEVICE|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
41362157|NCT04808115|DRUG|KDS-1001|"Cycles 1-6 (14 days per cycle)~1 x 109/KDS-1001 cells/infusion administered on day 1 of each cycle"
41499424|NCT06189729|BEHAVIORAL|Text reminder|Participants will receive trimonthly text reminders through instant messaging mobile applications or short message service.
41499425|NCT06189729|BEHAVIORAL|HIV self-test|Participants will receive trimonthly text messages asking them to choose a pickup point run by the delivery company to collect the free HIV self-test. Upon receiving the delivery instruction, the self-test kit with bilingual (Chinese and English) instructions would be delivered to the designated location.
41499426|NCT00642252|DRUG|Fluoride|Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
41499427|NCT00642252|DRUG|Fluoride|Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
41499428|NCT04504123|DRUG|Doxycycline Hyclate|Doxycycline Hyclate capsules, USP 50 mg
41362158|NCT05961059|BIOLOGICAL|2.5 μg InvaplexAR-Detox|2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
41362159|NCT05961059|BIOLOGICAL|10 μg InvaplexAR-Detox|10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
41362160|NCT05961059|BIOLOGICAL|0.1 μg of dmLT|0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).
41362161|NCT05961059|BIOLOGICAL|Placebo|Placebo vaccination with commercially available saline solution.
41362162|NCT02244827|DRUG|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
41362163|NCT05568251|DEVICE|transcranial Direct Current Stimulation|Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).
41362164|NCT05568251|PROCEDURE|Cognitive training|Participants will be administered Game of Dice Task concurrent with the tDCS session
41362165|NCT03609775|DRUG|ACT-541468|One tablet of 50 mg ACT-541468 will be administered orally.
41362166|NCT03609775|OTHER|ACT-541468 placebo|Matching ACT-541468 placebo will be administered orally as 1 tablet.
41362167|NCT03609775|OTHER|Ethanol 10%|Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
41362168|NCT03609775|OTHER|Ethanol placebo|Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
41499429|NCT04504123|DRUG|Placebo|Placebo
41362169|NCT01233284|DRUG|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
41499430|NCT02739945|PROCEDURE|Cubital tunnel release|The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
41499431|NCT01283035|DRUG|Akt Inhibitor MK2206|Given PO
41499432|NCT01283035|OTHER|Laboratory Biomarker Analysis|Correlative studies
41499433|NCT04166565|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.
41499434|NCT04166565|DRUG|Bortezomib|Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.
41499435|NCT04166565|DRUG|Cyclophosphamide|"Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
41499436|NCT04166565|DRUG|Dexamethasone|Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
41499437|NCT01434810|DEVICE|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
41499438|NCT01434810|DEVICE|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
41499439|NCT01775189|DRUG|ALO-02 weight-matched placebo|crushed sugar spheres (powder) x 1 dose
41499440|NCT01775189|DRUG|crushed ALO-02 30 mg/3.6 mg|crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
41499441|NCT01775189|DRUG|oxycodone weight-matched placebo|crushed lactose tablets (powder) x 1 dose
41499442|NCT01775189|DRUG|crushed oxycodone IR 30 mg|Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
41499443|NCT04365777|OTHER|OAA/S=5|Prior to anesthesia induciton, EEG signatures will be recorded at Observer's Assessment of Alertness/Sedation (OAA/S) score of 5 (awake, eye-close state) for few minutes.
41499444|NCT04365777|OTHER|OAA/S=3|Given sedative anesthetics (propofol, midazolam or dexmetomidine), EEG signatures will be recorded after reaching steady state of OAA/S=3 (responds only after name called loudly and/or repeatedly) for few minutes.
41499445|NCT04365777|OTHER|OAA/S=1|Increasing drug concentration, EEG signatures will be recorded after reaching steady state of OAA/S=1 (does not respond to noxious stimuli) for few minutes.
41499446|NCT04197817|DRUG|JS002|JS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design
41362170|NCT01233284|DRUG|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
41362171|NCT01233284|DRUG|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
41362172|NCT01233284|DRUG|tiotropium bromide 1.25µg once daily|IMP
41499447|NCT04197817|DRUG|Placebo|Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design
41499448|NCT04034407|PROCEDURE|Damage control surgery|"All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis."
41499449|NCT05290727|OTHER|Aquoral Lipo (Esteve)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
41499450|NCT05290727|OTHER|Hyabak (Thea)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
41499451|NCT00631657|DRUG|Esmirtazapine|One esmirtazapine 4.5 mg tablet once a day
41499452|NCT00631657|DRUG|Placebo|One placebo tablet once a day
41499453|NCT03219190|BEHAVIORAL|LST High School Online|The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
41362173|NCT00403429|DRUG|capecitabine|
41362174|NCT06452212|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
41362175|NCT02492321|DRUG|EBI-005|
41362176|NCT02492321|DRUG|Placebo Comparator|
41362177|NCT00918905|DEVICE|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
41362178|NCT00021346|DRUG|carboplatin|
41362179|NCT00021346|DRUG|gemcitabine hydrochloride|
41025677|NCT02401672|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
41025678|NCT03152305|OTHER|Intracranial pressure variations|Self-measure of ICP will be performed outside and during menstrual migraine attacks.
41025679|NCT04139811|OTHER|Pars Plana Vitrectomy|vitrectomy with and without ILM peeling
41362180|NCT05443802|DRUG|Insulin 0.05 IU/kg/h|In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
41362181|NCT05443802|DRUG|Insulin 0.10 IU/kg/h|In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.
41362182|NCT04923009|PROCEDURE|ICE visualization and map construction|Radio-frequency ablation of atrial fibrillation
41160846|NCT01910740|OTHER|Social Interaction|To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
41362183|NCT01369394|OTHER|Behavioral: Computer-based tailoring system|"Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website."
41362184|NCT03679117|BEHAVIORAL|Mindfulness Training|Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
41362185|NCT00957827|DRUG|keflex|keflex 500 mg BID 5 days
41499454|NCT05831241|DIETARY_SUPPLEMENT|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
41499455|NCT05831241|OTHER|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
41499456|NCT06473155|BEHAVIORAL|Experimental: Humanistic Integrative Psychotherapy and Identity Exploration (HIP+EYME)|Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME.
41499457|NCT06473155|BEHAVIORAL|Experimental: Humanistic Integrative Psychotherapy, Identity, and Geniotype Exploration (HIP+EYME+GENIOTYPE)|Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME. Also, participants will answer the Geniotype questionnaire and the results will be worked with the adolescents.
41499458|NCT04953572|GENETIC|autologous peripheral blood mesenchymal stem cell|Transplantation of autologous peripheral blood mesenchymal stem cell
41499459|NCT04953572|PROCEDURE|Microfracture|Microfracture
41499460|NCT04953572|COMBINATION_PRODUCT|Microfracture + collagen membrane|Microfracture plus collagen membrane transplantation
41160847|NCT03595137|DEVICE|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
41362186|NCT00957827|DRUG|placebo|placebo BID for five days
41362187|NCT06046989|BEHAVIORAL|Building Emotion Awareness and Mental Health (BEAM)|BEAM is based on best-practices in telehealth and science-based program design principles aimed at promoting parental mental health and supportive parenting. The BEAM Program mobile application is designed and managed by MindSea. The weekly one-on-one check-ins with peer coaches (parents who previously participated in another research group-based mental health intervention) will use the secure videoconferencing platform Zoom (Healthcare license) and direct messaging through the BEAM app. Peer coaches will also engage with participants on the community peer support forum. Monthly drop-in group peer support sessions will be facilitated by peer coaches and/or mental health professionals on the BEAM research team. The BEAM program's content emphasizes self-compassion, effective communication practices, and building social support networks.
41362188|NCT00606463|DEVICE|Cardiac Ablation (Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
41499461|NCT04953572|PROCEDURE|Autologous osteochondral transplantation|Autologous osteochondral transplantation
41499462|NCT00002737|BIOLOGICAL|recombinant interferon alfa|
41499463|NCT00002737|DRUG|chemotherapy|
41499464|NCT00002737|DRUG|isotretinoin|
41499465|NCT02678650|DRUG|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
41499466|NCT02678650|DRUG|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
41499467|NCT03429010|PROCEDURE|"New guideline anesthesia strategy team"|"New guideline anesthesia strategy team"
41499468|NCT06632756|BEHAVIORAL|Individual and Group Treatment for Smoking Cessation|Positive psychology-based individual treatment and groups
41499469|NCT01822275|DRUG|Chemotherapy with Temodar.|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
41499470|NCT01822275|RADIATION|Radiation therapy|
41499471|NCT02021513|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
41499472|NCT02021513|DIETARY_SUPPLEMENT|Olive Oil|Placebo group
41499473|NCT01398514|DRUG|Escitalopram|Escitalopram 10mg/day or matched pill placebo
41499474|NCT05250973|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
41362189|NCT01474993|DRUG|Sulforaphane-rich Broccoli Sprout Extract|"30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing \~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to \~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:~1. Subjects with body weight less than 101 lbs will receive \~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)~2. Subjects with body weight 101 lbs to 199 lbs will receive \~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)~3. Subjects with bidy weight \> 199 lbs will receive \~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)"
41362190|NCT01474993|DRUG|Placebo|15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
41362191|NCT00933543|DRUG|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
41362192|NCT00933543|DRUG|Vehicle cream (placebo)|Cream application followed by illumination with red light.
41362193|NCT00933543|PROCEDURE|PDT|Photodynamic Therapy - Light dose 37 J/cm2
41362194|NCT00457951|DRUG|Open-Label|ODSH administered open-label
41362195|NCT00457951|DRUG|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
41362196|NCT00457951|DRUG|ODSH|Randomized, Blinded, ODSH Arm
41362197|NCT00329836|OTHER|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
41362198|NCT04513249|DIAGNOSTIC_TEST|dynamics of coagulation parameters|the effects of fresh frozen plasma administered during a plasma exchange therapy on viscoelastic tests
41362199|NCT05122364|BEHAVIORAL|Telerehabilitation and telecoaching|Language Sessions online and coaching parents online to improve language and social outcomes of their children
41362200|NCT05122364|BEHAVIORAL|Face to Face Language sessions|Language sessions Face to Face at sohag phoniatrics unit
41362201|NCT03100929|DIAGNOSTIC_TEST|Ultrasound|Pre-operational ultrasound for the detection of fetal heart rate, fetal presentation and presence of nuchal cord.
41362202|NCT01506310|BEHAVIORAL|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
41362203|NCT01506310|OTHER|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
41362204|NCT01506310|OTHER|Behavioral therapy and exercise|"General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change"
41362205|NCT00055939|DRUG|exatecan mesylate|
41499475|NCT05250973|DRUG|Cyclophosphamide|Cyclophosphamide will be administered either orally or IV.
41499476|NCT05250973|DRUG|Bortezomib|Bortezomib will be administered by SC injection or IV.
41362206|NCT02369406|DRUG|Nevirapine|
41362207|NCT02369406|DRUG|Kaletra|
41362208|NCT02369406|DRUG|Lamivudine|
41362209|NCT02369406|DRUG|Zidovudine|
41362210|NCT01579383|BIOLOGICAL|ALD403|Single Dose IV infusion on Day 1
41362211|NCT01579383|BIOLOGICAL|ALD403|Single Dose subcutaneous injection on Day 1
41362212|NCT01579383|BIOLOGICAL|Sumatriptan|Single Dose subcutaneous injection on Day 1
41362213|NCT03373656|BIOLOGICAL|Vaccination|"Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:~hepatitis B vaccine measles-rubella combined vaccine"
41362214|NCT03373656|OTHER|No Vaccination|Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.
41362215|NCT01941472|OTHER|fluid challenge|A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
41362216|NCT04116905|BEHAVIORAL|Intensive Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision sessions and is aimed at achieving and maintaining at least a 15% decrease in weight from baseline. It is implemented during a 12-month period with the most intensive application during the first 4 months. To help participants achieve and maintain weight loss, partial diet replacement with very low calorie diet, strengthend exercise strategies. Mobile phone applications (apps) will be used to manage metabolic syndrome during weight loss program. Optional medications on metabolic syndrome will be utilized based on a preset algorithm and participant progress.
41499477|NCT05250973|DRUG|Dexamethasone|Dexamethasone will be administered orally or IV.
41499478|NCT00018356|PROCEDURE|exercise|
41499479|NCT00018356|DRUG|testosterone|
41499480|NCT03980574|DIETARY_SUPPLEMENT|R Drink|R Drink is a dietary supplement drink containing filtered reverse osmosis water and 150 mg/L of both USP Grade calcium chloride and magnesium chloride, 10 mg/L Biotin (vitamin B7), 500 mg/L of Niacinamide (B3) and 550 mg/L of Choline.
41499481|NCT00930163|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
41499482|NCT00930163|DRUG|placebo|Subcutaneous repeating dose
41499483|NCT01900951|DRUG|Temozolomide|
41160848|NCT03595137|DEVICE|Sono only|In group S, sono-guided internal jugular vein cannulation was performed after induction of anesthesia
41160849|NCT05360199|BEHAVIORAL|PROMs|evaluate the impact of recall bias on post proms scores
41362217|NCT04116905|BEHAVIORAL|Conventional Treatment|Participants assigned to conventional treatment and education are offered metabolic syndrome management and social support every 1 month, aimed at achieving and maintaining a 5% decrease in weight in 1 year. Mobile phone applications (apps) will also be used in the weight loss program.
41499484|NCT03242200|OTHER|Mobile Health App|Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
41499485|NCT05603312|GENETIC|AAV-GAD Dose 1|Bilateral infusion of AAV-GAD Dose 1
41499486|NCT05603312|GENETIC|AAV-GAD Dose 2|Bilateral infusion of AAV-GAD Dose 2
41362218|NCT01343121|OTHER|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
41362219|NCT01343121|OTHER|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
41362220|NCT01343121|OTHER|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
41362221|NCT00027027|DRUG|rhuMAb 2C4|
41362222|NCT04169620|OTHER|aquatic Ai Chi|"The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
41362223|NCT04169620|OTHER|control|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
41362224|NCT01345162|DRUG|Ketorolac postoperative|Ketorolac 10mg 1cp x 3/die
41362225|NCT01345162|DRUG|postoperative Patrol|acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
41362226|NCT01345162|DRUG|intraoperative analgesia|ketorolac 30 mg iv
41362227|NCT01345162|DRUG|intraoperative analgesia|Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
41362228|NCT03276858|DRUG|CRN00808|Investigational drug
41362229|NCT03276858|DRUG|Placebo Oral Solution|Placebo
41362230|NCT03276858|DRUG|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
41362231|NCT03276858|DRUG|Placebo oral capsule|Placebo
41362232|NCT00340938|PROCEDURE|Blood testing|
41362233|NCT04646668|COMBINATION_PRODUCT|E-cigarette and Heat not burn|Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).
41362234|NCT03971773|OTHER|hypnosis|patient with cancer will undergo sessions of hypnosis
41362235|NCT05863065|OTHER|Exposure to a Virtual Reality scenarios|Exposure to a personalized, relaxing Virtual Reality scenario deployed by a Head-mounted tool (Oculus Quest 2). The administration was deployed in one session.
41362236|NCT05302609|BIOLOGICAL|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in reinforcement of scleral thinning.
41362237|NCT01224171|DRUG|vedolizumab|Vedolizumab for intravenous infusion
41362238|NCT01224171|OTHER|Placebo|Placebo intravenous infusion
41362239|NCT03306589|BIOLOGICAL|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
41362240|NCT03306589|BIOLOGICAL|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
41362241|NCT03306589|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
41362242|NCT03306589|DRUG|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
41362243|NCT00974727|OTHER|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
41362244|NCT04784559|DRUG|Plitidepsin|"Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes."
41362245|NCT04784559|DRUG|Dexamethasone|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
41362246|NCT04784559|DRUG|Remdesivir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
41362247|NCT04784559|DRUG|Favipiravir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
41362248|NCT00002102|DRUG|Trimetrexate glucuronate|
41499487|NCT05603312|PROCEDURE|Sham Surgery|Sham infusion
41362249|NCT00002102|DRUG|Leucovorin calcium|
41362250|NCT04041401|OTHER|PICU storybook|Narrative and developmentally appropriate intervention
41499488|NCT06584890|OTHER|decision|decision-making process regarding patient discharge from the Intensive Care Unit (ICU)
41362251|NCT05384756|DRUG|Alemtuzumab|Given IV
41362252|NCT05384756|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
41362253|NCT05384756|RADIATION|Intensity-Modulated Radiation Therapy|Undergo TMLI
41362254|NCT05384756|DRUG|Sirolimus|Medication to prevent the development of graft-versus-host disease (GVHD)
41362255|NCT03025295|DRUG|Dexmedetomidine|Dexmedetomidine is common used to improve the prognosis and life quality of patients.
41362256|NCT03025295|DRUG|Saline|It is safe Placebo.
40841628|NCT06325319|OTHER|Community engagement using M-MAMA Champions to improve awareness on obstetric danger signs, bith preparedness and complication readiness among pregnant women|Community engagement using M-MAMA Champions to improve awareness of obstetric danger signs, birth preparedness, and complication readiness among pregnant women. The empowered M-MAMA Champions will deliver the intervention to pregnant women in their communities. A total of three (3) sessions will be held, whereby each will take two (2) hours. The sensitization will take place at one of the study participant's residential area, where women will gather up and be sensitized on the subject by the M-MAMA Champion as a facilitator using a well-prepared brochure (package).
40841629|NCT00206934|DRUG|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
40841630|NCT00206934|DRUG|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
40841631|NCT02943915|DEVICE|Ekso GT Rehabilitation Therapy|Walking Improvement for Spinal Cord Injuries with Exoskeleton
40841632|NCT02943915|DEVICE|Body Weight Supported (BWS) Treadmill Training|Standard gait training using BWS PT and overground training
40841633|NCT03599323|DRUG|Clotrimazole 1% (Empecid L Cream, BAYB5097)|Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).
40841634|NCT01825941|DRUG|metoclopramide|10 milligrams, administered intravenously over 15 minutes
40841635|NCT01825941|DRUG|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
40841636|NCT01825941|DRUG|placebo|
40841637|NCT00175266|DRUG|alemtuzumab|
41160850|NCT03047902|OTHER|Group 1 - Parents will be present for the Questionnaire.|"In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.~In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them."
41362257|NCT02984228|BIOLOGICAL|PRP|
41362258|NCT02984228|DRUG|Hyaluronic Acid|
41362259|NCT02984228|DEVICE|Ultrasound|
41362260|NCT03740724|GENETIC|FCX-013|FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.
41362261|NCT03740724|DRUG|veledimex|Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
41362262|NCT01533974|OTHER|Acceptance & Commitment Therapy (ACT)|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
41362263|NCT01533974|OTHER|Cognitive Behavioral Therapy (CBT)|The control condition will be the current group-delivered CBT smoking cessation program at GH.
41362264|NCT04530227|DRUG|Biological: Camrelizumab|PD-1
41362265|NCT04530227|DRUG|Pemetrexed|chemotherapy
41362266|NCT04530227|DRUG|Nab-paclitaxel|chemotherapy
41362267|NCT00433979|DRUG|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
40841638|NCT00175266|PROCEDURE|islet transplant|
41362268|NCT03858621|DRUG|fentanyl NOL guided|Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
40841639|NCT00175266|DRUG|infliximab|
40841640|NCT03839758|PROCEDURE|TSA standard|Glenoid preparation will be done with 2D CT-Scan
41160851|NCT03047902|OTHER|Group 2- Parents will not be present for the Questionnaire|
41160852|NCT02581189|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
41160853|NCT02581189|DRUG|Dasabuvir|Tablet
41160854|NCT02581189|DRUG|Ribavirin|Tablet
40841641|NCT03839758|PROCEDURE|RTSA standard|Glenoid preparation will be done with 2D CT-Scan
41362269|NCT04781946|PROCEDURE|Endoscopic pneumatic balloon dilation|Using endoscopy, pneumatic balloon dilation may be used to treat stenosis of the gastric sleeve.
41362270|NCT04781946|PROCEDURE|Gastric peroral endoscopic myotomy (G-POEM)|Gastric per-oral endoscopic myotomy (G-POEM) is a recent innovation offering a minimally invasive endoscopic approach. G-POEM allows for the creation of a tunnel and subsequent myotomy from the gastric cardia to the gastric pylorus.
41362271|NCT04781946|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|The Roux-en-Y gastric bypass is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine.
41362272|NCT06296602|OTHER|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest.
41362273|NCT01219686|DRUG|escitalopram, pindolol|escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
41362274|NCT01219686|DRUG|escitalopram|escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
41362275|NCT01219686|DRUG|escitalopram|escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
41362276|NCT05357105|OTHER|Numerical Pain Scales|Patients who are about to receive regional nerve blocks will be administered a numerical pain scale (NRS) before, during and after the offset of the nerve block.
41362277|NCT03200041|PROCEDURE|Blood sample|20 ml blood sample taken from vein in arm
41362278|NCT04000074|BEHAVIORAL|Telephonic Services|Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
41362279|NCT04000074|BEHAVIORAL|In-Person Services|Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
41362280|NCT05941494|DRUG|Propofol|Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.
41362281|NCT05941494|DRUG|Sevoflurane|Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.
41362282|NCT05941494|DRUG|Ephedrine|The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
41362283|NCT05941494|DRUG|Phenylephrine|Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
41362284|NCT04652609|OTHER|PRESIONA|Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
41362285|NCT01974310|PROCEDURE|Vitrectomy & Intraocular gas fill|
41362286|NCT01974310|PROCEDURE|Postoperative face-down positioning|
41362287|NCT02217020|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
41362288|NCT00421928|DRUG|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
41499489|NCT05249452|OTHER|Preconditioning with azathiprine and hydroxyurea (3 months)|Preconditioning with azathiprine and hydroxyurea (3 months) before alemtuzumab/TBI conditioning and matched sibling donor allogeneic stem cell transplantation.
41499490|NCT04234659|DEVICE|Clinical placement of a temporary IMPELLA® mechanical circulatory support device.|Surgical placement of the IMPELLA® device for life threatening cardiogenic shock not responsive to other medical treatment.
41499491|NCT05804916|DEVICE|Surface Guided Radiation Therapy (SGRT)|SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection
41499492|NCT01903135|PROCEDURE|Blood test analysis in the clinical labs|for specific measurement of plasmatic bicarbonate
40841642|NCT03839758|PROCEDURE|TSA Blueprint|Glenoid preparation will be done with Blueprint software
41160855|NCT04983225|DRUG|Human Dental Pulp Stem Cells|Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
41362289|NCT00421928|DRUG|placebo|matching placebo twice a day (BID) during 15 weeks
41362290|NCT00421928|DRUG|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
41362291|NCT04901702|DRUG|Onivyde|Given intravenous on Days 1 and 8
41362292|NCT04901702|DRUG|Talazoparib|Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6
41362293|NCT04901702|DRUG|Temozolomide|Given once a day on Days 1-5.
41362294|NCT03534089|OTHER|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.
41499493|NCT01903135|PROCEDURE|Pneumologist consult to establish the diagnosis of OHS|"complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.~Medical history, previous treatments."
41499494|NCT00003324|PROCEDURE|conventional surgery|
41499495|NCT00003324|RADIATION|radiation therapy|
41499496|NCT01136967|DRUG|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
41499497|NCT02493192|DRUG|pethidine and haloperidol injection|
40841643|NCT03839758|PROCEDURE|RTSA Blueprint|Glenoid preparation will be done with 2D CT-Scan
40841644|NCT02218944|BEHAVIORAL|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
40841645|NCT03239015|DRUG|Gefitinib|Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
41362295|NCT03534089|OTHER|Low level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).
41362296|NCT03534089|OTHER|High level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
41362297|NCT02043704|DRUG|IV Acetaminophen|Details covered in arm description.
41362298|NCT05732324|PROCEDURE|IVUS guided PCI optimization|PCI to long lesion will be optimized according to the IVUS.
40841646|NCT03239015|DRUG|Erlotinib|Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
41160856|NCT04983225|OTHER|Saline solution|Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.
41362299|NCT05732324|PROCEDURE|FFR guided PCI optimization|PCI to long lesion will be optimized according to the FFR.
41362300|NCT05732324|DIAGNOSTIC_TEST|FFR measurement|Fractional flow reserve protocol will be applied for both FFR-guided and IVUS-guided PCI groups. FFR will be measured according to the standard practice using intravenous adenosine. FFR will be recorded before PCI at the distal third of the coronary artery and after PCI at the same location. In FFR optimization group more than one post PCI FFR measurements could be acquired if the operators performed additional optimization. In IVUS optimization group only one post PCI FFR measurement will be recorded after which the procedure will be considered to be finished, and no further interventions will be undertaken. The same FFR measurements will be performed at 9-12 months follow-up.
41362301|NCT05373472|BIOLOGICAL|COVID-19 mRNA vaccine|2 doses of vaccine on Day 0 and Day 21
41362302|NCT05373472|BIOLOGICAL|Placebo|2 doses of placebo on Day 0 and Day 21
41362303|NCT03856242|DRUG|Tamsulosin Oral Capsule|Tamsulosin Oral Capsule - alpha-1-adrenoblocker for treatment LUTS/BPH 0.4 mg
41362304|NCT03856242|PROCEDURE|TURP|Routine transurethral prostatic resection
41362305|NCT04309175|DEVICE|base rate programming of a permanent cardiac pacemaker|Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
41362306|NCT04269629|DRUG|Insect Venom|Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
41362307|NCT00308568|BEHAVIORAL|Mailed educational brochure|
41362308|NCT02508012|OTHER|Immuno monitoring|treatment optimization
40841647|NCT03239015|DRUG|Afatinib|Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
40841648|NCT03239015|DRUG|Trastuzumab|Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.
40841649|NCT03239015|DRUG|Oxazolidine|Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.
40841650|NCT03239015|DRUG|Olaparib|Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.
40841651|NCT03239015|DRUG|Everolimus|Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.
40841652|NCT03239015|DRUG|Cabozantinib|Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.
41362309|NCT01205646|DRUG|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
41362310|NCT01205646|DEVICE|PET Scan|2 scans \[about 1-2 weeks apart\] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
41362311|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
41362312|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
40841653|NCT03239015|DRUG|Vemurafenib|Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
40841654|NCT03239015|DRUG|Dabrafenib|Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
40841655|NCT03239015|DRUG|Palbociclib|Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.
41362313|NCT01197846|DRUG|Quetiapine|quetiapine 300 mg or 600 mg
41362314|NCT01197846|DRUG|Placebo|Placebo
41362315|NCT02082743|BEHAVIORAL|Outdoor activity in recess time|Outdoor activity in recess time
41362316|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
41362317|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
41362318|NCT05850637|RADIATION|adjuvant ultra-hypofractionated radiotherapy|adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer
40841656|NCT03239015|DRUG|PD-1/L1 inhibitor plus anti-angiogenic agent|PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
41160857|NCT01061853|DRUG|TOPICAL SIROLIMUS (RAPAMUNE*)|APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE\*)1mg/ml bid during 3 months
41160858|NCT01061853|DRUG|TOPICAL BETAMETHASONE 0.05%|APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE\*)0.05% bid during 3 months
41160859|NCT01021202|PROCEDURE|Percutaneous dilation tracheostomy|Percutaneous dilation tracheostomy using Ciaglia blue rhino system (Cook medical, Limerick, IRELAND). Tracheostomy is conducted by two experienced physicians with (video-)bronchoscopic control and continuous monitoring of ECG, blood pressure, pulse and peripheral oxygen saturation.
41362319|NCT04673760|BEHAVIORAL|Specialized palliative home care|"Specialist palliative home care teams will initiate care as usual, including managing a systematic and collaborative process of advance care planning with patients, family caregivers, GPs and SPITEX nurses using the Betreuungsplan, information packages and regular case meetings. The GP was additionally provided with educational palliative care information by the study team."
41362320|NCT02911285|DRUG|N-acetylcysteine|1200mg bid (2400mg/day)
41362321|NCT02911285|DRUG|Placebo|Placebo pills bid
41362322|NCT02911285|BEHAVIORAL|Cognitive behavioral therapy|CBT for AUD/SUD, one hour/once a week
41362323|NCT04865016|DEVICE|Tecnis +2.75 D (ZKB00) and Tecnis Symfony (ZXR00)|This study included 30 eyes of 15 cataract patients undergoing cataract surgery with implantation of a low add (+2.75 Diopters \[D\]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group) and 30 eyes of 15 patients with implantation of an EDOF (Tecnis Symfony \[ZXR00\]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
41025680|NCT06573580|OTHER|The essential public health service（EPHS）for COPD|"Each group plans to recruit 3,000 participants. For the intervention group, the community-based management includes adding COPD management-related content to the primary public health service. This includes: Providing at least four follow-ups during the project at the 3rd, 6th, 9th, and 12th months. During each follow-up, patients must complete the COPD Patient Follow-up Questionnaire and receive oral health education and targeted clinical advice from the general practitioner (GP). In addition, the GPs must also distribute educational booklets and materials, record symptom assessment results and acute exacerbation situations, and provide targeted clinical advice and clinical decisions to the COPD patients according to the checklist of Chinese guideline for management of COPD in primary care. At the baseline and the last follow-up, patients need to undergo a routine physical examination, pulmonary function test, and bronchodilator test at their community health centers"
41025681|NCT01070810|DRUG|D5W|Dextrose 5%
41025682|NCT01070810|DRUG|Thiamine|Thiamine 200mg in 50ml D5W
41025683|NCT00647231|DRUG|HKT-500 Topical Patch|Treatment with Ketoprofen Topical Patch
41025684|NCT00647231|OTHER|Placebo Patch|Treatment with placebo patch
41025685|NCT05222568|BEHAVIORAL|Lateral positioning|After the DLT intubation, the patient is placed in lateral decubitus position
41025686|NCT05222568|DEVICE|Cuff pressure measurement|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning
41025687|NCT02308202|DRUG|doxazosin|
41025688|NCT02308202|DRUG|Perindopril|
41025689|NCT02308202|DRUG|Placebo|
41025690|NCT00840970|DEVICE|non-coated Intranasal Splint|placement of non-coated intranasal splint following FESS
41025691|NCT00840970|DEVICE|Sinexus Intranasal Splint|placement of Sinexus Intranasal Splint placed following FESS
41025692|NCT05341921|BEHAVIORAL|Alternate Nostril Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
41025693|NCT05341921|BEHAVIORAL|Bhramari Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
41025694|NCT05341921|BEHAVIORAL|Sheetali Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
41362324|NCT03375866|OTHER|Pretzels|Subjects consume 240 kcal of pretzels daily for 16 weeks.
41025695|NCT01910844|DRUG|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
41025696|NCT01910844|DRUG|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
41362325|NCT03375866|OTHER|Mixed nuts|Subjects consume 240 kcal of mixed nuts daily for 16 weeks.
41362326|NCT06399458|DIAGNOSTIC_TEST|For hypermobility; Beighton score and Brighton revised 1998 Criteria|Beighton score and Brighton revised 1998 Criteria
41362327|NCT02079077|DRUG|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
41025697|NCT02286882|DRUG|PF-06409577 or Placebo|PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
41025698|NCT06330441|PROCEDURE|endoscopic ultrasonography|endoscopic ultrasonography - frequency defined by arm
41025699|NCT06330441|PROCEDURE|magnetic resonance|magnetic resonance - frequency defined by arm
41362328|NCT02079077|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
41362329|NCT03031613|PROCEDURE|PEEP group|Application of 5cmH20 positive end expiratory pressure
41362330|NCT03031613|PROCEDURE|ZEEP group|No application of positive end expiratory pressure
41362331|NCT02457130|DRUG|Ticagrelor|
41362332|NCT02457130|DRUG|Clopidogrel|
41362333|NCT04099940|BEHAVIORAL|Virtual Reality Avatar Therapy (VRAT)|The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
41362334|NCT04099940|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
41362335|NCT02488265|OTHER|Balance Training|Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
41362336|NCT02488265|OTHER|Screening to prevent falls|Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
41362337|NCT03955731|DEVICE|Magmaris resorbable magnesium scaffold|Implantation of Magmaris resorbable magnesium scaffold
41362338|NCT03643744|DRUG|Celecoxib 200mg|14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
41362339|NCT03643744|DRUG|Placebo|14 placebo capsules taken 1 in the morning and 1 in the evening.
41362340|NCT01647477|BEHAVIORAL|interview|25 minutes of semi directive interview
41362341|NCT01647477|BEHAVIORAL|questionnaires|questionnaires to answer at baseline 45 minutes
41025700|NCT06330441|DIAGNOSTIC_TEST|laboratory examination|hematology, biochemistry, Na+, K+, Cl-, Ca2+, bilirubin, ALT, AST, GGT, ALP, lactate dehydrogenase, creatinine, urea, fasting glycemia, HbA1c, alpha-amylase, LPS, albumin, total protein, CA19-9, CEA
41362342|NCT01932528|DRUG|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606.
41362343|NCT02879968|OTHER|Non-interventional study|
41362344|NCT02399345|DRUG|ombitasvir/paritaprevir/ritonavir, dasabuvir|tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
41025701|NCT05996887|OTHER|standard care protcol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to standard care protocol.
41025702|NCT05996887|OTHER|enhanced recovery protocol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to following the recommendation of ERAS society guidelines.
41362345|NCT02399345|DRUG|sofosbuvir (SOF)|tablet
41362346|NCT02399345|DRUG|ribavirin (RBV)|tablet
41362347|NCT02715635|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
41362348|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice|140 ml containing \~8 mmol of inorganic nitrate
41362349|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
41025703|NCT03556761|DRUG|Oral furosemide|Furosemide (Lasix), 20 milligram, PO, PO, daily
41025704|NCT03556761|DRUG|Placebo Oral Tablet|Placebo, PO, daily
41362350|NCT05173532|OTHER|Balance Training|static and dynamic balance and gait stability exercises
41362351|NCT05173532|OTHER|Breathing and Stretching Exercises|static stretching while performing diaphragmatic breathing
41362352|NCT04621474|DIAGNOSTIC_TEST|Narrow band imaging (NBI)|Narrow-band imaging uses specific light wavelengths of 415 nm (blue) and 540 nm (green) due to a special filter which is electronically activated by a switch in the endoscope.
41362353|NCT02708524|DEVICE|Senofilcon C Contact Lens|
41362354|NCT02708524|DEVICE|Comfilcon A Contact Lens|
41362355|NCT02708524|DEVICE|Lotrafilcon B Contact Lens|
41362356|NCT02708524|DEVICE|Samfilcon A Contact Lens|
41362357|NCT01028859|DRUG|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 \~ mg/m2; Day 1, Day 8 every 3 weeks
41362358|NCT01812564|BIOLOGICAL|Platelet Poor Plasma (PPP)|
41362359|NCT01812564|BIOLOGICAL|Platelet Rich Plasma (PRP)|
41362360|NCT04844866|GENETIC|MB-CART2019.1|MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
41362361|NCT04844866|DRUG|R-GemOx or BR plus polatuzumab vedotin|Immunochemotherapy will be administered as per arm description.
41362362|NCT05396196|DEVICE|Kinesio® Tape|Manual Fascial Glide Application
41362363|NCT00628680|DEVICE|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
41362364|NCT00628680|DRUG|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
41362365|NCT00820365|DRUG|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
41362366|NCT02247167|PROCEDURE|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
41362367|NCT01582828|PROCEDURE|Epicardial (surgical) ablation|"* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure"
41362368|NCT01582828|PROCEDURE|Hybrid|"Epicardial (surgical) ablation~* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure~Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation"
41362369|NCT02493829|BIOLOGICAL|AML Cell Vaccine|
41362370|NCT06001021|DRUG|Psychopharmacological Intervention|Escitalopram 5-10 mg in antenatal period; Sertraline 12.5-25 mg in postnatal period) and/or Benzodiazepine (Alprazolam, 0.25-0.50 mg).
41362371|NCT06001021|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT intervention from a trained psychologist in CBT.
41362372|NCT06001021|OTHER|Combination of Psychopharmacological Intervention and CBCT|Medication will be prescribed by a consultant gynecologist and CBCT (conditions: with or without Zikr) will be provided by a trained psychologist.
41499498|NCT02493192|OTHER|birth ball|
41362373|NCT06001021|OTHER|Placebo and No Intervention|Control waitlist group will be provided with either a placebo by a consultant gynaecologist or no intervention by a trained psychologist
41362374|NCT06018402|OTHER|physical therapy|The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity).
41362375|NCT06018402|OTHER|physical therapy + espb|"the same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally."
41362376|NCT03417999|DRUG|Dexmedetomidine|Dose-escalation of atomized intranasal dexmedetomidine
41362377|NCT01289964|PROCEDURE|Dry Cupping or fire cupping|5 dry cupping treatments, application twice a week, non standardised procedure
41362378|NCT03115021|DEVICE|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
41362379|NCT03115021|DEVICE|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
41362380|NCT03115021|DEVICE|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
41362381|NCT03115021|DEVICE|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
41362382|NCT04035369|PROCEDURE|Tap and Inject (TAI)|"Patients randomized to the TAI group will have a 0.2 mL vitreous specimen collected and a 0.1 mL anterior chamber paracentesis performed to be sent for standard cultures, Gram stain, and sensitivities.~Intravitreal injection of the following antibiotics: Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL (amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy) and an intravitreal injection of dexamethasone 400 mcg/0.1 mL"
41362383|NCT04035369|PROCEDURE|Pars Plana Vitrectomy (PPV)|Patients randomized to the PPV group will undergo a three-port PPV. The patient should be added to the OR list as an A-case (maximum 6 hours wait) and no intravitreal injection should be performed prior to the surgery. A 0.1 mL aqueous humor simple immediately before the surgery. A 0.2 mL vitreous specimen will be obtained after the sclerotomies are placed. The PPV procedure should be limited to core vitrectomy, air fluid exchange and intravitreal injections (antibiotics and dexamethasone - Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL or amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy and an intravitreal injection of dexamethasone 400 mcg/0.1 mL). Other tamponades such as silicone oil should be avoided if possible. The PPV will then be completed by the surgeon and the vitreous specimen will be sent for standard cultures, Gram stain, and sensitivities.
41362384|NCT02400268|OTHER|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
40841657|NCT05176756|BEHAVIORAL|Gamification and Social Support|Participants will be entered into a points and levels-based game designed to help them meet their step count goals. At the start of each week, the participant will receive a set amount of points. Each day their step goal is not met, they lose points. If the participant meets a certain point value at the end of the week, they will either advance one level (of five total levels); if they do not, they will drop one level. Each participant will also select a family member or friend or the study coordinator to serve as a support partner. At the beginning of the intervention, the participant and support partner will identify at least 3 ways in which they can help the participant meet their step goals. This partner will receive a weekly email reminding them of these approaches and updating them on the participant's progress.
40841658|NCT05176756|BEHAVIORAL|Attention control|Participants will receive a daily text message with their step count from the day prior.
40841659|NCT02068417|DEVICE|shock waves|extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
40841660|NCT03006887|DRUG|lenvatinib|lenvatinib capsules
40841661|NCT03006887|DRUG|pembrolizumab|pembrolizumab intravenous infusion
40841662|NCT03809819|PROCEDURE|laparoscopic Vecchietti vaginoplasty|Patients who underwent laparoscopic Vecchietti vaginoplasty
41362385|NCT02400268|OTHER|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
41362386|NCT04096781|BEHAVIORAL|SDMT|The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.
41362387|NCT04096781|BEHAVIORAL|Usual Care|The participants will receive usual care.
41362388|NCT04920331|BIOLOGICAL|Erenumab|140mg single intravenous administration (60 minutes)
40841663|NCT03809819|DIAGNOSTIC_TEST|FSFI questionnaire|Completion of FSFI questionnaire
40841664|NCT03809819|DIAGNOSTIC_TEST|UDI-6 questionnaire|Completion of UDI-6 questionnaire
40841665|NCT03809819|DIAGNOSTIC_TEST|IIQ-7 questionnaire|Completion of IIQ-7 questionnaire
41362389|NCT03726840|OTHER|Fragrance|peppermint, rosemary, and zest/pulp will increase memory recall for navigation and improve reaction times for braking, compared to performance during unscented conditions
40841666|NCT02337166|DEVICE|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
40841667|NCT02337166|PROCEDURE|Periodontal flap surgery|
41025705|NCT02148094|DRUG|Truvada|The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
41025706|NCT02779218|PROCEDURE|Paired Associative Stimulation|Patient with Paired Associative Stimulation only
41025707|NCT02779218|PROCEDURE|Paired Associative Stimulation + Motor Imagery exercises|Patient with Paired Associative Stimulation + Motor Imagery exercises
41025708|NCT02779218|PROCEDURE|Placebo Paired Associative Stimulation + Motor Imagery exercises|Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
41362390|NCT02146352|DEVICE|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
41499499|NCT05321368|BEHAVIORAL|LINKED-HEARTS Program|The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.
41025709|NCT05234099|DIAGNOSTIC_TEST|18F-FDG Positron emission tomography - MRI|All the examinations will be performed in the supine position on the same integrated 3T PET-MRI scanner
41025710|NCT05234099|DIAGNOSTIC_TEST|Multiparametric ultrasound imaging|Acquisitions of respiratory muscles (diaphragm, intercostal muscles) will be performed using two 6 MHz central frequency linear transducer (SL 10-2) driven by two identical ultrafast ultrasound devices.
41025711|NCT05234099|DIAGNOSTIC_TEST|Surface electromyography|sEMG recordings will be performed in the left side on the sternocleidomastoid muscle, the intercostal parasternal muscle, and the external oblique muscle using pairs of 20-mm-diameter silver chloride surface electrodes.
41025712|NCT05234099|DIAGNOSTIC_TEST|Transdiaphragmatic preasure measurmement|Esophageal and gastric pressures will be measured using 8-cm balloon-catheters.
41362391|NCT05644613|OTHER|aerobic exercise on land|aerobic exercise on land in form of walking on the treadmill
41499500|NCT06003296|PROCEDURE|Calcaneocuboid arthrodesis|Calcaneocuboid arthrodesis in triple arthrodesis
41499501|NCT05056896|DRUG|Aspirin|Capsule taken orally
41499502|NCT05056896|OTHER|Placebo|Capsule taken orally
41499503|NCT00704847|DRUG|Oral Salmon Calcitonin|0.8mg SMC021, twice daily
41499504|NCT00704847|DRUG|Oral Salmon Calcitonin (Placebo)|0.8mg Placebo, twice daily
41499505|NCT02940132|DRUG|SC10914|SC10914 will be administered orally.
41499506|NCT02345837|DEVICE|endometrial sampling|injury to the endometrium
41499507|NCT02345837|DRUG|clomiphene citrate|ovulation induction by 100mg clomiphene citrate
41499508|NCT01473524|DRUG|Obeticholic Acid (OCA)|OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.
41499509|NCT01473524|DRUG|Placebo|Matching placebo tablets were administered orally once daily.
41499510|NCT06292403|OTHER|Strength Training|training time will be 30 minutes therapy, once a day, 3 days a week for 8 weeks. were allowed to rest for 3-5 min during each training.
41499511|NCT06292403|OTHER|Mirror therapy|Participants in the (trial group) mirror and strength training group observed the reflection of the exercising arm and leg in the mirror. Participants in the (control group) strength training only group will exercise without a mirror entirely.
41362392|NCT05644613|OTHER|aerobic exercise in water|aerobic exercises in water in form of walking on the treadmill
41362393|NCT05692427|DEVICE|Cryopen - Cryotherapy|Cryotherapy with N20
41499512|NCT06484842|OTHER|The combined psychological resilience and self-efficacy intervention|Based on the content of the literature analysis and the group's previous research, a joint intervention programme on psychological resilience and self-efficacy for patients undergoing surgery for oesophageal cancer has been developed. The programme consists of 6 sessions in total, including preoperative period and one month after discharge, covering the period when patients' postoperative symptoms occur most severely. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospital stay; considering the smooth implementation of the intervention after the patient will be discharged from the hospital, we will conduct the intervention in an individual, offline face-to-face format during the patient's outpatient review, and set up a WeChat group in case the patients are at home to conduct the intervention in the form of an online punch card.
41499513|NCT06484842|OTHER|The mindfulness intervention|The oesophageal cancer surgery patients in the single intervention group will receive 5 sessions of mindfulness intervention consistent with the mindfulness intervention component of the combined intervention programme. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospitalisation; we will conduct the intervention in an individual, offline face-to-face format during the patients' outpatient review, and set up a WeChat group in case the patients are at home in the form of an online punch card. Each session will include a pre-session reflection and post-session homework. The whole process will be supervised and reminded by interventionists, who will respond to patients' questions in a timely manner to ensure patients safety and the smooth implementation of the intervention. Adjustments and improvements will be made at any time according to the needs of patients undergoing oesophageal cancer surgery.
41499514|NCT04859543|DEVICE|FoundationOneHeme|Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.
41362394|NCT05964933|PROCEDURE|Complete Pulpotomy|"Complete caries removal and excision of the entire coronal pulp to the level of the root canal orifices will be performed. After haemostasis, the pulp chamber will be filled with Biodentine® and a final direct restoration placed in 1 or 2 visits.~If there is no bleeding from the exposed pulp, pulpectomy and root canal treatment will be performed instead, and the patient will be excluded from the study."
41362395|NCT05964933|PROCEDURE|Pulpectomy and Root Canal Treatment|After complete caries removal and pulp exposure, Pulpectomy will be performed to remove all pulp tissues. Conventional root canal treatment will be performed using rotary instrumentation followed by obturation with gutta percha and traditional sealers in 1 or 2 visits. A final restoration will be placed to ensure a good coronal seal, and this may include full coronal coverage restorations if clinically indicated.
41025713|NCT05234099|DIAGNOSTIC_TEST|Magnetic stimulation of the phrenic nerves|In order to quantify the contractile fatigue in diaphragm induced by the ventilatory task (described below), we will use bilateral anterior magnetic stimulation of the phrenic nerves using two Magstim 200 stimulator.
41025714|NCT05234099|DIAGNOSTIC_TEST|Ventilation against inspiratory loading|A POWERbreathe KH2 device (POWERbreathe International Ltd) will be connected on the inspiratory side of the two-way valve. Level of inspiratory loading will be randomized in order to produce different amounts of muscle work in each subject.
41025715|NCT02297152|DEVICE|FLIP HOLE|The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
41362396|NCT02668510|BIOLOGICAL|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
41362397|NCT02668510|DRUG|Normal saline|placebo injection of normal saline immediately following shockwave therapy
41362398|NCT00553319|DRUG|Placebo|Placebo group
41499515|NCT01229579|DRUG|Zinc Sulfate|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
41499516|NCT01229579|OTHER|Placebo|2.5 ml placebo syrup daily with containing no elemental zinc from day 14 to 18 weeks of age.
41499517|NCT06459128|DEVICE|Limbic Care|"Limbic Care is an AI-enabled smartphone application that delivers cognitive behavioral therapy (CBT) interventions and psychoeducation to users via an interactive, conversational interface using AI. Participants can choose from three courses (sleep, worry, and low mood) that sets the type of content they will see in the app. For each course, different interventions and psychoeducation material will appear in the to do list section of the app on a fixed schedule. The app also allows users to engage in open-ended conversation with the AI, which serves as an non-interventional, empathetic listener."
41499518|NCT06459128|DEVICE|Digital Workbook|The digital workbook in PDF format will be provided to participants via the Internet. Participants can choose from three workbooks that each focus on a different topic: sleep, worry, and low mood. Each workbook contains psychoeducation material and CBT intervention worksheets, consisting of text, images, and response boxes to write in (if printed out).
41499519|NCT03497169|DRUG|Lisdexamfetamine Dimesylate|Patients are tested for their normal prescription lisdexamphetamine medication
41499520|NCT06355999|BEHAVIORAL|Color Feedback|Feedback is given about the correctness of the response on the color dimension
41362399|NCT00553319|DRUG|Adderall-XR|Adderall-XR 60mg/day
41362400|NCT00553319|DRUG|Adderall-XR|Adderall-XR 80mg/day
41362401|NCT02365246|DEVICE|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
41362402|NCT00367146|DRUG|MMF|
41362403|NCT03529045|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System is a commercially available device that will be used by licensed medical practitioners trained in the use of VNS Therapy, per the practitioners' medical judgement.
41499521|NCT06355999|BEHAVIORAL|Shape Feedback|Feedback is given about the correctness of the response on the shape dimension
41499522|NCT00482586|OTHER|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
41499523|NCT00482586|OTHER|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
41499524|NCT00482586|PROCEDURE|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
41499525|NCT03772990|DRUG|Calcium Chloride|Calcium Chloride
41499526|NCT03772990|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride
41499527|NCT00002282|DRUG|Clotrimazole|
41499528|NCT00002282|DRUG|Fluconazole|
41362404|NCT06346639|OTHER|16-day hot and cold acclimation|Acclimation program will consist of 8 brief cold water immersions (CWI; 14°C 5 min) and 8 hot water immersions (HWI; 45°C 5 min). Heat and cold sessions will be performed on separate days (i.e., 1st day hot exposure, 2nd day cold exposure, 3rd day hot exposure, etc.).
40841668|NCT06523257|DIAGNOSTIC_TEST|Spirometry|"Spirometry is a simple test used to diagnose and monitor lung diseases by measuring how much air a person can breathe out in one forced breath.~After the baseline spirometry, and only if there is clear evidence of an airflow limitation/obstruction, i.e., if the FEV1/FVC (forced expiratory volume in the first second/forced vital capacity) ratio is less than 70% or less than the 5th percentile of the distribution of values measured in the reference population, a bronchodilator test will be performed using standardised post-bronchodilator spirometry (200 µg salbutamol), in order to identify persistent airflow limitation/obstruction."
40841669|NCT00445276|DRUG|Diacerein|
40841670|NCT03320590|DIAGNOSTIC_TEST|Time Lapse (material to observe embryonic development)|The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
40841671|NCT00463554|DEVICE|GYNECARE TVT-SECUR* System|A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency
40841672|NCT04397458|DRUG|Saline|0.9% saline on each side
41499529|NCT06475274|DRUG|RMC-035|Protein, a recombinant variant of A1M. Concentrate for solution for infusion.
40841673|NCT04397458|DRUG|Bupivacaine|0.25% bupivacaine (50mg) on each side
40841674|NCT04397458|DRUG|Dexamethasone|3mg preservative-free dexamethasone on each side
40841675|NCT01517386|PROCEDURE|thoracic surgery|unilateral thoracic surgery under paravertebral block and general anesthesia
40841676|NCT05950620|OTHER|Medical obesity management.|Dietician visits, education, anti-obesity medications, and/or referral for metabolic-bariatric surgery as indicated by American Academy of Pediatrics guidelines for obesity management.
40841677|NCT02297555|DEVICE|ENDOBARRIER®|This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
40841678|NCT03343600|DRUG|Imatinib|Imatinib 100 mg/tablet, 2 tablets daily
40841679|NCT03343600|DRUG|Placebo|Placebos 2 tablets daily
40841680|NCT02048033|DEVICE|Regular endoscopy + endogastric suturing|Patients will get the usual endoscopy used for diagnosis. In addition, they will receive an endoscopic surgery using the APOLLO Endosuregery technique. The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch
41362405|NCT02098291|DRUG|G17DT|
41362406|NCT06249074|OTHER|Gluten-free diet|Diet with gluten elimination followed by all participants for 8 weeks
40841681|NCT02048033|DIAGNOSTIC_TEST|Regular endoscopy|Patients will get the usual endoscopy used for diagnosis.
40841682|NCT01204762|DRUG|pegIFN|Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
40841683|NCT01204762|DRUG|pegIFNα-2a|Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
40841684|NCT01204762|DRUG|PegIFN lambda|Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
40841685|NCT01204762|DRUG|Entecavir|Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
40841686|NCT04651829|OTHER|oral food challenge 1|First oral food challenge after a short period of several weeks of avoidance of CMP to confirm diagnosis of CMPA
40841687|NCT04651829|OTHER|oral food challenge 2|Second oral food challenge to test tolerance after 4 months of age if confirmed CMPA
41025716|NCT01653431|DEVICE|Transcranial direct current stimulation|
41025717|NCT02706353|DRUG|APX005M|"Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.~Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase."
41025718|NCT02706353|DRUG|Pembrolizumab|Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
41025719|NCT00665119|DRUG|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
41025720|NCT00665119|DRUG|placebo|NaCl 0.9 %
41362407|NCT06249074|OTHER|Gluten capsules supplementation|2 g of gluten given in 3 capsules daily for 4 weeks (week 5 to week 8)
41025721|NCT06531759|DRUG|Fentanyl|Fentanyl soaked nasal packs.
41362408|NCT06249074|OTHER|Placebo capsules supplementation|Rice starch in gastrosoluble capsules given in 3 capsules daily for 4 weeks (week 5 to week 8).
41499530|NCT06475274|DRUG|Placebo|Identical to RMC-035 intervention devoid of the active substance.
41499531|NCT05652738|DEVICE|Passive cooling application|Passive cooling application for asphyxiated neonates and their effect on myocardial function and hemodynamics
41499532|NCT05652738|DEVICE|cooling using Blanket roll III|standard care using Blanket roll III in asphyxiated neonates and their effect on myocardial function and hemodynamics
41499533|NCT04750798|DEVICE|BWI Medical Device|Participants will be treated with commercially approved BWI medical devices following routine clinical practice. No specific intervention will be observed for this study.
41362409|NCT01966367|BIOLOGICAL|CD34 Stem Cell Selection Therapy|The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
41499534|NCT04750798|DEVICE|Varipulse Catheter|Participants treated with Varipulse Catheter in the main study will be part of the VARIPURE sub-study. No specific intervention will be observed for this study.
41499535|NCT06272981|DEVICE|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.
41499536|NCT01231399|DRUG|fluorouracil|Given IV
41499537|NCT01231399|DRUG|leucovorin calcium|Given IV
41499538|NCT01231399|DRUG|oxaliplatin|Given IV
41499539|NCT01231399|DRUG|everolimus|Given orally
41499540|NCT01231399|OTHER|laboratory biomarker analysis|Correlative studies
41499541|NCT01231399|OTHER|immunohistochemistry staining method|Correlative studies
41499542|NCT01231399|GENETIC|microarray analysis|Correlative studies
41499543|NCT04829357|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures the subjects would receive as part of SOC.
41499544|NCT04584385|DIAGNOSTIC_TEST|EEG|EEG monitoring
41499545|NCT00000378|DRUG|Sertraline|12 week trial dose up to 200mgs
41499546|NCT00000378|DRUG|Nortriptyline|12 week trial dose adjusted to therapeutic level
41499547|NCT03577548|OTHER|Auto- questionnaires|10 auto-questionnaires are submitted to the patient during his/her consultation (which is part of the standard care).
41499548|NCT04208958|BIOLOGICAL|VE800|VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.
41499549|NCT04208958|DRUG|Nivolumab|Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
40841688|NCT05152810|OTHER|Transcranial Magnetic Stimulation sessions|"* 10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~* 2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase"
40841689|NCT05152810|OTHER|Evaluations|"Before the first stimulation session, just after the 10th session, at 6 weeks, at 12 weeks and at 24 weeks.~The assessment included the collection of AEs/EIGs, the TAC, the VAS on desire to smoke, the TCQ, the QSU, BDI-II (except at S1), the CO tester, GoNoGo, the PQI and the ISI."
41025722|NCT04252235|DEVICE|Air purifier|The intervention is the placement of active HEPA air purifiers in the bedroom and living room of the true air purifier arm. These air purifiers have been shown to reduce levels of particles in the home.
41025723|NCT04252235|DEVICE|Sham air purifier|The intervention is the placement of sham HEPA air purifiers in the bedroom and living room. These purifiers look identical to real HEPA air purifiers, but do not filter the air.
41025724|NCT01597206|DEVICE|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
41362410|NCT02204722|DRUG|600mg/day of Imatinib|
41499550|NCT04208958|DRUG|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection.
41499551|NCT00787059|DRUG|Ad5.hAC6|Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10\^9 vp to 10\^12 vp in 5 dose groups
41499552|NCT00787059|DRUG|Sucrose (3%)|
41499553|NCT00451048|DRUG|sunitinib malate|Given orally
40841690|NCT03802877|BEHAVIORAL|Resource bank|See intervention arm descriptions
41362411|NCT02204722|DRUG|400mg/day of Imatinib|
41499554|NCT05855044|OTHER|Rosemary oil application|Application of Rosemary oil (10%) to both hands and both feet once a day for 24 weeks
41499555|NCT00818987|OTHER|Open reduction internal fixation; reduction and immobilization|
41499556|NCT06173843|OTHER|PFAS / heavy metal testing, exposures|PFAS / heavy metal concentrations, exposure survey
41499557|NCT06028880|BEHAVIORAL|Free2Be|Free2Be is a manualized 13-week face-to-face group intervention for SM individuals with one pre-session and plus 12 intervention sessions. The themes of each session are: Human nature \& Relation with suffering (S1), Emotional regulation \& Multiple selves (S2), Creative hopelessness \& Values (S3), Compassionate attention (S4), Compassionate acceptance (S5), Self-criticism; Compassion \& Flows of compassion (S6), Compassionate imagination; Compassionate self (S7), Early experiences; Stigma and shame; \& Compassionate cognitive desfusion (S8), Compassionate thinking (S9), Difficult emotions: Shame \& Anger (S10), Coming out \& Compassionate behaviour (assertiveness) (S11), Positive emotions \& Preparing for the future (S2).
41499558|NCT03462979|DEVICE|Immunochromatographic lateral flow test|The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
41499559|NCT01755767|DRUG|Tivantinib|Tivantinib tablets
41499560|NCT01755767|DRUG|Placebo|Matching placebo tablets
41499561|NCT05254600|BEHAVIORAL|RISE for Nurse Leaders Program|Psychoeducational sessions designed to impact resilience, insight, self-compassion, and empowerment
41499562|NCT06558149|PROCEDURE|Those whose opioids were adjusted according to hemodynamic parameters|Patient who will be adjusted according to hemodynamic parameter
41499563|NCT06558149|PROCEDURE|Those whose opioids were adjusted according to NOL monitoring|Patient who will be adjusted according to NOL monitoring
41499564|NCT00855179|DRUG|Red vine leaf extract (AS 195)|Antistax film-coated tablet 360 mg
41499565|NCT00855179|DRUG|Placebo|Placebo tablets identical to those containing Anstistax 360 mg
41499566|NCT04753697|DRUG|CC-93538|Subcutaneous
41499567|NCT04753697|OTHER|Placebo|Subcutaneous
41499568|NCT05388513|PROCEDURE|Surgical Resection|Surgically treated patients included
41499569|NCT00052299|DRUG|cytarabine|
41499570|NCT00052299|DRUG|etoposide|
41499571|NCT00052299|DRUG|gemtuzumab ozogamicin|
41362412|NCT06196372|OTHER|MenoMind intervention group|To implement the MenoMind program, the women in the initiative group were divided into groups of 4-5 according to their convenient days and hours, and it was done via the Zoom© program. MenoMind program was carried out via video on WhatsApp© program for women who could not or did not want to use the Zoom© program. The researcher provided support to the women for eight weeks, in different groups, 2-3 days a week and at different times, depending on their availability. Each session is approximately 50 minutes. lasted. In addition, make-up sessions were organized for women who could not attend the sessions for various reasons or had difficulty complying with the program (day/date).
41362413|NCT03798366|DRUG|GLPG1690|Film-coated tablets of GLPG1690 for oral use.
41362414|NCT03798366|DRUG|Placebo|Film-coated tablets of GLPG1690 matching placebo for oral use.
41362415|NCT04956133|BEHAVIORAL|Physical Activity|Participants will receive the IMPACT program, which includes a combination of aerobic, resistance, balance, and flexibility exercises conducted 1:1 and delivered online by a physical activity specialist via Zoom. The IMPACT program follows basic physical activity progression principles (i.e., principles of frequency, intensity, time, type, overload and progression). Tailoring will be used to promote fitness and wellness benefits, while ensuring safety. In addition, prominent behaviour change techniques will be provided by physical activity specialists within each 1:1 session. Discussions and worksheets will be provided, depending on participants needs.
41362416|NCT03351582|BEHAVIORAL|Grief and Communication Family Intervention|This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
41362417|NCT06247462|DRUG|Ibuprofen 600 mg|600 mg of ibuprofen was ingested 12- and 1-hours prior to exercise.
41362418|NCT06247462|DRUG|Placebo Corn Starch|600 mg of corn starch (placebo) was ingested 12- and 1-hours prior to exercise.
41362419|NCT03338608|PROCEDURE|Anterior Cervical Decompression and Fusion|Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.
41362420|NCT03338608|PROCEDURE|Vertical Platysma Incision|A vertical platysma Incision will be used for the anterior cervical decompression and fusion surgical procedure
40841691|NCT03802877|BEHAVIORAL|ePlatform|See intervention arm descriptions
40841692|NCT03802877|BEHAVIORAL|Health coach|See intervention arm descriptions
40841693|NCT00288262|DRUG|melatonin 0.5 mg|
40841694|NCT00938522|DRUG|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
41362421|NCT03338608|PROCEDURE|Transverse Platysma Incision|A transverse platysma incision will be used for the anterior cervical decompression and fusion surgical procedure
41362422|NCT05325502|DIETARY_SUPPLEMENT|caffeine|two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon
40841695|NCT00938522|DRUG|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
40841696|NCT03337009|BEHAVIORAL|Naloxone Navigator (NN)|Patients prescribed chronic opioid therapy will be identified and recruited to enroll in the study. Patients randomized to receive the web-based animated video (Naloxone Navigator) will be sent a link to the video after enrollment. The web-based, animated video provides education on what is an opioid overdose, how to prevent it, how to recognize an overdose, and how to respond with naloxone. This video also encourages patients to pick up naloxone from a pharmacy under a standing order.
40841697|NCT02162966|DRUG|High Dose Colistin|High Dose Colistin
40841698|NCT02162966|DRUG|Standard Dose Colistin|Standard Dose Colistin
40841699|NCT05548985|DRUG|Midodrine Oral Tablet|oral midodrine tablet (5 mg) 90 min before performing spinal block
41025725|NCT01597206|OTHER|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
41025726|NCT05323305|PROCEDURE|ultrasound guided regional block|Bupivacaine injection by the use of ultrasound in the pectointercostal fascial plane in one group and in the trasversus thoracic plane in the other group.
41362423|NCT05325502|DIETARY_SUPPLEMENT|mannitol|two doses per day: 200 mg in the morning \& 100 mg in the afternoon
41362424|NCT02409251|BEHAVIORAL|Education and feedback|
41362425|NCT03641599|DIAGNOSTIC_TEST|echocardiography|echocardiographic assessment of the RV and LV systolic function
41362426|NCT04862273|DIAGNOSTIC_TEST|Native T1 CMR|Observed method
41362427|NCT04862273|DIAGNOSTIC_TEST|Web-based ATTR probability estimator (Pfizer, New York)|Observed method
41362428|NCT04862273|DIAGNOSTIC_TEST|99mTc-DPD scintigraphy|Reference method
41362429|NCT04862273|DIAGNOSTIC_TEST|Laboratory screening for multiple myeloma / AL amyloidosis|Reference method
41362430|NCT04862273|PROCEDURE|Cardiac biopsy|If non-invasive tests for CA (99mTc-DPD scintigraphy, biochemistry) are inconclusive
41362431|NCT05877495|BEHAVIORAL|Nutritional Education Intervention|A 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. The content of the intervention will be loaded soon.
41499572|NCT00052299|DRUG|idarubicin|
41362432|NCT04058860|DEVICE|NIRS monitoring|Cerebral and somatic near-infrared spectroscopy (rScO2) measurements
41362433|NCT04058860|DEVICE|Cox monitoring|Cerebral autoregulation monitoring
41362434|NCT04058860|DEVICE|Sublingual microscopy|Sublingual mucosal microcirculation measurements during surgery using side dark field (SDF) imaging
41362435|NCT01103661|DEVICE|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
41499573|NCT00052299|DRUG|mitoxantrone hydrochloride|
40841700|NCT05548985|DRUG|Metoclopramide|oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
40841701|NCT00498888|PROCEDURE|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
41025727|NCT03767491|DEVICE|Smartphone-delivered CBT for OCD|12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
41025728|NCT06329635|DRUG|Intrathecal Nicardipine|First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml (4mg) of nicardipine is injected into the EVD or LD drain tube, followed by 2 ml normal saline solution, and then the EVD or LD tube is clamped for 2 hours, and then kept open as clinically necessary until the next dose (q12h) of medication.
41025729|NCT06329635|OTHER|No intervention|"A simulated intrathecal administration operation is performed by a dedicated physician who is unblinded to the group assignment, the EVD or LD tube is not opened, and no drug is given. The simulated administration process needs to be out of the patient's view (if awake patient) and out of the presence of study team personnel."
41025730|NCT05747677|DRUG|HH-120 Nasal Spray|HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
41025731|NCT05820750|DEVICE|photodynamic therapy|root canal treatment of primary molars using photodynamic therapy
41025732|NCT05820750|PROCEDURE|pulpectomy with metapex|root canal treatment using standard technique
41025733|NCT01544244|PROCEDURE|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
41025734|NCT01544244|PROCEDURE|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
41025735|NCT02261818|BEHAVIORAL|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
41025736|NCT05243108|DIETARY_SUPPLEMENT|dietary nucleotides|1.2 g/d NTs (5 '-AMP, 5' -CMP, 5 '-GMPNa2, 5' -UMPNa2) ;
41025737|NCT05243108|DIETARY_SUPPLEMENT|placebo|placebo
41025738|NCT05520957|PROCEDURE|Tracheostomy|We collected data from all tracheotomised patients including age, sex, existing comorbidities, duration indicators (length of endotracheal intubation, day of tracheotomy, length of stay in the intensive care unit (ICU), and total length of hospital stay), respirator weaning marked with YES / NO. From the laboratory parameters, we analyzed: lactate, urea, creatinine, potassium and D-dimer. They were collected at two time intervals, before tracheotomy and after tracheotomy.
41362436|NCT01393925|DRUG|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
41362437|NCT04686591|DRUG|AZD9977 capsule 50 mg|100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
41362438|NCT04686591|DRUG|[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)|One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
41362439|NCT04686591|DRUG|[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)|One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
41362440|NCT02956226|DRUG|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
41362441|NCT02956226|DRUG|Placebo|Olive oil and flavors solution.
41499574|NCT05444257|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
41499575|NCT05179876|DRUG|Macitentan|Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (\>=) 2 year to less than (\<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.
41499576|NCT05179876|DRUG|Selexipag|Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms.
40841702|NCT00498888|PROCEDURE|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
40841703|NCT00498888|PROCEDURE|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
41025739|NCT04296617|OTHER|Medical Chart Review|Review of medical chart
41025740|NCT03176160|OTHER|Palliative regimen consisting of LITT|Minimally invasive technique to necrotize intracranial lesions
41362442|NCT02956226|DRUG|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
41499577|NCT05179876|DRUG|Macitentan/Tadalafil FDC|Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.
41499578|NCT01326923|DRUG|Cetuximab|Single arm phase II study of chemotherapy
41499579|NCT02506283|DEVICE|Zamar Therapy CT clinic|Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
41499580|NCT02437903|DEVICE|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
40841704|NCT00498888|PROCEDURE|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
40841705|NCT06277648|PROCEDURE|PENG block|PENG block was performed by the primary investigator (B.C) following proper skin disinfection with the patient in the supine position. Under the guidance of a low-frequency curvilinear ultrasound probe, the iliopubic eminence and the psoas tendon were identified, and local anaesthetic as 30 mL 0.375% bupivacaine was injected between the periosteum and psoas tendon following negative aspiration.
40841706|NCT06277648|PROCEDURE|SIFIB|The high-frequency linear probe was placed medial to the anterosuperior iliac spine in a parasagittal orientation to visualize the bow tie appearance formed by the sartorius's internal oblique and iliacus muscles. The needle tip was placed under fascia iliaca through an in-plane approach, and local anaesthetic as 30 mL 0.375% bupivacaine was injected from the caudad to the cephalic direction.
40841707|NCT00084149|DRUG|Abacavir sulfate, Lamivudine, and Zidovudine|antiretroviral therapy
40841708|NCT00084149|DRUG|Lopinavir/Ritonavir|antiretroviral therapy
40841709|NCT03031119|DRUG|Placebo|Tablets administered once or twice daily, with food, in Part A.
40841710|NCT03031119|DRUG|PF-06835919|Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
41025741|NCT01858454|PROCEDURE|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
41025742|NCT01858454|PROCEDURE|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere \[Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.\].
41025743|NCT06214546|OTHER|Regular walking|Participants perform 6 overground walking trials (12.5 m) without support system. Participants perform all measurements (regular walking, Myosuit, ZeroG) on one single measurement day.
41499581|NCT04371094|DEVICE|a device to facilitate endotracheal intubation|a device to facilitate endotracheal intubation
40841711|NCT03031119|DRUG|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
40841712|NCT01657734|OTHER|MR imaging|MR imaging
40841713|NCT02552862|DRUG|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
40841714|NCT02552862|DRUG|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
41025744|NCT06214546|DEVICE|Myosuit|Participants perform 6 overground walking trials (12.5 m) while wearing the Myosuit. ZeroG and Myosuit intervention will be performed in random order.
41025745|NCT06214546|DEVICE|ZeroG|Participants perform 6 overground walking trials (12.5 m) while walking in the ZeroG. ZeroG and Myosuit intervention will be performed in random order.
40841715|NCT00372541|DRUG|ceftriaxone|
41025746|NCT03686774|DRUG|Memantine|"Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery."
41362443|NCT03475173|DEVICE|LSFG-NAVI|laser-speckle blood flow of ocular arteries and veins
40841716|NCT01093872|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Upon recruitment, all patients will undergo a 1 week treatment consisting of 5 rTMS sessions~Repetitive TMS consists of 1000 stimulations/ day at 1 Hz and 110% of the motor threshold, for five consecutive days over the left AC."
40841717|NCT00311909|DEVICE|Thalamic deep brain stimulation|
40841718|NCT01183065|DRUG|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
40841719|NCT03446417|DRUG|ZN-e4|Oral dose, tablet, daily dosing
40841720|NCT04285489|DEVICE|Hakim Shunt Programmable System|patient accept Hakim Shunt Programmable System due to HCP
40841721|NCT03189901|DRUG|Regular management+Levosimendan|Patients are treated with regular management recommended in guidelines and levosimendan.
40841722|NCT00771524|DRUG|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
41025747|NCT03686774|OTHER|no memantine|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment"
41362444|NCT00580827|DRUG|Placebo|Matched placebo.
41362445|NCT00580827|DRUG|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
41362446|NCT00580827|DRUG|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
41499582|NCT06380881|DRUG|SHR-2017|SHR-2017
41499583|NCT02154295|DEVICE|Infraredx Test Catheter|
41499584|NCT04868968|DRUG|DFV890|100 mg of DFV890 film coated tablets twice daily (b.i.d.). for 3 days starting in the morning of Day 1 and 100 mg of DFV890 in the morning on the fourth day.
40841723|NCT05018026|BEHAVIORAL|Nutri-Grade labels|All beverage products in the arm are displayed with the Nutri-Grade label. This label was proposed by the Ministry of Health in Singapore to be implemented at the end of 2021. It will apply to all pre-packaged non-alcoholic beverages sold in Singapore. It will have four color-coded grades wherein Grade A, corresponding to the lowest sugar and saturated fat thresholds, will be in green and Grade D, corresponding to the highest sugar and saturated fat thresholds, will be in red.
40841724|NCT00783458|DRUG|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
40841725|NCT00783458|DRUG|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
40841726|NCT02175914|DRUG|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
40841727|NCT03255746|BEHAVIORAL|Sleep Enhancement|This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.
40841728|NCT03255746|BEHAVIORAL|Health Education|This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
40841729|NCT04408911|DRUG|Midazolam vs. Lormetazepam|In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
40841730|NCT03514901|OTHER|Experimental combination beyond Focal Progression|"Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed.~Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning.~Local treatment (i.e. surgery, radiotherapy)."
40841731|NCT03514901|DRUG|Pembrolizumab or Nivolumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.
40841732|NCT00660985|DRUG|Adapalene|Gel, 0.3%, 2g, once daily for 30 days
41025748|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
41025749|NCT00384085|DRUG|Insulin Glargine|Subcutaneous injection once-a-day
41025750|NCT00384085|DRUG|Premixed Insulin|Subcutaneous injection twice-a-day.
41025751|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
41362447|NCT00580827|DRUG|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
41362448|NCT04654819|DEVICE|Dental anesthesia simulator usage|Training on dental anesthesia simulator
41362449|NCT00348686|DRUG|Candesartan|16 mg once daily in oral tablet form
41362450|NCT00348686|DRUG|Candesartan|32 mg once daily in oral tablet form
41362451|NCT00348686|DRUG|Felodipine|5 mg once daily in oral tablet form
41362452|NCT00348686|DRUG|Felodipine|10 mg once daily in oral tablet form
40841733|NCT00660985|DRUG|Adapalene|Gel, 0.1%, 2g, once daily for 30 days
40841734|NCT06340490|BIOLOGICAL|RJMty19 (CD19-CAR-DNT cells)|Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
41362453|NCT00690209|PROCEDURE|Autologous bone marrow derived stem cells myocardial transplantation|
41362454|NCT03480360|DRUG|Cyclophosphamide|14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
41362455|NCT03480360|DRUG|Fludarabine|30 mg/m2 daily for 5 days
41362456|NCT03480360|RADIATION|Total Body Irradiation|200 centigray (cGy) for one day (day -1)
41362457|NCT03480360|DRUG|Tacrolimus|1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.
41362458|NCT03480360|DRUG|cellcept|dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.
41362459|NCT03480360|DRUG|g-csf|5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \> 1000/mcL for 3 days.
41362460|NCT03480360|PROCEDURE|Peripheral Blood Transplant|cell dose goal: \< 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight
41362461|NCT02533011|OTHER|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
41362462|NCT00431132|DRUG|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
40841735|NCT04309058|DRUG|Vitamin D drops|Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
40841736|NCT02713867|BIOLOGICAL|Nivolumab|
40841737|NCT01357460|DEVICE|Implantation of intrabronchial valves (IBV) (Spiration IBV)|"In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of new air during inspiration."
40841738|NCT02424292|OTHER|Physical activity|Physical activity in a personalised program.
40841739|NCT01720238|DRUG|Entecavir|0.5mg qd
41025754|NCT04170127|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser
41025755|NCT03572491|BIOLOGICAL|influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
41025756|NCT01286818|BIOLOGICAL|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
40841740|NCT01720238|DRUG|Lamivudine plus Adefovir Dipivoxil|Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
40841741|NCT05633966|DRUG|Kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)
40841742|NCT01095120|DRUG|Tesetaxel|"For subjects in Cohort A, a flat dose of 40 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the Cycle 1 flat dose may be increased by 5 mg in Cycle 2, and the Cycle 2 flat dose may again be increased by 5 mg in Cycle 3.~For subjects in Cohort B, a flat dose of 50 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the dose may be increased by 10 mg in Cycle 2.~For subjects in Cohort C, a dose of 27 mg/m2 will be administered in Cycle 1. In subsequent cycles, depending on tolerability, the dose will be increased to 35 mg/m2 in Cycle 2."
40841743|NCT04922905|OTHER|NEURO +|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed."
40841744|NCT04922905|OTHER|NEURO -|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)"
41025757|NCT01286818|DRUG|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
41025758|NCT01286818|DRUG|levofolinate|IV infusion, 200 mg/m² every 2 weeks
41025759|NCT01286818|DRUG|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
40841745|NCT05340166|PROCEDURE|Genicular nerve radiofrequency neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
40841746|NCT05340166|PROCEDURE|Genicular nerve chemical neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
40841747|NCT05104671|OTHER|scapular stabilization exercises.|"General Instructions: For all exercises, perform the retraction of the scapula, without performing the elevation of the shoulders, taking the lower angle of the scapula back and down.~The exercise intensity was described as repetitions, sets, and holding time. Commonly, 10-20 repetitions and three to five sets held for 3-10 seconds were performed.and the exercises will be:~1. towel slide~2. Scapular Clock:~3. Scapular Proprioceptive Neuromuscular facilitation:~4. Inferior Glide.~5. Scapular Orientation Exercise (SOE):~6. Protraction and retraction in front of a mirror:"
40841748|NCT05104671|OTHER|Thoracic manipulation.|• Thoracic Thrust Manipulation: The participants were in high sitting and in prone lying position. The therapist was standing next to the patient in a diagonal stance and also behind the patient during high sitting. Thoracic thrust manipulation demonstrated to manipulate specific thoracic segment mainly mid thoracic.
41025760|NCT04096092|OTHER|No intervention|No intervention
41025761|NCT04864015|DEVICE|Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable|Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
41025762|NCT03047616|OTHER|Blood and Urine Collection|
41025763|NCT05242679|OTHER|Myofascial release technique along with conventional physiotherapy exercises|Myofascial release technique was performed using a tennis ball along with conventional physiotherapy exercises.
41025764|NCT05242679|OTHER|Conventional physiotherapy exercises|Conventional physiotherapy exercises were performed including the range of motion/flexibility exercises, strength training, postural control, functional exercises, and gait training.
41025765|NCT04287062|DRUG|Suvorexant|Dual orexin receptor antagonist
41025766|NCT04287062|DRUG|Placebos|Weight and color matched placebo
41025767|NCT04091841|DRUG|protein supplement|Three sachet of protein supplement to be mixed in with water used daily.
41025768|NCT04091841|OTHER|Carbo Mass|Three sachet of Carbo Mass supplement to be mixed in with water used daily.
41025769|NCT01348529|BEHAVIORAL|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
40841749|NCT05104671|OTHER|Myofascial release.|The subject will be treated with IASTM.applied to the pectoral muscles and medial brachium with the subject in supine and the glenohumeral joint(GH). placed in 120 º abduction to place adequate tension on the selected tissues in the style of pectoral tightness test .The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers with the instrument held at a 45 º angle to the skin.The same IASTM protocol of 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers was applied to the posterior cuff musculature of the GH joint with the subject in prone and arms in 90 º abduction and internal rotation draped over the side of the plinth . While in the same position, the technique was applied to the periscapular musculature including the, trapezoids, rhomboids, teres minor, teres major, and latissimus dorsi.
41362463|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
41499585|NCT06633822|DIAGNOSTIC_TEST|Digital planning|The digital methodology will consist of obtaining a digital scan and a computed tomography (CBCT) that will be aligned using a digital program for the elaboration of a digital wax-up and fabrication of a printed surgical template.
41025770|NCT01418300|DRUG|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
40841750|NCT04607122|DRUG|Landiolol|Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.
41025771|NCT04998240|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration:~Intramuscular~Storage Conditions: 2°C to 8°C"
41266763|NCT02148367|DRUG|Erythropoietin|"This is a double blind randomized placebo-cotrolled study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.~Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock."
41499586|NCT06633822|DIAGNOSTIC_TEST|Analogic planning|The analog wax-up will be elaborated based on a silicone impression and periapical radiographs with parallel technique, which will allow us to elaborate an essix-type surgical splint.
41499587|NCT02722915|PROCEDURE|fMRI|collection of functional brain data for 1 hour per day
41499588|NCT02722915|BEHAVIORAL|Neurofeedback|Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 \& 4; controls without AVH: Days 2 \& 3)
40841751|NCT04607122|DRUG|Saline|Continuous infusion of saline solution at the same rate as landiolol infusion.
41362464|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
41362465|NCT01475214|OTHER|Inactive placebo capsule|microcrystalline cellulose
41362466|NCT04918524|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
41362467|NCT04918524|DRUG|Hydroxychloroquine|100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
41362468|NCT04918524|DRUG|Aspirin|100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
41025772|NCT04998240|BIOLOGICAL|Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),|"Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein), manufactured by Johnson and Johnson in the United States of America.~Dose formulation: One dose (0.5 ml) contains contains 5 x 10 10 virus particles~Mode of administration: Intramuscular~Storage Conditions: 2°C to 8°C"
41025773|NCT04998240|BIOLOGICAL|Placebo - Normal saline (0.9% sodium chloride solution)|"Placebo - Normal saline (0.9% sodium chloride solution)~Dose formulation: Not Applicable~Mode of administration: Intramuscular~Storage conditions: 15°C to 30°C"
41025774|NCT06567509|OTHER|Core stability exercises and Short foot exercises|Core stabilty exercises are the exercises where subjects will be trained to perform exercises like: Curl ups, bridging, side bridges, Planks, and Quadripedal stance exercises in a phased manner, each phase lasting 2 weeks. Complexities and duration of exercises will be increased in each phase. Short foot exercises for control group will include traditional treatment of stretching and strengthening of foot musculature.
41025775|NCT06567509|OTHER|Conventional foot exercises and short foot exercises|Ankle dorsiflexion, Plantar flexion, Inversion and Eversion range of motion exercises
41025776|NCT00887172|DRUG|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
41025777|NCT00887172|DRUG|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
41025778|NCT00887172|DRUG|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
41025779|NCT02014961|PROCEDURE|Dermal biopsy|Skin biopsy
41025780|NCT02014961|BEHAVIORAL|Gastro-intestinal questionnaire|Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
41025781|NCT02014961|GENETIC|Whole-exome sequencing|Whole-exome sequencing (WES)
41025782|NCT04280198|BEHAVIORAL|Triple P Parenting Videos|Four video clips from the online Triple P Parenting program will be used to promote specific positive parenting practices.
41362469|NCT04918524|DRUG|low molecular weight heparin Enoxaparin|40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
40841752|NCT00450645|DRUG|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
40841753|NCT02472236|DRUG|PEX168|200µg,injected subcutaneously,once a week.
40841754|NCT02472236|DRUG|Digoxin|0.5mg,oral,two times.
40841755|NCT05518526|DRUG|Liposomal Annamycin (L-Annamycin)|Study drug consists of L-Annamycin as a lyophilised powder in 50-mL single-use vials containing 45 mg of L-Annamycin must be reconstituted with 45 mL of 0.9% sodium chloride injection between 34 to 42℃, USP, and then diluted 1:1 with 0.9% sodium chloride injection between 34 to 42℃ in non-polyvinyl chloride IV bags before intravenous infusion. The dose of L-Annamycin will be intravenously applied during 2 hours infusion on D1, D8, and D15 of each 28-day cycle (up to Cycle 6th).
40841756|NCT02678299|DRUG|PREBEN|
40841757|NCT05611814|OTHER|Osteopathic Manipulative Treatment|Targeted anatomical structures are Scalene Muscles (Anterior/Middle/Posterior), Sternocleidomastoid Muscles (SCM), Suboccipital region, Cervical Paraspinal Muscles, Levator Scapulae Muscles, Upper Thoracic Paraspinal Muscles, Upper Trapezius Muscles, Atlanto-occipital (OA), Atlanto-axial (AA), C2-C7 vertebrae, T1-T4 vertebrae, Rib 1 bilaterally. Techniques include Suboccipital Myofascial Release, Soft tissue inhibition, kneading stretching, Facilitated Positional Release, and muscle energy technique.
40841758|NCT05611814|OTHER|Sham treatment|"Targeted anatomical structures are Thoracic Paraspinal Muscles, Lumbar Paraspinal Muscles, Lower Trapezius Muscles, Sacrum, Supraspinatus, T5-T12, and Rib 2-12. Techniques include Soft tissue inhibition, Stretching, Kneading, counterstrain, Facilitated Positional Release, and muscle energy technique.~L1-L5"
40841759|NCT00431119|DRUG|Azathioprine or Mycophenolate mofetil|
40841760|NCT01032824|BEHAVIORAL|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
40841761|NCT01032824|OTHER|Group Arm|10-session didactic telephone group
40841762|NCT01032824|OTHER|Book Arm|Book only.
40841763|NCT05001139|DEVICE|Relizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
40841764|NCT02093338|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|
40841765|NCT02093338|OTHER|Placebo Comparator: maltodextrin|Placebo
40841766|NCT00336635|BIOLOGICAL|cell-culture derived smallpox vaccine|
40841767|NCT05701891|COMBINATION_PRODUCT|Physiotherapy with integrated Virtual Reality|A 12-week personalised, VR-integrated physiotherapy intervention.
41025783|NCT04280198|BEHAVIORAL|Activity Boxes|There will be about 4 planned activities per week within activity boxes provided to families. The activities will be a context in which the positive parenting behaviors can be practiced. Each activity will take about 15 minutes. Families can pick each week whether they'd like their parenting practice to be embedded in reading activities, nature walks/active games, or arts and crafts. Instructions will be included with each activity, including prompts to allow the parent to apply learnings from that week's parenting video and to allow interactions to be child-led.
41025784|NCT06071039|COMBINATION_PRODUCT|3D spacer Fabric Based Mattress|For the patients in the intervention group, the 3D spacer fabric-based mattress was used instead of the operating room theater mattress. The pressure level of the patients was monitored throughout the surgery.
41025785|NCT05802745|OTHER|Reintubation|Patients requiring re-intubation for acute respiratory failure.
40841768|NCT05701891|OTHER|Physiotherapy (usual care)|A 12-week usual physiotherapy care intervention.
41025786|NCT00260923|DRUG|aliskiren|
41025787|NCT03237689|DRUG|Hydrocortisone|Low dose hydrocortisone (10mg)
40841769|NCT03610373|BEHAVIORAL|Modular Approach to Therapy for Children (MATCH)|MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
40841770|NCT04093986|OTHER|Chart Review|Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
40841771|NCT04093986|OTHER|Survey|Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
40841772|NCT02971553|DEVICE|Upright Resuscitator with PEEP|
40841773|NCT02971553|DEVICE|Upright Resuscitator|
40841774|NCT03222947|GENETIC|Deoxyribonucleic acid analysis|This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
40841775|NCT00164411|BIOLOGICAL|Tetanus-diphtheria toxoids (Td)|
40841776|NCT00164411|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
40841777|NCT00164411|BIOLOGICAL|23-valent polysaccharide vaccine|
40841778|NCT04237246|DRUG|Tacrolimus|"24 hour long acting advegraf"
40841779|NCT04159792|OTHER|no intervention|No intervention
40841780|NCT00586976|DRUG|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
40841781|NCT00586976|DRUG|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
40841782|NCT00156390|DEVICE|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
40841783|NCT00156390|OTHER|LV lead placement as per standard of care (without echo guidance)|
40841784|NCT04029298|BEHAVIORAL|Lifestyle Interventions|Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence
40841785|NCT00924443|DRUG|clofarabine|
40841786|NCT04429399|OTHER|decrease the positive end expiratory pressure (PEEP)|decrease the PEEP going from high (according to ExPress Trial) to low level
41025788|NCT03237689|DRUG|Placebo Oral Tablet|capsules of starch 1500 powder
41499589|NCT02722915|OTHER|PANAS|to assess the mood before and after the fMRI and after 1 week during a telephone interview
40841787|NCT04429399|OTHER|mechanical features assessment|evaluation of the mechanical features of respiratory system
40841788|NCT04429399|OTHER|shunt assessment|evaluation of the pulmonary shunt during two different ventilation setting
40841789|NCT06280885|BEHAVIORAL|Exercise|Participants will be randomised to either the FIERCE exercise programme involving supervised exercise prescription
40841790|NCT06280885|BEHAVIORAL|Health Behaviour Change (Pedometer)|Participants in both arms will be provided with a pedometer as a health behaviour change intervention
40841791|NCT03888118|DEVICE|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
40841792|NCT04566406|PROCEDURE|Laparoscopic adrenalectomy|Preoperative staging in all cases consisted of computed tomography or/and magnetic resonance imaging. Prior to surgery, a routine panel of laboratory tests was carried out. The catecholamines metabolites (metanephrine, normetanephrine, and methoxytyramine) were measured from 24-hour urine collection. All patients were preoperatively treated with phenoxybenzamine or alternative doxazosin.Additionally, beta-blockers in case of coexisting tachycardia were given. In the morning of the operation, preinduction blood pressure was measured. Pneumoperitoneum was achieved by insufflating CO2 gas to an intraperitoneal pressure of 12 mmHg. The operative method in our department was laparoscopic transperitoneal lateral total adrenalectomy. Intraoperatively SBP and diastolic blood pressure (DBP) were measured and recorded every 10 minutes. To treat hypertensive and hypotensive episodes, intravenous doses of urapidil, ephedrine, nitrates, MgSO4, norepinephrine, or ß-blockers were administered.
40841793|NCT05792527|DRUG|L-carnitine|One 500 mg tablet twice daily after meals
40841794|NCT00082381|DRUG|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
40841795|NCT00082381|DRUG|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
40841796|NCT01506011|DRUG|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
40841797|NCT03034902|DEVICE|Combined EEG and fNIRS|The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany
41025789|NCT01614405|DRUG|Truvada and Kaletra|one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
41025790|NCT04720417|DRUG|Defactinib Hydrochloride|Given PO
41025791|NCT04720417|DRUG|Raf/MEK Inhibitor VS-6766|Given PO
41025792|NCT04720417|PROCEDURE|Biopsy|Undergo tumor biopsy
41025793|NCT01115439|DRUG|artesunate plus sulfadoxine-pyrimethamine (AS+SP)|artesunate plus sulfadoxine-pyrimethamine (AS+SP)
41025794|NCT04502160|PROCEDURE|Vascular Access Creation|arteriovenous fistula creation
40841798|NCT01839136|PROCEDURE|Intrauterine transfer of gametes|
41025795|NCT02746692|OTHER|Fit15|"Group-based high-intensity circuit training based on functional movement patterns (e.g. squats, push-ups, burpees, jumps, ropeskipping).~Total duration 15 minutes circle training: 20s workout, 10 rest"
41025796|NCT02746692|OTHER|Endurance|Moderate intensity ergometer training. Total duration 50 minutes
41499590|NCT02722915|OTHER|AVHRS|to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
41025797|NCT03505476|DEVICE|Entac Medical device application|Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
41025798|NCT03505476|OTHER|Patient Daily Assessment|The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
41499591|NCT02722915|OTHER|SF36|questionnaire about life quality after 1 week during a telephone interview
41499592|NCT02887456|DRUG|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
41499593|NCT02887456|DRUG|Endodontic treatment using MTA paste|Endodontic treatment using MTA paste
41025799|NCT03505476|OTHER|Patient Discharge Assessment|The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
41025800|NCT01785524|DRUG|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
41025801|NCT01785524|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
41025802|NCT05395624|DRUG|18F-OP-801|18F Hydroxyl Dendrimer
41025803|NCT05319314|DRUG|GCC19CART|Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)
41499594|NCT04539912|DEVICE|angulated screw retained crown|ASC abutment was used in AG;
41499595|NCT04539912|DEVICE|cemented crown|prefabricated Ti abutment was used in CG
41499596|NCT01596738|DRUG|Tranexamic Acid|"1. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~2. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
41499597|NCT01596738|DRUG|Saline|"1. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~2. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
41499598|NCT05440201|OTHER|Amount of anticoagulant Clexane|Change (increase/decrease) the amount of Clexane administered at the dialysis start.
41499599|NCT00592618|DRUG|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
41499600|NCT04308707|OTHER|Breaking bad news skills|Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.
41499601|NCT05470205|DRUG|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
41499602|NCT05470205|DRUG|SHAPE measurement (Definity ultrasoud contrast agent)|Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
41499603|NCT06632821|OTHER|No intervention will be used.|University students' health literacy, physical activity, back pain and posture habits will be evaluated.
41499604|NCT01315327|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
41499605|NCT01315327|DRUG|Olive oil|Placebo
40841799|NCT01839136|PROCEDURE|Intrauterine transfer of embryos|
40841800|NCT01789216|DRUG|NSAID|
40841801|NCT01789216|DRUG|Gabapentinoids|
40841802|NCT01789216|DRUG|placebo|
40841803|NCT04005079|DRUG|Pilocarpine|2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
40841804|NCT04005079|DRUG|Ofloxacin|Standard of care
40841805|NCT04005079|DRUG|Prednisolone|Standard of Care
40841806|NCT03649724|DRUG|Placebo|Placebo (0.25 ml normal saline) will be administered subcutaneously once every twelve weeks for 48 weeks.
41025804|NCT01539291|DRUG|Idelalisib|Idelalisib tablet(s) administered orally twice daily
41025805|NCT00517920|DRUG|ABT-869|0.25 mg/kg QD
41025806|NCT00009737|DRUG|5-Fluorouracil|425mg/m2 iv daily from day 1 to day 5 every 28 days.
41025807|NCT00009737|DRUG|Leucovorin|20mg/m2 iv daily from day 1 to day 5 every 28 days.
41025808|NCT00009737|DRUG|Capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 every 21 days.
41025809|NCT05829239|BIOLOGICAL|ADI-PEG20|Intramuscular injection weekly for 8 weeks
41025810|NCT05829239|OTHER|Placebo|Intramuscular injection weekly for 8 weeks
41499606|NCT02762461|PROCEDURE|IVF or ICSI|
41499607|NCT06125808|DRUG|HRO350|Active substance phospholipid esters from herring roe oil (PEHeRo)
41499608|NCT06125808|DRUG|Placebo|Placebo; as a sunflower oil in capsules similar to the interventional drug product HRO350 in terms of appearance, smell and taste.
41266764|NCT04448366|BEHAVIORAL|Cognitive behavioral therapy|Patients in the CBT group will receive usual care. In addition, they will undergo one pre-surgery and six post-surgery face-to-face sessions of CBT. In the pre-surgery session, management of expectations towards surgery will be addressed. In the six post-surgery sessions, attention will be paid to psycho-education concerning the biological link between endometriosis-related pain and stress, relaxation training, cognitive stress management, and management of anxiety, catastrophizing and hypervigilance. The CBT sessions will be coordinated by a registered psychotherapist who is experienced in CBT and has knowledge about endometriosis. All CBT will be individual sessions.
41499609|NCT03456453|BEHAVIORAL|NIDA Standard for HIV Prevention|The NIDA Standard is a manualized, HIV prevention education intervention focused on reducing risky sexual and drug use practices. It will be adapted for Facebook in this pilot trial.
41499610|NCT03745313|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|Repair of the tricuspid valve through a transcatheter approach
41499611|NCT05368311|OTHER|Dietary recommendations including protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations and 2 protein enriched bars per day to be eaten 45 minutes before lunch and dinner.
41499612|NCT05368311|OTHER|Dietary recommendations without protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations.
41499613|NCT00902317|PROCEDURE|Cryoplasty (PolarCath peripheral balloon catheter)|Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.
40841807|NCT03649724|DRUG|Eligard 22.5Mg Suspension for Injection|Eligard 22.5Mg Suspension for Injection will be administered subcutaneously, in accord with manufacturer's direction, once every twelve weeks for 48 weeks.
40841808|NCT02044861|DRUG|PFK-158|IV dose escalation
40841809|NCT01175395|DRUG|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
40841810|NCT02816619|BEHAVIORAL|Personalized Physical Activity coaching program|
41499614|NCT00902317|PROCEDURE|Laser Angioplasty (Spectranetics)|The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.
41499615|NCT00902317|PROCEDURE|SilverHawk Atherectomy|Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.
41499616|NCT00902317|DEVICE|Viabahn Endograft|The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.
41499617|NCT00902317|PROCEDURE|"Angioplasty/Stent (Guidant Absolute stent)"|A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
41499618|NCT01439009|DRUG|Tolvaptan|Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
41499619|NCT01439009|DRUG|Placebo of tolvaptan|Once-daily oral administration of one placebo tablet in the morning
41499620|NCT02620852|OTHER|Complete a health questionnaire|Complete a health history questionnaire.
40841811|NCT02816619|BEHAVIORAL|Free practice of physical activity|
41025811|NCT05761691|PROCEDURE|Dental treatment|Children treated for ECC under general (DGA) and local anesthesia (LA).
41025812|NCT02520934|DRUG|Miglustat|combine miglustat and ERT to see if neurologic manifestations can be improved
41025813|NCT02520934|DRUG|ERT|enzyme replacement therapy
41025814|NCT05409443|PROCEDURE|Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)|"* Electrodes are positioned along the lateral sacral crest lateral to the inflection points of the S1, S2 and S3 lateral foraminal walls along first to third transverse sacral tubercles maintaining a craniocaudal line with an interelectrode distance of no more than 15mm.~* The appropriate locations are confirmed in both AP and lateral views and the tines are deployed. Following injection of lidocaine, lesions are performed at 85 degrees Celsius for 180 seconds at each site for bipolar sites and 80 degrees Celsius for 90 seconds for the monopolar site. Following ablation, the tines are retracted for all electrodes prior to removal."
41025815|NCT05409443|PROCEDURE|Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)|"* To target the L4 medial branch and L5 dorsal ramus, an electrode will be placed in parallel between the junction of the L5 transverse process and superior articular process and the sacral ala and S1 superior articular process.~* A periforaminal electrode position will be used to target the lateral branches from S1 to S3. An 22-G cannula with a 5-mm exposed tip will be directed to a location approximately 3-5mm lateral to the PSFA of S1, S2, and S3. The analog clock positions for the probes at S1 and S2 levels will be 1:00, 3:00, and 5:30 on the right, and 6:30, 9:00, and 11:00 on the left. For the S3 level the positions at 1:30 and 4:30 on the right, and 7:30 and 10:30 on the left will be used (6,18).~* The appropriate locations are confirmed in both AP and lateral views. Following injection of lidocaine, monopolar RFA is performed for 90 seconds at 80 degrees Celsius at each location."
41025816|NCT04635046|PROCEDURE|Transfer or extirpation of the peroneus longs tendon|Tendon transfer or extirpation of peroneus longus or brevis tendon, ligamental reconstruction +/- calcaneal osteotomy
41025817|NCT00249145|DRUG|risperidone|
41025818|NCT04636892|OTHER|MindMics earbud|Novel noninvasive wearable infrasound sensor
41025819|NCT02671669|BEHAVIORAL|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
41025820|NCT02671669|BEHAVIORAL|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~* Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~* Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
41025821|NCT05109910|PROCEDURE|Pelvic lymph node dissection|Bilateral extended pelvic lymph node dissection
41025822|NCT05942508|DRUG|TQB2450 Injection + Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody
41025823|NCT03578900|DRUG|Xeros|
41025824|NCT03578900|DRUG|Citric Acid based Mouthwash|
41025825|NCT02639884|DEVICE|SedLine EEG|
41025826|NCT02639884|DEVICE|RRa monitoring|
41025827|NCT02005341|DEVICE|nanOSS|
41025828|NCT02005341|DEVICE|Autograft|
41025829|NCT04547959|DEVICE|cervical interbody cage C-CURVE|ACDF: Anterior Cervical Discectomy and Fusion with a C-CURVE cage
41025830|NCT02921412|DEVICE|fanfilcon A|contact lens
41025831|NCT04962971|DIETARY_SUPPLEMENT|X|exocyan
41025832|NCT04962971|DIETARY_SUPPLEMENT|Y|exocyan
41025833|NCT04962971|DIETARY_SUPPLEMENT|Z|exocyan
41025834|NCT05170698|PROCEDURE|Coaltion excision and arthroereisis|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
41025835|NCT05170698|PROCEDURE|Coalition excision and corrective osteotomies|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
41025836|NCT02450994|DRUG|Dexamethasone|
41025837|NCT02450994|DRUG|Placebo|
41025838|NCT02773979|DRUG|Chloroquine|Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
41025839|NCT02773979|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
41025840|NCT02773979|OTHER|Placebo|Placebo
41025841|NCT03864900|BEHAVIORAL|The medication adherence intervention|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
41266765|NCT03649152|DRUG|Propagermanium|Immediate release capsule
41266766|NCT03649152|DRUG|Placebo|Placebo capsule
40841812|NCT01086176|DEVICE|NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)|on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
41499621|NCT02620852|DEVICE|Provide a saliva sample for genetic testing|Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
41499622|NCT02620852|OTHER|Screening advice based on a comprehensive risk assessment|Receive a screening schedule recommendation
40841813|NCT01587365|BIOLOGICAL|BMS-962476|
40841814|NCT01587365|BIOLOGICAL|Placebo matching with BMS-962476|
40841815|NCT01850355|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
41499623|NCT02620852|OTHER|Screening advice based on a basic risk assessment|Receive a screening schedule recommendation
40841816|NCT01536483|DRUG|Butyrate enemas|"Seven enemas~* Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)~* The study remains blinded for the investigation team through the intervention of a clinical research nurse~* According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention~* Installation time and retention is setted at 15 minutes~* Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C~* Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist"
40841817|NCT02837042|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks.
40841818|NCT03750331|OTHER|Ap'Telecare|an internet application on a computer, tablet or smartphone
40841819|NCT03750331|OTHER|traditional schedule|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule
40841820|NCT00248716|DRUG|Ferrous gluconate and iron polysaccharide complex|Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
40841821|NCT02553538|BEHAVIORAL|Patient Navigation|Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
40841822|NCT00094107|DRUG|Axitinib [AG-013736]|VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
40841823|NCT01436266|DRUG|Misoprostol|400 mcg buccally 2 hours prior to procedure
40841824|NCT01436266|OTHER|Folic acid|2mg buccally 2 hours prior to procedure
40841825|NCT05954767|DRUG|IS-001|IV injection of IS-001 drug substance with near infrared (NIR) imaging
41025842|NCT04620434|DEVICE|Video laryngoscopic view|The glottic view on the screen of the video laryngoscope during laryngoscopy with a C-MAC video laryngoscope, which installed with Macintosh blade.
41499624|NCT04799301|BEHAVIORAL|Diet with no soda|Weight-maintaining diet without soda, with all carbohydrates originating from sources other than corn and sugar cane
41499625|NCT04799301|BEHAVIORAL|Diet with 50% of carb intake from soda|Weight-maintaining diet with 50% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
41499626|NCT04799301|BEHAVIORAL|Diet with 20% of carb intake from soda|Weight-maintaining diet with 20% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
40841826|NCT01093066|DRUG|optimal TURB|The TURB will always try to be optically complete.
40841827|NCT04354883|PROCEDURE|External Chest Compressions on Manikin in Underwater Setting|Two different methods of CPR in an analogue model of mircogravity
41266767|NCT03135912|DRUG|Experimental Drug SESC 01|Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
41499627|NCT03944824|OTHER|Exercise Plan using resistance bands|Exercise under the guidance of an exercise physiologist using elastic resistance bands and weekly meeting with an exercise physiologist for 12 weeks
41499628|NCT03944824|DIAGNOSTIC_TEST|Modified Fried Frailty Scale|Patients will be screened for frailty pre and post with sit-to-stand test, timed up and go test, handgrip strength test and administered the low physical activity questionnaire. These components together consist of the Modified Fried Frailty Index.
41025843|NCT04620434|DEVICE|Direct laryngoscopic view|The glottic view evaluated by the anesthesiologist who performing tracheal intubation, by direct laryngoscopy with C-MAC installed with Macintosh blade.
41025844|NCT05057676|BEHAVIORAL|Immediate Autoimmune Intervention Mastery Course (AIM)|Immediate access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
41025845|NCT05057676|BEHAVIORAL|Immediate Question and Answer sessions. (AIM Q and A sessions)|Immediate access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
41266768|NCT03135912|DRUG|Placebo|Dosage method of SESC 01, without active ingredients.
41266769|NCT03135912|DRUG|Terbinafine Hydrochloride|Topical terbinafine hydrochloride cream.
41499629|NCT00927797|DRUG|Cyclophosphamide, Pentostatin, Rituximab|
40841828|NCT04259684|DRUG|gases Nitric Oxide (gNO)|Participants in the intervention group will receive gNO blended into the fresh gas flow of the cardiopulmonary bypass (CPB) oxygenator and maintained at 20 ppm via an Ikaria INO Max DSIR (Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA), with continuous sampling of NO and NO2 concentration from a port adjacent to the oxygenator. The gNO delivery will be initiated when the patient is on CPB and stopped once the patient comes off CPB.
40841829|NCT05258539|OTHER|Questionnaire|"Telephone calls at 2, 3 and 5 years with :~* Lifestyle follow-up questionnaire.~* Satisfaction questionnaire."
40841830|NCT00069355|DRUG|Propranolol|
40841831|NCT03968185|OTHER|Interfascial infiltration|"Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
40841832|NCT03968185|OTHER|Standard medical treatment|"Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
40841833|NCT03441503|OTHER|Child HCAHPS: Automated day-of-discharge survey|Child HCAHPS surveys will be administered on the day of discharge via an electronic interactive patient care system on inpatient televisions.
40841834|NCT00599638|DRUG|pregabalin|75mg bid titrating to 150mg bid on day 4
40841835|NCT00599638|DRUG|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
41266770|NCT03998657|DEVICE|Exablate Prostate Treatment|The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.
40841836|NCT00599638|DRUG|Placebo|Placebo
40841837|NCT03459456|BEHAVIORAL|Provocation OC task (Provoc)|used to evoke OC-related distress
41266771|NCT05115084|OTHER|no intervention|no intervention
41266772|NCT06391398|BEHAVIORAL|Stoma care education with the Stoma Care Training Belt|Stoma care education
41266773|NCT03780829|BEHAVIORAL|hypoxia|intermittent cycles of normoxia-hypoxia
41266774|NCT03780829|BEHAVIORAL|sham hypoxia|intermittent cycles of sham hypoxia
41266775|NCT03780829|DRUG|D-cycloserine|NMDA agonist treatment
41266776|NCT03780829|DRUG|sham-NMDA agonist|sham-NMDA agonist treatment
41266777|NCT03780829|BEHAVIORAL|exercise training|bimanual massed practice training
41266778|NCT01106040|DRUG|Lymphoseek|The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
41266779|NCT02229734|RADIATION|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
41266780|NCT02229734|DRUG|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
41266781|NCT00364182|DRUG|Recombinant Coagulation Factor IX (BeneFIX)|100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
41266782|NCT00364182|DRUG|Recombinant Coagulation Factor IX (BeneFIX)|50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
41266783|NCT01958957|DRUG|Ginkgolides Meglumine Injection|25mg, intravenous drip, once a day. Number of Cycles: 14 days.
41266784|NCT03075163|PROCEDURE|Acupressure|"Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.~In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team."
41362470|NCT03950271|DRUG|SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine|"1. Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~2. postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles."
41362471|NCT04808141|DEVICE|Digital program|Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.
41362472|NCT04808141|OTHER|Conventional PT|Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled PT sessions.
41362473|NCT05984225|OTHER|Online learning|"The students performed a 10-week Online Learning (OL) program based on Professional Ethics. The program included:~1. Synchronous learning (1 session/week, 1 hour each).~2. Asynchronous learning: i) OL classes were recorded; ii) Moodle platform: for read breaking news, upload tasks or solve any doubt they may have through discussion forums; iii) An OL specific syllabus that consisted of five themes from the ethics knowledge; iv) An OL glossary, including the concept, explanation of the concept, and source; v) Bullet-point videos highlighting the most important issues of each theme; vi) Podcasts about Professional Ethics, Ethics in physiotherapy; vii) Links to websites; viii) Gamification using mobile Apps regarding ethical decision-making, healthcare, and Ethics or Professional Ethics, as well as an OL crossword; ix) OL activities were created and personalized comments about the activities were reported by the teachers to give feedback to the students."
41025846|NCT05057676|BEHAVIORAL|Delayed Autoimmune Intervention Mastery Course (delayed AIM course)|Delayed access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
41362474|NCT04264949|OTHER|Education in the use of smartphone app (Mon coach dos)|In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos
41362475|NCT04264949|OTHER|conventional care|conventional care and the therapeutic education program
41362476|NCT03555227|PROCEDURE|USG PECS2 with Drug A (active)|Ultrasound guided Pecs 2 blocks with 0.25% levobupivacaine
41362477|NCT03555227|PROCEDURE|USG PECS2 with Drug P (placebo)|Ultrasound guided Pecs 2 blocks with placebo (0.9% saline)
41362478|NCT03555227|PROCEDURE|Wound infiltration with Drug P (placebo)|Wound infiltration at the end of surgery with Drug P (0.9% saline)
41160860|NCT04337034|BEHAVIORAL|Mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an eight-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three targets (goals) in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and family members. Family members will be informed about the participant's target activities and the planned strategies for reaching the targets. The participants will practice the target activities in their home environment supported by mobile phone calls and SMS. In addition they will be given information about stroke and their blood pressure will be measured.
41362479|NCT03555227|PROCEDURE|Wound infiltration with Drug A (active)|Wound infiltration at the end of surgery with 0.25% levobupivacaine
41362480|NCT04006821|DRUG|PD-1 antibody|Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
41362481|NCT04006821|DRUG|Apatinib mesylate|Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
41362482|NCT04439708|OTHER|Blood and aqueous humor biomarker of treatment response|Blood analyses and aqueous humor analysis
41362483|NCT01177826|PROCEDURE|Sample collection|Stool sample
40841838|NCT03459456|BEHAVIORAL|Trier Social Stress Test (TSST)|used to evoke anxiety unrelated to OCD (e.g., performance anxiety)
41160861|NCT04337034|PROCEDURE|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured.
41362484|NCT04129736|DRUG|Teriflunomide 14 MG|Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
41499630|NCT04170751|DRUG|16 mcg / cc of norepinephrine(group N)|In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
40841839|NCT03459456|BEHAVIORAL|Exposure provocation task|used to elicit overt OCD rituals
40841840|NCT05172674|DIAGNOSTIC_TEST|ultrasound according routine antenatal care|ultrasound examinations at 11-14, 19-22 and 33-35 weeks
40841841|NCT04232215|DEVICE|HeraBEAT™|A wireless Smart Fetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy
41025847|NCT05057676|BEHAVIORAL|Delayed AIM Question and Answer sessions|Delayed access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
41025848|NCT02591394|BEHAVIORAL|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
41025849|NCT02591394|BEHAVIORAL|Usual Care|"Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers."
41025850|NCT00000597|DRUG|antilymphocyte serum|
41025851|NCT00000597|DRUG|nandrolone|
41362485|NCT04678804|PROCEDURE|Mucogingival surgery for single recession coverage|"The control group will be treated with a coronally advanced flap with vertical incisions (CAF) associated to an autologous connective tissue graft. The graft will be harvested from the palate in the area apical to the gingival margin of the second molar with an epithelial-connective harvesting technique to obtain a connective graft of 1 mm in thickness.~Subsequently, the graft will be shaped in order to match height and width of the recipient site on the recession according to the technique proposed by Zucchelli in 2003. The test group will receive the same flap design with the same technique, then the porcine derived xenogeneic graft will be shaped in order to match height and width of the recipient site on the recession. In particular, the matrix will be reduced in thickness as suggested by the manufacturer to obtain a standardized thickness of 3 mm."
41362486|NCT01861587|DEVICE|tDCS|20 minutes of either real or sham stimulation
41362487|NCT00370994|PROCEDURE|Caudal epidural injection|Caudal epidural injection with catheterization
41362488|NCT00370994|PROCEDURE|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
41362489|NCT00943566|DRUG|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
41362490|NCT00943566|DRUG|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
41499631|NCT04170751|DRUG|0.4 unit / cc of vasopressin(group V)|In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
41025852|NCT00188097|BEHAVIORAL|Diagnosis of variceal bleeding and dits control in cirrhosis|
41160862|NCT00799747|DRUG|AZD4017|ascending single doses (start dose 2 mg), oral suspension
41362491|NCT02050945|BEHAVIORAL|Resistance training|
41362492|NCT02050945|BEHAVIORAL|Endurance training|
41025853|NCT00871481|BIOLOGICAL|ipilimumab|Given IV
41025854|NCT00871481|DRUG|cyclophosphamide|Given IV
41025855|NCT00871481|PROCEDURE|biopsy|Optional correlative studies
41025856|NCT00871481|BIOLOGICAL|aldesleukin|Given SC
41362493|NCT04186754|PROCEDURE|Comprehensive functional care plan|The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy.
41499632|NCT00899041|PROCEDURE|Total Knee Arthroplasty (TKA)|28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
41025857|NCT00871481|OTHER|immunohistochemistry staining method|Correlative studies
41025858|NCT00871481|GENETIC|polymerase chain reaction|Correlative studies
41025859|NCT00871481|OTHER|immunoenzyme technique|Correlative studies
41025860|NCT00871481|BIOLOGICAL|therapeutic cytotoxic T lymphocytes|Given IV
41025861|NCT02515162|PROCEDURE|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
41160863|NCT00799747|DRUG|Placebo|placebo
41160864|NCT04528953|BEHAVIORAL|Interval walking and Qigong exercise|"Interval walking: The subjects will be asked to complete daily 30 minutes of walking in two 15-minute bouts with the rest interval for at least 0.5 an hour and not more than 2 hours between each bout.~Qigong exercise: mind-body exercise using the six healing sound Qigong exercise will be used because it is easy to learn, requires minimal physical capability, and can be performed even in a sitting body position."
41160865|NCT01271036|DEVICE|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
41499633|NCT01420471|DRUG|Triamcinolone|Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
41025862|NCT02515162|PROCEDURE|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
41160866|NCT02979613|DRUG|TAF|25 mg tablet administered orally once daily
41160867|NCT02979613|DRUG|TDF|300 mg tablet administered orally once daily
41160868|NCT02979613|DRUG|TAF Placebo|Tablet administered orally once daily
41362494|NCT04186754|PROCEDURE|Traditional intervention without rehabilitation|Clinical control by nursing professionals and exclusively pharmacological treatment
41362495|NCT01594424|DRUG|Tocilizumab|Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
41160869|NCT02979613|DRUG|TDF Placebo|Tablet administered orally once daily
41025863|NCT06532448|DIAGNOSTIC_TEST|Single dose low-risk penicillin challenge|Initial screening to establish low risk allergy status followed by a single dose challenge using a standard penicillin dose. All challenges will be oral, conducted in a hospital setting and will be followed by a 1 hour monitoring period.
41160870|NCT04410354|DRUG|Merimepodib|400 mg (total daily dose of 1200 mg) for 10 days
41160871|NCT04410354|DRUG|Matching Placebo|0 mg (total daily dose of 0 mg) for 10 days
41160872|NCT04410354|DRUG|Remdesivir|200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)
41160873|NCT03753750|DEVICE|Noninvasive spinal cord stimulation|Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
41160874|NCT03193216|DRUG|Alginates|Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
41160875|NCT01748578|DRUG|EBI-005-1|EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
41160876|NCT01748578|DRUG|EBI-005-1 Placebo|
41362496|NCT01594424|DRUG|Intravenous Immunoglobulin|All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg \[maximum 140 g per dose\] on days 1 and 30).
41362497|NCT01255449|DRUG|albuterol|400 mcg by inhalation
41362498|NCT02569268|OTHER|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
41362499|NCT02241460|DRUG|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
41160877|NCT06045871|PROCEDURE|Corticotomy followed by compression osteogenesis|Surgical corticotomy supra apical in anterior maxilla then application of the compression osteogenesis concept via traction on miniscrews implanted above the corticotomy line
41362500|NCT02241460|DRUG|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
41025864|NCT05416619|DEVICE|REMO®|The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles. REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation. The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment.
41362501|NCT03937739|OTHER|Nutritional and constipation questionnaire|Alcohol and smoking habits, daily activity, frequency of food consumption and the constipation scoring according to Agachan et all. were examined using questionnaire
41025865|NCT05780645|DRUG|ALXN2050 MR Prototype Tablet|Participants will receive various doses of the MR Prototype Tablet orally.
41025866|NCT05780645|DRUG|ALXN2050 Immediate Release (IR) Tablet|Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.
41025867|NCT05780645|DRUG|ALXN2050 MR Prototype Mini-Tablet|Participants will receive various doses of the MR Prototype Mini-Tablet orally.
41025868|NCT02348164|OTHER|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
41025869|NCT02348164|OTHER|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
41025870|NCT05393310|OTHER|post isometric relaxation|The therapist will apply Post isometric relaxation ensure that foot will not actually move and only a static muscle contraction apply and held for 20 seconds. This will be followed by 2-3 second of relaxation, and then the foot passively stretched to dorsiflexion up to the palpated barrier and/or tolerance to stretch. This will continue until no further gains achieved 2 sets of 5 repetitions a day for 3 days a week for 4 weeks
41025871|NCT05393310|OTHER|MWM group|MWM group will receive inferior tibiofibular, talocrural, or cubometatarsal MWM 2-8 treatment sessions over 4 weeks.
41025872|NCT05251792|OTHER|Ocular examination|All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
41025873|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
41025874|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
41025875|NCT06061458|DIAGNOSTIC_TEST|speech auditory brainstem response|A diagnostic objective test to evaluate the speech process in hearing impaired children
41025876|NCT06039332|PROCEDURE|Fitting of the audioprocessor with the auditory implant BCI602|to compare the performance with BB system in two fitting-configurations (active comparator: DSL v5, experimental: DSL-BCD) using audiometric and subjective measures
41025877|NCT02740348|BEHAVIORAL|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
41025878|NCT02740348|BEHAVIORAL|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
41025879|NCT00171587|DRUG|PTK787/ZK 222584 (vatalanib)|
41025880|NCT02021279|DEVICE|MatriStem Pelvic Floor Matrix|
41160878|NCT04226651|DEVICE|Virtual Reality Device|The Virtual Reality system (PlayStation 4 VR, Sony Inc.) is a simple and easy to use distraction device. The system consists of a screen mounted on a binocular headset connected to a console or personal computer. The head-mounted display provides a high-resolution visual display and unmutes the sound from the headphones using a soundproof mechanism that provides clear sound.
41160879|NCT04226651|DEVICE|Protective glasses|Each patient was informed about the dental procedure and was provided with protective glasses. All patients were told that they were wearing these glasses to ensure a pain- and stress-free treatment, and that the dentist would devote additional attention to the treatment.
41160880|NCT05614024|OTHER|Real fNIRS Neurofeedback|Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
41160881|NCT05614024|OTHER|Sham-Control fNIRS Neurofeedback|Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
41362502|NCT02391649|BEHAVIORAL|Self-learning program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5:Dealing with \[physical and mental health\] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
40841842|NCT04232215|DEVICE|Doppler fetal heart rate monitor|A hand-held ultrasound transducer that uses the Doppler Effect to provide an audible simulation of the heart beat and displays the number of beats per minute.
41025881|NCT02021279|PROCEDURE|native tissue repair|
41025882|NCT04021680|OTHER|pre-eclampsia screening program|This screening program included the use of ultrasound, biomarkers and maternal factors in calculating the risk of developing preeclampsia.
41025883|NCT00440765|DRUG|bortezomib|dose as determined (observational study) by treating physician
41025884|NCT01669343|DRUG|Letrozole|Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
41362503|NCT02391649|BEHAVIORAL|Psycho-education program (in Phase 2)|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
41362504|NCT06051461|DIETARY_SUPPLEMENT|Oral lipid emulsions|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).
41362505|NCT02978404|DRUG|Nivolumab|Nivolumab is administered to patients to a maximum of 2 year.
41362506|NCT02978404|RADIATION|Radiosurgery|Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
41362507|NCT00137982|PROCEDURE|Treatment of ectopic pregnancy|
41362508|NCT03525912|DRUG|Ketamine|continuous infusion of low dose ketamine for postoperative pain
41362509|NCT05728528|DRUG|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
41362510|NCT05728528|DRUG|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
41362511|NCT01475513|DRUG|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
41362512|NCT05043896|PROCEDURE|Li-ESWT|Li-ESWT twice weekly for 4 weeks
41362513|NCT05043896|DRUG|Tadalafil 2.5Mg Tab|tadalafil 2.5mg once daily
41362514|NCT00548366|OTHER|Sodium restriction|4 gram sodium diet
41160882|NCT03003923|BEHAVIORAL|Taste exposure|Exposure to the same vegetable
41362515|NCT00548366|OTHER|Sodium restriction|2 gram sodium diet
41362516|NCT02579889|DEVICE|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
41160883|NCT03003923|BEHAVIORAL|Nutritional education|Eat Well and Strive for Five nutritional education
41160884|NCT03974451|DEVICE|IOL implantation experimental|Implantation of of PhysIOL trifocal FineVision® POD F IOL
41362517|NCT02579889|DEVICE|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
41499634|NCT01420471|OTHER|Saline-impregnated spacer|Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
41499635|NCT04737096|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
41499636|NCT04737096|DRUG|Placebo|placebo
41499637|NCT04737096|DEVICE|tDCS|tDCS
41499638|NCT03878667|DIETARY_SUPPLEMENT|Curves Calcium|Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).
40841843|NCT01700010|DRUG|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
40841844|NCT02792023|OTHER|Immunochemical fecal occult blood test|Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
40841845|NCT02792023|DEVICE|Colonoscopy|A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
40841846|NCT02792023|DEVICE|Upper endoscopy|An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
41025885|NCT02579291|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
41499639|NCT03878667|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium (providing 950 mg/d as carbonate)
41499640|NCT03878667|DIETARY_SUPPLEMENT|Placebo|Dextrose placebo
41499641|NCT00261092|DRUG|Oxaliplatin|
41499642|NCT00524732|BIOLOGICAL|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
41499643|NCT05053503|DEVICE|Sparrow Ascent Therapy System|Transcutaneous auricular neurostimulation (tAN)
41499644|NCT05053503|DRUG|Lofexidine|Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
41499645|NCT05053503|DRUG|Extended-release injectable naltrexone|Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.
41499646|NCT02573844|DRUG|Proklama|
41499647|NCT02573844|DRUG|Placebo|
41499648|NCT01274676|DEVICE|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
41499649|NCT01274676|DEVICE|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
41499650|NCT03021889|BEHAVIORAL|Nutritional therapy|The nutritional therapy intervention group received monthly nutritional guidelines for 12 weeks focusing on the diet for dyslipidemia, based on the recommendation of the type I diet of the Clinical Protocol and Therapeutic Guidelines for Management of HIV Infection in children and adolescents. In addition, participants in the intervention group received weekly phone calls for nutritional counseling.
41499651|NCT03021889|BEHAVIORAL|Control group|The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
41499652|NCT00788138|DIETARY_SUPPLEMENT|Vitamin D3|250,000 IU of vitamin D3
41499653|NCT00788138|DIETARY_SUPPLEMENT|Placebo|Matching Placebo
41499654|NCT04152187|OTHER|Inspiratory muscle training|The treatment group will receive inspiratory muscle training.
41499655|NCT04116762|DEVICE|TissuePatchDS-P™|The therapy to be used in the intervention arm is TissuePatchDS-P™. This is a preformed, standard-sized artificial adhesive that will be used between the parotid tissue and subcutaneous tissue. It can be cut to an appropriate size for the defect. The intention of this installation is to seal and close the potential space that is created with removal of superficial parotid tissue
41499656|NCT04116762|DEVICE|Surgical Drain|A surgical drain used in superficial parotid surgery is a thin polyvinylchloride (PVC) tube, with perforations at the end, which is placed at the end of the procedure before the surgical wound is closed in the cavity created following removal of parotid tissue. The tube is connected to a closed vacuum system attached to a plastic bottle outside of the patient's body which acts to remove the fluid that collects after an operation.
41499657|NCT05949710|BEHAVIORAL|aerobic exercise(AE)|The participants will receive AE three times per week.
41499658|NCT06377514|DEVICE|Test IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the Test IOL Model DEN00V in both eyes for the duration of the study
41499659|NCT06377514|DEVICE|Control IOL Model DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model DCB00 in both eyes for the duration of the study
41499660|NCT02876107|DRUG|Carboplatin|Given IV
41499661|NCT02876107|OTHER|Laboratory Biomarker Analysis|Correlative studies
41499662|NCT02876107|DRUG|Paclitaxel|Given IV
41499663|NCT02876107|BIOLOGICAL|Panitumumab|Given IV
41499664|NCT01307111|DRUG|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
41499665|NCT01307111|DRUG|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
41025886|NCT02579291|OTHER|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
41499666|NCT01345578|DRUG|human hepatocyte transplantation|"Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein.~The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant.~If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation."
40841847|NCT05369481|DRUG|Sildenafil 2%|Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
40841848|NCT05369481|DRUG|Minoxidil 5 %|Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
40841849|NCT04809259|DEVICE|Isothermal pouch|The study will verify it the use of an isothermal pouch to maintain the content of an elastomeric pump at 10° to 15°C avoids unacceptable meropenem degradation over the 24 hour infusion period.
41362518|NCT00703729|DEVICE|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
41362519|NCT00703729|OTHER|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
41499667|NCT01345578|RADIATION|Preparative Radiation Therapy|Just prior to the hepatocyte transplant, a portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 7.5-10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT).
41499668|NCT05866185|BEHAVIORAL|Therapy|The standard of care procedures for adults with clinically elevated anxiety and/or depression from their mental health provider.
41499669|NCT05866185|BEHAVIORAL|Therapy + Adhere.ly|Participants receive therapy as usual enhanced with a simple, HIPAA-compliant, web-based application to help mental health providers implement homework during therapy for adults with elevated anxiety and/or depression. The three major components of the app help providers to (1) Practice interactive, digitized therapeutic exercises with patients in-session; (2) Remind patients to practice exercises for homework, and (3) Review homework during the next session.
41499670|NCT05916274|BIOLOGICAL|Blood and fecal samples|Blood and fecal samples will be performed
41499671|NCT05916274|PROCEDURE|Coolonic biopsies|colonic biopsies will be analysed
41499672|NCT04888559|OTHER|Breakfast product: Whole grain|This intervention is a whole grain-based breakfast product containing oats and barley.
41499673|NCT04888559|OTHER|Breakfast product: Reference|This intervention is a rice-based breakfast product.
41499674|NCT02188914|RADIATION|Positron emission tomography scan|
41499675|NCT02188914|OTHER|Magnetic resonance imaging|
41499676|NCT01824043|DRUG|intravitreal ranibizumab injections|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
41499677|NCT00117910|DRUG|pegfilgrastim|
40841850|NCT00129961|DRUG|sirolimus|
40841851|NCT00129961|DRUG|cyclosporine or tacrolimus|
40841852|NCT05963971|BEHAVIORAL|PEDALL|twenty-six hour nutrition education intervention delivered virtually over a six month period
40841853|NCT05963971|OTHER|Standard of care|Nutrition education per institutional standard of care
40841854|NCT04773236|DRUG|sodium bicarbonate 8.4%|mixing the sodium bicarbonate with 2%lidocaine and 1:80.000 epinphrine using mixing pen (onset buffering system)
40841855|NCT04773236|DRUG|2%lidocaine with 1:80.000 epinphrine|injection
40841856|NCT04773236|DEVICE|Mixing pen (onset buffering system)|Premixing of the two solutions sodium bicarbonate and lidocaine with epinphrine before the local anesthesia adminstration to the patient
40841857|NCT03250572|DIAGNOSTIC_TEST|serum ferritin|serum samples and ferritin ELISA test
41025887|NCT05324475|DIETARY_SUPPLEMENT|BCAA|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1
41499678|NCT02287155|BEHAVIORAL|occupation based health promotion|"The description of the intervention is provided in the detailed description of the study."
41499679|NCT02382055|BEHAVIORAL|REACH|REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
41499680|NCT02382055|BEHAVIORAL|Supportive Psychotherapy|The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
40841858|NCT04110080|PROCEDURE|multimodal pain management|Regional anesthesia techniques, specifically rectus sheath and transabdominal plane blocks, for pain management will be performed.
41499681|NCT02382055|BEHAVIORAL|Inpatient Behavioral Treatment|Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
41499682|NCT04333030|OTHER|questionnaire|Tobacco Use and Risk Questionnaire
40841859|NCT04110080|OTHER|goal directed fluid management|Intraoperatively fluids will be administered based on hemodynamic parameters, in addition to clinical judgement.
40841860|NCT04110080|OTHER|preoperative carbohydrate loading|Patient's nutrition will be optimized preoperatively by administering carbohydrate drinks, and limiting fasting time.
40841861|NCT04110080|PROCEDURE|Donor nephrectomy|All patient will have laparoscopic nephrectomy procedure with transplant surgery.
40841862|NCT04110080|PROCEDURE|regional anesthesia|transabdominal plane and rectus sheath nerve block
40841863|NCT04936347|PROCEDURE|cold knife|Transcervical resection of adhesions is performed with scissors to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
40841864|NCT04936347|PROCEDURE|hot knife|Transcervical resection of adhesions is performed with bipolar electric cutting to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
40841865|NCT02925741|OTHER|Silk-Like Linens|Synthetic moisture-wicking fabric
40841866|NCT06184958|DRUG|Lidocaine group|Group A: Lidocaine group( 25 patients) will receive 5 mg/Kg lidocaine in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
40841867|NCT06184958|DRUG|Ketamine group|Group B:Ketamine group(25 patients) will receive 0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
41499683|NCT04829058|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures that were performed in subjects within this study are identical to the surgical procedures the subjects would have received as part of SOC.
40841868|NCT06184958|DRUG|Placebo group|Group C:placebo group (25 patients) will receive placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
40841869|NCT02092766|DRUG|artesunate|
40841870|NCT02092766|DRUG|quinine|
40841871|NCT06504069|BEHAVIORAL|Prosocial VR intervention|A five-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include five weekly sessions, each lasting between 10 to 15 minutes. Each session will depict a different daily life scenario-home, school, street, park, and shopping mall, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
40841872|NCT00395850|DRUG|Disulfiram|Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
40841873|NCT00685737|DRUG|1-MNA|Capsule
40841874|NCT00685737|DRUG|Placebo|Capsule
40841875|NCT02095509|DRUG|Enoxaparin|Drug class: Low-molecular weight heparin
40841876|NCT01711593|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
40841877|NCT01711593|PROCEDURE|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
40841878|NCT06338202|DRUG|Mavacamten|As detailed in the product label
40841879|NCT02372422|OTHER|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
40841880|NCT02372422|OTHER|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
40841881|NCT04583956|OTHER|Placebo|Risankizumab placebo will be given at an equal volume at the same schedule.
41362520|NCT02908594|DEVICE|Medical Exercise Peddler 3000, Medi-Bike, Taiwan|"A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes."
40841882|NCT04583956|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
41160885|NCT03974451|DEVICE|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
41160886|NCT01655992|DRUG|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
41362521|NCT06111755|OTHER|SmokefreeTXT|National Cancer Institute's SmokefreeTXT is a text message quit smoking program available nationally. Users sign up and choose a target quit date that is within 2 weeks of their signup date. Users receive 3-5 text messages per day for up to 2 weeks pre-quit and 6 weeks post-quit. The quit date can be reset as often as needed by the user.
40841883|NCT04583956|BIOLOGICAL|Risankizumab|Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.
40841884|NCT00120601|DRUG|Naltrexone|
41362522|NCT06111755|DEVICE|Smartband|A smartband that will track smoking in real-time and ask the individual to confirm/deny smoking. Participants will be asked to wear the smartband during their waking hours and to charge it overnight.
40841885|NCT00120601|DRUG|Acamprosate|
40841886|NCT00618878|PROCEDURE|Electroacupuncture|twice a week for 26 treatments in total
40841887|NCT00618878|PROCEDURE|Laser Therapy|twice a week for a total of 26 treatments
41362523|NCT03116789|DIETARY_SUPPLEMENT|probiotics|Two capsules for daily
41362524|NCT02300922|DRUG|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
41362525|NCT02300922|DRUG|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
40841888|NCT04650425|BEHAVIORAL|Cognitive tasks|Patients will perform the coffee-tea task and the virtual T-maze task, both in the acute and chronic phase after stroke.
40841889|NCT05768815|BEHAVIORAL|Breaking the Cycle Program|BTC is a prevention and early intervention program in Toronto, Canada, serving substance-using pregnant and/or parenting women with children under six years of age. Established by the Canadian Mothercraft Society in 1995, BTC is funded by the Community Action Program for Children and the Canadian Prenatal Nutrition Program through the Public Health Agency of Canada. BTC provides three program components that act synergistically: a) individualized services for mothers, b) individualized services for children, and c) relational interventions that enhance the mother-child relationship and promote infant mental health. Coordinated supports are offered through formal partnerships across service sectors. In 2004, BTC was recognized by the United Nations as an exemplary program serving pregnant and parenting women with substance use problems, and their young children.
41025888|NCT05324475|DIETARY_SUPPLEMENT|Micronutriments|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g
41160887|NCT01655992|DRUG|S1 generic|40mg／m2 bid four weeks on two weeks off
41362526|NCT02300922|DRUG|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
41362527|NCT06173973|DIETARY_SUPPLEMENT|Kenetik; Ketone Concentrate|Ketone Supplement
41362528|NCT06173973|DIETARY_SUPPLEMENT|Isocaloric dextrose placebo|Drink that is taste and visually matched to Ketone supplement
41362529|NCT05288439|DIAGNOSTIC_TEST|Resting-state functional connectivity MRI|participants will undergo functional MRI
41362530|NCT05288439|OTHER|Neurocognitive battery with quality-of-life assessment|Cognitive and quality of life assessments performed by a trained neuropsychologist
41362531|NCT05303051|DEVICE|Application Validation|After creating accounts, participants in both groups will download the Azumio Instant Diabetes Test and provide a Photoplethysmography (PPG) waveforms by placing their index finger over their smartphone camera for 20 seconds to provide PPG waveform data for the study .
41362532|NCT04245813|BEHAVIORAL|Interdisciplinary educational program|Interdisciplinary educational component based on the Clinical Practice Guide for Heart Failure
41362533|NCT02023476|RADIATION|MRI|MRI- imaging on the upper arm
41499684|NCT04933448|OTHER|Ketogenic Diet|The ketogenic diet (KD) is an alternative feeding regimen that has been in use since 1921. It is a high-fat, low carbohydrate, and moderate protein diet. There are various forms of the KD. The classic KD consists of long-chain triglycerides with a fat-to-combined-protein-and-carbohydrate ratio that can vary. At the investigating institution, it is standard of care to initiate a ketogenic diet at a ratio of 2:1, and to increase the ratio to 3:1 or 4:1 as needed to achieve ketosis.
41499685|NCT01520870|DRUG|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
41160888|NCT05846048|OTHER|semi-structures questionaire|semi -structured questionnaire prepared by the researcher collect sociodemographic data , awareness ,attitudes about marital rape and health consequences
40841890|NCT05768815|BEHAVIORAL|Maxxine Wright Program|Founded in 2005 and located in Surrey, British Columbia, the Maxxine Wright Community Health Centre (MWCHC) supports women who are pregnant and/or have young children and are impacted by substance use and/or violence. Women do not need to have children in their care to receive services. The program is funded and operated by the Fraser Health Authority, with additional in-kind support from the BC Ministry for Children and Family Development and the BC Ministry of Social Development and Poverty Reduction. MW addresses maternal substance use and exposure to violence through women-centered, trauma-informed, culturally grounded, and interdisciplinary approaches. Primary services offered include addiction counselling, primary health care, and group therapy to address interpersonal violence. Within MW, child-focused services are limited to primary health (e.g., well baby checks, childcare).
41025889|NCT05324475|DIETARY_SUPPLEMENT|standard treatment + placebo|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo
41025890|NCT05372601|DIETARY_SUPPLEMENT|Relax+|Prebiotics, daily administered
41025891|NCT05372601|DIETARY_SUPPLEMENT|Maltodextrin|Placebo, daily administered
41025892|NCT03591692|PROCEDURE|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
41025893|NCT03591692|PROCEDURE|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
41025894|NCT05355389|BEHAVIORAL|Cognitive training|For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
41362534|NCT00792922|DRUG|Azithromycin|Comparison of community coverage rate
41362535|NCT00792922|DRUG|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is \>5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
41362536|NCT00749866|DRUG|Gentamicin|Nebulised 80mg twice daily
41362537|NCT00749866|DRUG|Saline|Nebulised 4mls 0.9% Saline twice daily
41362538|NCT05455060|DRUG|Chinese herbal formula (CHF)|Each CHF capsule, weighing 500mg, is composed of Xiao-Feng-San 200mg, Zhen-Ren-Huo-Ming-Yin 200mg, Dictamnus dasycarpus 50mg and Houttuynia cordata 50mg. Patients will take the medicine 2 times a day (6gm BID for BW≥40kg), for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW\<40kg; 1.5gm BID for BW\<20kg)
41362539|NCT05455060|DRUG|Placebo|The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group.
41499686|NCT04182724|DRUG|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib was administered 250 mg p.o. qd Nab-paclitaxel was administered 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
40841891|NCT00418977|BEHAVIORAL|"Family-Based Therapy (Maudsley Method)"|The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.
40841892|NCT00418977|BEHAVIORAL|Individual Supportive Psychotherapy|The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
40841893|NCT03909451|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
40841894|NCT03909451|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
40841895|NCT05849519|DRUG|Coenzyme I for Injection + conventional treatment|The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days
40841896|NCT05849519|DRUG|Conventional treatment|The control group was treated with conventional treatment
40841897|NCT05840588|DRUG|Antibiotic Treatment|Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid
41160889|NCT02299427|BEHAVIORAL|dog safety|use of dog safety website at home for about 2 weeks
41160890|NCT02299427|BEHAVIORAL|transportation safety|use of transportation safety website at home for about 2 weeks
41499687|NCT06581783|DRUG|Simethicone plus NAC|Drug simethicone plus N acetylcysteine will be given before endoscopy with different time intervals
41499688|NCT02183181|DRUG|Meloxicam capsule|
40841898|NCT05840588|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium breve PRL2020 treatment|Probiotic Bifidobacterium breve PRL2020
40841899|NCT02578329|BEHAVIORAL|Intensively advised Mediterranean diet|Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
40841900|NCT02578329|BEHAVIORAL|usual low-fat dietary advice|usual low-fat dietary advice for cardiovascular disease
40841901|NCT00485966|DRUG|CX-3543|360 mg/m2 daily x 5 q 21 days
40841902|NCT03867942|DRUG|Monolayer group|Monolayered combination of gemigliptin and rosuvastatin
40841903|NCT03867942|DRUG|Bilayer group|Bilayered combination of gemigliptin and rosuvastatin
41160891|NCT04385628|BEHAVIORAL|the patient' relatives satisfaction questionnaire|The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
41160892|NCT04335695|BEHAVIORAL|Vascular Rehabilitation|Vascular rehabilitation is a supervised exercise therapy program that includes healthy lifestyle changes to help patients gain strength, energy and confidence to return to daily activities. A program of supervised exercise rehabilitation is considered a primary treatment for people with Peripheral Artery Disease and Intermittent Claudication. In addition, patients will be given a wrist-worn activity tracker and be in contact with a research coordinator every 3 months after they are discharged from the Vascular Rehab program.
41160893|NCT03761134|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
41160894|NCT03761134|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
41160895|NCT03761134|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
41160896|NCT03761134|DRUG|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
41499689|NCT02183181|DRUG|Meloxicam tablet|
41499690|NCT05250648|DRUG|complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes|In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
41499691|NCT05250648|PROCEDURE|complete cytoreductive surgery without HIPEC|in the arm without HIPEC, only complete cytoreductive surgery will be performed
41499692|NCT06097455|GENETIC|ARI0003|Treatment with ARI0003 cells
41499693|NCT05977946|DEVICE|Volta System|The Volta System is a wearable, battery-operated, neurostimulation system designed to deliver tAN or taVNS. The device will be used to deliver two 30-minute sessions of active or sham therapy according to the participant's randomization group (taVNS or tAN).
41499694|NCT06107335|DRUG|Human Albumin (colloid)|Fluid replacement will be achieved with colloid (5% albumin infusion). A bolus infusion of up to 500 milliliters (mL) of 5% Albumin will be administered prior to the placement of neuraxial anesthesia. If stroke volume variation (SVV) drops to less than 13% during the infusion of albumin, the infusion will be halted. At the completion of the placement of the spinal/combined spinal-epidural (CSE) anesthesia, study participants will receive the remaining albumin infusion if it was initially halted and SVV increases back to \>13% during the procedure (to a total maximum of 500 mL albumin for the entire procedure).
41499695|NCT06107335|DRUG|Lactated Ringer's Injection (crystalloid)|Fluid restriction will be achieved with crystalloid (lactated ringer's injection) administered at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr), administered during the procedure.
41160897|NCT01858064|DRUG|OROS-MPH|Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
41025895|NCT05355389|BEHAVIORAL|Motor training|For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
41025896|NCT02097875|DRUG|BLZ-100|
41362540|NCT00019331|BIOLOGICAL|aldesleukin|
41362541|NCT00019331|BIOLOGICAL|ras peptide cancer vaccine|
40841904|NCT03631420|BIOLOGICAL|Human Umbilical Cord Derived-Mesenchymal Stem Cells|Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
40841905|NCT03922165|PROCEDURE|Adenotonsillectomy|Routine AT per clinical care.
41025897|NCT04365322|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
41025898|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
41025899|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
41025900|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
41025901|NCT00560833|DRUG|esmirtazapine|
41362542|NCT00019331|BIOLOGICAL|sargramostim|
40841906|NCT05476523|OTHER|NeuraLight|NeuraLight is an investigational software-based platform used for measuring eye movements in response to visual stimuli and captured using a simple webcam
41025902|NCT00560833|DRUG|Placebo|
41362543|NCT00019331|DRUG|DetoxPC|
40841907|NCT01612208|DEVICE|Periarticular Locking Plate (NCB, Zimmer)|The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
40841908|NCT01612208|DEVICE|MotionLoc Screw|The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
40841909|NCT01862367|DRUG|catridecacog|No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
41025903|NCT01151553|DEVICE|CRT Therapy|Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
41025904|NCT03779529|DIETARY_SUPPLEMENT|Olive oil|Intervention includes dosage and amount of biophenols administered daily
41025905|NCT00043446|DRUG|intravenous T900607-sodium|
41025906|NCT06416488|BEHAVIORAL|HIIT intervention|Modified HIIT in Tabata mode, which followed a pattern of 3 sets, with each set consisting of 4 repetitions of 20 seconds of high-intensity exercise followed by 10 seconds of rest, at least 3 times per week.
41025907|NCT06416488|BEHAVIORAL|General health education|General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.
41025908|NCT00875953|PROCEDURE|standard neck dissection|standard surgical technique
41025909|NCT00875953|PROCEDURE|Harmonic Scalpel Dissection|harmonic scalpel used for neck dissection after flaps are raised.
41025910|NCT01877421|DRUG|2 mg KSL-W|
41362544|NCT02177227|DEVICE|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
41362545|NCT04225182|DEVICE|traditional rehabilitation protocol|muscular strengthening protocol with traditional rehabilitation protocol without orthosis
41362546|NCT04225182|DEVICE|with instrumented Orthosis|8 weeks of muscular strengthening with the orthosis connected to the phone app associated
41362547|NCT02983968|OTHER|Description of the cirrhosis management|
41362548|NCT02067208|DEVICE|wedged insole|Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
41362549|NCT00033683|DRUG|CMF regimen|
41362550|NCT00033683|DRUG|cyclophosphamide|
40841910|NCT03805516|BEHAVIORAL|SCOPP-CW|The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.
40841911|NCT03805516|BEHAVIORAL|Control|This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.
41025911|NCT01877421|DRUG|4 mg KSL-W|
41025912|NCT01877421|DRUG|6 mg KSL-W|
41025913|NCT01877421|DRUG|10 mg KSL-W|
41025914|NCT01877421|DRUG|20 mg KSL-W|
41160898|NCT00812825|DRUG|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
41025915|NCT01877421|DRUG|30 mg KSL-W|
41025916|NCT01877421|DRUG|50 mg KSL-W|
41025917|NCT01877421|DRUG|75 mg KSL-W|
41025918|NCT01877421|DRUG|100 mg KSL-W|
41025919|NCT01877421|OTHER|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
41362551|NCT00033683|DRUG|docetaxel|
41362552|NCT00033683|DRUG|epirubicin hydrochloride|
41362553|NCT00033683|DRUG|fluorouracil|
41362554|NCT00033683|DRUG|methotrexate|
41362555|NCT00033683|DRUG|tamoxifen citrate|
41362556|NCT00033683|PROCEDURE|adjuvant therapy|
41362557|NCT00033683|RADIATION|radiation therapy|
41362558|NCT00565721|DRUG|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
41362559|NCT01955642|DRUG|Clopidogrel|75 mg milligrams per days of PLAVIX
41362560|NCT06313242|DRUG|Polyethylene Glycol Electrolytes Powder (II)|Polyethylene Glycol Electrolytes Powder (II) was used for bowel preparation.
41362561|NCT06313242|OTHER|Low residue diet|Low residue diet 1 day before the test, fasting from 20:00 pm.
41362562|NCT06313242|OTHER|Normal diet|Normal diet 1 day before the test, fasting from 20:00 pm.
41362563|NCT05131139|DEVICE|Continuous Glucose Monitoring System|Eversense 524 CGM System and ROME CGM System.
40841912|NCT02881528|DRUG|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
41362564|NCT02723461|DRUG|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
41362565|NCT02723461|DRUG|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
41362566|NCT04657809|COMBINATION_PRODUCT|Insulin film|Insulin suspension vials
41362567|NCT04657809|DEVICE|Fast dissolving film|Fast dissolving film
41362568|NCT02594150|OTHER|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
41362569|NCT04984629|DEVICE|HYDRAFIL|The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.
41362570|NCT00145080|BEHAVIORAL|Disease Management Assessment|
41362571|NCT01070381|DEVICE|nelfilcon A contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
40841913|NCT02881528|DRUG|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
40841914|NCT04628065|BEHAVIORAL|#BabyLetsMove|This intervention will use mobile phones to promote the adoption and maintenance of physical activity, exercise and reduced TV time among overweight or obese, Black, pregnant (\<16 weeks) adolescents (15 - 19 years) enrolled in Mississippi's WIC program.
40841915|NCT02161107|BIOLOGICAL|Grass-SPIRE|Intradermal injection
40841916|NCT02161107|BIOLOGICAL|Placebo|Intradermal injection
41362572|NCT01070381|DEVICE|ocufilcon D contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
41362573|NCT02519127|OTHER|Low glycaemic load diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
41362574|NCT02519127|OTHER|Western diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
41362575|NCT01310491|BEHAVIORAL|Health coaching|Telephone based health coaching supported by tele-monitoring.
41362576|NCT02957500|DEVICE|Mediclore® (adhesion barrier)|
41362577|NCT03196401|DRUG|Durvalumab|durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
41362578|NCT03196401|RADIATION|Radiation therapy|concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
41362579|NCT01777022|OTHER|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
41362580|NCT02452034|DRUG|Posaconazole IV solution|Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
41362581|NCT02452034|DRUG|Posaconazole powder for oral suspension|Posaconazole once daily by PFS for a minimum of 10 days
41362582|NCT03236701|OTHER|Egg White replacement|Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
41362583|NCT02936206|DRUG|Fulvestrant|fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
40841917|NCT01099436|DRUG|cyclophosphamide|
40841918|NCT01099436|DRUG|docetaxel|
40841919|NCT01099436|DRUG|doxorubicin hydrochloride|
40841920|NCT01099436|DRUG|zoledronic acid|
40841921|NCT01099436|PROCEDURE|neoadjuvant therapy|
40841922|NCT03764930|OTHER|Unsuspected Retinoblastoma|To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
40841923|NCT04790292|DRUG|group M|10mg morphine in 5ml normal saline + 10ml of 0.25% bupivacaine ( total volume 15 ml) were injected intra-articularly
40841924|NCT04790292|DRUG|group MD|10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly
41362584|NCT02936206|DRUG|Tamoxifen|14 days of treatment with tamoxifen 20mg orally each day
41362585|NCT02369380|DEVICE|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
41362586|NCT05220020|PROCEDURE|TACE(Transcatheter arterial chemoembolization)|Hepatic arterial chemoembolization treatment
41362587|NCT05220020|DRUG|Lenvatinib|Experimental group(Synchronous treatment group): the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.Control group:(Sequential treatment group)patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
41362588|NCT01522391|DRUG|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
41362589|NCT01522391|DRUG|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
41362590|NCT05663775|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA)
41362591|NCT05202249|PROCEDURE|muscle layer fixation of thoracic drainage tube|The thoracic drainage tube is fixed on the muscle layer of the uniport
41362592|NCT01551043|BIOLOGICAL|CART-19|
41362593|NCT04647682|OTHER|physical activity program|"* 30 second chair test,~* balance with joint-feet and semi-tandem stance~* 4 meters comfortable walking test were evaluated"
41362594|NCT03574727|PROCEDURE|Injection to or release of anterior cutaneous nerves|Patients who have undergone at least one injection to the nerves
41362595|NCT04440176|BIOLOGICAL|MenABCWY|Neisseria meningitidis group A, B, C, W, and Y vaccine
41362596|NCT04440176|BIOLOGICAL|Saline|Placebo
41362597|NCT04981080|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment, including noninstrumented uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and urethral pressure profilometry, was performed with the patient in a sitting position according to the recommendations by the International Continence Society.
41362598|NCT04480905|DEVICE|Dynamic tape|The dynamic tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
41362599|NCT04480905|DEVICE|Sham tape|The 3M™ Soft Cloth Tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
41362600|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the FC formulation
41362601|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
41362602|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
41362603|NCT04698200|OTHER|Cold exposure|Whole body resting cold (+10 degrees centigrade) and heat (+40 degrees centigrade) for 60 minutes.
41362604|NCT03961984|PROCEDURE|Biodesign® anal fistula plug|Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
41362605|NCT05604781|DEVICE|Symfony & Synergy IOL combination|The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.
41362606|NCT01672762|DRUG|ipragliflozin|oral
41362607|NCT04027504|DIETARY_SUPPLEMENT|Fitabisc|Biscuits containing antioxidants
41499696|NCT06107335|DEVICE|Edwards HemoSphere monitor with ClearSight-Acumen finger cuff|Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device. The Edwards HemoSphere monitor with ClearSight-Acumen (CSA) finger cuff is a hemodynamic monitoring system that obtains continuous blood pressure readings from a cuff on the finger. In study participants, the finger cuff will be placed on the middle finger of one of the hands. The Edwards device can be used to predict impending intraoperative hypotension before its occurrence. The device has the ability to assess vasodilatory status using systemic vascular resistance (SVR), volume status using stroke volume variation (SVV) and stroke volume (SV) and the use of Carbon Monoxide (CO) to assess for underlying cardiac suppression. It also incorporates the hypotension prediction index (HPI), an algorithm that uses the arterial waveform to predict early phases of intraoperative hypotension.
41499697|NCT02810379|PROCEDURE|written informed consent|
40841925|NCT01504204|DRUG|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
41160899|NCT00812825|DRUG|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
41362608|NCT03647098|DRUG|Chemotherapy.|pemetrexed, 500mg/m2, ivgtt every 21 day.
41362609|NCT03573921|DRUG|Gastrograﬁn|Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.
41362610|NCT03573921|OTHER|Saline solution (control treatment)|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
40841926|NCT01504204|DRUG|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
41160900|NCT00812825|DRUG|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
41362611|NCT02651311|OTHER|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
41362612|NCT02651311|DRUG|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
41362613|NCT02651311|DRUG|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
41362614|NCT01053143|BIOLOGICAL|A/H1N1 pandemic influenza vaccine (non- adjuvanted)|0.5 mL, Intramuscular
41362615|NCT02380599|OTHER|Spinal Manipulation|Mid-thoracic spinal manipulation to T3-5 region
41499698|NCT02810379|PROCEDURE|video+written informed consent|
41362616|NCT02380599|OTHER|Spinal Mobilization|Mid-thoracic spinal mobilization to T3-5 region
41362617|NCT02380599|OTHER|Sham Ultrasound|Sham ultrasound to T3-5 region
41362618|NCT02966912|DIETARY_SUPPLEMENT|400 mg of Magnesium Oxide twice daily for 24 weeks|
41499699|NCT05602363|DRUG|AS-1763|oral tablet, twice daily
40841927|NCT01705912|OTHER|Complete intervention|The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
41362619|NCT02966912|OTHER|Open label (none)|
40841928|NCT01705912|OTHER|Basic intervention|The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
41362620|NCT04863898|BEHAVIORAL|Drug-use stigma reduction intervention for HIV care and treatment clinic staff|We will adapt the HP+ health facility HIV stigma-reduction intervention to focus on drug stigma in HIV CTCs. The intervention will address key stigma drivers, including fear, awareness of stigma, and stigmatizing attitudes and beliefs, through a participatory training approach that involves all levels of staff and is grounded in social cognitive theory principles. The approach seeks to reduce stigma through fostering empathy, interpersonal interactions (contact strategies) and building efficacy for stigma reduction through awareness, skills, and knowledge building. The intervention consists of five-2.5 hour participatory training sessions.
41499700|NCT05986695|BEHAVIORAL|Alert|Interruptive alert. The prototype alert is in the form of a chart note with evidence-based practice guidelines that will actively display in the clinician's list of daily alerts (like an inbox) that must be cleared daily. It is interruptive because can only be dismissed from the clinician's inbox list after signing the note
41499701|NCT05986695|BEHAVIORAL|Peer comparison report|Clinicians will receive an email describing their recent SGLT2 and MRA prescribing performance relative to their peers.
40841929|NCT04474314|DRUG|IMR-687|Oral administration of once daily IMR-687
40841930|NCT04474314|DRUG|Placebo|Oral administration of once daily Placebo
40841931|NCT01896583|DRUG|ASP7147|300 mg, tablet, twice per day for 4 weeks oral
40841932|NCT01896583|DRUG|Placebo|
40841933|NCT02001584|DRUG|Baclofen|
40841934|NCT02001584|DRUG|Memantine|
40841935|NCT02001584|DRUG|Placebo|
40841936|NCT05823272|OTHER|ONS|oral nutritional supplement
40841937|NCT02115360|DRUG|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
40841938|NCT02115360|DRUG|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
40841939|NCT02258113|DEVICE|Ocusweep|A novel reaction-time based visual field device.
40841940|NCT02258113|DEVICE|Ocusweep OcuRT|Vision based choice reaction time test method
40841941|NCT06061107|BEHAVIORAL|Handbook for Geriatric Prearranged Medical Care Consultation|"The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care. There are three measurement time points: pre-test, two weeks after intervention, and one month after intervention."
40841942|NCT05179499|DRUG|Norepinephrine|Norepinepherine should be prepared and delivered at a concentration of 16 micrograms/ml
40841943|NCT05179499|OTHER|Balanced Crystalloid|IV fluids administered as per standard care
40841944|NCT06530888|OTHER|Process-based Cognitive Behavioral Therapy (PBT)|Intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
40841945|NCT06530888|OTHER|Routine practice (r-PT)|Intervention planning as usual.
41362621|NCT05699304|PROCEDURE|Thyroidectomy|Thyroidectomy
41362622|NCT06148805|OTHER|pilates exercise and diaphragm manual technique|pilates exercises
40841946|NCT05098509|DRUG|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
41362623|NCT04951726|DRUG|Neostigmine|cholinesterase inhibitor
41362624|NCT03287089|DRUG|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
41499702|NCT06228599|OTHER|Treatment Plan|A matched treatment regimen will be administered for approximately 12 weeks based on recommendations made by the MTB.
41499703|NCT02478203|DEVICE|Airtraq|videolaryngoscope for difficult airway
41499704|NCT02478203|DEVICE|Glidescope|videolaryngoscope for difficult airway
40841947|NCT05098509|DRUG|Placebo|Matching Placebo for RAD011
40841948|NCT04437992|GENETIC|NIPT|The test, which requires two 10 ml tubes of blood, will be performed simultaneously with the chemical biomarkers of the combined test at 10-12 weeks of gestation
40841949|NCT03674879|OTHER|Text Message|Patient contact attempted with text message.
41160901|NCT00812825|DRUG|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
41160902|NCT00812825|DRUG|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
41499705|NCT02478203|DEVICE|direct laryngoscopy|gold standart for intubation
41160903|NCT03790878|BEHAVIORAL|Mindful Breathing|Training in a mindful breathing skill that reduces emotional distress
41160904|NCT03790878|BEHAVIORAL|Habituation|An exposure procedure that reduces emotional distress through habituation
41160905|NCT03790878|BEHAVIORAL|Control|No emotion regulation intervention, placebo
40841954|NCT02179814|DRUG|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
40841955|NCT02179814|DRUG|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
40841956|NCT02179814|DRUG|Placebo|Placebo at the second, third and fourth medication intake time point
40841957|NCT01600053|DRUG|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
40841958|NCT04129450|OTHER|Group medical visits with mindfulness-based stress reduction|Eight weekly 90 minute sessions of mindfulness-based stress reduction in group medical visits
40841959|NCT04129450|OTHER|Usual PCP care|Usual one on one PCP care for chronic lower back pain
40841960|NCT04151849|DRUG|GLP-1 receptor agonist|Treatment with GLP-1 agonist for up to 1 year.
40841961|NCT04151849|DRUG|SGLT2 inhibitor|Treatment with SGLT2 inhibitor for up to 1 year
40841962|NCT01176565|DRUG|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
40841963|NCT00922805|DIETARY_SUPPLEMENT|guar gum|guar gum (20 g/l of formula) for one week
40841964|NCT06303856|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
40841965|NCT03959787|OTHER|Educational|Educational pamphlet will be given to intervention group.
40841966|NCT03496636|PROCEDURE|Ovarian tissue transplant|Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
40841967|NCT06143982|BEHAVIORAL|Brief Intensive Trauma Treatment|BITT is an outpatient, intensive, one-week individual trauma therapy program. BITT is based on well-established protocols, consisting of two 90-minutes trauma therapy sessions a day (trauma exposure in the morning and EMDR in the afternoon), two psychomotor therapy sessions a day (1x60 minutes, 1x45 minutes), one 90-minutes psycho-education and social support skill training for parents a day, and a 90-minutes family therapy session at the end of the week (sharing the trauma narrative).
40841968|NCT03344172|DRUG|Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery Day 1 of Cycle 3: avelumab (10mg/kg)
40841969|NCT03344172|DRUG|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery
41025920|NCT06048523|PROCEDURE|Patient cohort|"* For patients: annual follow-up in Neurogenetic reference center, as part of routine care, with exhaustive standardised clinical evaluation~* Paraclinical monitoring (e.g. MRI, EEG, EMG, etc.) modelled on standard care according to current recommendations~* Biological samples offered to patients in the context of research:~  * Annual blood sample~ * Annual urine sample~ * Collection of 1 skin biopsy at the inclusion visit (for 30 patients)~ * Cerebrospinal fluid sample at the inclusion visit (for 15 patients"
41025921|NCT06048523|PROCEDURE|Control cohort|"* controls without LP: 1 visit for blood, urine and optional skin biopsy~* controls with LP: additional blood and cerebrospinal fluid tubes for blood sampling and LP as part of routine care, without longitudinal follow-up"
41025922|NCT02855502|DRUG|Prednisolone|
41025923|NCT02855502|DRUG|Placebo|
41025924|NCT01337245|DRUG|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
40841970|NCT02155530|DRUG|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
40841971|NCT02155530|DRUG|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
40841972|NCT01455220|DRUG|Tysabri ® (Natalizumab)|IV, monthly
40841973|NCT03094065|OTHER|News items with spin|Interpretation of news items with spin
40841974|NCT03094065|OTHER|News items without spin|Interpretation of news items without spin
40841975|NCT02486250|OTHER|Validation Study|
40841976|NCT02258087|RADIATION|LDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with low-dose-rate or brachytherapy using transrectal ultrasound guidance. Radiation sources (iodine-125 isotopes) are implanted into the prostate through transperineal needle insertion. Real time dose planning is applied. The prescribed dose to the whole prostate is 145 Gy.
41025925|NCT04842695|DEVICE|electroacupuncture group|compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
40841977|NCT02258087|RADIATION|HDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with one fraction of HDR brachytherapy. The prescribed dose to the whole prostate is 1x19 Gy. Ir-192 radioactive stepping source is used for the treatment with after-loading technique. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time intraoperative needle position update and dose optimization is applied.
41362625|NCT03287089|DRUG|Placebo Oral Tablet|Matching placebo
40841978|NCT04203420|OTHER|screening and confirmatory tests|screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test
40841979|NCT02786680|BEHAVIORAL|stroop test in condition DBS off|Patients were evaluated in DBS Off
41025926|NCT04321460|DRUG|LRG-002|Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus
41025927|NCT04321460|DRUG|Placebo|Capsules containing placebo
41025928|NCT04133935|PROCEDURE|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
41025929|NCT04133935|PROCEDURE|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
41025930|NCT06395285|DRUG|DF-003|140 mg on Days 1, 2, and 3 followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.
41025931|NCT03017508|DRUG|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
41025932|NCT03017508|DRUG|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
41025933|NCT00260052|DRUG|Erythropoietin administration|
41025934|NCT00608712|DRUG|Esomeprazole|Esomeprazole 20mg oral tablet
41362626|NCT06098976|DEVICE|Water Jet|The water jet works by directing a stream of water towards the gap between your teeth. The stream of water helps to loosen and remove plaque and food particles stuck in this area.
41362627|NCT06098976|DEVICE|Manual toothbrush|Manual toothbrush: The patients were taught to use the modified vertical method, and the patient brushed the teeth of the upper and lower jaws using traditional toothbrushes (Diamond, JolleyDent, Damascus, Syria), and anti-plaque toothpaste (Elgydium, UniPharma Co., Ltd, Ashrafiyat Sahnaya, Syria).
41362628|NCT00676468|OTHER|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
41362629|NCT00676468|OTHER|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
41499706|NCT05842174|DRUG|Hydroxychloroquine|Hydroxychloroquine to be administered intra-arterially at time of transarterial embolization as well as orally for 6 weeks following the procedure
40841980|NCT02786680|BEHAVIORAL|stroop test in condition DBS on|Patients were evaluated in DBS On
40841981|NCT01608451|DRUG|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
41025935|NCT00358735|DEVICE|ActiveCare CECT device|Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
40841982|NCT01608451|DRUG|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
40841983|NCT00640367|OTHER|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
40841984|NCT00640367|DRUG|Alteplase IV|intravenous recombinant tissue plasminogen activator
40841985|NCT01912534|DRUG|Valsartan|40, 80 and 160 mg tablets of Valsartan
41025936|NCT00358735|DRUG|Enoxaparin|Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
41025937|NCT04225845|BEHAVIORAL|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
41025938|NCT04225845|BEHAVIORAL|Cash transfer|One-time cash transfer of Rs.1000.
41025939|NCT06271551|DRUG|Transdermal estrogen|Participants (n=155) receiving transdermal estradiol for 12 months.
41025940|NCT06271551|DRUG|Active Comparator: Androgen deprivation therapy|Participants (n=155) receiving solely androgen deprivation therapy for 12 months.
41025941|NCT06271551|BEHAVIORAL|Resistance training|Participants (n=30 in each arm) performing supervised resistance training for six months.
41025942|NCT06021600|DRUG|Cladribine|Given by PO and Given by IV (vein)
41025943|NCT03554122|PROCEDURE|Shotblocker|Patients spinal injections were performed with Shotblocker placed onto injection site
41362630|NCT00676468|OTHER|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
41362631|NCT00003824|DRUG|cephalexin|500 mg oral bid for 3 days starting the night before resection
41362632|NCT00003824|PROCEDURE|surgical procedure|
41362633|NCT00003824|DRUG|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
41362634|NCT03720158|DIETARY_SUPPLEMENT|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy
40841986|NCT01912534|DRUG|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
41025944|NCT03554122|PROCEDURE|Placebo|Patients spinal injections were performed without Shotblocker
41160906|NCT06369883|DIAGNOSTIC_TEST|Spine radiography|Posterior-anterior and lateral spine radiography
41160907|NCT00985530|DRUG|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast \& dinner) during each 6 week cycle
41362635|NCT03720158|DIETARY_SUPPLEMENT|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
41362636|NCT02311764|DRUG|Carboplatin|Carboplatin will be administered weekly
41362637|NCT04298229|DRUG|Dapagliflozin 10 MG|SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
41362638|NCT04298229|OTHER|Protocolized Diuretic Therapy|Structured usual care arm with protocolized diuretic therapy based on urine output.
41025945|NCT04870567|RADIATION|Stereotactic ablative radiotherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
41025946|NCT04870567|RADIATION|High dose rate brachytherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
41025947|NCT06497010|DRUG|Biological: Tislelizumab|Intravenous (IV) infusion
41362639|NCT04805242|OTHER|Dextrose Prolotherapy Injection|"Subacromial injection: 5 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: Previously marked using a sterile 27 gauge injector (dental needle); A total of 10 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the infraspinatus, teres minor, supraspinatus insertion on the tuberculum majus, the subscapularis insertion on the tuberculum minus, the coracoid process and the long head of the biceps.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
41499707|NCT05842174|DRUG|Lipiodol|Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.
41025948|NCT06497010|DRUG|Biological: InnoPCV|Intramuscular (IM) injection
40841987|NCT00642863|DIETARY_SUPPLEMENT|Ferrous Sulfate (liquid) + vitamins A and D|a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
41025949|NCT04631666|BIOLOGICAL|DZIF-10c|SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion
41025950|NCT04631666|OTHER|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
41025951|NCT05754320|DEVICE|Tension band wire fixation|Tension band wire fixation
41025952|NCT05754320|DEVICE|Plate fixation|Tension band wire fixation
41025953|NCT05517343|OTHER|Real-time endoscopic optical diagnosis|The participants assigned to real-time notification group will received the endoscopic diagnosis of the resected colorectal polyps and recommended surveillance colonoscopy schedule right after the sedated colonoscopy.
41025954|NCT06338995|DRUG|LY3650150|Administered SC.
41025955|NCT06338995|DRUG|Placebo|Administered SC.
41025956|NCT06338995|DRUG|Standard therapy for INCS|Administered as intranasal spray.
41025957|NCT02528201|DRUG|Celecoxib 200 milligrams|Celecoxib 200 milligrams once a day
41025958|NCT02528201|DRUG|Celecoxib 400 milligrams|Celecoxib 400 milligrams once a day
41362640|NCT04805242|OTHER|Saline Injection|"Subacromial injection: 5 cc solution (saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: 5 cc solution (saline + 1% lidocaine solution) will be injected to the attachment areas of the previously marked tendons to the bone using a sterile 30 gauge injector.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
41499708|NCT05842174|DRUG|Placebo|Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
41025959|NCT02528201|DRUG|diclofenac 50 milligrams|diclofenac 50 milligrams three times a day
41025960|NCT01958918|DRUG|Ranibizumab|0.5 mg intravitreal injection
41025961|NCT01958918|DRUG|Aflibercept|2 mg intravitreal injection
41160908|NCT00985530|DRUG|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
40841988|NCT00642863|DIETARY_SUPPLEMENT|vitamins A and D|a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
41160909|NCT00935649|DEVICE|PinPointe FootLaser|Medical laser
41160910|NCT04208542|DRUG|ESP block|Ultrasound guided Erector spinae block (ESP) will perform.
41025962|NCT05809570|DIAGNOSTIC_TEST|Clinical examination|"A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient."
41362641|NCT00582842|BEHAVIORAL|Interview|The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
41362642|NCT00582842|BEHAVIORAL|survey instruments using Web-Based Data Collection System (WBDC) survey content|The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
41362643|NCT00532233|DRUG|QAX576|
41362644|NCT03600311|OTHER|Caloric Restriction|Participants will consume 15 kcal/kg FFM/day.
41025963|NCT04391231|DRUG|Pentoxifylline Oral Product|Blinded Pentoxifylline (in suspension with SyrSpend SF)
41362645|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Protein|Participants will ingest 30 g of protein following exercise.
41362646|NCT03600311|OTHER|Energy Balance|Participants will consume 40 kcal/kg FFM/day.
41362647|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Carbohydrate|Participants will ingest 30 g of carbohydrate following exercise.
40841989|NCT00642863|DIETARY_SUPPLEMENT|Ferrous sulfate (liquid)|Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
40841990|NCT04761848|DRUG|Cilostazol 50 MG|Cilostazol 50 MG tablet twice daily
40841991|NCT04761848|DRUG|Placebo|Placebo tablet twice daily
40841992|NCT03563365|OTHER|Replenix Power of 3 Cream with resveratrol|Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
41025964|NCT04391231|DRUG|Placebo|Placebo (SyrSpend SF only)
41025965|NCT04871139|PROCEDURE|Biopsy|Undergo biopsy
41025966|NCT04871139|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
41025967|NCT04871139|OTHER|Questionnaire Administration|Ancillary studies
41362648|NCT03600311|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
40841993|NCT03563365|DRUG|Adapalene and Benzoyl peroxide gel, 0.1%/2.5%|FDA approved topical agent for the treatment of acne
41362649|NCT00673075|DRUG|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
41362650|NCT00673075|DRUG|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
41362651|NCT02650518|OTHER|Short-course Antibiotics|3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
41362652|NCT02650518|DEVICE|Catheter Change|Urinary catheter change once randomization is complete.
41362653|NCT02361372|OTHER|Placebo|Placebo daily for 6 months
41362654|NCT02361372|OTHER|CaCO3|CaCO3 daily for 6 months
41362655|NCT02361372|OTHER|Kefir|Kefir daily for 6 months
41362656|NCT05290935|DRUG|Anti-PD-1 antibody camrelizumab|Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months
40841994|NCT04893421|DEVICE|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
40841995|NCT05943197|DIAGNOSTIC_TEST|dental prosthetics, biofilm response and oral microbiota|microbiota, biofilm, oral mucosa
40841996|NCT02657902|PROCEDURE|Fractures were treated with a Gamma 3 intramedullary nail|
40841997|NCT02657902|PROCEDURE|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
41025968|NCT04871139|OTHER|Radioactive Iodine|Given IV
41025969|NCT03857438|DRUG|Ongoing treatment for bipolar mania|Prescribed by the following doctor during hospitalization and after discharge
41025970|NCT03857438|DIAGNOSTIC_TEST|Audiovisual recording during guided presentation|Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures
41025971|NCT00907569|RADIATION|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
41025972|NCT01194115|DRUG|cephalexin & metronidazole|cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
41025973|NCT01194115|DRUG|placebo|placebo representing standard of care
41025974|NCT01231698|DRUG|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
41025975|NCT01231698|OTHER|control|standard treatment without strict heart rate control
41025976|NCT03096548|BEHAVIORAL|Sun Safety Ink! Program|The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
41362657|NCT05290935|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses
41362658|NCT06499129|BEHAVIORAL|Sensory ball, progressive relaxation exercise, training|The effect of sensory ball use on fatigue, peripheral neuropathy and anxiety will be examined
41362659|NCT00386529|DRUG|Aspirin enteric coated pellests 100mg|
41362660|NCT00517673|DRUG|GSK945237|
41362661|NCT00517673|DRUG|Sugar Pill|Placebo
41362662|NCT00809549|DRUG|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
41362663|NCT01967927|DRUG|18F-MISO|A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
40841998|NCT03613363|DEVICE|Helix Ventilator|The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.
41362664|NCT02251782|DEVICE|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
40841999|NCT05897697|OTHER|Interview|Structured interview
40842000|NCT00164957|DEVICE|continuous pump feeding|
40842001|NCT00164957|OTHER|intermittent bolus feeding|
40842002|NCT04495725|OTHER|Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products|We will randomize participants to one of the following four conditions for discounted vouchers: 1) a discounted voucher for a placebo soft-gel capsule product, 2) a discounted voucher for a high THC:low CBD soft-gel capsule product, 3) a discounted voucher for an equal THC:CBD soft-gel capsule product, or 4) a discounted voucher for a low THC:high CBD soft-gel capsule product. We will stratify randomization by history of cannabis use (no use in the past year, used in the past year and not near-daily or daily (used in the past year and \<20 days out of the last 30 days), near-daily or daily (\>= 20 days out of the last 30 days) baseline opioid analgesic prescription (chronic opioid treatment vs. not chronic opioid use), and primary pain condition (neuropathy, not neuropathy). Chronic opioid treatment is defined as prescribed opioids ≥90 non-overlapping days in the past 182 days. Randomization will occur in blocks to ensure equal randomization over time.
41362665|NCT02251782|DEVICE|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
41362666|NCT04730024|OTHER|Not applicable(observational study)|Not applicable(observational study)
41362667|NCT00103207|BIOLOGICAL|cetuximab|
41362668|NCT03570476|DRUG|Olaparib|Given orally
41362669|NCT03570476|PROCEDURE|Radical Prostatectomy|Undergo surgery
41362670|NCT03676712|DEVICE|scoliosis brace|Wear at least 18 hours a day
41362671|NCT05136989|BEHAVIORAL|Individual and collective semi-structured interviews|Individual and collective semi-structured interviews will be performed with professionals to identify levers (practices, knowledge, tools, regulations) which, at the level of services and establishments, enable the development of a policy of less recourse to coercion
41362672|NCT05136989|BEHAVIORAL|Individual semi-structured interviews with ex-patients|Individual semi-structured interviews will be performed with ex-patients in order to gather their experiences in the seven institutions concerned and to better understand the impact of their hospitalization in these institutions on their lives
41362673|NCT05136989|BEHAVIORAL|Observations out in the services|Observations will be carried out in the services in order to measure the gap between rhetoric and practice, and to observe the effective implementation of lesser use practices
41362674|NCT03834857|DEVICE|Stentrode|Implantation of Stentrode device
41362675|NCT01031784|DEVICE|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
41362676|NCT01031784|DEVICE|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
41362677|NCT01042561|DIETARY_SUPPLEMENT|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
41362678|NCT01042561|DIETARY_SUPPLEMENT|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
41362679|NCT00783055|OTHER|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
41499709|NCT04005352|BIOLOGICAL|Brolucizumab 6 mg|Intra-vitreal injection
41499710|NCT04005352|BIOLOGICAL|Aflibercept 2 mg|Intra-vitreal injection
41499711|NCT03265418|DEVICE|BioXmark liquid fiducial markers|Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).
41362680|NCT02561689|OTHER|Fissure sealing|"Procedure:~* The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~* Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~* The occlusal surface is sealed by the dentist or dental hygienist.~* Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years"
41499712|NCT03265418|OTHER|Imaging|"As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.~As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy."
41499713|NCT03265418|PROCEDURE|surgery or wait-and-see|"As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol."
41499714|NCT00335114|DRUG|cyclosporine ophthalmic emulsion|
40842003|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System|The LX2.3 Laser and LED Photobiomodulation system by THOR Photomedicine Ltd is a CE marked product and has a long track record of safety, usability, and effectiveness.
40842004|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System Sham-PBMT Setting|The sham setting consists of light of the same colour (white light with a red filter), applied in the same way as in the experimental group.
40842005|NCT02392403|DEVICE|Nucleus CI532 cochlear implant|
41362681|NCT03339440|BEHAVIORAL|Hearts & Parks|The Hearts \& Parks intervention will be looking to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) through attendance and participation in the Duke Healthy Lifestyles/Bull City Fit clinic/community program, affect children's health. The investigators will be looking at changes in BMI, physical activity, nutrition and overall health.
41362682|NCT01832272|PROCEDURE|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
41362683|NCT05894187|OTHER|animated video|Participants randomized to the intervention group will receive a link to a short survey gauging parent anxiety levels three days prior to their childs surgery date. If randomly assigned to watch the informative animated video, the survey will be followed by a link to a video which families are free to watch prior to your child's surgery date. Once participants and there family watch the video, they will be asked to rate the quality of the video on a scale of 0 (very bad) to 10 (excellent). Responses to this question will be used to confirm that participants watched the video to the end.
41362684|NCT01452685|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
41362685|NCT01452685|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
41362686|NCT01452685|DRUG|TAK-385|TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
41362687|NCT01452685|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
41362688|NCT01452685|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
41362689|NCT02280382|DEVICE|Femmeze®|Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
41362690|NCT02106715|OTHER|Training|Two exercises for training of core stability and mobility.
41362691|NCT00689299|BIOLOGICAL|Standardized Allergenic Extract, Cat Hair|Standardized Cat Hair Allergenic Extract sublingual drops
41362692|NCT00689299|BIOLOGICAL|Placebo|Placebo Sublingual Drops
41362693|NCT04370808|OTHER|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
41362694|NCT01004159|DRUG|cetuximab with irinotecan|Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
41362695|NCT04305158|DRUG|Nitrous Oxide|Patient receiving nitrous oxide are evaluated for success of the procedure
41362696|NCT00768040|DRUG|Aliskiren|300 mg once daily
41362697|NCT00768040|DRUG|Placebo|Matching placebo once daily
41362698|NCT05943340|OTHER|Proprioceptive exercises|Specific proprioceptive exercises for the shoulder that the patient has to do during the immobilization period.
41362699|NCT01828346|DRUG|Birinapant|"Dose escalation part: (Drug escalation dose levels)~* Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)~* Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR~* Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)"
41362700|NCT01828346|DRUG|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
41362701|NCT03491527|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
41362702|NCT03491527|PROCEDURE|Manipulation of the resin cement with MTA|Manipulation of the resin cement with MTA according to the manufacturer's recommendations.
40842006|NCT02209623|BIOLOGICAL|TDAP|
40842007|NCT06130982|BEHAVIORAL|Health Qigong·Yijinjing|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Yijinjing:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
40842008|NCT06130982|BEHAVIORAL|Health Qigong·Wuqinxi|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Wuqinxi:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
40842009|NCT06130982|BEHAVIORAL|Health Qigong·Baduanjin|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Baduanjin:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
40842010|NCT06130982|BEHAVIORAL|Walking|1-8weeks:While the experimental group received intervention, the control group underwent walking exercise. The intervention frequency is the same as the experimental group: 1 time/day, 5times/week,30 minutes/time, the total duration controlled within 50 minutes, and includes 3 contents.Warm up activity:head movements,neck movements,shoulder movements, chest expansion exercise,waist rotation,body rotation, lunge movements,leg movements,knee joint movements,ankle movements(15 min).Walk around the track and field (30 min).Cool down (5min) 8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
40842011|NCT00495378|DRUG|epoetin alfa|
40842012|NCT03485196|OTHER|Microsatellite instability|The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
40842013|NCT01147900|BIOLOGICAL|Boostrix™|Intramuscular, single dose
40842014|NCT01147900|BIOLOGICAL|Boostrix™-US formulation|Intramuscular, single dose
40842015|NCT00694304|DRUG|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
41025977|NCT03096548|BEHAVIORAL|Attention Control|Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
41499715|NCT06634225|DIAGNOSTIC_TEST|Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test|Patients will receive the care they need, in line with HAS recommendations. They will be asked to perform two gait analysis tests on a three-dimensional platform, equipped with sensors (medical device).
41499716|NCT02205190|DRUG|Fimasartan|
41499717|NCT02205190|DRUG|Rosuvastatin|
41499718|NCT02205190|DRUG|Fimasartan/Rosuvastatin combination|
41499719|NCT05129007|DEVICE|Oura ring|Photopletysmography based noninvasive device
41499720|NCT03393663|OTHER|CKD-related outcomes|the study is observational
41499721|NCT04730648|DRUG|PCSK9 inhibitor|For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.
41499722|NCT02695810|DRUG|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
41499723|NCT02695810|DRUG|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
41499724|NCT02695810|BEHAVIORAL|Exercise|Interval training, 5 times per week, 30 min per session
41499725|NCT00253448|RADIATION|radiation therapy|No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
41499726|NCT00253448|RADIATION|stereotactic radiosurgery|stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy
41499727|NCT02836210|DEVICE|27-gauge vitrectomy wound construction|Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
41499728|NCT06017024|DEVICE|microprocessor-controlled knee (MPK) assessment|The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests
41025978|NCT02779179|PROCEDURE|Periodontal treatment|"* Mechanical debridement (scaling, root planning, subgingival curettage)~* Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~* Antiseptic mouthrinses, gel or dentifrice~* Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
41025979|NCT05418621|DRUG|Enamel Matrix Derivative application|in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
41025980|NCT05418621|OTHER|Saline application|in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
41025981|NCT03059173|DIETARY_SUPPLEMENT|Myo-Inositol + Levomefolic acid|Dietary supplement Gynositol® MTHF containing myo-inositol (4 g) and Levomefolic acid on glucosamine salts(0.736 mg) in a same bags Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.
41025982|NCT03059173|DRUG|Clomiphene Citrate|Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
41362703|NCT03491527|PROCEDURE|Manipulation of the resin cement without MTA|Manipulation of the resin cement without MTA according to the manufacturer's recommendations.
41499729|NCT00224419|BEHAVIORAL|Motivational interviewing for smoking cessation|All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
41499730|NCT00224419|BEHAVIORAL|Cognitive behaviors therapy|6 counseling sessions delivered over the phone or in person
41499731|NCT00224419|DRUG|CBT + NRT|Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
41499732|NCT05901649|DRUG|Apalutamide|No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.
41499733|NCT05901649|DRUG|Enzalutamide|No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.
41499734|NCT05187390|PROCEDURE|VATS application|The chronic pain findings of the patients who underwent VATS will be questioned at the postoperative 1st and 3rd months.
41499735|NCT00401609|DRUG|gemcitabine|
41499736|NCT00401609|DRUG|vinorelbine|
41499737|NCT00401609|DRUG|cisplatin|
41499738|NCT00401609|DRUG|etoposide|
41499739|NCT00401609|DRUG|carboplatin|
41499740|NCT00448383|BIOLOGICAL|adalimumab|40mg every other week
41499741|NCT06186180|OTHER|inspiratory muscle training|They will perform 5 sets of 10 repetitions with a 1-minute rest between sets, 5 days a week, using a specific respiratory muscle training device
41499742|NCT00553306|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
41499743|NCT00553306|BIOLOGICAL|aldesleukin|Given subcutaneously
41499744|NCT00553306|DRUG|cyclophosphamide|Given IV
41499745|NCT00553306|PROCEDURE|biopsy|Optional correlative studies
41025983|NCT03059173|DIETARY_SUPPLEMENT|placebo|a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
41362704|NCT03491527|PROCEDURE|Fiber Post cimentation|Insertion of the cement on the root canal and on post surface. Light-cured for 40 seconds on each surface.
41499746|NCT00553306|OTHER|immunohistochemistry staining method|Optional correlative studies
41499747|NCT00553306|OTHER|flow cytometry|Correlative studies
41499748|NCT00553306|GENETIC|polymerase chain reaction|Correlative studies
41499749|NCT02842138|BIOLOGICAL|autologous anti-CD19 CAR T cells|Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
41499750|NCT04744883|OTHER|Spinal Manipulation Therapy (SMT)|2 SMT techniques are administered each session, both of which are scripted interactions between the physical therapist (PT) providing the SMT and the subjects: 1) Participants will lie on the SMT table for 20 mins, while the PT sits approximately 6 ft away. As part of the script, the PT will review with subjects the inclusion/exclusion criteria ostensibly to ensure that nothing has changed. 2) The PT will perform the 2 SMT techniques during the next 20 mins. 3) Subjects will sit upright in a chair for the remaining 20 mins, while the PT sits approximately 6 feet away. The PT will review home exercises with participant.
41025984|NCT06559488|DRUG|Bevacizumab Injection [Avastin]|Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.
41362705|NCT03491527|PROCEDURE|Dental Prepare|Confection of a indirect crown prepare with diamand burs.
41362706|NCT03491527|PROCEDURE|Dental impression|Dental impression whith silicone.
41362707|NCT03491527|PROCEDURE|Crown cimentation|Insertion of the cement on the inner surface of the crown. Light-cured for 40 seconds on each surface.
41362708|NCT03491527|PROCEDURE|Occlusal adjustment|Analysis of the occlusion with carbon paper.
41499751|NCT04744883|DRUG|Naloxone|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
41362709|NCT03955068|OTHER|Strict Classic Ketogenic Diet|Diet is administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates.
41362710|NCT02049385|DRUG|Diazoxide|A nondiuretic vasodilator thiazide-related agent
41025985|NCT06559488|PROCEDURE|Pars Plana Vitrectomy|routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients
41362711|NCT02049385|DRUG|Placebo|Placebo
41499752|NCT04744883|DRUG|Placebo|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
41499753|NCT04744883|BEHAVIORAL|Mindfulness Based Stress Reduction Therapy (MT)|Each MT session consists of (a) body scan meditation accompanied by awareness of breathing and other bodily sensations while in a lying position, (b) sitting meditation, focusing on awareness of breathing, bodily sensations, thoughts, and emotions (c) gentle movement exercises intended to develop awareness (mindfulness) during movement. In-session activities include suggestions for application of mindfulness as a method for responding positively to stress; dealing with the challenges of pain; and exercises focusing on the challenges and achievements patients experience in integrating mindfulness into their lives and the stressful situations they encounter. Additional discussion will focus on stress reactivity and they will be taught problem-solving skills to develop solutions to meet MT goals. Finally, patients will develop a written maintenance plan that includes a list of short- and long-term goals for applying mindfulness methods and a plan for dealing with possible setbacks.
41499754|NCT06414902|DRUG|ArabinoFuranosylGuanine [18F]F-AraG|Given by IV
41499755|NCT02153463|BEHAVIORAL|Physical Activity Counselling|Physical Activity Counselling weekly for 8 weeks
41025986|NCT06222996|BEHAVIORAL|vaccine hesitation training|Training will be given to primiparous expectant mothers on vaccine hesitation with the support of the web page created by the researcher
41025987|NCT06377839|BIOLOGICAL|Advanced platelet-rich fibrin in the ekstraction socket|Advanced platelet-rich fibrin is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Advanced platelet-rich fibrin is manufacturing from a blood sample.
41025988|NCT04443218|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient mitral valve.
40842016|NCT00711789|DRUG|Angiotensin II|Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol
40842017|NCT00711789|DRUG|Saline placebo|Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
40842018|NCT05533320|DEVICE|Cold Cap Therapy|Undergo scalp cooling
41362712|NCT05723172|DEVICE|active tACS|40 mins tACS for 10 consecutive daily sessions
41362713|NCT05723172|DEVICE|sham tACS|40 mins sham tACS for 10 consecutive daily sessions
41362714|NCT01505426|DRUG|ASP1941|oral
41362715|NCT01505426|DRUG|metformin|oral, concomitant use
41362716|NCT01505426|DRUG|Placebo|oral
41362717|NCT02711306|DIETARY_SUPPLEMENT|Glucomannan noodle|The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
41499756|NCT01884337|DRUG|Apixaban|
41499757|NCT06634056|DRUG|Pentoxifylline|Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
41499758|NCT06634056|OTHER|Placebo|One placebo orally three times a day and another placebo orally two times a day on day one of radiotherapy and continue treatment for 6 months.
41499759|NCT06634056|OTHER|α-Tocopherol|Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
41499760|NCT06349941|DEVICE|Movn app|Participants will receive a FitBit accelerometer to monitor physical activity. Participants will have a 2 week run-in period where physical activity levels will be monitored followed by a 12-week home-based exercise program delivered via a previously validated, commercially available smartphone platform called Movn (Moving Analytics, California)
40842019|NCT05533320|OTHER|Quality-of-Life Assessment|Ancillary studies
40842020|NCT05533320|OTHER|Questionnaire Administration|Ancillary studies
40842021|NCT05985096|DIAGNOSTIC_TEST|Virtual reality group|Participants in this group will be expected to meet their physical activity levels using the Oculus Quest 2 VR Goggles platform with Racket, Climb, Acron, Skiing, Cycling games.
41025989|NCT02711657|OTHER|Fibrocyte measurement and lung function test.|
41362718|NCT02711306|DIETARY_SUPPLEMENT|Placebo noodle|In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
41362719|NCT06448520|OTHER|Muscle Power Sprint Test|The Muscle Power Sprint Test (MPST) is an easy-to-perform field test of anaerobic capacity for children and adolescents. The only necessities for the administration of this test are an open space, a stopwatch and two cones or lines. Test subjects are encouraged to perform six 15-meter sprints at a maximal pace between the two cones/lines, with a 10-second rest in between each effort. The distance covered during these short runs corresponds well to the distances children cover during daily play activities. The power that is generated with each sprint can be calculated using the formula: power = (total mass x 15 m²)/time³.
41025990|NCT03947645|DEVICE|Ipsilesional stimulation|Device: ipsilesional transcranial stimulation, neuromuscular Stimulation over target muscle
41025991|NCT03947645|DEVICE|Contralesional stimulation|Device: contralesional transcranial stimulation, neuromuscular stimulation over target muscle
41362720|NCT00005068|DRUG|fluorouracil|
41362721|NCT00005068|DRUG|irinotecan hydrochloride|
41362722|NCT00005068|DRUG|leucovorin calcium|
41025992|NCT05890053|DRUG|HSK16149 40mg BID|HSK16149 40mg ， orally twice a day, treatment period; 52-weeks fixed dose.
41362723|NCT00005068|DRUG|oxaliplatin|
41025993|NCT00575848|DIETARY_SUPPLEMENT|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
41362724|NCT00967473|DEVICE|ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
41362725|NCT00664729|BEHAVIORAL|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
41362726|NCT00664729|BEHAVIORAL|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
41362727|NCT00664729|BEHAVIORAL|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
41362728|NCT02892357|DRUG|Treatment group|Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
41362729|NCT02892357|DRUG|Control group|sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
41362730|NCT02112396|BEHAVIORAL|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
41362731|NCT05460728|OTHER|Dry needling|A three-weekly session of DNT was administered with an acupuncture needle (0.30 × 50 mm; Huan Qiu, Suzhou, China). For each session, DNT was applied in the deltoid, biceps brachialis, wrist extensors and flexors, thenar muscles, vastus medialis, gastrocnemius medialis, and tibialis anterior (Hong, 1994). Following focal twitch responses (maximum three), the dry needle was left inserted for 15 minutes in each muscle.
41362732|NCT00617942|DRUG|Cohort 1 neo-adjuvant|"Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16"
41362733|NCT00617942|DRUG|Cohort 2 neo-adjuvant|Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
41362734|NCT00617942|DRUG|Cohort 1 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
41362735|NCT00617942|DRUG|Cohort 2 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
41362736|NCT04033718|DIAGNOSTIC_TEST|Inpatient lab bundling|The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.
41362737|NCT04033718|BEHAVIORAL|Inpatient navigation|Participants will be assigned a patient navigator who will support the patient and bedsider (treatment supporter/guardian) during the hospitalization. The navigator will be an HIV counselor who can provide counseling and health education, as well as support specimen transport, obtaining results, booking tests in other departments, linkages to ART clinic, and discharge planning
41362738|NCT06118853|BEHAVIORAL|yoga or gentle massage plus standard treatment for HSCT|The yoga sessions will be conducted at the patient's bedside, using one or more of the following techniques: gentle stretches (asanas), guided relaxation (savasana), slow and deep diaphragmatic breathing (pranayama), and meditative exercises focusing on natural breathing or visualization of a soothing place (dhyana). From these techniques, the integrative therapist will choose what best suits the patient for each session, based on their psychophysical state and symptoms presented, as there can be many variations during HSCT. Gentle massage is characterized by soft touches using light pressure, primarily using the palm of the hand, with a slow and steady rhythm across the entire body. It can be performed over clothing or even over the bedsheet and blanket.
41362739|NCT00954356|DRUG|XPF-001|Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
41362740|NCT00954356|DRUG|placebo|Single oral administration of 5 x 100 mg Placebo capsules.
41362741|NCT05033106|DRUG|Bevacizumab, Ranibizumab|• A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant and 0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye 1 mm posterior to the superior/inferior temporal limbus via 30 G needle. The two injections are done sequentially on two consecutive days starting with the eye of more advanced disease.
41266785|NCT03075163|DRUG|Ondansetron|Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
41362742|NCT04247802|OTHER|Backwards Walking (BW) programme|A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.
41362743|NCT04247802|OTHER|Usual Care|A 12 week physiotherapy exercise programme EXCLUDING backwards walking
41362744|NCT04390620|DEVICE|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
41362745|NCT04967729|DEVICE|Device: Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
41362746|NCT02276274|DRUG|SYR-322-MET|Oral administration of SYR-322-MET
40842022|NCT04956458|PROCEDURE|Lumbar motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
41362747|NCT02514889|BEHAVIORAL|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
41362748|NCT02514889|BEHAVIORAL|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits \& vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
40842023|NCT04956458|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
40842024|NCT03243175|DRUG|Apixaban 5 MG|Apixaban 5mg x 2 during 24 months
41362749|NCT04043676|DRUG|Ponatinib|All patient will take 15 mg/day ponatinib oral during 48 weeks.
41362750|NCT03736122|DRUG|BSG-001|"BSG-001 is in solution form, 4mg per vial (2mg/mL) with Inhalation as route of administration using nebulizer.~BSG-001 will be administrated as an approximately 5 - 30 minutes inhalation session daily for 3 cycles (in repeated 28 days cycle)."
40842025|NCT03243175|DEVICE|left atrial appendage closure|left atrial appendage closure
40842026|NCT02540265|DRUG|N1539|
40842027|NCT02540265|DRUG|Intravenous Placebo|
40842028|NCT04680949|DRUG|Anakinra|Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
40842029|NCT04680949|DRUG|Placebo|Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
40842030|NCT06354387|DRUG|Alectinib (Alecensa), Nivolumab (Opdivo)|Alectinib (Alecensa) in Combination with Nivolumab (Opdivo)
41499761|NCT04864314|DIETARY_SUPPLEMENT|Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity|Participants in the Experimental group will receive a daily dose of 250 mg of TetraSOD® in a capsule during 90 days. After treatment, the group will stop consumption of TetraSOD® and a wash-out period of three months will start
40842031|NCT01467388|PROCEDURE|selective laser trabeculoplasty (SLT)|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
40842032|NCT00001410|DRUG|Lysodase|
40842033|NCT04345172|DEVICE|sub-Tenon's block with a lacrimal dilator group or a Wescott scissors|"Local anaesthetic eye drops were installed into the conjunctiva, followed by iodine 5% aqueous drops to the conjunctival sac for 3 minutes.19 An eye lid speculum was inserted.~In group LD, the conjunctiva and Tenon's capsule were lifted together tightly with a blunt forceps like a tent in the inferonasal quadrant and a punctal dilatator (Castroviejo Lacrimal Dilatator, Katena Products, Inc, Denville, NJ, USA) was placed tangential to the globe creating a round and small hole at 5 mm posterior to limbus (Fig.1). The block was performed using smooth rounded tip, 19 G, 1 inch sub-Tenon's cannula (Visitec, Beaver-Visitec International Ltd, Warwickshire, UK).~In Group WS, after lifting the conjunctiva and Tenon's capsule together with a blunt forceps, incision was performed with a blunt tip Westcott scissors in the inferonasal conjunctival at 5 mm posterior to limbus to expose sub-Tenon's space."
40842034|NCT01987583|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
40842035|NCT01987583|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
40842036|NCT01879046|PROCEDURE|arthroplasty|Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
40842037|NCT03888209|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
40842038|NCT05178485|DRUG|Bupivacain|FDA approved drug
40842039|NCT05178485|OTHER|Normal Saline|FDA approved
40842040|NCT04137250|PROCEDURE|Hamstring|The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament
40842041|NCT04137250|PROCEDURE|Quadriceps tendon|orThe intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
40842042|NCT00472966|DRUG|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
40842043|NCT02351284|OTHER|Measurement|Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
40842044|NCT02231385|DRUG|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
40842045|NCT00196768|DRUG|Arsenic trioxide|
40842046|NCT00196768|DRUG|Trisenox|
40842047|NCT01302054|DRUG|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
40842048|NCT01302054|DRUG|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
40842049|NCT01452919|DRUG|LY2140023|Administered orally
40842050|NCT01452919|DRUG|Placebo|Administered orally
40842051|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
40842052|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
40842053|NCT04190277|DEVICE|Open-loop condition|Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
40842054|NCT04190277|DEVICE|Closed-loop condition|Closed-loop algorithm system paired with continuous glucose monitoring sensor
41025994|NCT00575848|DIETARY_SUPPLEMENT|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
41025995|NCT02448303|DRUG|Pembrolizumab|
41025996|NCT02448303|DRUG|Acalabrutinib|
41025997|NCT03197493|DRUG|carbidopa-levodopa 25-100 mg|High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
41025998|NCT00357305|DRUG|vorinostat|Given orally
41025999|NCT00357305|DRUG|cytarabine|Given IV
41362751|NCT04456114|DEVICE|Acid etched brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
40842055|NCT02356679|DRUG|Eupasidin-s Tab|three times per day, 1 tab for each time, PO, during 2weeks
40842056|NCT02356679|DRUG|Stillen Tab.|three times per day, 1 tab for each time, PO, during 2weeks
40842057|NCT01656694|DEVICE|DePuy Sigma HP Partial Knee|
40842058|NCT02110797|OTHER|biological markers and evaluation of the mineral density at the lumber spine using DEXA|
40842059|NCT03908476|DEVICE|Burst-capable SCS system|Subjects will be given Burst stimulation using a market-released Abbott SCS system. Burst stimulation may be achieved through surgical or non-surgical means.
41026000|NCT00357305|DRUG|etoposide|Given IV
41026001|NCT00357305|OTHER|pharmacological study|Correlative studies
41026002|NCT00357305|OTHER|laboratory biomarker analysis|Correlative studies
41026003|NCT05590091|OTHER|Parenteral nutrition;Enteral nutrition|The intelligent nutrition management system was used to carry out standardized nutrition management of patients after hematopoietic stem cell transplantation
41026004|NCT05557279|DRUG|500 mg NDS-446|All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
41026005|NCT05378945|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
41362752|NCT04456114|DEVICE|Sandblasted brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
41362753|NCT01403324|DRUG|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
40842060|NCT03908476|DEVICE|DRG Stimulator|Subjects will be implanted with a market-released Abbott DRG stimulation system.
40842061|NCT01966445|BIOLOGICAL|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
40842062|NCT05656781|OTHER|Brief Intervention and Contact (BIC) based on Word Health Organization (WHO)|Intervention based on: Clinical WHO - SUICIDE PREVENTION DOCUMENT MULTISITE INTERVENTION STUDY ON SUICIDAL BEHAVIOURS - SUPRE-MISS: PROTOCOL OF SUPRE-MISS. Brief Intervention and Contact with participants using follow up questions about mood or any suicide attempts.
40842063|NCT04522349|DEVICE|Greifer then Axon-Hook|Each participant is fitted with a Greifer and assessed after two weeks home-trial. Then he is fitted with Axon-Hook and assessed after two weeks home trial.
40842064|NCT04522349|DEVICE|Axon-Hook then Greifer|Each participant is fitted with a Axon-Hook and assessed after two weeks home-trial. Then he is fitted with Greifer and assessed after two weeks home trial.
41026006|NCT05378945|DRUG|Placebo (vehicle)|Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
41026007|NCT00721994|DEVICE|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
41026008|NCT00475826|DRUG|Statins and Ezetimibe|
41026009|NCT00520416|PROCEDURE|Carbon dioxide angiogram|see description of procedure
40842065|NCT01143584|DRUG|Cabergoline|"In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.~Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point."
40842066|NCT01143584|DRUG|cabergoline|"In the Rapid escalation group schedule of cabergoline dosing will be as follows:~Begin with 0.5 mg twice a week~1. mg twice a week - second week 1.5 mg twice a week - third week~2. mg twice a week - fourth week~4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also \>50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk."
40842067|NCT00120328|DRUG|SPP301|
40842068|NCT02706665|OTHER|SEDline monitor|The SEDline monitor gives us the Patient State Index (PSI), a dimensionless number within a range of 0 to100.
40842069|NCT03845595|DEVICE|(LF-rTMS) group|"The (LF-rTMS) (low frequency repetitive transcranial magnetic stimulation) group received 1-hertz (HZ) stimulation at 90% of motor threshold to the hot spot of the primary cerebral cortex, using a 70-mm figure- 8 coil and Magstim Rapid2 stimulator (Magstim Company, USA). Contralesional 1 HZ \*rTMS\* applied over the primary motor area hot spot at 90% of Active motor threshold . Each rTMS session consisted of 1,200pulses; lasting 20 minutes The optimal site of stimulation on the skull are known as the hot spot . Hot spots were found by searching for loci that triggered maximum visible contraction in the contralateral first dorsal interosseous \*FDI\* muscle, while the patient is contracting his whole limb as much as possible ."
40842070|NCT03845595|OTHER|Control group|neurodevelopmental technique (NDT) ( including Bobath and Brunnstrom approaches , proprioceptor and exteroceptor stimulation for the weak and inhibition for the hyperactive muscle groups, proprioceptive neuromuscular facilitation (PNF) specific techniques, Approximation and weight bearing, placing technique). Task-oriented training (moving, grasping and releasing bottles ,cups , small toys). Active participation of the whole hemiparetic upper extremity in different motor task training with coordination and Bilateral arm training exercise.
40842071|NCT01393938|OTHER|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
40842072|NCT03161574|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
40842073|NCT02273960|DRUG|BMS-986004 75 mg IV|BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
40842074|NCT02273960|DRUG|BMS-986004 225 mg IV|BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
40842075|NCT02273960|DRUG|BMS-986004 675 mg IV|BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
40842076|NCT02273960|DRUG|BMS-986004 1500 mg IV|BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
40842077|NCT04677127|BEHAVIORAL|Health Belief Model and Health Literacy Level based Education and Counseling|Patients given education and counseling constructed with health belief model (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cue to action, self-efficacy). The constructed education given through groups dichotomised by health literacy levels (low/high). Groups of 11-13, had weekly educations for 6 weeks, 6 weeks of counselling and 12 week of follow-up.
40842078|NCT03003507|DIETARY_SUPPLEMENT|Enteral Formula With Fructose|Low-carbohydrate Enteral Formula With Fructose
40842079|NCT03003507|DIETARY_SUPPLEMENT|Enteral Formula Without Fructose|Low-carbohydrate Enteral Formula Without Fructose
41499762|NCT04864314|DIETARY_SUPPLEMENT|Sham|Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days. After treatment, the group will stop consumption of placebo and a wash-out period of three months will start
40842080|NCT04672421|DEVICE|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after laparoscopic surgery)
41499763|NCT04925193|DRUG|Selinexor|Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).
40842081|NCT04672421|DEVICE|Placebo|No device after laparoscopic surgery
40842082|NCT05788913|BIOLOGICAL|Heparin|subcutaneous Heparin
40842083|NCT02533895|BIOLOGICAL|AV0113 DC-CIT|Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
40842084|NCT02533895|OTHER|Data evaluation|"For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc"
40842085|NCT03150277|BEHAVIORAL|Plyometric exercise|2 sets of 10 ankle hops, 3 sets of 5 hurdle hops, 5 drop-jumps from a height of 50 cm
41499764|NCT04925193|DRUG|Pomalidomide|Oral Table
41499765|NCT04925193|DRUG|Daratumumab|Injection
41499766|NCT04925193|DRUG|Carfilzomib|Injection
41499767|NCT04925193|DRUG|Dexamethasone|Oral tablet or injection
41499768|NCT00759187|DRUG|Fluoride|Brush twice daily
41499769|NCT00759187|DRUG|Triclosan/Fluoride|Half mouth toothbrushing twice daily for 4 days
41499770|NCT00759187|DRUG|Chlorhexidine Gluconate|Mouth rinsing twice a day for 4 days
41499771|NCT06634316|OTHER|Mediterranean diet|Mediterranean diet recommendations and daily physical exercise
40842086|NCT03150277|BEHAVIORAL|Heavy resistance exercise|10 single repetitions of back half squats at 90% of 1 repetition maximum
40842087|NCT02024126|OTHER|Exercise therapy|Exercise therapy
41026010|NCT01191489|DEVICE|High Flow Conditioned Oxygen Therapy in High Risk Patients|OptiFlow system (R) with nasal cannula.
41362754|NCT05657301|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
41499772|NCT06634316|DIETARY_SUPPLEMENT|Hypercaloric, hyperproteic oral nutritional supplement|Hypercaloric, hyperproteic oral supplement combined with Mediterranean diet recommendations (2 per day) and daily physical exercise
40842088|NCT01142427|OTHER|Cytology Specimen Collection Procedure|Correlative studies
40842089|NCT01142427|OTHER|Laboratory Biomarker Analysis|Correlative studies
40842090|NCT00479479|DRUG|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
40842091|NCT01722435|DRUG|Opiate Substitution Treatment|
40842092|NCT04599036|DEVICE|MARK|EMG controlled arm orthosis
41026011|NCT01191489|DEVICE|Non-invasive mechanical ventilation|Bilevel pressure support through a facial mask
41026012|NCT01191489|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.
41362755|NCT04435951|OTHER|Evaluation|No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.
41499773|NCT06634316|DIETARY_SUPPLEMENT|Protein module|Protein module (10g/day) combined with Mediterranean diet recommendations and daily physical exercise
40842093|NCT01331967|DRUG|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
40842094|NCT04351724|DRUG|Chloroquine or Hydroxychloroquine|Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available
41026013|NCT04192097|OTHER|Professionalism curriculum|"One year training program including ten two-hours sessions about~* Knowing yourself~* Interaction with patients and their families~* Teamwork and organization with colleagues"
41026014|NCT05912946|DRUG|Interferon|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. Interferon solution was configured according to the ratio of 3 million IU interferon +49ml normal saline. The urinary tube was clamped and the interferon solution was injected through the water inlet tube and retained for 30 minutes.
41026015|NCT05912946|DRUG|Sodium Hyaluronate|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sterile sodium hyaluronate solution was injected through the water inlet tube and retained for 30 minutes.
41026016|NCT05912946|DRUG|Sodium Chloride Injection|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sodium chloride injection was injected through the water inlet tube and retained for 30 minutes.
41362756|NCT04025736|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
41499774|NCT06634316|COMBINATION_PRODUCT|Vitamin D supplementation|Calcifediol supplement administered orally in order to reach sufficiency levels (30 ng/ml)
40842095|NCT04351724|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir 200mg/50mg 2-0-2
41362757|NCT04025736|DRUG|0.9% Sodium Chloride Injection|Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
41362758|NCT00000515|BEHAVIORAL|diet, reducing|
41362759|NCT05778734|BEHAVIORAL|CM-PST|CM-PST is a tailored behavioral intervention that enables young adults with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake.
41362760|NCT05778734|BEHAVIORAL|CM only|CM is a behavior therapy that rewards individuals for evidence of positive change (alcohol abstinence).
41362761|NCT00336960|DRUG|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
41362762|NCT00336960|DRUG|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
41362763|NCT00336960|PROCEDURE|conventional surgery|4-10 weeks after completion of chemoradiotherapy
41362764|NCT00336960|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
41362765|NCT00336960|PROCEDURE|tumor biopsy|at baseline and then at the time of surgical resection
41362766|NCT00336960|OTHER|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
40842096|NCT04351724|OTHER|Best standard of care|best standard of care
40842097|NCT04351724|DRUG|Rivaroxaban|2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable
40842098|NCT04351724|DRUG|Thromboprophylaxis|as local standard, most likely to be low molecular weight heparin
40842099|NCT04351724|DRUG|Candesartan|starting dose 4mg once daily, titrated to normotension
40842100|NCT04351724|DRUG|non-RAS blocking antihypertensives|This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others
41362767|NCT05000034|PROCEDURE|Weaning protocol|Application of a weaning protocol from the mechanical ventilation
41362768|NCT03419481|DRUG|pembrolizumab|200mg every 3 weeks infusion
41362769|NCT01884935|BIOLOGICAL|Natalizumab|As specified in the treatment arm
41362770|NCT02120573|OTHER|Workshop using Lecture and human model|workshop to teach CPR with lecture and human models
41362771|NCT02120573|OTHER|Workshop using Educational Film|workshops using film review about CPR
41362772|NCT02120573|OTHER|Workshop using Lecture, human model as well as Educational Film|using educational films and human model and lecture for training
41362773|NCT02120573|OTHER|Workshop using Lecture, human model, Educational Film as well as reference book|training volunteers with lecture, films, and human models and giving them reference book for referral
41362774|NCT00915226|PROCEDURE|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
41362775|NCT00915226|PROCEDURE|Squatting|Squatting
41362776|NCT03550040|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
41362777|NCT04951557|PROCEDURE|Transsphenoidal resection|Transsphenoidal resection of pituitary adenoma
41362778|NCT04796649|DEVICE|B-Cure laser pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
41362779|NCT04796649|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
41026017|NCT05237765|OTHER|controlled (automatic) massage|Massage methods that are performed with mechanical methods are called automated massage. Automated massage is also individual-controlled massage. This is because in automated massage, to relax, solve or reduce their pain, the individual applies the massage under their own control or under the control of someone else through a controller in a way where the duration and intensity of the massage in the body part of application vary. Individual-controlled massage devices may be in the form of chairs, cushions, beds and mattresses. These massage devices have functions such as vibrating, applying vacuum, imitating manual massage motions and applying heat.
41026018|NCT00173667|DRUG|Nifedipine 30 mg GITS|
41362780|NCT05896605|DRUG|Azathioprine|Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
41362781|NCT02819882|OTHER|No intervention|
41026019|NCT05811377|DRUG|Ferumoxytol|After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.
41026020|NCT05811377|DRUG|Gadobutrol|After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.
41026021|NCT05454293|OTHER|One Talk at a Time: Race|This intervention consists of short videos that include didactic modules and social modeling for having conversations with children about race, ethnicity, culture, and discrimination. The total intervention takes approximately 1.5-2 hours to complete online, and parents can move through the videos at their own pace.
41026022|NCT05454293|OTHER|One Talk at a Time: General|This intervention consists of short videos that include modules and handouts with tips for parent-child communication strategies for navigating difficult topics, such as dating and current events.
41026023|NCT01855009|DIETARY_SUPPLEMENT|MannaBears|Subjects will be administered 4 MannaBears daily
41026024|NCT01855009|DIETARY_SUPPLEMENT|AlgaeCal Calcium|Subjects will be administered 750 mg AlgaeCal Calcium
41026025|NCT01855009|DIETARY_SUPPLEMENT|Calcium carbonate|Subjects will be administered 1000 mg calcium carbonate
41026026|NCT01855009|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be administered 800 IU vitamin D3
41026027|NCT01610700|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
41026028|NCT01610700|DRUG|Placebo|Each actuation of placebo delivered the excipients only.
41026029|NCT01606982|DRUG|MDV3100|oral
41026030|NCT00686400|OTHER|TAU = treatment as usual|medication and psychosocial interventions to be chosen by treating psychiatrist
41026031|NCT04892134|OTHER|blood sample|40-50 ml of blood is taken
41026032|NCT01319318|PROCEDURE|Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
41026033|NCT02032901|DRUG|Daclatasvir|
41026034|NCT02032901|DRUG|Sofosbuvir|
41362782|NCT04542863|OTHER|18F-DX600 PET/CT|DX600, labeled with 18F will be used as a molecular imaging tracer for PET/CT scanning
41362783|NCT00005627|DRUG|carboplatin|
40842101|NCT04351724|DRUG|Remdesivir|200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards
41026035|NCT00268528|BEHAVIORAL|Compliance Monitoring|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
41026036|NCT00268528|OTHER|Laboratory Biomarker Analysis|Correlative studies
41026037|NCT00268528|DRUG|Mercaptopurine|Given PO
41026038|NCT00268528|DRUG|Methotrexate|Given PO
41026039|NCT00268528|OTHER|Questionnaire Administration|Ancillary studies
41026040|NCT00268528|OTHER|Study of Socioeconomic and Demographic Variables|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
41026041|NCT03354000|BEHAVIORAL|Take-home online training|We randomized patients to receive a link to access the online tutorial on their own. Participants in the take-home arm were given a paper handout with a link to the training materials and an outline of the steps for accessing the training curriculum.
41026042|NCT03354000|BEHAVIORAL|In-person online training|For participants randomized to the in-person training arm, a trained research assistant prompted participants to log into the learning platform and guided them in accessing the training materials for portal features that were of interest to them. The staff member provided further explanation or clarification if participants had questions about the training material.
41362784|NCT00005627|DRUG|docetaxel|
41362785|NCT00005627|DRUG|estramustine phosphate sodium|
41362786|NCT01609049|DRUG|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
41362787|NCT01609049|DRUG|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
41362788|NCT02052180|DRUG|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
41362789|NCT02052180|DRUG|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
41362790|NCT02976909|DRUG|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
41362791|NCT00153322|BEHAVIORAL|Nurtition and Physical Activity Education|
41362792|NCT02514109|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
41362793|NCT00669253|PROCEDURE|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
41362794|NCT00669253|PROCEDURE|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
41362795|NCT00669253|PROCEDURE|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
41362796|NCT02247102|DIETARY_SUPPLEMENT|Isomaltulose|"Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
41362797|NCT02247102|DIETARY_SUPPLEMENT|Sucrose|"Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
41362798|NCT04246359|DRUG|Rituximab Biosimilar|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
41362799|NCT04246359|DRUG|Pegylated Interferon α-2b|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
41362800|NCT05057000|OTHER|aerobic exercises + Diet|Frequency 5-6 days per week Intensity To perform moderate intensity for weight-bearing aerobic exercise Time Goal of 20-30 min per session of moderate-intensity aerobic activity per week
41362801|NCT05057000|OTHER|diet proram|diet program for anorexic adolescent girls
41362802|NCT05608824|DEVICE|Shear wave elastography and microvascular flow imaging.|Subjects will undergo serial SWE and MFI imaging throughout their rehabilitation episode of care to assess changes over time, status in rehabilitation and comparison to the contralateral extremity.
41362803|NCT00208702|DRUG|Triiodothyronine|
41362804|NCT00208702|OTHER|Placebo|
41362805|NCT00208702|DRUG|Sertraline|
41362806|NCT04391192|BEHAVIORAL|Virtual Overdose Response|All participants will be provided the phone number and encouraged to call when they use alone.
41362807|NCT04640792|PROCEDURE|Screening or Surveillance Conventionall colonoscopy|Patients in Group A (CC) will undergo Screening or Surveillance Conventual Colonoscopy, Patients in Group B (MEAC) will undergo Screening or Surveillance Colonoscopy with ME-ADPS Device
41362808|NCT02924311|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
41362809|NCT02536209|DRUG|MT-8554 low dose|
41362810|NCT02536209|DRUG|MT-8554 high dose|
40842102|NCT04351724|DRUG|Asunercept 400mg|asunercept 400mg once per week, up to 4 doses in total
40842103|NCT04351724|DRUG|Asunercept 100mg|asunercept 100mg once per week, up to 4 doses in total
40842104|NCT04351724|DRUG|Asunercept 25mg|asunercept 25mg once per week, up to 4 doses in total
40842105|NCT04351724|DRUG|Pentaglobin|7ml/kg/day for 12h for 5 days
41362811|NCT02536209|DRUG|Oxycodone hydrochloride|
41362812|NCT02536209|DRUG|Placebo|
41362813|NCT00300989|DEVICE|Inion OTPS Biodegradable Fixation System|
41362814|NCT05427084|DRUG|Canagliflozin|Canagliflozin tablet 300mg PO daily
41362815|NCT05427084|DRUG|Placebo|Placebo tablet
41362816|NCT03627442|PROCEDURE|Mastectomy with PhotonBlade|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with PhotonBlade
41362817|NCT03627442|PROCEDURE|Mastectomy with Bovie|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with Bovie
41362818|NCT01500291|OTHER|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
41362819|NCT05465850|DIAGNOSTIC_TEST|Modified USPHS criteria|It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
41362820|NCT00666640|DEVICE|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
41362821|NCT00666640|DEVICE|CT scan of hip|Computed Tomography scan
41362822|NCT05734534|OTHER|BFR during training|Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
41362823|NCT05734534|OTHER|BFR during rest|Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
41499775|NCT06634316|COMBINATION_PRODUCT|Physical exercise|Physical exercise adapted to patients with heart failure (Cardiac rehabilitation)
41499776|NCT05035212|BIOLOGICAL|RSVpreF|RSV vaccine (RSVpreF)
41499777|NCT05035212|BIOLOGICAL|Placebo|Placebo
41499778|NCT00422552|DRUG|Indacaterol (QAB149)|
40842106|NCT05932368|OTHER|evaluation|examining files and taking records
41362824|NCT00902590|OTHER|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
41362825|NCT00902590|OTHER|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
40842107|NCT02032407|DRUG|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
41362826|NCT04797676|PROCEDURE|different methods of specimen acquisition|After informed consent, the investigators use two methods to obtain specimens for patients with pancreatic ductal adenocarcinoma, who needs eus-fnb for auxiliary diagnosis and had the opportunity of surgery. One method is EUS-FNB with wet suction technique, the other is surgery (including radical operation and cytoreductive surgery). Both methods are used on the same patient to remove deviations in results caused by tumor heterogeneity.
40842108|NCT05153213|PROCEDURE|Finger lengths|Vernier caliper was used to measure finger length
40842109|NCT05153213|PROCEDURE|Conventional method|Gillis gauge was used to measure occlusal vertical dimension
40842110|NCT06188299|OTHER|Restricted Fluid Administration|Restrictive fluid administration generally consists of partial or no replacement for the intravascular expansion from anesthesia, in which case vasopressors are usually administered, no replacement for the third space loss, and only partial replacement for deficits from preoperative fasting.
40842111|NCT05649592|DIAGNOSTIC_TEST|Magnetic Resonance Hydrolipid Separation Imaging|"MRHS was used to measure different muscle percent fat of core muscles. MRHS, also called Dixon imaging, mainly used the different resonant frequency between the hydrogen nuclei in water and in fat to perform the data acquisition at different echo times (TE). The Dixon sequence basically acquires two images, one image with water and fat signals in-phase and the other with water and fat signals out-of-phase: the sum and subtraction of the two images allow the production of a water-only image and a fat-only image. Scanning equipment: 3.0T superconducting Siemens Skyra Scanner.~Scanning parameters: TR5.36ms, TE1.24ms, Flip Angle 9°, number of layers was 44-60, thickness of layer was 5.0 mm, layer interval 1.0mm, FOV50cm×50cm, the scanning time was 12s×5."
41362827|NCT00623350|OTHER|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
41362828|NCT00623350|OTHER|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
41499779|NCT04733261|OTHER|Diaphragmatic mobility|Therapist will manually make contact with Pisiform Hypothenar region and last three fingers among the underneath the costal cartilage of the 7th in the direction of 10 ribs. For the duration of participant's inhalation, the counselor drag softly within a upward course accompany the increase motion of the ribs. For the period of expiration, the counselor will deepens make contact with in the direction of the internal costal border. Taking place consequent breathing, the counselor wanted on the way to expand traction as well as slickly make deeper the contact.
40842112|NCT01397604|DRUG|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
40842113|NCT01397604|DRUG|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
40842114|NCT01397604|OTHER|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
40842115|NCT01432990|DEVICE|Robot gait training|Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.
41362829|NCT04392531|DRUG|Cyclosporine|In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
40842116|NCT01432990|OTHER|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
40842117|NCT02387489|BEHAVIORAL|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
40842118|NCT02387489|BEHAVIORAL|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
40842119|NCT01257035|OTHER|18F-FAZA-PET/CT|Contrast fluid injected prior to scan
41362830|NCT04392531|DRUG|Standard treatment|Standard of care according to hospital protocol
40842120|NCT03393949|DRUG|Methylprednisolone 1 mg•kg-1|Patients in Group M received methylprednisolone 1mg•kg-1
40842121|NCT03393949|DRUG|isotonic saline 1mg•kg-1|Patients in Group C received isotonic saline 1mg•kg-1
40842122|NCT01399216|DIETARY_SUPPLEMENT|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
40842123|NCT01399216|DIETARY_SUPPLEMENT|Placebo|for 8 weeks
40842124|NCT05716204|OTHER|High force lateral distraction|High force lateral distraction on the affected hip.
40842125|NCT05716204|OTHER|Placebo distraction group|Placebo lateral distraction on the affected hip.
40842126|NCT04502368|PROCEDURE|Fiberoptic Bronchoscopy (FOB)|FOB under full sedation (RASS sedation scale -5) and full paralysis.
40842127|NCT04502368|PROCEDURE|Bronchoalveolar Lavage (BAL)|BAL under full sedation (RASS sedation scale -5) and full paralysis. Lavage: NaCl 0,9% 50ml x 3 in lung region targetted according to RX/CT scan.
40842128|NCT04502368|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|Realtime thoracic impedance coupled with ventilation parameters recording.
40842129|NCT04502368|DIAGNOSTIC_TEST|Arterial Blood Gas test (ABG)|Multiples Arterial Blood Gas test (ABG) via arterial catheter.
40842130|NCT05632783|DRUG|Chondroitin Sulfate Sodium|Chondroitin sulfate 800 mg tablets
40842131|NCT05632783|OTHER|Placebo|Placebo tablets
41362831|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) peptide vaccine|Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF). TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96
41362832|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine|Will receive peptide pulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
41499780|NCT04733261|OTHER|Chest Physiotherapy|Patients allocated to the control group and interventional group received pulmonary rehabilitation two times a day beginning happening the day of entrance on the way to the intensive care unit. It consists of side-lying positioning with the head of the bed horizontal for at least 20 min with the most affected lung on chest x-ray positioned uppermost is also known as postural drainage, 4 sets of 6 cycles of expiratory chest wall vibrations , and airway suctioning at least three times through the endotracheal and tracheotomy tube disperse in the course of the management
41499781|NCT05903014|DRUG|n-acetylcysteine|we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
40842132|NCT00871962|OTHER|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2\<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
40842133|NCT06523062|DEVICE|blood pressure measurement|automated blood pressure measurement on 3 occasions at each consultation, twice with one month apart
40842134|NCT03841760|DIAGNOSTIC_TEST|PSMA PET/CT|"For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes."
40842135|NCT04772781|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuflex®
40842136|NCT04772781|DRUG|Ibuflex®|Ibuflex® + placebo of S (+) - Ibuprofen
40842137|NCT00911573|DRUG|Tigecycline|50 mg IV every 12 hours up to 14 days
40842138|NCT00911573|DRUG|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
40842139|NCT05538546|DIAGNOSTIC_TEST|Complete blood count|Complete blood count will be conducted at 12th month and 24th month from baseline.
40842140|NCT05538546|DIAGNOSTIC_TEST|Transient elastrography|Transient elastrography, and endoscopy will be conducted at 12th month and 24th month from baseline.
41499782|NCT05903014|BEHAVIORAL|Motivational Enhancement Therapy|Motivational enhancement therapy with individual and/or group session to maintain and increase subject's motivation to quit smoking
40842141|NCT05538546|DIAGNOSTIC_TEST|Endoscopy|Endoscopy will be conducted at 12th month and 24th month from baseline.
40842142|NCT05903261|RADIATION|SBRT|stereotactic body radiation therapy (SBRT)
40842143|NCT01043588|PROCEDURE|TURP|TransUrethral Resection of the Prostate
40842144|NCT01043588|PROCEDURE|PVP|Photo selective Vaporization of the Prostate
40842145|NCT02186717|DIETARY_SUPPLEMENT|Chewing gum|Patients will be asked to chew gum three times a day for 30 minutes each time
40842146|NCT00242307|DRUG|Roflumilast|
40842147|NCT00619099|DRUG|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
41026043|NCT00465166|PROCEDURE|Ultrasound|Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
41362833|NCT01977573|DRUG|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
41499783|NCT04784533|DRUG|CTP-543|Oral dosing
40842148|NCT00619099|DRUG|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
40842149|NCT00500760|DRUG|Cisplatin|Administered intravenously (IV; in a vein)
40842150|NCT00500760|RADIATION|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
40842151|NCT00500760|DRUG|Panitumumab|Administered intravenously
41026044|NCT03039413|DRUG|Copper Cu 64 TP3805|Given IV
41026045|NCT03039413|PROCEDURE|Positron Emission Tomography|Undergo Cu-64-TP3805 Positron Emission Tomography scan
41026046|NCT03039413|PROCEDURE|Computed Tomography|Undergo Cu-64-TP3805 Computed Tomography scan
40842152|NCT04276974|OTHER|Organic diet|Organic plant-rich foods (2000kcal for women, 2500kcal for men)
40842153|NCT04276974|OTHER|Non-organic diet|Likewise Non-organic plant-rich foods (2000kcal for women, 2500kcal for men)
40842154|NCT01612455|BEHAVIORAL|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
40842155|NCT06026956|OTHER|Tele-Assessment|Tele-Assessment
40842156|NCT06044714|PROCEDURE|Manual Standardized Stress Acupuncture (MSSA)|Participants in the experimental group will receive 4 weekly sessions of MSSA, which consists of 8 acupuncture points: bilateral auricular (ear) shen men, GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. Needles are left in situ for 30 minutes per session.
40842157|NCT06044714|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will receive four sessions of MBSR group psychotherapy (no more than 10 participants per group session) via Microsoft Teams. The first session will be 90 minutes followed by three 60-minute weekly sessions.
40842158|NCT02153814|PROCEDURE|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
40842159|NCT02153814|PROCEDURE|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
40842160|NCT04397328|DRUG|Hydroxychloroquine|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
40842161|NCT04397328|DRUG|Placebo|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
40842162|NCT06025812|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
40842163|NCT06025812|BIOLOGICAL|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells).
40842164|NCT04807387|DEVICE|Vaginal Stent A|Ring stent
40842165|NCT04807387|DEVICE|Vaginal Stent B|Flower stent
40842166|NCT04807387|DEVICE|Vaginal Stent|Vaginal stent chosen from A or B that is the most comfortable
40842167|NCT00000480|PROCEDURE|electrophysiology|
40842168|NCT00000480|DRUG|anti-arrhythmia agents|
40842169|NCT00000480|DEVICE|defibrillators, implantable|
40842170|NCT04216407|PROCEDURE|Remote ischemic preconditioning|An orthopedic tourniquet was tied to the right lower extremities of the patients in RIPC arm, and tourniquet application was performed before the anhepatic phase in 3 periods of 3 minutes with an interval of 3 minutes.
40842171|NCT06301750|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
40842172|NCT06301750|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
41026047|NCT01545011|OTHER|Inspiratory muscle training|Inspiratory muscle training
41362834|NCT01977573|DRUG|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
41026048|NCT04000451|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
41026049|NCT04000451|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
41026050|NCT04000451|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
41026051|NCT00145431|DRUG|torcetrapib/atorvastatin|
41026052|NCT00145431|DRUG|atorvastatin|
41026053|NCT00145431|DRUG|fenofibrate|
41026054|NCT04462328|DRUG|Durvalumab|Durvalumab will be administered over 60 minutes
41026055|NCT04462328|DRUG|Acalabrutinib|Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
41362835|NCT00697424|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
41499784|NCT04784533|DRUG|Placebo|Oral dosing
40842173|NCT06301750|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
40842174|NCT01755650|RADIATION|18F FPM|
40842175|NCT00048113|DRUG|Alicaforsen|
40842176|NCT03704610|DRUG|Infliximab|An initial period with 2 injections with infliximab allowing the determination of the primary criteria Then an extension with infliximab with 3 supplementary perfusions
40842177|NCT03704610|DRUG|Placebo|An initial period with 2 injections with placebo allowing the determination of the primary criteria Then an extension with infliximab with 5 supplementary perfusions
40842178|NCT02209974|DRUG|Fluticasone|Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
40842179|NCT02209974|DRUG|Inhaled Placebo|
40842180|NCT05895539|OTHER|An automated patient-reported outcome data collection and adverse event surveillance tool|Patients received a short prompt to provide information on treatment satisfaction and side effects
40842181|NCT01458028|DRUG|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
40842182|NCT01458028|DRUG|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
40842183|NCT00169221|DRUG|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
40842184|NCT00169221|RADIATION|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
40842185|NCT01233388|OTHER|Text message surveillance|Text message surveillance for vaccine adverse events
40842186|NCT02211456|PROCEDURE|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
40842187|NCT03869879|OTHER|Feedback-assisted physical therapy|The system uses unobtrusive, wearable, inertial sensors with real-time algorithms to provide real-time feedback on: step time asymmetry, foot clearance, arm swing, trunk lateral range, and foot strike angle during gait.
40842188|NCT03869879|OTHER|Traditional physical therapy|Therapists will treat these patients with traditional therapeutic modalities and practices.
40842189|NCT04357977|DIAGNOSTIC_TEST|RBA-2|Collection of non-invasive in vivo saliva from confirmed cases of both infected and non-infected COVID-19 patients or site staff at the testing site and compare the test results using the RBA-2 against the standard test results used for diagnosis.
40842190|NCT05204433|OTHER|no intervention|no intervention
40842191|NCT05345028|DIETARY_SUPPLEMENT|lecithin-based delivery form of Boswellia serrata|250 mg for 5 days
40842192|NCT05345028|COMBINATION_PRODUCT|Placebo|250 mg for 5 days
41362836|NCT05618769|COMBINATION_PRODUCT|LONG LOVE Framework|In order to identify modifiable influencing factors, clinical data of the infants included in our multidisciplinary framework will be continuously collected by eHealth (Luscii Healthtech BV, Netherlands). Study visits take place at 1-1,5 3, 6, 12 and 18 months of age. Outdoor air quality measurements will be conducted using RIVM Luchtmeetnet. Indoor air quality measurements will be collected during a period of 6 weeks using a commercial available device. Lung function analysis using impedance pneumatography (Ventica Recorder, Revenio Research LTD, Finland) will take place during 2 nights at 3, 6 and 12 months of age. In the event of modifiable influencing factors medical or lifestyle interventions will be undertaken.
40842193|NCT02145351|DEVICE|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
40842194|NCT02145351|DEVICE|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
41362837|NCT00091039|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|
41362838|NCT00091039|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
41362839|NCT00091039|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
41362840|NCT00091039|DRUG|carboplatin|
41362841|NCT00091039|DRUG|paclitaxel|
41362842|NCT00091039|RADIATION|radiation therapy|
41362843|NCT02943876|OTHER|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
41362844|NCT00000758|DRUG|Fluorouracil|
41362845|NCT05223764|OTHER|Follow up survey|phone call follow-up to investigate women's decision not to return for embryo transfer after cancer treatment.
41362846|NCT03954054|BEHAVIORAL|"Choizitaconso - therapeutic patient education programme"|"Choizitaconso is a therapeutic patient education programme that teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms.~It lasts for 10 weeks for each participant and consists of the following 5 modules, including one optional module focusing on the family environment:~1. Understand the mechanisms that trigger and/or maintain alcohol-related difficulties~2. Plan and evaluate personalized controlled drinking strategies~3. Understand and identify external and internal influences (e.g., thoughts and emotions), identify and manage risk situations~4. Identify alcohol effects and alcohol-related expectations (by developing self-observation skills)~5. Family environment: learning how to evaluate and take care of oneself (e.g., how to express feelings)~Each module consists of 2 to 4 collective workshops that each last 120 minutes and involve 5 to 10 persons."
41362847|NCT03956459|OTHER|Patients with a cancer for which a FDG-PET scanner must be performed|"For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:~* Discovery MI~* Discovery IQ~Only one contrast agent injection (FDG) will be given for both scanners."
40842195|NCT06360107|OTHER|brief video|brief video about depression
40842196|NCT02214745|OTHER|Questionnaire|Questionnaire developed for this purpose by the investigators
40842197|NCT01840098|DIETARY_SUPPLEMENT|low leucine content drink|
40842198|NCT01840098|DIETARY_SUPPLEMENT|high leucine content drink|
40842199|NCT01840098|DIETARY_SUPPLEMENT|low leucine + HMB drink|
40842200|NCT01840098|DIETARY_SUPPLEMENT|Control/carbohydrate|
40842201|NCT01840098|BEHAVIORAL|36 hour fasting|
40842202|NCT01232855|GENETIC|protein expression analysis|
41362848|NCT05997511|BEHAVIORAL|Card-Sorting Activity (Pre-intervention design)|Study team members within each country will free list misinformation or misconceptions that they commonly encounter in clinical practice or daily life. Each item will be used to create paired cards - one containing the misinformation and a second containing the corresponding correct information. During qualitative interviews, we will ask CHWs to participate in a series of card sorting activities, which is a participatory research method that can inform the design of health interventions.
41362849|NCT05997511|BEHAVIORAL|SMS Crafting (Pre-intervention design)|A two-person team consisting of one local communication expert and one clinician will draft clinically correct, easy-to-understand SMS messages designed to counter identified misinformation. We will draft messages that use various styles and use cognitive interviewing with CHWs to assess their understanding of and responses to each style. The final messages used in our intervention will be determined by CHW preference.
41362850|NCT05997511|BEHAVIORAL|SMS Messaging|Final messages will be sent via SMS to all CHWs working in our study area. CHWs will also be provided with contact information for a helpline staffed by a local team member who can answer follow-up questions in the local language.
41362851|NCT04725734|OTHER|Pregnant women|The patients will complete a questionnaire for each quarter
41362852|NCT01882101|PROCEDURE|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
41362853|NCT01882101|PROCEDURE|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
41362854|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
41362855|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
40842203|NCT01232855|GENETIC|western blotting|
40842204|NCT01232855|OTHER|flow cytometry|
40842205|NCT01232855|OTHER|laboratory biomarker analysis|
40842206|NCT04004013|DIETARY_SUPPLEMENT|Lifenol®|"Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
40842207|NCT04004013|DIETARY_SUPPLEMENT|Placebo|"Maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
40842208|NCT04978818|DRUG|Vaxelis|Eligible infants will be block randomized to one of two study arms.
40842209|NCT04978818|DRUG|PedvaxHIB|Eligible infants will be block randomized to one of two study arms.
40842210|NCT05587374|DRUG|Cadonilimab|Cadonilimab 10mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 14 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
40842211|NCT05587374|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
40842212|NCT05587374|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
40842213|NCT05587374|RADIATION|Intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
40842214|NCT05042102|COMBINATION_PRODUCT|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
41026056|NCT00323102|DRUG|Multihance|
41026057|NCT05776485|OTHER|Progressive resistance training|Only the control group: 3 exercise bouts within the study period. Comparison between exercised and non-exercised leg.
40842215|NCT05042102|COMBINATION_PRODUCT|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
40842216|NCT05042102|COMBINATION_PRODUCT|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
40842217|NCT05042102|COMBINATION_PRODUCT|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
40842218|NCT06503380|OTHER|No intervenrion.|This study will respect the medication choices of researchers in the study, without specifying which medication to choose for treatment, dosage, mode of administration (including single drug, combination therapy, or sequential therapy), and duration of administration.
40842219|NCT04752332|DRUG|Abemaciclib|Administered orally.
40842220|NCT04752332|DRUG|Standard Adjuvant ET|Administered according to label instructions.
40842221|NCT04752332|DRUG|Placebo|Administered orally.
40842222|NCT05257369|DEVICE|Blue-Green LED photoherapy|Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
40842223|NCT01970059|DRUG|Extended-Release Carvedilol Sulfate|
40842224|NCT01970059|DRUG|Sustained-release Metoprolol Succinate|
40842225|NCT04999163|DEVICE|Aortix System|Aortix is indicated as a partial circulatory support device to increase renal perfusion and reduce the incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery who are at heightened risk of developing AKI.
40842226|NCT06536556|OTHER|First Assessment|pre-treatment assessment
40842227|NCT06536556|OTHER|Second Assessment|4 days post-treatment assessment
40842228|NCT01341717|DRUG|Sitagliptin|100 mg once daily for 6 months
40842229|NCT01341717|DRUG|Glimepiride|1 mg/2 mg/3 mg once daily
40842230|NCT01341717|DRUG|Metformin|\>=1000 mg twice daily
40842231|NCT01341717|DRUG|Insulin|TDD \> 10 IU once/twice daily
40842232|NCT04268173|OTHER|Community-Based, Client-Centered Prevention Home|Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.
41026058|NCT05776485|OTHER|Cross-sectional comparison between healthy and tendinopathic group|Comparison of primary and secondary outcomes.
41362856|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
41362857|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
40842233|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
41362858|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
41499785|NCT00567905|DIETARY_SUPPLEMENT|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
40842234|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
40842235|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
40842236|NCT05434598|DEVICE|ChromoSeq|Novel, streamlined whole genome sequencing approach
40842237|NCT03989323|OTHER|Estimation of the incidence of the irAE|Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
40842238|NCT00261573|DRUG|galantamine hydrobromide|
40842239|NCT00076349|DRUG|bendamustine and rituximab|Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
40842240|NCT03004755|OTHER|Tissue Harvest|
40842241|NCT00910169|OTHER|inpatient treatment|Hospitalisation modalities are described but are naturalistic
40842242|NCT02450968|DRUG|Dexamethasone|
40842243|NCT02450968|DRUG|Placebo|
40842244|NCT03502174|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
40842245|NCT03688568|DRUG|Imatinib Mesylate|Imatinib given orally as dose escalation treatment.
41026059|NCT01690650|DRUG|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
41026060|NCT01485952|DRUG|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
41026061|NCT01485952|DRUG|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
41026062|NCT01485952|DRUG|Placebo|Once daily administration (immediate release capsule)
41026063|NCT01459276|BIOLOGICAL|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
41499786|NCT01423123|DRUG|Paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
41499787|NCT01423123|BIOLOGICAL|trastuzumab|4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
41499788|NCT01423123|DRUG|Neratinib|Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
40842246|NCT00584207|PROCEDURE|radiofrequency ablation|Intraoperative RFA of uterine fibroids
40842247|NCT05590949|OTHER|Physical Evaluation|Participants will be assessed at Timepoint 0 (last dose of denosumab injection) and then at 9,12,18 and 24 months following discontinuation of denosumab. The evaluation will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work for bone turnover markers (including serum carboxy-terminal collagen crosslinks (CTX) in serum and bone specific alkaline phosphatase). Bone turn-over markers should be drawn in the morning, after at least 8 hours of fasting (water, black coffee and plain tea allowed).
40842248|NCT05590949|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry scans|Dual-energy X-ray absorptiometry (DEXA) scans will be performed at the 12 months timepoint , and then at the 24 month timepoint.
40842249|NCT05590949|DIAGNOSTIC_TEST|Trabecular Bone Score|TBS is an innovative gray-level texture measurement that utilizes lumbar spine DEXA images to discriminate changes in bone microarchitecture. Specifically, TBS measures bone quality through tridimensional bone areas with different trabecular and microstructural characteristics. The combination of TBS microstructure evaluation with bone density measured by DEXA has been shown to be superior to either measurement alone in the assessment of fracture risk.
40842250|NCT06546137|DIAGNOSTIC_TEST|whole genome sequencing|whole genome sequencing of genomic DNA extracted from buccal swab
40842251|NCT02591368|PROCEDURE|Ligament reconstruction tendon interposition|In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.
40842252|NCT02591368|PROCEDURE|Suspensionplasty with one-suture construct|In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.
40842253|NCT02591368|PROCEDURE|Suspensionplasty with two-suture construct|In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
40842254|NCT01306656|DRUG|10,000 IU Vitamin D3|"Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week"
40842255|NCT01306656|OTHER|Placebo|"Month 1: Placebo once a week~Months 2-6: Placebo once a week"
40842256|NCT01306656|DIETARY_SUPPLEMENT|Vitamin D|Daily multivitamin with 400 IU vitamin D.
40842257|NCT05120141|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
41026064|NCT01459276|BIOLOGICAL|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
40842258|NCT05120141|OTHER|American Dental Association (ADA) Ref Toothbrush|Participants will use soft bristled Toothbrush for brushing teeth twice daily.
41362859|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
41362860|NCT05961124|DRUG|Niraparib|Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
41362861|NCT05360212|PROCEDURE|Anatomy-based fitting (ABF)|MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
40842259|NCT05120141|OTHER|Prototype 1 Mouth Rinse|Participants will use 20 mL of Prototype 1 Mouth Rinse for 30 seconds after brushing twice daily.
40842260|NCT05120141|OTHER|Prototype 2 Mouth Rinse|Participants will use 20 mL of Prototype 2 Mouth Rinse for 30 seconds after brushing twice daily.
40842261|NCT05120141|OTHER|Prototype 3 Mouth Rinse|Participants will use 20 mL of Prototype 3 Mouth Rinse for 30 seconds after brushing twice daily.
41026065|NCT02552836|BEHAVIORAL|Interpersonal Psychotherapy|A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
41362862|NCT05360212|PROCEDURE|Standard Fitting|These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
41362863|NCT05360212|PROCEDURE|Standard fitting+ ABF|Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
41026066|NCT02552836|BEHAVIORAL|Supportive Psychotherapy|A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
41026067|NCT03396783|BIOLOGICAL|blood test|during the visit, nurse will make a blood test for biological and immunological analysis
41362864|NCT05671302|BEHAVIORAL|Walk Together|Receive training in the use of a study-provided blood pressure cuff and hypertension education; engage in hypertension self-management goal-setting; identify barriers to self-management adherence and utilize shared problem-solving to address barriers; connect to existing clinic resources to address environmental barriers; promote relationship strengths; practice communication and behavioral skills to address relationship concerns; engage family in support of patient self-management goals.
41362865|NCT00489216|BIOLOGICAL|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"
41499789|NCT00866658|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
41362866|NCT02127580|PROCEDURE|BAV|
41362867|NCT02127580|PROCEDURE|without BAV|
41362868|NCT03606265|DEVICE|App+Web|Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event
41499790|NCT00866658|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
41499791|NCT00866658|DEVICE|Pen auto-injector|
41499792|NCT00866658|DRUG|Sulfonylurea|Sulfonylurea if given, to be continued at a stable dose.
41499793|NCT00866658|DRUG|Basal Insulin|To be continued at a stable dose.
41499794|NCT04302714|PROCEDURE|Hysteroscopic injection|Hysteroscopic injection
41499795|NCT04302714|PROCEDURE|Cervical injection|Cervical injection
41499796|NCT04591223|BEHAVIORAL|Competency-based physical training (CbM)|The intervention to be added to online social work treatment as usual (OSW) is a well-designed, one-on-one structural physical workout module which will be offered by a licensed senior physical trainer in public sports ground or gymnasium. The aim is to strengthen participants' sense of competence, improve their physical fitness, self-confidence and self-image through an outcome-driven Circuit training. One of the chief advantages of Circuit training is its adaptability. Circuit training can be performed with gym equipment and/or bodyweight exercises which is deemed to be suitable for beginner and easy to practice at home on oneself. Participants can continue to replicate the exercise with or without any equipment. The program will be delivered in six one-hour sessions, including face-to-face and online mode, over one month.
41362869|NCT03606265|DEVICE|Treatment as usual|Patients will be offered the usual treatment for their pain, which is not changed by study participation
41499797|NCT05952518|DEVICE|Sprint PNS system|Temporary electrical stimulation of the medial nerve with implanted wires and wearable stimulator
41499798|NCT05952518|PROCEDURE|Radiofrequency Ablation|Thermal ablation of the medial nerve
41499799|NCT00529139|DEVICE|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
41499800|NCT00529139|DEVICE|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. \<90 mg/dL (\<15 mmol/L)
41499801|NCT05478252|DRUG|Semaglutide J|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
41499802|NCT05478252|DRUG|Semaglutide B|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
41026068|NCT03396783|OTHER|electromyogram and walk test|during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
41026069|NCT04651023|DIETARY_SUPPLEMENT|Nelumbo nucifera Leaf Extract|Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
41026070|NCT04818346|DRUG|INCB054707|INCB054707 will be administered once daily
41026071|NCT04818346|DRUG|Placebo|Placebo or INCB054707 will be administered once daily
41026072|NCT04091399|DRUG|Stamatological tamponade Contipro|The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
41026073|NCT00389935|DRUG|Thalidomide|Thalidomide 50 - 200 mg once at nightime
41026074|NCT00207441|BEHAVIORAL|Arthritis Self management program|
41026075|NCT00207441|BEHAVIORAL|Chronic Disease Self Management Program|
41362870|NCT02456272|DEVICE|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
41499803|NCT03912597|DEVICE|Virtual Reality|The 4-minute virtual reality video depicts a day in a life of a student with depression. The one-take video, filmed with a 360° camera, is designed to provide users with an immersive experience that simulates what it feels like to have depression. The user interface consisted of a Google Cardboard VR headset attached to a smartphone.
41499804|NCT03912597|DEVICE|Brochure|Participants read an informational brochure about depression depicting standard information about depression, including symptoms and information on how to support someone with depression.
41026076|NCT06531356|BIOLOGICAL|autologous amniotic fluid|10 cc of amniotic fluid aspirated after opening uterine incision in cesarean section, then Injected in edges of skin before closure
41026077|NCT06531356|OTHER|No amniotic fluid injected in skin edges|conventional closure of skin
41026078|NCT03737370|DRUG|Docetaxel|Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.
41026079|NCT03737370|RADIATION|Radium 223|Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.
41499805|NCT03912597|DEVICE|Standard Video Control|The 4-minute standard video depicts a similar storyline as was shown in the VR video. The standard video is filmed from a third-party perspective with multiple takes edited into a final video, following the standard filming style of these videos. The standard video will be viewed from a laptop with headphones attached.
41499806|NCT00001028|DRUG|Pentamidine isethionate|
40842262|NCT05120141|OTHER|Listerine Cool Mint Mouth Rinse|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
41026080|NCT00847873|BEHAVIORAL|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse
41026081|NCT00847873|BEHAVIORAL|Cognitive behavioral therapy addressing substance abuse|This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
41026082|NCT01617291|OTHER|Induced therapeutic hypothermia|induced therapeutic hypothermia
41026083|NCT00523029|BEHAVIORAL|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
41026084|NCT03549689|DRUG|Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)|Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.
41362871|NCT02456272|PROCEDURE|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
40842263|NCT05120141|OTHER|Hydroalcohol Mouth Rinse|Participants will use 20 mL of Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
40842264|NCT06172946|DEVICE|powerbreath|Previous studies have confirmed the efficacy of implementing IMT as part of a RR program in a certain profile of patients with COPD, showing improvements in maximum inspiratory pressure, perception of well-being, and other respiratory diseases, and dyspnea during exercise. (Gandullo et al., 2022)
40842265|NCT06172946|DEVICE|TRANSCUTANEOUS ELECTRICAL DIAPHRAGMATIC STIMULATION|Transcutaneous electrical diaphragmatic stimulation (TEDS) has been used to improve respiratory muscle strength in patients with respiratory muscle weakness. A previous study reported that patients with chronic obstructive pulmonary disease (COPD) showed increased lung volume and oxygen saturation after a single session of TEDS. (Hsin et al., 2022)
40842266|NCT01195493|OTHER|Essential Oils solution|(Essential oils solution, Listerine®, Johnson \& Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
41362872|NCT04838678|DRUG|Neuropeptide Y|intra-arterial infusion of neuropeptide Y
41026085|NCT03549689|DRUG|Current tenofovir alafenamide (TAF)-containing ART regimen|Continuation of current TAF-containing ART for 96 weeks.
41026086|NCT00201383|DRUG|cisplatin|
41362873|NCT03682926|OTHER|Electro-stimulation|Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
41362874|NCT02972658|DRUG|Lanabecestat|Administered orally
41499807|NCT00001028|DRUG|Dapsone|
41026087|NCT00487201|PROCEDURE|endoscopic balloon dilatation|
41026088|NCT00487201|PROCEDURE|plastic stent placement|
41026089|NCT02021435|DIETARY_SUPPLEMENT|salt substitute|Free salt substitute provided
41026090|NCT02094989|OTHER|posture dependence of VCG-ECG-transformation|
41499808|NCT04032717|DRUG|Q-Griffithsin (Q-GRFT) enema|Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
41499809|NCT04032717|OTHER|Placebo enema|Approximately 125mL of 0.9% sodium chloride solution
41499810|NCT02173314|OTHER|SAFE FC|SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
41499811|NCT03351465|BEHAVIORAL|Coordinated Anxiety Learning and Management|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living42 that directly incorporates our previously optional modules for depression into the main program. The computerized internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed.
41499812|NCT06473012|BEHAVIORAL|Cognitive Behavioral Therapy for Caregivers of Older Adults|Cognitive Behavioral Therapy Intervention for Caregivers of Older Adults is designed to be implemented in a group setting with 12 to 15 caregivers in a group. It consists of 6 weekly sessions, and each session lasts for 90 minutes to 120 minutes. The content of the intervention is based on lifestyle intervention, CBT and effective communication skills. Home practices will be assigned to the participants in between each weekly session.
41499813|NCT06473012|BEHAVIORAL|Control intervention for Caregivers of Older Adults|The control group receives 6 weekly education sessions on useful healthcare information (mental health, physical health, health ageing and dementia). Each session lasts for 90 minutes to 120 minutes.
41499814|NCT05286801|BIOLOGICAL|Atezolizumab|Given IV
41499815|NCT05286801|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41499816|NCT05286801|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
41499817|NCT05286801|OTHER|Fludeoxyglucose F-18|Given FDG
41160911|NCT05619900|OTHER|There is no intervention|This is an observational study. There is no intervention. The purpose of the project is to create a database of patients diagnosed either prenatally or after birth with a lysosomal storage disease. The database will be utilized to assess patient outcomes, build on existing clinical management, improve medical decision making, and improve quality of care.
41160912|NCT03838419|RADIATION|intraoperative radiotherapy|IORT with 21 Gy prescribed to the 90% isodose line
41160913|NCT03838419|RADIATION|whole breast irradiation|hypofractionated WBI Total dose 40.05 Gy (15 x 2.67 Gy)
41160914|NCT06312995|DEVICE|T3DDY01|Digital acquisition of the patient's forearm using Intel RealSense D415 cameras (CE devices certified according to EN/IEC 60825-1 2007 - Safety of Laser product as Class I Laser Devices, i.e., Non-Hazardous Laser Radiation). The patient's arm is placed on a support to allow the plaster nurse to position the wrist at the correct angle needed to treat the fracture.
41160915|NCT06312995|DEVICE|PLASTER|Standard treatment plaster for fractures.
41362875|NCT05296239|OTHER|SimpleC Wellness Platform with Social Robot Interaction|"Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia."
41362876|NCT04865380|DRUG|Tranexamic Acid 100 MG/ML|1g IV x 1 dose of Tranexamic Acid administered preoperatively.
41362877|NCT05597592|PROCEDURE|Feasability of a personalised physical rehabilitation program at home|Monitoring of the realization of a personalised physical rehabilitation program at home by patients with neuromuscular and neurodegenrative disease
41362878|NCT01658527|DRUG|Orteronel|"Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy"
41362879|NCT01658527|DRUG|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
41499818|NCT05286801|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41499819|NCT05286801|PROCEDURE|Positron Emission Tomography|Undergo PET-CT and/or FDG-PET
41499820|NCT05286801|BIOLOGICAL|Tiragolumab|Given IV
41160916|NCT05753319|OTHER|Physiotherapy in the emergency department after a fall|Realization of a physiotherapy assessment.
41362880|NCT01967992|BEHAVIORAL|Behavioral: Low Carbohydrate, Ketogenic Diet|
41362881|NCT01967992|BEHAVIORAL|American Diabetes Association Diet|
41362882|NCT01967992|BEHAVIORAL|Mindfulness and Positive Affect Skills|
41499821|NCT05286801|PROCEDURE|X-Ray Imaging|Undergo x-rays
41499822|NCT00879411|DRUG|Micardis|
41499823|NCT01318486|OTHER|Heparin free dialysis technique|Saline flushes or predilution
41160917|NCT00349648|PROCEDURE|acromioplasty|
41160918|NCT06477237|BIOLOGICAL|HB0017 Q4W|HB0017 at W0,1,2,4,8+HB0017Q4W
41160919|NCT06477237|BIOLOGICAL|HB0017 Q8W|HB0017 at W0,1,2,4,8+HB0017Q8W
41160920|NCT06477237|BIOLOGICAL|placebo|placebo at W0,1,2,4,8+HB0017Q4W
41160921|NCT03945851|PROCEDURE|fMRI|All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.
41499824|NCT01318486|DEVICE|Evodial|Evodial dialyer
41499825|NCT05592314|OTHER|No intervention|No intervention
41499826|NCT03196219|DRUG|C16G2|C16G2
41160922|NCT00092209|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium|
41160923|NCT00092209|DRUG|Comparator: placebo, losartan, hydrochlorothiazide|
41160924|NCT01547247|DEVICE|soft straight distal cap D-201-14304 Olympus attached to the tip of the colonoscope|Colonoscopy with transparent cap attached to the tip of the colonoscope and water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
41026091|NCT01803997|BEHAVIORAL|Pink and Dude Chef Afterschool Cooking Program|12 educational cooking classes: two classes per week for six weeks (2 hours each)
41026092|NCT03156465|DEVICE|Hybrid L24|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
41026093|NCT05051241|DRUG|GFH018|Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
41499827|NCT03196219|DRUG|Placebo|Varnish Placebo
41499828|NCT05351671|DRUG|RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)|After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at 10 mg/kg every 8 hours for total of 3 doses.
40842267|NCT01195493|OTHER|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
41026094|NCT06397794|OTHER|Quantitative surveys and qualitative interview|All participants will complete online surveys on topics including demographic and socioeconomic information, medical history (parent and child), pregnancy history, and mental health and well-being. They will then participate in a qualitative interview about their pregnancy and parenting experiences as gestational parents with Lyme disease.
40842268|NCT05009667|DEVICE|Angiography-derived Index of Microcirculatory Resistance|"caIMR will be measured by pressure sensors which are produced by Suzhou Rainmed Medical Technology Co., Ltd.~caIMR is calculated based on angiography images and Hyperemic Pa estimated from resting Pa according to prespecified equation."
40842269|NCT05009667|DEVICE|Pressure wire-based Index of Microcirculatory Resistance|"IMR will be measured by thermodilution method with pressure wire and arterial physiological detector which are produced by St. Jude Medical.~IMR = Pd ∙Tmn"
40842270|NCT00015951|BIOLOGICAL|bevacizumab|
41026095|NCT01777919|DRUG|Temozolomide|
41160925|NCT01547247|PROCEDURE|water immersion colonoscopy|Colonoscopy without transparent cap using water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
40842271|NCT00015951|DRUG|cytarabine|
40842272|NCT00015951|DRUG|mitoxantrone hydrochloride|
40842273|NCT03395951|DRUG|Diuretics|Observation of hemodynamics during diuretics treatment within clinical indication.
41160926|NCT04565210|OTHER|Music exposure|Participants will be offered individual sessions of music. They will be exposed for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
41160927|NCT04565210|OTHER|Silence|Participants in this group will be offered individual silence session for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
40842274|NCT04218591|OTHER|PRP|Platelet rich plasma
40842275|NCT04218591|OTHER|Placebo|Saline
40842276|NCT02690649|OTHER|Health Messaging (Non-Procedural)|Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
41160928|NCT05459142|DRUG|Medical Abortion|Medical Abortion
41499829|NCT05351671|DRUG|RLS-0071 (loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses)|After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at a loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses.
41499830|NCT05351671|DRUG|Placebo (saline dosed every 8 hours for a total of 3 doses)|After challenge with inhaled LPS, subjects will receive IV infusion of placebo (saline) dosed every 8 hours for a total of 3 doses.
40842277|NCT00058682|DRUG|Anidulafungin|
40842278|NCT01012323|BIOLOGICAL|NewGam|The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
40842279|NCT00119496|DRUG|rosiglitazone|oral tablet, 4mg bd for 4 weeks
40842280|NCT00119496|DRUG|theophylline|Oral theophylline, 200mg bd
41026096|NCT01777919|DRUG|Disulfiram|
41026097|NCT01777919|DRUG|Copper|
41026098|NCT03397446|DRUG|Lisdexamfetamine dimesylate|50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
41026099|NCT01873794|DEVICE|Bright white light|
41026100|NCT01873794|DEVICE|Dim red light|
41026101|NCT00958035|DRUG|bimatoprost ophthalmic 0.03% solution|Apply one drop of study medication along the upper eyelid margin once daily in the evening
41026102|NCT00958035|DRUG|vehicle sterile solution (placebo)|Apply one drop of study medication along the upper eyelid margin once daily in the evening
41160929|NCT01956071|DEVICE|WAPD|The objective was to assess workers' acceptability of the Pennington Pedal Desk.
41026103|NCT00601926|BIOLOGICAL|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
41499831|NCT06232330|DEVICE|Group A|This group will receive TOA which include Weight transfers from a standing position and stepping in various star-type directions, Sit-ups from different heights with the hemiplegic lower limb behind the normal lower limb, From a kneeling position alternately projecting the lower limb forward, From a standing position with a limited base of support turning head and trunk right to left, Continuous walking on a treadmill for 10 minutes, Ascending and descending of stairs, Crossing 4 obstacles with continuous walking, Walking while simultaneously pushing a stroller, Walking while holding an object, Walking on different surfaces and slopes, The intervention took place for 5 days a week for 6 week for 20 minutes. Pre measurement was taken before the intervention and after 6 weeks post measurement was taken.
41499832|NCT06232330|DEVICE|Group B|This group will receive PNF techniques for trunk control. Rhythmic initiation and Rhythmic stabilization for a span of 20 minutes on both sides. In rhythmic initiation patient will move passively from trunk flexion into extension and then back to the flexed position When the patient is relaxed and moving easily, ask for active assisted motion Then begin resisting the motion then patient will perform independently in rhythmic stabilization Resist an isometric contraction of the patient's trunk flexor muscles patient will match the resistance in front and then in back
41026104|NCT02790385|DEVICE|Negative Pressure Wound Therapy|
41026105|NCT02790385|OTHER|Standard Gauze Treatment|
41362883|NCT01723527|DRUG|Methadone|Clinic-Based Methadone Maintenance Treatment
41026106|NCT04193813|OTHER|Observational|Observational study
41026107|NCT00002408|DRUG|Crofelemer|
41026108|NCT00834457|DRUG|abacavir/3TC/zidovudine|continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks
41026109|NCT00834457|DRUG|abacavir /3TC plus ritonavir boosted lopinavir|fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
41026110|NCT02212223|DIETARY_SUPPLEMENT|Vitamin D3|
41026111|NCT01707602|BIOLOGICAL|INTANZA® 15|intradermal vaccination
41026112|NCT01707602|BIOLOGICAL|Vaxigrip®|Intramuscular vaccination
41026113|NCT01707602|BIOLOGICAL|INTANZA® 15 T|transcutaneous vaccination
41026114|NCT05812261|OTHER|Creating an electro-anatomical map|After the routine pulsed-field ablation procedure, the operator will create an electro-anatomical map using the ablation catheter and a 3D mapping system.
41026115|NCT03961594|OTHER|expansion volémique|cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
41026116|NCT00746954|DRUG|Acetazolamide|Cabonic Anhydrase inhibitor
41026117|NCT00746954|DRUG|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
41362884|NCT01723527|DRUG|Buprenorphine|Clinic-Based Buprenorphine Maintenance Treatment
40842281|NCT00119496|DRUG|beclomethasone|inhaled beclomethasone, 200mcg bd
40842282|NCT00119496|DRUG|inhaled beclomethasone and oral theophylline|inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
41026118|NCT01165281|DRUG|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
41026119|NCT01165281|DRUG|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
41026120|NCT01326364|PROCEDURE|Stereotactic body radiotherapy|Standard of Care
41026121|NCT01326364|DRUG|Iodixanol|IV, calculated per patient
40842283|NCT00265265|DRUG|Atomoxetine|
40842284|NCT02788058|DRUG|EGFR-TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
41026122|NCT01326364|DRUG|Iohexol|IV, Calculated per patient
41026123|NCT02063503|OTHER|physiotherapy|every group receives 2 treatments every week during 9 consecutive weeks
41026124|NCT03041415|BEHAVIORAL|ALED Alone Physical Activity Program|• 12-week class focused on teaching self-regulatory skills to increase regular PA
41026125|NCT03041415|BEHAVIORAL|ALED + Our Voice PA Program|"* 12-week class focused on teaching self-regulatory skills to increase regular PA~* Neighborhood assessment, consensus-building, \& advocacy program in which participants are taught skills to promote neighborhood-level changes in support of regular Physical activity"
41362885|NCT01723527|BEHAVIORAL|Employment-based drug abstinence reinforcement|
41362886|NCT06050811|DIETARY_SUPPLEMENT|2'-Fucosyllactose|2'-Fucosyllactose given orally with water or food for four weeks, followed by a three week washout period.
41362887|NCT06050811|DIETARY_SUPPLEMENT|Placebo|Maltodextrin given orally with water or food for four weeks, followed by a three week washout period.
41026126|NCT03888144|DRUG|Oxycodone|5 mg of oxycodone taken by mouth every 6 hours for 5 days
41026127|NCT03888144|DRUG|Ketorolac|10 mg of ketorolac taken by mouth every 6 hours for 5 days
41026128|NCT03830671|DRUG|18-month regimen containing 6 anti-TB drugs|Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
41362888|NCT01122719|DEVICE|Drug Eluting Stent|
41499833|NCT04717492|OTHER|Observational|Observational
40842285|NCT02788058|RADIATION|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
41499834|NCT04889924|RADIATION|Axillary Radiotherapy|Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain
41499835|NCT04889924|PROCEDURE|Lymphadenectomy|Axillary Lymph node dissection
41499836|NCT02817945|DRUG|68Ga-NOTA-3P-TATE-RGD|68Ga-NOTA-3P-TATE-RGD were injected into the patients before the PET/CT scans
41499837|NCT03226535|DEVICE|Ultrasound-CT Fusion|The Clear Guide SCENERGY is an Ultrasound-CT fusion device which supplements existing ultrasound and CT capabilities. The participants randomly selected (out of 20 patients) for use of the Clear Guide SCENERGY (test group) will receive ultrasound-CT fusion guidance from the MDs performing the procedure.
41499838|NCT04117919|DRUG|paper mulberry leaf|Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
41499839|NCT04117919|DRUG|Triamcinolone (Encort-A) 0.1%15g/Tube|only Topical steroids
41160930|NCT04747847|DRUG|Atorvastatin and anakinra|Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day in children with acute KD at least 1 year old with CAA
41499840|NCT05443581|BEHAVIORAL|dietary intervention|Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.
41499841|NCT01806766|PROCEDURE|Ceramic on Ceramic bearing|cementless Total Hip Arthroplasty with Ceramic on ceramic bearing
41499842|NCT01806766|PROCEDURE|Ceramic on Highly crosslinked polyethylene bearing|Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
41499843|NCT06632977|OTHER|Genetic testing|undergo genetic testing
41499844|NCT06632977|DRUG|Valemetostat Tosylate|Given PO
41499845|NCT06632977|PROCEDURE|Magnetic Resonance Imaging|undergo Magnetic Resonance Imaging
41499846|NCT06632977|PROCEDURE|Computed Tomography|undergo Computed Tomography
41499847|NCT06632977|PROCEDURE|Bone scan|undergo Bone scan
41499848|NCT06632977|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET
41499849|NCT06632977|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
41499850|NCT06632977|PROCEDURE|Biospecimen Collection|undergo blood collection
41499851|NCT06632977|DRUG|Carboplatin|Given IV
41499852|NCT06632977|DRUG|Cabazitaxel|Given IV
41499853|NCT06632977|DRUG|Abiraterone Acetate|Given PO
41499854|NCT06632977|DRUG|Enzalutamide|Given PO
41499855|NCT06632977|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
41499856|NCT05265273|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
41499857|NCT06075576|DIAGNOSTIC_TEST|Intervention|No test articles will be used in the study. However, while taking measurements, the subject's eye will be exposed to light or light flashes that are about the same or lesser intensity than those in a routine eye exam in an eye care provider's office.
41499858|NCT02432157|DRUG|HTS 3%|3% HTS at a dose of 250 ml every 6 hours for 7 days
41499859|NCT02432157|DRUG|Standard fluid management|Routine fluid management strategy as pre-specified by our SAH management protocol.
41499860|NCT05652335|DRUG|JNJ-79635322|JNJ-79635322 will be administered as SC injection.
41499861|NCT01025271|DRUG|Daptomycin|one dose of daptomycin (10 milligrams of the drug per kilogram of the subject's body weight
41499862|NCT06137118|DRUG|AZD0486|Investigational Product administered via intravenous infusion.
41499863|NCT05134337|DRUG|LOXO-305|Oral LOXO-305
41499864|NCT05134337|DRUG|Itraconazole|Oral itraconazole
41499865|NCT05134337|DRUG|Rifampin|Oral rifampin
41499866|NCT05418244|OTHER|Inhaled Isopropyl Alcohol|Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares
41499867|NCT05418244|DRUG|Oral Ondansetron|4 mg oral disintegrating ondansetron tablet once
41499868|NCT05418244|OTHER|Inhaled Placebo|Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares
41499869|NCT05326230|DEVICE|Paradise™ (PRDS-001) Renal Denervation Ultrasound System|Following renal angiogram according to standard procedures, subjects remain blinded and are randomized to treatment with renal denervation or sham control
40842286|NCT03320330|OTHER|Laboratory Biomarker Analysis|Correlative studies
40842287|NCT03320330|BIOLOGICAL|Pepinemab|Given IV
40842288|NCT03320330|OTHER|Pharmacological Study|Correlative studies
41160931|NCT00509821|DRUG|Enzastaurin 500 milligram (mg) Once Daily (QD)|1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression, given with and without radiotherapy treatment.
41499870|NCT05326230|DEVICE|Renal Angiogram|Following renal angiogram according to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure
41499871|NCT05819723|OTHER|CAM score|"The CAM scores assess the presence of delirium rapidly and accurately and also differentiates delirium from other cognitive impairment with a sensitivity of 94-100% and specificity of 90-95%.~It is an algorithm that consists of four features:~(i) Acute and fluctuating variation in mental status, (ii) Inattention, (iii) Incoherent or disorganized thinking, and (iv) Altered level of consciousness. CAM scores indicate delirium if the first two features are present and either the third or fourth feature is present."
41499872|NCT00020371|DRUG|BMS-247550|
41499873|NCT00020371|DRUG|filgrastim|
41499874|NCT04769414|DRUG|Gemcitabine fluorouracil|"chemotherapy protocol given as:~* Gemcitabine 1000mg/m2 IV short infusion~* Leucovorin 400 mg/m2 IV short infusion~* Flourouracil 400 mg/m2 direct IV shot~* Flourouracil 2000 mg/m2 contineous infusion over 46 hours~The whole regimen will be repeated bi-weekly"
41499875|NCT03112330|DEVICE|Plasma rich platelet injection|Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
41499876|NCT03112330|DEVICE|Saline nasal spray|two puffs of isotonic saline nasal spray twice daily
41499877|NCT06498869|DRUG|Ketamine Hcl 50Mg/Ml Inj|This group will be administered ketamine (0.25-0.50 mg/kg)
41026129|NCT02641080|DRUG|Aspirin|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
41026130|NCT02641080|DEVICE|Portable Compression Device|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
41026131|NCT06098599|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.
41026132|NCT03471689|BEHAVIORAL|Mindfulness meditation|Participants will be trained to use mindfulness meditation to reduce pain perception.
41026133|NCT03471689|BEHAVIORAL|Positive reappraisal|Participants will be trained to use positive reappraisal to reduce pain perception.
41026134|NCT03600285|DEVICE|TB1-K|Use of TB1-K for preservation and transport of donated kidneys
41362889|NCT05879016|OTHER|Functional Correction Technique|A single I strip will be used for this technique. Taping will be done by applying moderate (25-35%) degree of stretching to the middle 1/3 of the tape, with the stretched area centered on the trigger point. The ends of the tape will be adhered without stretching.
41026135|NCT02687334|DRUG|100% Oxygen|We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
41362890|NCT05879016|OTHER|Fascia Correction Technique|Y tape will be applied to prevent fascia adhesions. In the Y tape application, first the tail strips of the Y will be adhered with maximum tension so that the muscle fiber is transverse. Then it will be glued so that its base is in front of the pain point. No tension will be applied to the ends of the tape. The application will be applied when the patient is in a resting position and his joints are in a tense position.
41362891|NCT05879016|OTHER|Star Taping Technique|4 I tapes of the same length between 15 cm and 20 cm will be glued on top of each other. After the first I tape is adhered, the 2nd I tape will be adhered at 90 degrees, then the 3rd and 4th I tapes will be adhered at 45 degrees to obtain a star appearance. There will be no tension at the ends of the tapes
41362892|NCT05879016|OTHER|Sham Comparator|I shape tape will be adhered for sham purpose without applying any tension.
41362893|NCT03582254|RADIATION|[18F]-FDG PET/MR|"\[18F\]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:~* prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),~* after two chemotherapy cycles (PET#2),~* at the end of the first-line chemotherapy regimens (PET#3)."
41362894|NCT03982069|BIOLOGICAL|FluMist live attenuated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.
41362895|NCT03982069|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
41362896|NCT03531099|PROCEDURE|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
41362897|NCT03531099|BIOLOGICAL|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
41362898|NCT03531099|DEVICE|MRI|MRI exam will be regularly performed during patient follow up.
41362899|NCT03531099|OTHER|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
41362900|NCT03531099|PROCEDURE|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
41362901|NCT05535803|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Autologous olfactory mucosa-derived mesenchymal stem cells
41026136|NCT03977844|OTHER|Technical Assistance|"TA for Individual Programs TA uses experts to train program staff via webinars and site visits, using the same toolkits as CEP, in a train the trainer approach. TA provides a series of webinars and as needed site visits, focused in the example of depression care on team support for assessment, treatment support as appropriate with medication and/or psychotherapy, case management and educational resources and access to intervention toolkits. It also includes webinars and training toolkits for agencies on domains of social risk factors for health (financial security and housing security) as well as disaster preparedness and recovery."
41160932|NCT00509821|DRUG|Enzastaurin 250 mg Twice Daily (BID)|1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression, given with and without radiotherapy treatment.
41160933|NCT02445183|OTHER|None, N/A|
41362902|NCT05535803|OTHER|Patients treated according to current clinical protocols|Patients treated according to current clinical protocols
41362903|NCT02592980|GENETIC|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
41362904|NCT02592980|DRUG|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
41362905|NCT01099670|DRUG|NRL001|Rectal suppository Placebo
41362906|NCT01099670|DRUG|Placebo|Placebo
41362907|NCT05021159|OTHER|MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)|the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
41362908|NCT05649020|DRUG|Dose of prilocaine|With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
41362909|NCT03937882|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
41362910|NCT03937882|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
41362911|NCT02249273|OTHER|Diagnostic approaches|General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
41362912|NCT04264611|OTHER|Experimental: Short Foot Exercise Group|Short foot exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
41362913|NCT04264611|OTHER|Experimental: Towel Curl Exercise Group|Towel curl exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
41362914|NCT03054311|BEHAVIORAL|Lifestyle Matters|
41362915|NCT01639599|DRUG|Dexamethasone iv injection|Dexamethasone 5mg iv during anesthesia induction
41362916|NCT01639599|DRUG|Dexamethasone, haloperidol|dexamethasone + haloperidol 1mg
41362917|NCT01639599|DRUG|Dexamethasone, haloperidol|Active Comparator: dexamethasone + haloperidol 2mg
41499878|NCT05017961|DEVICE|Autograft|An autograft bone will be harvested from proximal tibia or posterior superior iliac crest. First the bony landmarks of the posterior iliac crest or proximal tibia are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. After 1 cm skin incision and gentle dissection of subcutaneous soft tissue, the bone harvesting device inserted through the skin and subcutaneous tissues until it reaches the cortical bone. Then, manual pressure is used to position the bone harvesting device against the dense cortical bone. A battery-powered power instrument is then will be used to drill the harvesting device into the medullary cavity. After the harvesting device insertion the cancellous strips of bone will be harvested and applied to the fracture site gap.At the conclusion of autograft bone harvesting procedure, the wound will be closed with 3-0 Nylon and a sterile dressing will be applied to the harvest site.
41499879|NCT05017961|DEVICE|Allograft only|The jar containing allograft tissue and cryopreservation solution will be placed in a sterile basin containing a warm (35°C to 39°C; 95°F to 102.2°F) sterile irrigant (Normal saline or 5% Dextrose in Lactated Ringer's Solution). The jar containing the allograft will remain in this solution until the contents of the jar flows freely upon inversion. The jar will be removed from the warm solution once free-flowing. Sterile gauze or the optional strainer will be used to decant the cryopreservation solution into a waste container. 5% Dextrose in Lactated Ringer's Solution will be added to the indicated fill line to immerse the allograft tissue. The cap will be replaced and inverted twice to suspend tissue until ready for use. 5% Dextrose will be decanted in Lactated Ringer's Solution prior to use. Implant will be used within 2 hours of thawing.
41160934|NCT01797978|DRUG|Intravenous methylene blue administration|Initial history taking and physical examination --\> enrollment --\> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
41160935|NCT01797978|DRUG|Placebo|
41362918|NCT05421559|PROCEDURE|thyroidectomy|removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle
41362919|NCT06010264|OTHER|Kinesiotape|"In the kinesiotaping group, kinesiotape was applied from the first postoperative day in addition to conservative treatment.~Kinesiobant application was performed regularly until the 6th week by a researcher with a certificate in kinesiobanting in accordance with the lymphatic correction and pain inhibition techniques described by Kenzo Kase.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
41499880|NCT05017961|DEVICE|Allograft combined with BMAC|A bone marrow aspiration kit will be used for bone marrow aspiration. First the bony landmarks of the posterior iliac crest and sacroiliac joint are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. Then, the bone marrow aspiration trochar and needle are percutaneously inserted through the skin and subcutaneous tis- sues until it reaches the posterior iliac crest. The trajectory of the needle will be parallel to the iliac crest, or perpendicular to the Anterior Superior Iliac Spine (ASIS) or Posterior Superior Iliac Spine (PSIS), depending on the harvest site used. After the trochar is inserted into the posterior iliac crest but prior to aspiration, 1 mL of heparin (1,000 U/mL) will be preloaded into the syringe. Approximately 60 mL of bone marrow will be aspirated, which requires the use of two 30-mL syringes. At the conclusion of BMAC harvesting, a sterile dressing will be applied to the harvest site.
41499881|NCT03697863|PROCEDURE|Noninvasive Respiratory Support|Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist
41499882|NCT04293900|OTHER|24-hour dietary recall|Dietary intake assessment conducted by a Registered Dietitian Nutritionist. This assessment will occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
41499883|NCT04293900|OTHER|Hand grip strength|Measurement of grip strength using a hand dynamometer. This will test occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
41499884|NCT04293900|OTHER|International Physical Activity Questionnaire|Survey about physical activity over the previous 7 days. This survey will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
41499885|NCT04293900|OTHER|Patient-reported outcomes survey|Survey about symptoms and side effects experienced during cancer treatment. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
41499886|NCT04293900|OTHER|Pittsburgh Sleep Quality Index|Survey about sleep habits and quality over the past month. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
41499887|NCT04293900|OTHER|Functional Assessment of Cancer Treatment - Lymphoma|Survey about quality of life for people with a diagnosis of lymphoma. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
41499888|NCT04293900|OTHER|urine sample (optional)|Collect three urine samples either in the clinic or at home. This specimen collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
41499889|NCT04293900|OTHER|fecal sample (optional)|Collect a fecal sample either in the clinic or at home. This sample collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
41499890|NCT02189980|OTHER|Aromatherapy blend|A blend of 45% ginger, 25% peppermint, 5% spearmint, and 25% cardamom essential oils
41026137|NCT03977844|OTHER|Community Engagement and Planning|CEP for Coalitions CEP creates multi-sector networks to collaborate in evidence-based and community-prioritized toolkits or intervention materials. CEP supports a series of biweekly to monthly meetings to develop network and individual program capacity, prepare stakeholders as co-leads, and create a written training plan following CPPR principles \[48, 64\]. CEP councils consider local context, i.e., cultural assets and stakeholder input. Disaster preparedness and public health sectors will be encouraged to offer education/resources on social determinants and disasters within CEP training plans. CEP will be supported by a Learning Collaborative, meeting 2-3 times, using activities such as project examples, tabletop exercises and self-assessment to identify gaps and formulate goals for improvement.
41026138|NCT03977844|OTHER|Community Resources (CR)|The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
41160936|NCT02262364|BIOLOGICAL|APS|See above
41362920|NCT06010264|OTHER|Shamtape|"In the sham taping group, sham tape was applied from the first postoperative day in addition to conservative treatment. Medical flasters were used as sham tape. Sham tapes were applied by cutting in the same fan shape as in kinesioband.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
41362921|NCT06010264|OTHER|Standard Physiotherapy Program|Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain
41362922|NCT05342727|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
41362923|NCT05342727|DEVICE|transcranial alternating current stimulation (tACS)|In tACS, alternating electrical currents at the frequency of interest (8 Hz for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
41362924|NCT05450380|DEVICE|LIFT001|"The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face."
41499891|NCT02189980|OTHER|Duration of effectiveness of the essential oil blend|Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.
41499892|NCT02189980|OTHER|Participant comfort using the nasal clip delivery system|Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.
41499893|NCT00660400|DRUG|5-azacitidine|Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M\^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
41499894|NCT00660400|PROCEDURE|Allogeneic Hematopoietic Cell Transplantation (HCT)|"Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.~* Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.~* The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.~* All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant."
41499895|NCT06017076|OTHER|Oral energy drinks|Patients drank energy drinks (Red Bull®) 250ml about 2-2.5 hours before operation.
41160937|NCT04939883|DRUG|Carvedilol|Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications
41499896|NCT06017076|DEVICE|Warming matress|From the end of anesthesia, warming matriss at 40 ℃ was used to keep warm until the end of surgery.
40842289|NCT01862653|DEVICE|Auricular Acupuncture|Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
40842290|NCT01010152|DRUG|Codeine Sulfate|30 mg Tablet
40842291|NCT02891382|BEHAVIORAL|Diabetes education|Participants interact with a diabetes educator (DE), every two weeks.
40842292|NCT02891382|BEHAVIORAL|Goal setting|Goals for weight loss and change in levels of HbA1c
40842293|NCT02891382|BEHAVIORAL|Companion Support|Patient has a companion/team support partner to support achieving goals.
40842294|NCT02891382|BEHAVIORAL|Individual Reward|The cash reward is given to the patient with diabetes.
40842295|NCT02891382|BEHAVIORAL|Shared Reward|Patients with diabetes and their companion support will each receive 50% of the cash reward.
41362925|NCT05080686|DEVICE|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.
41362926|NCT03846323|OTHER|Visiting policies: 24 hours a day, 7 days a week|
41362927|NCT03846323|OTHER|Restriction of visiting policies < 6 hours|
41362928|NCT03773146|OTHER|1X Airtime Incentive|An incentive given in the form of airtime
41362929|NCT03773146|OTHER|Lottery Airtime Incentive|An incentive given in the form of airtime
41362930|NCT06321796|COMBINATION_PRODUCT|MTP-101P|"MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.~Duration: 12.5 Weeks"
41362931|NCT06321796|COMBINATION_PRODUCT|Vancomycin|"Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 10 Days"
41362932|NCT06321796|COMBINATION_PRODUCT|Magnesium Citrate|"Magnesium citrate is a common over-the-counter laxative and bowel cleanse.~Duration: 1 Day"
41362933|NCT06321796|COMBINATION_PRODUCT|Antacid|"The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12.5 weeks"
41362934|NCT06321796|COMBINATION_PRODUCT|Placebo MTP-101P|"The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12.5 weeks"
41362935|NCT06321796|COMBINATION_PRODUCT|Placebo Vancomycin|"Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 10 days"
41362936|NCT04850105|OTHER|Data Collection|"Data on each patient will be collected at study enrollment and at each follow-up visit.~No mandatory visits, tests, or assessments are required for this study. All visits will be scheduled and conducted according to the clinical site's normal clinical practice."
41499897|NCT03951025|DIETARY_SUPPLEMENT|Melatonin oral administration|One tablet with1 mg of melatonin and 82 mg of excipients
41499898|NCT03951025|DIETARY_SUPPLEMENT|Melatonin sublingual administration|One tablet with 1 mg of melatonin and 82 mg of excipients
41499899|NCT00405808|DRUG|Rimonabant|Once daily in the morning
41499900|NCT00405808|DRUG|Placebo|Once daily in the morning
41499901|NCT06634290|DEVICE|intramedullary nailing augmentation|Treatment of pertrochanteric hip fractures with intramedullary nailing with cephalic augmentation with bone cement
41499902|NCT06634290|DEVICE|intramedullary nailing|Treatment of pertrochanteric hip fractures with intramedullary nailing without cephalic augmentation
40842296|NCT05097352|BEHAVIORAL|High Intensity Interval Training (HIIT)|Twenty minutes of HIIT will be completed three days a week for six weeks.
40842297|NCT05097352|OTHER|Waitlist|Waitlist participants will be tested on the outcomes at the same time points as the treatment group.
40842298|NCT04654078|DRUG|IN-C004 with water|One time dose of IN-C004 taken with water
40842299|NCT04654078|DRUG|IN-C004 without water|One time dose of IN-C004 taken without water
40842300|NCT04654078|DRUG|K-CAB tab. with water|One time dose of K-CAB tab. taken with water
40842301|NCT03610009|DEVICE|2D ultrasound|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.
40842302|NCT03610009|DEVICE|SonoAVC|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
40842303|NCT03203291|DEVICE|TPAD (Tethered Pelvic Assist Device)|Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
40842304|NCT01060436|DEVICE|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
40842305|NCT03239938|BEHAVIORAL|Modern pain neuroscience approach|The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
40842306|NCT03239938|BEHAVIORAL|Usual care evidence-based physiotherapy|The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
40842307|NCT03772054|DRUG|Sevoflurane|Inhalation anesthetic agent
41362937|NCT04531891|OTHER|Fatigue protocol|During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
41362938|NCT05502406|PROCEDURE|Instrument Assisted Soft tissue Mobilization|Using a C shaped IASTM tool gentle horizontal stroking at an angle of 45 degree will be given over the cervicodorsal fascia
41499903|NCT04461158|BEHAVIORAL|Patient Navigator Services|The navigator services most commonly provided include facilitation and coordination of care, practical support, including transportation and financial assistance, appointment scheduling and reminders, education and psychosocial support
40842308|NCT03772054|DRUG|Propofol|Intravenous anesthetic agent
40842309|NCT04797806|DRUG|Anlotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle.
40842310|NCT04797806|DRUG|Icotinib|Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
40842311|NCT05578378|DRUG|Cladribine|Cladribine combine with cytarabine will be intravenous on days 1-5; G-CSF will be hypodermic injection on day0-5,4 weeks per cycle.
40842312|NCT05578378|DRUG|Fludarabine|"Control arm~Patients in the control arm received the investigator's choice of one of the following three regimens:~FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~a high-dose cytosine arabinoside-based regimen; a high-dose methotrexate-based regimen"
41499904|NCT02927366|DRUG|QCC374|0.03 mg (2 capsules of 0.015 mg) BID 0.06 mg (1 capsule of 0.06 mg) BID 0.12 mg (2 capsules of 0.06 mg) BID
41362939|NCT05502406|PROCEDURE|Manual Myofascial Release|"Participants will receive myofascial release through velvet glove technique on upper trapezius and sternocleidomastoid muscle using four strokes in the following fashion:~* Begin superior to the clavicle with a loose fist and move the back of the hand over the upper trapezius, fastening the tissue and bringing it over the table.~* The next stroke addresses the curve of the neck, again hooking the tissue while moving the bak of your fist towards the table.~The last stroke goes over the entire cervical spine hooking over the sternocleidomastoid muscle bringing it into myofascial release. Stay away from the carotid pulse, and incase a pulse is felt, do not apply pressure and reposition your hand"
41499905|NCT02927366|DRUG|Placebo Matching|"Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID"
41499906|NCT06030986|DIAGNOSTIC_TEST|ILCOR Utstein OHCA Core Outcome|ILCOR Utstein OHCA Core Outcome
41499907|NCT06063616|OTHER|Reiki|Level I Reiki was applied to 9 points and nearby areas for 30 minutes, three sessions a week, for a total of four weeks, in the first three hours of the HD treatment, by the researcher, who completed his second level training according to the Usui method, in line with the Reiki/Sham Reiki Application Protocol.
40842313|NCT01651091|OTHER|Meditation Awareness Training|Psychotherapy Intervention
40842314|NCT01651091|OTHER|Treatment as usual|
40842315|NCT03891628|BEHAVIORAL|Modified Attachment and Biobehavioral Catch-up|Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
40842316|NCT03891628|BEHAVIORAL|Modified Developmental Education for Families|Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
40842317|NCT04086992|OTHER|Remote monitoring|Caregivers will be able to monitor blood pressure from home and upload in a cloud-based application on a hand-held tablet. In addition, this technology will administer surveys to the caregiver to assess for therapy side effects and adherence. Nurse-led telemedicine visits will also be utilized. The healthcare team will be able to monitor these parameters remotely.
40842318|NCT04809155|BEHAVIORAL|Girl2Girl|The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later.
41362940|NCT03047408|PROCEDURE|Video polysomnography|the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
41499908|NCT06063616|OTHER|Sham Reiki|Sham Reiki was applied to 9 points and nearby areas in accordance with the Reiki/Sham Reiki Application Protocol, for a total of four weeks, three sessions per week, for 30 minutes, in the first three hours of the HD treatment, by two students who had not received Reiki training, and were given training on the application by the researcher.
41499909|NCT02987452|OTHER|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
40842319|NCT05042180|BEHAVIORAL|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
40842320|NCT05042180|BEHAVIORAL|CBT|The active comparator receives 14 conventional cognitive behavioral therapy sessions with
40842321|NCT02942654|DRUG|LY900014|Administered subcutaneously (SC)
40842322|NCT02942654|DRUG|Insulin Lispro|Administered SC
40842323|NCT01174212|PROCEDURE|Prophylactic Antibiotics|Preoperative Antibiotics
41499910|NCT02987452|OTHER|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
41499911|NCT02987452|OTHER|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
40842324|NCT01174212|PROCEDURE|Control Antibiotics|Antibiotics will be held until intraoperative cultures have been obtained.
40842325|NCT04524624|DEVICE|AI-based CDSS|"1. Automatically identifying acute ischemic stroke lesions on DWI.~2. Classification of stroke subtypes and mechanisms.~3. Evidence-based alerts and guidelines for early stroke management.~4. Guideline-recommended secondary stroke prevention strategies."
40842326|NCT04038762|PROCEDURE|cuff deflation-inflation -deflation method|Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
40842327|NCT02319135|DRUG|Azacitadine|
40842328|NCT02319135|DRUG|Fludarabine|
40842329|NCT02319135|DRUG|Cytarabine|
40842330|NCT02319135|DRUG|Lenograstim|
40842331|NCT02319135|DRUG|Filgastrim|
40842332|NCT05807984|RADIATION|Carbon ion radiation therapy DT: 74Gy/20 fractions|patients with unresectable local recurrent rectal cancer will be treated with carbon ion radiation therapy as re-irradiation
40842333|NCT03459638|OTHER|Screening for DM, ASCVD, MetS and OSAS|Finger stick analysis, questionnaires and clinical measurements
40842334|NCT02658656|DEVICE|ReWalk 6.0|Exoskeletal Assisted Walking Device
40842335|NCT02090361|PROCEDURE|skin graft|Epidermization of the defect by applying a thin layer of autologous epidermis
41160938|NCT04939883|DRUG|Placebo|Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
41499912|NCT05651789|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.
41499913|NCT05651789|DRUG|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
40842336|NCT04450329|DRUG|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.
41026139|NCT03977844|OTHER|Community Resources + eBT|"The CR+eCBT app consists of the functionality of the CR app along with an interactive component to support CBT-informed coping with mood and stressors at the individual level. This component was developed previously by our group using participatory methods with community partners and includes interactive support to enhance social support networks, support cognitive restructuring (framed through partnered input as Catch it, Check it, Change it), and encourage pleasant activities \[65\]. Participants will receive text message notifications (with frequency set by participants, up to several times per day) and can either reply back to messages to explore content or click a link in the message to access the interactive mobile app."
41026140|NCT03874000|BIOLOGICAL|Sintilimab|Given IV
41026141|NCT03874000|DRUG|Metformin Hydrochloride|Given PO
41362941|NCT03223025|DRUG|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
41362942|NCT03223025|DRUG|Nordilet®|0.03 mg/kg daily subcutaneous injections
41362943|NCT02546739|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
41362944|NCT06151821|BEHAVIORAL|Guided meditation|Meditation with guidance
41362945|NCT00211198|DRUG|ONTAK (denileukin difitox, DAB389IL-2)|
41362946|NCT00911508|DEVICE|Left atrial ablation|"St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path~Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF~Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System~Bard: Stinger~Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath"
41362947|NCT00911508|DRUG|Rate or Rhythm Control Therapy|"Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg"
41362948|NCT02358720|RADIATION|Arm A|1x24Gy high dose IMRT on spinal bone metastasis
41362949|NCT02358720|RADIATION|Arm B|fractionated conformal RT 10 x 3 Gy on spinal bone metastasis
41362950|NCT01572129|DRUG|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
41026142|NCT01594905|DRUG|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
41026143|NCT00648869|DRUG|metformin tablet, metformin gum|500 mg, 250 mg
40842337|NCT04450329|DRUG|Eylea (Aflibercept)|Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
40842338|NCT01501123|DRUG|Haloperidol|5mg IM
40842339|NCT01501123|DRUG|Midazolam|IM midazolam
41026144|NCT03070522|DRUG|Prednisone|oral prednisone for 7 days during pulmonary exacerbation
41026145|NCT03070522|DRUG|Placebos|Placebo
41026146|NCT00335907|PROCEDURE|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
41026147|NCT01762761|DRUG|eltrombopag|TPO-R agonist
41026148|NCT01762761|DRUG|placebo|placebo
41160939|NCT04360642|OTHER|singing|Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities:
41160940|NCT04935762|DRUG|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
41362951|NCT01572129|DRUG|Placebo|Placebo in addition to the chronic daily dose of 75 mg
41362952|NCT00529594|DRUG|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
40842340|NCT01331928|DRUG|Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)|capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
41362953|NCT00529594|DRUG|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
41362954|NCT00816543|DRUG|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
41362955|NCT00816543|DRUG|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
41362956|NCT00816543|DRUG|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
41026149|NCT02545894|BEHAVIORAL|Cognitive therapy|"The tasks are:~* visually tracking a picture as it moves across the computer screen~* pressing a button every time a picture is seen on the screen~* pressing a button every time a specific picture is seen on the screen~* Pressing a button every time a specific sound is heard~* Matching objects to a picture~* Matching gestures to objects~* Matching two connected objects~* Sorting objects by categories~* Matching sounds to objects~* Complete the category and odd on out with objects~* Choosing target objects by pointing~* Choosing objects to complete the category by pointing"
41026150|NCT03178734|DEVICE|Foley Catheter vs Self-Contained Valved Catheter|This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
41026151|NCT06534736|PROCEDURE|Electrotherapy and physical agents|It will comprise of hot pack for 10 minutes, Tens for 10 minutes.
41160941|NCT00277342|PROCEDURE|measurement of lipid-induced hepatic insulin resistance|
41362957|NCT04380480|COMBINATION_PRODUCT|Concurrent chemoradiotherapy combined with enteral feeding by percutaneous endoscopic gastrostomy|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
41362958|NCT06498570|DEVICE|Intracorneal rings|The (ICRS), intracorneal rings segments implantation surgery
41362959|NCT01866280|BEHAVIORAL|Normal sleep|Normal sleep= sleep 2300-0700
41362960|NCT01866280|BEHAVIORAL|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
41362961|NCT01866280|BEHAVIORAL|Late sleep|Late sleep=sleep at 0230-1030 hours
41362962|NCT01866280|BEHAVIORAL|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
41499914|NCT05485987|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
41499915|NCT02494986|DRUG|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
40842341|NCT03281304|DRUG|CP-690,500 5 mg|CP-690,550 5 mg tablet BID
40842342|NCT03281304|DRUG|CP-690,550 10 mg|CP-690,550 10 mg tablet BID
40842343|NCT04455945|PROCEDURE|Open Rectal cancer surgery|Open sphincter preserving surgery for rectal cancer
41160942|NCT02329223|BIOLOGICAL|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
41160943|NCT02329223|OTHER|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
40842344|NCT04455945|PROCEDURE|Laparoscopic Rectal cancer surgery|Laparoscopic sphincter preserving surgery for rectal cancer
40842345|NCT00428870|PROCEDURE|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
41160944|NCT04462497|OTHER|Prototype device|Patients will receive the prototype head and neck support device to be used intraoperatively.
41160945|NCT04518761|PROCEDURE|Elective surgery|Any patient who needs to undergo an elective surgery.
41362963|NCT02846337|PROCEDURE|ULTRAFILTRATION|"Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.~Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.~Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device."
41499916|NCT03482258|DIETARY_SUPPLEMENT|Prebiotic|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This equates to 10g GOS (VGOS is primarily 69% GOS, 23% Lactose).
41499917|NCT03482258|DIETARY_SUPPLEMENT|Maltodextrin|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This will be matched to VGOS for lactose (3.3g per dose of maltodextrin will be lactose).
41499918|NCT02033057|PROCEDURE|Muscular electrostimulation and percutaneus muscular biopsy.|Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
41499919|NCT06469281|OTHER|27T51|Intravenous (IV) infusion
41499920|NCT06469281|DRUG|Cemiplimab|IV infusion
40842346|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~4. Trilaciclib: 240mg/m2, d1, d2, d8 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
41362964|NCT02846337|PROCEDURE|ENHANCED MEDICAL TREATMENT|"* Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample~* Medical care adjustment in order to apply European and American guidance for chronic heart failure care~* Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed~* Physical rehabilitation suggestions by a physiologist~* Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance."
41026152|NCT06534736|PROCEDURE|Post Facilitation Stretch|Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles
41160946|NCT01701271|OTHER|Hair loss prevention lotion|For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
40842347|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
40842348|NCT05257343|DIETARY_SUPPLEMENT|Liquid Placebo Supplementation|8-weeks of supplementing with a visually identical liquid placebo supplement.
40842349|NCT05257343|DIETARY_SUPPLEMENT|Liquid Iron Supplement (Blood Builder ®)|8-weeks of supplementing with a liquid iron supplement (Blood Builder ®)
41362965|NCT05162534|OTHER|effect of COVID-19 exposure|effect of COVID-19 exposure
40842350|NCT05571774|OTHER|collection data|collection data
40842351|NCT00410306|DRUG|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
40842352|NCT03590951|OTHER|Retrospective chart review|A retrospective chart review was conducted to evaluate the effect of body mass index on obstetric, anesthetic and neonatal complications in patients who underwent cesarean section at our institution
40842353|NCT03782441|DEVICE|Prototype 0.5|Investigational Medical Device collecting spectral Raman data from tissue
40842354|NCT03381027|PROCEDURE|Baby Massage|Structured massage of the baby
41362966|NCT01241643|DRUG|CYT107|repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
41362967|NCT00039936|BEHAVIORAL|Cognitive Behavior Treatment|
41362968|NCT00039936|BEHAVIORAL|Self Help|
41362969|NCT00039936|BEHAVIORAL|Partial Self Help|
41362970|NCT02718365|PROCEDURE|Wedge resection|A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
41499921|NCT06469281|DRUG|Bevacizumab|IV Infusion
41499922|NCT06525311|DRUG|K-808|K-808 single or multi dose extended-release tablets
41499923|NCT04577833|DRUG|Niraparib|Niraparib will be administered orally.
41499924|NCT04577833|DRUG|Abiraterone Acetate (AA)|Abiraterone Acetate will be administered orally.
40842355|NCT04132674|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Taking one oral tablet of B/F/TAF once-daily for 72 weeks
41362971|NCT02718365|PROCEDURE|Segmentectomy|A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
41499925|NCT04577833|DRUG|Prednisone|Prednisone will be administered orally.
41499926|NCT02278055|DRUG|Radium-223|
41499927|NCT02329535|DRUG|Micronized progesterone|vaginal caps 400 mg daily up to 36 weeks of gestation
40842356|NCT05577637|DRUG|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
40842357|NCT06422637|DIAGNOSTIC_TEST|Liquid Biopsy Early Screening|An early screening model for lung cancer aids in identifying individuals with early-stage lung cancer. Those with positive indications of lung cancer will subsequently undergo confirmatory clinical assessments using Low-Dose Computed Tomography (LDCT) in sequence. Ultimately, a definitive diagnosis of lung cancer is established through surgical and pathological examination.
40842358|NCT06219421|OTHER|Clinical data reuse|Clinical data reuse
40842359|NCT02073851|DEVICE|TriGuard™HDH|TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
40842360|NCT00086099|DRUG|Idarubincin and Amufostine (Ethyol)|Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
40842361|NCT00086099|DRUG|Idarubincin|Idarubincin (12mg/m2) and ara-C(N-18)
41362972|NCT02198040|OTHER|Manual Therapy|"* 5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~* 15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~* 15 minutes. Passive muscle stretching (within the limits of mobility).~* 15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~* 10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
41362973|NCT02198040|OTHER|Educational group|"* Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
41026153|NCT06534736|PROCEDURE|Scapular Stabilization Exercise|Scapular Stabilization exercises protocol will consist of scapular wall slide exercise, scapular retraction, wall Ball Circle exercises, scapula squeeze, wall press ups. Exercise program 3 sets of 5 - 10 repetition for 10 seconds hold a 20 second break between each sets. The intervention will be applied 2 weeks 3 times a week and 30 min per session. Post Facilitation stretch of the targeted muscles also will be carried out during the sessions
41362974|NCT02663024|BIOLOGICAL|idursulfase beta|IV, weekly infusion for 24 weeks
41362975|NCT02663024|BIOLOGICAL|idursulfase|0.5 mg/kg, iv, weekly infusion for 24 weeks
41026154|NCT05907369|OTHER|Active EC training|The active EC includes pairing contamination-related pictures (CSs) with pleasant pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels.
41362976|NCT02636049|DRUG|Triferic|Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
41362977|NCT04020042|OTHER|Ultrasound image guidance|Epidural landmarks will be determined with using ultrasound image
41362978|NCT04020042|OTHER|Landmark palpation|Epidural landmarks will be determined with palpation
41362979|NCT03417102|DRUG|fitusiran|solution for injection; by subcutaneous (SC) injection
41362980|NCT03417102|DRUG|Bypassing agents|solution for injection; by intravenous (IV) injection
41362981|NCT02319798|OTHER|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
41362982|NCT02319798|OTHER|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
41362983|NCT06313567|DRUG|Metronomic capecitabine group|500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
41362984|NCT06313567|OTHER|Observation|observation
41362985|NCT06078059|BIOLOGICAL|Knee aspiration + UCB-MSCs|Knee aspiration and the application of cultered allogeneic umbilical cord blood-derived mesenchymal stromal stem cells (UCB-MSCs).
41362986|NCT06078059|OTHER|Knee aspiration|Knee aspiration
41362987|NCT00003159|DRUG|carboplatin|
41362988|NCT00003159|DRUG|cisplatin|
41362989|NCT00003159|DRUG|docetaxel|
41362990|NCT00003159|DRUG|gemcitabine hydrochloride|
41362991|NCT00003159|DRUG|ifosfamide|
41362992|NCT00003159|DRUG|mitomycin C|
41362993|NCT00003159|DRUG|paclitaxel|
41362994|NCT00003159|DRUG|vinblastine sulfate|
41362995|NCT00003159|DRUG|vinorelbine tartrate|
41362996|NCT00003159|PROCEDURE|conventional surgery|
41362997|NCT00003159|PROCEDURE|neoadjuvant therapy|
41362998|NCT05021731|DRUG|Rifampicin plus Isoniazid|Administration of rifampicin plus isoniazid for latent tuberculosis
41362999|NCT05021731|DRUG|Rifapentine plus Isoniazid|Administration of rifapentine plus isoniazid for latent tuberculosis
41363000|NCT05021731|DRUG|Rifampicin alone|Administration of rifampicin alone for latent tuberculosis
41363001|NCT03487549|COMBINATION_PRODUCT|VP-102 Cantharidin topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.
41363002|NCT03487549|COMBINATION_PRODUCT|VP-102 Cantharidin, topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.
41363003|NCT06347523|PROCEDURE|The VR-based preoperative rehabilitation program;|Patients are provided with VR headsets for personalized pre-rehabilitation educational videos prior to surgery. These videos cover psychological counseling, nutritional advice, and exercise instructions. Additionally, patients engage in VR interactive functional training. After surgery, patients continue with VR technology interactive functional training and watch postoperative educational videos. This intervention is initiated upon the patient's admission and continues until their discharge.
41363004|NCT06347523|PROCEDURE|standard nursing care,|Patients in the control group receive traditional preoperative rehabilitation methods, which may include the following interventions: Joint exercises and rehabilitation exercises guided by a physical therapist. Written or verbal rehabilitation educational materials.
41499928|NCT06551714|PROCEDURE|Phase 1 cardiac rehabilitation|"Day 1:Patients were informed about the surgery, positioning and mobilization.Range of motion (ROM), respiratory control, diaphragmatic breathing, pursed lip breathing, thoracal expansion exercises, assisted coughing,forced expiration techniques, which are the components of active breathing techniques cycle (ABTC), were taught.The use of incentive spirometry (IS) was demonstrated.Patients were performed 10 repetitions of IS exercises, and 5 repetitions ABTC and were asked to repeat them every hour.The patient was made to sit for 10 minutes and was walked 60 meters twice a day.~2:ROM, IS and diaphragmatic breathing exercises were applied 10 times each.ABTC was repeated in 5 sets. 120 meters was walked 5 times during the day.~3:Sitting time was increased to 30 minutes and walking distance was increased to 240 meters.5 steps were climbed.~4:Walking distance was increased to 360 meters.One flight of stairs was climbed.Discharge training was given."
41499929|NCT06551714|PROCEDURE|Neurophysiological facilitation techniques|"In addition to the phase 1 cardiac rehabilitation program for the group receiving neurophysiological facilitation (NPF) techniques:~NPF techniques such as perioral stimulation, intercostal tension, anterior basal lift, vertebral pressure, moderate manual pressure and abdominal co-contraction were applied for ten times for ten seconds.~Diaphragm facilitation exercise was performed by inhaling against resistance and holding the breath against resistance for 5 seconds.~Unilateral and bilateral upper extremity proprioceptive neuromuscular facilitation (PNF) movements combined with breathing were performed.~NPF techniques were performed 10 times each day throughout the treatment, while other applications (diaphragm facilitation, combined breathing exercise with upper extremity PNF technique and respiratory facilitation) were performed 5 times on the first day and 10 times on the other three days."
41499930|NCT01877044|DIETARY_SUPPLEMENT|NAXUS|
41499931|NCT01877044|DIETARY_SUPPLEMENT|Placebo|
41499932|NCT03694899|BEHAVIORAL|phone contact|patients will be called prior to their outpatient appointment
40842362|NCT00616694|DRUG|Actonel|Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
40842363|NCT00366327|DRUG|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
40842364|NCT01733433|PROCEDURE|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
40842365|NCT01420822|DRUG|Fluticasone|Collection of safety data
41363005|NCT00953173|DEVICE|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
40842366|NCT01392287|DRUG|Memantine|"Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8"
40842367|NCT00001088|BIOLOGICAL|APL 400-047|
40842368|NCT00001088|DRUG|Bupivacaine hydrochloride|
41026155|NCT05907369|OTHER|Sham EC training|The active EC includes pairing contamination-related pictures (CSs) with neutral pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels, the same as active EC training.
41026156|NCT05907369|OTHER|Active tDCS|For the active tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum. The brain stimulation is delivered with a 2mA current intensity for 20 minutes in 10 sessions (5 days a week).
41363006|NCT05564962|DIAGNOSTIC_TEST|Quality and Independence of Gait Classification Scale for Duchenne Muscular Dystrophy (QIGS-DMD)|MFM is a valid and reliable measure to evaluate the severity of the motor deficit of both ambulatory and non-ambulatory children with neuromuscular diseases. MFM consists of 32 items in 3 dimensions and is scored as a percentage of the maximum possible score which higher scores indicate better functional status. VLERS is a 10-item ordinal scale that identifies the functional status of the lower limbs. According to VLERS, level 1 indicates that the patient can walk independently and climb stairs without assistance while level 10 indicates is the patient is bedridden.
41363007|NCT00427687|DRUG|AGG-523|
41363008|NCT00665002|BIOLOGICAL|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
41026157|NCT05907369|OTHER|Sham tDCS|For the sham tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum, the same as active tDCS. The device is on for 20 minutes, but the current intensity is under the threshold of affecting cortical activity modulation. The participants receive the sham tDCS in 10 sessions (5 days a week).
41499933|NCT02414776|DRUG|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
41026158|NCT01272934|DRUG|Diclofenac Sodium|Topical gel 1%-4 times daily
41026159|NCT01272934|OTHER|Placebo|Topical gel-4 times daily
41026160|NCT03021382|OTHER|data collection, non-intervention|
41026161|NCT06127069|DEVICE|chitosan brush|debridement of periodontal pockets with ultrasonic scaler first and after with chitosan brush for 2 minutes
41026162|NCT06127069|DEVICE|ultrasonic scaler|debridement of periodontal pockets only with ultrasonic scaler
41026163|NCT00755989|DRUG|morphine topical gel|morphine gel 0.1%, applied every 12 hours to stage 2-3 wound, during their hospital stay
41026164|NCT00755989|DRUG|placebo|topical gel without morphine
41026165|NCT02454426|DRUG|Vortioxetine|open label treatment
41499934|NCT03654599|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
41499935|NCT03654599|BEHAVIORAL|Digital Stories Intervention|Digital Stories Intervention Videos contain the following content: caregiver burden, positive and cognitive coping, support from other family and friends, fear of losing the patient, spirituality, guilt of being sick, and expressing emotions/feelings
41499936|NCT03654599|BEHAVIORAL|Information Control Intervention|Information Control Intervention Videos include Information about post-HCT. The topics in the IC include specific guidelines to return to wellness post HCT through (1) an exercise plan, (2) a nutrition (dietary) plan, (3) pain management, (4) information about the complications, (5) caregiver responsibilities, (6) social support, (7) preventing from infections, and (8) symptom management. Participants randomized to the IC will receive the full set of DS modules only after the final 3-month post-intervention data collection point has passed and they can view them as desired.
41499937|NCT06632938|DRUG|ABBV-382|Subcutaneous (SC) Injection
41499938|NCT06632938|DRUG|ABBV-382|Intravenous (IV) Infusion
41499939|NCT06632938|DRUG|Placebo for ABBV-382|IV Infusion
41499940|NCT06632938|DRUG|Placebo for ABBV-382|SC Injection
41026166|NCT05972447|PROCEDURE|Immediate implant placement of Ultrawide diameter dental implants|immediate placement of ultrawide diameter dental implants in a fresh extraction socket of mandibular molar teeth
41026167|NCT05007457|OTHER|Telerehabilitation|"Patients belonging to the experimental group will receive the brochure and, weekly a telematic comparison will take place lasting about 30 minutes, with a physiotherapist to be asked questions. The physiotherapist will be able to evaluate and modify the training program based on the patient's response.~The tele-rehabilitation sessions will take place: once / week for the first month, once every 2 weeks for the second month and from the third month from the third month the patient can contact the professionals in case of doubts or questions regarding the exercises he is taking place at home."
41026168|NCT00819182|BEHAVIORAL|Paced respiration|Breathing exercise
41363009|NCT00665002|DRUG|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
41363010|NCT00665002|DRUG|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
41363011|NCT05228873|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
41363012|NCT05869513|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
41499941|NCT04916444|DEVICE|rTMS|repetitive transcranial magnetic stimulation is a painless, noninvasive form of neurostimulation. This study uses an accelerated protocol in which the neurostimulation pulses are delivered in 4 sessions per day over 4 consecutive days (16 total sessions). Active or sham rTMS will be provided at 9 weeks following botox injections.
41026169|NCT00819182|BEHAVIORAL|Sham comparator: fast shallow breathing|sham breathing exercise
41363013|NCT05869513|DIETARY_SUPPLEMENT|Krill oil|Superba Krill Oil
41363014|NCT05869513|OTHER|Home-based resistance exercise|Home based resistance band and body weight exercise
41363015|NCT00915421|PROCEDURE|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
41499942|NCT03879434|DEVICE|Ostenil® Mini|Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation
41499943|NCT03013855|DEVICE|FIT-SOC|Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
41363016|NCT01592773|DRUG|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
41026170|NCT01455441|OTHER|Training and liraglutide|
41363017|NCT03506165|COMBINATION_PRODUCT|Periodontal treatment|oral hygiene instructions, periodontal debridement and removal of other etiologic factors
40842369|NCT05715515|DIAGNOSTIC_TEST|Panbio™|"The Panbio™ COVID-19/Flu A\&B Rapid Panel Professional use device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in nasopharyngeal swabs, collected by a trained health worker.~The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users"
41026171|NCT01455441|OTHER|Training and placebo|
41026172|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video and brochure
41363018|NCT03923062|DEVICE|chemicalpeeling|"Cleansing and degreasing the face with alcohol .~* The patients must be sitting at an angle of 45.~* A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~* We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~* We then will wait for a few minutes and will observe the frost developing.~* The patient will be then allowed to wash her face."
40842370|NCT04915417|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|Patients will receive 27-30 Gy in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost to the metabolically active areas of the gross tumor volume (GTV) to a maximum of 45 Gy. Patients will be treated every other day.
41026173|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video
41026174|NCT01801059|OTHER|questionnaire administration|Ancillary studies
41026175|NCT05404022|OTHER|Tailored nutrition and physical activity programme|"Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations.~Nutrition prescription may include any or all of the following:~1. Information on side-effects that may affect eating and their mitigation~2. Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes~3. Feedback on assessment of food intake and how to improve~4. a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments.~5. a recipe book Making the most of every bite~6. tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required"
41363019|NCT03923062|DEVICE|cryopeeling|Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
41363020|NCT03923062|COMBINATION_PRODUCT|microneedling|"Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~* After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~* The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions"
41363021|NCT00608426|BEHAVIORAL|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
41363022|NCT01365897|DRUG|Modafinil|Modafinil 200mg
41363023|NCT03445494|PROCEDURE|Brace|A brace to be weared according to protocol
41363024|NCT03445494|PROCEDURE|Normal sling|A normal sling to be weared according to protocol
41363025|NCT06368596|DIAGNOSTIC_TEST|Fusobacterium detection|"One vaginal and one cervical swab will be collected from participants (both cases and controls) before surgery.~During surgical intervention, routine biopsies of the endometriotic tissue will be done for all endometriosis types; further, small biopsies of apparently healthy endometrial tissue and of healthy peritoneum will be done, as per routine procedure.~In the control group routine biopsies needed for the specific condition and small biopsies of endometrial tissue will be carried out.~During these routine biopsies, a small additional quantity of tissue will be taken, which will be analyzed for the search for Fusobacterium."
41363026|NCT03550508|BIOLOGICAL|Anti-RANKL Monoclonal Antibody|JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
41363027|NCT00697242|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
41499944|NCT03013855|DEVICE|FIT-DRE|Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
41363028|NCT00697242|BIOLOGICAL|Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL|Intramuscular injection, 3 doses
41363029|NCT04939441|DRUG|Tenofovir alafenamide|Subjects will be treated for 96 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy
41363030|NCT00570492|DRUG|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
41499945|NCT03642639|DEVICE|MICRUSFRAME and GALAXY coils|MICRUSFRAME and GALAXY Coils
41499946|NCT00247494|DRUG|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
41499947|NCT05229003|DRUG|Anlotinib|Anlotinib 8mg or 10mg, d1-9，q2w
41363031|NCT00570492|DRUG|Placebo nasal spray|Placebo nasal spray
40842371|NCT03705975|OTHER|Manual treatment|Scapula mobilization, glenohumeral joint mobilization
40842372|NCT00357383|DRUG|Azithromycin (T1225)|
41363032|NCT02403427|DEVICE|VoiceDiab expert system|"Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.~Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab."
41363033|NCT03342807|DRUG|Insulin|Insulin infusion for subjects in Group Insulin.
41363034|NCT03342807|DEVICE|Aphesis|Aphesis for subjects in Group Aphesis.
41026176|NCT00824109|DEVICE|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
41363035|NCT02930889|DEVICE|Prostate Artery Embolization|Prostate Artery Embolization
40842373|NCT05459753|RADIATION|(18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET|Participants will receive an injection of 8 mCi \[18F\]FEOBV PET tracer and undergo a CT of the head.
40842374|NCT05459753|RADIATION|Dihydrotetrabenazine (DTBZ) PET|Participants will receive an injection of 15 mCi \[11C\]DTBZ PET tracer and undergo a CT of the head.
40842375|NCT03776461|DEVICE|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
40842376|NCT03442582|BIOLOGICAL|Afluria Influenza Vaccine|"Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)"
41026177|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
41026178|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
41026179|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
41026180|NCT03753126|RADIATION|4-dimensional volume-rendered computed tomography|
41026181|NCT02440152|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
41026182|NCT03749226|DRUG|Aztreonam lysine|nebulization
41363036|NCT03334994|PROCEDURE|Intervention group:(Group B) connective tissue graft combined with immediate implant.|Patients will be treated with connective tissue graft combined with immediate implant.
41363037|NCT05615948|DRUG|VTS-K|Proprietary oral formulation of 486mg aspirin and 80mg ketamine
40842377|NCT05760534|DRUG|Remimazolam|0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
41266786|NCT00511043|DRUG|PTK787|PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
41266787|NCT04858893|DIAGNOSTIC_TEST|CoMDA associated with Neural Net 91 classificator|
41363038|NCT04046289|DIETARY_SUPPLEMENT|Low Calcium Milk|50 mg calcium/day
40842378|NCT01297205|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
40842379|NCT05019391|DEVICE|transcranial doppler|it provides an accurate, noninvasive, and simple method for the diagnosis of VBI. Through the diagnosis results, it will be clear about the blood flow status of single vessel and vascular compliance, which is helpful for accurate reflection of the subtle changes of VBI
41363039|NCT04046289|DIETARY_SUPPLEMENT|Regular Calcium Milk|400 mg/day
41363040|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 1|regular calcium milk + probiotic
41026183|NCT03749226|DEVICE|Aerogen Solo|Aerogen's vibrating mesh technology, available within the Aerogen® Solo has been adopted for use of conventional mechanical ventilation. Aerogen Solo utilizes active vibrating mesh technology, where energy applied to the vibrational element, causes vibration of each of the 1000 funnel shaped apertures within the mesh. The mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimized for targeted drug delivery to the lungs. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) Aeroneb Solo showed an excellent aerosol delivery profile for Aztreonam lysine (AZLI) in an in vitro model of MV with short drug delivery time.
41026184|NCT03749226|DEVICE|CombiHaler|The inhalation chamber CombiHaler™ spacer for mechanical ventilation and critical care (ICU) allows using both a vibrating mesh nebulizer such as Aeroneb ™, and a pMDI. It saves 50% of the nebulized drug when used in invasive ventilation. The inhalation chamber CombiHaler® is integrated on a circuit of a breathing device in invasive ventilation in particular for connexion of an Aeroneb® Pro or an Aeroneb® Solo. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) a better aerosol delivery performance (30%) was obtained using the Conbihaler spacer.
41026185|NCT05302466|DEVICE|gymnastics plus silicon dental bite pad|Gymnastics (see below) plus dental bite pads. The dental bite pads TJ Motion (BELY Balance GmbH \& Co. KG, Weisendorf, Germany) are made of medical silicone. Accordingly, they are BPA- and latex-free, odourless, tasteless and dimensionally stable. The splints are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise. After use, the splints are rinsed with water and placed dry in the corresponding storage box.
41026186|NCT05302466|OTHER|gymnastics only|Gymnastics, which are completed daily (7x/week), each consist of three to six exercises and have a total duration of three minutes. The gymnastic programme contain low-intensity exercises from functional gymnastic or physiotherapy.
41026187|NCT02804958|PROCEDURE|STEMI treated with primary PCI|Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
41026188|NCT05599529|OTHER|Differential attainment|Differential attainment related to covid, ethnicity and international graduate status
41363041|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 2|regular calcium milk + probiotic
41266788|NCT04500704|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
41363042|NCT01678287|DRUG|ASP1941|oral
41363043|NCT01678287|DRUG|Placebo|oral
41363044|NCT00019565|PROCEDURE|magnetic resonance imaging|
41363045|NCT00019565|PROCEDURE|positron emission tomography|
41363046|NCT00019565|RADIATION|fludeoxyglucose F 18|
41363047|NCT02280265|DRUG|Recombinant Human Coagulation Factor VIII for injection|Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
41363048|NCT05079100|OTHER|postpartum contraception method counselling|It will be face-to-face counseling with females about the use of postpartum contraception methods within 6 weeks postpartum.
41363049|NCT02187718|PROCEDURE|Sentinel Node Procedure under Local Anaesthesia|
41363050|NCT02187718|PROCEDURE|Sentinel Node Procedure under General Anaesthesia|
41363051|NCT02529358|BEHAVIORAL|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
41363052|NCT02529358|BEHAVIORAL|Personalized text messages|Patients write their own messages
41363053|NCT02529358|BEHAVIORAL|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
41363054|NCT00808197|PROCEDURE|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
41499948|NCT05229003|DRUG|Penpulimab|Penpulimab 200mg, d6, q2w
41363055|NCT05389761|DIETARY_SUPPLEMENT|fibroDAO®|One DAO enzyme capsule is taken with water 20 minutes before each meal, 3 times a day. DAO enzyme capsules contains 0.3 mg DAO enzyme divided into 2 white/beige tablets (each gastro-resistant tablet contains 0.15 mg DAO enzyme) and 80 mg magnesium divided into 2 lilac tablets (each immediate-release tablet contains 40 mg of Mg).
41363056|NCT05389761|DIETARY_SUPPLEMENT|Placebo|One placebo capsule is taken with water 20 minutes before each meal, 3 times a day. Placebo capsules consist of microcrystalline cellulose and gelatin capsules with the same shape, size and colour as the DAO enzyme.
41499949|NCT05229003|DRUG|Irinotecan|Irinotecan 180mg/m2, d6, q2w
41499950|NCT02109653|DRUG|LGX818|Oral LGX818 300mg daily
41026189|NCT06358521|OTHER|Physiotherapist-led primary care model for hip and knee pain|"1. Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~2. Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~3. Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral.~4. Additional PT care: Patients who require community PT but do not have the appropriate coverage for community-based services will be managed by the PT who provided the assessment in the primary care setting."
41026190|NCT06358521|OTHER|Usual physician-led primary care model for hip and knee pain|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
41026191|NCT01231711|BEHAVIORAL|Vets Prevail|"The intervention has two primary components that are both delivered over the Internet:~The first component is a structured series of brief peer-to-peer instant messaging Chats structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).~The second component consists of six 30-minute e-Learning Lessons using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills."
41026192|NCT00059475|DRUG|Glycoprotein 100 (GP100): 209-217 (210M)|
41026193|NCT00059475|DRUG|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
41026194|NCT00059475|DRUG|Montanide ISA 51|
41026195|NCT00059475|DRUG|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
41026196|NCT00059475|DRUG|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
41026197|NCT00059475|DRUG|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
41026198|NCT03943095|OTHER|Potassium Nitrate|The test dentifrice contains 5% w/w potassium nitrate.
41026199|NCT03943095|OTHER|Stannous Fluoride|The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
41363057|NCT01992900|DRUG|Eurartesim dispersible oral tablet|The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
41363058|NCT01992900|DRUG|eurartesim film coated tablet|The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
41363059|NCT02450656|DRUG|Afatinib|Tablet
41363060|NCT02450656|DRUG|Selumetinib|Capsule
41363061|NCT02450656|DRUG|Docetaxel|
41363062|NCT00481533|DRUG|Methyl-Ergonovine-Oxytocin|
41363063|NCT00481533|DRUG|Oxytocin|
41363064|NCT02227420|DRUG|Anakinra|Anakinra 100mg s.c. x 5
40842380|NCT05717023|BEHAVIORAL|Online guided self-help intervention for sexual distress following sexual assault|4 Sessions of guided self-help will be shared with the participants. These will be in the form of handout and video recordings that participant access through Qualtrics. The intervention is based on research on sexual trauma, psychosexual difficulties and materials developed by Bart's NHS Foundation Trust Sexual Wellbeing Service. It has been made in collaboration with clinicians within the service, experts by experience and the chief investigator.Within the document there are scripts for each session which are read out in the video recordings. The handouts depict the visual images for the video and the materials provided to participant.
40842381|NCT05549154|DRUG|High-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
41363065|NCT04390711|OTHER|High density lipoprotein isolation, detection and in-vitro study.|All blood samples were taken on the day of cardiac catheterization after overnight fasting.High density lipoprotein from each participants was isolated and further collected for carbamylation level detection and in-vitro study.
41363066|NCT05823155|PROCEDURE|Detailed penicillin allergy evaluation|The intervention group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Components of penicillin allergy evaluation include verification of allergy history (drug involved including dose and route of administration, exact manifestation of labelled allergy and timing of occurrence after use of alleged culprit, history of skin tests or in vitro testing for diagnosis of allergy, subsequent rechallenge of the same or similar antibiotics), followed by skin test (prick test and intradermal test) and oral provocation test as appropriate.
41363067|NCT00144417|DRUG|Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Moxifloxacin 400mg daily, 8 weeks
41363068|NCT00144417|DRUG|isoniazid|isoniazid, oral, 300 mg, daily, 8 weeks
41363069|NCT05070182|DIAGNOSTIC_TEST|REE - Resting Energy Expenditure|"REEs represent 60-70% of the needs for a sedentary person and 50% of physically active people.~For the measurement of REE will be used the metabolic computer (Medical Graphics, Ultima CCM, Minneapolis, USA), which with continuous recording of breath-to-breath volume (Vt), respiratory rate (RR) of ventilation per minute volume (MV) ), of inhaled and exhaled gases (O2 and CO2) has the ability to calculate the values of VO2, VCO2 and with the help of equations the values of REE and RQ.~All patients in the study will be monitored with the metabolic computer. Their measurements will be recorded every day during their stay in the ICU."
41363070|NCT05070182|DIAGNOSTIC_TEST|Transcranial Doppler|"The measurement of flow velocities in the middle cerebral artery will be done with the transcranial Doppler using a low frequency (2 MHz) ultrasound head.~All patients entering the study will be examined with the TCD every day during their stay in the ICU."
41499951|NCT02354014|DRUG|Bedaquiline (TMC207)|TMC207 oral tablet adult formulation (containing 100 mg TMC207 per tablet) administered as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive an age appropriate oral tablet formulation containing 20mg TMC207. Bedaquiline (TMC207) tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. In Cohort 3, dose of TMC207 8 mg/kg qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw with intakes at least 2 days (48 hours) apart for 22 weeks will be administered. In cohort 4, TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3.
41499952|NCT02354014|DRUG|Background Regimen (BR)|Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
41499953|NCT04029311|DEVICE|Nuance Pro|Study compares Nuance Pro plus Automatic Positive Airway Pressure (autoPAP) vs TAP PAP plus autoPAP
41499954|NCT04029311|DEVICE|autoPAP|autoPAP
41026200|NCT04101799|BEHAVIORAL|For Our Children's Sake|Parental support with the aim to support positive parenting and promote healthy child development. Conducted in group-format with weekly 2.hour sessions conducted by trained group leaders according to a programme manual.
41026201|NCT04101799|OTHER|Active control|Participating in everyday activities that may include parenting activities in the control prisons
41363071|NCT01922869|DIETARY_SUPPLEMENT|Flavonoids|
41363072|NCT04156984|DRUG|Golimumab Prefilled Syringe|See arm description
41363073|NCT00529646|DRUG|APD791|
41499955|NCT04029311|DEVICE|TAP PAP|TAP PAP
41499956|NCT06499740|BEHAVIORAL|Adapted SAFETY-A for PC|This intervention is a suicide prevention intervention that will be adapted from the evidence-based SAFETY-Acute program. The specific intervention components will be determined from information gathered in this study but the investigators anticipate will include components such as safety planning, lethal means restriction, psychoeducation, motivation building, and care linkage.
41499957|NCT06499740|BEHAVIORAL|Treatment as Usual|Treatment as usual delivered in participating clinics.
40842382|NCT05549154|DRUG|low-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
41026202|NCT00461903|DRUG|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
41026203|NCT00105027|OTHER|Standard Care|CRVO: observation; BRVO: standard care
41026204|NCT00105027|DRUG|intravitreal triamcinolone injection|1 mg dose
41026205|NCT00105027|DRUG|intravitreal triamcinolone injection|4 mg
41026206|NCT00770016|DRUG|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
41026207|NCT06489808|DRUG|Linperlisib|Linperlisib RP2D D1-14
40842383|NCT05549154|DRUG|placebo|placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
40842384|NCT03401060|DRUG|Denosumab|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
41363074|NCT04104399|DRUG|XC101-D13H|XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
41363075|NCT04104399|DRUG|Placebo|Placebo supplied as matching capsules
41363076|NCT03797781|OTHER|Lower limb immobilisation (leg brace) with varying levels of protein intake|Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake
41363077|NCT03124329|PROCEDURE|Coronally Advanced Flap|Coronally advanced flap will be performed. Briefly, sulcular incisions will be made. Oblique incisions will be made on each papilla requiring root coverage. In the region coronal to the mucogingival junction (MGJ), mucoperiosteal flap will be elevated. Apical to the MGJ, sharp dissection will be performed to the periosteum allowing split-thickness flap elevation to be performed. Epithelium is removed from the papillae adjacent to the recession and the flap is coronally positioned and stabilized with interproximal sutures and apico-coronal interrupted sutures to close the vertical releasing incisions.
41499958|NCT04543890|RADIATION|Hyperfractionated radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
41499959|NCT04543890|RADIATION|Hypofractionated radiotherapy|Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
41499960|NCT04543890|DRUG|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
41499961|NCT04543890|DRUG|Cisplatin|Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
40842385|NCT03401060|DRUG|Placebo|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
40842386|NCT05363826|COMBINATION_PRODUCT|photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)|"Intravenous injection of Photobac® 24 hours before surgical removal of recurrent GBMF.~Immediately after resection, the cavity will be treated with 50 joules/ square cm of 787nm light. This treatment will add a maximum of 50 minutes to the surgery"
40842387|NCT05494372|OTHER|safety precautions|Nursing safety precautions on CPB
40842388|NCT04487457|OTHER|Blood samples|Blood samples
40842389|NCT05381285|OTHER|No intervention|Non-interventional study
40842390|NCT03773107|DRUG|Carfilzomib|Irreversible proteasome inhibitor
40842391|NCT03773107|DRUG|Ruxolitinib|Oral JAK inhibitor
41499962|NCT05632328|DRUG|AGEN1423|via IV, dosage per protocol, once every 2 weeks for up to 8 weeks
41499963|NCT05632328|DRUG|Botensilimab|via IV, dosage per protocol, once evert 2 weeks, up to 2 years
41499964|NCT05632328|DRUG|Gemcitabine|per standard care
41499965|NCT05632328|DRUG|Nab-paclitaxel|per standard care
40842392|NCT03773107|DRUG|Dexamethasone|glucocorticoid
40842393|NCT00590577|DRUG|Paliperidone palmitate 25 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64
40842394|NCT00590577|DRUG|Paliperidone palmitate 150 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64
40842395|NCT00590577|DRUG|Placebo|Placebo i.m. Days 1, 8, 36, 64
41026208|NCT06489808|DRUG|Rituximab|rituximab 375 mg/m2 D0
41499966|NCT05129605|DIAGNOSTIC_TEST|Prostate cancer screening|Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
41499967|NCT05198518|DEVICE|Microcurrent TENS device|The study device is a handheld micro-current TENS emitter intended to be used for the relief of postoperative pain after FESS. The design of the study device was optimized to provide transcutaneous nerve stimulation to the regional areas associated with the sinuses.
41499968|NCT05198518|DEVICE|Sham Device|The sham device appears and operates identically to the active device, including indicator lights and haptic vibration, however it emits a weak direct current that is non-therapeutic.
41026209|NCT06489808|DRUG|Gemcitabine|gemcitabine per regimen dosage
41026210|NCT06489808|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1
41363078|NCT03124329|PROCEDURE|Intrasulcular Tunneling|Initial sulcular incisions are made and small, contoured blades and mini curettes are used to create the recipient pouches and tunnels. The tunnel will be subperiosteal in location. The incision is extended to one adjacent tooth both mesially and distally. This incision maintains the full height and thickness of the gingival component and enables access beneath the buccal gingiva. The connective tissue beyond the mucogingival line will be dissected and free the buccal flap from its insertions to the bone around each tooth. Muscle fibers and any remaining collagen fibers on the inner aspect of the flap, which prevent the buccal gingiva from being moved coronally, are cut. The papillae are kept intact and undermined to maintain their integrity and carefully released from the underlying bone, which allows the coronal positioning of the papillae. An envelope, full-thickness pouch, and tunnel are created and extended apically beyond the mucogingival line by blunt dissection
41363079|NCT03124329|BIOLOGICAL|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|The VISTA approach begins with a Vestibular Incision Subperiosteal Tunnel Access. Through this incision a subperiosteal tunnel is created, exposing the facial osseous plate and root dehiscence. This tunnel will be extended at least one or two teeth beyond the teeth requiring root coverage to mobilize gingival margins and facilitate coronal repositioning. Additionally, the subperiosteal tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla. The mucogingival complex is then advanced coronally and stabilized in the new position with the coronally anchored suturing technique, which entails placing a horizontal mattress suture apical to the gingival margin of each tooth. The suture is tied to position the knot at the midcoronal point of the facial aspect of each tooth, which is secured with help of composite resin to prevent apical relapse of the gingival margin during initial stages of healing.
41363080|NCT03124329|DEVICE|Leukocyte-Platelet Rich Fibrin (L-PRF)|"Immediately prior to surgery, 72 mL of blood should be drawn from each patient by venipuncture of the antecubital vein and collected in a sterile glass test tube without any anticoagulant. Tubes should be centrifuged at 2,700 rpm for 12 minutes within 2 minutes after blood draw. For individuals on anti-coagulant therapy or supplements to interfere with coagulation, centrifugation will be for 18 minute. After centrifugation, each L-PRF clot will be separated from the portion of red blood cells (red thrombus), obtaining a fibrin clot with a red small portion in order to include the buffy coat richer in leucocytes. The L-PRF clot is condensed and modeled on a sterile surgical plate. L-PRF will be used within 60 minutes after the preparation."
41363081|NCT01486979|DRUG|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
41363082|NCT01486979|DRUG|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
41363083|NCT03044730|DRUG|Capecitabine|Given PO
41363084|NCT03044730|OTHER|Laboratory Biomarker Analysis|Correlative studies
41363085|NCT03044730|BIOLOGICAL|Pembrolizumab|Given IV
40842396|NCT00590577|DRUG|Paliperidone palmitate 100 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
41026211|NCT06489808|DRUG|Ifosfamide|Ifosfamide 5g/m2 D2
40842397|NCT00907166|DRUG|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
41266789|NCT04500704|DRUG|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
40842398|NCT00907166|DRUG|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
40842399|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
40842400|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
40842401|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
40842402|NCT02470884|DEVICE|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
41026212|NCT06489808|DRUG|Carboplatin|Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)
41026213|NCT06489808|DRUG|Etoposide|Etoposide 100mg/m2 D1-3
41026214|NCT06489808|DRUG|Dexamethasone|Dexamethasone 40mg D1-4
41026215|NCT06489808|DRUG|Cisplatin|Cisplatin 100mg/m2 D1, continuous intravenous infusion
41026216|NCT06489808|DRUG|Ara-C|Ara-C 2g/m2 q12h D2
41266790|NCT03538769|OTHER|electronic alert and clinical decision support system|Providers taking care of patients will receive an electronic alert and will be guided to use a clinical decision support system
41499969|NCT02789553|OTHER|First starch meal then meal with glucose syrup|Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
40842403|NCT04648514|PROCEDURE|Using of hydraulic lifter device for closed sinus lifting|Using of recent closed minimally invasive technique (hydraulic left technique) by hydraulic lifter device for closed sinus lifting then evaluation of the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement for patients with posterior edentulous maxilla .
40842404|NCT04648514|BEHAVIORAL|patient satisfaction evaluation after using hydraulic lifter device|Evaluation of patient satisfaction numerically will be done after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
41363086|NCT02628574|DRUG|TRX518 monotherapy|comparison of different (ascending) doses of TRX518 monotherapy
40842405|NCT03891368|OTHER|Virtual Learning Collaborative|InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.
41026217|NCT06489808|DRUG|Vinorelbine|Vinorelbine 20mg/m2 D1
41026218|NCT06489808|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome 18mg/m2 D1
41499970|NCT02789553|OTHER|First meal with glucose syrup then starch meal|Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
41363087|NCT02628574|DRUG|TRX518 with gemcitabine|comparison of different (ascending) doses of TRX518 in combination with gemcitabine
41363088|NCT02628574|DRUG|TRX518 with pembrolizumab|comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
41363089|NCT02628574|DRUG|TRX518 with nivolumab|comparison of different (ascending) doses of TRX518 in combination with nivolumab
41363090|NCT06381024|DEVICE|remote patient monitoring|"Cureety is a digital telemonitoring platform, specifically designed to monitor signs and symptoms of disease progression and AEs in cancer patients. The digital tool is adaptable to specific treatments and disease settings. The platform collects various data including treatment delays, dose reductions, quality of life and safety data. In terms of safety, once configured for the treatment and disease setting, the patient responds to an electronic PRO (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0.10 Depending on the responses, an algorithm classifies patients as either correct, compromised, state to be monitored, or critical state. Depending on the classification, patients are notified of the actions to be taken."
41363091|NCT04594473|BEHAVIORAL|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|\[see arm/group descriptions\]
41363092|NCT06326658|OTHER|Bufei Yishen Prescription Granule|The comparison group was given Bufei Yishen Prescription Granule.The course of treatment was the same as that of the experimental group.
41026219|NCT03598504|DEVICE|Wearable EMG/Vibration device|The device is a combination of an EMG recorder/detector and a vibrator
41363093|NCT04184674|OTHER|Pneumotachograph|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
41499971|NCT04540406|DRUG|NBT-NM108|Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
41499972|NCT04540406|OTHER|Usual Care Only|Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.
41499973|NCT06579781|BEHAVIORAL|Morehouse Family Health Study's Parent Toolkit 2.0|Parent Toolkit 2.0 is designed to equip parents and caregivers with skills to talk to their teens about sex and contraception and ultimately influence their teens' decision-making and behaviors around sex. The Georgia Campaign for Adolescent Power \& Potential (GCAPP) developed the Parent Toolkit intervention. Morehouse School of Medicine's (MSM) Health Promotion Research Center tested and adapted it through an OPA Innovation Network grant, creating Parent Toolkit 2.0.
41499974|NCT06579781|BEHAVIORAL|Morehouse Family Health Study's General Health Guide|General Health Guide provides information to parents on how to promote health in their families.
41499975|NCT02346591|BEHAVIORAL|Jauntly|Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.
41499976|NCT02346591|BEHAVIORAL|Online stress management information|Online educational information about stress management
41499977|NCT05670535|OTHER|Visual analogue scale (VAS) for dyspareunia|Dyspareunia scores between 0 to 10 points
41499978|NCT05670535|OTHER|Visual analogue scale (VAS) for vaginal dryness|Vaginal dryness scores between 0 to 10 points
41499979|NCT05670535|OTHER|The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)|Sjögren's Syndrome Disease Activity Index scores between 0 to 3 points
41363094|NCT04184674|OTHER|Esophageal catheter|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
41363095|NCT04184674|OTHER|Transthoracic and / or transesophageal cardiac ultrasound|"The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
41363096|NCT04184674|OTHER|Electrical impedance tomography (EIT) for pediatric patients|For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
41499980|NCT05670535|OTHER|The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)|Sjögren's Syndrome Patient Reported Index scores between 0 to 10 points
41499981|NCT00641225|DRUG|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
41363097|NCT06280404|DEVICE|Lap cholecystectomy|Body first approach in laparoscopic cholecystectomy in cases with obscure Calot's triangle
41499982|NCT00094003|DRUG|NS-9 [Poly I: Poly C]|
41499983|NCT05853042|DIAGNOSTIC_TEST|high-sensitivity cardiac troponin testing|Lithium heparin plasma samples will be measured with Mindray Bio-Medical CL-1200i Chemiluminescence Immunoassay Analyzer.
41499984|NCT02955381|DEVICE|Restylane Silk, 1.0 ml|Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
41499985|NCT02955381|DEVICE|Saline, 1.0 ml|Simple saline solution. To be used as placebo (control). No active ingredients.
41499986|NCT00790335|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
41499987|NCT05572671|BEHAVIORAL|Laboratory task modeling smoking lapse behavior|Participants will complete a task (the behavioral intervention) designed to model smoking lapse behavior in the laboratory; during the task, they will be given the option of delaying smoking in exchange for monetary reinforcement.
41499988|NCT00097032|DRUG|risperidone; quetiapine|
40842406|NCT03891368|OTHER|Technical Assistance|Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
41363098|NCT00396864|DRUG|NPI-0052|NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation
41363099|NCT03922945|DRUG|VI-0521 oral capsule|Phentermine/Topiramate
41363100|NCT03922945|DRUG|Placebo oral capsule|Inactive drug
41499989|NCT02697240|DRUG|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
41363101|NCT03922945|BEHAVIORAL|Lifestyle Modification|The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
41363102|NCT06263504|PROCEDURE|at correcting malocclusions or restoring the integrity of the dentition|Patients in this group will receive standard treatment aimed solely at correcting malocclusions or restoring the integrity of the dentition without interfering with the musculoskeletal system.
41026220|NCT02386566|DRUG|natalizumab|As described in the treatment arm
41363103|NCT06263504|PROCEDURE|comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.|): Patients will receive comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.
41363104|NCT02612129|DRUG|arimoclomol|
41363105|NCT02612129|DRUG|Placebo|
41363106|NCT02182505|DRUG|Berodual® Respimat®, low dose|
41363107|NCT02182505|DRUG|Berodual® Respimat®, high dose|
41499990|NCT05414344|BEHAVIORAL|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
41499991|NCT05414344|BEHAVIORAL|Trauma-Informed and Peer-Supported Brief Intervention|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
41499992|NCT05414344|BEHAVIORAL|Assessment only|Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
41499993|NCT06369220|DIAGNOSTIC_TEST|cobas® liat CT/NG/MG nucleic acid test|The cobas® CT/NG/MG nucleic acid test for use on the cobas® Liat® System is an investigational, automated, qualitative in vitro nucleic acid diagnostic test that utilizes real-time polymerase chain reaction (PCR) for the direct detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) nucleic acid in male/female urine and vaginal swabs (clinician-collected and self-collected) in cobas® PCR Media.
41499994|NCT06369220|OTHER|Standard of Care (SOC): Clinician's Standard Practice|Standard of care (SOC) is defined as the traditional/typical diagnosis and treatment steps in practice recommended by the CDC guidelines that rely upon clinical syndromic presentations and/or external laboratory testing.
40842407|NCT06454149|OTHER|MALT lymphoma|New diagnosis with gastric MALT lymphoma
40842408|NCT04578561|PROCEDURE|Prophylactic mesh use|After laparotomy sutured clousur the abdominal wall wound is reinforced using a suprafascial synthetic mesh.
41026221|NCT03359096|DEVICE|Therapeutic HGNS|Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve. Patient will undergo activation of the implanted device one month post-operatively. A functional threshold (in volts) is obtained based on tongue motion during device stimulation. For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.
41266791|NCT04413955|DEVICE|Seraph®-100 Microbind® Affinity Blood Filter|Use of an extracorporeal broad-spectrum sorbent hemoperfusion filter to removed SARS-CoV-2 virus and circulating cytokines from the blood
41266792|NCT05398614|BIOLOGICAL|SENL101|Patients will be treated with CD7 CAR-T cells
41266793|NCT04067830|OTHER|Best Practice|Receive usual care
41266794|NCT04067830|PROCEDURE|Laparoscopic Surgery|Undergo laparoscopic surgery
41266795|NCT04067830|OTHER|Quality-of-Life Assessment|Ancillary studies
41266796|NCT04067830|OTHER|Questionnaire Administration|Ancillary studies
41266797|NCT04067830|DEVICE|Respiratory Muscle Training Device|Use power lung device to complete RMT
41266798|NCT04067830|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo video-assisted thoracic surgery
41363108|NCT02182505|DRUG|Berodual® MDI|
41363109|NCT04667611|BEHAVIORAL|Psychosocial interventions|Cognitive behavioural therapy (CBT) based individual and group intervention
41363110|NCT05599555|BIOLOGICAL|mRNA BNT162b2 vaccine|mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China)
41363111|NCT05599555|BIOLOGICAL|CoronaVac vaccine|Inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China)
41363112|NCT04278846|DRUG|Depofoam bupivacaine|The study drug Depofoam bupivacaine will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
41363113|NCT04278846|DRUG|Bupivacaine hydrochloride (HCl)|The study drug bupivacaine HCl will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
41026222|NCT03359096|DEVICE|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds"
41026223|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
41363114|NCT01990417|OTHER|Passive stretching|Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
41363115|NCT04431856|BEHAVIORAL|Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|UP-COVID is a group therapy session with each session lasting approximately 60-90 minutes. The sessions will focus on cognitive and behavioral strategies for managing their own distress, anxiety and sadness related to COVID-19, as well as, strategies related to parenting in the midst of the crisis.
41026224|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
41026225|NCT04499157|DRUG|MEMOPTIC|Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
41026226|NCT04499157|DRUG|usual treatment of glaucoma|Patients will receive only their usual treatment of glaucoma.
41026227|NCT02958644|DIETARY_SUPPLEMENT|Synbiotics|12g / day synbiotics (fructo-oligosaccharide and probiotics) supplemented orally for 90 days
41026228|NCT02958644|DIETARY_SUPPLEMENT|Placebo|12g / day placebo (polydextrose) supplemented orally for 90 days
41026229|NCT04640051|PROCEDURE|LAAO|LAAO by use of 3D in silico simulation by FEops HEARTguide as part of the pre-procedural assessment and device size selection
41160947|NCT03640208|BEHAVIORAL|Education presented by trained caregiver|After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
41363116|NCT04431856|BEHAVIORAL|SHG|Brochure that details techniques for coping with stress.
41499995|NCT05708092|BEHAVIORAL|NeuroResource Facilitation (NRF)|"NRF is defined as a specialized service that promotes access to services and coordinates care specific to the needs of individuals with brain injury.~Possible resources include vocational services, medical assistance, Social Security (SSI or SSDI if appropriate), and other organizations that can support reentry. If needed to gain access to services and organizations, the facilitator will also provide participants with a summary that includes results from brain injury screenings questionnaire, neurocognitive (thinking abilities) tests, and symptoms. The researchers will share information and coordinate with prison and parole staff about participation in the study. Participant's information will also be shared with resources that could help participants after release, such as funding sources and brain injury services. After release from SCI, the NRF facilitator will assist the participant with all the preparation and logistics associated with the resources the participant applied to."
41499996|NCT03608865|DRUG|Durvalumab with Tremelimumab|Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis. Durvalumab 1500mg + tremelimumab 750 mg will be administered as a 60 minute each one IV infusion every 4 weeks. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site.
41499997|NCT01910012|DRUG|ADI-PEG 20|
41499998|NCT03214393|DIAGNOSTIC_TEST|Doppler|Doppler will be done to pregnant women with Pre-Eclampsia
41499999|NCT03214393|DIAGNOSTIC_TEST|serum antibodies|serum antibodies will be measured for pregnant women with Pre-Eclampsia
40842409|NCT03807284|BEHAVIORAL|A group psychosocial course|A 2 hour, weekly group psychosocial therapy RCAS course that aims to improve confidence and help adjustment after a stroke.
40842410|NCT02126007|BEHAVIORAL|Sleep and Rhythm Intervention|
40842411|NCT02126007|BEHAVIORAL|Dietary Modifications|
40842412|NCT01919216|DRUG|Citalopram|
40842413|NCT01406015|DRUG|Spironolactone|50 mg once daily for 6 weeks.
41026230|NCT01525290|DRUG|Alteplase|Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
41026231|NCT01525290|DRUG|Placebo|lyophilised powder to be reconstituted as solution indistinguishable from the active drug
41026232|NCT01327534|DRUG|Prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
41026233|NCT01327534|DRUG|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
41026234|NCT01602315|DRUG|BYL719 as film-coated (FC) whole tablets|Oral alpha-specific PI3K inhibitor
41026235|NCT01602315|DRUG|BYL719 as dispersible tablets (DT)|New formulation of the oral alpha-specific PI3K inhibitor
41160948|NCT03439345|DRUG|Fenofibrate 145 mg|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
41363117|NCT06309524|DEVICE|Tricuspid transcatheter edge-to-edge repair|Transcatheter tricuspid leaflets approximation
41363118|NCT03872739|PROCEDURE|enhanced computed tomography|undergoing enhanced computed tomography
41363119|NCT03579004|DRUG|Paclitaxel|Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
41026236|NCT01602315|BIOLOGICAL|cetuximab|Recombinant chimeric monoclonal antibody driven against EGFR
41500000|NCT01794559|DEVICE|PEER Interactive Report|The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
41500001|NCT05597319|PROCEDURE|Liver resection|Liver resection, different kind of according to pathology
40842414|NCT01406015|DRUG|Placebo|Placebo-matching spironolactone once daily for 6 weeks.
41363120|NCT03579004|DRUG|Cisplatin|Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
41363121|NCT03579004|DRUG|Fluorouracil|Fluorouracil is used in two cycles of neoadjuvant chemotherapy
41363122|NCT03579004|RADIATION|chemoradiotherapy|Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.
41363123|NCT03579004|PROCEDURE|Ivor Lewis esophagogastrectomy|Open Ivor Lewis esophagogastrectomy
41500002|NCT03940625|DIAGNOSTIC_TEST|Cardiac MRI and echocardiography, laboratory parameters|Cardiac MRI including cine imaging (volumetric determination of LV-EF), late gadolinium enhancement, strain analysis, T1 mapping and T2 mapping Echocardiography including 3D-EF, diastolic function and strain analysis Determination of laboratory parameters including cardiac enzymes (Troponin T and high sensitivity Troponin T) and cardiac markers (BNP and NT-pro BNP)
41500003|NCT02864810|DRUG|[18F]GP1|\[18F\]GP1 PET/CT imaging for detecting thromboembolism
41500004|NCT04521582|DRUG|Amlodipine|The facility-based community health worker will receive protocol-driven training to initiate amlodipine for hypertensive patients. These patients will receive lifestyle counseling by Female Community Health Volunteer through home visits (5 times \[including baseline and end of the study\] in the active municipality and 3 times \[including baseline and end of the study\] in the control municipality).
40842415|NCT03403023|DEVICE|Tear Film Imager|The TFI is an imaging device based on standard camera that uses white light to image the tear film in an ultra high resolution. DES patients in this study will be imaged before and 3 months after initiation of treatment with Restasis (the treatment indicated for their condition).
40842416|NCT03403023|DRUG|Restasis|Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
40842417|NCT00304863|DRUG|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
40842418|NCT03238118|OTHER|Attention bias modification training|"Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
40842419|NCT03238118|OTHER|Attention Control Training|"Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
41026237|NCT01602315|DRUG|BYL719 drink suspension|Oral alpha-specific PI3K inhibitor
41026238|NCT02211833|DRUG|BI 2536|
41026239|NCT02211833|DRUG|Pemetrexed|
41026240|NCT00320346|BIOLOGICAL|Pandemic Influenza Vaccine|
41026241|NCT03309436|DRUG|Clomiphene Citrate protocol|Take CC 100mg/d at the same time with Gn until hCG injection.
41363124|NCT00749489|PROCEDURE|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
41026242|NCT03309436|PROCEDURE|Procedure|When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
41026243|NCT02278276|DRUG|sodium polysulthionate|Bioavailable composition of α-sulfur
41026244|NCT02278276|DRUG|Placebo|400 mg capsules containing placebo
41026245|NCT06534567|OTHER|Mediterranean Diet|Mediterranean diet adherence
41026246|NCT06534567|OTHER|Physical activity|Physical activity level
41026247|NCT03365765|DRUG|Apatinib|Apatinib tablet
41026248|NCT03365765|DRUG|Oxaliplatin|Oxaliplatin Intravenous
41026249|NCT03365765|DRUG|5-fluorouracil|5-fluorouracil Intravenous
41026250|NCT01273831|DRUG|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
41026251|NCT01273831|DRUG|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
41026252|NCT03778216|BEHAVIORAL|Family Based Treatment|
41363125|NCT06085222|BEHAVIORAL|Emotional Engagement Distress Tolerance Intervention|2.5 hour computerized intervention with smart phone support focused on building tolerance of emotional distress
41500005|NCT04521582|BEHAVIORAL|Lifestyle counselling|Female Community Health Volunteer will provide lifestyle counseling at the participant's home
41500006|NCT02656888|DRUG|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
41026253|NCT02405455|PROCEDURE|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
41026254|NCT02405455|DEVICE|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
41026255|NCT00968604|GENETIC|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
40842420|NCT03238118|OTHER|Psychoeducation|Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
41026256|NCT02798198|OTHER|T2DM|T2DM without DKD
41026257|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
41026258|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
41160949|NCT03439345|DRUG|Placebo Oral Tablet|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
41363126|NCT06085222|BEHAVIORAL|Health Education Intervention|2.5 hour computerized intervention with smart phone support focused on building healthy habits that support stress management
41363127|NCT03328741|BEHAVIORAL|Online Osteoarthritis treatment|6 week online-program
41363128|NCT03328741|BEHAVIORAL|Face-to-face osteoarthritis treatment|3 months face-to-face program
40842421|NCT06071156|DRUG|Anakinra|Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences
40842422|NCT02747511|DRUG|Haloperidol|
40842423|NCT02747511|DRUG|Placebo|
40842424|NCT00391612|DEVICE|Exhale® Drug-Eluting Stent|Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours
41026259|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
41026260|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
41026261|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
41026262|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
41026263|NCT03750487|BEHAVIORAL|e-screening & brief intervention (e-SBI)|Computer-delivered screening and brief motivational intervention targeting alcohol and drug use + goal-setting and content reinforcement
41160950|NCT06262776|BIOLOGICAL|Recombinant zoster vaccine adjuvanted (SHINGRIX)|2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.
41160951|NCT02001389|DRUG|EVP-6308|Arms 1, 2, 3, 4
41160952|NCT05482893|DRUG|PT886|PT886 monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.
41160953|NCT05482893|DRUG|Paclitaxel|Chemotherapy as a combination partner to PT886 in Part C: Cohort 1
41363129|NCT01473108|DRUG|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
41160954|NCT05482893|DRUG|Gemcitabine|Chemotherapy as a combination partner to Abraxane and PT886 in Part C: Cohort 2
41160955|NCT05482893|DRUG|Abraxane|Chemotherapy as a combination partner to Gemcitabine and PT886 in Part C: Cohort 2
41160956|NCT05482893|DRUG|KEYTRUDA® (pembrolizumab)|Immune checkpoint inhibitor as a combination partner to PT886 in Part D: Cohort 3, 4, and 5.
41363130|NCT01473108|DRUG|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
41363131|NCT01473108|DRUG|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
41363132|NCT01473108|DRUG|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
41363133|NCT02115620|OTHER|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
41363134|NCT00016068|DRUG|ganciclovir|
40842425|NCT00391612|DEVICE|Sham control|5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
41363135|NCT00016068|DRUG|valganciclovir|
41363136|NCT00052013|DRUG|PTK787/ZK 222584|
40842426|NCT04042727|DRUG|Dexmedetomidine Hydrochloride|Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.
40842427|NCT04042727|OTHER|Normal Saline|0.5% sodium chloride (NaCl). The investigational pharmacy will prepare the normal saline placebo 250mL bag for infusion by patient's bedside nurse. Infusion will be 1mcg/kg/hr.
40842428|NCT02141139|DRUG|NSAIDS (ketorolac and ibuprofen)|
41160957|NCT05482893|DRUG|Oxaliplatin|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
41160958|NCT05482893|DRUG|Leucovorin|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
41363137|NCT04866147|PROCEDURE|Cardiothoracic surgery|Cardiac \& large intrathoracic vessels, respiratory, thoracic, mediastinal \& diaphragmatic procedures
40842429|NCT04343118|PROCEDURE|Hardware Removal|elective removal of plate osteosynthesis at the clavicle
40842430|NCT02929212|OTHER|Solid Meal|Subjects will receive solid meals during meal study
40842431|NCT02929212|OTHER|Liquid Meal|Subjects will receive liquid meals, during meal study
41160959|NCT05482893|DRUG|Fluorouracil|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
41160960|NCT05482893|DRUG|Capecitabine|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
41160961|NCT01395914|DRUG|Anamorelin HCl|
41160962|NCT01395914|DRUG|Placebo|
41363138|NCT04866147|PROCEDURE|Breast surgery|Breast resections \& mastectomies
41363139|NCT04866147|PROCEDURE|Gastrointestinal surgery|Digestive \& spleen
41363140|NCT04866147|PROCEDURE|Genitourinary surgery|Urinary tract, genital \& retroperitoneal tissue
41363141|NCT04866147|PROCEDURE|Orthopaedic surgery|Back \& neck, shoulder \& upper arm, hip \& thigh, knees \& lower leg
41363142|NCT00699582|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
41363143|NCT00699582|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
40842432|NCT02929212|DRUG|Acetaminophen|All subjects given acetaminophen to measure gastric emptying
40842433|NCT02929212|OTHER|Single, 600 kcal meal|Subjects will receive a single, 600 kcal meal during meal study
40842434|NCT02929212|OTHER|Multiple, 200 kcal meals|Subjects will receive three, 200 kcal meals, during meal study
40842435|NCT06530771|DIAGNOSTIC_TEST|ultrasound|Conventional US, SWE, and AP of thyroid nodules were conducted successively with a Supersonic Aixplorer system (SuperSonic Imagine, Aix-en-Provence, France) using a 5-14 MHz linear transducer.
40842436|NCT04778800|DRUG|almonertinib|Patients was given a standard dose of 110mg/day of almonertinib, orally, and the first efficacy evaluation was carried out 4 weeks later. If the patient's lungs and/or other parts of the disease (PD) progress, then leave the group to receive other treatment; if the patient's lungs If the brain and other parts are stable or relieved and the brain has not progressed, continue the original dose treatment, and evaluate the effect every 8 weeks. Until the patient's lungs and/or other parts progress (PD), then leave the group to receive other treatment; if If the patient's lungs and other parts are stable or relieved and the brain is progressing, the dose of almonertinib can be increased to 165mg/day, orally ± radiotherapy (the investigator's decision), and then the efficacy will be evaluated every 8 weeks until the patient's lungs and/ Or there is progress (PD) in other parts, then the group will receive other treatment.
40842437|NCT04778800|DRUG|LM-first line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
41363144|NCT00699582|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
41363145|NCT01379404|DEVICE|Bioelectric Impedance Analysis|Bioimpedance devices are compact, portable, easy to use, relatively inexpensive and can be used to make repeated non-invasive measurements. Bioimpedance measures the impedance to the flow of an electric current through body fluids and consists of two components, resistance and reactance. Resistance is a measure of electrical current a substance will oppose and is inversely related to tissue fluid content. Reactance is the capacitative component of impedance and indicates energy stored by cell membranes and organelles; due to this property, reactance is associated with tissue cell mass. These raw measures provide a measure of volume as determined by vector length and the RXc graph method.
41363146|NCT05133102|OTHER|Sample collection|Collection of saliva sample
40842438|NCT04778800|DRUG|LM-second line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
40842439|NCT05549661|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40842440|NCT05549661|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
40842441|NCT05549661|DRUG|Onvansertib|Given PO
41026264|NCT03750487|BEHAVIORAL|Control e-SBI|Computer-delivered screening and brief motivational intervention targeting healthy eating and exercise
41026265|NCT03396744|DEVICE|Light|Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
41026266|NCT04064281|OTHER|the healthy Cantonese diet|After a 1-week run-in period, the intervention group will eat the healthy Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
41363147|NCT05205681|DIAGNOSTIC_TEST|Pre-operative imaging|Use of pre-operative imaging or the diagnosis of acute appendicitis
41363148|NCT01030731|DRUG|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
41363149|NCT05770882|DRUG|Chidamide|Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.
41363150|NCT05770882|DRUG|Regorafenib|Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.
40842442|NCT05549661|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
41026267|NCT04064281|OTHER|the typical Cantonese diet|After a 1-week run-in period, the control group will still eat the typical Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
41026268|NCT03994861|DIAGNOSTIC_TEST|Assessment of disability and behavior (by questionnaires)|Assessment of disability and behavior (by questionnaires)
41026269|NCT02073513|DEVICE|Kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
41026270|NCT02073513|DEVICE|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
41363151|NCT01453439|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based CBT. During the sessions, participants will receive education about BDD and CBT, learn to develop more helpful thoughts and beliefs, gradually enter anxiety provoking situations while reducing compulsions (repetitive behaviors), and learn relapse prevention techniques.
41026271|NCT05561127|COMBINATION_PRODUCT|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
41363152|NCT01453439|BEHAVIORAL|Supportive Psychotherapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based SPT. During the sessions, participants will receive education about BDD and SPT, learn about factors that may affect their symptoms (for example, relationships, work, stress), and learn to cope with challenges in their life by improving self-esteem and positive coping skills.
41363153|NCT02391194|DRUG|AVB-620|
41363154|NCT00470223|DRUG|cisplatin|
41363155|NCT00470223|DRUG|doxorubicin hydrochloride|
41026272|NCT05561127|OTHER|Control|Standard of Care Endoscopic Dilation
41026273|NCT03850119|PROCEDURE|Nanofat injection|Lipoaspirate, harvested during the surgery, is centrifuged for 1 minute at 2000 rpm to discard infiltration fluid. The residual fat is passed back and forth between two 10cc syringes interlocked with Tulip connecting pieces (2.4, 1.4 and 1.2 diameter, each 10 passes for a total of 30 passes). This is injected intradermally before the intradermal sutures are placed. The donor site is always entirely sutured (both sides) by the same person.
41363156|NCT00470223|DRUG|etoposide|
41363157|NCT00470223|DRUG|ifosfamide|
41363158|NCT00470223|DRUG|methotrexate|
41363159|NCT00470223|DRUG|zoledronic acid|
41363160|NCT00470223|PROCEDURE|conventional surgery|
41363161|NCT05946837|DRUG|Indocyanine green (ICG) dye|ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
41363162|NCT05946837|DEVICE|NIRF-LI imaging|Near-infrared fluorescence lymphatic imaging (NIRF-LI) imaging will be done to assess the drainage of ICG laden lymph from ICG injection sites toward regional nodal basins for 60 minutes before, during and after the Neuroglide pad treatment
41363163|NCT05946837|DEVICE|Neuroglide pad|After injection of Indocyanine green (ICG) dye and NIRF-LI imaging the subject will lie on the Neuroglide pad for the one-hour PCT treatment session.
41500007|NCT02656888|DRUG|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
41500008|NCT04220970|OTHER|BIA-ALCL|Observational : no intervention
41363164|NCT03824756|OTHER|NGO supported GMP program|An International NGO has signed a contract with Government to support in implementing the growth Monitoring and Promotion (GMP) program. This program will be implemented at Community clinics. It will ensure the sustainability of community clinics in the selected areas through capacity building and follow up with community groups, community support groups, and Government Health and Family Planning service providers.
41363165|NCT03824756|OTHER|Non-supported GMP program|This is control arm of the study. In this arm, there will be Government's usual GMP program implemented at community clinics without any NGO support.
41363166|NCT02968277|DEVICE|LifeWalker Upright|LifeWalker (LW) upright walker
41363167|NCT02968277|DEVICE|Predicate Device|Individual's personal walker
41363168|NCT02968277|DEVICE|Standard Rollator|A control rollator device
41363169|NCT01019733|PROCEDURE|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
41363170|NCT06337773|BEHAVIORAL|8-weeks's on-line precision nursing education program|The intervention involved 8-weeks's on-line precision nursing education program, including Qigong exercise, and mindfulness training.
41500009|NCT03096912|DRUG|Ribociclib|Ribociclib Oral 600 mg x 1 a day 21 days on 1 week off in 28 days cycles
41500010|NCT01128608|PROCEDURE|24-Hr Esohpageal pH Monitoring|There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.
41363171|NCT03235245|DRUG|Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
41363172|NCT03235245|DRUG|Encorafenib + Binimetinib|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
41363173|NCT00174460|DRUG|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
41363174|NCT00174460|OTHER|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
41363175|NCT00283153|BEHAVIORAL|Facial Affect Recognition Training|A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
41363176|NCT00283153|OTHER|Stories of Emotional Inference|Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
41363177|NCT03814642|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
41363178|NCT03814642|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
41363179|NCT03814642|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg tablet
41363180|NCT00241891|BEHAVIORAL|Single behavior intervention|Focused on changing beverage choices which may have a significant impact on weight.
41363181|NCT00241891|BEHAVIORAL|Multiple behavior interventions|Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
41363182|NCT00241891|BEHAVIORAL|Control Intervention unrelated to weight|Focused on standard intervention strategies unrelated to weight including bullying prevention.
41500011|NCT01128608|PROCEDURE|PCO2 Acid Perfusion and 0.1N HCI Perfusion|A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
40842443|NCT00741403|DRUG|CPI-613|CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
41363183|NCT02012257|PROCEDURE|AMSA nerve block injectio|Sites of injection
41363184|NCT03929237|OTHER|observe when return to school after surgery|Short written questionnaire asking when they returned to school and what accommodations, if any, the school made available for them
41363185|NCT04084275|BEHAVIORAL|breastfeeding education|
41363186|NCT04084275|BEHAVIORAL|personal hygiene education|In this training, the puerpera was informed about personal hygiene to prevent infection.
41363187|NCT04084275|BEHAVIORAL|nutrition education|In this training, the amount of nutrients that breastfeeding women should take daily was explained.
41363188|NCT04084275|BEHAVIORAL|fatigue education|In this training, suggestions were made to prevent the negative effects of fatigue
41363189|NCT04084275|BEHAVIORAL|sleep education|In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.
41363190|NCT04084275|BEHAVIORAL|pilates exercises education|In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
41363191|NCT03737305|DEVICE|TMJ Condilar Distraction Device|The patients will perform condylar distraction with the condylar distraction device in an ambulatory basis.
41363192|NCT03737305|DEVICE|Conventional Physical Therapy|Conventional Physical Therapy, performed in office by a experienced physical therapist for the TMJ condition.
41363193|NCT02745093|DRUG|Mifepristone|Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
41500012|NCT03109561|OTHER|Resting State Indirect Calorimetry|The investigator will measure the amount of oxygen participants breathe in and the amount of carbon dioxide they breathe out using a portable unit. Participants will be asked wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.
41500013|NCT03109561|GENETIC|ApoE|The investigator will conduct a genetic test on DNA isolated from from the participants blood. Participants will be asked to provide about 2 tablespoons.
40842444|NCT06256471|OTHER|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months for detection of impact of parasitic infection on these diseases courses
40842445|NCT02427503|PROCEDURE|Asthma with NP and require surgery|To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
40842446|NCT04547582|DEVICE|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
40842447|NCT04030247|DRUG|Plant Sterol|Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
40842448|NCT01650272|DRUG|5% MInoxidil milky lotion|Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
41363194|NCT02745093|DRUG|Misoprostol|The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
40842449|NCT01650272|DRUG|5% Minoxidil solution|Patient receive 5% Minoxidil solution (Propylene glycol solvent )
40842450|NCT03659877|BEHAVIORAL|Physical activity|Participants will undertake a variety of typical daily physical activities, such as laying down, sitting, walking whilst wearing accelerometers and gas analysis equipment.
40842451|NCT01252979|DIETARY_SUPPLEMENT|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
41026274|NCT05495503|DEVICE|Prototype (814A-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
41026275|NCT05495503|DEVICE|Prototype (814B-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
41026276|NCT05495503|DEVICE|Prototype (814C-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
41363195|NCT01427855|OTHER|High saturated fat red meat diet|4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))
41363196|NCT01427855|OTHER|High saturated fat non-meat diet|4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
41363197|NCT01427855|OTHER|High saturated fat white meat diet|4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))
41363198|NCT01427855|OTHER|Low saturated fat red meat diet|4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))
41363199|NCT01427855|OTHER|Low saturated fat white meat diet|4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))
41363200|NCT01427855|OTHER|Low saturated fat non meat diet|4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
41363201|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg， KN046 5mg/Kg
41363202|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg ， KN046 3mg/Kg
41363203|NCT04984668|DRUG|GT90001/KN046|GT90001 4.5mg/Kg / KN046 5mg/Kg
41160963|NCT03868098|DRUG|Crisaborole 2%|Crisaborole ointment 2% (application rate A, B, C) for 15 days (double blind)
41160964|NCT03868098|DRUG|Placebo ointment|Placebo ointment (vehicle)
41363204|NCT04984668|DRUG|GT90001+KN046|GT90001 4.5mg/Kg， KN046 3mg/Kg
41363205|NCT04984668|DRUG|GT90001+KN046|GT90001 3mg/Kg ， KN046 3mg/Kg
41363206|NCT01298011|DRUG|Gemcitabine and Abraxane|3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
41363207|NCT02083406|DRUG|800mg OZ439 prototype formulation 1|
41363208|NCT02083406|DRUG|800mg OZ439 prototype formulation 2|
41160965|NCT01263275|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|Each tDCS session lasting continuously for 20 minutes at 2 mA
41160966|NCT03003832|OTHER|Change in electronic health record default for new opioid analgesic prescriptions|
41363209|NCT02083406|DRUG|800mg OZ439 prototype formulation 3|
41363210|NCT02083406|DRUG|960mg PQP|
41363211|NCT00692159|DRUG|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
41160967|NCT03952728|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
41160968|NCT03952728|BEHAVIORAL|Diabetes support and education|Behavioral intervention focused on diabetes support and education
41160969|NCT00402584|DRUG|sibutramine|
41266799|NCT01328457|DRUG|Paromomycin sulfate|Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).
41266800|NCT05220267|DRUG|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).
41266801|NCT02418130|DRUG|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
41266802|NCT02418130|DRUG|Placebo|
41266803|NCT03390413|PROCEDURE|Robot|Renal cancer treated with robotic surgery
41266804|NCT03390413|PROCEDURE|Cryoablation|Renal cancer treated with cryoablation
41266805|NCT01136239|DRUG|N-acetycysteine (600mg twice daily)|N-acetycysteine (600mg twice daily) for one year
41266806|NCT01136239|DRUG|Placebo|Placebo (600mg twice daily)
41266807|NCT01446809|DRUG|Doxorubicin Hydrochloride|Given IV
41266808|NCT01446809|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
41266809|NCT01446809|DRUG|Ifosfamide|Given IV
41266810|NCT01446809|OTHER|Laboratory Biomarker Analysis|Correlative studies
41266811|NCT01446809|DRUG|Pazopanib Hydrochloride|Given PO
41266812|NCT01446809|OTHER|Pharmacological Study|Correlative studies
41266813|NCT01446809|OTHER|Placebo|Given PO
41266814|NCT01446809|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41266815|NCT01907620|OTHER|blood sample|
41266816|NCT05752214|OTHER|WEB Register|Observational, non-profit, multicentre longitudinal study on the assessment of quality of life and its association with demographic variables and visual function of visually impaired patients attending the visual rehabilitation service.
41266817|NCT02921451|DEVICE|Restorelle Smartmesh|Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
41266818|NCT03064763|DRUG|Talimogene laherparepvec|Talimogene laherparepvec will be administered as an intralesional injection.
41266819|NCT00145444|DRUG|olanzapine|
41266820|NCT00145444|DRUG|ziprasidone|
41266821|NCT02236169|DRUG|Ipratropium bromide HFA-134a inhalation aerosol|
41266822|NCT02236169|DRUG|Atrovent CFC inhalation aerosol|
41266823|NCT04314050|DRUG|Tramadol|tramadol and paracetamol will perform
41266824|NCT04314050|DRUG|Dexmedetomidine|dexmedetomidine and paracetamol will perform
41266825|NCT04314050|OTHER|control|paracetamol will perform
41266826|NCT02140255|DRUG|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
41266827|NCT02140255|DRUG|Nevirapine (NVP)|Administered orally. Dosed according to study step/participant's age/participant's weight.
41363212|NCT01955005|BEHAVIORAL|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
41363213|NCT01955005|OTHER|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
41363214|NCT01951833|DEVICE|EasyOne Pro and Ecomedics|LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
41363215|NCT03943524|DEVICE|Interax-AI|Interax-AI is a drug interactions detection module for the electronic clinical history software DrApp
41363216|NCT00303602|DRUG|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
41363217|NCT00303602|DRUG|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
41363218|NCT01391026|BEHAVIORAL|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
41363219|NCT00224757|PROCEDURE|Transoesophageal echocardiography|TEE
41363220|NCT02809651|DEVICE|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
41363221|NCT02277418|DEVICE|VAVL|Videolaryngoscope
41363222|NCT02277418|DEVICE|MIL|Direct laryngoscopy
41363223|NCT04559048|DRUG|FK506|FK506 (tacrolimus), a calcineurin inhibitor, is widely used as an immunosuppressant to lower the risk of organ rejection after organ transplantation
41363224|NCT06417658|PROCEDURE|Endoscopic Supraorbital Eyebrow Craniotomy|The Endoscopic Supraorbital Eyebrow Craniotomy is a minimally invasive neurosurgical procedure used to access and remove brain tumors located in the anterior skull base region. In this approach, surgeons make a small incision within the eyebrow area to gain access to the underlying pathology, avoiding larger incisions and more extensive tissue disruption associated with traditional open craniotomies.
41363225|NCT06417658|PROCEDURE|Conventional Frontal Craniotomy|The Conventional Frontal Craniotomy is a traditional surgical approach used to access and treat lesions located in the frontal region of the skull base. In this procedure, surgeons make a single or multiple large incisions in the scalp overlying the frontal bone to gain access to the underlying pathology.
41363226|NCT05896800|DEVICE|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
41363227|NCT04071899|OTHER|Scale vaidation|It's just filling a scale in order to validate it in French
41363228|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with low-carbohydrate-high-protein content
41363229|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with high-carbohydrate-low-protein content
41363230|NCT02172820|BEHAVIORAL|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
41363231|NCT05486715|DRUG|Vit D|Vit D
41363232|NCT01851031|PROCEDURE|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
41363233|NCT00556088|DRUG|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
41500014|NCT03109561|DIAGNOSTIC_TEST|Metabolism|To more accurately measure the amount of carbohydrates, fats and proteins that the participants bodies metabolize, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study). The total amount of urine to be collected is approximately 4 teaspoons.
41500015|NCT03109561|OTHER|Cognitive Challenge|Participants will be asked to follow simple instructions that are displayed on computer screen.
41500016|NCT06213493|DIAGNOSTIC_TEST|measurement of RNAs|RNAs will be measured in heart tissues and in peripheral blood mononuclear cells
41500017|NCT01879163|BIOLOGICAL|MVA85A-IMX313|Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
41363234|NCT03166774|OTHER|Program of support of the sexual health|Patients included in the study have to answer to a questionnaire
41363235|NCT00381017|DRUG|Peg interferon alpha-2b|
41363236|NCT00859495|DRUG|Doxorubicin|A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
41500018|NCT01879163|BIOLOGICAL|MVA85A|Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
41363237|NCT00859495|DRUG|Cisplatin|Platinum-based antineoplastic
41363238|NCT00859495|DRUG|Pemetrexed|Folate Analog Metabolic Inhibitor
41363239|NCT00859495|RADIATION|Radiotherapy|Standard procedure given 3 weeks after last dose of chemotherapy
41363240|NCT03204331|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
41363241|NCT03204331|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
41363242|NCT03204331|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
41363243|NCT03204331|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
41363244|NCT01439932|DEVICE|algometer|"Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people \[Andrew 1987\]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). \[Linda et al 2007\]"
41500019|NCT06079567|DIAGNOSTIC_TEST|Validation of new COMs for FSHD2 patients|Monitoring of commonly used and new COMs in FSHD2 patients
41363245|NCT03268603|DRUG|Autologous Adipose-derived Mesenchymal Stromal Cells|The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.
41363246|NCT03060109|OTHER|Blood draw within 12 hours of injury|
41363247|NCT00142714|PROCEDURE|Sympathetic manipulation on sexual arousal in women|
41363248|NCT02010099|DRUG|PP110 Gel|
41363249|NCT02010099|DRUG|PP110 Medicated wipes|
40842452|NCT04943120|PROCEDURE|"Snow-plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
41363250|NCT02010099|DRUG|Preparation-H Cream|
41363251|NCT02635503|PROCEDURE|transrectal specimen extraction|After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
40842453|NCT04943120|PROCEDURE|Bulk fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
41363252|NCT02635503|PROCEDURE|Conventional laparoscopic surgery|High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
41500020|NCT06632262|DRUG|ABSK061 + ABSK043|Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
40842454|NCT04235712|OTHER|Harmonized Depression Outcome Measures|This is an observational study where outcome measures will be extracted from patients' medical records and from questionnaires to provide information back to the clinician.
40842455|NCT02784600|DEVICE|Bioinductive implant|
41500021|NCT06632262|DRUG|ABSK061+ABSK043 in combination with CAPOX|Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
40842456|NCT01848366|DEVICE|Biowave Treatment|Twelve weekly treatments
41363253|NCT02285699|DRUG|SSRIs|12-weeks of standard SSRi treatment for those interested in Phase II of the study.
40842457|NCT06014281|BEHAVIORAL|SOS Meditation|"Focused-attention meditation technique will be used to train participants, specifically the SOS meditation technique. The SOS meditation technique is an easy-to-learn approach where participants are instructed to dissociate their attention from physical awareness, thoughts, and emotions by mentally slowly repeating a calming word or phrase (chosen by the participant themselves).~SOS Meditation Instructions:~* Close your eyes very gently, in a relaxed way, as you do when we go to sleep~* Your attention should be fully alert. Try not to put any strain on your eyes or try to look up.~* Focus your eyes about eight to ten inches into the field of darkness in front of you on the horizontal plane~* Mentally repeat the (chosen) calming word~* Sit lovingly and calmly to see what comes up, as if you were watching a movie screen and waiting to see what appears on it."
41026277|NCT05495503|DEVICE|Prototype (814D-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
41500022|NCT06330181|OTHER|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart"
40842458|NCT03117413|OTHER|Positron emission tomography scan|"* Binaural hearing assessments: speech recognition in noise and sound source localization~* Voice perception assessment: voice/non-voice discrimination task, free categorization task~* Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)"
40842459|NCT00468975|DRUG|PF-610,355|
40842460|NCT00468975|DRUG|Salmeterol|
40842461|NCT01805037|DRUG|brentuximab vedotin|Given IV
40842462|NCT01805037|BIOLOGICAL|rituximab|Given IV
41500023|NCT06330181|OTHER|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
40842463|NCT01805037|OTHER|laboratory biomarker analysis|Correlative studies
40842464|NCT03046979|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
40842465|NCT06530134|OTHER|Driving situation and video feedback|At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation using video feedback.
40842466|NCT06530134|OTHER|Driving situation and usual recommendations (without video feedback)|"At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation without video feedback, according to the usual recommendations.~Comparison of responses to all questionnaires and interview grids sent before and after driving, to patients and professionals will determine whether video feedback promotes awareness of the difficulties of driving post-stroke patients."
40842467|NCT00351325|DRUG|BMS-663513|mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
41026278|NCT06573905|OTHER|no intervention|no intervention. this is observational study.
41026279|NCT03644979|OTHER|Skydiving|Tandem skydiving (with an experienced instructor)
41026280|NCT00765245|DRUG|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
41026281|NCT00765245|DRUG|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
41026282|NCT00765245|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
41026283|NCT00982020|DRUG|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
41026284|NCT00982020|BEHAVIORAL|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
40842468|NCT02100306|BEHAVIORAL|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
40842469|NCT02100306|BEHAVIORAL|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
40842470|NCT00506194|DRUG|Insulin|
40842471|NCT00506194|DRUG|OAD|Gliclazide-MR, Metformin, Glimepiride
40842472|NCT01569230|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
40842473|NCT01569230|PROCEDURE|sham acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
41026285|NCT00982020|BEHAVIORAL|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
41363254|NCT03150706|DRUG|Avelumab|"Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.~Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
41363255|NCT06412471|DRUG|SSGJ-707|bispecific antibody
41363256|NCT06412471|DRUG|carboplatin|chemotherapy
41363257|NCT06412471|DRUG|Pemetrexed|chemotherapy
41363258|NCT06412471|DRUG|paclitaxel|chemotherapy
41363259|NCT06412471|DRUG|PD-1/L1|Immune checkpoint inhibitors
41363260|NCT06412471|DRUG|Paclitaxel-albumin|chemotherapy
41363261|NCT03370133|DRUG|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
41500024|NCT04068194|DRUG|Avelumab|Given IV
41500025|NCT04068194|PROCEDURE|Biopsy|Undergo biopsy of tumor
40842474|NCT01569230|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
41026286|NCT01334697|DRUG|recombinant human cardiotrophin-1|Single dose intravenous administration
41363262|NCT03370133|DRUG|Ustekinumab|Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.
41363263|NCT03370133|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points.
41500026|NCT04068194|PROCEDURE|Biospecimen Collection|Correlative studies
41500027|NCT04068194|PROCEDURE|Computed Tomography|Undergo CT scan
41500028|NCT04068194|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
40842475|NCT01569230|OTHER|Waiting|No interventions were applied to the patients in this group.
41500029|NCT04068194|DRUG|Peposertib|Given PO
41500030|NCT04901988|DRUG|Nivolumab 10 MG/ML|Eligible patients randomised to Arm B will receive 480 mg nivolumab monotherapy 4 weekly via IV infusion for up to 2 years.
41500031|NCT00043628|PROCEDURE|Stem Cell Mobilization|
41500032|NCT03458182|OTHER|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
40842476|NCT05583760|PROCEDURE|Experimental: Osteopathic manipulation TUG for scaphoid bone|The sequence of execution of the scaphoid TUG technique shall be applied as follows. Patient in the supine position. The inner hand of the intervener makes contact with the pisiform through the hypothenar eminence and ulnar border of the hand over the scaphoid tubercle, the outer hand reinforces the contact. The thumbs are directed to the sole of the patient's foot. The parameters are sought by bringing the sole of the foot into eversion, thus bringing the scaphoid into internal rotation (the direction of correction). In order to reduce the slack, the operator drops his body weight backwards while increasing the internal rotation parameter of the scaphoid. The manipulation is performed by associating a rapid traction movement with an increase of the correction parameter towards the internal rotation of the scaphoid.
41026287|NCT01334697|OTHER|Placebo|Single dose intravenous administration
41026288|NCT01218724|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
41363264|NCT02440191|RADIATION|3DCRT|conventional radiotherapy
41500033|NCT01596660|DRUG|Bupivacaina 0.5%|Bupivacaina 0.5% 20cc
41500034|NCT01596660|DRUG|placebo comparator|20 cc of saline solution 0.9%, to infiltrate each side.
41500035|NCT02873741|PROCEDURE|Perianal and Digital Anorectal Exam|The physician will inspect the outside of the anus and use a gloved finger to feel the anus for any masses.
41026289|NCT05774808|PROCEDURE|Aortic valve replacement|An aortic valve prosthesis is surgically implanted to treat AR
41363265|NCT06334380|OTHER|Virtual Reality Modules Only|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team.
41500036|NCT02873741|PROCEDURE|Cervical Swabs|A speculum will be inserted into the vagina to visualize the cervix. The sample for research tests will be collected with one ThinPrep cytobroom inserted into the cervix. Collection will be same for the sample to be paced in the RNA storage solution for future biomarker studies.
41026290|NCT05774808|PROCEDURE|Mitral valve annuloplasty|Surgical repair of the mitral valve in which a prosthetic ring is implanted to treat MR
41026291|NCT04544046|OTHER|Supportive Oncology Care at Home|Remote monitoring of symptoms, vital signs, and body weight with home-based care to address any concerning issues identified.
41026292|NCT04544046|OTHER|Usual Care|Standard care arm will receive standard oncology care and attend regular clinic visits.
41026293|NCT00345397|DEVICE|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
41026294|NCT04459611|BIOLOGICAL|sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
41363266|NCT06334380|OTHER|Virtual Reality Modules + Live Physical Therapist Support|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team. Participants will also have access to up to three live PT sessions via Zoom where they can ask questions and complete modules with PT feedback.
41363267|NCT02551900|OTHER|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
41363268|NCT02551900|OTHER|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
41363269|NCT02551900|OTHER|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
41363270|NCT02119728|DRUG|HPPH|Undergo photodynamic therapy with HPPH
41363271|NCT02119728|DEVICE|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
41500037|NCT02873741|PROCEDURE|Anal Swabs|The anal cytology specimen will be collected by inserting a saline moistened cotton-tipped swab into the anus, rotating it clock-wise for 20 seconds, and placed in SurePath. The first twenty participants will have anal cells collected in two different ways for validation/optimization: 1) saline moistened Dacron swab placed directly in ThinPrep medium and 2) Medscand Cytobrush Plus, a special brush, placed directly into ThinPrep medium. After validation/optimization is complete for up to 20 participants, the best collection method will be selected and will be used for all future enrolled participants.
41160970|NCT05632016|PROCEDURE|erector spinae block (ESP)|the erector spinae plane block will be performed bilaterally using a high-frequency-curved ultrasound transducer (Mindray 35C50EB, China) placed in a longitudinal orientation 3 cm lateral to the spinous process at two different levels, one above the angle of kyphosis at T8- T10 and another below the angle of kyphosis at L3. An 8- cm 22-gauge block needle (EchoStim; Benlan Inc, Oakville, Canada) is inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane below erector spinae muscle, the block will be performed by injection of 10 mL of bupivacaine at each point.A total volume of 40 ml of diluted bupivacaine with a total dose of 3mg/kg with variable concentrations according to body weight will be given for each patient.
41160971|NCT04017949|DRUG|Corticosteroid injection|1 cc (40 mg) of a corticosteroid (kenalog) is given
41266828|NCT02140255|DRUG|Lopinavir/Ritonavir (LPV/r)|Administered orally. Dosed according to study step and participant's age.
41266829|NCT02140255|DRUG|Raltegravir (RAL)|Administered orally. Dosed according to study step and participant's age.
41363272|NCT02119728|PROCEDURE|therapeutic conventional surgery|Undergo standard of care surgery
41363273|NCT00222066|PROCEDURE|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
41363274|NCT05551182|DRUG|Nicergoline|The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
41363275|NCT04153526|PROCEDURE|Blood sampling|Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.
41500038|NCT02873741|PROCEDURE|High Resolution Anoscopy (HRA)|High Resolution Anoscopy is a procedure that allows for examination and evaluation of the anal canal. Using a small thin round tube called an anoscope, the anal canal is examined with a high resolution magnifying instrument called a colposcope. Application of a mild acidic liquid (acetic acid or diluted vinegar) or a brown iodine-based solution (Lugol's) onto the anal canal facilitates evaluation of abnormal tissue such as anal dysplasia. If abnormal staining is seen using acetic acid (dense white lesion) or Lugol's solution (bright yellow lesion) a biopsy of that area will be obtained.
41500039|NCT06066294|BIOLOGICAL|Regimen 1|WHO Pre-qualified rabies vaccine (Rabivax-S), WHO recommended PrEP Vaccination Schedule, 2 visits, 0.2ml 2 sites (0.1ml each site) on day 0 and day 7
40842477|NCT05583760|PROCEDURE|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|The intervention will be performed in the same way as the intervention group, without actually performing the TUG manipulation on the scaphoid bone, only placing it in tension.
40842478|NCT06186115|COMBINATION_PRODUCT|Gold|Intra articular
41266830|NCT02140255|DRUG|VRC01|40 mg/kg administered subcutaneously.
40842479|NCT03999086|PROCEDURE|Intervention|We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion
40842480|NCT03999086|OTHER|Control Group|Laboratory analysis to guide transfusion
41363276|NCT04153526|PROCEDURE|Surplus Tumour Tissue sample collection from surgery|In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.
41500040|NCT06066294|BIOLOGICAL|Regimen 2|WHO Pre-qualified rabies vaccine (Rabivax-S), Government of India approved vaccination schedule, 3 visits, 0.1ml 1 site on day 0, 7 and 28
41500041|NCT04084600|OTHER|Kinesiotherapy Protocol|Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.
40842481|NCT05647785|DEVICE|Long-term follow-up of cerena™|Long term follow-up for eligible participants from the RESTORE study
40842482|NCT05647785|DEVICE|Long-term follow-up of attune™|Long term follow-up for eligible participants from the RESTORE study
40842483|NCT03046524|OTHER|Chart Review|Data between the years of 1/1/2002 and 12/31/2013 analyzed.
41026295|NCT04459611|DRUG|pemetrexed|500 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
41363277|NCT04153526|OTHER|Collection or archival tumour tissue (If available)|Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.
41363278|NCT01666301|DRUG|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
41363279|NCT00815373|DRUG|Dorzolamide+Timolol Maleate0.5%|Cosopt\* b. i. d.
41363280|NCT00815373|DRUG|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom\* QHS
41363281|NCT03851302|OTHER|Active Remote Ischemic Conditioning|The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
41363282|NCT03851302|OTHER|Sham Remote Ischemic Conditioning|The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
41363283|NCT03851302|OTHER|Isometric hand exercise|Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
41363284|NCT00002624|PROCEDURE|adjuvant therapy|
41363285|NCT00002624|PROCEDURE|diagnostic thoracoscopy|
41363286|NCT00002624|PROCEDURE|therapeutic thoracoscopy|
41363287|NCT00002624|PROCEDURE|video-assisted surgery|
41363288|NCT00002624|RADIATION|radiation therapy|
41363289|NCT05445999|DEVICE|High-Definition transcranial electrical stimulation|According to the results of structural phase magnetic resonance and electroencephalogram, four optimal stimulation parameters will be determined.Transcranial electrical stimulation devices (Sorterix)will be used for intervention.In each cycle, the stimulation will be performed every night during weekdays,a total of 10 times.A maximum of four cycles of intervention will be performed for each patient, depending on the efficacy and the their wishes.
41363290|NCT05311358|DEVICE|The engineer-built system, video-game based Kinect sensor|There are 3 computer games using Kinect sensor to detect movement of trunk and upper extremities of the children.
41363291|NCT00877929|DRUG|Telmisartan 80|Telmisartan 80 mg
41500042|NCT04084600|OTHER|Manual Therapy Protocol|Manual therapy protocol: is a manual treatment intended to the release of fascias and soft tissues.
40842484|NCT02102399|BEHAVIORAL|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
40842485|NCT02102399|BEHAVIORAL|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
40842486|NCT00057408|DRUG|olanzapine (Zyprexa)|Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
40842487|NCT00057408|DRUG|Placebo|Matching Placebo
40842488|NCT04795700|BEHAVIORAL|MSC intervention|Patients in the intervention group had access to conventional care, in addition to receiving the 8 weeks MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The intervention is mainly out-of-hospital intervention, supplemented by short-term in-hospital intervention. Among them, the first and second weeks of the intervention project in the hospital phase focus on guiding the research subjects to understand the content of mindful self-compassion and emotions, and carry out basic mindful self-compassion training; the content of the 3-8th week of the intervention program outside the hospital, Focus on the maintenance of mindful self-compassion training and the promotion of mindful life. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
41026296|NCT04459611|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.
41026297|NCT04459611|DRUG|albumin-bound paclitaxel|260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
41500043|NCT04084600|OTHER|Traditional Massage|Traditional Massage is a gentle and superficial massage.
41500044|NCT00152698|DRUG|Irbesartan|
41500045|NCT02841163|DRUG|Herbal medicine|Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
41026298|NCT06533839|PROCEDURE|Permanent colostomy|A long-term (permanent) colostomy will be performed in the diseased colon or rectum.
41026299|NCT03734224|PROCEDURE|Adhesix mesh|Adhesix mesh
41026300|NCT03734224|PROCEDURE|Progrip mesh|Progrip mesh
41026301|NCT03952247|DEVICE|Single Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
41026302|NCT03952247|DEVICE|Conventional Multi Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
41026303|NCT00907270|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
41026304|NCT06280365|OTHER|Mulligan Mobilization with Movement Technique|Mobilization Technique
41363292|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
40842489|NCT02414620|DEVICE|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
40842490|NCT03001778|OTHER|Usability Testing|"Usability testing of ready made workouts in a group format."
40842491|NCT05746936|PROCEDURE|Roux en-Y gastric bypass|gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis
41026305|NCT02199782|OTHER|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
41363293|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
41363294|NCT02855996|OTHER|Fathers in Action/Padres Activos (FA/PA) program|The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
41363295|NCT05199285|BIOLOGICAL|Ipilimumab|Given IV
41363296|NCT05199285|BIOLOGICAL|Nivolumab|Given IV
40842492|NCT01641822|DRUG|AZLI|Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
40842493|NCT01641822|DRUG|Placebo to match AZLI|Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
41026306|NCT04427280|DIAGNOSTIC_TEST|Throat/nose swabs|Throat/nose swabs will initially be collected at baseline (D0) as part of the diagnostic workup for SARS-CoV-2 infection. Subsequent throat/nose swabs will be taken at D7 (if an inpatient), D14, D28, D42 and D56. Two samples will be taken, one for standard of care testing and one for lateral flow assay and storage for further analysis later such as quantitative PCR.
41026307|NCT04427280|DIAGNOSTIC_TEST|Saliva collection|Saliva will be collected at each study visit, by asking the participant to provide a small amount of saliva (approximately 0.5mL) will be collected. Saliva will be tested by the lateral flow assay when available and excess material stored.
41266831|NCT02140255|DRUG|DTG|Administered orally. Dosed according to participant's weight.
41266832|NCT02140255|DRUG|VRC07-523LS|40 mg/kg administered subcutaneously.
41266833|NCT05579925|BIOLOGICAL|CM310|CM310 600 mg + 300 mg, subcutaneous injection
41363297|NCT02896686|RADIATION|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure."
41363298|NCT02896686|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
41363299|NCT02896686|PROCEDURE|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
41363300|NCT04384120|DEVICE|Blood Flow Restriction Therapy|Blood flow restriction cuffs which are FDA approved will be provided to patients randomized into the BFR group. Patients will be provided video instruction and training on how to conduct the traditional therapy exercises with the use of BFR.
40842494|NCT01641822|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
40842495|NCT02271945|DRUG|MEDI-551 12 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
40842496|NCT02271945|DRUG|MEDI0680 2.5 mg/kg|Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
41363301|NCT04384120|PROCEDURE|Traditional Therapy|Patients will be provided video instruction and training on how to conduct the traditional therapy exercises.
41363302|NCT00513331|PROCEDURE|Endoscopy|Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
41363303|NCT00513331|PROCEDURE|Radiofrequency ablation protocol|Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
41363304|NCT00513331|PROCEDURE|Endoscopic mucosal resection protocol|Excision of lesion using DUETTE, marketed by Wilson-Cook
41363305|NCT03092076|DRUG|Ticagrelor|180 mg loading dose
41500046|NCT02841163|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
41363306|NCT05814965|PROCEDURE|endodontic treatment in the form of root canal treatment|Patients will receive endodontic treatment, and inflammatory markers will be assessed
41026308|NCT04427280|DIAGNOSTIC_TEST|Blood collection|Approximately 30mL of blood will be taken at each study visit.
41026309|NCT00317239|DRUG|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
41363307|NCT05814965|PROCEDURE|endodontic treatment|Patients will receive endodontic treatment in the form of root canal treatment, and inflammatory markers will be assessed along with metabolic markers assessment
41363308|NCT05814965|DIAGNOSTIC_TEST|assessment of inflammatory marker|assessment of inflammatory markers
41363309|NCT05814965|DIAGNOSTIC_TEST|inflammatory markers will be assessed along with metabolic markers assessment|inflammatory markers will be assessed along with metabolic markers assessment
41363310|NCT01393444|DEVICE|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
41363311|NCT00800189|RADIATION|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
41363312|NCT01410331|BIOLOGICAL|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
41363313|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
41363314|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
41363315|NCT01410331|BIOLOGICAL|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
41363316|NCT04426227|OTHER|Gaze training|A training module in gaze training for peripheral nerve blockade
41500047|NCT02841163|PROCEDURE|Pharmacopuncture|Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
41363317|NCT04426227|OTHER|Discovery learning|A phase of discovery learning guided by novice operators themselves
41363318|NCT04168359|DEVICE|absorbable semi-barbed suture|Positioning the intrapulmonary nodules of patient in this group with a absorbable semi-barbed suture positioning device
41363319|NCT03385395|DRUG|OctaAlpha1|For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
41363320|NCT03385395|DRUG|Glassia|For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
40842497|NCT02271945|DRUG|MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
40842498|NCT00351182|DRUG|Telithromycin|
40842499|NCT00351182|DRUG|Doxycycline|
41026310|NCT00317239|DRUG|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
41026311|NCT01098448|OTHER|scaling and root planing|scaling and root planing as a single therapy
41026312|NCT01098448|DRUG|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm
41026313|NCT01098448|DRUG|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
41026314|NCT01098448|OTHER|surgery|periodontal surgery in residual pockets of \>4mm
41026315|NCT01098448|DRUG|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
41026316|NCT01098448|OTHER|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm and periodontal surgery in residual pockets of \>4mm
41026317|NCT01098448|OTHER|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets \>4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
41363321|NCT04676581|OTHER|Leech Therapy|Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)
41363322|NCT04274972|DIAGNOSTIC_TEST|Microbiome evaluation|The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated
41363323|NCT01243047|DRUG|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
41363324|NCT04777422|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
41363325|NCT01947166|DIETARY_SUPPLEMENT|Nestle Impact Advanced Recovery nutritional supplement|Before Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days (15 servings total) on postoperative day minus 5 through postoperative day 1 in addition to normal diet. After Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days on postoperative day 2 through postoperative day 6.
41363326|NCT02443727|DRUG|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
41363327|NCT02443727|OTHER|Placebo|Dosage and details described in arm.
41363328|NCT06265389|DRUG|Pentoxifylline Oral Tablet|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form as an adjunct therapy to the usual pneumonia treatment for 5 days and the control group includes 50 children with community-acquired pneumonia with the standard pneumonia treatment.
41363329|NCT04421430|OTHER|Distraction cards|The distraction cards contain various hidden pictures and patterns which are visible only when looked at carefully. During a procedure, the child is expected to focus on the cards and answer the questions asked about what they see in them. Just before the venipuncture, the researcher showed the distraction cards participants the distraction cards and asked them to check them and then asked them questions about what they saw on the cards and kept asking questions until the end of the venipuncture. The distraction cards intervention and venipuncture were terminated at the same time.
41363330|NCT04421430|OTHER|Virtual reality|The virtual reality participants put on the virtual reality glasses and headsets about two minutes before the venipuncture and watched the 3D Dinosaur Animation movie throughout the procedure. The virtual reality intervention and venipuncture were terminated at the same time.
41363331|NCT04421430|OTHER|Buzzy|Buzzy® applies high frequency vibration and concentrated cold at injection site for procedural pain management and distraction before the shot in children and adults. Buzzy® was placed on the injection site (antecubital fossa) of the Buzzy® participants, and cold application and vibration was turned on 60 seconds before the procedure. After the 60 seconds, the nurse moved Buzzy® about 3 cm above the injection site and applied a tourniquet and performed the procedure. Buzzy® was on throughout the procedure. The Buzzy® intervention and venipuncture were terminated at the same time.
41363332|NCT02766699|DRUG|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
41363333|NCT00955682|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose (Booster)
41363334|NCT00955682|BIOLOGICAL|Meningitec™|One intramuscular dose (Booster)
41363335|NCT06305793|DRUG|IVIG (intravenous immunoglobulin)|Participants will receive IVIG for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).
41363336|NCT06305793|DRUG|IVIG Placebo|"Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo.~Participants will receive placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months)."
41363337|NCT06305793|BEHAVIORAL|Coordinated Care|Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
41363338|NCT06305793|BEHAVIORAL|Usual Care|Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with IVIG administration.
41363339|NCT04429269|DIAGNOSTIC_TEST|mammography and ultrasound screening|Patients screened by both mammography and ultrasound.
41363340|NCT01349881|DRUG|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
41363341|NCT01349881|DRUG|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
41363342|NCT01349881|DRUG|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
41363343|NCT01349881|DRUG|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
41026318|NCT01098448|OTHER|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets \>4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets \>5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
41026319|NCT06529328|OTHER|core stability|"In this study the experimental group will perform core stability exercises 3 times per week for an 8-week period and each session of 30 to 45 minutes, the core stability exercises will work on abdominals and trunk muscles with challenges.Subjects received 25 min conventional therapy in addition to 30 30-minute trunk stabilization exercise program conducted for 3 days\\week on non-consecutive days.~Passive stretching exercises are applied to all tight muscles, including the hamstrings and calf muscles in the lower limb. It is performed five times initially, building up to ten repetitions, stretching for 5 times, and then allowing relaxation for 5time. Strengthening exercises for back, hip, and knee extensor muscles (for 10 minutes)."
41026320|NCT02306915|DRUG|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
41026321|NCT06288113|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41363344|NCT03418727|DRUG|Brimonidine|Two products delivered in sequence twice daily.
41363345|NCT03418727|DRUG|Brimonidine Mono Therapy|Brimonidine given twice daily along with placebo drops
41363346|NCT03418727|DRUG|sodium carboxymethylcellulose|Placebo given twice daily.
41363347|NCT03418727|DRUG|Corticosteroid Eye Drop|Eye drop to be administered after Brimonidine in treatment arm 1
41363348|NCT01697631|DRUG|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
41026322|NCT06288113|PROCEDURE|Computed Tomography|Undergo PET/CT and SPECT/CT
41026323|NCT06288113|OTHER|Gallium Ga 68 Gozetotide|Given IV
41026324|NCT06288113|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
41026325|NCT06288113|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41026326|NCT06288113|OTHER|Questionnaire Administration|Ancillary studies
41026327|NCT06288113|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
41026328|NCT04823338|BEHAVIORAL|Conectar Jugando Online Program|Online play sessions with modern board and card games guided by the study researchers
41266834|NCT02051907|DEVICE|KAM1403 Gel|
41266835|NCT02051907|DEVICE|aloevera gel|
41363349|NCT01697631|DRUG|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
41363350|NCT00771420|DRUG|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
41363351|NCT00771420|DRUG|CAM-3001|Dosed at 0.1mg/kg.
41363352|NCT00771420|DRUG|CAM-3001|Dosed at 0.3mg/kg
41363353|NCT00771420|DRUG|CAM-3001|Dosed at 1.0 mg/kg.
41363354|NCT00771420|DRUG|CAM-3001|Dosed at 3.0 mg/kg.
41363355|NCT00771420|DRUG|CAM-3001|Dosed at 10 mg/kg.
41363356|NCT00771420|OTHER|Placebo|Active: Placebo 5:1 for arms 2-6
41363357|NCT00195117|BEHAVIORAL|Intervention Group|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
40842500|NCT05699564|OTHER|Early biomarker-based cardiological assessment|We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
40842501|NCT00790478|DRUG|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
40842502|NCT00790478|OTHER|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
41500048|NCT02841163|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
40842503|NCT02742311|PROCEDURE|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
40842504|NCT02087722|DRUG|KI1001|
40842505|NCT02087722|DRUG|Placebo|
40842506|NCT00710385|DRUG|Heroin|Heroin (25 mg)
40842507|NCT00710385|DRUG|Naloxone|.4 mg
40842508|NCT00710385|DRUG|Low Bup Dose|4 and 8 mg
40842509|NCT00710385|DRUG|High Bup Dose|8mg and 16 mg
40842510|NCT00710385|DRUG|Low Bup/Nal Dose|Buprenorphine/Naloxone 4/1 mg, 8/2 mg
40842511|NCT00710385|DRUG|High Bup/Nal Dose|Buprenorphine/Naloxone 8/2 mg, 16/4 mg
40842512|NCT00710385|DRUG|Placebo (PCB)|Placebo control administration
40842513|NCT02029794|PROCEDURE|HPV self-colleciton|Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
40842514|NCT02029794|PROCEDURE|visual inspection with acetic acid (VIA)|
40842515|NCT02029794|DRUG|3-5% acetic acid|
40842516|NCT03637712|DEVICE|Computer Algorithm|This device is a computer algorithm that runs in the background during routine screening or surveillance colonoscopy that is designed to aid in the detection of polyps
41266836|NCT03867630|PROCEDURE|Transforaminal Block|Epidural block via neural foramen of lumbar spine
40842517|NCT03837132|BEHAVIORAL|Palliative care assessment|Patients with advanced pancreatic cancer will have regular palliative care assessment with palliative care team
40842518|NCT02419170|PROCEDURE|Standard of care surgery|
40842519|NCT02419170|PROCEDURE|Apheresis|
40842520|NCT02419170|DRUG|Cyclophosphamide|
40842521|NCT02419170|BIOLOGICAL|Personalized mature dendritic cell vaccine|
40842522|NCT03898076|DEVICE|Flash Glucose Monitoring|Continuous Glucose Monitoring (CGM) values will be downloaded from CGM device for a period of 90 days.
40842523|NCT03898076|OTHER|A1c|A1c levels will be collected from Hospital EMR prior to CGM data downoad
41363358|NCT03220620|OTHER|GDT|individualized fluid therapy
41363359|NCT05257876|OTHER|Breathing exercise|Participants will receive breathing exercise training, and a 4-week self exercise
41363360|NCT03950531|OTHER|No intervention|
41363361|NCT04762420|OTHER|Dose of sugammadex according to SSD and QSD|At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.
41363362|NCT03809702|DRUG|Pregabalin|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
41363363|NCT03809702|DRUG|Placebo|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
41363364|NCT04643158|DRUG|AZD1402|Randomised participants will receive oral inhalation of AZD1402, via DPI.
41363365|NCT04643158|DRUG|Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
41363366|NCT04643158|DRUG|Short acting beta agonist (SABA) (rescue medication)|"In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)"
41363367|NCT04643158|DRUG|Run-in medications (ICS-LABA combination)|"During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care."
41363368|NCT00012870|BEHAVIORAL|Behavioral Management|
41363369|NCT04839900|OTHER|Proactive iCCM|CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children \< 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
41363370|NCT02612168|DEVICE|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
41500049|NCT02841163|PROCEDURE|Chuna manipulation|Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
41363371|NCT03778281|DRUG|Baclofen|Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
41363372|NCT03778281|DRUG|Methoxyclopramide|Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
41363373|NCT04905160|OTHER|COMPASSION Digital Biomarker|Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
41363374|NCT00584428|PROCEDURE|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
41500050|NCT02565537|PROCEDURE|LASIK|WFG vs. WFO LASIK
41500051|NCT02782806|DEVICE|Masimo Rad-67 Pulse Oximeter|Noninvasive pulse oximeter
40842524|NCT03898076|OTHER|Predictive A1c|Predictive A1c will be calculated based on the first 15 days of CGM data using time in range (TIR), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), continuous overall net glycemic action (CONGA). Predictive A1c will be correlated with actual A1c.
41500052|NCT02784873|OTHER|High intensity interval training|High intensity interval training within a standard cardiac rehabilitation programme
41500053|NCT06391775|BIOLOGICAL|GEN1055|Intravenous (IV) administration.
41500054|NCT06391775|BIOLOGICAL|Pembrolizumab|IV administration
40842525|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 50 mcg QD
40842526|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 25 mcg BID
40842527|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 15 mcg BID
40842528|NCT00064402|DRUG|Salmeterol|Salmeterol MDI 42 mcg BID
40842529|NCT00064402|DRUG|Placebo|Placebo BID
41266837|NCT02257424|DRUG|Trametinib 2 mg daily|
41363375|NCT04191928|DRUG|Apixaban|Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
41363376|NCT01511211|DRUG|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
41500055|NCT06391775|DRUG|Standard Chemotherapy|IV administration
41500056|NCT02052193|DRUG|Dabrafenib|Measurement of toxicity related to UV exposure
41500057|NCT02052193|DRUG|Vemurafenib|Measurement of toxicity related to UV exposure
41500058|NCT05604989|DRUG|Probiotic Combination Cap/Tab|The Perfect Probiotics® capsule will be given as an intervention, which is composed of mostly Lactobacillus acidophilus \& Bifidobacterium lactis.
41500059|NCT05604989|DRUG|intravitreal Anti-VEGF injection|Intravitreal anti-VEGF injection treatment in the neovascular AMD patients.
41500060|NCT05803174|DIAGNOSTIC_TEST|blood sample|"Blood collection Circulating serum concentrations of melatonin and dopamine were determined from fasting blood samples. Participants were required to fast from 10 pm the previous evening. A 5 mL serum blood sample was collected from the antecubital vein between 8.30 am and 10 am.~Tear collection Tear samples were collected using Schirmer's strip without anesthesia between 8:30-10:00am. Tears were extracted in 200 μl of 1 X Phosphate Buffered Saline with 0.1% Tween-20 (PBST).~Saliva collection Saliva samples were collected via the passive drool method with subjects in a seated position. Subjects were asked to rinse their mouth with water 10 minutes prior to saliva collection and to refrain from using lip makeup during the sampling period."
41500061|NCT05862285|DRUG|Ipatasertib|Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
41363377|NCT01511211|DRUG|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
41363378|NCT00265109|DRUG|Levetiracetam|The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
41363379|NCT03024151|DRUG|Comthyroid|T4/T3 combination replacement
41363380|NCT03024151|DRUG|Synthroid|T4 mono replacement
41363381|NCT06035341|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
41363382|NCT00602043|RADIATION|F-18 16 alpha-fluoroestradiol|Undergo \[\^18F\] FES PET
41363383|NCT00602043|RADIATION|fludeoxyglucose F 18|Undergo standard clinical FDG PET/CT
41363384|NCT00602043|PROCEDURE|positron emission tomography|Undergo \[\^18F\] FES PET
40842530|NCT03405519|PROCEDURE|Radiotherapy planning using both CT and MRI scans|Patients' radiotherapy will be planned using CT and MRI scans in order to establish the best methodology for planning of radiotherapy for nodal disease
40842531|NCT01954563|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
40842532|NCT01278407|DRUG|Donepezil 5 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
41160972|NCT02179710|BEHAVIORAL|Adherence dashboard motivational interviewing|These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
41500062|NCT05862285|DRUG|Tiragolumab|Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
41500063|NCT05862285|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy and in combination with tiragolumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
40842533|NCT01278407|DRUG|Donepezil 10 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
40842534|NCT01278407|DRUG|Donepezil matched placebo|
40842535|NCT01501552|OTHER|Training and support (T&S)|Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
40842536|NCT01501552|OTHER|Financial incentive|Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
40842537|NCT01501552|OTHER|E-SBI (online screening and brief intervention)|Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
40842538|NCT06047496|BEHAVIORAL|Time restricted eating|Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period.
41160973|NCT04106583|DEVICE|WAVE, as part of the SMART COIL System|WAVE, as part of the SMART COIL System
41363385|NCT00602043|PROCEDURE|positron emission tomography|Undergo standard clinical FDG PET/CT
41363386|NCT00602043|PROCEDURE|computed tomography|Undergo standard clinical FDG PET/CT
41363387|NCT00602043|OTHER|laboratory biomarker analysis|Correlative studies
41363388|NCT03102164|PROCEDURE|cardiac rehabilitation|The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
41500064|NCT05738317|DRUG|Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel|Adebrelimab is recommended to be administered with an infusion pump. The infusion pipeline is equipped with a 0.22-micron online filter membrane. Intravenous injection or bolus injection is not allowed. At the end of infusion, flush the infusion tube with sufficient 5% glucose or physiological saline, and do not share the same infusion tube with other drugs. In each treatment cycle, Adebrelimab should be given intravenously first.
41500065|NCT00517127|DRUG|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
41500066|NCT00517127|DRUG|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
41363389|NCT01262040|OTHER|Narrow Band Imaging (NBI)|The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
41363390|NCT05204901|DEVICE|Insertion and withdrawal of a magnetic-tipped wire into the lumen of the nasogastric tube for tracking of its position|In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
41500067|NCT05585879|DEVICE|Pure-Vu EVS|"Subjects will be enrolled until 115 inadequate bowel prep cases via SOC are accrued and subsequently treated with Pure-Vu EVS. Inadequate OCs defined as such if any of the following are met:~* Boston Bowel Preparation Score (BBPS) \< 6 (Adequacy is defined as BBPS of 2 or greater in each segment)~* Inability to identify \> 5mm polyps"
41026329|NCT05668494|OTHER|immediate loading of implants|This is a randomized control clinical trial including 24 implants, immediately loaded with definitive abutment protocol and 24 implants immediately loaded with with temporary abutment protocol
41363391|NCT03705858|DRUG|Ac-Lintuzumab|225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
41363392|NCT06003582|OTHER|Infant Parent Support|Therapeutic Intervention
41363393|NCT04592822|DRUG|WD-1602|dabigatran etexilate mesylate granules for oral suspension
41363394|NCT04592822|DRUG|Pradaxa®|dabigatran etexilate capsules
40842539|NCT03921177|DIETARY_SUPPLEMENT|Multiple micronutrient supplement|Preconception to 12-weeks gestation: daily (coded) multiple micronutrient supplement containing 15-nutrients (vitamins and minerals) providing an approximate recommended dietary allowance for pregnant women, approximating the UNICEF UNIMAP formulation (UN micronutrient preparation).
41363395|NCT05206201|DRUG|ZY19489 Capsule|Two part study with single and multiple dose
40842540|NCT03921177|DRUG|Placebo Oral Tablet|Preconception to 12-weeks gestation: identical tablet
40842541|NCT02602665|PROCEDURE|Shallow catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
40842542|NCT02602665|PROCEDURE|Deep catheter tip placement|deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
40842543|NCT01165970|DRUG|Glandosane|according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
40842544|NCT01165970|DEVICE|Saliva natura|Saliva substitute without restriction to be used
41026330|NCT01141361|PROCEDURE|GPS recording(s) of walking capacity in PAD patients|Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
41026331|NCT03640910|DEVICE|OT Equators® (Rhein83)|Attachment systems to retain an implant overdenture
41026332|NCT03640910|DEVICE|Locator® (Zest)|Attachment systems to retain an implant overdenture
41363396|NCT05206201|DRUG|Placebo Capsule|Two part study with single and multiple dose
41363397|NCT06444399|DRUG|Deucravacitinib|6 mg administered orally twice daily for 24 weeks.
41026333|NCT00333593|DEVICE|Large pore dialyser|
41363398|NCT02994043|BEHAVIORAL|Mindfulness-Based Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
41026334|NCT00333593|DEVICE|Standard dialyser|
41363399|NCT02994043|BEHAVIORAL|Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
41500068|NCT03928730|PROCEDURE|resection and removal|Surgical resection or removal for histopathological examination
41500069|NCT06633081|DEVICE|handheld dynamometer|handheld dynamometer is a device that measure muscle strength
41500070|NCT00956800|OTHER|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
41500071|NCT00956800|OTHER|Normal care|Control group will receive 5 routine office visits in one year
41500072|NCT06633302|OTHER|Simulated multi-day heatwave exposure|Older adults exposed to a multi-day simulated heat wave exposure
41500073|NCT00869336|DRUG|Luliconazole Cream 1% - 2 wks|Topical cream applied daily for 2 weeks
40842545|NCT03164330|BEHAVIORAL|Workplace Wellness Program|Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
41363400|NCT05596864|DIAGNOSTIC_TEST|gastric contrast ultrasound|"Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity with oral water, contrast agent and ultrasound contrast agent before the examination to remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous echo area and form a good acoustic sound. Interface contrast, more clearly showing the gastric wall hierarchy and the ultrasound examination method of the lesions.~In this way, not only the changes of the gastrointestinal mucosa can be found, but also the submucosal tumors of the gastrointestinal tract can be clearly displayed, the internal structural characteristics of the tumor, the extent of the lesions, the depth of infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can be displayed."
41363401|NCT01673373|DEVICE|iCAST™ Rx Stent System|All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
41500074|NCT00869336|DRUG|Placebo Comparator -2 wks|Placebo cream applied daily for 2 weeks
40842546|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - No Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
40842547|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - Moderate Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, \& waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); \& (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
41026335|NCT01629082|DRUG|Clofarabine|
41500075|NCT00869336|DRUG|Luliconazole Cream 1% - 4 wks|Topical cream applied daily for 4 weeks
41026336|NCT01629082|DRUG|Lenalidomide|
41026337|NCT06353971|DRUG|Briquilimab|Subcutaneous Injection
41026338|NCT06535893|DRUG|TN|Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
41026339|NCT06535893|DRUG|TN-1|Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
41026340|NCT05571943|DRUG|Difamilast|Difamilast Ointment 1%
41026341|NCT04133844|BIOLOGICAL|Blood sample|Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
41026342|NCT05515055|OTHER|Blood test|1 blood sample extra to standard of care is taken
41500076|NCT00869336|DRUG|Placebo Comparator - 4 wks|Placebo cream applied daily for 4 weeks
41500077|NCT05758909|DEVICE|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
41500078|NCT01059344|DRUG|Mesalamin|4.8g/day, 800 mg tablets
41500079|NCT01140399|DRUG|Furosemide or Furosemide and Dopamine|"Patients randomized to pharmacological treatment receive~* either intravenous diuretics at escalating doses up to 20 mg/h~* or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m."
41500080|NCT01140399|DEVICE|Ultrafiltration|"All loop diuretics will be discontinued. Rate of fluid removal will be based on the extent of fluid overload as assessed by increase in body weight vs the patient's known dry weight~* less than 3 kg 200 ml/h~* more than 3 kg and less than 5 kg 300 mlh~* more than 5 kg 500 mlh~Criteria for achievement of target UF goals are removal of \> 50% and \<70% of fluid excess based on the estimated increase in body weight Diuretic infusion is allowed provided that a minimum of 3 hours after the end of the UF session have elapsed, at a maximum cumulative dose of 100 mg furosemide, till start of the next UF session The use of inotropic agents is prohibited"
41500081|NCT05552963|DEVICE|Multi-Channel Irreversible Electroporation (IRE) Generator|The multi-channel IRE Generator is intended for use during cardiac Pulsed Field Ablation (PFA) therapy. This device is used in conjunction with a compatible ablation catheter to create a closed electrical circuit capable of delivering pulsed electrical field energy.
41500082|NCT05552963|DEVICE|Multi-Channel Circular IRE Catheter|The multi-channel circular IRE Catheter is indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and when used with an IRE Generator, for cardiac ablation.
41500083|NCT03122925|DEVICE|MR|MR
41500084|NCT05575258|OTHER|44-Day Diet Conventionally Sourced - YELLOW Diet|Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.
41500085|NCT05575258|OTHER|44-Day Diet Agro-Ecologically Sourced - GREEN Diet|Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).
41026343|NCT06387043|OTHER|Balance exercises with Virtual Reality Glasses|Balance exercises with Virtual Reality Glasses
41026344|NCT06387043|OTHER|Balance Exercises with Stroboscopic Glasses|Balance Exercises with Stroboscopic Glasses
41363402|NCT04311515|RADIATION|Tau Positron emission tomography (PET)|Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
41363403|NCT04311515|RADIATION|Fluorodeoxyglucose (FDG) Positron emission tomography (PET)|Measurement of neuronal function with FDG PET can help to understand the relationship between target engagement and potential clinical effects. FDG PET will be acquired using stringent quality control. Since glucose metabolism captures all neuronal activity, in order to isolate effects due to treatment, patients will be maintained in a consistent state during the tracer uptake period. Subject motion during image acquisition will be minimized and monitored. Images will be quality controlled, processed, and measured quantitatively using methods that maximize signal to noise associated with technical and physiologic variability
41363404|NCT04311515|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF) Biomarkers|A broad set of biomarkers are being assessed in this study to indicate whether this treatment is able to impact multiple pathways associated with AD related to neurodegeneration
41363405|NCT04311515|DIAGNOSTIC_TEST|Blood Biomarkers|Changes in blood biomarkers may be observable if treatment affects cerebral amyloidosis and loss of nerve cells
41500086|NCT00999323|DEVICE|stent implantation in coronary artery|Percuatenous Coronary Intervention with implanatation of a stent
41026345|NCT06387043|OTHER|Balance Exercises with Visual-Based Metaphor Training|Balance Exercises with Visual-Based Metaphor Training
41026346|NCT06387043|OTHER|Traditional Balance Exercises|Traditional Balance Exercises
41026347|NCT00606424|DRUG|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
41026348|NCT03450551|DEVICE|Twin Block, Herbst, Frog distalising appliance|To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.
41026349|NCT00709722|DRUG|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
41026350|NCT00610051|DRUG|Alprostadil|central venous access continuous delivery with 500mcg/48 hours in active arm
40842548|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - High Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
41363406|NCT04311515|BEHAVIORAL|Rating Scales|Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
41363407|NCT04311515|DRUG|PU-AD|PU-AD 30mg daily for 6mos
41363408|NCT04311515|DRUG|Placebo|Placebo 30mg daily for 6mos
40842549|NCT03164330|BEHAVIORAL|Wellness Activities - Low Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
41363409|NCT04647708|DRUG|M5049|Participants will receive low oral dose of M5049, twice daily in Part A.
41363410|NCT04647708|DRUG|M5049|Participants will receive ascending oral dose of M5049, twice daily in Part A.
41363411|NCT04647708|DRUG|M5049|Participants will receive high oral dose of M5049, twice daily in Part B.
41363412|NCT04647708|DRUG|Placebo|Participants will receive placebo matched to M5049.
40842550|NCT03164330|BEHAVIORAL|Wellness Activities - High Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
41026351|NCT03843502|DRUG|Kava Dietary Supplement|Participants will be given three 75mg kava capsules.
41026352|NCT02736539|DRUG|CBS 2004 (galacto-oligosaccharides)|CBS 2004 active treatment
41026353|NCT02736539|DRUG|Placebo|Placebo treatment
41026354|NCT03806738|OTHER|Intervention-specific Carevive questionnaire|includes standard of care questions with additional decision-making questions
41363413|NCT03776435|RADIATION|Abdomen CT|Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
41363414|NCT03773510|DRUG|Trabectedin discontinuation|"Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
41363415|NCT03773510|DRUG|Trabectedin continuation|Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
41363416|NCT00985114|DEVICE|EndoBarrier|EndoBarrier implant
41026355|NCT03806738|OTHER|Standard of Care questionnaire|includes the standard of care questions that are already in place for Carevive questionnaires
40842551|NCT05167903|OTHER|Normal Diet|All praticipants in ND will perform supervised and monitored RT three time per week for the 10 weeks of intervention. The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum).
40842552|NCT05167903|BEHAVIORAL|Time-restricted eating|All participants in TRE will perform supervised and monitored RT three time per week for the 10 weeks of intervention. Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm, and to avoid consumption of food or caloric drinks during the fasting period (8 h eating window with 16 h of fasting).
40842553|NCT04448353|DIAGNOSTIC_TEST|vascuCAP|adverse event and phenotype classification model
40842554|NCT05845463|DEVICE|Cerebro endoscopy quality control tool|The AI provides feedback via a separate screen to the endoscopists to inform them which part of the upper GI tract have been adequately visualised.
40842555|NCT05859750|DRUG|AK104|AK104 (6mg/kg) on day 1, IV, Q2W
40842556|NCT05859750|DRUG|AK104|AK104 (10mg/kg) on day 1, IV, Q2W
40842557|NCT05859750|DRUG|Gemcitabine|Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W
40842558|NCT05859750|DRUG|Nab-Paclitaxel|Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W
40842559|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Palbociclib|Continuation of CDK4/6 inhibitor Palbociclib
40842560|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Palbociclib|Discontinuation of CDK4/6 inhibitor Palbociclib
40842561|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor -Palbociclib|Continuation of CDK4/6 inhibitor -Palbociclib
40842562|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor -Palbociclib|Discontinuation of CDK4/6 inhibitor -Palbociclib
40842563|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Abemaciclib|Continuation of CDK4/6 inhibitor Abemaciclib
40842564|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Abemaciclib|Discontinuation of CDK4/6 inhibitor Abemaciclib
40842565|NCT00206882|DRUG|corticosteroids|
40842566|NCT00307866|PROCEDURE|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
40842567|NCT00745797|RADIATION|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
41026356|NCT02399267|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
40842568|NCT04506801|DIETARY_SUPPLEMENT|Probalans senior|Participants were told to consume 9 drops of study probiotics/placebo once a day for next 12-week intervention.
40842569|NCT04506801|OTHER|Placebo|Participants were told to consume 9 drops of study placebo one a day for the next 12-week intervention
41026357|NCT02399267|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
41160974|NCT03868735|DEVICE|CleanSweep Closed Suction System|Device with balloon sweeping technology
41026358|NCT02399267|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =\< 8 cm H2O with PEEP =\< 5 cm H2O.
41026359|NCT02399267|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
40842570|NCT06028360|OTHER|Progressive Muscle Relaxation|Intervention will be applied for 15-20 minutes 3 consecutive days a week for 1 week
40842571|NCT06028360|DEVICE|Virtual Reality Therapy|Therapy through VR will be given for 8 minutes 3 times a week on consecutively for 1 week
40842572|NCT06464523|BEHAVIORAL|Face to face education|In addition to the standard cervical cancer screening programme service, participants in this group received individual face-to-face health education on HPV and cervical cancer prevention through home visits and were given educational brochures. Participants in this group were interviewed a total of four times (four times face-to-face) during the research period.
40842573|NCT06464523|BEHAVIORAL|Online education|In addition to the standard cervical cancer screening programme service, participants in this group received individual health education on HPV and cervical cancer prevention online via video call via WhatsApp application and were given a digital education brochure. Participants in this group were interviewed a total of four times (four times remotely) during the research process.
40842574|NCT06407102|OTHER|Collection of nasal cells during programme surgery|During programmed surgery (meatotomy, septoplasty or turbinoplasty for example, or other programmed surgeries), the surgeon will take an atraumatic sample from the nasal cavity using a dedicated device (brush) from the healthy nasal mucosa.
40842575|NCT03522831|DRUG|Salbutamol|Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
40842576|NCT03522831|DRUG|Placebo|Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
40842577|NCT02968628|OTHER|Video Electroencephalogram (EEG)|Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.
40842578|NCT02968628|OTHER|Point-of Care Blood Sugar Testing|One-time heel-stick point-of-care blood sugar testing at time of EEG.
40842579|NCT02968628|OTHER|Medical Record Data Extraction|Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.
40842580|NCT02968628|OTHER|Maternal Questionnaire|One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.
40842581|NCT01699074|DIETARY_SUPPLEMENT|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
40842582|NCT01699074|DIETARY_SUPPLEMENT|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
40842583|NCT01699074|DIETARY_SUPPLEMENT|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
40842584|NCT01699074|DIETARY_SUPPLEMENT|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
40842585|NCT01699074|DIETARY_SUPPLEMENT|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
40842586|NCT00007644|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
40842587|NCT03495791|OTHER|YouTube Video|Educational Video
41160975|NCT03521206|BEHAVIORAL|ACP+ programme|Training program for nursing home staff.
41160976|NCT01742949|DEVICE|Heated humidification (ThermoSmart)|Heated Humidification (ThermoSmart) Turned On
41160977|NCT01742949|DEVICE|No Humidification|Heated Humidification (ThermoSmart) Turn Off
41363417|NCT00985114|BEHAVIORAL|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
41363418|NCT06403605|DEVICE|Mirragen Wound Matrix|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
41363419|NCT06403605|DEVICE|Fibracol|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
41363420|NCT06182839|DRUG|Canagliflozin 300Mg Tab|Patients will get 1 pill of Canagliflozin 300 mg daily for one year.
41363421|NCT06182839|DRUG|Placebo|Patients will get 1 pill of placebo daily for one year.
41363422|NCT00993382|DRUG|Celivarone|"Pharmaceutical form: capsule~Route of administration: oral"
41363423|NCT00993382|DRUG|Amiodarone|"Pharmaceutical form: capsule~Route of administration: oral"
41363424|NCT00993382|DRUG|Matching placebo|"Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake"
41500087|NCT02405884|OTHER|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
40842588|NCT05774847|OTHER|No intervention|No intervention
40842589|NCT04097860|BEHAVIORAL|Text message including biomarker of breast pumping adequacy|The intervention group will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the participant is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
41363425|NCT00639600|PROCEDURE|human pancreatic islet transplantation|human pancreatic islet transplantation
41363426|NCT05604976|DEVICE|Percutaneous coronary intervention|Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter
41363427|NCT04579458|PROCEDURE|Collection of tears and saliva.|Saliva and ocular tears will be collected.
41363428|NCT01130220|OTHER|Focus Group|"A single focus group will be held until a saturation of themes has been identified."
41363429|NCT04450420|OTHER|Simulation based curriculum|See arm/group description
41363430|NCT04450420|OTHER|Standard training|See arm/group description
41363431|NCT05107700|PROCEDURE|Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
41026360|NCT06535126|DRUG|CanProFem-AK|Dosage form - vaginal suppositories (100 mg). Dosage regimen - single intravaginal administration of suppository. Vaginal suppositories are inserted as deeply as possible while the participant is lying down; the participant must remain in a horizontal position for 45 minutes after the administration. The total duration of volunteer participation in the study is one day. Medical observation (including gynaecological monitoring with vaginal bacterial swab test) of the subject condition after the drug administration will be carried out after 3, 6, 9, 12 and 24 hours. Repeated laboratory blood and urine tests will be performed after 24 hours. Participants of the study will be closely monitored for 24 hours after the initial administration of the drug to detect any immediate adverse events. If the subject experiences an immediate adverse event, appropriate treatment will be provided.
41363432|NCT05107700|PROCEDURE|Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
41363433|NCT06016296|OTHER|Combined Movement and Storytelling Intervention|The 40-minute sessions will include three moments: (i) warm-up (5 minutes), which consists of joint mobility exercises and introduction to the motor story of the week; (ii) main part (25 minutes), which incorporates the narration of the motor story by the educator initially, as well as the participation of the children, through their own corporeality with movements based mainly on FMS (locomotion skills and object control) and two way verbal interaction based on questions allusive to the narration delivered by the educator or direct verbal participation cast by each child and; (iii) cool down (10 minutes), where space is provided for the children to gradually return to calm, together with feedback on the contents addressed during the session.
40842590|NCT01882868|DRUG|Aflibercept|Pharmaceutical form: Concentrated solution (100 mg/4 mL \[25 mg/mL\], 200 mg/8 mL \[25 mg/mL\]) for infusion; Route of administration: Intravenous
41026361|NCT05840653|OTHER|psychotherapeutic intervention|The group that will receive 5-week positive psychotherapy-based hope placement psychoeducation
41026362|NCT01067079|OTHER|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
40842591|NCT01882868|DRUG|Levofolinate|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
40842592|NCT01882868|DRUG|Irinotecan|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
41026363|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1mg, tid
41363434|NCT06148025|BIOLOGICAL|BCG vaccine|0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus
40842593|NCT01882868|DRUG|5-FU|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
40842594|NCT01369186|DRUG|Morphine|i.v. bolus injection
40842595|NCT01369186|DRUG|Placebo|i.v. bolus injection
41026364|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
41160978|NCT01567670|DRUG|Naloxone|2 mg x 1-2
41363435|NCT06148025|BIOLOGICAL|Yellow Fever vaccine|0.5ml injected subcutaneously
41363436|NCT06148025|DRUG|Vancomycin Oral Capsule|500mg every 6 hours for 3 days
41363437|NCT06148025|DRUG|Neomycin Oral Product|1000mg every 6 hours for 3 days
41363438|NCT04255329|OTHER|Montessori reading roundtable|Such book is written in a way to adaptate to people with cognitif and sensory impairments. Indeed, text is written in large characters and structured to not involve episodic memory. Each person read one page aloud in his turn. After the reading phase, the participants discuss the questions about their opinions and distant memories.
41363439|NCT04255329|OTHER|Usual reading|The readen text is a normal, currently used in a everyday life support such as a journal article.
41363440|NCT02974673|PROCEDURE|Ejaculatory test|Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
41363441|NCT04391660|DRUG|0.5% sodium hypochlorite solution|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress. This same antiseptic will be used at each dressing change.
41363442|NCT04391660|DRUG|0.5% sodium hypochlorite solution and 70% ethanol|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
41363443|NCT03604016|DRUG|Besifovir dipivoxil|Besifovir dipivoxil 150 mg
41363444|NCT03604016|DRUG|L-carnitine|Besifovir dipivoxil 150 mg
41363445|NCT03604016|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
41363446|NCT01349816|DRUG|PT003|PT003 MDI administered as two puffs BID for 7 days
41363447|NCT01349816|DRUG|PT001|PT001 MDI administered as two puffs BID for 7 days
41363448|NCT01349816|DRUG|PT005|PT005 MDI administered as two puffs BID for 7 days
41363449|NCT03400228|DIETARY_SUPPLEMENT|Probiotic|The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).
41363450|NCT03400228|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
41363451|NCT00682539|DRUG|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
41363452|NCT00682539|DRUG|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
41363453|NCT00682539|DRUG|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
41363454|NCT00682539|PROCEDURE|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
41363455|NCT01730768|DRUG|AQW051|
41363456|NCT01730768|DRUG|Placebo|
41363457|NCT00216827|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
41363458|NCT04027127|OTHER|netrin-1 value on admission to hospital|
40842596|NCT01031862|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
40842597|NCT00332553|DRUG|Raloxifene|
41026365|NCT01569516|DRUG|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
41363459|NCT03459092|DRUG|Botulinum toxin type A|Botulinum toxin injection in the horizontal extraocular muscles.
40842598|NCT00332553|DRUG|medroxyprogesterone acetate|
40842599|NCT00332553|DRUG|estrogen|
40842600|NCT00332553|DRUG|17 beta estradiol|
40842601|NCT05684185|BIOLOGICAL|Intramuscular (IM) rabies post-exposure prophylaxis|one-site, 0.5 mL at Day 0, D3, D7 and D14
40842602|NCT05684185|BIOLOGICAL|Intradermal (ID) rabies post-exposure prophylaxis|two-site, 0.1 mL at Day 0, D3 and D7
40842603|NCT03038854|OTHER|Test GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
41363460|NCT03459092|PROCEDURE|Strabismus surgery|Strabismus surgery on the horizontal extraocular muscles
41363461|NCT05944731|DEVICE|Continuous glucose monitor|Continuous Glucose Monitoring (CGM) device is a small electronic tool that you put on your skin, and it tells you the amount of glucose in your body. It is different from a finger prick glucose machine in that you do not need to prick your finger to get some blood to put on the reader paper like you have to do for a finger prick glucose machine.
41363462|NCT00579605|BEHAVIORAL|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
41363463|NCT04367324|DEVICE|Low-level laser therapy|The low-level laser was applied to each patient in low-level laser therapy group.
41363464|NCT01352923|OTHER|blood test|preparation of blood platelets
41363465|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
41363466|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
41363467|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
40842604|NCT03038854|OTHER|Standard GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
40842605|NCT03038854|OTHER|Cows' milk|Homogenized store-bought full fat cow's milk.
40842606|NCT05392803|DEVICE|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy; then sham treatment after a 7-day washout period"
41026366|NCT01569516|DRUG|Placebo|0mg, tid
41363468|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
41363469|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
41363470|NCT01733394|DRUG|"Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand"|
41363471|NCT01733394|DRUG|lamotrigine|
41363472|NCT05314621|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%)|Pataday® Once Daily Relief Extra Strength (eyedrop)
41363473|NCT05314621|DRUG|Fluticasone Propionate|Flonase® Allergy Relief (nasal spray)
41363474|NCT05314621|DRUG|Tears Naturale|Tears Naturale® II (eye drop)
41363475|NCT05314621|DRUG|Saline nasal spray|Saline nasal spray (nasal spray)
41363476|NCT03436212|DEVICE|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device
41363477|NCT02809963|DRUG|Eplerenone|50 mg tablets, oral use.
40842607|NCT05392803|DEVICE|Sham then Active Treatment|"Application of 30 days of sham treatment; then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy after a 7-day washout period"
40842608|NCT06264856|PROCEDURE|bronchoscopic sputum suction|"Bronchoscopy is a medical procedure in which a flexible tube called a bronchoscope is passed through the mouth or nose and into the lungs. Bronchoscopic suction is a technique used during bronchoscopy to remove secretions, mucus, or foreign objects from the airways.~The bronchoscope is equipped with a suction port and a suction channel that allows the doctor to remove fluids or other material from the airways. The suction port is connected to a vacuum source, and the suction channel runs through the bronchoscope and terminates at the tip of the instrument."
41026367|NCT02371369|DRUG|Pexidartinib|Each capsule contains 200 mg of pexidartinib for oral administration
41160979|NCT01567670|DRUG|naloxone placebo|h2o placebo spray
41363478|NCT02809963|DRUG|Placebo|50 mg tablets, oral use
41363479|NCT02297867|DRUG|ADSCs|autologous ADSCs
41026368|NCT02371369|DRUG|Placebo|Placebo capsule matching pexidartinib capsule for oral administration
41026369|NCT01063205|DRUG|Placebo|Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
41026370|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
41026371|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
41026372|NCT00310687|PROCEDURE|BLOOD DRAW|
41363480|NCT04515602|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
41363481|NCT04515602|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
41363482|NCT04515602|DRUG|PARPi|For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
41363483|NCT01679756|PROCEDURE|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
41363484|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to genotype|Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
41363485|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to plasma levels|Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, \> 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and \> 25 nM receive 0 mg (Placebo)
41363486|NCT02648152|DEVICE|Osteoarthritis|Total Hip Arthroplasty
41363487|NCT04805606|DRUG|CKD-843 A|Single Dose
41363488|NCT04805606|DRUG|CKD-843 B|Single Dose
41363489|NCT04805606|DRUG|CKD-843-R|QD, PO
41363490|NCT03243201|DRUG|Colloidal silver nanoparticles|Contains 10ppm colloidal silver nanoparticles
41363491|NCT03243201|OTHER|Purified Water|Purified water will be given as placebo
41363492|NCT03578341|BIOLOGICAL|Orally Colostrum|Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
41363493|NCT04348825|DEVICE|Electroconvulsive therapy|
41363494|NCT05798559|BEHAVIORAL|Sleep Training|These are the trainings given by the researchers in order to regulate the sleep routine and environment. Content will be presented to improve sleep processes by arranging living habits.
41363495|NCT02705859|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
41363496|NCT02705859|DRUG|Trastuzumab|Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
41500088|NCT01291771|PROCEDURE|Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire|The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
41500089|NCT05412355|PROCEDURE|ERAS protocol|ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.
40842609|NCT06264856|PROCEDURE|negative pressure aspiration suction|The procedure involves inserting a catheter into the airway and applying negative pressure to the catheter to suction out the secretions or fluids. The patient could receive sputum suction as medical routine (every 2-4 hrs) if needed.
40842610|NCT05224037|DIAGNOSTIC_TEST|iLivTouch|Eligible subjects will undergo liver stiffness and controlled attenuation parameters examination with two devices on the same day
40842611|NCT01506661|DRUG|Zostavax (varicella zoster virus) vaccine|Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
40842612|NCT02156336|DRUG|Ranolazine|Oral administration, BID; for a maximum of 51 days.
40842613|NCT02156336|DRUG|Placebo|Oral administration, BID; for a maximum of 51 days.
40842614|NCT05105815|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
40842615|NCT01702506|DRUG|dacomitinib fasted|Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
40842616|NCT01702506|DRUG|dacomitinib fed|Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
41363497|NCT05299905|PROCEDURE|Virtual reality using Semi-CAVE|The Semi-CAVE will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The participant will stand in the middle of the area, giving them a viewing angle of roughly 180 degrees. The participant will be wearing a safety harness secured to an overhead guide rail, if necessary. The participant may be standing freely, on a treadmill, or on a step stool depending on the type of activity to be performed. The participant will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar.
41363498|NCT05299905|PROCEDURE|Virtual reality using the HMD|The HMD will be a commercially available device that uses handheld controllers to control movement while in the VE. The researchers will use a room-scale set-up where a 3 m x 3 m square space is required. Oculus Quest 2 Controllers will be used to interact with the VE. The user will be positioned at the center of the square by default. A therapist will assist them through a separate program called the Observation Module. This program will let the therapist view what the patient can see in the HMD. This will also be used by the therapist to guide the patient navigate through the VE and give instructions for the activities.
41500090|NCT02889523|DRUG|Tazemetostat|Tablets 200 mg, to be administrated per os
41500091|NCT02889523|DRUG|Rituximab|375 mg/m²/dose, D1
41500092|NCT02889523|DRUG|Cyclophosphamide|750 mg/m²/dose, D1
41500093|NCT02889523|DRUG|Vincristine|1.4 mg/m²/dose (max 2 mg), D1
41500094|NCT02889523|DRUG|Doxorubicin|50 mg/m²/dose, D1
41500095|NCT02889523|DRUG|Prednisolone|40 mg/m2 in the morning D1 to D5
40842617|NCT01702506|DRUG|dacomitinib+antacid|Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
40842618|NCT01623388|PROCEDURE|Oral glucose tolerance test for Phase I|Oral glucose tolerance test for Diabetic patients in phase I
40842619|NCT06107660|DRUG|Liposomal bupivacaine|Patients will receive either liposomal bupivacaine as part of the ESPB .
40842620|NCT06107660|DRUG|Bupivacaine|This is the control group comparator as this is standard of care at the investigator's institution.
40842621|NCT02645617|DRUG|Varnish|Topical application to the teeth
41160980|NCT00131547|BEHAVIORAL|Dietary Counseling|Dietary Counseling, use of a food diary and pedometer
41160981|NCT01628783|DRUG|escitalopram 10 mg|orally once daily
41363499|NCT03965416|OTHER|White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
41363500|NCT03965416|OTHER|Without White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
41363501|NCT01363973|DEVICE|VITALSTIM transcutaneous electrical stimulation|
41363502|NCT03924960|BEHAVIORAL|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
41363503|NCT03924960|BEHAVIORAL|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
41363504|NCT03924960|BEHAVIORAL|Control|Usual care control group
41363505|NCT01741558|DRUG|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
41500096|NCT04201626|PROCEDURE|Adapted ERAS|"Each woman in the intervention group will attend a preoperative counseling session with nurse and doctors. In addition to the standard preoperative counseling, explaining the purpose, process, and the importance of ERAS protocol compliance will be added to the session. Preoperative nutrition and laboratory assessment will be done according to adapted ERAS protocol on that same visit.~During admission, the intervention group participants are provided with care according to adapted ERAS protocol including no bowel preparation, no extended fasting before surgery, balanced intravenous crystalloid, thromboprophylaxis, multimodal pain control reducing opioid usage, multimodal anti-emetics medications, stepping diet up to regular diet within 24 hours, chewing gum for post-operative ileus prevention, early removal of Foley's catheter, and promote early ambulation using care checklist plan."
41500097|NCT05228535|DIETARY_SUPPLEMENT|Human milk fortifier|Human milk fortifier added to human breast milk at day 1 vs day 8 of feeds
40842622|NCT04364620|DRUG|AB-16B5|AB-16B5 is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU).
40842623|NCT04364620|DRUG|Docetaxel|Docetaxel is an anticancer chemotherapy drug approved in the treatment of non-small cell lung cancer
41026373|NCT04258696|DEVICE|diode laser|using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken
41026374|NCT04258696|DEVICE|ultrapak Knitted retraction cord|using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
41026375|NCT06213597|OTHER|routine swallowing rehabilitation|Routine swallowing rehabilitation training mainly included oral and facial muscle training, ice stimulation therapy, Mendelssohn maneuver training, and tongue root resistance training. The subjects were treated twice a day, Monday through Saturday, for 20 min each time for 2 weeks. All operations were performed by the same trained and qualified professional rehabilitation therapist.
41026376|NCT06213597|DEVICE|real repetitive transcranial magnetic stimulation|In the rTMS group, 5 Hz rTMS was applied to the hot spot of the supraglottic motor cortex of the affected hemisphere at a treatment intensity of 80% resting motor threshold for 10 min, with a total of 250 pulses (with an interval of 11 s for every 1 s of continuous stimulation), and the treatment was performed once a day for 6 d per week for 2 weeks.
41160982|NCT01628783|DRUG|Placebo|once daily
41363506|NCT01741558|DRUG|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
41160983|NCT03074045|DRUG|Levonorgestrel (Kyleena, BAY86-5028)|Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
41363507|NCT05853835|DRUG|LPX-TI641|LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
41363508|NCT01853319|DRUG|Regorafenib (Stivarga, BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
41363509|NCT05132751|DEVICE|Machine Learning Ventilator Decision System|Artificial intelligence ventilator system for personalized mechanical ventilation
41363510|NCT00077727|DRUG|Extended-release galantamine hydrobromide|
41363511|NCT03028649|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate and a placebo supplementation|
41363512|NCT01710709|DRUG|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
41363513|NCT01968473|DEVICE|NMES Device comfort|NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
41363514|NCT05953896|COMBINATION_PRODUCT|Hyaluronic acid gel|For the Hyaluronic acid gel group: HA gel was injected 2-3mm apical to the coronal tip of the involved papillae and the needle was directed coronally with an angulation of 45° to the long axis of the tooth, and the bevel directed apically until papilla became blanched. The injection was given at each papilla at the following intervals baseline, one week and two weeks.
41363515|NCT05953896|COMBINATION_PRODUCT|Multilayer L-PRF membranes|For the multilayer L-PRF group: A single semilunar incision is made in the buccal vestibule, apical to the muco-gingival junction in the mid interproximal area of the papilla to be treated.Tunneling of the incisions has maintained the full height and thickness of the gingiva. Multilayer L-PRF membranes were prepared according to Pinto's protocol immediately prior to the surgery and placed in the tunnel then incision was closed with simple interrupted sutures.
41363516|NCT00005803|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous transplantation
41363517|NCT00005803|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
41363518|NCT00005803|DRUG|Carmustine|Given IV
41363519|NCT00005803|DRUG|Cyclophosphamide|Given IV
41363520|NCT00005803|DRUG|Cyclosporine|Given PO
41363521|NCT00005803|DRUG|Cytarabine|Given IV
40842624|NCT03775564|OTHER|REMEDRUGBY PROGRAM|"* 1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~* 2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~* 5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~* 8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~* 10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~* 12th General Debriefing session Including : - 3 tournaments~* 8 hours of Touch Rugby"
40842625|NCT03775564|OTHER|TOUCH RUGBY PROGRAM|Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day
41363522|NCT00005803|DRUG|Etoposide|Given IV
41363523|NCT00005803|DRUG|Fludarabine Phosphate|Given IV
41363524|NCT00005803|OTHER|Laboratory Biomarker Analysis|Correlative studies
41500098|NCT04856501|BEHAVIORAL|PALS intervention condition|The Play and Learning Strategies (PALS) intervention provides parents with behaviors that, collectively, are known as a responsive parenting style. Four constructs make up this responsive parenting style: 1) contingent responsiveness, (responses are conditionally linked to the child's signals) 2) warm sensitivity (high levels of affection and understanding of child states), 3) maintaining vs. redirecting attention, and 4) verbal scaffolding (providing child appropriate language supports). Parents assigned to this intervention will be paired with a coach who will guide them through the program over the course of 9 weekly sessions. The intervention (ePALS) will be implemented via an internet adaptation through the Children's Learning Institute's ENGAGE platform. However, ePALS could easily be adapted for other platforms and accessed with any web-enabled device.
40842626|NCT03775564|OTHER|TAU|Treatment as usual
40842627|NCT03087526|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
41363525|NCT00005803|DRUG|Melphalan|Given IV
41363526|NCT00005803|DRUG|Mycophenolate Mofetil|Given PO
41363527|NCT00005803|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplantation
41363528|NCT00005803|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic transplantation
41500099|NCT04856501|BEHAVIORAL|Control condition|Families assigned to the control condition will be provided with a website with information corresponding to milestones of toddler development. Control families will be asked to review that week's materials before the each of the 9 weekly coach calls. The active control condition serves three important purposes: 1) Maintains an active line of communication and accurate contact records for Post-test 1 and Post-test 2 session scheduling; 2) Masks participant's awareness of intervention vs. control assignment; and 3) Approximates communication with intervention staff such that results showing ePALS effects are attributable to intervention rather than regular communication with an interventionist.
40842628|NCT00135109|DRUG|SPM 927|
41363529|NCT00005803|BIOLOGICAL|Therapeutic Autologous Lymphocytes|IV donor lymphocyte infusion
41363530|NCT00005803|RADIATION|Total-Body Irradiation|Undergo radiotherapy
41363531|NCT02271763|OTHER|ultrasound|subjects' neck will be scanned using ultrasound
41363532|NCT04710628|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.
41363533|NCT04710628|DRUG|Lenvatinib 10 mg|Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab)
41363534|NCT04540627|DRUG|Palivizumab|Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
41363535|NCT04540627|DRUG|Placebo|Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
41363536|NCT04540627|OTHER|RSV-A Memphis 37b virus|Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
41500100|NCT06633432|OTHER|Acupuncture|Administer medication at each acupoint a total of three times: (1) the night before surgery, (2) the night of surgery, and (3) the first night after surgery. In the acupuncture group, the acupuncture and moxibustion successively acupunctured four points with a depth of 10-20mm. Select the specific depth based on the subject\&#39;s body type (tall, short, fat, thin). After the puncture, the acupuncture and moxibustion lifted and twisted the needle handle, and then retained the needle for 20 minutes.
41500101|NCT06633432|OTHER|Sham-acupuncture stimulation|The sham acupuncture group received non skin breaking comfort needles at the corresponding points for acupuncture and moxibustion and retained the needles for 20 minutes. Non transdermal comfort needles can cause patients to experience a needle like sensation similar to piercing the skin, but in reality, they do not break the skin.
41500102|NCT01963143|BIOLOGICAL|Gammaplex (5%)|
41500103|NCT01963143|BIOLOGICAL|Gammaplex 10|
41500104|NCT04798131|OTHER|Active neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will continuously receive visual feedback computed from the fMRI signal analyzed with the hallucinations decoder. Patients will be trained to maintain the brain state associated with the no-hallucination state using appropriate coping strategies. A 5th fMRI scan will be performed at 1 month post-treatment.
41500105|NCT04798131|OTHER|Sham neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will receive a random feedback and a 5th run at 1 month post-treatment.
41500106|NCT05629897|OTHER|Sessions of cognitive stimulation|40 sessions of cognitive stimulation of approximately 20 minutes duration per session are carried out, using the COPERIA platform.
41500107|NCT04625244|OTHER|Video assisted home therapy|Subjects will follow along with prerecorded therapy videos.
41363537|NCT01421693|DRUG|Ceftriaxone|"* ≥2-\<14 years - 60mg/kg/ once daily for 7 days~* 14 years and older - 2g once daily for 7 days~* Intravenous infusion. Vials of crystalline powder."
41363538|NCT01421693|DRUG|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
41363539|NCT00106860|DRUG|a benzodiazepine drug|
41363540|NCT02274987|OTHER|Specialized tumor board recommendation|A combination of up to four FDA approved drugs based on the molecular profile of the patient's tumor as determined by gene expression analysis, WES and predictive modeling.
41500108|NCT05855135|DEVICE|OPTIMIZER® Integra CCM-D System (Treatment Arm)|"The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a Cardiac Contractility Modulation - Defibrillator. All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years."
40842629|NCT02073669|PROCEDURE|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)|
40842630|NCT03042130|OTHER|Standard of care|standard of care
41500109|NCT03854682|PROCEDURE|Radiofrequency microtenotomy|A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
41500110|NCT03854682|BEHAVIORAL|Strength training|Non-surgical treatment consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
41500111|NCT03925350|DRUG|Niraparib|300 mg PO daily
40842631|NCT03042130|DRUG|Iron Carboxymaltose|Two IV doses
40842632|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
41026377|NCT06213597|DEVICE|sham repetitive transcranial magnetic stimulation|The sham rTMS group supplemented pseudomagnetic stimulation at the hotspot of the representative area, tilted the magnetic stimulation coil at 90°, and the same noise was emitted by the instrument during the treatment, but no stimulation was performed, and the group was treated once a day, 6d per week, for 2 weeks.
41363541|NCT02274987|RADIATION|Standard radiation therapy|Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.
41363542|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
41500112|NCT03238612|DRUG|FFA, clarithromycin, oseltamivir|2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
41500113|NCT03238612|DRUG|Oseltamivir alone|2-day course of oseltamivir 75mg plus placebo capsules twice daily followed by oseltamivir 75mg twice daily for 3 days as control
41500114|NCT03888781|DEVICE|Echocardiography|An echocardiogram (also called an echo) is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of your heart. These echoes are turned into moving pictures of your heart that can be seen on a video screen.
41266838|NCT02257424|DRUG|hydroxychloroquine (HCQ)|hydroxychloroquine (HCQ) is 600 mg orally every 12 hours
41266839|NCT02257424|DRUG|dabrafenib 150 mg orally twice a day|
41500115|NCT02452983|DRUG|Sertraline|
41500116|NCT02452983|PROCEDURE|Bone Marrow Aspirate/Biopsy|
41363543|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
41363544|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
41363545|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
41363546|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
41026378|NCT01438411|DRUG|Cholic Acid|10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
40842633|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
40842634|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
40842635|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
41026379|NCT00411307|DRUG|OROS hydromorphone HCI|
41026380|NCT04964089|DRUG|KSI-301|Intravitreal Injection
41363547|NCT02151045|PROCEDURE|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
41363548|NCT02151045|PROCEDURE|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
41363549|NCT01652027|DRUG|FVIII concentrate|usual treatment as directed by treating physician
41500117|NCT04710979|BEHAVIORAL|Yoga Intervention|This group will have in-person, 60 minute yoga sessions three times per week for 12 weeks. These sessions will also include a sharing circle to provide group feedback as to how the practice felt and integration into ones' daily life. There will be biweekly themes established for these sessions (i.e. common yoga poses, importance of breath) and biweekly in-person workshops will be offered. These will be specialty classes for participants to experience additional exposure to meditation and breathing. They will be a longer format so participants can delve deeper into yogic philosophy and practice. There will also be a private Facebook group for participants to connect with each other and for the research staff to maintain contact and share information with the participants (eg. weekly reminder for yoga sessions and workshops).
41500118|NCT05801952|DEVICE|Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System|The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices: Aerobika\* OPEP Device (Trudell Medical International), Flutter - PARI O-PEP Device (PARI Respiratory Equipment, Inc.) and PEP - PARI PEP® S System (PARI Respiratory Equipment, Inc.).
40842636|NCT02184429|DRUG|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
40842637|NCT02184429|DRUG|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
40842638|NCT02184429|DRUG|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
40842639|NCT00973492|OTHER|functional insulinotherapy class|"The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later."
40842640|NCT01192828|DRUG|taurine|Take Taurine for 4 1/2 days, two doses per day
40842641|NCT04079881|DRUG|Insulin|to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
40842642|NCT02648672|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
40842643|NCT02648672|DRUG|Placebo|
41026381|NCT04964089|DRUG|Aflibercept|Intravitreal Injection
41363550|NCT05457712|DIETARY_SUPPLEMENT|protocol|The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.
41363551|NCT05457712|OTHER|Control|Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Instituto de Cardiologia de and Hospital Santo Antonio de Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
41500119|NCT05798026|DRUG|EU103|EU103 will be administered via intravenous infusion.
41363552|NCT03521089|DEVICE|Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001|Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
41363553|NCT01032057|DRUG|capecitabine|
41363554|NCT01032057|DRUG|gemcitabine hydrochloride|
41363555|NCT01032057|PROCEDURE|quality-of-life assessment|
41363556|NCT01032057|RADIATION|3-dimensional conformal radiation therapy|
40842644|NCT04397419|DIETARY_SUPPLEMENT|Red Bull Energy Drink|"The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
40842645|NCT04397419|OTHER|Still water|"The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
40842646|NCT00859157|PROCEDURE|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
40842647|NCT00265031|DRUG|Cyclophosphamide|
40842648|NCT00265031|DRUG|Adriamycin|
40842649|NCT00265031|DRUG|Etoposide|
40842650|NCT00265031|DRUG|Procarbazine|
40842651|NCT00265031|DRUG|Prednisone|
40842652|NCT00265031|DRUG|Vincristine|
40842653|NCT00265031|DRUG|Bleomycin|
40842654|NCT00265031|PROCEDURE|radiation therapy|
40842655|NCT04387266|RADIATION|modified reduce-volume target IMRT|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
41026382|NCT04964089|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
41363557|NCT01976494|DEVICE|The domestic PCA equipment 'Accufuser Omnibus®'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
40842656|NCT00002961|DRUG|cyclophosphamide|Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
40842657|NCT00002961|DRUG|cyclosporine|"graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.~When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy."
41026383|NCT05668182|PROCEDURE|TRUMATCH Graft Cage|TRUMATCH Graft Cage for surgical repair of segmental long bone defect
41160984|NCT03074045|DRUG|Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)|COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
41363558|NCT01976494|DEVICE|Imported PCA equipment 'Infusor SV®, Baxter, USA'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
41363559|NCT04797572|DEVICE|Free Margin Cusp Sizer|The free margin cusp sizer will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length.
41363560|NCT00461552|DRUG|Leptin|weight based, sub-cutaneous injection, twice daily
40842658|NCT00002961|DRUG|etoposide|Day 4 (arms A/B): 40 mg/kg over four hours intravenously
40842659|NCT00002961|DRUG|methotrexate|"methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is \>2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted."
40842660|NCT00002961|PROCEDURE|allogeneic bone marrow transplantation|Bone marrow infusion given on day 0
40842661|NCT00002961|RADIATION|Total Body Irradiation|Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) \[200 cGy twice a day (BID)\].
40842662|NCT00002961|DRUG|Busulfan|"Conditioning Regimen Arm B:~Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.~Patients \</= 20kg to receive busulfan 1.0 mg/kg/dose IV\*\*Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients \>20kg and 1.25 mg/kg/dose by mouth (po) for patients \</= 20 kg."
40842663|NCT00002961|DRUG|Mesna|Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.
41363561|NCT00461552|OTHER|Placebo|weight based, sub-cutaneous injection, twice daily
41363562|NCT02117362|BIOLOGICAL|1 mg/kg GR-MD-02|1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
41500120|NCT03741699|DRUG|Pre-treatment with rLH (Luveris 75 IU),|Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
40842664|NCT00002961|RADIATION|Radiation|"Central Nervous System (CNS) therapy:~a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) \>/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses \>3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.~Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-"
40842665|NCT05945160|DRUG|Alpha Lipoic Acid 300mg|A naturally occuring mitochondrial antioxidant
40842666|NCT05945160|DRUG|Coenzyme Q10 200mg|A naturally occuring mitochondrial antioxidant
40842667|NCT05423392|PROCEDURE|Tooth extraction of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Tooth extraction will be following up with the methodological procedures in order to define the effectiveness of anesthetics during indicated dental procedure.
40842668|NCT05423392|PROCEDURE|Endodontic dental treatment of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Endodontic dental treatment will be following up with the methodological procedures in order to define the effectiveness of anesthetics during dental treatment.
40842669|NCT05423392|PROCEDURE|Conservative tooth restoration of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Conservative tooth restoration will be following up with the methodological procedures in order to define the effectiveness of anesthetics during conservative tooth restoration.
40842670|NCT06504186|DRUG|Blinatumomab|"* Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles."
40842671|NCT03755908|DEVICE|Forced oscillation technique (FOT)|FOT will be measured using the TremoFlo C-100 Airwave Oscillometry System (Thorasys , Montreal, Quebec, Canada). R5, R20, R5-20 (resistances in the reported frequency), X5 (reactance in 5hz) and Ax5 (reactance area in 5hz) will be reported.
40842672|NCT02690714|BIOLOGICAL|Plasminogen (Human) intravenous|Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.
40842673|NCT00980759|RADIATION|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
40842674|NCT00980759|RADIATION|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
40842675|NCT02949388|DRUG|Placebo|Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
40842676|NCT02949388|DRUG|400 mg (200 mg BID)|Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart
40842677|NCT02949388|DRUG|300 mg (150 mg BID)|Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
40842678|NCT05946512|BEHAVIORAL|yoga|yoga breathing techniques for dysfunctional breathing
40842679|NCT05946512|BEHAVIORAL|social contact|social contact as active comparator
40842680|NCT06429189|BEHAVIORAL|Home-based combined exercise program with self-selected intensity|Before the beginning of the exercise program, participants will receive an education session on how to use Borg's Perceived Rate of Exertion Scale (RPE) to monitor their effort during aerobic and resistance training and tips on when they may increase the exercise intensity. During the training sessions, participants in the intervention group will be asked to choose their preferred load to execute each exercise in the resistance component, told to perform the aerobic exercises at their preferred speed, and informed that they can stop exercising whenever they need to rest. The exercise professional may suggest increasing loads in specific exercises, but these increases will not be imposed on the participants. Attendance to the sessions in the intervention and control groups will be registered. Additionally, women in this group will be encouraged to perform brisk walking at their preferred intensity and receive a pedometer to increase walking motivation.
40842681|NCT03880344|DEVICE|Vibration Therapy|Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
40842682|NCT03880344|COMBINATION_PRODUCT|Physiotherapy|Physiotherapy as post-operative rehabilitation programme for 6 months.
40842683|NCT00036257|DRUG|CP-461|
40842684|NCT03339973|BIOLOGICAL|allo-APZ2-PAOD|Suspension of ABCB5-positive mesenchymal stem cells in pre-filled syringe
41500121|NCT00552578|DRUG|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)
40842685|NCT03339973|DRUG|Placebo|Solution for injection in pre-filled syringe
40842686|NCT05257707|DIAGNOSTIC_TEST|Molecular biology|"Samples will be taken as part of routine care consultations. These include~* Smears taken with cytobrushes adapted to the anatomical site (cervix, vulva, vagina, penis, anus, upper aerodigestive tract...).~* Blood samples taken to isolate plasma, cells or serum.~* CSF and effusion samples taken with a suitable puncture needle (lumbar puncture, ascites puncture, pleural puncture, etc.).~* Urine samples collected in sterile ECBU jars.~* Biopsies taken according to the recommendations of good clinical practice using specific forceps adapted to the anatomical site.~* Surgical parts.~* Eyebrows.~* Saliva samples or gargle samples."
41500122|NCT00552578|DRUG|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
41500123|NCT06565078|DRUG|Immune Globulin Subcutaneous (Human), 20% Solution|CUVITRU 20% Solution
41500124|NCT04688892|DEVICE|Cupping|dynamic cupping
41500125|NCT05424822|DRUG|JNJ-80948543|JNJ-80948543 will be administered as SC or IV injection.
41500126|NCT02955758|BIOLOGICAL|Pembrolizumab|Given IV, 200mg fixed dose, every 3 weeks
41500127|NCT04528992|OTHER|Blood Flow Restriction Therapy|BFR is a rehabilitation method that involves wearing a tight band around the exercising extremity to briefly limit blood flow while doing light weight exercises. The response is similar to heavy weight training or lifting but without the stress on the extremity that is still healing from surgery. Will be given after 2 weeks standard postoperative physical therapy per surgeon's ACL reconstruction protocol following surgery.
41500128|NCT04528992|OTHER|Standard Postoperative Physical Therapy|This is the surgeon's standard postoperative physical therapy protocol after ACL reconstruction.
41500129|NCT06548555|OTHER|systematic educational intervention|This is a non-interventional study and does not impose a therapy protocol, or a diagnostic/therapeutic procedure. Patients are treated according to the local prescribing information, and routine medical practice in terms of visit frequency and types of assessments performed and only these data is collected as part of the study.
41026384|NCT01617629|BIOLOGICAL|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
41026385|NCT02343458|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
41026386|NCT02343458|DRUG|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
41026387|NCT02343458|DRUG|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
41026388|NCT02343458|DRUG|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
41026389|NCT04288687|DRUG|Niraparib Pill|Niraparib 200 mg by mouth daily (2 x 100 mg pills)
41026390|NCT01114646|DEVICE|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
41026391|NCT01114646|DEVICE|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
41500130|NCT06634381|BEHAVIORAL|CRF Visual Aid|After all qualitative interviews and associated quantitative data analysis are complete, the visual aid will be created to illustrate, through a type of Venn Diagram, how the data are related.
41500131|NCT05942625|DRUG|HS-10390 tablet|Oral administration of specified dose of HS-10390
41500132|NCT05942625|DRUG|Placebo tablet|Oral administration of matching dose ofplacebo
41500133|NCT05910112|PROCEDURE|Pleural interventions|eg thoracocentesis, chest drain, indwelling pleural catheters, thoracoscopy
41500134|NCT05705648|DIETARY_SUPPLEMENT|medium chain triglyceride oil|Medium chain triglyceride oil
40842687|NCT04716920|OTHER|Tai Chi|Attend Tai Chi exercise classes
40842688|NCT04716920|DEVICE|FitBit|Wear FitBit
40842689|NCT04716920|OTHER|Support Group Therapy|Join Tai4Chijoint group
40842690|NCT04716920|OTHER|Questionnaire Administration|Ancillary studies
41026392|NCT00698529|BEHAVIORAL|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
41026393|NCT00698529|BEHAVIORAL|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
41500135|NCT05705648|DIETARY_SUPPLEMENT|Safflower oil|Safflower oil
41500136|NCT05252598|DRUG|Psilocybin|1mg encapsulated psilocybin
40842691|NCT04716920|OTHER|Quality-of-Life Assessment|Ancillary studies
40842692|NCT05321251|DRUG|Insulin|see arm description
40842693|NCT05321251|PROCEDURE|Tarsorrhaphy|see arm description
41026394|NCT00698529|BEHAVIORAL|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
41026395|NCT03868904|DEVICE|OCS Lung System|No active interventions are part of this study. This study will collect long-term survival and BOS data in subjects who were part of the INSPIRE trial.
41026396|NCT03361813|OTHER|trans-cutaneous ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a transcutaneous route
41026397|NCT03361813|OTHER|trans-oral ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a trans-oral route
41160985|NCT06478732|OTHER|health services|Implement comprehensive heart failure management for patients in the experimental group using the HeartMed-HF digital therapy
41363563|NCT02117362|BIOLOGICAL|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
41363564|NCT02117362|BIOLOGICAL|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
41363565|NCT02117362|BIOLOGICAL|8 mg/kg GR-MD-02|8 mg/mg GR-MD-02
41160986|NCT00519714|DIETARY_SUPPLEMENT|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
41500137|NCT05252598|DRUG|Inonotus Obliquus Whole Extract|1mg encapsulated chaga mushroom
41363566|NCT02117362|BIOLOGICAL|Ipilimumab|3 mg/kg ipilimumab on Days 1, 22, 43, and 65
41363567|NCT03759340|DRUG|ATI 502 0.46% Topical Solution|apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)
40842694|NCT02759536|RADIATION|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
41363568|NCT03725904|DIAGNOSTIC_TEST|Progesterone analysis in saliva|Analysis of salava progesterone
41363569|NCT04327505|DRUG|Hyperbaric oxygen|1.6- 2.4 ATA, 30-60 min (excluding compression/recompression)
40842695|NCT02759081|DEVICE|cap-assisted water exchange|a transparent cap was mounted to the tip of colonoscopy when water exchange was performed.
40842696|NCT02759081|PROCEDURE|water exchange|water was infused and suctioned at the same time during insertion of colonoscope
40842697|NCT04043078|OTHER|Exercise|The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
40842698|NCT03664804|OTHER|No Study Drug was Administered in this Study|No study drug was administered in this study
40842699|NCT03616886|DRUG|Paclitaxel|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
41363570|NCT05158504|OTHER|Motivation|Motivational notifications were sent via SMS message to the nurses in the motivation group (n=30) at 07.00, 12.00 and 16.00 for 21 days.
40842700|NCT03616886|DRUG|Carboplatin|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
41363571|NCT05578664|DRUG|Pembrolizumab injection plus metastasis directed treatment (surgery or RT)|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1
41363572|NCT05578664|OTHER|Tumor resection or RT|Tumor resection or RT will be applied within 42 days from randomization.
41363573|NCT00765726|BIOLOGICAL|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
41363574|NCT00765726|PROCEDURE|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
40842701|NCT03616886|DRUG|MEDI4736|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
40842702|NCT03616886|DRUG|MEDI9447|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
40842703|NCT02784769|OTHER|measurement of skin autofluorescence|
41160987|NCT00519714|DIETARY_SUPPLEMENT|Placebo|Placebo
41160988|NCT00543166|DRUG|dehydroepiandrosterone|50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
41363575|NCT02218424|DRUG|Magnesium|
41363576|NCT02218424|DRUG|Normal saline|
41363577|NCT02143427|BEHAVIORAL|Social Skills Training|"Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.~Arms: Social Skills Training"
41363578|NCT02143427|BEHAVIORAL|Treatment Program with techniques to activate resources|"Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.~Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training"
41363579|NCT02138929|DRUG|Everolimus|Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
41500138|NCT06633328|DRUG|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with severe aplastic anemia
41500139|NCT06633328|OTHER|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with severe aplastic anemia
41500140|NCT06618001|DRUG|JNJ-89853413|JNJ-89853413 will be administered.
40842704|NCT02784769|OTHER|skin biopsy collection|
40842705|NCT04180085|DRUG|Belatacept Injection|9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft
40842706|NCT02133365|BEHAVIORAL|Mindfulness and Interoceptive Exposure|The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
40842707|NCT02032654|DRUG|Flucloxacillin|
40842708|NCT02032654|DRUG|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
40842709|NCT05242094|PROCEDURE|Pulmonary Rehabilitation Program|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. The author's pulmonary rehabilitation program was programmed based on previous experience in patients with COPD. A holistic pulmonary rehabilitation program with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Based on the patient's submaximal exercise tolerance test results, the qualification for one of the respiratory physiotherapy models differing in therapy intensity was performed. Rehabilitation models included exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
41026398|NCT06482658|PROCEDURE|Transrectal perilesional/regional systematic biopsy (PB/RSB)|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra) through transrectal prostate biopsy. The location of these nine cores depended on the shape and location of the suspicious lesion.
41363580|NCT02138929|DRUG|LDE 225|"Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase."
41363581|NCT05961761|DRUG|Propranolol|propranolol 40 mg x2 daily
41363582|NCT05961761|DRUG|Pembrolizumab|pembrolizumab 2 mg/kg every 3 weeks
41363583|NCT06049823|PROCEDURE|Alveolar ridge preservation|Different grafting strategy of alveolar ridge preservation with different sealing materials
41363584|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at t=0 via IM route
41026399|NCT06482658|PROCEDURE|Combination of transrectal systematic biopsy and targeted biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five transrectal targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core transrectal prostate biopsy.
41026400|NCT01068431|OTHER|bandaging with trico as active controller|In general non-elastic bandaging is the compression treatment in lymphedema
41026401|NCT05889936|BEHAVIORAL|Lev|Lev includes three sessions using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev also include two homework assignments. The second session can be repeated if needed. Lev-s and Lev are described in two manuals.
41026402|NCT01233817|OTHER|Progressive strength training|the systematic increase in resistance weights
41363585|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at T=0 via the IM route
41363586|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at t=0 via the SC route
41363587|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at T=0 via the SC route
41363588|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
40842710|NCT04732949|DRUG|SNG001|SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
40842711|NCT04732949|DRUG|Placebo|Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
41363589|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
41363590|NCT00440362|BIOLOGICAL|AVX502|2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
40842712|NCT00524017|BIOLOGICAL|cetuximab|given IV
41363591|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
41363592|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the IM route
41363593|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the SC route
41363594|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the IM route
41363595|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the SC route
41363596|NCT03359382|OTHER|Resistance or home exercise combined with eccentric exercise|"First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )"
41363597|NCT04784806|OTHER|Ground beef|Subjects will consume a 106g patty of cooked ground beef.
41363598|NCT04784806|OTHER|Ground pork|Subjects will consume a 118g patty of cooked ground pork
41363599|NCT04784806|OTHER|Tofu|Subjects will consume a 113g patty of cooked tofu
41500141|NCT05009511|BEHAVIORAL|Learning through feedback|The goal of this investigation is to examine the influence of feedback timing on learning and brain function.
41500142|NCT00269243|DRUG|Quinapril|
41500143|NCT04510051|DRUG|Cyclophosphamide|Given IV
40842713|NCT06019806|OTHER|POSTURAL CORRECTION four exercises|"The program will involve four exercises, including two strengthening exercises and two stretching exercises.~1. Chin tuck (deep cervical flexor)~2. Strengthening shoulder retractors~3. Sternocleidomastoid muscle stretch~4. Pectoralis stretch Participants will be instructed to perform three sets of 12 repetitions for the strengthening exercises, with a 30-second rest period allotted between each set. For the stretching exercises, participants will be instructed to hold each stretch for 30 seconds, with a 30-second rest period allotted between each exercise The experimental group will also receive postural Correction education"
40842714|NCT06019806|OTHER|postural Correction education with a manuscript|The control group would receive postural Correction education and they would be provided with a manuscript. They would be then guided to follow these guidelines as a home plan for four weeks. At the end of the Fourth week, they would be assessed.
41500144|NCT04510051|DRUG|Fludarabine|Given IV
41500145|NCT04510051|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given intraventricularly
41500146|NCT05541653|OTHER|Financial Well-being Interventions|Tax preparation; access to public benefits; financial counseling and microgrants
40842715|NCT01088854|DEVICE|CPAP|unique session of 30-minute of continuous airway positive pressure
41026403|NCT05653505|OTHER|Remote Ischemic Conditioning|Remote ischaemic conditioning (RIC) refers to a process whereby periods of intermittent ischemia, typically via the cyclical application of a blood pressure cuff to a limb at above systolic pressure, confers systemic protection against ischemia in spatially distinct vascular territories.
41026404|NCT01336127|BEHAVIORAL|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
41026405|NCT03494257|DRUG|Brinzolamide-Brimonidine fixed combination|Simbrinza 0.2%-1% Ophthalmic Suspension
41026406|NCT05415683|DIAGNOSTIC_TEST|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
41026407|NCT05447546|DRUG|HT-6184|Oral capsule
41026408|NCT05447546|DRUG|HT-6184 Placebo|Oral capsule
41026409|NCT04198779|DEVICE|APPLI|The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.
41026410|NCT00406029|DRUG|Preladenant|1 mg BID capsules
41026411|NCT00406029|DRUG|Preladenant|2 mg BID capsules
41026412|NCT00406029|DRUG|Preladenant|5 mg BID capsules
41363600|NCT04784806|OTHER|Beyond Meat|Subjects will consume a 113g BeyondMeat patty.
41363601|NCT04606797|DRUG|Nicotine patch|Nicotine transdermal patches as per product monograph
40842716|NCT01292564|DEVICE|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
40842717|NCT01292564|DEVICE|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
40842718|NCT02202538|DEVICE|Indego|Indego
41363602|NCT05858645|DRUG|deucravacitinib|Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
40842719|NCT02702687|BEHAVIORAL|PEF Feedback|Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.
40842720|NCT02702687|BEHAVIORAL|Control Feedback|Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.
41363603|NCT03778476|OTHER|Isometric Exercise|Participants will be asked to hold a submaximal voluntary contraction of the quadriceps muscle as long as they can (task failure).
41363604|NCT05475119|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.
41500147|NCT05541653|OTHER|Place-based Interventions|Vacant lot greening; abandoned house remediation; trash cleanup; and tree planting.
41500148|NCT06633666|DEVICE|Acupuncture|"1. Fatigue Principal points: Pishu (BL 20), Ganshu (BL 18), Shenshu (BL 23), Baihui (GV 20), Guanyuan (RN 4), Zusanli (ST 36), Sanyinjiao (SP 6)~2. Anxiety/ depression Principal points: Yintang (EX-HN3), Baihui (GV 20), Taichong (LR 3), Neiguan (PC 6), Danzhong (RN 7)~3. Cognitive impairment/ memory loss Principal points: Baihui (GV 20), Sishencong (EX-HN1), Fengfu (GV 16), Taixi (K 13), Xuanzhong (GB 39), Zusanli (ST 36)~4. Insomnia Principal points: Zhaohai (K 16), Shenmai (BL 62), Shenmen (HT 7), Sanyinjiao (SP 6), Anmian (EX-HN22), Sishencong (EX-HN1)"
41500149|NCT03961659|DRUG|Liraglutid|Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
41500150|NCT03961659|DRUG|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
41500151|NCT03961659|DRUG|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
41500152|NCT01790477|PROCEDURE|Auricular Acupuncture|Application of auricular acupuncture to 5 points on the ear
41500153|NCT03889080|DIAGNOSTIC_TEST|functional MRI|functional MRI scan of the brain
41363605|NCT05475119|DEVICE|High Flow Nasal Cannula (HFNC)|High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute
41500154|NCT04511598|DEVICE|"Bellus 3D Face Camera"|The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.
41500155|NCT04511598|DEVICE|"Planmeca ProMax 3D Proface"|The lasers scan the facial geometry and the digital cameras capture the color texture of the face.
41500156|NCT03864016|DRUG|Induction and maintenance of anesthesia|The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
41500157|NCT03864016|DRUG|Adaptation of sufentanil doses according to the usual protocol|At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
41363606|NCT05582382|OTHER|logistic regression of known prognostic markers of severity of COVID19|"An observational longitudinal follow up of all consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department . The risk assessment score at initial presentation will be calculated for each patient using clinical assessment scoring of ALA \& ALKA and compared with the currently proposed clinical risk assessment scoring system~The utility of the risk score in triaging patients on their initial visits to emergency department (ED) will be validated against the following measured outcomes:~1. Hospital admission on the first encounter to ED~2. Admission to ICU for the duration of the COVID-19 hospitalization~3. In hospital and out of hospital mortality~4. Return to ED following initial discharge (within the current covid illness period, Maximum 30 days from the initial diagnosis)"
41363607|NCT04401982|DRUG|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
41026413|NCT00406029|DRUG|Preladenant|10 mg BID capsules
41026414|NCT00406029|DRUG|Placebo|BID capsules
41026415|NCT00406029|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
41363608|NCT02479022|DRUG|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
41363609|NCT02479022|DRUG|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
41500158|NCT03864016|DRUG|Adjustment of sufentanil doses according to pupillometry|At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
41500159|NCT05238454|BIOLOGICAL|SCTV01C|intramuscular injection
41500160|NCT05238454|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
41500161|NCT05238454|BIOLOGICAL|Comirnaty|intramuscular injection
40842721|NCT02024880|DEVICE|Protective catheter group|The tip of this catheter is protected on insertion of the catheter.
41026416|NCT00406029|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
41363610|NCT02479022|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
41363611|NCT03612635|DEVICE|Implantation of a cardiac implantable electronic device|All patients enrolled in the registry underwent cardiac implantable electronic device implantation
41500162|NCT04839692|DRUG|Hyaluronic acid filler|Hyaluronic acid filler treatment of the lips with Restylane Kysse, which is a FDA approved treatment for lip augmentation.
40842722|NCT02024880|DEVICE|Conventional catheter group|A standard embryo catheter
40842723|NCT04645745|DIETARY_SUPPLEMENT|myo-inositol, alpha-lactalbumin, folic acid|Evaluating the improvement vs the baseline after three and six months of treatment
40842724|NCT05031078|BIOLOGICAL|Gardasil|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap."
41026417|NCT03697785|DEVICE|Beacon Care System|Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
41363612|NCT01831570|OTHER|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
41363613|NCT05818176|DEVICE|NAVIRFA® Navigation System|radiofrequency ablation by NAVIRFA® Navigation System.
41363614|NCT05818176|DEVICE|ultrasound|radiofrequency ablation by ultrasound
41363615|NCT04983849|DRUG|metronidazole hydrogel|scaling and root planning in adjunct to the use of metronidazole in the periodontal pocket
41363616|NCT04983849|PROCEDURE|scaling and root planning|scaling and root planning
41363617|NCT02213666|DEVICE|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
41500163|NCT06002789|DRUG|MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy|For MSI-H/MSS (dMMR/pMMR) mixed sMPCC, a combination of neoadjuvant chemotherapy with mFOLFOX6 and immunotherapy with PD-1 monoclonal antibody are applied.
40842725|NCT05031078|DRUG|Lidocaine injections|"1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg."
41363618|NCT03549546|BIOLOGICAL|Blood samples|"Blood samples will be collected in patients undergoing lung cancer surgery:~* before lung cancer surgery,~* the next day lung cancer surgery,~* 3 days after lung cancer surgery. They will be treated in flow cytometry."
41500164|NCT06002789|DRUG|All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy|For all-MSI-H (dMMR) sMPCC, single-drug PD-1 monoclonal antibody immunotherapy is applied.
41500165|NCT05260060|BEHAVIORAL|Treatment as usual: Control|Treatment usually delivered in service that may include but is not limited to cognitive behaviour therapy, exposure, eye movement desensitisation and reprocessing , behaviour therapy, family therapy.
41500166|NCT05260060|BEHAVIORAL|Group Metacognitive Therapy (Group-MCT): Experimental|Group metacognitive therapy (Group-MCT) focuses on developing adaptive control of worry, repetitive negative thinking and attention and modifies beliefs that maintain unhelpful thinking patterns. Treatment is 6 to 8 weekly sessions delivered by two trained mental health professionals, guided by a treatment manual, lasting approximately 90 minutes each session.
41500167|NCT03661697|DEVICE|Laser Therapy|"Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face."
40842726|NCT00556413|BIOLOGICAL|cetuximab|
40842727|NCT00556413|DRUG|fluorouracil|
40842728|NCT00556413|DRUG|irinotecan hydrochloride|
41500168|NCT03661697|OTHER|Basic Skin Care Regimen|Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks
40842729|NCT00556413|DRUG|leucovorin calcium|
40842730|NCT00556413|DRUG|oxaliplatin|
40842731|NCT02580786|BEHAVIORAL|Breastfeeding peer support|
41160989|NCT06031870|DEVICE|Vaginal pessary|In the pessary group, all patients received a cube pessary, which was individually adapted to each patient. These pessaries exist in sizes 0 (25 mm edge length) to 9 (75 mm edge length). Patients were instructed by a physician or a trained nurse on how to autonomously manage the pessary, including daily changing and cleaning. After one week of treatment, all patients had an office visit to check if fitting was correct and if autonomous handling of the pessary was feasible. Treatment duration was 12 weeks.
41160990|NCT06031870|BEHAVIORAL|Standard care|Standard care consisted of a pelvic floor group exercise course led by a midwife, a physiotherapist, or an osteopath. Courses were in general once a week for a minimum of seven to a maximum of twelve weeks. The course was chosen by the patient, and the study team had no influence on the choice.
41363619|NCT04896476|DEVICE|EchoMark|The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.
41363620|NCT00863434|DRUG|clofarabine|Given IV
41363621|NCT00863434|DRUG|cytarabine|Given IV
41363622|NCT00863434|BIOLOGICAL|filgrastim|Given SC
41500169|NCT03661697|OTHER|Lytera|cosmeceutical serum applied to face daily for 12 weeks
41500170|NCT03769207|DEVICE|Ambulatory ECG|Eligible participants are asked to wear the ambulatory ECG monitor
41500171|NCT03147755|OTHER|No intervention|No intervention
41363623|NCT02715089|GENETIC|Precise treatment|During screening stage, all patients should accept next-generation sequencing (NGS) test.
41026418|NCT05306652|OTHER|Supervised physical activity|patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions
41026419|NCT05306652|OTHER|Unsupervised physical activity|patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
41026420|NCT00003498|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41363624|NCT00422227|DRUG|Etanercept , Methotrexate|"* Etanercept: 25 mg twice weekly over 16 weeks, SC~* Methotrexate: \> 7.5 mg/week and no more than 25 mg/week, PO"
41363625|NCT00422227|DRUG|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"* Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
41363626|NCT02576951|DRUG|Galcanezumab|Administered SC
41363627|NCT02576951|DRUG|Placebo|Administered SC
41363628|NCT03825848|PROCEDURE|trans jugular intrahepatic portal systemic shunt|Shunting left or right PV branch in the TIPS procedure
41363629|NCT03464929|DEVICE|Airtraq indirect laryngoscopy|Attempt to intubation using the Airtraq device
41363630|NCT03464929|DEVICE|King Vision indirect laryngoscopy|Attempt to intubation using the King Vision device
41363631|NCT00231959|DRUG|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
41363632|NCT00231959|DRUG|Placebo|sugar pill
41363633|NCT03486067|DRUG|CC-93269|Specified dose on specified days
41363634|NCT04234841|DIAGNOSTIC_TEST|Blood test|Blood test
41363635|NCT05789823|PROCEDURE|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery achieve by thrombectomy. Ischemic post-conditioning consists of briefly repeated 4 cycles × 5 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
41363636|NCT05789823|PROCEDURE|Mechanical thrombectomy alone|Successful recanalization was achieved by mechanical thrombectomy without subsequent ischemic post-conditioning.
41363637|NCT03484780|DEVICE|VisONE ADS|VisONE stimulator and leads for delivering continual Synchronized Diaphragmatic Stimulation
41363638|NCT00038116|PROCEDURE|embryonic dopamine cell implant surgery|Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.
41363639|NCT00038116|PROCEDURE|placebo|sham surgery
41363640|NCT01475942|DIETARY_SUPPLEMENT|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
41363641|NCT04346017|DIAGNOSTIC_TEST|Cytokines dosage|Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).
41500172|NCT04855578|OTHER|In-Hopsital Patient Educational Brochure|The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.
41363642|NCT04346017|DIAGNOSTIC_TEST|Complement dosage|Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.
40842736|NCT00547950|DRUG|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid\*1year.
41026421|NCT06536166|DRUG|Ruxolitinib|IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.
41026422|NCT06536166|DRUG|Placebo|IBM patients treated by placebo, twice a day, during 12 months.
41363643|NCT02038244|OTHER|Multimodal integrative medicine inpatient treatment program|
41363644|NCT04888507|DRUG|Pozelimab|Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
41363645|NCT04888507|DRUG|Cemdisiran|SC administration
41363646|NCT06198179|OTHER|upper limb children action-observation training (UPCAT)|upper limb children action-observation training (UPCAT) without visual Feedback
41363647|NCT06198179|OTHER|upper limb children action-observation training (UP-CAT) with visual feedback|upper limb children action-observation training (UP-CAT) with visual feedback: Mirror therapy as visual feedback
41363648|NCT03244280|DRUG|MOB015B|Topical formulation
41363649|NCT01012765|DRUG|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
41363650|NCT01012765|DRUG|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
41363651|NCT01012765|DRUG|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
41363652|NCT01638546|OTHER|Laboratory Biomarker Analysis|Correlative studies
41363653|NCT01638546|OTHER|Placebo|Given PO
41500173|NCT04855578|OTHER|Physician Education about Gabapentinoid Prescription|An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.
41500174|NCT05471492|DRUG|Investigational Product|PF-06480605 150 mg
41500175|NCT05471492|DRUG|Placebo|Placebo
41500176|NCT04011670|OTHER|200 mg caffeine tablet|"* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
41500177|NCT04011670|OTHER|Non-active tablet|"* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
41500178|NCT00513279|DRUG|GSK618334|GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
41500179|NCT00513279|DRUG|GSK618334 matching placebo tablets|GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
40842737|NCT00116363|GENETIC|investigational drug INGN 241|
40842738|NCT02831322|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
40842739|NCT00216489|DRUG|rabeprazole sodium|
41363654|NCT01638546|DRUG|Temozolomide|Given PO
41363655|NCT01638546|DRUG|Veliparib|Given PO
41363656|NCT04246996|DRUG|gentamicin sulfate|Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
41363657|NCT04246996|OTHER|Catheter clamping only|Subjects in the control arm will have their standard-of-care transurethral catheter clamped for 1 hour post-placement to maintain subject masking to study arm.
41363658|NCT02567721|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
41363659|NCT01143662|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
41363660|NCT01143662|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
41363661|NCT01820169|DEVICE|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
41363662|NCT05353881|OTHER|No intervention|No intervention
41363663|NCT05381740|DEVICE|Novel rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. High-frequency rTMS (5Hz) will be delivered using 42 10 second trains of 50 pulses each (total 2100 pulses) for a period of 22 minutes. Immediately after the completion of rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
41500180|NCT04992650|PROCEDURE|Fat grafting|Fat grafting
41500181|NCT06634030|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
41500182|NCT06634030|DRUG|Saline|Normal saline
41500183|NCT00444379|DRUG|Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir|Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
41500184|NCT04522115|OTHER|exercises|"Group(1) aerobic training: Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.~Group(2) resistance exercise: training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated."
41500185|NCT01807286|DRUG|Pomalidomide|"Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I."
41500186|NCT01807286|DRUG|Melphalan|Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
40842740|NCT04337008|OTHER|blood draw|20 mL blood draw will be performed at J1 et J7
40842741|NCT06334874|DRUG|Astaxanthin Oral Capsule|12 mg of astaxanthin oral capsule
40842742|NCT06334874|DRUG|Placebo|starch placebo capsule
40842743|NCT01992211|DRUG|Rosuvastatin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
40842744|NCT01992211|DRUG|Metformin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
40842745|NCT01992211|DRUG|BCWP_C003|Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.
40842746|NCT03525132|PROCEDURE|Laser Doppler Velocimetry + Optic Adaptative Camera|Fluxometry measure while subject is sitting in front of the optic adaptative camera
40842747|NCT00514462|DEVICE|diode laser|wavelength at 830nm, 9.7J/cm2 for 10 min
40842748|NCT00418587|DRUG|Cholecalciferol|800 IU oral daily
40842749|NCT00418587|DRUG|Cholecalciferol|2000 IU oral daily
40842750|NCT00418587|DRUG|Cholecalciferol|4000 IU oral daily
40842751|NCT03156439|DRUG|BIS-001 ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
40842752|NCT03102567|DRUG|GLPG1205 50mg q.d.|oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
41026423|NCT04292301|DEVICE|STrategically Acquired Gradient Echo (STAGE)|The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
41026424|NCT02211300|DEVICE|The OptiScanner|treatment of blood glucose per standard of care
41026425|NCT02211300|DEVICE|YSI 2300 STAT Plus™|
41160991|NCT06031870|PROCEDURE|Pelvic floor muscle training|Twelve pelvic floor physiotherapy sessions were prescribed by the study physician. Pelvic floor physiotherapy was performed in individual courses by trained physiotherapists. The patient was free to choose the physiotherapist and the study team had no influence on the choice.
41160992|NCT02827799|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This behavioral intervention includes training on managing the sleep environment (stimulus control), managing dysfunctional beliefs and attitudes about sleep (cognitive therapy), relaxation (progressive muscle relaxation), changing sleep behaviors (sleep hygiene), and managing sleep duration and continuity (sleep restriction).
40842753|NCT03102567|DRUG|Placebo oral capsule|oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
40842754|NCT03102567|DRUG|GLPG1205 250 loading dose and 50mg q.d. maintenance dose|Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
40842755|NCT03083145|DIETARY_SUPPLEMENT|Whey Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
40842756|NCT03083145|DIETARY_SUPPLEMENT|Pea Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
40842757|NCT03083145|BEHAVIORAL|Snack Tray Choices|Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
40842758|NCT02880150|OTHER|Stress test|
40842759|NCT05718960|OTHER|Reassurance-alone|To be informed of the absence of organic disease and provided a diagnostic explanation of functional dyspepsia
40842760|NCT05718960|BEHAVIORAL|Traditional dietary advice|To receive the same information as reassurance-alone group but also recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre
41160993|NCT02827799|BEHAVIORAL|Heart Failure Self-Management Education|This intervention includes learning about how to manage one's heart failure. This includes understanding when to seek treatment, monitoring oneself for daily signs and symptoms, daily weight, dietary changes, physical activity, and adherence to medication taking.
40842761|NCT04491851|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
40842762|NCT04491851|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
40842763|NCT03300206|DEVICE|Breast Biopsy|A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
40842764|NCT05457088|OTHER|1.5 protein|dietary plan having dietary protein of 1.5 gr/kg/day
40842765|NCT05457088|OTHER|0.8 protein|dietary plan having dietary protein of 0.8 gr/kg/day
41160994|NCT04075097|BEHAVIORAL|Aerobic exercise|1 session
41160995|NCT04075097|BEHAVIORAL|Iyengar yoga|1 session
41160996|NCT02358499|DRUG|Posaconazole|Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
41160997|NCT06374342|DEVICE|Bone defect|Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.
41160998|NCT06374342|DEVICE|Spine fusion|Spinal fusion is a surgery procedure that reinforces your back structure and stability by linking two vertebrae together
41160999|NCT06374342|DEVICE|Cage filling|Intervertebral fusion with cages is a surgical procedure used to stabilize the spine by fusing adjacent vertebrae. The cages, typically made of materials like titanium or plastic, and pre-filled with bone graft substitutes are placed between the vertebrae to maintain the proper spacing and alignment.
41161000|NCT04633213|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
41161001|NCT04633213|DRUG|Placebo|Ophthalmic Solution
41500187|NCT01807286|DRUG|Dexamethasone|Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
41500188|NCT01807286|BEHAVIORAL|Questionnaires|Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
40842766|NCT04958746|DRUG|Ciprofol|intravenous bolus
40842767|NCT04958746|DRUG|Propofol|intravenous bolus
40842768|NCT00438334|DEVICE|Programmable directional/omni-directional hearing aid|
40842769|NCT06289309|DEVICE|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
40842770|NCT00251251|DEVICE|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
40842771|NCT00251251|DEVICE|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
41161002|NCT04362176|BIOLOGICAL|pathogen reduced SARS-CoV-2 convalescent plasma|Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.
41161003|NCT04362176|BIOLOGICAL|Placebo|Lactated Ringer's solution with multivitamins
41161004|NCT01905371|DRUG|Dextroamphetamine|
41363664|NCT05381740|DEVICE|Sham rTMS Approach|Participants in this arm will receive sham rTMS given over the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. Immediately after the completion of sham rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
41363665|NCT03341091|OTHER|Tai-chi group|The Tai-chi group received a 16-week 10-step simplified Tai-chi training programme in which additional measures were implemented to enhance participants' engagement.
41363666|NCT04331314|DEVICE|Use of Symbios Bone Graft Material|Patients will receive Symbios Bone Graft Material according to randomization Group.
41363667|NCT04331314|DEVICE|Algipore Bone Substitution Material|Patients will receive Algipore Bone Substitution Material according to randomization Group.
41363668|NCT00705627|DRUG|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
41363669|NCT02078674|BIOLOGICAL|Monovalent Avian Influenza VLP (H7N9)|
41363670|NCT02078674|BIOLOGICAL|Matrix-M1™ adjuvant|
41363671|NCT02078674|BIOLOGICAL|Placebo|
41363672|NCT00100542|BEHAVIORAL|Psychiatric interviews|Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
41363673|NCT04192292|DRUG|Sulfonylurea|Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.
41363674|NCT04192292|DRUG|DPP4 Inhibitor|Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.
41363675|NCT03558230|BEHAVIORAL|Standardized Constraint-Induced Movement Therapy|The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
41363676|NCT03558230|BEHAVIORAL|Vibration|Vibration applied to the wrist.
41363677|NCT03558230|BEHAVIORAL|Placebo (for vibration)|No vibration applied to the wrist.
41363678|NCT04162145|DEVICE|Active BRIDGE device placement|The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
41363679|NCT04162145|DEVICE|Inactive BRIDGE device placement|The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
41363680|NCT05069623|BIOLOGICAL|VB10.2129|0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0
41363681|NCT05069623|BIOLOGICAL|VB10.2210|3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0
41500189|NCT00908310|DRUG|Omniscan|OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
41500190|NCT02286687|OTHER|Laboratory Biomarker Analysis|Correlative studies
41500191|NCT02286687|OTHER|Pharmacological Study|Correlative studies
41500192|NCT02286687|DRUG|Talazoparib|Given PO
41500193|NCT04892225|BEHAVIORAL|Technology-supported behavioral intervention (text message)|A simple text message regarding the salt and fluid restriction in order to reduce the inter-dialytic weight gain will be send on daily basis to all the individuals in the intervention group.
40842772|NCT01532869|DRUG|Placebo|Subcutaneously weekly, Weeks 0-48
40842773|NCT01532869|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Weeks 0-48
40842774|NCT01532869|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Week 48-96
41161005|NCT01905371|OTHER|Physical Therapy|One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
41161006|NCT01905371|DRUG|Placebo|
41161007|NCT06140485|DIETARY_SUPPLEMENT|NW Low-Glu®|One NW Low-Glu® capsule contains Mas Cotek powdered Extract 300 mg (from leaves of Ficus deltoidea Jack by aqueous solvent extraction) + Cinnamomum cassia L. powdered Extract 100 mg + Black seed powdered extract 250 mg (from seeds of Nigella sativa L. by 70% hydro-alcoholic extraction).
41161008|NCT06140485|DRUG|Metformin|Patients in the active comparator arm will receive a total of 2000 mg of metformin per day.
41363682|NCT04553497|DEVICE|Interferential current|"Interferential current or sham were applied to the patients before the each exercise session. Pre-modulated bipolar method with the currier frequency of 4 kHz by a combination therapy unit (Sonopuls 692, Enraf-Nonius) with two electrodes (8×6 cm) was used. One electrode was placed on the lateral part of the deltoid muscle; the other was placed on the trapezium muscle close to the shoulder. Subjects were told that in order to produce an effect, the intensity of the stimulator must be maintained at a strong but comfortable level at all times. The sham interferential current therapy consisted of the placement of the same pads for the same time but no electrical stimulation was applied to the probes."
41363683|NCT04553497|OTHER|Rehabilitation program|The orthopedic rehabilitation programme was applied to all patients three times a week for 4 weeks under the guidance of the same physiotherapist. The first phase (0-3 weeks) involved the elbow, wrist, and hand active range of motion (ROM) and pendulum (clockwise and counterclockwise) exercises in the 0-2 weeks of the non-displaced fracture. For displaced fractures, elbow, wrist, and hand active range of motion was started immediately, but pendulum exercises were initiated two weeks later. The patients were instructed to continue exercises 3-5 times per day for 30 minutes. After two weeks, active assistive ROM and isometric exercises were performed supine position. During the second phase (3-6 weeks), active forward elevation in supine was carried out and then progressed to sitting and standing position. At the end of the sixth week, a home exercise program was given by the physiotherapist, including resistance exercises using an elastic band (Thera-Band).
41363684|NCT01072227|PROCEDURE|Sample Collection|Tissue
41026426|NCT03899870|PROCEDURE|Rectal resection|Patients underwent anterior or low anterior resection. Patients with tumors in the lower third of the rectum where anal sphincters could not be preserved underwent abdominoperineal resection. In majority of the cases, inferior mesenteric artery (IMA) was ligated caudal to the origin of the left colic artery. For the tumors of the upper rectum, partial excision of the mesorectum was performed up to the minimum of 5 cm from the inferior aspect of the tumor. For the tumors of the middle and low rectum a total mesorectum excision was done with the minimum distal mucosal margin of 1 to 2 cm. Ileostomy was performed in cases where colon was poorly prepared, anastomotic leak test was positive or colonel anastomosis was made. In most of the cases, open surgery was performed. Laparoscopic surgery was performed in selected cases. Wide local excision was performed in selected cases with T1 tumors without locoregional lymphadenopathy.
41026427|NCT03899870|DRUG|Neoadjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil \[5-FU\] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
41026428|NCT03899870|DRUG|Adjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
41363685|NCT04679064|DRUG|Niraparib|PARP-inihibitor
41363686|NCT04679064|DRUG|Dostarlimab|PD-1 inihibitor
41026429|NCT03892486|OTHER|The high PUFA diet group|Assumptions of nutritional intervention: in a randomized manner volunteers will be assigned to one of two groups: a control group which will receive general nutritional recommendations, based on the Polish nutrition pyramid, and the intervention group which will receive nutritional recommendations, based on the Polish nutrition pyramid and will consume at least 4 tablespoons of olive oil or 30 grams of nuts every day for 12 weeks.
41363687|NCT04679064|DRUG|Pegylated liposomal doxorubicin|Chemotherapy drug
41363688|NCT04679064|DRUG|Paclitaxel|Chemotherapy drug
41363689|NCT04679064|DRUG|Gemcitabine|Chemotherapy drug
41363690|NCT04679064|DRUG|Topotecan|Chemotherapy drug
41363691|NCT04679064|DRUG|Bevacizumab|Chemotherapy drug
41363692|NCT02573142|BEHAVIORAL|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
41363693|NCT02573142|BEHAVIORAL|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
41363694|NCT02577107|DRUG|ranibizumab|
41363695|NCT02577107|DRUG|Conbercept|
41363696|NCT06170827|DRUG|AIO-001|AIO-001 Solution for SC injection.
41363697|NCT01655368|BEHAVIORAL|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
41363698|NCT01655368|BEHAVIORAL|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
41363699|NCT01230827|DRUG|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
41363700|NCT01230827|DRUG|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
41363701|NCT01230827|DRUG|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
41026430|NCT05148000|BIOLOGICAL|QM1114-DP|QM1114-DP
41026431|NCT01479036|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
41026432|NCT01479036|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
41363702|NCT05245240|PROCEDURE|Dietary and physical intervention|"Low-caloric diet (energy deficit 600 kcal/day based on indirect calorimetry measurements), individually tailored by a nutritional specialist according to patients' individual food preferences.~Mild to moderate intensity exercise of aerobic/endurance type, performed 3 times a week for 30-90 minutes."
41026433|NCT05854290|BEHAVIORAL|CRT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
41363703|NCT06087133|BEHAVIORAL|StEP:Prenatal|StEP is a health care-based intervention based on elements of Social Cognitive Theory, in which registered dietitians with additional certified lactation counselor training (RD/CLC) provide individual and group-based support for healthy diet, physical activity, other lifestyle behaviors, stress reduction, and healthy gestational weight gain. StEP:Prenatal will be delivered remotely. There are up to 8 sessions scheduled around the routine prenatal care visits and designed to be offered from the first trimester of pregnancy through delivery.
41363704|NCT06087133|OTHER|Routine Care|Routine care includes routine prenatal and post-partum primary care visits, on-site WIC services and referrals for additional services as needed (e.g., women with poor weight gain, obesity, or diabetes may be offered additional nutrition visits).
41363705|NCT00204568|DRUG|Adriamycin|60 mg/m2, d1, W d22
41363706|NCT00204568|DRUG|Trofosfamide|300 mg absolute d1-7, followed by 150 mg absolute continuously
41161009|NCT03688997|OTHER|Simulator training|bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).
41363707|NCT01267682|BEHAVIORAL|Cognitive Stimulation|Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
41161010|NCT00301730|BIOLOGICAL|aldesleukin|
41161011|NCT00301730|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
41161012|NCT00301730|BIOLOGICAL|trastuzumab|
41363708|NCT01482598|DEVICE|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
41363709|NCT01375491|DRUG|Doxycycline|generic doxycycline 100mg twice daily
41363710|NCT01375491|OTHER|Placebo|Placebo comparator to doxycycline
41363711|NCT02330406|DRUG|Anagliptin|Suiny 100 mg
41363712|NCT02330406|DRUG|Sitagliptin|Januvia 50 mg Glactiv 50 mg
41363713|NCT05214131|DEVICE|gogoband|use of biometric alarm to wake patient prior to wetting
41363714|NCT05214131|DEVICE|SNEA group|standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred
41500194|NCT04628897|BEHAVIORAL|Exposures|"1. Total area of available floor space inside the home (m2)~2. Frequency that child plays outdoors~3. Total number of physical hazards in the home (presence of open stairwells, stove height)~4. Total number of fine-motor activity items available to the child~5. Presence of gross-motor activity items available to the child across each category (e.g., fixed, portable: ball equipment, push/pull equipment, riding equipment, rocking and twisting equipment)~6. Hemoglobin concentration (g/L)."
41161013|NCT00301730|DRUG|paclitaxel|
41161014|NCT00301730|PROCEDURE|conventional surgery|
41161015|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
41161016|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
41161017|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
41363715|NCT02643316|DRUG|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
41363716|NCT02643316|DRUG|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
41363717|NCT03514394|BEHAVIORAL|Usual Care|The clinic's usual care includes counseling, substance use disorder treatment, peer support services, and some elements of traditional BA (not the modified BA).
41363718|NCT03514394|BEHAVIORAL|Modified Behavioral Activation (Task Sharing)|This intervention will include all core elements of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. The intervention will also include a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA.
41363719|NCT02445768|OTHER|Cognitive multisensory rehabilitation|
41500195|NCT02692144|OTHER|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
41500196|NCT00261781|BEHAVIORAL|Treadmill training|Walking on a treadmill 3 times per week for 6 weeks
41026434|NCT05854290|BEHAVIORAL|CBT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
41026435|NCT05854290|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications for the persons with MCI, such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
41026436|NCT05854290|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15-minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).~Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking."
41026437|NCT00746603|DRUG|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
41026438|NCT03013647|DRUG|Methyl Aminolevulinate|"Patients will be treated with Daylight Photodynamic therapy, following these steps:~1. mild curettage of the AK lesions~2. application of a chemical sunscreen SPF 30~3. application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories)~4. exposition to daylight, for 120 minutes~5. cleaning of the face"
41026439|NCT06296940|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a brief, evidenced based intervention for PTSD. WET is generally delivered individually across 5 sessions in which the therapist guides the patient through writing exercises. Across exposure sessions, participants experience habituation so that their symptoms decrease by the end of treatment. WET has an established evidence base in general outpatient psychotherapy for PTSD, but has not been adapted or tested in residential SUD treatment settings.
41026440|NCT06296940|BEHAVIORAL|Treatment as Usual|Treatment as Usual will include a variety of standard care services offered in short term residential treatment. For example, participants receiving TAU will participate in individual case management/general counseling sessions focused on their substance use disorder and its consequences, group based psychoeducation sessions, group based counseling sessions (e.g., relapse prevention planning), individual services with a medical provider and pharmacotherapy (e.g., for withdrawal, relapse prevention, or co-occurring conditions)
41363720|NCT03159715|BEHAVIORAL|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
41363721|NCT03159715|BEHAVIORAL|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
41363722|NCT03159715|BEHAVIORAL|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
41363723|NCT05384821|DRUG|Vincristine|IV, D1-D22-D43 and D64
41363724|NCT05384821|DRUG|Irinotecan|Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)
41363725|NCT05384821|DRUG|Temozolomide|Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)
41363726|NCT05384821|DRUG|Etoposide|Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)
41363727|NCT05384821|DRUG|Cis-Retinoic acid|Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
41363728|NCT04084860|DRUG|CI-581a|CI-581a during weeks 1 and 6 at 0.71 mg/kg
41500197|NCT01137071|BIOLOGICAL|Monoclonal antibody Hu3S193|"30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation."
41026441|NCT02086591|DRUG|Doxycycline|
41161018|NCT06105047|BEHAVIORAL|Cognitive tests|". Patients will perform experimental task in four conditions : control, mime, emotion, dual In a control condition : they will be asked to read the sentence aloud; in a motor-only condition, they will also be asked to mime the sentence; in an emotional-only condition, they will be asked to read the sentence while listening to music; in a dual condition, they will be asked to both mime and listen to music. Immediately after each condition, they will realize a recognition task~* quiz : Geneva Music Induced Checklist, GMIAC, Coutinho \& Scherer, 2017"
41161019|NCT00196118|DEVICE|Günther Tulip Vena Cava Filter|
41363729|NCT04084860|DRUG|CI-581b|CI-581b during weeks 1 and 6 at 0.0125 mg/kg
41500198|NCT03764098|DRUG|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
41500199|NCT03764098|OTHER|Placebo|Placebo
41500200|NCT04575064|OTHER|Standard of Care (SoC)|Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
41363730|NCT04084860|BEHAVIORAL|MBRP|MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).
41026442|NCT03803904|OTHER|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
41026443|NCT06038877|OTHER|Interviews|Individual semi-structured interviews
41026444|NCT06038877|OTHER|Qualitative analysis|Thematic analysis of the content of responses
41500201|NCT04575064|DRUG|Remdesivir|Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days or until discharge from hospital, whichever occurs first
41026445|NCT06398353|OTHER|Real acupuncture|Real acupuncture twice a week for two weeks
41026446|NCT06398353|OTHER|Sham acupuncture|Sham acupuncture twice a week for two weeks
41026447|NCT01538875|DRUG|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
41026448|NCT01538875|DRUG|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
41026449|NCT05758662|DIAGNOSTIC_TEST|18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)|Patients undergo a hybrid 18F-NaF-PET CT scan and TTE at five years after TAVI
41026450|NCT00182689|DRUG|sorafenib tosylate|Given orally
41161020|NCT04827186|PROCEDURE|Spleen Transplantation/Removal|Spleen transplantation/removal and kidney transplantation alone or simultaneous kidney and pancreas transplantation in highly sensitized patients with either a positive flow cytometry cross-match (FCXM) (T or B cell positive) or a complement-dependent cytotoxicity (CDC) cross-match (B cell positive).
41161021|NCT04340726|PROCEDURE|One time abutment|
41161022|NCT03705533|DRUG|Telmisartan|Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
41363731|NCT04084860|BEHAVIORAL|MET|MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).
41363732|NCT00324519|DEVICE|Foley bulb|
41363733|NCT00324519|DRUG|misoprostol|
41500202|NCT05769010|DRUG|SHR-A1811|SHR-A1811: intravenous
41500203|NCT05769010|DRUG|Pyrotinib|Pyrotinib: oral
41500204|NCT05769010|DRUG|Bevacizumab|Bevacizumab: intravenous
41161023|NCT03705533|DRUG|Micardis|Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
41363734|NCT04542252|DRUG|SyB V-1901|SyB V-1901 10 mg via IV infusion for 2 hours
41363735|NCT04542252|DRUG|Cyclosporine|200 mg Capsule
41363736|NCT05751850|DRUG|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
41363737|NCT05751850|DRUG|nab-paclitaxel; gemcitabine|nab-paclitaxel in combination with gemcitabine
41363738|NCT02554409|BIOLOGICAL|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
41026451|NCT05909189|OTHER|LEADing Dementia End-of-Life Planning Conversations|The LEAD Intervention is self-administered and delivered through an interactive, web-based platform designed according to recommended functionalities and user-designed principles. Through three distinct modules, the LEAD Intervention will facilitate the advance care planning processes of 1) defining care recipients' values and preferences for care, 2) developing advance care planning congruence within the pair, or a shared understanding of the care recipient's values and preferences, through conversation(s), and 3) encouraging ongoing advance care planning conversation and documentation that can be shared beyond the pair. All modules will include video tutorials to introduce the goals and tasks as well as provide interactive resources to provide support and education relevant to the content of each module. The three modules are intended to be followed in a sequential pattern.
40842775|NCT06110000|OTHER|pragmatic set of interventipons|"The pragmatic set included 6 interventions as follows.~1. Pragmatic posterior capsular stretch (PPCS)~2. Serratus anterior stretch (SAS)~3. Rotator cuff facilitation (RCF)~4. Acromioclavicular joint mobilization.~5. Pectoralis minor stretch~6. Thoracic manipulation Five to ten sweeps per minute are administered three to four times. The applied force is combined with deep breathing. The subject is asked to report discomfort and the applied force is adjusted."
41363739|NCT02206776|DRUG|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
41363740|NCT02206776|DRUG|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
41500205|NCT01866098|DRUG|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
41500206|NCT01866098|DRUG|Placebo|
41500207|NCT01667237|BEHAVIORAL|Home-based pulmonary rehabilitation program|The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
41363741|NCT04141098|DEVICE|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
41363742|NCT01569568|OTHER|MRI scanning|1H MRS, DTI, FMRI
41500208|NCT05456958|OTHER|MRI Biofeedback|We will use state-of-the-art fMRI and neurofeedback of brain signals in order to teach patients with PTSD to self-regulate pathological brain activity that is associated with their symptoms. Indeed, feedback information is crucial for learning, where rt-fMRI-based neurofeedback makes information about brain activity accessible to our consciousness (Ros et al., 2014; Sitaram et al., 2017). It thus provides a reinforcement signal to induce personalized learning mechanisms, allowing individuals to search for appropriate cognitive strategies to voluntarily control brain activity. The feedback signal will come from activity within either the amygdala or PCC.
41500209|NCT05456958|OTHER|Sham-MRI Biofeedback|In the sham-control arm (N=20), individuals will receive fake neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
40842776|NCT06110000|OTHER|scapular strengthening exercise.|• Subjects in Group B receive strengthening exercises (exercise will perform with 15 repetitions for each set- 3sets/day, 3 days /week for 6 weeks. In Scapular strengthening exercises, treatment protocol will involve the individualized for focus muscle Serratus anterior (Dynamic hug, Scaption with external rotation, Diagonal PNF (shoulder flexion horizontal flexion, external rotation),Trapezius - Upper trapezius (unilateral shoulder shrug, rowing, forward shoulder flexion, shoulder abduction in scapular plane above 120 degrees, Middle trapezius (prone shoulder horizontal abduction, scaption, horizontal abduction with external rotation), Lower trapezius (Unilateral scapular retraction, prone bilateral shoulder external rotation at 90 degrees of abduction, prone shoulder abduction), Levator Scapulae (horizontal abduction with shrug, horizontal abduction with ER, prone shoulder extension, Rhomboids (ER at 90° of abduction, ER at 0° of abduction, Horizontal abduction, Shoulder extension)
41363743|NCT01569568|BEHAVIORAL|Cognitive testing|Behavioral testing
41363744|NCT01189396|DRUG|A006|Albuterol DPI with 180 mcg Albuterol/inhalation
41363745|NCT01189396|DRUG|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
41363746|NCT01189396|DRUG|Proventil-HFA|Albuterol MDI with 90 mcg Albuterol/inhalation
40842777|NCT04421209|DRUG|Propranolol Hcl 40mg Tab|40mg PO BID for the three days prior to surgery, 40mg PO BID the day of surgery and on post-op days 1 and 2.
41363747|NCT06070766|DRUG|Ketamine|The use of ketamine in chronic conditions.
41363748|NCT02798159|DRUG|TD0025|
41363749|NCT02798159|DRUG|Sildenafil Citrate 50mg|
41363750|NCT01294319|DRUG|Mifepristone|
41363751|NCT01294319|DRUG|Placebo|
41363752|NCT01294319|DRUG|Spironolactone|
41363753|NCT01294319|DRUG|Combined|
41363754|NCT01294319|DRUG|Dexamethasone|
41363755|NCT04040725|DRUG|Rogaratinib|Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.
41363756|NCT02461173|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
41363757|NCT02461173|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
41363758|NCT02461173|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
41363759|NCT02461173|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
41363760|NCT02461173|DEVICE|shepherd catheter|
41363761|NCT00166504|DRUG|ezetimibe (+) simvastatin|simvastatin/ezetimibe 10/20 mg
41363762|NCT00166504|DRUG|atorvastatin|atorvastatin 10 mg
41363763|NCT00984958|DEVICE|Bulkamid|injection of Bulkamid in the urethra
41363764|NCT00984958|DEVICE|Bulkamid expectation|expectance
41363765|NCT04318015|DRUG|Hydroxychloroquine|All treatment will be administered orally.
41363766|NCT04318015|DRUG|Placebo oral tablet|All placebo will be administered orally
40842778|NCT04421209|DRUG|Placebo oral tablet|Placebo tablets administered with the same schedule of Propranolol tablets
41500210|NCT01568970|BEHAVIORAL|Return-to-work Rehabilitation + Follow up|3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
40842779|NCT04295863|DRUG|Nivolumab Standard|For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks
40842780|NCT04295863|DRUG|Pembrolizumab Standard|For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks
40842781|NCT04295863|DRUG|Nivolumab Extended|For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks
40842782|NCT04295863|DRUG|Pembrolizumab Extended|For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks
40842783|NCT02505568|DRUG|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
41026452|NCT04930029|OTHER|Ten year evaluation|Clinical, biological and endoscopic evaluation
41026453|NCT04666493|OTHER|Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum|The Facing Your Fears program (FYF; Reaven et al. 2011) is a CBT-based group treatment program that has been adapted for the needs of children with high-functioning ASD. The current project will adapt the FYF program for virtual delivery and examine its effectiveness.
41026454|NCT05227079|DEVICE|MultCROC multibite forcep|Alligator style 2.4 mm diameter jaws that can hold up to six samples in one pass through endoscope.
41026455|NCT05227079|DEVICE|Conventional double bite forcep|Use of conventional double bite forceps that can store up to two specimens in one pass through endoscope
41500211|NCT01568970|BEHAVIORAL|Return-to-work rehabilitation|3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
41500212|NCT01688492|DRUG|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson \& Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
40842784|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
41026456|NCT00426075|DEVICE|Elastic stockings|
41026457|NCT02065128|OTHER|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
41026458|NCT00293735|DRUG|labetalol (seizure prevention)|"20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours"
41026459|NCT00293735|DRUG|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
41026460|NCT04333277|OTHER|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10\^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
40842785|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
41161024|NCT02055053|DRUG|0.5% Bupivicaine|Local anesthetic
41161025|NCT00371618|PROCEDURE|Fluoroscopy|
41161026|NCT02930837|DRUG|alteplase|
41500213|NCT01177475|OTHER|blood samples , feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
41500214|NCT01177475|OTHER|blood samples, feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
40842786|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
40842787|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
40842788|NCT03615339|DIETARY_SUPPLEMENT|Molkosan|Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
40842789|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (UV treated)|"Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated).~The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
41026461|NCT04333277|OTHER|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
41026462|NCT04663815|BEHAVIORAL|Animal-assisted activity|The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.
41026463|NCT04663815|OTHER|Control intervention|The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
41161027|NCT02782598|DEVICE|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
41161028|NCT01913288|OTHER|Biological Maternal Sounds|
41363767|NCT03641690|OTHER|Empirical antimicrobial therapy|All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
41363768|NCT04557189|DRUG|TAK-951|TAK-951 SC injection
41363769|NCT04557189|DRUG|Ondansetron|Ondansetron IV injection
41363770|NCT04557189|DRUG|Ondansetron Placebo|Ondansetron placebo-matching IV injection
41363771|NCT04557189|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
41363772|NCT05499208|OTHER|Giving side position with patient turning and movement system|To provide effective breastfeeding by placing the mother in position.
41363773|NCT03715127|DRUG|Psilocybine oral capsule|single dose of psilocybin (0.215mg / kg body weight)
41363774|NCT03715127|DRUG|Placebo oral capsule|single dose of placebo (100% mannitol)
41363775|NCT03985358|OTHER|Opioid counseling plus standard of care instructions|Same counselor (investigator on the study) will use the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher) to counsel patients
40842790|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (untreated)|"commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
40842791|NCT04511065|OTHER|Newsletter using a virtual mode of delivery|Newsletter creation where topics in the newsletter are chosen by participants in the intervention group.
40842792|NCT03068208|PROCEDURE|Methylene blue-mediated photodynamic therapy|The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
40842793|NCT01691976|DRUG|Oestrogen Patches|
40842794|NCT01691976|DRUG|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
40842795|NCT04591236|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to Parkinson patients.
41026464|NCT00522249|DRUG|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
41363776|NCT06336109|OTHER|Hypertonic saline knee and shoulder injection|"0.25 mL injection with hypertonic saline (7%) in the infrapatellar fat pad.~1.2 mL injection with hypertonic saline (7%) in the deltoid muscle."
41363777|NCT00156962|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
41363778|NCT00156962|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
40842796|NCT04591236|DEVICE|Treadmill gait training|Treadmill gait training was applied to Parkinson patients.
40842797|NCT00519662|DRUG|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
40842798|NCT01476631|BEHAVIORAL|Walking|"* 7 days prior to baseline participants must wear a blinded pedometer~* At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale."
40842799|NCT01075984|DRUG|Posaconazole|
41363779|NCT00914472|BIOLOGICAL|heparin sodium - APP|Heparin 5000 IU / mL
41363780|NCT00914472|BIOLOGICAL|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
41363781|NCT00261599|DRUG|AQUAVAN® (fospropofol disodium) Injection|
40842800|NCT01075984|DRUG|Dextrose 5% in water|
40842801|NCT03481621|DEVICE|Acupuncture|Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).
40842802|NCT03481621|OTHER|Standard care|PT, pain medications, nerve block, etc
40842803|NCT04699461|DRUG|Loncastuximab Tesirine|IV infusion
40842804|NCT04699461|DRUG|Idelalisib|Oral tablet
40842805|NCT05906355|DEVICE|the wearable filtrating artificial Kidney Device|the wearable filtrating artificial kidney device rapidly for rapid relief of fluid overload in patients
40842806|NCT05906355|DEVICE|traditional hemodialysis machine|the hemodialysis machine currently used in clinical practice to reduce fluid overload in patients
40842807|NCT00961714|DEVICE|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
41363782|NCT00261599|DRUG|Midazolam HCI|
41026465|NCT00522249|DRUG|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
41026466|NCT00522249|DRUG|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
41363783|NCT00816244|DRUG|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
41363784|NCT00453349|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
41363785|NCT00453349|DRUG|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
41363786|NCT05813574|OTHER|Observational patient reported outcomes|Of COVID-19 patients
41363787|NCT04045431|DEVICE|PAAG-OA|Intra-articular injection of 6ml PAAG-OA in the target knee (incl. five (5) years follow-up) period.
41363788|NCT04045431|DEVICE|Synvisc-One|Intra-articular injection of 6ml Synvisc-One in the target knee
41363789|NCT03673150|OTHER|non intervention|Observational study / non intervention
41363790|NCT04162873|DRUG|Celecoxib|Given PO or via feeding tube
41363791|NCT04162873|OTHER|Placebo|Given PO or via feeding tube
41363792|NCT04162873|OTHER|Quality-of-Life Assessment|Ancillary studies
41363793|NCT04162873|OTHER|Questionnaire Administration|Ancillary studies
41026467|NCT02799082|DRUG|Vehicle|topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
41026468|NCT02799082|DRUG|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
41026469|NCT05954871|DRUG|GDC-1971|GDC-1971 capsules or tablets will be administered as specified in each treatment arm.
40842808|NCT02737150|DEVICE|CoreValve Evolut R|
41026470|NCT05954871|DRUG|Osimertinib|Osimertinib tablets will be administered as specified in each treatment arm.
41026471|NCT05954871|DRUG|Cetuximab|Cetuximab, solution for infusion will be administered as specified in each treatment arm.
41026472|NCT00650949|DRUG|CYT997|Escalating doses (100mg/m\^2 to 150mg/m\^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
41026473|NCT00650949|DRUG|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
41026474|NCT02357212|PROCEDURE|coronary angiography|invasive procedure performed to determine coronary anatomy
41026475|NCT02357212|PROCEDURE|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
41026476|NCT04750252|BIOLOGICAL|StroMel|Autologous MSC
41026477|NCT00932893|DRUG|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
41026478|NCT00932893|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
41026479|NCT00932893|DRUG|Docetaxel|Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
41026480|NCT01591746|DRUG|Botulinum Toxin Type A|
41026481|NCT01591746|DRUG|Placebo|5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
41026482|NCT03681301|OTHER|virtual reality simulator|Additional self-directed learning and practice using virtual reality simulator
41363794|NCT00308659|PROCEDURE|FOB protected distal microbiological samplings|
40842809|NCT02737150|DEVICE|Edwards Sapien 3|
40842810|NCT02737150|PROCEDURE|Local anesthesia with conscious sedation|
40842811|NCT02737150|PROCEDURE|General anesthesia|
40842812|NCT04427449|BIOLOGICAL|CD44v6-specific CAR gene-engineered T cells|4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10\^6 cells/kg body weight
40842813|NCT00153192|DRUG|Marinol (dronabinol)|
40842814|NCT00094432|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
40842815|NCT00094432|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
40842816|NCT05686642|DRUG|LT3001 Drug:high dose|Administered by intravenous infusion.
41026483|NCT02011841|DRUG|Rifaximin|rifaximin 1200 mg/day orally for 6 months
41026484|NCT02011841|DRUG|Ciprofloxacin|ciprofloxacin 500 mg/day orally for 6 months
41026485|NCT06337929|OTHER|CAPOEIRA TRAINING|The protocol of the capoeira training program and the movements (blows, dodges and flourishes) will be based on the Capoeira Abadá method.
41026486|NCT06337929|OTHER|CONTROL GROUP|The protocol of the control group will be based on an intervention with capoeira movements, however, without important cardiovascular, neuromuscular and metabolic demands, being an activity with stretching movements from positions of the capoeira modality itself.
41026487|NCT05882851|BEHAVIORAL|determination of the current nutritional status of patients|No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
41026488|NCT04221516|DRUG|Camrelizumab|Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.
41026489|NCT06434961|DRUG|SHR6508 plus oral placebo tablets|SHR6508 plus oral placebo tablets
41026490|NCT06434961|DRUG|Cinacalcet plus intravenous placebo|Cinacalcet plus intravenous placebo
41266840|NCT06544226|DEVICE|UH100|"This is a non-interventional pilot study. Given the within-subject and longitudinal design used in this study, traditional intervention settings are not applicable. All participants will receive weekly and tri-point assessments,~* Weekly (twice per week) Assessments: Physical vitals such as BMI, Blood Pressure, Heart Rate~* Weekly (once per week) Assessments: Sit-Up-Squat-Stand Test, Video diary entries, GAD-7, and PHQ-9.~* Tri-point (week 1, 8, 6) assessments: EDE-Q, Patient Acceptance Questionnaire and the Food-specific Stop Signal Task."
41363795|NCT01038609|DRUG|Hydrocodone/Acetaminophen Extended Release|
41363796|NCT01038609|DRUG|Acetaminophen|
41363797|NCT01038609|DRUG|Morphine Extended Release|
41363798|NCT01038609|DRUG|Placebo|
41363799|NCT06175845|PROCEDURE|Intraductal biliary radiofrequency ablation|Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction
40842817|NCT05686642|DRUG|Placebo|Administered by intravenous infusion.
41026491|NCT02015897|PROCEDURE|Physical TherapyA|"Group A:~* Skin care~* Manual lymphatic drainage~* Bandaging using Coban™2Lite~* Guidance on physical activity"
41026492|NCT02015897|PROCEDURE|Physical TherapyB|"Group B:~* Skin care~* Bandaging using Coban™2Lite~* Guidance on physical activity"
41026493|NCT05462366|OTHER|Sample collection|Collect breast-milk and feces from mother-infant-pairs.
41026494|NCT06232408|DRUG|RP-1664|RP-1664 will be supplied as immediate-release solid dosage form for oral self-administration.
41026495|NCT00397423|DRUG|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd\*5 days,3 months interval for 4 times
41026496|NCT00397423|DRUG|NS|NS 1ml iH Qd\*5 days, 3 months interval for 4 times
41026497|NCT00353275|DRUG|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
41363800|NCT00026819|DRUG|Rofecoxib|
41363801|NCT04174430|BIOLOGICAL|severe bronchiolitis|Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease
40842818|NCT05686642|DRUG|LT3001 Drug:low dose|Administered by intravenous infusion.
40842819|NCT04197388|DEVICE|Inspiratory muscle training device|Inspiratory muscle training, 6 cycles of 30 breaths for 12 weeks.
40842820|NCT01858753|BIOLOGICAL|Autologous fibroblasts|
41363802|NCT04854356|OTHER|Exercise with blood flow restriction (BFR)|All participants completed high-intensity interval exercise plus (1) BFR applied during exercise phase, or (2) BFR applied during interval phase, or (3) no BFR applied.
40842821|NCT01858753|BIOLOGICAL|placebo sterile saline|
41500215|NCT05667675|BEHAVIORAL|Community Support Worker|Participants in the intervention group will have a structured review of their financially related needs and resources with a trained CSW, who will have a thorough understanding of potential income supports and community support agencies. The CSW will use a structured approach to identify financial needs and benefits for which the family is eligible The CSW will work intensively with families in the intervention arm to identify and meet their goals. They will conduct weekly meetings to complete forms, and provide advocacy (in person and by telephone) as needed up to six meetings as needed for system navigation.
40842822|NCT00428844|DRUG|daptomycin|6 mg/kg
40842823|NCT00428844|DRUG|daptomycin|8 mg/kg
40842824|NCT00428844|DRUG|vancomycin|1 gram
40842825|NCT00428844|DRUG|teicoplanin|6 mg/kg; used only at UK sites
40842826|NCT00428844|DRUG|nafcillin|1-2 gram
40842827|NCT00428844|DRUG|oxacillin|1-2 gram
40842828|NCT00428844|DRUG|flucloxacillin|1-2 mg
40842829|NCT02694497|OTHER|Chlamydia care as usual|
40842830|NCT02254395|DEVICE|Deep Brain Stimulation|
40842831|NCT04412447|DEVICE|Functional Electrical Stimulation|Electrical stimulation of motor-nerves innervating the musculature of the lower limb.
40842832|NCT04713501|BEHAVIORAL|PARTS Program|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
41026498|NCT00353275|DRUG|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
41026499|NCT00364858|DRUG|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
41026500|NCT05772767|OTHER|Biological sample collection|Collection of tumor tissue and blood for stem cell culture and organoids generation.
41026501|NCT05772767|OTHER|Dissecting ciliogenesis players|Assessment of cilium-related transcriptome in glioblastoma stem cells. Modulation of cilium-related genes and administration of cilium-targeted drugs to glioblastoma stem cells in vitro and ex vivo in glioblastoma brain organoids.
41026502|NCT05772767|DIAGNOSTIC_TEST|Validating ciliogenesis players|Cilium-related signature will be studied in tumor tissue to evaluate its prognostic role.
41026503|NCT03223389|DIETARY_SUPPLEMENT|C-8 dietary oil|Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
41026504|NCT03223389|DIETARY_SUPPLEMENT|Tricaprylin|Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
41026505|NCT03223389|DIETARY_SUPPLEMENT|Olive oil|Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
41026506|NCT01658683|BEHAVIORAL|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
41026507|NCT04864808|BEHAVIORAL|Behavioral Parent Training|Parents will receive sessions of behavioral parent training with components specifically targeted toward parents with ADHD. The number of sessions will be informed based on stakeholder feedback. Treatment will be delivered via telehealth.
41026508|NCT01199081|DRUG|Dronedarone|"Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily"
41026509|NCT01799174|PROCEDURE|UVA-1 Phototherapy|
41026510|NCT01799174|PROCEDURE|Placebo|
41363803|NCT06425185|OTHER|Single-leg stance under different instability conditions|"Participants will perform three attempts of 20 seconds of single-leg stance on the floor and on the 7 selected configurations of the BB. The order of measurement will be randomized. The description of the chosen configurations can be found in the Detailed Description section. In all cases, the participant's objective is to ensure that the edges of the BB are not in contact with the floor.~The position of the participant on the BB will be a single-leg stance on the randomly chosen foot, with the contralateral knee slightly flexed and hands placed on the hips. Participants will look at a fixed point placed 3 meters in front of them.~A rest period of 30 seconds will be allowed between trials. The physiotherapist responsible for supervising the measurements will be the one to adjust the BB configurations when needed."
41363804|NCT02062749|DRUG|Oxaliplatin|Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
41363805|NCT02286206|DRUG|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
41363806|NCT01687985|DRUG|BLI801 laxative - low dose|BLI801 laxative - oral solution
41363807|NCT01687985|DRUG|BLI801 laxative - high dose|BLI801 laxative - oral solution
41363808|NCT05358158|PROCEDURE|Intraoperative air leak test|A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
40842833|NCT06545695|DRUG|Erlotinib|Part B will be the dose escalation component, in which the subject will initiate 50 mg erlotinib,8 weeks later escalate to 75 mg, and then 8 weeks later to 100 mg erlotinib pending tolerance after each 8-week period.
40842834|NCT01455194|DRUG|Ciclesonide|During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
40842835|NCT03134781|BEHAVIORAL|DoIT workout|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management. FFIT was performed 3 times/week with 48 hours recovery between sessions for 40 weeks.
40842836|NCT03134781|BEHAVIORAL|DoIT workout - Detraining|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training, performed according to a periodized model of exercise prescription for a 20-week period (3 times/week). Immediately after a 20-week detraining period (no training was performed) was followed.
40842837|NCT03134781|BEHAVIORAL|Control - No training|No training was performed during a 40-week period. Participation only in measurements.
40842838|NCT02727491|DRUG|Dextromethorphan|Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).
40842839|NCT02727491|DRUG|Placebo|Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
40842840|NCT05018858|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
40842841|NCT03189836|BIOLOGICAL|ACTR707|autologous T cell product
40842842|NCT03189836|BIOLOGICAL|rituximab|CD20-directed cytolytic antibody
41161029|NCT03715738|OTHER|arm 1 : Creaform3D + MyotonPRO|"After inclusion,are carried out:~* estimation of the volume of the breast to be reduced with the 3D digital camera~* measurement of breast density by Likert scale and MyotonPRO~The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair to be as still as possible over a period of 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~In peroperative, the weight of tissues removed is weighed (in grams). The removed weight is recorded in the observation notebook.~In postoperative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete."
41363809|NCT05358158|PROCEDURE|Intraoperative chest drain removal|Chest drain is removed intraoperatively.
41363810|NCT05358158|PROCEDURE|Standard chest drain placement|Chest drain is left in pleura.
41363811|NCT03216499|DRUG|HIF-2alpha Inhibitor PT2385|Given PO
40842843|NCT06263231|DRUG|INT230-6|INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.
41363812|NCT03216499|OTHER|Pharmacological Study|Correlative studies
41363813|NCT03216499|OTHER|Laboratory Biomarker Analysis|Correlative studies
40842844|NCT06263231|DRUG|Eribulin|Eribulin IV
40842845|NCT06263231|DRUG|Trabectedin|Trabectedin infusion
40842846|NCT06263231|DRUG|Pazopanib|Pazopanib pill
40842847|NCT05273541|BIOLOGICAL|Coronavirus vaccination|Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
40842848|NCT05037058|OTHER|Quality improvement activities|Quality improvement activities
40842849|NCT00708695|BEHAVIORAL|Nurse Home Visiting|Visits from nurses from mid-pregnancy to child age 2 years.
40842850|NCT04593407|PROCEDURE|Endoscopic mucosal resection (EMR)|"Endoscopic mucosal resection (EMR) is an endoscopic resection technique that allows the removal of large colorectal lesions using a conventional lift-and-cut procedure or an underwater technique"
40842851|NCT04593407|PROCEDURE|Endoscopic submucosal dissection (ESD)|"Endoscopic submucosal dissection (ESD) is an endoscopic procedure that allows dissection of larger colorectal lesions in one piece using endoknives.~The procedure is technically more difficult, much more time-consuming than EMR, mandates multiday hospital admission and has an increased risk of perforation."
41363814|NCT03216499|OTHER|Pharmacogenomic Study|Correlative studies
40842852|NCT03108508|DIETARY_SUPPLEMENT|Prod1|60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
40842853|NCT03108508|DIETARY_SUPPLEMENT|Prod2|1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
41026511|NCT05089396|OTHER|Maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
41026512|NCT03793881|BEHAVIORAL|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
41026513|NCT03793881|BEHAVIORAL|Dietary Prescription|Dietary prescription according to guidelines.
41026514|NCT04277598|BIOLOGICAL|APO-2|APO-2: dose adjusted gel for topical administration.
41026515|NCT04277598|OTHER|Placebo|Placebo gel for topical administration.
41026516|NCT02723617|OTHER|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
41026517|NCT02723617|OTHER|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
41026518|NCT02723617|OTHER|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
40842854|NCT03108508|DIETARY_SUPPLEMENT|Prod3|120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
40842855|NCT05295355|DRUG|Tiotropium Bromide Combined With Odaterol|2 puffs once daily at the same time of the day for 52 week
41026519|NCT02723617|OTHER|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
41026520|NCT03297879|DRUG|Exenatide or metformin hydrochloride|Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
41026521|NCT03739996|DRUG|Oral Cabotegravir (CAB)|30 mg tablets administered orally
41026522|NCT03739996|DRUG|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|NRTIs will not be provided by the study. Participants will obtain NRTIs outside of the study through routine care.
41026523|NCT03739996|DRUG|Long-Acting Injectable Cabotegravir (CAB LA)|600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection
41026524|NCT03739996|BIOLOGICAL|VRC07-523LS|40 mg/kg administered as an intravenous (IV) infusion
41363815|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with WVT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. WVT was used to fill the tooth when the months were January, March, May, July, September, and November.
41500216|NCT05667675|BEHAVIORAL|Control|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. For this proposal, participants in the comparator group will receive Usual care, defined as: Participants in both groups will receive a written summary of available resources.
40842856|NCT05141461|PROCEDURE|Group C|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalen area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 100 ml of NACI will be given intravenously within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
41026525|NCT03739996|DRUG|Standard of Care (SOC) Oral ART|SOC ART will not be provided by the study. Participants will obtain SOC ART outside of the study through routine care.
41026526|NCT00726531|BEHAVIORAL|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
41026527|NCT00726531|BEHAVIORAL|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
41026528|NCT00726531|OTHER|Treatment As Usual|Treatment as usual by the general practitioner
41026529|NCT06059469|DIAGNOSTIC_TEST|Ga-PSMA PET/CT|Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment
41026530|NCT03748498|DEVICE|laser|Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
41026531|NCT00217789|PROCEDURE|Bronchoalveolar Lavage and Venipuncture|
41026532|NCT02503280|DRUG|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\^8 (200 million) hMSCs.
41026533|NCT02503280|DRUG|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
41026534|NCT02503280|DRUG|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline \[PBS\] and 1% human serum albumin \[HSA\]).
40842857|NCT05141461|PROCEDURE|Group Dex|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalene area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 5 mg dexamethasone intravenously will be given in 100 ml NACI within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
40842858|NCT02136056|BEHAVIORAL|Self-management program (SMP)|A self-management course
40842859|NCT04028466|DRUG|Vonoprazan|Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
40842860|NCT04028466|DRUG|Omeprazole|Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
40842861|NCT02983994|DEVICE|TURBUHALER®|
40842862|NCT02983994|DEVICE|SPIROMAX®|
40842863|NCT06050785|DRUG|Vancomycin|ACL graft will be soaked in vancomycin versus gentamycin
40842864|NCT03793491|OTHER|TCI scale|TCI scale : Evaluation of the patient's personality with the TCI before that the treatment by continuous infusion started.
40842865|NCT03793491|OTHER|PDQ-39 scale|PDQ-39 scale: Comparison of life quality before and after the starting of he treatment by continuous infusion.
40842866|NCT04516772|DEVICE|Visian TICL|The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
40842867|NCT03680872|DEVICE|Bidirectional Neural Bypass System|These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.
40842868|NCT06298201|OTHER|E-Based Physical Exercise Intervention|The intervention comprises a 6-months home-based resistance training for the lower extremities, conducted twice weekly.
40842869|NCT03511456|PROCEDURE|PELD operation|"Under local anesthesia, the introduction of 20G needles could be performed with fluoroscopy. After the needle traveled through TFS space, extremely care was needed to avoid nerve root injury.~Discography was recommended. The following steps were performed as usual: the needle was replaced by a guide wire; a 9 mm incision was made in the skin; a tapered cannulated dilator was inserted along the guide wire; and finally a working cannula was inserted.~The remove of disc was performed carefully under endoscope. The first step was to locate the annulus fibrosis of L5/S1 disc, then by using nerve dissector and bipolar elliquence, soft tissue including fat tissue, muscle and fibers of ligaments were pushed cephalad until the blue stained herniated disc was visible and removed."
40842870|NCT05644275|OTHER|Data collection (demographic, clinical, functional and biomechanical outcomes in patients after ACL injury (conservative therapy and/or surgery) in patients of different ages and healthy controls)|Analysis of existing data from previous research projects MechSens (EKNZ 2019-01315) and RetroBRACE I and II (EKNZ 2019-00491 and EKNZ 2020-00551) as descriptive statistics (mean, standard deviation, range) for all parameters (for female or male patients with ACL injury and healthy subjects).
40842871|NCT04690244|OTHER|Tai Chi Chuan trainings|10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
40842872|NCT00224341|DEVICE|Pacemaker Vitatron Selection 9000|
40842873|NCT00224341|DEVICE|Pacemaker Vitatron T70|
41026535|NCT02503280|DEVICE|Biosense Webster MyoStar NOGA Injection Catheter System|Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug
41026536|NCT06136546|DRUG|Infliximab|Intravenous infusion of infliximab
41026537|NCT06136546|OTHER|Placebo|Intravenous infusion of saline solution (matching in color and consistency in infliximab)
41026538|NCT02766608|DRUG|BFF MDI 320/9.6 μg|Blinded Treatment
41026539|NCT02766608|DRUG|BFF MDI 160/9.6 μg|Blinded Treatment
41026540|NCT02766608|DRUG|FF MDI 9.6 μg|Blinded Treatment
41026541|NCT02766608|DRUG|BD MDI 320 μg|Blinded Treatment
41026542|NCT02766608|DRUG|Symbicort® TBH 400/12 μg BID|Open Label
41026543|NCT04504877|DRUG|Cannabidiol|Cannabidiol 300 mg daily for 4 weeks
41026544|NCT03299049|DRUG|Cabotegravir Tablets|CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.
41026545|NCT03299049|DRUG|Rilpivirine Tablets|"RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light."
41026546|NCT03299049|DRUG|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
40842874|NCT03774342|PROCEDURE|Coronary Artery Bypass Grafting|Patients undergoing coronary artery bypass grafting
40842875|NCT04159584|OTHER|Medical Music|Enrolled subjects will undergo 30 minutes of medical music listening
40842876|NCT02054884|DRUG|Arm A: F16IL2 in combination with paclitaxel|"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
41363816|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with SBT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. SBT was used to fill the tooth when the months were February, April, June, August, October, and December.
41363817|NCT05413655|DRUG|EX039|The dosage form of EX039 is the capsule for oral use
41363818|NCT05413655|DRUG|Placebo|The dosage form of Placebo is the capsule for oral use
41363819|NCT01381237|BEHAVIORAL|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
41363820|NCT01641731|OTHER|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
41363821|NCT00872586|DRUG|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
41363822|NCT00872586|DRUG|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
41363823|NCT03219996|OTHER|prognosis|The participants were divided into two groups based on survival at their hospital discharge.
41363824|NCT02354599|DRUG|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
41363825|NCT02354599|DRUG|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
40842877|NCT02054884|DRUG|Arm B: Paclitaxel|"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
40842878|NCT00520260|DRUG|bromfenac|0.09%, BID, 6 weeks
41026547|NCT03299049|DRUG|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
41363826|NCT02354599|DRUG|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
41363827|NCT05586789|DRUG|Ranquilon|Two 1 mg tablets 3 times per day for 28 days
41363828|NCT05586789|DRUG|Placebo|Two tablets 3 times per day for 28 days
41363829|NCT03900182|DEVICE|Hyperbaric Oxygen Therapy|The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
41363830|NCT03807258|OTHER|Transcranial magnetic stimulation (TMS)|Evaluations by TMS
41363831|NCT03260699|DEVICE|OCSI Rehabilitator brace|Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
41363832|NCT04951882|BIOLOGICAL|human derived umbilical cord derived mesenchymal stem cells|intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
41363833|NCT06308796|OTHER|Application of CaP dental mousse|Application of calcium phosphate (CaP) mousse on dental surfaces at home, once a day for 3 months; followed, as maintenance, once a day for just one week a month.
41363834|NCT06519903|BEHAVIORAL|BREATH technique|The BREATH techniques include deep breathing, rapid breathing, and alternate nostril breathing exercises. Participants were first instructed on the breathing exercises (at the lowest point of breathing, close the left nostril with the right index finger and exhale through the right nostril): Breathe in through the right nostril, then close it with your thumb and breathe out through the left nostril. This cycle was repeated at least three more times.
41363835|NCT02365961|DRUG|ropivicaine|
41363836|NCT02365961|DRUG|clonidine|
41500217|NCT03936712|DIETARY_SUPPLEMENT|Energy Drink|Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing ED (RB) and a caffeine and taurine free beverage drink (PL). All sessions were arranged in the early evening hours to avoid any time of day effects. The two definitive test sessions were separated by an interval of seven days to allow sufficient recovery between tests and to ensure caffeine washout. To avoid identification, two opaque and unmarked cans of RB or PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks were similar in volume, texture, and appearance. One can of RB drink (i.e., 250ml) contained 80 mg of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg vitamin B6 and 487 kJ of energy.
40842879|NCT00520260|DRUG|ketorolac|0.4%, BID, 6 weeks
40842880|NCT04851756|DEVICE|CRet|In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min F.M with CRet on capacitive mode (180-250VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (110-140W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (180-250VA) on the mentioned area. A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes.
41026548|NCT00512135|DRUG|IncobotulinumtoxinA (Xeomin) (20 units)|Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
41026549|NCT02774109|DIETARY_SUPPLEMENT|Fish oil|Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
41363837|NCT02365961|DRUG|Epinephrine|
41363838|NCT02365961|DRUG|Noropin|
41363839|NCT03868059|DRUG|LPCN 1021|LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
41363840|NCT01453296|DRUG|GW642444|GW642444 25 μg; Novel dry powder inhaler
41363841|NCT01453296|DRUG|Placebo|Matching placebo; Novel dry powder inhaler
41363842|NCT00034476|DRUG|sPLA2 Inhibitor|
41500218|NCT03936712|DIETARY_SUPPLEMENT|Placebo Drink|The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine, but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate (1 %), supplemented by flavorings, of sodium citrate, acesulfame K, sucralose, potassium sorbate and RB (a flavoring that contains propylene glycol E1520 (0.23 mL).
41500219|NCT04780568|DRUG|Osimertinib|Given PO
41500220|NCT04780568|DRUG|Tegavivint|Given IV
41500221|NCT03171974|DRUG|Dexamethasone|dexamethasone will be injected intracapsular under US
41500222|NCT03171974|DEVICE|US|dexamethasone will be injected intracapsular under US
41026550|NCT02774109|DIETARY_SUPPLEMENT|Placebo|Five 1000mg sunflower oil soft capsules per day for 8 weeks
41266841|NCT05706935|DIAGNOSTIC_TEST|MeMed BV® test|The MeMed BV® test is an automated semiquantitative immunoassay that measures three nonmicrobial (host) proteins (TRAIL, IP-10, and CRP) in serum samples and is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection.
41363843|NCT04945291|BEHAVIORAL|New way of counting calories using the hands|The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
41363844|NCT04945291|BEHAVIORAL|Mobile applications|the participant will use a mobile application to log their calories
41500223|NCT03452878|BEHAVIORAL|Aggressive behavior|Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
41500224|NCT02621749|DEVICE|Renal replacement therapy|Patients receive renal replacement therapy according to institutional standards
41500225|NCT03994783|DRUG|Rituximab|2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.
41500226|NCT03994783|DRUG|Methylprednisolone|Intravenous infusion of methylprednisolone
41500227|NCT03994783|DRUG|Intravenous Immunoglobulin|High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
41026551|NCT02774109|PROCEDURE|Hotpacking|Hotpacking 15min on low back, three times a week for 8 weeks
41026552|NCT02774109|PROCEDURE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
41363845|NCT02107781|DEVICE|AbViser abdominal compartment pressure measuring device|AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
41026553|NCT04498650|DRUG|PQ912|PQ912 50 mg tablets and 150 mg tablets
41026554|NCT04498650|DRUG|Placebo|Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
41266842|NCT00664248|DRUG|IDP-110|Topical application for 12 weeks
41266843|NCT00664248|DRUG|Clindamycin|Topical application for 12 weeks
41266844|NCT00664248|DRUG|Benzoyl peroxide|Topical application for 12 weeks
41266845|NCT00664248|DRUG|Vehicle|Topical application for 12 weeks
41266846|NCT04566367|DIAGNOSTIC_TEST|blue laser imaging|The intervention is the push on demand activation of blue laser imaging technique during gastroscopy.
41266847|NCT06427551|DRUG|Ropivacaine|The local anesthetic was dosed on the patient's weight (50-59kg: 120mg, 60-61kg: 140mg, 70-79kg: 160mg, ≥80kg: 180mg)
41266848|NCT04878367|BEHAVIORAL|Five active practices of living rules for responding to fine dust.|"1. Check the fine dust weather forecast~2. Check the operation time and filter of the air purifier~3. Window ventilation~4. Inhalant is used or not~5. Bad fine dust: Refrain from going out"
41266849|NCT02780076|OTHER|Functional training program|Patients treated for hip fracture participate in a functional training program during their short-term stays at nursing homes. The program is initiated by the nurses 4 times a day for 3 weeks as part of the habitual routine.
41266850|NCT02194153|DRUG|Metalyse weight-adjusted|
41266851|NCT04544722|BEHAVIORAL|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
41363846|NCT04678089|DRUG|Bortezomib|Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
41363847|NCT01444638|DEVICE|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
41363848|NCT00169273|BEHAVIORAL|Structured behavioral weight loss group|Structured group weight loss program
41363849|NCT00169273|BEHAVIORAL|Weight loss and cognitive-behavioral depression group|Structured group program for weight loss and depression
41363850|NCT03661281|DIAGNOSTIC_TEST|Jebsen Taylor Hand function test|consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
41363851|NCT03661281|DIAGNOSTIC_TEST|Pinch strength|Measured in every splint position using a standard dynamometer
41363852|NCT03661281|DIAGNOSTIC_TEST|Grooved pegboard test|Time will be measured and compared between control, MP splint and IP splint
41363853|NCT03514160|BEHAVIORAL|Group exercise|Group exercise based on the American College of Sports Medicine guidelines.
41363854|NCT05463146|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
40842881|NCT04851756|DEVICE|Sham CRet|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (0W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (0VA) on the mentioned area.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes."
41363855|NCT05463146|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
41363856|NCT05463146|OTHER|Deep breathing exercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
41363857|NCT02224261|OTHER|Physical Therapy protocol|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords, and patient education."
41500228|NCT03994783|PROCEDURE|Plasma Exchange|Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.
41500229|NCT05938907|OTHER|concentrated growth factor|Implanting concentrated growth factor into the area of root apical bone defect
40842882|NCT04797962|BEHAVIORAL|Case management|dedicated case management to address social support needs
40842883|NCT04383938|DRUG|APR-246 (eprenetapopt) + Pembrolizumab|APR-246 D1-4 + Pembrolizumab D3
40842884|NCT00267150|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
40842885|NCT02951429|DRUG|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
40842886|NCT02951429|DRUG|Placebo|Placebo matched with sildenafil.
40842887|NCT02951429|DRUG|Sildenafil|Sildenafil will be given as 20 mg, TID.
40842888|NCT06075966|OTHER|Non-fusion group|Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
40842889|NCT06075966|OTHER|Fusion group|Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University
40842890|NCT02257203|BEHAVIORAL|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
40842891|NCT02257203|BEHAVIORAL|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
40842892|NCT06050616|OTHER|MRI scans|"Neuroimaging data will be collected with magnetic resonance imaging (MRI).~Structural neuroimaging will include T1 and T2-weighted scans, and diffusion tensor imaging (DTI).~Functional neuroimaging will include scans under the stop-signal task, monetary incentive delay task, and emotional faces task, and resting state."
40842893|NCT06050616|OTHER|Psychological measures|"Cognitive performance assessed by Wechsler Adult Intelligence Scale 4th Edition.~Personalities assessed by NEO Five-Factor Inventory (NEO-FFI), Substance Use Risk Profile Scale (SURPS), and Temperament and Character Inventory (TCI).~Other psychological assessments include Interpersonal Reactivity Index, Perceived Stress Scale, Kirby Monetary Choice Questionnaire, Passive Avoidance Learning Paradigm, and Stimulus-response compatibility."
40842894|NCT06050616|OTHER|Life experiences|Self-report questionnaires on experiences of bullying and trauma.
41363858|NCT02224261|OTHER|Control|Control protocol includes standard progressive active and action-assisted arm exercises \& patient education.
41363859|NCT01566747|DRUG|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
41363860|NCT04885166|OTHER|Web-based placebo presentation|This presentation will discuss the prevalence of psychological disorders in college students, their etiologies, psychiatric medications, and students' personal experiences navigating college with a diagnosis of an anxiety and learning disorder, respectively. Attention-deficit/hyperactivity disorder and stimulant medications will be addressed, but diversion and medication misuse will not be discussed.
41363861|NCT04885166|BEHAVIORAL|Web-based simulation active intervention|This intervention engages students in interactive discussions with virtual humans to (a) learn about the actual prevalence of NMUPS and diversion and their related risks, (b) practice using refusal strategies when approached for their medication in high-risk situations, and (c) understand how to effectively communicate with prescribers and avoid medication misuse.
41363862|NCT00374920|DRUG|MEM 1003|
41363863|NCT03249259|DRUG|Choline alfoscerate|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
41363864|NCT03249259|DRUG|Placebo|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
41363865|NCT00405665|DRUG|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
41363866|NCT00405665|DRUG|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
41363867|NCT03944096|PROCEDURE|FMT+MTX|FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
41363868|NCT03470272|DEVICE|FB Professional LED Red light therapy|FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs. Measure before and after effects of device unit. Three measurements before of circumference of abdomen area and three measurements after comparing the results.
41500230|NCT05938907|OTHER|bone substitute|Implanting bone substitute into the area of root apical bone defect
41500231|NCT05938907|COMBINATION_PRODUCT|concentrated growth factor + bone substitute|Implanting concentrated growth factor + bone substitute into the area of root apical bone defect
41500232|NCT05945732|DRUG|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~Trastuzumab (T-DXd) to be administered according to the SmPC.~Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC."
41500233|NCT06266650|OTHER|Osteopathic Treatment Technique- Muscle Energy Treatment|Muscle Energy Treatment involves a patient actively using their muscles on request from a precisely controlled position, in a specific direction, against a distinctly executed counter force. During Muscle Energy Treatment, the physician positions the area of treatment into a position of resistance, which is the restrictive barrier. The physician then instructs the patient to use the targeted muscles for 3-5 seconds in the direction of ease while the physician provides a counterforce. The physician then tells the patient to stop contracting their muscles and evaluate the area for decreased tension, then repositions the patient into their new restrictive barrier. These steps are repeated three to five times and then the dysfunction is reevaluated.
40842895|NCT06050616|BIOLOGICAL|Blood and urine samples|Blood and urine samples will be collected but will not undergo analysis in this study. Instead, these samples will be stored in a biobank for potential analysis in future research.
40842896|NCT06050616|OTHER|Mental health symptoms|"Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview."
40842897|NCT02603848|DRUG|Ibuprofen|(10mg/kg; maximum 600 mg) every six hours as needed
40842898|NCT02603848|DRUG|Morphine|0.2 mg/ kg morphine suspension (maximum 10mg) every four hours as needed
41363869|NCT03470272|DEVICE|Effects of Red Light LED Therapy on Body Contouring|Intervention is to take a sample and measure before and after using a sham unit (placebo) and take three measurements of abdominal before treatment and three measurements after sham treatment and compare to controlled treatment.
41363870|NCT05947981|DIETARY_SUPPLEMENT|Dextrose 5%, normal saline|Decrease fasting hours
40842899|NCT04465812|BEHAVIORAL|Self-monitoring and personalized feedback on smartphone app|"1. Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~2. Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index \> 15 to assess detail clinical status and recommend outpatient visit if necessary;~3. Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS\>49 or SDS\>52 to assess detail clinical status and recommend outpatient visit if necessary;~4. Patients will complete cognitive training games every week on app;~5. Medical staff will send health information on app"
40842900|NCT00892138|BEHAVIORAL|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
41026555|NCT03793192|OTHER|PACE2 Intervention|Written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
41026556|NCT06321718|PROCEDURE|PENG + LFCN block versus S-FICB|1. Group (A) will receive PENG + LFCN block:
41363871|NCT04393961|DEVICE|Premier Biotech COVID-19 IgG/IgM Rapid test Cassette|"Current emergency situation, there are large numbers of COVID-19 Antibody tests being made available at a record pace.~The protocol is designed to be test agnostic. However, for this first volley, we have chosen the The COVID-19 IgG and IgM Rapid Test provided by Premier Biotech.~We chose the Precision Bio test for 4 reasons~1. It is available as a single use test kit in one sealed unit.~2. It's a rapid test, with results available in 10 minutes.~3. It has clear and easy to read instructions already included~4. It has one of the lowest false positive rates of known tests at the moment"
41363872|NCT01716299|OTHER|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
41363873|NCT01716299|OTHER|application of a confirmation test|use of rapid confirmation test
41363874|NCT04322552|DRUG|Apatinib Mesylate|Apatinib at a dosage of will be administered daily from on D5 through D16
41363875|NCT04322552|DRUG|Digoxin tablet|Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12
41363876|NCT02274363|OTHER|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
41363877|NCT02662075|DEVICE|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
41363878|NCT03259607|DRUG|Nicorette Extra Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
41363879|NCT03259607|DRUG|Nicorette Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
41363880|NCT03259607|DRUG|Nicorette Extra Mint 4mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
41363881|NCT03259607|DRUG|Nicorette Mint 4 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
41363882|NCT01855919|DRUG|Duloxetine|Administered orally
41363883|NCT01855919|DRUG|Placebo|Administered orally
41500234|NCT06588257|BIOLOGICAL|Non-infectious adjuvanted recombinant nonavalent HPV vaccine|Non-infectious adjuvanted recombinant nonavalent HPV vaccine. Three doses (0, 2, 6 months). (Trade name GARDASIL 9 -MSD).
41363884|NCT04959162|DEVICE|E-learning|Development of theoretical knowledge using a E-learning platform before attending a hands-on course in musculoskeletal ultrasound
41363885|NCT04959162|DEVICE|Conventional preparation|Attending a hands-on course in musculoskeletal ultrasound with no preparation before course start
41363886|NCT02590211|BEHAVIORAL|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
41363887|NCT05657379|OTHER|Other: Product X moisturizer|Product X moisturizer containing Hyaluronic Acid and Rosa Damascena Flower Water
41363888|NCT01582932|DRUG|Calcipotriene 0.005% Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
41363889|NCT03672474|DEVICE|Photobiomodulation REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
41363890|NCT03672474|DEVICE|SHAM REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
41363891|NCT05336877|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention is required in this study.
41363892|NCT05336877|DEVICE|Single-Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber transvenous pacemaker as a comparator to the Aveir VR LP system study arm. No device intervention is required in this study.
41363893|NCT04977778|DRUG|Fatty Acids Compounds (F.A.G.) Mouthwash|Fatty Acids Compounds (F.A.G.) Mouthwash
41363894|NCT04977778|DRUG|Stannous Fluoride (SF) Mouthwash|Stannous Fluoride (SF) Mouthwash
41363895|NCT03815006|DEVICE|Free Style Libre 2|FreeStyle Libre 2 (FSL2) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days and a hand-held reader which is designed to largely replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of type 1 diabetes (T1D).
41363896|NCT00957736|GENETIC|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
41363897|NCT00957736|OTHER|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
41363898|NCT04102124|DRUG|SHR3680|Tablet. Specifications of 80mg
41363899|NCT04102124|DRUG|SHR3162|Tablet. Specifications of 10mg、40mg、50mg and 100mg
41363900|NCT04102124|DRUG|SHR3680(Placebo)|Tablet. Specifications of 80mg
41363901|NCT04102124|DRUG|SHR3162(Placebo)|Tablet. Specifications of 10mg、40mg、50mg and 100mg
40842901|NCT02706379|OTHER|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
40842902|NCT00931801|DRUG|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
40842903|NCT00931801|DRUG|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
40842904|NCT00931801|DRUG|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
40842905|NCT04228432|OTHER|Dedicated and coordinated monitoring|"* Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~* Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6."
40842906|NCT03040115|OTHER|Non-Interventional Study|
40842907|NCT02136147|DRUG|methylphenidate medication|
41500235|NCT02609776|DRUG|Amivantamab|The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
41266852|NCT04544722|BEHAVIORAL|lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
41266853|NCT01750814|BIOLOGICAL|GC3102C|a single dose (0.5 mL) intramuscularly on the deltoid muscle
41266854|NCT01750814|BIOLOGICAL|GC FLU inj.|a single dose (0.5 mL) intramuscularly on the deltoid muscle
40842908|NCT02136147|DRUG|atomoxetine medication|
40842909|NCT02136147|DRUG|lisdexamphetamine medication|
40842910|NCT02136147|DRUG|guanfacine medication|
40842911|NCT04827303|OTHER|Kinesio taping|A 10-15 cm sized I band was applied to the trapezius muscles of the first group patients with the patient's neck in lateral flexion. Then, while the patient's neck is flexed, a Y-shaped 15-20 cm tape will be affixed between C1-7 with the arms of the Y up, and I tape of 5-10 cm is attached on the arms. In group 2 patients, 1 cc lidocaine diluted with 4 cc saline (SF) was applied to the trigger points palpated manually in the trapezius muscles. After the trigger point was squeezed between the thumb and index finger, a few cc of local anesthetic mixture was applied into the trigger point with the injector and exited. In the 3rd group patients, a few cc local anesthetic mixture will be applied intradermally over the trigger point without entering into the trigger points palpated manually in the trapezius muscles. Patients were checked 72 hours and 1 week after the first applications.
40842912|NCT01150968|BEHAVIORAL|End of life education|Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
40842913|NCT03175146|RADIATION|Stereotactic Body Radiation Therapy|5 treatments given over 2 weeks
41266855|NCT05378009|BEHAVIORAL|relaxation and physical activity|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)
41266856|NCT05378009|BEHAVIORAL|relaxation|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)
41266857|NCT02917460|GENETIC|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
41363902|NCT00952146|PROCEDURE|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
41363903|NCT02308839|DEVICE|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
41363904|NCT04220645|OTHER|Opportunstic treatment|opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
41363905|NCT04220645|OTHER|Standard of care|Referral at discharge
41363906|NCT00044811|DRUG|Fexofenadine|
41363907|NCT03902158|DEVICE|Glasses|The patient will wear virtual reality glasses during anesthesia
41363908|NCT03902158|BEHAVIORAL|Distraction techniques|The patient will undergo distraction techniques
40842914|NCT05282420|PROCEDURE|intravitreal injection of Ranibizumab|intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)
40842915|NCT05282420|PROCEDURE|intravitreal injection of Aflipercept|intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)
40842916|NCT05282420|DRUG|Ranibizumab|Ranibizumab
40842917|NCT05282420|DRUG|Aflibercept|Aflipercept
40842918|NCT01090063|DRUG|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
40842919|NCT00057369|DRUG|dalbavancin|
40842920|NCT04161755|DRUG|Atezolizumab|Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
40842921|NCT04161755|BIOLOGICAL|RO7198457|RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
40842922|NCT04161755|DRUG|mFOLFIRINOX|mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
40842923|NCT02925728|OTHER|Finger-Food|Finger-Food at lunch and having diner
40842924|NCT02925728|OTHER|Without Finger-Food|Without finger-food
40842925|NCT00667667|DEVICE|vertical vibration device (Vibrafit whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
40842926|NCT00667667|DEVICE|side alternating vibration device (Board 3000 whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device
40842927|NCT00667667|BEHAVIORAL|stretching and wellness (control group)|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
40842928|NCT02795325|DRUG|DCR-PH1|IV infusion of DCR-PH1
40842929|NCT02795325|OTHER|Placebo|
40842930|NCT00006026|DRUG|rubitecan|
40842931|NCT00127309|DRUG|Glutathione|
40842932|NCT03067376|DRUG|[14C]-CORT125134|
41363909|NCT01354834|DRUG|hMG|Patients with a condition
41363910|NCT01914289|PROCEDURE|Resection|
41363911|NCT01914289|RADIATION|Radiotherapy|
40842933|NCT01614171|BIOLOGICAL|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
40842934|NCT05329870|OTHER|SNP array|SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT
40842935|NCT01266317|DRUG|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
40842936|NCT04794881|OTHER|24 hours|Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture
40842937|NCT04794881|OTHER|48 hours|Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
40842938|NCT05060965|DRUG|Nicotine lozenge|Nicotine replacement therapy
40842939|NCT05060965|DRUG|Nicotine gum|Nicotine replacement therapy
40842940|NCT05060965|DRUG|Nicotine patch|Nicotine replacement therapy
40842941|NCT05060965|OTHER|Maryland Quitline|Telephone-based tobacco cessation service
40842942|NCT05060965|OTHER|John Hopkins Tobacco Treatment Clinic|Clinic-based tobacco cessation service
40842943|NCT01443832|DIETARY_SUPPLEMENT|Fe57 and Fe58-FeSO4 stable isotopes|\[57Fe\] and \[58Fe\]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
40842944|NCT06106763|OTHER|Mandala coloring|Mandala coloring page
40842945|NCT06259890|OTHER|measurement of salt intake|measurement of salt intake without intervention
40842946|NCT05462639|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
40842947|NCT02841241|DRUG|Esmolol|Esmolol infusion
40842948|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
41026557|NCT04600648|DIAGNOSTIC_TEST|Serum insulin level|Measure levels before and after weight loss related to bariatric surgery
41026558|NCT04600648|DIAGNOSTIC_TEST|Serum Leptin test|Measure levels before and after weight loss related to lifestyle change weight loss
41026559|NCT04448184|DRUG|Tranexamic Acid|"Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously."
41363912|NCT04993183|BEHAVIORAL|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.
41363913|NCT01976403|BEHAVIORAL|Pain Booklet|The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
41363914|NCT06058572|DRUG|Rifaximin with allogeneic stem cell transplant|Tab Rifaximin 200 mg will begiven orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care posttransplant treatment
41363915|NCT06058572|PROCEDURE|Allogeneic stem cell transplant|Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.
41363916|NCT02053415|DIETARY_SUPPLEMENT|Krill oil low dose|3 capsules krill oil per day
41363917|NCT02053415|DIETARY_SUPPLEMENT|Krill oil high dose|9 capsules krill oil per day
41363918|NCT05617417|OTHER|Local applied injectable platelet-rich fibrin in women with stress urinary incontinence|Injectable platelet-rich fibrin was prepared by centrifuging venous blood taken from women with stress urinary incontinence and applied locally to the anterior vaginal wall of the patients.
41363919|NCT01080157|DEVICE|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
41363920|NCT04761835|BIOLOGICAL|Peanut powder or peanut butter|Commercially available peanut powder or peanut butter.
41363921|NCT01383317|DEVICE|Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)|Disposable sterile thigh tourniquet
41363922|NCT01383317|DEVICE|Sham RIPC|Disposable sterile thigh tourniquet
41363923|NCT02101866|DRUG|Vapendavir 300 mg tablet|tablet - single dose
41363924|NCT02101866|DRUG|Vapendavir 132 mg capsules|2 capsules - single dose
41363925|NCT04454632|OTHER|Mirror therapy|affected arm stay behind the mirror while exercising
41363926|NCT04454632|OTHER|Visual feedback|visual feedback from mirror
41363927|NCT04344431|COMBINATION_PRODUCT|Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)|One session per day of HBOT in addition to the standard treatment with normobaric oxygen
41363928|NCT04946721|DIAGNOSTIC_TEST|The standard care exam and biological specimens' collection|During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.
41363929|NCT03331939|OTHER|no stimulation|Vagal nerve stimulator will be set to no stimulation
41363930|NCT03331939|OTHER|beta (25-30 Hz)|Vagal nerve stimulator will be set to beta (25-30 Hz)
41363931|NCT03331939|OTHER|Theta (5 Hz)|Vagal nerve stimulator will be set to beta (5 Hz)
41363932|NCT03492242|DRUG|Immune checkpoint inhibitor|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
41363933|NCT03017131|BIOLOGICAL|Aldesleukin|Given SC
40842949|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
41363934|NCT03017131|DRUG|Cyclophosphamide|Given IV
41363935|NCT03017131|DRUG|Decitabine|Given IV
41363936|NCT03017131|BIOLOGICAL|Genetically Engineered NY-ESO-1-specific T Lymphocytes|Given IV and IP
41363937|NCT03017131|OTHER|Laboratory Biomarker Analysis|Correlative studies
41363938|NCT04677816|DRUG|Standard of Care Neoadjuvant Chemotherapy (NAC)|"Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician."
41363939|NCT04677816|DIETARY_SUPPLEMENT|Vitamin D3|Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.
41363940|NCT04677816|OTHER|Drug Diary|Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.
40842950|NCT03385330|OTHER|LOWER oxygen saturation target group|We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
40842951|NCT03385330|OTHER|HIGHER oxygen saturation target group|We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
41363941|NCT03324282|DRUG|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
41363942|NCT03324282|DRUG|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
41363943|NCT04630067|DRUG|AZD3427|Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
41363944|NCT04630067|DRUG|Placebo|Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.
41363945|NCT01922336|BIOLOGICAL|SB2|IV infusion
41363946|NCT01922336|BIOLOGICAL|EU Remicade|IV infusion
41363947|NCT01922336|BIOLOGICAL|US Remicade|IV infusion
41363948|NCT01454895|BEHAVIORAL|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
41500236|NCT02609776|DRUG|Amivantamab|Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
41363949|NCT01454895|BEHAVIORAL|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
41363950|NCT01454895|BEHAVIORAL|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
41363951|NCT02649673|DRUG|LCL161|
41363952|NCT02649673|DRUG|Topotecan|Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.
41363953|NCT02649673|DRUG|Pegylated GCSF (PEG-GCSF)|Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
41363954|NCT05078476|OTHER|Manchester Short Splint|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
41363955|NCT05078476|OTHER|Relative Motion Flexion|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
41363956|NCT04824092|DRUG|Tafasitamab|Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.
41363957|NCT04824092|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
41363958|NCT04824092|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
41363959|NCT04824092|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
41363960|NCT04824092|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
41363961|NCT04824092|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
41363962|NCT04824092|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
41363963|NCT04824092|DRUG|Tafasitamab placebo|0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
41363964|NCT04824092|DRUG|Lenalidomide placebo|Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
41363965|NCT06066242|OTHER|Different induction chemotherapy regimens|azacitidine combined with venetoclax or chemotherapy with or without venetoclax
41363966|NCT00000912|DRUG|Indinavir sulfate|
41363967|NCT00000912|DRUG|Abacavir sulfate|
41363968|NCT00000912|DRUG|Amprenavir|
41363969|NCT00000912|DRUG|Nelfinavir mesylate|
41363970|NCT00000912|DRUG|Efavirenz|
40842952|NCT03335254|DRUG|TSX-011|TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
41266858|NCT04335799|BEHAVIORAL|Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training|12-month evidence based weight loss intervention with additional training on stress management strategies
41266859|NCT04335799|BEHAVIORAL|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics|12-month evidence based weight loss intervention with an attention control of general women's health topics
41363971|NCT00000912|DRUG|Levocarnitine|
40842953|NCT01477112|DIETARY_SUPPLEMENT|Betacarotene|6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation
41363972|NCT00000912|DRUG|Adefovir dipivoxil|
41363973|NCT00000912|DRUG|Saquinavir|
41363974|NCT02488564|DRUG|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
40842954|NCT01477112|DIETARY_SUPPLEMENT|Controls. No treatment|Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
40842955|NCT02128074|DRUG|KRX-0502|1g tablets of KRX-0502
41266860|NCT00355316|OTHER|Blood draw|
41266861|NCT05025215|BEHAVIORAL|Precise Aerosol Inhalation Nursing Program|The precise aerosol inhalation nursing program was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc.
41363975|NCT02488564|DRUG|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
41363976|NCT02488564|DRUG|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
41363977|NCT02488564|DRUG|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
41363978|NCT02785094|BEHAVIORAL|Observation|Observation of Participants' behaviour
41363979|NCT05647746|DEVICE|Compumedics Somfit HSAT device, WatchPAT HSAT device, Compumedics Grael /E-series PSG system|Each intervention is a separate diagnostic device. They will all be operating at the same time
41363980|NCT05440227|DRUG|PG2 Lyo. Injection 500mg|PG2 Lyo. Injection 500mg (reconstituted with 0.9% normal saline 500ml) will be administered weekly for 8 weeks.
41363981|NCT05440227|DRUG|Placebo 0.9% normal saline|0.9% normal saline 500ml will be administered weekly for 8 weeks.
41363982|NCT06400420|OTHER|Exercise|classic futsal training program
41363983|NCT03188458|OTHER|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 \[approximately 4-8 weeks of age\]).
41363984|NCT00848965|DRUG|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
41363985|NCT00848965|DRUG|Placebo|Placebo comparator
41363986|NCT04535921|OTHER|FCR7 questionnaire|A 7 item questionnaire about fear of cancer recurrence
41363987|NCT05451693|BEHAVIORAL|Outreach-ER|The intervention is similar to other care intervention/support programs such as REACH or New York University Caregiver Intervention (NYCUI). The Intervention is designed to be delivered over phone/virtual and in-home and will be conducted by Amplio, LLC consultants.
41363988|NCT05177666|DRUG|Targeted therapy|Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.
41363989|NCT00629135|DRUG|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
41363990|NCT04099329|BEHAVIORAL|Pre-game Safety Huddles|Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
41363991|NCT04112862|OTHER|sodiumlactate|intravenous sodiumlactate 600mmol/L
41363992|NCT01408953|BIOLOGICAL|bevacizumab|"Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.~A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient."
41363993|NCT05398341|DEVICE|The BEAR® Implant|"The BEAR Implant is a bovine collagen-based implant. The bovine tissue is sourced from countries that are free of bovine spongiform encephalopathy \[BSE\] and is further treated to remove bovine cell fragments and DNA.~The BEAR® (Bridge Enhanced ACL Restoration) Implant is a bovine extracellular matrix collagen-based implant for treatment of anterior cruciate ligament (ACL) injuries. The BEAR® Implant is indicated for skeletally mature subjects at least 14 years of age with a complete rupture of the ACL. Subjects must have an ACL stump attached to the tibia to construct the repair."
41500237|NCT02609776|DRUG|Lazertinib|Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
40842956|NCT02700594|OTHER|Joint mobilization|"Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings."
40842957|NCT02312778|OTHER|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
40842958|NCT00016991|DRUG|gefitinib|
40842959|NCT00909740|DRUG|MEGF0444A|Intravenous escalating dose
41500238|NCT02609776|DRUG|Carboplatin|Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
41500239|NCT02609776|DRUG|Pemetrexed|Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
41500240|NCT00025012|DRUG|isotretinoin|
41500241|NCT06633185|DRUG|phenytoin cream|application of the cream after internal anal sphincterotomy versus non application.
40842960|NCT03305393|DEVICE|Adaptiv CRT|Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
40842961|NCT02794545|PROCEDURE|cART course|The investigators would start regular cART course immediately for early infection patients to achieve functional cure.
40842962|NCT05539209|BEHAVIORAL|OKquit|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys plus OKquit Smartphone App including tailored messages and on-demand content designed to assist participants in their cessation attempt.
40842963|NCT05539209|BEHAVIORAL|Standard Helpline Care|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys.
40842964|NCT00556270|DRUG|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
40842965|NCT03002714|OTHER|Exercise|
41026560|NCT02811237|OTHER|HESTIA|"Management based on the HESTIA rule:~* If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
41026561|NCT02811237|OTHER|sPESI|"Management based on the simplified PESI score:~* If the sPESI score =0, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
41363994|NCT04212221|DRUG|MGD013 monotherapy|MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.
41363995|NCT04212221|DRUG|MGD013 in combination with Brivanib Alaninate|After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
41363996|NCT02837874|PROCEDURE|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
41363997|NCT02837874|PROCEDURE|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
41500242|NCT06633185|DRUG|no phenytoin cream|Non application of the phenytoin cream
41500243|NCT03196635|DEVICE|Patient-Assisted (PA) Breast Compression|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views CC \& MLO.
40842966|NCT04793334|PROCEDURE|sleeve gastectomy|routine sleeve gastrectomy
40842967|NCT00175409|PROCEDURE|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
40842968|NCT00175409|PROCEDURE|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
40842969|NCT02116998|BIOLOGICAL|GEN-004 with Aluminum Hydroxide Adjuvant|"GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~* GB104: ABC transporter, substrate-binding protein~* GB144: Maltose/maltodextrin binding protein, ABC transporter~* GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL."
40842970|NCT02116998|BIOLOGICAL|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
40842971|NCT02116998|BIOLOGICAL|Streptococcus pneumoniae inoculation|Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
40842972|NCT03470753|OTHER|Number of Exercises|Subjects will receive either 2 or 4 exercises to evaluate the short-term recall and performance.
40842973|NCT03470753|OTHER|Type of Instruction|The type of instruction in phase 1 will be compared: Instruction by providing a handout only vs being instructed by a provider and practiced by the patient with provider feedback.
41026562|NCT03125668|BEHAVIORAL|Educational Program|At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.
40842974|NCT03470753|OTHER|Delivery Type|In phase 2 subjects will be provided 4 exercises using only a handout vs delivered to them electronically with the addition of a video.
40842975|NCT03470753|OTHER|Mobile Reminder|A text-message based mobile reminder tool will be utilized to engage with subjects via texting on a daily basis to provide reminders and encouragement to perform their home exercises.
41161030|NCT05964556|OTHER|Functional Movement Screen (FMS)|FMS is an analysis system that evaluates muscle strength imbalance and functional performances on the dominant-non-dominant side in athletes. It aims to detect stability and mobility that can be ignored in the asymptomatic active population and athletes. It consists of 7 basic parameters determined by Gray Cook (Deep Squat, Hurdle Step, -In-line Lunge, Shoulder Mobility, Active Straight Leg Raise, Trunk Stability, Rotatory Stability). The athletes were evaluated after giving verbal instructions to the athletes about the head, trunk, knee and foot positions. For each parameter, the athletes were given points between 0-3 values. The total score was determined as 21 points. Completing the movement completely and without compensation was given 3 points, and 2 or 1 points were given according to the activation of the compensation mechanism and balance disorders. In case of any pain during or at the end of the movement in the evaluated parameter, 0 points were given to the athletes.
41363998|NCT03153436|BIOLOGICAL|Myoinositol|
41363999|NCT04647006|PROCEDURE|thyroid|Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
41364000|NCT01997827|DEVICE|metal-ceramic RBFDP|Rehabilitation of tooth loss with a metal-ceramic RBFDP
41364001|NCT01997827|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
41500244|NCT03196635|DEVICE|Technologist-Controlled (TC) Breast Compression|TC compression will be conducted per standard of care practices at the site.
41500245|NCT05618028|DRUG|ABBV-525|Oral; Tablet
40842976|NCT05993962|DIETARY_SUPPLEMENT|Fortified yoghurt|Food-grade vitamin B12 in the form of methylcobalamin (purity: 99%) was used for fortification. Yoghurts were Greek-style and locally produced by a yoghurt company in British Columbia, Canada. The pre-measured vitamin B12 was added into yoghurt vats in amounts that corresponded to the chosen dosage (50 µg of B12 per 150 g). The yoghurt was packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
40842977|NCT05993962|OTHER|Control yoghurt|Yoghurts were locally produced by a yoghurt company in British Columbia, Canada. Yoghurts produced were Greek-style and packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
40842978|NCT05505526|OTHER|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
40842979|NCT05505526|OTHER|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
40842980|NCT04699877|DRUG|Gilteritinib|Oral
40842981|NCT05760404|PROCEDURE|Surgery for colorectal cancer|Patients undergoing upfront surgery or surgery after neoadjuvant therapy for colorectal cancer with curative intention
40842982|NCT05760404|OTHER|in vitro study|on tissues from colorectal resections
40842983|NCT03931694|DEVICE|e-DOL|e-health program (smartphone and web platform)
40842984|NCT04293367|OTHER|High Intensity Interval Training (HIIT)|"HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery)."
40842985|NCT02551419|DIETARY_SUPPLEMENT|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
40842986|NCT02551419|DIETARY_SUPPLEMENT|placebo|6 months' supplementation with the placebo drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
40842987|NCT04356040|DEVICE|TactiFlex SE|Radiofrequency ablation with the TactiFlex SE ablation catheter. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.
40842988|NCT04356040|DEVICE|TactiFlex SE - High Standard Power|Radiofrequency ablation with the TactiFlex SE ablation catheter. Subjects in the High Standard Power Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.
40842989|NCT04056780|OTHER|Sample collection study|Sample collection and collection of laboratory values
40842990|NCT00357825|DRUG|[S,S]-Reboxetine|
41364002|NCT03957629|DRUG|Tenofovir Disoproxil Fumarate|Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.
41364003|NCT03957629|DRUG|PEG-Interferon alfa 2a|Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
41364004|NCT01404884|PROCEDURE|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
41364005|NCT04151420|OTHER|Remote monitoring tool (infections questionnaire) validation|"There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD.~Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies."
41364006|NCT01251666|OTHER|Colonoscopy|Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
41364007|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
41364008|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
41364009|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
41364010|NCT04717310|DRUG|Vehicle|Twice a day (BID)
41364011|NCT04430140|DEVICE|CT Scan|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)\*: 0.6"
41364012|NCT02546102|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
41364013|NCT02546102|BIOLOGICAL|Placebo|Control, autologous monocytes-enriched PBMC.
41364014|NCT04913584|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
41364015|NCT00477542|DRUG|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"
41364016|NCT05647889|DRUG|Jet lidocaine|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
41364017|NCT05647889|COMBINATION_PRODUCT|Ice|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
41364018|NCT05647889|OTHER|Standard PVC procedure|Standard PVC procedure will be applied
40842991|NCT00046553|DRUG|RU-486 (Mifepristone)|
40842992|NCT06150794|DEVICE|Excimer laser|Excimer laser will be started at a dose of 300 mj/cm2 and increases 50-100 mj/cm2 each session. The aim of treatment is to deliver a dose that induces visible redness in the psoriatic lesion (supra-erythematous dose), but not induce a blister.
41500246|NCT04423887|OTHER|Lower Extremity Resistance Exercise Training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
41500247|NCT04423887|OTHER|Home Exercise Plan|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
41500248|NCT04423887|DEVICE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
40842993|NCT06150794|DRUG|Methotrexate Injection|A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit, followed by a 2.5-mg intramatrical methotrexate injection into each side of the nail at a point 2.5 mm proximal and lateral to the junction of proximal and lateral nail folds.
41266862|NCT05025215|BEHAVIORAL|Traditional Aerosol Inhalation Nursing Method|The traditional aerosol inhalation nursing method is carried out according to the operation of aerosol inhalation.
41500249|NCT04423887|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
41500250|NCT04423887|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
41500251|NCT01548118|BIOLOGICAL|HPV 16/18 vaccine, 0,5ml|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
41500252|NCT01548118|BIOLOGICAL|Placebo control, 0.5ml|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
41266863|NCT06213662|DRUG|Botulinum toxin type A for injection|Botulinum toxin was injected into the upper esophageal sphincter of each patient
41266864|NCT05595148|PROCEDURE|Immediate WBAT|Men or women over 18 years who present with a fracture of the acetabulum, pelvis, distal femur, proximal tibia, distal tibia, who will undergo fracture fixation within 7 days of their injury and consent to the research study.
41364019|NCT00730366|DRUG|sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
41364020|NCT00730366|DRUG|Chloroquine|Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
41364021|NCT05239390|DRUG|SCI -110|"Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA. Dronabinol Capsules (dronabinol solution in sesame oil in soft gelatin capsules) are 2.5 mg - cream, oblong, soft-gel capsules. In an NDC 49884-867-02 Bottle of 60 capsules packaged in a well-closed container and stored in a locked refrigerator, 2° to 8°C. Protect from freezing, in accordance with the Israeli legal requirements (Israel Narcotic Drugs Act). Storage conditions should be monitored on a daily basis.~PEA - Manufactured by Pharmacies Inc. 767 Front st. Suite 202. Catasauqua, PA 18032 www.pharmacures.com. 1-888-334-3130. 400 mg PEA tablets, in a 60 mL barrier bottle, 30/400 mm, Bottle of 30 capsules packaged in a well-closed container and stored in RT (20° to 25°C). Storage conditions should be monitored on a daily basis."
41364022|NCT05454696|OTHER|Exercise|Patients in the exercise group will participate in online clinical pilates exercise sessions under the supervision of a physiotherapist twice a week. The exercises will be done via the Zoom application and will continue for 6 weeks. The exercise program will last one hour with a warm-up and cool-down period. The exercises will be done by adhering to the basic principles of clinical pilates. The exercise program includes mat exercises that provide general body strengthening and stretching. Progression will be provided according to the health status of the patients and their compliance with exercise. The intensity of exercise will be planned as medium according to the Rating of perceived exertion (RPE) Scale.
41364023|NCT05454696|OTHER|online physical activity counselling|CG will receive online physical activity counselling by a physiotherapist only once. The importance of physical activity after surgery and the points to be considered during physical activity will be explained to the patients.
41364024|NCT01559142|DRUG|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
41364025|NCT01559142|DRUG|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
41364026|NCT00987857|PROCEDURE|2 yearly endoscopy|2 yearly endoscopy versus endoscopy at need
41364027|NCT00987857|PROCEDURE|comparison of screening methods|2 yearly endoscopy versus endoscopy at need
41364028|NCT00987857|PROCEDURE|diagnostic endoscopic procedure|2 yearly endoscopy versus endoscopy at need
41364029|NCT00987857|PROCEDURE|endoscopic biopsy|2 yearly endoscopy versus endoscopy at need
41364030|NCT00987857|PROCEDURE|endoscopic procedure|2 yearly endoscopy versus endoscopy at need
41364031|NCT00987857|PROCEDURE|quality-of-life assessment|QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need
41364032|NCT00987857|PROCEDURE|screening method|All Barretts patients to be screened
41364033|NCT04662957|DIETARY_SUPPLEMENT|Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo|Oral supplementation with multi-strain probiotic preparation
40842994|NCT03562468|DIETARY_SUPPLEMENT|300 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment with 300 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
40842995|NCT03562468|DIETARY_SUPPLEMENT|1000 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment 1000 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
40842996|NCT03562468|DIETARY_SUPPLEMENT|Placebo|Treatment with placebo capsules will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
40842997|NCT00566254|DRUG|Zonisamide|8mg/kg per day for approximately 24 weeks.
40842998|NCT00566254|DRUG|Placebo|
40842999|NCT02423980|DRUG|Glucagon|
40843000|NCT01818284|DRUG|Filgrastim|5 µg/kg in the morning daily for 4 days.
41364034|NCT04662957|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin as placebo
41364035|NCT02198911|OTHER|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
40843001|NCT01818284|DRUG|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
40843002|NCT01818284|PROCEDURE|Apheresis Procedure|"The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained."
40843003|NCT03892135|OTHER|Interviews with parents of children with juvenile idiopathic arthritis|Interviews with parents of children with juvenile idiopathic arthritis
40843004|NCT03892135|OTHER|Interviews with children with juvenile idiopathic arthritis|Interviews with children with juvenile idiopathic arthritis
40843005|NCT03892135|OTHER|Interviews with Physicians|Interviews with Physicians
41026563|NCT03125668|BEHAVIORAL|Telephone follow-up|"After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).~During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment."
41500253|NCT01548118|BIOLOGICAL|HPV 16/18 vaccine, 1.0ml|Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
41500254|NCT01548118|BIOLOGICAL|Placebo control, 1.0ml|Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
41500255|NCT00637650|PROCEDURE|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
41364036|NCT02198911|OTHER|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
41364037|NCT02198911|OTHER|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
41364038|NCT04948606|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
41500256|NCT00637650|PROCEDURE|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
41500257|NCT01027195|DEVICE|Bipolar Radiofrequency (Aquamantys 6.0)|
41364039|NCT04406155|PROCEDURE|3D-RWC-TVS with bowel preparation|"Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.~Bowel preparation is based on a low-residue diet given in the two days before the examination and a rectal enema administered a few hours before the procedure."
40843006|NCT02832336|DRUG|Vivarin|Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
40843007|NCT02832336|DRUG|Fiber|Fiber will be used as placebo.
41026564|NCT03125668|BEHAVIORAL|Face to face counseling|They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
41026565|NCT05014100|DRUG|Orelabrutinib tablet|Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
41026566|NCT05014100|DRUG|Lenalidomide|"Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days~Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up"
41026567|NCT03424746|DRUG|disodium EDTA|Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
41026568|NCT00774735|DRUG|GSK1349572|30 mg given in combination with lopinavir/ritonavir
40843008|NCT06083818|OTHER|Application of an anterior cruciate ligament injury prevention protocol for female football players with dynamic knee valgus for 12 weeks.|12-week ACL Injury Prevention Protocol
40843009|NCT06083818|OTHER|Placebo - Conventional fitness programme|Conventional training and physical preparation programme
41026569|NCT00774735|DRUG|GSK1349572|30 mg in combination with darunavir/ritonavir
41026570|NCT02418325|BIOLOGICAL|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
41026571|NCT02418325|OTHER|Liberation therapy|
41026572|NCT00930358|DRUG|MEOPA|anaesthetic gaz inhalation
41364040|NCT04406155|PROCEDURE|3D-RWC-TVS without bowel preparation|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
41026573|NCT00930358|DRUG|general anaesthesia|Anaesthetic intravenous route
41026574|NCT05507606|DRUG|Osimertinib|osimertinib 80mg/d
41500258|NCT01027195|DEVICE|Standard Bovie Electrocautery|
40843010|NCT02158208|OTHER|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
40843011|NCT02158208|OTHER|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
41026575|NCT05507606|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years
41500259|NCT00789737|DRUG|Welchol|Welchol 625mg tablets
40843012|NCT02158208|OTHER|Blood sample drawn into a 5 mL dry tube|
40843013|NCT02158208|OTHER|16 blood samples drawn into 6 mL heparinized tubes|
40843014|NCT00642317|BEHAVIORAL|Questionnaire|Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
41026576|NCT05507606|DRUG|Carboplatin|Carboplatin AUC5, d1; was stopped after 4 cycles
41026577|NCT05507606|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
41026578|NCT04483479|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
41026579|NCT00813930|BEHAVIORAL|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
41026580|NCT05477823|RADIATION|External beam radiation therapy|Standard of care EBRT
41026581|NCT05477823|RADIATION|Prostate brachytherapy boost|Standard of care BTX
41026582|NCT05477823|DRUG|Androgen deprivation therapy|Standard of care ADT
41364041|NCT03742258|DRUG|Cyclophosphamide|Given IV
41500260|NCT00789737|DRUG|Placebo|placebo
41364042|NCT03742258|DRUG|Doxorubicin Hydrochloride|Given IV
41364043|NCT03742258|DRUG|Prednisone|Given PO
41364044|NCT03742258|BIOLOGICAL|Rituximab|Given IV
41364045|NCT03742258|DRUG|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
40843015|NCT02246608|DEVICE|NPWT Standard of Care plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
40843016|NCT02246608|DEVICE|Routine NPWT Standard of Care|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
41266865|NCT05595148|OTHER|No Intervention: Delayed WBAT|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
41364046|NCT03742258|DRUG|Vincristine Sulfate|Given IV
41364047|NCT06297213|DRUG|R-2487|R-2487 DP
41364048|NCT05948800|DIETARY_SUPPLEMENT|Nasal irrigation with seawater isotonic solution|Isotonic sea water: product from the market, Aqua Maris nasal spray (manufacturer JGL, Rijeka), applied in accordance with the approved Instructions for Consumers.
41364049|NCT01376076|DRUG|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
41364050|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
41364051|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
41364052|NCT03327740|DRUG|DTG based ARV regimen with ABC|ARV regimens containing DTG and ABC
41364053|NCT03327740|DRUG|DTG based ARV regimen without ABC|DTG based ARV regimens that do not contain ABC
41364054|NCT03327740|DRUG|RAL or EGV based ARV regimens with ABC|RAL or EGV based regimens containing ABC
41364055|NCT03327740|DRUG|RAL or EGV based regimens without ABC|RAL or EGV based ARV regimens that do not contain ABC
41364056|NCT03327740|DRUG|Any other DTG based ARV regimen as monotherapy|Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
41364057|NCT01920165|OTHER|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
41364058|NCT06138912|RADIATION|plain radiography (x-ray)|Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained
41364059|NCT05852301|OTHER|no intervention|no intervention, observational study only
41364060|NCT00057642|DRUG|Sertraline|
41364061|NCT00057642|DRUG|Venlafaxine Extended Release|
41364062|NCT00473187|DRUG|somatropin|
41364063|NCT04411316|COMBINATION_PRODUCT|Catheter directed thrombolysis plus anticoagulation|"Patients will be randomized to pharmacomechanical catheter directed thrombolysis plus anticoagulation.~PCDT will be AngioJet along with alteplase."
41364064|NCT04411316|DRUG|Anticoagulation|Patients will receive anticoagulation alone. Anticoagulation will be heparin only.
41364065|NCT04369560|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|60-cm wide bore 3T scanner (Siemens AG, Erlangen, Germany) with a 32-channel pelvic phased-array coil placed over the bladder.
41364066|NCT04369560|DRUG|Gadobutrol intravesical administration (4mM)|A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).
41364067|NCT04369560|DRUG|Ferumoxytol intravesical administration (5 mM)|An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
41364068|NCT04312152|DIETARY_SUPPLEMENT|Q10 Ubiquinol|Q10 Ubiquinol (50 or 100 mg b.i.d. depending on body weight) in capsules containing also Vit. E and Vit. B complex, as described above. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
40843017|NCT01160432|DRUG|Methadone, naloxone|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient's individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week's periods for four weeks.
41364069|NCT04312152|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
41364070|NCT04312152|DIETARY_SUPPLEMENT|Multi-Vitamin B complex|Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
41364071|NCT02390167|DEVICE|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
41364072|NCT03498963|PROCEDURE|bronchoalveolar lavage|Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
41364073|NCT03984682|PROCEDURE|Joint Crisis Plan|A Joint Crisis Plan will be drafted with the patient and a nurse
41364074|NCT02432027|DRUG|C-82 Topical Gel, Placebo|placebo
41364075|NCT02432027|DRUG|C-82 Topical Gel, 1%|active
40843018|NCT03652467|DRUG|Conventional TACE|Conventional chemoembolization drugs are injected through hepatic artery.
40843019|NCT03652467|DRUG|Deferoxamine and conventional TACE|Deferoxamine is injected before conventional transarterial chemoembolization.
41266866|NCT00000704|DRUG|Zalcitabine|
41364076|NCT02432027|DRUG|Daivonex cream|comparator
41364077|NCT02432027|DRUG|Diprosis gel|comparator
41364078|NCT06373380|DRUG|HB-200|HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every 3 weeks intravenously for 5 doses and then every 6 weeks thereafter.
41364079|NCT06373380|OTHER|Placebo|Patients in the placebo arm will be receiving vehicle on the same schedule. Patients will receive treatment with HB-200 alternating therapy or placebo until recurrence or for a total duration of 1 year.
41364080|NCT01797042|BEHAVIORAL|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
41500261|NCT03778827|BEHAVIORAL|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of weekly individual parent training sessions and center-based therapy for a total of 13 weekly treatment hours.
41500262|NCT05742932|DEVICE|Trauma surgery using Global D's implants.|Major or minor participants who will be treated by an trauma surgery with ORTRAUTEK® or MINITEK/MICROTEK® implant(s).
40843020|NCT03834935|DRUG|Elidel (pimecrolimus 1%)|topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
41364081|NCT02257502|DRUG|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
41364082|NCT00189059|DRUG|amitriptyline|
40843021|NCT03834935|DRUG|Cold Cream|Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
41026583|NCT05477823|DIAGNOSTIC_TEST|Positron emission tomography (PET)/magnetic resonance imaging (MRI)|Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
41026584|NCT00755586|PROCEDURE|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 \* 10e8 cells in the m. biceps brachii.
41026585|NCT00755586|PROCEDURE|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 \* 10e8 cells in the m. biceps brachii.
41364083|NCT00412555|DRUG|oseltamivir [Tamiflu]|30-75mg po daily for 6 weeks
41364084|NCT03240003|BEHAVIORAL|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of GC-MRT
41364085|NCT03240003|BEHAVIORAL|modified GC-MRT|group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified
41364086|NCT03240003|BEHAVIORAL|Non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
41364087|NCT01356615|DRUG|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
41364088|NCT01356615|DRUG|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
41364089|NCT03102541|OTHER|None intervention|
41364090|NCT03466216|DRUG|AlphaMedix|There is only a single treatment intervention.
41364091|NCT01478490|DRUG|mirabegron|oral
41026586|NCT00755586|PROCEDURE|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
41026587|NCT02755389|DRUG|0 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
41026588|NCT02755389|DRUG|15 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
41364092|NCT01478490|DRUG|metoprolol|oral
41364093|NCT03822390|DEVICE|CAD-CNN system|The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
40843022|NCT03000036|DRUG|Doxorubicin|Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
41364094|NCT00526214|DRUG|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
41364095|NCT03978949|DRUG|Bacillus Licheniformis|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
41364096|NCT03978949|DRUG|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
41364097|NCT04226209|OTHER|PSSE|Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
41364098|NCT00888992|BEHAVIORAL|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
41364099|NCT00888992|BEHAVIORAL|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
41364100|NCT02127931|DEVICE|Groundskeeper for ADHD group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
41364101|NCT02127931|DEVICE|Groundskeeper for control group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
41364102|NCT04762810|DRUG|Cyclophosphamide and glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
41364103|NCT04762810|DRUG|Glucocorticoids|Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
41500263|NCT06484725|GENETIC|Oncotype DX assay|Oncotype DX assay (Genomic Health, Inc, Redwood City, Calif) is a 21 gene panel developed to predict the risk of tumor recurrence in patients with ER-positive and human epidermal growth factor 2 (HER2)- negative breast cancer (BC); nowadays, this test represents a standard of care to guide adjuvant chemotherapy decision recommended in several guidelines. According to Oncotype DX Recurrent Score (RS)® a high RS shows a worse prognosis and predicts chemotherapy benefit in patients with ER-positive HER2-negative BC.
41500264|NCT01404286|BEHAVIORAL|Physical exercise|After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
41364104|NCT05630742|OTHER|chronic non-neoplastic pain|comparison of questionnaires scores
41364105|NCT01191359|BIOLOGICAL|oral immunotherapy|orally applied specific immunotherapy
41364106|NCT02496715|DRUG|Fluticasone propionate 100 mcg / salmeterol 50 mcg|Brand inhaler containing pMDI containing fluticasone and salmeterol
41364107|NCT02496715|DRUG|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg|Generic inhaler containing pMDI containing fluticasone and salmeterol
41364108|NCT02496715|DRUG|Placebo|Placebo inhaler
41364109|NCT01605370|DRUG|Nebivolol|Nebivolol 2.5 mg once daily
41364110|NCT01605370|DRUG|Metoprolol succinate|Metoprolol succinate 50 mg once daily
41364111|NCT01372020|OTHER|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
41161031|NCT05964556|OTHER|Isokinetic Muscle Evulation of Knee Muscles|The isokinetic knee flexor and extensor group muscle strengths of the athletes participating in the study were measured on the dominant and non-dominant sides. Measurements were performed with an ISOMED 2000 (D\&R Ferstl GmbH, Hemau, Germany) isokinetic measuring device. The test protocol was adjusted to be concentric/concentric. Measurements were made at angular velocities of 60°/sec and 180°/sec. At an angular speed of 60°/sec, the athlete was asked to perform 10 repetitions of voluntary knee flexion/extension at maximum strength. Then, after resting for 30 seconds, 30 repetitions of knee flexion/extension were performed at an angular velocity of 180°/sec. Before starting the test in both angular speeds, 3 repetitive attempts were made to learn the movement. The following parameters were evaluated at 60°/sec and 180°/sec angular speed.
41364112|NCT01467817|BEHAVIORAL|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
41364113|NCT01467817|BEHAVIORAL|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
41364114|NCT05453318|PROCEDURE|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
41364115|NCT02283801|DRUG|Eslicarbazepine acetate|
41364116|NCT02283801|DRUG|Lamotrigine|
41364117|NCT00166595|DRUG|Risperidone|
41364118|NCT00884195|BEHAVIORAL|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
41364119|NCT00884195|BEHAVIORAL|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
41364120|NCT04917666|BEHAVIORAL|Horticultural therapy|A structured 8-session group therapy program, in which participants learn about plants, green spaces, plant-human interactions. During the program, the participants are guided by therapist to grow or take care of both indoor and outdoor plants, do small horticulture projects (like cooking, making drinks, herb projects).
41364121|NCT04917666|OTHER|Comparison|4 session of semi-structured and free engagement in activities of their choice. The activities that they could choose are mostly table-top activities which are solitary in nature, and does not require social interaction.
41364122|NCT05139550|DEVICE|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises~ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises~bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities~Lift can, Lift pencil, Lift paper clip, Stack checkers,Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
41364123|NCT03788109|PROCEDURE|device: combined solid state HRiM|The HRiM catheter (Medical Measurement Systems, Enschede, The Netherlands) incorporating 36 pressure sensors, spaced at 2 cm in the stomach and esophagus and at 1 cm in the LES and upper esophageal sphincter (UES), and 16 impedance channels throughout the esophagus, will be placed transnasally, after topical anesthesia. Manometry will be used to record pressures in the stomach, the esophagus, the LES and the UES. In this way, it is possible to detect and characterize TLESRs, and to measure GA. The impedance channels will be used to measure bolus movement, and thus to detect and characterize gastro-esophageal reflux.
41500265|NCT04096755|DIAGNOSTIC_TEST|Procedure|serum and urine samples will be taken for analysis
41500266|NCT01796418|DRUG|Beraprost sodium|
41500267|NCT03460639|RADIATION|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
41500268|NCT03460639|RADIATION|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
41500269|NCT03460639|DIAGNOSTIC_TEST|Control group|In this group, we will only induce fatigue.
41500270|NCT06632301|DEVICE|Primary hip replacement with cementless stem|Total Hip Arthroplasty is today one of the most established surgical orthopaedic procedures worldwide.
41500271|NCT02602600|DRUG|Liraglutide|"* Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~* Weight maintenance diet for 2 weeks"
41500272|NCT01247207|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
41500273|NCT00866190|DRUG|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
41500274|NCT00866190|DRUG|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
41500275|NCT01192867|DRUG|Placebo|Placebo will be administered orally QD for 56 weeks
41500276|NCT01192867|DRUG|RO4917838|RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
41500277|NCT01192867|DRUG|Antipshychotics (Standard of Care)|Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
41161032|NCT06483269|PROCEDURE|PRP infiltration|"a single intra-articular infiltration of 5 mL of PRP-O will be performed by the infiltrating physician.~It is specified that the PRP-O used within the study will be produced following the guidelines and standards for the production of blood products for non-transfusion use as already in place at the Unified Metropolitan Transfusion Service IOR site.~PRP (Platelet Rich Plasma) is produced from platelet pool from donor buffy coat.~PRP contains 1,000,000 PLT/mml +/- 20%, as required by current regulations."
41161033|NCT04753281|OTHER|Lifestyle counselling|brief psychological intervention, based on the behaviour change whee
41161034|NCT03021031|OTHER|Observational|Observational study
41161035|NCT05047497|DIAGNOSTIC_TEST|questionaire and ventilatory function test|we assessed the arterial blood gases and the ventilatory functions and quality of life of whole three groups
41500278|NCT01751737|PROCEDURE|Prostate Cancer Imaging|After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
41364124|NCT03682991|OTHER|Aggressive Risk Factor Control|"1. Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2. Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3. Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4. Blood Pressure management to achieve a target systolic blood pressure (SBP) of \<120/80 mm/Hg~5. Smoking cessation facilitated through local resources already established at each site"
41364125|NCT03682991|OTHER|Standard of Care|Recommendations based on current guidelines
41364126|NCT03846895|DEVICE|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
41364127|NCT04696601|DIAGNOSTIC_TEST|Olfactory test|The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.
41500279|NCT02648932|BIOLOGICAL|Haplo-Cord Transplant|For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
41500280|NCT02648932|PROCEDURE|Matched Unrelated Donor Transplant|
41500281|NCT05008601|DEVICE|Wrist-word optical heart rate and ECG measurement device|Aino ECG: wrist-word optical heart rate and ECG measurement device
41500282|NCT04900519|BIOLOGICAL|STI-6643|Anti-CD47 human monoclonal antibody
41500283|NCT03741400|DEVICE|Neofect RAPAEL Smart Glove|The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
41500284|NCT03361930|DEVICE|Ankle-foot orthosis|"Two custom ankle-foot orthoses for the involved lower leg; cast, rectified and fitted by same certified orthotist to reduce clinician variability.~The cast is rectified according to the specifications of Hylton (1987) to produce tone-reducing features in the foot plate; the tone-reducing ankle-foot orthosis is manufactured on this cast. The orthotist then remodels the cast with a flat foot plate; the plain ankle-foot orthosis is then manufactured."
41500285|NCT05822258|OTHER|Walk under 3 conditions (normal, physical tasks, verbal tasks)|"Each patient will have 2 visits :~* First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~* A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~* Normal condition without addition of additional physical and verbal tasks~* Condition with added physical tasks: The physical task of holding a ball in the center of a tray~* Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions."
41161036|NCT05023941|DRUG|Acetazolamide|Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.
41364128|NCT01456559|OTHER|Lower body negative pressure (LBNP)|"The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.~Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20."
41026589|NCT02755389|DRUG|60 L/min oxygen via high-flow nasal cannulae|Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
41161037|NCT05023941|DEVICE|Doctormate® (twice daily for 6 days)|Start RIPC training twice daily, 6 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the seventh day. At that time, the subject should have finished 13 times of RIPC training.
41364129|NCT03931629|PROCEDURE|CONVENTIONAL PHACO|Cataract surgery by means of Femtosecond Laser-Assisted Cataract Surgery,
41364130|NCT04642911|OTHER|Long term follow up|Undergo long term follow up, including copy number measurement safety evaluations diseases specific product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study
41364131|NCT02895477|DEVICE|hearing aid|
41364132|NCT06118840|DEVICE|True-AI-integrated intracranial aneurysms diagnosis strategy|The True-AI deep-learning based model for intracranial aneurysms detection had a patient-wise sensitivity, lesion-wise sensitivity and specificity of 0.96, 0.87, and 0.80 in the internal validation dataset.
41364133|NCT06118840|DEVICE|Sham-AI-integrated intracranial aneurysms diagnosis strategy|The Sham-AI deep-learning based model for intracranial aneurysms detection is designed to have a sensitivity close to 0% and a similar specificity to the True-AI. In the internal validation dataset, the Sham-AI had a patient-wise sensitivity, lesion-wise sensitivity, specificity of 0.02, 0.01, and 0.80, respectively.
41364134|NCT03220880|DRUG|Intranasal dexmedetomidine|Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
41364135|NCT03016260|BIOLOGICAL|Infliximab|Anti-TNF alpha originator
41364136|NCT03016260|BIOLOGICAL|Adalimumab|Anti-TNF alpha originator
41364137|NCT03016260|BIOLOGICAL|Etanercept|Anti-TNF alpha originator
41364138|NCT03016260|BIOLOGICAL|Golimumab|Anti-TNF alpha originator
41364139|NCT03016260|BIOLOGICAL|Certolizumab Pegol|Anti-TNF alpha originator
41364140|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
41364141|NCT03016260|BIOLOGICAL|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
41364142|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
41364143|NCT00231621|DRUG|topiramate|
41026590|NCT00467181|DRUG|Fenoldopam|
41364144|NCT03037138|OTHER|Blood flow Rate profiling|Blood flow rate profiling during dialysis session
41364145|NCT03846856|OTHER|Biopsy|Biopsy taken during surgical procedure
41364146|NCT04064463|BEHAVIORAL|Standard care|standard treatment for substance use disorders, along with sample monitoring
41364147|NCT04064463|BEHAVIORAL|Contingency management|Participants can earn reinforcement for attending group and abstinence from alcohol
41364148|NCT00401726|DRUG|Venlafaxine ER|
41364149|NCT00401726|BEHAVIORAL|Dialogues Time to Talk Program|
41364150|NCT06365476|DEVICE|focused extracorporeal shock wave therapy (ESWT)|The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.
41364151|NCT05393986|DRUG|CT048 Autologous Injection (CT048)|up to 3 times CT048 Autologous Injection infusion
41364152|NCT04766411|OTHER|Unresisted sprint training|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
41364153|NCT04766411|OTHER|Resisted sprint training with load equal to 10% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
41364154|NCT04766411|OTHER|Resisted sprint training with load equal to 20% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
41364155|NCT04766411|OTHER|Control trial|Participants will not perform any sprint training protocol
41364156|NCT00683852|DRUG|Aripiprazole 5mg|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
41364157|NCT00683852|DRUG|Aripiprazole 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
41364158|NCT00683852|DRUG|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
41026591|NCT03883672|BEHAVIORAL|Personality and transactional factors|"1. Pre-admission transplant questionnaire: given and collected by the transplant physician during the pre-graft consultation before entering hospitalization (approximatively 15 days before). To be completed by the patient on site (approximately 45 minutes to complete the questionnaire)~2. Transplant admission questionnaire: given during the first days of hospitalization. To be completed within 6 days and returned to the transplant physician (approximately 30 minutes to complete the questionnaire)~3. Post-transplant follow-up questionnaire: given in consultation at 6 months by the transplant physician (between 30 and 45 minutes to complete the questionnaire in consultation)"
41026592|NCT05695859|DRUG|99mTc-DARPinG3 SPECT/CT|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection
41026593|NCT04815603|DRUG|BGE-117|Active Treatment
41026594|NCT04815603|OTHER|Placebo|Placebo
41026595|NCT06432712|DRUG|Dexamethasone 4mg|2.5ml of Dexamethasone 4mg/ml will be administered via periapical infiltration with a 23 gauge needle to the experimental group.
41364159|NCT05568212|DRUG|Durvalumab|Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL
41026596|NCT04485403|DRUG|Ibuprofen|800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight \<70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing\> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
41026597|NCT04913857|BEHAVIORAL|24-week SUDOKU Training Programme|12-week face-to-face training session and a 12-week facilitated self-practice
41026598|NCT04913857|OTHER|Control Arm (wait-list)|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
41026599|NCT06347419|OTHER|Physiotherapy evaluation|In the physiotherapy evaluation, patients' spinal stability, rotary stability, and body awareness will be assessed.
41026600|NCT02069600|DEVICE|Continuous Positive Airway Pressure|"CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing"
41026601|NCT01579344|DRUG|Radioiodine therapy|Radioiodine therapy with NaI131
41026602|NCT06074926|BEHAVIORAL|Associative Conditioning|There will be 3 planned activities per week (9 total) within play kits provided to families. Children will first taste their assigned target vegetable and then complete an activity with their parent following provided instructions. Activity instructions will include positive parenting skills adapted from evidence-based parenting programs (i.e., Parent-Child Interaction Therapy (PCIT) and Triple-P) designed to promote positive parent-child interactions.
41026603|NCT06074926|BEHAVIORAL|Repeated Exposure|There will be 3 planned exposures per week (9 total). Exposures will include only individual tastes of the child's assigned target vegetable.
41026604|NCT04996784|OTHER|Capillary blood sampling|The capillary blood sample will be obtained by pricking the fingertip using contact-activated lancet (BD Microtainer). A total of five blood drops (10 μL each) will be collected by a micropipette and will be dropped off on the blotting paper 903 S\&S (Whatman).
41026605|NCT00512759|DRUG|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
41026606|NCT05036122|DEVICE|LabClasp|Non-invasive device that estimates blood \[lactate\] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood \[lactate\] and return a value to the subject via an accompanying tablet within 20 seconds.
41364160|NCT05568212|DRUG|Olaparib tablet|Olaparib tablets (100 mg and 150 mg strengths) supplied in high-density polyethylene (HDPE) bottles.
41364161|NCT05568212|DRUG|Single-agent chemotherapy|Investigator's choice single-agent chemotherapy regimen
41364162|NCT05568212|DRUG|Platinum doublet chemotherapy|Investigator's choice platinum doublet chemotherapy
41364163|NCT01941160|DIETARY_SUPPLEMENT|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
41364164|NCT01941160|DIETARY_SUPPLEMENT|Placebo|Placebo capsule twice daily
41026607|NCT06574204|DRUG|Erythromycin|The researchers injected 30 units of erythromycin into the inner right wrist of the subjects, which is a liquid dosage form.
41026608|NCT06574204|DRUG|Azithromycin|The researchers injected 30 units of azithromycin into the inner right wrist of the subjects, which is a liquid dosage form.
41026609|NCT06574204|OTHER|physiological saline|The researchers injected 10-20 μl of physiological saline into the inner left wrist of the subjects, which is a liquid dosage form.
41364165|NCT04609436|DEVICE|"Cardiac monitoring with the wireless device SmartCardia"|Monitoring of arrhythmia with a wireless device (SmartCardia)
41364166|NCT05635110|DRUG|VX-548|Tablets for oral administration.
41364167|NCT05635110|DRUG|Omeprazole|Tablets for oral administration.
41364168|NCT05635110|DRUG|Rifampin|Capsules for oral administration.
41364169|NCT05024721|DRUG|HIP2101|Test drug
41364170|NCT05024721|DRUG|RLD2101|Reference drug
41364171|NCT05024721|DRUG|HPP2101|Placebo drug
41364172|NCT05024721|DRUG|HPP2102|Placebo drug
41364173|NCT03266159|DRUG|GSK525762 Besylate tablets|GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings. It will be administered with 240mL of liquid.
41364174|NCT03266159|DRUG|Trametinib tablets|"Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal."
41364175|NCT01631123|OTHER|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
41364176|NCT01631123|OTHER|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
41364177|NCT00452166|DRUG|rosiglitazone|
41364178|NCT00770731|DRUG|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
41364179|NCT00770731|DRUG|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
41026610|NCT01627392|BEHAVIORAL|Smoking abstinence|6 hour smoking abstinence
41364180|NCT00770731|DRUG|Velcade (Bortezomib)|Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
41266867|NCT03591900|DEVICE|insulin pump/CGMS|"A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009)."
41266868|NCT01997502|DEVICE|Pulse CO-Oximetry Technology|"In addition to the standard pulse oximeter used for clinical care, up to six SpHb finger sensors will be applied to the patient. Additional sensors may also be applied to the forehead, neck, chest and ears.~Masimo FDA cleared pulse CO-Oximeter devices: Radical-7, Rad-87, Rad-57, Pronto, Pronto-7, for the noninvasive measurement of SpO2, PR, PI, PVI, SpCO, SpMet, and SpHb, total hemoglobin and respiratory rate.~No treatment decisions will be made based on the new technology and no extra medical procedures are required for the study."
41266869|NCT01997502|OTHER|Blood draw|4mL arterial blood samples (up to 1 per hour), outside standard of care, are drawn throughout the surgical procedure and sent to UCDMC lab/Masimo lab for analysis.
41266870|NCT00334503|DRUG|Miglitol|
41266871|NCT03002974|DRUG|Anakinra 100 mg|100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
41266872|NCT03002974|DRUG|Triamcinolone Acetonide 40 mg|1 mL intramuscular injection of a 40 mg/mL injectable suspension
41266873|NCT03002974|DRUG|Placebo to Anakinra 100 mg|sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
41266874|NCT03002974|DRUG|Placebo to Triamcinolone Acetonide 40 mg|1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
41266875|NCT01275222|DRUG|RAD001|RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
41266876|NCT01275222|DRUG|Imatinib 600mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.
40843023|NCT03000036|DEVICE|Achieva, Philips Medical Systems (3T magnet)|Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
41364181|NCT04198376|PROCEDURE|Group A The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
40843024|NCT03000036|DRUG|Gadoterate Meglumine|LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
41364182|NCT04198376|PROCEDURE|Group B Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
41364183|NCT00917917|BEHAVIORAL|Type of physical activity (resistance, endurance)|"To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.~Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities."
41364184|NCT00917917|BEHAVIORAL|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
41364185|NCT03556202|DRUG|Mirikizumab|Administered SC
41364186|NCT03803956|DEVICE|Active PBMT|The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
41364187|NCT03803956|DEVICE|Placebo PBMT|The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
41364188|NCT04691570|DRUG|ANX005|ANX005 is provided as a solution for IV infusion
41364189|NCT04449432|BEHAVIORAL|GROWell (Interactive Obesity Treatment Approach)|Personalized messaging via cell phone to support healthy eating behaviors during pregnancy and through 6 months postpartum
41364190|NCT04449432|BEHAVIORAL|Attention Support Control|Personalized messaging via cell phone to support healthy behaviors during pregnancy and through 6 months postpartum
41364191|NCT02582593|DEVICE|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
41364192|NCT02582593|DEVICE|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
40843025|NCT00772681|DRUG|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
40843026|NCT00189904|BIOLOGICAL|IMVAMUNE (MVA-BN)|
40843027|NCT02411370|BEHAVIORAL|phonetic tests|
40843028|NCT03755661|BEHAVIORAL|MI&TXT4MSM|brief in-person intervention followed by text messaging
40843029|NCT04190524|OTHER|Application of cricoid pressure|The study first involves recording a baseline image of the neck anatomy using ultrasound, which is a non-invasive, non-irradiating, non-painful imaging modality. Once the baseline anatomy has been imaged, conventional cricoid pressure will be applied with fingers and/or with the ultrasound probe itself and an image will be recorded. The force applied to the cricoid cartilage will be 30 newtons, as determined by a thin force measurement sensor (Tekscan flexiforce sensor) placed in between the patient's skin and the finger (or ultrasound probe).
40843030|NCT04190524|OTHER|Application of Left lateral paratracheal pressure|Next, left lateral paralaryngeal pressure will be applied at the level of the cricoid cartilage with fingers and/or the ultrasound probe itself, and the image will again be recorded. Left lateral paralaryngeal pressure will be 30 newtons, as determined by a thin force measurement sensor placed in between the patient's skin and the finger (or ultrasound probe).
41364193|NCT03567811|PROCEDURE|Submaximal bicycle exercise stress test on Days 1 and 2|Identical submaximal stress tests were performed on both days to see if Day 1 exercise reduced performance on Day 2, or caused changes between BOLD scans during cognitive testing between Day 1 and Day 2.
41364194|NCT00821886|DRUG|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
41364195|NCT00821886|DRUG|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
41364196|NCT00821886|DRUG|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
41364197|NCT02406131|OTHER|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
41364198|NCT04902547|BEHAVIORAL|Patient Education Workshop (PEWs)|The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.
41364199|NCT04902547|PROCEDURE|Multidisciplinary Tapering Program|"The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up."
41364200|NCT05089773|PROCEDURE|The arterial switch operation|"The ASO is a procedure that emerged as an anatomically as well as physiologically appropriate solution to the transposition of the great arteries. The aorta and pulmonary artery are detached from their native roots and reattached to the opposite root; thus, the pulmonary root becomes the neo-aorta, and the aortic root becomes the neo-pulmonary artery.~The coronary arteries are transplanted from the aorta/neo-pulmonary artery to the pulmonary artery/neo-aorta."
41364201|NCT04156464|DRUG|Phenobarbital|Phenobarbital loading dose followed by a taper will be given to control acute alcohol withdrawal syndrome
41364202|NCT04156464|DRUG|Lorazepam|Ativan will be given according to our institutional alcohol withdrawal protocol to control acute alcohol withdrawal syndrome
41364203|NCT02449005|BIOLOGICAL|BM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
41364204|NCT02449005|OTHER|Fibrin glue/collagen fleece|The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect
41364205|NCT02449005|PROCEDURE|Open flap debridement|Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials
41364206|NCT04522635|DRUG|(100 ml of Albumin 25%)|single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
40843031|NCT05876845|OTHER|Combined pre-, pro-, and post-biotic supplement|Participants will take 2 capsules daily with water, with their first meal of the day.
41364207|NCT05870358|DRUG|Melatonin 3 MG|In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
41364208|NCT03999203|DRUG|Citric acid|Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
41364209|NCT03999203|DEVICE|Leicester Cough monitor|Ambulatory cough monitor to assess cough frequency over a 24 hour period
41364210|NCT03999203|OTHER|fractional exhaled nitric oxide testing (FeNO)|Measurement of exhaled nitric oxide to give an indication of airway inflammation
41364211|NCT03999203|OTHER|Patient reported outcome measures|A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
41364212|NCT05771246|DIAGNOSTIC_TEST|Radiographic evaluation|Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.
41364213|NCT05737108|DIETARY_SUPPLEMENT|Bilberry capsule product|A specific bilberry capsule product, containing bilberry dried extracts at 23.2 mg and bilberry powder at 3.2 mg will be given to participants for oral intake for 30 days. 30 days of Bilberry capsule product or placebo with crossover to the other.
41364214|NCT05737108|DIETARY_SUPPLEMENT|Placebo(starch)|30 days of placebo or Bilberry capsule product with crossover to the other.
41364215|NCT04701931|DEVICE|Maestro2 OCTA|The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
41364216|NCT04701931|DEVICE|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
41364217|NCT04701931|DEVICE|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
41364218|NCT01384773|OTHER|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
41364219|NCT01384773|DEVICE|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
41364220|NCT00384072|DRUG|bazedoxifene BZA-20|
41364221|NCT01347905|OTHER|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
41364222|NCT05494047|DRUG|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|15μg Hemagglutinin Antigen (HA) of each of the four strains
41364223|NCT05430724|PROCEDURE|Controlled hypotention|"The procedure to be applied to the cases to be included in the study:~Patients randomized by the sealed envelope method will be divided into 2 groups (40 patients in each group).~The sealed envelopes that determine which group the patient will belong to will be randomly selected by the patient.~Standard general anesthesia will be applied to all patients. Before starting the surgical procedure; Group N (Nicardipine infusion) will be administered at a dose of 5-15mg/h, and Group E (Esmolol infusion) at a dose of 50-300mcg/kg/min.~2) General anesthesia will be applied to all groups. Patients will be administered controlled hypotension (mean arterial pressure 50-60 mmHg)."
41364224|NCT03716128|DIAGNOSTIC_TEST|18F-PET|Bone biopsy and 18F-PET
41364225|NCT02748096|PROCEDURE|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
41364226|NCT02748096|PROCEDURE|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
41364227|NCT02780869|DEVICE|HEMOBLAST Bellows|
40843032|NCT05035433|PROCEDURE|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
41364228|NCT02780869|DEVICE|Absorbable gelatin sponge, USP with thrombin|
41364229|NCT00072085|BIOLOGICAL|aldesleukin|
41364230|NCT00072085|BIOLOGICAL|gp100 antigen|
41364231|NCT00072085|BIOLOGICAL|incomplete Freund's adjuvant|
41364232|NCT06437223|DRUG|Tonabersat|Tonabersat 40mg. Two tablets per day
41364233|NCT06437223|DRUG|Placebo|Placebo 40mg, Two tablets per day
41364234|NCT00038571|DRUG|PS341 (Bortezomib)|1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
41364235|NCT06174428|DEVICE|Oral/Throat cancer test|The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
41364236|NCT05403502|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.
41364237|NCT04204967|DRUG|Fentanyl Transdermal System|in the experimental arm transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
41500286|NCT00609999|DRUG|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected \& will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 \& at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib \& Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib \& Erlotinib given daily for 28 days for purpose of scheduling evaluations.
41500287|NCT04622319|DRUG|DS-8201a|Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
41364238|NCT04204967|DRUG|Remifentanil|"In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl"
41500288|NCT04622319|DRUG|T-DM1|Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
40843033|NCT05035433|PROCEDURE|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
40843034|NCT02037217|DEVICE|ExAblate Transcranial MRgFUS System|
40843035|NCT03778385|OTHER|Exercise|Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.
40843036|NCT05899582|PROCEDURE|Extracranial-Intracranial Bypass Surgery|Extracranial-intracranial bypass surgery plus medical treatment
40843037|NCT05899582|OTHER|Medical treatment alone|Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.
40843038|NCT03704714|DRUG|Cyclophosphamide|Given IV
41364239|NCT00074399|DRUG|Nevirapine|Tablet taken orally daily. Dosage depends on age and body surface area
41364240|NCT00074399|DRUG|Nevirapine placebo|Placebo tablet taken orally daily
41364241|NCT03260543|DIETARY_SUPPLEMENT|fermented ginseng powder|tablets (2 tablets/day, 125 mg \& 500 mg/day) for 12 weeks.
41364242|NCT03260543|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
41364243|NCT02787655|BEHAVIORAL|Aerobic exercise + Cognitive Training Group|stationary bicycling
41364244|NCT02787655|BEHAVIORAL|Cognitive training Only|20 minutes of cognitive training using Mindfit program
41364245|NCT02493712|DRUG|High dose|6 capsules of IBD98-M, twice a day
41364246|NCT02493712|DRUG|Low dose|4 capsules of IBD98-M
41364247|NCT02493712|DRUG|Placebo|Placebo
40843039|NCT03704714|DRUG|Doxorubicin Hydrochloride|Given IV
40843040|NCT03704714|BIOLOGICAL|Nivolumab|Given IV
40843041|NCT03704714|DRUG|Prednisone|Given PO
40843042|NCT03704714|OTHER|Quality-of-Life Assessment|Ancillary studies
40843043|NCT03704714|BIOLOGICAL|Rituximab|Given IV
40843044|NCT03704714|DRUG|Vincristine Sulfate|Given IV
40843045|NCT01620944|DRUG|Atazanavir|Capsule, oral, 300 mg, Once daily (QD), 96 weeks
40843046|NCT01620944|DRUG|Ritonavir|Tablets, oral, 100 mg, QD, 96 Weeks
40843047|NCT01620944|DRUG|Lamivudine|Tablet, oral, 300 mg, QD, 96 Weeks
41364248|NCT03521622|BEHAVIORAL|brief counseling|Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention
41364249|NCT04548349|DRUG|Altreno|Acne patients will be assigned to Altreno once daily.
41364250|NCT04548349|DRUG|Benzoyl peroxide|Acne patients will be assigned to BPO leave-on gel once daily.
41364251|NCT01623518|BIOLOGICAL|ChAdOx1-NP+M1|"Dose escalation in a 3+3 study plan;~5 x10\^8 vp, 5 x10\^9 vp, 2.5 x10\^10 vp, 5 x10\^10 vp"
41364252|NCT04115202|PROCEDURE|lumbar arthrodesis|two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
41364253|NCT02363504|OTHER|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
41500289|NCT06332989|OTHER|stroke-APP|Ambulane paramedics will use an online application to fill in several observations on scen
40843048|NCT01620944|DRUG|Tenofovir/Emtricitabine|Tablets, oral, 300/200 mg, QD, 48 Weeks
40843049|NCT01746173|DRUG|Cyclophosphamide|
41364254|NCT00303004|DRUG|Bosentan and Sildenafil|
41364255|NCT06195033|PROCEDURE|Surgical protocol guided by artificial intelligence software|At present, the indications for internal fixation of intertrochanteric fractures are not clear. We developed an artificial intelligence software to assist surgeons in determining whether to immobilize lateral and medial posterior wall fractures.
41364256|NCT05574920|DIAGNOSTIC_TEST|Al18F-NOTA-FAPI-04 PET/CT scan|Patients enrolled underwent PET/CT after injection of Al18F-NOTA-FAPI-04 to image lesions of breast cancer.
41364257|NCT04558515|DIAGNOSTIC_TEST|Novel malaria diagnostics & tools|Next generation microscopy tools for malaria diagnosis and medical applications
41364258|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg twice daily (BID)
41364259|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg once daily (OD)
41364260|NCT03960788|DRUG|Gadoxetate Sodium|Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
41364261|NCT03131856|BEHAVIORAL|Nutritional intervention programme|The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
41364262|NCT03108560|PROCEDURE|sublobar resection|Patients receive sublobar resection, which includes wedge resection and segmentectomy.
40843050|NCT01746173|DRUG|Doxorubicin|
41364263|NCT03108560|PROCEDURE|lobectomy|patients receive lobectomy
41364264|NCT02473029|RADIATION|Vascular tomodensitometry|
41364265|NCT02473029|OTHER|Magnetic resonance angiography|
41364266|NCT02473029|OTHER|Vascular ultrasonography|
41364267|NCT02473029|OTHER|Retinal angiography|
41364268|NCT02473029|OTHER|Retinal optical coherence tomography|
41364269|NCT06498453|DEVICE|Trak-Physio knee condition|The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.
41364270|NCT06498453|DEVICE|Trak-Physio in shoulder condition|The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.
41364271|NCT06498453|OTHER|Knee conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
41364272|NCT06498453|OTHER|Shoulder conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
41364273|NCT02213965|DEVICE|Peripheral IV catheter|Intravenous access according to Instructions For Use
40843051|NCT01746173|DRUG|Vincristine|
41364274|NCT01490385|DEVICE|LED Phototherapy|
41364275|NCT06331884|DRUG|AK1967 (Procizumab)|DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)
41364276|NCT06331884|DRUG|Placebo|Application of placebo
41364277|NCT01211860|DRUG|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
41364278|NCT03633461|DRUG|OC-02 (simpinicline) nasal spray|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
41364279|NCT03633461|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
41364280|NCT01101321|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
41364281|NCT01101321|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
40843052|NCT01746173|DRUG|Etoposide|
41364282|NCT03661658|PROCEDURE|Using short dental implant|Using short dental implant for patients with atrophic posterior mandible.
41364283|NCT03661658|PROCEDURE|Inferior alveolar nerve lateralization with simultaneous implant placement|Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
40843053|NCT01746173|DRUG|Prednisone|
40843054|NCT01746173|DRUG|Filgrastim|
40843055|NCT01746173|DRUG|Plerixafor|
40843056|NCT01746173|PROCEDURE|Stem Cell Collection|
40843057|NCT01746173|DRUG|Palifermin|
40843058|NCT01746173|DRUG|Gemcitabine|
40843059|NCT01746173|DRUG|Busulfan|
40843060|NCT01746173|DRUG|Melphalan|
40843061|NCT01746173|PROCEDURE|Stem Cell Transplant|
41364284|NCT05962073|DEVICE|HFNC|High-flow oxygen therapy before intubation for preoxygenation
41364285|NCT02020681|DEVICE|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
41364286|NCT02020681|OTHER|Placebo|Formulation of Curodont Repair without the peptide P11-4
41364287|NCT02020681|DEVICE|Fluoride|Single application on day D90
41364288|NCT00223990|BIOLOGICAL|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine
41364289|NCT00223990|BIOLOGICAL|RabAvert|RabAvert rabies vaccine
41364290|NCT05417581|PROCEDURE|adipose surgery|A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
41364291|NCT06272773|DEVICE|Forced Oscillation Test|Participant will breathe normally through the device which sends different frequency sounds into the airways, monitoring the response coming back from central and peripheral airways to calculate airway impedence, reactance and resistance.
41364292|NCT05853926|DIAGNOSTIC_TEST|Spinal Manipulation With Laser Therapy|Spinal Manipulation With Laser Therapy in Chronic Lower Backache
41364293|NCT05853926|DIAGNOSTIC_TEST|Dry Needling|Dry Needling in Chronic Lower Backache
41364294|NCT01738906|OTHER|Orange juice|
41364295|NCT01738906|OTHER|maltodextrin|
41364296|NCT01738906|OTHER|Vodka|
41364297|NCT01738906|OTHER|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
41364298|NCT01738906|OTHER|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
41364299|NCT03000920|OTHER|SMS before invitation|A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
41364300|NCT03000920|OTHER|SMS Reminder 1|If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
41364301|NCT04372251|PROCEDURE|Sinus tarsi approach (STA)|Osteosynthesis
41364302|NCT04372251|PROCEDURE|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Osteosynthesis
41364303|NCT05323370|OTHER|24h urine|Urine samples will be collected at home over 24 hours
41364304|NCT05323370|OTHER|urine sample|A urine sample of 20cc will be collected
41364305|NCT01988844|OTHER|Assessment|The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
41500290|NCT06218667|DRUG|Copanlisib|Dose level 1 (starting dose): 45 mg of copanlisib IV weekly x 3 weeks on/1 week off Dose level 2 (standard dose): 60 mg of copanlisib IV weekly x 3 weeks on/1 week off
41500291|NCT06218667|DRUG|Degarelix|Degarelix (GnRH antagonist): 240 mg loading dose sub-cutaneous once on C1D1; 80 mg maintenance dose on C2D1 and C3D1.
40843062|NCT05196685|DIAGNOSTIC_TEST|Carotid Doppler USG|All Doppler ultrasonography measurements will be made in a dimly lit room at room temperature, with the patient in the supine position, the head slightly hyperextended, the patient looking to the left when measuring the right side, and the patient looking to the right when measuring the left side. In all patients, common carotid artery (CCA), internal carotid artery (ICA) and vertebral artery (VA) gray scale and color Doppler ultrasonography wşll be performed using the GE 9L Linear Probe. Color Doppler examination will be performed with a frequency of 4.0/8.0 MHz.
40843063|NCT01416480|DRUG|Theobromine 300mg|Capsule, b.i.d.
40843064|NCT01416480|DRUG|Levodropropizine 10mg|Syrup, t.i.d.
40843065|NCT02974842|DEVICE|MAKO 7|Hysteroscopic cell sampling
40843066|NCT06525987|BEHAVIORAL|Physical activity|Randomization to a 24-week physical exercise program
40843067|NCT01667874|DRUG|Collatamp G sponge|Collatamp G is an antibiotic impregnated sponge
40843068|NCT03769987|OTHER|observation|observe patients every 6 months
40843069|NCT01196962|DEVICE|Central venous catheter|Central venous catheter insertion to subclavian vein
40843070|NCT01422668|OTHER|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
40843071|NCT01939366|DRUG|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
40843072|NCT01939366|DRUG|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
40843073|NCT01939366|DRUG|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
40843074|NCT01939366|DRUG|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
40843075|NCT01939366|DRUG|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
40843076|NCT03214731|DRUG|Artesunate|Artesunate was produced by pharmaceutical factory for research specifically
40843077|NCT03214731|OTHER|placebo|placebo was produced by pharmaceutical factory for research specifically
40843078|NCT01263015|DRUG|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
40843079|NCT01263015|DRUG|Atripla|Atripla once daily on an empty stomach
40843080|NCT01263015|DRUG|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
40843081|NCT01263015|DRUG|Abacavir/Lamivudine Placebo|matching placebo taken once daily
40843082|NCT01263015|DRUG|Dolutegravir placebo|matching placebo taken once daily
40843083|NCT01263015|DRUG|Atripla placebo|matching placebo taken once daily on an empty stomach
41364306|NCT04872374|DIETARY_SUPPLEMENT|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement 10 days before performing the eccentric exercise session
41364307|NCT04872374|DIETARY_SUPPLEMENT|Whey Protein|subjects will receive 20 g/die of the dietary supplement 10 days before performing the eccentric exercise session
41364308|NCT04746729|OTHER|No intervention|No intervention
41364309|NCT02259452|PROCEDURE|SPECT Lung Perfusion Scan|
41364310|NCT02259452|PROCEDURE|SPECT Heart Perfusion Scan|
41500292|NCT06218667|PROCEDURE|Radical Prostatectomy|Standard treatment
40843084|NCT01500304|PROCEDURE|Minimally invasive inguinal lymph node dissection|Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
40843085|NCT04329494|PROCEDURE|Biopsy|Undergo biopsy
40843086|NCT04329494|DRUG|Cisplatin|Given via PIPAC
40843087|NCT04329494|DRUG|Doxorubicin|Given via PIPAC
40843088|NCT04329494|DRUG|Fluorouracil|Given IV
40843089|NCT04329494|DEVICE|Intraperitoneal Chemotherapy|Undergo PIPAC
40843090|NCT04329494|DRUG|Irinotecan|Given IV
40843091|NCT04329494|DRUG|Leucovorin|Given IV
40843092|NCT04329494|DRUG|Mitomycin|Given via PIPAC
40843093|NCT04329494|DRUG|Oxaliplatin|Given via PIPAC
40843094|NCT04329494|OTHER|Quality-of-Life Assessment|Ancillary studies
40843095|NCT04329494|OTHER|Questionnaire Administration|Ancillary studies
40843096|NCT00076232|DRUG|Acyclovir|400 mg tablet taken orally twice daily
40843097|NCT00076232|DRUG|Acyclovir placebo|Oral tablet taken twice daily
41364311|NCT02259452|PROCEDURE|Pulmonary Function Tests|
41364312|NCT03014700|BIOLOGICAL|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
41364313|NCT03014700|BIOLOGICAL|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
41364314|NCT00391820|DRUG|TD-5108|
40843098|NCT01059383|DRUG|VECAM 40/300|1 capsule, orally, once daily at bedtime.
40843099|NCT01059383|DRUG|Esomeprazole 20 mg|1 capsule, orally, once daily 30-60 min. before dinner
41364315|NCT06150404|BEHAVIORAL|White Noises and Maternal and/or Paternal voices|"The intervention group will receive white noise and maternal and/or paternal voice for a maximum of 4 hours per day, alternated as follows: 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice, 1-hour break, 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice. The intervention is expected to start at 08:00 in the morning and conclude at 13:00 and will be delivered from the day after the enrollment - when the parents provide their voice recording - until the day of discharge.~The device for administering white noise and maternal and/or paternal voice will be placed approximately 30 cm from the head of the infant in the incubator and at the foot of the infant in the open crib.~The volume will be 45 dB for infants in incubators and infants in open cribs."
41364316|NCT02361307|PROCEDURE|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
41364317|NCT02361307|PROCEDURE|Conventional ADL training|The control group receive the conventional ADL training programme
41364318|NCT03612869|DRUG|LYS-SAF302|Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
41500293|NCT06217211|DIETARY_SUPPLEMENT|Remolacha|BJ or PL will be administered 3 h before the start of the NO2- evaluation test since the peak in blood occurs 2-3 h after ingesting NO3-. Both drinks (BJ and PL) will be provided in an unlabeled 140ml maroon red plastic bottle. Participants will receive a randomly assigned bottle. containing 140 ml (\~ 12.8 mmol, \~ 808 mg NO3-) of BJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, United Kingdom) or PL.
41500294|NCT06571513|BEHAVIORAL|Written Exposure Therapy|During session one of the written exposure therapy intervention, the therapist will provide psychoeducation about PTSD and the rationale for the proposed intervention. Psychoeducation and treatment rationale are scripted to ensure consistency. The therapist will provide the participant with instructions for writing about the same trauma memory (their recent sexual assault) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
40843100|NCT00256516|OTHER|Eco-Atkins diet (high vegetable protein and vegetable fat)|
40843101|NCT00256516|OTHER|NCEP diet|
40843102|NCT03323190|BEHAVIORAL|Inpatient COPD education|
40843103|NCT00083486|DRUG|epoetin alfa|
40843104|NCT05591716|PROCEDURE|Bilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis.The ureteroscope was extracted together with the case with the ureteral revision: there was no damage to the ureter.Next, this procedure is performed from the other side. Urine was excreted from the bladder using a Nelaton catheter.
40843105|NCT05591716|PROCEDURE|Unilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis. The ureteroscope was extracted together with the body with revision of the ureter: there was no damage to the ureter. Urine was excreted from the bladder using a Nelaton catheter.
40843106|NCT05950360|DEVICE|Electromagnetic tracking system, surface electromyography|arm elevation in the scapular plane, overhead reaching to the target 15° backward to the frontal plane, pull-up with overhead reaching forward and backward.
40843107|NCT05771961|DIAGNOSTIC_TEST|coronary pressure/temperature sensor-tipped guidewire|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire will be first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
40843108|NCT05771961|DIAGNOSTIC_TEST|Angiography-derived index of microcirculatory resistance (IMRangio)|Angiography-derived index of microcirculatory resistance (IMRangio) will be calculated by an anticipated software
41364319|NCT03382639|DRUG|Luvadaxistat|TAK-831 tablets.
40843109|NCT04193774|DIAGNOSTIC_TEST|Conjunctival swab|Swab of the conjunctival fornices of both eyes
40843110|NCT04193774|DRUG|Oxybuprocaine Hydrochloride 0.4% Eye Drops|One drop of topical anesthesia in one eye
41026611|NCT03216837|DEVICE|Cathodal transcranial direct current stimulation|The primary intervention will be cathodal (inhibitory) tDCS over the contralesional M1. Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle. The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp. tDCS will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
41026612|NCT03216837|DEVICE|Sham transcranial direct current stimulation|Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle.The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp and then ramp down over 30 seconds to 0 milliamps. Sham will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
41026613|NCT06171113|DRUG|GSK4024484C|Doses administrated orally with 240 mL of water.
41364320|NCT03382639|DRUG|Placebo|Luvadaxistat placebo-matching tablets.
41364321|NCT03728647|BEHAVIORAL|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
41364322|NCT03728647|BEHAVIORAL|regular health education|The traditional education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
41364323|NCT03164304|DRUG|Magnesium Sulfate|intravenous
41364324|NCT02925780|DEVICE|Resin infiltration|"Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
41364325|NCT02925780|DEVICE|Microabrasion|"The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
41500295|NCT06571513|BEHAVIORAL|Unemotional Writing|During the unemotional writing sessions, the therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did the day before the session from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. The participant will self report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
41500296|NCT01121848|DRUG|Leucovorin|"Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:"
41500297|NCT01121848|DRUG|OXALIPLATIN|"Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:"
41500298|NCT01121848|DRUG|5-Fluorouracil|"Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:"
40843111|NCT04193774|DRUG|artificial tears|One drop of artificial tears in the other eye
40843112|NCT02393053|PROCEDURE|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
40843113|NCT02393053|PROCEDURE|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
41026614|NCT06171113|DRUG|Placebo|Doses administrated orally with 240 mL of water.
41026615|NCT01154634|DRUG|AZD2516, 5 mg|Capsule, oral
41026616|NCT01154634|DRUG|AZD2516, 16 mg|Capsule, oral
41026617|NCT01154634|DRUG|AZD2516, 40 mg|Capsule, oral
41026618|NCT01154634|DRUG|Placebo|Capsule, oral
41026619|NCT02065466|DRUG|nab-paclitaxel|
41026620|NCT02065466|DRUG|Temozolomide|
41026621|NCT02065466|DRUG|Bevacizumab|
41026622|NCT03571295|DEVICE|King Vision aBlade|endotracheal intubation performed with King Vision aBlade
41026623|NCT03571295|DEVICE|direct laryngoscopy|endotracheal intubation performed with direct laryngoscopy
41026624|NCT03058731|DEVICE|Matristem|Paraesophageal hernia repair with MatriStem Surgical Matrix
41026625|NCT03058731|DEVICE|Control|Paraesophageal hernia repair with other biologic mesh
41364326|NCT04910204|OTHER|FES Therapy combined with task-specific training (FEST+TST)|The FEST+TST protocol consists of a 1-hour session, 3 to 5 days a week, for up to 12 weeks (40 sessions total) in addition to conventional occupational and physical therapies according to the standard of care.
41364327|NCT01331876|BEHAVIORAL|Cognitive and behavioral Therapy|15 CBT sessions with a psychologist expert in OCD treatment
41500299|NCT06598878|PROCEDURE|AR gait training|Participants will walk on a pathway projected in augmented reality (AR), following the instructions provided on the pathway Each session will last for 60 minutes, conducted three times per week, over a period of six weeks.
41500300|NCT00086281|DRUG|Xyrem (X)|Xyrem (Sodium Oxybate) Oral Solution
41500301|NCT00086281|DRUG|Zolpidem (Z)|Zolpidem 10 mg oral tablets
41500302|NCT00086281|DRUG|Modafinil (M)|Modafinil Oral Tablets
41026626|NCT04572347|OTHER|Observational|It is an observational study, and no intervention will be provided.
41364328|NCT06050707|RADIATION|Radiotherapy - Low risk group|20 fractions completed in 4 weeks
41364329|NCT06050707|RADIATION|Radiotherapy - Standard risk group|25 fractions completed in 5 weeks
41364330|NCT06050707|RADIATION|Radiotherapy - Intermediate risk group|30 fractions completed in 6 weeks
41026627|NCT06532266|DEVICE|TechTrade Ready Heat Half Body Temperature Management Blankets|"The thermal blanket will be placed on top of the cotton blanket. Newborn will be first covered with conventional warm blanket then adding the thermal blanket on top. The thermal blanket will be placed inside a pillowcase like cotton blanket to avoid direct contact with mother or newborn."
41026628|NCT06532266|OTHER|Control|3 layers of 100% cotton woven blankets
41364331|NCT06050707|RADIATION|Radiotherapy - High risk group|35 fractions completed in 7 weeks
41364332|NCT01616173|DRUG|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
41364333|NCT01616173|DRUG|Dexamethasone|8mg/2mL
41364334|NCT01616173|DRUG|Saline|2mL
41364335|NCT06342440|DIAGNOSTIC_TEST|DENEB|A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.
41364336|NCT04465903|OTHER|Turkish Version of Sydney Swallow Questionnaire|The Turkish Version of Sydney Swallow Questionnaire consists of 17 questions related with dysphagia.
41364337|NCT05895591|OTHER|Anti-aging cosmetic care product|"* frequency of application: Once a day (in the morning)~* modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~* area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)~* quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm"
41500303|NCT00086281|DRUG|Placebo (P)|Placebo Oral Solution
41500304|NCT06016738|DRUG|Palazestrant|Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.
41500305|NCT06016738|DRUG|Fulvestrant|Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle
41500306|NCT06016738|DRUG|Anastrozole|Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle
41500307|NCT06016738|DRUG|Letrozole|Participants will be treated with letrozole once daily on a 4 week (28 day) cycle
41500308|NCT06016738|DRUG|Exemestane|Participants will be treated with exemestane once daily on a 4 week (28 day) cycle
41500309|NCT03485209|DRUG|tisotumab vedotin|Given into the vein (IV; intravenously)
41500310|NCT03485209|DRUG|pembrolizumab|200mg or 400mg given by IV
41500311|NCT03485209|DRUG|carboplatin|AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV
41500312|NCT03485209|DRUG|cisplatin|100mg/m\^2 given by IV
41500313|NCT05266339|OTHER|Cross-education training|The strengthening exercises for rotator cuff muscles will be performed in the contralateral side of the affected side.
41500314|NCT05266339|OTHER|Standard exercise program|The standard exercise program, which prepared according to The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair, will be applied.
41500315|NCT03017612|DEVICE|Raindrop Near Vision Inlay|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
41364338|NCT04382066|DRUG|Plitidepsin 1.5 mg/day|"Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
41026629|NCT02075593|DRUG|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
41026630|NCT03758898|OTHER|Treatment|Chest physiotherapy and mobilization were applied twice a day, 8 times in total.
41026631|NCT03758898|OTHER|Group 2|Only mobilization was applied twice a day, 8 times in total.
41026632|NCT04530799|OTHER|Identification of biomarkers for IAPA via patient sampling|Blood, BAL, microbiome
41026633|NCT06534359|OTHER|Transpyloric tube feeding|Tube feeding into the small bowel
41026634|NCT06534359|OTHER|Gastric tube feeding|Tube feeding into the stomach
41026635|NCT02564198|DRUG|Ramucirumab|Administered IV
41026636|NCT05184413|OTHER|Multimodal treatment|A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
41026637|NCT05184413|OTHER|Unimodal treatment|An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
41026638|NCT04724811|PROCEDURE|Open reduction and internal fixation (ORIF)|"Approaches used:~* Intrapelvic approach +/- iliac window~* Kocher-Langenbeck approach"
41026639|NCT03701724|DEVICE|Systematic maintenance rTMS|Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
41026640|NCT03701724|DEVICE|rTMS course in case of relapse|Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
41364339|NCT04382066|DRUG|Plitidepsin 2.0 mg/day|"Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
41364340|NCT04382066|DRUG|Plitidepsin 2.5 mg/day|"Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
41364341|NCT06236425|BIOLOGICAL|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
41364342|NCT06236425|DRUG|Pembrolizumab|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
41364343|NCT06236425|DRUG|Platinum based chemotherapy|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
41364344|NCT06236425|DRUG|Cyclophosphamide|Participants who proceed to TBio-4101 treatment will receive Cyclophosphamide as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
41364345|NCT06236425|DRUG|Fludarabine|Participants who proceed to TBio-4101 treatment will receive Fludarabine as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
41364346|NCT06236425|DRUG|Aldesleukin|After completion of TBio-4101 infusion, Aldesleukin will be administered every 8 hours, for up to 6 doses.
41364347|NCT00658918|DRUG|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
41500316|NCT06396767|DIAGNOSTIC_TEST|DIA measured via Ultrasonography|Ultrasound will be used to measure Diaphragmatic Inspiratory Amplitude (DIA) of patients before and after elective cardiac surgery to determine if there is a correlation between changes in DIA and postoperative pulmonary complications.
41500317|NCT02598856|DRUG|Intranasal (IN) naloxone 1x|Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
40843114|NCT01972789|DRUG|Ranibizumab|Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
40843115|NCT02708485|OTHER|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
40843116|NCT03652519|BEHAVIORAL|Exercise Training|Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
40843117|NCT02301624|BIOLOGICAL|Eculizumab|Intravenous administration of eculizumab.
41364348|NCT00658918|DRUG|Placebo|placebo
40843118|NCT02301624|DRUG|Placebo|Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.
41364349|NCT03462628|PROCEDURE|CPVI plus low-voltage substrate modification|CPVI plus low-voltage substrate modification in the left atrium during SR
41364350|NCT03462628|PROCEDURE|CPVI alone|circumferential pulmonary vein isolation
41500318|NCT02598856|DRUG|Intranasal (IN) naloxone 2|Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
41500319|NCT02598856|DRUG|Intravenous (IV) naloxone|Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
41500320|NCT02598856|DRUG|Intramuscular (IM) naloxone|Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
40843119|NCT01081743|OTHER|Intervention of the social worker|Systematic home visits and regular follow-ups by phone from a social worker
40843120|NCT00279812|DIETARY_SUPPLEMENT|50ug selenium enriched yeast|Selenomethionine supplement (50ug/d Se) for 12 weeks
40843121|NCT00279812|DIETARY_SUPPLEMENT|100ug selenium enriched yeast|Selenomethionine supplement (100ug/d Se) for 12 weeks
40843122|NCT00279812|DIETARY_SUPPLEMENT|200ug selenium enriched yeast|Selenomethionine supplement (200ug/d Se) for 12 weeks
40843123|NCT00279812|DIETARY_SUPPLEMENT|Control onion|3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
40843124|NCT00279812|DIETARY_SUPPLEMENT|Enriched onion|3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
41500321|NCT02115932|OTHER|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
41500322|NCT06299930|PROCEDURE|Neoadjuvant chemotherapy|Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy
41026641|NCT03701724|DEVICE|sham rTMS|The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.
41161038|NCT05023941|DEVICE|Doctormate® (forth daily for 3 days)|Start RIPC training forth daily, 3 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the forth day. At that time, the subject should have finished 13 times of RIPC training.
41161039|NCT04957407|OTHER|pepsinogen|diagnostic value of pepsinogen for severe atrophy and gastric cancer
41364351|NCT03883659|OTHER|Smartphone|patients with frozen shoulder in the smartphone group will use the smartphone to conduct the home exercise program. The patients will be asked to follow the description to have mobility assessment at least 1 week and do the individualized exercise themselves.
41364352|NCT03883659|OTHER|traditional paper hangouts|patients with frozen shoulder in the smartphone group will use the paper hangouts to conduct the home exercise program. The content of the paper hangouts were description of the home exercise.
41364353|NCT00039377|DRUG|imatinib mesylate|Given PO
41364354|NCT00039377|DRUG|methotrexate|Given IT and IV
41364355|NCT00039377|DRUG|vincristine sulfate|Given IV
41364356|NCT00039377|DRUG|leucovorin calcium|Given IV and PO
41364357|NCT00039377|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
41364358|NCT00039377|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
41364359|NCT00039377|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
41364360|NCT00039377|RADIATION|total-body irradiation|Undergo TBI
41364361|NCT00039377|DRUG|tacrolimus|Given IV or PO
41364362|NCT00039377|BIOLOGICAL|filgrastim|Given SC
41364363|NCT00039377|DRUG|etoposide|Given IV
41364364|NCT00039377|DRUG|cyclophosphamide|Given IV
40843125|NCT00279812|OTHER|Placebo|Placebo supplement for 12 weeks
41026642|NCT00504829|DRUG|LCP-AtorFen|40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia
41026643|NCT00504829|DRUG|atorvastatin|dyslipidemia and mixed dyslipidemia
41026644|NCT00504829|DRUG|fenofibrate|dyslipidemia and mixed dyslipidemia
41026645|NCT06171867|DEVICE|PNEUMACRIT|Monitoring of breathing
41026646|NCT03617809|PROCEDURE|Preoperative warming|The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
41364365|NCT00039377|DRUG|cytarabine|Given IV
41364366|NCT00039377|OTHER|laboratory biomarker analysis|Correlative studies
41364367|NCT05994105|BEHAVIORAL|Art based Augmented Reality|The participants will be provided 14 sessions management plan
41364368|NCT05371340|DIETARY_SUPPLEMENT|Quercetin (500 mg)|Once-daily 500 mg Quercetin
41364369|NCT05371340|OTHER|Placebo (500 mg)|Once-daily 500 mg methylcellulose 9E4M)
41364370|NCT03142464|OTHER|Suspension of the IV fluids|No IV fluids prescription, IV catheter filled with saline solution
41364371|NCT01944761|BEHAVIORAL|Exercise Program|"Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) \[10 mins\], ii) aerobic training/fitness games \[30 mins\], iii) organized sports \[30 mins\], iv) cool down (i.e. stretching, low intensity games) \[10 mins\] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week."
41364372|NCT03301168|BIOLOGICAL|BPX-501 T cells|T cells transduced with CaspaCIDe® safety switch
41500323|NCT06299930|PROCEDURE|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy
41500324|NCT03778398|OTHER|Neurologic music therapy|Customized piano training
41500325|NCT03847298|OTHER|Physical activity and physical fitness assessment|Physical fitness was assessed using Munich Physical Fitness Test (MFT). The SenseWear Armband metabolic holter device was used to record the physical activity level for consecutive 7 days. The functional exercise capacity of the individuals was assessed by the six-minute walking test (6MWT) and cardiorespiratory capacity was assessed by maximal exercise test on the treadmill.
41500326|NCT05868512|DIAGNOSTIC_TEST|Dry needling|Dry Needling Along With Routine Physical Therapy for Chronic Neck Pain
41500327|NCT05868512|DIAGNOSTIC_TEST|Therapeutic ultrasound|Therapeutic ultrasound Along With Routine Physical Therapy for Chronic Neck Pain
41364373|NCT03301168|DRUG|Rimiducid|administered to inactivate BPX-501 cells in the event of GVHD
41364374|NCT03198585|DRUG|Empagliflozin 10 MG|Capsule, once a day for 90 days
41364375|NCT03198585|OTHER|Placebo|Capsule, once a day for 90 days
41364376|NCT01180452|PROCEDURE|enteroscopy|endoscopic enteroscopy to do biopsies on jejunum
41364377|NCT03520842|DRUG|Methotrexate|Given PO
40843126|NCT03334383|DEVICE|Sponge|Compressed cellulose sponge for use in laparoscopic surgery to retract the intestines from the surgical field.
40843127|NCT02517671|DEVICE|Enhanced External Counterpulsation (EECP)|EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
40843128|NCT00154362|DRUG|Oxcarbazepine|
40843129|NCT00961194|DRUG|Ketamine|"Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
40843130|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
40843131|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
41364378|NCT03520842|OTHER|Pharmacokinetic Study|Correlative studies
41364379|NCT03520842|DRUG|Regorafenib|Given PO
41364380|NCT04946331|DEVICE|Electrical impedance tomography system|Which can use the applied current and measurement voltage through the body surface electrode group, and use the reconstruction algorithm to construct an image imaging system that exceeds the cross-sectional, which can provide images of the internal physiological changes of the chest contour, in order to quantify the changes in lung function caused by rib fractures.
40843132|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
40843133|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
40843134|NCT02677857|BEHAVIORAL|Common intervention components for Lifestyle|Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.
41364381|NCT04271189|DRUG|Metformin-Sitagliptin-Empaglifozin-Pioglitazone|1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
41364382|NCT04271189|DRUG|Standard of care|Usual medical care to treat diabetes.
41364383|NCT01031667|DRUG|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
41364384|NCT02418000|DRUG|E6201|Single Group Assignment
41364385|NCT00368212|BEHAVIORAL|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
41026647|NCT06534437|DRUG|MEN1703|MEN1703 is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
41364386|NCT00368212|BEHAVIORAL|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
41364387|NCT03164291|DRUG|Rifabutin|Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
41364388|NCT04107961|BIOLOGICAL|Vaccine|Single intramuscular injection into the deltoid region
41364389|NCT04107961|OTHER|Placebo|Single intramuscular injection into the deltoid region
41364390|NCT03908658|OTHER|Inspiratory muscle Training and Nasal High Flow|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Nasal High Flow will support respiratory muscles and thus reduce the work of breathing. By this mechanism the endurance of the respiratory muscles will increase in parallel with the strenght
41364391|NCT03908658|DEVICE|Inspiratory muscle training and Venturi mask|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Venturi mask is usually applied after extubation in every day clinical practice for oxygen supplementation
41364392|NCT05882487|GENETIC|KL002 injection solution|Neurosurgical delivery of KL002 to the brain
41026648|NCT06534437|DRUG|Glofitamab|Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
41026649|NCT04382118|OTHER|Data collection from routine medical records|Data collection from routine medical records (clinical and radiological data)
41026650|NCT00619021|DRUG|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m\^2, 800 mg/m\^2, 1000 mg/m\^2, 1200 mg/m\^2
41026651|NCT04788732|DEVICE|ECG and EEG monitoring|the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
41026652|NCT00510029|DRUG|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
41026653|NCT04262999|OTHER|effect of sodium valproate on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate drug therapy.
41364393|NCT00364234|DEVICE|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
41364394|NCT03339622|COMBINATION_PRODUCT|PPP001|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
41364395|NCT03339622|COMBINATION_PRODUCT|placebo|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
40843135|NCT06502938|DEVICE|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
40843136|NCT06502938|PROCEDURE|Traditional artificial percutaneous coronary intervention|Doctors perform traditional percutaneous coronary intervention
40843137|NCT00169507|BIOLOGICAL|Pneumococcal (vaccine)|
40843138|NCT00123045|BEHAVIORAL|health education|
40843139|NCT03990506|PROCEDURE|Epi-on PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
40843140|NCT03990506|PROCEDURE|Epi-Off PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized topography-guided PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
40843141|NCT06480149|OTHER|SMALC|Classical shoulder massage was applied to both shoulders of the patient for 10-15 minutes each.
41500328|NCT04430478|DIAGNOSTIC_TEST|Volume flow guided angioplasty|Volume flow measurements using DUS will be obtained at the end of each balloon dilation, at 24 hours, 6 months, and one year after index procedure.
40843142|NCT06480149|OTHER|no application|In the control group, there was no massage application and only pain and sleep quality were evaluated.
41364396|NCT02103400|OTHER|Experimental group|Exercise Training Group
41364397|NCT02103400|OTHER|Control group|Exercise control group
41364398|NCT02380417|PROCEDURE|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
41364399|NCT02380417|DRUG|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
41364400|NCT02380417|DEVICE|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
41364401|NCT04273594|DEVICE|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
41364402|NCT03794310|DRUG|NPF-08 （1-day treatment）|NPF-08 will be administered on the day of colonoscopy.
41500329|NCT04264026|DRUG|3,4-methylenedioxymethamphetamine|Bottles are labeled with a unique container number, protocol number, IMP name, lot number, sponsor name and a statement that the IMP is restricted to clinical trial use only.
40843143|NCT01299402|DIETARY_SUPPLEMENT|Soulera Herbal Blend|This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
40843144|NCT01299402|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
41026654|NCT04262999|OTHER|effect of levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on levetiracetam drug therapy.
41364403|NCT03794310|DRUG|NPF-08 （2-day split dose）|NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
41364404|NCT03794310|DRUG|Moviprep（1-day treatment）|Moviprep will be administered on the day of colonoscopy.
41364405|NCT02546193|DEVICE|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
41500330|NCT04338204|DRUG|tofacitinib|Observational study
41500331|NCT01178710|DRUG|Simvastatin|20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
41500332|NCT06288230|DRUG|vesemnogene lantuparvovec|Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.
41364406|NCT02546193|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
41364407|NCT04945239|BEHAVIORAL|Amplification of Positivity Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
41364408|NCT04945239|BEHAVIORAL|Stress Management Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for activity exercises designed to decrease stress.
41364409|NCT05474482|OTHER|kinesio taping with exercises|Kinesio taping with full stretch of 75 to 100 % for 2 days session per week and exercises for 3 days session per week for total 8 weeks.
41364410|NCT05474482|OTHER|Kinesio taping without exercises|Kinesio taping with a full stretch of 75 to 100 % for 2 days session per week without exercises for 8 weeks.
41364411|NCT05474482|OTHER|Kinesio taping without stretch as control|kinesio taping without any stretch for 2 days session per week for total 8 weeks.
40843145|NCT03737877|OTHER|Diet modification|"The parents will have four group sessions with a nutritional therapist, where in depth advice and information about the diet will be provided. Ongoing support will also be provided throughout the study by use of a closed Facebook or WhatsApp group (whichever the parents choose as most appropriate). The diet is based on five main principles:~* Eat at least seven portions of different varieties of fruit and vegetables each day.~* Have a 12 hour overnight break from food (water only during this time).~* Drink a Kefir drink each day - provided free of charge.~* Eat a microbiome friendly, protein rich, breakfast from our menu.~* Reduce sugar and artificial sweeteners."
40843146|NCT00820872|BIOLOGICAL|trastuzumab|
40843147|NCT00820872|DRUG|carboplatin|
41364412|NCT06099860|OTHER|Kinesio Taping|Kinesio tape with a 5 cm width was used. Participants were positioned on the side lying on the non-involved side with the hip joint of the involved side flexed to 45 degrees and the femur supported in neutral rotation. First, the tape was placed over the area between the ASIS and PSIS to protect the skin. Next, two strips of tape were applied over the first tape to correct anterior innominate rotation. The first piece was applied at the ASIS and pulled firmly to the PSIS in a straight anterior-to-posterior direction. The second piece was applied in an arching manner pulled firmly from the ASIS to the PSIS. the tape was changed once every 3 days
41364413|NCT06099860|OTHER|Balance Training (BT)|The balance training was performed on the Biodex balance system, participants wwere instructed to stand on a podium and stabilize themselves to keep the cursor in the middle of co-centered circle on the displayed screen/monitor. Stability level of platform was set on eight for first two sessions and then reduced to one level on every two sessions so that in the 9th and 10th session the stability level was four. From session four onwards, the participants performed the limit of stability exercises with Biodex Balance System. The participants performed this exercise protocol two times in each session. Total 12 sessions were given in time period of six weeks.
41364414|NCT06099860|OTHER|Hot Pack and Stretching Exercises|A hot pack was applied for 20 minutes, stretching exercises were performed.
41500333|NCT04697082|PROCEDURE|Open surgery|Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.
41500334|NCT04697082|PROCEDURE|Minimal invasive surgery|In the operating room, after the patient was placed in the prone position, the region was removed by stretching the buttocks with adhesive bands and cleaning the area with 10% povidone iodine. The largest pit was excised, and hairs in the cavity were removed with forceps. Then, the whole cavity was curetted meticulously and irrigated with SS. After haemostasis, the cavity volume was measured
41500335|NCT04697082|OTHER|Platelet rich plasma administration|Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
41500336|NCT00093275|DRUG|HP184|
41500337|NCT00359593|BEHAVIORAL|Knowledge translation intervention package|
41500338|NCT06633952|DEVICE|MediTrain|MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
41500339|NCT06633952|DEVICE|Worder|Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
41026655|NCT04262999|OTHER|effect of sodium valproate+levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate+levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate+ levetiracetam drug therapy.
41026656|NCT04262999|OTHER|control group|Control group individuals will be systemically healthy.
41500340|NCT06633952|DEVICE|noninvasive neurostimulation device|A noninvasive neurostimulation device will be used to deliver theta frequency stimulation or sham stimulation to the frontal part of the brain.
41500341|NCT06633952|DEVICE|wrist worn multi-sensor watches|Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
41500342|NCT04137016|OTHER|Mobile application|
41026657|NCT04481256|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
41026658|NCT04481256|DRUG|Bintrafusp alfa|Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
41026659|NCT04481256|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
41364415|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
41364416|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
41026660|NCT04481256|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
41026661|NCT02446808|DEVICE|Intraoperative nerve monitoring|Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
41026662|NCT06161909|DRUG|sintilimab|200mg fixed dose Q3W,1 year
41026663|NCT00224159|BEHAVIORAL|Drug and Dietary behavior|
40843148|NCT00820872|DRUG|docetaxel|
40843149|NCT00820872|DRUG|lapatinib ditosylate|
40843150|NCT02248402|BIOLOGICAL|Vax-DC/MM|
40843151|NCT05441956|DRUG|TGRX-326|Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
41500343|NCT01740635|DEVICE|EPIC WheelS Training Program|Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
41026664|NCT03636152|PROCEDURE|MRI carotid|To assess the carotid atherosclerotic plaques
41026665|NCT03636152|PROCEDURE|APWV|Doppler measurement of the APWV
41026666|NCT03636152|DRUG|Hydroxychloroquine|Active Drug
41026667|NCT03636152|DRUG|Matching Placebo|Matching Placebo for the control group.
41364417|NCT01377194|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
41364418|NCT03947073|OTHER|Education|Three cartoon illustrated educational videos with information on gestational diabetes will be provided to the patient in addition to standard of care.
41364419|NCT00807651|PROCEDURE|AHSCT|All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation(AHSCT) and be treated with immunosuppression.
41364420|NCT00807651|DRUG|Insulin therapy|All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
41500344|NCT05307510|DEVICE|Prefabricated splint|Subjects will be provided either a prefabricated splint
41500345|NCT05307510|DEVICE|Custom Orthosis|Subjects will be evaluated by an occupational therapist who will fabricate a custom orthosis.
41500346|NCT06201156|DEVICE|Metered Dose Inhaler With Spacer Device|Bronchodilator Therapy
41500347|NCT06008275|DRUG|Neratinib Oral Tablet|240mg oral daily. Dosing will follow standard dose escalation procedures
41500348|NCT06008275|DRUG|Ruxolitinib Oral Tablet|20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure
41500349|NCT02871219|DRUG|Lenalidomide|Given PO
41500350|NCT02871219|BIOLOGICAL|Obinutuzumab|Given IV
41500351|NCT04691726|DRUG|lidocaine 10mg/ml|bolus i.v. + continuous i.v. infusion
41500352|NCT04691726|DRUG|Placebo|bolus i.v. + continuous i.v. infusion
41500353|NCT04691726|DRUG|Metamizole|2,5 g i.v. BD
41500354|NCT04691726|DRUG|Morphine|continuous i.v. infusion adjusted to VAS scale score
41500355|NCT05232266|DRUG|Caralluma Fimbriata|Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
41500356|NCT05232266|DRUG|Placebo comparator - Microcrystalline cellulose|Placebo comparator in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
41500357|NCT03839823|COMBINATION_PRODUCT|Docetaxel / Capecitabine|"Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle. Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²/day)"
41500358|NCT03839823|COMBINATION_PRODUCT|Capecitabine / Vinorelbine|"Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion ).~Capecitabine twice daily on day 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles.~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2/day \[oral\] or (25 to 30 mg/m2 \[IV infusion\]"
41500359|NCT03839823|COMBINATION_PRODUCT|Paclitaxel / Gemcitabine|"Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 - 1250 mg/m2)"
41500360|NCT03839823|DRUG|Ribociclib|Dose: 600 mg (200 mg \* 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
40843152|NCT02337985|DRUG|Prednisone|Given PO
40843153|NCT02337985|BIOLOGICAL|Rituximab|Given IV
40843154|NCT02337985|DRUG|Etoposide|Given IV
41026668|NCT03103529|OTHER|Active Rehabilitation|
41161040|NCT02024750|BEHAVIORAL|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
41161041|NCT01089387|BIOLOGICAL|injection of bone marrow mononucleated cells|Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.
41161042|NCT00092313|DRUG|MK0966, rofecoxib|
41364421|NCT03809260|DRUG|Metformin (part 1)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d\~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
41364422|NCT03809260|DRUG|Vancomycin|11d: Vancomycin 250 mg bid, 12\~17d: Vancomycin 500 mg bid
41364423|NCT03809260|DRUG|Metformin (part 2)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
41500361|NCT03839823|DRUG|Letrozole OR Anastrozole|"Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician."
41500362|NCT03839823|DRUG|Goserelin|"Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant"
41500363|NCT04328311|OTHER|Watermelon Juice|500 mL watermelon juice (What a Melon), containing \~1 g of L-citrulline.
41500364|NCT04328311|OTHER|Water|500 mL low nitrate water
41500365|NCT06282783|DRUG|Topiramate|Single dose of 400mg
41500366|NCT05660967|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.
41364424|NCT03067701|DRUG|Carbon Monoxide|In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
41364425|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
41500367|NCT05660967|DRUG|Lenalidomide|Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.
41500368|NCT03184155|DRUG|Nicardipine|200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
41500369|NCT03184155|DRUG|Sterile Saline|Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
40843155|NCT02337985|DRUG|Doxorubicin Hydrochloride|Given IV
41364426|NCT01111331|DRUG|Warfarin 25 mg|25 mg Warfarin single dose
41364427|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
40843156|NCT02337985|DRUG|Vincristine Sulfate|Given IV
40843157|NCT02337985|DRUG|Cyclophosphamide|Given IV
41500370|NCT06633198|PROCEDURE|Passive Heting|The lower limbs will be immersed in warm (42C) circulating water for 60 minutes.
40843158|NCT02337985|BIOLOGICAL|Filgrastim|Given SC
40843159|NCT02337985|BIOLOGICAL|Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells|Given IV
41500371|NCT05997732|DRUG|Phenylephrine Hydrochloride|Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.
40843160|NCT01893736|OTHER|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
40843161|NCT01893736|OTHER|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
40843162|NCT01066962|DRUG|darunavir/ritonavir QD + raltegravir BID|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)"
40843163|NCT01066962|DRUG|darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)"
40843164|NCT04629027|DRUG|Immune checkpoint inhibitor|the patients receive necessary treatment without special intervention
41500372|NCT05997732|DRUG|Isoproterenol Hydrochloride|Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.
41500373|NCT05997732|DRUG|Norepinephrine Bitartrate|Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.
41500374|NCT05997732|DRUG|Propranolol Hydrochloride|Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.
41500375|NCT05997732|DRUG|Phentolamine Mesylate|Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.
40843165|NCT01895309|DRUG|Enbrel (etanercept)|
40843166|NCT01895309|DRUG|SB4 (proposed biosimilar to etanercept)|
40843167|NCT04314076|OTHER|Rhythmic auditory stimulation|RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.
41364428|NCT01111331|DRUG|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
41364429|NCT00266617|DRUG|epoetin alfa|
41364430|NCT00292513|DEVICE|standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)|
41364431|NCT03536689|DIAGNOSTIC_TEST|Amniotic fluid index|Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index
41364432|NCT04536142|DIAGNOSTIC_TEST|MRI|A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.
41500376|NCT05997732|DRUG|Phenylephrine Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.
41500377|NCT05997732|DRUG|Isoproterenol Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.
41500378|NCT05997732|DRUG|Propranolol Hydrochloride|Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.
41500379|NCT03722667|BEHAVIORAL|Technology-based Component|This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.
41364433|NCT04536142|DIAGNOSTIC_TEST|neuropsychological tests and qualitative assessment|"Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe"
41364434|NCT00213668|DIETARY_SUPPLEMENT|glutamine (dipeptiven)|
41364435|NCT04176809|OTHER|Routine Assessment of HRQoL coupled with Therapeutic Information|Participants will complete the EORTC-QLQ-C30 and EORTC-QLQ-BR23 questionnaires before their consultation via the CHES software. The scores will then be generated and provided to clinicians in a graphic form, describing scores course. Access to CHES web portal will also be open to participants outside consultation time points, to enable them to monitor HRQoL if necessary. Workshop 1, will help patients to recognize and react to the occurrence of possible adverse effects, and anticipate their occurrence through appropriate preventive means. In workshop 2, participants will have the opportunity to express their representations and experiences related to their diet and the consequences of disease and treatments on diet. In workshop 3, participants can describe their experiences of fatigue and how their life is affected by it. Moreover, they can identify possible causes and finally discuss solutions to better this symptom. Every month, a reminder letter will also be sent to participants.
41364436|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
41364437|NCT02255942|OTHER|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
41500380|NCT03722667|BEHAVIORAL|TechSupport|"The TechSupport intervention is the combination of both an behavioral and emotional intervention.~Technology-based Components: This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.~Positive Psychological Training (PPT): This intervention will include a structured online training and skill building for PPT accessible by smartphone on techniques to promote optimism, resilience, well-being, and self-confidence."
41364438|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
41500381|NCT05576077|BIOLOGICAL|TBio-4101|TBio-4101 is an autologous selected and expanded tumor infiltrating lymphocyte (TIL) product generated following ex vivo expansion of tumor reactive TIL population found in tumor harvest. After preparation with non-myeloablative lymphodepletion chemotherapy (cyclophosphamide and fludarabine) followed by low dose radiation,TBio-4101, and IL-2.
41500382|NCT05576077|DRUG|Pembrolizumab|Pembrolizumab will be administered after TIL infusion and continue every 3-6 weeks for up to 2 years.
41500383|NCT04708574|BEHAVIORAL|Lifestyle intervention|
41500384|NCT04708574|OTHER|Placebo - Control|
41500385|NCT05452941|DIAGNOSTIC_TEST|Diagnostic test on urine samples|Testing by BinaxNOW® S. pneumoniae and serotype-specific urine antigen detection (UAD) assays (UAD-1 and UAD-2).
41500386|NCT04380961|DRUG|Sirukumab|Participants will receive single dose infusion of sirukumab on Day 1.
41500387|NCT04380961|DRUG|Placebo|Participants will receive placebo IV single dose infusion on Day 1.
41500388|NCT04380961|OTHER|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
41500389|NCT05154461|OTHER|Alginate|BHB covered in alginate will be realised in stomach-duodenum
41500390|NCT05154461|OTHER|Pea-protein|BHB covered in pea-protein will be released in ileum-colon
41500391|NCT01977274|OTHER|gynecological cancer|blood and tumor samples
41500392|NCT04888598|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) Angiography|Measurement of retinal vessel density and distribution in the macula using new generation OCT device
41500393|NCT01982812|DRUG|Oral Levetiracetam|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
41500394|NCT01982812|DRUG|Standard AED|Active comparitor, Standard AED
41500395|NCT03805711|DEVICE|HLT® Transcatheter System|Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).
41161043|NCT00092313|DRUG|Comparator: oxycodone and acetaminophen|
41364439|NCT02255942|OTHER|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
41364440|NCT03165227|DRUG|BI 685509|Taken orally
41364441|NCT03165227|DRUG|Placebo|Taken orally
41364442|NCT00124865|BIOLOGICAL|rFla-MBP|
41500396|NCT06629844|OTHER|The VR dementia education group|The intervention group will receive the VR dementia education program, which will be conducted once for each participant, and each session will accommodate a maximum of 20 participants. The VR dementia education program will follow the flow below, integrating video dramatizations, VR experiences, lectures, and discussions. The program is designed to simulate real-life dementia care situations, encourage reflection, and enhance nursing students' understanding of dementia management. The following are the steps for intervention: Introduction (3 minutes), Pre-Program Questionnaire (10 minutes), Lecture Introduction (2 minutes), Bad Drama (Unfriendly Communication) (10 minutes), Bad VR (10 minutes), Discussion (5 minutes), Lecture 1: What is Dementia? (10 minutes), Good VR (10 minutes), Good Drama (10 minutes), Lecture 2: What Can We Do to Support PLWD? (5 minutes), N-impro (10 minutes), Post-Program Questionnaire (10 minutes), Conclusion (5 minutes).
41364443|NCT00808665|DRUG|Dexmedetomidine|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
40843168|NCT04314076|OTHER|Gait Training|Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.
40843169|NCT03961412|BEHAVIORAL|family-based intervention|The participants will identify their accompanying influential person(s) (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
40843170|NCT03961412|BEHAVIORAL|Participant only intervention|Only participant will attend the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
41026669|NCT06508554|OTHER|Haptonomy|5. With the energy work, we will move on to the stage of harmonizing the intuitive and heart energy fields. It will be ensured that the mother's communication with her baby has a spiritual dimension as well as a physical one. 6. Then the stage of touching and communicating with the baby will begin. The hands of the researcher and the pregnant woman will be placed on the pregnant woman's uterus. Then, the pregnant woman will be the first to call her baby. This call to the baby will be repeated 2-3 times. 7. The pregnant woman and her uterus will be touched and exercises will be performed to adapt to the fetus. The aim is to increase the emotional awareness of the pregnant woman and to enable her to play intrauterine games with her baby (such as calling the baby, shaking her belly, moving the baby to the touched area with the mother's voice). Haptonomy will be completed with a deep relaxation exercise that will support the heart-uterus connection accompanied by breathing exercises.
41161044|NCT00317603|BIOLOGICAL|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
41161045|NCT04315129|DIAGNOSTIC_TEST|Smart Catheter Biosensor|A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection
41161046|NCT04019249|BEHAVIORAL|Healthy Weight Coaching|Healthy Weight Coaching is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
41364444|NCT00808665|DRUG|0.9% Saline|Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
41364445|NCT01621139|PROCEDURE|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
41364446|NCT04737226|DIAGNOSTIC_TEST|myotonometric assessment|The measurement method of the device is based on the free oscillation technique. Firstly, the probe of the device is placed perpendicular to the skin and a pre-pressure is applied to compress the subcutaneous tissue. Then, a short mechanical impulse is applied, causing damped oscillation on the tissue and the co-oscillation is recorded by an accelerometer.
40843171|NCT03718858|PROCEDURE|Interscalene Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
40843172|NCT03718858|PROCEDURE|Superior Trunk Nerve Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to Superior Trunk Nerve.
40843173|NCT03331523|DRUG|Calcipotriene/Betamethasone Dipropionate|Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)
40843174|NCT03331523|DRUG|Taclonex®|Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
40843175|NCT03331523|DRUG|Placebo|Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
41026670|NCT05090072|BEHAVIORAL|Advance Directives|The palliative care physician engaged patients and their caregivers in an open discussion about patients' answers to the Advance Directives document, to explore and clarify all doubts and questions prompted by the document
41026671|NCT05090072|BEHAVIORAL|Control|The palliative care physician undergone a conference with both patients and caregivers and evaluated patients' symptoms using the the Edmonton Frail Scale (Bruera, 1991), adapted to the Portuguese population. The Advance Directives theme wasn't approached during this conference.
41026672|NCT05486949|DRUG|AZD4205 and carbamazepine|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
41026673|NCT05486949|DRUG|AZD4205 and itraconazole|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
41026674|NCT05144191|DEVICE|Insignia uncemented Hip Stem|Device: Replacement of arthritic hip with Insignia uncemented Hip Stem
41026675|NCT03186846|DEVICE|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. • Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
41026676|NCT03186846|DEVICE|placebo|Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
41364447|NCT04737226|DIAGNOSTIC_TEST|Ankle mobility assessment|The knee to wall lunge test will use in a standing position while the heel in contact with the ground and the knee was in line with second toe. Athletes will do lunge forward and inclinometer will be place at the middle anterior tibial crista and measurement will be record.
41364448|NCT05240872|BIOLOGICAL|PRP injection|Plantar fascia injection therapy with PRP
41364449|NCT05240872|BIOLOGICAL|ABI injection|ABI injection
41364450|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard XP|
40843176|NCT04085913|DRUG|Lidocaine Epinephrine|Preincision injection, as is current practice
40843177|NCT04085913|DRUG|Bupivacaine Hydrochloride-EPINEPHrine|Preincision injection
40843178|NCT04085913|DRUG|Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine|Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
40843179|NCT05891158|DRUG|Fazirsiran|Fazirsiran SC injection
40843180|NCT03029507|BEHAVIORAL|ACT Enhanced ShipShape|The ACT components focus on: a) thoughts, feelings, and bodily sensations that are often present in the context of efforts to lose weight or improve fitness; b) limitations of previous efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness of experiences; and e) identification of personal values and setting and pursuing values-consistent goals in order to achieve improved quality of life.
41026677|NCT02488512|DRUG|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) \[45-46\], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
41026678|NCT06535867|DIAGNOSTIC_TEST|mHealth|The mobile health (mHealth) program will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers.
41364451|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard CR|
41026679|NCT02348216|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
41026680|NCT02348216|DRUG|Fludarabine|Administered according to package insert
41026681|NCT02348216|DRUG|Cyclophosphamide|Administered according to package insert
41026682|NCT02348216|DRUG|Levetiracetam|Administered according to package insert
41026683|NCT02348216|DRUG|Tocilizumab|Administered according to package insert
41026684|NCT02348216|DRUG|Dexamethasone|Administered according to package insert
41026685|NCT02348216|DRUG|High-dose methylprednisolone|Administered according to package insert
41026686|NCT02348216|DRUG|Bendamustine|Administered according to package insert
41026687|NCT02348216|DRUG|Rituximab|Administered according to package insert
41026688|NCT02348216|DRUG|Doxorubicin|Administered according to package insert
41026689|NCT02348216|DRUG|Prednisone|Administered according to package insert
41026690|NCT02348216|DRUG|Vincristine|Administered according to package insert
41026691|NCT02348216|DRUG|Ifosfamide|Administered according to package insert
41026692|NCT02348216|DRUG|Carboplatin|Administered according to package insert
41026693|NCT02348216|DRUG|Etoposide|Administered according to package insert
40843181|NCT03029507|BEHAVIORAL|Standard ShipShape (SS)|The materials and format of the Standard SS-only protocol are based on recommendations from the Navy and Marine Corps Public Health Center. These include: a) education for nutrition and physical activity; b) creating and documenting goals for weight loss and physical fitness; c) a food diary to track eating habits throughout the program; d) developing behavioral strategies to initiate/maintain an exercise program; e) monitoring of physical activity (pedometer provided by the study); and f) identifying and overcoming personal triggers for over-eating.
41026694|NCT02348216|DRUG|Gemcitabine|Administered according to package insert
41026695|NCT02348216|DRUG|Oxaliplatin|Administered according to package insert
41026696|NCT02348216|DRUG|Cisplatin|Administered according to package insert
41026697|NCT02348216|DRUG|Methylprednisolone|Administered according to package insert
41026698|NCT01836692|RADIATION|Intensity Modulated Radiotherapy treatment|Intensity Modulated Radiotherapy treatment
41026699|NCT00047463|DEVICE|continuous positive airway pressure (CPAP)|a mask treatment for sleep apnea
41026700|NCT00047463|DEVICE|Placebo-CPAP|Placebo-CPAP
41026701|NCT03566641|DEVICE|Negative pressure wound therapy|The application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound.
41026702|NCT03566641|OTHER|standard care dressing|The application of a standard care dressing (instead of negative pressure wound therapy) across the surface of wound.
41026703|NCT00600964|DRUG|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
41026704|NCT00600964|DRUG|GX15-070MS|GX15-070MS at various doses and schedules
40843182|NCT04907045|BEHAVIORAL|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
40843183|NCT04907045|BEHAVIORAL|Practice Facilitation|In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
40843184|NCT04907045|BEHAVIORAL|Standard Implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
40843185|NCT04621487|DRUG|Amoxicillin|14 days 1 gr bid
40843186|NCT04621487|DRUG|Metronidazole|14 days 500 mg bid
40843187|NCT04621487|DRUG|Clarithromycin|14 days 500 mg bid
41026705|NCT04523129|DRUG|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
41026706|NCT04523129|DRUG|Vehicle topical ocular, eye drops|Vehicle
41026707|NCT06534606|PROCEDURE|Electrotherapy and physical agents|"Moist heat therapy: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~• TENS application: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks."
41026708|NCT06534606|PROCEDURE|Headache SNAGs|"Headache SNAGs (Sustained Natural Apophyseal Glides) 5 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~• Frequency: 3 times a week for 2 weeks. 6 sessions in total."
41026709|NCT06534606|PROCEDURE|Sternocleidomastoid Release|Sternocleidomastoid Release: Group B will also receive Sternocleidomastoid release in addition with headache SNAGs. Release to the sternocleidomastoid muscle will be given once per session for 5-8 minutes.Frequency: 3 times a week for 2 weeks. 6 sessions in total.
41026710|NCT02705131|DEVICE|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
41026711|NCT02705131|DEVICE|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
41026712|NCT04768647|DEVICE|TNM|TNM is a small portable head set that can be used by the participants at home to stimulate the vestibular system
41026713|NCT03936244|DEVICE|Transurethral Resection of the Prostate (TURP)|Randomized allocation to M-TURP or PK-TURP
41026714|NCT06535399|DRUG|BMS-986369|Specified dose on specified days
41266877|NCT01275222|DRUG|Imatinib 800mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.
41266878|NCT03712826|DRUG|Anti-TNF Drug|Crohn patient with antiTNF treatment
40843188|NCT04621487|DRUG|Pantoprazole 40mg|40 mg bid 14 days
40843189|NCT04621487|DRUG|according to antibiogram|according to antibiogram
40843190|NCT00843154|DRUG|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
40843191|NCT00843154|DRUG|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
40843192|NCT02966470|DEVICE|Obtain grip strength from a standardized gripometer|Obtain grip strength from a standardized gripometer, 3 times on each hand
40843193|NCT02654938|DRUG|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
40843194|NCT02654938|DRUG|Placebo|5% infusion solution of dextrose
40843195|NCT00709878|PROCEDURE|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
40843196|NCT06264258|BEHAVIORAL|DVx-T1D™ app|The intervention group will be introduced to the DVx-T1D™ app and the participants will go home with the tablets that has the game installed. Participants will be asked to play the game for 20 mins or more daily. The aim of the app is to impart good behavioral changes in children with T1D in terms of diabetes education, on how to treat a low or a high blood sugar event and make healthy eating choices.
40843197|NCT02387008|DEVICE|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
40843198|NCT02387008|DEVICE|GUIDOR® membrane|horizontal bone augmentation with synthetic GUIDOR® membrane
40843199|NCT02387008|DEVICE|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
40843200|NCT04671992|DEVICE|Out of-Plane Technique and In-Plane on|A comparison of out of-plane technique and in-plane
40843201|NCT04999527|DRUG|DISC-0974|DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
40843202|NCT04999527|DRUG|Placebo|Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
41026715|NCT04768010|DRUG|Misoprostol|Participants will started by receiving 100 micrograms of oral misoprostol twice daily. If adverse effects are not noted dose can be titrated up to 200 micrograms of misoprostol twice daily. Participants will receive a total of five doses.
41026716|NCT01224041|DRUG|Tacrolimus|oral
40843203|NCT06276790|PROCEDURE|ultrasound-guided/hysteroscopic curettage|ultrasound-guided/hysteroscopic curettage
40843204|NCT06276790|PROCEDURE|Procedure/Surgery: laparoscopic removal of the pregnancy lesion|laparoscopic removal of the pregnancy lesion
41364452|NCT01824368|PROCEDURE|Extracorporeal Photopheresis Procedure (FEC)|"The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex."
40843205|NCT03483298|OTHER|ICSI|The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI
40843206|NCT04145674|DRUG|D-methadone|Patients will take one tablet of 25 mg d-methadone once daily at 6 pm over a period of 30 days
40843207|NCT04145674|OTHER|Placebo|Patients will take one tablet of placebo once daily at 6 pm over a period of 30 days
40843208|NCT03263780|DRUG|18F-Fluciclovine|Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-Fluciclovine)
40843209|NCT04882787|DEVICE|BTE hearing aid|Amplification
40843210|NCT05890482|BEHAVIORAL|Islamic Trauma Healing|Manualized, lay-led psychosocial intervention
41364453|NCT00969462|DRUG|Doxorubicin|measurements of serum Doxorubicin levels
41364454|NCT01586013|DRUG|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
40843211|NCT02678923|DRUG|MDCO-216|
40843212|NCT02678923|DRUG|Placebo|
40843213|NCT02961491|DRUG|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
40843214|NCT05229250|OTHER|Cycling test|RAMP and MULTI-STAGE test
40843215|NCT05229250|OTHER|Occlusion tests|Occlusion test before and after exercise
41026717|NCT00648479|DEVICE|The Guiding Star|
41026718|NCT00648479|DEVICE|fluoroscopy (OEC 9800 - General Electric)|
41026719|NCT02632578|BIOLOGICAL|2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)|Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
41026720|NCT01931839|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
40843216|NCT05229250|DEVICE|NIRS during cycling|NIRS devices measuring oxygenation during exercise
41500397|NCT06629844|OTHER|The control group|The intervention begins with an introduction to the VR dementia program, outlining its objectives and setting participant expectations. A pre-program questionnaire follows to assess baseline knowledge, attitudes, and intention to assist people with dementia. A brief lecture introduces a dramatization showing ineffective communication with a PLWD, followed by a VR scenario highlighting poor care practices. After discussing these observations, participants attend a lecture explaining dementia's symptoms and progression, with culturally adapted video content for Indonesian audiences. Next, a positive VR scenario demonstrates best practices in dementia care, followed by a video on supportive communication. A second lecture offers practical strategies for caregiving and communication, complemented by an N-impro session to deepen understanding. The session concludes with a post-program questionnaire and final reflection to encourage real-world application of the learned skills.
41364455|NCT05937373|DEVICE|Continuous Glucose monitor|Perioperative glucose management beginning preoperative through postoperative monitoring
41500398|NCT03134092|OTHER|Probabilistic Risk Communication Tool (PRT)|The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
41500399|NCT03134092|OTHER|Narrative Enhanced Risk Tool (NERT)|Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale around prolonged opioid uses. Narrative videos are developed from actual patients sharing their stories - put into a in a structured format of \~ 2-minute length and recorded.
41500400|NCT05606614|GENETIC|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
41500401|NCT04842786|OTHER|Coconut oil|Coconut oil, Parachute oil composition: 92% lauric (C12) fatty acid, 6% oleic fatty acid, 2% linoleic fatty acid
41500402|NCT02456935|DRUG|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
41500403|NCT02456935|DRUG|Esomeprazole 40 mg QD|Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.
41500404|NCT01960049|PROCEDURE|ropivacaine + iv PCA|
40843217|NCT05229250|DEVICE|CPET|Cardiopulmonary exercise testing (heart rate, pulmonary gas exchange) during exercise
41364456|NCT05937373|OTHER|Standard of Care|no study intervention. participant follows current medical providers recommendations for glucose management
41364457|NCT02899884|OTHER|No Intervention|
41364458|NCT01190839|BIOLOGICAL|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
41364459|NCT01190839|DRUG|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
41364460|NCT01230073|DEVICE|Home-Monitoring|Home-Monitoring
41364461|NCT01230073|DEVICE|Follow-up by Home-Monitoring|Follow-up by Home-Monitoring
41364462|NCT00412425|DRUG|Palonosetron|0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
41364463|NCT02314299|DRUG|MTP-131|
41364464|NCT05748145|DRUG|Metronidazole Oral|Metronidazole will be administered per os at 500 mg x 3/day, for 10 days prior to surgery.
41500405|NCT01960049|PROCEDURE|saline and IV PCA|
41500406|NCT00094861|DRUG|Palifermin|
41500407|NCT00094861|DRUG|Placebo|
40843218|NCT05229250|DEVICE|Echo-Doppler examination|Peak systolic velocity and vascular stiffness measurements in the iliac-aortic tract
40843219|NCT05726474|BEHAVIORAL|Combined exercise|Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
41364465|NCT03107065|DEVICE|Thermi Radiofrequency|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
41364466|NCT01004861|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
41364467|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch (Pitch-Patch Tissue Reinforcement Device))|The Pitch-Patch is a single-use device intended to reinforce the rotator cuff following or during repair by sutures or suture anchors where weakness exists in the soft tissue.
41364468|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented without a synthetic polyester patch|Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch.
41026721|NCT01931839|DRUG|Ivacaftor|Film-coated tablet, oral use
41026722|NCT02206802|DRUG|5% minoxidil topical foam|5% minoxidil topical foam
41364469|NCT03608124|BEHAVIORAL|Behavior management techniques|Pediatric dentists will be questionnaired regarding their adopted behavior management techniques for pediatric patients
41364470|NCT03085160|BEHAVIORAL|Learning to Breathe|Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
41500408|NCT00094861|RADIATION|Radiotherapy|
41500409|NCT00094861|DRUG|Paclitaxel|
41500410|NCT00094861|DRUG|Carboplatin|
41500411|NCT04156958|DRUG|Fruquintinib|Fruquintinib will be administered orally at a dose of 5 mg/d, 3 weeks on, 1 week off (4 weeks as a cycle) until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
41500412|NCT02258854|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
40843220|NCT05726474|BEHAVIORAL|High interval training|Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
41266879|NCT03712826|DRUG|Ustekinumab|Crohn disease with ustekinumab treatment
41364471|NCT03085160|BEHAVIORAL|Health Education|Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
41364472|NCT03425240|DEVICE|Nerve Stimulation|Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.
41364473|NCT03127072|DEVICE|Radiofrequency Ablation (RFA)|The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue
41364474|NCT03127072|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
41500413|NCT02926482|BEHAVIORAL|Prescriber Recruitment Bundle (PRB)|The Prescriber Recruitment Bundle (PRB) is a bundle pharmacotherapy capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) prescriber education forums, c) prescriber-friendly workflow and risk-reduction strategies, d) academic detailing to recruit OUD prescribers, e) telemedicine, and f) organizational leadership and culture to support building OUD pharmacotherapy capacity.
41500414|NCT05545384|DRUG|Immediate Azathioprine (1st attack)|"Patients randomized in Immediate Azathioprine group will benefit from immediate treatment with azathioprine. Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg."
41500415|NCT05545384|DRUG|Immediate Rituximab (1st attack)|"Patients randomized in Immediate Rituximab group will benefit from immediate treatment with rituximab. Rituximab 375mg/m2 IV will be given at D1 and D15 and repeat every 6 months for 2 years.~Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime."
41500416|NCT05545384|DRUG|Standard of care|Patients in this group will be treated according to standard care
41500417|NCT05720065|DRUG|Botulinum toxin type A|Randomized double-blind administration
41500418|NCT05720065|DRUG|Isotonic saline 0,9%|Randomized double-blind administration
41500419|NCT03148561|DRUG|Misoprostol|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
41500420|NCT06396065|DRUG|AK112 Injection|Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
41500421|NCT06396065|DRUG|Placebo Injection|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
41266880|NCT02181933|DRUG|Nevirapine|
41364475|NCT01921582|DRUG|Methylphenidate|"* Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~* Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
41364476|NCT01921582|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:~* Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~* Phase 2 aims to reduce food intake and restructure eating-related cognitions;~* Phase 3 focuses upon relapse prevention"
41026723|NCT02390804|DEVICE|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
41500422|NCT06089434|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE) with limited number of TEE clips|The intervention group would be limited to fewer than 20 TEE clips per case (versus the average of \~ 80-100 TEE clips per case).
41500423|NCT06089434|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist|The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.
41500424|NCT06633796|DEVICE|AMADEO|304 / 5.000 The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy, functional occupational therapy and polyarticular mobilization of the fingers with a robotic arm (Amadeo). The sessions will be scheduled 2 times a week for 5 consecutive weeks.
41500425|NCT06633796|PROCEDURE|Standard of care|The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy and occupational therapy for functional purposes. The sessions will be scheduled 2 times a week for 5 consecutive weeks.
41500426|NCT00004137|BIOLOGICAL|filgrastim|
41500427|NCT00004137|DRUG|carboplatin|
41026724|NCT02390804|DEVICE|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
41026725|NCT04561570|DEVICE|Vivity ACRYSOF IQ IOL Group|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
41026726|NCT04561570|DEVICE|ACRYSOF IQ IOL Control Group|Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
41026727|NCT01551862|PROCEDURE|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
41026728|NCT02169934|DRUG|Radiolabeled TRV130|A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
41026729|NCT04286035|DRUG|Bupivacaine Injection|Femoral nerve block with 20 ml %0.375 bupivacaine
41026730|NCT04286035|DRUG|Bupivacaine Injection|Adductor canal block with 20 ml %0.375 bupivacaine
41026731|NCT02779257|DRUG|Pasireotide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
41026732|NCT02779257|DRUG|Diazoxide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
41026733|NCT05217732|DRUG|ZX-7101A|tablet
41026734|NCT05217732|DRUG|Placebo|Tablet
41026735|NCT03707366|BEHAVIORAL|FHF-T|FHF-T employs mentoring, consisting of relationship development, advocating for and empowering youth, and skill-building activities to promote positive youth development. Mentors meet individually for 2-3 hours per week for 30 weeks with each teen they mentor, in order to engage teens in positive youth development activities and provide skills training in areas including emotion recognition, perspective-taking, problem solving, effective communication, managing anger, healthy coping and resisting peer pressure for deviant activities. Youth also attend group workshops over the course of the program, in which they engage with other participants and mentors in skill-building activities.
41026736|NCT03956303|DRUG|Chirocaine %0.5|Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
41026737|NCT03956303|DRUG|Chirocaine Heavy 40|Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl
41026738|NCT03956303|DRUG|Chirocaine Heavy 60|Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl
41026739|NCT03956303|DRUG|Chirocaine Heavy 80|Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl
41026740|NCT05413187|DRUG|Medical Grade Cannabis oil|MGC, 30% CBD and 1.5% Δ9-THC
41026741|NCT05413187|DRUG|Placebos|Olive oil and Chlorophyl
41026742|NCT04225208|DRUG|[14C]-AZD4205, single 50 mg oral dose administrated on day 1|Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
41026743|NCT02842398|BEHAVIORAL|Balance Master|
41026744|NCT02842398|BEHAVIORAL|Customary Care|
41026745|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
40843221|NCT03597061|BEHAVIORAL|Healthy Start to Feeding|The intervention provides parent education and skills training on a responsive feeding approach to introduction of healthy foods in infancy. Session content is manualized and administered by interventionists with expertise in child development and behavioral strategies for managing child eating behaviors under the supervision of a licensed clinical child psychologist and pediatric occupational therapist. Sessions are conducted individually with participants and primary caregivers and include educational content, handouts and instructions, modeling of skills by the interventionist, caregiver practicing of skills in session, establishment of behavioral goals, and problem solving barriers to implementation of treatment content. Content will include topics such as allowing infants' own hunger and satiety cues to guide the feeding experience, introducing healthy foods, parental attunement to infant satiety cues, and promoting infants' own self-feeding.
41026746|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
41026747|NCT02117570|BIOLOGICAL|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
41026748|NCT01557946|DRUG|citalopram|citalopram 20-40 mg daily
41026749|NCT03946332|BEHAVIORAL|Physical exercises|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
41026750|NCT03946332|BEHAVIORAL|Optional physical exercises|patients will be proposed for the physical exercises and will practice them if they want.
41026751|NCT02227160|BEHAVIORAL|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
41026752|NCT02227160|BEHAVIORAL|Outpatient counseling and support groups|Usual mental health care
41026753|NCT05269264|DIAGNOSTIC_TEST|Assessor A (first measurement): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
41026754|NCT05269264|DIAGNOSTIC_TEST|Assessor B: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
41026755|NCT05269264|DIAGNOSTIC_TEST|Assessor A (second measurement: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
41161047|NCT03704649|BEHAVIORAL|Participatory video|Participatory video education is an intervention model that gives communities the film-making skills necessary to make videos that can be used in nutrition promotion. For the purposes of this study, we will be using a participatory video model as an approach to educate participants in a school-based girls club on nutrition education topics. Participants are taught how to use film equipment and accompanied to draft scripts, create characters, video-record the shots, and act (if they wish) in the video. These videos will be used in the group as a means of sharing nutrition information with students and in stimulating discussion around the nutrition topic.
41161048|NCT02480777|BIOLOGICAL|Autologous Human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
41266881|NCT02181933|DRUG|Zidovudine (ZDV)|
41266882|NCT02181933|DRUG|Lamivudine (3TC)|
40843222|NCT01033318|DRUG|MK1809|single oral doses of MK1809
40843223|NCT01033318|DRUG|Comparator: Losartan|single oral doses of 100 mg Losartan
41364477|NCT01139645|DRUG|Rabeprazole or Esomeprazole or Lanzoprazole|1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
41364478|NCT04331236|BEHAVIORAL|Cognitive Behavioral Therapy|CBT trains individuals to identify and reframe dysfunctional thoughts to help improve mood and behavior. CBT intervention also includes teaching relaxation and mindfulness strategies, as well as ways to help improve functioning through the use of behavioral goal setting.
40843224|NCT01033318|DRUG|Comparator: Placebo|Placebo to MK1809
41026756|NCT05269264|DIAGNOSTIC_TEST|Assessor A (2 weeks later): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
41364479|NCT04331236|OTHER|Yoga|Yoga consists of physical exercises, breathing techniques, and meditation designed to condition the physical body, calm the mind, and stabilize emotions.
41026757|NCT04547972|OTHER|Higher-load resistance training|This intervention will have one arm and one leg of each participant training with \~80% of their one repetition maximum
41026758|NCT04547972|OTHER|Lower-load resistance training|This intervention will have one arm and one leg of each participant training with \~30% of their one repetition maximum
41364480|NCT02626078|OTHER|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
41026759|NCT05013892|RADIATION|NTS-WBRT (normal tissue sparing whole brain radiation therapy)|Radiation
41364481|NCT01711073|DRUG|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
41026760|NCT05013892|DRUG|Memantine|Capsule, taken orally
41026761|NCT01480700|OTHER|Nutritional study|subjects consume 2 eggs per day during 4 months
41026762|NCT03839238|BIOLOGICAL|hESC derived MSC like cell|Different dosage of hESC derived MSC like cell for the meniscus injured patients
41026763|NCT01870700|DRUG|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
41026764|NCT01870700|DRUG|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
41026765|NCT02578394|DRUG|Anakinra 100mg and Placebo Depo-Medrone|Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.
41026766|NCT02578394|DRUG|Depo-Medrone 120mg and Placebo (Anakinra)|Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
41026767|NCT01731171|DIETARY_SUPPLEMENT|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
41026768|NCT01731171|DIETARY_SUPPLEMENT|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
41026769|NCT04420299|DRUG|Bemiparin|Bemiparin at therapeutic dose for 10 days
41026770|NCT04420299|DRUG|Bemiparin|Bemiparin at prophylactic dose for 10 days
41026771|NCT05820022|OTHER|Research Barriers Scale|This scale was prepared after a detailed literature review and sent to five physiatrists for review and feedback. It consists of 21 items with Likert-type responses and two open-ended questions. It is designed to measure the barriers that individuals or groups face in conducting research. The scale includes a list of potential barriers and asks respondents to rate the extent to which they experience each barrier. Examples of barriers that may be included in such a scale could include lack of funding, limited access to resources or equipment, time constraints, difficulty finding participants or accessing data, institutional or administrative hurdles, and so on.
41026772|NCT02419157|DRUG|Selective enamel etching with 36% phosphoric acid|Etch: selective 36% phosphoric acid enamel etching
41026773|NCT02419157|DRUG|No selective enamel etching with 36% phosphoric acid|Non-etch: without phosphoric acid selective enamel etching
41026774|NCT02419157|DEVICE|Clearfil SE Bond|
41364482|NCT05836389|PROCEDURE|Pulmonary veins isoltation in bilateral thoracoscopy|Ablation of the atrial fibrillation performin isolation of the pulmonary vein. The procedure is video-assisted, access is minimally invasive: access to the heart is provided to instruments and camera via small bilateral chest incisions
41364483|NCT04337463|DRUG|ATG-008|Tablet
41364484|NCT04337463|DRUG|Toripalimab|IV infusion
41364485|NCT03899558|DEVICE|Humidified nasal high-flow device|Humidified nasal high-flow device which delivers warmed, humidified air at flow rates of up to 60 litres per minute via a nasal cannula interface. Intended delivery at 30 L/min at 37 degrees Celsius, if tolerated.
41364486|NCT00383292|DRUG|tasisulam|Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
41364487|NCT02387827|BEHAVIORAL|Diet+ short term versus long -term physical activity|
40843225|NCT03681613|OTHER|NEMEX program combined with a CNS-focused protocol|"The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training."
40843226|NCT03681613|OTHER|NEMEX program|The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.
40843227|NCT03409341|OTHER|Blood and tumor tissue analysis, Clinical response.|DNA sequencing and functional testing of peripheral blood mononuclear cells. DNA and RNA sequencing and immune cell analysis of tumor. Clinical response at 12 months.
41026775|NCT02419157|DEVICE|Xeno V|
41026776|NCT04256733|BIOLOGICAL|Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through the Koko Digidoser nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. The concentration will never exceed 1000 micromolar. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
41026777|NCT04256733|BIOLOGICAL|Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer|Participants will be repeatedly exposed to a sub-threshold dose of aerosolized capsaicin through the KoKo Digidoser nebulizer during treatment sessions. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
41026778|NCT04199247|BEHAVIORAL|Sub symptom aerobic exercise|Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
41026779|NCT02512718|DRUG|Omegaven|Comparison of FOLE vs. SOLE
41026780|NCT02512718|DRUG|Soybean oil lipid emulsion|Comparison of FOLE vs. SOLE
41026781|NCT05826236|DEVICE|Periarticular compression|Periarticular knee compression using a sphygmomanometer.
41026782|NCT04818411|OTHER|Routine physical therapy treatment with the Stabilization exercises|The program was based on specific training of the transversely oriented abdominal muscles with coactivation of the lumbar multifidus at the lumbosacral region, training of the gluteus maximus, the latissimus dorsi, the oblique abdominal muscles, the erector spinae, the quadratus lumborum, and the hip adductors and abductors. Initially, we focused on the specific contraction of the transversely oriented abdominal muscles. After approximately 2 weeks, loading was progressively increased throughout the intervention period. The women were required to exercise for 30 to 60 minutes, 3 days a week, for 3-4 weeks.
41026783|NCT04818411|OTHER|Routine physical therapy treatment + High-velocity thrust manipulation|: For high-velocity thrust technique, a modified Chicago technique was used. For this procedure, the lumbopelvic region was targeted. The side to be treated was chosen, based on the subject's report of her most symptomatic side. The physical therapist, performed passively side bend the subject toward the painful side, rotate the upper body in the direction opposite to the side bending, and then deliver a quick posterior and inferior thrust at a grade V including a small-amplitude/high-velocity therapeutic movement. A maximum of 2 attempts per side was permitted if no pop was heard following the first attempt. If the subject showed improvement of 50% or less after the first treatment, the intervention was categorized as a failure, the examination and intervention were repeated, and the subjects were asked to return 2 to 4 days later. If the subject showed greater than 50% improvement, the intervention was categorized as a success, and study participation was concluded.
41026784|NCT00006127|DRUG|amifostine|
41026785|NCT03300388|DIETARY_SUPPLEMENT|Omega-3 (DHA-rich dietary supplement)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
41026786|NCT03300388|DIETARY_SUPPLEMENT|Placebo (olive oil)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
41026787|NCT03300388|OTHER|Resistance training|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
40843228|NCT00614484|RADIATION|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
41026788|NCT05950802|DRUG|Cyclophosphamide|Higher dose than traditional conditioning chemo
41026789|NCT05950802|RADIATION|TLI|radiation given with conditioning chemo
41266883|NCT00384020|DRUG|Paroxetine (Seroxat)|
41266884|NCT00384020|DRUG|Escitalopram (Lexapro)|
41266885|NCT03360760|DRUG|Doxorubicin|60mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
41266886|NCT03360760|DRUG|Cisplatin|100mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
41266887|NCT03360760|DRUG|Methotrexate|High dose of methotrexate (8-12g/m\^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
41364488|NCT02506673|DEVICE|Zeiss, Cinema ProMED (audiovisual equipment)|
41364489|NCT02506673|DRUG|Midazolam|
41364490|NCT02506673|DEVICE|Skin Conductance Monitor|
41364491|NCT01878708|DRUG|PEG-L-asparaginase|
41266888|NCT03360760|DRUG|Ifosfamide|12g/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
41364492|NCT01878708|DRUG|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
41364493|NCT00512928|DRUG|acenocoumarol|max 5 mg per day during 10 weeks
41500428|NCT00004137|DRUG|paclitaxel|
41500429|NCT00004137|DRUG|topotecan hydrochloride|
41026790|NCT03143829|OTHER|eSSET-CINV|This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
41161049|NCT02470299|DRUG|Ketorolac|"Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds~Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
41161050|NCT02470299|OTHER|Placebo|"Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
41364494|NCT00512928|DIETARY_SUPPLEMENT|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
41364495|NCT04460651|DRUG|Icosapent ethyl (IPE)|"Participants in this arm will receive study medication IPE with the following dosage schedule:~8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)"
41364496|NCT04460651|DRUG|Placebo|Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
41500430|NCT04126590|BIOLOGICAL|KN044|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg."
41500431|NCT06595004|DRUG|HCP1004|Test Drug
41500432|NCT06595004|DRUG|RLD2401|Reference drug
41500433|NCT04943276|DEVICE|Embr Device|The Embr thermal device will be worn at all times from study start to the study endpoint.
41500434|NCT03359954|RADIATION|Radiation Therapy|Undergo radiation therapy
41500435|NCT03359954|PROCEDURE|Therapeutic Conventional Surgery|Undergo breast surgery
41500436|NCT01953978|DRUG|Dexamethasone|Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
41500437|NCT01953978|OTHER|Placebo|Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
41500438|NCT01953978|DRUG|Morphine|Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
41161051|NCT01827449|DEVICE|Fluidotherapy warming device|Device uses airborne heated cellulose particles which are blown against the skin to provide convective warming.
41161052|NCT03022383|DEVICE|DRI OCT Triton plus|OCT Machine used for diagnostic purposes
41161053|NCT00655083|DRUG|Nepadutant|0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
41161054|NCT00655083|DRUG|Nepadutant|0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
41161055|NCT02750553|DRUG|SHR0534|
41364497|NCT05794334|OTHER|Low Dye Taping|This second group also contains 20 participents.French functional method is similar to the Ponseti method. In this technique, the patient undergoes 30-minute daily session for 2 weeks and then twice a week until achieving foot correction. It consists of stretching of triceps surae to improve tibio-talar joint function. daily manipulations of the newborn's foot, stimulation and strenghtening of the muscles around the foot (particularly the peroneal muscles) and temporary immobilization of the foot with elastic and nonelastic adhesive taping so that the reduction achieved by.The average time of this method ranges between 6 to 8 weeks, with all the deformities being corrected apart from equinus. This method reports a 93% success rate
41364498|NCT00816712|DRUG|Comparator: Testosterone 300 mg, intramuscular injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 300 mg, Intramuscular injection."
41500439|NCT01953978|DRUG|Zofran|Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
41500440|NCT01953978|DRUG|Paracetamol|Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
41500441|NCT01953978|DRUG|Ibuprofen|Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
41500442|NCT06393946|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
41500443|NCT00001110|PROCEDURE|Bronchoalveolar lavage|
41500444|NCT02863055|DRUG|Nintedanib|Nintedanib 200 mg administered twice daily
41500445|NCT02863055|DRUG|Placebo|Matching placebo administered twice daily
41500446|NCT06491732|DEVICE|Electrical Impedance Myography|EIM is an impedance-based technology in which an imperceptible, high-, multi-frequency (e.g., 1 kHz to 10 MHz) electrical current is applied across two electrodes; the resulting voltage signals are measured across two sense electrodes
41500447|NCT04819841|GENETIC|nula-cel Drug Product|nula-cel is administered via IV infusion following a myeloablative conditioning regimen
41026791|NCT05919810|OTHER|Probiotic|Oral probiotic
41026792|NCT05919810|DIETARY_SUPPLEMENT|Oral herbal powder supplement|oral herbal powder
41026793|NCT02174536|BIOLOGICAL|Decidual stromal cells|Decidual stromal cells (approximately 1x10\^6 cells/kg) will be infused intravenously.
41026794|NCT02174536|BIOLOGICAL|Placebo|
41161056|NCT02750553|DRUG|Placebo|
41364499|NCT00816712|DRUG|Comparator: Testosterone 100 mg, Intramuscular injection|"Day 1 \& 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 100 mg, Intramuscular injection."
41364500|NCT00816712|DRUG|Comparator: Placebo given by Intramuscular Injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Placebo given as intramuscular injection."
41364501|NCT00545584|DRUG|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
41364502|NCT00545584|BEHAVIORAL|Comparator: Diet|Diet
41500448|NCT04748965|DIAGNOSTIC_TEST|Digital Subtraction Angiography|Compare optical coherence tomography lesion sizing and characteristics compared to traditional digital subtraction angiography
41500449|NCT03563911|BEHAVIORAL|Brief Mindfulness-Based Intervention (BMBI)|The BMBI is be based on a BMBI which demonstrated analgesic effects in a previous study. Relative to full-length interventions, we will employ a brief intervention; the 20-minute BMBI session will include education on the foundational concepts of mindfulness and its relevance to chronic pain (5 minutes) and a guided mindfulness practice involving focused attention on the breath and monitoring of thoughts, feelings, and body sensations (15 minutes). BMBI participants will be encouraged to practice the taught mindfulness technique at home at least 20 minutes/day for 1 week (a handout and link to an online guided mindfulness practice will be provided).
41500450|NCT03563911|BEHAVIORAL|Control/Nutrition Education|The Control intervention will involve nutrition education, adapted from an existing manual of cognitive-behavioral therapy for opioid-treated chronic pain. Control intervention protocol will match the BMBI in terms of time / structure to control for the non-specific, non-mindfulness effects of BMBI. The 20-minute Control session will include education on the relationship between diet and pain (10 minutes) and recommendations for a healthy diet (10 minutes). Control participants will be encouraged to prepare healthy meals at home at least 20 minutes/day for 1 week (a handout and link to online resources will be provided).
41500451|NCT00094406|PROCEDURE|Bronchoscopy|
40843229|NCT00614484|DRUG|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
40843230|NCT00614484|DRUG|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
40843231|NCT06208566|BEHAVIORAL|Conversational Agent Zenny|The intervention group involves a newly developed conversational agent self-care program. This program consists of 40 separate modules based on empirically supported techniques. Modules include the following core sections: cognitive behavioral skills, interpersonal relationships, positive psychological growth, relaxation, goal setting, and emotional regulation skills. The modules focus on cognitive-behavioral skills for reducing emotional distress, improving behavioral activation and healthy behaviors, and problem-solving skills. The intervention was delivered via a decision-tree based conversational agent in WhatsApp messenger.
40843232|NCT06208566|BEHAVIORAL|Web-based Wellness Resources|"The control group involved referral to a menu of freely-available evidence-based wellness resources linked from the study website, Your Healthiest Self: Wellness Toolkits, Doing What Matters in Times of Stress, and How Right Now. These website choices involved self-selection of relevant modules for improving mood, reducing stress and anxiety, addressing relationship problems, and other wellness topics. These programs required only access to the websites and could be completed in a self-help format by participants at their own pace."
40843233|NCT04572750|BEHAVIORAL|EMPOWER-ED|An electronic app that runs on a variety of platforms and provides education and tools designed to promote self-driven reduction of benzodiazepines.
41500452|NCT00094406|PROCEDURE|Bronchoalveolar lavage|
41500453|NCT00094406|DRUG|Endotoxin|
41500454|NCT00094406|DRUG|Carbon Monoxide|
40843234|NCT03925051|DRUG|Prolia®|mAb targeting RANKL. human monoclonal antibody targeting RANKL.
40843235|NCT03925051|DRUG|CMAB807|human monoclonal antibody targeting RANKL.
40843236|NCT02980627|BEHAVIORAL|Therapy with Mobile App Enhancement|"Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies."
40843237|NCT00337584|PROCEDURE|Pre-surgical screening|
41161057|NCT00924599|BEHAVIORAL|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
41364503|NCT00545584|BEHAVIORAL|Comparator: Physical Activity|Physical Activity
41364504|NCT04148976|DIETARY_SUPPLEMENT|Placebo|A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
41364505|NCT04148976|DIETARY_SUPPLEMENT|Dietary portfolio|A mixture of functional foods divided into 30g individual packets.
41500455|NCT04480710|DRUG|CRV431 75mg|1 x 75mg softgel capsule
41500456|NCT04480710|DRUG|Placebo (1 softgel)|1 x placebo softgel capsule
41500457|NCT04480710|DRUG|CRV431 225mg|3 x 75mg softgel capsule
41364506|NCT03507049|PROCEDURE|iFuse|ifuse will be implanted as described in section on the active comparator arm of the study.
41500458|NCT04480710|DRUG|Placebo (3 softgels)|3 x placebo softgel capsule
41364507|NCT03507049|PROCEDURE|sham group|sham surgery will be performed as desrcribed in section on sham comparator.
41364508|NCT03507049|RADIATION|fMRI study|Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
41500459|NCT03463408|DRUG|nivolumab|240 mg every 2 weeks
41500460|NCT03463408|DRUG|ipilimumab|1 mg/kg every 6 weeks
41364509|NCT04399499|DEVICE|MitraClip implantation|The MitraClip® procedure is performed under general anesthesia and orotracheal intubation. The procedure is usually guided by 2 and 3-dimensional transesophageal echocardiography and fluoroscopy. This catheter-based technology is inserted through femoral venous access and advanced in the left atrium through the transseptal puncture. The MitraClip® is provided by 2 arms able to grasp the anterior and posterior mitral leaflets. The goal is to approximate both leaflets creating a double orifice mitral valve mimicking the edge-to-edge surgical repair procedure (Alfieri stitch).
41364510|NCT03258710|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
41364511|NCT00991458|DRUG|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
41364512|NCT00991458|DRUG|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
41500461|NCT00244478|DIETARY_SUPPLEMENT|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
41500462|NCT00244478|DIETARY_SUPPLEMENT|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
41500463|NCT04036877|OTHER|Mood Disorder Assessment|Assess depression, anxiety, HRQOL, and financial toxicity in both bladder cancer patients and their caregivers via telephone survey
41500464|NCT06530628|BEHAVIORAL|Adult patients resident in Pavillon C of the Pierre Garraud Hospital|"Adult patients resident in Pavillon C of the Pierre Garraud Hospital, aged over 70, polypathological, with or without undernutrition.~The intervention involves the diffusion of culinary odors using diffusers in the unit's hallways, 20 minutes before lunch, from Monday to Friday, for a period of three weeks.~This experiment will be repeated over 18 weeks (6 cycles), alternating meals without olfactory stimulation (cycles 1, 3 and 5) and meals with stimulation (cycles 2, 4 and 6).~The 3-week rhythm corresponds to the menu cycle proposed by the Unité Centrale de Production Alimentaire (UCPA). Thus, the menu will be the same whether or not it is associated with the diffusion of culinary scents."
41500465|NCT04184505|DRUG|Azacitidine|75mg/mq/day subcutaneously for 7 days every 28 days
40843238|NCT05028270|PROCEDURE|Balloon technology;Microcatheter technology|Describe each group's intervention in sufficient detail, including how and when to give the intervention Suspend or modify the criteria for interventions that have been assigned to the subject (such as changing the dose of the drug due to hazards or subject requirements or improvement/deterioration of the condition, etc.) Strategies to improve the compliance of intervention programs, and other measures to monitor compliance (such as the return of drug tablets, laboratory inspections, etc.) Related care and interventions allowed or prohibited during the trial
40843239|NCT03591172|DRUG|Propolis|Using propolis as a final irrigation in revascularization
40843240|NCT03591172|DRUG|Nano-propolis|Using Nano-propolis as a final irrigation in revasculariztion
40843241|NCT03591172|DRUG|saline|Using saline as a final irrigation in revasculariztion
41161058|NCT00924599|BEHAVIORAL|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
41161059|NCT04047225|DEVICE|THE ANALGESIA NOCICEPTIVE INDEX (ANI)|Utilisation of the ANI during the operation
41161060|NCT05790187|OTHER|Presentation of differents face pictures|Test 1: Unmasked face vs. masked face Test 2: Unmasked face up vs. unmasked face down Test 3: Face masked right side vs. face masked reverse
41161061|NCT03891498|DRUG|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
40843242|NCT02816463|DEVICE|Ambu AuraGain|
40843243|NCT02816463|DEVICE|LMA Supreme|
40843244|NCT04384627|RADIATION|Delineating the GTV according to the pretreatment or post-IC tumor extension|Delineating the GTV according to the pretreatment or post-IC tumor extension
41161062|NCT04665778|OTHER|hospital bedroom booking|Patient in high risk of hospitalization group benefits a dedicated process to find and book a bedroom
41266889|NCT03360760|PROCEDURE|definitive surgery|Including limb-sparing procedure and amputation
41266890|NCT03360760|OTHER|pre surgical chemotherapy|chemotherapy that given before definitive surgery
41266891|NCT03121391|PROCEDURE|Ventilator withdrawal algorithm|"Steps and decision trees in the algorithm include in descending order:~Ascertain patient consciousness, perform cuff-leak test, evaluate for indications for pre-medication, select a withdrawal method, assess for respiratory distress with Respiratory Distress Observation Scale, medicate for respiratory distress with morphine, make an extubation decision, ascertain need for continuous morphine, ascertain need for supplemental oxygen, assess for post-extubation stridor, treat post-extubation stridor"
41266892|NCT02686229|OTHER|no interventions|
41266893|NCT04530162|PROCEDURE|Ultrasound guided nerve block|nerve block using bupivacaine and dexamethasone.
41266894|NCT03135366|BEHAVIORAL|Keheala|
41266895|NCT03135366|OTHER|Standard of Care|Patients receive medication for a week or two weeks at a time. They are assigned a friend or family member 'supporter' to verify the patient's at-home treatment and instructed to return to the clinic with the patient during medication refills.
41266896|NCT01973309|DRUG|Vantictumab combined with paclitaxel|Vantictumab combined with paclitaxel will be administered IV.
41266897|NCT06199167|BEHAVIORAL|Action Observation Therapy|The Action Observation Therapy group watched each ADL activity for two minutes through pre-prepared videos and then repeated the movement they watched for three minutes. In the 15-session treatment, a total of 18 ADL activities.
41266898|NCT06199167|BEHAVIORAL|Photo Observation|The Photo Observation group observed the photographs taken from the video for two minutes and then practised the movement described for three minutes. In the 15-session treatment, a total of 18 ADL activities.
41500466|NCT04184505|DRUG|Standard Chemotherapy|"1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~2. cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)"
41500467|NCT04184505|PROCEDURE|Allogeneic stem cell transplantation|Allogeneic stem cell transplantation
40843245|NCT00849108|DRUG|BMS747158|"dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
40843246|NCT06001619|DRUG|Prostate hyperplasia medication|The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.
40843247|NCT06001619|DRUG|LhRH-antagonist|The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.
40843248|NCT01807377|DRUG|PF-05175157|200 mg tablet administered twice per day for 14 days
40843249|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
40843250|NCT01807377|OTHER|Placebo|Placebo administered twice per day for 14 days
40843251|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
40843252|NCT04182061|BEHAVIORAL|The AMTE protocol|The AMTE program is an adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018) to be applied as an internet-based protocol. Like the UP-A, the program AMTE implements a set of core principles to address common factors underling youth anxiety and depressive symptoms. It includes the following 10 modules: (1) Understanding emotional problems and disorders, (2) Getting to know your emotions and behaviors, (3) Enjoy your positive activities, (4) Mindful emotion awareness, (5) Being flexible in your thinking, (6) Confronting physical sensations, (7) Situational emotion exposure, (8) How to regulate the emotional avoidance, (9) Respiratory relaxation training, and (10) Relapse prevention.
40843253|NCT05082415|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
40843254|NCT02431390|DEVICE|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
40843255|NCT02431390|BEHAVIORAL|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
40843256|NCT04157283|DIAGNOSTIC_TEST|MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)|"1. Neurophysiological Evaluation:~   Visual Evoked Potential (VEP).~2. Imaging Evaluation:~   Conventional MRI.~3. Cerebrospinal Fluid (CSF):~4. Sexual dysfunction measure: through the international index of erectile function (IIEF), female sexual function questionnaire (SFQ) and the sexual Quality of life male and female version (SQoL) (American Psychiatric Association, 1994).~5. Depressive symptoms assessment through The BDI (The Beck Depression Inventory) which is the most common instrument measuring the severity of depression.~6. Fatigue symptoms were evaluated through fatigue subscale of Multiple Sclerosis Quality of Life-54(MSQOL-54)."
40843257|NCT05606341|DRUG|CpG1018|"0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
40843258|NCT05606341|DRUG|CpG1018|"0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
41266899|NCT03404778|DEVICE|Biomet Comprehensive Reverse Shoulder|Designed to eliminate the potential for scapular notching, this reverse shoulder system combines a a true locking mechanism that minimized wear and oxidative breakdown with a modular central screw for secure fixation.
41500468|NCT00343356|DRUG|Trement|
41500469|NCT02803424|OTHER|Volume controlled ventilation|During anesthesia and surgical procedure, volume-controlled ventilation will be applied with an inspiration:expiration ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg) without ventilatory mode change.
40843259|NCT05606341|DRUG|CpG1018|"0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
40843260|NCT05606341|DRUG|Placebo|Sterile saline injection supplied by the NYU Investigational Pharmacy.
40843261|NCT04046250|DRUG|TK-112690|TK112690 treatment pre-methotrexate treatment
40843262|NCT04046250|DRUG|Placebo TK-112690|Placebo
40843263|NCT01846650|DRUG|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
40843264|NCT01846650|DRUG|XELODA|Single oral XELODA 2000mg qd
41266900|NCT00323999|PROCEDURE|Hysteroscopic resection of fibroids, polyps and endometrium.|
41266901|NCT05647330|DRUG|Hydroxychloroquine Combined With Gemcitabine|Hydroxychloroquine combined with chemotherapy
41266902|NCT01371461|DRUG|Paroxetine|
41266903|NCT02172157|DRUG|BI 1744 CL i.v.|
41500470|NCT02803424|OTHER|Autoflow-volume controlled ventilation|After tracheal intubation, volume-controlled ventilation will be initiated with an I:E ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg). Immediately after CO2 pneumoperitoneum with steep Trendelenburg positioning, Autoflow-volume controlled ventilation will be applied instead of volume-controlled ventilation. Immediately after CO2 desufflation and supine positioning, volume-controlled ventilation will be applied again.
41500471|NCT05679401|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
41500472|NCT05679401|PROCEDURE|Plasma exchange (PLEX)|PLEX removes the patient's pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
41500473|NCT05679401|DRUG|Cyclophosphamide (CYC)|Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.
41500474|NCT05679401|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
41026795|NCT06283849|BEHAVIORAL|strategies to break up SB|Participants will be asked to implement strategies to break up their SB every hour for at least 8 hours a day for one week. Strategies will be developed through collaboration with participants during the first study interview and may include (but are not limited to): calf raises, brief (\~5 min) self-paced walking), squats, sit to stand, etc. Participants will wear an activity monitor for assessment of SB and walking. This device (activPAL, PALTechnologies, Glasgow, Scotland) is not an investigational device; it is used for monitoring sedentary behavior.
41026796|NCT00185029|PROCEDURE|Ferumoxtran-10 enhanced MRI (MRL)|
41026797|NCT00533390|DRUG|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
40843265|NCT03645512|BEHAVIORAL|Corporate Athlete Resilience (CAR) Training Program|A 1-day training program developed by the J\&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.
40843266|NCT04254120|BEHAVIORAL|Cognitive-behavioral therapy|Psychological treatment focusing on changing cognitions and behaviors using information processing theory and learning theory approaches.
40843267|NCT04254120|BEHAVIORAL|Integrated motivational interviewing and cognitive-behavioral therapy|Motivational interviewing is a psychological treatment approach focusing on increasing motivation by eliciting patient talk favoring behavior change and resolving patient ambivalence about change.
40843268|NCT04132596|DEVICE|Transcutaneous spinal cord stimulation|Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes
40843269|NCT04132596|OTHER|Activity Based Therapy|Physical therapy
40843270|NCT00126984|BIOLOGICAL|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
40843271|NCT00126984|BIOLOGICAL|DTPa/Hib containing vaccine|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
40843272|NCT00126984|BIOLOGICAL|Meningitec|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
40843273|NCT00126984|BIOLOGICAL|Mencevax ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
40843274|NCT06484361|DRUG|68Ga-PSMA|all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
41026798|NCT05268666|DRUG|JBI-802|LSD1/HDAC6 inhibitor
41026799|NCT04044729|DRUG|Cannabidiol|500mg dose, suspended in medical grade olive oil and then mixed into chocolate pudding
40843275|NCT06484361|DRUG|68Ga-RM2|all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
40843276|NCT02708355|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
40843277|NCT02708355|DRUG|Placebo|Placebo capsules
40843278|NCT03013049|PROCEDURE|Non cultured epidermal cell suspension|Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
41026800|NCT04044729|DRUG|Placebo|Placebo
41026801|NCT05156723|BIOLOGICAL|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
41026802|NCT05156723|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
41026803|NCT03346759|DEVICE|Tampon A|24 Tampax Pearl Regular Tampons for use during a single menstrual period.
41026804|NCT03346759|DEVICE|Tampon B|24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
41026805|NCT01220908|DEVICE|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
41026806|NCT01220908|DEVICE|Coils|Lung Volume Reduction Coil(s)
41026807|NCT04685577|DRUG|Nefopam|Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
41026808|NCT04685577|OTHER|Placebo (Vehicle)|Participants will receive vehicle with out the investigational product
41026809|NCT06288815|DIETARY_SUPPLEMENT|Oral fluid|"Postoperation~* Off IV fluid immediately postoperative~* Allow patients drink oral fluid as protocol for 24hr"
41026810|NCT06288815|DIETARY_SUPPLEMENT|IV fluid|"Postoperation~* IV fluid replacement as protocol for 24hr~* Allow patients drink oral fluid as usual"
41026811|NCT04266028|BIOLOGICAL|DM-101|DM-101 administered by subcutaneous (SC) injection
41026812|NCT04266028|BIOLOGICAL|Placebo to match DM-101|Placebo to match DM-101 administered by SC injection
41026813|NCT03498183|DRUG|MIBI-Tc99m/Iodine-123|Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.
41026814|NCT00931151|DIETARY_SUPPLEMENT|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
41026815|NCT02276300|DRUG|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
41026816|NCT02276300|DRUG|Sargramostim|Sargramostim is part of Her2 vaccination
41026817|NCT02276300|DRUG|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
41026818|NCT02276300|DRUG|Imiquimod|Imiquimod is part of Her2 vaccination
41364513|NCT00991458|DRUG|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
41026819|NCT04674059|OTHER|patient survey|A questionnaire will be delivered by the health care providers at Ndera Hospital, Kigali, Rwanda or CHUK, Hospital, Kigali, Rwanda. The questions will explore the patient's clinical characteristics, the current treatment and their experience with the mental health care system.
41364514|NCT05451758|OTHER|Mindfulness-based stress reduction (MBSR)|The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
41364515|NCT00003309|BIOLOGICAL|filgrastim|
41026820|NCT00855829|DEVICE|Miniature Actilady device active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~1. The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~2. Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
41026821|NCT00855829|DEVICE|Miniature Actilady device not active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
41026822|NCT05003817|DEVICE|Percutaneous left ventricular unloading|Percutaneous left ventricular unloading involves the placement of a mechanical pump which draws blood from the left ventricle and returns it into the aorta at flow rates approaching native cardiac output.
41026823|NCT05117645|DIAGNOSTIC_TEST|Computed tomography|All patients will be examined by multislice CT scanner,Light speed 5X GE 8 detector elements scanner or GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) or Toshibe Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Axial scanns will be done commences at 1 cm above the diaphragm and ending at lesser trochanters then coronal and sagittal reconstruction images will be exposed.
41026824|NCT04066218|OTHER|Interviews|"* Participation will serve as verbal consent.~* Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~* REDCap link will be sent for PROMIS SexFS Brief.~* PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~* Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool."
41161063|NCT06354192|BEHAVIORAL|Precision Nudging for Hypertension Management|The hypertension digital health intervention under study combines behavioral science theory with a type of machine learning called reinforcement learning to enable precision nudging: the selection, assembly, and delivery of behavioral science-based messages created to address barriers to, and promote, management of hypertension. The behavioral design process used for the hypertension DHI intentionally includes research on traditionally underserved populations, such as racial and ethnic minorities and people with lower incomes or educational attainment. By including the right ingredients to meet a diverse set of needs and by effectively personalizing the content each individual sees based on their own reactions, the intervention aims to improve health equity by matching each individual to the right behavioral approach.
41026825|NCT03931434|DIETARY_SUPPLEMENT|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
41026826|NCT03931434|DIETARY_SUPPLEMENT|Placebo|Placebo
41026827|NCT06059703|PROCEDURE|Blood punction|Peripheral blood sampling (5 ml) at inclusion and 3 months after treatment
41161064|NCT04321915|OTHER|Analysis of intestinal microbiota in autism spectrum desorder|This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis
41266904|NCT02172157|DRUG|BI 1744 CL oral|
41266905|NCT02312570|DEVICE|PRP Concepts Fibrin Bio-Matrix|Administration of PRP Concepts Fibrin Bio-Matrix to wound in addition to usual and customary care
41266906|NCT02312570|OTHER|Usual and Customary Practice|Ussual and customary care of non-healing pressure wounds
41266907|NCT00005979|DRUG|FOLFIRI regimen|
41364516|NCT00003309|DRUG|cisplatin|
41364517|NCT00003309|DRUG|cyclophosphamide|
41364518|NCT00003309|DRUG|etoposide|
41364519|NCT00003309|DRUG|vincristine sulfate|
41364520|NCT00003309|PROCEDURE|adjuvant therapy|
41364521|NCT00003309|RADIATION|radiation therapy|
41026828|NCT06059703|PROCEDURE|Central blood sampling|Central blood sampling (2 ml) at inclusion and 3 months after treatment
41026829|NCT06059703|PROCEDURE|Intracranial pressure measurement|Intracranial pressure measurement at sinus level with micro-catheter at inclusion and 3 months after treatment
41266908|NCT00005979|DRUG|fluorouracil|
41266909|NCT00005979|DRUG|irinotecan hydrochloride|
41266910|NCT00005979|DRUG|leucovorin calcium|
41364522|NCT01169662|DIETARY_SUPPLEMENT|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
41364523|NCT01169662|DIETARY_SUPPLEMENT|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
41364524|NCT05620966|DEVICE|CGX Systems Quick-20m|The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.
41364525|NCT01430559|DRUG|Meloxicam|7.5mg x2 once a day for 12 weeks
41364526|NCT01430559|DRUG|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
41026830|NCT04589819|DRUG|Teriparatide|Teriparatide, an injectable synthetic parathyroid hormone, will be tested to evaluate its efficacy for decreasing the convalescence after a diaphyseal tibial stress fracture, a specific bone stress injury.
41026831|NCT04589819|DRUG|Placebos|Placebo will be a sugar solution of the manufacturer's design.
41026832|NCT00112073|DRUG|bapineuzumab|IV, Q13w
41026833|NCT00112073|OTHER|placebo|IV Q13w
41364527|NCT06056245|PROCEDURE|Preoperative step|"* Explanation of the surgery and use of the IV-PCA pump.~* Signed informed consent."
41026834|NCT03789539|BIOLOGICAL|LD Universal Influenza Vaccine Uniflu|low dose Universal Influenza Vaccine Uniflu
41364528|NCT06056245|DRUG|Intraoperative|Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
41026835|NCT03789539|BIOLOGICAL|HD Universal Influenza Vaccine Uniflu|High dose Universal Influenza Vaccine Uniflu
41364529|NCT06056245|DRUG|Post-operative|Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
41026836|NCT03789539|BIOLOGICAL|Placebo|Placebo saline
41026837|NCT00990223|DRUG|Eplerenone or Placebo|Eplerenone 100 mg or Placebo, daily for 10 days.
41364530|NCT05637086|DRUG|Phenytoin|Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use
41364531|NCT05637086|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy
41364532|NCT05637086|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
41364533|NCT02075580|BEHAVIORAL|psychological support (interactive/cognitive strategies)|"* cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~* metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~* psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~* questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
41364534|NCT03795233|BIOLOGICAL|Fecal microbiota transplant G3 capsules|After standard of care therapy with oral vancomycin, frozen oral FMT capsules will be provided in a formulation designed to deliver the product to the large intestine. 30 FMT capsules will be administered over a 2 hour period under direct observation
41364535|NCT03795233|OTHER|Oral Vancomycin alone|Standard of care will be provided with oral vancomycin therapy.
41364536|NCT05426694|OTHER|Scapular clock exercises|In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.
41364537|NCT05426694|OTHER|Stretching and strengthening exercises|Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
41026838|NCT05287867|BIOLOGICAL|Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)|Approx 161-420cc autologous blood is drawn and processed into PPP, PRP, and PL, amount dependent on condition. Using sterile technique with patient sedated, US or x-ray is used to guide needles bilaterally into multifidus, specifically LM, TF, IAF. Once the lamina is reached the physician injects 2.5 cc of PPP into the multifidus muscle on one side and then repeat this on the opposite side for each level. The physician guides a needle into the supraneural transforaminal space to perform an epidural injection with 2cc of 4x PL and 1 cc of 0.5% ropivacaine. Next, a needle will then be guided into the facet joint to perform an intra-articular injection with 1cc of 14x PRP. Any tendon insertion areas will be injected using ultrasound guidance with platelet lysate dextrose. The supraspinous/interspinous, SI ligaments at the involved degenerative levels will be injected with 4x PL/12.5% dextrose/0.125% ropivacaine. If L5/S1 is involved, the iliolumbar ligaments will also be injected.
41026839|NCT05287867|OTHER|Sham procedure|"Approximately 161-420 cc of autologous blood is drawn to maintain patient blinding. While lying prone, the patient's back will be exposed and prepped sterilely.~Provider puts patient in conscious sedation and several needles are placed into the low back. The provider inserts needle into the facet joint and then removes. Then inserts the needle midline to ligament and removes (1 needle per level) mimicking normal needle placement, but not injecting anything."
41026840|NCT01059617|BIOLOGICAL|GSK Biologicals' FluLaval®|Intramuscular injection
41026841|NCT01059617|BIOLOGICAL|Placebo (saline)|Intramuscular injection
41026842|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
41364538|NCT04752111|DRUG|Esmolol|administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery
41026843|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
41026844|NCT04612179|DEVICE|The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system|"Investigational device: SUPRAFLEX CRUZ™ Sirolimus eluting Coronary Stent System The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system consists of a balloon ex-pandable Sirolimus eluting stent, premounted on a stent delivery system. The active pharmaceutical ingredient in the SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent is Sirolimus (also known as Rapamycin).~The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system is indicated for improving coronary luminal diameter in patients with symptomatic Ischemic heart disease due to discrete de-novo stenotic lesions and in-stent restenotic lesions in native coronary arter-ies with a reference vessel diameter of 2.00 mm to 4.50 mm."
41026845|NCT05941650|DIETARY_SUPPLEMENT|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
41026846|NCT05941650|OTHER|Corn Starch|This group will receive 12 g of corn starch as a control group.
41026847|NCT03200938|DEVICE|formocresol and zinc oxide.|Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide
41026848|NCT03200938|DEVICE|PBS CIMMO cement.|Removal of the coronary pulp from primary molar teeth, use of PBS cement
41026849|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
41026850|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
40843279|NCT03013049|PROCEDURE|Non cultured dermal cell suspension|Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
41026851|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
41026852|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
41026853|NCT04092426|OTHER|opthalmologic examination|opthalmologic examination : Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination
41026854|NCT05578404|DRUG|Cholecalciferol|Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.
41026855|NCT05578404|DRUG|Placebo|matching placebo to Vit D
41026856|NCT02202135|DRUG|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
41026857|NCT02202135|DRUG|Vancomycin|IV vancomycin 15mg/kg every 12 hours
41026858|NCT02202135|DRUG|Aztreonam|IV aztreonam 1 g every 8 hours
41026859|NCT05356559|DIETARY_SUPPLEMENT|Intervention|12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks
41026860|NCT05356559|OTHER|Control|Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks
40843280|NCT05941013|DEVICE|Ultrasound detectable cuffed endotracheal tube (USD-ETT)|Intubation with a novel ultrasound-detectable endotracheal tube
40843281|NCT01471925|DRUG|Nexium®|
40843282|NCT01471925|DRUG|Esomeprazol (40mg) + Sdium Bicarbonate (721mg)|
40843283|NCT05304897|PROCEDURE|PRP treatment|PRP treatment for bronchopleural fistula
41161065|NCT04321915|OTHER|Analysis of neuroinflammation markers in autism spectrum desorder|This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.
41026861|NCT03779386|OTHER|music|music during labor and delivery
41161066|NCT00014222|BIOLOGICAL|epoetin alfa|40,000 IU
41161067|NCT00014222|BIOLOGICAL|filgrastim|5 mg/kg/d - days 2-13
41026862|NCT03973190|PROCEDURE|Immediate alveolar regeneration after exodontia|The extractions will be performed under local anesthesia, without making a mucoperiosteal flap, making an intraassucular incision and using appropriate periotomes, elevators and forcépes, minimizing the surgical trauma of surrounding tissues. Thorough curettage of the alveolus will be performed at the time of extraction to ensure removal of all granulation tissue and stimulate bleeding from the bone base, to form blood clot and promote healing. The sutures will be removed after 7 days of surgery, except for patients in group 3, in which sutures will not be made.
41026863|NCT03973190|PROCEDURE|installation of dental implant and collection of biological material|The material was collected for histological analysis, extracted with trephine drill of 2.0 mm in diameter. Samples were removed before the incision. A linear incision was then made on the alveolar ridge in the region and flap detachment. The initial insertion of the implant was performed using the contra-angle at 30 rpm, the final insertion of the implant was performed with manual torque wrench, where the insertion torque was measured and the value was tabulated, not exceeding 60 N. cm. The component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. The prosthetic component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. the tabulated values and the incision was sutured.
41026864|NCT03973190|DEVICE|ISQ analysis|The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
41161068|NCT00014222|DRUG|cyclophosphamide|75, 600 and 830 mg/m2
41161069|NCT00014222|DRUG|doxorubicin hydrochloride|60 mg/m2
41161070|NCT00014222|DRUG|epirubicin hydrochloride|60 mg/m2
41161071|NCT00014222|DRUG|fluorouracil|500mg/m2
41161072|NCT00014222|DRUG|paclitaxel|175 mg/m2
41161073|NCT02414555|DRUG|vasopressor|Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
41161074|NCT02414555|DRUG|fluid bolus|
41161075|NCT02414555|DEVICE|oesophagus doppler (CardioQ)|
41161076|NCT02414555|DRUG|Normal Saline|
41161077|NCT02414555|DEVICE|arterial cannulation|
41161078|NCT02414555|DEVICE|intravenous peripheral line insertion (17 gauge)|for fluid bolus administration
41161079|NCT02414555|DRUG|Elo-Mel Isoton (balanced acetat-based infusate)|
41364539|NCT05020470|DEVICE|Virtual Auricular Point Acupressure (APA)|Participants will learn how to self-administer APA by themselves.
41364540|NCT05020470|OTHER|In-Person Training|Participants will receive in-person training to self-administer APA.
41364541|NCT05020470|OTHER|Usual Care|Participants will continue to do whatever they are instructed by theirs physicians.
41500475|NCT06410313|DEVICE|ChampioNIR Ridaforolimus Eluting Peripheral Stent System|ChampioNIR implantation in Patients with Superficial Femoral Artery Disease and/or Proximal Popliteal Artery disease
40843284|NCT05979168|BEHAVIORAL|Phone call and text Messages|The intervention consists of recommended lifestyle counselling (on a healthy diet, physical activity, smoking, alcohol intake, medication adherence and continuity of care). This counselling will be provided through the research nurse at baseline and for six months (tentative plan phone call once a month; frequency and duration will be finalized based on formative study) by calling on participants' given mobile numbers. In addition, text message reminders on the same topics will be delivered regularly (2-3 times a week) for six months. The counselling and message will focus on three domains of COM-B; capabilities needed, opportunities and practical tools, and motivation strategies informed by behaviour change techniques.
40843285|NCT00902174|DRUG|imatinib mesylate|Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
40843286|NCT00902174|DRUG|Placebo|Placebo to imatinib 100 mg film coated tablets
40843287|NCT06155539|OTHER|No intervention|No intervention
40843288|NCT02445066|DIETARY_SUPPLEMENT|Vitamin D3|
40843289|NCT03668834|PROCEDURE|Dermabrasion with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. Dermabrasion will be done using Manekshaw's dermabrader until tiny pinpoint bleeding spots are seen and extended 5mm beyond margins to prevent halo phenomenon.~3. The denuded area will be washed with PBS and covered with a PBS moistened gauze piece.~4. With 18 G needle attached to tuberculine syringe, few small drops of non cultured epidermal cell suspension will be placed over the denuded surface and spread evenly.~5. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
40843290|NCT03668834|PROCEDURE|Dermaroller with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit.~2. Microneedling will be done with a device containing 540 microneedles in 8 rows, each 0.25 mm in length. Microneedling will be extended 5 mm beyond margins to prevent halo phenomenon.~3. The roller will be passed repeatedly over the skin in a star-shaped way for about 10 minutes~4. The noncultured epidermal cell suspension will be carefully transferred to a tuberculin syringe.~5. NCES will be applied to the skin surface with a tuberculin syringe with an 18G needle and spread evenly after dermarolling treatment.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
40843291|NCT03668834|PROCEDURE|Liquid nitrogen induced blister with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. The site to be grafted is outlined with a surgical marking pen.~3. To induce blisters on the achromic areas, freezing with liquid nitrogen spray was performed during 10 to 20 seconds inside round circles previously drawn on the skin.~4. The patient is asked to visit 24 hours later.~5. The blister fluid is aspirated and NCES taken in tuberculin syringe with 18 G needle is injected into it such that the blister roof is preserved.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
40843292|NCT00678834|DIETARY_SUPPLEMENT|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
40843293|NCT00678834|DIETARY_SUPPLEMENT|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
41026865|NCT05166018|DIAGNOSTIC_TEST|SuMO Patient|"The current study is interventional insofar as the patient is collecting all of his socio-medical information. The analysis of the data provided by the patient makes it possible to establish a long-term prognosis for the patient but does not in itself constitute a parallel medical approach.~SUMO allows the surgeon to transmit post-operative advice developed by the surgeons themselves."
41026866|NCT02439346|DRUG|BAY1143269 tablet|BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
41026867|NCT02061384|DRUG|13-cis retinoic acid|Accutane is used for the treatment of severe acne
41026868|NCT02061384|DRUG|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
41026869|NCT03862118|OTHER|PRP|platelet rich plasma will be delivered by intradermal method using mestherapy needle.
41026870|NCT01715805|DRUG|Cariprazine|Cariprazine capsules 1.5 to 4.5 mg/day
41026871|NCT01715805|DRUG|Placebo|Dose-matched placebo capsule once per day
41026872|NCT01715805|DRUG|Antidepressant Therapy (ADT)|ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
41026873|NCT00382343|DRUG|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
41026874|NCT01273272|BEHAVIORAL|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
41026875|NCT01273272|BEHAVIORAL|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
41026876|NCT01229345|DRUG|Breakfast & exercise|1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
41364542|NCT05643794|DRUG|rozanolixizumab|Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
41364543|NCT05643794|OTHER|Placebo|Study participants will receive Placebo during the dosing periods as pre-defined.
41364544|NCT00282607|DRUG|DA-8159|
41364545|NCT05150392|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
41364546|NCT01575158|DRUG|Citalopram|
41364547|NCT01575158|DRUG|Clomipramine|
41364548|NCT01575158|DRUG|placebo|
41500476|NCT05826795|PROCEDURE|Early goal-directed therapy (EGDT)|The principle of hemodynamic optimization to achieve the defined goals.
40843294|NCT00678834|DIETARY_SUPPLEMENT|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
40843295|NCT01940536|DRUG|Tranexamic Acid|antifibrinolytic
41026877|NCT00564083|PROCEDURE|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
41026878|NCT02885233|BEHAVIORAL|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
41364549|NCT04226053|OTHER|Parenting, Child Development|The treatment group will consist of mothers that were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby. The research-informed program model combines tailored, one-on-one sessions with an expert clinical social worker in-person every three months, provision of essential baby items including books, toys, clothing, and equipment (retail value of in-kind items over three years averages $10,000), and connections to vital community resources (e.g., housing, entitlements, child care, social services).
41026879|NCT02885233|BEHAVIORAL|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
41364550|NCT03159455|DRUG|BI 1467335|Duration - 28 days
41364551|NCT03159455|DRUG|Placebo|Duration - 28 days
41364552|NCT04229342|PROCEDURE|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy (POEM) is an endoscopic modality for the management of achalasia cardia. In this study, we will evaluate the impact of two different techniques of posterior POEM on the incidence of gastroesophageal reflux disease (GERD).~Posterior POEM will be performed using the standard technique. The myotomy beyond the GEJ will be different in the two groups. In one group, the sling fibers will not be spared from dissection and in the second group, the sling fibers will be selectively spared from myotomy."
41364553|NCT04370041|DEVICE|Dokimos Plus aortic valve|Dokimos Plus aortic valve
41364554|NCT06205212|OTHER|high-flow nasal oxygen|preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min
41364555|NCT06205212|OTHER|facemask|preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min
41364556|NCT00953576|DRUG|ketoconazole|
41364557|NCT00953576|DRUG|hydrocortisone|
41364558|NCT00953576|DRUG|dutasteride|
41364559|NCT00953576|DRUG|lapatinib|
41364560|NCT03388450|DRUG|Omega 3|Enteral 1000 mg omega 3 fatty acid.
41364561|NCT03388450|DRUG|Placebo|Enteral nutrition without omega 3 fatty acid.
41364562|NCT01745159|DRUG|tacrolimus|
41364563|NCT01317368|DRUG|Naropine|"20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
41364564|NCT01317368|DRUG|Naropine|"20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
41364565|NCT01317368|OTHER|Placebo|"20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Saline 0,9% will be given as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
41364566|NCT04443855|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
41500477|NCT02552303|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
41500478|NCT02552303|DRUG|Armodafinil|Active medication
41500479|NCT02552303|DRUG|Placebo|Placebo for Nuvigil (armodafinil)
41500480|NCT00203593|BEHAVIORAL|Exercise|
40843296|NCT01940536|DRUG|Placebo|Placebo
40843297|NCT02248636|DRUG|Cholinesterase inhibitor|This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
40843298|NCT02248636|DRUG|Sham discontinuation|This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
40843299|NCT04721548|DRUG|Minoxidil Topical Foam|Apply 1 mL of solution twice a day.
40843300|NCT04721548|DRUG|Placebo|1 mL of solution twice a day.
40843301|NCT03697681|DRUG|Tranexamic acid|Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.
40843302|NCT03697681|DRUG|0.9% NaCl (normal saline)|The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
40843303|NCT00473538|BEHAVIORAL|Structured exercise training|
40843304|NCT00473538|BEHAVIORAL|Hypocaloric hyperproteic diet|
40843305|NCT04368793|BEHAVIORAL|Remote pulmonary rehabilitation|The pulmonary rehabilitation intervention includes respiratory exercise, barehanded aerobic training, exercise prescription of elastic band impedance training, respiratory muscle strength training, etc.
40843306|NCT00258466|RADIATION|radiation therapy|
41500481|NCT00203593|DEVICE|Blood volume|
41500482|NCT00203593|PROCEDURE|VO2max test|
41500483|NCT00203593|PROCEDURE|Lower body negative pressure|
41500484|NCT00203593|BEHAVIORAL|Heart Rate|
40843307|NCT06113536|DIAGNOSTIC_TEST|Ultrasonographic evaluation|Ultrasonographic evaluation for assessment of possible meniscal extrusion
41026880|NCT02441452|OTHER|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
41364567|NCT04443855|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
41364568|NCT04443855|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
41500485|NCT00203593|PROCEDURE|Blood Pressure|
41500486|NCT00203593|BEHAVIORAL|Total Peripheral Resistance|
41500487|NCT03886415|DRUG|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group
41500488|NCT04808310|DEVICE|Quantitative flow ratio|Quantitative flow ratio (QFR) is a computer method that estimates the hemodynamic relevance of a coronary stenosis based on three-dimensional quantitative coronary angiography (3D QCA)
41500489|NCT04808310|DIAGNOSTIC_TEST|Assessment of angiographic severity of the stenosis|The indication to coronary stent intervention will be based on angiography
41500490|NCT05279300|DRUG|CS5001|CS5001 will be administered every 3 weeks (21 days) by intravenous (IV) infusion, and 3 weeks (21 days) is considered as one treatment cycle.
40843308|NCT00668538|DRUG|Brentan (miconazole)|Vaginal suppository 1200 mg at day 6
40843309|NCT03187223|DRUG|Melphalan|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
41026881|NCT05507268|OTHER|no intervention|no intervention
41026882|NCT03251846|DEVICE|Pops! One personalized mobile platform|Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months. Primary outcomes will be measured at baseline and 6-month follow-up.
41026883|NCT01055639|BEHAVIORAL|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
41026884|NCT01055639|BEHAVIORAL|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
41026885|NCT05875324|DEVICE|virtual reality application|VR was used for 10 minutes a day in the sitting position for three weeks, twice a week, by watching a walking video before beginning the exercises. Patients were instructed to imagine themselves walking while concentrating on walking and watching the video. The patients were asked to stop watching video by removing their VR glass if they experienced discomfort such as dizziness and nausea during the VR application. They were told to continue watching the video when the discomfort was gone. In cases where similar discomforts recurred, the treatment was terminated.
41026886|NCT05875324|OTHER|exercise|activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were provided an exercise program for at-home practice.
40843310|NCT03187223|DRUG|Bendamustine|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
40843311|NCT02935413|DEVICE|tDCS|Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
40843312|NCT02935413|BEHAVIORAL|Standard rehabilitation|Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
40843313|NCT02166541|PROCEDURE|BCSK|"The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier."
40843314|NCT02166541|PROCEDURE|Traditional spinal manipulation|Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.
41026887|NCT03319043|DRUG|Chanqin granules|All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
41026888|NCT04908891|OTHER|Clinical Scapular protocol (ClinScaP)|the psychometric properties of two tests: Clinical Scapular protocol (ClinScaP) in PwMS and healthy controls.
41026889|NCT04908891|OTHER|the prevalence of trunk, scapula and upper limb impairments.|To investigate the prevalence of trunk, scapula and upper limb impairments in PwMS and stroke patients.
41026890|NCT04908891|OTHER|the interaction between trunk, scapula and upper limb impairments.|To investigate the interaction between trunk, scapula and upper limb impairments in PwMS and stroke patients.
41026891|NCT06238323|BEHAVIORAL|LAFIYA|LAFIYA will be a modified version of the Many Men Many Voices (3MV) targeted at addressing reducing stigma and increasing HIV self-testing uptake among young sexual minority men. LAFIYA will be developed into a comprehensive intervention manual for a large-scale trial using the ADAPTT-IT framework.
41026892|NCT00786357|BEHAVIORAL|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
41500491|NCT01422187|DRUG|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
41500492|NCT01400802|BIOLOGICAL|Insulin Lispro|Dosage form- Subcutaneous Injection
41500493|NCT04496115|BEHAVIORAL|Mindfulness|Mindfulness training
41026893|NCT00786357|BEHAVIORAL|Sleep Enhancement Training System|4 week program of readings and relaxation programs
40843315|NCT02166541|PROCEDURE|INRS|"The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy."
41026894|NCT04558957|DEVICE|FLEBOGRIF|The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.
41026895|NCT05360524|PROCEDURE|Laminectomy alone versus laminectomy and fusion|"laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.~Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis."
41364569|NCT04443855|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of drinking water for children \< 36 months.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times as food preparation, defecation, and contact with feces."
41500494|NCT06470178|COMBINATION_PRODUCT|corhot1: chemotherapy combined with fruquintinib|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
40843316|NCT03954613|COMBINATION_PRODUCT|Ebicomb|Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
41500495|NCT06470178|COMBINATION_PRODUCT|corhot2: chemotherapy combined with fruquintinib|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
41500496|NCT03952585|PROCEDURE|Biopsy|Undergo tissue biopsy
40843317|NCT04870918|BEHAVIORAL|self-care intervention|Health education will be carried out by the nurse.
40843318|NCT00004245|DRUG|sodium salicylate|
40843319|NCT05157139|DRUG|Oral Capsule|Oral Capsule of vanillin \& wheat germ oil
40843320|NCT01587092|BEHAVIORAL|WorkStation|Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.
40843321|NCT01587092|BEHAVIORAL|Usual Working Condition|Participants will be asked to continue working at their desk in their usual manner.
40843322|NCT00001967|DRUG|HAART|
40843323|NCT00027911|BIOLOGICAL|NY-ESO-1 peptide vaccine|
41266911|NCT05825066|DRUG|Nab paclitaxel|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
41500497|NCT03952585|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41500498|NCT03952585|DRUG|Cisplatin|Given IV
40843324|NCT00027911|BIOLOGICAL|sargramostim|
40843325|NCT03044184|DRUG|Tranexamic Acid|Transamine is an antifibrinolytic medication given systemically via the intravenous route
40843326|NCT01639755|DEVICE|new texture shaped breast implants|breast implant surgery
40843327|NCT02262754|DRUG|PF-06372865|Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
40843328|NCT02262754|DRUG|Placebo|Placebo for PF-06372865 and placebo for naproxen daily
40843329|NCT02262754|DRUG|Naproxen|500 mg BID for 4 weeks
40843330|NCT00900367|OTHER|high performance liquid chromatography|
40843331|NCT00900367|OTHER|laboratory biomarker analysis|
40843332|NCT00900367|PROCEDURE|spectroscopy|
40843333|NCT03900273|OTHER|No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS)|Novel measures of Cognitive and Everyday function
40843334|NCT03900273|OTHER|Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)|Established measures of Cognitive and Everyday Function
40843335|NCT04608734|DRUG|Buccal midazolam|The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.
40843336|NCT04608734|DRUG|Intranasal midazolam|Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
40843337|NCT00606983|DRUG|Tamsulosin|oral administration of Tamsulosin
40843338|NCT03715946|DRUG|Nivolumab Injection|A fully human anti-programmed death 1 (PD-1) monoclonal antibody
40843339|NCT03715946|RADIATION|Radiotherapy (RT)|45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
40843340|NCT00938691|PROCEDURE|Intradermal Suture|
40843341|NCT00938691|PROCEDURE|Intradermal Suture|
41364570|NCT04443855|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
41026896|NCT00099983|DRUG|Risperidone|Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
41026897|NCT00099983|DRUG|Placebo|Placebo
41026898|NCT03839667|BEHAVIORAL|intensive diet intervention|the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
41026899|NCT03839667|BEHAVIORAL|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
41026900|NCT03839667|BEHAVIORAL|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
41026901|NCT01437592|DRUG|insulin degludec|For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
41026902|NCT02137629|DRUG|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
41026903|NCT00835406|DRUG|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
41500499|NCT03952585|PROCEDURE|Computed Tomography|Undergo CT
41026904|NCT00835406|DRUG|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
40843342|NCT03650790|DIAGNOSTIC_TEST|Blood test|For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
41026905|NCT03111225|DIAGNOSTIC_TEST|massage|a 15 minutes thoracic massage will be added to the regular physical therapy treatment
41026906|NCT05350293|OTHER|Molded abutment|"The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner."
41500500|NCT03952585|OTHER|Fludeoxyglucose F-18|Receive FDG
41500501|NCT03952585|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
41500502|NCT03952585|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41500503|NCT03952585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41364571|NCT04443855|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
41364572|NCT00113321|DRUG|Decitabine|20 mg/m2 IV over 1 hour daily x 5 days.
41364573|NCT01977664|OTHER|no intervention|
41500504|NCT03952585|BIOLOGICAL|Nivolumab|Given IV
40843343|NCT00867555|DIETARY_SUPPLEMENT|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
40843344|NCT00164515|BEHAVIORAL|Personalized exercise programme (PEP)|Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
41364574|NCT06428331|DRUG|SKB518 for injection|SKB518 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
41364575|NCT01272349|OTHER|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
41364576|NCT01272349|OTHER|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
41500505|NCT03952585|PROCEDURE|Positron Emission Tomography|Undergo PET
40843345|NCT02053961|DEVICE|Deep Transcranial Magnetic Stimulation|1Hz dTMS real treatment
40843346|NCT02053961|DEVICE|Deep Transcranial Magnetic Stimulation|1Hz dTMS SHAM treatment
40843347|NCT04691908|BIOLOGICAL|QazCovid-in®-vaccine against COVID-19|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
40843348|NCT04691908|OTHER|Placebo|Placebo (sodium chloride buffs, solvent for the preparation of dosage forms for injection 0.9%)
41364577|NCT02978300|DEVICE|NIV/HFNC|Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
41364578|NCT02978300|DEVICE|HFNC|Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
41364579|NCT06326138|DRUG|Edoxaban Pharmacokinetics and Pharmacodynamics|Participants will be received single oral doses of edoxaban 60 mg.
41500506|NCT03952585|OTHER|Quality-of-Life Assessment|Ancillary studies
40843349|NCT03561935|DRUG|Propafenone|prescribing propafenone for the management of premature ventricular complex
41364580|NCT03356860|DRUG|Paclitaxel|80mg/m2 IV weekly from week 1 to week12
41364581|NCT03356860|DRUG|Epirubicin|90 mg/m2 IV Q 2 weeks from week 14 to week 20
41364582|NCT03356860|DRUG|Cyclophosphamide|600 mg/m2 IV Q 2 weeks from week 14 to week 20
41364583|NCT03356860|DRUG|Durvalumab|Durvalumab 1500 mg IV at week 14 and 18
41364584|NCT06303011|OTHER|Transcutaneous Electrical Nerve Stimulator|TENS will be applied on sacral and parasacral area. Frequency 10Hz, Pulse duration 200μs, Stimulation duration 20min
40843350|NCT03561935|DRUG|Indenol|prescribing indenol for the management of premature ventricular complex
40843351|NCT05386316|OTHER|Multilevel intervention for racial disparities in severe maternal morbidity and mortality|"In addition to standard enhance prenatal care (EPC) services, the following will be offered.~Community level. We will make EPC services (i.e., MIHP and Healthy Start) available via telehealth with flexible hours to women who are eligible for Healthy Start (primarily minority women) who decline traditional (i.e., home visiting) services.~Provider/practice level. We will provide actionable maternal health-focused anti-racism training to health system administrators, physicians, residents, midwives, nurses, front desk staff, schedulers, public health officers, EPC staff, doulas, WIC staff, and lactation consultants.~System level. Counties will implement equity focused community care maternal safety bundles. Community care is care provided by outpatient, EPC, community-based organizations, and linkages between hospital care and these settings."
41026907|NCT05350293|OTHER|3D printed abutment|A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
41364585|NCT06303011|OTHER|TENS on para sacral area with Abdominal Massage|TENS on para sacral area with Abdominal Massage. Frequency 10Hz Pulse duration 200μs Stimulation duration 20min
41364586|NCT05946564|DRUG|Pioglitazone (ACTOS®)|Patient will be randomize in the intervention group receive treatment by pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
41364587|NCT05946564|DRUG|Placebo of Pioglitazone|Patient will be randomize in the intervention group receive treatment by placebo of pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
41364588|NCT03502265|OTHER|Otteroo|Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
41364589|NCT00280059|DRUG|Pregabalin|dose 150-600 mg/day given BID
41364590|NCT00280059|DRUG|Lamotrigine|dose 100-500 mg/day given BID
41364591|NCT04480359|DRUG|Bawei Shenqi Pill|5.1g, once a day, 3month, oral
41364592|NCT04480359|DRUG|Bawei Shenqi Pill placebo|5.1g, once a day, 3month, oral
41364593|NCT04480359|DRUG|Meloxicam|7.5mg, once a day, 3 month, oral
41500507|NCT03952585|OTHER|Questionnaire Administration|Ancillary studies
41500508|NCT04762277|DRUG|Spesolimab - solution for infusion|Solution for infusion
41500509|NCT04762277|DRUG|Placebo matching spesolimab - solution for infusion|Solution for infusion
41500510|NCT04762277|DRUG|Spesolimab- solution for injection|Solution for injection
41500511|NCT04762277|DRUG|Placebo matching to spesolimab- solution for injection|Solution for injection
41500512|NCT02730299|DRUG|NiCord® (omidubicel)|
41500513|NCT02730299|OTHER|Cord Blood Unit|Cord blood unit
40843352|NCT05386316|OTHER|Standard Enhanced Prenatal Care (EPC) services|"Pregnant women in comparison counties will receive whatever EPC services (MIHP and/or Healthy Start) they naturalistically choose to receive.~Maternal Infant Health Program (MIHP). All women in Michigan who are Medicaid insured are eligible for MIHP. MIHP offers monthly home visiting and care coordination to supplements regular care during pregnancy and up to 12 months post birth. MIHP offers care coordination; risk assessment; individual care plan; evidence-based interventions; transportation; education; and referrals.~Healthy Start. Health Start is a federally funded program for minority women that offers more intensive EPC services delivered by race/ethnicity matched community health workers. Community health workers offer peer support; resilience and problem solving; risk assessment; facilitating provider-client communication; collaborative care; system navigation, including transition from prenatal care to postnatal primary care; and supportive referrals."
40843353|NCT00328861|DRUG|Natural Killer (NK) Lymphocytes|Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
40843354|NCT00328861|BIOLOGICAL|IL-2|IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.
40843355|NCT00328861|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
40843356|NCT00328861|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 day intravenous on days -6 through -2.
40843357|NCT01990859|BIOLOGICAL|Ipilimumab|
40843358|NCT04622813|DRUG|nefopam, ketoprofen, paracetamol|Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery
40843359|NCT04622813|DRUG|saline infusion, ketoprofen, paracetamol|Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery
40843360|NCT00125021|DRUG|Capecitabine|Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
40843361|NCT00125021|DRUG|OSI-774|Given once daily
41026908|NCT03860194|DIETARY_SUPPLEMENT|Protison with High Protein 51(Original Flavor)|Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
41364594|NCT00980850|BIOLOGICAL|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
41364595|NCT00980850|BIOLOGICAL|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
41364596|NCT02627157|DEVICE|Dynamic Scheimpflug Analyzer|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
41364597|NCT05519189|DRUG|Ropivacaine|Peri-anal infiltration of Ropivacaine
41364598|NCT05519189|OTHER|Failure to perform peri-anal ropivacaine infiltration|Failure to perform peri-anal ropivacaine infiltration
41364599|NCT03934333|DRUG|BDA MDI 160/180 mcg|Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.
41364600|NCT03934333|DRUG|Pulmicort Flexhaler 180 mcg|Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.
41364601|NCT00953849|DRUG|Celecoxib|Celecoxib (400 mg twice daily)
41364602|NCT00953849|DRUG|Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
41364603|NCT00953849|DRUG|Celecoxib plus Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
41364604|NCT06338670|DEVICE|Cochlear Osia 3 Sound Processor|Osia 3 Sound Processor including sound processor magnets and Osia 3 Aqua +
41364605|NCT06338670|DEVICE|Cochlear™ Osia® 2 Sound Processor|Osia® 2 Sound Processor
41364606|NCT03580031|DRUG|hCG|A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose
41364607|NCT03580031|DRUG|Saline Solution|2 ml of normal saline will be injected 48 hours after first triggering dose
41364608|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet for 1 day (Trt C).
41364609|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
41364610|NCT01288742|DRUG|TMC435|One 150-mg capsule once daily for 7 days (Trts B and D).
41364611|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
41364612|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet for 1 day (Trt A)
41500514|NCT04325204|BEHAVIORAL|Faith-based Home Activity Toolbox (Faith-HAT)|"They will select activities from Faith-HAT at least 3 times a week. Possible examples of these activities include devotional readings, prayer, music, religious images, and video and audio recorded sermons.~Faith-HAT will be placed on online, which requires little technical know-how by users. The PI will provide training to participants on how to use the Faith-HAT and online diary on the tablet computer provided by the project."
40843362|NCT00333918|DRUG|bromfenac ophthalmic solution|
40843363|NCT00333918|DRUG|placebo comparator|
40843364|NCT04839120|DRUG|MDPK67b|Two subgroups (Panels A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
40843365|NCT04839120|DRUG|Placebo|Two subgroups (Panel A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
40843366|NCT06130111|PROCEDURE|Mastectomy|Mastectomy as a surgical procedure for breast cancer (regardless of perioperative treatment).
40843367|NCT06168617|DIAGNOSTIC_TEST|Performance tasks in daily life|Evaluation of performance tests executed by patients in real-life situations.
40843368|NCT00800410|BEHAVIORAL|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
40843369|NCT03229941|PROCEDURE|Blood Transfusion|Blood Transfusion
40843370|NCT01299116|DRUG|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
40843371|NCT01299116|DRUG|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
40843372|NCT01299116|DRUG|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
40843373|NCT01299116|DRUG|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
40843374|NCT01299116|DRUG|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
40843375|NCT03664765|OTHER|UA and RMT|daily oropharyngeal and respiratory muscle exercises
40843376|NCT03664765|OTHER|Sham exercise|Daily sham exercises
40843377|NCT03648216|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
40843378|NCT01873248|DRUG|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
40843379|NCT03579641|DEVICE|HeartLogic Sensors|HeartLogic Sensors
40843380|NCT04867460|PROCEDURE|Ultrasound guided venous access|Access of the axillary vein using ultrasound guidance.
40843381|NCT00017290|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
40843382|NCT00017290|BIOLOGICAL|keyhole limpet hemocyanin|
40843383|NCT00017290|BIOLOGICAL|sargramostim|
40843384|NCT00017290|DRUG|cyclophosphamide|
40843385|NCT00017290|DRUG|prednisone|
40843386|NCT00017290|DRUG|vincristine sulfate|
40843387|NCT01257022|BEHAVIORAL|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
41161080|NCT00919009|PROCEDURE|TACE (Transcatheter Arterial Chemoembolization )|"TACE will be performed according to National Cancer Center protocol:~Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions"
41364613|NCT04541394|DEVICE|MolecuLight|MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time.
41364614|NCT00733122|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
40843388|NCT03994198|DIETARY_SUPPLEMENT|Alpha-lactalbumin|A protein fraction of whey protein, higher in tryptophan
40843389|NCT03994198|DIETARY_SUPPLEMENT|Collagen peptides|Collagen peptides from bovine sources
40843390|NCT03661086|DEVICE|O2matic|O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
40843391|NCT04945109|OTHER|Mankai beverage|Recommended background healthy diet with Mankai supplementation after main meal (300 ml)
41364615|NCT06254794|DEVICE|Blood flow restriction with Delfi Personalized Tourniquet System (PTS)|Standard of care physical therapy exercises with the use of the Delfi PTS cuff
40843392|NCT04945109|OTHER|Water (control)|Recommended background healthy diet with water supplementation after main meal (300 ml)
40843393|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
40843394|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
40843395|NCT03052530|DEVICE|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
40843396|NCT05614648|DRUG|Clonidine Micropellets|0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
40843397|NCT05614648|DEVICE|Tuohy epidural needle|18-gauge Tuohy epidural needle using a custom-built injector
40843398|NCT03893877|DEVICE|nasal cannula|experimental group will be applied nasal cannula
40843399|NCT03893877|DEVICE|nasal mask|active comparator group will be applied nasal mask
40843400|NCT01726985|OTHER|Parameter Based Clinical Disposition|"Parameter Based Clinical Disposition'~Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:~* NT-ProBNP reduction of \> 23% from peak value during admission~* Fluid Reduction of \> 1.3L (orders for I/O q8h required)~* Serum Sodium of \> 135 mmol/L the day of planned discharge"
40843401|NCT05126628|DRUG|Proxalutamide|Proxalutamide 300mg q.d.(3 tablets of 100mg each) for 14 days.
40843402|NCT05126628|DRUG|Placebo|Placebo 3 tablets q.d. for 14 days
40843403|NCT06459336|OTHER|Intensive constraint-induced movement therapy|Intensive protocol of CIMT will be given for 6hrs for 6 days to make total of 36 hours
40843404|NCT06459336|OTHER|Distributed constraint-induced movement therapy|Distributed protocol of CIMT will be given for 2.25hrs two times a week for 8 weeks making total of 36 hours
40843405|NCT01662947|DEVICE|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
40843406|NCT01662947|DEVICE|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
40843407|NCT05283590|DIAGNOSTIC_TEST|Automated echocardiographic inferior vena cava measurement|Patients will be place in supine position. view: subcostal view, importantly supine is standard position for IVC measurement, the IVC is larger in the right lateral decubitus position and vice versa, alternatively directly through a transhepatic approach. Measures will be performed in the two dimensional mode close to the hepatic vein (1 - 3cm from the IVC connection to the right atrium). The IVC will be measured by MM-Mode manually and with the automated mode (both measures will be recorded. In the manual mode this measure requires concurrent utilization of M-Mode and two dimensional mode
40843408|NCT05418595|OTHER||
40843409|NCT02872532|PROCEDURE|Testicular tissue cryopreservation|Testicular tissue will be removed
40843410|NCT01501994|OTHER|GRUVE accelerometer (MUVE, inc.)|Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.
40843411|NCT01501994|OTHER|walking workstation|The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
40843412|NCT01501994|PROCEDURE|exercise counseling|After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
40843413|NCT04722757|PROCEDURE|ta-IPAA|A trans-anal port (gelpoint path, Applied Medical®) will be used for transanal acces and pneumopelvis will be created. The initial purse string is to be placed approximately 3cm above the dentate line, followed by a rectotomy. The perirectal dissection is then continued and should be pursued for at least 5cm. More proximal dissection can be done by transabdominal access. After completion of the proctectomy, a double purse string anastomosis is performed after creation of the J-pouch. A defunctioning loop ileostomy can be placed according to surgeon's preference.
41364616|NCT06254794|OTHER|Physical therapy|Standard of care physical therapy exercises
41026909|NCT06213025|BEHAVIORAL|web-based Educational program promoting response and willingness to handle elderly|promote the response and willingness of gerontological nurses in handling elderly abuse cases. By employing a rigorous experimental design, this research seeks to contribute evidence-based insights that can inform educational strategies to empower nurses in safeguarding the well-being of elderly individuals.
41026910|NCT02427529|DRUG|Human Chorionic Gonadotropin|The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
41026911|NCT02427529|DRUG|Placebo|
41026912|NCT02427529|OTHER|Low calorie diet|
41026913|NCT05760066|OTHER|Resistance Training Preconditioning|Resistance training prior to disuse-induced atrophy followed by another period of resistance training
41026914|NCT05760066|OTHER|Control|Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
41500515|NCT04622215|DIAGNOSTIC_TEST|ICIQ questionnaire|questionnaire
41026915|NCT02794493|DRUG|Traditional Chinese Medicine Formula LC09|
41026916|NCT02794493|OTHER|Placebo|
41364617|NCT01868126|DRUG|DE-117 ophthalmic solution|
41364618|NCT01868126|DRUG|latanoprost ophthalmic solution|
41364619|NCT01868126|OTHER|Placebo|
41500516|NCT02240030|DRUG|CVT-301 Low Dose|
41500517|NCT02240030|DRUG|CVT-301 High Dose|
41500518|NCT02240030|OTHER|Placebo|
41500519|NCT02032056|DIETARY_SUPPLEMENT|Probiotic (10^9 CFU/day)|
41500520|NCT02032056|DIETARY_SUPPLEMENT|Probiotic (10^8 CFU/day)|
40843414|NCT04722757|PROCEDURE|tabd-IPAA|Patients in the control group will undergo a rectal dissection by laparotomy, Pfannenstiel incision, (hand-assisted) laparoscopy, single port laparoscopy or robotic surgery, but performed from the abdominal side (tabd-IPAA). Dissection will be performed down to the pelvic floor and include the distal rectum. It is anticipated that most dissection will occur using the TME plane, however, close rectal dissection is also acceptable. Transection of the distal rectum approximately 2 cm above the dentate line will be performed using a linear stapler of the surgeon's choice. After placing the anvil in the J-pouch, a circular stapler will be introduced through the sphincter and a circular anastomosis will be performed. A defunctioning loop ileostomy can be placed according at the surgeon's discretion.
40843415|NCT05237947|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
41026917|NCT03165201|DEVICE|LiverMultiScan|We will study participants who are due to be evaluated for possible liver transplant rejection. There will be no change to usual care as part of the study, but patients will get an additional MRI scan, so that the results can be compared to the biopsy results. Each centre has a consultant radiologist specialising in liver imaging with experience in post-transplant review; the radiologist will review the MRI scans and inform the patient's doctor if any structural liver abnormalities are found (e.g. abnormal vessels, haemangiomas, tumours or cysts) as this may have implications for the patient's planned biopsy.
40843416|NCT05237947|OTHER|Questionnaire Administration|Ancillary studies
40843417|NCT05237947|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
40843418|NCT05237947|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
40843419|NCT01076413|BEHAVIORAL|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
40843420|NCT01076413|BEHAVIORAL|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
40843421|NCT04692142|OTHER|Flipped classroom teaching method|Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.
40843422|NCT05423249|DRUG|Ferrous sulfate|Oral ferrous sulfate 325 mg once daily, containing 65 mg of elemental iron to treat non-anemic iron deficiency
40843423|NCT05423249|DRUG|Prenatal|Oral prenatal vitamin once daily for both groups
40843424|NCT05423249|DRUG|Docusate Sodium|Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation
40843425|NCT05423249|DRUG|Ascorbic Acid 500Mg Tab|Oral ascorbic acid 500 mg daily, to improve absorption of oral iron
40843426|NCT05423249|DRUG|Placebo|Oral placebo pill once daily
40843427|NCT05245188|OTHER|Chocolate milk shakes - Product 1|11.3 glucose
40843428|NCT05245188|OTHER|Chocolate milk shakes - Product 2|8.84 glucose
41026918|NCT04832204|DRUG|Apatinib and Camrelizumab for Injection|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
41026919|NCT03647501|DEVICE|Interbody cage (titanium)|Subject will be implanted with a 3D-printed titanium cage during their lumbar interbody fusion surgery.
41026920|NCT03647501|DEVICE|Interbody cage (PEEK)|Subject will be implanted with a poly-ether-ether-ketone (PEEK) cage during their lumbar interbody fusion surgery.
41026921|NCT01787526|DRUG|ferric carboxymaltose|1 g intravenously per infusion
41364620|NCT06338527|OTHER|Aromatherapy|Lavender oil was used for aromatherapy intervention.
41364621|NCT06338527|OTHER|No intervention|No aromatherapy intervention was performed during the period of the study.
41026922|NCT01787526|DRUG|oral iron|oral tablets of 100mg iron over 8 weeks, total dose 10g
41026923|NCT02677545|DRUG|Ticagrelor|
41026924|NCT02677545|DRUG|Clopidogrel|
41364622|NCT01379339|DRUG|Cabazitaxel 10mg/m2|"* Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
41500521|NCT02032056|OTHER|Placebo|
40843429|NCT05245188|OTHER|Chocolate milk shakes - Product 3|4.24 glucose
40843430|NCT05245188|OTHER|Chocolate milk shakes - Product 4|4.36 glucose
40843431|NCT00644436|DEVICE|Tetrix|single topical application
40843432|NCT00644436|DEVICE|Tetrix|Single topical application
40843433|NCT02295605|OTHER|water-based exercises|water-based exercise strengthening protocol for lower limb muscles
40843434|NCT02295605|OTHER|land-based exercises|land-based exercise strengthening protocol for lower limb muscles
40843435|NCT03355677|PROCEDURE|Case finding Clinic|Case finding clinic - participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 3 quality of life and functionality questionnaires the MRC dyspnoea score and the COPD diagnostic questionnaire. They will then be asked to perform FeNO CO and spirometry measurements.
40843436|NCT03355677|PROCEDURE|At Risk Case Clinics|Complex Case Clinic participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 6 quality of life and functionality questionnaires . They will then be asked to perform FeNO CO and spirometry measurements. Participants inhaler technique will be checked and any errors corrected. Smoking cessation advice and support will be given if necessary. Each participant will be given an individualised self management plan.
40843437|NCT03355677|OTHER|Usual Care|The control surgeries selected by the HHRA will continue with usual care.
40843438|NCT02508324|BIOLOGICAL|haplo-identical cells (donor)|Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10\^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.
41364623|NCT01379339|DRUG|Cabazitaxel 12.5mg/m2|"* Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
41364624|NCT01379339|DRUG|Cabazitaxel 15mg/m2|"* Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
40843439|NCT02508324|BIOLOGICAL|umbilical cord blood unit (CBU)|Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 nucleated blood cells/kg
40843440|NCT02710942|BEHAVIORAL|SPHERE|
40843441|NCT02710942|BEHAVIORAL|PRISM|
40843442|NCT04708002|OTHER|early integrated palliative approach model|From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.
40843443|NCT01391988|PROCEDURE|Electric scalpel|Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.
40843444|NCT01391988|PROCEDURE|Harmonic scalpel|Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
40843445|NCT01441700|PROCEDURE|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
40843446|NCT01761500|OTHER|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
40843447|NCT05623215|RADIATION|Radiographs of the knee for radiostereometric analysis (RSA)|RSA radiographs will be made 5 and 10 years after the total knee arthroplasty.
40843448|NCT03405428|OTHER|Allen test|Before induction, with firm occlusive pressure held on both the radial and ulnar arteries, the patient is asked to clench his or her fist several times until the palmar skin is blanched. The patient is then instructed to unclench the fist, and then ulnar artery pressure is released while maintaining occlusion of the radial artery. Overextension of the hand and wide spreading of the fingers should be avoided because it can lead to falsely abnormal results. The time required for palmar capillary refill is noted. An abnormal Allen test result was defined as a recovery time of more than 10 seconds.
40843449|NCT03405428|OTHER|Radial artery diameter measurement by ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the radial artery will be scanned. The diameter of the radial artery will be measured and recorded.
40843450|NCT03405428|OTHER|Ulnar artery doppler ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the ulnar arter will be scanned. The blood fow of ulnar artery will be measured and recorded.
41026925|NCT02677545|DRUG|Aspirin|
41026926|NCT02176148|DRUG|fluocinonide 0.05% cream|
41500522|NCT03240263|PROCEDURE|Inspiratory Muscle Training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Resistance adjusted to the highest tolerable load.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
41500523|NCT03240263|PROCEDURE|Endurance training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Low training resistance adjusted to \<10% maximal inspiratory pressure.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
41026927|NCT05968612|DRUG|Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet|Film-coated tablet administered orally.
41026928|NCT05968612|DRUG|Lumacaftor 200 mg Film-Coated Tablet Formulation|Film-coated tablet administered orally.
41026929|NCT01316848|DRUG|tivozanib|tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
41026930|NCT00938925|PROCEDURE|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
41026931|NCT00938925|PROCEDURE|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
41364625|NCT01379339|DRUG|Cabazitaxel 17.5mg/m2|"* Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
41026932|NCT06119659|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
41364626|NCT01379339|DRUG|Cabazitaxel 20mg/m2|"* Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
41364627|NCT02430064|OTHER|Low PAMP diet|
41364628|NCT02506101|DEVICE|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
40843451|NCT03048604|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
41364629|NCT05500742|DIETARY_SUPPLEMENT|Coenzyme Q10|Soft 100 mg capsules containing coenzyme Q10 in vegetable oil provided by Pharma Nord
41364630|NCT05500742|DIETARY_SUPPLEMENT|Selenium|100 mcg tablets provided by Pharma Nord
41364631|NCT05500742|DIETARY_SUPPLEMENT|Resveratrol|350 mg capsules provided by NOW Foods
41364632|NCT05500742|DIETARY_SUPPLEMENT|TA-65 MD|100 unit capsules provided by TA Sciences
41364633|NCT05500742|OTHER|Placebo-1|Soft capsules containing vegetable oil, externally identical to coenzyme Q10 capsules, provided by Pharma Nord
41364634|NCT05500742|OTHER|Placebo-2|Tablets containing excipients, externally identical to selenium tablets, provided by Pharma Nord
41364635|NCT03190304|DRUG|Neprilysin|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
41364636|NCT03190304|DRUG|Enalapril|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
40843452|NCT00952887|BIOLOGICAL|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
40843453|NCT00952887|BIOLOGICAL|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
40843454|NCT01976260|DEVICE|Fractional Radiofrequency|
40843455|NCT01976260|DEVICE|1550-nm Fractional Photothermolysis|
40843456|NCT01409369|DRUG|RO4995819|single oral dose
40843457|NCT01409369|DRUG|activated charcoal|orally 3 times daily, Days 1-7
40843458|NCT03951116|DRUG|FCN-437|FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
40843459|NCT05380167|DIETARY_SUPPLEMENT|BRJ Nitrate|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink with nitrate.
41026933|NCT06119659|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
41026934|NCT06119659|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
41026935|NCT01863017|DEVICE|tDCS|
41364637|NCT03391063|OTHER|polyamide|metal reinforced polyamide denture base material
41364638|NCT03391063|OTHER|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
41364639|NCT02040376|DRUG|Metformin|Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
41500524|NCT05092152|DRUG|Esketamine hydrochloride|2 mg per kilogram of body weight
41500525|NCT05092152|DRUG|Propofol|1.5 mg per kilogram of body weight
41500526|NCT04610879|DRUG|Carbamazepine|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
41500527|NCT04610879|DRUG|Levetiracetam|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
40843460|NCT05380167|DIETARY_SUPPLEMENT|BRJ Placebo|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink without nitrate
40843461|NCT00988572|OTHER|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
41026936|NCT06300541|PROCEDURE|Colectomy|Observational study.
41026937|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of powder form dissolved in one cup of tap water prior to breath test
41026938|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
41364640|NCT02040376|DRUG|Placebo|Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
40843462|NCT03600454|DRUG|General anesthesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol
40843463|NCT03600454|DRUG|Spinal anesthesia|The level of puncture will be L4 - L5. 10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid
40843464|NCT03600454|DRUG|General anesthesia and epidural analgesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2 µg/kg and propofol. A thoracic epidural catheter will be placed with 3 ml of xylocaine 2% (with epinephrine 1/200.000).
40843465|NCT04538079|DEVICE|Multimodal objective non-invasive Monitoring|Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
40843466|NCT02732431|OTHER|Sleep Symptom|Questionnaires, skin allergy test, overnight polysomnography
40843467|NCT05273463|BEHAVIORAL|Video-Based Intervention|15-minute video about what to expect before, during, and after your surgery
41364641|NCT06080308|OTHER|No intervention|No intervention
41364642|NCT01476982|DEVICE|ClearView Scan|Assessment with ClearView device
41364643|NCT06410833|DRUG|Rituximab|Rituximab weekly until B%\<0.5% or B#\<20×10\^6/L
41364644|NCT06410833|DRUG|Belimumab|Belimumab every four weeks
41364645|NCT01488695|DEVICE|GlideScope Groove|GlideScope Groove
41364646|NCT01488695|DEVICE|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
41500528|NCT04610879|BEHAVIORAL|Parent based sleep (PBS) intervention|The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.
41500529|NCT02294461|DRUG|Enzalutamide|Oral
41500530|NCT02294461|DRUG|Placebo|Oral
41500531|NCT00006019|DRUG|azacitidine|
41500532|NCT00006019|DRUG|sodium phenylbutyrate|
41500533|NCT06633900|DRUG|IM naltrexone|The study drug is an intramuscular injection of naltrexone (380mg), administered every 4 weeks via an injection in the ventrogluteal region.
41500534|NCT06633900|BEHAVIORAL|Usual Care|Participants assigned to usual care will receive a harm reduction bundle in clinic. It will include the following components: 1) intranasal naloxone 4mg x 2, 2) participant choice of safer consumption kits based on substances and route used (specific materials for inhaled use vs. injecting, based on common use practices in the region), 3) fentanyl test kits with 2 lateral flow assays per package along with instructions to minimize false positive results, and 4) information about universal overdose precautions (behavioral modifications to optimize safety like using in the presence of others, use a test dose of new substances, etc.)
40843468|NCT05273463|BEHAVIORAL|Classroom-Based Intervention|Virtual 30-minute course with an Orthopedic nurse about what to expect before, during, and after your surgery
40843469|NCT02219503|DRUG|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
40843470|NCT02219503|DRUG|Dasabuvir|Tablet
40843471|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
40843472|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 2.4g extended release tablet|SPD476 2.4g administered Once Daily (QD)
40843473|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 4.8g extended release tablet|SPD476 4.8g administered Once Daily (QD)
40843474|NCT00545103|DRUG|Placebo|Placebo administered Once Daily (QD)
40843475|NCT06092775|DEVICE|DEXA scan,X_ray|"DEXA scan detect osteoporosis~,X_ray show subclinical vertebral fractures"
40843476|NCT04379076|DRUG|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
40843477|NCT04379076|DRUG|Placebos|Intramuscular (IM) placebo (normal saline) at the same frequency
40843478|NCT06347939|DIAGNOSTIC_TEST|Mediastinal lymph nodes cryobiopsies|EBUS Mediastinal lymph nodes cryobiopsies
40843479|NCT01694979|OTHER|Minimum expiration effort|Subjects perform a forced expiration at minimum effort
40843480|NCT01694979|OTHER|Moderate expiration effort|Subjects perform a forced expiration at moderate effort
40843481|NCT01694979|OTHER|Maximum expiration effort|Subjects perform a forced expiration at maximum effort
40843482|NCT01262664|DRUG|Prohibitin-TP01|Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
40843483|NCT01364740|DEVICE|PMP-300E|Data collected from Level 3 device
41364647|NCT03618576|PROCEDURE|Balance specific exercise|Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
41364648|NCT06088017|DRUG|CKD-391(2)|QD, PO
41364649|NCT06088017|DRUG|CKD-331, D337|QD, PO
41364650|NCT00475657|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
41364651|NCT00475657|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
41364652|NCT05689229|DRUG|Colistin|COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
41364653|NCT00483431|DIETARY_SUPPLEMENT|Placebo|
41364654|NCT00483431|DIETARY_SUPPLEMENT|MK7|
41364655|NCT02604134|PROCEDURE|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
40843484|NCT01364740|DEVICE|In-lab PSG|Data collected from Type I In-Lab Polysomnography
40843485|NCT04216355|DRUG|Azacitidine|Low-dose AZA
40843486|NCT04216355|DRUG|CAG Protocol|Short term CAG derived regimen
40843487|NCT04383275|DRUG|capecitabine and trastuzumab|In IRIS-A cohort, patients who met the inclusion criteria(ER，PR\<10%, T≤2cm or ER,PR ≥10% 1cm\<T≤2cm）would be given capecitabine for 6 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
40843488|NCT04383275|DRUG|endocrine therapy and trastuzumab|In IRIS-B cohort, patients who met the inclusion criteria(ER,PR ≥10% T≤1cm) would be given endocrine therapy (premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane) combined with standard trastuzumab for 1 year and complete endocrine therapy for 5 years.
40843489|NCT01570049|DRUG|Bendamustine|for injection
40843490|NCT04268745|BEHAVIORAL|Balance training|Progressive balance training within virtual environments
40843491|NCT04268745|BEHAVIORAL|Traditional Vestibular Rehabilitation|Progressive balance training and gaze stability exercises
40843492|NCT02746185|DRUG|rivaroxaban|rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
40843493|NCT02746185|DRUG|Low-molecular-weight heparin|dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
40843494|NCT02364440|DEVICE|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
40843495|NCT00964561|DRUG|Ciprofloxacin and Valortim|Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
40843496|NCT00964561|DRUG|Placebo Antibiotic and Valortim|Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
40843497|NCT00964561|OTHER|Placebo Antibiotic and Placebo Valortim|Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
40843498|NCT00510978|BIOLOGICAL|Bifidobacterium infantis 35624|1 sachet/day for one year
40843499|NCT00510978|BIOLOGICAL|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
40843500|NCT00510978|BIOLOGICAL|Placebo|1 sachet per day for 1 year
40843501|NCT02836431|DRUG|Dexmedetomidine 1mcg/kg Intranasal|DEX 1 mcg/kg Intranasal
41161081|NCT05484713|DIAGNOSTIC_TEST|Cardiac imaging|Baseline - 2D transthoracic echocardiography, 128-multislice CT coronary angiography, CCTA of peripheral lower limbs vessels 12-months follow-up - 128-multislice CT coronary angiography with transthoracic echocardiography
40843502|NCT02836431|DRUG|Dexmedetomidine 2mcg/kg Intranasal|DEX 2 mcg/kg Intranasal
40843503|NCT02836431|DRUG|Dexmedetomidine 1mcg Intravenous|DEX 1 mcg/kg Intravenously
40843504|NCT05047432|OTHER|Non-interventional trial|Non-interventional trial
40843505|NCT02161419|DRUG|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
40843506|NCT02161419|DRUG|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
40843507|NCT01739543|DEVICE|Hem-Avert|Application of Hem-Avert
40843508|NCT05122429|BEHAVIORAL|e-Health Treatment|Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.
40843509|NCT06191107|DEVICE|Removable Partial Denture|Integration of removable partial dentures made of PEEK for the treatment of tooth loss.
40843510|NCT03688100|BEHAVIORAL|Behavioral Activation Therapy|The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
40843511|NCT03688100|DRUG|Medication Management|Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
40843512|NCT00547027|BEHAVIORAL|print-based physical activity intervention|individually-based, print-based physical activity intervention
40843513|NCT00547027|BEHAVIORAL|usual care|print-based materials of nutritional information
40843514|NCT02339792|OTHER|E-learning|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
41026939|NCT01408589|DRUG|Atomoxetine, Strattera|Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
41026940|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
41026941|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
41026942|NCT05827224|DEVICE|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
41161082|NCT05484713|DEVICE|3D printing of the aortic valve|3D printing of the aortic valve based on CCTA image acquisition
41161083|NCT02125097|DEVICE|Barrel™ Vascular Reconstruction Device (VRD)|Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio \< 2.
41161084|NCT01202669|OTHER|No intervention planned, observational study only.|No intervention planned, observational study only.
41161085|NCT02178397|DRUG|ERLOTINIB WITH CHEMOTHERAPY|
41026943|NCT05827224|DEVICE|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
41161086|NCT02178397|DRUG|CHEMOTHERAPY ONLY|
41161087|NCT02234635|OTHER|Diffractive multifocal IOLs group|Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
41500535|NCT06634108|DRUG|Genistein|The genistein capsules are manufactured and obtained from MCS Formulas, and each capsule contains 250 mg genistein and 50 mg inulin. The genistein is certified to be 98% pure genistein by HPLC and is certified by Good Laboratory Practice (GLP). They will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood and stool samples are collected. Then, participants will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before collecting fasting blood and stool samples. Afterward, participants will take 750 mg of genistein BID (1500 mg total) for 4 weeks before collecting fasting blood and stool samples. Afterward, participants will have a washout for 6 weeks before returning for fasting blood and stool sample collection.
41161088|NCT01491763|DRUG|Imatinib|600 mg p.o. from day 1 until consolidation
41161089|NCT03359187|OTHER|Normal saline with salt/Soda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
41161090|NCT03359187|OTHER|Clinacanthus nutans|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
41364656|NCT02604134|DRUG|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
41364657|NCT02604134|DRUG|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
41364658|NCT00074789|BEHAVIORAL|Modified Interpersonal Therapy|Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
41364659|NCT00074789|BEHAVIORAL|Attention control/usual care|Participants will receive the usual care for depression.
41364660|NCT04406324|OTHER|No intervention|No Intervention. The study consists in a prospective clinical longitudinal follow-up
41500536|NCT05174195|DRUG|Desogestrel 0.075 milligram|Inserted after 3 months use of DESOGESTREL
41026944|NCT05827224|DEVICE|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
41026945|NCT05219318|DRUG|Combination PD-1/PD-L1 ICI + VEGFR-TKI|The study will enroll patients achieving an objective response beween the end of the 11th month and the end of the 13th month of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC)
41500537|NCT05174195|DRUG|Implanon NXT® subdermal implant|Inserted immediately
41026946|NCT05219318|OTHER|Treatment pause|Combination regimens discontinuation until progression with the possibility to resume initial combination regimens at progression
41026947|NCT01797146|PROCEDURE|Catheter Reminder and Evaluation Program|"This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~1. Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~   * Type and duration of urinary catheter use.~  * Indication of urinary catheter _________~  * Type and duration of central venous catheter use~  * Indication of urinary catheter _________~2. Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified."
41161091|NCT03359187|OTHER|Boesenbergia rotunda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
41161092|NCT00502983|BEHAVIORAL|Interview|Interview lasting approximately 50 minutes.
41161093|NCT05657132|DRUG|herbal intracanal medication paste|study the effect of costus herbal paste on enterococcus faecalis bacteria
41161094|NCT05657132|DRUG|Meta paste|compare the effect of Costus paste with meta paste in reducing the number of enterococcus faecalis
40843515|NCT01890668|OTHER|Osteopathic Manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy step, initiation of breastfeeding, baby posture...) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility...) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
40843516|NCT01890668|OTHER|No Osteopathic manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy steps, initiation of breastfeeding, baby posture...) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.~Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
40843517|NCT00799539|DRUG|bortezomib|From cycles 1-4, 1.3mg/m\^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
40843518|NCT00799539|DRUG|bortezomib|From cycles 5-9, 1.3mg/m\^2 on days 1, 8, 22, and 29 of each 6-week cycle
40843519|NCT00799539|DRUG|melphalan|9 mg/m\^2 once daily on days 1-4 of each 6-week cycle
40843520|NCT00799539|DRUG|prednisone|60 mg/m\^2 once daily on days 1-4 of each 6-week cycle
41161095|NCT02455284|DEVICE|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
40843521|NCT05314959|OTHER|Physician Awareness|The patients' pre-visit Control Preference Scale responses are shared with their physician.
40843522|NCT05314959|OTHER|Usual Care|The patients' pre-visit Control Preference Scale responses are not shared with their physician.
40843523|NCT01098526|DRUG|GSK1349572|GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
40843524|NCT01098526|DRUG|Efavirenz|Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
40843525|NCT06097546|DIAGNOSTIC_TEST|laboratory test (RAI14 and MACC-1 )|Measurement of serum RAI14 and serum MACC-1 levels by immunochemical assays
41161096|NCT04847778|DEVICE|Use of Insulclock system, both Insulclock device and Insulclock 360 app.|"Visit 5, during week 4.~Randomization will be applied:~Active group will use all functionalities of Insulclock 360. They will have reminders, all their information and statistics at the disposition of the patient and healthcare providers, they have the assistance if desired of an ally or caregiver, a bolus calculator and the rest of functionalities described in the protocol."
41500538|NCT04829175|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this registry. The surgical procedures being performed within the registry are identical to the surgical procedures patients would receive as part of SOC.
40843526|NCT06520358|OTHER|Acute Intermittent Hypoxia (AIH)|Acute intermittent hypoxia refers to brief (acute), repetitive (intermittent) episodes of breathing oxygen-deprived air (hypoxia) alternating with breathing ambient room air.
40843527|NCT06520358|BEHAVIORAL|Task specific Airway Protection Training|The vLVC maneuver involves training participants to volitionally prolong closure of the laryngeal vestibule during swallowing, beginning with swallow onset and sustaining closure for at least 2 seconds.
40843528|NCT06520358|OTHER|Sham AIH|Sham AIH will be delivered using methods identical to AIH, except a normoxic gas mixture (\~21% O2) will be delivered. The gas mixture with normoxic air will effectively serve as a sham.
40843529|NCT04556422|OTHER|Aerobic exercise|15 minutes of aerobic exercise using stationary bicycle
40843530|NCT04556422|OTHER|Sauna bathing|Passive heat exposure
40843531|NCT04552106|DIETARY_SUPPLEMENT|3 caps x3/day|3 capsules 3 times daily for 28 days
40843532|NCT04552106|DIETARY_SUPPLEMENT|3 caps x2/day|3 capsules 2 times daily for 28 days
41500539|NCT03122197|DRUG|Letrozole Oral Tablet|Administration: Letrozole will be given orally once daily.
41161097|NCT04847778|DEVICE|Use of Insulclock system, both Insulclock device and Insulclock app on masked mode.|"Visit 5, during week 4.~Randomization will be applied:~Masked group will remain with the masked system, without functionalities."
41161098|NCT06084455|OTHER|Aerobic exercise|30 minutes of aerobic exercise on a stationary bike
41161099|NCT04889833|BEHAVIORAL|hypnosis therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calm ocean to be played at least once daily for 7 preoperative days, the day of surgery, and for 7 days postoperatively.
41161100|NCT05750342|DIETARY_SUPPLEMENT|Experimental Product Caqui|Supplement extracted from persimmon
41500540|NCT03122197|DRUG|Temozolomide|50 mg/m2 TMZ administered orally once daily
40843533|NCT04552106|DIETARY_SUPPLEMENT|2 caps x3/day|2 capsules 3 times daily for 28 days
40843534|NCT04552106|DIETARY_SUPPLEMENT|2 caps x2/day|2 capsules 2 times daily for 28 days
40843535|NCT04552106|DIETARY_SUPPLEMENT|3 caps x1/day|3 capsules 1 times daily for 28 days
40843536|NCT01057524|DEVICE|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
40843537|NCT01057524|OTHER|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
40843538|NCT03400813|BEHAVIORAL|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing is a early and short adaption protocol of EMDR developed by Shapiro E. EMDR is a psychotherapeutic approach that can rapidly process disturbing experiences adaptively together with the aid of eye movements or other forms of bi-lateral stimulation.
40843539|NCT00715858|DRUG|doxycycline|capsule, 100 mg, b.i.d., 12 months
40843540|NCT00715858|DRUG|rifampin|capsule, 300 mg, od, 12 months
40843541|NCT00715858|DRUG|placebo|placebo matched to rifampin; placebo matched to doxycycline
40843542|NCT03110575|DRUG|TNX-102 SL|2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
41026950|NCT06169917|BEHAVIORAL|Paced Resonance Frequency Breathing|Participants are required to pace their breathing to their pre-determined individual resonance frequency.
41026951|NCT06169917|BEHAVIORAL|Paced Breathing at Natural Frequency|Participants are required to pace their breathing to their pre-determined individual breathing frequency at rest.
41026952|NCT06169917|OTHER|Heat Stimulations|Participants will undergo a heat stimulation procedure on their left and right foot (the order of which is counterbalanced across participants). During this procedure, there are 10 blocks, with an inter-stimulus interval of 30 seconds between two blocks. During a block, six 6-second heat stimulations (48 degrees) are given. Between the stimulations, the temperature quickly returns to baseline (32 degrees).
41161101|NCT05750342|DIETARY_SUPPLEMENT|Control product placebo|Product with identical characteristics to the experimental product.
41161102|NCT02005029|DRUG|Erythromycin|
41161103|NCT02005029|DRUG|placebo|
41364661|NCT06001164|PROCEDURE|ACL reconstruction: Double bundle|DB: Two tunnels were created on the femoral side through an anteromedial portal. These tunnels were created manually. On the tibial side, the tunnels were created using a guide to ensure they matched the anatomic insertion site of the ACL at the tibia. The hamstring grafts for the procedure were then harvested from the same leg and doubled. The femoral side was fixed from the inside out, whereas the tibial side was fixed from the outside in. bioresorbable screws were used.
41364662|NCT06001164|PROCEDURE|ACL reconstruction: Single bundle|SB: The femoral tunnel was created using an anteromedial portal. A freehand technique was used. For the tibial tunnel, a tibial guide was used to ensure it was positioned at the midpoint of the tibial ACL attachment site. The tendons of the semitendinosus and gracilis muscles were then harvested, doubled over, and inserted through the tibial tunnel, extending into the femur, and fixed with metallic or bioabsorbable interference screws.
41364663|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
41364664|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
40843543|NCT00247455|DRUG|Low fibre breakfast cereal (puffed rice/cornflakes)|
40843544|NCT00247455|DRUG|High fibre cereal (All Bran/Bran Flakes)|
40843545|NCT00748319|OTHER|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
40843546|NCT03212456|DRUG|opioid-free group|We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
40843547|NCT03212456|DRUG|Opioid Group|This group will receive fentanyl in the induction of anesthesia.
41364665|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-3|Dynamic Light Therapy
41364666|NCT01220024|DRUG|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
41364667|NCT01220024|DRUG|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
41364668|NCT03414372|BEHAVIORAL|Tough Talks Online|Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.
40843548|NCT03212456|PROCEDURE|transversus abdominal plane block with ropivacaine|The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side
40843549|NCT03212456|PROCEDURE|transversus abdominal plane block with placebo|the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
40843550|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Escalating dose 2 X 10\^9, 4 X 10\^9, 8 X 10\^9/mL
40843551|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Escalating dose 8 X 10\^9, 4 X 10\^9, 8 X 10\^9 mL
41364669|NCT03414372|BEHAVIORAL|Tough Talks Clinic|Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.
41364670|NCT03414372|BEHAVIORAL|Standard of Care|Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
40843552|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day (8:8:8)|Dosed 8 X 10\^9, 8 X 10\^9, 8 X 10\^9 mL
41500541|NCT00665938|OTHER|Infant formula|"Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics"
41500542|NCT03626688|DRUG|Ralinepag|Active
41161104|NCT00640185|DRUG|ABT-089|Subjects will take up to two 40 mg tablets once daily for 8 weeks.
40843553|NCT01433094|BEHAVIORAL|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
40843554|NCT01433094|BEHAVIORAL|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
40843555|NCT05017532|BEHAVIORAL|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+)|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+) is a personalized CR treatment targeting social cognition (e.g. theory of mind, emotion recognition) using virtual reality to emulate daily social interactions
40843556|NCT02350504|BEHAVIORAL|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
40843557|NCT02910102|DRUG|RVT-101 35 mg|RVT-101 once daily, oral, 35-mg tablets
40843558|NCT02910102|DRUG|Placebo|Placebo once daily, oral
41161105|NCT00640185|DRUG|Placebo|Subjects will take one or two placebos once daily for the duration of the study.
40843559|NCT04194125|DRUG|177Lu-DOTATOC|Four administrations of 5,55GBq up to 7,4 GBq 177Lu-DOTATOC will be administered at 8-week intervals.
40843560|NCT03005808|DRUG|Ropivacaine|Surgery for appendicitis
41161106|NCT03284489|OTHER|Collection of medical datas from ICU patients|Collection of medical datas from ICU patients with pancreatitis on a secured electronic database
41161107|NCT01233414|BEHAVIORAL|Parent Training|The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.
41161108|NCT01233414|OTHER|Psychoeducational Program|The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
40843561|NCT03936647|PROCEDURE|surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
41161109|NCT04340466|OTHER|No intervention|No intervention
41161110|NCT04064723|DEVICE|Randomization between prosthetic components|Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.
41161111|NCT02936492|DRUG|BAY1003803 0.01% lipophilic cream|Topical administration for 22 h per day
41161112|NCT02936492|DRUG|BAY1003803 0.1% lipophilic cream|Topical administration for 22 h per day
41161113|NCT02936492|DRUG|BAY1003803 0.01% ointment|Topical administration for 22 h per day
41161114|NCT02936492|DRUG|BAY1003803 0.1% ointment|Topical administration for 22 h per day
41364671|NCT01249404|BIOLOGICAL|Botulinum toxin type A|I.M. injection on day 1 (single treatment cycle)
41364672|NCT01249404|DRUG|Placebo|I.M. injection on day 1 (single treatment cycle)
41364673|NCT05951881|OTHER|Emergency Care Unit - medicines|"The same group of patients admitted to the emergency room will respond separately to a pharmacist and a pharmacy assistant about their daily medication.~The two medical records will be compared in order to evaluate the work of the pharmacy assistant on the basis of 3 sources :~* the Electronic Medical Record~* the patient's medication history~* the reference pharmacy"
41364674|NCT01842282|DRUG|Amlexanox|
41500543|NCT03626688|DRUG|Placebo|Placebo
41500544|NCT04514068|PROCEDURE|Acupuncture|In each session, acupuncture are applied unilaterally or bilaterally on P6 acupoint. Each acupuncture needle will be stimulated by transcutaneous electric device.
41500545|NCT04514068|PROCEDURE|Sham acupuncture|Sham acupuncture
41500546|NCT01625832|PROCEDURE|intermittent coronary sinus occlusion|Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
41364675|NCT00616005|DRUG|Temodar and Irinotecan|Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle \& every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, \& 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
41161115|NCT02936492|DRUG|Lipophilic cream vehicle|Topical administration for 22 h per day
41364676|NCT03987165|OTHER|Music Therapy|"Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby."
41364677|NCT00352404|DEVICE|Endomicroscope|
41161116|NCT02936492|DRUG|Ointment vehicle|Topical administration for 22 h per day
41364678|NCT04004026|OTHER|Assesment|3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
41161117|NCT02936492|DRUG|Clobetasol propionate|Topical administration for 22 h per day
41161118|NCT01474421|DRUG|AQW051|Patients will receive AQW051 in a high dose once daily orally for 28 days.
41161119|NCT01474421|DRUG|AQW051|Patients will receive AQW051 in a low dose once daily orally for 28 days.
41161120|NCT01474421|DRUG|Placebo|Patients will receive placebo once daily orally for 28 days.
41364679|NCT05107557|BIOLOGICAL|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
41364680|NCT02889861|DRUG|IMCgp100|Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
41364681|NCT04196231|DRUG|IDegLira|IDegLira will be started at 16 dose steps (16 U insulin degludec plus 0.58 mg liraglutide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements doses of IDegLira will be titrated individually twice per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IDegLira could be titrated to 50 dose steps (50 U insulin degludec plus 1.8 mg liraglutide).
41364682|NCT04196231|DRUG|IGlarLixi|IGlarLixi will be started at 10 dose steps (10 U insulin glargine plus 5 mcg lixisenatide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements, doses of IGlarLixi will be titrated individually once per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IGlarLixi could be titrated to 60 dose steps (60 U insulin degludec plus 20 mcg lixisenatide).
41364683|NCT04196231|DRUG|Insulin/Canaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to canaglifozin, according to the current clinical practice and the drugs' data sheet. Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required (HbA1c \>7.5 after 12 weeks).
41364684|NCT04196231|DRUG|Insulin/Dapaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to dapaglifozin, according to the current clinical practice and the drugs' data sheet. Dapagliflozin will be started at 10 mg daily per oral administration
41364685|NCT04196231|DRUG|Insulin/Empaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to empaglifozin, according to the current clinical practice and the drugs' data sheet. Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required (HbA1c \>7.5 after 12 weeks).
41500547|NCT00737750|DEVICE|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
41500548|NCT00737750|DEVICE|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
41500549|NCT00737750|BEHAVIORAL|Control|Voluntary quadriceps muscle contractions.
41500550|NCT03047330|DRUG|Estradiol withdrawal|one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
41500551|NCT03047330|OTHER|Fragmented sleep|Fragmented sleep will be experimentally induced.
41500552|NCT03265288|DRUG|LAU-7b|LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
41500553|NCT03265288|DRUG|Placebo oral capsule|Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
41500554|NCT06323148|DRUG|Osimertinib|Adjuvant osimertinib for three years after radical surgery
40843562|NCT03936647|DEVICE|WEB embolization device|WEB embolization device
41161121|NCT04973332|DEVICE|Intracranial thrombectomy stent|Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset
41026953|NCT02852213|DRUG|AAV2-hAADC|Initially, subjects will be enrolled sequentially into 2 dose groups. 3 subjects will be enrolled in Cohort 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as infusate volume of up to 160μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Cohort 2 may commence after the last subject in Cohort 1 is treated and followed through Month 3 post-op, with approval of the data safety monitoring board (DSMB). Cohort 2 will receive a higher dose (4.2 x 10\^11 vg, 160 uL). Upon DSMB review of Cohort 1/2 results, Cohort 3 (4-12 yo) and 4 (aged \>/= 13 yo) will be dosed (1.6 x 10\^12 vg, 60uL) in 1-2 sites bilaterally in-between the SNc and VTA. Cohort 5 will follow (aged 24-47 months) at 1.3 x 10\^12 vg, 500uL. Final safety and clinical outcome assessments will be performed 1 year post-surgery. Follow-up analysis will be performed for 2 years post-op. Subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates.
41161122|NCT04659200|DIAGNOSTIC_TEST|Venous blood was collected for biochemistry testing.|For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
40843563|NCT02737384|BIOLOGICAL|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
41161123|NCT01885936|DRUG|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
41364686|NCT04196231|DRUG|Basal Bolus|Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization. The insulin titration will be guided by the medical staff, according to the following algorithm: adding 2 units of basal insulin for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units of basal insulin for prebreakfast plasma glucose \< 80 mg/dL. The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day) and will be titrated twice a week until achieving pre-prandial glucose values ranging from 80-130 mg/dL.
41364687|NCT02160743|DIETARY_SUPPLEMENT|CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)|
41364688|NCT05403775|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.
41364689|NCT05403775|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
41364690|NCT03691831|DRUG|Active|A-101 45% (hydrogen peroxide 45% topical solution)
40843564|NCT01340599|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given PO
40843565|NCT01340599|OTHER|placebo|Given PO
40843566|NCT01340599|OTHER|immunohistochemistry staining method|Correlative studies
41161124|NCT01885936|DRUG|Placebo|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
41161125|NCT02689752|DRUG|fruquintinib|fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
41161126|NCT00308919|DRUG|WST09|Treatment with WST09 Vascular Photodynamic therapy
41364691|NCT03691831|OTHER|Vehicle|Vehicle solution containing isopropyl alcohol and water
41500555|NCT06323148|DRUG|No adjuvant therapy|No adjuvant therapy
40843567|NCT01340599|OTHER|immunoenzyme technique|Correlative studies
40843568|NCT01340599|OTHER|questionnaire administration|Ancillary studies
40843569|NCT01340599|PROCEDURE|therapeutic conventional surgery|Undergo radical prostatectomy
40843570|NCT01340599|OTHER|high performance liquid chromatography|Correlative studies
40843571|NCT01340599|OTHER|mass spectrometry|Correlative studies
40843572|NCT01841255|DEVICE|Mouthpiece (Umox)|Device used to perform preoxygenation in the operating room context
40843573|NCT01841255|DEVICE|facemask|
40843574|NCT06203587|RADIATION|[68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347|The dose of \[68Ga\]Ga-NOTA-WWH347 or \[18F\]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8-3.7 MBq \[0.05-0.1 mCi\]/kg, and was administered as an intravenous push, with a single dose given once.
40843575|NCT03441698|DEVICE|Genuine acupuncture (A)|A) Acupuncture is administered bilaterally to the acupuncture point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpii radialis. Sharp acupuncture needles were inserted into a depth of a half body-inch. The needles are manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
40843576|NCT03441698|DEVICE|Sham acupuncture (B)|B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6. The telescopic Park Sham Device was used. The needle looks identical to a real needle, but is blunt and glides upward into its handle instead of penetrating. The marking tubes holds the needle in place. The therapist give an illusion of manipulating the needle by turning it three times until it touched the skin, but no deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
40843577|NCT03441698|OTHER|Rest|C) Rest means resting for 30 minutes, either sitting or lying down. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
40843578|NCT02736981|BEHAVIORAL|Behavioral Weight Loss (BWL)|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
40843579|NCT02736981|BEHAVIORAL|BWL + Autonomous Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
40843580|NCT02736981|BEHAVIORAL|BWL + Extrinsic Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
40843581|NCT00052156|BIOLOGICAL|CancerVax vaccine (CANVAXIN)|
40843582|NCT01496755|DRUG|Placebo|Single/multiple doses
40843583|NCT01496755|DRUG|RG7667|Single/multiple ascending doses
40843584|NCT01435967|OTHER|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
40843585|NCT00370838|DRUG|Levetiracetam|The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
40843586|NCT00370838|DRUG|Clonidine|The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
41161127|NCT06480370|DEVICE|ISIS IOM System|Application of TES at different stimulation circuits, with different stimulation parameters and recording montages.
40843587|NCT03322670|OTHER|Signs of CAP and a positive chest X-Ray|"* collection of clinical examination data~* biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)~* self-reported questionnaires on duration of symptoms and restriction of activity~* telephone contact on day 28 and day 90 if hospitalized before day 28"
40843588|NCT03322670|OTHER|Patients directly hospitalized|"* collection of clinical examination data~* telephone contact on day 28 and retrieval of hospitalization report~* telephone contact on day 90"
40843589|NCT03322670|DIAGNOSTIC_TEST|Control patients|- bacteriological examinations (urine)
40843590|NCT03322670|OTHER|Patients with partial participation|- collection of clinical examination data
41161128|NCT00655369|DRUG|PD 0200390|oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
41161129|NCT00655369|DRUG|PD 0200390|oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
41161130|NCT00655369|DRUG|PD 0200390|oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
41161131|NCT00655369|DRUG|PD 0200390|oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
41161132|NCT00655369|DRUG|PD 0200390|oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
41161133|NCT00655369|DRUG|Placebo|oral placebo daily dose, 3 capsules per dose during a six week treatment period.
41161134|NCT00888407|BEHAVIORAL|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
41161135|NCT00888407|BEHAVIORAL|Nutrition - Small group educational session|Small group session with diet \& nutrition focused, topic related resources provided.
40843591|NCT03322670|OTHER|Signs of CAP and a negative chest X-Ray|"* collection of clinical examination data~* telephone contact on day 28"
40843592|NCT04904848|OTHER|Survey evaluation|examine the convergent validity and reliability of a Turkish version
41161136|NCT05830305|OTHER|Mobile health intervention|A protocol-based intervention via phone calls, which includes anti-hypertensive drug adjustment and reinforcement of lifestyle modification, will be implemented.
40843593|NCT05116696|PROCEDURE|For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery|"For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy"
40843594|NCT03002272|DEVICE|TAVR|subjects that underwent TAVR more than 3 years ago
40843595|NCT03002272|DEVICE|SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
40843596|NCT00399100|PROCEDURE|HBO - hyperbaric oxygen treatment|
40843597|NCT05424250|BEHAVIORAL|occasional aversive imagination|During six of the 27 exposure trials, participants in the experimental group are asked to imagine their most feared outcome towards spiders as vividly as possible while completing the specific trial.
40843598|NCT05424250|BEHAVIORAL|Exposure|• All participants complete an exposure training session (approx. 75 min) with seven exposure steps, which are repeated between one and five times (e.g. Step 4: directing the spider with a pen by touching its legs at least five times per repetition; this step must be repeated five times before continuing to the next step). One repetition per step is considered one trial, therefore each participant aims to complete 27 exposure trials.
40843599|NCT06264297|PROCEDURE|Radiofrequency|Pulsed radiofrequency (PRF) is a nonablative pain treatment that uses radiofrequency current in short high-voltage bursts, resulting in interruption of nociceptive afferent pathways. This study aims to show how the variation in radiofrequency voltage applied to the dorsal root ganglion (DRG) affects the treatment of neuropathic pain.
41026954|NCT04877912|DIAGNOSTIC_TEST|MRI Abbreviated Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
41026955|NCT04877912|DIAGNOSTIC_TEST|Abbreviated MRI Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
41026956|NCT05970029|BEHAVIORAL|Communication style|The verbal communication between the nurse and the patient at the time of analgesic administration
41026957|NCT03566719|OTHER|Exercise program|Intervention group has been submitted to an exercise program directed to prevent and reduce fall risk
41026958|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence A|Starting from 0° position, shift to position +20°, then tilt to -20°, and finally back to the 0° position.
41161137|NCT02489721|DEVICE|PICC and Midline|Peripherally inserted central venous catheter
41026959|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence B|Starting from 0° position, shift to position -20°, then tilt to +20°, and finally back to the 0° position and collect the last group of figures.
41161138|NCT04143906|DRUG|Vinorelbine|injection
41161139|NCT04143906|DRUG|Gemcitabine|injection
41161140|NCT04143906|DRUG|Carboplatin|injection
41161141|NCT00880152|BEHAVIORAL|Mindfulness-based stress reduction|An 8-week course in mindfulness training
41364692|NCT05023239|OTHER|UG-SZM Group|The patients will be receive Ultrasound-Guided Suprazygomatic Maxillary Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine .
41026960|NCT05971979|OTHER|No intervention|No intervention
41026961|NCT02621762|DEVICE|Magnesium|Magnesium in dialysate increased
41026962|NCT02621762|DEVICE|Bicarbonate|Bicarbonate in dialysate increased
41161142|NCT06235853|DIAGNOSTIC_TEST|Blood serum: sUPAR, PAI-1, IL-8.|The concentration of described biomarkers were measured in serum.
41161143|NCT06235853|DIAGNOSTIC_TEST|Urine: IL-8, APOE, VEGF.|The concentration of described biomarkers were measured in urine.
41161144|NCT05175300|DEVICE|Prosthesis with CoPXE couple.|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
41161145|NCT05175300|DEVICE|Prosthesis with CoC torque.|Prosthesis with ceramic-on-ceramic (CoC) torque.
41364693|NCT05957315|DEVICE|Mobile Cardiac Outpatient Telemetry Device (MCOT)|Application of a Philips/Biotel MCOT device
41364694|NCT01089075|DRUG|Hydrocortisone|20 mg po for 7 days (2 tablets)
41364695|NCT01089075|DRUG|Placebo|2 tablets po
41364696|NCT01273207|DRUG|Cyclosporine Inhalation Solution (CIS)|CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
40843600|NCT01812512|BEHAVIORAL|Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF|The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
40843601|NCT06160830|DIETARY_SUPPLEMENT|synbiotic|Two capsules of synbiotic per day, each containing 500 mg of synbiotic
40843602|NCT06160830|OTHER|placebo|Two capsules of placebo containing maltodextrin per day
41026963|NCT04040803|DEVICE|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS) are two (CE marked medical devices) new, non-invasive (over the scalp) brain stimulation (NIBS) techniques. Both tACS and tRNS deliver a weak current continuously across the brain using pads placed over the scalp, which has been shown safe and well-tolerated by healthy adults and patients. These two techniques are able to softly alter physiological function within the brain. tACS can influence the brainwaves which have been demonstrated to play important roles in movement, sensation, and thinking functions. tACS and tRNS have been investigated for several years and have been shown to be safe, well tolerated and produce beneficial results in hand movement, hearing, and working memory.
40843603|NCT05518708|DRUG|BI 3032950|BI 3032950
40843604|NCT05518708|DRUG|Placebo|Placebo
40843605|NCT05455502|DRUG|VX-548|Tablet for oral administration.
41026964|NCT02677805|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
41026965|NCT02677805|DRUG|Placebo|injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
41161146|NCT01650727|DRUG|Dinaciclib|Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m\^2 up to a maximum dose of 14 mg/m\^2.
41161147|NCT01650727|BIOLOGICAL|Rituximab|Rituximab 375 mg/m\^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
41161148|NCT04759118|BEHAVIORAL|modified childbirth education program|The participants in the intervention group are pregnant women and their husbands. The instructors employed teaching methods such as a group discussion, watching videos, and brainstorming, as well as questions and answer periods, demonstrations, childbirth simulation, and practice. The primary investigator (PI) will teach particular sessions, including maternal-fetal attachment skills, parenting skills, comfort measures, childbirth positions, as well as knowledge about anatomy and physiology during pregnancy and birth Classes consisted of 120-minute sessions held once a week for four weeks.
41364697|NCT05659342|OTHER|ELDOA Technique|"the patients treated with ELDOA technique, followed for 3 alternative days for 4 weeks.~the ELDOA techniques for level L4/L5 and L5/S1 were applied. the ELDOA positions hold for one minute, 3 alternative days for 4 weeks under supervision.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
41364698|NCT05659342|OTHER|Mechanical Lumbar Traction|"Mechanical Traction Technique: traction unit, 50% of body weight was applied with the patients lying in supine position, with the hip and knee at 90 degree flexion, and legs were supported. Traction were applied for 3 alternative days for 4 weeks.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
41364699|NCT04576962|OTHER|Immunization Information System Review|Extraction of county- and state-level data on HPV vaccine completion from Indiana's Immunization Information System
40843606|NCT05764174|BEHAVIORAL|Factual messages|Messages with descriptive data on COVID-19 vaccines
40843607|NCT05764174|BEHAVIORAL|Narrative message|Messages with emotional descriptions on COVID-19 vaccines
40843608|NCT05764174|BEHAVIORAL|Mixed message|Messages with both descriptive data and emotional descriptions on COVID-19 vaccines
40843609|NCT00548236|BEHAVIORAL|Telephone-Based exercise intervention|Exercise counselling offered via telephone calls
40843610|NCT05879068|DRUG|PM8002|IV infusion
40843611|NCT05879068|DRUG|Paclitaxel|IV infusion
40843612|NCT06004570|DIETARY_SUPPLEMENT|Complex product|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica, rutin, vitamin B6, vitamin B12, folic acid Single oral dose - 2 capsules
40843613|NCT06004570|DIETARY_SUPPLEMENT|Polyphenol-rich extracts|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica Single oral dose - 2 capsules
41026966|NCT02677805|DRUG|Botulinum Toxin A - Open Label|Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
41026967|NCT04755595|DRUG|Botox Cosmetic Injectable Product|Acetylcholine release inhibitor and a neuromuscular blocking agent
41026968|NCT04755595|DEVICE|Juvéderm Voluma XC|Gel implants consisting of cross-linked hyaluronic acid
41026969|NCT04755595|DEVICE|Juvéderm Volbella XC|Gel implants consisting of cross-linked hyaluronic acid
41026970|NCT05036083|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
41026971|NCT05036083|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
41026972|NCT05036083|OTHER|Electronic Health Record Review|Medical records reviewed
40843614|NCT06004570|OTHER|Placebo|Single oral dose - 2 capsules
40843615|NCT02819401|OTHER|pediatric formula|high-fiber enteral formula
40843616|NCT02461082|DEVICE|Expiratory muscle strength training (EMST)|The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).
40843617|NCT02461082|OTHER|Transcranial magnetic stimulation (TMS)|A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
40843618|NCT01587235|DRUG|Ezetimibe/simvastatin|Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
40843619|NCT01587235|DRUG|Other Statin|Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
41364700|NCT04681469|DRUG|Niraparib|"For all patient's population:~* Niraparib 200 mg/day: day -49 to day -21;~* Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~* Niraparib 200 mg/day: day -21 to day -7~* Dostarlimab 500 mg iv: day -7~* Radiological assessment (day -1, ± 3 days),~* Surgery (original margin) at day 0 (±3 days)~* Standard postoperative (chemo)radiotherapy according to pathologic report;~* Maintenance Niraparib, 200 mg/day for 6 months~* Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
41364701|NCT05025306|DRUG|ziziphus honey|ziziphus honey obtained form ziziphus spina-christi trees also called sidr tree
41364702|NCT01809717|OTHER|Weight Lifting Exercises|
41364703|NCT04667585|RADIATION|De-escalated radiation dose|Reduced dose of radiation applied to remaining radiation therapy when favorable interim PET-CT signature is produced
41364704|NCT04667585|RADIATION|Standard radiation dose|Standard dose of radiation applied to remaining radiation therapy when favorable PET-CT signature is not produced
41364705|NCT04667585|OTHER|18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)|The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
41364706|NCT00902122|DRUG|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
41364707|NCT00902122|PROCEDURE|surgery|removal of thyroid tumor
41364708|NCT00902122|DRUG|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
41500556|NCT03298217|DEVICE|Measurement of the peak tidal inspiratory flow (PTIF)|"In patients with bronchiolitis sverity mWCAS / 3-5 :~Nasopharyngeal aspiration and comfortable placement of the infant upon admission; Clinical evaluation: respiratory rate, respiratory distress scores rating (Silverman and m-WCAS); If the patient is eligible: information and collection of parental consent; If signed parental consent obtained: progressive (on at least 10 min) withdrawal of HFNC support and maintenance if necessary of conventional oxygen therapy (maximum 1 L/min); Application of the spirometer for the recording of 20 consecutive spontaneous respiratory cycles for PTIF measurements; Respiratory support with HFNC; flow adapted to the need of the patients (equal to the measured PTIF)."
41026973|NCT05036083|DRUG|Iodinated Contrast Agent|Given IV
41500557|NCT05336383|DRUG|Radiation Therapy|Given by Infusion
41500558|NCT06626399|DIAGNOSTIC_TEST|Diagnosis of SSI|Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.
41500559|NCT02520297|DRUG|TRV130|Drug
40843620|NCT04204356|BEHAVIORAL|Language treatment for improving discourse production|All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.
40843621|NCT04204356|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. The use of tDCS as an adjunct to speech and language therapy has been found to improve aphasia treatment effects in post stroke patient populations.
41026974|NCT00910481|DEVICE|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
41026975|NCT04943289|BIOLOGICAL|DUOC-01|DUOC-01 is a population of cells expanded from donor human umbilical cord blood mononuclear cells. DUOC-01 cells are derived from CB CD14+ monocytes. DUOC-01 will be administered along with hydrocortisone via intrathecal injection.
41364709|NCT00902122|RADIATION|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
41364710|NCT02569398|DRUG|Atabecestat, 5 mg|One atabecestat, 5 mg tablet orally once daily up to 54 months.
41364711|NCT02569398|DRUG|Atabecestat, 25 mg|One atabecestat, 25 mg tablet orally once daily up to 54 months.
41364712|NCT02569398|DRUG|Placebo|One matching placebo tablet orally once daily up to 54 months.
41364713|NCT02386605|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
41364714|NCT02386605|BEHAVIORAL|Relaxation Skills|Relaxation and mindfulness skills training group for comparison condition for negative symptoms of schizophrenia
41364715|NCT04722731|BEHAVIORAL|Confident Parents - Brave Children (CPBT)|"Session 1: Psychoeducation.~Session 2: How to decrease criticism and rejection. Skills that provide a warm parenting style and acceptance of the child: validation and child directed play/activities.~Session 3: Strategies to increase the autonomy of the child. The parents will learn how to use a stepladder approach to decrease overprotective behaviours.~Session 4: How to decrease modelling of anxious behaviours and how to be a brave role model.~Session 5: How to recognise and respond when your child is anxious. How to help your child approach new or scary things by using a stepladder approach.~Session 6: Review of the principles and skills learned during the program. The group members will make a plan for how to continue the work on their own."
41364716|NCT04722731|BEHAVIORAL|"Self-help book What all parents ought to know"|Participants in the control group will receive a self-help parenting book containing general research-based parenting strategies. They will be instructed to read the book within the 10 weeks from baseline to post.
41364717|NCT00121251|DRUG|Capecitabine|Given PO
41364718|NCT00121251|DRUG|Gemcitabine Hydrochloride|Given IV
41364719|NCT00121251|DRUG|Sorafenib Tosylate|Given PO
41364720|NCT05281146|DIETARY_SUPPLEMENT|Chickpeas and crushed peanuts fortified biscuit|This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months. The chickpeas and crushed peanuts fortified biscuit consisted of wheat flour (extract 72%), Chickpea flour, crushed peanuts, wheat germ, Skimmed milk, corn oil, egg, sugar, Cinnamon, baking powder, salt, and vanilla.
41364721|NCT05281146|OTHER|Cognitive stimulation for the mothers|"I. Sessions for mothers~* Informing mothers about the most common causes of poor school achievement~* Clarification of mother's and family roles in improving student's cognitive abilities~* Defining cognitive functions needed for learning and school achievement~  o Attention, perceptive reasoning, memory, problem solving, proper use of language~* Identifying sensory functions necessary for the growth of cognitive functions~* Explaining factors that assist in academic excellence"
41364722|NCT05281146|OTHER|Cognitive stimulation for students|"* Activities to improve focus and visual attention~* Activities to improve visual memory~* Activities to improve vigilance and auditory attention~* Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~* Training on skills of problem-solving"
41364723|NCT00433368|DRUG|L-Ornithine L-Aspartate|
41364724|NCT02089165|DIETARY_SUPPLEMENT|Krill oil|Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
41364725|NCT02089165|DIETARY_SUPPLEMENT|Krill meal|Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
41364726|NCT02089165|DIETARY_SUPPLEMENT|Fish oil|Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
41364727|NCT04566016|PROCEDURE|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery will be randomly allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1) or treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
41364728|NCT04755062|BEHAVIORAL|Micronutrient-dense plant-rich Intervention|"The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes."
41364729|NCT05199389|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
41364730|NCT03802500|DIAGNOSTIC_TEST|Nerve conduction study|"Physical examination of muscle strength is conducted using the Medical Research Council (MRC) scale in 6 muscles bilaterally.~Patients with an MRC score of less than 48 of 60 are diagnosed with critical illness polyneuromyopathy (CIPNM).~The evaluation is completed by a routine neurological examination. In patients meeting the inclusion criteria, the screening Peroneal nerve test (PENT test) is performed on the day of study enrollment and subsequently in 1 week intervals until pathologic findings are detected or patient is discharged from the ICU.~PENT measures the peroneal nerve Compound muscle action potential (CMAP) amplitude in one leg. If the PENT is normal, the contra-lateral peroneal nerve is measured. An abnormal condition is identified if the peroneal nerve CMAP amplitude is reduced below the normal limits of the participating centre in at least one leg. In Lausanne, the abnormal response is \< 2,5 mV."
41364731|NCT04559802|PROCEDURE|Transmucosal Technique|Dental implant will be placed in transmucosal manner (Healing abutment is exposed in the mouth).
41161149|NCT05721209|DEVICE|C-Mill with AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training. The AR/VR feedback will include computer generated obstacles and objects projected as images on the treadmill. Participants will be asked to use these projections as stepping cues and step on some images of objects while avoiding stepping on the images of obstacles.
41161150|NCT05721209|DEVICE|C-Mill without AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training.
41026976|NCT04791358|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
41364732|NCT04559802|PROCEDURE|Submerged Technique|Dental implant will be installed in submerged manner (implant is completed covered by soft tissue).
41364733|NCT05747170|OTHER|Olfactory sstimulation|"The odors being tested (natural odor, neutral odor, chemical odor) are part of the 40 fragrances made by International Flavors and Fragrances (IFF) and each is contained in an approximately 15-mL glass bottle. The selected odors will be administered using a small paper strip (15 cm length and 0.7 cm width) that will be soaked in the selected odor and placed under the subject's nose at a minimum distance to prevent direct contact of the strip with the skin; the strip will be moved alternately from one nostril to the other.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be randomized according to a computer-generated sequence."
41364734|NCT00357643|DRUG|Calcium 500 mg/day and vitamin D 700 IU/day|
41364735|NCT06335225|BEHAVIORAL|Precise nutritional intervention|Diabetic precision nutrition prescription based on the results of nutrigenomics.
41364736|NCT06335225|BEHAVIORAL|Conventional nutritional intervention|Conventional diabetes nutrition prescription.
41364737|NCT04032002|OTHER|Explorations|On Day 1 vascular fonctions explorations performed
41364738|NCT04032002|OTHER|Blood samples|On Day 1 35ml taken
41364739|NCT05980494|DRUG|normal Saline|normal saline cyrstalloids infusion with rate of 4ml/kg /h for 3 hours
41026977|NCT04289649|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
41026978|NCT04289649|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
41026979|NCT04289649|DRUG|K-924 LD Placebo|Pitavastain 2 mg
41026980|NCT04289649|DRUG|K-924 HD Placebo|Pitavastain 4 mg
41161151|NCT05721209|DEVICE|Zeno 3-Layer Walkway|Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.
41161152|NCT05721209|DEVICE|Hunova|Used to conduct fall-risk assessment.
41161153|NCT00333502|DRUG|Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer|Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
41161154|NCT00003478|PROCEDURE|conventional surgery|
41161155|NCT00003478|RADIATION|iodine I 131 monoclonal antibody 81C6|
41161156|NCT00003478|RADIATION|radiation therapy|
41026981|NCT04497701|DRUG|PEG-rhG-CSF group|Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.
41026982|NCT04497701|DRUG|rhG-CSF group|Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
41026983|NCT02507089|BEHAVIORAL|Tailored sleep health education materials.|Tailored sleep health materials.
41026984|NCT02507089|BEHAVIORAL|Generic sleep health education materials.|
41026985|NCT02523833|DRUG|Salbutamol|Salbutamol after spirometry, plethysmography and forced oscillation technique.
41026986|NCT05146791|PROCEDURE|Inlay Bristow|A modified Bristow procedure
41026987|NCT05146791|PROCEDURE|Bristow|Traditional Bristow procedure
41161157|NCT05798247|OTHER|Characteristics description|Caregivers who follow the patients of the study group will be contacted to collect these patients clinical and epidemiological characteristics
41161158|NCT06365125|BEHAVIORAL|eCHECKUP TO GO|Single session, web-based intervention for college students aimed at increasing awareness of consequences related to heavy alcohol use and increase motivation to modify one's alcohol use.
41026988|NCT04836260|DRUG|SARS-CoV-2 convalescent plasma|Included patients will receive at least one unit of convalescent plasma with NTAB titer ≥1:160 at maximum 3-7 days after diagnosis by RT-PCR or symptom onset. A second unit of plasma from a different donor can be proposed 24h after the first unit if immunocompromised and/or the patient received less than 3-5ml/kg of plasma volume. Additional units can be exceptionnally infused, at the investigator discretion.
41026989|NCT06155981|OTHER|Coke Zero|Coca-Cola Zero Sugar drink will be given.
41500560|NCT06600126|BEHAVIORAL|Coping Skills Training|The Coping Skills Training arm will consist of 12 weekly 30-minute sessions via videoconferencing or phone. A trained research staff member will deliver sessions that focus on building coping skills for patients with COPD, such as progressive relaxation training, pleasant activity scheduling, and building communication skills. Caregivers will also participate, learning how to support the patient in using these skills. Participants will complete assignments between sessions to reinforce their learning. Additionally, participants will receive a Coping Skills Training workbook.
40843622|NCT06005519|OTHER|low AGE diet education|Participants were divided into ten-person groups. Each group was individually invited for a face-to-face meeting where they were provided with a 50-minute low-AGE diet education prepared in accordance with the recommendations of the American Diabetes Association and the Turkish Society of Endocrinology and Metabolism. During the first 20 minutes of the education, a PowerPoint presentation highlighted the importance of choosing plant-based, low-AGE foods and emphasized cooking methods such as boiling, steaming, and preparing meals with added liquids. Participants were advised against frying, roasting, and grilling. Additionally, information was provided on marinade techniques and the use of spices or ingredients such as lemon or vinegar to lower pH in meals. Following the education, participants were given a dietary diary to record their food intake and were asked to self-assess their diet adherence on a scale of 1 to 10 on a weekly basis.
40843623|NCT02484222|DRUG|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
40843624|NCT01270256|DRUG|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
40843625|NCT01270256|DRUG|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
40843626|NCT02607228|DRUG|Alobresib|Tablet administered orally once daily.
40843627|NCT02607228|DRUG|Enzalutamide|Capsules administered orally once daily.
40843628|NCT01412385|BIOLOGICAL|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
40843629|NCT01412385|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
40843630|NCT01412385|BIOLOGICAL|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
40843631|NCT05556538|PROCEDURE|Transforaminal Epidural Steroid Injection|Patients are placed in the prone position, with a pillow under their abdomen (to reduce lumbar lordosis) and taken to the operating table. The procedure area is cleaned 3 times with povidone-iodine antiseptic and covered with a sterile cover. In order to view the foramen to be processed, the fluoroscopy arm is evaluated at AP-oblique / cranial or caudal angles to obtain an optimal image. Local anesthetic (3 cc 2% prilocaine) is injected into the skin and subcutaneous tissue. The spinal Quincke 21-gauge 90 mm needle is advanced by targeting the relevant foramen under the guidance of fluoroscopy image. Needle position is confirmed by taking a lateral view. Needle aspiration is checked for blood. 1-2 ml of contrast material is injected to confirm that there is no vascular distribution and that it is in the epidural space. When distribution without vascular invasion is observed, an injection of a mixture of 10 mg dexamethasone, 1 cc saline and 1 cc (0.5%) bupivacaine is performed.
40843632|NCT01371045|OTHER|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
40843633|NCT05241145|DRUG|IVMED-80|Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
40843634|NCT05241145|OTHER|Placebo|This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
41364740|NCT05980494|DEVICE|lung ultrasound|Lung ultrasound by Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID:1385 will scan For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines for a total of 28 sectors will be identified
40843635|NCT01716455|DRUG|SSP-004184|
40843636|NCT03342625|DEVICE|High Instensity Focused Ultrasound|High Intensity Focused Ultrasound guided by MRI
40843637|NCT00154128|DEVICE|occlusal appliance|
40843638|NCT06543329|PROCEDURE|polyglactin 910|75 PARTICIPANT, Vicryl suture was used in subcuticular suture
40843639|NCT06543329|PROCEDURE|poliglecaprone 25|75 PARTICIPANT, monocryl suture was used in subcuticular suture
41026990|NCT06155981|OTHER|Coke|Coca-Cola drink will be given.
41364741|NCT05980494|DEVICE|inferior vena cava measurements|The inferior vena cava was explored in the subxiphoid window in its sagittal view-just below the junction between the inferior vena cava and suprahepatic veins which lie approximately 0.5 to 3 cm from the right atrium, following the American Society of Echocardiography guidelines.; The (IVC distensibility index (dIVC) was calculated as (maximum diameter - minimum diameter)/minimum diameter.
41026991|NCT06054646|BIOLOGICAL|Amnion collagen|A collagen extract sourced from the human amniotic membrane
41026992|NCT06054646|BIOLOGICAL|Platelet-rich plasma|Autologous preparation of PRP
41364742|NCT05980494|DIAGNOSTIC_TEST|passive leg raising test (PLRT)|"Regardless of CVP (i.e., during blind PLR), noninvasiveΔPLR systolic arterial pressure (SAP) more than 17% reliably identify fluid responders. During CVP-guided PLR, in case of sufficient change in CVP (at least of 2 mmHg), noninvasiveΔPLR SAP perform better (cutoff of 9%). These findings, in sedated patients who had already undergone volume expansion and/or catecholamines, have to be verified during the early phase of circulatory failure (before an arterial line)."
41026993|NCT02799433|BEHAVIORAL|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
41026994|NCT02799433|BEHAVIORAL|Usual services|Control condition
41026995|NCT04450823|OTHER|no intervention|no intervention study, survey amongst health workers
41026996|NCT01523691|BEHAVIORAL|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
41026997|NCT01523691|BEHAVIORAL|Control sleep|Regular amounts of sleep across study protocol
41026998|NCT01118390|DEVICE|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
41026999|NCT01118390|OTHER|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
41027000|NCT05203029|OTHER|Online exercise|Patients in each group will be added to the specific group on Whatsapp, and the schedule and information about the exercise will be explained there. Furthermore, patients will be joined to particular pages on Instagram, and exercises will be performed through Live on that pages. All the patients will exercise for 12 weeks, two or three times every week.
41027001|NCT04915469|OTHER|Standardized enhanced adherence counseling package|A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
41027002|NCT06534463|OTHER|All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.|The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
41027003|NCT06439758|DRUG|Metformin|Metformin 1000 mg/day for 6 months
41027004|NCT06439758|BEHAVIORAL|Lifestyle|Dietary lifestyle modifications
41027005|NCT05219201|DEVICE|partial-body cryotherapy chamber session|"The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions)."
41027006|NCT01513850|DRUG|Hepabulin IV|I.V.
41161159|NCT06365125|BEHAVIORAL|Text messaging boosters|Text messages sent a few times per week following completion of eCHECKUP TO GO to reinforce concepts and assist with goal setting and goal attainment in everyday life
41364743|NCT05980494|DEVICE|pulse pressure variation|patients will be temporarily sedated and paralyzed and on fully controlled mechanical ventilation. No spontaneous breathing effort will be detected on the mechanical ventilator waveform monitor ensuring that the respiratory changes in arterial pressure reflected only the effects of positive pressure ventilation. Modes of ventilation is selected to volume or pressure controlled ventilation, depending on the decision of the primary physicians. A tidal volume will be not less than 8 ml/ kg (predicted body weight). The preset respiratory rate will be at 14 breath/min. Positive end expiratory pressure (PEEP) will be between 8 and 10 cmH2O. The plateau pressure was kept at below 30 cmH2O. In all patients, radial artery cannulation will be done for invasive blood pressure monitoring (using a 20 G cannula), PPV is calculated directly on Nihon Kohden monitores at base line.
41364744|NCT02077868|OTHER|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
41364745|NCT02077868|DRUG|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
41364746|NCT03911401|DRUG|0.3% OPA-15406|Twice daily
41364747|NCT03911401|DRUG|1% OPA-15406|Twice daily
41500561|NCT06600126|BEHAVIORAL|COPD Education|The COPD Education arm will consist of 12 weekly 10-minute sessions via videoconferencing or phone. A trained research staff member will provide scripted general support and encouragement without using specific psychoeducational techniques. Caregivers will also participate. Additionally, participants will receive a COPD Education workbook with material from The COPD Foundation, which is also available on the Foundation's website. This program augments usual care, providing an attention control for comparison.
41500562|NCT03330054|DEVICE|fundoscope|Fundoscope for eye examination
40843640|NCT06543329|PROCEDURE|polypropylene|75 PARTICIPANT, Prolene suture was used in subcuticular suture
41027007|NCT02073968|DRUG|Carboplatin|Given IV
41364748|NCT03911401|DRUG|Placebos|Twice daily
41364749|NCT00920166|DIETARY_SUPPLEMENT|Pétunia 1|Infant formula used for non breastfed children
41364750|NCT00920166|DIETARY_SUPPLEMENT|Regular formula|Infant formula used for non breastfed children
41027008|NCT02073968|PROCEDURE|Computed Tomography|Undergo PET-adjusted IMRT
41027009|NCT02073968|RADIATION|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
41364751|NCT02861521|DEVICE|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
41364752|NCT02861521|DEVICE|Sham|Sham shoe modification
41364753|NCT01388322|DRUG|Enoxaparin|40 mg (4000 IU) women \<80 kg at the time of randomization or 60 mg (6000 IU) women\> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
40843641|NCT06543329|PROCEDURE|polyester|75 PARTICIPANT, Polyester suture was used in subcuticular suture
40843642|NCT04607369|DEVICE|EyeCTester|Smartphone app that allows vision testing
41027010|NCT02073968|DRUG|Paclitaxel|Given IV
41027011|NCT02073968|PROCEDURE|Positron Emission Tomography|Undergo PET-adjusted IMRT
41027012|NCT02073968|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
41027013|NCT00147966|DRUG|rituximab|treatment with rituximab
41027014|NCT00450424|OTHER|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
41027015|NCT00450424|OTHER|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
41027016|NCT05018845|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41027017|NCT00326508|DRUG|Daclizumab|
41027018|NCT05856292|OTHER|Teach Back|Standard cancer pain educational intervention enhanced with teach-back method
41027019|NCT05856292|OTHER|Placebo|Standard cancer pain educational intervention without enhancement
41027020|NCT02081300|DRUG|Oral testosterone undecanoate, LPCN 1021|
41027021|NCT02081300|DRUG|Topical testosterone gel 1.62 %|
40843643|NCT03517462|DRUG|Ivermectin 3Mg Tab|ivermectin tablet
41500563|NCT01104779|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
40843644|NCT06023615|OTHER|mHealth app/dashboard|In the interventional group, the subject would receive the standard care that is provided to all post-transplant kidney recipients plus an additional remote monitoring system and follow-up by utilizing an app known as the mHealth app/dashboard. This app is integrated with home-based monitoring of blood pressures, glucoses, and pharmacist-led scheduled televisits.
40843645|NCT01005927|DIETARY_SUPPLEMENT|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
40843646|NCT00115661|DRUG|Rosiglitazone|
40843647|NCT00548899|DRUG|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
40843648|NCT06371976|OTHER|Blood sampling|Blood samples of 5 mL are taken at 4 stages of the study. Samples are taken from an arterial catheter inserted as part of the treatment, for a total volume of 20 mL maximum for the study.
40843649|NCT06371976|OTHER|Vital status|Patients will be followed until their discharge from intensive care, or at most until D28, and their vital status will be collected at the end of their participation in the study.
40843650|NCT03869476|DIAGNOSTIC_TEST|Non-invasive diagnosis score|"* spleen fibrosis by elastography~* plasma cytokines levels~* mutationnal landscape by NGS~* CD34 circulating cells"
41364754|NCT04400773|OTHER|Plyometric exercises|Types of exercises include resistance tubing 90-90 external rotation, plyometric push-up, reverse overhead throws, rotational wall throw, overhead medicine ball, chest passes.
41364755|NCT04400773|OTHER|Strength training exercises|Types of exercise include push-ups, resisted external rotation, overhead presses, biceps curl, bench presses and triceps kick backs.
41364756|NCT04409262|DRUG|Remdesivir|Participants will receive intravenous (IV) RDV
41364757|NCT04409262|DRUG|Tocilizumab|Participants will receive IV TCZ
41364758|NCT04409262|DRUG|Placebo|Participants will receive IV placebo matched to TCZ
41364759|NCT05234762|DRUG|ES-481|Dose escalation during two Treatment Periods
41364760|NCT05234762|OTHER|Placebo|Placebo dosed at same dosing as ES-481
41364761|NCT04468100|BIOLOGICAL|Tigerase®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
41364762|NCT04468100|BIOLOGICAL|Pulmozyme®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
41364763|NCT03741257|DRUG|Hypertonic saline|resuscitation fluid
41364764|NCT05899946|OTHER|A community-based network training program|A 3-phase program including establishing a community-based network, video competition, and Video promotions will be conducted.
41500564|NCT01104779|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
41500565|NCT03900286|DIETARY_SUPPLEMENT|Total Dietary Replacement|Total Dietary Replacement
41500566|NCT05769257|DRUG|IS-001|Intravenous injection of IS-001 investigational drug
41500567|NCT01236911|OTHER|Calcium Measurement|after moderate-severe TBI (less as 24 hrs)
40843651|NCT00544284|DRUG|bortezomib|
41364765|NCT02626962|DRUG|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
41500568|NCT06019598|OTHER|Licorice|Ecologic sweet licorice pastilles made from Glycyrrhiza glabra grown in Calabria, Italy, with a GA content of 29.9 ±2.0 mg/g.
41500569|NCT06632847|OTHER|IMT based Resistance training|IMT with device group is trained twice daily, with the morning session and afternoon session. The intensity will increase progressively in this group, starting at 60% Maximal Inspiratory Pressure (MIP) and reaching 75% by the end of study. POSITION: Patient will be in sitting position. FREQUENCY: 4 TO 5 times per week. INTENSITY: 60 to 75% of MIP (gradually increment the load by 10%every 2 weeks to reach 75 to 80 %MIP). Time: 15 to 20 minutes.
40843652|NCT00544284|DRUG|temozolomide|
40843653|NCT00544284|OTHER|pharmacological study|
40843654|NCT03852095|OTHER|minor trauma|following the management of the patient's fracture in the emergency department, the patients / parents are recalled 2 months (J60) after the visit to the emergency room, and are interviewed by following the pre-established interrogation form, which checks the good agreement of the patient. treatment performed with the given sheet and recommendations, and assesses the satisfaction.
40843655|NCT00652080|DRUG|API 31510|Topical Cream; 3% active; AM \& PM application
40843656|NCT04456374|OTHER|Performance testing|Soccer-specific performance will be evaluated by measuring flexibility, jumping ability, maximum speed, repeated spring ability, agility and endurance.
40843657|NCT06135610|DIAGNOSTIC_TEST|Postive SAR-CoV-2 PCR nasopharyngeal swab|Diagnosed Covid-19 confirmed by a positive of SAR-CoV-2 PCR nasopharyngeal swab.
40843658|NCT05418491|OTHER|No intervention is used in the current study. Interventions were given in the original A.R.T. study|The current study is a post-intervention study; interventions were given in the original A.R.T. study
40843659|NCT02785614|DRUG|trazodone hydrochloride prolonged-release tablet|150 mg, oral administration, 1 per day
40843660|NCT02785614|DRUG|trazodone hydrochloride tablet|50mg, oral administration 3 times per day
41364766|NCT02626962|DRUG|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
41364767|NCT04704908|DRUG|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
41027022|NCT02985658|DRUG|Veliparib|"Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.~At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.~The patient will receive therapy as long as there is therapeutic benefit"
41027023|NCT02985658|DRUG|Cisplatin|Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
40843661|NCT05900973|DRUG|Darolutamide Oral Tablet [Nubeqa]|Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer
40843662|NCT00346229|BIOLOGICAL|filgrastim|
40843663|NCT00346229|BIOLOGICAL|pegfilgrastim|
40843664|NCT00346229|DRUG|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
40843665|NCT00346229|PROCEDURE|hyperthermia treatment|
40843666|NCT03806608|PROCEDURE|Crestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
40843667|NCT03806608|PROCEDURE|Subcrestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
41027024|NCT02985658|DRUG|Vinorelbine|Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
41027025|NCT06193993|DRUG|Abiraterone Acetate|Upon successful registration, patients would be initiated on 500 mg once daily (two 250 mg tablets), plus prednisolone 5 mg twice daily orally for mCRPC and 5mg once daily orally for mHSPC.
41027026|NCT00701389|DRUG|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
41027027|NCT00701389|DRUG|sumatriptan|single oral dose of 100 mg sumatriptan
41027028|NCT00701389|DRUG|sumatriptan placebo|single oral dose
40843668|NCT04785599|BEHAVIORAL|Exercices|An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.
40843669|NCT04785599|BEHAVIORAL|Informative talk|An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center
40843670|NCT04785599|DEVICE|Compression garment|"Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity."
41364768|NCT06186154|DIETARY_SUPPLEMENT|Folinic acid (oral); Cyanocobalamin sublingual|"* Vitamin B12 (also known as Cyanocobalamin) daily sublingual supplementation of 1000 mcg/day and folinic acid orally 1mg/day~* Laboratory: Complete blood count, electrolytes, reticulocytes, creatinine, urea, alkaline phosphatase (ALP), alanine transaminase, ferritin, total homocysteine, lactate and hemoglobin A1c. Routine blood will be collected as regular standard of care with each visit. MMA will also be assessed. Peripheral serum values (CBC, B12) will serve as a representation of central micronutrient availability~* Clinical Evaluation: the Newcastle mitochondrial disease adult scale (NMDAS)"
41364769|NCT06046937|DRUG|Monolaurin|applied thinly twice a day
41364770|NCT06046937|DRUG|Mupirocin ointment|applied thinly twice a day
40843671|NCT04519853|BEHAVIORAL|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks
40843672|NCT03801434|DRUG|Ruxolitinib|Given PO
40843673|NCT01354366|OTHER|Infant formula|
40843674|NCT05133700|OTHER|Interview or focus group discussion|There is no intervention. This is a qualitative piece of work only
40843675|NCT05133700|OTHER|Review of submitted medicines audit tools|There is no intervention. This is a qualitative piece of work only
40843676|NCT02686502|BEHAVIORAL|Lifestyle|As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
41364771|NCT04916132|PROCEDURE|Kidney Biopsy|Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis
40843677|NCT04803955|DRUG|16mg，KB|16mg,Q8h±3min,Day1-Day7
40843678|NCT04803955|DRUG|Placebos|16mg,Q8h±3min,Day1-Day7
40843679|NCT02562807|DRUG|TAS-303 18mg single-dose|
40843680|NCT02562807|DRUG|Placebo 18mg single-dose|
41364772|NCT04715867|DRUG|Rabix-VC|Rabix-VC will be locally manufactured by Incepta Vaccine Ltd
41364773|NCT05579509|DRUG|Midazolam and Fentanyl|Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
41364774|NCT05579509|BEHAVIORAL|Educational Reassurance|Patients in the nonpharmacologic group will receive intraprocedural education and reassurance without pharmacologic sedation. They will have the option to receive more pharmacologic sedation at any point during the nerve block (cross-over to titrated sedation group).
40843681|NCT02562807|DRUG|TAS-303 9mg single-dose|
40843682|NCT02562807|DRUG|Placebo 9mg single-dose|
40843683|NCT01133119|DRUG|Standard of Care|Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
41027029|NCT00701389|DRUG|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
41027030|NCT02417246|DRUG|brand name metoprolol ER|This medication will be taken for 7 to 28 days
40843684|NCT01133119|DRUG|Standard of Care plus bupivacaine|"Subcutaneous dose of 0.25% bupivacaine infiltrated around the entry site of the femoral artery/vein sheath, just prior to sheath removal.~Participants will receive a dose of up to 0.8mL/kg (up to 2.0 mg/kg) of 0.25% bupivacaine, with the final amount at the discretion of the physician."
40843685|NCT00255775|DIETARY_SUPPLEMENT|broccoli sprout extract|
40843686|NCT00255775|PROCEDURE|complementary or alternative medicine procedure|
40843687|NCT02854254|DEVICE|peripherally inserted central catheter|peripherally inserted central catheter
41364775|NCT00958399|DIETARY_SUPPLEMENT|Placebo|Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
40843688|NCT02854254|DEVICE|peripherally venous access|standard over-the-needle intravenous catheter
40843689|NCT01773304|OTHER|Dietary meal intervention|Test meals with different protein types (dairy versus meat)
40843690|NCT05859997|BIOLOGICAL|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
40843691|NCT05940818|BEHAVIORAL|the intensive oral care|the intensive oral care
41027031|NCT02417246|DRUG|Generic A|This medication will be taken for 7 days
40843692|NCT05697796|PROCEDURE|Two different surgical methods|SSLF：sacrospinal ligament fixation EHUS：Extraperitoneal high sacral ligament suspension
40843693|NCT04933461|DEVICE|Safety lancet|There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
40843694|NCT02210416|PROCEDURE|inguinal hernia surgery|
40843695|NCT05733078|DRUG|Vitamin C|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
40843696|NCT05733078|DRUG|Oral Rehydration Salt Formulations|The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
40843697|NCT02660892|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
40843698|NCT03882645|OTHER|CHH-diet|"This study took the DASH Diet as the basic model and developed the Chinese Heart Healthy Diet ( CHH-diet) according to the principles in the 2016 Dietary Guidelines for Chinese Residents. The nutrients targets in CHH-diet are set as following: fat % of total kcal: 25-27% (saturated: 6%; monounsaturated: 12%; polyunsaturated: 8%); carbohydrate % of total kcal: 55-60%; protein % of total kcal: 17-19%; dietary fiber: 30 g/day; sodium: 3000 mg/day; potassium: 3700 mg/day; magnesium: 500 mg/day; calcium: 1200 mg/day. The total energy will be set according to how much participants are eating in run-in period."
40843699|NCT03882645|OTHER|local usual diet|The nutrients targets and total energy in usual diet are set according to how much participants are eating in run-in period.
40843700|NCT05040360|DRUG|Capecitabine|Given PO
40843701|NCT05040360|DRUG|Temozolomide|Given PO
41027032|NCT02417246|DRUG|Generic B|This medication will be taken for 7 days
41161160|NCT06353919|OTHER|Yoga Nidra|"Recordings were created to allow participants access to a variety of Yoga Nidra practices. Participants will be instructed to complete a 30-minute Yoga Nidra 3-5 times per week, at any time of day or night (including before bed and/or during bouts of sleeplessness). This duration and frequency is informed by previous studies.~Related to intentionally decreasing BZRA use, the recording requests each practitioner to set a resolve/personal goal at the start of each practice, and they are asked to repeat it again at the end. In our study, participants will be asked to develop a short and simple resolve in their own words, related to reducing BZRA use, improving sleep and decreasing anxiety, and they will be asked to recite it at each practice."
41364776|NCT00958399|DIETARY_SUPPLEMENT|Resistant Starch|25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
41364777|NCT00958399|DIETARY_SUPPLEMENT|Resistant starch + soluble fiber|25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
41364778|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch|25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
40843702|NCT02911064|BEHAVIORAL|Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being. These questionnaires should take about 15 minutes total to complete.
40843703|NCT04985669|DRUG|Prucalopride 2mg|one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
40843704|NCT05521321|BEHAVIORAL|Stanford Cannabis Awareness and Prevention curriculum|Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session course administered in a school classroom setting.
40843705|NCT01729208|DEVICE|Dual Focus Soft Contact Lens|
40843706|NCT01729208|DEVICE|Single Vision Soft Contact Lens|
41027033|NCT00003801|PROCEDURE|management of therapy complications|
41027034|NCT00003801|PROCEDURE|quality-of-life assessment|
40843707|NCT03041363|DRUG|Triheptanoin|Triheptanoin will be administered for 7 days 4 times daily.
40843708|NCT04361305|DRUG|Dapoxetine|30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks
40843709|NCT04361305|DRUG|Tadalafil|5 mg tablets every day for 8 weeks
40843710|NCT04361305|DRUG|Tadalafil|5 mg tablets every day for 8 weeks
40843711|NCT05354193|OTHER|vasoplegic syndrome|"In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure \< 65 mmHg, cardiac index \< 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock"
40843712|NCT00480389|DRUG|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
40843713|NCT04693377|PROCEDURE|Cryosurgery|Undergo cryoablation
40843714|NCT04693377|OTHER|Quality-of-Life Assessment|Ancillary studies
40843715|NCT04693377|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
40843716|NCT03150732|DRUG|Systemic nalbuphine|Patients will receive systemic nalbuphine 10 mg
40843717|NCT03150732|DRUG|Local nalbuphine|Patients will receive local nalbuphine 10 mg
40843718|NCT00945230|PROCEDURE|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
40843719|NCT05435118|OTHER|EMONO + audiovisuals tool|EMONO + use of audiovisuals tool on smartphone or tablet
40843720|NCT06330610|OTHER|Intermittent enteral nutrition|Patients will receive intermittent enteral nutrition, defined as 3 60-minute administrations every 8 hours.
40843721|NCT02898298|BEHAVIORAL|Positive Emotion Regulation Training|Participants will receive a 3-session psycho-educative training on emotion regulation.
40843722|NCT02272218|PROCEDURE|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
40843723|NCT04186507|COMBINATION_PRODUCT|Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)|"To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat."
40843724|NCT03639142|OTHER|Prunus domestica|Patients will receive prunes at dose 3,5 g/kg/d (max.100mg/day) in three portions a day, for 4 weeks (amount of prescribed prunes will be calibrated with the weight that child ought to have on WHO growth charts at 50th percentile). Prunes should be introduced every day in three meals. Prunes can be chopped or grinded before eating them. They can be eaten alone or child may eat them as a part of bigger meal (which is preferred version). Prunes can be introduced with yogurt, cereals, nuts and seeds as a morning meal.
40843725|NCT03639142|DRUG|Polyethylene Glycol 4000|Patients will receive PEG at dose 0,5 g/kg/d once daily orally, for 4 weeks.
40843726|NCT01636128|DRUG|difluoromethylornithine|500 mg oral for 14 days, combined with sulindac for 15 days
40843727|NCT01636128|DRUG|Sulindac|150 mg oral for 15 days, combined with DFMO for 14 days
41364779|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch + soluble fiber|25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
41364780|NCT03860870|DRUG|Clenbuterol Oral Product|Subjects ingest 4x20 microgram clenbuterol tablets
40843728|NCT00908037|DRUG|eltrombopag|thrombopoietin receptor agonist
40843729|NCT00908037|DRUG|Placebo|placebo for comparison
40843730|NCT04088526|COMBINATION_PRODUCT|intervention group|Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.
40843731|NCT05675228|OTHER|data collection|Knowledge about genital herpes
40843732|NCT01113580|BIOLOGICAL|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
40843733|NCT02373514|DRUG|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
40843734|NCT02373514|DRUG|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
40843735|NCT05552066|OTHER|Standard follow up|Patients enrolled into front phase will be followed in a standard way without any additional procedure except satisfaction questionnaire
41364781|NCT03860870|DRUG|Placebo|Subjects ingest placebo tablets
41364782|NCT02089022|OTHER|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
41364783|NCT04839627|OTHER|serum progesterone measurement|progesterone levels measurement on the day of the embryo transfer on all AMP cycles
41364784|NCT00967889|GENETIC|gene expression analysis|
41364785|NCT00967889|GENETIC|protein analysis|
41364786|NCT00967889|OTHER|biologic sample preservation procedure|
41364787|NCT00967889|OTHER|laboratory biomarker analysis|
41364788|NCT03762187|BEHAVIORAL|Self-affirmation|Individuals select important values and then write about why that value is important to them.
40843736|NCT05552066|OTHER|short circuit|"Patients included in the post phase will have to complete the cem@santé application. If no contraindications are identified by the plateform with the remote PRO collection, patients will undergo chemotherapy directly the next day (without any medical validation)."
40843737|NCT04067661|BEHAVIORAL|CHIP|The couples-based HIV prevention intervention consists of four couples counseling sessions focused on relationship skills to decrease HIV risk behaviors.
40843738|NCT04067661|BEHAVIORAL|Control|Enhanced standard of care, which includes information and referrals on HIV risk and prevention.
40843739|NCT04545710|DRUG|Abemaciclib|Abemaciclib 150mg BID
40843740|NCT04545710|DRUG|Osimertinib|Osimertinib 80mg daily
40843741|NCT05977829|DIAGNOSTIC_TEST|Ultrasound|Transvaginal ultrasound to carry out uterine surveillance
40843742|NCT05977829|DIAGNOSTIC_TEST|Hysteroscopy|Outpatient hysteroscopy to carry out uterine surveillance
40843743|NCT00877370|DRUG|ertapenem|One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
40843744|NCT03586115|DEVICE|Critical flicker frequency assessment|All patients will undergo critical flicker frequency assessment to evaluate the presence of minimal hepatic encephalopaty. In addition, hepatic elastometry will be assessed to evaluate the presence of advanced liver fibrosis.
41161161|NCT06353919|OTHER|Sleep Hygiene, Anxiety, and Benzodiazepine Receptor Agonist Education|Participants will be instructed to access excerpts from standardized and trusted materials through our online platform for 30 minutes, 3-5 times per week.
41500570|NCT06632847|OTHER|Theraband Resistive training|IMT training is form of exercise designed to strengthen the muscle that are involve in inhalation, primarily the diaphragm and intercostal muscles. Thera-band resistive training perform twice daily, with morning and afternoon session. Training will be perform 3 times per week. POSITION: patient will be in standing position. INTENSITY: moderate intensity (black and green thera-band used to provide medium resistance). Time: 15 to 20 minutes
40843745|NCT05522595|DEVICE|S360|"In the first part of the intervention, after the CISS questionnaire completion by the patient, participant's eyes movements measurement will be performed using the reference procedure (standard of care).~A first diagnosis is established according to the interpretation of the results by a first evaluator.~In the second part of the intervention, the participant's eyes movements will be measured using the medical device S360.~A second diagnosis is established according to the interpretation of the software's displayed data by a second evaluator."
40843746|NCT02517372|DRUG|CRD007|
40843747|NCT03468894|BEHAVIORAL|Treadmill desk walking|See intervention arm description
40843748|NCT00480870|DRUG|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
40843749|NCT00480870|DRUG|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
41161162|NCT02671578|DRUG|Nitrous Oxide|The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
41161163|NCT01174485|PROCEDURE|exercise|combined resistance and aerobic training
41500571|NCT04666805|DRUG|Tamoxifen|20 mg/d, oral administration
41500572|NCT04666805|DRUG|Toremifene|60 mg/d, oral administration
41500573|NCT04666805|DRUG|Anastrozole|1 tablet (1 mg) per day, oral administration
40843750|NCT06519097|DRUG|Vitamin E Delta Tocotrienol|"Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration.~400 mg orally, twice daily"
40843751|NCT06519097|OTHER|Placebo|"Placebo contains no active ingredients.~465 mg pure olive oil orally, twice daily"
40843752|NCT03057470|DRUG|50% bolus insulin correction|Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
40843753|NCT03057470|DRUG|100% bolus insulin correction|Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
41027035|NCT02981394|PROCEDURE|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
41027036|NCT01547572|PROCEDURE|The study group will get a video and leaflet on enhanced recovery|The study group will get a video and leaflet
41161164|NCT00010270|BIOLOGICAL|LMB-9 immunotoxin|
41027037|NCT01547572|PROCEDURE|The control group will receive a leaflet only|The control group will receive a leaflet only
41364789|NCT03762187|BEHAVIORAL|Positive living counseling|Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
41364790|NCT04009122|DIETARY_SUPPLEMENT|IGEN0206|Group A
41364791|NCT04009122|OTHER|Placebo|Group B
41500574|NCT04666805|DRUG|Letrozole|Adjuvant therapy with letrozole for 5 years or until the disease relapses. Patients who have received tamoxifen adjuvant therapy for 5 years should continue to take Letrozole until the disease relapses. The recommended dose of Letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals. For patients with advanced breast cancer, treatment with Letrozole should continue until tumor progression is confirmed. Patients with liver and/or renal dysfunction (creatinine clearance rate ≥ 10 mL/min) do not need to adjust the dosage.
41500575|NCT04666805|DRUG|Exemestane|The recommended dose of Exemestane for adult and older patients with early and advanced breast cancer is one 25 mg tablet administered orally once a day after a meal. After 2-3 years of tamoxifen treatment, patients with early breast cancer should continue to use Tamoxifen in the case of no recurrence or contralateral breast cancer, until the completion of 5-year sequential adjuvant therapy with tamoxifen and exemestane. Patients with advanced breast cancer should continue to take Exemestane until the tumor progresses.
41500576|NCT00188110|PROCEDURE|Water-Enema Computed Tomography|
41500577|NCT00103714|DRUG|denufosol tetrasodium (INS37217)|
41364792|NCT06217627|BIOLOGICAL|secretome|The secretome is the secretions of MSCs or explants from umbilical cord tissues. It contains diverse trophic molecules including cytokines, chemokines, angiogenic factors, and growth factors.
41364793|NCT02705001|OTHER|all admissions except accident and emergency|No additional intervention, retrospective study
40843754|NCT03057470|DRUG|150% bolus insulin correction|Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
40843755|NCT03057470|OTHER|0% bolus insulin correction|Patients will receive no bolus insulin correction for post-exercise hyperglycemia
40843756|NCT02825212|DRUG|Harvoni|12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
40843757|NCT02825212|DRUG|Epclusa|once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
40843758|NCT02357589|PROCEDURE|2D laparoscopic cholecystectomy|
40843759|NCT02357589|PROCEDURE|3D laparoscopic cholecystectomy|
40843760|NCT00099866|DRUG|vildagliptin|
40843761|NCT00099866|DRUG|Metformin Comparator|
40843762|NCT04022655|OTHER|ICU Care|No intervention
41027038|NCT06325098|DIAGNOSTIC_TEST|Anti-nephrin antibodies|Assessment of anti-nephrin antibodies on serum samples and in vitro study of permeabilizing effect on 3D organ-on-a-chip models and STED microscopy on healthy human kidneys.
41027039|NCT06325098|DIAGNOSTIC_TEST|u-RPC cultures|Urine sample collection for u-RPC cultures
41027040|NCT06573346|OTHER|Cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
41027041|NCT04989270|PROCEDURE|General Anesthesia|General anesthesia with intubation, ventilation, intravenous and inhalational anesthetics, opioids and muscle paralysis
40843763|NCT03299361|OTHER|Magnetic resonance image (MRI)|Diffusion tensor magnetic resonance imaging (DTI) of MRI reveals tissue microstructure based on random movements of water molecules. Here we monitored, by means of DTI, median nerve integrity in CTS patients before and after corticosteroid injection. This information may help to explain the hypothesis regarding the effect of corticosteroid to the median nerve, to identify which anatomic location of median nerve relevant to the symptom relief of CTS after corticosteroid injection, and be useful for the clinical follow-up of patients with nerve entrapments following conservative treatment.
40843764|NCT00709410|BIOLOGICAL|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10\^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
40843765|NCT04467125|DRUG|Eutectic Lidocaine Prilocaine|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
40843766|NCT04467125|DRUG|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider.
40843767|NCT01017445|OTHER|Boonme stick exercise|individual exercise daily
40843768|NCT00860834|BEHAVIORAL|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
40843769|NCT00860834|BEHAVIORAL|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
40843770|NCT02068872|PROCEDURE|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of \> 40 or \> 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
40843771|NCT01671631|OTHER|Measurement of intracoronary pressure|
40843772|NCT06175624|OTHER|Clinically Helathy|"Our study will include 25 people with clinically healthy patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
40843773|NCT06175624|OTHER|Gingivitis|"Our study will include 25 people with gingivitis patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
40843774|NCT06175624|OTHER|Periodontitis|"Our study will include 25 people with periodontitis patients.~Non-surgical periodontal treatment will be applied to individuals with periodontitis, serum and gingival crevicular fluid samples will be collected before the treatment, clinical measurements and gingival crevicular fluid and serum collection will be repeated 12 weeks after the treatment. CTRP-1 analysis will be performed by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study."
41364794|NCT06126627|BEHAVIORAL|Stress induction|Induction of anticipatory stress to compare voice and speech control and production with and without exposure to stress.
40843775|NCT01624090|DRUG|Mithramycin|30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
40843776|NCT06203418|BEHAVIORAL|Multi-Family Therapy|Multi family therapy for anorexia nervosa (MFT-AN) draws on the same principles as FBT but is delivered in a more intensive format to help families to overcome a sense of isolation and stigmatization and to maximize their own resources. In the case of eating disorders, this program utilizes FBT principles (both approaches are guided by the family-based treatment philosophy, which stresses the impact of ED on family functioning and attempts to mobilize families as the primary agents of change in achieving recovery), and also utilizes learning from structural, systemic, strategic, narrative, and psychodrama-based family therapy practices,(Knatz et al., 2015). Generally between 5-7 families take part in MFT, sharing their experiences, learning by example, and providing support for one another. Study will utilize virtual adaptation of manualized treatment published by Simic et al 2021
41027042|NCT04989270|PROCEDURE|Regional Anesthesia|Spinal Anesthesia, Epidural Anesthesia
41027043|NCT00131794|BIOLOGICAL|BCG|
41027044|NCT02331134|DRUG|Filgrastim|Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
41027045|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) Low Dose|BLB201 10\^6 PFU
41027046|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) High Dose|BLB201 10\^7 PFU
41027047|NCT05655182|DRUG|Placebo|The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).
41364795|NCT02361606|BEHAVIORAL|An Internet Cognitive-Behavioral Intervention|We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
41364796|NCT03301792|BEHAVIORAL|Group prenatal care|Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
41364797|NCT06177145|OTHER|HASCV-R program|"Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
40843777|NCT04420260|DIETARY_SUPPLEMENT|Group A: oropharygeal spray and immunostimulant emulsion|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of 3 natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.~Intervention 2. Preparation in an emulsion functional food presentation for oral administration, that contains the 8 bioactive compounds that have demonstrated antiviral activity and modulation of the inflammatory response recognized at the moment in the immune activation against the virus."
40843778|NCT04420260|DIETARY_SUPPLEMENT|Group D:Placebo oropharyngeal spray + Placebo taken PO|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of Placebo substances of routine use in humans.~Intervention 2. Preparation in an emulsion presentation for oral administration that contains the Placebo compounds"
40843779|NCT02645630|OTHER|Right Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.
41027048|NCT06531746|OTHER|Extracorporeal shock wave|"participants will receive 2000 ESWT impulses, with 1500 targeting the taut band and 500 surrounding the taut band, with an energy flux density of 0.10 mJ/mm and frequency of 8 Hz, by using an~EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number:~EM12681015\], Italy, shock wave generator."
41027049|NCT06531746|OTHER|Selected physical therapy program|Stretching and strengthening of Iliopoas muscle and Stretching and strengthening of Lower back muscles
41500578|NCT04669301|BEHAVIORAL|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies.
40843780|NCT02645630|OTHER|Left Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.
41027050|NCT06485778|RADIATION|Photon intensity modulated radiation therapy (IMRT)|Patients will receive bilateral cervical nodal irradiation with the primary post operative site excluded (30 fractions).
41027051|NCT06485778|OTHER|Life questionnaire's|EORTC QLQ C30/HN 35 and MDADI
41161165|NCT00613223|DRUG|Vandetanib and Etoposide|Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
41161166|NCT05943210|RADIATION|Short Course Radiation Therapy (scRT)|Eligible patients will receive short course radiation therapy (scRT) of 25Gy over 5 days (fractions) for their localized rectal cancer. Research bloods stool and tissue will be collected at three time points: Baseline, end of radiation therapy and at surgery.
40843781|NCT02645630|OTHER|Sham Cervical Manipulation|The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
40843782|NCT04378231|DRUG|Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension|dry suspension of amoxicillin clavulanate potassium
40843783|NCT02212678|DRUG|N-acetylcysteine capsule|N-acetylcysteine capsule
41161167|NCT05943210|PROCEDURE|Total Mesenteric Excision (TME)|Subjects are expected to undergo total mesenteric Excision(TME) even if subjects have achieved complete response by imaging.TME is a specific surgical technique used in the treatment of rectal cancer in which the bowel with the tumor is entirely removed along with surrounding fat and lymph nodes.
41161168|NCT00498758|DEVICE|APOS System - biomechanical wedge shoe|
41161169|NCT03424525|DRUG|11C-Trimethoprim|\[11C\]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.
40843784|NCT00534833|BIOLOGICAL|DTaP-HB-PRP~T vaccine|0.5 mL, Intramuscular
40843785|NCT00534833|BIOLOGICAL|Tritanrix-HepB/Hib™|0.5 mL, Intramuscular
40843786|NCT00534833|BIOLOGICAL|Oral Polio Vaccine|0.5 mL, Oral
41161170|NCT04433949|OTHER|Best Practice|Receive standard of care
41161171|NCT04433949|RADIATION|Low Dose Radiation Therapy|Undergo LDRT
40843787|NCT06365983|PROCEDURE|Connective Tissue with Free Gingival Graft|The de-epithelialized free gingival grafting will begin with two horizontal incisions, 1.0 to 1.5 mm apical to the margin of the soft tissue of the adjacent teeth and two vertical incisions to delimit the area to be grafted. Along the coronal horizontal incision, the blade will be oriented almost perpendicular to the bone surface, and once an adequate thickness of soft tissue is obtained, it will be rotated to become almost parallel to the external surface of the palate. The graft thickness will be maintained uniform and the wound will be protected with absorbable collagen sponge derived from swine (Spongostan; Ethicon, Somerville, USA) and maintained with compressive sutures with non-absorbable 5-0 monofilament thread (Microsuture, São Paulo), anchored to the soft tissue apical to the area of the palatal wound. Immediately after suture completion, drops of high viscosity cyanoacrylate adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
40843788|NCT06365983|PROCEDURE|Connective Tissue with Linear Incision|The linear technique (Lorenzana ER, Allen EP 2000) will begin with a horizontal incision 2 mm apical to the gingival margin, perpendicular to the palate, which is deepened to the bone crest. Next, a second incision is made to divide the flap and expose the connective tissue bed. The thickness of the outer portion of the flap should be at least 1 mm, with uniformity throughout its extension to reduce the risk of epithelial tissue necrosis. Subsequently, internal lateral incisions (mesial and distal) and the base incision will be made, connecting the vertical incisions to delineate horizontal and vertical boundaries. Immediately after graft removal, an absorbable hemostatic collagen sponge derived from swine (Spongostan; Ethicon, Somerville, USA) will be placed and sutured using non-absorbable 5-0 monofilament thread (Microsuture, São Paulo).Immediately after suturing is completed, drops of high viscosity cyanoacrylate adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
41027052|NCT05522140|BEHAVIORAL|Nature-based social intervention (NBIS)|"Nature-based social prescribing is a multicomponent, multi-level, behaviorally based complex intervention applaied by facilitators after a specific training. It comprises: a psychosocial component and nature-based activities. The psychosocial component is adapted from the group dynamic of Circle of Friends methodolgy focused on loneliness(Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Prague and the target population (partitipants) of adults who lives in Prague. Participants start with an individual session and then meet once a week for two hours for 10 weeks.~At the first meeting together, participants select the nature-based activities they wish to conduct through a co-created menu."
41500579|NCT04669301|BEHAVIORAL|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
40843789|NCT05121324|DRUG|Standardized seizure protocol|The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
41027053|NCT05522140|BEHAVIORAL|Usual care + menu with nature based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
41161172|NCT06363513|DRUG|Aescin in Horse Chestnut|Can aescin reduce bleeding in early hemorrhoid
41027054|NCT00016289|BIOLOGICAL|recombinant interleukin-12|Given intraperitoneally
41161173|NCT06363513|DRUG|Flavonoid|Can combine aescin and MPFF reduce bleeding in early hemorrhoid
41027055|NCT03850392|DEVICE|cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)|cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval
41161174|NCT03925519|OTHER|Supervised aerobic exercise|
41161175|NCT00932555|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
41364798|NCT01522963|DRUG|Nicotine lozenge|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
41500580|NCT03337269|OTHER|Educational video|Approximately 7 minute video on the HPV vaccine
41500581|NCT03337269|OTHER|Educational handout|One page handout on the HPV vaccine
41500582|NCT03337269|OTHER|Control|Control
41500583|NCT06589505|DEVICE|Software as a Medical Device|The subject will undergo treatment using the Software as a Medical Device
41364799|NCT06517927|DIAGNOSTIC_TEST|Clinical and radiographic dental examination|complete clinical oral examination + intra-oral and panoramic x-rays
41364800|NCT03176979|OTHER|Contrast Agent|Given IV
41500584|NCT05151354|OTHER|Psychotherapy|Patients receive 8 weeks of inpatient psychotherapeutic treatment. Treatment consists of individual and group psychodynamic psychotherapy, as well as an individual combination of art, music, body-oriented and relaxation therapies, which are also carried out in group settings. Treatments is provided by an interdisciplinary team of psychotherapists with a medical or psychology degree, art of music therapists, social workers, physiotherapists and specialist nurses.
41500585|NCT05326776|DRUG|Pitocin|At each session, 4mcg/2ml oxytocin or 2ml isotonic saline (0.9% sodium chloride; placebo control) will be injected into the middle of the dorsal forearm. Sessions will be separated by at least 48 hours to ensure drug clearance.
41500586|NCT05529667|DRUG|INCB054828, Paclitaxel|"phase 1\>~- Approximately 3-12 patients will be enrolled. The dose escalation will be three patients registered for each cohort until the first dose-limiting toxicity appears during the four weeks of treatment and observation.~phase 2\> Phase 2 studies will be extended to a total of 30 patients with a two-phase recommended dose. Patients will be treated until the time of disease progression, intolerable toxicity, rejection of the patient, or withdrawal of consent."
41500587|NCT02988128|DEVICE|Treatment for intracranial aneurysms|Embolization of aneurysms
40843790|NCT05121324|DRUG|Conventional seizure protocol|"The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal.~for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg)."
41027056|NCT06573398|COMBINATION_PRODUCT|SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin|Stereotactic body radiation therapy (SBRT): 30 \~ 40 Gy/5f, Week 1, Day 1 \~ Day 5, 6-8 Gy/time, once a day; 3 weeks as a cycle, for 4 cycles Tislelizumab: 200 mg, i.v., single infusion, 21 days as a cycle for 4 cycles, on Day 1 of each treatment cycle; Thymalfasin: 4.8 mg, subcutaneous injection, twice a week, on Day 1 and Day 4 of each week during Weeks 1 \~ 13; Albumin-bound paclitaxel: 125 mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; Gemcitabine: 1000mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; After 4 cycles of preoperative neoadjuvant therapy, radical surgery will be evaluated by the MDT team within 2-4 weeks after completion of chemotherapy + immunotherapy.
41027057|NCT01754714|DRUG|SAMe 1000 mg|1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
41500588|NCT02988128|DEVICE|Treatment for Acute Ischemic Stroke|Revascularization of an intracranial blood vessel
41500589|NCT05296538|OTHER|Broad-Minded Affective Coping Intervention|The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.
41500590|NCT05296538|OTHER|Risk Assessment and Signposting|A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
41500591|NCT06303778|OTHER|Stand Down mobile app|The Stand Down mobile app is a smartphone-based stand-alone intervention designed to help persons manage drinking and alcohol-related problems on their own. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support.
41027058|NCT01754714|DRUG|SAMe 1500 mg|1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
41364801|NCT03176979|PROCEDURE|Digital Tomosynthesis Mammography|Undergo CESM with DBT
41500592|NCT06303778|OTHER|Standard Care|Participants assigned to the standard care condition will receive standard MAUD care delivered by their CPSs and will not receive access to SD-App. Three medications, naltrexone, disulfiram, and acamprosate, have been approved by the Federal Drug Administration and topiramate has been recommended by the VA/DoD clinical practice guidelines for SUD. MAUD includes these four medications. All medication decisions will be between the CPS and the Veteran and not influenced by study participation.
41027059|NCT01754714|DRUG|SAMe 2000 mg|2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
41364802|NCT03176979|PROCEDURE|Dual-Energy Contrast-Enhanced Digital Spectral Mammography|Undergo CESM with DBT
41364803|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
41364804|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
41364805|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
41364806|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
41364807|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
40843791|NCT03673020|BIOLOGICAL|ASV® AGEN2017 + QS-21 Stimulon® adjuvant|Neoantigen Vaccine
40843792|NCT00454181|DRUG|Interferon-alpha|500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
40843793|NCT00454181|OTHER|placebo|200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
40843794|NCT02832024|DEVICE|plaque excision system|
40843795|NCT02832024|DEVICE|stent|
40843796|NCT02832024|DEVICE|Balloon|
40843797|NCT01073007|DRUG|Simvastatin|Simvastatin 40 mgrs daily for three months.
40843798|NCT06175013|DEVICE|Sérum PURIFIANT|Application of Sérum PURIFIANT only, twice daily during 112 days
40843799|NCT06175013|DEVICE|Sérum PURIFIANT in association Sérum BOOSTER|Application of Sérum PURIFIANT twice daily during 112 days AND Application of Sérum BOOSTER before the Serum PURIFIANT, twice weekly
40843800|NCT02147769|DEVICE|NIRS monitoring|All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
40843801|NCT00598325|BIOLOGICAL|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
40843802|NCT00072774|DRUG|DVS-233 SR|
40843803|NCT04003402|DRUG|ASP8062|oral
40843804|NCT04003402|DRUG|Alcohol|oral
40843805|NCT04003402|DRUG|ASP8062 Placebo|oral
40843806|NCT04003402|DRUG|Alcohol Placebo|oral
41364808|NCT01044095|BIOLOGICAL|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
41364809|NCT01044095|BIOLOGICAL|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
41364810|NCT04065711|DEVICE|Soliton's Rapid Acoustic Pulse (RAP)|Treatment for the temporary improvement in the appearance of cellulite.
41500593|NCT05895955|BIOLOGICAL|TetraFluvac TF vaccine|"The vaccine is a seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria Lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus\] produced by The Government Pharmaceutical Organization (GPO), Thailand.~Each prefilled dose of TetraFluvac TF contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
40843807|NCT04816604|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
40843808|NCT04816604|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) delivery
40843809|NCT00399399|DRUG|azathioprine|
40843810|NCT00399399|DRUG|cyclophosphamide|
40843811|NCT05832749|DEVICE|Ophtesis Bio 3% ophthalmic viscosurgical device|Intraocular surgery of the anterior segment, including cataract extraction and intraocular lens (IOL) implantation. The viscoelastic properties of OphtesisBio 3.0% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues.
40843812|NCT05832749|DEVICE|Healon Endocoat 3% ophthalmic viscosurgical device|"Healon@ EndoCoat OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including:~* Cataract surgery with an intraocular lens~* Cataract surgery without an intraocular lens~* Secondary intraocular lens implantation~Healon@ EndoCoat maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation."
40843813|NCT01026220|BIOLOGICAL|bleomycin sulfate|Given IV or SC
40843814|NCT01026220|DRUG|doxorubicin hydrochloride|Given IV
40843815|NCT01026220|DRUG|liposomal vincristine sulfate|Given IV
40843816|NCT01026220|DRUG|vinorelbine tartrate|Given IV
41027060|NCT02747940|DRUG|flunarizine and/or pregabalin|
41027061|NCT00411021|PROCEDURE|Pipelle (Endometrial Sampling)|
41364811|NCT01194076|BEHAVIORAL|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
41364812|NCT05359094|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline α-cellulose) supplement with a Plant-Dominant Low-Protein Diet
40843817|NCT01026220|DRUG|cyclophosphamide|Given IV
40843818|NCT01026220|DRUG|etoposide phosphate|Given IV
40843819|NCT01026220|DRUG|prednisone|Given IV
40843820|NCT01026220|BIOLOGICAL|filgrastim|Given IV or SC
40843821|NCT01026220|DRUG|ifosfamide|Given IV
40843822|NCT01196416|DRUG|Cisplatin|Given IV
40843823|NCT01196416|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
40843824|NCT01196416|OTHER|Laboratory Biomarker Analysis|Correlative studies
40843825|NCT01196416|OTHER|Pharmacological Study|Correlative studies
40843826|NCT01196416|DRUG|Temozolomide|Given PO
40843827|NCT01196416|DRUG|Vinblastine Sulfate|Given IV
40843828|NCT05504551|PROCEDURE|ultrasound guided superficial cervical plexus block|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
40843829|NCT02401204|OTHER|Longitudinal surveillance study|"Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected."
40843830|NCT03470363|DRUG|Sevoflurane Volatile Liquid|
40843831|NCT03470363|DRUG|Bupivacaine / SUFentanil|
41364813|NCT05359094|DIETARY_SUPPLEMENT|Probiotics|Probiotics(Pediococcus acidilactici GKA4) supplement with a Plant-Dominant Low-Protein Diet
41364814|NCT04774029|PROCEDURE|Basivertebral nerve block|Temporary intraosseous basivertebral nerve block using lidocaine
41364815|NCT04774029|DRUG|Lidocaine induced basivertebral nerve block|Intraosseous lidocaine basivertebral nerve block
41364816|NCT04791111|OTHER|Questionnaire|validated questionnaire to assess side effects secondary to antimuscarinics treatment in neurogenic bladder
41364817|NCT06329245|OTHER|Do not take any interventions|Do not take any interventions
40843832|NCT00028574|DRUG|gabapentin|
40843833|NCT00028574|OTHER|placebo|
40843834|NCT02127177|DEVICE|Continuous Positive Airway Pressure Ventilator|CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
40843835|NCT05251038|DRUG|Sotorasib|Intervention instruction outlined in protocol
40843836|NCT05251038|DRUG|Liposomal Irinotecan (nal-IRI)|Intervention instruction outlined in protocol
40843837|NCT05251038|DRUG|5 Fluorouracil (5FU)|Per standard of care
41364818|NCT03783312|DRUG|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
40843838|NCT05251038|DRUG|Leucovorin (LV)|Per standard of care
40843839|NCT05251038|DRUG|Gemcitabine (GEM)|Per standard of care
40843840|NCT05251038|DRUG|Nab paclitaxel|Per standard of care
40843841|NCT05604963|PROCEDURE|Total Thyroidectomy|Total Thyroidectomy - surgical removal of entire thyroid gland
40843842|NCT05604963|PROCEDURE|Hemithyroidectomy|Hemithyroidectomy - surgical removal of partial thyroid gland
40843843|NCT06393881|DRUG|UI059|take UI059 once a day for 7 days
41161176|NCT02188277|DRUG|Xeomin|"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius."
40843844|NCT06393881|DRUG|UIC202201|take UIC202201 once a day for 7 days
41161177|NCT02188277|DRUG|Botox®|Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
40843845|NCT03969186|BEHAVIORAL|Intervention|Telehealth intervention monitoring weight and medication adherence accompanied by a weekly phone call to monitor symptoms.
40843846|NCT05259839|DRUG|ABBV-383|Intravenous (IV) Infusion
40843847|NCT05259839|DRUG|Dexamethasone|Oral; Tablet or IV Infusion
40843848|NCT05259839|DRUG|Lenalidomide|Oral; Capsule
40843849|NCT05259839|DRUG|Pomalidomide|Oral; Capsule
40843850|NCT05259839|DRUG|Nirogacestat|Oral; Tablet
40843851|NCT05259839|DRUG|Daratumumab|Subcutaneous Injection (SC)
40843852|NCT01869660|BEHAVIORAL|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
40843853|NCT05323097|OTHER|Drowning-related OHCA|Drowning-related out-of-hospital cardiac arrest (OHCA): YES
40843854|NCT01363934|DRUG|GC1113|"Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously."
40843855|NCT01363934|DRUG|Darbepoetin alfa|Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
40843856|NCT02262962|OTHER|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
40843857|NCT00450034|PROCEDURE|drug - oriented multifaceted intervention|oriented multifaceted intervention
40843858|NCT03372005|BEHAVIORAL|Floorball|This intervention will have one week of testing before the first 12 weeks of floorball, followed by one week of testing before the last 27 week training period.
40843859|NCT05875493|DRUG|JAB-21822|2 discrete single doses
40843860|NCT05875493|DRUG|JAB-21822|2 discrete single doses
40843861|NCT05254873|OTHER|Long term follow-up|Long term follow-up for patient who completed the EYE-TAR(MA) study.
41027062|NCT05694624|DRUG|Para Aminohippurate|Measurements of renal plasma flow and glomerular filtration rate
41027063|NCT04793321|DEVICE|Baby carrier|"* It is made in china.~* It is made of Cotton-Polyester.~* It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~* It is suitable for newborn to 12-months baby~* It is available online at babyshopstores https://www.babyshopstores.com/"
41161178|NCT04458987|BEHAVIORAL|Expert patient in addictology|"EP's Intervention, with patients hospitalized for addiction withdrawal. These are weekly individual interviews, in room, proposed by the EPs to inpatients.~The content of the intervention will be defined trough the results of step one of the study."
40843862|NCT02643732|DRUG|Methylphenidate (overencapsulated)|10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
40843863|NCT02643732|DRUG|Placebo (Over-encapsulated tablet)|Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
40843864|NCT01343732|DEVICE|Deep TMS|deep transcranial magnetic stimulation
40843865|NCT00212706|DRUG|ONO-8025 (KRP-197)|
40843866|NCT04588181|BEHAVIORAL|cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
40843867|NCT05893472|COMBINATION_PRODUCT|combination of venetoclax and HAA regimen|Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.
40843868|NCT01411384|PROCEDURE|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
40843869|NCT01411384|DEVICE|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
40843870|NCT03437824|DRUG|Cyanocobalamin|1,000 mg, Once
40843871|NCT03437824|DRUG|Placebo|0.9% Sodium Chloride, Once
40843872|NCT04564872|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
40843873|NCT04564872|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
40843874|NCT04564872|DRUG|Linagliptin 5 mg QD|Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
40843875|NCT04147806|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
40843876|NCT04147806|RADIATION|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
40843877|NCT04147806|DRUG|Dexamethasone|4 mg by mouth on treatment days only
40843878|NCT04147806|DRUG|Tamsulosin|0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.
40843879|NCT05025696|OTHER|Blacksoap(R)|Blacksoap(R)
41364819|NCT03783312|DRUG|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
41364820|NCT03783312|DRUG|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
41364821|NCT06086613|DRUG|AGA2115|"In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection."
41364822|NCT06086613|DRUG|Placebo|"In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection."
41364823|NCT02986321|DRUG|CHF6001|Dose response: Test one of 4 different doses of CHF6001
41364824|NCT02986321|DRUG|Budesonide|active control
41364825|NCT02986321|DRUG|Placebo|placebo control
40843880|NCT05551052|DIAGNOSTIC_TEST|Next-Gen CRC Screening Test|The Next-Gen CRC Screening Test is a blood-based screening test for detection of CRC.
41500594|NCT05895955|BIOLOGICAL|Vaxigrip vaccine|"Vaxigrip vaccine is commercially available seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like strain and A/Darwin/9/2021 (H3N2)-like strain and B/Austria/1359417/2021-like strain and B/Phuket/3073/2013-like strain, manufactured by Sanofi Pasteur, Ltd. France.~Each prefilled dose of Vaxigrip vaccine contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
41500595|NCT03604315|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
41500596|NCT03604315|PROCEDURE|Computed Tomography|Undergo \[18F\]FTT PET/CT
41500597|NCT03604315|RADIATION|Fludeoxyglucose F-18|Given IV
41500598|NCT03604315|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
41500599|NCT03604315|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
41500600|NCT03604315|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FTT PET/CT
41500601|NCT01216787|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
41500602|NCT01216787|OTHER|pharmacological study|
41500603|NCT01216787|PROCEDURE|therapeutic conventional surgery|
41500604|NCT01216787|OTHER|laboratory biomarker analysis|Correlative studies
40843881|NCT01079936|DRUG|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
40843882|NCT01079936|DRUG|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
40843883|NCT01079936|PROCEDURE|Stem Cell Infusion|Stem cell infusion on Day 0.
40843884|NCT01821482|BIOLOGICAL|Dendritic and Cytokine-induced Killer Cells|
40843885|NCT05147428|OTHER|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
40843886|NCT01141491|BIOLOGICAL|Trivalent ganglioside vaccine|Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
41161179|NCT04322916|DEVICE|RM Pressfit vitamys|Implantation of a RM Pressfit vitamys hip cup
41500605|NCT03156335|DEVICE|Focused Ultrasound|MR-guided Focused Ultrasound (MRgFUS) offers the possibility of lesioning deep brain targets, while obviating the need for open surgical approaches. There is no radiation, incision, or burr hole, and lesions are generated in real-time under MR image guidance. Intracranial FUS for other applications, essential tremor most notably, has been shown to be safe and effective, recently receiving Health Canada approval for this indication. The technology, methods and procedures used in this study are identical to those in essential tremor.
41500606|NCT06483503|DEVICE|EFOV Colonoscope|Routine colonoscopy using the EFOV lens in the colonoscope.
40843887|NCT01141491|BIOLOGICAL|OPT-821|Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
40843888|NCT01573156|DRUG|Light activated WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 \& 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
40843889|NCT03667690|DRUG|Rezafungin for Injection|Intravenous antifungal therapy
40843890|NCT03667690|DRUG|Caspofungin|Intravenous antifungal therapy
40843891|NCT03667690|DRUG|Fluconazole|Oral antifungal therapy
40843892|NCT03667690|DRUG|intravenous placebo|Normal saline
40843893|NCT03667690|DRUG|oral placebo|Microcrystalline cellulose
40843894|NCT01424280|DRUG|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
40843895|NCT01424280|DRUG|Placebo|Single dose of matching placebo tablets
40843896|NCT00094848|DRUG|TRAIL-R1 mAb (TRM-1; HGS-ETR1)|
40843897|NCT01560455|DEVICE|single stent|single stent
40843898|NCT01560455|DEVICE|two stent|culotte
40843899|NCT00188903|PROCEDURE|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
40843900|NCT00003552|DRUG|allogeneic lymphocytes|
40843901|NCT00003552|DRUG|anti-thymocyte globulin|
40843902|NCT00003552|DRUG|cyclophosphamide|
40843903|NCT00003552|DRUG|fludarabine|
41161180|NCT05261230|BEHAVIORAL|Vedic Counselling|Trauma focused Vedic Counselling intervention was delivered by trained and experienced therapist of Yoga and Vedanta.12-week sessions were provided on one to one bases on personalised approach.
41161181|NCT05261230|BEHAVIORAL|Standard Care|The active control group received standard psychosocial care provided by the participating psychologists and psychiatrists.
40843904|NCT01799551|BEHAVIORAL|Ca CBT|Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
41500607|NCT06365918|DRUG|VG2025|Given by Intraperitoneal
41500608|NCT06379724|DRUG|Tranexamic acid|100mg/mL 10mL vials x2 of injectable tranexamic acid will be filled into a 20 milliliter syringe with a spray tip.
40843905|NCT01294163|DRUG|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
40843906|NCT01294163|DRUG|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
40843907|NCT01294163|DRUG|Propofol|Hourly dose of 2-4 mg/kg
40843908|NCT00967096|DRUG|Rifaximin|Rifaximin for Bone marrow transplant patients
40843909|NCT05477914|OTHER|questionnaire|questionnare about nutritional knowledge of pregnant women
40843910|NCT02093910|DRUG|Monosialotetrahexosylganglioside|
40843911|NCT04166539|BEHAVIORAL|Questionnaires|You will be asked to complete a questionnaire about your family history of neurological diseases and current and past physical thinking activities.
40843912|NCT04166539|BEHAVIORAL|Interviews|Behavioral and Memory interviews will take place with the patient.
40843913|NCT04166539|OTHER|Blood draw|Have a sample of blood drawn (4.2-5 tablespoons) for clinical and research tests.
40843914|NCT04166539|RADIATION|Magnetic Resonance Imaging|Each MR examination takes about 45 minutes and does not require the use of needles, medication or contrast enhancement. You will lie on your back and enter the MR scanner for the study, during which time you will hear knocking noises. People with pacemakers, aneurysm clips, cochlear implants, or metal/foreign objects in their eyes are not permitted to undergo MR studies. We will review your implants and determine your eligibility.
40843915|NCT04166539|DIAGNOSTIC_TEST|Echocardiogram|Each echocardiogram takes about 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
40843916|NCT00000466|DRUG|estrogens, conjugated|
40843917|NCT00000466|DRUG|medroxyprogesterone|
41500609|NCT06379724|DRUG|Thrombin JMI|The wound base is then sprayed with a film of Thrombin-JMI
40843918|NCT00000466|DRUG|progesterone|
40843919|NCT00000466|DRUG|estrogen replacement therapy|
40843920|NCT01309685|DRUG|Varenicline|
40843921|NCT06142006|OTHER|Diabetes Staging System (DSS) use among Primary Care Teams|Evaluate the feasibility of using the DSS in PACT clinics to increase SGLT2i and/or GLP-1 agonist use in Veteran DM2 patients with cardiovascular disease
41027064|NCT04793321|DEVICE|Biodex Balance System|"* The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~* It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~* The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance."
41027065|NCT04793321|OTHER|Infant mannequin|The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .
41027066|NCT04793321|DEVICE|Biodex gait trainer 2 TM|"Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~* Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~* Heart Rate Monitoring~* Handrail~* Open Platform"
40843922|NCT03358134|DRUG|Secukinumab|anti IL17 therapy (subcutaneous)
40843923|NCT03549559|DRUG|11C-Martinostat|Imaging probe for evaluating the activity of histone deacetylase in the heart
41161182|NCT03410953|BIOLOGICAL|Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).|"The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
41161183|NCT01620398|BEHAVIORAL|BALANCE|
41500610|NCT06379724|PROCEDURE|skin graft|Skin is taken from uninjured part of the participant's body and used to surgically cover a wound or injured area with skin that contains the epidermis and a portion of the dermis.
41500611|NCT06632600|DRUG|LXE408|LXE408 administered by oral route
41500612|NCT06632600|DRUG|Placebo|Placebo administered by oral route
40843924|NCT03549559|DEVICE|PET-MRI|Siemens PET-MR Scanner (Biograph MMR)
40843925|NCT04861428|OTHER|IQOS|IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).
41500613|NCT06632600|DRUG|Benznidazole|Benznidazole administered by oral route (administered as standard of care)
40843926|NCT04861428|OTHER|Smoking as Usual|Cigarette smoking
40843927|NCT06292676|OTHER|skills retained for home birth delivery in emergency|skills on mannequin for home birth scenario in emergency
40843928|NCT04872517|DEVICE|Meridian Electroacupuncture Analysis Device (MEAD)|use MEAD to detect energy change in patient with head and neck cancer
40843929|NCT02516319|DRUG|ICG Dye|
41027067|NCT04680221|DRUG|Liposomal bupivacaine|Deposition of liposomal bupivacaine
41027068|NCT04680221|PROCEDURE|TAP block|Transversus abdominis plane block performed to deposit anesthetic
41027069|NCT04680221|DRUG|Deposition of saline|Deposition of saline
41027070|NCT03074006|DRUG|TEW-7197|50mg tablets (doses will be determined through dose-escalation part)
41027071|NCT02223390|BEHAVIORAL|Improving AIDS Care after Trauma (ImpACT)|
41500614|NCT05042258|DRUG|Dupilumab|12 week dupilumab administration
41500615|NCT02646852|DRUG|PLX038|
41500616|NCT06436066|OTHER|Self-Acupressure|"Applications include the following parameters;~1. Patient Information Form (before and after application)~2. Neuropathic Pain Questionnaire - DN4 (before and after application)~3. Neuropathic Pain Questionnaire - Short Form (before and after application)~4. Providing self-acupressure training (before application)~5. Delivery of the self-acupressure training booklet (before application)~6. Sending weekly reminder messages (during implementation)~7. Calling the patient for a check-up after 3 months and re-evaluating with the same scales (After the application)~8. Self-Acupressure - Satisfaction Evaluation Form with Visual Analogue Scale (After application)"
41500617|NCT06634303|DEVICE|Brain cooling|Brain cooling intervention in acute ischemic stroke patients post mechanical thrombectomy
40843930|NCT04326088|OTHER|Reconstruction group|Patients with primary tumor which underwent free flap reconstruction group.
40843931|NCT04326088|OTHER|Recurrent group|Patients with recurrent tumor which underwent free flap reconstruction group.
40843932|NCT01283685|OTHER|breathing helium-hyperoxia|40% O2, 60% He
41500618|NCT05146297|BEHAVIORAL|Clinical trial match-list|Creation and dissemination educational materials designed to inform and empower patients' participation in their cancer treatment including the consideration of clinical trial participation and provide clinical trials' patient navigators (CTPN) to further aid with education about clinical trials.
41500619|NCT05146297|BEHAVIORAL|Match-list intervention|Providers by intervening at the clinical and systems levels to provide them with tools and processes and informational and practical support to facilitate CT consideration, discussion, and offer to aid with education about clinical trials and facilitate CT consideration at a treatment decision node.
41500620|NCT02901548|DRUG|Durvalumab|Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
41500621|NCT02901548|PROCEDURE|Cystoscopy with Biopsy|Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
41500622|NCT06632392|OTHER|Simulation training|Theory and simulation training
41500623|NCT06632392|OTHER|Theory training|Theory training
41500624|NCT03139227|PROCEDURE|Bio specimen Collection|Patients undergo collection of blood and urine
41500625|NCT03139227|DIETARY_SUPPLEMENT|Dietary Intervention|Consume celery-banana bread
41500626|NCT03139227|OTHER|Laboratory Biomarker Analysis|Correlative studies
41500627|NCT04386616|DRUG|MSTT1041A|Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
40843933|NCT01283685|OTHER|breathing supplemental oxygen|oxygen (4 L/min) provided by nasal cannula
41027072|NCT03176693|DRUG|Phenoxybenzamine|Non-selective alpha blocker
41027073|NCT03176693|DRUG|Doxazosin|Selective alpha blocker
41500628|NCT04386616|DRUG|MSTT1041A-matched Placebo|Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
41500629|NCT04386616|DRUG|UTTR1147A|Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
41500630|NCT04386616|DRUG|UTTR1147A-matched Placebo|Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
41500631|NCT05509400|DRUG|Rimegepant|DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)
41500632|NCT05509400|DRUG|Placebo|DB Phase: matching placebo
41027074|NCT03000894|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
41027075|NCT02288429|DRUG|colistimethate sodium|
41027076|NCT00853450|DRUG|AZD6482|Single intravenous infusion during a maximum of 5 hours
41500633|NCT05509400|DRUG|Rimegepant|OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines
41027077|NCT00853450|DRUG|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
40843934|NCT00119964|BEHAVIORAL|internet based weight management tools|
40843935|NCT04977219|BEHAVIORAL|Prism Adaptation Training|Therapists administering PAT followed the protocol developed by the Kessler Foundation (2014).PAT sessions lasted approximately 30 minutes during which patients with left sided neglect don 20 diopter prism goggles deviating their visual field to the right while aiming their finger at a series of visual targets.
40843936|NCT02532985|OTHER|Negative Control|No added fiber beverage
40843937|NCT02532985|OTHER|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
40843938|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
40843939|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
40843940|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
41027078|NCT00853450|DRUG|ASA|75 mg orally once daily during 7 days in each treatment arm
41027079|NCT04257318|OTHER|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregnancy
41027080|NCT06397404|DIAGNOSTIC_TEST|Venous excess ultrasound score (VExUS) protocol|All patients upon admission undergo ultrasound assessment of diameter and collapsibility of the inferior vena cava, hepatic vein Doppler, portal vein Doppler, intra-renal venous Doppler.
41027081|NCT05227508|DIETARY_SUPPLEMENT|BRIZO|A capsule containing 400 mg. SC012 (unique soy extract)
41027082|NCT05227508|OTHER|placebo|Comprecel microcrystalline cellulose
41027083|NCT05331742|DRUG|Vaccine|patients who have received vaccine against coronavirus disease infection
41027084|NCT00697749|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
41027085|NCT00697749|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
41027086|NCT00780091|OTHER|classical monitoring strategy|intensive on-site monitoring, consistently with the pharmaceutical industry practices
41027087|NCT00780091|OTHER|optimized monitoring strategy|optimized on-site monitoring, depending on patient's risk
41500634|NCT06397027|DRUG|Ziftomenib|Given by IV
41500635|NCT06397027|DRUG|Venetoclax|Given by PO
41500636|NCT06397027|DRUG|Azacitidine|Given by PO
41500637|NCT06625918|DEVICE|Ultraviolet B exposure to produce vitamin D synthesis|Exposure using a UV skin care device on vitamin D production and immune response in healthy adults
41500638|NCT06144632|DEVICE|THERMOCOOL STSF Bi- Directional Navigation Catheter|THERMOCOOL STSF will be used in conjunction with TRUPULSE Generator to give pulsed field (PF) ablation or radiofrequency (RF) ablation.
41500639|NCT06144632|DEVICE|TRUPULSE Generator|TRUPULSE Generator will be used to deliver PF/RF ablation.
41500640|NCT02172235|DRUG|Pioglitazone|
41500641|NCT02172235|DRUG|Pioglitazone - low dose|
41500642|NCT02172235|DRUG|BI 10773 - low dose|
41500643|NCT02172235|DRUG|BI 10773 - medium dose|
40843941|NCT00649831|DRUG|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
40843942|NCT00649831|DRUG|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
40843943|NCT02424682|OTHER|No intervention|No intervention administered in this study
40843944|NCT00478309|OTHER|counseling intervention|
40843945|NCT00478309|OTHER|educational intervention|
40843946|NCT02861482|DEVICE|Bakri Balloon|Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped
41027088|NCT00759109|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
41027089|NCT00759109|OTHER|Observation (no treatment)|No treatment was given to participants enrolled in the control arm (Arm B).
41027090|NCT04793412|DEVICE|Cochlear Implant|Cochlear implantation of a device from one of the three manufacturers available in the US.
40843947|NCT02861482|DRUG|Oxytocin|using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
40843948|NCT02861482|DRUG|Hemabate|using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
40843949|NCT02861482|DRUG|Duratocin|using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
41027091|NCT04557722|PROCEDURE|0-30° Biplanar Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-30 degree technique of C-Arm.
41500644|NCT02172235|DRUG|BI 10773 - high dose|
41500645|NCT05645159|OTHER|Blended learning in heart disease|The intervention included face-to-face classes and online resources (Moodle, online syllabus, videos, websites, podcasts, activities, apps, forums, emails, tutoring).
41500646|NCT03796494|PROCEDURE|Straight abutment|This is the classic abutment, straight and anti-rotational for dental implants which have been tested before
41500647|NCT03796494|PROCEDURE|Slim abutment|This is the new concept of the prostheses abutment, slim and anti-rotational to improve the width of biologic space
41500648|NCT04810637|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
41500649|NCT06382480|OTHER|Diet with specific macronutrient composition.|The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat.
41500650|NCT04939194|BEHAVIORAL|Fast Track Protocol|We will apply 22 items of ERAS society
41500651|NCT01265810|OTHER|supersaturated calcium-phosphate|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
41500652|NCT01265810|OTHER|sodium chloride 0.9 %|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
40843950|NCT02861482|PROCEDURE|Uterine Massage|continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon
40843951|NCT02861482|PROCEDURE|B-lynch Suture|One of conservative surgical procedures if Bakri Balloon didn't work
40843952|NCT02861482|PROCEDURE|Uterine Artery Embolization using sponges|One of conservative surgical procedures if Bakri Balloon didn't work
40843953|NCT02861482|PROCEDURE|Cervical cerclage|One of conservative surgical procedures if Bakri Balloon didn't work
40843954|NCT02861482|PROCEDURE|Hysterectomy|Hysterectomy with all the above measures not working
40843955|NCT02861482|DRUG|Blood Product|transfusion of blood product if necessary no matter which surgical procedure has been taken
40843956|NCT02092311|PROCEDURE|Combined Microscopic Varicocelectomy|After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
40843957|NCT02092311|PROCEDURE|Inguinal and Subinguinal varicocelectomy|Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
41027092|NCT04557722|PROCEDURE|New 0-90° Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-90 degree technique of C-Arm.
41027093|NCT00558675|BIOLOGICAL|AlloStim|single intravenous infusion of 1 x 10\^9 AlloStim cells
41027094|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7
41027095|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7 and day 14
41500653|NCT02315196|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
41500654|NCT02315196|DRUG|epirubicin hydrochloride|Given IV
41500655|NCT02315196|DRUG|carboplatin|Given IV
41500656|NCT02315196|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
41500657|NCT02315196|DRUG|paclitaxel|Given IV
40843958|NCT00185874|BIOLOGICAL|Intratumoral Dendritic Cell Immunotherapy|
41027096|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7, day 14 and day 21
41500658|NCT02315196|OTHER|laboratory biomarker analysis|Correlative studies
41500659|NCT02315196|OTHER|quality-of-life assessment|Ancillary studies
41500660|NCT01188278|DRUG|Imatinib|Drug being observed but not provided
41500661|NCT02407405|DRUG|Selumetinib|orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
40843959|NCT00185874|BIOLOGICAL|autologous dendritic cells|
40843960|NCT01701934|DRUG|Roflumilast|500 mcg, oral, once daily for 6 months
40843961|NCT01701934|DRUG|Placebo|One placebo pill daily, for 6 months
40843962|NCT05413148|BIOLOGICAL|Subtenon injection of Wharton jelly derived mesenchymal stem cells|Single subtenon's injection for single eye
41027097|NCT06310213|DEVICE|Non-Invasive Pressure Monitor|Modified smart soft contact lens and cap with reader coil
41027098|NCT05218252|PROCEDURE|Posterior interosseous artery flap|The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects
41027099|NCT01842789|DEVICE|Acessa Procedure|Acessa Procedure
41027100|NCT05902195|BEHAVIORAL|Personal Resource Building and Inclusive Volunteering Intervention (PVI)|PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
41027101|NCT05902195|OTHER|Usual care|Usual stroke care services include medical and health services offered by the hospitals or community-based organisations.
41027102|NCT02228213|BIOLOGICAL|MIS416|Intravenous administration weekly for 52 weeks
41027103|NCT02228213|DRUG|Saline|Intravenous administration weekly for 52 weeks
41027104|NCT04892654|DRUG|Doravirine|Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor
41027105|NCT04892654|DRUG|Dolutegravir|Antiretroviral, Integrase strand transfer inhibitors
41027106|NCT04892654|OTHER|Triple cART regimen|Participant standard triple cART regimen
41027107|NCT01320410|DRUG|ISM®|
40843963|NCT05413148|BIOLOGICAL|Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes|Single subtenon's injection for single eye
40843964|NCT05413148|OTHER|Placebo|Single Subtenon injection of saline for a single eye
40843965|NCT05408026|DRUG|Daratumumab|"Daratumumab (and hyaluronidase) will be given over 3-5 minutes subcutaneously (under the skin) in the clinic at alternating left/right abdominal sites. Patient will take dexamethasone orally (by mouth) either before coming to clinic or in clinic, before other medications.~Only for the first cycle, patient will receive on Day 1 daratumumab (which is mixed with a compound called hyaluronidase) and dexamethasone, 1 day before patient start the other 2 medications."
40843966|NCT05408026|DRUG|Pomalidomide|On day 2 of cycle 1, patient will start the other medications and will therefore receive bortezomib administered subcutaneously (SC) over 3-5 minutes and dexamethasone given orally (by mouth), either before coming to clinic or in clinic, before bortezomib. Patient will also start pomalidomide on the same day, which patient will take that evening at home and every evening for 21 days.
40843967|NCT05901103|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
40843968|NCT02088567|PROCEDURE|Total Knee Arthroplasty|Total knee arthroplasty, per the usual practice of the physician.
41027108|NCT04509531|BEHAVIORAL|Wise Intervention (SA, ITP and resilience)|The intervention will be based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. This will include activities such as reading scientific information about social behavior and its role in people's well-being and mental health, the meaning of online victimization experiences and ways to react to them, experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change. Furthermore, it provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
41500662|NCT01025453|DRUG|Temsirolimus and Sorafenib|Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
40843969|NCT02088567|OTHER|Application of dHACM|Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
41027109|NCT04509531|BEHAVIORAL|Standard preventive intervention|The control intervention will involve scientific information and education about internet risks such as sexting and grooming.
41027110|NCT03575130|DRUG|Ripasudil eye drops|Rho-kinase-Inhibitor (IMP)
41027111|NCT03575130|DRUG|Optive eye drops|Artificial tears (placebo)
41027112|NCT03575130|PROCEDURE|Descemetorhexis|Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
40843970|NCT04759365|DRUG|ASN51|ASN51 formulation for oral capsule
40843971|NCT04759365|DRUG|Placebo|Placebo formulation for oral capsule
40843972|NCT04246957|BEHAVIORAL|general quality of life questionary|Every patient will have to fill out a general quality of life questionary : DLQI (Dermatology Life Quality Index)
40843973|NCT04246957|BEHAVIORAL|specific quality of life questionary|Every patient will have to fill out a specific quality of life questionary : Hair Specific Skindex 29.
41027113|NCT05550246|DRUG|Atomoxetine|Treatment given for 3 nights
41027114|NCT05550246|DRUG|Oxybutynin|Treatment given for 3 nights
41027115|NCT04267172|BEHAVIORAL|Surgical simulation training in primary Total Hip Arthroplasty|The simulation-based and cognitive learning package will be delivered to a randomised sub-group of 50% of the Surgical Residents recruited into this study. This will be delivered in a supervised non-clinical setting within a dedicated University-owned simulation laboratory over a 4-week period for between 1 to 2 hours per week, over 3 to 4 consecutive but separate six-month placements.
41027116|NCT04267172|OTHER|No intervention: Surgical Resident Control Group|Control Group
41500663|NCT05792579|PROCEDURE|stoma closure|early closure of stoma in trauma patients
41027117|NCT04267172|OTHER|No Intervention: Consultant and Fellow Comparator Group|Comparator Group
41364826|NCT04570124|DEVICE|Home Blood Pressure Telemonitoring|Women will complete a 9-question survey (pre-education) prior to discharge and will go over an education video a study team member. Once discharged, women will be asked to measure their blood pressure daily for the first postpartum week, and then weekly until postpartum week 6. Women who have a doctor's visit scheduled during the first 10 days, a member of the study team will meet them there to assess blood pressure and answer any questions. Women who do not have a visit scheduled they will have a telehealth visit during days 8-10 to complete the same assessments. At the final visit, participants will measure their blood pressure via HBPT, prior to returning the unit, complete a post-education questionnaire, a post-study questionnaire and have any questions or concerns addressed.
41027118|NCT03574792|DRUG|Gabapentin|Given PO
41027119|NCT03574792|DRUG|Methadone|Given PO
41500664|NCT06255665|DRUG|JNJ-79032421|JNJ-79032421 will be administered.
40843974|NCT05238883|DRUG|HFB200301|Participants will be administered HFB200301 as described in the experimental arm.
41027120|NCT03574792|DRUG|Oxycodone|Given PO
41027121|NCT03574792|OTHER|Quality-of-Life Assessment|Ancillary studies
41027122|NCT03574792|OTHER|Questionnaire Administration|Ancillary studies
41500665|NCT06255665|DRUG|JNJ-79032421|JNJ-79032421 will be administered at RP2D regimen.
40843975|NCT05238883|DRUG|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
40843976|NCT04471324|DEVICE|EBUS cryo probe|patients receive a transbronchial cryo biopsy with the EBUS cryo probe from ERBE and an ultra thin bronchoskope
40843977|NCT05041348|DIAGNOSTIC_TEST|CT at the level of the third lumbar vertebra (L3)|Muscle mass loss was defined as an skeletal muscle mass index (SMI) less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
41027123|NCT03574792|DRUG|Venlafaxine|Given PO
41027124|NCT03574792|DRUG|Venlafaxine Hydrochloride Extended Release|Given PO
41027125|NCT00874744|DRUG|Bevacizumab|1.25mg bevacizumab (0.05ml)
41027126|NCT00874744|DRUG|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
41027127|NCT01870843|DRUG|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
40843978|NCT06342596|DRUG|[14C]-LY3473329|Administered orally
40843979|NCT06342596|DRUG|[14C]-LY3473329|Administered IV
41027128|NCT01886547|OTHER|Prostate health screening|
41027129|NCT04177693|DIETARY_SUPPLEMENT|Epigallocatechin gallate (EGCG)|800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months
41027130|NCT04177693|DRUG|Clomiphene Citrate|100 mg for 5 days
41027131|NCT04177693|DRUG|Letrozole|5 mg for 5 days
41027132|NCT01213017|DRUG|certolizumab pegol|400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
41027133|NCT00965523|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m\^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
41027134|NCT00647920|BIOLOGICAL|adalimumab|40 mg adalimumab sc, every other week
41027135|NCT00647920|BIOLOGICAL|placebo|placebo sc, every other week
41027136|NCT02800707|OTHER|Sucralose|Sweetner
41027137|NCT02800707|OTHER|Stevia|Sweetner
41500666|NCT06376851|DIAGNOSTIC_TEST|AI-enabled quantitative coronary plaque analysis (AI-QCPA)|The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.
41500667|NCT03048552|BEHAVIORAL|Family CONNECT|Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
40843980|NCT06342596|DRUG|LY3473329|Administered orally
41500668|NCT06336395|DRUG|Prednisolone|Oral
41161184|NCT01620398|BEHAVIORAL|Control diet|Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
41500669|NCT06336395|DRUG|Dexamethasone|Oral
40843981|NCT02886871|BEHAVIORAL|Step Goal Delivery by Smartphone|
40843982|NCT02661672|DEVICE|Apollo Device|The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.
40843983|NCT02661672|DEVICE|Artemis Device|The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
40843984|NCT01894438|BEHAVIORAL|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
40843985|NCT01894438|BEHAVIORAL|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
40843986|NCT00610389|BIOLOGICAL|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
41500670|NCT06336395|DRUG|Vincristine|Intravenous
41500671|NCT06336395|DRUG|Methotrexate|Oral/ intrathecal/intravenous/subcutaneous
41500672|NCT06336395|DRUG|L-Asparaginase|Intramuscular
41500673|NCT06336395|DRUG|Pegylated asparaginase|Intravenous
41500674|NCT06336395|DRUG|Erwinase|Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)
41500675|NCT06336395|DRUG|Dasatinib|Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
41500676|NCT06336395|DRUG|Imatinib|Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
41500677|NCT06336395|DRUG|Cyclophosphamide|Intravenous
41500678|NCT06336395|DRUG|Cytarabine|Subcutaneous/ Intravenous
41500679|NCT06336395|DRUG|Mercaptopurine|Oral
40843987|NCT02505360|OTHER|Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3|
40843988|NCT03419065|BEHAVIORAL|Relaxation Intervention|Relaxing Music combined with Progressive Muscle relaxation and guided imagery
40843989|NCT03870412|DRUG|PEG-rhG-CSF|The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
40843990|NCT01417364|DRUG|Testosterone enanthate|100 mg. IM weekly throughout study
40843991|NCT01417364|DRUG|Testosterone enanthate|100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
40843992|NCT01417364|DRUG|Placebo|Injected IM weekly throughout study
41364827|NCT06062394|BEHAVIORAL|Penn Med Healthy Heart Program|Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.
41500680|NCT06336395|DRUG|Thioguanine|Oral
40843993|NCT01120990|OTHER|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
41027138|NCT05387291|BEHAVIORAL|Intervention group|The intervention group will undergo an education program related to the circumcision process for the child's relatives/guardians.
40843994|NCT05808010|BIOLOGICAL|Mononuclear cells|2 times gastric submucosal injection of mononuclear cells (10\^8) at 1 month interval
41027139|NCT05387291|BEHAVIORAL|Control group|The control group will receive the usual intervention of the center.
41027140|NCT00057915|BIOLOGICAL|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
41027141|NCT01813240|DRUG|Minocycline|
41027142|NCT01813240|DRUG|placebo|
40843995|NCT05808010|DRUG|Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|Orally delivered tablets for 7 months. Take it according to the instructions.
40843996|NCT00003691|BIOLOGICAL|filgrastim|
40843997|NCT00003691|DRUG|cisplatin|
40843998|NCT00003691|DRUG|doxorubicin hydrochloride|
40843999|NCT00003691|DRUG|paclitaxel|
40844000|NCT06202079|DRUG|GZR4 Injection|GZR4 injection s.c., once-weekly, treat-to-target dose
40844001|NCT06202079|DRUG|Insulin Degludec|Insulin Degludec s.c., once-daily, treat-to-target dose
40844002|NCT03761810|DRUG|S6G5T-3|Once a day topical cream
40844003|NCT03761810|DRUG|S6G5T-8|Once a day topical cream
40844004|NCT02986815|OTHER|[11C]Acetate Brain Imaging|Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the \[11C\]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
41027143|NCT01547650|OTHER|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
41027144|NCT02524704|DEVICE|CT scan|Applied only when part of the patient's standard care
41027145|NCT03866993|BIOLOGICAL|AK105|IV infusion
41027146|NCT03866993|DRUG|Paclitaxel|IV infusion
41027147|NCT03866993|DRUG|Carboplatin|IV infusion
41027148|NCT03866993|DRUG|Placebo|IV infusion
41027149|NCT05218655|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
41027150|NCT06170333|DRUG|8% sulphur and A. vera soap|Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
41027151|NCT05516199|BEHAVIORAL|Antenatal breastmilk expression|Stimulation of the breast by hand/handexpression of breastmilk during pregnancy from week 34
41027152|NCT05516199|BEHAVIORAL|Breastfeeding consultation|60 min standardized breastfeeding consultation with a trained midwife, with focus on practical breastfeeding skills
41027153|NCT03174886|DRUG|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
41027154|NCT03174886|DRUG|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
41027155|NCT00127608|PROCEDURE|Collection of clinical samples|"The following samples were obtained from each subject:~* Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~* Papule swabs (PS) from four papules~* Crusts from two lesions~* One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique."
41027156|NCT04307212|OTHER|50% heart rate reserve (HRR) low intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)
41027157|NCT04307212|OTHER|75% HRR moderate intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)
41027158|NCT04307212|OTHER|Control no exercise|Trained and untrained participants will have a no exercise control day
41027159|NCT04923386|OTHER|None (not interventional)|This is not an intervention
41027160|NCT00877448|BIOLOGICAL|Adjuvanted Multimeric-001 250 Mcg|
41027161|NCT00877448|BIOLOGICAL|Multimeric-001 250 Mcg|
41027162|NCT00877448|BIOLOGICAL|Phosphate Buffered saline|
41027163|NCT00877448|BIOLOGICAL|Adjuvanted PBS|
40844005|NCT06531031|DIAGNOSTIC_TEST|InfectID-BSI (Bloodstream Infection) qPCR Assay|"InfectID-BSI technology targets nucleic acid sequences unique to the target analyte. The qPCR raw data collected from InfectID-BSI's 9 assay tubes is analysed by Microbio's InfectID-Client (InfectID-BSI-associated software) and the result is reported as an analyte-detection if the unique target analyte is present or no result if the unique target analyte is absent.~InfectID-BSI is carried out with whole blood from a venous puncture (EDTA). DNA is extracted from a sample of the collected blood using a validated DNA extraction instrument according to the manufacturer's instructions. The extracted DNA is then added to the InfectID-BSI qPCR reagent panel which consists of 9 reaction tubes (6 for bacteria, and 3 for yeast species). The panel is subjected to real-time qPCR using a process of Melt Curve analysis using the Rotor-Gene Q MDx qPCR instrument. The assay report identifies the species present in the sample upon completion. Results are generated within 3 hours."
40844006|NCT00184756|DRUG|somatropin|
40844007|NCT05095168|DRUG|CAN106|CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.
40844008|NCT05095168|DRUG|Placebo|placebo
40844009|NCT04115982|DRUG|Cholecalciferol|One vial every 15 days during 2 months
40844010|NCT04115982|DRUG|Placebos|One vial every 15 days during 2 months
40844011|NCT03160885|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
40844012|NCT03160885|DRUG|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
40844013|NCT00084487|DRUG|becatecarin|Given IV
40844014|NCT05714137|BEHAVIORAL|Evaluation of the Effect of Proximal Massage and Fist Clenching in Reducing the Risk of Phlebitis From Peripheral Venous Catheter|"Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers.~Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of 2 days a day for four days, lasting between 30 seconds - 1 minute."
40844015|NCT02058394|PROCEDURE|Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
40844016|NCT00122655|DRUG|non-nucleoside reverse transcriptase inhibitors|
40844017|NCT00122655|DRUG|nucleoside reverse transcriptase inhibitors|
40844018|NCT00122655|DRUG|protease inhibitors|
40844019|NCT00801021|DRUG|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
40844020|NCT01452503|DEVICE|Path Women's Condom|comparison between 3 types of female condoms
40844021|NCT01452503|DEVICE|FC2 female condom|comparison between 3 types of female condoms
41027164|NCT00877448|BIOLOGICAL|Adjuvanted Multimeric-001 500 Mcg|
41027165|NCT00877448|BIOLOGICAL|Multimeric-001 500 Mcg|
40844022|NCT01452503|DEVICE|Reddy 6 female condom (V-Amour)|comparison between 3 types of female condoms
40844023|NCT05203159|OTHER|Ocean sound|The experimental group will listen to ocean sound, starting at the 1st minute before the ROP examination and ending at the 5th minute after the ROP examination.
40844024|NCT05203159|OTHER|Routine|No sound will be played before, during and after the ROP examination.
40844025|NCT00784537|DRUG|ABVD|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm A (Observation)"
40844026|NCT00784537|DRUG|ABVD and Radiotherapy|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk)."
41027166|NCT00877448|BIOLOGICAL|Multimeric-001 125 Mcg|
40844027|NCT05500430|DEVICE|Air abrasion sandblasting aluminum oxide particles (Al2O3) AquaCare single (Velopex, Medivance Instruments Ltd., London, UK)|Air abrasion sandblasting aluminum oxide particles (Al2O3) Aqua Care single (London, UK) will be done for the defective area then repairing with bioactive injectable composite, Beautiful Flow Plus X F00 (Shofu, Japan).
40844028|NCT05030480|DIAGNOSTIC_TEST|renal functions|urea, creatinine, GFR
40844029|NCT03665584|DEVICE|FxCO2 Laser|The FxCO2 laser allows a microablative effect in soft tissue.
40844030|NCT03665584|DEVICE|Sham Laser|The Sham laser will be used on the participants who receive the sham treatment.
40844031|NCT02430324|OTHER|posttraumatic cerebral infarction|the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
40844032|NCT04736615|DEVICE|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
40844033|NCT04736615|BEHAVIORAL|Behavior change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
40844034|NCT03048877|DRUG|Apatinib Oral Tablet|Apatinib Mesylate Tablets
40844035|NCT03048877|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
41027167|NCT06182670|DEVICE|Gingival Former Abutment|"GFA is positioned on the sub-crestal implant during the surgery and it is no longer removed. This follows the one abutment one time concept and should prevent bone loss and transmucosal tunnel."
41027168|NCT06182670|PROCEDURE|Subcrestal Implant|Placement of the endosseous sub-crestal dental implant through dedicated drills with 35 Newton insertion torque. It is positioned 2 mm under the crestal bone.
41027169|NCT06182670|DEVICE|Healing Abutment|A healing abutment is positioned on crestal implant during surgery. It is removed at prosthetic finalization.
41027170|NCT06182670|DEVICE|Prosthetic Crown|A zirconia prosthetic crown finalizes the implant rehabilitation.
41500681|NCT06336395|DRUG|Rituximab|Intravenous
40844036|NCT00223704|DRUG|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
40844037|NCT00223704|DRUG|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
40844038|NCT00223704|DRUG|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
40844039|NCT03001687|DIETARY_SUPPLEMENT|enteral supplementation with vitamin D|"Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)"
40844040|NCT03001687|OTHER|blood collection 3mL|all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
40844041|NCT04094675|DRUG|Sirolimus|Use of sirolimus 2 mg by mouth daily for 1 year
41027171|NCT06182670|PROCEDURE|Crestal Implant|Placement of the endosseous crestal implant through dedicated drills with 35 Newton insertion torque at level of the alveolar bone.
41500682|NCT06336395|DRUG|Doxorubicin|Intravenous
41500683|NCT06336395|DRUG|Fludarabine|Intravenous
41500684|NCT03685422|OTHER|Virtual Reality|Before surgery, consented patients are given a Virtual Reality headset with pre-installed relaxation apps to choose a preferred scenario. Patient will be asked on their satisfaction on the VR experience after the intervention. Visual analog scale-anxiety (VAS-A), Spielberger State-Trait Anxiety Inventory (STAI) and EQ-5D-3L questionnaires will be conducted during this period.
41027172|NCT05588518|COMBINATION_PRODUCT|desensitizing agents -10% Propolis|"10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives."
41027173|NCT05900947|OTHER|analysis of carotid atherosclerotic plaque|To assess the presence of air pollutants (benzene, toluene, xylene, and ethylbenzene) or of microplastics within tissues from atherosclerotic plaques by Chromatographic analyses.
41027174|NCT06108063|DRUG|Losartan|12.5 mg oral Losartan taken for 28 days total (4 week postoperative).
41364828|NCT03397472|DEVICE|magnetic field modulation device|use the device with magnetic field modulation to treat insomnia
41364829|NCT03397472|DEVICE|placebo device|use the sleep pillow without magnetic field modulation treatment
41364830|NCT05476965|COMBINATION_PRODUCT|induction therapy; surgery; radiotherapy|Radiotherapy: de-escalation radiotherapy or standard radiotherapy
41364831|NCT04327531|BEHAVIORAL|turkish physicians|turkish physicians, who work active in pandemic hospital.
41364832|NCT06510192|BEHAVIORAL|Yuva Sath|The Yuva Sath Intervention comprises 6 one-on-one sessions with peer counselors who will use an intervention manual. The intervention also includes weekly phone text check-ins by peer counselors
41364833|NCT04253652|OTHER|Fasted breath samples|Will be completed pre and post iron therapy
41364834|NCT04253652|OTHER|IBS-SSS|Will be completed pre and post iron therapy
41364835|NCT04253652|OTHER|Daily diary|Monitoring stool form, consistency and frequency on a daily basis for 4 weeks
41364836|NCT04253652|OTHER|Exploratory research: stool samples|Completed pre and post iron therapy for a subset of patients enrolled in the study
41364837|NCT02978339|DRUG|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
41364838|NCT01512758|DRUG|Alisertib|Alisertib enteric-coated tablets
41364839|NCT05767437|BEHAVIORAL|Abdominal drawing-in maneuver exercise|From the supine position to the hook-lying position (hip joint at 40 degrees and the knee joint at 80 degrees) and pull the navel deeply to the lumbar region through the Stabilizer™ Pressure Biofeedback that stabilize transversus abdominis muscle. At this time, subjects are controlled to maintain contraction while keep breathing lightly, to contract slowly, also to not move the pelvis and chest while exercising
41364840|NCT05767437|BEHAVIORAL|sham|Release pain or upper limb mobilization
41364841|NCT06062810|DRUG|Crizotinib - Usual|"* XALKORI - crizotinib capsule (high dose)~* XALKORI 250 mg taken orally twice daily"
41364842|NCT06062810|DRUG|Crizotinib - Study|"* XALKORI - crizotinib capsule (low dose)~* XALKORI 200 mg taken orally twice daily"
41364843|NCT03154424|PROCEDURE|External fixation in treatment the distal radius fracture|Compare two techniques
41364844|NCT02249858|PROCEDURE|Cranial Vault Hold|
41364845|NCT02249858|PROCEDURE|Cervical HVLA|
41364846|NCT01811004|DEVICE|miraDry|miraDry
41364847|NCT01811004|DEVICE|Nd:YAG Laser|Nd:YAG 1440 nm Laser
41027175|NCT06108063|DRUG|Placebo - Losartan|Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).
41364848|NCT01811004|DEVICE|Botox®|Botox®
41364849|NCT00052403|DRUG|monoclonal antibody anti-anb3 integrin|
41364850|NCT00052403|PROCEDURE|anti-cytokine therapy|
41364851|NCT00052403|PROCEDURE|antiangiogenesis therapy|
41364852|NCT00052403|PROCEDURE|antibody therapy|
41364853|NCT00052403|PROCEDURE|biological response modifier therapy|
41364854|NCT00052403|PROCEDURE|growth factor antagonist therapy|
41364855|NCT00052403|PROCEDURE|monoclonal antibody therapy|
41364856|NCT01986179|OTHER|Telephone Interpretation|Professional interpretation provided over the phone by a national network of certified medical interpreters
41364857|NCT01986179|OTHER|Video Interpretation|Professional interpretation provided over video by a national network of certified medical interpreters
41364858|NCT06453421|OTHER|Pulmonary rehabilitation|Enrolled patients are subjected to a personalized respiratory rehabilitation treatment aimed both at weaning from the tracheostomy tube and at functional recovery
41364859|NCT02482727|DEVICE|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
41364860|NCT05482776|OTHER|High intensity functional training|"HIFT is an exercise modality that emphasizes functional movements through exercises that involve a large amount of muscle mass and that can be adapted to the level of physical condition of each subject. Although it has similarities and is compared to HIIT, they are different.~In this discipline, functional exercises with an external load such as squats, pull-ups, or functional exercises with our own weight, are mixed with other aerobics such as running, rowing or cycling. This mix results in a high-intensity training that improves parameters of physical condition in general and performance."
41364861|NCT05482776|OTHER|classic training group|This intervention consists of carrying out their conventional weekly physiotherapy training sessions where strength, coordination and balance are trained.
41364862|NCT04246918|DIETARY_SUPPLEMENT|Branched Chain Amino Acid|Branched chain amino acid is a group of three amino acids known for there role in muscle growth.
41364863|NCT04246918|DIETARY_SUPPLEMENT|Whey Protein concentrate powder|Whey protein will be given to the standard treatment arm including in the same amount of 1.5gm/kg/IBW.
41364864|NCT02502591|DRUG|Pudendal Nerve Block|An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
41364865|NCT01258751|DRUG|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
41027176|NCT06089304|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.
41027177|NCT06167447|OTHER|questionnaire and examination|Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.
41027178|NCT05745857|DRUG|Avastin|Orally administered
41027179|NCT05745857|DRUG|Erbitux|Orally administered
41161185|NCT04986670|BEHAVIORAL|Nutritional Counseling|Medical oncology providers will refer participants to oncology RDs for remotely delivered medical nutrition therapy counseling. For cohort 1, participants will receive nutrition counseling for 8 months. The counseling will be provided on a weekly basis during the first 6 months and every other week during the last 2 months (for cohort 1 only). For cohort 2, participants will receive nutrition counseling for 6 months. The ultimate frequency of nutrition counseling being provided to each participant will also be adjusted according to the participant's preference and needs.
41161186|NCT04986670|OTHER|Medically Tailored Meals (MTMs)|Medically tailored meals will be provided to participants in the intervention group for a total of 24 weeks for both cohorts. During the first 8 weeks of the intervention, 3 meals/day will be provided each week for a total of 168 meals per participant. It will be followed by less frequent meal provision during the subsequent 16 weeks following this schedule: 3 meals/day will be provided every other week for the next 8 weeks (a total of 84 meals per participant); and 3 meals/day will be provided every four weeks during the last 8 weeks (a total of 42 meals per participant). The number of meals provided to each participant may be adjusted according to participant's preference and needs.
41027180|NCT05745857|DEVICE|Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy|Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope
41027181|NCT03706599|BEHAVIORAL|Therapeutic education on fever|Session for therapeutique education on fever
41027182|NCT03706599|BEHAVIORAL|Therapeutic education on household accidents|Session for therapeutic education on household accidents
41027183|NCT06240312|DEVICE|Images of eye at 2 eye pressures|subject images of the eye's optic nerve head are studied
41027184|NCT05237622|DEVICE|High Flow|Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data on lung volume changes will be measured using electrical impedance tomography.
41027185|NCT02806986|BIOLOGICAL|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
41027186|NCT00664612|DEVICE|AirTraq|Laryngoscopy with AirTraq
40844042|NCT06508840|OTHER|Verbal Health Literacy training session|"Five respiratory physiotherapists and half (6/12) weight management programme advisors, will receive a two hour Verbal Health Literacy training session. The training session will focus on three techniques: simple language, 'Teachback' and 'Chunk and check'. They will also receive implementation support from a Health Literacy Officer.~All pulmonary rehab patients will attend programmes run by physiotherapists trained in Verbal Health Literacy techniques.~Weight management programme service users will attend programmes run by trained and untrained staff."
41027187|NCT02826226|DEVICE|multiple-breath-washout test|
41027188|NCT02826226|DRUG|Bronchodilator Agents|
41027189|NCT03221036|DRUG|Vedolizumab IV|Vedolizumab IV infusion
41027190|NCT03221036|DRUG|Placebo|Matching-placebo IV infusion
41027191|NCT01754558|PROCEDURE|Ajust system|The use of Ajust system for stress incontinence
41027192|NCT01754558|PROCEDURE|TVT/TVT-O|sling surgery
41027193|NCT00600600|DRUG|Tigecycline|Tigecycline dosage based on age and clinical status of patient.
41027194|NCT00918294|DEVICE|QuickOpt|The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
41027195|NCT03891524|DRUG|JNJ-70033093 25 mg|Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
41027196|NCT03891524|DRUG|JNJ-70033093 50 mg|Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
41027197|NCT03891524|DRUG|JNJ-70033093 100 mg|Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.
41027198|NCT03891524|DRUG|JNJ-70033093 200 mg|Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
41161187|NCT04986670|BEHAVIORAL|Nutrition Prescription|Oncology providers will advise participants with lung cancer to follow evidence-based nutrition recommendations using a Nutrition Prescription. The Nutrition Prescription aims to enhance providers' role in communicating basic nutrition advice to participants with lung cancer. It contains seven recommendations, adapted from the newly released Cancer Prevention Recommendations by WCRF/AICR with strong evidence-base.
41364866|NCT04160884|PROCEDURE|Indocyanine Green Injection through Peripheral Vein|After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
41027199|NCT03891524|DRUG|Placebo|Participants will receive placebo matching to JNJ-70033093, orally.
41027200|NCT03891524|DRUG|Enoxaparin 40 mg|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
41027201|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - coronal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
41027202|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - caudal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~T1-T4 posteriorly, anode over \~C5-T1 anteriorly
41027203|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - rostral|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~C3-C5 posteriorly, anode over \~C5-T1 anteriorly
41027204|NCT04727866|DEVICE|intermittent theta burst stimulation (iTBS)|3 minutes of iTBS (a form of repetitive TMS) will be delivered during a 5-minute interval of DCS
41027205|NCT04293887|DRUG|Recombinant human interferon α1β|Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
41027206|NCT03283670|DRUG|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
41027207|NCT03283670|DRUG|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
41027208|NCT03283670|DRUG|Placebo Gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
41027209|NCT05831293|BEHAVIORAL|Mindfulness Based Stress Reduction Program|In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
41027210|NCT06535529|DRUG|Acetazolamide|Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics
41027211|NCT06535529|DRUG|Dapagliflozin 10mg|patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics
40844043|NCT06502847|OTHER|Exosome profile study|Neonatal serum and maternal exosome profiles will be studied in all groups.
40844044|NCT02103972|DIETARY_SUPPLEMENT|GM080|
41027212|NCT04847453|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
40844045|NCT02103972|DIETARY_SUPPLEMENT|Maltodextrin|
41027213|NCT04847453|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
41364867|NCT01618929|DRUG|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
40844046|NCT05808517|BEHAVIORAL|Tai Chi|Tai Chi (TC) is a traditional Chinese exercise, also known as a mind-body exercise. It is suitable as an alternative or supplementary form of routine physical exercise for older adults. TC focuses on gentle and rhythmical movements while maintaining a meditative state. Low to moderate activities have benefits to improve sleep disturbances in older adults. In addition, growing evidence widely supports meditation as a potential intervention to improve sleep disturbances through reducing repetitive negative thoughts such as worry and rumination.
40844047|NCT05808517|OTHER|repetitive transcranial magnetic stimulation|The brain stimulation technique repetitive transcranial magnetic stimulation (rTMS) provides the opportunity to non-invasively modulate cortical excitability. In general, low-frequency rTMS (≤ 1 Hz) is thought to inhibit cortical excitability.
40844048|NCT00300352|DRUG|Folic Acid|
40844049|NCT05460156|BEHAVIORAL|Bridges Self-management Support|Self-management support intervention tailored for people with neuromuscular diseases
40844050|NCT00209794|DRUG|Sulfadoxine-Pyrimethamine (Fansidar)|
41027214|NCT04847453|PROCEDURE|Computed Tomography|Undergo CT scan
41364868|NCT00715780|DRUG|soluble human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40844051|NCT00244491|BEHAVIORAL|Care Transitions Intervention|
40844052|NCT06086483|DRUG|Ropivacaine 0.2% Injectable Solution|"20 mL 0.5% ropivacaine was injected into the PENG block~20 mL 0.5% ropivacaine was injected into the Adductor Canal block"
40844053|NCT06086483|DRUG|0.9%sodium chloride|"20 mL 0.9% sodium chloride was injected into the PENG block~20 mL 0.5% sodium chloride was injected into the Adductor Canal block"
40844054|NCT01229449|DRUG|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
40844055|NCT01229449|DRUG|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
40844056|NCT01229449|DRUG|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
41027215|NCT04847453|DRUG|Dexamethasone|Given PO
41027216|NCT04847453|DRUG|Ixazomib Citrate|Given PO
41027217|NCT04847453|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41027218|NCT04847453|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41027219|NCT04847453|PROCEDURE|Transabdominal Ultrasound|Undergo transabdominal ultrasound
41027220|NCT04847453|DRUG|Venetoclax|Given PO
41027221|NCT04847453|PROCEDURE|X-Ray Imaging|Undergo x-ray
41027222|NCT05548790|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S)|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
41027223|NCT05548790|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
41027224|NCT05548790|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
41027225|NCT05548790|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
41364869|NCT00715780|DRUG|biphasic human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
41027226|NCT03588572|DRUG|Venlafaxine hydrochloride capsules|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
41027227|NCT04975568|OTHER|App and face-to-face physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites. During the app used they will have 6 face-to-face sessions in 6 people groups with a physical Therapist in a 3 months period
41027228|NCT04975568|OTHER|App physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites.
41364870|NCT00715780|DRUG|insulin NPH|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
41364871|NCT00715780|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
41364872|NCT00715780|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
41364873|NCT00715780|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40844057|NCT01229449|DRUG|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
41364874|NCT01461018|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
41364875|NCT02135848|DRUG|GSK1278863|GSK1278863
41027229|NCT05505838|DRUG|Patisiran|Patisiran administered by intravenous (IV) infusion
40844058|NCT01229449|DRUG|Placebo|Two placebo tablets, single dose taken orally with 300 ml water
41364876|NCT02135848|DRUG|Placebo|Placebo
41364877|NCT00291109|DRUG|letrozole 2.5 mg|
41364878|NCT02104232|BEHAVIORAL|THPP-I|
41364879|NCT02104232|BEHAVIORAL|EUC|
41364880|NCT02110589|DEVICE|Epidetect|Topically aplied muscle tonicity monitor (EMG recording)
41364881|NCT05824273|BEHAVIORAL|LungTalk|LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool.
41364882|NCT05824273|BEHAVIORAL|Non-tailored intervention - Standard of practice|ACS Lung Screening Informational Video
40844059|NCT05095415|OTHER|Occupational Therapy Pre-operative Consult|Preoperative education will be given by the treating orthopedic surgeon first and will then be followed by a consult with a final semester, occupational therapy student. The pre-operative education will include the importance of attending therapy, what to expect at therapy, typical duration of therapy for their specific diagnosis, and address any questions of ther participant. Participants will be given educational materials and access to education videos to watch if they so choose.
40844060|NCT05095415|OTHER|Typical Pre-Operative Education|Participants will receive all preoperative education from their orthopedic surgeon and will not be spoken to directly about the therapeutic process until their first scheduled therapy appointment.
40844061|NCT03010020|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.
41027230|NCT02846987|DRUG|Abemaciclib|
41027231|NCT03890341|DRUG|Drospirenone/Ethinylestradiol|A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.
41027232|NCT03890341|DRUG|Midazolam|Midazolam 2 mg will be administered orally on Days 1, 13 and 19.
41027233|NCT03890341|DRUG|JNJ-64530440|A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.
40844062|NCT03010020|BEHAVIORAL|Traditional Counseling|GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
41027234|NCT03487835|OTHER|Kinesiotape|
41027235|NCT03487835|OTHER|No application|This group have no application during study time
41027236|NCT00034034|PROCEDURE|Acupuncture|
41027237|NCT04777279|BEHAVIORAL|individual physical exercise group|The participants in physical exercise group will receiving individual physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks.
41027238|NCT04777279|DIETARY_SUPPLEMENT|individual Branched-Chain Amino Acids supplements group|The participants in nutrition supplements group will receiving Branched-Chain Amino Acids 5 g Branched-Chain Amino Acids every day for 12 weeks.
41364883|NCT00672490|DRUG|Quetiapine Fumarate|"Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets"
41364884|NCT00672490|DRUG|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
41364885|NCT01856920|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
41364886|NCT04085120|PROCEDURE|0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
41364887|NCT04085120|PROCEDURE|10% lignocaine injection|Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
41364888|NCT04454021|PROCEDURE|hip arthroscopy|hip arthroscopy was performed when symptoms were not alleviated by nonsurgical treatment
41364889|NCT03104465|BEHAVIORAL|Mindfulness Training|interactive. web-based mindfulness training complemented with mobile application
41364890|NCT00417911|DRUG|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
40844063|NCT03860363|DEVICE|Blood drainage post cardiac surgery|Blood drainage post cardiac surgery with Thoraguard Surgical Drainage System.
40844064|NCT03311347|OTHER|+Gz accelerations and positive pressure breathing|
40844065|NCT03222414|DEVICE|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
40844066|NCT03222414|DEVICE|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
40844067|NCT03222414|OTHER|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
40844068|NCT03594214|DIAGNOSTIC_TEST|serum vitamin d level measured by ELISA kit|serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
41027239|NCT04777279|OTHER|combination of physical exercise and nutrition supplements group|The participants in physical exercise group will receiving physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks and 5 g Branched-Chain Amino Acids every day for 12 weeks.
41027240|NCT01296568|DRUG|LY2603618|Administered intravenously
40844069|NCT01953913|DRUG|Afatinib|Patient will receive afatinib once daily
41027241|NCT01296568|DRUG|Pemetrexed|Administered intravenously
41027242|NCT01296568|DRUG|Gemcitabine|Administered intravenously
41027243|NCT01793792|DEVICE|LVIS™ and LVIS™ Jr|The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
41027244|NCT00004026|DRUG|CT-2584|
41027245|NCT00004026|DRUG|chemotherapy|
41027246|NCT06003595|OTHER|Data collection on patient reported long-term outcome of SSRF hardware removal|One prospective follow-up visit will be performed. On this visit the patient reported long-term outcome will be documented through a health survey.
41027247|NCT02125058|PROCEDURE|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
40844070|NCT06231433|DEVICE|CO2 Vaginal Laser|CO2 Vaginal laser
41027248|NCT02125058|PROCEDURE|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
41161188|NCT04986670|OTHER|Nutrition Assessment|Oncology care providers will assess the nutritional status of patients with lung cancer using PG-SGA Short Form (the Scored Patient-Generated Subjective Global Assessment). PG-SGA is an interdisciplinary patient assessment in oncology and other chronic catabolic conditions. The short form contains four patient generated historical components (weight history, food intake symptoms, and activities and function).
40844071|NCT06386341|PROCEDURE|Maxillomandibular Advancement Surgery|Surgery where the upper and lower jaw are repositioned.
41027249|NCT01977118|DRUG|streptokinase|50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
41027250|NCT01977118|OTHER|Saline irrigation|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
41027251|NCT03650205|DRUG|Ivabradine|Ivabradine capsule
41027252|NCT03650205|DRUG|Placebo|Placebo oral capsule.
41027253|NCT06381479|DIETARY_SUPPLEMENT|probiotics|each capsule contains Lactiplantibacillus plantarum and Lacticaseibacillus paracasei, 2 caps daily use
41027254|NCT06381479|DIETARY_SUPPLEMENT|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
41027255|NCT03510481|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
41027256|NCT03510481|DRUG|Normal Saline|Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
41027257|NCT03510481|DRUG|artemether 20mg/lumefantrine 120mg (AL)|Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
40844072|NCT06297473|BEHAVIORAL|Telephone-/video follow-up|"The yearly routine review of patients takes place by using a telephone or video interview rather than in-person interview in the endocrine outpatient department.~All other assessments, e.g. biochemical, MRI, is conducted as usual."
40844073|NCT06297473|BEHAVIORAL|In-person follow-up|The yearly routine review on patients takes place at the endocrine outpatient department
40844074|NCT05505409|DRUG|Pirfenidone|Drug:pirfenidone CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
41027258|NCT02239523|PROCEDURE|Letter Group|At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.
41027259|NCT02239523|PROCEDURE|Intervention Group|The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
41027260|NCT04897893|OTHER|Eicosapentaenoic acid monoglycerid (MAG-EPA)|MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).
41364891|NCT04855474|DIETARY_SUPPLEMENT|Amino Acid Intake|Participants will consume hourly (8 hours) isoenergetic, isonitrogenous beverages containing one of the three protein intakes (0.2g/kg/d, 1.2 g/kg/d, 2.0g/kg/d) assigned in a randomized order between the three metabolic trials. Drinks will be enriched with stable isotope \[13C\]phenylalanine. The use of stable isotope \[13C\]phenylalanine will allow for the determination of the fate of AA in the body (incorporation into body protein or oxidation) which can be used to determine protein (AA) requirements.
41364892|NCT03606018|DRUG|Insulin Lispro Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
41364893|NCT03606018|DRUG|Humalog® Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
41364894|NCT03264560|BEHAVIORAL|Telepsychiatry|A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
40844075|NCT05505409|DRUG|glucocorticoid and immunosuppressant|Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
41027261|NCT00187798|DRUG|Metformin HCl|Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
41027262|NCT06182865|DRUG|Ga-68 Dolacga Injection|Ga-68 Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
41364895|NCT06157411|BEHAVIORAL|Mindful Eating Intervention (AC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Mindful eating program: group sessions one evening a week (8x2h) and home exercises (30 min/day).~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1~Focus groups: Each participant will be asked to describe the program and talk about their perceptions and feelings, as well as the potential changes in behavior they have observed in their daily life."
41027263|NCT04442516|OTHER|Questionnaire, sampling of blood, urine and saliva|We are following patients who are receiving Cisplatin as part of their cancer therapy.
41027264|NCT06128616|DEVICE|ESWT|Extracorporeal Shock Wave Therapy
41027265|NCT06128616|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
41027266|NCT06128616|OTHER|Serial Casting|Serial Casting
41027267|NCT06128616|BEHAVIORAL|Physical Therapy|Physical Therapy
41364896|NCT06157411|BEHAVIORAL|Conventional Dietetic Intervention (DC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1"
41364897|NCT00408408|BIOLOGICAL|bevacizumab|15 mg/kg IV
40844076|NCT01571856|DRUG|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
41027268|NCT06128616|BEHAVIORAL|Occupational Therapy|Occupational Therapy
41027269|NCT00172510|PROCEDURE|blood drawing|
41027270|NCT05746039|DRUG|Semaglutide Pen Injector|Once weekly subcutaneous injection
41027271|NCT02889081|OTHER|maternal biological folate level|supplementation status and serum level
41027272|NCT02889081|OTHER|maternal biological Vitamin D level|supplementation status and serum level
41027273|NCT02063646|DIETARY_SUPPLEMENT|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
41364898|NCT00408408|DRUG|capecitabine|825 mg/m2 orally
41364899|NCT00408408|DRUG|cyclophosphamide|600 mg/m2 IV
41364900|NCT00408408|DRUG|docetaxel|100 mg/m2 IV
41364901|NCT00408408|DRUG|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
40844077|NCT01571856|OTHER|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
40844078|NCT00847015|DRUG|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
40844079|NCT00847015|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m\^2
41027274|NCT02063646|DIETARY_SUPPLEMENT|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
41027275|NCT00511862|DEVICE|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
41027276|NCT06573333|PROCEDURE|Umblical Cord Clamping|Umbilical Cord will be clamped using a plastic clamp at the noted time after delivery of the neonate
41027277|NCT05346510|PROCEDURE|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
41027278|NCT04117828|DIETARY_SUPPLEMENT|Dates|Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
40844080|NCT00847015|DRUG|cisplatin|cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.
41027279|NCT02270346|DEVICE|Inspiratory muscle training|"Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
41027280|NCT02270346|DEVICE|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
41027281|NCT02092948|RADIATION|[124I] PSCA-Minibody PET/CT imaging of the whole body|Whole body Imaging
41027282|NCT00985218|DEVICE|SMART System|microfluidic embryo culture system
41027283|NCT00985218|DEVICE|Culture dish|Standard IVF culture dish
41364902|NCT00408408|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV
41364903|NCT01215045|DEVICE|AcrySof ReSTOR Aspheric +4|Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
41364904|NCT03007472|DEVICE|CI532|Cochlear implant
41364905|NCT03007472|DEVICE|Nucleus 7|Sound processor
41364906|NCT00517166|DEVICE|CAT (Combat Arms Tourniquet)|device
41027284|NCT02995668|OTHER|Strength-Function|Preoperative functional and strength capabilities training.
41364907|NCT02332616|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
41161189|NCT04986670|BEHAVIORAL|Nutrition Toolkit|Patients will receive a printed copy of a Nutrition Toolkit from providers. Evidence-based nutrition recommendations have been compiled for cancer survivors from 4 sources into a Nutrition Toolkit. The sources include: (1) AmericanCancer Society (ACS) Nutrition and Physical Activity Guidelines for Cancer Survivors; (2)World Cancer Research Fund / American Institute for Cancer Research (WFRF/AICR) Cancer Nutrition Guide; (3) National Cancer Institute (NCI) Eating Hints; and (4) National Comprehensive Cancer Network (NCCN) Guidelines for Cancer Survivors. The Nutrition Toolkit outlines topics about the impact of cancer treatment on dietary intake patterns and quality, strategies to manage treatment-related eating issues, maintaining a healthy weight post treatment, and evidence-based recommendations and practical. Nutrition Toolkit strategies for improving diet quality and maintaining an optimal weight for cancer survivors.
41161190|NCT04986670|BEHAVIORAL|Monthly Emails|Monthly emails will be sent to participants to encourage the use of the toolkit with healthy recipes and general nutrition information.
41364908|NCT02332616|DRUG|Isotonic Sodium Chloride|Placebo
40844081|NCT01895946|DRUG|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
40844082|NCT01895946|DRUG|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
41027285|NCT02995668|OTHER|Balance-Proprioception|Preoperative proprioceptive and balance capabilities training
41364909|NCT06409182|DEVICE|Hemopill|HemoPill® acute capsule (Ovesco Endoscopy, Tuebingen, Germany) is a swallowable, wireless, sensor capsule designed for in vivo detection of liquid blood or hematin. The capsule has integrated optical microsensor for blood detection, by transmitting red and violet light via LEDs. It allows the detection of blood by photometric measuring method, in small volumes or in unprepared digestive tract. The dimensions of the capsules are 7.0mm x 26.3mm. The maximal examination time is 9 hours. The HemoPill® receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute capsule. It allows a real-time, wireless, telemetric data transmission. Once activated, the HemoPill® acute capsule can be swallowed by patients with real-time measurement of HemoPill® Indicator (HI). An HI value in the red range suggests a positive finding - liquid blood or hematin has been detected.
41364910|NCT05706831|OTHER|Combinatory effect of music stimulation and neurostimulation|music
41364911|NCT03805685|PROCEDURE|Non-Cardiac Surgery|Non-cardiac surgery
41364912|NCT03134001|DEVICE|patients receiving oral analgesics via the PCoA™ Acute|PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
41364913|NCT04390724|OTHER|Y90 radioembolization|Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant
41027286|NCT06223945|DIAGNOSTIC_TEST|Prevention algorithm|Development of an algorithm for the prevention of thrombohemorrhagic complications
41364914|NCT04435093|OTHER|MFM-Play|Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
41364915|NCT02666079|DEVICE|LightPath® Imaging System.|Intra-operative use of the LightPath® Imaging System.
41027287|NCT05176327|DEVICE|Exoskeleton training with Ekso NR|Walking exercise with Ekso NR
41027288|NCT00765908|DEVICE|Angioplasty balloon|90 second balloon inflation x 2
41027289|NCT00765908|DEVICE|Angioplasty balloon|30 seconds or less balloon inflations x 2
41027290|NCT00614211|PROCEDURE|Total Abdominal Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
41161191|NCT02373605|OTHER|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
41161192|NCT02373605|OTHER|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
41027291|NCT00614211|PROCEDURE|Total Laparoscopic or Robotic Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
41161193|NCT04241783|OTHER|descriptive|correlation
41364916|NCT03429569|DRUG|Cross linking|Accelerated cross-linking procedure: (Total duration: 40 minutes)
41027292|NCT02473952|DRUG|IGIV-C|IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
41027293|NCT02473952|DRUG|Placebo|
41027294|NCT02680600|DRUG|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
41161194|NCT00352053|DRUG|Tenofovir DF|Tenofovir DF 300-mg tablet, administered orally, daily + OBR
41364917|NCT01708473|DRUG|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
41364918|NCT01708473|DRUG|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
41364919|NCT01708473|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
41364920|NCT00033514|BIOLOGICAL|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
41027295|NCT02680600|OTHER|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
41027296|NCT02680600|OTHER|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
41161195|NCT00352053|DRUG|Placebo|Tenofovir DF Placebo administered orally, daily + OBR
41161196|NCT02923817|BIOLOGICAL|Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection|
41161197|NCT00452985|DRUG|Docetaxel|60-75 mg/m²
41161198|NCT00452985|DRUG|Carboplatin|AUC 5
41161199|NCT02895698|DEVICE|Dry cupping|Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
41161200|NCT02895698|OTHER|Stretching exercises|"* The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~* Standing self-stretching of the calf muscles.~* Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~* All stretches were done six times and the duration of each stretch is 30 seconds."
41161201|NCT04323332|DRUG|Traditional Chinese Medicine Prescription|Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
41364921|NCT00033514|DRUG|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
41364922|NCT05638594|DRUG|Pyrotinib|320mg, qd
41161202|NCT00003212|DRUG|doxorubicin hydrochloride|
41161203|NCT00003212|DRUG|ifosfamide|
41364923|NCT05638594|DRUG|Trastuzumab|8 mg/kg first dose, then 6 mg/kg，q3w
41364924|NCT05638594|DRUG|Dalpiciclib|125mg , qd，d1-21, q4w
41364925|NCT05638594|DRUG|Letrozole|2.5mg，qd
41364926|NCT05638594|DRUG|Pertuzumab|840 mg first dose, then 420 mg, q3w
41364927|NCT05638594|DRUG|Docetaxel|75 mg/m2, q3w
41364928|NCT05638594|DRUG|Carboplatin|AUC 6, q3w
41364929|NCT05638594|DRUG|Gonadotropin-releasing hormone agonist|Every 4 weeks for 5 cycles, premenopausal patients only
41364930|NCT02834351|OTHER|Muscle Biopsy|"A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups."
41364931|NCT01556503|DEVICE|VivaScope System|VivaScope System, Model#s 1500 and 2500
40844083|NCT03855683|BEHAVIORAL|Unified Protocol for The Treatment of Emotional Disorders|Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
40844084|NCT04147546|DIAGNOSTIC_TEST|Additional screening using ultra sensitive RDTs|At each ANC visit, study nurses will perform an HS-RDT for participants in the intervention arm
41027297|NCT02680600|OTHER|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R\&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
41027298|NCT02680600|OTHER|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
41027299|NCT02680600|OTHER|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
41027300|NCT02680600|OTHER|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
41027301|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
41027302|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
41027303|NCT01917045|DRUG|Morphine|morphine 0. 5mg/ml
41027304|NCT02999308|OTHER|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
41027305|NCT01420406|OTHER|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
41027306|NCT01420406|OTHER|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
41364932|NCT06049511|BEHAVIORAL|oral self care protocol|An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education. Interventions were made for 21 days from the beginning of chemotherapy treatment.
41364933|NCT06049511|BEHAVIORAL|standard care|the patients received standard nursing care provided at the clinic to prevent oral mucositis.
41364934|NCT01219959|DRUG|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
41364935|NCT01219959|DRUG|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
40844085|NCT04147546|DRUG|Dihydroartemisinin-piperaquin|All pregnant women with a positive HS-RDT will be treated with a full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home
40844086|NCT04147546|OTHER|Reminders|Before each scheduled ANC visit, reminders using SMS or phone call will be used. This is order to increase ANC attendance
40844087|NCT02880917|DEVICE|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
40844088|NCT02880917|DEVICE|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
40844089|NCT02880917|OTHER|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
40844090|NCT00435084|DRUG|APO866|
41161204|NCT05182970|DRUG|Metformin|Individualised target dose of 2000 mg daily depending on tolerability.
41161205|NCT01336387|DRUG|retinoid 9cUAB30|Given PO
41161206|NCT01336387|OTHER|placebo|Given PO
41161207|NCT01336387|OTHER|pharmacological study|Correlative studies
41161208|NCT01336387|OTHER|laboratory biomarker analysis|Correlative studies
40844091|NCT04755452|PROCEDURE|Low intra-abdominal pressure|7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
40844092|NCT04755452|PROCEDURE|High (standard) intra-abdominal pressure|12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
40844093|NCT00199823|GENETIC|Intracoronary aotologous stem cell transplantation|
41161209|NCT01336387|OTHER|cancer prevention|Disease prevention
41161210|NCT06280118|OTHER|Fatigue|Fatigue was created in the participants by rehearsing the process of removing and transporting earthquake victims from the rubble through the prepared track.
41364936|NCT03570658|DRUG|RO7049389|RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
41364937|NCT03570658|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to RO7049389.
40844094|NCT01055678|DRUG|EF5|An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
40844095|NCT01055678|PROCEDURE|Partial or Total Mastectomy|A small tissue sample will be removed from the excised tissue and will be stored for later analysis.
40844096|NCT03695822|DRUG|Mirabegron 25mg|The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
40844097|NCT05896813|DRUG|CMOP+Chidamide|Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
41364938|NCT06413030|DIAGNOSTIC_TEST|10 Meter Walk Test|Gait Speed Test
41364939|NCT02412241|OTHER|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
41364940|NCT02412241|PROCEDURE|Technical measure|Undergo standard CT scan
41364941|NCT02412241|PROCEDURE|Technical measure|Undergo standard ultrasound
40844098|NCT00934674|DRUG|SKI-606 (Bosutinib)|"Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal"
40844099|NCT01447160|DRUG|Cortisone|intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
41027307|NCT01420406|OTHER|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
41027308|NCT01420406|OTHER|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
41027309|NCT01891825|PROCEDURE|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
41364942|NCT03207516|DIETARY_SUPPLEMENT|Sourdough --> Brewer's Yeast|Impact of bakery products with sourdough or brewer's yeast on digestive function
41364943|NCT03207516|DIETARY_SUPPLEMENT|Brewer's Yeast --> Sourdough|Impact of bakery products with sourdough or brewer's yeast on digestive function
40844100|NCT00857974|OTHER|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
40844101|NCT03464149|DIAGNOSTIC_TEST|One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)|Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)
40844102|NCT03574402|DRUG|Avitinib Maleate|300mg orally (PO) twice daily (BID) on day 1-28.
40844103|NCT03574402|DRUG|Afatinib|40mg orally once a day, 28 days as one cycle.
40844104|NCT03574402|DRUG|Crizotinib|250mg PO QD on days 1-28. 28 days as one cycle.
40844105|NCT03574402|DRUG|X-396|225mg PO QD on days 1-28. 28 days as one cycle.
40844106|NCT03574402|DRUG|Chidamide|30mg orally twice weekly, 28 days as one cycle.
40844107|NCT03574402|DRUG|Pyrotinib Maleate|400mg PO QD on days 1-28. 28 days as one cycle.
40844108|NCT03574402|DRUG|AZD3759|200mg PO BID on days 1-28. 28 days as one cycle.
40844109|NCT03574402|DRUG|Pirotinib|60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.
40844110|NCT03574402|DRUG|Nimotuzumab|400mg, iv gtt. on day 1,8,15. 21 days as one cycle.
40844111|NCT03574402|DRUG|Pemetrexed|500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.
41161211|NCT00927550|DRUG|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
40844112|NCT03574402|DRUG|Cisplatin|75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.
40844113|NCT03574402|DRUG|Sintilimab|200mg iv gtt. Q3W on day1. 21 days as one cycle.
41161212|NCT00927550|DRUG|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
41500685|NCT06633237|OTHER|Core training program in female amateur basketball players|The intervention consists of a core training program specifically designed to improve core and trunk stability in female amateur basketball players. The program is integrated into the warm-up routine and is applied twice a week over an 8-week period. Each session lasts approximately 12-15 minutes and includes five exercises. The training program is divided into three phases of progression, gradually increasing the difficulty of the exercises over the 8 weeks by incorporating more dynamic and functional movements.
40844114|NCT03574402|DRUG|Gemcitabine|1g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
40844115|NCT03574402|DRUG|Gemcitabine|1.25g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
40844116|NCT03574402|DRUG|Carboplatin|AUC5 iv gtt. Q3W on day1. 21 days as one cycle.
40844117|NCT00093821|DRUG|tanespimycin|Given IV
40844118|NCT00093821|OTHER|pharmacological study|Correlative studies
40844119|NCT00093821|OTHER|laboratory biomarker analysis|Correlative studies
40844120|NCT02501200|DRUG|CKD-391|Investigational product is prescribed to all of randomized subjects for two times.
40844121|NCT02501200|DRUG|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
40844122|NCT02175368|DEVICE|Adhese One F Upgrade|
40844123|NCT06275308|OTHER|Ventilation manipulation|Effects of ventilation manipulation to achieve desired levels of end tidal carbon dioxide
41161213|NCT01654835|OTHER|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP \<80 mmHg)will trigger an page to be sent to all anesthesia providers in \<1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
41161214|NCT01654835|OTHER|standard of care|A Low Blood Pressure condition as specified (SAP \<80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
41161215|NCT00231517|DRUG|topical opiod|
41161216|NCT00231517|DRUG|morphine sulphate in intrasite gel|
41500686|NCT02875652|BIOLOGICAL|Blood sampling|3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
41500687|NCT03694327|DEVICE|CT-101-M|Mobile Application
41500688|NCT03694327|DEVICE|QuitGuide|Mobile Application
40844124|NCT06583733|BEHAVIORAL|KOKU Bladder|"In this intervention the participants will receive treatment with the KOKU app ( based digital health program with behavior change techniques to improve bladder health ) for 12 weeks.~After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires."
40844125|NCT06583733|BEHAVIORAL|recommendations|"In this intervention the participants will receive recommendations for self- managing urinary symptoms, which they must follow for 12 weeks.~After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires."
40844126|NCT06128122|PROCEDURE|Intrarticular and subcutaneous dextrose injection with timed measurement of dextrose levels|"Step one: 30 mL of 12.5%/0.1% lidocaine will be injected into the knee using an inferomedial approach. Using ultrasound guidance, a 20-gauge 2-inch I.V. catheter will be placed in the suprapatellar pouch, by which samples of synovial fluid from the pouch will be withdrawn and analyzed for glucose level.~Step two: 3 mL of D5W will be injected into a marked spot on the back of the upper arm. A sensor/transmitter (Dexcom G7 Dexcom) is placed at the site of injection. The sensor/transmitter will begin providing dextrose levels at 5 minute intervals beginning one-half hour after placement of the sensor/transmitter, transmitted to a paired smart phone."
40844127|NCT03496766|DRUG|Tipifarnib|Tipifarnib 600 mg will be administered until progression
40844128|NCT04499859|DRUG|Ezetimibe 10mg + Rosuvastatin 5mg|Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin
40844129|NCT04499859|DRUG|Rosuvastatin 20mg|20mg of Rosuvastatin as a standard treatment for AMI patients
40844130|NCT00221494|DRUG|citalopram + tiodothyronine, or + pindolol, or + placebo|
40844131|NCT03366467|OTHER|SADE|The SADE: the sensory stimuli addressed are visual and auditory, as follows: (i) Visual sensation. All ceiling fluorescent lighting are removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, in the child's visual field. (ii) Auditory stimuli include rhythmic music, which was heard via loudspeakers.
40844132|NCT03366467|OTHER|RDE|The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.
40844133|NCT03346967|COMBINATION_PRODUCT|adipose-derived mesenchymal stem cells|Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure
40844134|NCT01571453|DRUG|Vortioxetine (Lu AA21004)|10 mg/day
40844135|NCT01571453|DRUG|Venlafaxine extended release|150 mg/day
40844136|NCT01654809|BIOLOGICAL|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
40844137|NCT01654809|BIOLOGICAL|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
40844138|NCT01654809|BIOLOGICAL|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
40844139|NCT01072253|PROCEDURE|eye amputation|
40844140|NCT04617015|DRUG|Ipratropium Bromide|All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.
40844141|NCT05412628|DIAGNOSTIC_TEST|Oral swab test|In this study, we will perform tissue biopsy at esophageal tumor site in esophageal cancer patients and perform random biopsy at middle esophagus in patients without esophageal cancer. Besides, we will take oral swab in all participants.
40844142|NCT03964792|GENETIC|DREPAGLOBE drug product|Each patient will receive a single IV infusion of DREPAGLOBE drug product
40844143|NCT03992092|DEVICE|C-MAC VS|C-MAC Video Stylet
40844144|NCT03992092|DEVICE|Flexible Bronchoscopy|Flexible Bronchoscopy
40844145|NCT03342092|OTHER|Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation + anthropometric measures and data collected from the personal interview with school nurse
40844146|NCT02706587|DEVICE|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
40844147|NCT02706587|DEVICE|Sham control|No electrostimulation
40844148|NCT00020878|DRUG|celecoxib|Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
40844149|NCT03794674|OTHER|No intervention.|No intervention, since this is a validation study
40844150|NCT02264548|RADIATION|Radio-Ablation|Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
40844151|NCT01936415|DEVICE|Vanguard|A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
40844152|NCT01936415|DEVICE|Regenerex|
40844153|NCT00805064|DRUG|triamcinolone and bevacizumab|
40844154|NCT05702086|OTHER|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts) is a psychoeducational serious game (an e-intervention that utilizes gaming for serious purposes) that teaches established cognitive behavioural therapy strategies and techniques across seven levels or modules. The game is designed to address depressive symptoms in youth by helping them cope with negative thoughts and feelings, represented in the game as GNATs-Gloomy Negative Automatic Thoughts. SPARX was originally designed and developed at the University of Auckland with the specific needs of certain underserved groups of youth in mind, including Māori rangatahi, the Indigenous young people of Aotearoa, New Zealand.
40844155|NCT05106010|OTHER|Balance Flow Yoga|The yoga class is based on hatha yoga which includes physical poses and mindful movement integrated with breath. Conducted in a local yoga studio for 75 minutes duration, twice per week and also open to the public. The specific yoga techniques reflect the objectives of our study and focus on addressing some of the physical, mental and emotional factors that potentially contribute to falls such as balance, balance confidence, strength, coordination, proprioception, core training strategies, and breathing techniques integrated with mindfulness practices and yoga philosophy. The practices will incorporate a combination of seated, kneeling, standing and lying postures and transitions between positions with individual modifications provided on an as-needed basis. The yoga classes will be co-designed by registered yoga teachers and taught by two trained and experienced and yoga teachers blinded to study testing measures.
40844156|NCT03996317|OTHER|Room air|Avoidance of hyperoxygenation
40844157|NCT05240521|OTHER|ARM A|30 IBS-C patients will receive GA-AT0119 for 28 days, followed by a washout period of 28 days and Placebo for another 28 days
40844158|NCT05240521|OTHER|ARM B|30 IBS-C patients will receive Placebo for 28 days, followed by a washout period of 28 days and GA-AT0119 for another 28 days
40844159|NCT03922087|OTHER|No intervention|No intervention
40844160|NCT00504894|DRUG|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
40844161|NCT00504894|DRUG|Propofol|A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
41161217|NCT06232317|OTHER|Virtual Reality Software|The ReCognitionVR virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
40844162|NCT00504894|DRUG|Thiopental|A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
40844163|NCT05236244|OTHER|İntervention group|Diaphragmatic Breathing Exercises
40844164|NCT04917913|DIETARY_SUPPLEMENT|Digestive enzyme blend|Subjects will take 3 capsules (one per meal) of digestive enzymes (50mg) daily for 30 days.
40844165|NCT04917913|DIETARY_SUPPLEMENT|Placebo|Subjects will take 3 capsules (one per meal) of a placebo (50mg) daily for 30 days.
40844166|NCT00592332|DRUG|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
40844167|NCT00592332|OTHER|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
40844168|NCT00358839|DRUG|CGRP|
40844169|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
40844170|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
40844171|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
40844172|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
40844173|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
40844174|NCT06194344|BEHAVIORAL|Individualized imagery|Study personnel will assist participants to create scripts that foster relaxation and safety. Objects, places, and/or scenarios that foster participant relaxation, sense of safety, and/or positive emotions will be identified. Participants will write or type the generated scenario using highly detailed elements (e.g., including visual, olfactory, auditory, tactile, and gustatory sensations, as applicable) associated with the imagery. Study personnel will assist with recording the imagery scripts; audio files will be recorded using an audio recording application. The imagery scripts will be played at night via Bluetooth earbuds connected to the Muse app and script recording while laying down to sleep. The imagery rehearsal prompts will play for approximately 15 minutes, based on 10-20-minute recommendations across imagery rehearsal therapy (IRT) studies
40844175|NCT06194344|BEHAVIORAL|Control|Participants will wear the earbuds, with use of Muse S headband to collect outcome data without the individualized imagery scripts.
40844176|NCT02905006|DRUG|Bimekizumab|Subjects will be randomized to receive a combination of injections of Bimekizumab.
41161218|NCT06232317|OTHER|Traditional Orientation Methods|Standard-of-care methods to orient patients after surgery
41161219|NCT01489462|BEHAVIORAL|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
41161220|NCT01489462|BEHAVIORAL|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
41161221|NCT01489462|BEHAVIORAL|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
41364944|NCT04191590|PROCEDURE|nasal brushing and bacteriological sample|A nasal brushing as well as a bacteriological sample using a swab under general anesthesia at the beginning of the endonasal surgery procedure
40844177|NCT02905006|OTHER|Placebo|Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
40844178|NCT05485324|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
41364945|NCT04130204|DRUG|DYV700|Proprietary transdermal delivery platform
41364946|NCT04130204|DRUG|Placebo|Vehicle transdermal delivery platform
41364947|NCT04130204|DRUG|Colchicine 0.6 mg|Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
41500689|NCT01329783|OTHER|maraviroc|No intervention is distributed during this trial.
40844179|NCT03628274|DEVICE|Magnetic Resonance Imaging (MRI) 7 Tesla|An MRI performed as part of the project
40844180|NCT03628274|DEVICE|Magnetic Resonance Imaging (MRI) 1,5 Tesla|An MRI performed as part of the care
40844181|NCT01742689|DRUG|Desmopressin intranasal spray|10 microgram per puff, 40 microgram is Descript
40844182|NCT01742689|DRUG|Placebo intranasal spray|Saline spray identical to desmopressin, administered as 4 sprays
40844183|NCT01742689|DRUG|Indomethacin suppository|Indomethacin suppository 100 milligram single dose
40844184|NCT01067365|DRUG|Androxal|12.5 mg once daily
40844185|NCT01067365|DRUG|Androxal|25 mg once daily
40844186|NCT02238834|DRUG|FP-025|Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
40844187|NCT02238834|DRUG|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
40844188|NCT02238834|DRUG|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
40844189|NCT02238834|DRUG|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
40844190|NCT02336542|BIOLOGICAL|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
41027310|NCT01891825|PROCEDURE|Percutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
41027311|NCT01921348|DEVICE|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
41027312|NCT01921348|DEVICE|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
41027313|NCT04245735|DIAGNOSTIC_TEST|perfusion index|To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation.
40844191|NCT02336542|BIOLOGICAL|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
40844192|NCT02336542|BIOLOGICAL|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
41027314|NCT05991141|OTHER|Apnea|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The experimental group (EG) added throughout the 6 minutes intervention the following breathing pattern cyclically: 5 seconds breathing normally followed by 10 seconds of low volume apnoea, performing a total of 24 cycles of normal breathing continued by apnoea.
41027315|NCT05991141|OTHER|Control Intervention|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The Control group (CG) performed this protocol breathing normally.
41027316|NCT04712318|PROCEDURE|Relex Smile|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was min -0.75D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(ViscotMedster).
41364948|NCT02115802|DEVICE|Activa PC+S|Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
41500690|NCT04017650|BIOLOGICAL|Cetuximab|Given IV
41500691|NCT04017650|DRUG|Encorafenib|Given PO
41500692|NCT04017650|BIOLOGICAL|Nivolumab|Given IV
41500693|NCT03844386|BIOLOGICAL|MVA.tHIVconsv3|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
41500694|NCT03844386|BIOLOGICAL|MVA.tHIVconsv4|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
40844193|NCT02336542|BIOLOGICAL|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
40844194|NCT03664583|BEHAVIORAL|ACHRU-Community Partnership Program (CPP)|The intervention is a 6-month community navigation and self-management program for patients with diabetes and at least one additional chronic condition, and their caregivers, to improve health outcomes. The intervention will be provided by an interprofessional team of providers and consists of six core components.
40844195|NCT04675996|DRUG|INT-1B3|60-min i.v. infusions twice per week in 21-day cycles
40844196|NCT01633177|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
40844197|NCT01633177|DRUG|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
40844198|NCT01633177|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
40844199|NCT01633177|DRUG|Fish oil placebo|Fish oil placebo
40844200|NCT00896441|DRUG|Citalopram|"Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI."
40844201|NCT01731093|DRUG|AT-001|
40844202|NCT01731093|DRUG|Placebo|
40844203|NCT03137498|DRUG|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose
41027317|NCT04712318|PROCEDURE|Relex smile with fresh corneal lenticule implantation|"VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule.~The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision.~In pseudophakic patients with hyperopic astigmatism residual refraction, corneal topography-guided intrastromal fresh lenticular implantation should be performed according to the low K values."
41027318|NCT01490346|DRUG|Initiation of anti-retroviral therapy|Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
41027319|NCT00983229|PROCEDURE|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
41027320|NCT04445584|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI
41027321|NCT01313559|DRUG|Pasireotide|Given IM
41027322|NCT01313559|DRUG|Everolimus|Given PO
40844204|NCT03137498|DRUG|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection x 1dose
41027323|NCT01313559|OTHER|Laboratory biomarker analysis|Correlative studies
41027324|NCT00444158|DRUG|MOA-728|
41364949|NCT05608811|BEHAVIORAL|Social Skills Training|"Intervention:~The training is planned as 8 sessions. During this 4-week period, 2 sessions were held each week. The training, which will be held via Zoom, was carried out as a group or individual application. The first session was planned as four basic skills, the second session communication skills, the third session assertiveness skills, the fourth session conflict management skills, the fifth session social life skills, the sixth session friendship flirting skills, the seventh session health maintenance skills, and the eighth session professional/work skills."
41364950|NCT00188058|DEVICE|Setting of positive end-expiratory pressure|
41364951|NCT05577572|DIETARY_SUPPLEMENT|Probiotics packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Probiotics packets is taken from day 1\~56.
41364952|NCT05577572|DIETARY_SUPPLEMENT|Placebo packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Placebo packets is taken from day 1\~56.
40844205|NCT06152549|BEHAVIORAL|Maltreatment and Abuse Chronology of Exposure Scale as a stress challenge|The first group (N=250) will receive the Maltreatment and Abuse Chronology of Exposure (MACE) scale first, to assess early life adversity, followed by the standardized test questions. A POMS will be administered before each challenge.
41027325|NCT04069572|DEVICE|Vibrotactile Stimulation|Application of VCR stimulation to the belly and back of patients with pelvic pain, functional abdominal pain, or low back pain or to the temporal region for patients with migraine.
41027326|NCT04069572|DEVICE|Sham Stimulation|Low-frequency sham of VCR stimulation
41027327|NCT01722591|DEVICE|Cardiapex device|Cardiapex percutaneous transapical access and closure system
41027328|NCT03662945|OTHER|Mobile Geriatric Team intervention|Person-centred intervention based on Comprehensive Geriatric Assessment
41364953|NCT00843128|DEVICE|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
40844206|NCT06152549|BEHAVIORAL|Standardized Maths and Verbal Questions such as the ones used in SATs|The second group (N=250) will be presented with the standardized test questions (Math/Verbal) to assess their stress level, measured through POMS, followed by the Maltreatment and Abuse Chronology of Exposure (MACE) scale.
41364954|NCT00843128|DEVICE|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
41364955|NCT00787527|DRUG|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
41500695|NCT03844386|OTHER|Placebo|The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
41364956|NCT00787527|DRUG|Cyclophosphamide|750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle
40844207|NCT06152549|BEHAVIORAL|Chronology of Perceived Discrimination Scale (CPDS)|The group will also receive the Chronology of Perceived Discrimination Scale (CPDS) to assess type and timing of perceived discrimination during the first 18 years of life. A POMS will be administered before and after the intervention/challenge.
40844208|NCT06152549|BEHAVIORAL|International Personality Item Pool (IPIP-NEO)|Participants in both groups will be presented with the abbreviated version of the IPIP-NEO a personality questionnaire that provides ratings on the Five Factor Personality Model. The research team sees this task as non-stressful and even potentially soothing and envisions that it will help to restore an individual's mood before taking the next stressful test and again at the completion of the online session.
41027329|NCT02243787|DRUG|COVA322|
41364957|NCT00787527|DRUG|Doxorubicin|50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
41027330|NCT02243787|OTHER|Placebo|
41027331|NCT04538014|DRUG|Lu AF88434|Oral solution
41027332|NCT04538014|DRUG|[11C]-Lu AF88434|\[11C\]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
41027333|NCT02665000|PROCEDURE|Structured training programme|Participants will undergo 5-days training sessions
41027334|NCT02235766|OTHER|Echocardiographic assessment|
41027335|NCT01034124|DRUG|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
41027336|NCT01012882|BIOLOGICAL|sublingual immunotherapy with allergen extract|sublingual application
41027337|NCT01012882|BIOLOGICAL|sublingual immunotherapy with placebo|sublingual application
41027338|NCT02012829|BEHAVIORAL|GPs communication skills and CRC screening|GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
41027339|NCT02349711|DIETARY_SUPPLEMENT|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
41027340|NCT02349711|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
41027341|NCT00244738|DIETARY_SUPPLEMENT|Castor oil|Patients who received castor oil for labor induction
41027342|NCT00244738|DIETARY_SUPPLEMENT|Sunflower oil|Patients who received sunflower oil as a placebo
41027343|NCT04857359|DRUG|Dipraglurant|Oral 50mg and 100mg tablet
41027344|NCT04857359|DRUG|Placebo|Oral matching placebo tablet
41027345|NCT01193556|DEVICE|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
41364958|NCT00787527|DRUG|Vincristine|1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
41364959|NCT00787527|DRUG|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
41500696|NCT06102681|OTHER|intervention group|we will measure, consider and compare patients pain level, quality of life and recovery process. For these aims we will use numeric pain scale, nottingham health profile and postoperative recovery index.
41027346|NCT01193556|DEVICE|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
41027347|NCT04203719|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
41027348|NCT04203719|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
41027349|NCT01513304|PROCEDURE|Manual therapy|
41027350|NCT02591693|BEHAVIORAL|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
41027351|NCT01421810|DRUG|Dexamethasone|1 mg PO
41027352|NCT01421810|DRUG|rhCG|25 mcg IV
41027353|NCT05046938|BEHAVIORAL|Motivational İnterviewing|Students with food addiction will be provided with motivational interviews about food addiction in 5 sessions, each of which varies between 6-8 groups.
41027354|NCT05706558|PROCEDURE|Esophagectomy|Esophagectomy
41027355|NCT03765437|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
41027356|NCT02684591|DRUG|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
41027357|NCT02684591|DRUG|Placebo|Placebo
41027358|NCT03073603|DRUG|Discontinuation of disease modifying therapy|Participants who will discontinue their current MS drug. No other changes to their treatment occur.
41027359|NCT03073603|DRUG|Standard of Care|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
41027360|NCT01176903|DRUG|Glycopyrrolate|pressurized metered dose inhaler
41027361|NCT01176903|DRUG|Tiotropium|inhalation powder, hard capsule
41027362|NCT01176903|DRUG|placebo|pressurized metered dose inhaler
41364960|NCT01928186|DRUG|Fluorothymidine F-18|Undergo FLT PET
41364961|NCT01928186|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
41364962|NCT01928186|OTHER|Laboratory Biomarker Analysis|Correlative studies
41500697|NCT05560061|OTHER|Gait practice on an uneven terrain surface|Participants will walk back and forth on an uneven terrain surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
41500698|NCT05560061|OTHER|Gait practice on a flat terrain surface|Participants will walk back and forth on a level surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
41500699|NCT03448497|OTHER|Non-interventional|Non-interventional
41500700|NCT06448013|DRUG|Venetoclax|Given by PO
41500701|NCT06448013|DRUG|Gemtuzumab|Given by IV
40844209|NCT02733965|OTHER|Pharmaceutical Consultations|"The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient.~Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing pharmaceutical interventions following the pharmaco-therapeutic analysis (18).~These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T"
40844210|NCT02733965|OTHER|No Pharmaceutical Consultations|
40844211|NCT05318820|DRUG|HMPL-523|This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
40844212|NCT00306644|DRUG|Rosiglitazone|study drug
40844213|NCT00861328|DRUG|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
40844214|NCT00861328|DRUG|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
40844215|NCT06415773|DRUG|HTD1801|HTD1801 1000 mg BID administered orally BID as four capsules
40844216|NCT06415773|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablet administered orally QD
41027363|NCT01557660|DRUG|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
40844217|NCT01269502|DEVICE|"Temp Touch Diabetica Solutions inc."|Daily measurement of skin temperature on feet for one year
40844218|NCT01269502|OTHER|Inspection|Inspection of feet daily for one year
40844219|NCT05701436|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
40844220|NCT05701436|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
40844221|NCT05701436|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
40844222|NCT05701436|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
40844223|NCT05701436|DRUG|Oxaliplatin, Leucovorin, fluorouracil|Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
41500702|NCT06448013|DRUG|Ziftomenib|Given by PO
41500703|NCT00674349|PROCEDURE|surgery|staging surgery
41500704|NCT00203710|DEVICE|Concentric Retriever Device|
41027364|NCT05252026|BEHAVIORAL|PROCARE-I (UP-A for indicated purposes)|This intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
41027365|NCT05252026|BEHAVIORAL|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
41500705|NCT02260297|DEVICE|Wrist Actigraphy(motion sensors)with light sensors-Jawbone Up 2|
41500706|NCT03423017|OTHER|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~* Respiratory rate, respiratory signs, stridor : first and second visit~* 24h holter-ECG : first and second visit~* 24h impedance pH-metry : first visit~* Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~* 24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit~* succimetry procedure : at first visit only between birth and 2 months"
41500707|NCT03423017|OTHER|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs~* Respiratory rate, respiratory signs, stridor~* 24h holter-ECG~* 24h impedance pH-metry~* Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)~* 24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index~* Succimetry procedure : at first visit only between birth and 2 months"
41500708|NCT04479553|DRUG|Qizhi Tongluo Capsules|Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
41500709|NCT04181827|DRUG|JNJ-68284528|Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).
41027366|NCT04285606|BEHAVIORAL|Patient-led rehab with short immobilization|Short immobilization followed by patient-led shoulder rehab
41027367|NCT03981003|DIAGNOSTIC_TEST|Blood sample|2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
41027368|NCT05330663|DIETARY_SUPPLEMENT|Low protein diet with Fresubin® renal|Low protein diet with Fresubin® renal Dosage: 1 bottle per day as a replacement for one regular meal. All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight.
41500710|NCT04181827|DRUG|Pomalidomide|Pomalidomide 4 mg will be administered orally.
40844224|NCT05701436|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
40844225|NCT04967339|DEVICE|Foot deformity correcting insoles|Foot deformity correcting insoles (e.g. insoles with medial arch support for plano-valgus deformity)
40844226|NCT04967339|DEVICE|Lateral wedge insoles|Lateral wedge insoles
40844227|NCT00100594|DRUG|Efavirenz|
41027369|NCT05330663|OTHER|Low protein diet with normal food|All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight/day.
41027370|NCT01771003|DEVICE|CellAegis' autoRIC™ Device|Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
41027371|NCT01853449|DRUG|Fentanyl Citrate|
41027372|NCT01853449|OTHER|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
41027373|NCT01853449|DRUG|Placebo|0.9% saline
41027374|NCT00245557|DRUG|Sertraline|"Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day.~Duration of treatment was 12 weeks."
40844228|NCT00100594|DRUG|Lamivudine/zidovudine|
41027375|NCT06535919|BEHAVIORAL|Treatment as Usual|Individuals will receive residential level of care followed by treatment at their partial hospitalization program.
41027376|NCT01784705|DEVICE|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
40844229|NCT01949519|DRUG|Lycopene and Docetaxel|During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
41027377|NCT01784705|DEVICE|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
40844230|NCT06007625|OTHER|Machine learning-based prediction model|This model will utilize patient characteristics and disease features to determine the disease's prognosis. The scoring system will also include management information to facilitate prediction of clinical outcomes of different management strategies and potential management that would yield the best prognosis.
40844231|NCT05102253|PROCEDURE|Dense cranial electroacupuncture stimulation (DCEAS)|"DCEAS will be conducted for 2 sessions per week for 12 consecutive weeks. Electrical stimulation will be conducted on six pairs of forehead acupoints located on the frontal, parietal, and temporal scalp areas. The acupoints includes: Bai-Hui (GV20), Yin-Tang (EX-HN3), left and right Si-Shen-Cong (EX-HN1), Tou-Lin-Qi (GB15), Shuai-Gu (GB8), Tai-Yang (EX-HN5) and Tou-Wei (ST8).~Disposable acupuncture needles will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation, followed by electrical stimulation. The stimulation intensity will be adjusted to a level at which patients felt most comfortable. Each session of treatment will last 30 min."
40844232|NCT05102253|PROCEDURE|Transcutaneous electrical acupoint stimulation (TEAS)|"TEAS will be done for 3 times per week for 12 consecutive weeks by participants at home. A training workshop will be conducted to instruct participants how to use TEAS stimulator. Briefly, TEAS will be delivered on the bilateral Nei-Guan (PC6), which is located on the anterior forearm, between the tendons of the palmaris longus and ﬂexor carpi radialis, at the junction of the distal sixth and proximal ﬁve sixths of the line connecting the middle points of the wrist and elbow crease.~Constant current electrical impulses will be produced from a TEAS apparatus. Two electrode pads will be adhered onto the acupoint skin. The pulse amplitude will be adjusted to a level at which the perception of 'strong but comfortable' is achieved. Each session of treatment will last 30 min."
40844233|NCT05102253|OTHER|Wait-list control: Routine care|The routine care may include medications, advocacy intervention, and CBT. Post-trial treatment of TEAS+DCEAS will be offered to serve as a compensation for their participation.
41027378|NCT05855629|DIETARY_SUPPLEMENT|Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule|Lactobacillus Rhamnosus 1,5 х 10\*9, Inulin 25mg, D-chiro-inositol 250mg
41027379|NCT05855629|DRUG|Topical Adapalene, Benzoyl Peroxide Gel|Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml
41027380|NCT04157829|DEVICE|Scintilling lamp|Lamp with a standardized scintilling
41027381|NCT04157829|DEVICE|Classic lamp|Lamp without a scintilling
41027382|NCT02009618|DRUG|Rifaximin|Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
41027383|NCT02009618|DRUG|placebo|
41027384|NCT01626365|PROCEDURE|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
41027385|NCT01626365|PROCEDURE|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
41027386|NCT05104658|OTHER|Patient-targeted rehabilitation offers|In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
41027387|NCT03086447|DEVICE|Investigational Contact Lens|Senofilcon C Toric
41027388|NCT03086447|DEVICE|Marketed Contact Lens|Air Optix for Astigmatism
41027389|NCT00870779|DRUG|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
41500711|NCT04181827|DRUG|Bortezomib|Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).
41500712|NCT04181827|DRUG|Dexamethasone|Dexamethasone 20 mg/day (10mg/day for participants \>75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants \>75 years of age) in DPd treatment.
41500713|NCT04181827|DRUG|Daratumumab|Daratumumab 1800 mg will be administered SC.
41027390|NCT06463535|DRUG|Omega 3|SRP + OMEGA 3
41027391|NCT06463535|PROCEDURE|SRP alone|Scaling and root planning
41027392|NCT04413604|OTHER|Young children's milk (1-<3)|young children's milk containing protein, energy and fat and micronutrients, in accordance with global and local nutritional recommendations for ages 1-3.
41500714|NCT02769273|DEVICE|Percutaneous Transluminal Angioplasty|
40844234|NCT01344720|DRUG|etoricoxib|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die."
40844235|NCT01344720|DRUG|oxycodone|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy)."
40844236|NCT02524873|DEVICE|Geneticure Collection Kit for Pharmaocogenetics of Hypertension|Buccal (cheek) swab kit for DNA collection for analysis of genes for hypertension
40844237|NCT01628003|DEVICE|Brain MRI|Brain MRI
40844238|NCT01628003|DEVICE|MRI|Physical examination Neuropsychological testing Questionnaires
41364963|NCT01928186|DRUG|Run-in (short pre-surgery course) of endocrine-targeted therapy|Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
40844239|NCT00597493|DRUG|Sorafenib and Temozolomide|Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
40844240|NCT00808548|OTHER|counseling, emotional support|
40844241|NCT00808548|OTHER|emotional support|emotional support during the interview
40844242|NCT00808548|OTHER|emotional support|emotional supporting during the interview
40844243|NCT06100874|DRUG|Sacituzumab Govitecan|Trop-2-directed antibody-drug conjugate, 180 mg single-dose glass vial, via intravenous infusion per protocol.
40844244|NCT06100874|DRUG|Trastuzumab|Humanized IgG1 kappa monoclonal antibody, 150mg single-dose vial, via intravenous infusion per protocol.
40844245|NCT06100874|DRUG|Trastuzumab and Hyaluronidase-oysk|Recombinant monoclonal antibody, 6 mL vial, via subcutaneous injection per protocol.
41364964|NCT02724631|DEVICE|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
41364965|NCT06023927|OTHER|Clinical observation, diagnostic testing|Glaucoma evaluation including structural and functional diagnostic testing at baseline and 3 subsequent follow-up visits over a period of 9 months
41364966|NCT01348464|PROCEDURE|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
41364967|NCT04864964|PROCEDURE|combined conventional and pulsed radiofrequency (CCPRF)|Patients with trigeminal neuralgia who underwent combined conventional and pulsed radiofrequency (CCPRF) for treatment of pain.
41364968|NCT04954560|DRUG|losartan and eprosartan|. Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
41364969|NCT05007366|BEHAVIORAL|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
41364970|NCT05007366|BEHAVIORAL|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
41500715|NCT02156167|DEVICE|CP810 and Codacs™ system test|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
40844246|NCT06117124|RADIATION|Digital X-Ray Radiogrammetry|An x-ray of the left hand will be taken by a Radiographer. This will be uploaded to PACS and analysed using BoneXpert software. This calculates bone density as a 'Bone Health Index', and provides a standard deviation score for age, gender and bone age.
40844247|NCT06117124|DIAGNOSTIC_TEST|Quantitative Ultrasound (QUS)|The MiniOmni Bone Densitometer will be used to measure bone density at three peripheral sites on both sides of the body (left and right): the distal radius (lower arm), mid-tibia (lower leg) and phalynx (hand). The speed of ultrasound (speed of sound) through the bone will be measured and converted to a standard deviation score.
40844248|NCT01349764|DRUG|Vitamin D3|
40844249|NCT05325385|OTHER|There are no interventions - this is a database study only|There are no interventions - this is a database study only
40844250|NCT02291588|DRUG|AMG 811|A single dose of AMG 811 or placebo will be adminstered.
40844251|NCT02291588|DRUG|Placebo|contains no active drug
40844252|NCT03317119|OTHER|Laboratory Biomarker Analysis|Correlative studies
40844253|NCT03317119|DRUG|Trametinib|Given PO
40844254|NCT03317119|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
40844255|NCT06254924|BEHAVIORAL|QI App Users|QI App users will be asked to complete a daily, 2-question mood and stress survey. They will be encouraged to use the QI App to practice mindfulness skills including meditation, drawing, coloring, breathing, and walking. They will be encouraged to use the QI App to help them participate in asynchronous group running activities.
41364971|NCT02318082|DRUG|Interleukin-2|
41364972|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
40844256|NCT06254924|BEHAVIORAL|Parents/Guardians of QI App Users|Parents/Guardians of QI App users will be informed that their child is using the QI App for a 6-week period.
40844257|NCT05284916|BEHAVIORAL|liver diseases admissions|The different patterns of liver disease related admissions after the era of DAAS
40844258|NCT01143987|DRUG|Cinacalcet|starting with 25 mg daily dose with titration, maximum dose 100 mg daily
40844259|NCT03286283|DEVICE|J-Plasma|Dermal resurfacing procedure with J-Plasma.
40844260|NCT01765725|BEHAVIORAL|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
40844261|NCT02409719|OTHER|Schedule|Illustrative daily planner to point the day that the exercise was performed
40844262|NCT02409719|OTHER|Verbal Information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
40844263|NCT00737633|DRUG|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
40844264|NCT01124955|OTHER|Acupuncture|The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)
40844265|NCT01124955|OTHER|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
40844266|NCT03897842|DEVICE|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
40844267|NCT02215343|DIETARY_SUPPLEMENT|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R\&D Centre Europe).
40844268|NCT02215343|DIETARY_SUPPLEMENT|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
40844269|NCT06581172|DIAGNOSTIC_TEST|D_dimer|DIC score including FDPs,D_dimer
40844270|NCT05830877|OTHER|the acupuncture group|"The primary choice is to puncture GB20 with a quick puncture, which means regulate the mind and open the way. ①Scalp acupuncture: Du 20(Baihui), EX-HN 3(Yintang), EX-HNl(Sishencong); ②Select acupoints from six acupoints for mind-regulating, ear points (both sides): heart, lung, and Shenmen; body points (both sides): LI20(Yingxiang), EXTRA 12(Anmian), ST36(Zusanli) as the main hole. ③Sleeping three needles(both sides): HT7(Shenmen), PC6(Neiguan), SP6(Sanyinjiao); ④Opening four gates: LI4(Hegu) , LR3(Taichong) ⑤Abdominal four needles:ST25(Tianshu), CV12(Zhongwan), CV4(Guanyuan). For body acupuncture, a 0.3 mm×40 mm needle was used to insert directly for 0.5-1.0 cun, and twisting to gain the qi; for auricular points, a 0.25 mm×40 mm needle was used for 2-3 minutes without manipulating the needle. The acupuncture points were retained for 30 min, and the treatment was performed once every other day, three times a week, and the curative effect was evaluated after 4 weeks of treatment."
40844271|NCT05830877|OTHER|the placebo acupuncture group|Subjects in the placebo acupuncture group will receive non-insertive acupuncture using the sham needle supported by the Park device. This needle has a retractable shaft and a blunt tip, they could not penetrate the skin. We gently placed the sham needle and Park device on the skin. The sham needle is then no longer manipulated to minimize any physiological effects. The selected acupoints and needle retention time were the same as for the acupuncture group. Since oblique insertion is required for acupuncture points on the head, the fixed acupuncture body of the Park device could not be used. Therefore, blunt needles are used to stimulate the head points to reduce the amount of stimulation produced by acupuncture. At the end of the treatment, the acupuncturist also used a dry cotton swab to press the acupoints so that patients could feel the withdrawal of 'real' needles.
40844272|NCT06412913|DEVICE|MJ-Flex The New Metaizeau Nail|Intramedullary implantation of the MJ-Flex elastic nail in long bones to provide bone fixation
40844273|NCT01306383|OTHER|SODIS Bottle|SODIS Bottles used by SODIS group to treat their drinking water
40844274|NCT02628548|BEHAVIORAL|Cognitive training program|8 week cognitive training program
40844275|NCT03196531|DRUG|Loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
40844276|NCT03196531|DRUG|Loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
40844277|NCT02248363|OTHER|Multimodal rehabilitation|Multimodal rehabilitation (MMR) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
40844278|NCT03247127|RADIATION|Hippocampal avoidance whole brain radiotherapy|Planning target volume(PTV) for whole brain is Whole brain parenchyma plus2mm margin excluding metastases and HA region, 30Gy in 10 fractions will be delivered to PTVwhole brain. Bilateral Hippocampus will be contoured according to Radiation Therapy Oncology Group 0933 and hippocampal avoidance region is Hippocampi + 5mm margin. According to Radiation Therapy Oncology Group 0933 trial, dose to 100% of the hippocampus could not exceed 9 Gy, and maximal hippocampal dose could not exceed 16 Gy; dose to 100% of the hippocampus exceeding 10 Gy
41027393|NCT03200392|DEVICE|laser root surface conditioning & laser DGG harvesting|laser root surface bio-modification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage
41364973|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
41364974|NCT01873027|DEVICE|OFDI|"* OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
41364975|NCT01873027|DEVICE|IVUS|"* IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
41364976|NCT05831956|PROCEDURE|Laparoscopic colectomy|Patients who under went laparoscopic colectomy
41500716|NCT05937152|DRUG|Eptinezumab|Intravenous (IV) infusion of 300 mg
41500717|NCT05937152|DRUG|Placebo|Intravenous (IV) infusion of placebo (looks exactly like the study drug, but it contains no active ingredients)
41500718|NCT06633536|DRUG|Ravulizumab|open-label arm with ravulizumab administrated within the scope of routine clinical practice
41027394|NCT03200392|DEVICE|laser root surface conditioning & blade DGG harvesting|laser root surface bio-modification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage
41500719|NCT05659693|BEHAVIORAL|digital literacy education specific to menopause|Education; It is planned as 5 sessions in the form of presentation, homework, scenario and sending reminder messages. The training is planned to last approximately 20 minutes with a power point presentation prepared by the trainer. The survey will be evaluated in the first session. Women will be told what digital literacy is, why it is important, how to verify information and resources, security of accounts, resources, money and devices, access to information, understanding and valuing information. A screening and access to information session will be held with a scenario prepared on menopausal symptoms, taking into account the variables of information and resource security, access to information, understanding and valuing information, with examples on the digital platform. The woman will be given a scenario homework on menopausal symptoms. Interim evaluation will be made in the fourth week of the training. The final evaluation will be made in the fifth session.
41500720|NCT06296927|OTHER|Emotional Freedom Technique|The researcher will apply the Emotional Freedom Technique to women in the intervention group who apply for mammography screening for 30-40 minutes before the screening.
41500721|NCT05713253|DEVICE|ELITA System|Each subject will receive a SILK lenticule removal procedure on one eye and a commercially available laser vision correction procedure on their fellow eye (Feasibility Phase). Subjects will receive a lenticule removal procedure on both eyes to reduce or eliminate myopic refractive errors (Pivotal Phase). The second eye treatment will be considered only after the first eye 1-week follow up visit has been completed and safety criteria are met.
41500722|NCT02518672|DIETARY_SUPPLEMENT|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
41500723|NCT02518672|DIETARY_SUPPLEMENT|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
41500724|NCT06427837|OTHER|Same 2nd course|The same snack food will be served in the second course
41500725|NCT06427837|OTHER|Different 2nd course|A different snack food will be served in the second course
41500726|NCT00670202|DRUG|Fasudil Hydrochloride|Fasudil 40 mg three times a day x 14 days
41500727|NCT00670202|DRUG|Placebo Oral Tablet|Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
41027395|NCT03200392|PROCEDURE|blade DGG harvesting|De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
41027396|NCT01806480|BEHAVIORAL|Person-centred proactive breastfeeding telephone support|Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
41027397|NCT03513029|DEVICE|VytronUS Ablation System|Catheter Ablation for Paroxysmal Atrial Fibrillation
41364977|NCT05099458|BIOLOGICAL|Additional blood sampling (100 ml)|only an additional blood volume will be collected at the same time of the standard blood collection for these patients
41364978|NCT02812823|DEVICE|High-resolution anorectal manometry|Recording of conventional manometric parameters after insertion of the catheters.
41364981|NCT04932564|DRUG|Leflunomide tablet|"Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.~The dosing for children will be as follows:~1. \<20 kg - 100 mg x 1 day followed by 10 mg every alternate day~2. 20-40 kg - 100 mg x 2 days, followed by 10 mg daily~3. \>40 kg - Usual adult dose.~This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD."
41500728|NCT04816591|DEVICE|Experimental: Interventional Cohort: Treatment Arm|Standard of Care Surgery + Embolization
41027398|NCT04265079|OTHER|Additional weight at hand|Added weight of an inactive hand orthosis (300 gram)
41027399|NCT05937022|DEVICE|Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to one of the two experimental groups will receive 20 minutes of active stimulation with a 2mA intensity over the corresponding brain regions.
41027400|NCT05937022|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to the sham control group will receive 30 seconds of active stimulation over brain regions identical to either the left DLPFC or the right VLPFC experimental tDCS group.
41364982|NCT02038699|DRUG|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
41364983|NCT04675034|BIOLOGICAL|MEDI7352|Dose A: MEDI7352 Q2W
41364984|NCT04675034|BIOLOGICAL|MEDI7352|Dose B: MEDI7352 Q2W
40844279|NCT03292276|DEVICE|Amadeo Training|"To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups."
40844280|NCT05104970|DRUG|SunnyD insta ampoule|Cholecalciferol 200000 IU insta ampoule
40844281|NCT05104970|DIETARY_SUPPLEMENT|SunnyD STAT softgel capsule|Cholecalciferol 200000 IU softgel capsule
40844282|NCT05104970|DRUG|Placebo SunnyD insta ampoule|Olive oil
40844283|NCT05104970|DIETARY_SUPPLEMENT|Placebo SunnyD STAT softgel capsule|Olive oil
40844284|NCT03350555|DEVICE|Additioned Endoscopy|To evaluate the use of additioned endoscopy in ERCP treatment.
40844285|NCT03316950|DEVICE|IntraGen RF|IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
40844286|NCT03316950|DEVICE|DiVA|DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
40844287|NCT03316950|DEVICE|Placebo (DIVA/IntraGen combined)|"(DIVA/IntraGen combined) IntraGen RF: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.~DiVA: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner."
40844288|NCT00330681|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
40844289|NCT00330681|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
40844290|NCT05169060|DRUG|Fish Oil Concentrate, 1000 Mg Oral Capsule|Oral capsules, 2 grams or 4 grams per day.
40844291|NCT05169060|DRUG|Salsalate Oral Tablet|Oral tablets, 1.5 gram or 3.0 gram per day.
40844292|NCT06505486|DRUG|Gemcitabine-Oxaliplatin Regimen|Hepatic arterial infusion chemotherapy (HAIC) of gemcitabine and oxaliplatin (GEMOX) plus systemic gemcitabine chemotherapy (GEM-SYS) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitor.
40844293|NCT01014039|PROCEDURE|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
40844294|NCT05111028|BIOLOGICAL|Autologous Room Temperature stored Platelet transfusion|An autologous transfusion of platelets stored at 22°C for 7 days.
40844295|NCT05111028|BIOLOGICAL|Autologous Cold Stored Platelet transfusion|An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
40844296|NCT03881904|DRUG|0.075mg gestodene/0.03mg ethinylestradiol|OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
40844297|NCT03251950|BEHAVIORAL|healthy eating and gardening|15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating
40844298|NCT00997360|DRUG|PKI-179|
40844299|NCT02403401|DRUG|Levonorgestrel (BAY98-7196)|Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
40844300|NCT04890314|OTHER|Patient-reported questionnaire|Validated questionnaires administered at baseline, 8 months following treatment, and 12 months following treatment.
40844301|NCT05378061|DRUG|Pituitary adenylate cyclase activating polypeptide-38|Study participants will be allocated to receive continuous intravenous infusion of 10 pmol/kg/min PACAP-38.
41500729|NCT04816591|OTHER|Active Comparator: Interventional Cohort: Control Arm|Standard of Care Surgery Only (Control)
40844302|NCT05378061|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
40844303|NCT00332891|DRUG|SR58611A|
40844304|NCT00376766|DRUG|levetiracetam|
40844305|NCT02169856|BEHAVIORAL|EFTs (emotional freedom techniques)|The Emotional Freedom Techniques (EFTs) which has been pioneered by Gary Craig is a form of alternate medicine which works by tapping on body energy meridian points. Unlike drugs the EFTs has no side effects too
40844306|NCT02169856|DRUG|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
40844307|NCT02169856|DRUG|Inj. Midazolam 0.7mg/kg|Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
40844308|NCT02169856|DRUG|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
40844309|NCT02169856|DRUG|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia
40844310|NCT02169856|DRUG|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
40844311|NCT02169856|DRUG|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
40844312|NCT02169856|DRUG|Drug: Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
40844313|NCT02169856|DRUG|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
41364985|NCT04675034|BIOLOGICAL|MEDI7352|Dose C: MEDI7352 Q2W
41500730|NCT04816591|DEVICE|Experimental: Observational Cohort: Treatment Arm|Standard of Care Medical Management + Embolization
40844314|NCT04367090|DRUG|Docetaxel, trastuzumab|Docetaxel and trastuzumab once per cycle
40844315|NCT04367090|DRUG|Pyrotinib|Pyrotinib 400/320 mg orally daily
40844316|NCT03903887|BIOLOGICAL|anti-PD1 antibody-activated TILs|Participants would receive one dose of anti-PD1 antibody-activated TILs at the final cycle of docetaxel and cisplatin (DP) regimen chemotherapy.
40844317|NCT05271331|DRUG|ESP block with saline|Bilateral ultrasound guided injection of saline in the erector spinae plane (below erector spinae plane muscle group and above the transverse process of the vertebra)
40844318|NCT05271331|DRUG|Wound infiltration with saline|Blinded injection of saline in the skin, subcutaneous tissue and muscles at the site of surgical incision
40844319|NCT05271331|DRUG|ESP block with local anesthetic|Bilateral ultrasound guided injection of local anesthetic (ropivacaine 0.35%, 40ml) in the erector spinae plane (below erector spinae plane muscle group and above the tranverse process of the vertebra)
40844320|NCT05271331|DRUG|Wound infiltration with local anesthetic|Blinded injection of local anestetic (ropivacaine 0.35%, 40ml) in the skin, subcutaneous tissue and muscles at the site of surgical incision.
40844321|NCT03247725|OTHER|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
40844322|NCT03247725|OTHER|Treatment as usual (medical)|Patients will be offered the usual treatment for their pain, which is not changed by study participation
40844323|NCT06379282|BEHAVIORAL|HIT|Exercise training only
40844324|NCT06379282|BEHAVIORAL|EXE+ Nutritional Guidance|Exercise Training + Nutritional Guidance
40844325|NCT03131882|DRUG|Hyaluronic Acid|1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
40844326|NCT03131882|DRUG|Triamcinolone Acetonide|1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
40844327|NCT01227863|DRUG|MAXINOM®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
40844328|NCT01227863|DRUG|Maxitrol®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
40844329|NCT02625714|DRUG|Renexin®|Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
40844330|NCT02625714|DRUG|SID142|Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
40844331|NCT02495454|DRUG|Ga101|
40844332|NCT01132586|DRUG|Lenalidomide|Given PO
41027401|NCT06128135|OTHER|Technology acceptance questionnaire for prostheses users.|One questionnaire, which is for prosthesis users, where will be 15 questions to identify what kind of activities the person uses the prosthesis, how much is the use time and what is the main problem with the device.
41027402|NCT06128135|OTHER|Technology acceptance questionnaire for relatives of prostheses users.|One questionnaire, where there will be between 8 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
41027403|NCT06128135|OTHER|Technology acceptance questionnaire for therapists|One questionnaire, where there will be between 9 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
40844333|NCT01132586|DRUG|Cytarabine|Given IV
40844334|NCT01132586|DRUG|Idarubicin|Given IV
40844335|NCT01132586|OTHER|Pharmacological Study|Correlative studies
41027404|NCT03404024|BIOLOGICAL|Stage 1-Low dose VM202RY|Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)
41027405|NCT03404024|BIOLOGICAL|Stage 1-Middle dose VM202RY|Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)
41027406|NCT03404024|BIOLOGICAL|Stage 1-High dose VM202RY|Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)
41027407|NCT03404024|DRUG|Stage 2-Placebo|Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
41027408|NCT03404024|BIOLOGICAL|Stage 2-Low dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)
41027409|NCT03404024|BIOLOGICAL|Stage 2-High dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
41364986|NCT04675034|BIOLOGICAL|MEDI7352|Dose D: MEDI7352 Q2W
41364987|NCT04675034|BIOLOGICAL|Placebo|Placebo to match MEDI7352 Q2W
40844336|NCT01132586|OTHER|Laboratory Biomarker Analysis|Correlative studies
40844337|NCT01946126|OTHER|No Intervention|There is no intervention in this study.
40844338|NCT03691363|BEHAVIORAL|M-STEP|Youth will be assessed using actigraphy at baseline, and will then be asked to exercise for 1) a duration of 10 minutes \> MVPA at baseline with 2) HR\>120 while being monitored by a Fitbit. Youth will be asked to exercise daily, and intensity and duration will be increased every few days for a goal of 60 minutes per day at a HR\>140 (low end of MVPA). The intervention will be 6 weeks in duration.
40844339|NCT06010407|OTHER|Survey|"* Working Alliance Inventory~* Attitude Towards Psychiatry-30 Scale"
40844340|NCT00237263|DRUG|Entacapone|
40844341|NCT02322190|PROCEDURE|Extracorporeal Photopheresis (ECP)|Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment.
40844342|NCT02322190|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
40844343|NCT04891185|DRUG|Indocyanine green|Administration of the IMP: Indocyanine green, 0,25mg/kg of body weight, intravenous bolus injection
40844344|NCT04958226|DRUG|Capivasertib|Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.
40844345|NCT04958226|DRUG|Midazolam|Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.
40844346|NCT04040621|DRUG|Ceftazidime-avibactam|Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.
41500731|NCT04816591|OTHER|Active Comparator: Observational Cohort: Control Arm|Standard of Care Medical Management Only (Control)
41027410|NCT03404024|DEVICE|C-Cathez® Catheter|Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
41027411|NCT05487924|OTHER|SVV-GDHT|GDHT guided by SVV using Flotra/Vigileo monitor
40844347|NCT02195167|DRUG|Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
40844348|NCT05102968|BEHAVIORAL|Home-based rehabilitation supporting with the mobile application|For patients with mobile application supportive rehabilitation, patients managed rehabilitation exercise by themselves after the surgery without supervision. Rehabilitation protocol and exercise instruction video were available in the application. Patient could communicate with the physician and therapist via the application.
40844349|NCT05102968|BEHAVIORAL|Supervised rehabilitation by the therapist|For patients with therapist supervised rehabilitation, patients attended one-on-one instructions with a therapist (once a week at post-operative 2nd\~12th week and once two weeks at post-operative 13th\~24th week; totally 16 sessions in the 6-month rehabilitation program) and exercised under supervision at hospital. Subjects would receive additional sessions based on the rehabilitation progress. Subjects could cancel scheduled sessions by personal reasons. We provided telephone consultation without APP communication for subjects in the supervised group.
40844350|NCT02259855|DRUG|Tipranavir|
40844351|NCT02259855|DRUG|Ritonavir|
40844352|NCT02259855|DRUG|Pegylated interferon|
40844353|NCT02259855|DRUG|Ribavirin|
40844354|NCT04788056|PROCEDURE|Parasternal Subpectoral Plane Block|Nerve block catheter inserted into plane between rib cartilages and pectoralis muscle.
40844355|NCT04291768|OTHER|Shortened antibiotic treatment|Shortened antibiotic treatment of 5 days. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
40844356|NCT04291768|OTHER|Standard antibiotic treatment|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
40844357|NCT05934331|DRUG|LM302+Toripalimab|LM-302 in combination with Toripalimab.
40844358|NCT01875718|DRUG|UC1010|
40844359|NCT01875718|DRUG|Placebo|
40844360|NCT03294850|PROCEDURE|Bariatric surgery|Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied
40844361|NCT03294850|DEVICE|HepQuant SHUNT Dual Cholate Liver Diagnostic Kit|For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.
40844362|NCT06397235|DRUG|DEB-TACE+HAIC|"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~RALOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; Raltitrexed, 3 mg/m2 infusion for 0.5 hour."
40844363|NCT06397235|DRUG|DEB-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
40844364|NCT03032549|DIETARY_SUPPLEMENT|RTD|Ready to Drink Supplement
40844365|NCT03032549|DIETARY_SUPPLEMENT|Placebo|Placebo
40844366|NCT04971941|DEVICE|Dental Vibe|Use of Dental Vibe during dental anesthesia intervention
40844367|NCT02349750|PROCEDURE|endometrial scratch injury|ESI using No.8 neonatal feeding tube
40844368|NCT02447978|BIOLOGICAL|Infanrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
40844369|NCT02447978|BIOLOGICAL|Pediarix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
40844370|NCT02447978|BIOLOGICAL|Kinrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
40844371|NCT02917915|OTHER|Canadian Standardized PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
40844372|NCT02917915|OTHER|Traditional PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
40844373|NCT02636712|DEVICE|ImageReady™ MR Conditional Pacing System|
40844374|NCT04842305|DIAGNOSTIC_TEST|Blood- and saliva tests|Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
41027412|NCT05487924|OTHER|O2ER-GDHT|GDHT guided by O2ER
41027413|NCT05487924|OTHER|conventional care|conventional fluid therapy without GDHT
41027414|NCT01789944|BEHAVIORAL|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
40844375|NCT02204488|PROCEDURE|Total Joint Arthroplasty|Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
40844376|NCT02204488|PROCEDURE|Trapeziectomy|Trapeziectomy
40844377|NCT01872013|DRUG|ASP7991|oral
40844378|NCT01872013|DRUG|Placebo|oral
40844379|NCT03698565|OTHER|Nerve stimulation of the ulnar nerve|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
40844380|NCT01973504|DRUG|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
40844381|NCT01973504|DRUG|Control|Crystalloid solution IV infusion drip to keep vein open
40844382|NCT06331689|OTHER|Mortality ratio|Mortality rates at 30-day, 90-day and 1-year intervals
40844383|NCT00629798|DRUG|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients \> or = to 4 years of age or 1.0 mg/kg IV for patients \< 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
40844384|NCT03006224|OTHER|One Lung Ventilation|
40844385|NCT02453555|DRUG|Linagliptin|
40844386|NCT02453555|DRUG|Empagliflozin placebo + linagliptin placebo low dose|Matching placebo empagliflozin + linagliptin
40844387|NCT02453555|DRUG|Empagliflozin + linagliptin low dose|tablet
40844388|NCT02453555|DRUG|Linagliptin placebo|Matching placebo linagliptin
40844389|NCT02453555|DRUG|Empagliflozin + linagliptin high dose|tablet
40844390|NCT02453555|DRUG|Empa + lina highdose placebo|
40844391|NCT05403229|DRUG|Topiramate|The topiramate arm receives additional oral topiramate for 6 weeks. The dose of topiramate is started from 25mg orally daily with the weekly escalation of 25mg to a maximum of 100mg.
40844392|NCT05403229|DRUG|Systemic Steroids|Both groups receive a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.
40844393|NCT06065436|DRUG|Collagenase Clostridium Histolyticum|Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
40844394|NCT06065436|DEVICE|Storz Duolith LiSWT|Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2. These treatments will occur four separate times, before each of the four separate CCH injection series.
40844395|NCT01870648|DRUG|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
40844396|NCT01870648|DRUG|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
40844397|NCT03461081|DRUG|telmisartan/amlodipine and atorvastatin|Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days
40844398|NCT03784807|DIAGNOSTIC_TEST|synovial calprotectin, confocal laser microscopy|Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria
40844399|NCT00331188|DRUG|Sanvar® (vapreotide)|
40844400|NCT03821116|OTHER|Milk|Swedish milk from cow.
40844401|NCT03821116|OTHER|Soured milk (filmjölk)|Swedish soured milk (from cow milk).
40844402|NCT05385484|BEHAVIORAL|Receives mobile banking account with incentives to save|Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.
40844403|NCT04316364|DRUG|SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Paclitaxel (Albumin Bound) will be administered intravenously on Day 1,8,15 of each 21-day cycle Drug: Carboplatin will be administered intravenously on Day 1 of each 21-day cycle
40844404|NCT04316364|DRUG|SHR-1316、Chemotherapeutic|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
40844405|NCT04316364|DRUG|Placebo、Chemotherapeutic|Drug: Placebo, will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
41027415|NCT05718622|DEVICE|real EECP|Real EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 150 millimeters of mercury.
41027416|NCT05718622|DEVICE|sham EECP|Sham EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 75 millimeters of mercury.
41027417|NCT03699306|PROCEDURE|NG tube insertion method|a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
41161222|NCT04233983|PROCEDURE|Laparoscopic Endometriosis Surgery|Patient with ERROR(endometrioma related reduction in ovarian reserve), and endometrioma larger than 3 cm diameter will be operated after IVF\&ICSI procedure. Operation will be done by senior surgeons of our department. Laparoscopic endometrioma operation procedure consists of excision of endometrioma cyst with its capsule from ovary without using any electric modality to prevent ovarian damage.
40844406|NCT01635803|DRUG|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
40844407|NCT01635803|DRUG|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
40844408|NCT04349033|BEHAVIORAL|Emotional Disclosure and Brain Education|Patients are interviewed about a number of aspects of their lives (stress, other illnesses, personality, adverse childhood experiences), and these are explored as part of education of the brain's role in their pain.
40844409|NCT04349033|BEHAVIORAL|Emotional Disclosure Only|Patients are interviewed about a number of aspects of their lives, but without brain education
40844410|NCT04349033|BEHAVIORAL|Pain Information Control|Patients are interviewed about their pain history and other basic, non-disclosure information about their health.
40844411|NCT01272765|OTHER|Placebo|Placebo
40844412|NCT01272765|DIETARY_SUPPLEMENT|IHBG-10|500 mg IHBG-10
41027418|NCT03913364|DIETARY_SUPPLEMENT|Probiotic|B. bifidum 900791-containing ice cream
41027419|NCT03913364|DIETARY_SUPPLEMENT|Placebo|Placebo ice-cream
41027420|NCT05282004|DRUG|SOK583A1|SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
41027421|NCT02919852|PROCEDURE|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
41027422|NCT03499158|OTHER|nerve conduction study|nerve conduction study
41027423|NCT00085410|DRUG|bortezomib|Given IV
41161223|NCT03410108|DRUG|Brigatinib|Brigatinib tablet
41161224|NCT01165502|DRUG|CM3.1-AC100|MAD study with repeated subcutaneous (sc) doses
41161225|NCT01165502|DRUG|Placebo|Placebo for compound CM3.1-AC100 s.c.
41161226|NCT02868619|OTHER|Functional MRI|functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
41027424|NCT06152094|OTHER|BP Activate Letter|"Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and computer-generated medication recommendations that might improve your blood pressure, along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss."
41027425|NCT06152094|OTHER|Control Letter|Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
41027426|NCT03248739|DEVICE|Clear Bactiseal 'large' catheter (EVD)|Antibiotic-impregnated 'large' catheter (inner diameter 1.9 mm, outer diameter 3.4 mm)
41027427|NCT03248739|DEVICE|Orange Bactiseal 'small' catheter (EVD)|Antibiotic-impregnated 'small' catheter (inner diameter 1.5 mm, outer diameter 3 mm)
41027428|NCT06057246|OTHER|Test meal with postprandial samples|The mixed-nutrient test meal consists of a sandwich made with bread, spread cheese, air-cured beef, and one apple. Nutritional composition of the meal will be: total energy (TE) content 532 kcal, carbohydrates 68,4 g (49.3% TE), total fat 17.1 g (29.5% TE), protein 27.8 g (21.4% TE), and fibre 6 g. Before and over 4 hours after the meal, venous blood samples will be taken for biochemical evaluations at the time points -15'; 0'; 15'; 30'; 60'; 120'; 180'; 240'.
41027429|NCT05359042|OTHER|Electronic Patient Reported Outcomes platform|The ePRO tool is developed by a third-party vendor, Conversa, and engages the patient in a chat-based interaction to assess patient symptoms and provide educational material.
41027430|NCT05359042|OTHER|Health Related Quality of Life Surveys|Surveys will be administered to participants
41027431|NCT01908777|OTHER|High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin|
41027432|NCT05008510|DRUG|Sabizabulin|Sabizabulin (Veru-111)
41027433|NCT05008510|DRUG|Sacituzumab Govitecan-hziy|Sacituzumab govitecan-hziy
41027434|NCT05008510|DRUG|Sabizabulin/Sacituzumab govitecan-hziy Combo|Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
41161227|NCT02868619|OTHER|ADO-BEDS scale|Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
41027435|NCT00318006|PROCEDURE|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
41027436|NCT00318006|PROCEDURE|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
41027437|NCT01287442|PROCEDURE|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
41027438|NCT03274700|DRUG|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
41161228|NCT02868619|OTHER|R-CMAS scale|Evaluate the anxiety
41161229|NCT04059913|DRUG|Roxadustat|Roxadustat will be dosed orally per dose and schedule specified in the arm description.
41161230|NCT04167085|DRUG|Doxycycline|Doxycycline, 100 mg twice a day for 2 months
41161231|NCT04167085|OTHER|Placebo|Matching placebo, twice a day for 2 months
41161232|NCT01002547|DRUG|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
41161233|NCT01002547|DRUG|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
41161234|NCT01002547|DIETARY_SUPPLEMENT|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
41161235|NCT01002547|DRUG|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
41161236|NCT01002547|DIETARY_SUPPLEMENT|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
41161237|NCT01002547|DRUG|Vitamin E-placebo|Placebo of vitamin E will be given to arm 3.
40844413|NCT04119102|DRUG|Duobrii|duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
40844414|NCT04508491|OTHER|Rhythm control|Rhythm control with medications or any procedure
41027439|NCT03274700|DRUG|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
41027440|NCT03753958|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
41161238|NCT05643443|OTHER|Gradual increase of force|steady force
41161239|NCT02900222|PROCEDURE|endoscopic choroid plexus coagulation|A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
41027441|NCT03753958|RADIATION|aPDT|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
41027442|NCT04365036|DRUG|Toripalimab|toripalimab 240mg, d1, intravenous drip
41027443|NCT04365036|DRUG|Pegaspargase|pegaspargase, 2000U/m2, d1, intravenous drip
41027444|NCT04365036|DRUG|Gemcitabine|gemcitabine, 1000mg/m2, d1,d8, intravenous drip
41027445|NCT04365036|DRUG|Oxaliplatin|oxaliplatin, 130mg/m2, d1, intravenous drip,
41027446|NCT04365036|RADIATION|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
41027447|NCT01705457|DRUG|Dietary Supplement: vitamin A|"25000 IU/day vitamin A for 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
41027448|NCT01705457|DRUG|placebo|
41161240|NCT01670188|DEVICE|Pneumatic SCD - VenaFlow System (DJO Global)|
41500732|NCT06443411|OTHER|Monitoring of cerebral hemodynamics|A specially designed pair of goggles will be put on the patient's head. The closed eyelids, along with the surrounding tissues, will be in contact with a thin, elastic, non-allergic film used to seal water filled inside the goggles. Pulse waves, including those originating from cerebrospinal fluid pulsation, will be transmitted from the eyelids to the water, where they will be detected by a pressure sensor and recorded with a laptop.
41027449|NCT03867331|BIOLOGICAL|5 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
41027450|NCT03867331|BIOLOGICAL|15 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
41027451|NCT03867331|BIOLOGICAL|30 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
41027452|NCT03867331|OTHER|Plasmodium falciparum challenge|Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites
41027453|NCT00761059|DRUG|Glucose 20%|The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
41027454|NCT00761059|DRUG|Aqua|The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
41027455|NCT05368805|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5
41027456|NCT05368805|DRUG|Dabigatran Etexilate|Dabigatran Etexilate will be administered as a single oral dose 150mg on the morning of day 1 and morning of day 5
41027457|NCT05368805|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5
41161241|NCT04163185|DRUG|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 tablet taken once upon the earliest onset of migraine pain.
41161242|NCT04163185|DRUG|Placebo|Placebo tablet taken once upon the earliest onset of migraine pain.
41161243|NCT04585568|OTHER|Biosensors|Measures of blood flow and preassures
41161244|NCT00410423|DRUG|Bortezomib with mitoxantrone, etoposide and cytarabine|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
41161245|NCT00410423|DRUG|Bortezomib 1.0mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
41161246|NCT00410423|DRUG|Bortezomib 1.3mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
41161247|NCT01960114|DRUG|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
41027458|NCT00214136|RADIATION|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
41027459|NCT04442594|PROCEDURE|virtual reality session|"The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation."
41161248|NCT01960114|DRUG|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
41161249|NCT03214250|DRUG|APX005M|Administer intravenously once every 28-day Cycle
41161250|NCT03214250|DRUG|Nivolumab|Administer intravenously twice every 28-day cycle
41161251|NCT03214250|DRUG|Nab-Paclitaxel|Administer intravenously on 3 times every 28-day cycle
41161252|NCT03214250|DRUG|Gemcitabine|Administer intravenously 3 times every 28-day cycle
41161253|NCT02768077|DRUG|Melatonin(Circadin®)|
41161254|NCT02768077|DRUG|Placebo|
41500733|NCT05195801|DEVICE|USG|Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
41027460|NCT05083767|OTHER|Experimental|The study protocol of WBV includes twelve weeks of whole-body vibration training provided to the Type 2 diabetic patients. It was recommended to all participants that they follow their regular diet and medication during the training. Two sets of six 1-minute vibration squats were designed with 20 seconds of rest, 3 times weekly for a duration 12 weeks (total workout time 36 minutes a week), using a vertical vibration machine. The six static positions consisted of (a) a deep squat position (knee angle 900) (b) an elevated squat position (knee angle 1250) (c) an elevated squat position (with elevated heels) (d) a slight knee flexion1 (hand straps with shoulder bending) (e) a slight knee flexion (hand straps with shoulder abduction) and (f) a slight knee flexion 3 (hand straps with elbow flexion). The training load steadily increased from the initial vibration of 30 Hz and the platform amplitude was raised from 2 mm at week 1 to 40 Hz and from 4 mm at week 5 to the completion of training.
41027461|NCT05083767|OTHER|Control|The control group was advised to their normal physical activity level, diet, and medication.
41027462|NCT04107090|OTHER|lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
41027463|NCT04107090|OTHER|tracheal IL-6 level|tracheal IL-6 level was measured before and after recruitment maneuver
41364988|NCT00962624|DRUG|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
41364989|NCT05718024|DRUG|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
41161255|NCT05818436|PROCEDURE|Procedure: prosthetic functioning|Prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts
41161256|NCT05818436|DEVICE|Conventional dental prosthesis|: conventional prosthetic treatment new prosthesis
41364990|NCT05718024|DRUG|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
41364991|NCT04897126|RADIATION|Shexiang Baoxin pill（MUSKARDIA）|On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.
41364992|NCT04897126|RADIATION|Placebo|On the basis of routine treatment, Placebo were added to 4 capsules / day, 3 times per day until the end of follow-up.
41027464|NCT04107090|OTHER|US guided lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
41027465|NCT04632992|DRUG|Entrectinib|Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
41027466|NCT04632992|DRUG|Inavolisib|Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
41161257|NCT05762471|DRUG|GSBR-1290|Patients will receive GSBR-1290 or matching Placebo
41364993|NCT01510704|DRUG|APD421|IV
41364994|NCT01510704|DRUG|Placebo|IV
41364995|NCT00450814|DRUG|Cyclophosphamide|Given IV
41364996|NCT00450814|OTHER|Laboratory Biomarker Analysis|Correlative studies
41364997|NCT00450814|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
41364998|NCT00450814|OTHER|Pharmacological Study|Correlative studies
40844415|NCT04508491|OTHER|Rate control|Rate control
40844416|NCT05727800|DRUG|VX-668|Suspension for oral administration.
41364999|NCT03580707|DRUG|BRV vs LEV in randomized double blinded, crossover fashion|Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
41365000|NCT06518148|DIAGNOSTIC_TEST|1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)|diagnostic test;UCVA, IOP, Electrophysiological study
41365001|NCT05936190|DRUG|Lidocaine IV|Intravenous infusion rate of lidocaine is 2 mg/kg/min
41365002|NCT05936190|DRUG|Lidocaine|Intravenous infusion rate of lidocaine is 1 mg/kg/min
41365003|NCT03759002|DIAGNOSTIC_TEST|Imaging|Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness
40844417|NCT05727800|DRUG|Placebo|Suspension for oral administration.
40844418|NCT06169852|DEVICE|Neuromodulation eXperiment Testbed system (NEXT) stimulation|Initial studies in this aim will use NEXT to stimulate and record neural activity at clinically effective sites.
40844419|NCT06014099|BEHAVIORAL|Long peripheral venous catheters for blood collection|used LPC for blood collection
40844420|NCT06014099|BEHAVIORAL|Midline catheter for blood collection|used MCs for blood collection
40844421|NCT06014099|BEHAVIORAL|SPCs for blood collection|used SPCs for blood collection
40844422|NCT04814056|DRUG|Afatinib Dimaleate|Afatinib is the second-generation TKI drug, which can irreversibly bind to receptors of erbB family. Afatinib will be administered orally at a dose of 40 mg per time, Q.D. If a patient cannot tolerate a dose of 40mg due to adverse reactions, when the adverse reactions restore to level 1 (CTCAE 5.0) or below, the dosage could be adjusted to 30mg per day, Q.D.
41365004|NCT03759002|OTHER|Blood sampling|Blood sampling will performed on all participants for measuring hematological parameters including MPV.
41365005|NCT03726320|BEHAVIORAL|Education Counseling Session for PSA Screening|counseling from extensively trained CHW
41365006|NCT03726320|BEHAVIORAL|General Health Counseling Coaching|coaching using an educational tool focused on dietary and lifestyle modification
40844423|NCT05660447|DRUG|Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]|One drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
40844424|NCT05660447|DRUG|Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud|Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
40844425|NCT02390180|OTHER|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
40844426|NCT04458415|OTHER|Traxi Panniculus Retractor (TPR)|Surgeon uses the Traxi Panniculus Retractor (TPR) surgical retraction device to retract the panniculus during C-Section.
40844427|NCT04458415|OTHER|Silk Tape|Surgeon uses silk tape to retract the panniculus during C-Section.
40844428|NCT00386165|DRUG|larazotide acetate|larazotide acetate 4 mg capsules
41027467|NCT04632992|DRUG|Alectinib|Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
41161258|NCT05762471|DRUG|Placebo|Patients will receive GSBR-1290 or matching Placebo
41161259|NCT06058117|OTHER|No intervention|no intervention, this is an observational study
41161260|NCT00269841|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
41161261|NCT00269841|DRUG|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
41365007|NCT05707702|BIOLOGICAL|Probiotic oral lozenges|Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.
41365008|NCT05707702|OTHER|Standard of care for oral dysplasia|Oral dysplasia standard of care includes clinical surveillance and risk factor reduction (such as smoking cessation).
41365009|NCT04915365|DRUG|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
41365010|NCT04915365|DRUG|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
40844429|NCT01563185|DRUG|800 mg ibuprofen/26.6 mg famotidine|Oral tablet taken three time per day
40844430|NCT05729984|BEHAVIORAL|Paula exercises|The patients will perform Paula exercises after the cesarean delivery
40844431|NCT05729984|BEHAVIORAL|Gum chewing|The patients will be given chewing gum and will be asked to chew it after the cesarean delivery
40844432|NCT06147583|OTHER|Simulation of an insulin pump failure|The intervention will consist in simulating an insulin pump failure by suspending insulin infusion and monitoring the consequent hyperglycemia.
40844433|NCT01288547|DIETARY_SUPPLEMENT|theobromine|700 mg theobromine in gelatin capsules given one time only
40844434|NCT01288547|DIETARY_SUPPLEMENT|Caffeine|120 mg caffeine in capsules given one time only
40844435|NCT01288547|DIETARY_SUPPLEMENT|caffeine + theobromine|120 mg caffeine and 700 mg theobromine in capsules given one time only
40844436|NCT01288547|DIETARY_SUPPLEMENT|placebo|cellulose in capsules given one time only
40844437|NCT05790980|DEVICE|Abdominal ultrasound|Abdominal US to exclude splenomegaly and hepatomegaly or liver cirrhosis Echocardiology to show cardiac dysfunction
41027468|NCT04632992|DRUG|Ipatasertib|Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
41027469|NCT04632992|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
41027470|NCT04632992|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
41161262|NCT00269841|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
41161263|NCT04140422|OTHER|Hyperosmolar eye drops|Application of one preservative-free hyperosmolar eye drop, when waking up and one eye drop 30 min later to one eye by the investigators
41161264|NCT04140422|OTHER|Placebo|Application of one preservative-free lubricating eye drop, when waking up and one eye drop 30 min later to the fellow eye by the investigators
41365011|NCT03029793|OTHER|Biomarkers Testing|CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
40844438|NCT03460912|DEVICE|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.They compared each others(bipolar vs monopolar) via amplitudes and latency values.
40844439|NCT01377870|BIOLOGICAL|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
40844440|NCT01377870|BIOLOGICAL|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
40844441|NCT04424927|BIOLOGICAL|PRV-015|Fully human monoclonal antibody against interleukin 15 (IL-15)
40844442|NCT04424927|OTHER|Placebo|Placebo
40844443|NCT06383468|DRUG|AK120|300mg Q2W subcutaneous injection thereafter until week 50.
40844444|NCT06114719|DRUG|Silymarin|Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).
40844445|NCT00448305|DRUG|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
40844446|NCT00448305|DRUG|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
40844447|NCT00448305|DRUG|Paclitaxel|Paclitaxel 90 mg/m² weekly
40844448|NCT05032339|DIAGNOSTIC_TEST|IUO Plasma Cell Disorders Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of plasma cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, plasma cell disorders.
40844449|NCT01700712|DIETARY_SUPPLEMENT|Probiotic Lactobacilli reuteri|
40844450|NCT01700712|DIETARY_SUPPLEMENT|Placebo|
40844451|NCT02139904|DRUG|Vinorelbine|Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
40844452|NCT02139904|OTHER|Active Symptom Control|
41161265|NCT05021965|PROCEDURE|different combined of tooth bleaching procedure|The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.
41365012|NCT03029793|OTHER|Functional Imaging analysis|The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
40844453|NCT00471887|BIOLOGICAL|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
40844454|NCT01792518|DRUG|Placebo|
40844455|NCT01792518|DRUG|Linagliptin 5mg|
40844456|NCT03053869|DRUG|Benzodiazepine - limited use strategy|"1. No routine use of any intraoperative benzodiazepines.~2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
40844457|NCT03053869|DRUG|Benzodiazepine - Ad libitum strategy|"1. Administration of some benzodiazepine to most patients undergoing cardiac surgery.~2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
40844458|NCT04872985|DRUG|Pyrotinib|400 mg orally once per day
40844459|NCT04872985|DRUG|Epirubicin|100 mg/m2,q3W\*4
41027471|NCT04632992|DRUG|Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
40844460|NCT04872985|DRUG|Doxorubicin Hydrochloride Liposome Injection|30mg/m2, q3w\*4
40844461|NCT04872985|DRUG|Cyclophosphamide|600 mg/m2, q3w\*4
40844462|NCT04872985|DRUG|Docetaxel|100 mg/m2, q3w\*4
40844463|NCT04872985|DRUG|Nab paclitaxel|120mg/m2 qw\*12
40844464|NCT04872985|DRUG|Placebo|400 mg orally once per day
40844465|NCT03984656|DRUG|lidocaine treatment|The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.
41027472|NCT04632992|DRUG|Tucatinib|Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
41027473|NCT04632992|DRUG|Investigator's Choice of Chemotherapy|Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
41027474|NCT04632992|DRUG|Paclitaxel|The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
41027475|NCT04632992|DRUG|Tiragolumab|Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
41365013|NCT05005715|DRUG|Dexmedetomidine|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
41365014|NCT05005715|DRUG|normal saline|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
41365015|NCT01295073|DRUG|Trientine Hydrochloride|"Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.~All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery."
41365016|NCT01295073|OTHER|For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.|see above
41365017|NCT02549040|DRUG|Treatment A: Doravirine 100 mg film coated tablet|Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
41365018|NCT02549040|DRUG|Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)|Single doravirine NF Type 1 dose (150 mg tablet \[40% drug loaded granule\]) administered orally at the start of Period 1
41365019|NCT02549040|DRUG|Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)|Single doravirine NF Type 2 dose (150 mg tablet \[30% drug loaded granule\])administered orally at the start of Period 3
41365020|NCT02549040|DRUG|Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)|Single doravirine NF Type 3 dose (150 mg tablet \[50% drug loaded granule\])administered orally at the start of Period 4
41365021|NCT02549040|DRUG|Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)|Single doravirine NF Type 4 dose (100 mg tablet \[30% drug loaded granule\]) administered orally at the start of Period 5
41365022|NCT04944121|DRUG|RSLV-132|10 mg/kg RSLV-132 administered by intravenous infusion
41365023|NCT04944121|DRUG|Sodium Chloride 0.9%|0.9% sodium chloride administered by intravenous infusion
41365024|NCT05115812|PROCEDURE|Pre-Operative Information|Demographics (e.g., age, gender), patient characteristics (e.g., BMI, American Society of Anesthesiologists class), and pre-operative medical history (e.g., tobacco use; comorbidities: hypertension, cardiopulmonary disease, diabetes; indication for RAT; lesions; previous renal revascularization; serum creatinine level).
41365025|NCT05115812|PROCEDURE|Intra-Operative Data|Operative time, total OR time, concomitant procedures, transfusions, conversions, intraoperative adverse events, autotransplantation technique
41365026|NCT05115812|OTHER|Post-Operative Data (up to discharge)|Postoperative adverse events, discharge status, hospital length of stay, information on enhanced recovery program
41365027|NCT05115812|OTHER|Short-Term Follow-Up Data|Adverse events, re- admissions, re-operations related to the index procedure
41365028|NCT01829529|DRUG|Amoxicillin|Amoxicillin
41365029|NCT05352451|BEHAVIORAL|Interventional Survey|Complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member. The first interview, will ask about some basic information. In the second and last interview, will ask about experience of the coaching sessions and about how you feel about your decisions regarding your treatment and care. At each of the two time points, you and your caregiver will be interviewed separately. The video-conferencing, will be conducted through Zoom, which is a secure, widely used software which allows people to communicate remotely with computers, tablets, or smart phones. The software is available free of charge to you if you have a computer or other suitable device and internet.
41365030|NCT01527058|DRUG|68Ga-BNOTA-PRGD2|"Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs"
41365031|NCT05782504|BEHAVIORAL|Patient-centered teleprehabilitation|"Education about the consequences of stress and low physical activity levels with examples of how improving stress tolerance and physical activity can influence QoL and oncological treatment outcomes.~Exercise therapy based on shared-decision making and using a patient-centered approach. The goal will be to strive for 150-220 min. of moderate physical activity/week, including a home exercise program (at least 1 session/week) of 30-45 min. moderate aerobic exercise, 20 min. of strength training and 10 min. cool down. The latter is guided by Physitrack software.~Stress management, including questioning personal stress experiences and perceptions, relevant stressors, and stress coping strategies. Next, 3 different relaxation strategies will be explained. Also, cognitive-emotional approaches to stress management and identification of uplifts will be introduced.~Motivational interviewing will be used during the whole intervention."
41161266|NCT05803902|DRUG|Experimental drug 9MW1911|Experimental drug administered with IV infusion
41161267|NCT05803902|DRUG|Placebo|Placebo administered with IV infusion
41161268|NCT00300963|DRUG|Talnetant|
41365032|NCT03247140|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
41365033|NCT03247140|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
41365034|NCT05720923|DEVICE|Analysis with Ergometer|The analysis with the ergometer aims at assessing neuromuscular function
41365035|NCT03844282|DIAGNOSTIC_TEST|Clinical assessment (SCAT5)|The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
41365036|NCT03844282|DIAGNOSTIC_TEST|ImPACT|ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online or using desktop software in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
40844466|NCT03984656|DRUG|serratus plane block treatment|"The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~* anterior serratus large muscle (serratus anterior)~* intercostal muscle~* 4th and 5th ribs~* pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block."
40844467|NCT00932165|DRUG|Exemestane|"Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal."
41365037|NCT03844282|BEHAVIORAL|CANTAB|"Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) platform includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.~The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test."
40844468|NCT03354624|DRUG|Sterile solutions of recombinant human nerve growth factor (NGF)|The intramuscular injections of NGF cause muscle soreness.
40844469|NCT01953900|GENETIC|GD2 T cells|"On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.~Dose Level 1: 1x10\^6 cells/m\^2~Dose Level 2: 1x10\^7 cells/m\^2~The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:~Dose Level 7: 1 x 10\^7 cells/m2~Dose Level 8: 1 x 10\^8 cells/m\^2~Dose levels 9-11 will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine prior to administration of the T cells.~Dose Level 9: 1 x 10\^8 cells/m\^2~Dose Level 10: 5 x 10\^8 cells/m\^2~Dose Level 11: 1 x 10\^9 cells/m\^2~The previously planned dose levels 3-6 will not be studied."
40844470|NCT01953900|BIOLOGICAL|VZV vaccine|Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.
40844471|NCT01953900|DRUG|Fludarabine|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
41161269|NCT02641106|OTHER|Video Directly Observed Therapy|Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
41365038|NCT03844282|DIAGNOSTIC_TEST|I-PAS/Dx100|I-PAS™ (now re-named Dx 100) is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
41365039|NCT03844282|BIOLOGICAL|Saliva sample|Micro RNA's (miRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include miRNA and other markers of injury.
41365040|NCT03844282|OTHER|fMRI|RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
41365041|NCT00175734|PROCEDURE|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
41365042|NCT00175734|PROCEDURE|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
41365043|NCT04486586|DEVICE|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm\^2; estimated total charge 0.048 C/cm\^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).
41161270|NCT02641106|OTHER|In-Person DOT|Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
41161271|NCT01831726|DRUG|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
41161272|NCT00999141|BIOLOGICAL|FS VH S/D 4 s-apr|FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
41161273|NCT03793322|DRUG|Indocyanine-Green(ICG)|ICG was administered intravenously 24 hours before the operation , or directly into the portal vein branches supplying the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
40844472|NCT01953900|DRUG|Cyclophosphamide|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
40844473|NCT03657095|DRUG|Esuberaprost|Sodium tablets
40844474|NCT03657095|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
40844475|NCT02796508|BEHAVIORAL|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
40844476|NCT02796508|BEHAVIORAL|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
40844477|NCT01828411|DEVICE|Transpharyngeal ultrasonography|Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
40844478|NCT01828411|DEVICE|Duplex sonography|Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
40844479|NCT02524418|PROCEDURE|Cholangiopancreatoscopy|An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
40844480|NCT04424693|DRUG|Tdap Vaccine Administration|Tdap vaccinations are routinely given during pregnancy between weeks 27 and 36 per guidelines of American College Obstetrics and Gynecology (ACOG) -- but this study uniquely is trying to establish that the earlier Tdap vaccinations reduce preeclampsia by more than 50%
40844481|NCT03180307|DRUG|OTL38|0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
40844482|NCT03180307|DEVICE|near infrared camera imaging system|Infrared imaging used to excite OTL38 for fluorescence
40844483|NCT03180307|PROCEDURE|laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
40844484|NCT05079477|BEHAVIORAL|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
40844485|NCT05079477|BEHAVIORAL|Exposure to calorie information|Calories for all beverages and foods
40844486|NCT03230682|DRUG|antidepressant|regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
41365044|NCT04486586|DEVICE|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).
40844487|NCT02641717|OTHER|vaginal swab|
40844488|NCT05011526|BIOLOGICAL|MVC-COV1901|Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
41161274|NCT03254992|DEVICE|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
41365045|NCT04019028|DEVICE|low frequency rTMS + Navigation System|1Hz low-frequency rTMS stimulation over primary motor area using navigation system
40844489|NCT05011526|BIOLOGICAL|AZD1222|Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
40844490|NCT00503321|DRUG|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
40844491|NCT00503321|DRUG|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
40844492|NCT01772576|DEVICE|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
40844493|NCT04499222|DEVICE|Portex|nasotracheal intubation with PORTEX POLAR \[Smiths Medical International, Hythe, United Kingdom\] nasotracheal tube.
40844494|NCT04499222|DEVICE|Mallinckrodt|nasotracheal intubation with Mallinckrodt TaperGuard \[Covidien, Ireland\] nasotracheal tube.
40844495|NCT03671915|DEVICE|Continuous Glucose Monitoring|collection of glucose data
40844496|NCT03671915|DEVICE|External Insulin Pump|Insulin delivery
40844497|NCT03671915|DEVICE|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
40844498|NCT03671915|OTHER|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
40844499|NCT02412332|PROCEDURE|Bone marrow harvesting|Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.
40844500|NCT02412332|PROCEDURE|Liposuction|Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
40844501|NCT01797913|DRUG|gemcitabine|gemcitabine，1000mg/m2，ivgtt，DAY1\&DAY8
40844502|NCT05147805|DRUG|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
40844503|NCT05147805|DRUG|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
41161275|NCT03254992|DEVICE|ASD - Tangible task|Experimental group using Keyboard with more real activity.
41161276|NCT03254992|DEVICE|TD - Abstract task|Control group using Kinect with more virtual activity.
41161277|NCT03254992|DEVICE|TD - Tangible task|Control group using Keyboard with more real activity.
41365046|NCT04019028|DEVICE|only low frequency rTMS|1Hz low-frequency rTMS stimulation over primary motor area
41365047|NCT04019028|DEVICE|Sham low frequency rTMS + Navigation System|1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
40844504|NCT05670132|OTHER|Neurocardiac rehabilitation program|Patients receiving a neurocardiac rehabilitation program for 12 weeks.
41161278|NCT01355471|DRUG|CD07805/47 Gel|applied topically once daily
41161279|NCT01355471|DRUG|Placebo|applied topically once daily
41365048|NCT05956782|BEHAVIORAL|Breathe Easier|See Intervention Group (IG) description.
41365049|NCT04914650|OTHER|Telerehabilitation|Providing multidisciplinary rehabilitation to individuals with spinal cord injury or brain injury using virtual conference methods
41365050|NCT00495963|PROCEDURE|bronchoaleolar lavage|
40844505|NCT05670132|OTHER|Standard of care|No intervention during the neurocardiac rehabilitation program
40844506|NCT05417308|DRUG|Minoxidil|Applied topically
40844507|NCT05417308|DRUG|Minoxidil|Given PO
41161280|NCT00132951|DRUG|Telithromycin|Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
41161281|NCT00132951|DRUG|Azithromycin|Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
41161282|NCT00812721|OTHER|Preservative Free Saline|One drop will be instilled into each eye once
41161283|NCT00812721|OTHER|Optive|One drop will be instilled into each eye once
41161284|NCT00812721|OTHER|Refresh Moderate/Severe|One drop will be instilled into each eye once
41161285|NCT00812721|OTHER|Systane|One drop will be instilled into each eye once
41161286|NCT00812721|OTHER|Systane Ultra|One drop will be instilled into each eye once
41161287|NCT02852655|DRUG|MK-3475|
41161288|NCT04868318|OTHER|Very-high protein enteral formula|Peptamen® Intense VHP (37% protein)
41365051|NCT00495963|PROCEDURE|Bronchoscopy|
41365052|NCT04138758|DRUG|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
41365053|NCT04138758|DRUG|LABA/ICS|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
41365054|NCT04391894|DRUG|ECF843|Topical ocular eye drop
41365055|NCT04391894|OTHER|ECF843 vehicle|Topical ocular eye drop
41365056|NCT00736840|DEVICE|c13 methacetin solution with breath analyzer|Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
41365057|NCT01827462|BIOLOGICAL|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
41365058|NCT01827462|BIOLOGICAL|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
41365059|NCT01827462|BIOLOGICAL|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
41365060|NCT02063802|DRUG|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
40844508|NCT05417308|OTHER|Quality-of-Life Assessment|Ancillary studies
40844509|NCT05417308|OTHER|Questionnaire Administration|Ancillary studies
41027476|NCT04632992|DRUG|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
41365061|NCT02063802|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
40844510|NCT02809378|DRUG|Palonosetron|newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
40844511|NCT02809378|DRUG|sevoflurane|Inhalational anesthetics Halogenated.
40844512|NCT02809378|DRUG|remifentanil|ultra-short acting opioid anesthetics
40844513|NCT02809378|DRUG|pentothal sodium|intra-venous anesthetics for anesthesia induction
40844514|NCT02809378|DRUG|propofol|intra-venous anesthetics for anesthesia induction and maintenance
40844515|NCT03750643|DRUG|LY3454738|Administered IV
40844516|NCT03750643|DRUG|LY3454738|Administered SC
40844517|NCT03750643|DRUG|Placebo|Administered IV
41027477|NCT06532344|DRUG|ONO-7913|Specified dose on specified days
41027478|NCT06532344|DRUG|ONO-4538|Specified dose on specified days
41027479|NCT06532344|DRUG|Oxaliplatin|Specified dose on specified days
41027480|NCT06532344|DRUG|Levofolinate|Specified dose on specified days
41027481|NCT06532344|DRUG|Irinotecan|Specified dose on specified days
41027482|NCT06532344|DRUG|Fluorouracil|Specified dose on specified days
41027483|NCT00046345|DRUG|Atazanavir (BMS-232632)|
41027484|NCT00709384|PROCEDURE|Prophylactic surgical lesion|A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
41365062|NCT02063802|DRUG|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
41161289|NCT04868318|OTHER|Standard-high protein enteral formula|Peptamen® (16% protein)
41161290|NCT03090633|DEVICE|Fetoscopy|Minimally invasive in-utero surgery
41500734|NCT04879680|PROCEDURE|sentinel node detection|Under general anesthesia 5 ml at 2.5mg/ml of Infracyanine ® (Laboratoire SERB; France) were injected circumferentially around the areola. Two ml of patent blue-V dye (Laboratoire Guerbet, Aulney-Sous-Bois, France) were injected in combination in the cohort of patients undergoing the procedure after primary chemotherapy. This was followed by a breast massage to facilitate absorption into the lymph vessels, then the surgical lights were turned off and image were obtained under near-infrared light using a first generation Near Infra Red (NIR) device \[K\]. Course of subcutaneous lymphatic drainage pathway fluorescence was followed up to where it disappeared to enter to deeper axilla and an incision was performed at that place. Lymphatic duct identification using the NIR camera allowed localization and removal of the sentinel lymph node(s).
41500735|NCT01035983|DRUG|Frovatriptan 2.5 mg|
41365063|NCT02063802|BEHAVIORAL|Healthy habits program|
41365064|NCT00656331|DRUG|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
41365065|NCT00511966|OTHER|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
40844518|NCT04188145|DRUG|Fluoropyrimidine|"Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15)."
40844519|NCT04188145|DRUG|Bevacizumab|"Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab"
40844520|NCT03684694|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion.
41027485|NCT06297538|DEVICE|gamma transcranial alternating current stimulation (tACS)|Transcranial alternating current stimulation (tACS) will be delivered using a BrainSTIM (EMS, Italy) connected to two electrodes (5x5cm) enclosed in sponges soaked with saline solution. One electrode will be centred over the first dorsal interosseus (FDI) hotspot and the other over P3. tACS will be delivered at peak-to-peak amplitude of 1 milliampere (mA), and with 3-seconds ramp-up and down periods. The stimulation frequency will be 70 Hz, as representative of the endogenous motor network-related gamma frequency.
41027486|NCT06297538|DEVICE|sham transcranial alternating current stimulation (tACS)|Sham-tACS will consist of ramp-up and down periods and only 1-second stimulation at 1 mA amplitude.
41027487|NCT05361473|DEVICE|The NeoHilda Point of care method|This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
41500736|NCT01846910|BEHAVIORAL|Tooth Whitening|1. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used
40844521|NCT03684694|DRUG|Ibrutinib|Oral capsule.
40844522|NCT01780753|DRUG|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
41027488|NCT05361473|PROCEDURE|Traditional evaluation|Traditional way of evaluation
41027489|NCT03299140|BEHAVIORAL|Family Focused Therapy|
41027490|NCT05273892|BEHAVIORAL|Diet + Activity + Sleep|Personalized lifestyle behavior change counselling
41027491|NCT05273892|BEHAVIORAL|Diet + Activity|Personalized lifestyle behavior change counselling
41027492|NCT03112616|OTHER|Vibration sessions|The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
41365066|NCT00511966|DRUG|Rabeprazole|As prescribed
41365067|NCT03737812|DRUG|elezanumab|solution for infusion
41365068|NCT03737812|DRUG|placebo|solution for infusion
41365069|NCT05121818|PROCEDURE|PCI|Primary percutaneous coronary intervention
41365070|NCT01938027|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
41365071|NCT01334138|OTHER|A 4-week diet, low in sodium.|"Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.~Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires."
41365072|NCT04350749|BIOLOGICAL|PRF is added in the test group.|The PRF membrane can be considered as a biological membrane
41365073|NCT01760317|PROCEDURE|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
41365074|NCT05652361|OTHER|Additional visualisation of surgical assistance during surgery|Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques
41365075|NCT02155166|DRUG|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
41365076|NCT02155166|DRUG|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
41500737|NCT01846910|BEHAVIORAL|Motivational Counseling|Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
41500738|NCT05727618|DRUG|Pituitrin|The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
41500739|NCT05727618|DRUG|normal saline|Intravenous infusion of normal saline at the same dose and speed
41500740|NCT06035809|BEHAVIORAL|SMART|A movement and body-based intervention in which participants are encouraged to explore the use of sensory equipment, which may help reduce symptoms related to psychological trauma/PTSD. Sensory equipment includes exercise balls, mini-trampoline, weighted blankets, and a hammock swing.
41500741|NCT01496300|PROCEDURE|Manual Intervention|Implantation of acetabular component without the use of the navigation system information
41500742|NCT01496300|PROCEDURE|Navigated Intervention|Navigated implantation of acetabular component using OrthoPilot image free navigation system
40844523|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Unified protocol|"Treatment condition:~The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week."
41027493|NCT02835534|DRUG|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
41500743|NCT06518603|DRUG|Caffeine citrate 20mg/kg/day|Caffeine citrate 20mg/kg/day given orally once daily for 28 days
41500744|NCT06518603|DRUG|Placebo-Sterile water 1ml/kg/day|Placebo-sterile water 1mg/kg/day given orally once daily for 28 days
41500745|NCT00045864|DRUG|Recombinant Human Interleukin-2 and Rituximab|
41500746|NCT01896999|PROCEDURE|Biopsy|Undergo biopsy
41500747|NCT01896999|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41500748|NCT01896999|DRUG|Brentuximab Vedotin|Given IV
41500749|NCT01896999|PROCEDURE|Computed Tomography|Undergo CT
41027494|NCT02835534|DRUG|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
41365077|NCT00367380|OTHER|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
41365078|NCT00367380|OTHER|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
41365079|NCT00367380|OTHER|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
41500750|NCT01896999|BIOLOGICAL|Ipilimumab|Given IV
41500751|NCT01896999|BIOLOGICAL|Nivolumab|Given IV
41500752|NCT01896999|PROCEDURE|Positron Emission Tomography|Undergo PET
41500753|NCT04429438|BIOLOGICAL|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after conventional chemotherapy will be treated with multiple 4SCAR gene-engineered T cells
41500754|NCT06632249|OTHER|Practice with the virtual reality game|4 weeks of practice with the virtual reality game, totalling 20 sessions, 5 supervised in the laboratory and 15 at home with remote monitoring.
41500755|NCT04400682|DRUG|FAVIRA 200 MG Film Tablet|FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.
41500756|NCT04400682|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
41500757|NCT04244578|DEVICE|Active tDCS|Active tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
41365080|NCT03655951|BEHAVIORAL|Web-based resource on adolescent sexual health|Web-based resource on adolescent sexual health than the intervention.
41365081|NCT03655951|BEHAVIORAL|Alternate web-based resource on adolescent sexual health|This is a different web-based resource on adolescent sexual health than the intervention.
41365082|NCT00372073|DRUG|seliciclib|1200 mg bid x 3 days every 2 weeks
41365083|NCT00372073|DRUG|placebo|1200 mg bid x 3 days every 2 weeks
41365084|NCT02736487|DEVICE|True-Washout-Sham Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
41027495|NCT06532838|PROCEDURE|Optimized treatment strategies|The optimized strategies based on 6-hour threshold from symptom onset. For malperfused patients with symptom onset within 6 hours, central repair will be performed immediately. Additional stenting will be used in patients with persistent malperfusion. For malperfused patients with symptom onset beyond 6 hours, individualized delayed central repair according to the different types of MPS will be performed after organ function improved and the patient could tolerate central repair.
41027496|NCT06532838|PROCEDURE|Traditional treatment strategies|Immediate central repair will be performed for patients with coronary and cerebral malperfusion syndrome. However, for patients with mesenteric and lower extremity malperfusion syndrome, interventional therapy will be administered through fenestration and/or stenting to ﬁrst alleviate organ ischemia. Once the patients had a resolution of organ failure, corrective open aortic repair will be performed.
41365085|NCT02736487|DEVICE|Sham-Washout-True Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
41027497|NCT03391648|OTHER|Observation|Observation only
41027498|NCT00889421|DRUG|Apremilast|oral dose of 30 mg BID for 6 months
41161291|NCT00557349|DRUG|Omeprazole|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
41365086|NCT05845554|DIAGNOSTIC_TEST|The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.|The extracted gDNA from bile sample will be analyzed by BileCAD to determine the level of CINs.
41365087|NCT04797364|DIAGNOSTIC_TEST|Pharmacogenetic Testing|Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
41365088|NCT05579938|DIETARY_SUPPLEMENT|Enzyme-containing lozenge|A lozenge containing 3 active enzymes
41365089|NCT05579938|DIETARY_SUPPLEMENT|Placebo lozenge|Identical placebo lozenge
41365090|NCT03253380|OTHER|Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients|Early rehabilitation of MV patients in the respiratory ICU
41365091|NCT05416086|DEVICE|cryoablation procedure using the iCLAS Cryoablation System|all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon
41161292|NCT00557349|DRUG|Famotidine|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
41365092|NCT03087682|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
41365093|NCT03198559|DRUG|Disulfiram, (National Drug Code) NDC 0378-4141-01|This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
41365094|NCT03198559|DRUG|Vorinostat, NDC 00006-0568-40|This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
41365095|NCT06478706|DRUG|ETD001|Twice daily doses
41365096|NCT06478706|DRUG|Placebo|Twice daily doses
41365097|NCT04073680|DRUG|Serabelisib|Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications
41161293|NCT02218775|DRUG|LY2456302|Mood and Anxiety Disorders
41365098|NCT04073680|DRUG|Canagliflozin 300mg|All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib
41365099|NCT03674645|DEVICE|MRI acquisitions|Procedure of the study is an MRI exam without any injection or invasive procedure, that will be performed on the Siemens Magnetom Aera imager of Liryc institute (L'Institut de RYthmologie et modélisation Cardiaque) (Xavier Arnozan site - Bordeaux)
41027499|NCT00439777|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
41027500|NCT00439777|DRUG|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
41161294|NCT05820321|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (400mg) during 8-days. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will return to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
41365100|NCT03182673|DRUG|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
41365101|NCT03182673|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
41365102|NCT03182673|DRUG|SHR3162|SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
41365103|NCT04673552|PROCEDURE|laparotomy|Any open procedure such as laparotomy or lumbotomy for acute necrotizing pancreatitis will be evaluated, with assessment of results, complications and deaths
41365104|NCT05223504|DEVICE|Continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
41365105|NCT02414100|OTHER|Laboratory Biomarker Analysis|Correlative studies
41365106|NCT02414100|OTHER|Cytology Specimen Collection Procedure|Correlative studies
41365107|NCT06003283|DRUG|Rituximab|IV rituximab
41365108|NCT05557292|DRUG|RMC-5552|Given IV
41365109|NCT02487524|OTHER|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
41365110|NCT02487524|OTHER|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
41365111|NCT02487524|OTHER|QST|Quantitative sensory testing.
41500758|NCT04244578|DEVICE|Sham tDCS|Sham tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), but the current will be applied for 30 s and will be ramped down without the participants awareness.
41500759|NCT06176989|DRUG|Enasidenib|100mg PO (orally) once daily, on days 1-28 of a 28-day cycle
41027501|NCT06050421|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as resistant depression, avoidant and obsessive-compulsive personality disorders, mood disorders, anorexia nervosa and autism spectrum disorder.
41027502|NCT06050421|OTHER|Treatment As Usual|he TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
41027503|NCT06050421|OTHER|No intervention|All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
41027504|NCT06389812|OTHER|Dual-task exercise traning|To assess the dynamic effects of each intervention, only one session (30 mins) will be provided. The chair-based exercise session consists of three parts 5 min of active stretching exercises to warm-up, 20 mins of resistance band exercises in a sitting position (Elliott-King et al., 2019) (please see the link for detailed descriptions for seated resistance band workout) and 5 min of passive stretching exercises to cold down. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function
41365112|NCT05621109|BEHAVIORAL|Weight loss intervention|"Subjects will receive very low-calorie diet for 8-10 weeks to introduce a rapid weight loss of approximately 10%. Once target weight is achieved, participants will be reintroduced to foods to introduce weight stability.~The male will follow the maternal randomization, i.e. weight loss if BMI ≥25 until a BMI of 23 or a weight loss of approximately 10% is obtained.~During weight loss maintenance, subjects will receive dietary counseling to follow a diet high in protein (corresponding to 22-25E%), high fiber and wholegrain while fulfilling the requirements for essential fatty acids, micronutrients and trace elements in accordance with Nordic Nutrition Recommendations (NNR) 2012.~Throughout the study period participants will be encouraged to follow the official recommendations for physical activity as recommended by the Danish health authorities 2022."
41027505|NCT05710523|BEHAVIORAL|I-ACE training|"The I-ACE training encompasses a training on the non-pharmacological therapies' methodology and a training on awareness of body language which favors a passage from implicit to explicit knowledge. It allows the reading of the subjective relational experience of the care situation by the professional caregiver and a comparison of shared readings of the situation itself by the group of colleagues, and with the residents. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia.~Ten monthly supervisions, each lasting two hours, on theatrical exercises guided by an expert actor, with the help of a psychologist-psychotherapist who promotes understanding and awareness of self-reading in the relationship with the other."
41027506|NCT05710523|OTHER|Standard non-pharmacological therapies (NPT) training|"The standard NPT training encompasses a training on the non-pharmacological therapies' methodology. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia."
41027507|NCT02688634|DRUG|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
41027508|NCT05515302|OTHER|Audio Clip|Selected Audio clips will be introduced to the study subjects during the Burns Dressing Changes. The Audio Clips will be selected as per subjects preference.
41027509|NCT02394743|RADIATION|18FDG-PET|
41027510|NCT04574544|DRUG|Zinc Supplementation|The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
41027511|NCT04574544|BEHAVIORAL|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
41365113|NCT04066205|BEHAVIORAL|SLEEPSAMRT|SLEEPSMART will be designed to improve sleep by providing guidance and structure to assist JIA children and their parent in adhering to the intervention protocol. The intervention will be interactive and personalized; users will interface with three primary components:1) monitoring: daily records of sleep and symptoms; 2) skill building modules: sleep education, sleep skills training, relaxation techniques, positive coping skills, and reward systems for activity participation for reducing sleep deficiency; and 3) assignment review and personalized feedback via behavioral assignments for skill implementation and tailored feedback. Modules will take an estimated 30 minutes each week to complete and will include multimedia elements to enhance learning.
41365114|NCT00804596|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
41365115|NCT03471494|OTHER|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
41365116|NCT00137527|DEVICE|Optimizing hemodynamic and anesthetic parameters to improve cerebral perfusion|
40844524|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Affect phobia treatment|The aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
40844525|NCT05016843|OTHER|Treatment condition: Waitlist control|The waitlist condition is a control condition without any intervention.
40844526|NCT05016843|OTHER|Treatment length: 8 weeks|Participants will partake in their treatment condition for 8 weeks.
40844527|NCT05016843|OTHER|Treatment length: 16 weeks|Participants will partake in their treatment condition for 16 weeks.
40844528|NCT05016843|OTHER|Access to a moderated forum|During their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition.
40844529|NCT05016843|OTHER|No access to a moderated forum|Participants will not have access to a moderated forum, hence their treatment is self-guided.
40844530|NCT02950844|OTHER|Novel mapping algorithm|"Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF."
40844531|NCT03582995|PROCEDURE|Flap Surgery for root coverage with Alloderm and xenograft|A coronally positioned FLAP technique with AlloDerm® GBR and osseous xenograft will be used for root coverage
40844532|NCT03582995|PROCEDURE|Tunnel Surgery for root coverage with Alloderm and xenograft|A coronally positioned TUNNEL technique with AlloDerm® GBR and osseous xenograft will be used for root coverage.
40844533|NCT01681524|DRUG|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
41027512|NCT00319423|PROCEDURE|Patient education and supervised exercise|Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
41027513|NCT03884283|DEVICE|FIBERGRAFT BG Matrix|Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with autograft and bone marrow aspirate (BMA)
41027514|NCT03584594|DIAGNOSTIC_TEST|Presepsin measurement|Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).
41365117|NCT04220229|DRUG|Cabozantinib S-malate|Given PO
41365118|NCT04220229|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
41365119|NCT04648943|PROCEDURE|Ex-Press mini shunt insertion|
41365120|NCT04648943|PROCEDURE|Trabeculectomy|
41365121|NCT06287554|OTHER|PRONE POSITION|early placed in prone positions within 24 hours of intubation
41365122|NCT02661789|DRUG|Goserelin 3.6 mg implant|Pharmacologically induced biphasic sex-steroid hormone fluctuation
41365123|NCT02661789|DRUG|Placebo|Injection of saline
41365124|NCT00603369|BEHAVIORAL|group intervention|13-session intervention
41365125|NCT00603369|BEHAVIORAL|group intervention|2-session intervention
41365126|NCT04061668|OTHER|single needle path PECS I and II block group|The probe is placed inferior to the clavicle . The US probe is placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised . The probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles ise identified at 4th rib at the level of thoraco-acromial artery , the needle is inserted in plane with the probe from caudal to cranial using an inclined manner, 15mL of bupivacaine is put into the potential space between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject another 15 ml of bupivacaine in the plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection is visualised.
41027515|NCT03754023|DIAGNOSTIC_TEST|Urine-TIMP-IGFBP7 biomarker for AKI|Urine-TIMP-IGFBP7 biomarker for AKI
41027516|NCT03062891|PROCEDURE|Online CBT for insomnia|See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
41027517|NCT04660357|OTHER|survey study|survey study
41365127|NCT04061668|OTHER|double needle path PECS I and II block group|The US probe will be initially placed below outer third of the clavicle after skin sterilization showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised, then the needle will be inserted in plane with the probe and 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis muscles. In the second puncture , the US probe will be moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle will be inserted in plane with the probe from caudal to cranial in an inclined way, 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
41365128|NCT03601429|DIETARY_SUPPLEMENT|Lactogyn|capsules
41365129|NCT03601429|DIETARY_SUPPLEMENT|Placebo|capsules
41365130|NCT06446297|OTHER|Focus Group.|Participants in each focus group will attend a face-to-face (or virtual) meeting that lasts approximately 90 minutes. This will be composed of a briefing period, interview period supported and guided by an interview schedule and finishing with a debrief period. The same process will be followed if individual semi-structured interviews are undertaken.
41365131|NCT03285581|DEVICE|truSculpt RF|Subjects will receive RF treatments
41365132|NCT03010046|DRUG|ANX005|Single ascending dose intravenous infusion
41365133|NCT03010046|DRUG|IVIg|IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.
41365134|NCT03010046|DRUG|Placebos|0.9% saline intravenous infusion
41365135|NCT02735876|DRUG|acalabrutinib|
41027518|NCT02451345|BEHAVIORAL|Personalized risk model+website+coaching intervention|"A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.~The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care."
41027519|NCT00298233|DRUG|Oseltamivir|Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
41365136|NCT02735876|DRUG|ibrutinib|
41365137|NCT02735876|DRUG|rituximab|
41365138|NCT05907031|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
41365139|NCT05907031|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
41027520|NCT04621305|OTHER|normal saline|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered
41365140|NCT03964311|OTHER|Emergency Room Evaluation Tool (ER2)|Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
41365141|NCT02974764|OTHER|No intervention/exposures|
41365142|NCT01747733|DEVICE|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
41365143|NCT02183220|DRUG|Metamizol|
41365144|NCT02183220|DRUG|Acetylsalicylic acid (ASA)|
41365145|NCT02183220|DRUG|Metamizol placebo|
41365146|NCT02183220|DRUG|ASA placebo|
41500760|NCT00293943|PROCEDURE|Pulmonary vein ablation|
41365147|NCT04212026|DRUG|Nivolumab|The patients start treatment with nivolumab on day 1 after IRE and will be given nivolumab at a flat dose of 240 mg every 2 weeks (q2wk) for 5 cycles until Week 8.
41365148|NCT04372121|DRUG|75 mg linzagolix tablet|For oral administration once daily
41365149|NCT04372121|DRUG|200 mg linzagolix tablet|For oral administration once daily
41365150|NCT04372121|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
41365151|NCT04372121|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
41365152|NCT04372121|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
41365153|NCT04372121|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
41365154|NCT00125736|DRUG|E0671|One 50 mg capsule is orally administered three times daily (150 mg/day)
41365155|NCT00125736|DRUG|rabeprazole sodium|One 10mg tablet is administered orally each day
41365156|NCT00125736|DRUG|E0671 placebo|One 50 mg capsule is orally administered three times daily (150 mg/day)
41365157|NCT00187655|DRUG|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
41365158|NCT05102773|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
41365159|NCT05102773|PROCEDURE|Computed Tomography|Undergo CT
41365160|NCT05102773|OTHER|Laboratory Biomarker Analysis|Correlative studies
40844534|NCT01717326|DRUG|Grazoprevir|100 mg tablet orally QD
41365161|NCT05102773|OTHER|Questionnaire Administration|Complete questionnaire
41365162|NCT01270139|PROCEDURE|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
41365163|NCT01270139|PROCEDURE|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
41365164|NCT01270139|DEVICE|Stenting|60 - in sirolimus-eluting stenting control
41365165|NCT03854669|DEVICE|pain reporting accuracy|pain reporting accuracy will be assessed by the Focused Analgesia Selection Task (FAST) procedure. The FAST is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities, applied on the non-dominant arm with the Medoc® Thermal Sensory Analyzer II. The subjects will receive 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), each presented 7 times in a random block-ordered design (49 stimuli in total).
41365166|NCT05478707|DRUG|Dulaglutide|GLP1-RA
41365167|NCT05478707|DRUG|Placebo|Saline placebo
41365168|NCT05478707|BEHAVIORAL|exercise training|supervised high intensity interval training
41365169|NCT02609087|DRUG|Sevoflurane|
41500761|NCT06525103|DEVICE|electromagnitic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology.~* Frequency : 50 or 60 Hz.~* Intenisty: 0-100 .Input voltage: 230 V"
41500762|NCT06525103|DEVICE|whole body vibration|"Crazy fit machine.~* Input voltage:220 V.~* Frequency : 30 Hz.~* Maximum power: 1500W.~* Intensity:1 to 50 levels."
40844535|NCT01717326|DRUG|Elbasvir|Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
40844536|NCT01717326|DRUG|Placebo to Elbasvir|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
40844537|NCT01717326|DRUG|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
40844538|NCT03845959|DRUG|TD0019 oral capsule|TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
40844539|NCT03845959|DRUG|Placebo oral capsule|Placebo
40844540|NCT03076723|OTHER|Change in shunt opening pressure|An individually determined change in shunt opening pressure is compared to no change in opening pressure.
40844541|NCT03076723|OTHER|Simulated change in shunt opening pressure|The shunt opening pressure is reset to the same setting.
40844542|NCT06134843|COMBINATION_PRODUCT|DERMASEAL|plasma film containing metallic silver microparticles and fibrin
40844543|NCT04927572|DRUG|FMX114|Active Comparator
40844544|NCT04927572|OTHER|Vehicle|Placebo Comparator
41365170|NCT02609087|DRUG|Propofol|
41365171|NCT00995202|PROCEDURE|Standard Monitoring CEA|No specific follow-up of CEA
40844545|NCT05503056|OTHER|art therapy|six sessions of art therapy with licensed therapists
40844546|NCT05503056|OTHER|nothing|no intervention to this group
40844547|NCT03389178|DIAGNOSTIC_TEST|Cohen Perceived Stress Scale-10 (PSS-10)|Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score \< 19 will be entered into Phase II as control
40844548|NCT06115356|DIAGNOSTIC_TEST|Vitamin D Plasma Level|Blood test measured in ng/ml
40844549|NCT06115356|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis (BIA) technique|Measurements of body composition were conducted with Bioelectrical Impedance Analysis (BIA) technique, asking the participants to stand on the device barefoot to complete the analysis. Among all parameters, BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass were recorded.
41365172|NCT00995202|PROCEDURE|Intensive Monitoring CEA|CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.
41365173|NCT00995202|PROCEDURE|Standard Monitoring Imagery|Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years
40844550|NCT06115356|DIAGNOSTIC_TEST|Ferritin|Ferritin plasma levels were measured in μg/L
40844551|NCT06115356|DIAGNOSTIC_TEST|C reactive protein (CRP)|CRP plasma levels were measured in mg/L
40844552|NCT06115356|DIAGNOSTIC_TEST|Inflammation-based prognostic scores|Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS), Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Lymphocyte-to-monocyte ratio (LMR), Systemic immune-inflammation index (SII) were calculated using blood test results
41365174|NCT00995202|PROCEDURE|Intensive Monitoring Imagery|Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal
41365175|NCT03701971|OTHER|evaluation of the intensity of pruritus|evaluation of the intensity of pruritus with various questionnaires
41365176|NCT00013689|DRUG|Fansidar (pyrimethamine and sulfadoxine)|
40844553|NCT06115356|OTHER|Liver biopsy|A liver biopsy was used to study nonalcoholic steatohepatitis (NASH) and fibrosis according to the Kleiner-Brunt classification
41027521|NCT04621305|DRUG|Bolus Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.
40844554|NCT02793791|PROCEDURE|minimally invasive ablation therapies|Including RFA (radiofrequency ablation);MWA (microwave ablation); PEI (percutaneous ethanol injection),etc.
40844555|NCT02684188|BEHAVIORAL|Enhanced rural discharge and transition|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
40844556|NCT00135252|PROCEDURE|nasal cannula oxygen delivery|
40844557|NCT00135252|PROCEDURE|supplemental oxygen delivery by hood|
40844558|NCT04294914|OTHER|Cold Pressor Test|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.
40844559|NCT04294914|OTHER|Cold Pressor Test + Virtual Reality|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
40844560|NCT01896245|DRUG|sevoflurane 1,0|anesthesia induction with propofol, remifentanil, and sevoflurane 1,0 MAC; afterwards tracheal intubation
40844561|NCT01896245|DRUG|sevoflurane 1,2|anesthesia induction with propofol, remifentanil, and sevoflurane 1,2 MAC; afterwards tracheal intubation
41027522|NCT04621305|DRUG|Continuous Infusion Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
41027523|NCT05989399|DIAGNOSTIC_TEST|circulating neutrophils|evaluation of circulating neutrophils level
41027524|NCT03462667|BEHAVIORAL|Stoma Boot Camp|Educational session designed to prepare people for living life with a stoma.
41365177|NCT04220502|DRUG|Magic Shave Powder Gold|Depilatory Cream for facial hair removal
41365178|NCT04220502|DEVICE|Traditional Shaving Methods|Continued facial hair removal using traditional razors
41365179|NCT02287831|BIOLOGICAL|umbilical cord mesenchymal stem cells|
41365180|NCT01647204|OTHER|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
40844562|NCT01896245|DRUG|sevoflurane 1,4|anesthesia induction with propofol, remifentanil, and sevoflurane 1,4 MAC; afterwards tracheal intubation
41027525|NCT03462667|OTHER|Standard of Care|Patients receive normal pre-surgery standard of care.
41500763|NCT02169700|PROCEDURE|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
41500764|NCT03629080|BIOLOGICAL|HB-101 vaccine|HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
41365181|NCT04064099|DEVICE|Custom-fitted sports mouthguard|Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
41365182|NCT02917369|OTHER|Normal lung tissue|The investigators will extract total protein, DNA and RNA from LCLC patients.
41500765|NCT03629080|BIOLOGICAL|placebo|Saline will be used for placebo.
41500766|NCT05097794|DRUG|BR1015-1|- Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.
41500767|NCT05097794|DRUG|BR1015-2|- Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.
41500768|NCT05097794|DRUG|BR1015-1 + BR1015-2|- Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
41500769|NCT02829151|DRUG|Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )|Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
40844563|NCT00908102|OTHER|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
40844564|NCT00908102|OTHER|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
41365183|NCT05422950|OTHER|Relationship between physical condition and functionality in post-covid patients|Correlation study between the physical condition and functionality of patients after intubation due to covid 19
41365184|NCT06006481|OTHER|Survey|Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale
41365185|NCT03952416|BEHAVIORAL|Enhanced Medical Rehabilitation (EMR)|"EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity)."
41365186|NCT02039687|DRUG|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
41365187|NCT02039687|OTHER|Placebo|Formulation buffer
41365188|NCT05406882|DRUG|Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules|Live Combined Bifidobacterium and Lactobacillus Tablets：probiotics. Compound Glutamine Entersoluble capsules：combined traditional Chinese medicine and glutamine
41365189|NCT02681692|DEVICE|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
41365190|NCT05177861|DIAGNOSTIC_TEST|EMG|Electromyelography
41365191|NCT00456586|DRUG|KW-6002 (istradefylline)|
41365192|NCT00280540|DRUG|Valsartan/Hydrochlorothiazide|
41365193|NCT01006785|DRUG|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
41365194|NCT01006785|DRUG|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
41365195|NCT02406586|DRUG|Salsalate|Salsalate 750 mg
41365196|NCT02406586|DRUG|Carvedilol|Carvedilol 3.125 mg
41365197|NCT02406586|DRUG|Placebo|One tablet
41365198|NCT02406586|DRUG|Intralipid 20%|24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
41365199|NCT04111913|DRUG|Anlotinib Hydrochloride|anlotinib once daily on days 1-14 of 21days cycle.
41365200|NCT04884009|DRUG|SHR-1701； Famitinib|SHR-1701+ Famitinib
41365201|NCT04884009|DRUG|SHR-1701|SHR-1701
41500770|NCT02829151|DRUG|Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel|Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty
41500771|NCT02829151|DRUG|Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol|Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
41500772|NCT00400699|OTHER|counseling intervention|
40844565|NCT00908102|OTHER|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
41365202|NCT01593800|DIETARY_SUPPLEMENT|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
41365203|NCT00182494|BEHAVIORAL|Modified diabetes prevention protocol & Metformin|
41500773|NCT00400699|OTHER|study of socioeconomic and demographic variables|
41500774|NCT00400699|PROCEDURE|psychosocial assessment and care|
40844566|NCT00908102|OTHER|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
41365204|NCT06319365|BEHAVIORAL|yoga|the yoga practice of the group should completed at the end of 12 weeks
40844567|NCT06276166|OTHER|No intervention|No intervention
41365205|NCT00430235|DRUG|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
41500775|NCT05148260|BEHAVIORAL|Learning Through Play plus (LTP+)|Group-1: Experimental (n=40 participants) will receive the LTP+ which consist of a total of 12-group integrated treatment sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother/child pair per sub-group.
41500776|NCT05148260|BEHAVIORAL|Psychoeducation|Group-2: Controlled (n=40 participants) will receive 'psychoeducation' which consist of a total of 12-group sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother-child pair per sub-group.
40844568|NCT05656482|OTHER|Cats fed with PRO PLAN® LIVECLEAT®|Patient with domestic cats fed with an egg product containing anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®)
41365206|NCT04130360|BEHAVIORAL|Problem-solving|The steps of problem-solving are explained to the participants. Then, they are presented two conflictive situations and they are asked to apply the problem-solving steps to find a solution. Once they finish, they are asked to apply the steps in a conflictive situation they have experience in the last month. In the end, they are reminded of the steps and encouraged to practice them in their daily conflicts.
41365207|NCT01247649|DEVICE|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
41365208|NCT01142011|DRUG|Belimumab|"The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour."
41365209|NCT01013805|RADIATION|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5"
41365210|NCT01013805|DRUG|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
41365211|NCT01013805|DRUG|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
41365212|NCT01013805|DRUG|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
40844569|NCT00146380|DRUG|Zidovudine/Lamivudine and either Nevirapine or Nelfinavir|"Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum~ARVs continued for those that meet WHO treatment criteria"
41365213|NCT01013805|PROCEDURE|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
41365214|NCT01866891|OTHER|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
40844570|NCT00146380|BEHAVIORAL|Breastfeeding for 6 months postpartum|Exclusive breastfeeding till five and one half months with rapid weaning over 2 weeks and cessation of breastfeeding at 6 months when ARVs are discontinued
40844571|NCT03641560|DRUG|Enzalutamide|Enzalutamide will be administered orally
40844572|NCT03641560|DRUG|Androgen deprivation therapy (ADT)|All participants will be required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
41500777|NCT03813615|BEHAVIORAL|treadmill walking (Proof-of-Concept)|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear dosing schedule for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx. Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology. setting.
40844573|NCT03931798|DIAGNOSTIC_TEST|Visual Scanning Test|The Visual Scanning Test (VST) involved a visual search for a target between similar visual distractors, projected in the far space, so as to simulate the search within a visual field. It is overall composed by four trials, each trial contained 20 cases and made up by 20 stimuli. On about the 80% of cases, the test provided the presence of target in the left, center or in right hemispace. In the remaining 20% of cases, the test provided the presence of a catch trial (absence of the target), to assess the presence of frontal disturbances or malingering. The test is constructed according to an increasing attentional load for the target on the left-hemispace. Participants, sitting in front a blank wall, were required to actively and free explore the projected visual field to search for the visual target, naming its identification (saying YES or NO). During the task, the examiner annotated the reaction times and the errors.
40844574|NCT01021904|BIOLOGICAL|Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)|0.5cc I/M Site deltoid Lt Rt 3-dose regimen: 0, 2, 6 months
40844575|NCT06335953|BEHAVIORAL|Pharmacist-led deprescribing intervention|The intervention consists of the following strategies: 1) Pharmacists will participate in a 20-minute webinar and receive a laminated tip sheet about the study; 2) Eligible patients and their care partners will receive a single deprescribing educational brochure by mail; 3) Patients and their care partners will have a single telemedicine visit in which the pharmacist will perform medication reconciliation and identify potential adverse effects and concerns related to medicines; 4) The pharmacist will send the PCP up to 3 deprescribing recommendations in the EHR using a standardized template; 5) With the PCP's approval, the pharmacist will call the patient or care partner to implement the deprescribing recommendations and document changes in the EHR.
40844576|NCT04816058|BEHAVIORAL|Determining the level of ankle instability|Ankle instability
40844577|NCT06544291|DRUG|CBD 300mg|3 Nantheia™ (100mg) softgel capsules and 3 placebo (0mg) softgel capsules will be administered to participants on one of the three test session days.
41365215|NCT04892095|OTHER|No intervention|This is an observational cross-sectional study. No intervention is considered.
41365217|NCT00332930|BIOLOGICAL|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
41365218|NCT00332930|BIOLOGICAL|HIV gag-pol antigens and interferon-gamma (IFN-y)|
41365219|NCT05799482|OTHER|Qualitative Interview|Qualitative, semi-structured interview
41365220|NCT04721626|DRUG|Chlorhexidine Gluconate|"Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)"
41365221|NCT04721626|DRUG|Povidone-iodine|"Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine."
41365222|NCT04721626|DRUG|Tetracycline Ointment|Postoperative: \~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).
41365223|NCT04594122|BEHAVIORAL|Improve hygiene practice of pork sellers|includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
41365224|NCT00496691|BEHAVIORAL|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
41365225|NCT00781027|PROCEDURE|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
41365226|NCT00483782|BIOLOGICAL|bevacizumab|
41365227|NCT00483782|DRUG|carboplatin|
41365228|NCT00483782|DRUG|paclitaxel|
41365229|NCT00483782|OTHER|questionnaire administration|
41365230|NCT00483782|OTHER|study of socioeconomic and demographic variables|
41365231|NCT00483782|PROCEDURE|quality-of-life assessment|
41365232|NCT01380847|GENETIC|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
41365233|NCT00944762|BEHAVIORAL|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
41365234|NCT00944762|BEHAVIORAL|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
41365235|NCT03339999|DRUG|AGN-242428|AGN-242428 administered as an oral capsule(s) once daily.
41365236|NCT03339999|DRUG|Placebo|Placebo administered as an oral capsule(s) once daily.
41365237|NCT02789566|DRUG|Primaquine|Primaquine 30 mg taken after meal in the morning.
41365238|NCT06224491|OTHER|Reflex locomotion according to Vojta|Tactile stimulation according to Vojta´s reflex locomotion
41500778|NCT03813615|BEHAVIORAL|treadmill walking Dose-Finding / Escalation|Six doses of aerobic training ( 90mins/wk, 150 mins/wk, 225 mins/wk, 300 mins/wk \& 450mins/wk) delivered following either a standard linear (i.e., each dose of exercise is performed at the same intensity \& duration) or non-linear (i.e., exercise dose is continually altered \& progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule 3 to 6 times weekly (over a 7-day period) for a minimum 2 weeks. Aerobic training treatment will be implemented \& may be monitored using TeleEx. Patients may also perform up to three aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided a plan for their unsupervised session(s) verbally or via Portal Secure Messaging (PSM), as appropriate.
40844578|NCT06544291|DRUG|CBD 600mg|6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.
40844579|NCT06544291|DRUG|Placebo 0mg|6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.
40844580|NCT03899051|PROCEDURE|interdental papilla reconstructive surgery with PRF|Papilla reconstruction would be done with platelet rich fibrin
40844581|NCT03899051|PROCEDURE|interdental papilla reconstructive surgery with subepithelial connective tissue graft|Papilla reconstruction would be done with subepithelial connective tissue graft
40844582|NCT05767190|BEHAVIORAL|Motivational interviewing|During the intervention, the trained-nurse will provide a motivational interviewing-based intervention consisting of one session divided into two parts: educational (the concepts of sleep apnea and the symptoms, and the CPAP treatment will be focused on) and training activity (using MI not directly advocate for behavioral change (i.e., use CPAP as prescribed), but asks key questions to help the patient explore conflicting feelings about the change, weighs the positive consequences and negatives of this change, and allows the patient to realize the discrepancy between current risk behavior (i.e. not using CPAP as directed) and the patient's self-identified goals. The intervention will be tailored on the patient's stage of change based on Prochaska and DiClemente transtheoretical model (1982), in fact, the nurse will use MI not only at the beginning of therapy but also in every contact with the patient throughout the treatment (subsequent follow-up visits, phone calls, etc.).
40844583|NCT03574428|DRUG|GNbAC1|Monoclonal Antibody infused i.v.
40844584|NCT03574428|OTHER|GNbAC1 Placebo|Equivalent to GNbAC1 Buffer
40844585|NCT05553184|DRUG|Formoterol Fumarate 12 micrograms Inhalation Powder|At time 60 minutes, a total of 48 micrograms will be inhaled within 3 minutes: 4 inhalations of 12 micrograms of fumarate formoterol (Oxeze® Turbuhaler®).
40844586|NCT05553184|DRUG|Nicotinic Acid 50 MG Oral Tablet|a total dose of 1050 MG will be ingested. From time 0 to 180 minutes, doses of 150 MG will be repeated every 30 minutes.
41027526|NCT05014009|BEHAVIORAL|FIFA11+ and multidirectional training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time."
40844587|NCT05553184|OTHER|Acute Cold Exposure|Participants will be fitted with a liquid-conditioned tube suit. The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
40844588|NCT05553184|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|PET imaging using C11-palmitate (time 90), C11-acetate (time 120) and F18-Fluorodeoxyglucose (FDG) (time 150)
41161295|NCT05820321|OTHER|Beetroot juice NO3 depleted|The participant will intake beetroot juice depleted in NO3. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
41161296|NCT05063981|DRUG|Mepolizumab|Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control
41161297|NCT02132598|DRUG|cabozantinib|
40844589|NCT05553184|DIAGNOSTIC_TEST|Indirect calorimetry|will be repeated every hour, for 20 minutes, using Vmax29n.
40844590|NCT05553184|DIAGNOSTIC_TEST|dual-energy x-ray absorptiometry (DEXA scan)|Whole body scan
40844591|NCT05553184|PROCEDURE|Biopsy|After local anesthesia with 2% xylocaine without epinephrine, 100-200 mg of subcutaneous adipose tissue will be sampled by needle (14G) biopsy
40844592|NCT05553184|PROCEDURE|iv lines|for stable tracer perfusion and blood sampling
40844593|NCT05553184|PROCEDURE|Electromyogram (EMG)|Surface electrodes will be used to measure skeletal muscle activity and shivering intensity
41161298|NCT00069628|DEVICE|GlucoWatch® G2™ Biographer (GW2B)|
41161299|NCT00069628|DEVICE|Continuous Glucose Monitoring System (CGMS)|
40844594|NCT00273156|BEHAVIORAL|Telephone quitline|
40844595|NCT05540782|BEHAVIORAL|PROMIS-SF v2.0 -Cognitive Function 8a|Patient-Reported Outcomes (PROs)
40844596|NCT04189029|OTHER|Extensive phenotyping|Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.
41365239|NCT01938443|DRUG|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
41365240|NCT01938443|DRUG|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
41365241|NCT06345573|BEHAVIORAL|Mental stress|Two consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part).
40844597|NCT03822000|OTHER|Survival|Elderly patients with fall-induced femoral fracture who were survived.
40844598|NCT03822000|OTHER|Death|Elderly patients with fall-induced femoral fracture who were dead.
40844599|NCT01092663|DRUG|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
40844600|NCT01092663|DRUG|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
40844601|NCT06497296|DRUG|Lidocaine|Lidocaine spray in both group with same puff number, but the timing before EGD insertion is different
40844602|NCT03688620|OTHER|Passive enhanced safety surveillance|Prospective data collection starting at Visit 1 (Day 1) and ending at Visit 2 (Day 8 or when the ADR card was returned by mail) for all subjects who have previously been vaccinated against influenza in preceding seasons or aged ≥9 years at the time of vaccination, or ending at Visit 4 (Day 36 or when the last ADR card was returned by mail) for children aged \<9 years who have not previously been vaccinated against influenza in preceding seasons). Subjects had up to 14 days post vaccination to return their ADR card (at the next study visit or by mail).
41365242|NCT03193918|DRUG|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
41365243|NCT03193918|DRUG|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
40844603|NCT06386679|BIOLOGICAL|allogenic amniotic fluid mesenchymal stem cell|Intra-articular AFCC injection will be given for single knee for each patient in single dose, 20 million of AFCC in each dose
40844604|NCT00895453|DRUG|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
40844605|NCT00895453|DRUG|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
40844606|NCT00895453|DRUG|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
40844607|NCT06583577|DEVICE|3D Ostomy simulator|The ostomy simulator is 3D printed model created in collaboration with Earl E. Bakken Medical Devices Center at the University of Minnesota. The anatomically accurate model is created by analyzing de-identified segmental imaging after bowel diversion surgeries. The Stratasys J750 Polyjet 3D Printer is utilized to create the simulator using usual synthetic material.
40844608|NCT02597088|OTHER|Laboratory studies of the effect of human milk handling using a rage surface area bottle (study device)|Using laboratory studies of the effect of storage and heating on expressed human milk, the investigators will compare milk handled in regular bottle and bottle warmer and milk handled using the study device (large surface area bottle)
41161300|NCT02115334|BEHAVIORAL|professional therapists delivering the PHPA|PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
41161301|NCT02115334|BEHAVIORAL|parents executing the PHPA|PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.
41161302|NCT02115334|BEHAVIORAL|health education|health education of the children with DD.
41365244|NCT03193918|DRUG|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
41365245|NCT00232128|PROCEDURE|Radiofrequency Ablation of pulmonary neoplasms|
41365246|NCT03845426|OTHER|Root canal treatment.|Once pulpal necrosis has been diagnosed, root canal treatment will be carried out by the patient's general practitioner. This is an end point for the tooth in the study.
41365247|NCT01005966|DRUG|Sodium Fluoride Toothpaste|Test product
41365248|NCT01005966|DRUG|Amine Fluoride Toothpaste|Test product
41365249|NCT01005966|DRUG|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
41365250|NCT01005966|DRUG|Placebo|placebo and washout treatment
41365251|NCT01005966|DRUG|675 ppmf toothpaste|dose response
40844609|NCT03972878|OTHER|control snack|dry fruit snack (200 kcal) + 250 ml water
40844610|NCT03972878|OTHER|control cream|commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water
40844611|NCT03972878|OTHER|cream version 1|commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water
41365252|NCT05124145|OTHER|No intervention (surveillance system)|The surveillance network will collect data on all consecutive COVID-19 cases
41365253|NCT04353323|OTHER|Blood sampling|3 blood samples (D0, D15 and D30) will be taken from each participant
41500779|NCT05842044|DRUG|Ketorolac|15-30mg Ketorolac administered via injection during intraoperative period every six (6) hours during post-surgery (inpatient) period.
41161303|NCT05256771|DEVICE|EMS|Abdominal muscle stimulation using EMS
41365254|NCT05849051|BEHAVIORAL|Newly developed warnings with images at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
41365255|NCT05849051|BEHAVIORAL|FDA proposed text-only warnings at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
41365256|NCT00265876|DRUG|AZD0530|Taken daily every 4 weeks
41365257|NCT00265876|DRUG|gemcitabine hydrochloride|1000mg/m2 IV weekly
41365258|NCT00021125|PROCEDURE|adjuvant therapy|
41365259|NCT00021125|RADIATION|radiation therapy|
41365260|NCT00364338|BEHAVIORAL|gourment cooking workshop|
41161304|NCT05256771|DEVICE|1064 nm diode laser|Adipose tissue heating using 1064 nm diode laser
41161305|NCT05256771|DEVICE|RF/PEMF|Collagen re-modelling and reduction in subcutaneous fat using RF/PEMF
41161306|NCT06086522|DRUG|QN-302|Phase 1 dose-finding study, the study design is for QN-302 to be given once a week, intravenously over 60 min, on Day 1, Day 8, and Day 15 of a 28-Day cycle.
41365261|NCT05238220|DRUG|Valganciclovir|continuation of valganciclovir prophylaxis up to 12 months with absence of demonstrated anti-CMV immunity
41365262|NCT01979692|PROCEDURE|confocal laser microscopy CLM at trans thoracic needle biopsy TTNB|
41365263|NCT01979692|DEVICE|CT guided trans thoracic needle biopsy|
41365264|NCT02850666|BEHAVIORAL|Interdisciplinary process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
41500780|NCT05842044|DRUG|Acetaminophen|1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
41161307|NCT02174159|DRUG|Ulonivirine|MK-8507 administered as a single oral dose
41161308|NCT04048798|OTHER|Oxygen therapy via HFNC|Oxygen treatment will be applied to the patients via HFNC before and after surgery
41161309|NCT04048798|OTHER|Oxygen therapy via face mask|Oxygen treatment will be applied to the patients via face mask before and after surgery
41500781|NCT05842044|DRUG|Oxycodone|"Standardized regimen of Oxycodone administered orally (PO) on demand for moderate pain during post-surgery (inpatient) period.~At discharge 5mg Oxycodone will be administered to participants on demand if pain score is greater than 7, or if participant required greater than 25mg Oxycodone during the hospitalization."
41500782|NCT05842044|DRUG|Hydromorphone|Standardized regimen of Hydromorphone administered intravenously (IV) on demand for severe pain during post-surgery (inpatient) period.
40844612|NCT03972878|OTHER|cream version 2|commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water
41365265|NCT03810599|OTHER|Early cardiac rehabilitation|"This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons."
41365266|NCT04273360|OTHER|Systematic use group|Patients in this group will be subjected to initial systematic PR, which will be re-evaluated every day every day between day 0 and day 14
41365267|NCT04273360|OTHER|Restrictive use group|Patients in this group will be subjected to PR only in case of severe agitation, defined by a RASS ≥ +3 on any given day between day 0 and day 14
41365268|NCT03055208|RADIATION|gamma knife radiosurgery (15 Gy to 50% isodose)|Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
41365269|NCT01106066|DRUG|Oxaliplatin, S-1, radiotherapy|Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (___mg/m2 iv weekly x 4 weeks)
41365270|NCT02345902|DRUG|Haloperidol|haloperidol 1.25 mg P.O q.d
41365271|NCT02345902|OTHER|Placebo|placebo 1.25 mg P.O q.d
41365272|NCT02345902|OTHER|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
41365273|NCT04997512|DEVICE|Freestyle libre|A glucose sensor (flash) which measures interstitial blood glucose every 15 minutes or on demand.
41365274|NCT04997512|OTHER|Nurse led structured intervention - hypoglycaemia education and diabetes treatment modification modification|An education programme surrounding avoidance of hypoglycaemia at baseline. Regular review (weeks 2, 4, 12 and 24) and adjustment of diabetes medications based on freestyle libre data.
41500783|NCT05842044|DRUG|Ibuprofen|400mg Ibuprofen tablets administered orally (PO) every eight (8) hours for 5 days.
41500784|NCT03275064|BIOLOGICAL|LNA043|LNA043 intra-articular injection
40844613|NCT03972878|OTHER|cream version 3|commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water
40844614|NCT03972878|OTHER|control chocolate bar|commercial chocolate bar (200 kcal)+ 250 ml water
41500785|NCT03275064|OTHER|Placebo|Placebo intra-articular injection
41500786|NCT04792762|OTHER|GIP(1-30)NH2|Intravenous administration of the peptide hormone GIP(1-30)NH2 during a stepwise glucose clamp
40844615|NCT03972878|OTHER|chocolate bar version 1|commercial chocolate bar (200 kcal), version 1+ 250 ml water
41161310|NCT01083407|DRUG|0.12% Chlorhexidine Digluconate|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
41161311|NCT01083407|OTHER|Toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
41500787|NCT04792762|OTHER|GIP(1-42)|Intravenous administration of the peptide hormone GIP(1-42) during a stepwise glucose clamp
41500788|NCT04792762|OTHER|Saline|Intravenous administration of saline during a stepwise glucose clamp
41500789|NCT03646123|DRUG|brentuximab vedotin|1.2 mg/kg by IV infusion
41500790|NCT03646123|DRUG|doxorubicin|25 mg/m\^2 by IV infusion
41500791|NCT03646123|DRUG|vinblastine|6 mg/m\^2 by IV infusion
41500792|NCT03646123|DRUG|dacarbazine|375 mg/m\^2 by IV infusion
41500793|NCT03646123|DRUG|G-CSF|Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
41500794|NCT03646123|DRUG|nivolumab|240 mg by IV infusion
41500795|NCT04120038|DEVICE|Self-Management for Amputee Rehabilitation using Technology [SMART]|Participants will complete a 6-week tablet-based education program for individuals with LLA that will provide them with self-management education.
41500796|NCT03457532|DRUG|Gumarontinib Tablets|25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
40844616|NCT05790720|DRUG|Propofol|Patients older than 65 years of age will receive an intravenous infusion of Propofol with prespecified plasma targets. During its administration, registration of BIS values, frontal electroencephalography, and clinical signs of consciousness will be performed.
40844617|NCT04836247|BEHAVIORAL|Disclosing Recovery: A Decision Aid and Toolkit|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
40844618|NCT04836247|BEHAVIORAL|Mindfulness|Participants will be able to choose from several guided meditations to promote mindfulness
40844619|NCT05899296|DEVICE|dental syringe ( NumBee)|assess the capability of NumBee to reduce anxiety and pain during injection
40844620|NCT05899296|DEVICE|Traditional dental syringe|compare the level of anxiety of the traditional dental syringe and the Number dental syringe
40844621|NCT03779074|DRUG|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
40844622|NCT03779074|DRUG|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days
40844623|NCT03779074|DRUG|14D high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
40844624|NCT01601210|DRUG|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
40844625|NCT04199143|DRUG|Nitrous Oxide-Oxygen|The medical product used in this study is a gas for common medical use in various domains including anesthesic, consisting in the equimolar mixture of nitrous oxide and oxygen. Subjects will receive a mixture of 50% N2O / 50% O2 for 1 hour.
40844626|NCT04199143|DEVICE|Tissue Pulsatility Imaging - TPI|Tissue Pulsatility Imaging (TPI) is a variation of ultrasonic Doppler strain imaging we are developing to measure the local expansion and relaxation of the brain tissue over the cardiac cycle to characterize and image perfusion.
40844627|NCT04199143|DEVICE|Magnetic Resonance Imaging - MRI|Structural and Functionnal (including BOLD and ASL) MRI will be aquired in this study
40844628|NCT02207959|DRUG|Proflavine Hemisulphate salt|The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.
40844629|NCT02207959|PROCEDURE|White-light examination|standard white light examination
40844630|NCT02207959|PROCEDURE|Imaging with High Resolution Microendoscope|HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
40844631|NCT04805710|DRUG|clopidogrel combined with rivaroxaban arm|Patients who have been selected will be randomized to the clopidogrel combined with rivaroxaban arm. clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily
40844632|NCT03718897|DIAGNOSTIC_TEST|Endoscopic retrograde cholangiopancreatogram|Biopsy specimens are attained via endoscopic retrograde cholangiopancreatogram in patients with suspicious biliary tract cancer.
40844633|NCT00992823|DRUG|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
40844634|NCT00992823|BIOLOGICAL|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
40844635|NCT05101213|BIOLOGICAL|Virus-specific Cytotoxic T-lymphocytes|Given IV
41161312|NCT00287157|DRUG|Sublingual Tizanidine HCl|
41161313|NCT02410317|DRUG|Ropivacaine|
41161314|NCT02410317|DRUG|Morphine|
41161315|NCT05388097|OTHER|Managed Services|coordination of care and assistance with community resources (food, transportation)
41161316|NCT00555997|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
41365275|NCT03121625|BIOLOGICAL|Autologous CAR-T|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
40844636|NCT03846557|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the Acurate Neo Transcatheter Heart Valve
41161317|NCT00555997|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
41161318|NCT00555997|DRUG|Placebo|"0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo"
41161319|NCT04528147|BEHAVIORAL|Yi Jin Jing Tiger Roaring Speech Rehabilitation|A traditional Chinese medicine treatment
41161320|NCT04528147|BEHAVIORAL|Conventional Speech Rehabilitation|A active speech rehabilitation method recommended by the Parkinson's Foundation of America
40844637|NCT06124456|OTHER|Usual Care Control Group|Subjects in the usual care control group will receive health education as the attention control. The program will consist of eight 150-minute bi-weekly sessions covering major health issues relating to general health and NAFLD, to be obtained from publicly accessible resources from the Hong Kong Department of Health. Health education information on non-communicable diseases (e.g., cancers, diabetes, coronary heart diseases, obesity, and mental illness), infectious diseases (e.g., COVID-19), and a healthy lifestyle (e.g., balanced diet, physical activity, good sleep, tobacco use, alcohol cessation, and stress management) will also be distributed to the subjects in the exercise groups through recorded presentation videos and leaflets/pamphlets during the first 16 weeks.
41027527|NCT05014009|BEHAVIORAL|FIFA11+ and linear sprint training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time."
41027528|NCT05497778|DRUG|Gemcitabine|Given by IV (vein)
41027529|NCT05497778|DRUG|Nab paclitaxel|Given by IV (vein)
41027530|NCT05497778|DRUG|IM156|Given by PO
41365276|NCT01219179|OTHER|Sterile water feedings|"Control group- no intervention~Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed.~The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.~The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L."
41365277|NCT04225026|DRUG|GC4419 (avasopasem manganese)|90 mg, by 60-minute IV infusion, prior to each fraction of RT
41365278|NCT01165268|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 7 days
41365279|NCT03596385|DRUG|Beta blocker|long-term maintenance beta-blocker therapy
41500797|NCT05616637|DIAGNOSTIC_TEST|Navicular Drop Test|While participants in sitting position, the navicular tuberosity (NT) will be palpated.The most distal protruding portion of the medial NT will be marked. Participants will be asked to stand with equal weight on both feet. The new distance will be measured. The navicular drop test (NDT) results will then be obtained by comparing the measured values between the sitting and standing positions. Each measurement will be repeated three times and the average of the 3 measurements will be calculated. The expression in mm of the distance between the two marks will be considered the amount of ND. The amount of navicular fall of 10 mm or more will be interpreted as pes planus. Measurements will be made on both extremities. As a result of the measurements, if pes planus is present in a single extremity, that extremity, if it is present in both extremities, the extremity with higher NDT or if it is equal on both sides, the dominant extremity will be tested.
41027531|NCT03475641|DRUG|Femoral nerve blockade|The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
41027532|NCT03475641|PROCEDURE|The current standard treatment|Tumescent anesthesia.
41027533|NCT04297046|DEVICE|PCA (patient controlled analgesia)|Intravenous Patient-Controlled Analgesia was used for postoperative pain control with a bolus dose of 25 mg Tramadol and a lockout interval of 20 min. The pain was evaluated at different times after the operation, both at rest and movement (Dynamic VAS) at the 0., 2., 6., 12. hours and 24h later. All patients received 1 g iv paracetamol 8 hourly intervals regularly. 75 mg im diclofenac sodium was given as rescue analgesic.
41027534|NCT05039268|DRUG|3K3A-APC Protein|3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
41027535|NCT03261557|BEHAVIORAL|CBT + SST|"It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
41027536|NCT03261557|BEHAVIORAL|Psychoeducation, habits and healthy lifestyle|"Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
41027537|NCT02717949|DRUG|sofosbuvir/ledipasvir|sofosbuvir ledipasvir fixed dose combination given once a day by mouth
41027538|NCT02717949|DRUG|sofosbuvir|sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
41027539|NCT02717949|DRUG|Ribavirin|ribavirin 1200 mg given orally in divided dose for those \>75kg and 1000 mg in divided dose for those \<75 kg.
41027540|NCT03984266|DIAGNOSTIC_TEST|NGS panel|A next-generation-sequencing panel, which contains a group of genes that specifically cause disease, for mutational analysis in newborns.
41027541|NCT03868436|DRUG|Methoxyflurane 3mL|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
41027542|NCT01070290|DRUG|ARQ 197|120 mg capsule administered twice daily
41027543|NCT01070290|DRUG|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
41027544|NCT03574454|OTHER|Machine Learning (ML)|Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma
41027545|NCT06529367|OTHER|Snellen chart|"Patients will be asked to use the 5 feet distance for standardization, which allows for visual acuity assessment from 20/16 to 20/200.~Patients will be asked to wear their current corrective lens for distance, to take the test at home in a place with good lighting and to test each eye separately.~Office-based vision testing will be performed by a trained ophthalmic technician in a dimmed room with the Snellen chart illuminated on a screen. Patients will be asked to wear their current corrective lens for distance and an eye occluder will be used to test each eye separately."
41027546|NCT02923037|PROCEDURE|Yoga|Complete guided and home yoga sessions
41027547|NCT02923037|OTHER|tape measurement of arm|Ancillary studies
41027548|NCT02923037|OTHER|Quality-of-Life Assessment|Ancillary studies
41027549|NCT02923037|OTHER|ldex measurement of arms|
41027550|NCT06534307|BEHAVIORAL|Questionnaire Child Behaviour Checklist|The Child Behavior Checklist comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of problems.
41027551|NCT06534307|BEHAVIORAL|Questionnaire Young Self Report|The Questionnaire Young Self Report comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score.
41027552|NCT06534307|DIAGNOSTIC_TEST|physical examination|physical development examination including height (in cm), weight (in g) and tanner states
41027553|NCT06534307|DIAGNOSTIC_TEST|metabolic examination|metabolic development using blood analysis including blood components, metabolic parameters (Glucose, HbA1c, cholestrol)
41027554|NCT06534307|BEHAVIORAL|Questionnaire Reynolds Intellectual Assessment Scales and Screening|"The RIAS is standardized intelligence test. The RIAS provides an Total Intelligence Index (GIX, estimate of the general intelligence/g-factor), Verbal Intelligence Index (VIX) and the Nonverbal Intelligence Index (NIX). Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better cognitive performance."
41027555|NCT06534307|DIAGNOSTIC_TEST|electroencephalogram|neurocognitive development
41365280|NCT05599373|DEVICE|Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
41027556|NCT06534307|OTHER|Questionnaire Movement Assessment Battery for Children|"The M-ABC-2 is an standardized test to assess the motoric development. Adding up subscores addressing manual dexterity, aiming and catching, and balance delivers a total score of the motoric performance.~Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better performance."
41027557|NCT06534307|OTHER|Questionnaire Continuous Performance Test|The CPT measures selective attention, sustained attention as well as impulsive behavior. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean worse performance.
41027558|NCT06534307|OTHER|Questionnaire Diagnostic System for Mental Disorders|The FBB-ADHS assesses a total score for ADHD-like behavior and subscores for the symptom trias of ADHD (attention deficit, motoric hyperactivity as well as impulsive behavior, Questionnaire scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of symptoms.
41027559|NCT06534307|DIAGNOSTIC_TEST|kidney function tests|urine examination (proteomics, cytokines, lipidomics)
41027560|NCT06534307|OTHER|Questionnaire Five to Fifteen|The FTF 5-15R is a questionnaire to evaluate the child's developmental outcome in different areas of everyday life (cognition, language, and motor impairment as well as social, emotional, and behavioral problems). Individual item scores are added up per area and divided by the number of items. This results in a common scale value. Range of Percentile scores from 0 to 100 (0-90: no developmental problem; 90 and higher: hint for developmental problem). Higher scores mean worse developmental outcome.
41027561|NCT06534307|DIAGNOSTIC_TEST|cardiovacular examination|measurement of pulse wave velocity
41027562|NCT03196765|DRUG|Sobetirome (NV1205)|Once a day oral dose of the study drug
41027563|NCT02928692|DRUG|Minocycline|
41027564|NCT02928692|DRUG|Placebo|
41027565|NCT00574860|DRUG|EN3285|Oral rinse
41027566|NCT00574860|DRUG|Placebo|Oral rinse
41365281|NCT05599373|DEVICE|Left Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
41365282|NCT05599373|DEVICE|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
41365283|NCT04629105|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Longeveron Mesenchymal Stem Cells (LMSCs)
41365284|NCT04629105|OTHER|Placebo|Placebo
41365285|NCT02911311|DRUG|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
41365286|NCT02911311|DEVICE|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
41365287|NCT01979640|PROCEDURE|39 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
41365288|NCT01979640|PROCEDURE|37 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
41365289|NCT01979640|PROCEDURE|35 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
41365290|NCT03553121|OTHER|walking|walking and not walking
41365291|NCT03553927|DIETARY_SUPPLEMENT|Low Energy Diet|Caloric restriction to achieve weight loss
41365292|NCT03553927|OTHER|NHS advice on healthy eating|Advice on energy requirements as per the British Dietetic Association
41365293|NCT02409017|PROCEDURE|Insulin drip|
41365294|NCT02776631|DEVICE|Pinloc|Internal fixation device
41365295|NCT02776631|DEVICE|Hansson Pins (LIH)|Internal fixation device
41027567|NCT00574860|OTHER|Standard of care|This will be the therapy most commonly used the the institution treating the patient
41027568|NCT04534829|PROCEDURE|Fluoroscopic-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under fluoroscopic-guidance
41027569|NCT04534829|PROCEDURE|Ultrasound-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under ultrasound-guidance
41027570|NCT04173221|OTHER|Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
41027571|NCT04173221|OTHER|Sublingual SDF-Measurement without communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
41027572|NCT03293342|BEHAVIORAL|D CBT|"Intervention:~a 3-5 session treatment of dental fear.~* Psychoeducation about anxiety~* Exploration of the individual anxiety~* Exposure to the frightening stimuli (no hiding, but actively showing in detail all components of dental treatment, preferably utilizing a mirror while doing treatment)."
41027573|NCT03293342|COMBINATION_PRODUCT|Control|"Intervention:~Traditional treatment of dental fear common sense/ benzodiazepine"
41365296|NCT03622294|DEVICE|Bella Blankets protective coverlets|Bella Blankets protective coverlets is a Class II 510(k) Cleared (2008) single-use, adhering, non-woven fabric sheet applied to the mammography equipment receptor plate to provide a more comfortable mammogram.
41365297|NCT04500925|PROCEDURE|UNILATERAL THYROIDECTOMY|
41365298|NCT01869231|DIETARY_SUPPLEMENT|olive oil|
41365299|NCT01869231|DIETARY_SUPPLEMENT|olive oil and chewing gum|
41365300|NCT01869231|DIETARY_SUPPLEMENT|chewing gum|
41365301|NCT01869231|DIETARY_SUPPLEMENT|water|
41365302|NCT03428139|PROCEDURE|pulsed radiofrequency|Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.
41365303|NCT03428139|DRUG|pulsed radiofrequency plus alpha lipoic acid|Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
41365304|NCT05031156|PROCEDURE|Splinting of OT Bridge system|splinting of implant abutment using titanium wire followed by pick up using the patient's denture
41365305|NCT04600518|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
41027574|NCT01911052|OTHER|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
41027575|NCT01911052|OTHER|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
41027576|NCT01923181|DRUG|semaglutide|Once-daily oral administration as tablets.
41027577|NCT01923181|DRUG|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
41027578|NCT01923181|DRUG|oral placebo|Once-daily oral administration as tablets.
41027579|NCT02352493|DRUG|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
41027580|NCT02352493|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
41027581|NCT06067074|PROCEDURE|Volar Locking Plate|Surgery
41027582|NCT06067074|PROCEDURE|Plaster Cast|Non-operative treatment with a plaster cast
41027583|NCT06377553|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded; The catheter will be flushed with 0.9% saline solution; The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
41027584|NCT06377553|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the pelvis and abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired when necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
41027585|NCT06377553|OTHER|Rectal Ultrasound Gel Injection|About 50ml of ultrasound gel will be placed into the vagina using the blunt end of the ultrasound gel tube or a Foley catheter or a syringe with a blunt Christmas tree end. No ultrasound probe will be inserted into the vagina, no external ultrasound probe will be used. No ultrasound study will be performed. The ultrasound gel will only be used to distend the vagina and improve the quality of MRI images; this is standard of practice in MRI for endometriosis and for several other gynecological diseases.
41027586|NCT02303964|BIOLOGICAL|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
41027587|NCT02303964|DRUG|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
41027588|NCT02859194|PROCEDURE|Veno-veno-arterial ECMO|
41027589|NCT02277626|DEVICE|Electro Flo 5000|Airway clearance device
41027590|NCT02277626|DEVICE|Incourage Vest System|Airway Clearance Device
41027591|NCT06112210|OTHER|HBOT group|The HBOT will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The HBOT group will be exposed to 100% oxygen at 2.2 ATA (atmospheres absolute). Session will last 70 minutes.
41027592|NCT06112210|OTHER|CON group|The placebo protocols will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The CON group will be exposed to normobaric ambient pressure (1 ATA). The session will last 70 minutes.
41027593|NCT05091034|BEHAVIORAL|Controlling Asthma Program for Adolescents (CAMP Air)|Controlling Asthma Program for Adolescents (CAMP Air) is an e-health intervention grounded in social cognitive theory and motivational interviewing to guide teens through asthma self-care and how to navigate the health care system. It makes use of various interactive and personalized approaches.
41027594|NCT05091034|BEHAVIORAL|Attention Control Asthma Education Intervention|Using Asthma Plus, an asthma education program, teens learn about asthma and other conditions relevant to asthma and adolescents.
41365306|NCT05771974|DEVICE|Compression therapy using surgical gloves|Intervention group wear two-layer of normal-sized surgical gloves on both hands during chemotherapy infusion
41365307|NCT06066463|BEHAVIORAL|questionnaires|Self reported female gender
41027595|NCT05186324|OTHER|Interview|"During each interview, patients will be asked questions to collect demographic and clinical information, and asked a set of open-ended questions with probes to describe their experiences with Fabry disease (symptomology and impacts on patient's lives \[i.e., activities of daily living, school/work, ability to take holidays/vacation\]), and pegunigalsidase alfa treatment (experience of infusions and schedule) and their experience of change in symptoms and impacts over the BRIGHT-F51 clinical study.~A semi-structured discussion guide will be used to conduct the approximately 60-minute interviews. The use of open-ended questions avoids bias and questions will not be read verbatim to allow for a free-flowing discussion."
41365308|NCT02400658|DEVICE|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
41365309|NCT00883896|OTHER|Placebo|Part 1: Placebo SC administration every 2 weeks X 10 weeks.
41365310|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
41365311|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
41365312|NCT00883896|OTHER|Placebo|Part 2: Placebo SC administration every 2 weeks X 10 weeks
41365313|NCT00883896|DRUG|ILV-094|Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
41365314|NCT03044327|PROCEDURE|LPS challenge|LPS inhalation and bronchial instillation
41365315|NCT02359942|DRUG|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
41365316|NCT03029052|BEHAVIORAL|Reconciliation|In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
41365317|NCT02515890|DRUG|Dexmedetomidine|Selected subjects received this drug during a portion of the study
41365318|NCT02515890|DRUG|Midazolam|Selected subjects received this drug during a portion of the study
41365319|NCT02515890|DEVICE|Peripheral nerve stimulation|Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.
41365320|NCT02515890|DRUG|Ketamine|Selected subjects received this drug during a portion of the study
41365321|NCT03262246|OTHER|medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy
41365322|NCT03095365|OTHER|Dry needling|Insertion of solid filament needles in the muscle
41365323|NCT03095365|OTHER|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
41365324|NCT03095365|OTHER|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
41365325|NCT02139891|DEVICE|Cardiac Resynchronization Therapy with MultiPoint Pacing|
41365326|NCT05945173|PROCEDURE|Evaporation time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 5 seconds.
41365327|NCT05945173|PROCEDURE|Evaporation time for 25 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 25 seconds.
41365328|NCT05945173|DEVICE|alcohol/water-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an alcohol/water-based universal adhesive (Scotchbond Universal Plus; 3M).
41365329|NCT05945173|DEVICE|acetone-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an acetone-based universal adhesive (Gluma Universal Bond; Kulzer).
41365330|NCT03672565|BEHAVIORAL|Phase One: Standardized Brief Intensive ERP|Participants will be randomized to receive ERP sessions at the hospital or at relevant community locations. In the introductory session, participants will be provided with psychoeducation about OCD and the treatment model, will develop a list of potential exposures, and will attempt initial exposure and response prevention (ERP) exercises. The session will end with an assignment of ERP homework. In the seven days following the introductory session, youth and parents will receive two 3-hour sessions, separated by a three day break. The sessions will begin with a brief review of homework completion and success. Following this, with parent observation, the clinician will guide the youth through escalating ERP exercises. The session will end with ERP homework planning. Other evidence-based treatment strategies (e.g., addressing motivation, discussing parental accommodations) may be implemented as deemed necessary by the clinician in order to encourage effective engagement in ERP exercises.
41027596|NCT06534060|BIOLOGICAL|Genetic: MB-105|MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.
41027597|NCT00164801|DRUG|Baclofen, Diltiazem|
41027598|NCT05024812|DRUG|fruquintinib＋toripalimab + SOX|phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W.
41027599|NCT05394623|DIAGNOSTIC_TEST|HDV-Ab (IgG), HDV-RNA, RNA genotype|Anti-HDV was evaluated semiquantitatively by means of end-point dilutions. Quantitative HDV-RNA was performed by means of LightCycler 2.0. Genotyping of HDV was performed by direct sequencing of the delta antigen region.
41027600|NCT04166318|DRUG|Capecitabine|Given PO
41027601|NCT04166318|DRUG|Fluorouracil|Given IV
41027602|NCT04166318|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41027603|NCT04166318|DRUG|Mitomycin|Given IV
41027604|NCT04166318|OTHER|Quality-of-Life Assessment|Ancillary studies
41027605|NCT04166318|OTHER|Questionnaire Administration|Ancillary studies
41027606|NCT01465893|DRUG|Vitamin D|vitamin D ,50000 unit /week
41027607|NCT01465893|DRUG|Vitamin D withheld|do not receive anything
41027608|NCT03737214|DRUG|Lucerastat|Administered in hard gelatin capsules containing 250 mg of lucerastat.
41027609|NCT00066092|DRUG|pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
41027610|NCT00066092|DRUG|filgrastim|Filgrastim given daily for PBPC mobilization
41027611|NCT00066092|DRUG|pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
41027612|NCT03495024|DRUG|Varenicline|Oral medication approved to facilitate smoking cessation
41027613|NCT04679220|PROCEDURE|Preheating|For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
41027614|NCT01964573|DRUG|Rotigotine|"Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
41027615|NCT01964573|OTHER|Placebo|"Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.~Frequency:~Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
41027616|NCT02546544|DRUG|Linsitinib|
41027617|NCT02855905|OTHER|Exercise/Rest and cold/neutral temperature|Subjects were either exercising or resting in either cold or neutral environmental temperature
41027618|NCT03251469|DRUG|Tranexamic Acid 15mg/kg , iv, Single Dose|Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
41027619|NCT03251469|DRUG|Normal Saline, 100mg, iv, Singe dose|Normal Saline, 100mg, administered intravenously, preoperatively in single dose
41027620|NCT06525883|OTHER|No intervation|No intervention was made to the groups
41027621|NCT04781764|PROCEDURE|surgery|surgery
41027622|NCT05544994|OTHER|Aerobic Exercise Training|Aerobic training will be performed 3 days a week for 12 weeks at 60%-%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.
41027623|NCT05544994|OTHER|Home exercise program|Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 to 5 days a week.
41027624|NCT05363033|DEVICE|sarcopenia nursing guidance mobile application was developed|The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care
41027625|NCT02105363|OTHER|measure of skin movement on surface of the back|
41027626|NCT02105363|OTHER|Measurement of skin movement on surface of back|
41027627|NCT05759234|DRUG|HS248 pieces|The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
41027628|NCT01540123|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
41027629|NCT01540123|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
41027630|NCT06281691|DIAGNOSTIC_TEST|Xpert® Bladder Cancer Detection Test|A urine sample is analyzed with the Xpert® Bladder Cancer Detection Test
41027631|NCT00782340|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
41027632|NCT00782340|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
41027633|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
41027634|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
41027635|NCT01902849|OTHER|blood sampling for IL measurement|"Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~* T0- before the induction of anesthesia (venous cannula insertion time)~* T1- after induction but before starting surgery~  * In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~ * In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~* T2, T3- at 2 and 24 hours after surgery"
41027636|NCT03068403|PROCEDURE|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
41027637|NCT05353335|OTHER|Re-timing of anti-hypertensive drug|The intervention will consist of shifting the anti-hypertensive medication from morning/early dose to an evening/later dose
41027638|NCT05353335|OTHER|Current regimen|The participants will begin on their current regimen.
41027639|NCT04304690|OTHER|blood sample|2 blood samples at T0 and 3 months
41027640|NCT02938416|DEVICE|Isokinetic strengthening exercise|Isokinetic strengthening exercise provides muscle training throughout the range of motion of a joint at a pre-set constant speed of angular velocity. It can be performed in an eccentric or concentric way in a controlled manner, and is evidenced to be an effective and safe training method in patients with anterior cruciate ligament reconstruction, burn injury, ankle instability, osteoarthritic knee, and chronic stroke in the past literatures.
41027641|NCT02938416|DEVICE|Isotonic strengthening exercise|Isotonic strengthening exercise keeps the tension remained unchanged during the muscle's length changing. As the muscle's force changes via the length-tension relationship during a contraction, an isotonic contraction will keep force constant while velocity changes. There are two types of isotonic contractions: (1) concentric and (2) eccentric. In a concentric contraction, the muscle tension rises to meet the resistance, then remains the same as the muscle shortens. In eccentric, the muscle lengthens due to the resistance being greater than the force the muscle is producing.
41027642|NCT02938416|BEHAVIORAL|isometric strengthening exercise|home exercise education on isometric quadriceps strengthening on the day of out-patient appointment
41027643|NCT03744156|BEHAVIORAL|Cognitive Behavioral Treatment-Insomnia|8 session Cognitive Behavioral Therapy for Insomnia. Individualized sessions with a therapist.
41027644|NCT03744156|BEHAVIORAL|Sleep Hygiene Education|8 Session Sleep Hygiene Education. Individualized sessions with a therapist.
41027645|NCT05093517|DRUG|REMD-477|A biologic glucagon receptor agonist to which randomized subjects are assigned 2:1
41027646|NCT05093517|DRUG|Placebo Subcutaneous injection|Placebo for REMD-477 to which subjects will be randomized 1:2.
41027647|NCT01318187|DRUG|paracetamol|1 gr
41027648|NCT01318187|DRUG|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
41027649|NCT01318187|DRUG|Paracetamol|1 gr intravenous
41027650|NCT01318187|DRUG|Paracetamol|intravenous 1 gr
41027651|NCT01318187|DRUG|Morphine|0.1 mg/kg intravenous
41027652|NCT04321837|DIETARY_SUPPLEMENT|Coral Complex 3|Coral-derived calcium supplement fortified with vitamin D3
41365331|NCT03672565|BEHAVIORAL|Phase Two: Flexible Patient Driven Intensive ERP|"Families will have the opportunity to access up to four additional once/week 3-hour intensive ERP sessions.~Three days prior to each additional ERP session (sessions 3-6), families will be prompted to fill out online forms and decide how to proceed with treatment for that week with the following options:~* They may select that they would like to receive and complete the next ERP session, and up to four 3-hour ERP sessions during Phase Two. Completion of all four ERP session will automatically end Phase Two.~* They may opt to delay receiving a treatment session by one week for any reason. Families will be allowed to take a week off up to two times during Phase Two. If both weeks off are utilized, at the next decision point families must either opt to complete an ERP Session or end their participation in Phase Two.~* They may select to end their participation in Phase Two at any decision point and for any reason (e.g., don't perceive it as helpful, have improved substantially)."
41027653|NCT04321837|DRUG|Ibandronate|Bisphosphonate
41027654|NCT04321837|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3
41027655|NCT03606642|DRUG|Dual Antiplatelet (DAPT) Therapy|"DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID."
41027656|NCT03606642|DEVICE|The Synergy® stent|IVUS guided stent
41027657|NCT01153633|DEVICE|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|"The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
41027658|NCT01153633|DEVICE|Normal Saline and Placebo Gel|"The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
41027659|NCT05019638|DRUG|Regional anesthesia group|bupivacaine 0.25% with epinephrine 1:400,000.
41027660|NCT05019638|DRUG|Local multimodal analgesia group|5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
41500798|NCT05616637|OTHER|Lower Extremity Length Measurement|Lower extremity length will be recorded to normalize dynamic balance test data. The person will lie in the supine position. The distance between the umbilicus and the anterior superior of the spina iliaca will be measured in cm with the help of a tape measure. If there is no asymmetry, it will be assumed that there is no rotation in the pelvis, and it will be started to measure the length of the lower extremity. If pelvic asymmetry is detected, the pelvic position will be corrected manually. Then, the most inferior point of the spina iliaca anterior superior and the most distal point of the medial malleolus will be marked and measured and recorded. Lower extremity length and data in 3 different directions will be used in cm. The purpose of using formulas is to easily provide comparisons with other studies using the same type of data. The data obtained from the formula is expressed as a percentage of the length of the limb.
41500799|NCT05616637|OTHER|Y Balance Test|While the individual tries to balance on one bare foot at the midpoint of the assembly, the individual will also be asked to reach as far as possible with the other foot in the anterior, posteromedial and posterolateral directions, touch the tip of the toe, and then immediately return to the starting position without disturbing the balance. The test will be evaluated for 3 repetitions. Situations where the participant will be requested to repeat the test: the foot on the ground passes the reference point or the heel lifts off the ground, perturbations caused by the environment, contact of the foot with the ground, and loss of balance when returning to the starting position. 10 seconds between 3 repetitions during testing will be given. Each participant will be given the right to try 6 times before starting the test in order to eliminate the possible learning parameter. The test will be repeated 3 times in each direction and the closest distance in cm will be recorded.
41500800|NCT01996618|DRUG|Ranolazine|After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
41500801|NCT04283019|DRUG|CBD|CBD will be orally ingested
41500802|NCT04283019|DRUG|THC|THC will be orally ingested
41500803|NCT04782674|DIAGNOSTIC_TEST|Saliva Testing|Saliva EBV-DNA Detection comparing with PBMC and plasma EBV-DNA
41500804|NCT03276078|DRUG|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
41500805|NCT01013558|DRUG|Remifentanil|0.15 microgram/kg/min continuous infusion.
41500806|NCT01013558|DRUG|saline|continuous infusion
41027661|NCT06416215|OTHER|Psychological intervention based on WBT and cognitive restructuring|Participants will engage in 6 weekly group session of two hours. One part will be held by a trained dietician and will focus on nutritional education, particularly emphasizing the adoption of healthy and sustainable eating behaviors. The remaining part will be dedicated to a group psychological intervention inspired by the principles of Well-Being Therapy and will be held by a trained psychologist. During these sessions, participants will be introduced to the six dimensions of psychological well-being and will be gradually provided with cognitive-behavioral strategies to enhance psychological well-being and seek a balance between the presented dimensions. Participants will be given cognitive-behavioral tools to recognize justification cognitive mechanisms and replace them with more functional cognitions. These objectives will also be achieved through the use of a food diary to highlight emotions and thoughts experienced during food intake.
41365332|NCT03672565|BEHAVIORAL|Follow-Up Phase: Booster Calls|Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
41365333|NCT00511602|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder
41365334|NCT00511602|DRUG|Technosphere Placebo|Technosphere Inhalation Powder
41365335|NCT03229512|DRUG|Sildenafil|Topical 1% Sildenafil Cream
41365336|NCT02219750|DRUG|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
41365337|NCT00854776|DRUG|lansoprazole|30 mg once daily
41365338|NCT00854776|DRUG|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
41365339|NCT01593566|DRUG|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
41365340|NCT01593566|DRUG|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
41365341|NCT05804539|BEHAVIORAL|Manual therapy|The therapist checks the range of motion of the cervical joints and gives manual treatment to the restricted joints. Throughout the examination, the subject lied in a supine position on a professional rehabilitation bed with the seventh cervical vertebra (C7) on the edge of the bed and the other the body above the C7 were placed off the bed. The therapist held the subject's occipital bone with one hand and the radial aspect of the second metacarpophalangeal joint of the other hand to grip the spinous process of the sixth cervical vertebra and slowly pushed the occiput downward to check the joint mobility of the fifth cervical vertebra and the sixth cervical vertebra. After the examination, the restricted joint was accurately located and treated with targeted manual therapy. For example, stretching was performed with the right side of C4-C5 flexed, closing only the right side of the subject's C4-C5 as much as possible to increase joint mobility on the right side of C4-C5.
41365342|NCT05804539|BEHAVIORAL|Tai Chi|Based on the characteristics of young people and the need to correct their FHP, the classic Yang's 24 Forms of Tai Chi has been improved. The movements are mostly upper limb movements and the lower limb movements have been simplified to make the movements easy to learn. The modified Tai Chi exercise retains the traditional Tai Chi movements but is simple and easy to learn; at the same time, it increases the movement of the shoulder and neck joints. The subjects performed each exercise session in a group setting at the school gymnasium, with a professional Tai Chi instructor guiding them through a warm-up session, followed by a Tai Chi exercise session.
41365343|NCT05804539|BEHAVIORAL|Tai Chi and Manual therapy|Intervention content of MSG included 15-min Tai Chi exercise and 15-min manual therapy, with the order of intervention being Tai Chi exercise first and then manual therapy.
41365344|NCT00402311|PROCEDURE|DOC-PG: integrated multidisciplinary assessment|
41365345|NCT00402311|PROCEDURE|Usual care: assessment by GP or one of the regional services|
41365346|NCT02491333|OTHER|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
41365347|NCT02491333|OTHER|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
41365348|NCT02491333|DRUG|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
41365349|NCT02491333|DRUG|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
41365350|NCT06191562|DEVICE|Tympanostomy tube|Participants will receive an ear tube in the usual location (anterior-inferior) in one ear and a new location (posterior-inferior) in the other ear during surgery.
41365351|NCT04284579|DEVICE|IV cannula|We measure the time duration needed for IV cannulation
41365352|NCT00409565|DRUG|Cetuximab|"* Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~* Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations"
41365353|NCT00409565|DRUG|Bevacizumab|Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
41365354|NCT04914182|RADIATION|LASER|Laser will be applied in specific points for perineal lacerations.
41365355|NCT04914182|RADIATION|CONTROL|"A control group of sham laser will create for the patients the impression that laser is being played, with the lights of the instrument of on mode turned on, without biological effects."
40844638|NCT06124456|OTHER|Moderate-intensity Exercise Intervention|The walking time in each session will be 50 minutes for the moderate-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
41365356|NCT04725864|DRUG|Progesterone vaginal tablet|The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.
41365357|NCT03977363|DRUG|Anticoagulant drugs|Anticoagulant drugs
41365358|NCT02221882|DRUG|LY3164530|Administered IV.
41365359|NCT00650689|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
41500807|NCT06046794|OTHER|Analyze of GemCore status|Genomic analyze of GemCore status
41365360|NCT00650689|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
41365361|NCT03473821|BEHAVIORAL|MOTIFS|o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
41365362|NCT03054116|DIAGNOSTIC_TEST|Airflow pertubation device|Participants have airway resistance measured at the mouth by tidal breathing into a mouth-piece connected to the airflow perturbation device.
41365363|NCT01066546|DRUG|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
41365364|NCT00390741|BEHAVIORAL|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
41500808|NCT04197050|DRUG|Sacubitril / Valsartan Oral Tablet|After recruiting participants and collecting the baseline information, sacubitril/valsartan group will receive sacubitril/valsartan and optimal pharmaceutical treatment (OPT). The control group will receive valsartan and OPT. A CMR scan and a post-processed imaging procedure will later be carried on in order to detect the cardiac impairment.
41500809|NCT00115830|DRUG|Atorvastatin|
41500810|NCT00115830|DRUG|Rosuvastatin|
41500811|NCT00292786|BEHAVIORAL|Walking Practice with Functional Electrical Stimulation|
41500812|NCT00292786|BEHAVIORAL|Walking Practice|
41500813|NCT04252092|OTHER|Sensory training|15 session,20 minutes sensory training program
41500814|NCT04252092|OTHER|Electrical stimulation|15 session,20 minutes electrical stimulation program
41365365|NCT05267964|PROCEDURE|Epping resection arthroplasty|Follwing the described epping resection arthroplasty, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
41365366|NCT05267964|PROCEDURE|CMC I prosthesis|Follwing the described CMC I prosthesis procedure, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
41500815|NCT04696289|DIAGNOSTIC_TEST|Standardized catheterization assessment|"There are four components to the pulmonary vein assessment.~1. Angiography: pulmonary artery wedge injection and/or selective pulmonary vein injection.~2. Intravascular ultrasound: manual pullback of IVUS catheter from lobar segment to left atrium.~3. Pressure assessment: pulmonary vein pressure (mmHg) measured before and after (if applicable) intervention.~4. Compliance testing: the compliance of the vein will be measured using a compliant conventional balloon."
41027662|NCT06416215|OTHER|Basic Nutritional Intervention|Participants will receive treatment as usual (TAU) by participating in 6 weekly group sessions of two hours of a Basic Nutritional Intervention (BNI) held by a trained dietician. This course focuses on promoting healthier lifestyles through nutritional education, diet monitoring using a dedicated food diary, and recommendations for proper physical activity.
41027663|NCT05114681|OTHER|Assessment of Oral care as per patient personal choice|We just inquire from patients or attendants about products used, the timing for oral care.
41027664|NCT03900260|DEVICE|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
41027665|NCT05441345|OTHER|questionnaires with collection of stool and urine|questionnaires will be completed (GPAQ, SarQoL, EQ-5D-3L, SF36), with collection of stool (for care and research) and urine
41027666|NCT02544906|DRUG|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
41365367|NCT02173158|DRUG|lomitapide|
41365368|NCT00072982|DRUG|fish oil|The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
41027667|NCT02544906|DRUG|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
41027668|NCT04223011|BEHAVIORAL|In-Hospital Recovery Coach Intervention|The recovery coach will meet with the patient at least once during the hospital admission, during which he/she will reinforce the importance of continuing medication treatments, if initiated, as well as community and social supports for recovery and will discuss the plan for engaging in these services. This will include recommendations for suitable community resources for recovery services, or for housing, transportation, or other external barriers that may make it more difficult to engage in outpatient treatment. The recovery coach will encourage the participant to complete a relapse prevention plan, and help the patient organize post-discharge appointments and review medications. If applicable, family members and significant others will be encouraged to be present for these encounters.
41500816|NCT01990482|DIETARY_SUPPLEMENT|caffe|
41500817|NCT01990482|DIETARY_SUPPLEMENT|Water|
41027669|NCT01250860|OTHER|Derotational manual therapy techniques in selected segments in spine|Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.
41027670|NCT01250860|BEHAVIORAL|Sham therapy|
41027671|NCT01822860|DRUG|Chlorthalidone 12.5 mg|
41500818|NCT04175600|DRUG|Selexipag|Selexipag tablet will be administered orally.
41027672|NCT01822860|DRUG|Hydrochlorothiazide 25 mg|
41027673|NCT01822860|DRUG|Placebo|
41027674|NCT02590718|PROCEDURE|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
41365369|NCT00072982|DRUG|borage seed oil|Borage oil 13 capsules divided doses daily for 18 months
41365370|NCT00072982|DRUG|combination fish oil and borage seed oil|Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
41500819|NCT04175600|DRUG|Placebo|Matching placebo tablets will be administered orally.
41365371|NCT02599727|OTHER|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
41365372|NCT02599727|OTHER|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
41500820|NCT01398215|PROCEDURE|transvaginal NOTES ventral hernia repair|ventral hernia repair via the transvaginal approach
41365373|NCT04424758|OTHER|Video information about mammography screening|A video informing about mammography screening
41500821|NCT05160584|OTHER|No intervention|There is no interventional treatment component for participants with RRMM in this study.
41500822|NCT02942030|OTHER|Computerized assesment battery|All participants will do a computerized assessment battery to identify specific attentional profile
41027675|NCT04059926|OTHER|insert apossing lumen metal stent|insert apossing lumen metal stent
41500823|NCT05214105|OTHER|Biospecimen/DNA collection and analysis|Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).
41365374|NCT04424758|OTHER|Video information about smart energy systems|A video informing about smart energy systems
41365375|NCT04639895|PROCEDURE|Virtual Reality|The Virtual Reality group will be involved in the Standard treatment protocol and will perform personalized activities of daily living in a virtual city environment (Reh@City).
41365376|NCT04639895|PROCEDURE|Paper and Pencil|The paper and Pencil group will be involved in the Standard treatment protocol and will perform personalized cognitive paper-and-pencil tasks, using the Task Generator tool.
41365377|NCT04639895|PROCEDURE|Control Group|The standard treatment protocol.
41500824|NCT04807647|OTHER|"Orhan OSMAN's track Don't Let Your Baby Cry in the Kolik album will be played on the music player."|white noise will be played while breastfeeding
41500825|NCT04332393|DRUG|Metformin|Metformin tablets according to glycemic control. Initial dose: 425 mg before meals (breakfast, lunch and supper) and 1700 mg around 22:00. Modifications may take place according to glycemic control
41500826|NCT00828737|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
41365378|NCT02760420|DRUG|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
41365379|NCT02760420|DRUG|Placebo|Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
41027676|NCT04092660|BEHAVIORAL|Behaviour change Intervention Based on Health Action Process Approach Model|"The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~1. Health Pamphlet at the initial screening~2. Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~3. Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~4. Booster phone calls in between the follow-up visits"
41027677|NCT04092660|DEVICE|Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard|"Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances \[MAA\] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device."
41500827|NCT06251050|DRUG|lithium-containing mouthwash|The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.21 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
41027678|NCT04386681|BEHAVIORAL|Reentry Continuum for Brain Injury (RCBI)|"Pre-Release RCBI Treatment Procedures (BICS and ICAN). BICS: consists of 12 weekly two- hour sessions. Sessions focus on brain injury education, coping skills for the various symptoms of brain injury, depression management, stress management, and self- advocacy.~ICAN: delivered once a week for 6 weeks for 2 hours per session. ICAN primarily focuses on poor perspective-taking and inability to make social inferences about others' behaviors that are related to negative attributions, and employs role playing exercises and a novel perspective-positioning technique to elicit affective and cognitive empathy to alter negative attributions and reduce anger.~Post-Release RCBI Resource Facilitation. Working with their resource facilitator, alongside their corrections case manager, to work on brain injury specific reentry planning, resource, and needs identification."
41027679|NCT04626791|DRUG|Acalabrutinib|Given PO
41027680|NCT04626791|DRUG|Bortezomib|Given SC
41027681|NCT04626791|DRUG|Cyclophosphamide|Given IV
41027682|NCT04626791|DRUG|Cytarabine|Given IV
41027683|NCT04626791|DRUG|Doxorubicin Hydrochloride|Given IV
41027684|NCT04626791|DRUG|Prednisone|Given PO
41027685|NCT04626791|BIOLOGICAL|Rituximab|Given IV
41027686|NCT04626791|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given IV
41027687|NCT04880759|OTHER|bike desks in the classroom|Children will use bike desks for 13 weeks during school time
41027688|NCT05801601|BEHAVIORAL|Many Ways of Being, an innovative sexual health promotion program focused on addressing rigid gender norms and promoting healthy relationships|The Many Ways of Being program is a gender-synchronous program informed by Equimundo's existing single-gender Manhood 2.0 and Sisterhood 2.0 programs. The curriculum is designed to shift unequal gender attitudes and behaviors and provide skill-building on maintaining healthy relationships, making healthy and informed decisions around sex, and avoiding risky sexual behaviors.
41027689|NCT05801601|BEHAVIORAL|A career readiness program|Youth enrolled in the control condition will receive a career readiness curriculum, either International Youth Foundation's Passport to Success, LAYC's Next Generation program or LAYC's Career Readiness Curriculum, depending on the site and implementation period. These programs equip young people with a range of professional, employment readiness, and practical skills that will help them stay in school and acquire the education, professional skills, employment
41027690|NCT00001022|DRUG|Zidovudine|
41161321|NCT05189171|DEVICE|MicroOrganoSphere (MOS) drug screen|Patient-derived models of cancer, called MOS, will be generated from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and a drug screen using standard-of-care drugs used will be completed (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab). Subjects will receive standard-of-care therapy for CRC dictated by their treating physicians.
41500828|NCT06251050|DRUG|Plcacebo mouthwash|Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
40844639|NCT06124456|OTHER|Vigorous-intensity Exercise Intervention|The walking time in each session will be 25 minutes for the vigorous-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
41027691|NCT00001022|DRUG|Zalcitabine|
41027692|NCT00001022|DRUG|Didanosine|
41027693|NCT02970344|BEHAVIORAL|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
41027694|NCT03579836|DRUG|BEY1107|Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
41027695|NCT03579836|COMBINATION_PRODUCT|Gemcitabine|Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
41161322|NCT00920699|DRUG|CoQ10|Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
41161323|NCT00249119|DRUG|risperidone|
41161324|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 10gM|"* 140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
41027696|NCT03269812|PROCEDURE|laparoscopic assisted pull-through oeration|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
40844640|NCT05673525|DEVICE|Transcatheter Aortic Valve Implantation (KOKA-VALVE)|Transcatheter Aortic Valve Implantation
41027697|NCT01383538|DRUG|FOLFIRINOX, IPI-926|"Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle."
41027698|NCT02300714|PROCEDURE|oblique view approach|
41027699|NCT01213758|OTHER|Measuring liver function by PET/CT|Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
41027700|NCT01200381|OTHER|Quarterly remote follow ups and remote monitoring|Quarterly remote follow ups and remote monitoring
41027701|NCT01200381|OTHER|Quarterly remote follow ups + additional phone calls and remote monitoring|Quarterly remote follow ups + additional phone calls and remote monitoring
41027702|NCT01200381|OTHER|Quarterly in clinic follow ups and remote monitoring|Quarterly in clinic follow ups and remote monitoring
41027703|NCT01965067|DRUG|sugammadex|"sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state"
40844641|NCT01089790|DRUG|Dutogliptin|400 mg tablet, once daily
40844642|NCT01089790|DRUG|Sitagliptin|100 mg capsule (each capsule contains two 50-mg tablets), once daily
40844643|NCT05533710|PROCEDURE|erector spinae plane block|Patients will receive ESB. In the lateral decubitus, after skin sterilization, ESP block will be performed at the level of T9
40844644|NCT05533710|PROCEDURE|transversus abdominis plane block|patients will receive TAP block in supine position after skin sterilization, TAP block will be performed between internal oblique and transversus abdominis muscles
41500829|NCT06251050|DRUG|lithium-containing mouthwash|Effective lithium salt concentrations screened in the Phase I trial is used as active interventions in this group of interventions. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
40844645|NCT06156501|PROCEDURE|ACL Reconstruction|Reconstruction of the anterior cruciate ligament
40844646|NCT05216471|RADIATION|chest X-ray|Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory
40844647|NCT00001009|DRUG|Dextran sulfate|
41027704|NCT02669329|DEVICE|CoolSculpting device with vacuum applicator.|The CoolSculpting device with a vacuum applicator will be used to perform the treatments.
41027705|NCT02362399|DRUG|sildenafil citrate|single oral dose of 50 mg
41027706|NCT02362399|OTHER|placebo|single oral dose of placebo tablet
41027707|NCT02323191|DRUG|Atezolizumab|Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
41027708|NCT02323191|DRUG|Emactuzumab|Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
41027709|NCT01786694|DEVICE|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
41027710|NCT02745379|PROCEDURE|BFPSCs+ DFDBA+ PRF|
41027711|NCT02745379|PROCEDURE|DFDBA + PRF|
41027712|NCT05222230|OTHER|FFP3 Mask|Participans will wear FFP3 respirators during the study.
41027713|NCT04859166|PROCEDURE|Organoids|A part of the tumor of approximately 1 cm3 will be removed from the primary tumor.
41027714|NCT05571917|BEHAVIORAL|Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)|This intervention is an integrated psychosocial treatment of two established treatments for chronic pain and Opioid Use Disorder (OUD). This intervention focuses on reducing pain interference and preventing relapse to opioid misuse.
41027715|NCT05571917|BEHAVIORAL|Enhance Usual Care (EUC)|This intervention consists of psychoeducational materials about chronic pain treatment resources, signs and management of opioid overdose and overdose prevention. This intervention also consists of a brief, remote visit with a study therapist, lasting approximately 15 minutes.
41027716|NCT02281006|DRUG|Trans-tympanic injection of a sodium thiosulfate gel|A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
41027717|NCT04376541|DRUG|Fentanyl|amount of fentanyl used in both groups
41027718|NCT05318729|DEVICE|Vibration tool|Therapeutic mini massager for scar management, desensitization, muscle stimulation, oral stimulation and sensory re-education. Seek pain relief for sore achy muscles, tendons or bones.
41027719|NCT00418535|DRUG|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
40844648|NCT05637892|OTHER|No intervention|This is a prospective observational study with no intervention
41027720|NCT01468402|PROCEDURE|Magnetic Resonance Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
41027721|NCT00745732|DRUG|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
41027722|NCT00745732|RADIATION|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
41365380|NCT01743781|BEHAVIORAL|video|view a 10-minute informational video about comprehensive eye examination
40844649|NCT04891107|DEVICE|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|Participants will walk using the music-based, rhythm-modulating wearable sensor system (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 5 times a week for 4 weeks.
41161325|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 20gM|"* 280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
41500830|NCT03565679|DEVICE|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
41365381|NCT00719511|DRUG|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
41365382|NCT00719511|DRUG|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
41365383|NCT00719511|DRUG|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
41365384|NCT00719511|DRUG|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
41500831|NCT03565679|DEVICE|CO-OXIMETRY SENSORS|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
41365385|NCT05584917|BEHAVIORAL|tegner acticity scale|phone call to complete the tegner activity scale after surgery
41365386|NCT04384276|OTHER|The Weigh Easy System|By use of a small user-friendly luggage scale, the family can easily and safely obtain a weight within the comfort of their own home. Using the Weigh Easy eClipboard, a message will be sent to the family on a weekly basis via Cerner's Message Center that will include a link. The link will be used by parents to enter and submit the patient's current weight. Upon submission, the weight will be transmitted into the patient's EMR after it's reviewed and accepted by a member of the study team. When the weight is received in the system, an alert will be triggered that will notify the study team of its arrival. While the Weigh Easy eClipboard function does qualify as a device, as the investigators will be making clinical decisions based off of the data received through the form, the device is not being used investigationally on this study. The eClipboard function is a standard part of the Cerner framework and has been previously investigated and vetted by for safety and efficacy.
41365387|NCT04384276|OTHER|Retrospective Control|No interventions will be administered to the historical control group.
41365388|NCT00132665|PROCEDURE|A: Radiotherapy alone|Procedure/Surgery: A: Radiotherapy alone
41365389|NCT00132665|DRUG|B: CBDCA and Radiotherapy|Drug: B: CBDCA and Radiotherapy
41365390|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 10 mg, daily, 24-48 weeks
41365391|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24-48 weeks
41365392|NCT01016912|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
41365393|NCT01016912|DRUG|Peginterferon alfa-2b|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
41365394|NCT01016912|DRUG|Ribavirin|Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
41365395|NCT04932980|DRUG|Aflibercept|administration of anti-VEGF Aflibercept (Eylea)
41365396|NCT04932980|DRUG|Brolucizumab|administration of anti-VEGF Brolucizumab (Beovu)
41365397|NCT04932980|PROCEDURE|early treat and extend (T&E)|extension of treatment intervals (T\&E) from the beginning of treatment
41365398|NCT03723746|BIOLOGICAL|JNJ-67670187|Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.
41365399|NCT03723746|BIOLOGICAL|Placebo|Participants will receive matching placebo in all cohorts.
41365400|NCT06005792|BIOLOGICAL|XmAb27564|Subjects to receive four doses of XmAb27564 at one of six escalating dose-levels administered subcutaneously every 2 weeks (Q2W).
41365401|NCT06005792|BIOLOGICAL|Placebo|Subjects to receive four doses of placebo administered subcutaneously every 2 weeks (Q2W).
41365402|NCT02641665|PROCEDURE|Cardiac valve surgery|Aortic or mitral valve replacement/repair performed in isolation of in addition to coronary artery bypass graft(s).
41365403|NCT06088511|BEHAVIORAL|e-Health System with nutritional advice|"A 12-week intervention consisting of a 4-weekly group-based, face-to-face supervised sessions, and an 8-week self-management phase will be arranged to the experimental group. The features of the System will be introduced to the users and their family members in the first two face-to-face sessions. The users and their family members will then be able to start using the System with the mobile app. In the other two sessions, all participants in the experimental group will learn how to accurately complete their dietary records in the e-Health System and will be provided with nutritional advice.~For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants are required to fill in their dietary record in the e-Health System every day, and will be provided with nutritional advice to improve high-quality protein and leucine intake, which is essential for muscle building."
41365404|NCT06088511|BEHAVIORAL|The Exercise Training|For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants in the experimental group will also be suggested to continually practise exercise training at home for 30 minutes at least 5 times per week. Participants can review the self-learning exercise videos embedded in the System. The exercise trainings include: a) progressive resistance training to improve muscle strength; and b) brisk walking exercise to maintain walkability.
40844650|NCT04736134|BIOLOGICAL|BMS-986326|Specified dose on specified days
41365405|NCT04004299|DIAGNOSTIC_TEST|HCV RNA self-test|Self-test set including instruction manual (video available as well), finger prick device, tube and envelope to safely transport biological material. Patient takes capillary blood sample, collects it in the tube and sends the sample to the lab by regular post mail.
41365406|NCT04879576|OTHER|Treatment|Telerehabilitation including pulmonary rehabilitation and posture exercises at 8 weeks in total with 2 sessions per week
41027723|NCT05205135|BEHAVIORAL|SHARE Programme|"SHARE is Singapore's first 'Hospital-to-Home' programme to screen, identify and provide targeted interventions for caregivers at-risk of caregiver burden. Our interventions include psychosocial and emotional preparation of caregivers' mental resilience, and long-term engagement initiatives to connect caregivers into an integrated network of peers and community support services, delivered by programme facilitators and care support nurses.~Key stakeholders essential for the success of share include ward nurses and clinicians who refer caregivers to SHARE and community partners and hospital leaders.~This study seeks to recruit all of these individuals to better understand their experience of SHARE and the facilitators and barriers to its successful rollout to better evaluate the feasibility of SHARE in the hospital to home setting."
41027724|NCT03930017|BIOLOGICAL|Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)|Influenza virus (quadrivalent, split virion, inactivated) of the strains that comply with the World Health Organization (WHO) recommendations (Northern Hemisphere) and European Union (EU) decision for the 2018/2019 season. The quadrivalent vaccine is propagated in fertilised hens' eggs from healthy chicken flocks.
41027725|NCT04255160|DRUG|Estradiol (mylan or vivelle dot patch)|Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
41027726|NCT04255160|OTHER|Placebo|A placebo patch that is visually similar to the estradiol patch will be used for the group not receiving estradiol.
41027727|NCT01592630|DRUG|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
41027728|NCT01592630|DRUG|Saline|On-Q pumps containing saline to be attached to TAP catheters
41027729|NCT01235039|DRUG|VIAject®25|Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
41027730|NCT01235039|DRUG|VIAject®7|One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
41027731|NCT01235039|DRUG|Insulin Lispro|One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
41027732|NCT05745740|DRUG|RC48-ADC|RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
41027733|NCT05745740|DRUG|Pyrotinib|Pyrotinib 400 mg by oral once a day.
41027734|NCT01181921|DRUG|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
41027735|NCT05036148|OTHER|Data analysis|MH registry data will be screened for MH positive diagnosis
41027736|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
41027737|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
41027738|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
41027739|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
41027740|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
41027741|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
41027742|NCT04387552|BEHAVIORAL|Prenatal Safe Sleep Mobile Health (mHealth) Messaging|Participants will receive prenatal Safe Sleep mHealth messaging starting at 34 weeks gestation until birth of their baby.
41027743|NCT04387552|BEHAVIORAL|Prenatal Breastfeeding Mobile Health (mHealth) Messaging|Participants will receive prenatal Breastfeeding mHealth messaging starting at 34 weeks gestation until birth of their baby.
41027744|NCT04387552|BEHAVIORAL|Postnatal Safe Sleep Mobile Health (mHealth) Messaging|Upon birth of baby, participants will begin receiving postnatal Safe Sleep mHealth messaging for a two month period.
41027745|NCT04387552|BEHAVIORAL|Postnatal Breastfeeding Mobile Health (mHealth) Messaging|Upon birth of baby, participants will begin receiving postnatal Breastfeeding mHealth messaging for a two month period.
41027746|NCT06152536|OTHER|Vegetarian Meal|"meal with vegetarian protein and meal with animal protein"
41365407|NCT01425242|DRUG|Aliskiren|Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
41365408|NCT01425242|DRUG|Amlodipine|Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
41365409|NCT03396172|OTHER|Control|The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
40844651|NCT04736134|OTHER|Placebo matching BMS-986326|Specified dose on specified days
40844652|NCT04736134|BIOLOGICAL|Multiple Ascending Dose SC|Specified dose on specified days
41027747|NCT00003289|DRUG|7-hydroxystaurosporine|
41027748|NCT03376321|DRUG|Pimodivir 600 mg|Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
41027749|NCT03376321|DRUG|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
41027750|NCT03376321|OTHER|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
41027751|NCT00320658|BIOLOGICAL|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
41027752|NCT00320658|BIOLOGICAL|CPG 7909|Adjuvant
41027753|NCT00548769|DRUG|Formulation A|Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
41027754|NCT00548769|DRUG|Formulation B|Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
41027755|NCT00548769|DRUG|Formulation C|Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
41027756|NCT00548769|DRUG|Formulation D|Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
41027757|NCT05148715|DRUG|Tacrolimus|Single dose intravenous tacrolimus over 4 hour infusion at a dose of 0.02 mg/kg ideal body weight diluted with 0.9% sodium chloride starting 4-8 hours before scheduled organ recovery.
41027758|NCT05148715|DRUG|Placebo|Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.
41027759|NCT05944419|DEVICE|Immediate implant surgery|Placement of immediate implant and immediate provisionalization after tooth extraction
41161326|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement, 20gNoM|"* 280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
41365410|NCT03396172|DEVICE|FreeDom|Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
41365411|NCT03440398|PROCEDURE|Robotic NSM|Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction
41365412|NCT03440398|PROCEDURE|Open NSM|Open nipple-sparing mastectomy and immediate breast reconstruction with implant
40844653|NCT04736134|OTHER|Multiple Ascending Dose Placebo|Specified dose on specified days
41027760|NCT05383248|BEHAVIORAL|High Reward - High Variance|Computerized reward learning task designed to increase reward responsiveness
41365413|NCT01467531|DRUG|Dolutegravir|50mg q 24h
41365414|NCT01467531|DRUG|Rlipivirine|25mg q24h
40844654|NCT03898128|DRUG|Anti-CD22 Immunotoxin|Clinical data (treatment, survival, adverse events) of patients treated with anti-CD22 immunoconjugates from 2014 will be collected
41027761|NCT05383248|BEHAVIORAL|High Reward - Low Variance|Computerized reward learning task designed to have minimal effect on reward responsiveness
41027762|NCT02600130|BIOLOGICAL|Longeveron Mesenchymal Stem Cells|via peripheral intravenous infusion
41027763|NCT02600130|BIOLOGICAL|Placebo|via peripheral intravenous infusion
41027764|NCT01990235|BEHAVIORAL|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
41027765|NCT02066935|OTHER|kidney transplant patient|kidney transplanted patients for at least one year
41027766|NCT01046110|DRUG|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
41027767|NCT01046110|DRUG|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
41027768|NCT04876508|OTHER|Accupressure|Patients in the experimental group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
41161327|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 40gM|"* 560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
41365415|NCT01467531|DRUG|GSK1265744|30mg q24h
41365416|NCT03564691|DRUG|MK-4830|MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
41027769|NCT03058770|OTHER|Sensorimotor retraining|Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.
41027770|NCT03058770|OTHER|Relaxation technique|Subjects will perform guided relaxation by using the Jacobson technique.
41027771|NCT02221115|DEVICE|Google Glass|The device is a wearable, voice-controlled Android device that resembles a pair of eyeglasses and displays information directly in the user's field of vision
41365417|NCT03564691|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV Q3W.
41365418|NCT03564691|DRUG|Carboplatin|Carboplatin will be administered IV Q3W.
41027772|NCT03882125|BEHAVIORAL|Mindfulness-based relapse prevention|Psychosocial intervention integrating mindfulness practice and cognitive behavioral relapse prevention approaches
41027773|NCT00463450|DRUG|Gynodian® Depot (BAY86-5032)|Injection monthly
41027774|NCT00463450|DRUG|BAY86-4980|orally
41027775|NCT02646423|BEHAVIORAL|Prior CD Decision App|The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
41027776|NCT03811912|DRUG|CTP-543|CTP-543 administered as 8 mg tablet.
41027777|NCT03811912|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
41161328|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement, 40gNoM|"* 560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
41365419|NCT03564691|DRUG|Pemetrexed|Pemetrexed will be administered IV Q3W.
41365420|NCT03564691|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily.
41365421|NCT03564691|DRUG|Paclitaxel|Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).
41365422|NCT03564691|DRUG|Cisplatin|Cisplatin will be administered IV Q3W.
41365423|NCT03564691|BIOLOGICAL|MK-4830A|MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.
41365424|NCT04169789|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
41365425|NCT03792230|BEHAVIORAL|Video|Video group receive body mechanic education via CD material,
40844655|NCT03902119|DEVICE|INYBI tool|Patients will lie down in supine position so that the INYBI tool will contact the suboccipital muscles at the posterior arch of the atlas. The therapist will adapt the height of the tool for each individual. All patients will use the softest head of the device. A 50Hz vibration speed will be set sup during 5 minutes.
40844656|NCT03902119|OTHER|Manual suboccipital inhibition|Patients will lie down in supine position.The therapist will be seated at the head of the treatment table. The therapist will keep the metacarpophalangeal joints in a flexed position, while therapists fingertips of both hands will contact with the suboccipital muscles at the posterior arch of the atlas.
40844657|NCT06542289|DEVICE|BlinkER device.|Participants will use the BlinkER System for 8-16 hours daily (removed during sleep) at approximately 10 blinks/minute. The stimulation cycle will be ON and OFF to achieve the desired blink rate. Participants will receive training on device usage before starting the study.
41365426|NCT03792230|BEHAVIORAL|Brochure|Brochure group receive body mechanic education via written material (brochure)
41365427|NCT02384096|DEVICE|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
41365428|NCT02384096|DEVICE|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
41365429|NCT05288764|DEVICE|Bispectral Index|Comparing Bispectral index values (usually adopted during general anaesthesia monitoring) to Ketamine concenetration at the effector site calculated with Domino model pump (usually adopted for Ketamine infusion during general anaesthesia)
41365430|NCT02509429|DEVICE|Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|The insuline used is usual patient insuline. There is no specific insulin for this protocol
41365431|NCT02509429|DEVICE|Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend|The insuline used is usual patient insuline. There is no specific insulin for this protocol
41365432|NCT01256866|DRUG|Dexmedetomidine|
41365433|NCT01256866|DRUG|Midazolam|
41365434|NCT04340167|BIOLOGICAL|Autologous humanized anti-CD22 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.
41365435|NCT02944058|PROCEDURE|Multiloc nail|Intervention is surgery with Multiloc nail
41365436|NCT02944058|PROCEDURE|Philos plate|Intervention is surgery with Philos plate
40844658|NCT01985568|BEHAVIORAL|Sequential BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Sequential BT will be asked not to begin exercise during months 0-6. They will receive a progressive exercise program and exercise behavior support during months 7-12.
40844659|NCT01985568|BEHAVIORAL|Standard BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Standard BT will begin exercise immediately upon starting the 6 month dietary weight loss intervention. They will receive a progressive exercise program and exercise behavior support during months 0-6.
40844660|NCT06543342|BEHAVIORAL|Bystander Brief Motivational Intervention|Group-based interactive intervention, conducted in two sessions, including multiple tasks and exercises to identify different levels of risk behavior, different types of strategies, and practicing responding to different scenarios. Personal goals for helping friends stay safe, and identifying whether intervention as a bystander was successful are included.
40844661|NCT00365274|DRUG|Cyclophosphamide|Given IV 750 mg/m\^2 day 1
40844662|NCT00365274|DRUG|Doxorubicin hydrochloride|Given 50 mg/m\^2 IV day 1
40844663|NCT00365274|DRUG|vincristine sulfate|Given 1.4 mg/m\^2 IV
40844664|NCT00365274|DRUG|prednisone|100 mg orally daily days 1 - 5
40844665|NCT00365274|DRUG|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
41027778|NCT04916639|DEVICE|Device: Physiomer undiluted seawater nasal spray|"In this study, subjects are asked to adhere to the following dosage during the 3 weeks of the study:~* Nasal wash four times every day~* These washes are to be carried out in each nostril~* By continuously pressing the spray for 3 seconds in each nostril~* Subjects are recommended to distribute the 4 nasal washes as follows:~  * 1st : morning~ * 2nd : midday~ * 3rd : afternoon~ * 4th : evening Subjects will be instructed to maintain daily nasal wash over the 3 weeks study period even in case of earlier nasal symptoms resolution, in order to assess the impact of nasal wash on viral load and other symptoms."
40844666|NCT02504307|DEVICE|Sirolimus Eluting Stent Inspiron|Angioplasty with Sirolimus Eluting Stent Inspiron implantation
40844667|NCT02504307|DEVICE|Bare Metal Stent|Angioplasty with Bare Metal Stent Cronus implantation
40844668|NCT04322825|DEVICE|TENS incorporated into the Mollii suit|trans cutaneous electric stimulation,
40844669|NCT03466736|DIAGNOSTIC_TEST|[18F]flutemetamol PET scan|Each subject will receive an amyloid PET scan with \[18F\]flutemetamol
40844670|NCT01914653|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
41027779|NCT00975234|PROCEDURE|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
41027780|NCT00975234|PROCEDURE|Revascularisation|Revascularisation surgery
41027781|NCT01617421|BEHAVIORAL|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation \[9\]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
40844671|NCT05210426|OTHER|Pilates exercises|The Pilates Group completed a 10-week Pilates program. The intervention was performed in 20 sessions. In the first session, introduction and explanations regarding the principles and benefits of Pilates was made in a language that preschool children can understand. Exercises were supervised, and they were taught via gamification. In addition, the participation of the children was encouraged and stickers were given to increase their motivation at the end of the sessions. No adverse events occurred during intervention. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week.
41365437|NCT05861882|OTHER|functional movement screen|FMS consists of seven test component which are used to evaluate various main movement models.Individuals completed one by one deep squat, high stepping, single line lunge, shoulder mobility, straight leg raises, trunk stability push-ups, rotation stability which are component tests. Subcomponent tests assess asymmetry by measuring the individual bilaterally. Each component test was scored on an ordinal scale (0 to 3 points), with a maximum score of 3, based on the quality of the movement. Less than 3 points indicated that the individual performed some form of compensation or was unable to complete the entire movement.While individuals were doing these tests, they were recorded in the video , the final scoring was done by evaluating the images. The scores of the component tests were summed, resulting in a composite score between 0 and 21 points, with a maximum score of 21
40844672|NCT04590417|DRUG|Estradiol valerate 2 mg, cyproterone acetate 25 mg|The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
40844673|NCT03871972|DRUG|Umbilical Cord Blood Unit|3 infusions of umbilical cord blood (UCB) unit (TNC \> 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
40844674|NCT03879304|OTHER|multimodal physiotherapy program with RV|Physiotherapy Programm includes: respiratory physiotherapy, stretching, resistance training, aerobic training and adaptation and training with virtual reality glasses and relaxation.
40844675|NCT03879304|OTHER|traditional physiotherapy program|Multimodal physiotherapy Programm includes: traditional physiotherapy, stretching, massage.
40844676|NCT00235287|DRUG|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
40844677|NCT00235287|DRUG|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
41027782|NCT02571218|DEVICE|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
41027783|NCT02571218|DEVICE|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
40844678|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
40844679|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
40844680|NCT00083928|DRUG|Å6 subcutaneous injection|
40844681|NCT04228094|OTHER|TDApp1: an eHealth intervention|TDApp1 is a tool that uses GRADE heuristics to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
41027784|NCT01584063|BEHAVIORAL|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
41027785|NCT04708873|OTHER|High intensity interval training|4x4 min intervals of high intensity treadmill running (80-95% of HRR, RPE 7-10 on Borg's category ratio scale of perceived exertion) interspersed with active recovery (slow jogging or fast walking at 50-70% HRR). HIIT-Resistance exercises 2 sessions per week, RPE 5 (hard) 6-8 RM, 1-3 sets of as many repetitions as possible in 60 seconds, active recovery 20-60 seconds b/w exercises,
41027786|NCT04708873|OTHER|Moderate Intensity Continuous Training|Moderate intensity continuous Aerobic exercises (Stationary cycling for 15-20 min followed by treadmill walking for 15-20 min) at 55-70% 55-70% of HRR, RPE 3-4 on Borg's category ratio scale of perceived exertion. The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
41027787|NCT00761501|DRUG|PN400|Oral
41027788|NCT00761501|DRUG|Naproxen (Proxen S)|Oral
41027789|NCT00761501|DRUG|Naproxen (Naprosyn E)|Oral
41027790|NCT04504045|DRUG|Metformin|500 mg tablet
41027791|NCT04504045|DRUG|Caffeine|As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
41027792|NCT04504045|DRUG|Efavirenz|As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.
41027793|NCT04504045|DRUG|Losartan|As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.
41027794|NCT04504045|DRUG|Omeprazol|As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.
41027795|NCT04504045|DRUG|Metoprolol|As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.
41027796|NCT04504045|DRUG|Midazolam|As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
41027797|NCT03938701|DRUG|Adalimumab-800CW|Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging
41027798|NCT03938701|DEVICE|Fluorescence Imaging|"Fluorescence Imaging Rheumatoid Arthritis (RA):~Open-air camera - a camera that enables detection of fluorescent signals.~Fluorescence Imaging inflammatory bowel disease (IBD):~Molecular Fluorescence Endoscopy - a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fibre-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed during standard clinical colonoscopy."
41161329|NCT00945698|DIETARY_SUPPLEMENT|Maize-soy flour|"* No food supplement during the primary trial period (6 to 18 months of age)~* 1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
41161330|NCT02431832|DRUG|Augmentin tab|
41365438|NCT05861882|OTHER|survey application|Participants are evaluated with kasari physical activity survey. According to the FIT score, physical activity level is commented as sedentary between 0-20, poor between 21-40, normal between 41-60, good between 61-80 and perfect between 81-100
41365439|NCT05861882|OTHER|Y balance test|YBT, which is performed in the standing position on one leg , is dynamic a test. Participants stood on the footplate in the centre of the Y Balance Test area and then, it was given instruction them that they should maintain a single leg stance while reaching as far as possible with the opposite leg and return to the starting position on the centre platform without losing balance.In the test, individuals were asked to reach the maximum distance in 3 directions (anterior, posteromedial and posterolateral), allowing 3 trials for each leg. The maximum reach distance was recorded for each consecutive trial
41027799|NCT06364046|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres are loaded with irinotecan. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is irinotecan 80mg/ m2. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
41027800|NCT06364046|DRUG|Serplulimab|Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
41027801|NCT06364046|PROCEDURE|Intravenous chemotherapy|Intravenous chemotherapy with irinotecan 65mg/m2 on day 1 and day 8, given once every 21 days
41027802|NCT05738395|DIAGNOSTIC_TEST|Questions|Questions
41027803|NCT02290665|OTHER|Thermosensitive gel rectal formulation|
41027804|NCT02290665|OTHER|Saline enema|
41027805|NCT01073618|DRUG|voriconazole IV|6 mg/kg iv q 12 hours (loading) then maintenance
41027806|NCT04144673|OTHER|Silver Hydrosol|Silver quantity will be 7 doses per day, with 50 mcg per dose.
41027807|NCT04144673|OTHER|Placebo|Placebo water with no active ingredients
41027808|NCT04434404|DRUG|L-Carnitine 500Mg Oral Tablet|"eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months."
41027809|NCT02752620|OTHER|Osteopathic Manipulative Treatment|
41027810|NCT02752620|OTHER|Exercise Therapy|
41027811|NCT05190081|OTHER|TASK TRAINING|A special program including motor and cognitive tasks was prepared. Both lower and upper extremity motor tasks and verbal, arithmetic, auditory, and visual cognitive tasks were planned based on evidence. The dual-task and single-task training were held 2 days a week, 40 minutes, for a total of 10 sessions for 5 weeks. A patient-appropriate task was selected for each cognitive task each week.
41027812|NCT00920192|DRUG|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
41027813|NCT05490459|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
41027814|NCT06536036|DRUG|SIM0270|Use according to the prescribed protocol
40844682|NCT06432166|DRUG|2-hydroxybenzylamine acetate|2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks
41027815|NCT02699281|DRUG|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
41027816|NCT02699281|DRUG|Placebo|um-PEA like placebo twice a day
41027817|NCT05860036|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
41027818|NCT05860036|DRUG|VRd|Bortezomib, Lenalidomide and Dexamethasone
41500832|NCT04719260|BEHAVIORAL|Nutrition Thinking®|In the first session, the nutritionist will carry out the anamnesis through the Empathy Map and assessment of the nutritional status to define the Nutrition Briefing. The steps described by Design Thinking as understanding, observation, and point of view comprise the first phase of this session. The ideation process will proceed from the definition of the Nutrition Challenge. Prototyping is the final stage of the first session, where an initial prototype of the diet will be co-created based on visual thinking tools and the description underlying the creation of diets. Within 24 hours the individual will receive a summary of the material developed by email. The period between sessions will comprise the testing phase and the follow-up sessions the iteration phase where the experience and previous steps are revisited in order to create new insights, anthropometric measurements will be seen as reflections of the experience and not as primary outcomes of the intervention.
41500833|NCT04719260|BEHAVIORAL|Standard Nutritional Approach|In the first session the nutritionist will carry out the food and nutritional anamnesis and assessment of the nutritional status. From this information, the nutritionist will generate the diagnostic hypothesis and determine the specific nutritional needs. The professional will be responsible for generating the dietary prescription defining the characteristics of the diet that will be delivered printed to the individual after a period of 15 days, in the second session of the protocol. The follow-up session will be based on adherence to the established conduct and monitoring of anthropometric variations.
41500834|NCT03734315|DEVICE|Ostenil®|Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.
41500835|NCT05930548|OTHER|Low Shrinkage Giomer|Low shrinkage giomer resin composite shows both sustained fluoride release and recharge, and low volumetric shrinkage of less than 1% with low resultant polymerization shrinkage stress. Such remarkable feature is due to the novel SRS (Steric Repulsion Structured) molecule which is designed to decrease polymerization shrinkage through molecular steric repulsion resulting in a stable restoration microstructure (AlQranei MS et al, 2021). Thus, low shrinkage giomers are best indicated in class V cavities where the dentin bonding agent does not have high strength (Algailani U, et al 2022).
41500836|NCT01210612|DEVICE|Unilateral CAI|five-toed socks usage
41500837|NCT05937997|PROCEDURE|high intensity physiotherapy|high intensity exercises for 3 weeks inpatient rehabilitation
41500838|NCT05937997|PROCEDURE|moderate intensity physiotherapy|moderate intensity exercises for 3 weeks inpatient rehabilitation
41500839|NCT05937997|PROCEDURE|low intensity physiotherapy|low intensity exercises for 3 weeks inpatient rehabilitation
41500840|NCT04734405|DRUG|Prof-001|Prof-001 cream
41500841|NCT04734405|DRUG|Fluconazole 150 mg|Fluconazole capsule
41500842|NCT04734405|DRUG|Placebo cream|ointment base to mimic Prof-001
41500843|NCT04734405|DRUG|Placebo capsule|encapsulated lactose powder to mimic 150 mg fluconazole capsule
41500844|NCT04693897|DRUG|Mirabegron 50 MG|Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
40844683|NCT06432166|OTHER|Placebo|Placebo taken three times per day for 16 weeks.
41500845|NCT04693897|DRUG|Solifenacin Succinate 5 MG|Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
40844684|NCT04328272|DRUG|Hydroxychloroquine 200 Mg Oral Tablet|Hydroxychloroquine administered orally with water
40844685|NCT04328272|DRUG|Azithromycin 500Mg Oral Tablet|Azithromycin administered orally with water
40844686|NCT04328272|DIETARY_SUPPLEMENT|Glucose tablets|administered orally with water
40844687|NCT02795091|OTHER|manual cleaning|manual clean the rag and floor towel
40844688|NCT02795091|DEVICE|machine clean|machine clean the rag and floor towel
40844689|NCT03399955|DRUG|Paromomycin|Paromomycin (20 mg/kg/d) IM for 14 days
41027819|NCT01887431|OTHER|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
41365440|NCT05861882|OTHER|Core stabilization assessment|The flexor muscle endurance test is initiated with the subject in a sitting position, with the back leaning against an apparatus angled 60 degrees from the floor. Both knees and hips are flexed to 90 degrees and the support apparatus is withdrawn and the time the person maintains the position is recorded The extensor muscle endurance test is performed with the upper trunk extended towards the end of the bed on which the test is performed and the pelvis, knees and hips fixed. The time the upper trunk maintains its level is recorded The lateral bridge test was performed with the individual lying in the full side bridge position (left and right side separately). Individuals supported themselves on one elbow and their feet while lifting their hips off the floor to form a straight line from head to toe. The test was terminated when the individual lost the straight back posture and/or their hips touched the floor.
41365441|NCT00899626|GENETIC|protein analysis|
41365442|NCT00899626|GENETIC|proteomic profiling|
41365443|NCT00899626|OTHER|biologic sample preservation procedure|
41365444|NCT00899626|OTHER|laboratory biomarker analysis|
41365445|NCT00899626|OTHER|medical chart review|
41365446|NCT00899626|PROCEDURE|diagnostic colonoscopy|
41365447|NCT00899626|PROCEDURE|diagnostic endoscopic procedure|
41365448|NCT00899626|PROCEDURE|diagnostic endoscopic surgery|
41365449|NCT00899626|PROCEDURE|diagnostic surgical procedure|
41365450|NCT00899626|PROCEDURE|endoscopic surgery|
41365451|NCT00899626|PROCEDURE|screening colonoscopy|
41365452|NCT01378624|OTHER|Bronchoscopy|"In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.~The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies."
41365453|NCT00490828|DRUG|Hydrocortisone|Hydrocortisone
41365454|NCT03734601|RADIATION|Total body irradiation (TBI)|Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning
41365455|NCT03734601|DRUG|Anti-thymocyte globulin (ATG)|Given intravenous (IV), Dose 1.5 mg/kg x 5 days
41027820|NCT01887431|OTHER|Conventional therapy|3-month routine clinic visits
41027821|NCT02843789|DRUG|Tocilizumab|
41027822|NCT00424437|DRUG|Inhaled human insulin|
41365456|NCT03734601|DRUG|Tacrolimus|Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)
41027823|NCT00016133|BIOLOGICAL|BCG vaccine|
41365457|NCT03734601|DRUG|Mycophenolate mofetil (MMF)|Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.
41365458|NCT03734601|RADIATION|Total lymphoid irradiation (TLI)|9 x 120 cGy over 11 days
41027824|NCT00016133|BIOLOGICAL|autologous tumor cell vaccine|
41027825|NCT00016133|DRUG|fluorouracil|
41365459|NCT02713633|OTHER|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
41365460|NCT02713633|OTHER|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
41365461|NCT03083613|DRUG|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
41365462|NCT03083613|DRUG|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
41365463|NCT02364362|DRUG|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m\^2
41365464|NCT02364362|DRUG|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m\^2
41365465|NCT02364362|DRUG|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m\^2
41365466|NCT00028496|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
41365467|NCT00028496|BIOLOGICAL|sargramostim|Given subcutaneously
41365468|NCT00028496|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|Given intradermally
41161331|NCT06297031|OTHER|heat application|• Thermophore Application: Before the application, the thermophore was wrapped in a towel to prevent skin damage. Studies in the literature indicate that the surface temperature of the thermophore should be 38-45 °C. For this reason, water with a temperature of 70°C when measured with a thermometer was added into the thermophore. Similarly, studies in the literature indicate that thermophore application should be applied for 10-30 minutes. Therefore, the application takes 20 minutes. The researcher stayed with the woman for 20 minutes.
41500846|NCT06233331|DRUG|Dose Level 1 ACU-D1 ointment|"ACU-D1 is a topical therapeutic agent that has pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (PTTC) as its major active ingredient. PTTC is a novel proteasome inhibitor that has antiangiogenic and anti-inflammatory activities that reduce pro-inflammatory cytokines. ACU-D1 ointment contains a range of 2.5% to 10% weight by volume of PTTC.~Level 1 will consist of 2.5% ACU-D1 ointment, used twice daily for 4 weeks."
40844690|NCT03399955|DRUG|Ambisome|AmBisome® (20 mg/kg total dose) IV over 7 days
40844691|NCT03399955|DRUG|Miltefosine|Miltefosine oral (allometric dosing) for 42 days (arm 1) or 28 days (arm 2)
41365469|NCT02680158|DEVICE|Oculeve Intranasal|Oculeve device, intranasal (test) application for approximately 3 minutes.
41365470|NCT02680158|DEVICE|Sham|Sham device (control), intranasal application for approximately 3 minutes.
41365471|NCT02680158|DEVICE|Oculeve Extranasal|Oculeve device, extranasal (control) application for approximately 3 minutes.
41500847|NCT06233331|DRUG|Dose Level 2 ACU-D1 ointment|Level 2 will consist of 5% ACU-D1 ointment, used twice daily for 4 weeks.
41500848|NCT06233331|DRUG|Dose Level 3 ACU-D1 ointment|Level 3 will consist of 10% ACU-D1 ointment, used twice daily for 4 weeks.
41500849|NCT06233331|PROCEDURE|Vulvar/ Perianal Biopsy|3 vulvar or perianal biopsies are to be performed at the screening as well as at the end of the study (week 4).
40844692|NCT01761812|OTHER|MRI with gadofosveset and MR elastography|
40844693|NCT02346513|DEVICE|Ceramic on Metal Articulation|Patients have THA with ceramic on metal articulation
40844694|NCT02346513|DEVICE|Non-Ceramic on Metal Articulation|Patients have THA with non-ceramic on metal articulation
41027826|NCT00016133|DRUG|leucovorin calcium|
41500850|NCT01804348|DEVICE|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
41027827|NCT00016133|PROCEDURE|adjuvant therapy|
41027828|NCT04571346|PROCEDURE|trans-obturator procedure|TOT procedure will be done using silicon-coated polypropylene tape that will be inserted at the mid-urethral portion. In group 1, a classical vertical vaginal incision will be done proximal to the external urethral meatus with dissection along the axis of the urethra till the mid-urethral zone that is identified by palpating the urethral catheter balloon through the vaginal at the bladder neck, while in group 2, two paramedian incisions will be done 1cm long in the anterior vaginal wall 2 cm apart parallel to the urethra till identification of the mid-urethral portion, communication will be done between the two incisions 1 cm wide in this area creating a tunnel where the tape will be placed, this technique provides healthy tissues proximal and distal to the tape that allows more stabilization and less migration. The rest of the procedure is the same as the standard procedure of Trans-obturator outside-in tension-free technique.
41027829|NCT01476046|DRUG|GSK1995057 single dose|Single intravenous dose
41027830|NCT01476046|DRUG|Placebo|Single intravenous dose
41027831|NCT05427331|DRUG|FMT capsule|Patients with insomnia need to take FMT capsules orally in an empty stomach in the morning, 16 capsules once a week, for 4 consecutive weeks
41027832|NCT04824547|OTHER|exercise|All exercises programs will applied two sessions per week, totally eight week..
41500851|NCT02397187|BEHAVIORAL|LOOP|"The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
41500852|NCT06007924|DRUG|Avutometinib|Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off
41500853|NCT06007924|DRUG|Defactinib|Defactinib 200 mg twice daily 3 weeks on/1 week off
41500854|NCT05005312|DRUG|PF-07321332|Tablet
41500855|NCT05005312|DRUG|Ritonavir|PK Boosting agent
41500856|NCT02683512|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
41500857|NCT02643355|DRUG|Olanzapine|
41500858|NCT02643355|DRUG|Clonidine|
41500859|NCT03133650|DRUG|WST 11-mediated VTP therapy|Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
41500860|NCT00093561|DIETARY_SUPPLEMENT|lycopene|
40844695|NCT03117179|OTHER|Discharge from patient after consultation in emergency department|Discharge from patient after consultation in emergency department
40844696|NCT00551291|DRUG|Mycophenolate mofetil|1 gm twice daily orally until end of study.
40844697|NCT00551291|DRUG|Prednisone|10 mg/day orally until end of study.
40844698|NCT00551291|DRUG|Erythropoietin Beta|Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.
40844699|NCT01067469|DRUG|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
40844700|NCT01067469|DRUG|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
40844701|NCT01067469|DRUG|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
41500861|NCT04697095|OTHER|Blood samples|: The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.
41500862|NCT05557032|PROCEDURE|cardiopulmonary resuscitation|pulse checks during cardiopulmonary resuscitation
41500863|NCT01890447|OTHER|Web-based survey questionnaire|Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
41500864|NCT02015559|DRUG|mucoadhesive oral wound rinse|Given PO
41500865|NCT02015559|OTHER|laboratory biomarker analysis|Correlative studies
41500866|NCT00985491|DEVICE|Endobarrier Liner|Medical device placed endoscopically in the duodenum
41500867|NCT01366430|PROCEDURE|Gufoni|For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.
41500868|NCT01366430|PROCEDURE|Sham|The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.
41027833|NCT02566395|RADIATION|Radiation|1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days
41027834|NCT02566395|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
41027835|NCT02566395|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI containing 1 x 10E8/kg donor T-cells
41027836|NCT02566395|BIOLOGICAL|Haploidentical Stem Cell Transplantation|2-10 x 10E6/kg donor CD34+ selected cells
41027837|NCT02346565|PROCEDURE|Exercise ECG|
41027838|NCT02346565|PROCEDURE|Stress Echocardiography|
41027839|NCT05305144|PROCEDURE|Vascular and ophthalmological examinations|"Part. 1 - Vascular checkup examinations:~After collecting classic clinical parameters (weight, height, waist circumference), the in-depth vascular workup of each participant will include the following measurements:~* Measurement of central arterial pressure,~* Measurement of arterial stiffness,~* Continuous blood pressure measurement (beat-to-beat),~* Heart rate measurement,~* 24-hour blood pressure measurement with QKD (holter).~Part. 2 - Ophthalmological examinations:~After dilating the pupil, a series of examinations will be conducted on the participant:~* Auto-refractometry~* Measurement of the axial length of the globe~* Color retinophotography of the retina,~* Adaptive Optics Exam~* SS-OCT-A exam"
41027840|NCT01357798|DRUG|Botulinum toxin type A|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
41027841|NCT01357798|DRUG|0,9% saline|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
40844702|NCT05835583|BEHAVIORAL|The theory based integrated program|The theory-based integrated program is administered by a nurse trained in motivational interviewing.In the 12-hour intervention, this program uses motivational interviewing skills to increase the patient's attitude towards medication, enhance the support of significant others around them, and increase the patient's control over their own behavior.
40844703|NCT02924740|BEHAVIORAL|Pelvic Floor Muscle Training|Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
40844704|NCT02924740|BEHAVIORAL|Vaginal Tampon Training|Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
40844705|NCT01295424|OTHER|No intervention|Observational study, no interventions
40844706|NCT00439374|DRUG|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
40844707|NCT00439374|OTHER|Placebo Oil|Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative
41027842|NCT01274546|DEVICE|cruciate-retaining Foundation Knee system|subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
41027843|NCT01169324|OTHER|Alteration of DBS stimulator settings|Alteration of DBS stimulator settings
41365472|NCT00852800|DRUG|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
41027844|NCT06491121|OTHER|Technology supported High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home, supported by a smartphone application
41027845|NCT06491121|OTHER|Moderate Intensity Training|patients will perform a 12-week MIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory continuous load, general resistance and core muscle training, all at moderate intensity. Phase 2 is a similar 12-week MIT program at home with an exercise program on paper.
41027846|NCT06491121|OTHER|High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home with an exercise program on paper.
41365473|NCT00852800|DRUG|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
41365474|NCT02056808|DRUG|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
41365475|NCT03760562|DRUG|Glucocorticoids|Oral Glucocorticoids.
41365476|NCT05587621|DRUG|statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran|dietary advice for low cholesterol food
41365477|NCT03048981|DRUG|Fish oil|Blood samples before and after 10 day intake of maximum dose fish oil
41365478|NCT00122395|BEHAVIORAL|Screening via pen and paper|
41365479|NCT00122395|BEHAVIORAL|Screening via audiotape|
41365480|NCT03380091|DRUG|Metformin|Oral medication daily
40844708|NCT06106919|OTHER|surveys (Fertiqol and WHOQOL-BREF)|surveys (Fertiqol and WHOQOL-BREF)
40844709|NCT02077400|DRUG|Cephazolin|Cephazolin
40844710|NCT02774304|DEVICE|arterial line|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
41365481|NCT03380091|DRUG|Vitamin D|Oral medication daily
41365482|NCT04150523|OTHER|Survey|The study will involve a 22 question online survey, administered through the online survey platform conjoint.ly. Conjoint.ly is a web-based survey tool used to conduct survey research, evaluations and other data collection activities. Participants will complete a conjoint.ly survey and choose between treatment (antibiotic vs no antibiotic) scenarios.
41365483|NCT01396811|DRUG|33525|Daily for 14 days
41365484|NCT01396811|DRUG|Placebo|Daily for 14 days
41365485|NCT03576807|DRUG|CD20 CAR-T cells|A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
41365486|NCT00082134|DRUG|ILX651|
41365487|NCT02688751|RADIATION|time-resolved CT Angiography|A multi-phase contrast CT
41365488|NCT02688751|PROCEDURE|Contrast Enhanced Ultrasound|A ultrasound scan with micro bubble contrast injection
41365489|NCT02487576|OTHER|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
41365490|NCT02487576|OTHER|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
41027847|NCT05729074|DRUG|IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
41027848|NCT05729074|DRUG|IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
41027849|NCT05729074|DRUG|IN-A002 Ointment 1% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
41027850|NCT05729074|DRUG|IN-A002 Ointment 3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
41027851|NCT05729074|DRUG|IN-A002 Ointment 5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
41027852|NCT05729074|DRUG|IN-A002 Ointment 1%|Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
41027853|NCT05729074|DRUG|IN-A002 Ointment 3%|Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
41027854|NCT05729074|DRUG|Elidel Cream 1% (pimecrolimus)|Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
41365491|NCT04466852|OTHER|telemedicine-guided consultation|Educational material is provided as short audiovisual films for understanding heart failure condition and management, how medicines work and their side effects, general advise on diets, exercise and importance of refraining from toxic exposure (smoke, alcohol, narcotics and damaging illegal medicines). Additionally, the patient (eventually assisted by their relatives and caregivers) can use this platform for learning basic important warning signs or cardiac decompensation based on feedback on recording regular measurements (weight, blood pressure and pulse and blood tests when needed) and symptoms. The cardiologist guides the patient and their Family/Basic doctors on the need for follow-up based on the parameters recorded. Videoconsultations with participation of the cardiologist, the Family/Basic doctor and the patient and relatives are used on demand.
41365492|NCT02486263|OTHER|Study Arm - acid suppression plus feeding bundle|"* Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~* Total fluid volume restriction (120-140 milliliters/kilogram/day)~* Feeding duration over 30 minutes~* Infant feeds with right side down~* Infant is placed on back following feeds"
41365493|NCT02486263|OTHER|Conventional arm - acid suppression only|-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
41365494|NCT03149731|DEVICE|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
41365495|NCT05561192|OTHER|Diaphragmatic breathing exercises|The initial proposal is for the first week to be adaptive, that is, learning to perform the exercises freely. During this period, students will be able to experience the activities and solve any doubts, as well as understand the process of a respiratory cycle, in which they will be initiated through a cycle of 12 times per minute. In the second and third weeks, the exercises will consist of 10 breathing cycles per minute (complete cycle consisting of 6 seconds, 2:2:2). It is important to note that each cycle contains the inspiration time, brief pause and expiration time in seconds. In the last week, each cycle will last 16 seconds, consisting of 4 seconds of inspiration, 4 seconds of pause and 8 seconds of expiration (4:4:8). Thus, the objective is to reduce the number of respiratory cycles per minute, as the intervention progresses.
41500869|NCT01366430|PROCEDURE|Barbecue|For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
41027855|NCT01474603|DIETARY_SUPPLEMENT|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
41027856|NCT04211103|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
41027857|NCT02596451|DRUG|Diclofenac Sodium gel, 1%|
41027858|NCT02596451|DRUG|Voltaren® Gel|
40844711|NCT02774304|DEVICE|Cheetah®|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
41027859|NCT02596451|DRUG|Placebo|
41027860|NCT05031910|OTHER|Medical Device Usage and Evaluation|Undergo virtual reality imaging via VR/3D-CEPs
40844712|NCT05215730|DEVICE|MedCu wound dressings with copper oxide (COD)|Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.
41027861|NCT05031910|OTHER|Best Practice|Receive standard of care
41027862|NCT05031910|PROCEDURE|Resection|Undergo surgical resection
41027863|NCT01889420|DRUG|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~1. Everolimus daily for 28 days of a 28 day cycle;~2. Pomalidomide daily for 21 days of a 28 day cycle~3. Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
41027864|NCT01639001|DRUG|Crizotinib|250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
41027865|NCT01639001|DRUG|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
40844713|NCT05308771|DEVICE|VPC syringe|Use of the visual pressure control syringe for epidural space detection
41027866|NCT01639001|DRUG|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
41365496|NCT05561192|OTHER|Cardiorespiratory and strength exercise|"During the first two weeks, students will complete two laps of the circuit, with a 15-second break between one station and another and a 1-minute break between one lap and another. These first two weeks will focus on adaptation and technical learning of the exercises to be performed. From the third to the sixth week, one lap will be added to the circuit, totaling three laps, maintaining the aforementioned intervals. From week 7 to week 12, progressions will be carried out, reducing the interval time between one lap and another on the circuit to 30 seconds. For the purpose of controlling the intensity of the exercise, a subjective perception of effort scale will be used, composed of values from 1 to 10, the first being equivalent to very light effort activity, and ten, equivalent to maximum effort activity."
41500870|NCT03277118|DEVICE|Wireless Wearable Device|Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
41500871|NCT02556463|DRUG|MEDI9197|Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
41500872|NCT02556463|BIOLOGICAL|durvalumab|Subjects will receive durvalumab every 4 weeks
40844714|NCT05659472|BEHAVIORAL|Combination mindfulness spiritual-based cognitive therapy plus hypnosis|The intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis.
40844715|NCT05659472|BEHAVIORAL|Mindfulness-based cognitive therapy|The program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning.
40844716|NCT05379101|DIAGNOSTIC_TEST|Cardiac magnetic resonance image (CMR)|A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
40844717|NCT05379101|DIAGNOSTIC_TEST|Transthoracic Echocardiogram (TTE)|An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
40844718|NCT05379101|DIAGNOSTIC_TEST|Six-minute Walk Test|A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
40844719|NCT03561818|OTHER|Hospital-based pulmonary rehabilitation|The patients who undergo two days pulmonary rehabilitation under supervision in our clinic and three days a week at home during two months will taken as hospital group. The exercises include breathing exercises, treadmill (15sc), cycle training (15sc), arm ergometer training (15sc), peripheral muscle training and stretching exercises with free weights.
41266912|NCT05825066|DRUG|Gemcitabine|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
40844720|NCT03561818|OTHER|Home-based pulmonary rehabilitation|The patients who follow a home-based pulmonary rehabilitation program for two months comprising breathing exercises, training in chest hygiene techniques, peripheral muscle strengthening training and self-walking for 5 days in a week for two months. An exercise follow-up form will give to the patients to record their daily exercises. A similar form will fill by physiotherapist once a week during phone call.
40844721|NCT00000643|DRUG|Pyrimethamine|
40844722|NCT00000643|DRUG|Leucovorin calcium|
40844723|NCT03135977|DRUG|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
41266913|NCT05825066|OTHER|Radiological Assessments|CT imaging of chest abdomen and pelvis will be performed every 8 weeks. MRI may be used.
40844724|NCT04635813|PROCEDURE|Thyroidectomy|Thyroidectomy
40844725|NCT03134131|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
41266914|NCT05825066|DRUG|mFOLFIRINOX|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
41266915|NCT01988389|DIETARY_SUPPLEMENT|whole apples (WA)|
41266916|NCT01988389|DIETARY_SUPPLEMENT|apple juice (AJ)|
41266917|NCT02972320|DRUG|temozolomide|temozolomide maintain therapeutic
41027867|NCT02312739|PROCEDURE|In-office Transcervical Sterilization (Essure®)|The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
41500873|NCT05026996|DRUG|Pelacarsen|Single subcutaneous injection of pelacarsen
40844726|NCT05480709|BEHAVIORAL|Psychocardiological Rehabilitation|Psychocardiological Rehabilitation: Regular cardiac rehabilitation with in-depth psychological and psychotherapeutic care, individual and group counseling, relaxation training, and interdisciplinary specialist psychiatric and psychosomatic visits.
40844727|NCT00343707|DRUG|vestipitant|
40844728|NCT00343707|DRUG|paroxetine|
40844729|NCT02718040|DEVICE|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
40844730|NCT03974373|PROCEDURE|BFP removal|The surgical procedure was performed using the technique with intrabuccal access, already consecrated in the literature (Materasso 2006). The Bichat fat ball access was made by means of a small incision no more than 3 mm in length in the soft tissue located in the lower aspect of the zygomatic counterfoot, taking care to visualize and protect with the retractor the Stensen's conduit. With the aid of blunt-tipped or hemostatic scissors dissection was performed, taking care to preserve the membrane surrounding the ball of fat. After removal of one side, pressure was removed to remove air and the procedure was started on the opposite side, after the removal of the two sides was realized simple suture with silk thread. There were no formal indications for sending the samples for anatomic and / or histological examination.
40844731|NCT01862549|BEHAVIORAL|Dialectical Behavior Therapy for children|
41365497|NCT05561192|OTHER|Cooperative sports activities group|"Intervention with cooperative sports activities will be based on the pedagogical model for teaching sports called Cooperative Learning or Cooperative Learning. This pedagogical model has some predominant characteristics, such as student learning occurring with and through other students, through an approach that facilitates and enhances positive interdependence, where teachers and students act as co-learners. Thus, this teaching model encompasses two key points of cooperative learning: promoting interaction between students and interaction between students and teachers.~Also, in the planning of intervention classes with sports, the five points described as fundamental for learning to be considered cooperative will be considered. These are: face-to-face interaction, positive interdependence, individual responsibility, group processing, and social skills."
41365498|NCT05561192|OTHER|Traditional physical education class|The comparator group will take physical education classes normally, following the traditional menu in the discipline, without changes in the conduct of activities.
41500874|NCT01589289|DEVICE|Immunochromatographic HAT tests (DSD)|Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND
41500875|NCT01589289|DEVICE|Card Agglutination Trypanosoma Test|Card Agglutination Trypanosoma Test on whole blood and as dilution
41500876|NCT01589289|DEVICE|TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)|"TB POC Nucleic Acid Amplification Test: microPCR handheld device (Molbio Diagnostics PVT ltd, India)"
41500877|NCT01589289|DEVICE|TB 3-marker RDT (Tulip diagnostics)|TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation
41500878|NCT01589289|DEVICE|Cryptococcal Antigen Lateral Flow Assay (Immy)|Cryptococcal Antigen Lateral Flow Assay (Immy, USA)
41500879|NCT00528411|DRUG|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
41500880|NCT00528411|DRUG|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
41500881|NCT00528411|DRUG|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
41500882|NCT04596514|PROCEDURE|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)
41500883|NCT04596514|PROCEDURE|usual procedure according to guidelines|Treatment as described in the guidelines from the European Resuscitation Council, the Norwegian Resuscitation Council, and other local national guidelines
40844732|NCT01862549|BEHAVIORAL|Treatment as Usual|
40844733|NCT01656070|DRUG|oral cholecalciferol 1000000 UI (vitamin D3)|
40844734|NCT01656070|DRUG|Placebo|
40844735|NCT04693351|DRUG|Troriluzole|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
41027868|NCT02312739|DRUG|Standard Oral pain medications|one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
41027869|NCT02312739|DRUG|Intramuscular Ketorolac|30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
41027870|NCT02312739|DRUG|Placebo pills|Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
41027871|NCT02312739|OTHER|Oxygen|Oxygen at 5L/min given to patients randomized to the active comparator arm
41027872|NCT02312739|OTHER|Nitrous Oxide|Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
40844736|NCT04693351|DRUG|Placebo|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
40844737|NCT03033199|DRUG|Probiotic Agent|probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
40844738|NCT03033199|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
40844739|NCT00004689|DRUG|amithiozone|
40844740|NCT00004689|DRUG|clarithromycin|
40844741|NCT00004689|DRUG|ethambutol|
41365499|NCT00000856|DRUG|Foscarnet sodium|
41027873|NCT04852614|DIAGNOSTIC_TEST|Pharmacokinetic test|Blood samples will be collected 48 hours after the first dose on day 3 of the observed intake of the study medication at the following time points: t=0 (pre-dose), 1, 2, 3, 4, 8 and 12 hours post ingestion (7 samples) (3 mL each), Breast milk samples will be collected by emptying both breasts at 0, 2, 4, 8 and 12 hours (5 samples).
41365500|NCT00000856|DRUG|Ganciclovir|
41027874|NCT00793416|DEVICE|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
41365501|NCT04176237|OTHER|UV Dosimetry Laboratory|The UV Dosimetry Laboratory is a one hour lesson that incorporates science and health education - kids hypothesize what UV levels will be around the school yard, go and measure UV, review their results, and then come up with a SunSmart plan for playing in the school yard.
41365502|NCT04832243|OTHER|Survey questionnaire|Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
41365503|NCT04692285|DRUG|Zolpidem|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
40844742|NCT00004689|DRUG|rifampin|
41365504|NCT04692285|DRUG|Placebo|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
41365505|NCT01480401|OTHER|low-sodium diet (1500 mg daily)|
41365506|NCT00475839|DEVICE|Tension-free Vaginal Tape|
41365507|NCT00475839|DEVICE|Monarc sub-fascial hammock|
41365508|NCT00125138|DRUG|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
41365509|NCT00125138|DRUG|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
41365510|NCT00125138|DRUG|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
41365511|NCT00125138|DRUG|Placebo|Syrup formulation
41365512|NCT05640141|PROCEDURE|MRI evaluation|"Multimodal MRI evaluation :~* T1 structural,~* Resting echo planar imaging~* Diffusion-weighted imaging~* Arterial sping labeling~* Fluid-attenuated inversion recovery"
41365513|NCT05640141|BEHAVIORAL|Actimetry & IMU|"Evaluation of daily activities and life rythms (physical activity, inactivity, sleep) using actimeters (Motion 8), inertial sensors (GaitUP) and questionaires during 14 days :~* Actimetry : evaluation of daily activity and inactivity, sleep rythms~* Inertial sensors : gait evaluation during daily activities~* Questionaires : sleep (Spiegel \& St Mary's Hospitral) and fatigue (MFI-20)"
41365514|NCT05640141|BEHAVIORAL|Gait evaluation|"Evaluation of gait characteristics (spatio-temporal parameters \& non-linear characteristics) in virtual environment :~* Locomotor simple task : gait only in congruent environment~* Locomotor dual task : gait in similar environment combined with a visually displayed Stroop task~* Sensorimotor gait adaptaition : evaluation of the adaptation capability throughout a split-belt treadmill sequence (realized in simple or dual -combined with the visual Stroop task-)"
40844743|NCT00004689|DRUG|streptomycin|
40844744|NCT03240159|DRUG|Degarelix|"Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix"
41027875|NCT03732092|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised|Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected three stimuli: 1) 1-octene-3-ol, 2) pyridine, 3) water. We presented these three stimuli in front of the patients nose for 3 seconds.
41027876|NCT05239806|BIOLOGICAL|SCTV01C|Day 0; intramuscular injection
41365515|NCT05640141|BEHAVIORAL|Neuropsychological evaluation|"Complete neuropsychological examination including attentional and executive functions, learning and retrieval abilities in episodic memory and general cognitive skills :~* Divided attention (TAP; test of attentional performance)~* California Verbal Learning Test~* The Rey-Osterrieth Complex Figure~* Symbol search and coding (WAIS-IV)~* Go/No-go (TAP)~* Flexibility (TAP)~* Original task of multimodal integration~* Verbal fluencies (GREFEX)"
41500884|NCT02026115|BEHAVIORAL|PAINReportIt|PAINReportIt is a software program first developed with an electronic MPQ (1970 version) and now includes questions about analgesics used by the patient and a shortened version of the pain Barriers Questionnaire (BQ). PAINReportIt is designed as an interactive, touch screen method for assessment of pain. It can be self-administered and requires little or no patient computer experience and minimal or no provider time for administration. Directions for self-administration allow the patient to read instructions on-screen and practice making all types of selection responses that are available in the program. Directions from the paper and pencil tools were modified to address the touch screen method of recording patient responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both of these individuals have authorized the modifications, presentation format, and computerized use of their tools.
41027877|NCT05239806|BIOLOGICAL|SCTV01E|Day 0; intramuscular injection
41027878|NCT05239806|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
41027879|NCT05239806|BIOLOGICAL|Comirnaty|Day 0; intramuscular injection
41027880|NCT05239806|BIOLOGICAL|SCTV01E|Day 180; intramuscular injection
41365516|NCT03279731|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
41365517|NCT03279731|DRUG|Placebo|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
41365518|NCT01446835|DEVICE|nelfilcon A contact lens with print|Investigational spherical contact lens
41365519|NCT01446835|DEVICE|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
41365520|NCT04786327|PROCEDURE|Minimal invasive flap technique|contained defect treated with Minimally invasive flap
41365521|NCT04786327|PROCEDURE|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin|contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft
41027881|NCT01515085|PROCEDURE|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
41027882|NCT01504438|DEVICE|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
41365522|NCT04786327|COMBINATION_PRODUCT|minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S|contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
41365523|NCT03266211|OTHER|Questionnaire Patients|Patient will have to answer a quiz which is about their vaccination against tetanus.
41365524|NCT03266211|OTHER|Questionnaire General practitioner|General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.
41027883|NCT01504438|DEVICE|STAR Total Ankle Replacement|STAR Total Ankle Replacement
41027884|NCT02349958|DEVICE|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
41365525|NCT03865550|DRUG|Isotonic saline|Placebo
41365526|NCT03865550|DRUG|Ketamine Injectable Solution|Active comparator
41027885|NCT02349958|DEVICE|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
41365527|NCT02114346|DRUG|Atorvastatin|
41365528|NCT02114346|DRUG|Placebo|
41365529|NCT02114346|DRUG|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
41365530|NCT05756062|DIETARY_SUPPLEMENT|Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)|Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months
41365531|NCT05141058|BIOLOGICAL|Coronavirus-specific T cell (CST)|Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after hematopoietic stem cell transplantation (HSCT).
41365532|NCT00034801|DRUG|olanzapine|
41365533|NCT00034801|DRUG|ziprasidone|
41365534|NCT01041742|PROCEDURE|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
41365535|NCT04526262|DEVICE|transcranial magnetic resonance guided focused ultrasound BBB disruption|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.0 system, and this will be performed twice every 3 months.
41365536|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
41365537|NCT04751851|BEHAVIORAL|Long duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
41365538|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.
41027886|NCT02349958|DEVICE|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
41027887|NCT02349958|DEVICE|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
41027888|NCT00822510|BEHAVIORAL|Telephone Interpersonal Counseling|Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
41027889|NCT00822510|BEHAVIORAL|Telephone delivered education only|Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
41365539|NCT04751851|BEHAVIORAL|Long duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.
41365540|NCT03222869|DIAGNOSTIC_TEST|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
41365541|NCT02960802|PROCEDURE|kidney transplantation|
41027890|NCT00233935|OTHER|placebo|Given PO
41027891|NCT00233935|DRUG|defined green tea catechin extract|Given PO
41027892|NCT02607579|DRUG|Exparel|
41027893|NCT02607579|DRUG|Ropivacaine|
41027894|NCT04634357|DRUG|ET140203 T Cells|"Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct"
41365542|NCT03089229|DRUG|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
40844745|NCT03442660|OTHER|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional diagnostic or treatment procedures will be required. Subjects will be asked to complete electronic (or on paper when it's not possible to use electronic version) questionnaires.
40844746|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
40844747|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
41027895|NCT02431975|DRUG|Nevirapine|"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."
41027896|NCT02431975|DRUG|Zidovudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices."
41027897|NCT02431975|DRUG|Lamivudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices."
41027898|NCT02431975|DRUG|LPV/r|"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices."
41027899|NCT04870801|DRUG|Respirogen Micro-Oxygen|Enteral (rectal) delivery of Respirogen Micro-Oxygen
41027900|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 2 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
41027901|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 10 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
41027902|NCT04473404|OTHER|Placebo|The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.
41027903|NCT01017172|OTHER|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
41027904|NCT05473195|DRUG|BVL-GSK098 9mg|BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
40844748|NCT06256419|DRUG|GLP-1 receptor agonist|Eligible patients with T2DM were required to have received GLP-1RA as monotherapy or in combination with other antidiabetic agents. GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM.
40844749|NCT06256419|DRUG|responders group and nonresponders group|"For all the patients with type 2 diabetes who were initially enrolled in the study, blood samples were obtained for genotyping before the administration of GLP-1 receptor agonists. Patients were re-screened according to whether they had used GLP-1 RA continuously for more than 6 months and had completed the specified follow-up tasks.~Patients were divided according to the type of T2DM susceptibility genes. Or all were divided into responses group and nonresponses group according to whether they had glycemic response (△HbA1c↓ ≥1.0%) and weight response (△weight↓ ≥3.0%) after taking GLP-1 receptor agonist for 6 months.~According to the above grouping, the variables that can predict the efficacy of the drug were identified, and the weight of the influence of these variables on the efficacy was evaluated."
40844750|NCT01566487|DRUG|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
40844751|NCT00389675|DRUG|Darusentan|Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily
40844752|NCT00389675|DRUG|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
40844753|NCT04041245|DEVICE|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~   They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
40844754|NCT02191813|DRUG|Seresis®|
40844755|NCT02191813|DRUG|Placebo|
40844756|NCT05077007|PROCEDURE|Percutaneous nephrolithotomy|Endoscopic stone Extraction from the kidney by making a puncture and dilate a tract direct into the kidney through muscle wall and renal parenchyma
40844757|NCT05077007|PROCEDURE|Extracorporeal Shock Wave Lithotripsy|Using Shock waves from outside the body targeted at a kidney stone causing the stone to fragment. The stones are broken into tiny pieces.
40844758|NCT02924909|DRUG|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
40844759|NCT05919485|PROCEDURE|tDCS|"0.06mA/cm2 from each electrode with total density of 0.054/cm2 for 20 minutes for 5 days a week, for 10 days and a total of 10 sessions in 14 days.~Brain area; DLPFC / LPC"
41365543|NCT03089229|DRUG|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
41365544|NCT04964882|DIAGNOSTIC_TEST|ultrasound examination of air insufflation in the upper esophageal region and stomach|Presence of air insufflation is assessed using ultrasound in the upper esophageal region and stomach during face mask ventilation
41365545|NCT04445454|BIOLOGICAL|Mesenchymal stromal cells|Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Liège as described in IMPD and its SOPs.
40844760|NCT01014468|DRUG|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
40844761|NCT01014468|DRUG|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
40844762|NCT01640262|OTHER|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
40844763|NCT00225095|DRUG|Mesenchymal Stem Cells|
40844764|NCT00225095|DRUG|Hyaluronan|
40844765|NCT06389110|DRUG|Alleance®|Atropine sulfate 0.01%, ophthalmic solution.
40844766|NCT06389110|DRUG|Placebo|Ophthalmic solution.
40844767|NCT05387057|BEHAVIORAL|Exergame training according to the 'Brain-IT' exergame-based training concept|For an overview, our 'Brain-IT' exergame-based training concept consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) visuospatial skills. According to the training concept, each participant is instructed to train 5x/week for 24 min per session resulting in a weekly exercise volume of 120 min. All training sessions are planned to take place at participant's homes using the exergame training system 'Senso Flex' (Dividat AG, Schindellegi, Switzerland). For a detailed description of the complete 'Brain-IT' exergame-based training concept with sufficient details to allow full replication, consider our methodological paper (doi: 10.3389/fnagi.2021.734012).
40844768|NCT05387057|BEHAVIORAL|Usual Care|The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
40844769|NCT03708666|OTHER|Telemonitoring of blood pressure|Blood pressure monitoring at least once a week.
40844770|NCT00950742|DRUG|Trastuzumab|Load: 4mg/kg-maintain:2mg/kg/week
40844771|NCT00950742|DRUG|BIBW 2992|Increased dose cohorts from low dose to MTD
40844772|NCT03271905|DRUG|salbutamol sulfate and ipratropium bromide|Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
40844773|NCT03271905|DEVICE|Mesh nebulization|Nebulization with Mesh device.
40844774|NCT03461094|DEVICE|Preload assessment and volume expansion|Fluid therapy perform
41365546|NCT00496782|DRUG|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
41365547|NCT00496782|PROCEDURE|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
41365548|NCT02930928|OTHER|Accuracy of weight estimation|Computer based comparison
41365549|NCT01258803|DRUG|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
40844775|NCT01853956|DRUG|Alprazolam 0.25 mg|Reference product
40844776|NCT01853956|DRUG|Alprazolam 0.25 mg|Test product
40844777|NCT04038567|BEHAVIORAL|Mobile mindfulness-based training|The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
40844778|NCT01835834|PROCEDURE|zirconia bridge restoration|
40844779|NCT06542991|OTHER|transcranial magnetic stimulation|During treatment, the patient underwent cTBS targeting the left SMA for 7 consecutive days. Each treatment day comprised six rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
40844780|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (EoE) food introduction-1st|1 serving size of food proven to induce histologic and clinical symptoms in EoE
40844781|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (E0E) food introduction-2nd|Either 1 serving size of different food (not food in arm 1) to induce histologic and clinical symptoms in EoE or Increase the food in arm 1 to 2 serving size a day
40844782|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (EoE) Food introduction-3rd dose|Either 1 serving size of different food (not food in arm 1 or 2) to induce histologic and clinical symptoms in EoE or Increase the food in arm 2 to 2 serving size a day or unlimited amounts of food arm 1
40844783|NCT05247866|DRUG|Dupilumab|"All patients will receive open label dupilumab at the following doses \>12 years of age \> 40 kg 300 subcutaneous (SQ) weekly~6-11 years of age 5-15 kg 100 mg SQ every 2 weeks (Q2W) 15-30 kg 200 mg SQ Q2W \>30-60 kg 300 mg SQ Q2W"
40844784|NCT05943782|PROCEDURE|onlay manufactured by milling|indirect restorations for treating mutilated molars manufactured by CAD/CAM subtractive technique
40844785|NCT05943782|PROCEDURE|Onlay manufactured by 3D printing|indirect restorations for treating mutilated molars manufactured by CAD/CAM additive technique
40844786|NCT05794828|DRUG|Bupivacaine Injection|Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
41027905|NCT05473195|DRUG|Ethionamide 250mg|Ethionamide 250 mg po OD (Eto250)
41027906|NCT05473195|DRUG|Ethionamide 250 mg|Ethionamide 750 mg po given in a single or divided dose (Eto750)
41027907|NCT05473195|DRUG|Isoniazid 300 MG|Isoniazid 300 mg po OD (INH)
41027908|NCT02832895|OTHER|Transcranial doppler examination|Assessment of frontal bone window for transcranial doppler
41027909|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 1
41365550|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
41365551|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
41365552|NCT01258803|DRUG|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
41365553|NCT01258803|DRUG|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
41365554|NCT01258803|DRUG|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
41365555|NCT00267202|DRUG|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
41500885|NCT02026115|BEHAVIORAL|PAINConsultN|PAINConsultN for hospice nurses. Our previous studies support the feasibility and clinical effect of PAINConsultN. This narrative and graphic tool provides decision support for the nurse's clinical decisions regarding management of the patient's pain. Based on the PAINReportIt output and published cancer pain guidelines, PAINConsultN generates an algorithm-based consultation report with a list of recommendations that could be useful to provide improved pain relief. If the patient's PAINReportIt output indicates the pain level is consistent with the patient's goals for pain management and represents no pain or a mild pain level, the consultation report acknowledges the therapy plan and reinforces its consistency with pain guidelines.
41500886|NCT02026115|BEHAVIORAL|PAINUCope|We tested the prototype of the PAINUCope component of the intervention in three completed studies. PAINUCope is a multimedia, computer generated tool that provides tailored patient information to overcome their misconceptions about pain and to help them engage in self-care activities that contribute to reducing their pain. PAINUCope focuses on two crucial aspects of pain management: 1) reporting cancer pain; and 2) safe and effective use of pain medicines. All the educational materials were written at a 6th grade reading level and presented as 21st Century best-practices, evidence-based facts or scripts for the person living with cancer or sickle cell disease (in one study). The facts or scripts are customized to the patient's need for this type of health information. The patient's responses on PAINReportIt govern the specific health information that is shared with the patient via PAINUCope.
41500887|NCT02877459|DEVICE|AeriSeal System|Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
41500888|NCT05555823|DRUG|ATR-002|300 mg tablets for oral intake
41500889|NCT05555823|DRUG|Placebo|matching tablets for oral intake
41500890|NCT05555823|DRUG|Repaglinide|0,5 mg tablets for oral intake
41500891|NCT05555823|DRUG|Celecoxib|100 mg capsules for oral intake
41500892|NCT04480021|BEHAVIORAL|MITHRA|A mobile based application (app) in CBOs to screen, track and treat mild to moderate depression among low income women using Healthy Activity Program (HAP),a WHO-recommended evidence-based intervention.
41500893|NCT04480021|BEHAVIORAL|EUC|Group education on depression by community health workers
41500894|NCT06629038|BEHAVIORAL|observation alone|observation of maximal mouth opening and range of motion of shoulder abduction
41500895|NCT02388906|DRUG|Ipilimumab|Specified dose on specified days
41500896|NCT02388906|DRUG|Nivolumab|Specified dose on specified days
41500897|NCT02388906|OTHER|Placebo matching Ipilimumab|Specified dose on specified days
41500898|NCT02388906|OTHER|Placebo matching Nivolumab|Specified dose on specified days
41500899|NCT03803787|DRUG|Inhaled budesonide|Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
41500900|NCT05811806|DEVICE|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
41500901|NCT02581397|DRUG|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
41500902|NCT02581397|DRUG|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
41500903|NCT02581397|DRUG|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
41027910|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 2
41500904|NCT00788944|PROCEDURE|blood draw|Test Article was not provided to subjects for this study.
41500905|NCT04308226|BEHAVIORAL|Patient Navigation|The navigator's principal role is to guide participants through the lung cancer screening (LCS) process. The navigator will work within the existing Boston Health Care for the Homeless (BHCHP) clinical structure and collaborate with participants' primary care providers (PCPs) to facilitate LCS low-dose computed tomography (LDCT) referral, completion, and timely follow-up by addressing participants' barriers to LCS completion and enhancing participants' self-efficacy. The navigator's secondary role is to offer brief tobacco counseling for participants who currently smoke.
41500906|NCT03651830|DEVICE|Prosthetic Foot Emulator|Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.
41500907|NCT03651830|DEVICE|Commercially available prosthetic feet|"Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet."
41027911|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 3
41027912|NCT01363323|DRUG|Placebo|
40844787|NCT01555125|DRUG|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
40844788|NCT01555125|DRUG|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
40844789|NCT01555125|DRUG|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
40844790|NCT01338584|BEHAVIORAL|Pelvic floor muscle training 3 weeks before radical prostatectomy|Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).
40844791|NCT01338584|BEHAVIORAL|Intensive preoperative pelvic floor muscle training|Patient started to learn pelvic floor muscle 3 weeks before surgery
40844792|NCT00682318|DRUG|Fish Oil|"Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days"
40844793|NCT00682318|DIETARY_SUPPLEMENT|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
40844794|NCT00682318|DIETARY_SUPPLEMENT|Ethanol|"Part 1 \& Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution"
40844795|NCT00682318|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|"Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b."
40844796|NCT00682318|DIETARY_SUPPLEMENT|Omega-6 polyunsaturated fatty acid|"Part 2b:~Control omega-6 fatty acid alimentary diet (\<130 mg/day EPA/DHA)"
40844797|NCT04628988|DRUG|CC-90011|Capsule
40844798|NCT04628988|DRUG|Abiraterone|Tablet
40844799|NCT04628988|DRUG|Prednisone|Tablet
40844800|NCT01810315|DRUG|TFV 1% gel|
40844801|NCT01810315|DRUG|Estradiol vaginal cream|
40844802|NCT01326832|DEVICE|Primoris|Total hip arthroplasty with the new Primoris femoral component
40844803|NCT05730972|DEVICE|Transcutaneous electrical acupoint stimulation|The patients are taken in the recumbent or sitting position, and the local skin at the acupoints is routinely disinfected. A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral acupoint group, so as contralateral side.
40844804|NCT05730972|DEVICE|Sham transcutaneous electrical acupoint stimulation|The electroacupuncture instrument has a normal screen display as the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, but could not output current normally.
40844805|NCT05730972|DRUG|Routine palliative treatment|The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
40844806|NCT02992509|DEVICE|EMED detruset(TM) intravesical electrical stimulation|"There will be a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks. The electrical parameters utilized will be those previously determined to be appropriate for OAB and UUI. As the beneficial effect of electrical stimulation is dependent on a maximal level of stimulation, the stimulation voltage will be increased during the first minute of treatment until the maximum tolerated by the patient is established and then backed-off by 1-2 Volts. The therapy will continue for 15 minutes in total for each session. The VAS will be marked by the patient before each treatment session throughout the therapy period, and other questionnaires will be administered."
40844807|NCT01457846|DRUG|AZD4547|Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
41365556|NCT00267202|DRUG|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
40844808|NCT01457846|DRUG|paclitaxel|Infusion administered once a week, 3 weeks on and 1 week off
41365557|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
41365558|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
40844809|NCT03918707|DIAGNOSTIC_TEST|Rapid Whole Genome Sequencing (rWGS)|rWGS will be performed on blood samples from subjects in the prospective group in addition to standard of care laboratory testing and imaging studies. Blood samples will also be obtained from biological parents (if available), to determine if variants are inherited or de novo and for variant segregation.
41027913|NCT01363323|DRUG|Moxifloxacin|
41027914|NCT02396641|OTHER|Best Supportive Care Checklist|
41027915|NCT06319885|BEHAVIORAL|Text messaging|Participants receive text messages related to their alcohol consumption.
41365559|NCT01920087|DRUG|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
41027916|NCT06446635|DEVICE|Semiflex Dome Catheter System|"Abces: In patients that present with a perianal abscess/sinus the semiflex dome catheter is inserted under general anesthesia. A small cut is made to drain and irrigate the septic sinus.~Fistula: Under general anesthesia the seton is removed, the internal opening is excised and the internal opening is closed with a 2-0 Vicryl cross stitch.~Both: Before surgery, the length of the tract is measured on MRI or CT. A Semiflex Catheter with the appropriate length and a diameter is selected. If during surgery appears that this is not the appropriate size, a different size catheter can be used. The catheter is fixed on a Renasys Adhesive gel patch (Smith and Nephew). The catheter is connected with a tubing system to a vacuum pomp with an average vacuum pressure of 80 cm H2O. The tube will be taped on the patient. After every 2-3 days the catheter will be exchanged by a 3-6 mm shorter catheter."
41027917|NCT03787368|DRUG|BAY1213790|Single intravenous infusion of BAY1213790 (Two different doses)
41027918|NCT03787368|DRUG|0.9% sodium chloride solution|Single intravenous infusion of Placebo (0.9% sodium chloride solution)
41365560|NCT01920087|DRUG|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
41365561|NCT01079260|DIETARY_SUPPLEMENT|Standard ONS|Standard ONS
41365562|NCT01079260|DIETARY_SUPPLEMENT|High Energy, low volume ONS|High energy, low volume ONS
41365563|NCT00787280|BEHAVIORAL|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
41365564|NCT00787280|BEHAVIORAL|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
41365565|NCT04140942|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.
41500908|NCT05260112|OTHER|ERICA|"Over 6 weeks, participants receive evidence-based video learning modules twice a week via a secure and HIPAA-compliant text messaging platform. These modules include: patient education on interstitial cystitis, bladder training, trial of an elimination diet, pelvic floor physical therapy including at-home myofascial trigger point release, guided mindfulness practice, and cognitive behavioral therapy for chronic pain.~At the end of each week, participants receive a check-in message. They also have the opportunity to text questions and concerns, which will be answered using an algorithm-based, clinically validated responses."
41500909|NCT04851873|GENETIC|OAV101|Gene Therapy - 1.1e14 vector genome (vg)/kg as a one-time IV infusion was administered over approximately 60 minutes.
41500910|NCT04320342|DRUG|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
41500911|NCT04320342|DRUG|Glycopyrronium Bromide|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
41500912|NCT04320342|DRUG|Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
41500913|NCT04467450|DRUG|botulinum toxin type A|ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa
41500914|NCT04467450|DRUG|Methyl Prednisolonate|ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa
41500915|NCT03244683|DIETARY_SUPPLEMENT|Ensure Surgical|Subjects randomized to the intervention arm will consume two Ensure Surgical for 5-7 days.
41500916|NCT03244683|OTHER|Nutrition counseling|All study subjects will be provided with nutrition counseling at the time of study enrollment.
41500917|NCT03244683|OTHER|Low-intensity exercise therapy|Patients randomized to the intervention arm will also be provided with verbal and written instructions for light resistance training. The exercises will be performed at home during the preoperative study period.
41500918|NCT06609226|DRUG|Etavopivat A|Participants will receive an oral dose of Etavopivat A.
41500919|NCT06609226|DRUG|Etavopivat B|Participants will receive an oral dose of Etavopivat B.
41500920|NCT01260519|DRUG|Heparin|unfractionated heparin 2000 unites
41500921|NCT03125980|DRUG|capecitabine plus oxaliplatin before and after surgery|"Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Repeat every 3 weeks (Q3W)"
41500922|NCT03125980|DRUG|capecitabine plus oxaliplatin after surgery|"Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Q3W"
41500923|NCT03303209|OTHER|Patient-centered opioid tapering protocol|All patients who entered the study agreed to partner with their pain physician on a patient-centered opioid tapering program. The research component of the study was to observe patient response (in terms of change in MEDD and pain intensity) at month 4.
41500924|NCT04521738|DRUG|SAR441255|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
41500925|NCT04521738|DRUG|placebo|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
41500926|NCT01831401|PROCEDURE|Operating table position 0° head down (Horizontal)|
41500927|NCT01831401|PROCEDURE|Operating table position 7° head down.|
41500928|NCT01831401|PROCEDURE|Operating table position Y° head down|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).
41500929|NCT01831401|DEVICE|Standard straight acetabular component introducer without alignment guide.|
41027919|NCT00144573|DRUG|MRA(Tocilizumab)|
41500930|NCT01831401|DEVICE|Modified 35° acetabular component introducer.|
41365566|NCT04140942|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
41365567|NCT01320774|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
41365568|NCT03328572|OTHER|E-max Endocrown|Endocrown preparation
41365569|NCT03328572|OTHER|Cerasmart Endocrown|Endocrown preparation
41500931|NCT01831401|DEVICE|Inclinometer-assisted acetabular component introducer.|
41027920|NCT05382416|BEHAVIORAL|SHARE! Peer Toolkit Training|The SHARE! Peer Toolkit training is designed to improve the performance of peer workers in their provision of peer support. The training covers each of the 12 tools in the Peer Toolkit, which are taught through brief presentations followed by group discussions and interactive exercises to help people competently use each of the tools. Training sessions are typically two hours each, three times per week for 10 weeks.
41027921|NCT02699177|DEVICE|CBF measurements|CBF measurements
41027922|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 30mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
41027923|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 60mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
41027924|NCT03790982|DRUG|AD-35 30 mg + Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
41027925|NCT03790982|DRUG|AD-35 60 mg|AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
41027926|NCT06189040|DRUG|BNT162b2 30µg|intramuscular administration of 30µg
41365570|NCT03342209|DEVICE|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy|"A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.~The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.~Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes."
40844810|NCT01520025|RADIATION|PET MPI imaging with 18F-Fluorodeoxyglucose|"Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.~18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.~Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)"
41027927|NCT06189040|DRUG|BNT162b2 20µg|intramuscular administration of 20µg
41027928|NCT06189040|DRUG|BNT162b2 6µg|intradermal administration of 6µg
41027929|NCT06189040|DRUG|mRNA-1273 100µg|intramuscular administration of 100µg
41027930|NCT06189040|DRUG|mRNA-1273 50µg|intramuscular administration of 50µg
41365571|NCT04617379|BEHAVIORAL|Stretching|One-year stretching program for 15 minutes every day
41365572|NCT01347359|BEHAVIORAL|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
40844811|NCT00953563|DEVICE|Unite Biomatrix|collagen based, decellularized equine pericardial dressing for skin surface wounds
40844812|NCT03629912|BEHAVIORAL|Socially-Based Exercise Intervention for Older Adults|A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
40844813|NCT03404622|DRUG|IUCD|IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
40844814|NCT02622646|DRUG|Recombinant VIII factor|"Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~1. Describe PK parameters in patients on prophylaxis treatment with Advate®~2. Analyze differences in PK parameters in non-controlled vs well controlled patients~3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence)."
40844815|NCT01075503|PROCEDURE|brachial plexus block|0.5% Ropivacaine 40ml
40844816|NCT02561559|RADIATION|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
40844817|NCT05787106|OTHER|Cyberball task|"The game consists of ball throws between animated characters lasting about 50 throws. In the rejection condition, after 2 or 3 throws, the participant no longer receives the ball (no more passes). In the control conditions (all included), the participant receives the ball as often as the others."
40844818|NCT00493961|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
41365573|NCT01347359|BEHAVIORAL|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
41500932|NCT04140162|DRUG|Daratumumab|"Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)~Sites will continue to use IV daratumumab to treat existing study patients until the IV daratumumab stock on site has been exhausted. The sites will then transition existing patient to SQ daratumumab. New patients will be started on SQ 1800mg daratumumab.~Induction- Cycles 1-2 (days 1, 8,15, 22), Cycles 3-6 (Weeks 9-24- two weeks (days 1, 15 ) Consolidation- Every 4 weeks on day 1 Maintenance- Every 8 weeks on day 1"
41500933|NCT04140162|DRUG|Lenalidomide|"Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression"
41500934|NCT04140162|DRUG|Bortezomib|Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)
41500935|NCT04140162|DRUG|Dexamethasone|Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV weekly
41500936|NCT04821700|BIOLOGICAL|Carotid Stenosis|To investigate if the concurrent presence of carotid stenosis has any effect on future outcomes of patients with ischemic stroke and atrial fibrillation
41500937|NCT05918744|BEHAVIORAL|Sleep Extension|Participants will extend their time in bed by one hour for 2 weeks while being monitored.
40844819|NCT04571996|DRUG|ODM-104|Capsule
40844820|NCT04571996|DRUG|Paracetamol|Rapidly dissolving tablet
40844821|NCT04044976|DRUG|Caffeine Citrate|Infants will receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth.
40844822|NCT02924012|OTHER|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
40844823|NCT02924012|OTHER|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
40844824|NCT02924012|OTHER|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
40844825|NCT00141115|DRUG|levetiracetam|Levetiracetam 1500 mg BID
40844826|NCT04214678|PROCEDURE|Underwater clip closure|Closure of post-resection defect with endoscopic clips by underwater technique
40844827|NCT04214678|PROCEDURE|Conventional clip closure|Closure of post-resection defect with endoscopic clip by conventional technique
41027931|NCT06189040|DRUG|ChAdOx1-S [Recombinant]|intramuscular administration of not less than 2.5 x 10\^8 infectious units
41365574|NCT06410755|DEVICE|Monitoring system using a insole-type gait analyzer|The researcher provides feedback over the phone once a week in accordance with the subjects' amount of exercise and walking level collected only to the experimental group using the insole-type gait analysis system. Check the stability of data collection, and if an abnormality occurs, take action and record it by phone or in person
41365575|NCT01967134|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
41365576|NCT03169127|DRUG|Ibuprofen 600 mg|After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
40844828|NCT02895945|BIOLOGICAL|Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)|In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.
40844829|NCT05570409|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil 1g bid for 6 months
41500938|NCT05597735|DRUG|Tecovirimat|"The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~* 25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~* 40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days."
41500939|NCT05597735|DRUG|Placebo|The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
41500940|NCT01140555|DEVICE|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
41500941|NCT03467880|OTHER|Clinical Observation|No treatment given but observation with IOS
41500942|NCT00003445|DRUG|docetaxel|
41500943|NCT01510782|DRUG|Placebo to BI 655064|intravenous infusion of escalating doses
41500944|NCT01510782|DRUG|Placebo to BI 655064|subcutaneous injection of escalating doses
41500945|NCT01510782|DRUG|BI 655064|intravenous infusion of escalating doses
41500946|NCT01510782|DRUG|BI 655064|subcutaneous injection of escalating doses
41500947|NCT06456034|BEHAVIORAL|Perinatal palliative care|Intervention group will receive specialized perinatal palliative care support from moment of severe perinatal diagnosis. This intervention is aimed at 5 major care components, namely 1. Support offered by a fixed perinatal palliative care team, 2. that team has received specialized perinatal palliative care training, 3. care is structured within a new perinatal palliative care approach or pathway, including fixed means of communication with team members, 4. psychological support is structurally being offered to parents and healthcare providers, and 5. debriefings after every perinatal death are being organized in the involved team.
41500948|NCT03019159|DEVICE|Teleconsulting|
41500949|NCT04685408|BEHAVIORAL|TEAM|TEAM is informed by principles of social cognitive theory TEAM uses nurses and peer educator dyads (PEDs) composed of patients and their care partners to co-deliver an intervention intended to help reduce future stroke risk. Team begins with one 60-minute 1:1 orientation session, in which the nurse and PED meet with the patient and his/her care partner. This is followed by 6 hour-long group sessions with 6-8 patients and their care partners held approximately weekly. The first orientation session will be done approximately 1 week post baseline, followed by group sessions were done at 2, 4, 6, 8, 10 and 12 weeks post-baseline.
41500950|NCT04685408|BEHAVIORAL|ETAU|ETAU will consist of an orientation visit with a nurse who will provide patient-education materials on stroke risk adapted from the American Heart Association materials and cover common risk factors such as hypertension, obesity, high salt/high fat diet and diabetes. Patients will also receive basic written information in their language of preference and tailored to the reading level of most patients at the clinic. Patients will be offered the opportunity to bring a family member with them to this visit who may also ask questions and who can assist them with understanding written materials for those with limited literacy. The nurse in ETAU will then follow-up with participants with a series of 9 brief phone calls spaced out over the course of 6 months (approximately every 2 weeks during months 1 and 2, then approximately monthly thereafter). Content will reinforce materials provided in the orientation visit and the nurse will be available to answer questions that may arise.
41500951|NCT00391963|DEVICE|Bispectral index, Entropy|
41500952|NCT00806286|DRUG|CS7017 tablets|CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
41500953|NCT00806286|DRUG|Paclitaxel|Intravenous (IV), 200 mg/m\^2, once every three weeks for up to 18 weeks
41500954|NCT00806286|DRUG|Carboplatin|IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks
41500955|NCT00806286|DRUG|Placebo Tablets|Placebo tablets matching CS-7017 tablets
41500956|NCT01942889|DIETARY_SUPPLEMENT|Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program|Vit E, Vit C, Selenomethionine, Zinc gluconate
41500957|NCT02218801|OTHER|Evaluation of treatment for liver metastasis|
41500958|NCT01001624|OTHER|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
41500959|NCT01001624|OTHER|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
41500960|NCT01054404|DRUG|Furosemide|Furosemide 0.3 mg/kg
41500961|NCT01054404|DRUG|Placebo|Placebo (up to 5mL)
41500962|NCT05648188|BIOLOGICAL|Sample|Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7
40844830|NCT05570409|DRUG|Prednisolone|initially 1mg/kg in a step-down regime for 6 months
40844831|NCT05570409|DRUG|Mycophenolate Mofetil Placebo|MMF matching Placebo
41365577|NCT03290196|DRUG|EXPAREL 1.3 % in 20 ML Injection|EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
40844832|NCT05570409|DRUG|Prednisolone Placebo|Prednisolone matching placebo
40844833|NCT01554995|DRUG|LCB01-0371|LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
40844834|NCT01554995|DRUG|Linezolid|Linezolid 600 mg (Cohort 9) none
41365578|NCT02784665|DEVICE|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the
41500963|NCT05653284|DRUG|AK130|IV infusion, specified dose on specified days.
41500964|NCT04130750|COMBINATION_PRODUCT|treatment of drug screening|Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
41500965|NCT02612259|DIETARY_SUPPLEMENT|TRYPTOPHAN|at the dose of 3,5 m/kg/ day divided in two capsules
41027932|NCT03295201|OTHER|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
41027933|NCT03295201|OTHER|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
41365579|NCT02784665|DEVICE|577-TL|"All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.~100 microns light spot size, 0.05 seconds duration, 80 \~ 200 milliwatts of power"
40844835|NCT01804309|PROCEDURE|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
40844836|NCT03392623|DRUG|Retinoic acid|topical administration in melasma lesions
41027934|NCT00389324|BIOLOGICAL|Immune Globulin Intravenous (Human)|This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
41027935|NCT05124457|DRUG|Insulin Detemir|Patients are to receive insulin detemir
41027936|NCT05124457|DRUG|Insulin NPH|Patients are to receive insulin NPH
41027937|NCT03080519|PROCEDURE|Endovascular Therapy|Balloon angioplasty and stenting for renal artery stenosis
41365580|NCT02528331|DEVICE|Transcranial magnetic stimulation|
41365581|NCT02528331|BEHAVIORAL|Cognitive behavioral therapy|
41365582|NCT03672006|BIOLOGICAL|alteplase (recombinant t-PA)|Medication administered to dwell in central venous catheter
41365583|NCT03672006|DRUG|Heparin|Medication administered to dwell in central venous catheter
41500966|NCT02612259|OTHER|PLACEBO|at the dose of 3,5 m/kg/ day divided in two capsules
41500967|NCT06124495|DRUG|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
41500968|NCT05029921|DRUG|Ustekinumab|Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.
41027938|NCT03491735|OTHER|collection of data from patient files|recording of patient data and its input into an excel sheet from which statistics will be derived
41365584|NCT06432582|DIAGNOSTIC_TEST|hepatomiR|hepatomiR is a CE-certified test intended for gauging liver-related outcomes. It quantifies the levels of hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-151a-5p in human plasma samples. A proprietary algorithm is then used to compute a liver function score (hepatomiR p-score).
41365585|NCT01659411|OTHER|Observational|Yearly clinical visits
41365586|NCT00468013|BEHAVIORAL|Resilience Building Exercises|Weekly exercises for 6 weeks
41365587|NCT00468013|BEHAVIORAL|Journaling|Weekly exercises for 6 weeks
41365588|NCT05162599|DEVICE|Diagnostic study, experimental evaluative cross-sectional study|This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference test) and the new device
41365589|NCT04501380|DRUG|AEMCOLO (Rifamycin SV MMX)|Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
41365590|NCT01972282|DEVICE|WATCHMAN Left Atrial Appendage Closure|
41365591|NCT05147766|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
41365592|NCT02844751|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|\[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
41365593|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
41365594|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
41365595|NCT03063515|DRUG|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
41500969|NCT05806619|OTHER|histopathological analysis; morphological and non-morphological magnetic resonance|The surgical material removed during surgery was subjected to histological analysis. Morphological and non-morphological magnetic resonance examination before the neurosurgical surgery, according to clinical practice.
41500970|NCT00599378|BEHAVIORAL|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
40844837|NCT03392623|DEVICE|colorimetry measurement|Measurement of erythema and luminosity through a colorimeter
40844838|NCT03392623|DRUG|sunscreen|topical administration in melasma lesions
40844839|NCT03392623|DRUG|Niacinamide|topical administration in melasma lesions
41027939|NCT02553330|DRUG|Placebo Cream|
41027940|NCT02553330|DRUG|Ruxolitinib Phosphate Cream|
41027941|NCT04332705|DIAGNOSTIC_TEST|Detection of Cryptosporidium infection|A biopsy or a surgical sample will be collected from every participant
41027942|NCT00646802|DRUG|Progesterone|1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days
41027943|NCT00646802|DRUG|Placebo|1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
41365596|NCT05543980|DEVICE|Sham device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 33ºC.
41365597|NCT05543980|DEVICE|Leg heat therapy device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 42ºC.
41365598|NCT04880148|DIETARY_SUPPLEMENT|Thyme and Honey-based oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
41365599|NCT04880148|DIETARY_SUPPLEMENT|Placebo oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
41500971|NCT05201248|DRUG|Epcoritamab|Subcutaneous Injection (SC)
41500972|NCT05201248|DRUG|Cyclophosphamide|IV Injection
41500973|NCT05201248|DRUG|Rituximab|Intravenous (IV) Infusion
41500974|NCT05201248|DRUG|Doxorubicin|IV Infusion
41027944|NCT02083523|BEHAVIORAL|Motivational Interview with Normative Feedback|NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.
41365600|NCT04135300|GENETIC|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
41365601|NCT02891096|PROCEDURE|inspiratory muscle strength|"Measurements:~* in- and expiratory muscle strength (5min)~* lung function (FVC, FEV1, PEF, PCF) (10 min)~Questionnaires:~* ISCoS core data-set~* ISCoS pulmonary function data sets~* ISCoS quality of life questionnaire~* questionnaire on individual respiratory muscle training, regular physical exercise and therapies~* individual medication/vaccination and other medical complications will be assessed from patient's medical records~All measurements will be performed at each of the 4 measurement time-points (up to 4 times during inpatient rehabilitation) and last about 40 min per patient and measurement time-point in total (time with patient)."
40844840|NCT05652387|BEHAVIORAL|Father Inclusive Prenatal Care|Pregnant and parenting couples participate in co-parenting and parenting education, and job skills and education readiness
40844841|NCT00604045|BEHAVIORAL|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
40844842|NCT00604045|BEHAVIORAL|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
40844843|NCT04194814|DRUG|crisaborole (2%) ointment|twice daily application on one forearm for 4 weeks (randomised site allocation)
41027945|NCT02083523|BEHAVIORAL|Motivational Interview|The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
41027946|NCT03701555|OTHER|PvP001 placebo|placebo
41027947|NCT03701555|DRUG|PvP001 100 mg|PvP001 100 mg
41027948|NCT03701555|DRUG|PvP001 300 mg|PvP001 300 mg
41027949|NCT03701555|DRUG|PvP001 900 mg|PvP001 900 mg
41365602|NCT00106769|DRUG|VRC-WNVDNA017-00-VP|
41365603|NCT02581657|DRUG|PE0139 Injection|PE0139 Injection
41365604|NCT02581657|DRUG|Placebo Injection|Placebo Injection
41500975|NCT05201248|DRUG|Vincristine|IV Infusion
40844844|NCT04194814|DRUG|betamethasone valerate 0.1% cream|twice daily application on one forearm for 4 weeks (randomised site allocation)
41500976|NCT05201248|DRUG|Prednisone|Oral; Tablet
41500977|NCT05201248|DRUG|Lenalidomide|Oral; Capsule
40844845|NCT05501951|OTHER|tDCS stimulation|The transcranial direct current stimulation (tDCS) method has emerged in the recent years as a non-invasive, safe, cheap, convenient and effective means to modulate brain functions and behaviours
40844846|NCT05501951|OTHER|Sham stimulation|For the sham group, the electrode positioning will be randomly allocated to be identical to either the DLPFC or the OFC group, and active stimulation will be delivered for the first 30 seconds only
40844847|NCT01042652|DRUG|Raltegravir|Raltegarvir 400mg bid
40844848|NCT04460846|DIETARY_SUPPLEMENT|Alkaline water|1.5 liters per day
40844849|NCT04460846|DIETARY_SUPPLEMENT|Reverse osmosis water|1.5 liters per day
40844850|NCT03639506|PROCEDURE|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte
40844851|NCT03639506|COMBINATION_PRODUCT|autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|autologous mitochondria transplantation
40844852|NCT03639506|DRUG|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
40844853|NCT02940483|DRUG|5-Azacytidine|5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
40844854|NCT03665311|BIOLOGICAL|25% Albumin fluid|25% Albumin fluid (100 mL)
40844855|NCT03665311|OTHER|Normal Saline|0.9% Normal Saline (100 mL)
40844856|NCT04900285|DEVICE|Delta Dental Oral Device|"The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described."
40844857|NCT06360614|OTHER|Hand massage application|2 sessions of hand massage every day, 2 days a week (Monday and Friday) for 4 weeks
41500978|NCT05896735|PROCEDURE|Ultrasound-guided axillary vein catheterization|All axillary vein catheterizations were performed according to standard central venous catheterization procedures, which were performed under ultrasound guidance at the bedside. Before the operation, patients were placed in a supine position with the upper limb placed in a natural position, and the ultrasound probe and wires were wrapped with a sterile protective sheath. Ultrasound pre-scanning the axillary artery and axillary vein, and pay attention to using the minimum pressure to control the ultrasound probe to avoid crushing the blood vessels. The operator holds the ultrasound probe and puncture needle to puncture the axillary vein under the guidance of ultrasound. After drawing out of the dark red blood, the guide wire was inserted and the puncture needle was withdrawn. The three-lumen CVC catheter was then inserted using the Seldinger technique.
41500979|NCT04722146|DRUG|Teclistamab|Participants will receive teclistamab.
41500980|NCT04722146|DRUG|Daratumumab|Participants will receive daratumumab.
41500981|NCT04722146|DRUG|Pomalidomide|Participants will receive pomalidomide.
40844858|NCT06360614|OTHER|routine monitoring and nursing care|Routine monitoring and nursing care for 4 weeks
40844859|NCT04889482|OTHER|No intervention|No intervention
40844860|NCT06206655|DIAGNOSTIC_TEST|rapid ACTH stimulation test|Take 2ml blood/saliva sample at baseline. Then, we will inject synacthen 250mcg IV to patients and collect 2ml blood/saliva after 30minutes and 60 minutes.
40844861|NCT01835730|DRUG|PE0139 Injection|
40844862|NCT01835730|DRUG|Placebo|
40844863|NCT04212689|DEVICE|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
40844864|NCT04212689|OTHER|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
41500982|NCT04722146|DRUG|Lenalidomide|Participants will receive lenalidomide.
40844865|NCT05091515|OTHER|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
40844866|NCT02540291|DRUG|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
40844867|NCT02916251|DRUG|ZP4207(dasiglucagon) glucagon analogue|Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
40844868|NCT02916251|DRUG|Glucagon (Native glucagon)|Cross-over design with single s.c. administration in euglycemic T1D
40844869|NCT01577472|DRUG|High Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
40844870|NCT01577472|DRUG|Low Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
40844871|NCT01577472|DRUG|High Dose Placebo|Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
41027950|NCT03701555|DRUG|Maximum Feasible Dose (MFD) of PvP002|MFD of PvP002
41500983|NCT04722146|DRUG|Bortezomib|Participants will receive bortezomib.
41500984|NCT04722146|DRUG|Nirogacestat|Participants will receive nirogacestat.
41027951|NCT03701555|DRUG|Maximum Tolerated Dose (MTD) of PvP001|Maximum Tolerated Dose (MTD) of PvP001
41027952|NCT03701555|DRUG|MTD of PvP001 following 7 days of PPI treatment|Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
41365605|NCT00759993|DRUG|chromium piccolinate|1000mg tab
41365606|NCT00759993|DRUG|placebo for chromium piccolinate|
41365607|NCT01939015|DEVICE|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
40844872|NCT01577472|DRUG|Low dose Placebo|Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
40844873|NCT01147848|DRUG|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
41027953|NCT03701555|OTHER|PvP002 placebo|Placebo
41027954|NCT03701555|DRUG|PvP001 600 mg|PvP001 600 mg
41365608|NCT01939015|DEVICE|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
41027955|NCT03701555|DRUG|PvP003 placebo|Placebo tablet orally.
41027956|NCT03701555|DRUG|PvP003|PvP003 tablet orally.
41027957|NCT03701555|DRUG|PvP003 150 mg|PvP003 150 mg
41027958|NCT05783180|DRUG|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™|Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD)
41027959|NCT05783180|DRUG|Placebo|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Placebo)
41365609|NCT00000740|DRUG|Sitamaquine|
41365610|NCT02442284|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
41365611|NCT02442284|DRUG|Ribavirin|Tablet
41365612|NCT03629405|OTHER|C - pH 4 Cosmetic Product WO 3741|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
41365613|NCT03629405|OTHER|D - pH 5.8 Cosmetic Product WO 4081-1|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
41365614|NCT01813682|OTHER|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
41365615|NCT01813682|OTHER|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
41027960|NCT05264376|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
41027961|NCT05264376|BEHAVIORAL|Educational Control|We selected a T1D management/Eating disorder psychoeducational comparison condition previously tested (Olmsted et al., 2002) to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures by Dr. Olmsted will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
41365616|NCT05492552|BEHAVIORAL|Active-at-home-HF|Increase daily step count by 2,000 and weekly telephone calls.
41365617|NCT02778477|DRUG|PF-06423264|Multiple ascending dose of PF-06423264
40844874|NCT01147848|DRUG|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
40844875|NCT01147848|DRUG|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
40844876|NCT01147848|DRUG|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
40844877|NCT04450095|DRUG|Ambrisentan 10 MG|be given once a day for 5 days, starting 48 hours before surgery
41027962|NCT03464097|DRUG|Ozanimod|Specified dose on specified days
41027963|NCT03464097|OTHER|Placebo|Specified dose on specified days
40844878|NCT05862090|DRUG|RLD2301|Take it once a day per period.
40844879|NCT05862090|DRUG|RLD2007|Take it once a day per period.
41027964|NCT04598282|DEVICE|Prokera Slim|Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.
41365618|NCT02778477|OTHER|Placebo|Multiple dose of placebo
41365619|NCT03114150|BEHAVIORAL|Cardiorespiratory fitness training|Physical exercise of moderate intensity designed to improve cardiorespiratory fitness
41365620|NCT03114150|BEHAVIORAL|Functional fitness training|Physical exercise of light intensity designed to improve functional fitness
41365621|NCT05346731|DRUG|Ondansetron|Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
41365622|NCT05346731|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
41365623|NCT05346731|DRUG|Aprepitant|"Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight \> 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally"
40844881|NCT02967601|BEHAVIORAL|STAI (State Trait Anxiety Inventory) questionaire|Each patient would fill the STAI questionaire before Cesarean Section (on the same day, in the morning)
40844882|NCT01836328|DRUG|Parenteral /oral methadone ratio 1:2|"See arm/group descriptions"
40844883|NCT01836328|DRUG|Parenteral /oral methadone ratio 1:1.2|"See arm/group descriptions"
40844884|NCT05417191|BEHAVIORAL|Conventional fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
40844885|NCT05417191|BEHAVIORAL|Enriched fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
40844886|NCT04797871|BEHAVIORAL|Resistance training|Participants will complete a 2-days-a-week training routine: Resistance training (RT, 50-75% 1RM (one-repetition maximum), 4 sets, 8-12 repetitions, 4 exercises). The warn up include Light Intensity Continuous Training (8-10 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by Physiotherapists and Graduated in Sports Sciences.
40844887|NCT04797871|BEHAVIORAL|Standard care|This group will be allocated to standard care and therefore no supervised exercise regimen according to scientific guidelines for general physical activity and return to sport provided by the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease.
41027965|NCT04598282|OTHER|Standard of Care|Standard of care includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
41027966|NCT00059657|DRUG|Ecraprost in lipid emulsion|
41027967|NCT03103620|DEVICE|COBRA PzF Coronary Stent System|COBRA PzF Coronary Stent System
41027968|NCT04182022|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions and verified abstinence from alcohol.
41027969|NCT04182022|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions only with no contingency on alcohol use.
41027970|NCT04898335|DEVICE|Tendyne Mitral Valve System|Tendyne Mitral Valve System for mitral valve disease in a commercial setting
41027971|NCT02258477|DIETARY_SUPPLEMENT|Sequence 1|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
41365624|NCT05346731|DRUG|Olanzapine|Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
41365625|NCT03287960|DRUG|Setmelanotide|Once daily subcutaneous injection
41365626|NCT03287960|DRUG|Placebo|Once daily subcutaneous injection
41365627|NCT03161184|BEHAVIORAL|SUSTAIN Smartphone training of CHW (SP+)|"Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics."
41365628|NCT03161184|BEHAVIORAL|SUSTAIN Paperbased training of CHW (SOC)|SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
41365629|NCT02356770|DEVICE|Collagen Matrix 10808|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
41365630|NCT02356770|PROCEDURE|Connective tissue graft|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
41365631|NCT05829434|DRUG|Magrolimab|Patients will receive magrolimab on day 1; 4: IV 1 mg/kg; day 8: IV 15 mg/kg; day 11, 15 and 22: IV 30 mg/kg (plus 30 mg/kg for 5 weeks weekly and then q2w until the end of consolidation)
41365632|NCT05829434|DRUG|7+3|"Patients will receive during Induction cycle 1: cytarabine at 100 mg/m² on study days 1-7 as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on study days 3, 4, 5~* optional during Induction cycle 2: cytarabine at 100 mg/m² on days 1-7 of the second induction cycle (i.e. study days 29-35) as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on days 3, 4, 5 of the second induction cycle (i.e. study days 31, 32, 33)~* optional during Consolidation cycle: cytarabine at 1 g/m² administered on days 1, 3, 5 of each consolidation cycle as an infusion for 2 hours every 12 hours (for patients \< 60 years up to 3 CONS cycles and for patients ≥ 60 years up to 2 CONS cycles)"
41365633|NCT05829434|DRUG|CPX-351|"Patients will receive during Induction cycle 1: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 1, 3, 5~* optional during Induction cycle 2: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 29 + 30~* optional during Consolidation cycle: CPX-351 with daunorubicin 29 mg/m² and cytarabine 65 mg/m² on days 1, 3"
40844888|NCT02274740|DRUG|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
40844889|NCT02274740|DRUG|metformin|Pharmaceutical form:tablet Route of administration: oral
40844890|NCT02394717|BEHAVIORAL|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
41365634|NCT04473989|DRUG|recombinant teriparatide for injection|weekly subcutaneous administration of 40 ug
41365635|NCT04473989|DRUG|Placebo|weekly subcutaneous administration of 40 ug
40844891|NCT01745042|OTHER|Clinical exams|Physiological and biochemical tests; quality of life questionnaire; body composition measurement
41365636|NCT03813316|DRUG|DPP-4 inhibitor|Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
41365637|NCT03813316|DRUG|SGLT2 inhibitor|Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)
41365638|NCT03813316|DRUG|SGLT2 inhibitor and DPP-4 inhibitor|Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
41365639|NCT01979029|PROCEDURE|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
41365640|NCT01979029|PROCEDURE|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
41500985|NCT02084602|DRUG|Artesunate|Orally administration of artesunate 4mg/Kg by three days
41365641|NCT05702840|BEHAVIORAL|Resistance exercise training + weight loss group|Doing resistance exercises as well as following the weight watchers weight loss programme for a 12-week period
41365642|NCT05702840|BEHAVIORAL|Weight loss only group (WL)|Only following the weight watchers weight loss programme for a 12-week period
41365643|NCT05342870|DRUG|Dexmedetomidine|Following a sequential allocation scheme, the dexmedetomidine dose for each patient was determined by the Dixon up-and-down method. The dexmedetomidine dose for the first patient was 0.5 µg/kg. The dose was then adjusted in 0.1 µg/kg increments for the following patients depending on the success of the previous patient's block. If a patient experienced tourniquet pain prior to T0 + 50 minutes the next patient received a higher dose. If a patient did not experience pain at T0 + 50 minutes of tourniquet time the dose for the following patient was decreased. Identical syringes containing the solution mix were prepared by the principal investigator and handed to the blinded anesthesiologist in the room. Stopping rules were set at 6 independent crossovers in the same direction (no pain to pain or pain to no pain), with a minimum number of 20 patients
41500986|NCT02084602|DRUG|Mefloquine|Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
41500987|NCT04918589|DRUG|Tranexamic acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
41500988|NCT04918589|DRUG|Normal Saline|40 mL topical of 0.9% normal saline
41500989|NCT06604884|DEVICE|Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Vantage Embolization Device with Shield Technology™
41500990|NCT02055664|DRUG|Ropivacaine 0.2%|
40844892|NCT03693781|DRUG|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
40844893|NCT03693781|DRUG|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
41500991|NCT02055664|DRUG|Chlorure de sodium 0.9%|
41500992|NCT00901212|DEVICE|Device programming|6-month period
40844894|NCT03693781|DRUG|Placebo Oral Tablet|Corresponding tablets for 30 weeks
40844895|NCT02861859|DRUG|Olanzapine|Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
40844896|NCT02861859|DRUG|Olanzapine Placebo|Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
40844897|NCT00501865|DRUG|GW273225|GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
40844898|NCT01356199|DIETARY_SUPPLEMENT|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
40844899|NCT01356199|DIETARY_SUPPLEMENT|PLACEBO|PLACEBO. 6 per day for 8 months.
40844900|NCT06528912|OTHER|Radiotherapy|Follow-up
41500993|NCT01463215|DRUG|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
41500994|NCT04141826|DIETARY_SUPPLEMENT|Hydrolysed whey|500 mL solution of 25 gram hydrolysed whey per day during 4 weeks
41500995|NCT04141826|DIETARY_SUPPLEMENT|Intact whey|500 mL solution of 25 gram intact whey per day during 4 weeks
41500996|NCT04141826|DIETARY_SUPPLEMENT|Caseinate|500 mL solution of 25 gram casein ate per day during 4 weeks
41500997|NCT03101644|DRUG|Darunavir|The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
41500998|NCT00683631|OTHER|TheraSphere HUD|TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
41500999|NCT06462560|OTHER|Vivo Online Exercise Program|Virtual online exercise programs conducted by the Vivo team consisting of multiple time a week group live programs
41501000|NCT06462560|OTHER|Medbridge Home program|At home exercise program accessed through exercise descriptions and short vidoes
41501001|NCT04204291|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
41501002|NCT06195319|DRUG|Simufilam|100 mg of \[14C\]-simufilam
41501003|NCT05479916|DIETARY_SUPPLEMENT|Low glycated milk protein|40 grams of protein dissolved in 600 mL of water
41501004|NCT05479916|DIETARY_SUPPLEMENT|High glycated milk protein|40 grams of protein dissolved in 600 mL of water
41501005|NCT03906578|DIETARY_SUPPLEMENT|Vivomixx®|Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus
41501006|NCT03906578|OTHER|Placebo|Placebo with similar appearance to probiotic
41501007|NCT03212170|DRUG|[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging|18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
41501008|NCT05249673|OTHER|global postural reeducation|"GPR interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
41501009|NCT05249673|OTHER|neck stabilization training|"Each exercise session will be comprised 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.~performed. The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient."
41501010|NCT04522323|BIOLOGICAL|MEDI5752|MEDI5752
41501011|NCT04522323|DRUG|Axitinib|INLYTA
41501012|NCT04522323|DRUG|Lenvatinib|LENVIMA
41365644|NCT02431559|DRUG|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
41365645|NCT02431559|DRUG|Pegylated Liposomal Doxorubicin|PLD was administered as an IV infusion in accordance with local prescribing information.
41501013|NCT03620968|OTHER|cognitive training|15 minutes day of brain training by an APP
40844901|NCT00580762|PROCEDURE|Roux-en-y gastric bypass (RYGB)|
40844902|NCT00102284|DRUG|levodopa|
40844903|NCT00102284|DRUG|rivastigmine|
40844904|NCT00102284|DRUG|pergolid|
40844905|NCT00102284|DRUG|modafinil|
40844906|NCT03217214|DIAGNOSTIC_TEST|Thermography|Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
41365646|NCT02431559|DRUG|Motolimod|Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
41027972|NCT02258477|DIETARY_SUPPLEMENT|Sequence 2|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
41027973|NCT02258477|DIETARY_SUPPLEMENT|Sequence 3|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
41027974|NCT02258477|DIETARY_SUPPLEMENT|Sequence 4|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
41501014|NCT01892280|BEHAVIORAL|Teenwork intervention|Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
41501015|NCT01892280|BEHAVIORAL|Text message reminders|Text message reminders to check blood glucose levels at self-selected times
41501016|NCT01703624|DRUG|glycopyrronium bromide|glycopyrronium bromide suspension in HFA
41501017|NCT01322867|DRUG|alprazolam tablet|0,25 mg oral tablets given once
41501018|NCT01322867|DRUG|alprazolam oral solution|0,75 mg/ml Oral Solution (Drops) given once
41501019|NCT06197269|OTHER|Short duration antibiotics|antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment
41501020|NCT06197269|OTHER|Standard duration antibiotics|Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.
41501021|NCT00375895|DRUG|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
41501022|NCT01382654|DRUG|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
41501023|NCT01382654|DRUG|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
41501024|NCT01382654|DRUG|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
41501025|NCT01382654|DRUG|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
41501026|NCT01382654|DRUG|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
41501027|NCT05422638|BEHAVIORAL|RBSTE|8-week health promotion group focused on supporting coping with racism and empowerment
41501028|NCT05422638|BEHAVIORAL|PCT|8-week health promotion group focused on providing support and facilitating problem solving
41501029|NCT03295981|DRUG|Zoledronic Acid|4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
41365647|NCT03145584|DRUG|Continuous Bupivacaine via Adductor Canal Saphenous Catheter|12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.
41365648|NCT03145584|OTHER|Single Shot Adductor Canal Saphenous Block with Bupivacaine|A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation
41365649|NCT00561795|DRUG|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
41365650|NCT00561795|DRUG|carboplatin|IV over one hour every 3 weeks of 6 cycles
41365651|NCT00561795|DRUG|paclitaxel|IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles
41365652|NCT02756182|DEVICE|TDOC air-charged catheter|Urodynamic study utilizing a single catheter technique to measure WP \& AC measurements
41365653|NCT06076174|OTHER|6-week home-based exercise programme|All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.
41365654|NCT01234558|DRUG|GLYX-13|single IV dose
41365655|NCT01756846|OTHER|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
41027975|NCT01979653|DRUG|dexmedetomidine alone or dexmedetomidine + midazolam|
41027976|NCT05688813|PROCEDURE|Regional anesthesia intervention|Ultrasound-guided caudal and sacral erector spinae blocks were administered
41365656|NCT01756846|OTHER|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
41027977|NCT02579642|DRUG|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
41365657|NCT04090294|DRUG|Roflumilast|"Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test.~patients will receive Roflumilast 500 Mcg. Tablet once daily for three months"
41365658|NCT00374452|OTHER|ATHENA-CDS-HTN plus Guideline Link|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
41365659|NCT00374452|OTHER|Guideline Link Only|Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
41365660|NCT05642091|DEVICE|ultrasound Elastography|application of shear wave force by ultrasound elastography
41365661|NCT01730222|DRUG|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
41365662|NCT01730222|DRUG|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
41365663|NCT01730222|DRUG|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
41365664|NCT01730222|DRUG|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
41365665|NCT01081002|DRUG|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
41365666|NCT01081002|DRUG|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
41365667|NCT05129566|PROCEDURE|IOL Clareon AutonoMe|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
41365668|NCT05129566|PROCEDURE|IOL Hoya iSert 251|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
41365669|NCT02433704|DEVICE|New Intraosseous|Intraosseous administration of prophylactic antibiotics
41365670|NCT02433704|DRUG|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
41365671|NCT02654184|PROCEDURE|supine position|Anesthesia induction with sevoflurane for the patient while he is in supine position.
41365672|NCT02654184|PROCEDURE|Right lateral position|Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
41365673|NCT02895386|DEVICE|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
41365674|NCT02895386|OTHER|Sham procedure|Sham procedure + continuing current antihypertensive medications.
41365675|NCT01663155|DEVICE|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
41365676|NCT00710840|PROCEDURE|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
41365677|NCT00710840|PROCEDURE|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
41365678|NCT02637869|OTHER|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
41365679|NCT04920838|DRUG|Nitazoxanide and Ciclésonide|Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.
41027978|NCT02579642|DRUG|Placebo|Normal saline administered with usual induction drugs for ECT
41365680|NCT04920838|DRUG|Telmisartan 20Mg Oral Tablet|20 mg tablet daily
40844907|NCT03123991|BEHAVIORAL|UP-A adapted as a preventive intervention|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
41365681|NCT04920838|DRUG|Paracetamol|"Tablets containing 500 mg of paracetamol. One to two tablets every 4-6 hours as required, to a maximum of 6 tablets (3 grams) daily in divided doses.~Duration of treatment: up to 14 days"
41365682|NCT04920838|DRUG|Fluoxétine and Budésonide|Inhaled Budésonide: 400mcg BID per day and oral Fluoxétine : 80mg tablets daily (divided into two daily intakes of two tablets of Fluoxétine 40 mg) during 7 days.
41365683|NCT01111058|DRUG|Everolimus (RAD 001)|10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).
41365684|NCT01111058|OTHER|Placebo|
41365685|NCT05555134|BEHAVIORAL|educational intervention|will also have an extra educational intervention, a group intervention (4-6 people) through a one-hour training session via zoom, which will be given by the PI (extensive experience in the subject) a week after discharge from the ER. Information will be reinforced and doubts will be solved
41365686|NCT03241134|OTHER|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
41365687|NCT03241134|OTHER|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
41365688|NCT04303741|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
41365689|NCT04303741|DRUG|Apatinib|Apatinib 250mg will be administered daily until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
41365690|NCT04303741|DRUG|Eribulin|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
41365691|NCT03373422|DRUG|BAY1128688|Various dosing OD (once daily) and BID (twice daily)
41365692|NCT03373422|DRUG|Placebo|Matching placebo tablets
41365693|NCT03193281|DRUG|Dasatinib|"In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).~Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment."
41027979|NCT05209113|OTHER|Education|A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
41365694|NCT03193281|DRUG|Imatinib|Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
41365695|NCT05205642|DEVICE|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
41365696|NCT05205642|DEVICE|Peripheral Arterial Tonography (PAT) using the EndoPAT™ device|A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.
41365697|NCT05205642|DIAGNOSTIC_TEST|Endothelin|For Endothelin levels we will use the Endothelin ELISA kit from R\&D company, and for measurement 1 cc of serum will be needed.
41365698|NCT03331393|OTHER|Non-interventional|Non-interventional
41365699|NCT00296569|DRUG|MK0686|
41365700|NCT05433116|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy
41365701|NCT05433116|DRUG|Lenvatinib|20mg once daily orally, start concomitant to cycle 2 of pembrolizumab
41365702|NCT01101906|DRUG|OSI-906|OSI-906 administered orally
41365703|NCT01101906|DRUG|Placebo|Matching placebo administered orally
41365704|NCT05503758|DEVICE|Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|The MyotoPRO device is a portable objective device for measuring the contractile (tone), and biomechanical (stiffness) properties of lumbar paravertebral muscles (LPVMs).
41365705|NCT05801679|DRUG|Sugammadex|Fifteen minutes after ICU arrival, subjects will be administered sugammadex (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
41365706|NCT05801679|OTHER|Placebo|Fifteen minutes after ICU arrival, subjects will be administered placebo (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
41365707|NCT00758576|DEVICE|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
41365708|NCT05094258|PROCEDURE|unicondylar knee prosthesis with mobile insert|Patients with unicondylar knee replacement using the mobile insert option
41365709|NCT05094258|PROCEDURE|unicondylar knee prosthesis with fixed insert|Patients with unicondylar knee replacement using the fixed insert option
41365710|NCT03391427|DRUG|Lidocaine|This group will receive lidocaine infusion
41365711|NCT03391427|DRUG|Ketamine|This group will receive Ketamine infusion
41365712|NCT03391427|DRUG|Lidocaine+ketamine|This group will receive mixture of ketamine and lidocaine infusion
41365713|NCT03391427|DRUG|Saline|This group will receive saline infusion
41365714|NCT04211506|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.
41365715|NCT01619631|BEHAVIORAL|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
41365716|NCT01619631|BEHAVIORAL|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
41365717|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
41365718|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
41365719|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
41365720|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
41365721|NCT05693233|DEVICE|EXO On, EXO Off, EXO Removed treadmill (Uphill_incline 10°) walking and simultaneous evaluation|"- After filling out the consent form for 10 subjects who meet the selection criteria, a total of three evaluations are conducted: one pre-evaluation and one post-evaluation for the knee assist robot and hip assist robot.~Pre-evaluation: Evaluation simultaneously with walking on an inclined treadmill (Uphill_incline 10°) for 5 minutes without wearing knee and hip assist robots (speed 1.5 m/s)."
41365722|NCT02013999|OTHER|Virtual reality program for upper extremity rehabilitation|
41365723|NCT02013999|OTHER|standard occupational therapy|
41027980|NCT03351023|OTHER|no intervention-this was an observational study|
41365724|NCT03176823|DEVICE|CellAegis Technologies autoRIC device|The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.
40844908|NCT03123991|BEHAVIORAL|Same than experimental group (EG), after EG finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
40844909|NCT04651608|BEHAVIORAL|manuel acupressure|Acupressure was applied once by the researcher 30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child. 3 fingers were placed on the child's wrist with their fingers and the region (point P6) between the flexor carpi radians and palmaris longus 1 cm below. Acupressure was applied to the wrist of the child by press for 2 minutes. The same procedure was applied to the other wrist. Then, data were recorded in accordance with the data collection procedure.
40844910|NCT04651608|BEHAVIORAL|sea-band acupressure|30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child, sea-band acupress was applied by the researcher. The P6 point on the wrist was identified and marked with the child's own fingers. A sea band was attached to both wrists of the child by the researcher. The attached sea-band was allowed to remain for 15 minutes and was removed by the researcher at the end of the period. Separate sea-band was attached to each child. Acupress wrist bands, which are produced in separate sizes for adults and children, were used during the application, taking into account the physical development of the child, pediatric for the age range of 5-12, and adult size sea-band for the age of 12. Acupress application with sea-band was done once. Then, data were recorded in accordance with the data collection procedure
40844911|NCT04651608|BEHAVIORAL|placebo manuel acupressure|Placebo manual acupress was applied in the next protocol for the child who was administered manual acupressure.
40844912|NCT04651608|BEHAVIORAL|placebo sea-band|Placebo sea-band was applied in the next protocol for the child who was administered sea-band acupressure.
40844913|NCT03748459|OTHER|Closure with Permanent Suture|Skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
40844914|NCT03748459|OTHER|Closure with Resorbable Suture|Skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty.
41027981|NCT02063789|DRUG|Human immunoglobulin intravenous|After GC5107A Intravenous injection, evaluate platelet increase
41027982|NCT02199457|DEVICE|SVSS and reference devices|Blood pressure will be measured with standard mercury manometer
41027983|NCT02199457|DEVICE|SVSS and reference devices|Body temperature taken with infrared thermometer
41027984|NCT02199457|DEVICE|SVSS and reference devices|Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.
41365725|NCT03176823|OTHER|Best Practice Management of Traumatic Brain Injury|Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
41365726|NCT05773885|DEVICE|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|"The patients will carry out motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy).~The motor exercises will be performed using inertial sensors for the acquisition and processing of the movement performed by the patient. This data is shown to the patient with visual and auditory feedback in a serious games environment. The exercises will cover the rehabilitation of balance and lower limbs, for example Balance on one leg, March in place, Stand on tiptoe, Squat, etc. The physiotherapists involved in the study will define a protocol of exercises in TR mode customized according to the characteristics and needs of the patient. The exercises in the speech therapy and cognitive domains will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
41365727|NCT05773885|OTHER|Conventional rehabilitation|"The patients will carry out conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.~The motor exercises will concern the rehabilitation of balance, trunk, and lower limbs and will be performed with a physiotherapist who will customize the treatment based on the characteristics and needs of the patient. The occupational therapy, speech therapy, psychotherapy treatments will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
41027985|NCT02199457|DEVICE|SVSS and reference devices|Measurement of respiration rate
41027986|NCT05309512|BIOLOGICAL|KN052|0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg, 9mg/kg, RP2D once every two or three weeks intravenously
41027987|NCT05443035|PROCEDURE|Antimicrobial PDT and Papacarie Deproteinization|Selective removal of carious tissue with curette + antimicrobial PDT (methylene blue 5 Evilux, Color index 52015, Fórmula \& Ação + red laser at 660 nm) + deproteinization of enamel with Papacárie DuoTM + restoration.
41027988|NCT05443035|PROCEDURE|Conventional caries treatment|Selective removal of carious tissue with curette + restoration.
41027989|NCT05443035|PROCEDURE|Antimicrobial PDT and 5% NaOCl Deproteinization|Selective removal of carious tissue with curette + application of methylene blue and low-level laser (aPDT) + deproteinization of adjacent enamel with 5% NaOCl + restoration.
41027990|NCT01283789|DRUG|Lapatinib and RAD-001|"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."
41027991|NCT05367453|DIETARY_SUPPLEMENT|Tropical juice with probiotics (B.coagulans)|Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)
41027992|NCT05367453|OTHER|a Tropical juice with no probiotics|Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics
41027993|NCT05367453|OTHER|lactase tablet|lactase tablet
41027994|NCT05367453|OTHER|placebo tablet (cornstarch)|placebo tablet (cornstarch)
41027995|NCT00585949|PROCEDURE|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
41027996|NCT00585949|PROCEDURE|Angiography|Angiography is an imaging technique to see coronary blood vessels.
41027997|NCT03781518|PROCEDURE|ridge splitting in group and khoury shell technique in the other group|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
41027998|NCT00882674|DRUG|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
40844915|NCT02479139|BIOLOGICAL|Vehicle|Vehicle for ANT-1207 liniment formulation without active ingredient.
40844916|NCT02479139|BIOLOGICAL|ANT-1207|Botulinum toxin Type A topical liniment (ANT-1207).
40844917|NCT02568592|DIETARY_SUPPLEMENT|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
40844918|NCT02568592|DIETARY_SUPPLEMENT|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
41027999|NCT01673334|DEVICE|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
41028000|NCT06116773|OTHER|Training|"Training group is supervised exercise group and will be included in a supervised cardiac rehabilitation program for 3 days a week. The program will start 2 weeks after CABG surgery and continue for 8 weeks, totaling 24 sessions. Aerobic, resistance, balance and stretching exercises will be applied within the program. Total exercise time is aimed to be ≥150 min/week for 8 weeks. A home-based exercise program will be recommended.~Moderate-intensity continuous aerobic training will be implemented using an upright exercise bike (5 minutes warm-up, 20 minutes load, 5 minutes cool down, 5 minutes recovery). Rhythmic unloaded aerobic exercises or low-load (0.5-1 kg) resistance exercises (starting from the 6th week post-op) will be performed for an average of 15-20 minutes. Balance exercises will progress from easy to difficult depending on the person's performance. Stretching exercise for the gastrocnemius muscle will be performed for 4 repetitions in a short stretching period of 15 seconds."
41028001|NCT06116773|OTHER|Control|"Patients will be informed about secondary prevention approaches which is routinely performed after discharge after CABG operation and will be recommended a home-based exercise program. Patients will be called by phone once a week and exercise monitoring will be provided. Recommended home exercise program includes:~* Breathing exercises~* Moderate intensity (RPE 4-6) walking (150 min/week).~* Posture exercises (shoulder elevation-depression, 90 degree shoulder flex-extend, 90 degree shoulder abd-add, neck joint range of motion exercises)~* They will be advised to continue range of motion exercises in the early post-operative period. (Twice a day, 10 repetitions).These exercises include ankle dorsi-plantar flexion, hip abduction-adduction, hip internal-external rotation, hip flexion-extension, arm elevation-depression in the supine position; flexion-extension in the sitting position; hip abduction-adduction, hip hyperextension and counting movements in the standing position."
41028002|NCT06533163|DEVICE|Oncomagnetic device|OncoMAGNETX has developed a portable wearable noninvasive magnetic device (Oncomagnetic device) for the treatment of GBM.
41028003|NCT03939273|DRUG|Vancomycin Oral|500 mg thrice per day for seven days
41028004|NCT03939273|DRUG|Metronidazole Oral|500 mg thrice per day for seven days
41028005|NCT03939273|DRUG|Ciprofloxacin Pill|500 mg twice per day for seven days
41028006|NCT03939273|DRUG|Fluconazole Oral Product|200 mg once per day for six days
41028007|NCT03939273|DRUG|Placebos|seven day course of placebo tablets and capsules identical in appearance and number to active treatment
41028008|NCT04672434|DRUG|Sym021|Sym021 is a humanized anti-PD-1 antibody.
41028009|NCT04672434|DRUG|Sym024|Sym024 is an anti-CD73 antibody.
41028010|NCT00524134|DRUG|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
41028011|NCT06458361|PROCEDURE|Type of bowel resection, surgical complexity score, intraoperative blood loss, perioperative erythrocyte transfusion, type of anastomosis|Basic information about ovarian cancer patients and factors associated with preoperative, intraoperative and postoperative periods
41028012|NCT03116139|DIAGNOSTIC_TEST|V/Q imaging|Standard of care
41028013|NCT03116139|DIAGNOSTIC_TEST|Computed tomography scan|Standard of care
40844919|NCT02568592|DIETARY_SUPPLEMENT|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.
41028014|NCT04880941|BEHAVIORAL|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
41028015|NCT03931577|DIAGNOSTIC_TEST|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.
41028016|NCT03931577|PROCEDURE|Communication skill enhancement|Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.
41028017|NCT05015153|OTHER|Pulmonary rehabilitation (PR)|20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months
41028018|NCT04949230|OTHER|No Intervention Used|There is no intervention in this study
41028019|NCT01471002|DEVICE|Galil Medical patented 17G Cryoablation Needles|
41028020|NCT05281692|DIAGNOSTIC_TEST|Enhanced Preservation Media (EPM-IX)|EPM-IX is a clinical specimen collection medium that inactivates pathogens, preserves nucleic acids, and integrates DNA/RNA purification. EPM-IX eliminates the need for additional extraction reagents or kits and purifies DNA/ RNA from the entire sample to enable optimal test performance.
41028021|NCT04511715|DRUG|Intravitreal Bevacizumab IVB|Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment
41028022|NCT04511715|OTHER|Follow-up with regular examination for determination of DR progression|regular examination for determination of DR progression
41028023|NCT00439959|DRUG|GSK625433/placebo|
41028024|NCT03854344|DRUG|Lidocaine Hydrochloride|Injected subcutaneously for skin graft harvesting
41028025|NCT03854344|DRUG|Liposomal bupivacaine|Injected subcutaneously for skin graft harvesting
41028026|NCT03854344|DRUG|Bupivacaine Hydrochloride|Used for regional nerve block for skin graft harvesting
41028027|NCT04284423|DIAGNOSTIC_TEST|joint fluid lactate|Analysis of lactate level in joint fluid to determine presence of septic joint
41028028|NCT01882634|DEVICE|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
41028029|NCT05919537|DRUG|HMBD-001|HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly
41028030|NCT05919537|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV once every 3 weeks
41028031|NCT05919537|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
41028032|NCT05919537|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
41028033|NCT06039748|OTHER|AngioQFA|FFR measured by pressure wire, AngioQFA computed by coronary angiographic images
41028034|NCT01177111|OTHER|Sunflower seed oil|Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
41028035|NCT01177111|OTHER|Mustard seed oil|Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
40844920|NCT04194073|DEVICE|Pulse oximeter calibration population (NightOwl)|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
41028036|NCT05637138|DEVICE|tcpCO2 measure|Measurement of tcpCO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
41028037|NCT05637138|DEVICE|tcpO2 measure|Measurement of tcpO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
41028038|NCT05637138|DEVICE|measurement of tissue conductivity to CO2: KS|measurement of tissue conductivity to CO2: KS by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
41028039|NCT05637138|DEVICE|measurement of microcirculation|measurement of microcirculation by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
40844921|NCT06441149|OTHER|AI-based informed consent|Patients receiving personalized data-based informed consent procedure before bronchoscopy
41028040|NCT06452459|OTHER|No interventinon|No intervention is anticipated. This is an observational study.
41028041|NCT01542775|BEHAVIORAL|Aerobic Exercise Group|12 weeks Aerobic exercise
41028042|NCT01542775|BEHAVIORAL|Control Group|maintaining usual activities
41028043|NCT03647514|DRUG|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
41028044|NCT03647514|DRUG|Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
41028045|NCT01099319|DIETARY_SUPPLEMENT|Renalof|One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
41028046|NCT01099319|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) every 8 hours, for 6 months
41028047|NCT04191902|BEHAVIORAL|orientation|patients will be oriented
41028048|NCT03615157|OTHER|Exercise rehabilitation|Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
41028049|NCT01807273|OTHER|Walking test|
41028050|NCT00254982|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
41028051|NCT02317575|BIOLOGICAL|LY900014|Administered SC
41028052|NCT02317575|BIOLOGICAL|Insulin Lispro|Administered SC
41028053|NCT05504460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Treatments in the test group will lasts for 12 months, and symptomatic treatment will be provided based on the actual symptoms of the subjects. Subjects in the test group will be required to receive inhalation for at least 4 days every 7 days with at least 3780L inhaled every 7 days (It is recommended to inhale at least 540L per day; If the flow rate is 3L/min, it is recommended that the cumulative inhalation time should be at least 3 hours per day. If the flow rate is 1.5L/min, it is recommended that the cumulative inhalation time should be at least 6 hours per day).
41028054|NCT05504460|OTHER|basic treatment|supportive treatment determined by the investigator based on the condition of the patients
41028055|NCT04109989|DEVICE|HominisTM Surgical System|Trans-vaginal gynecological procedures
41028056|NCT01782131|DRUG|Posaconazole|POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD
41028057|NCT01782131|DRUG|Voriconazole|VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID
41365728|NCT01401179|DRUG|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
41365729|NCT03601611|DRUG|Tocilizumab (RoACTEMRA®)|Prednisolon will be given in case of worsening of symptoms
41365730|NCT00182793|BIOLOGICAL|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
41028058|NCT01782131|DRUG|Placebo|Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
41028059|NCT02765932|PROCEDURE|Dummy Movements|The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
41028060|NCT02765932|PROCEDURE|Psychosensory Therapy|The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
41028061|NCT05676411|DRUG|Benzoyl Peroxide Topical|Topical benzoyl peroxide cream will be applied to the shoulder skin twice a day for 2 days leading up to and in the morning of surgery.
41365731|NCT00182793|DRUG|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
41028062|NCT05676411|PROCEDURE|Electrocautery surgical skin incision|The skin incision will be made entirely using electrocautery at the beginning of shoulder replacement.
41028063|NCT02863991|DRUG|ONC201|375 mg or 625 mg ONC201
41365732|NCT00182793|DRUG|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
41365733|NCT00182793|DRUG|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
41365734|NCT00182793|DRUG|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
41365735|NCT00182793|PROCEDURE|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
41501030|NCT05811897|BEHAVIORAL|Self-Managed Online Treatment|"Self-help online cognitive-behavioural therapy focusing on post-traumatic stress, sleep and mood. The content is divided into three modules :~* Coping with my trauma: psychoeducation about PTSD, cognitive restructuring prolonged exposure to avoided situations and memories (14 sessions)~* Sleeping better: psychoeducation about, sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education), Imagery Rehearsal Therapy (10 sessions)~* Improving my mood: psychoeducation about depression, behavioural activation; relaxation and mindfulness exercises; problem-solving strategies (6 sessions)~A small portion of material is unlocked each week, and access to one module will be accessible after the completion of a previous one. Access to the online material will be unlimited in time. Participants complete self-report questionnaires after each module, the platform then provides feedback and suggests corresponding modules."
41501031|NCT05811897|BEHAVIORAL|Therapist-Assisted Online Treatment|Same online intervention. Supervised graduate psychology students will provide brief regular weekly contacts for up to 30 weeks by video chat or phone, according to the participant's preference.
41501032|NCT03062163|OTHER|Resveratrol lipoic Acid|Transdermal patch loaded with resveratrol and lipoic acid
40844922|NCT06441149|OTHER|Standard informed consent|Standard informed consent
40844923|NCT04060784|PROCEDURE|Immediate implant placement and provisionalization|Failing tooth will be extracted and immediate placed endosseous implant
40844924|NCT05338879|OTHER|Non-Interventional|No study treatment will be administered on this study.
40844925|NCT00732108|DRUG|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
40844926|NCT00732108|DRUG|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
41161332|NCT05017883|DRUG|TAA05 cell injection|"Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
41161333|NCT01876771|DRUG|[177]Lu-DOTA-TATE|Peptide receptor radionuclide therapy (PPRT)
41501033|NCT03062163|OTHER|Placebo|Transdermal patch loaded with normal saline
40844927|NCT04739878|PROCEDURE|Airway Ultrasound|Comparison between Airway ultrasound and CT cervical
41028064|NCT02863991|DRUG|Dexamethasone|20 mg dexamethasone
41028065|NCT01994486|DRUG|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
41365736|NCT00182793|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
41501034|NCT04060290|OTHER|Observational study|Observational study of this study, no interventions involved
41365737|NCT00182793|PROCEDURE|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
41501035|NCT03377101|DRUG|Copanlisib|Given IV
41501036|NCT03377101|DRUG|Fulvestrant|Given IM
41501037|NCT03377101|OTHER|Laboratory Biomarker Analysis|Correlative studies
41501038|NCT03377101|DRUG|Palbociclib|Given PO
41501039|NCT05145179|DRUG|SSGJ-705|0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
41501040|NCT04735926|DRUG|Calcifediol 75mcg|Soft gelatin capsule. Oral administration once per week
40844928|NCT03995355|DEVICE|9618X investigational lipid eye drops|Test Eye Drops
40844929|NCT03995355|DEVICE|Blink® Tears|Control Eye Drops
40844930|NCT05267340|BEHAVIORAL|TARA|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
40844931|NCT05267340|BEHAVIORAL|Psycho-Education|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components
40844932|NCT02416895|OTHER|In vivo immunity model|A measure of in vivo immune function.
41028066|NCT00222339|BEHAVIORAL|task-specific training|
41501041|NCT04735926|DRUG|Calcifediol 100mcg|Soft gelatin capsule. Oral administration once per week
41501042|NCT04735926|DRUG|Calcifediol 125mcg|Soft gelatin capsule. Oral administration once per week.
41501043|NCT04735926|OTHER|Placebo|Soft gelatin capsule. Oral administration once per week.
41501044|NCT04735926|OTHER|Placebo|Soft gelatin capsule. Oral administration once per week.
41501045|NCT00351884|DRUG|Vildagliptin AM|
41501046|NCT00351884|DRUG|vildagliptin pm|
41501047|NCT00351884|DRUG|placebo|
41501048|NCT05135403|DEVICE|Defibrillation|External defibrillation from a wearable cardioverter defibrillator
41501049|NCT05250011|DRUG|Dapagliflozin|Dapagliflozin, prescribed as per approved indication and current medical practice. Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.
41365738|NCT00182793|RADIATION|radiation therapy|"After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy."
41365739|NCT01909492|PROCEDURE|Blood Draw|Patients will provide a serum sample for research.
40844933|NCT03107494|DEVICE|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
40844934|NCT04840225|OTHER|Measurement of biomarkers for inflammation and anemia|Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements
40844935|NCT01167660|DEVICE|The Thrombo-Monitor (ThM)|Non-invasive measurement of coagulation status and comparison to standard blood coagulation tests. In healthy neonates - immediately after birth, before the administration of vitamin K. Coagulation tests will be done on an umbilical cord blood sample. In sick neonates, coagulation studies will be done according to the medical condition.
40844936|NCT06319859|DRUG|Morphine|The patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally
40844937|NCT06319859|DRUG|Placebo|The patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
40844938|NCT00088894|DRUG|gemcitabine hydrochloride|Given IV
40844939|NCT00088894|BIOLOGICAL|bevacizumab|Given IV
40844940|NCT00088894|OTHER|placebo|Given IV
41365740|NCT01909492|PROCEDURE|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
41365741|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 9-17)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
41365742|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 18-59)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
41365743|NCT03518996|DEVICE|rTMS/iTBS/tACS|Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
41365744|NCT03518996|DEVICE|Sham TMS/tACS|Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
41161334|NCT05018949|PROCEDURE|Lower limb angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
40844941|NCT00088894|OTHER|laboratory biomarker analysis|Correlative studies
40844942|NCT00088894|OTHER|pharmacogenomic studies|Correlative studies
40844943|NCT00088894|OTHER|pharmacological study|Correlative studies
40844944|NCT01706783|DRUG|somapacitan|Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 (somapacitan) in an escalating order
40844945|NCT01706783|DRUG|Norditropin NordiFlex®|Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
41365745|NCT05752591|DIAGNOSTIC_TEST|Diagnostic testing|Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
41365746|NCT01822782|BIOLOGICAL|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
40844946|NCT03719989|DRUG|azacitidine plus R-GDP|azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 every 21 days, up to 6 cycles
40844947|NCT00615173|DRUG|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
41365747|NCT05539664|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|The experimental group used the experimental medical device Hydrogen-Oxygen Generator with Nebulizer(Shanghai Asclepius Meditec Co., Ltd. ) The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
41365748|NCT05539664|DEVICE|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen)|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen). The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
41161335|NCT03809650|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
41365749|NCT03077074|OTHER|low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
40844948|NCT00615173|DRUG|cyclophosphamide or azathioprine|Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
40844949|NCT05934864|GENETIC|84-gene penal|84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
40844950|NCT05755568|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
40844951|NCT03246659|DRUG|111In-CP04|Radiopharmaceutical preparation
40844952|NCT03246659|DRUG|111In-CP04 with co-administration of gelofusine/gelaspan|Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
40844953|NCT02448290|DRUG|docetaxel plus selumetinib|Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
40844954|NCT06344156|DRUG|Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy|Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines
40844955|NCT05385588|OTHER|cognitive functional assessment|"* Self-administered questionnaire~* Cognitive and functional tests~* Medical questionnaire~* Sampling for biobank (28-32 ml will be collected)"
40844956|NCT00005107|DRUG|N-monomethyl-L-arginine|
40844957|NCT04891484|DRUG|Ondansetron group|patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
40844958|NCT04891484|DRUG|Saline group|patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
41501050|NCT04051034|DIETARY_SUPPLEMENT|Omega 3|"Active: 1.25 g capsules/420 35-count bottles \[1.25 g capsule contains min. 750 mg EPA + 250 mg DHA\] and heat therapy, increase internal body temperature 1.2 C above baseline.~Placebo: 14,700 1.25 g capsules/420 35-count bottles \[1.25-gram high oleic safflower oil capsule\]"
40844959|NCT03267914|OTHER|Tray|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
40844960|NCT03267914|OTHER|Brush|Patients will brush with the fluoride for 2 minutes each day.
40844961|NCT01943240|DRUG|Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels|
40844962|NCT01943240|DRUG|10 cc of 0.375% ropivacaine pectoral nerve block|
40844963|NCT02579681|DRUG|dimethyl fumarate|dimethyl fumarate administered as per the arm description
40844964|NCT06545331|DRUG|XB010|IV administration of XB010
40844965|NCT06545331|DRUG|Pembrolizumab|IV administration of Pembrolizumab
40844966|NCT05989659|OTHER|Exposure: Home dialysis or facility-hemodialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
40844967|NCT05243303|DEVICE|Active taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. Through this bipolar clip electrode, afferent nerve fibers within the auricular branch of the vagus nerve will be stimulated. Subjects self-administer the stimulation on a daily basis for 3 months.
40844968|NCT05243303|DEVICE|Sham taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. However, active stimulation of the afferent nerve fibers within the auricular branch of the vagus nerve will not occur, because the electrode wire is electrically interrupted. Subjects self-administer the sham taVNS on a daily basis for 3 months.
40844969|NCT00436592|DEVICE|NeuroFlo™ Catheter|45 minute Treatment
40844970|NCT01174173|DRUG|Ranolazine|ranolazine 1000 mg PO BID for 3 months
40844971|NCT00738218|OTHER|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
40844972|NCT00673283|DEVICE|bi-plane chest radiography|Bi-plane radiography of the thorax
40844973|NCT00898391|OTHER|laboratory biomarker analysis|Correlative studies
40844974|NCT00898391|GENETIC|polymerase chain reaction|Correlative studies
40844975|NCT00898391|GENETIC|polyacrylamide gel electrophoresis|Correlative studies
40844976|NCT00898391|GENETIC|DNA analysis|Correlative studies
41365750|NCT03280446|DEVICE|Intragen fractional radiofrequency with NeuViVa|The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
40844977|NCT01961648|DEVICE|Rebreathing bag|
40844978|NCT01961648|DEVICE|Sham rebreathing|
40844979|NCT01961648|DEVICE|Mask|
40844980|NCT00236756|DRUG|topiramate|
40844981|NCT00002822|DRUG|carboplatin|
40844982|NCT00002822|DRUG|cisplatin|
40844983|NCT00002822|DRUG|cyclophosphamide|
40844984|NCT00002822|DRUG|doxorubicin hydrochloride|
40844985|NCT00002822|DRUG|etoposide|
40844986|NCT00002822|DRUG|ifosfamide|
40844987|NCT00002822|DRUG|mesna|
40844988|NCT00002822|DRUG|vincristine sulfate|
40844989|NCT00002822|RADIATION|radiation therapy|
41365751|NCT02503969|OTHER|Exposure to having a long-term condition.|"Long-term conditions are self-reported: twelve named conditions are recorded, along with an other condition - these shall all be considered with the exception of the named condition cancer."
41365752|NCT02221258|BIOLOGICAL|FURESTEM-RA Inj.|Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
41365753|NCT01670331|BEHAVIORAL|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
41365754|NCT03162380|OTHER|Date collection|Date collection
40844990|NCT02693379|DEVICE|D-VIA|"D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.~Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment."
40844991|NCT03813992|DRUG|MED2005|Topical Product
40844992|NCT02275533|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41365755|NCT04352166|DRUG|extended-release buprenorphine (BXR)|Three monthly injections will be provided during the course of the 12 week trial.
41365756|NCT04352166|DRUG|sublingual buprenorphine (BSL)|On a weekly basis patients will be provided with sublingual buprenorphine to take up to 24 mg daily.
41365757|NCT02433015|OTHER|Electronic Cigarette|eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
41365758|NCT02433015|OTHER|Tobacco Cigarette|Smoke own brand of cigarette as previously
41365759|NCT04031352|OTHER|implementation of CATCH scale|subject completed the CATCH scale
41365760|NCT06174402|DRUG|Fenofibrate|Fenofibrate 200 mg/day
41365761|NCT06174402|DRUG|Placebo|1 tablet/ day
41365762|NCT06174402|DRUG|UDCA|UDCA 13-15mg/kg/day
40844993|NCT02275533|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41365763|NCT06256861|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
41365764|NCT06256861|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
41028067|NCT06263777|OTHER|Nurses training program on early detection of disability|It included four main elements, which are: a booklet defining different disabilities, a list of the guidelines for early detection, a guide for family guidance for families of children with disabilities, a monitoring and follow-up form for 8 cases of children with disabilities). The program consisted of twelve training sessions with a total of 48 hours (4 hours per session) and was based on the techniques of lecture, dialogue, working groups, cooperative learning techniques and participatory learning
41365765|NCT04487782|OTHER|Focus Groups|The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.
41365766|NCT03738462|DEVICE|Conformis Hip System|The Conformis Hip System is an FDA cleared, uncemented, primary total hip replacement device composed of femoral and acetabular components. The system incorporates the use of a pre-operative CT scan to design patient-specific implants and instruments. Using patient imaging (CT scan), a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. In addition, each Conformis Hip System device is shipped with an additional (optional) femoral stem (Cordera Femoral Stem).
41365767|NCT01659437|DRUG|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
41028068|NCT00817089|DRUG|Placebo Oral Tablet|Placebo pill
41028069|NCT00817089|DRUG|Naltrexone|50 mg of naltrexone prior to challenge session
41365768|NCT01659437|DRUG|Streptomycin intramuscular injection|daily intramuscular drug injection
41365769|NCT00000172|DRUG|Galantamine|
41501051|NCT04051034|OTHER|Placebo|Active: 1.25 g capsules \[1.25-gram high oleic safflower oil capsule\] and heat therapy, increase internal body temperature 1.2 C above baseline.
41501052|NCT05972148|OTHER|Digital scanning|Five intraoral scans, one for each arch before the insertion of scanbodies, were obtained. The implant locations were then marked, and the software trimmed a 6mm diameter circular section of the scan from the implant locations to allow the scanbodies to be added. Abutment-level polyetheretherketone (PEEK) scanbodies were hand-tightened onto each implant and not moved for the remainder of the scans. Scanbodies were scanned using a circular scan path, and scanning was finalized.
41501053|NCT05972148|OTHER|Photogrammetry|Rectangular-shaped titanium photogrammetry scanbodies were hand-tightened onto the Implants. Scanbodies were not moved before completing all scans for each arch. A total of five scans of each arch were obtained using a photogrammetry device. Measurements were successfully recorded by turning them green on the computer screen.
41501054|NCT06164093|OTHER|RNA sequencing is performed on the remaining LPCs|RNA sequencing is performed on the remaining LPCs previously transplanted back into the patients. And the results are analysed combined with the data from the previous clinical trial. (Please note that patients will not receive cell transplantation again as they have already received the treatment in the previous trial \[NCT03655808\])
41501055|NCT06164093|OTHER|Immunofluorescence staining is performed in the surgically resected lung tissue sections|The aim of this intervention is to detect Krt5 protein expression by staining the surgically resected lung tissue sections. This is done to confirm the presence of a small number of LPCs in the lung tissue of patients with bronchiectasis and to investigate their distribution.
41501056|NCT00737763|DRUG|efalizumab|Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
41501057|NCT00737763|DRUG|placebo|Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
41501058|NCT01565057|OTHER|sedimenting meal|The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
41501059|NCT00049179|DRUG|cytarabine|ind and consol: 200 mg/m2/d continuous IV days 1-7
41501060|NCT00049179|DRUG|gemtuzumab ozogamicin|ind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8
40844994|NCT02275533|OTHER|Clinical Observation|Undergo standard of care clinical observation
40844995|NCT02275533|PROCEDURE|Echocardiography|Undergo ECHO
40844996|NCT02275533|BIOLOGICAL|Nivolumab|Given IV
40844997|NCT06017869|BIOLOGICAL|MNV-201|Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by leukapheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.
40844998|NCT02421679|DRUG|TNX-102 SL|TNX-102 Sublingual tablets
40844999|NCT00446082|DRUG|Pasireotide|
40845000|NCT05073198|OTHER|Education brochure|In the content of the brochure about testicular cancer and CCTM prepared in line with the literature; It includes information such as the definition of testicular cancer, testicular cancer risk factors and symptoms, the importance of early diagnosis in testicular cancer, how CCTM is performed, and what to do in case of differences after the examination. Expert opinion was obtained from three faculty members (a professor from the Department of Urology, a professor in Public Health Nursing and a physician faculty member) regarding the content validity of the educational brochure created before the research.
40845001|NCT04266756|DRUG|Selexipag matrix tablet|Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.
40845002|NCT04266756|DRUG|Selexipag encapsulated pellets|Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.
41365770|NCT03389217|DEVICE|Real-tDCS + rehabilitation programme|tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
41365771|NCT03389217|DEVICE|Sham-tDCS + rehabilitation programme|The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
41365772|NCT05714176|DRUG|Ferric Pyrophosphate Liposomal|30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
41365773|NCT05714176|DRUG|Lactoferrin|30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.
41365774|NCT05714176|DRUG|Iron Dextran Injection|30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.
41365775|NCT04717505|OTHER|Gait Assessments|"10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device."
40845003|NCT04266756|DRUG|Selexipag Immediate-release (IR) tablet|Participants will receive Selexipag immediate-release tablet orally under fasted condition.
41501061|NCT03471923|DIAGNOSTIC_TEST|Neurological Examination|The family members and healthy volunteers will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of cervical dystonia and other sensory abnormalities. If the subject is found to have cervical dystonia or any other sensory abnormalities, the subject will be excluded from the study.
41501062|NCT03471923|DIAGNOSTIC_TEST|Assessment of Non-Motor Features|All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.
40845004|NCT04687371|OTHER|Proprioceptive vestibular exercise|To assess effects of proprioceptive vestibular exercises training in patients with peripheral vestibular hypofunctions
41501063|NCT01327508|DEVICE|TRIGEN SURESHOT Distal Targeting Instrumentation.|image-guided localization system
41501064|NCT01327508|OTHER|Free-hand technique|Free-hand technique utilizes x-rays to find screw holes.
41501065|NCT01621477|DRUG|clofarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
40845005|NCT04687371|OTHER|Standard vestibular rehabilitation exercises|To assess effects of standard vestibular rehabilitation exercises in patients with peripheral vestibular hypofunctions
40845006|NCT04687371|OTHER|Controlled|First and last measurement will be taken. There will be no intervention. study will include 9 patients.
40845007|NCT02722707|DEVICE|magnetic anal sphincter augmentation for fecal incontinence|Surgical placement of HUD called FENIX for female patients that have failed conservative therapy and less invasive therapies or who are not candidates for such therapies
40845008|NCT06019377|BEHAVIORAL|Stronger Youth Networks and Coping (SYNC)|SYNC is a 10-module online curriculum adapted from evidence-based cognitive change methods, including Coping Effectiveness Training (CET), co-facilitated by service providers in Independent Living Programs (ILPs; federally-funded transition skill-building services accessed by most foster youth in the US) and near-peers (have lived experience in foster care). SYNC aims to increase youth capacity to appraise stress and regulate emotional responses, to flexibly select adaptive coping strategies, and to specifically promote informal and formal help-seeking as an effective coping strategy.
40845009|NCT02578173|DEVICE|AVERT PLUS|
41028070|NCT06260657|OTHER|Histological analysis on fetal ethmoids|Immunohistological analysis (immunohistochemical or immunofluorescent) on fetal ethmoids
41501066|NCT01621477|DRUG|cytarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
41501067|NCT01621477|DRUG|busulfan|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
41501068|NCT01621477|DRUG|Plerixafor|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: Hematopoietic Stem Cell Mobilizer
40845010|NCT02728297|PROCEDURE|Staged ETS|Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
40845011|NCT05350189|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|At discretion of attending physician
41365776|NCT04717505|OTHER|Arthritis Impact Measurement Scales 2|It is a multidimensional, disease-specific, self-administered questionnaire designed to measure health status outcomes in patients with arthritis.
41365777|NCT04717505|OTHER|Visual Analogue Scale|The Visual Analogue Scale is a reliable and easily applicable scale used to measure the pain intensity of patients, accepted in the world literature.
41028071|NCT02984540|OTHER|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
41028072|NCT02984540|OTHER|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to \<40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
41365778|NCT04717505|OTHER|Standardized Mini Mental Test|Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.
41365779|NCT03853993|BIOLOGICAL|Quadrivalent influenza vaccine|Received single dose QIV (15µg/0.5ml)
41365780|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)
41365781|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)
41365782|NCT02832986|OTHER|Medical Questionary|"The medical questionary will contain :~* Date of initial infection by Herpes zoster~* Localisation~* Severity~* Presence of postherpetic pain~* Postherpetic pain Intensity~* Postherpetic pain duration~* Antiviral treatment~* History of chronic pathologies~* Concomitant treatment"
41365783|NCT02643420|DRUG|SPI-2012|Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
41365784|NCT02643420|DRUG|Pegfilgrastim|Single-dose subcutaneous injection administered on Day 2 of each cycle
41365785|NCT02643420|DRUG|Docetaxel|Standard therapy
41365786|NCT02643420|DRUG|Cyclophosphamide|Standard therapy
41365787|NCT05663749|DRUG|Metformin|1000mg for 8 weeks
41365788|NCT05663749|DRUG|Topiramate|50mg for 8 weeks
41365789|NCT06240468|OTHER|not have|not have
41365790|NCT04665492|DIAGNOSTIC_TEST|EEG recording 1|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). EEG device usbamp (company Guger Technologies, Austria) will be used."
41365791|NCT04665492|DIAGNOSTIC_TEST|EEG recording 2|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). This intervention will take place six month after EEG recording 1. EEG device usbamp (company Guger Technologies, Austria) will be used."
41365792|NCT04665492|DIAGNOSTIC_TEST|Sensory Test|Test for mechanical sensations of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. Semmes-Weinstein Monofilaments will be used
41365793|NCT04665492|DIAGNOSTIC_TEST|Brief Pain Inventory 1|This questionnaire that ask about any acute or chronic pain
41365794|NCT04665492|DIAGNOSTIC_TEST|Multidimensional health locus of control|Questionnaire that test personal belief about control of one's own health
41365795|NCT04665492|DIAGNOSTIC_TEST|Sensory test thermal|"Test of thermal sensations (thermal roller) of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. A Somedic SenseLab Rolltemp device will be used"
41501069|NCT01621477|DRUG|cyclophosphamide|Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
41161336|NCT03545321|BEHAVIORAL|MOON+|MOON+ is an intervention to support the pharmacy and pharmacist to improve opioid safety and naloxone provision. Materials include educational trainings, materials for use with pharmacists, information for patients, and materials for standardizing overdose safety at the pharmacy
41365796|NCT04665492|DIAGNOSTIC_TEST|Neuropathic pain symptoms|Questionnaire that test for neuropathic pain symptoms
41365797|NCT04665492|DIAGNOSTIC_TEST|McGill pain questionnaire|Questionnaire assess three separate components of experiencing pain; the sensory intensity, the emotional impact and the cognitive evaluation of pain.
41365798|NCT04665492|DIAGNOSTIC_TEST|Pain Catastrophising Scale|Questionnaire use to identify individual pain experience.
41365799|NCT06514170|OTHER|No intervention|No intervention
40845012|NCT03585049|OTHER|Vaginal swabs|The protocol includes the secondary use of vaginal swabs that are primarily used for routine diagnostic assessment in a vulvovaginal clinic
41028073|NCT03203213|PROCEDURE|Sampling of a few drops of blood, lock of hair and urine|Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
41028074|NCT01224262|BIOLOGICAL|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)|A single vaccination of Fluzone alone
41028075|NCT01224262|BIOLOGICAL|LIQ001 (0.45mg)|A single vaccination of 0.45 mg LIQ001
41161337|NCT02865759|BEHAVIORAL|Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
41365800|NCT03831282|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
41365801|NCT05151952|RADIATION|Other: Registry|Registry of cancer patients who receive proton radiation therapy.
41365802|NCT04759001|BIOLOGICAL|Donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
41365803|NCT04759001|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
41365804|NCT05515887|DRUG|Shenqu Xiaoshi Oral liquid|The dosage was determined by age: 3-4 years old, 5 ml/dose; 5-14 years old 10 ml/dose. Taken half an hour after meals, three times a day.
41501070|NCT01621477|DRUG|antithymocyte globulin (rabbit)|Given on Day -4, Day -3, Day -2, and Day -1 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
41501071|NCT01621477|BIOLOGICAL|stem cells|Patients undergo T cell replete Hematopoietic stem cell infusion on Day 0 and Day +1. Patients undergo natural killer (NK) cell transplantation on day +6 (Day 0 is first stem cell infusion).
41501072|NCT01621477|DRUG|Tacrolimus|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
41501073|NCT01621477|DRUG|mycophenolate mofetil|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
41501074|NCT02969174|OTHER|zimin Lu,Guo Sa|chengzhong Liu
41501075|NCT05314816|DIAGNOSTIC_TEST|Blood culture identification panel|multiplex PCR panel to be performed on positive blood cultures
40845013|NCT04528056|DRUG|Sulfasalazine|Sulfasalazine is an anti-inflammatory and immunosuppressive drug
40845014|NCT04528056|DRUG|Ambrisentan|Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
40845015|NCT04528056|DRUG|Sulfasalazine's placebo|Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
40845016|NCT04528056|DRUG|Ambrisentan's placebo|Ambrisentan's placebo is similar to Ambrisentan in form and dosage
40845017|NCT01796821|DRUG|Vehicle gel|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
41028076|NCT01224262|BIOLOGICAL|LIQ001 (1.8mg)|A single vaccination of 1.8 mg LIQ001
41028077|NCT04552782|BEHAVIORAL|Alcohol CBM|Trains approach or avoidance responses to alcohol cues.
41161338|NCT00514813|DRUG|Dynepo|Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject
41028078|NCT04552782|BEHAVIORAL|PTSD CBM|Trains approach or avoidance responses to trauma cues.
41028079|NCT04552782|BEHAVIORAL|Alcohol Sham|Will not train approach or avoidance responses.
41161339|NCT04145609|BEHAVIORAL|Multidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic|Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach
41161340|NCT03719118|GENETIC|genotyping for three genes (TPMT, NUDT15 and FTO)|Patients who carry any heterozygotic variants receive 50 mg AZA or 25 mg 6-mercaptopurine (6-MP), while those who have any homozygotic variants are recommended to take other alternative drugs instead of thiopurines
41161341|NCT03719118|OTHER|non-genotyping|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping. Conventional regimen starts with 50 mg of AZA, then the dose is increased by 25 mg in every 1-2 weeks to 2.0-2.5 mg/kg along with regular monitoring of general blood tests including WBC counts.
41161342|NCT04568356|DIAGNOSTIC_TEST|Direct Antigen Tests for COVID-19|Rapid Antigen diagnostic device performance comparative to RT-PCR
41161343|NCT04194541|DEVICE|Cutimed Sorbact Hydroactive B wound dressing|Wound dressing applied and changed as needed.
41161344|NCT04194541|DEVICE|Cutimed Siltect wound dressing|Wound dressing applied and changed as needed.
41365805|NCT01011959|BIOLOGICAL|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
41501076|NCT06348706|DRUG|Dipeptidyl peptidase 4 (DPP-4) inhibitor|Intervention group received Dipeptidyl peptidase-4 (DPP-4) inhibitors supplementation in a dose of 50 mg with main meal for 6 months.
41501077|NCT01794897|DRUG|Experimental: Valacyclovir treatment|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
41501078|NCT01794897|DRUG|Placebo comparator|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
41501079|NCT02368951|DRUG|BAY1187982|A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
41501080|NCT05263310|BEHAVIORAL|Prepare for Your Diabetes Care|Educational video and Action Plan handout
41501081|NCT05263310|BEHAVIORAL|Usual Care|Control arm patients will continue with usual care
41365806|NCT04745052|OTHER|Clinical observation index|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
41365807|NCT03051906|BIOLOGICAL|Durvalumab|Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).
41365808|NCT03051906|BIOLOGICAL|Cetuximab|Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.
41365809|NCT03051906|RADIATION|Intensity modulated radiation therapy (IMRT)|A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
41365810|NCT00960869|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
41365811|NCT00960869|DRUG|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
41365812|NCT01061762|BEHAVIORAL|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
41365813|NCT01061762|BEHAVIORAL|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
41365814|NCT01061762|BEHAVIORAL|Health Counseling|3-session of health improvement counseling to serve as an attention control.
41365815|NCT03373916|BEHAVIORAL|Peer mentorship|The peer mentor will meet with the participant for the first time while the participant is still in the hospital. Sessions will be scheduled according to the participant's preferences, with a suggested maximum frequency of twice weekly for the first two weeks, weekly for weeks 3 to 8, and then every other week for the last month. Allowable meeting locations include public places in the community (e.g., coffee shop, park), the participant's home, or a research clinic space or by phone. Session content is flexible and allows for the peer mentor to provide general supportive listening, validation, and sharing. Session duration is on average 1 hour with at least 15 minutes discussing hope or belongingness according to semi-structured conversation guides. The session structure and content are intentionally highly flexible to allow for genuineness in the peer relationship, thereby increasing acceptability and implicit belongingness.
41028080|NCT04552782|BEHAVIORAL|PTSD Sham|Will not train approach or avoidance responses.
41028081|NCT03011216|BEHAVIORAL|Adaptive emotional cognitive control training|Is supposed to train ability to continuously update emotional material in working memory.
41365816|NCT03373916|BEHAVIORAL|Enhanced Usual Care|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
41028082|NCT03011216|BEHAVIORAL|Adaptive non-emotional feature match task|Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
41365817|NCT02185729|DRUG|Intralipid|Infusion of Intralipid (soybean-derived fat)
41365818|NCT02185729|DRUG|ClinOleic|Infusion of ClinOleic (olive oil-based)
41365819|NCT02185729|DRUG|Dextrose|Infusion of dextrose (sugar) without fat
41365820|NCT02185729|OTHER|Saline (control)|Infusion of 0.9% normal saline
41365821|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
41365822|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
41365823|NCT01189201|DRUG|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
41365824|NCT01189201|DRUG|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
41365825|NCT00561262|OTHER|questionnaire administration|
41365826|NCT00561262|PROCEDURE|high-intensity focused ultrasound ablation|
41365827|NCT00561262|PROCEDURE|quality-of-life assessment|
41365828|NCT00976521|DRUG|Abciximab local infusion|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
41365829|NCT00976521|OTHER|No local infusion|Intervention without local infusion
41501082|NCT06532851|OTHER|Progressive Resistance Exercise (PRE)|A structured exercise regimen focusing on increasing muscular strength and endurance through progressive resistance.
41028083|NCT06536309|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titrated to maximally targeted dose
41028084|NCT06536309|DRUG|Valsartan|Valsartan titrated to maximally targeted dose
41028085|NCT06425393|DIAGNOSTIC_TEST|Urea beath test (UBT)|H. pylori infection will be tested using a 13C-urea breath test Kit for all enrolled family members, following the manufacturer's instructions. The sensitivity and specificity of the assay are both over 95%, according to the manufacturer's introduction.
41365830|NCT00976521|PROCEDURE|Thrombus aspiration|Thrombus aspiration
41028086|NCT00795600|DRUG|insulin detemir|Insulin detemir once daily plus insulin aspart at mealtime
41028087|NCT00795600|DRUG|insulin NPH|Insulin NPH once daily plus insulin aspart at mealtime
41365831|NCT03350763|DEVICE|Tannenbaum 10 Fr biliary stent|Tannenbaum 10 Fr biliary stent
41365832|NCT03350763|DEVICE|Self-expandable metallic biliary stent|ie WallFlex biliary RX
41365833|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 66%33%|Salt substitute composed of 66% potassium chloride and 33% sodium chloride
41501083|NCT06532851|OTHER|Aerobic Exercise|An exercise program focusing on cardiovascular conditioning using a stationary bike.
41501084|NCT06532851|OTHER|Control|A set of general strength and balance exercises that do not target the specific therapeutic goals of the other interventions.
41365834|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 33%/66%|Salt substitute composed of 33% potassium chloride and 66% sodium chloride
41365835|NCT04308668|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
41365836|NCT04308668|OTHER|Placebo|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
41365837|NCT03751462|DEVICE|Purkinjemeter|The Purkinjemeter will be used for assessment of IOL wobbling, tilt and decentration in patients with pseudoexfoliation syndrome or traumatic cataract
41365838|NCT00630760|DRUG|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
41365839|NCT00185146|DRUG|Pactimibe|
41028088|NCT05422911|DRUG|Abiraterone acetate|YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
41028089|NCT05422911|DRUG|Apalutamide|Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
41028090|NCT05422911|DRUG|Enzalutamide|Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
41028091|NCT03934502|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).
41028092|NCT01318889|DRUG|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
41028093|NCT03571061|PROCEDURE|whole colon water immersion and sigmoid water immersion|we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
41365840|NCT02348710|BEHAVIORAL|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
41365841|NCT02348710|BEHAVIORAL|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
41501085|NCT06246799|DRUG|Tirzepatide|Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.
41365842|NCT01785342|OTHER|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
41501086|NCT06246799|DRUG|Pioglitazone|Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.
41501087|NCT06246799|DRUG|Sitagliptin|Sitagliptin: will be administered as a 100mg dose once daily.
41501088|NCT06246799|DRUG|Metformin HCI XR|Metformin will be administered at a dose of 1000mg for the first 4 weeks and then the dose increased to 2000mg.
41501089|NCT03518801|BEHAVIORAL|Prolonged Exposure|psychotherapy
41501090|NCT03518801|DRUG|Cannabidiol|active medication
41501091|NCT03518801|DRUG|placebo|non-active medication
41028094|NCT03942718|OTHER|Exercise|Participants will obtain an individualized exercise program based on entrance examination on treadmill.
41028095|NCT03783923|DRUG|Deflazacort|Deflazacort tablet will be administered as per the dose and schedule specified in the arm.
41028096|NCT04991753|OTHER|Placebo|Placebo infusion will be administered intravenously.
41028097|NCT04991753|DRUG|Nipocalimab|Nipocalimab infusions will be administered intravenously.
41028098|NCT02157558|DRUG|Fexofenadine|All subjects will receive 180 mg fexofenadine
41028099|NCT02157558|DRUG|Telotristat etiprate|All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
41028100|NCT01477034|DIETARY_SUPPLEMENT|Vitamin D3|2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
41365843|NCT00715052|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
41365844|NCT00243477|DRUG|Escitalopram|Escitalopram 10mg or placebo once a day
41365845|NCT01917396|DRUG|Fleet enema|
41365846|NCT05782660|OTHER|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
41365847|NCT05782660|OTHER|No Cash Benefit|No monthly cash benefit.
41365848|NCT02600559|DRUG|OTO-201 (ciprofloxacin)|
41365849|NCT04656262|DRUG|Cyclophosphamide|Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
41365850|NCT04656262|DRUG|Doxorubicin|Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
41501092|NCT03696225|BEHAVIORAL|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
40845018|NCT01796821|DRUG|SR-T100 gel with 1.0 % SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
40845019|NCT01796821|DRUG|SR-T100 gel with 2.3% SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
40845020|NCT01202058|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|"Design Original Protocol~Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting."
40845021|NCT01202058|DEVICE|XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
40845022|NCT05886777|BIOLOGICAL|Combination [RSVpreF+BNTb162b2]|Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
41028101|NCT00215852|DRUG|Alferon LDO|500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
41028102|NCT02866682|DRUG|Prograf|Brand Drug for the duration of the study.
41028103|NCT02866682|DRUG|Tacrolimus|Generic
41028104|NCT03418844|OTHER|Self-questionnaires of living conditions and quality of life|Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)
41161345|NCT04194541|DEVICE|Sorbion Sana multi-star wound dressing|Wound dressing applied and changed as needed.
41161346|NCT00004758|DRUG|carbamazepine|
41161347|NCT00004758|DRUG|corticotropin|
41365851|NCT05948670|DEVICE|DISC-MVP|DISC-MVP is a digital program grounded in validated psychotherapies (e.g., cognitive behavioral therapy), that enlists a relational agent (Woebot) to engage users in therapeutic conversations and generates responses through a controlled process using large language models.
41161348|NCT00004758|DRUG|nitrazepam|
41161349|NCT00004758|DRUG|pyridoxine|
41365852|NCT05948670|DEVICE|DISC-CON|DISC-CON is a digital program grounded in validated psychotherapies (e.g., including cognitive behavioral therapy) that uses a virtual relational agent (Woebot) to engage users in therapeutic conversations with responses that are selected from a list based on natural language processing.
41365853|NCT02370173|DEVICE|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
41365854|NCT02370173|DEVICE|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
41365855|NCT05760781|DRUG|STSG-0002 Injection|Intravenous infusion
41365856|NCT05038007|DRUG|Liposomal bupivacaine|As prior described
41161350|NCT00004758|DRUG|valproic acid|
41161351|NCT00004758|PROCEDURE|Surgery|
41365857|NCT05038007|DRUG|Bupivacaine Hydrochloride|As prior described
41365858|NCT05929872|OTHER|Non-invasive brain stimulation|ACTIVE transcranial direct current stimulation( tDCS)
41365859|NCT05929872|OTHER|Sham non-invasive brain stimulation|SHAM tDCS
41365860|NCT02847364|DIETARY_SUPPLEMENT|chewing gum|The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
40845023|NCT05886777|BIOLOGICAL|Bivalent BNT162b2 (original/Omi BA.4/BA.5)|Bivalent BNT162b2 given as an intramuscular injection
40845024|NCT05886777|BIOLOGICAL|RSVpreF|RSVpreF given as an intramuscular injection
40845025|NCT05886777|BIOLOGICAL|QIV|Licensed QIV given as an intramuscular injection
40845026|NCT05886777|BIOLOGICAL|Normal Saline Placebo|Normal saline (0.9% sodium chloride solution for injection)
40845027|NCT03134339|DRUG|Nicotine saline 0.00mcg/kg/s|saline 0.00mcg/kg/s
41365861|NCT05534620|DRUG|Treosulfan|IV infusion
41365862|NCT05534620|DRUG|Fludarabine|IV infusion
40845028|NCT03134339|DRUG|Nicotine 0.24 mcg/kg/s|nicotine 0.24 mcg/kg/s
40845029|NCT03134339|DRUG|Nicotine 0.048 mcg/kg/s|nicotine 0.048 mcg/kg/s
41501093|NCT03696225|BEHAVIORAL|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
41501094|NCT00667901|DRUG|riluzole|
40845030|NCT03134339|DRUG|Nicotine 0.024 mcg/kg/s|nicotine 0.024 mcg/kg/s
40845031|NCT04087135|OTHER|direct laryngoscopy|Participants will intubate the hemoptysis cadaver model in simulation with direct laryngoscopy MacIntosh blade.
40845032|NCT04087135|OTHER|videolaryngoscopy McGrath|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade)
40845033|NCT04087135|OTHER|videolaryngoscopy McGrath with suction|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade) and a suction they will advanced directly before the optic of the camera.
40845034|NCT00375167|BEHAVIORAL|Recovery Workbook Training (psychoeducational training)|The Recovery Workbook uses an educational process to increase awareness of recovery, increase knowledge and control of the illness, increase awareness of the importance and nature of stress, enhance personal meaning, build personal support, and develop goals and plans of action. The intervention period of 30 weekly sessions recommended by Spaniol and colleagues was shortened to 12 weekly sessions to accommodate for clinical and participant commitment. No workbook content was excluded, and all practice exercises were covered.
40845035|NCT00375167|BEHAVIORAL|ACT as usual|Assertive Community Treatment services provided as per established and evidence-based fidelity standards.
40845036|NCT00003775|DRUG|leflunomide|
40845037|NCT01474070|DEVICE|Intraocular Pressure Measurement|Intraocular pressure is measured with GAT and with DCT
40845038|NCT05600582|BIOLOGICAL|CodaLytic|CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009
40845039|NCT01918332|DRUG|Valsartan 160mg|
40845040|NCT01918332|DRUG|Rosuvastatin 20mg|
40845041|NCT01918332|DRUG|Valsartan 160mg placebo|
40845042|NCT01918332|DRUG|Rosuvastatin 20mg placebo|
41365863|NCT01461187|OTHER|exercise during pregnancy|supervised aerobic physical exercises twice a week.
41365864|NCT01884142|OTHER|Aerobic Exercise Training|
41365865|NCT02933333|BIOLOGICAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
41365866|NCT02933333|BIOLOGICAL|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
41501095|NCT00667901|GENETIC|protein expression analysis|
41501096|NCT00667901|GENETIC|reverse transcriptase-polymerase chain reaction|
41501097|NCT00667901|GENETIC|western blotting|
41501098|NCT00667901|OTHER|immunohistochemistry staining method|
41501099|NCT00667901|OTHER|laboratory biomarker analysis|
41501100|NCT00667901|OTHER|pharmacological study|
41501101|NCT00667901|PROCEDURE|neoadjuvant therapy|
41501102|NCT00667901|PROCEDURE|therapeutic conventional surgery|
40845043|NCT02300519|OTHER|blood sampling|Samplings will be taken on 4 citrated S-monovette tubes, 3 citrated tubes and 1 EDTA tube, namely 36.5 ml for each volunteer
40845044|NCT03051919|OTHER|observation|
40845045|NCT05727514|OTHER|music composition|4-session music composition program for participants lead by a composer-mentor, includes optional viewing of online string quartet performances of final musical scores
41028105|NCT03418844|DIAGNOSTIC_TEST|Cardiac, pulmonary, auditory and biological assessment|"Patients will perform :~* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~* Blood tests"
41365867|NCT02933333|BIOLOGICAL|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
41028106|NCT01808313|DRUG|ambrisentan|Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
41028107|NCT01916018|OTHER|Clinical and radiologic exams and blood samples|
41365868|NCT00003410|DRUG|motexafin gadolinium|
41365869|NCT00003410|PROCEDURE|magnetic resonance imaging|
41365870|NCT00003410|PROCEDURE|surgical procedure|
41501103|NCT00006630|DRUG|Vaccinia Immune Globulin (Human)|
41501104|NCT04272749|BEHAVIORAL|Assess opinons on the milk beverages|Questionnaires and consumption behaviors of dairy and non-dairy milks, including whole, 2% fat, 1% fat, skim, unsweetened almond, sweetened almond, unsweetened coconut, sweetened coconut, unsweetened soy, sweetened soy, unsweetened rice, and sweetened rice.....
40845046|NCT03683888|BEHAVIORAL|HealthSnap|HealthSnap provides personalized lifestyle reports and track progress over time using an electronic lifestyle record (ELR). HealthSnap Assessment is a simple, quick and not invasive tool that uses an algorithm that includes a questionnaire, physical measurements, dietary data and body fat indices
40845047|NCT03683888|BEHAVIORAL|dietary counseling|Dietary counseling by RD. Low Calorie and/or Low Carb dietary plans will be discussed and provided to the study participant
40845048|NCT02974049|DRUG|Albendazole|"Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole"
40845049|NCT02974049|DRUG|Ivermectin|Subjects in Arms 1 and 4 will receive 200mg/kg body weight
40845050|NCT02974049|DRUG|Diethylcarbamazine|Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
41365871|NCT03881072|OTHER|Ultrasounicelastography|Observing the correlation between endometrial elasticity score, endometrial blood flow index (PI, RI, S/D, endometrial thickness, morphology) and clinical pregnancy rate.
41365872|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-single dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only
40845053|NCT01046214|DRUG|Bupropion HCl|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
41028108|NCT04145752|PROCEDURE|Nurse-led femoral nerve block|The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)
41028109|NCT00581529|RADIATION|IMRT|Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
41028110|NCT02796326|DEVICE|improved tracheal balloon dilatation|Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
41365873|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-multiple dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks
40845054|NCT01046214|DRUG|Bupropion HCl|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
40845055|NCT06583785|OTHER|Black rice (Intervention)|210 g of cooked black rice
40845056|NCT06583785|OTHER|Brown rice (Control)|210 g of cooked brown rice
40845057|NCT01909765|OTHER|Dorsal slit|Skin and mucosa incision made together
40845058|NCT01909765|OTHER|Double incision|Skin and mucosa incision made separately
40845059|NCT06228859|PROCEDURE|overdentures with different attachments|different types of overdenture attachments in relation to retention, bite force, and periimplant tissue health.
41365874|NCT01390376|DRUG|DAAOI-1|DAAOI-1 1g
41365875|NCT01390376|DRUG|DAAOI-1|DAAOI-1 2g
41365876|NCT01390376|DRUG|placebo|starch pill
41365877|NCT01657773|OTHER|Ultrasound examination and Colonoscopy examination|
41365878|NCT02147132|DRUG|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
41365879|NCT02147132|DRUG|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
41365880|NCT02147132|DRUG|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
40845060|NCT00498355|DRUG|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
40845061|NCT03761069|DRUG|PTC299|PTC299 will be administered per the treatment arm description
40845062|NCT03973762|DEVICE|DR Grading with CAD|A CAD system is used to make DR grading.
40845063|NCT03973762|OTHER|DR Grading by expert panel|DR Grading by expert panel
40845064|NCT01567995|DRUG|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
40845065|NCT01567995|DRUG|Vehicle (base cream)|Vehicle (base cream)
40845066|NCT05597618|OTHER|Training Program to be Developed for Empowering New Graduated Nurses|"The training program, which will be prepared based on structural and psychological empowerment theories, will consist of two parts: face-to-face theoretical training and online training.~1. Theoretical Education Part In the theoretical part, empowerment based on structural and psychological empowerment theories, effective communication, problem-solving and decision-making, time management, stress management, and nursing legislation will occur. In addition, the subject related to the institution's promotion (organizational chart, vision, mission, values, etc.) will be included.~2. Online Education Part In the online part; Videos of theoretical education subjects, institutional information, and documents (institutional instructions and procedures, institution vision-mission-values, management chart, etc.), nursing-related legislation (nursing law, nursing regulation), nursing ethical codes and case studies of sample subjects are included."
40845067|NCT06143033|OTHER|DIME Beauty Luminosity Eye Serum|Test product contains: Water/Aqua, Organic Aloe Vera Juice, Lycium Barbarum (Goji Berry) Fruit Extract, Vitis Vinifera (Grape Seed) Extract, Cucumis Sativus (Cucumber) Extract, Glycerin, Niacinamide, Squalane, Camellia Seed Oil, DL-Panthenol (Vitamin B5), Carbomer, Sodium Hyaluronate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Phenoxyethenol, Caprylyl Glycol, Acacia Senegal Gum, Caffeine, Helianthus Annuus (Sunflower) Seed Oil, Malus Domestica (Apple) Fruit Stem Cell Extract, Argania Spinosa (Argan) Sprout Stem Cell Extract, Tetrahexyldecyl Ascorbate (Vitamin C), Acetyl Tetrapeptide, Acetyl Hexapeptide-8, Vitamin E Mixed Tocopherols, Sodium Hydroxide.
40845068|NCT03410121|DEVICE|IPolysite ® Mini série 3108 or Polysite ® Standard, série 4108.|Implantation of intravenous medical device in thoracic location
40845069|NCT03410121|DEVICE|Vital Port®Minititanium|Implantation of intravenous medical device in humeral location
40845070|NCT00644111|DRUG|Bupivicaine, Hydromorphone|0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
40845071|NCT00644111|DRUG|Saline Placebo|Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
41028111|NCT01343082|DRUG|DE-111 ophthalmic solution|
41028112|NCT04937374|OTHER|Rehmannia glutinosa leaf extract|One capsule to be taken after breakfast.
41028113|NCT04937374|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken after breakfast.
41365881|NCT02147132|DRUG|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
41365882|NCT05631158|DIAGNOSTIC_TEST|MRI|"The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires.~All the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan.~For future proving the value of our study, we will also collect and store blood samples at the initial visit."
41365883|NCT01494753|DRUG|T2345|One drop at 8.00pm.
41365884|NCT01494753|DRUG|Prostaglandin|One drop at 8.00pm.
41365885|NCT06212973|DRUG|Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln|Epinastine Hydrochloride Eye Drops + Simulating Azelastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
41365886|NCT06212973|DRUG|Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln|Azelastine Hydrochloride Eye Drops + Simulating Epinastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
41365887|NCT01710839|DRUG|0.5mg Ranibizumab|intravitreal injections
41365888|NCT01710839|PROCEDURE|Targeted Pan Retinal Photocoagulation|Targeted Pan Retinal Photocoagulation based on wide field angiography
41365889|NCT00103831|DRUG|Oral Taxane|
41365890|NCT01698749|DRUG|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
41365891|NCT03062852|DEVICE|Medication safety vest|"The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention."
41365892|NCT04805892|DIAGNOSTIC_TEST|BIOZEK COVID-19 Antigen Rapid Test|The BIOZEK COVID-19 Antigen Rapid Test is used for the detection of SARS-CoV-2 antigens in nasopharyngeal swab specimens from individuals who are suspected of having COVID-19.
41365893|NCT01539616|DRUG|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
41365894|NCT01539616|DRUG|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
41365895|NCT01539616|DRUG|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
41365896|NCT01539616|DRUG|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
41501105|NCT02875964|DEVICE|electroencephalogram|Implanting electrode to measure brain activity
41501106|NCT02875964|DEVICE|magnetoencephalogram|Implanting electrode to measure brain activity
41028114|NCT06173219|COMBINATION_PRODUCT|Radiotherapy combined with immunotherapy|(1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
41365897|NCT03541616|DEVICE|ECG Patch, pocket ECG monitor|Two consecutive 14-day ECG monitor patches or one single 28-day pocket ECG monitor (28-days total monitoring) implemented at the time of hospital discharge .
41365898|NCT01211795|DRUG|topical intraoral ketoprofen gel|20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
41501107|NCT00900198|PROCEDURE|Biopsy|Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
41365899|NCT01211795|OTHER|Placebo Gel|An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
41365900|NCT05782738|PROCEDURE|Percutaneous Coronary Intervention|Use dedicated two stents technique for treatment of coronary bifurcation stenosis
41365901|NCT02442427|DRUG|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
41365902|NCT02442427|OTHER|Placebo|An equal volume of 0.9% normal saline
41365903|NCT03326882|DEVICE|Endotracheal intubation|
41365904|NCT00504816|DRUG|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
41365905|NCT00504816|DRUG|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
41365906|NCT02118909|DRUG|Pracinostat|
41501108|NCT06437574|DRUG|Vytorin|Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.
41501109|NCT06437574|DRUG|Ezetimibe|Ezetimibe is a drug that targets one of the primary sources of cholesterol, absorption in the gut.
41501110|NCT06633913|DEVICE|spTMS-TBS-spTMS|This study uses fMRI in combination with single-pulse TMS (spTMS) and theta-burst stimulation (TBS) to determine if the two effects coming from each are related to one another, and if there will be changes in brain activity when undergoing spTMS that are induced by TBS. Additionally, by stimulating the dlPFC in both patients and healthy controls with this paradigm, researchers are able to specifically compare the after-TBS single-pulse TMS-evoked brain responses with before-TBS responses to observe if TBS will change neural pathways disrupted in those who display high negative affect (e.g. depression, anxiety).
41501111|NCT01449812|BIOLOGICAL|Infanrix+Hib™|Intramuscular, one dose
41501112|NCT01449812|BIOLOGICAL|Poliorix™|Intramuscular, one dose
40845072|NCT04858282|OTHER|mobile application (BC-SDM)|"The mobile application (BC-SDM)includes four functions to support SDM activity: Understanding breast cancer, Surgical approach, Choose the right breast cancer knowledge, and Let's make a decision for myself. Patients first read the information in Understanding breast cancer and Surgical approach to receive a tailored education in breast cancer"
40845073|NCT03570320|OTHER|Modification of opioid prescription method|Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
40845074|NCT04231916|DEVICE|Thermal imaging device|
41028115|NCT00612612|DRUG|obatoclax mesylate|Given IV
41028116|NCT00612612|DRUG|fludarabine phosphate|Given IV
41028117|NCT00612612|BIOLOGICAL|rituximab|Given IV
41365907|NCT02118909|DRUG|Itraconazole|
41028118|NCT00612612|OTHER|laboratory biomarker analysis|Correlative study
41028119|NCT01428960|DIETARY_SUPPLEMENT|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
41028120|NCT01470755|DRUG|salbutamol|Metered dose inhaler, 100µg+300µg per puff, administered one day
41028121|NCT01470755|DRUG|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
41028122|NCT01470755|DRUG|Salbutamol -dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
41365908|NCT02118909|DRUG|Ciprofloxacin|
41365909|NCT00706901|BEHAVIORAL|Arm 1 GMI|Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller \& Rollnick 2013) and based on a manualized protocol (Martino \& Santa Ana 2013; Santa Ana \& Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.
41365910|NCT00706901|BEHAVIORAL|Arm 2 IHMD|Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.
41365911|NCT00706901|BEHAVIORAL|Arm 3 TCC|TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
41365912|NCT01773460|DRUG|Everolimus|Everolimus is given beyond progress (comparison with placebo)
41365913|NCT01773460|DRUG|Everolimus-placebo|Everolimus-placebo
41365914|NCT00976989|DRUG|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
40845075|NCT03135938|PROCEDURE|Grading Inferior Oblique Anterior Transposition surgery|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes.
40845076|NCT03135938|PROCEDURE|Classic Inferior Oblique Anterior Transposition surgery|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
41365915|NCT00976989|DRUG|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
40845077|NCT02929238|OTHER|Polypropylene Suture Right Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
40845078|NCT02929238|OTHER|Polypropylene Suture Left Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
40845079|NCT01791101|DRUG|Eltrombopag|
40845080|NCT01616251|OTHER|Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake|4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
41028123|NCT01470755|DRUG|salbutamol -dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
41028124|NCT02291718|DRUG|Isovue|iodine contrast
41028125|NCT00518024|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
41028126|NCT04652700|DRUG|ISL|ISL 60 mg tablet, QM, orally for up to 24 months
41028127|NCT04652700|DRUG|FTC/TDF|Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months
41365916|NCT00976989|DRUG|FEC|5-fluorouracil 500 mg/m\^2, epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2.
41365917|NCT00976989|DRUG|Docetaxel|75 mg/m\^2 for the first dose; 100 mg/m\^2 if no dose limiting toxicity occurs.
41365918|NCT00976989|DRUG|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m\^2. All treatments were given every three weeks by the IV route.
40845081|NCT00991406|DEVICE|FES|Surface stimulation to contract the muscles in the lower extremity
40845082|NCT04928560|DIAGNOSTIC_TEST|SMI|ULTRASOUND
40845083|NCT05836467|PROCEDURE|Valvular interventions|Any kind of intervention on heart valves
41028128|NCT04652700|DRUG|FTC/TAF|Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months
41028129|NCT04652700|DRUG|Placebo to ISL|Placebo ISL 0 mg tablets QM, orally for up to 24 months.
41028130|NCT04652700|DRUG|Placebo to FTC/TDF|Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months
41028131|NCT04652700|DRUG|Placebo to FTC/TAF|Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
41028132|NCT00045994|DRUG|ALT-711|
41028133|NCT03818217|DEVICE|Coach Pepper group|"Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training ."
41028134|NCT03818217|DEVICE|Tablet group|The Tablet provides a theratainment app including cognitive and physical training.
41028135|NCT05045521|OTHER|plyometric warm up group|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 \* 8 squat jumps, 2 \* 8 scissor jumps, and 2 \* 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos."
41365919|NCT01917149|DRUG|Benazepril|
41365920|NCT01917149|DRUG|Valsartan|
41365921|NCT01917149|DRUG|Metoprolol|
41365922|NCT02120274|DRUG|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
40845084|NCT04969692|PROCEDURE|warming to increase local skin (puncture site) temperature|According to the group of participants, investigator applies the warmer to the hands and wrists of the participants, makes a local temperature of 40℃ gradually, and maintains it for about 10 minutes in warming group (which is divided in to warming-palpation (WP) and warming-US (WU) group).
41365923|NCT02120274|DRUG|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
40845085|NCT01297582|DRUG|ONO-6950|1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
41365924|NCT05105958|DRUG|Tideglusib|1000 mg/day per os
40845086|NCT01297582|DRUG|ONO-6950|1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
40845087|NCT00293995|PROCEDURE|Repair of unilateral inguinal hernia|
40845088|NCT03968263|DEVICE|Hycon device(Routine protocol)|Hycon device will be activated half a turn every 3 days.
40845089|NCT03968263|DEVICE|Hycon device(Modified protocol)|The activation period of the hycon device will be modified.
40845090|NCT03968263|DEVICE|Hycon device(Routine protocol) and Vibration(Acceledent)|Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
40845091|NCT03968263|DEVICE|Hycon device(Modified protocol) and Vibration(Acceledent)|The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
40845092|NCT00867906|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
40845093|NCT00867906|BIOLOGICAL|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
40845094|NCT00911339|DRUG|Atorvastatin|Atorvastatin 10 mg associated with stent genous
40845095|NCT00911339|DRUG|Atorvastatin|Atorvastatin 80 mg associated with stent genous
40845096|NCT00804934|DRUG|Lucentis|0.5mg Lucentis every four months
40845097|NCT02567994|DRUG|Teneligliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
40845098|NCT02300740|DIETARY_SUPPLEMENT|Nicotinamide riboside|NIAGEN, ChromaDex
40845099|NCT02690441|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
40845100|NCT02690441|BEHAVIORAL|Physical Exercise|Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
40845101|NCT02690441|BEHAVIORAL|Placebo control|One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
40845102|NCT02345096|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae|
40845103|NCT02345096|DIETARY_SUPPLEMENT|Placebo|
40845104|NCT02130505|DIETARY_SUPPLEMENT|OGTT|Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
40845105|NCT01174394|PROCEDURE|DCEAS (Hwato®/ Dongbang®)|Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.
40845106|NCT01174394|PROCEDURE|Body electro-acupuncture (Hwato®/ Dongbang®)|Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
40845107|NCT01174394|PROCEDURE|n-CEA (Strietberger®)|Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion
40845108|NCT01174394|DRUG|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
40845109|NCT06398717|PROCEDURE|adductor canal block|"group C will receive a unilateral adductor canal block alone, using an ultrasound to identify the location of the nerve.~group H will receive unilateral peri-hamstring injection combined to adductor canal block, After the adductor canal block, the transducer will be moved posteriorly till identifying the site of injection group O will receive unilateral anterior obturator nerve block combined with adductor canal block, The anterior branch of the obturator nerve is located using ultrasound"
40845110|NCT02670967|DIETARY_SUPPLEMENT|Soluble Fibre|
41365925|NCT02628184|OTHER|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
40845111|NCT02299284|OTHER|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|
40845112|NCT04888013|OTHER|Positive Birth Environment|The intent is to surround the woman and her caregivers with specific types of auditory, visual, and tactile stim uli. One key feature of the ambient room is what is missing-the standard hospital bed. As an alternative, a portable double-sized mattress with several large pillows is set up in a corner of the room. The intent is to allow the woman freedom in positioning and to permit close contact with support people, and to limit the routine use of continuous elec tronic fetal heart rate monitoring and other technologies during normal labor. Lighting is dimmed. A wide variety of music selections are also available.
40845113|NCT00718770|DRUG|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
40845114|NCT02506023|DRUG|Desmopressin|Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
40845115|NCT04088591|DRUG|Ascorbic Acid 500Mg/Ml Inj|Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours
40845116|NCT04088591|DRUG|Dextrose in Water|50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
40845117|NCT00898456|GENETIC|gene expression analysis|
40845118|NCT00898456|GENETIC|molecular genetic technique|
40845119|NCT00898456|GENETIC|polymorphism analysis|
40845120|NCT00898456|GENETIC|protein expression analysis|
40845121|NCT00898456|OTHER|diagnostic laboratory biomarker analysis|
41365926|NCT02835989|OTHER|CP@Home|Community paramedics (CPs) will be assigned to visiting the participants for a first time the week following the initial EMS call. Participants will complete the informed consent process with a CP on their first visit. This visit will also include a full assessment and risk analysis that will take approximately 90 minutes and will be located in the participant's home. As a result of the initial visit, the CP will make all relevant clinical referrals and decisions based on predetermined @Home algorithms. A second visit will be made to the participant 2-4 weeks following the initial call for a streamlined follow-up and reassessment during a 30 minute period. A final visit will be made 6-8 weeks following the initial call for a final evaluation of their situation. It is anticipated the patient will be discharged from the CP@Home program at this point. If the patient calls EMS following the third visit, if they meet the inclusion criteria, they will be re-entered into the CP@Home program.
41365927|NCT00752895|DIETARY_SUPPLEMENT|American ginseng|Given orally
41365928|NCT00752895|DIETARY_SUPPLEMENT|Placebo|Given orally
41365929|NCT03188276|DRUG|Ledipasvir-Sofosbuvir|15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
41028136|NCT05045521|OTHER|resistance warm up|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6\*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest"
41365930|NCT03188276|DRUG|Daclatasvir-Sofosbuvir|17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
41365931|NCT05404321|OTHER|Establishment of ex vivo breast cancer organoid models|This study includes 2 steps: The constitution of a collection of tumor and blood samples and the analysis of the ex vivo response of the tumor samples to the treatments for the development of functional tests and the research of predictive biomarkers of this response
41365932|NCT05745974|DIAGNOSTIC_TEST|lymphocytic count|taking blood samples and COVID-19 swab
40845122|NCT05215158|DRUG|Dexmedetomidine|to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
40845123|NCT00959556|OTHER|laboratory biomarker analysis|
40845124|NCT03615066|DRUG|Placebo|Tablet(s) administered orally every 7 days for 24 doses in fasted state
40845125|NCT03615066|DRUG|Selgantolimod|Tablet(s) administered orally every 7 days for 24 doses in fasted state
40845126|NCT03615066|DRUG|TAF|Tablet(s) administered orally once daily with food
40845127|NCT03502902|DRUG|HEC 68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
41365933|NCT04582968|OTHER|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Drug combined with radiation
41365934|NCT02935816|RADIATION|Whole body MRI|We have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. We hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men
41365935|NCT05677841|OTHER|Stabilization exercise+lifestyle recommendation|Exercise program was given both spinal stabilization exercises focusing on the pelvic floor 3 days a week for eight weeks and a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
41501113|NCT06579534|OTHER|Health education strategy|Based on the concept of precise health care, investigators design risk awareness, self-health management and fall prevention care measures, and provide inpatients with high-risk groups with frailty and falls with health education guidance on muscle endurance training and fall prevention. This study adopts purposive sampling, randomization, assignment, and parallel experiments to divide into a control group and an experimental group. The control group uses conventional health education guidance to provide fall prevention education, and the experimental group uses multimedia health education videos to provide education to patients or primary caregivers. Provide health education on the risk, management and prevention of falls.
41365936|NCT05677841|OTHER|lifestyle recommendations|The control group will be given a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
40845128|NCT03502902|DRUG|Placebo|Placebo
41028137|NCT05045521|OTHER|control warm up group|"participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6\*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests."
41365937|NCT04367142|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
41365938|NCT04367142|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
41028138|NCT05774600|BEHAVIORAL|SSW Works|SSW Works is a behavioral, culturally tailored online intervention for skin cancer prevention amongst outdoor workers in the United States.
41028139|NCT05774600|BEHAVIORAL|Minimal Information Control|Provision of online materials for skin cancer prevention.
41028140|NCT02991209|DRUG|Testosterone|
41028141|NCT02991209|DRUG|Placebos|
41365939|NCT00938743|DRUG|Atomoxetine|40-80 mg atomoxetine once daily, including titration 10 weeks
41365940|NCT05780359|DEVICE|Drug eluting stent|Sirolimus drug-eluting self-expanding stent available from 20mm to 250mm in length, 3.5mm to 7.5mm in diameter of superficial femoral and proximal popliteal arteries (SFA/PPA) cases for inhibiting in-stent restenosis and improve long-term outcome.
41365941|NCT05780359|DEVICE|drug coating balloon|A proprietary lipophilic coating technology that uses magnesium sterate as excipient, facilitates paclitaxel transfer to the vessel wall, enhances drug delivery, and brings minimal downstream effect. Available from 20mm to 300 mm in length, 3mm to 12 mm in diameter, fits every SFA cases, reduces radiation exposure time.
40845129|NCT06245538|BEHAVIORAL|Seated rest|Participants will be resting while seated on a comfortable chair for 20 minutes
40845130|NCT06245538|BEHAVIORAL|Exercise at moderate intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)
40845131|NCT06245538|BEHAVIORAL|Exercise at vigorous intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)
40845132|NCT05471557|PROCEDURE|pain delivery|Experimental pain paradigm delivered that is short-term and painful but not harmful.
41028142|NCT03971617|DRUG|Hydrogen|each hydrogen tablet contains 80mg magnesium
41028143|NCT03971617|DRUG|Placebo oral tablet|matching placebo tablet
41365942|NCT00545974|DRUG|memantine|memantine 10mg BID
41365943|NCT00545974|DRUG|Placebo pill|Placebo pill BID
41365944|NCT02136927|DRUG|SPARC1210|
41365945|NCT02136927|DRUG|Reference1210|
41365946|NCT06481215|BIOLOGICAL|GNR-068|The investigational product GNR-068 was administered as a subcutaneous injection at a single dose of 45 mg.
41365947|NCT06481215|BIOLOGICAL|Stelara®|The reference product Stelara® was administered as a subcutaneous injection at a single dose of 45 mg.
41365948|NCT05144269|OTHER|Multimodal exercises|Telehabilitation including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises
41365949|NCT00133276|DRUG|Escitalopram|OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
41365950|NCT00133276|OTHER|Placebo|
41501114|NCT02341391|BIOLOGICAL|TissueGene-C(Low dose)|3.0 x 10\^6 cells
41501115|NCT02341391|BIOLOGICAL|TissueGene-C(Medium dose)|1.0 x 10\^7 cells
41501116|NCT02341391|BIOLOGICAL|TissueGene-C(High dose)|3.0 x 10\^7 cells
40845133|NCT02849015|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
40845134|NCT02849015|BIOLOGICAL|NK immunotherapy|Natural killer cell(each treatment: about 10 billion cells transfusion in 3 times, i.v.)
40845135|NCT00095173|DRUG|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
41365951|NCT04021602|BEHAVIORAL|Diabetes Prevention Program|Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 6 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
41501117|NCT04482673|DRUG|Daily Vitamin D3|6000 IU vitamin D3 daily
41365952|NCT04021602|BEHAVIORAL|Breastfeeding Education|Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
41365953|NCT04021602|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
41501118|NCT04482673|DRUG|Daily placebo|Placebo daily
41501119|NCT04482673|DRUG|Bolus vitamin D3|Bolus 20,000 IU vitamin D3 daily for 3 days
41501120|NCT04482673|DRUG|Bolus placebo|Bolus placebo daily for 3 days
41501121|NCT02917070|OTHER|Patients|In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
41501122|NCT04595032|DEVICE|3DCRT, IMRT, VMAT, SBRT|Radiation treatment
41501123|NCT02908048|OTHER|Blood samples|Blood samples collected at varying intervals over a two to three year period.
40845136|NCT00095173|DRUG|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
40845137|NCT00095173|DRUG|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing \< 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing \> 100 kg, monthly
40845138|NCT00418574|BIOLOGICAL|Abagovomab|2 mg/ml SC (subcutaneously)
40845139|NCT00418574|BIOLOGICAL|Placebo|2 mg/ml SC (subcutaneously)
41501124|NCT00898573|DRUG|lapatinib ditosylate|
40845140|NCT05067738|OTHER|same day discharge|same day discharge
40845141|NCT00769457|DEVICE|Access Arm|Active OptiVol-System with CareAlert via CareLink
41501125|NCT00898573|GENETIC|fluorescence in situ hybridization|
41028144|NCT06047717|OTHER|Virtual Reality Driving Task|"Participants will steer a virtual car with the goal of staying in the center of a single-lane roadway while traveling at a constant speed of 26.6 m/s (approximately 60 miles/hr). The roadway alternates between a series of straights and turns of different radii to both the left and the right. This allows for careful control of task difficulty, and for the repeated presentation of specific conditions across multiple trials (i.e. turns in the road) in a randomized order. In addition, the density of the visual texture elements in the virtual environment that provide optic flow (OF) signal is also varied. The low-density OF condition has no road texture or foliage, and only the solid road edges on a flat-black ground plane. The medium-density OF condition has sparse textural elements distributed on the ground plane, and the high-density OF condition has high density road texture and a canopy of road-side trees that provide texture extending far above the horizon."
41028145|NCT02997358|DRUG|Doxorubicin|75 mg/m² Day 1 of each 3-weeks cycle
41028146|NCT02997358|DRUG|Trabectedin|150 μg/m²/day s.c From day 3 to day 9
41028147|NCT05883306|DRUG|[14C]LXI-15028|\[14C\]LXI-15028
41501126|NCT00898573|GENETIC|gene expression analysis|
41501127|NCT00898573|GENETIC|mutation analysis|
40845142|NCT04530500|GENETIC|COVID-19 Androgen Sensitivity Test (CoVAST)|The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.
41028148|NCT00123227|DRUG|Rosiglitazone|
41028149|NCT00002980|DRUG|decitabine|
41501128|NCT00898573|GENETIC|polymerase chain reaction|
41501129|NCT00898573|GENETIC|reverse transcriptase-polymerase chain reaction|
41501130|NCT00898573|OTHER|cell sorting|
41501131|NCT00898573|OTHER|immunohistochemistry staining method|
41501132|NCT00898573|OTHER|laboratory biomarker analysis|
41501133|NCT06442787|DEVICE|conventional splints|only intermediate and final splint will be used during the surgery
41501134|NCT06442787|DEVICE|cutting guides and positioning guides|patient's specific manufacturing cutting guide and positioning guide related with orthognathic surgery
41501135|NCT06442787|DEVICE|cutting guides and fixation plates|patient's specific manufacturing cutting guide and fixation plates related with orthognathic surgery
41501136|NCT01158092|DEVICE|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
41501137|NCT01158092|OTHER|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
41501138|NCT02174289|DEVICE|Targeted left ventricular endocardial lead placement|The left ventricular endocardial lead will be passed through the intra-atrial septum
41501139|NCT01028924|DRUG|Teduglutide|subcutaneous (SC), single dose
41501140|NCT03953768|DEVICE|Vagal nerve stimulation (VNS)|Implantation with vagal nerve stimulator for epilepsy
41501141|NCT01159080|DRUG|routine dose tacrolimus and less myfortic|oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day
40845143|NCT04916379|DIETARY_SUPPLEMENT|Momordica charantia|Momordica Charantia: 2000 mg per day for 12 weeks
40845144|NCT04916379|OTHER|Placebo|Placebo: 2000 mg per day for 12 weeks
40845145|NCT05371548|DEVICE|SAM mobile application|See description of intervention group
41501142|NCT01159080|DRUG|reduced dose tacrolimus and conventional myfortic|low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day
41365954|NCT06231849|DIAGNOSTIC_TEST|stool analysis|stool analysis to determine number of gut microbiota in subjects with opioid use and its effect on its intoxication.
41365955|NCT01594164|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
40845146|NCT05047146|OTHER|Morphological classifications of HCC|Morphological classifications of Hepatocellular carcinoma
40845147|NCT03605316|PROCEDURE|Deep brain stimulation (DBS)|Neurosurgical treatment by stereotactic implantation of electrodes in the brain that affects the functioning of subcortical neuronal circuits
40845148|NCT05293925|BEHAVIORAL|announcement of cessation of treatment|"The first 40 outpatients for whom an announcement to stop anti-tumour treatments is made at the Institut Curie Paris, in a conventional oncology consultation or in Palliative Care Day Hospital.~Categorical variables will be described by numbers and percentages. Quantitative variables will be described by the mean, standard deviation, median of the distribution as well as the minimum, maximum and interquartile range and compared by a Student's t test or a Wilcoxon test according to the normality of the variables."
40845149|NCT02492282|DEVICE|Closed-Loop propofol and remifentanil system by Bispectral Index|
40845150|NCT02492282|DEVICE|Open-Loop propofol and remifentanil by Target Controlled Infusion|
40845151|NCT02492282|DRUG|propofol|
40845152|NCT03216746|BEHAVIORAL|Oral orientation and App for smartphone|66 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
40845153|NCT03216746|BEHAVIORAL|Oral orientation|71 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes.
41365956|NCT01594164|RADIATION|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
40845154|NCT03216746|BEHAVIORAL|Video orientation and App for smartphone|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
40845155|NCT03216746|BEHAVIORAL|Video orientation|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes.
40845156|NCT06077890|OTHER|Digital Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be able to access home-based rehabilitation strategies through dynamic content provided by SIMPLI.REHAB digital tool.
41501143|NCT04289480|DEVICE|ENTERPRISE 2 device|The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.
41501144|NCT06052280|OTHER|Telerehabilitation exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the TrE group will continue with prescribed self-training at home through telerehabilitation, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The TrE arm will be supported by a telerehabilitation device which will be installed and tested at the patients' home immediately after the outpatient intensive program. The device will track any access and exercise duration, so that the physiotherapists will be able to remotely monitor both the actual duration of each session and their weekly frequency. One session per week will be directly and online supervised by a physiotherapist, while the other two will be recorded only."
40845157|NCT06077890|OTHER|Conventional Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be given home-based strategies in a printed paper brochure.
41365957|NCT03568968|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 500mg administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
41501145|NCT06052280|OTHER|Home self-exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the HSE group will continue with prescribed self-training at home, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The HSE arm will be given a booklet containing detailed explanations and pictures of the assigned exercises, in order to guide them in the correct execution of the requested movements. Subjects in this group will be asked to fill in a training diary to keep track of the training sessions and their duration. Once a week a physiotherapist will contact patients to discuss possible problems encountered in performing the exercises and to help in solving them."
41365958|NCT03568968|OTHER|Placebo|Placebo drug, administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
41365959|NCT03551158|DIAGNOSTIC_TEST|Echocardiography|Cardiac imaging for the assessment of the left atrium anatomy and function.
40845158|NCT02339194|PROCEDURE|Denture fabrication technique|"Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied."
40845159|NCT06137651|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40845160|NCT06137651|PROCEDURE|Computed Tomography|Undergo CT scan
40845161|NCT06137651|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40845162|NCT06137651|RADIATION|Radiation Therapy|Undergo radiation therapy
40845163|NCT06137651|PROCEDURE|Resection|Undergo surgery
41365960|NCT05210959|OTHER|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) is an instrument that assesses the quality and quantity of motor development opportunities available in the home for infants aged 3 to 18 months. In this study, the Turkish version of the AHEMD-IS were constructed. Also, the validity and reliability of this version were examined.
41365961|NCT00442741|DRUG|Patupilone|
41365962|NCT00442741|DRUG|Patupilone + Omeprazole|
40845164|NCT06137651|DRUG|Trotabresib|Given PO
40845165|NCT06137651|DRUG|Vinorelbine|Given IV
41028150|NCT06530407|OTHER|Static streching exercise|Static stretching exercises were applied to the M. Gastrocnemious and M. Hamstring muscle groups. The exercises were applied as a set, with three repetitions for 15 seconds on each leg, with a 20-second rest between repetitions. Static stretching was applied by slowly stretching the relevant muscle group to the point of sensitivity, without straining the pain threshold, and waiting in that position. All stretching exercises lasted an average of 6 minutes.
41365963|NCT05962658|OTHER|qEEG|qEEG data was collected with patients and healthy individuals in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
41365964|NCT05184868|DRUG|AT247|Ultra rapid acting prandial insulin aspart
41365965|NCT05184868|DRUG|NovoLog|Rapid acting prandial insulin aspart
41365966|NCT05184868|DRUG|Fiasp|Fast acting prandial insulin aspart
41365967|NCT01481064|BEHAVIORAL|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
41365968|NCT04799821|OTHER|Control|Participants will be asked to refrain from walnut intake and to follow an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
40845166|NCT03245983|BEHAVIORAL|Questionnaire and interview|Cancer patients will answer questionnaires and will be interviewed by a pshychologist to assess their spirituality and quality of life toward their disease
41365969|NCT04799821|OTHER|Walnut intake|Participants will be asked to consume walnuts along with an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
41365970|NCT02713490|DRUG|EXPAREL|EXPAREL and bupivacaine HCl
40845167|NCT00764673|DEVICE|3DKnee|Subjects with knee osteoarthritis and willing to participate in the study
40845168|NCT03327558|DRUG|Apriso 0.375G ER CAP|ER capsule
40845169|NCT03327558|DRUG|APRISO 375 mg extended-release capsules|375 mg extended-release capsules
40845170|NCT03465267|DEVICE|Armeo power|"Intervention with Armeo power rehabilitation robot for upper extremity (made by Hocoma), which provide assistive force.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
40845171|NCT03465267|DEVICE|Armeo spring|"Intervention with Armeo spring rehabilitation robot for upper extremity (made by Hocoma), which is operated only by participants, without any assistive force from robot.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
40845172|NCT04505579|DEVICE|Anterior Vertebral Body Tethering|Anterior Vertebral Body Tethering (AVBT) is a technique that utilizes growth modulation to remodel the shape of the vertebra and straighten scoliotic curves in skeletally immature individuals. In this technique, screws are inserted at each vertebral level for the length of the convex side of the curve. A strong cord is connected through the screw tulip heads and used to initially straighten the curve as each level is fixed with a set screw. Following surgery and during the growth period the spine begins to remodel according to the Hueter-Volkmann Law, bone growth is relatively inhibited in areas of increased pressure (convex or tethered side) and relatively stimulated in areas of decreased pressure or tension (concave side).
40845173|NCT01590654|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
40845174|NCT01590654|DRUG|Multiple Ascending Dose (MAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
40845175|NCT06433089|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block was performed before surgery
40845176|NCT00005859|DRUG|tipifarnib|
40845177|NCT00391625|DRUG|GA-GCB|15-60 U/kg every other week via intravenous infusion
40845178|NCT00395421|DRUG|NM283 plus Peg-IFNα-2a|200 mg QD 180 µg QW
40845179|NCT00771056|DRUG|Hydroxychloroquine|400mg by mouth daily x 1 year
41365971|NCT02713490|DRUG|Bupivacaine|Single dose of bupivacaine HCl 0.5%
41365972|NCT00332982|BEHAVIORAL|Focused knowledge translation strategies|
41365973|NCT03343665|DRUG|Nivolumab 40 mg in 4 ml Injection|40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
41365974|NCT01213121|DRUG|Quetiapine|oral tablet/25-600mg per day/once a day/six weeks
41365975|NCT06497816|OTHER|No intervention|No intervention
41365976|NCT03186950|PROCEDURE|Restoration with Stainless Steel Crowns|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.
41365977|NCT03186950|PROCEDURE|Restoration using BulkFill CR|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
41365978|NCT05414422|DRUG|PCN-101|Concentrate for solution for infusion
41365979|NCT05414422|DRUG|Placebo|Concentrate for solution for infusion
41365980|NCT04620005|OTHER|Observational|Survey
40845180|NCT05392036|OTHER|baseline physical therapy treatment along with shockwave therapy|Group A, this group will receive conventional therapies along with shockwave therapy. Basic treatment includes icing (15-20 min) to control inflammation, rest, cessation of pain causing activity, anti-inflammatory (NSAIDs) and basic stretching and strengthening exercises. Shockwave therapy is a non-invasive therapeutic modality with convenience, effectiveness and safety. It is used to treat various musculoskeletal disorders without surgery. A session of 30-45 min will include icing 15 min and 5-10 min of shock wave therapy session will be commenced with strengthening and stretching exercises.
40845181|NCT05392036|OTHER|baseline physical therapy treatment along with therapeutic ultrasound|"This group will receive therapeutic ultrasound along with conventional treatment. Conventional therapy includes icing, rest, anti-inflammatory drugs, and basic strengthening and stretching exercises. A session of 30-45 min will include icing for 10-15 min therapeutic ultrasound 15min with a frequency 1-3MHz and the session will be ended with strengthening and stretching exercises.~Only eligible patients who have fulfilled the inclusion criteria will be included. A daily session of 30-45min for 2 consecutive weeks will be given. A baseline assessment will be done and the patient will be allocated randomly to both groups for two weeks. Re-assessment will be done after 2 weeks. For long term, effects re-assessment will be done after 6 weeks"
40845182|NCT04167137|DRUG|SYNB1891|SYNB1891 was administered as an IT injection over a dose range of 1 x 10\^6 to 3 x 10\^8 live cells in Arm 1 and 1 x 10\^7 to 3 x 10\^7 in Arm 2.
40845183|NCT04167137|DRUG|Atezolizumab|Atezolizumab was administered in accordance with its recommended dose and schedule (1200 mg IV Q3W).
40845184|NCT02106494|DRUG|APF530|
40845185|NCT02106494|DRUG|Ondansetron|
40845186|NCT02106494|DRUG|Ondansetron placebo|
40845187|NCT02106494|DRUG|APF530 placebo|
40845188|NCT02106494|DRUG|Fosaprepitant|
41365981|NCT03748628|DRUG|EDP-305|\[14C\]EDP-305
40845189|NCT02106494|DRUG|Dexamethasone|
41365982|NCT05704829|DRUG|Trastuzumab deruxtecan|T-DXd i.v.
40845190|NCT03133923|BIOLOGICAL|≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥3.0 lgCCID50/ml but \<3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
41028151|NCT03900936|DIAGNOSTIC_TEST|Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
41028152|NCT02696850|DRUG|Budesonide|Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
41028153|NCT02696850|DRUG|Saline alone|Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
41028154|NCT01601301|DEVICE|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
41365983|NCT05704829|DRUG|Standard-of-Care|Chemotherapy+T+P
41365984|NCT04749862|OTHER|Online symptom reporting|Online symptom reporting questionnaire with linked self-management advice
41365985|NCT01617265|PROCEDURE|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
41365986|NCT01617265|PROCEDURE|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
41365987|NCT02296541|BIOLOGICAL|DNA Nat-B env|4 mg to be administered as 1 mL intramuscularly (IM) by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
41365988|NCT02296541|BIOLOGICAL|DNA CON-S env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
41365989|NCT02296541|BIOLOGICAL|DNA Mosaic env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
41365990|NCT02296541|BIOLOGICAL|MVA-CMDR|1×10\^8 plaque forming units (pfu) to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
41365991|NCT02296541|BIOLOGICAL|Placebo for DNA Nat-B env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
41365992|NCT02296541|BIOLOGICAL|Placebo for DNA CON-S env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
41365993|NCT02296541|BIOLOGICAL|Placebo for DNA Mosaic env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
41365994|NCT02296541|BIOLOGICAL|Placebo for MVA-CMDR|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
41365995|NCT01319422|DRUG|Pomalidomide|Comparison of different dosages and schedules of drug
41365996|NCT05029102|DRUG|TAS 102|35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle
41365997|NCT05029102|DRUG|Anlotinib|10mg，per oral，once daily，days 1-14 of each 21-day cycle
41365998|NCT06347458|BIOLOGICAL|BG1805|A single infusion of BG1805 Injection administered intravenously.
40845191|NCT03133923|BIOLOGICAL|≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
40845192|NCT03133923|BIOLOGICAL|Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)|Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day
41365999|NCT03077646|BEHAVIORAL|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
41366000|NCT03077646|BEHAVIORAL|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
41366001|NCT03077646|BEHAVIORAL|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
41366002|NCT05300126|BEHAVIORAL|Hypnosis|Four sessions of 15 minute hypnosis, based on standardised script, focused on symptom management for the patients and of resource development for relatives.
41366003|NCT04651660|DEVICE|Neuro Cochlear Implant System|"Before the mastoidectomy, the ear canal is cleaned, the insert earphone is connected to the Eclipse (Oticon Medical software) preamplifier and placed into the ear canal. The EEG scalp electrodes (active, ground electrode) are placed on the patient's head. After the posterior tympanotomy, the reference electrode (eCochG probe) is placed on the cochlear promontory.~The CI electrode array will be inserted following one of the two possible techniques while the eCochG will be recording. The surgeon will either manually insert the array using the Oticon Medical stylet and following the surgery guides and recommendations from Oticon Medical or will control the Robotol insertion angle and drive the robotic arm in the same way."
41366004|NCT01560806|OTHER|Commune Hypertension Management|"People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.~Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI"
41366005|NCT02226276|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
41366006|NCT02226276|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
41366007|NCT02226276|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
41366008|NCT02226276|BIOLOGICAL|trastuzumab|Given IV
41366009|NCT02226276|RADIATION|copper Cu 64-DOTA-trastuzumab|Given IV
41366010|NCT02226276|PROCEDURE|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
41501146|NCT02117700|DIETARY_SUPPLEMENT|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
41501147|NCT02117700|DIETARY_SUPPLEMENT|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
41501148|NCT02117700|OTHER|Placebo twice/day|Placebo capsules twice/day for 16 weeks
41501149|NCT05703269|RADIATION|single fraction stereotactic radiosurgery (SSRS)|SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions.
40845193|NCT01263145|DRUG|Akt Inhibitor MK2206|Given PO
40845194|NCT01263145|OTHER|Laboratory Biomarker Analysis|Correlative studies
40845195|NCT01263145|DRUG|Paclitaxel|Given IV
40845196|NCT01263145|OTHER|Pharmacological Study|Correlative studies
41501150|NCT05703269|RADIATION|fractionated stereotactic radiosurgery (FSRS)|FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions.
40845197|NCT01649024|DRUG|Tremelimumab|Given IV
40845198|NCT00866814|DEVICE|Bard Ventrio Hernia Patch|The Ventrio Hernia Patch is a self-expanding, non-absorbable, sterile prosthesis for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.
40845199|NCT06425432|DEVICE|OVITZ xwave aberrometer|wavefront aberrometer
41366011|NCT02226276|BIOLOGICAL|ado-trastuzumab emtansine|Given IV
41366012|NCT02226276|OTHER|laboratory biomarker analysis|Correlative studies
41366013|NCT04474717|DIAGNOSTIC_TEST|Breath Condensate Collection|Breath Condensate Collection
41366014|NCT04474717|DIAGNOSTIC_TEST|clinical examination, spirometry|spirometry
41366015|NCT04474717|DIAGNOSTIC_TEST|blood monocyte assay|study of blood monocytes in the laboratory of cell technology
41366016|NCT05751421|DRUG|Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution|zynrelef will be administered during surgery
41366017|NCT05751421|DRUG|Bupivacaine HCl 0.5% Injectable Solution|adductor canal block will be performed using bupivacaine before surgery
41366018|NCT05751421|PROCEDURE|primary total knee replacement|primary total knee replacement
41366019|NCT02028182|BIOLOGICAL|Lyral®|Alergen panel containing ascending doses of Lyral (0.10 mg/cm\^2, 0.20 mg/cm\^2 and 0.40 mg/cm\^2) and negative control
41501151|NCT01467986|DRUG|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
40845200|NCT04377152|DRUG|68Gallium-PSMA-11|PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET).
40845201|NCT04377152|PROCEDURE|Positron Emission Tomography (PET)|A PET scan is an imaging test that helps reveal how your tissues and organs are functioning using a radioactive drug (tracer) to show this activity
40845202|NCT05141604|OTHER|Field expansion view|Overlaid small window on HMD to show the part of the scene in the blind field into portions of the participants' remaining, seeing, field of vision
41501152|NCT01467986|DRUG|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
41366020|NCT06040905|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg/day (150mg/b.i.d)
41366021|NCT06040905|OTHER|Placebo|Starch, dextrin
41501153|NCT01467986|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
41501154|NCT01467986|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
40845203|NCT04720092|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Granules for oral suspension, 10 mg, oral, single dose
40845204|NCT04720092|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 10 mg, oral, single dose
40845205|NCT00006056|DRUG|anti-thymocyte globulin|
40845206|NCT00006056|DRUG|busulfan|
40845207|NCT00006056|DRUG|cyclophosphamide|
40845208|NCT00006056|DRUG|cyclosporine|
41028155|NCT02221206|DEVICE|Mini-Screw implant|Mini-screw implants (VectorTASTM8\*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
41366022|NCT02411032|BEHAVIORAL|Reminder|Customer gets mailing that reminds them to take their medication.
41366023|NCT02411032|BEHAVIORAL|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
41501155|NCT01467986|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
41501156|NCT01467986|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
41501157|NCT02755155|DRUG|Human serum albumin infusion 4%|Continuous infusion of 15mL/kg of bodyweight over 24h/day
41501158|NCT02755155|DRUG|Human serum albumin infusion 20%|Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
40845209|NCT00006056|DRUG|etoposide|
40845210|NCT00006056|DRUG|filgrastim|
40845211|NCT00006056|DRUG|methotrexate|
40845212|NCT00006056|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
40845213|NCT04003987|DRUG|Liposomal bupivacaine|20ml
40845214|NCT04003987|DRUG|bupivacaine, 0.125%|60ml
40845215|NCT05967949|DRUG|chidamide|This subset of patients received chidamide as first-line maintenance therapy.
41028156|NCT03137862|OTHER|Gluten free bread|patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
41366024|NCT02411032|BEHAVIORAL|Fresh start framing|The fresh start event will be highlighted in the mailings.
40845216|NCT01910467|DEVICE|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases \>5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
40845217|NCT01910467|DEVICE|NIRS not visible and treatment as usual|NIRS not visible and the patients will be treated according to routine
40845218|NCT05606055|DRUG|BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato|This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
40845219|NCT00151502|DRUG|Atorvastatin|
41028157|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 3g/day|"patients will have to continue the GFD supplemented with 3 gr of gluten friendly bread daily for 12 weeks"
41028158|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 6g/day|"patients will have to continue the GFD supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
41028159|NCT05274945|RADIATION|Radiotherapy|radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil
40845220|NCT01599741|RADIATION|Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.|Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
40845221|NCT01599741|RADIATION|Normal dose DSA with conventional X-ray imaging technology|Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
40845222|NCT02343705|DEVICE|Latella Knee Implant System|
40845223|NCT03907033|DRUG|Liposomal bupivacaine|Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
41366025|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
41366026|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
40845224|NCT03907033|DRUG|Bupivacaine Hydrochloride|We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
40845225|NCT01679886|RADIATION|Rubidium PET|Rubidium PET
41028160|NCT05274945|DRUG|consolidation chemotherapy|6 cycles of FOLFOX or CAPOX
41028161|NCT05274945|PROCEDURE|TME or APR|total mesorectal excision or abdominoperineal resection
41028162|NCT05302765|OTHER|Normal Saline Intravenous Fluids|Administration of normal saline intravenous fluids (20 milliliters/kilogram).
41028163|NCT00347308|BEHAVIORAL|Eyebrow Position|Photography of brow positions
41028164|NCT00951600|DRUG|oxcarbazepine 300 mg/5mL oral suspension|
41028165|NCT02143622|BIOLOGICAL|LJM716|antibody
41028166|NCT02143622|BIOLOGICAL|cetuximab|antibody
41028167|NCT02201602|DRUG|Gliclazide|
41028168|NCT02201602|DRUG|Glibenclamide|
41028169|NCT01528228|DEVICE|TENS Treatment with functional or disabled unit|TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
41028170|NCT00053833|DRUG|irinotecan|
41366027|NCT06285019|PROCEDURE|TOMOX-HAIC|Oxaliplatin 85mg/m\^2 plus Raltitrexed 3mg/m\^2, 21 days for a cycle
41366028|NCT06285019|DRUG|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle
41366029|NCT06285019|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, 21 days for a cycle
41366030|NCT04675502|OTHER|supervised Exercise training|warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises
40845226|NCT03610776|DEVICE|Portion control plate|Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.
40845227|NCT03610776|DEVICE|Conventional plate|Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
40845228|NCT00930007|OTHER|Blood sampling|Blood sampling for later hormone measurements
40845229|NCT03317782|DEVICE|NoL index|The NoL/PMD-200 (Medasense Biometrics Ltd, Ramat Yishai, Israel) is a multi-parameter index (0-100) that incorporates heart rate, heart rate variability (0.15-0.4 Hz band power), plethysmograph wave amplitude, skin conductance level, number of skin conductance fluctuations (NSCF), and their time derivatives9 using a non-linear regression technique. A higher index indicates higher nociception, and an index \<20 indicates adequate analgesia.
40845230|NCT06124794|BIOLOGICAL|PROTOXIN|Clostridium botulinum toxin type A
40845231|NCT04462965|COMBINATION_PRODUCT|Toripalimab|Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
40845232|NCT04462965|COMBINATION_PRODUCT|Temozolomide|Placebo：Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
40845233|NCT02235545|DEVICE|St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
40845234|NCT03846284|DRUG|Bupivacaine|caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
40845235|NCT03846284|DRUG|Magnesium sulfate 50mg|caudal block with bupivacaine 0.25% 1mg/kg plus Magnesium sulfate 50 mg diluted in 10 cm saline.
40845236|NCT03846284|DRUG|Magnesium sulfate 30 mg|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, fol I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
41028171|NCT02565641|DRUG|Capecitabine|Capecitabine will be administered orally at 830 mg/m\^2 BID (equivalent to a total daily dose of 1660 mg/m\^2) as intermittent treatment (given days 1 to 21 q4w).
41028172|NCT02565641|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m\^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
41028173|NCT02861781|OTHER|Collection of blood samples and tissues|Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
41366031|NCT04675502|OTHER|home exercise trainig|Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
41501159|NCT04719455|BEHAVIORAL|Adherence Improving self-Management Strategy|An in-person delivered intervention imbedded in regular follow-up care during 9-months. Patients will receive an electronic monitoring System to track medication intake and a pedometer to count daily amount of steps. During the baseline visit, the health care professional (HCP) will use pre-tested materials for informing and motivating patients; and collaboratively set goals and plans for medication adherence and physical activity. During regular follow-up consultations with the HCP, personalized visual reports of medication intake and amount of steps will be evaluated to enhance patients awareness of their (non-)adherence and (in)activity and identify any problems and solutions to reduce undesired behaviour. The control group will receive usual treatment only.
41366032|NCT00727662|OTHER|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
41366033|NCT00727662|OTHER|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
41501160|NCT04719455|OTHER|Regular care|Treatment as usual (appointments with nurse/nurse practioner with regular content)
41028174|NCT03988179|DIAGNOSTIC_TEST|The Cholinesterase Inhibitor Prognosticator (ChIP) application for iPad|The first part of this application will be used, consisting of a visual vigilance test based on the Continuous Performance Test (CPT). Stimuli consist of a one digit number presented in the middle of the screen. For each trial the application randomly selects a specific number as the target stimulus. Patients are instructed to keep their dominant trigger finger close to the screen and press a button which is located at the bottom of the screen, whenever the target appears. In case another stimulus appears the patient is instructed to do nothing. Each stimulus is presented until the patient presses the button (maximum 3 sec.). Stimuli are presented in a random fashion with a 1, 2, 3, 4, or 5 second inter-stimuli-interval blank, which randomly varies. After an 8 stimuli practice trial, the test starts and a total of 50 stimuli are presented with a 50% target rate. Full-trial duration is approximately 5 minutes. During the trial, reaction time and accuracy of response are registered.
41028175|NCT02443181|DEVICE|Activa PC+S|Implementation of closed loop DBS for essential tremor
41028176|NCT00714168|BEHAVIORAL|Standard Behavioral Weight Loss Program|This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
41028177|NCT00714168|BEHAVIORAL|Stepped-Care Weight Loss Program|In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
41028178|NCT00174993|DRUG|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
41028179|NCT00174993|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
41161352|NCT02600897|DRUG|Lenalidomide|All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
41366034|NCT05795127|PROCEDURE|First metatarsophalangeal joint arthrodesis|Surgery leadin to bony uninon in firts metatarsophalangeal joint
41501161|NCT04430309|BEHAVIORAL|Baduanjin exercise program|The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.
41501162|NCT04430309|BEHAVIORAL|Brisk walking program|The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.
40845237|NCT04091295|DRUG|DeltaRex-G|Intravenous infusions of DeltaRex-G for treatment of advanced pancreatic cancer and sarcoma that have failed standard therapies
41501163|NCT06010849|DIAGNOSTIC_TEST|Trunk control|Trunk control
41501164|NCT00316095|DRUG|telmisartan|
40845238|NCT00278811|PROCEDURE|mobile crisis team|
40845239|NCT01779635|DEVICE|oXiris as first filter|2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots
40845240|NCT01779635|DEVICE|M150 as first filter|start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
40845241|NCT03473899|DEVICE|rESWT|"rESWT will be performed as follows:~* Nine rESWT sessions~* Three sessions per week~* rESWT device: Swiss DolorClast (Electro Medical Systems, Nyon Switzerland), EvoBlue handpiece, 15 mm applicator~* 2500 rESWs per session, with energy density between 0.12 and 0.16 mJ/mm\^2, depending on what the patient tolerates~* rESWs applied at 15 Hz~* Application of rESWs in prone position, with the patient lying on an examination table~* Exact location of the application of rESWs determined by clinical and ultrasonographic examinations~* Treatment of both the side of injury and the entire affected muscle (from distal to proximal in order to relax the affected muscle)~* No use of local anesthesia.~In addition, patients will receive a specific rehabilitation program."
40845242|NCT03473899|DEVICE|Sham-rESWT|"Sham-rESWT will be performed as rESWT described in Arm rESWT + RP, but with a specially designed placebo EvoBlue handpiece that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves. This is achieved by blocking the projectile shortly before it strikes the metal applicator. The placebo EvoBlue handpiece will not emit any radial shock wave energy.~In addition, patients will receive a specific rehabilitation program."
41501165|NCT00316095|DRUG|simvastatin|
41501166|NCT04733703|OTHER|questionnaire|assessment of postoperative quality of recovery with the QoR-15
41366035|NCT03242811|DIAGNOSTIC_TEST|MRI scan of knee, ankle and wrist|"At the day of the intervention, the subject is informed about the study by a nurse and provides written informed consent.~Girls must leave urine tests to rule out pregnancy. The questionnaire for the study is answered by the subject and weight and length are measured. The subject is asked to self-assess his/her puberty.~After detailed information on how a magnetic camera examination is carried out, an examination of five selected growth zones (knee joint, ankle joint including heel leg and wrist) is performed using 1.5 Tesla magnetic camera with dedicated cartilage sequence."
41366036|NCT05375058|OTHER|Observational Study|Observational Study; the study did not involve any interventions
41028180|NCT05009849|OTHER|Yoga Exercises|The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
41501167|NCT06484699|PROCEDURE|open repair of perforated peptic ulcer|group (A) includes patients with perforated peptic ulcer that will be operated by open repair approach
41501168|NCT06484699|PROCEDURE|laparoscopic repair of perforated peptic ulcer|group (B) includes patients with perforated peptic ulcer that will be operated by laparoscopic repair approach
41501169|NCT05657119|BEHAVIORAL|MI FSN - Lethal Means Reduction|"Motivational Interviewing lethal means reduction, firearm storage supplies, Tailored text messages~* Participate in a 15-20-minute motivational interviewing (MI) session conducted by trained University of Michigan research staff focused on encouraging suicide lethal means~* Be offered to take home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement"
41501170|NCT05657119|BEHAVIORAL|Scripted FSN - Lethal Means Reduction|"Scripted lethal means reduction, firearm storage supplies, tailored text messages~* Participate in a 10-15-minute scripted session focused on gun safety and lethal means reduction~* Be offered to home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement"
41501171|NCT05657119|BEHAVIORAL|General Firearm Safety Intervention - General Firearm Safety|"General information on gun safety, firearm storage supplies, tailored text messages~* Participate in a 10-minute scripted conversation about safe gun storage practice~* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes~* Receive 4 weeks of tailored text message reminders and encouragement"
41501172|NCT05657119|BEHAVIORAL|General Firearm Comparison - General Firearm Safety|"firearm storage supplies~\* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes"
41501173|NCT04276922|BEHAVIORAL|Visual Arts|"Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
41028181|NCT01329601|BEHAVIORAL|StaCog, stage specific cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
41028182|NCT01329601|BEHAVIORAL|booklet based training|Home based training of episodic memory using paper-pencil exercizes
41028183|NCT00559559|DEVICE|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
41028184|NCT00559559|PROCEDURE|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
41028185|NCT05135910|DRUG|Hallux Terbinafine Subungual Gel|Hallux Terbinafine Subungual Gel (HSG) administered every 1 to 2 months over 44 weeks.
41161353|NCT02600897|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
40845243|NCT04353700|BEHAVIORAL|Yoga group|During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks, including 5 minutes of warm-up exercise, 15 to 30 minutes of dynamic flow yoga postures, 10 minutes of weight barring standing postures, and 5 minutes of cool-down. These in-home sessions were a repeat of what participants learned during the first week of training session at UML. We progressively increased the intensity of the home practice sessions by adding the number of sun salutation (SS) over the 12 weeks.
40845244|NCT04886791|PROCEDURE|Vaginal NOTES hysterectomy|Vaginal assited NOTES hysterectomy
40845245|NCT04886791|PROCEDURE|Vaginal hysterectomy|Vaginal hysterectomy
40845246|NCT06418451|PROCEDURE|sacrospinous ligament fixation (SLFF)|SSLF is a surgical procedure used to treat vaginal apex prolapse by fixing the vaginal apex to the right sacrospinous ligament. The procedure involves marking and incising the posterior vaginal wall, dissecting the vaginal rectal space, and placing sutures on the outer one-third of the ligament. These sutures connect the vaginal apex to the attachment point of the right uterosacral ligament. Anterior/posterior vaginal wall repair procedures can be performed if needed, without using implant materials. SSLF provides enhanced support for the vaginal apex.
40845247|NCT06418451|PROCEDURE|modified ischial spinous fascia fixation (modified ISFF)|The modified ISFF procedure involves making a midline incision along the posterior fornix of the vagina, exposing the ischial spine fascia. Two sutures are placed around the ischial spine and passed through the mucosa of the anterior and posterior vaginal walls, lifting the vaginal apex and anterior wall towards the spine. The procedure also allows for additional anterior/posterior vaginal wall repair if necessary, without using implant materials.
40845248|NCT00559988|DRUG|Home Monitoring Guided OAC|"Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
40845249|NCT00559988|DRUG|Physician-Directed OAC|"Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
40845250|NCT06543680|OTHER|Dental restoration|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
40845251|NCT01008449|DEVICE|Surgical staples|Surgical staples will be used once for wound closure.
40845252|NCT01008449|DEVICE|Absorbable Surgical Suture|Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
41028186|NCT04570826|OTHER|Meditation.|The caregivers received eight sessions lasting each one two hours with the following sequence: before each practical exercises they always received 15 minutes about scientific theoretical evidence explaining the importance of doing them: to get a comfortable posture they received 25 minutes of mobility, flexibility, balance, strength and endurance exercises. To increase lung capacity, 25 minutes of costal, diaphragmatic and clavicular breathing exercises. Finally, to have an open attitude without distractions or judging they practiced 25 minutes of body awareness exercise observing sensations, thoughts and perceptions with gratitude and compassion.
41366037|NCT04594616|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
40845253|NCT04409093|PROCEDURE|Nail bed repair with eponychial sent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will be secured under the eponychial fold with suture. The stent can be the native nail plate, suture container foil, or nonadherent gauze (i.e. Xeroform). If the injury avulsed the nail plate and the patient presents without it, either the foil from the suture wrapper/container or a piece of nonadherent gauze (i.e. Xeroform) will be used as a stent. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
40845254|NCT04409093|PROCEDURE|Nail bed repair without eponychial stent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will not be secured under the eponychial fold. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
41028187|NCT04570826|OTHER|Scientific descriptions about meditation.|The control group received scientific descriptions about meditation.
41028188|NCT00736996|DRUG|Pioglitazone|30 - 45mg tablet daily for 6 months
41028189|NCT00736996|DRUG|Placebo|Matching tablet daily for 6 months
40845255|NCT06054139|OTHER|Refeeding Syndrome|Patients who developed Refeeding Syndrome despite proper nutrition while receiving treatment in the ICU
41366038|NCT00086060|BEHAVIORAL|Exercise regimen|Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
41366039|NCT00086060|BEHAVIORAL|Relaxation training|Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
41366040|NCT00086060|BEHAVIORAL|Standard Care|Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
41366041|NCT02605135|DEVICE|Continued Pessary Use|Pessary Fitting
40845256|NCT00208351|DEVICE|Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished/blasted finished cementless femoral component for use in total hip replacement.
40845257|NCT00208351|DEVICE|Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
40845258|NCT00208351|DEVICE|Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
40845259|NCT00208351|DEVICE|Ultima LX Collarless Stem - Polished finished|A collarless polished finished cementless femoral component for use in total hip replacement.
40845260|NCT03911024|BEHAVIORAL|HIV|At the completion of each EMA, participants in the intervention group (n=50) will receive messages that address:1) unsafe sexual behaviors, 2) alcohol/drug use, 3) PrEP interest, and 4) HIV testing. In addition, participants will have access to a button in the app that will link them to resources when/if they are the victim of sexual assault. Finally, intervention arm youth will be asked to set a behavioral goal related to HIV prevention during this session. Those goals will include increasing condom use, PrEP use, non-occupational post-exposure prophylaxis (nPEP) use, reducing number of sexual partners, not having sex with using drugs or drinking alcohol, avoiding IV drug use, getting testing for HIV, and testing and treating sexually transmitted infections (STIs) as needed
40845261|NCT03911024|BEHAVIORAL|General health|Participants in the attention control condition (n=50) will answer the same EMA items as the Intervention group. However, the intervention messages will contain content related to nutrition, physical activity, sleep hygiene, and tobacco use. Finally, control arm youth will be asked to set a behavioral goal related to general health during this session.Those goals will include getting 7+ hours of sleep, eating \>= 5 servings of fruits or vegetables, not using tobacco products, exercising at least 60 minutes.
40845262|NCT00470418|DRUG|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
40845263|NCT00470418|DRUG|Placebo|placebo comparator
41028190|NCT00736996|BEHAVIORAL|Endurance Exercise Training|Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
41366042|NCT05623059|DRUG|Slow Release DHEA|DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.
41366043|NCT00714831|BEHAVIORAL|Physical activity intervention|3-months physical activity intervention
41366044|NCT00714831|BEHAVIORAL|Health educational program|Health education sessions and stretching sessions
40845264|NCT04839445|PROCEDURE|General anesthesia + TAP block|Post induction TAP block for intra and postoperative analgesia.
40845265|NCT04839445|PROCEDURE|General anesthesia + ESP block|Pre induction ESP block for intra and postoperative analgesia.
41028191|NCT00377767|BEHAVIORAL|To change structure and roles of primary care teams to optimize prevention of obesity|
41366045|NCT00231322|DRUG|praziquantel|
41028192|NCT03916003|DRUG|primaquine|Primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
41028193|NCT03144557|OTHER|Education|Education protocol included 4 individual sessions of verbal and graphic instructions to correct inhalation technique in patients with COPD
41028194|NCT00288496|DRUG|polyethylene glycol bowel lavage solution|
41028195|NCT00153738|DRUG|phytosterol|
41366046|NCT04371705|PROCEDURE|Erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes using ultrasound guide.
41366047|NCT04371705|OTHER|control|placebo
41501174|NCT04276922|BEHAVIORAL|Music|"Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation."
41501175|NCT04276922|BEHAVIORAL|Dance/Movement|"Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
40845266|NCT06007053|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning.
40845267|NCT06007053|BEHAVIORAL|Supportive Therapy|The supportive therapy treatment consists of 12 sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
40845268|NCT01177566|DRUG|pimecrolimus|pimecrolimus 1% cream twice daily
40845269|NCT01177566|DEVICE|topical medical device|Eletone cream three times daily
40845270|NCT01298271|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
40845271|NCT03576716|DRUG|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
41366048|NCT00262457|DEVICE|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
41366049|NCT04493658|DIAGNOSTIC_TEST|Questionnaires|Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects
41366050|NCT04493658|DIAGNOSTIC_TEST|Tear fluid sampling|Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.
41366051|NCT04493658|DIAGNOSTIC_TEST|Impression Cytology|Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.
41366052|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
41366053|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
41366054|NCT00734916|DIETARY_SUPPLEMENT|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
41366055|NCT05370300|DIAGNOSTIC_TEST|Blood test|Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
41366056|NCT02534428|OTHER|wool clothing|superfine merino wool ensembles for baby wear
40845272|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
41028196|NCT01610323|OTHER|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
41028197|NCT01610323|OTHER|Standard Care|
41366057|NCT01874821|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
41366058|NCT01874821|OTHER|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
41366059|NCT02598362|DRUG|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
41366060|NCT03145376|DIAGNOSTIC_TEST|geriatric assessment|"1. Clinical evaluation and geriatric assessment with:~   1. CIRS: CIRS (Cumulative Illness Rating Scale)~  2. ADL (Activities of Daily Living);~  3. IADL (InstrumentalActivities of Daily Living);~  4. Mini Nutritional Assessment;~  5. Evaluation of quality of life (Short Form 36, SF-36).~2. Making a traditional 12-lead ECG.~3. A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~4. transthoracic echocardiogram."
41028198|NCT04607967|DEVICE|High Flow Nasal Oxygen|"Study participants are suffering from an acute hypoxemic respiratory distress. They have to be treated with oxygen-therapy that could be administered using a conventional oxygen device (study group CO) or High Flow Nasal Oxygen (study group HNFO). During the first 60 minutes following patients admission, patients will be randomized to one of the two study groups. In both groups, the failure of the treatment will be evaluated by the need for a therapeutic escalation fours hours after the treatment initiation."
41028199|NCT05189574|PROCEDURE|Endoscopic negative pressure therapy|Endoscopic placement of a sponge in/at staple line leaks under negative pressure.
41366061|NCT00978705|DRUG|Autologous cultured keratinocyte cell|3x10\^7 cell/ vial
41501176|NCT04276922|BEHAVIORAL|Writing/Poetry|"Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
41028200|NCT01750567|DRUG|Metformin|Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
41028201|NCT00152295|DRUG|Asoprisnil/Premarin|10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
41028202|NCT00958919|DRUG|naloxone|10 mg naloxone in 25 ml total volume
41366062|NCT02849873|DRUG|IDP-123 Lotion|Lotion
41366063|NCT02849873|DRUG|Tazorac Cream|Cream
41366064|NCT04881149|DEVICE|TempSure treatment|Self-controlled, single-arm study using the TempSure device.
41028203|NCT00958919|DRUG|normal saline|25 ml
41028204|NCT01076400|DRUG|adavosertib|Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
41028205|NCT01076400|DRUG|Topotecan|Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.
41366065|NCT01538680|DRUG|Regorafenib (BAY73-4506)|"Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):~Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.~Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol"
41366066|NCT04758624|DEVICE|Deep Brain Stimulation|Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
41366067|NCT05142904|DEVICE|Radiofrequency ablation|Ultrasound-guided radiofrequency ablation of the solitary autonomous thyroid nodule.
41366068|NCT05142904|DRUG|Radioactive iodine|I-131 according to standardized doses-calculation.
41366069|NCT05142904|DRUG|Radioactive iodine|I-131 according to local standard.
41028206|NCT01076400|DRUG|Cisplatin|Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.
41501177|NCT04276922|BEHAVIORAL|Control|Control Group will only complete surveys at baseline and 12 weeks later.
41028207|NCT01076400|DRUG|Placebo to adavosertib|Placebo to adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
41028208|NCT00567242|BEHAVIORAL|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
41028209|NCT00567242|BEHAVIORAL|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
41028210|NCT02460991|DEVICE|DEB-TACE|
41028211|NCT02460991|DRUG|Sorafenib|
41028212|NCT00908440|BEHAVIORAL|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
41028213|NCT01748994|DRUG|Pioglitazone|30mg per day for four months
41028214|NCT01748994|DRUG|Placebo|
41028215|NCT00360308|DRUG|Placebo|
41028216|NCT00360308|DRUG|E2007|
41028217|NCT00360308|DRUG|E2007|
41161354|NCT02600897|DRUG|Polatuzumab Vedotin|Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
41366070|NCT04941261|BIOLOGICAL|middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
41366071|NCT04941261|BIOLOGICAL|high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
41366072|NCT04941261|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
41366073|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
41366074|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
41501178|NCT00929890|BEHAVIORAL|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
40845273|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB and superficial PIPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
41366075|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
41501179|NCT00929890|BEHAVIORAL|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
41501180|NCT01679717|OTHER|Early mobilisation after CMC1-surgery|Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
40845274|NCT00935441|BEHAVIORAL|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
40845275|NCT00935441|BEHAVIORAL|usual case management|telephone contact with a case manager
41366076|NCT05633394|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
40845276|NCT05367323|DEVICE|Pressure algometry (Baseline 2.2-Pound Dolorimeter) and Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|Both instruments are used for the assessment of the L4-5 interspinous space pain pressure threshold and the biomechanical-viscoelastic properties of L4-5 supraspinous ligament respectively
41028218|NCT01360359|OTHER|Core Stabilization|"3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning."
41366077|NCT02647021|BEHAVIORAL|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
41366078|NCT02647021|BEHAVIORAL|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
41366079|NCT04030364|BEHAVIORAL|CrossFit group exercise classes|"The group classes will occur at a local CrossFit gym facility. Participants will be free to attend up to 6 regularly-scheduled, free, 1-hr group classes per week at the local exercise facility for a period of 3-months. The recommendation will be to aim to attend at least three classes/week but there will no prescribed minimum. Classes will be supervised by experienced trainers.~Trainers will work collaboratively with participants to adapt the skill and workout of the day within each group class to the individual participant's physical limitations and needs. As such, each participant may complete a slightly different movement or workout on any given day based on their functional status at that time. However, all participants will be actively included in the community of the group class and will experience a relative stimulus that is moderately challenging for them."
41366080|NCT02177370|DRUG|Fenoterol MDI|
41501181|NCT05396521|OTHER|Blood Flow Restriction|Group 2 (experimental) will receive standard of care physical therapy to be done with blood flow restriction therapy (BFR). This method includes standard of care physical therapy while occluding blood flow.
41501182|NCT05396521|OTHER|Standard of Care Physical Therapy|Group 1 (Control) will receive standard of care physical therapy.
41501183|NCT04349436|BIOLOGICAL|RP1, intra-tumoral injection, oncolytic virus|Genetically modified herpes simplex type 1 virus
41501184|NCT03938623|OTHER|Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
41501185|NCT02686736|BEHAVIORAL|Internet-based educational intervention|The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
40845277|NCT03869606|DEVICE|NICOM by Cheetah Medical|Observational measurement, Cardiac Output, Pre- and Post Anesthesia
40845278|NCT05987436|OTHER|Supervised Aerobic Exercise|Group 1 exercised for six weeks, five sessions per week under the supervision of a medical doctor in the aerobic exercise laboratory.
40845279|NCT00013169|BEHAVIORAL|Strong Patient Focus|
41501186|NCT04668911|OTHER|Swab|PCR test for SARS-CoV2, oral and nasal swab
41501187|NCT01404923|DRUG|anti spasmodic agents|best standard of care prescriptions
41501188|NCT01404923|DRUG|alverine citrate, simeticone|on-demand therapy
40845280|NCT00727558|DEVICE|nelfilcon A|spherical soft contact lens
40845281|NCT00727558|DEVICE|narafilcon A|spherical soft contact lens
40845282|NCT05975060|BIOLOGICAL|XBB.1.5 Vaccine (Booster)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine (Booster)
41366081|NCT02177370|DRUG|DSCG MDI|
41366082|NCT00475527|DRUG|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
41366083|NCT05425082|OTHER|Motor relearning program|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions
41501189|NCT04142957|OTHER|COPD Pal|'COPD Pal' aims to allow people with COPD to track and manage their condition. It enables patients to log symptoms (e.g. COPD assessment Test), wellness (e.g. quality of life such as EQ-5D), and medications, to help them become more engaged in their own care.
41501190|NCT01365312|DRUG|Ethanol lock|Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
40845283|NCT05975060|BIOLOGICAL|XBB.1.5 Vaccine (single dose)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine ( single dose)
41028219|NCT01360359|OTHER|Trunk Motion and Fitness|"3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises"
41501191|NCT01365312|DRUG|Heparinized saline|0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
41501192|NCT03675230|DEVICE|Tomotherapy HD|Patients with Medulloblastoma receiving Tomotherapy
41501193|NCT03675230|DEVICE|3DCRT|Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
41501194|NCT03480386|BEHAVIORAL|Home Based Pulmonary Rehabilitation|Twice daily exercise routine six days a week of 3 minutes of personal breathing, 5 exercises with 10 reps each, and 6 minutes of walking with weekly health coach calls.
41028220|NCT04100447|DRUG|Tranexamic Acid|A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
41028221|NCT06386666|DEVICE|Disposable fibrous ring sutures|A new disposable fibrous ring suture device developed and produced by 2020 (Beijing) Medical Technology Co., Ltd
41028222|NCT01844323|OTHER|Palbociclib Formulation Reference|Single 45 mg dose; Dosage form is capsule taken orally.
41028223|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
41028224|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
41028225|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
41028226|NCT06342544|DRUG|immediate treatment with corticosteroids|Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.
41366084|NCT05425082|OTHER|Neurodevelopmental therapy|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions.
41366085|NCT03684902|PROCEDURE|emergency midline exploratory laparotomy|Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
41366086|NCT05630326|OTHER|comparing, prevalence|Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
41366087|NCT05630326|OTHER|assessment|comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
41366088|NCT05630326|OTHER|association|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
41366089|NCT05630326|OTHER|evaluation|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
41366090|NCT05707364|BEHAVIORAL|Pre-visit Lab Workflow|"1. Based on buy-in from the providers/staff one or both of the practices below will be introduced into the clinic workflow to order pre-visit labs.~   1. All procedures are within the standard of care, only the order of operations is being changed. After sharing lab results with patient from the most recent routine physical, physician records labs for the next calendar year in EMR.~  2. Prior to appointment, Medical Assistant (MA) will review notes and orders to setup pre-visit labs.~2. Patient contacted to complete labs prior to the scheduled routine physical.~3. Resulted labs are triaged based on urgency.~4. After Visit Summary used to communicate about labs and surveys."
41366091|NCT03028506|OTHER|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
41028227|NCT06342544|DRUG|addition of rituximab if recurrence|rituximab added if ocular symptoms reappear as corticosteroids are tapered off. Rituximab will be given at a dose of 500mg/6months for 12 months.
41028228|NCT02385448|DRUG|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
41028229|NCT02385448|DRUG|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
41028230|NCT03666039|BEHAVIORAL|Trainings app|Sensorimotor trainings app for at home Training (tablet-based)
41028231|NCT04118621|DEVICE|chest ultrasound|detection of postoperative pulmonary complications after cardiothoracic surgery
41366092|NCT05018390|OTHER|Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. Osteopathic manipulations will consist in corrective micro-movements applied on synovial joints, on the skull, the teeth and/or visceral structures of the abdomen or the thorax. Local pressures won't exceed a few tens of grams/cm². Practitioners will realize between 15 and 25 technical gestures per participant. Treatment will last 30 minutes (plus or minus 5 minutes) on average. The technical gestures are referenced in the Glossary of Osteopathic Terminology published by the American Association of Colleges of Osteopathic Medicine (2017).
41028232|NCT03792594|OTHER|arthroscopic repair with bone marrow concentration|arthroscopic repair with bone marrow concentration
41028233|NCT03792594|OTHER|arthroscopic repair|arthroscopic repair only
41028234|NCT03655158|DEVICE|ozone device ( Ozonytron XL )|The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
41028235|NCT06534580|DEVICE|Virtual Reality|"A range of virtual reality software, delivered through the DR.VR (TM) device."
41366093|NCT05018390|OTHER|Sham Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. They will receive 20 gestures that will be standardized and different from actual osteopathic manipulations (but not identifiable as sham manipulations by the participants). The duration of the sham treatment will be the same as the actual treatment.
41366094|NCT01034345|DRUG|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
41366095|NCT01034345|DRUG|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
41366096|NCT00004219|DRUG|granisetron hydrochloride|
41366097|NCT00004219|DRUG|lerisetron|
41366098|NCT00004219|RADIATION|radiation therapy|
41366099|NCT04115904|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
41366100|NCT04884204|BEHAVIORAL|Lee Symptom Scala|Symptom identification and management with Lee Symptom Scale in follow up care
41366101|NCT03759795|BEHAVIORAL|ACTr (Acceptance and Commitment Training)|The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
41366102|NCT04795570|PROCEDURE|Transurethral resection of the prostate or bladder|All patients undergoing TUR P/B will undergo a blood draw within 6 months after surgery to determine hormonal status and coagulation disorders.
41366103|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
41366104|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
41366105|NCT00598442|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
41366106|NCT03335189|DEVICE|ASyMS-Can|Data reported by the participants will be sent to a secure, encrypted clinical central server hosting the risk-alerting algorithms. The web interfaces will provide a clinical portal for the nurses to screen and follow any alerts being triggered, as well as review patient-specific information. Based on these back-end computations, participants will receive automated self-care notifications on their mobile phones. If incoming symptom reports indicate severe adverse effects a designated clinic nurse will receive an 'amber alert', or 'red alert', that will require response within 30 minutes. Nurses will handle alerts during business hours (9 am to 5 pm). After-hour alerts will be sent to the oncologist or nursing supervisor on call as per usual care. Patients will be instructed that clinicians will not receive alerts during the evening hours or night and instructed to follow usual practice of contacting their family physician, or oncologist on call, or call 911, as required.
41366107|NCT00287261|DRUG|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
41366108|NCT03878576|OTHER|REFERENCE: white bread - BGL0 [RP]|Determination of glycemic response after consumption of BGL0.
41366109|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL2 [IP1]|Determination of glycemic response after consumption of BGL0.
41366110|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL3 [IP2]|Determination of glycemic response after consumption of BGL0.
41366111|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL4 [IP3]|Determination of glycemic response after consumption of BGL0.
40845284|NCT02243891|PROCEDURE|Atrial fibrillation ablation|Percutaneous catheter ablation for Atrial fibrillation.
40845285|NCT02243891|PROCEDURE|ROX Coupler insertion|The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
40845286|NCT01959243|DRUG|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
40845287|NCT01959243|DRUG|Vehicle|Ophthalmic solution to be applied as directed.
41366112|NCT05762315|BEHAVIORAL|Audio Storytelling|The audio session is designed to deliver audio narrative developed following the Transformative Storytelling Technique and provide re-structurization of internal caregiver self-stories.
41366113|NCT04518644|DRUG|Nilotinib|The recommended dosing of nilotinib is 400 mg orally twice daily
41366114|NCT01040000|DRUG|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
40845288|NCT01959243|DRUG|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
40845289|NCT01959243|DRUG|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
40845290|NCT02468349|OTHER|Telemedicine|Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
41366115|NCT02702115|BIOLOGICAL|SB-318|A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
41366116|NCT01741610|BIOLOGICAL|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
40845291|NCT05082311|OTHER|Observational study|This is an observational study
40845292|NCT04919096|DRUG|SCB-420|Subjects randomised to SCB-420 arm will receive a total of 3 doses of SCB-420 as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
40845293|NCT04919096|DRUG|Aflibercept|Subjects randomised to Aflibercept arm will receive a total of 3 doses of Aflibercept as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
40845294|NCT06320314|OTHER|tested product (2039125 03)|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
40845295|NCT03652675|BEHAVIORAL|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|This intervention consists of an adaptation of the National Institutes of Health (NIH) Clinician's Guide (CG; NIAAA, 2007) in conjunction with the previously tested HealthCall smartphone app program (Hasin et al., 2013; Hasin et al., 2014). Participants will complete a brief baseline meeting (\~20 minutes) with a counselor to discuss alcohol use, liver function, and HIV medication adherence. They will track their drinking using HealthCall for 60 days, with brief follow-up meetings with their counselor to check in about their drinking 30 and 60 days later.
40845296|NCT03981068|RADIATION|Re-irradiation|Cisplatin for all eligible patients, nimorazole for all SCC
40845297|NCT00559676|DRUG|capecitabine|
40845298|NCT00559676|DRUG|fluorouracil|
40845299|NCT00559676|DRUG|irinotecan hydrochloride|
40845300|NCT00559676|DRUG|leucovorin calcium|
40845301|NCT00559676|DRUG|oxaliplatin|
40845302|NCT00559676|OTHER|laboratory biomarker analysis|
40845303|NCT00559676|OTHER|pharmacological study|
41161355|NCT02600897|DRUG|Rituximab|Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
41366117|NCT02248272|OTHER|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
41501195|NCT06156774|OTHER|Chimeric Antigen Receptor T-cells (CAR-T) therapy|Patients will be treated with CAR-T cell product as per routine clinical practice.
41501196|NCT05976230|DRUG|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
41501197|NCT02878122|PROCEDURE|Cancer treatment|Chemotherapy and laparoscopic surgery
41501198|NCT06043687|DRUG|Dentifrice Paste|Scaling and Root planing followed by dentifrice usage
40845304|NCT00486668|DRUG|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
40845305|NCT00486668|DRUG|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
40845306|NCT00486668|DRUG|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
40845307|NCT00486668|DRUG|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
40845308|NCT00486668|DRUG|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
40845309|NCT05785936|PROCEDURE|Desensitization|Patients that received apheresis and anti-cluster of differentiation antigen 20 for desensitization priori to kidney transplantation
40845310|NCT01727414|DRUG|OROS-Methylphenidate and placebo for inattentive type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
40845311|NCT01727414|DRUG|OROS-Methylphenidate and placebo for combined type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
41366118|NCT02248272|OTHER|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
40845312|NCT01508260|PROCEDURE|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.
40845313|NCT01508260|DRUG|Furosemide|20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
40845314|NCT04544683|DRUG|Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate|Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).
40845315|NCT01085292|DRUG|NOX-E36|Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
40845316|NCT01085292|DRUG|NOX-E36|Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
40845317|NCT03617055|DIAGNOSTIC_TEST|serum cystatin c|Blood sample for serum cystatin c will be taken on the first and third days of life for all neonates with clinical or laboratory signs of perinatal asphyxia who are admitted to NICU for early detection of AKI in the study group.
41366119|NCT02528461|DRUG|Galactose|A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
41366120|NCT02528461|PROCEDURE|Gastroscopy|
41366121|NCT02528461|PROCEDURE|Liver biopsy|
41366122|NCT02528461|PROCEDURE|Fibroscan|
41366123|NCT02528461|PROCEDURE|Liver vein catheterization|
41366124|NCT02528461|DRUG|Sofosbuvir|
41366125|NCT01075568|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
41366126|NCT02263976|DRUG|BEA 2180 BR|
41366127|NCT02263976|DRUG|Placebo|
41366128|NCT02263976|DEVICE|Respimat® A 4|
41501199|NCT05156905|DRUG|Cirmtuzumab|Cirmtuzumab will be given in combination with docetaxel.
41501200|NCT02257697|DRUG|Mizoribine (MZR)|
41501201|NCT02257697|DRUG|Cyclophosphamide (CTX)|
41366129|NCT02263976|DRUG|Methacholine Chloride|methacholine challenge test
41366130|NCT02263976|DRUG|Spiriva|
41366131|NCT03871803|DRUG|Controlled withdrawal of beta-blockers|Controlled withdrawal of previos doses of beta-blockers after diagnosis of chronotropic incompetence
41366132|NCT03871803|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary Exercise Testing to evaluate the chronotropic incompetence and the primary endpoint (functional capacity)
41366133|NCT02833779|OTHER|Individual exercises|
41366134|NCT02833779|OTHER|Group exercises|
41366135|NCT02653131|DRUG|Dipeptidyl peptidase-4 inhibitor|
41366136|NCT03302260|BEHAVIORAL|CardioPrevent® Program|This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
41366137|NCT01670552|DRUG|Nimesulide + Pantoprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
41366138|NCT01670552|DRUG|Naproxen + Esomeprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
41366139|NCT05109949|DRUG|Dapagliflozin 10Mg Tab|Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
41501202|NCT03638544|DIETARY_SUPPLEMENT|Reduced gluten bread and Pasta compared o normal gluten bread and Pasta|Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
41501203|NCT03426163|DEVICE|Virtual reality|Application of knee MRI transformed virtual reality system
40845318|NCT02750839|PROCEDURE|proximal humerus fracture fixation|Mini-invasive proximal humerus fixation with plate, patient in beach chair position, general anesthesia, a small incision lateral to shoulder is made to insert the plate under scope control
40845319|NCT05464615|DRUG|Amoxicillin|We will initially administer 1/5th (56 mg) of the goal dose of amoxicillin (256 mg) by oral route following the procedure outlined below. The total goal dose to be administered is amoxicillin 256 mg (3.2 ml of 400 mg/5 ml). These were numbers that came about for significance in relabeling penicillin allergies in patients in previous studies.
41028236|NCT04481347|DEVICE|Sleep EEG recording using a DREEM® headband|Sleep EEG recording using a Dreem® headband (Rythm, Paris, France), an EEG recording device adapted to sleep conditions and completely non-invasive
41366140|NCT05109949|DRUG|Empagliflozin 25 MG|Daily morning dose per oral of Empagliflozine 25 mg for 7 days
41366141|NCT05109949|OTHER|Placebo|Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
41366142|NCT02467504|DRUG|hrIL-2 active|hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
41366143|NCT02467504|DRUG|hrIL-2 placebo|hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
41366144|NCT02467504|DRUG|MTX|Methotrexate (oral administration)
41366145|NCT02467504|DRUG|Folic Acid|Folic Acid (oral administration)
41366146|NCT02467504|DRUG|Loxoprofen|Loxoprofen (oral administration)
41366147|NCT03429894|DEVICE|Percutaneous Coronary Intervention|Drug eluting stent implant
41501204|NCT06498882|OTHER|Press Needle Acupoint Stimulation Combined with Breast Massage|Press needle acupoint stimulation and breast massage were administered. Key press needle acupoints were identified for selection: Dan zhong (RN17), bilateral Ru gen (ST18), bilateral Shao ze (SI1), bilateral Zu san li (ST36) and bilateral San yin jiao (SP6). The areas were sterilized with 75% alcohol before installing 0.22\*1.55mm press needles. Within 4-6 hours post-surgery, mothers received acupoint stimulation through needle pressing. This procedure was administered by nurses who had undergone six-month standardized training in traditional Chinese medicine techniques. Instructions were then given to mothers and their family members to stimulate the acupoints pulsatively every 3-4 hours for 20-30 minutes per session, removing the press needles after 24 hours. Additionally, a specialized nurse massaged the back, both breast areas, and armpits for 10-15 minutes, three times daily over three days, using a circular and oscillating breast massage device.
41028237|NCT04481347|OTHER|Montreal Cognitive Assessment (MoCA)|Neuropsychological assessment using the The Montreal Cognitive Assessment (MoCA) questionnaire to detect postoperative cognitive dysfunction
41161356|NCT01808521|DRUG|N-Acetylcysteine|IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
41161357|NCT03917537|GENETIC|HNSCC patients have used Nivolumab|Using Whole-Genome Analysis on Cancer Tissue of Patients with Platinum-refractory Head and Neck Squamous cell carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
41161358|NCT01842919|OTHER|Kinesthetics tests|
41161359|NCT01842919|OTHER|Psychological questionnaires|
41161360|NCT01842919|OTHER|structural Magnetic ResonanceImaging (MRI)|
41366148|NCT03539120|OTHER|Follow up for survival|No intervention, this is an observational study of survival outcomes.
41366149|NCT03642249|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
41366150|NCT03642249|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
41501205|NCT06498882|OTHER|routine care|Very early skin-to-skin contact was initiated by researchers within 30 to 40 minutes after birth, with newborns, optionally wearing caps, being placed on the mothers' chests. Mothers were encouraged to breastfeed 8 to 10 times per day to ensure steady milk production. It was ensured by researchers that mothers completely emptied one breast before switching to the other to maintain cleanliness. Additionally, mothers were guided by researchers on maintaining a well-balanced diet, achieving emotional stability, and securing adequate sleep to facilitate effective breastfeeding.
41501206|NCT02935621|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
41366151|NCT03642249|BEHAVIORAL|E-learning|delirium care video
41028238|NCT04481347|DEVICE|Intraoperative EEG recording using a Sedline® monitoring|Intraoperative brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
41028239|NCT06530316|DRUG|RET Inhibitor|RET inhibitors for neoadjuvant treatment
41028240|NCT06530316|PROCEDURE|Surgery|Operable patients receive surgery after neoadjuvant therapy
41028241|NCT02087800|BEHAVIORAL|F phase lab session|F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
41366152|NCT04780230|DEVICE|tDCS active|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
41366153|NCT04780230|DEVICE|tDCS sham|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
41366154|NCT06347146|BEHAVIORAL|Financial Literacy Training (FLT) workshops|Adolescents and youths and their caregivers will receive six 1-2 hour workshop sessions that cover components on saving, and financial management. The sessions will: introduce participants to saving, saving strategies, career planning, and the utilization of financial institutions, including saving in banks.
41366155|NCT06347146|BEHAVIORAL|Mentorship|Each adolescent and youth will have a mentor who will visit with them monthly for the duration of the intervention. The one-to-one mentorship program is intended to help AYaAIDS overcome a variety of challenges they face in daily life by fostering meaningful and lasting relationships with near peer or adult role models. Resilience theory posits that having a supportive adult outside the family reduces the impact of stress on AY's mental health. Mentors will be high school students who will be trained by the schools or NGO staff depending on study condition. All mentors will be reimbursed for their transport expenses to the field, plus an equivalent of a $5 gift card for airtime per visit.
40845320|NCT04152798|PROCEDURE|Laparoscopic hiatal hernia repair with ProGrip™ mesh|Suturing of the right and left diaphragmatic crura using 3 to 4 interrupted nonabsorbable stitches with additional reinforcement of crura repair with ProGrip™ mesh
40845321|NCT04152798|PROCEDURE|Laparoscopic primary posterior crural repair|Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable sutures
41366156|NCT06347146|BEHAVIORAL|Income Generation Activity (IGA)|Participants will be trained on investing in income-generating activities (IGA) during the FLT workshops and will be allowed to use up to 30% of their matched savings to invest in an IGA intended to benefit the adolescent and youth (AY) and their caregiving families. The IGA portion is intended to promote economic stability.
41501207|NCT02935621|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
40845322|NCT03848949|DEVICE|Evenup|Orthotic which increases effective leg length.
40845323|NCT05532605|OTHER|cardiac rehabilitation phase I protocols|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own.
40845324|NCT05532605|OTHER|Cardiac rehab phase I protocols + Mindfullness base therapy|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own. Plus Mindfullness base therapy
40845325|NCT01154751|DEVICE|SUPERA Interwoven self-expanding nitinol stent|Insertion of stent at stenotic area
40845326|NCT02687087|DEVICE|Visco-ease|19.6 mg/mL of LMS-611
40845327|NCT02687087|DEVICE|Placebo|Physiological Saline
40845328|NCT05071014|DRUG|Pembrolizumab|Pembrolizumab: 200mg/dose delivered by IV infusion
40845329|NCT05071014|PROCEDURE|Image-guided cryoablation|Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.
40845330|NCT03150628|DRUG|Perioperative chemotherapy|Perioperative chemotherapy
40845331|NCT03150628|PROCEDURE|Cytoreduction|Cytoreductive surgery
41161361|NCT00678899|DEVICE|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
41161362|NCT05838976|DIAGNOSTIC_TEST|Shorter Version of the CTQ-SSS|The intervention in this study is the administration of the shorter version of the CTQ-SSS, a validated questionnaire designed to assess the severity of symptoms and functional limitations associated with carpal tunnel syndrome. The CTQ-SSS consists of 8 items related to symptom severity and 2 items related to functional status. The scores for each set of items are combined to generate symptom severity and functional status scores, which will be used to assess the validity and reliability of the CTQ-SSS in patients with carpal tunnel syndrome undergoing nonsurgical management.
41161363|NCT03628690|DEVICE|BandGrip|Topical skin closure device
41501208|NCT04181606|DRUG|Esmolol infusion|The Esmolol loading dose will be 0.5 mg/kg fat free mass/min administered over the first 3 minutes, followed by a maintenance dose of 0.25 mg/kg fat free mass/min for the remainder of the protocol (maximum of 60 minutes).
40845332|NCT03150628|DRUG|HIPEC|Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
40845333|NCT00302913|DRUG|Adjustment of clopidogrel dose|
40845334|NCT04777292|DEVICE|Use of a mobile health application until app completion|Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.
40845335|NCT01682356|DIETARY_SUPPLEMENT|Beetroot Juice (BRJ)|double-blind placebo-controlled cross-over study
40845336|NCT01682356|DIETARY_SUPPLEMENT|placebo|double-blind placebo-controlled cross-over study
40845337|NCT03589755|BEHAVIORAL|Mindfulness meditation|The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
40845338|NCT05735535|DRUG|Antiviral Agents|two-drug one-pill once day
40845339|NCT03218748|BEHAVIORAL|Honest, Open, Proud (HOP)|"Three lessons, one for each two-hour session plus one booster session~1. Considering the pros and cons of disclosure:~   Discussion of one's idea of identity and mental illness, weighing the costs and benefits of (non-) disclosure~2. Different ways to disclose:~   Discussion of different levels of (non-) disclosure, considering costs and benefits of each level, selecting persons to disclose to and how to test them out, anticipating responses of others to one's disclosure~3. Telling one's story:~   Practice how to tell one's story, identifying peers who might be helpful with the coming out process~4. Booster session Reviewing previous intentions to disclose one's mental illness, discussion whether one disclosed and evaluating this experience"
40845340|NCT05529329|PROCEDURE|overlay|Lithium Disilicate partial coverage of hypo-mineralized defected enamel
40845341|NCT04130698|BEHAVIORAL|Distress Tolerance|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.
40845342|NCT04130698|DRUG|transdermal nicotine patch|Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
40845343|NCT04130698|BEHAVIORAL|Active Health Control|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
41161364|NCT03628690|DEVICE|Suture|Wound closure
41161365|NCT02056600|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
41161366|NCT02056600|DRUG|gemigliptin/metformin HCl sustained release|Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
40845344|NCT02027753|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution Route of administration: subcutaneous
40845345|NCT02027753|DRUG|Metformin|Pharmaceutical form: tablet Route of administration: oral
40845346|NCT02027753|DRUG|DPP-4 inhibitor|Pharmaceutical form: tablet Route of administration: oral
41366157|NCT06347146|BEHAVIORAL|Youth Development Accounts (YDA)|Each adolescent and youth (AY) will receive a youth development account, which is a matched savings account held in the AY's name in a financial institution under the Central Bank (Bank of Uganda). Any of the AY's family members, relatives, or friends is encouraged to contribute towards the YDA. The account is then matched with money from the program. The match cap (maximum family contribution to be matched by the program) will be an equivalent of US$10 a month per family or US$200 for the 20-months intervention period. AY who save the maximum amount will have $600 ($200 plus $400 in match-a 2:1 match rate).
40845347|NCT02027753|DRUG|Sulphonylurea|Pharmaceutical form: tablet Route of administration: oral
40845348|NCT00877396|BIOLOGICAL|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
40845349|NCT00877396|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
40845350|NCT02474251|OTHER|Continuous positive airway pressure device|GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits
40845351|NCT05825391|DRUG|Adjustment of Antiplatelet Drugs|The maximum platelet aggregation rate induced by arachidonic acid (AA-MPA)≥20%, give aspirin 200mg qd. The maximum platelet aggregation rate induced by adenosine diphosphatase (ADP-MPA)≥36.4% for flow diversion, give ticagrelor 60mg bid. ADP-MPA≥42.9% for stent-assisted coil embolization，give ticagrelor 60mg bid. ADP-MPA\<20%, give clopidogrel 37.5mg qd. The timing of drug adjustment should be at least 1 day before stent implantation, and the LTA testing should be performed again 48 hours after the drug adjustment. For patients whose ADP-MPA does not reach the normal range, a second antiplatelet drug adjustment should be performed: ticagrelor overdose: reduce to 45mg bid; ticagrelor resistance, increase to 90 mg bid.
40845352|NCT03497364|DRUG|bupivacaine|0.5 % bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection according to the height of subjects (1.7 ml for 173\~174cm, 1.65 ml for 170\~172cm, 1.6 ml for 168\~169cm, 1.55 ml for 165\~167cm, 1.5 ml for 163\~164cm, 1.45 ml for 160\~162cm, 1.4 ml for 158\~159cm, 1.35 ml for 155\~157cm, 1.3 ml for 153\~154cm, 1.25 ml for 150\~152cm, 1.2 ml for 148\~149cm)，1.15 ml for 145\~147cm).
40845353|NCT03497364|DRUG|ropivacaine|0.5 % ropivacaine (1% ropivacaine (1.5 ml) + cerebrospinal fluid (1.5 ml)) was injection according to the height of subjects (2.300 ml for 173\~174cm, 2.225 ml for 170\~172cm, 2.15 0ml for 168\~169cm, 2.075 ml for 165\~167cm, 2.000 ml for 163\~164cm, 1.925 ml for 160\~162cm, 1.850 ml for 158\~159cm, 1.775 ml for 155\~157cm, 1.700 ml for 153\~154cm, 1.625 ml for 150\~152cm, 1.55 0ml for 148\~149cm, 1.475 ml for 145\~147cm)
40845354|NCT02731612|DRUG|lurasidone|Atypical Antipsychotic
40845355|NCT02731612|OTHER|Placebo|Inactive substance
40845356|NCT06013189|OTHER|Gas Flow Adjustment|Decreased gas flow causes PaCO2 to elevate and prevents alkalosis
40845357|NCT05848362|OTHER|Blood Glucose Measurement Values Taken by Different Methods|"In total, blood samples will be collected from 3 different sites (central venous catheter, capillary, arterial catheterization) in the same patient. In total, with 5 different techniques from 3 different regions from the same patient;~ARTERIAL BLOOD SAMPLE i) Washing with 5 cc 1% Heparin fluid ii) Washing with 10 cc 1% Heparin fluid CAPILAR BLOOD SAMPLE iii) Right / Left Fingertip iv) Thumb base CENTRAL VENOUS CATHETERIZATION BLOOD SAMPLE will be collected."
40845358|NCT03057080|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
40845359|NCT05165485|DRUG|Revefenacin|Revefenacin DoseA
40845360|NCT05165485|DRUG|Tiotropium|Tiotropium DoseB
40845361|NCT05165485|DRUG|Revefenacin Placebo|Placebo for Revefenacin administered with Tiotropium
41366158|NCT01068015|OTHER|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
41366159|NCT02903121|DRUG|Tamoxifen|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
41366160|NCT02903121|DRUG|Placebo|Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
41501209|NCT04181606|DRUG|Saline infusion|Saline will be rate/volume matched to the calculated esmolol dose.
40845362|NCT05165485|DRUG|Tiotropium Placebo|Placebo for Tiotropium administered with Revefenacin
40845363|NCT02683863|DRUG|BG00012 (DMF) (Tecfidera®.)|Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
40845364|NCT05145244|OTHER|NO intervention|No intervention
40845365|NCT00379054|BEHAVIORAL|telephone based skills training intervention|
40845366|NCT01392612|DRUG|erythropoietin|Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
40845367|NCT00002148|DRUG|OPC 14117|
40845368|NCT04303299|DRUG|Oral|Anti virus treatment
41028242|NCT02087800|BEHAVIORAL|L phase lab session|L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
41028243|NCT02873169|OTHER|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
41028244|NCT04785404|PROCEDURE|primary skin closure|skin will be stitched after stoma reversal to heal by primary intention
41028245|NCT04081207|BEHAVIORAL|AAC for Language Recovery (AAC-LaRc)|iPads will be programmed with a personalized communication application (app) and a structured 4-step intervention will be employed to instruct patients how to cue themselves during anomic events via pictures, text, or speak buttons.
41366161|NCT02903121|DRUG|Tamoxifen (open label)|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
41501210|NCT04181606|OTHER|Pre exercise baseline|Subject rests quietly while drug infusion begins (3 min loading dose followed by 10 min of maintenance dose) until heart rate and blood pressure stabilize.
41501211|NCT04181606|OTHER|Isometric handgrip exercise|The subject will grip at 40% of their maximum and maintain that grip for 90 seconds. Once at rest and once during heavy intensity cycling.
40845369|NCT03753139|DEVICE|Heart rhythm monitoring with portable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.~4. Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel."
40845370|NCT03761342|BEHAVIORAL|Multiple Traffic Light Label|The United Kingdom's Multiple Traffic Light label has repeatedly demonstrated effectiveness and has been widely implemented in Europe. The label shows how much calories, fats, saturated fats, sugar and salt are present in a product, with associated traffic light signals for high (red), medium (amber) and low (green) percentages for each attribute.
40845371|NCT03761342|BEHAVIORAL|Nutri-Score Label|In late 2017, France began voluntary implementation of one FOP label, termed Nutri-Score, adapted from its predecessor, the 5-colour Nutrition Label. Consumer acceptability and understanding of the NS label has been demonstrated in several studies. It provides a letter score as a composite grade of a product's nutrition quality from A (best) to E (worst).
40845372|NCT00527982|DRUG|Celecoxib|600 mg by mouth daily for a total of 12 months.
40845373|NCT05194527|OTHER|Biomarker validation and VOC profile identification|Validation of a panel of plasma markers for the early diagnosis of acute intestinal ischemia with a panel consists of I-FABP, VIL-1, and SM22. Identification of an acute intestinal ischemia specific VOCs profile and evaluate exhaled breath analysis as a diagnostic tool for intestinal ischemia.
41161367|NCT05424211|DEVICE|Music Therapy Mobile Application|The authorities determined by taking consultancy from TÜMATA (Turkish Music Research and Promotion Group) will be uploaded to the mobile application developed by the software specialist. The maqams (Rast, Nihavent and Neva) to be used in the application will be played to the patients 3 times in half an hour at different times of the day via the mobile application. Rast tonality will be played in the morning, nihavent tune will be played at noon and neva tune will be played in the afternoon.
41366162|NCT00130754|DRUG|Thymoglobuline|IV 7.5 mg/kg
41366163|NCT01200758|DRUG|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
41366164|NCT01200758|DRUG|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
41366165|NCT01200758|DRUG|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
41366166|NCT01200758|DRUG|Doxorubicin|Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
41366167|NCT01200758|DRUG|Vincristine|Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.
41366168|NCT01200758|DRUG|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
41366169|NCT01247376|DEVICE|Cooling and compression|Cooling and compression of the knee postoperatively with an Aircast device.
41366170|NCT01003691|BIOLOGICAL|RN6G|Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
41366171|NCT01003691|BIOLOGICAL|Placebo|Intravenous, multiple dose with experimental dose
41366172|NCT01732380|DRUG|Raltitrexed|
41366173|NCT01732380|DRUG|Oxaliplatin|
41366174|NCT01732380|RADIATION|Radiotherapy|
41366175|NCT05712343|DRUG|Valacyclovir group|The valacyclovir group will be received, valacyclovir (500 mg, 3 times a day for 3 days)
41366176|NCT05712343|OTHER|Control group|The control group will receive placebo medication, three times a day for 3 days.
41366177|NCT05263973|OTHER|Music|The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination
41366178|NCT01265927|DRUG|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
41366179|NCT05919940|DIETARY_SUPPLEMENT|Dietary Supplement: additional substitution of protein|"Day one (admission) no nutrition is applied.~Protein target is increased as follows:~* to a level of 1,2g/kg/d on day 1 after ICU admission~* to a level of 1,4g/kg/d on day 2 after ICU admission~* to a level of 1,6g/kg/d on day 3 after ICU admission~* to a level of 1,8g/kg/d on day 4 after ICU admission~* to a level of 2,0g/kg/d from day 5 onwoards~Additional protein is given within 2 hours after mobilization respectively:~* to 0,125g/kg/d on day 1 after ICU admission~* to 0,2g/kg/d on day 2 after ICU admission~* to 0,25g/kg/d on day 3 after ICU admission~* to 0,3g/kg/d from day 4 after ICU admission onwoards"
41366180|NCT05919940|DEVICE|Neuromuscular electrical stimulation|twice daily 60 minutes till day 28 or ICU discharge
41366181|NCT05919940|OTHER|Early Mobilization|at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
40845374|NCT06043609|OTHER|This is an observational cohort study|This is an observational cohort study
41366182|NCT02179580|DRUG|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
41366183|NCT02179580|DRUG|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
41366184|NCT04419220|OTHER|Doppler Ultrasound|Flow measurements using Doppler ultrasound
41501212|NCT04181606|OTHER|Semi-recumbent cycling|Subjects will pedal for 2-4 minutes at a very light intensity (20W), followed immediately by 5 minutes at a moderate intensity (at a workload intended to elicit 85% of the oxygen consumption observed at the lactate threshold), and 5 minutes of cycling at a heavy intensity (at a workload estimated to elicit oxygen consumption half way between those observed at the lactate threshold and respiratory compensation point). Subjects will then continue cycling at the heavy intensity for 90 seconds while performing isometric handgrip exercise.
41501213|NCT04026386|BEHAVIORAL|Center Based or In Home Early Intervention Program|This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment or in home to treat social communication deficits in children with developmental disorders.
41501214|NCT02002286|DRUG|Tripterygium Wilfordii Hook F extract (TwHF extract)|The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
41501215|NCT02002286|DRUG|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
41501216|NCT06308094|DIAGNOSTIC_TEST|CT|Pre-ablation CT is clinically acquired in patients undergoing catheter ablation. This study entails additional acquisition of the left ventricle to assess extracellular volume (ECV)
41501217|NCT05623618|BEHAVIORAL|PACE labelling|PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
41501218|NCT02572414|BEHAVIORAL|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.
41501219|NCT02572414|BEHAVIORAL|Health Awareness Control Intervention|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
41501220|NCT01897038|DRUG|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
41501221|NCT01897038|DRUG|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
41501222|NCT06624878|DRUG|esketamine|0.2 mg/kg esketamine infused intravenously after induction of general anesthesia.
41501223|NCT06624878|DRUG|placebo|a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.
41501224|NCT03745157|DRUG|Insulin Degludec/Insulin Aspart|Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
41501225|NCT00741286|DRUG|Aspirin|Asprin (100mg) plus placebo
41501226|NCT00741286|DRUG|cilostazol|Aspirin (100mg) plus cilostazol (200mg)
40845375|NCT02508909|PROCEDURE|Videoscopic ilioinguinal dissection|Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
40845376|NCT04964596|DIAGNOSTIC_TEST|colonoscopy|colonoscopy
40845377|NCT04964596|DIAGNOSTIC_TEST|FIT test|faecal immunochemical test
40845378|NCT04964596|DIAGNOSTIC_TEST|CT colonography|noninvasive medical imaging technique that uses computed tomography to visualize the interior of the colon and rectum especially to screen for polyps or cancerous growths
40845379|NCT03521479|DRUG|Squaric Acid Dibutyl Ester|Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
40845380|NCT02904148|PROCEDURE|Shoulder mobilisation|early shoulder mobilisation
40845381|NCT00175448|PROCEDURE|physiotherapy|See Detailed Description.
40845382|NCT02113358|DRUG|Intravenous colloid bolus with Voluven|
41366185|NCT00208858|DRUG|Topiramate|
41366186|NCT02354027|DRUG|SHR3824 metformin|"Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin"
41366187|NCT01939236|DRUG|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
41366188|NCT01939236|DRUG|Placebo (gummeline)|"Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days."
41366189|NCT04115488|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
41366190|NCT00643006|BEHAVIORAL|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
40845383|NCT05196555|PROCEDURE|Repair of cleft palate with intravelar veloplasty (IVVP)|A triangular flap is designed comprising new epithelial tissue which will be turned over to help close the nasal mucosa. Using a single hook, the oral mucosa and gland layer is separated from the muscle layer. Dissection of the greater palatine nerve-vessel bundle. The anterior palatal flap is raised by a curved elevator. The closure of the nasal mucosa and muscle is completed. Dissection of Velo Palatine Levator begins from the posterior rim of muscle and 5 mm from the midline.
40845384|NCT01363115|DIETARY_SUPPLEMENT|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
40845385|NCT01363115|DIETARY_SUPPLEMENT|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
40845386|NCT01363115|BEHAVIORAL|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
40845387|NCT03595488|DRUG|Dupilumab|dupilumab 300 mg subcutaneous injection every 2 weeks
40845388|NCT02516228|DEVICE|GTEN 100|"Stimulation will be focused on the seizure generating cortex. All patients enrolled in the study will have a pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.~During this baseline period, two two-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone. Using the localization information, patients will be treated with the device for five concurrent days."
40845389|NCT01867138|DRUG|Cefazolin|
40845390|NCT01867138|DRUG|Vancomycin|
40845391|NCT01867138|DRUG|Amikacin|
40845392|NCT00473408|DEVICE|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
40845393|NCT00473408|PROCEDURE|Blood sample|See protocol.
40845394|NCT00473408|PROCEDURE|Tumor sample|See protocol.
41366191|NCT00643006|BEHAVIORAL|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
41366192|NCT04189198|DRUG|Articaine|Supraclavicular block with 30 ml articaine 2%
41366193|NCT04189198|DRUG|Bupivacaine|Supraclavicular block with 30 ml bupivacaine 0.5%
41501227|NCT04667754|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
41501228|NCT03901976|DEVICE|bed exit detection|bed exit detection to avoid patients fall
41501229|NCT05228938|PROCEDURE|VNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
40845395|NCT02666105|DRUG|Exemestane|One 25 mg tablet once daily for a minimum of 6 weeks
40845396|NCT03417934|PROCEDURE|Hip Arthroscopy Procedure|The purpose of this pilot study is to evaluate the effects of hip distraction without a perineal post on the lower extremity during hip arthroscopic procedures by peri-operative monitoring of various prognostic markers for venous, nerve and tissue injury.
40845397|NCT05161689|BEHAVIORAL|HUG-M+|A multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire HIV Continuum of Prevention and Care.
41501230|NCT05228938|PROCEDURE|laparoscopic|laparoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
40845398|NCT05526339|DEVICE|High-flow nasal oxygenation combined with nasopharyngeal airway|The patients receive an oxygen flow of 30 L/min for preoxygenation with a high-flow oxygenation device before losing of conscious. At the time of the abolition of the eyelash reflex, the gas flow was increased to 60 L/min with an inspired oxygen fraction 100% and the nasopharyngeal airway was placed.
40845399|NCT05526339|DEVICE|Regular nasal cannula combined with nasopharyngeal airway|The patients receive an oxygen flow of 6 L/min for preoxygenation with a regular nasal cannula until the end of procedure. At the time of abolition of the eyelash reflex, the nasopharyngeal airway was placed.
41028246|NCT00214877|DRUG|Methylene Blue|
41028247|NCT04825275|DRUG|Posaconazole Pill|300 mg (three 100 mg tablets) orally
41028248|NCT03094572|OTHER|visual motor tasks|"This exercise involves manipulating an object that corresponds to a racket, this racket has a virtual avatar that animated a virtual ball. The purpose is to make it bounce to a given height. This comes close to ping-pong game."
41028249|NCT01798550|DRUG|Enoxaparin|Twice daily dosing
41028250|NCT04057495|OTHER|further fasting|2 hours of fasting
41028251|NCT04057495|OTHER|white bread consumption|113 grams of white bread consumption
41028252|NCT04057495|OTHER|mango consumption|330 grams of mango consumption
41501231|NCT02996487|DRUG|Vancomycin|
41501232|NCT02996487|OTHER|Placebo|
41501233|NCT03997851|DRUG|Acetaminophen|Topical acetaminophen gel
40845400|NCT03094715|DEVICE|Thrombectomy|Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).
41501234|NCT03997851|DRUG|Carbomer 980|Topical vehicle gel
40845401|NCT03094715|OTHER|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
40845402|NCT03565237|BIOLOGICAL|RIXUBIS: On-Demand|RIXUBIS used under standard clinical practice in India: On-Demand treatment.
40845403|NCT03565237|BIOLOGICAL|RIXUBIS: Prophylaxis|RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.
40845404|NCT02726022|DRUG|Peginterferon alfa-2a|As per treating physician discretion and according to summary of product characteristics.
40845405|NCT02726022|DRUG|Ribavirin|As per treating physician discretion and according to summary of product characteristics.
40845406|NCT00288327|BEHAVIORAL|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
40845407|NCT00288327|BEHAVIORAL|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
40845408|NCT03824587|DRUG|Tenapanor|Active Drug
40845409|NCT03824587|DRUG|Placebo|Inactive Drug
40845410|NCT03824587|DRUG|Phosphate Binder Agents|standard of care phosphate binder use at study entry was maintained throughout the entire study
40845411|NCT05508893|RADIATION|CT Angiography|A CTA will be performed on asymptomatic individuals
40845412|NCT05508893|DIAGNOSTIC_TEST|Exercise stress test|A routine exercise stress test will be performed on a bicycle
40845413|NCT04343716|BEHAVIORAL|Low-carbohydrate diet|A diet low in daily carbohydrates (\<40 grams/day) provided as prepared meals.
40845414|NCT02768753|PROCEDURE|The Axillary Bilateral-breast Approach|
40845415|NCT02768753|PROCEDURE|The bilateral Axillo-breast Approach|
41028253|NCT05649657|OTHER|Cyclic aerobic and resistance training|Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25\~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2\~3 sessions per week and about 70 sessions in total.
41366194|NCT06163768|PROCEDURE|Insulin resistance|Steps to conduct testing and treatment according to the approved regimen at Ho Chi Minh City University of Medicine and Pharmacy Hospital. The researcher did not intervene in the treatment process.
41366195|NCT02425774|PROCEDURE|Vagus stimulation|
41366196|NCT02425774|PROCEDURE|Sham stimulation|
41501235|NCT03350607|OTHER|Non interventional study|Non interventional study (collect of data)
41501236|NCT01370447|DRUG|EPI-743|EPI-743 (oral solution \[100 mg/mL\] or liquid-filled capsules \[100 mg or 200 mg\]) will be administered per dose and schedule specified in the arm.
41501237|NCT05138991|PROCEDURE|Echocardiogram Recording|Undergo assessment via echo
41501238|NCT05138991|OTHER|Questionnaire Administration|Ancillary Studies
41501239|NCT05138991|PROCEDURE|Stress Cardiac Magnetic Resonance Imaging|Undergo assessment via CMR
41501240|NCT05138991|DEVICE|Wireless Synchronized Cardiac Function Monitoring Device|SphygmoCor® Xcel Oscar 2™ Ambulatory Blood Pressure Monitor
41501241|NCT02665104|DEVICE|transcranial Doppler (TCD) and INVOS monitor|Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
41501242|NCT04409483|DRUG|Lopinavir-Ritonavir Drug Combination|400mg/100mg taken orally twice daily for 14 days.
41501243|NCT04409483|COMBINATION_PRODUCT|Standard Care|Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily
41028254|NCT04587089|PROCEDURE|Irrigation|Irrigation and aspiration in the root canals with 1% sodium hypochlorite (Milton's solution).
41366197|NCT02425774|DRUG|Prucalopride|
41366198|NCT02425774|DRUG|Placebo|
41366199|NCT06328192|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
41366200|NCT00918489|DRUG|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
41366201|NCT05441722|BEHAVIORAL|Exercise prehabilitation|Exercise on a cycle ergometer 24 hours before chemotherapy infusion.
41501244|NCT00606164|DRUG|Bryostatin for Injection|A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
41501245|NCT00606164|DRUG|Placebo|A single one-hour intravenous infusion of placebo on Day 1
41501246|NCT04949711|BEHAVIORAL|ridesharing voucher|Ridesharing vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
41501247|NCT04949711|BEHAVIORAL|online shopping voucher|Online shopping vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
41501248|NCT00273039|DRUG|paroxetine|
41501249|NCT02213289|DRUG|Trastuzumab|Trastuzumab
41501250|NCT02213289|DRUG|ABT-806|ABT-806
41501251|NCT02213289|DRUG|Bemarituzumab|Bemarituzumab
41366202|NCT04087005|OTHER|hominis placental pharmacopuncture|Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
41028255|NCT04587089|PROCEDURE|Filling with Guedes-Pinto Paste|The root canals will be filled with Guedes-Pinto Paste, which is a composite of 3 medications: Rifocort® (dermatologic ointment), camphorated paramonochlorophenol (PMCC) and iodoform. It will be prepared at the moment of use with the same proportion in volume of 3 visually identical parts, one for each of its components.
41028256|NCT04587089|PROCEDURE|Filling with CTZ Paste|The powder that composes the CTZ paste will be previously manipulated in a 1:1:2 ratio (500mg of Chloramphenicol, 500mg of Tetracycline and 1,000mg of Zinc Oxide) by Formula \& Ação (F\&A) and incorporated into the eugenol liquid at the time of use, with the aid of a flexible spatula nº 24 and on a sterile glass plate. The cleaning of the coronary chamber must be carried out with saline solution and drying with sterile cotton balls and the CTZ paste must be inserted into the cavity.
41028257|NCT06046313|DRUG|Decitabine for Injection|6mg/m2, ivgtt qd d1-10
41028258|NCT06046313|DRUG|VENCLYXTO|100mg p.o.d1, 200mg p.o.d2, 400mg p.o.d3-21,adjust by blood concentration
41501252|NCT02213289|DRUG|Ramucirumab|Ramucirumab
41501253|NCT02213289|DRUG|Nivolumab|Nivolumab
41501254|NCT02213289|DRUG|Standard cytotherapy|FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
41501255|NCT04317482|BEHAVIORAL|Standard social stress task|Participants will be asked to respond in detail to three scenarios. This is a standard social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
41501256|NCT04317482|BEHAVIORAL|Stressful experience in the ED|Participants will be asked to imagine and then describe both feelings and bodily sensations experienced at their most stressful ED visit, in order to help them more fully re-experience the situation. In this regard, the second condition is more similar to stress imagery employed by Sinha et al, which elevated cortisol to a greater degree than a social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
41028259|NCT00916877|RADIATION|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
41028260|NCT00930111|OTHER|2-week rotation|Attending physician is assigned to a 2-week rotation.
41028261|NCT00930111|OTHER|4-week rotation|Attending physician is assigned to a 4-week rotation.
41028262|NCT02239510|DRUG|Senna|1 capsule (50 mg) Senna daily for 12 weeks
41028263|NCT02239510|DRUG|Linzess|1 capsule (145 mcg) of Linzess once daily for 12 weeks
41501257|NCT03578367|DRUG|Asciminib add-on|Asciminib 60 mg or 40 mg taken orally once daily.
41501258|NCT03578367|DRUG|Imatinib|Imatinib 400 mg taken orally once daily
41501259|NCT03578367|DRUG|Nilotinib|Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)
41501260|NCT03578367|DRUG|Asciminib single agent|Asciminib 80 mg taken orally once daily
41501261|NCT00103220|DRUG|SJG-136|Given IV
41028264|NCT00899223|OTHER|biologic sample preservation procedure|
41028265|NCT01748916|OTHER|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
41028266|NCT01748916|OTHER|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
41028267|NCT01748916|OTHER|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
41028268|NCT01462994|OTHER|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
41366203|NCT03400202|DEVICE|Skin imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).
41366204|NCT03400202|OTHER|Facial cleanser|Facial cleanser prior to procedures.
41501262|NCT06259188|DEVICE|Respiratory Muscle Training Device|In the both groups the initial pressure load will be set to the resistance level corresponding to the 40% of the MIP and MEP measurement. Participants will be asked to rest following 5 breathing cycles and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. In breathing exercise device group participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. In IMT+EMT group, patients will be able to practice different to device. As the progression progresses, the perceived exertion level will be increased by 5-10% every week, to be in the range of 4-6 according to the Modified Borg scale.
41501263|NCT06259188|DEVICE|Personalized Breathing Exercise Device|Personalized Breathing Exercise Device
41501264|NCT00832156|BIOLOGICAL|Cultured autologous keratinocytes|The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
41366205|NCT02632773|BEHAVIORAL|Responsive Intervention|Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
41366206|NCT02632773|BEHAVIORAL|Directive Intervention|Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
41366207|NCT01435876|PROCEDURE|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
41028269|NCT05234346|DRUG|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
41366208|NCT01435876|PROCEDURE|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
41366209|NCT01435876|PROCEDURE|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
41366210|NCT01435876|PROCEDURE|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
41366211|NCT00958282|DRUG|lisdexamfetamine/Behavior Therapy|
41366212|NCT00958282|OTHER|placebo|
41366213|NCT04165174|DRUG|Terepril monoclonal antibody; Apatinib|Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
41028270|NCT05234346|OTHER|Placebo|No Description for the intervention
41028271|NCT05388448|DRUG|Sanfetrinem Cilexetil|"Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules"
41028272|NCT05388448|DRUG|Amoxicillin/clavulanic acid|Amx/CA will be administered orally as Amx/CA 250/125 mg, 1 tablet twice daily for 14 days alongside with sanfetrinem cilexetil.
41028273|NCT05388448|DRUG|Rifampicin|Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.
41028274|NCT05933915|OTHER|group-based laughter yoga|"Midwives in the intervention group of the research will apply 8 sessions of laughter yoga, 2 sessions a week. Laughter yoga will be practiced by researchers with leadership certification. Each session will take an average of 45 minutes. Laughter Yoga sessions will be held on the web through the Zoom program. Each session will consist of groups of 8 people."
41366214|NCT04165174|RADIATION|SBRT|6-10Gy/F,5-8F
41366215|NCT03189680|OTHER|Exercise therapy|3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
41366216|NCT03301246|DEVICE|Artimes Pro Low Profile Dilatation Catheter|Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
41366217|NCT05470530|DRUG|Dexamethasone|Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
41366218|NCT01823575|DEVICE|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
41366219|NCT01823575|DEVICE|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
41366220|NCT01265719|OTHER|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
41366221|NCT01265719|OTHER|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
41366222|NCT05648305|PROCEDURE|Root Canal Treatment/ Re-treatment|The provision of Root Canal Treatment for teeth with Endodontic infection or to prevent Endodontic infection.
41366223|NCT00005874|DRUG|rubitecan|
41366224|NCT02988115|DRUG|bempedoic acid|bempedoic acid 180 mg tablet
41366225|NCT02988115|OTHER|placebo|Matching placebo tablet
41366226|NCT00036621|DRUG|BMS-275291|
41366227|NCT02440490|BEHAVIORAL|Computerised cognitive training|
41366228|NCT02440490|BEHAVIORAL|Video watching|
41366229|NCT01652651|BEHAVIORAL|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
41366230|NCT02329834|DRUG|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
41366231|NCT02329834|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
41366232|NCT00250731|BEHAVIORAL|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
41366233|NCT00250731|OTHER|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
41366234|NCT02278042|OTHER|Beverage Consumption|
41366235|NCT02779842|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. formulation number SR15-39-Z12-002.
40845416|NCT00806143|DEVICE|repetitive transcranial stimulation (rTMS)|"Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.~In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days."
41366236|NCT05502809|DRUG|Deep-frozen platelets|Cryopreserved platelets
41366237|NCT00209079|DRUG|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
41366238|NCT03029572|DRUG|Diet supplementation|Micronutriment supplementation therapy
41366239|NCT03029572|PROCEDURE|Bariatric surgery|Roux-en-Y gastric bypass provided in both arms.
40845417|NCT00806143|DEVICE|unilateral stimulation|Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
40845418|NCT00456651|DEVICE|CPAP (Continuous Positive Airway Pressure)|
40845419|NCT04845178|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
41366240|NCT00646737|DRUG|Mycophenolate sodium|Mycophenolate sodium
41366241|NCT02011646|BEHAVIORAL|Healthy Weight|The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.
41366242|NCT02011646|BEHAVIORAL|Controlled Intervention|"The Weight of the World is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web."
41366243|NCT00366665|DEVICE|Legacy 20000|
41366244|NCT00366665|DEVICE|Infinit system|
40845420|NCT04845178|DRUG|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/PhEur
40845421|NCT02632994|DRUG|LY2503029|Administered orally.
40845422|NCT02632994|DRUG|LY3023414|Administered orally.
41366245|NCT02108561|OTHER|Post Surgical Her2 testing|Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
41366246|NCT04585191|BEHAVIORAL|Conversation Aid|"Intervention is a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? that patients receive prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
41366247|NCT04585191|OTHER|Attention Control Educational Handout|Attention control is an existing health education handout that provides some general health advice geared towards older patients.
41028275|NCT05927129|DRUG|Antidepressant|Patients will receive standardized treatment with antidepressant, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
41366248|NCT06452485|OTHER|No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups.|Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.
41366249|NCT05119738|BIOLOGICAL|Three doses of BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine)
41366250|NCT05119738|BIOLOGICAL|Two doses of Coronavac and one dose BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)
41501265|NCT05422625|DEVICE|PTNS Treatment|Patients will be placed in a comfortable position, sitting or supine. The treatment leg will be propped up comfortably on a footrest but draped and out of view from the patient. A 34-gauge needle electrode will be inserted at a 60-degree angle 5 cm cephalad to the medial malleolus and slightly posterior to the tibia. A PTNS surface electrode will be placed on the ipsilateral calcaneus as well as 2 inactive sham surface electrodes, 1 under the little toe and 1 on the top of the foot. When the PTNS lead set is connected to the Urgent PC stimulator, a current level of 0.5 to 9 mA at 20 Hz is selected based on each patient's foot and plantar motor and sensory responses. Treatment lasts 30 minutes and given once weekly for 12 consecutive weeks.
41501266|NCT05422625|DEVICE|Sham PTNS Treatment|"Patients will be positioned similarly as PTNS patients. A Streitberger needle will be used at the tibial nerve insertion site as described above to simulate needle placement. Three electrodes will be placed on the patient's foot, two active TENS electrodes and one inactive TENS electrode. The TENS grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe. Another gel electrode will be placed on the top of the foot just above the small toe for conduction. These two electrodes will be connected to the TENS unit lead wires for sham stimulation. A third, inactive, gel electrode, will be placed near the medial aspect of the calcaneus to mimic the PTNS treatment. The TENS electrode will be connected by lead wires to the TENS unit set at 20 HZ. The TENS unit will be turned on and stimulation slowly increased to the patient's first sensory level and then turned off."
41501267|NCT02074618|OTHER|Physical exercise.|Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
41501268|NCT06603987|RADIATION|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
41501269|NCT06603987|DIAGNOSTIC_TEST|［18F］FBPA|Intravenous injection of ［18F］FBPA and radiation exposure from PET-CT scan.
41501270|NCT00872638|PROCEDURE|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
41501271|NCT00872638|PROCEDURE|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
41501272|NCT03678285|OTHER|HIFRT Workout|A single high intensity functional resistance training (HIFRT) exercise bout.
41501273|NCT04229667|OTHER|Improved Community Health Volunteer (CHV) program|"Multi-modal intervention targeting intensive household monitoring of high-needs patients using monthly visits to measure blood pressure and blood sugar, adherence to treatments and compliance with clinics visits, and motivational interviewing to facilitate behavior change and psychosocial support."
41501274|NCT03526783|PROCEDURE|Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass (150 cm alimentary limb, 50 cm biliopancreaty limb)
41501275|NCT03526783|PROCEDURE|Mini/One anastomosis gastric bypass|Laparoscopic Mini/One anastomosis gastric bypass (200 cm biliopancreatic limb)
41501276|NCT00447993|COMBINATION_PRODUCT|Low Dose NT-501|Low Dose NT-501 Implanted in study eye and fellow eye received sham surgery
41028276|NCT05927129|OTHER|Psychotherapy IPT|The participants will receive standardized IPT treatment for 12 weeks. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
41028277|NCT05927129|OTHER|The combination of antidepressant and IPT|The participants will receive standardized IPT treatment for 12 weeks. Also，long-term antidepressant will be administered in accordance with clinical guidelines. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
41366251|NCT06377670|PROCEDURE|Wassel IV Thumb Duplication Surgery|This intervention involves the surgical correction of Wassel IV thumb duplication, which is a congenital hand anomaly. The study retrospectively evaluates the outcomes of various surgical techniques that have been employed to correct this condition, with a focus on functionality and aesthetics of the thumb post-surgery. Data collected post-intervention include preoperative metacarpophalangeal angle, type of skin flap, surgical reconstruction technique, immobilization method, and postoperative complications. Additionally, patient satisfaction and daily pain levels are assessed using standardized questionnaires. Each patient serves as their own control, with outcomes compared to their contralateral healthy thumb.
41366252|NCT01789333|DEVICE|UVA Light with irradiance exposure of 9 mW/cm2|"The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes)."
41366253|NCT01789333|DRUG|Riboflavin 0.1% ophthalmic solution|"The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin)."
41366254|NCT02999295|BIOLOGICAL|Ramucirumab|Ramucirumab (8 mg/kg) is administered.
41366255|NCT02999295|BIOLOGICAL|Nivolumab|Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
41366256|NCT01509066|OTHER|Diet|Dietary approaches for PCOS
41366257|NCT02906527|DRUG|Non-exposed group|Non-exposed group / Patients receiving VKA
41366258|NCT02906527|DRUG|Exposed group|Exposed group / Patients receiving DOAC
41366259|NCT01499498|DRUG|Sildenafil and Boceprevir|25mg once/800mg three times a day
41366260|NCT05500911|PROCEDURE|sinus lift|when residual bone height is \>4 mm sinus lift through crestal approach procedure will be performed and after sinus flor elevation, OSSIX® Bone will be placed in the sinus cavity.
41366261|NCT05500911|PROCEDURE|implant placement|Implant will be placed in edentulous area
41366262|NCT02828852|OTHER|Blood sample|"In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed."
41366263|NCT00963040|DRUG|Syntocinon|4 actuations in each nostril for a total dose of 32 IU
41366264|NCT00963040|DRUG|Sterile water|4 actuations in each nostril
41366265|NCT00963040|DRUG|Syntocinon|8 actuations in each nostril for a total dose of 64 IU
41028278|NCT06121713|DIETARY_SUPPLEMENT|GCE + Low ALA|Participants will consume a pill containing 200mg green coffee extract and 200mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
41366266|NCT00963040|DRUG|Sterile water|8 actuations in each nostril
41366267|NCT04084652|DIETARY_SUPPLEMENT|Mycoprotein ingestion|The ingestion of mycoprotein
41366268|NCT02247726|DRUG|Saline Placebo (0.5mL injection)|
41501277|NCT00447993|COMBINATION_PRODUCT|High Dose NT-501|High Dose NT-501 Implanted in study eye and fellow eye received sham surgery
41501278|NCT00013091|BEHAVIORAL|Self-management therapy; Psychoeducational group therapy|
41501279|NCT05346926|DEVICE|3D-printed cast|The 3D-printed casts are produced using 3D print technology based on software by Belgian software company: The patient's forearm is scanned with a tablet (duration: approx. 5 min), whereupon the cast is printed overnight according to the scan (duration: approx. 4h) and adjusted to the patient during the next appointment.
41501280|NCT05346926|DEVICE|Conventional cast|A conventional plaster cast is applied for treatment of the distal radius fracture.
41028279|NCT06121713|DIETARY_SUPPLEMENT|GCE + High ALA|Participants will consume a pill containing 200mg green coffee extract and 400mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
41366269|NCT02247726|DRUG|RSV F vaccine (0.5mL injection)|
41366270|NCT02503111|DEVICE|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
41366271|NCT02503111|OTHER|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
41366272|NCT01283724|DRUG|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
41366273|NCT01247467|OTHER|Breast Tumor Blocks|
40845423|NCT05360719|BEHAVIORAL|Group tele-exercise|This tele-exercise class will be tailored to the physical and emotional needs of individuals with SCI based on results of our feasibility study, the initial emergent themes from qualitative data collection in this study, and input from our co-leader with lived experience (examples: seated exercise to accommodate wheelchair users, active co-leader with SCI).The research clinician will lead the instruction of each class while our co-leader will model movements alongside her and offer tailored modifications as needed. Each 45-minute class provides a comprehensive fitness experience to maximize functional independence and improve global physical activity engagement. Elements incorporated into each class session include a collective check-in and breathing meditation, postural control, trunk and shoulder strength, cardiovascular fitness, and body awareness.
40845424|NCT03052023|PROCEDURE|dual approach laparoscopic inguinal hernioplasty|after pneumoperitoneum is done preperitoneal pneumo-dissection is done and then peritoneal incision done . dissection preperitoneally and sac dissection will be easy approached
40845425|NCT03052023|PROCEDURE|TAPP|pneumoperitoneum is done and then through abdominal approach peritoneal dissection in done and sac reduction and then mesh fixation
41028280|NCT06121713|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo pill (500mg insoluble microcrystalline cellulose, 5mg magnesium stearate, 5mg silicon dioxide) prior to a 75g oral glucose tolerance test
41028281|NCT04844281|DEVICE|Precision1® Daily Disposable Toric Contact Lens|Soft, toric contact lens used to correct distance vision and astigmatism.
41028282|NCT04634487|OTHER|No intervention|No intervention
41028283|NCT04269772|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
41028284|NCT04269772|OTHER|Treatment As Usual|Treatment as usual, unrestricted, as provided by prison and community providers.
41028285|NCT00335660|DRUG|AV608|
41366274|NCT05641467|OTHER|virtual reality glasses|OculusQuest 2 128GB brand virtual reality glasses will be used in our research. OculusQuest 2 128GB is the original all-in-one gaming system for virtual reality. It can only be used as desired with the VR headset and controllers. It adapts to its environment. In this way, it can be played standing and sitting in small and large areas. When glasses will be used on another pregnant women within the scope of COVID-19 measures, disinfection will be provided with 'DiverseyOxivir Plus (hydrogen peroxide)' surface disinfectant. Before the episiotomy repair, the video glasses will be opened, the video will be adjusted to suit the woman. In order for the repair method to be the same for all women, It will be planned to use absorbable, synthetic, braided, sterile surgical thread produced from 1-0 polyglactin.
40845426|NCT03052023|PROCEDURE|(lichtenstein) repair|inguinal incision is done and inguinal canal approach anteriorly and then sac dissection and excision then mesh fixation to posterior wall and closure the incision in layers
41028286|NCT03765879|OTHER|Verum VGAIT (Video-Guided Acupuncture Imagery Treatment)|In VGAIT treatment sessions, participants will re-watch the video of themselves receiving acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied.
41028287|NCT03765879|OTHER|Sham VGAIT (Video-Guided Acupuncture Imagery Treatment)|In sham VGAIT treatment sessions, participants will re-watch this video of themselves receiving the sham acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied.
41366275|NCT03586102|DIETARY_SUPPLEMENT|High protein supplementation|To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive \> 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.
41366276|NCT03586102|DIETARY_SUPPLEMENT|Standard protein supplementation|Infants assigned to the standard protein supplementation group will receive fortified human milk (\< 4.5 g/kg/day of enteral protein)
41366277|NCT04038411|DRUG|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
41366278|NCT00063076|DRUG|Targretin Gel 1%|Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
41366279|NCT02094131|OTHER|Voldyne group (VG)|"VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
41366280|NCT02094131|OTHER|Cliniflo group (CG)|"CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
41366281|NCT03195166|DIAGNOSTIC_TEST|FloTrac sensor/Vigileo|blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
41366282|NCT02643121|OTHER|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
41028288|NCT00948831|BIOLOGICAL|Osteocel Plus|biologic
41028289|NCT00788840|DRUG|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
41366283|NCT06044857|DRUG|68-Ga PSMA11|Will be injected/assessed in line with its FDA label.
41366284|NCT00466284|DRUG|Tarceva (erlotinib)|
40845427|NCT02138357|DRUG|buprenorphine transdermal delivery system (BTDS)|
40845428|NCT02138357|DRUG|Placebo for BTDS patch|A placebo patch will be manufactured to mimic the BTDS patch.
40845429|NCT04518163|DRUG|Tranexamic Acid|Intravenous 1 gm tranexamic acid in 100 ml saline by slow infusion before skin incision
40845430|NCT04518163|DRUG|placebo to TA|Intravenous 110 ml saline by slow infusion before skin incision
40845431|NCT04518163|DEVICE|Bakri Balloon|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
40845432|NCT00812565|DRUG|Placebo|Commercially available 0.9% isotonic sodium chloride solution.
40845433|NCT00812565|BIOLOGICAL|octagam 10%|octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
40845434|NCT05257902|DRUG|choline alphoscerate|400mg bid/day
41028290|NCT00788840|DRUG|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
41028291|NCT00279123|DRUG|pantoprazole infusion|
41028292|NCT00279123|DRUG|pantoprazole bolus|
40845435|NCT05257902|DRUG|Placebo|Placebo 1T bid/day
41028293|NCT00279123|DRUG|no treatment|
41028294|NCT05450874|PROCEDURE|hepatectomy|
40845436|NCT02631265|OTHER|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
40845437|NCT02631265|OTHER|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
40845438|NCT02631265|OTHER|Exercise 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
40845439|NCT03468322|DRUG|AC-203|The investigational product is formulated as 1% topical ointment
40845440|NCT03468322|DRUG|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
40845441|NCT03244826|OTHER|Shared Care|Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team
40845442|NCT03244826|OTHER|Standard Care|The usual care provided by the transplant center at DFCI.
40845443|NCT00136669|PROCEDURE|Acupuncture|
40845444|NCT00857519|DRUG|Melphalan, Carboplatin|Intra-arterial chemotherapy.
40845445|NCT05117177|DRUG|Inupadenant|Oral administration
41028295|NCT05926297|PROCEDURE|Application NaOCl gel + HA gel|First step: application of NaOCl gel Second step: NSMD Third step: application of HA gel
41028296|NCT05926297|PROCEDURE|Non-surgical mechanical debridement|Only mechanical debridement with curettes ans scaler tips
41366285|NCT01617343|BEHAVIORAL|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|"Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s."
41028297|NCT03006406|DRUG|Long term GnRH-a (3.75mg)|patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
41501281|NCT06234943|OTHER|Chlamydia trachomatis and Neisseria gonorrhea self-swab(s) and/or urine collection. Clinical assessment and prescribing of treatment for participants with positive test results|Participants will be tested by self-swab sample (pharyngeal, vaginal or rectal) and/or urine sample (urogenital) for Chlamydia trachomatis and Neisseria gonorrhea. Selection of swab(s) or urine-based testing will be determined by the individual's sexual risk factors. Participants who have positive CT and/or NG test results will undergo clinical assessment of the CT and/or NG infection by the pharmacist and a prescription will be issued for treatment as appropriate.
41501282|NCT01194817|DEVICE|High-Flexion Knee Replacement System using Cemented Fixation|
40845446|NCT05117177|DRUG|Inupadenant|Oral administration
40845447|NCT05117177|DRUG|Inupadenant|Oral administration
40845448|NCT00075556|DRUG|capecitabine|
40845449|NCT00075556|PROCEDURE|conventional surgery|
41501283|NCT01194817|DEVICE|High-Flexion Knee Replacement System using Cementless Fixation|
41501284|NCT04875936|BEHAVIORAL|Motor Imagery and Real-Time fMRI Neurofeedback|Survivors of left-hemisphere stroke (\<10 weeks post-stroke) or healthy volunteers will use right-hand motor imagery coupled with fMRI neurofeedback to help them re-engage the left hemisphere by shifting brain activation leftward relative to the initial left-right asymmetry. Following group assignment, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. During the MRI sessions they will receive real time neurofeedback about how well they are engaging the left side of their brain compared to the right side. They will also practice the same task for 30 min a day as homework using the most effective motor imagery strategy that worked for them in the MRI scanner.
40845450|NCT00075556|PROCEDURE|neoadjuvant therapy|
40845451|NCT00075556|RADIATION|radiation therapy|
40845452|NCT04708509|DEVICE|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. Patients will be followed for 72 hours after extubation, when the clinical outcome case report form will be completed.
40845453|NCT03541902|DRUG|Cabozantinib|Given PO
40845454|NCT03541902|DRUG|Sunitinib Malate|Given PO
41028298|NCT04321720|OTHER|3-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g mustard flour (3 g per l), followed by a ten-minute post-intervention rest period.
41028299|NCT04321720|OTHER|6-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g mustard flour (6 g per l), followed by a ten-minute post-intervention rest period.
41366286|NCT02405273|PROCEDURE|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
41366287|NCT02405273|PROCEDURE|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
41366288|NCT00750061|DRUG|Lithium Carbonate|"The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks."
41366289|NCT00750061|DRUG|Placebo|Matching placebo
41501285|NCT04875936|BEHAVIORAL|Motor Imagery and Sham fMRI Neurofeedback|Survivors of left-hemisphere stroke (\<10 weeks post-stroke) or healthy volunteers will practice right-hand motor imagery coupled with sham fMRI neurofeedback. As the experimental group, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. However, during the MRI sessions they will receive sham neurofeedback on the basis of another participant's brain activity. Like the experimental group, they will also practice the same task for 30 min a day as homework.
41501286|NCT06633718|DRUG|Meropenem and Pralurbactam|3g，q8h，120min infusion
41501287|NCT06633718|DRUG|Saline|100mL，q8h，60min infusion
41501288|NCT06633718|DRUG|Ceftazidime-avibactam|2.5g，q8h，120min infusion
41501289|NCT06633718|DRUG|Metronidazole|0.915g，q8h，60min infusion
41501290|NCT00396565|DRUG|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
41501291|NCT00396565|DRUG|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
41501292|NCT00396565|DRUG|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
41501293|NCT04164472|BEHAVIORAL|Friend to Friend (F2F) with Coaching|Friend to Friend (F2F) with Coaching has 14 small group sessions and 8 classroom sessions as led by school staff with coaching from the Children's Hospital of Philadelphia (CHOP) research team. The program aims to improve problem solving and prosocial behaviors, and decrease aggressive behaviors.
41501294|NCT04286451|BEHAVIORAL|Sleep Restriction|Women will be undergo 4 nights of sleep restriction.
41501295|NCT04286451|BEHAVIORAL|Habitual Sleep|Women will be undergo 4 nights of habitual sleep.
41501296|NCT03201445|DRUG|Filgotinib|200 mg tablet administered orally once daily
41501297|NCT03201445|DRUG|Placebo|Placebo to match filgotinib tablet administered orally once daily
41501298|NCT03201445|DRUG|Standard of Care|Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
41366290|NCT02743117|BIOLOGICAL|Monovalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
41366291|NCT02743117|OTHER|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
41501299|NCT03105102|DRUG|Placebo for Risankizumab SC|Placebo for Risankizumab SC Subcutaneous (SC) Injection
41501300|NCT03105102|DRUG|Risankizumab IV|Risankizumab IV Intravenous (IV) infusion
41501301|NCT03105102|DRUG|Placebo for Risankizumab IV|Placebo for Risankizumab IV Intravenous (IV) infusion
41501302|NCT03105102|DRUG|Risankizumab SC|Risankizumab SC Subcutaneous (SC) injection
41501303|NCT03105102|DRUG|Risankizumab On-Body Injector (OBI)|Subcutaneous (SC) injection; on-body injector (OBI)
41501304|NCT04810065|OTHER|SingStrong: Strong lungs through Song|"Participants who have been clinically diagnosed with Covid-19 and who continue to suffer residual adverse effects on the lung health will be invited to participate in the study.~The intervention will involve biweekly hour-long breathing and singing classes that are designed to correct dis-ordered breathing, and retrain the principal muscles of respiration.~Pre and post evaluation of participant bio-psychosocial health and wellness will be conducted. Triangulation of data using focus groups and individual interviews will be conducted after conclusion of the intervention,"
41501305|NCT05758077|DEVICE|Selective Cytopheretic Device|"The Selective Cytopheretic Device (SCD) is comprised of tubing, connectors, and a synthetic hollow fiber membrane cartridge. The device is connected in series to a commercially available CKRT hemofilter. Blood from the CKRT circuit is diverted after the CKRT hemofilter through to the extracapillary space (ECS) of the SCD cartridge. Blood circulates through the SCD ECS and then it is returned to the patient via the venous return line of the CKRT circuit. Regional citrate anticoagulation is used for the entire CKRT and SCD blood circuit.~The SCD cartridge incorporates a synthetic hollow fiber membrane with the ability to bind activated leukocytes to its extracapillary surface; and when used in a CKRT extracorporeal circuit in the presence of regional citrate anticoagulation, the SCD modulates inflammation."
41501306|NCT05758077|OTHER|Standard of Care|Standard of care CKRT for the subject's condition, as appropriate
41028300|NCT04321720|OTHER|12-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g mustard flour (12 g per l), followed by a ten-minute post-intervention rest period.
41366292|NCT02919709|BIOLOGICAL|blood taking|
41501307|NCT01624701|OTHER|Ex vivo expanded cord blood cells|Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
41501308|NCT05142397|PROCEDURE|Focused Ultrasound|Focused ultrasound generates heat effects, mechanical effects and cavitation effects that denature the diseased tissues, facilitate necrosis and allow them to be replaced by surrounding normal healthy tissues.
41501309|NCT03223844|DRUG|Dextroamphetamine Sulfate|Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
41028301|NCT04321720|OTHER|Warm water only|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
41028302|NCT04387253|DIAGNOSTIC_TEST|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Presence of SARS-COV-2 virus in samples taken from mother and father. Circulating anti-SARS-COV-2 antibodies in the mother.
41366293|NCT05331326|DRUG|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
41366294|NCT02395445|DEVICE|orotracheal intubation|
41366295|NCT02005458|DRUG|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
41366296|NCT02005458|DRUG|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
41366297|NCT02005458|DRUG|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
41366298|NCT02005458|DRUG|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
41366299|NCT00325351|DRUG|Sagopilone (ZK 219477) + carboplatin|Chemotherapy for recurrent ovarian cancer
41366300|NCT02665858|OTHER|OCT Imaging|
41366301|NCT00451191|DRUG|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
41366302|NCT03844620|OTHER|Best Practice|Receive SOC
41366303|NCT03844620|OTHER|Laboratory Procedure|Undergo ctDNA testing
41366304|NCT03844620|OTHER|Quality-of-Life Assessment|Ancillary studies
41366305|NCT03844620|OTHER|Questionnaire Administration|Ancillary studies
41366306|NCT03844620|DRUG|Regorafenib|Given by mouth
41366307|NCT03844620|DRUG|Trifluridine and Tipiracil Hydrochloride|Given by mouth
41366308|NCT04017416|BEHAVIORAL|I-PLAN|The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
41366309|NCT03107273|OTHER|Dynamic cultures of in vitro hematopoietic stem cells|Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
41366310|NCT04658511|DEVICE|Ultrasound|On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
41366311|NCT03914703|PROCEDURE|EZ Pass Suture Passer|Instruments used to help with rotator cuff or ACL repair
41366312|NCT02695316|OTHER|Focus Group Discussion in native Language|Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
41366313|NCT02695316|OTHER|Focus Group Discussion|Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
41028303|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
41366314|NCT02695316|OTHER|One-to-one Interview|One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
41366315|NCT02695316|OTHER|Retrospective Quantitative Analysis|Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
41366316|NCT01689831|BIOLOGICAL|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
41366317|NCT01689831|BIOLOGICAL|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
41366318|NCT06304064|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs)
41366319|NCT01090167|DRUG|clofarabine|Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
41366320|NCT01020812|PROCEDURE|TACE|Standard of Care
41366321|NCT01020812|PROCEDURE|SBRT|Standard of Care
41366322|NCT02160262|DRUG|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
41366323|NCT00017108|DRUG|chlorambucil|
41028304|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
41366324|NCT00017108|DRUG|cyclophosphamide|
41366325|NCT00017108|DRUG|fludarabine phosphate|
41366326|NCT03868085|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|DXA scan
41366327|NCT01363999|DRUG|atorvastatin|single dose of atorvastatin on day 1
41366328|NCT01363999|DRUG|dalcetrapib|single dose of dalcetrapib on day 1
41028305|NCT00898677|DRUG|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
41028306|NCT00898677|DRUG|Comparator: Placebo|placebo to rizatriptan
41028307|NCT01294839|DEVICE|Right ventricular lead location|RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.
41366329|NCT04366869|DEVICE|overdenture|removal of overdenture at night
41366330|NCT04366869|DEVICE|occlusal splint|occlusal splint on overdenture
41366331|NCT04366869|DRUG|Botox|Botox injection i masseter in temporalis
41366332|NCT05557266|BEHAVIORAL|Mindfulness-based intervention|An mindfulness instructor will conduct meditations lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have audio files designed ad hoc with the practice of the week so they can do it individually at home.
41366333|NCT05557266|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have video files designed ad hoc with the practice of the week so they can do it individually at home.The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
41366334|NCT00118885|BEHAVIORAL|Tai Chi Chih|
41366335|NCT02569931|OTHER|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
41366336|NCT02569931|OTHER|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
41366337|NCT02569931|PROCEDURE|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
41366338|NCT03485976|DRUG|Ixekizumab|Treatment at the FDA-approved psoriasis dosing
41366339|NCT03547674|OTHER|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
41366340|NCT03547674|OTHER|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
41366341|NCT03547674|OTHER|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.
41366342|NCT03547674|OTHER|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
41366343|NCT03562676|OTHER|weightlessness|parabolic flight
40845455|NCT04311931|OTHER|Active Dance Program|All Creative Dance sessions comprised five phases: 1) opening ritual (5 min), in which participants will be welcomed and will be informed about the objectives and structure of the session; 2) warm-up (15 min), in which body muscle groups will be activated through the introduction of basics elements of movement; 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives described above. This phase will end with a choreography composition; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience and they will fill a sheet with attendance, exercise intensity perception (Borg Scale) and satisfaction's (Caregiver Treatment Satisfaction questionnaire).
40845456|NCT01906528|DRUG|Mivacurium|Effect of Mivacurium in males vs females
40845457|NCT02215005|DRUG|Telmisartan|
41028308|NCT06180564|OTHER|Intra-operative Infra-red thermography|. In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature \>3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.
41366344|NCT03826849|BEHAVIORAL|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
41366345|NCT00405756|DRUG|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
41366346|NCT00405756|DRUG|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
41366347|NCT00405756|DRUG|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
41366348|NCT00405756|DRUG|Aspirin|"Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion"
41366349|NCT00405756|DRUG|Placebo|"Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression."
41366350|NCT00405756|DRUG|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
41028309|NCT06348394|OTHER|Intracardiac Echocardiography|Transesophageal echocardiography will be performed under general anesthesia.
41366351|NCT00405756|DRUG|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
41366352|NCT03131531|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
41366353|NCT00646217|BEHAVIORAL|Self Care Talk|6 weekly telephone sessions
41366354|NCT05674682|PROCEDURE|HIV testing|venipuncture or digital puncture for HIV testing
41366355|NCT03672136|DRUG|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
41366356|NCT03672136|OTHER|Concurrent Chemoradiotherapy|Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
41366357|NCT06510348|DIETARY_SUPPLEMENT|Supplemental Parenteral Nutrition (SPN)|Nutritional targets are based on ESPEN guidelines recommendation (calories administration based on indirect calorimetry study, proteins 1.3 g/kg/day). From the first day of ICU admission indirect calorimetry will be performed daily in order to evaluate energy requirements. On the fourth day, the patient will undergo a gastric residual volume measurement and a paracetamol absorption test. If gastrointestinal dysfunction is detected, the patient will be assigned to a study group based on the randomization protocol. The SPN group will gradually initiate supplemental parenteral nutrition in order to achieve the target of 80% by the fifth day. Trophic feed will be administered to cover the remaining 20% of the targeted nutrition intake.
41366358|NCT02000674|DRUG|Succinylcholine : 1mg/kg|
41366359|NCT02000674|DRUG|Rocuronium : 1.2 mg/kg|
41366360|NCT03707249|DRUG|Ferric Carboxymaltose Injectable Product|iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
41366361|NCT03707249|DRUG|Normal Saline 0.9% Infusion Solution Bag|250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
41501310|NCT04832009|DRUG|Dextrose 20 % in 500 ML Injection|Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
41501311|NCT04832009|DRUG|Intralipid|Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
41366362|NCT03575741|DIAGNOSTIC_TEST|Balance Tests|"Following balance exercises will be performed by the participants:~1. Bipedal, hip wide stand, eyes open and hands on hips, 60sec~2. Bipedal, hip wide stand, eyes closed, hands on hips, 30sec~3. Tandem-stand, eyes open, hands on hips, 60sec (front foot chosen by participant)~4. Tandem-stand, eyes closed, hands on hips, 30sec (same front foot)~5. One-leg-stand, eyes open, hands on hips, 30sec (randomized supporting leg)~6. One-leg-stand, eyes open, hands on hips, 30sec (other leg)~7. Bipedal, hip wide stand, eyes open, hands on hips, counting backwards in steps of two (367 - 365 - 363 - ...), 60sec~The rest between the trials will last for at least 30sec, but can be extended by the participants as long as they want. The overall measurement will not exceed 30 minutes."
41366363|NCT05846412|OTHER|Catheter Ablation and M-TEER|Already included in arm descriptions.
41366364|NCT04590976|OTHER|Semi-Structured Interview Healthcare Professional|Interview
41366365|NCT04590976|OTHER|Semi-Structured Interview Patients|Interview
41366366|NCT04590976|OTHER|Think Aloud Interview Patients|Interview
41366367|NCT04590976|OTHER|Discrete Choice Experiment (DCE) Patients|DCE Questionnaire
41366368|NCT05597852|DEVICE|SpaceOAR|SpaceOAR hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
41366369|NCT00004409|DRUG|collagenase|
41501312|NCT04832009|DRUG|Saline|Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
41501313|NCT04832009|DRUG|Ascorbic acid|"(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant."
41501314|NCT06633848|PROCEDURE|spinal surgery|spinal surgery
40845458|NCT02215005|DRUG|Ramipril|
41028310|NCT02824068|DRUG|glucosidase alfa|Long-term use in an observational study of licenced drug
41028311|NCT00681317|DRUG|AZD6280|oral
41366370|NCT05208749|DEVICE|Rotablation of shockwave|Patients will be randomized to treatment with rotablation or shockwave
41366371|NCT03593317|DRUG|Spironolactone|The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
41028312|NCT05052970|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
41028313|NCT05052970|DRUG|Bortezomib for Injection|Bortezomib (1.3 mg/m\^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
41028314|NCT05052970|DRUG|Dexamethasone Acetate Tablets|Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
40845459|NCT03090555|PROCEDURE|Translational manipulation|After the patient receives an interscalene block on the affected side, a physical therapist performs a series of thrust manipulations on the participant's affected shoulder. The participant's identified limitations of physiological and accessory motion revealed during manual examination guided the physical therapist's choice of technique, which primarily consisted of an accessory superior to inferior accessory gliding motion performed in a physiological position of limited motion. Additional gliding manipulations in combined movement positions such as increased flexion or abduction plus internal or external rotation were utilized until full passive physiologic motion was restored.
41366372|NCT03593317|DRUG|Placebo|Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
41366373|NCT03581708|OTHER|lung cancer|If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
41028315|NCT06336070|BEHAVIORAL|HIIT program (8 weeks)|Metabolic Power Training: A High Intensity Interval Training (HIIT) intervention, 3 times per week (30 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
41366374|NCT01978717|PROCEDURE|epidural anesthesia|
41366375|NCT01978717|PROCEDURE|general anesthesia|Patients received general anesthesia for surgery
41366376|NCT04534868|OTHER|taking macroscopic and dermoscopic pictures of suspicious skin lesions|"If there is any diagnostic doubt about a skin lesion, teledermoscopy will be used, if the patient agrees.~* A table containing the useful information about the patient for the lesion's analysis will be completed.~* The pictures will be taken with a Fotofinder Handyscope. The photos will be integrated into the patient's electronic medical record (CareConnect program).~* The photo is anonymized via a serial number assigned by the Handyscope application.~* Sending photos and information via a secure email address to the dermatologists.~* Response from the dermatologist (Prof. Tromme or Dr Harkemanne) in the following days also via email.~* Contact (consultation or telephone call depending on the diagnosis) with the patient to communicate the results and the procedure to be followed.~* This information (emails containing the dermatological report) will be saved in the patient's computerized medical file (CareConnect program) then deleted from the mailbox"
41366377|NCT01821001|DRUG|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
41366378|NCT05401552|OTHER|Meal|Comparison of two breakfast meals containing the same amount of phosphorus but one in the form of inorganic additives
41366379|NCT00773994|OTHER|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
41028316|NCT06336070|BEHAVIORAL|MPI program (8 weeks)|Muscle Power Intervention (MPI), 2 times per week (45 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
41028317|NCT05402267|PROCEDURE|Adenoidectomy|Adenoidectomy will be conducted in OA and CA groups
41366380|NCT02928198|DEVICE|ABSORB BVS|
41366381|NCT04272320|DRUG|Bupivacaine Hydrochloride|Ultrasound-guided Transversalis Fascia Plane Block with 0.5 ml/kg %0.25 bupivacaine
41366382|NCT05523427|DIETARY_SUPPLEMENT|Two probiotic strains (L. plantarum and L. acidophilus)|A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.
41366383|NCT00575003|DRUG|CYT003-QbG10|6 subcutaneous injections
41366384|NCT01527760|DRUG|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
41501315|NCT05846646|DRUG|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
41501316|NCT05846646|DRUG|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label
41501317|NCT05846646|RADIATION|PULSAR|1st day of Cycles 1, 2 and 3.
41501318|NCT00549679|DRUG|GSK256066|PDE4 inhibitor
41501319|NCT00549679|DRUG|Placebo|Placebo
41501320|NCT01994291|DRUG|Ranibizumab|"Intravitreal Injection supplied as:~* 10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~* 6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~* Adminstered once a month for 12 weeks"
41501321|NCT01994291|DRUG|Placebo|"Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks"
41366385|NCT04274569|OTHER|NaF vanish|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
41366386|NCT04274569|OTHER|NaF-TCP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
41366387|NCT04274569|OTHER|NaF-CPP-ACP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
41366388|NCT00016211|RADIATION|radiation therapy|
41366389|NCT02806804|BIOLOGICAL|one dose test vaccine|
41501322|NCT01994291|DRUG|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
41366390|NCT02806804|BIOLOGICAL|one dose commercially available trivalent influenza vaccine|
41501323|NCT01994291|DRUG|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
41366391|NCT02806804|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
41366392|NCT03081858|DRUG|TSD-001|Administered via intravesical instillation.
41366393|NCT05221658|DRUG|HLX07+HLX10+ Cisplatin+5-FU|HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2
41366394|NCT05221658|DRUG|HLX07|HLX07 1000mg iv Q2w
41366395|NCT05694052|BEHAVIORAL|Multifaceted Intervention of environment control|Dynamic light therapy, auditory masking, and rationalization of ICU nocturnal patient activities.
41366396|NCT03933358|OTHER|Thyroid hormone levels|This is an observational study. Exposure: Different thyroid hormone levels.
40845460|NCT03090555|PROCEDURE|Manual therapy|The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
40845461|NCT04672850|DIETARY_SUPPLEMENT|Probiotic|The participants will consume 2 capsules daily for three months
41366397|NCT04491591|OTHER|Breast Reconstruction Education and Support Tool (BREASTChoice)|The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record
41366398|NCT04491591|OTHER|Attention Control Website|-(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)
41366399|NCT04491591|OTHER|Clinician Survey|-Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
41366400|NCT05936827|DIAGNOSTIC_TEST|Ergometry|"Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion.~The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine.~ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams \& Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)"
40845462|NCT04672850|DIETARY_SUPPLEMENT|Placebo|The participants will consume 2 capsules daily for three months
40845463|NCT00186901|DRUG|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
40845464|NCT00186901|OTHER|Placebo|Placebo
41366401|NCT05936827|DIAGNOSTIC_TEST|Ergospirometry|"VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion.~Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)"
41366402|NCT01127529|BIOLOGICAL|Protein C Concentrate (Human)|Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
41366403|NCT05842590|OTHER|Composite Veneer Restoration|This is a single-arm study. Direct composite veneer Restorations will be performed to all patients.
41366404|NCT04058782|OTHER|Imaging evaluation for vascular assessment|At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
41366405|NCT00887562|DRUG|Idebenone|900 mg/day for 1 month
41366406|NCT00887562|DRUG|Idebenone|2250 mg/day for 1 month
41366407|NCT00887562|OTHER|Placebo|Placebo - No idebenone
41366408|NCT03240042|PROCEDURE|nasotracheal intubation|The participants either receive intubation via nasal route.
41366409|NCT03240042|PROCEDURE|orotracheal intubation|The participants either receive intubation via oral route.
41366410|NCT04374604|DIAGNOSTIC_TEST|Placental growth factor|On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
41501324|NCT02538965|DRUG|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
41501325|NCT05289973|DEVICE|TruNatomy Files|Newly introduced endodontic file with high flexibility.
41501326|NCT05289973|DEVICE|HyFlex EDM Files|Endodontic files
41501327|NCT04595422|OTHER|Educational Intervention|Undergo training consisting of a 60-minute educational session
40845465|NCT06303063|DEVICE|SINOMED IAS Stent System|Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
41366411|NCT04273802|DRUG|CPX-351 in cohort A|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.~If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.~If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1."
41366412|NCT04273802|DRUG|CPX-351 in cohort B|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.~In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1."
41366413|NCT01836900|DEVICE|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
41501328|NCT04595422|OTHER|Educational Intervention|Receive lung cancer screening educational materials
41501329|NCT04595422|OTHER|Questionnaire Administration|Complete questionnaire
41501330|NCT04595422|OTHER|Survey Administration|Ancillary studies
41501331|NCT05169632|DEVICE|Computerized Gaming Rehabilitation Program 1|Brain training games with physical exercise component.
41501332|NCT05169632|DEVICE|Computerized Gaming Rehabilitation Program 2|Cognitive training games with physical exercise component.
41501333|NCT06168123|BEHAVIORAL|Quality of life questionnaires will be assessed in addition to standard care|Quality of life questionnaires will be assessed in addition to standard care
41501334|NCT05713383|BEHAVIORAL|Auditory Feedback|Sound amplification is used to accentuate participants' footsteps, while asking them to step softly so as to reduce this sound.
41366414|NCT04773691|DEVICE|Active rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC"
41366415|NCT04773691|DEVICE|Placebo rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation."
41366416|NCT04773691|OTHER|Questionnaires|questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
41366417|NCT04773691|DEVICE|Breathalyzer|estimation of blood alcohol level
41366418|NCT00867594|DRUG|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
41366419|NCT02771782|BIOLOGICAL|BCG vaccine (SSI)|
41501335|NCT02774642|BEHAVIORAL|CBTI-PE|Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence
41501336|NCT02774642|BEHAVIORAL|Hygiene-PE|The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
41501337|NCT04236882|OTHER|Focus Group|Attend focus group
41501338|NCT04236882|BEHAVIORAL|Health Education|Receive educational material on healthy homes
41366420|NCT02771782|BIOLOGICAL|TDaP-IPV vaccine|
41366421|NCT05772039|DRUG|Topical application of 38% Silver Diammine Fluoride Solution|"* Application of petroleum jelly on lips and around the mouth for prevention of temporary silver tattoo.~* Before SDF application, the affected area will be thoroughly dried and isolated using the cotton rolls or dri-angle.~* Isolation throughout the procedure and following three minutes is considered most desirable.~* The varnish should be allowed to be in place for 60 seconds. This is the most critical step in the process. Applied varnish will be dried with gentle flow of compressed air.~* SDF will be applied with a microbrush to all carious lesions and to all pits and fissures on posterior (molar) teeth for 60 seconds.~* To avoid gingival or mucosal irritation, contact of varnish with any oral tissue other than affected area will be avoided.~* If the application time is shorter due to unforeseen reasons reapplication will be considered."
41366422|NCT05772039|DRUG|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish|"* According to manufacturer, Clinpro® White Varnish can be applied to tooth surfaces where plaque is present. A prophylaxis is not required.~* The applicator brush provided along is used to thoroughly mix the varnish inside the single-unit dose pack, since components of all sodium fluoride varnishes are separate during storage.~* Excessive contact with soft tissue should be avoided.~* Only enough varnish to form a thin coating on the desired treatment area should be used.~* After application, patient should be instructed to close their mouth to set the varnish.~* Rinsing or suctioning immediately after application is not recommended.~* The operator might appreciate the formation of a thin coating on the teeth and the patient should be informed that they may feel a thin coating when rubbing the treated area with their tongue."
41366423|NCT04718376|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
41501339|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based sleep intervention
41501340|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based health coaching sessions
41501341|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based counseling sessions
41501342|NCT04236882|OTHER|Interview|Complete interview
41501343|NCT04236882|OTHER|Questionnaire Administration|Ancillary studies
41501344|NCT06194942|OTHER|chiropractic manipulation|Chiropractic manipulation is a manual therapy technique commonly used by chiropractors. It involves the application of controlled, sudden force to a specific joint, often with the goal of improving joint function, reducing pain, and promoting overall musculoskeletal health.In the context of thoracic chiropractic manipulation, the chiropractor focuses on the vertebrae and joints in the thoracic spine.
40845466|NCT06303063|DEVICE|Neuroform Atlas Stent System|Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
40845467|NCT05167591|DIAGNOSTIC_TEST|Drug concentration measurement|Measurement of paracetamol concentration in capillary, venous plasma and saliva samples after standard premedication with paracetamol
41366424|NCT05713019|DEVICE|Adenosine triphosphate (ATP) solution inhalation from nebuliser|ATP and 0.9% saline solution will be inhaled from a nebuliser on separate days, and their effects will be examined.
41366425|NCT05713019|DIAGNOSTIC_TEST|Inhalational challenge with increasing concentrations of capsaicin solutions|Coughs are counted for one minute after single-breath inhalations of 0.9% sodium chloride and capsaicin solutions of increasing concentrations (0.98-500 μm) generated from a dosimeter (P.K. Morgan Ltd, Gillingham, UK) set at a dosing period of 1 s. The concentration that caused more than 2 or 5 coughs was recorded as C2 and C5, and the data is analysed as log10 C2 or C5.
41366426|NCT05713019|DEVICE|Recording of Cough Count and frequency using the Hyfe Cough Monitor|"All enrolled study participants will be provided with a dedicated Android phone or watch loaded with the Hyfe Research application to monitor and record their cough sounds. The participant will be provided with a carrying case to ensure the phone stays within five feet of their mouth. They will be asked to wear the phone for the duration of 3 weeks, and keep the phone within five feet of their mouth over nights - keeping it, i.e., on a bedside table.~Hyfe is a research use only tool which does not provide clinical diagnosis. Cough collection within this study will not lead to specific medical interventions or differential clinical management. Hyfe records only short snippets (\<0.5 seconds). As such, the recordings will not be identifiable. Conversations or acoustic environments are not recorded. The informed consent form will explicitly describe exactly what is recorded."
41366427|NCT05713019|PROCEDURE|Collection of exhaled breath condensate|EBC will be collected by asking the subject to breathe normally onto a handheld breath collection apparatus from Respire Diagnostics, Imperial College, that will cool the exhaled breath to allow for condensation of the exhaled air. The subject will breathe for 2 periods of 5 minutes each separated by a 3-4 min rest to allow the collection of up to 500 uL of liquid. The liquid will be stored for later analysis.
41366428|NCT05713019|DIAGNOSTIC_TEST|Continuous laryngoscopic examination|Continuous laryngoscopy testing is performed based on previous methodology. Continuous laryngoscopy testing is performed by placing a fibreoptic nasendoscope in the posterior nasopharynx and securing it using specialist headgear. A small quantity of lubricating jelly is used to ease passage of the scope. Video images of the laryngeal inlet are, thereafter, continuously recorded whilst a subject performs various manoeuvres including respiratory movements and cough. These movements will be observed and recorded before and following the various aspects of the challenge protocol and thus allow us to evaluate laryngeal movement abnormalities and for example position of the vocal folds. The size and change in size of the glottic aperture will be evaluated.
41366429|NCT05713019|DIAGNOSTIC_TEST|Sputum induction|"Sputum is induced by inhalation of an aerosol of sterile 3% saline solution and subsequently increasing to 4% and 5% during 3 periods of 5 minutes each. Particular care is taken to avoid contamination with saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their nose after each inhalation. Sputum samples are collected into sterile pots. Peak flow measurements are made after each inhalation. If there is a fall in peak flow of 20% or more or if symptoms occurred during the procedure, the induction is stopped.~Sputum plugs are selected and one portion is used to perform differential cell counts. To perform differential cell counts, dithiothreitol is added to the sputum plug and mixed vigorously on a plate shaker to solubilize the sputum. Cytospins are then prepared, and differential cell counts obtained."
41366430|NCT05713019|DIAGNOSTIC_TEST|Spirometric measurements|Spirometry (FEV1 and forced vital capacity, FVC) is measured using a dry wedge spirometer (Vitalograph, Buckinghamshire, UK).
41366431|NCT05713019|DIAGNOSTIC_TEST|Blood sample collection|Venous blood (30 cc) will be taken from a vein in the forearm. This test causes a transient discomfort as a needle is used to obtain the blood sample. The blood sample will be used for measuring various proteins and for getting white blood cells to obtain some types of stem cells.
41366432|NCT05026060|DIAGNOSTIC_TEST|Imaging|4-minutes eASL sequence without injection of contrast product added to each of the clinical MRs with standard ASL sequences performed for the care of the patient for 3 years.
41366433|NCT02730312|BIOLOGICAL|XmAb14045|Administered IV weekly up to 8 weeks, with or without step-up dosing
41366434|NCT00618046|DRUG|Oxcarbazepine|
41366435|NCT02821975|OTHER|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
41366436|NCT02408016|BIOLOGICAL|Aldesleukin|Given SC
41366437|NCT02408016|BIOLOGICAL|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
41366438|NCT02408016|DRUG|Cyclophosphamide|Given IV
41366439|NCT02408016|OTHER|Laboratory Biomarker Analysis|Correlative studies
41366440|NCT02408016|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
41366441|NCT02145429|BEHAVIORAL|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
41366442|NCT00895817|DRUG|Swallowed fluticasone|440 µg twice daily for 8 weeks
41366443|NCT00895817|DRUG|Esomeprazole|40 mg once daily for 8 weeks
41366444|NCT02398292|OTHER|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
41366445|NCT02398292|OTHER|Control|Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
41366446|NCT02297672|RADIATION|Stranded palladium seed interstitial implant|Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
41366447|NCT02297672|DEVICE|3 dimensional breast ultrasound|guidance of placement of interstitial needles in breast
41366448|NCT02297672|DEVICE|Computerized tomography (CT)|Breast CT for planning and assessing interstitial implantation of radioactive seeds
41366449|NCT02602028|DRUG|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
41366450|NCT02176031|DRUG|Natalizumab|
41366451|NCT02176031|DRUG|Methylprednisolone|
41366452|NCT00514059|DRUG|Boostrix polio|1 dose (0.5 ml) i.m.
41366453|NCT04513132|DEVICE|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
41366454|NCT04513132|DEVICE|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
41366455|NCT03793517|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
41366456|NCT03793517|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
41366457|NCT03793517|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
41366458|NCT03328962|BEHAVIORAL|Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication|structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
41366459|NCT01395420|DRUG|CAZ104|IV Infusion
41366460|NCT01395420|DRUG|CAZ104|IV Infusion
41366461|NCT01487109|DRUG|CTP-499|600 mg tablet twice daily
41366462|NCT01487109|DRUG|Placebo|Matching placebo tablet
41366463|NCT05461404|OTHER|Topical Emollient Therapy|Application of high-linoleate (\>60% linoleic acid) SSO to the epidermis.
41366464|NCT04867668|BEHAVIORAL|Anti-vaping and anti-smoking digital advertising|Delivery of social media based advertising to prevent vaping and smoking among young adults ages 18-24.
41366465|NCT05517031|OTHER|ASDAS score , VAS score, BASFI score , Katz ADL index|Scores that done on patient to fullfill criteria of diagnosis , and measure affection of disease on patients and their daily living activity
41366466|NCT00310440|DEVICE|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
41366467|NCT00310440|OTHER|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
41366468|NCT04312711|DIAGNOSTIC_TEST|3D-TOF-MRA|"The Principle of 3D-TOF-MRA is based on the flow effect of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases."
40845468|NCT05551507|DRUG|IN10018 in combination with PLD|IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
40845469|NCT02554981|DRUG|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
40845470|NCT06368908|DEVICE|Transcutaneous Functional Magnetic Muscle Stimulation|Peripheral neuromuscular system stimulation will be conducted for the quadriceps femoris muscle using a magnetic stimulator (Tesla stym, Iskra Medical, Otoče, SLO). For magnetic stimulation, we will use pulse trains (20-50 Hz) with intensities ranging from 0.5 to 2.5 Tesla. The stimulation trains will be up to 3-6 seconds long, and the duty cycle will be varied from 1:1 to 1:10. Muscles will be stimulated with a magnetic field intensity that triggers visible contraction. The stimulation will last for 55 minutes per selected limb and will be performed 5 days a week.
40845471|NCT03459365|DEVICE|Euflexxa|Aspirations performed before each injection and at six weeks.
41366469|NCT03892967|OTHER|Interview|Participate in interview
41366470|NCT03892967|OTHER|Quality-of-Life Assessment|Ancillary studies
41366471|NCT03892967|OTHER|Questionnaire Administration|Ancillary studies
41366472|NCT03935945|BEHAVIORAL|Personalized Feedback Intervention|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes. PFI highlights discrepancies between one's own drinking and typical drinking; reframes use in terms of personal, social, financial, and health consequences; and, offers strategies for reducing alcohol use. The feedback is non-confrontational in tone, seeks to increase motivation to reduce drinking and is based on the information provided during the baseline assessment
41366473|NCT03820388|DRUG|Propofol 2mg/kg|2 mg/kg
41366474|NCT03820388|DRUG|Etomidate 0.3 mg/kg|0.3 mg/kg
41366475|NCT03820388|DRUG|Propofol 1 mg/kg|1 mg/kg Propofol
41366476|NCT03820388|DRUG|Etomidate 0.15 mg/kg|0.15 mg/kg Etomidate
41366477|NCT04170725|OTHER|Patient and Healthy Volunteers training protocol|Patients and Healthy Volunteers will undergo a 14-day endurance training protocol. No study drugs will be administered. Patients and Healthy Volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Patients and Healthy Volunteers will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
41501345|NCT06194942|OTHER|sham manipulation|"Sham manipulation refers to a simulated or placebo form of a manual therapy intervention, often used in research studies, especially in clinical trials involving chiropractic or physical therapy. the term sham manipulation likely implies a procedure that mimics the physical aspects of a real chiropractic manipulation but does not involve the actual therapeutic forces or movements.~The chiropractic treatment group received thoracic chiropractic manipulations (HVLA) twice a week for a total of six sessions over three weeks, while the control group received sham manipulations."
40845472|NCT00294255|DRUG|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
40845473|NCT03532139|DRUG|Enoxaparin|Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
41366478|NCT02452892|DEVICE|LFMS|Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
41366479|NCT05454839|OTHER|Survey|Interviewer-administered survey
41366480|NCT05454839|OTHER|Focus group|Focus group for selected participants
41366481|NCT03405324|DEVICE|tDCS|a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
41501346|NCT05592548|DEVICE|cold atmospheric plasma|Cold atmospheric plasma will be generated on the skin surface using an electric device
41501347|NCT02640690|BEHAVIORAL|Trauma Center Trauma Sensitive Yoga Intervention (TCTSY)|(10) 1-hour sessions of trauma sensitive yoga
41366482|NCT03405324|DEVICE|sham tDCS|sham tDCS
41366483|NCT02711085|OTHER|No intervention|No intervention - observational study
41366484|NCT03529552|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Placement of an SMS bioresorbable interference screw (DEDIENNE Santé)
41366485|NCT01256424|DRUG|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
41366486|NCT01256424|DRUG|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
41366487|NCT01256424|DRUG|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
41366488|NCT01256424|DRUG|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
41366489|NCT04490421|DRUG|Camrelizumab combined with Apatinib, Etoposide and Cisplatin|Camrelizumab combined with Apatinib, Etoposide and Cisplatin
41366490|NCT06101940|DIAGNOSTIC_TEST|Brain MRI scan|Normal brain MRI scan to evaluate the integrity of the nervous system
41366491|NCT03772574|DEVICE|Facemask preoxygenation|Standard facemask preoxygenation
41366492|NCT03772574|DEVICE|THRIVE preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
41366493|NCT04974294|BIOLOGICAL|PPV23|random allocation 1:1:1 IM injection
41366494|NCT04974294|BIOLOGICAL|PCV13|random allocation 1:1:1 IM injection
41366495|NCT04974294|OTHER|Saline for injection|random allocation 1:1:1 IM injection
41366496|NCT00054821|PROCEDURE|Ankle distraction permitting motion|External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted
41501348|NCT02640690|BEHAVIORAL|Cognitive Processing Therapy|(12) 1.5 hour sessions of cognitive processing therapy
41501349|NCT06604520|DRUG|Vortioxetine|Individuals with bvFTD and mood symptoms will receive approximately 12 weeks of treatment with vortioxetine
41501350|NCT00577395|DRUG|placebo|oral tablet once a month for 12 months
41366497|NCT00054821|PROCEDURE|Ankle distraction without motion|External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
41366498|NCT05973565|OTHER|Musicokinetic Training|The intervention protocols are either a) synchronous learning format, b) asynchronous remote video- based, and c) control.
41366499|NCT03319368|OTHER|Targeted gown and glove use|Gown and glove use for high risk care activities in high risk residents
41366500|NCT01306682|BIOLOGICAL|Trivalent influenza vaccine|0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
41366501|NCT01306682|BIOLOGICAL|Normal saline|0.5ml normal saline administered into deltoid muscle of non dominant arm
41366502|NCT00594958|BIOLOGICAL|IC51|6 mcg, intramuscularly \[i.m.\], 0.5 mL
41366503|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (0.5 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)
41366504|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (1 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)
41366505|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel (0.5 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)
41366506|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel 1 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
41366507|NCT00218439|DRUG|Paroxetine|10 mg for 1 week followed by 20 mg for 3 weeks
41366508|NCT00218439|DRUG|Placebo|
41366509|NCT00329433|DRUG|Desirudin (Iprivask™)|Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
41366510|NCT00329433|DRUG|Heparin|The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
41366511|NCT01768182|DIETARY_SUPPLEMENT|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
41366512|NCT01768182|OTHER|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
41366513|NCT01540721|DRUG|Marketed paracetamol|marketed formulation
41366514|NCT01540721|DRUG|Experimental paracetamol formulation|Experimental formulation
41366515|NCT00275704|DRUG|Flaxseed|
41501351|NCT00577395|DRUG|risedronate|tablet, 150 mg once a month for 12 months
41366516|NCT01654666|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
41028318|NCT05975658|DEVICE|Gabi SmartCare Pediarity System [Gabi Band, Gabi Monitor App, Gabi Analytics]|Gabi SmartCare has created a monitoring system named Pediarity System that obtains pediatric vitals data through non-invasive means through a Gabi band. When paired with a proprietary algorithm and software - Gabi Analytics - the cloud-based platform measures blood oxygen levels, pulse rate (and variability), respiratory rate, actigraphy, inter-beat interval, and tracking for the time the device is worn (or not worn by the child). Three LEDs on the monitor are used for capturing this information. Peak wavelengths for the red, infrared, and green LEDs operate at 660nm, 950nm, and 526nm respectively. The Gabi band features an optical front end coupled with an analog front end using 24 bits. Bluetooth data transmission is utilized on a mobile phone application with a tablet-based system in a CSV format for the purpose of offline data processing.
41028319|NCT02823145|DRUG|ZX008 (Fenfluramine Hydrochloride)|
41028320|NCT01641887|OTHER|Decision Aid|Patients will use a decision aid administered on a computer.
41366517|NCT01654666|PROCEDURE|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
41366518|NCT01654666|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
41366519|NCT06411158|OTHER|Interventionist-guided training|Interventionist-guided training at baseline (i.e., approximately 6 weeks postpartum), followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session approximately 4 weeks later, and then continued HEP. Two exercise sets per day are encouraged between baseline and 6 months postpartum (i.e., time of the primary outcome), followed by at least 3 times-per-week exercise sets until 12 months postpartum. Home exercises will be encouraged using a PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
41366520|NCT06411158|DEVICE|Home pelvic floor exercises guided by the leva® device|Home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. Between baseline and 6 months postpartum, twice-daily exercise sets will be encouraged, followed by at least 3 times-per-week exercises from 6 to 12 months postpartum. As in Arm 1, the PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
41366521|NCT06411158|OTHER|Education|Education will be provided on pelvic floor muscle function and continence mechanisms. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.
41366522|NCT06510023|BEHAVIORAL|Type of reward presented|Three different types of rewards were presented to both groups during the computerized task: one dollar, one penny, and no reward.
41366523|NCT05728658|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
41366524|NCT04576702|BIOLOGICAL|Investigational aIIV4c|Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
41366525|NCT04576702|BIOLOGICAL|IIV4c|Licensed, Non-adjuvanted, Cell-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
41366526|NCT04576702|BIOLOGICAL|aIIV4|Licensed, MF59-Adjuvanted, egg-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
41366527|NCT04576702|BIOLOGICAL|RIV4|Licensed, Recombinant Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
41366528|NCT05310227|DEVICE|Nerivio|The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache
41366529|NCT04220294|PROCEDURE|Subcutaneous tissue closure|Subcutaneous tissue closure with 2-0 vicryl suture.
41366530|NCT01579240|OTHER|Internet exercise program|12 voluntary weekly visits to website
41366531|NCT02174952|BEHAVIORAL|Self-help version of the New Forest Parenting Programme|
41366532|NCT00967356|DRUG|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
41366533|NCT00967356|DRUG|Placebo|Oral suspension
41366534|NCT04144881|DIAGNOSTIC_TEST|coronary computed tomography|patients randomized in this arm will perform computed coronary tomography 6 months after the index percutaneous revascularization on unprotected left main artery
41366535|NCT02696980|DEVICE|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
41366536|NCT05499546|DEVICE|SCALE EYE|Polyp size measurement using the SCALE EYE functionality
41366537|NCT01405989|DRUG|darexaban|oral
41366538|NCT01405989|DRUG|ketoconazole|oral
41366539|NCT02331680|DRUG|OPC-41061|
41366540|NCT02331680|DRUG|OPC-41061|
41366541|NCT02331680|DRUG|Placebo|
41366542|NCT03319602|DEVICE|Double trunk mask add above a nasal canulae|oxygenation only with nostril prongs
41366543|NCT05588466|OTHER|CDS Alone|The practices in the 'CDS alone' arm will receive an updated CDS for HTN management.
41366544|NCT05588466|OTHER|CDS plus practice facilitation|The practices in the 'CDS plus practice facilitation' arm will receive an updated CDS for HTN management plus practice facilitation to support the adoption of the CDS.
41366545|NCT03395613|DEVICE|NPWT|Negative pressure wound thearpy on closed surgical wounds
41366546|NCT06261658|PROCEDURE|Cryopreserved Ovarian Tissue Reimplantation|Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
41366547|NCT04192552|OTHER|PAUSE Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl \<50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure."
41501352|NCT00745784|BEHAVIORAL|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
41501353|NCT05419011|BIOLOGICAL|Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5|Given SC
41501354|NCT05419011|PROCEDURE|Biopsy|Undergo biopsy
41501355|NCT05419011|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41501356|NCT05419011|PROCEDURE|Colonoscopy|Undergo SOC colonoscopy
41501357|NCT05419011|DRUG|Nogapendekin Alfa|Given nogapendekin alfa inbakicept (N-803) SC
41501358|NCT05419011|DRUG|Placebo Administration|Given SC
41501359|NCT05419011|OTHER|Questionnaire Administration|Ancillary studies
41501360|NCT05892692|BEHAVIORAL|Ecological Momentary Intervention|Participants will receive hypothetical and real-time behavioral feedback using a smartphone application which provides ecological momentary responses to their current behaviors. By providing safety tips and advice, the intervention may decrease incidences of sexual assault and risky sex compared to a control group.
41501361|NCT06075953|DRUG|Tamoxifen|For premenopausal women: 20 mg or 5 mg tamoxifen orally for postmenopausal women: For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (5 mg) or standard dose (20 mg) of tamoxifen
41501362|NCT06075953|DRUG|Exemestane|for postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally
41501363|NCT06075953|DRUG|Letrozole|for postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily,
41366548|NCT04192552|OTHER|ASRA Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl \>80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~\*Low-dose heparin bridging can be used if at high A-TE risk"
41366549|NCT00667537|DRUG|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
41366550|NCT04495400|PROCEDURE|Thoracolumbar Fracture Fixation|The is surgery is preformed on patients who have had a blunt trauma fractures between the T10 and the L2. The surgical management for more severe/unstable fractures usually involves posterior instrumentation with percutaneous or open pedicle screw fixation. While the traditional open pedicle screw fixation technique has demonstrated good radiologic and clinical outcomes, a minimally invasive percutaneous approach has been increasingly used in recent years.
41366551|NCT04786782|DIAGNOSTIC_TEST|PPG-detecting software|Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.
41501364|NCT06075953|DRUG|Anastrazole|for postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily;
41501365|NCT06075953|DRUG|Testosterone + Anastrazole|Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
41501366|NCT06075953|DRUG|Elacestrant|Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.
41501367|NCT06075953|DRUG|Z-endoxifen|Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.
41501368|NCT05914688|DRUG|LY3209590 (Formulation 1)|Administered SC.
41501369|NCT05914688|DRUG|LY3209590 (Formulation 2)|Administered SC.
41501370|NCT02455518|DRUG|Oxycodone/acetaminophen|
41501371|NCT02455518|DRUG|Hydrocodone/acetaminophen|
41501372|NCT02455518|DRUG|Codeine/acetaminophen|
41501373|NCT02455518|DRUG|Ibuprofen/acetaminophen|
41501374|NCT00111423|DRUG|Pegsunercept (PEG sTNF-RI)|
41501375|NCT05096429|BEHAVIORAL|PROVIDENT|Each of the state's 39 municipalities will be randomised to the intervention (PROVIDENT) or comparator condition. An interactive, web-based tool will be developed to visualize the PROVIDENT model predictions. Municipalities assigned to the treatment arm will receive neighborhood risk predictions from the PROVIDENT model, and state agencies and community-based organizations will direct resources to neighborhoods identified as high risk. Municipalities assigned to the control arm will continue to receive surveillance information and overdose prevention resources, but they will not receive neighborhood risk predictions from this study.
41501376|NCT00275574|PROCEDURE|acupuncture|acupuncture
41501377|NCT03547037|DRUG|JNJ-63723283|JNJ-63723283 will be administered intravenously.
41501378|NCT03547037|DRUG|Erdafitinib|Erdafitinib will be administered orally.
41501379|NCT04775849|DEVICE|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed uni- or bilateral
41501380|NCT04001946|DEVICE|Button Huggie|low profile, external securement device for G-buttons
41501381|NCT03097848|PROCEDURE|RFA|for eligible cases, radiofrequency ablation will be given only.
41366552|NCT04786782|DIAGNOSTIC_TEST|LSM and PLT count|Patients whose LSM \>15kPa, or PLT count \< 150\*10\^9 should be screened with upper GI endoscopy
41366553|NCT03415815|PROCEDURE|Surgeries|Radical resection of esophageal cancer
41366554|NCT00711009|DRUG|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
41366555|NCT00711009|DRUG|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
41366556|NCT00711009|DRUG|raltegravir (RAL)|RAL 400 mg BID
41366557|NCT06241131|DRUG|Desflurane Inhalant Product|The Desflurane was inhaled at a starting concentration of 1 MAC, and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
41366558|NCT04586608|DIETARY_SUPPLEMENT|MCT/ω-3 fatty acids|The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.
41366559|NCT04586608|DIETARY_SUPPLEMENT|soybean oil-based IVFE|soybean oil-based IVFE
41366560|NCT03833908|DEVICE|MAF-1217|Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
41366561|NCT06145269|DRUG|New oral anticoagulant (rivaroxaban) and Marevan (warfarin)|comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)
41366562|NCT05699382|OTHER|practiced mindfulness through the application for 6 weeks|Physicians working at a tertiary hospital were recruited and randomly divided into two groups, a study group (SG) in which participants practiced mindfulness through the application for 6 weeks
41366563|NCT02961231|BIOLOGICAL|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
41366564|NCT02961231|BIOLOGICAL|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
41366565|NCT02961231|BIOLOGICAL|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
41366566|NCT02961231|BIOLOGICAL|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
41366567|NCT01588899|DEVICE|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
41366568|NCT03852446|DRUG|Indoximod HCL (F2) tablets|The doses will be ascending per cohort from 600 mg to 2400 mg
41366569|NCT03852446|DRUG|Indoximod base formulation|Single oral administration of 1200 mg
41366570|NCT03852446|OTHER|Placebo|The matching placebo doses will be ascending per cohort from 1 to 4 tablets
41366571|NCT03852446|DRUG|Indoximod HCL (F2) tablets|Single oral administration of 1200 mg
41366572|NCT05578820|BIOLOGICAL|Stimotimagene copolymerplasmid|Gene therapy drug, Intratumoral administration
41366573|NCT05578820|DRUG|Ganciclovir|Antiviral drug, Intravenous administration
41366574|NCT03039959|DIAGNOSTIC_TEST|No intervention|No intervention
41366575|NCT00804323|PROCEDURE|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
41366576|NCT05853276|BEHAVIORAL|Brush DJ app|Brush DJ app is a mobile app which can be freely downloaded. This app was chosen as part of the intervention as it was recognized by the NHS to reduce the risk of gum disease and tooth decay among its users. This app was built around the info given in the public health England Delivering Better Oral Health Toolkit.
41366577|NCT03651960|OTHER|ROBOT PROTOTYPE|The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
41366578|NCT04855682|OTHER|Retrospective observation after 24 months after the spinal procedure|Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process
41366579|NCT04855682|OTHER|Retrospective observation after 12 months after the spinal procedure|Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes
41501382|NCT03097848|DRUG|Sorafenib|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
41501383|NCT03451214|OTHER|Diet Zinc|4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
41366580|NCT04855682|OTHER|Prospective evaluation of patients after 12 and 24 months after the spinal procedure|Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes
41366581|NCT06267859|COMBINATION_PRODUCT|The use of a combination of microelements and vitamins against the background of physiotherapy|If necessary, necessary microelements and vitamins will be added to the treatment process. At the same time, physiotherapeutic procedures will be added at the rehabilitation stage.
41366582|NCT03006952|DRUG|Pentoxifylline|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
41366583|NCT03006952|DRUG|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
41366584|NCT04257656|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
41366585|NCT04257656|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
41366586|NCT01604512|DIAGNOSTIC_TEST|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
41366587|NCT03557073|BEHAVIORAL|Postoperative phone call|The intervention is a phone call on the day following surgery.
41366588|NCT02500732|DRUG|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
41366589|NCT02500732|DRUG|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
41366590|NCT02132065|DRUG|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
41366591|NCT00983125|DRUG|Clonidine|"Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour."
41366592|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test at 90° of hip flexion|anterior drawer test at 90° of hip flexion
41366593|NCT04957706|DIAGNOSTIC_TEST|Lachman test|Lachman test
41366594|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test|anterior drawer test
41366595|NCT04957706|DIAGNOSTIC_TEST|pivot-shift test|pivot-shift test
41366596|NCT03434665|PROCEDURE|Transradial celiac artery angiography|"* After completion of transradial diagnostic coronary angiography and/or PCI, before removal of the radial arterial sheath, selective angiography of the celiac artery will be performed.~* Technically, a 0.35-inch wire is advanced into the descending aorta. A 125 cm 5-French Judkins right catheter is inserted over this wire, which is then removed. The distal tip of the catheter is brought in front of the ostium of the celiac artery and positioning is confirmed with angiography of the celiac artery. Two or three views will be obtained to determine the optimal view to visualize the left gastric artery anatomy. All material is removed and hemostasis is obtained as per clinical routine for coronary angiography."
41366597|NCT06366191|OTHER|prevention algorithm|a health watch adapted to stress and dissociative symptoms
41366598|NCT06366191|OTHER|Standard care|Standard care for post traumatic stress disorder
41366599|NCT06155851|PROCEDURE|Upper Endoscopy|Endescopy
41366600|NCT01728870|OTHER|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
41366601|NCT01728870|OTHER|Exclusive Enteral Nutrition (Modulen)|
41366602|NCT03205605|DRUG|oxybutynin|patch
41366603|NCT03205605|DRUG|oxybutynin|gel
41366604|NCT06177925|DRUG|Adebrelimab|Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.
41366605|NCT06177925|DRUG|Carboplatin/Cisplatin|Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
41366606|NCT06177925|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
41028321|NCT01335711|DRUG|ChronVac-C + SOC|"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)"
41028322|NCT01335711|DRUG|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
41366607|NCT06177925|RADIATION|Radiation therapy|IMRT for thoracic of 45--55Gy in 15-22 fractions，SBRT for metastases during the concurrent chemoradiotherapy phase
41366608|NCT05796401|BEHAVIORAL|Cognitive training|"Cognitive reinforcement using digital applications (PSYCARE application) during 12 weeks~+/- virtual reality based cognitive remediation application : 24 sessions over 12 weeks (only for patients who have a higher cognitive deficits (TMTB score \>110s))"
41501384|NCT06089200|PROCEDURE|Transversus Abdominal Plane Block|20 cc of bupivacaine 0.2% was given to the transversus abdominis plane
41366609|NCT05796401|DRUG|Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC|"Personalised neuroprotective medication adapted to the individual's biological profile :~* Vitamin B12 : 500 micrograms per day~* Folinic acid : 50 mg per day~* Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~* N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks"
41366610|NCT05796401|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
41366611|NCT01884675|DRUG|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
41366612|NCT01884675|DRUG|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
41366613|NCT01539473|DRUG|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
41366614|NCT01539473|DRUG|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
41366615|NCT04601389|BIOLOGICAL|"Omalizumab (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
41366616|NCT04601389|BIOLOGICAL|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
41366617|NCT04159558|DEVICE|Mobile application|Experimental group will use a mobile application to help them in their self-care
41366618|NCT01636076|DRUG|QMF149|delivered via Concept1 device
41366619|NCT01636076|DRUG|Salmeterol|delivered via Accuhaler®
41366620|NCT01007227|OTHER|Lifestyle instruction|Instruction dietetic and exercise therapy
40845474|NCT03532139|DRUG|Enoxaparin + Rosuvastatin|"Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness"
40845475|NCT03532139|OTHER|Thromboprophylaxis|standard of care therapy
40845476|NCT05013970|OTHER|Clinical assessment|Clinical assessment including Visual Analog Scale (VAS) for Knee Pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire
41501385|NCT06089200|PROCEDURE|Spinal Morphine|100 µg was administered intrathecally preoperatively
41501386|NCT06091540|BEHAVIORAL|Feasibility and Efficacy of Individual SH+ Intervention|The key parameter of interest will be the extent of psychological distress encountered by the participants. In addition, various secondary outcomes will also be evaluated, encompassing depression, anxiety, post-traumatic stress disorder (PTSD) symptoms, psychosocial well-being, and grief levels. The evaluation of the intervention's effectiveness on the sample of interest will hinge on the comparison of scores obtained during the pretest and posttest measurement phases.
41501387|NCT06125730|OTHER|DIME Beauty Eyelash Boost Serum|The test product contains Water, Glycerin, Amino Acids (Sodium PCA, Sodium Lactate, Arginine, Aspartic Acid, PCA, Glycine, Alanine, Serine, Valine, Proline, Threonine, Isoleucine, Histidine, Phenylalanine), Hyaluronic Acid, Panthenol, Aloe Leaf Extract, Niacinamide, Purslane, Chebulic Fruit Extract, Apple Fruit Extract, Tocopherol, Phenoxyethanol, Hexanediol, Ethylhexylglycerin, Biotinoyl Tripeptide-1, Myristoyl Pentapeptide-4.
41501388|NCT06470438|DRUG|JNJ-88998377|JNJ-88998377 will be administered.
41501389|NCT05320887|OTHER|Normal Nicotine Content Vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
41501390|NCT05320887|OTHER|Normal nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
40845477|NCT05013970|OTHER|Radiographic imaging|MRI of the knee
40845478|NCT02348307|DRUG|FYU-981, (Oral single dosing)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
40845479|NCT02348307|DRUG|Placebo, (Oral single dosing)|Subjects randomized to the placebo arm receive placebo.
40845480|NCT05207683|OTHER|echocardiography|All the patients will be subjected to thorough medical history and clinical examination and the results of the previous investigations will be collected aiming for reaching the diagnosis of the etiology of pulmonary hypertension. ct pulmonary angiography and then right heart catheterization will be done in case of undiagnosed etiology.
41366621|NCT04966442|BEHAVIORAL|GrandAides|Enhanced post acute care for patients recently admitted for congestive heart failure
41366622|NCT03853915|DIAGNOSTIC_TEST|[18-F]- FDG - PET|\[F-18\]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, \[F-18\]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
40845481|NCT01286571|DRUG|BI 135585|one oral single dose per subject
40845482|NCT01286571|DRUG|BI 135585|one oral single dose per subject
41366623|NCT04704869|BIOLOGICAL|Cryoprecipitate|Cryoprecipitate is a blood product high in fibrinogen. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
41366624|NCT04704869|BIOLOGICAL|Red Blood Cells|RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.
41366625|NCT04704869|BIOLOGICAL|Plasma|Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.
41366626|NCT04704869|BIOLOGICAL|Platelets|Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.
41366627|NCT04704869|BIOLOGICAL|Whole Blood|Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.
40845488|NCT03134690|PROCEDURE|delayed start|In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .
41366628|NCT04102761|PROCEDURE|Intradiscal PRP & BMC Injections|The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
41501391|NCT05320887|OTHER|Low nicotine content vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
41501392|NCT05320887|OTHER|Low nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
41501393|NCT05369312|DRUG|BPI-442096|Subjects will receive BPI-442096 until disease progression
41501394|NCT03573310|DRUG|JNJ-64619178|JNJ-64619178 capsules to be administered orally.
41501395|NCT00340678|DRUG|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
41501396|NCT00340678|DRUG|Placebo|Treatment with placebo corresponding to each dose of losartan.
41501397|NCT04647565|OTHER|interviews|interviews (human and social sciences)
41501398|NCT02226601|DRUG|Aprepitant|3 days perioperative Aprepitant once a day
41501399|NCT02226601|DRUG|Placebo|3 days perioperative Placebot once a day
40845489|NCT03134690|PROCEDURE|Conventional|In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
40845490|NCT00810784|BEHAVIORAL|Education|(1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
40845491|NCT03147534|DEVICE|InstaTemp MD|The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.
40845492|NCT03147534|DEVICE|"Welch Allyn, rectal"|"The Welch Allyn rectal thermometer is intended to measure human body temperature."
40845493|NCT03147534|DEVICE|"Welch Allyn, oral"|"The Welch Allyn oral thermometer is intended to measure human body temperature."
40845494|NCT03147534|DEVICE|Covidien, tympanic|The Covidien tympanic thermometer is intended to measure human body temperature.
40845495|NCT03907462|BEHAVIORAL|SMART 2.0|SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.
41366629|NCT04433260|OTHER|Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index|The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
41366630|NCT04433260|OTHER|Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.|Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
40845496|NCT04548518|BIOLOGICAL|GPO Tri Fluvac vaccine|Each dose of Tri Fluvac contains a total of 45 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (≤ 5.75 μg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (≤ 1.0μg), formaldehyde (≤ 100μg), tween 80 (≤ 0.9μg), triton x-100 (≤0.05μg) and gentamicin (≤0.075μg).
41366631|NCT04433260|OTHER|Informed consent|Participants will need to give their consent to participate to the survey after reading PIS
41366632|NCT03547219|DRUG|Escitalopram|
41366633|NCT05970042|BEHAVIORAL|GameDay Ready|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. The GameDay Ready program promotes increasing physical activity, reducing sedentary time, and improving dietary habits through education, behavioral self-monitoring, and goal setting. Each 60-minute intervention session includes a brief educational component followed by a group discussion of weekly progress. Following a short warmup walk, participants engage in group-based competitive physical activities and then a short cooldown walk. Participants then set individual and group-based goals for the upcoming week and discuss strategies for overcoming barriers to achieving goals. The program is sensitive to intersectional influences of gender, race, and rurality on health; and strategies to enhance motivation are threaded throughout the program.
41366634|NCT05970042|BEHAVIORAL|Walking and General Health Education|Participants receiving the comparison program will complete a 12-week walking and general health education program. Group sessions meet once per week at a publicly accessible walking track, and each 60-minute session consists of a brief educational component on a health topic followed by walking and socializing during the remainder of the session.
41366635|NCT02203305|DEVICE|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
41366636|NCT02203305|OTHER|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
41366637|NCT02585089|OTHER|Spanish cured-pork ham|"Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).~Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day."
41366638|NCT02585089|OTHER|Cooked pork ham|Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
40845497|NCT04548518|BIOLOGICAL|Licensed influenza vaccine|The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020
41028323|NCT01888315|DEVICE|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
41028324|NCT01888315|DEVICE|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
41501400|NCT03239223|DRUG|ABI-1968|Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
40845498|NCT05806866|BEHAVIORAL|Cognition scores, cognitive instrumental activities of daily living scores|A detailed neuropsychological test battery will be applied. The Functional Activitites Questionnaire (FAQ) subscores will be used to define cognitive and motor instrumental activities of daily living function
40845499|NCT00393614|DRUG|levetiracetam|20 mg pr. kg a day
40845500|NCT05201950|OTHER|Virtual simulation|Virtual simulation using Full-Code, a virtual simulation software with a bank of emergency medicine cases
41028325|NCT01888315|DEVICE|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
41028326|NCT01888315|DEVICE|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
41028327|NCT05793905|COMBINATION_PRODUCT|Buffered lidocaine in inferior alveolar nerve block injection|Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars
41028328|NCT05793905|DRUG|lidocaine 2% in inferior alveolar nerve block injection|Lidocaine 2% with epinephrine 1.80000 in IANB injection in the treatment of bilateral primary mandibular molars
40845501|NCT05201950|OTHER|Team based in situ simulation|In situ simulation, using a high fidelity manikin in the critical care area of the emergency department, with team members consisting of multiple junior doctors and nurses, facilitated by senior emergency medicine doctors and nurses.
41366639|NCT06493617|OTHER|Cervical Mobilization|The technique is used to mobilize a specific cervical or upper thoracic segment (C2-C3 through T3-T4) in a posterior to anterior direction. The therapist gently applies pressure in an anteroposterior direction in the plane of the facet joint to assess mobility, resistance, end feel, and pain provocation. Gentle oscillations can be used to either inhibit pain (grades I and II) or restore motion (grades III and IV). Slight variations in depth and direction of force can be used to optimize the therapeutic effects of this technique.
41366640|NCT06493617|OTHER|Traditional physical therapy treatment|tendon gliding exercises, median nerve gliding exercise, strengthening exercises for 60 minutes
41366641|NCT00649220|DRUG|Memantine|memantine tablets, twice a day (bid), for 20 weeks
41366642|NCT02716402|RADIATION|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
41366643|NCT05499052|DRUG|REKOVELLE®|"Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio."
41366644|NCT05822973|DEVICE|3.0 monocryl suture|incision will be closed with absorbable suture
40845502|NCT01908439|OTHER|whole-body vibration|High amplitude whole-body vibration
40845503|NCT00696969|DRUG|Amphotericin B Deoxycholate|1 mg/kg e.o.d for 30 days
40845504|NCT00696969|DRUG|Ambisome + Miltefosine|Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
40845505|NCT00696969|DRUG|Ambisome and Paromomycin|Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
40845506|NCT00696969|DRUG|Miltefosine and Paromomycin|Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
40845507|NCT03979599|PROCEDURE|ultra-sound guided transversus abdominis plan block|comparing ultrasound guided transversus abdominis plan block using combination of magnisum sulphate and levobupivacaine versus levobupivacaine
40845508|NCT03979599|DRUG|magnesium sulphate& levobupivacaine|magnesium sulphate\& levobupivacaine
41366645|NCT05822973|DEVICE|3.0 nylon suture|incision will be closed with non-absorbable suture
41366646|NCT02651740|DRUG|Rifaximin|400mg tid\* 3d
41366647|NCT02651740|PROCEDURE|Fecal microbiota transplantation|Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
41366648|NCT00486720|DRUG|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
41366649|NCT00486720|DRUG|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
41366650|NCT04672694|PROCEDURE|Vagus nerve block|Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.
41366651|NCT04672694|PROCEDURE|No vagus nerve block|No vagus nerve block will be conducted during the surgery.
41366652|NCT02985996|DRUG|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
41366653|NCT02985996|DRUG|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
41366654|NCT06423521|OTHER|Standard of Care (SOC)|The SOC intervention constitutes the common clinical practice of care that is habitually performed after cardiac surgery to manage anticoagulation therapies.
41366655|NCT06423521|OTHER|Remote Patient Monitoring (RPM)|The RPM intervention involves the use of a remote patient monitoring (RPM) system with a portable coagulometer for the clinical follow-up and self-management of International Normalized Ratio (INR) control in patients undergoing anticoagulant therapy post-cardiac surgery. Patients were provided with a Coagulometer-CoaguChek® (Roche Diagnostics, Switzerland) kit and test strips, along with written instructions for conducting measurements. They were also enrolled in a monitoring platform. Patients received regular text messages on their smartphones to report their INR values and symptoms related to anticoagulant therapy. The clinical team received notifications if patients\&amp;#39; reports fell outside therapeutic standards and then responded with medication adjustments via text message.
40845509|NCT03979599|DRUG|Levobupivacaine|levobupivacaine
40845510|NCT01232985|DEVICE|RD047-26|RD047-26 emollient gel
40845511|NCT03854383|DRUG|Isosorbide mononitrate|Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women
40845512|NCT03854383|DRUG|Misoprostol|Used intravaginally to ripe the cevix in induction of labor
40845513|NCT03579173|DIAGNOSTIC_TEST|Infant PFT|Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
40845514|NCT03579173|DIAGNOSTIC_TEST|Lung Clearance Index|The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
40845515|NCT03579173|DIAGNOSTIC_TEST|Passive tidal breathing|During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
40845516|NCT00819117|DEVICE|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
40845517|NCT00528996|DRUG|BEA 2180 BR|Solution
40845518|NCT00528996|DRUG|Tiotropium Bromide|Solution
40845519|NCT00528996|DRUG|Placebo|Solution
40845520|NCT05928416|DIAGNOSTIC_TEST|Saliva sample|"During the inclusion visit :~* a neurological examination is taken~* a saliva sample is taken"
41366656|NCT05498207|BEHAVIORAL|Maya App|Participants will utilize the Maya App for at least 20 minutes per day, 2 days per week, for 6 weeks. Additionally, participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
40845521|NCT05928416|DIAGNOSTIC_TEST|Saliva sample|"During the inclusion visit :~* a saliva sample is taken"
41366657|NCT05721482|BEHAVIORAL|Caregiver Training|"A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth. Participants will receive session materials so they can follow along. Each MIM session consists of material related to mindfulness-the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Group interaction centers on sharing ideas toward effective practice and practical daily challenges to being mindful. Each class begins with a prompt for participant contemplation during the next hour that reference a unique weekly theme which will be reiterated in the session materials.~The DASH portion, led by the Registered Dietitian, focuses on education to increase vegetables, fruits, whole grains and decrease intakes of fat and sodium, sugar sweetened beverages and sweets. Education includes adapting traditional Soul food dishes to meet the DASH dietary guidelines."
41028329|NCT04088786|DRUG|nanoliposomal irinotecan|The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
41028330|NCT00432380|BIOLOGICAL|Rotarix™|oral doses
41028331|NCT00432380|BIOLOGICAL|Placebo|oral dose
41028332|NCT00941239|DRUG|metformin ER|850mg daily for 30 days
41028333|NCT00941239|DRUG|metformin|850 mg daily for 30 days
41366658|NCT00772031|DRUG|propranolol LA|Propranolol LA up to 240 mg/day
41366659|NCT00772031|DRUG|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
41366660|NCT00772031|DRUG|placebo|an inactive substance
41366661|NCT04504682|BEHAVIORAL|Ambulation|Patients will be encouraged to ambulate for 20 minutes of every hour.
41366662|NCT01430520|DRUG|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
41366663|NCT01430520|DRUG|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
41366664|NCT01784094|DEVICE|StromaGlide|
41366665|NCT04946916|DIAGNOSTIC_TEST|blood sample taken|Comparaison of Neurofilament light chain serum concentration between the arms
41366666|NCT02426359|DRUG|Q301 Cream|
41366667|NCT02426359|DRUG|Placebo|
41366668|NCT00563602|OTHER|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
41366669|NCT04556149|DEVICE|imPulse™ Una e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
41366670|NCT04556149|DEVICE|Philips Lumify Ultrasound System|Point-of-care ultrasound
41366671|NCT00940719|DIETARY_SUPPLEMENT|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
41366672|NCT05901506|OTHER|a Nurse-led, Motivational Interview|Family member participants will receive three counselling sessions: (1) preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions at weeks 2 \& 3, with 30-45 min, respectively. The sessions can be delivered via face-to-face, zoom meeting, or telephones. Before each session, the nurse will first assess the family member's readiness to engage in ACP based on the State to Change algorithm. Family members who have never thought about ACP will be in the pre-contemplation state. Family members who are willing to discuss end-of-life care will be in the contemplation state. Those who are ready to talk about end-of-life planning will be in the planning state. Readiness-based ACP goals will be established, and state-matched motivational interview counseling will be customized for each participant.
41366673|NCT02073292|PROCEDURE|c-RFA|
41366674|NCT02073292|PROCEDURE|tRFA|
41366675|NCT01240629|OTHER|laboratory biomarker analysis|Correlative study
41366676|NCT01240629|OTHER|questionnaire administration|Correlative study
41366677|NCT01240629|DRUG|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
40845522|NCT03908970|DRUG|1% OPA-15406|Twice daily
40845523|NCT03908970|DRUG|Placebos|Twice daily
40845524|NCT00915291|OTHER|Web-based educational modules|Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians
40845525|NCT03412383|DRUG|Pyrotinib|Pyrotinib 400mg/day
41028334|NCT01123759|OTHER|Feeding low mercury fish|Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
41028335|NCT03912259|DRUG|Dupilumab|"Pharmaceutical form: solution,~Route of administration: SC"
41501401|NCT04546880|OTHER|Breathing exercises|"Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During the diaphragmatic breathing, attention is focused on the correct abdominal breathing.~The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over breathing."
41501402|NCT04546880|OTHER|Stabilization exercises|"Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability."
40845526|NCT01688908|PROCEDURE|Endoscopic Screening|"1. Upper G.I. endoscopic examination with Lugols Iodine in esophagus~2. Biopsy at the visually abnormal sites~3. Pathologic examination of all biopsy tissue specimens~4. Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~5. Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions."
40845527|NCT00400569|DRUG|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
40845528|NCT05244733|BEHAVIORAL|Social Engage (S-ENGAGE)|S-ENGAGE uses the process of action planning to foster sustained behavior change. Action planning involves: 1) select a goal; 2) develop ideas to meet this goal; 3) choose one or more of these ideas; 4) identify concrete steps to implement the goal (i.e., form an action plan); 5) identify and address barriers if needed.
40845529|NCT05244733|BEHAVIORAL|The Healthy Lifestyles Education Program|The healthy lifestyles education program is a self-guided psychoeducational program, including a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources.
40845530|NCT05997706|PROCEDURE|Testicular biopsy|Testicular biopsy is a clinical procedure for extraction of testicular tissue
40845531|NCT04507971|BIOLOGICAL|MET-3|Human microbiome supplementation derived from bacterial strains isolated from fecal matter and grown in a laboratory environment
40845532|NCT00223249|DRUG|Quetiapine|
40845533|NCT02847104|OTHER|dynamic insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and dynamic insulin protocol
40845534|NCT02847104|OTHER|static insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and static insulin protocol
41028336|NCT03912259|DRUG|Placebo|"Pharmaceutical form: solution,~Route of administration: SC"
41028337|NCT03912259|DRUG|Emollient (moisturizer)|"Pharmaceutical form: cream,~Route of administration: topical use"
41366678|NCT02982122|OTHER|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
41501403|NCT06041789|DRUG|Donepezil|10 mg tablet
41501404|NCT06041789|DRUG|Placebo|Donepezil placebo tablet
41366679|NCT04710459|PROCEDURE|cryotherapy|Group 1 included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy. Group 2 included include 30 patients, they were subjected to chemoradiotherapy.
41366680|NCT06036940|OTHER|Preoperative patient education given with three different methods|To determine the effect of preoperative patient education given by three different methods on the level of perioperative anxiety in children aged 4-7 years.
41501405|NCT05984186|DEVICE|High Velocity Therapy|FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM
41501406|NCT04222972|DRUG|Pralsetinib|Administered orally
41501407|NCT04222972|DRUG|Carboplatin|Administered IV
41501408|NCT04222972|DRUG|Cisplatin|Administered IV
41501409|NCT04222972|DRUG|Pemetrexed|Administered IV
40845535|NCT04666194|PROCEDURE|Cold forceps|
40845536|NCT04666194|PROCEDURE|Cold snare|
40845537|NCT04666194|PROCEDURE|Hot snare|
41028338|NCT00788554|PROCEDURE|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
41028339|NCT00788554|PROCEDURE|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
41028340|NCT00003878|DRUG|polifeprosan 20 with carmustine implant|
41028341|NCT00003878|PROCEDURE|conventional surgery|
41028342|NCT01465490|BEHAVIORAL|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
41501410|NCT04222972|DRUG|Pembrolizumab|Administered IV
41501411|NCT04222972|DRUG|Gemcitabine|Administered IV
41501412|NCT04222972|DRUG|Paclitaxel|Administered IV
41366681|NCT04476641|OTHER|CELL|inject the DC-CIK(dendritic cell activated and cytokine induced killer cell)
41366682|NCT05677373|DRUG|BRD4 Inhibitor PLX2853|Given PO
41366683|NCT05677373|DRUG|Trametinib|Given PO
41366684|NCT05677373|PROCEDURE|Computed Tomography|Undergo CT with contrast
41366685|NCT05677373|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI with contrast
41366686|NCT05677373|PROCEDURE|Biospecimen collection|Undergo collection of blood
41501413|NCT04222972|DRUG|Nab-Paclitaxel|Administered IV
41366687|NCT05677373|PROCEDURE|Biospecimen collection|Correlative studies
41366688|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
41366689|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
41366690|NCT03799198|OTHER|Weight Management Program (WMP)|As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
41366691|NCT03799198|DRUG|Medication for chronic weight management (Rx)|"Following listed 5 drugs will be administered as prescribed by the study doctor:~1) Orlistat (Xenical® pills, per os \[p.o.; by mouth\]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\])."
41366692|NCT05538507|DRUG|smart soup|Severe AD, mild or moderate AD and MCI will be given smart soup
41366693|NCT05538507|DRUG|Donepezil|Severe AD and mild or moderate AD will be given donepezil
41366694|NCT05538507|DRUG|Memantine|Severe AD will be given memantine
41366695|NCT05538507|DRUG|Placebo|patients with MCI will be given placebo
41366696|NCT05238246|BEHAVIORAL|Behavioral guidance with tell-show-do|The effect of tell-show-do technique during dental treatment on behavior in pediatric patients was evaluated and compared.
41366697|NCT05238246|BEHAVIORAL|Behavioral guidance with robot|The effect of the tell-show-do and distraction technique during dental treatment on behavior in pediatric patients was evaluated and compared.
41366698|NCT01546909|BIOLOGICAL|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
41366699|NCT01791166|BIOLOGICAL|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
41366700|NCT03744858|PROCEDURE|Peripheral blood draw|Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.
41501414|NCT03629756|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
41366701|NCT03104270|DRUG|Elotuzumab|Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
41366702|NCT03104270|DRUG|Pomalidomide|Pomalidomide PO at 3mg
41366703|NCT03104270|DRUG|Carfilzomib|Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
41366704|NCT03104270|DRUG|Dexamethasone|Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
41366705|NCT05805332|OTHER|pulmonary rehabilitation|The participants would undergo pulmonary rehabilitation.
41366706|NCT05737927|DRUG|Glucose 8 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
41501415|NCT03629756|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
41501416|NCT03207386|BEHAVIORAL|Youth VIP|Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
41501417|NCT04893018|BIOLOGICAL|Efineptakin alfa|Given IM
41501418|NCT02046486|DRUG|Ticagrelor 180mg whole tablets|
41501419|NCT02046486|DRUG|Ticagrelor 180mg crushed and dispersed|
41501420|NCT03781401|DEVICE|Ambulatory blood pressure monitoring|
41501421|NCT01091324|DRUG|Dextromethorphan|60 mg, bid
41501422|NCT01091324|DRUG|Silymarin|150 mg , tid
41501423|NCT01091324|DRUG|sugar pill|placebo
41501424|NCT03907878|BIOLOGICAL|Ligelizumab|Liquid in vial
41501425|NCT05744180|OTHER|Interventional|The FitScore is a machine learning algorithm embedded within the electronic health record that identifies patients most likely to benefit from remote patient monitoring.
41501426|NCT01130597|DRUG|patiromer|Active investigational drug
41501427|NCT01130597|DRUG|spironolactone|
41501428|NCT04963153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40845538|NCT05858879|OTHER|Notification of patients and clinicians|"Notification Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or US mail that will inform them of the CAC identified on their previous chest CT scan and a recommendation that they discuss this finding and initiation of lipid-lowering therapy with their clinician. The clinicians will be notified of these findings by an earlier EHR message that will be sent 2 weeks before the patient notification.~Usual Care The usual care arm will not receive any additional notification beyond this standard of care."
41501429|NCT04963153|PROCEDURE|Bone Scan|Undergo bone scan
40845539|NCT03675984|BEHAVIORAL|asymmetrical stabilization exercise|Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
40845540|NCT03158181|OTHER|Non interventional study|None intervention will be conduct on patient. Only the operating room will be randomized to have an intervention or not (Bundle of measure for optimizing the discipline of personnel in the operating room)
40845541|NCT03157765|PROCEDURE|endometrial biopsy|endometrial biopsy
41501430|NCT04963153|PROCEDURE|Computed Tomography|Undergo CT
40845542|NCT01447121|DEVICE|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
40845543|NCT00756210|OTHER|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
40845544|NCT05819619|DRUG|Prophylactic use of ibuprofen and ondansetron post misoprostol administration|Prophylactic use of ibuprofen and ondansetron post misoprostol administration
40845545|NCT05819619|DRUG|Use of ibuprofen and ondansetron at symptom onset post misoprostol administration|Administration of ibuprofen or ondansetron only when experiencing pain or nausea respectively post misoprostol administration.
40845546|NCT05994079|DEVICE|High intensity focused ultrasound|"Parameters:~Transducer frequency 7-2-mhz 1.5-9.0-mm focal depth. The pulse duration for each individual exposure ranged from 25 to 40 milliseconds.~Energy per ultrasound pulse ranged from 1.0 to 1.5 J"
40845547|NCT05994079|OTHER|topical firming creams|medical topical firming creams
41366707|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
41366708|NCT05737927|DRUG|Glucose 16 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
41366709|NCT05737927|DRUG|Glucose 12 g uncoated beads|After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
41501431|NCT04963153|PROCEDURE|Echocardiography|Undergo echocardiography
41501432|NCT04963153|DRUG|Enfortumab Vedotin|Given IV
41366710|NCT05737927|DRUG|Glucose 12 g coated beads (60% w/w)|After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
41501433|NCT04963153|DRUG|Erdafitinib|Given PO
41501434|NCT04963153|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
40845548|NCT03235089|DEVICE|Test Lens|Daily disposable contact lens
40845549|NCT03235089|DEVICE|Control Lens|Focus Dailies All Day Comfort contact lens (nelfilcon A)
41501435|NCT03444376|DRUG|GX-188E|GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device
41501436|NCT03444376|DRUG|KEYTRUDA®|pembrolizumab(100mg/4mL/vial), Intravenous administration
40845550|NCT02113332|DRUG|Liraglutide|
40845551|NCT02113332|DRUG|Placebo|
40845552|NCT05586841|DRUG|Dalpiciclib|Dalpiciclib: 100 mg/d or 125 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
40845553|NCT05586841|DRUG|Chidamide|Chidamide: 25 mg/BIW or 20 mg/BIW, po., q2w. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
40845554|NCT00774683|DRUG|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
40845555|NCT02193412|PROCEDURE|noxious stimulus|standardized noxious stimulus with tetanic stimulation
40845556|NCT02193412|PROCEDURE|change in operating table slope: head-down tilt position|-30°
40845557|NCT02193412|PROCEDURE|change in operating table slope: head-up tilt position|+30°
41501437|NCT00143390|DRUG|exemestane|take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
41501438|NCT00143390|DRUG|anastrozole|take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
41028343|NCT01546194|OTHER|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
41501439|NCT05076240|PROCEDURE|FilmArray® analysis|FilmArray® multiplex PCR analysis to diagnose ventilator associated pneumonia in COVID-19 ARDS
41501440|NCT06486454|DEVICE|HistoSonics Edison System|Histotripsy with the HistoSonics Edison System for the full or partial destruction of liver tumors
41028344|NCT06006182|OTHER|Grape Powder|Freeze-dried grape powder
41028345|NCT03165045|DRUG|Spiolto® Respimat®|6 weeks
41028346|NCT04018027|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg administered twice daily
41028347|NCT04018027|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg administered twice daily
41501441|NCT03997617|DIAGNOSTIC_TEST|Personalized Functional Profiling|During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.
41028348|NCT04018027|DRUG|difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg administered twice daily
41028349|NCT04018027|DRUG|Placebo|Oral Placebo administered twice daily
41028350|NCT06417281|DRUG|5 Aminolevulinic Acid|3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
41028351|NCT05031624|DRUG|CDX-0159|Single subcutaneous dose of one of four dosages of CDX-0159
41501442|NCT05071976|DIAGNOSTIC_TEST|ICG-NIR angiography|Capture NIR video of flap site beginning at time of ICG injection. At time of subjective peak intensity, capture video of flap and recipient wound bed. Measure rate of ICG egress from the global flap at 60, 120, and 180 seconds after initial dye injection from intraoperative video
41028352|NCT05031624|DRUG|Normal saline|Single subcutaneous dose of normal saline
41028353|NCT05647447|DRUG|Osanetant|Osanetant 200 mg orally, twice per day
41028354|NCT00462384|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
41501443|NCT04144361|PROCEDURE|sleeve with plication|sleeve with plication
41501444|NCT04144361|PROCEDURE|sleeve without plication|sleeve without plication
41501445|NCT06602960|BEHAVIORAL|Accurate Sleep Data Feedback|Participants will receive accurate feedback about their sleep data.
40845558|NCT05805644|DEVICE|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of delivering RMIT as well as RMTT. It can provide zero, partial or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial or full assistance for the patient.~Impairment oriented training will focus on the following movements:~1. Diagonal movement~2. Shoulder abduction~3. Shoulder adduction~4. Shoulder flexion~5. Shoulder extension~6. Elbow flexion~7. Elbow extension~Task-specific training will focus on the following activities:~1. Picking up a cup/glass by the side and drink~2. Brushing hair~3. Cleaning unaffected upper limb (hand to arm)~4. Wiping table~5. Wiping wall~6. Sliding card on table to a designated location~7. Clipping a clothe peg"
40845559|NCT02272166|DRUG|propofol|
41366711|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
40845560|NCT02272166|DRUG|Sevoflurane|
40845561|NCT02389439|DRUG|Pyronaridine-artesunate|
41366712|NCT04856072|DEVICE|Deep Brain Stimulation|Personalized Deep Brain Stimulation of Fornix
41366713|NCT00863265|DRUG|Ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
41366714|NCT00863265|OTHER|Phytosterols + ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
41366715|NCT00863265|OTHER|Placebo|
41366716|NCT01021423|DRUG|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
41366717|NCT01021423|OTHER|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
40845562|NCT01574885|DEVICE|Halotherapy|The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
40845563|NCT01574885|DEVICE|Placebo|The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
40845564|NCT02326233|BIOLOGICAL|Pen of SB5|
40845565|NCT02326233|BIOLOGICAL|PFS of SB5|
40845566|NCT00609739|DRUG|cyclosporine|Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients \>40 kg with normal renal function (creatinine \<1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
41366718|NCT01786707|BIOLOGICAL|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
41028355|NCT04623294|PROCEDURE|Oxygen supply of high-low-high procedure|"The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
41366719|NCT01786707|OTHER|Hyperbaric oxygen therapy|
41366720|NCT01786707|DRUG|Insulin|Insulin dose as per clinical management
41366721|NCT01786707|DRUG|Metformin|Metformin dose as tolerated
40845567|NCT00609739|DRUG|cytarabine|3000 mg/m\^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m\^2/day) on days -9 through -4.
40845568|NCT00609739|DRUG|filgrastim|Patients with absolute neutrophil count (ANC) \<0.2 x 10\^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10\^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
40845569|NCT00609739|DRUG|methotrexate|MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m\^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m\^2 IV on days +3, +6, and +11.
40845570|NCT00609739|DRUG|methylprednisolone|Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
40845571|NCT00609739|DRUG|mitoxantrone hydrochloride|10 mg/m\^2 over 30 minutes intravenously (IV) on days -9 through -7.
40845572|NCT00609739|PROCEDURE|allogeneic bone marrow transplantation|Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 \>10\^8/kg recipient weight. Infused on Day 0.
41366722|NCT02116374|OTHER|Physiopathology study|
41366723|NCT05672810|DIAGNOSTIC_TEST|serum level of Ferritin and D-dimer|Blood venous sample
41366724|NCT04651153|DRUG|UCB7853|Subjects will receive UCB7853 at pre-specified time-points.
41366725|NCT04651153|OTHER|Placebo|Subjects will receive Placebo at pre-specified time-points.
41366726|NCT00874718|BEHAVIORAL|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
41366727|NCT00874718|BEHAVIORAL|General education|Non-specific educational program for general health.
40845573|NCT00609739|PROCEDURE|umbilical cord blood transplantation|Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
40845574|NCT00609739|DRUG|Cis-Retinoic acid|Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m\^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
40845575|NCT03565614|BEHAVIORAL|Reablement|Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.
40845576|NCT03565614|BEHAVIORAL|Traditional home care|Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
40845577|NCT02331017|BEHAVIORAL|Speech perception tests and self-rating questionnaire|Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
40845578|NCT06094400|OTHER|Meditation|Participants in the intervention group will be furnished with a tablet incorporating a pre-installed Muse Meditation App and a set of headphones. They can choose their preferred immersive soundscape for the meditation session.
40845579|NCT06094400|OTHER|Control|Participants allocated to the control group will similarly wear the portable EEG headband, but they will receive a rest session without any additional intervention
40845580|NCT03703297|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
40845581|NCT03703297|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
41028356|NCT04623294|PROCEDURE|Oxygen supply of low-high-low procedure|"The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
40845582|NCT03703297|OTHER|Placebo|Placebo IV (intravenous infusion)
40845583|NCT02497690|BEHAVIORAL|Telemedicine|Half of subjects will undergo six months of ART administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.
41028357|NCT04982042|OTHER|Pulmonary Rehabilitation|The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
41028358|NCT03113539|OTHER|Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm|"On the same day, the subject will do :~1. Modified low-dose, EKG-gated CT without contrast~2. Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols."
41366728|NCT05763030|BEHAVIORAL|Adapted Sleep Well, Bee Well (SWBW)|The SWBW is a 3-week multilevel behavioral sleep intervention that targets organizational (daycare worker-parent), interpersonal (parent-child, daycare worker-child), and individual (child) levels. It provides parent education supporting parent-child interaction at bedtime, helps to adopt a bedtime routine and early bedtime (Table 4). At the beginning of the 3-week intervention period, the parent and teacher co-develop tailored sleep health goals towards meeting the Bedtime, Environment, and Duration (BED) recommendations139-141 for the child. Parents receive an inexpensive bedtime kit, a storybook, and an informational brochure. The parent and child select four activities from the kit to perform at bedtime every night. The brochure has a section for the parents to write sleep goals. During the intervention, daycare teachers provide daily feedback support to parents at pick-up or drop-off. The program has a manualized structured curriculum suitable for use by paraprofessionals.
41028359|NCT03342534|DEVICE|DC-stimulator (Neuroconn, Germany)|A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.
41028360|NCT01316744|DRUG|ketamine hydrochloride|
41366729|NCT05824559|DRUG|ME-344|ME-344 will be administered intravenously (IV)
41028361|NCT01316744|OTHER|pharmacogenomic studies|
41028362|NCT01316744|OTHER|questionnaire administration|
41028363|NCT01316744|PROCEDURE|assessment of therapy complications|
41028364|NCT01316744|PROCEDURE|quality-of-life assessment|
41028365|NCT04596566|OTHER|Therapeutic diet Intervention|The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1
41028366|NCT00529828|PROCEDURE|Consumption of CLA enriched food|
41028367|NCT03229330|PROCEDURE|Low-level Light Therapy|Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
41028368|NCT03229330|COMBINATION_PRODUCT|Conventional treatment|Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
41028369|NCT04880551|RADIATION|Fluoroscopy|In this study the patient will be exposed to radiation during the fluoroscopy for lungs. There is a small chance of alopecia. There is a rare chance that the patients skin may turn red or be damaged.
41028370|NCT03095417|BEHAVIORAL|Physical Exercise Intervention|In home exercise intervention.
41028371|NCT03095417|BEHAVIORAL|Cognitive Training Intervention|Online cognitive training modules.
41028372|NCT03095417|BEHAVIORAL|Stretching Control|In home stretching.
41028373|NCT03095417|BEHAVIORAL|Cognitive Control|Online control puzzles and games.
41028374|NCT01116817|DRUG|Lumbar puncture (Lopinavir/ritonavir monotherapy)|Lumbar puncture at week 0
41028375|NCT01116817|DRUG|Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)|Lumbar puncture at week 0
40845584|NCT02497690|BEHAVIORAL|In-person ART|Half of subjects will undergo six months of ART administered in person. Therapy will be provided in the usual manner.
41028376|NCT06574100|DRUG|Cannabidiol|Patients in the first arm cross-over will receive either a single bolus dose of 250mg buccally administered or 1000mg CBD powder and cross over to vice-versa after 21 days.
41028377|NCT06574100|DRUG|Cannabidiol|Patients will be randomised to receive 3000mg oral CBD fasting or Fed, they will the cross over to the other group 21 days following the first administration.
41028378|NCT01219738|DRUG|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
41028379|NCT01219738|DRUG|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
41028380|NCT01219738|DRUG|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
41028381|NCT01219738|DRUG|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
41028382|NCT01219738|DRUG|Placebo|A single inhaled dose of placebo from a DPI.
40845585|NCT02481609|DRUG|N-acetyl cysteine (NAC)|
41028383|NCT05364697|DEVICE|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloy-based stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
41028384|NCT04105023|DIETARY_SUPPLEMENT|genistein|Administered orally once every 12 hours
41028385|NCT04105023|DIETARY_SUPPLEMENT|Placebo|Administered orally once every 12 hours
41028386|NCT03950193|OTHER|Questionnaires to evaluate psychic development of the child|Child Behaviour Checklist. This test, completed by parents and with 52 questions, is designed to screen children at high risk for emotional problems, mood disorders, anxiety, pervasive developmental problems, attention deficit and hyperactivity, antonymic reactions (oppostion, provocation) and sleep problems.
41028387|NCT03209908|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
41028388|NCT01850160|DRUG|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
41028389|NCT01850160|DRUG|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
41028390|NCT01850160|DRUG|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
41028391|NCT00881725|DRUG|Metformin|500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
41366730|NCT05824559|DRUG|Bevacizumab|Bevacizumab will be administered intravenously (IV)
41366731|NCT01463059|BIOLOGICAL|Placebo|Placebo solution for injection, administered as subcutaneous injections
40845586|NCT02152774|DRUG|Rho-Kinase Inhibitor|
40845587|NCT01083589|DRUG|Imatinib Mesylate|Oral 400 mg daily
40845588|NCT01083589|DRUG|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
40845589|NCT02540993|DRUG|Finerenone (BAY94-8862)|Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
40845590|NCT02540993|DRUG|Placebo|Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
40845591|NCT02756494|BIOLOGICAL|Ischemic Stroke|Ischemic Stroke in Chinese Young Adults
40845592|NCT01257607|DRUG|MIM-D3 Ophthalmic Solution|28 Days, BID
40845593|NCT01257607|DRUG|Placebo Ophthalmic Solution|28 Days, BID
40845594|NCT05288140|OTHER|use of diary|a diary is made for the experimental group where the events and events during the period of sedation and intubation are explained
40845595|NCT04476199|COMBINATION_PRODUCT|Venetoclax and Decitabine|The prognosis of acute myeloid leukemia (AML) patients aged over 60 years is poor and allogeneic stem cell transplantation (allo-SCT) is the only curative option.The association VEN-DEC is a promising combination therapy for AML elderly patients who are fit and eligible for allo-SCT.
40845596|NCT02237638|BIOLOGICAL|hVEGF26-104/RFASE|Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.
40845597|NCT06453928|DEVICE|Hybrid Closed Loop Insulin Pump System|Patients will be started on an automated insulin delivery system.
40845598|NCT04356352|DRUG|Lidocaine|1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
40845599|NCT04356352|DRUG|Esmolol|0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
41028392|NCT05187377|DRUG|Growth Hormone|Growth hormone will be administered subcutaneously once daily. A starting dose of 0.15 mg/kg/week divided daily for 2 weeks to ensure safety and tolerance. The dose will then be increased to 0.3 mg/kg/week for 10 weeks. Doses will be titrated based on IGF-1 levels and monitored every four weeks up to a maximum dose of 0.45 mg/kg/week based on the package insert.
41028393|NCT05187377|DRUG|Saline|Placebo (saline) will be administered subcutaneously once daily.
41028394|NCT01083030|DEVICE|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
41028395|NCT01083030|COMBINATION_PRODUCT|DCB|Drug Coated Balloon Angioplasty
41028396|NCT05275777|DRUG|ADG106|Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
41161368|NCT00611728|DRUG|SU011248 & Irinotecan|"Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 \& 1/2 hrs on 1st day of each cycle \& then again on days 14 \& 28.~Sutent is approved for adult subjects w some forms of kidney cancer. It is considered investigational for brain tumors. Dosing will begin on day 1 of cycle 1 \& continue daily for 4 wks by mouth.~Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered investigational for brain tumors. Irinotecan dose will depend on your height \& weight. Irinotecan will be given intravenously over 90 min on days 1, 14 \& 28 of 6wk cycle.~You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, \& then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, \& then within 1 week prior to completion of every other cycle."
40845600|NCT04356352|OTHER|Placebo|saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
41366732|NCT01463059|BIOLOGICAL|Olokizumab 60 mg|Olokizumab 60 mg solution for injection, administered as subcutaneous injections
41366733|NCT01463059|BIOLOGICAL|Olokizumab 120 mg|Olokizumab 120 mg solution for injection, administered as subcutaneous injections
40845601|NCT04919837|OTHER|Low vision aids|the assisting devices fitting for low-vision patients
40845602|NCT05885802|OTHER|No specific intervention other than routine anesthesia protocol|No specific intervention other than routine anesthesia protocol
41028397|NCT05275777|DRUG|Doxorubicin|Administered as an intravenous infusion.
41028398|NCT05275777|DRUG|Cyclophosphamide|Administered as an intravenous infusion.
41028399|NCT05275777|DRUG|Paclitaxel|Administered as an intravenous infusion.
41161369|NCT00067119|DRUG|Aggrenox|
41161370|NCT00067119|DRUG|Placebo|
41366734|NCT01463059|BIOLOGICAL|Olokizumab 240 mg|Olokizumab 240 mg solution for injection, administered as subcutaneous injections
41366735|NCT01008059|DRUG|Alfentanil|No drug treatment before alfentanil
41366736|NCT05870865|DRUG|ASN008|ASN008 topical gel applied twice daily.
41028400|NCT02167022|OTHER|Physical and occupational therapy|The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
41028401|NCT01081587|PROCEDURE|Access to a Computerized Clinical Decision Support System (CCDDS)|Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
41028402|NCT01081587|BEHAVIORAL|Education of Healthcare workers|Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.
41028403|NCT01081587|OTHER|Local assistance by a dietician|Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
41028404|NCT05637463|OTHER|No intervention|no intervention was made
41028405|NCT01990443|DRUG|Reslizumab IV|Reslizumab 220-mg intravenous (IV)
41028406|NCT01990443|DRUG|Reslizumab SC|Reslizumab 220 mg administered subcutaneous (SC)
41028407|NCT02842567|DRUG|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
41028408|NCT02842567|DRUG|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
41028409|NCT00672477|DRUG|Methylnaltrexone|
41028410|NCT00672477|DRUG|Placebo|
41028411|NCT01112995|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|1 pill formulation to be given once a day for 4 weeks
41028412|NCT01112995|DIETARY_SUPPLEMENT|Sugar pill (placebo)|placebo identical to the active product will be given
41028413|NCT06110312|BEHAVIORAL|NavCare-EU|NavCare-EU is a person- and family-centered intervention in which navigators collaborate with older persons and their close family caregivers across the continuum of supportive, palliative, and end-of-life care,. NavCare-EU is based on the existing and successfully tested Nav-CARE intervention from Canada. Navigators focus on connecting clients to social supports, both formal and informal, advocating for clients in meeting their quality-of-life goals, resourcing by identifying needs and negotiating access to meeting those needs, and engaging clients in what is most meaningful to them. Navigators are selected, trained, and mentored volunteers or professionals. NavCare-EU is based on the existing and successfully tested Nav-CARE(c) intervention from Canada.
41028414|NCT05857046|DRUG|Melatonin 10 MG|Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
41028415|NCT05857046|OTHER|Placebo|Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days
41366737|NCT05870865|OTHER|ASN008 Matching Vehicle|The ASN008 matching vehicle formulation matches the formulation of each ASN008 topical gel dose, but contains no ASN008.
41366738|NCT00933816|DRUG|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
41366739|NCT04113122|DIAGNOSTIC_TEST|Skin biopsy|A 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
41501446|NCT06602960|BEHAVIORAL|Inflated Sleep Data Feedback|Participants will receive inflated feedback about their sleep data, suggesting better sleep quality than detected by Fitbit (actual sleep hours +10%).
41028416|NCT00811083|DRUG|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
41028417|NCT03015077|DIETARY_SUPPLEMENT|oral glutamine|L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
41028418|NCT03015077|DIETARY_SUPPLEMENT|placebo|in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
41028419|NCT03015077|RADIATION|Radiotherapy|All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
41028420|NCT02773589|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy
41028421|NCT02176889|DIETARY_SUPPLEMENT|Lactospore|Bacillus coagulans MTCC 5856
41161371|NCT03390270|OTHER|Admission with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
41161372|NCT03280108|DEVICE|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision
41161373|NCT03280108|DEVICE|AcrySof Monofocal IOL|AcrySof Monofocal IOL Model SN60AT for single vision
41366740|NCT04113122|DIAGNOSTIC_TEST|Subcutaneous fat biopsy|"An abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration.~In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29."
41366741|NCT03639493|DRUG|Exforge® tab 10/160mg, Crestor® tab 20mg|Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
41366742|NCT03639493|DRUG|CJ-30060 10/160/20mg|Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
41366743|NCT05434741|BEHAVIORAL|Weekly Group Skills|The topics covered in group CBT sessions are: 1.) Domains of Healthy Aging; 2.) Stress and anxiety; 3.) Adherence and Engagement in Primary/Preventative Care; 4.) Depression and Distress; 5.) Physical Activity; 6.) Stigma/Self-Compassion; 7.) Substance Use; 8.) Acceptance of Uncertainty and Uncomfortable Emotions; 9.) Diet; 10.) Behavioral Activation; 11.) Frailty and Memory/Cognition; and 12.) Wrap-Up and Maintaining Gains.
40845603|NCT01242852|PROCEDURE|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS \& hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions \& endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
40845604|NCT04359979|DRUG|Tamsulosin|selective alpha1 receptor antagonist
40845605|NCT01816802|DEVICE|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
40845606|NCT05653817|DRUG|Carrilizumab|Carrilizumab 200mg Q3W d1
41366744|NCT05434741|OTHER|"One-time Trifold Brochure titled HIV: 50 Years or Older"|"Participants in the education only group will receive a one-time trifold brochure titled HIV: 50 Years or Older. This brochure contains information on the prevalence of HIV among people aged 50 and older, defines medication adherence and drug resistance, encourages physical activity and proper nutrition, and addresses the health risk behavior of tobacco-smoking for people living with HIV. Participants receive one brochure in the information-only group."
41366745|NCT05151887|OTHER|Muscle protein synthesis|The meals contain a total of 0.45 g protein/kg body mass (36 g protein for an 80 kg person). To account for differences in body mass, the investigators will scale the meal content to ensure 0.45 g/kg body mass for different body mass ranges (i.e., 65-75 kg, 75-85 kg, etc.). As such, carbohydrate, fat, and total energy content of the meals will also be scaled to body mass. The test meals are composed out of regular whole food items which will be purchased from local shops. The muscle protein synthetic response following meal ingestion will be assessed by the use of stable isotope tracer methodology
40845607|NCT05653817|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel 125 mg/m2 d1,8
40845608|NCT05653817|DRUG|Apatinib|Apatinib mesylate tablets for treatment: 250mg
40845609|NCT06034353|BEHAVIORAL|Pharmacist-led Cognitive Behavioral therapy|Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
40845610|NCT06024018|DEVICE|high intensity electromagnetic technology device, diet restriction, and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months. Also they will undergo high intensity electromagnetic technique (40 minutes for every session) on abdomen of males which will be 3 sessions per week for 3 months
41028422|NCT02176889|OTHER|Placebo|
41028423|NCT03873649|OTHER|Bronchoscopy with lavage|"Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response."
41028424|NCT02298218|DRUG|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
40845611|NCT06024018|BEHAVIORAL|diet restriction and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months.
40845612|NCT01623739|PROCEDURE|Placement of a dental implant|Type 1 implant placement Type 2 implant placement
41028425|NCT03874676|OTHER|PEACE Rounds|PEACE Rounds are a routine process for providing self help to clinicians who care for difficult patients from the perspective of ethics and the need for cross-disciplinary communication. PEACE Rounds participants will be interviewed about how they experience the rounds and for their perspective on the effects on their own wellness and resilience.
41028426|NCT06389240|OTHER|6 weeks post-operatively early weight bearing|Early mobilization 6 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
41028427|NCT06389240|OTHER|10 weeks post-operatively weight bearing (standard of care)|Standard of care mobilization at 10 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
41028428|NCT02628119|PROCEDURE|Intra-procedural access flow|"Intra-procedure access flow technique:~Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min."
41028429|NCT02628119|PROCEDURE|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
41028430|NCT06478927|DRUG|Palbociclib capsules|Palbociclib capsules, oral, 125 mg/dose, qd, take 3 weeks and then stop for 1 week, 28d for one treatment cycle until disease progression or intolerable toxicity.
41028431|NCT06535360|BIOLOGICAL|Platelet transfusion|platelet administration through intravenous access
41028432|NCT06024746|DRUG|Finerenone|Oral finerenone.
41028433|NCT06024746|DRUG|Empagliflozin|Oral empagliflozin.
41028434|NCT01285375|DEVICE|CDC solution|2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
41028435|NCT01285375|DEVICE|UW-solution|500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
41028436|NCT00025350|DRUG|gefitinib|
41028437|NCT00844454|PROCEDURE|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
41028438|NCT00844454|PROCEDURE|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
41028439|NCT06208618|OTHER|Education and Motivational Interviews|"The diabetes education aimed at supporting diabetes self-management in adolescents will include the following topics:~* What is Diabetes?~* Treatment in Diabetes~* Insulin Therapy~* Nutritional Therapy~* Physical Activity/Exercise~* Acute Complications of Diabetes~  * Hypoglycemia~ * Hyperglycemia~ * Diabetic Ketoacidosis~* Diabetes Management in Illness~Motivational interviews will consist of the following stages:~* First Meeting - Pre-awareness (Pre-contemplation)~* Second Meeting - Awareness (Contemplation)~* Third Meeting - Preparation~* Fourth Meeting - Taking Action (Action)~* Fifth Meeting - Maintenance~* Sixth Meeting - Termination or Review"
41366746|NCT03978689|DRUG|CUE-101|CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
41366747|NCT03978689|DRUG|KEYTRUDA®, Pembrolizumab|KEYTRUDA® is first-line therapy in HPV16 and HLA A\*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C\&D according to the schedule described in the protocol.
41366748|NCT00872131|DRUG|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
41366749|NCT01234662|PROCEDURE|SPA|Spinal anesthesia and opioids
41366750|NCT01234662|PROCEDURE|CSE|CSE and epidural opioids
41366751|NCT01234662|PROCEDURE|CSEPCEA|CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
41366752|NCT00368069|DRUG|Keppra® extended release formulation - XR|500mg extended release oral tablet, 2 tablets once daily
41366753|NCT00368069|DRUG|Placebo|oral tablets, 2 tablets once daily
40845613|NCT01549873|DRUG|propofol|Propofol adjusted to maintain the bispectral index at 40-60.
40845614|NCT01549873|DRUG|Desflurane|Desflurane adjusted to maintain the bispectral index at 40-60.
41028440|NCT04656158|OTHER|Physical activity involving exposure to nature: Therapeutic horticulture|2 sessions of 90 minutes of therapeutic horticulture and 2 sessions of 90 minutes of handiwork
41028441|NCT05469568|OTHER|Circuit training followed by telerehabilitation|Patients participate in an ambulatory rehabilitation program (12 weeks) and then gain access to mobile application to record their movement activities. This application will aslo inlude a library with exercise vidoes from the ambulatory program. These videos should inspire patients to do the exercises at home.
41028442|NCT05469568|OTHER|Usual care|Patients have usual information about importance of regular movement activities and recommendation of proper exercises
41028443|NCT00765115|DRUG|LY450139|
41366754|NCT00140816|BEHAVIORAL|Increased intake of dairy products|
41366755|NCT02104726|OTHER|Fluoroscopy guided steroid injection|We want to compare if there is a difference between the two arms, with the assumption that with fluoroscopy will deliver the steroid more accurately and see better outcomes.
41366756|NCT02104726|OTHER|Blind Steroid Injection|Want to compare it to fluoroscopy guided, with assumption that it will be less effective in reducing pain
41501447|NCT06602960|BEHAVIORAL|Deflated Sleep Data Feedback|Participants will receive deflated feedback about their sleep data, suggesting poorer sleep quality than detected by Fitbit (actual sleep hours -10%).
41501448|NCT06602960|BEHAVIORAL|Accurate Sleep Data Feedback + Sleep-related Educational Information|Participants will receive accurate feedback about their sleep data along with sleep-related educational information.
41501449|NCT06581055|DRUG|Luspatercept|As per COMMANDS Trial (NCT03682536) study protocol
41028444|NCT00765115|DRUG|placebo|
41028445|NCT00148057|BEHAVIORAL|Low-fat diet|
41028446|NCT04922593|DRUG|LY03010; paliperidone palmitate|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
41028447|NCT04922593|DRUG|INVEGA SUSTENNA|INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
41028448|NCT04984642|OTHER|diet|have OGTT,normal diet, high fat diet, low calorie diet, and ketogenic diet in turn
41366757|NCT05386368|DRUG|ReCell|"The perioral area of the face will be treated with CO2 laser. Randomization would occur before study initiation with subjects assigned either left perioral or right perioral RECELL treatment based on their subject enrollment number. The study team member who prepares and blinds the RECELL will create the list of subject ID numbers with subject ID number randomly assigned to either left perioral or right perioral treatment group. This will be completed prior to any patient enrollment in the study. Intraoperatively, RECELL and Placebo will be provided to surgeons and assistants in opaque application devices prepared by a trained, designated study team member.~Both the treatment and placebo sides, will be dressed with a standard autologous cell suspension post treatment dressing (Telfa Clear and Xeroform)."
40845615|NCT02641067|DRUG|Doravirine|Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
41366758|NCT02569996|DRUG|Rituximab|Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
41366759|NCT00135694|DRUG|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
41366760|NCT00135694|PROCEDURE|liver transplant|Occurs at study entry
41366761|NCT00135694|DRUG|corticosteroids|3-month course of corticosteroids
40845616|NCT02307162|DRUG|RPL554|Phosphodiesterase 3 and 4 Inhibitor
41366762|NCT00135694|OTHER|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
41366763|NCT03781167|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
41028449|NCT05703282|DRUG|AD-104-A|PO, Single-Dose, AD-104-A
41366764|NCT05600101|BEHAVIORAL|Care.Coach|"Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates."
41366765|NCT03584152|DRUG|Norco 5Mg-325Mg Tablet|Opioid Analgesics
41366766|NCT03584152|DRUG|Tylenol 325Mg Caplet|Non opioid analgesics
41366767|NCT03584152|DRUG|Ibuprofen 200 mg|Non opioid analgesics
41366768|NCT03611907|DEVICE|"Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)"|In this intervention a 17-Gauge needle is used to aspirate the follicles
41366769|NCT03611907|DEVICE|"Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)"|In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
41501450|NCT06581055|DRUG|Epoetin Alfa|As per COMMANDS Trial (NCT03682536) study protocol
41028450|NCT04076228|DRUG|Pembrolizumab|pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.
41028451|NCT01475526|OTHER|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
41028452|NCT00487110|DRUG|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
41028453|NCT00487110|DRUG|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
41028454|NCT00131157|PROCEDURE|expert support for interpretation of spirometry|
41501451|NCT04704661|PROCEDURE|Biopsy|Undergo tissue biopsy
41501452|NCT04704661|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40845617|NCT02307162|DRUG|Placebo|Dummy solution
40845618|NCT02462993|DRUG|Aloe Vera|Local drug delivery of aloe vera gel
40845619|NCT05870683|DRUG|Tegoprazan|Included in dual eradication medication.
41028455|NCT06529497|DRUG|Racecadotril|The intervention group will receive racecadotril+ORS+Zinc
41028456|NCT01490060|DRUG|Fosaprepitant|150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.
41501453|NCT04704661|DRUG|Ceralasertib|Given PO
41501454|NCT04704661|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41501455|NCT04704661|PROCEDURE|Echocardiography|Undergo ECHO
40845620|NCT05870683|DRUG|Amoxicillin|Included in dual eradication medication.
41161374|NCT05611489|PROCEDURE|Open appendectomy|performed With the patient in supine position.incision made lateral to McBurney's point.layers of the abdomen is exposed. If the cecum can be visualized, it can be mobilized and used to identify the appendix. Once the appendix is identified, the mesoappendix should be dissected and the appendiceal vessels divided between clamps. The appendiceal vessels are then ligated with silk sutures. A silk purse-string suture can then be placed around the appendiceal base.A 15-blade knife is then used to excise the appendix proximal to the right angle clamp.The appendiceal stump mucosa can be obliterated using electrocautery. Then good haemostasis and layered closure is done.
41501456|NCT04704661|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41501457|NCT04704661|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40845621|NCT05870683|DRUG|Esomeprazole|Included in dual eradication medication.
40845622|NCT05036291|DRUG|NB004 tablets|"Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA ."
40845623|NCT02626390|OTHER|Frequent instructions/feedback and an Internal Focus of Attention|
40845624|NCT02626390|OTHER|Minimal instructions/feedback and an External Focus of Attention|
41501458|NCT04704661|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
41501459|NCT06256107|DEVICE|Virtual Reality Headset|Virtual Reality Headset
41501460|NCT03845803|OTHER|Reducing sedentary behaviour|Implementing sit/stand workstations at work
41366770|NCT05960006|OTHER|No intervention|There are no risks associated with participation because only waste material (blood and ascites) will be used for analysis and no additional blood collection or paracentesis will be performed in addition to standard-of-care. Moreover, hospital admittance and discharge, indication for interventional procedures, indication/initiation/duration/dosing of ceftriaxone, indication/timing/frequency of blood withdrawal for standard of care biochemical analysis and microbiological culturing as the indication, timing, frequency and duration of paracentesis are all decided by the treating physician independent of participation in the study. There are no extra site visits nor extra days of hospital admission. There is no direct benefit for participants of this explorative study. .
41366771|NCT02264132|DRUG|Pramipexole ER tablet|
41366772|NCT02264132|DRUG|Pramipexole IR tablet|
40845625|NCT03584243|PROCEDURE|A crosslinking with oxygen treatment|"A supplemental oxygen system during the cross linking will be used to apply filtered, humidified oxygen across the surface of the eye through a mask. The oxygen flow will be turned on immediately prior to initiation of irradiation, and will continue through the irradiation period. The supplemental oxygen flow will be shut off following completion of the programmed irradiation time.~All subjects will be evaluated at screening, day 3, and 1, 3, 6, 12 and 24 months after treatment. At the same time all the potential adverse effects will be relieved."
41366773|NCT03242291|OTHER|Conventional resin-based flowable composite|assessment of marginal integrity of Conventional resin-based flowable composite
41366774|NCT03242291|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
41366775|NCT04686773|BIOLOGICAL|AZD1222|"AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box."
41366776|NCT04686773|BIOLOGICAL|rAd26-S|"Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box"
41366777|NCT03374982|DEVICE|DentalVibe|The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.
41501461|NCT04462887|BEHAVIORAL|Nursing intervention program|The intervention consisted of structured information (SI) provided in a booklet, nursing telephone support (NTS) and access to a nurse pager 24h/day. The SI booklet, Sudden Cardiac Arrest: A Survivor's Experience, contains 2 components: a descriptive component including individual verbatim statements about experiences of others during the first year of recovery and a management component outlining successful strategies used by others in dealing with issues in recovery. The NTS telephone calls included: check-in about current concerns, assessment of the topic for the week, review of common recovery experiences, discussion of behavioral strategies for dealing with the topic for the week, provision of positive feedback for strategies already working well, anxiety reduction statements, practice of new behaviors using role-playing and problem solving techniques, summarization, setting specific goals for the upcoming week, and collaborating on a learning assignment for the subsequent week.
41501462|NCT05886387|OTHER|High PEEP + Recruitment maneuvers|The use of a High PEEP (positive end-expiratory pressure) level after recruiting collapsed alveoli can protect from mechanical ventilation associated lung injury
41501463|NCT05886387|OTHER|Standard PEEP. Low positive end-expriatory pressure|Mechanical ventilation is managed with a low standard PEEP without recruitment manneuvers
41501464|NCT03349086|BEHAVIORAL|Voice Exercise|Voice exercise will consist of sustained pitches and pitch glides on a variety of different vocal facilitators.
41501465|NCT06583473|BEHAVIORAL|Interactive digital health application|The study program will provide an integrated interactive digital health application (LINE app on smartphones, incorporating information about biodata recording, health education, questionnaires, and online Q\&A)
41501466|NCT05575076|DRUG|Simufilam|simufilam 100 mg oral tablet, twice daily
40845626|NCT06169488|PROCEDURE|Lumbar Interbody Fusion|Fusion of one or two lumbar levels with either a transforaminal lumbar interbody fusion (TLIF) or an anterior lumbar interbody fusion (ALIF) procedure.
40845627|NCT06169488|BEHAVIORAL|Multidisciplinary rehabilitation|Outpatient multidisciplinary rehabilitation based on the treatment model described by Brox et al and Hellum et al consisting of a cognitive approach and supervised physical and functional training.
40845628|NCT00248456|DRUG|Calcipotriol plus betamethasone dipropionate ointment|
40845629|NCT02629003|DRUG|[11C]Cimbi-36|
40845630|NCT02629003|DRUG|[11C]Cimbi-36-5|
40845631|NCT03040986|OTHER|Laboratory Biomarker Analysis|Correlative studies
41501467|NCT06625632|DRUG|Antiemetic Drug|All participants in the two groups will receive antiemetic drugs (ondansetron 4 mg) every 12 hours, for 5 days.
41501468|NCT06625632|DIETARY_SUPPLEMENT|Vitamin B6|All participants in the two groups will receive vitamin B6 (50 mg), once daily, for 5 days.
40845632|NCT03040986|DRUG|Selumetinib Sulfate|Given by mouth (PO)
40845633|NCT05974319|OTHER|Dry heat application|Dry heat application: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. The researcher will heat the thermoregulated electric pad and set it to 42°C. After making sure that there are no contraindications in the application of the electric pad device, a dry heat of 42°C will be applied to the determined area with the electric pad for 5 minutes.
41028457|NCT01490060|DRUG|Dexamethasone|Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)
41028458|NCT01490060|DRUG|5HT3 receptor antagonist|5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy
41028459|NCT01490060|DRUG|Ifosfamide-based chemotherapy (AI)|Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.
41366778|NCT00479973|DIETARY_SUPPLEMENT|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day"
41028460|NCT01490060|DRUG|Doxorubicin|25 mg/m\^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m\^2) as part of AI Chemotherapy.
41366779|NCT00479973|DIETARY_SUPPLEMENT|Placebo|Placebo. 2 capsules after the two largest meals of the day
41366780|NCT05283161|DRUG|cannabidiol and tetrahydrocannabinol|CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.
41366781|NCT05283161|DRUG|Placebo|The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.
41366782|NCT05487807|DRUG|Nicotine patch|Will be receiving nicotine therapy
40845634|NCT05974319|OTHER|Dry cold application|Dry cold applicaiton: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. After the researcher is sure that there are no contraindications in the application of the gel pad, dry cold will be applied to the determined area with the gel pad for 3 minutes.
41366783|NCT05487807|BEHAVIORAL|text messaging|Will be enrolled in an texting app
41366784|NCT05180071|DEVICE|TEMA elbow system|Total elbow replacement
40845635|NCT05859243|BEHAVIORAL|Traditional concurrent training|The subjects will perform two sessions per week of traditional concurrent training, consisting of strength training followed by aerobic exercise over 12 weeks, with progressive intensities and training volumes. Each traditional concurrent training session will consist of specific warm-up performed on equipment for upper and lower limbs with a load of less than 30% of the training load. Then the bench press, low row, leg press, extension and knee flexion exercises will be performed. Participants will be instructed to perform the concentric phase of the movement in one second and the eccentric phase in two seconds. After strength training, aerobic training (walking outdoors or on a treadmill) will be performed with intensity based on the adapted BORG effort perception scale (ranged to 0 = minimum effort, to 10 = maximal effort).
41161375|NCT05611489|PROCEDURE|Conventional Lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
41366785|NCT02316782|DEVICE|Blinded IVUS assessment|Only the angiogram is used for stent placement
40845636|NCT05859243|BEHAVIORAL|Concurrent training consisting of strength training combined with dance classes|Each concurrent training session associated with dance classes will consist of the same strength training as the traditional concurrent training group, but the traditional aerobic training will be replaced by a dance class. Each dance class will consist of a 5-minute general warm-up with joint mobility exercises and dynamic stretching. Then the main part will be performed with the elaboration of choreography, lasting approximately 20 minutes. Finally, there will be a 5-minute cool-down with stretching exercises. Classes will be held in four different dance modalities, divided into four modules.
40845637|NCT02082730|DEVICE|ASARM|The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
41366786|NCT02316782|DEVICE|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
41366787|NCT05710666|DRUG|trastuzumab deruxtecan (T-DXd) (IV)|Administered as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle for up to six cycles.
41366788|NCT03433443|BEHAVIORAL|Case manager assisted rehabilitation|In addition to receiving usual physical rehabilitation the patients in the intervention group had a case manager assigned. A team of three case managers delivered the intervention: a medical doctor specialized in social medicine, an occupational therapist, and a social worker. The case managers were all experienced case managers for non-surgical low back pain patients. The allocation to the case manager was random, and all patients had a main case manager assigned. The case managers involved the other case managers if their special knowledge were needed. Barriers for the patient's rehabilitation were discussed with the multidisciplinary team also including a surgeon, a physiotherapist, and a nurse.
40845638|NCT04512924|BEHAVIORAL|Enhanced mobile app with standard of care and education|Group 1 will download an enhanced mobile app that will include education and support resources related to food allergy and its management.
40845639|NCT04512924|BEHAVIORAL|Enhanced mobile app with standard of care, education and support resources|Group 2 will download an enhanced mobile app that will include education and support resources related to food allergy and its management, a symptom monitoring and tracking system that allows mobile app users to log symptoms they may experience as caregivers of children newly diagnosed with food allergy, e.g. fatigue and anxiety, and symptom based interventions (recommendations) that may improve a caregiver's ability to self-manage experienced symptoms.
41028461|NCT01490060|DRUG|Mesna|Prior to ifosfamide (Day 1) - 500 mg/m\^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m\^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m\^2. The mesna infusion complete 24 hours after last dose of ifosfamide.
41028462|NCT01490060|DRUG|Ifosfamide|2.5 g/m\^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m\^2).
41028463|NCT01490060|DRUG|Vincristine|2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.
41028464|NCT01163734|DRUG|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
41501469|NCT06625632|OTHER|Home care advice|All participants in both groups will be advised to eat small portions of food, drink plenty of liquids, and avoid fatty and fried foods. Additionally, they should steer clear of highly spiced foods, foods and beverages with strong odors, caffeine, and consume neither very hot nor very cold foods and liquids.
41366789|NCT03433443|BEHAVIORAL|Usual physical rehabilitation|The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.
41366790|NCT00006382|PROCEDURE|bronchoscopic and lung imaging studies|
41366791|NCT00006382|PROCEDURE|comparison of screening methods|
41366792|NCT00006382|PROCEDURE|computed tomography|
41366793|NCT00006382|PROCEDURE|radiography|
41501470|NCT06625632|OTHER|Kinesiotaping|It will be applied for all participants in the experimental group only for 5 days. The participant will be asked to stand in erect position, her hands beside her body then applying the kinesiotape from origin (from top to bottom where the stomach is placed on the abdominal region) to insertion (alongside the gastric curvature) with tension 25% for 5 days.
41366794|NCT00006382|PROCEDURE|study of high risk factors|
41366795|NCT04738799|BEHAVIORAL|Carbohydrate-Last Meal Sequence|Carbohydrates consumed last during mealtimes for 6 days
41366796|NCT04738799|BEHAVIORAL|Carbohydrate-First Meal Sequence|Carbohydrates consumed first during mealtimes for 6 days
41501471|NCT01650584|DRUG|ISTA Tears|sterile ophthalmic solution
41501472|NCT01650584|DRUG|Systane|Sterile ophthalmic solution
41501473|NCT04507841|DRUG|Niraparib|Niraparib was used as 100mg capsules once a day since cycle 1 / day 1. The daily dose (e.g. 200 mg is 2 capsules of 100 mg) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors (the best in the morning). The patient must swallow all the capsules completely and do not chew the capsules. You may drink water or eat when taking medicine.
41501474|NCT02422134|OTHER|Cytokine group|Testing the efficacy of adding Cytokine to embryo transfer medium
41501475|NCT04429347|DRUG|Gabapentin|Friday night: 1 capsule of 300 mg, Saturday night: 2 capsule of 300 mg (total 600 mg), Sunday night: choice of 1 or 2 capsule of 300 mg (total of 300 or 600 mg)
41501476|NCT04429347|DRUG|Placebo|Friday night: 1 capsule, Saturday night: 2 capsule, Sunday night: choice of 1 or 2 capsules
41501477|NCT04429347|DRUG|Tizanidine|Friday night: 1 capsule of 2 mg, Saturday night: 2 capsule of 2 mg (total 4 mg), Sunday night: choice of 1 or 2 capsules of 2 mg (total of 2 or 4 mg)
41501478|NCT03819894|DIAGNOSTIC_TEST|Introduction of a lower female hs-cTn threshold|The new female hs-cTn threshold will be baed on current recommendations for each of the assays used (hs-cTn T and I). The hospitals are the unit of randomization. At 5-month intervals, randomly selected hospitals will be advised that they are to transition to the intervention phase. For all men, the standard of care, overall population threshold will be used throughout the entire study.
41366797|NCT03378921|BIOLOGICAL|Fecal microbiota transplantation|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
41366798|NCT03378921|BIOLOGICAL|Placebo|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
41501479|NCT02759692|DEVICE|TEST Contact Lens|
41501480|NCT02759692|DEVICE|CONTROL Contact Lens|
41501481|NCT00833001|DEVICE|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
41501482|NCT05014841|BEHAVIORAL|Speech Tasks|Listen to 20-minutes of speech sounds in English, Spanish, and/or Mandarin.
41501483|NCT01410500|DRUG|Carfilzomib|Carfilzomib was administered as an intravenous (IV) infusion over approximately 10 minutes on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles at a dose of 20 mg/m² on Days 1 and 2 of Cycle 1 and 27 mg/m² for all infusions thereafter until Cycle 12. For Cycle 13 and higher for those still receiving carfilzomib, the carfilzomib infusion schedule was abridged to Days 1, 2, 15, and 16 of each subsequent 28-day cycle. Carfilzomib treatment was continued until disease progression, diagnosis of a new malignancy, unacceptable toxicity, withdrawal of consent, or the study was terminated
41501484|NCT03212248|DIAGNOSTIC_TEST|Thoracic Ultrasound (TUS)|
41501485|NCT06174597|PROCEDURE|UCA-PSCs/bFGF or bFGF Intramuscular injection|After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.
41501486|NCT04540679|OTHER|VIP4SCI|Technology-enabled self-management \& rehabilitation solution
41501487|NCT06079346|DRUG|OT-101|OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene
41501488|NCT06079346|DRUG|mFOLFIRINOX|Folinic acid, 5-FU, Irinotecan, Oxaliplatin
41501489|NCT04345913|PROCEDURE|Biopsy|Undergo biopsy
41501490|NCT04345913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41501491|NCT04345913|PROCEDURE|Computed Tomography|Undergo CT scan
41028465|NCT01163734|OTHER|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
41028466|NCT06268912|PROCEDURE|Cold Mepivacaine|change the temperature, 3% at 5ºC
41028467|NCT06268912|PROCEDURE|Mepivacaine at room temperature|no change the temperature of anesthesia
41028468|NCT06175728|DEVICE|S-Press|Leg Strengthening Device that can be used in supine and seated positions
41028469|NCT05778214|DEVICE|Interventional Robotic System|Cerebral angiography was performed by using the interventional robotic system
41028470|NCT01205685|DRUG|OSI-906|"In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~* Dose level 2 = 150 mg twice a day~* Dose level 1 = 100 mg twice a day~* Dose level -1 = 100 mg twice a day~* Dose level -2 = 100 mg twice a day"
41028471|NCT01205685|DRUG|Erlotinib|"During the safety run phase of the study:~* Dose Level 2 = 100 mg/d~* Dose Level 1 = 100 mg/d~* Dose Level -1= 75 mg/d~* Dose Level -2 = 50 mg/d"
41028472|NCT01205685|DRUG|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
41501492|NCT04345913|DRUG|Copanlisib Hydrochloride|Given IV
41161376|NCT05171361|PROCEDURE|Pancreaticogastrostomy versus Pancreaticojejunostomy with Dunking Technique|To compare between the outcomes of pancreaticogastrostomy and pancreaticojejunostomy with dunking technique after Pancreaticodudenectomy
41366799|NCT01323829|OTHER|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
41366800|NCT03660657|DRUG|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.
41366801|NCT03660657|DRUG|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
41366802|NCT03831581|PROCEDURE|Erector Spinae Plane Block|In patients with chest pain, ultrasound-guided Erector Spinae Plane Block block was performed at T5 transverse process in the cephalo-caudal direction with Tuohy 18 gauge needle in plane until the needle tip was located in the interfascial plane between the transverse process and the erector spinae muscles, 20 ml of bupivacaine 0.5% was administered and a catheter was inserted if indicated.
41366803|NCT03061162|RADIATION|pulsed low dose rate radiation therapy|Pulsed low dose rate 3-dimensional conformal radiation therapy
41366804|NCT04835142|DRUG|Double blind control period A140|experiment arm： Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv) Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
41366805|NCT04835142|DRUG|Open single period A140|Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
41366806|NCT02282839|DIETARY_SUPPLEMENT|Glutamine|Powder that soluble in water for drinking, 10g TID (total 30 g per day)
41366807|NCT02282839|DIETARY_SUPPLEMENT|Placebo|Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
41366808|NCT03054272|BEHAVIORAL|Video|A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.
41366809|NCT00591305|DIETARY_SUPPLEMENT|diindolylmethane (DIM)|3-month DIM
41366810|NCT00591305|DEVICE|585 nm pulsed dye laser|once-time PDL
41366811|NCT02616120|DRUG|SQJZ herbal mixtures|The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
41366812|NCT02616120|DRUG|Placebo|placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
41366813|NCT05367895|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|"Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use."
41366814|NCT00975793|OTHER|Early Goal Directed Therapy (EGDT)|Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
41366815|NCT05324800|DIETARY_SUPPLEMENT|Curcuma Longa Extract Mixture|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
41366816|NCT05324800|DIETARY_SUPPLEMENT|placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
41366817|NCT02786368|BEHAVIORAL|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
41366818|NCT02786368|BEHAVIORAL|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
41366819|NCT04146259|DRUG|calcium carbonate and alphacalcidol|treatment for hypocalcemia
41366820|NCT03329053|BEHAVIORAL|The EAPC Exercise Prescription (EXPERT) Tool|"During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.~The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication."
41366821|NCT03329053|BEHAVIORAL|Standard Cardio-Care Lifestyle Counselling|During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
41366822|NCT02311660|DEVICE|Vagus Nerve Stimulation Device|Cyberonics VNS System
41366823|NCT05001672|DRUG|Tenofovir alafenamide|Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B virus infection. It is a prodrug of tenofovir. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016 and the TAIWAN Food and Drug Administration (TFDA) in April 2017.
41366824|NCT03927209|DRUG|BI 1467335|tablet
41501493|NCT04345913|DRUG|Eribulin Mesylate|Given IV
41501494|NCT04345913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41501495|NCT05762692|DEVICE|High-flow nasal oxygenation device|The patients included will be oxygenated by HFNO device during the operation
41161377|NCT00002432|DRUG|Foscarnet sodium|
41501496|NCT01729403|DRUG|aleglitazar|150 mcg orally daily, 16 weeks
41501497|NCT01729403|DRUG|metformin|patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
41028473|NCT01205685|DRUG|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
41028474|NCT05680168|DEVICE|Extracorporeal electromagnetic stimulation|Electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia).
41028475|NCT05680168|BEHAVIORAL|Pelvic floor exercises|Pelvic floor muscle training in serial training sessions with our therapist
41028476|NCT03452917|DRUG|Placebo|500 patients will 2 ml of normal saline
40845640|NCT05551611|OTHER|Playgroup|The mobile game will be sent to the students via a link and the students are allowed to install it on their mobile phones with android and ios operating systems. The internet required for the download was provided by the researcher. For the students who did not have a smart phone in the playgroup, the game would be started from the researcher's phone and the game was played sequentially. All students were allowed to use headphones while playing the game. In order to log in to the game, an account was created on behalf of each student, and the game user name and password were sent to the students by e-mail. It was ensured that they did not communicate with anyone and did not receive help during the game with the supervision of the researcher. Waited until each participant completed the game. Then, the mobile game was deleted from the smartphones of all participants, and the download link was inactive until the research process was completed.
40845641|NCT05551611|OTHER|Control group|The researcher gave a theoretical lesson through the presentation prepared in the powerpoint program about the birth management of a breech-presented fetus in the classroom as in the traditional education method.
41028477|NCT03452917|DRUG|sodium nitrite 45 mg|500 patients will receive 45 mg IV sodium nitrite
41028478|NCT03452917|DRUG|sodium nitrite 60 mg|500 patients will receive a dose of 60 mg IV sodium nitrite
41028479|NCT05531396|OTHER|Agility Training|Participants will receive 60 minutes of exercise, twice a week, for a total of 8 weeks, and training will be conducted by a well-trained physical therapist. The intervention will comprise a 5-minute warm-up, 45 minutes of main exercise, and a 10-minute cool-down period, for a total of 60 minutes each session. During the warm-up and cool-down, participants will do static and dynamic whole-body stretching exercises.
41028480|NCT05531396|OTHER|Health Education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education. The home-based exercise program will emphasize how to safely and properly perform stretching and whole-body exercises.
41028481|NCT00822029|DRUG|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
41028482|NCT00822029|OTHER|PLACEBO|patient receiving one tablet (oral use) placebo by week
41028483|NCT06141135|OTHER|Preimplantation genetic testing for aneuploidy (PGTA)|24 chromosome screening for aneuploidy in the preimplantation embryo(blastocyst stage)
41028484|NCT00210834|DRUG|epoetin alfa|
40845642|NCT04794023|DEVICE|Corneal Ablation|Corneal ablation for the treatment of myopia with/without astigmatism following flap creation using femtosecond laser.
41028485|NCT00373789|DRUG|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
41028486|NCT00373789|DRUG|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
41028487|NCT04668157|DRUG|TAK-536|TAK-536 granule formulation
41366825|NCT05341011|BEHAVIORAL|PEERS® Social Skills Training|"The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session."
41501498|NCT01729403|DRUG|placebo|orally daily, 16 weeks
41028488|NCT04944342|OTHER|No intervention.|No intervention.
41028489|NCT02952079|DEVICE|Blephex|Lid margin exfoliation
41028490|NCT02952079|DEVICE|MiboFlo|Lid warming treatment
41161378|NCT04958941|BEHAVIORAL|Experimental: Intervention group|During 2 months participants will be able to asses their mood and practice in real time their emotional regulation skills with an ecological momentary interventions APP.
41161379|NCT03857737|PROCEDURE|endoscopic submucosal dissection|Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.
40845643|NCT05688488|DRUG|Curcumin|Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
40845644|NCT05688488|DRUG|Mitomycin-C|Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
40845645|NCT02392936|PROCEDURE|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
41161380|NCT03857737|PROCEDURE|Surgery|Surgery for EGC include Distal, proximal, or total gastrectomy, which will be performed according to the location and macroscopic tumor type by experienced surgeons.
41161381|NCT02248753|DRUG|Pharmacological cardioversion - Flecainide|
41161382|NCT02248753|PROCEDURE|Electrical cardioversion|
40845646|NCT04059432|DIAGNOSTIC_TEST|Tooth Wear and Musculoskeletal Disorders evaluation|"Evaluation of dental wear by BEWE (Basic Erosive Wear Examination: score 0-3) examination and Musculoskeletal disorders are listed by the NORDIC questionnaire developed by Kuorinka et al. (2001)"
41366826|NCT04730791|DIAGNOSTIC_TEST|Algo(s)rithm/ IASP clinical criteria|IASP clinical criteria for identifying nociplastic pain. The criteria is completed by the healthcare professional and includes questions about the patient's clinical picture.
41366827|NCT04730791|DIAGNOSTIC_TEST|Pressure Pain Threshold|The pain pressure threshold (PPT) is used to measure pain sensitivity in body areas. The test quantifies the minimum amount of pressure in a given area, during an increasing skin pressure stimulus, which is capable of altering the feeling of pressure in pain.
41366828|NCT00081276|DRUG|triapine|Given IV
41366829|NCT00081276|DRUG|cisplatin|Given IV
40845647|NCT05758428|DRUG|Ensifentrine|14 Subjects enrolled will use one 3 mg/2.5 mL ampule for the 3 mg dose, subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID). On the dosing day (Day 1), subjects will receive a single dose of 3 mg ensifentrine. On Day 4, subjects will receive multiple doses of 3 mg ensifentrine BID for 3 days (Day 4 to Day 6), and a morning dose will be administered on Day 7.
40845648|NCT05758428|DRUG|Ensifentrine|14 subjects will be enrolled in this cohort, then randomly assigned to one of 2 treatment sequences (6mg and 1.5mg single dose). Subjects will 2 different dose levels of study drug. Two 3 mg/2.5 mL ampules will be needed for the 6 mg dose (5 mL total volume) and the 1.5 mg dose will be achieved using an appropriate dilution protocol described in the pharmacy manual.
41366830|NCT00081276|OTHER|laboratory biomarker analysis|Correlative studies
40845649|NCT01844778|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
40845650|NCT01844778|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution was administered via nebuliser
40845651|NCT01844778|DRUG|Colistimethate|Colistimethate was administered via nebuliser.
41028491|NCT03845257|DIAGNOSTIC_TEST|Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling|Blood sampling (eosinophil count; eosinophilia is defined as \>300/µl (or \>150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
40845652|NCT00381030|DRUG|carvedilol plus nurse management|
41161383|NCT02248753|DRUG|Metoprolol|
40845653|NCT05930236|DIAGNOSTIC_TEST|Lumbar medial branch block|The lumbar medial branch block on three lumbar levels (L3-L4, L4-L5 and L5-S1) will be performed by ultrasound-guidance in a longitudinal plane and the correct placement of the needle will be verified by radiography to show if the two modalities are equivalent.
40845654|NCT05930236|DRUG|Lidocain|Linisol infiltration with depomedrol and omnipaque
40845655|NCT05930236|DRUG|Methylprednisolone|infiltration with linisol and omnipaque
40845656|NCT05930236|DRUG|Omnipaque|infiltration with linisol and methylprednisolone
40845657|NCT04857411|BEHAVIORAL|Peers LEAD plus HLWD|Combined Peers LEAD and Healthy Living with Diabetes is a culturally-appropriate program to increase medication adherence
40845658|NCT04720300|OTHER|MaaS app|The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app.
40845659|NCT04720300|OTHER|No app|students receive no app or housing information
40845660|NCT03739515|OTHER|HSCP intervention|A team of HSCPs (physiotherapist, occupational therapist, medical social worker) will provide comprehensive functional assessment to older patients
40845661|NCT03739515|OTHER|ED routine care|ED staff including consultants and nurses will provide patients with routine ED medical care.
40845662|NCT05900492|PROCEDURE|cesarean section|caesarean delivery, is the surgical procedure by which one or more babies are delivered through an incision in the mother's abdomen
40845663|NCT00518297|DRUG|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
40845664|NCT00518297|DRUG|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
41028492|NCT00435370|DRUG|Tropisetron|10 mg/day
41028493|NCT00435370|DRUG|Placebo|placebo
41028494|NCT00435370|DRUG|Risperidone|6mg/day
40845665|NCT00518297|DRUG|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
40845666|NCT01087216|DEVICE|Group Laser = Arm A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
40845667|NCT01087216|DRUG|Bras B : The group control|patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
41028495|NCT02838602|RADIATION|Carbon ions therapy|External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
41161384|NCT02248753|DRUG|Verapamil|
41161385|NCT02248753|DRUG|Digoxin|
41161386|NCT02248753|DRUG|Pharmacological cardioversion - Amiodarone|
41161387|NCT01107106|DRUG|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
41366831|NCT02895074|PROCEDURE|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
41366832|NCT02895074|PROCEDURE|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
40845668|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
40845669|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
40845670|NCT00440830|DRUG|placebo|placebo patch applied to smokers
40845671|NCT00440830|DRUG|placebo|placebo patch applied to nonsmokers
40845672|NCT04619277|DEVICE|drug-coated balloon|drug-coated balloon
40845673|NCT02114255|OTHER|Placebo|Administration of 0.9% NaCl.
40845674|NCT02114255|BIOLOGICAL|BCG|Vaccination with the live attenuated BCG vaccine.
40845675|NCT02597140|DRUG|lidocaine|Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.
40845676|NCT02597140|DRUG|normal saline|Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
40845677|NCT02597140|DRUG|propofol|Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
40845678|NCT05697068|BEHAVIORAL|COVID Prevention Program (CPP)|This project is a promotor/a-led COVID-19 Prevention Program (CPP) for Latino patients of a Federally Qualified Health Center (FQHC) who are recently diagnosed with SARS-CoV-2. The program will implement immediate risk reduction strategies to prevent household spread of COVID-19, followed by risk reduction strategies to prevent community spread. Patients and household members who agree to participate will be patients of the FQHC (the covered entity) and will have completed a broad consent that authorizes program activities (e.g., COVID-19 testing, individualized counseling). Patients are free to refuse to participate in the CPP without impact on other services they may receive at the clinic. Research activities will be managed by study's measurement team, which involves surveys conducted on index patients at baseline, 1-, 6-, 12-, and 24-months. Written informed consent will be obtained for all research activities occurring outside of clinical care.
40845679|NCT04832763|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
41028496|NCT02838602|RADIATION|Advanced external radiotherapy by Xrays or protons|Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
41028497|NCT00229008|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
41028498|NCT00229008|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
41028499|NCT05996354|DEVICE|Concave Supra-arch Branched stent-graft system|To evaluate the efficacy and safety of the Concave Supra-arch Branched stent-graft system for endovascular treatment of aortic arch diseases.
41028500|NCT01387568|DRUG|Lidocaine Infusion|children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg-1.h-1. and were continued up to 6 hours postoperatively
41028501|NCT01387568|DRUG|saline Infusion|children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
41028502|NCT05685108|DEVICE|Ultrasound stimulation intensity|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve.
41028503|NCT05685108|DEVICE|Ultrasound stimulation site|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve and the cervical vagus nerve.
41028504|NCT03445468|BIOLOGICAL|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
41028505|NCT03445468|BIOLOGICAL|IL-YANG Flu Vaccine Pre-filled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
41028506|NCT01024387|DRUG|AMG 479|
41028507|NCT04268017|DEVICE|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
41028508|NCT00113438|DRUG|Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin|Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
41028509|NCT01952340|DIETARY_SUPPLEMENT|Flaxseed|Milled flaxseed
41028510|NCT01952340|DIETARY_SUPPLEMENT|Placebo|Wheat germ/wheat bran and mixed dietary oils
41028511|NCT03119103|DEVICE|Functional Bed Sheet|All participants sleep on the functional bed sheet that is placed under a normal bed sheet. The device collects pressure sensor information and informs on body position, respiration rate, and respiration patterns.
41028512|NCT02313012|DRUG|CC-90003|CC-90003 PO once daily
41366833|NCT02895074|DRUG|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
41028513|NCT03219944|PROCEDURE|Platelet Rich Fibrin|: Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone
41366834|NCT02895074|DRUG|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
41501499|NCT05129020|DEVICE|Sparrow Fledging Therapy System|tAN sessions will be administered up to four times per day for up to 20 days total. Active tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
41028514|NCT03219944|PROCEDURE|sub epithelial connective tissue graft|sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone
41028515|NCT02182193|DRUG|BIBF 1120 capsules charge 1|
41028516|NCT02182193|DRUG|BIBF 1120 capsules charge 2|
41028517|NCT02182193|DRUG|BIBF 1120 drinking solution|
41028518|NCT04936022|OTHER|Isometric Exercise|Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).
41028519|NCT04936022|BEHAVIORAL|Standard care lifestyle advice|Healthy lifestyle advice for hypertension, given by a healthcare professional.
40845680|NCT04832763|OTHER|Medical Chart Review|Review of medical charts
40845681|NCT04832763|OTHER|Physical Performance Testing|Undergo physical function testing
40845682|NCT04832763|OTHER|Quality-of-Life Assessment|Ancillary studies
40845683|NCT04832763|OTHER|Questionnaire Administration|Complete questionnaire
40845684|NCT02547051|OTHER|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
41028520|NCT02395354|DEVICE|Placing a self-expanding metallic stent|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center~* Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~* Clips can be placed at the distal end of the prosthesis according to the endoscopist.~* Prosthesis removal time in 4 weeks."
41028521|NCT02395354|DEVICE|A balloon dilatation|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center.~* Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~* Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~* It shall be deemed failure to expansion if required\> 2 expansions."
41161388|NCT01107106|DRUG|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
41501500|NCT05129020|DEVICE|Sham Sparrow Fledging Therapy System|Participants randomized to the sham group will have the device earpiece applied at the same timepoints and for the same duration as the active group, but stimulation will not be turned on. tAN sessions will be administered up to four times per day for up to 20 days total. Sham tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
41501501|NCT01165528|PROCEDURE|type of mechanical ventilation|patients are randomized to receive one of the two types of mechanical ventilation for ARDS
41501502|NCT03927014|OTHER|thiol/disulfide levels|Venous blood will sample from the antecubital veins for measuring the serum concentration of thiol/disulfide levels. The serum thiol/disulfide levels will measure using commercially available reagent kits, which is produced to detect human thiol/disulfide levels (Rel Assay Diagnostics Gaziantep, Turkey). The thiol/disulfide levels measurements were performed in accordance with the company's protocol.
41501503|NCT05926583|GENETIC|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
41501504|NCT05926583|GENETIC|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
41501505|NCT00625053|PROCEDURE|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
41501506|NCT00625053|PROCEDURE|Open midline incisional hernia repair|"* Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~* Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need."
41161389|NCT06047613|BIOLOGICAL|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
41501507|NCT04823975|BEHAVIORAL|Health Insurance Education Program (HIEP)|\[See arm/group description\]
41501508|NCT03133338|DEVICE|pelvic binder|The requirement of angioembolization can be predicted by the presence of intravenous contrast extravasation (ICE) on computed tomography (CT)
41501509|NCT05022589|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, \~30 minutes per session.
40845685|NCT05492357|OTHER|Liquid platelet-rich fibrin|Liquid platelet-rich fibrin is prepared from the patient's blood and injected into the extraction socket every two weeks (up to 3 months = Just 4 times of application)
41501510|NCT06634147|BEHAVIORAL|Exercise|"Multicomponent individualized exercise intervention As mentioned earlier, patients in the control group (G0) will receive the usual care currently provided to other patients, which includes a referral to physical therapy if needed.~The intervention for the multicomponent physical exercise intervention group (G1) will consist of a multicomponent physical training program that includes progressive and supervised aerobic endurance, strength, and balance training lasting 4-7 days during their hospitalization. This will be supervised by the research team from the Geriatrics Unit. Additionally, after hospital discharge, they will receive individualized guidelines to engage in multicomponent physical exercise for 3 months, along with individualized recommendations from the Nutrition and Dietetics Service of HUN.~The multicomponent physical training program will consist of chair squat exercises. The main part of the training will utilize machines for strength training for the lower extremit"
41366835|NCT05936801|OTHER|Anterior Chest Compression technique|"Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs."
41366836|NCT05936801|OTHER|Abdominal Thrust Technique|Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
41366837|NCT04325126|OTHER|Exposure factors|Exposure factors，such as diet，exercise，environment
41366838|NCT05628012|BEHAVIORAL|Circadian Based Time Restricted Eating|Personalized schedule to restrict eating based on DLMO, approximately \~4h prior to DLMO or sleep onset.
41501511|NCT06037005|OTHER|Cognitive Behavioral Therapy Group|Group intervention program based on cognitive behavioral approach of ten sessions; It was completed in approximately one and a half months (May-June 2022) in the Faculty of Nursing, by dividing the experimental group into two separate groups, two days a week for each group. Each session was held for approximately one hour. The last measurement was made three months after the last therapy session (September 2022).
41501512|NCT02216097|DRUG|PF-04457845|4mg PF-04457845 tablet taken once daily for 7 days.
41501513|NCT02216097|DRUG|Placebo|Matching placebo tablet taken once daily for 7 days.
41366839|NCT04117282|OTHER|gait training|training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
41366840|NCT05299060|PROCEDURE|cyanoacrylate adhesive (SecurePortIV®)|Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
41366841|NCT05299060|PROCEDURE|standard cure|"The standard cure consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus)."
41366842|NCT04518826|DEVICE|fractional flow reserve|FFR is a physiological functional parameter indicating the severity of ischemic myocardium perfused by a diseased coronary artery. It is measured by a pressure wire placed in the coronary artery and calculated by the ratio of pressures distal and proximal to the stenosis.
41366843|NCT05604482|DIAGNOSTIC_TEST|CXCR4-PET|New imaging modality using CXCR4 for imaging in GCA
41366844|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
41501514|NCT04707781|DIAGNOSTIC_TEST|chest CT|assessment of interstitial lung disease using chest CT
41501515|NCT06632119|DEVICE|high-intensity laser therapy|high-intensity laser therapy (HILT) machine, ASA laser
41501516|NCT06632119|DEVICE|Sham-HILT|Sham-HILT, HILT machine without laser release
41501517|NCT04862910|OTHER|Kinect Based Virtual Reality Training|The participant will receive the game instructions from the examiner.Protocol will be implemented 3 steps Warm Up phase Activity phase and cool down phase. The games will be played under the supervision and guidance of the therapist.Games are selected from Kinect games Kinect Sports Kinect Adventures and Your Shape Fitness Evolved. Three treatment sessions per week will be given to each participant. Total duration of each treatment session will be 45 Minutes.Participants will be instructed to walk outdoors for 30 Minutes daily. Routine Medication and routine diet will be continued.
41501518|NCT04862910|OTHER|Control Group|"* They will be instructed to walk outdoors daily for 30 Minutes.~* They will continue their daily activities with a routine diet and routine Medication"
41501519|NCT00270907|DRUG|CT-2103|135 mg/m\^2 IV on Day 1.
41501520|NCT00270907|DRUG|Gemcitabine|1000 mg/m\^2 IV on Day 1 and 8.
41501521|NCT03694483|DIAGNOSTIC_TEST|Genetic analysis for the detection of prostasomes|"Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged.~The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing."
41501522|NCT06413043|DRUG|Selenium|Add on Selenium (100mcg once daily) with Vitamin B Complex and Standard Treatment for Grave's Disease
41501523|NCT06323356|DRUG|TAK-279|Specified drug on specified days.
41501524|NCT05427201|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique designed to alter network function
41161390|NCT06047613|OTHER|Hetero-questionnaires and auto-questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself."
41366845|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
41366846|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
41366847|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
41366848|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
41366849|NCT03584412|BEHAVIORAL|ACT OPEN|Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
41366850|NCT03584412|OTHER|Waiting list control|Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
41501525|NCT05427201|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
41161391|NCT06047613|OTHER|Magnetic Resonance Imaging (MRI)|MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
41366851|NCT00001568|DRUG|2-Fluoro-2-deoxyglucose|
41366852|NCT02534324|DRUG|Antihypertensive meds|Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
41366853|NCT02545504|DRUG|Andecaliximab|800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
41501526|NCT01567475|DRUG|Everolimus and rituximab|One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
41501527|NCT02125877|DRUG|Deferasirox dispersible tablet|Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
41501528|NCT02125877|DRUG|Defearisox film-coated tablet|Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
41366854|NCT02545504|DRUG|Placebo|Administered intravenously on Days 1 and 15 of each treatment cycle
41366855|NCT02545504|DRUG|Leucovorin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
41366856|NCT02545504|DRUG|5-fluorouracil|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
41366857|NCT02545504|DRUG|Oxaliplatin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
41366858|NCT04582331|OTHER|Smartphone-based voice and self-reported symptom collection|Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
41161392|NCT03965221|BEHAVIORAL|LYNX|Access to the LYNX mobile app which includes the Sex Pro score tool, sex diary, badges, PrEP information and video testimonials, HIV/STI testing reminders and geo-location features, and asynchronous chat feature.
41161393|NCT03965221|BEHAVIORAL|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
41501529|NCT03837002|OTHER|foot care protocol|foot assesment, foot care, foot care education
41501530|NCT04031755|DRUG|Minocycline|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
41366859|NCT00988910|DRUG|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
41501531|NCT04031755|DRUG|Placebos|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
41161394|NCT05633849|DIETARY_SUPPLEMENT|SMP group|Participants were instructed to take two 500 mg softgels of LIPINOVA(SPM group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
41366860|NCT00988910|DRUG|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
41366861|NCT02596074|DRUG|Omiganan (CLS001) topical gel|
41366862|NCT02596074|DRUG|Vehicle topical gel|
41366863|NCT03243318|DIAGNOSTIC_TEST|MEPs induced by TMS|Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials
41366864|NCT00505765|DRUG|AL-108|AL-108, 5 mg/day- one spray in each nostril once per day
41366865|NCT00505765|DRUG|AL-108|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
41366866|NCT00505765|DRUG|Placebo|Placebo- 3 sprays in each nostril, twice per day
41366867|NCT00505765|DRUG|Placebo|Placebo- one spray in each nostril, once per day
41366868|NCT04772118|OTHER|Carevive PROmpt™|Patient Reported Outcomes Mobile Patient (Carevive PROmpt™), a digital cancer symptom monitoring platform.
41366869|NCT02528149|PROCEDURE|tissue of adjacent part and aneurysm of renal aneurysm|the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
41366870|NCT02528149|OTHER|blood sample|
41366871|NCT03354065|DIETARY_SUPPLEMENT|TIME OF FEEDING|Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
41366872|NCT05829018|DIAGNOSTIC_TEST|Mixed meal test|Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals
41366873|NCT01233076|DEVICE|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
41366874|NCT01233076|DEVICE|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
41366875|NCT02101957|DRUG|RP103|
41366876|NCT02101957|DRUG|Placebo|
41366877|NCT04106674|PROCEDURE|Open reduction internal stabilisation (ORIF)|Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
41366878|NCT05637827|OTHER|No intervention|There was no intervention in each group, and only the natural development was observed
41501532|NCT06551571|OTHER|Intrapartum Care Model|- The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations
41501533|NCT03357718|DRUG|Precedex|2 µg/kg oral
41501534|NCT03357718|DRUG|Midazolam|0.5 mg/kg
41501535|NCT00038532|DRUG|Amprenavir/ritonavir|
41161395|NCT05633849|DIETARY_SUPPLEMENT|Placebo group|Participants were instructed to take two 500 mg softgels of olive oil placebo after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
41161396|NCT00695370|DRUG|Pegfilgrastim (drug)|
41366879|NCT05986708|OTHER|interview|In addition to routine treatment and care, the patients in the application group were interviewed by the researcher once a week for 6 weeks, within the first hour of HD treatment, for a total of 6 sessions, each session being approximately 30 minutes-1 hour, within the scope of the guided self-determination method.
41366880|NCT04606225|DRUG|Losartan|administration of losartan (50 mg) (oral) Cozaar Oral Tablet
41366881|NCT04606225|DRUG|Placebo Oral Tablet|administration of placebo (oral)
41366882|NCT01491152|DEVICE|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
41366883|NCT04302311|DIAGNOSTIC_TEST|Holter monitoring|Use of smart device application and technologies to assess for arrhythmias
41366884|NCT04302311|DIAGNOSTIC_TEST|Kardia/AliveCor monitoring|Kardia/AliveCor monitoring
41501536|NCT00038532|DRUG|Saquinavir/ritonavir|
41501537|NCT00038532|DRUG|Efavirenz|
41501538|NCT01959854|DEVICE|carboxymethylcellulose|0.25% carboxymethylcellulose preservative free
41501539|NCT01959854|DEVICE|xanthan gum|0.2% xanthan gum preservative free
41501540|NCT05740618|DRUG|Mannitol Inhalant Product|A sugar alcohol indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.
41366885|NCT02254616|BEHAVIORAL|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
41366886|NCT02254616|BEHAVIORAL|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
41366887|NCT02254616|BEHAVIORAL|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
41161397|NCT02661503|DRUG|Bleomycin|
41161398|NCT02661503|DRUG|Etoposide|
41366888|NCT02254616|BEHAVIORAL|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
41366889|NCT02107716|PROCEDURE|Lidocaine injection with bicarbonate|bicarbonate added to change pH
41366890|NCT02107716|PROCEDURE|lidocaine injection|Lidocaine injection with pH unchanged
41366891|NCT01125852|PROCEDURE|Angiographic embolization|Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.
41366892|NCT01125852|PROCEDURE|Therapeutic endoscopy|Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
41366893|NCT02168465|BEHAVIORAL|teaching self-management of an intermittent catheter|Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
41366894|NCT04661917|DRUG|BAY2327949|60 mg of BAY2327949 (2 tablets of 30 mg, orally) once daily for 28 days.
41366895|NCT04661917|DRUG|Placebo|Matching placebo orally once daily for 28 days.
41366896|NCT06103773|DRUG|TollB-001 tablets|TollB-001 treatment
41366897|NCT06103773|DRUG|TollB-001 placebo|TollB-001 Placebo
41366898|NCT05196386|BEHAVIORAL|Admission conciliation interview|Previous treatment conciliation at hospital admission
41366899|NCT05196386|BEHAVIORAL|Discharge conciliation interview|Allocated treatment during hospital stay
41366900|NCT05196386|BEHAVIORAL|Targeted pharmaceutical interview|Specific information about treatment delivered by pharmacist
41501541|NCT05938504|OTHER|ONS_320275|Subjects will consume two packs (165ml/pack) of placebo ONS (ONS_320275) orally daily at any time of day.
41501542|NCT05938504|OTHER|ONS_211567|Subjects will consume two packs (165ml/pack) of test ONS (ONS_211567) orally daily at any time of day.
41161399|NCT02661503|DRUG|Doxorubicin|
41501543|NCT02667067|DEVICE|Simplify Disc|Simplify Disc at one level in the cervical spine.
41366901|NCT04428164|OTHER|The Richards-Campbell Sleep Questionnaire (R-CSQ)|"Tool developed to assess patient satisfaction and comfort in the hospital setting.~The R-CSQ is a scale used to measure different aspects of sleep quality. This scale allows the patient to rate their quality and amount of sleep on a scale of 0-100. The R-CSQ allows the patient to rate six different components of their sleep, including sleep depth, sleep latency, awakenings, returning to sleep, sleep quality, and noise."
41366902|NCT04428164|OTHER|Revised American Pain Society Outcome Questionnaire (APS-POQ-R)|The APS-POQ-R can be utilized to measure perceived levels of pain in patients. The APS-POQ-R scale is a validated scale that is used in the hospital setting with reliable and consistent results. This scale measures five aspects of a patient's perception and experiences with pain and a sixth aspect including nonpharmacological interventions.
41366903|NCT04019080|OTHER|Anti-fibrostic drugs|The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden
41161400|NCT02661503|DRUG|Cyclophosphamide|
41161401|NCT02661503|DRUG|Vincristine|
41366904|NCT00316966|BEHAVIORAL|Multidisciplinary dietary intervention|
40845686|NCT05492357|OTHER|Advanced Platelet-rich fibrin plus|A-PRF+ is placed into the extraction socket immediately after tooth extraction
40845687|NCT02640495|DRUG|Intravenous Artesunate as part of standard medical practice|Intravenous Artesunate 2.4 mg/kg
40845688|NCT03712488|DEVICE|flowcytometry|four colour flowcytometry
40845689|NCT02954666|DEVICE|radio-frequency ablation|"Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval \< 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval \< 600 ms after 5 minute of waiting time; 5 radiofrequency applications \> 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
41161402|NCT02661503|DRUG|Procarbazine|
41161403|NCT02661503|DRUG|Prednisone|
41161404|NCT02661503|DRUG|Brentuximab Vedotin|
41161405|NCT02661503|DRUG|Dacarbazine|
41161406|NCT02661503|DRUG|Dexamethasone|
41366905|NCT05754970|PROCEDURE|laser treated|"The second surgical stage was done after a healing period 12 ± 4 weeks (T1) where all the healing abutments were placed. Each healing abutment had repeated the two surfaces as twice follows: laser-treated/machined/ laser-treated/machined. Experimental healing abutment was removed after 30 ± 7 days, the same time as the soft tissue biopsy.~After the healing period (30 ± 7 days), before starting with the prosthetic restoration of the fixtures, an impression was taken of the small-diameter Has, and circular sections (diameter 5 mm) soft tissues around them were retrieved for analysis."
41366906|NCT06125327|DRUG|SC1011|Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
41366907|NCT06125327|DRUG|Placebo comparator|Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
41366908|NCT01478542|DRUG|Conventional Vincristine|
41366909|NCT01478542|DRUG|Liposomal Vincristine|
41366910|NCT01478542|DRUG|Ricover-scheme rituximab|
41366911|NCT01478542|DRUG|optimised rituximab-schedule|
41366912|NCT03315780|DRUG|Dulaglutide|Administered SC
41366913|NCT03315780|DRUG|Placebo|Administered SC
41366914|NCT05292352|BEHAVIORAL|LFSD|"Assessment of child's usual diet to assess sugar intake in relation to the total usual diet.~Consultation with a nutritionist to help families identify foods high in sugar. Removal of foods and drinks high in free sugar from the home.~Counseling using motivational interviewing, patient-centered goal setting to help parents and participating youth identify barriers to compliance with the intervention. Provision of a study provided LFSD with sufficient quantity to meet the needs and adapted to meet the preferences of the entire household for the first 4 weeks. Facilitated grocery shopping trips every 3 months during year 1."
41366915|NCT01693042|BIOLOGICAL|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (\> 3 months) infarct area
41366916|NCT05469451|PROCEDURE|Low level laser therapy|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
41366917|NCT00847002|DEVICE|Standard Wound Care|
41366918|NCT00847002|DEVICE|Flexitouch System with Standard Wound Care|
41366919|NCT00088660|BIOLOGICAL|PANVAC™-VF|
41366920|NCT04869358|DRUG|Ofatumumab|Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter
41366921|NCT00722462|PROCEDURE|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
41366922|NCT00722462|PROCEDURE|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
41366923|NCT03922191|OTHER|Data extraction from medical files|Data extraction from medical files
41366924|NCT02267031|PROCEDURE|mechanical ventilation|"Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg."
41366925|NCT01784081|OTHER|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
41366926|NCT01241591|DRUG|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
41501544|NCT02667067|DEVICE|Anterior Cervical Discectomy & Fusion|"This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®\|C Disc trial."
41501545|NCT06233591|DRUG|LP-10 (Liposomal Tacrolimus)|Liposomal oral rinse formulation of Tacrolimus
41501546|NCT05663866|DRUG|Dexamethasone|Dexamethasone will be administered orally.
41366927|NCT01241591|DRUG|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
41366928|NCT01241591|BIOLOGICAL|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
41366929|NCT01241591|OTHER|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
41366930|NCT01199874|BIOLOGICAL|Rotavirus vaccine|live attenuated oral rotavirus vaccine; lyophilized; 1 ml
41366931|NCT04430491|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
41366932|NCT04205773|DEVICE|CompuFlo|After priming with 5 mL saline, the catheter was connected to CompuFlo to record the occurrence of pulsatile waveforms and/or their disappearance during its removal
41366933|NCT05864105|BIOLOGICAL|PM8002|PM8002 20mg/kg Q2W
41501547|NCT05663866|DRUG|Montelukast|Montelukast will be administered orally.
41501548|NCT05663866|DRUG|Methotrexate|Methotrexate will be administered subcutaneously.
41501549|NCT05663866|DRUG|Amivantamab|Amivantamab will be administered intravenously.
41501550|NCT05663866|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
41501551|NCT06352918|OTHER|Palmar grasp reflex stimulation|This initiative is stimulated by applying gentle pressure to the palm of the baby's palm while he or she is awake, lying on a flat surface in a symmetrical supine position.
41501552|NCT06111261|DRUG|Albumin solution|200ml of 20% Human Serum Albumin
41501553|NCT06111261|DRUG|Balanced crystalloid solution|Balanced crystalloid solution
41501554|NCT05062889|DRUG|5-Fluorouracil continuous infusion FOLFOXIRI schedule|3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
41366934|NCT05864105|DRUG|FOLFOX regimen|day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
40845690|NCT04288700|DRUG|oral propranolol|oral propranolol therapy at a dose of 1 mg/kg/d (Inderal 20 mg/5 mL) in three divided doses. If the child will tolerate the treatment with no side effects, therapy will continue in an outpatient clinic. Blood glucose level will be also measured in a periodic manner during therapy. The dose will be increased gradually to 2 mg/kg/d in three divided doses if there will be no adverse effects from the initial therapy.
41366935|NCT05025891|OTHER|Teleconsultation|Patients are randomized into groups in which there are either teleconsultations alone or with the help of a mediator to carry out their follow-up care
41366936|NCT02164058|DEVICE|TandemHeart System|
41366937|NCT02164058|PROCEDURE|Percutaneous coronary intervention|
40845691|NCT04288700|DRUG|Oral Captopril|A test dose of 0.1 mg kg) will be administered orally with pulse rate and blood pressure monitored at 0.5, 1 and 2 h and at each follow up. If the test dose is tolerated, captopril administration will start at 0.15 mg kg) per dose 8-hourly. Pulse rate and blood pressure will be monitored 4-hourly and doses will be withheld if hypotension is documented. After 24 h, the dose will be increased to 0.3 mg kg) per dose 8-hourly .
40845692|NCT04288700|DRUG|intralesional propranolol injection|intralesional propranolol injection 1 mg/mL
40845693|NCT04288700|DRUG|topical Timolol maleate 0.5% eye drops|To be Applied on the surface of the lesions three times daily
40845694|NCT03077204|BIOLOGICAL|1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
41366938|NCT04469309|OTHER|Group I Brandt-Daroff Exercises|"In group I Brandoff Exercises will be performed using standard method, in which the patient is in the sitting position on examination table, the patient moves into the lying position on the affected side on the shoulder, with the head angled upward with about 45. The patient stays in this for 30 s and then goes back to the sitting position, looks forward and remains in this position for 30 s as well. The patient repeats the same procedure for the other side, too.~The patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks. Pre, mid and post assessment."
41161407|NCT05739799|PROCEDURE|IPL|Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded.
41501555|NCT05062889|DRUG|5-Fluorouracil bolus FOLFOX schedule|400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.
40845695|NCT03077204|DEVICE|Aviator Anterior Cervical Plating System|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
41366939|NCT04469309|OTHER|Group II Half-Somersault Maneuver|In group II Half-Somersault Maneuver will be done, the patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks.
41366940|NCT00423137|DRUG|BIBW 2948 BS|Capsule
41366941|NCT00423137|DRUG|Placebo|Capsule
41366942|NCT02419443|DRUG|Gabapentin|Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
41366943|NCT02419443|DRUG|Placebo|Control group
41366944|NCT00735839|BIOLOGICAL|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
41366945|NCT00735839|BIOLOGICAL|Placebo|Saline placebo (0.5 ml) single injection on Day 1
41366946|NCT02173470|OTHER|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
41366947|NCT04095494|BEHAVIORAL|Nitrous oxide use|In order to evaluate the perception of the Nantes health students we wish to place an anonymous survey concerning their training, their knowledge of the legislative framework governing the use of EMONO and their personal and professional experience around nitrous oxide.
41501556|NCT05062889|DRUG|5-Fluorouracil continuous infusion FOLFOX schedule|2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
41501557|NCT05062889|DRUG|Oxaliplatin FOLFOX and FOLFOXIRI schedule|85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
41501558|NCT05062889|DRUG|Oxaliplatin CAPOX schedule|130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
41366948|NCT04297111|DIETARY_SUPPLEMENT|Probiotic|GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.
41366949|NCT04297111|OTHER|Placebo|Maltodextrin capsule, no active ingredient
41366950|NCT01274104|DIETARY_SUPPLEMENT|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
41366951|NCT01274104|OTHER|Placebo|Placebo
40845696|NCT04678791|DRUG|Nimotuzumab|Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.
40845697|NCT04678791|DRUG|Cisplatin|Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
40845698|NCT04678791|RADIATION|External-beam radiation|Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.
40845699|NCT04678791|RADIATION|Brachytherapy|Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 \~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
40845700|NCT03583736|BEHAVIORAL|Virtual visit|Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
40845701|NCT03583736|BEHAVIORAL|Office visit|Scheduled office visit with oncologist following uterine cancer diagnosis.
41366952|NCT02874222|OTHER|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
41366953|NCT02207127|PROCEDURE|MRI, DISE, and Surgery|MRI, DISE, and Surgery
41366954|NCT05749159|BEHAVIORAL|physiotherapy|New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
41366955|NCT01390727|DEVICE|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
41366956|NCT01390727|OTHER|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
41366957|NCT00766870|DRUG|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
41366958|NCT00766870|DRUG|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
41366959|NCT00766870|DRUG|Placebo|Per oral doses, twice daily as capsules during 10 weeks
40845702|NCT01453907|DRUG|"ETI-204, Anthim"|intravenously, single dose
40845703|NCT01453907|DRUG|placebo|intravenously, single dose
40845704|NCT03370562|DRUG|Dexmedetomidine|Administration of 10 mcg intravenous dexmedetomidine
40845705|NCT03370562|DRUG|Placebo|Administration of normal saline
41366960|NCT00394862|DRUG|multivitamin|
41366961|NCT03417648|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
40845706|NCT02143466|DRUG|Part A - AZD9291 in combination with AZD6094|Part A - AZD9291 and AZD6094 administered in different doses to investigate the safety and tolerability of this combination and define the combination dose for further clinical evaluation in Part B.
41161408|NCT05739799|PROCEDURE|Diode|patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
41366962|NCT03417648|OTHER|Supplement|unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
41366963|NCT06316076|BIOLOGICAL|CD19-CAR-DNT cells|Lentiviral vector-transduced DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
41366964|NCT05119751|DRUG|tree 12 SQ-Bet|DAILY DOSE OF AIT TABLET
41366965|NCT05119751|DRUG|GRASS 2800 BAU|DAILY DOSE OF AIT TABLET
41366966|NCT05119751|DRUG|RAGWEED 12 AMB A 1-U|DAILY DOSE OF AIT TABLET
41366967|NCT05119751|DRUG|HDM 12 SQ-HDM|DAILY DOSE OF AIT TABLET
41366968|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter KS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter KS implants.After osseointegration, both dental implants will receive definitive prosthesis.
41501559|NCT05062889|DRUG|L-Leucovorin|200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
40845707|NCT02143466|DRUG|Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in Asian subjects and to define the combination dose for further clinical evaluation in Part B.
41501560|NCT05062889|DRUG|Capecitabine|Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
41501561|NCT05062889|DRUG|Irinotecan|165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.
41501562|NCT05062889|DRUG|Trifluridine/Tipiracil|35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.
41501563|NCT05062889|DRUG|Trastuzumab|4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes). To be repeated every two weeks for a maximum of 12 cycles.
41501564|NCT05062889|DRUG|Tucatinib|300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal) for a maximum of 12 biweekly cycles.
40845708|NCT02143466|DRUG|Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in non-Asian subjects and to define the combination dose for further clinical evaluation in Part B.
41028522|NCT01019330|OTHER|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
40845709|NCT02143466|DRUG|Part A - AZD9291 in combination with intermittent selumetinib|Part A - AZD9291 and selumetinib (intermittent treatment) administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.
40845710|NCT02143466|DRUG|Part A - AZD9291 in combination with MEDI4736|"Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
41028523|NCT01019330|OTHER|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
41028524|NCT03509935|OTHER|Intervention Ultrasound Group|"Protocol:~* US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~* US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~* Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced."
41028525|NCT03286023|RADIATION|stereotactic radiotherapy|stereotactic radiotherapy for brain metastases
41028526|NCT03077282|DRUG|Prasaprohyai|Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
41028527|NCT01713595|DRUG|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
41028528|NCT01091311|DEVICE|Blephasteam|Eye lid warming goggles
40845711|NCT02143466|DRUG|Part B - AZD9291 in combination with AZD6094|Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.
41028529|NCT01764984|DEVICE|Total knee arthroplasty|Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
41028530|NCT04959045|OTHER|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
41161409|NCT03220165|DRUG|MGL-3196|oral, 100 mg
41161410|NCT00500981|PROCEDURE|Volume challenge|
41161411|NCT00500981|PROCEDURE|Ultrasound evaluation of internal jugular vein|
41161412|NCT02241161|OTHER|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
41161413|NCT02241161|OTHER|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
41161414|NCT02241161|OTHER|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
41161415|NCT04833842|OTHER|Web-based childbirth preparation program developed based on health belief model and supported by motivational interview|In the three-month study, primigravida women in the initiative group will be given a web-based childbirth preparation program, which is prepared based on the Health Belief Model and supported by motivational interviews. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
41161416|NCT04833842|OTHER|Web-based childbirth preparation program based on health belief model|In the three-month study, a web-based childbirth preparation program based on the Health Belief Model will be applied to primigravida women in the control group. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
41161417|NCT01314898|DRUG|3 mg PF-03882845|3 mg PF-03882845, single oral dose
41501565|NCT01736969|DEVICE|RD047-023|Experimental hydrogel
41501566|NCT01736969|DEVICE|Predicate Device|
41501567|NCT04683029|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered intravenously.
41501568|NCT04683029|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered subcutaneously.
41501569|NCT04683029|DRUG|Placebo|Placebo will be administered intravenously or subcutaneously.
41501570|NCT05158036|OTHER|Classic massage group|Classic massage application will be given to the Classic massage group
41501571|NCT05158036|OTHER|Connective tissue masage|Connective tissue masage application will be given to the Connective tissue masage group
41501572|NCT03578549|DEVICE|Pulse Oximetry|Pulse Oximeter is being applied with a special holding tool to test the oximeter for its ability to measure pulpal blood flow, but no effect of the oximeter is being measured. Thus, to that degree the use is observational rather than interventional.
41501573|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5421|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
41161418|NCT01314898|DRUG|10 mg PF-03882845|10 mg PF-03882845, single oral dose
41501574|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5424|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
41161419|NCT01314898|DRUG|30 mg PF-03882845|30 mg PF-03882845, single oral dose
41161420|NCT01314898|DRUG|100 mg PF-03882845|100 mg PF-03882845, single oral dose
41161421|NCT01314898|DRUG|Spironolactone|100 mg spironolactone, single oral dose
41161422|NCT02585141|DEVICE|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
41161423|NCT02585141|PROCEDURE|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
41161424|NCT02585141|DRUG|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
41161425|NCT02612805|OTHER|Aerobic training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
41501575|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5429|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection
41501576|NCT06361875|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|Pharmaceutical form: suspension for injection in prefilled syringe -Route of administration:Intramuscular injection
41501577|NCT06361875|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|Pharmaceutical form:suspension for injection in pre filled syringe -Route of administration:Intramuscular injection
41501578|NCT06361875|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|Pharmaceutical form:suspension for injection in pre filled syringe-Route of administration:Intramuscular injection
41501579|NCT05856006|OTHER|upper trapezius stretching plus neck isometrics|upper trapezius stretching plus neck isometrics
41501580|NCT05856006|OTHER|upper trapezius stretching with mid-lower trapezius strengthening exercises plus neck isometrics|"Mid-Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra"
41501581|NCT02140385|PROCEDURE|Abdominoplasty-Scarpa's fascia preservation|Thicker abdominal flaps will be preserved during the surgery.
41501582|NCT02140385|PROCEDURE|Abdominoplasty-Scarpa's fascia ablation|Thinner abdominal flaps will be preserved during surgery.
41501583|NCT02140385|DEVICE|Lymphoscintigraphy|Post-operative lymphatic imaging will be conducted using a common radiographic medium
41501584|NCT02140385|DEVICE|3D Imaging|Post-operative 3-dimensional photography will take place at a regularly scheduled clinic appointment.
41501585|NCT02140385|DEVICE|Abdominal ultrasound|Post-operative abdominal ultrasound will be used to determine the presence of fluid collections (seromas).
40845712|NCT02143466|DRUG|Part B - AZD9291 in combination with selumetinib|Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent \[4 days on/3 days off\]) to further investigate the safety and tolerability of this combination.
40845713|NCT02143466|DRUG|Part B - AZD9291 in combination with MEDI4736|"Part B - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
41161426|NCT02612805|OTHER|Combined training|"Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.~Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.~Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed."
41161427|NCT02612805|OTHER|Training placebo|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
41161428|NCT03106935|DRUG|Levothyroxine|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
41161429|NCT02621047|DRUG|Alectinib|Participants will receive alectinib as per the dosage schedule mentioned in arm description.
41501586|NCT06536140|OTHER|Home observations and interview|"If persons want to participate, the person will be invited one week before the first observation for a 'warm-up' phone call (W1) as a preparation for the three observations and follow-up interview.~During the observations, SH will be an active participant, offering to help with activities of daily life with the person, so opportunities are created to observe and ask questions (sensory ethnography). The person will be asked to take pictures or make drawings of important things in the house as the observer will be able to better understand how they feel about exercise and PA (visual ethnography). Six weeks after the last observation (W10), formal follow-up interviews (30-60 min) with questions based on the observations that took place, will be held to explore specific issues in-depth."
41161430|NCT05093023|GENETIC|Real-Time PCR|Genomic DNA was extracted from 2 ml of venous blood. ABCB1 1236 G\>A and 3435 G\>A were genotyped using predesigned TaqMan SNP genotyping assays on a stepOne PCR instrument in accordance with the manufacturer's protocol.
41161431|NCT00556764|DRUG|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
41161432|NCT00556764|DRUG|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
40845714|NCT02143466|DRUG|Part C - AZD6094 monotherapy (Japan only)|Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC.
40845715|NCT02143466|DRUG|Part C - AZD9291 in combination with AZD6094 (Japan only)|Part C combination cohort - AZD9291 80mg OD administered in combination with AZD6094 400mg OD (AZD6094 dose in which DLTs have not been identified in the Japanese monotherapy cohort) in order to confirm the safety, tolerability, pharmacokinetics and preliminary anti-tumor activities of this combination in Japanese subjects. The 400mg OD dosing schedule will be initiated in the first cohort. The dose may be subsequently reduced in further cohorts in response to emerging safety, or PK findings or other reasons identified in the savolitinib programme.
40845716|NCT02143466|DRUG|Part D - AZD9291 in combination with AZD6094|Part D - AZD9291 80mg OD administered in combination with AZD6094 300mg OD to further evaluate the safety, tolerability, pharmacokinetics and antitumor activity in terms of ORR and PFS in patients with locally advanced or metastatic cMET positive EGFRm+ and T790M-negative NSCLC, following progression on EGFR-TKI treatment. The choice of AZD6094 dose of 300 mg is based on results from preclinical and clinical studies. Clinical testing of the 300 mg OD dose will enable better assessment of impact of lower AZD6094 exposure on overall tolerability and hepatotoxicity risk as well as exploration of the efficacy and overall safety profiles with a dose meaningfully lower than the current dose of 600 mg OD.
40845717|NCT00915551|DRUG|PEP005 (Ingenol Mebutate) gel, 0.015%|once daily for 3 consecutive days
40845718|NCT00915551|DRUG|Vehicle Gel|once daily for 3 consecutive days
40845719|NCT05170178|BEHAVIORAL|inclusion and familiarization|"* presentation of the study purpose and the protocol to the volunteer~* clinical examination to check inclusion and exclusion criteria~* Familiarization with the crying of one assigned baby, by listening to several bath cries from this baby"
41028531|NCT01173393|PROCEDURE|PARAMEDIC COOLING|"For patients randomised to paramedic cooling:~* LMA/ Intubation and ventilation with 100% oxygen~* Measure temperature using tympanic probe and record~* Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR~* If temperature \>34.5ºC, infuse further 10mL/kg stat~* After ROSC, infuse further (max 2 litres) ice-cold saline~* If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg."
41028532|NCT02817789|DRUG|Ticagrelor alone|180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
41028533|NCT02817789|DRUG|Combination lysine acetylsalicylate - clopidogrel|75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
41028534|NCT00275093|DRUG|temsirolimus|Given IV
41161433|NCT04695314|DEVICE|Massage|Foot reflexology board (JAPAN TSUBO HH-700) with massage focused at the base of the second and third toes
41161434|NCT04695314|PROCEDURE|Experimental insert|Raised shoe insert, insert used for massage
41161435|NCT04695314|PROCEDURE|Sham insert|Flat shoe insert, insert used for massage
41501587|NCT03961490|OTHER|No interventional study|No interventional study
41161436|NCT00922441|DRUG|Fimasartan 60 mg group|Fimasartan 60 mg
41501588|NCT05930496|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41501589|NCT05930496|OTHER|Exercise Intervention|Receive exercise intervention
41501590|NCT05930496|OTHER|Exercise Intervention|Receive tele-coaching intervention
41501591|NCT05930496|BEHAVIORAL|Health Education|Receive health-related information
41501592|NCT05930496|OTHER|Interview|Ancillary studies
41501593|NCT05930496|OTHER|Questionnaire Administration|Ancillary studies
41501594|NCT06229548|DRUG|SYH2053|subcutaneous injection
41501595|NCT06229548|DRUG|Placebo|subcutaneous injection
40845720|NCT05170178|BEHAVIORAL|fMRI acquisition and closure|"* Second phase of familiarization, listening again to bath cries of their assigned baby. These cries will be different from those listened during the first familiarization phase.~* MRI acquisition: after acquisition of the anatomical images (5 min), the subjects will listen to 64 cries divided into 4 functional MRI sessions of 10 minutes each. The cries will be those of their baby or of unknown babies, evoked in a painful (vaccination) or a non-painful (bath) situation, presented in a pseudo-random order. Participants will be asked to assess whether they recognize their baby (yes/no) and whether they recognize a pain cry (yes/no).~* debriefing~* Protocol ending"
40845721|NCT01088594|DRUG|pioglitazone/rosiglitazone/placebo|single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
40845722|NCT01088594|DRUG|rosiglitazone/pioglitazone/placebo|single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
40845723|NCT01088594|DRUG|placebo/pioglitazone/rosiglitazone|single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
41028535|NCT00275093|OTHER|laboratory biomarker analysis|Correlative studies
41028536|NCT00275093|OTHER|pharmacological study|Correlative studies
41028537|NCT05046457|DIETARY_SUPPLEMENT|Beta-cryptoxanthin (BCX)|Subjects will be randomised into one of the three study treatment arms.
41028538|NCT03856346|DIAGNOSTIC_TEST|Biometry|Biometry for phaco-vitrectomy procedures pre- and postoperatively
41028539|NCT02467777|DEVICE|Bair Hugger|
41501596|NCT06599580|BEHAVIORAL|Training caregivers to screen children for malnutrition relapse|Caregivers enrolled in the trial who are assigned to the two experimental arms, will be provided mid-upper arm circumference tapes and trained on how to screen their child for malnutrition relapse and asked to bring their child back to the clinic if relapse is detected.
41501597|NCT06599580|OTHER|Reduced follow-up schedule|Caregivers in one of the caregiver mid-upper arm circumference screening arms, will be asked to adhere to a reduced follow-up clinic visit schedule for when they bring their child to the clinic for planned visits. The standard of care includes monthly visits for the first 3 months post recovery, but those randomized to the reduced follow-up schedule arm, will not bring their child to the clinic for planned visits 1 month and 2 months after baseline.
41501598|NCT04820205|DRUG|Intranasal dexmedetomidine and ketamine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
41501599|NCT04820205|DRUG|Oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
41501600|NCT06632665|OTHER|transcutaneous vagus nerve stimulation+virtual reality+routine physical therapy|"Transcutaneous vagus nerve stimulation Location The left auricular branch vagus nerve will be stimulated by the modified dot -like electrodes will be fitted to the cymba conchae.frequency:Stimulation perform for 30 minutes per day for 4 weeks .~duration 600 pulses (intratrain pulse) frequency =20 Hz ; Pulse duration =0.3ms ,lasting 30 seconds each time ,stimulating once every 5 minutes"
41501601|NCT06632665|OTHER|transcutaneous vagus nerve stimulation+routine physical therapy|"Transcutaneous vagus nerve stimulation Location The left auricular branch vagus nerve will be stimulated by the modified dot -like electrodes will be fitted to the cymba conchae.Stimulation perform for 30 minutes per day for 4 weeks .~Routine physical therapy Stretching Areas :upper chest ,neck flexors ,shoulder flexor and adductors ,elbow and wrist flexors 10 minute per session,and stretches will held for 10s -30swith four repetition of each.30 minutes per day for 4 weeks Upper extremity Proprioception ,coordination,speed and agility increase such as followReach and grasp Handle turning simulated eating task Inserting object Opening bottle strenghtening exercise Muscles biceps brachii brachialis Coracobrachialis triceps brachii wrist extensors 10 minute per session for 4 weeks"
41501602|NCT05283720|DRUG|Epcoritamab|Subcutaneous Injection (SC)
40845724|NCT01088594|DRUG|pioglitazone/placebo/rosiglitazone|single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
40845725|NCT01088594|DRUG|rosiglitazone/placebo/pioglitazone|single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
40845726|NCT01088594|DRUG|placebo/rosiglitazone/pioglitazone|single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
40845727|NCT03926988|DEVICE|NeVa Stent Retriever|mechanical neurothrombectomy
41028540|NCT02467777|DEVICE|VitaHeat|
41028541|NCT04455919|OTHER|Wait-list group|The wait-list group benefit from a 8-week yoga program after the interventional group
41028542|NCT04455919|OTHER|Yoga group|During 8 weeks, the intervention group attended weekly yoga sessions and had to practice poses at home
41028543|NCT05056103|DEVICE|TrachFlush|The attending nurses activate the TrachFlush when there are secretions present in the larger airways that need to be removed. If this results into a push of airway secretions past and above the cuff of the endotracheal tube, no further action is needed. If unsuccessful, the nurse will perform a standard tracheal suctioning procedure to remove the secretions. In a subset of patients with an endotracheal tube that allows subglottal suctioning, the exact amount of airway secretions present above the cuff will be measured each time the TrachFlush is used.
41161437|NCT00922441|DRUG|Fimasartan 120 mg group|Fimasartan 120 mg
41161438|NCT00922441|DRUG|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
41161439|NCT01280383|DEVICE|non-invasive neurally adjusted ventilatory assist|non-invasive neurally adjusted ventilatory assist in critically ill patients
41161440|NCT02025361|DRUG|intrarectal lidocaine gel|intrarectal local anesthetic application
41501603|NCT05283720|DRUG|Lenalidomide|Oral; Capsule
41501604|NCT05283720|DRUG|Ibrutinib|Oral; Capsule
41501605|NCT05283720|DRUG|Rituximab|Intravenous (IV); Injection
41161441|NCT02025361|DRUG|periprostatic nerve blockade|periprostatic local anesthetic application
41501606|NCT05283720|DRUG|Cyclophosphamide|IV; Injection
41501607|NCT05283720|DRUG|Doxorubicin Hydrochloride [HCl]|IV; Injection
41501608|NCT05283720|DRUG|Prednisone|Oral; Tablet
41501609|NCT05283720|DRUG|Polatuzumab Vedotin|IV; Injection
41501610|NCT05283720|DRUG|Venetoclax|Oral; Tablet
41028544|NCT01496352|DRUG|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
41028545|NCT01496352|DRUG|Placebo|DFA-02 placebo
41161442|NCT02157129|DEVICE|LipoAerosol© inhalation|LipoAerosol© inhalation, 5x/d for 30min
41366969|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter TS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter TS implants.After osseointegration, both dental implants will receive definitive prosthesis.
41366970|NCT02530580|DRUG|20 mg AZD7325|A single 20 mg oral dose of AZD7325
41366971|NCT02530580|DRUG|Placebo|A single oral dose
41366972|NCT02979275|PROCEDURE|Open heart surgery on cardiopulmonary bypass.|Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
41366973|NCT04374331|OTHER|video-assisted training|The patients in the VAT group watch a training video in the patient rooms before RCR. The VAT prepared by the researchers consisted of information about things to pay attention to in the hospital in the early period after RCR (nursing care on post-operative day 1, early mobilization, pain control, shoulder protection, and wearing/removing the shoulder sling), maintaining ADL at home (bathing, nutrition, eating, sleeping position, driving, doing household chores, sexual life, worship, and safety measures to be taken at home) and gradual exercise programs (for the first 90 days after discharge).
41366974|NCT04422301|OTHER|Blood flow restriction|an alternative method to produce strength and muscle hypertrophy with lower intensities
41366975|NCT06012695|DRUG|NBM-BMX Capsule|Each capsule contains 100 mg of the active ingredient.
41501611|NCT05283720|DRUG|CC-99282|Oral; Capsule
41028546|NCT01772953|DRUG|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
41028547|NCT05331183|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
41366976|NCT06012695|DRUG|Temozolomide|TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.
41366977|NCT06012695|RADIATION|Standard radiotherapy|A total dose of 60 Gy will be administered in 6 weeks.
41501612|NCT05283720|DRUG|Pirtobrutinib|Oral; Tablet
41501613|NCT06634355|DRUG|Sugammadex|In an ex-vivo placenta perfusion study, placental transfer of sugammadex is measured.
41501614|NCT03893630|DRUG|Acetylsalicylic Acid 81 mg|Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
41501615|NCT03893630|DRUG|Acetylsalicylic Acid 162 mg|Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
41501616|NCT03893630|OTHER|Control|Standard of Care
41501617|NCT04547842|DRUG|Mirtazapine 30 MG|mirtazapine is given in arm M to prevent PONV
41501618|NCT04547842|DRUG|Dexamethasone|Dexamethasone is given in arm D to prevent PONV
41501619|NCT02218554|GENETIC|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
41501620|NCT03910387|DRUG|Gemcitabine|Given gemcitabine/nab-paclitaxel combination therapy
41501621|NCT03910387|DRUG|Nab-paclitaxel|Given gemcitabine/nab-paclitaxel combination therapy
41501622|NCT03910387|DRUG|Telotristat Ethyl|Given PO
41501623|NCT06634017|BIOLOGICAL|Platelet rich fibrin|Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
41501624|NCT03039426|DRUG|Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
41028548|NCT05331183|DRUG|IVA|Tablets for oral administration.
41028549|NCT01659918|DRUG|Montelukast|
41028550|NCT01659918|DRUG|Singulair|
41161443|NCT02157129|OTHER|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
41161444|NCT05671744|OTHER|Cell-based non-invasive prenatal testing|Blood sampling
41161445|NCT01243398|PROCEDURE|quality-of-life assessment|
41501625|NCT03039426|DRUG|Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
41161446|NCT02189369|OTHER|Day 3 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer
41161447|NCT02189369|OTHER|Day 5 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
41366978|NCT01205464|DRUG|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
41366979|NCT01205464|DRUG|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
41366980|NCT02843113|BEHAVIORAL|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
41366981|NCT05666466|DIAGNOSTIC_TEST|extratympanic electrocochleograhy|electrophysiological test
41366982|NCT01749241|DRUG|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
41366983|NCT01749241|DRUG|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
41366984|NCT00136344|DRUG|Cefuroxime|
41366985|NCT00136344|DRUG|Levofloxacin|
41366986|NCT02711163|DIETARY_SUPPLEMENT|Extensively Hydrolyzed formula|
40845728|NCT03842072|DEVICE|Cervical collar|cervical collars prescribed will be use immediately following anterior cervical discectomy and fusion surgery.
41366987|NCT02711163|DIETARY_SUPPLEMENT|Amino acid formula|
41366988|NCT00435266|PROCEDURE|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
41366989|NCT06471686|DRUG|Acamprosate|2 pills three times a day
41366990|NCT02383966|DRUG|Cetuximab|Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m\^2) on Day 1 and a subsequent dose of 250 mg/m\^2 on Day 8 and Day 15 of each 21-day treatment cycle.
41366991|NCT02383966|DRUG|Cisplatin/Carboplatin|Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.
41366992|NCT02383966|DRUG|5-fluorouracil|Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
41366993|NCT05352958|PROCEDURE|Diaphragmatic ultrasound|duration 15 minutes, performed at M0, M3, M6 and M9
41366994|NCT05352958|OTHER|Electro-physiological exploration of the diaphragm|duration between 30 and 60 minutes performed at M0
41366995|NCT05994690|DRUG|Standard Intervention Rc|3 consolidation courses (HAM + HA3E + FLA)
41366996|NCT05994690|DRUG|Investigational Intervention Rc|2 consolidation courses (HAM + FLA)
41366997|NCT05994690|DRUG|Standard Intervention Ri|No addition of GO to first induction course
41366998|NCT05994690|DRUG|Investigational Intervention Ri|Addition of GO to first induction course
41366999|NCT02800096|BEHAVIORAL|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
41367000|NCT02800096|BEHAVIORAL|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
41367001|NCT06230107|BEHAVIORAL|Mindful Eating|Analyze the impact of Mindful Eating on changes in dietary habits, episodes of binge eating, body image dissatisfaction, quality of life and anthropometric data (weight, BMI and waist circumference) in Participants with obesity and BED.
41367002|NCT05066516|DRUG|FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin|FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin
41501626|NCT06633289|OTHER|Experimental formula|New hydrolyzed rice protein-based formula
40845729|NCT02992535|DEVICE|Intense Pulse Light Energy delivery (IPL)|
40845730|NCT04114110|OTHER|RTLS data|data extraction from RTLS
41161448|NCT00816153|OTHER|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
41161449|NCT05624489|BEHAVIORAL|Engagement Strategies|The study's mobile app (Oralytics) will be used to deliver engagement prompts. The prompts contain messages that leverage three engagement strategies: reciprocity, reciprocity by proxy, and curiosity.
41161450|NCT06111443|DRUG|Dapagliflozin 10 mg [Farxiga]|Dapagliflozin 10 mg \[Farxiga\] for 3 months after catheter ablation of atrial fibrillation
41367003|NCT05602558|BIOLOGICAL|LYB001|The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
41367004|NCT05602558|BIOLOGICAL|Placebo|Aluminium hydroxide adjuvant
41367005|NCT05493579|OTHER|Implant supported overdenture|Implant supported overdenture compared to complete denture
41367006|NCT04551248|BIOLOGICAL|10 or 13-valent pneumococcal conjugate vaccine|a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.
41501627|NCT06633289|OTHER|Control formula|Commercially available amino acid-based formula.
41367007|NCT04551248|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5-mL dose administered intramuscularly or subcutaneously only.
41367008|NCT04551248|BIOLOGICAL|Influenza vaccine|One dose of trivalent influenza vaccine in flu seasons.
41501628|NCT01392625|BIOLOGICAL|Autologous hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
40845731|NCT00123604|DRUG|Carvedilol|25 mg twice daily for five months.
40845732|NCT00123604|DRUG|Metoprolol|200 mg twice daily for five months.
40845733|NCT02437084|DRUG|Atorvastatin|Study subjects will receive atorvastatin 40 mg for 10 weeks.
40845734|NCT01276223|DRUG|Difluprednate 0.05% ophthalmic emulsion|Topical ocular steroid
40845735|NCT01276223|OTHER|Difluprednate vehicle|Inactive ingredients used as Run-In and placebo comparator
40845736|NCT04607876|OTHER|Technological Facilitator|See Enhanced Intervention Arm for full description.
40845737|NCT04607876|OTHER|Standard of Care|Risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
40845738|NCT04660396|DEVICE|BVA-100|"The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin (a commonly used tag is 131I, resulting in 131I -HSA). Data inputs to the software come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and transudation rate are reported, with statistics showing the quality of the results. The subject blood samples and calibration standards are measured in a gamma counter, whose output is automatically, or manually, input to this calculation program."
40845739|NCT01600092|BIOLOGICAL|RotaTeq™ experimental formulation|
41367009|NCT02246205|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
40845740|NCT01600092|BIOLOGICAL|RotaTeq™ existing formulation|
40845741|NCT00868036|PROCEDURE|Patch Testing|"Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing."
40845742|NCT06056856|PROCEDURE|Penile skin graft substituttion urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
40845743|NCT06056856|PROCEDURE|Buccal Mucosal Graft substitution urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
40845744|NCT01754571|BEHAVIORAL|Cognitive behavior therapy|Behavior therapy, including Relaxation, cognitive rebuilding.
40845745|NCT01950312|DRUG|gevokizumab|
40845746|NCT01290744|DRUG|Clofazimine|Clofazimine 100mg daily for 12 months after completion of MDT.
40845747|NCT01290744|DRUG|Placebo|Daily for 12 months
40845748|NCT02146027|DIETARY_SUPPLEMENT|Fermented Milk Drink Yakult 40|Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10\^8 CFU/g). Intervention will be used for 12 weeks.
40845749|NCT02146027|DIETARY_SUPPLEMENT|Fermented Milk Drink Yakult 40|Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
40845750|NCT06039917|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
41028551|NCT04497441|OTHER|Electronic Survey questionnaire|"This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Survey Questionnaire contained following sections:~Section I: Minimum required personal details Section II: 10 Questions regarding the source of COVID-19 information Section III: 6 Questions regarding perception of the COVID-19 information~The very first part of the Questionnaires seeks responders' consent for giving responses to the survey questions. participation Section II \& III contained all closed ended questions. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms."
41028552|NCT03792061|BEHAVIORAL|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
41367010|NCT03769753|DEVICE|IRE Device|For use in ablating soft tissue
41367011|NCT00277862|DRUG|Pegylated IFN- alpha 2b|
41367012|NCT00277862|DRUG|Ribavirin|
41367013|NCT04660929|BIOLOGICAL|CT-0508|anti-HER2 CAR macrophages
40845751|NCT06039917|OTHER|Manually remind the patients|Medical staff remind patients to review manually.
41028553|NCT00670124|DEVICE|Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero|The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
41367014|NCT04660929|BIOLOGICAL|Pembrolizumab|anti-PD antibody
41367015|NCT03439319|DEVICE|MyndMove®|This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
41367016|NCT03439319|OTHER|Conventional Therapy|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
41367017|NCT03953651|OTHER|Follow-up|Onset of Major Adverse Cardiovascular Event of death from all causes will be collected at 3 and 6 months after inclusion.
41367018|NCT05115682|BEHAVIORAL|High-intensity Intermittent Exercise|The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).
41367019|NCT01002846|PROCEDURE|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
41028554|NCT00476944|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
41367020|NCT06227819|DIAGNOSTIC_TEST|BVA-200|Blood samples collected for measurement with the BVA-100 will also be tested with the BVA-200. The BVA-200 uses whole blood collection cartridges which allow for a precise amount of blood to be measured without the need to first centrifuge and then pipette plasma aliquots. A small amount of whole blood from each sample will be set aside for BVA-200 use, while the remainder of the blood sample is used for BVA-100 measurement. The BVA-200 device was developed with the support of the Department of Defense through Phase I (W81XWH19C0048) and Phase II (W81XWH20C0025) SBIR contracts.
41367021|NCT00425165|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution one time during the study.
41367022|NCT02516449|OTHER|Patient decision aid|"The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?"
41367023|NCT04784208|DIAGNOSTIC_TEST|Blood test for Thyroid stimulating hormone (TSH)|Blood test for Thyroid stimulating hormone (TSH)
41367024|NCT04466657|DIETARY_SUPPLEMENT|Antioxidation Therapy|Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
41501629|NCT01392625|BIOLOGICAL|Allogeneic hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
41501630|NCT04588025|DEVICE|Point-of-care Portable Perfusion Phantom, P4|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
40845752|NCT02752373|DEVICE|Brain Sentinel Seizure Detection and Information System|The Brain Sentinel® GTC Seizure Detection and Information System is an ambulatory system designed to continuously monitor and perform real-time analysis of surface electromyography (sEMG) data to detect GTC seizures and to provide an alarm to alert caregivers within 30 seconds of bilateral, appendicular, tonic extension that a seizure is occurring. The System is for recording and storing sEMG data, which is subsequently reviewed by a trained healthcare professional in the outpatient clinical setting. The Brain Sentinel® GTC Seizure Detection and Information System is intended for real time monitoring of pediatric and adult patients who have an arm circumference ranging from at least 16 cm to no greater than 51 cm at the biceps. It may be used in the home or healthcare facilities for real-time monitoring during the day, night, or for continuous monitoring, including during the titration of, or the withdrawal from anti-epileptic drugs.
41367025|NCT04466657|OTHER|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
41367026|NCT01085331|DRUG|Pimasertib|Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
41367027|NCT01085331|DRUG|Placebo|Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
41501631|NCT02593110|BEHAVIORAL|Supervised Treadmill Exercise Therapy|Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
41501632|NCT02593110|DRUG|Telmisartan|Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.
40845753|NCT03083223|OTHER|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
41161451|NCT04561583|DEVICE|LED light source system for endoscope|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
41161452|NCT04561583|DEVICE|Pinpoint Endoscopic Fluorescence Imaging System|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
40845756|NCT05102006|DRUG|LBL-007 Injection|LBL-007 Injection; dose A or dose B; Q3W
41161453|NCT01963442|RADIATION|Chest X-ray|at Day 0, Day 30 and relapse
41367028|NCT01085331|DRUG|FOLFIRI|Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
41367029|NCT03811782|BEHAVIORAL|Single-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Single-task Training instructions (20 minutes) and cool down (5 minutes).
41501633|NCT02593110|OTHER|"No exercise control group"|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
41501634|NCT02593110|DRUG|Placebo|
41501635|NCT01883349|PROCEDURE|Kidney Transplant|Kidney Transplant Surgery
41501636|NCT01883349|OTHER|No kidney transplant|The control group was made up of subjects without ESRD and were not on the renal transplantation waitlist.
40845757|NCT05102006|DRUG|Toripalimab Injection|Toripalimab is infused with a fixed dose of 3 mg/kg intravenously every three weeks
40845758|NCT02402283|DRUG|Metronidazole benzoate oral granules|Single oral dose of 400 mg
41367030|NCT03811782|BEHAVIORAL|Dual-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Dual-task Training instructions (20 minutes) and cool down (5 minutes).
41367031|NCT03811782|BEHAVIORAL|Analogy Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Analogy Training instructions (20 minutes) and cool down (5 minutes).
41367032|NCT01425268|DEVICE|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
41367033|NCT01425268|PROCEDURE|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
41028555|NCT05234398|BIOLOGICAL|Blood and saliva samplings|At each protocol visits, on the occasion of a care collection, additional blood and saliva samples will be taken specifically for the study, with a total volume of blood of 38 mL, and a saliva sample of 1.5 to 2 mL per visit (inclusion, month 1, month 4, month 6, month 9 and month 12), corresponding to routine care.
41028556|NCT04174092|OTHER|completing self-questionnaires|completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism
41028557|NCT02099006|DRUG|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
41028558|NCT02099006|DRUG|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
41028559|NCT02099006|DRUG|Ketoprofen|To be applied topically at a 10% concentration
41028560|NCT02099006|DRUG|Ketamine|To be applied topically at a 10% concentration
41028561|NCT02099006|DRUG|Loperamide|To be applied topically at a 5% concentration
41028562|NCT02099006|DRUG|Gabapentin|To be applied topically at a 6% concentration
41028563|NCT02099006|DRUG|placebo|Compounding base to be used alone as a placebo
41028564|NCT04123639|PROCEDURE|PTA|Percutaneous transluminal angioplasty
41028565|NCT02167633|PROCEDURE|Decompression surgery|Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.
41028566|NCT02167633|RADIATION|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume
40845759|NCT02402283|DRUG|Flagyl 400 mg Tablets|Single oral dose of 400 mg
40845760|NCT00196508|DEVICE|High Viscosity DERMABOND|
40845761|NCT00979927|DRUG|SPC3649|5 weekly doses
40845762|NCT00979927|DRUG|saline|5 weekly doses
41028567|NCT02167633|RADIATION|Fractionated Radiotherapy|"Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.~Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume."
41028568|NCT02167633|DRUG|Glucocorticoids|All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
40845763|NCT03028935|BEHAVIORAL|Exercise Intervention|Undergo instructor-led exercise program
40845764|NCT03028935|BEHAVIORAL|Nutritional Intervention|Undergo instructor-led nutritional education program
40845765|NCT05375214|DEVICE|Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)|Novel intermittent theta burst stimulation protocol with individualized targets in the brain for stimulation using structural and functional MRI inputs
41028569|NCT02167633|DRUG|Pantoprazole|All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
41028570|NCT01383070|BEHAVIORAL|Lactational Counseling by Cell phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
41028571|NCT04134663|DRUG|vasoconstrictor and oxytocin treatment|intransal administration of vasoconstrictor and oxytocin
41028572|NCT04134663|DRUG|vasoconstrictor's placebo and oxytocin treatment|intransal administration of vasoconstrictor's placebo and oxytocin
41028573|NCT04134663|DRUG|vasoconstrictor and oxytocin's placebo treatment|intransal administration of vasoconstrictor and oxytocin's placebo
41028574|NCT05906121|DRUG|lidocaine-ketamine infusions|Lidocaine and ketamine are infused over a period of 30 minutes. The dosage of lidocaine is 4mg/kg is maintained throughout the infusions, and the dosage of ketamine is increased within the first three infusions from 0.15mg/kg at the first, to 0.25mg/kg at the second and 0.5mg/kg at the third infusion. In case patients already experiencing sufficient analgesic effect and/or improvement in quality of life after the 1st or 2nd infusion or if side effects do not allow a further dose increase, no further step up of ketamine dosage is made. As a part of this study, at the end of the first, second and third infusion, side effects will be screened using customized questionnaires (SF - MPQ, BDI-II)
41028575|NCT05786677|OTHER|Physiotherapy protocol|"the physiotherapy protocol which will include: 4. Exercise in the form of: d. Breathing exercise e. Aerobic exercise (walking on treadmill with a speed of 3 miles per hour and 0% inclination) f. Bridging exercise 5. Manual techniques in the form of:~1. Suboccipital release~2. Diaphragm release~3. Clavi-pectoral myofascial release 6. Home Routine~c. Hot tub bath for 30 minutes d. Breathing exercise"
41367034|NCT04087551|OTHER|Developing the list of items for BRFES|The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
41501637|NCT03408379|OTHER|Collection of blood sample in aneurysm|"In case of an endovascular treatment :~* A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure.~* Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.~In case of a surgery treatment :~* A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery.~* A Tissue sample will be taken during the surgery~* Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit."
41501638|NCT04492644|OTHER|No intervention|No intervention
41501639|NCT01144247|DRUG|alloreactive CTL|cellular immunotherapy with alloCTL
41501640|NCT06494462|OTHER|virtual reality training|students will watch a video about subcutaneous injection or students will play a about subcutaneous injection by virtual reality glasses
41501641|NCT06113302|DRUG|Luspatercept|Given by SC or (Injection)
40845766|NCT05382611|DIAGNOSTIC_TEST|ngs next generation sequencing|the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS
40845767|NCT06000605|OTHER|Fed|Participants will eat a light meal prior to testing and be fed a light meal during testing.
40845768|NCT06000605|OTHER|Fasted|Participants will completely abstain from calories for 72 hours prior to testing and not receive any calories during testing.
40845769|NCT02443818|DRUG|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
40845770|NCT03594812|DEVICE|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45º. The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis.
40845771|NCT03594812|DEVICE|Radiofrequency without power|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45ºC (Celsius degrees). The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis. In this group, the radiofrequency device was switched off.
40845772|NCT03594812|DEVICE|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
40845773|NCT05549557|DRUG|IMM40H|IMM40H is a monoclonal antibody with a molecular generated from ImmuneOnco's antibody platform. IMM40H targets CD70 (a tumor cell marker).
41028576|NCT05786677|DRUG|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRIs)
41028577|NCT02359721|DRUG|tablet clarithromycin 500 mg (Clarino-500) orally|orally
41028578|NCT00000435|DRUG|dnaJ peptide|dnaJP1 was taken in pill form at 25mg/day for 6 months
41028579|NCT00000435|DRUG|None-placebo|placebo was taken in pill form at 25mg/day for 6 months
41028580|NCT05903560|PROCEDURE|endovascular recanalization via radial approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach
41367035|NCT03535337|BEHAVIORAL|CPS|Assessment of participant's medication adherence and barrier problem solving via phone conversation
41367036|NCT03535337|BEHAVIORAL|SMS|Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.
41367037|NCT03088306|DRUG|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
41501642|NCT03766412|OTHER|High School start time|The time that the school starts
41501643|NCT04762498|BIOLOGICAL|Pegloticase|IV dose of pegloticase q4 weeks co-administered with weekly oral methotrexate
41501644|NCT04762498|DRUG|Methotrexate (MTX)|15 mg oral dose methotrexate administered weekly
41501645|NCT00922740|DRUG|VA106483|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
41501646|NCT00922740|DRUG|Placebo|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
40845774|NCT05964543|DRUG|Q-1802 Injection,Oxaliplatin Injection,Capecitabine|Q-1802：A dose Q-1802 will be administered intravenously Q2W. XELOX（oxaliplatin，capecitabin）: 21 days as a cycle Oxaliplatin will be administered 130mg/m2 as a 2-hour IV infusion,administer once on the first day, with 21 days as a cycle Capecitabine will be administered 1000mg/m2 orally twice daily (D1-D14),21ds is one cycle.
40845775|NCT00490776|DRUG|Panobinostat|Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
41028581|NCT05903560|PROCEDURE|endovascular recanalization via femoral approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach
41028582|NCT05437627|DIAGNOSTIC_TEST|The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults|"Assessment of stuttering severity: The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults will be applied for assessment of severity of stuttering. (3).~Automatic detection and severity assessment of stuttering using MATLAB version 8.1.0.604 R2013a (7). Stuttering detection system has three main steps which are acoustic processing, feature extraction and classification/recognition"
41501647|NCT03159338|BIOLOGICAL|Platelet rich fibrin|Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.
41501648|NCT03159338|BIOLOGICAL|Placebo|In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
41501649|NCT04173832|DRUG|Tianqi Pingchan Granule Combined With Amantadine|Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
41367038|NCT03088306|DRUG|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
41367039|NCT03088306|DRUG|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
41367040|NCT03088306|DRUG|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
41367041|NCT03088306|DRUG|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
41367042|NCT03088306|DRUG|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
41367043|NCT03088306|DRUG|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
41367044|NCT03088306|DRUG|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
41367045|NCT04545645|BEHAVIORAL|median nerve mobilization|The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.
41501650|NCT04173832|DRUG|Placebo Combined With Amantadine|Placebo and Amantadine are given to patients simultaneously
41501651|NCT05439083|BIOLOGICAL|9-valent HPV vaccine|All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.
41501652|NCT06633809|OTHER|Immediate endovascular therapy|The best medical therapy includes intravenous fibrinolysis, anticoagulants or antiplatelet, but NOT any immediate endovascular therapies.
41501653|NCT04207463|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
41501654|NCT04207463|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
41501655|NCT05746832|PROCEDURE|Endoscopic stenting Retrograde Cholangiopancreatography (ERCP)|Assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large \[≥ 20 mm\] or multiple \[≥ 3 sized ≥ 15 mm\] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
41028583|NCT00422539|DRUG|70% trichloroacetic acid|
41161454|NCT01963442|BIOLOGICAL|blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry|
41501656|NCT05986591|COMBINATION_PRODUCT|Test Product - Tiotropium Bromide Inhalation Powder 18 mcg|Test Product
41501657|NCT05986591|COMBINATION_PRODUCT|Spiriva Handihaler (Tiotropium Bromide) 18 mcg|RLD
41501658|NCT05986591|COMBINATION_PRODUCT|Placebo|Placebo Product
41501659|NCT04811560|DRUG|Bleximenib|Bleximenib is administered orally.
41028584|NCT06021717|DRUG|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
41028585|NCT06021717|DRUG|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
41028586|NCT03585647|PROCEDURE|hip arthroplasty|Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.
41028587|NCT00725894|DEVICE|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
41028588|NCT00661492|DRUG|cetuximab|Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
41028589|NCT00661492|DRUG|Mitoxantrone|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
41028590|NCT00525317|DRUG|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"|120 mg x 3 or placebo
41161455|NCT01963442|DRUG|Augmentin|2 tablets 3 times a day for 5 days from Day 3
41161456|NCT01963442|DRUG|Placebo (for Augmentin)|2 tablets 3 times a day for 5 days from Day 3
41161457|NCT01963442|DRUG|Beta-Lactams|administered from Day 0 to Day 3
41501660|NCT04234932|DRUG|Netarsudil Ophthalmic|Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)
41501661|NCT06549855|DRUG|Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)|"1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks~2. MA, 320mg/MPA, 500mg, po, once a day"
41367046|NCT04545645|BEHAVIORAL|Neural stress provocation with cognitive auditory distraction|Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.
41367047|NCT04545645|BEHAVIORAL|Providing neural stress with a motor distraction|The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.
41367048|NCT04545645|BEHAVIORAL|Neural stress provocation with auditory and motor cognitive distraction.|The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
41367049|NCT01874288|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
41367050|NCT00989417|OTHER|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
41367051|NCT04215159|DRUG|Trastuzumab biosimilar|1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
41367052|NCT04215159|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
41367053|NCT04215159|DRUG|Irinotecan Hydrochloride|100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks.
41028591|NCT04446663|DRUG|Toripalimab|Toripalimab 240mg ivdrip, every 3 weeks for 6 cycles, with 3 cycles combined with induction chemotherapy, 3 cycles combined with concurrent chemoradiotherapy
41028592|NCT04446663|DRUG|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 260 mg/m2, d1 of every cycle, every 3 weeks for 3 cycles before radiotherapy
41367054|NCT05951257|BEHAVIORAL|Personalized multimodal intervention involving hypnosis and/or music|"The three intervention modalities (music and/or hypnosis) will begin by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself. The hypnosis modality consists in visiting in imagination a pleasant place that the participant will choose and to live some metaphorical stories. The musical modality consists of listening to one or two pieces of music chosen by each participant and which brings him/her well-being, according to them. These two types of work will be preceded by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself."
41028593|NCT04446663|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiotherapy Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiotherapy
41367055|NCT02850757|DEVICE|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
41367056|NCT02850757|DEVICE|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
41367057|NCT05294510|OTHER|STAR Sick Child Job Aid|The STAR Sick Child Job Aid is a modified ICCM protocol that includes the addition of a point-of-care C-reactive protein (CRP) test to inform antibiotic treatment decisions for children presenting with febrile acute respiratory illness who do not have any danger signs. If CRP ≥ 40 mg/L, the village health worker (VHW) will dispense amoxicillin per local guidelines. If CRP \< 40 mg/L, the VHW will advise symptomatic care alone including acetaminophen for fever and additional fluids to maintain hydration.
41367058|NCT02030067|DRUG|RX-3117|
41367059|NCT04650932|DEVICE|Deep brain stimulation|Patients with idiopathic Parkinson's disease who have previously been implanted with the Boston Scientific VerciseTM DBS system for at least 3 months. These patients will already be receiving high-frequency dorsal STN stimulation as part of the standard of care for PD. Once patients have provided consent and are enrolled in this study, they will receive simultaneous low-frequency stimulation of the ventral STN to examine if there are any effects on cognitive performance.
41367060|NCT06231186|RADIATION|iHD-SRT|received isotoxic individualized fSRT, with BED 10\>50Gy and \<100Gy, and strict OAR limits
41367061|NCT00275834|DRUG|Zonisamide|zonisamide 400 mg, 200 mg, or placebo
41028594|NCT04446663|RADIATION|intensity-modulated radiotherapy|Definitive IMRT of ≥66 Gy will be given .
41161458|NCT01618227|DEVICE|Joint Active Systems (JAS) Static progressive splint|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises throughout the study. Upon receipt of the splint, subjects will be instructed in proper application and use by their treating therapist or a representative of the company. Subjects will be instructed to follow the daily splint wearing protocol provided by the device manufacturer.
41161459|NCT01618227|PROCEDURE|Rehabilitation without splinting|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises without additional splinting.
41161460|NCT04719819|PROCEDURE|Spinal anaesthesia for caesarean section|Descriptive questionnaire with open and closed questions, to be completed during the procedure
41367062|NCT02924467|BEHAVIORAL|1 Notice|1 Reminder notification via autodialer
41367063|NCT02924467|BEHAVIORAL|2 Notices|2 Reminder notifications via autodialer
41028595|NCT05893108|DRUG|Ethosomal gel bearing losartan 5%|A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%
41028596|NCT05893108|DRUG|triamcinolone acetonide 10 mg/ml|intralesional injection
41028597|NCT03238235|DRUG|givinostat|suspension of givinostat (10 mg/mL)
41028598|NCT03238235|DRUG|placebo|suspension manufactured to mimic givinostat
41367064|NCT02924467|BEHAVIORAL|3 Notices|3 Reminder notifications via autodialer
41367065|NCT05780749|DIETARY_SUPPLEMENT|DDI-IBS-001|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.
41367066|NCT05780749|OTHER|DDDI-IBS-001 placebo|The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.
41367067|NCT00318032|DRUG|multi-factorial intervention|
41367068|NCT02146911|DRUG|Bupropion|
41367069|NCT02146911|DRUG|Varenicline|
41501662|NCT02318303|DRUG|GSP 301-1 NS (QD)|GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril
41161461|NCT01990911|DEVICE|Renal denervation|In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.
41161462|NCT01990911|DRUG|Medical therapy|Subjects will continue on their standard medical therapy as prescribed by their treating physician
41161463|NCT04376242|BEHAVIORAL|use of virtual reality|The intervention is a virtual reality program designed to immerse participants in a gaming experience to improve anxiety and fear during an oral food challenge.
41367070|NCT02146911|BEHAVIORAL|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
41161464|NCT04376242|BEHAVIORAL|use of standard technology|the active comparator group will be allowed standard technology for distraction during oral food challenge which can include TV, non-VR gaming, tablets and smart phones.
41161465|NCT01026883|OTHER|Blood draw|A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
41161466|NCT03526471|DEVICE|Omega™ Left Atrial Appendage (LAA) Occluder|catheter delivery of Omega device in the left atrial appendage
41161467|NCT01533558|DRUG|caspofungin|normal dosage for caspofungin, not adapted for the study
41501663|NCT02318303|DRUG|GSP 301-2 NS (BID)|GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril
41501664|NCT02318303|DRUG|GSP 301 Placebo NS|GSP 301 placebo NS administered as 2 sprays/nostril
41501665|NCT02318303|DRUG|Olopatadine HCl-1 NS (QD)|Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril
41501666|NCT02318303|DRUG|Olopatadine HCl-2 NS (BID)|Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril
41501667|NCT02318303|DRUG|Mometasone Furoate-1 NS (QD)|Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril
41161468|NCT00550771|DRUG|doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|doxorubicin 60 mg/m\^2 IV push + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
41161469|NCT00550771|DRUG|PLD, cyclophosphamide, trastuzumab, paclitaxel|PLD 35 mg/m\^2 IV over 60 minutes + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
41161470|NCT04748497|OTHER|Standardization of evaluation and follow-up|"Standardization of evaluation and clinical and sportive follow-up of athletes.~Made-to-measure technical supports will be tested regarding the Paralympic regulations."
41161471|NCT04115371|BEHAVIORAL|Intervention|Geriatric assessment and care coordination provided by a multidisciplinary team in the emergency department including transitional care nurses, social workers, pharmacists, occupational therapists, and physical therapists.
41161472|NCT05221684|PROCEDURE|Lymph node harvesting|Lymph node harvesting after radical resection for rectal cancer with curative intent
41161473|NCT00657475|DRUG|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
41161474|NCT00657475|DRUG|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
41161475|NCT06413017|DRUG|Nimotuzumab|Nimtuzumab：400mg,i.v.,once a week,until tumor progression、Death or untalerable toxicity
41161476|NCT06413017|DRUG|ICIs(Immune checkpoint inhibitors)|Use it as it is describe in the instructions from the specification
41161477|NCT00905814|DRUG|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
41161478|NCT00905814|DRUG|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
41367071|NCT04190199|OTHER|Observational|Cross-sectional only
41367072|NCT02045940|DRUG|GSK2881078|Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
41367073|NCT02045940|DRUG|Placebo|Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
41367074|NCT02509195|DRUG|Triumeq|Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
41367075|NCT02738931|DRUG|Dolutegravir 50 mg tablet|A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
41367076|NCT02738931|DRUG|Lamivudine 300 mg tablet|"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."
41367077|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
41367078|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
41367079|NCT04692324|PROCEDURE|Biospecimen Collection|Undergo collection of CSF samples
41367080|NCT04692324|OTHER|Electronic Health Record Review|Review of medical records
41367081|NCT04692324|OTHER|Survey Administration|Ancillary studies
41367082|NCT05397002|PROCEDURE|patient specific inverted L mandibular osteotomy modified with inferior alveolar nerve relocation|preoperative CBCT was requested for virtual planning and fabrication of cutting and drilling guides. Cutting lines were outlined to be consisted of four cuts; lateral ostectomy to uncover and lateralize the inferior alveolar nerve (IAN), posterior cut run horizontally from the anterior border of the ramus to a point just above the mandibular foramen, two anterior vertical cuts run from the anterior end of the lateral ostectomy to the inferior mandibular border. The guide was removed and the osteotomy lines were completed then the mandibular setback was oriented and fixed using pre-bent plates osteosynthesis. Plane transfer was checked using CBCT and Inferior alveolar nerve function was assessed.
40845776|NCT06171646|BEHAVIORAL|breathing exercise|The patients in the intervention group will first be informed by the researcher about pursed lips and diaphragmatic breathing exercises through a face-to-face interview technique, and then the breathing exercises will be taught practically to each patient for approximately 30 minutes, and the first session will be held. Each session takes place once a day in the morning, lasts 10-15 minutes and is applied every day; Sessions other than the first session will consist of 10 pursed lip breathing exercises, relaxation (2 minutes) and 10 diaphragmatic breathing exercises; Three days a week, the researcher will be reminded via online video call once a day in the morning, and on the other days, the patients will be reminded by phone call that they will be asked to do themselves, and breathing exercises will be performed for a total of four weeks.
41028599|NCT04095377|OTHER|No intervention, this is a retrospective study.|No intervention, this is a retrospective study.
41028600|NCT04710797|PROCEDURE|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels~* The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve"
41028601|NCT04710797|PROCEDURE|Comprehensive staging surgery with no Lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes"
41367083|NCT01985555|DRUG|Volitinib(HMPL-504)|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
41367084|NCT00138723|DRUG|SPM 907|
41367085|NCT02004457|BEHAVIORAL|ABBT|
41028602|NCT00058266|DIETARY_SUPPLEMENT|genistein|Given orally
41028603|NCT00058266|PROCEDURE|conventional surgery|Patients undergo surgery
41028604|NCT02011880|DIETARY_SUPPLEMENT|Chinese Herbs|"Dietary Supplement:Experiment group:~Fructus Cnidii,Psoralea Corylifolin L.，monkshood~-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g，Psoralea Corylifolin L. 15g，monkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Dietary Supplement:Contrast Group:~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity"
41028605|NCT00363766|DRUG|LY573636-sodium|A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
41028606|NCT01732393|DRUG|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
41028607|NCT01732393|DRUG|Placebo|
41028608|NCT03870763|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
41028609|NCT03870763|DRUG|Peginterferon Beta-1a|Administered as specified in the treatment arm.
41161479|NCT01296178|DRUG|IDARUBICINE|"Administration of chemotherapy induction~Idarubicin IV Dose of 12 mg/m2/day days 1 to 3"
41367086|NCT02004457|OTHER|TAU|
41367087|NCT02576106|DEVICE|Cryoablation|
41367088|NCT00895999|BEHAVIORAL|Interpersonal Therapy for Pain (IPT-P)|IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.
41501668|NCT02318303|DRUG|Mometasone Furoate-2 NS (BID)|Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril
41501669|NCT00010530|PROCEDURE|Meditation|
41028610|NCT03870763|DRUG|Placebo|Administered as specified in the treatment arm.
41028611|NCT03349710|BIOLOGICAL|Nivolumab|Specified dose on specified day
41028612|NCT03349710|DRUG|Cetuximab|Specified dose on specified day
41028613|NCT03349710|DRUG|Cisplatin|Specified dose on specified day
41028614|NCT03349710|RADIATION|Radiotherapy|Specified dose on specified day
41028615|NCT05796752|DRUG|Memantine|Cognition-enhancing medication
41028616|NCT05796752|BEHAVIORAL|ComB Behavioral Therapy|Therapy for BFRBs
41501670|NCT06474208|DRUG|Formulation 1|Oral suspension of Vericiguat (BAY1021189) in single dose (SD).
41501671|NCT06474208|DRUG|Formulation 2|Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.
41501672|NCT06474208|DRUG|Formulation 3|Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.
41367089|NCT00895999|BEHAVIORAL|Enhanced Support and Connection to Counseling|Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
41367090|NCT02133612|DRUG|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
41367091|NCT02889926|BIOLOGICAL|a swab according to the method of Levine|A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.
41367092|NCT02889926|BIOLOGICAL|Bacteriological referred to biopsy|Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
41367093|NCT03914131|DRUG|Xinnaoning Capsule|Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
41367094|NCT03914131|OTHER|Xinnaoning Capsule Simulator|Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
41501673|NCT06474208|DRUG|Formulation 4|Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose and flavor in SD.
41501674|NCT06474208|DRUG|Formulation 5 (placebo)|Matching placebo of formulation 1 in SD.
41501675|NCT02234219|PROCEDURE|Heart-shape anastomosis|a new operation approach for Hirschsprung disease
41501676|NCT02234219|PROCEDURE|Soave anastomosis|traditional approach for Hirschsprung disease
41501677|NCT05329259|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One dose of 13vPnC (0.5mL) will be administered intramuscularly.
41501678|NCT04774744|OTHER|Educational Intervention|Receive digital health coaching program
41501679|NCT04774744|OTHER|Questionnaire Administration|Ancillary studies
41501680|NCT04774744|OTHER|Supportive Care|Receive standard of care support services
41501681|NCT06633627|OTHER|Recording of brain activity using electroencephalography (EEG)|Electroencephalography (EEG) responses to sensitivity stimuli applied to the teeth in patients with and without dentine hypersensitivity will be compared
41501682|NCT01537939|BEHAVIORAL|ASUKI Step Worksite Pedometer Intervention|The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
41501683|NCT00328848|BEHAVIORAL|Behavioral|Group Treatment(patient education, self management support, caregiver support)
41367095|NCT03219372|DRUG|Pravastatin Pill|statin
41367096|NCT03219372|DRUG|Placebo Oral Tablet|placebo
41367097|NCT04893174|BIOLOGICAL|UMC119-06-05|"Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.~Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05"
41367098|NCT04893174|DEVICE|Hyaluronic acid|IA injection of hyaluronic acid.
41367099|NCT05205941|DRUG|MMV688533|Not exceeding 200mg
41367100|NCT05981560|OTHER|Group A - Closed Chain Exercise|17 participants were in experimental group giving them closed chain exercise plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks
41501684|NCT00328848|BEHAVIORAL|behavioral|patient education, self management support, caregiver support
41501685|NCT05298761|DRUG|Lignocaine|Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs
41501686|NCT01616030|OTHER|Knee-extension strength training of the fractured limb|Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
41501687|NCT03585634|BEHAVIORAL|Dads in Gear Program|
41501688|NCT00567684|DEVICE|Computed Tomography Urography (CTU)|CTU performed at least a day before or after the IVU procedure.
41501689|NCT00567684|OTHER|Intravenous Urography (IVU)|A routine IVU procedure performed prior to or after CTU.
41501690|NCT05695131|DEVICE|GlenXRose Virtual Reality Speech Therapies|Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations
41501691|NCT06247371|BEHAVIORAL|Decision aid|The Singapore developed HF DA is a A3 sized one-page poster designed to convey information about HF medications options (ACEI and ARNI only) and their pros and cons. The DA contains informative attributes of both medications that are presented side by side for comparison. These attributes include subsidized cost, frequency of use, duration of use, route of administration, low blood pressure side effect rate and benefits such as non-hospitalization rate and survival rate.
41501692|NCT03900598|DRUG|JNJ-67856633|JNJ-67856633 capsule will be administered orally.
41501693|NCT01322230|OTHER|Control|Multimedia Control
41501694|NCT01322230|OTHER|WISEMD Original|Current WISEMD
41028617|NCT06494111|DRUG|Pravastatin|Given by PO
41028618|NCT06494111|DRUG|Pentoxifylline|Given by PO
41028619|NCT06494111|DRUG|Tocopherol|Given by PO
41028620|NCT03574220|DRUG|Pembrolizumab|200mg IV every 21 days over 6 months
41161480|NCT01296178|DRUG|ARA-C|ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7
41501695|NCT01322230|OTHER|Social Networking|Social networking feature
41028621|NCT03574220|RADIATION|Stereotactic body radiotherapy|50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
41367101|NCT05981560|OTHER|Group B - Neuromuscular Training Exercise|17 participants were in experimental group giving them neuromuscular training plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks.
41367102|NCT01348828|DEVICE|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
41367103|NCT05906043|BEHAVIORAL|Exercise Intervention|Exercise intervention
41367104|NCT05906043|BEHAVIORAL|Acceptance and Commitment Therapy|ACT will be used for patients with psychological disability as well as for those with sleep disturbance
41367105|NCT05906043|DIETARY_SUPPLEMENT|Probiotic|Use of a probiotic
41501696|NCT01322230|OTHER|Social Networking plus Emotional Design|social networking features plus user interface enhancements
41028622|NCT03495336|OTHER|coffee abstention phase|no coffee consumption for 2 weeks
41028623|NCT03495336|OTHER|LR Coffee consumption|for 4 weeks participants consumed only LR Turkish coffee
41028624|NCT03495336|OTHER|DR Coffee consumption|for 4 weeks participants consumed only DR Turkish coffee
41028625|NCT04578262|PROCEDURE|Epley Manoeuvre|This manoeuvre is constituted by five steps. In the first step, while the patient is in supine posture the head will be positioned 45 degrees turned towards the unaffected ear and the head slightly overhang on the edge of the couch. In this second step maintaining the previous position of the head, physiotherapist will turn head 45 degrees turned towards the affected ear. Next, in the third step, the whole body will turn until is located 135 degrees from the baseline supine position. In the fourth step, while the head keeps turned to the affected ear the subject will be incorporated until he is sitting. In the fifth step, while the subject is seated with the head in neutral position the chin will be bended 20 degrees. Each procedure will be held among 30 seconds or two minutes, while the dizziness or the nystagmus vanish. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
41028626|NCT04578262|PROCEDURE|Sham Manoeuvre|The sham manoeuvre consist is going to star with the participant in a neutral seated position. Sum to it, head is rotated 45 degrees towards the unaffected vestibule. After that, the participant will be guided by the physiotherapist to a lateral decubitus position towards the affected side on which his nose will be pointing above. To conclude, the seated position will be reached again without head rotation. Each position of the sham manoeuvre will be maintained along one minute. During all the process the videonystagmography glasses will be dressed by participants and they will be indicated not to close eyes in the intervention. After the execution of the manoeuvre, also this group will be evaluated 48 hours after. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
41028627|NCT03403725|DRUG|MEN1309|MEN1309 solution for intravenous infusion once every 3 weeks
41028628|NCT06234345|DRUG|Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg|Participants randomized to this group will receive 1 capsule per inhalation twice a day
41028629|NCT06234345|DRUG|Comparator - Trimbow®|Participants randomized to this group will receive 2 triggering twice a day
41028630|NCT00377195|RADIATION|Involved Field Radiotherapy|"The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days."
41028631|NCT03269032|OTHER|American Diet|"According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, \>11% Saturated Fatty Acids, \<12% Monounsaturated Fatty Acids, and \>8% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
41028632|NCT03269032|OTHER|Mediterranean-style Diet|"The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, \<7% Saturated Fatty Acids, \>18% Monounsaturated Fatty Acids and \<5% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
41028633|NCT02162810|DRUG|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
41161481|NCT02615834|PROCEDURE|Gentle chest pressure|Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
41367106|NCT03907059|DIETARY_SUPPLEMENT|whey protein|supplementation individually adjusted to 1.6g/kg/day
41367107|NCT03907059|DIETARY_SUPPLEMENT|soy protein|supplementation individually adjusted to 1.6g/kg/day
41367108|NCT06252831|DRUG|"AS-Probionorm"|"Dosage form - powder for the preparation of a solution for oral administration. Dosage regimen -1 sachet (1 g) take 2 times a day with an interval of 12 hours. Apply 15-20 minutes before meals in the morning and evening. Before use, the medicine is mixed with 30-50 ml of boiled water at room temperature, resulting in a cream-colored suspension. The resulting aqueous suspension should be drunk without achieving complete dissolution. The diluted drug cannot be stored. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis.~The total duration of each subject's participation in the clinical trial is no more than 21 ± 1 days. Throughout the entire study period, the research subject has the opportunity to contact the research team on all questions relating to the nature of this study. After completion of the entire observation period of 21 days, there is no follow-up of study subjects under the trial protocol."
41367109|NCT02550418|DRUG|Budesonide|
41367110|NCT04096924|DEVICE|Guidewire for echo-guided interventions|Under echocardiography guided treatment of ASD with a novel interventional guidewire
41501697|NCT00002444|DRUG|Nitazoxanide|
41501698|NCT06630169|COMBINATION_PRODUCT|Cryopreserved AURN001|Corneal Endothelial Cells and Y27632
41501699|NCT03706937|OTHER|Semi directive interview|Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
41501700|NCT02466841|PROCEDURE|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
40845777|NCT06351722|DIAGNOSTIC_TEST|Before non-surgical periodontal treatment|"Clinical Measurements and Laboratory Measurement Saliva and serum samples will be collected from all patients initially. Clinical parameters will also be recorded initially. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing.~Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time PCR."
41367111|NCT04096924|DEVICE|Cook lunderquist guidewire|Subjects with ASD treated with amplatzer using the Cook lunderquist guidewire.
41367112|NCT01614028|PROCEDURE|Total Hip Arthoplasty|
41367113|NCT04908787|DRUG|BD0801|Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
41367114|NCT04908787|DRUG|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2
41367115|NCT04908787|DRUG|Placebo|Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
41501701|NCT02448368|DRUG|RDEA3170,10 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
41501702|NCT02448368|DRUG|RDEA3170, 2.5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
41501703|NCT02448368|DRUG|RDEA3170, 5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
41501704|NCT02448368|DRUG|RDEA3170, 10 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
41501705|NCT02448368|DRUG|RDEA3170, 2.5 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
41501706|NCT00413881|PROCEDURE|WAVEFRONT- GUIDED LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
41501707|NCT00413881|PROCEDURE|CONVENTIONAL LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
41367116|NCT04908787|DRUG|Topotecan|Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2
41367117|NCT04908787|DRUG|doxorubicin liposome|Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
41367118|NCT04907201|PROCEDURE|Cryoneurotomy|Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.
41367119|NCT01979250|PROCEDURE|DSAEK surgery|"Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK)."
41367120|NCT06145945|DRUG|0.5% Ropivacaine|20ml 0.5% ropivacaine is sprayed intraperitoneally
41501708|NCT01617252|DEVICE|Optiflow / Facial mask|J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
41501709|NCT05856630|DRUG|Goserelin Acetate Sustained-Release Microspheres for Injection|10.8mg, Single dose, subcutaneously（SC）
41028634|NCT02162810|DRUG|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
41028635|NCT04367168|DRUG|Colchicine|Colchicine 1mg, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
41028636|NCT04367168|DRUG|Placebo oral tablet|Placebo, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
41028637|NCT03561779|DRUG|YYD302 2ml|YYD302 2ml
41367121|NCT06145945|DRUG|Saline|20ml saline is sprayed intraperitoneally
41367122|NCT03344029|BIOLOGICAL|SP Shz TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
41367123|NCT03344029|BIOLOGICAL|Hualan TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
41367124|NCT01933269|DRUG|FACBC|
41367125|NCT02070952|RADIATION|CyberKnife Stereotactic Ablative Body Radiation Therapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
41367126|NCT05141422|DRUG|SHR2150 tablet、efavirenz|SHR2150 tablet single dose, Efavirenz single dose.
41367127|NCT01821391|DRUG|NDL-PDT|Metvix natural daylight photodynamic therapy
41501710|NCT05856630|DRUG|Zoladex 10.8 MG Drug Implant|10.8mg, Single dose, subcutaneously（SC）
41501711|NCT05076214|BEHAVIORAL|Aerobic exercise in group|"The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~Week 1- 6: 12-18 repetitions (reps) x 2 set per exercise and muscle 30 seconds (s) rest between exercise Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~Week 1- 6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises Mixed sessions~Week 1- 6: 35 s work time per exercise 25 s rest between exercises x 2 rounds Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
40845778|NCT06351722|PROCEDURE|non-surgical periodontal treatment|Treatment will be performed using ultrasonic devices followed by root planing with gracey curettes. SRP will be completed in two visits, each consisting of quadrants every 2 days. Oral hygiene instructions will include demonstrating proper brushing techniques and the use of interdental cleaning aids as needed. Saliva and serum samples will be collected again at the 3-month follow-up visit, all clinical parameter records will be repeated by the same clinician (ZTE), and oral hygiene instructions will be reconfirmed as needed. After the collection of 3-month records and samples, all patients with persistent pockets will be subjected to a standard periodontitis treatment protocol.
40845779|NCT06351722|DIAGNOSTIC_TEST|3rd month after non-surgical periodontal treatment|"All clinical and laboratory evaluations described under the heading Before non-surgical periodontal treatment will be repeated in the 3rd month after NSPT."
40845780|NCT01705678|DIETARY_SUPPLEMENT|Krill oil|Krill oil 300 mg DHA/EPA daily for 6 weeks
41028638|NCT03561779|DRUG|Active comparator: Synovian Inj.|Active comparator: Synovian Inj.
41367128|NCT01821391|DRUG|c-PDT|Metvix conventional photodynamic therapy
41367129|NCT01821391|DRUG|placebo c-PDT|Metvix placebo conventional photodynamic therapy
41367130|NCT00755560|DRUG|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
41367131|NCT00755560|DRUG|Placebo|Placebo BID for 15 days
41367132|NCT01857570|RADIATION|Volume Computed Tomography of the wrist and carpus|
41367133|NCT03890731|DRUG|BAY73-4506 (Regorafenib, Stivarga)|Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
41367134|NCT02702076|DRUG|Apomorphine|Continuous subcutaneous infusion of apomorphine during waking day
41367135|NCT02702076|DRUG|Placebo|Continuous subcutaneous infusion of placebo during waking day
40845781|NCT01705678|DIETARY_SUPPLEMENT|Fish oil|Fish oil 500 mg DHA/EPA daily for 6 weeks
40845782|NCT01595555|BEHAVIORAL|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
40845783|NCT01707381|DRUG|BOL-303259-X|Topical ophthalmic solution
41028639|NCT02258633|OTHER|Interactive interview and tailored family centered seatbelt safety intervention|
41028640|NCT05282524|DEVICE|Transvaginal ultrasound performed by a woman herself (with remote healthcare professional supervision)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
41367136|NCT05259124|DEVICE|positional perfusion index variation|positional perfusion index variation to predict spinal anesthesia-induced hypotension in elderly patients
41367137|NCT02960191|DEVICE|Magnetic resonance imaging (MRI)|
41367138|NCT06379854|OTHER|chest physiotherapy|Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy
41367139|NCT06379854|OTHER|trunk rotation exercises,deep diaphragmatic also chest physiotherapy|"Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy~Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Deep Diaphragmatic Breathing Exercise F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy TLFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises TFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises"
41367140|NCT01734070|OTHER|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
41501712|NCT05076214|BEHAVIORAL|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together
41501713|NCT01987310|DRUG|atorvastatin|atorvastatin 20 mg per day for 6 months
40845784|NCT01707381|DRUG|Timolol maleate|Topical ophthalmic solution
41028641|NCT04559139|DRUG|Cisplatin|Given IV
41028642|NCT04559139|DRUG|Gemcitabine Hydrochloride|Given IV
41028643|NCT04559139|PROCEDURE|Lymphadenectomy|Undergo portal lymphadenectomy
41028644|NCT04559139|PROCEDURE|Partial Hepatectomy|Undergo partial hepatectomy
41028645|NCT02824276|DRUG|Oxycodone or morphine sulfate immediate release (MSIR)|Oxycodone or morphine sulfate immediate release (MSIR)
41028646|NCT02824276|DRUG|Placebo Treatment|Lactose (Appearance and Weight-matched placebo capsules)
41028647|NCT04592757|DEVICE|Virtual mirror therapy via VR headset|Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
41028648|NCT05081414|BEHAVIORAL|Program for Teaching Self-Care in HF (PEAC-IC)|As described previously
41028649|NCT00325299|DRUG|Magnesium|
41028650|NCT01851005|DRUG|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
41028651|NCT01851005|DRUG|Sevoflurane|Control Vol% to maintain BIS 40\~45
41367141|NCT02852239|DRUG|dabrafenib|Single dose dabrafenib 100 mg
41367142|NCT00689611|DRUG|Bupropion HCl ER|150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
41501714|NCT01987310|BEHAVIORAL|lifestyle counseling|lifestyle modification by dietician counseling and follow up
41028652|NCT01851005|DRUG|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40\~45 and changes of vital signs within 20%.
41028653|NCT01851005|DRUG|Normal saline|Use as placebo
41367143|NCT00689611|DRUG|Placebo|Placebo
41367144|NCT03011931|DRUG|Simvastatin|20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
41501715|NCT01390532|DEVICE|3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)|"Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (\>85% PHR).~Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA)."
41501716|NCT00195338|DRUG|etanercept|
40845785|NCT01443507|OTHER|endurance exercise of different duration and intensity|Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
41028654|NCT01851005|DRUG|Rocuronium|0.8 mg/kg for induction
41028655|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
41028656|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 60mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
41367145|NCT05784142|RADIATION|hypofractionated radiation therapy|"* Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~* Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~* Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity."
41367146|NCT01834937|DEVICE|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
41367147|NCT05469711|DEVICE|PlayPhysio|The gamification will be switched on at day 28 for the participants in arm 1. The trial will run for a further 84 days with the mid-point review half way through this section of the trial.
41367148|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN HEALTHY WITH INTRASUBJECT CONTROL|The corresponding product (HFA -Mepentol®- or EVOO - Farmaoliva®- depending on the study group assigned) will be applied to the subject's right heel, while the contralateral, left, heel will remain as a control. To ensure that the product is completely absorbed into the skin, the subject will then be asked to remain lying face up, at an angle of 30º to the bed, for one hour. The Doppler and infrared laser probes will then be placed on each heel (on the calcaneal tuberosity), for approximately four hours. The subjects will be asked to keep their lower body immobile, but will be able to move their arms and neck gently. Average values for capillary blood flow, local temperature and tissue oxygenation will be collected at 15-minute intervals, although the first 15-minute reading, while the parameters are becoming established, will be discarded.
41501717|NCT06222333|BEHAVIORAL|Respiratory physiotherapy|In this group of patients, in addition to routine analgesic treatment, triflow use and deep breathing training would be given by the physiotherapist. Patients in this group will do breathing exercises 8 hours a day, 10 times an hour.
41501718|NCT06222333|DRUG|Conservative Treatment|Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.
41501719|NCT01380600|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10\^6 pfu/kg, 1x10\^7 pfu/kg, 3x10\^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
41501720|NCT04228835|DIAGNOSTIC_TEST|Fluorescence Cholangiography|Administration of ICG for fluorescence cholangiography
41501721|NCT05646797|DRUG|ASP2074|intravenous (IV) infusion
41501722|NCT05669755|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
41501723|NCT05669755|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
41028657|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
41501724|NCT05669755|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
41501725|NCT05102552|DRUG|SPN-817, Treatment B|SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
41028658|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
41501726|NCT05102552|DRUG|SPN-817, Treatment C|SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
41501727|NCT05102552|DRUG|BIS-001, Treatment A|BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
41028659|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
41028660|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
41028661|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
41028662|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
41161482|NCT00168714|DRUG|BG9418 (interferon beta-1a)|Exposure to Avonex during pregnancy
41161483|NCT05755217|DIETARY_SUPPLEMENT|Dark chocolate|Single oral dose of 1g/kg of dark chocolate (70% cocoa).
41161484|NCT05755217|DIETARY_SUPPLEMENT|White chocolate|Single oral dose of 1g/kg of white chocolate (4% cocoa).
41161485|NCT06283511|OTHER|educational workshops|patient will be proposed to assist to educational workshops + the possibility to assist to a physical rehabilitation programme
41161486|NCT03922295|PROCEDURE|Endoscopic tympanoplasty|"In the double flap group, graft is placed via elevation of both posterior and anterior flaps.~In the single flap group, graft is placed via elevation of posterior flap only"
41028663|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
41161487|NCT04528537|OTHER|questionnaire|16-item quality of recovery questionnaire for the postanesthesia care unit (QoR-PACU)
41161488|NCT02449993|DEVICE|MammaTyper™|MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
41028664|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 8 cycles. Then pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle until progression or intolerable toxicities.
41028665|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 8 cycles.
41161489|NCT01605435|DRUG|Ghrelin Group 1|The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
41161490|NCT01605435|DRUG|Ghrelin Group 2|The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
41161491|NCT05041725|DRUG|Remimazolam Injection [Byfavo]|Remimazolam injection and continuous infusion for postoperative sedation, 0.2 mg/kg for 1 min and continuous infusion of 1-2 mg/kg/hour
41161492|NCT04999956|PROCEDURE|dynamic navigation surgery|immediate implant placement using dynamic navigation
41161493|NCT04999956|PROCEDURE|freehand surgery|immediate implant placement using freehand surgery
41161494|NCT02945007|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 under fed or fasted conditions.
41161495|NCT03115671|DIETARY_SUPPLEMENT|Vayarin|Vayarin capsule
41161496|NCT03164525|DIAGNOSTIC_TEST|Critical care pain observation tool (CPOT)|test validity and reliability of Thai-version CPOT and BPS
41367149|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN PATIENTS WITH INTRASUBJECT CONTROL|In the second, clinical phase, the measurement protocol will be different, although certain aspects will remain unchanged. The product in question (HFA -Mepentol®- or EVOO -Farmaoliva®- according to the randomisation group assigned) will be applied to the intervention heel (right), leaving the contralateral (left) heel as a control. In addition, every patient will receive the standard PU prevention measures described in the protocol applicable for persons at risk of this condition. The intervention will be carried out in the morning, after bathing, as is customary in acute-care hospital units. The data will be collected at 15-minute intervals, although the first interval will be discarded, as described above. This procedure will be repeated every day during hospitalisation, to assess the cumulative action of the barrier cream. Each measurement will last approximately one hour each day.
41367150|NCT02460185|BEHAVIORAL|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
41501728|NCT05044312|OTHER|Sleeping Disturbances|most common complaints of patients after surgery and may affect the ability to carry out daily activities, quality of life, and post-surgery recovery.
41501729|NCT02112487|DRUG|Macitentan|10 mg once daily
41501730|NCT06633120|OTHER|IVM|Immature oocytes will be retrieved from small ovarian follicles and matured overnight in the laboratory prior to undergoing fertilization and embryo culture.
41501731|NCT06633562|DRUG|Nezavist SDD|Formulated as a spray dried dispersion (SDD) suspended in a flavored diluent.
41501732|NCT06633562|DRUG|Placebo|Formulated in a diluent that matches the Nezavist SDD suspension in appearance.
41028666|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 8 cycles. Then dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle until progression or intolerable toxicities.
41028667|NCT04563858|DIAGNOSTIC_TEST|Validation|Assessment of Polish version of the 4AT
41161497|NCT01887990|DRUG|Ketamine|single dose IV 0.2 mg/kg ketamine
41161498|NCT01887990|DRUG|placebo|saline infusion
41161499|NCT06132906|PROCEDURE|Orthognathic surgery (lefort1)|"1. All patients will be treated under general anesthesia.~2. The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~3. The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~   1. External reference marking~  2. Incision and subperiosteal dissection~  3. Maxillary osteotomy~  4. Pterygomaxillary disjunction,~  5. Septal, vomerine, and lateral nasal osteotomies~  6. Down fracture~  7. Mobilization of the maxilla~  8. Application of stent in one group and the locating guide in the other group.~  9. Maxillary fixation~  10. Occlusal evaluation~  11. Wound debridement and closure"
41161500|NCT00478439|DIETARY_SUPPLEMENT|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
41161501|NCT00478439|DIETARY_SUPPLEMENT|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
41161502|NCT01960985|OTHER|Physicaltherapy|
41161503|NCT00601471|OTHER|proximal tibiofibular manipulation|proximal tibiofibular manipulation
41161504|NCT00601471|OTHER|distal tibiofibular manipulation|distal tibiofibular manipulation
41161505|NCT00601471|OTHER|no intervention|no intervention / control
41161506|NCT05501847|RADIATION|Patient with no ventricular hypertrophy|"Patients without LVH ≥ 12 mm will routinely receive a bone scan as part of the study.~In case of cardiac fixation on bone scan, the patient will be managed as part of routine care according to a standardized care protocol that follows Guillmor's algorithm: monoclonal abnormality testing on biological blood samples +/- genotyping, in order to specify the senile or mutated character of TTR cardiac amyloidosis and to give the genotype."
40845786|NCT04599595|DEVICE|Peristeen (Coloplast)|"Patients with severe intestinal dysfunction impairment (PAC QoL score ≥ 32) will be offered the adoption of the TAI (Transanal Irrigation) with Peristeen Device as a way to manage their own evacuation, replacing any other measure used until that moment (suppositoires, clisms exceptionally cc) with the exception of the possible intake of macrogols and/or prebiotics and/or probiotics which instead patients can continue. This treatment will be proposed to all patients with severe impairment of intestinal function.~The TAI training with Peristeen will be carried out at the surgical clinic of the Surgical Department of the Ferrara University Hospital, Italy, by the health personnel involved in the study, usually in a single session, but more sessions may be necessary, with the continuation of the TAI for 4 weeks or with patient's exclusion from the study if the guarantees of appropriate use of the device will not be reached."
40845787|NCT01179165|OTHER|Diagnostic|Diagnostic non-invasive tests:Dopplerechocardiography, cardiac MRI
40845788|NCT00794066|PROCEDURE|measuring the ankle brachial index|"Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de)."
40845789|NCT00354666|DRUG|GSK159797|
40845790|NCT04161170|DEVICE|Digital integrated healthcare platform|Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
40845791|NCT05400993|COMBINATION_PRODUCT|Chidamide|Chidamide: take orally twice a week,4 tablets/time (20mg/ time), the interval between two doses should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), the day before chemotherapy, 30 minutes after breakfast； Chidamide: 20mg, orally, twice a week, oral for two weeks and one week, a total of 8 cycles； Epirubicin 90mg/m2 , ivgtt, d1 Cyclophosphamide 600mg/m 2, ivgtt, d1 Q3w, 4 cycle； sequential Docetaxel 100 mg/m 2, IVGtt, D1 Q3w, 4 cycle。
40845792|NCT04405076|BIOLOGICAL|Biological: mRNA-1273|Sterile liquid for injection
40845793|NCT04405076|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
40845794|NCT04405076|BIOLOGICAL|mRNA-1273.351|Sterile liquid for injection
40845795|NCT03665116|DIETARY_SUPPLEMENT|L-arginine|L-arginine capsule
40845796|NCT00002077|DRUG|Fluconazole|
40845797|NCT06341933|OTHER|Duration of Surgery|Total surgery time in minutes
40845798|NCT06341933|OTHER|Volume of Fluid in Surgery|Fluid volume given during surgery in ml
41367151|NCT01451177|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
41501733|NCT03574350|BEHAVIORAL|KS in Kangaroo Position|KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.
41501734|NCT03574350|BEHAVIORAL|KS in incubator|The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
40845799|NCT06341933|OTHER|Blood Loss|Blood loss during surgery in ml
40845800|NCT05658380|DRUG|atropine|patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia
40845801|NCT05658380|DRUG|Isotonic saline|patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
41161507|NCT00065819|BEHAVIORAL|HIV Symptom Education Program|
41161508|NCT00487318|DRUG|standard of care|peginterferon/RBV
41161509|NCT00487318|DRUG|fluvastatin|Add fluvastatin at 20-40 mg/day to standard of care
41161510|NCT03180008|BEHAVIORAL|Fit and Strong!|Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.
41501735|NCT06539533|OTHER|pilates training|The Pilates that will be used in this study are articulating bridge, Hundreds, Plank , rolls up, one leg stretch, lift leg supine.
41501736|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
40845802|NCT04293302|OTHER|No intervention|No intervention
40845803|NCT04046978|OTHER|ConM SOSIP 50 ug and ConS UFO 50 ug|Intramuscular injection of synthetic viral immunogens ConM SOSIP and ConS UFO
40845804|NCT04046978|OTHER|Mos3.1 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.1
40845805|NCT04046978|OTHER|Mos3.2 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.2
40845806|NCT04046978|OTHER|Mos3.3 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.3
40845807|NCT04046978|OTHER|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug|Intramuscular injection of synthetic viral immunogens Mos3.1, Mos3.2 and Mos3.3
40845808|NCT00371982|DRUG|Fish oil (Maxepa)|
40845809|NCT01704703|DRUG|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
41501737|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
41501738|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
40845810|NCT01704703|DRUG|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
40845811|NCT02868658|BIOLOGICAL|Blood sampling|
40845812|NCT02868658|OTHER|Nasal swab|
40845813|NCT01515046|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)"
41367152|NCT03714139|PROCEDURE|immediate loading|"The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden \& Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day."
41367153|NCT03714139|PROCEDURE|non implant loading|Control implants will receive a healing screw and will remain unloaded
41367154|NCT06333431|DEVICE|Glass Waterfall group|Except for the preparation the gastroscopy procedure takes approximately 20 minutes, patients will be asked to focus on portative glass waterfall during the procedure.
41367155|NCT06333431|DEVICE|white noise group|Except for the preparation of the patient for the procedure, since the gastroscopy procedure takes approximately 20 minutes, 20-minute white noise be listened using phone
41367156|NCT01526343|DEVICE|Reveal XT implantation|The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
41367157|NCT05886374|DRUG|HMPL-415S1|HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
40845814|NCT01653236|DRUG|Boceprevir|
41367158|NCT05975762|PROCEDURE|surgical rib fixation|open reduction and internal rib fixation
41367159|NCT01162031|DRUG|Velcade|IV
41367160|NCT02874469|OTHER|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
41367161|NCT03165409|BIOLOGICAL|Nivolumab|Melanoma intervention
41501739|NCT03902730|OTHER|Traditional Back Squat|Participants will complete traditional back squat in this four treatment crossover design.
41501740|NCT03902730|OTHER|Barefoot Back Squat|Participants will complete barefoot back squat in this four treatment crossover design.
41501741|NCT03902730|OTHER|Box Squat|Participants will complete box squat in this four treatment crossover design.
41501742|NCT03902730|OTHER|Traditional Back Squat with Chains|Participants will complete traditional back squat with chains in this four treatment crossover design.
41501743|NCT04663347|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
41501744|NCT04663347|DRUG|rituximab and lenalidomide|28-day cycles
41501745|NCT04663347|DRUG|rituximab and bendamustine|28-day cycles
41501746|NCT04663347|DRUG|rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin|21-day cycles
41161511|NCT03180008|BEHAVIORAL|Fit and Strong! Plus|The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
41501747|NCT04663347|DRUG|gemcitabine and oxaliplatin|28-day cycles
41501748|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
40845815|NCT01653236|DRUG|Peginterferon alfa-2b|
40845816|NCT01653236|DRUG|ribavirin|
40845817|NCT04856904|DRUG|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks
40845818|NCT04856904|DRUG|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks
40845819|NCT03599479|DEVICE|Virtual reality group|Virtual reality group The study intervention is to provide acute pain management for the subject undergoing fluoroscopic pain intervention by using the virtual reality program provided by the collaborator through virtual reality device (headset, headphone, and smartphone) that are commercialized on the market.
40845820|NCT06386705|DRUG|TSN084|TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
40845821|NCT02772900|OTHER|Beetroot-based nutritional gel|100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
40845822|NCT02772900|OTHER|Placebo|100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
40845823|NCT01438177|DRUG|Velcade|
40845824|NCT01438177|DRUG|Cyclophosphamide|
40845825|NCT01438177|DRUG|Chloroquine|
40845826|NCT03412253|PROCEDURE|Single-Anastomosis Gastric Bypass surgery (SAGB).|We checked the effect of SAGB on patients suffered from T2DM with BMI 25-30
41367162|NCT03165409|BIOLOGICAL|Ipilimumab|Melanoma intervention
41501749|NCT04663347|DRUG|rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone|21-day cycles
41501750|NCT04663347|DRUG|Lenalidomide|28-day cycles
41501751|NCT04663347|DRUG|rituximab, ifosfamide, carboplatin, and etoposide phosphate|21-day cycles
41501752|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
41501753|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until disease progression or unacceptable toxicity.
41501754|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
41367163|NCT03334604|DIETARY_SUPPLEMENT|Multispecies probiotic|Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10\^9 Colony Forming Units (CFU), twice daily, orally.
40845827|NCT06329024|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
40845828|NCT06329024|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
40845829|NCT03204669|OTHER|Trace elements replacement|
40845830|NCT00025246|DRUG|imatinib mesylate|Given orally
40845831|NCT00025246|OTHER|laboratory biomarker analysis|Correlative studies
40845832|NCT06514833|BEHAVIORAL|lifestyle recommendations to nap regularly|Participants will receive lifestyle recommendations to nap regularly for 15-30 minutes between 12:00 and 15:00
40845833|NCT06514833|OTHER|No recommendations to nap regularly|No lifestyle recommendations to nap regularly
40845834|NCT06549660|DEVICE|Active PBMT|Active with a dose of 165 J per site, resulting in a total dose of 495J.
40845835|NCT06549660|DEVICE|Placebo PBMT|Placebo, without therapeutic dose.
40845836|NCT04843371|DIAGNOSTIC_TEST|Photoplethysmography|Photoplethysmography (PPG) is a non-invasive technique that can detect volumetric changes in the peripheral blood. It only requires skin contact and relies on light absorption. PPG is a good indicator of the cardiovascular dynamics in the human body. PPG has been incorporated into various new smartphones and wearable devices such as, smartwatches and fitness wristbands making it readily available to all consumers. This sensor can record biometrics such as, heart rate, blood pressure, oxygen saturation, etc.
40845837|NCT01870310|PROCEDURE|Catheterised renal denervation|
40845838|NCT05486585|OTHER|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
40845839|NCT00067782|DRUG|Atazanavir (immediate switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
40845840|NCT00067782|DRUG|Atazanavir (Week 24 switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
40845841|NCT02359227|DRUG|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
40845842|NCT04181177|OTHER|Cosmetic product|"Cosmetic balm: application twice daily on the whole body in sufficient quantity to cover all the xerosis areas. It contains an I-modulia(r) complex which decreases the sensation of itching, CER-OMEGA which are lipids similar to those of the skin, help repair and nourish the skin, finally Avène Thermal Spring Water which have soothing and softening properties.~Targeted education action consist in advices and preventive measures (including hygiene) regarding xerosis and associated dermatological signs / symptoms. Emollient and application tips and other supportive care tips will be provided. The targeted educational action will be monitored by the medical and paramedical teams (specialized nurses)."
40845843|NCT03221361|DEVICE|thermoplastic complete denture|a device used ti substitute teeth for edentlous patient made of thermoplastic resin
40845844|NCT03221361|DEVICE|conventional acrylic resin complete denture|A device used to substitute the teeth for edentlous patient made of acrylic resin
40845845|NCT02467842|BIOLOGICAL|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria
41367164|NCT03334604|OTHER|Placebo|Placebo identical in taste, smell and color to the multispecies probiotic.
41367165|NCT00060320|DIETARY_SUPPLEMENT|black cohosh|
41367166|NCT00060320|OTHER|placebo|
41367167|NCT01801475|DRUG|Ondansetron|Pregnant \& non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
41501755|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and then every 8 weeks for a total of 2 years.
41501756|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
41501757|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
41501758|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until transplant or disease progression.
41367168|NCT04217941|PROCEDURE|Health education with practical demonstration of nasal ointment|Health education with practical demonstration of medicine was compared to health education without practical demonstration
41501759|NCT05275920|OTHER|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
41501760|NCT05275920|OTHER|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
41501761|NCT04303780|DRUG|AMG 510|21 day cycles
41367169|NCT04217941|DRUG|Health Education and practical demonstration of Nasal spray and intranasal ointment|We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
41367170|NCT04619043|DEVICE|Ankle Orthotic|
41367171|NCT00648765|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fed
41367172|NCT00648765|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fed
41367173|NCT05190094|DRUG|Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)|A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
41367174|NCT01411124|DRUG|gabapentin enacarbil|600 mg investigational compound
41367175|NCT01411124|DRUG|diphenhydramine|50 mg active comparator
41367176|NCT01411124|DRUG|placebo|placebo
41367177|NCT04271111|BEHAVIORAL|Online Treatment for Interpersonal Stress|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
40845846|NCT02467842|BIOLOGICAL|NBP607-Y|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata
40845847|NCT02467842|BIOLOGICAL|NBP607-V|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
40845848|NCT04401878|DRUG|Sphenopalatine Ganglion Block using 2% lidocaine|Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril. The patients are then examined by TCD.
40845849|NCT03754114|OTHER|ICP + PbtO2 guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg and to avoid PbtO2 dropping below 20 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada for patients with severe TBI. The devices are used in standard care at hospitals participating in this research study. Doctors adjust their treatment choices to try to achieve these ICP and PbtO2 goals. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
40845850|NCT03754114|OTHER|ICP guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull, but PbtO2 is not used to guide care. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada, and are routinely used in patients with severe TBI. Doctors adjust their treatment choices to try to achieve this ICP goal. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
40845851|NCT02407782|DRUG|Ivermectin|oral ivermectin, 200μg/kg given at baseline and at day 10.
40845852|NCT02407782|DRUG|Permethrin|topical permethrin 5% cream applied at baseline and at day 10.
40845853|NCT04582955|DRUG|Chidamide in combination with chemotherapy|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
40845854|NCT05095857|DRUG|S-ketamine|S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
41161512|NCT03022045|DRUG|risankizumab|risankizumab administered by subcutaneous injection
41367178|NCT04271111|BEHAVIORAL|Physical Health Education Tool|Intervention designed to improve physical health through exercise, eating habits, and sleep
41367179|NCT05248633|RADIATION|radiotherapy|radiotherapy with a dose of 40-50 Gy
41501762|NCT04303780|DRUG|Docetaxel|21 day cycles
41367180|NCT05248633|DRUG|Bortezomib Injection|subcutaneous Bortezomib 1.3mg/m2 d1,8,15,22
41367181|NCT05248633|DRUG|Lenalidomide|Lenalidomide 25mg for 21 days
41367182|NCT05248633|DRUG|Dexamethasone|Dexamethasone 40mg d1,8,15,22
41367183|NCT04196959|DIETARY_SUPPLEMENT|TYR sphere|TYR sphere is a powdered protein substitute for patients with tyrosinaemia.
41367184|NCT04591782|OTHER|PomJuice|Drink 8 oz pomegranate juice
41367185|NCT04591782|OTHER|Water|Drink 8 oz water
41367186|NCT04591782|OTHER|Sugar Water|Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in
41367187|NCT02730832|OTHER|Questionnaires completed at D0|
41367188|NCT02730832|OTHER|Questionnaires completed at D15 (test-retest for 30 patients)|
41501763|NCT05895786|DRUG|PF-06823859|anti-interferon beta therapy
41501764|NCT05895786|DRUG|Placebo|Placebo for PF-06823859
41501765|NCT04514484|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41501766|NCT04514484|DRUG|Cabozantinib S-malate|Given PO
41501767|NCT04514484|PROCEDURE|Computed Tomography|Undergo CT
41501768|NCT04514484|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41501769|NCT04514484|BIOLOGICAL|Nivolumab|Given IV
41501770|NCT05567185|DRUG|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
41501771|NCT01115478|DIETARY_SUPPLEMENT|Vitamin A|Daily oral dose of 2500 IU from enrollment until delivery
41501772|NCT01115478|DIETARY_SUPPLEMENT|Zinc|Daily oral dose of 25 mg from enrollment until delivery
41501773|NCT01115478|OTHER|Placebo|Daily oral dose from enrollment until delivery
41501774|NCT06574360|DRUG|S1RA plus NMDAE|Use of an S1R agonist plus an NMDA enhancer for the treatment of treatment-resistant schizophrenia.
41501775|NCT06574360|DRUG|S1RA plus Placebo Cap|Use of an S1R agonist plus placebo as a comparator
40845855|NCT05095857|OTHER|Isotonic saline (placebo)|Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
40845856|NCT04071418|RADIATION|3D-printing Template-assisted CT-guided I-125 Seeds Implantation|(1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seeds implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume; Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc. Regular follow-up was conducted after treatment.
40845857|NCT06358092|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|HVPG is a measurement used to assess portal hypertension, a condition characterized by increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. HVPG measurement involves inserting a catheter into the hepatic vein via jugular vein puncture to directly measure the pressure within the liver. By comparing the pressure in the hepatic vein with that in the portal vein, HVPG provides valuable information about the severity of portal hypertension and helps in predicting clinical outcomes in patients with liver cirrhosis and related conditions. HVPG measurements are crucial in guiding treatment decisions, assessing treatment response, and predicting the risk of complications such as variceal bleeding and liver failure.
41161513|NCT02383927|DRUG|Tipifarnib|FTase inhibitor
41367189|NCT05119114|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|A standardized multi-parametric MRI protocol will be implemented for all patients. All sequences will be acquired on a 1.5 Tesla scanner. After completion of the MRI study, the digital imaging and communication data will be sent to a diagnostic workstation for post-processing and analysis. Patients of the study will be subjected to detailed structural MRI for detection of signs of neurodegenerative changes. Volumetric high-resolution 3D scans will be used for quantitative study.
41367190|NCT01899573|DEVICE|AccuCinch® Ventriculoplasty System|Percutaneous intervention for the treatment of functional mitral regurgitation
41367191|NCT01307527|DRUG|Riboflavin|0.1%, applied every 5 minutes for 60 minutes
41367192|NCT01307527|DEVICE|Kera-X|3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes
41367193|NCT03174028|DEVICE|laparoscopic pull-through|laparoscopic pull-through
41367194|NCT03783026|DRUG|Apremilast|Tablets for oral administration
40845858|NCT06358092|DIAGNOSTIC_TEST|Two-Dimensional Shear Wave Elastography|2D-SWE is a non-invasive imaging technique used to assess tissue stiffness, particularly in the liver. This technology utilizes ultrasound to generate shear waves within the tissue being examined. By measuring the speed of these shear waves as they propagate through the tissue, 2D-SWE can provide quantitative information about tissue elasticity or stiffness. In the context of liver disease, including cirrhosis and fibrosis, 2D-SWE is valuable for evaluating the degree of liver stiffness, which correlates with the severity of liver fibrosis. This information aids in diagnosis, staging, and monitoring of liver diseases, allowing for early detection of complications and assessment of treatment response. Compared to traditional biopsy-based methods, 2D-SWE offers the advantage of being non-invasive, rapid, and repeatable, making it a preferred modality for assessing liver stiffness in clinical practice.
40845859|NCT00310622|DEVICE|HyperQ Signal recording|
40845860|NCT06547489|DRUG|zelquistinel|Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
40845861|NCT02581969|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered 20-30 IU/kg 3 times a week
40845862|NCT02581969|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered only for bleeding episodes
41161514|NCT06229626|OTHER|intensive reeducation|"* 1 group physiotherapy session per week at the ICM or by videoconference from home for 6 weeks~* 2 sessions per week at home with video support sent by e-mail for 6 weeks"
40845863|NCT05327361|DRUG|Liftactiv B3|Participants will apply a dime size amount of the serum to 1 side of the face.
40845864|NCT05327361|OTHER|Sunscreen|Participants will apply a dime size amount of sunscreen to cover the other half of the face.
41367195|NCT01132040|DRUG|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
41367196|NCT03226574|DRUG|Resiniferatoxin|single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
41367197|NCT03478982|DRUG|Staccato Alprazolam|single dose for inhalation
41367198|NCT03478982|DRUG|Placebos|single dose for inhalation
41367199|NCT05082922|BEHAVIORAL|Hybrid treatment|Transdiagnostic emotion-focused treatment provided by a psychologist with, when needed, support of a medical doctor (ensuring adherence to medical guidelines) and a physiotherapist (providing assessment and treatment support in exposure for physical activities). Depending on the length of the waiting period (randomly assigned to be either 4, 5 or 6 weeks), the treatment period varies between 14-16 weeks and contains 10-15 sessions.
41367200|NCT02144311|PROCEDURE|PET/CT Scan|
41367201|NCT02144311|PROCEDURE|MRI|
41367202|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
41367203|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
41367204|NCT02504099|DRUG|ribavirin|Tablet
41367205|NCT02554084|OTHER|Optical Coherence Tomography|Digital images of tear film
41161515|NCT02859558|DRUG|elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy|Participants received one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food or one tablet of bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg by mouth daily with or without food. Other non-study-provided ARV regimens were allowed for participants who were pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF or BIC/FTC/TAF, or for participants whose local health care/primary care provider preferred starting a different initial ARV regimen.
41161516|NCT05139498|PROCEDURE|Conservative management for placenta accreta spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
41367206|NCT02996266|DEVICE|Targeted Temperature Management|Prophylactic normothermia
41367207|NCT02996266|OTHER|Standard Care|No intervention to control temperature unless fever occurs
40845865|NCT01008085|DEVICE|Stentys coronary stent|Self-expanding Nitinol stent
41367208|NCT00906516|DRUG|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
41367209|NCT00508872|DRUG|5-Fluorouracil|400 mg/m\^2 IV over 15 minutes, followed by 2400 mg/m\^2 IV Over 46 Hours
41028668|NCT00801827|DRUG|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
41028669|NCT01817205|PROCEDURE|TACE with Hyperthermia Treatment|"Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter."
41028670|NCT06099613|BIOLOGICAL|EG-COVII|EG-COVII is a bivalent vaccine to prevent SARS-CoV-2 infection against wild type and Omicron variants
41367210|NCT00508872|DRUG|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
41367211|NCT00508872|DRUG|Leucovorin|400 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
40845866|NCT01008085|DEVICE|Balloon-expandable stent|VISION/Driver
40845867|NCT03968848|DRUG|acalabrutinib|A 50-mg single oral dose of acalabrutinib will be administered.
40845868|NCT03649009|OTHER|Normal Saline|Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days after recruitment and randomization.
40845869|NCT03649009|DRUG|Thiamine|IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
40845870|NCT03649009|DRUG|Hydrocortisone|If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
40845871|NCT03649009|OTHER|Metoclopramide|If patient develop nausea after IV thiamine infusion, IV metoclopramide 10mg stat will be given. If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given.
40845872|NCT05944627|BIOLOGICAL|FURESTEM-OA Kit Inj.|FURESTEM-OA Kit Inj. is a combination medical product in which FURESTEM-OA Inj. (solution 1) is the primary mode of action and CAM Inj. (solution 2) acts as an auxiliary. The product is administered after mixing solution 1 and solution 2.
40845873|NCT05944627|BIOLOGICAL|Placebo|placebo administration in Phase 2a clinical trial
40845874|NCT05367128|OTHER|Dual task training|All participants will receive cognitive dual task training for 30 min/session, 2-3 sessions/week for 4-6 weeks (a total of 12 sessions). The cognitive dual task training includes 15 min of cognitive task combining with standing task and 15 min of cognitive task combining with walking task. The differences among group are the instructions of task prioritization given by the therapist
41367212|NCT00508872|DRUG|Oxaliplatin|85 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
41367213|NCT04366258|DEVICE|Transcranial Photobiomodulator|Delivers laser-generated Near-Infrared Radiation (NIR) to forehead at 3 doses of irradiance - High (770 mW/cm2), Middle (300 mW/cm2), and Low (50 mW/cm2).
41367214|NCT04366258|DEVICE|Sham|Transcranial Photobiomodulator delivers sham irradiance dose of 0 mW/cm2.
41367215|NCT02208427|DRUG|Rifapentine and Isoniazid for 3 months|weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
40845875|NCT04365452|DEVICE|Invia Motion|Invia Motion NPWT system at cesarean delivery
40845876|NCT05755802|PROCEDURE|PENG block|"A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
40845877|NCT05755802|PROCEDURE|Shoulder block|The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it Will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. A 50 mm nerve block needle will be used in the long axis view for the block. After confirming extravascular placement of the needle, injectate will be given below the supraspinatus fascia and then during axillary nerve block,The posterior surface of the humerus will be visualised in the short axis view. So, the circumflex artery will be visualised longitudinally. After confirming extra-vascular placement of the needle, injectate will be given into space.
41028671|NCT01509859|DEVICE|PFNA proximal femur nail device (Synthes)|"synthes PFNA proximal femur nail device"
41028672|NCT01509859|DEVICE|INTERTAN proximal femur nail device (Smith&Nephew)|"Smith\&Nephew INTERTAN proximal femur nail device"
41028673|NCT00674310|DRUG|Ropinirole Hydrochloride|Restless Leg Syndrome
41028674|NCT05437146|BEHAVIORAL|puppet|pain and fear during blood collection
41028675|NCT00991926|DRUG|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
41161517|NCT05139498|PROCEDURE|Cesarean hysterectomy for placenta accreta spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
41367216|NCT02208427|DRUG|Isoniazid for 9 months|daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
41028676|NCT00991926|OTHER|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
41367217|NCT04203082|BEHAVIORAL|Exposure Intervention|Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
40845878|NCT00378261|PROCEDURE|Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.|
40845879|NCT02975726|DEVICE|Peritoneal Dialysis Catheter|Peritoneal dialysis catheter insertion in order to drain access fluid within the belly for patients with liver cirrhosis and refractory ascites.
41367218|NCT04203082|OTHER|Usual Care|Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
40845880|NCT02975726|PROCEDURE|Large Volume Paracentesis|Insertion of a needle into the peritoneal cavity where ascites accumulates, then attaching the needle to a collection system that drains the ascites by gravity. This procedure is part of the standard care for the treatment of refractory ascites.
40845881|NCT02975726|BIOLOGICAL|25% Human Serum Albumin injection|Patients will be given Human Serum Albumin after the initial drain of ascites fluid: 100cc for 5-10L drainage, 200cc for 10-15L drainage.
40845882|NCT02975726|PROCEDURE|Bloodwork|Monthly bloodwork will be done as part of usual standard of care.
40845883|NCT05372549|OTHER|Oxidative stress|Oxidative stress occurs as soon as there is an imbalance between pro- / antioxidants, and molecules exhibiting antioxidant properties are at the forefront of fertility treatment and preservation. Oxidated stress will be measured by blood sample
40845884|NCT05372549|OTHER|cf-DNA|cfDNA, extracted from blood plasma in samples collected will uncover the potential role of cfDNA as a stress signal released in response to oxidative stress
40845885|NCT05372549|OTHER|MAGENTA AI|Non-invasive technique analyzing images of oocytes that can differentiate oocytes with a higher reproductive potential reflective of their quality
40845886|NCT02464722|DRUG|Dexmedetomidine|1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
40845887|NCT02464722|DRUG|Remifentanil|1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
40845888|NCT02464722|DRUG|Epinephrine|Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
41028677|NCT01895465|DEVICE|Slitted diaper|A diaper where a slit is made through which a urine collection bag is pulled through
41028678|NCT04917679|DRUG|Eltrombopag plus diacerein|In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10\^9/L as follows: (1) if platelet count is less than 150 × 10\^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10\^9/L to 250 × 10\^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10\^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10\^9/L.
41028679|NCT04917679|DRUG|Eltrombopag|In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10\^9/L to 150 × 10\^9/L.
41028680|NCT01055743|PROCEDURE|Radical resection|Radical resection of hepatocellular carcinoma
41028681|NCT01055743|DRUG|Fluorouracil Implants|Implanted during the surgical treatment
41028682|NCT01672632|OTHER|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
41367219|NCT01013207|DEVICE|CPAP Pre Nexus (S9)|This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
41367220|NCT01013207|DEVICE|Nexus (S9)|The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
40845889|NCT02464722|DRUG|Propofol|Anesthesia was induced with propofol 2 mg kg-1
40845890|NCT02464722|DRUG|Rocuronium|Anesthesia was induced with rocuronium 0.6 mg kg-1
40845891|NCT02305238|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
40845892|NCT05974813|DIETARY_SUPPLEMENT|L-Citrulline|6 g (3 g every 12 h) of L-citrulline for six days
40845893|NCT05974813|DIETARY_SUPPLEMENT|Placebo|6 g (3 g every 12 h) of maltodextrin for six days
40845894|NCT06190080|OTHER|Digestive endoscopy|Digestive endoscopies are performed in the operative room under general anaesthetic 3 months after the introduction or change of treatment. Biopsies of the upper, middle and lower thirds of the esophagus will be taken and analyzed for pathology.
40845895|NCT00219778|DRUG|mifepristone|
40845896|NCT06145958|DRUG|Luteinising Hormone-Releasing Factor Analogue|Androgen Deprivation Therapy
40845897|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
41161518|NCT00961610|BEHAVIORAL|Internet peer-support group|"The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date."
40845898|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
40845899|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
40845900|NCT02442258|DRUG|ABT-493|A single dose of ABT-493 will be given orally in combination with ABT-530.
40845901|NCT02442258|DRUG|ABT-530|A single dose of ABT-530 will be given orally in combination with ABT-493.
40845902|NCT05533970|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct.
40845903|NCT01761695|OTHER|Diagnosed as CML|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
40845904|NCT00266682|DEVICE|Pacing Lead|
40845905|NCT02540668|DRUG|Lanabecestat|Administered orally
40845906|NCT02540668|DRUG|Warfarin|Administered orally
40845907|NCT05416307|DRUG|ELA026|Single or multiple daily doses of ELA026
40845908|NCT00830492|DRUG|clomiphene citrate|100 mg from cycle day 3 through 7
40845909|NCT00830492|PROCEDURE|Ultrasound|cycle day 8
41028683|NCT01822652|GENETIC|iC9-GD2 T Cells - frozen|"Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.~Subjects will receive one of the following dose levels (cells/m2):~* Dose Level 1 = 1 x 10\^7~* Dose Level 2 = 1 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
41028684|NCT01822652|GENETIC|iC9-GD2 T Cells - fresh|"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1 x 10\^8~* Dose Level 2 = 1.5 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
41028685|NCT01822652|DRUG|Cytoxan|Cyclophosphamide (500 mg/m2/day x 2 days, for patients \<12 kg = 16.7 mg/kg/day x 2 days)
41028686|NCT01822652|DRUG|Fludara|Fludarabine (30 mg/m2/day x 3 days, for patients \<12 kg = 1 mg/kg/day x 3 days)
41028687|NCT01822652|DRUG|Keytruda|Pembrolizumab (2 mg/kg on Day -1 and on Day 21).
41028688|NCT01822652|GENETIC|iC9-GD2 T cells|"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1.5 x 10\^8~* Dose Level 2 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
41028689|NCT02024334|DRUG|Leflunomide|
40845910|NCT00830492|DRUG|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
40845911|NCT00830492|DRUG|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
41028690|NCT05748028|OTHER|Rehabilitation|All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.
41161519|NCT06538519|PROCEDURE|total hip replacement using lateral approach|In the lateral approach partial detachment of the anterior one-third of the gluteus medius muscle.
41367221|NCT01013207|DEVICE|CPAP Post Nexus (S9)|After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
40845912|NCT00830492|DRUG|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (\<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
40845913|NCT00830492|DRUG|rFSH|150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
40845914|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
40845915|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection simulation|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
40845916|NCT01116973|OTHER|PICC|Peripheral inserted catheter placement to take the reading
40845917|NCT03565835|DRUG|Abiraterone Acetate|Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
40845918|NCT03565835|DRUG|Prednisone|Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
40845919|NCT03740568|DRUG|Low Progesterone|"Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 \<10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.~Group 2b (Restored Progesterone Group, P on D5 \>10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
40845920|NCT03740568|DRUG|Normal Progesterone|"Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
40845921|NCT05013788|OTHER|Social Media Enhanced Education|Along with usual asthma education received,participants will receive asthma education via various social media platforms ,Facebook, Twitter, Instagram, and/or Snapchat. Topics of education will include background on asthma and pathophysiology, asthma severity classification, asthma triggers, different medications and indications for when to take them, how to use an inhaler technique, and symptom monitoring.Online resources from the American Lung Association and the National Asthma Education and Prevention Program will also be posted.
40845922|NCT05013788|OTHER|Usual Asthma Education|For patients who are admitted to Children's Memorial Hermann for asthma exacerbation, asthma education is provided to patients and families on the day of discharge by the nurse and respiratory therapist on triggers, Signs \& Symptoms, Medication Use, Medication Delivery, Peak Flow, Zones and how to respond to each, and Cleaning equipment.Nursing staff are responsible for printing out education sheets to give to patients and showing an education video that is 20 minutes long. An asthma action plan are given to families on discharge. Patients that are discharged from the emergency room are given the same educational materials by the nurses and/or respiratory therapists except for the asthma video. Patients receive a variable amount of asthma education when going to usual clinic visits. The education provided is dependent on the provider, and usually limited in length to the time of the visit
40845923|NCT00311259|DRUG|Melatonin (drug)|
40845924|NCT00311259|DRUG|Laktose|
40845925|NCT05517694|OTHER|Pelvic floor exercises and behavioral therapy|Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.
41501776|NCT05418114|DRUG|Magnesium sulfate|. One group (Group A) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate. Other group (Group B) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine.
41501777|NCT04279236|OTHER|Abbreviated Profile Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on 2 occasions.
41501778|NCT04279236|OTHER|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on 2 occasions.
41501779|NCT04279236|OTHER|Additional follow-up visit|There is an additional follow-up visit after surgery (compared to the routine clinical practice of the surgeons/clinics).
41028691|NCT05748028|OTHER|Administration of Clinical scales|All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.
41028692|NCT03770572|GENETIC|Low dose AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at low dose
41028693|NCT03770572|GENETIC|High dose AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at high dose
41028694|NCT02965560|DIAGNOSTIC_TEST|plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.|
41028695|NCT05319678|OTHER|evaluation with Meludia music software|"Measurement instruments:~1. - MuMu Questionnaire~2. MuRQoL Questionnaire~3. Questionnaire for subjects aged 6-17 years~4. Music tool Meludia (www.meludia.com)~5. Acoustic analysis of the voice: the Praat programme~6. Audiological tests"
41161520|NCT06538519|PROCEDURE|total hip replacement using anterior approach|the anterior approach using an internervous plane between the tensor fascia latae and the sartorius muscle.
41161521|NCT06538519|DEVICE|gait analysis at 6wks, 3 months and 18 months|gait analysis done in the gait lab at the mentioned postoperative periods
41161522|NCT01133925|DEVICE|Resolute Sprint|Zotarolimus Eluting Stent (Resolute Sprint) implanted in overlap
41161523|NCT01133925|DEVICE|Sirolimus Eluting Stent|Cypher stents implanted in overlap
41161524|NCT01133925|DEVICE|Paclitaxel Eluting Stent|Taxus stents implanted in overlap
41161525|NCT01133925|DEVICE|Zotarolimus eluting stent|Endeavor stents implanted in overlap
40845926|NCT05517694|OTHER|Respiratory exercises|"Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.~Respiratory exercises will be given 6 breaths/minute with expiration and inspiration times of 7 seconds and 3 seconds, respectively. At least 10 diaphragmatic breaths will be given in each session, 2 times a day, 7 days a week, 8 weeks."
40845927|NCT00254891|DRUG|PF-3512676 + Paclitaxel + Carboplatin|"* PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.~* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
40845928|NCT00254891|DRUG|Paclitaxel + Carboplatin|"* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
40845929|NCT00671606|PROCEDURE|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
40845930|NCT06502834|DIETARY_SUPPLEMENT|D piger|Probiotic d piger
40845931|NCT06502834|DIETARY_SUPPLEMENT|Placebo|Placebo
40845932|NCT01054625|BIOLOGICAL|zalutumumab|Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
41367222|NCT05279963|PROCEDURE|electroacupuncture|"The prespecified acupoints applied here will include bilateral Sanyinjiao(SP6), Shenshu(BL23), Ciliao(BL32), Zhongliao(BL33), Zhibian(BL54) .~Acupuncture treatment is carried out by acupuncturists who have been well trained. Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China). Electroacupuncture procedures will be performed with electronic instruments (Hans-100A, Nanjing Jisheng Medical TechnologyCo., Ltd, China). Two paired of acupoints (i.e., two Shenshu(BL23) and two Ciliao(BL32), respectively) are connected to the EA apparatus. Alternating-frequency mode is selected and frequency is 2/100 Hz. EA intensity is determined in accordance with patients' endurance. EA will last for 30 min for each treatment. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks."
41367223|NCT05279963|DRUG|Amitriptyline|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of individual participants will be recorded on diary cards.
41367224|NCT05279963|PROCEDURE|sham electroacupuncture|"In the trunk region, the points are 5 cm away from respective acupoints. In the lower limb region, the point is 3 cm away from Sanyinjiao(SP6). All points will only receive shallow insertion.~Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China).The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the electric needle group."
40845933|NCT05230485|OTHER|CPAP level|The level of continuous distending pressure (or positive end-expiratory pressure) chosen on CPAP
40845934|NCT03207802|DEVICE|Discontinuation of using device|Subject will be instructed to discontinuation of use of device
40845935|NCT01441466|OTHER|Isolation|Patients in this arm are nursed together (in the same room) independent of viral agent
40845936|NCT04113551|DRUG|MPH (Concerta)|MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.
40845937|NCT04113551|DRUG|MPH (Ritalin)|MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
40845938|NCT04113551|DRUG|Atomoxetine (ATO)|Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
40845939|NCT04113551|DRUG|Guanfacine (GFC)|Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
40845940|NCT03959917|PROCEDURE|transurethral resection of the prostate|Surgical removal of benign prostatic tissue
41161526|NCT04978012|DRUG|Fluzoparib and Camrelizumab|Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
41367225|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
41367226|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
41028696|NCT06534801|DRUG|Oxycodone will be administered intravenously in the group 1|Oxycodone will be administered intravenously 30min before the end of surgery, and Dixon sequential method will be used for the study
41028697|NCT00171977|DRUG|Imatinib Mesylate|
41028698|NCT02013765|DRUG|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
41028699|NCT02408614|OTHER|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
41028700|NCT02408614|OTHER|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
41028701|NCT02408614|OTHER|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
41028702|NCT02408614|DEVICE|Treadmill|
41028703|NCT02138214|PROCEDURE|Thyroidectomy|Undergo total thyroidectomy
41367227|NCT05950529|OTHER|Placebo lozenge control (sorbitol only)|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
41367228|NCT05950529|OTHER|No product|no product
41367229|NCT00206752|RADIATION|Radiation therapy|definitive external beam radiation in the ipsilateral neck.
41367230|NCT00206752|RADIATION|definitive external beam radiation in the ipsilateral neck|definitive external beam radiation in the ipsilateral neck
41367231|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN|8 lessons over 6-8 weeks
41367232|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
41028704|NCT02138214|PROCEDURE|entral lymph node dissection (CLND)|Undergo total thyroidectomy with ipsilateral prophylactic CND
41028705|NCT02138214|OTHER|Quality-of-life assessment|Voice evaluation, interviews, ancillary studies
41367233|NCT04899570|DRUG|Zanubrutinib|160mg Bid, oral, d1-21 in a 21-day cycle for 8 cycles.
41367234|NCT04899570|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
41367235|NCT04899570|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
41501780|NCT00858481|DRUG|Spinosad Creme Rinse - Vehicle Control|One or two, 10-minute topical applications (7 days apart)
41028706|NCT02513017|BEHAVIORAL|Stimulus Control Instructions and Sleep Restriction Therapy|Please refer to arm/group descriptions.
41028707|NCT00694460|BIOLOGICAL|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
41028708|NCT00694460|BIOLOGICAL|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
41028709|NCT00694460|BIOLOGICAL|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
41028710|NCT00694460|BIOLOGICAL|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
41028711|NCT00694460|BIOLOGICAL|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
41161527|NCT02187445|DRUG|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
41501781|NCT00858481|DRUG|Spinosad Creme Rinse|0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
40845941|NCT06524232|OTHER|Practice Facilitation (PF)|Practices will meet with practice facilitators monthly and apply tests of change using a Plan-Do-Study-Act approach, guided by the PF team. Facilitators will confirm that practices have established workflows for substance use disorder (SUD) screening and interventions and perform checks periodically to ensure progression. PF will entail: implementing protocols/algorithms for evidence-based screening and interventions, promoting decision support tools and templates to support practice workflow, optimizing electronic health record (EHR) use to pull clinical data monthly to guide the improvement process, developing patient registries (e.g., for those with SUD) to identify needed care and optimize delivery of evidence-based interventions, encouraging proactive, team-based care with assigned roles and responsibilities, and enhancing the understanding of evidence-based SUD interventions, including counseling and referral resources to ensure practices have appropriate intervention options.
40845942|NCT06524232|OTHER|Learning Collaborative (LC)|Virtual LC sessions will be held monthly and will include participants presenting anonymized cases to clinical experts, targeted brief didactics related to the content of the cases, and time for open discussion and Q\&A. Participant-generated ideas for topics to be covered during virtual LC sessions will be encouraged. Some specific topics will include optimal SUD screening approaches; prescribing medications for opioid use disorder (OUD) in primary care; pragmatic issues around integrated SUD care within primary care such as compliance with state and federal requirements, note templates/visit frequency, and when/how to escalate care for patients with severe or worsening SUD; medications for alcohol use disorder (AUD); and motivational interviewing.
40845943|NCT06524232|OTHER|Performance Incentives (PI)|We will work closely with key stakeholders and the Steering Committee to co-design the PI strategy, refining the specific performance metrics to ensure that they align with other ongoing efforts in our partnering organizations. We plan to base the incentive on achieving a threshold target for the percentage of eligible adult patients screened for SUD, or the percentage improvement in screening, for quarters 1 and 2. For quarters 3 and 4, after practices have had time to implement and improve their processes for screening for SUD, the incentives will evolve to become a composite of (1) patients screened for SUD (the same as used in quarters 1 and 2) and (2) achieving a threshold target for the percentage of persons with SUD who received evidence-based interventions.
40845944|NCT04256252|DRUG|Rituximab|A scheduled therapeutic regimen with low-dose rituximab was performed.
40845945|NCT04654455|OTHER|Describe the evolution of dry eye between 1 month and 3 months post-LASIK|Dry eye will be assessed through the OSDI (Ocular Surface Disease Index) questionnaire. The questionnaire will be dispensed during consultations by an orthoptist or an intern/junior doctor, at 1 month and at 3 months post-LASIK.
40845946|NCT03484390|BEHAVIORAL|Mindfulness-based stress reduction|
40845947|NCT03484390|BEHAVIORAL|Wellness Group|
40845948|NCT06583447|BEHAVIORAL|Calorie-restricted diet (CRD)|"Standardized lifestyle interventions for all obese children and their parents will be constructed by endocrinologists and dietitians to increase physical activity and healthy eating habits. Physical activity interventions include decreasing time spent in sedentary activities, increasing the amount of physical activity, and recommending at least 60 minutes of moderate-intensity exercise per day. Individualized dietary counseling is provided to address the comorbidities in obese children.~Based on the standardized lifestyle intervention, the study subjects in the control group will be treated with CRD. Total daily energy intake will be restricted to 80% of the energy requirement for each age group in the Dietary Reference Intakes of Nutrients for Chinese Residents DRIs 2013. A daily food diary will be kept for at least one weekday and one weekend per week."
40845949|NCT06583447|BEHAVIORAL|Time-restricted eating (TRE)|Based on the standardized lifestyle intervention mentioned by the calorie-restricted diet (CRD) intervention, TRE is administered to the study subjects in the intervention group. The eating window is limited to 12 hours per day, with the last meal no later than 7:00 p.m., and the study subjects are free to choose their eating window. Energy intake is not restricted during the eating period, and calorie-free, sugar-free beverages (water, tea, coffee) are allowed during the fasting period. A daily food diary will be kept for at least one weekday and one weekend per week.
40845950|NCT00006656|DRUG|carmustine in ethanol|
40845951|NCT00006656|PROCEDURE|conventional surgery|
40845952|NCT00293020|DRUG|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
41161528|NCT02057302|DRUG|Xuezhikang capsule|
41161529|NCT02694796|BEHAVIORAL|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
41161530|NCT00620633|BIOLOGICAL|WT1-sensitized T cells|Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
41161531|NCT00825214|DEVICE|Zapperclick|Device deliveres small piezoelectrical discharge to bite site (forearm)
41161532|NCT00825214|DEVICE|Inactivated zapperclick device|placebo
41161533|NCT05362513|DRUG|Ivermectin Tablets|Group B received a single dose of oral ivermectin 200 mcg per kg
41161534|NCT05362513|DRUG|Permethrin Cream|Group A received Permethrin 5% twice with a one-week interval.
41161535|NCT01229527|DRUG|Remifentanil|Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
41161536|NCT01229527|DRUG|Remifentanil|Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
41161537|NCT01229527|DRUG|Meperidine|Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
41501782|NCT00858481|DRUG|Spinosad Creme Rinse|1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
41367236|NCT04899570|DRUG|Epirubicin|Epirubicin 70mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
41501783|NCT00858481|DRUG|Spinosad Creme Rinse|2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
41501784|NCT03685578|DEVICE|EmboTrap® Revascularization Device|EmboTrap® Revascularization Device
40845953|NCT03341455|BEHAVIORAL|Capacity building to support families affected by IPV & substance misuse|Training targeted groups (mothers, fathers, preschool teachers, community officers managing preschools) separately with the aim to identify and support high-risk families early enough to arrest the cycle of violence that results in children themselves becoming victims and perpetrators of such violence.
40845954|NCT06544759|BEHAVIORAL|Aa educational Documentry|"The Gift of Life: Become an Organ Donor, Transform the Future! is an informative and captivating documentary that delves into the world of organ transplantation and the powerful implications of organ donation. This documentary aims to dispel common misconceptions about organ donation and shares a heartwarming real-life story that highlights the life-saving potential of organ transplants. Through its comprehensive exploration of the subject and engaging storytelling, the documentary not only educates but also inspires profoundly. The documentary challenges preconceptions and aims to cultivate a culture of empathy, generosity, and life-saving commitment through its meticulous examination of the topic. The documentary serves as a powerful tool to raise awareness about the importance of organ donation and its potential to make a positive change in the world."
40845955|NCT04943432|BEHAVIORAL|Behavioral Activation|8 sessions of harm reduction-focused Behavioral Activation for Substance Use
40845956|NCT01265303|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
40845957|NCT02430987|DIAGNOSTIC_TEST|Female sexual function index questionnaire|"Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese with 19 items measuring female sexual function. Cut-off points of \>23 and \> 26.5 were adopted to define a diagnosis of Female Sexual Function based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM -IV- TR) by the American Psychiatric Association, duration criteria \> 24 weeks.~A score of 5 or less on the combination of items comprising the desire domain of the FSFI questionnaire was used to define the diagnosis of Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women We consider that a score of 6 or more the woman does not present with HSDD."
41028712|NCT06151262|DRUG|Trilaciclib+mFOLFIRINOX|This was a single-arm, exploratory study of the combination of Trilaciclib and mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line therapy. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every four cycles to assess tumor response.
41028713|NCT01573702|PROCEDURE|Stereotactic Radiosurgery|21 Gy daily for 5 days
41028714|NCT01573702|DRUG|Erlotinib|150mg once daily
41161538|NCT03211897|DRUG|Haloperidol Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
41161539|NCT03211897|DRUG|Ziprasidone Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
41161540|NCT03211897|DRUG|OLANZapine Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
41161541|NCT03211897|DRUG|Midazolam injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
41161542|NCT01995318|OTHER|Kinesiotaping|Application of anti-edema type kinesiotaping to injured ankle.
41161543|NCT03431480|BIOLOGICAL|Autologous Human Placental Cord Blood Mononuclear Cells|Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
41161544|NCT03494985|DEVICE|Experimental Oralbalance Moisturizing Gel|Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
41367237|NCT04899570|DRUG|Vindesine|Vindesine 4mg intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
41367238|NCT04899570|DRUG|Prednisone|Prednisone 60mg/m2 orally d1-5, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
41367239|NCT00873496|DRUG|Hydroxychloroquine|
41367240|NCT03406780|BIOLOGICAL|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
41367241|NCT03406780|DRUG|Placebo|Placebo
41501785|NCT03685578|DEVICE|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
41501786|NCT03685578|DEVICE|CEREGLIDE 71 Intermediate Catheter|CEREGLIDE 71 Intermediate Catheter
41501787|NCT04208750|DEVICE|Vision R-800 Phoropter|Refraction utilizing the Vision R-800 Phoropter with resulting glasses
41501788|NCT04208750|DEVICE|Standard Phoropter|Refraction utilizing the standard phoropter with resulting glasses
41501789|NCT02069431|DRUG|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
40845958|NCT02430987|DIAGNOSTIC_TEST|Evaluation of presence of metabolic syndrome|The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol \< 50mg/dL; (3) triglycerides \> 150mg/dL; (4) arterial blood pressure (SAH) \> 130/85mmHg; and (5) fasting glucose \> 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.
40845959|NCT02430987|DIAGNOSTIC_TEST|Evaluation of the body mass index|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group
40845960|NCT06339970|OTHER|Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|In this group 21 patients will perform Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
40845961|NCT06339970|OTHER|Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|In this group 21 patients will perform Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
41367242|NCT05596695|OTHER|Minimizing blood pressure variability|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anaesthesia.
41501790|NCT02069431|OTHER|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
40845962|NCT06584071|DRUG|PM8002|PM8002 via IV infusion, Q3W
40845963|NCT06584071|DRUG|PM1009|PM8002 via IV infusion, Q3W
40845964|NCT06584071|DRUG|atezolizumab|atezolizumab,1200mg, via IV infusion, Q3W
40845965|NCT06584071|DRUG|bevacizumab|bevacizumab,15mg/kg, via IV infusion, Q3W
40845966|NCT02321761|DRUG|Amantadine hydrochloride|Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
41367243|NCT05195242|DRUG|Dexamethasone|ATC code H02AB02
41367244|NCT04163419|DRUG|Tanezumab|Tanezumab 10 mg SC
41367245|NCT04163419|DRUG|Placebo|Placebo 10 mg SC
41367246|NCT02707562|DRUG|GLPG1837 dose 1|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
41367247|NCT02707562|DRUG|GLPG1837 dose 2|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
41367248|NCT02707562|DRUG|GLPG1837 dose 3|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
41367249|NCT03658031|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg administered each morning before breakfast
41367250|NCT01072175|DRUG|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
40845967|NCT00679874|OTHER|Cardio-vascular MRI|Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
40845968|NCT04878913|DRUG|C21|C21 was administered in the VP-C21-006 trial
40845969|NCT04878913|DRUG|Placebo|Placebo was administered in the VP-C21-006 trial
40845970|NCT00418054|DRUG|Nitazoxanide plus peginterferon alfa-2b|
41161545|NCT03494985|DEVICE|Biotene Original Oral Rinse|Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
41367251|NCT01072175|DRUG|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
41501791|NCT06360055|DRUG|Dabigatran Etexilate|Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on an empty stomach on the morning of day 1 and day 16 of the trial period.
40845971|NCT00418054|DRUG|Peginterferon alfa-2b|
40845972|NCT02666612|PROCEDURE|Blood samples|
40845973|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
40845974|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
41161546|NCT03494985|DEVICE|Biotene Moisturizing Mouth Spray|Participants sprayed one jet directly into their mouth. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
41367252|NCT05374109|BEHAVIORAL|SYV: Sauti ya Vijana (The Voice of Youth intervention)|Mental health is associated with ART adherence and HIV outcomes. SYV was designed to address the specific challenges of young people living (YPLWH) with HIV in Tanzania. SYV includes 10 group sessions (two sessions held jointly with caregivers) lasting approximately 90 minutes and two individual sessions delivered by trained young adult group leaders who use a manualized protocol that is designed to scale in low resource settings. The intervention is applied to the Social Action Theory (SAT), a theoretical framework used to determine factors that influence health behavior. Building off a SAT resilience framework for YPLWH, components of evidence-based treatment models to influence cognitive, self, and social regulation to improve behavioral health outcomes will be strategically used.
41367253|NCT04259749|OTHER|Flavor Ban|Only flavored tobacco products are banned
41367254|NCT04259749|OTHER|Menthol Ban|Mentholated products are banned
41367255|NCT04259749|OTHER|All flavored and mentholated products available|No bans: All tobacco products are available
41367256|NCT00903357|DRUG|Montelukast first, then placebo|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
41028715|NCT04827199|DEVICE|Artificial Urinary Sphincter implantation|"Device preparation (recharge, settings, pairing) Patient preparation Calibration procedure (to verify the device is in full working prior to implantation)~Implantation procedure which includes:~* Perineal approach and bulbar urethral dissection~* Inguinal approach~* Cuff implantation around the urethra~* Transmission cable passing~* Surgery test procedure~* Implantation of the Control Unit~* Closure of the inguinal incision~* Closure of the perineal incision~* Implant disabled mode activation"
41028716|NCT06371885|DEVICE|shock wave therapy|shock wave therapy will be applied one session per week, each ESWT session will involve 2,000 pulses of the focus probe at 4-bar pressure and 5 Hz frequency for twelve weeks
41367257|NCT00903357|DRUG|Placebo first, then Montelukast|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
41161547|NCT03494985|OTHER|Water|Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use. After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required.
41161548|NCT04620122|OTHER|Progressive Muscle Relaxation Training and Music Therapy|Progressive Muscle Relaxation Training and Music Therapy have applied to the participants two sessions for a week during two months.
40845975|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
40845976|NCT01264770|DRUG|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
41367258|NCT00899327|GENETIC|DNA methylation analysis|
41367259|NCT00899327|GENETIC|RNA analysis|
40845977|NCT01264770|DRUG|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
40845978|NCT00377364|DRUG|Drug: Acetaminophen, Drug: Placebo|Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
40845979|NCT01979458|DEVICE|PSE|
40845980|NCT06149377|PROCEDURE|Test cohort|
40845981|NCT06055569|OTHER|Rehabilitation protocol: AOT+NMES|Action observation and neuromuscular electrical stimulation followed by motor execution
41161549|NCT02611921|DRUG|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
41028717|NCT06371885|OTHER|traditional physical therapy|the traditional physical therapy will be in form of (10 minutes hot pack around wrist and forearm and 10 minutes of gentle stretching exercises for wrist joint, three sessions per week for twelve weeks
41028718|NCT05451303|DEVICE|OralViome Cancer Testing System|The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
41028719|NCT03738865|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
41161550|NCT02611921|DRUG|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
41367260|NCT00899327|GENETIC|cytogenetic analysis|
41367261|NCT00899327|GENETIC|gene expression analysis|
41367262|NCT00899327|GENETIC|mutation analysis|
41367263|NCT00899327|GENETIC|polymerase chain reaction|
41367264|NCT00899327|GENETIC|protein expression analysis|
41367265|NCT00899327|OTHER|laboratory biomarker analysis|
41367266|NCT02042742|DIETARY_SUPPLEMENT|punicalagin and hydroxytyrosol mixture|Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
41367267|NCT02042742|DIETARY_SUPPLEMENT|Control supplement (maltodextrin)|During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
41367268|NCT01584193|PROCEDURE|Ultrasound-guided subclavian vein puncture|Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
41367269|NCT01584193|PROCEDURE|Cephalic vein dissection|Central venous access port implementation through cephalic vein dissection and cutdown
41367270|NCT05531916|OTHER|Pressurized gloves and foot caps|Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).
41367271|NCT04133909|DRUG|Placebo|Placebo is a 0.9% sodium chloride solution. It will be administered as a subcutaneous (SC) injection delivered once every 4 weeks using a pre-filled safety syringe.
41367272|NCT04133909|BIOLOGICAL|Mepolizumab|Mepolizumab is a sterile liquid formulation. It will be administered as a SC injection (100 mg/mL) delivered once every 4 weeks using a pre-filled safety syringe.
41367273|NCT00641017|BIOLOGICAL|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
41367274|NCT00641017|BIOLOGICAL|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
41028720|NCT03738865|DRUG|Novo Glucagon|1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
41367275|NCT02724189|DEVICE|MyPreOp assessment|MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.
41028721|NCT01786356|DEVICE|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
41367276|NCT02724189|OTHER|Nurse led assessment|Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
41367277|NCT00716365|DEVICE|HemCon bandage|5 cm X 5 cm
41367278|NCT00761462|DRUG|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
41367279|NCT00761462|DRUG|Non-quinolone antibiotic|Common used dose and route
40845982|NCT06055569|OTHER|Rehabilitation protocol: Action Observation Therapy (AOT)|Action observation followed by motor execution
40845983|NCT06055569|OTHER|Observation of motor-neutral stimuli (MNO)|Motor-neutral observation followed by motor execution
40845984|NCT03698656|BEHAVIORAL|Spiritual Interview|Three patient interviews (45 to 60 minutes) will be conducted by the study nurse at the beginning of the study and approximately 2 and 4 month later, according to the program of the medical care. Each interview will be conducted according the active listening method of Carl Rogers.
40845985|NCT05368168|DEVICE|Posterior tibial nerve stimulation (PTNS)|"Posterior tibial nerve neurostimulation in postoperative patients treated for rectal neoplasms for 6 weeks at a rate of 2 sessions per week (12 sessions).~The sessions will be carried out by the nursing staff of the anorectal functional testing cabinet. The sessions will begin 3 weeks after hospital discharge for patients without lateral ileostomy and after ileostomy closure for patients with lateral ileostomy."
40845986|NCT06071481|DRUG|Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution|2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol
40845987|NCT03679026|OTHER|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
40845988|NCT06041633|DIAGNOSTIC_TEST|Clinical|Questionnaire
40845989|NCT06222294|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
40845990|NCT06222294|DRUG|Propofol Medium and Long Chain Fat Emulsion Injection|Loading dose: 0.3-0.5mg/kg Maintenance dose: IV Propofol Medium and Long Chain Fat Emulsion Injection, dose range 0.3-4.0mg/kg/h, increment or decrement of 0.3-0.6mg/kg/h
40845991|NCT02275156|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
40845992|NCT06421922|DIETARY_SUPPLEMENT|Group 1 received a regular constipation diet|Group 1 received only regular constipation diet, the constipation diet included 2 litres of water, 2 portions of vegetables, 3 portions of fruits and legumes 2 times a week. Followed 8 weeks.
40845993|NCT06421922|DIETARY_SUPPLEMENT|Group 2 received a constipation diet rich in soluble fiber|Soluble fiber (resistant starch) (5 g/day) was added to the constipation diet in group 2 as 1 sachet/day (5 g/day) during the initial 4 weeks and 2 sachets/day (10 g/day) in the following 4 weeks.
41028722|NCT01786356|OTHER|B&L MI60|same-day bilateral cataract surgery with implantation of intraocular lens B\&L MI60 in one eye
41028723|NCT03047447|BEHAVIORAL|Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome|30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes
41028724|NCT00775918|DRUG|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
41028725|NCT01391104|DRUG|Sildenafil|Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
41028726|NCT01391104|DRUG|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
41367280|NCT03833609|BEHAVIORAL|Online yoga training (Group A)|The yoga training program is a structured low-intensity Vishwas-Raj (18). This yoga program consists of stretching, strengthening, meditation and deep breathing, and has been shown to be effective among adults with RA. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
41367281|NCT03833609|BEHAVIORAL|Online aerobic dance training (Group B)|The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
41367282|NCT06270160|DIAGNOSTIC_TEST|HIVST|Peer navigators will demonstrate how to use an HIVST kit, including how to 1) open the kit, 2) collect the oral fluid samples, and 3) read the results. In addition to HIVST education, participants will be offered optional pre-test counselling and SMS contact information to connect with their peer navigator. If participants do not want post-test counselling, the PN will follow up within two weeks. If the participants report testing positive, then they will be immediately scheduled for confirmatory testing and enrolled in the support programs at MARPI for young people living with HIV.
41028727|NCT02438449|PROCEDURE|Breast Reconstruction Surgery|AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
41028728|NCT03846843|DRUG|OCR-002 IR Oral Tablet|OCR-002 3 gram immediate release (IR) tablet for oral administration
41367283|NCT06270160|DEVICE|mHealth|The investigators are collaborating with the WelTel non-profit agency for a supportive SMS intervention. The WelTel system will manage the SMS intervention on their structured mobile phone platform (all SMS interactions are logged). Weekly 2-way supportive messages will automatically be sent on the same weekday with WelTel software to Arm 2+3 participants. The peer navigator will ask Arm 2+3 participants to respond to the SMS within 48 hours to confirm their wellbeing and will follow-up with non-responders. The Arm 2+3 peer navigators and Research Coordinator will access the server every 24-48 hours to triage and respond to participants who express a problem or need.
41367284|NCT06270160|BEHAVIORAL|Creating Futures Livelihoods program|Creating Futures is a group intervention that aims to help young people build their livelihoods, and was designed for use with youth (18-24) in urban informal settlements in South Africa.
41501792|NCT06360055|DIETARY_SUPPLEMENT|D-mannose|Subjects will take 3g (1g\*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose specification in the instructions).
41028729|NCT03846843|DRUG|OCR-002 Oral Solution|OCR-002 5 gram solution for oral administration
41028730|NCT03846843|DRUG|OCR-002 IV Solution|OCR-002 5 gram solution for intravenous (IV ) administration
41028731|NCT03933293|DRUG|AK102|450mg, Q4W, subcutaneous injection
41028732|NCT03933293|DRUG|Statins|Lipid-lowering therapies
41028733|NCT03933293|DRUG|Ezetimibe|Lipid-lowering therapies
41028734|NCT05812573|OTHER|no intervention|No intervention, only observation
41028735|NCT05056246|DRUG|maridebart cafraglutide|Solution for injection
41028736|NCT04302792|BEHAVIORAL|Texture-modified foods for cancer patients (Stage 2)|Participants (cancer patients that require texture-modified foods) will be expected to evaluate a maximum of three meals over a 2-weeks period.
41028737|NCT04302792|BEHAVIORAL|Taste-optimised foods for cancer patients (Stage 3)|Participants (cancer patients with taste \& smell alterations) will be expected to evaluate three foods at home over a period of one month.
41028738|NCT05884034|OTHER|Telerehabilitation|Subjects will participate in a six-week self-care education program with weekly synchronous meetings using Google Meet or WhatsApp and an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with a schedule for weekly organization.
41367285|NCT03250728|BIOLOGICAL|Peripheral blood puncture|"Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~* the endothelial permeability~* the protein C system"
41367286|NCT02173821|PROCEDURE|Blood sampling|Blood sample will be collected at a single visit
41367287|NCT05278663|DRUG|E6742|E6742 tablet.
41367288|NCT05278663|OTHER|Placebo|E6742-matching placebo tablet.
41367289|NCT01734499|BEHAVIORAL|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in."
41501793|NCT05204082|DEVICE|Single Use Vein Entry Indicator Device|Electronic pressure sensing device, integrated to a conventional needle catheter, and which indicates continuously during intravenous cannulation whether the tip of the needle is inside or outside of a vein, to assist a clinician in intravenous cannulation.
41501794|NCT05599061|OTHER|FFR>0.80+ OCT with findings indicative of vulnerable plaque|Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI
41501795|NCT05599061|OTHER|FFR>0.80+ OCT with findings indicative of vulnerable plaque|OPTIMAL MEDICAL TREATMENT (OMT)
41501796|NCT05083182|DRUG|Ustekinumab|Ustekinumab will be administered as subcutaneous injection.
41501797|NCT05083182|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
41501798|NCT02424643|BEHAVIORAL|Monetary Incentive|$20 Amazon.com gift card
41501799|NCT02424643|BEHAVIORAL|Altruistic Incentive|"A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey"
41028739|NCT05884034|OTHER|Education|Participants will receive an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with orientations on the importance of reading and implementing the guidelines described in the booklet.
41028740|NCT01645709|DRUG|Verapamil|
41028741|NCT01645709|DRUG|Placebo|
41028742|NCT06257147|BEHAVIORAL|multifaceted antibiotic stewardship intervention|Group 3 wards will receive a multifaceted antibiotic stewardship intervention. Physician education will be provided as in Group 1. All consecutive patients fulfilling inclusion and exclusion criteria for study eligibility will be assessed by an Antibiotic Stewardship team. A trained nurse will first assess the patients for clinical and host criteria to determine eligibility for short-course antibiotic therapy. The antibiotic susceptibility test results and the prescribed antibiotics treatment will be reviewed. An Infectious Diseases physician will subsequently make written recommendations for the duration and choice of antibiotic therapy, and provide an appointment within 2 weeks after hospital discharge to review patients' clinical condition when indicated.
41028743|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 8-session version|Emotion Regulation Therapy will be administered over 8 individual sessions on a weekly basis, resulting in a total required time commitment of 9 hours over the course of 8 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
41367290|NCT01734499|BEHAVIORAL|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
41367291|NCT01734499|BEHAVIORAL|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
41367292|NCT03010332|BIOLOGICAL|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
41367293|NCT02852876|DRUG|ASP2151|Oral
41367294|NCT02852876|DRUG|Placebo|Oral
41367295|NCT06158087|DEVICE|pEGASUS Stent System|Endovascular intervention with p64/p48 MW HPC pEGASUS Stent System was performed in patients diagnosed with intracranial aneurysms
41367296|NCT05054985|DEVICE|Multi-Branched Thoracoabdominal Stent Graft System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
40845994|NCT06421922|DIETARY_SUPPLEMENT|Group 3 received a constipation diet supplemented with probiotic yogurt.|"Bifidobacterium İnfantis 35624 (B. İnfantis 35624)\&#34; strain, which is specific to IBS, was added to yogurt in group 3, consumed before the lunch. The follow-up period was 8 weeks."
41367297|NCT05571982|PROCEDURE|Tidal volume breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
40845995|NCT04514211|DRUG|Propofol|General anesthesia using propofol infusion
40845996|NCT04514211|DRUG|Sevoflurane|General anesthesia using sevoflurane
40845997|NCT01467830|PROCEDURE|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|use of absorbable sutures to fixate mesh inguinal hernia repair.
40845998|NCT06431230|BEHAVIORAL|standard high-intensity interval training|The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. It is based on the standard physical exercises: squats, push-ups, sit-ups, toe-touches, mountain climber, jumping jacks, standing abs twist and squat to side.
40845999|NCT06431230|BEHAVIORAL|plyometric high-intensity interval training|The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. However, there is a difference, comparing to the St-HIIT, related to different exercises used in protocol. This kind of HIIT programme will be based on plyometric exercises: jumping jacks, skip A, skip C, jumps back into a push-up position and returns to the squat position, throwing the legs out of support and jumping out, jumping out of a squat.
40846000|NCT05077293|OTHER|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
41367298|NCT05571982|PROCEDURE|Vital capacity breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
41501800|NCT02424643|BEHAVIORAL|Dashboard Incentive|"A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data."
41501801|NCT01542151|OTHER|Time of labor induction|Assigned time of labor induction - morning or evening
41501802|NCT06323447|DIAGNOSTIC_TEST|PointCheck|Binary classification of severe neutropenia
41501803|NCT02151877|DRUG|Inhaled Nitric Oxide|delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
41501804|NCT02151877|DRUG|placebo|inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
40846001|NCT05077293|OTHER|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
40846002|NCT02166827|DEVICE|NeuroAD|Synchronized TMS and cognitive stimulation to 6 brain areas.
40846003|NCT02166827|DEVICE|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
40846004|NCT06065891|PROCEDURE|PALN resection|Resection of paraaortic lymph nodes in pancreatic cancer
41501805|NCT05603533|OTHER|Music and video-based group exercise therapy|Each exercise session will last up to 45min. The participants will follow this group exercise therapy twice a week for four months.
41501806|NCT05597150|DIETARY_SUPPLEMENT|Magnesium Citrate|Each participant should receive a high-magnesium diet for 1-3 weeks and take magnesium supplements for 4-6 weeks.
41501807|NCT04086407|DEVICE|Dual-axis inclinometer attached to the subject's forehead with tape|This is the first clinical trial in the industry to address OSA symptom severity and snoring as a direct function of head pitch and roll angle. The head pitch and roll angle can be used with high consistency to predict OSA symptom severity. The apnea equation is based on the gravitational crush forces of the mass of the tongue and nearby tissue on the upper air way and is valid for most OSA sufferers.
40846005|NCT01439373|DRUG|GSK2336805|Active Investigational Drug
40846006|NCT01439373|DRUG|Pegylated interferon alfa-2a|Standard of Care drug
40846007|NCT01439373|DRUG|Ribavirin|Standard of Care drug
40846008|NCT01439373|DRUG|GSK2336805 Matching Placebo|Placebo of Investigational Drug
40846009|NCT03603106|DRUG|P03277|"Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s."
40846010|NCT03603106|DRUG|Placebo|"Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s."
40846011|NCT00731471|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
40846012|NCT05401318|PROCEDURE|Tumor tissue sampling for organoid development|Fresh tissue from colorectal tumors will be sampled and cultivated in 3D cultures for drug testing.
40846013|NCT01008904|DRUG|magnesium oxide|Given PO
40846014|NCT01008904|OTHER|questionnaire administration|Ancillary studies
40846015|NCT01008904|PROCEDURE|quality-of-life assessment|Ancillary studies
40846016|NCT06002568|PROCEDURE|Silent|Apply wave file created in silence.
40846017|NCT06002568|PROCEDURE|Binaural beats|Apply wave file which is intended to generate binaural beats by applying waves of different frequency (1Hz difference) in each ear.
40846018|NCT04633824|OTHER|Retrospective Electronic Medical Record Review|Patients will be assessed retrospectively for evidence of successful or failed epidural extension in the setting of need for cesarean section
40846019|NCT02652468|DRUG|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
40846020|NCT02652468|DRUG|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
40846021|NCT02652468|DRUG|Cyclophosphamide|Given IV for 2 days
40846022|NCT02652468|RADIATION|Total nodal irradiation|Undergo total lymphoid irradiation
40846023|NCT02652468|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
41367299|NCT03615742|OTHER|Placebo|Inhalation of air through a Turbuhaler that contains no medication, as a control.
41367300|NCT03615742|DRUG|Budesonide|1.6mg of budesonide from a Turbuhaler.
41367301|NCT03615742|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control.
40846024|NCT02652468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
40846025|NCT02652468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
40846026|NCT02652468|DRUG|Mycophenolate Mofetil|Given PO
40846027|NCT02652468|DRUG|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10\^5 cells/kg ideal BW of the patient
40846028|NCT02652468|BIOLOGICAL|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10\^5 cells/kg ideal BW of the patient
41367302|NCT03615742|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
41367303|NCT06394427|OTHER|cycles of neoadjuvant therapy and duration of waiting for surgery|We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
41367304|NCT04678557|COMBINATION_PRODUCT|VC-01 Combination Product|PEC-01 cells loaded into an Encaptra Drug Delivery System
41367305|NCT04916808|DIAGNOSTIC_TEST|DCISionRT Test|The Prelude DCISionRT Test was developed by Prelude Corporation and is performed at its CLIA laboratory facility. The biomarkers used to evaluate the biologic signature of DCIS tissue are based on over a decade of research including the University of California, San Francisco, Yale University as well as Prelude Corporation. The test is prognostic for 10-year recurrence risk and predicts RT treatment benefit for invasive breast cancer. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing and is accredited by the College of American Pathologists (CAP).
41367306|NCT00934661|DRUG|Extended Release Epidural Morphine (EREM)|A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
40846029|NCT03508609|BIOLOGICAL|CLBS16|GCSF-mobilized autologous CD34 cells
41367307|NCT00934661|DRUG|Placebo|A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
40846030|NCT05188703|BEHAVIORAL|Patient Navigation|Participants will be assigned to a patient navigator and will have quarterly appointments. Patient navigators will assist with access and coordination of medical care.
40846031|NCT05229029|DRUG|TCM Formula|TCM herbs：White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.
40846032|NCT05229029|DRUG|Placebo|Mainly made of dextrin and caramel, containing 1/30 concentration of experimental group drugs
40846033|NCT01462890|BIOLOGICAL|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
40846034|NCT01462890|DRUG|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
40846035|NCT01462890|DRUG|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
40846036|NCT01462890|OTHER|specialized pathology review (Germany only)|before randomization
40846037|NCT04107441|DRUG|AX-8 Part 1|5, 10, 20, and 40 mg AX-8 orally disintegrating tablets (ODTs), up to 80 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved on the back of the tongue while the subject is in a sitting position. The subjects will be instructed not to suck, chew or swallow the tablet, i.e. to allow it to dissolve on the back of the tongue without any further intervention.
40846038|NCT04107441|DRUG|AX-8 Part 2|5 and 40 mg AX-8 orally disintegrating tablets (ODTs), 45 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved in the mouth while the subject is in a sitting position. The subjects will be instructed to actively move the tablet around in their mouth (i.e. active oral manipulation of the tablet) until it is fully dissolved.
40846039|NCT06343909|OTHER|Hip abductor strengthening exercise|in this group 15 participants will perform hip abductor streghtning along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 reputations will be performed.
40846040|NCT06343909|OTHER|Intrinsic foot muscle strengthening along with conventional exercises|in this group 15 participants will perform Intrinsic foot muscle strengthening along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 repitations will be performed.
40846041|NCT00837759|DRUG|Insulin|
40846042|NCT00837759|DRUG|Lansoprazole|
40846043|NCT00837759|DRUG|Sitagliptin|
40846044|NCT00837759|BIOLOGICAL|Diamyd|
41367308|NCT05398939|DIAGNOSTIC_TEST|Blood test and skin evaluation|The patients received blood tests for serum 25-hydroxyvitamin D level and skin evaluation for severity of acne vulgaris and lesion counts.
41367309|NCT01040806|BEHAVIORAL|Usual care|Patients will receive their usual medical care
40846045|NCT00837759|DRUG|GAD65 (Diamyd)|
40846046|NCT04084847|DIETARY_SUPPLEMENT|berberis vulgaris=barberry|10 grams of barberry powder will be consumed daily for 8 weeks.
40846047|NCT04084847|DIETARY_SUPPLEMENT|Placebo|Placebo powder
40846048|NCT04780464|DRUG|Doxorubicin|60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
40846049|NCT04780464|DRUG|Doxorubicin|12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
40846050|NCT04780464|DRUG|Cyclophosphamide Oral Product|100 mg BD on day 1 to day 7 of each 14 day cycle until PD
41367310|NCT01040806|BEHAVIORAL|Health coaching|Peer health coaches will counsel patients with diabetes
41367311|NCT00948896|DRUG|trimethoprim-sulfamethoxazole (TS; TMP/SMX)|daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
41501808|NCT02733380|DRUG|Chidamide|30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops
41501809|NCT02733380|DRUG|Vinorelbine|20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
41501810|NCT02733380|DRUG|Liposomal Doxorubicin or mitoxantrone|20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
41501811|NCT02733380|DRUG|Dexamethasone|10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
41501812|NCT02733380|DRUG|Thalidomide|100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks
41501813|NCT04129229|DEVICE|LinguaFlex Tongue Retractor (LTR)|The LinguaFlex Tongue Retractor (LTR) is a small, flexible, implanted tongue retaining device that lessens the backward movement of the tongue during sleep. The LTR's flexible shaft and a nubbed tether passes through the center of the tongue beneath the tongue blade (frenulum area) and connects to a disc (head) that rests on the external surface of the tongue base mucosa. Underneath the tongue, on the external surface of the frenulum, a small anchor secures the shaft that can be adjusted to tension the LTR to maximize therapeutic effect and maintain comfort.
40846051|NCT04780464|DRUG|Prednisolone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD
40846052|NCT04780464|DRUG|Prednisone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
40846053|NCT04001283|DRUG|Sodium Nitrite|Intravenous drug infusion
40846054|NCT04001283|DRUG|0.9% Sodium-chloride|Matched placebo
40846055|NCT04394715|OTHER|Electronic Alert|"Providers will see an automated electronic alert for each eligible hyperlipidemia patient at high risk for future atherosclerotic CVD events. This alert will appear when the provider enters the order entry screen in the patient's medical record during the patient's first eligible outpatient visit. The alert consists of a pop up that notifies the physician that the patient is at very high risk for ASCVD events, displays the most recent cholesterol values and the patient's current lipid lowering therapy. It also includes a link to full treatment guidelines for hyperlipidemia, which includes a continuing medical education (CME) option to obtain CME credits."
40846056|NCT04770844|OTHER|Acquisitions|"Three acquisitions of 1 hours during hospitalization will be realized:~* a few days after hospitalization,~* in the middle of the hospitalization,~* a few days before hospital discharge. The child will be lying on his back in a heated cradle and filmed with a specific camera. The signal will be obtained by 2k ZED 2 stereo camera in order to obtain a three-dimensional location of the child"
40846057|NCT00439036|BEHAVIORAL|Behavior Therapy|The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
41501814|NCT06408935|DRUG|Guselkumab|Guselkumab will be administered IV and SC.
40846058|NCT00439036|BEHAVIORAL|Drug Counseling|
40846059|NCT06516549|OTHER|Skipping rope and informational pamphlet|The provision of a skipping rope and an informational pamphlet to the intervention arm participants will happen during the participant interview within the overall DASH cohort study. The enumerator conducting the survey interview will provide each participant in the intervention group with a skipping rope and pamphlet and will read a short script explaining how to use the rope, outlining the main benefits of physical activity for adolescents, and asking participants to read the pamphlet in their own time.
40846060|NCT02055300|DRUG|LY03005|
41367312|NCT00948896|DRUG|sulfadoxine-pyrimethamine (SP)|monthly dosing given as a single dose, 500mg/25mg tabs
41367313|NCT00948896|DRUG|dihydroartemisinin-piperaquine (DP)|monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
41367314|NCT04027582|OTHER|didactic teaching and simulator practice|the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
41501815|NCT02446600|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41501816|NCT02446600|DRUG|Carboplatin|Given IV
41501817|NCT02446600|DRUG|Cediranib Maleate|Given PO
41501818|NCT02446600|PROCEDURE|Computed Tomography|Undergo CT
41501819|NCT02446600|PROCEDURE|Echocardiography|Undergo ECHO
41501820|NCT02446600|DRUG|Gemcitabine|Given IV
41367315|NCT05797467|DRUG|FOLFOX chemotherapy regimens|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
41367316|NCT05797467|DRUG|Bevacizumab|Targeted therapy regimens are recommended based on gene testing results. For colorectal cancer patients with KRAS/NRAS/BRAF gene mutations, it is recommended to use Bevacizumab in combination with chemotherapy. For right-sided colon cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Bevacizumab. For left-sided colon and rectal cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Cetuximab.When using targeted therapy in combination with chemotherapy, the treatment course should be synchronized with chemotherapy (Bev 5mg/kg iv d1 or Cet 500mg/m2 iv d1).
41367317|NCT00283673|BEHAVIORAL|Exercise|
41501821|NCT02446600|DRUG|Gemcitabine Hydrochloride|Given IV
41501822|NCT02446600|OTHER|Laboratory Biomarker Analysis|Correlative studies
41501823|NCT02446600|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41501824|NCT02446600|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41501825|NCT02446600|DRUG|Olaparib|Given PO
41501826|NCT02446600|DRUG|Paclitaxel|Given IV
41501827|NCT02446600|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
41501828|NCT02446600|OTHER|Pharmacological Study|Correlative studies
40846061|NCT02055300|DRUG|Placebo|
40846062|NCT02055300|OTHER|Meal|
40846063|NCT02055300|DRUG|Pristiq|
40846064|NCT00700505|DEVICE|FlowPants(R) Garment|"The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.~The garment is activated and begins to heat up 5-15 minutes prior to voiding."
41028744|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 16-session version|Emotion Regulation Therapy will be administered over 16 individual sessions on a weekly basis, resulting in a total required time commitment of 18 hours over the course of 16 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
41028745|NCT06044623|DRUG|CDK 4/6 inhibitors|Either Palbociclib, Ribociclib or Abemaciclib
41028746|NCT06044623|DRUG|Endocrine therapy|Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
41028747|NCT04844424|DRUG|Milvexian|Milvexian will be administered orally or via nasogastric route as tablets or capsules.
41028748|NCT06077006|OTHER|questionnaires Only|questionnaires Only
41028749|NCT02359669|BEHAVIORAL|StimuLearn Intervention|"* StimuLearn apps~* Cognitive questionnaires"
41028750|NCT02359669|BEHAVIORAL|Without StimuLearn intervention|Cognitive Questionnaires
41028751|NCT03467659|OTHER|Cracked whole wheat porridge|Large particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
41367318|NCT05324839|DRUG|Botulinum toxin type A|injecting different dosage to different group
41367319|NCT01060410|GENETIC|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
41367320|NCT01060410|DRUG|Cyclophosphamide|intravenous injection, 0.2g, once every two days
41367321|NCT01060410|OTHER|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
41367322|NCT00965562|DRUG|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
41367323|NCT00965562|DRUG|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
41501829|NCT02446600|OTHER|Quality-of-Life Assessment|Ancillary studies
41501830|NCT05743881|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
41501831|NCT05743881|BIOLOGICAL|mRNA-1365|Sterile liquid for injection
41501832|NCT05743881|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) solution for injection
41501833|NCT05743881|DRUG|Nimenrix|Solution for injection
41501834|NCT00428116|DRUG|HAART|Combination first line antiretrovirals as previously described.
41501835|NCT01939574|OTHER|Chemoradiation Therapy|"* Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~* Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight."
41501836|NCT01939574|OTHER|Adjuvant Therapy|"* Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events\> grade 2 are noted.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight."
41501837|NCT06242821|OTHER|Observation|Patients who chose to be part of the study, but do not wish to participate in PT or Yoga, will be monitored with routine imagine, and survey follow up.
41501838|NCT06242821|OTHER|Physical Therapy|Patients will either be randomized or self select to participate in Physical Therapy as per standard of care for non-operative AIS.
41501839|NCT06242821|OTHER|Yoga|Patients will either be randomized or self select to participate in the Yoga intervention. This will consist of online 20 min yoga classes, 2 times per week for 6 months. The class will be a set protocol, and patients will be given the protocol to do at home if desired.
41501840|NCT05429632|DRUG|mocravimod|S1PR modulator
40846065|NCT02277119|DEVICE|Maestro|OCT machines used for diagnostic purposes
40846066|NCT02277119|DEVICE|iVue|OCT machines used for diagnostic purposes
41501841|NCT04540497|DRUG|Inebilizumab|Inebilizumab is a monoclonal antibody that depletes B cells.
41501842|NCT04540497|OTHER|Placebo|Placebo
40846067|NCT05390658|OTHER|Not application|Not application
41161551|NCT02037750|BEHAVIORAL|LINKS|"In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations."
41367324|NCT00965562|DRUG|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
41367325|NCT04245982|PROCEDURE|Gingival biopsy|Two gingival biopsies from each participant were collected.
41367326|NCT00609934|DRUG|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
41501843|NCT04597632|DRUG|brolucizumab|brolucizumab 6 mg/0.05 mL solution for intravitreal injection
41501844|NCT06632639|OTHER|Corrective exercise protocol|The program requires 60 minutes consisting of a ten-minute warm-up, a forty-minute Thera-band exercise, and a ten-minute cool-down. Thera-band exercises are to improve the external rotators, and the extensors and for strengthening the quadriceps and the gluteus. A set consists of 15 reps, each of the exercise methods consisted of three sets.
41501845|NCT06632639|OTHER|Lateral wedged insoles with subtalar strapping|A silicon rubber 10 mm lateral wedge has a 10 mm lateral elevation and a 75 mm width, which has an approximately 7.6 inclination. This silicon rubber material is usually used for cosmetic remodeling and has a natural form-fit to the skin. The 75 mm width silicon rubber is scaphoid shaped and it is suitable for attachment to a barefoot of all of the subjects. The rational for using this inclination is that 7.6 is approximately the median between 5 and 10. Patients will be instructed to use the wedge in an appropriate shoe (not high heels or narrow-toed shoes), 1 h a day during the first week. The duration of use gradually will be increased to the minimum of 8 h a day.
40846068|NCT03489928|DRUG|Oral Misoprostol|Prostaglandin E1 - 100ug tablet, divided in half by pharmacy staff to be administered by mouth.
40846069|NCT03489928|DRUG|Vaginal Misoprostol|Prostaglandin E1 - 100ug oral tablet, divided in quarters by pharmacy staff, vaginal placement of one or two quarters as needed every 6 hours
40846070|NCT03489928|DRUG|Dinoprostone|Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
40846071|NCT05399004|OTHER|Survey Administration|Complete surveys
40846072|NCT04518488|OTHER|Exercises|Personalized and individualized exercises for lower limb soft-tissue sarcoma of each participant in this group.
40846073|NCT04518488|OTHER|Informational Support Group (Control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period.
40846074|NCT02353728|DRUG|Nilotinib|
40846075|NCT03330184|DRUG|Berberine Hydrochloride group|
41161552|NCT03411928|DEVICE|Tracheolator|'Tracheolator' non-occlusive tracheal dilation balloon manufactured by Disa Life Sciences, Cape Town, South Africa.
41367327|NCT00609934|RADIATION|external beam radiotherapy|3000cGy in 10 fractions
41367328|NCT06392282|DRUG|MV-140|MV-140 use - sublingual spray approved for recurrent UTI prevention
41367329|NCT04761770|OTHER|Geriatric assessment (GA) pre-transplant|Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.
41367330|NCT04761770|DRUG|conditioning regimen|"Based on the Geriatric assessment.~1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -\> Myeloablative (MA) regimen~2. HCT-CI/Age \>4 AND/OR any IADL impairment (more vulnerable) -\> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen"
41501846|NCT06470373|DRUG|RBS-001 Solution for intravitreal injection|Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
41501847|NCT06470373|DRUG|Eylea® Solution for intravitreal injection|Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
40846076|NCT03330184|DRUG|Bifidobacterium group|
40846077|NCT03330184|DRUG|Berberine Hydrochloride and Bifidobacterium group|
40846078|NCT03330184|DRUG|placebo|
40846079|NCT02073019|DRUG|BL-8040|
40846080|NCT02073019|DRUG|Placebo|
40846081|NCT01308229|DEVICE|Nile PAX® paclitaxel-eluting coronary stent|Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
40846082|NCT00260624|DRUG|Escitalopram (Lexapro)|
40846083|NCT02464046|DRUG|JNJ-42847922|Participants in arm JNJ-42847922 then Placebo will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.
41501848|NCT04244604|OTHER|Acute Salt (sodium chloride)|Varied amounts of salt (sodium chloride) will be added to a very low sodium soup to determine the effects of a single high sodium meal on measures of vascular function and autonomic regulation of blood pressure
41501849|NCT04939376|PROCEDURE|IVF|In vitro fertilization
41501850|NCT05450601|DRUG|HCP2102-1|Take once daily for 2 weeks orally
41501851|NCT05450601|DRUG|HPP2104-1|Placebo drug. Take once daily for 2 weeks orally
41501852|NCT05450601|DRUG|HCP2102-2|Take once daily for 6 weeks orally
41501853|NCT05450601|DRUG|HPP2104-2|Placebo drug. Take once daily for 6 weeks orally
41501854|NCT05450601|DRUG|RLD2106-1|Take once daily for 2 weeks orally
41501855|NCT05450601|DRUG|HPP2103-1|Placebo drug. Take once daily for 2 weeks orally
41501856|NCT05450601|DRUG|RLD2106-2|Take once daily for 6 weeks orally
41501857|NCT05450601|DRUG|HPP2103-2|Placebo drug. Take once daily for 6 weeks orally
41501858|NCT05382286|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
41501859|NCT05382286|DRUG|Pembrolizumab|Administered intravenously
41501860|NCT05382286|DRUG|Paclitaxel|Administered intravenously
41028752|NCT03467659|OTHER|Semolina wheat porridge|Large particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
41028753|NCT03467659|OTHER|Whole wheat flour porridge|Small particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
41028754|NCT03467659|OTHER|Refined wheat flour porridge|Small particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
41028755|NCT03467659|OTHER|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
41028756|NCT03467659|OTHER|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
41028757|NCT06387251|OTHER|30 day wellness program|30 days and will evaluate the effects of sponsor-designed 30-day wellness program consisting of 3 supplement and functional food products, recommended diet, physical activity, hydration and mindfulness activities.
41028758|NCT02656446|DEVICE|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
41028759|NCT02656446|DEVICE|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
41028760|NCT03971643|DRUG|vilobelimab|IV infusions of vilobelimab diluted in sodium chloride.
41028761|NCT04344821|DIETARY_SUPPLEMENT|Curves Calcium|"Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)"
41161553|NCT04630470|BEHAVIORAL|massage therapy with lavender oil|massage therapy with lavender oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
41161554|NCT04630470|BEHAVIORAL|massage therapy with baby oil|massage therapy with baby oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
41161555|NCT05052749|OTHER|High Intensity Resistance Training (HIRT)|High Intensity Resistance Exercises Supervised High Intensity Resistance Training with 15 minutes of cycling as a warm-up activity then HIRT through Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
41161556|NCT05052749|OTHER|Low-moderate Resistance Exercise Training|Supervised Low-moderate Resistance Training with 15 minutes of cycling as a warm-up activity then Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
41161557|NCT06398171|OTHER|Exercise|Participants will perform 8 sessions of 4 sets of knee extension exercises during 1 month
41161558|NCT04549142|OTHER|There is no intervention|There is no intervention
41161559|NCT02253147|DEVICE|TEOSYAL® RHA Ultra Deep|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27Gauge ½ disposable sterile needles."
40846084|NCT02464046|DRUG|Placebo|Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
40846085|NCT05089864|OTHER|Stent Placement Timing - Early|Stent placement 5-7 weeks after STAR procedure
41161560|NCT02541942|OTHER|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
41367331|NCT04761770|PROCEDURE|Allogeneic CD34+ selected stem cells|Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
41367332|NCT06518330|DRUG|Intake of Methylphenidate|Intake of Methylphenidate
41367333|NCT01787019|OTHER|Oral feeding|
41367334|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with single donor cornea
40846086|NCT05089864|OTHER|Stent Placement Timing - Late|Stent placement 12-14 weeks after STAR procedure
41028762|NCT04344821|DIETARY_SUPPLEMENT|Placebo|Dextrose Placebo
41028763|NCT06447038|DIAGNOSTIC_TEST|albumin creatinine ratio|Albumin creatinine ratio, this test is routinely performed in urine.
40846087|NCT01254825|PROCEDURE|Adductor-Canal-Block, Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
40846088|NCT01254825|PROCEDURE|Adductor Canal Block, Placebo (saline)|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
40846089|NCT05494034|DEVICE|Reveal LINQTM|"implantable cardiac monitoring device (Reveal LINQTM)"
40846090|NCT05965739|OTHER|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
40846091|NCT05965739|OTHER|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
40846092|NCT05965739|OTHER|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.
40846093|NCT05965739|DEVICE|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
40846094|NCT05965739|DEVICE|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
40846095|NCT00209300|DRUG|Pentasa|
41367335|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea
41367336|NCT01501019|OTHER|Exercise training|"Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.~Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.~Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity."
41367337|NCT02651246|OTHER|data collection|
41367338|NCT06386276|PROCEDURE|Colorectal bowel resection|The TrEnd is a single-institutional retrospective/prospective study, conducted in a high-volume referral centre for the endometriosis diagnosis and management, with the aim of systematically collecting data from consecutive patients undergoing segmental sigmoid colon/rectal resection for deep endometriosis.
41367339|NCT01604642|OTHER|blood tests and muscular biopsies|blood tests and muscular biopsies
41367340|NCT04448548|OTHER|blood sample taking|For study purposes, blood sample was taken during the first medical examination from patients with suspected infection.
41367341|NCT04584827|OTHER|lactate level|Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.
41367342|NCT04584827|OTHER|Glasgow Outcome Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
41367343|NCT00579514|GENETIC|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
41367344|NCT05284162|BEHAVIORAL|Health coaching|The health coaching program includes four monthly health coaching sessions for three months.
41367345|NCT03427931|OTHER|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.
41367346|NCT01588873|DRUG|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|"The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment."
41367347|NCT04077112|BEHAVIORAL|Parent Child Interaction Therapy|Behavioral parent training program targeting parent-child relationship
41367348|NCT04826042|OTHER|thoracic epidural catheterization|thoracic epidural catheterization
41367349|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
41367350|NCT01580696|OTHER|Non-vaccine clinically matched control group|HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
41501861|NCT05382286|DRUG|nab-Paclitaxel|Administered intravenously
41501862|NCT05382286|DRUG|Gemcitabine|Administered intravenously
41501863|NCT05382286|DRUG|Carboplatin|Administered intravenously
41501864|NCT05372614|PROCEDURE|Biopsy|Correlative studies
41501865|NCT05372614|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41501866|NCT05372614|PROCEDURE|Computed Tomography|Undergo CT scan
41501867|NCT05372614|PROCEDURE|Echocardiography|Undergo echocardiography
40846096|NCT04680819|DIETARY_SUPPLEMENT|Anatolian Propolis|Health workers who agree to participate in the study will be accepted as the study group, and healthcare professionals who do not agree to participate in the study will be considered as the control group. The study group will be asked to take 20 drops of Propolis drop form twice a day in the morning / evening, and the control group will not receive any treatment and both groups will be followed. In this process, patients diagnosed with COVID-19 will be determined. PCR test positivity taken from the throat for the diagnosis of COVID-19 will be accepted. The research will cover a period of 1 month. At the end of 1 month, patients diagnosed with COVID-19 in the study and control groups will be compared. Thus, the protective properties of Anatolian propolis will be determined.
41501868|NCT05372614|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
41028764|NCT05286918|PROCEDURE|The intervention (CRP-guided) group|"The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to \<5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
41028765|NCT00142974|DRUG|Tegaserod|
41028766|NCT03023735|OTHER|None. This is an observational study|
41028767|NCT00581945|DRUG|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
41028768|NCT00581945|DRUG|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
41028769|NCT06572436|BEHAVIORAL|Multimedia information training|The multimedia information training consisted of a 5-minute video containing detailed amniocentesis and chorionic villus sampling application information. A 5-minute video was developed by the authors and used for research purposes only. The video was designed to provide pregnant women with a comprehensive overview of the amniocentesis and chorionic villus sampling procedure, its benefits, and potential risks, and included real-life images to depict all aspects of the procedure.
41028770|NCT01056744|DEVICE|Percutaneous coronary intervention with stent implantation|"Percutaneous coronary intervention with implantation of either:~- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)"
41028771|NCT00815841|DRUG|METHYLPHENIDATE|15-20mg during one of the two sessions
41028772|NCT04968548|PROCEDURE|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
41161561|NCT04641416|DIAGNOSTIC_TEST|Routinely performed echo, ECG and hemodynamic monitoring|The pump data of patients on the ICU or normal ward are stored in a continuous data acquisition system (CDAS) on a notebook which is operated in battery operation, and analyzed afterwards with a mat-lab based software. For outpatients a mobile data-recorder will allow a continuous data acquisition for a period up to 2 months on a SD card. During this non-invasive pump data monitoring, routinely available hemodynamic monitoring, ECG and echo data will be collected.
41367351|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
41367352|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
41501869|NCT05372614|DRUG|Neratinib Maleate|Given PO
41501870|NCT05372614|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
41501871|NCT05454670|PROCEDURE|Two-flap palatoplasty|Two-flap palatoplasty used to correct cleft palate defect. The cleft palate is closed by separation of the nasal and the oral mucosa layers. Then approximation of the nasal mucosa layer, muscle layer is secured in the posterior palate and then the oral mucosa layer is secured
40846097|NCT03256318|OTHER|No intervention|No intervention; surveys/questionnaires only
41367353|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
41367354|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
41028773|NCT02340039|DIETARY_SUPPLEMENT|Polyphenols|Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
41028774|NCT03895060|DEVICE|autogenous ring blockls with GBR covered by collagen membrane|"* A crestal incision is made using No. 15 blade extending over the anterior maxilla, an anterior vertical releasing incision is made and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge and the lateral aspect of the maxilla~* Autogenous onlay ring blocks is taken by a trephine bur from the chin area and then fixed by screws to the deficient maxillary alveolar height.~* Equally autogenous and xenograft bone particles is packed around the screw to fill the defect area completely.~* The collagen membrane is fixed to the alveolar ridge by bone tacks and the mixture of autogenous and xenograft bone is then packed.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
41028775|NCT06064617|DEVICE|Contact Lens|Coopervision Biofinity Multifocal Lens
41028776|NCT05658861|OTHER|Milk containing A1 and A2 beta-casein|Single dose of commercial milk
41028777|NCT05658861|OTHER|Milk containing only A2 beta-casein|Single dose of A2 milk
41028778|NCT01168050|DRUG|Nilotinib|Nilotinib 400 mg twice per day
41028779|NCT05113004|DRUG|Hydroxychloroquine 400mg/d|Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
41028780|NCT05113004|DRUG|Leflunomide 20mg/d|Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.
41028781|NCT05113004|DRUG|Mycophenolate mofetil 2000mg/d|Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
41028782|NCT05113004|DRUG|Placebo of Hydroxychloroquine 400mg/d|Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
41028783|NCT05113004|DRUG|Placebo of Leflunomide 20mg/d|Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
41028784|NCT05113004|DRUG|Placebo of Mycophenolate mofetil 2000mg/d|Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
41161562|NCT03690284|DEVICE|Conventional Double Lumen Tube|Patient will be intubated with Mallinckrodt Double Lumen endotracheal tube for single lung ventilation during thoracic surgery
41367355|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
41367356|NCT04677738|DIETARY_SUPPLEMENT|B. breve|Probiotic capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve B-3 in the morning before breakfast for 12 weeks.
41367357|NCT04677738|DIETARY_SUPPLEMENT|Placebo|Placebo capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
41028785|NCT01748435|DRUG|Qutenza|Single treatment with Qutenza
41028786|NCT02789787|PROCEDURE|Maxillary Protraction|"Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate."
41501872|NCT06455540|PROCEDURE|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the superior hypogastric plexus block will be performed on all the patients. The block will contain 20 mL of 0.75% ropivacaine hydrochloride or 0.9% normal saline. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
41501873|NCT03550001|PROCEDURE|Injection CNP before NAT|Injection carbon nanoparticle via rectal mucosa before neoadjuvant therapy
41161563|NCT03690284|DEVICE|VivaSight Double Lumen Tube|Patient will be intubated with the VivaSight double lumen endotracheal tube with an integrated camera for single lung ventilation during thoracic surgery
41161564|NCT02661490|BIOLOGICAL|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
41161565|NCT02661490|DRUG|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
41161566|NCT02661490|BIOLOGICAL|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
41161567|NCT01245335|DEVICE|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
40846098|NCT04816318|OTHER|Social and public health measures against COVID-19|"1. Viral spread (for both outcomes) 1.1. Total lockdown 1.2 Partial lockdown (geographical, step-wise/graduated response) 1.3 Curfew 1.4 School closure 1.5 Closure of shopping malls, gyms, churches, parks 1.6 Remote work 1.7 Restrictions to national/subnational mobility 1.8 Prohibition of mass gatherings~2. Health systems response (for COVID-19 deaths outcome) 2.1 Interventions to increase testing capacity 2.2 Interventions to increase the number of ICU/critical beds~3. Mitigation strategies (for both outcomes) 3.1 Direct social assistance (in-kind/cash) 3.2 Cash transfer 3.3 Withdrawal of pension funds"
40846099|NCT04816318|OTHER|Control|The comparator is a counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred (see Statistical Analysis Plan for definitions)
40846100|NCT05817032|BEHAVIORAL|Telerehabilitation|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have a hybrid approach (10-12 in person, 24-26 virtual) or fully virtual.
40846101|NCT05817032|BEHAVIORAL|Standard rehabilitation care|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have 10-12 in person exercise.
40846102|NCT00688272|DRUG|Ciprofloxacin|Given 500mg BID x 6 days
40846103|NCT00688272|DRUG|Eltrombopag|Given QD x 6 days
40846104|NCT00688272|DRUG|Placebo|Given QD x 6 days
40846105|NCT01851785|BEHAVIORAL|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
40846106|NCT04940884|BEHAVIORAL|Supervised exercise training|SET Participants underwent 24 sessions of moderate-intensity exercise training (MICT) at 70% maximum predicted heart rate for 30 min in each session
40846107|NCT04940884|BEHAVIORAL|Aerobic exercise training|All recruited subjects were instructed to walk \>=8000 steps per day in the community. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised aerobic exercise training (SET) with the intensity at 70% of maximum predicted heart rate and the remaining participants follow the above home exercise training (HET) instruction without additional supervised exercise training.
41161568|NCT01245335|DEVICE|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
41161569|NCT02399683|BIOLOGICAL|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
41367358|NCT00272194|DEVICE|Ambu Laryngeal Mask|
41501874|NCT04032249|BEHAVIORAL|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food
41501875|NCT04032249|BEHAVIORAL|Intervention Group (IG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food, but also, they will have monitored the self-control of the weight in order to compare the impact of self-weighing versus not doing it
41501876|NCT04794101|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR Intermediate Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
41501877|NCT04794101|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR Low Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
41501878|NCT05595642|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W
40846108|NCT02086422|DRUG|ivabradine|
41161570|NCT01956955|DRUG|enoxaparin ,alteplase, unfractionated heparin|
41161571|NCT00115817|DRUG|Atorvastatin|
40846109|NCT02086422|DRUG|Placebo|
40846110|NCT02086422|OTHER|Exercise|
40846111|NCT00486382|BIOLOGICAL|Leish-111f + MPL-SE Adjuvant|
40846112|NCT00881465|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.
41161572|NCT02950714|OTHER|LIN_NOW|The Lupus interactive navigator (LIN) was developed to facilitate and support engagement and self-management for persons with lupus. It is a web-based program that provides access to relevant information, resources, support, and other tools to help them manage their illness. It is accessible by the Internet and compatible for use with computer, tablet, and mobile device. The content for the LIN was based on the results of focus group discussions and web-based surveys of persons with lupus and health care providers. Medical researchers, writers, designers and programmers worked with clinical experts affiliated with the Canadian Network for improved outcomes in Systemic Lupus Erythematosus (CaNIOS) and persons with lupus to provide the written content and interview videos.
41161573|NCT02950714|OTHER|LIN_WAIT|Usual care for three months prior to access to the LIN
41161574|NCT04255121|DRUG|2% adrenaline lidocaine associated with 4.2% sodium bicarbonate|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
41367359|NCT00272194|DEVICE|Aintree Exchange Catheter|
41367360|NCT00272194|DEVICE|Laryngeal Mask Airway|
41367361|NCT02706327|DEVICE|CAD/CAM Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
41367362|NCT02706327|DEVICE|Semi-custom Insole|Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
40846113|NCT00881465|BEHAVIORAL|Wait-list control|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
40846114|NCT04192773|DRUG|IV Lidocaine|IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
41501879|NCT05595642|DRUG|Placebo|Participants will receive SC placebo Q2W
41501880|NCT06510205|DEVICE|Mentor Breast implants|"Mentor breast implants are circular or waterdrop-shaped devices with shells made of successive cross-linked layers of silicone elastomer. The shell is filled with Mentor's proprietary formulation of silicone gel.~Mentor breast implants are available in smooth and textured shells, both supplied in sterile form."
40846115|NCT04594928|DRUG|GLPG3667|GLPG3667 capsules
40846116|NCT04594928|DRUG|Placebo|Matching placebo capsules
40846117|NCT02964585|DRUG|Canagliflozin|100 mg
40846118|NCT02964585|DRUG|Placebo|1 tablet daily for 16 weeks
40846119|NCT05228561|OTHER|Mobile Application Supported Nutrition and Diabetes Education|With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.
40846120|NCT02850406|DRUG|Voxelotor|"* Part A: Voxelotor will be administered as oral capsules or tablets~* Part B: Voxelotor will be administered as oral capsules or tablets~* Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~* Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension"
40846121|NCT01189591|DEVICE|Slow-wave deprivation|Using acoustic tones to suppress slow-wave sleep
40846122|NCT06409364|DRUG|Fludrocortisone|small white tablet containing 100mcg of fludrocortsone
41028787|NCT02789787|PROCEDURE|Orthognathic Surgery|The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
41028788|NCT04177511|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked.~The electrode is positioned in the cymba concha of the left ear."
40846123|NCT06409364|DRUG|Placebo|Matched placebo tablet,
41028789|NCT06262347|BEHAVIORAL|Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)|The TOME intervention is a modified version of the personally-tailored opioid overdose prevention education and naloxone distribution (PTOEND) intervention (Winhusen et al. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug Alcohol Depend. Nov 1 2020;216:108265). Modifications include updating the knowledge assessment/education to reflect changes in the drug supply (i.e., the current high prevalence of fentanyl and increasing prevalence of xylazine) and the addition of items specific to pregnancy. Like PTOEND, TOME is a computer-guided intervention which utilizes REDCap to complete assessments and automatically generate personally-tailored feedback reports.
41028790|NCT06262347|BEHAVIORAL|Control|Participants randomized to the control condition will be offered three SAMHSA handouts.
41161575|NCT04255121|DRUG|2% adrenaline lidocaine|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an adrenaline lidocaine solution
41161576|NCT01659177|DRUG|LY2140023|Administered orally
41161577|NCT04785586|BEHAVIORAL|Healthy Weight Coaching|Lifestyle intervention based on Healthy Weight Coaching (HWC) is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
41161578|NCT04785586|BEHAVIORAL|Individual meetings|Individual sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
41161579|NCT04785586|BEHAVIORAL|Group meetings|Group sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
41367363|NCT02706327|OTHER|Control|15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
40846124|NCT00467233|PROCEDURE|Laser Treatment|Laser treatment to half of the face at each study visit
40846125|NCT00467233|PROCEDURE|Acid Peel|Acid peel to half of the face at each study visit
40846126|NCT02048488|DRUG|TSR-011|Number of cycles until progression or unacceptable toxicity develops.
40846127|NCT02522130|DRUG|Lidocaine|intracervical injection
40846128|NCT02522130|DRUG|oral misoprostol|oral treatment
40846129|NCT02522130|DRUG|naproxen|oral treatment
40846130|NCT02522130|OTHER|placebo|oral treatment
40846131|NCT02825199|DIETARY_SUPPLEMENT|Caffeine|capsule: 300mg caffeine
40846132|NCT02825199|DIETARY_SUPPLEMENT|Non caffeine|capsule: placebo (maize starch)
40846133|NCT03462381|DIETARY_SUPPLEMENT|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
40846134|NCT02428205|DRUG|Propranolol|Participant will receive Propranolol prior to each EIBI session
40846135|NCT02428205|DRUG|Placebo|Participant will receive placebo prior to each EIBI session
40846136|NCT02934737|OTHER|Progression of diabetes|
41028791|NCT05014165|OTHER|Cord blood Sample Collection|Obtain banked cord blood samples from consecutive childhood leukemia patients
41367364|NCT06172374|GENETIC|Sano Genetics Testing Kit|Genetic testing spit collection tubes for DNA testing
41501881|NCT05591703|BEHAVIORAL|Clinical Outcomes and Questionnaires|Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.
41367365|NCT01642862|DRUG|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
40846137|NCT05532891|OTHER|COVID-19 pandemic|Pandemic group underwent surgery during the COVID-19 pandemic. Pre-pandemic group underwent surgery prior to the pandemic.
40846138|NCT02237261|DRUG|Bendamustine, Bortezomib, Prednisone|"Cycle 1 (d1-42) - Induction:~Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4~Cycle 2-9 (d1-28) - Consolidation:~Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4"
40846139|NCT05583019|DEVICE|GENEActiv Accelerometry Device|a watch like wearable sensor
40846140|NCT05583019|DEVICE|Centrepoint Insights Watch (CPIW) Accelerometry Device|a watch like wearable sensor
41367366|NCT03149341|OTHER|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
41028792|NCT05014165|OTHER|Case identification and recruitment|Cases meeting eligibility and who have given consent through APEC14B1 for future contact for non-therapeutic studies
41028793|NCT05014165|OTHER|Questionnaire Administration|The family will be given an option to complete questionnaire on paper, online, or over the telephone.
41028794|NCT02249572|RADIATION|gamma knife radiosurgery|Leksell Perfection model gamma knife.
40846141|NCT05583019|DEVICE|Apple Watch Accelerometry Device|a watch like wearable sensor
40846142|NCT05583019|DEVICE|Polysomnography|Sleep monitor
40846143|NCT05583019|DEVICE|Videography|Thermal Camera
40846144|NCT03450265|DEVICE|Hemopatch|Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
41028795|NCT01463605|DRUG|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
40846145|NCT03450265|DEVICE|Tachosil|Applied according to the current instruction for use (IFU).
40846146|NCT00242593|DRUG|Rosiglitazone|4 mg twice daily oral rosiglitazone or placebo pill for 18 months
40846147|NCT05458856|DRUG|Triptorelin embonate 22.5 mg|A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
40846148|NCT03369236|DRUG|Danicopan|Danicopan was administered as an oral tablet.
40846149|NCT03369236|DRUG|Placebo|Matching placebo was administered as an oral tablet.
40846150|NCT05377944|DRUG|BAT2306|150 mg/1 ml/injection (2 injections/visit)
40846151|NCT05377944|DRUG|EU-approved Cosentyx|150 mg/1 ml/injection (2 injections/visit)
40846152|NCT03853070|DEVICE|ED Coil / Electro-detach Generator v4|The ED Coil is used for vascular embolization with a platinum coil at the target lesion in a patient's blood vessel. The ED Detach Generator is intended to for use solely to detach the platinum coil from the delivery catheter of the ED Coil.
40846153|NCT02575703|DRUG|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi \[¹⁴C\]-LY3023414
40846154|NCT02654665|BEHAVIORAL|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
40846155|NCT02654665|DRUG|Liraglutide|GLP-1 agonist
40846156|NCT01554800|DRUG|ACP-501|A single dose infusion
40846157|NCT05333380|DEVICE|ECG/PPG monitoring|"The enrolled patients will wear an ECG patch and watch at the same time to collect ECG and PPG data respectively. The data collection time is from the day of hospitalization to before the ablation operation, and from 2 hours after the removal of ECG monitoring equipment to before leaving the hospital. The monitoring duration of each patient shall not be less than 18 hours."
40846158|NCT06583915|PROCEDURE|TENS|Non-pharmacological method which is widely used by medical and paramedical professionals for the management of acute and chronic pain using electric pulse generator, lead wires and electrodes.
40846159|NCT06583915|PROCEDURE|Dry Needle|Invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.
40846160|NCT04036929|DRUG|Estrogen-bazedoxifene|Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
40846161|NCT04036929|DRUG|Placebo oral tablet|Placebo oral tablet
40846162|NCT00004274|DRUG|Estrogen|
40846163|NCT04088110|DRUG|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
40846164|NCT04088110|DRUG|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
41367367|NCT03752502|PROCEDURE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
41028796|NCT01259193|DRUG|Sorafenib and Zoledronic Acid|Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
41028797|NCT02977546|DEVICE|Noninvasive pulse contour analysis|For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)
40846165|NCT04088110|DRUG|Aromatase Inhibitors|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
40846166|NCT02530177|OTHER|Clinical Assessments|
40846167|NCT02530177|BEHAVIORAL|Questionnaires|
40846168|NCT02530177|OTHER|Saliva sample|(only once, preferably at baseline)
41367368|NCT03752502|PROCEDURE|Peripheral electrical stimulation (PES)|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia.
41367369|NCT03752502|PROCEDURE|Sham tDCS|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
41367370|NCT04357834|OTHER|Equipment with smartwatch throughout hospital stay on the general ward|Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.
41367371|NCT00273260|BEHAVIORAL|individualised bone density feedback and education|
41367372|NCT04081246|DEVICE|Bipolar transurethral modified en bloc resection of bladder tumour|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
41367373|NCT02675699|BEHAVIORAL|Optimisation + HENRY|"HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend."
40846169|NCT03006692|OTHER|With arterial blood gas, parameters not being normal can be corrected|If arterial blood gas is analysed answers provide the possibility to make more accurate diagnosis and treat specific abnormal parameters (e.g. electrolytes, oxygenation and so forth).
41367374|NCT02675699|BEHAVIORAL|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
41367375|NCT01345227|PROCEDURE|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
41367376|NCT04993547|OTHER|Parent and peer presence|Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
41367377|NCT00004173|DRUG|oxaliplatin|
41367378|NCT00004173|DRUG|paclitaxel|
41367379|NCT06284252|OTHER|Virtual Gaming Simulation|Two-dimensional virtual game simulations that can be played on computers will be developed using the recorded videos. Games will focus on physical examination of the heart, abdomen and respiratory system. The developed games will be played to the intervention group.
41367380|NCT05392543|OTHER|Brunnstrom movement therapy.|"Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery."
41367381|NCT05392543|OTHER|Mirror Therapy|"Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session."
41367382|NCT04754022|OTHER|Restrictive Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is \<75 g/L (\<7.5 g/dL; \<4.7mmol/L) intraoperatively and/or postoperatively.
41367383|NCT04754022|OTHER|Liberal transfusion strategy|Patients will receive a RBC transfusion if their Hb concentration is \<95 g/L (\<9.5 g/dL; \<5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or \<85 g/L (\< 8.5 g/dL; \<5.3mmol/L) on the ward.
41367384|NCT01054443|DRUG|Placebo|Tablet
40846170|NCT05157581|DEVICE|Extracorporeal photopheresis (ECP)|Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.
40846171|NCT05157581|DRUG|Methoxsalen Injection|Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
40846172|NCT02391519|PROCEDURE|Collection of myometrial, cord blood, and placental tissue samples|We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
41028798|NCT02977546|DEVICE|Pulmonary artery catheterization|As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
41161580|NCT05586516|DRUG|IOA-289|IOA-289 will be administered orally twice daily (BID), starting from C0D1. Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1.
41367385|NCT01054443|DRUG|Lusutrombopag|Tablet
40846173|NCT05131230|DEVICE|CytoSorb® treatment|Patients with Acute on Chronic Liver Failure (ACLF) due to Severe Alcoholic Hepatitis in combination with systemic inflammation and ACLF grade ≥2 will be enrolled in this study. Every patient that is screened, fulfills the inclusion/exclusion criteria, and consents to the study, will be allowed to enter the study. Patients will receive Standard of Care treatment for alcoholic hepatitis plus treatment with the CytoSorb® 300 mL device.
40846174|NCT00230503|DRUG|pradefovir mesylate|
40846175|NCT00230503|DRUG|adefovir dipivoxyl|
41028799|NCT05620758|OTHER|Nd YAG laser|patients from those diagnosed with TMD will receive Nd YAG laser 1064 nm
41028800|NCT05620758|OTHER|diode laser (980 nm)|patients from those diagnosed with TMD will receive a diode laser (980 nm)
41028801|NCT05620758|OTHER|diode laser (940 nm)|patients from those diagnosed with TMD will receive a diode laser (940 nm)
41028802|NCT05620758|OTHER|diode laser (660 nm)|patients from those diagnosed with TMD will receive a diode laser (660 nm)
41028803|NCT05620758|OTHER|diode laser (635 nm)|patients from those diagnosed with TMD will receive a diode laser (635 nm)
41367386|NCT03589066|DRUG|LY03003|28 mg intramuscular suspension
41367387|NCT03856502|DRUG|8 mg of dexamethasone|Effect of intrathecally administered dexamethasone in spinal anaesthesia for surgical correction of the hip fracture.
40846176|NCT06486415|DIAGNOSTIC_TEST|serum BHCG testing|Taking 5ml blood samples every 2 hours for 5 times for measurement of BHCG. Blood samples will be taken from the median cubital and cephalic veins which is located inner side of the elbow.
40846177|NCT05328752|DRUG|XXB750|XXB750
40846178|NCT05328752|DRUG|Placebo|Placebo
40846179|NCT03578887|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program (DPP).
40846180|NCT03578887|PROCEDURE|Roux-en-Y Gastric Bypass or Sleeve Gastrectomy|Subjects undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy with their own surgical team
40846181|NCT00888485|BEHAVIORAL|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
40846182|NCT06430723|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty using short stem via an minimally invasive anterolateral approach
40846183|NCT05080374|OTHER|Spinal Manipulation + exercise program|high-speed, low-amplitude spinal manipulation plus a trunk exercise program
40846184|NCT05080374|OTHER|Spinal manipulation + Kinesiotaping|high-speed, low-amplitude spinal manipulation plus elastic bandage (Kinesiotaping) application to the trunk area
40846185|NCT05080374|OTHER|spinal manipulation + respiratory exercise|high-speed, low-amplitude spinal manipulation plus a breathing exercise program for the diaphragmatic muscles
40846186|NCT06120439|COMBINATION_PRODUCT|PECS II combined with intercostal nerve blockade;|The patient was in a supine position, and under ultrasound guidance, the needle tip was first placed in the plane between the pectoralis major and minor muscles, and 10ml of 0.3% ropivacaine was injected. The needle was then advanced into the space between the pectoralis minor and serratus anterior muscles, and 20ml of 0.3% ropivacaine was injected. Intercostal nerve blockade: The range of intercostal blockade was determined based on the location of the breast surgery. The needle was inserted into the intercostal space from the posterior axillary line, and 3ml of 0.3% ropivacaine was injected into each intercostal space.
40846187|NCT06120439|COMBINATION_PRODUCT|General anesthesia with laryngeal mask|The C Group underwent general anesthesia induction using TCI propofol 3-3.5μg/ml, TCI remifentanil 1-2ng/ml, sufentanil 0.3μg/kg iv, midazolam 0.05mg/kg iv, and rocuronium 0.6mg/kg iv after loss of consciousness. After muscle relaxation, the laryngeal mask was inserted, and mechanical ventilation was performed with a tidal volume of 6ml/kg. Anesthesia maintenance included propofol 3-4μg/ml and remifentanil 1-2ng/ml.
40846188|NCT00235911|DRUG|budesonide/formoterol Turbuhaler|
40846189|NCT03313336|DRUG|EMLA test patch|EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
40846190|NCT03313336|DRUG|EMLA current reference patch|EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
41028804|NCT01344460|DRUG|Gadobutrol (Gadovist, BAY86-4875)|a single bolus injection of approx. 0.1mmol/kg
41367388|NCT03856502|DRUG|12,5 mg of 0,5 % of levobupivacaine|Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
41367389|NCT03608345|OTHER|space maintainer|Space maintainers are applied after the missing teeth in pediatric dentistry for protection of size of extracted area.
41367390|NCT00455039|DRUG|GW572016|Dose: 1500 mg daily
41367391|NCT00161291|DRUG|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
41367392|NCT03730064|DRUG|N-acetyl cysteine (NAC)|Experimental medication with N-acetyl cysteine (NAC) for six weeks
40846191|NCT03313336|DRUG|Placebo Patch|Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
41028805|NCT00798798|DEVICE|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
41367393|NCT04001374|DRUG|Ticagrelor|90mg tablet bid for 12 months
41501882|NCT06421077|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation
40846192|NCT06233097|DRUG|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
40846193|NCT06233097|DRUG|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
40846194|NCT03424122|DRUG|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
40846195|NCT03424122|DRUG|Rituximab|Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
41161581|NCT00352378|DRUG|Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine|"Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14"
41161582|NCT01414556|OTHER|Glucose-dependent Insulinotropic polypeptide|infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
41161583|NCT01414556|OTHER|saline|
41367394|NCT04001374|DRUG|ASA|enteric coated aspirin 81mg-100mg daily p.o. for 12 months
41367395|NCT02123186|OTHER|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
41501883|NCT05498428|DRUG|Amivantamab|Amivantamab will be administered subcutaneously by manual injection.
41501884|NCT05498428|DRUG|Lazertinib|Lazertinib will be administered as an oral tablet.
41501885|NCT05498428|DRUG|Carboplatin|Carboplatin will be administrated by IV infusion.
41028806|NCT05207696|OTHER|retrospective data analysis|The data of the patients who underwent papilla reconstruction surgery by one of the authors (S.O.B.) using semilunar incision with either PRF or CTG in the maxillary anterior teeth were included in the study. All selected patients had consent for using their data.The data of the patients included in the study were analyzed.(Baseline (BL) and follow-up (T1( first month) , T3 (third month), T6 (sixth month)) clinical data including periodontal evaluations (gingival index (GI), plaque index (PI), papillary bleeding index, pocket depth (PD), keratinized tissue width (KTW), gingival recession), papilla-associated recordings (alveolar crest-interdental contact point (AC-IC), alveolar crest-papilla tip (AC-PT), papilla tip-interdental contact point (PT-IC), papilla height loss (PHL), interdental tissue stroke (ITS) and papilla presence index (PPI)) and patient satisfaction were analyzed.)
41028807|NCT06350019|PROCEDURE|Penile revascularızation|The importance of resistive index in the preoperative evaluation of vascular-induced erectile dysfunction, predicting the success of penile revascularization surgery, and postoperative patient management was investigated.
40846196|NCT03424122|DRUG|Bendamustine|Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
41161584|NCT02847637|DRUG|Emicizumab|Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.
41161585|NCT02847637|DRUG|Factor VIII (FVIII)|FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.
41161586|NCT01099683|DRUG|NRL001|Single rectal administration of 2 mg NRL001 in a 2 g suppository
40846197|NCT03424122|DRUG|Ibrutinib|Ibrutinib administered orally once daily.
41161587|NCT01099683|DRUG|Placebo|All subjects will receive rectal suppository containing placebo
41161588|NCT04854902|PROCEDURE|Free gingival graft|1.5-2 x 5 x 10 mm size epithelialized graft harvested from the palate is stabilized in the mandibular anterior single-tooth recession region
41161589|NCT04854902|PROCEDURE|Cyanoacrylate|N-Butyl-Cyanoacryle is applied to stabilize the graft to the recipient bed and to coat the donor site wound
41161590|NCT04854902|PROCEDURE|Suture|The graft is stabilized with 6/0 polyvinylidene fluoride suture to the recipient bed
41161591|NCT00463580|DRUG|Infliximab|Participants will receive three infusions 5mg/kg of infliximab (at Baseline, Week 2 and Week 6)
41161592|NCT00463580|DRUG|Placebo|Participants will receive three infusions of a placebo (at Baseline, Week 2 and Week 6)
41367396|NCT06443437|OTHER|bee-buzzy vibrating cold application marionette doll|"* Bee-buzzy will be attached to the arm of the preschool child (who is included in the bee-buzzy group) by the researchers, where the phlebotomy will be performed on the child. It reduces pain through its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee-buzzy will be tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse will perform a phlebotomy.~* A marionette doll group; while the nurse is going to perform the phlebotomy operation on the preschool child, one of the researchers will try to distract the child by paly with marionette doll. The researchers will receive training in play therapy"
40846198|NCT01369732|DRUG|recombinant human erythropoietin|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
41161593|NCT06149052|OTHER|SMART TRAINING|Patients in Group A received SMART training intervention. For sensory stimulation planter massage was given, and it was applied to entire planter surface. Grade III anterior to posterior talocrural joint mobilization was given (26). For balance, single and double leg stance was performed. For functional training, lateral hops and SEBT was performed. And at the end, for resistance training, theraband was used with normal ankle joint movement. There is a progress in focus between the five domains over the 3weeks, as described below: The domains S and M are present across the whole intervention. In week 1, the main focus is on the A domain, in week 2 on the R domain, and in week 3 on the T domain. During the 3-week intervention period, 3 training sessions was held per week each lasting approximately 45 - 60 min, including 10 min warm up
41367397|NCT06443437|OTHER|Rotuine care|children in control group will receive routine hospital are
41501886|NCT05498428|DRUG|Pemetrexed|Pemetrexed will be administered by IV infusion.
41501887|NCT05498428|DRUG|Direct Oral Anticoagulant (DOAC)|DOAC will be administered orally.
40846199|NCT01369732|DRUG|saline|We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
40846200|NCT06180707|DRUG|pregabalin gel|10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide
40846201|NCT06180707|DRUG|gel with 5% potassium nitrate and 2% sodium fluoride|gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
41367398|NCT03779373|OTHER|Use of a decision support system on the EV1000 monitor (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical deicsion support system for fluid administration called AFM (assisted fluid management)
41367399|NCT03230760|DEVICE|acupuncture|Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
41367400|NCT01966458|DEVICE|HeartWare® VAS (HVAD)|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
41161594|NCT06149052|OTHER|FIRE training|Patients in Group B was received foot intensive rehabilitation (FIRE).The FIRE intervention was include the progressive balance training, ankle and hip strengthening, range of motion exercises and foot massage. Plantar massage consisted of two, 1-min plantar massages with a 1-min rest between sets. Four previously established exercises were targeted the IFMs including the short-foot, toe-spread-out, hallux extension, and lesser-toe extension
41161595|NCT01618071|DIETARY_SUPPLEMENT|High-fat meals varying in their fatty acid composition|70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
41161596|NCT06308497|OTHER|Probiotic Treatment|Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day Probiotic supplementation with daily assumption of Limosilactobacillus Reuteri Prodentis® tablet (PerioBalance, Gum®)
41367401|NCT01966458|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
41367402|NCT02977741|DRUG|Olanzapine|
41367403|NCT06202950|BEHAVIORAL|Yoga|Applying yoga for one hour a week for eight weeks to an adolescent with type 1 diabetes
41367404|NCT06202950|BEHAVIORAL|Mindfulness|Applying mindfulness for one hour a week for eight weeks to an adolescent with type 1 diabetes
41367405|NCT02040415|DRUG|DW-1030(eperisone HCl) 75mg|
41367406|NCT02040415|DRUG|Myonal Tab.(eperisone HCl) 50mg|
41367407|NCT02040415|DRUG|Placebo drug of DW-1030|
41367408|NCT02040415|DRUG|Placebo drug of Myonal Tab.|
41367409|NCT02033720|OTHER|No treatment|No therapeutic hypothermia was induced.
41367410|NCT02033720|OTHER|Therapeutic hypothermia|Hypothermia was induced after successful resuscitation from cardiac arrest.
41367411|NCT03817658|DRUG|SHR-1210|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~SHR-1210 was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
41367412|NCT03817658|DRUG|Placebo|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
41367413|NCT00229931|DRUG|Triamcinolone acetonide|4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
41367414|NCT00229931|PROCEDURE|laser|Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
41367415|NCT06187454|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a method for noninvasive brain stimulation, where a weak electrical current is delivered through two scalp electrodes by a portable battery-powered stimulator.
41367416|NCT06187454|DEVICE|Sham Transcranial direct current stimulation|For sham tDCS, the electrode positions and stimulation parameters will be the same as that used for anodal stimulation except that the current will be delivered only for the initial 30 seconds.
41367417|NCT05888545|DEVICE|anti-adhesion diaphragm|Participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure.
41367418|NCT01308476|PROCEDURE|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
41367419|NCT01308476|PROCEDURE|control group|no daily SMS to remind of treatment with tiotropium
41367420|NCT05600842|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
41367421|NCT02679924|DEVICE|Hyaluronic Acid filler|The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
41367422|NCT02679924|OTHER|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
41367423|NCT06181903|BEHAVIORAL|Emotional freedom technique group|Control group
41367424|NCT05523674|OTHER|Warm-up exercise|The warm-up exercise will be performed on a treadmill.
41367425|NCT05523674|OTHER|Warm-up exercise with Blood Flow Restriction|The warm-up exercise will be performed on a treadmill and pressure cuffs will be used for the blood flow restriction technique.
40846202|NCT06180707|OTHER|Placebo gel|placebo gel (carbopol-based gel 1%) for topical application to teeth before bleaching with hydrogen peroxide
41161597|NCT06308497|OTHER|Standard Treatment|Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day
41161598|NCT01493999|DRUG|Clopidogrel reloading|Up to three times 600 mg clopidogrel
41161599|NCT01493999|DRUG|Prasugrel|60 mg prasugrel in patients with HPR
41161600|NCT00360750|DRUG|carboplatin|
41161601|NCT00360750|DRUG|cytarabine|
41161602|NCT00360750|DRUG|etoposide|
41367426|NCT02316652|PROCEDURE|Scaling and root planing|Mechanical instrumentation
41367427|NCT02316652|PROCEDURE|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
41367428|NCT02139020|OTHER|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
41367429|NCT02463604|PROCEDURE|Coronary Angiography|Coronary angiography is performed following usual site standards
41501888|NCT05498428|DRUG|Low Molecular Weight Heparin (LMWH)|LMWH will be administered subcutaneously.
40846203|NCT01660503|DIETARY_SUPPLEMENT|0 grams SCF|Given in snack foods (muffins and flavored beverage)
40846204|NCT01660503|DIETARY_SUPPLEMENT|10 grams SCF|Given in snack foods (muffins and flavored beverage)
40846205|NCT01660503|DIETARY_SUPPLEMENT|20 grams SCF|Given in snack foods (muffins and flavored beverage)
40846206|NCT05908201|BEHAVIORAL|early time restricted eating|The intervention group will eat in a prescribed daily feeding window (9am-5pm) and follow their normal exercise and resistance training routines. We will allow up till +/-1 hour for the eating window start and end times while aiming for an 8 hour eating window.
40846207|NCT02252965|DRUG|Metformin IR|Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
40846208|NCT02252965|DRUG|Metformin XR|Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
40846209|NCT00762541|DEVICE|MEL 80 Treatment of High Myopia|The reduction or elimination of myopia \> -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE ≤ -12.00 D.
40846210|NCT05563831|OTHER|national registry|The investigators will collect demographic, clinical, biological and imaging characteristics of patients with PROS.
40846211|NCT04223414|DEVICE|Analgesia Nociception Index (ANI)|"ANI will be used to analyse the autonomic nervous system's response to volume expansion.~ANI will be assessed during surgery, before during and after the volume expansion"
40846212|NCT03824093|BEHAVIORAL|AFIX Only|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates.
40846213|NCT03824093|BEHAVIORAL|AFIX+ Provider Communication Training|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates along with communication training for providers and poster and brochure displays.
40846214|NCT00154882|DRUG|Paclitaxel (Phyxol) , Cisplatin|
40846215|NCT04846465|OTHER|Screening in picture archiving and communication system (PACS) .|Screening in picture archiving and communication system (PACS) , the images of the participants who underwent computed tomography (CT) of the femur and acetabulum.
40846216|NCT05132777|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
40846217|NCT05132777|DRUG|Osimertinib Mesylate Tablets|Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).
40846218|NCT04823624|DRUG|MBG453|intravenous infusion
40846219|NCT05463263|DRUG|STP938|Small molecule
40846220|NCT06547515|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
40846221|NCT01575925|DRUG|4 mg Oral POM + 40 mg Oral DEX|
40846222|NCT01575925|DRUG|2 mg Oral POM + 40 mg Oral DEX|
40846223|NCT04619355|DEVICE|NIRS-IVUS|Near-infrared spectroscopy-intravascular ultrasound can be implemented in parallel with intravascular ultrasound and provides important information for predicting prognosis by measuring the lipid component of atherosclerotic plaques.
40846224|NCT04665531|PROCEDURE|Erector Spinae Catheter|Patients in the experimental group will receive the Erector Spinae Catheter with an initial bolus ob 20ml 0,5% levobupivacaine prior the surgery and will be administered local anesthetics for 48 hours post-operatively.
40846225|NCT04665531|PROCEDURE|Intercostal block|Patients in the comparative group will receive standard treatment, i.e. the multi-level intercostal block with 20ml 0,5% levobupivacaine administered at the end of the surgery by the surgeon.
40846226|NCT04665531|DRUG|Ropivacaine 0.2% Injectable Solution|Patients in the experimental group will receive Ropivacaine 0,2% continous infusion of 5ml/h with boluses 15ml/4h by the Erector Spinae Catheter for 48 hours post-operatively.
41161603|NCT00360750|DRUG|vincristine sulfate|
41161604|NCT00360750|OTHER|clinical observation|
41367430|NCT04115501|OTHER|Fraction of Inspired Oxygen|Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
41367431|NCT04158518|RADIATION|Toxicities reduced treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
40846227|NCT05487183|BEHAVIORAL|Medoc cutaneous probe|A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH
41501889|NCT05306509|BEHAVIORAL|NiCE|Participants will receive an initial conversation led by a trained senior nurse within eight weeks after initial oncologic diagnosis or relapse/recurrent disease diagnosis, with an introduction to the intervention and learning about the goals, values, hopes, and fears of each patient and family. The PPC team will then follow each patient by ongoing regular conversations (related to the child and family's conditions) led by the same nurse, every 4 weeks for six months, when symptom assessment and management, goal-directed supportive care, team collaboration, and care coordination will be delivered according to the family's needs. Increased PPC involvement, end-of-life care and bereavement care will be involved when necessary. If a participant feels any discomfort or distress during the intervention, a break will be taken until they feel better. If not, the central contact person will come and discussion about the participant's feeling and wiliness to continue the intervention.
41501890|NCT05306509|OTHER|Routine PPC|Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
40846228|NCT05487183|BEHAVIORAL|Quantitative sensory testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
40846229|NCT05487183|BEHAVIORAL|Computer tasks|QST and computer tasks are used to measure changes in pain intensity
40846230|NCT03327168|DRUG|Adenosine|Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
40846231|NCT03327168|OTHER|Cold exposure|Controlled cold exposure is performed before and during PET/CT scan.
40846232|NCT01403116|DRUG|Oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
40846233|NCT01403116|DRUG|topical testosterone gel|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
41367432|NCT04158518|RADIATION|Conventional treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
40846234|NCT06260306|OTHER|Hip activation home exercise program|The hip activation HEP group will receive a combination of hip musculature activation exercises used by previous researchers that show an increase in hip muscle recruitment. Each participant will perform their respective intervention program at home twice weekly for eight weeks.
41367433|NCT01424657|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography
41367434|NCT01424657|PROCEDURE|MRCP|magnetic resonance cholangiopancreatography
41367435|NCT05351970|PROCEDURE|Barbed|Efficacy of barbed and monofilament closure regarding incisional hernia
41367436|NCT00394121|DRUG|Fluticasone propionate/formoterol fumarate|
41367437|NCT06388538|OTHER|Conservative treatment (non-operative treatment)|Conservative treatment consists of medical therapy (see fluid, anti-pain drugs and antibiotics, except for radiologic drainage)
41367438|NCT06388538|OTHER|Surgical treatment (operative treatment)|"Surgical treatment (operative treatment) is explained as follows:~1. Open surgery management, i.e. traditional open surgery approach with any kind of technique: either reconstructive (with or without ileal/colonic stoma protection) or non-reconstructive (see Hartman procedure)~2. Laparoscopic approach, i.e. emergency laparoscopic resection with the characteristics mentioned above"
40846235|NCT06260306|OTHER|Hip activation plus core stabilization home exercise program|The hip activation plus core stabilization HEP group will receive the same hip exercises, plus core stabilization exercises used by previous researchers. Each participant will perform their respective intervention program at home twice weekly for eight weeks.
40846236|NCT05262283|OTHER|No intervention|No intervention was made.
40846237|NCT00002506|BIOLOGICAL|recombinant interferon alfa|
40846238|NCT00002506|DRUG|isotretinoin|
40846239|NCT03590249|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure. Treatment will last approximately 45 minutes.
40846240|NCT05548062|OTHER|Hydroxyurea|Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.
40846241|NCT05548062|OTHER|Ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.
40846242|NCT04767984|DRUG|Atorvastatin Calcium|Given PO
40846243|NCT04767984|PROCEDURE|Biopsy of Colon|Undergo colonoscopy with biopsy
41161605|NCT00360750|PROCEDURE|adjuvant therapy|
41367439|NCT04668066|DRUG|PF-07242813|PF-07242813 given intravenously or subcutaneous
41161606|NCT00360750|RADIATION|radiation therapy|
41161607|NCT00461123|DRUG|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
41161608|NCT00461123|DRUG|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
41161609|NCT02822040|OTHER|Intraoral Scan|All patients will have an intraoral scan performed for measurements to be taken on.
41161610|NCT00907517|DRUG|MK-8776|IV infusion
41161611|NCT00907517|DRUG|Cytarabine|IV infusion
41367440|NCT04668066|DRUG|Placebo|Placebo given intravenously or subcutaneous
41367441|NCT06263543|DRUG|Sacituzumab govitecan|IV infusion of 10 mg/kg on Days 1 and 8 of each continuous and consecutive 21-day cycles. The first infusion will last approximately 3 hours and subsequent infusions will last 1-2 hours if prior infusions were well tolerated.
41367442|NCT04468555|OTHER|Global postural reeducation|It consisted of Global Postural Re-Education sessions divided into 3 sessions and performed with a frequency of 1 per week for 3 weeks. The sessions were performed individually, with an approximate duration of 40 minutes and all of them were assessed by the same physiotherapist.
40846244|NCT04767984|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41161612|NCT03394183|OTHER|Cardiac Rehabilitation|Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
41161613|NCT03143296|OTHER|Simulated reverberant environment|Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.
41161614|NCT06389929|BEHAVIORAL|Education|In line with the skill they will determine for one of the applications in the Skill Checklists (Breastfeeding Education Skill Control Form, Breast Care and Giving Care to Mothers with Breast Engorgement Skill Control Form, Breast Self-Examination (KKMM) Training Skill Control Form) apply.
41161615|NCT01100268|DRUG|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
41161616|NCT05290857|OTHER|Restart DOAC within 7 days of clinical hemostasis after GI bleeding|"In patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis (as judged by the clinical team).~High thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 5 or higher (ii) Atrial fibrillation or atrial flutter with CHA2DS2VASc score or 3 to 4 with recent ischemic stroke, TIA or systemic embolism (within 6 months) (iii) VTE (proximal DVT or PE) within 3 months (iv) Recurrent VTE (proximal DVT or PE) (v) VTE (proximal DVT or PE) associated with antiphospholipid syndrome (if eligible for DOAC) (vi) VTE (proximal DVT or PE) associated with active non-GI cancer (vii) None of the above but considered high thrombotic risk as per investigator"
41161617|NCT05290857|OTHER|Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding|"In patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis (as judged by the clinical team).~Moderate thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 3 to 4 (ii) VTE (proximal DVT or PE) beyond 3 months~The type and dose of DOAC will be according to patient and physician choice and will be prescribed by the clinical care team."
41161618|NCT05915832|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
41367443|NCT04637087|OTHER|Atrial fibrillation risk electronic health record alert|Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation
40846245|NCT04767984|DRUG|Placebo Administration|Given PO
41161619|NCT05915832|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
41367444|NCT04274361|DRUG|Ketamine|Ketamine infusion
41367445|NCT04274361|DRUG|Placebo|Placebo infusion
41367446|NCT04772339|OTHER|Heel-Rise Test|The Heel Rise test for endurance will be performed while the participant stands on a box with 10 ° inclination on one leg. Participants will be allowed to get support from the wall at the point at shoulder level with two fingertips in order to maintain balance. A metronome of 30 beats per minute will be used to maintain the heel-rise frequency every 2 seconds. The participant will be asked to rise as high as possible with each heel rise, then lower the heel to the starting position, and with the next warning, he/she will be asked again. The participant will be asked to adapt to the pace of the metronome as much as possible and to continue the test as much as possible. The test will be terminated when the participant stops, fails to maintain frequency, or performs a proper heel raise. The number of heel raises obtained at the end of the test will be used for data analysis.
41367447|NCT04772339|OTHER|Paper Grip Test (PGT)|In the paper grip test, a paper is placed under the individual's thumb and the person is asked to squeeze this paper strongly between the big toe and the ground. The paper is pulled by the person performing the test and the individual is asked to hold the paper with his/her thumb as much as he/she can. When the person applies the maximum force, the height of the medial longitudinal arch is measured with a digital caliper in millimeters. The time that the individual can maintain the MLA height with this maximum force is recorded with a stopwatch.
41367448|NCT05140902|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
40846246|NCT04767984|OTHER|Questionnaire Administration|Ancillary studies
41367449|NCT02983305|DEVICE|Head-Mounted Display|Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
41367450|NCT03156946|BEHAVIORAL|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
41367451|NCT03156946|BEHAVIORAL|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
41367452|NCT04833465|OTHER|No Intervention|No Intervention
41367453|NCT03997695|OTHER|Core stabilization exercise group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
41501891|NCT06332495|OTHER|Questioning the patient during hygiene care|The study examines how patients and caregivers feel when using the bedpan. Over the course of a day, collecting all this information would take just under 7 minutes. Over the duration of patient participation (2 days), we estimate that it would take a total of 15 minutes per patient to collect this information. The objectives are focused on pain and discomfort, and on the alteration of the (patient's) skin condition through objective observation of redness or stage I pressure sores by the caregiver.
41501892|NCT00805961|RADIATION|Radiation therapy|Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
41501893|NCT00805961|DRUG|Temozolomide|Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
41501894|NCT00805961|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
41501895|NCT00805961|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
41501896|NCT00805961|DRUG|Everolimus|Everolimus 10mg by mouth daily, beginning Week 11
40846247|NCT05432479|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks
40846248|NCT05432479|DIETARY_SUPPLEMENT|Placebo|Placebo
40846249|NCT02713659|BEHAVIORAL|Early Literacy Promotion|Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
41367454|NCT03997695|OTHER|Core stabilization exercise plus kinesio taping group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
41367455|NCT03303352|PROCEDURE|EUS FNA|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
40846250|NCT02713659|BEHAVIORAL|Standard Literacy Promotion|Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
40846251|NCT04274556|OTHER|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
40846252|NCT03330639|OTHER|Capsaicin|Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.
40846253|NCT03330639|OTHER|Placebo|This group will receive the saline placebo solution.
40846254|NCT01892891|DRUG|VBY-036|Cathepsin S inhibitor
41367456|NCT02024997|OTHER|Magnetic Resonance Imaging (MRI)|
41367457|NCT01992146|DRUG|Target-controlled naloxone-infusion|
40846255|NCT05800275|DRUG|Tucatinib Oral Tablet|300 mg, twice daily
40846256|NCT05800275|DRUG|Capecitabine tablets|1000 mg/m², twice daily on days 1-14 of each 21-day cycle
40846257|NCT05800275|DRUG|Trastuzumab Injection|Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly
40846258|NCT01158391|DEVICE|NTrainer® Intervention|
40846259|NCT01158391|DEVICE|Control Intervention|
40846260|NCT01620528|DRUG|elagolix|oral tablet
40846261|NCT01620528|OTHER|placebo|oral tablet
40846262|NCT03044808|DRUG|Lidocaine|
40846263|NCT03044808|DRUG|Saline|
40846264|NCT05047848|DRUG|Chidamide|chidamide 30mg orally，Biw
40846265|NCT05047848|DRUG|Fulvestrant|Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
40846266|NCT00527332|DRUG|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
40846267|NCT00527332|DRUG|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
40846268|NCT00527332|DRUG|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
40846269|NCT00527332|DRUG|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
41161620|NCT02730000|PROCEDURE|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
41367458|NCT01992146|DRUG|Placebo|
40846270|NCT00527332|DRUG|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
40846271|NCT00527332|DRUG|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
40846272|NCT00527332|DRUG|Morphine|5 mg is given IV (intravenously) before end of surgery
40846273|NCT01307462|DRUG|fluticasone propionate|Given inhaled PO
40846274|NCT01307462|DRUG|montelukast sodium|Given PO
40846275|NCT01307462|DRUG|azithromycin|Given PO
41367459|NCT01266967|DRUG|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
40846276|NCT04473664|DRUG|Quizartinib|Single oral dose, 30 mg tablet
40846277|NCT04492761|BEHAVIORAL|qualitative study|The qualitative approach will be based on content analysis of - Isemi-structured nterviews of families
40846278|NCT03054324|DIAGNOSTIC_TEST|Fractional Flow Reserve|Coronary fraction flow reserve (FFR), the ratio of the mean coronary pressure distal to a coronary stenosis to the mean aortic pressure during maximal coronary blood flow (hyperemia), defines the hemodynamic significance of coronary artery narrowing.
40846279|NCT00002921|DRUG|suramin|
40846280|NCT00002921|DRUG|therapeutic hydrocortisone|
40846281|NCT03951558|OTHER|Diet for calciuria prevention|Dietary recommendations for water, salt, calcium and proteins according to age and DIR
40846282|NCT03951558|DRUG|Hydrochlorothiazide|Hydroclorothiazide recommendations for hypercalciuria
40846283|NCT05017818|OTHER|Observational retrospective data|Non-intervention
40846284|NCT00005014|DRUG|Risperidone|
40846285|NCT03801603|BEHAVIORAL|HPV vaccination training and education|1) Training of providers and clinic staff on the importance of providing a strong HPV vaccination program and 2) HPV vaccination education for parents and the community.
40846286|NCT01734759|DRUG|Taste Test|"Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~* Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~* Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~* H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg"
41367460|NCT04201223|BEHAVIORAL|FLARE Intervention|\[See arm/group descriptions\]
41367461|NCT02568176|DRUG|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
41367462|NCT02568176|DRUG|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
41367463|NCT02568176|DRUG|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
41367464|NCT02326909|DEVICE|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
41367465|NCT02326909|DEVICE|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
41367466|NCT03194165|BIOLOGICAL|Dolutegravir|Dosage
41367467|NCT03194165|BIOLOGICAL|Raltegravir|Dosage
41367468|NCT03194165|BIOLOGICAL|Rilpivirine|Dosage
41367469|NCT03194165|BIOLOGICAL|Nevirapine|Dosage
41367470|NCT03194165|BIOLOGICAL|Atazanavir|Dosage
41161621|NCT02730000|PROCEDURE|ART with Riva Self Cure|Occlusal-proximal ART restorations in primary molars using Riva Self Cure will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
41367471|NCT03194165|BIOLOGICAL|Darunavir|Dosage
41367472|NCT03194165|BIOLOGICAL|Ritonavir|Dosage
41367473|NCT02208518|PROCEDURE|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
41367474|NCT02208518|DEVICE|EUS-elastography|
41367475|NCT02760680|DEVICE|WatchPAT 200 (TM)|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
41367476|NCT02760680|OTHER|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
41367477|NCT04505007|OTHER|Specialized heart function clinic|This information has already been provided.
41367478|NCT03664570|DEVICE|VIPUN Balloon Catheter|The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.
41161622|NCT00743496|BIOLOGICAL|Anti-GD2 antibody|Anti-GD2 antibody
41161623|NCT00700947|DRUG|Beta-blocker therapy (TOPROL-XL® )|Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
41161624|NCT00239681|DRUG|Rosuvastatin|Oral
41161625|NCT00239681|OTHER|Placebo|Oral
41367479|NCT02016638|OTHER|Polysomnography and ambulatory blood pressure recording|
41161626|NCT02749175|DEVICE|Cricoid force sensor monitor system|Comprise of a sensor and a monitor system
41161627|NCT02749175|DEVICE|Sham Cricoid force sensor monitor system|Comprise of a sensor and a sham monitor system
41367480|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|1% chocolate milk
41367481|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Pea-based beverage
41367482|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Maltodextrin placebo
41367483|NCT03970330|DRUG|Naltrexone|4.5mg daily dose, taken orally
41367484|NCT03970330|DRUG|Norethindrone Acetate|5 - 15mg daily dose, taken orally
41367485|NCT03970330|DRUG|Placebo|daily placebo pill, taken orally
41367486|NCT00220311|DRUG|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
41367487|NCT04522128|BEHAVIORAL|Behaviour Change Technique Intervention to Improve Quality of Life|"The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group."
41367488|NCT00638248|DRUG|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
41367489|NCT00638248|DRUG|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
41367490|NCT00638248|DRUG|Placebo|Placebo i.v. bolus
41367491|NCT02507609|OTHER|Moderate neuromuscular blockade|TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
41367492|NCT02507609|OTHER|Deep neuromuscular blockade|PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
41367493|NCT04100902|DRUG|ODACTRA 12 SQ-HDM Sublingual Tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
41367494|NCT04100902|DRUG|Placebo sublingual tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
41367495|NCT00116246|PROCEDURE|McRobert's manoeuvre|
40846287|NCT02333019|BEHAVIORAL|Let's Talk About Sex|Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.
40846288|NCT02333019|BEHAVIORAL|Websites; preventing teen pregnancy|Two general web sites with information about preventing teen pregnancy
40846289|NCT06398925|DRUG|OCT461201 50 mg|Oral capsule
40846290|NCT06398925|DRUG|OCT461201 100 mg|Oral capsule
41367496|NCT03437980|DRUG|propofol|A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
40846291|NCT06398925|DRUG|OCT461201 150 mg|Oral capsule
40846292|NCT06398925|DRUG|OCT461201 450 mg|Oral capsule
40846293|NCT06398925|DRUG|Placebo|Placebo capsule
40846294|NCT00971295|DRUG|Metformin|850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
40846295|NCT00971295|DRUG|Eslicarbazepine acetate|
40846296|NCT04887987|OTHER|Pilates training + active PBMT|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive active PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
40846297|NCT04887987|OTHER|Pilates training + sham PBMT|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive sham PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
40846298|NCT04887987|OTHER|Multicomponent training + active PBMT|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive active PBMT on the lumbar region imediately before each workout.
40846299|NCT04887987|OTHER|Multicomponent training + sham PBMT|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive sham PBMT on the lumbar region imediately before each workout.
41501897|NCT06500611|OTHER|Sensory Integration and Vestibular Exercise with Routine Physical Therapy|"1. Stand with feet hip-width apart 5 rep~2. Sit in chair without backrest 5 rep~1.Stand with feet hip -width apart 5 rep~2.Sit to stand sit on chair without backrest and perform sit to stand repeatedly 5 rep~1.Tandem Walk one foot directly in front of the other.2 sets 5 steps forward and backward~2.Patientwalk forward cross an obstacle, continue walk. Walk Lateral Walk Backward 2 sets~1. Stand and slowly move head side to side and up down 10 repetition~2. Fix gaze and move head side to side or up and down 10 repetitions~1. Stand on one leg for 10 seconds hold on. Repeat 5 times on each leg.~2. Stand and rotate body to right and left 10 rotations~1. Walk on straight line , zigzag pattern, walk while looking your shoulder 5 rep~2. Sit and swing your legs back and forth 5rep~3. Play catch in standing. 2 sets 5-8 catches.~Static stretching 30 sec hold 5 times"
41028808|NCT01716247|OTHER|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
41367497|NCT02836795|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
41367498|NCT03130556|DRUG|Glasdegib|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
41367499|NCT03130556|OTHER|High Fat, High Calorie Meal|A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.
41367500|NCT03130556|DRUG|Rabeprazole|A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
41367501|NCT04261153|OTHER|Cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
41367502|NCT02815670|DRUG|Idarucizumab|
41367503|NCT06393504|DRUG|Daridorexant|Daridorexant received during or shortly prior to pregnancy.
41367504|NCT06393504|DRUG|Non-orexin receptor antagonist insomnia medication|Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
41367505|NCT06393504|OTHER|No insomnia medication|No insomnia medication received during or shortly prior to pregnancy.
41028809|NCT05491473|DEVICE|Closed incisional negative pressure wound therapy (iNPWT) system|The closed incisional negative pressure wound therapy (iNPWT) system (PREVENA Incision Management System, KCI, an Acelity company, San Antonio, Texas, USA)
41028810|NCT01546415|DRUG|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
41028811|NCT00655980|DRUG|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
41028812|NCT00655980|DRUG|Nitrous oxide and placebo|
41028813|NCT00655980|OTHER|standard of care|
41367506|NCT02973399|DRUG|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
41367507|NCT02014753|DEVICE|cobalt-chromium everolimus-eluting stent (CoCr-EES)|
41367508|NCT00727246|DRUG|CDP-Choline|1000 mg CDP-Choline 2 x per day for 6 weeks.
41367509|NCT00727246|DRUG|Placebo|Treatment with placebo for 6 weeks
41367510|NCT02441517|DRUG|Enzalutamide|Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
41028814|NCT01169870|DRUG|Genexol-PM|Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
41028815|NCT01169870|DRUG|Paclitaxel|
41028816|NCT02458105|BEHAVIORAL|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
41367511|NCT01508221|DRUG|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
41367512|NCT01508221|DIETARY_SUPPLEMENT|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
41367513|NCT03068429|DRUG|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
40846300|NCT02276417|OTHER|Blood collection|Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
40846301|NCT02276417|OTHER|Urine collection|Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
40846302|NCT02276417|OTHER|Bioimpedance Analysis|The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.
40846303|NCT02276417|OTHER|Cognitive Function Tests|Cognitive function tests will be administered at 3, 6 and 12 months.
40846304|NCT02276417|OTHER|Quality-of-life Questionnaires|Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
40846305|NCT02276417|OTHER|Physical Function Tests|Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.
40846306|NCT02276417|OTHER|Blood Collection|The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
40846307|NCT02936284|BEHAVIORAL|Music Enhancement|
40846308|NCT02936284|BEHAVIORAL|Play Date|
40846309|NCT04036500|DRUG|Estradiol Tablets|Patients will be given estradiol: 1 mg oral or 1 mg sublingual.
40846310|NCT02027948|OTHER|nutritional and functional assessments|"Patients will undergo nutritional \& functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, \& baseline weight loss. Patients will receive chemotherapy \& radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) \& radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, \& post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, \& Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as normal nutrition, at risk for malnutrition, or malnourished \& receive the appropriate intervention."
40846311|NCT05564806|DRUG|YH004|All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
41028817|NCT02458105|BEHAVIORAL|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
41028818|NCT05739058|DEVICE|Violet-Blue Light Treatment / FlashHeal Device|"FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz."
41367514|NCT04141566|PROCEDURE|Perineal pseudocontinent colostomy|"The procedure is performed in 2stages: as a usual APR starting by a laparoscopic approach esnsuring a complete mesorectal excision,then a perineal approach ensuring an extended excision of the entire internal and external sphincter complex, allowing the excision of the specimen.~8to10cm of tof the colon is resected and harvested as a free graft, stripped of its meso and epiploics , then from its mucosa and placed in an antibiotic solution for 10min. This graft is wrapped snugly around the end of the colon 2-3 cm from its distal end for 1 and a half round. Absorbable 3.0 Sutures are taken to hold it in place. The end of the colon is brought out as a stoma in the perineum.~Colonic irrigations are started from the third day according to the protocol previously reported. Patients and one of their family members are daily educated and assisted while performing colonic irrigations by specialized nurses."
40846312|NCT06375681|BEHAVIORAL|Visual and / or Auditory Cognitive Tasks (1)|"Seven sessions (\~45-75 minutes) of cognitive tasks in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements."
40846313|NCT06375681|BEHAVIORAL|Visual and / or Auditory Cognitive Tasks (2)|"Two sets of 10 sessions (\~20 minutes) of cognitive tasks either at home or in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements."
41028819|NCT05004324|BIOLOGICAL|FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL|the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
41367515|NCT04141566|PROCEDURE|Permanent left iliac colostomy|After a usual laparoscopic APR, the perineal wound is closed and a permanent left iliac colostomy is performed
41367516|NCT00512226|OTHER|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2\* MRI analysis.
41367517|NCT00148174|BEHAVIORAL|Intensive telephone followup|Telephone calling
41367518|NCT05317949|OTHER|Integrated neuromuscular training program group|Integrated neuromuscular training program group will do plyometric training, speed and sensitivity training, resistance training for 3 days in a week and total for eight weeks.
41367519|NCT05317949|OTHER|General fitness exercises program group|General fitness exercises program group will do general fitness exercise for 3 days in a week and total for eight weeks.
41367520|NCT05566366|OTHER|Qualitative research interview|Qualitative research interview Administration of quantitative scales
41367521|NCT00596466|DRUG|pregabalin|pregabalin
41367522|NCT04079699|DIAGNOSTIC_TEST|Liquid Biopsy|Measuring biomarkers in blood and urine samples
41367523|NCT04079699|DIAGNOSTIC_TEST|Standard biopsy|Histological examination of tissue biopsies
41367524|NCT02267460|BIOLOGICAL|AA4500|
41367525|NCT02267460|DEVICE|ErecAid® Esteem® Manual Vacuum Therapy System|
41161628|NCT05086341|DEVICE|My COPD|In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
40846314|NCT06350474|OTHER|Discontinuation of dornase alfa (Dnase)|Discontinuation of current dornase alfa (Dnase) therapy during 6-week study period.
40846315|NCT06350474|OTHER|Continuation of dornase alfa (Dnase)|Continuation of current dornase alfa (dnase) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily)
41161629|NCT00949598|DRUG|letrozole|Given orally
41367526|NCT02267460|PROCEDURE|Investigator Modeling|
41161630|NCT00949598|DRUG|tamoxifen citrate|Given orally
41367527|NCT04095611|PROCEDURE|SPAIRE|To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
41367528|NCT04095611|PROCEDURE|LATERAL|surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
41367529|NCT06197776|DRUG|cisplatin-based chemoradiotherapy combined with immunotherapy|"Chemotherapy:cisplatin-based chemotherapy~GP/TP/PF/TPF~Choice of chemotherapy regimen is decided by patient's doctor in charge.~Radiation: Intensity Modulated Radiation Therapy~All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).~Immunotherapy:PD-1 blocking antibody"
41367530|NCT05249504|OTHER|VIVIFRAIL|"VIVIFRAIL is a set of physical activity programs (designed according to several elderly functional level profiles) aimed to prevent motor disability and improve quality of life. It works endurance, flexibility, balance and strength.~https://web.archive.org/web/20210907041944/https://vivifrail.com/"
41367531|NCT05249504|OTHER|Nutrition|Sessions to learn about personal nutrition habits, offer nutritional advice, and acquire skills to incorporate simple healthy nutrition guidelines into everyday life. A visit to a supermarket to make it easier to read and understand the basic information on nutrition labels.
41367532|NCT05249504|BEHAVIORAL|Psychology|Relaxation techniques to manage mood, a photo-elicitation dynamic to address loneliness, and a dynamic to collectively develop a map of health assets in the neighborhood or territory to obtain information on community resources. Finally, a group visit is planned to a community facility previously agreed upon by the participants.
41367533|NCT05249504|BEHAVIORAL|Personal autonomy|Review practical cases on personal autonomy, the proper use of medications, and discover basic cognitive stimulation strategies.
41161631|NCT04391218|OTHER|Multidisciplinary Approach Group|Geriatricians will introduce medication review data on a Clinical Decision Support System, that will help both pharmacists and physicians in medication reconciliation, highligting potentially inappropriate prescriptions according to Beers' criteria and STOPP/START criteria, and potential controindicated and major Drug-Drug Interactions according to Micromedex. Before Hospital at Home discharge, nurses will instruct patients and/or caregivers to the use of an App, where daily drug therapy at discharge will be inserted and scheduled. This App will automatically create an alert everytime a drug dose needs to be taken, alongside an image of the specific drug packaging. The App will register if and when the patient actually takes the drug, or the reason for the delayed/missed dose.
41161632|NCT04493983|PROCEDURE|laparoscopic salpingo-oophorectomy|Laparoscopic bilateral salpingo-oophorectomy
41161633|NCT04493983|PROCEDURE|Laparoscopic bilateral salpingo-oophorectomy|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
41367534|NCT05249504|OTHER|Community resources|Learn about community resources
41367535|NCT05249504|OTHER|Standard recommendations|Usual advice provided at primary care office accompanied to booklets about healthy lifestyles
41367536|NCT02722902|DRUG|Carnitor|"CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~across the inner mitochondrial membrane."
41367537|NCT02722902|DIETARY_SUPPLEMENT|IntraLipid|Lipid emulsion for infusion
41367538|NCT02722902|DIETARY_SUPPLEMENT|Placebo|Saline will be used as placebo
41367539|NCT01258738|BIOLOGICAL|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
41367540|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
40846316|NCT01879969|PROCEDURE|classic procedure of planning|analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
40846317|NCT01879969|PROCEDURE|computer assisted orthognathic planning and surgery of asymmetric patients|
41367541|NCT01258738|OTHER|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
41367542|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
41367543|NCT06234566|PROCEDURE|Conventional dental implant surgery|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed with serum irrigation at a speed of 800 rpm.
41367544|NCT06234566|PROCEDURE|Low Speed Drilling Without Irrigation|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed at a speed of 50 rpm without serum irrigation.
41367545|NCT00491595|DRUG|High Dose Soy isoflavones|
41367546|NCT05766410|DRUG|Palbociclib|CDK4, 6 inhibitor
41367547|NCT05766410|DRUG|Ribociclib|CDK4, 6 inhibitor
41367548|NCT05766410|DRUG|Abemaciclib|CDK4, 6 inhibitor
41367549|NCT05766410|DRUG|Letrozole|Endocrine therapy
41367550|NCT04406259|DRUG|Verapamil|"Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache.~The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test."
41367551|NCT03698032|DIETARY_SUPPLEMENT|Water|Participants will consume water only
41367552|NCT03698032|DIETARY_SUPPLEMENT|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
41367553|NCT03698032|DIETARY_SUPPLEMENT|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
41367554|NCT00431106|DRUG|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
41367555|NCT00431106|DRUG|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
41367556|NCT00431106|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
41367557|NCT04583410|DRUG|Nicotine patch|"NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
41367558|NCT04583410|DRUG|Placebo patch|"PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
41367559|NCT04201652|PROCEDURE|Superficial local anesthetic infiltration|Superficial infiltration of local anesthetic for carpal tunnel release.
41367560|NCT04201652|PROCEDURE|Deep local anesthetic infiltration|Deep and superficial infiltration of local anesthetic for carpal tunnel release.
40846318|NCT05330091|DIETARY_SUPPLEMENT|Once Daily Women's Probiotic|Active product
40846319|NCT05330091|OTHER|Placebo|Placebo product
40846320|NCT03311789|DRUG|PD-1 inhibitor + Gemcitabine + Cisplatin|Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
40846321|NCT06132737|DRUG|[90Y]Y-PentixaTher|\[90Y\]Y-PTT i.v. injection
40846322|NCT03883087|DRUG|HQP1351|40 mg tablet, taken orally once every other day of a 28-day cycle
41367561|NCT00501072|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
41367562|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~* Depth of isthmocele~* Width of isthmocele~* Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os"
41367563|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - Without Isthmocele|Location of implantation of the GS amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac
41367564|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites (A: fundal, B: anterior, C: posterior)~Size of gestational sac"
41367565|NCT04994860|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
41367566|NCT04994860|DRUG|Sildenafil|Oral Sildenafil ( Revatio) 20 mg film coated tablets
41367567|NCT05164068|BEHAVIORAL|Information video|The video contents were clear and adapted to the characteristics of the population of Guatemala. The video provided a simple description of the biopsy, its risks and benefits, complications and general recommendations, and was presented preoperatively
41367568|NCT01321866|PROCEDURE|Cutting balloon angioplasty|Angioplasty of fistula stenosis using a cutting balloon
41367569|NCT01321866|PROCEDURE|Angioplasty|Angioplasty of fistula stenosis using a non-cutting balloon
41367570|NCT02133716|OTHER|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
41367571|NCT02133716|BEHAVIORAL|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
41367572|NCT02662348|DRUG|Recombinant Human Interleukin-2|Given SC
41367573|NCT02662348|DRUG|HER2Bi-Armed T Cells|Given IV
41367574|NCT06180473|OTHER|questionnaire|PPQ, TTAQ PTCS
41501898|NCT06500611|OTHER|Vestibular Exercise with Routine Physical Therapy|"Vestibular exercise~1. Stand with feet hip -width apart and slowly move head side to side and up down.10 repetitions for each direction.~2 .Fix your gaze on object while moving your head side to side or up and down. 10 repetitions for each movement.~1.Patient will stand on one leg for 10 second. Hold onto a stable support if needed. 5 times on each leg.~2. Stand with feet hip-width apart and rotate body to the right and left. 10 rotations in each direction.~1. Walk on a straight line or in a zigzag pattern or walk while looking over your shoulder. (5 rep)~2. Sit on a stable chair and swing your legs back and forth, similar to a pendulum. (5rep)~3. Catch and Throw play catch with a partner while standing. 2 sets of 5-8 catches.~Routine Physical Therapu Static stretching exercises for 30 sec hold with 30 sec rest. 5 times for each muscle group"
40846323|NCT01149902|BIOLOGICAL|Cyclophosphamide, Docetaxel, Dendritic cells, OK-432|Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35
40846324|NCT03147989|DRUG|MultiHance|gadolinium contrast agent
40846325|NCT01440205|BEHAVIORAL|Easy list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly easy."
40846326|NCT01440205|BEHAVIORAL|Challenging list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly difficult."
40846327|NCT01440205|BEHAVIORAL|Control|No check box element
41028820|NCT05004324|BIOLOGICAL|Placebo|the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
41028821|NCT02266628|BIOLOGICAL|RSV-F Vaccine|
41028822|NCT02266628|BIOLOGICAL|Saline Placebo|
41028823|NCT05599594|OTHER|Aromatherapy|6 drops of aromatic oils used by the researcher will be dripped by the aromatic oils to take the fragrance by inhalation for 30 minutes.
41028824|NCT03673436|PROCEDURE|Lumbar spinal fusion|The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
41028825|NCT04495712|DRUG|spironolactone|aldosterone blocker
41028826|NCT04495712|DRUG|placebo|identical in appearance to spironolactone study drug
41028827|NCT04178551|OTHER|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
41028828|NCT02806739|DIETARY_SUPPLEMENT|Soy Group (Soy Protein + Isoflavones)|Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
41028829|NCT02806739|DIETARY_SUPPLEMENT|Control Group (Minimize Soy Intake)|Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
41028830|NCT00987298|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
41028831|NCT02009475|OTHER|Interval exercise training|
41028832|NCT02009475|OTHER|Continues aerobic training|
41367575|NCT04972773|BEHAVIORAL|Mindfulness meditation (MM)|"Towards this additional MM practice, participants will be able to use any combination of the MM apps: Insight timer, which focuses on community/group-like therapy, Healthy minds, which focuses on resilience that is essential in disability adjustment, and Smiling mind, that reminds patients of their family/support structures. These three options were chosen for delivering free MM with different focuses that would cater to the variety of SCI patients needs. Participants will be alerted if they are not achieving 30 minutes of additional MM per week. This will guarantee that the treatment group have a higher time spent on MM for dose-response analysis. Participants will receive a reminder email (see attached) on the Sunday evening of a week with \<30 minutes of additional MM encouraging them to use their mindfulness app."
41367576|NCT03946072|PROCEDURE|Transseptal Aortic Approach Catheter Ablation Procedure|The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or radio frequency (RF) device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.
41367577|NCT03946072|PROCEDURE|Retrograde Aortic Approach Catheter Ablation Procedure|The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.
41501899|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for > 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for greater than 2 days prior to discharge home
41028833|NCT05588089|OTHER|Training group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers."
41028834|NCT01197950|DEVICE|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
41501900|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for < 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for less than 2 days prior to discharge home
41028835|NCT01197950|DEVICE|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
41501901|NCT00950131|OTHER|Presentation of information about drug approval and level of warning|Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
41028836|NCT04409964|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia
41161634|NCT03955952|PROCEDURE|Bariatric Surgery|"Patients chosen using the following codes:~Current Procedural Terminology (CPT): 43633, 43634, 43770, 43775, 43644, 43645, 43659, 43842, 43843, 43844, 43845, 43846, 43847 International Classification of Diseases (ICD): 44.31, 43.82,44.95, 43.89, 44.38, 44.39, 44.68 Healthcare Common Procedure Coding System (HCPCS): S2082, S2085"
41501902|NCT04191499|DRUG|Inavolisib|Participants will receive oral inavolisib on Days 1-28 of each 28-day cycle.
41501903|NCT04191499|DRUG|Placebo|Participants will receive oral placebo on Days 1-28 of each 28-day cycle.
41501904|NCT04191499|DRUG|Palbociclib|Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
41028837|NCT04409964|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
41028838|NCT04409964|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
41028839|NCT02326103|DRUG|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
41161635|NCT00853021|BIOLOGICAL|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
41161636|NCT00853021|BIOLOGICAL|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
41501905|NCT04191499|DRUG|Fulvestrant|Participants will receive intramuscular (IM) fulvestrant approximately every 4 weeks.
41501906|NCT06013839|DRUG|talfirastide|TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).
41501907|NCT01345487|OTHER|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
41501908|NCT01345487|OTHER|Animal protein|Protein in the form of minced pork/beef
41028840|NCT02326103|DRUG|Placebo|
41028841|NCT00274534|DRUG|Tiotropium|
41161637|NCT00000578|DRUG|theophylline|
41161638|NCT00000578|DRUG|beclomethasone|
41161639|NCT03535480|DRUG|G-CSF|G-CSF subcutaneously during five days
41161640|NCT03535480|COMBINATION_PRODUCT|ASCOT|G-CSF subcutaneously during five days, aphaeresis to hematopoietic stem cell collection and catheterism for ovarian artery infusion
41161641|NCT01202305|PROCEDURE|Lymph node biopsy|Inguinal lymph node biopsy
41028842|NCT00274534|DRUG|Salmeterol|
41028843|NCT02509624|DRUG|Selonsertib|6 mg tablets administered orally in fed state
41028844|NCT03424876|DRUG|Imatinib 400mg|exposure 400 mg/day or 600mg/day,
41367578|NCT03690102|OTHER|T-CPR|Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
41367579|NCT03690102|OTHER|ERC standardized BLS course|Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
41367580|NCT01215968|BIOLOGICAL|LY2189265|1.5 mg administered subcutaneously
41367581|NCT01215968|DRUG|Placebo|Administered subcutaneously
41367582|NCT03839446|DRUG|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.
41367583|NCT01035021|DRUG|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
41367584|NCT02045017|DRUG|Pomalidomide and Dexamethasone|
41501909|NCT01316315|DRUG|Active|A 5 mg single dose given intravenously via syringe pump over 1 minute.
41501910|NCT01316315|DRUG|Placebo|Same as active
41501911|NCT03717025|PROCEDURE|SUCTION BLISTER EPIDERMAL GRAFTING|"1. Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.~2. Blister formation is induced by using suction apparatus.~3. Recipient site is surgically prepared by doing dermabrasion.~4. After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.~5. The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.~6. The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.~7. Donor area is dressed with dry sterile pads.~8. The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days)."
41501912|NCT03717025|PROCEDURE|MINI PUNCH GRAFTING|"1. Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.~2. The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.~3. The donor area is either upper lateral portion of thigh or gluteal region.~4. Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.~5. Hemostasis is achieved by pressing a saline soaked gauze piece over the area.~6. For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.~7. For the donor area only surgipad and micropore are used.~8. Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days)."
41501913|NCT03717025|PROCEDURE|NON CULTURED EPIDERMAL CELL SUSPENSION|"1. About one-tenth the size of recipient area is selected as the donor site.~2. Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.~3. The area is dressed with Bactigras gauze.~4. Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.~5. Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.~6. Epidermal cell suspension is carefully transferred to a tuberculin syringe.~7. With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.~8. This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.~9. The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal."
41367585|NCT01420770|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
41367586|NCT01252914|DEVICE|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
41367587|NCT06090227|DRUG|Metformin + Standard of Care|Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
41367588|NCT06090227|OTHER|Placebo + Standard of Care|Administration of daily placebo tablets with standard of care for 6 months.
41501914|NCT04648696|DRUG|Vancomycin CI|The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin
41028845|NCT03424876|DRUG|Sunitinib 37.5Mg Oral Capsule|exposure 37.5 mg/day, continuous taking, or 50 mg/day (4/2)
41028846|NCT01702233|DRUG|Traumeel S inj|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
41028847|NCT01702233|DRUG|Fortecortin/Dexamethasone 8 mg/2 ml inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
41028848|NCT01702233|DRUG|Saline inj|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
41028849|NCT05604729|DRUG|Botulinum toxin type A|Botulinum Neurotoxin type A
41028850|NCT05604729|DRUG|Placebo|Saline solution
41028851|NCT00208208|DRUG|Ziprasidone|
41367589|NCT05489146|DEVICE|transcranial random noise stimulation and functional electrical stimulation facilitated task practice|Participants were randomized to one of the two intervention groups \[transcranial current stimulation (tRNS) and functional electrical stimulation (FES) or FES with sham tRNS\] before pre-intervention testing. After randomization, participants underwent pre-intervention testing, followed by intervention 3 times per week for 6 weeks. Each intervention session lasted for 1 hour, where tRNS or sham-tRNS were delivered concurrently with the FES-facilitated task practice. tRNS or sham-tRNS was delivered for the first 30 minutes. Both tRNS and sham tRNS were delivered by the Starstim system. FES was delivered using the Neuromove system. All participants were treated by a licensed occupational therapist, who was trained on a manualized protocol.
40846328|NCT02807688|BEHAVIORAL|Health Promotion Intervention|"The intervention package consists of the following elements:~i. educational sessions on the importance of diet and fitness; ii. motivational interviews to maintain participants in the program, to discuss participants' physical conditions, habits and opinions as to diet and fitness; iii. monitoring the participation in the program and health behaviour, specifically for diet and fitness, and adherence to the intervention on diet and fitness; iv. regular physical exercise under the guide and supervision of an expert trainer."
41367590|NCT03343002|DRUG|fentanyl at 10-15 min before end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
41367591|NCT03343002|DRUG|fentanyl at end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
41367592|NCT05609838|OTHER|Hot water foot bath|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
41367593|NCT00817752|DIETARY_SUPPLEMENT|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
41501915|NCT04648696|DRUG|Vancomycin II|Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
40846329|NCT06517810|DEVICE|QUELIMMUNE (SCD-PED)|QUELIMMUNE device used as part of clinical practice.
40846330|NCT00005834|BIOLOGICAL|filgrastim|Arms 1 and 2: 300 mcg (pts \</= 60 kg) or 480 mcg (pts \> 60 kg), SC beginning day 5
40846331|NCT00005834|DRUG|cisplatin|Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
41028852|NCT04461522|PROCEDURE|Ultrasound-guided drug injection|The injection drugs were glucocorticoids and anesthetic drugs (1ml+2% lidocaine hydrochloride 0.5ml+0.9% sodium chloride 0.5ml), and the injection sites were subacromion deltoid bursa/coracoid bursa/biceps longhead tenosynosheath/glenohumeral joint bursa, etc.
40846332|NCT00005834|DRUG|cyclophosphamide|Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
40846333|NCT00005834|DRUG|dexamethasone|Arms 1 and 2: 40 mg/d PO days 1-4
41028853|NCT05298774|DEVICE|G-tech WPS|G-tech WPS patches applied and activated within 4 hours of surgery
41028854|NCT05569395|OTHER|Neuro mobilization|"For median nerve stretching, the participants' dominant forearms will be in the supination position while the shoulder will be depressed and abducted 90 degrees.~In this position, while the participant's head is lateral flexed to the opposite side, the wrist and finger will be extended and median nerve stretching will be performed. After staying in this position for 30 seconds, the participants will relax by placing the wrist and head in the neutral position. Thus, a set for median nerve stretching will be completed. For median nerve gliding, the dominant side of the individuals' forearms will be in supination, while the shoulder will be placed in a depression and 90 degree abduction position. In this position, the participant will flex the wrist and fingers while lateral flexing the head to the opposite side, and extend the wrist and fingers while the head is lateral flexed to the same side."
41028855|NCT05569395|OTHER|Sham neuro mobilization|Sham neuromobilization will be applied to the nondominant side upper extremities of the participants.
41028856|NCT02194621|DRUG|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
41028857|NCT02194621|DRUG|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
40846334|NCT00005834|DRUG|etoposide|Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
40846335|NCT00005834|DRUG|thalidomide|Arm 2: 800 mg/d (max dose) PO daily
40846336|NCT03760679|DEVICE|Laryngeal mask Supreme evaluation|Device: Laryngeal mask Supreme evaluation
40846337|NCT03760679|DEVICE|i-gel evaluation|Device: i-gel evaluation
40846338|NCT04565795|DEVICE|Uriprene® Degradable Temporary Ureteral Stent|Assess adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.
40846339|NCT02380040|DEVICE|PPG|A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
40846340|NCT05313737|OTHER|Automated message|Automated message via phone call (audiocare)
40846341|NCT05313737|OTHER|Opt-out scheduling|Scheduling via non-automated phone call
40846342|NCT02999633|DRUG|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
40846343|NCT02999633|DRUG|dexamethasone|Pharmaceutical form:pills Route of administration: oral
41028858|NCT02194621|DRUG|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
41028859|NCT00706121|DRUG|Vitamin E|400 IU daily by mouth for 7 - 12 years
41028860|NCT00706121|DRUG|Selenium|200 mcg daily for 7 - 12 years
41367594|NCT02717910|BEHAVIORAL|Health game|Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.
41367595|NCT02717910|BEHAVIORAL|Web page|Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
40846344|NCT02999633|DRUG|dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
41367596|NCT05459987|BEHAVIORAL|Lifestyle changes|"Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet with intermittent fasting 16:8 (5 times/week for 12 weeks).~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
40846345|NCT02999633|DRUG|acetaminophen|Pharmaceutical form:pills Route of administration: oral
41367597|NCT05858216|DRUG|Chlor-Trimeton.|Package dose of Chlor-Trimeton will be administered
41367598|NCT01852565|DRUG|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
41501916|NCT05992766|OTHER|Reformer Pilates|Reformer Pilates exercises activates the lumbopelvic muscles and supports functional movement. Activated muscles support the spine and reduce the load on the spine by correcting the posture, helping the core muscles such as the abdomen and spine stay healthier by attaching them to a neutral pelvis Pilates consists of a sliding platform working with the help of a pulley system specific to the use, allowing the individual to apply certain resistances, and providing the opportunity to exercise sitting, standing, or lying down.
41501917|NCT05992766|OTHER|Hammock Yoga|Hammock Yoga is performed with a silk hammock, which is an auxiliary equipment. The most distinctive characteristic that makes Hammock Yoga different from other exercises is the spine traction provided by the upside-down posture, and the smooth and shiny silk hammock allows strengthening exercises. The Hammock Yoga aims to reduce the load on the spine by upside-down postures that defy the laws of physics.
41367599|NCT01852565|DRUG|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
41367600|NCT05874882|OTHER|resveratrol mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a resveratrol mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
41367601|NCT05874882|OTHER|chlorhexidine mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a chlorhexidine mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
41501918|NCT05992766|OTHER|Traditional mat exercises|The mat exercises help build core strength, stamina, and motor control of the abdominal and lumbar trunk musculature. The exercises focus on the re-education of a precise co-contraction pattern of local muscles of the spine. Also mat exercise increases the level of endorphins and the stimulation of mechanoreceptors, causing biomechanical stress to support healing in tissues.
41501919|NCT03362606|BIOLOGICAL|OC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, abdominal cavity or tumor injection each time
41501920|NCT01476332|DRUG|cis-urocanic acid 0,5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
41501921|NCT01476332|DRUG|cis-urocanic acid 2.5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
40846346|NCT02999633|DRUG|ranitidine|Pharmaceutical form:solution Route of administration: intravenous
40846347|NCT02999633|DRUG|diphenhydramine|Pharmaceutical form:solution Route of administration: intravenous
40846348|NCT01364311|DIETARY_SUPPLEMENT|Vitamac® Tag and Nacht capsules|"Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.~Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks"
41028861|NCT00706121|DRUG|Vitamin E placebo|1 pill by mouth daily for 7 - 12 years
41028862|NCT00706121|DRUG|selenium placebo|1 pill by mouth daily for 7 - 12 years
41028863|NCT06428747|DIAGNOSTIC_TEST|b. Detection of micro particles and their subtypes by flow cytometery on(BECKMAN COULTER CytoFLEX flow cytometer).|detection of micro-particles
41028864|NCT05392634|DRUG|Meropenem 1000 mg|Group B: prolonged antibiotic prophylaxis \>72 hours (5 days) from the moment of the skin incision in accordance with the selected clinic drug + correction of the appointment based on clinical events after 5 days.
41028865|NCT05392634|DRUG|Amoxicillin+clavulanic acid 1200 mg or Cefuroksim 1500mg|Group A: antibiotic prophylaxis within 24 hours from the moment of skin incision according to local clinical practice;
41028866|NCT00711685|PROCEDURE|coronary artery bypass grafting via midline sternotomy|
40846349|NCT05354687|OTHER|Small-group Teaching|The Small-group Teaching will include theoretical lectures and laboratory practice. Theoretical training will be given in 2 hours and will last 2 week. After the theoretical training, laboratory practice will be made with mannequins, pressure injury models and photographs in the nursing skills laboratory. Laboratory practices will be done in groups of about 10 students. Laboratory application will take 1 week.
40846350|NCT05354687|OTHER|Self-directed Learning|The training will be given in two stages. The first stage of the training will be given via the mobile application for 2 weeks. Students will be able to access the training individually, wherever and whenever they want, via the mobile application. In the second stage, students will individually conduct laboratory practice. Students who start using the mobile application will make laboratory applications individually, whenever they want when the laboratory is available. Models and materials that students will need will be available in the laboratory. They will be able to get help from the trainer when they need it. Individual laboratory application will take 1 week.
40846351|NCT04420663|DIAGNOSTIC_TEST|Pleural Manometry|Recording pleural pressure during therapeutic thoracocentesis using a simple water manometer.
40846352|NCT00865319|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
41028867|NCT04198610|PROCEDURE|Non surgical periodontal therapy|Procedure/Surgery: non surgical periodontal therapy and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
41028868|NCT04971382|DRUG|Curcumin|Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery
41501922|NCT01476332|DRUG|Placebo for cis-UCA, eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
41501923|NCT00438217|DRUG|Triptorelin (GnRH agonists)|
41501924|NCT00438217|DRUG|Leuprolide (GnRH agonists)|
41501925|NCT01915758|DRUG|clindamycin1%/tretinoin 0.025% gel|clindamycin1%/tretinoin 0.025% gel
41501926|NCT01915758|DRUG|vehicle gel|vehicle gel
41501927|NCT01200992|BIOLOGICAL|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
41501928|NCT01200992|BIOLOGICAL|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
40846353|NCT00865319|RADIATION|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
41028869|NCT05864339|BEHAVIORAL|A designed empathy intervention|Students watch 4 smokers' videos, read the textual materials, fill out the HEMs and discuss a quit counseling plan for an assigned smoker using the 5As counseling skilll.
41028870|NCT05864339|BEHAVIORAL|Smoking cessation counseling tutorial|Students watch 4 smokers' videos, read the textual materials, and discuss a quit counseling plan for an assigned smoker using the 5As counseling skill.
41367602|NCT05874882|OTHER|placebo mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a placebo mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
41501929|NCT00456300|DRUG|Exenatide|In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
41501930|NCT00456300|DRUG|Insulin|Each subject received a baseline study with insulin alone
41501931|NCT04389892|DIAGNOSTIC_TEST|Contrast enhanced harmonic endoscopic ultrasound|"During the echoendoscopy the image was fixed on the region of interest (pancreatic cyst) and the extended pure harmonic detection mode was selected. 2,4ml contrast enhancement (Sonovue-Bracco Italy) was injected in the right antecubital vein of the participants followed by a flush of 5ml 0.9% saline solution to ensure that the entire quantity of the agent goes in to the blood flow.~After the administration the pancreatic cyst was observed for at least 120 seconds.We followed the enhancing behavior of the cyst wall, the septa and the solid components. Arterial enhancement (contrast uptake) was considered the first 25-30 seconds after injection and the venous phase (wah-out) 30-45 seconds after injection.~EUS-FNA was performed in all patients without contraindications"
41501932|NCT04495036|OTHER|data collection (21-items-patient descriptive survey)|"Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:~* Demographic data of telemedicine users and non-users~* Subjective disease perception of the dermatology patients~* Use of internet, telemedicine and telemedicine insurance model~* Patients´ willingness for additional features of telemedicine~* Advantages and disadvantages telemedicine and face-to-face consultation~* Suitable fields of dermatology for telemedicine from the patient's perspective~* Recommended structure of telemedical services by users and non-users"
40846354|NCT01453608|DRUG|Ferinject (ferric carboxymaltose)|Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
41367603|NCT05881590|OTHER|Hybrid pulmonary rehabilitation|Technology-enabled 8-week pulmonary rehabilitation programme using the Active+me REMOTE App
41367604|NCT01288820|DRUG|Dihydroartemisinin/piperaquine + primaquine|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
41367605|NCT01288820|DRUG|Artesunate-amodiaquine + primaquine|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
41367606|NCT05682638|BIOLOGICAL|LVRNA009|100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart
40846355|NCT01453608|DRUG|Placebo (saline)|Subjects will receive Placebo (saline) intravenously on Day 0
40846356|NCT05503225|DRUG|Colchicine 0.5 MG|0.5mg Orally Taken Colchicine
41028871|NCT04000165|DRUG|AG-348|This is a nonrandomized, intra-patient dose escalating clinical study. AG-348 will be administered starting at 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
41161642|NCT03294421|PROCEDURE|combined access tympanomastoidectomy|Trans canal surgery with the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation allowing better visualization and removal of the cholesteatoma before mastoid debridement. In this surgery, mastoid debridement is conducted only if there was no full endoscopic removal of the cholesteatoma. The other procedures of this type of surgery are similar to the standard tympanomastoidectomy technique.
41161643|NCT03294421|PROCEDURE|standard closed tympanomastoidectomy|"1. Supine position and general anesthesia with orotracheal intubation~2. Antisepsis and placing of sterile fields~3. Local anesthesia of the external auditory canal with lidocaine 2% and adrenaline 1:100. 000 UI~4. Retroauricular incision~5. Removal of the temporal muscle fascia~6. Elevation of the surgical flap of the tympanic meatus~7. Visualization and exploration of the cholesteatoma~8. Exploration of the ossicular chain~9. Mastoid debridement~10. Conservation of the upper posterior wall of the auditory conduct~11. Removal of the cholesteatoma~12. Tympanoplasty with the temporal fascia~13. Retroauricular suture with vycril 3.0 and mononylon 4.0"
41161644|NCT03128541|DIAGNOSTIC_TEST|Ultrasound spine|A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
41161645|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Low Dose|Single or two-dose intramuscular injection.
41161646|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Medium Dose|Single or two-dose intramuscular injection.
41161647|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A High Dose|Single or two-dose intramuscular injection.
41367607|NCT05682638|OTHER|0.9%NaCl|1.0ml/dose, 2 injection with 28 days apart
41367608|NCT01418066|DRUG|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
41367609|NCT01418066|DRUG|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
40846357|NCT04575207|DIAGNOSTIC_TEST|caFFR|caFFR is a new index of physiological assessment of coronary artery stenosis severity, based on angiographic images. Through two-dimensional analysis and three-dimensional reconstruction of two coronary angiography image series with an angle-off \> 30 degrees, combined with fluid mechanics, TIMI frame counting method, and optimized CFD algorithm, the pressure drop from coronary ostium to every point in the vessel can be obtained, and then the caFFR value of each point in the vessel can be computed. The cutoff value in this trial is caFFR ≤ 0.80 for myocardial ischemia.
40846358|NCT04575207|DIAGNOSTIC_TEST|FFR|FFR is a widely used, pressure-based functional assessment index of coronary stenoses obtained with an intracoronary pressure wire fitted with pressure sensors. The pressure wire passes through the stenosis and directly measures the pressure distal to the stenosis. FFR value can be obtained by combining the pressure at the coronary ostium and the distal pressure to the stenosis. The cutoff value in this trial is FFR ≤ 0.80 for myocardial ischemia.
40846359|NCT05870878|OTHER|Standard care|Individual lifestyle consultation
40846360|NCT05870878|OTHER|Lifestyle program|Lifestyle program focusing on lifestyle advice, coping with stress and adherence to a healthy(er) lifestyle. This program consists of 3 group sessions and an online platform.
40846361|NCT06229054|DRUG|Dexmedetomidine|Dexmedetomidine (DEX), an α2-agonist with more promising pharmacokinetic and pharmacodynamic characteristics than clonidine has been proved to have a positive effect on postoperative pain intensity and to reduce opioid consumption
40846362|NCT06229054|DRUG|Bupivacaine Hydrochloride|local anesthesic which works through blocking sodium channels
40846363|NCT04892108|PROCEDURE|STARR (Stapled Trans Anal Rectal Resection)|Patients randomly assigned to surgical intervention of STARR (Stapled Trans Anal Rectal Resection)
41161648|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Modified|Single or two-dose intramuscular injection.
40846364|NCT04892108|PROCEDURE|LVR (Laparoscopic Ventral Rectopexy)|Patients randomly assigned to surgical intervention of LVR (Laparoscopic Ventral Rectopexy)
40846365|NCT04796350|DEVICE|AGN1 LOEP treatment|the implantation site is injected with the AGN1 implant material
40846366|NCT03504748|DEVICE|deep rTMS|
40846367|NCT03504748|DEVICE|placebo deep rTMS|
41028872|NCT05707234|DEVICE|VRH|The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).
41161649|NCT00434577|BIOLOGICAL|Placebo|Single intramuscular injection
41161650|NCT01705314|DIETARY_SUPPLEMENT|vitamin D supplements|Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
41161651|NCT01705314|DIETARY_SUPPLEMENT|placebo|7mls of placebo drops per week for 8 months.
41161652|NCT03291873|PROCEDURE|PRK|PRK using Alcon-Wavelight Excimer Laser EX 500
41367610|NCT01495793|DRUG|Rotigotine|"Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied."
41367611|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing under fasting condition
41367612|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing after high-fat meal
41367613|NCT02454621|BEHAVIORAL|Volitional help sheet|Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
41367614|NCT00401310|DRUG|Comparator: Placebo|Placebo IV infusions 1hr/daily over 7 days.
41367615|NCT00401310|DRUG|Comparator: MK0724|MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
40846368|NCT03787992|DRUG|Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo|"The initial dose of AST2818 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
41028873|NCT05707234|DRUG|Midazolam sedation|During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
41028874|NCT06532591|DRUG|cadonilimab+paclitaxel+carboplatin|PD-1/CTLA-4 bispecific antibody，Cadonilimab 10mg/kg IV, q3w, paclitaxel 175mg/m2 ivgtt d1, q3w, carboplatin AUC 5 ivgtt d1, q3w
41028875|NCT03813329|DIETARY_SUPPLEMENT|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
41028876|NCT03813329|DIETARY_SUPPLEMENT|Acute Sodium Bicarbonate|3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
41028877|NCT03813329|DIETARY_SUPPLEMENT|Calcium carbonate (placebo)|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
41028878|NCT05673200|PROCEDURE|Biopsy|Undergo biopsy
41028879|NCT05673200|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41367616|NCT05383976|OTHER|Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program|This intervention will utilize the existing Penn Medicine CRC patient navigation program. There will be a monthly list of patients with unfilled coloscopies provided, that are risk-stratified according to the machine learning algorithm and select high-risk criteria. The navigation team will prioritize timely outreach and navigation to high-risk patients according to a script that communicates risk.
41367617|NCT02415491|OTHER|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|"MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency."
41367618|NCT04930562|DRUG|BN101|BN101 is an orally ROCK2 selective inhibitor
41501933|NCT04495036|OTHER|data collection (23-items-physician descriptive survey)|"To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:~* Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)~* Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective"
40846369|NCT03787992|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
40846370|NCT03787992|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
40846371|NCT03787992|DRUG|Placebo AST2818 80mg//40 mg|The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
41501934|NCT05377034|COMBINATION_PRODUCT|SIRT-Y90 with Atezolizumab + Bevacizumab|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.
40846372|NCT06012110|DEVICE|Transcutaneous electrical stimulation|While participants are supine with a pillow placed below the knees for comfort, one 30-minute transcutaneous electrical stimulation session will be performed at a frequency of 50 Hz, pulse width of 400 microseconds and individualized amplitude will be completed.
41501935|NCT05377034|COMBINATION_PRODUCT|SIRT-Y90 with Placebo (IV)|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by placebo at every 3 weeks for 18 months.
40846373|NCT03299283|DIAGNOSTIC_TEST|BioFire test platform|Analysis of analyte stability under various conditions as measured by BioFire test platforms
40846374|NCT01224080|DEVICE|Adiana placement|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
40846375|NCT01091818|DRUG|dexmedetomidine|Dexemedethomidine is given as major sedative drug
40846376|NCT01091818|DRUG|Midazolam|Midazolam is given as major sedative drug
41028880|NCT05673200|PROCEDURE|Computed Tomography|Undergo CT
41028881|NCT05673200|DRUG|Decitabine and Cedazuridine|Given PO
41161653|NCT04282564|OTHER|Co-OP treatment|"The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke"
41367619|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser|The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
41367620|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL|
41367621|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Program|Papás Saludables, Niños Saludables is a 10 week program for fathers and their children that meets weekly. Each session is 90 minutes long: 15 min introduction, 30 min pull-out sessions for fathers and children, and 45 min active play sessions together. Fathers are encouraged to improve their eating and physical behaviors to lose weight and to be healthy role models for their child. Children are encouraged to help their fathers lose weight and improve their health. The program has been adapted to contextualize the information for low-income Hispanic families and changed to US food and physical activity guidelines. Mothers will be provided a Handbook and will be sent short videos, recipe links, and short motivational messages every week covering the same topics as in the sessions.
41028882|NCT05673200|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41028883|NCT05673200|DRUG|Paclitaxel|Given IV
41028884|NCT05673200|BIOLOGICAL|Pembrolizumab|Given IV
41028885|NCT05401292|DRUG|Hibiclens|antiseptic/antimicrobial skin cleanser for skin wound and general skin cleansing
41367622|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Wait-list Control|The same program as above delivered to the wait-list control after the T1 follow-up data has been collected.
41028886|NCT05401292|DRUG|Isopropyl Alcohol 70% Topical Application Solution|First aid antiseptic
41028887|NCT05732168|DIAGNOSTIC_TEST|A test battery for evaluation of muscle strength, balance and functional performance|Subjects with chronic ankle instability (CAI) were evaluated with five tests of strength, balance and functional performance.
41028888|NCT05130112|DEVICE|high flow nasal cannula and nasal cannula|"HFNC was administered using the MyAIRVO 2 device (Fisher \& Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher \& Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..~NC is administered for 10 min."
41161654|NCT00592735|PROCEDURE|laparoscopic gastric banding|standard surgical procedure
41367623|NCT03606473|DRUG|d-amphetamine|is used to stimulate dopamine release in the brain
41028889|NCT02687880|PROCEDURE|Testicular biopsy|Subjects will undergo a surgical procedure to harvest their testicular tissue.
41028890|NCT06384651|DRUG|Intraosseous Vancomycin Injection|"* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* IO Injection will take place into the medial malleolus."
41028891|NCT06384651|DRUG|Intravenous Vancomycin|• Patients will receive the orthopedic surgeon's standard of care pre-operative antibiotic regimen for TAA patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL normal saline (NS))
41161655|NCT02675998|DRUG|Tenapanor|
41161656|NCT02675998|DRUG|Placebo|
41161657|NCT05195905|DEVICE|PMEG|All devices that will be modified in this study protocol are commercially available in the United States. The commercially available endografts will be used to construct a fenestrated/branched device for this intervention.
41367624|NCT03606473|RADIATION|[C-11]NPA|PET radiotracer
41501936|NCT04566289|DEVICE|PiCSO|Percutaneous coronary intervention
40846377|NCT00000382|BEHAVIORAL|Infant-Parent Psychotherapy|
41028892|NCT02661906|OTHER|SKY|Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
41028893|NCT03009526|DRUG|Sulfadoxine-pyrimethamine|500 mg sulfadoxine and 25 mg pyrimethamine
41028894|NCT03009526|DRUG|dihydroartemisinin-piperaquine|40 mg dihydroartemisinin and 320 mg piperaquine
41028895|NCT05319691|BEHAVIORAL|Yoga|The trial will be 24 weeks long and divided into two distinct parts: an initial 12-week Treatment Phase during which, yoga participants will receive a reproducible standardized weekly yoga intervention delivered virtually with additional resources for home practice, followed by a 12-week Follow-up Phase.
41028896|NCT03318575|DEVICE|autoRIC|Automated Remote Ischemic Conditioning
40846378|NCT00000382|BEHAVIORAL|Child Protective Services|
40846379|NCT00000382|BEHAVIORAL|Psychoeducational Home Visitation|
40846380|NCT00000382|BEHAVIORAL|Parent Education|
40846381|NCT03589222|DRUG|Selinexor|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle
40846382|NCT03589222|DRUG|Daratumumab|daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
40846383|NCT03589222|DRUG|Bortezomib|bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9
41501937|NCT03975231|DRUG|Dabrafenib|Given PO
41501938|NCT03975231|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41501939|NCT03975231|DRUG|Trametinib|Given PO
41028897|NCT03318575|DEVICE|autoRIC Sham|Automated Remote Ischemic Conditioning Sham
41501940|NCT06444178|DRUG|Aspirin|Oral administration
41161658|NCT04835233|DRUG|Methyldopa 250 MG|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
40846384|NCT03589222|DRUG|Dexamethasone|dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
40846385|NCT05701566|DEVICE|virtual reality headset|use of virtual reality headset during colonoscopy as a substitute to sedation.
40846386|NCT05701566|OTHER|colonoscopy with standard sedation.|use of standard sedation during colonoscopy.
40846387|NCT05852860|OTHER|Clinician Nudge|"The clinician nudge will use the BPA functionality within the electronic medical record to deliver a message with a defaulted option to refer to the health system's tobacco treatment program. Changing the default to no referral will require an explanation using the options provided or by entering free text."
40846388|NCT05852860|OTHER|Patient Nudge|The patient nudge will deliver a message within 72 hours of a patient's next scheduled clinic visit. The message will be delivered through the Penn patient portal (MyPennMedicine) or by text with security measures for privacy.
40846389|NCT03344627|DRUG|Meropenem standard dose|"* Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection."
41367625|NCT02049008|OTHER|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
40846390|NCT03344627|DRUG|Meropenem high dose|"* Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection"
40846391|NCT06037408|DRUG|20mM sodium pyruvate nasal spray|The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2 (N115). Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
41028898|NCT00584688|DRUG|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
41028899|NCT02096653|PROCEDURE|X-ray SI joint steroid injection|Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
41501941|NCT06444178|DRUG|REGN9933|Administered intravenous (IV)
41501942|NCT06444178|DRUG|REGN7508|Administered IV
41501943|NCT06444178|DRUG|Rivaroxaban|Oral administration
41501944|NCT06500208|DRUG|Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide|Adebrelimab 1200mg i.v. q3w combined with nab-paclitaxel 100mg/m2 qw\*12w followed by epirubicin 90mg/m2 and cyclophosphamide 600mg/m2 q3w for 4 cycles
41501945|NCT00198250|DRUG|venlafaxine|Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks
41501946|NCT06063850|GENETIC|AAV9-hSyn1-miGRIK2|AMT-260 is an AAV9 gene therapy product that locally delivers miRNA silencing technology to target the GRIK2 gene and suppress aberrantly expressed GluK2 containing kainate receptors. Intervention will be a one-time intracerebral administration of AMT-260.
41501947|NCT04201691|OTHER|classic rehabilitation|The intervention is conventional rehabilitation that included streching, balance and coordination training. The intervention is applied to participants, manually.
41501948|NCT04201691|OTHER|classic rehabilitation+mobilization|Another intervention is manuel therapy that included gliding technics, rotational technics at cervical region. (in addition to classic rehabilitation). The intervention is applied to participants, manually.
41028900|NCT02096653|PROCEDURE|Landmark-guided SI steroid injection|Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
41028901|NCT02855060|DEVICE|Pelvic Binder|
41028902|NCT01299493|OTHER|Systems-level intervention to promote colon cancer screening|Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
41028903|NCT00097812|DRUG|zoledronic acid|
41028904|NCT03579459|BIOLOGICAL|Clostridium difficile vaccine|Toxoid based Clostridium difficile vaccine
41028905|NCT03579459|BIOLOGICAL|placebo|Normal saline solution
41028906|NCT04251468|DEVICE|GEPII|Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)
41028907|NCT04251468|DEVICE|Ion-selective electrodes|Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.
41028908|NCT01234506|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside|SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
41028909|NCT03815071|DRUG|Ips-nsc cells|Total dose of ips-nsc cells will be administered at day0.
41028910|NCT03124641|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
41161659|NCT02723305|OTHER|No intervention|
41161660|NCT00316459|DRUG|ERB-041|
41161661|NCT02647125|DRUG|Huachansu|Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
41161662|NCT02647125|RADIATION|thoracic radiation|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
41161663|NCT02236598|DRUG|K+ supplement|
41161664|NCT02236598|DRUG|Placebo|
41501949|NCT03548337|BIOLOGICAL|13vPnC|13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative
41501950|NCT05411198|DEVICE|XEN45 (Glaucoma Gel Stent)|Ab externo implant
41501951|NCT00742118|PROCEDURE|Colic biopsies|colic biopsies and analysis
41028911|NCT03124641|PROCEDURE|Conventional cold storage (CCS)|Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement
41028912|NCT03272438|DEVICE|Accelerometer|Participants use an accelerometer to monitor their steps activity
41501952|NCT06410248|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41028913|NCT03272438|BEHAVIORAL|Step goal|Participants are given a daily step goal to aim for
41028914|NCT03272438|BEHAVIORAL|Consistent contexts|Participants plan to take steps in contexts that are similar from day to day
41028915|NCT03272438|BEHAVIORAL|Inconsistent contexts|Participants plan to take steps in contexts that vary from day to day
41028916|NCT04369027|DIAGNOSTIC_TEST|passive leg raising|"passive leg raising: to raise the legs of the patients by adjusting the angle of the patient's bed during one minute.~Tidal volume challenge: an increas by 2ml/Kg of the tidal volume during one minute"
41028917|NCT05742373|OTHER|Exercise training in the fasted state|Four weeks of moderate intensity cycling exercise, three times a week without eating breakfast meal
41028918|NCT05742373|OTHER|Exercise training in the fed state|Four weeks of moderate intensity cycling exercise, three times a week, after eating breakfast meal
41028919|NCT03354676|OTHER|MetS+|Data processing from Patient Medical Files
41028920|NCT03354676|OTHER|MetS-|Data processing from Patient Medical Files
41028921|NCT04777565|OTHER|Robotic surgery|Cochlear implant surgery with HEARO procedure
41028922|NCT04804358|BEHAVIORAL|Exposition Test|"During this test (7 minutes) participants will be exposed to photos evoking positive or negative emotions (anger, disgust, sadness and fear) interspersed with emotionally neutral photos.~The test sequence is composed of 3 blocks as follows:~* 12 photos evoking positive emotions (2 min)~* Pause of 30 seconds (white screen)~* 12 photos presenting a neutral emotional valence (2 min)~* Pause of 30 seconds (white screen)~* 12 photos evoking negative emotions (2min)~In each block, photos will be selected and presented to the participant in a randomized and sequential manner. In total, 30 photos will be presented in 7 minutes to each participant (10 seconds per photo).~The participant must be at rest in front of the computer screen during these 7 minutes with optimal visibility. The photos will be presented sequentially using software (E-Prime or Visual Basic 6.0). During this exposure test, a heart rate recording will be made using a BIOPAC MP160 recording system."
41501953|NCT06410248|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41501954|NCT06410248|OTHER|Questionnaire Administration|Ancillary studies
41501955|NCT06410248|PROCEDURE|Resection|Undergo surgical resection
41501956|NCT06410248|DRUG|Temozolomide|Given PO
41501957|NCT06410248|DRUG|Triapine|Given PO
41501958|NCT06551974|BEHAVIORAL|Guided self-help plus IPT|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours. Participants will also attend a weekly online forum with interactional materials, and an online interpersonal group session.
41501959|NCT06551974|BEHAVIORAL|Guided self-help|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours.
41501960|NCT06551974|BEHAVIORAL|TAU|The Treatment as Usual is the usual or routine care provided to participants in the outpatient setting.
41501961|NCT00431483|BEHAVIORAL|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
41028923|NCT04725331|BIOLOGICAL|BT-001|Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose \[Phase I, Part A\]; one dose lower and at Recommended Dose for Part B \[Phase I, Part B\] by intra-tumoral (IT) route.
41028924|NCT04725331|DRUG|Pembrolizumab [KEYTRUDA®]|Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
41028925|NCT05643066|DRUG|0.1 mg/kg esketamine|Esketamine 0.1 mg/kg was intravenously injected first.
41501962|NCT03596814|OTHER|No Interventional study|Retrospective data
41501963|NCT04560998|DRUG|Semaglutide|Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
41501964|NCT04560998|DRUG|Placebo (semaglutide)|Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
41501965|NCT01143766|DRUG|Gabapentin|gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
41028926|NCT05643066|DRUG|0.2 mg/kg esketamine|Esketamine 0.2 mg/kg was intravenously injected first.
41028927|NCT05643066|DRUG|0.9% saline|0.9% saline was intravenously injected first.
41028928|NCT05643066|DRUG|Propofol|Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
41161665|NCT00899379|DRUG|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
41161666|NCT00899379|DRUG|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
41161667|NCT04287634|OTHER|Segmental Mobilization|Hot fermentation =10 minutes Soft tissue mobilization =5 minutes Targeted segmental mobilization= 3 sets of 10 repetitions Home plan exercise= cervical muscles stretching, postural care.
41501966|NCT01143766|OTHER|Standard sedation regimen|Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
41501967|NCT06104995|OTHER|Interventional video|The educational video comprises of health care professionals explaining the durability of the back against the popular belief that the back is fragile and the multifactorial nature of back pain.
40846392|NCT06037408|OTHER|Saline Placebo control nasal spray|The placebo is 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2. Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
41161668|NCT04287634|OTHER|Entire Spine Mobilization|Hot fermentation=10 minutes Soft tissue mobilization=5 minutes Entire spine mobilization =3 sets of 10 repetitions Home plan exercises=cervical muscles stretches, postural care.
41501968|NCT06104995|OTHER|Control video|The control video is a neutral video with no content addressing back beliefs (fragility and need for protection).
41501969|NCT01630577|OTHER|volume expansion using modified gelatin|Volume expansion using modified gelatin was determined according to a procedure formulated by modifying guidelines produced by Weil and Henning. The maximum volume infusion during the study test was fixed at 400 ml.
41501970|NCT04315571|DEVICE|Gore® Viatorr® Endoprosthesis with controlled expansion|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is a minimally invasive procedure in which a new path is made through the liver to carry blood from the portal vein to the heart, thus helping to alleviate the problems associated with elevated portal vein pressure.
41501971|NCT04315571|PROCEDURE|Large Volume Paracentesis with albumin infusion|For therapeutic (large-volume) paracentesis, a 14-gauge cannula attached to a vacuum aspiration system is used to collect up to 8 L of ascitic fluid. Concurrent infusion of IV albumin is recommended during large-volume paracentesis to help avoid significant intravascular volume shift and postprocedural hypotension.
41501972|NCT00492986|DRUG|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
41501973|NCT01767038|PROCEDURE|OCT Spectralis|
41501974|NCT01767038|PROCEDURE|microperimetry|
41501975|NCT03226028|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlists of different music genres. Music listening session will be given for 30 minutes before and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
41501976|NCT05184543|OTHER|Routine Exercise Program|8 weeks of routine basketball training will be done. Dynamic stretching exercises, in which large muscle groups are exercised, can be applied for 20 minutes.
40846393|NCT04479124|DIAGNOSTIC_TEST|COVID-19 PCR|Nasopharyngeal samples were analyzed by PCR for the detection of Novel Coronavirus 2019 DNA
40846394|NCT03420885|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines the traditional Chinese medicine and traditional Chinese philosophy and embrace the body, breath and spirit. Ba Duan Jin consists of eight main movements. According to traditional theory, every movement has unique effect to different Zang-fu organs.
40846395|NCT03420885|BEHAVIORAL|Health Education|Health education includes work, rest, diet and other basic programs according to the different conditions of participants.
41161669|NCT05205252|DRUG|Tazemetostat|Orally, twice daily in continuous 28-day cycles.
41161670|NCT05205252|DRUG|Tafasitamab|Intravenously, 12 mg/kg, once daily on Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.
41161671|NCT05205252|DRUG|Lenalidomide|Orally, 10 mg or 20 mg based on kidney function, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles.
41501977|NCT05184543|OTHER|Core Stability Exercise Program|In addition to the 8-week routine basketball training, 20 min core stability exercises will be given to the Core Group. Core stability exercises will be performed on the stable surface for the first 4 weeks, and core stability exercises will be performed on unstable surfaces for the next 4 weeks.
41501978|NCT05184543|OTHER|Body Weight Neuromuscular Warm-Up Program|Each 20-minute program consists of 5 different parts. The beginning of the program consists of low-speed running exercises with the ball. The running track for each exercise will include 4 basketball court areas. The second part consists of active stretching exercises. The third part consists of exercises focusing on general strength. The fourth part consists of plyometric, balance, and jump exercises. The final section consists of a sprint with sudden changes of direction and basketball movements.
41501979|NCT05852691|DRUG|Tobemstomig|Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.
41501980|NCT05852691|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.
41161672|NCT05205252|DRUG|Acalabrutinib|Orally, 100 mg, twice daily.
41161673|NCT05205252|DRUG|Daratumumab (Intravenously)|Intravenously, 16 mg/kg actual body weight, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
41161674|NCT05205252|DRUG|Mosunetuzumab|Subcutaneously, step-up doses on Cycle 1 Days 1 (5 mg), 8 (45 mg) and 15 (45 mg) and then 45 mg from Cycle 2 through 12 on Day 1 of the 28-day cycle.
41161675|NCT05205252|DRUG|Daratumumab (Subcutaneously)|Subcutaneously, 1800 mg, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
41161676|NCT05205252|DRUG|Hyaluronidase-Fihj|Subcutaneously, 30,000 units, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
41161677|NCT05205252|DRUG|Pomalidomide|Orally, 4 mg, once daily on Days 1 to 21 of continuous 28-day cycles.
41161678|NCT05205252|DRUG|Dexamethasone 20mg|Orally, 20 mg or 40 mg, once daily on Days 1, 8, 15, and 22 of continuous 28-day cycles.
41161679|NCT01612221|DRUG|N-acetylcysteine|N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
41161680|NCT01612221|OTHER|Placebo arm|Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.
41501981|NCT05852691|DRUG|Nab-Paclitaxel|Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
41161681|NCT04873297|DRUG|Metoclopramide 10mg|Tab. Metoclopramide 10mg TDS via NG tube
41161682|NCT04873297|DRUG|Placebo|Placebo 10 ml of plain water Via NG
41028929|NCT00991250|BIOLOGICAL|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
41161683|NCT04034602|OTHER|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
41161684|NCT04034602|OTHER|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
41161685|NCT00005845|DRUG|tipifarnib|Given PO
41161686|NCT00005845|OTHER|laboratory biomarker analysis|Correlative studies
41161687|NCT00005845|OTHER|pharmacological study|Correlative studies
41161688|NCT02171247|DRUG|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
41161689|NCT02171247|DRUG|Visipaque 320|Visipaque 320 is standard protocol.
41161690|NCT02637258|OTHER|Ultrasonographic Measurements of Optic Nerve Sheath Diameter|Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter
41161691|NCT05300698|DEVICE|MRI|compare between MRI and ultrasound for indirect assessment of ocular layers
40846396|NCT04372459|BEHAVIORAL|Online integrated and stepped psychosocial care|"This program features four levels of care, increasing in intensity of psychosocial care as patients move from one level to the next one.~Step 1: Screening and monitoring of several psychosocial variables through the central mobile application of the program (App ICOnnecta't).~Step 2: Online guided and self-help psychoeducation Campus in which patients can consult videos and online resources, co-constructed between health professionals and patients, containing reliable and rigorous information related to the oncological process.~Step 3: Online community of psychosocial support. Participants can choose from 12 cancer-related discussion forums and share with the community any health-related question that worries them fostering, thus, debate and stimulating peer-support.~Step 4: Intensive online group psychotherapy (App ICOnnecta't Videoconsultation), based on the Group Positive Psychotherapy program for cancer survivors (Ochoa, Sumalla, Maté, Castejón, Rodríguez et al., 2010)."
41161692|NCT05207631|OTHER|Systematic and standardised assessment of inhalers and implementation of a prescribing guide|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.
40846397|NCT04372459|BEHAVIORAL|Usual psychosocial care|This active control group will receive the standard psychosocial treatment for cancer survivors in the participating centers, led by a clinical psychologist and consisting of 8 individual, 45/60-minute sessions, each of which every 1-2 months, focused on providing emotional support and psychoeducation during the first year of primary cancer treatment.
40846398|NCT05374213|BEHAVIORAL|Mindfulness-Based Intervention|Mindfulness practices use a non-stigmatizing approach, combining secularized eastern meditative practices with western psychological advances to improve stress-management and self-care. Participants learn to generate less distress, engage more positively and fully in their lives and experiences, and respond more adaptively to challenges instead of reacting in automatic and unhelpful ways.
40846399|NCT02386501|DRUG|ADXS31-164|
40846400|NCT04629846|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.
40846401|NCT04629846|DRUG|QL1209|QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
40846402|NCT04629846|DRUG|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
40846403|NCT04629846|DRUG|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4
40846404|NCT04629846|PROCEDURE|surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
40846405|NCT04196673|DEVICE|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
40846406|NCT04196673|DEVICE|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
41028930|NCT00991250|DRUG|Temodal® or Dacarbazine Medac®|"Dacarbazine (5-\[3,3-Dimethyl-1-triazenyl\]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver."
41028931|NCT06057389|DIETARY_SUPPLEMENT|aronia melanocarpa extract|aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst；twice a day，one at a time) combined with an energy-restricted diet
41028932|NCT04331600|DRUG|Chloroquine phosphate|Oral chloroquine phosphate for 14 days
41028933|NCT04331600|OTHER|Telemedicine|Telemedical supervision for 42 days
41028934|NCT01450358|OTHER|Antibiotic regimen|The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
41028935|NCT02571452|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
41028936|NCT02571452|BEHAVIORAL|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
41028937|NCT06491004|DIAGNOSTIC_TEST|PTX3 assay|PTX3 dosage by the in vitro medical device in evaluation.
41028938|NCT02090738|DRUG|Acetazolamide group|
41028939|NCT02090738|DRUG|Standard regimen group|
41028940|NCT05127343|PROCEDURE|Sealing deep pits and fissures|Application of the pit and fissure sealant
41367626|NCT02049008|OTHER|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
41367627|NCT00101374|DRUG|Leflunomide|
41367628|NCT04447183|DRUG|Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)|rhTSH: 0.9 mg IM daily on two consecutive days;radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
41028941|NCT05537389|DEVICE|In-line filter|"All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.~In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.~In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed."
41367629|NCT04447183|OTHER|radioactive iodine|radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
41367630|NCT00598585|DRUG|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
41367631|NCT00598585|DRUG|Placebo|Placebo pills 3X/day for 6 weeks
41367632|NCT03550989|OTHER|Non-Exposure Event|Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.
41501982|NCT05375877|DEVICE|iATROS|"The digital eHealth platform of iATROS in combination with a wearable will be used independently by the subjects of the study. In particular, the reminder function is used to remind patients to record their ECGs, take medication and perform other tasks they may have created themselves, or to use other iATROS functions, such as teleconsultation or remote medical data reporting. Furthermore, the designed training program for atrial fibrillation patients teaches them how to deal with their own disease.~If unhealthy or dangerous vital signs are detected during the use of these medical devices over a longer period of time, the patient receives feedback through the application for medical presentation. This includes the detection of atrial fibrillation recurrences."
41028942|NCT00352534|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo radiotherapy
41028943|NCT00352534|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41028944|NCT00352534|PROCEDURE|Chest Radiography|Undergo chest X-ray
41028945|NCT00352534|PROCEDURE|Computed Tomography|Undergo CT
41028946|NCT00352534|BIOLOGICAL|Dactinomycin|Given IV
41028947|NCT00352534|DRUG|Doxorubicin Hydrochloride|Given IV
41367633|NCT03550989|OTHER|Exposure Event|Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).
41367634|NCT03416023|DEVICE|TIES® (Transcutaneous Implant Evacuation System)|Transcutaneous Implant Evacuation System
41367635|NCT03441828|PROCEDURE|Quality of surgical field conditions|evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
41367636|NCT03441828|DRUG|Deep Neuromuscular Block|maintenance of a deep neuromuscular block by infusion of rocuronium
41367637|NCT03441828|DRUG|Moderate Neuromuscular Block|maintenance of a moderate neuromuscular block.
41367638|NCT01716221|DRUG|bupropion & Citalopram|
41367639|NCT01716221|DRUG|Bupropion & Placebo|
41367640|NCT01716221|DRUG|Placebo & Citalopram|
41367641|NCT01716221|DRUG|Placebo & Placebo|
40846407|NCT00705146|DEVICE|Comfort Cool thumb splint by North Coast Medical|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
41028948|NCT00352534|PROCEDURE|Echocardiography|Undergo echocardiography
41028949|NCT00352534|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41028950|NCT00352534|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41028951|NCT00352534|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
41028952|NCT00352534|DRUG|Vincristine Sulfate|Given IV
41028953|NCT00159211|DRUG|UMULINE NPH|UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
41028954|NCT00159211|DRUG|pioglitazone|30mg daily. After 2 months, if HbA1c has not decreased at least of 1%, the dosage should be increased to 45 mg daily
41028955|NCT04896489|DRUG|Hydrocortisone 20 MG|Participants receive Hydrocortisone 20 MG
41028956|NCT04896489|OTHER|Placebo|Participants receive placebo
41367642|NCT01148108|DRUG|Canfosfamide HCl for injection|30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
41367643|NCT03702192|DEVICE|novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR|novel antithrombotic management protocol
41028957|NCT04393701|PROCEDURE|Additional blood sampling|Additional blood sampling on blotting paper will be done in neonates in Normandy, France, compared to National neonatal screening program
41028958|NCT06341218|OTHER|Pediatric Cardiopulmonary Resuscitation Training Based On Team Resource Management|"The sociodemographic information form, Pediatric CPR knowledge level and teamwork attitudes pretest were administered to the healthcare teams just before the training intervention.~The intervention group received a 3-hour training intervention on technical/non-technical skills for CRM-Based Pediatric CPR Training To measure pediatric CPR team performance, 5 different scenarios were prepared by the researcher by INACLS standards. One day after the training intervention, simulation application including pediatric cardiac arrest scenarios was applied to all CPR teams in the intervention(5 groups) and control(5 groups) groups. The scenario content was based on a 5-year-old male patient diagnosed with Pneumonia+Septic Shock.~Pediatric CPR skill levels of the healthcare teams were evaluated during the simulation practice. Immediately after the simulation, the post-intervention post-test of Pediatric CPR knowledge level and team attitudes of the healthcare teams was performed."
41028959|NCT02256501|BIOLOGICAL|Mono Nuclear Cell (MNC) transplantation|Intracoronary administration of autologous bone marrow derived mononuclear cells
41028960|NCT04181710|PROCEDURE|Kidney transplant|Organ preserved in preservation solution
41028961|NCT04968067|DEVICE|App group|In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
41028962|NCT04968067|DEVICE|Nursing telephone advice (NTA) group|All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
41028963|NCT00846664|PROCEDURE|Logan Short Arc Banding|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
41028964|NCT01337089|DRUG|Nabiximols|
41028965|NCT04425226|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.
41028966|NCT04425226|DRUG|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
41028967|NCT01678326|PROCEDURE|EUS-Rendezvous or direct intervention|
40846408|NCT00705146|DEVICE|Custom made thermoplastic & neoprene splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
41367644|NCT05617274|PROCEDURE|Sectioning of the full arch mandibular fixed prosthesis|The one unit full arch fixed prosthesis is sectioned at the midline into two pieces
40846409|NCT02488993|OTHER|Prospective Phase Rifaximin-α 550mg|Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
40846410|NCT02488993|OTHER|Prospective Phase No Rifaximin-α 550mg|Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
40846411|NCT02488993|OTHER|Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
40846412|NCT04855019|PROCEDURE|shoulder periarticular injection, suprascapular and axillary nerve block|"In the PI group, a mixture of 30 ml bupivacaine 0.5% and 30 ml saline solution will be injected by the orthopedist after the wound is closed.~In the CSAB group, a total of 20 ml 0.5% bupivacaine, 10 ml to the suprascapular notch, 10 ml to the axillary nerve, will be administered preoperatively by the anesthesiologist under ultrasound guidance."
40846413|NCT01961063|DRUG|busulfan|Given IV
40846414|NCT01961063|BIOLOGICAL|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Given IV
40846415|NCT01961063|OTHER|pharmacological study|Correlative studies
40846416|NCT01961063|OTHER|laboratory biomarker analysis|Correlative studies
40846417|NCT00734721|BEHAVIORAL|Preoperative information and perioperative care|Patients receive different information and care in addition to the basic medical consultation.
40846418|NCT03582696|BEHAVIORAL|CHANGE Study|The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
40846419|NCT04394650|BIOLOGICAL|CC-98633|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633.~During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection."
40846420|NCT00880594|DRUG|Desipramine|"Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum."
40846421|NCT03602859|DRUG|Niraparib|Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)
40846422|NCT03602859|DRUG|Dostarlimab (TSR-042)|Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
40846423|NCT03602859|DRUG|Standard of care|Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.
40846424|NCT03602859|DRUG|Dostarlimab-Placebo|Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
40846425|NCT03602859|DRUG|Niraparib-Placebo|Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.
40846426|NCT04868149|PROCEDURE|Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)|Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.
40846427|NCT06200883|DRUG|Placebo oral vial|In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks
41367645|NCT05794347|OTHER|Traction|Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
40846428|NCT06200883|DRUG|Choline Bitartrate|In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
41367646|NCT03194724|OTHER|Vitamin A supplementation|Bi annual vitamin A supplementation programme
41367647|NCT03517150|DEVICE|mandibular advancement device|
41367648|NCT04717700|DRUG|Selinexor 20 MG Oral Tablet|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
41367649|NCT04717700|DRUG|Bortezomib Injection|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
41367650|NCT04717700|DRUG|Lenalidomide capsule|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
40846429|NCT05809063|OTHER|observational|document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units
41028968|NCT01678326|PROCEDURE|Advanced ERCP Biliary Access Techniques|
41161693|NCT05222009|DRUG|PEG-rhG-CSF|PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
41161694|NCT05222009|DRUG|PEG-rhG-CSF|PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
41161695|NCT01940692|DRUG|1.5g intravenous Exacyl|intravenous administration of 1.5g Exacyl preoperatively
41161696|NCT01940692|DRUG|3.0g intra-articular Exacyl|3g Intra-articular Exacyl administration postoperatively
41501983|NCT00006183|PROCEDURE|Cardiopulmonary Bypass with Two Different Intra-Operative Hematocrits|
41028969|NCT03357601|BEHAVIORAL|HIIT|The participant will perform HIIT where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 20 seconds of high intensity interval exercise at an all out intensity separated by 2 minutes of active recovery at 30% MHR. The interval will be repeated six times. Once completing all six intervals, participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
41028970|NCT03357601|BEHAVIORAL|MCEET|The participant will perform MCEET, where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 14 minutes of moderate, continuous endurance exercise at 70% MHR. Participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
41367651|NCT04717700|DRUG|Dexamethasone Oral|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
41161697|NCT05609721|OTHER|no intervention, only observational study|no intervention, only observational study
41161698|NCT04092621|DRUG|Amiodarone in Parenteral Dosage Form|Amiodarone IV
41161699|NCT04092621|DRUG|Amiodarone Pill|Amiodarone tablet
41161700|NCT04092621|PROCEDURE|Direct Current Cardioversion (DCC)|Convert arrhythmia back to sinus rhythm
41367652|NCT06300281|BEHAVIORAL|Neuromuscular Exercise|A Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization
41367653|NCT06300281|BEHAVIORAL|Aquatic Exercise|The exercise program will begin with a 10-minute warm-up period, including straight, sideways, back walking, cycling without equipment on the parallel bar, lower extremity strength exercises, standing on tiptoes and pressing on the heels, weight transfer, resistant exercises with auxiliary devices, calisthenic exercises, hamstring and quadriceps femoris stretching. It will end with a cooling period including exercises.
41367654|NCT01237665|DRUG|IXO regimen|"IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22."
41028971|NCT02423382|PROCEDURE|Silicone oil removal|The patients in each group will receive the same procedure of silicone oil removal.
41028972|NCT05363345|DEVICE|bile duct stone removal|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
41028973|NCT02726815|OTHER|Questionnaire|Questionnaire based study using a symptom assessment tool
41367655|NCT03076827|PROCEDURE|Total hip replacement|Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
41028974|NCT03430154|OTHER|No treatment given|No treatment given
41028975|NCT05336240|BEHAVIORAL|Physician Communication 2 Virtual (PCOM2-virtual)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.
41028976|NCT05336240|BEHAVIORAL|Physician Communication Standard (PCOM-standard)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
41161701|NCT04092621|DRUG|Rate-control therapy|one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
41161702|NCT05166798|BEHAVIORAL|Cognitive control training|The five intervention groups will receive either 1, 5, 10, 15 or 20 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT).
41501984|NCT00006183|PROCEDURE|Thoracic Surgery|
41501985|NCT04635527|DRUG|IBI318|before surgery IBI318 intravenous injection Q2W,after surgery IBI318 intravenous injection Q4W
41501986|NCT04635527|PROCEDURE|cTACE|conventional transarterial chemoembolization
41501987|NCT04635527|DRUG|placebo|before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W
41501988|NCT03523338|DRUG|Apalutamide|Participants will receive apalutamide 240 mg orally once daily.
41501989|NCT03523338|DRUG|ADT (Standard of Care)|Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
41501990|NCT03283384|DRUG|Letrozole|Letrozole 2.5 mg daily.
41028977|NCT03399110|DRUG|Oxaliplatin|oxaliplatin 130 mg/m2
41501991|NCT03283384|DRUG|Chemotherapy|Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).
41501992|NCT03283384|DRUG|Ribociclib plus letrozole|Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).
41501993|NCT06011707|BEHAVIORAL|OPT-IN|Parents will be provided with online access to 6 compulsory video-based modules and 8 optional video-based modules. These modules will teach them about child development, behavioural principles, and naturalistic developmental intervention principles. These modules will promote skills that parents can use to increase their child's social and communication behaviours and minimize behaviours that interfere with learning (e.g., temper tantrums).
41501994|NCT06011707|OTHER|Psychoeducational control|This control intervention will provide parents with 6 compulsory and 8 optional modules that will teach them about autism and its developmental course.
41501995|NCT05024864|DIAGNOSTIC_TEST|Urea breath test|"After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (breath bag). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and active H. pylori infection diagnosis is made based on previously established cut-off levels for H. pylori infection. In patients tested positive, eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.~Control of successful H. pylori eradication 6 weeks after completed eradication therapy is recommended to the treating physician."
40846430|NCT05786469|DRUG|Veltassa Oral Powder Product|"The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient"
41028978|NCT03399110|DRUG|Capecitabine|Capecitabine 1000mg/m2
41028979|NCT05517239|DRUG|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
41028980|NCT00919282|DRUG|gemcitabine, folinic acid, 5-FU|gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
41028981|NCT01823744|DIETARY_SUPPLEMENT|micronutrient supplementation|
41028982|NCT04877301|DEVICE|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter
41028983|NCT04877301|PROCEDURE|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter
41161703|NCT04599387|OTHER|Remote Exercise Prescription|Exercise sessions will follow the recruitment meeting as prescribed by the BioGradient system, and will be tailored to the patient progress and limitations. In the beginning of each exercise session safety criteria will be collected and will allow participation . In addition, every 8 weeks and during the first exercise session outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect session data and discuss progress and limitation with the participant.
41501996|NCT06278480|DEVICE|MegaCarti®|Medical devices containing allogeneic cartilage
41028984|NCT06221605|DIETARY_SUPPLEMENT|Probiotic|The intervention lasted for 6 months and 3 visits (at 0 month, 3rd and 6th month respectively).
41501997|NCT06278480|PROCEDURE|microfracture|microfracture
41501998|NCT01958073|DRUG|Conjugated Estrogen Vaginal Cream|
41028985|NCT03867734|DRUG|Aztreonam|2g IM Aztreonam
41028986|NCT01903655|OTHER|telomere length|
41028987|NCT00977041|BEHAVIORAL|Neurofeedback|"Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and Do whatever is necessary to make and keep the bar wide. This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly."
41161704|NCT04599387|OTHER|Usual Care|Exercise sessions will be initiated by the patient only. In the beginning of each exercise session safety criteria will be collected and will allow participation . Every 8 weeks and once after recruitment outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect outcome session data
41161705|NCT03389997|DIAGNOSTIC_TEST|nasal swabs|Iterative nasal swabs will be performed to screen for virus shedding
41161706|NCT02067455|OTHER|adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography|
41367656|NCT03076827|PROCEDURE|Hemi-arthroplasty|Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
41367657|NCT06245850|BEHAVIORAL|Baduanjin|chinese baduanjin
41367658|NCT06245850|BEHAVIORAL|Rational emotive behavior therapy|Rational emotive behavior therapy
41501999|NCT01958073|DRUG|Estradiol Ring|
41502000|NCT01958073|DRUG|Placebo|
41161707|NCT03891485|BIOLOGICAL|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, or other second line according to physician's choice)
41367659|NCT02790476|OTHER|Letters|"The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone."
41367660|NCT05707819|DRUG|Sintilimab (PD-1 Antibody)|Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
41502001|NCT04829994|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures subjects would receive as part of SOC.
41367661|NCT05405738|PROCEDURE|2 flap palatoplasty technique|cleft palate repair by 2 flap palatoplasty technique
41367662|NCT05405738|OTHER|normal group|control normal group
41502002|NCT00551668|PROCEDURE|proximal patellar surgery|Initial proximal patellar surgery
41161708|NCT03179059|DIAGNOSTIC_TEST|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
41502003|NCT00551668|PROCEDURE|Nonoperative|Nonoperative without surgery
40846431|NCT05786469|OTHER|Placebo|"The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient"
40846432|NCT01431391|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
40846433|NCT01431391|DRUG|leuprolide acetate|45.0 mg depot injection, 2 doses 6 months apart
41161709|NCT03179059|DIAGNOSTIC_TEST|Pregnancy test at follow up survey|We will provide a free pregnancy tests in for the future use, they are randomly selected from intervention #1 treatment group.
41367663|NCT05405738|PROCEDURE|Furlow with buccinator technique|cleft palate repair by Furlow with buccinator technique
41502004|NCT06292585|PROCEDURE|MMA embolization plus medical therapy|Patients assigned to the intervention group will receive endovascular embolization treatment within 2 hours after enrollment.
41502005|NCT06292585|DRUG|Medical therapy alone|Patients will receive the best conservative treatment recommended by the guidelines, and conservative treatment will be the same in both groups. Conservative treatment includes medication and general treatment. Drug therapy can be divided into hemostatic treatment, antihypertensive treatment, and symptomatic treatment. Specific local clinical diagnosis and treatment standards shall prevail or refer to corresponding clinical guidelines.
40846434|NCT03337464|OTHER|cycling exercise|5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
40846435|NCT02643342|DEVICE|Orthokeratology|
41161710|NCT00721825|DRUG|Neuroaid|Neuroaid capsules, 4 capsules, three times per day, during one month
41502006|NCT03353883|DRUG|Triptorelin SR|GnRH agonist depot( Decapeptyl) will be taken in the previous mid luteal cycle in group A and the first day in group B
41502007|NCT04106661|OTHER|Tai Chi|Physical activity requiring slow, controlled whole body movement and weight shifting.
40846436|NCT02353390|OTHER|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
40846437|NCT05987956|DRUG|Alectinib - Usual|"Usual Alectinib Chemotherapy (NDC...01)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
40846438|NCT05987956|DRUG|Alectinib - Study|"Study Alectinib Chemotherapy (NDC...86)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
40846439|NCT02188654|DRUG|Metformin|500mg/day retarded formulation of metformin
40846440|NCT02188654|DRUG|Placebo|500 mg/day of placebo tablets
40846441|NCT05949489|DIAGNOSTIC_TEST|WOMAC pain subscale|"The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale is a self-reported questionnaire that is used to measure pain in people with osteoarthritis (OA). The subscale consists of five items that ask about the intensity, frequency, and duration of pain in the hip and knee joints.~The WOMAC Pain Subscale has been shown to be a reliable and valid measure of pain in people with OA. It has been used in a number of clinical trials and is considered to be a standard measure of pain in OA.~The WOMAC Pain Subscale is scored on a scale of 0 to 4, with 0 indicating no pain and 4 indicating severe pain. The total score for the subscale is the sum of the scores for the five items. A higher score indicates more pain."
40846442|NCT00320463|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|
40846443|NCT00002517|DRUG|cytarabine|
40846444|NCT00002517|DRUG|daunorubicin hydrochloride|
40846445|NCT00002517|DRUG|dexamethasone|
40846446|NCT00002517|DRUG|etoposide|
41028988|NCT05704959|DIAGNOSTIC_TEST|povidone iodine|Reference measurements were made simultaneously with two separate calibrated pulse oximeter devices from the index, middle and ring fingers of both hands of the participants. One layer of 10% povidone iodine was applied to the index finger, two layers to the middle finger, and three layers to the ring finger of one hand of the participant's choice. Two pulse oximetry measurements were made with the fingers of the other hand, immediately after the application of povidone-iodine and three minutes later, and it was noted on the data collection form.
41028989|NCT01466816|DIETARY_SUPPLEMENT|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
41028990|NCT04025073|OTHER|Dietary Approaches to Stop Hypertension|The DASH diet will have a reduced caloric intake by 400 kcal/day, when compared to the standard hospital diet. The DASH diet will be planned according to the following: total daily energy intake 1,900 kcal; total daily fat intake 27%; daily intake of saturated fatty acids 6%; total daily protein intake 18%; total daily carbohydrates intake 55%; cholesterol 150 mg/day; sodium 2,300 mg/day; potassium 4,700 mg/day; calcium 1,250 mg/day; magnesium 500 mg/day; and fiber 30 g/day.
41367664|NCT00936052|OTHER|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
40846447|NCT00002517|DRUG|idarubicin|
40846448|NCT00002517|DRUG|mitoxantrone hydrochloride|
40846449|NCT00002517|DRUG|thioguanine|
40846450|NCT00002517|PROCEDURE|allogeneic bone marrow transplantation|
40846451|NCT00002517|RADIATION|radiation therapy|
40846452|NCT06104098|DEVICE|D005 vaginal mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
40846453|NCT02547584|PROCEDURE|Catheter ablation|Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
40846454|NCT02430116|PROCEDURE|Ischemic postconditioning|In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
41028991|NCT04025073|OTHER|Nutrition education program|The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.
41367665|NCT02061293|DRUG|Psilocybin|
41367666|NCT02061293|DRUG|Diphenhydramine|
40846455|NCT03576573|DEVICE|PROCOTYL® C|Hip Arthroplasty
40846456|NCT06212830|DRUG|Gabapentin|Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
40846457|NCT06212830|DRUG|Targin|Targin 5 mg twice a day after the procedure for 48 hours
40846458|NCT06212830|DRUG|NSAID|Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
40846459|NCT06212830|DRUG|Paracetamol|Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
40846460|NCT01057563|DEVICE|drug (paclitaxel)-eluting balloon (DEB)|BMS implantation after lesion predilation with DEB
41161711|NCT00721825|DRUG|Neuroaid matched Placebo|Neuroaid matched placebo 4 capsules three times per day during one month
41161712|NCT01639014|DRUG|F2695|75 mg OD in 2 capsules
41161713|NCT01639014|DRUG|placebo|2 capsules
41161714|NCT05910502|BEHAVIORAL|Autism Family Empowerment Coaching and Training Program|Participants in the intervention group will be connected with Project AFECT Coaches who will provide: Coaching to (1) assure parents understand diagnosis, (2) assist parents in finding accurate, current information about autism, (3) guide parents to free online autism training resources, (4) empower parents to evaluate child's intervention plan holistically, and (5) provide emotional support to reduce stress; Navigation to (1) help family access autism treatments, and (2) connect to early intervention and educational services.
41367667|NCT02061293|BEHAVIORAL|Motivational Enhancement and Taking Action (META)|Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
41367668|NCT02637518|OTHER|Assessment of frailty tools in elderly people|Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
41367669|NCT05723120|OTHER|Assessment Respiratory and Neuromuscular|Comparative Score
41367670|NCT06209099|PROCEDURE|Nonoperative Management (NOM)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)
41367671|NCT06209099|PROCEDURE|Local Excision (LE)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)
41367672|NCT06209099|PROCEDURE|Total Mesorectal Excision (TME)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)
41367673|NCT06380049|DEVICE|EMG Analysis Software|Surface electromyography devices are non-invasive tools that measure electrical activity produced by skeletal muscles through sensors placed on the skin.
41028992|NCT03965052|DRUG|PRO 179|"* Generic name: Travoprost~* Distinctive denomination: Bristrio® (PRO-179)~* Active principles: Travoprost 0.004%.~* Pharmaceutical form: Ophthalmic solution~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Sophia Laboratories, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene."
41028993|NCT03965052|DRUG|Travatan 0.004 % Ophthalmic Solution|"* Generic name: Travoprost~* Distinctive denomination: Travatan®~* Active ingredients: Travoprost 0.004%~* Pharmaceutical form: Ophthalmic solution.~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Alcon Laboratories Inc.~* Description of the solution: transparent solution, free of visible particles.~* Consult information to prescribe."
41028994|NCT03616210|PROCEDURE|Protective ventilation|Protective ventilation strategy with tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O.
41028995|NCT02066298|DRUG|Mometasone 220mcg BID|Mometasone is an ICS
41028996|NCT02066298|DRUG|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
41028997|NCT02066298|DRUG|Placebo|
41028998|NCT02818738|DRUG|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
41028999|NCT02818738|OTHER|Placebo|matching verum
41029000|NCT03216174|PROCEDURE|NESS-EFTR|NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
41029001|NCT05078944|DEVICE|Active acupuncture|Acupoints: Principal: GV20, EX-HN1, GV24 and bilateral PC6, HT7, ST36, KI3, SP6. Additional: CV6 and bilateral GB39, ST40, SP10 Sterile stainless steel disposable acupuncture needles (size 0.30 × 50 mm, Hwato brand, China) are used. After sterilization, a small plastic ring will be fixed over the acupuncture point with plaster to facilitate maintenance of blinding for the participant, and then the needle will be inserted through the plaster inside the ring. The electric stimulator (SDZ-Ⅲ electroacupuncture apparatus, Hwato brand, China) is applied to GV20, GV24, bilateral PC6 and HT7, dilatational wave, 10/50 Hz and tolerable electric current. Needles placed in other acupoints will be manually stimulated by rotation every 15 minutes. Each session lasts for 45 min.
41161715|NCT03267069|OTHER|survey|surveys will be administered at inclusion and follow-ups
41161716|NCT00983424|DRUG|Cyclosporins|dose escalation, administered orally twice a day
41161717|NCT00983424|DRUG|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
41161718|NCT02223871|DRUG|ACT-451840:|ACT-451840 500 mg was provided in 100 mL amber glass bottles formulated as a powder for oral suspension. The ACT-451840 suspension was prepared extemporaneously by addition of 25 mL of water and administered orally under fed condition.
41161719|NCT02223871|OTHER|Plasmodium falciparum-infected human erythrocytes:|Each participant was inoculated on Day 0 with approximately 1,800 viable Plasmodium falciparum-infected human erythrocytes administered intravenously.
41367674|NCT05198739|OTHER|Video Interaction Project (VIP) program|Video Interaction Project (VIP) is a strengths-based, family-centered intervention designed to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines. In VIP's core component, a VIP coach video-records the parent / child for 3-5 minutes playing/reading with a provided toy and/or book, then reviews the video with the parent to facilitate self-reflection on the interaction and identifies and reinforces strengths. In the US, VIP is delivered in the context of pediatric primary care visits, with a COVID-19 remote adaptation (see Section 6 for details). Research staff will delivery VIP through video calls with subjects in Brazil.
41367675|NCT04340102|BEHAVIORAL|BecomeAnEx|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
41367676|NCT05655195|DEVICE|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.
41367677|NCT05655195|DEVICE|GENUS device (sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
41502008|NCT02121392|DEVICE|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
41029002|NCT05078944|DEVICE|Sham acupuncture|"Sham acupoints: SA1 (5 cun lateral to GV5), SA2 (5 cun lateral to GV4), SA3 (1 cun lateral to BL56).~After sterilization, pragmatic placebo needles with blunt tip (size 0.30 × 50 mm, Hwato brand, China) are used. When their tips are pressed against the skin through plastic rings, participants will feel a pricking sensation. The electric stimulator is applied to bilateral SA1 and SA2 with no current output. The mental wire has been cut off with a same outlook as the electroacupuncture group. Needles placed in SA3 will be manually rotated every 15 minutes. Each session lasts for 45 min."
41029003|NCT05078944|DRUG|Donepezil Hydrochloride|Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily.
41029004|NCT03443466|DEVICE|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
41029005|NCT03443466|DEVICE|Loss of resistance (LOR)|Using loss of resistance technique only
41029006|NCT02342067|DRUG|Cenicriviroc|CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
41029007|NCT02342067|DRUG|Pioglitazone|PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
41029008|NCT03736525|BEHAVIORAL|Design For Wellness (DWELL)|Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.
41029009|NCT03736525|BEHAVIORAL|Wait list control group|Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
41029010|NCT01977911|OTHER|Stem cell based tissue engineered partial laryngeal implants|Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.
41029011|NCT00721526|DRUG|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
41029012|NCT01831089|DRUG|PM01183 + paclitaxel +/- bevacizumab|"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"
41029013|NCT04495673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (2 5-visit blocks of 46 minutes) of active tDCS to DLPFC (dorsolateral prefrontal cortex)
41029014|NCT04495673|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (1 5-visit block of 46 minutes of active tDCS and 1 5-visit block of sham tDCS)
41029015|NCT04495673|BEHAVIORAL|Cognitive Training|Executive functioning tasks
41029016|NCT06381908|OTHER|Calorie-restriction with low carbohydrate|Calorie-restriction and low carbohydrate availability
41029017|NCT06381908|OTHER|Calorie-restriction with moderate carbohydrate|Calorie-restriction and moderate carbohydrate availability
41029018|NCT00546728|DRUG|Exenatide|exenatide 10 mcg twice daily
41029019|NCT00546728|DRUG|Metformin|metformin 500 twice daily
41029020|NCT04946240|OTHER|Supervised (BRACE) Group|Supervised (BRACE) protocol include static, dynamic and anticipatory balance exercises, chair rise, stair climbing and floor transfer comes under the category of resistance exercises. 6 minutes walk test, marching in space and cycling comes in aerobic. count reverse for 50 remember 5 words, 5 animals, repeat 5 words, spell forward and backwards and cont even numbers comes in cognitive exercises.
41367678|NCT02452320|DRUG|intravenous acetaminophen|administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
41367679|NCT02452320|DRUG|Placebo|Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
41367680|NCT04183868|DRUG|Empagliflozin 10 MG|10 mg tablet daily
41367681|NCT04183868|DRUG|Glimepiride 2 mg|starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily
41367682|NCT01438281|DRUG|SYL1001|SYL1001 eye drops. topical administration
41367683|NCT04112108|PROCEDURE|PTMC|percutaneous mitral ballooning with Inoue balloon
41367684|NCT02366546|DRUG|TBI-1301|TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
41367685|NCT02366546|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
41029021|NCT04946240|OTHER|Conventional Balance Exercises Group|The home plan included Balance and Resistance exercises of BRACE protocol were provided to the control group but that was not supervised. Control group participants were also same assessed as the S-BRACE group. Before giving the training plan for home, it was elaborated in detail. For the convenience of participants, the BRACE protocol was also translated into Urdu and was given in the printed form. The data were collected at baseline, after 3 weeks, 6, 9 and then after 12 weeks of training
41029022|NCT02912533|DRUG|JR-131|
41367686|NCT02366546|DRUG|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
41367687|NCT05813769|DIETARY_SUPPLEMENT|Dairy protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
41367688|NCT05813769|DIETARY_SUPPLEMENT|Plant protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
41367689|NCT04543526|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.
41367690|NCT03628534|DEVICE|Saline Enhanced Radiofrequency (SERF) ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
41502009|NCT02121392|DEVICE|Adductor Canal Nerve Block Sham Catheter|Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
41502010|NCT02121392|DRUG|Bupivacaine|In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
41502011|NCT05352412|BEHAVIORAL|Shared Decision Making Aid|Patients will be randomized to the shared decision making aid intervention.
41029023|NCT03502343|DRUG|Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy|"All patients will receive slow (over 30-40 minutes) intravenous administration of nab-paclitaxel (125 mg/m2) on days 1 and 15, and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a 28- day cycle (every 4 weeks). Treatment will discontinue if disease progression or intolerable toxicity is observed, if the patient withdraws from the study, or at the physician's discretion.~Dose reduction of the chemotherapeutic agent and/or delay of administration is allowed if serious treatment-related AEs occur, according to specified guideline in study protocol (Level 1: 100% -\> 80%; Level 2: 80% -\> 60%). If dose reduction is needed more than Level 2, the patient will be dropped from the trial."
41367691|NCT05147831|OTHER|Remote Ischemic Preconditioning|Place blood pressure cuff around upper, non-dominant arm (e.g. upper left arm in a right-handed patient). Inflate blood pressure cuff to a pressure set at 50 mmHg higher than baseline systolic BP to induce ischemia of arm for 5 minutes. Completely deflate blood pressure cuff to allow for 5 minutes of reperfusion. Subjects would undergo 4 cycles of ischemia and reperfusion,
41367692|NCT06111963|DIAGNOSTIC_TEST|Serology tests|CD4, CD25, IL17
41161720|NCT02223871|DRUG|Artemether 20 mg and lumefantrine 120mg combination tablet:|Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally was immediately followed by food or drinks rich in fat (e.g., milk).
41367693|NCT04984824|BEHAVIORAL|Nap duration|A cognitive battery which will be repeated at 1505, 1530, 1600 and 1900. Material for the picture encoding task will be learned at 1630 and will be tested at 2000.
41367694|NCT04108416|PROCEDURE|Cleft lip and palate repair|The intervention is the currently used cleft lip and palate repair technique at the University Hospital Basel and University Childrens Hospital Basel
41367695|NCT05544500|DIETARY_SUPPLEMENT|Functional Gum|Functional gum containing a proprietary composition of a herbal extract and vitamins
41367696|NCT05544500|DIETARY_SUPPLEMENT|Basic Chewing Gum|Sugar-free chewing gum
41367697|NCT05544500|DIETARY_SUPPLEMENT|Placebo|Sugar-free tablet
41367698|NCT04772417|DIAGNOSTIC_TEST|Standardized 1-minute sit-to-stand test|The individuals perform two tests from a standardized chair (seat height 46cm).
41502012|NCT05352412|BEHAVIORAL|Baseline Counseling As usual|Patients will be randomized to the baseline counseling as usual.
41502013|NCT06259305|OTHER|Creation of a memory track combined with the baby's heartbeat|This is as described above
41502014|NCT04294628|PROCEDURE|Biopsy|Undergo biopsy
41502015|NCT04294628|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41502016|NCT04294628|PROCEDURE|Computed Tomography|Undergo CT scan
41502017|NCT04294628|PROCEDURE|Echocardiography|Undergo ECHO
41502018|NCT04294628|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41502019|NCT04294628|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41502020|NCT04294628|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
41502021|NCT06582056|PROCEDURE|Investigational Procedure|It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.
41367699|NCT04772417|DIAGNOSTIC_TEST|Individualized 1-minute sit-to-stand test|The individuals perform two tests from an individualized chair (seat height adjusted so that the starting position elicits a knee flexion angle of 90°).
41367700|NCT02881866|DRUG|Furosemide|
41502022|NCT05496491|RADIATION|Neoadjuvant Chemoradiotherapy|5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)
41502023|NCT05496491|DRUG|Adjuvant Chemotherapy|8 cycles of CAPOX (Capecitabine bid 1000 mg/m2, twice daily, day 1-14, every 3 weeks and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively, 12 cycles of folinate, fluorouracil and oxaliplatin (FOLFOX)
41502024|NCT05496491|DRUG|Consolidation Chemotherapy|CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
41502025|NCT02713555|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
41161721|NCT02223871|DRUG|Primaquine:|Rescue treatment to ensure clearance of Plasmodium falciparum, to be taken as a single oral 45 mg dose with food only if gametocytes were identified after administration of Riamet® rescue medication.
41161722|NCT06263738|PROCEDURE|Whole Body Hyperthermia|Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes
41367701|NCT02881866|DRUG|Saline|
41367702|NCT02808182|DRUG|Nicotinic acid|oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
41367703|NCT02808182|OTHER|[7,7,8,8-2H]-palmitate|using i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to +360 min
41367704|NCT02808182|OTHER|[U-13C]-palmitate|oral administration of \[U-13C\]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
41367705|NCT02808182|PROCEDURE|Biopsy|A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
41367706|NCT02808182|OTHER|liquid meal|At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
41367707|NCT01157819|DRUG|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
41367708|NCT01157819|DRUG|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
41367709|NCT04347174|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
41367710|NCT04347174|DRUG|Placebo|All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
41367711|NCT05338749|BEHAVIORAL|Cognitive Training|Gamified cognitive training intervention to improve mental speed and attention.
41367712|NCT04828993|DRUG|tafamidis meglumine|Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
41367713|NCT05246852|BEHAVIORAL|healthy lifestyle education|A total of 6 sessions on physical activity, nutrition, substance abuse, sexual life, check-up, accidents and injuries will be organized for the adolescents in the intervention group. The sessions will be organized every other week. Each session will be conducted in three stages. First Stage: The researcher will provide training on the subject of the session for nearly 15 minutes. Second Stage: The researcher will show animation film (nearly 3 to 5 minutes) developed by him/her related to the session. Third Stage: Groups of six will be created for the Philips 66 technique application and a spokesman will be chosen. Each group will have an online meeting and discuss the session subject in six minutes under the administration of the researcher. The spokesman of each group will present the discussion outcome in the big group meeting at the end of the discussion. The researcher will summarize the subject after the presentation of each spokesman and terminate the session.
41502026|NCT02713555|PROCEDURE|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
41502027|NCT05819710|DRUG|TS-142|Single dose of 5 mg of TS-142
40846461|NCT01057563|DEVICE|bare-metal stent (BMS)|BMS implantation
40846462|NCT01057563|DEVICE|Drug (paclitaxel)-eluting balloon (DEB)|BMS implantation followed by post-dilation with DEB
40846463|NCT02385435|DRUG|Bupivacaine|Caudal Bupivacaine 2 mg/kg single shot
40846464|NCT02385435|DRUG|dexmedetomidine 1μg.kg-1|Caudal dexmedetomidine 1μg.kg-1, single shot
40846465|NCT02385435|DRUG|dexmedetomidine 2μg.kg-1|Caudal dexmedetomidine 2μg.kg-1, single shot
40846466|NCT01311440|OTHER|Modified Atkins diet treatment|Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
40846467|NCT06283589|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
40846468|NCT05094141|OTHER|Virtual reality|Virtual reality game
40846469|NCT06526091|OTHER|Cerebral NIRS monitoring at delivery|Application of cerebral NIRS monitoring immediately after delivery and during optimum cord management
41502028|NCT05819710|DRUG|TS-142|Single-dose of 10 mg of TS-142
41502029|NCT05819710|DRUG|Zopiclone|Single-dose of 7.5 mg of zopiclone
41502030|NCT05819710|DRUG|Placebo|Single-dose of placebo
41502031|NCT00187993|DRUG|Growth hormone|
41029024|NCT01918345|BEHAVIORAL|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
41502032|NCT05384171|BEHAVIORAL|Measurement-Based Transition Assistance (MBTA)|Measurement-Based Transition Assistance (MBTA) asks Veterans about their well-being and then provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.
41502033|NCT06295692|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
41161723|NCT06263738|PROCEDURE|Cold Water Plunge|Participants in the heat exposure and cold plunge group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes followed by a cold plunge session in 49 degree (Fahrenheit) water, lasting up to 10 minutes.
40846470|NCT05490927|BEHAVIORAL|Microaggression Recall and Relapse Analogue Task|Participants will engage in a microaggression recall task followed by the McKee Experimental Relapse Analogue Task
41367714|NCT04337827|DRUG|Rituximab|"Weekly x 4 weeks.~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto Long Term Follow Up (LTFU)."
41502034|NCT01164696|DRUG|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Zevalin was administered according to the directives in the approved package leaflet.
41502035|NCT03364868|DRUG|Oral Insulin|treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
41502036|NCT03364868|OTHER|Placebo|treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
41502037|NCT02383810|DRUG|Elsiglutide|
41502038|NCT02383810|DRUG|Placebo|
41502039|NCT02811432|OTHER|Kangaroo mother care|Skin-to-skin care (target: at least 18 hours per day)
40846471|NCT02965885|DRUG|TAS-116|TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.
41161724|NCT06167681|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.
41161725|NCT03226353|DEVICE|somofilcon A|contact lens
41161726|NCT03226353|DEVICE|omafilcon A|contact lens
41161727|NCT01768741|PROCEDURE|Laparoscopic liver resection|participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
41161728|NCT01768741|PROCEDURE|Open liver resection|participants will be performed with open hepatectomy using laparotomic instruments
41161729|NCT05014906|DRUG|Minocycline 45 MG|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
41161730|NCT05014906|DRUG|Azelaic acid|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
41161731|NCT03614221|DRUG|Lindioil ointment|Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
41161732|NCT03614221|DRUG|Protopic ointment 0.1%|Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
41161733|NCT02745314|OTHER|Frailty measurement|Frailty measurement under Fried at el criteria
41161734|NCT02745314|OTHER|Comprehensive Geriatric Assessment|Multidimensional Geriatric Assessment
41161735|NCT00326703|PROCEDURE|Hypobaric hypoxia|
41161736|NCT04542200|BIOLOGICAL|Antibody testing|The antibody results include understanding modifications from environments at work and the community.
41161737|NCT05457322|BEHAVIORAL|Behavioral intervention one|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
41161738|NCT05457322|BEHAVIORAL|Behavioral intervention two|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
41161739|NCT04809168|OTHER|Questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
41161740|NCT02345707|DRUG|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
41161741|NCT02345707|DRUG|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
41161742|NCT02345707|DRUG|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
41161743|NCT02345707|DRUG|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
41161744|NCT02345707|DRUG|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
41161745|NCT02181998|DRUG|Full dose tenecteplase|
41161746|NCT02181998|DRUG|Unfractioned heparin|
41161747|NCT02181998|DRUG|Enoxaparin|
41161748|NCT03412513|DRUG|Mirabegron|Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
41161749|NCT03412513|DRUG|Placebo|Placebo po daily for 8 weeks to Placebo comparator group.
41161750|NCT05896540|BEHAVIORAL|ENFOCATE|ENFOCATE is a comprehensive program of sexual education for adolescents. Its design follows the guidelines of the Intervention Mapping Approach and the orientations proposed by the Framework for Gender-Transformative Health Promotion. The intervention has a participative focus, thus the activities are designed to promote processes of knowledge, understanding, application and reflection in the adolescents. The activities aim to improve the capacity for critical thinking, increase the motivation to listen and learn actively, and to improve interpersonal abilities. The execution of the intervention uses three pillars: (i) preventive sexual behavior; (ii) gender equity; and (iii) mental health. The intervention consists of ten weekly sessions, each lasting one hour. The teams that will perform the intervention will be composed of at least two professionals of the psychosocial area (mainly psychologists, social workers and/or guidance counsellors) of the schools included in the study.
41161751|NCT02788617|DEVICE|Diafert|The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
41161752|NCT03966534|OTHER|Blood diversion|Diversion of initial blood obtained at venipuncture to biochemistry tube in order to try and reduce incidence of blood culture contamination
41161753|NCT03910777|DIAGNOSTIC_TEST|Early Warning Score|National early warning score (NEWS) is another early warning scoring system recommended by the Royal College of Physicians in London to detect early clinical deterioration in hospitalized patients
41161754|NCT06194318|BIOLOGICAL|Candidate vaccine, SCB-1019|The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
41161755|NCT06194318|BIOLOGICAL|placebo|placebo
41161756|NCT04092959|BEHAVIORAL|Walking|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
41367715|NCT04337827|DRUG|Acalabrutinib|"100mg twice per day (BID) x 4 weeks (28 day cycle)~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto LTFU."
41367716|NCT04337827|DIAGNOSTIC_TEST|CT scans|2 weeks (day 36 ± 5 days) after end of cycle 1 treatment.
41367717|NCT05464108|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the EGGIM score independently when the patients is eligible. In addition, they can not see the OLGIM score of the patients.
41367718|NCT06323655|DRUG|Tasimelteon|oral capsule
41029025|NCT01918345|BEHAVIORAL|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
41029026|NCT05507411|RADIATION|Neoadjuvant Radiotherapy|41.4Gy/23F
41029027|NCT05507411|DRUG|Neoadjuvant Chemotherapy|Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW
41029028|NCT05507411|DRUG|Immunotherapy|Camrelizumab 200mg Q3W
41367719|NCT06323655|DRUG|Active Control Placebo|oral capsule
41502040|NCT02811432|OTHER|Standard care|Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
41029029|NCT05868083|DRUG|SNC-109 CAR-T Cells|SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
41029030|NCT04797247|DRUG|lerodalcibep|PCSK9 inhibitor
41029031|NCT01881308|DRUG|TNF inhibitors|
41029032|NCT01881308|DRUG|Synthetic DMARD(s)|
41367720|NCT06323655|DRUG|Tasimelteon Placebo|oral capsule
41367721|NCT06323655|DRUG|Active Control|oral capsule
41367722|NCT00043134|DRUG|decitabine|
41502041|NCT02960022|DRUG|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
41502042|NCT02960022|DRUG|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
41029033|NCT01881308|DRUG|Co-medication: Synthetic DMARDs|Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
41367723|NCT01214382|DRUG|Sertraline|Single dose sertraline 100 mg, tablet and solution
41367724|NCT03083262|OTHER|no intervention|None, there is no intervention
41367725|NCT05058066|DEVICE|Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm abutment|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
41502043|NCT02960022|DRUG|prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
41502044|NCT03791723|DRUG|Sacubitril-Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
41029034|NCT00617149|BEHAVIORAL|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
41029035|NCT00680316|DRUG|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
41367726|NCT05058066|DEVICE|Baha® BIA300 Implant (diameter 4.5mm; length 4mm) with 6mm abutment|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment. In addition to the difference in abutment shape and the wider diameter, the test implant incorporates small-sized threads at the implant neck and the moderately rough TiOblast™ (Dentsply, Mölndal, Sweden) surface on the intraosseous part of the implant6-8.
41367727|NCT05058066|PROCEDURE|Early loading|Loading the implant at 3 weeks after implantation (instead of 6 weeks after implantation)
41367728|NCT01858402|DRUG|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
41367729|NCT01858402|DRUG|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
41367730|NCT01952821|OTHER|Six-Minute Walk Test|
41367731|NCT01952821|OTHER|10-Meter Walk Test|
41502045|NCT03791723|DRUG|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
41502046|NCT06029179|DRUG|sodium zirconium cyclosilicate (SZC)|40 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.
41029036|NCT00680316|DRUG|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
41029037|NCT02464735|DEVICE|Polysomnography|
41029038|NCT03925636|DIETARY_SUPPLEMENT|Specific Carbohydrate Diet|The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.
41029039|NCT00434057|DEVICE|MelaFind(R)|Biopsy ratio comparison
41367732|NCT01952821|OTHER|30-Second Chair Stand|
41367733|NCT01952821|OTHER|Linear Analog Scale of Function|
41367734|NCT01952821|OTHER|Modified Brief Fatigue Inventory|
41367735|NCT01952821|OTHER|FACIT-Fatigue|
41502047|NCT06029179|DRUG|sodium polystyrene sulfonate|40 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks.
41161757|NCT04092959|BEHAVIORAL|Chinese square dancing group|Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
41367736|NCT02368860|DRUG|oxaliplatin, irinotecan, capecitabine|fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
41367737|NCT02468973|BEHAVIORAL|Life style counseling|Life style counseling for chronic patients by medical students
41367738|NCT00458055|DRUG|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
41367739|NCT01000311|BIOLOGICAL|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
41367740|NCT01000311|BIOLOGICAL|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
40846472|NCT05515939|DEVICE|InPen Insulin Pen|The InPen is a reusable smart insulin pen for people living with diabetes. The device uses Bluetooth technology to send dose information to a mobile application. The InPen can be used to deliver insulin, help calculate insulin doses, and estimate carbohydrates for meals
40846473|NCT03432559|DIAGNOSTIC_TEST|endoscopy|endoscopy of pharynx, upper esophagus, mid esophagus, cardia, gastric fundus, und gastric body
40846474|NCT00230542|DRUG|Carboplatin|Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
40846475|NCT00230542|DRUG|Pemetrexed|Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
40846476|NCT03085186|DRUG|Crizotinib|
40846477|NCT02687698|OTHER|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
40846478|NCT00654459|DIETARY_SUPPLEMENT|Mixture of Berberine, Policosanol, Red Yeast, Placebo|A tablet one a day for 6 weeks
41029040|NCT00758953|DRUG|Danazol Once Weekly|semi-solid
40846479|NCT05753163|COMBINATION_PRODUCT|HAIC-FOLFOX combined with Sintilimab and Regorafenib|HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2) was given every 4-6 weeks for 2-4 cycles depending on pts' health status, in combination with Sintilimab (200mg, iv, d1) and regorafenib (80mg, po, d1-21) every 3 weeks for up to 6 months .
40846480|NCT01822613|DRUG|LJM716|LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
41367741|NCT01000311|BIOLOGICAL|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
40846481|NCT01822613|DRUG|BYL719|BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
40846482|NCT01822613|DRUG|Paclitaxel|In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
40846483|NCT01822613|DRUG|Docetaxel|In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
40846484|NCT01822613|DRUG|Irinotecan|In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
41029041|NCT00758953|DRUG|Danazol Twice Weekly|semi-solid
41029042|NCT00758953|DRUG|Placebo Once Weekly|semi-solid
41029043|NCT00758953|DRUG|Placebo Twice Weekly|semi-solid
41029044|NCT05642572|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41029045|NCT05642572|DRUG|Capmatinib|Given PO
41029046|NCT05642572|PROCEDURE|Computed Tomography|Undergo CT scan
41029047|NCT05642572|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41029048|NCT05642572|DRUG|Osimertinib|Given PO
41029049|NCT05642572|BIOLOGICAL|Ramucirumab|Given IV
41029050|NCT03907501|DIETARY_SUPPLEMENT|Synbiotic|an herbal prebiotic plus probiotic
41367742|NCT01000311|BIOLOGICAL|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
41367743|NCT01000311|BIOLOGICAL|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
41367744|NCT05368766|OTHER|VExUS score|The venous excess ultrasound (VExUS) score incorporates hepatic venous, intrarenal venous Doppler, inferior vena cava (IVC) assessment, and portal vein Doppler
41367745|NCT05368766|DRUG|Diuretic Effect|Response to diuretic therapy
41367746|NCT02778594|DRUG|BIA 3-202|nebicapone 50 mg tablets; oral use
41367747|NCT02778594|DRUG|Placebo|Nebicapone matching placebo tablets
41367748|NCT02778594|DRUG|levodopa 100 mg / benserazide 25 mg|Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
41367749|NCT06447870|DRUG|biologic therapy(eg:IFX,ADA,UST,VDZ)|The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.
41029051|NCT03907501|DIETARY_SUPPLEMENT|Probiotic|Triphala alone
41029052|NCT03907501|DIETARY_SUPPLEMENT|Placebo|Inert capsule
41029053|NCT02695238|PROCEDURE|Prophylactic Manual Rotation of persistent occipital posterior presentation|prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
41367750|NCT01098266|DRUG|NGR-hTNF plus Best Investigator's Choice (BIC)|"* NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
41367751|NCT01098266|DRUG|Placebo plus Best Investigator's Choice (BIC)|"* Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
41367752|NCT06152991|DRUG|GODEX|"The amount of active ingredient per dose (1 capsule)~* Carnitine Orotate 150mg~* liver extract antitoxic fraction 12.5㎎~* Adenine Hydrochloride 2.5mg~* Pyridoxine Hydrochloride 25mg~* Riboflavin 0.5mg~* Cyanocobalamin 0.125mg~* Biphenyl Dimethyl Dicarboxylate 25mg"
41367753|NCT06152991|DRUG|Placebo|"* Anhydrous lactose 50mg.~* Colloidal silicon dioxide 12mg.~* Amorphous cellulose 50mg.~* Lactose monohydrate 215.625mg.~* Magnesium stearate 7mg.~* Upper and lower brown opaque capsules 77mg."
41367754|NCT02831595|DEVICE|GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis|
41367755|NCT01317199|DRUG|Muscadine Plus Grape Skin Extract|Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
41367756|NCT01317199|DRUG|Low-dose MPX|Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
41367757|NCT01317199|DRUG|High-dose MPX|Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
41029054|NCT05947513|DRUG|Curcumin|Curcumin formulation with enhanced bioavailability which contains food-grade curcumin 35% (w/w) combined with the galactomannan fiber from fenugreek seeds.
41029055|NCT05947513|RADIATION|Palliative radiotherapy|As per the treatment guidelines of the Tikur Anbessa Hospital Radiotherapy Center, standard-of-care palliative or non-radical radiotherapy entails treatment of advanced cervical cancer patients at a biologically effective dose of 45-55 Gy over the course of three to five weeks.
41029056|NCT01024127|OTHER|Laboratory Biomarker Analysis|Correlative studies
41029057|NCT06175494|BIOLOGICAL|Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
41161758|NCT04092959|BEHAVIORAL|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
41161759|NCT02156388|BIOLOGICAL|GW003|freeze-dried powder；single SC injection
41161760|NCT05939739|BIOLOGICAL|Blood samples|Samples collected during blood sampling for array CGH (1 EDTA tube for index case and 2 biological relatives)
41161761|NCT05939739|OTHER|Consultation for results delivery|at 4 months
40846485|NCT03416075|DEVICE|Mechanical ventilation|Noninvasive and/or invasive mechanical ventilation were performed when patients had respiratory failure.
41029058|NCT06175494|BIOLOGICAL|Recombinant COVID-19 Variant Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
40846486|NCT03098745|DEVICE|Omafilcon A|contact lens
41502048|NCT06634433|BEHAVIORAL|Health Personnel Attitude|The intervention consists of a two-phase Training of Trainers Program (TTP) designed for health professionals aimed at enhancing interprofessional education (IPE) skills. Phase 1 includes three days of online theoretical training, focusing on topics such as interprofessional collaboration, communication, and conflict resolution. Phase 2 involves two days of face-to-face practical sessions, where participants engage in scenario-based learning and small group discussions to apply IPE concepts. The effectiveness of the program is assessed through pre-test and post-test evaluations, measuring changes in participants\&#39; knowledge, attitudes, and competencies in interprofessional education.
40846487|NCT03098745|DEVICE|Somofilcon A|contact lens
40846488|NCT03098745|DEVICE|Omafilcon A - Proclear (PC)|contact lens
40846489|NCT03689855|DRUG|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
41029059|NCT06175494|BIOLOGICAL|Placebo|boost with saline
41029060|NCT01203189|DRUG|ketoconazole 2% foam|Subjects in the Foam (F) group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
41029061|NCT01203189|DRUG|ketoconazole 2% shampoo|Subjects in the Shampoo (S) group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
41029062|NCT01271335|BIOLOGICAL|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
41029063|NCT02334735|BIOLOGICAL|DC Vaccine|"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10\^6 cells)"
41161762|NCT05939739|OTHER|Study Humanities and Social Sciences|Interview offered to 20 families with positive results and 10 families with negative results
41367758|NCT01317199|DRUG|Placebo oral capsule|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
41367759|NCT03491982|DEVICE|Remote Cardiac Rehab|Remote Cardiac Rehab
41367760|NCT01929551|OTHER|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
41367761|NCT01929551|OTHER|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
40846490|NCT03689855|DRUG|Atezolizumab|The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).
40846491|NCT03689855|PROCEDURE|Peripheral blood draw|-Baseline and Cycle 2 Day 1
41367762|NCT01929551|OTHER|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
41367763|NCT01929551|OTHER|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
41367764|NCT01929551|OTHER|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
41367765|NCT01929551|OTHER|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
41029064|NCT02334735|BIOLOGICAL|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
41029065|NCT02334735|BIOLOGICAL|Poly-ICLC|1.4 mg
41367766|NCT01929551|OTHER|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
41367767|NCT04678180|BEHAVIORAL|Combined HRT and ERP|tic training using the principles of HRT and ERP as to reduce tic intensity
41367768|NCT01403636|DRUG|SAR245409|Pharmaceutical form:capsule Route of administration: oral
41502049|NCT02437240|BEHAVIORAL|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
41029066|NCT03956498|OTHER|Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy|"* Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~* Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24."
41029067|NCT06141798|OTHER|Hemodialysis|Number of weekly hemodialysis treatment
41029068|NCT03405467|OTHER|general and specific data|General and specific data collected
40846492|NCT03689855|PROCEDURE|Biopsy|"* If archival biopsy tissue not available, participant will undergo biopsy at baseline~* When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan."
40846493|NCT02402413|PROCEDURE|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
40846494|NCT02402413|PROCEDURE|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
40846495|NCT02402413|DEVICE|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
40846496|NCT05611502|DEVICE|TMS|TMS will be administered in a pattern that is either excitatory or inhibitory.
41161763|NCT01530659|DRUG|NT-501|Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
41161764|NCT01530659|PROCEDURE|Sham|Non-penetrating sham procedure to mimic implant procedure in the other eye.
41161765|NCT05273177|OTHER|Chronic ankle instability|Persistent condition of ankle instability after a first ankle sprain episode.
41029069|NCT00709163|DRUG|Nesiritide|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
41029070|NCT00709163|DRUG|5% Dextrose|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
41367769|NCT00197704|DIETARY_SUPPLEMENT|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
41029071|NCT06431919|DRUG|Simvastatin 20mg|Simvastatin fixed dose of 20 mg per day
41029072|NCT06431919|DRUG|Carvedilol 3.125 mg|Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate
41029073|NCT04901611|BEHAVIORAL|Parental touch|Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
41029074|NCT00345774|DRUG|PRX-08066|
41029075|NCT05298085|DRUG|Oxytocin nasal spray|Study treatment will be administered intranasally daily for 12 weeks. The daily dose of OT will be adapted according to age at the beginning of the study
41029076|NCT05298085|DRUG|Placebo|Study treatment will be administered intranasally daily for 12 weeks.
41029077|NCT03155750|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
41029078|NCT03155750|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
41029079|NCT04911543|DRUG|[18F]-JNJ-70099731|\[18F\]JNJ-70099731 injection will be administered intravenously.
41029080|NCT00221936|BEHAVIORAL|Self-administration or nurse administered medication|
41029081|NCT06425120|DRUG|Xuesaitong Soft Capsule|Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.
41029082|NCT06425120|DRUG|Placebo|Each participant in the placebo group will take matching placebo.
41029083|NCT06533618|DIAGNOSTIC_TEST|Continuous glucose monitoring system|All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.
41029084|NCT01651429|BEHAVIORAL|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
41029085|NCT05036629|DEVICE|MRI Protocol|"Eye-tracker Eyelink (eye movements) BIOPAC : (electrodermal resistance) INVIVO Precess : breathing, arterial pressure, pulse,~* NIRS Oxymon artinis medical system~* tES (transcranial electrical stimulation, Neuroelectrics)"
41029086|NCT05983601|DEVICE|Transcranial Direct Current Stimulation|The anode electrode will be placed at the midline of the Cz according to international 10-20 EEG system, and the cathode electrode will be placed at the midline of forehead. In this way, both hemisphere of motor cortex can be stimulated which is used as protocol in various balance studies (Siedel-Marzi and Ragert, 2020b; Saruco et al., 2017). Participants will continue their training with tDCS (2mA) for 20 minutes. This application will continue three times a week for four weeks. In the end of the study, participants will be asked to guess which group they were in (active or sham).
41029087|NCT00010517|PROCEDURE|Acupuncture|
41029088|NCT01643473|BEHAVIORAL|Adherence Intervention|Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
41367770|NCT00197704|OTHER|Placebo|Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
41029089|NCT01643473|OTHER|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
41029090|NCT01230697|DRUG|Sorafenib|Sorafenib 800mg/die oral
41367771|NCT03007680|OTHER|Core muscle activation|
41367772|NCT02272738|DRUG|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
41029091|NCT00030550|DRUG|thalidomide|
41029092|NCT05601531|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
41029093|NCT05601531|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration.
41029094|NCT05601531|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
41029095|NCT06206005|OTHER|Observational study|evaluate implant survival, peri-implant outcome of 4 implant retained mandibular OVD after 10 years of function.
41367773|NCT02272738|DRUG|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
40846497|NCT00004874|RADIATION|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
41029096|NCT02405286|OTHER|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
41029097|NCT04100226|DIETARY_SUPPLEMENT|Vitamin D3 (1.25 (OH)2 cholecalciferol)|"Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients."
41029098|NCT00059683|PROCEDURE|cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
40846498|NCT03922620|DRUG|Liposomal bupivacaine|Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area
41029099|NCT05494112|DIETARY_SUPPLEMENT|Celastrol|same dose of Celastrol will be given every day for a period of 90-days to all participants.
41029100|NCT05951322|DEVICE|Shockwave therapy|Radial extracorporeal shock wave device, it is serial number (1107394), medispec and connected to electrical supply 115/220 A C frequency.
41029101|NCT05951322|DEVICE|Phonophoresis|Pagani ultrasound apparatus 200 cosistts of multi frequency head(1 and 3 MHz), surface area 4 cm², continuous and pulsed mode, main voltages: 100-240-VAC.50/60Hz.
41029102|NCT05436782|OTHER|core strengthening exercises|•Group B (experimental group) received routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in the lower extremity in D1 flexion pattern and D1 extension pattern up to the patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure was measured at baseline and 6th-week interval
41029103|NCT05436782|OTHER|Routine physical therapy|•Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks
41029104|NCT05818449|OTHER|DigiNet intervention|"Patients with initial diagnosis of NSCLC stage IV in the model region receiving the following interventions:~* broad NGS-based molecular diagnostics and, based thereupon, personalized treatment information within the national Network Genomic Medicine (nNGM) lung cancer~* regular clinical follow-up visits and data documentation in the shared central digital database by participating physicians~* monthly assessment of patient-reported outcomes (PRO) on quality of life, anxiety, and depression~* incorporation of PROs into treatment by physicians~* treatment monitoring and counseling in the case of critical conditions by expert committee"
41029105|NCT04671511|PROCEDURE|Targeted Axillary Dissection|Sentinel Node Biopsy (SNB; using Tc99 +/- Blue dye) + Radioactive Seed Localisation (RSL) of clipped node using I125 seed = Targeted Axillary Dissection (TAD)
41029106|NCT04671511|DIAGNOSTIC_TEST|Ultrasound of the axilla|Prospectively recorded preoperative ultrasound of the axilla. Number of suspicious nodes recorded. Biopsy and clipping of the positive node.
41029107|NCT02641548|DEVICE|Sock of silicone|
41029108|NCT02641548|OTHER|Heel cream|
41367774|NCT02875262|DRUG|Deferoxamine|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
41367775|NCT02875262|OTHER|placebo|placebo (NaCl 0.9%) in equal dose to treatment
41367776|NCT06048601|DIAGNOSTIC_TEST|18F-florbetaben PET/CT|18F-florbetaben positron emission tomography/computed tomography
41367777|NCT02185131|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
41367778|NCT02185131|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
41367779|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|30 μg
41367780|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|60 μg
41367781|NCT06113731|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
41367782|NCT02719093|DRUG|recombinant FSH|Subcutaneous injection
41367783|NCT02564627|PROCEDURE|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
41367784|NCT02564627|PROCEDURE|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
41367785|NCT02564627|DIETARY_SUPPLEMENT|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
41367786|NCT04416009|DEVICE|NİCaS|whole body bioimpedence method
41502050|NCT02437240|BEHAVIORAL|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
41029109|NCT05917730|BEHAVIORAL|Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)|"Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell."
41161766|NCT03892122|DRUG|Propofol Fresenius|"Propofol will be infused with TCI (Target Controlled Infusion) pump. TCI system has been developed to provide improved convenience and control during intravenous anaesthesia. The basic principle is that the anesthetist sets and adjusts the target blood concentration- and depth of anesthesia-as required on clinical grounds.~Infusion rates are altered automatically according to a validated pharmacokinetic model. TCI technology uses different pharmacokinetic modeling to control the infusion rate of the pump, which allows for a direct control of the sedative agent brain concentration rather than its blood concentration. (de vito 2017) The development of target-controlled infusion (TCI) technology has increased the number of indications for propofol sedation in clinical practice. Furthermore, several studies have demonstrated that propofol-based TCI allows for the accurate control of sedation during DISE and results in an authentic reproduction of the sleep process."
41161767|NCT03892122|DRUG|Dexmedetomidine|is a selective alpha-2 adrenergic receptor agonist, which seems to act on the locus coeruleus (LC) or to the preoptic hypothalamus to decrease wakefulness, with almost no effect on respiratory depression. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsyn¬aptic alpha2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique as¬pect that patients remain easily arousable and cooperative. Comparing with propofol, dexmedetomidine provides a state of sedation closer to natural sleep and lesser upper airways muscular relaxing effect, even at the increased anesthetic dosage Otherwise, Dexmedetomidine is characterized by a slightly longer onset of action (5-10 minutes), and patients take longer timing to recover..The sedative action of Dexmedetomidine can be reached by means of infusion technique (starting dose: 1 μg/kg over 10 minutes; maintenance infusion rate: 0,7 μg/kg/h).
41161768|NCT01626729|BEHAVIORAL|Traffic Light|A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.
41161769|NCT01626729|BEHAVIORAL|Traffic Light+|A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.
41161770|NCT01626729|BEHAVIORAL|Facts Up Front|A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.
41367787|NCT01826305|PROCEDURE|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
41367788|NCT01826305|PROCEDURE|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
41502051|NCT06634134|BEHAVIORAL|Adjusting training advice|Based on discomfort related to the menstrual cycle the female cyclist can choose to adjust the suggested training.
41502052|NCT00901576|DRUG|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
40846499|NCT03922620|DRUG|Peripheral Nerve Block|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block).
40846500|NCT03291392|GENETIC|Gene expression or biomarkers exploration|
40846501|NCT04766554|DEVICE|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions|In the intervention group, an alarm threshold below 15% of the baseline rSO2 value will be established. Based on the predetermined algorithm the rSO2 will be maintained at or above 85% of the baseline measurements. If the rSO2 reaches levels below 15% of the baseline values or below 50% in absolute value for over 30 seconds, protocol-based interventions will be performed to restore rSO2 to baseline levels.
41029110|NCT01636310|OTHER|Nicotine|Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
41029111|NCT00026533|DRUG|thalidomide|
41029112|NCT00931177|OTHER|weight|weight and dehydration scores
41502053|NCT00901576|DRUG|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
41502054|NCT00901576|DRUG|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
41029113|NCT00931177|OTHER|weight and dehydration score|weight and dehydration score
41029114|NCT02761564|OTHER|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
41029115|NCT02761564|OTHER|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
41502055|NCT05805410|BEHAVIORAL|robotic hippotherapy|A custom designed cable-driven robotic system that mimics horseback movement during walking was used in this study.
41502056|NCT05805410|BEHAVIORAL|Conventional physical therapy|Stretching of trunk and leg muscles, followed by sitting and standing balance training, and conventional treadmill walking.
40846502|NCT06429800|DRUG|ATA3219|ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.
41502057|NCT06630533|OTHER|Baduanjin Exercise Group|Baduanjin exercises (Eight-Part Exercises or Eight-Part Brocades), an important part of Qigong, consist of eight postures (1-holding the hands high with palms up, 2- posing as an archer shooting, 3- holding one arm aloft, 4- looking backwards, 5- swinging the head and lowering the body, 6- moving the hands down the back and legs and touching the feet, 7- thrusting the fists and making the eyes glare, and 8- raising and lowering the heels).
41502058|NCT06620133|OTHER|Pain education and patient-led goal setting|8 week program delivered via five, up to 1-hour telehealth sessions. The sessions will be scheduled at approximately fortnightly intervals. Participants will also be prescribed approximately 30 minutes of online activities with each session. Pain education will be based on Explain Pain and the curriculum will have specified learning objectives adapted for each individual participant. Participants will access the online education curriculum through Pathwright. For patient-led goal setting, the healthcare practitioner will take an initial history of the participants physical activity behaviours and problems related to their back pain. The participant will prioritise their problems according to impact in their life. Strategies will then be discussed, and the participant will, in collaboration with the healthcare practitioner, set goals and strategies to work on independently between sessions.
41502059|NCT06620133|OTHER|Supervised group exercise|Participants will be asked to attend 1-2 sessions of online supervised group exercise each week for 8 weeks. The sessions will be performed in small groups (up to 8 people) and be led by a trained healthcare practitioner. The prescribed exercises will be able to be performed at home with minimal equipment and will mostly involve bodyweight resistance training targeting the major muscle groups.
41502060|NCT03138655|DRUG|Vedolizumab|Vedolizumab IV infusion.
40846503|NCT02873338|DRUG|Dociparstat sodium|Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.
40846504|NCT02873338|DRUG|Idarubicin|Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.
41502061|NCT06633705|DRUG|Vaginal Cream with Applicator|Vaginal Cream that contains estriol (1mg estriol in 1 g cream)
41502062|NCT06492135|DRUG|survodutide|survodutide
41502063|NCT05256394|BEHAVIORAL|Pain Manager + tailored implementation support|Individualized training, technical assistance, and workflow assessments.
41367789|NCT04586127|OTHER|AYA NA-SB Questionnaire|Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
41502064|NCT04355065|BEHAVIORAL|Cognitive Traning with The Secret Trail of Moon|Patients are pharmacologically stable and receive a cognitive intervention with our videogame once a week in the hospital.
41502065|NCT04355065|BEHAVIORAL|Cognitive Traning with Therapeutic Chess|This group is pharmacologically stable. This group performs cognitive training through a therapeutic chess protocol designed by a chess psychologist. The training is done from home and we contact them weekly to correct the exercises done and to follow up.
41502066|NCT04355065|DRUG|Control Group|"These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group."
41502067|NCT01397643|OTHER|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
41502068|NCT01397643|OTHER|Operative|For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
41502069|NCT06633926|BEHAVIORAL|Nutrition Education|Given nutrition education
41502070|NCT06633926|BEHAVIORAL|Lifestyle Counseling|Given lifestyle recommendations
41502071|NCT06633926|OTHER|Yoga|Participate in yoga
41502072|NCT06633926|PROCEDURE|Marma therapy|Participate in marma therapeutic touch
41502073|NCT06633926|OTHER|Educational Intervention|Attend online HEI sessions
41502074|NCT06633926|OTHER|Quality of Life Questionnaire Administration|Self-reported questionnaires are given to participants to complete
41502075|NCT06634160|DIAGNOSTIC_TEST|Fibroscan|Evaluation of the prevalence of steatosis by measuring ultrasound attenuation with Fibroscan® (non-invasive method, at a distance from a meal (3h fasting)).
41502076|NCT06634160|OTHER|Sample collection|20 mL whole blood sample
40846505|NCT02873338|DRUG|Cytarabine|Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
41367790|NCT04460495|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo ASL scan
41367791|NCT04460495|PROCEDURE|pH-Weighted amine CEST|Undergo pH Weighted amine CEST
41367792|NCT04460495|PROCEDURE|Oxygen-weighted SAGE-EPI|Undergo Oxygen-weighted SAGE-EPI
41367793|NCT01162109|DIETARY_SUPPLEMENT|Zinc sulfate|"A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis."
41502077|NCT05528510|DRUG|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered as SC injection.
41367794|NCT04741880|DRUG|Lidocaine IV|"Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
41502078|NCT05528510|DRUG|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered as SC injection.
41502079|NCT05528510|DRUG|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered as SC injection.
41502080|NCT05528510|OTHER|Placebo|Placebo will be administered as SC injection.
40846506|NCT01898013|DRUG|Pregnenolone|
40846507|NCT01898013|DRUG|Placebo|
40846508|NCT01631097|DRUG|Tivozanib hydrochloride|Single oral capsule 1.5 mg tivozanib hydrochloride
41502081|NCT03307265|DEVICE|Personalized weighted jacket|Patients in this group will wear a jacket with weights (1,5 to 2% of the total body mass) strategically placed in order to correct their imbalance.
41161771|NCT01626729|BEHAVIORAL|Facts Up Front+|A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.
41502082|NCT03307265|DEVICE|Control jacket|Patients in this group will wear a jacket with weights (200 grams maximum) evenly distributed.
41502083|NCT03333044|BEHAVIORAL|Community Health Worker (CHW)-led health|Patients contacted a maximum of 10 times over 2 weeks to attend diabetes management sessions led by community health workers. Enrolled patients attend 5 Monthly group sessions led by a CHW held at the clinic
41502084|NCT03333044|BEHAVIORAL|HIT-enabled|During one on one visit, CHWs will assess social needs of patients using mobile technology. CHWs will give referral sources to patients generated by mobile app, and they will track through mobile app.
41502085|NCT03333044|BEHAVIORAL|Physician enabled care coordination|Forms on patient goal setting and referrals made are uploaded into EHR to physician
41502086|NCT06632535|OTHER|Chiropractic care|Chiropractic treatment will involve a personalized treatment plan within the context of a general care protocol administered by a chiropractor at the Osher Clinical Center for Integrative Health. The treatment plan will be customized to the patient's clinical needs following the current evidence and clinical practice guidelines.
41161772|NCT01626729|BEHAVIORAL|No label control group|No label control group
41502087|NCT06632535|OTHER|Group medical visits|Participants will simultaneously enroll in virtual group medical visits with group discussion, practice based learning, and curricular themes pertaining to chronic pain management, healthy aging, and pillars of lifestyle medicine.
41502088|NCT04819334|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
41502089|NCT00378612|DEVICE|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
40846509|NCT01553643|DRUG|Chinese Herb Huang-Chi-Wu-Wu-Tang|Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
40846510|NCT01553643|DRUG|placebo|at a rate of 3g two times per day
41161773|NCT02685007|OTHER|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
41161774|NCT03524950|DRUG|Dexmedetomidine|Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1μg/Kg10minutes as loading dose, followed by 0.7μg/Kg/h for maintenance.Group C add dexmedetomidine 0.7μg/Kg10minutes as loading dose, followed by 0.5μg/Kg/h for maintenance.
41161775|NCT00004016|BIOLOGICAL|recombinant interferon gamma|
41161776|NCT02391545|DRUG|Duvelisib|PI3K Inhibitor
41161777|NCT02391545|DRUG|Rituximab|monoclonal antibody
41161778|NCT02391545|DRUG|Obinutuzumab|monoclonal antibody
41161779|NCT00005968|DRUG|irofulven|
41161780|NCT02966418|PROCEDURE|Mild Hypoxia Preconditioning|Patients will be treated with mild hypoxia ( Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%)×7 days，twice a day in the morning and in the afternoon before surgery.
41502090|NCT00813800|DRUG|Varenicline|Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
41367795|NCT04741880|DRUG|Saline|"Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
41367796|NCT03735056|OTHER|MS Nurse Support|MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
41367797|NCT03735056|OTHER|Peer Support|Peer Support will be delivered by Peer Support Workers using information provision and supportive listening to provide support and advice to patients at diagnosis, and to provide patients the opportunity to talk freely, extensively and confidentially about their experiences, thoughts and feelings about MS diagnosis and its effects on their lives in a non-judgmental and safe environment. Peer Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
41367798|NCT01108588|DRUG|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
41367799|NCT01108588|DRUG|Aspirin|Aspirin 300 mg daily
41367800|NCT01108588|DRUG|Clopidogrel|Clopidogrel 75 mg daily
41367801|NCT01108588|DRUG|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
41367802|NCT02535858|DEVICE|Heart and respiratory rate and VE|To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
41367803|NCT02535858|DEVICE|Heart and respiratory rate and video|Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
41367804|NCT03528811|DIAGNOSTIC_TEST|Five points test of Tongji university|"In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data."
41502091|NCT02652611|PROCEDURE|SI Screw Removal Surgery|
41502092|NCT02652611|PROCEDURE|Non-screw removal treatment (non-operative management)|
41502093|NCT04138823|DRUG|BI 891065|film-coated tablets
41502094|NCT06633406|OTHER|Age-appropriate Wechsler Intelligence Test|"2.5-6 years: Wechsler Preschool and Primary Scale of Intelligence for children (WPPSI IV)~7-16 years: Wechsler Intelligence Scale for Children (WISC V)~\>17 years: Wechsler Adult Intelligence Scale (WAIS IV)"
41502095|NCT06633406|OTHER|Disruptive Behavior Disorders Rating Scale|Dutch version of the Disruptive Behavior Disorders Rating Scale
41502096|NCT06633406|OTHER|Social Responsiveness Scale|"3-18 years: social responsiveness scale 2 (SRS-2)~\>19 years: Social Responsiveness Scale - Adult version (SRS-A)"
41502097|NCT05649137|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
41502098|NCT05649137|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
41502099|NCT05649137|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
41502100|NCT02274506|DRUG|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
41502101|NCT02274506|DRUG|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
41502102|NCT02274506|PROCEDURE|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
41502103|NCT05620537|OTHER|observation|There are no interventions.
41502104|NCT04720131|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks.
41161781|NCT02966418|PROCEDURE|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) ×7 days，twice a day in the morning and in the afternoon before surgery.
41161782|NCT02277587|DRUG|Plenadren|Oral Tablets: 20-25-30 mg
41161783|NCT02277587|DRUG|Conventional glucocorticoid therapy|Oral Tablets: 20-25-30- 37.5 mg
41367805|NCT04064047|PROCEDURE|Trans rectal ultrasound guided prostate biopsy|The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
41367806|NCT04064047|PROCEDURE|Trans rectal ultrasound|Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
41367807|NCT04064047|PROCEDURE|Prostate biopsy|Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
41161784|NCT04081428|RADIATION|Stereotactic Body Radiotherapy|Daily collection of breath and blood before and after each of the 5 radiotherapy treatment sessions. Before and after daily cone beam CT image collection
41161785|NCT00978497|DRUG|placebo|oral BID
41161786|NCT00978497|DRUG|ANA598|oral 200mg BID
41161787|NCT00978497|DRUG|ANA598|oral 400mg BID
41161788|NCT00978497|DRUG|Peginterferon|180 μg dose via subcutaneous injection weekly
41161789|NCT00978497|DRUG|Ribavirin|oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
41161790|NCT04193709|DEVICE|Spinal Cord Epidural Stimulation|For arm 2, optimal stimulation parameters (cathode/anode configuration, stimulation frequency and voltage; placement of electrode from L1 to S1) will be identified for blood pressure and bladder pressure to achieve a bladder capacity in the target normative range of 400-450 mLs. Spinal cord epidural stimulation will then be used in a controlled lab setting for the regulation of blood pressure and heart rate to maintain normative values (target systolic pressure of 110-120 mmHg) and bladder pressure below 10 cmH2O during bladder filling up to the targeted capacity (fill volume of 400 mLs).
41161791|NCT01480440|DEVICE|Trabecular Metal Reverse Shoulder System|Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
41367808|NCT04064047|PROCEDURE|Periprostatic nerve block|Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
41367809|NCT02195531|BEHAVIORAL|Education and feedback|The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
41367810|NCT05276726|DRUG|JAB 21822|Administered orally
41367811|NCT01752244|DIETARY_SUPPLEMENT|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
41161792|NCT05336136|DEVICE|Custom mask|Custom mask based on 3D facial photograph for administration of non-invasive ventilation
41161793|NCT05336136|DEVICE|Current commercial mask|Current commercial mask used for administration of non-invasive ventilation
41161794|NCT00411177|PROCEDURE|post-dilution on-line hemodiafiltration|post-dilution on-line hemodiafiltration, 3 times a week 4 hours
41161795|NCT00411177|PROCEDURE|high flux hemodialysis|High-flux hemodialysis, 3 times a week 4 hours
41367812|NCT01752244|DIETARY_SUPPLEMENT|Alfacalcidol|Alfacalcidol
41502105|NCT04720131|DRUG|apatinib|"Apatinib A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle) The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group.~The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage."
41161796|NCT03461211|BIOLOGICAL|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
41161797|NCT01406808|BEHAVIORAL|genetic risk score for coronary risk factors|genetic risk score based on coronary artery disease genetic risk variants (SNPs)
41161798|NCT04359264|OTHER|Cash transfer|Cash transfer of $1000
41161799|NCT02860858|BIOLOGICAL|Intravitreous aflibercept injection|
41161800|NCT06350370|PROCEDURE|Natural orifice specimen extraction|We perform laparoscopic colorectal cancer resection, intracorporeal anastomosis and transanal or transvaginal specimen extraction
41161801|NCT02573883|DEVICE|Fractionated Carbon Dioxide Laser|Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
41161802|NCT02573883|DRUG|Clobetasol Propionate 0.05% ointment|Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
41367813|NCT01352871|BEHAVIORAL|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
41367814|NCT01352871|DRUG|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
41367815|NCT01795846|OTHER|Allergen specific immunotherapy and placebo injections|
41367816|NCT05367076|BEHAVIORAL|Web-based Aerobic Exercise Program|"Community based FTTs will use a web-based platform to deliver a 12-week exercise training program (120-minute group sessions of aerobic activity 3 times/week). Each session will include:~* Warm-up activities~* Aerobic activities and fitness training in a game-like fashion~* Organized sports/games~* Cool down activity~* Snack/reward time"
41502106|NCT04720131|DRUG|Capecitabine|Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle)
41502107|NCT06348615|DEVICE|Anti-cellulite cream-gel Medical Device (DEFBODY)|one bottle of 400 ml, twice a day
41161803|NCT05534464|OTHER|Milk|Twenty grams of the deuterium (2H) - labelled skimmed milk powder mixed with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. Protein free cookies are served alongside to equal macronutrient composition with the other two protein sources.
41161804|NCT05534464|OTHER|Sorghum|Twenty grams of the deuterium (2H) - labelled whole grain sorghum cooked with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference.
41367817|NCT02699918|PROCEDURE|nocturnal oximetry|nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
41367818|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
41367819|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
41367820|NCT01655810|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg orally twice daily
41367821|NCT00999453|OTHER|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
40846511|NCT01979133|DRUG|Icariin|Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
40846512|NCT00692419|BEHAVIORAL|Symptom management nurse intervention|A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
41367822|NCT03763448|PROCEDURE|Infrapatellar Fat Pad preservation|In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
41367823|NCT03763448|PROCEDURE|Infrapatellar Fat Pad resection|In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
41367824|NCT04456621|RADIATION|PBT|Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
41367825|NCT03582631|PROCEDURE|Emergency abdominal surgery|Emergency surgery for high-risk abdominal pathology using a protocol for optimized perioperative care
41367826|NCT01080794|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.~M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).~Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS."
41502108|NCT05464524|OTHER|Main questionnaire|10-15 minute questionnaire asking about environmental factors (i.e daily lifestyle questions), quality of life, comorbidities among others.
41502109|NCT05464524|OTHER|Optional 12-week follow up questionnaire|A 5-minute questionnaire asking about changes to the quality of life and DFU status since the initial questionnaire.
41502110|NCT00209105|DRUG|DEX-CRF stimulation test|1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
41502111|NCT00209105|BEHAVIORAL|Psychosocial stress induction|Laboratory stress induction, no drug administration
40846513|NCT00692419|BEHAVIORAL|Feedback intervention|Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
41029116|NCT03153917|OTHER|melatonin and cortisol sampling|The study will take place over 15 days during which the nurses will wear an actigraphic wristband and will fulfill a sleep log. During 3 periods of 24 hours selected during these 15 days, including a 12h day shift (Day 2), a 12h night shift (Day 8) and a rest (Day 13), the participants will collect their urine by 4 to 8 hour periods, note the corresponding urine volumes and for each period, sample a 5 mL tube which will be analyzed later (6-sulfatoxymelatonin and urinary cortisol assays). The subjects will complete questionnaires at the beginning of the study (Horne and Ostberg, Insomnia Severity Index, Epworth, Pichot, Hospital Anxiety and Depression) and the days corresponding to the urine sampling (Karolinska and St Mary Hospital).
41029117|NCT02520635|DRUG|supra-early TEMODAL® chemotherapy|
41029118|NCT02520635|DRUG|standard TEMODAL® chemotherapy|
41029119|NCT02520635|RADIATION|Radiotherapy 60Gy|
41029120|NCT01682837|DRUG|Potassium chloride powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
41029121|NCT01682837|DRUG|Potassium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
41029122|NCT01682837|DRUG|Potassium magnesium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
41029123|NCT01682837|DRUG|Placebo|1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
41029124|NCT05531539|DEVICE|WELMO sensors vest|Wearing of a vest equipped with lung auscultation and EIT sensors for signal acquisition and transmission
41029125|NCT05377398|BEHAVIORAL|Digital individual-level intervention (Bit Habit)|"All participants in the intervention group receive access to the BitHabit app for the 1-year intervention period. The BitHabit app was designed in the StopDia project, and it aims to help its users to adopt healthier lifestyles and habits.The content and approach of the app is based on habit formation theories and the Self-Determination Theory. The app provides an extensive library of suggested lifestyle habits that was created according to lifestyle guidelines and recommendations. The habits are related to diet, physical activity, sleep, positive mood, stress management, smoking, and alcohol consumption. Users of the app select these habits from the library to their shopping basket to complete in their everyday life. The app also allows the users to report and monitor their performance and progress."
41029126|NCT05377398|BEHAVIORAL|Group-based healthy lifestyle and green power intervention|The group-based healthy lifestyle intervention is based on the Supportive Environment Theory (SET). The intervention is implemented in accordance with DiClemente and Prochaska's Stages-of-Change Model which is often used as framework for lifestyle change as well as Shazer and Berg's Solution Focused Brief Therapy. We expect participants to increase knowledge about healthy lifestyle choices and notice the beneficial effect of exercise, healthy diet and staying in nature. The intervention includes 12 to 16 hours of group activities during a period of 8 weeks. Interventions comprehend guided activities in nature, related to healthy relationship to food and exercise, as well as reflecting on shared experiences. In addition to group meetings, participants have access to material for mental well-being on an electronic learning environment.
41367827|NCT02141776|DEVICE|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
41161805|NCT05534464|OTHER|Black beans|Twenty grams of the deuterium (2H) - labelled black beans cooked with water and mashed into a puree, will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. A carbohydrate drink is served alongside to equal macronutrient composition with the other two protein sources.
41161806|NCT05927506|BEHAVIORAL|Other|Observational study of behavior cognitive and motor control
41161807|NCT06003738|PROCEDURE|fascia iliaca compartment block|"Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of 0.25% bupivacaine will be injected."
41161808|NCT06003738|PROCEDURE|pericapsular nerve block|The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of 0.25% bupivacaine will be injected .
41161809|NCT06003738|PROCEDURE|palcebo fascia iliaca compartment block|"Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of normal saline will be injected."
41161810|NCT06003738|PROCEDURE|palcebo pericapsular nerve block|The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of normal saline will be injected .
41161811|NCT00926302|DRUG|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
41367828|NCT02141776|OTHER|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
41367829|NCT04479774|OTHER|Compelled Body Weight Shift Technique|"Routine Physical Therapy with 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
41502112|NCT00209105|PROCEDURE|Brain imaging of sad mood , self-reference, reward|Brain imaging
41502113|NCT00209105|BEHAVIORAL|Acoustic startle|No drugs involved
41502114|NCT01827865|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
41502115|NCT01827865|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
41502116|NCT04307576|DRUG|Omitted Doxorubicin|Omission of IV Doxorubicin
41502117|NCT04307576|DRUG|Omitted Vincristine+Dexamethasone pulses|Omission of Vincristine+Dexamethasone pulses
41502118|NCT04307576|DRUG|Inotuzumab Ozogamicin+Standard Maintenance Therapy|Addition of IV Inotuzumab ozogamicin before Maintenance Therapy
41367830|NCT04479774|OTHER|Compelled Body Weight Shift Technique without insole|"Routine Physical Therapy without 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
41367831|NCT00821847|OTHER|DEXA scan|DEXA scan
41367832|NCT00116610|DRUG|picoplatin|
41367833|NCT04697342|BEHAVIORAL|strategy of education|"one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education"
40846514|NCT03946085|DIETARY_SUPPLEMENT|Lumega-Z|A specially-formulated carotenoid supplement formula that utilizes a micronized, lipid-based liquid form of delivery.
40846515|NCT03946085|DIETARY_SUPPLEMENT|AREDS2|A commercially-available multivitamin soft gel formula.
41161812|NCT00926302|DRUG|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
41367834|NCT06384872|OTHER|Shoe Cushioning Position and Properties|The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively, while remaining within the range of values of shoes available on the market (linear equivalent stiffness: about 40 to 60 and 50 to 80 N/mm, at the rear and forepart of the shoe, respectively). We expect a difference in shoe weight lower than 30 g between the three versions (for size 42). The difference in cushioning properties between shoe versions will be created by modifying the type of foam and the foaming process.
41367835|NCT02415907|DRUG|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose
41367836|NCT02415907|DRUG|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose
41367837|NCT06055868|OTHER|Group Meeting (Focus Group)|Focus Group Discussions (FDGs) will be recorded, transcribed, and coded.
41367838|NCT06055868|OTHER|Questionnaires|Given electronically or via phone by study team staff
41367839|NCT03043287|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX®)100 to 200 U
41367840|NCT03839316|DEVICE|tDCS|A constant current stimulator (ZMI Electronics LTD.,Taiwan,2012) will be used through 2 saline-soaked surface gel-sponge electrodes (22 cm2 active area). Real stimulation consisting of thirty minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex (C3 and C4 of the international 10-20 EEG electrode system).
41161813|NCT06089109|BEHAVIORAL|Kentucky Violent Death Reporting System|The Kentucky Violent Death Reporting System (KYVDRS) addresses the need for accurate surveillance and data analysis by combining data from death certificates, coroner/medical examiner reports, police reports, crime laboratory reports, toxicology reports, and child fatality review team reports.
41161814|NCT06089109|BEHAVIORAL|Implementation and Effectiveness of VIP Corps Training|Implement and evaluate the effectiveness of VIP Corps training aimed at students enrolled in helping professions in their last program year. intervention efficacy to change in students' knowledge, attitudes, and practices of intimate partner violence (IPV) screening, detection, and referrals; participant practices will be the primary, longer-term outcome; while changes in knowledge and attitudes will be short-term outcomes. Secondary outcomes will include changes in detecting symptoms of a) SU/D and b) depression and/or anxiety and providing appropriate resources.
41161815|NCT03075111|DIAGNOSTIC_TEST|ImmunoXpert|Host based immune response test distinguishing viral versus bacterial infection
41161816|NCT00563745|DEVICE|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
41161817|NCT05550077|DIAGNOSTIC_TEST|Optical Coherence Tomography|Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography
41161818|NCT05550077|PROCEDURE|Percutaneous transluminal angioplasty and stenting|Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
41161819|NCT02264353|DRUG|Donepezil|Donepezil 10mg before sleep
41161820|NCT02264353|DRUG|placebo|One piece of placebo before sleep
41367841|NCT03839316|DEVICE|sham tDCS|For sham tDCS, the same electrode positions were used. The current was ramped up to 2 mA and slowly decreased over 30 seconds to ensure the typical initial tingling sensation
41367842|NCT00520273|DEVICE|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
41367843|NCT04861688|COMBINATION_PRODUCT|Traditional Chinese Medicine (NeuroAiD II™ (MLC901)|NeuroAiD II™ (MLC901) contains the extracts of 9 botanical active ingredients blended with commonly used excipients. The 9 botanical active ingredients are traditional herbs well documented in the Pharmacopoeia of the People's Republic of China.
41367844|NCT04861688|OTHER|Placebo|Placebo with same appearance as active intervention
41367845|NCT00555711|DEVICE|Modulated Imaging|Modulated Imaging
41367846|NCT02144662|DRUG|Ranibizumab|0.5mg ranibizumab intravitreal injection
41029127|NCT05377398|BEHAVIORAL|Individual-level healthy lifestyle intervention|The individual-level healthy lifestyle intervention follows the principles and theoretical background of the group-based intervention, but the intervention is carried out entirely on the electronic learning environment. The participants complete activities and exercises independently or with a friend in their own time.
41161821|NCT05192226|BEHAVIORAL|Counterfactual Strategy|Participants in this intervention condition will think about their past and identify how a less than desirable physical activity event could have turned out better using counterfactual thinking (i.e., If only I... then....). After identifying actions they could have taken to reach a better outcome in their physical activity event, they will then apply those thoughts to the future upcoming week so they can be realized.
41161822|NCT03204500|COMBINATION_PRODUCT|Active treatment with dual therapy|Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.
41161823|NCT03204500|DRUG|Placebos|Administered orally under the same conditions
41161824|NCT03307083|OTHER|Check list FOR (Foundation for Oral Rehabilitation)|the surgeon uses this check list during the pre surgery consultation
41367847|NCT04274985|OTHER|Questionnaire application|Patients will complete the mentioned questionnaires.
41367848|NCT01377142|DEVICE|Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
41367849|NCT01377142|DEVICE|Vaginal mesh hysteropexy|Uphold device used which includes sacrospinous ligament fixation
41502119|NCT04307576|DRUG|Imatinib|p.o. Imatinib
41502120|NCT04307576|DRUG|6-tioguanine+Standard Maintenance Therapy|Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
41502121|NCT04307576|DRUG|Blinatumomab|IV Blinatumomab
41029128|NCT05377398|BEHAVIORAL|Mini-intervention for substance use|The mini-intervention for substance use follows the principle of the ASSIST-linked brief intervention created by WHO. This brief intervention is a phone-call lasting 3 to 15 minutes and given to the participant according to their risk score calculated with the ASSIST questionnaire which is included in the baseline survey. The intervention includes presenting the participant with their test score and associated health problems related to their level of risk. Especially in primary health care context, brief intervention according to the ASSIST score has been found to be successful in moderating risk for substance use. The intervention is not intended as a stand-alone treatment and in cases where high risk substance use is detected, the professional should encourage the participant to seek specialized drug and alcohol assessment and treatment.
41029129|NCT02633384|OTHER|SMOFlipid|Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
41367850|NCT02567331|DRUG|Capecitabine|Participants will receive 1250 mg/m\^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
41367851|NCT01042431|OTHER|No Intervention|No intervention
41367852|NCT01978067|PROCEDURE|transvaginal resection of Uterine Scar|Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
41367853|NCT01151085|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
41367854|NCT05248685|BIOLOGICAL|Dual CD33/CLL1 CAR T|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10\^6 (±20%) to dose 2: 5×10\^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10\^5 (±20%)
41367855|NCT04293211|OTHER|Simulation|To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
41367856|NCT03781310|DRUG|Tocilizumab|IV Tocilizumab once every 4 weeks at reduced dose according to algorithm.
41367857|NCT06109766|BEHAVIORAL|Promoting First Relationships|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family or over Zoom. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
41502122|NCT04098289|PROCEDURE|Hysteroscopic septum resection|Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.
41502123|NCT04098289|PROCEDURE|In vitro fertilization|Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).
41502124|NCT05628727|OTHER|Time Restricted Feeding|This group will use the 16:8 method every day, eating only during an 8-hour period that will commence at wake-up time.
41502125|NCT05628727|OTHER|5:2 Fasting|This group will use the 5:2 method and fast for two non-consecutive days of the week.
41502126|NCT01860677|DEVICE|Fisher Wallace Cranial Stimulator|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
41502127|NCT01858272|DRUG|H5.020CMV.PDGF-b and limb compression bandage|
41502128|NCT03122977|PROCEDURE|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
41502129|NCT03122977|PROCEDURE|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
41161825|NCT04774783|DEVICE|Low-Level Laser Therapy|The TheraTouch LX2 device includes a 9-diode cluster probe which emits a combination of LED and laser light. The cluster probe includes four 650 nm LED diodes capable of delivering a total of 40 mW and five 850 nm laser diodes capable of delivering a total of 1000 mW of power. LLLT will the applied with the cluster probe directly in contact with the subject's skin. LLLT dosages will vary according to the location of the subject's pain and may require multiple applications during a session. Each individual application will typically range from 4-16 Joules.
41161826|NCT06545721|OTHER|Adjusting dietary structure + exercise + behavioral intervention|Adjusting to a healthy diet involves consuming low GI and low-fat foods, avoiding sugary drinks, increasing dietary fiber intake, reducing saturated fat while increasing omega-3 unsaturated fat intake, and limiting trans fat consumption. A weight loss program includes a high-protein diet, exercise, and behavioral intervention with daily total energy needs calculated based on ideal body weight (kg) x 15-20 kcal/kg/d; developing a daily meal plan with regular protein supplementation; limiting salt intake to ≤5 g/d; ensuring adequate water consumption at 2-3L/d; aiming for a dietary fiber intake of 25-30g/d; recommending micronutrient supplementation as needed; maintaining daily aerobic exercise (40 minutes at 70-80% HRmax) along with resistance training (20 minutes); establishing an early bedtime before 11pm and an early wake-up time.
41161827|NCT06329271|BEHAVIORAL|Early-Weight bearing|The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
41029130|NCT02633384|OTHER|Lipofundin|Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
41029131|NCT02233660|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
41029132|NCT02233660|PROCEDURE|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
41029133|NCT06390735|BEHAVIORAL|Mommy ReachOut Intervention|The momy reachOut intervention is a web-based psycho-education with 4 sessions, released over a two week period.
41029134|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
41029135|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.
41029136|NCT05266690|DIETARY_SUPPLEMENT|Roquette Glucidex 2|Roquette Glucidex 2: Maltodextrins with high degree of polymerization
41029137|NCT05266690|DIETARY_SUPPLEMENT|Pharmacosmos Dextran 10|Pharmacosmos Dextran 10: Dextran with high degree of polymerization
41029138|NCT05266690|DIETARY_SUPPLEMENT|Roquette Glucidex 40|Roquette Glucidex 40: Glucose syrup
41029139|NCT05266690|DIETARY_SUPPLEMENT|Promitor 70|Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
41029140|NCT06496256|DEVICE|Barrigel|Barrigel is an absorbable gel based on Non-Animal Stabilized Hyaluronic Acid (NASHA™) that is injected into the peri-rectal space
41161828|NCT01674452|BEHAVIORAL|home-based group (HBG)|Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
41367858|NCT02500173|RADIATION|Radiation|Radiation therapy
41367859|NCT04408326|DRUG|Angiotensin II|Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
41367860|NCT04408326|DRUG|Interleukin-1 receptor antagonist|Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
41367861|NCT02862366|OTHER|Blood sampling|Blood sampling every 6 month following the routine calendar of visit
41367862|NCT02896959|PROCEDURE|Arthroscopic rotator cuff repair|
41367863|NCT03749031|OTHER|Orange juice + Orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
41502130|NCT02322203|DIETARY_SUPPLEMENT|Niacin Extended Release|Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days. Subjects will then be escalated to 2000 mg/day for 14 weeks.
41029141|NCT06496256|DEVICE|Transrectal Ultrasound|All subjects will have a transrectal ultrasound (TRUS) conducted. In the control subjects this will act as a sham procedure. For the investigational subjects, the TRUS will be used to visualize the placement of the needle
41029142|NCT06367374|DRUG|Sonrotoclax|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in combination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg daily target dose is reached and continuing for at least 12 cycles (each cycle is 28 days).~Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
41029143|NCT06367374|DRUG|Zanubrutinib|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
41029144|NCT06019650|BEHAVIORAL|ECMAP|The therapist will deliver 12-week training program comprised of 6 sessions at the participant's home/outpatient clinic depending upon the participants' choice within 3 months. The first two sessions will be offered weekly and then fortnightly.
41029145|NCT02475408|DEVICE|Amplatzer vascular plug|
41029146|NCT02270320|BEHAVIORAL|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
41029147|NCT06636188|OTHER|Digi-Coach Chatbot|Participants will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer related concerns in the chatbot.
41029148|NCT03415620|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlist of different music genres. Music listening session will be given for 30 minutes before, during and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
41029149|NCT04180826|OTHER|Observational|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed, according to the usual care.~In a second step, the patient will be verticalized (from 0° to 90°). Intracranial hemodynamics parameters in supine position and during verticalization will be continuously recorded by attaching the ATYS TCD-X® transcranial Doppler helmet attached with glasses.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the ATYS TCD-X® helmet."
41029150|NCT00032292|DRUG|Visilizumab|
41029151|NCT00221793|PROCEDURE|Deep brain stimulation|Brain Stimulation of the Subthalamic Nucleus
41029152|NCT04296565|BEHAVIORAL|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff
41161829|NCT01674452|BEHAVIORAL|supervised exercise group (SEG)|Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
41161830|NCT00119756|DRUG|paliperidone palmitate|
41161831|NCT02571283|DRUG|Cocktail|Administered as a single dose injection.
41161832|NCT02571283|DRUG|Exparel|Administered 20 minutes+ before additional medications.
41161833|NCT02571283|DRUG|Marcaine|Administered 20 minutes or more after Exparel is administered.
41161834|NCT04817657|BIOLOGICAL|Ad26.COV2.S|Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1\*10\^11 virus particles per milliliter (vp/ml) as intramuscular injection.
41161835|NCT06411210|DRUG|Semaglutide Pen Injector|Escalated to 2.4mg or max tolerated dose
41161836|NCT06411210|DRUG|Placebo|Matched placebo.
41161837|NCT02578667|DEVICE|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
41161838|NCT01695525|OTHER|Yoga|Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
41502131|NCT05969249|DEVICE|Upper limb in vibration training|"The stroke subjects were all involved in the training,wear upper and lower extremity vibrators,the posture for intervention is hemiplegic upper limbs with shoulder joints slightly bent and abducted at 45 degrees, with elbows bent at 90 degrees and wrists centered. The elbow angle of this posture is set by the elbow joint rotation axis of the upper limb vibrator.~The set angle is the movable angle range of 80-110 degrees of elbow bending. The vibration rehabilitation password accepted by all subjects is Try to keep the elbow joint bent at 90 degrees during the vibration process, Resist the force of the vibration and try not to move."
41029153|NCT04296565|BEHAVIORAL|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
41029154|NCT05233826|BIOLOGICAL|COVI-VAC|Intranasal, live attenuated vaccine against SARS-CoV-2
41029155|NCT04695093|OTHER|Ultra Low Emission Zone (ULEZ)|"The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~1. In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~2. In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area."
41367864|NCT03749031|OTHER|Orange Juice|16 oz. orange juice per day for 4 weeks
41367865|NCT03749031|OTHER|Apple Juice and Apple Pomace|16 oz. apple juice and apple Pomace per day for 4 weeks
41367866|NCT03749031|OTHER|Apple Juice|16 oz. apple juice per day for 4 weeks
41367867|NCT00031616|DRUG|brivudine phosphoramidate|
41161839|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the pamphlet about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
41161840|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the webinar last for half an hour about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
41161841|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the SMS about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
41161842|NCT02679313|DEVICE|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
41367868|NCT00919620|BEHAVIORAL|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
41367869|NCT05932979|DRUG|L-arginine|L-arginine 2-amino-5-guanidino-pentanoic acid is a proteinogenic amino acid that is a natural constituent of the protein diet.
41367870|NCT05932979|OTHER|Placebo|Starch
41367871|NCT00173758|PROCEDURE|co-culture of embryos and endometrial cells|
41367872|NCT01737463|PROCEDURE|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
41367873|NCT05338827|PROCEDURE|Polyvinyl Chloride Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
41367874|NCT05338827|PROCEDURE|Wire-Reinforced Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
41161843|NCT00104013|DRUG|xaliproden (SR57746A)|
41161844|NCT01137123|DRUG|adjuvant chemotherapy|Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
41367875|NCT04369911|PROCEDURE|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
41367876|NCT01723358|DEVICE|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
41367877|NCT05741242|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Personalized Synthetic Long Peptide Vaccine
41502132|NCT03630107|OTHER|WO 5101 Shampoo for Scalp and Hair|Wash the hair at least three times a week for a period of four weeks
41367878|NCT02058940|DRUG|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
41367879|NCT02925650|DRUG|Posiphen|oral solid dosage form capsule
41367880|NCT02925650|DRUG|Placebo|oral solid dosage form capsule
41367881|NCT00561041|BEHAVIORAL|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
41367882|NCT00561041|BEHAVIORAL|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
41367883|NCT01621763|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
41367884|NCT04711031|OTHER|FLUS|The participating GPs use ultrasonography on a weekly basis and will use the ultrasonography device already available to them; however, the ultrasound machine system and type of transducer will be reported. The GPs will use a 14-zone FLUS scanning protocol that has previously been validated in a general practice setting. Each of the scanning zones on the patient's left side can be denoted from 1L to 7L and from 1R to 7R on the right side. Each scanning zone should be assessed using FLUS. The transducer is placed in the middle of a scanning zone making a cross sectional image of an intercostal space and the underlying pleura blades. The patients will be examined in an upright position. The GPs will be trained in the 14-zone scanning protocol during a FLUS training program prior to recruitment of patients. FLUS pathological findings are predefined, and the variables will be dichotomized into present or not present for each scanning zone.
41367885|NCT01395342|OTHER|Exercise using stationary bicycle|"Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position."
41367886|NCT04282811|DRUG|Venetoclax|Patients treated with venetoclax-based regimens outside clinical trials in Italy
41367887|NCT01364506|OTHER|Water aerobic exercise|"The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).~The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11."
41367888|NCT04988035|DRUG|Danicopan|Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor
41367889|NCT04988035|OTHER|Placebo|Danicopan matching placebo tablet
41502133|NCT05495672|PROCEDURE|Local treatment|"Radical surgical resection, local radiotherapy, radiofrequency ablation (RFA) or interventional therapy (absolute alcohol or cryotherapy).~The equipment used for RFA of lung lesions consisted of the radiofrequency generator (CelonLab POWER), cold circulation pump (Celon Aquaflow Ⅲ), radiofrequency needle electrode (Celon proSurge: T20, T30 and T40 is an electrode length of 20, 30 and 40 mm respectively, and maximum output power of 20, 30 and 40 W; Olympus Surgical Technologies Europe, Hamburg, Germany)."
41502134|NCT01464931|DRUG|Denosumab|Adminstered by subcutaneous injection
41029156|NCT04191759|DIAGNOSTIC_TEST|Test-Retest reproducibility|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
41029157|NCT05492136|PROCEDURE|Additional margin coagulation|After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
41161845|NCT01137123|PROCEDURE|standard two field Lymphadenectomy|Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
41502135|NCT04960033|BEHAVIORAL|FRAX|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
41161846|NCT01137123|PROCEDURE|Total two field Lymphadenectomy|Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
41161847|NCT01137123|PROCEDURE|three field Lymphadenectomy|Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
41161848|NCT03853642|OTHER|Blood sampling|Blood sampling, Spirometry, Fraction exhaled Nitric Oxide
41367890|NCT04988035|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
41367891|NCT03986658|DEVICE|Linear Asymmetric rTMS System|Linear Asymmetric rTMS System
41367892|NCT02140268|DRUG|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
41367893|NCT02140268|DRUG|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
41367894|NCT02140268|DRUG|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
41367895|NCT00334893|DRUG|eribulin mesylate|Given IV
41367896|NCT02968095|BEHAVIORAL|Text Message Craving Program|Text messages targeting cravings delivered 2-3 times per day.
40846516|NCT05818267|DRUG|Regorafenib|The drug dose that taken by the subject is gradually increased to the maximum dose tolerated by the patient according to individualization. Specifically, the initial dose of 80 mg/day was gradually increased to 120 mg/day (80 mg/day in the first week, 120 mg/day in the second week, and a maximum tolerated dose of 160 mg/day). The maximum tolerated dose is 160 mg/day. The dose is administered once daily in a 4-week cycle (3 weeks of dosing and 1 week of rest) and the maximum dose achieved in the first treatment cycle is maintained.At the discretion of the investigator, regorafenib may be delayed or discontinued. Dose adjustments and interruptions due to toxicity are made according to the recommendations specified in the protocol.
40846517|NCT02420548|BEHAVIORAL|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
40846518|NCT02420548|BEHAVIORAL|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
40846519|NCT04108806|PROCEDURE|Endovascular therapy|Ballon dialtation of the diseased artery
41029158|NCT05712226|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 35 minutes.
41029159|NCT05436574|OTHER|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the elderly population housed in the establishments of UNIVI group.
41029160|NCT04572633|DEVICE|HistoSonics System|The HistoSonics System (System) is intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
41029161|NCT02324491|DRUG|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
41029162|NCT02324491|DRUG|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
41029163|NCT03200522|OTHER|Prudent diet|Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
41029164|NCT03200522|OTHER|Western diet|Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
41029165|NCT00558285|DRUG|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
41029166|NCT00558285|DRUG|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
41029167|NCT00558285|DRUG|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
41029168|NCT00558285|DRUG|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
41029169|NCT06531798|DRUG|Breztri Aerosphere|Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg
41367897|NCT02968095|BEHAVIORAL|Self-Help Manual Plus Control Texts|Self-help manual plus motivational text messages delivered 2-3 times per day.
41367898|NCT03572465|DEVICE|Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)|Acoustic Radiation Force Impulse (ARFI), Magnetic Resonance Elastography (MRE)
41502136|NCT04104802|DEVICE|MRI|"All patients included will benefit from both methods of assessing anatomical relationships between the facial nerve and the parotid tumor:~1) New medical imaging technique evaluated: 3 Tesla Parotidic MRI High Resolution with Specific Sequences and Gadolinium Injection 2) Standard Gold: Intraoperative Exam"
41029170|NCT02055352|DRUG|Budesonide|Budesonide 400 mcg twice a day via Breezhaler® device
41029171|NCT02055352|DRUG|Fluticasone|Fluticasone 250 mcg twice daily via Accuhaler® device
41029172|NCT02055352|DRUG|Indacaterol|Indacaterol 150 mcg once daily via Breezhaler® device
41029173|NCT02055352|DRUG|Salmeterol|Salmeterol 50 mcg twice daily via Diskus® device
41029174|NCT05869305|DIETARY_SUPPLEMENT|whey protein isolate|Take 1 sachet/day for 12 weeks.
41367899|NCT00050050|BEHAVIORAL|Cognitive behavioral therapy|
41367900|NCT00050050|DRUG|Drug therapy|
41367901|NCT05852002|DRUG|35 kDa hyaluronan fragment|100 mg of 35kDa hyaluronan fragment was injected deeply into abdominal fat layer once a day for 28 consecutive days.
41367902|NCT00006162|BEHAVIORAL|exercise and diet|
41367903|NCT03331302|DRUG|Hyperpolarized Xenon-129 MRI (Experimental)|MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
41367904|NCT03331302|DRUG|Radioactive Xenon-133 scintigraphy (Active Comparator)|Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
41367905|NCT03455556|BIOLOGICAL|Anetumab Ravtansine|Given IV
41367906|NCT03455556|BIOLOGICAL|Atezolizumab|Given IV
41367907|NCT03455556|OTHER|Laboratory Biomarker Analysis|Correlative studies
41367908|NCT03374709|DRUG|Oxtellar XR 150Mg Extended Release Tablet|Oxtellar XR
41367909|NCT03480334|OTHER|Nivolumab plus radiotherapy|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
41029175|NCT05869305|DIETARY_SUPPLEMENT|isolated soy protein|Take 1 sachet/day for 12 weeks.
41502137|NCT02837614|DRUG|dexamethasone acetate|1 milliliter of dexamethasone (4milligram) administered in the deltoid muscle before commencement of surgical procedure
41502138|NCT02837614|DRUG|submucosal dexamethasone injection|Local anesthesia was achieved using 2% lignocaine hydrochloride and 1:100 000 adrenaline and a standard technique was followed to block Inferior alveolar, lingual and long buccal nerve in all patients. In Group B patients, 1 ml of dexamethasone was administered in submucosa. Investigators divided 1 ml Dexamethasone is into 0.4 milliliter, 0.3 milliliter and 0.3 milliliter parts. Following the local anesthesia, each part of dexamethasone was injected submucosally in the buccal, lingual and retromolar region around the tooth to be extracted. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation and tooth elevated. The flap was sutured using three simple interrupted 3-0 black braided silk suture. All patients were given amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively.
41502139|NCT02837614|PROCEDURE|Third molar surgery|Surgical access was gained through standard Terrence Ward's incision to raise a full thickness mucoperiosteal flap. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation. The tooth sectioned at cemento-enamel junction whenever required and a Coupland elevator is used to elevate tooth or fragmented tooth out of socket. The socket examined for any debris and sharp bony margins smoothened. The empty socket was irrigated copiously and flap was sutured using three simple interrupted 3-0 black braided silk suture.
41502140|NCT02837614|DRUG|Amoxicillin and paracetamol|Amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively (every 6 hours 1 tablet for 2 days).
41502141|NCT03709979|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
41502142|NCT03128021|DRUG|Escitalopram Pill|Double-blinded, randomly assigned
41502143|NCT03128021|OTHER|Placebo|Double-blinded, randomly assigned
41502144|NCT03128021|DRUG|Levomilnacipran Pill|Double-blinded, randomly assigned
41502145|NCT02361242|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
41502146|NCT06101329|DRUG|Lenacapavir Tablet|Tablets administered orally without regard of food
40846520|NCT06294847|DRUG|Ursolvan|single dose of Ursolvan® (10mg/kg) orally within 24 hours before the surgical intervention, followed by a daily dose of 10mg/kg in two divided doses for 30 days.
40846521|NCT06294847|DRUG|Placebo|Patients will receive a single dose of placebo orally within 24 hours before the surgical intervention, followed by two doses per day for 30 days
41029176|NCT05869305|DIETARY_SUPPLEMENT|placebo|Take 1 sachet/day for 12 weeks.
41029177|NCT02962830|DRUG|Sufentanil|intra-amniotic injection of 10 micrograms of Sufentanil
41502147|NCT06101329|DRUG|Lenacapavir Injection|Injection administered subcutaneously
40846522|NCT06303232|OTHER|MANUAL LYMPHATIC DRAINAGE|"MLD was performed after the moist heating of 10 minutes in supine position with both knees bent. It will start from the abdominal lymph drainage followed by the central lymph drainage.~Then, by stimulating the bilateral axillary lymph nodes, the flow of the fluid was directed to the axillary lymph node. Each session lasted for approximately 45 minutes, for 7 days"
40846523|NCT06303232|OTHER|THERAPEUTIC ULTRASOUND|The participants of group B will receive a treatment of manual lymphatic drainage and ultrasound after the moist heat of 10 minutes. After MLD of 45 minutes, ultrasound will be performed in small circular pattern from periphery to the center towards the areola with following parameters: Mode: pulsed, Frequency: 1MHz, Intensity: 1W/cm2, Time: 8 minutes. Treatment was given for 7 consecutive days
40846524|NCT01997671|OTHER|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
41029178|NCT02264834|DRUG|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
41029179|NCT02264834|DRUG|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
41029180|NCT02264834|PROCEDURE|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
41029181|NCT00766376|DEVICE|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
41502148|NCT06101329|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)|200/300mg fixed dose combination (FDC) tablets administered orally
41502149|NCT06021626|DRUG|CRD3874|"Starting dose is 0.1 mg/kg for weekly IV infusion of CRD3874-SI.~Cohort CRD3874-SI Dose level (mg/kg)~1. 0.1~2. 0.3~3. 0.9~4. 1.8~5. 2.7~6. 4.05"
41502150|NCT05124886|OTHER|Moderately High Oxalate (MOx) Diet|Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.
41502151|NCT02720874|BEHAVIORAL|Rheumatoid arthritis educational booklet|Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
41502152|NCT02720874|BEHAVIORAL|Multidisciplinary rheumatologic care|At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
41502153|NCT02720874|BEHAVIORAL|Nurse education and monthly calls|Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.
41502154|NCT02720874|BEHAVIORAL|Monthly healthcare coordinator calls|During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
41367910|NCT03754881|BEHAVIORAL|Pulmonary rehabilitation|"In this study, we'll educate pulmonary rehabilitation to patients and make reservation for re-visiting outpatients clinics with PR diary after 8 weeks.~we want to confirm whether patients, who perform home based PR during more than 30 minutes in 3 days per week, present improved dyspnea score or quality of life compared with non-compliance group."
41367911|NCT02155816|DIETARY_SUPPLEMENT|Omega 7 + 3|Ingestion of omega 7 + 3 daily for 8 weeks.
41502155|NCT02720874|BEHAVIORAL|Technology-based symptom monitoring and reporting|When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
41367912|NCT02155816|DIETARY_SUPPLEMENT|Omega 3|Omega 3 daily for 8 weeks.
41367913|NCT02155816|DIETARY_SUPPLEMENT|Placebo|Medium chain triglycerides
41502156|NCT03220347|DRUG|CC-90010|CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
41502157|NCT01843296|DRUG|Magnesium Sulfate|Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
41029182|NCT05054335|OTHER|Functional Assessment|Undergo walking function assessment with optical motion capture
41029183|NCT05054335|PROCEDURE|X-Ray Imaging|Undergo bi-plane dynamic X-ray imaging
41029184|NCT03089190|DIETARY_SUPPLEMENT|DC7-2|Effects on appetite
41029185|NCT03089190|DIETARY_SUPPLEMENT|DC7-2 + potato protein isolate|Effects on appetite
41029186|NCT03089190|DIETARY_SUPPLEMENT|Potato protein isolate|Effects on appetite
41029187|NCT03089190|DIETARY_SUPPLEMENT|Placebo|Inactive whey protein, not expected to affect appetite.
41029188|NCT02945865|OTHER|Pain assessment|Pain assessment with assessment tools
41029189|NCT06303752|DRUG|ADRC injection|Allocated patients will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.
41367914|NCT02068001|PROCEDURE|Roux-en-Y Gastric Bypass|
41367915|NCT02547064|PROCEDURE|Glidescope guided intubation|
41367916|NCT02547064|DEVICE|GlideScope®|
41367917|NCT04145531|DRUG|IM JZP-458|IM JZP-458 will be administered in Part A, Cohorts 1 \& 2
41367918|NCT04145531|DRUG|IV JZP-458|IV JZP-458 will be administered in Part B
41367919|NCT01994070|DRUG|Electrical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
41367920|NCT01994070|DRUG|Chemical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
41367921|NCT02114723|DEVICE|Medical Taping Concept|"The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
41367922|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
41029190|NCT06303752|DRUG|ADRC001 injection|Allocated patients will receive injection of 5 ml suspension including 30 million allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
41367923|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
41502158|NCT01843296|PROCEDURE|Spinal Anesthesia|Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
41502159|NCT01843296|DRUG|Bupivacaine|
41029191|NCT02976766|DRUG|Gypenosides|Participants will receive gypenosides 360 mg/day (120 mg three times a day) for 10 days.
41029192|NCT02976766|DRUG|Placebo|Participants will receive placebo three times a day for 10 days.
41029193|NCT05061121|OTHER|combined effect|Compare the short- and mid-term effects of Mulligan's SNAGs, Myofascial release, and their combination on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
41029194|NCT00179088|BEHAVIORAL|Patient may be able to put weight on the operated leg|
41029195|NCT01028573|DRUG|PEG-ELS (Golytely)|4L consumed evening before colonoscopy
41029196|NCT01028573|DRUG|PEG-ELS (Golytely)|2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
41367924|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
41502160|NCT01843296|DRUG|Fentanyl|
41029197|NCT01028573|DRUG|Miralax mixed with Gatorade|238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
41029198|NCT01028573|DRUG|Miralax|1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
41029199|NCT06370091|OTHER|Gum of Xylitol|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
41029200|NCT06370091|OTHER|Gum of sugar free|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
41029201|NCT06370091|OTHER|Gum of sugar|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
41029202|NCT06370091|OTHER|Paraffin wax|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
41029203|NCT03989817|DRUG|Vasoactive Intestinal Peptide (VIP) and Saline|12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.
41029204|NCT03727204|PROCEDURE|On-pump cardiac surgery|All participants will undergo on-pump cardiac surgery
41029205|NCT05816421|BEHAVIORAL|KEEP|The KEEP model focuses on optimizing the role of foster/kin parents as the agents of positive change for children and youth. Parent KEEP groups for children (ages 4-12) and KEEP-Safe groups for teens (ages 13-19) are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-10 foster/kin parents attends each week. Each KEEP group follows a manualized curriculum that emphasizes tailoring the content to the unique needs of the parents and youth in the group. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting.
41029206|NCT05816421|BEHAVIORAL|Non-Affinity KEEP|Non-Affinity KEEP
41029207|NCT05123365|DRUG|N-Acetylcysteine|Given PO
41029208|NCT04842955|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
41029209|NCT04842955|DEVICE|Sham tACS over the superior parietal cortex|Single session of sham tACS over the superior parietal cortex
41029210|NCT04920760|DIETARY_SUPPLEMENT|Vitamin A supplement|The supplementation protocol will be the additional care established by World Health Organization (WHO) and the United Nations International Children ʹs Fund (UNICEF) for measles (1998)(i.e. of 200,000 IU, or 50,000-100,000 IU for children \> 1 or for infants of \< 1 year of age, respectively).
41029211|NCT03697291|DEVICE|PS wire|The wiring connection used to convey ECG signal from inside the body
41029212|NCT04617028|DRUG|Jaktinib|Jaktinib Hydrochloride Tablets administered orally twice daily
41161849|NCT03293472|DRUG|Ropivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients \< 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml \> 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
41161850|NCT03293472|DRUG|Bupivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine~Device:~The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
41161851|NCT06123949|DEVICE|Galvanic Vestibular Stimulation|Galvanic Vestibular Stimulation (GVS) is a non-invasive technique that uses low-level electrical currents to stimulate the vestibular system, affecting balance, posture, and eye movements. It has applications in research, clinical assessment, and rehabilitation of vestibular and balance-related issues, as well as potential applications in cognitive and motor function enhancement.
41161852|NCT05518877|DRUG|Ketamine|Administration of Ketamine
41161853|NCT04904237|DRUG|Aza-Ven-allo-HSCT|aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
41029213|NCT04617028|DRUG|Placebo to match Hydroxycarbamide|Placebo to match Hydroxycarbamide Tablets administered orally twice daily
41029214|NCT04617028|DRUG|Hydroxycarbamide Tablets|Hydroxycarbamide Tablets administered orally twice daily
41029215|NCT04617028|DRUG|Placebo to match Jaktinib|Placebo to match Jaktinib Tablets administered orally twice daily
41161854|NCT03262155|BIOLOGICAL|Blood test|
41029216|NCT04444154|BEHAVIORAL|Control group|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment.
41029217|NCT04444154|BEHAVIORAL|Group with active participation|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with a demonstration of brushing methods in the sink with active participation (use of plate developer and then the Oral B electric toothbrush with special orthodontic head) during the bonding appointment as well than at each check-up appointment.
41029218|NCT04444154|BEHAVIORAL|Group with video and quizz|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with have an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
41161855|NCT04457089|DRUG|Simvastatin 40mg|Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
41161856|NCT04414397|DEVICE|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC injectable gel
41029219|NCT03696121|DRUG|Desmopressin Injection|Single dose 20 micrograms in 50ml Normal Saline as intravenous injection infused over 20 minutes
41029220|NCT03696121|DRUG|Normal saline|Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes
41029221|NCT06464393|DRUG|ketamine-lidocaine-dexmedetomidine|Patients will be administered 0,8 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations just before induction of anesthesia.
41029222|NCT06464393|DRUG|fentanyl|Patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9% just before induction of anesthesia.
41029223|NCT02015234|DRUG|TNX-102 SL|TNX-102 SL 2.8 mg taken daily at bedtime.
41161857|NCT04414397|OTHER|No-treatment control|Participants received no treatment for 3 months during the Control Period.
41161858|NCT03779321|OTHER|Acceptability|Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals
41161859|NCT01647152|DRUG|Ustekinumab|
40846525|NCT06579846|DRUG|Cytisinicline and exercise|"Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change.~Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25.~Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes."
41161860|NCT01645358|DEVICE|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
41161861|NCT01645358|DEVICE|Total Face mask (Respironics)|"The total face mask is the classical interface for NIV delivery"
41502161|NCT03947944|PROCEDURE|SMILE using manifest refraction planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
40846526|NCT06579846|DRUG|Cytisinicline|Same intervention as the experimental group without directed exercise prescription
40846527|NCT03502668|DRUG|ASTX727 LD|oral decitabine (LD) + cedazuridine (E7727)
40846528|NCT03502668|DRUG|ASTX727 SD|oral decitabine (SD) + cedazuridine (E7727)
40846529|NCT03905902|BIOLOGICAL|DCVAC/OvCa|activated autologous dendritic cells
40846530|NCT03905902|BIOLOGICAL|DCVAC/OvCa placebo|placebo for activated autologous cells
40846531|NCT03779581|OTHER|Self Correction exercises|Active self-correction exercises to restore movements in different planes as close to physiologically normal as possible.
41029224|NCT02357836|DRUG|Itraconazole|"Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure."
41029225|NCT02206529|BEHAVIORAL|Social Network Engagement+Std Treatment|
41029226|NCT02206529|BEHAVIORAL|Standard Treatment|Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
41029227|NCT02883725|OTHER|data collection|
41161862|NCT02413593|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
41161863|NCT02413593|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
41161864|NCT04344756|DRUG|Tinzaparin or unfractionated heparin|Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
41502162|NCT03947944|PROCEDURE|SMILE using vector planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
41502163|NCT05316155|DRUG|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
41502164|NCT00224289|DRUG|Latanoprost 0.005%|Latanoprost 0.005% ophthalmic solution QHS 8 weeks
41502165|NCT03687411|PROCEDURE|Neuraxial ultrasonography|Ultrasound gel is applied to lower back lumbar spine of patient and placed with an ultrasound probe around the sacral region. The graphical interface of the software integrated with ultrasound machine will help identify the sacrum. The probe is moved in until the L3/4 interspinous space is identified for skin surface marking. Once the longitudinal scan is completed, the investigator will turn the probe 90° clockwise for transverse scan to identify ligamentum flavum.
41502166|NCT04261907|DRUG|ASC09/ritonavir group|ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment
40846532|NCT03779581|DEVICE|orthotic devices|the orthotic devices designed to correct the scoliosis curve
40846533|NCT04429724|DIAGNOSTIC_TEST|Diagnostic test Covid-19|Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
40846534|NCT03390309|OTHER|Partially Hydrolyzed Formula|Partially Hydrolyzed Whey Protein Infant Formula
40846535|NCT03390309|OTHER|Normal Formula|Normal Formula
41161865|NCT04978688|DRUG|Relugolix|Administered as an oral tablet once daily.
41161866|NCT04978688|DRUG|E2/NETA|Administered as an oral tablet once daily.
41161867|NCT01475019|DRUG|Orlistat|Tablet, 120 mg, three times daily, for six months
41161868|NCT01475019|DRUG|Sibutramine|Tablet, 10 mg, once daily, for six months
41161869|NCT01475019|BEHAVIORAL|Diet and physical exercise|Hypocaloric diet and regular physical exercise
41367925|NCT00482664|DRUG|Placebo|Tablets for oral administration
41367926|NCT03741075|PROCEDURE|BUA|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
41367927|NCT03741075|DRUG|topical tranexamic acid|topical application of 200ml saline contains 2 gm tranexamic acid to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
41367928|NCT03741075|DRUG|placebo|topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
41367929|NCT00876902|DRUG|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg \[approximately 0.27 mg/kg\] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
41367930|NCT00876902|DRUG|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
41367931|NCT06199856|DIAGNOSTIC_TEST|ultrasound scan|ultrasound scan
41367932|NCT01084824|DRUG|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
41367933|NCT01084824|DRUG|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
41367934|NCT06126601|OTHER|Pancreatectomy|"Patients who underwent pancreatectomy will be enrolled. Serum amylase and lipase will be measured preoperatively. During surgery, blood samples will be taken after completing the pancreatic anastomosis and at the end of the operation during skin suture. Patients will be followed up during hospital stay, 3 and 6 months after discharge. The clinical outcome (complications, rescue pancreatectomy) will be recorded and analysed.~Postoperative blood samples, according to clinical standard, will be taken at the 1, 2, 3, 5 and 7 day postoperatively. In addition to amylase several more parameters will be examined intra- and postoperatively: leucocytes, lipase, CRP, bilirubin, transaminases, AP, GGT, creatinine, interleukin-6, PCT. Intraoperative 1-2ml of pancreas juice will be taken for the evaluation of amylase and lipase levels."
41502167|NCT04261907|DRUG|lopinavir/ritonavir group|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment
41367935|NCT05803876|OTHER|Diagnostic test - monitoring|"Continuous measurement of blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) Atys Medical TCD-X®. The probe attachment system on the patient's head looks like a pair of glasses; it is light and comfortable. The orientation of the robotic probe is automatically readjusted to ensure stable recording quality over time. (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk."
41502168|NCT04518293|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Single pill
41367936|NCT06384599|DEVICE|VT Cryoablation System|All subjects will receive a cryoablation procedure using the VT Cryoablation System (catheter, stylets, and console)
41367937|NCT02136446|DEVICE|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
41367938|NCT02136446|DEVICE|Pajunk® Nerve Block Catheter|Nerve Block Catheter
41367939|NCT06302829|OTHER|Dry needling|AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30min
41502169|NCT04518293|DRUG|telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg|Signle pill
41502170|NCT04518293|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg .|oral tablet
41502171|NCT04518293|DRUG|telmisartan 40 mg/amlodipine 5 mg|oral tablet
41502172|NCT04518293|DRUG|Telmisartan 20 mg/indapamide 1.25 mg|oral tablet
41502173|NCT04518293|DRUG|telmisartan 40 mg/indapamide 2.5 mg|oral tablet
41502174|NCT04518293|DRUG|Amlodipine 2.5 mg/indapamide 1.25 mg|oral tablet
41502175|NCT04518293|DRUG|amlodipine 5 mg/indapamide 2.5 mg|oral tablet
41502176|NCT06158555|DRUG|250 ML NaCl 4.5 MG/ML Injection|Bolus 250 ml crystalloid. Usually 0.9% saline or compound sodium lactate solution at discretion of attending clinician
41502177|NCT03153449|DEVICE|ATTUNE Revision Knee System in Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their anatomy is such that the use of revision components are required to perform primary total knee arthroplasty
41367940|NCT06302829|OTHER|intramusuar electrical stimulation|Myofascial trigger point would be targeted by direct intramuscular electrical stimulation by using direct electrode placement method, where anode pole and the cathode pole of the stimulator connected to the needles of the MTrPs of the shoulder girdle muscles .AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30 min
41367941|NCT02613910|DRUG|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
41367942|NCT02613910|DRUG|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
41367943|NCT02613910|DRUG|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
41367944|NCT02613910|DRUG|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
41502178|NCT00384930|DRUG|tadalafil|2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
41502179|NCT00384930|DRUG|tadalafil|5 mg tadalafil tablet by mouth once a day for twelve weeks.
41502180|NCT00384930|DRUG|tadalafil|10 mg tadalafil tablet by mouth once a day for twelve weeks.
41502181|NCT00384930|DRUG|tadalafil|20 mg tadalafil tablet by mouth once a day for twelve weeks.
41502182|NCT00384930|DRUG|placebo|Placebo tablet taken by mouth one a day for twelve weeks
41502183|NCT06608485|DEVICE|HARMONIC 700 Shears|There is no intervention, beyond necessary clinical care, in this study. HARMONIC 700 Shears for vessel transection were used according to instructions for use.
41502184|NCT06067828|DRUG|Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).
41502185|NCT06067828|DRUG|Treatment B: Budesonide and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.
41502186|NCT06067828|DRUG|Treatment C : Placebo|Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.
41367945|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Patients|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
41502187|NCT03704415|PROCEDURE|Extended endoscopic sinus surgery|ESS of all sinuses
41502188|NCT03704415|PROCEDURE|Limited endoscopic sinus surgery|Partial ethmoidectomy
41367946|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Caregiver|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
41502189|NCT00459043|DRUG|ZD6474|Taken orally once every morning
41502190|NCT00459043|DRUG|Docetaxel|Given on the first day of every treatment cycle (every 3 weeks)
41502191|NCT06634095|BEHAVIORAL|Moulage group|The experimental group is trained with a moulage-supported standardized patient simulation. Participants in the experimental group practice during the specified moulage-supported standardized patient simulation. Moulage-supported simulations regarding pressure ulcers will be created and training will be provided.
41502192|NCT02572245|DEVICE|PF-06410293 PFS|PF-06410293 40 mg administered subcutaneously by Prefilled syringe
41029228|NCT02323919|BEHAVIORAL|SystemCHANGE|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
41029229|NCT02323919|BEHAVIORAL|CHANGE+|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
41367947|NCT04654299|PROCEDURE|External biliary stent|The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
41367948|NCT00671645|DRUG|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
41029230|NCT02323919|BEHAVIORAL|Usual Care|Participants will receive only the routine care provided to CRP patients. This care consists of assessment of exercise capacity, graduated exercise training (consisting of exercising three times a week at the cardiac rehabilitation center on treadmill or cycle, counseling about safe exercise {warm-up procedures, pulse taking, attending to body cues for exertion levels} and advisement to exercise on days between CRP sessions). At the end of the CRP, individuals are given an exercise prescription that includes their target heart rate and they are counseled to exercise at least 5 times a week for 30 minutes. This information is provided by the CRP personnel, usually in the form of individual informal conversations during exercise at the CRP.
41029231|NCT04735133|DEVICE|pNBYT|pNPWT device (80mm Hg) was placed in the pNPWT group for seven days The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
41502193|NCT02572245|DEVICE|PF-06410293 PFP|PF-06410293 40 mg administered subcutaneously by prefilled pen
41502194|NCT01499433|DRUG|caspofungin|Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
41502195|NCT02724228|DRUG|BMN 111|BMN 111 will be administered subcutaneously daily.
41029232|NCT05441930|DRUG|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
41029233|NCT05441930|DRUG|Control|Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
41029234|NCT02280603|DRUG|DA-4001C|1ml by topical application twice a day
41029235|NCT02280603|DRUG|5% minoxidil|1ml by topical application twice a day
41029236|NCT04711265|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|Intramuscular injection with 3 doses of QHPV
41029237|NCT01663493|PROCEDURE|FNB|
41029238|NCT06529653|PROCEDURE|autogenous bone wedge|autogenous bone block harvested from chin and adjusted to be wedged intercortical in split ridge
41029239|NCT00651508|DRUG|KOS-1584|25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
41367949|NCT01437982|DRUG|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
41502196|NCT00767624|DRUG|Antidepressant|Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
41502197|NCT00767624|BEHAVIORAL|Desensitization Therapy for Insomnia|
41502198|NCT00767624|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|
41502199|NCT06633003|DIETARY_SUPPLEMENT|Antrodia cinnamomea Products|"Placebo-controlled crossover design:~* Dietary Supplement: Antrodia Cinnamomea Products~* Dietary Supplement: Placebo"
41029240|NCT05257525|OTHER|Esophageal manometry catheter at various PEEP levels and tidal volumes|Participants will undergo placement of an esophageal manometry catheter before planned sternal closure. This catheter will be used to measure esophageal pressure which is a surrogate for pleural (intrathoracic) pressure. Esophageal pressure will then be used to estimate changes in respiratory system mechanics and hemodynamics following sternal closure and across different levels of positive end-expiratory pressure (PEEP) and tidal volumes.
41029241|NCT00987207|DRUG|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
41367950|NCT01437982|DRUG|Prednisolone Acetate 1% Oph Susp|Ocular administration of study drug. at least once within any indication of the label.
41367951|NCT03148509|DRUG|risperidone|DA receptor-mediated drugs
41367952|NCT03148509|DRUG|aripiprazole|DA receptor-mediated drugs
41367953|NCT03148509|DRUG|bupropion|DA receptor-mediated drugs
41367954|NCT04798560|PROCEDURE|Pancreaticoduodenectomy|Patients udergo pancreaticoduodenectomy for periampullary tumors. All of them are observed for developing POPF
41367955|NCT01138995|DEVICE|Ness L300|The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
41367956|NCT01138995|DEVICE|Ankle-foot orthosis|"The Control Group will walk with a usual ankle-foot orthosis (AFO)."
41367957|NCT01973205|DRUG|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
41367958|NCT01973205|DRUG|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
41367959|NCT02531282|BEHAVIORAL|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
41502200|NCT06633003|DIETARY_SUPPLEMENT|Antrodia cinnamomea Products|"A arm :~Stage I :~• Dietary Supplement: Antrodia Cinnamomea Products~Stage II:~• Dietary Supplement: Placebo~B arm :~Stage I :~• Dietary Supplement: Placebo~Stage II:~• Dietary Supplement: Antrodia Cinnamomea Products"
41502201|NCT00776750|BIOLOGICAL|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
41502202|NCT02787408|DEVICE|EW Tricuspid Transcatheter Repair System|Treatment with the EW Tricuspid Transcatheter Repair System
41502203|NCT06570187|DRUG|Dexmedetomidine|Dexmedetomidine will be administered with an initial dose of 0.2 μg/kg/hour, infusion rate is to be titrated based on response for at least 24 hours.
41502204|NCT06570187|DRUG|Propofol|Propofol will be administered as the comparator sedative with the standard treatment of sepsis and septic shock.
41502205|NCT03597464|DRUG|Voclosporin|Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)
41502206|NCT03597464|DRUG|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
41502207|NCT03486691|OTHER|Routine measurement of left lobe|Routine preoperative measurement of left lobe
41502208|NCT03486691|OTHER|control group|no routine preoperative measurement of left lobe
41502209|NCT01425411|DRUG|valsartan|80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
41502210|NCT05782127|DRUG|Onureg + Venetoclax|Combination of Onureg and Venetoclax
41502211|NCT06489626|DRUG|Methylprednisolone 4 milligram Tab|6-day 4 milligram methylprednisolone oral taper
41502212|NCT06489626|DRUG|Dexamethasone injection|4 milligram intravenous dexamethasone will be administered intraoperatively
41367960|NCT02531282|BEHAVIORAL|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
41367961|NCT03310281|DEVICE|HOLD: Videogame|Videogame-like digital therapy
41367962|NCT03501134|DEVICE|NovoTTF|We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.
41029242|NCT00987207|OTHER|No injection|No cyclosporine A is administered before aortic cross-declamping.
41029243|NCT06534203|OTHER|Investigation - Observational Study|In this study, there will be no intervention, instead, it will be an observational study aimed at identifying the specific physical demands of caregivers working in long-term care facilities. This information will inform future interventions that can help reduce the occurrence of work-related musculoskeletal injuries.
41029244|NCT04464304|DEVICE|Smartphone|Patients will participate in a similar game to the VR cohort, but will use a smartphone device.
41029245|NCT04464304|DEVICE|Virtual Reality (Oculus Quest)|Patients will participate in a game using VR.
41367963|NCT04398030|DEVICE|coil-reinforced soft polymer indwelling cannula|Insulin infusion set will be used for up to 7 days of continuous use or until failure
41367964|NCT04398030|DEVICE|soft Teflon indwelling catheter|Insulin infusion set will be used for up to 7 days of continuous use or until failure
41367965|NCT04519827|OTHER|New Rice-based hydrolysate|A rice-based hydrolysed infant formula with new ingredient
41367966|NCT04519827|OTHER|Amino Acid-based infant formula|An amino acid-based infant formula
41367967|NCT00014066|DRUG|hematoporphyrin derivative|
41367968|NCT00014066|RADIATION|brachytherapy|
41367969|NCT05648695|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
41367970|NCT05648695|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
41367971|NCT01636011|OTHER|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
41367972|NCT01636011|OTHER|Light Touch sham|Light Touch sham
41367973|NCT03939429|DRUG|QPX2015|antibiotic
41367974|NCT03939429|DRUG|Placebo oral capsule|Placebo comparator
41367975|NCT03841331|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
41367976|NCT03841331|DRUG|Matching Placebo Tablets|Placebo Tablets
41367977|NCT05461742|BEHAVIORAL|Physical activity intervention|While the final content and structure of the intervention will be informed by community advisory board, participants will receive a culturally adapted, Social Cognitive Theory and Transtheoretical Model-based PA intervention. The evidence-based, theory guided aerobic physical activity intervention will systematically build upon the investigators' prior studies and includes the following components: goal setting, in-person physical activity sessions, and written materials.
41367978|NCT04129879|PROCEDURE|ABC technique|The intraperitoneal use of methylene blue diluted isotonic sodium chloride solution to visualize endometriotic lesions
41502213|NCT00606346|BIOLOGICAL|Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
41367979|NCT03383406|DRUG|Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy|"Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion."
41367980|NCT00379639|DRUG|Romidepsin|7, 10 or 12 mg/m\^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
41367981|NCT00379639|DRUG|Gemcitabine|800 or 1000 mg/m\^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
41367982|NCT01648517|DRUG|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
41367983|NCT01648517|DRUG|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
41502214|NCT00606346|DRUG|No Biologics|Treatments will be prescribed according to investigator judgement.
41502215|NCT03218488|DRUG|Ustekinumab|Participants will not receive any intervention as part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab in clinical practice (patients should either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development.
41502216|NCT03170531|DIAGNOSTIC_TEST|Custom Designed Spine Coil|During the participant's MR scan, the custom spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.
41502217|NCT03170531|DIAGNOSTIC_TEST|FDA approved spine coil|During the participant's MR scan, the FDA spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging. Volunteers may receive up to 3 scans to allow for comparisons of changes to the calibration files as we continue to test the coil and improve its performance.
41502218|NCT06632964|BIOLOGICAL|Recombinant oncolytic adenovirus injection solution of VT-101|Active ingredient: VT-101 recombinant oncolytic adenovirus Specifications: 2×10\^10 IFU/ml, 0.5ml/ capsule Method of administration: intravesical perfusion
41502219|NCT04940559|DRUG|Danicopan - Tablet|Oral tablet.
41502220|NCT04940559|DRUG|Danicopan - Softgel|Oral softgel capsule.
41502221|NCT04940559|DRUG|Danicopan - LFC|Oral LFC.
41367984|NCT05731830|OTHER|Data extraction|"The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. We will investigate: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, and the ArpaLazio website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php), which provides the concentration of NO, NO2, NOx, PM10, PM2.5, O3, CO, C6H6, SO2 expressed in micrograms per cubic meter (µg/m3). Hourly data are available for all gaseous pollutants, while the levels of PM10 and PM2.5 are expressed daily. Data will be obtained from the air quality monitor closest to each participant's residence that was active for the entire year, and short-term (daily and weekly) and long-term (annual) air pollution exposure will be quantified as daily, weekly, and annual average 24-h pollutants level of measurements before TTS."
41367985|NCT05731830|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACE, defined as the composite of all-cause mortality, non-fatal MI, transient ischemic attack (TIA)/stroke, and hospitalization for heart failure, and the recurrence of TTA in the past months will be investigated and collected.
41367986|NCT02710825|OTHER|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
41502222|NCT01326650|DRUG|Vitamin D|daily oral vitamin D supplement of 100 micrograms for three years
41502223|NCT01326650|DRUG|placebo|daily oral placebo supplement for three years
41502224|NCT00843635|DRUG|Tadalafil|Given orally
41502225|NCT00843635|OTHER|Placebo|Given orally
41502226|NCT06264180|BIOLOGICAL|Vusolimogene Oderparepvec|Genetically modified Herpes Simplex Type 1 Virus.
41502227|NCT06264180|BIOLOGICAL|Nivolumab|Anti-PD-1 Monoclonal Antibody
41502228|NCT06264180|BIOLOGICAL|Nivolumab + Relatlimab|Nivolumab: Anti-PD-1 Monoclonal antibody. Relatlimab: A lymphocyte activation gene-3 (LAG-3) blocking antibody.
41502229|NCT06264180|BIOLOGICAL|Pembrolizumab|A programmed death receptor-1 (PD-1)-blocking antibody indicated.
41502230|NCT06264180|DRUG|Single-agent chemotherapy|Dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel.
41502231|NCT03020537|BIOLOGICAL|Fluzone|Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
41502232|NCT05096260|BEHAVIORAL|Motivational Interviewing based SMS/MMS and web content|Our primary framework that will guide the web content is Self-Determination Theory (SDT). SDT differentiates between autonomous (conscious choice and are personally relevant) and controlled behavioral regulation (performed due to pressure or coercion by external or internal forces). Messages that enhance autonomy and perceived competence and are consistent with a person's values and goals will be more effective in changing behavior than messages focusing on external rewards. To link vaccination to broader values and goals, participants will select 3-4 goals from approximately 20 values/goals. Individually tailored messages will link each of these values to vaccination. We will also tailor testimonials based on member values and communication style preference.
40846536|NCT05165225|DRUG|Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment|Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m\^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m\^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m\^2 d1 iv Q3W for 4 cycles
40846537|NCT02708420|DEVICE|Glidescope|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
41029246|NCT03057119|BEHAVIORAL|Psycho-educational content (5 Minutes)|The interventionist will discuss substance use and misuse and the influence of substance use on self care.
41029247|NCT03057119|BEHAVIORAL|Readiness Assessment (10 minutes)|The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
41367987|NCT02710825|OTHER|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
41367988|NCT00951587|DEVICE|PillCam™ (Capsule Endoscopy)|Medical Device
41367989|NCT00201682|DRUG|Etanercept|25 mg SQ twice weekly weeks 1-5
41367990|NCT00201682|DRUG|Rituximab|(375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
41367991|NCT04816942|BIOLOGICAL|Convalescent Plasma|Two units of ABO compatible COVID-19 convalescent plasma will be administered.
40846538|NCT02708420|DEVICE|Macintosh Laryngoscope|This technique involves a laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
40846539|NCT05989854|BEHAVIORAL|Exercise|8 week exercise intervention, 3x/wk
40846540|NCT00197925|BIOLOGICAL|Onco-peptide loaded autologous dendritic cells|
40846541|NCT03546088|DEVICE|fiberoptic naso-tracheal intubation|The trachea will be intubated under direct fiberoptic view after a fiberoptic upper airway examination. The flexible nasolaryngoscope will be armed with an intubating tube and passed inside tracheal lumen trough one of the nostrils.
40846542|NCT03546088|DRUG|Topical anaesthesia|Topical anaesthesia with lidocaine will be provided through nebulisation and instillation. The intubating tube will be lubricated with a gel containing lidocaine.
41029248|NCT03057119|BEHAVIORAL|Goal-Setting (5 minutes)|The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.
41029249|NCT03057119|BEHAVIORAL|Identifying and prioritizing needs (5 minutes)|The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
41367992|NCT04457310|DRUG|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
41367993|NCT04457310|DRUG|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
41367994|NCT04457310|DRUG|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
41367995|NCT04457310|DRUG|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
41367996|NCT04457310|OTHER|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
41367997|NCT02404792|OTHER|High-intensity cardiovascular and resistance exercise|
41367998|NCT02404792|OTHER|Moderate-intensity cardiovascular and resistance exercise|
41502233|NCT02976285|PROCEDURE|arthroscopic rotator cuff repair with a polyester patch|Patients were operated under general anesthesia and a supraclavicular nerve block, in a beach-chair position with 80° forward shoulder flexion and traction between 3-5 kg. After washing and draping a standard viewing portal was placed at the dorsal softspot. Further portals included, a lateral, a dorso-lateral, an antero-lateral and an anterior portal. If additional pathologies were present, they were treated simultaneously and mostly involved the long head of the biceps tendon, treated with tenodesis or tenotomy respectively. After a thorough bursectomy, the rupture was fully visualized and thereafter its size was estimated. Following debridement of the footprint, we used a triple row repair and implanted the patch.
41029250|NCT03057119|BEHAVIORAL|Explanation of Peer Navigator and Session wrap (5 minutes)|The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
41161870|NCT00917631|PROCEDURE|Co-bedding (caring for twins in the same incubator)|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
41161871|NCT03348969|DRUG|Mitomycin c|Neoadjuvant Mitomycin C
41161872|NCT04885764|BIOLOGICAL|Astrazeneca/Oxford Vaccine|Viral non replicated vector vaccine contains the gene that encodes for the spike protein on the surface of the SARS-CoV-2 virus given Intramuscular injection in 2 doses 3 months apart
41367999|NCT00020995|PROCEDURE|therapeutic dietary intervention|
41368000|NCT03665558|DEVICE|Temporary DDD pacing|Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
41368001|NCT03859908|DRUG|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
41368002|NCT03859908|DRUG|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
41368003|NCT05351749|BEHAVIORAL|New-prescription Alert|An enhanced drug alert notification in the Michigan Medicine electronic health record (EHR) that is tailored to the specific type of inappropriate Direct Oral Anticoagulant (DOAC) use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter a newly prescribed DOAC prescription.
41368004|NCT05351749|BEHAVIORAL|New-prescription Alert with referral option|An enhanced drug alert notification in the EHR that is tailored to the specific type of inappropriate DOAC use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter new DOAC prescription. This alert will ALSO include an option for referral to the anticoagulation clinic pharmacist for assistance.
41368005|NCT05351749|BEHAVIORAL|Existing-prescription notification to prescriber|Prescriber receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
41368006|NCT05351749|BEHAVIORAL|Existing-prescription notification to pharmacist|Pharmacist receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
41368007|NCT04976205|RADIATION|Total Marrow (Lymph-node) Irradiation|To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
41161873|NCT04885764|BIOLOGICAL|Sinopharm vaccine|Inactivated vaccine given intramuscular injection in 2 doses 3 weeks apart
41368008|NCT00148109|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
41368009|NCT00148109|DRUG|Cetuximab|Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
41368010|NCT06108531|OTHER||
41368011|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed fragment-specific system|Anatomical reduction, achieved by the open technique.
41368012|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed volar locking plate|Anatomical reduction, achieved by the open technique.
41502234|NCT03960840|BIOLOGICAL|Rapcabtagene autoleucel single agent|Single infusion of rapcabtagene autoleucel
41502235|NCT03960840|DRUG|Ibrutinib|Tablets or capsules for oral daily use
41029251|NCT02161718|DRUG|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
41029252|NCT02161718|DRUG|Placebo + olanzapine|Oral tablet, taken once daily
41029253|NCT04591834|OTHER|Observational|An observational study in subjects with the severe form of MPS II.
41029254|NCT04019847|DEVICE|STAK Tool|Medical stretching device
41368013|NCT05815758|DRUG|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
41368014|NCT05815758|DRUG|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
41368015|NCT05136612|OTHER|conventional physiothrapy|Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.
41502236|NCT02654119|DRUG|Cyclophosphamide|Given IV
41502237|NCT02654119|OTHER|Laboratory Biomarker Analysis|Correlative studies
41368016|NCT05136612|OTHER|robotic rehabilitation|The study group will be included in the rehabilitation program with the Hocoma brand Armeo Spring pediatric upper extremity robot for 30 minutes a day, 3 days a week, for 6 weeks at hospital. Armeo spring robot enables the individual to perform active movement by carrying the weight of the upper extremity of children who have active movement in their upper extremities but do not have enough strength to overcome gravity with their upper extremities. The individual is actively involved in the study during the study. With the adjustments made, it becomes suitable for use for right and left extremities. In the process of working; The games named High Flyer, Frisbee, Balloons, Goalkepper, Save the Monster, Fishing, Helicopter Rescue, which are included in the Armeo Spring robot and created to increase shoulder, elbow and wrist movements, will be used.
41368017|NCT02291952|BEHAVIORAL|Meal schedule|
41368018|NCT02617602|PROCEDURE|Goal directed therapy|"Based on transpulmonary thermodilution data, the following interventions will be implemented:~Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;~cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:~* decreased heart rate (HR): dobutamine, dopamine;~* normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine."
41368019|NCT02617602|OTHER|Control|
41368020|NCT02824042|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
41368021|NCT02824042|DRUG|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
41502238|NCT02654119|DRUG|Paclitaxel|Given IV
41502239|NCT02654119|BIOLOGICAL|Trastuzumab|Given IV
41502240|NCT06369233|DEVICE|MegaShield®-SP|MegaShield®-SP application Lumbar discectomy or laminectomy
41502241|NCT06369233|DEVICE|Guardix-SP Plus|Guardix-SP Plus application Lumbar discectomy or laminectomy
40846543|NCT03546088|DRUG|Light sedation|The patient will be sedated with a combination of midazolam, fentanyl administered intravenously in small boluses until the desired level of sedation is achieved as expressed of The Observer's Assessment of Alertness/Sedation Scale (OAA/S) of 4 or 5.
41368022|NCT05111652|OTHER|observational|observational electromiographic musculature activation
41368023|NCT02291068|BEHAVIORAL|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
41502242|NCT04660331|OTHER|Communication Intervention|Undergo communication strategy intervention
41502243|NCT04660331|OTHER|Communication Skills Training|Undergo communication training sessions
41502244|NCT04660331|BEHAVIORAL|Healthcare Activity|Participate in interview
41502245|NCT04660331|BEHAVIORAL|Healthcare Activity|Undergo environmental scan
41502246|NCT04660331|OTHER|Survey Administration|Complete survey
41502247|NCT05476952|PROCEDURE|"he patients who are administered rocuronium according to LBW were categorized as LBW, and The group number for those administer according to TBW was categorized as K."|Patients will be divided equally and validly by the one who will be placed in opaque sealed envelopes on a self-paid basis. One group will be given 0.6 mg/kg rocuronium on an LBW basis (Curon ® 50 mg/5 mL \[Mustafa Nevzat, Istanbul, Turkey\]), and the other group will be given 0.6 mg/kg rocuronium on a TBW basis.
41502248|NCT06632470|DRUG|Secretome injection|Patient will receive 3 ml of secretome intramuscular injection every two weeks for four months
41502249|NCT06632470|DRUG|Vitamin B12 Injection|Patient will receive 1 ampule of vitamin b 12 intramuscular injection as a placebo drug every two weeks for four months
40846544|NCT05954429|DRUG|serplulimab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10"
40846545|NCT05954429|DRUG|Fruquintinib|5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
40846546|NCT01647334|RADIATION|Adaptive radiotherapy|
40846547|NCT05767827|DRUG|ropivacaine, lidocaine with adrenaline|Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
40846548|NCT05767827|DRUG|Dexmedetomidine, ropivacaine, lidocaine with adrenaline|Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
41368024|NCT05119101|DRUG|Dexamedotomidine added to Magnesium sulfate|we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
41368025|NCT05119101|DRUG|Magnesium sulfate|we will give mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
41368026|NCT04508504|PROCEDURE|Preop PENG block|Ultrasound-guided injection of 20 mL 0.5% ropivacaine according to the method described by Giron-Arango L in 2018. A needle is inserted at the inguinal level under ultrasound guidance to pass beneath the psoas tendon on top of the iliopubic eminence where the local anesthetic is injected.
41502250|NCT04699188|DRUG|JDQ443|KRAS G12C inhibitor
41502251|NCT04699188|DRUG|TNO155|SHP2 inhibitor
41502252|NCT04699188|BIOLOGICAL|tislelizumab|Anti PD1 antibody
41502253|NCT00096837|DRUG|Motexafin Gadolinium Injection|
41502254|NCT00235404|OTHER|Multicomponent treatment|Specialized care in preparing recharge to home
41502255|NCT00235404|OTHER|usual care|Usual recharge directly from hospital to home
41502256|NCT00274118|DRUG|telmisartan|
41502257|NCT00274118|DRUG|enalapril|
41502258|NCT05725863|OTHER|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a structured group intervention developed by Segal et al. (2002). The intervention consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
41502259|NCT01692366|DRUG|SAR302503|"Pharmaceutical form:Capsule~Route of administration: oral"
40846549|NCT05532904|BEHAVIORAL|Personalized multidisciplinary day-hospital intervention|"This 6-week program of care will include:~* group education sessions including a psycho-education component (1 session / week)~* a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.~* if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).~* if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)"
40846550|NCT06582134|BEHAVIORAL|Sham BMBI|Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g., 1-2-3 and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
40846551|NCT06582134|BEHAVIORAL|BMBI|Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g. A-B-C and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
40846552|NCT03312426|DRUG|BMS-986205|Single dose, 100 mg administered at Day 1 and at Day 15.
40846553|NCT03527524|OTHER|exercise with ball|exercise with ball
40846554|NCT03527524|OTHER|exercise without ball|exercise without ball
40846555|NCT06583603|BEHAVIORAL|Barriers to Implementing Sensory Strategies Survey|Survey, see arm description
40846556|NCT06553872|DRUG|Pirtobrutinib|Pirtobrutinib is a non-covalent BTKi that has preserved activity in the presence of mutations that drive BTKi resistance.
41029255|NCT04019847|OTHER|Standard treatment|Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain AROM and function
41029256|NCT01246726|PROCEDURE|CT SCAN|Prior to radiotherapy + after radiotherapy completion
41029257|NCT01246726|PROCEDURE|MRI scan|Prior to radiotherapy + after completion of radiotherapy
41368027|NCT04508504|PROCEDURE|Placebo block|Ultrasound-guided placebo injection of 5 mL 0.9% normal saline. Using the same landmarks as for the PENG group, a needle is inserted in the inguinal region under ultrasound guidance, whereby a subcutaneous injection of 5 mL of 0.9% saline is made.
41368028|NCT04508504|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the preop PENG block
41029258|NCT01246726|PROCEDURE|3D Ultrasound scan|Prior to radiotherapy + after completion of radiotherapy
41502260|NCT06403280|DIETARY_SUPPLEMENT|Alcoholic drink|Participants will receive vodka with rum flavored orange juice with a target blood alcohol of 0.4 ‰ 30 minutes after alcohol consumption. The required amount of vodka will be calculated with the Widmark formula.
40846557|NCT06553872|DRUG|Brexucabtagene Autoleucel|Brexucabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (brexu-cel).
40846558|NCT05989958|COMBINATION_PRODUCT|HepaCure|HepaCure will be administered in extracorporal dialysis for single dose or multiple doses with different treatment duration on top of DPMAS.
40846559|NCT01277484|DRUG|Decitabine|"1. Dose finding study (cycle 1-cycle4)~* Indicated dose for 5 consecutive days every 28 days~* Cohort 1: 5mg/m2 of decitabine~* Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model"
40846560|NCT00002122|DRUG|Azithromycin|
40846561|NCT00002122|DRUG|Rifabutin|
40846562|NCT00002122|DRUG|Fluconazole|
40846563|NCT01408342|DRUG|Alemtuzumab and Rituximab|"* Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3~* Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25~* Cyclosporine 3 mg/kg starting day 21"
41029259|NCT03963895|DRUG|AB002 Dose 1|AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
41029260|NCT03963895|DRUG|AB002 Dose 2|AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
41029261|NCT03963895|DRUG|placebo|placebo administered on Day 1 as a single intravenous infusion
41029262|NCT03538626|BIOLOGICAL|VRC-HIVMAB091-00-AB|N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.
41029263|NCT03538626|BIOLOGICAL|rHuPH20|Recombinant human hyaluronidase PH20 (rHuPH20) is the active ingredient of the investigational ENHANZE™ Drug Product (EDP). EDP is a purified preparation of rHuPH20.
41029264|NCT06300021|DIETARY_SUPPLEMENT|TPG capsule|A dietary supplement product in capsule form containing 300 mg Turmipure Gold®
41029265|NCT06300021|DIETARY_SUPPLEMENT|TPG ready to drink|Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar
41029266|NCT06300021|DIETARY_SUPPLEMENT|TPG dairy analog|Ingredient stick containing 300 mg Turmipure Gold® mixed in 240 mL oat milk
41368029|NCT04508504|DRUG|Normal Saline|5 mL 0.9% Normal saline will be injected for the Placebo block
41368030|NCT04827420|BEHAVIORAL|Mi Quit Care|Demonstrating the feasibility, effectiveness, and cost-effectiveness of electronically delivered smoking cessation interventions via patient portals in Federally Qualified Health Care (FQHC) settings has the potential for wide-spread dissemination and significant public health impact. on patient populations with demonstrated high rates of smoking.
41029267|NCT06300021|DIETARY_SUPPLEMENT|TPG probiotic drink|Ingredient stick containing 300 mg Turmipure Gold® mixed in a 100 mL probiotic yogurt drink base
41029268|NCT06300021|DIETARY_SUPPLEMENT|TPG gummies|Pectin gummies containing 300 mg Turmipure Gold®
41029269|NCT06300021|DIETARY_SUPPLEMENT|TPG sport bar|Sport nutrition bar containing 300 mg Turmipure Gold®
41029270|NCT02289391|DRUG|Anesthesia induction|-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
41029271|NCT02289391|DRUG|Anesthesia maintenance|"* Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60."
41029272|NCT02289391|DRUG|Assisted anesthesia|Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
41029273|NCT01987713|BEHAVIORAL|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
41029274|NCT01202773|DRUG|LY2127399|Administered Subcutaneously (SC)
41029275|NCT01202773|DRUG|Placebo Q4W|Administered SC
41029276|NCT01202773|DRUG|Placebo Q2W|Administered SC
41029277|NCT01058200|DEVICE|iCup|new vacuum extractor: sterile disposable plastic cup
41368031|NCT05191199|DIAGNOSTIC_TEST|Penile Duplex Study|A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
41368032|NCT02976961|OTHER|Supportive care|Information, guidance, supportive care, and psychological intervention
41502261|NCT06403280|DIETARY_SUPPLEMENT|Placebo drink|Participants will receive a non-alcoholic rum flavored orange juice.
41502262|NCT01635816|BIOLOGICAL|JE Vaccine existing facility|Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
41502263|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
41368033|NCT05003206|OTHER|Functional magnetic resonance imaging|Preoperative and postoperative functional magnetic resonance imaging (fMRI) scanning. fMRI is a new neuroimaging method. Its principle is to use magnetic resonance imaging to measure the changes of hemodynamics caused by neuronal activity.
41368034|NCT05003206|DEVICE|Deep Brain Stimulation|For PD patients treated with DBS, the neurologist will turn off the stimulator before MRI scan
41368035|NCT00000131|PROCEDURE|Photocoagulation Therapy|
41368036|NCT05358821|DRUG|SAGE-718|SAGE-718 oral softgel lipid capsules
41368037|NCT05358821|DRUG|Placebo|SAGE-718-matching oral capsules
41368038|NCT01432470|DRUG|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
41368039|NCT01432470|DRUG|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
41502264|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
41029278|NCT01058200|DEVICE|reference cup|reference cup of the obstetrical ward: metallic cup
41368040|NCT04793126|DIAGNOSTIC_TEST|Urodynamic study|comparison between the urodynamic study of the patients before pelvic prolapse surgical repair and 6 months later.
41368041|NCT00928863|OTHER|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
41502265|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
41029279|NCT00084058|DRUG|Lopinavir/ritonavir|
41029280|NCT00084058|DRUG|Saquinavir|
41029281|NCT06101693|DIAGNOSTIC_TEST|Plasma biomarker levels|"This study will investigate the diagnostic utility and performance of:~1. Alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity, in whom~2. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity.~3. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L~4. The prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L).~The diagnosis of heart failure will be determined according to international guidelines, when there are symptoms and/or signs of HF in association with objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures. Non-invasive testing with rest and diastolic stress echocardiography will be used to evaluate for evidence of raised filling pressures, in order to make the study procedures applicable to usual clinical practice."
41029282|NCT03248284|PROCEDURE|Tendon biopsy procedure|Two tendon biopsy specimens will be obtained from one Achilles tendon with enthesitis.
41368042|NCT02675660|DIETARY_SUPPLEMENT|L-Homoarginine|125 mg L-homoarginine once daily
41368043|NCT02675660|DRUG|Placebo|placebo capsules once daily
41368044|NCT04952792|DRUG|Apixaban 2.5 milligram Oral Tablet|Apixaban 2.5mg/12h, oral, 28 days
41502266|NCT04974749|BIOLOGICAL|REPLAGAL|REPLAGAL IV infusion.
41502267|NCT03990597|OTHER|Placebo Administration|Applied topically
41502268|NCT03990597|OTHER|Questionnaire Administration|Ancillary studies
41502269|NCT03990597|DRUG|Wound Dressing Material|Applied StrataXRT topically
41502270|NCT03596645|DRUG|Golimumab|Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
41502271|NCT03596645|DRUG|Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
41368045|NCT06042465|OTHER|acupuncture and Tui-na manipulations|"i. Patients in supine position with knee elevated 20-30 degrees bending using a pillow below.~ii. Acupuncture needle using 0.25 mm diameter and 1.5-inch length. iii. Choose 'A shi point' to inject the acupuncture needles. iv. Inject 4 acupuncture needles respectively at the upper, lower, lateral and medial edge of the patella, along the medial and lateral edge at the posterior surface of patella.~v. Connect the needles with electro-therapy, selecting high frequency and strength that the patients have sensation and acceptable. Time duration is 30 minutes each time. Infra-radiation is provided and warm above the treatment region.~vi. Tui-na manipulations using the method of 'Tui-na'. Time duration is 2-5 minutes. Patella is pushed up and elevated during treatment.~vii. No external herbal medicine for TCM group , other medication such as painkiller is required to record"
41368046|NCT06042465|OTHER|Physiotherapy|"i. Total 12 sessions of physiotherapy for 8 weeks training; ii. Treatment: Closed kinetic chain exercises program will be used when appropriate, which include:~1. Mini walk squat exercise~2. Forward step up~3. Lateral step up~4. Terminal knee extension~5. Knee taping~6. Unstable base training~7. Pain control~8. Manual Therapy Each session will approximately cost each patient 1 hours' time. There is no Chinese medicine is allowed for PT group , other medication such as painkiller is required to record."
41368047|NCT02109965|DRUG|Dexmedetomidine|Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
41368048|NCT02109965|DRUG|Midazolam|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
41368049|NCT02109965|DRUG|Propofol|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
41502272|NCT04802174|DRUG|Lurbinectedin|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
41502273|NCT04802174|DRUG|Berzosertib|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
40846564|NCT02119390|BEHAVIORAL|Staff-delivered intervention sessions|In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.
40846565|NCT02119390|OTHER|Demographic Questionnaire|Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
41368050|NCT03750058|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
41368051|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- crioablation|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the cryoablation technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated using a cryoablation balloon. Cryoablation procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
41368052|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- pulsed field ablation (PFA)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the pulsed field ablation (PFA) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a PFA electrode. PFA procedures are performed under general anesthesia. The procedure is performed using X-ray fluoroscopy.
41368053|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- radiofrequency ablation (RF)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the radiofrequency ablation (RF) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a RF electrode. RF procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
41368054|NCT05677516|PROCEDURE|Electrophysiological study (EPS)|"In the electrophysiological study (EPS), electrophysiological parameters such as the recovery time of sinus rhythm (SNRT), Wenckebach's point, AH and HV intervals are measured. The examination begins with venous access through the femoral vein. Then, diagnostic electrodes are inserted into the right atrium, right ventricle and coronary sinus, with which electrophysiological tests are performed. The SNRT is measured after 60 seconds of atrial pacing with a 600ms cycle. The Wencjabach point is determined by stimulation in the incremental protocol. AV and HV intervals are measured during sinus rhythm using an electrode placed on the bundle of His. EPS is performed under local anesthesia. EPS will be performed both before and after pulmonary vein isolation. In patients with atrial fibrillation, during ablation, only the HV interval will be measured.~The procedure is performed using X-ray fluoroscopy."
40846566|NCT02119390|OTHER|Questionnaires|Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
40846567|NCT06306118|DEVICE|Multiple stereotactic Tumor Biopsies during a Brain Tumor Resection|For pre-resection biopsy cases (3 target per patient), the targets will be selected from metabolite hotspots on MR-spectroscopy imaging and/or amino acid tracer uptake hotspots on PET imaging. Depending on the tumor location and surgical procedure, all biopsies will be performed via one single or multiple entry points.
41029283|NCT00005854|DRUG|cyclophosphamide|
41502274|NCT06632483|DRUG|Vericiguat (Verquvo, BAY1021189)|Prescibed as per local label
41502275|NCT05289947|OTHER|Placebo|Caramel, chocolate brown, flavor (E_1982648), dextrin
41502276|NCT05289947|DRUG|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
41029284|NCT00005854|DRUG|cyclosporine|
41029285|NCT00005854|DRUG|methotrexate|
41029286|NCT00005854|PROCEDURE|allogeneic bone marrow transplantation|
41368055|NCT05677516|DIAGNOSTIC_TEST|Holter EKG|Holter ECG is a 24-hour, non-invasive ECG recording using a portable recorder and electrodes placed on the patient's chest. The Holter ECG will be performed three times: on the day preceding and on the first day after pulmonary veins isolation, and after 3 months of observation.
41368056|NCT05677516|OTHER|Questionnaire|The survey will be conducted after 3 months of observation and will include questions about the number of hospitalizations due to atrial fibrillation, heart palpitations, changes in pharmacotherapy.
41368057|NCT05714501|DEVICE|Millipede System|Mechanical thrombectomy
41368058|NCT03487159|DEVICE|MRE (Magnetic Resonance Elastography)|The device is using to evaluate liver fibrosis stage
41368059|NCT02129439|DRUG|SB012|"The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation."
41029287|NCT00005854|PROCEDURE|in vitro-treated bone marrow transplantation|
41029288|NCT00005854|RADIATION|radiation therapy|
41029289|NCT06302543|PROCEDURE|autologous bone marrow cells injection|under general anesthesia bone marrow aspiration done followed by cell concentration and transvaginal ovarian injection
41029290|NCT04554862|DRUG|Magnesium sulfate|magnesium sulfate will be added to the block
41029291|NCT04554862|DRUG|Ketorolac Tromethamine|ketorolac will be added to the block
41368060|NCT02129439|DRUG|Placebo|"Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required."
41368061|NCT01319539|DRUG|Akt Inhibitor MK2206|Given PO
41368062|NCT01319539|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41029292|NCT04554862|PROCEDURE|supraclavicular block|it is done by ultrasound- guided
41029293|NCT05890183|BEHAVIORAL|Cognitive training|This systematic cognitive training program will be delivered by telehealth sessions in which each patient logs into their Posit Science account and joins a Zoom videoconference with 4-8 other patients and two cognitive coaches. The first 12 weeks focus on neurocognitive training and the second 12 weeks focus on social cognitive training. Patients have two CT sessions on each of two days each week to complete 4 hours/week of computerized cognitive training for the first 6 months. Thus, each patient will receive 48 hours of neurocognitive training and 48 hours of social cognitive training in the first 6 months. In the second 6 months, the number of hours per week is trimmed to half the dosage.
41029294|NCT05890183|BEHAVIORAL|Aerobic Exercise Program|The Aerobic Exercise Program group sessions will be conducted by Zoom videoconferencing. The group exercise training sessions are a combination of moderate intensity aerobic conditioning (1-min intervals) and moderate to high intensity strength and callisthenic conditioning (1-min intervals). The exercise dosage goal is 150 minutes/week of moderate aerobic activity, over 4 days, including for the first 6 months two group sessions (45 min duration) and two individual sessions personalized to the patient's choice of exercise (30 min duration) in the target heart rate zone. After the first 6 months, the group exercise sessions are once a week but the goal remains 150 minutes/week of moderate exercise.
41029295|NCT05890183|BEHAVIORAL|Moderated Online Social Therapy (MOST)|MOST combines: (1) evidence-based, interactive, user-directed web-based interventions; (2) secure and supportive peer-to-peer web-based social networking; (3) moderator support; and (4) on-demand web chat with registered clinicians. A Motivation Track on the MOST platform will be used to encourage intrinsic motivation for self-improvement for both groups and, for the CT\&E group, involvement in our exercise program.
41368063|NCT01319539|OTHER|Pharmacological Study|Correlative studies
41368064|NCT01319539|OTHER|Laboratory Biomarker Analysis|Correlative studies
41368065|NCT00777920|DRUG|Ambrisentan|Tablet administered orally once daily
41502277|NCT01336452|RADIATION|DCE MRI|DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
41368066|NCT03754270|OTHER|Advice in lifestyle|Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive instructions and advice on lifestyle according to current clinical practice. Life style advice is quite subjective and it means that the patients are encouraged to stop smoking, to avoid alcohol, to lose weight, to be more physically active and to avoid sleeping on supine position.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.
41161874|NCT05287698|OTHER|Cold vapor|Before surgery, socio-demographic data of the patients, ASA and Mallampati scores, sore throat level, and dysphagia level will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
41161875|NCT04854278|OTHER|Massive Open Online Course (MOOC)|Combination of knowledge training with video scenarios and game-based learning provided to endovascular team members: surgeons, nurses and anesthetists
41368067|NCT03754270|DEVICE|Cervical collar|"Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it. CC is marketed for indications of various diseases such as traumatic cervical injury, cervical disc herniation and other neck problems and allows adjustment of the elevation level to achieve sufficient effect, i.e., extending the neck.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed."
41368068|NCT01973920|DRUG|Oshadi Icp|
41368069|NCT00563927|PROCEDURE|Conventional RT|
41368070|NCT00563927|DRUG|Cisplatin|
41368071|NCT00563927|DRUG|5-fluorouracil|
41368072|NCT01362231|DRUG|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
41368073|NCT00042575|DRUG|Duloxetine|
41368074|NCT02593331|DRUG|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
41368075|NCT02593331|OTHER|Placebo|Participants will receive a single dose of placebo on Day 1.
41502278|NCT05523154|PROCEDURE|Biospecimen Collection|Undergo collection of bile samples
41502279|NCT05523154|OTHER|Laboratory Procedure|Undergo routine laboratory testing
41368076|NCT00579059|DEVICE|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
41368077|NCT00579059|DEVICE|Regular Maxim® Knee System|Used for total knee replacements
41368078|NCT05275166|BEHAVIORAL|Induction of alcohol craving|Presentation of images that may induce craving for alcohol. Recording of brain activity
41368079|NCT05275166|OTHER|Questionnaires|Questionnaires related to alcohol, quality of life, anxiety and depression
41368080|NCT05896709|OTHER|MK-RS|The embryos are assessed by the AI-enhanced MK analysis together with RS analysis.
41368081|NCT04792216|OTHER|Wild Salmon|Wild salmon fillets
41368082|NCT04792216|OTHER|Farmed Salmon|Farm salmon fillets
41368083|NCT02028052|PROCEDURE|ROSE|The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
41368084|NCT02028052|DEVICE|22 gauge Vizishot needles|
41368085|NCT04718363|OTHER|PNF stretching|A contract-relax PNF stretching technique will be applied to hamstring muscle.
41368086|NCT04718363|OTHER|Non-vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring non-vibration foam rolling.
41502280|NCT05523154|DEVICE|Nanopore Sequencing|Undergo nanopore sequencing
41502281|NCT05043441|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 10 weeks through Zoom videoconferencing with psychoeducation materials provided.
41502282|NCT05043441|BEHAVIORAL|Psychoeducation|The psychoeducation control group will receive care as usual with psychoeducation materials provided.
41502283|NCT00024284|DRUG|carboplatin|
41502284|NCT00024284|DRUG|irinotecan hydrochloride|
41368087|NCT04718363|OTHER|Vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring vibration foam rolling (48 Hz).
41368088|NCT01052558|DEVICE|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
41502285|NCT02941757|BEHAVIORAL|Mediterranean diet Intervention|"1. Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.~2. Peer-education and support~3. Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.~4. Email or text message encouragement and reminders during the intervention."
41502286|NCT03145181|DRUG|Teclistamab (IV)|Participants will receive IV infusion of Teclistamab.
41029296|NCT05890183|BEHAVIORAL|Chorus Participatory Text Messaging Program|The Chorus text messaging program is a web-based application that allows clinicians to create a broad range of automated SMS text messages and interactive voice responses using a simple, accessible graphical user interface. It will target encouragement to exercise and social feedback on completed exercise in the CT\&E group.
41029297|NCT05890183|BEHAVIORAL|Healthy Living Group (HLG)|The Healthy Living Group (HLG) meets two sessions/week to discuss wellness, nutrition, insight, recovery, independent living, social skills, and hobbies for the first 6 months and then one session/week for the next 6 months.
41029298|NCT00138931|PROCEDURE|Blood draw (genetic testing)|Blood draw (genetic testing)
41029299|NCT00359112|DRUG|metformin|
41161876|NCT03275441|DIAGNOSTIC_TEST|Electroretinography|An additional electroretinogram performed after 10 minutes of dark adaptation.
41161877|NCT02810483|DRUG|Topiramate|"Increase phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
41161878|NCT02810483|DRUG|Placebo Comparator|"ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
41161879|NCT05000411|DRUG|Compound Danshen Dropping Pills (CDDP)|The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.
41161880|NCT05000411|DRUG|Placebo|The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .
41161881|NCT01689285|DRUG|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
41161882|NCT01689285|DRUG|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
41161883|NCT02917083|GENETIC|CAR T Cells|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:~Dose Level One: 2x10\^7 cells/m2. Dose Level Two: 1x10\^8 cells/m2. Dose Level Three: 2x10\^8 cells/m2."
41502287|NCT03145181|DRUG|Teclistamab(SC)|Participants will receive SC injection of Teclistamab.
41029300|NCT00359112|DRUG|sulphonylurea|
41161884|NCT05582590|DRUG|Fludarabine|Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY
41029301|NCT00359112|DRUG|Avandamet|
41029302|NCT00178490|DRUG|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
41368089|NCT01052558|PROCEDURE|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
41502288|NCT01878461|DRUG|Vehicle|
41502289|NCT01878461|DRUG|M518101|
41502290|NCT06292533|DEVICE|Er:YAG laser|Ultrapulse is a is a laser beauty device using erbium-doped yttrium aluminium garnet laser (er:YAG). Er:YAG laser is a laser with wavelength of 2940nm which is able to penetrate into the dermis to a depth of 3-4 mm, and energy absorption occurs in the area of the dermal papilla, resulting in an increase in blood circulation of the papilla and activation of metabolism in the hair follicle.
41029303|NCT06442371|OTHER|High Intensity interval training + Quranic Listening|In this group, participants will receive protocol of High Intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down session along with Quranic listening meditation.
41029304|NCT06442371|OTHER|High intensity interval training|In this group, participants will receive only High intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down periods with no Quranic listening meditation
41161885|NCT05582590|DRUG|Cyclophosphamide|Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY
41161886|NCT05582590|BIOLOGICAL|NEXI-003 T cells|Adoptive Cell Therapy specified dose on specified day(s)
41161887|NCT05526456|PROCEDURE|Esophagectomy|McKeown, Ivor-Lewis, and Sweet procedure
41161888|NCT05892822|OTHER|Amyotrophic Lateral Sclerosis|All ALS patients included in this group.
41161889|NCT03322514|DIETARY_SUPPLEMENT|Inulin-Propionate Esters|Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.
41161890|NCT03322514|DIETARY_SUPPLEMENT|Inulin|Inulin
41161891|NCT05017688|PROCEDURE|Blood and stool sample collection|Collection of blood samples (55 mL) Collection of fecal samples (10g)
41161892|NCT01929564|OTHER|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
41161893|NCT01929564|OTHER|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
41368090|NCT03520361|DRUG|Oral sulfate solution (OSS)|Compositions/177ml : Sodium sulfate 17.5g, Potassium sulfate 3.13g, Magnesium sulfate 1.6g
41368091|NCT03520361|DRUG|2L PEG/Asc|Compositions/1L : Sodium chloride 2.89g, Potassium chloride 1.015g, Anhydrous sodium sulfate 7.5g, Polyethylene glycol 3350 100g, Ascorbic acid 4.7g, Sodium ascorbate 5.9g
41502291|NCT06210919|BIOLOGICAL|TRTP-101|Intradermal injection of the each of four sites
41502292|NCT06634368|BEHAVIORAL|Hospital GamePlan4Care|The Hospital GamePlan4Care intervention will include access to a written VA Care Transitions handbook, access to the GamePlan4Care website for skills training, 11 emails encouraging them to visit the website, and four phone calls with a dementia care specialist to tailor the training to the caregiver's needs over a 3-month period.
41502293|NCT06634368|OTHER|Health Education|Caregivers in the health education arm will receive a VA Care Transitions Handbook, 4 emails with a weblink to a general caregiving topic, and 4 phone calls to confirm that the emails were received over a 3-month period.
41502294|NCT06575595|BIOLOGICAL|Tulisokibart|single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C)
41029305|NCT06461858|OTHER|cuevas medek technique (exercise)|The first group, known as the experimental group, group A, receives Cuevas Medek exercises once a week, for 45 minutes per session,for 6 weeks
41368092|NCT03950947|DEVICE|Amplatzer vascular plug|See above
41029306|NCT06461858|OTHER|conventional therapy|Group B, referred to as the conventional therapy group (Routine physical therapy), follows a regimen of conventional therapy once a week for 6 weeks for 20 mints.
41029307|NCT04846504|BEHAVIORAL|MMBFM program with clinician coach support|Clinician-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed.
41029308|NCT04846504|BEHAVIORAL|MMBFM program with peer coach support|Peer-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed. Peers will be women with lived experience of perinatal depression who are trained on the coaching protocol.
41029309|NCT04846504|BEHAVIORAL|Patient facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
41029310|NCT04846504|BEHAVIORAL|Patient facing plus clinic facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams, plus recommendation of / referral to the Mindful Mood Balance for Moms study by OB clinicians at the 4 study sites. OB clinicians will choose from printed materials (e.g., flyers, posters in exam rooms and waiting rooms, prescription pads) and electronic medical record prompts (e.g., smart lists, dot phrases) to facilitate engagement in the Mindful Mood Balance for Moms course. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
41029311|NCT01053026|DRUG|olmesartan|(1) Olmesartan treatment or (2) Life modification and exercise training
41029312|NCT02647658|BEHAVIORAL|Guideline Based Care plus Psychologically Informed Physical Therapy|PCP care is enhanced with a prompt referral to physical therapy (PT) that includes psychologically informed coaching directed towards education and reduced fear of movement
41029313|NCT02647658|BEHAVIORAL|Guideline Based Care (GBC)|Management decisions are made between PCPs and patients with the guidance of best evidence but with no specific directives
41029314|NCT02654080|BIOLOGICAL|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
41029315|NCT02654080|BIOLOGICAL|rVSV HIV envC vaccine|1 × 10\^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
41029316|NCT02654080|BIOLOGICAL|Placebo|"Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)."
41029317|NCT05975190|OTHER|Respiratory training and relaxation techniques under adjuvant radiation therapy in DIBH in breast cancer|R\&R training provided on an MP3-player for daily practice
41029318|NCT03746860|DRUG|Tablet, Dispersible|1 tablet/day with 12 SQ-HDM per lyo-tablet
41029319|NCT01925183|DRUG|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
41368093|NCT03950947|OTHER|Sham Controll|Angiography of the RIMA without occlusion
41368094|NCT03677609|BEHAVIORAL|Mindset & Communication Training|The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
41368095|NCT02007824|DEVICE|ULSD-12D|wound cleansing and debridement using ULSD-12D
41029320|NCT01925183|DRUG|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients \<75kg; orally
41029321|NCT01925183|DRUG|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
41029322|NCT04482751|DRUG|Corifollitropin alfa|AMH will be measured during ovarian stimulation with corifollitropin alfa
41029323|NCT03043183|PROCEDURE|perioperational nutrition surpport|Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
41368096|NCT02007824|DEVICE|SONOCA-180|wound cleansing and debridement using SONOCA-180
41368097|NCT03780673|DRUG|Simvastatin|Simvastatin 20 mg/day for 12 months
41368098|NCT03780673|DRUG|Rifaximin|Rifaximin 400/8 hours for 12 months
41029324|NCT00349089|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
41029325|NCT00349089|DRUG|Cisplatin|"Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
41502295|NCT02097680|DRUG|Letrozole|One Letrozole 2.5 mg capsule every two days during four months
41502296|NCT02097680|DRUG|Placebo|One placebo capsule every two days during four months
41502297|NCT01793948|DRUG|metformin hydrochloride|Given PO
41502298|NCT01793948|OTHER|placebo|Given PO
41029326|NCT00349089|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
41029327|NCT03867877|OTHER|Periodized training with motor practice|Exercises at 75-80% of the subject's maximum for strength exercise using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
41029328|NCT03867877|OTHER|Simple Periodized Training|Exercises at 75-80% of the subject's maximum for strength using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and for hypertrophy day at 60-75% of subjects' maximum strength. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes exercise using contractions warm-up, 50 minutes of training and five minutes of cool-down.
41029329|NCT00438386|DRUG|Aripiprazole|
41029330|NCT05956652|DEVICE|Hydra Transcatheter Aortic Valve System|The Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
41161894|NCT00155376|DRUG|morphine and glucagon|
41368099|NCT03780673|DRUG|Placebo of Simvastatin|Placebo of Simvastatin once a day for 12 months
41368100|NCT03780673|DRUG|Placebo of Rifaximin|Placebo of Rifaximin/8 hours for 12 months
41502299|NCT01793948|OTHER|laboratory biomarker analysis|Correlative studies
41502300|NCT06175988|OTHER|Visceral adiposity|Visceral adiposity assess by the visceral adiposity index
41502301|NCT01941082|DRUG|RO6867461|Single or multiple ascending dose by intravitreal injection
41502302|NCT05260580|OTHER|No Intervention: Routine care|
41502303|NCT03972735|OTHER|Psychiatric interview|PANSS, MADRS, PSP, YMRS
41502304|NCT03972735|OTHER|Clinical, diagnostic and functional evaluation|ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS
41502305|NCT03972735|OTHER|neuropsychological assessment|WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS
41502306|NCT03972735|OTHER|NECT PROGRAM|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.
41502307|NCT05852561|OTHER|Group Superficial+Deep Serratus Anterior Plan Block|The block will be performed after induction of general anesthesia and surgical positioning. 15 ml of 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and latissimus dorsalis muscles. The same concentration of block fluid will be applied between the serratus anterior and the outer intercostal muscle.
41502308|NCT05852561|OTHER|Group Deep Serratus Anterior Plan Block|30 ml 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and outer intercostal muscle.
41502309|NCT05921552|BEHAVIORAL|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo surgery. Exercises will be performed using resistance tubes (Bodylastics Inc) and the included accessories (handles and anchor straps) to perform resistance exercises. During Zoom sessions, certified exercise trainers will guide participants to utilize equipment to perform resistance exercises with proper form. Each groups resistance training session will span approximately 1 hour, including a brief warm-up, stretching, and 2 sets of ≥12 repetitions for each of 5 exercises: single arm chest press, single arm row, lateral raise, squat (or chair stand), and resistance tube deadlift.
41368101|NCT03651375|DRUG|Sequential chemotherapy - 3 courses of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
41368102|NCT03651375|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
41368103|NCT00876291|DIETARY_SUPPLEMENT|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
41502310|NCT05921552|BEHAVIORAL|Aerobic Training|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
41502311|NCT00292058|DEVICE|Videoconference equipment (telepsychiatry)|
41502312|NCT00154869|DRUG|Peginterferon Alfa-2a plus Ribavirin|
41502313|NCT00842205|DRUG|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
41502314|NCT00842205|DRUG|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
41502315|NCT05438043|DRUG|Daratumumab|Daratumumab will be administered either intravenously or subcutaneously.
41502316|NCT05438043|DRUG|Carfilzomib|Carfilzomib will be administered intravenously.
41502317|NCT05438043|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
41368104|NCT00876291|DIETARY_SUPPLEMENT|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
41368105|NCT00920582|BIOLOGICAL|Teplizumab Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
41502318|NCT05438043|DRUG|Lenalidomide|Lenalidomide will be administered orally.
41368106|NCT00920582|DRUG|Placebo|IV dosing daily for 14 days repeated at Week 26
41368107|NCT00920582|BIOLOGICAL|Teplizumab 33.3% Herold Regimen|One third full dose of teplizumab IV for 14 days, repeated at Week 26
41368108|NCT00920582|BIOLOGICAL|Teplizumab Curtailed Herold Regimen|Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
41368109|NCT03710824|DRUG|Nintedanib|diagnosed IPF patients initiating treatment with nintedanib
41368110|NCT00288431|DRUG|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
41368111|NCT00288431|DRUG|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
41368112|NCT05453552|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
41368113|NCT05453552|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
41368114|NCT05453552|DRUG|Busulfan|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
41368115|NCT05453552|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
41368116|NCT05453552|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
41368117|NCT05453552|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
41368118|NCT05557201|BIOLOGICAL|Lymphocyte immunophenotyping|If the patient accepts the ancillary study, a blood sample will be taken (1 EDTA tube of 3 ml and 2 lithium heparin tubes of 10 mL each) for lymphocyte immunophenotyping in flow cytometry on fresh blood and for the constitution of the biological collection (plasma/mononuclear cells).
41368119|NCT03722641|OTHER|Bread reference|Commercially available white wheat bread
41368120|NCT03722641|OTHER|Product 1: Milk|Developed reference product based on milk
41368121|NCT03722641|OTHER|Product 2: Full fat milk + oat|Developed product based on full fat milk with addition of oat
41368122|NCT03722641|OTHER|Product 3: Skim milk + oat, high fibre|Developed product based on skim milk with addition of oat giving a high fiber content to the product
41502319|NCT05438043|DRUG|Pomalidomide|Pomalidomide will be administered orally.
41502320|NCT06582849|OTHER|Standard assistance|Standard assistance includes all community and institutional resources currently available for which the participant qualifies.
41368123|NCT03722641|OTHER|Product 4: Skim milk + oat, low fibre|Developed product based on skim milk with addition of oat giving a lower fiber content to the product
41368124|NCT04442932|DEVICE|Blood Collection|K3-EDTA venous whole blood 9 mL 1 venous draw
41368125|NCT03026426|BEHAVIORAL|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.~Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists."
41368126|NCT01704482|DRUG|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
41368127|NCT01704482|DRUG|placebo|
41368128|NCT03080675|DIETARY_SUPPLEMENT|Nutrional blend of ingredients including vitamins and fish oil|
41368129|NCT03080675|DIETARY_SUPPLEMENT|Control|
41368130|NCT04766528|OTHER|3 maximal aerobic tests|Maximal aerobic tests will be performed before diet intervention, after the first diet and after the second diet
41368131|NCT04446273|DEVICE|Bi-Manu-Track|The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.
41368132|NCT04136041|DEVICE|Smartphone Application|The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
41368133|NCT01074320|OTHER|Other|Observational study
41368134|NCT03993314|DRUG|Chloroprocaine|Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
41368135|NCT03993314|DRUG|Bupivacaine|1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
41368136|NCT03935074|DRUG|intra-arterial administration of melphalan|
41368137|NCT04331431|PROCEDURE|Spinal cord tumor resection|Excision of intradural tumors
41368138|NCT00528125|PROCEDURE|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
41368139|NCT00528125|PROCEDURE|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
41502321|NCT06582849|OTHER|Enhanced assistance|Enhanced assistance includes gift cards and checks to support food, housing, utilities, transportation, pharmacy, and other non-medical costs
41502322|NCT03583086|DRUG|Vorolanib|Given by mouth
41502323|NCT03583086|BIOLOGICAL|Nivolumab|Given by IV
41502324|NCT05786664|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41502325|NCT05786664|OTHER|Electronic Health Record Review|Review of records
41502326|NCT05786664|OTHER|Quality-of-Life Assessment|Complete quality-of-life questionnaires
40846568|NCT02561221|BEHAVIORAL|Lifestyle Counseling|"Trained health coaches delivered the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
41368140|NCT03024294|OTHER|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
41502327|NCT05786664|OTHER|Survey Administration|Complete surveys
41502328|NCT01666392|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
41502329|NCT01666392|DIETARY_SUPPLEMENT|Placebo|Placebo
41502330|NCT05681351|DRUG|Olezarsen|Administered as SC injection.
41502331|NCT04616430|DRUG|Topical endoxifen|topical solution
40846569|NCT05446571|DRUG|Letermovir|Maternal daily administration of 240 milligrams of letermovir (1x240 mg-tablets) up-until delivery or TOP Placebo of Valaciclovir ; daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP
40846570|NCT05446571|DRUG|Valacyclovir|Maternal daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP Placebo of letermovir : (1x240 mg-tablets) up-until delivery or TOP
41029331|NCT03699982|OTHER|Daily calorie target based on resting energy expenditure|"Resting Energy Expenditure will be determined using the Harris-Benedict formula and indirect calorimetry testing. Additionally, a 48 Hour Dietary Recall will be completed to estimate approximate caloric intake at baseline.~Participants will be instructed to increase their daily calorie intake based on the highest REE/caloric intake, whether by indirect calorimetry, the Harris-Benedict formula, or patient's estimated current caloric intake."
41029332|NCT02983734|DRUG|D-cycloserine|Partial agonist of N-methyl-D-aspartate (NMDA) receptor
41029333|NCT02983734|DRUG|Placebos|Sugar pill
41029334|NCT06303765|OTHER|Practice Resource for Driving After Stroke (PReDAS)|"1. Provision of written copy of PReDAS for occupational therapist to review~2. 1:1 online training session to use the PReDAS (1 hour in length)"
41029335|NCT03387852|DRUG|SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
41368141|NCT06248762|OTHER|Adappt|An app to support parents of children with a NDD
41368142|NCT03313297|DRUG|AZD4017|AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (\> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
41029336|NCT03387852|DRUG|Dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
41029337|NCT03387852|DRUG|Fluticasone or Fluticasone/salmeterol combination|Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
41502332|NCT04616430|DRUG|Placebo|topical
41502333|NCT00516152|DRUG|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|"Day Preparative Regimen for GVHD Prophylaxis~* 7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 3 Fludarabine 30 mg/m(2)IV~* 2 REST Tacrolimus 0.01 mg/kg CIVI~* 1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~  * 1 Methotrexate 5mg/m(2)IV~ * 3 Methotrexate 5mg/m(2)IV~ * 6 Methotrexate 5mg/m(2)IV~ * 7 G-CSF 5mcg/kg SQ daily~ * 11 Methotrexate 5mg/m(2)IV~ * 90 Evaluate Response"
40846571|NCT00145132|PROCEDURE|β-CIT-SPECT, Neurophysiology|β-CIT-SPECT scans and EEG recordings, two assessments each
40846572|NCT01794676|GENETIC|Blood draw|Blood draw
40846573|NCT05024708|OTHER|Cardiac exercises and tests|Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)
41502334|NCT04170465|DRUG|Metformin Hydrochloride 850 mg Tablets|Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles
41502335|NCT04170465|DRUG|AC-T chemotherapy regimen|AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
41029338|NCT03387852|DRUG|Placebo for SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
41029339|NCT03387852|DRUG|Placebo for dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
41029340|NCT02415400|DRUG|Apixaban|
41029341|NCT02415400|DRUG|vitamin K antagonist|
41029342|NCT02415400|DRUG|Acetylsalicylic acid|
41368143|NCT03313297|DRUG|Placebo|Matching placebo
41368144|NCT05273515|OTHER|Virtual Reality and 3D Reconstruction|Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
41368145|NCT02303470|BEHAVIORAL|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
41368146|NCT02303470|BEHAVIORAL|Moderate Exercise|
41368147|NCT05665257|DEVICE|Inspiratory muscle training|
41368148|NCT05665257|DEVICE|Mini-PEP|
41368149|NCT04449016|OTHER|High intensity interval training|Repeated, brief, and intense exercise bouts separated by active recovery
41368150|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
41368151|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
41368152|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
41368153|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
41368154|NCT00984386|DRUG|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
41368155|NCT05467995|BIOLOGICAL|AK111|AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
41368156|NCT05467995|BIOLOGICAL|Placebo|Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
41502336|NCT06551441|BEHAVIORAL|High Intensity Interval Training (HIIT)|"The HIIT intervention consist of 4 intervals with each lasting 4 minutes (4x4min). If a participant reports discomfort related to the length of the intervals or start to feel unmotivated by performing the same exercise, we will use another HIIT protocol: 10x1min.~The 4x4min HIIT consists of a warm-up period of 10 minutes with a target heart rate at 60-70% of HRmax, followed by 4 HIIT intervals with a target HR ≥85%. The intervals are separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following this, a cool down period of three minutes at warm up intensity is performed.~The 10x1min HIIT consists of a 10-minute warm-up period.The warm-up is followed by 10 intervals, each lasting 1 min at 100% of maximal workload, separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following the intervals, a cool down period of three minutes at warm up intensity is performed."
41502337|NCT05690490|PROCEDURE|Endoscopic mucosal resection with circumferential incision|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion with an offset of 2-5 mm. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
41502338|NCT05690490|PROCEDURE|Endoscopic submucosal dissection|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision is made around the lesion. Then dissection will be performed in the submucosal layer.
41368157|NCT02735382|BEHAVIORAL|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
41368158|NCT02735382|BEHAVIORAL|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
41368159|NCT03853434|PROCEDURE|Embolization|Angiographic embolization
41368160|NCT04529031|BEHAVIORAL|Reminder Focused Positive Psychiatry|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
41368161|NCT04529031|BEHAVIORAL|attentional control condition (group process)|This group process will undergo telehealth relaxation therapy twice a week for 6-week. Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy
41368162|NCT04596046|PROCEDURE|steroid injecting|Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
41368163|NCT05607342|DRUG|Osanetant|To evaluate the effect of Osanetant on the testosterone levels.
41368164|NCT03049592|OTHER|HIBISCUS counseling|Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
41368165|NCT02221804|BEHAVIORAL|14 days of voluntary step count reduction to no more than 1500 steps/day.|
41368166|NCT03772210|DEVICE|tDCS|Current will be administered to subject groups as specified in arm descriptions.
41368167|NCT03772210|OTHER|Sham|Apparent Stimulation administered
41368168|NCT04056234|PROCEDURE|Joint puncture|Patient requiring joint puncture for diagnostic or therapeutic reasons.
41368169|NCT02270385|BEHAVIORAL|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
41368170|NCT02270385|BEHAVIORAL|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
41368171|NCT04008290|DRUG|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
41368172|NCT04008290|DRUG|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
40846574|NCT04773834|OTHER|Digital diabetes prevention program (dDPP)|The digital diabetes prevention program is through the Noom app, and the three devices (Fitbit physical activity tracker, Fitbit weight scale, and self-check hemoglobin a1c kit). This is a one year diabetes prevention program where participants will be expected to participate in 5 to 7 interviews over a 18 month period.
40846575|NCT04773834|OTHER|Adapted dDPP-EHR tool|This is a product of Phase 1 and 2 of this study where participants will receive detailed text messaging regarding their engagement levels in Noom app.
40846576|NCT06584084|DEVICE|WPM-SEMG prototype|Measurements will be done with the rigid matrix. The flexible electrode matrix will be used only on a lower percentage of volunteers depending on the results obtained with the rigid matrix
41368173|NCT02731924|PROCEDURE|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
41368174|NCT01616992|DRUG|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
40846577|NCT05889078|BEHAVIORAL|A 4-week walking intervention|Participants will walk along a predetermined route 3 times per week for a period of 4 weeks, answering a pre- and post-intervention questionnaire as well as weekly questionnaires measuring their affect and other variables related to wellbeing. Participants will be randomly assigned to one of two conditions (nature vs urban setting), determining whether the predetermined route they will walk is in a nature or urban setting.
40846578|NCT01960153|DRUG|Tadalafil|Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
41368175|NCT05180734|BIOLOGICAL|JS001/Placebo|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
41368176|NCT05180734|BIOLOGICAL|JS001/placebo combine with Postoperative Adjuvant Chemotherapy|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
41368177|NCT05390294|PROCEDURE|Surgical intervention with or without postoperative adjuvant therapy|Surgical intervention with or without postoperative adjuvant therapy
41368178|NCT05727696|PROCEDURE|Henry approach; volar approach|Radial Shortening : Supine position, general anesthesia, volar approach, Henry approach, osteotomy 1 inch from radio-carpal joint surface, shortening 2.5 mm of distal shaft radius, fixation by small DCP or small T plate.
41368179|NCT05727696|PROCEDURE|dorsal approach|Capitate Shortening : Supine position, general anesthesia, dorsal approach, separation between 2nd and 3rd compartments of extensor tendons, osteotomy \& shortening 2.5 mm of capitate, compression by Herpert screw.
40846579|NCT01960153|DRUG|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
41029343|NCT02415400|OTHER|Acetylsalicylic acid placebo|
41368180|NCT06219499|DRUG|ONC-841|ONC-841 is a humanized monoclonal antibody.
41029344|NCT02577705|BEHAVIORAL|Self Empowerment Groups|The Self Empowerment Groups (SEG) curriculum draws key components from the S.E.L.F. tool within Sanctuary, focusing the four domains: creating personal, emotional, moral and physical safety (S), processing and managing emotions (E), recognizing loss and letting go (L), and developing goals for a sense of future (F). S.E.L.F. establishes a common language that all people who have experienced adversity can use to organize their lives and work towards building stable foundations to support their goals and invest in their potential.
40846580|NCT03090672|DRUG|Normal Saline|Normal Saline IV delivery
40846581|NCT03090672|PROCEDURE|Tissue Stromal Vascular Fraction|tSVF
40846582|NCT03090672|BIOLOGICAL|Platelet Rich Plasma|PRP
40846583|NCT03090672|PROCEDURE|Cellular Stromal Vascular Fraction|cSVF
41368181|NCT06219499|OTHER|Placebo|Placebo
41368182|NCT04039282|DEVICE|myfood24|online website for dietary analysis
41368183|NCT05354115|DIAGNOSTIC_TEST|Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel|Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril. After the nasal sampling, the operators will collect two nasopharyngeal swab one from each nostril of each subject.
41368184|NCT03396406|DEVICE|Pulsed radiofrequency (PRF)|received PRF at 42°C for 8 minutes followed by CRF at 60°C for 270s
41368185|NCT03396406|DEVICE|thermocoagulation|received sole CRF at 70°C for 270 s
41368186|NCT04060758|DRUG|PA5108 Latanoprost FA SR Ocular Implant|Ocular Implant
41368187|NCT03115723|PROCEDURE|Percutaneous coronary intervention|
41368188|NCT03115723|PROCEDURE|Coronary angiography|
41161895|NCT05171465|DEVICE|Neqstent or Contour|All patients included will be treated the same: after catheterizing the affected vessel and microcatheterizing the aneurysm with a microcatheter of 0.021'' or 0.027'', the intrasaccular device (Neqstent® or Contour®) will be positioned. Depending of the operator preference, the use of an intrasaccular device could be associated with coiling (mandatory in the case of Neqstent®). Treatment must be performed without previous double antiplatelet treatment (allowing antiplatelet after aneurysm exclusion). Before the treatment all patients should undergo a flat panel CT.
41368189|NCT04487626|DEVICE|AI|After taking standard bowel preparation regimen, patients receive colonoscopy under the AI system device. During the withdrawal phase, bowel preparation quality is assessed by AI-associated scoring system. The withdrawal time is targeted at least 6min. Every detected polyp will be removed and obtained for pathological assessment.
41368190|NCT03360695|OTHER|Proactive Psychiatry Consultation (PPC)|Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.
41368191|NCT03360695|OTHER|Enhanced Usual Care (EUC)|At enrollment, study staff will inform the treating oncologist of the psychiatric diagnosis and will inform the oncologist, patient, and caregiver of available psychosocial services.
41368192|NCT00717665|DEVICE|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
41368193|NCT00717665|OTHER|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
41368194|NCT01285726|OTHER|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
41368195|NCT02331459|OTHER|Multicomponent training intervention|"Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)~Legend:~min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching"
41368196|NCT02331459|OTHER|Nutritional intervention|"Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)"
41368197|NCT03979924|BEHAVIORAL|Trismus rehabilitation|"The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,...) in order to strengthen the stretching."
41368198|NCT01600677|DEVICE|Computerized medication delivery unit|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.
41029345|NCT02577705|BEHAVIORAL|Financial Empowerment|The Financial Empowerment curriculum developed for this study consisted of interactive exercises, worksheets, and journal assignments that fostered understanding and practice of banking, building credit and debt management, making the most of one's money, and setting financial goals for oneself and one's family. Content focused on identifying and harnessing the internal and external resources that participants can leverage to begin taking steps towards financial self-sufficiency.
41029346|NCT02577705|BEHAVIORAL|Matched Savings|Participants were assisted with opening a savings accounts at a local non-profit federal credit union (with 1:1 matches of up to twenty dollars per month) over the course of 12 months.
41368199|NCT01600677|OTHER|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
41368200|NCT03152721|DEVICE|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
41161896|NCT00740597|GENETIC|gene expression analysis|
41161897|NCT00740597|GENETIC|polymerase chain reaction|
41161898|NCT00740597|GENETIC|western blotting|
41161899|NCT00740597|PROCEDURE|neoadjuvant therapy|
41161900|NCT00740597|PROCEDURE|therapeutic conventional surgery|
41161901|NCT00740597|RADIATION|intensity-modulated radiation therapy|
41368201|NCT03152721|OTHER|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
41368202|NCT00329706|PROCEDURE|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
41368203|NCT03948061|OTHER|Cherry juice|FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
41368204|NCT03948061|OTHER|Placebo beverage|Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
41368205|NCT03133702|OTHER|Forensic cases|Forensic cases which were admitted to the Emergency Department
41368206|NCT03526848|DRUG|3BNC117|Intravenous infusion of 3BNC117
41368207|NCT03526848|DRUG|10-1074|Intravenous infusion of 3BNC117
41368208|NCT03526848|OTHER|Analytical treatment interruption|Analytical treatment interruption
41368209|NCT00444028|DRUG|inhaled Loxapine 0.625 mg|Single 0.625 mg (lowest) dose of inhaled loxapine
41368210|NCT00444028|DRUG|inhaled Loxapine 1.25 mg|Single 1.25 mg (2nd) dose of inhaled loxapine
41368211|NCT00444028|DRUG|inhaled Loxapine 2.5 mg|Single 2.5 mg (3rd) dose of inhaled loxapine
41368212|NCT00444028|DRUG|inhaled Loxapine 5 mg|Single 5 mg (4th) dose of inhaled loxapine
41368213|NCT00444028|DRUG|inhaled Loxapine 10 mg|Single 10 mg (5th) dose of inhaled loxapine
41368214|NCT00444028|DRUG|inhaled Placebo (0 mg)|Single placebo dose of inhaled loxapine
41368215|NCT06540872|DRUG|[68Ga]Ga-FAPI-46|Participants receive the weakly radioactive drug \[68Ga\]Ga-FAPI-46 through their vein and lie in an imaging device (PET/MRI) for 30 minutes. After a break of 30 minutes, they will lie in the imaging device for another 15 minutes.
41368216|NCT00542165|DRUG|Alfuzosin|
41368217|NCT04637373|DIAGNOSTIC_TEST|Hysteroscopy|adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
41368218|NCT04525066|DRUG|Hyaluronic acid|Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
41368219|NCT04525066|OTHER|No Hyaluronic Acid Injection Injection|Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
41368220|NCT00660816|DRUG|erlotinib hydrochloride|Given orally once daily on days 2-19.
41502339|NCT02159079|OTHER|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
41502340|NCT06456866|OTHER|interpretation|interpretation of blood gases samples
41029347|NCT01744236|DRUG|Liraglutide|Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
41029348|NCT01744236|DRUG|Sitagliptin|Sitagliptin 100mg will be given once daily for 12 weeks.
41368221|NCT00660816|DRUG|pemetrexed disodium|Given IV over 10 minutes on day 1
41368222|NCT00660816|DRUG|docetaxel|IV over 60 minutes on day 1.
41368223|NCT05100693|OTHER|Fetoscopic Endoluminal Tracheal Occlusion with the Smart-TO Balloon|Fetal Endoscopic Tracheal Occlusion using the Smart-TO balloon and non-invasive balloon removal by the peripheral magnetic field of an magnetic resonance scanner.
41368224|NCT05117658|DRUG|HA121-28 tablet|HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
41368225|NCT04301024|OTHER|assessing the nitrous oxide misuse|assessing the nitrous oxide misuse among teenagers consulting in an addioctology center dedicated to young drug users in montpellier
41368226|NCT01471197|BIOLOGICAL|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
41368227|NCT01471197|BIOLOGICAL|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
41368228|NCT01995656|DRUG|Placebo - Capsule|Administered orally
41368229|NCT01995656|DRUG|LY3108743 - Capsule|Administered orally
41368230|NCT01995656|DRUG|Placebo - Solution|Administered orally
41368231|NCT01995656|DRUG|LY3108743 - Solution|Administered orally
41368232|NCT04621227|DRUG|PF-06882961|120 mg and 200 mg BID
41368233|NCT04621227|DRUG|Rosuvastatin|10 mg single dose
41368234|NCT04621227|DRUG|Midazolam|2mg single dose
41368235|NCT03359811|DRUG|Local Anesthetic Solution|A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
41368236|NCT03359811|DRUG|Bupivacaine HCl|30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.
41368237|NCT03359811|DRUG|Liposomal Bupivacaine|65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
41368238|NCT00096031|BIOLOGICAL|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
41029349|NCT01744236|DRUG|Exenatide|Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
41161902|NCT04572997|DRUG|Apremilast|Apremilast was taken orally twice daily (except Day 1). Patients received tablets in blister/bottles sufficient for one month. To mitigate potential gastrointestinal side effects (primarily mild-to-moderate nausea and diarrhoea), dose titration was implemented in this study in accordance with the Summary of Product Characteristics (SmPC). A titration pack included tablets of 10, 20 and 30 mg for a period of one month. During the first 5 days, the dosage was up-titrated. The initial dose on day 1 was 10 mg in the morning; this was increased to 10 mg in the morning and evening on day 2. The evening dose was further increased by 10 mg (to 20 mg) on day 3. On day 4, the morning dose was increased to 20 mg, so that 20 mg was taken twice daily, and on day 5 the evening dose was increased to 30 mg. From Day 6 onwards, patients received the 30 mg dose twice a day. Subsequent packs included only tablets of 30 mg strength.
41029350|NCT01744236|DRUG|Liraglutide placebo|Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
41029351|NCT01744236|DRUG|Sitagliptin placebo|Sitagliptin-placebo be given once daily for 12 weeks.
41029352|NCT01744236|DRUG|Exenatide placebo|Exenatide-placebo (saline) will be administered intravenously
41029353|NCT01744236|DRUG|L-NMMA|
41029354|NCT05465941|PROCEDURE|Biopsy|Undergo biopsy
41029355|NCT05465941|DRUG|Pegylated SN-38 Conjugate PLX038|Given IV
41029356|NCT05465941|PROCEDURE|Computed Tomography|Undergo CT
41029357|NCT05465941|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
41029358|NCT00274053|DRUG|tiotropium|
41161903|NCT01282697|DRUG|Combined administration of irinotecan and rapamycin|This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
41161904|NCT00761410|DEVICE|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
41161905|NCT05746533|PROCEDURE|Hip Arthroscopy|Hip Preservation surgeries
41161906|NCT05646589|BEHAVIORAL|Person-centred care transition support|Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.for persons who are to be discharged from hospitals after stroke or TIA
41161907|NCT05646589|BEHAVIORAL|Regular care transition|Regular care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
41161908|NCT05675839|OTHER|Film (Wit) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life)|Film (Wit) (https://www.youtube.com/watch?v=2s4ozvI_hzY\&t=160s) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life) (https://www.youtube.com/watch?v=XsabHOiF0CY\&t=284s)
41029359|NCT04344067|DEVICE|Far Infrared Therapy|The WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to conduct FIR therapy in this study. The electrified ceramic plates of the emitter generated electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 milliwatt (mw) /cm2 when the top radiator was set at a distance of 30 and 20 cm above the skin surface respectively.
41029360|NCT05684887|OTHER|Digital based contact tracing|"* Listing of contacts by SARS-CoV-2 positive individuals in Mamal Pro app + verification and validation by a health care worker.~* Immediate access to the contact list in Mamal Pro once validated by the health care worker.~* Contacts are immediately notified by text message automatically sent to all contacts with phone numbers and later called by the HCWs responsible for carrying out the contact tracing at the district level.~* Contacts will be invited to go to the nearest testing facilities/units to get tested.~* Those who are unable or refuse to come for testing are followed up by phone for 10 days for the occurrence of COVID-19 symptoms.~* Information about the contact tracing process during communication with contacts are recorded in Mamal Pro digital contact tracing module."
41029361|NCT02081651|DIETARY_SUPPLEMENT|Parmigiano Reggiano cheese|
41029362|NCT03091751|DRUG|BeneFIX|BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
41161909|NCT03101033|DEVICE|Mechanical epidural neuroplasty|Guided by X-ray transillumination,an epidural needle will be inserted through sacral hiatus. A catheter （BS epidural catheter, BioSpine Co., Ltd, Korea） will be inserted through the epidural needle to the epidural space where disc herniation locates, mechanical adhesiolysis will be implemented.
41029363|NCT04986553|DEVICE|Arthrex Clavicle Plates|Arthrex Clavicle Plate for treatment of clavicle fractures
41029364|NCT02053233|DEVICE|Walkbot group|"The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.~The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state."
41029365|NCT02053233|DEVICE|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
41029366|NCT02254447|DRUG|Candesartan Cilexetil in formulation 1|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
41029367|NCT02254447|DRUG|Candesartan Cilexetil in formulation 2|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
41029368|NCT02254447|DRUG|ATACAND|Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration
41029369|NCT06099171|DRUG|Cannabidiol and β-Caryophyllene Patch|Cannabidiol with its decongestant activity has a soothing action in the area of application, thanks to the association with B-caryophyllene which assists its activity
41368239|NCT05277610|DIAGNOSTIC_TEST|iron studies|Pulmonary function testing was performed using standardized spirometry for asthmatic patients with iron deficiency anemia and those without iron deficiency anemia
41368240|NCT01644968|DRUG|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
41368241|NCT01644968|DRUG|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
41368242|NCT01644968|DRUG|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
41368243|NCT01644968|BIOLOGICAL|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
41368244|NCT01644968|BIOLOGICAL|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
41368245|NCT01644968|BIOLOGICAL|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
41368246|NCT01644968|BIOLOGICAL|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
41368247|NCT02039869|DEVICE|Confocal endomicroscopy|The probe allows microscopic evaluation of tissue in real time during endoscopy.
41368248|NCT02039869|DRUG|Proton pump inhibitor|Acid suppressing medication (over the counter)
41368249|NCT02039869|DRUG|Sucralfate|Coating agent for damaged intestinal lining.
41368250|NCT01880996|OTHER|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
41368251|NCT01673204|DRUG|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
41368252|NCT01673204|DRUG|Placebo|
41368253|NCT02195882|PROCEDURE|Exercise program of the scapular muscle stabilizers|
41368254|NCT01000909|PROCEDURE|Ultrasound (venous pressure measurement)|increased venous pressure is predictive for chronic venous insufficiency
41368255|NCT00784225|DRUG|selenium|200 mcg daily for 7-12 years
41368256|NCT00784225|DRUG|vitamin E|400 IU daily by mouth for 7-12 years
41029370|NCT06099171|DEVICE|Oxygen-Ozone Therapy|Ozone (O3) is a molecule consisting of 3 atoms of oxygen in a dynamically unstable structure. O3 has the capacity to modulate inflammation. O3 when in contact with human fluids and tissues rapidly reacts, generating many reactive oxygen species, as hydrogen peroxide (H2O2), superoxide ion, and hydroxyl radical (OH-). It is suggested that through moderate oxidative stress generated by these reactive byproducts, O2O3 might produce positive effects in several pathologies, including musculoskeletal affections. Moreover, O2/O3 may directly regulate prostaglandins (PGS) and bradykinin, and suppress several proinflammatory mediators, such as IL-6, IL-8 and TNF-α
41368257|NCT00784225|DRUG|vitamin E placebo|daily for 7-12 years
41368258|NCT00784225|DRUG|selenium placebo|daily for 7-12 years
41368259|NCT04830358|BIOLOGICAL|EuPCV15|15-valent Pneumococcal conjugate vaccine
41161910|NCT03101033|DRUG|Transforaminal epidural compound betamethasone injection|Guided by X-ray transillumination, A puncture needle will be inserted to the intervertebral foramen in the vicinity of affected nerve root, and steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.
41368260|NCT04830358|BIOLOGICAL|Prevenar13|13-valent Pneumococcal conjugate vaccine
41368261|NCT05208398|DRUG|Apixaban|5 mg twice daily, on top of standards of care.
41502341|NCT04177784|OTHER|Online Educational Videos|The videos were developed by the researchers based on a prior study to test if specific information about obesity and weight control influence weight bias.
41368262|NCT05208398|DRUG|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations
41368263|NCT03263052|DRUG|Tacrolimus XR (Envarsus)|Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
41368264|NCT01770080|DRUG|Euminz®|3 to 5 time topical use of study drug.
41368265|NCT01770080|DRUG|Placebo|3 to 5 time topical use of study drug.
41368266|NCT03391258|PROCEDURE|Bone Regeneration with GLAM technique|Bone regeneration with GLAM technique in full arch implant supported rehabilitation
41368267|NCT03217058|BEHAVIORAL|Clinic-based screening and behavioral interventions|As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
41368268|NCT02205580|DRUG|continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion|
41368269|NCT02205580|DRUG|continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion|
41368270|NCT02205580|DRUG|continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion|
41368271|NCT05874609|OTHER|Teaching with VR spine simulator|The participants spent 30 minutes with the VR spine simulator after receiving the didactic teaching session. The learning objective with the VR simulator is to review the 3D lumbar spine anatomic model，learn the sonoanatomy presented by a dynamic ultrasound scan of the sagittal and transverse plane, and practice a preprocedural ultrasound scan.
41368272|NCT05874609|OTHER|Traditional didactic teaching|A 30-min traditional didactic teaching session of spine ultrasonography. This session was consisted of general spine anatomy, sonographic technique and sonoanatomy, description of five key spine ultrasonographic views (transverse spinous process view, transverse interlaminar view, parasagittal oblique interlaminar view, parasagittal articular process view, parasagittal transverse process view), and a stepwise technique of preprocedural lumbar spine scan
41502342|NCT03300583|BEHAVIORAL|Focus groups|Focus group discussion led by the PI and facilitated by another researcher.
41502343|NCT03300583|BEHAVIORAL|Semi-structured interviews|1:1 semi-structured interviews led by the PI
41502344|NCT06505200|OTHER|No intervention|No intervention
41502345|NCT03831165|COMBINATION_PRODUCT|Melatonin 3 mg|melatonin and placebo
41502346|NCT03831165|DRUG|Acyclovir|Only acyclovir 200 mg twice a day
41368273|NCT02652676|PROCEDURE|Reversible Pulmonary Artery Banding|A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
41368274|NCT02652676|PROCEDURE|GORE-TEX DualMesh EMERGE PLUS Biomaterial|The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
41368275|NCT01892046|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
41368276|NCT00561912|DRUG|Decitabine|15 mg/m\^2 IV Daily over one hour for 5 days
41368277|NCT00561912|DRUG|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
41368278|NCT04465643|DRUG|Nivolumab|Nivolumab 4.5 mg/kg Q3W x 2
41368279|NCT04465643|DRUG|Ipilimumab|Ipilimumab 1 mg/kg Q3W x 2
41368280|NCT06523348|DIAGNOSTIC_TEST|quadricipital muscle ultrasound|ultrasound depth measurement of the quadriceps muscle
41368281|NCT02954939|DRUG|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
41368282|NCT02954939|DRUG|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
41161911|NCT03101033|DRUG|Caudal epidural compound betamethasone injection|steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan® Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected through the epidural catheter after mechanical epidural neuroplasty.
41368283|NCT00516945|DRUG|Lamivudine|
41368284|NCT04189874|DIAGNOSTIC_TEST|Conventional Stool Testing|Stools are tested using conventional culture techniques
41368285|NCT04189874|DIAGNOSTIC_TEST|BioFire FilmArray Gastrointestinal Panel|Molecular-based stool assay
41368286|NCT01980186|DEVICE|TUS transcranial 2D ultrasound|
41368287|NCT05908539|BEHAVIORAL|Equipment box|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction only.
41368288|NCT05908539|BEHAVIORAL|Equipment box with briefing|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction, and they are given verbal briefing on how to use the equipment.
41368289|NCT05908539|BEHAVIORAL|Exercise training|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises.
41029371|NCT05881044|OTHER|Psychiatric interview|"1. Psychiatric interview which include personal identification, present history, past history and family history~2. Complete physical and Neurological Examination.~3. Mini Neuropsychiatric Interview scale. (MINI): to diagnosis psychiatric disorders~4. Symptom checklist 90(SCL 90)~5. Quality of life questionnaire.~6. Hamilton Depression scale.~7. Hamilton Anxiety scale.~8. Socioeconomic scale (A.El.Gilany,A.El.Wehady,and M.EL.Wasify)"
41368290|NCT05908539|BEHAVIORAL|Exercise training with behavioral modification|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises. After finishing the exercise training program, a 6-week behavioral modification is provided. Two home visits and four telephone visits are conducted to empower the participants for exercise at home.
41368291|NCT01002573|DRUG|ibuprofen|Ibuprofen, 10 mg/kg
41029372|NCT05234294|OTHER|Survey|We will investigate symptoms through monthly surveys.
41161912|NCT03101033|DRUG|Epidural hyaluronidase injection|Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and caudal epidural compound betamethasone injection.
41368292|NCT01002573|DRUG|acetaminophen|Acetaminophen, 10mg/kg
41368293|NCT03864406|DRUG|Cobicistat|Each tablet of Tybost contains 150 mg of cobicistat.
41029373|NCT01290367|BIOLOGICAL|Single Dose MPCs Injection|Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
41029374|NCT01290367|PROCEDURE|Single injection of saline solution|Intradiscal control injection with saline solution
41029375|NCT01290367|PROCEDURE|Single injection of hyaluronic acid|Intradiscal control injection with hyaluronic acid
41368294|NCT03864406|DRUG|Darunavir/Cobicistat|Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
41368295|NCT03864406|DRUG|Rivaroxaban|Each tablet of Xarelto contains 10 mg of rivaroxaban.
41368296|NCT05007730|DIETARY_SUPPLEMENT|Transitional-state food therapeutic nutrition supplement|"Participants will consume at least one snack-sized package of the transitional-state food supplements per day across the intervention trial."
41368297|NCT01573988|OTHER|Increasing eating frequency|"The subjects receive the same breakfast with two sequences :~* breakfast in one intake at 8:00~* breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions."
41368298|NCT05603975|DRUG|Esketamine 0.1mg/kg intravenous injection|"The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change."
41368299|NCT05603975|DRUG|Normal saline|"The Normal saline was administered intravenously at 0.1ml per kilogram of body weight 1min before the dressing change."
41368300|NCT03805763|PROCEDURE|Large extent of ILM Peeling|The extent of ILM peeling is 4DD
41368301|NCT03805763|PROCEDURE|Small extent of ILM Peeling|The extent of ILM peeling is 2DD
41368302|NCT04159610|DRUG|WO3970|Application of cream to each axilla
41368303|NCT04159610|DRUG|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only
41368304|NCT05174429|BEHAVIORAL|Risk-Targeted Behavioral Activation|"The behavioral activation component of the treatment program focused on goal setting, structuring and scheduling activities, increasing success and achievement experiences, and problem-solving. In order to maximize the impact of behavioral activation on disability reduction, goal setting and scheduling of activities focused primarily on resumption of discontinued activities as opposed to focusing on the scheduling of pleasant activities. One objective of goal setting and activity scheduling was to reduce the discrepancy between the client's pre-injury activity repertoire and the client's current activity repertoire.~Behavioral activation was supplemented by a collection of techniques designed to reduce catastrophic thinking and perceptions of injustice, two psychosocial risk factors that have been shown to contribute to prolonged work-absence."
41368305|NCT04430387|DEVICE|The saliva ejector|A thin suction tube that draws water, saliva, blood, and debris from the mouth to provide patient comfort, preventing patient from constantly having to sit up and spit while maintain a clear operative field. It is connected through the low-volume suction hose in the dental chair. It can be held by the dental assistant, the dental provider or by the patient. In practice, it can be also contoured and hang by the cheek of the patient due to its light weight.
41368306|NCT04430387|DEVICE|The high-volume evacuator|The high-velocity air evacuation device. It is connected through the high-volume suction hose in the dental chair. It is operated by a dental assistant during the dental treatment, owing to the challenge posed by the rigid disposable attachment and bulky high-volume suction hose.
41368307|NCT04430387|DEVICE|The DryShield|The device is attached to the high-volume suction hose to provide continuous suction of intraoral fluid and debris, and also simultaneous isolation to both maxillary and mandibular quadrants on the same side. Other advantages of these devices include retracting the tongue and cheek, and prevention of aspiration.
41368308|NCT02318641|DEVICE|oximetry|Retinal oximetry will be performed with Oxymap.
41368309|NCT01519700|DRUG|EP2006|Eligible patients will be teated with EP2006
41368310|NCT01519700|DRUG|Filgrastim|Eligible patients will be teated with Filgrastim
41368311|NCT02260804|BIOLOGICAL|CT-P10|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
41029376|NCT01290367|BIOLOGICAL|Single Dose MPCs Injection|Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
41368312|NCT02260804|BIOLOGICAL|Rituxan|375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
41368313|NCT02334891|OTHER|Standard|Standard management
41368314|NCT06349109|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test (CPET), the gold standard for the assessment of cardiorespiratory fitness, will be used. The Modified Bruce/half Bruce protocol with will be used. In addition, dyspnoea, leg fatigue and general fatigue will be recorded every three minutes at rest, during the test and during the post-test recovery phases using the Modified Borg Scale and blood pressure will be recorded with a sphygmomanometer. The test will be continued until individuals reach the end of the protocol or until the last point at which they wish to stop the test. The test will be terminated if the patient wishes to terminate the test, severe breathlessness, leg fatigue or general fatigue, loss of coordination, progressive chest pain, ST segment elevation or depression of more than 2 mm, oxygen saturation of 80% or less, reaching 85% or more of the predicted heart rate. Oxygen consumption (VO2peak) will be used as the primary outcome measure for cardiorespiratory fitness.
41368315|NCT06349109|OTHER|Atrial-Ventricular Strain Analysis|Atrial-Ventricular strain will be evaluated by a specialist physician using Speckle Tracking Echocardiography. During the evaluation, standard echocardiographic measurements will be made with transthoracic echocardiography. With these measurements, images suitable for strain analysis will be obtained. Deformation analysis will be performed using the speckle tracing method for the appropriate images obtained and hemodynamic parameters obtained by the analysis will be recorded.
41368316|NCT06349109|OTHER|Arterial Stiffness Measurement|Arterial stiffness will be assessed using the pulse wave velocity (PWV) technique with the Mobile-O-GRAPH (TG) (LE.M., Stolberg, Germany), an oscillometer-based device. After the patients have rested sufficiently, measurements will be taken in an upright sitting position in a quiet and sufficiently bright environment at room temperature, with the device manso placed 2-3 cm above the chiibital fossa in the non-dominant upper limb and the arms raised to the level of the heart. Pulse propagation velocity will be calculated in m/sec with the help of a computer. A high velocity data indicates a high level of arterial stiffening and a low velocity data indicates a low level of arterial stiffening.
41368317|NCT06349109|OTHER|Physical Activity Level|Physical activity level will be assessed with the Child Physical Activity Questionnaire.
41368318|NCT06349109|OTHER|Physical Activity Barriers Assesment|"Physical Activity Outcome Expectancies (child survey) and Physical Activity Home Environment Scale (Child) will be used in children, while  Physical activity barriers (Parent) will be used in family members."
41502347|NCT02730663|DEVICE|Niti-S SPAXUS Stent|Endoscopic Ultrasound-Guided Transluminal drainage
41029377|NCT02687152|OTHER|N-hydroxy-nor-L-arginine|
41029378|NCT02563912|OTHER|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
41029379|NCT02563912|OTHER|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
41029380|NCT03871387|DRUG|Deep Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 \& PTC= 1\~2 (TOF = train-of-four. PTC = post-tetanic count)~* TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
41029381|NCT03871387|DRUG|Control Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1\~2~* TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
41368319|NCT05015504|BEHAVIORAL|Time restricted feeding|In Phase II the study subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week.
41368320|NCT04973527|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
41368321|NCT01715480|DIETARY_SUPPLEMENT|Broccosprouts® (Brassica Protection Products LLC) homogenate|"In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks."
41368322|NCT02491463|BIOLOGICAL|GSK3389245A_LD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
41368323|NCT02491463|BIOLOGICAL|GSK3389245A_HD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
41368324|NCT02491463|BIOLOGICAL|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
41368325|NCT02491463|DRUG|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
41368326|NCT02062541|OTHER|Funct. assessment+fast rehabilitation|
41029382|NCT05531994|DRUG|Montelukast sodium oral thin films with water (T)|Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL
41502348|NCT05786846|DRUG|Iodinated contrast agents|Patients who use iodinated contrast agents clinically
41502349|NCT06633159|DEVICE|MitraClip|surgical intervention to correct mitral regurgitation by percutaneous transcatheter implantation of the MitraClip G4 clip on the mitral valve leaflets
41502350|NCT03671616|BIOLOGICAL|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
41029383|NCT05531994|DRUG|Montelukast sodium chewable tablets with water (R)|Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL
41502351|NCT03763357|DEVICE|Heat Therapy (HT)|Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.
41368327|NCT02062541|OTHER|Funct. assessment+usual rehabilitation|
41502352|NCT04232280|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
41502353|NCT04232280|OTHER|Placebo|0.9% sodium chloride (normal saline) injection
41029384|NCT03999606|BEHAVIORAL|Music Training - Choir participation|"Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform."
41029385|NCT03691038|DRUG|Pregabalin 75mg bid|Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
41029386|NCT03691038|DRUG|Pregabalin 25mg, 50mg|Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
41368328|NCT02062541|OTHER|usual assessment+fast rehabilitation|
41502354|NCT03597529|DRUG|Melatonin|melatonin
41502355|NCT00866944|DRUG|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
41502356|NCT00866944|DRUG|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
41502357|NCT00866944|DRUG|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
41502358|NCT02851745|DRUG|Linagliptin|
41502359|NCT02851745|DRUG|Placebo|
41502360|NCT04257045|OTHER|Interview|Participate in semi-structure, in-depth qualitative interviews
41502361|NCT04257045|OTHER|Questionnaire Administration|Complete questionnaires
41502362|NCT04257045|OTHER|Survey Administration|Complete survey
41502363|NCT06079671|BIOLOGICAL|Volrustomig|IV Infusion
41502364|NCT06079671|OTHER|Placebo|IV Infusion
41502365|NCT05515874|DRUG|Feraheme|"Ferumoxytol contains iron and is used for the treatment of anemia, so it may affect any iron supplementation prescribed by a physician. Iron is metabolized in the liver, so impaired liver function could interfere with the metabolism of ferumoxytol.~Patients will receive up to a total maximum ferumoxytol dose of 4 mg/kg (71.6 µmol Fe/kg) of body weight, diluted in 200 mL of 0.9% normal saline, at a rate of 10 ml/minute for 20 minutes, The injection rate and maximum dosage are well within the safety thresholds regarding the FDA recommendation of ferumoxytol use."
41502366|NCT04764825|DRUG|Methadone|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age."
41502367|NCT04764825|DRUG|Morphine|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age."
41502368|NCT02874885|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
41502369|NCT02483208|DRUG|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
41368329|NCT03252223|DRUG|Recombinant Follicle Stimulating Hormone|A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
41368330|NCT03151200|DEVICE|Computer based binocular treatment|Binocular amblyopia treatment involves presenting stimuli over a computer screen to the amblyopic eye those are at higher contrast compared to the stimuli that are presented to the good eye, which balances the performances of the two eyes and over time improves the amblyopic eye vision.
41368331|NCT03151200|DEVICE|Transcranial magnetic stimulation|TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
41368332|NCT03210909|DRUG|BMS-986231|BMS-986231
41368333|NCT05816525|PROCEDURE|Partial removal of carious tissue|Nonselective carious tissue excavation will be performed in the periphery of the cavity to achieve a good marginal seal. In the pulpal wall selective, partial carious tissue excavation is performed to the soft dentin, removing tissue only the amount that is necessary for placing the restoration. The tooth is restored with high-viscosity glass-ionomer cement.
41368334|NCT05816525|PROCEDURE|Final restoration|The teeth will be restored with composite resin after 12 months follow up, if the tooth is asymptomatic, responds to sensibility tests and there are no periapical changes radiographically. Glass ionomer cement will be only partially removed to create space for the final restoration.
41368335|NCT02360358|DRUG|Tiscover|two step procedure, week 0 and week1. Dosage depends on wound size.
41502370|NCT02483208|DRUG|Advate|Advate infusion to analyze pharmacokinetics.
41029387|NCT04160182|BEHAVIORAL|Energy Conservation Work Simplification Education|"The intervention will last approximately 45 minutes, and will be provided once/week for 6 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. At beginning of the intervention, the participant and interventionist prioritize the 5 most critical fatigue-related problems that they would like to solve during the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge and examples on how to apply the knowledge to everyday fatigue-related problems. The workbook contains: (a) information regarding fatigue in breast cancer survivors, (b) knowledge regarding fatigue management strategies, and (c) worksheets to develop skills to recognize and solve fatigue-related problems. Participants will retain the workbook after study completion."
41029388|NCT06115759|BEHAVIORAL|T-REX Twente precautions|The intervention group receives the new T-REX Twente precautions, allowing for more independent activities through the use of the tube model (keeping elbows close to the sides).
41368336|NCT02360358|OTHER|AS210|two step procedure, week 0 and week1. Dosage depends on wound size.
41368337|NCT00135265|BEHAVIORAL|smoking cessation, practice change|Providers will be trained in a brief smoking cessation intervention for teens.
41368338|NCT01491802|DRUG|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
41502371|NCT05060744|DEVICE|Antacid|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
41368339|NCT01491802|DRUG|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
41368340|NCT01682343|DIETARY_SUPPLEMENT|Calcium|Milk-calcium supplement
41502372|NCT05060744|OTHER|Control|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
41502373|NCT06108076|DRUG|Ketone Monoester (KE)|Ketones are a nutritional supplement currently used by athletes for their performance enhancing effects - specifically their cardio-pulmonary benefits
41502374|NCT03900897|DEVICE|MED-EL SYNCHRONY PIN Cochlear Implant|Subjects will be implanted with the MED-EL SYNCHRONY PIN Cochlear Implant System with +FLEX24, +FLEX28, +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO 2 (single-unit) external audio processors.
41502375|NCT03900897|OTHER|Cochlear Implant|Chart review of subjects implanted with a MED-EL cochlear implant under 6 years of age between January 2005 and October 2020.
41502376|NCT01693796|OTHER|blood and urine samples ; Echography|
41502377|NCT02832180|DRUG|OC containing EE and NET|
41502378|NCT02832180|DRUG|BMS-986142|
41502379|NCT06128070|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41502380|NCT06128070|PROCEDURE|Chest Computed Tomography|Undergo chest CT
41502381|NCT06128070|PROCEDURE|Echocardiography|Undergo ECHO
41502382|NCT06128070|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
41368341|NCT06287112|DEVICE|Endoscopic transpapillary gallbladder drainage (ETGBD)|Fully covered self-Expandable metal stent with Endoscopic transpapillary gallbladder drainage (ETGBD) in patient with cystic duct low insertion
41368342|NCT00938457|RADIATION|stereotactic radiation therapy|Patients undergo stereotactic body radiation therapy
41368343|NCT00938457|PROCEDURE|implanted fiducial-based imaging|radiation therapy treatment planning
41368344|NCT00938457|PROCEDURE|cone-beam computed tomography|radiation therapy treatment planning
41368345|NCT00610922|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
41368346|NCT01005186|BEHAVIORAL|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
41368347|NCT02211287|OTHER|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q\&A form and can help answer frequent family questions.
41368348|NCT02211287|OTHER|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
41368349|NCT01103375|DRUG|erlotinib hydrochloride|Given PO
41368350|NCT01103375|DRUG|isotretinoin|Given PO
41368351|NCT01103375|OTHER|laboratory biomarker analysis|Correlative study
41368352|NCT01103375|GENETIC|protein expression analysis|Correlative study
41368353|NCT01708369|DRUG|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
41368354|NCT01708369|DRUG|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
41368355|NCT01708369|DRUG|Oseltamivir|Oseltamivir 150 mg orally
41029389|NCT06115759|BEHAVIORAL|Usual (restrictive) sternal precautions|The control group is not allowed to lift, push, or pull for the first 6 weeks. There is little to no evidence for the current strict precautions currently implemented in the department.
41029390|NCT01660763|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
41029391|NCT01660763|DRUG|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
41368356|NCT01708369|DRUG|Aspirin|Aspirin 650 mg orally will be given
41368357|NCT01345266|PROCEDURE|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
41368358|NCT00000549|DRUG|estrogen replacement therapy|
41368359|NCT00000549|DRUG|hormone replacement therapy|
41368360|NCT00000549|DRUG|estrogens|
41368361|NCT00000549|DRUG|progestins|
41368362|NCT06264076|DEVICE|A novel instrument for ligament balancing in total knee arthroplasty|Patients will be evaluated perioperatively for ligament balance. When indicated, the novel instrument will guide puncturing of the medial collateral ligament in a systematic and step-wise fashion. Achieved ligament balance will be observed and controlled by computer navigation and a ligament tensor.
41368363|NCT02868294|DEVICE|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
41368364|NCT03398759|DRUG|Butorphanol|IV injection during induction
41368365|NCT03398759|DRUG|Placebos|IV injection during induction
41368366|NCT04708366|DRUG|NER1006|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
41368367|NCT04708366|DRUG|MoviPrep|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
41368368|NCT04708366|DRUG|Macrogol 400|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
41368369|NCT00078663|BEHAVIORAL|Oral Care|
41368370|NCT00974896|DRUG|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
41368371|NCT06448611|OTHER|Blood Test|Research and quantification of Circulating Tumor Cells
41368372|NCT03096899|OTHER|Observational|Best Supportive Care
41368373|NCT05587933|PROCEDURE|cholecystectomy|cholecystectomy
41368374|NCT05587933|DRUG|Antispasmodic|Antispasmodic
41368375|NCT04022473|DRUG|Bafiertam|Over-encapsulated capsule to mask treatment
41368376|NCT04022473|DRUG|Tecfidera|Over-encapsulated capsule to mask treatment
41502383|NCT06128070|DRUG|Methotrexate|Given IV
41502384|NCT06128070|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41502385|NCT06128070|DRUG|Ruxolitinib Phosphate|Given PO
41368377|NCT02898662|DRUG|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
41029392|NCT04098692|DRUG|Derazantinib capsule|300 mg derazantinib oral administration (3x100 mg capsules)
41029393|NCT04098692|DRUG|[14C]-Derazantinib solution for infusion|100 μg \[14C\]-derazantinib intravenous administration
41029394|NCT04098692|DRUG|[14C]-Derazantinib capsule|300 mg \[14C\]-derazantinib oral administration (3x100 mg capsules)
41029395|NCT02391402|BEHAVIORAL|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
41029396|NCT02391402|BEHAVIORAL|Treatment as Usual|"TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
41029397|NCT00724282|DRUG|Eszopiclone|Eszopiclone 3 mg by mouth daily at bedtime for 9 days
41029398|NCT00724282|DRUG|Placebo|Placebo by mouth daily at bedtime for 9 days
41029399|NCT01090804|DEVICE|BreatheMAX breathing device|secretion clearance, breathing exercise
41029400|NCT05581446|DIAGNOSTIC_TEST|Visual Analogue Scale|pain type severity determination and quality of life assessment
41029401|NCT03999619|BEHAVIORAL|Move 2 Learn|10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
41029402|NCT05983445|DRUG|genakumab|200mg s.c.
41029403|NCT05983445|DRUG|placebo for Diprospan|i.m.
41029404|NCT05983445|DRUG|placebo for genakumab|s.c.
41029405|NCT05983445|DRUG|Diprospan|7mg i.m.
41029406|NCT04748354|BEHAVIORAL|Otago Exercise Program|An individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist
41029407|NCT04748354|OTHER|Usual Care|Clinical care provided by a geriatrician.
41029408|NCT00623220|OTHER|N2O|EMONO
41029409|NCT00623220|OTHER|oxygen|oxygen
41029410|NCT04897295|DEVICE|Active transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
41029411|NCT04897295|DEVICE|Sham transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
41368378|NCT02898662|DRUG|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
41029412|NCT04393545|DEVICE|hallux valgus night splint|The HV night splint holds the hallux in abduction in order to provide a correct position. The SP group was given splints consisting of a rigid polyethylene bar along the medial of the hallux, and soft polyform and Velcro fastener parts.
41029413|NCT04393545|OTHER|exercise|The exercises involved strengthening the AbdH (abductor hallucis) and plantar fascia muscles, and stretching the hallux
41029414|NCT04393545|OTHER|Electrotherapy|Two self-adhesive electrodes were used. One was placed over the medial distal end of the first metatarsal and the other was attached to the motor point of the AbdH (inferior and posterior to the navicular tuberosity).21 The stimulation intensity was increased until a contraction was observed without causing discomfort and pain. Twenty-minute HVPGS was applied in total over three weekly sessions for four weeks.
41029415|NCT06370637|OTHER|MASD Control Arm|Tthe research coordinator HANS team will provide participants with a daily survey, a weekly survey, a Bristol stool scale and a 200 ml container with the specific cream for the arm assigned. Participants will be directed to apply the cream liberally after each bowel movement after cleaning the area in their usual manner. The research coordinator HANS team will review the instructions of application with the patient.
41029416|NCT05903274|DRUG|JSP191|Subjects will receive intravenous JSP191
41029417|NCT03032926|BEHAVIORAL|Open Trial|Behavioral Intervention
41029418|NCT00153049|DRUG|Telmisartan|
41029419|NCT00153049|DRUG|Hydrochlorothiazide|
41029420|NCT00153049|DRUG|Telmisartan + Hydrochlorothiazide|
41368379|NCT01955291|DEVICE|Reinforced Feedback in Virtual Environment (RFVE)|"The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task."
41368380|NCT01955291|OTHER|Traditional Neuromotor Rehabilitation|The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
41368381|NCT04983589|DRUG|Pilocarpine HCl|Pilocarpine HCl ophthalmic solution 1.25% ocular drops.
41368382|NCT04983589|DRUG|Vehicle|Oxymetazoline HCl and pilocarpine HCl placebo ocular drops.
41368383|NCT05038397|DEVICE|Theraspere|Prior to the administration of TheraSphere, the patient should undergo hepatic arterial catheterization using balloon catheterization or other appropriate angiographic techniques to prevent extrahepatic shunting. Following the placement of the hepatic catheter, 75 MBq to 150 MBq (2 mCi to 4 mCi) of Tc-99m MAA is administered into the hepatic artery to determine the extent of A-V shunting to the lungs and to confirm the absence of gastric and duodenal flow. When the possibility of extrahepatic shunting has been evaluated and the patient deemed acceptable for treatment, TheraSphere may be administered.
41368384|NCT03099096|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
41368385|NCT05375045|DEVICE|dental implantation|an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.
41368386|NCT05040282|DEVICE|Implanon NXT|women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.
41368387|NCT05084118|DRUG|Landiolol HCl|continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours
41368388|NCT05084118|DRUG|Placebo|continous application of isotone saline solution for 72 hours
41368389|NCT00438815|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
41502386|NCT06128070|DRUG|Tacrolimus|Given IV
41502387|NCT02598947|OTHER|Manual therapy|Exercise, behaviour change interventions and manual therapy
41161913|NCT05168514|OTHER|Massage|"Patient Identification Form, Pittsburgh Sleep Quality Index and McGill Pain Scale Short Form will be applied to patients with written and verbal consent. Scales and massage application will be done before the pharmacological agent is administered to the patients.~Back massage will be applied to the experimental group for 10 minutes every day for 10 days. Routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the experimental group before and after each massage and scores will be recorded for 10 days.~The control group will not be interfered with, and the routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the control group simultaneously with the experimental group and scores will be recorded for 10 days."
41161914|NCT05939089|DIAGNOSTIC_TEST|ECG, Echocardiography, cTnI, NT-ProBNP|All pediatric cancer survivors are evaluated with cardiological examination, ECG, transthoracic echocardiography (transesophageal echocardiography when required), NT-proBNP, cTnI, kidney function tests, liver function tests, fasting blood glucose, cholesterol panel, iron, iron binding capacity, ferritin, transferrin saturation, B12, vitamin D, folic acid, urinanalysis, hemogram and a questionnaire about living with heart failure.
41502388|NCT05403086|DRUG|Psilocybin|Psilocybin, \[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate.
41502389|NCT05403086|DRUG|Ketamine|ketamine hydrochloride injection, for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic and has a molecular formula of C13H16ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is (±)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.
41502390|NCT00237393|DRUG|Quetiapine|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
41368390|NCT00002110|DRUG|Cysteamine|
41502391|NCT00237393|DRUG|Placebo|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
41502392|NCT01716975|DRUG|EVP-6124|Arms 1, 2
41502393|NCT01716975|DRUG|Placebo|Arm 3
41368391|NCT00002110|DRUG|Zidovudine|
41368392|NCT00592423|OTHER|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
41368393|NCT01829321|DRUG|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
41368394|NCT01829321|DRUG|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
41368395|NCT03108352|DRUG|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)
41368396|NCT03108352|OTHER|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 \~ 11)
41502394|NCT00506792|DRUG|QAU145|
41502395|NCT00506792|DRUG|Placebo|
41502396|NCT02358135|OTHER|Collaborative Connected health, (CCH)|CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
41502397|NCT02358135|OTHER|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
41502398|NCT06630221|DRUG|Eltrombopag (EPAG)|100 mg, 28-day cycles, 3+ cycles
41502399|NCT02750748|DRUG|Naltrexone|
41502400|NCT02750748|OTHER|Intravail|
41502401|NCT06353269|DRUG|Estring Vaginal Product|estradiol vaginal ring, exchanged every 12 weeks
41502402|NCT06353269|DRUG|Vagifem|vaginal estrogen tablet, used twice per week
41502403|NCT06353269|DRUG|Estrace 0.01% Vaginal Cream|vaginal estrogen cream, used twice per week
41161915|NCT06477991|DRUG|Tireilizumab（PD-1 inhibitor）|"Neoadjuvant immunotherapy phase :~1. Pharmaceuticals: Tireilizumab: 200mg, intravenous infusion, Q3W, at least 4 cycles, the number of specific neoadjuvant immunotherapy cycles was determined according to the results of MRD dynamic monitoring.~2. MRD dynamic monitoring time node: dynamic monitoring at the initial diagnosis and after the fourth cycle of neoadjuvant immunotherapy. Blood monitoring points were 1-2 weeks after immunotherapy. If the two consecutive MRDs were negative, the watch and wait strategy was adopted. If the MRD was still positive after 8 cycles of neoadjuvant immunotherapy, surgical treatment was performed."
41502404|NCT01865942|PROCEDURE|open surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
41502405|NCT01865942|PROCEDURE|Minimal access surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
41502406|NCT06634186|DIETARY_SUPPLEMENT|Dietary intervention|The aim of the dietary intervention is the implementation of a fiber-enriched diet. Therefore, patients receive dietary counseling, supplemented with propionate, that functions as fiber-surrogate.
41368397|NCT05324774|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously."
41368398|NCT05324774|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~9 doses(2mg) of the drug will be injected intravitreously."
41368399|NCT02539160|DRUG|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
41368400|NCT00265382|DRUG|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
41368401|NCT04227561|PROCEDURE|Pudendal nerve block|"Pudendal nerve block will be performed under general anesthesia and guided by neurostimulation.~The local anesthetic solution (chirocaine 2.5mg/ml) will be injected in the ischiorectal fossa with a needle (a BBraun Stimuplex Ultra 360 22G 50mm needle) connected to a neurostimulator (Stimuplex HNS 12 neurostimulator). The neurostimulator will be used to determine the localization of pudendal nerve and to identify the precise site of injection. The contraction of the anal sphincter or bulbocavernosus muscle occurs when the pudendal nerve is reached.~These procedure will be performed bilaterally."
41502407|NCT00025259|BIOLOGICAL|Bleomycin Sulfate|Given IV or SC
41502408|NCT00025259|DRUG|Cisplatin|Given IV
41502409|NCT00025259|DRUG|Cyclophosphamide|Given IV
41502410|NCT00025259|DRUG|Cytarabine|Given IV
41502411|NCT00025259|DRUG|Dexamethasone|Given IV
41502412|NCT00025259|DRUG|Doxorubicin Hydrochloride|Given IV
41368402|NCT04227561|PROCEDURE|Penile nerve block|"The local anesthetic solution (chirocaine 2.5mg/ml) will be injected under the fascia of Scarpa with a real-time ultrasound guidance.~These procedure will be performed bilaterally."
41368403|NCT00106717|PROCEDURE|Narrative medicine|
41368404|NCT04088227|DRUG|Experimental Group|Patients will receive platelet rich plasma injection two times prior to surgery.
41368405|NCT04088227|OTHER|Control Group|Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
41502413|NCT00025259|DRUG|Etoposide|Given IV
41502414|NCT00025259|BIOLOGICAL|Filgrastim|Given SC
41502415|NCT00025259|RADIATION|Involved-Field Radiation Therapy|Undergo IFRT
41502416|NCT00025259|DRUG|Prednisone|Given orally
41502417|NCT00025259|DRUG|Vincristine Sulfate Liposome|Given IV
41502418|NCT01192048|OTHER|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
41502419|NCT06633068|DRUG|Adding perineural Nalbuphine to Bupivacaine in superficial cervical nerve block|Adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries
41502420|NCT06027385|DIAGNOSTIC_TEST|molecular-based screening|Test for three mutations in the CTNS gene and one mutation in the SMA1 gene.
41368406|NCT02720627|DRUG|cortexolone 17α-propionate|CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
41368407|NCT03290274|DEVICE|Deep brain stimulation (fornix)|Deep brain stimulation at fornix
41368408|NCT03290274|DEVICE|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation AT Basal nucleus of Meynert
41502421|NCT06235684|OTHER|Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion|During the first year, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at month 3, at month 12 and in case of unscheduled visit. Questionnaires and standardised voice collection will be collected (optionally) at different time points using the Colive web app. Physical activity and sleep quality will be optionally monitored via a smartwatch that will be provided to interested participants. Biological sample(s) and imaging data will be collected at different time points (baseline; 3 months; 12 months; unscheduled visit). A long-term follow-up (starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term follow-up medical data are collected on a yearly basis, and questionnaires are collected every 6 months.
41502422|NCT04215146|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
41502423|NCT04215146|BIOLOGICAL|Pelareorep|Pelareorep 4.5 x 10\^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.
41502424|NCT04215146|DRUG|Avelumab|Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.
41502425|NCT00004230|DRUG|captopril|
41502426|NCT00004230|DRUG|cyclophosphamide|
41502427|NCT00004230|PROCEDURE|autologous bone marrow transplantation|
41368409|NCT01720901|DRUG|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
41368410|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
41368411|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
41368412|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
41368413|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
41368414|NCT03647995|DIETARY_SUPPLEMENT|Probiolife by Green Made (Pharma M)|A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)
41368415|NCT03647995|OTHER|Placebo|A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
41368416|NCT05954117|PROCEDURE|Adipose tissue biopsies|"During the 2 surgical time, when patient is under general anesthesia, two adipose tissue biopsies of 20cc each (one from abdominal subcutaneous adipose tissue and one from omental adipose tissue) are taken and characterize by oxygraphy (respirometry).~Before the 2 surgical times (before and after chemotherapy) patients will have evaluation of the muscle strength, cachexia (by scan analysis), energy expenditure, anthropometric criteria and biochemical inflammatory."
41368417|NCT05619185|BEHAVIORAL|CRAFT Web-Based Intervention|Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
41368418|NCT05619185|BEHAVIORAL|Phone-Based CRAFT|The phone-based CRAFT intervention consists of six individual sessions with a CRAFT clinician that will explore what they learned from the WBI and additional skills they need. Session content includes positive reinforcement of non-drinking SM behaviors, refraining from interfering in SM's consequences of alcohol use, communication skills, and self-care.
41368419|NCT05619185|BEHAVIORAL|CRAFT Workbook|The self-directed CRAFT workbook Table 1.Partners Connect WBI has a parent and partner version that uses CRAFT to help the CP help with understanding, self-care, communication, and actions (e.g., how to react when a partner has been using substances and when they have not been using substances, how to talk to partner so that they are more likely to be heard) and includes more information about communicating than the WBI and several interactive worksheets.
41368420|NCT05619185|BEHAVIORAL|Gottman Self-Guided Resources|"To match time spent reviewing the website, CPs will receive an orientation guide that includes the website URL and a 4-week guide for how they can navigate this website for 20-30 minutes per week (e.g., read article 'It's Not My Fault!': Why Defensiveness is Damaging and write down one tool to dissolve defensiveness you're willing to try). We will send reminder emails each week to visit the website and include questions in the emails and our first online follow-up survey asking CPs approximately how many times they visited the website and how long they spent viewing content on the website. Reminder emails will be programmed such that CPs get directed automatically to the website if the CP notes no time spent on it."
41368421|NCT05818475|OTHER|Angiography-guided PCI|Non-culprit lesion treatment will be based on visual estimation by angiography. The evaluation of PCI result will be also based only on angiography.
41368422|NCT05818475|OTHER|Angiography-derived FFR PCI indication and planning|Non-culprit lesion treatment will be based on angiography-derived FFR result. In case of positive assessment, PCI will be planned according to the virtual PCI plan based on the physiology pullback curve.
41368423|NCT00918502|DEVICE|AVIVO system|Non invasive external monitoring device
41368424|NCT03094468|DRUG|P-3058 (terbinafine hydrochloride 10%)|Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
41368425|NCT03094468|DRUG|Vehicle of P-3058|Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
41368426|NCT03086252|PROCEDURE|Red Blood Cell Transfusions (RBCT)|Undergo patient-driven RBCT
41368427|NCT03484858|OTHER|High glycaemic index meal and exercise|
41368428|NCT03484858|OTHER|High glycaemic index meal and rest|
41266918|NCT02647151|DRUG|METHYLAMINOLEVULINATE HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
41368429|NCT03484858|OTHER|Low glycaemic index meal and exercise|
41368430|NCT03484858|OTHER|Low glycaemic index meal and rest|
41368431|NCT04279041|PROCEDURE|root canal preparation|root canal preparation
41502428|NCT00004230|PROCEDURE|peripheral blood stem cell transplantation|
41502429|NCT00004230|RADIATION|radiation therapy|
41502430|NCT02122692|DRUG|Lu AE58054 30 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
41502431|NCT02122692|DRUG|Lu AE58054 30 mg + itraconazole 200 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
41502432|NCT02122692|DRUG|Itraconazole|Itraconazole capsules, once daily, Day 12-13, orally
41502433|NCT00911027|DRUG|Contrast-enhanced ultrasound guided biopsy|"One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part"
41368432|NCT01794221|PROCEDURE|stitches and skin adhesive|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
41368433|NCT01794221|PROCEDURE|stitches only|standard of care
41368434|NCT00829595|BIOLOGICAL|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
41368435|NCT01367366|PROCEDURE|PET and EBUS-TBNA|PET and EBUS-TBNA once, respectively
41368436|NCT02917421|RADIATION|Radiation|(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
41368437|NCT00126321|DRUG|cladribine|2-chlorodeoxyadenosine, 2-CdA
41368438|NCT04748731|BEHAVIORAL|Internet mentalization-based video feedback intervention to improve parental sensitivity in mother-infant dyads with maternal depressive symptoms|a weekly online brief intervention using video-feedback and psycho-educational materials on early parenting
41368439|NCT04748731|BEHAVIORAL|Psycho-Educational Intervention|Reception of psycho-educational materials
41368440|NCT04109573|PROCEDURE|high resolution anal manometry|functional studies before and after anal laser ablation
41368441|NCT05534958|DEVICE|Accexible|Speech Analysis
41368442|NCT00001426|DRUG|Cyclophosphamide|
41368443|NCT00001426|DRUG|Paclitaxel|
41368444|NCT00001426|DRUG|Cisplatin|
41368445|NCT00001426|DRUG|G-CSF|
41368446|NCT00846573|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
40846584|NCT03465995|DEVICE|NKI i-PAS Diagnostic Protocol|"The NKI i-PAS:~The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for eye tracking with the following properties: a head mounted display, a sampling rate of 100 frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil area measurement with a spatial resolution less than 0.1 o. The testing protocol includes: optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal), self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time, gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical horizontal. Several quantitative measures are computed from the data acquired in each test, and these measures are then employed in a multivariate diagnostic assessment."
41029421|NCT02358577|DEVICE|In-bed cycling|In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
41368447|NCT00712634|BIOLOGICAL|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
41368448|NCT01325376|BEHAVIORAL|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
41368449|NCT01325376|BEHAVIORAL|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
41368450|NCT02491918|PROCEDURE|cataract surgery|cataract surgery in children
41368451|NCT02491918|PROCEDURE|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
41368452|NCT04784676|OTHER|restoration|indirect restoration
41368453|NCT03938857|DRUG|Fentanyl|Fentanyl standard of care
41368454|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
41368455|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)
41368456|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
41368457|NCT01761461|DRUG|TS-1, oxaliplatin|
40846585|NCT00465140|DRUG|creatine supplementation|
41368458|NCT03113773|DRUG|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10\^6 - 3.0 X 10\^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10\^6 IU will be allowed per day.
41368459|NCT03113773|DRUG|Placebo Injection|Dextrose 5%
41368460|NCT03592251|DIETARY_SUPPLEMENT|Olive Oil Placebo|6 months placebo supplementation
41368461|NCT03592251|DIETARY_SUPPLEMENT|EPA-rich|6 months placebo supplementation
41368462|NCT03592251|DIETARY_SUPPLEMENT|DHA-rich|6 months placebo supplementation
41368463|NCT05585008|DEVICE|two different denture manufacturing technique (heat cure pack and press technique(heat cure acrylic,Acrostone,Egypt)/3d printed dneture(HARZ lab,Russia))|retention for the two groups will be measured at 0,1 and 3months, patient satisfaction will be recorded, and accuracy of the denture base will be measured on the software.
41368464|NCT00190385|PROCEDURE|Ultrasonographic screening|Ultrasonographic screening
41368465|NCT02112565|DRUG|RNR inhibitor COH29|Given PO
41368466|NCT02112565|OTHER|laboratory biomarker analysis|Correlative studies
41368467|NCT02112565|OTHER|pharmacological study|Correlative studies
41368468|NCT01220817|DRUG|3 POMx capsules|3 POMx capsules daily
41368469|NCT01220817|DRUG|1 POMx capsule|1 POMx capsule daily
41368470|NCT04469140|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
41368471|NCT05160766|BIOLOGICAL|Comirnaty(BTN162b2)|Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection
41368472|NCT05160766|BIOLOGICAL|Spikevax (mRNA-1273)|Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection
41161916|NCT06353802|DIAGNOSTIC_TEST|Chronic non-specific neck pain and lumbar reposition sense|"In order to evaluate the lumbar joint repositioning error using the Joint Positioning Sense, the following guidelines were followed: (I) The participants were to stand with their arms at their sides, their feet externally rotated (about 20 degrees).~(II) With the feet flat on the floor and the arms resting on the front of the thighs, the person was seated in a height-adjustable seat that measured the length of the shank. (III) With a belt fastened, the iPhone® was positioned upright just above the iliac crest, (IV) the inclination of the inclinometer was 0°; (V) The inclinometer's 0° point was set as the initial position. (VI) The individual was passively guided by the assessor to a 30° flexion within the range of 0 to 30°; (VII) the subject was to memorize this position for 10 s; (VIII) the subject actively returned to the initial position. (IX) Subsequently, the participant was required to actively replicate the position three times."
41161917|NCT04526314|OTHER|observational|observational
41368473|NCT00717899|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
41368474|NCT03564860|PROCEDURE|Device data collection|Collection of device electrograms and 12-lead ECG during a device follow-up visit
41368475|NCT00953589|DRUG|ribavirin|Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day
41368476|NCT03431129|DIAGNOSTIC_TEST|Hyperpolarized gas and proton lung MRI|Lung MRI for participants undergoing radiation therapy (RT)
41368477|NCT02740751|DIETARY_SUPPLEMENT|Still-Tee|The mothers of the babies will receive Still-Tee galactogogue tea
41368478|NCT01070849|OTHER|educational booklet|"Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the back book of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell."
41368479|NCT01070849|OTHER|IRENA|Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.
41368480|NCT01070849|OTHER|RÜCKGEWINN|For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
41368481|NCT03964896|OTHER|Survey|Complete survey
41368482|NCT03964896|OTHER|Survey Administration|Ancillary studies
41368483|NCT03964896|BEHAVIORAL|Telephone-Based Intervention|Receive telephone calls
41368484|NCT04584619|DEVICE|Spine fusion surgery with Clariance Idys TLIF 3DTi|Posterior fusion of the lumbar spine with Clariance Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).
41368485|NCT00045136|DRUG|melphalan|
40846586|NCT00465140|BEHAVIORAL|aerobic exercise training|
41161918|NCT00497692|DRUG|Lactoserum|
41161919|NCT06233474|DRUG|Allocetra|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state
41161920|NCT06233474|OTHER|Placebo|The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.
41161921|NCT02924181|DEVICE|SmartTouch Catheter|Pulmonary vein (PV) isolation guided by CF information
41368486|NCT00045136|PROCEDURE|peripheral blood stem cell transplantation|
41368487|NCT00045136|RADIATION|holmium Ho 166 DOTMP|
41368488|NCT00267917|DEVICE|Berodual Respimat|
41368489|NCT00267917|DEVICE|Berodual HFA-MDI|
41368490|NCT01579994|DRUG|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
41368491|NCT03957291|DRUG|Chlorhexidine|chlorhexidine administration prior to ophthalmic surgery (compared to Povidine iodine )
41368492|NCT03957291|DRUG|Povidone-Iodine|Povidine iodine administration prior to ophthalmic surgery (compared to chlorhexidine)
41502434|NCT00911027|PROCEDURE|ultrasound guided systematic biopsy|Current practice of ultrasound guided systematic biopsy
41502435|NCT06632379|DRUG|Atorvastatin 10 mg|Participants will be assigned to 10 mg Atorvastatin
41502436|NCT06632379|DRUG|Placebo|Participants will be assigned to identical appearing placebo
41502437|NCT03883308|BEHAVIORAL|Multi-domain cognitive training|The cognitive exercises are designed to train executive functions and memory.
41502438|NCT03883308|BEHAVIORAL|Cross-word puzzle training|The active control group will be asked to complete a variety of crossword puzzles using the same curriculum assigned to the TG group.
40846587|NCT00945932|DRUG|GW870086X|Investigational product
40846588|NCT00945932|DRUG|Placebo|Placebo control
40846589|NCT04238130|DIAGNOSTIC_TEST|Perioperative ctDNA Dynamic Monitoring|To apply ctDNA dynamic monitoring in early stage NSCLC patients with driver mutations positive at baseline
41502439|NCT03079635|DIETARY_SUPPLEMENT|Control|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
41502440|NCT03079635|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
41502441|NCT02953977|BEHAVIORAL|Diabetes Prevention Program|An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
41502442|NCT02421224|BEHAVIORAL|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
41502443|NCT02421224|BEHAVIORAL|Deposits|Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
41502444|NCT02421224|BEHAVIORAL|Small Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
41502445|NCT02421224|BEHAVIORAL|Large Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
41502446|NCT02421224|BEHAVIORAL|Teammate|Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.
41502447|NCT02421224|BEHAVIORAL|Team Bonus|If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
41502448|NCT06442462|DRUG|SPG302|small synthetic molecule
41502449|NCT06442462|DRUG|Placebo|Placebo
41502450|NCT04615650|PROCEDURE|Surgical treatment|Surgical treatment of suprasyndesmotic ankle fractures
41502451|NCT04615650|DEVICE|Ankle orthosis|Non-surgical treatment of suprasyndesmotic ankle fractures
41502452|NCT01723618|DRUG|CRD007|
41502453|NCT04278716|OTHER|Safe return to play checklist|this objective checklist will be utilized by the physical therapy staff and surgeon to determine whether an athlete is safe to return to their sport
41502454|NCT05898165|OTHER|Development of an algorithm|Prospective verification of a developed algorithm to predict the risk of a new onset Atrial Fibrillation
41502455|NCT00576316|DRUG|Symbicort Turbuhaler 160/4.5|
41502456|NCT05871034|PROCEDURE|phacoemulsification|cataract extraction
41502457|NCT03414086|OTHER|Healthy Control|Ten healthy adult patients evaluating serum, PBMC's, and RNA.
41502458|NCT03414086|OTHER|Myositis in Remission|Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.
41502459|NCT03714828|DRUG|Injection of TVEC into target lesions - week 1-2|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient."
41161922|NCT02879539|DEVICE|MP3000 sound coding strategy or ACE strategy with lower stimulation|
41368493|NCT05942742|DEVICE|MRI Linac|External radiotherapy will be performed at Linac MRI, 25 fractions of radiation will be delivered for each patient.The MR-linac offers the ability to individualise and adapt daily treatment plans based on the position or anatomy of the day, following either a simple 'virtual couch shift' adapt-to-position (ATP) approach, or a more complex full reoptimisation adapt-to-shape (ATS) method based on the recontouring of relevant structures. During each radiation therapy, T2-weighted images and diffusion images will be purchased.Treatment plans can be produced and checked by appropriately trained Radiation Oncologists. Each radiation oncologist will decide based on the anatomy of the day the type of workflow to be used (ADP or ATS) for treatment.Patients will undergo accurate image acquisition, registration and interpretation to make sound clinical judgements and proceed to safe and accurate treatment delivery.
41368494|NCT03588312|PROCEDURE|Aortoplasty using autologous pericardial patch|hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
41368495|NCT06063382|BEHAVIORAL|Exam|Academic exam based on the Brazilian National High School Exam (ENEM).
41368496|NCT02312934|DRUG|Transdermal nicotine|Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
41368497|NCT02312934|OTHER|Placebo Transdermal Patch|Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
41368498|NCT00943007|DEVICE|Stealth Station|Neuronavigation based on preoperative MRI
41368499|NCT00943007|DEVICE|PoleStar N20|Intraoperative MRI guided surgery
41368500|NCT05471401|DEVICE|Balloon-tipped catheter|Gastric balloon
41368501|NCT04532086|DIAGNOSTIC_TEST|Uterocervical angle|Transvaginal ultrasound examination will be performed at 18-28 weeks gestation in (197) pregnant women with live singleton fetuses, attending routine prenatal care services. Measuring length of uterine cervix at (18-28) weeks \& evaluation of dilatation of internal os \& measurement of uterocervical angle between(18-28)weeks gestational age.
41368502|NCT02828098|DRUG|Part 1: BO-112|Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
41368503|NCT02828098|DRUG|Part 2: BO-112|"BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year."
41368504|NCT01961310|BIOLOGICAL|Plasma analysis for bacterial translocation|1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
41368505|NCT01961310|BIOLOGICAL|Stool analysis|DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
41368506|NCT03311295|DEVICE|ARTO System|The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
41368507|NCT04533204|BEHAVIORAL|mnemonic strategy training|training using mnemonic strategies
41368508|NCT04533204|BEHAVIORAL|spaced retrieval training|training using spaced retrieval
41368509|NCT04690673|DRUG|Paracetamol|1 g oral paractamol
41368510|NCT04690673|DIAGNOSTIC_TEST|Paracetamol concentration measurements and lipidomic assessment|Paracetamol concentration is measured from saline-, urine-, venous blood- and fingerprick- samples at timely intervals. Also serum lipidomic assessment is performed from venous blood samples.
41368511|NCT05671731|DIETARY_SUPPLEMENT|Beneo Synergy 1|
41368512|NCT05671731|BEHAVIORAL|Project FUN|Project FUN, a culturally tailored online nutrition and physical activity program is based on the Health Promotion/ Transtheoretical Model. It includes 8 modules offered in a password-protected learning management system along with a workbook also used to assure intervention completion.
41368513|NCT03804723|DRUG|oral Prednisone 5mg|patients randomized to this arm will stop prednisone 5 mg
41368514|NCT00004808|DRUG|fluconazole|
41368515|NCT02714621|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
41368516|NCT03986905|DRUG|Scopolamine Nasal Gel|All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
41368517|NCT03986905|OTHER|Placebo|placebo nasal gel + placebo patch
41368518|NCT00182572|DRUG|buprenorphine|
41368519|NCT00182572|DRUG|naltrexone|
41368520|NCT00182572|PROCEDURE|behavior therapy|
41368521|NCT00182572|PROCEDURE|voucher-based contingency management|
41368522|NCT04923776|DRUG|Carboplatin|The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
41368523|NCT04923776|DRUG|Etoposide|The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
41368524|NCT04923776|DRUG|Atezolizumab|The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
41368525|NCT04923776|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
41368526|NCT00542321|OTHER|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
41502460|NCT03714828|DRUG|Injection of TVEC into target lesions 3wks after 1st injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the second and subsequent doses."
41368527|NCT00542321|DEVICE|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
41368528|NCT00136994|DRUG|Ziprasidone|
41368529|NCT02117466|DRUG|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
41368530|NCT02117466|DRUG|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
41368531|NCT02545270|PROCEDURE|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
41368532|NCT02545270|PROCEDURE|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
41368533|NCT02545270|PROCEDURE|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
41368534|NCT05270564|PROCEDURE|Drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
41368535|NCT05270564|PROCEDURE|No drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
41502461|NCT03714828|DRUG|Injection of TVEC into target lesions 2wks after 2nd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
41502462|NCT03714828|DRUG|Injection of TVEC into target lesions 2wks after 3rd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
41502463|NCT00002825|BIOLOGICAL|filgrastim|
41029422|NCT02358577|OTHER|Usual Care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
41029423|NCT01895387|DIETARY_SUPPLEMENT|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
41029424|NCT01895387|DIETARY_SUPPLEMENT|Dietary intervention-Refined rice|Subjects in the control group maintained their usual diet of refined rice
41029425|NCT01260246|DRUG|sitagliptin|pill, 100mg/daily for 6 months
41029426|NCT01260246|DRUG|placebo|placebo match for 6 months
41029427|NCT05212974|OTHER|Questionnaires|The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.
41161923|NCT03455218|DRUG|Nitric Oxide|20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass
41368536|NCT04621604|OTHER|blood samples|Extra blood samples will be collected during chemotherapy administration to analyze pharmacokinetics of the iPD1
41368537|NCT01858701|DEVICE|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
41368538|NCT01858701|DEVICE|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
41502464|NCT00002825|DRUG|docetaxel|
41502465|NCT06621004|DRUG|Patients will receive propranolol 1-2 mg.|Patients will receive propranolol 1-2 mg. prepared in a 10 ml syringe (100 ug/ml).
41502466|NCT06621004|DRUG|Patient receives magnesium sulphate|Magnesium sulphate 10%: 1g ampoule (10ml), will be prepared in a syringe pump to be given at a rate of 40 ml/hr . Another syringe of 10 ml 0.9% sodium chloride will be prepared to be given in group (P).
41502467|NCT06063057|BIOLOGICAL|low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml
41029428|NCT02445820|DRUG|HES|2500 mL of balanced HES 130/0.4
41029429|NCT02445820|DRUG|Crystalloid|2500 mL of balanced crystalloid.
41029430|NCT05548595|DIETARY_SUPPLEMENT|Investigational|2 tablets are taken with water around the same time every day, ideally after a meal
41161924|NCT03455218|DRUG|Placebo|INOmax device connected to oxygenator, but no gas is delivered
41161925|NCT03455218|DEVICE|INOmax|All patients will have the INOmax device connected to the oxygenator
41029431|NCT05548595|OTHER|Placebo|2 tablets are taken with water around the same time every day, ideally after a meal
41029432|NCT01926106|DEVICE|nIPPV|one of the twins was randomly allocated to nIPPV
41029433|NCT01926106|DEVICE|nCPAP|another of the twins was allocated to nCPAP
41029434|NCT06532682|DRUG|dapagliflozin|dapagliflozin 5 MG/10 MG once daily
41029435|NCT06532682|DRUG|ACE inhibitor|ACE inhibitor
41029436|NCT06210256|PROCEDURE|unidirectional valve apparatus|In the unidirectional valve group, we attached the unidirectional valve device to the lumen's distal port when one-lung ventilation initiated.
41161926|NCT06308549|BEHAVIORAL|MyDiaMate|MyDiaMate programme
41161927|NCT00546702|DRUG|Insuline Glulisine|
41161928|NCT00344539|BIOLOGICAL|AMA1-C1/Alhydrogel®|AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
40846590|NCT05945303|PROCEDURE|Coronary Artery Bypass Grafting surgery|Assessing the reliability of predicting fluid responsiveness in adults undergoing coronary artery bypass graft surgery using ultrasonography of the internal jugular vein for assessment of vessel distensibilty in relation to stroke volume variation (SVV) measured by electrical cardiometry.
41029437|NCT06210256|PROCEDURE|occluding the non-ventilated endobronchial lumen|In the closed operative lumen group, we closed the lumen's distal port of non-ventilated lung when one-lung ventilation initiated.
41029438|NCT04586855|DIAGNOSTIC_TEST|Diagnostic Ultrasound|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
41029439|NCT04586855|DIAGNOSTIC_TEST|Transnasal Fiberoptic Laryngoscopy|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
41029440|NCT00354705|BEHAVIORAL|Questionnaire|Two questionnaires taking 30 minutes to complete.
41161929|NCT00344539|BIOLOGICAL|CPG 7909 Oligodeoxynucleotide (VaxImmune®)|CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
41161930|NCT04826419|OTHER|ozone therapy|The treatment session of oxygen-ozone was 80 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) five times a week for the first week.The treatment session of oxygen-ozone was 40 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) twice a week after first week.
41161931|NCT03412578|PROCEDURE|Massage Therapy|Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
41368539|NCT00834366|DRUG|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
41368540|NCT02662959|DRUG|Irinotecan|180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
41368541|NCT01142362|BIOLOGICAL|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
41368542|NCT06523322|BEHAVIORAL|Let's Cook Together|The 8-week Let's Cook Together program is intended to increase: caregiver knowledge of the benefits of a whole foods approach to eating; preparedness for caregiving; and caregiver self-efficacy for managing patients' nutrition-related side effects. The entire program will be delivered remotely. Caregivers will be recruited to participate in an 8-week remote culinary medicine intervention, including four remote synchronous culinary workshops (one 90-minute introductory event and three, 90-minute culinary/cooking sessions), and four bi-weekly caregiver coaching telephone calls (lasting 15-20 minutes).
40846591|NCT03033264|DRUG|Dinoprostone|10 mg of a Dinoprostone vaginal insert.
41029441|NCT02742727|BIOLOGICAL|anti-CD7 CAR-pNK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
41029442|NCT01681693|DRUG|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
41029443|NCT02295111|DEVICE|EA treatment|Electro acupuncture and traditional Chinese Medicine Health consult
41029444|NCT02295111|BEHAVIORAL|TCM health consult|Traditional Chinese Medicine Health Consult without needling
41029445|NCT02295111|OTHER|Usual Care|Standard NHS care
41029446|NCT01431066|DEVICE|Sham pulsed radio-frequency electromagnetic device|Disabled PRFE device
41029447|NCT01431066|DEVICE|ActiPatch PRFE Device|Actipatch PRFE device
41029448|NCT03574129|BEHAVIORAL|Adolescent Transition Package|Clinic level intervention composed of an adolescent transition package with tools to support health care workers to disclose HIV status to adolescents and to track transition to adult care.
40846592|NCT03033264|DEVICE|Double lumen cervical ripening balloon.|Double lumen cervical ripening balloon.
40846593|NCT06323707|BEHAVIORAL|Exercise|Eight sessions of moderate intensity aerobic exercise using recumbent bike within the cancer institution.
40846594|NCT06323707|BEHAVIORAL|Self-management e-module|Eight 15 minute self-management e-modules related to exercise and physical activity for cancer survivors.
41029449|NCT03595345|PROCEDURE|Liver transplantation|Liver transplantation
41029450|NCT03145116|DEVICE|CT ASPHINA 509|Intraocular lens
41029451|NCT04701021|BIOLOGICAL|TENDU|The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.
41029452|NCT05226208|DIAGNOSTIC_TEST|Visual analogue scale (VAS)|In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.
41029453|NCT05226208|DIAGNOSTIC_TEST|General anxiety scale (GAD-2) and survey|In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.
41029454|NCT03032120|DIETARY_SUPPLEMENT|Orange juice|Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
41029455|NCT03032120|DIETARY_SUPPLEMENT|Control|Lean and obese subjects drank one single dose (5 mL/kg body weight) of an energy and sugars-matched orange-flavored drink (control), followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
41029456|NCT03431168|DRUG|Azithromycin/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
41029457|NCT03431168|DRUG|Placebo/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
41161932|NCT00162552|DRUG|pentoxifylline|Patients with severe cirrhosis treated with Pentoxifylline
41161933|NCT00162552|DRUG|PLACEBO|Patients with severe cirrhosis treated with a placebo
41368543|NCT03802331|DRUG|BI 1323495,|single oral doses
41368544|NCT05775666|BIOLOGICAL|UCLM802 Cell Injection|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
41368545|NCT01171274|BEHAVIORAL|Hatha Yoga|"* 9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~* One class of 90 minutes per week, 10 minutes training at home each day."
41368546|NCT01171274|BEHAVIORAL|Information regarding exercises and behaviour|"* 9 weeks of exercises practiced at home.~* Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
41368547|NCT00913874|DRUG|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
41368548|NCT00913874|DRUG|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
41029458|NCT06100926|DEVICE|software|virtual reality scene
41029459|NCT00395044|DRUG|Placebo|Placebo
41029460|NCT00395044|DRUG|Gabapentin|
41029461|NCT03786601|OTHER|Observation|The participants were assigned to different groups according to the results of HPV detection.
41029462|NCT01563861|GENETIC|RNA analysis|
41368549|NCT00239694|BIOLOGICAL|Pneumococcal Vaccine|One time preventative vaccine
41368550|NCT00239694|BIOLOGICAL|Meningococcal Vaccine|One time preventative vaccine
41368551|NCT05245266|DIAGNOSTIC_TEST|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
41368552|NCT03033641|DEVICE|Ablation procedure|All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
41368553|NCT00517517|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
41368554|NCT02185820|DRUG|Carfilzomib|
41368555|NCT02185820|DRUG|Pomalidomide|
41368556|NCT02185820|DRUG|Dexamethasone|
41368557|NCT05428176|OTHER|Best Practice|Receive usual care
41368558|NCT05428176|OTHER|Internet-Based Intervention|Undergo eHealth intervention
41368559|NCT05428176|OTHER|Quality-of-Life Assessment|Ancillary studies
41368560|NCT05428176|OTHER|Questionnaire Administration|Ancillary studies
41029463|NCT01563861|GENETIC|gene expression analysis|
41029464|NCT01563861|OTHER|immunohistochemistry staining method|
41029465|NCT01563861|OTHER|laboratory biomarker analysis|
41161934|NCT01120561|DRUG|trastuzumab-MCC-DM1|Intravenous repeating dose
41502468|NCT06063057|BIOLOGICAL|medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml
41502469|NCT06063057|BIOLOGICAL|high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml
41161935|NCT06192017|DIAGNOSTIC_TEST|WomEC|The study will collect pipelle biopsies from post-menopausal women presenting with AUB entering to the EC diagnostic process at the clinical consultancy or emergency room. In the study an endometrial biopsy by aspiration will be collected (i.e., pipelle biopsy) and it will be used for (1) diagnostic purposes following current procedures (i.e., pathological examination and diagnosis); (2) placed in a collection tube for WomEC test.
41029466|NCT05870098|DIAGNOSTIC_TEST|All participants|"1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine."
41368561|NCT01731821|PROCEDURE|pancreaticojejunostomy|"Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
41368562|NCT06511102|BEHAVIORAL|GPT Support|The computer interface used for the essay writing task follows a split-screen design. The writing instructions and text input field are administered on a survey platform, placed on the left half of the screen. ChatGPT is placed on the right half of the screen for technology assistance.
41368563|NCT00001961|PROCEDURE|MRI|
41368564|NCT05747157|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.
41368565|NCT04524663|DRUG|Camostat Mesilate|Camostat Mesilate administered as oral tablets
41368566|NCT04524663|DRUG|Placebo|Placebo to match camostat mesilate
41368567|NCT04524663|OTHER|Standard of Care Treatment|Standard of Care Treatment for COVID-19 Infection
41368568|NCT05943249|PROCEDURE|magnetic resonance|
41368569|NCT00274573|DRUG|Tiotropium bromide|
41368570|NCT02486458|DRUG|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
41029467|NCT04336202|RADIATION|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
41029468|NCT06306534|OTHER|Auditory Nerve Acute (ANA) Electrode Array|To measure eABRs when stimulating the human auditory nerve
41029469|NCT01925716|OTHER|Corn oil|corn oil 56 g/day for 21 days
41029470|NCT01925716|OTHER|Olive oil|olive oil 56 g /day for 21 days
41161936|NCT02169778|BEHAVIORAL|Intermittent energy restricted diet|
41161937|NCT02169778|BEHAVIORAL|Continuous energy restricted diet|
41161938|NCT02189577|DRUG|CHF 5259|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
41161939|NCT02189577|DRUG|Placebo|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
41161940|NCT02748902|DRUG|ingenol mebutate 0.05% gel|Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
41161941|NCT00243633|PROCEDURE|Real-time contrast-enhanced ultrasound sonography|
41161942|NCT04564547|DRUG|Islatravir|ISL capsule taken by mouth.
41161943|NCT04564547|DRUG|Ulonivirine|Ulonivirine tablet taken by mouth.
41368571|NCT02486458|DRUG|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
41368572|NCT04853368|DRUG|ABBV-576|Oral capsules
41368573|NCT04853368|DRUG|Galicaftor|Oral capsules
41368574|NCT04853368|DRUG|Placebo|Oral capsules
41368575|NCT04853368|DRUG|Navocaftor|Oral capsules
41368576|NCT04853368|DRUG|ABBV-119|Oral capsules
41368577|NCT05315687|DEVICE|Y-90 SIR-Spheres|Y-90 SIR-Spheres
41368578|NCT05315687|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo Y90 radioembolization
41161944|NCT04564547|DRUG|BIC/FTC/TAF|BIC/FTC/TAF tablet taken by mouth.
41161945|NCT04564547|DRUG|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
41161946|NCT04564547|DRUG|Placebo to Ulonivirine|Placebo tablet matched to ulonivirine taken by mouth.
41161947|NCT04564547|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
41161948|NCT02427958|DRUG|Leuprorelin|Suspension for injection.
41368579|NCT05315687|OTHER|Systemic Therapy|Systemic Therapy
41368580|NCT04645225|DEVICE|. MEFV genetic testing|For mutation analysis, 2 ml blood will be with drawn from both patient and control groups in order to obtain genomic DNA. Extraction of DNA molecule from peripheral blood lymphocytes will be done using standard procedures, then amplification of MEFV gene will be done by polymerase chain reaction(PCR). Reversed hybridization technique will be used for identification of MEFV gene mutation.
41368581|NCT03556254|DRUG|GGT|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
41368582|NCT03556254|DRUG|SGT|In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
41368583|NCT01889342|BEHAVIORAL|Metacognitive therapy|
41368584|NCT01889342|BEHAVIORAL|Cognitive behavioral therapy|
41368585|NCT06119789|DRUG|Imatinib|imatinib treatment based on molecular alterations
41029471|NCT05043337|BEHAVIORAL|Maternal voice|"The recordings were made in a quiet and separate consultation room. For infants in the maternal voice group, mothers were recorded what they wanted to say to their baby and read an independently published children's book, Xiao Qi's yellow persimmon which describes how mothers with premature babies care for their infants. After reviewing the quality of the recordings, the maternal voice recordings were edited for 13 minutes using a sound organizer. Respiration, heart rate, oxygen saturation, and Neonatal Infant Pain Scale (NIPS) were measured and recorded 3 minutes before, during, 1 minute, 3 minutes, and 10 minutes after the puncture."
41368586|NCT05909176|BEHAVIORAL|GYN Residency Training|The combined care model will be implemented and during months 5-14.
41029472|NCT05043337|BEHAVIORAL|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture.
41368587|NCT05909176|BEHAVIORAL|Social Media Campaign|The social media campaign will be implemented along with the combined care model in months 15-18.
41368588|NCT04564534|OTHER|MoCA cognitive assessment|cognitive assessment using the validated MoCA test administered via an application on an iPad
41368589|NCT04936126|DRUG|Quetiapine|Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment for the study period
41368590|NCT04936126|DRUG|Amantadine|Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment for the study period
41368591|NCT04936126|DRUG|Pramipexole|Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment for the study period
41368592|NCT04259541|DIAGNOSTIC_TEST|Psychodiagnostic|Intensity and frequency of specific symptoms, signs of problems in mental health
41368593|NCT00938002|DIAGNOSTIC_TEST|Acceler8 Pheno|
41368594|NCT00845598|DRUG|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily"
41368595|NCT00845598|DRUG|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
41368596|NCT01695681|OTHER|Gluten-free diet|Dietary advice by clinical dietitian
41368597|NCT00483119|DRUG|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
41368598|NCT00483119|DRUG|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
41368599|NCT00223158|DRUG|Liothyronine|
41368600|NCT03195946|DRUG|Lu AF35700|tablets for oral use, 10 mg/day
41368601|NCT03195946|DRUG|Midazolam|syrup for oral use, 4mg/day
41368602|NCT03195946|DRUG|Cocktail of CYP450 substrates|Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
41368603|NCT05635695|OTHER|Free Museum visit|People are tested when they arrive at the museum. Then, they freely visit the different rooms for 45 to 75 minutes. No instructions are given.
41368604|NCT05635695|OTHER|Cultural pathways App|Cultural pathways in the park of the museum will be proposed to people with a smartphone application that will give directions, cultural and sustainable health contents, points of interest with games and specific information about the pathways (distance, noise level, walkability, practical information). There will be two possible levels: contemplative or active.
41368605|NCT00781001|DRUG|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
41368606|NCT02108158|DRUG|Azzalure|
41368607|NCT04938882|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
41368608|NCT04938882|DRUG|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
41368609|NCT04938882|DRUG|Compound lidocaine at low concentration|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
41368610|NCT04938882|DRUG|Compound lidocaine at high concentration|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
41368611|NCT03135730|GENETIC|ROHHAD|Suspected and Confirmed ROHHAD cases
40846595|NCT05474222|OTHER|Horizon Eagle Fatherhood Program - classroom instruction|The intervention group (the Horizon Eagle Fatherhood Programming) receives 40 hours of classroom instruction
41368612|NCT01365026|BEHAVIORAL|PVS: Programa de Vida Saludable|Lifestyle counseling and prescription
41368613|NCT00690612|DRUG|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
41368614|NCT00142428|DRUG|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
41368615|NCT01493440|DRUG|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
41368616|NCT05632094|DIETARY_SUPPLEMENT|L-Carnitine|The clozapine-intoxicated patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose was 50 mg/kg IV every 8 h.
41368617|NCT01161173|DRUG|Erlotinib|Erlotinib was provided in the retail versions of the product.
41368618|NCT02182076|DRUG|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
41368619|NCT06510322|DRUG|Sildenafil|Orally administered phosphodiesterase-5 (PDE-5) inhibitor, which enhances nitric oxide signaling in platelets and blood vessels.
41368620|NCT06510322|OTHER|Placebo|Matched capsule not containing any medication
41368621|NCT01912482|OTHER|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
41368622|NCT01912482|OTHER|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
41368623|NCT04800406|PROCEDURE|Dental Implants|Resorbable blast media surface treated dental implant and Acid etched surface treated dental implant.
40846596|NCT02549131|PROCEDURE|Randomizing to Suture or Staple closure of Cesarean section|Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.
40846597|NCT00428389|DRUG|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm\^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
41368624|NCT00588120|DRUG|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."
40846598|NCT00428389|DRUG|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm\^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
40846599|NCT04791631|PROCEDURE|Epiretinal membrane surgery|Surgery for epiretinal membrane i.e. standard 3-port pars plana vitrectomy and epiretinal membrane and internal limiting membrane peel. Phakic patients will undergo cataract surgery.
40846600|NCT01870726|DRUG|INC280|"Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily."
40846601|NCT01870726|DRUG|Buparlisib|Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
40846602|NCT01781780|BEHAVIORAL|General Nutrition Recommendations|
41368625|NCT01026727|DRUG|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
41368626|NCT01026727|DRUG|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
41502470|NCT06063057|BIOLOGICAL|Enterovirus type EV71 vaccine (Vero cell), Inactivated|Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)
41368627|NCT06287801|OTHER|Annual Wellness Visit|Completion of a structured Annual Wellness Visit (AWV) questionnaire administered by an assigned practice staff member for Medicare beneficiaries deemed by study algorithm as high-risk. Those responses will then be used by the primary care team to place any needed referrals and offer any indicated personal health advice and create a care plan for the coming year. Routine usual care from the primary care practice will occur.
40846603|NCT01781780|BEHAVIORAL|Breakfast Recommendation|
40846604|NCT01781780|BEHAVIORAL|No Breakfast Recommendation|
40846605|NCT03178669|DRUG|cobitolimod|Rectal administration
40846606|NCT03178669|DRUG|Placebo|Solution manufactured to mimic cobitolimod
40846607|NCT03440489|DIAGNOSTIC_TEST|Six-minute walking test|physical performance of the muscle measured by these tests
40846608|NCT03440489|DIAGNOSTIC_TEST|30 seconds chair stand test|physical performance of the muscle measured by these tests
40846609|NCT02798471|DRUG|Edoxaban|15 or 30 mg tablets for participants 12 years of age to \<18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
41502471|NCT05162508|OTHER|Nasopharyngeal swab|Nasopharyngeal swab available in Standard Of Care (SOC) will be analysed (Full-length SARS-CoV-2 RNA sequencing and Transcriptomic analyses)
41502472|NCT04815655|PROCEDURE|Cartilage tympanoplasty|is the reconstruction of the tympanic membrane (TM) by using catilage
41502473|NCT01831258|DEVICE|SensAwake On|
41502474|NCT01831258|DEVICE|SensAwake Off|
41502475|NCT03812744|DRUG|Whole coffee cherry extract (WCCE)|100mg WCCE
41502476|NCT03812744|DRUG|Placebo Oral Capsule [CEBOCAP]|Silica Oxide
40846610|NCT02798471|DRUG|Standard of Care|Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
40846611|NCT02741765|BEHAVIORAL|Sham rTMS|Subjects will participate in daily sessions of sham-rTMS
40846612|NCT02741765|OTHER|Real rTMS|Subjects will participate in a combination of rTMS
40846613|NCT02741765|BEHAVIORAL|Supervised aerobic exercise|
40846614|NCT05930691|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement|Prediction of intracranial pressure by using Ultrasonography on optic nerve sheath diameter.
40846615|NCT01673620|DRUG|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg tablet administered once daily
40846616|NCT01673620|DRUG|Placebo|Matching placebo tablet administered once daily
41502477|NCT04267029|DIAGNOSTIC_TEST|TADPOL battery (deep clinicolaboratory profile)|"profile dimensions:~* hemolytic~* allergic~* cardiorenal~* inflammatory~* leukoagglutinating~* exploratory bioarchive"
41502478|NCT00368017|DRUG|pioglitazone|30 mg once a day for 12 weeks
40846617|NCT05830825|PROCEDURE|Vertebral Body Tethering (VBT)|Vertebral Body Tethering surgery with the Tether™ in UK
40846618|NCT00258323|DRUG|cisplatin|20mg/m2d/IV continuous infusion x days
40846619|NCT00258323|DRUG|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
40846620|NCT00258323|DRUG|Iressa|250mg po qd days 1-28 then x 2 years
40846621|NCT00258323|PROCEDURE|conventional surgery|conventional surgery
40846622|NCT00258323|RADIATION|radiation therapy|150 cGy bid
40846623|NCT02751476|OTHER|Point of Use (PoU) water treatment flocculent disinfectant.|A household level point of use water treatment of a flocculent disinfectant will be tested.
40846624|NCT02751476|OTHER|Point of Use (PoU) water treatment chlorine disinfectant|A household level point of use water treatment of a chlorine disinfectant will be tested.
41368628|NCT06287801|OTHER|Geriatric Resources and Assessment for the Care of Elders|The practice will initiate the Geriatric Resources and Assessment for the Care of Elders (GRACE) program for Medicare beneficiaries deemed by study algorithm as high-risk and meeting other study criteria (see below). After completion of the in-home structured annual wellness visit (AWV) and GRACE assessment by the NP/SW team, responses will be reviewed and applied to construct an individualized care plan using the GRACE protocols inclusive of advance care planning, health maintenance, medication management, assistance with any difficulty walking, falls, dementia, depression, chronic pain, malnutrition, weight loss, urinary incontinence, visual impairment, hearing impairment, or caregiver burden.
41368629|NCT03560765|DEVICE|MED|Training in the use of mainstream electronic devices with accessibility options
41368630|NCT03560765|OTHER|Buddy|A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
41368631|NCT02497261|PROCEDURE|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
41368632|NCT04570033|DIAGNOSTIC_TEST|We assessed sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism|We prospectively enrolled 65 consecutive patients with PHPT who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.
41368633|NCT04159740|OTHER|Tissue and blood collection|Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
41368634|NCT05185908|PROCEDURE|Measurement of the optic nerve sheath diameter by ultrasound-guidance.|Measurement of the optic nerve sheath diameter (ONSD) by ultrasound guidance can be used in the diagnosis of increased ICP. The investigators interrogated the effects of lateral 45° downward position and CO2 insufflation on ONSD in patients undergoing laparoscopic transperitoneal nephrectomy.
41368635|NCT02784730|PROCEDURE|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
41368636|NCT02784730|PROCEDURE|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
41368637|NCT00881374|DRUG|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
41368638|NCT00354991|DRUG|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
41368639|NCT00982800|DRUG|Gabapentin|200mg 3x/day for 3 days (9 doses total)
41368640|NCT00982800|DRUG|Placebo Sugar Pill|
41502479|NCT00368017|DRUG|placebo|1 pill once a day for 12 weeks
41502480|NCT00026299|DRUG|ZD1839|
41502481|NCT00026299|DRUG|oxaliplatin|
41502482|NCT00751556|DRUG|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
41502483|NCT00751556|DRUG|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
41161949|NCT01801423|DRUG|Hydroxyurea|Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at \~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
41161950|NCT04493697|DEVICE|Experimental 1|A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
41161951|NCT04493697|DEVICE|Experimental 2|A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
41502484|NCT00362466|DRUG|Dasatinib|Tablets, Oral, Once daily, 5-7 years
41502485|NCT00362466|DRUG|Imatinib|Tablets, Oral, Once daily, 5-7 years
41502486|NCT02013674|BIOLOGICAL|Allogeneic hMSCs|Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
41502487|NCT03039270|OTHER|With sonic activation (SMART Device®)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM, SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the sonic activation side, immediately after the gel's application, sonic activation(Smart Sonic Device, FGM, SC, Brazil) was performed for 1.5 minutes in total for side (30 seconds per tooth). After the time of 30 seconds in each of the three anterior teeth of the respective side, the gel was removed from teeth with cotton. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
41368641|NCT00961727|OTHER|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; \[1\] an expert derived, multi-centre validated severity of illness score, \[2\] an inter-professionally developed documentation record into which the severity of illness score is embedded, \[3\] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and \[4\] an educator-developed education-implementation program.
41368642|NCT05033821|BEHAVIORAL|Adapted FOY+ImPACT|The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
41368643|NCT05130736|DEVICE|Robot rehabilitation|Effectiveness of using a rehabilitation robot in post-COVID-19 rehabilitation
41368644|NCT02701374|DRUG|TRK-700|
41368645|NCT02701374|DRUG|Placebo|
41368646|NCT05222841|DIETARY_SUPPLEMENT|Spermotrend|Patients who are treated with Spermotrend (536,62g) are given 3 capsules every day for 3 months, taken orally every 8 hours.
41368647|NCT04307004|OTHER|Unattended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.
41368648|NCT04307004|OTHER|Attended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.
41368649|NCT04307004|OTHER|Ambulatory blood pressure monitoring|Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.
41368650|NCT04307004|OTHER|Home blood pressure monitoring|Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
41368651|NCT03898882|DRUG|oxytocin|PK measurements of oxytocin
41368652|NCT03898882|DEVICE|Shore durometer|The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
41368653|NCT03937531|PROCEDURE|Bladder Scanner|PVR will be measured by using a bladder scanner.
41368654|NCT03845166|DRUG|XL092|oral doses of XL092
41368655|NCT03845166|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)
41368656|NCT03845166|DRUG|Avelumab|Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)
41502488|NCT03039270|OTHER|Control (Without sonic activation)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM,SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the side allocated for application without sonic activation, gel was kept for 10 minutes, after which it was removed from the teeth. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
41502489|NCT05465954|PROCEDURE|Biospecimen Collection|Correlative studies
41502490|NCT05465954|BIOLOGICAL|Efineptakin alfa|Given IM
41502491|NCT05465954|BIOLOGICAL|Pembrolizumab|Given IV
41502492|NCT05465954|PROCEDURE|Biopsy|Undergo tumor biopsy
41502493|NCT05521659|OTHER|Standardized oral care protocol|Standardized oral care protocol (3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate)
41502494|NCT02826538|DEVICE|fracture fixation with patient specific guides|Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
41502495|NCT02826538|DEVICE|standard procedure of fracture fixation|the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
41502496|NCT06470282|DRUG|Enfortumab Vedotin|Given intravenously (IV)
41368657|NCT05450900|DRUG|Choriogonadotropin Alpha|drug, active
41368658|NCT05450900|DIETARY_SUPPLEMENT|biotin|supplement, oral
41368659|NCT05450900|OTHER|Microcellulose filler|supplement, oral
41368660|NCT02512120|DEVICE|volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
41502497|NCT06470282|BIOLOGICAL|Pembrolizumab|Given IV
41502498|NCT06470282|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Undergo standard of care, IMRT
41502499|NCT06470282|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
41502500|NCT06470282|PROCEDURE|Cystoscopy (CS)|Undergo cystoscopy
41502501|NCT06470282|PROCEDURE|Computed Tomography (CT)|Undergo CT imaging
41502502|NCT06470282|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI imaging
41502503|NCT06470282|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET Scan, may be combined with CT (PET/CT)
41502504|NCT01297985|BEHAVIORAL|BRIDGES Peer-Led Education|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a week course to an 8-week course, meeting for 2 1/2 hours once a week.
41502505|NCT06598423|DEVICE|Specialized soft contact lens 1|These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 2 in material, comfort, and lens geometry. They differ only in their spectral profile.
41161952|NCT06073444|DEVICE|Picterus JP|Picterus JP is a medical device consisting in a smartphone app which is use to take images of the skin of the newborn, a color calibration card that must be placed in the newborn chest to calibrate color and lighting in the images and a server to analyze data and estimate bilirubin level
41161953|NCT01172899|PROCEDURE|laparoscopic adjustable gastric band|Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
41161954|NCT01172899|BEHAVIORAL|Combined life style interventions|Control group will receive standard therapy consisting of combined lifestyle interventions.
41161955|NCT04509414|DRUG|Dexmedetomidine|For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.
41161956|NCT04509414|DRUG|Midazolam|For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.
41161957|NCT01470664|DRUG|FST-100|0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)
41161958|NCT01470664|DRUG|FST-100 (Component #1)|0.6% PVP-Iodine ophthalmic solution alone
41161959|NCT01470664|DRUG|FST-100 Vehicle|FST-100 Vehicle
41161960|NCT02835937|OTHER|No-Transfuse|Patients will not receive an otherwise-indicated red blood cell transfusion
41161961|NCT00420225|DEVICE|Low-weight prolypropylene mesh|
41161962|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
41161963|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
41161964|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
41161965|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
41161966|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
41161967|NCT01649297|DRUG|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
41161968|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
41161969|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
41161970|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
41161971|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
41161972|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
41161973|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
41161974|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
41161975|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
41161976|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
41161977|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
41161978|NCT01649297|DRUG|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
41161979|NCT01649297|DRUG|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
41161980|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
41161981|NCT01649297|DRUG|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
41161982|NCT04840498|BEHAVIORAL|Autism Research|Measuring aspects such as self esteem, social skills, and social anxieties.
41161983|NCT04364750|DIETARY_SUPPLEMENT|L-Histidine|1 capsule (0.6g) twice daily
41161984|NCT04364750|DIETARY_SUPPLEMENT|High-FODMAP beverage|High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.
41368661|NCT02512120|DEVICE|autoflow-volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
41368662|NCT03431246|BIOLOGICAL|Gardasil and Gardasil-9|All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.
41368663|NCT00761891|OTHER|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
41502506|NCT06598423|DEVICE|Specialized soft contact lens 2|These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 1 in material, comfort, and lens geometry. They differ only in their spectral profile.
40846625|NCT02751476|DEVICE|Point of Use (PoU) ceramic water filter|A household level point of use water treatment of a ceramic water filter will be tested.
40846626|NCT02751476|OTHER|Standard Severe Acute Malnutrition Treatment|Standard CMAM treatment.
40846627|NCT00994643|BIOLOGICAL|Rituximab|Given IV
40846628|NCT00994643|BIOLOGICAL|Interleukin-2|Given SC
40846629|NCT06017791|OTHER|tunnel technique with a 3D printed PEEK shell to fill the skeletal subnasal depression|"The area will be anesthetized using infiltration technique with 1.5ml of anesthetic solution containing Articaine Hydrochloride 68 mg/1.7 ml with Adrenaline 0.017 mg/1.7 ml~Two bilateral full thickness vertical incisions will be created using a #15 blade. One on each side of the frenum~A subperiosteal tunnel connecting the two vertical incisions will be created using a periosteal elevator/tunneling knife until the complete communication between the two ends is established~The custom made PEEK framework will be inserted from the incision on one side and eased through until it sits in the subnasal concavity.~Once fitted in place the shell will be fixed in place using two mini screws bilaterally, one on each side.~The two vertical incisions will be closed by interrupted sutures 6-0 Polyglycolic acid suture material"
41161985|NCT04364750|DIETARY_SUPPLEMENT|Low-FODMAP beverage|Low-FODMAP beverage (10g glucose) consumed twice daily.
41161986|NCT04364750|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.|Total of 50 billion CFU/capsule taken twice daily.
41161987|NCT04364750|OTHER|Placebo|Enteric coated capsule with no active ingredient, taken twice daily
41161988|NCT00204516|BIOLOGICAL|mRNA coding for melanoma associated antigens|mRNA vaccine s.c. applied weekly
41161989|NCT00204516|DRUG|GM-CSF|Given s.c. as adjuvant drug one day after vaccine
41161990|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
41161991|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
41161992|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
41161993|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
41161994|NCT02186314|DEVICE|Pacemaker Biotronik: apical stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
41161995|NCT02186314|DEVICE|Pacemaker Biotronik: bifocal stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
41161996|NCT05745181|BIOLOGICAL|CAR-T Cell Infusion|Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.
41161997|NCT00874484|DRUG|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
41161998|NCT02654457|PROCEDURE|Women with Breast Cancer|IVD Study
41161999|NCT03703141|DIETARY_SUPPLEMENT|sucralose 48 mg (splenda)/day for ten weeks|volunteers will take sucralose or placebo daily for 70 days
41162000|NCT02362347|DEVICE|London Health Sciences Centre - Compression Vest|London Health Sciences Centre - Compression Vest
41162001|NCT02362347|OTHER|exercise|exercise
41162002|NCT05511558|DRUG|[14C]-Fosgonimeton|Carbon-14 Radiolabeled Fosgonimeton
41162003|NCT00113997|DRUG|REG1|
41162004|NCT05799157|DRUG|VDMN-21 Patch Low Dose|Microneedle patch containing 125 mcg of active drug
41162005|NCT05799157|DRUG|VDMN-21 Patch High Dose|Microneedle patch containing 250 mcg of active drug
41162006|NCT05799157|DRUG|Vehicle Patch|Placebo microneedle patch containing no active drug (i.e., placebo)
41162007|NCT02082418|DIETARY_SUPPLEMENT|Alpha-lactalbumin|Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).
40846630|NCT02215824|DRUG|BIWH 3|
40846631|NCT02215824|DRUG|Placebo|
40846632|NCT05307809|OTHER|Blood sample collection|Blood sample collection
41162008|NCT02082418|DIETARY_SUPPLEMENT|Whey|commercially available whey protein
41162009|NCT02082418|DIETARY_SUPPLEMENT|Casein|commercially available casein protein
41162010|NCT04739488|DEVICE|Inhaler training|This training was given to both intervention groups. How the patients used their inhaler medication was evaluated. The steps to use the correct inhaler medication were taught sequentially. It was applied with the patient. At the end of the training, brochures prepared by the researchers were given to the patients.
41502507|NCT05886868|DRUG|BL0020|"Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage."
40846633|NCT05307809|OTHER|Skin sample collection|Skin sample collection
40846634|NCT06584266|DIAGNOSTIC_TEST|Transoesophageal echocardiography|Imaging data obtained with transoesophageals echocardiography will be retained as well as data from transthoracic echocardiography and from other imaging modalities, if available
40846635|NCT06584266|PROCEDURE|Catheter ablation|Cathether ablation of atrial fibrillation substrate using one of available methods.
40846636|NCT06583707|PROCEDURE|Dry needling with and without ultrasound guidance|The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.
40846637|NCT03865485|BEHAVIORAL|Parenting for Lifelong Health (PLH)|The Parenting for Lifelong Health (PLH) initiative is focused on the development, evaluation, and dissemination of parenting programs to reduce violence against children and improve child wellbeing in LMIC. It was established to address the need to develop low-cost, evidence-based parenting programs that can be integrated within existing service delivery systems in LMIC. The PLH for Young Children from 2-9 y. (PLH 2-9) program includes general content like one-on-one time/child-led play; praising and rewarding children; instructions, household rules, and routines; managing difficult behaviours: ignore and consequences; reflection and moving on. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
41162011|NCT04739488|BEHAVIORAL|Breathing exercises|"This training was given only to the group that received breathing exercise and inhaler training.~Pursed lips breathing exercises were taught to the patients. Patients were asked to continue their breathing exercise for 10 minutes before using their inhaler medication.~Thus, it was evaluated whether breathing exercises performed before using inhaler drugs provided benefit on drug effectiveness."
41162012|NCT03096977|DIAGNOSTIC_TEST|Scale for the assessment and rating of ataxia (SARA)|Clinical evaluation of the manual dexterity through the SARA scale.
41162013|NCT03096977|DEVICE|JAMAR hand dynamometer|"Clinical evaluation of the prehension force using a JAMAR Dynamometer.~The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort.~Verbal encouragement is given during four successive tentative: the last three are averaged.~Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand"
41162014|NCT03096977|DEVICE|Vibratory sensibility testing|"Test carried out using a tuned fork applied to the styloid radial process.~Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration.~Repeat 3 times for each hand."
41162015|NCT03096977|DEVICE|Sermes and Weinstein test|"Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level.~Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament.~The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others.~The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response yes when he perceives the contact and the response time must be less than 3 sec."
41162016|NCT03096977|DEVICE|Weber test|"Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately.~The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes.~To determine the discrimination threshold:~Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value.~Perform the test 3 times."
41162017|NCT02230423|PROCEDURE|Nasal surgery|
41162018|NCT01963572|OTHER|SG will be screened every time when they visit the clinics.|
41162019|NCT04035330|COMBINATION_PRODUCT|etidronate in sodium hypochlorite|using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml
41162020|NCT04035330|COMBINATION_PRODUCT|sodium hypochlorite|irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
41162021|NCT03614286|DIAGNOSTIC_TEST|culture and pcr|The swab immersed in Diamond's Modified medium culture tube and squeezed for cultivation and examined daily with a light microscope to identify T. vaginalis Samples from culture will be placed in 1 ml of a commercial PCR transport medium (AMPLICOR; Roche Diagnostic Systems, Branchburg, N.J.) and kept at 4°C until arrival at the laboratory within 4 days of collection. An equal volume of specimen diluent (AMPLICOR) was added to the sample , and the preparation was mixed, incubated at room temperature for 10 min, and stored at -70°C until tested.
41162022|NCT04418180|DRUG|Fenofibrate|Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr
41162023|NCT04418180|DRUG|Placebo|oral distilled water
41162024|NCT00474383|DRUG|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
41502508|NCT05997836|OTHER|Implementation Facilitation|Implementation Facilitation involves and External Facilitator (from outside of the participating medical center) and an Internal Facilitator (from inside the participating medical center) working together to help BHIP teams within the site adopt care practices that are more consistent with the CCM
41162025|NCT00474383|DRUG|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
40846638|NCT04534270|DRUG|Dapagliflozin|Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight\>30kg), for 12 weeks
41162026|NCT00941109|DRUG|decitabine|Cohort 1: 30 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
41162027|NCT00941109|DRUG|decitabine|Cohort 2: 60 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
41162028|NCT00941109|DRUG|decitabine|Cohort 3: 120 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
41162029|NCT00941109|DRUG|decitabine|Cohort 4: 240 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
41162030|NCT02733835|DRUG|Remifentanil|Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
41162031|NCT04341415|PROCEDURE|Auricular neuromodulation|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELEC®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient.~Compress soaked with Oxygenated water on the concha (to stop potential bleeding).~Placing an opaque dressing on the ear and a non-occlusive Band-Aid"
41162032|NCT04341415|PROCEDURE|Control|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle).~Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid."
41162033|NCT05303090|DRUG|H101|H101 intratumorally injection starts at day 0.
41162034|NCT05303090|DRUG|Tislelizumab|Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
41162035|NCT05303090|DRUG|lenvatinib|lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
41162036|NCT02565888|DRUG|Daclatasvir|
41162037|NCT02565888|DRUG|Atazanavir|
41162038|NCT02565888|DRUG|Ritonavir|
41162039|NCT02565888|DRUG|Cobicistat|
41162040|NCT00235014|DRUG|trandolapril|2 mg QD
41368664|NCT05358301|DIETARY_SUPPLEMENT|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l. Each capsule of SYNBIO®slim contains the probiotic strain Lactiplantibacillus Plantarum IMC 510 at a concentration of 15 billion live cells (CFU/capsule). The assumption is of n°1 capsule/day, preferably at breakfast, for 3 months. The capsules can be opened and their content can be dispersed in a cold liquid or at intake temperature or in semi-solid food. Always store in original container or in a clean covered container, out of the reach of children. When stored in a dry, clean environment, out of direct sunlight, the product has a shelf-life of at least 24 months. Samples of probiotic supplement in closed and sealed boxes will be provided to subjects participating at the beginning of the study, in quantities sufficient for the entire duration of the study (90 capsules for 3 months).
41368665|NCT05358301|DIETARY_SUPPLEMENT|Placebo|N°1 capsule/day of placebo food supplement (i.e., capsules without added probiotics), with the same intake modalities as probiotic.
41162041|NCT00235014|DRUG|trandolapril/verapamil|180/2 mg QD
41162042|NCT00235014|DRUG|placebo|1 tablet QD
41162043|NCT00235014|DRUG|verapamil|SR 240 mg QD
41162044|NCT04799418|DEVICE|Open Label Extension Study|This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.
41368666|NCT06341452|DEVICE|Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control|Patients will be treated for 12 weeks thrice weekly Hemodialysis or Hemodiafiltration sessions resulting in 36 sessions per patient.
41368667|NCT03135873|DIETARY_SUPPLEMENT|Mastiha|Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).
40846639|NCT00789672|DRUG|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
40846640|NCT00789672|DEVICE|patching|2 hours daily patching
40846641|NCT00789672|DRUG|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
41162045|NCT02927899|OTHER|Survey Administration|Ancillary studies
41162046|NCT02927899|DIETARY_SUPPLEMENT|Tomato-Soy Juice|Receive tomato-soy beverages with or without varying levels of arugula seed powder
41162047|NCT04061863|DRUG|Nivolumab|Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
41162048|NCT03618927|BEHAVIORAL|Daily physical activity intervention|
40846642|NCT02899702|DRUG|PRIVIGEN (CSL Behring)|"Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
40846643|NCT02899702|DRUG|Albumin|"4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
41029473|NCT05043337|BEHAVIORAL|Maternal voice combined with lullaby|"The recordings were made in a quiet and separate consultation room. For infants in the  Maternal voice combined with lullaby group,  mothers were recorded what they wanted to say to their baby and read an independently published children's book-Xiao Qi's yellow persimmon , and giving mother listening to the Brahms Lullaby at the same time, the maternal voice recordings were edited for 13 minutes using a sound organizer. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture."
41036589|NCT06380231|OTHER|kangaroo mother care (KMC)|"Kangaroo mother care is a simple care that aims to protect the health and well-being of premature babies, where skin-to-skin contact is achieved by placing the premature baby in an upright position, face down, between the parent's breasts, wearing only a diaper and a cap.~Before the experimental group infant was given to the mother, his/her hat was put on, and clothes were removed. The infant was placed in an upright position (approximately 60°) between the mother's two breasts. To enable the infant to breathe, his/her head was positioned to the right or left with ear touching the mother's chest, arms and legs were flexed, and hip was abducted. The mother supported the infant's neck and back with one hand and the hips with the other. The infant's back was covered with a cotton blanket. An noninvasive pulse Co-oximetry was attached to the right wrist of the infant to evaluate heart rate, oxygen saturation, and perfusion index."
41162049|NCT05266625|BEHAVIORAL|BT-001|"Bt-001 is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, Bt-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
41162050|NCT05266625|OTHER|Control App|The app asks patients brief questions about their health but does not include any behavioral therapy.
41162051|NCT03184142|BEHAVIORAL|Simulation|Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)
41162052|NCT03184142|BEHAVIORAL|Video|Student watch a 15-minute intimidation video (see arm description).
41162053|NCT03184142|BEHAVIORAL|Control group|No intervention. The students suture for 70 minutes
41162054|NCT04131010|DEVICE|single operator video cholangioscopy|The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%
41162055|NCT02403284|DRUG|Liraglutide|Subcutaneous injection by patient
41162056|NCT02403284|DRUG|Sugar Pill|Subcutaneous injection daily
41162057|NCT03681353|BEHAVIORAL|Mobile Contingency Management, active|Participants are provided monetary reinforcement for providing oral fluid test results that suggest they have reduced cannabis use.
41368668|NCT03135873|DIETARY_SUPPLEMENT|Placebo|Placebo is designed to have identical characteristics with verum.
41162058|NCT06309485|DRUG|WGI-0301 at MTD/RP2D dose IV infusion, QW|WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
41162059|NCT06309485|DRUG|WGI-0301 at MTD/RP2D -1 dose IV infusion, QW|WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
41162060|NCT06309485|DRUG|Sorafenib 400 mg PO, BID continuously|Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
41162061|NCT06309485|DRUG|Sorafenib 400 mg PO, BID|Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
41368669|NCT02033486|DEVICE|TOBI + DBT|
41368670|NCT01045902|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
41368671|NCT01045902|DRUG|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
41368672|NCT00381134|DRUG|losartan 100 mg orally once daily|
41368673|NCT00381134|DRUG|spironolactone 25 mg orally once daily|
41162062|NCT02943707|PROCEDURE|Autologous bone marrow stem cells infusion|Autologous bone marrow stem cells are infused into proper hepatic artery
41502509|NCT05997836|OTHER|Centralized Technical Assistance|Centralized Technical Assistance involves having external experts available for ad hoc consultation related to collaborative BHIP care practices.
41162063|NCT02943707|DRUG|drugs such as Ursodeoxycholic Acid tablets|Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
41162064|NCT01090700|DRUG|TMC435|TMC435 150 mg daily for 7 days
41162065|NCT01090700|DRUG|Escitalopram|Escitalopram 10 mg daily for 7 days
41162066|NCT01090700|DRUG|TMC435 + Escitalopram|TMC435 150 mg + escitalopram 10 mg daily for 7 days
41368674|NCT00381134|DRUG|placebo once orally once daily|
41368675|NCT01382875|OTHER|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
41368676|NCT00473928|DRUG|POT-4|Single intravitreal injection.
41368677|NCT04149145|DRUG|M4344+Niraparib|The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
41368678|NCT04149145|DRUG|M4344+Niraparib|In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
41368679|NCT03616652|DRUG|Placebo|Placebo pill
41368680|NCT03616652|OTHER|Film sequence|The experimental group watches a film about the power of placebo effects.
41368681|NCT03616652|OTHER|Film sequence|The control group watches a film about sleep.
40846644|NCT06051006|OTHER|ESR and ECAP measurements|"Measurement of electrically evoked stapedial reflexes (ESRT) by stimulation via the cochlear implant. Measurement of the Electric compound action potentials (ECAPs) on the electrodes where the ESRT were performed.~The measurements and tests will be performed during a routine visit to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
40846645|NCT06051006|OTHER|Device setting|"The adjustment will be made by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The purpose of this setting is to modify the comfort thresholds using the ESR via a correction (according to the literature). The cochlear implant (CI) will therefore be set with the setting using the ESR (setting 2). The basic setting (setting 1) will be stored in memory in the CI. If ever the patient does not support setting 2, he/she will have the possibility of returning to the basic setting, without having to return to the Necker hospital for an additional setting.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
40846646|NCT06051006|OTHER|Speech audiometry|"This examination is part of the usual care for a patient with a cochlear implant. Fournier's monosyllabic test will be used. The test will be carried out by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The measurement will be performed under both setting conditions: setting 1 (current setting) and setting 2 (based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
41029474|NCT06290362|BEHAVIORAL|Cognitive Behavioural Theory-based group consultation|"Cognitive Behavioural Theory-based group consultation was given to the intervention group through an Instagram as online social media platform. This approach has been developed with the philosophy of Cognitive Behavioral Theory (Eskin, 2009).~For three days a week over eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. The participants were connected to the live broadcast of the research team, and they interacted via text messages. In this interaction, further suggestions related to the goals of the week were given, previous assignments were checked, homework for the next session was given, personal experiences and the needs of the participants were determined, and necessary feedback was provided. Instagram had the feature of maintaining the records of all participants\&#39; attendance at these events."
41029475|NCT01834417|DEVICE|TexiMat|
41029476|NCT01343511|BIOLOGICAL|human cord blood mononuclear cells|Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
41029477|NCT01343511|BIOLOGICAL|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
41029478|NCT06244147|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha Root Extract|Participants will take KSM-66 Ashwagandha root extract 300mg twice a day for the duration of the study.
41029479|NCT00004181|DRUG|busulfan|
41029480|NCT00004181|DRUG|cyclophosphamide|
41029481|NCT00004181|PROCEDURE|allogeneic bone marrow transplantation|
41162067|NCT03670199|OTHER|Dietary advice|Nutritional status assessment Explanation of standard nutritional advices with an written explanation sheet
41162068|NCT03670199|OTHER|Physiotherapist intervention|Respiratory capacity Functional capacity
41029482|NCT00004181|RADIATION|radiation therapy|
41029483|NCT00724347|BEHAVIORAL|Consonant Identification Training|Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
41036590|NCT03586648|DEVICE|senofilcon A Multifocal|TEST Lens
41036591|NCT03586648|DEVICE|senofilcon A Sphere|TEST Lens Sphere
41036592|NCT03586648|DEVICE|etafilcon A Multifocal|CONTROL Lens
41368682|NCT01854502|BEHAVIORAL|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
41368683|NCT01854502|BEHAVIORAL|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
40846647|NCT06051006|OTHER|Intelligibility in noise test|"The FraSimat is a measure of speech perception in noise. The test consists of 14 sentences of 3 words, recorded in the presence of background noise, which the child must listen to and repeat. The background noise remains fixed at 65dB HL and the speech intensity adapts according to the patient's responses. The measurement will be performed under two setting conditions: MAP 1 (current setting) and MAP 2 (setting based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
40846648|NCT06051006|OTHER|Cochlear implant datalogging, speech audiometry test, FraSimat test|"The follow-up visit (visit 2) will take place 1 month after visit 1 only for patients with a comfort levels threshold (via the eSRT) different from the current threshold (C-subjective).~At the start of the visit, cochlear implant datalogging will be recorded to determine the use of both settings (setting 2, using the ESR and setting 1, basic setting) while wearing the cochlear implant.~The datalogging will be recorded by an audioprosthetist at the Center for Research in Audiology at Necker Hospital.~If the patient has worn the new program (setting 2), the speech audiometry test and the FraSimat test (Intelligibility in noise test) will be performed again with the setting based on ESR."
41029484|NCT02951325|OTHER|Adjuvant RT|"Radiation therapy:~All patients will be offered conformal technique with IMRT +/- image guidance. The adjuvant RT will start within 8 weeks from the date of surgery if chemotherapy not planned or 4 weeks from the date of last adjuvant chemo cycle.~Dose:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) for the nodal PTV. For R1 and/or R2 resection increased to 54-56 Gy in 28 fractions based on the constraints achieved during planning.~Patient assessments:~Clinical:~* Toxicity:~  1. Weekly RT with toxicity scoring.~ 2. RTOG toxicity criteria at baseline, 6-8 weeks post RT and f/b 3 monthly x 2 years and 6 monthly x 5 years.~ 3. QOL will be assessed at baseline f/b 3-6 monthly.~* Disease evaluation:~  i. first f/u all patients will be at 6-8 week to assess toxicity. ii. Clinical evaluation of the disease will be done at each f/u visit. iii. CT scan (abdomen and pelvis) 6 monthly from visit 2 onwards up to 2 years f/b 12 monthly or as clinically indicated."
41029485|NCT05626829|DRUG|Tranilast|Tranilast capsules 100mg 3 times per day when reradiation
40846649|NCT01964677|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
40846650|NCT02425059|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
40846651|NCT02425059|DEVICE|NanoKnife|
40846652|NCT02123576|DRUG|Pentoxyfylline|
40846653|NCT02123576|DRUG|Placebo|
41029486|NCT01198600|DEVICE|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
41029487|NCT01198600|DEVICE|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
41029488|NCT01198600|DEVICE|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
41029489|NCT01054729|DRUG|Sofosbuvir|Sofosbuvir tablet(s) administered orally once daily
41029490|NCT01054729|DRUG|Placebo|Placebo to match sofosbuvir administered orally once daily
41029491|NCT01054729|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
41162069|NCT03670199|OTHER|Dietary intervention|Nutritional status assessment Presentation of the Nutrimus booklet by the coordinating dietitian Establishment or adaptation of a nutritional support (prescription of nutritional supplements if necessary). Delivery and explanation of the preoperative nutritional counseling support
41368684|NCT01559649|BEHAVIORAL|Establishing Validity and Reliability|Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
41368685|NCT01391260|OTHER|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
41502510|NCT06543173|PROCEDURE|Prophylactic Catheter-based VT Ablation|Prophylactic Catheter-based VT Ablation refers to a treatment strategy where participants undergo a procedure known as catheter-based ventricular tachycardia (VT) ablation shortly after receiving their primary implantable cardioverter defibrillator (ICD).
40846654|NCT02123576|DRUG|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
40846655|NCT06536192|OTHER|Model group|"1. Process: Theoretical knowledge will be given to students, and then different types of gynecological examinations will be explained practically on a model in the laboratory environment.~2. Process: The learner guide will be filled out.~3. Process: After 15 days, students will be taken back to the laboratory environment to fill out the learner guide again. In addition, SCS and SSSLS will be filled out for the last exam."
40846656|NCT05708339|OTHER|virtually fabricated ear prosthesis|virtually designed ear prosthesis
40846657|NCT05708339|OTHER|conventionally fabricated ear prosthesis|conventionally fabricated ear prosthesis
41029492|NCT01054729|DRUG|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
41029493|NCT05870306|PROCEDURE|pulmonary vein isolation and targeted radiofrequency ablation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins. Extra radiofrequency ablation will be performed on the targeted areas
41029494|NCT05870306|PROCEDURE|pulmonary vein isolation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins.
41036593|NCT03586648|DEVICE|etafilcon A Sphere|CONTROL Lens Sphere
40846658|NCT05995236|DRUG|PSMA radionuclide therapy|Collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy
40846659|NCT05411939|OTHER|Shared Decision-Making Tool|The Shared Decision-Making Tool (SDMT) is designed to provide a personalized, patient- centered framework for clinical discussions regarding treatment options for knee osteoarthritis. The tool functions through patient input of information such as pain severity and current symptoms, alongside other demographic information such as age, race, and comorbidities, to offer a series of outcomes to better illustrate how the patient's specific disease presentation will progress. Ultimately, using the SDMT may impact patient behavior if patients change their treatment preferences after utilizing the tool. This can empower them to seek additional support over time and maintain communication with their orthopedist to ensure they are on a healthier path.
40846660|NCT05411939|OTHER|Video|Short video that describes knee osteoarthritis and possible treatment options.
40846661|NCT05411939|OTHER|Standard of Care|Standard of care counseling for a patient presenting with knee osteoarthritis.
41029495|NCT04071002|OTHER|12 weeks physical therapy programme|The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
41029496|NCT02181530|OTHER|No Intervention|No treatment (intervention) is being administered as part of this study.
41029497|NCT06215846|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 VP, 5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
41162070|NCT03670199|OTHER|Intensify physiotherapist intervention|Respiratory capacity Functional capacity Tips adapted for physical activity and strengthening or maintenance of muscle mass Presentation of respiratory physiotherapy exercises to prevent postoperative bronchial congestion Nutrition and physical mobilization tips with the Nutrimus booklet
41162071|NCT02486159|DRUG|Herbal plaster (Sanfujiu)|The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
41162072|NCT02486159|PROCEDURE|Acupuncture|Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
41162073|NCT05738070|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI was done in 1.5T unit (Siemens, Magnetom, Essenza). Different parameters for SWI as follows at 1.5T: echo time (TE) = 40 ms, repetition time (TR) = 29 ms, slice thickness = 0.7 mm, flip angle = 25°, field of view (FOV) = 184 × 200, intersection gap = 0 mm, and matrix size = 322 × 225. MRA parameters were as follows: TR = 29 ms, TE = 7.15 ms, FOV = 168 × 200 mm, slice thickness = 0.7 mm, flip angle = 25°, with acquisition time of 3 minutes.
41162074|NCT00679549|DEVICE|CPAP Therapy|CPAP therapy is provided as an inpatient.
41162075|NCT06266442|OTHER|Whole genome sequencing testing|Whole genome sequencing
41162076|NCT00135785|DRUG|Bupropion|
41162077|NCT00135785|DRUG|Placebo|
41162078|NCT03015844|DRUG|131-I-meta-iodobenzylguanidine|
41162079|NCT03448289|BEHAVIORAL|RLPT|The Reproductive Life Plan Tool (RLPT) will be self-administered. Pediatricians will use the RLPT to assess women's need for well-woman primary care.
41162080|NCT03440983|DEVICE|MRI data acquiring in healthy volunteers|The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools
41162081|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally, once daily.
41162082|NCT04655183|DRUG|M4344|M4344 will be administered once daily or on an intermittent schedule in combination with niraparib.
41162083|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.
41162084|NCT04655183|DRUG|M4344|M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.
41162085|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally, once daily. Dose of niraparib will be escalated beyond the dose in Part 1A.
41029498|NCT06168708|PROCEDURE|Transurethral resection of the prostate (TURP)|TURP with addition of gentamicin on irrigation fluid to reduce infectious complications
41029499|NCT06168708|DRUG|Gentamicin|gentamicin 80 mg (2ml) /3L of irrigation solution (the first 9 Liters during resection and the first 6 Liters during post-operative irrigation)
41029500|NCT06168708|DRUG|normal saline|normal saline (2 ml) on the irrigation solution (placebo)
41029501|NCT06175819|OTHER|Manuka honey( MgO 850, UMF+20) loaded nano-formulation|Assessment of the efficacy of manuka-loaded nano-formulation and manuka honey-loaded gel on the improvement of acne vulgaris
41036594|NCT01169467|DRUG|Standard-of-Care plus Dexmedetomidine|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
41036595|NCT01169467|OTHER|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
41162086|NCT04655183|DRUG|Niraparib|Niraparib will be administered as single agent at the approved dose.
41162087|NCT03294941|COMBINATION_PRODUCT|HepQuant SHUNT Liver Diagnostic Kit|Serial testing over 48 weeks
41162088|NCT02763150|BEHAVIORAL|Lifestyle intervention|Intervention group will receive comprehensive behavioral weight loss program.
41162089|NCT02763150|OTHER|Health Promotion|The health promotion group will receive education on healthy eating and activity
41029502|NCT01965834|DRUG|Fenofibrate|Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \< 50 mL/min will receive a reduced dose of 54 mg orally daily.
41029503|NCT04498936|DRUG|Sofosbuvir and Ledipasvir|Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19
41368686|NCT00802152|OTHER|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
41368687|NCT02138227|BEHAVIORAL|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
41029504|NCT04498936|DRUG|Nitazoxanide|Evaluate the efficacy of Nitazoxanide in treatment of COVID-19
41029505|NCT04120506|DRUG|VPRIV|Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
41162090|NCT05579145|OTHER|5-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 5 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
41368688|NCT02138227|BEHAVIORAL|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
41502511|NCT06489535|OTHER|RETAIN|"There are 6 different modules that a participant in the RETAIN intervention group can be placed in: Reinforce Antibiotic Completion, Linkage to Antibiotic Treatment/Alternate Plan, Reinforce Recovery, Linkage to MOUD/Alternate Plan, Reinforce Treatment Attendance, and Harm Reduction Support. Participants may be assigned to no more than three modules at a time until they finish their antibiotics. After the completion of antibiotics, participants may only be in two modules. Participants' intervention can range from 15 minutes- 60 minutes depending on what modules they are placed in and how much support they feel they need. Interventions will begin at the two-week follow up after a participant has been discharged from Boston Medical Center (BMC)."
41502512|NCT06489535|OTHER|Unrelated videos|These videos unrelated to the study topics will last approximately 30-45 minutes. Depending on the method of communication, participants will watch a video (in person) or listen to a podcast (remote)
41502513|NCT06279728|DRUG|Datopotamab deruxtecan|6 mg/kg intravenous infusion Q3W (on Day 1 of each 21-day cycle)
41502514|NCT05194098|DEVICE|TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil|Active Session: Single session of standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes
41502515|NCT05194098|DEVICE|SHAM (inactive) TMS stimulation|Sham neurostimulation (SHAM) entails use of the sham side of the D-B80 A/P placed over the same anatomical target, without any active stimulation.
41029506|NCT02052349|DRUG|ABT-333|Dose of ABT-333
41029507|NCT00738842|DRUG|AZD6140|Oral tablets taken bid for 5 days
41368689|NCT04856852|OTHER|Iodine-125+Chemotherapy|Iodine-125: Iodine-125 if necessary, 0.6-0.8mCi, PD:120-150Gy Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
41502516|NCT03656588|DRUG|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
41502517|NCT03656588|DRUG|Iodine scrub and ChloraPrep alone|Iodine scrub and ChloraPrep alone
41502518|NCT05881525|BIOLOGICAL|TC-N201 cells|T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.
41029508|NCT00738842|DRUG|Placebo to match AZD6140|Oral tablets taken bid for 5 days
41029509|NCT03305120|OTHER|pain VAS evaluation|each patient has to answer to a questionnaire about pain
41029510|NCT03433742|OTHER|Blood levels drawn|The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.
41029511|NCT02958436|DRUG|REGN3500|
41029512|NCT02958436|DRUG|Placebo|
41029513|NCT05776563|OTHER|Magnetic Resonance Spectroscopy Imaging (MRSI)|baseline 1HMRSI imaging study, then will undergo intensification of their diabetes management for a period of 12-week and at the end of the intervention they will undergo 1H MRSI scanning to measure intracerebral and plasma glucose levels at euglycemia and following 2 hours of hyperglycemia using the clamp technique (target glucose 220 mg/dl) in the occipital region
41029514|NCT05525624|DEVICE|TRAMPRE|discharge interventions Transition Model is discharge interventions in parents of preterm infants.
41029515|NCT05525624|OTHER|Control Group|routine neonatal clinic discharge training of the hospital
41029516|NCT00408993|DRUG|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
41029517|NCT00408993|DRUG|Placebo|Placebo every day (QD), by mouth (PO)
41029518|NCT05430529|BEHAVIORAL|Standard Smoke Cessation Service|Both of the intervention group and control group will receive standard smoke cessation service, which is same as usual practice.
41502519|NCT05881525|DRUG|IL-2|Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.
41502520|NCT05881525|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
41368690|NCT04856852|OTHER|Surgical resection+Radiochemotherapy|"Surgical resection: Maximal surgical resection, including gross total resection, subtotal resection, and partial resection.~Radiation: total 60 Gy, 2 Gy per daily fraction (Monday to Friday) for 6 weeks. Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days."
40846662|NCT03973294|DEVICE|EIT-measurement|"The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface."
40846663|NCT05571020|OTHER|mat pilates|Both groups adapted for their rides by not participating in a different exercise and meal. In the study, they were not found in any store in the control groups. In the Mat-Pates Group, information about the 5 key elements of the study and pilates team, perspective (-neck-shoulder-waist-abdominal placement), lumbopel stabilization, scapular stabilization, review and information was covered. Then, in the study groups, it was purchased from groups of 5-6 people at most for one hour a day. In order to participate in all these application activities, he continues his life without participating in any evaluation.
40846664|NCT00051896|DRUG|GBR 12909|
40846665|NCT05526898|DEVICE|SyntrFuge System|Microsized Adipose Tissue
40846666|NCT05526898|DRUG|Triamcinolone Injection|Corticosteroid
40846667|NCT00345722|PROCEDURE|strawberry dietary intervention|
40846668|NCT01860950|DEVICE|anodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder
40846669|NCT01860950|DEVICE|cathodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC.
40846670|NCT01860950|DEVICE|sham tDCS|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session
40846671|NCT06583902|DRUG|Intravenous iron|Patients with an absolute deficiency (ferritin ≤100 μg/L) or functional deficiency (ferritin ≤ 300 μg/L with transferrin saturation ≤20%) receive iron supplementation, through a single administration of an iron preparation for intravenous use administered according to the doses present in the technical data sheet.
40846672|NCT06583902|OTHER|Retrospective case-control analysis|the only routine clinical data collection (Hb, iron status, direct and indirect Coombs test, IL6, erythropoietin dosage, number of units of blood components possibly transfused)
40846673|NCT02604914|DRUG|ND0612|Subcutaneous solution
40846674|NCT02604914|DRUG|LCIG|Intrajejunal Gel
40846675|NCT06523465|DRUG|Simvastatin combined with Amlodipine besylate|6-month treatment of Simvastatin combined with Amlodipine besylate
40846676|NCT06523465|DRUG|Simvastatin combined with Spironolactone and Amlodipine besylate.|6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
41162091|NCT05579145|OTHER|10-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 10 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
41162092|NCT02134847|OTHER|SCS intervention schedule|
41368691|NCT02974738|DRUG|Belzutifan|Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
41368692|NCT03517657|BEHAVIORAL|Bilateral Motor Priming + Task Specific Training (BMP + TST)|"Priming will always precede task specific training. During bilateral motor priming, the Rocker (Exsurgo Bilateral Primer, Aukland, New Zealand) will be used. For the individuals assigned to the bilateral priming group, both hands will be strapped in place in the vertically oriented plates which are attached via a mechanical linkage. They will move both wrists in rhythmic, symmetrical wrist flexion and extension for 15 minutes at a frequency of 1 Hz as cued by a metranome. Subjects do not need to have active flexion and extension of the affected hand as the less affected arm drives the weaker one (through an acutator underneath the surface) in in-phase bilateral symmetrical movement."
41368693|NCT03517657|BEHAVIORAL|Control Priming + TST (CP + TST)|The control priming intervention for the active comparator group will be intermittent cutaneous electric stimulation of the volar aspect of the paretic forearm, using a standard TENS unit delivered for 15 seconds (including 2-second ramp-up, 2-second ramp-down), once per minute, for 15 minutes. Intensity will be minimized
41368694|NCT00031902|BIOLOGICAL|bleomycin sulfate|
41368695|NCT00031902|BIOLOGICAL|rituximab|
40846677|NCT06523465|DRUG|Amlodipine besylate combined Spironolactone|6-month treatment of Amlodipine besylate combined with Spironolactone
40846678|NCT01767623|DRUG|Vemurafenib|Vemurafenib orally BID 960 or 720 mg.
40846679|NCT01940081|OTHER|Transthoracic echocardiography|
40846680|NCT01940081|OTHER|Exercise test|
40846681|NCT01940081|OTHER|24-hour Holter electrocardiogram|
40846682|NCT01940081|OTHER|Contrast-enhanced magnetic resonance imaging|
40846683|NCT01940081|OTHER|123-iodine metaiodobenzylguanidine imaging|
40846684|NCT01940081|OTHER|Blood samples|
40846685|NCT01940081|GENETIC|Genetic analysis|
40846686|NCT01940081|PROCEDURE|Invasive electrophysiological study|
40846687|NCT01940081|PROCEDURE|Endomyocardial biopsy|
40846688|NCT01940081|PROCEDURE|Intraoperative biopsy|
40846689|NCT01940081|PROCEDURE|Intraoperative mapping and/or ablation|
40846690|NCT06583564|PROCEDURE|ICG lymphangiography procedure|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
41368696|NCT00031902|DRUG|prednisolone|
41368697|NCT00031902|DRUG|vincristine sulfate|
40846691|NCT00955513|DRUG|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% twice a day
40846692|NCT00955513|DRUG|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% three times a day
40846693|NCT00955513|DRUG|Placebo|Placebo
40846694|NCT00383162|DRUG|Combination Product (sumatriptan succinate / naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
40846695|NCT00383162|DRUG|Placebo|Matching placebo tablet.
40846696|NCT04079114|DEVICE|Patients who received the Stafit Acetabular System|Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.
40846697|NCT05399290|DRUG|Doxycycline Hyclate|100 mg vs 20 mg doxycycline hyclate BID for 12 weeks
40846698|NCT06352255|PROCEDURE|Digital block|Frost's H technique
40846699|NCT06525090|OTHER|no intervention-child-administered questionnaires|The implementation of the research was started after getting approval from Mugla Sıtkı Kocman University Health Sciences Ethics Committee and TR Ministry of National Education Research, Competition and Social Activity. The purpose of the study was explained by the researchers to the administrators of the schools where the study was conducted and planning was made with the school administration. The data were collected in 15-20 minutes from the students who agreed to participate in the study during the course hours deemed appropriate by the administration. The purpose of the study and how to fill in the measurement tools was explained to the students, and it was stated that the research data would be kept confidential and used only by the researcher. The self-administered questionnaires were filled out on the paper. Verbal consent was obtained from the students participating in the study and written informed consent was obtained from their parents.
41502521|NCT05881525|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
41502522|NCT05881525|DRUG|Nab-paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
40846700|NCT00488826|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
41162093|NCT03510377|OTHER|Aquatic physical intervention|For structured aquatic physical intervention group, the Ai-Chi method was selected. Ai-Chi is a simple aquatic exercise and relaxation method that uses a combination of deep breathing and slow movements of the arms, legs and torso in continual flowing patterns. The Ai-Chi intervention will occur in an hydrotherapy pool (34C).
41162094|NCT03510377|OTHER|On-land physical intervention|For controlled comparison of the structured physical intervention group the Tai-Chi method was selected (the same movements as the Ai-Chi). The Tai-Chi intervention will occur in a room.
41368698|NCT03684343|OTHER|Filmed consultation with a dermatologist|"Patient will be seen by a dermatologist for a consultation which will be filmed. During the consult, a laterality test and a tactile sensitivity test will be performed.~After the consult, videos will be analysed by scientists to identify the frequency of occurrence of each behavior and the percentage of time passed to express each behavior."
41368699|NCT01445366|DEVICE|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
41368700|NCT01445366|DEVICE|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
41368701|NCT05682066|DEVICE|Innovalve MR system|Innovalve MR system
41368702|NCT00411892|DRUG|pioglitazone|Tablets, 45 mg/day.
41368703|NCT00411892|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
41368704|NCT01315158|DRUG|Propofol Alone|"Recommended Propofol doses before considering crossover:~* Induction: 2-2.5 mg/kg~* Maintenance: 0.1-0.2 mg/kg/min"
41368705|NCT01315158|DRUG|Propofol+Benzo/Opioids|"1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is \> 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg"
40846701|NCT00488826|BIOLOGICAL|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
40846702|NCT01211314|DRUG|Lercanidipine/enalapril fixed combination|Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
41368706|NCT05477927|BIOLOGICAL|Dual-targeting VEGFR1 and PD-L1 CAR-T cells|"In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design.~In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition."
41368707|NCT02090920|DRUG|Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
41368708|NCT02358707|OTHER|Ibuprofen phonophoresis|
41368709|NCT00323934|DRUG|MGCD0103|Oral dosage 2 times weekly.
41368710|NCT05910268|BEHAVIORAL|NIATx + ECHO|Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.
41368711|NCT02258893|OTHER|NO2 Scrubber|an NO2 scrubber that removes NO2 and particles
41368712|NCT02258893|OTHER|HEPA filter|a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
41029519|NCT05430529|BEHAVIORAL|Short Advice for Control Group|If the control group participant encountering difficulties in smoke cessation caused by alcohol usage, HCP will provide short advice to them. Participant will be urged not to drink during smoke quitting. If drinking is unavoidable, participant should not drink exceed the low-risk drinking portion recommended by Department of Health, which is 2 standard alcohol units for men and 1 stand alcohol unit for women per day. HCPs will remind participants to aware their drinking portion, in order to quit smoke successfully.
40846703|NCT02217917|DRUG|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
40846704|NCT02217917|DRUG|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
40846705|NCT02217917|DRUG|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
40846706|NCT02217917|DRUG|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
40846707|NCT02217917|DRUG|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
40846708|NCT06339931|OTHER|SMWLM combined Spinal traction with belt|Group A, therapist 1 will stand at the participant's ventral side and apply a transverse glide with the thumb on the involved lumbar spinous process. Therapist 2 will then abduct the affected leg by 10° and take the limb gently into hip flexion with the knee extended, while the glide will be sustained continuously by Therapist. Wrap the traction belt around both your hips and the proximal aspect of the patient's thighs.Apply traction by leaning backward and shifting your body weight onto your posterior leg.
41029520|NCT05430529|BEHAVIORAL|Brief Alcohol Intervention for Intervention Group|"During the face-to-face smoking cessation counseling session, HCPs will first play a 2 - 3 minutes short video with electronic devices to participants who are allocated to the intervention group.~After the short video, HCPs will ask participants to share their thoughts and willingness of alcohol control. Participants are expected to show 4 responses: (1) refuse to attempt alcohol control; agree to attempt alcohol control that (2) quit drinking totally, (3) quit drinking for 2 weeks, or (4) reduce the alcohol consumption. HCPs will deliver personalized advice according to participants' choices and encourage them to receive the WhatsApp message reminders.~In all participants, HCPs will invite them to receive WhatsApp messages reminders for incoming 4 weeks (3 messages per week).~In addition, HCPs can choose to discuss with participants the reasons for consuming alcohol.~Nevertheless, HCPs can also choose to provide AUDIT-based brief intervention to the participants."
41029521|NCT01259713|DRUG|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
41036596|NCT03266250|PROCEDURE|spinal anesthesia|Transthoracic echocardiography of inferior vena cava before spinal anesthesia
41162095|NCT03510377|OTHER|Non physical intervention|The people who will be part of the non physical intervention will practice guided imagery of the Ai-Chi method. The guided imagery intervention will occur in a room.
41162096|NCT06259513|PROCEDURE|omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO|Omission of SLNB in cT1-2N0 or Omission of ALND in patients with \</= 2 macrometastasis in SLNB
41162097|NCT06208878|OTHER|Non Interventional|Safety and Efficacy Assessment
41162098|NCT01630837|OTHER|frequency of oral hygiene|the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
40846709|NCT06339931|OTHER|SMWLM combined spinal traction without belt|Group B, therapist 1 will stand at the participant's ventral side and apply a transverse glide with the thumb on the involved lumbar spinous process. Therapist 2 will then abduct the affected leg by 10° and take the limb gently into hip flexion with the knee extended, while the glide will be sustained continuously by Therapist. Manual traction is applied by placing the patient over a rolled pillow while lying sideways. The roll should be 6-8 inches in diameter and should be placed at the level of the spine where the traction or separation is to occur. Pull the patient's legs toward you as you lean your body backward to apply a traction force.
40846710|NCT01218399|DRUG|Symbicort|
40846711|NCT04078581|OTHER|Questionnaire and fecal sample collection|Questionnaire and fecal sample collection in order to select donors for FMT.
41368713|NCT02258893|OTHER|Control|"a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles"
41368714|NCT05872165|DEVICE|phonophoresis|1 MHz, 1 W/cm2continuous mode of ultrasound therapy for 5 min. using ozonated gel as a coupling medium
41368715|NCT05872165|OTHER|conventional physical therapy|conventional TENS (100 Hz) for 30 min - hot pack for 20 min- stretching and strengthening exercises, wrist rest splints 3times per week for 4 weeks.
40846712|NCT00118430|BEHAVIORAL|Stepped Care|Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
41368716|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.
41368717|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.
41368718|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
40846713|NCT00118430|DRUG|Antidepressants|Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
40846714|NCT00118430|DRUG|Usual Care|This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
40846715|NCT06003088|DRUG|HSK7653(5mg)|Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
41368719|NCT02478606|OTHER|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
41368720|NCT04173520|DRUG|DDA|Follow up after SVR
41368721|NCT00602082|DRUG|capecitabine|
40846716|NCT06003088|DRUG|HSK7653(25mg)|Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
41029522|NCT01259713|DRUG|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
41368722|NCT00602082|DRUG|cisplatin|
40846717|NCT01053039|DRUG|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
41029523|NCT05870280|BEHAVIORAL|nurse coaching|Group coaching will be applied to individuals with diabetes, 5-8 people.
41368723|NCT00602082|DRUG|streptozocin|
40846718|NCT01053039|DRUG|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
41029524|NCT04283929|OTHER|Experimental: Intervention 1 (Int1)|This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.
41036597|NCT01478867|OTHER|Detection of gluten in feces|Detection of Gluten in Feces
41368724|NCT00602082|GENETIC|DNA analysis|
41368725|NCT00602082|GENETIC|RNA analysis|
41368726|NCT00602082|GENETIC|protein analysis|
41368727|NCT00602082|GENETIC|proteomic profiling|
40846719|NCT06548750|OTHER|Intrinsic and Ectrinsic Exercise|Intrinsic and extrinsic muscle strengthening exercises
40846720|NCT06548750|OTHER|Intrinsic Exercise|Intrinsic muscle strengthening exercises
40846721|NCT01622777|DRUG|Rosuvastatin|20 mg daily of oral rosuvastatin for 12 weeks
41368728|NCT00602082|OTHER|laboratory biomarker analysis|
41368729|NCT01296581|DRUG|X-82|Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
41368730|NCT03616782|DRUG|Ixazomib|Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
41368731|NCT02316574|BEHAVIORAL|Cognitive Behavioral Coping Skills Therapy|"Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use."
41368732|NCT01797458|PROCEDURE|Hall Technique|"Technique:~* Removal of dental plaque and rest of aliments from the cavity~* Selection of the SSC~* If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment~* Dry the crown and fill with glass-ionomer luting cement~* Place the crown over the tooth~* Removal of cement excesses from the crown margins~* The child should be asked to keep biting on the crown until the cement has set"
41502523|NCT05213039|OTHER|assessments|All of the children with cerebral palsy will be assessed by two different physiotherapist observers. The timed 360° turn test, Expanded and revised Gross Motor Function Classification System (GMFCS-E\&R) for functional motor levels of the subjects, lower extremity muscle tone will be measured with the Modified Ashworth Scale (MASH) at the beginning of the one-time study and recorded. Pediatric Berg Balance Scale, Timed Up and Go Test, Pediatric Functional Reaching test and Modified Four Square Stepping Test, 3m walking back test (3MGYT) will be performed.Evaluations will be made by two separate physiotherapists with at least 5 years of experience in this field. The time it took for individuals to complete activities during the tests with a stopwatch will be recorded.
40846722|NCT01622777|DRUG|Placebo|100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
41162099|NCT02526771|PROCEDURE|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
41502524|NCT06632431|OTHER|Endometrial cancer (EC)|"Endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy) Histopathological slides for these cases will be reexamined and staged according to both the Federation of Gynecology and Obestetrics (FIGO) 2009 and updated Federation of Gynecology and Obestetrics (FIGO) 2023 endometrial staging systems. Upstaging refers to reclassification to a higher stage in the FIGO 2023 system compared to Federation of Gynecology and Obestetrics (FIGO)2009, while downstaging is the opposite.~All patients underwent lymph node dissection except those with Stage IA-Grades I and II endometrioid endometrial cancer and tumor size \<2 cm."
41502525|NCT01564264|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
41502526|NCT04808505|BIOLOGICAL|Cipaglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
41029525|NCT04283929|OTHER|Experimental: Intervention 2 (Int2)|The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.
41029526|NCT04283929|OTHER|Experimental: Intervention 3 (Int3)|The data on VL results in the EMR showing detectable virus will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for at least 12 months and the VL result in the EMR shows \> 1000 copies/mm3. The alert will be displayed on the patient summary and on the consult sheets requesting actions to address treatment failure (change first line medication, start second line medication, repeat VL, counselling on treatment adherence). A report will also be added to regularly check for patients with high viral load.
41029527|NCT04906018|DEVICE|Ultrasound scans|Each subject will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
41162100|NCT02526771|PROCEDURE|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
41162101|NCT04108975|PROCEDURE|Rectus muscle reapproximation during CS|Reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures.
41162102|NCT04108975|PROCEDURE|Rectus muscle non reapproximation during CS|During CS rectus muscle non reapproximation will be done.
41162103|NCT00193596|DRUG|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
41162104|NCT00193596|DRUG|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
41162105|NCT00193596|DRUG|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
41502527|NCT04808505|DRUG|Miglustat|65 mg oral capsules
40846723|NCT03526510|RADIATION|Conventionally Fractionated versus Hypofractionated Boost|
40846724|NCT04306653|DRUG|ACTH|patients with acute gout will receive 100 IU ACTH IM
40846725|NCT04306653|DRUG|Betamethasone|patients with acute gout will receive 6 mg of betamethasone
40846726|NCT01922843|DRUG|DP001 softgel capsules|
40846727|NCT01922843|DRUG|Placebo|
41502528|NCT06633107|BEHAVIORAL|Cardiac、rehabilitation、exercise|"Routine cardiac rehabilitation treatment + corresponding rehabilitation exercise therapy prescription according to the condition: (1) slow walking + stairs climbing + standing aerobic exercise for patients with cardiac function level I; Grade II patients should take slow walking + standing aerobics; Grade III patients undergo bedside chair aerobics; Class IV aerobic exercises on bed.~After discharge aerobic exercise with the help of community exercise equipment. The duration is gradually increased from 10-20min to 30-40min each time; Gradually increase the intensity from 55% to 60% of the maximum heart rate and not exceed 85% (maximum heart rate (times / min) = 220 - age (years)); The frequency gradually increased from 3 days/week to 5 days/week"
41502529|NCT04759768|DRUG|Nalmefene Hydrochloride|3mg nasal spray
41502530|NCT04759768|DRUG|Nalmefene|1mg intramuscular injection
41502531|NCT03149757|BEHAVIORAL|YouTHrive|"The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before graduating from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; 3) daily mixed-media content with strategies to improve medication adherence' and 4) goal setting and monitoring."
41502532|NCT03149757|BEHAVIORAL|Information-only Control|Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence.
41029528|NCT06025331|PROCEDURE|BIO-RSA|Bony increased offset-reversed shoulder arthroplasty(BIO-RSA) will be performed.
41368733|NCT01797458|PROCEDURE|Non-Restorative Caries Treatment|"Technique:~* A high-speed bur should be used to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area~* Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)~* Show the cavity to patient/parents and give them tooth-brushing instructions~* Tell to parents that good plaque control is the key for this treatment~* The recall interval for these patients is every 3 months."
41368734|NCT01797458|PROCEDURE|Conventional Restoration|"Technique:~* Local anesthesia should be used when needed~* Perform complete caries removal and cavity preparation~* Use a matrix band and a wedge to tightly hold the band against the tooth~* Place the material (Compomer)~* Check contacts and occlusion, and polish the restoration"
41368735|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, qw|Subcutaneous injections of anti-IL6R every week
41368736|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, q2w|Subcutaneous injections of anti-IL6R every other week
41502533|NCT05827614|DRUG|BBI-355|Oral CHK1 inhibitor
41502534|NCT05827614|DRUG|Erlotinib|EGFR Inhibitor
41502535|NCT05827614|DRUG|Futibatinib|FGFR1-4 Inhibitor
41502536|NCT00125112|BEHAVIORAL|Internet-based intervention designed to reduce binge eating and improve healthy weight regulation|
41502537|NCT03819049|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.
41502538|NCT03819049|BIOLOGICAL|ExPEC4V|Participants will receive a single IM injection of ExPEC4V on Day 1.
40846728|NCT05370612|DEVICE|Dexcom G6 CGM|"Dexcom 6 CGM, an FDA approved device. Sensors will be placed on the abdomen per package instruction to collect continuous glucose data.~Experimental Group will wear CGM for the duration of their pregnancy.~Control Group will have CGM data collected for 10 days at enrollment and at 28-32 weeks into their pregnancy."
41368737|NCT03455842|DRUG|placebo|Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
41368738|NCT01716442|DRUG|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
41502539|NCT03819049|BIOLOGICAL|Prevnar 13|Participants will receive a single IM injection of Prevnar 13 on Day 1.
41502540|NCT03819049|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo on Day 1.
41502541|NCT02103504|DEVICE|DePuy Attune posterior stabilized fixed bearing total knee replacement|
41029529|NCT06025331|PROCEDURE|RSA|Conventional reversed shoulder arthroplasty(RSA) will be performed.
41029530|NCT02341300|DEVICE|Cast Iron Pot|Cast iron pot
41029531|NCT02341300|DEVICE|Alumnium Pot|Aluminum Skillet
41029532|NCT00319098|BIOLOGICAL|Adjuvanted pandemic influenza candidate vaccine|2 doses, intramuscular injection
41162106|NCT00193596|DRUG|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
41162107|NCT00193596|DRUG|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
41368739|NCT01716442|DRUG|Placebo|
41368740|NCT02137070|PROCEDURE|Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss
41368741|NCT02137070|OTHER|Non surgical/Community volunteers|Healthy adults with body mass index \>35 who will not undergo bariatric surgery for weight loss
41502542|NCT05853744|DRUG|lavender essential oil inhaled using cotton balls|cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
41502543|NCT05853744|DRUG|lavender essential oil inhaled using face mask|These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer throughout a face mask. A cotton ball soaked with water was put 10 cm next to the patient.
41502544|NCT05853744|DRUG|Distilled water|inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
40846729|NCT05370612|OTHER|Participant Finger Stick Glucose Monitoring|Standard of care for individual participant
41029533|NCT00319098|BIOLOGICAL|Fluarix|One intramuscular injection
41029534|NCT00319098|BIOLOGICAL|Placebo|One intramuscular injection
41029535|NCT01407185|OTHER|Resistive Exercise Training|Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
41368742|NCT01226992|DRUG|Vancomycin|"Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral"
41502545|NCT06632574|DRUG|paclitaxel cationic liposomes|Paclitaxel cationic liposomes is a modified new drug. In this study, administration is performed through arterial catheter infusion.
41502546|NCT05456503|DRUG|FPI-2620|Radiotracer
41502547|NCT02053337|DEVICE|Self adhesive foam dressing|Self adhesive foam dressing
41502548|NCT06200545|OTHER|PrEP eligibility assessment|PrEP eligibility assessment
41502549|NCT06200545|DIAGNOSTIC_TEST|Rapid HIV antibody testing prior to provision and/or refill of PrEP|Rapid HIV antibody testing prior to provision and/or refill of PrEP
41502550|NCT06200545|OTHER|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines
41502551|NCT06200545|BEHAVIORAL|Evaluation of barriers and facilitators to ongoing PrEP use|Evaluation of barriers and facilitators to ongoing PrEP use
40846730|NCT03725761|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan is a novel Antibody Drug Conjugate (ADC) based on a humanized anti-Trop-2 antibody (hRS7) conjugated to SN-38 payload.
40846731|NCT00119171|DRUG|Ispinesib|
41029536|NCT06358482|BEHAVIORAL|oscillating toothbrush|oscillating toothbrush
41029537|NCT06358482|BEHAVIORAL|standard manual toothbrush|standard manual toothbrush
41368743|NCT01226992|BIOLOGICAL|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
41029538|NCT04972500|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
41029539|NCT03538535|BEHAVIORAL|Go/No-Go Active Learning (GOAL)|Behavioral Activation psychotherapy adapted to engage go/no-go learning
41029540|NCT06094153|DIETARY_SUPPLEMENT|Placebo|Consume placebo (Maltodextrin) once daily before going to bed for 28 days
41368744|NCT06261827|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
41368745|NCT06261827|DRUG|200-ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
41368746|NCT00617266|OTHER|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
41368747|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
41368748|NCT00617266|OTHER|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
41502552|NCT06200545|OTHER|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement
41502553|NCT06200545|OTHER|Tracing for any missed PrEP visits|Tracing for any missed PrEP visits
41502554|NCT06200545|OTHER|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"
41502555|NCT06587035|DRUG|Somatrogon|Long-acting growth hormone for pediatric growth hormone deficiency.
41502556|NCT06633510|DEVICE|massimo|masimo is a device for the continuous noninvasive measurement of arterial hemoglobin functional oxygen saturation (SpO2), pulse rate (PR), pleth variability index (PVi) and pleth respiratory rate (Rrp) PI (perfusion index).
40846732|NCT00119171|DRUG|Capecitabine|
41029541|NCT06094153|DIETARY_SUPPLEMENT|HMO 1|Consume HMO 1 (Dietary supplement) once daily before going to bed for 28 days
41029542|NCT06094153|DIETARY_SUPPLEMENT|HMO 2|Consume HMO 2 (Dietary supplement) once daily before going to bed for 28 days
41029543|NCT00595244|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
41029544|NCT03037385|DRUG|pralsetinib (BLU-667)|pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
41029545|NCT04858737|BEHAVIORAL|e-predictD-Work intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps worker participants to develop their own personalized plans to prevent (PPP) depression; 3) nine intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the participants. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress. Worker participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 6 and 12 months.
41029546|NCT04858737|OTHER|Brief psychoeducational messages|The intervention consists of an App that weekly send short messages about stress and general health that will be extracted from brochures and websites of official agencies.
41368749|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
41368750|NCT03666494|DRUG|Ketamine Hydrochloride|As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
41368751|NCT03666494|DRUG|Propofol|As part of the patient's anesthetic induction, they will receive propofol.
41368752|NCT03666494|DRUG|Fentanyl|As part of the patient's anesthetic induction, they will receive fentanyl.
41502557|NCT06448260|OTHER|Questionnary|Data from theses patients will be collected in our personnal data base with ask of consent according to the law Then each patient alive will have questionnary to answer by phone or during a visit.
41502558|NCT00952731|DRUG|oral placebo|Oral placebo taken daily for 4-10 weeks.
41502559|NCT00952731|DRUG|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
41502560|NCT00952731|DRUG|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
41502561|NCT00952731|DRUG|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
41502562|NCT03443830|DRUG|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
40846733|NCT03046030|OTHER|Real acupuncture|Verum acupuncture will be applied on the right SP6 and SP9. For each subject, leg position, acupoint location, and needling parameters (1-2 cm depth, 120 rotations / minute, 90˚ insertion angle, moderate deqi sensations on a 0-10 scale) will be kept constant. For the low dose acupuncture group, needles will be rotated at one point and then the other in 15-second rotations with 20-30 second breaks. The specific starting acupoint will be randomized across subjects but kept consistent for each subject across sessions.
41029547|NCT03897608|BEHAVIORAL|short form 36|"The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates good health"
41029548|NCT04576208|DRUG|TAK-788|TAK-788 capsules
41029549|NCT04576208|DRUG|Antidiarrheal prophylaxis|Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.
41029550|NCT02579993|PROCEDURE|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
41029551|NCT02579993|PROCEDURE|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
41029552|NCT05056350|OTHER|Questionnaires|Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire
41368753|NCT01303159|DEVICE|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
41368754|NCT01240109|DRUG|Remifentanil|"* propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~* sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
41368755|NCT00429026|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) daily for 5 Days
41368756|NCT00429026|DRUG|Melphalan|70 mg/m\^2 IV Daily for 2 Days
41368757|NCT00429026|DRUG|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
41368758|NCT00429026|PROCEDURE|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
41368759|NCT02646501|DRUG|Antiarrhythmic drug|Antiarrhythmic drug
41368760|NCT02646501|PROCEDURE|percutaneous stellate ganglion block (PSGB)|percutaneous stellate ganglion block (PSGB)
41368761|NCT03195270|DRUG|[18F]FDG|10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection
41368762|NCT03195270|DEVICE|PET/MRI|PET/MRI hybrid scanner used as diagnostic device
41368763|NCT05478473|DRUG|Chidamide combined with Toripalimab|chidamide：oral, 30 mg/time, twice weekly; Toripalimab：intravenous drip, 240mg, once every 3 weeks
41368764|NCT06397248|OTHER|No intervention|No intervention
41368765|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.~Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c \< 6.2%, BP \< 120/75 mmHg, HDL-C 40 mg/dL , LDL-C \< 80 mg/dL, TG \< 120 mg/dL.~Follow-up study (Not provided)"
41368766|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.~Follow-up study (Not provided)"
41368767|NCT00542074|OTHER|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
41368768|NCT00542074|OTHER|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
41368769|NCT01590628|DRUG|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
41368770|NCT02059265|DRUG|Dasatinib|Given PO
41368771|NCT02059265|OTHER|Laboratory Biomarker Analysis|Correlative studies
41368772|NCT02064400|OTHER|Musculoskeletal Ultrasound|7-joint musculoskeletal ultrasound scan
41029553|NCT05056350|OTHER|back to work coaching|Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops
41368773|NCT02064400|OTHER|Semi-structured patient interview|Semi-structured patient interview
41502563|NCT02563392|PROCEDURE|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
41502564|NCT02563392|PROCEDURE|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
41502565|NCT03954834|DRUG|Tirzepatide|Administered SC
41502566|NCT03954834|DRUG|Placebo|Administered SC
41502567|NCT04542824|BIOLOGICAL|epcoritamab (monotherapy)|Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
41502568|NCT04542824|BIOLOGICAL|epcoritamab|Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
41029554|NCT05489926|DRUG|Pamiparib|Pamiparib, 60mg PO BID
41029555|NCT02174549|DRUG|Tirapazamine|Intra-arterial injection into the tumor feeding artery
41029556|NCT02174549|PROCEDURE|Conventional Transarterial Embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
40846734|NCT03046030|OTHER|Sham acupuncture|Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles \[20, 35, 104-106\]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling \[20, 35, 104\]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.
41029557|NCT02222220|DRUG|Metoclopramide|30 mg/day during 4 weeks
41368774|NCT06409741|PROCEDURE|Biliary sphincterotomy|"ERCP for biliary sphincterotomy will be performed during index admission for acute pancreatitis, prior to discharge or up till one month from discharge.~The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.~For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary.~If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be it will be counted as a technical failure, maintaining the established clinical follow-up."
41368775|NCT02665754|BIOLOGICAL|ILIT with extract of causal allergen|0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
41368776|NCT02665754|BIOLOGICAL|ILIT with normal saline|0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
41029558|NCT02222220|DRUG|placebo|
41162108|NCT03795402|DEVICE|Microneedle Device|Microneedle device will be used for collecting skin samples as a non-invasive method.
41368777|NCT02665754|DRUG|Rescue medication for allergic rhinitis|Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
41368778|NCT03641235|BIOLOGICAL|Sputum collection|Analysis of Sputum collection
41368779|NCT01738516|PROCEDURE|Electroencephalography|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
41368780|NCT01738516|PROCEDURE|Electroencephalography and additional experimental tasks|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
41368781|NCT03512106|OTHER|Acupuncture|Chinese traditional acupuncture
41368782|NCT04249934|DIETARY_SUPPLEMENT|Caffeinated Coffee|A single 8 ounce cup of regular starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
41368783|NCT04249934|DIETARY_SUPPLEMENT|DecaffeinatedCoffee|A single 8 ounce cup of decaffeinated starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
41368784|NCT00726882|PROCEDURE|Blood sample collection only|Approximately monthly collection of blood samples.
41368785|NCT00726882|DRUG|ABT-333|Previous treatment in prior ABT-333 studies.
41368786|NCT06346743|DRUG|Fenofibrate|Single dose of Fenofibrate will be given at dose of 10mg/Kg along with phototherapy for 24 hours before next blood sampling
41368787|NCT06346743|DEVICE|Phototherapy|only phototherapy will be given for 24 hours before next blood sampling
41368788|NCT04066842|OTHER|Observation|Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
41368789|NCT02563574|BEHAVIORAL|Motivational Interviewing|A type of counseling aimed at reducing consumption of alcohol.
41029559|NCT00844623|GENETIC|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
41029560|NCT03296995|DEVICE|Flash glucose monitoring system|Flash glucose monitoring systems in critically ill patients may improve glycemic control and reduce glucose variability.
41029561|NCT06526572|DIAGNOSTIC_TEST|Brain wave analysis using electroencephalography (EEG).|Asessment of pain with objective neurophysiological assessment through brain wave analysis using electroencephalography (EEG).
41368790|NCT02563574|OTHER|Questionnaire assessment|Several different types of questionnaires will be fill out by the participants.
41368791|NCT02563574|OTHER|Neurocognitive assessments|Several different types of neurocognitive assessment will be performed.
41029562|NCT06526572|DIAGNOSTIC_TEST|Numerical rate Scale (NRS)|Asessment of pain with the subjective numercal rate scale method (NRS
41029563|NCT01134874|BEHAVIORAL|Standard weight loss intervention|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.
41162109|NCT02108197|DEVICE|Continuous positive airway pressure (S9, ResMed)|
41029564|NCT01134874|BEHAVIORAL|Standard weight loss intervention plus technology|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
41029565|NCT01134874|BEHAVIORAL|Technology only|One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
41368792|NCT02563574|OTHER|Blood specimens|Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
41368793|NCT01727804|OTHER|Laser in caries prevention|
41368794|NCT06463132|COMBINATION_PRODUCT|PEP/Euflexxa|Euflexxa (PMA: P010029)
41368795|NCT06463132|DRUG|PEP|PEP (Purified Exosome Product)
41368796|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1\~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T\&E) regimen up to Week 56
41368797|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
41368798|NCT00390676|DRUG|ADH -1 and carboplatin|
41029566|NCT06239168|DIETARY_SUPPLEMENT|Citrus extract|As described in experimental arm
41029567|NCT06239168|DIETARY_SUPPLEMENT|Maltodextrin|As described in comparator arm
41029568|NCT06535217|PROCEDURE|Liver transplantation|Liver transplantation
41162110|NCT01327027|DRUG|Vasopressin, Arginine, ADH|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
41368799|NCT00390676|DRUG|ADH -1 and docetaxel|
41368800|NCT00390676|DRUG|ADH -1 and capecitabine|
41368801|NCT00003266|DRUG|methylphenidate hydrochloride|
41368802|NCT00003266|PROCEDURE|quality-of-life assessment|
41368803|NCT01629121|BEHAVIORAL|education intervention|"The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated."
41368804|NCT00382499|DRUG|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
41368805|NCT06380985|BEHAVIORAL|Personalized VR Alcohol Approach Bias Modification (ApBM) Condition|The Personalized VR ApBM will consist of 2D pictures representing alcohol or positive images (e.g., representing family or friends enjoying time together; sports, pets; travel and holidays, etc.) presented in a unique format in VR (e.g., landscape/portrait orientation), which will serve as the cue requiring a stimulus response. Participants are instructed to push the images away from them if they are presented in one format (e.g., landscape) and grab (using lever on VR controller) the images and pull towards themselves in response to a separate format (e.g., portrait pictures) across a virtual table. Each training session starts with 10 practice trials showing neutral objects (containers), followed by 240 training trials (120 alcohol and 120 non-alcohol trials). Training effect is achieved by altering the contingency of push vs. pull by image type (alcohol vs. positive).
41368806|NCT06380985|BEHAVIORAL|Sham Condition|Sham training is identical to ApBM, except the contingency of each orientation (e.g., portrait or landscape) representing a push vs. a pull is altered to diminish training effect.
41368807|NCT06032091|OTHER|No intervention|The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring. Previous studies show acceptability toward wearable devices among persons with dementia; however, if the care staff recognize discomfort or distress caused by the device, it will be immediately removed.
41029569|NCT05358145|BEHAVIORAL|Tinkering Activities|Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.
41368808|NCT02962999|DRUG|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
41502569|NCT04542824|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
41502570|NCT04542824|DRUG|gemcitabine and oxaliplatin|28-day cycles
41502571|NCT04542824|BIOLOGICAL|epcoritamab (maintenance)|28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
41162111|NCT01327027|DRUG|Placebo; Sterile Saline|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
41368809|NCT02962999|DRUG|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
41029570|NCT05358145|BEHAVIORAL|Control Tinkering Activities|Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.
41029571|NCT05358145|BEHAVIORAL|Board Games Activities|Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
41029572|NCT03028168|OTHER|Yôga|Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
41368810|NCT05726617|BEHAVIORAL|Avatar Intervention|8 weekly sessions of 60 minutes.
41368811|NCT01473602|DRUG|Teriparatide|Administered by SC injection
41029573|NCT03028168|OTHER|Breathing technique|Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
41029574|NCT03028168|OTHER|Control group|Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
41029575|NCT03064425|BIOLOGICAL|Vaginal and blood sample collection|The researchers will obtain approximately 20 mL of blood from participants. Participants will also undergo a pelvic exam where a sample of cells will be collected from the cervix using two small cytobrushes. In addition, a cervicovaginal lavage will be collected using saline.
41029576|NCT05276570|DRUG|ARO-RAGE|single or multiple doses of ARO-RAGE by inhalation of nebulized solution
41029577|NCT05276570|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
41029578|NCT04546087|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
41029579|NCT01953796|DRUG|clomiphene|For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
41029580|NCT04592367|PROCEDURE|Patient age at time of procedure of reconstruction of ACL|Primary reconstruction of ACL with no other concomitant ligament reconstructions. Treatment of cartilage og meniscal injury may be a part of the procedure
41029581|NCT06391112|OTHER|Painting Based Art intervention|Painting Based Art Effect of Intervention on Maternal Anxiety and Fetal Parameters
41029582|NCT06151249|COMBINATION_PRODUCT|Meritup oral solution|chemotherapy + Meritup
41029583|NCT05509751|BEHAVIORAL|GAM, exercise, health education|geriatric assessment, exercise and health education
41029584|NCT05509751|BEHAVIORAL|online chair-based exercise combined with health education|online chair-based exercise and health education for 12 weeks
41029585|NCT05421598|DRUG|Amlitelimab|Injection solution Subcutaneous injection
41029586|NCT05421598|DRUG|Placebo|Injection solution Subcutaneous injection
41029587|NCT05369650|DRUG|Lidocaine Hydrochloride, Injectable|The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.
41029588|NCT02188017|DRUG|Acthar gel|Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
41029589|NCT03161834|OTHER|Observational|
41029590|NCT04898608|OTHER|Intradialytic Exercise|"Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions.~To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 1RM for resistance protocols.~Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
41029591|NCT05126238|DRUG|Lithium Carbonate|In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.
41029592|NCT05126238|DRUG|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.
41029593|NCT00538161|OTHER|Ventilation strategy|
41029594|NCT05858528|DIAGNOSTIC_TEST|PEST screening questionnaire|PEST questionnaire to screen for PsA performed every 6 months
41368812|NCT01473602|DRUG|Placebo|Administered by SC injection
41368813|NCT01473602|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
41368814|NCT01473602|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
41368815|NCT00516698|GENETIC|polymorphism analysis|
41368816|NCT00516698|OTHER|high performance liquid chromatography|
41368817|NCT00516698|OTHER|laboratory biomarker analysis|
41368818|NCT00516698|PROCEDURE|radiomammography|
41368819|NCT00354120|DRUG|Alentuzumab|Alentuzumab
41368820|NCT00354120|DRUG|Globulina antilinfocitaria|Globulina antilinfocitaria
41368821|NCT05341531|OTHER|elderly patients undergoing non-cardiac surgery|Elderly patients 60 years and older undergoing major non-cardiac surgery \> 2 hours
41368822|NCT05333432|PROCEDURE|Multiparameric MRI with injection|"Participants have a prostate multiparametric MRI with gadolinium injection (T2, diffusion and perfusion sequences) every year.~PIRADS-V2 is used as decisional endpoint, and subjective score LIKERT as secondary analysis.~To compute sensivity and specificity, we consider LIKERT as suspicious and/or malignant (PIRADS-V2 = 3, 4 or 5) as positive."
41368823|NCT01970280|DRUG|Enoxaparin|
41368824|NCT01911546|DRUG|everolimus + low-dose tacrolimus|Patients are supplied everolimus (Zortress) + prograf
41368825|NCT01872832|DRUG|RDEA3170 and Placebo|
41502572|NCT04542824|DRUG|rituximab and lenalidomide|28-day cycles.
41502573|NCT03647670|DRUG|PF-04965842|orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
41029595|NCT05904964|DRUG|Disitamab vedotin|Disitamab Vedotin 2mg/kg was injected every 2 weeks,
41029596|NCT05904964|OTHER|Endocrine therapy|Doctors choose endocrine therapy independently
41029597|NCT05154864|PROCEDURE|SBUF-SMUF|Intra-operative continuous ultrafiltration
41029598|NCT04895267|DEVICE|Low-field thoracic magnetic stimulation (LF-ThMS)|A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.
41029599|NCT02919579|DRUG|Placebo (Intranasal)|Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
41029600|NCT02919579|DRUG|Esketamine|Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
41029601|NCT02919579|OTHER|Alcohol|Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
41029602|NCT02919579|DRUG|Placebo (Oral)|Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
41029603|NCT04045457|PROCEDURE|dry needling|insertion of needle into active myofascial trigger point
41029604|NCT05553691|DRUG|SPL026|Intravenous
41029605|NCT05235529|PROCEDURE|Aortic valve replacement|Surgery replacement od the aortic valve
41029606|NCT05235529|DEVICE|TAVI|Transcatheter aortic valve implantation
41029607|NCT06388018|OTHER|Clinical Observation|Undergo observation
41029608|NCT06388018|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41029609|NCT06388018|RADIATION|External Beam Radiation Therapy|Undergo EBRT
41029610|NCT06388018|PROCEDURE|High-Dose-Rate Vaginal Brachytherapy|Undergo vaginal brachytherapy
41029611|NCT06388018|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41029612|NCT06388018|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41029613|NCT06388018|OTHER|Questionnaire Administration|Ancillary studies
41162112|NCT04397146|DIETARY_SUPPLEMENT|Oral Nutrition Supplement (ONS)|Consumption of a portion of 300-320kcal (based on a standard single serve for ONS products) with a two hour follow-up. Products include: 2 Prototype Oral Nutrition Supplements (ONS) with 2.4kcal/ml and respectively 9.6% protein and 14.4% protein; 6 Commercially available Oral Nutrition Supplements with varying energy and protein levels.
41029614|NCT06388018|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
41029615|NCT00768274|DRUG|RVX000222|RVX000222 twice daily (b.i.d.) for 28 days
41029616|NCT00768274|DRUG|Placebo|Placebo twice daily (b.i.d.) for 28 days
41029617|NCT02328664|PROCEDURE|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
41029618|NCT04976738|DRUG|Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
41029619|NCT05542368|DIAGNOSTIC_TEST|Thyroid tests|Thyroid function test TSH ,T3,T4 Thyroid antibody test anti TPO,antithyroglobulin
41029620|NCT02276482|DRUG|Tedizolid Phophate|Tedizolid Phophate 200 mg, IV and/or oral for 6 days
41029621|NCT02276482|DRUG|Antibiotic comparator|Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.
41502574|NCT03647670|DRUG|Midazolam|substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
41029622|NCT02276482|DRUG|Aztreonam|In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.
41029623|NCT02276482|DRUG|Metronidazole|Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.
41029624|NCT03669081|DRUG|Ketorolac|Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
41029625|NCT03669081|DRUG|Pregabalin|Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
41029626|NCT03669081|DRUG|Placebo oral capsule|Placebo oral capsule was administered orally 30 minutes prior to operation.
41029627|NCT03669081|DRUG|Saline|Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
41029628|NCT04777682|PROCEDURE|ultrasound, double balloon enteroscopy|compare intestinal ultrasound versus double-balloon enteroscopy in diagnosis of malabsorption syndrome
41029629|NCT05711069|OTHER|Core Stability Exercise Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
41036598|NCT02495753|PROCEDURE|Vaginal Cleansing|The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.
41036599|NCT02495753|PROCEDURE|Abdominal Cleansing|The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
41162113|NCT03146754|OTHER|Methodology|No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)
41029630|NCT05711069|OTHER|Routine Football Training Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
41029631|NCT00663312|BEHAVIORAL|e.g., Protein and calorie controlled diet; Self-hypnotic relaxation|Pilot description
41162114|NCT02282059|DRUG|sunitinib|subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
41162115|NCT00897754|GENETIC|gene expression analysis|
41162116|NCT00897754|GENETIC|protein expression analysis|
41368826|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
41368827|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
41368828|NCT01475539|BIOLOGICAL|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
41029632|NCT01773226|DEVICE|"Autologous Protein Solution APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
41029633|NCT05481021|OTHER|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
41029634|NCT03339986|BEHAVIORAL|Reduction or Replacement|
41029635|NCT05348681|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
41029636|NCT05348681|DRUG|Placebo|Matching placebo
41029637|NCT04638010|BEHAVIORAL|Cancer control navigation (CNN)|Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only.
41029638|NCT04638010|BEHAVIORAL|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
41029639|NCT00086346|DRUG|Sirolimus (Rapamune)|
41029640|NCT00086346|DRUG|Cyclosporine or Tacrolimus|
41368829|NCT00482976|DRUG|Ruboxistaurin|
41029641|NCT01847846|DEVICE|CPAP mask - prototype|prototype mask, wore for all sleeps for 4 and 8 weeks (as randomly selected). Mask to be used in conjunction with participant's usual prescribed CPAP settings.
41029642|NCT02232529|DRUG|MIN-101|
41029643|NCT02232529|DRUG|Placebo|
41029644|NCT06052501|PROCEDURE|Removable of the full arch implant-supported prostheses|The intervention planned will be the removal of full arch implant-supported prostheses and the acquisition of a digital image through a facial scanner before and after this moment.
41368830|NCT00482976|DRUG|Placebo|
41368831|NCT04790682|BIOLOGICAL|assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.|"* At pre-screening NGS analysis on tumor tissue (slides). Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the main study, to have the possibility to follow the mutation using ctDNA.~* Main study will be initiated after results of the NGS and before initiation of pembrolizumab. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks (30 ml at Baseline then 20 ml of blood). Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 Week. An additional measurement will be performed if treatment is stopped before the end of the study (18 ml of blood).~* Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes before starting the treatment and at 6 weeks and (18 ml of blood)."
41029645|NCT05231668|DRUG|SAR439459|Powder for solution for infusion; IV infusion
41029646|NCT05231668|DRUG|Placebo|Solution for infusion; IV infusion
41029647|NCT02093299|DRUG|Clopidogrel|a blood sample is drawn on all patients to determine responder status
41029648|NCT02785406|DRUG|suvorexant|Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
41029649|NCT02785406|DRUG|Placebo (for suvorexant)|Subjects will receive placebo capsules once daily at 10 PM.
41029650|NCT02241226|BEHAVIORAL|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
41029651|NCT02250404|OTHER|cytology specimen collection procedure|Correlative studies
41029652|NCT02250404|OTHER|laboratory biomarker analysis|Correlative studies
41162117|NCT00897754|GENETIC|reverse transcriptase-polymerase chain reaction|
41162118|NCT00897754|OTHER|immunoenzyme technique|
41162119|NCT00897754|OTHER|immunohistochemistry staining method|
41162120|NCT00897754|OTHER|immunologic technique|
41162121|NCT02556541|PROCEDURE|IV puncture guided by ultrasound|
41162122|NCT03122483|DIAGNOSTIC_TEST|blood biomarker|
40846735|NCT03046030|OTHER|VGAIT|In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
40846736|NCT03046030|OTHER|VGAIT control|The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.
41029653|NCT03191084|DRUG|Low Dose THC Marijuana|Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
41029654|NCT03191084|DRUG|High Dose THC Marijuana|Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.
41029655|NCT03191084|DRUG|Placebo Marijuana|Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
41162123|NCT00711997|BIOLOGICAL|DTA-H19|Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
41162124|NCT05858801|DEVICE|PRIMUS|PRIMUS system
41162125|NCT04884490|DRUG|Co-trimoxazole|Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
41162126|NCT04884490|DRUG|Placebo|Placebo thrice (8 hourly) daily for 7 days orally.
41162127|NCT00281502|DRUG|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
41162128|NCT05654558|DEVICE|Auxiliary cantilever intrusion arches on initial archwires|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
41162129|NCT05654558|DEVICE|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
41502575|NCT05506150|BEHAVIORAL|Interviews|"Focused conversations to understand features of a GI bleed that are important to patients and families.~Patients and family members are invited to participate in focused conversations. For interviews and focus groups, criterion sampling will be used. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data includes self-reported demographic characteristics of the patient and family members. Qualitative data about participants will be obtained through individual interviews and focused groups and project team field notes."
41502576|NCT04898855|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Treatment includes sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
40846737|NCT02922179|DRUG|Long- and intermediate- acting insulins|alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
40846738|NCT03184285|PROCEDURE|baseline alert 1|measurement in supine position
40846739|NCT03184285|PROCEDURE|Anti-Trendelenburg-position (ATB)|measurement under ATB
41162130|NCT02137395|DRUG|Dexamethasone|dexamethasone administration, intravenously
41502577|NCT00620399|OTHER|lumbar corset|
41502578|NCT01998724|BEHAVIORAL|Tai Chi|24 week tai chi intervention designed for individuals with COPD
41502579|NCT01998724|BEHAVIORAL|Group Walking|24 week group walking intervention
41502580|NCT00014352|DRUG|docetaxel|
41029656|NCT02423473|PROCEDURE|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
41029657|NCT02423473|PROCEDURE|Composite resin restoration (Filtek Supreme - 3M)|Restorative procedure do treat tooth structure loss
41029658|NCT04093934|BEHAVIORAL|Psychosocial stimulation|Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
41162131|NCT02137395|DRUG|Placebo|saline administration intravenously
41162132|NCT00000441|DRUG|lorazepam (Ativan)|
41502581|NCT00014352|DRUG|doxorubicin hydrochloride|
41162133|NCT00000441|DRUG|carbamazepine (Tegretol)|
41162134|NCT04177628|BEHAVIORAL|Shared decision making supported by an in-consultation patient decision aid|After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.
41502582|NCT00014352|DRUG|estramustine phosphate sodium|
41502583|NCT00014352|DRUG|ketoconazole|
41502584|NCT00014352|DRUG|warfarin|
41502585|NCT06524453|BEHAVIORAL|Wheelchair accessible exercise program|"1. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes~2. Aerobic exercise~   * High intensity interval training~  * Arm ergometer or wheelchair running~  * 20 mins~3. Strengthening exercise~   * Shoulder and chest, elbow joint major muscle; shoulder and trunk stabilization exercise~  * 3 sets of 10~  * 20 minutes~4. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes"
41502586|NCT05965973|OTHER|Low fat diet|During 3 days, subjects eat a diet low in fat (percent of total caloric intake: 15.0% from proteins; 65.0% from carbohydrates; 20.0% from fat: 4.0% from saturated fat; 10.0% from monounsaturated fat; 6.0% from polyunsaturated fat
41502587|NCT05965973|OTHER|High fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 45.0% from carbohydrates; 40.0% from fat: 8.0% from saturated fat; 22.0% from monounsaturated fat; 10.0% from polyunsaturated fat
40846740|NCT03184285|PROCEDURE|ATB in narcosis|measurement under ATB in narcosis
41029659|NCT02755493|BEHAVIORAL|Sleep deprivation|
41029660|NCT01420796|OTHER|Swallowing exercise|"Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.~This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side."
41029661|NCT01420796|OTHER|Breathing Exercises|Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
41029662|NCT01420796|OTHER|Swallowing and breathing exercises|For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
41162135|NCT03228277|DRUG|Olmutinib|Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
41162136|NCT00621946|DRUG|Placebo|Placebo Matching Escitalopram
41502588|NCT04214249|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41029663|NCT04182425|OTHER|Infant formula|Healthy full-term infants fed on an infant formula marketed on the French market
41029664|NCT06516757|DIETARY_SUPPLEMENT|Boric Acid Suppository|Participants will complete a baseline questionnaire and a vaginal pH test before using the product, and additional questionnaires and a pH test after 3 and 7 days of product use.
41502589|NCT04214249|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41502590|NCT04214249|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41502591|NCT04214249|PROCEDURE|Computed Tomography|Undergo CT
41502592|NCT04214249|DRUG|Cytarabine|Given via continuous IV infusion
41502593|NCT04214249|DRUG|Daunorubicin Hydrochloride|Given IV
41029665|NCT05794854|OTHER|Abdominal aerobic endurance exercise|Subjects combined treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 days per wk for 10 weeks
41029666|NCT05794854|OTHER|Control training intervention|Subjects performed treadmill running (45 minutes) at 70% HRmax 4 days per week for 10 weeks
41029667|NCT03152552|DRUG|LIK066|LIK066 was supplied in different doses as tablets taken orally.
41029668|NCT03152552|DRUG|Placebo|Placebo was supplied as tablets and capsules taken orally.
41029669|NCT03152552|DRUG|Empagliflozin|Empagliflozin was supplied as capsules taken orally.
41029670|NCT05391282|OTHER|ultrasound assessment|Transfontanel ultrasound assessment before and after prone positioning
41029671|NCT06529666|BEHAVIORAL|Didatic Session 1: Core Foundation Course|A 45-minute foundational presentation covering key Weight Management Counseling (WMC) concepts, obesity bias, and cultural humility facilitated by a trained clinician-educator at the residency program delivered at baseline.
41029672|NCT06529666|BEHAVIORAL|The 3Ps Program|"6 email modules delivered over months 2-8). Each 3P module will allow the resident to:~(1) Prepare: Review relevant concepts and demonstration videos sent via an email to prepare for completing the VCA vignettes; (2) Practice: Respond to brief vignettes of various 5As WMC challenging scenarios by audio recording their spoken response on the VCA tool; and (3) Process: Reflect on actionable expert and crowdsourced analogue patient feedback on the quality of their responses to each VCA vignette."
41029673|NCT06529666|BEHAVIORAL|Didactic session 2|(months 8-10): This 45-minute session will discuss key barriers to WMC adoption in clinical practice using real-world cases captured from residents facilitated by a trained clinician-educator at the residency program.
41029674|NCT06529666|BEHAVIORAL|Email reinforcement|2 emails in months 10-12 covering key concepts in the preceding components.
41029675|NCT06529666|BEHAVIORAL|PowerPoint of the foundational course|Residents will receive a core foundation slides on weight management counselling
41502594|NCT04214249|PROCEDURE|Echocardiography|Undergo ECHO
40846741|NCT03184285|PROCEDURE|baseline in narcosis 1|measurement in supine position in narcosis
40846742|NCT03184285|PROCEDURE|passive leg raising|measurement under passive leg raising
40846743|NCT03184285|PROCEDURE|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
41162137|NCT00621946|DRUG|Escitalopram|Active Escitalopram
40846744|NCT03184285|PROCEDURE|baseline in narcosis 2|measurement in supine position
41162138|NCT02361177|DRUG|Oxytocin|Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
41162139|NCT00634218|BEHAVIORAL|Mail-based Self-help plus Internet-based Smoking Treatment|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
41502595|NCT04214249|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
40846745|NCT03184285|PROCEDURE|start capnoperitoneum|measurement in supine position
40846746|NCT03184285|PROCEDURE|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
40846747|NCT03184285|PROCEDURE|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
40846748|NCT03184285|PROCEDURE|ATB loss of capnoperitoneum|measurement under ATB
40846749|NCT03184285|PROCEDURE|baseline|measurement in supine position
40846750|NCT03184285|PROCEDURE|baseline alert 2|measurement in supine position
40846751|NCT03184285|PROCEDURE|torso position rising 30° at the beginning|measurement in the recovery unit
40846752|NCT03184285|PROCEDURE|torso position rising 30° at the end|measurement in the recovery unit
40846753|NCT03944291|PROCEDURE|Pudendal Nerve Block|Pudendal Nerve Block
41029676|NCT03397212|OTHER|NADA acupuncture|Ear acupuncture protocol described by National Acupuncture Detoxification Association
41029677|NCT03397212|OTHER|Sham acupuncture|Ear acupuncture using inactive sham points
41029678|NCT00731315|OTHER|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
41029679|NCT00731315|OTHER|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
40846754|NCT00705887|BEHAVIORAL|Brief Motivational Enhancement Intervention|The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
40846755|NCT01341028|PROCEDURE|Roux-en-Y gastric bypass (LRYGBP)|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
40846756|NCT01341028|PROCEDURE|LRYGBP+gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
41029680|NCT05001555|DRUG|Dexketoprofen/Vitamin B|1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
41029681|NCT05001555|DRUG|Dexketoprofen|1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
41368832|NCT06341582|DIAGNOSTIC_TEST|End-tidal carbon monoxide-corrected (ETCOc)|Early postnatal ETCOc levels
41368833|NCT00475774|BEHAVIORAL|Long-chain (C18:2) and medium chain fatty acid (C8 and C10).|
41368834|NCT01587716|DRUG|GSK2339345 (Inhaled) Single Dose|250, 1000 and 2000 microgram (proposed doses)
41368835|NCT01587716|OTHER|Placebo (Inhaled) Single Dose|Inhaled 0.9% sodium chloride solution
41368836|NCT01587716|DRUG|GSK2339345 (Inhaled) Repeat Dose|2000 microgram (proposed dose) administered 4 times a day for two consecutive days
41368837|NCT01587716|OTHER|Placebo (Inhaled) Repeat Dose|Inhaled 0.9% sodium cholride solution
41368838|NCT05879458|DRUG|Ritlecitinib|200 mg QD for 8 weeks followed by 100 mg for 16 weeks
41368839|NCT04997200|BEHAVIORAL|One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
41368840|NCT02293720|DEVICE|EndoBarrier|The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
41368841|NCT04279873|DIAGNOSTIC_TEST|Microbiological diagnostics on pulmonary secretion|Culture, 16s, 18s, next generation sequencing
41368842|NCT03270280|DRUG|Nigella Sativa Oil|The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
41368843|NCT03270280|DRUG|Normal saline|The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
41368844|NCT00281736|DRUG|HPPH|Given IV
41368845|NCT04067687|OTHER|Palliative home visit|a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
41368846|NCT00919607|DRUG|quetiapine fumarate extended-release|200mg,oral,single dose
41368847|NCT00919607|DRUG|quetiapine fumarate extended-release|300mg,oral,single dose
41368848|NCT00971100|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
41368849|NCT02477319|OTHER|Observational|
41368850|NCT03426774|DEVICE|Gentle Jogger|Passive Simulated Jogging device (Gentle Jogger)
41368851|NCT03426774|DEVICE|Gentle Jumper|Passive Simulated Jumping Device ( Gentle Jumper)
41368852|NCT04309149|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
40846757|NCT05406869|DEVICE|Pulsed Sonic Balloon Dilatation Catheter and Pulsed Sonic Generater|Deliver Pulsed Sonic Balloon Dilatation Catheter to the target vessel prior to placing a coronary stent or others
40846758|NCT02508428|DEVICE|Hip Replacement with crosslinked Marathon polyethylene|Comparison of Marathon and Enduron polyethylene
41368853|NCT04288960|DEVICE|Gwalk accelerometer walking trials|No intervention. Participants will wear a belt mounted accelerometer and complete walking trials to assess validity of the device
41368854|NCT01830621|DRUG|BBI608|
41368855|NCT01830621|DRUG|Placebo|
41368856|NCT01830621|OTHER|Best Supportive Care|
41368857|NCT01768169|DIETARY_SUPPLEMENT|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
41368858|NCT00204711|OTHER|SNAP II EEG System|A portable EEG monitor (SNAP II EEG System, Everest -St. Louis) is unique in that it monitors both low frequency EEG signals (1-40 Hz), which are typically used, and high frequency EEG signals (80-420 Hz), which are not usually used, and calculates a derived EEG parameter (the SNAP Index). The SNAP Index ranges from 100 (completely awake) to 0 (no brain activity) and has been shown in a few studies to correlate with increasing sedation and loss of consciousness in human volunteers and patients receiving general anesthesia during surgery.
41368859|NCT04437732|DEVICE|Apioc-P and Apioc-PT Contact Lens Design|Novel soft contact lens design
41368860|NCT01809847|DRUG|Ofatumumab|"Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy."
41368861|NCT06380374|OTHER|Gamification in Disaster Nursing Education|The contact information of the students who meet the inclusion criteria will be collected by the researchers. The topic of disaster nursing will be explained to all students enrolled in the course by the researcher in the classroom environment. Pre-tests will be taken from students attending the course on disaster nursing. Randomization will be carried out by the researcher, who does not have an active role in the research process. Students in the experimental and control groups will be hidden from the researchers, who will conduct the application until it begins. The Program will be carried out face-to-face. Students in the experimental group will be on the playground. Students will attend the sessions in groups of 6. Each student will compete independently within the group, and each group will have a winner. Students will encounter a total of 30 questions in each game round. The entire game process consists of 7 sessions. After the game process is completed, post-tests will be taken.
41368862|NCT03193996|DEVICE|4DCT|4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
41368863|NCT03445325|BEHAVIORAL|LiGHT v2.1|"The LiGHT mobile program strives to support youth and their families to adopt lifelong healthy behaviours in four areas - eating, physical activity, recreational screen time and sleep - to foster healthy growth and development, to prevent chronic diseases and manage unhealthy weights.~The program includes content that involve the family, and focus on behavioural therapy as well as dietary and physical activity patterns. LiGHT is intended to be engaging and fun, provide virtual and tangible rewards, and interact with participants multiple times per day. In addition, it will feature a mobile social support network and interaction with a live coach with specialized training in motivational interviewing to support youth/families in changing their health behaviours through messaging and phone calls."
41368864|NCT05710809|OTHER|Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement|Vestibular rehabilitation, balance- and progressive resistance training for three months' three times/week and Comprehensive Geriatric Assessement including corresponding interventions
41368865|NCT00429546|BEHAVIORAL|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
41368866|NCT00429546|OTHER|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
41162140|NCT00634218|BEHAVIORAL|Self-Help Manual plus Telephone counseling|Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
41368867|NCT03829995|OTHER|Drug counseling|Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
41368868|NCT03442270|OTHER|No Intervention|This is an observational study, so standard of care will be followed.
41368869|NCT06235034|OTHER|Diagnostic CT|radiotherapy will be designed on diagnostic CT. If plan is of sufficient quality, RT will be delivered to patient
41502596|NCT04214249|DRUG|Idarubicin Hydrochloride|Given IV
41502597|NCT04214249|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41502598|NCT04214249|BIOLOGICAL|Pembrolizumab|Given IV
41502599|NCT04214249|PROCEDURE|Punch Biopsy|Undergo a skin punch biopsy
41502600|NCT06630000|BEHAVIORAL|FACT|Two 90-minute FACT sessions led by a trained interventionist.
41502601|NCT06630000|BEHAVIORAL|Control|Two 90-minute sessions individually with a study interventionist, 2-weeks apart (focused on nutrition education).
40846759|NCT02508428|DEVICE|Hip Replacement with noncrosslinked Enduron polyethylene|
41162141|NCT00634218|BEHAVIORAL|Self-Help Manual|Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
41368870|NCT05127109|COMBINATION_PRODUCT|Nutrition Ecosystem pathway|"1. parenteral nutrition initiated within 72 hours of operative intervention~   * Provided as clinically appropriate: Ensure Enlive, Ensure High-Protein, Nepro with Carb-Steady/ProSource Gelatein Plus, and/or ProSource Gelatein Plus~2. metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~   * Q-NRG Metabolic Cart (Indirect Calorimeter) and Quark RMR Metabolic Cart (Indirect Calorimeter)~  * BWA 2.0 Advanced Bioelectric Impedance Spectroscopy (BIS)~  * Philips Lumify L12-4 broadband linear array transducer ultrasound~3. expedited delivery of oral nutrition supplements and~4. a team-based approach on proper documentation of nutrition delivery and intake"
40846760|NCT01506284|PROCEDURE|Forced oscillatory technique (FOT) and laser interferometry (LIR).|"FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.~LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient."
40846761|NCT05481047|DEVICE|HPI|based on HPI values, clinicians will administer drugs or fluids in order to avoid arterial hypotension
41368871|NCT05127109|OTHER|Comparator|retrospective cohort of 300 historical matched control subjects
41368872|NCT03427320|DRUG|[131]I-IAZA|Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
41502602|NCT05597748|DEVICE|Modified Herbst Approach|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
41502603|NCT05597748|DEVICE|Conventional Herbst Approach|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
41502604|NCT04611529|DRUG|Ibuprofen 400 mg|Ibuprofen 400mg
41502605|NCT04611529|DRUG|Topical diclofenac|Diclofenac 1% gel 4gm
41502606|NCT05773248|PROCEDURE|ERAS protocol|The main concepts of the ERAS protocol compared to standard care included the following aspects: preoperative counselling with a specially trained nurse, restrictive use of preoperative sedation, intraoperative fluid and opioid administration and drain placement, strict antiemetic prophylaxis, early mobilisation, bowel stimulation and removal of any catheters as well as early food intake. Additionally, the ERAS protocol included a 30-day telephone follow-up.
41502607|NCT00299286|DRUG|Lapatinib|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle."
41502608|NCT00299286|DRUG|Lapatinib-Placebo|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose."
40846762|NCT02478255|DRUG|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
40846763|NCT02478255|DEVICE|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
41036600|NCT01015989|OTHER|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
41036601|NCT01015989|OTHER|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
41036602|NCT05457608|DEVICE|Lens A|monthly replacement multifocal silicone hydrogel contact lens 15 minutes of daily wear
41502609|NCT03653884|DIAGNOSTIC_TEST|Ultrasound monitoring|Ultrasound monitoring is recommended during the third trimester in search of an increase in dilation and especially the appearance of a thrombus. A particular clinical form, related to abnormal umbilical vein involvement in the infra-hepatic portal system, must be individualized because of a high risk of thrombosis. It justifies the realization of an abdominal ultrasound in the first days of life. This is an aneurysm of the umbilical vein when the umbilical vein has a diameter greater than 9 mm, or a diameter of the subhepatic segment of the umbilical vein greater than 50% of the diameter of its intrahepatic segment.
41368873|NCT01308385|OTHER|Conditioned pain modulation|When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
41368874|NCT01672827|DRUG|[18F]Flutemetamol|No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
41368875|NCT05163964|BEHAVIORAL|Lifestyle Intervention|Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
40846764|NCT02600091|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
40846765|NCT02797496|OTHER|Asymmetric Motor Strengthening|"In the Asymmetric Motor Strengthening program, the principle is to concomitantly reinforce the body openers and stretch the body closers. One alternates two types of practice during a session. Active exercises consist of fatiguing series of rapid alternating movements against light weights working on movements of extension/abduction/external rotation/supination. Stretch postures consists of short 1-2 minutes bouts of flexor/internal rotator/adductor/pronator stretch. The duration of rehabilitation program is 8 weeks."
41368876|NCT02857062|DEVICE|E45 Eczema Repair Emollient|E45 Eczema Repair Emollient
41368877|NCT00261352|DRUG|Tesaglitazar|
40846766|NCT02797496|OTHER|Conventional therapy|Conventional therapy will include general stretch, strengthening and balance exercises, respiratory exercises and relaxation methods.
41368878|NCT00261352|DRUG|Metformin|
40846767|NCT00552604|DRUG|standardized cannabis extract|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
40846768|NCT00552604|DRUG|Placebo|Matching placebo capsules, twice daily
40846769|NCT05608551|BEHAVIORAL|Animal-assisted trauma-focused therapy|Animal-assisted trauma-focused therapy (AA TF-CBT) is a specific form of trauma treatment, in which one or more animals are integrated into the therapy. AA TF-CBT follows a structured, standardized therapy manual.
40846770|NCT05608551|BEHAVIORAL|Standard trauma-focused therapy|Standard trauma-focused therapy (AA TF-CBT) is a standardized trauma therapy following a structured manual.
41368879|NCT00261352|DRUG|Fenofibrate|
41368880|NCT03152643|PROCEDURE|blastocyst-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
41368881|NCT03152643|PROCEDURE|cleavage-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
41368882|NCT05115760|DIETARY_SUPPLEMENT|Dietary Supplement|Given Kate Farms pea protein oral nutrition supplement PO
41368883|NCT05115760|OTHER|Quality-of-Life Assessment|Ancillary studies
41502610|NCT04657224|DRUG|JNJ-64264681|JNJ-64264681 capsules will be administered orally.
41368884|NCT05115760|OTHER|Questionnaire Administration|Ancillary studies
41502611|NCT04657224|DRUG|JNJ-67856633|JNJ-67856633 capsules or tablets will be administered orally.
40846771|NCT02668913|OTHER|Diagnostic analysis|Molecular profiling
40846772|NCT00006433|DRUG|Doxil|
40846773|NCT00006433|PROCEDURE|heat treatment|
41029682|NCT03263377|DIETARY_SUPPLEMENT|The school feeding intervention|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
41368885|NCT05661006|DIETARY_SUPPLEMENT|Use of food supplement|"On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).~In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).~Intervention end on day 56 ±3 (fasted condition):~Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight \& height Collecting data regarding the palatability of the product"
41368886|NCT05661006|DIETARY_SUPPLEMENT|Use of placebo food supplement|On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
41368887|NCT05741658|DRUG|Dapagliflozin 10mg Tab|Participants will take one Dapagliflozin 10mg tablet once per day for 4 weeks.
41368888|NCT01773850|DEVICE|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
41368889|NCT03637101|DIAGNOSTIC_TEST|Ischemia modified albumin (IMA)|Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic
41368890|NCT05487027|BEHAVIORAL|Goldilocks work principle|"Using the Goldilocks work principle we have tried to find the just right distribution of physical strain in the home care sector. This is an intervention to test if it possible to distribute the physical strain experienced in the home care sector in a way that may be more health promoting for the workers."
41368891|NCT04999904|OTHER|Uneven Treadmill Intervention|Progressive proprioceptive training on the uneven treadmill with up to twelve training sessions. Subjects will be advanced through activities with progression pragmatically assessed by the physical therapists for the benefit and tolerance of the individual subject. Activities may include: slow walking, fast walking, inclined/declined walking, head turning, vision obstruction, dual task walking, fatigued walking, load carriage. Standard of care physical therapy is still provided.
41368892|NCT04999904|OTHER|Standard of Care Physical Therapy|Standard of Care Physical Therapy
41368893|NCT02430545|DRUG|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
41368894|NCT02430545|DRUG|Rifampin|Subjects receive rifampin 600 mg oral dose daily \[Day -6 to day 4\]
41368895|NCT05110118|DRUG|LY01008|Single intravenous injection
41368896|NCT05110118|DRUG|Avastin|Single intravenous injection
41368897|NCT01671462|DEVICE|BD HPV assay on Viper LT|
41368898|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with saline and the wound edges were sealed with tissue adhesive containing cyanoacrylate.
41502612|NCT05656261|GENETIC|Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys|On day of enrollment, participants will have 1 blood sample obtained to extract DNA for determining their APOL1 genotype, and will answer a survey asking about their attitudes/beliefs on kidney disease, hypertension, and diabetes, as well as genetic testing. Participants will receive their results via telephone shortly thereafter, and then complete the same survey at 3 months and 12 months post-enrollment, in order to evaluate if any of their attitudes or beliefs have changed since knowing their APOL1 genetic test result. Those who are interested, specifically those who carry the homozygous or compound heterozygous renal risk variant, will have the option to speak with a designated genetic counselor who is associated with the study site and approved by the IRB.
41502613|NCT01528007|DRUG|Naltrexone pharmacotherapy|Naltrexone 50mg when graving to gamble.
41502614|NCT01528007|DRUG|Placebo|Placebo pill with no active ingredients.
41502615|NCT02938377|BEHAVIORAL|Computerized Brief Intervention (CBI)|A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.
41502616|NCT02938377|BEHAVIORAL|CBT4CBT|9 computerized modules delivered at the participant's pace
41502617|NCT02938377|DRUG|Recommendation and Counseling for Alcohol Pharmacotherapy|The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
41502618|NCT05609630|DRUG|Upadacitinib|Oral tablet or Oral solution
40846774|NCT00398320|DRUG|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
40846775|NCT00398320|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
41029683|NCT05684016|OTHER|NeuroQuant|Reliably defines the volume of those parts of the brain that are important for memory and thinking.
41029684|NCT05684016|OTHER|Automated Neuropsychological Assessment Matrices|This is like an IQ test.
41502619|NCT05609630|DRUG|Tocilizumab|Subcutaneous injection or Intravenous infusion
41502620|NCT05867121|DRUG|RO7496353|RO7496353 will be administered as per the schedules specified in the respective arms.
41502621|NCT05867121|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
41368899|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth (the other side)|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
41368900|NCT06462924|DEVICE|DeepGad|Using the pre-contrast and low-dose Contrast-Enhanced Magnetic Resonance (CE-MRI) images as input and the true full-dose CE-MRI images as the ground truth. the Cycle GAN deep network (DeepGad), was trained to reconstruct the full-dose CE-MRI images from low-dose CE-MRI images.
41368901|NCT03183661|BIOLOGICAL|ALLO-ASC-CD|ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
41502622|NCT05867121|DRUG|Capecitabine|Capecitabine will be administered as per the schedules specified in the respective arms
41502623|NCT05867121|DRUG|S-1|S-1 will be administered as per the schedules specified in the respective arms.
40846776|NCT00398320|DRUG|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
41502624|NCT05867121|DRUG|Nivolumab|Nivolumab will be administered as per the schedules specified in the respective arms.
40846777|NCT01407445|DRUG|Placebo|1 tablet/ oral/ 3 times a day for 90 days
40846778|NCT01407445|DRUG|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for 90 days
40846779|NCT04253587|DEVICE|LabyrinthVR|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.
40846780|NCT04253587|DEVICE|Placebo Games|Commercially-available, narrative computer games marketed as cognitively enriching.
40846781|NCT04253587|DEVICE|Coherence|Head-mounted display virtual reality game designed to present an adaptive rhythm training routine.
41029685|NCT05684016|OTHER|EDSS|Extended Disability Status Score
41029686|NCT05684016|OTHER|Physical Examination|Physical Examination
41029687|NCT00554866|OTHER|blood sample and buccal swab sample|"one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
41029688|NCT03969238|BEHAVIORAL|Helpline|This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
41029689|NCT02541253|BIOLOGICAL|GC3110A|A single 0.5mL dose intramuscular injection
41029690|NCT02541253|BIOLOGICAL|GCFLU Pre-filled Syringe inj.|A single 0.5mL dose intramuscular injection
41029691|NCT00627705|DRUG|N-Acetyl Cysteine|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
41368902|NCT02319265|DRUG|Melatonin|Oral liquid
41368903|NCT03374774|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
41368904|NCT01751490|OTHER|physiotherapy|physiotherapy
41502625|NCT05867121|DRUG|Oxaliplatin|Oxaliplatin will be administered as per the schedules specified in the respective arms.
41368905|NCT01751490|PROCEDURE|shoulder stabilisation surgery|arthroscopic stabilisation surgery
41368906|NCT02210026|DEVICE|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
41502626|NCT05867121|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as per the schedules specified in the respective arms.
40846782|NCT04253587|DEVICE|Tablet|Tablet computer playing Labyrinth VR game but in 2.5D
40846783|NCT04183608|DRUG|Adalimumab|Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by 40mg EOW until V2 (W26)
40846784|NCT04183608|DIAGNOSTIC_TEST|Calprotectin|Fecal calprotectin dosing at home with IBDoc
40846785|NCT04183608|OTHER|e-Monitoring|"e-Monitoring at Week 6, Week 10, Week 14, Week 18, Week 22, Week 26, Week 34, Week 38, Week 42 and Week 48~The patient must complete the first 2 questions of the Mayo score:~* Stool frequency~* The frequency of bleeding~He must also complete the information on his injections"
40846786|NCT04183608|OTHER|Therapy Education|Patient Education at W0, W2, W14, W26 and W38.
41502627|NCT05867121|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedules specified in the respective arms.
41502628|NCT03278392|BEHAVIORAL|Trier Social Stress Test|Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).
41502629|NCT03278392|BEHAVIORAL|Placebo Non-stress task|Subject engages in a friendly conversation about a neutral or happy topic (e.g. recent holiday, favorite past-times) for 15 minutes with a familiar research staff member.
41502630|NCT04730037|DRUG|Edoxaban|- Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
41502631|NCT04730037|DRUG|Warfarin Potassium|- Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)
41502632|NCT04730037|DRUG|Warfarin Potassium placebo|- Warfarin K 1 mg placebo tablets once daily
41502633|NCT04730037|DRUG|Edoxaban placebo|- Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
41029692|NCT00627705|OTHER|Placebo - sugar pill|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
41162142|NCT00634218|BEHAVIORAL|Self-Help Manual plus Internet-based Intervention plus Telephone Counseling|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
41162143|NCT04201717|PROCEDURE|laparoscopic assisted left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
41162144|NCT04201717|PROCEDURE|total laparoscopic left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, all surgical area was flushed and drainage tubes were left.
41368907|NCT01100931|DRUG|YM155|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m\^2, dose level 2:5 mg/m\^2 , dose level 3:6 mg/m\^2, dose level 4:8 mg/m\^2, dose level 5:10 mg/m\^2 (MTD), dose level 6:12 mg/m\^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m\^2 (MTD)intravenous infusion over 72 hours every 21 days."
41368908|NCT01100931|DRUG|Carboplatin|Area under curve (AUC) of 6 intravenous on day 1
41368909|NCT01100931|DRUG|Paclitaxel|200 mg/m\^2 intravenous on day 1
41368910|NCT05258968|OTHER|Education on the Injeti Model of Self-Esteem|1 hour educational session
41368911|NCT06238544|DRUG|HRS-5965 tablets|HRS-5965 tablets until the end of study treatment
41368912|NCT01302366|DRUG|TBL12|
41368913|NCT04447963|DEVICE|Non-invasive treatment of facial wrinkles|Application of radiofrequency field which provides controlled heating to the skin.Therapeutic effect is observed when the tissue temperature reaches 40-45 degrees Celsius.
41368914|NCT05836259|GENETIC|TN-201|TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.
41368915|NCT03159052|DRUG|SHR3824|Once daily, 52 weeks
41368916|NCT03159052|DRUG|Placebo|Once daily, 24 weeks
41368917|NCT04893382|PROCEDURE|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
41368918|NCT04893382|PROCEDURE|Ringer's Lactate for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
41368919|NCT03871231|DEVICE|Unpinning Termination Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
41368920|NCT00656942|DEVICE|Quantitative Sensory Testing (QST)|QST consists of a series of heat and cold stimulation tests.
41368921|NCT02737410|BEHAVIORAL|Gut-directed Hypnotherapy|The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
41029693|NCT03197792|OTHER|All patients|"TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.~On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death."
41029694|NCT01815177|DEVICE|Arthroscopic transosseous fixation|
41368922|NCT04953182|OTHER|Pain scale registry|The nurses ask the patient about the pain filling every two hours during the hospitalization.
41368923|NCT00655226|BEHAVIORAL|Hepatitis C educational support groups|Hepatitis C educational support groups
41368924|NCT00655226|BEHAVIORAL|Cognitive Behavioral Therapy skills based group sessions|Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
41368925|NCT02283411|DEVICE|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
41162145|NCT00207233|BEHAVIORAL|MCT oil hypocaloric liquid diet|"The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
41368926|NCT01589185|DRUG|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
41368927|NCT01589185|DRUG|Placebo|Placebo administered as a single intravenous infusion
40846787|NCT06563388|PROCEDURE|Stereotactic Ablative Radiotherapy|Radiation therapy begins after 3 months of Standard of care
41029695|NCT01815177|DEVICE|Suture anchors|
41029696|NCT03379025|OTHER|Electronic cigarette|electronic cigarette and cartridge refills (also known as pods)
41029697|NCT02095262|OTHER|reactive auditory training|
41029698|NCT02095262|OTHER|Interactive auditory training|
41029699|NCT04001829|DRUG|Docetaxel|Given IV
41029700|NCT04001829|DRUG|Paclitaxel|Given IV
41368928|NCT02929017|OTHER|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
41368929|NCT02929017|OTHER|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
41368930|NCT03547921|DEVICE|iu22 ultrasound system - phillips|iu22 ultrasound system - phillips
41368931|NCT02689609|RADIATION|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
41368932|NCT06149273|BEHAVIORAL|Sleep School|Sleep school is a structured method for the treatment of insomnia, which is based on cognitive behavioral therapy for insomnia (CBT-I). The central element of the method is a workbook for the patients. The essential parts of the method are strengthening the patient's self-efficacy, introducing the therapeutic exercises, and supporting the continued use of the exercises. The main themes of the Sleep school are information about sleep and the factors affecting it, behavioural components of CBT-I, like restricting the time spent in bed, cognitive components of CBT-I, like constructive worrying -exercise, and the exercises that aim to calm down mind and the autonomic nervous system. The Sleep School is held by an educated nurse.
41368933|NCT06149273|BEHAVIORAL|Treatment as usual|Oral and written information about improving sleep habits given by an educated nurse.
41368934|NCT02647931|BEHAVIORAL|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
41368935|NCT03058861|BEHAVIORAL|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
41029701|NCT04001829|OTHER|Quality-of-Life Assessment|Ancillary studies
41029702|NCT04001829|OTHER|Questionnaire Administration|Ancillary studies
41029703|NCT03524326|DRUG|Lenvatinib Pill|24 mg oral daily
41029704|NCT03524326|DRUG|Lenvatinib Pill|20 mg oral daily
41029705|NCT03524326|DRUG|Lenvatinib Pill|14 mg oral daily
41029706|NCT03524326|DRUG|Cetuximab|400mg/m2 IV, then 500mg/m2 IV weekly
41029707|NCT03524326|DRUG|Lenvatinib Pill|10 mg oral daily
41029708|NCT03524326|DRUG|Lenvatinib Pill|4 mg oral daily
41029709|NCT05810922|OTHER|arbutus berry|consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
41029710|NCT02471924|OTHER|Trans thoraciq cardiac ultrasonography|Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
41029711|NCT06532955|DEVICE|Lymphaticovenous anastomosis using Microsure Motion Stabilizer|"The robot-assisted LVA is performed using the Microsure Motion Stabilizer, a telemanipulation tool that stabilizes a surgeon's movement during open microsurgical operations on extremities, specifically on veins and nerves that are close to the skin.~The surgeon controls a joystick, which directly copies the surgeon's movements in real-time to an instrument held by the device. The device's software scales down the motions and filters out tremor. Surgical technique and method of treatment are identical to conventional microsurgery. The device is equipped with genuine microsurgical instruments and is compatible with existing surgical microscopes. Instead of holding the instrument directly in hand, which is limited in precision and dexterity, the surgeon operates while the instrument's movements are stabilized. The modular design allows the surgeon to decide what level of manipulation assistance is required during a certain procedure."
41036603|NCT05457608|DEVICE|Lens B|daily disposable multifocal silicone hydrogel contact lens 15 minutes of daily wear
41368936|NCT03980665|DRUG|Arsenic Trioxide|a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
41368937|NCT03664700|DEVICE|LMA Protector|The LMA Protector will be inserted when a supraglottic device is needed
41502634|NCT04820530|DRUG|Iptacopan (LNP023)|Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral
41502635|NCT01730924|PROCEDURE|Pulmonary vein isolation using contact force sensing catheter|
40846788|NCT06563388|OTHER|Best Practice|Receive standard of care therapy
41368938|NCT03678909|PROCEDURE|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
41368939|NCT04373265|DRUG|Relacorilant|Relacorilant, 100 mg soft gel capsules orally once daily
41368940|NCT04373265|DRUG|Pembrolizumab|Pembrolizumab 400 mg infusion every 6 weeks
41368941|NCT01779466|DRUG|Desmopressin|
41162146|NCT00207233|BEHAVIORAL|LCT hypocaloric liquid diet|"The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
41029712|NCT06532955|PROCEDURE|Lymphaticovenous anastomosis (manual)|Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to an adjacent vein of similar size, thereby facilitating the outflow of lymphatic fluid in patients suffering from secondary lymphedema
41029713|NCT06535984|OTHER|White Noise|White Noise Group (n=30) The third researcher turned on white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the start of the eye examination and played it to the infants until the end of the examination.
41029714|NCT06535984|OTHER|Swaddling|Swaddling group (n=30) The third researcher swaddled each infant with its thin blanket. The swaddling involved bringing the infant's left hand close to the left buttock and wrapping it with the upper right end of the blanket. Similarly, she wrapped the baby's right hand with the upper left end of the blanket by bringing it closer to the right hip. She wrapped the baby's legs with the lower part of the blanket, ensuring that the baby's head could move freely.
41029715|NCT06535984|OTHER|White Noise+Swaddling|White Noise + Swaddling Group (n=30) The third researcher swaddled the infants in this group as described in the swaddling group and turned on the white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the examination started and played it to the infants until the examination was over.
41029716|NCT06104735|PROCEDURE|Synaptic Pairing Interval|Optimize interstimulus pairing between brain and spinal cord stimulation.
41029717|NCT06104735|PROCEDURE|Frequency|Compare 2 Hz continuous to intermittent theta burst frequency
41029718|NCT06104735|PROCEDURE|Bouts|Compare effects of 1, 2, or 4 bouts of SCAP
41029719|NCT06104735|PROCEDURE|Spacing|Compare 6 versus 12 minutes of rest in between bouts of SCAP
41029720|NCT06104735|PROCEDURE|Exercise|Task-oriented hand exercises
41029721|NCT06104735|PROCEDURE|SCAP plus Exercise|Compare interleaved versus serial bouts of SCAP and exercise.
41029722|NCT02025777|DEVICE|Capsule Endoscopy|
41029723|NCT00986999|DRUG|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
41029724|NCT00506961|DRUG|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
41029725|NCT00506961|DRUG|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
41029726|NCT02018055|DRUG|Aspirin+Ticagrelor|Aspirin+ Ticagrelor after 1month of standard DAPT (Aspirin+Ticagrelor)
41029727|NCT02018055|DRUG|Aspirin+Clopidogrel|Aspirin+ Clopidogrel after 1month of standard DAPT (Aspirin+Ticagrelor)
41162147|NCT00207233|PROCEDURE|Subcutaneous abdominal adipose tissue biopsy|"Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks."
41162148|NCT00415883|DRUG|Valsartan|
41368942|NCT01779466|DRUG|Placebo (not active)|
41029728|NCT03841786|OTHER|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet and will take a total of 1,000 mg of supplemental phosphorus per day in the form of neutral sodium phosphorus (K-Phos neutral®) for 1 week.
41029729|NCT03841786|OTHER|Control Diet|Participants will be asked to consume a normal diet supplemented with sodium and potassium chloride tablets commensurate with the extra sodium and potassium content consumed during the study diet period for 1 week
41029730|NCT05297045|DRUG|RGT001-075|Oral GLP1 Receptor Agonist
41029731|NCT05297045|OTHER|Placebo|Placebo comparator
41029732|NCT01281930|PROCEDURE|Full packing into abscess cavity|After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it
41029733|NCT01281930|PROCEDURE|Wick placement into abscess cavity|After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
41029734|NCT00911365|BIOLOGICAL|autologous mesenchymal stem cells|"4\*107 stem cell (100ml) Intra arterial infusion/ one time, then 4\*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-\> Total four times"
41029735|NCT00911365|BIOLOGICAL|normal saline|saline
41029736|NCT01637753|DRUG|Carmustine(BCNU)|Carmustine Sustained Release Implant
41029737|NCT01637753|PROCEDURE|Surgery|Routine tumor resection surgery
41162149|NCT00255944|BEHAVIORAL|Youthnet Internet-based program|Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
41162150|NCT00255944|BEHAVIORAL|Control Internet based program|The control program will deliver standard STD/HIV prevention messages.
41162151|NCT03988478|BEHAVIORAL|Detoxification & psychotherapeutic support|
41162152|NCT03800264|DRUG|Bisoprolol|PREVENTIVE DOUBLE BLINDED
41162153|NCT04682340|DIAGNOSTIC_TEST|Serum BPA|Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.
41162154|NCT04157959|DRUG|SHR4640 dose1|Tablet,dose1,QD
41029738|NCT06457009|COMBINATION_PRODUCT|Multi-component Intervention Package|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for asthma;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to individuals with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for undiagnosed asthma patients;~7. To actively include individuals whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;~9. Pay-for-population mechanism for medical practitioners."
41029739|NCT00752375|DRUG|Trimethoprim Sulfamethoxazole|"* Children \>3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~* Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~* Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year."
41029740|NCT00752375|DRUG|placebo|"* Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~* Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~* Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy."
41029741|NCT06535191|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|ASSET program is a manualized, theory-driven, 10-week soft skills intervention for autistic individuals, who seek employment or who wish to maintain employment by improving work-related social skills. Throughout a 10-week curriculum offered in a school-based group setting, ASSET addresses the following competencies for workplace success: Communication, Networking, Enthusiasm and Attitude, Teamwork, Problem-Solving and Critical Thinking, Professionalism, Mental Health and Stress Management, and Awareness of Self and Others.
41029742|NCT04236349|GENETIC|immunogenetics|blood samples at day 0, week 2, month 2; at the end of treatment (month 6 or month 9 or month 12 depend on treatment duration)
41029743|NCT01389973|DRUG|ustekinumab 90 mg|Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
41029744|NCT01389973|DRUG|ustekinumab 45 mg|Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
41029745|NCT01389973|DRUG|ustekinumab 180 mg|Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
41162155|NCT04157959|DRUG|Febuxostat dose2|Tablet,dose2,QD
41029746|NCT01389973|DRUG|Placebo|Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
41029747|NCT00598689|DRUG|0.3% hypromellose|0.3% hypromellose four times a day for 5 days prior to LASIK surgery
41162156|NCT00093743|DRUG|fludarabine phosphate|Given IV
41162157|NCT00093743|DRUG|cyclosporine|Given IV or PO
41162158|NCT00093743|RADIATION|total-body irradiation|Undergo TBI
40846789|NCT03360058|BEHAVIORAL|Small Talk Big Difference Immediate access training|Immediate access to 1 hour online training and supporting print materials for implementation in primary care practice
41162159|NCT00093743|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
41162160|NCT00093743|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplantation
41162161|NCT00093743|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplantation
41162162|NCT00093743|DRUG|mycophenolate mofetil|Given PO or IV
41162163|NCT00192166|BIOLOGICAL|CAIV-T|
41162164|NCT05563415|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
41502636|NCT05924607|OTHER|Standard clamshells method|The patient is asked to lie in a side-lying position with the weak limb up, both hips flexed at 45°, the knees flexed at 90°, and neither the feet nor back not in contact with the wall. Keeping both their heels and the first metatarsal head together, the patient separated their knees and rotated the weak limb upward. The patients is instructed not to tip it backward and to hold the pelvis in a neutral position
41162165|NCT03560414|PROCEDURE|simple plasma exchange|simple plasma exchange treatment
41162166|NCT03560414|PROCEDURE|conventional PDF treatment group|conventional PDF treatment group
41162167|NCT03560414|PROCEDURE|less plasma PDF treatment group|less plasma Plasma diafiltration treatment
41162168|NCT01213615|DEVICE|Valve replacement|Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
41502637|NCT05924607|OTHER|Targeted VMO strengthening|Targeted VMO strengthening The patient is asked to lie in a supine lying position with arm next to the body. After that asked the patient to perform SLR exercise in an external hip rotation with the simultaneous contraction of the ankle dorsiflexors. Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions
41502638|NCT06058286|OTHER|Continuous quality improvement|Continuous quality improvement (CQI) is an approach to develop healthcare providers' capacity to improve quality of care processes and improve adherence to clinical guidelines. Key features of CQI include systematic, data-guided activities, designing interventions (or changes to facility processes) with local conditions in mind, and iterative development and testing of interventions. The approach is based on the premise that valuable improvement in organisational processes can be achieved through bottom-up initiatives of stakeholders and providers. It requires a 'team-based' culture of staff working together to collect and use available data to evaluate the effect of local solutions. Facility staff drive the development of solutions to quality of care shortcomings that they feel are best suited to the local context, and CQI works within existing resource constraints so it does not require large long-term investments to sustain improvements.
41368943|NCT00361790|DRUG|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
41368944|NCT04563845|DRUG|GSK3640254|GSK3640254 will be administered.
41368945|NCT04563845|DRUG|Placebo|Placebo will be administered.
41029748|NCT03567226|BEHAVIORAL|WeChat Group|"Consenting participants will be randomized to either the intervention or the control arm after successfully wearing an accelerometer for one week. The WeChat Group will be a community forum to share information, encourage each other, and receive communications from the study team. In addition, the study team will disseminate the following information through the group:~1. Daily/Weekly Reminders to exercise~2. Health education materials regarding glaucoma and general health and exercise~3. Motivational content~4. Surveys to gauge what information participants found most interesting and useful to help them exercise"
41029749|NCT03567226|BEHAVIORAL|Counselling|Study participants in the control group will receive a handout telling them to increase walking and will be counseled that walking may be helpful for the eye at the return visit
41368946|NCT04563845|DRUG|Moxifloxacin|Moxifloxacin will be administered.
41368947|NCT04052711|DRUG|FMX-101|
41368948|NCT01873274|DIETARY_SUPPLEMENT|MK-7 containing capsule|
41368949|NCT01873274|DIETARY_SUPPLEMENT|basic yogurt enriched with MK-7|
41368950|NCT01873274|DIETARY_SUPPLEMENT|nutrient-enriched yogurt with MK-7|
41368951|NCT00576940|DRUG|Reconvan|isocaloric, immunomodulating entral diet
41368952|NCT00576940|DRUG|Peptisorb|isocaloric, isopeptic standard diet
41368953|NCT01678586|OTHER|Acupuncture|In true acupuncture the needles penetrate the skin.
41368954|NCT01678586|OTHER|Sham Acupuncture|In sham acupuncture the needles do not penetrate the skin.
41368955|NCT01678586|DRUG|Gabapentin|Gabapentin is a commonly prescribed drug used to treat neuropathic pain.
41368956|NCT01678586|DRUG|Sham Gabapentin|Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)
41368957|NCT04052425|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
41368958|NCT04052425|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
41502639|NCT00945100|DEVICE|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
41502640|NCT00945100|DEVICE|Eye Patch|2 hours patching daily
41502641|NCT03307629|DRUG|NOX66|NOX66 delivered as rectal suppository.
41029750|NCT04897516|DRUG|Short regimen of benznidazole|Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.
41029751|NCT04897516|DRUG|Short treatment with benznidazole|Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks.
41368959|NCT04008459|OTHER|Therapeutic exercise class|Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
41368960|NCT02369874|DRUG|MEDI4736|MEDI4736 Monotherapy
41368961|NCT02369874|DRUG|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
41368962|NCT02369874|DRUG|Standard of Care|Standard of Care
41368963|NCT01590095|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
41368964|NCT01590095|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
41368965|NCT01590095|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
40846790|NCT03360058|BEHAVIORAL|Small Talk Big Difference delayed access training|Delayed access (by 4 months) to 1 hour online training and supporting print materials for implementation in primary care practice
41502642|NCT03307629|RADIATION|Irradiation Therapy|Radiation per selected tumour lesion.
40846791|NCT04519697|DRUG|Mesenchymal Stem Cells|Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.
40846792|NCT04519697|OTHER|Placebo|Normal Saline
40846793|NCT02828020|DRUG|Ubrogepant|50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
40846794|NCT02828020|DRUG|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
40846795|NCT03874390|OTHER|ozone|gaseous ozone was applied on periodontal pocket two times in one week.
40846796|NCT02327494|DRUG|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
40846797|NCT03123328|DEVICE|Radical-7 Pulse CO-Oximeter and sensor|Noninvasive device that measures hemoglobin.
40846798|NCT04286516|DEVICE|Transcranial Magnetic Stimulation|Paired pulse transcranial magnetic stimulation
40846799|NCT04619498|DEVICE|PediAppRREST|PediAppRREST is a new audiovisual interactive app for tablets developed to support the management of pediatric cardiac arrest. It sequentially displays directions on recommended management interventions. It was specifically designed to guide the team leader to perform resuscitation interventions in the sequence/timing and modality reported by the American Heart Association Pediatric Advanced Life Support (AHA-PALS) guidelines.
40846800|NCT04619498|OTHER|AHA-PALS pocket reference card|It is a 10 cm x 16.5 cm, full-color, 2-sided, 6-panel card that shows the American Heart Association Pediatric Advanced Life Support (AHA-PALS) treatment algorithms. By providing a quick reference tool, it serves as a cognitive aid for healthcare providers who either direct or participate in the management of pediatric respiratory and/or cardiovascular emergencies, including cardiac arrest.
40846801|NCT02220426|DRUG|Xenon|Inhalation of hyperpolarized xenon gas
40846802|NCT03759106|OTHER|home written exercise program|exercises such as picking up objects, placing objects, frequently prescribed at discharge
40846803|NCT03759106|OTHER|telerehabilitation/exergame system|Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
40846804|NCT04840134|BEHAVIORAL|From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk|"The intervention will be delivered in two consecutive phases:~1. Intensive Intervention Phase (week 1-9), including 9 weekly peer-led group sessions (90min) and four one-on-one coaching sessions (60min); and~2. Follow-up Intervention Phase (weeks 10-24),consisting of 3 monthly group sessions (90min) and bi-weekly phone check-ins to provide ongoing support (15-20min).~Key intervention components:~1. Peer-led group sessions include personal stories of financial empowerment; practical information about available financial supports; basic financial coaching and mutual support/ accountability (e.g., goal/action check-ins);~2. One-on-one peer coaching sessions (throughout 24 weeks) to help participants identify their personal financial stressors and facilitate a personalized Financial Wellness Action Plan.~3. Support to navigate and access financial supports in the community (e.g., financial counseling, free tax prep, housing eviction prevention, debt relief)."
40846805|NCT05002491|OTHER|High protein diet|Normal vs high protein dietary feeding
40846806|NCT03596684|DIETARY_SUPPLEMENT|citrulline supplementation|2.5 g per os of citrulline on the morning and the evening (5 g/ jour) during 4 weeks.
40846807|NCT03596684|DIETARY_SUPPLEMENT|placebo supplementation|2.5 g of the product in the morning and in the evening during 4 weeks.
40846808|NCT03596684|PROCEDURE|glucose tolerance test|2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
40846809|NCT03141541|BEHAVIORAL|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
40846810|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, low dose|4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
41029752|NCT04897516|DRUG|Standard treatment with benznidazole|Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks
41029753|NCT02606838|DEVICE|Styx Lancing Device|Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
41029754|NCT04698980|DIAGNOSTIC_TEST|blood samples (venous and capillary at the fingertip)|For each participant, the intervention will be a fingertip sample to perform the STANDARD G6PD test and two blood samples on EDTA to perform the reference test
41502643|NCT05756283|BEHAVIORAL|Multimodal Prehabilitation|"EXERCISE~* Supervised exercise~  * High intensity interval training~ * Strength exercise~* Home-based exercise / promotion of physical activity~  * Low-moderate intensity aerobic training~ * Inspiratory muscle training~ * Low-moderate intensity strength training~NUTRITION: nutrition education and optimization. Intake of 0.4g/kg of whey isolate after every supervised training.~PSYCHOSOCIAL: mindfulness, cognitive reframing and coping strategies."
41502644|NCT00602368|OTHER|histological technique|
41502645|NCT00602368|OTHER|laboratory biomarker analysis|
41502646|NCT00602368|PROCEDURE|colposcopic biopsy|
40846811|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, medium dose|8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
40846812|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, high dose|12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
41036604|NCT04377165|BEHAVIORAL|Gamification|This will provide the user with the newsfeed function and the addition of a gamification function
41036605|NCT04377165|BEHAVIORAL|Newsfeed function|This will provide the user with reliable accurate information on the pandemic.
40846813|NCT01540669|DIETARY_SUPPLEMENT|Placebo powder|Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
40846814|NCT00679172|BIOLOGICAL|Dose of 5.0 x 10^9 CFU (Cohort 1)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
41502647|NCT00602368|PROCEDURE|colposcopy|
40846815|NCT00679172|BIOLOGICAL|Dose of 7.5 x 10^9 CFU (Cohort 2)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
40846816|NCT00679172|BIOLOGICAL|Dose of 1.1 x 10^10 CFU (Cohort 3)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
40846817|NCT00679172|BIOLOGICAL|Dose of of 1.7 x 10^10 CFU (Cohort 4)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
40846818|NCT00679172|OTHER|Placebo (Cohorts 1-4 pooled)|Excipients only, single dose, oral administration
40846819|NCT05749393|DRUG|Heparin sodium|Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
40846820|NCT05061498|DIAGNOSTIC_TEST|Additional Pacing maneuvers|In order to determine the optimal setting for pacemapping in all participants additional pacing maneuvers (output and cycle length) are performed
40846821|NCT00232856|DEVICE|drug-eluting stent|PCI
40846822|NCT01710098|DRUG|Degarelix|subcutaneous injection
40846823|NCT05910008|PROCEDURE|O-Arm Stereotactic imaging|Prior to electrode implantation, O-ARm stereotactic imaging (Magnetic Resonance Imaging)
40846824|NCT05910008|PROCEDURE|Standard Stereotactic imaging|Prior to electrode implantation, standard stereotactic imaging (Magnetic Resonance Imaging)
40846825|NCT05312294|BIOLOGICAL|Flu-M [inactivated split influenza vaccine] without preservative|Solution for intramuscular injection, 0.5 ml
40846826|NCT05312294|BIOLOGICAL|Flu-M [inactivated split influenza vaccine] with preservative|Solution for intramuscular injection, 0.5 ml
40846827|NCT00306540|DRUG|Quetiapine Fumarate|oral flexible dose
40846828|NCT00306540|DRUG|quetiapine fumarate placebo|oral 0 mg
40846829|NCT00916019|OTHER|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
41029755|NCT06534190|RADIATION|89Zr-Df-crefmirlimab PET scan|"89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later. All patients will undergo a 89Zr-Df-crefmirlimab PET scan at baseline and after treatment with the PD-1 antibody. All patients participating in this imaging trial will undergo preferably 2 but at least one tumour biopsy. The biopsy procedure(s) will be performed after the 89Zr-Df-crefmirlimab PET scan at baseline and/or after the 89Zr-Df-crefmirlimab PET on-treatment.~After the first PET scan and tumour biopsy the patients will start treatment with PD-1 antibody nivolumab or cetrelimab."
41029756|NCT06534190|DRUG|Nivolumab|Immunotherapy treatment with Nivolumab
41029757|NCT06534190|DRUG|Cetrelimab|Immunotherapy treatment with cetrelimab
41029758|NCT06534190|OTHER|zirconium Zr 89 crefmirlimab berdoxam|89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later
41029759|NCT00006060|DRUG|standard gadolinium contrast|
41029760|NCT06529692|BEHAVIORAL|Placebo Split-Belt Training|Walking on a split-belt treadmill in which the belt under the ACL leg will move at a speed that is minimally slower than the other belt.
41036606|NCT03962387|OTHER|Not applicable(observational study)|Not applicable(observational study)
41162169|NCT04991623|DEVICE|Kinesiology taping|We used kinesiology taping in abdominal muscles
41162170|NCT04991623|OTHER|Conventional physiotherapy|We used conventional physiotherapy to comparate
40846830|NCT02632487|BEHAVIORAL|Exercise|Center-based walking + balance, stretching, and light resistance
40846831|NCT02632487|BEHAVIORAL|Non-Exercise Physical Activity (NEPA)|Behavioral counseling paired with technology intervention to monitor physical activity
40846832|NCT03549715|DRUG|Durvalumab|1500 mg IV D1 every 28 days (2 doses for each patient)
40846833|NCT03549715|DRUG|Tremelimumab|75 mg IV D1 every 28 days ((2 doses for each patient)
40846834|NCT03549715|DRUG|MVAC Protocol|"1. Methotrexate 30 mg/m2 IV D1~2. Vinblastine 3 mg/m2 IV D1~3. Adriamycin (doxorubicin) 30 mg/m2 IV D1~4. Cisplatin 70 mg/m2 IV D1"
40846835|NCT03858530|DIAGNOSTIC_TEST|Ultrasound Examination|Grayscale ultrasound, Doppler ultrasound, ultrasound elastography with or without ultrasound intravenous contrast will be performed.
40846836|NCT02620488|BEHAVIORAL|Guided Imagery|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
40846837|NCT01209221|DRUG|Placebo - MAD|Once or twice daily doses of matching placebo to RO5271983 for 14 days
40846838|NCT01209221|DRUG|Placebo - SAD|Single dose of matching placebo to RO5271983 for up to 3 periods
41502648|NCT00602368|PROCEDURE|light-scattering spectroscopy|
40846839|NCT01209221|DRUG|RO5271983 - MAD|Once or twice daily doses of RO5271983 for 14 days
40846840|NCT01209221|DRUG|RO5271983 - SAD|Single dose of RO5271983 at each period (for up to 3 periods)
40846841|NCT05673070|DIETARY_SUPPLEMENT|Ritual Epre Multivitamin-mineral supplement|The Ritual Epre supplement uses methyl folate instead of folic acid and has higher vitamin D and biotin contents compared to the control supplement.
40846842|NCT05673070|DIETARY_SUPPLEMENT|control MVI|The control MVI supplement is a commercially available product from another brand. Since this MVI doesn't contain DHA, a pill of DHA will also be provided to participants in this group.
40846843|NCT03080636|OTHER|Aerobic exercise|30 minutes of treadmill exercise at 60-70% of heart rate reserve
41502649|NCT00602368|PROCEDURE|loop electrosurgical excision procedure|
41502650|NCT02365116|BEHAVIORAL|Peer mentorship|Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.
40846844|NCT03080636|OTHER|Resistance exercise|30 minutes of circuit resistance session at 40% of 1 maximun repetition test
40846845|NCT03080636|OTHER|Control session|30 minutes seated resting
41029761|NCT06529692|BEHAVIORAL|Split-Belt Training|Walking on a split-belt treadmill in which the treadmill belt under the ACL leg will move at a speed faster or slower than the belt under the Non-ACL leg.
41029762|NCT00783744|DRUG|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
41162171|NCT01880944|OTHER|NC-MRI, CE-MRI|non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
40846846|NCT00771290|PROCEDURE|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
41162172|NCT06337786|DEVICE|Digital app RB4.1|Standard routine care and the digital app RB4.1
41162173|NCT06337786|OTHER|Control arm|Standard routine care
41162174|NCT01258296|DRUG|Fentanyl|25 mcg/hr transdermal patch
41162175|NCT01258296|DRUG|Inactive patch|placebo patch (no drug)
41162176|NCT00448773|BEHAVIORAL|Online education|
41162177|NCT05715333|BIOLOGICAL|CM326|CM326 Injection
41162178|NCT05715333|OTHER|Placebo|Subcutaneous injection
41368966|NCT01590095|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
41368967|NCT01590095|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
41368968|NCT01590095|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
41368969|NCT00207116|DRUG|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
41368970|NCT03598712|DEVICE|Compression by chest bandage urgo K2®|"1. - Installation of a short stretch belt (urgo K2® kit)~2. - Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).~3. - Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device"
40846847|NCT00336414|DRUG|cyclophosphamide-prednisone-azathioprine|
40846848|NCT00856804|DRUG|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
40846849|NCT05483517|DEVICE|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A normal energy of high-PEMF with a rate of 2 pulse per second is applied to the patient.
41029763|NCT00783744|DRUG|Glimepiride|Glimepiride 3 or 4 mg
41029764|NCT00783744|DRUG|Metformin|At least 850 mg od
41029765|NCT00783744|DRUG|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
41029766|NCT01886976|BIOLOGICAL|CART-138 cells|
41029767|NCT01518205|DEVICE|LDL-apheresis|"The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.~LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
41036607|NCT02877290|DEVICE|non-invasive ventilation (NIV)|
41036608|NCT03836287|DRUG|Sofpironium Bromide Gel, 15%|Active
41036609|NCT03836287|DRUG|Vehicle|Vehicle gel
41036610|NCT00935025|DRUG|AZD1305|single and multiple oral doses, extended-release capsule
41162179|NCT05826392|OTHER|Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention|Web-Based, 30-minute self-administered intervention for adolescents
41162180|NCT06050018|OTHER|YesMilkdiet|In the YesMilkdiet the participants will consume Milk and dairy products
41162181|NCT06050018|OTHER|NoMilkdiet|In the NoMilkdiet the participants will not consume milk or dairy products only another sources of proteins
41162182|NCT01755247|DRUG|Topical Gel Vehicle|
41162183|NCT01755247|DRUG|8% NVN1000 Topical Gel|
41162184|NCT01755247|DRUG|8% NVN1000 Topical Gel and moisturizer|
41368971|NCT03598712|PROCEDURE|punctures|Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
41368972|NCT02337816|PROCEDURE|laparoscopic surgery, obtainment of biological samples|
41368973|NCT04281966|BEHAVIORAL|Ability School Engagement Program Conference|"The ASEP conference focuses on understanding the reasons behind why the young person is not attending school regularly, understand how the young person's non-attendance affects other conference participants, highlight the legal consequences of parents and/or guardians to ensure that their child attends school, and the development of a young person-centered Action Plan, which will specifically detail the actions that all parties are to take over the next three months to ensure that the young person re-engages with school and/or transitions into paid work."
40846850|NCT05483517|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(normal energy, a rate of 2 pulse per second) with the difference that the energy output doesn't export to the patient.
41368974|NCT06519578|DRUG|hepatic artery infusion chemotherapy|"HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W."
41368975|NCT02405624|PROCEDURE|continuous positive airway pressure|CPAP training for muscle strength
41368976|NCT05218148|DRUG|sintilimab|Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
41368977|NCT05218148|DRUG|Trastuzumab|Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
40846851|NCT05483517|BEHAVIORAL|physiotherapy|Physiotherapy includes shoulder range of motion (ROM), stretching and muscle strengthening exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
40846852|NCT01714999|PROCEDURE|Bursectomy|Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
40846853|NCT01714999|PROCEDURE|Bursal reconstruction|The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
40846854|NCT05322369|OTHER|periodontal charting only|Periodontal charting only
40846855|NCT04890015|PROCEDURE|Intraoperative transanal decompression tube placement|Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
41162185|NCT03046797|DEVICE|Fibroptic intubation through Boussignac valve opening|After patients being put in HELP position to facilitate both ventilation and intubation, mask ventilation will be continued and FOB intubation will be performed from Boussignac valve opening.
41368978|NCT05218148|DRUG|S-1 plus oxaliplatin|"Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) \< 1.25 m2, 50 mg for BSA 1.25 to \<1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area \&lt;1.25m2: Tegio 40mg bid day 1 \~ 14; Body surface area 1.25 \~ \&lt;1.5m2: Tegio 50mg bid day 1 \~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 \~ 14; 3 cycles before surgery and 3 cycles after surgery."
41368979|NCT06369766|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|"OCT is used to measure:~* peripapillary retinal nerve fiber layer (mean thickness in μm)~* ganglion cell-inner plexiform layer (volume in mm\^3 and mean thickness in μm)~* other retinal layers (inner nuclear layer, outer plexiform layer, outer nerve layer; volumes in mm\^3 and mean thickness in μm).~The scanner laser ophthalmoscopy-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability.~In a subgroup of participants, the angiography-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus."
41368980|NCT06369766|DIAGNOSTIC_TEST|Static retinal vessel analyzer|"Static retinal vessel analyzer is used to determine:~* central retinal arteriolar diameter equivalents (in μm)~* central retinal venular diameter equivalents (in μm)~* arteriolar-to-venular diameter ratio"
40846856|NCT00169208|DRUG|rituximab|375 mg/m² IV, D1 each cycle during 4 cycles
40846857|NCT00169208|DRUG|fludarabine|40 mg/m²/day IV , D1 each cycle during 4 cycles
40846858|NCT00169208|DRUG|mitoxantrone|10 mg/m² IV, D2-3-4 each cycle during 4 cycles
40846859|NCT06584409|DEVICE|Laser Pen|Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
40846860|NCT06584409|OTHER|Observation|"Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)~After 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months."
41368981|NCT06369766|DIAGNOSTIC_TEST|Dynamic retinal vessel analyzer|In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.
41368982|NCT06369766|DIAGNOSTIC_TEST|Laser speckle flowgraphy system|In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.
41368983|NCT06369766|OTHER|Questionnaire|All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations. Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.
41368984|NCT01946295|DRUG|Famotidine|100mg x 2 p.o.
41368985|NCT01946295|DRUG|Placebo|
41368986|NCT00707252|DRUG|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
41368987|NCT00707252|DRUG|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
41368988|NCT03975218|OTHER|Patients With Stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
41368989|NCT00821600|DRUG|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
41368990|NCT04277104|OTHER|Closed loop acoustic stimulation|The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants
41368991|NCT04277104|OTHER|Sham acoustic stimulation|Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.
41368992|NCT06520826|DRUG|Vadadustat|A synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl-hydroxylases for the treatment of anemia associated with chronic kidney disease. Intervention to be administered to maintain hemoglobin within a target range of 10-11 g/dL.
41368993|NCT06520826|DRUG|Erythropoiesis Stimulating Agent|Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.
40846861|NCT03296449|PROCEDURE|CPAP|A recruitment maneuver will be applied to the ventilated lung. Immediately continuous positive airway pressure, at a pressure of 2-3cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP).
40846862|NCT03296449|PROCEDURE|HFJV|A recruitment maneuver will be applied to the ventilated lung. Immediately, high-frequency jet ventilation, with a driving pressure of 0.5 atm and a respiratory rate of 100 cycles per minute will applied to the non-ventilated lung for 20 minutes using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland). Monsoone III is a recognised ventilator design for HFJV.
41036611|NCT00935025|DRUG|Placebo|single and multiple oral doses, capsule
41368994|NCT01092130|DRUG|Vitamin D|2000 IU vitamin D daily, for 6 weeks
41368995|NCT03389633|OTHER|rehabilitation|
41368996|NCT02643992|OTHER|DOAC concentration measurement|
41368997|NCT06517706|COMBINATION_PRODUCT|Combination of tDCS (device) with cognitive training (behavioral)|Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive two sessions of tDCS plus cognitive training with the Categorization Program
41368998|NCT06517706|BEHAVIORAL|Categorization Program|Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive cognitive training and sham tDCS
41368999|NCT01778673|PROCEDURE|Cast immobilization|
41369000|NCT01611142|BIOLOGICAL|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
41369001|NCT03283033|BEHAVIORAL|New salad bar|New salad bar placed in school
41369002|NCT03283033|BEHAVIORAL|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
41369003|NCT02526368|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
41369004|NCT02526368|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
41369005|NCT02526368|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
41369006|NCT01539512|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
41369007|NCT01539512|DRUG|Rituximab|Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
41369008|NCT01539512|DRUG|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
41369009|NCT03426995|DRUG|Placebo|Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
41369010|NCT03426995|DRUG|GSK3358699|GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
40846863|NCT04741672|BEHAVIORAL|Providing guidance after discharge routine procedure and calling one week after discharge.|Guidance will be given to mothers after routine discharge. After one week, she will be called by phone and her questions about infant care will be answered.
40846864|NCT04741672|BEHAVIORAL|Discharge routine procedure.|Discharge routine procedure.
41036612|NCT00549926|DRUG|Fluvastatin|
41036613|NCT00549926|DRUG|Pravastatin|
41036614|NCT00549926|DRUG|Pitavastatin|
41036615|NCT00549926|DRUG|Atorvastatin|
41036616|NCT02854540|DEVICE|Hydrogel electrode-based iontophoresis|Hydrogel was administered through iontophoresis, a process of transdermal drug delivery by use of a voltage gradient on the skin.
41036617|NCT00122018|DRUG|N-acetylcysteine|
41036618|NCT00122018|DRUG|fenoldopam|
41369011|NCT03426995|BIOLOGICAL|GM-CSF|The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
41369012|NCT03426995|BIOLOGICAL|LPS|LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
41369013|NCT03426995|OTHER|Cantharidin|This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
41369014|NCT02608073|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
41369015|NCT02608073|DRUG|Cisplatin|Participants will receive cisplatin, 100 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
41369016|NCT04952376|BEHAVIORAL|SMS delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients
41369017|NCT04952376|BEHAVIORAL|Personalized text message delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician
41369018|NCT04952376|BEHAVIORAL|Interactive or 2-way SMS delivery of information|This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.
41369019|NCT03051152|PROCEDURE|D1 gastrectomy|Gastrectomy with limited lymph node dissection
41369020|NCT03051152|PROCEDURE|D2 gastrectomy|Gastrectomy with extended lymph node dissection
41369021|NCT04726631|DRUG|Basal insulin analogue|Analogue insulin is a sub-group of human insulin
41369022|NCT04726631|DRUG|rapid acting insulin|Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating.
41369023|NCT04726631|DRUG|Neutral Protamine Hagedorn|is an intermediate-acting insulin
41369024|NCT04726631|DRUG|regular insulin|is a type of short-acting insulin.
41369025|NCT02079376|DEVICE|DIAMOND System|DIAMOND Implantable Pulse Generator (IPG)
41369026|NCT00764465|DRUG|Maraviroc|300 mg BID
41369027|NCT00764465|DRUG|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
41369028|NCT00764465|DRUG|Ritonavir|100 mg BID, 100 mg QD
41502651|NCT02365116|BEHAVIORAL|Enhanced Usual Care|The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
41369029|NCT01205568|DEVICE|Transcatheter Cutting Balloon therapy|
41369030|NCT01205568|PROCEDURE|High Pressure Balloon Angioplasty|
41369031|NCT02354040|BEHAVIORAL|Talking Rx|For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
41369032|NCT01569321|DEVICE|MRI|
41369033|NCT01569321|DEVICE|PET-CT scan|
41036619|NCT01598480|DRUG|Flamazine|Silver sulfadiazine cream
41036620|NCT01598480|DEVICE|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
41369034|NCT01569321|DEVICE|PEM scan with ClearPemSonic|
41036621|NCT05827978|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
41036622|NCT05827978|BIOLOGICAL|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Sterile suspension for injection
41036623|NCT01726192|PROCEDURE|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
41369035|NCT01098019|DRUG|Xeomin|Patients will receive Xeomin only at Day 0.
41369036|NCT01098019|DRUG|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
41369037|NCT06372158|DIETARY_SUPPLEMENT|Stage 1|Number 1-10 :General vitamin C powder group (Contains 1500 mg Ca); Number 11-20: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
41369038|NCT06372158|DIETARY_SUPPLEMENT|Stage 2|Number 11-20 :General vitamin C powder group (Contains 1500 mg Ca); Number 1-10: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
41369039|NCT03816969|DEVICE|Self-pressurized air-Q with blocker|"It has a drain tube through which a suction tube is passed like the Air-QILA blocker, and Instead of the pilot balloon and inflating cuff, the air-Q SP with blocker incorporates a self-regulating periglottic cuff at the end of this tube , a communication orifice at the junction of the peri-glottic cuff and the airway tube.~This communication between two spaces enables the cuff to dynamically regulate intra-cuff pressure depending on airway pressure. This distinguishing feature of the air-Q SP may result in reduced risk for airway morbidities related to cuff hyperinflation"
41502652|NCT00626392|DRUG|niacin extended-release (NER)|Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
41036624|NCT01726192|PROCEDURE|Placement of a femoral neurostimulating catheter|
41036625|NCT05239234|OTHER|Inferior vena cava-Aorta diameter index|Before the induction of general anesthesia, inferior vena cava-Aorta diameter index and inferior vena cava collapsibility index will be measured.
41502653|NCT00626392|DRUG|aspirin (ASA)|325 mg tablets administered once daily
41502654|NCT00626392|DRUG|aspirin placebo (ASA Pbo)|Tablets administered once daily
41502655|NCT04311671|DRUG|Moxidectin|2 mg tablets, encapsulated for blinding
41502656|NCT04311671|DRUG|Ivermectin|3 mg tablets, encapsulated for blinding
41502657|NCT04311671|DRUG|Albendazole|400 mg tablets
41369040|NCT03816969|DEVICE|Air-Q ILA blocker|A good seal will provide good ventilation, will guarantee the desired depth of anesthesia at lower gas flows and with lesser leaks to the esophagus, it will not cause rise in intragastric pressure thus preventing regurgitation However, When the cuff pressure is more than the mucosal perfusion pressure, it is likely to either cause postoperative pharyngo-laryngeal symptoms (sore throat, dysphagia, dysphonia) or cause local mucosal trauma and nerve injuries
41369041|NCT05126966|DRUG|Ranibizumab|Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.
41369042|NCT05126966|DRUG|Aflibercept|Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment
41369043|NCT05126966|DEVICE|Port Delivery System with ranibizumab (PDS)|PDS is an investigation intraocular drug delivery device designed to continuously deliver anti-VEGF therapy.
41502658|NCT01917981|DEVICE|Personal Heart Rhythm Monitor|
41162186|NCT03046797|DEVICE|Classic Fibroptic intubation|After patients being put in HELP position to facilitate both ventilation and incubation, mask ventilation will be terminated then FOB intubation will be done by an experienced anesthetist.
41502659|NCT01324505|DRUG|semaglutide|Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
41502660|NCT01324505|DRUG|placebo|Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
41502661|NCT01324505|DRUG|Microgyn®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
41502662|NCT03231566|BEHAVIORAL|Pain Neuroscience Education|See arm/group description
41502663|NCT03115268|BEHAVIORAL|Social support groups delivered in EVA Park|Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
41502664|NCT05736653|DEVICE|Task-specific PCMS|120 pairs of TMS and PNS volleys will be administered during electromyography-triggered functional electrical stimulation (FES)-assisted task-specific training (task-specific PCMS). In the task-specific PCMS, participants will first grasp a spherical ball when prompted by an auditory 'Ready' cue, and upon seeing a visual 'Go' cue will voluntarily extend the wrist and fingers to release the ball. After the 'Go cue', our customized stimulation delivery algorithm triggers the TMS and PNS only when the extensor digitorum communis (EDC) muscle activity exceeds a pre-determined threshold. The algorithm will then trigger FES to EDC after detecting EDC activity (\~2 ms after PNS) for the next 2 seconds, allowing the pairing of PCMS (TMS and PNS) with the voluntary movement of EDC without the confounding effects of FES.
41502665|NCT05736653|DEVICE|Task-specific sham-PCMS|120 pairs of sham-PCMS stimuli will be administered during task-specific practice. The TMS coil will be placed \~10 cm behind the participant's head, and PNS electrodes will be placed in the same position as for task-specific PCMS, but no stimulation will be delivered. Like the task-specific PCMS condition, participants will perform the same grasp and release a ball task in an identical manner. FES will be delivered after detecting voluntary EDC activity, similar to the task-specific PCMS condition.
41369044|NCT05647174|PROCEDURE|MGPOCUS-assisted bronchoscope-guided intubation|Application of ultrasound instruments that can detect magnetic signals to determine the position of the magnetised bronchoscopy to guide the direction of its advancement and thus optimise difficult endotracheal intubation.
41369045|NCT05647174|PROCEDURE|Bronchoscope-guided intubation|Routine bronchoscope- guided intubation.
41369046|NCT03981523|DRUG|Benznidazole|50 mg and 100 mg tablet taken orally
41369047|NCT03981523|DRUG|Nifurtimox|120 mg tablet taken orally
41369048|NCT05298904|DIAGNOSTIC_TEST|Genetic Health Screen Panel|This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).
41369049|NCT02958449|DEVICE|Test - Standard Closure with TissuGlu Surgical Adhesive|Patients randomized into the Test group, TissuGlu® will be applied to the chest wall after removal of the breast tissue using the custom applicator during a standard mastectomy procedure followed by normal wound closure (suturing technique) without drain placement.
41029768|NCT02537912|DIETARY_SUPPLEMENT|Sugarlock®|Subjects ingested 2 capsules (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
41029769|NCT02537912|DIETARY_SUPPLEMENT|Placebo|Subjects ingested 2 capsules placebo in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
41162187|NCT04125771|DIAGNOSTIC_TEST|Diclofenac + HBB with hysteroscopy|Giving Diclofenac + HBB with hysteroscopy
41162188|NCT04125771|DIAGNOSTIC_TEST|Diclofenav + placebo|Giving Diclofenac + placebo with hysteroscopy
41162189|NCT04007146|DIAGNOSTIC_TEST|Transcutaneous oxymetry measurement|Transcutaneous oxymetry measurement with transient hyperoxia period (2 periods of 30seconds at 60% of oxygen)
41162190|NCT05469113|DRUG|Repaglinide|Administered orally.
41162191|NCT05469113|DRUG|Selpercatinib|Administered orally.
41162192|NCT02781077|PROCEDURE|Structured, Progressive, Task-oriented exercise program|The intervention is walking related task-oriented exercise program with three progressive steps at moderate to high intensity. Each step consists of 60 minutes last ten tasks to optimize walking function of stroke individuals.
41162193|NCT06407713|OTHER|Intrinsic foot muscle training|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with intrinsic foot muscle training
41162194|NCT06407713|OTHER|Hip abductor muscle training|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with hip abductor muscle training
41369050|NCT02691845|BEHAVIORAL|BA (brief advice)|
41369051|NCT02691845|BEHAVIORAL|SHE (supervised and home-based exercise)|
41029770|NCT03207412|BIOLOGICAL|hAECs|human amniotic epithelial cells
41029771|NCT03207412|PROCEDURE|Minimally invasive implantation|Minimally invasive implantation with ultrasound guidance
41162195|NCT04098497|BEHAVIORAL|Mobile intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of mania, depression, medication adherence, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
41162196|NCT00176475|BIOLOGICAL|rituximab|Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
41029772|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
41162197|NCT00176475|BIOLOGICAL|therapeutic allogeneic lymphocytes|The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
41162198|NCT00064428|DRUG|fondaparinux - UFH not indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge
41029773|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
41162199|NCT00064428|OTHER|Control - UFH not indicated|Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
41162200|NCT00064428|DRUG|Fondaparinux - UFH indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
41162201|NCT00064428|DRUG|Control - UFH|UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
41162202|NCT01364441|DRUG|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
41162203|NCT01364441|DRUG|Placebo|Placebo dosed in the same manner as ONO-2952
41162204|NCT03924947|DRUG|Pancrelipase|Delayed release capsules
41162205|NCT03924947|DRUG|Pancrelipase|Delayed release capsules
41162206|NCT01750177|BEHAVIORAL|Television Viewing before mealtime|
41162207|NCT01750177|BEHAVIORAL|Video Game Playing|
41162208|NCT01750177|BEHAVIORAL|Computer Use|
41369052|NCT02691845|BEHAVIORAL|HE (health education)|
41369053|NCT02691845|BEHAVIORAL|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
41369054|NCT03993002|OTHER|Normoxia with Normocarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 30-40
41369055|NCT03993002|OTHER|Normoxia with Hypercarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 50-60
41369056|NCT03993002|OTHER|Hyperoxia with Normocarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 30-40
41369057|NCT03993002|OTHER|Hyperoxia with Hypercarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 50-60
41502666|NCT05736653|DEVICE|PCMS-rest|120 pairs of TMS and PNS volleys will be administered with the EDC muscle at rest every 10 s (\~20 min, 0.1 Hz). TMS will be used to elicit motor-evoked potentials (MEPs). Antidromic activation of spinal motor neurons will be elicited by supramaximal peripheral nerve stimulation (PNS) applied to the radial nerve near the elbow. Volleys will be timed to arrive in the spinal cord based on central and peripheral conduction times calculated for each subject so that the pre-synaptic terminal is depolarized via TMS \~1-2 ms before spinal motor neurons are depolarized via PNS at a pulse duration of 200us. We will also perform stimulation of the cervical roots (C-root) by placing the coil behind the neck and stimulating the C-root (C6 and C7 vertebrae), which innervate the finger extensor muscles. Conduction times will be calculated from latencies of the primary motor area (M1) MEP, C-root, and M-wave.
40846865|NCT06394245|OTHER|Progressive muscle exercises|The initiative was made with the Turkish Psychologists Association's Progressive Relaxation Exercises audio recorded. PGE consists of a recording of breathing exercises and progressive muscle stretching exercises, with music in the background that will relax the patient. The first part of the recordings takes approximately 10 minutes. It continues and includes information about the definition of relaxation exercise, its purpose, benefits and points to consider when starting the exercises, correct breathing in the appropriate position and what the environment should be like. The second part consists of how to contract and relax certain muscles in our body, which takes approximately 25-30 minutes, and the steps to exit this process after the relaxation session is over.
41369058|NCT02861157|BEHAVIORAL|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
41369059|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
41369060|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
41369061|NCT03372304|DRUG|Ropivacaine 0.2%|Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
41369062|NCT04959682|OTHER|Music Intervention|After rating levels of fatigue and relaxation, the professional health care musicians will play 30 minutes of patient-tailored, pleasant instrumental music with a combination of relaxing (on average 60-80 bpm) and lively, slightly more up-beat tempo to regulate arousal-levels
41369063|NCT04575909|BEHAVIORAL|Aprosodia Intervention|Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
41369064|NCT04575909|BEHAVIORAL|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention \[if relevant\]), hobbies, and other similar topics.
41369065|NCT02086240|DRUG|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
41369066|NCT00067431|DRUG|Divalproex Sodium (Depakote® Sprinkle Capsules)|
41369067|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus action observation training|Participants make an observation of actions related to the training they are going to perform before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
41369068|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus sham action observation training|Participants make a sham observation before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
41369069|NCT01945034|DRUG|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
41369070|NCT01945034|DRUG|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
41369071|NCT01945034|DRUG|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
41369072|NCT01945034|DRUG|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
41369073|NCT06137794|OTHER|"Use of I-Anticoagulation to make the decision and manage patients"|I-Anticoagulation will offer a flexible and efficient communication platform for healthcare professionals and AF patients. The tool is composed of two modules: an anticoagulation decision support system and a full-process patient management system.
41502667|NCT02656407|DEVICE|Ultrasound device|Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
41502668|NCT04434300|DRUG|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
40846866|NCT05437432|PROCEDURE|VITA AMBRIA|25 onlay restroations will be fabricated from Vita-ambria glass ceramic press system.
41029774|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
41029775|NCT04458584|PROCEDURE|Trapeziectomy with ligament reconstruction (I; LRTI)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with ligament reconstruction (I; LRTI)
41029776|NCT04458584|PROCEDURE|Trapeziectomy with suture suspensionplasty (II; SS)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with suture suspension-lastly (II; SS)
41502669|NCT04434300|DRUG|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
41029777|NCT04458584|PROCEDURE|Arthroscopic Trapeziectomy (III; AT)|Thumb basal joint arthroplasty (surgical) using Arthroscopic Trapeziectomy (III; AT)
41029778|NCT03293823|BEHAVIORAL|VSOP training|a computerized cognitive training of attention and processing speed
41029779|NCT03293823|BEHAVIORAL|MLA control|a computerized cognitive intervention of multiple mental leisure activities
41029780|NCT00863850|DRUG|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled \[14C\] bendamustine will be given on day 1 of cycle 1 only.
41369074|NCT02190162|DRUG|Tantum Verde® mouthwash|
41369075|NCT02190162|OTHER|Placebo mouthwash|Mouthwash with placebo solution
41369076|NCT06037486|DIAGNOSTIC_TEST|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
41369077|NCT01151865|DRUG|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
41369078|NCT01151865|DRUG|Saline placebo|An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
41369079|NCT01167699|DRUG|Oxycodone and naloxone|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
41369080|NCT03165851|OTHER|Risk-stratified therapy|Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
41502670|NCT04637932|PROCEDURE|Percutaneous Dilatation Tracheostomy|pro-seal laryngeal mask or intubation tube in bronchoscopy-guided percutaneous dilation tracheostomy procedure.
41502671|NCT05776251|DEVICE|taVNS|"Includes the use of Soterix Medical Device, which consists of a handheld smart-phone size device. There are two electrodes (designed for studies in infants) with small patches that the participant places on the external ear (the cymbals conchae and the tragus). The stimulation intensity is personalized for each participant based on perceptual threshold."
40846867|NCT05437432|PROCEDURE|IPS e.max press|25 onlay restroations will be fabricated from IPS e.max glass ceramic press system.
41029781|NCT05192122|OTHER|Discontinue maintenance therapy SOC|Continue maintenance therapy SOC
41029782|NCT02721212|DEVICE|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
40846868|NCT06457698|PROCEDURE|Double-puncture TMJ arthrocentesis under local anaesthesia|The first puncture involved carefully palpating the lateral rim of the glenoid fossa. A 5-cc syringe was prepared with a mixture of 3 cc of Ringer lactate and 1.8 cc of lidocaine with epinephrine. A 21-G needle connected to the syringe was gently inserted into the TMJ skin area. Once the needle tip made contact with the posterior slope of the eminence of the upper joint compartment, it was oriented vertically to access the upper compartment, allowing the surgeon to perform a validation step. For the second puncture, the joint was maintained at maximum distention with continuous inflow through the first portal, while the surgeon felt insufflation/distention in the anterior joint area. The second portal was established using a 21-G needle with successful fluid outflow. After completing an effective circuit, joint washing was carried out using intra-articular hydraulic pressure with at least 150 ml of Ringer lactate solution.
41029783|NCT02721212|OTHER|Conventional Rehabilitation|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
41502672|NCT04062266|DRUG|Azacitidine|Given SC or IV
40846869|NCT04374955|DIETARY_SUPPLEMENT|Activia Probiotics Shot|The product contains Actiregularis - at least 2x106 cfu / g.
40846870|NCT04374955|OTHER|Routine care|Routine care of the hospital will be provided.
41162209|NCT01750177|BEHAVIORAL|Sitting quietly|
41162210|NCT05659654|DRUG|Ursodeoxycholic acid|250 mg/capsule, 2 capsules per day, for 4 weeks
41162211|NCT02974725|DRUG|LXH254|LXH254 will be supplied as tablet for oral use.
41162212|NCT02974725|DRUG|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
41162213|NCT02974725|DRUG|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
41162214|NCT02974725|DRUG|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
41162215|NCT03199300|DRUG|Anthracyclines|Chemotherapy regimen containing anthracyclines.
40846871|NCT03190889|OTHER|HOME|At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.
40846872|NCT03190889|OTHER|TNMT|Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
41162216|NCT03199300|DRUG|Trastuzumab|Systemic treatment including trastuzumab.
41162217|NCT03199300|DRUG|Cisplatin|Chemotherapy including cisplatin.
41162218|NCT03199300|DRUG|Bleomycin|Chemotherapy including bleomycin.
41162219|NCT01683643|BEHAVIORAL|SBIRT|Screening, brief intervention, and referral to treatment.
41162220|NCT01683643|BEHAVIORAL|Control Group|Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
41162221|NCT02836054|PROCEDURE|lumbar puncture (LP)|
41162222|NCT02836054|PROCEDURE|brain MRI|
41162223|NCT03052283|DIAGNOSTIC_TEST|Questionnaire Patient Reported Outcome Measure (PROM)|non-interventional
41162224|NCT01398644|OTHER|Phlebotomy and erythrocytapheresis|Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
41162225|NCT06442293|DIETARY_SUPPLEMENT|Treatment 1|A dietary supplement containing beet root extract, arginine and citrulline
41369081|NCT00151658|DEVICE|Coronary Drug Eluting Stents for PCI|
41369082|NCT02780206|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
41502673|NCT04062266|DRUG|Venetoclax|Given PO
41369083|NCT04817410|DRUG|Emergency Department Initiated Oral Naltrexone|Emergency Department Initiated Oral Naltrexone
41369084|NCT05932420|DIETARY_SUPPLEMENT|Placebo|16.4g pure medium triglyceride oil mixed with 1 mM of bitter sucrose octaacetate. A dose of 25g of the placebo drink is provided immediately after each training session and 30 minutes before sleeptime throughout the training period.
41369085|NCT05932420|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime throughout the training period.
41369086|NCT02335359|DRUG|tranexamic acid diluted in 100 ml of saline solution (loading dose)|
41369087|NCT02335359|DRUG|tranexamic acid undiluted (continous infusion)|
41369088|NCT02335359|DRUG|Placebo|Saline
41369089|NCT01283282|DRUG|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
41369090|NCT01283282|DRUG|Placebo|Placebo PO qday for 6 weeks
41369091|NCT02466191|DRUG|Memantine|
41369092|NCT02466191|DRUG|Gabapentin|
41369093|NCT02198157|OTHER|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
41369094|NCT06168604|BEHAVIORAL|Pain Identification and Communication Toolkit|The Pain Identification and Communication Toolkit (PICT) is a multicomponent (6 module) intervention for family caregivers of persons with Alzheimer's disease and related dementias (ADRD). PICT consists of 4 weekly telephone sessions (30-60 minutes each) delivered by a trained interventionist
41369095|NCT06168604|BEHAVIORAL|Health Promotion Program|The attention control (AC) condition is referred to as the Health Promotion Program (HPP). The HPP will consist of 4 weekly telephone sessions (30-60 minutes each) but focus on caregiver health promotion topics, such as nutrition, exercise, and sleep.
41369096|NCT00917943|BEHAVIORAL|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
41369097|NCT00981695|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
41369098|NCT05919264|DRUG|FOG-001|FOG-001 will be administered IV at assigned doses in continuous cycles of 21 or 28 days
41369099|NCT05919264|DRUG|FOG-001|FOG-001 will be administered IV once weekly at the preliminary RP2D dose in continuous cycles of 21 or 28 days
41029784|NCT05294757|OTHER|Physical exercise|1. Hospital exercise cohort: Participants will be consecutively recruited from the scheduled patient list of the falls unit and the outpatient clinics of Hospital 1. After informed consent acquisition, patients will receive a baseline clinical evaluation. Ultrasound measurements and DXA scan will be conducted, and blood samples will be collected, processed, and stored. Patients will be included in the 16-week multicomponent physical exercise program described below. After the completion of the exercise program, at 16-week follow-up, clinical evaluation, ultrasound, DXA, and blood-sample testing will be repeated.
41029785|NCT03437499|PROCEDURE|Sustained Inflation|Application of positive pressure by face mask with T-piece resuscitator for a prolonged period of 15 seconds at a peak pressure of 25 cmH20 followed by PEEP set at 5 cmH2O
41369100|NCT04022265|DEVICE|implant placement|Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
41369101|NCT04881669|DEVICE|obturator|variable bulbs
41369102|NCT01413373|RADIATION|cone beam computed tomography|A preoperative CBCT is performed for all patients in this study for medical reason
41369103|NCT01413373|RADIATION|computer tomography|One cone beam computer tomography examination before surgery
41369104|NCT04029246|BEHAVIORAL|Follow up phone call|Telephone call to ask if patient has received letter and whether they would like an appointment
41502674|NCT06625567|OTHER|Animated video|Patients will watch an educational video describing the procedure before hysteroscopy without anesthesia
41502675|NCT01329900|DRUG|Ofatumumab|1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
41029786|NCT03437499|PROCEDURE|Positive Pressure Ventilation|Application of positive pressure by face mask with T-piece resuscitator at a peak pressure of 25 cmH20, PEEP set at 5 cmH2, for 40 inflations/minute
41029787|NCT01286259|DRUG|Disulfiram|Open label 500mg disulfiram per day by mouth for 14 days
41029788|NCT00001112|DRUG|Zidovudine|
41029789|NCT00001112|DRUG|Interferon gamma-1b|
41369105|NCT04029246|BEHAVIORAL|Incentive|Offer of a shopping voucher if patient attends for appointment
41369106|NCT01283802|PROCEDURE|INTRAOPERATIVE CHOLANGIO-ULTRASOUND|"Techniques are as follows:~1. Direct ultrasound exploration without any contrast agents.~2. IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);~3. IOCUS injection of an air bolus into the bile duct."
41369107|NCT02181543|DRUG|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
41502676|NCT01329900|DRUG|Ifosfamide|3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
41502677|NCT01329900|DRUG|Etoposide|150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
41502678|NCT01329900|DRUG|Mesna|"2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose."
41502679|NCT01329900|DRUG|G-CSF|6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
41502680|NCT01329900|PROCEDURE|Stem Cell Collection|Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
41369108|NCT06509880|DIETARY_SUPPLEMENT|Adenorine|"The immunostimulating effect of the drug is associated with its ability to activate the cells of the monocyte-macrophage system, thus increasing the functional activity of all parts of the body, stimulating the repair and regeneration of cells and tissues. It reduces the symptoms of the iflammatory process, stimulates the development of granulations and growth of epithelial tissues, accelerates the process of cleansing and healing of infected wounds. While with healthy people, it can be used as a phylactic drug that improves immunity protection. It was proved that when the drug is used externally, activation of macrophages occurs, thus accelerating wound cleansing process and stimulating reparative processes. In cases when thermal injury to the skin is more than 15-20% of the surface, there is a stress syndrome that suppresses the immune system. When exposed to DNA-Na, lymphocyte activation occurs, wound cleansing processes are accelerated."
41369109|NCT06509880|BIOLOGICAL|Placebo|Placebo
41369110|NCT06509880|DRUG|FOLFOX regimen|(Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days)
41029790|NCT02568787|DIETARY_SUPPLEMENT|rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
41369111|NCT06400160|DRUG|TB511|TB511 is a peptide drug conjugate (PDC) which composed of TAMpep826 peptide. TB511 is a white amorphous powder used for subcutaneous injections. TB511 is a peptide drug conjugate that combines a transporter peptide with a specific targeting of M2 macrophages and an apoptosis-inducing peptide (dKLA). As a transporter, the M2 binding peptide acts as a drug conjugate, explicitly binding to M2 macrophages and inducing cell penetration. In the cells, the dKLA component of TB511 binds to the mitochondrial membrane, destroys the mitochondrial membrane, and induces apoptosis by causing cytochrome release, leading to the destruction of the mitochondria and subsequent death of M2 macrophages.
41369112|NCT06400160|DRUG|Keytruda|KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.
41369113|NCT05235633|DIAGNOSTIC_TEST|Assessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment|Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.
41369114|NCT06238882|COMBINATION_PRODUCT|Nitroglycerin|Patients in the intervention group will receive four 8mg-patches (36 mg final dose) of transdermal nitroglycerin with 10 mg release in 24 hours, for 24 hours with 12-hour rest intervals (to avoid receptor saturation) during treatment with radiation therapy (30 Gy in 10 fractions, or 10 days of treatment).
41369115|NCT04987684|DIAGNOSTIC_TEST|SCINSEV and PECAP|To measure PECAP and SCINSEVs. To find whether electrodes are outside of the cochlear or within dead regions within the cochlear.
41369116|NCT00660153|DRUG|Tivozanib (AV-951) plus FOLFOX6|"Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15."
41369117|NCT02735772|PROCEDURE|transobturator approach for paravaginal repair|using TOT needle to apply suturs to white line
41502681|NCT04810026|BEHAVIORAL|Education|Healthy-lifestyle and diabetes-related virtual education (text and videos)
41029791|NCT02568787|DIETARY_SUPPLEMENT|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
41029792|NCT02696317|DEVICE|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
41029793|NCT02696317|DEVICE|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
41029794|NCT03691805|DEVICE|tDCS|The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
41029795|NCT03691805|DEVICE|Sham tDCS|The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
41162226|NCT06442293|DIETARY_SUPPLEMENT|Treatment 2|A traditional Chinese medicine (TCM)-based dietary supplement containing chrysanthemum extract and eucommia bark extract
41029796|NCT00129987|BEHAVIORAL|Self management education|
41029797|NCT04944875|PROCEDURE|Group headphone|The patients in the first group wore the headphones but did not listen the music or maternal voice. The standard sedation method was applied to all patients.
41029798|NCT04944875|PROCEDURE|Group music|The patients in the second group listened to classical music (Vivaldi's The Four Seasons violin concertos) by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
41162227|NCT06442293|DIETARY_SUPPLEMENT|Placebo|a placebo supplement that is similar in appearance to treatment 1
41029799|NCT04944875|PROCEDURE|Group maternal voice|The patients in the third group listened to maternal voice by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
41029800|NCT01053923|OTHER|Magnetic Resonance Imaging (MRI)|This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
41162228|NCT04522583|DIAGNOSTIC_TEST|Diagnosis of Myocardial Ischemia|Discharge diagnosis of myocardial ischemia
41162229|NCT02497196|DEVICE|Active tPCS|A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
41162230|NCT02497196|DEVICE|Active tDCS|A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
41162231|NCT02497196|DEVICE|Sham tPCS|Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
41162232|NCT02497196|DEVICE|Sham tDCS|Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
41162233|NCT03272698|DRUG|Ketamine|IV Ketamine 0.50 mg/kg
41162234|NCT03272698|PROCEDURE|ECT|ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
41162235|NCT04976283|DRUG|Pioglitazone|Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.
41162236|NCT04976283|DRUG|Empagliflozin|Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.
41162237|NCT04976283|DRUG|Pioglitazone + Empagliflozin|Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).
41162238|NCT03334695|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp in single-use vials.
41162239|NCT03334695|DRUG|Placebo|Placebo will be administered as sterile 0.9% saline for injection.
41162240|NCT01933529|DRUG|ARA 290|ARA 290 is injected s.c. once daily during the study period
41162241|NCT03042559|DEVICE|Protonics Knee brace|The Protonics system has been introduced to physical therapists as a potential treatment for PFPS. The system includes a brace set to resist knee flexion and a set of specific exercises to perform daily. Through resistance to knee flexion, the system is advertised to decrease retropatellar contact pressure due to changes in pelvis inclination and available hip rotation. Specifically, resistance to knee flexion is purported to increase hamstring activity and inhibit the activity of the tensor fasciae latae and psoas muscles. The manufacturer asserts that prolonged use of the system results in greater hamstring activation, which leads to permanent structural changes through reciprocal inhibition at the hip and pelvis. The warm-up consisted of the subject wearing the ProtonicsTM knee brace set at a moderate resistance level and flexing the knees while sitting, standing, and reclining in the supine and prone positions.
41502682|NCT04810026|BEHAVIORAL|Meal delivery|breakfast, lunch, and dinner adhering to the longevity diet macro-nutrient profiles
41502683|NCT04810026|BEHAVIORAL|Lifestyle coaching|calls with coach and/or nutritionist, access to Facebook community support group
41502684|NCT02647385|DRUG|Block with lidocaine for SAM and PEC I block|"Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.~Interventions: include pain assessment, inflammatory response and opioid consumption."
41502685|NCT06470828|DRUG|TAK-861|Oral tablet.
41502686|NCT06470828|DRUG|Placebo|TAK-861-matching placebo tablet.
41029801|NCT01503905|DRUG|Docetaxel|75mg/m2, iv injection, day1, every 21 days
41029802|NCT01503905|DRUG|epirubicin|80mg/ m2, iv injection, day1, every 21 days
41029803|NCT01503905|DRUG|cyclophosphamide|500 mg/m2, iv injection, day1, every 21 days
41029804|NCT01503905|PROCEDURE|Modified radical mastectomy or breast-conserving Surgery|Two weeks after four cycles of neoadjuvant chemotherapy
41029805|NCT01503905|DRUG|Docetaxel (post-operative)|Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
41029806|NCT01503905|DRUG|Epirubicin (post-operative)|Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
41029807|NCT01503905|DRUG|Cyclophosphamide (post-operative)|Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
41029808|NCT01503905|RADIATION|Radiation therapy|Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
41029809|NCT01503905|DRUG|Herceptin （post-operative)|Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
41029810|NCT01503905|DRUG|Tamoxifen (post-operative)|After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
41502687|NCT04919265|OTHER|No intervention - mother-infant cohort study|There are no interventions because it is a mother-infant cohort study
41162242|NCT03042559|DEVICE|Sports Cords|Subjects assigned to the sport cord group were asked to do the same warm-ups and exercises using the sport cord in the supine, standing, sitting, and prone positions. prone. The only difference is that subjects were asked to only walk backwards instead of forwards in order to avoid activation of the hip flexor muscle. The appropriate level of resistance for each subject was calculated by multiplying their weight in pounds by 0.3. Subjects were then given either light, medium, or heavy resistance cords according to the following classification scheme: light (pink color) with resistance 3 (R3), 0-30 lbs.; medium (orange color) with resistance 5 (R5) 0-50 lbs.; heavy (yellow color) with resistance 7 (R7) 0-70 lbs. All subjects completed three study visits, and a total of four measurements were taken at baseline, immediately following the first session, at two weeks, and at 4 weeks.
41162243|NCT03979547|BEHAVIORAL|Exercise intervention|"Moving Through Cancer: A Guide to Exercise for Cancer Survivors will serve as the framework for an American College of Sports Medicine certified exercise physiologist with additional Cancer Exercise training to teach proper warm up, use of equipment, exercise form, mode of activity, intensity of exercise, flexibility exercises, and cool down."
41162244|NCT00209222|DRUG|Rituximab|antibody
41029811|NCT03063229|DEVICE|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
41369118|NCT03012035|OTHER|positive treatment expectations|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
41369119|NCT03012035|OTHER|neutral treatment expectations|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
41162245|NCT00209222|DRUG|Cyclophosphamide|chemotherapy
41162246|NCT00209222|DRUG|Doxorubicin|chemotherapy
41162247|NCT00209222|DRUG|Vincristine|chemotherapy
41162248|NCT00209222|DRUG|Prednisone|corticosteroide
41162249|NCT00209222|DRUG|Cisplatinum|chemotherapy
41162250|NCT00209222|DRUG|Ara-C|chemotherapy
41369120|NCT05549271|PROCEDURE|Laparoscopic Mini-gastric bypass|The laparoscopic Omega Loop Bypass performed 5 years ago consisted of a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His, a narrow gastric tube calibrated to be approximately 1.5 cm wide, an Omega loop of 200 cm, a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler
41369121|NCT05549271|PROCEDURE|Laparoscopic Roux-en-Y Gastric ByPass (RYGBP)|The laparoscopic Roux-en-Y Gastric Bypass performed 5 years ago consisted of : a small gastric pouch (about 30cc), an antecolic alimentary limb, a gastro-jejunal anastomosis using a linear stapler, a 150cm long alimentary limb, a 50cm biliary limb, a latero-lateral jejuno-jejunal anastomosis, closure of the mesenteric defects.
41162251|NCT00209222|DRUG|Dexamethasone|corticosteroide
41162252|NCT00209222|DRUG|BCNU|chemotherapy
41162253|NCT00209222|DRUG|Melphalan|chemotherapy
41162254|NCT00209222|DRUG|Etoposide|chemotherapy
41369122|NCT00489411|DRUG|duloxetine hydrochloride|Given orally
41369123|NCT00489411|OTHER|placebo|Given orally
41029812|NCT03063229|OTHER|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
41029813|NCT03063229|PROCEDURE|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
41162255|NCT00209222|DRUG|G-CSF|growth factor
41162256|NCT00209222|PROCEDURE|chemotherapy: R-CHOP|immuno-chemotherapy
41162257|NCT00209222|PROCEDURE|chemotherapy: R-DHAP|immuno-chemotherapy
41162258|NCT00209222|PROCEDURE|chemotherapy: Dexa-BEAM|chemotherapy
41162259|NCT00209222|PROCEDURE|stem cell harvest|procedure
41029814|NCT03063229|DEVICE|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
41029815|NCT03063229|PROCEDURE|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
41162260|NCT00209222|PROCEDURE|total body irradiation|radiation
41162261|NCT00209222|PROCEDURE|high-dose chemotherapy: Cyclophosphamide|chemotherapy
41162262|NCT00209222|PROCEDURE|high-dose chemotherapy: Ara-C /Melphalan|chemotherapy
41162263|NCT02723383|DRUG|BACLOFEN|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
41162264|NCT02723383|DRUG|PLACEBO|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
41162265|NCT00308399|DRUG|Itopride|
41162266|NCT06060158|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6 sessions
41162267|NCT03380221|OTHER|Watermelon|Participants will consume 100 Kcal of watermelon fruit (2 cups) daily for 4 weeks.
41162268|NCT03380221|OTHER|Low fat cookies|Participants will consume 100 Kcal of low fat cookies daily for 4 weeks.
41162269|NCT05226988|DEVICE|robot-assisted|Participants received the 18-session robot-assisted intervention 3 sessions a week for 6 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
41369124|NCT03804554|OTHER|Non-Interventional|Non-Interventional
41369125|NCT01870765|DEVICE|non-invasive ventilation|non-invasive ventilation via face mask
41369126|NCT01870765|DEVICE|high-flow oxygen|high-flow oxygen via nasal cannula
40846873|NCT05019768|OTHER|accelerated custom-fast CXL|The accelerated custom fast CXL (aCFXL) has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin consumption rate and the corneal thickness at its thinnest point. By knowing both values, the mathematical model allows to objectively calculate both the exact UVA irradiation value (intensity), expressed in mW/cm2, and the irradiation time
40846874|NCT05019768|OTHER|Standard CXL|The standard CXL procedure has been carried on following the Dresden protocol
41029816|NCT03063229|OTHER|Food Diary|Participants will keep a 7 day weighed food diary.
41029817|NCT03063229|DEVICE|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
41029818|NCT03063229|OTHER|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
41029819|NCT03063229|PROCEDURE|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
41029820|NCT03063229|PROCEDURE|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
41029821|NCT03063229|DRUG|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
41029822|NCT03063229|DRUG|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
41029823|NCT03812458|BEHAVIORAL|website and brochure|website and brochure
41029824|NCT01211626|DRUG|ANA773|ANA773 Tosylate Capsule
41029825|NCT01211626|DRUG|Placebo|Matching Placebo Capsule
41029826|NCT05034003|DEVICE|Zirconia crown|Esthetic crowns for capping primary incisor with caries
41029827|NCT05034003|DEVICE|composite strip crown|Esthetic resin restoration for primary incisor with caries
41029828|NCT05750381|OTHER|Micrococcus luteus Blis Q24 balm|Balm formulation containing probiotic bacteria Micrococcus luteus Q24 for topical applications.
41369127|NCT01870765|PROCEDURE|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
41502688|NCT02473523|OTHER|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
40846875|NCT05094908|DRUG|Arnica Tincture|Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30 or 45, depending on the regimen to be evaluated.
40846876|NCT03286816|DRUG|SodiumChloride|
40846877|NCT03286816|DRUG|Sodium Lactate|
40846878|NCT01013857|BEHAVIORAL|Health coaching|Calling patients every week to discuss medication adherence
41029829|NCT05750381|OTHER|Placebo balm|Placebo balm formulation for topical applications.
41029830|NCT04218019|DEVICE|TTFields|The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
41029831|NCT03002181|OTHER|Education|70 minute education session.
41029832|NCT05005832|OTHER|multi day walking|Over the course of 14 days, the pilgrims will cover a distance of about 300 km.
41029833|NCT01538745|DRUG|Ketamine|0.3 mg/kg ketamine Intravenous push (IVP) over 5 minutes. Total of two possible doses.
41029834|NCT01538745|DRUG|Morphine|0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.
41036626|NCT04059276|DIAGNOSTIC_TEST|MRI|We will examine chronic (\>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
41036627|NCT04059276|DIAGNOSTIC_TEST|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
41369128|NCT04063748|BEHAVIORAL|Audiological rehabilitation|Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
41036628|NCT01247129|PROCEDURE|Delay procedure of SIEA flap.|Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
41036629|NCT06006520|OTHER|control|No exercises will be given.
41369129|NCT04063748|BEHAVIORAL|Placebo Rehabilitation|CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)
41369130|NCT04063748|BEHAVIORAL|Passive Control|No intervention in the passive control group for HA-users.
41502689|NCT02473523|OTHER|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
41369131|NCT05679570|DRUG|Satralizumab (Genetical Recombination)|"Efficacy Evaluation Period:~The study drug will be administered at a dose of 120 mg subcutaneously at initial, 2-week, 4-week, and 4-week intervals thereafter. Efficacy will be assessed after 24 weeks of study drug administration. Subjects who demonstrate efficacy and wish to continue treatment will receive the study drug for 24 weeks and moving to the continuous treatment period. In all other cases, the study will be terminated after 24 weeks of the efficacy evaluation period without the administration of study drug.~Continuation Dosing Period\[1\]:~Subjects who demonstrate efficacy during the efficacy evaluation period and wish to continue will receive continued 28 weeks (52 weeks total) treatment with satralizumab.~Continuation Dosing Period\[2\]:~Subjects completed continuation dosing period\[1\], clinically capable of continued administration, and wish to continue will receive continued treatment with satralizumab until the end of this study period."
41369132|NCT01973673|BEHAVIORAL|Bone health educational materials|
41369133|NCT03879811|DRUG|TMZ|Oral TMZ at 150mg/m2
41369134|NCT03879811|DRUG|Nivolumab|Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
41369135|NCT06111599|PROCEDURE|lumbar sympathetic blockade|Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic
41369136|NCT03592082|DRUG|Bismuth Subsalicylate|BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
41369137|NCT03592082|DRUG|standard antibiotic therapy|antibiotic therapy administered per standard protocol
41369138|NCT02031601|DRUG|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
41369139|NCT02031601|DRUG|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
41369140|NCT02031601|DRUG|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
41369141|NCT02031601|DRUG|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
41502690|NCT02473523|DEVICE|Biodex System 3 Dynamometer|"The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete."
40846879|NCT01013857|BEHAVIORAL|Health coaching plus home titration|Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
40846880|NCT05994833|BEHAVIORAL|VPT|The VPT will be comprised of weekly virtual visits with the participant for one month. During the visits, the physical therapist will review the exercises that were prescribed, adherence, provide feedback to the participant as they execute the exercises onscreen and make corrections, make any progression or adjustments to the exercises, review running cues they learned from the testing session and answer any questions. The therapist will also review any new activities that are initiated during the previous week (to control for confounders), changes in musculoskeletal pain and participation in running volume.
40846881|NCT00875290|DEVICE|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
40846882|NCT04674488|BIOLOGICAL|TILs|a single center, single-arm, open label, interventional study
40846883|NCT03811301|DEVICE|BrainConnexion|A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.
40846884|NCT00779207|BEHAVIORAL|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
40846885|NCT00779207|BEHAVIORAL|weight loss|10 percent weight loss through diet and behavioral modification
40846886|NCT01789606|DRUG|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
41029835|NCT02411721|BEHAVIORAL|Animal Assisted Intervention|"1. Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.~2. The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.~3. Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination."
41029836|NCT03958903|DEVICE|Amygdala recording and stimulation using Neuropace RNS|Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.
41162270|NCT05226988|DEVICE|Conventional rehabilitation intervention|Participants received the 18-session conventional rehabilitation intervention 3 sessions a week for 6 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
41162271|NCT04471480|DRUG|TC/PD-1 inhibitor/anlotinib|chemotherapy and immunotherapy plus antiangiogenic therapy
41162272|NCT04912700|BIOLOGICAL|COVID-19 vaccine|Full or partial reception of vaccine
41162273|NCT00784771|BEHAVIORAL|Hypnotherapeutic Olfactory Conditioning (HOC)|
41162274|NCT03976778|OTHER|Training program for family physicians on well-child care for children under-5 years|The researchers designed this intervention, which consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
41369142|NCT02031601|DRUG|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
41369143|NCT02031601|DRUG|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
41369144|NCT02031601|DRUG|Erlotinib|150mg po once a day daily until disease progression
41369145|NCT02031601|DRUG|Gefitinib|250mg po once a day daily until disease progression
41369146|NCT02031601|DRUG|Icotinib|125mg po three times a day daily until disease progression
41369147|NCT06478667|DRUG|levosemindan|inotropic agent
41369148|NCT06439186|DRUG|Lidocain|Local anesthesia
41369149|NCT01728675|OTHER|Exercise|Participants will perform two isokinetic eccentric exercise bouts
41029837|NCT03958903|BEHAVIORAL|Behavioral tasks|Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
41029838|NCT00874029|DEVICE|Halt Procedure|The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
41029839|NCT04593992|DEVICE|HTEMS|high-tone external muscle stimulation
41029840|NCT04593992|DEVICE|Placebo|Placebo stimulation
41029841|NCT00235703|DEVICE|Antimicrobial Prescribing Decision Support|
41162275|NCT00858247|DIETARY_SUPPLEMENT|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
41162276|NCT04938934|BEHAVIORAL|Lipids infusion|Lipids infusion via intestinal tube
41162277|NCT04938934|BEHAVIORAL|Sham infusion|Sham infusion via intestinal tube
41162278|NCT01497340|OTHER|Position at introitus level|After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
41162279|NCT01497340|OTHER|Position at Maternal Abdomen|Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
41162280|NCT00925288|BIOLOGICAL|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
41162281|NCT02434523|DRUG|Amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
41162282|NCT02434523|OTHER|Placebo|Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
41162283|NCT00651937|DRUG|Melphalan|100 mg/m\^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.
41162284|NCT00651937|PROCEDURE|Stem Cell Infusion|"Stem Cell Infusion is Day 0.~Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10\^6 CD34/kg On Day 0~High Dose (Arm 2) = Stem cell dose of between 10-15 x 10\^6 CD34/kg On Day 0."
41162285|NCT00651937|BEHAVIORAL|Questionnaires|Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
41162286|NCT00651937|DRUG|Granulocyte-colony stimulating factor (G-CSF)|5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.
41162287|NCT00651937|PROCEDURE|Apheresis|Collection of stem cells from blood collected either through CVC or from a vein in one arm.
41369150|NCT02708446|DRUG|Mifepristone|200mg oral mifepristone to both study arms
41369151|NCT02708446|DRUG|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
40846887|NCT01171391|DRUG|VA106483|1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
41162288|NCT03484078|DEVICE|Vibration Platform|The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.
41369152|NCT02708446|DRUG|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
41369153|NCT02064491|DRUG|Erlotinib|
41369154|NCT02064491|DRUG|Chemotherapy|
41369155|NCT01546311|DEVICE|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
41369156|NCT03770806|PROCEDURE|Femoral Nerve Block|Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.
41369157|NCT03770806|PROCEDURE|Adductor Nerve Block|Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg
41369158|NCT03770806|OTHER|No Block|routine iv and oral pain medication alone-observation only
41369159|NCT01958944|DRUG|Nitric oxide|
41369160|NCT01474291|BIOLOGICAL|Tocilizumab|Tocilizumab administered according to prescribing information and normal clinical practice.
40846888|NCT01171391|OTHER|Placebo|Placebo on Day 1
40846889|NCT03295773|DIAGNOSTIC_TEST|3DRA|
41029842|NCT02648698|DRUG|Antibiotics|Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
41029843|NCT05123209|BIOLOGICAL|IM83 CAR-T cells|3×10\^9 CAR-T cells
41029844|NCT05123209|COMBINATION_PRODUCT|The second-line treatment of liver cancer|approved by NMPA
41029845|NCT06532292|DEVICE|Biofeedback|To facilitate PFM function, electromyography biofeedback and electrical stimulation will be employed using an intravaginal probe, tailored to individual needs.
41036630|NCT06006520|OTHER|oro-granary exercises.|soft palate exercises language exercises facial exercises stomatognathic functions swallowing and chewing exercises
41162289|NCT03484078|DEVICE|Placebo Platform|The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.
41162290|NCT01660919|DRUG|placebo|
41162291|NCT01660919|DRUG|rosuvastatin|
41369161|NCT01411917|PROCEDURE|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
41369162|NCT03914456|OTHER|rehabilitation treatment|
41369163|NCT06191757|BEHAVIORAL|supported with the developmental support program|Babies were developmentally supported with the developmental support program
41369164|NCT06230822|DRUG|VUM02 Injection|VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.
41369165|NCT01518894|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
41029846|NCT06532292|DEVICE|HIFEM|The HIFEM device (i.e. BTL EMSELLA) is FDA approved and its indications are to provide entirely non-invasive electromagnetic stimulation of pelvic floor muscle for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.
41162292|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|Sym004 will be administered as an intravenous infusion at a dose of 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the investigational medicinal product (IMP) in combination with platinum-doublet chemotherapy regimen of cisplatin/gemcitabine (cisplatin 75 mg/m\^2 on Day 1 plus gemcitabine 1250 mg/m\^2 on Days 1 and 8 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
41162293|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of cisplatin/pemetrexed (cisplatin 75 mg/m\^2 plus pemetrexed 500 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
41162294|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin area under the concentration-time curve (AUC) = 6 milligram per millilitre per minute \[mg/mL/min\] plus paclitaxel 225 mg/m\^2 on Day 1 of 3-Week cycle intravenously for a maximum of 6 treatment cycles).
41369166|NCT01518894|DRUG|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
41029847|NCT00052065|DRUG|TLK286|
41369167|NCT01518894|DRUG|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
41369168|NCT01518894|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
41502691|NCT02473523|DEVICE|Jamar Hydraulic Hand Dynamometer|"A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete."
41029848|NCT00784043|DEVICE|Cochlear Implant|Bilateral Implantation in children
41029849|NCT02632149|DEVICE|PINS Vagus Nerve Stimulator|
41029850|NCT02308436|DEVICE|Candida Mouthwash with Curolox™ Peptide|Prophylaxis - protection and care of teeth against caries \& acidic challenges
41029851|NCT01181934|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
41029852|NCT01181934|DRUG|placebo|placebo - three times daily during each treatment period
41029853|NCT01181934|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
41029854|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily
41029855|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily
41029856|NCT02047019|DRUG|Candesartan Cilexetil|Candesartan Cilexetil, 16 mg, capsule, orally, once daily
41029857|NCT02047019|DRUG|Candesartan matching placebo|Candesartan matching placebo, capsule, orally, once daily
41029858|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
41029859|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
41029860|NCT05425004|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
41369169|NCT02438787|DRUG|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
41029861|NCT03738540|BEHAVIORAL|TALK study group|Telephone Delivered Intervention
41029862|NCT03738540|BEHAVIORAL|TALK control group|Telephone Delivered Intervention
41029863|NCT03575923|BEHAVIORAL|Urban street greening|The interventions are located on four publicly accessible sites; the total size of the floor area of green space in each of the intervention sites is small, ranging from 0.09 to 0.35 acres. Components of the interventions include tree and flower planting (expected to bloom by March 2018) and artificial tree decorations such as strings of small electric lights and tree socks (the interventions are hereafter collectively referred to as urban street greening). The total cost for all components across all four intervention sites is approximately £6,000, although this excludes artist fees connected to the project. All components of the interventions were implemented within a one week period in November 2017 by two arborists, two local artists, staff members at Southway Housing Trust, and local community members from Old Moat and a local school.
41029864|NCT02961972|DIETARY_SUPPLEMENT|monohydrate and micronized creatine|oral supplementation with creatine
41029865|NCT02961972|OTHER|placebo|oral supplementation with maltodextrin (control group)
41029866|NCT05095584|DIAGNOSTIC_TEST|3 meter backward walk test|validity and reliability of 3-meter backward walk test in lower limb amputation group
41029867|NCT00838344|OTHER|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
41369170|NCT02438787|DRUG|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
41369171|NCT02438787|DRUG|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
41369172|NCT02438787|DRUG|Golimumab 50 mg|Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
41369173|NCT01785199|PROCEDURE|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
41369174|NCT05056909|DEVICE|Kidney ACTion|AI-supported software for chronic kidney disease care
41369175|NCT05056909|OTHER|Standard of care|Standard of care
41369176|NCT02076646|DRUG|L19IL2 - Ph I|During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
41369177|NCT02076646|DRUG|L19IL2 at RD - Ph II|L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
41369178|NCT02076646|DRUG|DTIC|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
41369179|NCT00003695|DRUG|chemotherapy|
41369180|NCT00003695|PROCEDURE|surgical procedure|
41369181|NCT00519090|DRUG|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
41369182|NCT00519090|DRUG|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
41369183|NCT02120690|DEVICE|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
41369184|NCT06435052|BEHAVIORAL|Eye Movement Desensitization & Reprocessing Therapy|Eye Movement Desensitization and Reprocessing (EMDR) therapy will be administered face-to-face by a psychotherapist in a total of 12 sessions, with one session per week. The efficacy of EMDR therapy will be compared with Cognitive Behavioral Therapy in the treatment of Post-Traumatic Stress Disorder in Pakistan.
41369185|NCT06435052|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will be comparatively checked with Eye Movement Desensitization \& Reprocessing Therapy for its efficacy. It will be administered by psychotherapist in 14 sessions (each session per week)
41502692|NCT02473523|OTHER|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
41502693|NCT02473523|OTHER|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
41036631|NCT06006520|OTHER|aerobic exercises|We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; It includes activities such as walking, cycling, jogging, aerobic dancing, swimming.
41369186|NCT04398797|OTHER|PATINA algorithm|Once a week community nurses receive a list of community dwelling citizens deemed at risk of deterioration that can lead to hospital admission. Nurses assess each citizens situation and initiate intervention if needed (not part of the intervention).
41036632|NCT01586143|DRUG|paracetamol|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
41036633|NCT01586143|DRUG|Placebo|
41036634|NCT04493398|PROCEDURE|Gracey curette.|Root planed was performed with curettes (Gracey SAS, Hu-Friedy, Chicago, IL, USA).
41036635|NCT04493398|PROCEDURE|Ultrasonic scaler.|Debridement was performed with an ultrasonic scaler (Piezon Master 400 Perio Slim Tip®; Electro Medical System, Nyon, Switzerland).
41036636|NCT04493398|PROCEDURE|Erythritol air-polishing.|Treatment was performed with a low abrasive erythritol powder (Air-flow powder plus®, EMS, Nyon, Switzerland ) applied through a Perio-Flow hand piece connected to an airflow unit (Air-Flow Master®, EMS, Nyon, Switzerland).
41036637|NCT05221164|DRUG|Aspirin 162 mg|Daily aspirin 162 mg during pregnancy to prevent preeclampsia
41036638|NCT03943732|DIAGNOSTIC_TEST|FilmArray Pneumonia|FilmArray Pneumonia testing of tracheal sample
41036639|NCT00540280|RADIATION|Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin|Surgery + Chemo + RT
40846890|NCT01415492|BEHAVIORAL|HD2|The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
40846891|NCT01415492|BEHAVIORAL|HD2+|The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
41029868|NCT03508557|BEHAVIORAL|Advance care planning tools|Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
41369187|NCT05689164|BIOLOGICAL|fordadistrogene movaparvovec|gene therapy administered in a previous study.
41369188|NCT01641952|DRUG|Rituximab|Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
40846892|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
40846893|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
40846894|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
41029869|NCT02194426|DRUG|MP0250|Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
41029870|NCT02067247|DEVICE|BeamMed Speed-of-Sound bone strength test at forearm|BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
41369189|NCT05093660|DIAGNOSTIC_TEST|Blood specimen collection|Blood specimen collection for analysis of CRP (C-reactive protein), WBC (White blood cells) and LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
40846895|NCT00973245|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
40846896|NCT05113992|OTHER|aromatherapy massage|In the intervention group, 4% massage oil (3 ml jojoba fixed oil, 2% Frankincense and 2% Myrrh essential oil mixture) was applied on the skin on the forearm
40846897|NCT05113992|OTHER|classic massage|In the placebo massage group, jojoba fixed oil was applied to the skin on the forearm.
41029871|NCT00924950|DRUG|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
41029872|NCT00924950|DRUG|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
41369190|NCT05093660|DIAGNOSTIC_TEST|Saliva specimen collection|Saliva specimen collection for analysis of LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
41369191|NCT06091176|DEVICE|Amicomed®|This app helps users track their blood pressure readings over time with analysis and history features. It generates graphs and charts to display trends and patterns, and users can set reminders to take blood pressure readings. Additionally, the app offers personalized recommendations for lifestyle, including personalized diet plans, and physical exercise programs based on the user's information. Using cognitive-behavioral techniques and motivational levers, the app helps users overcome barriers to lifestyle changes and provides personalized feedback and coaching. It also includes a database of evidence-based strategies for behavior change, and users can receive notifications, reminders, and rewards to stay motivated.
41369192|NCT06091176|DEVICE|Digital Placebo|Subjects will be provided with a white label mobile app, which allows to (1) add blood pressure measurements, (2) access the history of recorded measurements. No notification system will be implemented.
41369193|NCT06091176|OTHER|Usual Care|Usual Care (UC): Subjects assigned to control group will receive care as usual care, including self-monitoring indications.
41029873|NCT02715128|DEVICE|Transcranial direct current stimulation (tDCS)|non-invasive electric brain stimulation method
41029874|NCT02062502|BIOLOGICAL|VARIVAX™ New Seed Process|Varicella virus vaccine live manufactured with a new seed process
41029875|NCT02062502|BIOLOGICAL|VARIVAX™ 2007 process|Varicella virus vaccine live manufactured with the 2007 process
41029876|NCT02062502|BIOLOGICAL|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
41029877|NCT00220194|DRUG|leuprolide acetate|
40846898|NCT02039856|OTHER|Multilevel stakeholder engagement|Structured, in-person stakeholder panel meeting of VA network, VA medical center, and primary care and women's health leaders using modified Delphi panel techniques to come to consensus on a quality improvement (QI) roadmap within each participating VA network, followed by intermittent progress reporting and post-24 months in-person capstone stakeholder panel meetings
41162295|NCT02083679|DRUG|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg on Day 1 and 12 mg/kg on Day 8 of a 3-Week cycle until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin AUC = 6 mg/mL/min plus paclitaxel 225 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
41369194|NCT03166891|DRUG|Chiauranib|Take 50mg orally once daily
41369195|NCT03028324|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
41369196|NCT00471237|DRUG|Ronacaleret|100mg, 200mg, 300mg, 400mg
41369197|NCT00471237|DRUG|Teriparatide|PTH (1-34)
41369198|NCT00471237|DRUG|Alendronate|Bisphosphonate
41369199|NCT04082494|DEVICE|Music via internet and noise canceling headphones|Optional music via internet and noise canceling headphones will be offered.
41369200|NCT04082494|OTHER|Beverages|Beverages will be optionally offered (with and without sugar, warm or cold).
41369201|NCT05228327|DEVICE|Occlusal splint treatment|Occlusal splint was made for 16 patients and they used just this occlusal splint for 3 months.
41502694|NCT02473523|OTHER|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
41029878|NCT03876041|DRUG|solumedrol|intravenous solution for injection
41029879|NCT03876041|DRUG|Dexamethasone phosphate|intravenous solution for injection
41162296|NCT02203045|OTHER|Total Knee Arthroplasty|
41369202|NCT05228327|PROCEDURE|Masticatory muscle injection|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Injection was repeated 3 times, once a week.
41369203|NCT05228327|COMBINATION_PRODUCT|Combination of occlusal splint and masticatory muscle injection treatments|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Occlusal splint was also made and they started to use the day which first injection was made. And continue to use the occlusal splint for 3 months. Injection was repeated 3 times, once a week.
41369204|NCT04724759|DRUG|Dexmedetomidine / Ketamine / Lidocaine|Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.
41369205|NCT04922164|BEHAVIORAL|Cue intervention|"Around 30 pieces of narrative information about how a mother behaves in specific decision context will be derived from our qualitative study to construct social normative cues.~For goal-related cues, words relating to each category of breastfeeding-related values, benefits and goals will be identified and used to construct the messages (e.g. attractive body shape, smart baby, natural, strong immunity and etc.). Each goal-priming message will be presented with brief priming words and a picture of an image of the desirable goal."
41369206|NCT03138265|BEHAVIORAL|HIIT Device: ergometer|Supervised exercise training.
41369207|NCT01489449|DEVICE|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
41369208|NCT01489449|COMBINATION_PRODUCT|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
41369209|NCT02345499|PROCEDURE|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
41502695|NCT02473523|OTHER|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
41029880|NCT03431077|DRUG|Angiotensin II|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.
41029881|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
41369210|NCT02345499|PROCEDURE|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
41369211|NCT02995239|DRUG|CJ-12420 formulation 2|CJ-12420 formulation 2
41369212|NCT02995239|DRUG|CJ-12420 formulation 1|CJ-12420 formulation 1
41369213|NCT00394173|DRUG|DNK333|DNK333 25mg b.i.d. given orally for 4 weeks
41369214|NCT00394173|DRUG|Placebo|Matching placebo
41502696|NCT00676780|DRUG|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
41502697|NCT04614753|OTHER|Dealcoholized Muscadine Wine|300 ml of Dealcoholized Muscadine Wine
41502698|NCT04614753|OTHER|Control Beverage|300ml of Sugar Water and Acid Content
41369215|NCT04188639|DRUG|Emicizumab Injection|All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks follow-up with Immunosuppressive therapy (IST) at the investigators discretion.
41369216|NCT02042573|DEVICE|rTMS|
41369217|NCT02042573|DRUG|SSRI (SEROPLEX ou ZOLOFT)|
41369218|NCT02042573|OTHER|Genetic samples|
41369219|NCT02341482|DRUG|PF-04958242|Administered as specified in the treatment arm
41369220|NCT02341482|DRUG|Itraconazole|Administered as specified in the treatment arm
41369221|NCT04865172|OTHER|Remote collection of passive and active data for 28 consecutive days|Passive sensor data: collected continuously for 28 days, from a multi-sensor wearable bracelet worn by each member of the dyad; Active questionnaire data: collected once a week during the four weeks of monitoring (and at the end of the 28 days for patient-caregiver dyads), from questionnaires filled by one partner of the dyad (for patient-caregiver dyads, this will be the caregiver) using a smartphone application.
41369222|NCT02059473|PROCEDURE|Rotator cuff repair|Physiotherapy \& Surgery
41029882|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
41369223|NCT02059473|PROCEDURE|Physiotherapy|
41369224|NCT03708926|DRUG|Abaloparatide|abaloparatide injection pen
41369225|NCT03708926|DRUG|Placebo|placebo injection pen
41369226|NCT04707768|DRUG|Vadadustat|oral tablets
41502699|NCT05042895|PROCEDURE|Group A|"Office diagnostic hysteroscopy for assessment of the following:~* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
41502700|NCT05042895|PROCEDURE|Group B|"Office diagnostic hysteroscopy for assessment of the following:~* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
41502701|NCT05985135|PROCEDURE|Muscle Biopsy|Needle muscle biopsy of the outer thigh muscle
41502702|NCT05985135|OTHER|Jell-O with Amino acids|An amino acid mixture containing 13C6 Lysine isotope label
41369227|NCT04707768|DRUG|Mircera®|intravenous administration
41369228|NCT01061398|PROCEDURE|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
41029883|NCT06531954|DEVICE|Vagus nerve stimulation|Vagus nerve stimulation group: Vagus stimulation was applied bilaterally through the ear. taVNS was performed with the Vagustim device. The stimulation pulse width was 300 microseconds, the frequency was 10 Hz, and it was biphasic with a 20-minute duration. Electrodes were placed on the concha and tragus parts of the ear, and the current was increased through these electrodes until the participant felt pain.
41029884|NCT06531954|BEHAVIORAL|Breathing exercise|Breathing exercise group: The content of breathing exercises was planned as thoracic expansion exercises. These exercises were applied to the lower, middle, and upper lobes in 3 sets of 3x10 (90 times breathing in one area) and lasted for an average of 20 minutes. Participants were asked to inhale as deeply as possible into the relevant area, hold their breath for 3 seconds, and then slowly exhale the entire breath.
41369229|NCT01061398|PROCEDURE|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
41369230|NCT05083975|DEVICE|Buzzy System|Vibrating Device
41502703|NCT05985135|DIETARY_SUPPLEMENT|Dextrose|Intravenous form of sugar
41502704|NCT04338269|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered at a fixed dose on Day 1 of each 21-day cycle by IV infusion every 3 weeks.
41502705|NCT04338269|DRUG|Cabozantinib|Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
41502706|NCT00111553|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
41502707|NCT02496663|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41502708|NCT02496663|PROCEDURE|Computed Tomography|Undergo CT scan
41502709|NCT02496663|PROCEDURE|Echocardiography|Undergo ECHO
41369231|NCT05083975|DRUG|Topical anesthetic|20% benzocaine gel (Opahl Topical Gel)
41369232|NCT05083975|DRUG|1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000|Local dental anesthetic agent
41369233|NCT01254734|PROCEDURE|transoral robotic surgery|Undergo transoral robotic microsurgery
41369234|NCT01254734|OTHER|laboratory biomarker analysis|Correlative studies
41502710|NCT02496663|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
41502711|NCT02496663|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41502712|NCT02496663|BIOLOGICAL|Necitumumab|Given IV
41369235|NCT01254734|PROCEDURE|quality-of-life assessment|Ancillary studies
40846899|NCT02039856|OTHER|Quality improvement (QI) education/training|Initial in-person and ongoing virtual team training in QI principles, methods, and project proposal development and refinement
40846900|NCT02039856|OTHER|Technical support|Research team provided technical review of and feedback on local QI project proposals, helped develop and/or recommend process/outcome measures, identified and shared relevant published literature (e.g., measures, interventions), and provided general technical support (e.g., how to analyze local data, how to conduct a local focus group)
40846901|NCT02039856|OTHER|Formative feedback|Research team provided aggregated all-site and local data from baseline patient and provider/staff surveys, 12-month patient surveys, and other data and findings to local teams for ongoing and new QI project idea development
40846902|NCT02039856|OTHER|External practice facilitation|Within and across site calls with local teams to review progress, identify needs, help solve problems, discuss current and new projects, as well as potential for spread
40846903|NCT02039856|OTHER|National policy guidance|VA Handbooks on policy and practice for PACT implementation guidance and on delivery of comprehensive women's health services disseminated to all VA facilities
40846904|NCT03009968|OTHER|Post-void residual free voiding trial|Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
40846905|NCT03736876|BEHAVIORAL|About Us|Each program session includes an initial soap opera-like story to build interest and illustrate key concepts, 2-3 group-based activities with reflection, individual app-based work on tablets to allow for personalization of the content, and a group-based debrief to reflect on the day and reinforce key messages. The group-based content is delivered by trained facilitators from the participating school-based health centers. The app-based content is housed on a secure website and accessed through tablets with unique log-ins for each participant. Activities are completed individually during the session (e.g., completing a poll; watching and responding to a brief video). Several lessons include homework activities that encourage communication between students and a caring adult.
40846906|NCT03675737|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
40846907|NCT03675737|DRUG|Cisplatin|Administered as an IV infusion on Day 1 Q3W
40846908|NCT03675737|DRUG|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
41029885|NCT04125693|DRUG|Rogaratinib (BAY1163877)|Participants will be treated with investigational drug following the treatment schedule and dosing instructions from the feeder-study protocol.
41029886|NCT04125693|DRUG|Combination drug|Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
41029887|NCT00871559|DRUG|REGN421(SAR153192)|
41029888|NCT01011010|DRUG|doxorubicin hydrochloride|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
41029889|NCT01011010|DRUG|mitomycin C|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
41029890|NCT01011010|DRUG|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
41029891|NCT01011010|OTHER|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
41369236|NCT04077060|DIAGNOSTIC_TEST|NIPT|"Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization \< 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing."
41502713|NCT02496663|DRUG|Osimertinib|Given PO
41502714|NCT06149806|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|efficacy and tolerability of Sacubitril/Valsartan in the treatment of chronic heart failure on complex congenital cardiopathy
40846909|NCT03675737|DRUG|oxaliplatin|Administered as an IV infusion on Day 1 Q3W
40846910|NCT03675737|DRUG|capecitabine|Administered orally BID on Days 1 to 14 Q3W
40846911|NCT03675737|DRUG|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
40846912|NCT01124591|BEHAVIORAL|Brief motivational intervention|two session delivered two weeks apart
40846913|NCT03037983|DEVICE|Repetitive transcranial magnetic stimulation|rTMS is a non-invasive procedure, in which the administration of a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention will be administered in 20 sessions lasting 50 minutes each over the course of 2-6 weeks. Up to two sessions may be scheduled per day with a one-hour interval in-between.
40846914|NCT03037983|DEVICE|Sham|Subjects will still attend treatment sessions as outlined in the rTMS intervention. However, the device will not deliver any stimulation to the subject.
40846915|NCT03504631|OTHER|No intervention|no intervention
40846916|NCT03334812|BIOLOGICAL|LNA043|LNA043 Single dose
40846917|NCT03334812|BIOLOGICAL|placebo to LNA043|placebo to LNA043 single dose
40846918|NCT01374178|DRUG|LY2963016|Administered subcutaneously
40846919|NCT01374178|DRUG|Lantus|Administered subcutaneously
40846920|NCT03875352|PROCEDURE|CHG technique|The CHG technique includes treatment using dressing with chlorhexidine.
40846921|NCT03875352|PROCEDURE|HMG technique|The HMG technique includes treatment using hydrophilic methacrylate gel and transparent foil.
41369237|NCT04077060|DIAGNOSTIC_TEST|combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is \>3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
40846922|NCT06199453|DRUG|Lutetium (177Lu) vipivotide tetraxetan|6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks
40846923|NCT04811482|BEHAVIORAL|TCIT-CALM (Teacher-Child Interaction Training-CALM)|This intervention is designed to treat early childhood anxiety. It is an adaptation of parent-child interaction therapy (PCIT), in which teachers rather than parents are targeted as the therapeutic agent of change. The intervention follows the procedures of the CALM protocol, in which caregivers are taught play therapy skills to support and address anxious behaviors and avoidance.
40846924|NCT03539991|OTHER|Internet-Based Intervention|Complete online courses
40846925|NCT03539991|OTHER|Meeting|Participate in virtual meetings
40846926|NCT03539991|OTHER|Survey Administration|Ancillary studies
40846927|NCT05946005|DRUG|honey|Tresno Joyo honey applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: MD252109001219
40846928|NCT05946005|DRUG|lidocaine|Dolones cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: DKL0922246629AI
41029892|NCT01011010|OTHER|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
41029893|NCT01032941|DRUG|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
41029894|NCT04475744|DRUG|G-CSF treatment for Bone marrow derived stem cell Mobilization|Mobilization treatment. On the fifth day, collection will be started.
41029895|NCT04475744|PROCEDURE|Platelet Rich Plasma ovarian injection|Mobilized peripheral blood will be obtained to prepare the PRP for injection. Both ovaries will be injected when proper anatomical access can be assessed.
41029896|NCT02197923|PROCEDURE|Myometrial biopsy|transvaginal ultrasound guided biopsy of the myometria
41369238|NCT00128336|BEHAVIORAL|Lifestyle: diet and exercise intervention|
41369239|NCT03057769|DRUG|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
41369240|NCT03057769|DRUG|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
41502715|NCT06102863|DRUG|statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
40846929|NCT05946005|DRUG|povidone-iodine|Betadine cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: PKD20501710037
40846930|NCT05946005|OTHER|control groups|no intervention is given
40846931|NCT02692378|DRUG|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
40846932|NCT05901402|BEHAVIORAL|aerobic and resistance exercise|The experimental group performed aerobic resistance exercise during pregnancy every day.
40846933|NCT02189278|BEHAVIORAL|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
40846934|NCT04986930|RADIATION|SBRT+mFOLFIRINOX|Stereotactic body radiotherapy: 3500 cGy (5 fractions) mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
40846935|NCT04986930|DRUG|mFOLFIRINOX|mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
40846936|NCT00714311|BEHAVIORAL|Transference-Focused Psychotherapy|Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week
40846937|NCT00714311|BEHAVIORAL|treatment by experienced community psychotherapists|Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
40846938|NCT02757612|RADIATION|laser diode|laser diode
41029897|NCT02197923|PROCEDURE|endometrial biopsy|transcervical endometrial biopsy
40846939|NCT05131022|DRUG|NX-5948|Oral NX-5948
41029898|NCT03293940|PROCEDURE|Cryoablation|The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.
41029899|NCT03293940|PROCEDURE|Therapeutic Peripheral Nerve Block (tPNB) Injection|"During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.~The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone."
41029900|NCT06276543|DEVICE|antibiotic-impregnated catheter|Hydrocephalus patient implant with antibiotic-impregnated catheter to shunt their cerebrospinal fluid.
41502716|NCT04003896|DRUG|Abemaciclib|"Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc."
41502717|NCT02553759|OTHER|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
41502718|NCT01665326|OTHER|Observational|This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).
41502719|NCT02032797|DRUG|Progesterone|
41502720|NCT02813265|DRUG|KPI-121 0.25% Ophthalmic Suspension|
41502721|NCT02813265|DRUG|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
41502722|NCT04909229|DEVICE|PEAR-003b PDT Intervention|The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.
41029901|NCT05792553|DEVICE|bonded tongue tamers|Enamel surface will be treated initially with 37% phosphoric acid for 30 seconds then tongue tamers will be bonded to the palatal/lingual surface of upper and lower central incisors
41029902|NCT05792553|DEVICE|customized bonded spurs|Composite restoration will be used to fabricate the customized bonded spurs with sharp ends and 3 mm in length.
41369241|NCT03057769|DRUG|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
40846940|NCT01736618|DEVICE|S-ICD System|
40846941|NCT04830488|BEHAVIORAL|e-learning didactic module|Participants utilize e-learning
41029903|NCT05792553|DEVICE|conventional fixed palatal spurs|conventional fixed palatal spurs will be fabricated by taking impression after band selection, then the spurs appliance will be fabricated from 0.9 mm stainless steel wire and soldered to the bands bilaterally.
41029904|NCT06057350|PROCEDURE|Tumor removal|Removal of incompletely removed early-stage colon cancer
41029905|NCT00687258|DEVICE|VitabranE ViE|Polysulfone dialyser with vitamin E alpha-tocopherol
40846942|NCT04830488|BEHAVIORAL|Personal reflection activities|Participants complete questionnaires
40846943|NCT03696589|BEHAVIORAL|Physical Activity Coaching|Based in the self-determination theory, participants will be coached on beneficial exercises, how to utilize supports and overcome barriers to PA engagement. Emphasis of exercise coaching will be on increasing aerobic exercise engagement and will include us of Fitbit devices to facilitate uptake and monitor aerobic exercise. Intervention will be delivered by a physical or occupational therapist, who will work with the participant to develop a plan, set goals and targets, and track changes. Additional resources that will support exercise engagement will be provided. Participants will have the choice to receive their face-to-face session either in person or remotely via secure video-based service.
40846944|NCT00379067|DRUG|Tamsulosin OCAS|Adrenoceptor antagonist
40846945|NCT00379067|DRUG|Placebo|placebo
40846946|NCT05877638|DEVICE|SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel|(FDA) 510(k) cleared wound care medical devices formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn serves as a protective gel dressing.
40846947|NCT05877638|DRUG|SILVADENE Cream 1% (silver sulfadiazine)|SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
40846948|NCT02642380|DRUG|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
40846949|NCT02642380|DRUG|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
41036640|NCT06568692|DRUG|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
41369242|NCT05550103|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
41369243|NCT05550103|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
41036641|NCT06568692|DRUG|Capecitabine|Commercially available capecitabine is a commonly used oral fluoropyrimidine.
41036642|NCT02243553|DRUG|Tipranavir capsule|
41036643|NCT02243553|DRUG|Tipranavir solution|
41036644|NCT02243553|DRUG|Ritonavir capsule|
41369244|NCT05550103|OTHER|Standard medical treatment|Standard medical treatment
41502723|NCT04909229|DEVICE|Fitbit|Patients will receive a Fitbit and receive standard of care
41502724|NCT04909229|BEHAVIORAL|Sleep education materials|Patients will receive sleep hygiene and healthy sleep tips.
41502725|NCT00193466|DRUG|Rituximab|
41502726|NCT00193466|DRUG|Fludarabine|
41502727|NCT00193466|DRUG|CAMPTH-1H|
41502728|NCT04667286|PROCEDURE|Prone Position (PP)|Prone the patients on oxygen for at least 10 hrs a day
41502729|NCT06634173|DIAGNOSTIC_TEST|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated Cancer associated fibroblasts as a marker of Tumor Micro-Environment and indirectly as a marker for malignancies.
41502730|NCT06015763|PROCEDURE|Endoscopy|Endoscopic biopsy
41502731|NCT05007821|DRUG|Linezolid 600 mg|One 600mg tablet taken orally once daily (QD) in the morning during weeks 1-26
41502732|NCT05007821|DRUG|Linezolid 1200 mg (QD)|Two 600mg tablets taken orally once daily (QD) in the morning during weeks 1-4
41502733|NCT05007821|DRUG|Linezolid 1200 mg (TIW)|Two 600mg tablets taken orally three times per week (TIW; Mon-Wed-Fri) in the morning during weeks 5-26
41502734|NCT05007821|DRUG|Bedaquiline 200 mg|Two 100mg tablets taken orally once daily in the morning during weeks 1-8
41502735|NCT05007821|DRUG|Bedaquiline 100 mg|One 100mg tablet taken orally once daily in the morning during weeks 9-26
41502736|NCT05007821|DRUG|Delamanid 300 mg|Six 50mg tablets taken orally once daily in the morning during weeks 1-26
41029906|NCT03980470|DEVICE|TrueFidelity|"TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms."
41369245|NCT05274620|BEHAVIORAL|IntelliCare|A mobile intervention that use principles of computerized therapy to decrease symptoms of depression
41369246|NCT04156802|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded)
41369247|NCT04156802|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
41369248|NCT04156802|DEVICE|Real TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded).
41369249|NCT04156802|DEVICE|Sham TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
41369250|NCT04098991|DRUG|Levothyroxine|All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
41369251|NCT04869124|DRUG|Dapagliflozin|Dapagliflozin propanediol (FORXIGA) tablet: 10 mg once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
41369252|NCT04869124|DRUG|Placebo|Placebo tablet, matching Dapagliflozin, once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
41369253|NCT01150942|BIOLOGICAL|JE vaccine|3 times, IM
41369254|NCT03332225|DRUG|Anakinra|Treatment with anakinra
41369255|NCT03332225|DRUG|Recombinant human interferon-gamma|Treatment with recombinant human interferon-gamma
41029907|NCT03219983|DRUG|Ropivacaine|Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score \> 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
41029908|NCT03219983|DRUG|liposomal bupivacaine|A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
41029909|NCT05718765|BEHAVIORAL|PACES intervention|"The exercise perception intervention program is divided into three stage, and every four weeks is a stage. The theme of the first stage is to make the patient have the intention to exercise. The theme of the second stage is to provide effective support for the patient, so that the patient can take the initiative to start exercise. The theme of the third stage is to enable patients to keep exercising.~The exercise intervention is a 12-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours for safety. Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE."
41036645|NCT02243553|DRUG|Caffeine|
41369256|NCT03332225|DRUG|Placebo|Treatment with Placebo
41369257|NCT04123743|DRUG|Trigonella foenum-graceum extract topical cream|Topical cream containing Trigonella foenum-graceum extract
41369258|NCT04123743|OTHER|Facial Wash|Wardah brand facial wash
41369259|NCT04123743|OTHER|Sunscreen Cream|Parasol sunscreen cream SPF 33
41369260|NCT04123743|OTHER|Placebo|Placebo topical cream
41369261|NCT05414682|OTHER|MIND+SOUL Diet|The MIND+SOUL Diet is an adapted brain-healthy soul food diet.
41369262|NCT01387061|PROCEDURE|hepatic resection|surgical resection of the liver for multiple HCC
41369263|NCT06050382|OTHER|PROGRESSIVE RELAXATION TRAINING|"Both intervention groups were instructed and trained by a physiotherapist 2times a week for 30 minutes each over 6 weeks, The sessions were held in a well-lit, clean and comfortable room with a temperature of 22-24 degrees. Women were asked to stop eating and wear comfortable clothes at least two hours before the sessions. Before the training, relaxation exercises and breathing techniques explained to the women.~The women lied in the supine position firstly. Then the therapist instructed them to contract and release different muscle groups. They practiced tensing a muscle group until they felt the slight contraction and then released it, simultaneously relaxing other muscle groups. During the session, women were instructed to contract the muscles for 10-20 seconds during deep diaphragmatic breathing and to relax for 30-40 seconds while exhaling."
41502737|NCT05007821|DRUG|Clofazimine 300 mg|Three 100mg capsules taken orally once daily in the morning during weeks 1-2
41502738|NCT05007821|DRUG|Clofazimine 100 mg|One 100mg capsule taken orally once daily in the morning during weeks 3-26
41502739|NCT05498779|PROCEDURE|Ablation therapy|Radiofrequency or microwave ablation
41502740|NCT06273267|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns the first year of follow-up (from the initial PPC intervention to one year to date post-intervention).
41369264|NCT05480891|PROCEDURE|Transnasal Esophagoscopy (TNE)|"While seated in an upright position a topical numbing medicine will be sprayed in your nose and the back of your throat.~A thin, flexible tube less than ¼ inch in diameter, will be placed in one of your nostrils and advanced to the back of your throat. When the tube reaches the back of the throat you will be asked to drink sips of water to help move the tube into and down the esophagus as it is advanced. The tip of the tube has a small light and camera built in that allows the doctor to see the structures of the mouth and esophagus as the tube is advanced. Once the tube is in the esophagus, the physician will examine your esophagus for any abnormal changes.~Once the visual inspection is complete the tube will be gently removed through your nose. The procedure will take approximately 10-15 minutes of time."
41502741|NCT06633094|OTHER|Educational videos|Internet will be used to deliver educational videos to subjects enrolled in the home management arm of the study which will be available on the Carilion Clinic Orthopaedic Education YouTube Channel. This will consist of a prerecorded video made by the three pediatric orthopaedic surgeons on this study explaining the nature of buckle fractures and treatment. Participants will be sent a link to the video over email (an example of a similar video in clinical use at Carilion Orthopaedics and the script of the video can be found in the study document attached).
41502742|NCT03601130|DEVICE|HydroxyColl Bone Graft Substitute|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
41502743|NCT03601130|DEVICE|DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
41502744|NCT05636514|DRUG|Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET|Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
41502745|NCT05636514|DRUG|Defactinib|"Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily"
41502746|NCT01160003|DRUG|GW870086X|5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
41502747|NCT01160003|DRUG|Placebo|placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
41502748|NCT03893565|DRUG|GSK2831781 - Double Blind Phase|GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
40846950|NCT04271033|DEVICE|Carotid Artery Stenting|"Carotid artery stenting according to local clinical experience and ESC/ESVS guidelines using exclusively CGuard™, MicroNet covered stent under proximal or distal intraprocedural cerebral protection according to tailored CAS algorithm."
41029910|NCT05718765|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 hemodialysis hours.
41029911|NCT01312909|DRUG|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
41029912|NCT01312909|DRUG|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
41029913|NCT01312909|DRUG|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
41162297|NCT04595526|PROCEDURE|Forced expiratory technique and induced sputum|The intervention is based on the patient's own attempt to deliver a sputum sample after instructions of proper huff forced exhalation and coughing technique. After an attempt to deliver a sputum sample the patient will receive a 0,9% isotonic saline by an inhalation mask to induce the sputum, thereafter the patient will again make an effort to expectorate a sputum sample repeating the forced expiratory technique.
41162298|NCT04595526|PROCEDURE|Tracheal suction|Tracheal suction is often used on intubated patients at the intensive care unit to collect sputum, and this method has become the standard procedure at several emergency departments.
41162299|NCT03184818|OTHER|Advanced care|The pharmacist will assess for symptoms of urinary tract infection and, for patients in Arm 1, prescribe antibacterials when appropriate. For patients in Arm 2, pharmacists will ensure optimal therapy and adapt or perform therapeutic substitution when appropriate (or work with the patient to discontinue therapy or just put the prescription on file in instances where the patient is assessed to have asymptomatic bacteriuria for which treatment is inappropriate).
41162300|NCT05163106|DRUG|Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet|Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
41502749|NCT03893565|DRUG|Placebo|Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
41502750|NCT03893565|DRUG|GSK2831781 - Open Label phase|GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.
41502751|NCT05054478|DRUG|Daratumumab|Daratumumab added to induction, first consolidation and second consolidation
40846951|NCT01955538|OTHER|Control|Psychiatric treatment as usual for 6 months according to best clinical practice.
40846952|NCT01955538|OTHER|Basic Body Awareness Therapy|20 weeks, 1 hour/week.
40846953|NCT01955538|OTHER|Mixed physical activity|20 weeks, 1 hour/week.
41029914|NCT04544462|OTHER|M2 Test|DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
41029915|NCT00396604|DRUG|indacaterol maleate|
41029916|NCT02575092|DRUG|Enalapril Maleate Tablets(as the program-based antihypertension)|
41029917|NCT02575092|DRUG|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
41029918|NCT02575092|DRUG|Placebo|
41162301|NCT05163106|DRUG|Goserelin|Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
41162302|NCT02906995|DRUG|Sublingual tablet 4 mg versus Nicorette Lozenge 4mg|"* One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~* The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge."
41029919|NCT04001465|PROCEDURE|Volumetric methacholine challenge unmodified|Bronchoprovocation challenge performed per volumetric method
41029920|NCT04001465|PROCEDURE|Modified volumetric methacholine challenge|Bronchoprovocation challenge performed per volumetric method modified to include use of ultrasonic spirometer fitted with vibrating mesh nebulizer
41162303|NCT05425173|OTHER|Conventional treatment|Chest Physical Therapy as required
41162304|NCT05425173|OTHER|Limb Range of Motion Exercises + Chest Physical Therapy|"Limb Range of Motion Exercises + Chest Physical Therapy~Frequency: 4 sessions Time: 5 to 10 minutes"
41369265|NCT01005810|DRUG|N-Acetylcysteine|1200 mg twice daily for 8 weeks
41029921|NCT03822923|OTHER|Experimental group|Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes
41029922|NCT03822923|OTHER|Control group|Conventional treatment
41029923|NCT03520634|OTHER|PD-L1 PET imaging|PD-L1 PET imaging
41162305|NCT02915354|DRUG|Etanercept|Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
41162306|NCT05990270|BEHAVIORAL|education|Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
41162307|NCT00334139|DRUG|Zoledronic Acid|every 4 weeks for 4 months
41162308|NCT00082511|DRUG|Prasterone (GL701)|"There were 4 arms to the study:~During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study."
41369266|NCT01005810|DRUG|placebo|2 capsules twice daily for 8 weeks
40846954|NCT06584435|DRUG|Tremelimumab|Tremelimumab is administered intravenously at a fixed dose of 240 mg every 3 weeks for 1 treatment cycle until tumor recurrence or intolerable toxic effects.
41029924|NCT01365494|BIOLOGICAL|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
41029925|NCT02692300|PROCEDURE|EEG-Guided Group|Device: Bispectral Index (BIS) processed electroencephalogram or MASIMO or NeuroSENSE
41162309|NCT02969005|RADIATION|surgical treatment|Use of a radiopaque localizer grid and methylene blue staining as an aid to resect the lesions
41162310|NCT04684771|DIETARY_SUPPLEMENT|MYOSTIM®|Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
41162311|NCT04684771|DIETARY_SUPPLEMENT|PLACEBO|Bars with no active ingredient and the same flavor (chocolate and red fruits).
41369267|NCT01005810|BEHAVIORAL|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
41029926|NCT02576574|DRUG|Avelumab|Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
41029927|NCT02576574|DRUG|Pemetrexed|Participants received Pemetrexed 500 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
41369268|NCT05900674|DRUG|Reteplase Injection|To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.
41369269|NCT02564094|DRUG|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
41369270|NCT05809219|OTHER|1 hour combined intervention ( Exercise and nutrition)|Subjects take oral supplement after exercise in the time period between 1-2 hours. They will take oral supplement during hemodialysis treatment.
41369271|NCT05809219|OTHER|3 hours combined intervention ( Exercise and nutrition)|"All procedures between 1 hour combined intervention and 3 hours combined intervention are the same. The only one different is the time interval between exercise and nutrition. In this arm, the time interval of exercise and nutrition is 2.5 to 4 hours. When we recruiting subjects, all interventions will be clearly introduced to them, including the same and the different parts among them."
41369272|NCT05809219|DIETARY_SUPPLEMENT|Nutrition intervention|"Subjects only take oral supplement during hemodialysis treatment. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
41369273|NCT02467543|OTHER|20% Ethanol|Unmedicated 20% Ethanol
41502752|NCT00245830|PROCEDURE|Ischemic Preconditioning|Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
41502753|NCT02635113|DEVICE|Gait Synchronized Vibration System|A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
41502754|NCT06549712|GENETIC|identify genetic determinants of the predisposition to develop respiratory failure|To identify the main common genetic determinants of severe COVID-19 by conducting a GWAS: in first phase we will compare SARS-CoV-2 positive patients with severe lung affection to healthy controls from the same geographic area, in order to provide initial data informing the research in the field in a timely fashion. This will be conducted in close collaboration with the University of Kiel COVID-19 genomic initiative. Later on, we will proceed to assess objectives 1 and 2 in the full cohort, including also infected controls who did not developed clinically significant symptoms
41502755|NCT06549712|GENETIC|identify genetic determinants of the predisposition to develop respiratory failure|To provide extensive genetic characterization of all patients managed at the Fondazione in order to facilitate other groups working on specific projects (e.g. on candidate genes such as SERPINA1 and ACE2 by the Intensive Care and Cardiology Units and other that may emerge from upcoming projects), in a large population and in a very timely fashion, and without incurring in any additional expenses for the Fondazione research network, and coordinate research efforts.
41369274|NCT02467543|OTHER|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol.
41369275|NCT02137473|OTHER|Human milk-based fortifier|
41369276|NCT02137473|OTHER|Bovine protein-based fortifier|
41369277|NCT05825911|DIAGNOSTIC_TEST|Rest/Stress MCG scan|All patients enrolled and receiving standard screening tests for CAD will undergo rest/stress MCG scan before CAG.
41369278|NCT05825911|DIAGNOSTIC_TEST|Rest MCG scan|This is an normal adult population with age-, and sex-matched control group. All participants enrolled will undergo rest MCG scan.
41369279|NCT04252196|DEVICE|usability evaluation of medical device|participants interact with medical device and rate it for usability
41369280|NCT02463500|OTHER|DFU|Standard care.
41369281|NCT00235300|BIOLOGICAL|Thymoglobulin [Anti-thymocyte Globulin (rabbit)]|1.5 mg/kg per day, for a maximum of 5 doses
41369282|NCT00235300|DRUG|Simulect (basliximab)|20 mg per day on 2 days
41369283|NCT01199952|BEHAVIORAL|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
41369284|NCT00036868|BIOLOGICAL|trastuzumab|
41369285|NCT00036868|DRUG|CMF regimen|
41369286|NCT00036868|DRUG|cyclophosphamide|
41369287|NCT00036868|DRUG|fluorouracil|
41369288|NCT00036868|DRUG|methotrexate|
41369289|NCT04893720|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive lumbar degeneration
41036646|NCT02243553|DRUG|Warfarin sodium|
41036647|NCT02243553|DRUG|Vitamin K|
41036648|NCT02243553|DRUG|Omeprazole|
41036649|NCT02243553|DRUG|Dextromethorphan hydrobromide|
41036650|NCT02243553|DRUG|Midazolam injection|
41036651|NCT02243553|DRUG|Midazolam oral solution|
41036652|NCT02243553|DRUG|Digoxin tablet|
41036653|NCT02243553|DRUG|Digoxin injection|
41036654|NCT03386903|DEVICE|Ture acupuncture|"Patients receive true acupuncture treatment by Zhoushi coordinated points at the Bai-hui (DU20), Shen-ting (DU24), bilateral Ben-shen (BG13), Shen-men (HT7), San-yin-jiao (SP6) with Deqi sensation. The needles are retained for 20 minutes in every course, three times per week and last for 3 months."
41036655|NCT03386903|DEVICE|Sham acupuncture|Patients receive sham acupuncture stimulation by non-acupoint points (superficial insertion, 0.2 cun, No needle sensation (de qi) is elicited) at the bilateral mid-point between Shuaigu(GB8) and Touwei(ST8), Touwei(ST8) and Yangbai(GB14), front tibia, the junction of biceps and triceps.
41036656|NCT01352598|RADIATION|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
41036657|NCT03460223|BIOLOGICAL|MSC|conventional plus MSC or placebo treatment
41036658|NCT03057795|DRUG|Brentuximab Vedotin|Given IV
41036659|NCT03057795|OTHER|Laboratory Biomarker Analysis|Correlative studies
41036660|NCT03057795|BIOLOGICAL|Nivolumab|Given IV
41036661|NCT06222450|BEHAVIORAL|Vestibular Rehabilitation Therapy (VRT)|customized VRT home exercise program per standard of care, includes gaze stabilization, habituation, balance and gait exercises, and endurance training
41036662|NCT02585895|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once every 2 weeks
41369290|NCT00363376|DRUG|zonisamide|Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).
41369291|NCT00363376|DRUG|olanzapine|olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects
41369292|NCT00363376|DRUG|Zonisamide|zonisamide ranging from 100mg to 600mg daily
41162312|NCT03096197|DEVICE|Exoskeleton-Assisted Walking|Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.
41162313|NCT03096197|DEVICE|Transcutaneous Lumbosacral Stimulation (TLS)|EAW+TLS. This group will receive 60 minutes of exoskeleton assisted overground walking with simultaneous Transcutaneous Lumbosacral Stimulation (TLS) followed by 15 minutes of overground training without exoskeleton.
41162314|NCT04782505|DRUG|DWJ1248|Camostat mesylate Tablet from Daewoong
41502756|NCT06549712|GENETIC|identify genetic determinants of the predisposition to develop respiratory failure|"To provide a coordination to manage the collaboration with other research consortia in the field, e.g. the An anonymized GWAS to urgently query host genetic predisposition to severe COVID-19 (SARS-CoV-2 infection) lung disease, and the COVID-19 Host Genetic Initiative (https://www.covid19hg.org). Indeed, collaboration among large networks analyzing several thousand cases will be ultimately necessary to clarify the genetic basis of COVID-19 susceptibility, and large collaborative networks are essential instruments for conducting human genetic research."
41502757|NCT04128683|DRUG|amisulpride|Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
41162315|NCT02025478|DIETARY_SUPPLEMENT|Breastmilk|"* A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
41162316|NCT05452421|DIETARY_SUPPLEMENT|Isotonic carbohydrate beetroot juice drink|An isotonic carbohydrate beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.2 g carbohydrate per 100 ml. Osmolality 304-310 mOsm/kg.
41502758|NCT04128683|DRUG|bromocriptine|Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
41502759|NCT06427707|DRUG|Intravenous Infusion of propofol, lidocaine, Magnesium sulfate|intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. the effect of either Propofol injection, or ketamine injection or dexmeditomidine injection on intraoperative bleeding
41502760|NCT06427707|DRUG|Intravenous infusion of ketamine, lidocaine, Magnesium sulfate|Patients will receive intravenous infusion of Ketamine 0.1-0.2 mg.kg-1.h-1 (intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. dose of 1 mg.kg-1), lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1.
41162317|NCT05452421|DIETARY_SUPPLEMENT|Beetroot juice drink|A beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.1 g carbohydrate per 100 ml. Osmolality 390-410 mOsm/kg.
41502761|NCT06427707|DRUG|Intravenous infusion of dexmedetomidine, lidocaine, Magnesium sulfate|Dexmeditomidine (Precedex® 200 mcg.2ml-1) with a rate of 0.2-0.6 mcg.Kg-1.h-1. lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1
41502762|NCT06312657|BEHAVIORAL|Drug Cue|Individualized drug cues paired with choice options reinforced by $0.25
41502763|NCT06312657|BEHAVIORAL|Money|Two money values will be tested ($0.25 and $4.00)
41029928|NCT02576574|DRUG|Paclitaxel|Participants received Paclitaxel 200 mg/m\^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
41029929|NCT02576574|DRUG|Gemcitabine|Participants received Gemcitabine 1250 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
41369293|NCT00363376|DRUG|Sugar Pill (placebo)|sugar pill (placebo) for zonisamide
41369294|NCT04822701|DRUG|BI 767551 intravenous|BI 767551 intravenous
41369295|NCT04822701|DRUG|BI 767551 inhaled|BI 767551 inhaled
41369296|NCT04822701|DRUG|Placebo intravenous|Placebo intravenous
41369297|NCT04822701|DRUG|Placebo inhaled|Placebo inhaled
41369298|NCT01509638|DRUG|Group 1 Standard of Care|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
41502764|NCT06312657|DRUG|Withdrawal|Participants will be maintained on an opioid agonist. Placebo will be substituted to produce mild-to-moderate withdrawal.
41502765|NCT05751343|DRUG|TACE-HACI, plus atezolizumab-bevacizumab|transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab
41029930|NCT02576574|DRUG|Gemcitabine|Participants received Gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
41029931|NCT02576574|DRUG|Carboplatin|Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
41029932|NCT02576574|DRUG|Cisplatin|Participants received Cisplatin 75 mg/m\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
41369299|NCT01509638|DRUG|Group 2 EXPAREL|Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
41369300|NCT03879824|PROCEDURE|Secondary Radial Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
41369301|NCT03879824|PROCEDURE|Secondary Femoral Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
41369302|NCT02379442|BIOLOGICAL|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
41369303|NCT00313716|DRUG|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
41369304|NCT00313716|OTHER|placebo|an inactive substance
41369305|NCT04828746|PROCEDURE|Ultrasound Guided Skin Marking|Using ultrasound for skin marking pre-procedure
41369306|NCT01615965|OTHER|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
41369307|NCT00689728|BIOLOGICAL|LY2127399|LY2127399 will be administered as a single IV infusion over 30 minutes.
41369308|NCT00689728|DRUG|Placebo|Placebo will be administered as a single IV infusion over 30 minutes.
41369309|NCT01404104|DRUG|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
41369310|NCT04114227|BEHAVIORAL|Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)|Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
41369311|NCT04114227|BEHAVIORAL|Supportive Psychotherapy (Treatment as Usual Control)|Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
41369312|NCT00002021|DRUG|Foscarnet sodium|
41369313|NCT04037579|OTHER|Survey|Non-randomised survey
41369314|NCT02005302|DRUG|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
41369315|NCT02005302|DRUG|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
41369316|NCT02005302|DIETARY_SUPPLEMENT|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
41369317|NCT02005302|DIETARY_SUPPLEMENT|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
41369318|NCT02679716|OTHER|MRI of the cerebral arteries|MRI of the cerebral arteries is performed
41369319|NCT01300715|PROCEDURE|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
41369320|NCT04718792|DRUG|Psilocybin|A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)
41369321|NCT00107666|DRUG|CTI-01 (ethyl pyruvate)|
41369322|NCT00386191|DRUG|clopidogrel (SR25990C)|oral administration
41369323|NCT04398160|OTHER|HVLA C3/C4 manipulation|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical. This procedure will increase the tension of the soft tissues to reduce the remaining slack and, finally, the thrust will be applied in pure rotation. Subsequently the head of the volunteer will be repositioned in the neutral position without applying any pressure and will wait 10 seconds in this position. Finally, the previous procedure will be repeated to the opposite side.
41369324|NCT04398160|OTHER|Sham technique|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical until the perception of tissue tension at the point of contact, holding this position for 10 seconds. The investigator then repositions the head of the volunteer in the neutral position without applying pressure, holding again this position for 10 seconds. Finally, the previous procedure will be repeated for the opposite side.
41502766|NCT01741883|BEHAVIORAL|Side effect prevention training (SEPT)|SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
41036663|NCT02585895|PROCEDURE|Low-density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants received apheresis for LDL-C according the their physician's prescription and local custom.
41369325|NCT01712529|BEHAVIORAL|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
41162318|NCT02600585|BIOLOGICAL|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
41369326|NCT01062230|DRUG|Bortezomib (Velcade)|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles."
41502767|NCT01741883|BEHAVIORAL|Attention Control group (ACG)|Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
41502768|NCT01728129|DEVICE|DANA Rapid|The DANA Rapid is a neurocognitive test self-administered on a small handheld computer. The DANA Rapid subtests measure simple reaction time, procedural reaction time, and reaction time sensitivity.
41502769|NCT01728129|OTHER|MACE|The MACE is currently the only standardized and Department of Defense-designated method for the initial evaluation of suspected concussion in military operational settings. The MACE documents the history of the injury-causing incident; assesses cognitive deficits in orientation, immediate memory, concentration, and delayed recalls; and involves a neurological screening by a clinician.
41369327|NCT04795674|BEHAVIORAL|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
41369328|NCT04795674|BEHAVIORAL|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
41369329|NCT02029729|DRUG|omaveloxolone|
41369330|NCT04888780|OTHER|The web-based Watson's Human Care Theory oriented training|Video calls were held every 15 days via the skype program with complete adherence to the schedule. In these interviews, the clinical picture of diabetes and the psychosocial status of adolescents were discussed. A total of 14 interviews with 15-day intervals were made with each adolescent. All video interviews were carried out by the first researcher and they were all recorded.
41369331|NCT03378882|BIOLOGICAL|Parasitic serologies|"Suspected angiostrongylosis - Angiostrongylus cantonensis:~* An aliquot of CSF and an aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies.~* A CSF aliquot will be sent to the CDC for PCR.~Suspected angiostrongylosis- Angiostrongylus costaricensis:~- An aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies."
41502770|NCT06214806|BEHAVIORAL|Grocery Vouchers|Participants will be given vouchers to buy groceries each month for five months.
41162319|NCT02600585|BIOLOGICAL|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
41369332|NCT03378882|PROCEDURE|Biopsy|"Suspected angiostrongylosis - Angiostrongylus costaricensis:~- A piece of biopsy or intestinal resection will be sent to the pathology laboratory for parasitic elements suggestive of Angiostrongylus costaricensis infection"
41369333|NCT00139269|DRUG|Docetaxel|
41369334|NCT00139269|DRUG|Cisplatin|
41162320|NCT03315910|BEHAVIORAL|Motivational Interviewing (MI)|two counseling sessions
41162321|NCT03315910|DRUG|Nicotine Replacement Therapy (NRT)|receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day
41369335|NCT00139269|DRUG|5-Fluorouracil|
41369336|NCT03841591|DRUG|Insulin|Women with GDM will receive insulin and tailored according to their blood glucose levels to achieve glycemic control. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
41369337|NCT03841591|DRUG|Metformin|Women with GDM will receive metformin and tailored according to their blood glucose levels to achieve glycemic control. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
41369338|NCT03841591|OTHER|Assessment of weight gain|Body weight will be measured monthly from the start of treatment till delivery.
41369339|NCT03386630|DRUG|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
41502771|NCT06633380|BEHAVIORAL|Standard Physical Activity - Fasted|30 minutes of walking at a self-selected pace that they must have completed 15 minutes prior to consumption of first meal in the morning.
41502772|NCT06633380|BEHAVIORAL|Standard Physical Activity - Post-Meal|30 minutes of walking at a self-selected pace to start 30 minutes after the start of the first meal in the morning.
41162322|NCT03315910|DRUG|Nicotine Lozenge|6 packs of NRT 2mg lozenge
41162323|NCT03315910|BEHAVIORAL|Message Framing|health communication literature and quitting messages
41162324|NCT03315910|OTHER|saliva sample|saliva samples from those reporting abstinence and analyze samples
41162325|NCT05404698|OTHER|Aerobic exercise|EX: 30 min of aerobic exercise (3/10 Borg scale) during hemodialysis treatment (between 30 min and 3h of treatment).
41162326|NCT05404698|OTHER|Control|CONT: participants will receive hemodialysis treatment only (usual care)
41162327|NCT00115947|DRUG|Terlipressin|
41162328|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
40846955|NCT05453045|DRUG|Albendazole|tablet administration after a meal contaning approximate 15 g of fat
41029933|NCT02576574|DRUG|Carboplatin|Carboplatin AUC 6 mg/mL\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
41029934|NCT02576574|DRUG|Avelumab Weekly|Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
41369340|NCT03386630|DRUG|Hyperbaric bupivacaine+Morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
41369341|NCT05697276|DRUG|Lidocaine|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
41369342|NCT05697276|DRUG|Bupivacain|Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
41369343|NCT00603824|DRUG|fondaparinux|fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if \>100 kg
41369344|NCT00603824|DRUG|argatroban or lepirudin|continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
41369345|NCT03107741|OTHER|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
41369346|NCT03107741|OTHER|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
41369347|NCT01283061|DRUG|Zafirlukast|Zafirlukast tablets 20 mg
41369348|NCT03522285|OTHER|investigation: erythrocyte sedimentation rate|investigations will be done to detect presence of infection and x-ray also for detection of infection or loosing of hip components
41369349|NCT05804669|DRUG|CRN04894|CRN04894 is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
41369350|NCT05921942|DRUG|Metformin|500 mg twice daily or 1000 mg once daily
41369351|NCT02427334|DRUG|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
41369352|NCT02427334|DRUG|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
41369353|NCT02427334|DRUG|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
41029935|NCT03783169|OTHER|Cardiovascular Sonographic Assessment|Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, \& radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)
41369354|NCT01984840|DEVICE|Telemedicine|
41369355|NCT01388946|DRUG|Ropivacaine 0.75|
41369356|NCT01388946|DRUG|Normal saline|
41369357|NCT04230746|DRUG|Bactrim DS 800Mg-160Mg Tablet|To study effect on urinary microbiome
41369358|NCT04230746|DRUG|Placebo oral tablet|To study effect on urinary microbiome
41369359|NCT02357017|DIETARY_SUPPLEMENT|NaCl tablets|
41369360|NCT06176222|DRUG|PRECEDEX INJ★ 2ML|patient received PRECEDEX INJ★ 2ML 0.1\~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
41369361|NCT06176222|DRUG|Normal saline|patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
41369362|NCT00405925|DRUG|Trizivir|
41369363|NCT00405925|DRUG|zidovudine,lamivudine,abacavir|zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
41369364|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
41502773|NCT06633380|BEHAVIORAL|Dispersed Physical Activity|10 minutes of walking at a self-selected pace to start 30 minutes after the start of each main meal throughout the day (i.e., three bouts total).
41369365|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
41369366|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
41369367|NCT01065077|DRUG|Placebo|Infusion of placebo during 48h
41369368|NCT04028739|DIETARY_SUPPLEMENT|curmin|curcumin 90mg/day cross-over
41369369|NCT00663208|DRUG|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
41369370|NCT00663208|DRUG|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
41369371|NCT02163759|DRUG|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
41369372|NCT02163759|OTHER|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
41502774|NCT06633380|BEHAVIORAL|Physical Activity Snacks|2 minutes of walking or marching on the spot at a self-selected pace every 30 minutes throughout the day for 7.5 waking hours.
41502775|NCT06633380|BEHAVIORAL|Muscle Strengthening|30 minutes of muscle strengthening exercises targeting the major muscle groups of the whole body, to start 30 minutes after the start of the first meal in the morning.
41029936|NCT01774903|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
41029937|NCT04579263|OTHER|Fecal microbiota|Transplantation of fecal microbiota of healthy donor with normal body mass index
41029938|NCT03877367|OTHER|Upper extremity manipulation|An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.
41029939|NCT05284994|DRUG|TQ-B3525 Tablets, Osimertinib Mesylate Tablets|TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
41502776|NCT03417687|DRUG|129Xe MRI|Evaluation of pulmonary function
41369373|NCT02163759|DRUG|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
41029940|NCT01649284|DRUG|afatinib|40, 30, and 20 mg film-coated tablets
41369374|NCT02163759|OTHER|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
41369375|NCT01493154|BIOLOGICAL|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
41369376|NCT01493154|DRUG|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
41369377|NCT02990273|BIOLOGICAL|Blood transfusion|
41369378|NCT03593109|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
41369379|NCT02854865|OTHER|echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
41369380|NCT04785300|DRUG|Dasatinib|100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles
41369381|NCT04785300|DRUG|Quercetin|Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles
41369382|NCT03613974|DRUG|Lidocaine|patients will receive different lidocaine concentrations
41369383|NCT03991520|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
41369384|NCT03991520|DRUG|Placebo|The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
41369385|NCT00633334|OTHER|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
41369386|NCT06401382|DEVICE|A modified aligner appliance with NiTi springs|The modified aligner appliance will be used until the final position is achieved.
41369387|NCT06401382|DEVICE|Conventional fixed appliances|The traditional fixed appliances with a standard prescription will be used.
41369388|NCT02543918|DRUG|Ixekizumab|Administered by SQ injection
41369389|NCT02543918|DRUG|Boostrix®|Administered by IM injection
41029941|NCT01568047|DRUG|Placebo|once-daily
41369390|NCT02543918|DRUG|Pneumovax®23|Administered by IM injection
41369391|NCT05664438|DIAGNOSTIC_TEST|MRI scan|MRI scan of cervical spine
41029942|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 5 mg single-dose
41369392|NCT04057586|PROCEDURE|Nonintubated|During surgery, patient is deeply sedated and respiration is maintained by spontaneous breath under the nasal high flow oxygen support.
41369393|NCT04057586|PROCEDURE|Intubated|During surgery, patient received standard general anesthesia and respiration is maintained by using mechanical ventilation.
41369394|NCT06089265|DRUG|PF-06801591|Active ketohexokinase inhibitor
41369395|NCT02094066|DRUG|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
41369396|NCT02094066|DRUG|serum physiologic|preoperative 100 cc ıv serum physiologic
41502777|NCT03417687|DRUG|133 Xe scintigraphy|Evaluation of pulmonary function
41502778|NCT06385275|DRUG|Vitamin K1 500 µg|One pill daily for 4 weeks.
41502779|NCT06385275|DRUG|K1 1000 µg|One pill daily for 4 weeks.
41502780|NCT06385275|DRUG|Vitamin K2 (MK-7) 300 µg|One pill daily for 4 weeks.
41502781|NCT06385275|OTHER|Placebo|Placebo pill daily for 4 weeks.
41502782|NCT05579366|DRUG|PRO1184|Intravenous infusion of PRO1184
41029943|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 15 mg single-dose
41029944|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 30 mg single-dose
41029945|NCT01568047|DRUG|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
41029946|NCT01568047|DRUG|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
41029947|NCT02012374|BEHAVIORAL|Intensive Language Action Therapy|
41029948|NCT02139501|DRUG|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
41029949|NCT04492046|OTHER|Manual Lymph Drainage|Manual lymph drainage is an effective therapeutic method used in the conservative treatment of lipedema. The application was performed on both lower extremities for 45 minutes.
41369397|NCT04001166|OTHER|Non-interventional study|This is a non-interventional study. Patients will be treated with any treatment deemed appropriate by the patient's physician.
41369398|NCT01966029|DRUG|BMN 110|All pateints receive treatment with BMN 110
41369399|NCT05669378|BEHAVIORAL|Appetite to Play +|In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.
41369400|NCT05011669|DRUG|Lurasidone|Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.
41162329|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
41369401|NCT01429194|PROCEDURE|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
41369402|NCT02841332|DRUG|F-MISO|"The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic."
41369403|NCT02841332|OTHER|Cerebral magnetic resonance imagery|"During the pre-therapeutic imagery session :~* Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~* magnetic resonance imagery spectroscopy sequence~* Perfusion magnetic resonance imagery sequence~* Diffusion magnetic resonance imagery sequence"
41369404|NCT02841332|DRUG|Bevacizumab|Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
41369405|NCT02841332|OTHER|Clinical examination|"During the examination, the following parameters will be checked :~* Neurological examination~* Corticotherapy prescribed~* General status of patient (world health organization score)~* Weight and height~* Control of arterial pressure~* Chirurgical and medical history~* Concomitant treatment"
41369406|NCT06188351|DEVICE|Three-Dimensional Navigation Atrial Septal Puncture|Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit
41369407|NCT06188351|DEVICE|Conventional Atrial Septal Puncture|Atrial septal puncture will be performed using traditioanl two-dimensional atrial septal puncture kit using traditional method.
41369408|NCT02454387|DRUG|ONO-4474 Part A1|Healthy volunteers
41369409|NCT02454387|DRUG|Placebo Part A1|Healthy volunteers
41369410|NCT02454387|DRUG|ONO-4474 Part A2|Healthy volunteers
41369411|NCT02454387|DRUG|Placebo Part A2|Healthy volunteers
41369412|NCT02454387|DRUG|ONO-4474 Part B|Healthy volunteers
41369413|NCT02454387|DRUG|Placebo Part B|Healthy volunteers
41369414|NCT02454387|DRUG|ONO-4474 Part C|Healthy volunteers
41369415|NCT02454387|DRUG|Placebo Part C|Healthy volunteers
41369416|NCT02454387|DRUG|ONO-4474 Part D|Healthy volunteers
41369417|NCT02454387|DRUG|Placebo Part D|Healthy volunteers
41369418|NCT05821998|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
41369419|NCT05821998|OTHER|Designed chest physical therapy program|Percussion, vibration and modified postural drainage
41369420|NCT02551601|OTHER|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
41369421|NCT05327517|PROCEDURE|Esophagectomy|Patients receive esophagectomy or definitive chemoradiotherapy according to patient preference
41369422|NCT00158002|DRUG|Topiramate|
41369423|NCT04167449|DIETARY_SUPPLEMENT|HRG80 Hydroponic Red Ginseng|Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
41369424|NCT04167449|DIETARY_SUPPLEMENT|Conventional White Ginseng|Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
41369425|NCT04167449|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule containing rice flour
41369426|NCT00001422|DRUG|fludarabine|
41369427|NCT03333564|DIETARY_SUPPLEMENT|VD3|50,000 IU VD3 / week for 8 weeks
41369428|NCT03333564|DIETARY_SUPPLEMENT|Omega3-FA|300 mg of omega3-FA once daily for 8 weeks
41369429|NCT03333564|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
41369430|NCT03333564|OTHER|Control|No intervention was given
41036664|NCT01516047|DRUG|Cohort 1|125 mg to 2000 mg abiraterone acetate suspension on Day 1
41369431|NCT00994045|BIOLOGICAL|Fibrinogen concentrate|Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
41369432|NCT00994045|BIOLOGICAL|Fresh Frozen Plasma|
41036665|NCT01516047|DRUG|Cohort 2|2000 mg abiraterone acetate suspension on Day 1
41369433|NCT03247608|BEHAVIORAL|Ambio Health Remote Monitoring|Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
41369434|NCT00283621|DRUG|Aranesp (darbepoetin alfa)|
41029950|NCT04492046|OTHER|Bandaging|Multilayered compression bandaging techniques have an assisting role in the further reduction of the volume of the limb and enhance the continuous pump mechanism via the active involvement of muscle pumps. All patients received bandages following Manual lymph drainage application.
41369435|NCT00283621|DRUG|Neulasta (pegfilgrastim)|
41369436|NCT00283621|DRUG|Adriamycin|
41369437|NCT00283621|DRUG|Ifosfamide|
41369438|NCT00638820|PROCEDURE|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
41369439|NCT00638820|DRUG|Campath, Busulfan, Clofarabine|"* 12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~* 11 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 10 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 9 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 8 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 7 Rest~* 6 Clofarabine 40 mg/m2 intravenously over 2 hours~* 5 Clofarabine 40 mg/m2 intravenously over 2 hours~* 4 Clofarabine 40 mg/m2 intravenously over 2 hours~* 3 Clofarabine 40 mg/m2 intravenously over 2 hours~* 2 Clofarabine 40 mg/m2 intravenously over 2 hours"
41369440|NCT00638820|PROCEDURE|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
41369441|NCT06006026|DRUG|Ropivacaine Hydrochloride 10 MG/ML [Naropin]|According to the specified dosage, dilute 1% ropivacaine to 0.2% and inject 1/2 of the total amount on each side.
41369442|NCT04085354|DRUG|Multi-Vitamin Tablets|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
41369443|NCT04085354|DRUG|Dapoxetine|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
41369444|NCT04085354|DRUG|Dapoxetine and folic acid.|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
41369445|NCT04085354|DRUG|Dapoxetine and vitamin B12|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
41369446|NCT01245829|OTHER|Swabbing of observation chart|The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
41369447|NCT00547404|DRUG|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
40846956|NCT06303895|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
41369448|NCT06091826|DRUG|NFL-101|Subcutaneous injections
41369449|NCT06091826|DRUG|Placebo|Subcutaneous injections
41369450|NCT02991911|BIOLOGICAL|MEDI3726 Post-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting
41369451|NCT02991911|BIOLOGICAL|MEDI3726 Pre-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting
41029951|NCT02185352|DRUG|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
41029952|NCT00208429|DEVICE|Pinnacle Acetabular System|
41369452|NCT02991911|BIOLOGICAL|MEDI3726 & Enzalutamide Combo|MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
41369453|NCT03907111|DEVICE|Chitosan Gauze|Gauze made by chitosan material
41029953|NCT02756624|DRUG|AC-170 0.24%|
41029954|NCT02756624|DRUG|AC-170 Vehicle|
41369454|NCT03907111|DEVICE|placebo|traditional gauze
41369455|NCT05347173|DRUG|Dexmedetomidine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)
41029955|NCT05764746|DRUG|Artemether-lumefantrine and Amodiaquine Drug Combination|AL and AQ will be given together for three days then followed by placebo for three days
41029956|NCT05764746|DRUG|Artemether-lumefantrine then Artesunate amodiaquine|AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days
40846957|NCT06303895|BEHAVIORAL|Swallowing rehabilitation training|"Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced."
40846958|NCT06303895|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
40846959|NCT06583694|BEHAVIORAL|Health promotion campaigns to correct the health problems|
40846960|NCT03802591|DRUG|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
41369456|NCT05347173|DRUG|Nalbuphine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)
41369457|NCT01229865|DRUG|VB-111|
41369458|NCT00031265|PROCEDURE|Family Intervention Telephone Tracking|
41369459|NCT01661426|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
41369460|NCT01661426|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
41369461|NCT06298721|BEHAVIORAL|Personalized outcome prediction tool + targeted interventions|"* TKA Personalized Outcome Prediction Tool to aid in setting expectations~* Mental Health Screening/Intervention~* Physical Therapy Pre-surgery Assessments \& Rehabilitation"
41369462|NCT06298721|BEHAVIORAL|Standard of Care TKA|- Standard of care preoperative TKA clinic appointment to discuss plan for surgery and get consent
41502783|NCT05579366|DRUG|PRO1184 intravenous infusion of PRO1184|Carboplatin intravenous infusion
41502784|NCT05579366|DRUG|PRO1184 intravenous infusion of PRO1184|Bevacizumab intravenous infusion
41162330|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
41369463|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
41369464|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
41369465|NCT00981331|PROCEDURE|Subtalar joint manipulation|The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
41369466|NCT00981331|PROCEDURE|Sham subtalar joint manipulation|The sham manipulation is conducted by placing the ankle in a non-manipulative position, and the operator simply engages the toggle board to simulate the audible noise of the toggle board dropping. No force or thrust is applied to the ankle.
41369467|NCT03392922|DEVICE|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery.
41369468|NCT03392922|DEVICE|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
41369469|NCT04983927|DEVICE|cASPECTS|Clinical decision support system for scoring ASPECTS score
41369470|NCT02763410|OTHER|PRBC transfusion|
41369471|NCT00524901|DRUG|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
41369472|NCT00524901|DRUG|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
41369473|NCT05901766|DIETARY_SUPPLEMENT|UNIMAP Multiple Micronutrient Supplement|Iodine Containing Multiple Micronutrient Supplement once daily
41369474|NCT02999516|OTHER|Motor imaginary|Participants imagine doing a motor task watching a video recording
41502785|NCT05579366|DRUG|PRO1184 intravenous infusion of PRO1184|Pembrolizumab intravenous infusion
41502786|NCT02942641|PROCEDURE|Indwelling urethral catheterization (Foley)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received indwelling urethral catheter as the intervention."
41502787|NCT02942641|PROCEDURE|Clean intermittent catheterization (CIC)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received CIC as the intervention."
41502788|NCT02942641|DEVICE|Foley|
41502789|NCT05304247|OTHER|questionnaire and clinical examination|Prevalence and Risk Factors of Black Tooth Stains and Their Relation With Caries Experience in Primary Teeth of A Group of Preschool Children
41369475|NCT02999516|OTHER|Non Motor imaginary|Participants watch a television documentary
41369476|NCT02999516|OTHER|tDCS|transcranial direct current stimulation (tDCS) stimulation during 20 minutes in the motor cortex (bilaterally) at 1mA of intensity.
40846961|NCT03802591|DRUG|CS1001 placebo|Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
40846962|NCT03802591|DRUG|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
40846963|NCT03802591|DRUG|Capecitabine|Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
40846964|NCT06350305|OTHER|questionnaire survey|subjects fill out questionnaires
41369477|NCT02999516|OTHER|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex (bilaterally) at 1mA of intensity and then 19 minutes and 30 seconds without any stimulation.
41502790|NCT01893346|DRUG|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
40846965|NCT03101085|DRUG|S-equol and Placebo|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
40846966|NCT03101085|DRUG|Placebo and S-equol|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
41029957|NCT05764746|DRUG|Artemether-lumefantrine|This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
41029958|NCT01405157|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
41029959|NCT01405157|DRUG|methylprednisolone|tablets 16 mg single dose
41029960|NCT04862143|DRUG|Alpelisib|Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.
41029961|NCT04862143|DRUG|Fulvestrant|Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.
41029962|NCT04862143|DRUG|Goserelin|Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.
41029963|NCT04733560|PROCEDURE|Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml 0.25% Bupivacaine prior to making any surgical incisions.
41369478|NCT02999516|OTHER|Neurofeedback|EEG monitoring of the cerebral cortex in real time with positive feedback in the computer screen when participants motor cortex is activated. The positive feedback consist in an object that moves to the top of the screen when activation occurs in the motor cortex. This task last during 20 minutes.
41369479|NCT02999516|OTHER|Neurofeedback sham|EEG monitoring of the cerebral cortex in real time with randomized feedback in the computer screen despite motor cortex activation. The positive feedback consist in an object that moves to the top of the screen in a randomized time. This task last during 20 minutes.
40846967|NCT04348006|DRUG|Bortezomib 3.5 MG|"VCD protocol~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)~* D, Dexamethasone oral: 40mg (days 1 to 4)~VRD protocol:~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* R, Lenalid® cap 25 mg po (day 1 to 21)~* D, Dexamethasone oral: 40mg (days 1 to 4)"
40846968|NCT01088022|DRUG|Aprepitant, Palonosetron, Dexamethasone|Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
41502791|NCT02591186|PROCEDURE|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
41502792|NCT06633471|DRUG|Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).|Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
41029964|NCT04733560|PROCEDURE|Sham Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml Normal Saline prior to making any surgical incisions.
41029965|NCT04733560|DRUG|Bupivacaine Injectable Product|Used for pudendal nerve block in the intervention arm
41029966|NCT01168817|DRUG|BAY60-4552 plus Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
41029967|NCT01168817|DRUG|Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
41029968|NCT01168817|DRUG|Placebo|Treatment with 3 tablets once daily for 4 weeks (Placebo)
41029969|NCT01044810|DRUG|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
41029970|NCT01311102|DRUG|Lidocaine|1.33 cc 2% liquid lidocaine
41029971|NCT01311102|DRUG|Normal Saline|1.33cc normal saline
41502793|NCT00308880|DRUG|Transamin|
40846969|NCT01088022|DRUG|Placebo, Palonosetron, Dexamethasone|Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
40846970|NCT05238805|RADIATION|Observational heart and kidney on siemens TEP scan|Same as arm description
41029972|NCT02332031|DRUG|Sorafenib (Nexavar, BAY43-9006)|Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
41029973|NCT02332031|DRUG|Levothyroxine|Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
41029974|NCT03217045|OTHER|nutrition protocol introduction|Growth comparison of 2 cohorts of infants evaluated in a before-after design
41029975|NCT04445818|BEHAVIORAL|More appreciation|
41029976|NCT04445818|BEHAVIORAL|Less criticism|
41029977|NCT04445818|BEHAVIORAL|More Fruit and Vegetable|
41029978|NCT02626559|DRUG|liposomal bupivacaine/plain bupivacaine peri-articular injection|Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
41029979|NCT04643444|DIAGNOSTIC_TEST|Blood sampling|Testing for the presence of SARS-CoV-2 antibodies
41029980|NCT04643444|OTHER|Online Questionnaire|Questions on working place, risk profiles and PPE
41029981|NCT05902715|DEVICE|oral implant placement with socket shield technique|tooth is split in socket shield configuration, implant is immediately placed
41029982|NCT04191057|DEVICE|Free light chains|Blood samples will be collected and analyzed
41029983|NCT04287933|DEVICE|Drain insertion|insertion of a drain
41029984|NCT01107574|DRUG|Gabapentin|Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
41029985|NCT01107574|PROCEDURE|Osteopathic Manipulative Medicine|Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
41029986|NCT01107574|OTHER|Gabapentin and Osteopathic Manipulative Medicine|Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
41029987|NCT02873611|DEVICE|MRI|patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
41502794|NCT03513055|OTHER|nurse inject premixed insulin|nurse inject premixed insulin，coaching in the injection technique
40846971|NCT05151757|OTHER|A standard image training set|The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma. Training is done in 3 modules.
40846972|NCT01303926|DRUG|cisplatin pemetrexed|Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
40846973|NCT01303926|DRUG|carboplatin paclitaxel bevacizumab|Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
40846974|NCT01670773|DRUG|CAT-1004|
40846975|NCT01670773|DRUG|Salsalate + DHA|
41029988|NCT02873611|PROCEDURE|genicular ablation procedure|
41029989|NCT06069492|OTHER|Wheat-containing food|One daily serving of 38 grams wheat-containing pasta contains either 5000 mg wheat protein (standard-dose group) or 650 mg wheat protein and 4350 gluten-free flour (low-dose group)
41369480|NCT01842412|BEHAVIORAL|exercise|one bout of exercise training
41369481|NCT02980211|DRUG|Alveolar Ridge Reconstruction|Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
40846976|NCT01670773|DRUG|Placebo|
40846977|NCT03975569|OTHER|Probiotic vaginal gel|Total daily administration of 2.5 ml of probiotic gel, containing three lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus pentosus KCA1 and Lactobacillus plantarum WCFS1). Final dosage per gram of gel: 10\^9-10\^10 colony forming units of lactobacilli.
40846978|NCT04522479|OTHER|Change the injection time of long acting GnRH-a|The whole dose of long acting GnRH-a drug was changed to be injected on day 21st-23rd day of menstruation
40846979|NCT03247959|BEHAVIORAL|Video game distraction and video distraction|video game distraction and video distraction will be advocated during the extraction procedure
40846980|NCT02918357|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
41029990|NCT02378142|DRUG|Pazopanib|
41029991|NCT03722160|DEVICE|Solo TympanostomyTube Device|The Solo Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
41029992|NCT00044382|DRUG|CC-5013|
41029993|NCT04703881|DIETARY_SUPPLEMENT|AYMES ActaGain|AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.
41029994|NCT01371318|OTHER|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
41029995|NCT02604784|DRUG|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Standard dosage of drugs for each PIPAC: Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m²) or Oxaliplatin (92 mg/m²) The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.
41369482|NCT00243620|DEVICE|Vacuum therapy (device)|
41369483|NCT04712968|BEHAVIORAL|Regular exposure to morning daylight|"Participants are asked to stay outside in morning daylight for minimum 30 minutes each day before 1 pm for 6 weeks. A specific plan for individual outdoor possibilities for daylight exposure is made (e.g. a walk, a stay in a park or in their garden, a bike trip). Furthermore a detailed instruction to the personal light tracker LYS Button and the matching LYS Insight app is provided. The LYS Insight app gives the user access to real-time insight of light stimulus. Further, the participants receive psycho-education on the connection between exposure to morning daylight and antidepressant effect. All participants in this group receive the intervention as add-on to usual treatment, which may comprise prescribed antidepressants, psychotherapy, including psycho-education and psychiatric care."
41369484|NCT00320073|DRUG|erlotinib hydrochloride|75 mg to 150mg
41369485|NCT00320073|DRUG|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
40846981|NCT00995657|DRUG|Fluticasone Propionate|Inhaled Fluticasone Propionate 50mcg bid
40846982|NCT00995657|DRUG|Fluticasone Propionate|Inhaled Fluticasone Propionate 250mcg bid
40846983|NCT02986854|BIOLOGICAL|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
40846984|NCT03036189|BEHAVIORAL|baa nnilah|7 meetings in the community led by a trained community facilitator
40846985|NCT06549530|DRUG|MVA-BN|All participants will receive 2 vaccinations of the same dose of MVA-BN vaccine 4 weeks apart (standard regimen).
40846986|NCT06527534|DRUG|Filgotinib|Patients will receive pills of Filgotinib 200 mg qd for 12 weeks
40846987|NCT06527534|DRUG|Adalimumab|Patients will receive subcutaneous injections of Adalimumab 40 mg q2wk for 12 weeks
40846988|NCT00767767|DRUG|Placebos|IV Saline infusion for 2 hours.
40846989|NCT00767767|DRUG|Propofol 0.45mcg/mL|IV Propofol infusion for 2 hours.
40846990|NCT00767767|DRUG|Propofol 0.90mcg/mL|IV Propofol infusion for 2 hours.
41369486|NCT00320073|DRUG|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
41369487|NCT00763126|BEHAVIORAL|stress level|Stress levels
41369488|NCT00900328|OTHER|laboratory biomarker analysis|Correlative Studies
40846991|NCT00767767|DRUG|Thiopental 1.5mcg/mL|IV Thiopental 1.5mcg/mL infusion for 2 hours
40846992|NCT00767767|DRUG|Thiopental 3mcg/mL|IV Thiopental 3mcg/mL infusion for 2 hours
41029996|NCT02604784|DRUG|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Escalating dosage of drugs for PIPAC: Cisplatin + Doxorubicin (from 15 mg/m² + 3 mg/m² to 100 mg/m² + 30 mg/m²) or Oxaliplatin (from 92 mg/m² to 300mg/m²).The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters.
40846993|NCT00360724|DRUG|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
40846994|NCT06099834|OTHER|Patients selection|Patient selection were selected according to selected criteria.
40846995|NCT06099834|OTHER|Implnat placement|dental implants were applied as recommended by the manufacturer.
40846996|NCT06099834|OTHER|Recall visits|Following the operations, the stability of the dental implants was measured at the 1st (T1), 4th (T4), and 12th (T12) weeks using Periotest (Periotest M, Modautal/Germany) and Osstell (Osstell AB-W\&H, Sweden) devices.
41029997|NCT05197959|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
41029998|NCT05197959|OTHER|Sensorimotor training|Sensorimotor training is a non-invasive, non-painful procedure using nerve stimulation to cue motor action. Nerve stimulation is applied the second through the fifth digit and the median nerve at the wrist. This stimulation is used to cue a motor action. The number of stimulations will indicate the amount of movements. For example, two pulses of stimulations to the index finger would require two flexion and extension actions with the index finger. Once the stimulation occurs, the participant will flex and extend the corresponding area where the nerve stimulation was felt. This will take \~ 30 minutes to complete.
40846997|NCT02828332|OTHER|Vineland II (VABS -II)|semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
40846998|NCT02828332|OTHER|Quality of life|Evaluation of the quality of life and comorbidities
41029999|NCT04231630|OTHER|Prolacta|Will receive outpatient supplementation with donor human milk product added to mother's own milk
40846999|NCT05781321|RADIATION|Accelerated Hypofractionated Radiation Therapy|Undergo short course RT
40847000|NCT05781321|PROCEDURE|Computed Tomography|Undergo CT simulation
40847001|NCT05781321|DRUG|Fluorodopa F 18|Given IV
40847002|NCT05781321|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40847003|NCT05781321|PROCEDURE|Positron Emission Tomography|Undergo PET
41030000|NCT04941300|OTHER|Mailed FIT Outreach|We will mail an introductory letter to eligible individuals describing the importance of CRC screening and noting that follow-up mail will include a FIT Kit. Two weeks later they will receive a packet via mail containing the FIT kit, a one-page invitation inviting FIT completion and FIT instructions, COVID-19 messaging, and a postage-paid envelope for return.
41369489|NCT04959266|DRUG|Adavosertib|Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
40847004|NCT05781321|OTHER|Quality-of-Life Assessment|Ancillary studies
40847005|NCT05781321|OTHER|Questionnaire Administration|Complete questionnaires
40847006|NCT05781321|RADIATION|Radiation Therapy|Undergo standard course RT
40847007|NCT05781321|DRUG|Temozolomide|Given PO
40847008|NCT05781321|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40847009|NCT03633812|OTHER|Observational study, Beta blocker medication history|Observational study, Beta blocker medication history
40847010|NCT04684953|PROCEDURE|Throid autotransplantation|Operative
40847011|NCT04684953|DRUG|Hormone|thyroid hormone replacement therapy
40847012|NCT06584305|PROCEDURE|AI-Powered Body Dysmorphic Disorder Screening Procedure|The AI-Powered Body Dysmorphic Disorder Screening Procedure involves using an AI tool to evaluate patients for Body Dysmorphic Disorder (BDD) before undergoing elective cosmetic surgery. The screening integrates the Body Dysmorphic Disorder Questionnaire (BDDQ) with additional psychological assessments. The AI system processes the collected data to produce a risk score, guiding surgeons in making informed decisions about the need for psychological evaluation or intervention, and determining the suitability of patients for surgery.
40847013|NCT00597415|DRUG|celecoxib|celecoxib 200mg
40847014|NCT00597415|DRUG|placebo|placebo
40847015|NCT02617654|DRUG|Liraglutide|Treatment with liraglutide for 52 weeks
40847016|NCT02617654|DRUG|Placebo for liraglutide|Placebo for liraglutide. Treatment once daily for 52 weeks
40847017|NCT03723109|PROCEDURE|Induction of anesthesia|Standardized TCI and RSI anesthesia induction
40847018|NCT04911972|PROCEDURE|Functional muscle transfer|Muscle transfer to restore lower limb function
40847019|NCT03841370|PROCEDURE|endodontic treatment|Color measurements of endodontically treated teeth (incisors, canines or premolar) will be collected regardless of technique, treatment time and sealer used.
40847020|NCT01078168|DRUG|Acitretin|30mg per day from Day 1 to Day 28
40847021|NCT01078168|DRUG|Placebo|Placebo
40847022|NCT03706183|DIAGNOSTIC_TEST|Ischemia-modified albumin|The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.
40847023|NCT03706183|DIAGNOSTIC_TEST|Hearing thresholds|The hearing levels will be determined for each group.
40847024|NCT03221309|OTHER|Evaluate model of care for HCV-infected adults with on-going opioid misuse|Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
41162331|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
41369490|NCT04959266|DRUG|Itraconazole|Patients will receive Itraconazole orally once daily for 7 days in arm A.
41369491|NCT04959266|DRUG|Rifampicin|Patients will receive Rifampicin orally once daily for 13 days in arm B.
41369492|NCT04959266|DRUG|Omeprazole|Patients will receive Omeprazole orally once daily for 5 days in arm C.
41162332|NCT00123435|DEVICE|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
41369493|NCT02992743|DRUG|letetresgene autoleucel (GSK3377794)|Letetresgene autoleucel (GSK3377794) as an IV infusion.
41369494|NCT02992743|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
41369495|NCT02992743|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
41369496|NCT05294627|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 test prior to prostate biopsy. Prostate biopsy is preformed irrespective of the Stockholm3 score.
41030001|NCT04941300|OTHER|Standardized navigation|"The standardized navigation includes, but is not limited to, the following key components:~1. Identification of individuals with abnormal FIT~2. Results review and colonoscopy order by provider~3. Results reporting to patient~4. Insurance approval for colonoscopy~5. Colonoscopy scheduling~6. Bowel preparation \& colonoscopy completion~7. Colonoscopy results provided to patient and CHC~8. Referral-to-Care for patients with CRC (if necessary)"
41030002|NCT05449639|DEVICE|Relief implantation|The device will be implanted by endoscopic procedure by a standard resectoscope.
41030003|NCT02501304|DEVICE|ReVENT Sleep Apnea System|The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
41369497|NCT04111224|DIAGNOSTIC_TEST|pentraxin 3 marker|Assess the role of pentraxin3 (PTX3) in the early diagnosis of ventilator-associated pneumonia (VAP).
41369498|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 5μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
41369499|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 20μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
41369500|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 40μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
41369501|NCT02067065|DRUG|Non-anesthesiologist propofol sedation|Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
41369502|NCT02067065|DRUG|Propofol sedation administered by an anesthesiologist|Propofol sedation by an anesthesiologist
41369503|NCT02067065|PROCEDURE|Colonoscopy|Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
41502795|NCT05371613|DRUG|tividenofusp alfa|Intravenous repeating dose
41030004|NCT04936412|DEVICE|Rehabilitation brace|Rehabilitation brace
41030005|NCT04772716|PROCEDURE|operation|The intervention was not decided by the investigator but studied following emergency or elective surgeries undergoing in the system
41030006|NCT02200822|DRUG|beta blockers|
41030007|NCT02200822|DRUG|RAAS blockers|RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
41030008|NCT06262529|OTHER|Cerebral MRI|Cerebral MRI at 72h / 3 months / 12 months
41162333|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
41369504|NCT01639846|DRUG|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
41369505|NCT01639846|DRUG|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
41369506|NCT02455960|DIETARY_SUPPLEMENT|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
41369507|NCT02455960|DIETARY_SUPPLEMENT|Placebo|
41369508|NCT06479317|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
41369509|NCT06479317|DRUG|Dexamethasone oral|Dexamethasone is given at 40mg every morning after meals for 4 consecutive days( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, dexamethasone is given 40mg every day for another consecutive 4 days).
41369510|NCT05069909|PROCEDURE|Denture Fabrication technique|Each patient received two sets of dentures fabricated using the two different techniques and their satisfaction and OHIP-EDENT were compared
41369511|NCT05850455|DRUG|Dexmedetomidine Hydrochloride 'Precedex' combined with|Dexmedetomidine Hydrochloride which is an Alfa 2 receptor agonist
41369512|NCT05850455|PROCEDURE|Lumbar epidural analgesia with Bupivacaine 0.25% 'Sunnypivacaine'|The epidural insertion point will be 2 segments upper than the surgical procedure level, 10 ml of Bupivacaine 0.25% will be injected in the epidural space to adjust the sensory level
41502796|NCT05371613|DRUG|idursulfase|Intravenous repeating dose
41502797|NCT04061525|PROCEDURE|Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration|Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
41369513|NCT05850455|PROCEDURE|General anesthesia|Propofol 2-3 mg/kg'Diprivan 1%', Fentanyl 'Fentanyl' 2 μg/kg, and Cisatracurium 'Cisatracure' 0.2 mg/kg will be administered to facilitate endotracheal intubation, and ventilation will be controlled to maintain the end-tidal carbon dioxide (CO2) between 32-38 mmHg, to maintain anesthesia, 2-3% Sevoflurane 'Sevoflurane', and 0.05 mg/kg of the muscle relaxant Cisatracurium will be added at 40-minute intervals according to the conditions of the operation. No other medication will be administered
41502798|NCT03255174|BIOLOGICAL|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
41502799|NCT00769873|DRUG|Enoxaparin|Lovenox 40mg SC daily (30mg SC daily if creatinine clearance \< 30) for 21 days
41502800|NCT06342115|DRUG|Ceftolozane-Tazobactam|In the intervention arm 3g of ceftolozane-tazobactam are given intravenously every 8 hours. Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.
41502801|NCT06342115|DRUG|Meropenem|The comparator arm consists of 2g of meropenem given intravenously every 8 hours.Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.
41502802|NCT05324410|DRUG|VX-840|Solution for oral administration.
41030009|NCT03373591|DRUG|Liposomal Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
41030010|NCT03373591|DRUG|Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
41030011|NCT05893654|DRUG|Melphalan Injection|7.5mg of melphalan injected via intra-arterial catheterization of the ophthalmic artery.
41030012|NCT05893654|RADIATION|Plaque brachytherapy|Brachytherapy will be performed using a 24-mm notched plaque with Ruthenium-106 seeds.
41030013|NCT00370162|DRUG|lactoserum|
41030014|NCT00001101|DRUG|ceftriaxone|
41030015|NCT00001101|DRUG|doxycycline|
41030016|NCT03522662|DRUG|GSK1070806|Single 10mg/kg infusion on Day 0
41030017|NCT01242527|DRUG|placebo|4 capsules (1g) daily for 12 weeks
41030018|NCT01242527|DRUG|omefas|2 capsules (1g) + 2 placebo daily for 12 weeks
41030019|NCT01242527|DRUG|omefas|3 capsules (1g) + 1 placebo daily for 12 weeks
41030020|NCT01242527|DRUG|omefas|4 capsules (1g)daily for 12 weeks
41030021|NCT02948179|PROCEDURE|Preimplantation Genetic Diagnosis|Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
41030022|NCT03411226|PROCEDURE|re-TREPP|repeated hernia repair via the TREPP technique
41030023|NCT05020483|DRUG|FEIBA|Administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously. Three small doses, 5 mg/kg each, will be available.
41030024|NCT05020483|DRUG|Placebo|Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.
41030025|NCT05651581|OTHER|Online module|online module including around 5 videos and several infographics covering the topics of symptoms transmission, prevention, vaccination, and treatment of the monkeypox virus.
41030026|NCT02545673|BEHAVIORAL|Enhanced linkage to care|
41030027|NCT02545673|BEHAVIORAL|Standard-of-care plus|
41030028|NCT02265237|DRUG|ombitasvir/paritaprevir/ritonavir|tablets
41030029|NCT02265237|DRUG|ribavirin|tablets
41030030|NCT03719456|PROCEDURE|Retrograde Intrarenal Surgery|
41030031|NCT04837638|BEHAVIORAL|Diet|No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
41030032|NCT06371794|PROCEDURE|skin punch biopsy|skin punch biopsy (around 4 mm2) from each studied subject.
41030033|NCT00133289|DEVICE|Pacemaker with Automatic Capture|
41030034|NCT03819335|DEVICE|mySugr app|mySugr is a mobile medical app for diabetes management. It has been developed by Roche Diabetes Care and it has two versions, free and Pro. It allows to carry out the diary of diabetes, including the collection and analysis of data on glycaemia, food, physical activity or insulin dose. In addition, it is compatible with continuous glucose measurement systems. It has the possibility to add functionalities such as estimation of HbA1c levels, more detailed data analysis or integration with Google Fit type motion sensors, as well as a bolus calculator, reminders for measuring blood glucose or photo gallery in the Pro version, which is the one that will be provided to the patients for the study.
41030035|NCT03819335|OTHER|Standard care|Face-to-face visits
41030036|NCT04318340|OTHER|Tapered applicator|An applicator inserted in 2 steps that tapers at the distal vagina
41030037|NCT04318340|OTHER|Standard applicator|A 2.6 cm standard applicator is inserted and sized up to a standard 3 cm applicator if tolerable.
41030038|NCT03286491|DIAGNOSTIC_TEST|Further cardiac imaging|Study patients will be reviewed whether they will have coronary interventions in 30 days
41030039|NCT05528120|DRUG|VC004 Capsules|Oral administration after fasting/high-fat meal
41030040|NCT05528120|DRUG|VC004 Capsules|Oral administration after high-fat/fasting meal
41030041|NCT04483869|OTHER|Thermography|thermographic image a 1, 3, 5 et 10 minutes of life
41030042|NCT05388903|DRUG|DS-2325a|Subcutaneous injection (starting dose 30 mg)
41030043|NCT05388903|DRUG|DS-2325a|Intravenous infusion (starting dose 100 mg)
41030044|NCT05388903|DRUG|Placebo|Subcutaneous injection
41030045|NCT05388903|DRUG|Placebo|Intravenous infusion
41502803|NCT05324410|DRUG|Placebo|Placebo matched to VX-840 for oral administration.
41502804|NCT05884684|OTHER|Reviewing Imaging with Participant|Post-operatively, the images taken during the procedure will be reviewed with the participant.
41502805|NCT04778488|DEVICE|Near-Infrared-Spectroscopy (NIRS)|Placement of 2 NIRS optodes on the patients' forehead, measurement of NIRS during cardiac arrest and up to 72h post return of spontaneous circulation
41502806|NCT05475327|OTHER|Conventional Physical Therapy|"Heating pad~A total of 3 sessions per week were given for 15 to 20 mins"
40847025|NCT03137628|OTHER|colectomy, GA and MV|"general anesthesia protocol: anesthesia induction (midazolam 0.1mg/kg, sufentanil 0.5ug/kg, etomidate 0.3mg/kg, cisatracurium 0.2mg/kg); anesthesia maintenance \[sevoflurane 1.5-3%, cisatracurium 0.1mg/kg/h, sufentanil is supplemented during the entire surgical procedure according to patients' anesthetic situation, dexmedetomidine（used conditionally）0.4ug/kg/h\].~mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5."
40847026|NCT01730586|DRUG|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
41162334|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
41162335|NCT00123435|DEVICE|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
41502807|NCT05475327|OTHER|Relaxation exercises|"The experimental group was given Progressive relaxation exercises along with Deep breathing exercises.~A total of 3 sessions per week were given for 15 to 20 mins."
40847027|NCT05318911|DIETARY_SUPPLEMENT|Novel yogurt drink|Novel ovine yogurt drink containing polar lipids
41162336|NCT00123435|DEVICE|Enhanced pedometer|Simple pedometer with the addition of web-based feedback.
41369514|NCT05850455|DRUG|Local infiltration with Lidocaine HCL 1%'Debocaine'|Lidocaine 1% which is a local analgesic as local infiltration
41369515|NCT04353427|BEHAVIORAL|The Seven Pathways to Healing, Health and Wellness curriculum|"The curriculum seeks to increase civic engagement by fostering a sense of community and a sense of social and personal responsibility in community. There will be 7 monthly session that will be approximately 1 hour in duration. Session topics include:~1. Education and Information (including mental health awareness, and a one-day certificate program in Mental Health First Aid)~2. Connection with Others~3. The Body as Temple~4. Emotional Healing~5. The Nature of Mind~6. Life Assessment~7. The Nature of Spirit"
41502808|NCT02882308|DRUG|Olaparib|50/25 mg BD split x 5 days
41502809|NCT02882308|DRUG|Cisplatin|60 mg/m\^2 d1-d5
41502810|NCT02882308|DRUG|Olaparib|300 mg BD x 21-28 days.
41502811|NCT02882308|DRUG|Durvalumab|1500 mg d1
41502812|NCT00871273|DRUG|capecitabine|film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
41502813|NCT01956305|DRUG|DS-7309|DS-7309 powder in bottle
41502814|NCT01956305|DRUG|placebo|placebo to match DS-7309 powder in bottle
41502815|NCT01956305|DRUG|Metformin|Metformin 500mg tablet for Cohort F
40847028|NCT05318911|OTHER|Placebo Drink|Placebo drink (skimmed milk)
40847029|NCT03121703|OTHER|lumbar stabilization exercise|lumbar stabilization exercise
40847030|NCT03121703|OTHER|trunk muscle strengthening exercise|trunk muscle strengthening exercise
41502816|NCT00811928|DRUG|Posaconazole|"40 mg/mL; 200 mg (5 mL) TID~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)"
41502817|NCT00811928|DRUG|Fluconazole|"50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);~400 mg QD~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)"
41502818|NCT04569669|DIAGNOSTIC_TEST|FFR and FFRCT|All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
41502819|NCT05019716|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
41502820|NCT05019716|PROCEDURE|Biopsy|Undergo biopsy
41030046|NCT01242475|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
41030047|NCT01242475|BIOLOGICAL|2 TU Tuberculin PPD RT 23 SSI|The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
41030048|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 1|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
41030049|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 2|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
41030050|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 3|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
41030051|NCT03674177|DRUG|Placebo (Normal Saline)|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
41030052|NCT00270491|DRUG|Paclitaxel|
41030053|NCT00270491|DRUG|Capecitabine|
41030054|NCT02832323|BIOLOGICAL|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
41030055|NCT02114892|DRUG|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
41030056|NCT02114892|DRUG|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
41030057|NCT03855722|PROCEDURE|RIPC|Remote Ischaemic Preconditioning
41030058|NCT03855722|PROCEDURE|Sham-RIPC|Sham procedure
41030059|NCT01793064|BEHAVIORAL|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
41030060|NCT01793064|BEHAVIORAL|Static Intervention (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
41162337|NCT01193023|OTHER|Pressure Support|Ventilation under pressure support
41162338|NCT01193023|DEVICE|NAVA|Ventilation under NAVA
41162339|NCT04124471|BEHAVIORAL|Open-ended semi-structured interviews|Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
41162340|NCT02371161|DRUG|R-DHAP/R-ICE|"R-DHAP/R-ICE 3 cycles every 21 days:~1. R-DHAP~   * Rituximab 375 mg/m2, e.v. day 1~  * Desamethasone 40 mg days 1-4~  * cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~  * Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~2. R-ICE~   * Rituximab 375 mg/m2, e.v. day 1~  * Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~  * Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~  * Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM"
41162341|NCT00951964|DRUG|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
41162342|NCT00951964|DRUG|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
41162343|NCT00468858|OTHER|Placebo|"Lyophilized, single dose vials and sterile water for~\> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"
41162344|NCT00468858|BIOLOGICAL|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
41162345|NCT00468858|BIOLOGICAL|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
41162346|NCT06080490|DRUG|TAC C/D ratio|Pharmacokinetics of TAC according to possible influencing factors
41162347|NCT06213064|BEHAVIORAL|Study Product, THC Product, Placebo|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 21-day product use period with a total of 9 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
41162348|NCT04839614|OTHER|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral|See arm description
41162349|NCT00176969|DRUG|Capsaicin|
41502821|NCT05019716|PROCEDURE|Chest Radiography|Undergo chest x-ray
41502822|NCT05019716|DRUG|Cisplatin|Given IV
41030061|NCT04141306|OTHER|Administrative data|Evaluation of month and year of birth, sex, referent doctor and surgeon
41162350|NCT04545983|OTHER|Motion Analysis|Cinematographic recordings will be made. Participants are seated on a crutch, adjustable in height, with their neck, shoulders and head free. Before recordings are made, participants will be instructed to perform the prescribed flexion and extension movement in about 10 seconds with 7 frames per second. Participants are placed on the crutch with their shoulder's perpendicular to the image intensifier to obtain sagittal images from the occiput till C7. As soon as the recording is started, the participant is instructed to move his head in the sagittal plane from maximal extension to maximal flexion, without moving the upper part of the body. It is important that the participants shoulders are kept as low as possible while making the recordings to ensure that all the cervical vertebrae are visible. The movement of the cervical spine should be as fluent as possible to prevent for sudden large rotations and translations between consecutive frames.
41162351|NCT01308047|DRUG|Bupivacaine|single dose of 15mg by a slow injection rate of 1 ml/s
41162352|NCT00498433|DRUG|Aliskiren|300 mg tablet once daily
41030062|NCT04141306|OTHER|Clinical data|Evaluation of diagnostic circumstances, vital status at last follow up
41030063|NCT04141306|OTHER|Histological data|Evaluation of Pathology report of thyroid surgery
41162353|NCT00498433|DRUG|Amlodipine|5 mg capsule once daily
41030064|NCT04141306|OTHER|Imaging data|Evaluation of scintigraphy, MRI, scan
41030065|NCT04141306|OTHER|Biological data|Evaluation of thyroglobulin, antithyroglobulin antibodies
41030066|NCT04141306|OTHER|Further treatment|Evaluation of surgery, radiotherapy, targeted therapy
41162354|NCT00498433|DRUG|Placebo of Aliskiren|Matching placebo of aliskiren 300 mg tablet
41162355|NCT00498433|DRUG|Placebo of amlodipine|Matching placebo of amlodipine 5 mg capsule
41162356|NCT00088452|DRUG|Ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
41030067|NCT02888405|OTHER|High-carbohydrate diet|
41030068|NCT02888405|OTHER|Low-carbohydrate diet|
41030069|NCT06533891|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
41162357|NCT00088452|DRUG|Lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
41162358|NCT00088452|DRUG|Valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
41162359|NCT00525018|DEVICE|contact heat evoked potential stimulator|
41162360|NCT01517490|OTHER|Insulin pump|Insulin pump therapy
41162361|NCT01517490|OTHER|Multiple daily insulin injections|Multiple daily insulin injections
41162362|NCT01517490|PROCEDURE|Bariatric surgery|Pre-operative weight loss and bariatric surgery.
41502823|NCT05019716|PROCEDURE|Computed Tomography|Undergo CT or PET-CT
41502824|NCT05019716|DRUG|Etoposide|Given IV
41502825|NCT05019716|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
41502826|NCT05019716|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41502827|NCT05019716|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
41502828|NCT06463522|PROCEDURE|Autologous Tumor-infiltrating Lymphocytes|Autologous Tumor-infiltrating Lymphocytes, 2.0\*10\^7/Kg, single intravenous infusion.
41502829|NCT01922440|OTHER|No intervention|This is a non-interventional study.
41502830|NCT05119907|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
41502831|NCT02052011|DRUG|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
41162363|NCT01517490|OTHER|Medical therapy for type 2 diabetes|Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
41369516|NCT03045107|PROCEDURE|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
41369517|NCT03045107|PROCEDURE|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
41369518|NCT02333110|RADIATION|spatially fractionated radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
41502832|NCT02052011|DRUG|Placebo|
41502833|NCT00816673|DRUG|placebo Circadin|Placebo tabs of Prolonged release melatonin
41502834|NCT00816673|DRUG|Circadin|prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
41502835|NCT05955196|PROCEDURE|BLOOD AND TUMOR|sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece
41502836|NCT06386289|DEVICE|Cereglide 92|Aspiration of cerebral large vessels occlusions
41030070|NCT06533891|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
41030071|NCT06533891|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
41030072|NCT03934385|BEHAVIORAL|Mental Rehearsal|After each exposure session, participants complete three rehearsal/retrieval exercises that involve viewing images of spiders and completing multiple-choice and free-response questions. Exercises involve retrieving information specific to the spider exposures, reflecting on the experience, and highlighting expectancy violation (i.e., that the participant's feared outcome did not occur).
41030073|NCT03934385|BEHAVIORAL|Exposure|All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.
41030074|NCT04936282|DRUG|Grafalon|When Borderline lesions are present in protocol biopsy, administer Grafalon ® 6 mg/kg/day in a single day. Then continue with the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day).
41030075|NCT04936282|DRUG|Normal Treatment|When Borderline lesions are present in protocol biopsy, administer the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day)
41030076|NCT05397522|OTHER|Supervised Exercise by a physiotherapist via face to face|The exercises are performed by the participants under the supervision of a physiotherapist via face-to-face.
41030077|NCT05397522|OTHER|Supervised Exercise by a physiotherapist via video conference|The exercises are performed by the participants under the supervision of a physiotherapist via video conference.
41030078|NCT00033254|RADIATION|radiation therapy|Undergo conventional radiation therapy
41030079|NCT00033254|DRUG|thalidomide|Given orally
41030080|NCT00033254|PROCEDURE|quality-of-life assessment|Ancillary studies
41030081|NCT06237283|BEHAVIORAL|Early shower|Start shower after drain removal
41030082|NCT01196975|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
41030083|NCT01196975|BIOLOGICAL|FluLavalTM-VB|Single intramuscular dose
41030084|NCT01196975|BIOLOGICAL|FluLavalTM-YB|Single intramuscular dose
41030085|NCT03149094|BEHAVIORAL|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
41030086|NCT03149094|BEHAVIORAL|CBSM-SMI control|this group will receive the LifeSum app.
41030087|NCT02979535|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC at Day 0, Months 6 and 12
41030088|NCT02979535|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC at Months 1, 7, and 13
41030089|NCT02979535|BIOLOGICAL|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
41030090|NCT02979535|BIOLOGICAL|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
41030091|NCT06019104|OTHER|Task-oriented training|"Task-oriented training is defined as an approach based on movement science and motor learning, where the patient makes functional movements specific to a certain task and receives feedback. Task-oriented training focuses on improving performance on functional tasks through targeted practice and repetition."
41030092|NCT06019104|OTHER|Control group|Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
41369519|NCT06165159|OTHER|children and adolescents with type 1 diabetes and their parents|"Children over the age of 8 with type 1 diabetes diagnosed more than 6 months ago in France, followed in one of the hospitals that are members of the Aide aux Jeunes Diabétiques (AJD) association.~Parents or people involved in the day-to-day life of children with type 1 diabetes diagnosed at least 6 months ago, whose child is being followed in France in one of the hospitals affiliated to the AJD association."
41369520|NCT00551694|DRUG|GSK256073A tablets|
41369521|NCT05588401|BIOLOGICAL|GenPHSat injection (Safety)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.
41369522|NCT05588401|BIOLOGICAL|GenPHSat injection (Efficacy)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the right biceps muscle.
40847031|NCT06341023|BEHAVIORAL|Functional Balance Intervention|Participants in the intervention group will undergo a multi-component FBI exercise program, both in a lab setting (Study 1) and at home (Study 2), for 2 days/week over 4 months. This evidence-based protocol, previously piloted with chronic stroke patients, older adults with mild cognitive impairment, and pre-frail older adults, focuses on improving physical (endurance, strength, balance, and gait) and cognitive function (processing speed, attention, and memory). The program consists of functional agility, functional strength, dual-task, and vestibular exercises, with each 1-hour session including 10 minutes dedicated to each component. The exercise order will be randomized for each session, preceded by a warm-up with gentle self-stretching exercises.
40847032|NCT06341023|BEHAVIORAL|Stretching|Participants in the control group will undergo a 4-month lab-based stretching program, with the same frequency and session length as the intervention group (1 hour/session for 2 days/week). The stretching regimen will include progressive stretches targeting upper and lower-limb muscles, core, and back muscles, followed by a 10-minute cool-down comprising relaxation and breathing exercises. These stretches are designed to improve performance in daily living activities. In Study 2, stretching participants will receive a detailed printed exercise manual for home-based training, ensuring consistency with the lab-based program. No additional equipment, such as computers or tablets, is required for the home stretching program.
40847033|NCT04585607|DEVICE|A medium cut-off dialyzer (Theranova) will be used for HDx.|"A medium cut-off dialyzer used for HDx (Theranova) must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription.~HD with MCO dialyzer (Theranova 400®, Baxter) vs. high-flux dialyzer (eg. Polyflux H, Baxter)"
41030093|NCT05970393|PROCEDURE|pressure support level tatrition|Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Upward and downward PS level adjustments were performed from the baseline PS level at a 1cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. PMI mean value was measured and calculated at every PS level. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O, and titrating PS was stopped until PMI was less than -1cmH2O and more than 3cmH2O.The inspiratory effort is measured as the pressure generated by inspiratory muscles using esophageal pressure monitoring.
41030094|NCT01952912|PROCEDURE|PkEP|
41030095|NCT01952912|PROCEDURE|OP|
41030096|NCT00237744|DEVICE|Robotics training for shoulder elbow.|training utilizing a robot to assist with movement practice
41162364|NCT06240546|DRUG|LPM6690176|Administered orally
41162365|NCT01772147|DRUG|Umeclidinium bromide 62.5mcg|Inhalation powder
41162366|NCT01772147|DRUG|Umeclidinium bromide 125mcg|Inhalation powder
41162367|NCT01772147|DRUG|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation powder
41162368|NCT01176136|BEHAVIORAL|Homework, Organization, and Planning Skills (HOPS) Intervention|HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
41162369|NCT00110955|DRUG|Darbepoetin alfa|Q3W 300 mcg darbepoetin alfa
41369523|NCT05588401|OTHER|Muscle Biopsy (Safety)|Participants undergo muscle biopsy 3 month after safety GenPHSat injection.
41369524|NCT02645682|DEVICE|anti-infection CVC|
41369525|NCT02645682|DEVICE|normal CVC|
41369526|NCT01860066|DRUG|QVA149|QVA149 via inhaler twice a day
41369527|NCT01860066|DRUG|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
41162370|NCT00110955|DRUG|Placebo|Q3W dosing of placebo
41369528|NCT00938366|DRUG|Cladribine|Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
41369529|NCT00938366|DRUG|Pantoprazole|Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
41369530|NCT03798652|DEVICE|Research CMR scan|CMR scanning at a 3Tesla scanner at King's College London
41369531|NCT03798652|DEVICE|Research 3D transthoracic echocardiogram|The scan is required to assess left ventricular systolic function
41369532|NCT03798652|OTHER|6-minute walk test|Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
41369533|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing|Offer of 3 OraQuick HIV self-test kits
41369534|NCT04131465|DIAGNOSTIC_TEST|Home HIV rapid testing|Offer of HIV rapid testing with Alere Determine HIV-1/2
41369535|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing and rapid testing|Offer of 3 OraQuick HIV self-test kits and HIV rapid testing with Alere Determine HIV-1/2
41369536|NCT01493791|DRUG|CDB-2914|
41369537|NCT00261859|BEHAVIORAL|BNI|behavioral- brief intervention
41369538|NCT00776828|DRUG|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
40847034|NCT04585607|DEVICE|A synthetic high-flux dialyzer (Polyflux)|A synthetic high-flux dialyzer (Polyflux) used for hemodialysis must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required.
40847035|NCT05772013|DRUG|Azithromycin Pill|"Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September)."
40847036|NCT05772013|DRUG|Placebo|The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
40847037|NCT00830180|BIOLOGICAL|Anti-NGF AB|Solution for injection, 10 mg, one injection/8 weeks
40847038|NCT03916484|BEHAVIORAL|AllyQuest HIV Medication Adherence app-delivered intervention|"AQ provides daily ART reminders and calendar; weekly tailored message; monthly appointment and refill reminders; social support via daily chat wall; daily challenge featuring skills-building and articles; education center; narrative collections; in app account rewards daily use by adding or subtracting small financial reward dependent on daily app use; personalized profile and avatar. Participants have 24-hour access to all features of the AQ app."
40847039|NCT03916484|BEHAVIORAL|AllyQuest HIV Medication Adherence app-delivered intervention + NSC|In AQ+, participants receive all of AQ and have the added ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve ART adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. AQ+ includes unprompted check-in messages from the NSC counselor and scheduled in-app NSC sessions approximately every other week.
40847040|NCT03869307|OTHER|Exercise|The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
40847041|NCT02012049|DRUG|Risperdal OD Tab. 2mg|1 tablet Risperdal OD 2 mg administered orally.
40847042|NCT02012049|DRUG|Risperdal Quicklet Tab. 2mg|1 tablet Risperdal Quicklet Tab. 2mg administered orally.
40847043|NCT02777827|DRUG|Abediterol 0.156 μg|Dry powder for inhalation
40847044|NCT02777827|DRUG|Abediterol 2.5 μg|Dry powder for inhalation
40847045|NCT02777827|DRUG|Abediterol 0.05 μg|Pressurised metered-dose inhaler
40847046|NCT02777827|DRUG|Abediterol 0.156 μg|Pressurised metered-dose inhaler
40847047|NCT02777827|DRUG|Abediterol 2.5 μg|Pressurised metered-dose inhaler
40847048|NCT02777827|OTHER|Placebo|Pressurised metered-dose inhaler and dry powder for inhalation.
40847049|NCT02607111|DRUG|Dalteparin|
40847050|NCT06454877|DEVICE|active heating|"Preheating will be performed for 15 minutes 30 minutes before surgery with a hot air blowing device in accordance with the normothermia care package so that the body temperature is 36-37 C°.~Active heating during surgery will be done with a heating bed placed on the operating table.~Patients taken to the postoperative care unit will continue to be heated with a hot air blower and the device will be turned off when the body temperature reaches 37 C°."
40847051|NCT06454877|BEHAVIORAL|pasive heating|"In accordance with the normothermia care package, the reflective blanket will be covered to cover the whole body 30 minutes before surgery.~During the operation, the body will be covered with a reflective blanket in accordance with the surgical intervention.~Patients taken to the postoperative care unit will continue to be warmed with reflective blankets."
40847052|NCT04992195|DIAGNOSTIC_TEST|Laboratory tests and Montreal Cognitive Assessment|Laboratory tests at baseline and 16 weeks (+/-4 weeks) after 2nd dose of vaccine and serological testing for IgG antibody. Participants who have a scheduled vaccination date shall undergo an MRI brain 16 weeks (+/-4 weeks) after the second dose of COVID-19 vaccination (either SinoVac or BioNTech). A face-to-face assessment 16 weeks (+/-4 weeks) will also be conducted after the 2nd dose of COVID-vaccine for evaluation of any clinical events, followed by a phone visit every 6 months. Cognitive assessment by MoCA will be performed at baseline, 16 weeks (+/-4 weeks) then every 12 months after the 2nd dose of COVID-19 vaccine.
40847053|NCT04992195|DIAGNOSTIC_TEST|Laboratory tests and Montreal Cognitive Assessment|Laboratory tests at baseline and serological testing for IgG antibody to exclude past COVID-19 infection. The timing of the second MRI brain, laboratory tests, clinical and cognitive assessment will be matched with the timing in the vaccination group are available.
40847054|NCT02316886|DEVICE|Coronary intervention|bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) + Optimal Medical Treatment
40847055|NCT02316886|DRUG|Optimal Medical treatment|
40847056|NCT04878952|OTHER|Garmin Vivofit Activity Tracker|Activity tracker that is worn on the wrist.
40847057|NCT04213378|DEVICE|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent re-stenosis with paclitaxel eluting PTCA balloon
40847058|NCT04213378|DEVICE|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent re-stenosis with SeQuent® Please paclitaxel eluting balloon
41030097|NCT00237744|DEVICE|Surface Functional Neuromuscular Stimulation|training utilizing FNS to assist with movement practice
41030098|NCT00237744|OTHER|whole arm motor learning|intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
41030099|NCT01801072|DRUG|Levetiracetam|Details covered in Arm Descriptions.
41030100|NCT03591744|DRUG|Bortezomib|Given SC
41030101|NCT03591744|BIOLOGICAL|Daratumumab|Given IV
41030102|NCT03591744|DRUG|Dexamethasone|Given IV and PO
41030103|NCT03591744|DRUG|Lenalidomide|Given PO
41030104|NCT03591744|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
41030105|NCT00728819|DEVICE|Tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
41030106|NCT00728819|DEVICE|Non-tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
41030107|NCT05094960|DIAGNOSTIC_TEST|Blood samples|5 blood samples for each patient during CABG (coronary artery bypass grafting) surgery pre/on/post cardiopulmonary bypass machine
41030108|NCT01517698|DRUG|Placebo|placebo to RO4917523 orally once a day for 12 weeks
41030109|NCT01517698|DRUG|RO4917523 0.5 mg|0.5 mg orally once a day for 12 weeks
41030110|NCT01517698|DRUG|RO4917523 1.5 mg|1.5 mg orally once a day for 12 weeks
41030111|NCT04425083|OTHER|no intervention|no intervention
41030112|NCT05719974|OTHER|rehabilitation protocol|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises The criterion-based rehabilitation protocol is relatively new. It was developed and recommended in 2016 by the Royal Dutch Society for Physical Therapy (KNGF), aiming to assure a more patient-tailored rehabilitation and to maximize the speed of a patient's progress. It's a three phases protocol with a criterion-based progression.
41030113|NCT06357728|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring sensor: All study participants wear the sensor on the back of either right or left upper arm for up to 10 days. Glucose levels will be recorded from the interstitial fluid every 5 minutes using intermittent/ flash glucose scanning. Data will be captured using a receiver.
41369539|NCT02438293|OTHER|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
41369540|NCT04182529|DEVICE|Photoneuromodulation therapy|low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800
41030114|NCT03277313|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
41502837|NCT06584292|PROCEDURE|caudal block|Caudal Block (CB) Procedure: The sacral hiatus was identified using an out-of-plane transverse ultrasound view at the level of the sacral cornua. The probe was then rotated longitudinally to visualize the sacrococcygeal ligament and sacral bone. A block needle was inserted through the sacrococcygeal membrane into the sacral canal using the in-plane technique, and 0.125% bupivacaine was administered at a dose of 1 mL/kg, with a maximum limit of 20 mL per side.
41502838|NCT06584292|PROCEDURE|Retrolaminar block|Retrolaminar Block (RL) Procedure: The RL block was performed with the patient in a lateral decubitus position. The ultrasound probe was positioned at the L4 vertebral level in a paramedian sagittal plane. The probe was moved medially until the vertebral laminae were visualized. The needle was inserted using the in-plane technique, advancing from the cephalad to caudal direction until it contacted the L4 lamina. A dose of 0.1 mL/kg of 0.25% bupivacaine was then injected into the retrolaminar space.
41030115|NCT00709280|DRUG|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
41030116|NCT00709280|DRUG|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
41030117|NCT04069975|OTHER|Sedation|The group of patients who did endoscopies with or without sedation. (This is a choice of themselves)
41030118|NCT06001398|BEHAVIORAL|Parent Acceptance and Commitment Therapy (PACT)|PACT is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature
41030119|NCT06001398|BEHAVIORAL|Control|The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate
41030120|NCT03518177|OTHER|Hospital-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, treadmill walking, cycle ergometer, arm ergometer training and strengthening trainning with free weights at hospital.
41030121|NCT03518177|OTHER|Home-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, free-walking, and strengthening training with free weights at home
41030122|NCT00884429|PROCEDURE|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
41162371|NCT02303847|DRUG|Ketamine|ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
41502839|NCT04537832|OTHER|No Intervention|No Intervention
41162372|NCT00387907|DRUG|larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
41162373|NCT00387907|DRUG|trastuzumab|administered as a 90-minute IV infusion on Day 1 of every week (qw)
41162374|NCT04176783|DRUG|Opioids|narcotic pain medicine
41162375|NCT04176783|DRUG|Opioid-Free|non narcotoc pain medication
41369541|NCT04182529|OTHER|Sham|Sham, no active stimulation will be given to subjects
41369542|NCT00004058|DRUG|tetradecanoylphorbol acetate|
41030123|NCT00884429|PROCEDURE|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
41030124|NCT00884429|PROCEDURE|3-Airway suction|Airway suction
41369543|NCT06167304|OTHER|Technology-implemented exercise therapy|Therapy plans are performed at home overseen by a remote physical therapist via SimpleTherapy.
41162376|NCT00261625|DRUG|alendronate|
41369544|NCT06167304|OTHER|Traditional Physical Therapy|Traditional physical therapy per Standard of care.
41369545|NCT04828980|DEVICE|Oculus Quest: TRIPP|This is a VR experience that focuses on meditation and mindfulness
41369546|NCT04828980|DEVICE|Oculus Quest: Angry Birds|This is an active gaming VR experience that utilizes controllers to aim and launch objects at targets.
41369547|NCT01999959|PROCEDURE|Pertubation|a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
41502840|NCT06608537|DRUG|neoadjuvant SCRT followed by Sintilimab plus CAPOX|Patientsreceived neoadjuvant treatment consisting of SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles) combined with CAPOX (oxaliplatin 130 mg/m2 intravenous infusion over 2 h on day 1, capecitabine 1000 mg/m2 orally twice daily from day 1-14, in every 3-week cycle for two cycles) 1 week later.
41502841|NCT04108208|DRUG|Apalutamide|Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.
41502842|NCT04108208|DRUG|Placebo|Matching placebo will be administered orally.
41502843|NCT04108208|DRUG|Androgen-deprivation Therapy (ADT)|Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
41502844|NCT05232812|RADIATION|3-[11C]-OHB|The PET tracer 3-\[11C\]-OHB is used to quantify 3-hydroxybutyrate uptake
40847059|NCT00562562|OTHER|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
41502845|NCT04150770|DRUG|infliximab|
41502846|NCT04076059|DRUG|Enzalutamide|Oral
41369548|NCT04358809|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19
41502847|NCT04076059|DRUG|Placebo|Oral
41369549|NCT04358809|OTHER|Placebo|Placebo along with Standard of care (SOC) treatment for COVID-19
41369550|NCT03235674|OTHER|High-intensity stair climbing exercise|High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
41502848|NCT04076059|DRUG|Androgen deprivation therapy (ADT)|All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
41030125|NCT02455986|BEHAVIORAL|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
41369551|NCT00690573|BIOLOGICAL|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
41369552|NCT04558658|DIAGNOSTIC_TEST|Complete Blood Count|neutrophil to lymphocyte ratio
41369553|NCT00207831|DRUG|Tegafur and Uracil|
41030126|NCT03669003|BIOLOGICAL|Gelfoam slurry|Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.
41030127|NCT03669003|PROCEDURE|CT-guided percutaneous lung biopsy|Biopsy of a lung nodule under CT guidance.
41030128|NCT06114420|PROCEDURE|salvage surgery|Some patients who cannot undergo surgery
41030129|NCT03836053|DRUG|AMG 420|28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks
41030130|NCT02802345|DRUG|Nintedanib|
41030131|NCT02802345|DRUG|Placebo|
41030132|NCT02802345|DRUG|Sildenafil|
41030133|NCT02959489|BEHAVIORAL|Alzheimer's Disease Risk Disclosure|Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
41030134|NCT02959489|BEHAVIORAL|Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure|"Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type."
41030135|NCT03049046|DRUG|CC100|synthetic caffeic acid phenethylester
41030136|NCT03049046|DRUG|Placebos|Diluent
41369554|NCT04901520|OTHER|High Intensity Training|High Intensity Training group performed resistance training with the intensity of 80 - 90 % of 1RM with 4 - 6 repetition
41369555|NCT04901520|OTHER|Moderate Intensity Training|Moderate Intensity Training group performed resistance training with the intensity of 65 - 75 % of 1RM with 8 - 10 repetition
41369556|NCT04901520|OTHER|Low Intensity Training|Low Intensity Training group performed resistance training with the intensity of 50 - 60 % of 1RM with 12 - 14 repetition
41369557|NCT01607489|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s,~1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration"
41369558|NCT02835794|DRUG|Omacetaxine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
41369559|NCT02835794|DRUG|Azacitidine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
41369560|NCT02835794|DRUG|G-CSF|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
41502849|NCT06634238|OTHER|Incremental shuttle walk test|Participants were recommended to wear comfortable clothing and appropriate shoes for the test. To minimize variability, one masked and one unmasked ISWT was performed on the same participant at the same time of day, one day apart
41502850|NCT01529710|DRUG|Myrrh|Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
41502851|NCT06067269|DRUG|Apalutamide|Given PO
41502852|NCT06067269|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40847060|NCT05623358|OTHER|Pharmacist-led HFrEF medication optimization|In addition to usual care, participants randomized to the intervention arm will receive co-management of medications by a clinical pharmacist with advanced training and expanded scope of practice, with the aim of achieving optimal medical therapy (OMT) for HFrEF as outlined by the 2021 Canadian Cardiovascular Society (CCS) HF guidelines. This will consist of, where possible, the combination of an angiotensin receptor-neprilysin inhibitor (ARNI), evidence-based beta-blocker, mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter 2 inhibitor (SGLT2i) at target doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines, unless the patient is unable to tolerate these agents/doses.
40847061|NCT05623358|OTHER|Usual care|Both the intervention group and comparator group will receive usual care by the multidisciplinary HF clinic, including standard-of-care clinical pharmacy services. The standard pathway in the HF clinic consists of an initial consultation with the multidisciplinary team (cardiologist, physician trainees, registered nurse and clinical pharmacist), follow-up visits approximately every 3 months with the nurse and cardiologist until discharge, along with telehealth nurse calls for medication titrations.
40847062|NCT02261766|DEVICE|Holter monitoring and Thumb ECG|5 days holtermonitoring and 30 days 30 seconds twice daily thumb ECG recording
41369561|NCT00394498|DRUG|Granulocyte Colony Stimulating Factor|
41369562|NCT00008216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
41369563|NCT02052206|PROCEDURE|Shoulder replacement surgery|
41369564|NCT05973422|DEVICE|SIGI Insulin Management System|Continuous subcutaneous insulin infusion with Sigi, and wearing the Dexcom G7 sensor using the Dexcom App.
41369565|NCT04964076|OTHER|No intervention|No intervention
41369566|NCT02839213|DRUG|Hyoscine Butyl bromide|
41369567|NCT02839213|DRUG|Saline|
41369568|NCT03190252|OTHER|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
41369569|NCT03190252|OTHER|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
41369570|NCT00977600|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
41369571|NCT00977600|DRUG|Ammonul|
41369572|NCT00977600|DRUG|Buphenyl|
41369573|NCT05903976|DRUG|P2Y12 inhibitor de-escalation|Comparing, in patients at High Bleeding Risk (HBR) after a recent Acute Coronary Syndrome (ACS), continuation of full-dose potent P2Y12 inhibitor with a P2Y12i de-escalation strategy transitioning to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg/bid.
41369574|NCT02001662|PROCEDURE|Intervention group, block no. 1 - Ropivacain|Intervention group: 1. block ropivacaine - 2. block saline
40847063|NCT03950310|DEVICE|Excimer laser catheter|The excimer laser catheter is equipped with multiple optical fibers on the periphery of the guide wire lumen corresponding to 0.014 inch, which is used for the purpose of reperfusion of barrier site of coronary artery. The connector on the front side is connected with the CVX-300 laser generator, and the tip at the top contact directly with the lesion. The laser catheter consisting of multiple optical fibers transmits the energy in the ultraviolet region from the CVX300 laser generator to the blockage in the blood vessel. The ultraviolet energy is transmitted from the tip of laser catheter, transpires the fibrous, calcified and arteriosclerotic lesion by light, and enables reperfusion in the lesion. The laser catheter has appropriate hydrophilic coating and easily follows the inside of coronary artery.
40847064|NCT00334711|DRUG|Sulfonylurea|
40847065|NCT05626127|OTHER|No interventions|As this is a observational study, there are no interventions.
40847066|NCT05864937|OTHER|infertily evaluation|All couples had undergone a standard infertility evaluation, which included medical history, physical examination, and assessment of tubal patency by either hysterosalpingography or laparoscopy and hormonal analysis on cycle day 3. A transvaginal ultrasound scan was performed on the second day of the cycle. On the same day, ovarian stimulation was carried out with recombinant FSH follitropin);rFSH;Gonal-F,MerckSerono,France,orfollitropin ; Puregon, MSD, France), urinary FSH (urofollitropin, Fostimon, France),orhMG(menotropin,Menopur,France)atastarting dose of 75 IU/day from the second day of the cycle.
40847067|NCT01108380|PROCEDURE|Plasma pheresis, Right portal vein embolization|"Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam."
40847068|NCT01735942|DRUG|Ingenol mebutate|
40847069|NCT01735942|PROCEDURE|cryotherapy|
40847070|NCT06070909|DEVICE|The EMG activations|The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb were recorded during exercises in standing external rotation (SER), side-lying position (SDER), scapular plane (SPER) and muscle architecture-based (MABER) positions
41369575|NCT02001662|PROCEDURE|Control group: 1. block - saline|Control group: 1. block saline - 2. block ropivacaine
41369576|NCT02937727|DEVICE|3T MRI compatible and LFP recordable G106R of Beijing Pins medical.|
41369577|NCT02433522|DRUG|rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
41369578|NCT02433522|DRUG|Placebo|
41502853|NCT06067269|PROCEDURE|Computed Tomography|Undergo PSMA-PET/CT
41502854|NCT06067269|OTHER|Gallium Ga 68 Gozetotide|Undergo PSMA-PET/CT
41502855|NCT06067269|RADIATION|Guided Stereotactic Body Radiation Therapy|Undergo guided SBRT
41502856|NCT06067269|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
41502857|NCT06067269|PROCEDURE|Positron Emission Tomography|Undergo PSMA-PET/CT
41502858|NCT06067269|OTHER|Questionnaire Administration|Ancillary studies
41030137|NCT01625793|DRUG|Interferon-alpha|Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
41030138|NCT05204355|DIAGNOSTIC_TEST|MRI|Patients will be imaged using MRI
41030139|NCT05204355|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe129 will be used to image the lungs of a subset of participants.
41030140|NCT05204355|DIAGNOSTIC_TEST|HRCT|High Resolution Computer Tomography
41502859|NCT06634251|OTHER|No intervention|This study is purely observational and does not involve any direct intervention. It utilizes retrospective analysis of computed tomography (CT) scans to simulate the fluoroscopic visualization and screw placement technique in the anterior column fixation corridor (ACFC) of the acetabulum. The objective is to define the optimal antegrade entry point and assess anatomical parameters without performing any physical intervention on the participants.
40847071|NCT03581838|BEHAVIORAL|Observed eating session|Eating a Jimmy Johns turkey or vegetarian sandwich
41030141|NCT02588391|BEHAVIORAL|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving match the child's skill level.
41030142|NCT02588391|BEHAVIORAL|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving are set to a consistent level.
41030143|NCT02588391|BEHAVIORAL|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
41030144|NCT03335358|BEHAVIORAL|Dyadic (couples-based) positive psychology intervention|Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
41030145|NCT01794325|OTHER|Trans-radial|Coronary angiography performed through trans-radial access
41030146|NCT01794325|OTHER|Trans-femoral|Coronary angiography performed through trans-femoral access
41369579|NCT03117556|PROCEDURE|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
41369580|NCT02961361|DRUG|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
40847072|NCT02982057|DEVICE|the ABSORB:bioresorbable vascular scaffold|
40847073|NCT02982057|DRUG|O.M.T|
40847074|NCT02636686|DRUG|Drisapersen|Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
41030147|NCT00299234|DRUG|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
41030148|NCT04223102|PROCEDURE|Tissue collection|A flexible sigmoidoscopy is a procedure in which a flexible tubularized camera approximately 1 cm in diameter is inserted into the anus and advanced proximally to the sigmoid colon (approximately 20 cm). At that time a rectal biopsy of the tumor will be obtained as well as a sample from \>5cm proximal to the tumor, with a separate biopsy forcep. Tattoo injection, as standard of care, will be performed within 1 cm distal to the tumor to identify the location in the future or for surgical intervention. If there is inability to get proximal to the tumor then a location at least 5 cm adjacent in any direction will be sufficient so long as it is grossly normal appearing.
41369581|NCT02961361|DRUG|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
41369582|NCT01381068|DEVICE|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
41502860|NCT05461196|BEHAVIORAL|CPMRx|Patients use a mobile application to track pain medication usage and pain scores.
41502861|NCT05319353|DRUG|Maribavir|Participants will receive maribavir.
41030149|NCT04098627|BEHAVIORAL|Laughter Therapy|Once weekly 30-minute long group laughter therapy session for 8 weeks
41030150|NCT06531720|DRUG|Chlorhexidine Gluconate|topical preparation applied on oral mucosa lesion containing 0,2% CHX
41030151|NCT06531720|DRUG|Choline Salicylate 8.7 % Oral Gel|topical preparation applied on oral mucosa lesion containing, ethanol-based
41030152|NCT06531720|OTHER|control group|no medication has been prescribed
41030153|NCT02966067|DEVICE|Microneedle Device (Experimental)|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
41030154|NCT02966067|DEVICE|30-gauge Short Hypodermic Needle|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
41030155|NCT03936491|DRUG|Methylphenidate|Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.
41502862|NCT02242045|DRUG|Idelalisib|150 mg tablet(s) administered orally twice daily
41502863|NCT06625892|BEHAVIORAL|the multidimensional interventions|The study participants will receive cognitive behavior therapy intervention for six weeks, one session per week, 45 minutes each time, and exercise training for twelve weeks, twice sessions per week, 60 minutes each time.
40847075|NCT04484207|OTHER|A short video intervention|Three minutes video of a veteran that shares his personal story
41502864|NCT05554081|DEVICE|Peezy urine collection device|use peezy collection to obtain urine sample
41502865|NCT03645239|PROCEDURE|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
40847076|NCT04484207|OTHER|A vignette intervention|A written description of the content of the video
40847077|NCT06515821|DIAGNOSTIC_TEST|ONCOSCREEN|Subjects samples will be tested with diagnostic tests.
40847078|NCT03310385|DRUG|GHX02|Herbal medicine originating from gualouhengryunhwan
40847079|NCT03310385|DRUG|Placebo|Placebo tablets
40847080|NCT05322226|BEHAVIORAL|Addiction follow-up before and after liver transplantation|Addiction consult and follow-up
41162377|NCT03722797|PROCEDURE|Metabolic Cost Testing Procedures|"The Oxycon Mobile™Portable VO2 Measurement system will be used to measure VO2 uptake during 2 walking tests. Test order will be randomized.~Treadmill Test: Participants will walk on a treadmill at constant speed, based on the participant's self-selected gait speed, for 2.5 minutes in each stage. Walking will occur at 75% of self-selected gait speed in stage 1, 100% in stage 2, and 125% in stage 3.~Over-ground Test: Participants will walk in an uncarpeted corridor on a course consisting of 2 cones, 20-meters apart. Participants will be instructed to walk at a constant speed for 2.5 minutes in each stage. Instructions will be to walk at their slow speed in stage 1, their usual, comfortable speed in stage 2, and their brisk speed in stage 3."
41369583|NCT02615158|BEHAVIORAL|Maternal Physical Activity and Nutrition|At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.
40847081|NCT04198675|BEHAVIORAL|Supervised EMG Biofeedback Exercise Training Group|Posture training and ergonomic arrangements in the workplace. EMG biofeedback training will be carried out with electromyography-controlled video game combined with PNF exercises. Each game sessions comprising the work-rest cycle covers performing the upper trapezius muscle contraction simultaneously the upper extremity PNF patterns.
41369584|NCT02615158|BEHAVIORAL|Parenting|Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.
41369585|NCT02615158|BEHAVIORAL|Child Safety|The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
41369586|NCT03642002|OTHER|Toning|"Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable"
41369587|NCT03642002|OTHER|Ocean drum & SOK melody|Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
41369588|NCT03642002|OTHER|SOK|Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
41369589|NCT03642002|BEHAVIORAL|Process|Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
41369590|NCT03642002|OTHER|Holding Harmonic Container|"Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment"
41369591|NCT01786837|DEVICE|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
41369592|NCT02826174|PROCEDURE|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
41369593|NCT02826174|PROCEDURE|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
41369594|NCT02826174|DRUG|Anti-Rejection Agents|Anti-Rejection Agents for both groups
41369595|NCT02826174|DRUG|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
41369596|NCT02268214|DRUG|Dapagliflozin|Tablets
41369597|NCT02268214|DRUG|Placebo for dapagliflozin|Tablets
41369598|NCT03348306|DEVICE|MRI|Brain and cardiac MRI in one time with gadolinium injection.
41369599|NCT03348306|BIOLOGICAL|Blood sample collection|A blood sampling is also collected for hematocrit measure.
41369600|NCT01587352|OTHER|Laboratory Biomarker Analysis|Correlative studies
41369601|NCT01587352|DRUG|Vorinostat|Given PO
41162378|NCT04795583|DRUG|Prednisone|Prednisone 25 mg capsules
41162379|NCT04795583|DEVICE|Point of Care testing device for C-reactive protein|Determination of C-reactive protein blood levels by point of care testing device
41369602|NCT03085940|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily initially
41369603|NCT03085940|DRUG|Placebo|Placebo
41369604|NCT04162717|BEHAVIORAL|The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment|"Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles."
41369605|NCT06316401|PROCEDURE|ESD of large LSTs under SA|endoscopic submucosal dissection of large colorectal lesions under spinal anesthesia
41369606|NCT00077766|DRUG|Darbepoetin alfa|Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
41369607|NCT00077766|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
41369608|NCT01624818|BEHAVIORAL|Cardiac habilitation program|physical activity three weeks
41369609|NCT01278823|PROCEDURE|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
41369610|NCT01278823|OTHER|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
41369611|NCT04885582|OTHER|HLA antigen results|HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.
40847082|NCT04198675|BEHAVIORAL|Home-Based Exercise Training Group|Posture training and ergonomic arrangements in the workplace. Posture correction exercises, contains strengthening, stretching, mobility and relaxation exercises, will be given as a home exercises program. Exercise diary and weekly calls will be use to maintain the exercise adherence
41369612|NCT01774734|OTHER|Physical therapy|"Physical therapy~* Provided by 2 experienced physiotherapist~* Applied to every patients 3 times weekly"
41369613|NCT01774734|DEVICE|Neck Strength Exerciser (NSE)|"* Neck strength exerciser use 10-20 minutes daily at home~* Plus traditional physical therapy three times weekly provided by two experienced physical therapist"
41369614|NCT02472600|DRUG|Colistin|
41369615|NCT02472600|DRUG|Neomycin|
41369616|NCT02472600|DRUG|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
40847083|NCT04198675|BEHAVIORAL|Posture Training/Ergonomic Regulations Group|Posture training and ergonomic arrangements in the workplace.
40847084|NCT03537196|DRUG|Sofosbuvir 400 mg and Daclatasvir 60 mg|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
40847085|NCT03537196|DRUG|Sofosbuvir 400 mg and Daclatasvir 90 mg|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day.
41162380|NCT03830515|DEVICE|microMend|Wound closure product consisting of tan array of tiny metal Microstaples affixed to adhesive backing. The device is the size and shape of a butterfly closure and intended for closure of skin wounds.
41369617|NCT02472600|DRUG|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
41162381|NCT05117385|DIETARY_SUPPLEMENT|Botanical extract|1 capsule per day
41369618|NCT05864209|OTHER|Phthalate- and Bisphenol-free Baby Products|3-month supply. Products include wipes and diaper cream.
41369619|NCT05864209|OTHER|Cloth Diapers|Subscription to cloth diaper service.
41369620|NCT05864209|OTHER|Conventional Disposable Diapers|3-month supply.
41369621|NCT05864209|OTHER|Conventional Baby Products|Products include wipes and diaper cream.
41369622|NCT03593031|BEHAVIORAL|Office Based Vergence and Accommodative Therapy|Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
41369623|NCT00535262|DRUG|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
41369624|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
41369625|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
41369626|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
41369627|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
41369628|NCT04429607|DEVICE|Erbium:YAG Laser|Erbium:YAG 2940nm will be performed using single spot, multiple pulses on lesions.
41369629|NCT04429607|DEVICE|Pulsed Dye Laser|PDL will be performed using settings of 6-10 J/s2 on lesions.
41369630|NCT04429607|DEVICE|Nd:YAG Laser|Nd:YAG 1064nm will be performed using settings of 60-110 J/s2 on lesions.
40847086|NCT03537196|DRUG|Ribavirin|"In case of cirrhosis:~* Ribavirin will be added to sofosbuvir/daclatasvir during the 12 weeks of treatment. The dose will be adapted to the patient weight although the vast majority of patients (weight \< 75 kg) will receive 500 mg x 2/day.~* In case of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks."
40847087|NCT03537196|DRUG|Sofosbuvir and Daclatasvir for 24 weeks|In case of cirrhose and of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
40847088|NCT01183468|BIOLOGICAL|Aralast NP 45 mg dose|- 45 mg/kg/week
41162382|NCT04584359|OTHER|HVLA|High velocity, low amplitude manipulation for the sacroiliac joint and T10-L2. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 5 minutes.
41369631|NCT04429607|PROCEDURE|Electrodessication and curettage|Electrodessication and curettage will be performed using an epilating needle, followed by curettage on lesions.
41369632|NCT04749316|PROCEDURE|AcuTENS|Stimulation of acupuncture points with TENS machine
40847089|NCT01183468|BIOLOGICAL|Aralast NP 90 mg dose|- 90 mg/kg/week
40847090|NCT01183468|BIOLOGICAL|Aralast NP 180 mg dose|- 180 mg/kg/week
40847091|NCT05476029|DIAGNOSTIC_TEST|Blood samples and alveolar lavage fluid were collected|Blood samples and alveolar lavage fluid were collected for exosome sorting and identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
40847092|NCT01545427|DRUG|Imatinib mesylate|200 mg bid for 6 months
40847093|NCT01545427|OTHER|Placebo|Placebo coated to match appearance of Gleevec identically.
40847094|NCT00169091|DRUG|Clozapine|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
40847095|NCT00169091|DRUG|Haloperidol|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
40847096|NCT02915978|DRUG|Fentanyl|Fentanyl delivered via sublingual spray
41030156|NCT03936491|DRUG|Atomoxetine|Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).\[6\] Use is only recommended in those who are at least six years old.\[6\] It is taken by mouth.\[6\]
41030157|NCT00206648|DRUG|Betaferon/Betaseron|Betaseron 250 µg SC every other day
40847097|NCT02915978|DRUG|Placebo|Matching placebo delivered via sublingual spray
40847098|NCT01153698|DRUG|dabigatran|anticoagulation
41030158|NCT00206648|DRUG|Betaferon/Betaseron|Avonex 30 µg IM once per week
41030159|NCT04464564|DRUG|AVP-786|oral capsules
41030160|NCT04464564|DRUG|Placebo|oral capsules
41030161|NCT00000129|PROCEDURE|Radial Keratotomy|
41030162|NCT01299246|PROCEDURE|Michigan Neuropathy Screening Instrument|Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
41030163|NCT05648591|DRUG|Iloperidone|oral tablet
41030164|NCT04269928|PROCEDURE|Endovascular chemical ablation of adrenal gland|Patients in this group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
41030165|NCT03633383|DEVICE|Transcatheter aortic valve|Self-expandable aortic valve prothesis
41030166|NCT03399734|DRUG|Perampanel|Single oral dose of 1 x 4-mg perampanel tablet
41030167|NCT03399734|DRUG|Perampanel|Single 4-mg dose of perampanel fine granules
41030168|NCT05937438|DRUG|Immune Checkpoint Inhibitors|Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year
41030169|NCT05845229|DIETARY_SUPPLEMENT|High-N-acylethanolamine meal|Milk (150 mL), white bread (46 g), jam (10 g), cocoa powder (15 g), whole-grain cereals (30 g).
41030170|NCT05845229|DIETARY_SUPPLEMENT|Low-N-acylethanolamine meal|Milk (150 mL), whole-grain bread (80 g), jam (10 g), butter (5 g), instant coffee (2 g), dried apples (30 g).
41030171|NCT00006172|DEVICE|Bright light box|60-min light therapy shortly after awakening
41030172|NCT00006172|DEVICE|High-output negative ion generator|60-min high-density ion exposure shortly after awakening
41030173|NCT00006172|DEVICE|Low-output negative ion generator|60-min low-density ion exposure shortly after awakening
41030174|NCT02860728|BEHAVIORAL|Individualized Resistance Training|Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
41030175|NCT03774641|DRUG|Lamictal|Blood-serum levels will be checked monthly during pregnancy and reference concentration will be maintained
41030176|NCT02730819|DRUG|Illuminate Cream|Topical compound applied daily
41030177|NCT01924325|DRUG|Apixaban|orally active direct factor Xa inhibitor
41030178|NCT01924325|DRUG|Clopidogrel|an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor
41030179|NCT01924325|DRUG|Aspirin|a non-steroidal anti-inflammatory drug
41030180|NCT01924325|DRUG|placebo|
41030181|NCT02357628|DEVICE|Wound treatment with RO-NPT|
41030182|NCT02357628|DEVICE|Wound Irrigation|
41030183|NCT05006365|DEVICE|Transcranial Pulse Stimulation|A total of 30 participants (both TPS group and the waitlist control group) will receive six 30 minute-TPS sessions (300 pulse in each session, total: 1800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up at 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on depressive symptoms.
41030184|NCT06532630|GENETIC|Anti-CD19-CAR-T cells|"Each subject will be infused with single dose of anti-CD19-CAR-T cells.~A classic 3+3 dose escalation will be employed."
41030185|NCT06532630|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
41030186|NCT06532630|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
41030187|NCT00000744|DRUG|Fluconazole|
41162383|NCT04584359|OTHER|global osteopathic protocol|Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.
41162384|NCT04584359|OTHER|pelvic floor muscle training|Pelvic floor muscle training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes. In this intervention, participants were instructed to perform three sequences of exercises: contractions and relaxations (three seconds of sustained contractions and six seconds of rest), ten sustained contractions (ten seconds of sustained contractions and 20 seconds of rest), and five contractions associated with a cough. These exercises were performed in the standing, sitting, and lying positions
41369633|NCT05234281|OTHER|Interdisciplincary concentrated group rehabilitation|"All arms receive a concentrated interdisciplinary rehabilitation with similar focus and structure:~Three phases:~1. Pre-intervention preparation (1-2 months): mobilize the patients' resources for change~2. Concentrated group intervention (2-5 days): (further described below)~3. Post-intervention follow-up (1 year): digital follow-up~The core intervention is based on the concentrated rehabilitation format:~1. Initiate treatment when the patient is ready for change~2. Focus on the behavioral patterns which maintain the disorder, identify situations where they can break the patterns (micro-choices).~3. Assist the patient when breaking the patterns.~4. Use long sessions to ensure that they face a broad range of potential micro-choices~5. Work side-by side with others going through an analogous pattern of change~6. Prepare them for taking responsibility for integrating the change into every-day living"
41369634|NCT01682876|BIOLOGICAL|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
41369635|NCT03752021|PROCEDURE|Myometrial Sampling|"A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review"
40847099|NCT03884647|DEVICE|DELPhI system|DELPhI software is acquiring and analyzing the TMS evoked response recorded with the EEG.
40847100|NCT01115374|PROCEDURE|Manual lymphatic drainage|Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
40847101|NCT01115374|DEVICE|low frequency sound waves|Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
40847102|NCT03409250|DRUG|Ranibizumab, Lucentis|Intravitreal injection with Lucentis (Ranibizumab)
41030188|NCT00352729|DEVICE|ACell dressing|dressing
41162385|NCT05085808|DRUG|Trazodone|Trazodone will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the trazodone arm.
41162386|NCT05085808|DRUG|Quetiapine|Quetiapine will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the quetiapine arm.
41162387|NCT05085808|DRUG|Placebo|Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
41162388|NCT03709056|DRUG|HSK3486|HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old
40847103|NCT05556694|DIAGNOSTIC_TEST|calculation of cumulative fluid balance|- We will calculate cumulative fluid balance as daily fluid balance within four days of the event of interest. Cumulative fluid balance will be computed as the sum of daily fluid balances over the previous 24 hours, calculated by total fluid input minus total fluid output on a specific day of ICU admission over the first four calendar days of mechanical ventilation. Insensible fluid loss, such as perspiration or evaporative water loss related to respiration will not be routinely assessed and will not be included in the calculation of cumulative fluid balance. The cumulative fluid balance from day 0 to day 1 will be labelled as day 1, and the following days as day 2 and day 3. Cumulative fluid balance at day 3 refers to the cumulative fluid balance during the first four calendar days.
40847104|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 2g/day|Chewing tablets containing Short-chain fructooligosaccharides 2g/day
40847105|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 4g/day|Chewing tablets containing short-chain Fructooligosaccharides 4g/day
40847106|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 8g/day|Chewing tablets containing short-chain Fructooligosaccharides 8g/day
41030189|NCT03130582|DRUG|high-dose etoposide|an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.
41030190|NCT04358445|OTHER|Magnesium-Rich Artificial Cerebrospinal Fluid|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the operating room in a special container. Finally, it will be used in the operation by the neurosurgeons. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
41030191|NCT06205524|BIOLOGICAL|TI-0010|Sterile liquid for injection
41030192|NCT06205524|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
41030193|NCT05512494|BIOLOGICAL|Quadrivalent Influenza Vaccine (Split Virion), inactivated|The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. The four influenza strains（including 4 antigens H1N1, H3N2, BV and BY, 15μg for each) in 0.5 mL of sodium chloride,disodium hydrogen phosphate,sodium dihydrogen phosphate water for per injection.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
41030194|NCT01519206|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
41030195|NCT06044298|OTHER|procedural sedation|"Participants, adverse events during and after gastrointestinal procedures with sedation administered were observed and recorded. No intervention was performed."
41030196|NCT01436994|PROCEDURE|Block and Replace|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
41369636|NCT03561272|OTHER|Smart Phone Application|Oral medication adherence phone application.
41030197|NCT01436994|PROCEDURE|Dose Titration|"The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.~Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.~Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil."
41369637|NCT03561272|OTHER|POD|Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
40847107|NCT02140749|DIETARY_SUPPLEMENT|Placebo|Chewing tablets without short-chain Fructooligosaccharides
41030198|NCT01436994|DRUG|carbimazole|Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
41030199|NCT01436994|DRUG|propylthiouracil|50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
41030200|NCT01436994|DRUG|thyroxine|25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
41030201|NCT02370602|DRUG|TAK-063|TAK-063 tablets
41030202|NCT02370602|DRUG|[^11C]T-773|\[\^11C\]T-773 IV solution
41030203|NCT06342362|DRUG|Magnesium sulfate|Participants would be randomly assigned to either the treatment group (receiving magnesium sulfate) or the control group (receiving a placebo or standard treatment).
40847108|NCT03129360|DRUG|Levetiracetam|Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.
41030204|NCT06342362|OTHER|placebo or standard treatment)|placebo or standard treatment)
41030205|NCT03424681|DRUG|Modafinil|Modafinil 300 mg by mouth daily
41369638|NCT03157804|PROCEDURE|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
41369639|NCT03157804|BIOLOGICAL|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
41369640|NCT03157804|OTHER|Laboratory Biomarker Analysis|Correlative studies
41369641|NCT03157804|BIOLOGICAL|Filgrastim|Given subcutaneously (SC)
41369642|NCT03157804|DRUG|Plerixafor|Given SC
41369643|NCT03157804|PROCEDURE|Bone Marrow Aspiration|
40847109|NCT03129360|DRUG|Placebo|Prepared in capsules to appear identical to levetiracetam.
40847110|NCT05420649|PROCEDURE|Non-intubated Laryngomicrosurgery|Non-intubated LMS was performed with assistance of Optiflow (HFNO).
40847111|NCT04480216|DEVICE|MAGUS|"An upper endoscopy will be performed with the use of fluoroscopy. The MAGUS will be placed under fluoroscopy. The good positioning and the absence of any complications will be confirmed by gastroscopy.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 2 and mashed food up to 7 days post procedure"
40847112|NCT03543943|PROCEDURE|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively.
40847113|NCT03543943|PROCEDURE|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
41030206|NCT03424681|OTHER|Placebo|Placebo
41030207|NCT06143215|BEHAVIORAL|2 weeks revision|In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 2-4-6 weeks revision times could change diabetic foot reulceration rate.
41369644|NCT02087020|PROCEDURE|Debridement, antibiotics and implant retention|DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (\> 9 litre) with 0.9 % sodium chloride and then closed.
41369645|NCT05405621|DRUG|BAT8009 for Injection|BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.
41369646|NCT05302999|DRUG|Gabapentin|Generic gabapentin
41369647|NCT05302999|DRUG|Placebo|Inert cellulose
40847114|NCT03543943|PROCEDURE|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
40847115|NCT05691010|RADIATION|Intensity-modulated radiation therapy|After cycles 1, 2, 3 or 4 of chemotherapy, patients will receive IMRT to the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy delivered in 5 daily fractions of 5 Gy
40847116|NCT05691010|DRUG|Carboplatin|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
40847117|NCT05691010|DRUG|Paclitaxel|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
41030208|NCT00506493|DEVICE|Cardioblate Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
41030209|NCT00506493|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
41030210|NCT03478891|BIOLOGICAL|VRC-EBOMAB092-00-AB (MAb114)|VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
41030211|NCT05655793|DIAGNOSTIC_TEST|Tear Fluid collection (Schirmer's strip)|Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.
41030212|NCT05655793|DIAGNOSTIC_TEST|Retinal imaging|The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
41369648|NCT03557775|DEVICE|Inspiratory Muscle Strength Training (IMST)|IMST will be conducted using an inspiratory pressure threshold trainer (Philips Respironics® Threshold IMT or POWERbreathe® Medic Plus), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
41369649|NCT03557775|DEVICE|Expiratory Muscle Strength Training (EMST)|EMST will be conducted using an expiratory pressure threshold trainer (EMST150®), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing out forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
41369650|NCT03557775|BEHAVIORAL|Voice Exercises|Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
41369651|NCT03734874|DIETARY_SUPPLEMENT|hesperidin|500 mg hesperidin as two capsuls
41369652|NCT03734874|OTHER|control|no supplementation
41369653|NCT01387958|DRUG|LCQ908|
41369654|NCT01387958|DRUG|Placebo|
41369655|NCT00006001|DRUG|semaxanib|
40847118|NCT05172804|BEHAVIORAL|Progressive muscle relaxation|PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement \[11\].
40847119|NCT05172804|BEHAVIORAL|Guided Imagery|Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin \[11\].
40847120|NCT05172804|BEHAVIORAL|Mindfulness Meditation|"Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction... how interesting) \[11\]."
40847121|NCT05172804|OTHER|Control group|Participants in the control condition will be instructed to sit with their eyes closed and relax during the intervention periods. Participants in the control group will follow an identical procedure and time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
40847122|NCT03465930|PROCEDURE|Supermicrosurgical lymphatico-venous anastomoses|Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
41030213|NCT00591292|DRUG|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
41030214|NCT03869775|DEVICE|perfusion index monitor|perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor
41030215|NCT03869775|DIAGNOSTIC_TEST|ewing test|ewing tests will be applied to diabetic patients undergoing spinal anesthesia for cardıovascular autonomous neuropathıa diagnosis
41030216|NCT06535750|OTHER|Exercise|Participants were randomly divided into two treatment groups. There are 10 patients in each group. The patients in the control group received a standard treatment programme, while the patients in the experimental group received strengthening exercises with theraband in addition to the standard treatment programme. Treatment sessions for both groups lasted 50-55 minutes and were performed three days a week. Details of the study groups are given below.
41030217|NCT00186303|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
41162389|NCT03709056|DRUG|Propofol|Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.
41162390|NCT01871168|PROCEDURE|TAP block|Infusion of 0.5-1% lidocaine
41369656|NCT02013726|DEVICE|MBI Scan: The LumaGEM®|The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
41369657|NCT02013726|DEVICE|3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®|The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
41369658|NCT02620566|PROCEDURE|Bupivacain- Caudal|Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
41369659|NCT02620566|PROCEDURE|Bupivacaine- Local|Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
41369660|NCT04228718|BEHAVIORAL|Zarit Burden Interview Scale|It is a questionnaire consisting of 22 items. A minimum score of 0 and a maximum score of 88 can be obtained. The higher the scale score, the higher the difficulty experienced.
41162391|NCT01871168|PROCEDURE|Sham TAP block|Infusion of saline
41162392|NCT05951621|OTHER|Qigong|An ancient Chinese system of postures, exercises, breathing techniques, and meditations designed to improve and enhance the body's QI.
40847123|NCT06468670|DRUG|sintilimab，programmed death 1 monoclonal antibody|"short-course radiotherapy~+sintilimab (200mg, iv, D1, Q3W)"
40847124|NCT04277039|OTHER|osteopathic treatment + cognitive training|This intervention is a combination of manipulative osteopathic treatment and cognitive training to be administered each week for a 12-week study period
40847125|NCT04277039|OTHER|osteopathic treatment|manual treatment using osteopathic procedure. 8 sessions for a 12 week study period
40847126|NCT04277039|OTHER|usual care|administration of non-steroid inflammatory drug according to international guidelines
40847127|NCT03865836|BIOLOGICAL|ATB200|
40847128|NCT03865836|DRUG|AT2221|
40847129|NCT00516256|BEHAVIORAL|CHESS System|Internet-based computer program for 6 months.
40847130|NCT00516256|BEHAVIORAL|Cancer Information Mentor|Phone calls to the patient for 6 months.
41369661|NCT04228718|BEHAVIORAL|Family Needs Survey (FNS)|It is a questionnaire consisting of 35 items prepared to determine the requirements. In the FNS survey; The points given to the items can be directly collected and the amount of family needs can be determined over the total score. The lowest score that can be obtained from FNS is 29 and the highest score is 87. As the scores obtained from the scale and subscales increase, it can be said that the families' level of necessity increases.
41369662|NCT04228718|OTHER|Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)|CHOP-INTEND uses a scale of 0-64 points. Higher scores indicate better motor function. It is used to reliably measure natural motor function decline in infants with SMA Type 1.
41369663|NCT04228718|OTHER|Hammersmith Functional Motor Scale Expanded (HMFSE)|It is an extended version of the 20-item HFMS. Based on another scale known as GMFM, 13 items were added and expanded HFMS to include these elements. Therefore, HFMSE is a scale used to evaluate motor functions in types 2 and 3 SMA. It contains 33 items with a total score of 66 on a scale of 0, 1, 2.
41369664|NCT01608321|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
40847131|NCT04576897|DIAGNOSTIC_TEST|Velacur|Ultrasound elasticity imaging
40847132|NCT00652886|DRUG|Oxandrolone|Tablets, 10mg, single-dose
40847133|NCT00652886|DRUG|Oxandrin|tablets, 10mg, single-dose
40847134|NCT06584110|OTHER|Buddy-Up Dyadic Physical Activity (BUDPA) program|"BUDPA program is an overall 16-week training which comprises three phases: the conditioning, consolidating and habituating phases.~i) Conditioning Phase (1st - 4th week) is the preparatory phase to introduce exercise movements in group training.~ii) Consolidating Phase (5th -12th week) is the training phase for group-based exercise. Each exercise training session will be followed by a 20-min debriefing and goal-setting session. Self-practice will be recorded on a simple logbook.~iii) Habituating phase (13th-16th week) aims at supporting the care dyad to integrate the partner exercises into their daily lifestyle. A video call meeting with the care dyad in week 13 and week 15 will be scheduled to offer the support."
40847135|NCT06584110|OTHER|Usual care with waiting list|Usual care group will be put on a waiting list to receive the intervention (BUDPA program) after 24-weeks (T2) the second evaluation timepoint.
40847136|NCT00345618|DRUG|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
40847137|NCT00345618|DRUG|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
40847138|NCT00345618|DRUG|Placebo (for idrabiotaparinux sodium)|"0.5 mL pre-filled syringe~Subcutaneous injection"
40847139|NCT00345618|DRUG|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
40847140|NCT00345618|DRUG|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
40847141|NCT00345618|DRUG|Enoxaparin|"Prefilled syringes as locally registered~Subcutaneous injection"
41030218|NCT00186303|PROCEDURE|ablative allogeneic hematopoietic cell transplant|
41030219|NCT06031701|BEHAVIORAL|Neuro-psychosocial teleassistance program|The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration. The intervention is aimed at strengthening aspects of social cognition, self-esteem, social skills and aims at a reduction of symptomatology and a general improvement of psychological well-being.
41030220|NCT04867564|DIAGNOSTIC_TEST|Echocardiography|Traditional echocardiography and speckle tracking echocardiography (STE) before and 1, 6, and 12 months after RT
41030221|NCT03137147|BEHAVIORAL|Intervention for Sleep and Pain in Youth|See arm description.
41030222|NCT00404339|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
41030223|NCT00404339|BIOLOGICAL|tetanus toxoid helper peptide|
41369665|NCT01608321|DEVICE|Sham device|Placebo Device that simulates active rTMS treatment
41369666|NCT01660152|OTHER|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
41369667|NCT01660152|PROCEDURE|management of therapy complications|Receive VED
41369668|NCT01660152|PROCEDURE|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
41030224|NCT00404339|PROCEDURE|adjuvant therapy|
41369669|NCT03723460|OTHER|Passive Dietary Monitoring|Passive dietary monitoring devices will be used to monitor dietary intake in household in communities in Ghana and Kenya
41369670|NCT05762276|DRUG|VXX-401|A synthetic PCSK9 peptide-based immunotherapy
41369671|NCT05762276|BIOLOGICAL|Placebo|Normal saline
40847142|NCT03993041|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|Study therapists will deliver cognitive-behavioral therapy (CBT) based on an emotion-focused, transdiagnostic protocol. CBT targets problematic thoughts, feelings, and behaviors through goal-oriented, systematic procedures. The intervention used in this study is designed to target emotional processing with an emphasis on present-focused awareness, cognitive flexibility, emotional avoidance, awareness and tolerance of physical sensations, and situation-based emotion exposure. The intervention is designed to help individuals better understand emotional experiences in order to respond to intense emotions in a more adaptive way.
40847143|NCT01608841|DRUG|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
40847144|NCT04804150|DEVICE|Vacuum suspension system active or inactive|The device will be plugged in, or won't be plugged in, depending of the randomization. The patient and the investigator will not know whether the device is plugged in or not, and if the medical device is active or not
40847145|NCT05405140|OTHER|Shock wave therapy with multiphasic neuroplasticity based training protocol|Interventions program will be based on Activity dependent neuroplasticity targeting relevant impairments included: task specific practice, motor learning, strengthening, postural awareness, Balance training, aerobic and conditioning exercises, range of movement with Shock wave therapy for most of time of the day .
40847146|NCT05405140|OTHER|Conventional physical therapy|The CP program focused on the facilitation of movements on the paretic side, range of motion, stretching exercises, upper and lower limb strengthening exercises, and improving balance, standing, sitting, transferring, patients received a program for at least 30 sessions, 5 times per week for 6 or more weeks.
40847147|NCT04292613|OTHER|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
40847148|NCT03937492|OTHER|GMI protocol|"This group follow GMI program split in 3 step:~1. left/right descrimination~2. visual motor imagery~3. mirror therapy~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
40847149|NCT03937492|OTHER|Standard Rehabilitation Protocol|"This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
40847150|NCT02242383|DRUG|Telmisartan|
40847151|NCT02242383|DRUG|Telmisartan in combination with hydrochlorothiazide|
40847152|NCT00324376|DRUG|Sevelamer hydrochloride|
40847153|NCT04841772|DIETARY_SUPPLEMENT|Recover Vegan Protein Supplement|Post exercise protein supplement (26g pea protein)
40847154|NCT04841772|DIETARY_SUPPLEMENT|Placebo|Post exercise placebo supplement (32g maltodextrin)
40847155|NCT03079219|DRUG|Experimental drug: Aprepitant|Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
40847156|NCT03079219|DRUG|Experimental drug: Ondansetron|Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
40847157|NCT03079219|DRUG|Experimental drug: Dexamethasone|Day 1: 12mg QD
40847158|NCT03079219|DRUG|Experimental drug: Olanzapine|Day 1 to Day 5: 10mg QD
40847159|NCT03079219|DRUG|Standard: Aprepitant|Day 1: 125mg QD, Day 2 to Day3: 80mg QD
40847160|NCT03079219|DRUG|Standard: Ondansetron|Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
40847161|NCT03079219|DRUG|Standard: Dexamethasone|Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
40847162|NCT03012867|OTHER|Diben, Fresenius Kabi|Patients receive Diben continously for 7 days
40847163|NCT03012867|OTHER|Fresubin original fibre, Fresenius Kabi|Patients receive Fresubin original fibre continously for 7 days
40847164|NCT03076294|DEVICE|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
40847165|NCT03076294|OTHER|Manual therapy (MT)|This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
40847166|NCT02764684|DRUG|Probiotic|The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
40847167|NCT01020253|DRUG|alendronate, alfacalcidol|Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
40847168|NCT05407857|BEHAVIORAL|multi-modal non-pharmacological intervention|multi-modal non-pharmacological intervention including the management with nutrition, exercise and cognitive programs
41162393|NCT05951621|BEHAVIORAL|guidance of nutrition and exercise|Provide health promotion and guidance to participants on diet and physical exercise
41162394|NCT02716753|BIOLOGICAL|seminal plasma|
41162395|NCT02716753|BIOLOGICAL|Physiological NaCL solution|
40847169|NCT04759469|BEHAVIORAL|High-intensity interval training|High-intensity interval training is a form of intermittent training using relatively high exercise intensity
40847170|NCT04759469|BEHAVIORAL|Moderate intensity interval training|Moderate intensity interval training is a form of intermittent training using moderate exercise intensity
41162396|NCT06061224|BEHAVIORAL|early mobilization (physical therapy)|"The investigators will consult rehabilitation department for Physical Therapy and patients will be grouped as clinically allocation.~Protocols for consideration of initiation The timing is 72 hours after admission to ICU, early mobilization doses and duration is as the protocol of rehabilitation department"
41369672|NCT04600206|OTHER|Self-report questionnaires|"In this longitudinal cohort study, patients and caregivers will not receive an intervention. In addition to the outcomes named in the section Outcome Measures patients and caregivers will complete self-report questionnaires for~Existential distress (Demoralization Scale-II, Death and Dying Distress Scale, Depressive Experiences Questionnaire, Revised Loss Orientation and Life Engagement in Advanced Cancer Scale, Sense of Dignity Item, Patient Dignity Inventory, Marwit-Meuser Caregiver Grief Inventory, Caregiver Guilt Questionnaire)~Need for and utilization of psychosocial support~Resources (Sources of Meaning and Meaning in Life Questionnaire, Questionnaire on the Defiant Power of the Human Spirit) and~Control variables (Memorial Symptom Assessment Scale, PHQ-9 and GAD-7)"
41369673|NCT00544570|BIOLOGICAL|filgrastim|
41369674|NCT00544570|DRUG|carmustine|
41369675|NCT00544570|DRUG|cyclophosphamide|
40847171|NCT05556577|DRUG|investigational medicine product (IMP)|Investigational medicine product (IMP) received at SURMOUNT-CN trial
40847172|NCT05556577|OTHER|placebo|Placebo received at SURMOUNT-CN trial
40847173|NCT05860153|DRUG|Levetiracetam|Group with oral levetiracetam at a dose of 15-20 mg/kg/day
40847174|NCT05860153|DRUG|Diazepam|Group with diazepam at a dose of 0.3 mg/kg/dose
40847175|NCT03598309|DRUG|Curcumin C3 complex®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
40847176|NCT03598309|DRUG|Lovaza®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
41369676|NCT00544570|DRUG|etoposide|
41369677|NCT00544570|DRUG|melphalan|
40847177|NCT03598309|OTHER|Placebo|Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
41369678|NCT00544570|PROCEDURE|autologous hematopoietic stem cell transplantation|
41369679|NCT00544570|PROCEDURE|peripheral blood stem cell transplantation|
41369680|NCT00544570|RADIATION|radiation therapy|
41369681|NCT00544570|RADIATION|total-body irradiation|
41369682|NCT04647773|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
41369683|NCT04647773|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
40847178|NCT04464096|OTHER|non|non
41369684|NCT04647773|DRUG|HSK16149 60mg BID|HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
41369685|NCT04647773|DRUG|HSK16149 80mg BID|HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
41369686|NCT04647773|DRUG|Pregabalin 150mg BID|Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
41369687|NCT04647773|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
41369688|NCT01934842|DEVICE|TAP20-C|
41369689|NCT01934842|DEVICE|SAFE-T-FILL|
40847179|NCT04071678|BEHAVIORAL|Careful examination during endoscopic procedures to identify lesions|When the AI model alarms, check carefully to confirm the lesion
40847180|NCT06220019|DRUG|TCM|We will perform subgroup analyses based on specific TCM interventions (such as Chinese patent medicines or external therapies) and the duration of TCM treatment (for example, comparing patients who receive continuous oral Chinese patent medicine for two months or more each year with those who do not). These analyses will assess the efficacy and safety of TCM.
40847181|NCT03197376|BIOLOGICAL|Pneumosil|10-Valent Pneumococcal Conjugate Vaccine
40847182|NCT03197376|BIOLOGICAL|Synflorix|Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
40847183|NCT04033783|OTHER|6MWT - accompanied|Assessor walks behind the patient
40847184|NCT04033783|OTHER|6MWT - not accompanied|Assessor does not walk behind the patient
40847185|NCT00196456|PROCEDURE|photosensitisation|
40847186|NCT02136628|PROCEDURE|Method RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
40847187|NCT00518193|DRUG|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
40847188|NCT01912690|OTHER|aerobic training|
40847189|NCT01912690|OTHER|aerobic and strength training|
41369690|NCT04605120|PROCEDURE|Cervical fusion|1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
41369691|NCT00677066|PROCEDURE|Home oxygen therapy|Administer oxygen at home or in hospital
41369692|NCT04436497|DRUG|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"
41369693|NCT04436497|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"
41369694|NCT05874895|PROCEDURE|Manual Lymphatic Drainage|Manual lymphatic drainage massage involves gently manipulating specific areas of the body to help lymph move to an area with working lymph vessels.
41369695|NCT05874895|PROCEDURE|Usual Care|Usual care provided for patients in septic shock.
41030225|NCT04931511|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|Gluteal muscle injection(Compound betamethasone 1ml + Sodium Chloride Injection 4ml) + Subacromial Ultrasound Guided injection(Sodium Chloride Injection 5ml)
41030226|NCT04931511|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|Gluteal muscle injection (Sodium Chloride Injection 5ml)+ Subacromial Ultrasound Guided injection (corticosteroid 1ml+Sodium Chloride Injection 4ml)
41030227|NCT04931511|BEHAVIORAL|Physical therapy|paticipant will be teached by the Physicaltherapist to reduce the shoulder pain at home
41030228|NCT02752997|OTHER|Pharmacist discharge medication services|Included in arm descriptions
41030229|NCT05928533|OTHER|clean and boost enamel cleanser of vista apex , RE GEN universal adhesive from vista apex , RE GEN Bio active flowable composite form vista apex|the clean and boost use to clean the tooth surface after cavity preparation without causing severe form of hypersensitivity then the RE GEN universal adhesive is applied by using a brush and cured with the RE GEN flowable composite for 20 seconds. Curing both together increase the bioactivity of the material.
41030230|NCT00002872|BIOLOGICAL|bleomycin sulfate|
41030231|NCT00002872|DRUG|doxycycline|
41030232|NCT00002872|OTHER|talc|
41030233|NCT02769091|DRUG|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
41030234|NCT02769091|DRUG|Placebo|
41030235|NCT00034762|DRUG|risperidone|
41162397|NCT05770908|OTHER|Therapeutic exercise program|"Therapeutic exercise program based on increasing resistance with elastic bands or weights. The programmes are composed of combinations of the following exercises:~* Scaption with elastic band.~* External rotation at 0º of abduction with elastic band.~* Internal rotation at 0º of abduction with elastic band.~* Shoulder protraction in supine position with weights.~* Low row with elastic band.~* Horizontal adduction stretching."
41162398|NCT05770908|OTHER|Multimedia animation information|Multimedia animation videos (including audio) showing the performance of the prescribed exercises.
41502866|NCT03645239|OTHER|Preoperative pain assessment|"Patients will be asked to rate, using a 0-10mm visual analog scale (VAS), their surgical anxiety level (On a scale of 0-100, with 0 being not anxious at all to 100 being extremely anxious, how anxious are you about your upcoming surgery?), their anticipated pain (On a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing after your upcoming surgery?), and using a categorical scale, their anticipated pain medication need (On a scale of 0 to 5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much pain medication do you anticipate needing after your upcoming surgery?)."
41369696|NCT02344758|DEVICE|Non-invasive lateral flow test for monitoring gluten intake|
41369697|NCT02344758|BEHAVIORAL|gluten-free diet (GFD)|
41502867|NCT03645239|OTHER|Questionnaires|Questionnaires including Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L, Edinburgh Postnatal Depression Scale (EPDS), Pain Catastrophizing Scale (PCS), Central Sensitisation Inventory (CSI), pain survey and breastfeeding questionnaire will be administered to the patient.
41162399|NCT05770908|OTHER|Paper-based information|Paper-based information showing the performance of the prescribed exercises, based on figures and a brief description of the exercise performance.
41369698|NCT02344758|BEHAVIORAL|gluten-containing diet|
41369699|NCT05058599|DIAGNOSTIC_TEST|DM|A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
41369700|NCT03924570|BEHAVIORAL|IPASS|IPASS is behavioral package to improve transitions of care by providing a framework to hands off.
41502868|NCT03645239|OTHER|Headspace|The mindfulness exercise mobile application, Headspace, will be downloaded into the patients' mobile devices. Patients will be asked to experience a mindfulness exercise for 10-30 minutes before delivery. HADS and pain score will be asked after the intervention.
41369701|NCT03433482|BIOLOGICAL|MenACWY liquid|At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.
41502869|NCT04257149|DIAGNOSTIC_TEST|Hemorrhagic stroke group (group A)|Group A: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
41030236|NCT01529957|DRUG|Nemonoxacin Malate Sodium Chloride|Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
41030237|NCT00004010|BIOLOGICAL|bleomycin sulfate|
41030238|NCT00004010|BIOLOGICAL|filgrastim|
41030239|NCT00004010|DRUG|ABVD regimen|
41030240|NCT00004010|DRUG|cyclophosphamide|
41030241|NCT00004010|DRUG|dacarbazine|
41030242|NCT00004010|DRUG|doxorubicin hydrochloride|
41030243|NCT00004010|DRUG|etoposide|
41030244|NCT00004010|DRUG|prednisone|
41030245|NCT00004010|DRUG|procarbazine hydrochloride|
41030246|NCT00004010|DRUG|vinblastine sulfate|
41030247|NCT00004010|DRUG|vincristine sulfate|
41030248|NCT00004010|RADIATION|radiation therapy|
41030249|NCT00668460|DRUG|Lactic acid (Dermacid)|
41162400|NCT02343978|DRUG|KWA-0711|
41162401|NCT01458964|DRUG|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
41162402|NCT00772655|DRUG|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 \[if platelets are below 150000/µl only 11 MBq/kg are administered).
41369702|NCT03433482|BIOLOGICAL|MenACWY|At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY_1) or in phase 2 of the study (subjects randomized to study arm ACWY_2), administered by intramuscular injection in the deltoid of the non-dominant arm.
41369703|NCT02444676|OTHER|Stratification and outcomes|No necessary
40847190|NCT05933668|BIOLOGICAL|YK0901 cells|On day 0, the TCR-T cells will be administered one time. Drug: Fludarabine + Cyclophosphamide+Oxaliplatin Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 300mg/m²/day×3 days Oxaliplatin：100mg×1day Drug: IL-2 After 18-24 hours of infusion of YK0901 cells, the patients will be given a small dose of IL-2 subcutaneously, 500,000 IU/time, twice a day (interval 10-12 hours), for 14 days.
40847191|NCT06238206|OTHER|Focus group discussion|The participant will be asked to take part in three separate focus group discussions implementing the co-design principle. Following the co-design principle the participants will actively contribute towards the primary outcomes. Open questions will be asked to guide the discussion. Interaction between participants will be encouraged.
40847192|NCT03323866|DRUG|Budesonide 0.5 MG/ML|2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
40847193|NCT03323866|DRUG|Mometasone nasal spray|Mometasone 50 mcg/spray 2 sprays twice daily
40847194|NCT06525233|OTHER|Physiotherapy and rehabilitation|The aerobic exercise is very crucial part of cardiac rehabilitation. This study compares the effects of interval and continuous training which are the two types of aerobic training on persons' life quality and exercise capacity diagnosed coronary artery disease patients.
40847195|NCT00306709|BEHAVIORAL|culturally adapted behavior change|Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
40847196|NCT00003569|DRUG|cisplatin|
40847197|NCT00003569|DRUG|dimesna|
40847198|NCT00003569|DRUG|paclitaxel|
41369704|NCT06365164|BEHAVIORAL|Tactile stimulation|The procedure consists of brief perioral tactile stimulation. The procedure is filmed in order to record and evaluate the response of the newborn to the stimulation. During the same intervention, each newborn will receive external stimulation (the experimenter repeatedly and regularly touches the corner of the infant's mouth slowly with the tip of his index finger) followed by facilitated self-stimulation (the experimenter will place the newborn's elbow close to his body, allowing him to touch his face alone with his hand). There will also be an initial phase and a final 30-second phase in which the newborn is observed without any stimulation.
41369705|NCT02638818|PROCEDURE|minimally invasive pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
40847199|NCT02572765|OTHER|PET/CT scan|PET/CT scan
40847200|NCT00005116|BEHAVIORAL|psychotherapy|
40847201|NCT02812927|DEVICE|Edelvaiss Multiline-8|Optimised infusion line
40847202|NCT02812927|DEVICE|Standard infusion line|
40847203|NCT03977493|DRUG|Xeomin|One injection of 2.5 to 40 U in each muscle. Injection repeated after 6 weeks if considered necessary
40847204|NCT03977493|DRUG|Placebo - Concentrate|One injection in each muscle.
40847205|NCT05096312|DIETARY_SUPPLEMENT|Zinc gluconate|oral zinc gluconate 200mg
40847206|NCT05096312|DRUG|Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]|Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening
40847207|NCT05096312|OTHER|Placebo|contains cornstarch
40847208|NCT03045341|DRUG|NB medication (Naltrexone Bupropion combination)|NB medication
40847209|NCT03045341|BEHAVIORAL|Behavioral Weight Loss (BWL) counseling|BWL counseling
40847210|NCT03045341|OTHER|Placebo|Placebo
40847211|NCT04942405|BIOLOGICAL|TURCOVAC|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,28
41369706|NCT02638818|PROCEDURE|traditional pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
41502870|NCT04257149|DIAGNOSTIC_TEST|Ischemic stroke group (group B)|Group B: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
40847212|NCT04942405|BIOLOGICAL|CoronaVac|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) vaccine at the schedule of day 0, 28
40847213|NCT01935414|DEVICE|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
40847214|NCT01935414|DEVICE|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
40847215|NCT01533662|DRUG|phenylephrine infusion|patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
41369707|NCT03401502|DRUG|Ranolazine|Oral, b.i.d
41369708|NCT03401502|DRUG|Placebos|Oral, b.i.d
40847216|NCT01533662|DRUG|patients receiving saline infusion|patients more than 60 years receiving 100micrograms of saline infusion
40847217|NCT03796351|DRUG|MT10107|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
40847218|NCT03796351|DRUG|Botox|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
40847219|NCT00490048|PROCEDURE|Induced sputum (inhalation of 3.5% saline)|
41369709|NCT02058849|DRUG|Beetroot|10g Beetroot powder mixed with 4-8 oz.
41369710|NCT02058849|OTHER|Placebo|Placebo
41030250|NCT02667912|PROCEDURE|Distal renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches of the renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus
41030251|NCT02667912|PROCEDURE|Conventional renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of the renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
41369711|NCT03093480|BIOLOGICAL|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
41369712|NCT02688881|DRUG|sirolimus|Rapamune
41369713|NCT03648021|DRUG|Paracetamol|"\>50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~\>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose"
41369714|NCT03648021|DRUG|Placebo|100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
41369715|NCT00083226|DRUG|doxorubicin|Given IV
41369716|NCT00083226|DRUG|bortezomib|Given IV
41369717|NCT04942951|DIAGNOSTIC_TEST|Gynecological examination|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
41369718|NCT04942951|OTHER|Pelvic Organ Prolapse Quantification (POP-Q)|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
41369719|NCT04942951|OTHER|Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire|ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.
41369720|NCT04942951|OTHER|Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire|PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
41369721|NCT05598411|DRUG|Oral Glucocorticoids|methylprednisolone 24mg qd, 2-week duration
41369722|NCT05598411|DRUG|Oral placebo|oral placebo 24mg qd, 2-week duration
41369723|NCT05138458|BIOLOGICAL|MT-101|CD5 ATAK cells
41369724|NCT05138458|OTHER|MT-101 + Conditioning (Lymphodepleting) Chemotherapy|IV administration of fludarabine and cyclophosphamide
41502871|NCT04257149|DIAGNOSTIC_TEST|Stroke mimic group (group C)|Group C: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
40847220|NCT03387358|DEVICE|Nasal bridle securement device for small bore feeding tubes|A Nasal bridle securement device is an alternative method to securing small bore feeding tubes which are most commonly secured with adhesive tape to the nose. A nasal bridle securement device instead secures the feeding tube to a cloth ribbon that is inserted in one nostril, over then nasal bridle and out the other nostril.
41030252|NCT01108653|OTHER|Usual care sick-leave management|Patients randomized to usual care. Follow up after discharge by general practitioner (GP) according to local practice.
41369725|NCT01348074|DRUG|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
41030253|NCT01108653|OTHER|Structuralised sick-leave program|Patients randomized to the structuralized program will get full time sick-leave for 2 weeks after discharge.Cardiologist will be responsible for individual adaption of each patient's sick-leave and follow-up.
41030254|NCT00742703|OTHER|Mineralized water|
41030255|NCT00742703|OTHER|Low mineralized water|
41030256|NCT04326491|DIAGNOSTIC_TEST|Breath Biopsy|Analysis of breath samples to identify volatile molecules specific to HCC
41369726|NCT03083795|BEHAVIORAL|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
41369727|NCT03306875|BEHAVIORAL|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
41369728|NCT06510257|DRUG|Reconyl|1 tablet of Reconyl, 3 times daily
41369729|NCT06510257|DRUG|Placebo tablet of Reconyl|1 tablet of placebo Reconyl, 3 times daily
41369730|NCT04344158|DRUG|AK105 Injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
41369731|NCT04344158|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
41369732|NCT04344158|DRUG|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
41369733|NCT00413322|DRUG|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
41369734|NCT00413322|DRUG|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
41369735|NCT02479594|BEHAVIORAL|competence-feedback|competence-feedback
41369736|NCT02479594|OTHER|control|control group without competence-feedback
41369737|NCT03998696|DRUG|Cisplatin 40 mg/m2|Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
41369738|NCT03998696|DRUG|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
41369739|NCT04196023|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
41502872|NCT06147830|OTHER|None (Observational study)|Not Applicable since Observational Study
41502873|NCT06260124|OTHER|Slow tempo|A single Greek traditional dance of slow tempo lasting 3-4 minutes.
41502874|NCT06260124|OTHER|Moderate tempo|A single Greek traditional dance of moderate tempo lasting 3-4 minutes.
41369740|NCT04196023|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
41369741|NCT01503866|DRUG|bardoxolone methyl|oral, single dose
41369742|NCT04548401|DRUG|Antiplatelet Drug|aspirin and/or clopidogrel or ticagrelor
41369743|NCT04698291|PROCEDURE|Blood Donation|The blood donation will take place at the Gene \& Health clinical assessment centre facilities. A trained member from Gene \& Health program will be responsible for taking the blood samples.
41502875|NCT06260124|OTHER|Fast tempo|A single Greek traditional dance of fast tempo lasting 3-4 minutes.
41369744|NCT00439010|DRUG|[123I] AV 39|
40847221|NCT06168266|DEVICE|Eccentric bike|Received eccentric cycling exercise
41369745|NCT03420456|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
40847222|NCT06168266|OTHER|conventional group|Received conventional treatment
40847223|NCT02343718|DRUG|Vinblastine|
40847224|NCT02343718|DRUG|Temsirolimus|
40847225|NCT04217213|PROCEDURE|Intercostal nerve block|In the experimental group, the surgeons used 0.5% ropivacaine combined with mecobalamine (0.5mg) before the operation to perform intercostal nerve block in the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity, and injected 5ml in each intercostal nerve block.In the control group, surgeons used 0.5% ropivacaine alone before the operation to perform intercostal nerve block through the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity. 5ml was injected into each intercostal nerve block.
40847226|NCT03299712|DEVICE|ArteFill|soft tissue filler
40847227|NCT02735954|OTHER|Marijuana|This is an observational study looking at the effects of marijuana on health, including lung health and sleep.
41030257|NCT01686711|DRUG|AD-4833 15 mg|
41030258|NCT01686711|DRUG|AD-4833 30 mg|
41162403|NCT00772655|DRUG|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
41162404|NCT00494208|DRUG|Testosterone|Testosterone ester
41162405|NCT05394389|OTHER|sensory stimulating therapy|therapy session in the snoozlen room accompanied by social support.
41162406|NCT05394389|OTHER|social support|ten minutes of conversing.
40847228|NCT03326622|OTHER|standard care|A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
41162407|NCT00175370|DRUG|Vancomycin|Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
41162408|NCT00574626|PROCEDURE|PBSCT|Peripheral Blood Stem Cell Transplant
41369746|NCT03082040|BEHAVIORAL|home-based breathing training|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
41369747|NCT03457701|DRUG|Daprodustat|Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
41369748|NCT03457701|DRUG|rhEPO|rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
41369749|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (57Fe)|57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
40847229|NCT03326622|OTHER|moderate exercise|A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
41502876|NCT03496610|DRUG|Liposomal Bupivicaine|Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
41502877|NCT03496610|PROCEDURE|QL Block|Patient will receive ultrasound guided QL Block
40847230|NCT04623229|PROCEDURE|MCS|Manual Cataract Surgery
40847231|NCT04623229|PROCEDURE|ReLACS Early|ReLACS with early administration of anesthesia
40847232|NCT04623229|PROCEDURE|ReLACS Standard|ReLACS with standard time administration of anesthesia
41030259|NCT01686711|DRUG|Placebo|
41030260|NCT06104215|BIOLOGICAL|BGT007H Injection|BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10\^8 cells,5.0 ×10\^8 cells, 1.0× 10\^9 cells,3.0 × 10\^9 cells,6.0 ×10\^9 cells.
41030261|NCT04475601|DRUG|Enzalutamide Pill|The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
41030262|NCT01800877|DRUG|Vasopressors|
41030263|NCT04867577|DIAGNOSTIC_TEST|CT scan of lung and spine|Dual energy CT scan of thorax and spine
41162409|NCT00574626|PROCEDURE|Bone Marrow Transplant|Bone Marrow Transplant
41162410|NCT01176435|DRUG|Levodopa|Solution taken orally three times a day.
41369750|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (58Fe)|58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
41030264|NCT03826277|OTHER|Melanostop peel|"Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol, 6% phytic acid, 3% tranexamic acid. (4 treatments, performed at 2-week intervals), in combination with home care products (twice daily):~* a facial tonic and cream containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid,~* sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR"
40847233|NCT06388317|BEHAVIORAL|Adaptive Step Goal (Intervention)|Receiving automated personalized daily step goals,
40847234|NCT06388317|BEHAVIORAL|Static Step Goal (Control)|Receiving fixed daily step goals of 10,000 steps per day
41369751|NCT05297162|DIAGNOSTIC_TEST|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"The prostate profile and ROIs will be drawn on PSMA PET and mpMRI and fused in real time with the TRUS image stack during biopsy. Biopsies, transrectal or transperineal according to lesion site, will be performed with patients in the dorsal lithotomy position, under antibiotic prophylaxis and local anesthesia, using 3D triplane transrectal ultrasound system (BK Medical, Analogic Ultrasound Group, Pro Focus, Transducer 8818, 6/9 MHz).~Biopsy cores will be numbered according to ROI number and topography. Specimens will be processed and evaluated by a genitourinary pathologist. Tumor foci will be quantified and graded according to the ISUP consensus conference on Gleason grading."
41369752|NCT02497274|OTHER|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
41369753|NCT06377267|DRUG|Bevacizumab|Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion.
41369754|NCT06377267|DRUG|Olaparib|Olaparib dosing is oral at 300 mg twice daily
41369755|NCT00107601|DRUG|Insulin|
41369756|NCT05461846|OTHER|integrated neuromuscular inhibition technique|is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
41030265|NCT05600608|DIETARY_SUPPLEMENT|Oral Stimulant Drink|please see description of the drink in the arm/ group section
41369757|NCT05793996|DRUG|Ferinject|The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.
41369758|NCT05793996|OTHER|Diet therapy|Patients will receive diet therapy to correct latent iron deficiency
41369759|NCT03626337|DRUG|Thiamine 100 MG/ML|100 mg thiamine provided as intramuscular injection
41369760|NCT00000565|PROCEDURE|intermittent positive-pressure breathing|
41369761|NCT00452127|DRUG|PRO131921|Escalating doses by IV infusion
41369762|NCT02696382|BEHAVIORAL|Progressive High Intensity Therapy (PHIT)|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
41369763|NCT02696382|BEHAVIORAL|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
41369764|NCT00714025|DRUG|RAD001|RAD001 10mg, daily, PO
41369765|NCT02672475|DRUG|Galunisertib|Given PO
41369766|NCT02672475|OTHER|Laboratory Biomarker Analysis|Correlative studies
41369767|NCT02672475|DRUG|Paclitaxel|Given IV
41369768|NCT05799976|BEHAVIORAL|Text message nudge|The text message nudge will be sent to patients 3 days and 1 day prior to a visit with the primary care practices and notify them of up to 3 care gaps based on electronic health record data. Care gaps will be selected based on availability and ranked in this order: influenza vaccination, pneumococcal vaccination, breast cancer screening, colorectal cancer screening, hemoglobin A1 testing, or statin therapy.
41502878|NCT03179215|DIAGNOSTIC_TEST|fluid challange|A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge
41502879|NCT04404283|DRUG|Brentuximab vedotin|1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks
41502880|NCT04404283|DRUG|Rituximab|375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
41502881|NCT04404283|DRUG|Lenalidomide|20 mg given by mouth (orally) daily
41502882|NCT04404283|OTHER|Placebo|Administered via intravenous infusion every 3 weeks
41502883|NCT05272150|DRUG|Guselkumab|Participants will receive guselkumab as subcutaneous injection.
41502884|NCT05272150|DRUG|Placebo|Participants will receive placebo as subcutaneous injection.
41030266|NCT01659021|DRUG|Idelalisib|150 mg tablets administered orally twice daily
41030267|NCT01659021|DRUG|Ofatumumab|Administered intravenously
41030268|NCT00022568|BIOLOGICAL|recombinant vaccinia-TRICOM vaccine|
41030269|NCT02256475|DRUG|NBI-98854|
41162411|NCT01176435|DRUG|Levodopa|Solution taken orally three times a day.
41162412|NCT01176435|DRUG|Placebo|Solution taken orally three times a day.
41162413|NCT02396758|DEVICE|Ekosonic® Endovascular Device ultrasonic infusion catheter|r-tPA will be administered via EKOS.
41162414|NCT02396758|BIOLOGICAL|Recombinant tissue plasminogen activator|Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.
41502885|NCT02425904|DRUG|Clofarabine|second-generation purine nucleoside analog
41502886|NCT05055050|DRUG|UGN-201|Intravesical 200 mg /50 ml x 1 dose
41502887|NCT03349983|BIOLOGICAL|MVA-BN-Brachyury/ FPV-Brachyury|Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months
41502888|NCT06633029|DEVICE|Prismaflex HF20|CRRT fluid management and reduction of uremic toxins.
41502889|NCT06633029|DEVICE|Prismaflex M60|CRRT fluid management and reduction of uremic toxins.
41030270|NCT02240082|BEHAVIORAL|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
41030271|NCT01017406|DEVICE|PSU heel cushion and plantar fascia specific stretching exercise|"* Wear heel cushion during daily activity~* Plantar fascia stretching exercise 3 times per day"
41369769|NCT02847663|DEVICE|Kryosauna Space Cabin|The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.
41369770|NCT02847663|OTHER|cold water tub|The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
41369771|NCT02196025|DEVICE|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
41369772|NCT02700893|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
41369773|NCT02700893|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
41369774|NCT00000658|DRUG|Bleomycin sulfate|
41369775|NCT00000658|DRUG|Vincristine sulfate|
41369776|NCT00000658|DRUG|Doxorubicin hydrochloride|
41502890|NCT05898932|OTHER|Medical Management|Participants will be managing condition with medication
41502891|NCT05898932|OTHER|Surgical Management|Participants will be managing condition with a surgery
41502892|NCT06230406|PROCEDURE|surgery for artherial and/or venous diseases|collection of vascular samples from surgery and blood samples
41030272|NCT00005853|BIOLOGICAL|anti-thymocyte globulin|
41502893|NCT05733221|DEVICE|3D Printed Model|3D Printed Model generated pre-operatively of the patients mandible.
41502894|NCT00043810|PROCEDURE|Gelonin|Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10\^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.
41369777|NCT00000658|DRUG|Cyclophosphamide|
41369778|NCT00000658|DRUG|Allopurinol|
41030273|NCT00005853|BIOLOGICAL|etanercept|
41369779|NCT00000658|DRUG|Methotrexate|
41030274|NCT02501460|OTHER|Educational handouts|Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.
41162415|NCT00702273|DRUG|150 µg Corifollitropin Alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
41369780|NCT00000658|DRUG|Cytarabine|
41369781|NCT00000658|DRUG|Leucovorin calcium|
41369782|NCT00000658|DRUG|Sargramostim|
41369783|NCT00000658|DRUG|Dexamethasone|
41369784|NCT02883400|DRUG|Spironolactone|spironolactone 25 mg up to 50 mg
41162416|NCT00702273|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
41369785|NCT02279602|DRUG|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
41369786|NCT02950831|OTHER|Accelerometry|Record of activity levels using a wrist worn accelerometer
41369787|NCT00923481|DRUG|Fostamatinib disodium|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
41369788|NCT03737409|OTHER|Ambulatory Oxygen Therapy|Supplemental oxygen delivered during exercise and activities of daily living via a portable oxygen concentrator
41369789|NCT03737409|OTHER|Sham Ambulatory Oxygen Therapy|Air delivered during exercise and activities of daily living via a portable oxygen concentrator that has been modified to deliver air
41369790|NCT04704752|DIAGNOSTIC_TEST|Swallowing Evaluation|Study Evaluation includes basic test batteries. These are observational.
41369791|NCT04765761|DEVICE|PLMA with introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be kept in-situ throughout the duration of positive pressure ventilation
41369792|NCT04765761|DEVICE|PLMA without introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be removed after insertion and patient will be ventilated using PLMA without the introducer in-situ throughout the duration of positive pressure ventilation
41369793|NCT05999227|DRUG|68Ga-FAPI-04|A fibroblast activation protein (FAP) -targeted PET imaging agent
41502895|NCT00043810|DRUG|Busulfan|130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
41369794|NCT05999227|DRUG|18F-FDG|A general glucose metabolism imaging agent
41369795|NCT03824015|BEHAVIORAL|Keeping Adults Physically Active (KAPA) intervention|The Keeping Adults Physically Active (KAPA) intervention included six 60-90 minute group motivational interviewing sessions which were supported by a pedometer and a file containing information about locally run physical activity services, a home exercise booklet and written information on different types of lifestyle and transport related physical activity. During sessions the KAPA participants created physical activity plans and reflected on their physical activity diaries and personal physical activity goals. Various sub-sets of behaviour change techniques were delivered to help support the participants in continuing to be active.
41369796|NCT03824015|OTHER|Usual Care|Usual care was delivered for the duration of the KAPA feasibility study. The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package. Upon initiating the KAPA feasibility study it was unknown what the service provider would deliver as usual care. Therefore a study objective was to describe the usual care package delivered by the service providers.
41369797|NCT04903938|BEHAVIORAL|Primary And Secondary Abilities Among The Individuals With Antisocial Personality Disorder Within The Scope Of Positive Psychotherapy: Their Relationship With Criminal Behaviors, Aggression And Anger|Participants will be given scales with validity and reliability studies in Turkish.
41369798|NCT05216289|DIETARY_SUPPLEMENT|Probiac|Oral probiotic composed of Lactobacillus acidophilus, Bifidobacterium lactis, vitamins and minerals - Exímia Probiac® (EP), in combination with 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
41369799|NCT05216289|OTHER|Placebo|Placebo + 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
41369800|NCT05571969|DRUG|2X-121 and dovitinib|"The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;"
41369801|NCT01065662|DRUG|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
41369802|NCT01065662|DRUG|cediranib|Taken orally daily
41369803|NCT05151809|OTHER|Clinical information|The investigators will recruit PBC patients and collect important clinical information and laboratory investigation, together with biological samples.
41502896|NCT00043810|DRUG|Fludarabine|40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
41502897|NCT06378398|DRUG|Omeprazole|Two 20 mg/day omeprazole tablets taken before the first meal each day for 25-45 days.
41502898|NCT06378398|DRUG|Aspirin|Two 81 mg/day aspirin tablets taken before the first meal each day for 25-45 days.
41369804|NCT04634565|DRUG|PF-06651600|oral PF-06651600 tablet 200 mg once daily
41369805|NCT05524376|OTHER|no intervention|no intervention
41369806|NCT02618681|OTHER||
41369807|NCT01784172|DEVICE|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
41502899|NCT04965077|DRUG|Recombinant Humanized Monoclonal Antibody MIL97 for Injection|"Dose escalation phase: The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL97 every 3 week on Day 1 of each cycle. Additional 1 or 2 dose cohorts will receive an intravenous infusion of MIL97 every 2 week on Day 1 of each cycle after last patient finishes DLT observation period.~Dose expansion phase: One or two recommended expansion doses (either Q3W or Q2W) will be selected from 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg) based on results of dose escalation phase. MIL97 will be administered via intravenous infusion for 60 to 90 minutes on Day 1 of each cycle."
41502900|NCT05946616|OTHER|Transcranial alternating current stimulation (tACS) combined with behavioral intervention|Transcranial alternating current stimulation (tACS) combined with behavioral intervention (memory interference).
41502901|NCT05946616|OTHER|Inactive (sham) stimulation combined with behavioral intervention|Inactive (sham) stimulation combined with behavioral intervention (memory interference)
41502902|NCT05754710|DRUG|Xeljanz|Juvenile Idiopathic Arthritis (JIA) patients with Xeljanz
41502903|NCT03690661|BEHAVIORAL|Intervention Video Game|"The intervention game employs evidence-based serious game mechanics (e.g., storylines, long-term goals, scaling difficulty) to design a learning environment that maximizes opportunities for adolescents with ASD to discover the functional utility of eye gaze cues."
41502904|NCT03690661|BEHAVIORAL|Placebo Control Game|The placebo game will have all the elements of the serious game mechanics of the intervention game (narrative storylines, long-term goals, scaling difficulty), but will not provide the learning opportunities regarding eye gaze cues.
41502905|NCT06336590|BEHAVIORAL|Morning Exercise|Exercise is changed from normal (6pm-11pm) exercise to morning (6am-11am) exercise.
41502906|NCT04239027|DRUG|RTH258/Brolucizumab|"Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients were treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment every 8 weeks (Q8W) or every 12 weeks (Q12W) depending on disease activity from Week 16/Week20 to Week 40/Week 44.~Brolucizumab was administered by an intravitreal (IVT) injection to the study. eye."
41369808|NCT01784172|DEVICE|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
41369809|NCT04624295|DRUG|Early aspirin Therapy|Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
41369810|NCT04624295|DRUG|Non-Early aspirin Therapy|Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
41369811|NCT01746082|BIOLOGICAL|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects \>/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
41369812|NCT04425876|DRUG|Fluzoparib|Fluzoparib combined with mFOLFIRINOX followed by maintenance Fluzoparib monotherapy
41369813|NCT03018756|DRUG|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
41369814|NCT03018756|DRUG|Placebo|0.9% saline solution will be inhaled via nebulizer
41369815|NCT01428570|DEVICE|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
41369816|NCT01729559|DRUG|5000 Units unfractionated Heparin Q 8 hr|Venous thromboembolic prophylaxis medication
41369817|NCT01729559|DRUG|30mg enoxaparin Q12 hr|Venous thromboembolic prophylaxis
41369818|NCT05626556|OTHER|SAVE system|The SAVE system will be implemented in end users' homes. Flood sensors will be installed in the bathroom and kitchen, presence sensors in the living room and bedroom, and the contact sensor will be installed at the entrance door. For the best user experience, the installation of the required software (for the sensors kit and the smartwatch) was done on the users' own smartphones. Thus, at the end of the installation, users will have the Aqara Home System in their homes (5 sensors and a sensor hub), a Samsung smartwatch and a SAVE Sensors Adapter, all of which are connected to a router with unlimited internet access.
41369819|NCT04156113|OTHER|Yo-Yo intermittent recovery test (level 1)|The Yo-Yo intermittent recovery test (level 1) will be administered once.
41369820|NCT04031469|OTHER|There is no intervention in this study|There is no intervention in this study
41369821|NCT02161809|BEHAVIORAL|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
41369822|NCT04754009|BEHAVIORAL|Trauma-Sensitive Yoga + TAU|Trauma-Sensitive Yoga is a movement-based approach that are used to integrate both mind and body, and promote body awareness and acceptance for those who have been exposed to traumatic events and currently experience trauma symptoms.
41369823|NCT04754009|BEHAVIORAL|Chen Style Tai Chi + TAU|Chen Style Practical Method tai chi is a martial art that is used as a form of self-defense and to maintain physical health and well-being.
41369824|NCT04754009|BEHAVIORAL|Treatment as Usual|Consists of traditional talk therapy for mental health.
41369825|NCT00443573|DRUG|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
41502907|NCT01233739|DRUG|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
41502908|NCT01233739|DRUG|Placebo|Administration of 2 capsules of placebo orally.
41369826|NCT05241574|RADIATION|Radiotherapy boost|Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.
41369827|NCT05241574|DRUG|Additional consolidation chemotherapy|Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
41369828|NCT04510870|DRUG|Ferric Carboxymaltose Injection|Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.
41369829|NCT04510870|DRUG|NaCl infusion|Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.
41502909|NCT06633016|DRUG|ABX-002|ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
41502910|NCT06633016|OTHER|Placebo|Comparator Placebo oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
41502911|NCT05128760|DIAGNOSTIC_TEST|characterization of aPL|characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)
41502912|NCT04727047|DEVICE|neuromuscular electrical stimulation|All subjects will receive standard rehabilitation for Achilles tendon repair. In addition, neuromuscular electrical stimulation will be applied to the calf muscles of the injured leg. The stimulation volume, the electrode placement and the intensity of the stimulation will be selected based on the mechanical strength of healing Achilles tendon. The intervention will be applied for 6 weeks after repair.
41502913|NCT06247839|DRUG|Psilocybin|COMP360 (Brand name of psilocybin to be used)
41162417|NCT00702273|DRUG|Placebo for Corifollitropin Alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
41502914|NCT03701308|PROCEDURE|Biospecimen Collection|Undergo blood collection
41502915|NCT03701308|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
41502916|NCT03701308|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41369830|NCT05346458|DEVICE|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients planned for an invasive coronary physiology (pressure-wire) study and who meet the inclusion criteria and none of the exclusion criteria can be enrolled. Participants will undergo preparation for their clinical procedure (angiogram with pressure wire study) in the normal manner. Arterial cannulation will be performed via the radial or femoral artery) under local anaesthesia. The sheath will be inserted and a pre-procedure blood sample taken for Troponin T level. A coronary angiogram will be performed as per standard clinical practice prior to cannulating the coronary artery to be studied. The pressure studies will be performed sequentially, first with a pressure wire before using the iKOs™ microcatheter. Following withdrawal of the iKOs™ microcatheter. A pressure wire assessment is repeated after the microcatheter is withdrawn. The case will then proceed as clinically indicated. Post-procedure the participant will be managed according to standard clinical practice.
41369831|NCT06419231|DIETARY_SUPPLEMENT|Butyrate Formulation|Butyrate Formulation capsule:3 capsules daily
41502917|NCT03701308|DRUG|Cytarabine|Given IV
41502918|NCT03701308|DRUG|Daunorubicin|Given IV
41502919|NCT03701308|PROCEDURE|Echocardiography|Undergo ECHO
41502920|NCT03701308|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
40847235|NCT01338857|DRUG|Sorafenib (Nexavar)|"Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.~Children/adolescents (\< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily~Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily~NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily"
41030275|NCT02501460|OTHER|Resistance training|"Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).~Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed."
41030276|NCT02501460|DIETARY_SUPPLEMENT|Supplementation|A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
41030277|NCT02501460|OTHER|Placebo|A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
41030278|NCT00875680|DEVICE|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
41369832|NCT06419231|DIETARY_SUPPLEMENT|Butyrate + Polyphenol Formulation|Butyrate + Polyphenol Formulation capsule: 3 capsules daily
40847236|NCT00500825|PROCEDURE|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
41030279|NCT05409417|DRUG|Experimental drug|Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
41030280|NCT01263743|BEHAVIORAL|Relaxation Response|The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.
41030281|NCT01263743|BEHAVIORAL|Relaxation Response|Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
41030282|NCT00244608|DRUG|Budesonide/Formoterol Turbuhaler|
41030283|NCT00244608|DRUG|Budesonide Turbuhaler (Pulmicort)|
41030284|NCT00244608|DRUG|Terbutaline Turbuhaler|
41030285|NCT03171025|DRUG|Nivolumab|Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
41162418|NCT00702273|DRUG|Placebo for RecFSH/Follitropin beta|Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
41369833|NCT06419231|DIETARY_SUPPLEMENT|Placebo|Placebo: 3 capsules daily
41369834|NCT05156775|OTHER|Serratus Plane Block (SPB)|While the patient is in the supine position, the arm will be abducted, the ultrasound probe will be placed over the mid-clavicular region of the thoracic cage in sagittal plane. Ribs will be counted until the fifth rib will be identified in the midaxillary line. the latissimus dorsi (superficial and posterior ), teres major (superior), and serratus muscle (deep and inferior)will be identified overlying the fifth rib. As an extra reference point, thoracodorsal artery will be used, this aids in the identification of the plane superficial to the serratus muscle, 30 ml 0.25 %bupivacaine will be injected between latissimus dorsi and serratus anterior muscles at the level of the 5th rib in the mid axillary line.
41502921|NCT03701308|DRUG|Uproleselan|Given IV
41502922|NCT06211491|OTHER|Urodynamic test|Urodynamic testing is performed using saline solution at the same temperature as body temperature (37 degrees) at two injection speeds of 10 mL/min and 100 mL/min, respectively.
41502923|NCT01734200|DIETARY_SUPPLEMENT|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
41502924|NCT01734200|DIETARY_SUPPLEMENT|Placebo|Placebo (1.5g/day)
41502925|NCT02806024|DRUG|Tranexamic Acid|
41502926|NCT02806024|DRUG|Placebo Drug|50 cc Normal Saline IV
41502927|NCT06633731|OTHER|Biocellulose Mask|Immediately after treatment, a Biocellulose Mask was applied to the subjects global face for 8 to 10 minutes.
41502928|NCT06633731|OTHER|Post Procedure Cream|Immediately after treatment and after Biocellulose Mask removal, the Post-Procedure Cream was applied to the subjects global face. Subjects were instructed to apply to the global face from days 1 - 3 post treatment.
41502929|NCT06633731|OTHER|Gentle Cleanser|Subjects were instructed to wash their face with the Gentle Foaming Cleanser twice daily for 12 weeks.
41502930|NCT06633731|OTHER|Facial Moisturizer|Subjects were instructed to apply the facial moisturizer twice daily to the global face from day 3 after treatment until next study visit.
41502931|NCT06633731|OTHER|sunscreen|Subjects were instructed to apply the bland sunscreen to the global face once daily in the morning, with re-application with extended sun exposure per FDA guidelines.
41502932|NCT06550973|PROCEDURE|pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique|Rescue techniques, such as pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique, wire-guided cannulation over a pancreatic stent and transpancreatic biliary sphincterotomy, will be used at the discretion of the endoscopist \[12\]. After deep cannulation, a cholangiogram to better define the characteristics of the stenosis will be done. The stent will then be inserted over a guidewire and deployed across the stenosis. All stents will be fully covered SEMSs or partially covered SEMSs of 10 mm diameter. The length of the stent will be chosen at the discretion of the endoscopist performing the procedure. A prophylactic pancreatic stent will be placed in patients who will be thought to be at high risk of post-procedure pancreatitis at the discretion of the treating endoscopist.
41502933|NCT05299606|DEVICE|Transbronchial Microwave Ablation|Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
40847237|NCT06583369|DRUG|Liangxue ointment（Traditional Chinese Ointment）|"The main ingredients of Liangxue Ointment include: Lithospermum sibiricum, Sanguisorba Sanguis, Rehmannia glutinosa, Gardenia, rhubarb, skullcap, borneol, dragon's blood, olibanum and myrrh.~Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses."
40847238|NCT06583369|DRUG|Urea cream|Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
41369835|NCT05156775|OTHER|Rhomboid intercostal nerve block (RIB)|In the rhomboid intercostal nerve block (RIB) group, the patient will be placed in a lateral position with the affected breast at the top. The ipsilateral arm will be extended to the same level as the ipsilateral chest and breast, and the scapula will be moved outward. On the oblique sagittal plane, a high frequency (6-12MHz) linear ultrasound probe will be placed on the medial edge of the scapula. The US landmarks, trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung will be identified. Under the aseptic condition, a 22-gauge needle will be inserted in the plan to the US probe at T5 to T6 levels. Then, 0.25% bupivacaine (30 mL) will be injected into the inter-fascial plane between the rhomboid major muscle and the intercostal muscle, the diffusion of bupivacaine in the fascia between the rhomboid muscle and the intercostal muscle will be visualized. Then, the patient will be positioned in supine position.
41369836|NCT02514642|DRUG|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
41369837|NCT02514642|DRUG|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
41030286|NCT04418804|DIAGNOSTIC_TEST|Chest ultrasound|"Each research volunteer will undergo a chest-directed ultrasound examination using a commercial device located in the Valley Hospital and approved for clinical use. After completing the above scan, the patient will undergo another ultrasound scan using a Vantage system device (by Verasonics), which is a research ultrasound device that will be provided on loan to the Haemek Hospital by the Weizmann Institute SAMPL Laboratory prior to the start of the trial. The scan will be made with a linear transducer sampled at a rate of about 8-12Mhz and / or with a curved transducer sampled at a rate of about 4-6Mhz.~The total estimated duration of the test is approximately 30 to 40 minutes per patient."
41030287|NCT06535061|OTHER|white noise|The experimental group was exposed to a white noise sound combined from 4 different sounds: ultrasound heartbeat sound, wave sound, vacuum cleaner sound and hair removal machine sound at 50 dBSPL 5 minutes before the procedure. The experimental group was exposed to white noise for a total of 15 minutes before, during and after the procedure. At the same time, the newborn in the experimental group I was given a pacifier.
41369838|NCT01963910|DRUG|30% Mannitol in vehicle cream|applied to one half of the upper lip following removal of capsaicin cream.
41369839|NCT01963910|DRUG|vehicle cream|application to the other half of the upper lip following capsaicin cream removal
41369840|NCT02641028|DRUG|CERC-501|CERC-501
41162419|NCT00702273|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
41162420|NCT00702273|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
41369841|NCT02641028|DRUG|Placebo|Placebo
41502934|NCT04712981|BEHAVIORAL|HOPE|Peer leaders/role models will be trained in HOPE intervention fundamentals and assigned to online community groups with participants.
41502935|NCT05567146|BEHAVIORAL|Experimental group|"It is planned to use the social media platform WhatsApp application to carry out the study. technique of gamification will have content in the form of points, ranking, penalties and rewards, which are the basic principles of gamification.~Studies have shown that these contents are effective techniques to increase the interest, encouragement, motivation and purpose of the participants."
41369842|NCT01781130|PROCEDURE|Steroid injection|
41369843|NCT04904952|DRUG|N-acetylcysteine tablet 600mg|N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
40847239|NCT04872790|DRUG|Dasatinib|Given PO
40847240|NCT04872790|DRUG|Methotrexate|Given IT
41030288|NCT03299595|OTHER|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
41030289|NCT04950101|OTHER|anal sampling|anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not
41162421|NCT00702273|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
41162422|NCT00702273|BIOLOGICAL|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
41162423|NCT05240547|OTHER|Spinal Manipulation|Spinal manipulative therapy delivered to the cervical spine by a chiropractor
41162424|NCT05240547|OTHER|Placebo|Sham manipulative treatment delivered to the cervical spine by a chiropractor
41162425|NCT01793298|DRUG|ASM-024|Ascending doses of ASM-024
41162426|NCT03738254|OTHER|The Guardians: A smartphone game|"The Guardians is a mix of two popular game genres: idle games (a game that doesn't require constant player input in order to progress in the game, but often progresses exponentially in response to a few user inputs, e.g., Cookie Clicker and Adventure Capitalist) and pet collection games (a game where the player seeks to collect all of the pets in a set, e.g., Pokemon or Neko Atsume). The game gives the player an in-game reward for completing a survey."
41162427|NCT03738254|OTHER|Paper Survey|Paper version of daily survey
41162428|NCT03738254|OTHER|Electronic Survey|Electronic version of daily survey administered via a smartphone app.
41162429|NCT05347797|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.
41162430|NCT04741815|DEVICE|Forced Air Warming|It consists of the WarmAir® unit and FilteredFlo® blankets. FilteredFlo® blankets are a cover designed to cover the entire body and extremities with air channels that provide the appropriate distribution of patient warm. The WarmAir® warming device connected to the shroud via a pipe; it has three temperature settings, 32.2 C, 37.8 C, and 43.3 C.
41162431|NCT04741815|DEVICE|Peripheral Carbon Fiber Warming|It was developed by the researcher. Designed as gloves and socks, these warming materials have three layers. The first layer in contact with the patient and the third layer in contact with the external environment is a thermal material to maintain body temperature. The second floor consists of a USB-connected carbon fiber warmer and foil.
41162432|NCT03932422|DIAGNOSTIC_TEST|Evaluate if the individuals are resistant hypertensive patients|Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
41162433|NCT02840071|OTHER|Psychological therapy|Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
41162434|NCT04775173|DRUG|Sirolimus|Use of different doses of the same drug
41369844|NCT04904952|DRUG|Placebo tablet 600mg|Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
41162435|NCT05610943|PROCEDURE|ultrasound-guided quadratus lumborum nerve block|The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
41369845|NCT00945815|BIOLOGICAL|epratuzumab|
41369846|NCT00945815|DRUG|clofarabine|
41369847|NCT00945815|DRUG|cytarabine|
41369848|NCT00945815|OTHER|laboratory biomarker analysis|
41369849|NCT04978376|BEHAVIORAL|Time restricted eating|We will compare the effects of time restricted eating alone and combined with resistance exercise of endurance exercise versus a no intervention control group.
41369850|NCT02612766|DIETARY_SUPPLEMENT|Pure, uncontaminated oats|
41369851|NCT00348348|DRUG|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
41369852|NCT00348348|DRUG|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
41369853|NCT04606862|DEVICE|Morley Medical Sepsis Software Device|The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
40847241|NCT04872790|DRUG|Prednisone|Given PO
40847242|NCT04872790|BIOLOGICAL|Rituximab|Given IV
41030290|NCT00710424|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
41030291|NCT00710424|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
41030292|NCT04191772|OTHER|Periodized, home-based running program|All participants will perform a home-based supervised exercise training program. Participants will receive weekly training instructions using a smartphone-based heart rate monitor application (Polar® app). Training sessions will involve running and the design of the training program will be based on linear periodization, where aerobic capacity is built firstly through a period of high-volume/low-intensity training before the proportion of high-intensity training is increased. The total duration of the exercise program will be 12 months with three weekly training sessions. Training progression will be dependent on initial VO2max values and running experience. VO2max classification is based on reference values described in V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics.
41030293|NCT06178666|BIOLOGICAL|BCG|Three dose levels of intradermal BCG
41030294|NCT02008383|BIOLOGICAL|Panitumumab|The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.
40847243|NCT04872790|DRUG|Venetoclax|Given PO
40847244|NCT04872790|BIOLOGICAL|Blinatumomab|Given IV
41162436|NCT05610943|PROCEDURE|ultrasound-guided Ilioinguinal Iliohypogastric Nerve Block|The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
41162437|NCT04461184|BEHAVIORAL|Internet Wellness Intervention for Aging|Internet technologies have emerged as a platform for performing wellness interventions that also have wide outreach. Previous studies that have used the internet for delivering health interventions have found that older adults valued this platform, used it for researching health information and social communications. Likewise, the effectiveness of delivering health-related information intended for behavior change through the internet is equal to that of print-based delivery, thereby lowering costs and expanding reach. Thus, the internet provides a unique platform for conducting interventions. The internet based wellness intervention will be a low cost method focused on older adults to help increase intrinsic motivation through autonomy, competence, and relatedness (Intrinsic Motivation) to help increase daily physical activity.
41162438|NCT05051475|PROCEDURE|Endoscopic radiofrequency ablation|Endoscopic ablation technique for Barrett's epithelium
41162439|NCT05051475|PROCEDURE|Endoscopic hybrid argon plasma coagulation|Endoscopic ablation technique for Barrett's epithelium
41162440|NCT03742817|OTHER|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
41162441|NCT02574897|OTHER|Electronic symptom survey|Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
41162442|NCT02574897|OTHER|Blinded Electronic Symptom Survey|Standard of care daily clinician interviews with blinded symptom surveys
41162443|NCT05056298|OTHER|Custom made insole|Custom made arch support insole with semi-rigid arch support will be made using the casting method, plaster cast of both feet in a subtalar neutral position will be taken from each subject by highly specialized orthotist. The negative casts will be placed in calcaneal vertical position and custommolded orthosis will be fabricated to positive molds obtained from the negative casts with the goal to control the pronation movement of the foot
41162444|NCT05056298|OTHER|Strengthening exercises of extrinsic foot muscles|Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.
41162445|NCT05056298|OTHER|Strengthening exercises of intrinsic foot muscles|The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .
41162446|NCT05056298|OTHER|Standard insole|Patient will be instructed to wear a standard prefabricated flat insole as a placepo treatment iniside his shoes for 2 months (8 weeks), 6 to 8 hours per day, and adhere to wearing the orthoses during outdoor walking and during extrinsic foot muscle training.
41162447|NCT01006447|BEHAVIORAL|Instructor contact|
41162448|NCT01006447|BEHAVIORAL|Instructor contact|
41162449|NCT04701970|PROCEDURE|relining of mandibular complete denture|Relining of mandibular dentures was performed by reducing one mm of the denture fitting surfaces and borders to make a right-angled border. apply two separate layers of Mucopren adhesive upon the vestibular surface of the mandibular denture and allow each layer to dry for about 40 seconds. then, the lower denture was inserted and molded in patient mouths; while biting in centric occlusion with the opposing maxillary complete dentures.
40847245|NCT04872790|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
40847246|NCT04872790|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
40847247|NCT04872790|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40847248|NCT06465745|DEVICE|AltaValve System.|Transcatheter Mitral Valve Replacement.
40847249|NCT05612425|BEHAVIORAL|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
41030295|NCT02008383|DRUG|Cabozantinib|"There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.~Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily."
40847250|NCT05612425|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
40847251|NCT03851432|DRUG|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 25 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
40847252|NCT03851432|DRUG|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 50 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
40847253|NCT03851432|DEVICE|Placebo plus metformin|Placebo: Tablets, Oral, 25/50 mg, Once daily, 24 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
40847254|NCT05133661|DIAGNOSTIC_TEST|HPV testing|Interviews will be conducted among women from the general population and HIV+ women after screening for HPV. A small subset of participants will be interviewed after receiving treatment for precancer. HPV test results and outcome of the precancer treatment if indicated will be documented.
40847255|NCT05360745|DIETARY_SUPPLEMENT|ARACOMPLEX®|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
40847256|NCT05360745|DIETARY_SUPPLEMENT|placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
40847257|NCT05017662|OTHER|Data collection|Participants will have surveillance visits every 3 months up to 5 years after their first dose of 177Lu-IPN01072 in Study OPS-C-001.
40847258|NCT02104947|DRUG|idarucizumab|idarucizumab
40847259|NCT03669289|OTHER|enhanced model of primary care|The SCHOOL STARS model of care includes pre-visit planning, standardized visit content, post-visit care coordination, and coordination between primary care and school.
40847260|NCT05301309|BEHAVIORAL|breastfeeding consultation|Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
40847261|NCT02220712|DRUG|OPC-14597 IMD|Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
41030296|NCT06534515|DEVICE|Tomatis auditory stimulation|Traditional Tomatis Method Protocol
41030297|NCT04975373|DRUG|Intrauterine injection of hyaluronic acid|operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
41030298|NCT03074422|PROCEDURE|Hypnosis|Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
40847262|NCT02950376|OTHER|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
41162450|NCT05930002|DRUG|Ivermectin Tablets|oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days.
41369854|NCT03522506|DRUG|TAK-925|TAK-925 intravenous infusion.
41369855|NCT03522506|DRUG|TAK-925 Placebo|TAK-925 placebo-matching given as saline intravenous infusion.
41369856|NCT03522506|DRUG|Modafinil|Modafinil tablets.
40847263|NCT02950376|OTHER|Virtual reality-based addiction assessment system|The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
41030299|NCT05273710|OTHER|Regular toast and juice|Participants consume a single test meal composed of regular whole wheat toast and apple juice, and zinc absorption is measured.
41030300|NCT05273710|OTHER|High phytate toast and juice|Participants consume a single test meal composed of high phytate whole wheat toast and apple juice, and zinc absorption is measured.
41162451|NCT05930002|DRUG|Colchicine 0.5 MG|0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
41030301|NCT05273710|OTHER|Regular toast and juice, with folic acid|Participants consume a single test meal composed of regular whole wheat toast and apple juice, with 400 mcg folic acid; and zinc absorption is measured.
41030302|NCT05879744|DRUG|CLN-978|CD19xCD3 T cell engager
41030303|NCT01060865|DRUG|Aliskiren|150 mg during the first two weeks , 300 mg for another 10 weeks
41030304|NCT06222866|DIAGNOSTIC_TEST|Anticoagulation monitoring|Evaluation of different monitoring modalities to find the most appropriate anticoagulation monitoring tool for UFH therapy
41030305|NCT04287920|DRUG|Acomprosate|Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
41162452|NCT05930002|DRUG|Standared managment|(Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks
41162453|NCT03927222|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
41162454|NCT03927222|DRUG|Temozolomide|Temozolomide is a chemotherapy drug given to all enrolled patients at the post-RT clinic visit as dose-intensified TMZ (100 mg/m2/day for 21 days).
41369857|NCT03522506|DRUG|Modafinil Placebo|Modafinil placebo-matching tablet.
41369858|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR)|The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
41502936|NCT03108053|PROCEDURE|Semirigid Ureteroscopy (URS) With Guide Wire|Semirigid URS is the operations used for ureteral stone disease. In routine practice it is most commonly done with the use of a guide wire. It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
40847264|NCT02950376|OTHER|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
40847265|NCT04118894|DEVICE|Foot and Ankle Devices|Wright devices used in foot and ankle procedures
41162455|NCT03927222|BIOLOGICAL|Tetanus-Diphtheria Toxoid (Td)|Before the first DC vaccination, patients will receive 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Prior to pp65 DC vaccination #4,(3±1) weeks after leukapheresis 2 the vaccine site will receive a pre-conditioning intradermal injection of Td (1 flocculation unit (Lf), in 0.3 mL of saline for a total of 0.4 mL).
41502937|NCT03108053|DEVICE|Semirigid Ureteroscopy (URS) Without Guide Wire|Semirigid URS is the operations used for ureteral stone disease . It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
41502938|NCT01791270|DEVICE|Continuous positive airway pressure (CPAP) therapy|"Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.~First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).~The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.~We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.~Procedures:~1. - Respiratory Polygraphy~2. - Ambulatory Blood Pressure Monitoring~3. - Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.~4. - ß1en subunit expression in peripheral blood leukocytes."
41502939|NCT05151289|BIOLOGICAL|Blood test at time of inclusion for sFlt-1/PlGF ratio|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the inclusion visit.
40847266|NCT05188131|DRUG|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
40847267|NCT05188131|DRUG|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
40847268|NCT06477913|DEVICE|Rauha|A dual mental health treatment consisting of digitally-administered Cognitive Behavioral Therapy combined with National Board Health and Wellness Coach (NBHWC) trained Mental Health Coaches
41369859|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up|"Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted."
41369860|NCT04897009|PROCEDURE|Biospecimen Collection|Undergo blood and tissue collection
41369861|NCT00587561|BEHAVIORAL|Social Cognition Interaction Training|manualized group therapy
41502940|NCT05151289|BIOLOGICAL|Follow-up blood test 2 to 4 weeks after inclusion|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the follow-up visit (about 2-4 weeks after inclusion). This second sample is not mandatory for the evaluation of the study's main endpoint.
41502941|NCT05151289|DIAGNOSTIC_TEST|Placenta analysis for all included patients, even in case of normal birthweight|"After delivery, the placenta of each included patient is sent to anatomo-pathology (even in case of normal weight of the baby at birth). An anatomopathologist referent, designated for the study in each center, performs an analysis (aware of the clinic but not of the sFLT-1/PlGF ratio results), according to the benchmark criteria grid. Local analysis will classify the placenta as vascular IUGR or nonvascular IUGR."
41502942|NCT05390801|OTHER|Survey|Survey developed by ophthalmologists from the Ophthalmology Department of the Necker-Enfants Malades Hospital, fill out only once by patients with congenital aniridia in order to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease.
41502943|NCT05578183|DEVICE|theta burst stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
41502944|NCT05578183|DEVICE|sham stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
41502945|NCT01727037|PROCEDURE|Bronchoscopic intrabullous autologous blood instillation|
41502946|NCT05394324|DEVICE|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with subject devices of this study.
40847269|NCT04023682|DRUG|Provodine Hand Sanitizer|Intervention with Provodine
40847270|NCT01925248|DIETARY_SUPPLEMENT|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
40847271|NCT01925248|DIETARY_SUPPLEMENT|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
40847272|NCT05191875|DRUG|Saccharomyces Boulardii 250 MG|"Saccharomyces Boulardii:~0.25 g \* 6, Produced by The French encyclopedia pharmaceutical Factory"
41369862|NCT00587561|BEHAVIORAL|WLC|wait-list control for 6 months, followed by the experimental group therapy
41162456|NCT03927222|BIOLOGICAL|GM-CSF|Granulocyte macrophage-colony stimulating factor (GM-CSF) is a sterile, white, preservative-free lyophilized powder in a vial containing 250 mcg that will be reconstituted in 0.5 mL of sterile water for injection and used as an adjuvant with the DC vaccine.
41162457|NCT03927222|BIOLOGICAL|111-Indium-labeling of Cells for in vivo Trafficking Studies|111-In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs labeled with 111-In (50 μCi / 5 x 10\^7 DCs) and given i.d. as the fourth vaccine. In up to 16 patients, the fourth vaccine will be labeled with 111-In (50 μCi / 5 x 10\^7 DCs) prior to injection.
40847273|NCT05191875|DRUG|Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate|"Ilaprazole:~5mg\*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g \* 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g\*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg \* 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD"
40847274|NCT04369157|PROCEDURE|Elective surgery|Patients will be scheduled to undergo elective orthopaedic (knee/hip replacement) or colorectal surgery.
41030306|NCT03956017|DRUG|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
41369863|NCT03917966|DRUG|SHR-1210+docetaxel+nedaplatin|neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; docetaxel 75mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
41369864|NCT03917966|DRUG|SHR-1210+Apatinib|SHR-1210, 200 mg, q2w; Apatinib, 250mg, qd; 4 weeks is a cycle, a total of 2 cycles
41369865|NCT04938726|DIETARY_SUPPLEMENT|Ketone Monoester|Ketone supplement will be taken by mouth at a dose of 15 mL twice per day
41369866|NCT03246685|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
41369867|NCT03246685|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
41369868|NCT04011514|BEHAVIORAL|Dedicated stroke nurse care in ED|A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
41369869|NCT01813760|DEVICE|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
41369870|NCT01656109|DRUG|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
41369871|NCT01160770|DRUG|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
41369872|NCT05628337|OTHER|Motivational texting|Health related information relevant to a subject's diagnosis and ongoing treatment
41369873|NCT05628337|OTHER|Control|Non-motivational text messages containing no specific health information
41369874|NCT02425670|OTHER|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
41369875|NCT03878368|DIETARY_SUPPLEMENT|Sulforaphane|Intervention soup with dietary sulforaphane
41369876|NCT03878368|DIETARY_SUPPLEMENT|Placebo|Control soup without dietary sulforaphane
41369877|NCT02050646|OTHER|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
41369878|NCT02050646|OTHER|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
41369879|NCT00733694|DEVICE|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
41369880|NCT01953380|BEHAVIORAL|extended information|
41030307|NCT03956017|DRUG|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
41030308|NCT01757964|BIOLOGICAL|Bacteriotherapy|
41030309|NCT00809757|DRUG|Levalbuterol|90 ug Levalbuterol (2 actuations)
41030310|NCT00809757|DRUG|Levalbuterol UDV TID|0.31 ug Levalbuterol UDV TID
41030311|NCT00809757|DRUG|Placebo|Placebo (2 actuations)
41030312|NCT04155931|OTHER|body temperature measurement|Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
41030313|NCT01492881|DRUG|Vorinostat|Oral, 400mg, taken days 4 through 11 of each cycle.
41030314|NCT01492881|DRUG|Bortezomib|subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
41030315|NCT01492881|DRUG|pegylated liposomal doxorubicin|Intravenous, 30mg/m2, Day 4
41030316|NCT02631798|DIETARY_SUPPLEMENT|Food grade dye mucosal staining|mucosal staining with food grade dye
41030317|NCT03286959|PROCEDURE|PCR with calcium hydroxide|
41030318|NCT03286959|PROCEDURE|PCR with RMGIC|
41030319|NCT03286959|PROCEDURE|PCR with direct composite|
41030320|NCT03329092|DRUG|ATM-AVI|"(Creatinine clearance \> 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI"
41030321|NCT03329092|DRUG|MTZ|For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
41369881|NCT01090648|DRUG|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
40847275|NCT00421135|DRUG|ZIO-201|ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
41369882|NCT00118872|DRUG|LGG yogurt|Lactobacillus GG containing yogurt
41030322|NCT03329092|DRUG|MER|"Where pathogen initially not suspected of being MER-resistant:~(Creatinine clearance \> 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h~Where pathogen initially suspected of being MER-resistant (Creatinine clearance \> 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h"
41030323|NCT03329092|DRUG|COL|"Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight \< 60 kg) followed by one of the following maintenance doses:~(Creatinine clearance \> 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.~(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion"
41369883|NCT00118872|OTHER|Placebo yogurt|Yogurt NOT containing the active LGG bacteria
41030324|NCT00952653|DRUG|Desvenlafaxine Succinate Sustained Release|50 mg DVS SR tablet days 1-6, period 2 only.
41162458|NCT02785575|OTHER|HeProCalc algorithm|Heparin and protamine dosage calculated by the algorithm HeProCalc
41162459|NCT00000725|DRUG|Interferon alfa-2a|
41162460|NCT00000725|DRUG|Zidovudine|
40847276|NCT03624127|DRUG|BMS-986165|Specified dose on specified days
40847277|NCT03624127|OTHER|Placebo|Specified dose on specified days
41502947|NCT03715504|DRUG|TP-3654|oral PIM inhibitor
40847278|NCT03624127|DRUG|Apremilast|Specified dose on specified days
40847279|NCT05067751|DEVICE|hearing aid with directionality|Hearing directionality allows users the ability to focus on voices and other signals of interest, reducing background noises that are unimportant.
40847280|NCT05825885|DRUG|E2|micronized E2 at a daily dose of 4-6mg,
41030325|NCT00952653|DRUG|Midazolam|4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
41162461|NCT00000725|DRUG|Interferon alfa-n1|
41162462|NCT01858051|DIETARY_SUPPLEMENT|Cholecalciferol|
41162463|NCT01858051|DIETARY_SUPPLEMENT|Placebo|
41162464|NCT04933162|DIETARY_SUPPLEMENT|High Protein and Low Fiber Diet|Protein intake will be increased to be \>40% calories from protein, and the fiber intake will remain \<15gm/day.
41162465|NCT04933162|DIETARY_SUPPLEMENT|Low Protein and High Fiber Diet|Increase fiber intake up to 40gms of fiber with a requirement to increase at least 15gms above baseline fiber, with 50-75% of total fiber intake from psyllium husk. Subjects will be allowed to slowly increase fiber every two days to reach goal by end of week 1. The total protein will be reduced to \<10% total calories from protein.
41162466|NCT00555646|DRUG|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 1: PH-10 with 544 nm LED light illumination.
41162467|NCT00555646|DRUG|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 2: PH-10 with ambient light illumination.
41502948|NCT05674851|OTHER|MRI|collection of MRI scans for mathematical model development
40847282|NCT05293236|DRUG|ApTOLL|ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)
40847283|NCT05293236|OTHER|Saline|Saline for intravenous infusion
40847284|NCT04492163|DEVICE|TTFields|"TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.~Other Names:~• TTFields"
40847285|NCT00435851|DRUG|Thyrogen, thyroid hormone withdrawal, iode 131|
40847286|NCT04189445|DRUG|Futibatinib|Futibatinib tablets will be dosed orally every day on a continuous 28-day cycle
40847287|NCT02379468|DRUG|Pedyphar Ointment|
40847288|NCT02379468|DRUG|Panthenol|Ointment
40847289|NCT02294734|DRUG|GSK2269557|Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
41162468|NCT00555646|DRUG|Control|No treatment control.
41162469|NCT00049335|DRUG|capecitabine|1,000 mg/m\^2/dose (2,000 mg/m\^2/day) BID, PO, on Days 1-14 of 21 day cycle
41369884|NCT00399542|DRUG|Lubiprostone|
41369885|NCT00399542|DRUG|Placebo|
41369886|NCT05604859|DRUG|Methylprednisolone|Methylprednisolone:1-2mg/kg/d(or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d),ivgtt,3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (methylprednisolone \> 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone \> 2mg/kg/d) was continued for another 3-5 days.
41369887|NCT05604859|DRUG|intravenous immunoglobulin|intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was continued for another 3-5 days.
41502949|NCT03749486|PROCEDURE|Cataract surgery|Cataract surgery will be done following ArcScan measurement
41502950|NCT05501678|DRUG|Diphenhydramine|25mg (and up to 50mg) Diphenhydramine given orally
41502951|NCT05501678|DRUG|Placebo|Matching Placebo given orally
41502952|NCT04215276|OTHER|Valsalva maneuver|pressure during Valsalva maneuver was measure using sphygmomanometer
41502953|NCT04215276|OTHER|Control|patient was not given any intervention
41502954|NCT04471129|OTHER|HFO/O2C/NIV|High-flow oxygen therapy + O2C + Non invasive ventilation
41502955|NCT04471129|OTHER|NIV/O2C/HFO|Non invasive ventilation + O2C + High-flow oxygen therapy
41502956|NCT02647827|OTHER|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
41030326|NCT03879018|BEHAVIORAL|Reach training with visual feedback|Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times
41030327|NCT04289753|BEHAVIORAL|EHR clinical decision support nudges|Clinical decision support nudges delivered within the EHR when conditions meet alert triggering criteria.
41030328|NCT04289753|BEHAVIORAL|Brief clinician education|Clinicians will be invited to view brief education material.
41030329|NCT06305572|DIAGNOSTIC_TEST|QFR|Patients suspected with CAD undergoing diagnostic coronary angiography with an indication for to perform invasive FFR were included. QFR was analyzed in an independent core laboratory (Uijeongbu Eulji Medical Center) using the software package QAngio XA 3D 2.1 (Medis Medical Imaging Systems, Leiden, the Netherlands).
41030330|NCT00377819|DRUG|alendronate|70 mg oral QW
41030331|NCT00377819|DRUG|Denosumab (AMG 162)|60 mg SC q 6 mos
41030332|NCT02594891|DEVICE|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
41030333|NCT02594891|DEVICE|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
41030334|NCT05741736|BEHAVIORAL|five-days small group-based lifestyle modification program|healthy lifestyle, based on the promotion of a particular dietary pattern, regular physical activity, psychological support, education, and small group intervention results in weight loss
41030335|NCT04841343|DRUG|Triamcinolone|Triamcinolone in sinus
41030336|NCT05155436|DRUG|Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg|Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.
41030337|NCT03257982|PROCEDURE|BCI-FES hand therapy|BCI-FES rehabilitation therapy of the upper limb
41030338|NCT00278707|DRUG|GTA: Glyceryltriacetate|
41030339|NCT02269293|DRUG|Paclitaxel|
41030340|NCT02269293|DRUG|Carboplatin|
41030341|NCT02269293|DRUG|Selinexor|
41030342|NCT05734313|BEHAVIORAL|Unified protocol for cognitive behavioral therapy (UP-CBT)|UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
41030343|NCT05734313|DEVICE|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
41030344|NCT06536075|RADIATION|Sialoscintigraphy|Sialoscintigraphy
41030345|NCT02818205|OTHER|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
41030346|NCT04915794|OTHER|Simulation of preeclamptic pregnancy care|It is an important step in providing safe care to patients, as a learning environment is provided in which environmental risks are minimized with simulation applications. Simulation-based trainings are environments that allow each student to learn, equitable, based on adult learning principles, and open to different learning styles. In these environments, interests and needs are defined together by the learner and the educator. By keeping the experiences of the learner at the forefront, the opportunity is given to learn by doing and is supported with feedback.
41030347|NCT02266238|DEVICE|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
41030348|NCT02266238|DEVICE|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
41030349|NCT02266238|PROCEDURE|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
41030350|NCT04054583|OTHER|Renovation of long-term residential care living spaces|Living spaces of the long term care facility will be renovated.
41030351|NCT02753751|OTHER|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
41030352|NCT06536296|OTHER|Music|Arm 1: Music only
41030353|NCT06536296|OTHER|Music and parent voice|Arm 2: Music and parent voice
41030354|NCT06536296|OTHER|Standard Care|Standard Care
40847290|NCT02294734|DRUG|Placebo|Dry powder for inhalation via DISKUS 'device'
40847291|NCT02370797|RADIATION|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
41030355|NCT01704092|DRUG|Dexmedetomidine|
41030356|NCT01895504|DEVICE|ColoAssist|Screening colonoscopy with the test instrument
41030357|NCT01895504|DEVICE|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
41030358|NCT03710434|DRUG|AZD4635 50 mg nano-suspension (reference)|Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.
41369888|NCT05604859|DRUG|Tocilizumab|Tocilizumab:4mg/kg, once
41369889|NCT05604859|DRUG|Low molecular weight heparin|Low molecular weight heparin:100U/kg, qd or q 12h,IH,4-7 days
41369890|NCT05604859|OTHER|conventional treatment|conventional treatment，including symptomatic and supportive treatment, antiviral treatment etc.
41369891|NCT01169116|RADIATION|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
41030359|NCT03710434|DRUG|AZD4635 solid oral formulation - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
41369892|NCT00478218|DRUG|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
41369893|NCT00478218|DRUG|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 \& 22
41369894|NCT00478218|DRUG|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
41369895|NCT04997577|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. A short-term memory component, in which listeners are asked to remember what a designated speaker said two sentences prior, was added to the auditory training paradigm to make the task more challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
41369896|NCT04997577|BEHAVIORAL|Auditory training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
41369897|NCT02160223|DRUG|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
41369898|NCT02160223|DRUG|Neostigmine|Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
41369899|NCT01874379|OTHER|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
41369900|NCT01874379|OTHER|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
41369901|NCT01874379|OTHER|Standard of Care|Normal Procedures, no complementary medicine intervention.
41369902|NCT03410693|DRUG|Rogaratinib (BAY1163877)|Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
41502957|NCT02647827|DEVICE|Acupuncture|Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
40847292|NCT05230849|DEVICE|dry needling|is a physiotherapy treatment for neurological patients and studies the efficacy of dry needling by studying several pre-treatment and post-treatment variables after the experimental treatment.
41030360|NCT03710434|DRUG|AZD4635 solid oral formulation - fed|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
41030361|NCT03710434|DRUG|Lansoprazole and AZD4635 50 mg solid oral formulation|Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.
41162470|NCT04563247|DIAGNOSTIC_TEST|IgG SARS CoV 2 antibodies|The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies
41162471|NCT04236245|DEVICE|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
41162472|NCT04595097|DEVICE|inspiratory muscle traiing|The patients are encouraged to inhale against a load to increase the inspiratory muscle strength and endurance
41162473|NCT03983018|DRUG|Rituximab|Infusion
41030362|NCT03710434|DRUG|AZD4635 solid oral formulation variant 1 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
41030363|NCT03710434|DRUG|AZD4635 solid oral formulation variant 2 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
41030364|NCT03710434|DRUG|[14C] AZD4635 IV microtracer - fasted|Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
41162474|NCT01588171|DRUG|Bemiparin|Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
41369903|NCT03410693|DRUG|Chemotherapy|Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
41369904|NCT03801070|PROCEDURE|endoscopic drainage of walled off pancreatic necrosis|transmural drainage and mechanical debridement of solid debris (necrosectomy)
41369905|NCT03977922|OTHER|Diet group|The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
41502958|NCT02647827|DRUG|Metformin|Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
41502959|NCT04554940|BIOLOGICAL|vosoritide|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
40847293|NCT05230849|OTHER|convencional treatment|is a physiotherapy treatment for neurological patients
40847294|NCT04060966|BEHAVIORAL|Cold-Pressor Task (CPT)|The CPT involves participants submerging their dominant forearm in ice-water (0-4°C) for 3 minutes.
40847295|NCT04060966|BEHAVIORAL|Control CPT|The control CPT involves participants submerging their dominant forearm in warm water (\~30°C) for 3 minutes.
40847296|NCT04060966|DEVICE|fMRI|Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.
40847297|NCT06515262|BIOLOGICAL|Anti-BCMA-GPRC5D CAR-T cells infusion|Subiects who meet the enrollment conditions will receive intravenous infusion of anti-BCMA-GPRC5D CAR-T Cells after lymphodepleting therapy.
40847298|NCT06372496|DRUG|Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate|Participants will receive FF/UMEC/VI
40847299|NCT06372496|DRUG|Inhaled corticosteroids/long-acting beta-2 agonists|Participants will receive ICS/LABA
40847300|NCT00710463|DEVICE|non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)|non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
40847301|NCT00500396|PROCEDURE|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
41030365|NCT04095858|DRUG|Efprezimod alfa|IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
41030366|NCT04095858|DRUG|Placebo|IV infusion, 100 ml at Day -1, Day 14, and Day 28.
41369906|NCT03112720|DEVICE|Epidural Blood Patch|A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
41369907|NCT03112720|DRUG|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
41369908|NCT01609608|PROCEDURE|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
41369909|NCT00343148|DRUG|AVI-4126 Injection (RESTEN-NG®)|
41369910|NCT02009072|PROCEDURE|Sutureless and glue free limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
41369911|NCT02009072|PROCEDURE|Sutured limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
41502960|NCT05826535|DRUG|IMPT-314|CAR T-cell therapy
41502961|NCT05909761|DRUG|UPLIZNA|Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.
41502962|NCT04513288|DIETARY_SUPPLEMENT|Experimental treatment L-citrulline (Protéocit®)|Enteral administration of citrulline for 5 days.
41502963|NCT04513288|OTHER|Placebo treatment|Enteral administration of iso-nitrogenous placebo for 5 days.
41502964|NCT06389799|DRUG|Pemigatinib|selective fibroblast growth factor receptor (FGFR) inhibitor, oral tablet
41502965|NCT06389799|DRUG|Retifanlimab|PD-1 inhibitor, Intravenous infusion
40847302|NCT06039358|DIETARY_SUPPLEMENT|Caffeine.|Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
40847303|NCT06039358|DRUG|Cellulose.|Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
40847304|NCT00417430|DRUG|ICI 182,780 (Faslodex)|
40847305|NCT03424460|BIOLOGICAL|Haemostasis tests|Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.
41030367|NCT04095858|DRUG|Methotrexate|IV, 15 mg/m\^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
41030368|NCT04095858|DRUG|Tacrolimus|Begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted
41030369|NCT04431323|BEHAVIORAL|ESPRIMO|"Participants will receive the intervention during Phase 2.~The intervention is based on the cognitive behavioral, the third-wave (mindfulness and acceptance and commitment therapy), and the positive psychology approach.~The frequency of the intervention and the specific content and aims of the psychological and physical intervention will be based on the results of the surveys and the focus group discussion (Pre-phase and Phase 1). In order to maximize the benefit of the integrated intervention, all the three components of the interventions (i.e., psychological, motor exercise and social components) will be administered in the same time period.~A preliminary theoretical framework of the intervention will be created prior to the survey phase according to the literature in the field. Specific aspects of this preliminary framework will be discussed during the co-creation phase and adapted after the analysis of the qualitative results."
41502966|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour infusion, every 3 weeks
41502967|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-min infusion, every 3 weeks
41030370|NCT02555046|PROCEDURE|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
40847306|NCT03424460|BIOLOGICAL|Monocytes and megacaryocytes culture and RNA extraction|Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.
40847307|NCT03424460|GENETIC|RNA extraction|RNA extraction from liver tissue
40847308|NCT03441230|DEVICE|Balloon characteristics|Different size balloon
40847309|NCT06555328|DRUG|CSU lower dose treatment|CSU lower dose treatment
41162475|NCT01588171|DRUG|Enoxaparin|Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
41369912|NCT05915780|DEVICE|Cycling|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
41369913|NCT05915780|DEVICE|Balance Board|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
41369914|NCT00455572|BIOLOGICAL|Immunotherapeutic GSK1572932A|Intramuscular injection, 8 doses
41502968|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour infusion, every 3 weeks
41369915|NCT00455572|DRUG|Cisplatin (CDDP)|Four cycles with doses based on patient's body surface area, intravenous administration
41502969|NCT05041309|BIOLOGICAL|Axicabtagene Ciloleucel|No investigational product will be administered
40847310|NCT06555328|DRUG|CSU high dose treatment|CSU high dose treatment
40847311|NCT06555328|DRUG|CSU non responders IgE - high dose treatment|CSU non responders IgE - high dose treatment
40847312|NCT06555328|DRUG|HS low dose treatment|HS low dose treatment
41502970|NCT05041309|BIOLOGICAL|Brexucabtagene Autoleucel|No investigational product will be administered
40847313|NCT06555328|DRUG|HS medium dose treatment|HS medium dose treatment
40847314|NCT06555328|DRUG|HS high dose treatment|HS high dose treatment
40847315|NCT05995899|DRUG|Tenapanor|IBS-C patients will ingest one capsule of tenapanor (50 mg per dose), twice daily, before breakfast and dinner for a total of 8 weeks
40847316|NCT02667470|DRUG|Solifenacin|Oral
40847317|NCT05182268|PROCEDURE|endoscopic ear surgery|a ear surgery via endoscopic
41369916|NCT00455572|DRUG|Vinorelbine|Four cycles with doses based on patient's body surface area , intravenous administration
41502971|NCT05041309|BIOLOGICAL|KITE-585|No investigational product will be administered
40847318|NCT05182268|PROCEDURE|microscopic ear surgery|a ear surgery via microscopic
40847319|NCT01656668|DRUG|BC1036|
40847320|NCT03052816|DRUG|Ice T|Ice/Tylenol/Toradol with dilaudid for breakthrough
40847321|NCT03052816|DRUG|Motrin/Percocet/Dilaudid for breakthrough|Standard regimen
40847322|NCT01630889|DRUG|Roxadustat|Oral capsule
41030371|NCT00216151|DRUG|Zoledronic Acid|Zoledronic Acid 4mg, every three months
41030372|NCT05248893|DRUG|AGN-151586|Intramuscular Injection
41030373|NCT04598152|DEVICE|TDCS - transcranial direct current stimulation|TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.
41502972|NCT05041309|BIOLOGICAL|KITE-718|No investigational product will be administered
40847323|NCT02223806|BEHAVIORAL|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
40847324|NCT02223806|BEHAVIORAL|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
40847325|NCT02669121|BIOLOGICAL|NoV Placebo-matching Saline|NoV placebo-matching saline (0.9% sodium chloride).
41030374|NCT01392352|DRUG|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
41502973|NCT05041309|BIOLOGICAL|KITE-439|No investigational product will be administered
41502974|NCT05041309|BIOLOGICAL|KITE-222|No investigational product will be administered
41502975|NCT05041309|BIOLOGICAL|KITE-363|No investigational product will be administered
40847326|NCT02669121|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.
41030375|NCT03793985|DRUG|T|CKD-391 40/10mg
41030376|NCT03793985|DRUG|R|D086 and D337 co-administration
41030377|NCT00333034|DRUG|Etanercept|
41030378|NCT02384148|OTHER|Circadian rhythm measurement|
41030379|NCT02384148|PROCEDURE|Skin biopsy|A 2mm diameter skin biopsy is performed by a physician using standard procedure.
41030380|NCT03599063|BIOLOGICAL|PF-06946860|PF-06946860 administered subcutaneously
41030381|NCT03599063|OTHER|Placebo|Placebo, administered subcutaneously
41030382|NCT02169908|DEVICE|Thermotest|
41030383|NCT02169908|DEVICE|von Frey hairs|
41502976|NCT04280926|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Fresh serum or lithium heparin plasma samples will be measured with the Atellica IM TnIH assay (Siemens Heatlhineers).
41502977|NCT02143921|BEHAVIORAL|Training intervention|Intervention group service providers received intervention training
41502978|NCT06632886|DIAGNOSTIC_TEST|AI-Assisted Non-Contrast CT for Multi-Cancer Screening|Participants identified by the AI model as having potential cancerous lesions, including those suspected of lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancer, will be required to undergo blood tests (for tumor markers) and additional imaging studies (such as contrast-enhanced CT, MRI, Endoscopy, etc.) to confirm the diagnosis of cancerous lesions.
40847327|NCT05319587|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
40847328|NCT05319587|DRUG|Cytarabine|Administered during cycle 1 at a dose of 2.0 g/m2/day by 4 hours IV infusion for 5 consecutive days and this dose will remain constant for all cohorts, including the expansion phase.
40847329|NCT02343198|DEVICE|Custom-built research muscle stimulator|Muscle stimulator
41369917|NCT00455572|PROCEDURE|Radiotherapy|Regimen will be based upon the site's own standard procedures
40847330|NCT00128986|PROCEDURE|Tomotherapy|3T MRS scans (3T magnetic resonance spectroscopy)
40847331|NCT05506527|OTHER|Sensorimotor program and plyometric exercise|"Children in study group A will receive combined plyometric exercises (vertical paradigm) and sensorimotor program~- Children of the study group B will receive sensorimotor program alone."
40847332|NCT01300572|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
40847333|NCT01300572|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
41369918|NCT04499521|DEVICE|BrachyGel VHPS|Packing system for administering brachytherapy in cervical cancer patients
40847334|NCT01300572|DRUG|Cyclosporine|Given PO or IV
40847335|NCT01300572|DRUG|Fludarabine Phosphate|Given IV
40847336|NCT01300572|BIOLOGICAL|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
40847337|NCT01300572|OTHER|Laboratory Biomarker Analysis|Correlative studies
40847338|NCT01300572|DRUG|Mycophenolate Mofetil|Given PO or IV
40847339|NCT01300572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
40847340|NCT01300572|OTHER|Pharmacological Study|Correlative studies
41030384|NCT05483426|OTHER|semi-structured Interviews|semi-structured interview conducted by a psychiatrist
41030385|NCT04510064|DRUG|Camrelizumab plus mFLOT regimen|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.
41030386|NCT04510064|PROCEDURE|R0 surgery|The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
41030387|NCT02243033|DEVICE|MR-guided laser focal therapy|Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
41369919|NCT00465101|DEVICE|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
41369920|NCT00887822|DRUG|Bevacizumab|7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
41369921|NCT00887822|DRUG|Placebo|Placebo matched to bevacizumab on Day 1 of every 3-week cycle
41369922|NCT00887822|DRUG|Capecitabine|1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
41369923|NCT00887822|DRUG|Cisplatin|80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
41369924|NCT01756651|DRUG|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
41369925|NCT05953610|DRUG|Acetazolamide 500 MG QHS|Acetazolamide
41369926|NCT05953610|DRUG|Eszopiclone 3 mg QHS|Eszopiclone
41369927|NCT04351594|DRUG|Biofreeze 4 % Topical Gel|Biofreeze gel with active manufactured ingredient (Menthol 4%)
41369928|NCT04351594|OTHER|Biofreeze placebo gel|Biofreeze gel with no active manufactured to have the same look, feel and odour as Biofreeze topical gel.
41369929|NCT06252545|BEHAVIORAL|semistructured interviews|Black subjects with pancreatic cancer will provide insight on their experience discussing clinical trials and preferences for communicating clinical trial information
41369930|NCT06252545|BEHAVIORAL|feedback|Black subjects with pancreatic cancer will provide feedback on mHealth app prototype.
40847341|NCT01300572|RADIATION|Total-Body Irradiation|Undergo TBI
40847342|NCT01300572|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
40847343|NCT04223908|OTHER|observational : questionnaries for assessment of health burden|The French IN-FOCUS study was designed to capture current and retrospective data in FCS or MCS. Patients were called by the participating centers and were proposed to answer a paper questionnaire or to connect to a web-based questionnaire The questionnaire was divided into sections specifically assessing various domains of their experience: demographic data, signs, symptoms and complications of the disease, healthcare circuit, management, relationship with healthcare providers, and burden of the disease on daily life. (Details are available as supplementary material S1). The questionnaire focused on symptoms because the interest of quality of life assessment tools is debated in rare diseases with episodic manifestations. Indeed, most of these tools refer to a limited recall period.
40847344|NCT05124171|BIOLOGICAL|BNT162b2|"ARM 1 receiving Pfizer-BioNTech vaccine~* Group 1.A: 18-64 years old~* Group 1.B: 65 years and older"
40847345|NCT05124171|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|"ARM 2 receiving SP/GSK subunit D614 vaccine~* Group 2.A: 18-64 years old~* Group 2.B: 65 years and older"
40847346|NCT05124171|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|"ARM 3 receiving SP/GSK subunit B.1.351 vaccine~* Group 3.A: 18-64 years old~* Group 3.B: 65 years and older"
40847347|NCT03834220|DRUG|Debio 1347|Debio 1347 oral tablets.
41369931|NCT00287612|PROCEDURE|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
41369932|NCT00287612|PROCEDURE|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
41502979|NCT01162746|DRUG|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
41502980|NCT01162746|DRUG|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
41502981|NCT00005000|DRUG|Nelfinavir mesylate|
40847348|NCT06141759|OTHER|Exercise|Cheneau brace and Schroth Best Practice exercise
41502982|NCT00005000|DRUG|Efavirenz|
41502983|NCT00005000|DRUG|Lamivudine|
40847349|NCT01192412|PROCEDURE|Intervention is blood pressure management approach|1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is \>105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP \<100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
40847350|NCT01192412|PROCEDURE|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is \<80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is \>85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
40847351|NCT05890469|COMBINATION_PRODUCT|Zirconia surface implant and guided bone regeneration|"The Straumann® PURE Ceramic Implant System is made from 100 % yttria-stabilized zirconia. Its surface features a topography characterized by macro- and micro-roughness to offer a structure for cell attachment and the osseointegration of this surface has been successfully proven. Owing to the increasing aesthetic standards in the field of implant dentistry and the concerns on sensitivity to titanium, there has been a growing interest towards metal-free implant rehabilitation.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
40847352|NCT05890469|COMBINATION_PRODUCT|Hydrophilic titanium surface implant and guided bone regeneration|"The Straumann® Standard Plus (SP) Implant is a Soft Tissue Level Implant with a smooth neck section of 1.8 mm. It has a fundamentally improved hydrophilic surface chemistry (SLActive®) which accelerates the osseointegration process in the early healing phase.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
40847353|NCT04569409|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Wagner grade 2 Foot Ulcer
40847354|NCT04569409|PROCEDURE|Vehicle Sheet|Application of Vehicle sheet to Diabetic Wagner grade 2 Foot Ulcer
40847355|NCT02170181|RADIATION|SBRT|SBRT to Oligometastases
41030388|NCT00799812|DRUG|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
41030389|NCT00799812|DRUG|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
41162476|NCT05113485|BEHAVIORAL|Diabetes Prevention Program-based lifestyle change intervention (DPP)|The DPP condition consists of 11 health education sessions over 12 weeks, including 2 virtual home visits, two virtual group education sessions and 7 telephone coaching calls. These sessions will teach DPP-based lessons on how to lose excess body fat through calorie restriction and increased physical activity. All dietary and physical activity recommendations are intended to be consistent with federal nutrition and physical activity guidelines.
41502984|NCT00005000|DRUG|Keyhole-Limpet Hemocyanin|
41502985|NCT00005000|DRUG|Stavudine|
41502986|NCT00005000|DRUG|Zidovudine|
41030390|NCT00799812|DRUG|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
41030391|NCT00799812|OTHER|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
41502987|NCT00005000|DRUG|Didanosine|
41502988|NCT06233903|DRUG|18F-mFBG|18F-mFBG positron emission tomography with CT (PET/CT) or positron emission tomography with MRI (PET/MRI)
41502989|NCT06632912|BIOLOGICAL|2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)|Two doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0 and 6 months.
41502990|NCT06632912|BIOLOGICAL|3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)|Three doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0, 2, and 6 months.
41502991|NCT00946816|BEHAVIORAL|Nutritional Intervention|Nutritional Intervention
41502992|NCT03195335|OTHER|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
41502993|NCT02101580|DRUG|ADI-PEG 20|
41502994|NCT06354660|DRUG|Retatrutide|Administered SC.
41502995|NCT06354660|DRUG|Placebo|Administered SC.
41502996|NCT05099172|DRUG|BAY2927088_formulation A|Oral administration
41502997|NCT05099172|DRUG|BAY2927088_formulation B_1|Oral administration
41502998|NCT05099172|DRUG|BAY2927088_formulation B_2|Oral administration
41502999|NCT05794503|DRUG|Neostigmine|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.
41503000|NCT05794503|DRUG|Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex
41369933|NCT04782882|BEHAVIORAL|Progressive muscle relaxation+laughter therapy|"Laughter therapy:Laughter therapy is a technique that changes the mood by breathing correctly and by combining childish exercises with laughter exercises to turn into real laughter for no reason.~Progressive muscle relaxation procedure:~the participants were asked to tighten and relax large muscle groups in the body with deep breathing exercises. Progressive muscle relaxation was applied to the muscles of the head and face, neck, chest, back, arms, hands, abdomen, hips, legs and feet. The procedure was applied in a dark environment and accompanied by candlelight and relaxing music."
41369934|NCT01351324|DIETARY_SUPPLEMENT|Absence or presence of fish oil|Oral dose of saturated fat with or without fish oil and a heparin infusion
41369935|NCT01815996|OTHER|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
41030392|NCT00799812|OTHER|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
41030393|NCT04717011|DIAGNOSTIC_TEST|PCR test|PCR test in two different semen samples from each patient: first with positive diagnosis for COVID-19 and the second after negative diagnosis for COVID-19.
41030394|NCT04388982|BIOLOGICAL|low dosage MSCs-Exos administrated for nasal drip|Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
41030395|NCT04388982|BIOLOGICAL|mild dosage MSCs-Exos administrated for nasal drip|Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
41030396|NCT04388982|BIOLOGICAL|high dosage MSCs-Exos administrated for nasal drip|Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
41369936|NCT04018716|DEVICE|MTA|Indirect capping with MTA
41369937|NCT04018716|DEVICE|Dycal|Indirect capping with Dycal
41369938|NCT01411761|DIETARY_SUPPLEMENT|Reflor|5 million unit/day, first 15 day of life
41503001|NCT02816411|DIETARY_SUPPLEMENT|Milk protein isolate|"Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water.~Placebo consisted of 365 ml water, 125 ml sugar-free cordial and 2g of low-calorie glucose/dextrose powder."
41503002|NCT02816411|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
41503003|NCT00841828|DRUG|Epirubicin|
41030397|NCT01595919|OTHER|Nutritional Intervention|Ad libitum amounts of beverage at a meal
41030398|NCT04050592|DRUG|Estradiol|Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.
41030399|NCT04050592|OTHER|Placebo|Those in groups A and B will switch from estradiol to placebo at the beginning of the 10th week after abrupt or tapered discontinuation of HT.
41030400|NCT02193620|DRUG|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
41503004|NCT00841828|DRUG|Cyclophosphamide|
41030401|NCT02193620|DRUG|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
41030402|NCT02193620|DRUG|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
41030403|NCT01065961|DRUG|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
41030404|NCT01065961|DRUG|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
41030405|NCT03985423|DRUG|Emapalumab-Lzsg|Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day \[SD\] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
41369939|NCT01411761|OTHER|serum physiologic|1 cc added to one feeding in a day
41503005|NCT00841828|DRUG|Docetaxel|
41030406|NCT06402435|DRUG|Lvonescimab (AK112)|8Gy\*3 SBRT (continuous irradiation) to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT (continuous irradiation) irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK112 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of albumin paclitaxel (125 mg/m2, d1, d8) and carboplatin (AUC=6, Q3W) were administered, followed by four cycles of sequential Doxorubicin 50mg/m2 (Q3W) + Cyclophosphamide 600mg/m2 (Q3W) for 4 cycles.The immunotherapy drug used was Lvonescimab (AK112).
41030407|NCT05503108|OTHER|Fasting Mimicking diet program|Fasting mimicking diet by L-Nutra, a 4-day low caloric, low protein, vegetarian diet 3 days prior to and the day of neoadjuvant chemotherapy administration. The FMD will take place every 4 weeks, thus in total 5 times (2x during ddAC, 3x during Paclitaxel) during the neoadjuvant chemotherapy.
41030408|NCT04889560|OTHER|Experimental group|Home-based version of a computerized cognitive training (CoRe)
41369940|NCT03737617|DRUG|Cuvitru 20 % Injectable Solution|Active
41503006|NCT00841828|DRUG|Lapatinib|
41503007|NCT00841828|DRUG|Trastuzumab|
41503008|NCT02054689|RADIATION|Fractionated Stereotactic Radiosurgery|SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
41503009|NCT06634329|OTHER|Oro or Nasogastric tube feeding|Parental involvement in their premature baby's feeding
41503010|NCT06088030|DRUG|Arsenic trioxide|Patients should be treated with the corresponding first-line chemotherapy regimen first, for example: Neuroblastoma: CAV (cyclophosphamide, pinarubicin, vincristine), PVP (cisplatin, etoposide) ,CT (cyclophosphamide, topotecan).If patients was evaluted as PD/SD after treatments, arsenic trioxide (ATO) will be administered 0.18mg/kg per day over six hours IV daily for ten days in combination with previous chemotherapy regimen on the third day of each treatment cycle. Other pediatric tumors with TP53 mutations not mentioned above will have similar treatment regimens. If the efficacy of the conventional standard chemotherapy regimen is evaluated as PD/SD, then the next course of treatment will be combined with ATO on the basis of the standard chemotherapy regimen.
40847356|NCT02610452|OTHER|Clown therapy|"The clowns intervene by twos: a game takes place.~1. The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.~2. The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.~3. The original game proposal is adjusted according to mutual empathy with those present.~4. The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.~5. The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled."
41030409|NCT04889560|OTHER|Control group|Computerized cognitive training (CoRe)
41030410|NCT04218929|OTHER|Study Formula (SF)|New infant formula for term infants fed ad lib
41030411|NCT04218929|OTHER|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
41030412|NCT06087445|DEVICE|NeuroLife EMG-FES Sleeve System|Participants will complete a 12-week training protocol (3x/week, 1-2 hours/session) which includes an activity-based upper extremity training paradigm where participants will complete multiple repetitions attempting functional tasks in different categories (grip, grip with rotation, pinch, and pinch with rotation) while using the closed-loop EMG-FES system on one forearm/hand. Each category includes \~10 functional tasks (e.g., grip - open a jar; pinch with rotation - nuts and bolts) that progressively increase in difficulty. Each session will include massed practice of 3 functional tasks (20-minute blocks for each task) with rest breaks as needed to avoid fatigue. Sessions will include \~60 minutes of task practice, but they may last 1-2 hours to account for setup time and rest breaks.
41030413|NCT01721018|BIOLOGICAL|HSV1716 Intra-pleural delivery|
41369941|NCT04746495|DRUG|Placebo|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
41369942|NCT04746495|DRUG|Eplerenone 50mg|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
41030414|NCT01776645|BEHAVIORAL|Compassion Cultivation Training Course|
41030415|NCT06496828|PROCEDURE|Biologically-oriented preparation technique|The preparation will be made according to the new principles of biologically oriented technique to receive monolithic and bi-layered all-ceramic crowns.
41030416|NCT06496828|PROCEDURE|Conventional method of preparation|Teeth prepared with shoulder margins to receive monolithic and bi-layered all-ceramic crowns
41030417|NCT02813226|OTHER|Molecular Imaging|Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
41030418|NCT00337766|DRUG|Desmopressin (DDAVP)|
41030419|NCT00337766|DRUG|Placebo|
41030420|NCT01970033|DRUG|Placebo|"* Run in period ：oral tablets of Placebo twice daily for 2 weeks~* Phase A : oral tablets of Placebo twice daily for 24 weeks~* Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks"
41030421|NCT01970033|DRUG|SP2086 50 mg b.i.d.|"* Run-in period: placebo twice daily for 2 weeks~* Phase A:SP2086 50 mg b.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d for 28 weeks"
41030422|NCT01970033|DRUG|SP2086 100 mg q.d.|"* Run-in period:placebo twice daily for 2 weeks~* Phase A: SP2086 100 mg q.d. for 24 weeks~* Phase B: SP2086 100 mg q.d. for 28 weeks"
41030423|NCT02255110|DRUG|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m\^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
41030424|NCT02255110|DRUG|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m\^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
41030425|NCT05601479|DRUG|Acetyl-L-carnitine|At the beginning of the first chemotherapy of the oxaliplatin regimen, Acetyl-L-carnitine 500mg will be given orally three times daily for 24 weeks. If subjects discontinue oxaliplatin-containing chemotherapy for various reasons (e.g., allergy to oxaliplatin), they will continue taking acetyl-L-carnitine until 24 weeks (unless acetyl-L-carnitine intolerance or other conditions interfere with medication).
41030426|NCT03383432|DEVICE|Intrauterine device|Copper T 380 A
41369943|NCT06056076|OTHER|Mini Squats Training|Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.
41030427|NCT03383432|RADIATION|Ultrasound|Transabdominal ultrasound
41030428|NCT03383432|PROCEDURE|uterine sounding sparing technique|we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
41030429|NCT03678948|DEVICE|Radiofrequency-Based Debridement|In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
41369944|NCT06056076|OTHER|Endurance Training|Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
41369945|NCT00936468|BIOLOGICAL|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
41369946|NCT04501874|DRUG|EMB-001|720 mg metyrapone/24 mg oxazepam mg BID
41369947|NCT04501874|DRUG|EMB-001 Placebo|Inactive comparator
40847357|NCT03419234|DRUG|Abiraterone Acetate|Given PO
41369948|NCT04622059|BEHAVIORAL|acoustic stimulation|"An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes."
41030430|NCT03678948|DEVICE|Mechanical Debridement|Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement
41369949|NCT02716207|DEVICE|CyberKnife|Radiation Therapy
40847358|NCT03419234|DRUG|Antiandrogen Therapy|Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
40847359|NCT03419234|DRUG|Cabazitaxel|Given IV
40847360|NCT03419234|OTHER|Laboratory Biomarker Analysis|Correlative studies
40847361|NCT03419234|PROCEDURE|Orchiectomy|Undergo standard of care surgical castration with bilateral orchiectomy
40847362|NCT03419234|OTHER|Pharmacological Study|Correlative studies
40847363|NCT03419234|DRUG|Prednisone|Given PO
40847364|NCT06166108|DRUG|transversus abdominis plane (TAP) block in Abdominal hysterectomy|Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.
41369950|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3
41369951|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5|Single dose, one spray in each nostril of Placebo nasal spray at Visit 5
41369952|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5
41369953|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3|Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3
41369954|NCT04490551|DIAGNOSTIC_TEST|Risk-based logistic regression model|The intervention will be a risk-based logistic regression model that takes multiple variables into account to calculate the risk of advanced neoplasia as an outcome.
40847365|NCT05353439|PROCEDURE|Biopsy|Undergo biopsy
40847366|NCT05353439|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41369955|NCT04490551|DIAGNOSTIC_TEST|FIT|FIT is a stool-based test that detects human blood in faeces.
41369956|NCT01041027|DRUG|Paclitaxel|Given IV
41369957|NCT01041027|DRUG|Carboplatin|Given IV
40847367|NCT05353439|PROCEDURE|Computed Tomography|Undergo CT scan
40847368|NCT05353439|BIOLOGICAL|Pembrolizumab|Given IV
40847369|NCT05353439|DRUG|Tazemetostat Hydrobromide|Given PO
40847370|NCT05353439|DRUG|Topotecan Hydrochloride|Given IV
40847371|NCT03222024|OTHER|routine medical care|This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
40847372|NCT00952900|BEHAVIORAL|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
40847373|NCT00952900|BEHAVIORAL|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
40847374|NCT01019369|DRUG|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
40847375|NCT01019369|DRUG|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
40847376|NCT05755659|DRUG|Fosaprepitant Dimeglumine for Injection|The specification of Fosaprepitant Dimeglumine for injection is 150 mg, and the usage and dosage is: when preventing nausea and vomiting caused by HEC, this product is used in combination with dexamethasone and 5-HT3 antagonist. The dosage of Fosaprepitant Dimeglumine for injection is 150 mg, and the infusion time is 20-30 minutes. The intravenous infusion is completed 30 minutes before the beginning of chemotherapy on the first day.
41030431|NCT06247306|BEHAVIORAL|ScanSTRESS fMRI-paradigm (Streit et al., 2014)|The task is conducted within the MRI scanner and consists of two runs each lasting 11:20 mins., employs a block design and has two different conditions (performance, relaxation), as well as two different task within each condition. Participants undergo the following 2 tasks during the performance condition under time pressure: 1) serial subtraction, 2) a figure matching task. During the performance condition, all participants receive feedback (work faster, mistake, too slow) and are reprimanded concerning their performance. Two investigators in white coats observe the participants with critical facial expression, which is projected to participants through live-video feed during the tasks. The relaxation condition includes easy versions of arithmetic and figure matching task without time constrains or any type feedback on their performance. Performance and relaxation phases are appear in alternating order.
40847377|NCT04901273|PROCEDURE|Homologous PRP injections|Patients will be treated with a single injection of Homologous PRP (5 ml) in the knee joint affected by osteoarthritis.
40847378|NCT04901273|PROCEDURE|Placebo injection (saline solution)|Patients will be treated with a single injections of saline solution (5 ml) in the knee joint affected by osteoarthritis
40847379|NCT01882504|DRUG|gevokizumab|
41030432|NCT06247306|BEHAVIORAL|real-time fMRI neurofeedback|"Two real-time fMRI neurofeedback sessions of 9:30 minutes each are conducted. During these sessions, the participants are instructed to regulate a feedback signal from the ACC. Participants are assigned to either the experimental or Yoke-control group through an automated double-blind procedure. In the neurofeedback sessions, participants in the experimental group receive a feedback signal indicating their current ACC activation. Participants in the control group receive the recorded feedback signal from another participant. The neurofeedback sessions follow a block structure with alternating feedback and rest periods.~Before, between, and after the two sections of the fMRI examination, subjective stress levels and alcohol craving are assessed, and saliva samples are collected for cortisol level determination."
41030433|NCT04665856|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
41030434|NCT04665856|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
41030435|NCT04665856|DRUG|Carboplatin|Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
41030436|NCT04665856|DRUG|Etoposide|Etoposide 100 mg/m\^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
41030437|NCT04665856|DRUG|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
41369958|NCT01041027|RADIATION|Internal Radiation Therapy|Undergo HDR brachytherapy
40847380|NCT05346653|DRUG|SGLT2i|dapagliflozin (10 mg daily)
40847381|NCT05346653|OTHER|No SGLT2i|No SGLT2i
40847382|NCT02758327|DRUG|TheraTears Lubricating Eye Drops|Sodium Carboxy-methylcellulose 0.25% eye Lubricant
40847383|NCT02177474|BEHAVIORAL|Telephone based peer support|
40847384|NCT04735146|OTHER|Adapted physical activity|"Participants in the experimental group will undergo the adapted physical activity program that will be co-designed during phase I of the study.~The 6-week program is aimed at improving the quality of life; increase the physical activity levels according to recommended guidelines; improving body awareness through an educational component; maintain and ameliorate the previous functions (for women previously active) and build the exercise background for sedentary women; increase physical fitness and functional capacity."
40847385|NCT02022436|DRUG|Contrast Ultrasound|Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
40847386|NCT05234203|DIETARY_SUPPLEMENT|HTB Rejuvenate|90 days of BID dosing of 2 capsules of HTB Rejuvenate
40847387|NCT02606058|PROCEDURE|Deferred cord clamping|Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
41369959|NCT01041027|RADIATION|External Beam Radiation Therapy|Undergo EBRT
41369960|NCT01041027|OTHER|Laboratory Biomarker Analysis|Correlative studies
41369961|NCT04369040|DEVICE|High-flow nasal oxygen therapy using a specific nasal cannula|Patient in this arm will received high-flow nasal oxygen therapy ventilation during the ENT surgery
40847388|NCT03605914|DRUG|diclofenac|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
40847389|NCT03605914|DRUG|Norco|The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
41503011|NCT02794597|BEHAVIORAL|SHINE intervention group|Includes all substance treatment services as well as the brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing: Sexual Health Initiative for Navigation and Empowerment (SHINE).
40847390|NCT03757377|DEVICE|BackBeat Moderato System|Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
40847391|NCT03757377|DEVICE|BackBeat Moderato Sytsem|Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
40847392|NCT02337634|DRUG|Placebo|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
40847393|NCT02337634|DRUG|Milk Thistle|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
40847394|NCT03111953|PROCEDURE|Roux-en-Y Gastric Bypass Surgery|"In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately \~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum."
40847395|NCT03111953|PROCEDURE|Biliopancreatic Diversion Surgery|In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, \~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, \~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
40847396|NCT01329939|DRUG|Montelukast|Age-dependent dose, nightly, 24 weeks
40847397|NCT01329939|DRUG|Placebo|Age-dependent dose, nightly, 24 weeks
40847398|NCT01329939|DRUG|Montelukast|Age-dependent dose, nightly, 24 weeks
40847399|NCT01329939|DRUG|Placebo|Age-dependent dose, nightly, 24 weeks
40847400|NCT05763771|BEHAVIORAL|Smart Phone App|Collection of data
41369962|NCT04369040|DEVICE|Flow Controlled Ventilation using a laryngeal tri-tube|Patient in this arm will received a laryngeal tri-tube ventilation during the ENT surgery
41369963|NCT04487275|DRUG|MLC901 or Placebo|groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
40847401|NCT05763771|OTHER|NIcotine Patches|Place on the skin
40847402|NCT01183455|DRUG|Aralast NP|Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
41503012|NCT05369728|OTHER|Coronary CT in 1st line compared to the strategy with functional test in 1st line in patient at Intermediate Risk of Developing Stable Coronary Disease:|Coronary CT in 1st line compared to the strategy with functional test in 1st line in Patients at Intermediate Risk of Developing Stable Coronary Disease:
40847403|NCT01183455|DRUG|Placebo|Participants will receive IV infusions of placebo once a week for 12 weeks.
40847404|NCT01227005|BIOLOGICAL|Transfusion of blood products|The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
40847405|NCT06300268|DEVICE|AdvaPro Sirolimus Eluting Coronary Stent System|Cardiac Stent
41369964|NCT02405182|OTHER|Magnetic Resonance Imaging|
41369965|NCT04651257|DEVICE|Contrast mammography (CEM)|Contrast mammography in pathological nipple discharge
41369966|NCT01769846|OTHER|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH \& Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.
40847406|NCT06262217|DEVICE|Mobile MRI scanner|Use of mobile MRI scanner in patients with suspected or confirmed acute stroke (including Transient Ischaemic attacks)
40847407|NCT03277365|OTHER|Receive genetic risk information|Risk scores are provided by ResearchKit app.
40847408|NCT05281055|PROCEDURE|Endovascular thrombectomy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombosuction, others, or combination methods.
40847409|NCT02658773|DRUG|lidocaine-Prilocaine cream|
40847410|NCT02658773|DRUG|placebo cream|
41369967|NCT06306417|OTHER|lifestyle intervention|lifestyle intervention
41369968|NCT06306417|DEVICE|acupuncture|acupuncture
41369969|NCT06306417|DEVICE|Sham acupuncture|Sham acupuncture
41503013|NCT06614192|DRUG|ABBV-400|Intravenous (IV) Infusion
40847411|NCT02789592|DRUG|Melatonin PR|For experimental treatment of RBD
40847412|NCT02789592|DRUG|Clonazepam|For experimental treatment of RBD
40847413|NCT02789592|DRUG|Melatonin PR placebo|Placebo pill manufactured to mask melatonin PR 2mg tablet
40847414|NCT02789592|DRUG|Clonazepam placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
40847415|NCT05648565|DEVICE|Radiofrequency ablation (RFA)|The NEUROMARK device is an in-office, disposable bipolar RFA device with a treatment tip consisting of micro electrodes which delivers RF energy while monitoring appropriate tissue contact to maximize delivery to posterior nasal nerve and its variable branching. After topical anesthesia consisting of oxymetazoline and 1% lido followed by 4% lidocaine, the device will be placed in the posterior inferior turbinate under endoscopic visualization. The device will be activated per manufacturer's instructions
40847416|NCT00201942|PROCEDURE|PET scan|
40847417|NCT04939792|DRUG|Vitamin D|Capsules ingested orally
40847418|NCT04939792|DRUG|Placebo|Capsule ingested orally
40847419|NCT04939792|DRUG|Vitamin D + L-cysteine|Capsule ingested orally
40847420|NCT04939792|DRUG|L-cysteine|Capsule ingested orally
41503014|NCT06614192|DRUG|Trifluridine/Tipiracil|Oral Tablet
41503015|NCT06614192|DRUG|Bevacizumab|IV Infusion
41503016|NCT04553874|OTHER||observational study without intervention
41369970|NCT05156346|OTHER|LEAVES|LEAVES consists of 10 modules of readings and exercises. Readings are filled with evidence-based information on grief-related topics (e.g., how to positively influence thoughts, emotions and behaviours), followed by exercises which encourage mourners to actively reflect on what was learned and apply their new knowledge into their grief journey and coping strategies (e.g., how to change attentional focus). Users are encouraged to work through one module per week and complete the assignments.
41030438|NCT05634226|DEVICE|Hands-free oral-positive pressure device (oPEP)|This is a pilot study using a novel, minimal risk, portable, hands-free oral-positive pressure device (oPEP) in patients with Fontan palliation that will examine whether using this device in both the acute and chronic phase will alter Fontan hemodynamics and create pulsatility in the Fontan circuit and thereby increasing cardiac output. This device is easy to use and poses no significant risk to human subjects. We will measure this through echocardiographic measures including pulsatility in different aspects of the Fontan circuit including IVC, hepatic veins, the Fontan conduit, and pulmonary arteries and aortic blood flow measurements. After demonstration of how to use the device appropriately, we will have patients use the device after their clinical echocardiogram for their clinic appointment. We will ask them to use the device at home 3-4 times a day for 10-15 mins and have them return in approximately 4 weeks to have another echocardiogram done with the same measurements.
41030439|NCT04933682|DRUG|ALXN2050|Oral tablet.
41503017|NCT05436314|OTHER|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is applied towards the flow direction of lymph vessels with special hand movements. MLD is made with very light, completely painless and rhythmic translational movements of the skin. MLD, by expert and trained physiotherapists (G.K, H.K) in this field. It will be applied with the techniques defined by Dr. Vodder. MLD ( to the neck region, abdominal region, axillary and inguinal lymph nodes) will be applied by following the lymphatic pathways specific to the anterior and posterior trunk, respectively. The treatment session will take approximately 45 minutes. It will be applied 5 days a week during 3 weeks.
41503018|NCT05436314|DRUG|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
41030440|NCT04933682|DRUG|Fluconazole|Oral tablet.
41503019|NCT05436314|OTHER|Sham Manual Lymphatic Drainage|Sham MLD will be administered by MLD-trained physiotherapists (G.K, H.K) with a protocol that is far from techniques that reveal the physiological effects of MLD. Sham application consists of applications that do not follow the lymphatic pathways from distal to proximal to the trunk, neck, and abdominal region, and superficial breathing. The session will take approximately 45 minutes.
41503020|NCT03131804|OTHER|Intradialytic aerobic low intensity exercise|Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
40847421|NCT02879578|DRUG|Valbenazine|
41030441|NCT04933682|DRUG|Rifampin|Oral capsule.
41030442|NCT03721380|BEHAVIORAL|Treatment as usual|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.
41369971|NCT05512585|OTHER|awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)|in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP
41369972|NCT02607904|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
41369973|NCT05913921|DRUG|Amphotericin B liposome for injection|IV infusion, 2.0 mg/kg
41369974|NCT05913921|DRUG|AmBisome|IV infusion, 2.0 mg/kg
41369975|NCT00000968|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
41503021|NCT06328062|DRUG|Mirogabalin|Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
40847422|NCT00387036|DRUG|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
40847423|NCT00387036|DRUG|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
40847424|NCT04382378|DEVICE|neuromuscular electrical stimulation|application of an electric current through electrodes placed on the skin over the targeted musclesto induce skeletal muscle contractions
41369976|NCT03954418|DIETARY_SUPPLEMENT|Acesulfame K, cyclamate, saccharine, aspartame|Intervention group receives a combination of multiple artificial sweeteners
41369977|NCT02044094|DRUG|Buprenorphine|A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.
41503022|NCT06328062|DRUG|Pregabalin|Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
41503023|NCT05486481|DRUG|Venetoclax|Given orally (PO)
41503024|NCT05486481|DRUG|Dexamethasone|Given PO
40847425|NCT05351775|DEVICE|Smartphone application|Patient is asked to do the first recording at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period.
40847426|NCT05351775|DEVICE|Bed sensor|The Emfit bed sensor will be used during the index hospitalization and in home-based monitoring after hospital discharge up to 3 months.
41030443|NCT02422277|DEVICE|LI-ESWT group|"The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.~-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week."
41369978|NCT02044094|DRUG|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.
41503025|NCT05486481|DRUG|Daratumumab|Given Subcutaneously (SC)
40847427|NCT05351775|DEVICE|Wrist-worn photoplethysmography (PPG) and accelerometer data logger.|Data collection with PDL is continued during initial hospitalization in the intervention group where the gold standard ECG is obtained and data can be used in algorithm development but will not be used to monitor treatment or for diagnosis.
40847428|NCT05351775|DEVICE|Patch-holter ECG|The patch-holter will be used during the index hospitalization and also in home if the home-based monitoring devices are signalling of a possible AF and it is not detected in the consequent ECG.
40847429|NCT06392269|DIAGNOSTIC_TEST|Tasso+SST|Clinical evaluation of capillary blood samples collected using the Tasso+SST device for downstream analyte testing.
41503026|NCT05486481|DEVICE|Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay|Lab test
40847430|NCT01340573|DRUG|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
40847431|NCT01340573|DRUG|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of \<65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of \>85 kg received 1200 mg of ribavirin daily.
40847432|NCT00167310|DRUG|Eicosapentaenoic acid (omega-3 fatty acid)|2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
41503027|NCT04918485|OTHER|preoperative psychological intervention|including closing the relationship between nurse and patient , knowledge education,
41503028|NCT00307918|DEVICE|acupuncture|
41503029|NCT03628625|DRUG|Letrozole 2.5mg|total dose 7.5 mg per day for 3 days
40847433|NCT00167310|DRUG|Placebo|2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
40847434|NCT00002218|DRUG|CI-1012|
40847435|NCT00723359|DRUG|BT062|biologic
40847436|NCT05345301|DIAGNOSTIC_TEST|Event related desynchronization measurement|Individuals will spend one hour and receive cues to open or close their hand while wearing a EEG cap and EMG sensors on their forearm.
40847437|NCT03876665|OTHER|No intervention|No intervention
41030444|NCT02422277|DRUG|PDE-5 inhibitors group|The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
41503030|NCT03628625|DRUG|Placebo|Folic acid for 3 days
41503031|NCT03628625|DRUG|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
41503032|NCT06382610|DIETARY_SUPPLEMENT|Melatonin|Melatonin will be administered in three different forms
41503033|NCT06622642|PROCEDURE|Transoral technique for mandibular angle fracture reduction|In transoral technique approach inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. A 5-hole 2mm miniplate with 2 holes anterior and 2 holes posterior to fracture line will be screwed to external oblique ridge and MMF will be removed and incision line will be closed.
40847438|NCT06584162|DRUG|Vedolizumab Injection|"Based on therapeutic drug monitoring, patients could be de-escalated based on a pharmacokinetic model:~Dosing interval Trough Target 20 mg/L~Adjust dosing interval to:~2 weeks \< 33 mg/L 2 weeks 2 weeks 33 - 46 mg/L 3 weeks 2 weeks ≥ 46 mg/L 4 weeks 3 weeks \< 20 mg/L 2 weeks 3 weeks 20 - 29 mg/L 3 weeks 3 weeks ≥ 29 mg/L 4 weeks 4 weeks \< 13 mg/L 2 weeks 4 weeks 13 - 20 mg/L 3 weeks Version number: 6.1, 24-06-2024 22 of 44 4 weeks ≥ 20 mg/L 4 week"
40847439|NCT01431963|DRUG|Lamictal|No comparison.
40847440|NCT06351059|DIAGNOSTIC_TEST|InModi acoustic emission analysis|All diagnosis tests
40847441|NCT03036618|DIETARY_SUPPLEMENT|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
40847442|NCT03036618|DIETARY_SUPPLEMENT|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
40847443|NCT00718341|DRUG|AF056|
40847444|NCT00718341|DRUG|Placebo|
41030445|NCT02121847|DRUG|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
41030446|NCT02121847|DRUG|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
41030447|NCT05779267|DRUG|NRX-101|D-cycloserine/lurasidone fixed dose combination
41030448|NCT01829412|OTHER|DW-MRI|MRI imaging with diffusion weighted sequences of the whole body
41030449|NCT05570526|DIETARY_SUPPLEMENT|Melatonin|Puritan's Pride ® Melatonin 5mg tablets orally once daily.
41030450|NCT05570526|OTHER|Placebo|Placebo tablet once daily.
41030451|NCT00856583|DRUG|Sertindole|Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
41030452|NCT00856583|DRUG|Risperidone|Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
41030453|NCT02534974|DEVICE|NOSTEN|
41162477|NCT05113485|BEHAVIORAL|Highly Microbiota-Accessible Foods (HMAFs) intervention|The Highly Microbiota-Accessible Foods (HMAFs) intervention approach includes 11 health education sessions, including two virtual home visits, two virtual group education sessions, and 7 telephone coaching sessions. These sessions are designed to help study participants to identify and consume optimally 6 daily instances of minimally processed, fiber-rich food sources, drawn from all four of the MyPlate.gov categories: vegetables, fruits, whole grains and plant-based protein-rich foods (e.g., legumes, nuts and seeds). Increased physical activity is also recommended as a way to optimize the microbial conversion of fiber-rich food sources to short chain fatty acids, which are then expected to reduce excess low-grade inflammation.
41162478|NCT02046941|BEHAVIORAL|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction.
41162479|NCT06006585|DRUG|BI 771716|BI 771716
41162480|NCT05699967|OTHER|data collection|Participants wear a wristband with a Photoplethysmography (PPG), heart rate and respiratory rate sensor continuously for 3 days. Once gateway and device are linked, all data will be transmitted continuously via Bluetooth to an in-house database. The Device Hub allows to control data availability and signal quality of the wearables, but no scores will be calculated and visualized. The data obtained for calculating the NEWS2 is solely observational and for the study staff. It has no clinical consequence on the treatment of the patient. It is analyzed whether the score with values form the wearables and Electronic Health Record (EHR) corresponds to the conventionally calculated NEWS2 score with values coming only from the EHR.
41162481|NCT03697083|OTHER|Reminders Through Association|Participants receive 8 text messages asking them to think of a reminder cue that will help them remember to pick up the prescription and use the cue.
41162482|NCT03697083|OTHER|Active Control|Participants receive 8 text messages asking them to think of where they plan to store their medication once they pick it up and to think about that location on their intended date of pickup.
41162483|NCT03697083|OTHER|Baseline Control|Participants receive 1 text message thanking participants for enrolling in the reminder program. Participants are not contacted further.
41162484|NCT02696863|BEHAVIORAL|questionnaire|
41162485|NCT03338257|BEHAVIORAL|Husky Reads Intervention|The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
41030454|NCT01323699|BEHAVIORAL|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
41030455|NCT05419648|BIOLOGICAL|1 additional tube of blood|For all the patients included, a specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
41162486|NCT03762590|OTHER|Doxy.me genetic education +/- Color Genomics genetic education|"Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website."
41162487|NCT03762590|OTHER|Color Genomics genetic education|Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
41162488|NCT03025997|DIETARY_SUPPLEMENT|Active yoghurt|Active yoghurt (containing encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
41162489|NCT03025997|DIETARY_SUPPLEMENT|Placebo yoghurt|Placebo yoghurt (containing non-encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
41162490|NCT03146325|DRUG|BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE|A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
41162491|NCT03146325|DRUG|MATCHING PLACEBO|TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
41369979|NCT02044094|DRUG|hydromorphone|"Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen)."
40847445|NCT05261009|DRUG|Peri-capsular Nerve Group (PENG)|PENG block for postoperative pain management
41030456|NCT06528119|OTHER|COVID 19 pandemic|Physiological indicators such as blood pressure, heart rate, respiratory rate, and consciousness status of COVID-19 patients are used to apply the START, MEWS, and qSOFA in COVID-19 patients.(COVID 19 病患).
41030457|NCT00019682|BIOLOGICAL|Aldesleukin|Given IV
41030458|NCT00019682|BIOLOGICAL|gp100 Antigen|Given SC
41030459|NCT00019682|DRUG|Montanide ISA 51 VG|Given SC
41030460|NCT00019682|OTHER|Quality-of-Life Assessment|Ancillary studies
41030461|NCT00019682|OTHER|Questionnaire Administration|Ancillary studies
41030462|NCT00019682|OTHER|Laboratory Biomarker Analysis|Correlative studies
41030463|NCT06534346|DRUG|15 mg DA-302168S tablet|"Qualified subjects will be randomly assigned to one of two dosing sequences in a 1:1 ratio. Either DA-302168S tablet with food on Day 1 and DA-302168S tablet without food on Day 6 (treatment sequence fed/fasted), or DA-302168S tablet without food on Day 1 and DA-302168S tablet with food on Day 6 (treatment sequence fasted/fed).~Each administration sequence consists of two cycles, with one administration per cycle and a 5-day washout period between each administration."
41030464|NCT05675345|DEVICE|HFNC only|HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
41030465|NCT05675345|DEVICE|HFNC + CNEP10|HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
41030466|NCT05675345|DEVICE|HFNC + CNEP20|HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
41030467|NCT05675345|DEVICE|HFNC + CNEP30|HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
40847446|NCT05261009|OTHER|Lumbar Plexus Block (LPB)|LPB for postoperative pain management
40847447|NCT05491434|DIETARY_SUPPLEMENT|Protein supplement|One líquid brick every day during 3 weeks
41030468|NCT00426504|PROCEDURE|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
41030469|NCT02330835|BEHAVIORAL|In the Drivers Seat|Multimedia student behavior management program for school bus drivers and school administrators
41030470|NCT02330835|BEHAVIORAL|School bus driver training videos|Basic bus driving safety videos
41030471|NCT01281358|OTHER|HOP-ON|A programme of activities which promote motor development
41369980|NCT02044094|DRUG|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
41369981|NCT04943627|DRUG|Balstilimab (BAL)|Anti-PD-1 Monoclonal antibody
41369982|NCT04943627|DRUG|Topotecan|Chemotherapy
41369983|NCT04943627|DRUG|Vinorelbine|Chemotherapy
41503034|NCT06622642|PROCEDURE|Transbuccal technique for mandibular angle fracture reduction|In transbuccal technique inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. extraorally a stab incision will be made with scalpel blade parallel to relaxed resting skin tension lines through which the cannula with a trocar will be inserted through facial tissue down to bone. Transbuccal instrument system will cionsist of transbuccal guide, mountable retractor, drill sleeve, drill guide, and 2mm drill bit. A 2mm titanium miniplate will be placed along buccal cortex and screwed through trocar system. MMF will be removed and incision line closed
41503035|NCT05709197|PROCEDURE|Braun anastomosis|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. In addition to the reconstruction technique used, a side-to-side anastomosis will be created between the afferent and efferent jejunal limbs of the gastrojejunostomy (GJ) at 20 cm distance from the GJ. The anastomosis will be hand-sewn with monofilament PDS 3-0 one-layer running suture.
40847448|NCT01605110|DRUG|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
40847449|NCT01605110|DRUG|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
40847450|NCT04224506|OTHER|No intervention|There is no intervention for this study.
41030472|NCT01281358|OTHER|SMILES|Details are provided on ways for parents to interact with their premature infants
40847451|NCT01219062|DRUG|morphine|periarticular infiltration with 0.25% Bupivacaine for 20 ml.
40847452|NCT01219062|OTHER|control|the patients will be received spinal anesthesia with 0.5% Isobaric Bupivacaine and postoperative pain control by intravenous (IV) Patient - control Analgesia (PCA)
41030473|NCT04157244|BEHAVIORAL|Tailored music listening intervention|The music intervention consists of listening to preferred soothing music at bedtime for 30 minutes every night for four weeks (28 sessions total). This theory based caregiver-assisted intervention builds on the evidence-based protocol of using individualized music to decrease agitation in nursing home residents. It also accounts for sleep-inducing properties of music.
41030474|NCT00587873|DRUG|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
41030475|NCT00587873|DRUG|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
41030476|NCT00587873|DRUG|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
41030477|NCT00375089|OTHER|Group 1|Individuals with Prader-Willi syndrome. Monitoring every 6 months.
41162492|NCT05600998|DRUG|Camrelizumab|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
41369984|NCT04943627|DRUG|Gemcitabine|Chemotherapy
41369985|NCT04943627|DRUG|Irinotecan|Chemotherapy
41369986|NCT04943627|DRUG|Pemetrexed|Chemotherapy
41369987|NCT02048501|OTHER|Resting Metabolic Rate (RMR)|Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
41369988|NCT02048501|OTHER|Duel-energy x-ray absorptiometry (DEXA)|During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
41369989|NCT02048501|OTHER|Visual Analog Scale (VAS)|Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
40847453|NCT01219062|DRUG|Bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
41162493|NCT05509283|BEHAVIORAL|Risk Reduction|Letter, patient portal, SMS and/or another modality
41162494|NCT05296447|OTHER|No Intervention|All subjects that previously received RGX-314 in a parent study
41162495|NCT01991925|OTHER|Interviews, questionaires, RAND-modified delphi method round|phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionnaires and focus group interviews
41162496|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal
41162497|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal
41030478|NCT00375089|OTHER|Group 2|Individuals with Early-onset Morbid Obesity.
41162498|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal
41162499|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal
41503036|NCT05709197|PROCEDURE|Standard Child reconstruction|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. The surgeon is able to perform the PD as normally would be done (antecolic, retrocolic, pylorus-preserving or with distal gastric resecting).
41503037|NCT03352466|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine.
41503038|NCT03352466|BIOLOGICAL|BioThrax|Commercially available anthrax vaccine
41503039|NCT03352466|OTHER|Placebo|Normal saline
41503040|NCT05365724|BIOLOGICAL|Omicron COVID-19 Vaccine (Vero Cell), Inactivated|2 doses of vaccine according to the immunization schedule of 0, 21-28 days
41503041|NCT04874155|DEVICE|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode.
41503042|NCT04874155|DEVICE|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode.
40847454|NCT00951652|BEHAVIORAL|CBT|
41503043|NCT04874155|DEVICE|NTX100 Neuromodulation System - Open-Label|Noninvasive peripheral nerve stimulation device programmed to active mode.
41503044|NCT04988087|DRUG|MHV370|MHV370 for 24 weeks
41503045|NCT04988087|DRUG|Placebo|Placebo for 24 weeks
41503046|NCT04128501|DRUG|Azacitidine|Given SC
41030479|NCT03747029|OTHER|No intervention is provided|No intervention is provided
41030480|NCT02964845|BEHAVIORAL|WISH with CHW and referral to HFM|6 intervention counseling sessions with a peer CHW, as well as CHW facilitated linkage to primary care and HIV risk reduction.
41030481|NCT02964845|OTHER|Enhanced Treatment as Usual|Linkage to Primary care.
41162500|NCT02251197|DRUG|BIII 890 CL|
41162501|NCT02251197|DRUG|Placebo|
41162502|NCT04364685|OTHER|Walking on soft-sand|The participants are required to walking on sand for 30 minutes. Walking is self-paced.
41162503|NCT04364685|OTHER|Walking on Levelled Surface|The Participants will be require to walk on the firm surface for 30 minutes. The participants would decide the pace of walking.
41162504|NCT06274450|COMBINATION_PRODUCT|skin care product|Subjects are uniformly using skin care products provided by the sponsor during the test. Skin care product include: WINONA sensitiveness relieving moisturizing cleansing foam, WINONA sensitiveness relieving moisturizing lotion, WINONA anti-sensitive tolerance-extreme moisturizing cream
41503047|NCT04128501|DRUG|Venetoclax|Given PO
41503048|NCT03289273|DRUG|Regorafenib (Stivarga, BAY73-4506)|As per the treating physicians discretion
41503049|NCT04612751|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
41503050|NCT04612751|DRUG|Durvalumab|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
40847455|NCT00951652|OTHER|Interpersonal and emotional processing therapy|
40847456|NCT00951652|BEHAVIORAL|supportive listening|
40847457|NCT02023047|DRUG|Nifedipine 12 mg coated suppositories|
41162505|NCT06274450|OTHER|Drinks with active ingredients Rosa Roxburghii and Pomegranate|Take drinks with active ingredients such as Rosa Roxburghii and Pomegranate. Drink every morning on an empty stomach, 20ml/2 sachets/day.
41162506|NCT02943642|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
41162507|NCT02943642|DRUG|Vorinostat|ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
41162508|NCT00396097|DRUG|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
41162509|NCT00396097|DRUG|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
41162510|NCT05598606|DRUG|Denosumab Injection|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)
41503051|NCT04612751|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle
41503052|NCT04612751|DRUG|AZD2936|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
41503053|NCT04612751|DRUG|MEDI5752|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
41503054|NCT04612751|DRUG|AZD7789|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
41503055|NCT05668585|DRUG|CFT1946|Specified oral dose on specified day
41503056|NCT05668585|DRUG|Trametinib|Specified oral dose on specified day
41503057|NCT05668585|DRUG|Cetuximab|Specified intravenous dose on specified day
41369990|NCT02048501|OTHER|Meal Stimulation Test|Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
41369991|NCT06091891|DRUG|Tranexamic acid|Without ROTEM-guidance, we maintain tranexamic acid infusion at 10mg/kg/h until the end of the surgery.
41369992|NCT06091891|DRUG|Tranexamic acid infusion under ROTEM-guidance|If diffuse bleeding occurs during surgery, we perform ROTEM testing and administer tranexamic acid based on the test results.
41369993|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks
41369994|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor
41369995|NCT03000075|DRUG|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
41369996|NCT03000075|DRUG|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
41030482|NCT01761435|BIOLOGICAL|Influenza vaccine|"Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :~A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.~B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.~The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline."
41030483|NCT06156930|OTHER|Intervention group lavender oil|The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.
41030484|NCT06156930|OTHER|Placebo group sesame oil|The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
41030485|NCT01223664|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
41030486|NCT01223664|DRUG|Conserved therapy|Oral or intravenous administration
41030487|NCT03198000|DRUG|F# 13418-148 Eye Drops|ocular clear liquid. Tetrahydrozoline 0.05%; Glycerin 0.40% 1-2 drops will be instilled as instructed over one day
41030488|NCT03198000|DRUG|F#13418-158 Eye Drops|ocular clear liquid Tetrahydrozoline 0.05%; Glycerin 0.20%, Hypromellose 0.2%, Polyethylene glycol 400 1.0% 1-2 drops will be instilled as instructed over one day
41030489|NCT03198000|DRUG|F# PF-004390 Eye Drops|Ocular clear liquid Tetrahydrozoline 0.05%; 1-2 drops will be instilled as instructed over one day
41030490|NCT02362880|RADIATION|Florbetaben|single dose of Florbetaben followed by PET scan
41030491|NCT04408469|BEHAVIORAL|Online EQuIP|This online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
41030492|NCT04408469|BEHAVIORAL|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
41030493|NCT03397901|PROCEDURE|Transverse colostomy|Transverse double-cavity colostomy
41030494|NCT01027910|DRUG|PCI-24781|Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
41030495|NCT01027910|DRUG|Doxorubicin|Administered intravenously on Day 4 of each 3 week cycle
41030496|NCT01027910|DRUG|GCSF|Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
41030497|NCT02129179|DRUG|Glucagon-Like Peptide 1|
41030498|NCT06068686|DRUG|Vildagliptin 50 MG|vildagliptin plus their metformin.
41369997|NCT01610752|BEHAVIORAL|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
41369998|NCT00079079|DRUG|carboplatin|
41369999|NCT00079079|DRUG|cisplatin|
41370000|NCT00079079|DRUG|gemcitabine hydrochloride|
41030499|NCT06068686|DRUG|Glimepiride 3 Mg Oral Tablet|glimepiride plus their metformin
41030500|NCT00387218|BEHAVIORAL|Exercise, Physical therapy|
41030501|NCT02652728|DRUG|Enalapril Orodispersible Minitablet|Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
41030502|NCT04741568|BEHAVIORAL|Parental psychoeducational Intervention|"The psychoeducation intervention for parents will focus on providing skills, knowledge and support motivation for caregivers of children with diabetes.~A brief (one-day or two half days) workshop, and a website with downloadable content will be made available to review and refresh any skills and techniques."
41370001|NCT00542646|PROCEDURE|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
41030503|NCT02855099|OTHER|Rehabilitation|The duration on the rehabilitation will be 3 month and will be a multidisciplinary program that includes supervised physical activity
41030504|NCT06535672|OTHER|kamishibai education|Patients in the intervention group will be given Kamishibai diabetes education.
41030505|NCT06535672|OTHER|routine education|Patients in the control group will be given routine diabetes education.
41030506|NCT03865212|DRUG|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1|Given IT and IV
40847458|NCT03074682|DEVICE|Lifeflow|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
40847459|NCT03074682|DEVICE|Push/Pull|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
40847460|NCT03074682|DEVICE|Pressure Bag|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
40847461|NCT03312205|BIOLOGICAL|Autologous CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
41370002|NCT04478591|OTHER|Questionnaires|All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).
40847462|NCT03665688|DEVICE|Outpatient Dilapan-S|After Dilapan-S placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue. Subjects will also be instructed to return to L\&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours. After the designated 12 hours' time or earlier, if indicated, subjects are to return and to be admitted to L\&D unit for standard protocol of labor induction.
40847463|NCT03665688|DEVICE|Inpatient Dilapan-S|"After Dilapan-S placement, subjects will be admitted to L\&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
40847464|NCT06315738|BIOLOGICAL|ST266|Patients randomized to investigative drug product (ST266) will receive either 0.5 mL/kg or 1.0 mL/kg of ST266 QD in addition to Standard of Care treatment; Patients randomized to SOC will receive standard of care treatment only.
40847465|NCT00148941|BIOLOGICAL|SB213503 lot 1|SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
40847466|NCT00148941|BIOLOGICAL|SB213503 lot 2|SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
40847467|NCT00148941|BIOLOGICAL|SB213503 lot 3|SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
40847468|NCT00148941|BIOLOGICAL|Infanrix|Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
40847469|NCT00148941|BIOLOGICAL|IPOL|IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
40847470|NCT00148941|BIOLOGICAL|M-M-R II|M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
40847471|NCT02518191|DRUG|GnRHa|3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
40847472|NCT00852501|OTHER|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
40847473|NCT05987787|PROCEDURE|laparoscopic sleeve gastrectomy without suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access.
41030507|NCT02255175|DRUG|Estradiol|Participants will receive transdermal estradiol (100μg/day) for 3 weeks
41030508|NCT02255175|DRUG|Progesterone|Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
41162511|NCT05598606|DRUG|Zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
41370003|NCT00175552|BEHAVIORAL|Psychotherapy Training|
41370004|NCT01144858|OTHER|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
41370005|NCT01664260|DRUG|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
41370006|NCT01664260|DRUG|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
41370007|NCT01636596|DRUG|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
41370008|NCT00406939|GENETIC|IL-12 gene|
41370009|NCT01715493|DRUG|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
41370010|NCT01715493|DRUG|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
41030509|NCT00518947|DRUG|Lithium|Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
41162512|NCT04605822|DEVICE|3D imaging Total Body Photography Vectra® WB360|3D Total Body Photography Vectra® WB360 (Canfield Scientific, Parsippany, New Jersey, USA) and its digital dermoscopic camera (VISIOMED® D200evo dermatoscope) and scoring of pigmented skin lesions. All participants of this study will undergo 3D TBP at baseline and the follow-up visits up to month 24.
41162513|NCT04605822|DEVICE|2D imaging FotoFinder ATBM® Master imaging system|2D imaging with FotoFinder® Mole Analyzer and scoring of pigmented skin lesions. All participants of this study will undergo 2D imaging FotoFinder ATBM® Master imaging system at baseline and the follow-up visits up to month 24.
40847474|NCT05987787|PROCEDURE|laparoscopic sleeve gastrectomy with suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access. At this point, it is applied running seromuscular stitches at the proximal third of the stapled line using unidirectional 2/0 barbed sutures to invaginate the staple line completely.
40847475|NCT05687513|DRUG|Yisui granule|Yisui granule
40847476|NCT05687513|DRUG|Placebo|placebo
41030510|NCT00518947|DRUG|verapamil|The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
41030511|NCT00518947|DRUG|verapamil plus lithium|
41030512|NCT05253703|OTHER|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session (see arm/group description).
41370011|NCT01331525|BIOLOGICAL|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
41370012|NCT05300256|DEVICE|Peripheral Heating|Peripheral heating of the feet
41370013|NCT05300256|DEVICE|Sham|Sham
41370014|NCT02184312|DRUG|Nevirapine XR low dose|
41370015|NCT02184312|DRUG|Nevirapine XR medium dose|
41030513|NCT06043921|OTHER|No intervention|There is no intervention associated with this observational study.
41370016|NCT02184312|DRUG|Nevirapine XR high dose|
41030514|NCT06002438|DIETARY_SUPPLEMENT|Whole egg powder|15g daily dose for 24 weeks
41030515|NCT06002438|DIETARY_SUPPLEMENT|Corn powder|15g daily dose for 24 weeks
41030516|NCT06002438|DIETARY_SUPPLEMENT|Supercereal Plus|Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.
41030517|NCT06002438|DIETARY_SUPPLEMENT|Micronutrient sprinkles|To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.
41030518|NCT06002438|DRUG|Sulfadoxine pyrimethamine|"Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18.~Infants \>= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18."
41030519|NCT03756558|DEVICE|Cross-Seal System|Use of the Cross-Seal system to close the femoral arteriotomy
41030520|NCT02059694|DRUG|Hyaluronidase|
41030521|NCT02059694|OTHER|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
41370017|NCT02184312|DRUG|Nevirapine (VIRAMUNE®)|
41370018|NCT00812045|DRUG|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
41370019|NCT00812045|DRUG|Placebo|
41370020|NCT03824574|DEVICE|Clear Mandibular Advancement Appliance|Clear Mandibular Advancement Appliance for treatment of skeletal class II patients with retrognathic mandible
41370021|NCT00001256|DRUG|prednisone and methotrexate|
41370022|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h) at post anesthetic care unit(PACU) over 6 hours for 3days .
41370023|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 5 days
41370024|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 7 days
41370025|NCT03892876|DIAGNOSTIC_TEST|Auditory High Frequency Tetanizing Stimulation|50 ms tone pips presented at high frequency for 120 seconds
41370026|NCT03892876|DIAGNOSTIC_TEST|Sham Comparator|auditory tone pips with interstimulus interval (ISI) 1 sec
41503058|NCT06006065|BEHAVIORAL|Upper limb somatosensory discrimination therapy|"Participants will receive three 45 minute sessions of upper limb somatosensory discrimination therapy per week for a period of 8 weeks.~Each session includes 30 minutes of component-based training, including graded practice of three components of somatosensation (i.e., tactile object recognition, texture discrimination and proprioception). Next, 15 minutes of occupation-based practice will be completed to enhance transfer to a functional context. This includes repetitive and structured practice of self-chosen activities of daily living, while attention is designated to the somatosensory aspects necessary for successful task completion (e.g., identification of button based on touch)."
41503059|NCT06006065|BEHAVIORAL|Upper limb motor therapy|Participants in the control group will receive an equal amount of motor training, including 30 minutes of unimanual motor tasks and 15 minutes of bimanual goal directed training. The unimanual motor tasks will be selected based on the main difficulties of the child (e.g., grip strength, supination). Bimanual goal directed training includes whole task practice of self-chosen activities of daily living. All therapy sessions will be performed under supervision of a trained physical and/or occupational therapist. Therapy adherence and progression will be closely monitored by the therapist.
41370027|NCT04392882|BEHAVIORAL|Legume enriched diet group|"* Replacing 1/3 refined rice intake with legumes three times per day~* Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~* Regular 30-min walk after dinner each day"
41370028|NCT00696891|BIOLOGICAL|HBV-MPL vaccine|3-dose intramuscular injection
40847477|NCT03395002|DRUG|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily via Discair® for two days.
40847478|NCT03395002|DRUG|Tiotropium 18 mcg Inhalation Powder|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® for two days.
40847479|NCT03395002|DRUG|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for two days
40847480|NCT06358144|BEHAVIORAL|Packaging imagery|Participants in the four intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the imagery themes. All participants will see the same four products, and each condition will see the products with the same imagery theme.
40847481|NCT06358144|BEHAVIORAL|No Imagery (Control)|Participants in the control condition will see the same four product packages, but without any added imagery.
41370029|NCT00696891|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
41370030|NCT02300194|DRUG|Topic Morphine|Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
41370031|NCT02300194|DRUG|Placebo|Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
41370032|NCT02122874|DEVICE|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
41370033|NCT02122874|OTHER|1200 Kcal diet|
41370034|NCT01483365|DRUG|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
41370035|NCT00003401|DRUG|carmustine|
41370036|NCT00003401|DRUG|cisplatin|
40847482|NCT01537822|PROCEDURE|Hysteroscopic morcellator|Morcellation will be performed with the HM (TRUCLEAR, Smith \& Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
41030522|NCT05860322|DIETARY_SUPPLEMENT|Inulin|"Inulin is a water soluble non-digestible carbohydrate, and it is available in more than 36,000 species of plants. It is often used as dietary fiber and has obtained the Generally recognized as safe status (GRAS) by the Food and Drug Administration (FDA)."
41370037|NCT00003401|DRUG|cyclophosphamide|
41370038|NCT00003401|DRUG|dexamethasone|
41370039|NCT00003401|DRUG|etoposide|
41370040|NCT00003401|DRUG|gemcitabine hydrochloride|
41370041|NCT00003401|DRUG|melphalan|
41370042|NCT00003401|DRUG|paclitaxel|
41370043|NCT00003401|PROCEDURE|bone marrow ablation with stem cell support|
41370044|NCT00003401|PROCEDURE|peripheral blood stem cell transplantation|
41503060|NCT04460560|DRUG|Terlipressin|"For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.~For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump"
41503061|NCT00710866|BIOLOGICAL|Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)|Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
41370045|NCT01220921|PROCEDURE|Lumbar Discectomy|Microsurgical removal of disc that is compressing a nerve root
41370046|NCT01220921|PROCEDURE|Single-level lumbar fusion|pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
41370047|NCT03741530|DRUG|Glibenclamide Tablets|Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
41370048|NCT03741530|OTHER|Standard management for ICH|Usual care and drug in hospital
41370049|NCT04613752|DEVICE|diaphragmatic function measurements and diaphragmatic ultrasound|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
41370050|NCT05016570|BEHAVIORAL|Picture narrative information format|Lung screening information formatted as picture narratives
41370051|NCT05016570|BEHAVIORAL|Text with pictures information format|Lung screening information formatted as text and non-narrative pictures
41503062|NCT01933477|OTHER|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
41503063|NCT00709488|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
41503064|NCT00709488|PROCEDURE|Placement of device in prostate urethra|Placement of device in prostate urethra
41503065|NCT00709488|DEVICE|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
41503066|NCT03457935|OTHER|blood samples|Blood samples
41030523|NCT05860322|OTHER|Placebo|Placebo control
41370052|NCT05016570|BEHAVIORAL|Text-only information format|Lung screening information formatted as text with no pictures
41030524|NCT02842775|OTHER|balance perturbation training|perturbation training on the split-belt balance perturbance treadmill,
41030525|NCT05735912|PROCEDURE|Endoscopic ultrasound-guided radio frequency ablation|Radiofrequency ablation performed under endoscopic ultrasound guidance of pancreatic insulinoma
41030526|NCT05735912|PROCEDURE|Surgery|Surgical resection of pancreatic insulinoma
41030527|NCT02998242|DRUG|Apatinib|
41370053|NCT02926352|BEHAVIORAL|Extinction Training|Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
41503067|NCT04312672|BIOLOGICAL|AAV5-hRKp.RPGR|Participants will not receive any intervention in this study. Participants from the retrospective (MGT009-NCT03252847) study will be follow-up.
41503068|NCT06188624|DRUG|TQB2922 for injection|TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
41503069|NCT04521101|OTHER|VAST Course|Educational course to teach non-technical skills
41503070|NCT05180916|DEVICE|TVNS|Cerbomed NEMOS
41503071|NCT03245866|OTHER|Observational/ no intervention|
41503072|NCT02193334|DRUG|KP-100IT|
41503073|NCT02193334|DRUG|Placebo|
41503074|NCT04813783|OTHER|Mucositis care training to be given in line with MASCC / ISOO 2019|Mucositis care training to be given in line with MASCC / ISOO 2019
41503075|NCT01458873|DRUG|sodium bicarbonate 4.2%|diluted sodium bicarbonate 50 ml
41503076|NCT01458873|DRUG|diluted sodium bicarbonate 2.1%|50ml
41030528|NCT02998242|RADIATION|SBRT to symptomatic bony metastatic bony site(s)|
41370054|NCT02926352|DEVICE|Low-Level Laser Therapy|1064nm light used to modulate a biological function and induce a therapeutic effect.
41370055|NCT02926352|DEVICE|Sham Low-Level Laser Therapy|Placebo dose version of LLLT.
41370056|NCT01225458|OTHER|shorter tests|Geriatric evaluation with MMS, GDS and ADL scoring
41370057|NCT01225458|OTHER|initial complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
41370058|NCT01225458|OTHER|follow-up complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
41503077|NCT01458873|DRUG|normal saline|50ml
41503078|NCT06133426|DEVICE|"Connected scale Body Comp Pro from Withings"|Use once a day from inclusion to week 7.
41503079|NCT04077190|DEVICE|Adipose-derived stem cells|5cc adipose derived stem cells.
41503080|NCT04077190|DEVICE|cortisone injection|cortisone injection
41503081|NCT02276950|PROCEDURE|Coronary artery bypass surgery|Primary isolated coronary artery bypass surgery with or without use of cardio-pulmonary bypass
41503082|NCT02276950|PROCEDURE|Heart valve surgery|Heart valve surgery, aortic valve replacement or other heart valve procedures
41503083|NCT05713851|DRUG|Dapagliflozin|dapagliflozin is given for 21 days vs standard of care
41503084|NCT05261139|DRUG|nirmatrelvir|PF-07321332
41503085|NCT05261139|DRUG|ritonavir|ritonavir
41503086|NCT03850548|OTHER|Prosthetic joint infection with Cutibacterium acnes|patients having a prosthesis infection with C.acnes identified by specific PCR
41030529|NCT05960539|PROCEDURE|surgical training|surgical residency focussed on visceral robotic procedures
41030530|NCT00775749|DRUG|transdermal nicotine patch|The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
41370059|NCT03320980|PROCEDURE|RALPPS|RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
41370060|NCT03320980|PROCEDURE|portal vein embolization + major liver resection|PVE on the first stage and major liver resection on the second stage
41370061|NCT00066274|DRUG|FOLFIRI regimen|
41370062|NCT00066274|DRUG|FOLFOX regimen|
41370063|NCT00066274|DRUG|fluorouracil|
40847483|NCT01537822|PROCEDURE|Resectoscope|Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
41030531|NCT00775749|DRUG|placebo patch|The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
41370064|NCT00066274|DRUG|irinotecan hydrochloride|
41370065|NCT00066274|DRUG|leucovorin calcium|
41370066|NCT00066274|DRUG|oxaliplatin|
41030532|NCT05644548|OTHER|No intervention|No intervention
41030533|NCT01785745|OTHER|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
40847484|NCT05901883|DRUG|CEL383|Subjects will receive CEL383
40847485|NCT05901883|DRUG|Placebo|Subjects will receive placebo
40847486|NCT03153995|PROCEDURE|soft tissue expansion|"Three surgeries will be carried out for group I patients:~* Soft tissue expansion (1st surgery); at baseline~* Alveolar ridge augmentation (2nd surgery); after five weeks~* Implant surgery (3rd surgery); after six months"
41370067|NCT02430168|PROCEDURE|Percutaneous nephrolithotomy|
41370068|NCT02430168|PROCEDURE|Retrograde intrarenal surgery|
41370069|NCT05188768|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
41370070|NCT05188768|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
41370071|NCT06519396|DEVICE|ultrasonography evaluation|Ultrasonographic measurements of the Achilles tendon were taken using Samsung Sonoace X7 ultrasound system equipped with an 8-13MHz linear transducer. After assuming a prone position on the examination table, the patients placed their feet against the wall and flexed their ankles to ensure optimal contact between the probe and the tendon. Measurements were taken separately on the right and left sides for each patient. Initially, the probe was positioned perpendicular to the long axis of the tendon for an axial plane assessment, followed by measurements of thickness (anterior-posterior), width (medial-lateral), and area at the level of the medial malleolus. The thickness and width measurements utilized the tendon's major axes, while the area measurements were automatically calculated by the device through continuous tracing of the tendon circumference in the same section
41370072|NCT06519396|DEVICE|tetrax device evaluation|A Tetrax device was used to assess static balance. The patient was positioned on the platform and subjected to tests in eight different positions. For each position, a test measurement was made for a duration of 32 seconds, for a total of approximately 5 minutes. The normal eyes-open position was taken as the reference. The effects of vision on balance were observed in the eyes-closed position. Balance is dependent on the back of the heels and the lower vertebrae in this position. Conversely, in the eyes-closed position with the head tilted 30 degrees forward, there is a load on the upper vertebrae and neck. Following the measurements, the Tetrax software program was used to calculate the Fall Index and Stability Index
41370073|NCT00796367|DRUG|VI-0521|7.5 mg phentermine and 46 mg topiramate
41370074|NCT00796367|DRUG|Placebo|placebo
40847487|NCT06195189|DRUG|Sunvozertinib|Sunvozertinib 200mg Quaquedie (QD)
40847488|NCT06195189|DRUG|Chemotherapy|Pemetrexed +platinum
40847489|NCT01073930|DRUG|PicoPrep|PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
40847490|NCT01073930|DRUG|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
40847491|NCT01073930|DRUG|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
41030534|NCT01785745|OTHER|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
41030535|NCT06535412|DRUG|IMC-002 + SOC|intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg
41370075|NCT00796367|DRUG|VI-0521|15 mg phentermine and 92 mg topiramate
41370076|NCT02074657|BIOLOGICAL|Activated and expanded natural killer cells (NKAEs)|Activated and expanded natural killer cells (NKAEs) from haploidentical donor
41370077|NCT05329441|BEHAVIORAL|Trier Social Stress Test (TSST)|In this mechanistic study, all participants will undergo a modified version of the Trier Social Stress Test (TSST), which is a well-validated psychosocial stress paradigm, adapted for adolescents that involves no deception and is considered a very mild stressor. The TSST comprises of two stress tests: a 5-minute arithmetic task and a 5-minute speech task. Due to repeated testing of the TSST, participants will be randomized to one task at T1 and complete the second task at T2 (counterbalanced design). Every 5 minutes, participants will provide ratings of their mood using a visual analogue scale (1-10) of eight mood states (Afraid, Confused, Sad, Angry, Energetic, Tired, Happy, and Tense) that will be used as potential behavioral responses to social stress. Glutamate and inflammation outcomes will be examined acutely and from T1 and T2.
41370078|NCT05398458|PROCEDURE|Lymphocele excision and space obliterated by pedicle Gracilis muscle only flap|By this procedure it has helped in reduction and complete resolution of the lymphocele with no recurrence in the past 2 years
41370079|NCT03072576|DEVICE|Xpert MTB/RIF Ultra|Next generation Xpert MTB/RIF assay, this cartridge is intended for the detection of M. tuberculosis in sputum as well as the detection of M. tuberculosis mutations associated with resistance to rifampin
41370080|NCT04348760|BEHAVIORAL|Rotation Diet|Based on the food-specific IgG measurement and relative distribution, a personalized food profile was created for each subject identifying 1 to 3 relevant food groups/nutritional clusters. Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week. No calorie restriction was imposed in the diet.
41370081|NCT05416034|DEVICE|Use of the ATLAS 2025 exoskeleton at home|Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
41370082|NCT04950452|BEHAVIORAL|Exercise Training|Supervised exercise training
41503087|NCT06632808|OTHER|Exercise|Deep cervical flexor muscle exercises target the deep neck muscles that play a crucial role in the stabilization of the cervical spine and the maintenance of proper posture. These muscles, particularly the longus colli and longus capitis, are responsible for the correct alignment of the head and neck. The exercises typically involve gentle flexion of the neck (bringing the chin towards the chest) with low-intensity, controlled movements. The goal is to strengthen these muscles, enhance spinal stability, and alleviate symptoms such as tension-type headaches. Additionally, these exercises support postural control and can reduce excessive strain on the neck.
40847492|NCT03422133|OTHER|Patient-oriented, personalized risk communication eHealth application|The application features simple and consistent design, large well-lit buttons that tolerate tremor, and simple language. The process will be applied in preoperative clinics at The Ottawa Hospital (TOH), where patients will be asked to provide their personal health history through a series of questions already used on our TOH preoperative health screener. These values will then populate the NSQIP Universal Risk Calculator, which we have calibrated to TOH data, to generate personalized risks of mortality, serious complications, and hospital length of stay. These risk estimates will be communicated directly to the patient using absolute risk estimates represented pictorially (best practice for risk communication to patients). Risk estimates will also be provided to the patient's clinician.
40847493|NCT06583421|BEHAVIORAL|4-week MVPA intervention|The 4-week MVPA intervention engaged in supervised aerobic exercise, resistance training and interesting sport for 60 minutes, 3 days/week (Monday, Wednesday and Friday). As shown in Table S1, participants completed four sessions including preparation module (15 min), training module (30 min), and relaxation module (15 min). Another aerobic module (15 min) was added in each Friday.
40847494|NCT02651220|DRUG|Epiduo® Forte Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
40847495|NCT02651220|DRUG|Adapalene and Benzoyl Peroxide Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
40847496|NCT02651220|DRUG|placebo gel|vehicle used as placebo
40847497|NCT00698334|DRUG|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
41030536|NCT06535412|DRUG|Placebo + SOC|intravenous injection of Placebo
41030537|NCT00700687|DRUG|PA32540|aspirin/omeprazole
41370083|NCT02784028|OTHER|SGM-101|Administration of SGM-101 prior surgery
41370084|NCT03237325|DRUG|SGX942|1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
41370085|NCT03237325|DRUG|Placebo|Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
41370086|NCT01069692|DRUG|SBR759A|SBR759A 6g daily
41370087|NCT01069692|DRUG|SBR759A|Placebo Comparator 0g daily
40847498|NCT00698334|DRUG|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
41162514|NCT04605822|DEVICE|Smartphone application (SkinVision®)|Smartphone application for all dermatoscopically documented pigmented skin lesions in all study participations and record of risk assessment of the health application (low, medium or high risk) to compare the app's accuracy in risk assessment with the AI tools and the dermatologist. The SkinVision® smartphone app is CE certified.of skin lesions. All participants of this study will undergo Smartphone application (SkinVision®) at baseline and the follow-up visits up to month 12.
41370088|NCT01069692|DRUG|SBR759A|SBR759A 3g daily
41370089|NCT01069692|DRUG|SBR759A|9g daily
41370090|NCT01069692|DRUG|SBR759A|12g daily
41370091|NCT03582917|DRUG|Alphacalcidol|Alphacalcidol 0,5mg tablet
41503088|NCT06632366|OTHER|Sexual Dysfunction in the Postpartum Period|The experimental group will receive mindfulness-based self-compassion training. The control group will not receive any intervention.
41503089|NCT00183560|BEHAVIORAL|Mindfulness based cognitive therapy (MBCT)|Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.
41503090|NCT00183560|DRUG|Antidepressants|Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
41503091|NCT00183560|DRUG|Placebo plus clinical management|Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
41503092|NCT06547411|DEVICE|PC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group I received pressure control ventilation (PC).
41503093|NCT06547411|DEVICE|VC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group II received volume control ventilation (VC).
41503094|NCT06547411|DEVICE|PRVC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group III received pressure-regulated volume control ventilation (PRVC).
41162515|NCT04605822|OTHER|Standard-of-care clinical assessment of the skin|Clinical skin examination with dermatoscope by an experienced dermatologist and risk assessment of pigmented lesions (melanoma vs. naevus). All participants of this study will undergo Standard-of-care clinical assessment of the skin at baseline and the follow-up visits up to month 24.
41370092|NCT05395845|BIOLOGICAL|platelets rich plasma|local ingection of platelets rich plasma
40847499|NCT05192434|BEHAVIORAL|Expressive Writing|Expressive writing (EW) is a safe, acceptable, and effective intervention for improving psychological adjustment. Via brief directed writing sessions, EW facilitates disclosure of traumatic events. At a basic level, emotional expression and disclosure are important because they reduce the need to unconsciously direct psychological energy towards suppressing emotions from traumatic events.
40847500|NCT05192434|BEHAVIORAL|Contingency Management|Contingency management (CM) is a proven strategy to reduce drug use and HIV risk behavior. Also known as a conditional cash transfer, CM reinforces positive behavior with tangible rewards. In the context of substance use treatment, monetary incentives are typically used to reinforce drug-negative urine specimens.
41162516|NCT03142321|DRUG|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab Injection
41162517|NCT00788164|BIOLOGICAL|TA-HPV|Given intramuscularly
41370093|NCT03796897|DIETARY_SUPPLEMENT|Leucine-enriched protein|Supplement contains 16g of protein given twice per exercise session (4 total exercise sessions)
41370094|NCT03796897|BEHAVIORAL|Habitual diet only|Habitual diet only (no supplementation) for 4 exercise sessions
41370095|NCT01396434|BIOLOGICAL|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
41370096|NCT00332059|DRUG|bimatoprost/timolol fixed combination|
41370097|NCT00935675|DRUG|Escitalopram|Escitalopram 10 mg once a day
41370098|NCT05525559|DRUG|ET0038|ET0038 for oral administration
41503095|NCT03706014|BEHAVIORAL|SIBS Program|Universal prevention program promoting positive sibling and family relationships conducted in an afterschool setting
41503096|NCT03706014|BEHAVIORAL|Control|Contact-equivalent attention control program in which students play educational games
41503097|NCT06552156|DIETARY_SUPPLEMENT|Dietary Emulsifier|Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.
41370099|NCT04433000|DIAGNOSTIC_TEST|Butterfly|Standardized lung ultrasound scan with two different instruments
41030538|NCT00700687|DRUG|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
41370100|NCT02218034|DRUG|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
41370101|NCT02218034|DRUG|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
41370102|NCT02218034|DRUG|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
41370103|NCT02218034|DRUG|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
41370104|NCT05495724|DRUG|Disitamab Vedotin Tislelizumab|Disitamab Vedotin 120mg will be administered on Day 1 of each cycle for 4 treatment cycles;Tislelizumab 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
41503098|NCT05786209|OTHER|Whole-body Balm|Balm will be applied to cover newborn's entire body (while avoiding the mouth, eyes, diaper area, and scalp), and gently massaged onto the skin until the balm is fully absorbed.
41503099|NCT05786209|OTHER|Wash and Shampoo|"Wash and shampoo will be used to cleanse newborn baby using an in tub bathing method."
41503100|NCT04663230|DIAGNOSTIC_TEST|cardiac magnetic resonance imaging|right atrial late gadolinium enhancement in % and cm2
41503101|NCT06173271|DIETARY_SUPPLEMENT|multi-intervention program and protein foods supplementation|This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.
41503102|NCT04529837|OTHER|Gauze|placement of gauze
40847501|NCT03100175|BEHAVIORAL|physiotherapy|strength training for upper and lower limbs fitness and balance work out
41030539|NCT00700687|DRUG|aspirin and [NSAID]|aspirin and \[NSAID\]
41030540|NCT05059691|OTHER|Electronic Health Record Review|Review of medical records
41030541|NCT05059691|PROCEDURE|Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy|Undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy
41370105|NCT05495724|DRUG|Disitamab Vedotin|Disitamab Vedotin
41370106|NCT04554355|BEHAVIORAL|School-based PA intervention|Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
41370107|NCT01092312|PROCEDURE|Vanguard Knee System with Signature Knee Guide|Use of Signature Knee Guide
41503103|NCT04529837|OTHER|No gauze|no gauze
41503104|NCT00776087|DEVICE|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
41503105|NCT00776087|DEVICE|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
41503106|NCT05107596|DRUG|64Cu-DOTA-ECL1i|Inject PET Radioisotope for imaging
41503107|NCT06598241|DEVICE|Borate-base Bioactive Glass Fiber Matrix (BBGFM)|Bioactive glass materials are biocompatible water-soluble inorganic ceramic materials that release their constituent ions when immersed in body fluids.
41503108|NCT04663191|PROCEDURE|anatomical resection|Anatomical resection with systematic lymph-node dissection
41503109|NCT06453850|DEVICE|Use of FLEXIGO delivery catheter|Use of FLEXIGO delivery catheter for implantation of ventricular pacing lead
41503110|NCT06626295|OTHER|exercise-snack group|Adolescents in the exercise-snacks group will perform 4 \&amp;amp;amp;#34;exercise-snacks\&amp;amp;amp;#34; sessions per day during 3 weeks in addition to multidimensional care program. These sessions will consist of 1-min various intense supervised exercises . They will also receive information about their attitudes to physical activity.
41503111|NCT04520009|BEHAVIORAL|Activity Restriction|Standard post-operative activity instructions (i.e., no bending, twisting, or lifting more than 10 lbs for 4 weeks, no return to work until cleared to do so).
41503112|NCT04520009|BEHAVIORAL|Activity as Tolerated|Instructions advising activity as tolerated and return to work based on patient discretion
41030542|NCT05552664|GENETIC|GIFT|GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.
41030543|NCT05761431|DRUG|SYHX2008 injection|Subcutaneous administration on Day 1.
41030544|NCT05761431|DRUG|Octreotide Acetate Microspheres for Injection injection|Intramuscular administration on Day 1.
41030545|NCT05761431|DRUG|Sandostatin ® injection|Subcutaneous administration on Day 1.
41370108|NCT01092312|PROCEDURE|Vanguard Knee System with conventional Instruments|Vanguard Knee System with conventional Instruments
41370109|NCT00009750|BIOLOGICAL|filgrastim|
41370110|NCT00009750|BIOLOGICAL|monoclonal antibody m170|
41370111|NCT00009750|DRUG|cyclosporine|
41370112|NCT00009750|DRUG|paclitaxel|
41370113|NCT00009750|PROCEDURE|peripheral blood stem cell transplantation|
41503113|NCT03857282|OTHER|Aerobic Exercises|5 to 10 min warm up exercises than 30min bicycle exercise and 5 to 10 min cool down exercises
41503114|NCT03857282|OTHER|Tai Chi Exercises|5 to 10 min warm up exercises and 30 min Tai Chi exercises and than than 5 to 10 min cool down exercises.
41370114|NCT00009750|RADIATION|indium In 111 monoclonal antibody m170|
41370115|NCT00009750|RADIATION|yttrium Y 90 monoclonal antibody m170|
41503115|NCT01874353|DRUG|Olaparib 300mg tablets|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
41503116|NCT01874353|DRUG|Placebo to match olaparib 300mg|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
40847502|NCT04715698|OTHER|ICG-guided drug selection|anti-hypertensive drug selection based on patient's hemodynamic profiling and physician's experience
40847503|NCT04715698|OTHER|empirical drug selection|anti-hypertensive drug selection based on physician's experience only
40847504|NCT03164694|DRUG|Apatinib|Apatinib was given 850 mg per day orally.
40847505|NCT03164694|DRUG|Pemetrexed|pemetrexed (500 mg/m2)
40847506|NCT03164694|DRUG|Carboplatin|carboplatin (AUC =5)
40847507|NCT01699568|DEVICE|RFA|Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
40847508|NCT00785343|DEVICE|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
41030546|NCT05761431|DRUG|Placebo to SYHX2008 injection|Subcutaneous administration on Day 1.
41030547|NCT01243450|DRUG|Tretinoin|Treatment of acne
41030548|NCT01243450|DRUG|placebo|treatment of acne
41370116|NCT01119118|DRUG|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
41370117|NCT05729035|RADIATION|POCUS|Point of Care Ultrasound is complementary to a medical examination performed by primary care physicians
41503117|NCT05293912|DRUG|SG2501|During study treatment, subjects will receive SG2501 treatment via IV infusion once every week at doses of: 0.01, 0.03, 0.1, 0.3, 1, 2, 4 and 6mg/kg.
41503118|NCT01860274|DEVICE|External Mesh for vein grafts|
40847509|NCT00785343|PROCEDURE|Conventional Therapy|Occupational therapy that is the current standard of care
40847510|NCT00662116|DRUG|alagebrium|200 mg (two 100 mg tablets) two times daily for 24 weeks
41030549|NCT03188939|PROCEDURE|single injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.
40847511|NCT00662116|DRUG|placebo|placebo tablets - two tablets taken twice daily
41030550|NCT03188939|PROCEDURE|intracluster injection supraclavicular brachial pieuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
40847512|NCT05561244|DEVICE|Weekly monitoring using the capillary International Normalised Ratio strategy|Patients in the interventional group will be monitored using the capillary International Normalised Ratio strategy every week, and more often if the International Normalised Ratio is not in the therapeutic target. Venous International Normalised Ratio punctures will also be performed as described for the control group in order to calculate the Time in Therapeutic Range equivalently in both groups. Specific training in handling the device and the dose adjustment protocol will be provided to nurses and prescribers.
40847513|NCT04095091|DEVICE|4D Planar US Transducer|This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.
40847514|NCT05169411|DIAGNOSTIC_TEST|Blood pressure|The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
41030551|NCT03188939|PROCEDURE|double injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
41030552|NCT00374530|DRUG|PGE2|
41030553|NCT06427785|DRUG|Remimazolam besylate|Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
41030554|NCT00381394|DRUG|sitamaquine|
41030555|NCT04976335|DEVICE|Versawrap membrane|Versawrap membrane will be placed between distal radius plate and flexor tendons
41030556|NCT05471973|OTHER|Multidisciplinary Team|Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
41030557|NCT05471973|OTHER|Outreach Visits|An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions
41030558|NCT05471973|OTHER|Multifaceted Intervention|These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay
40847515|NCT05169411|DIAGNOSTIC_TEST|Urine protein|Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear. We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
40847516|NCT04424342|OTHER|Pre-test procedure|The Turkish version of CPQ8-10 was subjected to a preliminary test on a group of 20 children, who were not included in the final study, in order to discuss the intelligibility of the items and to determine comprehension problems for children of this age group
40847517|NCT04424342|OTHER|Test re-test|The Turkish version of CPQ8-10 was administered to 50 children who were asked to complete the questionnaire on their own without any assistance. These 50 children were interviewed for a second time within two weeks to measure the reliability of the test-retest
40847518|NCT03009084|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
40847519|NCT02555384|OTHER|crowded drawing task|Marking inverted signs on a sheet where symbols are presented close to one another
40847520|NCT02555384|OTHER|uncrowded drawing task|Marking inverted signs on a sheet where there is a larger distance between symbols
40847521|NCT00494507|DRUG|Dichlorphenamide (double-blind)|50mg tablet; maximum dosage 400mg/day
40847522|NCT00494507|DRUG|Placebo (double-blind)|Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
40847523|NCT00494507|DRUG|Dichlorphenamide (open-label)|50mg tablet; maximum dosage 400mg/day
40847524|NCT03218930|BEHAVIORAL|Delayed antibiotic prescription|Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.
40847525|NCT03218930|BEHAVIORAL|Antibiotic prescribing guidelines|Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.
40847526|NCT03218930|BEHAVIORAL|Education|General practitioners will receive a package of educational sessions tailored towards their specific needs.
40847527|NCT03218930|BEHAVIORAL|Educational materials|Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
41030559|NCT05471973|OTHER|Measurement and Feedback|The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
41370118|NCT04921319|DIAGNOSTIC_TEST|VExUS score|"The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows:~* VExUS 0: The patient will likely tolerate more fluid if clinically needed.~* VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
40847528|NCT00172042|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
40847529|NCT04741763|DIETARY_SUPPLEMENT|EyePromise Visual Edge|A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
40847530|NCT06245213|DRUG|ANAVEX3-71 oral capsules|ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.
40847531|NCT06245213|DRUG|Placebo oral capsules|The placebo comparator for the study.
41030560|NCT04411108|OTHER|Kaia Back Pain App|The Kaia Back Pain App provides instructions on exercise execution to participants for one week
41030561|NCT04411108|OTHER|Physiotherapist Exercise Instructions and written handouts|Participants will be instructed by physiotherapists in exercise execution and receive handouts and exercise for one week
41162518|NCT00788164|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
41162519|NCT00788164|DRUG|imiquimod|Given topically
41162520|NCT03466229|DIETARY_SUPPLEMENT|Androferti|
41162521|NCT03466229|DIETARY_SUPPLEMENT|Placebo|
41162522|NCT00372177|RADIATION|Fab-fragment of Anti-human CD4|Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
40847532|NCT00274677|DRUG|Placebo|Experimental treatment arm
40847533|NCT00274677|DRUG|lamotrigine|Experimental treatment
40847534|NCT03932630|OTHER|Low carbohydrate diet|The study intervention will be an eucaloric low carbohydrate diet (15-20 % of carbohydrates) for 2 weeks.
40847535|NCT03932630|OTHER|balanced diet|The control intervention will be a energy-matched balanced diet (50 % of carbohydrates) for 2 weeks.
40847536|NCT05442190|DRUG|Hypericin|SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment.
40847537|NCT05442190|DRUG|Placebo|Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
40847538|NCT06583863|DRUG|Echinacea Extract|175 mg of Echinacea extract was provided as an immunlant therapy twice daily.
40847539|NCT06583863|DRUG|MetroNIDAZOLE 500 MG Oral Tablet [Flagyl]|500 mg of metronidazole was provided as an oral tablets twice daily
40847540|NCT06190886|DRUG|PTX-912|biologics
40847541|NCT04768803|BIOLOGICAL|acylated and unacylated ghrelin dosages|realization of plasma samples to evaluate of levels of ghrelin and collection of plasma and cells
41370119|NCT06120764|OTHER|guided imagery|"The experimental group will listen to Guided Imagery CD prepared by the Turkish Psychological Association for relaxation 10 minute before the chemotherapy infusion. The remained part of CD, containing relaxing music and wave sound, will be played for 30 minutes after the chemotherapy infusion starts. When the chemotherapy infusion starts, the patients will be given imagery suggestions by a researcher, together with listening CD throughout first 30 minutes of chemotherapy infusion. Participants will be encouraged to think of various images: the patient will be asked to imagine that the treatment is over, that he/she is much healthier, that he/she heals very fast, that he/she returns to his/her old life in a short time, that he/she imagines himself/herself doing whatever he/she wants to do first after recovery, and that he/she imagines an object, person, event, situation, food or anything else that will make him/her feel good."
41370120|NCT02631434|PROCEDURE|sit-to-stand test|
41370121|NCT02631434|PROCEDURE|six-minutes walking test|
40847542|NCT01675193|BEHAVIORAL|Disinvestment protocol|Omission of population-based child vision screening visits at 6-9 and 14-24 months: Children in the intervention group will not be eye screened at age 6-24 months
40847543|NCT01627028|PROCEDURE|Thai traditional massage|two hours of Thai traditional massage twice a week for 4 weeks
40847544|NCT01500668|DRUG|Botox|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
41030562|NCT02332486|DRUG|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
41370122|NCT03530267|DRUG|Aflibercept + mLV5FU2|Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
41370123|NCT03530267|DRUG|mFOLFOX7|Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
41370124|NCT05103462|BEHAVIORAL|Telehealth Physical Therapy|Weekly sessions of physical therapy provided using two-way, interactive, video technology consisting of education, advice and exercise instruction.
41370125|NCT05611944|DEVICE|Irrigation and suction through subcutaneus drains|Irrigation of wound will done by attaching 500cc saline to the drain on one side and let it flow freely from the other drain followed by suction of wound by attaching 60cc suction syringes on both sides creating suction pressure for 100 cc fluid.
41370126|NCT04752007|RADIATION|ASLR; CT; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
41370127|NCT04752007|RADIATION|Fig.Four; CT; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
41370128|NCT04752007|RADIATION|Supine; CT; SI joint movement: supine position|Baseline position
41370129|NCT04752007|RADIATION|ASLR; RSA; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
41370130|NCT04752007|RADIATION|Fig.Four; RSA; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
41370131|NCT04752007|RADIATION|Supine; RSA; SI joint movement: supine position|Baseline position
41370132|NCT01447069|DRUG|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains \<100 bpm
41370133|NCT00532441|DRUG|Erlotinib|Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
41370134|NCT00532441|DRUG|Docetaxel|Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
40847545|NCT01500668|DRUG|Placebo|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
40847546|NCT06256926|DRUG|Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)|Curcuma longa Extract containing 35% Curcuminoids Dose: One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
40847547|NCT06256926|DRUG|Placebo product|Placebo product Dose:One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
40847548|NCT05095948|PROCEDURE|Discussion|Undergo audio recording of clinic conversations
40847549|NCT05095948|OTHER|Electronic Health Record Review|Review of medical records
40847550|NCT05095948|OTHER|Questionnaire Administration|Complete questionnaires
41030563|NCT06475157|OTHER|No intervention|No intervention is applied.
41030564|NCT03891810|BEHAVIORAL|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
41162523|NCT04338347|BIOLOGICAL|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Extracellular Vesicles (EVs) from Cardiosphere-Derived Cells (CDCs)
41370135|NCT01250418|DRUG|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
41370136|NCT05056311|OTHER|Decision Aid Website|The (private) decision aid website contains information in text, graphic, and video form about hypospadias and considerations for choosing surgery and no surgery.
41370137|NCT02451137|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41370138|NCT02451137|DRUG|Insulin glargine, 100 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41370139|NCT02451137|DRUG|Insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
41370140|NCT02451137|DRUG|Background Therapy|Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
41030565|NCT05235880|OTHER|Virtual reality based games|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes virtual reality based games aiming improvement on upper extremities, trunk and cognitive functions.
41030566|NCT05235880|OTHER|Conventional exercises|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes conventional physiotherapy approaches aiming improvement on upper extremities, trunk and cognitive functions.
41030567|NCT06469320|OTHER|Online questionnaire|Pelvic floor dysfunction assessment questionnaire adapted from PFD-Sentinel
41030568|NCT01538017|DRUG|Xiapex|Collagenase Clostridium Histolyticum
41030569|NCT01538017|PROCEDURE|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
41030570|NCT03171233|OTHER|Mobilization with movement|Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
41030571|NCT03171233|OTHER|Self mobilization with movement|In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
41030572|NCT06404580|PROCEDURE|R anastomosis|R anastomosis
41030573|NCT01319006|DRUG|GSK1278863A|100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
41030574|NCT01319006|DRUG|GSK1278863A|100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
41030575|NCT01319006|DRUG|GSK1278863A|100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
41370141|NCT03171272|OTHER|Inspiratory Muscle Training|"Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments."
41370142|NCT01428882|DRUG|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
41370143|NCT01428882|DRUG|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
41370144|NCT06479850|BEHAVIORAL|KF-STRIDE®|Treatment group will receive 12 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
41370145|NCT01753765|DEVICE|Device: Cryo-Touch III Study treatment at Day 0.|Device: Cryo-Touch III Study treatment at Day 0.
41370146|NCT00242840|DRUG|No intervention; Observational study|
41370147|NCT03693846|DRUG|Nivolumab|IV infusion per institutional guidelines and the Package Insert
41030576|NCT02345512|DEVICE|Lycra Splinting Garment|Wearing of lycra splinting garment for 6 weeks
41030577|NCT01592708|OTHER|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
41030578|NCT02762526|PROCEDURE|Lipoabdominoplasty|
41030579|NCT06038773|DIAGNOSTIC_TEST|Diagnosis|"Baseline data were presented with descriptive statistics. Sociodemographic information, pregnancy status, surgical history, exercise habits, gynecologic, obstetric, urologic and gastrointestinal history of the patients were evaluated with the Patient Information Form.Pain intensity was evaluated with the McGill pain questionnaire short form. At the same time, the patients drew the areas where they felt the most pain with the pain maps scale. Pain intensity during sexual intercourse was evaluated with the Visual Analog Scale (VAS).Sexual Abuse Items on the Questionnaire (Modified from Badgley)."
41030580|NCT05909865|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
41162524|NCT03126214|DRUG|Anticoagulants|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
41370148|NCT03693846|DRUG|Ipilimumab|IV infusion per institutional guidelines and the Package Insert
41370149|NCT02967393|DRUG|ccIIV4|
41370150|NCT02967393|DRUG|IIV4|
41370151|NCT01243762|DRUG|dalotuzumab|Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy
41370152|NCT01243762|DRUG|MK-0752|Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy
41370153|NCT01243762|DRUG|ridaforolimus|Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy
41370154|NCT01243762|DRUG|MK-2206|Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
41370155|NCT05877846|DIETARY_SUPPLEMENT|Beta-hydroxymethyl butyrate supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
41162525|NCT06298968|DRUG|combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab|"Gemcitabine (1000mg/m²) and cisplatin (25mg/m²) on day1 and 8 every 3 weeks, with a total of 6 cycles.~Lenvatinib 8 mg once daily (QD) oral dosing, continuous use for 2 years. Adebrelimab 1200mg intravenously every 3 weeks, continuous use for 2 years."
41370156|NCT05877846|DIETARY_SUPPLEMENT|Vitamin D supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
41503119|NCT04746794|BEHAVIORAL|Population-level screening|"The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified."
41503120|NCT00753857|OTHER|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
41503121|NCT00753857|OTHER|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
41503122|NCT05702229|DRUG|Rilvegostomig|an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion
41503123|NCT05702229|DRUG|Volrustomig|an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion
41503124|NCT05702229|DRUG|FOLFOX|5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2
41503125|NCT05702229|DRUG|XELOX|capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1
40847551|NCT01854268|DRUG|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
40847552|NCT06329206|DRUG|GH2616 Tablets|GH2616 tablets will be given orally
40847553|NCT03188510|BIOLOGICAL|LY3074828|Administered SC
40847554|NCT02169765|OTHER|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and \>50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
40847555|NCT02169765|OTHER|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
40847556|NCT02461745|DRUG|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
40847557|NCT02461745|DRUG|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
41030581|NCT05909865|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
41030582|NCT01988818|DEVICE|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
41030583|NCT01988818|DEVICE|standard wound dressing|standard wound dressing after hip-knee or spinal surgery
41030584|NCT00081588|DRUG|TMC114|600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
41030585|NCT01367262|DRUG|LY2886721|Administered orally
40847558|NCT05801614|OTHER|Low carb diet|Low calori diet
41030586|NCT03326999|DRUG|Obturator nerve regional block|Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
41030587|NCT03326999|DRUG|Adductor canal regional block|Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
41030588|NCT03326999|DRUG|Saline|Saline as placebo comparator
41030589|NCT01389908|DRUG|olanzapine|Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
41030590|NCT04800029|OTHER|Telehealth in preventing suicide (TIPS)|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
41162526|NCT04649125|RADIATION|dose escalation|single fraction dose escalation to the tumour
41162527|NCT02440646|RADIATION|Coronary computed tomography angiography|The coronary arteries will be visualized with the MSCT scan CT 5000 Ingenuity (Philips, The Netherlands) or systems from any other vendors.
41370157|NCT05877846|DIETARY_SUPPLEMENT|Matching Beta-hydroxymethyl butyrate supplement without Vitamin D|Beta-hydroxymethyl butyrate (750 mg) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate per capsule. Frequency is 2 capsules twice daily (morning, evening)
41370158|NCT02096601|DRUG|LD/CD SC solution|Levodopa/carbidopa SC solution
41370159|NCT02096601|DRUG|Entacapone|Entacapone 200 mg oral tablet
41370160|NCT00078689|DRUG|Daclizumab|
41370161|NCT03653780|DEVICE|Ekso GT|Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
41503126|NCT05702229|DRUG|AZD7789|an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion
41503127|NCT05702229|DRUG|AZD0901|an anti Claudin18.2 ADC; IV infusion
41503128|NCT05702229|DRUG|5-Fluorouracil|5-FU, IV infusion, Q3W
41503129|NCT05702229|DRUG|Capecitabine|Oral take, Q3W
40847559|NCT04216576|OTHER|Paper Drug Diary|Participants will receive and use a paper Drug Diary and a paper medication calendar.
41503130|NCT01038362|OTHER|NCEP Step 1 diet plus Almonds|NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
41503131|NCT01038362|OTHER|No Almonds|NCEP Step 1 diet without almonds
41370162|NCT03027258|OTHER|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
41370163|NCT03857126|OTHER|Signal acquisition|ECG-PCG-CTG synchronized signals acquisition over a monitoring phase of 30 minutes. These signals will be acquired with passive non invasive sensors (abdominal and thoracic).
41370164|NCT01796899|OTHER|Brivaracetam 10 mg oral tablet|
41030591|NCT04800029|OTHER|Modified ED-SAFE|"Half of the ED discharged patients with suicide risk will be invited to receive post-discharge telephone counseling originally developed during the Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE) study. The participant will receive three coaching/counseling calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
41030592|NCT04800029|OTHER|Treatment as Usual (TAU)|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
41030593|NCT00856856|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
41030594|NCT05847777|RADIATION|CBCT|cone beam computer tomography
41370165|NCT01796899|OTHER|Brivaracetam 50 mg oral tablet|
41370166|NCT01796899|OTHER|Brivaracetam 75 mg oral tablet|
41370167|NCT01796899|OTHER|Brivaracetam 100 mg oral tablet|
41370168|NCT01796899|OTHER|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|
41030595|NCT03912857|DRUG|Camrelizumab|"Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
41030596|NCT06361082|PROCEDURE|ACL reconstruction|ACL reconstruction
41030597|NCT00816634|DRUG|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|"3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks"
41370169|NCT01642472|DRUG|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
41370170|NCT02463526|OTHER|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
41370171|NCT02463526|OTHER|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
41370172|NCT00003701|DRUG|carboplatin|
41370173|NCT00003701|DRUG|cisplatin|
41370174|NCT00003701|DRUG|doxorubicin hydrochloride|
41370175|NCT00003701|DRUG|methotrexate|
41503132|NCT04395066|DIAGNOSTIC_TEST|CD55|CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate downstream actions of all three complement activation pathways, and CD55 protects host cells from complement attack.
41503133|NCT02977312|DRUG|Imatinib|Observation of chronic myeloid leukemia (CML) patients in chronic phase (CP) treated with Cemivil
41503134|NCT05403255|OTHER|evaluation of the quality of life with questionnaires|"Questionnaire data will be collected among patients and their parents during follow-up consultations.~Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France."
41503135|NCT06290908|PROCEDURE|RPE-P/TLIF|patients with lumbar spinal stenosis and instability who met the inclusion and exclusion criteria were treated with RPE-P/TLIF
41503136|NCT05258383|OTHER|3D maps of physical doses|3D maps of physical doses delivered to organs by positioning imaging will be calculated based on the patient's CT image used by the treatment planning system (dosimetric calculation performed by Monte Carlo method).
41370176|NCT00003701|DRUG|paclitaxel|
41370177|NCT00003701|DRUG|vinblastine sulfate|
41370178|NCT00395317|OTHER|Placebo|placebo tablet
41370179|NCT00395317|DRUG|Firategrast 150 mg|150 mg tablet
41370180|NCT00395317|DRUG|Firategrast 300 mg|300 mg tablet
41370181|NCT02110966|DRUG|Mepivacaine|Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.
41370182|NCT02110966|DRUG|Mepivacaine plus Tramadol|0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
41370183|NCT06303960|DEVICE|Bilateral Cerebellar deep brain stimulation|Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then bilateral stimulation was activated after 1 month post-DBS
41503137|NCT01243437|DRUG|ciprofloxacin|"* For adults and children aged \> 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
41503138|NCT01243437|DRUG|doxyxcycline|"* For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
41503139|NCT02376816|BIOLOGICAL|rAAVrh74.MCK.micro-Dystrophin|"Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter."
41503140|NCT04707313|DRUG|Placebo (Cohorts 1 and 2)|4 matching placebo tablets taken twice daily
41503141|NCT04707313|DRUG|PF-06882961 (Cohorts 1 and 2)|Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
41503142|NCT04707313|DRUG|Placebo (Cohort 3)|2 matching placebo tablets taken twice daily
41503143|NCT04707313|DRUG|PF-06882961 (Cohort 3)|Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.
41370184|NCT06303960|DEVICE|Unilateral Cerebellar deep brain stimulation|Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then unilateral stimulation was activated after 1 month post-DBS
41030598|NCT04937569|DRUG|Ivermectin Tablets|4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast
41030599|NCT02039505|DRUG|Vedolizumab|Vedolizumab intravenous infusion
41030600|NCT02039505|DRUG|Vedolizumab placebo|Vedolizumab placebo
41030601|NCT05108337|PROCEDURE|Superficial cervical plexus block|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml 0.5% ropinacaine.
41030602|NCT05108337|OTHER|Control group|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
41030603|NCT00272701|DRUG|Esomeprazole|
41030604|NCT00272701|DRUG|Other PPI marketed in Sweden|
41162528|NCT02440646|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with Artis zee (Siemens, Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (with implantation of the medical device).
41370185|NCT01789307|DIETARY_SUPPLEMENT|corn syrup solids|oral ingestion 50 grams, 2 doses
41370186|NCT01789307|DIETARY_SUPPLEMENT|sucrose|oral ingestion 50 grams, 2 doses
41370187|NCT01907373|DRUG|olmesartan medoxomil|
41370188|NCT01907373|DRUG|olmesartan medoxomil+probenecid|
41370189|NCT00000362|BEHAVIORAL|Chin-down position|
41503144|NCT02875691|DIETARY_SUPPLEMENT|green tea extract|Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
41370190|NCT00000362|BEHAVIORAL|Thickened liquid administration|
41370191|NCT00227591|DRUG|lenalidomide|Given orally (PO)
41370192|NCT00227591|DRUG|prednisone|Given PO
40847560|NCT04216576|OTHER|OhMD APP|Participants will receive multiple text messages regarding administration over time on medication self-management over the course of 3 cycles of medication
40847561|NCT04901091|OTHER|Not Provided|Not Provided
41030605|NCT02194049|DRUG|BKM120|Given PO
41030606|NCT02194049|DRUG|cisplatin|Given IV
41030607|NCT02194049|DRUG|etoposide|Given IV
41030608|NCT03175653|OTHER|Oxycodone Pill A|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
41030609|NCT03175653|OTHER|Oxycodone Pill B|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
41030610|NCT04160819|OTHER|Assigned Interventions|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs.
41030611|NCT03058679|OTHER|Diet|food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks
41030612|NCT00618514|DEVICE|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
41162529|NCT02650726|DIETARY_SUPPLEMENT|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
41370193|NCT00227591|OTHER|laboratory biomarker analysis|Correlative studies
41370194|NCT06242886|BEHAVIORAL|Oxytocin massage|Oxytocin massage group: The mother was positioned on a chair with her breasts bare and free, placing her arms on the table at her height and her head on her arms. The researcher who applied the massage applied the massage up and down to either side of the spine between the mother's scapula bones with her thumbs in front and pressing her fists tightly and making small circular movements with her thumbs for three minutes. The mothers received four oxytocin massages over the course of 24 hours.
41370195|NCT06242886|BEHAVIORAL|and Breast massage|Breast massage group: The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
41370196|NCT01855594|DRUG|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
41370197|NCT01855594|DRUG|Placebo|placebo tablet, 6 week course of oral administration
41370198|NCT00778206|DRUG|Kuvan|-Recommended post-partum Assessments include: collection of baby's plasma at Birth, 1 Month and 6 months, and collection of mother's plasma and expressed breast milk sample at 1 Month.
41370199|NCT03503617|DEVICE|RehabTouch|Exercise using the motion sensing devices and a computer
41370200|NCT03503617|OTHER|Conventional tabletop exercise program|Exercise following printed sheets of exercises
41370201|NCT00499694|BIOLOGICAL|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
41370202|NCT00499694|DRUG|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
41503145|NCT02875691|DIETARY_SUPPLEMENT|placebo|Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
41503146|NCT02803658|BEHAVIORAL|smoking behavior|
41503147|NCT02803658|BIOLOGICAL|Sperm collection|
41503148|NCT00159237|PROCEDURE|blood test|
41503149|NCT05440890|OTHER|Best current rehabilitation protocol|Inflamation control and edema with physical agents, recover full pasive and active range of motion, normalize gait pattern, lower limb strengthening (specially quadriceps and hamstrings), neuromuscular control training, cycling, landings and running.
41503150|NCT05440890|OTHER|Cross-training protocol|Beginning on 2º week after ACLR, 3 times per week during 8 weeks, based on isotonic exercise at least to 80% of 1RM in leg extension. 5 sets o 6 repetions with 1,5 - 2 minutes between series.
41503151|NCT02676583|PROCEDURE|Tonsillectomy|Closure or not closure of tonsil fossa
41503152|NCT00720382|DRUG|0.15% azelastine hydrochloride|1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
41370203|NCT04852185|BIOLOGICAL|Vi-TT|Single-dose V-TT administered to children and adolescents between the ages of 9 months to 15 years.
41370204|NCT04852185|BIOLOGICAL|MCV-A vaccine|Single-dose of MCV-A vaccine (a meningococcal vaccine)
41370205|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
41370206|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
41370207|NCT02225626|DRUG|Other: standard breakfast|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
41370208|NCT02873806|PROCEDURE|Implantation of two iStent inject micro-bypass stents|- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
41370209|NCT02873806|DRUG|Topical travoprost|- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
41503153|NCT00720382|DRUG|Mometasone furoate|200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)
41030613|NCT00618514|DEVICE|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
41370210|NCT02873806|DEVICE|Two iStent inject micro-bypass stents|- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
41370211|NCT02873806|DRUG|Tobramycin|"Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
41370212|NCT02873806|DRUG|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~* Week 1: 1 drop four (4) times per day in the study eye~* Week 2: 1 drop three (3) times per day in the study eye~* Week 3: 1 drop two (2) times per day in the study eye~* Week 4: 1 drop one (1) time per day in the study eye"
41370213|NCT02079974|DRUG|Pravastatin|20 mg pravastatin sodium daily for 3 months
41370214|NCT02630992|DRUG|Amoxicillin-Clavulanate potassium|
41370215|NCT00003526|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41370216|NCT04516798|OTHER|vibration|local and whole-body vibration were applied
41370217|NCT04592666|DRUG|Almonertinib|the standard therapy of single agent almonertinib
41370218|NCT04592666|DRUG|Pemetrexed|standard dose
41370219|NCT04592666|DRUG|Carboplatin|AUC=5
41370220|NCT04361669|OTHER|Medication safety review|Implementation of a medication safety review using a clinical decision support system
41370221|NCT06130618|OTHER|Ozone|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 20 μg/mL ozone will be injected.
41503154|NCT05231629|DRUG|Dara-VRd intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
41030614|NCT01995123|BEHAVIORAL|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
41162530|NCT02650726|OTHER|Placebo|placebo 320mg daily for 24 weeks
41503155|NCT05231629|DRUG|AHCT intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
41030615|NCT01995123|BEHAVIORAL|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
41030616|NCT01995123|BEHAVIORAL|Standard Smoking Cessation Therapy|Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
41030617|NCT02268773|DRUG|Asasantin®|
41030618|NCT02268773|DRUG|Acetylsalicylic acid low dose|
41030619|NCT02268773|DRUG|Acetylsalicylic acid high dose|
41030620|NCT00464542|DRUG|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
41030621|NCT00783536|DRUG|Etanercept + Methotrexate|
41030622|NCT00783536|DRUG|DMARDS|
41030623|NCT01841723|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41030624|NCT01841723|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
41030625|NCT01841723|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
41030626|NCT01841723|PROCEDURE|Computed Tomography|Undergo CT
41030627|NCT01841723|DRUG|Ibrutinib|Given PO
41162531|NCT02032108|BEHAVIORAL|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
41162532|NCT05964270|DEVICE|e-coach multipel myeloma (MM)|In this study we developed a multimodal patient-centered MM e-coach between September 2019 and June 2020. The content of the intervention consist of eight modules and was tested in a pilot study between June 2020 and August 2020 (F-ITUMM) 22. The e-coach is digitally managed, following three phases of the tiers of VBHC as presented in Figure 1. The tiers are classified in health status, process of recovery and sustainability of health 30. Furthermore, all medication information plus current dose and frequency per unit time are integrated in the e-coach. Reminders are sent if a session or a medication unit time is exceeded. Feasibility was tested for patients as well as healthcare professionals. The F-ITUMM trial concluded that the MM e-coach has the potential to support both recently diagnosed MM patients and healthcare professionals during MM treatment, and is a promising application to improve adherence .
41370222|NCT06130618|DRUG|Lidocain|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 2% lidocaine will be injected.
41030628|NCT01841723|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
41030629|NCT03906370|DIAGNOSTIC_TEST|Diagnostic criteria for MS|The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
41030630|NCT06536062|PROCEDURE|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
41030631|NCT04827004|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib capsules given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
41030632|NCT03560427|DRUG|Duloxetine 60mg|"Patients will receive duloxetine, 60 mg tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
41503156|NCT05231629|DRUG|AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
41503157|NCT05231629|DRUG|AHCT intensification, Dara-R consolidation, Dara-R maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
41503158|NCT05231629|DRUG|Dara-VRd induction|Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
40847562|NCT06416254|OTHER|Fibre-enriched diet|The fibre-enriched diet contains fibre-enriched foods in which a portion of digestible carbohydrates are replaced with isolated dietary fibres. The fibre-enriched study foods are consumed as part of a full meal plan provided to participants.
41030633|NCT03560427|DRUG|placebo|"Patients will receive placebo tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
41162533|NCT01009138|BEHAVIORAL|Diabetes-Specific CBT (DS-CBT)|"5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:~* Problem Analysis and Definition~* Problem Solving Intervention~* Cognitive Restructuring~* Activation of personal and social Resources~* Goal Definition and Agreement"
41370223|NCT01718860|PROCEDURE|Quantitative measurement of neuromuscular transmission|Quantitative measurement of neuromuscular transmission with train-of-four watches.
41503159|NCT06633367|OTHER|Increasing time in nature|This intervention includes requesting an increase in time spent outdoors, eligibility to receive a prize, and information on peer performance.
41503160|NCT01526473|BIOLOGICAL|AVX901|Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
41162534|NCT01009138|BEHAVIORAL|Standard Diabetes Education|"Standard Diabetes Education Lesson including~* Health Care and specific Topics (e. g. Blood Pressure)~* Social Aspects of Living with Diabetes~* Diabetes Complications~* Sports, Activities and Exercise~* Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes~* Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy"
41503161|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) Low Dose|
41503162|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) Medium dose|
41503163|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) High dose|
41503164|NCT01123915|OTHER|Dimethyl Sulfoxide|
41503165|NCT01767948|DRUG|PCI-32765|PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
41503166|NCT00282451|DRUG|biphasic insulin aspart|
41503167|NCT00282451|DRUG|insulin aspart|
41503168|NCT06379685|DRUG|PRO-190|Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.
40847563|NCT06416254|OTHER|Control diet|The control diet contains non-fibre-enriched study foods. The control study foods are consumed as part of a full meal plan provided to participants.
41162535|NCT02897999|BIOLOGICAL|QBKPN|QBKPN Site Specific Immunomodulators
41162536|NCT02897999|OTHER|Placebo|Placebo
41162537|NCT00496834|DRUG|losartan potassium|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
41162538|NCT00496834|DRUG|Comparator: carvedilol|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
41370224|NCT04817319|PROCEDURE|Oral care with/without aerosolization|"These treatments involve instruments that produce aerosolization: ultrasonic scaler, rotary instrumentation for caries care, dental extraction, tooth polishing.~These care correspond to examinations of the oral cavity, intraoral X-rays or even periodontal pocket probing."
41370225|NCT02477072|PROCEDURE|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
41503169|NCT06379685|DRUG|Systane Ultra®|Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.
41503170|NCT04831359|DEVICE|Doppler ultrasound|Tissue Doppler ultrasound on pediatric patients
40847564|NCT01481077|DRUG|Latanoprost-PPDS|Sustained release for 12 weeks
40847565|NCT05311787|PROCEDURE|esophagectomy with simultaneous reconstruction|Subtotal resection of esophagus and simultaneous reconstruction by gastric pull-up or colon conduit
41370226|NCT02477072|PROCEDURE|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
41370227|NCT02477072|PROCEDURE|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
41370228|NCT02477072|PROCEDURE|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
41030634|NCT01153594|BEHAVIORAL|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
41030635|NCT04957602|OTHER|Blood collection|Blood collection (4\*10ml) before treatment initiation and after the first evaluation (usually 3-4 months after treatment initiation).
41030636|NCT03589456|OTHER|No intervention|There are no interventions associated with this registry as it is purely observational.
41030637|NCT04087057|OTHER|Interview|Participate in interview
41030638|NCT04087057|OTHER|Medical Chart Review|Patients' medical records are reviewed
41370229|NCT02477072|DRUG|Heparin|Heparin doses will be administered according to the assigned group.
41370230|NCT00552656|DEVICE|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
41370231|NCT06189482|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The observation group receives IOE for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2, as shown in the Appendix), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
41370232|NCT06189482|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The control group is provided with nutritional support as NGT, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
41370233|NCT05765318|PROCEDURE|QLB|QLB is ultrasound-guided injection of 30 ml bupivacaine 0.25% into quadratus lumborum plane posterior to the end of internal oblique muscle.
41370234|NCT01713374|PROCEDURE|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
41370235|NCT01713374|OTHER|no intervention|control visit
41370236|NCT01713374|PROCEDURE|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
41370237|NCT01713374|PROCEDURE|Cold pressure test|A hand will be placed in ice-cold water.
41030639|NCT04087057|BEHAVIORAL|Questionnaire|Complete questionnaires
41030640|NCT03998826|DRUG|Piroxicam|20mg piroxicam
41030641|NCT03998826|DRUG|Placebo|placebo
41030642|NCT06636175|DRUG|64Cu-LLP2A|64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
41370238|NCT01625559|BIOLOGICAL|MA09-hRPE|MA09-hRPE cells
41503171|NCT05395286|BEHAVIORAL|Innovation Lab|An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.
41503172|NCT00508131|OTHER|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
40847566|NCT00367835|DRUG|SPD503 (Guanfacine hydrochloride)|Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
40847567|NCT00367835|DRUG|Placebo|Placebo
40847568|NCT00753363|OTHER|Weight Loss|6 months of weight loss
40847569|NCT00753363|OTHER|Aerobic Exercise Training|6 months of aerobic exercise training
40847570|NCT04233619|DIAGNOSTIC_TEST|optical coherence tomography|non-invasive test performed by an Ophthalmologist that allows three-dimensional imaging of the retinal vasculature
41162539|NCT00496834|DRUG|Comparator: losartan (+) hydrochlorothiazide (HCTZ)|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
41162540|NCT00496834|DRUG|Comparator: carvedilol (+) hydrochlorothiazide|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
41370239|NCT01269528|OTHER|Methacholine Challenge Test (MCT)|MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
41370240|NCT01269528|OTHER|Monthly telephone contact|Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
40847571|NCT05812339|DEVICE|Gastric Alimetry System|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
41370241|NCT01269528|OTHER|Visits to the study site|Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
40847572|NCT04216225|OTHER|pre-hospital tourniquet placement|patients with extremity injuries presenting with or without pre-hospital tourniquet placement.
41370242|NCT01269528|OTHER|Blood Test|For assessing IgE levels, Eosinophils count and cytokines levels
40847573|NCT04318600|DRUG|human amniotic mesenchymal stem cell|human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).
40847574|NCT01683578|OTHER|Variable Ventilation|
40847575|NCT03688503|DIETARY_SUPPLEMENT|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
40847576|NCT03688503|DIETARY_SUPPLEMENT|placebo|placebo
40847577|NCT04279665|DEVICE|Virtual Reality (VR)|20 minutes of wearing a virtual reality headset with a choice of 4 environments based on their preference and another 20 minutes with a less immersive condition
40847578|NCT03701919|DRUG|Botulinum toxin pyloroplasty|Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
40847579|NCT03701919|DRUG|Normal saline pyloric injection|Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
40847580|NCT03295019|DEVICE|Test Oral Spray|HA formulation of FDA listed ingredients
40847581|NCT03295019|DEVICE|Placebo Oral Spray|Placebo formulation without the active ingredients
40847582|NCT06527417|DEVICE|Neuro Trac Myo Plus Pro|Electrical stimulation parameters; stimuli were monophasic, rectangular, stimulus duration 300 µs, frequency 25 Hertz, amplitude was increased up to a maximum of 100 milliampere until contraction was seen.
41370243|NCT01269528|OTHER|Fractional exhaled nitric oxide|Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
41370244|NCT01024894|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
41370245|NCT01977131|OTHER|Cells|
41370246|NCT05538442|OTHER|Physiological recordings|Physiological, cognitive, biological measurments
40847583|NCT06527417|OTHER|Trunk eccentric exercises|The control group performed back eccentric exercises for 4 weeks, 3 times a week, 3 times in each session
40847584|NCT04954157|DIAGNOSTIC_TEST|Phase-1: Breath Holding Test|In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
41162541|NCT04136964|OTHER|Neck COMI|Patients will be asked to fill a questionnaire booklet consisting of five patient-reported outcome measures twice within 14 days.
41162542|NCT03675308|BIOLOGICAL|Placebo|Placebo for risankizumab administered by subcutaneous injection
41162543|NCT03675308|BIOLOGICAL|Risankizumab|Risankizumab administered by subcutaneous injection
41162544|NCT03723915|BIOLOGICAL|Pembrolizumab|Given IV
41162545|NCT03723915|BIOLOGICAL|Wild-type Reovirus|Given pelareorep IV
41162546|NCT04050319|DIAGNOSTIC_TEST|Screening and diagnosis if injured|physical therapy
41162547|NCT03106298|DRUG|Iron Sucrose|All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
41162548|NCT00282698|DRUG|Insulin infusion with a goal|
41162549|NCT03968536|BEHAVIORAL|fall prevention|Training in physiotherapy sessions and ergonomic home development
41162550|NCT00349245|DRUG|Remifentanil|
41162551|NCT00349245|DRUG|Dexmedetomidine|
41370247|NCT02233673|BEHAVIORAL|Financial incentives|Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
41370248|NCT04632134|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|Transcutaneous vagal nerve stimulation (tVNS) will be performed using a noninvasive battery powered Transcutaneous Electrical Nerve Stimulation device (Nemos ©; Cerbomed, Germany). Electrical stimulation will be delivered by external electrodes through the skin surface at the conca of right external ear. Electrical current will be applied continuously with a pulse width of 200 μs and pulse frequency of 25 Hz. Stimulation amplitude will be adjusted between 0.1-6 mA, to a maximal amplitude level without causing patient discomfort.
41370249|NCT04632134|OTHER|Placebo|tVNS electrodes will be positioned in the right ear of the POTS patients without delivering stimulus (Sham)
41370250|NCT04632134|DEVICE|Home daily transcutaneous vagal nerve stimulation|The home stimulation will consist of 4 hours of stimulation by the tVNS device organized as a 4 sessions of 1 hour. The home stimulation will last for 14 consecutive days.
41370251|NCT02093156|OTHER|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
41370252|NCT00914940|DRUG|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
41370253|NCT00914940|DRUG|Tacrolimus|"Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules."
41370254|NCT00914940|DRUG|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
41370255|NCT00914940|RADIATION|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
41370256|NCT00914940|OTHER|Magnetic Affinity Cell Sorting|Device
40847585|NCT04954157|DIAGNOSTIC_TEST|Phase 2: 6-Minute Walk Test (6MWT)|In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
40847586|NCT06464419|DEVICE|ultrasound|Measurement of optic nerve sheath diameter by ultrasound
40847587|NCT00079677|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
40847588|NCT00079677|DRUG|Placebo|Matching placebo tablets once daily
41030643|NCT06636175|DEVICE|PET/CT|The results of 64Cu-LLP2A-PET/CT will not be provided to the patient or the treating oncologist/surgeon unless, in the judgment of the principal investigator, the images demonstrate an unsuspected abnormality that may warrant further evaluation.
41030644|NCT06025955|PROCEDURE|minimally invasive non- surgical therapy|hand and ultrasonic instrumentation will be done
41030645|NCT06025955|PROCEDURE|open flap debridement|flap surgery will be done
41030646|NCT06163105|PROCEDURE|Meibomian gland expression (MGX)|"The MGX procedure has a standardized protocol in lid spa at Chula's Refractive Surgery Center every 2 weeks (totally 6 sessions). During the study, all MGX procedures will be conducted by the same nurse following these steps:~1. Topical anesthesia by Tetracaine 0.5%~2. Clean the eyelids by gauzes with commercial available foam~3. Warm the eyelids by Blephasteam machine for 10 minutes~4. Instill Tetracaine 0.5% again~5. Use Mastrota paddle and Q-tip to squeeze the gland~6. Clean the lid margin by commercial available foam~7. Use Moxifloxacin 0.5% eyedrop"
41030647|NCT05412862|BEHAVIORAL|Positive Psychology + Motivational Interviewing|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in physical activity.
41030648|NCT00452101|DRUG|Aquamin F|
41162552|NCT01554293|DRUG|Matching placebo|Matching Placebo, single dose
41162553|NCT01554293|DRUG|PBL 1427 capsules|PBL 1427 capsules 20 mg and 150 mg, single dose
41162554|NCT00153023|DRUG|Telmisartan|
41162555|NCT00153023|DRUG|Valsartan|
41162556|NCT00057044|BEHAVIORAL|education and reminder|
41162557|NCT03175198|DRUG|Prazaxa® Capsules|Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg \[as 2 capsules of 75 mg\] twice a day (b.i.d)) or 220 mg (110 mg \[as 1 capsule of 110 mg\] b.i.d) for a treatment duration of 52 weeks.
41370257|NCT00914940|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
41370258|NCT00914940|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
41370259|NCT00914940|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
41370260|NCT05365204|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
40847589|NCT02554578|OTHER|Multidisciplinary follow-up programme supported by mHealth|"The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families."
40847590|NCT01640899|DEVICE|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
40847591|NCT04046731|DIAGNOSTIC_TEST|Skin Testing|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
41370261|NCT01406548|DRUG|BPS804 20mg/Kg|
40847592|NCT00742755|BEHAVIORAL|Prospective intervention|Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
40847593|NCT03332446|OTHER|cold water immersion|10 min at 12-15°C
40847594|NCT02676934|DEVICE|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
40847595|NCT02619643|DEVICE|Transcranial Magnetic Stimulation (Magstim)|
40847596|NCT00006196|DRUG|Vitamin D|
40847597|NCT04107207|DIETARY_SUPPLEMENT|Ginger Kombucha|Craft Ginger Kombucha, a fermented black tea
40847598|NCT04107207|DIETARY_SUPPLEMENT|Ginger Water|Placebo
40847599|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (ascending dose), daily for 14 days
40847600|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (optimized dose), daily for 28 days
40847601|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (20 mg), daily for 14 days
40847602|NCT02822261|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-66_R84-088)
40847603|NCT04767152|DIAGNOSTIC_TEST|MRI|The quantitative assessment of MRI parameters, The macromolecular proton fraction (MPF) (%) in brain tissue. Before the start of therapy - the starting point. Point 2. 36 ± 3 days after the start of the therapy. Point 3. After completing three courses of consolidation chemotherapy. Point 4. After confirmation of remission status, optionally provided.
40847604|NCT00234169|DRUG|VTP195183|"VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.~Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first."
40847605|NCT05938036|DRUG|ALT-100 mAb|Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.
40847606|NCT05938036|DRUG|ALT-100 (Placebo)|Normal saline solution via IV solution
40847607|NCT00386321|DRUG|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
40847608|NCT05061628|DRUG|JS006 as Monotherapy|"1. JS006 as Monotherapy dose-escalation: JS006, 18/ 60/ 180/ 600/ 1800mg, IV infusion, every 3 weeks (q3w).~2. JS006 as Monotherapy dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w)."
40847609|NCT05061628|DRUG|JS006 in combination with Toripalimab|"1. JS006 in combination with Toripalimab dose-escalation: JS006, 2 or 3 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~2. JS006 in combination with Toripalimab dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~3. JS006 in combination with Toripalimab indications expansion: JS006, RP2D, IV infusion, every 3 weeks(q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w)."
41030649|NCT05959850|DRUG|Ambroxol|Participants in the study will receive varying doses of ambroxol in solution, 3 times per day. Doses will be increased pending a safety review, up to a maximum of 1260mg/day. Blood tests will be conducted weekly to assess tolerance. Compliance will be monitored by returning used bottles. The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits. After the final follow-up, there will be an end of study safety visit occurring 4 weeks later. The total time of participation will be 32 weeks. This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits). These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks. Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).
41370262|NCT01406548|DRUG|Placebo to 20mg/Kg BPS804|
41370263|NCT04242121|DIAGNOSTIC_TEST|fluorescence flow cytometry|Countification of plasma cells by fluorescence flow cytometry (hematology analyzer XN-1000/20)
41370264|NCT04937543|DRUG|inhaled beclametasone|Adding belcamethasone to standard of care for Covid 19 positive patients
41370265|NCT04937543|DRUG|Inahaled beclomethasone / formoterol / glycopyrronium|Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
41370266|NCT05503160|BEHAVIORAL|Intervention|Structured (video-)call by qualified nursing staff with breast cancer patients, with the intention to overcome side effects, distress or non-adherence to endocrine therapy.
41370267|NCT02079493|DEVICE|Total Knee Arthroplasty|Knee replacement
41370268|NCT04427423|OTHER|physical therapy treatment|the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
41370269|NCT05856357|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
41370270|NCT03538496|DRUG|Bupivacaine Hcl 0.25% Inj|Single shot 20 ml 0.25 bupivacaine
41503173|NCT04388553|PROCEDURE|single shot lumbar Erector Spinae Plane block|unilateral (operative side), performed at L1 level, under ultrasound guidance
41503174|NCT02198183|DEVICE|Casmed Fore-Sight Elite|
41503175|NCT02198183|DEVICE|Non-invasive Cardiac Output Monitor (NICOM)|
41503176|NCT04618783|BIOLOGICAL|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
41503177|NCT04618783|BIOLOGICAL|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
41162558|NCT03935061|OTHER|Mulberry juice|On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
41370271|NCT01699061|DRUG|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
41370272|NCT01699061|DRUG|Placebo|Placebo tablet administered with a meal twice a day on Day 1
41503178|NCT04618783|BIOLOGICAL|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
40847610|NCT00554372|GENETIC|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
40847611|NCT04523961|DRUG|2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion|Topical anesthetic used to numb the skin prior to laser procedures
40847612|NCT04523961|DRUG|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion|Topical anesthetic used to numb the skin prior to laser procedures
40847613|NCT02747368|DEVICE|Ocusweep system|Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
40847614|NCT06086834|OTHER|McKenzie Retraction Exercises|McKenzie Retraction exercises 5 days a week and 10-15 times for active exercises and 5-6 repetitions of clinician assisted exercise for a period of 4 weeks and a rest interval of 2 minutes between exercises.
40847615|NCT06086834|OTHER|Bruegger's Exercise|Bruegger's Exercise will be started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time will be 30 seconds, 4 sets 12 times repetition, for duration of 30 mins per session, 5 days a week for a period of 4 weeks.
41370273|NCT00267826|DRUG|Rituximab|Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
41370274|NCT02800382|OTHER|Take samples|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
41370275|NCT01899417|DEVICE|ConforMIS iTotal® Knee Replacement|Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
41370276|NCT04447573|BIOLOGICAL|BCMA CAR-T|Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
41503179|NCT04618783|BIOLOGICAL|Three doses of control wIPV, vaccinated within one-month interval between doses|Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
40847616|NCT04015674|OTHER|Exercise group|Aerobic exercise on a stationary bicycle
41162559|NCT02036606|BEHAVIORAL|questionary|
41162560|NCT03025555|OTHER|PEEK|"Polyetheretherketone (PEEK) is a synthetic, tooth colored polymeric material that has been used as a biomaterial in orthopedics for many years but recently used as removable prosthetic material. Advantages of this polymer material are elimination of allergic reactions, high polishing qualities, low plaque affinity, and good wear resistance.~It has been proven that it shows high mechanical and biological properties. Studies evaluating the properties of this material are limited and need more clinical tests."
41370277|NCT03693482|DIAGNOSTIC_TEST|the Four Square Step test|A square will be formed by using four 90 cm long canes placed on the ground. The sequence will be explained and demonstrated to the participants. They will be allowed one practice trial and subsequently two trials. Instructions will be given and encouraged to complete the sequence as fast as possible without touching the canes. The sequence of trial was 1,2,3,4,1,4,3,2,1. If a participant touch the canes, or perform the test sequence inaccurately, or both feet of the participant do not make contact with the floor in each square, the trial will be considered as unsuccessful and the test will be repeated. One unsuccessful trial will be allowed. The best time will be taken as the score of FSST which are completed successfully.
41503180|NCT04618783|BIOLOGICAL|Three doses of control sIPV, vaccinated within one-month interval between doses|Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
41503181|NCT04020783|OTHER|NO Intervention|NO Intervention
41503182|NCT05746598|DRUG|Cisplatin injection|Cisplatin 75mg/m2
41503183|NCT00004315|DRUG|ursodiol|
41503184|NCT00381160|BEHAVIORAL|Reduction of sugar-sweetened beverage consumption|Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
40847617|NCT04015674|OTHER|Control group|In a rest
40847618|NCT01399866|DRUG|D-cycloserine|2 single weekly doses, 50 mg capsule
40847619|NCT01399866|DRUG|Placebo|
40847620|NCT00719888|DRUG|Cyclophosphamide|Given IV
40847621|NCT00719888|DRUG|Cyclosporine|Given IV and PO
41370278|NCT00349960|DRUG|NeoRecormon SC once-weekly versus once-every-other-week|
41503185|NCT01654003|OTHER|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
41162561|NCT03025555|OTHER|Bre.flex|Bre.flex is a nylon-based thermoplastic material, composed of nylon PA 12 (polyamide).Nylon exhibits high physical strength, heat resistance and chemical resistance. It can be easily modified to increase stiffness and wear resistance. Nylon resin can be semi-translucent and provides excellent esthetics but it is a little more difficult to adjust and polish.
41162562|NCT01093170|DRUG|RNA-144101|Intravitreous administration of RNA-144101
41162563|NCT01239537|DRUG|Seasonal Flu vaccine|1 dose of seasonal trivalent flu vaccine (Fluarix)
41162564|NCT05823519|DEVICE|Endologix Ovation Alto Endograft|Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
41030650|NCT05959850|DRUG|Placebo|Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.
41030651|NCT02972840|DRUG|Acalabrutinib|Administered orally (PO)
41030652|NCT02972840|DRUG|Bendamustine|Administered intravenously (IV)
41030653|NCT02972840|DRUG|Rituximab|Administered intravenously (IV)
41162565|NCT03840200|DRUG|Ipatasertib|Ipatasertib will be administered orally.
41162566|NCT03840200|DRUG|Rucaparib|Rucaparib will be administered orally.
41162567|NCT01373333|DRUG|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
41370279|NCT03416166|DEVICE|Transcatheter Tricuspid Intervention|Any available transcatheter tricuspid valve intervention
41370280|NCT01504074|BEHAVIORAL|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
41370281|NCT02822118|DRUG|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
41162568|NCT03354897|DRUG|Torasemide 5Mg Tablet|16 weeks treatment
41370282|NCT02822118|DRUG|Placebo|Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
40847622|NCT00719888|PROCEDURE|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit UCBT
40847623|NCT00719888|DRUG|Fludarabine|Given IV
40847624|NCT00719888|OTHER|Laboratory Biomarker Analysis|Correlative studies
41162569|NCT00438230|DRUG|Warfarin|
41162570|NCT00895089|DRUG|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
41162571|NCT00895089|DRUG|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
41162572|NCT04045522|DRUG|Zoledronic Acid|Based on routine treatment, 4 mg zoledronic acid (Novartis Pharma Stein AG, Switzerland, registration No. H20140218) was intravenously administered, once every 3-4 weeks, for 1-2 years.
40847625|NCT00719888|DRUG|Mycophenolate Mofetil|Given IV and PO
40847626|NCT00719888|RADIATION|Total-Body Irradiation|Undergo high-dose or moderate-intensity TBI
40847627|NCT00719888|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
41162573|NCT05127330|BEHAVIORAL|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge. Other mental health treatment is unrestricted.
41162574|NCT05127330|BEHAVIORAL|Treatment as Usual|Individuals will receive unrestricted routine mental health care in the community as appropriate for their condition.
41162575|NCT02730676|OTHER|Electronic Cigarette #1|VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
41162576|NCT02730676|OTHER|Electronic Cigarette #2|VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
41162577|NCT01211223|DRUG|Administration of Metronidazole plus Amoxicillin|Metronidazole plus Amoxicillin after, during and after root planning
41162578|NCT02480751|DRUG|Beraprost|
41162579|NCT02480751|DRUG|Placebo|
41162580|NCT06276101|BIOLOGICAL|NWRD08 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
41370283|NCT03432130|OTHER|Structural training program|15-week experimental structural training protocol
40847628|NCT00719888|DRUG|Thiotepa|Given IV
41370284|NCT04510662|DRUG|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
40847629|NCT05640895|PROCEDURE|Intravitreal injection site|Intravitreal injections will be made at varying sites; patients will report on pain perception
40847630|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 0.5g|Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
40847631|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
41030654|NCT02972840|DRUG|Placebo|Placebo comparator
41162581|NCT01276509|DRUG|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
41162582|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
41162583|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
41162584|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
41162585|NCT02440737|OTHER|Educational Intervention|"Receive publication, When Someone You Love is Being Treated for Cancer, a preliminary individualized Survivorship Care Plan (SCP), a final individualized SCP, and the REACH for Survivorship handbook."
41370285|NCT05728710|PROCEDURE|Endoscopic submucosal dissection|standard ESD performed and complicated with a perprocedural or delayed perforation
41370286|NCT04775693|DEVICE|RE (Robotic Exoskeleton)|Participants will continue to receive their prescribed standard of care physical therapy/gait training. They will also utilize the robotic exoskeleton twice a week during their inpatient stay and 3 times a week for 5 weeks as an outpatient (for outpatient, only if in the RE group). The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking. It uses sensors and participant motion to move. A licensed physical therapist will be assisting participants as they use the device.
41030655|NCT04352010|BEHAVIORAL|Res-Up!|Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.
41370287|NCT04775693|OTHER|SOC (standard of care)|Traditional physical therapist driven gait training.
40847632|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
40847633|NCT01563172|OTHER|Fluoride free dentifrice|A non fluoride dentifrice was given to participants of each arm at washout period
40847634|NCT02072369|OTHER|VAEDA Glove|Voice And EMG-Driven Actuated glove used during training
41030656|NCT04352010|BEHAVIORAL|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.
41030657|NCT04352010|OTHER|Wait-Control Group|In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
41030658|NCT02056301|DRUG|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
41030659|NCT02056301|DRUG|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
41030660|NCT03230279|PROCEDURE|Sacroiliac joint fusion|Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
41030661|NCT03230279|PROCEDURE|Sacroiliac joint radiofrequency ablation|Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
41030662|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
41370288|NCT00000147|DRUG|Methylprednisolone|
40847635|NCT02072369|OTHER|Occupational Therapy|novel upper extremity occupational therapy focused on the hand
41162586|NCT02440737|OTHER|Follow-Up Care|Complete Survivorship Care Planning session at end of treatment
41162587|NCT02440737|PROCEDURE|Psychosocial Assessment and Care|Undergo the NEST intervention
41162588|NCT02440737|OTHER|Questionnaire Administration|Ancillary studies
41162589|NCT02880306|OTHER|RA|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
41162590|NCT04266613|DIAGNOSTIC_TEST|TruGraf® Testing|5 mL collection PAXgene blood sample
41370289|NCT00000147|DRUG|Prednisone|
41370290|NCT05912673|DEVICE|renal doppler|Toshiba Aplio ultrasound machine and renal resistive index will be measured (peak systolic velocity- end diastolic velocity/ peak systolic velocity
41370291|NCT02081352|OTHER|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
41370292|NCT02081352|OTHER|Standard care|
41370293|NCT04988620|OTHER|Whole Blood transfusion|In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
41370294|NCT02686437|OTHER|TheraBand Kinesiology Tape|Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
41370295|NCT00457795|DRUG|brimonidine 0.1% (Alphagan® P)|Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
40847636|NCT05998174|OTHER|Faecal Microbiota Transplantation|treatment with capsules
40847637|NCT05861141|OTHER|Selected physical therapy program|"Patients will receive a selected physical therapy program for 1 hr, 3 times per week, for 3 successive months in the form of:~* Balance and postural control exercises for 15 minutes, including the following:~  * Standing on balance board.~ * Stoop and recovery.~* Gait training for 45 minutes, including the following:~  * Forward, backward, and sideways walking.~ * Walking with obstacles using wedges and rolls with different diameters and heights."
41162591|NCT00676897|DRUG|Simvastatin|Simvastatin 40mg PO or NGT
40847638|NCT05861141|DEVICE|Aerobic training|"Patients will receive the same selected physical therapy program as the control group for 15 minutes in addition to treadmill training for 45 minutes, 3 times per week, for 3 successive months.~Treadmill training: Will be practiced according to the following stages:~A- Warm up: 5 minutes.~B- The exercise phase: 35 minutes (three-minute stages), the speed will be increased gradually every 3 minutes intervals until the child no longer be able to walk at the current stage.~C- Cool down: 5 minutes."
40847639|NCT05691205|OTHER|PEEP|After a recruitment maneuver three levels of PEEP (14\>10\>6cmH2O) will be tested
40847640|NCT06525064|OTHER|Health-E You app|"When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app.~Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required."
40847641|NCT06068465|DRUG|pimavanserin tartrate|pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks
40847642|NCT06068465|DRUG|placebo|placebo, capsule, once daily by mouth for 6 weeks
41030663|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
41030664|NCT04598516|DIAGNOSTIC_TEST|serum creatinine assay|peak change in serum creatinine in a period of 5 days from baseline (day 0) will be determined
41030665|NCT04898153|DEVICE|aXess|Patients will be implanted with one Xeltis hemodialysis access device (aXess) in the arm
41030666|NCT05156138|OTHER|no interventions as it is a case control observational study|no interventions as it is a case control observational study
41030667|NCT01946711|DRUG|Budesonide|Inhalation
41030668|NCT01946711|DRUG|Budesonide|Nasal spray
41030669|NCT00418171|DRUG|Ziprasidone|
41030670|NCT00418171|DRUG|Olanzapine|
41030671|NCT03243526|OTHER|fluid therapy|fluid resuscitation guided by CVP or PPV
41030672|NCT05888376|DEVICE|Vascular access catheter to support dialysis or CRRT|A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT
41162592|NCT00676897|DRUG|Placebo|Corn Starch
41162593|NCT00198198|DRUG|Aripiprazole|
41162594|NCT02591706|DEVICE|MIS Implants|The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
41162595|NCT03429595|DRUG|ATx201|ATx201 GEL
41162596|NCT03429595|OTHER|ATx201 GEL Vehicle|Vehicle
41162597|NCT01655862|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
41162598|NCT00724750|DEVICE|Gauze suction (G-SUC)|Negative pressure wound therapy
41370296|NCT02721043|BIOLOGICAL|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
40847643|NCT00299117|BEHAVIORAL|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
40847644|NCT06584383|PROCEDURE|Exablate MRgFUS subthalamotomy|Exablate MRgFUS subthalamotomy for Parkinson's Disease
41030673|NCT01141894|OTHER|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
41370297|NCT02721043|DRUG|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
41030674|NCT01141894|OTHER|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
41030675|NCT03827629|DRUG|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
41030676|NCT03827629|DRUG|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
41030677|NCT03827629|DRUG|Treatment C: Naloxone HCL Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
41030678|NCT01485510|BEHAVIORAL|GIFT|An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
41030679|NCT01485510|BEHAVIORAL|FACS|A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
41162599|NCT00724750|DEVICE|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
41162600|NCT02995733|DRUG|PARTICS using QVAR|Patient takes inhaled corticosteroid at the time of rescue inhaler use
41370298|NCT02721043|DRUG|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
41370299|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
41030680|NCT05245864|OTHER|blood flow restriction|Blood flow to the legs will be mostly restricted temporarily during physical therapy exercises for the initial several weeks of physical therapy.
41030681|NCT05245864|OTHER|physical therapy standard of care|the current standard of care after surgery for ACL repair.
41030682|NCT06349902|BEHAVIORAL|Re-Link|The HCV nurse will attempt to contact the PWDU HCV via phone call and text. If unable to connect with a client via phone, an alert is added to the client's chart in the electronic medical record. When the client presents to the CBSUTP for their regular substance use follow up appointment, the chart alert is flagged by the administrative team and the client is connected with the HCV nurse via telemedicine. Clients who are connected to the HCV team are considered re-linked. The HCV nurse will provide an HCV intake as per program guidelines. Clients who would prefer to pursue treatment elsewhere will be supported with a referral to their family doctor or an alternative HCV program in the community. Clients who choose to be treated at the CBSUTP will receive a HCV consultation, DAA treatment and follow-up from the HCV clinical team onsite as per existing program guidelines.
41030683|NCT02559908|DEVICE|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
41030684|NCT03769623|DEVICE|Biolimus|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Biolimus
41030685|NCT03769623|DEVICE|Powerline|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Powerline
41030686|NCT05140278|DRUG|Argesun 60mg (1 step parenteral artesunate)|Each vial of powder contains 60mg artesunate. Each ampoule of 6 ml solvent contains: sodium bicarbonate 8.4mg/ml; arginine 20mg/ml.
41030687|NCT05140278|DRUG|Artesun 60mg (2-step parenteral artesunate)|Each vial of powder contains 60 mg artesunate. Each ampoule of 1 ml solvent contains 50 mg sodium bicarbonate. Each ampoule of 5 ml diluent contains 45 mg sodium chloride.
41030688|NCT02525107|DIETARY_SUPPLEMENT|Omega-3 capsules|SCD patients on Hydroxyurea
41030689|NCT02525107|DIETARY_SUPPLEMENT|Placebo|SCD patients on Hydroxyurea
41030690|NCT02525107|DIETARY_SUPPLEMENT|Omega-3 capsules|SCD patients not on Hydroxyurea
41030691|NCT02525107|DIETARY_SUPPLEMENT|Placebo|SCD patients not on Hydroxyurea
41162601|NCT03792893|OTHER|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
41162602|NCT03792893|OTHER|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
41162603|NCT06304597|DRUG|Imfinzi|Durvalumab is labeled to IRDye-680LT and will be administered in combination with fluorescently labelled nivolumab (Opdivo)
41162604|NCT06304597|DRUG|Opdivo|Nivolumab is labeled to IRDye-800CW and will be administered in combination with fluorescently labelled durvalumab (Imfinzi)
41162605|NCT01721174|PROCEDURE|SEMS only|The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.
41370300|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
41370301|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
41370302|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
40847645|NCT06584383|DRUG|Best Medical Treatment|Subjects will be managed according to conventional therapeutic guidelines (i.e., best medical treatment) for Parkinson's Disease
41030692|NCT01760954|DRUG|Elagolix|Elagolix tablets administered orally
40847646|NCT05040074|DEVICE|SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System|Transesophageal echocardiography-guided, implantable mitral valve clip repair system
41030693|NCT00725426|DRUG|Bosutinib|
41030694|NCT05358444|BEHAVIORAL|National Diabetes Prevention Program Lifestyle Intervention (DPP)|"The National Diabetes Prevention Program lifestyle intervention (DPP) is a 12-month long, group-based lifestyle intervention for adults at high-risk for type 2 diabetes. The DPP will be delivered by certified coaches from the Johns Hopkins Brancati Center. The program uses the CDC's Prevent T2 curriculum, with a total of 32-34 sessions delivered over a 12-month period. In the initial core period (first 6 months), there are at least 16 sessions delivered on a weekly basis. In the post-core period, additional (at least 6) sessions are offered over a 6 month period. Sessions are delivered either in-person or via a virtual synchronous platform (Zoom)."
41030695|NCT05358444|BEHAVIORAL|Family Diabetes Prevention Program (Family DPP)|The Family DPP has been developed as an augmented version of the National Diabetes Prevention Program Lifestyle Intervention (DPP). It includes all elements of the 12-month, group-based DPP lifestyle intervention, led by a CDC certified-coach using a CDC-approved curriculum (involving around 32-34 sessions). The augmentations of the Family DPP supplement the DPP's sessions to additionally address barriers to adults' own lifestyle change efforts related to being a caregiver of children AND to introduce basic concepts regarding healthy child habits related to dietary intake, physical activity and screen time, and sleep. The Family DPP will involve thus additional sessions that will be delivered to the adult DPP participant, and in which children, ages 5 through 12, may also be engaged.
41030696|NCT04148079|OTHER|physical therapy|low frequency currents (galvanic or TENS), medium frequency currents (interferential) and high frequency currents (short wave diathermy), all combined with an individualized exercise program and massage therapy
41030697|NCT02493361|DRUG|Pembrolizumab|
41030698|NCT02493361|DRUG|pIL-12|
41030699|NCT04177433|DRUG|Depo-Medrol Injectable Product|Corticosteroid
40847647|NCT04877236|DEVICE|Green Sun Medical Brace|"All patients in the study will receive the Green Sun Medical Whisper Brace. Each GSM brace will be custom-fabricated via computer-assisted design using the 3D torso scans and a treatment plan (e.g. placement of corrective forces) devised by the treating orthotist as inputs. The brace components are then assembled. Once fabricated, the GSM brace will be fit to the subject by representatives of the manufacturer and in consultation with the treating orthotist.~The GSM brace will be prescribed for the same number of hours per day as was the TLSO (generally 18-22 hours per day, individualized based on patient characteristics). Subjects and the family will be shown how to don and doff the brace, how to clean the brace cover, how to remove the temperature monitor, and how to remove the iButton and how to replace batteries in the GSM sensor board."
41503186|NCT01654003|OTHER|OPTIMIZED|In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
41503187|NCT04529954|DRUG|Valproic Acid delivered to ICV|Valproic Acid delivered to ICV via an implantable pump and catheter system
41503188|NCT04130516|DRUG|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
41503189|NCT04130516|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|pembrolizumab- anti-PD-1 antibody
41030700|NCT04177433|DRUG|Saline|Placebo
41030701|NCT01405391|DRUG|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
41030702|NCT04903093|DRUG|Abrocitinib tablet|Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
41030703|NCT04903093|DRUG|Abrocitinib Suspension F1|Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
41030704|NCT04903093|DRUG|Abrocitinib Suspension F2|Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
41030705|NCT04903093|DRUG|Abrocitinib Suspension F3|Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
41030706|NCT04903093|DRUG|Abrocitinib Suspension F4|Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
41030707|NCT04903093|DRUG|Abrocitinib Suspension F5|Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
41030708|NCT04903093|DRUG|Abrocitinib Suspension F6|Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
41030709|NCT04903093|DRUG|Famotidine|Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
41030710|NCT05108194|BEHAVIORAL|SMS Personalized Sleep Intervention|"All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a user dashboard, which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions."
41030711|NCT03466580|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
40847648|NCT00005824|BIOLOGICAL|filgrastim|
41030712|NCT01032967|PROCEDURE|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
41030713|NCT01032967|RADIATION|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
41503190|NCT05992857|PROCEDURE|Pancreaticoduodenectomy without retromesenteric omental flap|Resection of the pancreatic head, duodenum, distal common bile duct and gallbladder followed by reconstruction using pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy performed on the first jejunal loop.
41503191|NCT05992857|PROCEDURE|Pancreaticoduodenectomy with retromesenteric omental flap|All exposed peripancratic arteries should be covered with a retromesentric omental flap
41503192|NCT06492278|BEHAVIORAL|SMART-3RP|The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
40847649|NCT00005824|DRUG|busulfan|
40847650|NCT00005824|DRUG|cyclophosphamide|
40847651|NCT00005824|PROCEDURE|peripheral blood stem cell transplantation|
40847652|NCT04938011|DRUG|progesterone|the transfer of day 6 blastocyst on the 6th day of progesterone supplementation
41370303|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
40847653|NCT04938011|DRUG|progesterone|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
40847654|NCT00252616|BEHAVIORAL|trophic enteral feeds|10cc/hr
40847655|NCT04546542|OTHER|Parallel Assignment|We will evaluate 75 patients with pSS (Consenso Americano-europeu de 2002 / EULAR/ACR Classification Criteria, 2016) of both sexes at baseline and 6-months
40847656|NCT03942939|OTHER|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
40847657|NCT03942939|OTHER|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet
40847658|NCT05385250|OTHER|Bone sparring radiotherapy|Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
40847659|NCT05713435|DEVICE|intravaginal laser|application of intravaginal laser
40847660|NCT03846609|DEVICE|double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is used for removal of colonic polyp
40847661|NCT03846609|DEVICE|no double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is not used for removal of colonic polyp
40847662|NCT00447122|DRUG|Gemcitabine 1000mg/m2 30 minutes|1000mg/m2 30 minutes
40847663|NCT00447122|DRUG|Lapatinib 1000mg/d|1000mg/d
40847664|NCT00447122|DRUG|Lapatinib 1500mg/d|1500mg/d
40847665|NCT00447122|DRUG|Gemcitabine 1000mg/m2 100minutes|1000mg/m2 100minutes
40847666|NCT00447122|DRUG|Oxaliplatin 100mg/m2|100mg/m2
40847667|NCT03651609|PROCEDURE|Simple decompression of the ulnar nerve|Surgical HUA release 2-3 cm distal to medial epicondyle with minimal-incision technique .
41030714|NCT01517451|RADIATION|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
40847668|NCT03651609|BEHAVIORAL|Conservative treatment|Patients will be given pictured recommendations with descriptions, which limb positions should be avoided.
41030715|NCT01517451|DRUG|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
41030716|NCT01736826|BIOLOGICAL|Bloodwork, baseline|36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
40847669|NCT04135014|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
40847670|NCT04135014|DRUG|Dexmedetomidine|intranasal dexmedetomidine 2µg.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
40847671|NCT04135014|DRUG|Midazolam and Dexmedetomidine|oral midazolam 0.5mg.kg-1 and intranasal dexmedetomidine 1ug.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
40847672|NCT02878837|DRUG|Dexmedetomidine|
40847673|NCT02878837|DRUG|Midazolam|
40847674|NCT00567411|DRUG|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
40847675|NCT00567411|DRUG|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
40847676|NCT02511574|DRUG|natural progesterone|
40847677|NCT02511574|DEVICE|cervical pessary|
40847679|NCT02253784|DRUG|Dexamethasone|
40847680|NCT02253784|DRUG|Bupivacaine|
40847681|NCT04787991|DRUG|Nivolumab (Cohort A)|Nivolumab will be administered intravenously at 360 mg every 3 weeks for up to 2 years.
40847682|NCT04787991|DRUG|Ipilimumab (Cohort A, B and C)|For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.
41030717|NCT01736826|BIOLOGICAL|Blood work, Months 1 & 2|36 ml of blood are drawn at 1 \& 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
41030718|NCT01736826|BIOLOGICAL|Bloodwork, Months -1 to -6|36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
41030719|NCT00845910|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of every 3 week cycle
41030720|NCT00845910|DRUG|capecitabine [Xeloda]|900mg/m2 po on days 1-14 of every 3 week cycle
41030721|NCT00845910|DRUG|docetaxel|60mg/m2 iv on day 1 of every 3 week cycle
41030722|NCT03797534|OTHER|dose regime|The initial dose of the experimental group will be calculated by the Bayesian model.
41030723|NCT02239887|DEVICE|WaveCrest LAA occlusion device|Left Atrial Appendage Occlusion
41503193|NCT06492278|BEHAVIORAL|Health Education Program|This is a multiple behavior change program that addresses sleep, exercise, nutrition, substance use, and working with one's healthcare team.
40847683|NCT04787991|DRUG|Hydroxychloroquine (HCQ) (Cohort B)|Hydroxychloroquine will be administered orally daily for up to 2 years.
41030724|NCT05930093|DIETARY_SUPPLEMENT|Placebo|Placebo matching LivPhcD cap.
41162606|NCT01721174|PROCEDURE|EBRFA and SEMS|The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
41370304|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
41370305|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
41370306|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
40847684|NCT04787991|DRUG|Nab-paclitaxel (nP) (Cohort A, B and C)|Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
40847685|NCT04787991|DRUG|Gemcitabine (gem) (Cohort A, B and C)|Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
40847686|NCT04787991|DRUG|NG350A (Cohort C)|NG-350A will be administered intravenously on Cycle 1 Days 15 (1e12 viral particles), 17 (3e12 viral particles), and 19 (3e12 viral particles).
41030725|NCT05930093|DIETARY_SUPPLEMENT|2 cap.LivPhcD/per day|2 caps. LivPhcD cap. after meal, once a day
41370307|NCT04939805|DEVICE|Selective CRP apheresis using the PentraSorb®-CRP system|Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
41370308|NCT05868031|OTHER|alternative teaching methods|This study aimed to explore the potential benefits of alternative teaching methods in anatomy education, as well as to investigate the effectiveness of traditional lecture-based education in comparison. By examining the outcomes of these different approaches, we hope to understand better how students can best learn and retain knowledge in this field.
41030726|NCT05930093|DIETARY_SUPPLEMENT|4 cap.LivPhcD/per day|4 caps. LivPhcD cap. after meal, BID
41030727|NCT05930093|DIETARY_SUPPLEMENT|6 cap.LivPhcD/per day|6 caps. LivPhcD cap. after meal, TID
41030728|NCT01045447|DRUG|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
41030729|NCT01045447|DRUG|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
41370309|NCT02427542|OTHER|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
41370310|NCT02427542|OTHER|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
41370311|NCT04842318|DRUG|BR for 6 cycles +R for 8 cycles|The patients will be given Bendamustine (90mg/m2 d1,2, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 28 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
41370312|NCT04842318|DRUG|RCHOP for 6 cycles +R for 8 cycles|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
41370313|NCT04842318|DRUG|R2 for 6 cycles + R2 maintenance|The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed by Lenalidomide (25mg/d, po, D1-10, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
41370314|NCT04762706|BEHAVIORAL|CRUTCH Pathway|Patients will be offered referral to a behavioral medicine specialist in the novel Combined Rehabilitation Using Team Centered Help (CRUTCH) Pathway. Once enrolled, these patients will meet virtually with a psychiatrist. The psychiatrist will complete a 30-minute intake visit where he will review the patient's DT scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities. Following this assessment, psychotherapy, psychotropic medication, and referral for social work/financial services will be offered to the patient as indicated. If more frequent behavioral health follow-up is clinically indicated, it will be provided to the patients.
41370315|NCT04971486|BEHAVIORAL|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
41370316|NCT05131152|DRUG|Cyclosporine|0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.
41503194|NCT01038297|DRUG|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
41503195|NCT01038297|DRUG|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
41503196|NCT01797237|DEVICE|PFNA|
41503197|NCT01797237|DEVICE|InterTAN|
41503198|NCT05810584|DEVICE|Revision LR femoral stem|Revision LR is a modular femoral stem used for hip replacement
41503199|NCT03747510|DEVICE|CarpX Device|Transverse carpal ligament release with CarpX Device
41370317|NCT05131152|DEVICE|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
40847687|NCT05253781|DRUG|Low-dose aspirin|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
40847688|NCT05253781|OTHER|Placebo|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
40847689|NCT04445337|PROCEDURE|Stellate Ganglion Block|An injection of local anesthetic into the front of the neck. Medication used for the block include- clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml is delivered.
40847690|NCT03731078|OTHER|CBT Informed physical therapy Intervention|The 12 physical therapy sessions delivered in Massachusetts General Hospital outpatient physical therapy sites sessions include:1) evaluation and education; 2) strategy identification and goal setting; 3) functional strengthening part one; 4) functional strengthening part two; 5) pre-gait activities with distraction; 6) gait training with distraction and use of strategies; 7) minimizing tremor with use of strategies; 8) higher level balance training; 9) functional reintegration part one; 10) functional reintegration part two; 11) identification of strategies to limit recurrence; 12) education for relapse prevention.Patients will also be given and asked to complete the self-guided CBT workbookL Overcoming Functional Neurological Symptoms: A Five Area Approach. They will be asked to complete the first two chapters over the first 4 weeks and the remaining 8 chapters over the following 8 weeks.
40847691|NCT00756782|DRUG|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
40847692|NCT00756782|DRUG|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
40847693|NCT02171741|DRUG|BIBW 2992|continuous daily dosing for 20 or 13 days
40847694|NCT02171741|DRUG|Docetaxel|single infusion on day 1
40847695|NCT01289054|DRUG|Tasigna|
40847696|NCT01289054|DRUG|Gleevec|
40847697|NCT01371305|DRUG|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
41162607|NCT05056675|PROCEDURE|PENG block|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the test item (20 mL of ropivacaine 0.5%, Naropin). The anesthesiologist and the surgeon are blinded to the product injected.
41370318|NCT05059366|DEVICE|Manual Ventilation Grip Device|Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.
41370319|NCT05059366|OTHER|2VE|the standard 2VE technique for ventilation
40847698|NCT01371305|DRUG|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
40847699|NCT04246632|DEVICE|CapsoCam Colon Capsule Endoscopy|CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.
40847700|NCT03720002|DIETARY_SUPPLEMENT|HF2|placebo
40847701|NCT04369976|DEVICE|ARTIFICIAL GRAVITY COMBINED WITH EXERCISE|The passive control group will abstain from any exercise. Recordings of the participant's will include cardiovascular functioning cardiac output (CO), stroke volume (SV) mean arterial pressure (MAP) diastolic blood pressure (DBP), systolic blood pressure (SBP), and heart rate (HR), Electroencephalography ( EEG) as well as dynamic force and stance and muscle oxygenation. More specifically, after 6 training sessions (2 weeks), the centrifugation load will be increased and will be combined with either aerobic exercise (through an ergometer) or resistance training through elastic training bands. Functional connectivity and cortical-network features will be used by deep learning algorithms in order to define the optimal centrifuge training .
40847702|NCT04725487|OTHER|Standard integration program with social and health promoting intervention|"* Basic language course, internships, courses in Labour market knowledge and Danish culture~* Physical activity workshops~* Community gardening (garden workshops)~* Entrepreneurship course~* MindSpring course~* Family excursions~* Danish language workshops"
40847703|NCT04725487|OTHER|Standard integration program|Standard integration program (basic language course, internships, courses in Labour market knowledge and Danish culture)
40847704|NCT01793883|DRUG|40 mg Laninamivir Octanoate|
40847705|NCT01793883|DRUG|80 mg Laninamivir Octanoate|
41370320|NCT04487886|DRUG|Duvelisib|Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.
41370321|NCT04487886|DRUG|Placebo|A placebo to match duvelisib will be taken orally twice per day for 14 days.
41370322|NCT03313700|PROCEDURE|Robotic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, robotic distal gastrectomy will be performed in the experimental group.
41370323|NCT03313700|PROCEDURE|Laparoscopic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic distal gastrectomy will be performed in the comparator group.
41370324|NCT01337921|DIETARY_SUPPLEMENT|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
41370325|NCT05359289|BEHAVIORAL|Forest therapy training|Participants will experience nature-based interventions including forest hiking, horticultural therapy and green wellness activities for their mental health and physical conditions.
41370326|NCT05359289|BEHAVIORAL|Senior fitness training|The fitness program includes physics fitness of stamina, coordination and aerobic exercise in 12 weeks. Participants will join the senior fitness program including physical fitness, aerobic exercise and exercise prescription during the 12 weeks program.
41370327|NCT05359289|BEHAVIORAL|Board Games|Participants will play board games with each other.
41370328|NCT04561700|DIAGNOSTIC_TEST|Reporting of sucking patterns captured by Instrumented Bottle|In the intervention group, data on nutritive sucking and feeding cues captured by the Instrumented Bottle will be made available to speech therapists to document the feeding session and provide written recommendations in their weekly report.
41370329|NCT04561700|DIAGNOSTIC_TEST|Control|In the control group, the information captured by the Instrumented Bottle will not be made available to speech therapists and therefore, will not be used to document a feeding session or provide weekly recommendations.
41370330|NCT03781050|DRUG|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
41370331|NCT01280305|DRUG|raloxifene|raloxifene 60 mg bid
41370332|NCT01280305|DRUG|placebo|Placebo bid
41370333|NCT04121091|DRUG|Pramipexole Pill|Add-on pramipexole
40847706|NCT01793883|DRUG|Placebo|
40847707|NCT04792684|DIAGNOSTIC_TEST|Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel|Evaluate the performance of a preliminary panel of biomarkers
41370334|NCT01692457|DRUG|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
41370335|NCT00226226|PROCEDURE|Peripherally Inserted Central Catheter Placement|
41370336|NCT00781482|DRUG|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
41370337|NCT04014556|DEVICE|micropulse laser|"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."
41370338|NCT04014556|DRUG|Aflibercept|Aflibercept
40847708|NCT01791478|DRUG|PI3K inhibitor BYL719|Given PO
40847709|NCT01791478|DRUG|letrozole|Given PO
40847710|NCT01791478|OTHER|laboratory biomarker analysis|Correlative studies
41370339|NCT04590482|DRUG|letrozole|Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
40847711|NCT01791478|OTHER|pharmacological studies|Correlative studies
40847712|NCT03083678|DRUG|Afatinib|Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
40847713|NCT05961137|OTHER|Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol|Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
41370340|NCT04590482|DRUG|placebo|placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
41370341|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation ON|
41370342|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation OFF|
41370343|NCT05517291|DEVICE|paclitaxel-coated balloon angioplasty or bare mental stents implantation|paticipants who enrolled in this study will received paclitaxel-coated balloon angioplasty plus bailout stenting or primary bare mental stents implantation randomly
41370344|NCT00802295|DRUG|Gonadotrophins|Administration of standard ovarian stimulation protocol
41370345|NCT00802295|DRUG|Low dosis Gonadotrophin|
40847714|NCT05961137|OTHER|Conventional Prehospital Suspected Sepsis Protocol|Conventional protocol employing intravenous crystalloid infusion via gravity or pressurized-bag. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
40847715|NCT06526559|DEVICE|Barbed suture|Use of two absorbable barbed sutures for each arm in the ureteropelvic anastomosis in minimally invasive dismembered pyeloplasty
41370346|NCT06042556|OTHER|IUD self-removal guide|We previously developed an online guide for IUD self-removal through an iterative process including advice from key expert informants, focus groups, interviews, and a pilot clinical study. It includes an online animation, step-by-step guide, troubleshooting tips, and information about pregnancy and contraception.
41503200|NCT06412679|BEHAVIORAL|Life Skills Education|The RESETTLE-IDPs study compares two innovative delivery approaches for a culturally-adapted life skills education (LSE) intervention aimed at improving the mental health and well-being of internally displaced persons in Nigeria. The interventions are distinguished by their mode of delivery (in-person vs. WhatsApp-based), their focus on peer support and skill-building, and their tailoring to the specific needs and challenges of IDP populations.
40847716|NCT06526559|DEVICE|PGA suture|Use of two absorbable polyglactin sutures for each arm in the ureteropelvic anastomosis in minimally invasive dismembered pyeloplasty
40847717|NCT03262441|DRUG|Mycophenolate Mofetil 500Mg Tab|500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
40847718|NCT01846741|DEVICE|M106 VNS Therapy System|
40847719|NCT00424697|DRUG|placebo|
40847720|NCT00424697|DRUG|lorazepam|
40847721|NCT00424697|DRUG|GW876008|
40847722|NCT02481817|PROCEDURE|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
40847723|NCT02481817|PROCEDURE|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
40847724|NCT02481817|PROCEDURE|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
40847725|NCT00697710|DRUG|50 mg S-777469|S-777469, 50 mg BID
40847726|NCT00697710|DRUG|200 mg S-777469|S-777469, 200 mg BID
41503201|NCT05615831|BEHAVIORAL|Resistance Training with Blood flow restriction|Participants will perform six weeks of blood flow restriction (60% occlusion) combined with resistance training at 30% of 1RM. The intervention comprises five exercises: incline chest press, seated row, leg press, knee extension, and knee flexion. The protocol is as follows: 30 repetitions followed by three sets of 15 repetitions for a total of four sets and 75 repetitions per exercise. There will be a one-minute recovery between sets where the cuffs remain inflated and a four-minute recovery between exercises where the cuffs will be deflated.
41503202|NCT06523660|BEHAVIORAL|CHUCK CHUCK SKILLS: CHild's Understanding of Cognitive sKills|The intervention will consist of an online EF training that will be delivered across 10 sessions (one 1 hour session per week for ten weeks). It will target core EF components including inhibitory control, attention shifting, and working memory in children with Autism Spectrum Disorder aged 5 to 7 years. It will also provide strategies (e.g., behavioral principles, compliance training) for promoting behavioral regulation and emotion regulation in these children. Accompanied parent coaching will be provided to enhance children's generalization of EF skill attainment.
40847727|NCT00697710|DRUG|800 mg S-777469|S-777469, 800 mg BID
40847728|NCT00697710|DRUG|Placebo|Matching Placebo
41370347|NCT03580746|PROCEDURE|Taping and posteromedial release|
41370348|NCT03580746|PROCEDURE|Ponseti|
40847729|NCT04166617|OTHER|Conventional therapy|conventional physcial therapy rehabilitation for the upper limb
41370349|NCT01307189|DRUG|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
41370350|NCT01307189|DRUG|Placebo|Placebo diskus inhalation powder, once daily
40847730|NCT04166617|OTHER|Leap motion plus conventional therapya|leap motion plus conventional physcial therapy rehabilitation for the upper limb
40847731|NCT04169074|DRUG|Abemaciclib|Treatment will consist of a single neoadjuvant cycle of 10-21 days (+7 days). Abemaciclib will be administered from days 1-21. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
40847732|NCT00118950|DRUG|Metformin|Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.
40847733|NCT00118950|DRUG|Repaglinide|Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.
40847734|NCT00118950|DRUG|Placebo-Metformin.|Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.
40847735|NCT00118950|DRUG|Placebo-Repaglinide.|Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.
40847736|NCT00118950|OTHER|Diet-only.|Diet-only treatment. Duration: One month.
40847737|NCT00761202|DRUG|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
40847738|NCT00761202|DRUG|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
40847739|NCT02089126|DRUG|Gemigliptin/Glimepiride combination|
40847740|NCT03668093|OTHER|ICCM|comprehensive system for caries management
40847741|NCT03668093|OTHER|CAMBRA|Caries risk assessment model
40847742|NCT04557046|DIAGNOSTIC_TEST|Nasal Swab|Collection of one more nasal swabs
40847743|NCT04557046|DIAGNOSTIC_TEST|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
40847744|NCT04557046|DIAGNOSTIC_TEST|Throat swab|Collection of one more throat swabs
40847745|NCT04557046|DIAGNOSTIC_TEST|Fingerstick|Collection of capillary blood from one or more fingersticks
40847746|NCT04557046|DIAGNOSTIC_TEST|Saliva specimen|Collection of free drool
40847747|NCT04517643|OTHER|Therasphere Therapy|TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.
40847748|NCT02933502|DRUG|DSXS topical product|treatment daily for 28 days
40847749|NCT01052077|DRUG|OPC-34712|Tablets, Oral, 1 - 3 mg OPC-34712
40847750|NCT01052077|DRUG|Placebo|Placebo
41370351|NCT03053531|DEVICE|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
41370352|NCT02471898|DRUG|HTX-011|
41370353|NCT02471898|DRUG|Placebo|Saline
41503203|NCT06523660|BEHAVIORAL|Parent Psychoeducation|Group-based parent psychoeducation, which consists of 10 sessions, 1-hour weekly program delivered via telehealth, will be provided to the control group.
41370354|NCT03288987|DRUG|Bevacizumab + FOLFIRI-3|Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
41370355|NCT03947333|OTHER|My Diabetes Care|The My Diabetes Care is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
41370356|NCT03773354|BEHAVIORAL|Cognitive-behavioural therapy group for individuals with somatic symptom disorders|The intervention is a cognitive-behavioural therapy group for designed for individuals with a formal diagnosis of a somatic symptom disorder (i.e., Somatic Symptom and Related Disorders from the DSM-5) who are interested in learning self-management skills to cope with somatic symptoms and reduce emotional dysregulation, increasing their understanding of factors that contribute to somatic symptoms, and learning relaxation skills to help reduce stress.
41370357|NCT04489511|DRUG|STG-001|Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
41370358|NCT05420610|OTHER|Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.|The control group included patients being admitted when TPTD device was unavailable; and relatively stable patients without the need for TPTD. The adequacy of fluid resuscitation in the control group was monitored by traditional monitoring parameters including vital signs and hourly urine output.
41370359|NCT05420610|OTHER|Study group: TPTD device was implemented for monitoring.|TPTD device was implemented for monitoring; the inclusion criteria included patients suffering from 2nd degree burn greater than 40% TBSA; a combined 2nd to 3rd degree burn greater than 30% TBSA; or patients with inhalation injury despite the burned surface area.
41503204|NCT06632327|PROCEDURE|Surgical Procedure|undergo surgery
41503205|NCT06632327|DRUG|Cisplatin|Give cisplatin
41503206|NCT06632327|DRUG|Carboplatin|Give Carboplatin
41503207|NCT06632327|DRUG|Pemetrexed|Give Pemetrexed
41503208|NCT06632327|DRUG|Gemcitabine|Give Gemcitabine
41503209|NCT06632327|DRUG|Docetaxel|Give Docetaxel
41503210|NCT06632327|DRUG|Vinorelbine|Give Vinorelbine
41503211|NCT06632327|DRUG|Nivolumab|Give Nivolumab
41503212|NCT06632327|DRUG|Pembrolizumab|Give Pembrolizumab
41503213|NCT06632327|DRUG|Atezolizumab|Give Atezolizumab
41503214|NCT06632327|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
41503215|NCT06632327|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41503216|NCT06632327|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41503217|NCT06354634|OTHER|Resin polymer (NuSmile Bioflx) crown|Resin polymer (NuSmile Bioflx)crown
41503218|NCT06354634|OTHER|Stainless steel crown|Stainless steel crown
41503219|NCT06600269|PROCEDURE|Cycling Training|Cycling combined with priming strategies to enhance motor learning tasks. Each session will last for 15 minutes, conducted three times per week, over a period of two weeks.
41503220|NCT06106165|OTHER|In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|"The intervention includes a two-hour workshop, delivered in-person, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar"
41030730|NCT04823598|PROCEDURE|Coached pushing and Finnish manual perineal protection|"Pushing technique: Rest will be encouraged between uterine contractions. With the onset of uterine contraction, women will be instructed to breathe normally. They will then be instructed to take a deep breath and hold (closed-glottis), and push down strongly for as long as possible (up to 10 seconds). After pushing effort, normal breathing will be encouraged, then the same pushing instruction will be repeated again.~Fetal expulsion: The expulsion rate of the fetal head will be controlled by light pressure applied on the fetal occiput. Simultaneously, the thumb and index finger of the dominant hand will be used to support the perineum, while the bent middle finger will grasp the baby's chin. Once a good grip is achieved, the investigator slowly assists in the expulsion of the fetal head from the vaginal introitus. When most of the fetal head is out, the perineal ring will be pushed under the baby's chin."
41370360|NCT05603000|BEHAVIORAL|Emotion Focused Family Therapy|"The Emotion Focused Family Therapy (EFFT) intervention for this study will be delivered to groups of four to ten parents over six weekly sessions of two hours each. The goal of EFFT is to teach and empower parents to coach their child to process the emotions at the source of their mental health symptoms, to increase their child's adaptive behaviours, and to repair emotional injuries within the parent-child relationship. EFFT also targets parents' own emotional challenges that may prevent them from feeling capable or being able to support their child's treatment.~Each EFFT session will include introductions, psychoeducation about emotion and psychopathology, introduction of skills, experiential activities (e.g., chair work), open discussion and feedback, and homework activities covering the foci of EFFT: emotion coaching, behaviour coaching, therapeutic apology, and parental emotion blocks."
41370361|NCT00591552|DEVICE|Harmonic ACE23P Scalpel|Lymph node dissection
41370362|NCT00591552|DEVICE|Electrocautery|
41030731|NCT04823598|PROCEDURE|Uncoached pushing and Hands-poised perineal protection|Women will not be given any instructions regarding straining and breathing, and will be allowed to follow their own pushing impulses. During the expulsion of the fetal head, the hands of the researcher will be kept in the air and ready for the intervention, but pressure will not be applied to the fetal head or perineum unless necessary (fetal hypoxic appearance, strain detection with a risk of spontaneous laceration towards the anus in the midline).
41030732|NCT02007486|OTHER|Cardiopulmonary Exercise Testing|Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
41030733|NCT00898716|DRUG|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
41030734|NCT03177993|DRUG|3 drug dose - IDA|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
41162608|NCT05056675|PROCEDURE|Placebo|ll patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the placebo (20 mL of NaCL 0.9%). The anesthesiologist and the surgeon are blinded to the product injected.
41370363|NCT00661310|OTHER|Drug review 80+ -To reduce usage of hospital care|drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
41370364|NCT02821546|DRUG|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
41370365|NCT00069069|DRUG|Intransal instillation of E-selectin|Intranasal recombinant human E-selectin
41370366|NCT04766658|OTHER|Gargle Phonation|Subjects will gargle water while making sound
41370367|NCT04766658|OTHER|Water swallow|Subjects will hold water in their mouth for 5 seconds and swallow
41370368|NCT03478631|OTHER|High-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally high in nitrate content, such as beet, spinach, and kale
41370369|NCT03478631|OTHER|Low-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally low in nitrate content, such as peas, tomato, broccoli, carrots, and brussel sprouts
41370370|NCT05449431|OTHER|TLC1_TM6|Following this inclusion, patients are performing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
41370371|NCT05449431|OTHER|TM6_TLC1|Following this inclusion, patients are performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
40847751|NCT01052077|DRUG|ADT|
40847752|NCT02913716|DRUG|defactinib|Single oral dose of 400 mg \[14C\]-defactinib
41030735|NCT03177993|DRUG|3 drug dose - IDA with second dose of ivermectin|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
41030736|NCT03177993|DRUG|2 drug dose - DA|"Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
41030737|NCT00004093|DRUG|carboplatin|Carboplatin will be dosed at a target AUC of 5, and will be given on day 1 of each cycle
41030738|NCT00004093|DRUG|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of each 21-day cycle of induction chemo (following carboplatin on day 1).
41030739|NCT00004093|DRUG|paclitaxel|Paclitaxel will be given on day 1 of each week for 6 weeks at a dose of 50 mg/m2.
41030740|NCT00004093|DRUG|vinorelbine|Vinorelbine will be given on day 1 of each week for 6 weeks at a starting dose of 10 mg/m2, escalating up to 15 mg/m2 if no dose limiting toxicities are observed.
41030741|NCT00004093|RADIATION|radiation therapy|Radiation will be given at a dose ranging between 45 to 66 Gy, depending on patient-specific characteristics.
41030742|NCT00004093|DRUG|Navelbine|Navelbine will be administered at a dose of 10-15 mg/m2 in 100 cc NS to be administered over 10 minutes I.V. (one dose weekly during radiation therapy)
41030743|NCT00004093|DRUG|Taxol|Taxol will be administered at a dose of 50 mg/m2 in 250 cc of NS or D5W over 60 minutes, following Navelbine (one dose weekly during radiation therapy)
41030744|NCT02706457|OTHER|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
41030745|NCT04842357|OTHER|standardised video concerning clinical skill|watching a video concerning clinical skills.
41030746|NCT01082666|DEVICE|Continuous control of cuff pressure|Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
41030747|NCT01082666|DEVICE|Manual control of cuff pressure|Manual control of cuff pressure is a routine practice in ICU patients
41030748|NCT05662501|DEVICE|Pleioflow-RF|Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
41030749|NCT00723177|DRUG|AV411|Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
41030750|NCT00723177|DRUG|Placebo (PCB)|Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
41030751|NCT00125216|BEHAVIORAL|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
41030752|NCT00769366|BEHAVIORAL|Psychotherapy|humanistic-existential psychotherapy conducted in individual and group meetings
41030753|NCT00769366|DRUG|Medical therapy|Optimal medical therapy after Acute myocardial infarction
41030754|NCT00002912|DRUG|etoposide|
41030755|NCT00002912|DRUG|mitoxantrone hydrochloride|
41030756|NCT00002912|DRUG|valspodar|
41162609|NCT05712655|OTHER|Measurement of bilateral electromyographic activity of Masseter and Anterior Temporalis muscles.|Assessment was done by surface electromyography (sEMG) device.
41162610|NCT00788047|DRUG|Dextromethorphan|Dextromethorphan HCl 30 syrup single dose
41162611|NCT00788047|DRUG|Dimebon + Dextromethorphan|Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
41162612|NCT00151697|DRUG|Novomix 30|
41370372|NCT04307017|OTHER|StimaWell®EMS|The StimaWell®EMS device is a 12-channel medium-frequency device with modulated low frequency using a high-tech stimulation suit for the trunk and strap electrodes for the arms and legs allowing whole-body stimulation. The device has 70 preprogramed training programs based on goals (e.g., strengthening, endurance training, aerobic training).
41370373|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced α-lactalbumin formula|Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula and in standard infant formula
41370374|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced whey formula|Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
41370375|NCT02410057|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
41370376|NCT04177862|DRUG|Sublingual Sufentanil|30 mcg of sublingual sufentanil
41370377|NCT04177862|DRUG|IV Fentanyl|50 mcg of IV fentanyl
41370378|NCT03534817|BEHAVIORAL|Early Access CR|Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
40847753|NCT00595010|BEHAVIORAL|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
40847754|NCT05019534|DRUG|Vemurafenib Oral Tablet [Zelboraf]|Vemurafenib 960mg qd or 960mg bid (2 cohorts)
40847755|NCT05019534|DRUG|Cetuximab Injection [Erbitux]|Cetuximab 500mg/m2 Q2W
40847756|NCT05019534|DRUG|Camrelizumab|Camrelizumab 200mg Q2W
40847757|NCT01368081|DRUG|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
40847758|NCT01368081|DRUG|BI 10773|BI 10773 low dose tablet once daily
40847759|NCT01368081|DRUG|Placebo (low dose)|Placebo tablets once daily
40847760|NCT01368081|DRUG|BI 10773|BI 10773 high dose tablet once daily
40847761|NCT01368081|DRUG|Placebo (high dose)|Placebo tablets once daily
40847762|NCT01332747|DRUG|safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily"
40847763|NCT01332747|DRUG|compressed tablet of safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily"
41030757|NCT02872064|DRUG|Verteporfin|Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
41030758|NCT05090501|BEHAVIORAL|High Intensity Circuit Training|The participants will execute a 12-exercise High Intensity Circuit Training protocol. Each exercise will have an active part taking 30 seconds, in which exercisers are encouraged to do as many repetitions as possible, and a resting part taking 10 seconds in which the participants rest and are informed of the next exercise. Before and after the 12-exercise routine, the participants rate their affect, arousal and perceived exertion, while using a heart rate monitor and two IMU sensors on their arms and legs.
41030759|NCT00561223|DRUG|iloprost Inhalation|inhale 2.5 mg, repeat times one
41030760|NCT00561223|DRUG|iloprost|inhaled 2.5 mg, repeat times one
41030761|NCT01182753|RADIATION|carbon ion therapy|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
41030762|NCT01182753|RADIATION|proton therapy|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
40847764|NCT01332747|DRUG|Atorvastatin|atorvastatin 10 mgs once daily
40847765|NCT05105217|OTHER|Slit2 biomarker|"1.Assessment of slit2 level in SLE patients and its correlation with disease activity.~2-Assessment of slit2 level in SSC patients and its correlation with disease activity"
40847766|NCT01643824|RADIATION|Proton Beam Therapy|"- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 \<40%, and/or RLV30 \<30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30\<50% and RLV30\<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30\<60%, and/or RLV30\<50%~- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
40847767|NCT05500326|DRUG|Ivermectin Tablets|"ITCHY Study:~All participants will receive one dose of oral ivermectin 3mg on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~ITCHY2 Study:~Participants will receive one age-specific dose of oral ivermectin on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~Age specific ivermectin dose:~* 0.75mg of ivermectin will be given to participants aged 3 to 7 months~* 1.5mg of ivermectin will be given to participants aged 8 to 12 months~* 3mg of ivermectin will be given to participants aged 13 to 24 months"
40847768|NCT04014569|DEVICE|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA Algorithm
40847769|NCT00532506|DRUG|SK-0403|
40847770|NCT05428267|OTHER|questionnaire|Completion of questionnaires (IIEF5/FSFI, SF 36, Fatigue Scale Score, Self Esteem Inventory, Hospital Anxiety and Depression Scale) during the pre-transplant consultation, then during a consultation 6 months after transplantation
41030763|NCT00412087|DRUG|cholecalciferol (vitamin D3)|randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
41030764|NCT00412087|DRUG|cholecalciferol|randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3
41030765|NCT00412087|DRUG|cholecalciferol|cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
41030766|NCT06063629|PROCEDURE|Subcutaneous drain|The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.
41030767|NCT06063629|PROCEDURE|No drain|No drain will be inserted into patients allocated to this group
41030768|NCT02599168|DRUG|Propofol|
41030769|NCT02599168|DRUG|Dexmedetomidine|
41030770|NCT02599168|DRUG|Placebo (normal saline)|
40847771|NCT05428267|OTHER|blood collection|Collection of 2 tubes of 5mL of blood during a scheduled blood draw in the patient's care pathway. This sample will also be taken after the transplant (6 months later)
41370379|NCT00387829|DEVICE|DuraGen Plus Adhesion Barrier Matrix|Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
41370380|NCT04155606|DEVICE|microsurgery; endovascular interventions|microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
41370381|NCT01737359|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
41370382|NCT01737359|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
41370383|NCT01737359|DRUG|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
41370384|NCT05637931|DIAGNOSTIC_TEST|plexinD1|evaluation of the serum level of plexinD1
41370385|NCT05592639|PROCEDURE|Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy|Intervention is a Videoendoscopic radical inguinal lymphadenectomy (VEIL) which is a surgical technique utilised in removing inguinal lymph nodes.
40847772|NCT03737331|BEHAVIORAL|Fractal visual cueing|Walking to an external visual fractal (i.e., pink noise) stimulus.
40847773|NCT03737331|BEHAVIORAL|Periodic visual cueing|Walking to an external visual periodic (i.e., invariant) stimulus.
40847774|NCT03737331|BEHAVIORAL|Random visual cueing|Walking to an external visual random (i.e., white noise) stimulus.
40847775|NCT01153360|DRUG|liothyronine sodium|liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
40847776|NCT01153360|DRUG|placebo|vitamin B12
40847777|NCT05141084|OTHER|Education, lifestyle|The weight loss program itself is the intervention, which will involve lifestyle modifications and intervention.
40847778|NCT06546852|BEHAVIORAL|education|Patient education will be provide
40847779|NCT02476006|DRUG|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
41030771|NCT05768308|BEHAVIORAL|Internet CBT-UP intervention iCBT-UP|The self-helped internet intervention for students experiencing emotional difficulties, especially adjustment disorder. This intervention is based on transdiagnostic cbt principles - unified protocol (Barlow et al., 2018). It is a modular intervention consisting of six modules teaching different skills of dealing with emotions. Intervention is interactive and contains of video materials, quizes, texts and audio materials.
41030772|NCT05768308|BEHAVIORAL|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR) (Bernstein, Borkovec, Hazlett-Stevens, 2000). It is also a modular intervention and, similar to the i-cbt condition, consists of 5 modules. During the intervention, participants learn how to progressively tighten and relax different muscle groups.The first module is planned for two weeks and the rest of them for one week each. Intervention consists of video materials and audio guided relaxations. Participants are encouraged to train these relaxations once a day.
41162613|NCT00151697|DRUG|Novorapid and Amaryl|
41370386|NCT03669952|OTHER|None intervention|No interventions are realized, only observational study
40847780|NCT02476006|DRUG|placebo (for injection training only)|Pharmaceutical form:solution Route of administration: subcutaneous
40847781|NCT02476006|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
40847782|NCT02476006|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
40847783|NCT02476006|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
40847784|NCT02476006|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
40847785|NCT03327467|BIOLOGICAL|Cord Blood Infusion|IV infusion of umbilical cord infusion (sibling, autologous, or unrelated donor)
40847786|NCT01854424|OTHER|Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.|All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
40847789|NCT04463667|OTHER|exercise|Collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening.
41030773|NCT00005981|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
41162614|NCT00151697|DRUG|Lantus|
41370387|NCT02615665|PROCEDURE|Hepatic resection|Removal of a part of the liver during surgery
41370388|NCT00070070|BIOLOGICAL|TICE®-strain BCG|
41370389|NCT00070070|BIOLOGICAL|NY-ESO-1 protein|
41370390|NCT00070070|BIOLOGICAL|sargramostim|
41370391|NCT01574976|BEHAVIORAL|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
40847790|NCT06025409|DRUG|Leuprolide Acetate 11.25 MG/ML|Subcutaneous injection
40847791|NCT05265897|OTHER|CAQ|Informational document
41370392|NCT06514638|OTHER|Ultrasound imaging|Images of the vastus medialis were taken with the subject being lateral decubitus.
41503221|NCT06106165|OTHER|Online In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|"The intervention includes a two-hour workshop, delivered online, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar"
40847792|NCT05694299|DEVICE|Nasal bridle|Bridle Pro® Nasal Tube Retaining System (Applied Medical Technology Inc., Brecksville, OH, USA)
41370393|NCT00810654|DIETARY_SUPPLEMENT|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
41370394|NCT00810654|DIETARY_SUPPLEMENT|Placebo|Placebo
41370395|NCT01876901|PROCEDURE|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|"2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
41370396|NCT01876901|PROCEDURE|Colo-anal anastomosis (CAA)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch"
41370397|NCT00048438|DRUG|paricalcitol|
41370398|NCT04221373|DEVICE|Ekso™ powered exoskeleton|Powered exoskeletal-assisted walking (EAW) for early training
40847793|NCT05694299|OTHER|Nasal patch|Regular adhesive tape for medical use.
41370399|NCT04221373|OTHER|Standard of care|Participants will receive standard of care of acute inpatient rehabilitation.
41370400|NCT05332171|BEHAVIORAL|Pyhsiohterapy and rehabilitation|Before starting the exercise program, 10 repetitive warm-up exercises will be given including the lower and upper extremities and distal joints. The exercises will be started with 5 repetitions in the first week. Depending on the patient's tolerance, the intensity of the exercise will be increased as 10 repetitions, 15 repetitions and 20 repetitions, and optional rest will be allowed between exercises. It is aimed that the patients reach 20 repetitions in the 6th week at the latest.
41370401|NCT02804295|OTHER|Collaborative Care Intervention|All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
41370402|NCT00512070|DRUG|olanzapine and melatonin|In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
41370403|NCT04281121|DIETARY_SUPPLEMENT|omega 3 fatty acids|: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
41370404|NCT04128059|DRUG|BVRS-GamVac-Combi|"BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration"
41370405|NCT04128059|OTHER|placebo|placebo
41503222|NCT06634264|DEVICE|Soft Oral Appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
40847794|NCT06448039|DRUG|Fibroblast Growth Factor 2|Randomized double-blinded placebo-controlled treatment of 20 patients with chronic (\>6 month), dry tympanic membrane perforations will be repaired with a gelatin sponge soaked with FGF2 or saline in a 3:1 ratio, then covered with a fibrin glue. Up to four applications will be administered at 3 week intervals or until complete healing is observed.
40847795|NCT06448039|DRUG|Saline control|Randomized double-blinded placebo-controlled treatment of patients with chronic (\>6 month), dry tympanic membrane perforations will be repaired with a gelatin sponge soaked with saline, then covered with a fibrin glue. Up to four applications will be administered at 3 week intervals or until complete healing is observed.
40847796|NCT05562609|DRUG|Tranexamic acid|Ampoules and packaging for all arms will be identical in appearance.
40847797|NCT05562609|OTHER|Placebo|Ampoules and packaging for all arms will be identical in appearance.
41370406|NCT04895423|DRUG|Methotrexate therapy|Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
41370407|NCT04895423|DRUG|Mycophenolate mofetil therapy|Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
41503223|NCT04429308|PROCEDURE|Photodynamic Therapy|Photodynamic Therapy consists of (Levulan Kerastick (aminolevulinic acid HCL) topical solution, 20% + BLU-U Photodynamic Light Therapy)
41503224|NCT04429308|DRUG|Chemical Peels|Chemical peels consists of a combination of Jessner's Solution: Composed of Salicylic Acid (14%), Medical Grade Lactic Acid (14%), Medical Grade Resorcinol (14%), Denatured Ethyl Alcohol AND 35% Trichloroacetic acid peels
41503225|NCT06381466|DRUG|AZD0233|Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)
41503226|NCT06381466|DRUG|AZD0233 Placebo|Randomized participants will receive matching placebo orally as a SAD or MAD.
41503227|NCT01328665|OTHER|Expressive Writing|Writing intervention for cognitive appraisal of stressor.
41503228|NCT05231278|DEVICE|nCLE aided RANB biospy|nCLE aided RANB biopsy procedure using the Monarch® robotic-assisted navigational bronchoscopy platform and Cellvizio® I.V.E. system with AQ-Flex™ 19 Confocal Miniprobe™ used in combination with Fluorescein.
40847798|NCT03887858|DRUG|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration under fasting
40847799|NCT03887858|DRUG|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition
40847800|NCT04899453|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
40847801|NCT04899453|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
40847802|NCT04899453|DRUG|Zanubrutinib|160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase
40847803|NCT00389350|DRUG|Extract of Green and Black Tea|
40847804|NCT01705106|DRUG|capecitabine|Given PO
40847805|NCT01705106|DRUG|celecoxib|Given PO
40847806|NCT01705106|OTHER|pharmacological study|Correlative studies
40847807|NCT01705106|OTHER|laboratory biomarker analysis|Correlative studies
41503229|NCT05422794|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
41503230|NCT05422794|PROCEDURE|Biopsy|Undergo biopsy
41503231|NCT05422794|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41370408|NCT04895423|DRUG|Cyclosporine therapy|Cyclosporine per os 3 mg/m2 2 times a day within 12 months
41370409|NCT04895423|DRUG|Dupilumab therapy|Patients weighing \<30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to \<60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
41503232|NCT05422794|PROCEDURE|Computed Tomography|Undergo CT
41503233|NCT05422794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41503234|NCT05422794|DRUG|Nab-paclitaxel|Given IV
40847808|NCT01705106|OTHER|pharmacogenomic studies|Correlative studies
40847809|NCT00809653|DEVICE|No Face Mask|Subjects will not wear a face mask to reduce their personal air pollution exposure
41370410|NCT01662076|OTHER|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
41370411|NCT05872113|COMBINATION_PRODUCT|Hs-hWE cream|The cream was applied to the faces of subjects, the left facial area was put on the 0.5% Hs-WE cream.
41370412|NCT05872113|COMBINATION_PRODUCT|Placebo cream|The cream was applied to the faces of subjects, the right facial area was put on the placebo cream.
41370413|NCT02492152|DEVICE|Study group|Dianatal
41370414|NCT04318626|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
41370415|NCT04318626|DRUG|THK5351|F-18 THK5351 PET Imaging
41503235|NCT05422794|BIOLOGICAL|Pembrolizumab|Given IV
40847810|NCT00809653|DEVICE|Face Mask|Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.
40847811|NCT04883034|PROCEDURE|adductor canal block in outpatient clinic|perform adductor canal block in outpatient clinic for patient post total knee arthroplasty
41503236|NCT04112316|DRUG|liothyronine or placebo|Each treatment period of liothyronine or placebo will be approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo or LT3.
41503237|NCT03259867|DRUG|Nivolumab Injectable Product|a PD-1 immune check inhibitor
41503238|NCT03259867|COMBINATION_PRODUCT|Trans-arterial tirapazamine embolization|Embolization with Lipiodol and Gelfoam
40847812|NCT04883034|DRUG|Analgesics, etoricoxibe|anaelgetic oral intake
40847813|NCT03940118|DEVICE|Catheter secretion suctioning|Catheter secretion suctioning with prior nebulization of hypertonic saline
40847814|NCT03940118|COMBINATION_PRODUCT|Secretion suctioning + hypertonic saline|Catheter secretion suctioning with prior nebulization of hypertonic saline
40847815|NCT03940118|DEVICE|Ins-exsufflation|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
40847816|NCT03940118|COMBINATION_PRODUCT|Ins-exsufflation + Hypertonic saline|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
40847817|NCT00410605|BIOLOGICAL|bevacizumab|Given IV
40847818|NCT00410605|DRUG|lenalidomide|Given orally
40847819|NCT00410605|DRUG|dexamethasone|Given orally
40847820|NCT03890367|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
41370416|NCT03990012|PROCEDURE|IR Imaging|Subjects will undergo steady steady state and video IR imaging of the breasts.
41370417|NCT03990012|PROCEDURE|3D Scanning|Subjects will undergo 3D scanning of the breasts.
41370418|NCT01149174|DRUG|Mitomycin-C 40 mg|Intravesical instillation of Mitomycin-C
41370419|NCT03965754|BEHAVIORAL|Social norms|This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
41370420|NCT03965754|BEHAVIORAL|Loss framing|This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
41370421|NCT03965754|BEHAVIORAL|Email reminder|This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
41370422|NCT03199989|DRUG|CapeOX（Capecitabine+Oxaliplatin）|Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
41370423|NCT03199989|OTHER|Observation|Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
41370424|NCT05670470|DRUG|CTP0303|Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
41370425|NCT05670470|DRUG|Orafang Tab|Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
41370426|NCT06082427|DEVICE|Virtual reality hypnosis|VRH was delivered through a 3D virtual reality headpiece equipped with a head-tracking system based on hypnosis induction and suggestions (relaxation, comfort, and safety). The complete intervention lasted 17 minutes.
41370427|NCT03826446|PROCEDURE|Surgery|laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
41370428|NCT03707106|BEHAVIORAL|CBT smoking cessation|an established protocol for smoking cessation based on cognitive behavioral therapy
41370429|NCT03707106|BEHAVIORAL|virtual reality based cue exposure|smoking cue exposure in virtual reality
41370430|NCT03707106|BEHAVIORAL|progressive muscle relaxation|Progressive muscle relaxation for unspecific stress reduction
40847821|NCT03890367|BIOLOGICAL|Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular
40847822|NCT03890367|BIOLOGICAL|Meningococcal group C polysaccharide Conjugate vaccine adsorbed|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
40847823|NCT04485884|DRUG|IN-C005 dose A|One time dose of IN-C005 dose A taken orally.
40847824|NCT04485884|DRUG|IN-C005 dose B|One time dose of IN-C005 dose B taken orally.
41370431|NCT04668482|DEVICE|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
41370432|NCT04668482|DEVICE|SCS is switched on|Spinal cord stimulator is functioning
41370433|NCT05214911|DRUG|Desloratadine , Prednisolone|FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA
41370434|NCT05214911|DRUG|Desloratadine|Desloratadine 0.5 mg/mL (Desalex® - Eurofarma Laboratórios SA)
41370435|NCT05044182|PROCEDURE|Decompression and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
41503239|NCT03403075|BEHAVIORAL|ETAF|Therapeutic education and Physical activity
41503240|NCT03403075|BEHAVIORAL|Usual care|Usual care
41503241|NCT04583189|DIAGNOSTIC_TEST|Performance of the test antigenic and test RT-PCR|Each patient will have 1 test rapid antigenic Biosynex Covid-19 Ag-BSS with the results in 15-20 minutes and 1 reference test RT-PCR analyzed in microbiology laboratory of the hospital.
41370436|NCT05044182|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
41370437|NCT05588765|OTHER|Neck stretching exercises|Neck stretching exercises towards lateral flexion, ipsilateral flexion and rotation and towards flexion each for 30 sec and repeated 2-3 times
41370438|NCT02873598|DRUG|FOLFIRINOX or gemcitabine/abraxane|Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.
40847825|NCT04485884|DRUG|IN-C005 dose C|One time dose of IN-C005 dose C taken orally.
40847826|NCT04485884|DRUG|IN-C005 dose D|Oral administration of IN-C005 dose D once daily for 7 days.
41162615|NCT01170923|DEVICE|FDR-PET|FDR-PET performed after 1 cycle of chemotherapy
41370439|NCT02873598|RADIATION|SBRT|After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
40847827|NCT04485884|DRUG|IN-C005 dose E|Oral administration of IN-C005 dose E once daily for 7 days.
40847828|NCT04485884|DRUG|IN-C005 dose F|Oral administration of IN-C005 dose F once daily for 7 days.
40847829|NCT02685904|BIOLOGICAL|ENIA11|
40847830|NCT02685904|BIOLOGICAL|Placebo|
40847831|NCT00626405|BIOLOGICAL|bevacizumab|Given IV over 30-90 minutes
40847832|NCT00626405|DRUG|carboplatin|Given IV over 30 minutes
40847833|NCT00626405|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
41370440|NCT03484572|DIAGNOSTIC_TEST|Anthropometric measures|Weight (kg),Height (cm)Body mass index(kg/m²),Mid-upper arm-circumference(cm), tricipital skinfold (cm)
40847834|NCT00626405|DRUG|temozolomide|Oral temozolomide on days 1-5
40847835|NCT00848224|BEHAVIORAL|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
40847836|NCT02160691|DEVICE|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
40847837|NCT00187525|DRUG|Memantine|
40847838|NCT06208111|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy would be used as intervention strategy for women facing partner violence to Clear about actual problems, re-educate about the issue of domestic problems and mental health, Logical expectations, Identify negative automatic thoughts,Thinking errors, and Improve understanding to identify which stressors trigger negative emotions. Moreover, this intervention will help to Prepare women how to deal with stress and overcome the reaction.
40847839|NCT05770024|OTHER|imaging tests|X-ray radiography (RX); computer tomography (CT); magnetic resonance (MR); positron emission tomography (PET); single photon emission computed tomography (SPECT)
40847840|NCT05502510|BEHAVIORAL|MyHealthyPregnancy|MyHealthyPregnancy is a mobile application prescribed to expectant mothers in conjunction with normal prenatal care. The application uses behavioral decision science principles to identify risks of preterm birth and alert the mother and care team of these risks.
40847841|NCT06156241|BIOLOGICAL|Stem Cell|Stem cells derived from human cord tissue.
40847842|NCT04434014|DIETARY_SUPPLEMENT|proper diet|diet containing all essential vitamins
40847843|NCT02229929|DRUG|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
40847844|NCT02229929|DRUG|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
40847845|NCT02229929|DRUG|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
40847846|NCT02229929|DRUG|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
40847847|NCT02229929|DRUG|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
40847848|NCT02229929|DRUG|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
40847849|NCT06128746|DEVICE|Repetitive Transcranial Magnetic Stimulation|1 Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
41162616|NCT01170923|DEVICE|CT|CT performed after 3 cycles of chemotherapy
41162617|NCT01329185|DRUG|Valganciclovir|Valganciclovir 450mg twice a day for 14 days prior to transplant date
41162618|NCT01329185|DRUG|Placebo|1 capsule twice a day for 14 days prior to transplant date
41370441|NCT01579682|BEHAVIORAL|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
41370442|NCT01579682|BEHAVIORAL|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
41370443|NCT01767649|OTHER|Caesarean|Collection of tissues and blood
41370444|NCT01767649|OTHER|Vaginal delivery|Collection of tissues and blood
41370445|NCT03919669|DRUG|All Subjects|All subjects will be given the experimental tau PET radioligand \[18F\]MK-6240
41370446|NCT03774069|DEVICE|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient
41370447|NCT03774069|OTHER|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
41370448|NCT01340807|OTHER|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
41370449|NCT00219349|BEHAVIORAL|Cognitive Behavioral Therapy|14 weekly sessions of individualized CBT
41370450|NCT00219349|DRUG|escitalopram|10-20 mg per day for 12 weeks
41370451|NCT04082416|BIOLOGICAL|Placebo plus standard therapy|"Standard therapy comprises any of the following (alone or in combination):~corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )"
41030774|NCT00005981|DRUG|carmustine|Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
41030775|NCT01753193|BIOLOGICAL|Anifrolumab|Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
41030776|NCT00562159|DRUG|Placebo|Placebo sublingual tablet
41030777|NCT00562159|BIOLOGICAL|SCH 697243|SCH 697243 (2800 Bioequivalent Allergen Units \[BAU\] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
41030778|NCT00562159|DRUG|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
41030779|NCT00562159|DRUG|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
41030780|NCT00562159|DRUG|Mometasone 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
41030781|NCT00562159|DRUG|Prednisone 5 mg Rescue Treatment|"Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day~(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray."
41030782|NCT00562159|DRUG|Albuterol sulfate 108 mcg|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
41030783|NCT00562159|DRUG|Fluticasone propionate 44 mcg|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
41030784|NCT00562159|DRUG|Prednisone 5 mg|Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
41030785|NCT06266923|DRUG|SPH6516 tablets|SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle
41030786|NCT05947448|DRUG|Azilsartan Medoxomil Potassium Tablet|Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month
41030787|NCT05947448|DRUG|Nifedipine Sustained -release Tablets|Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；
41030788|NCT05947448|DRUG|Levoamlodipine Maleate Table|Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；
41030789|NCT04244461|BEHAVIORAL|Personalized Normative Feedback|The personalized normative feedback (PNF) focuses on behavioral norms, where participants see (1) how their perceptions compare to other same-gender veterans' actual drinking and (2) how their actual drinking compares to other same-gender veterans' actual drinking. The format of the intervention highlights typical days per week, drinks per occasion, and binge drinking as per traditional PNF interventions. PNF will also contain a video description of theories of normative influence (e.g., how individuals are affected by perceptions) and a description of the normative data sample. Participants also see enhanced PNF content that will focus on sharing with participants treatment information that the investigators obtained from a pilot sample.
41030790|NCT02473614|DEVICE|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimum of 3 hours per week.
41030791|NCT02473614|OTHER|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimum of 3 hours per week.
41030792|NCT02252055|BIOLOGICAL|ATDC_Nantes|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)"
41030793|NCT01891123|DEVICE|PK guided arm|the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
41030794|NCT01891123|DRUG|PTX 175mg/m2, DOC 75mg/m2|patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
41503242|NCT04207489|PROCEDURE|endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer|Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.
41030795|NCT01634698|DIETARY_SUPPLEMENT|retinyl palmitate (UNICEF, Melbourne, Australia)|the patients received an oral dose of 1500 IU or 2500 IU, once.
41030796|NCT03356912|DRUG|Cabazitaxel|"Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route"
41162619|NCT01689467|DIETARY_SUPPLEMENT|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
41162620|NCT01689467|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
41162621|NCT02840175|DRUG|etanercept|will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
41503243|NCT06505447|OTHER|Daytime light exposure|Participants will be exposed to a 10,000 lux light source within 3 feet of their face/eyes to promote the natural circadian rhythm for 2-3 hours from 10am to 12/1pm depending on their nap time at home
40847850|NCT06128746|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
41162622|NCT02840175|DRUG|adalimumab|will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
41370452|NCT04082416|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
41370453|NCT00093327|PROCEDURE|Acupuncture|
41370454|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"1. st line:~   * Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * Bevacizumab until PD or unacceptable toxicity~  * At PD patients will go to the 2nd treatment line.~2. nd line:~   * Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine."
41370455|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"Arm B~1. st line~   * Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~  * Bevacizumab until PD or unacceptable toxicity~  * At PD \< 3 months after last paclitaxel start 2nd treatment line.~  * At PD ≥ 3 months after last paclitaxel, start another 4 cycles~  * Bevacizumab until the next PD or unacceptable toxicity~  * At the next PD start the 2nd treatment line.~2. nd line:~   * Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~  * At PD \< 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~  * At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~  * At the next PD start 3rd treatment line."
41370456|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks
41370457|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks
41370458|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
41370459|NCT03312504|OTHER|Neuromuscular training program|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).
41370460|NCT03312504|OTHER|Standard-of-practice Warm-up (Control)|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
41370461|NCT01906762|DRUG|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
41370462|NCT01906762|DRUG|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
41503244|NCT06505447|OTHER|Daytime restricted feeding|Participant's nutrition, parenteral or enteral, will be restricted to the hours when they are normally awake at home.
41503245|NCT04731246|OTHER|Video-oculography / Neuropsychological evaluations|Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.
41503246|NCT01670591|BEHAVIORAL|PS - Prevention in School|
41503247|NCT06469632|OTHER|Active Comparator: Experimental Group 1|"Multimodal physiotherapy treatment composed of:~Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain.~Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity.~Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique."
40847851|NCT05750550|OTHER|Instrument Assisted Soft Tissue Mobilization|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
40847852|NCT03368235|DRUG|AZD9567|oral OD SGRM administered as suspension
40847853|NCT03368235|DRUG|Prednisolone|oral capsules of 20 mg prednisolone administered OD for two weeks
40847854|NCT01497782|OTHER|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
40847855|NCT00699335|DRUG|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
40847856|NCT02268994|DRUG|ferric citrate|1 g ferric citrate containing approximately 210 mg of ferric iron
40847857|NCT02268994|DRUG|Placebo|Matching placebo
41162623|NCT02840175|DRUG|Abatacept|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
41162624|NCT02840175|DRUG|Tocilizumab|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
41370463|NCT02787148|BEHAVIORAL|Cognitive behavioral therapy|
41030797|NCT03356912|DRUG|Prednisone|Prednisone should be administred by oral route
41370464|NCT04124302|DRUG|Insulin Glulisine|A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
41370465|NCT04124302|DRUG|Insulin Aspart|A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
41370466|NCT04124302|DRUG|Insulin Lispro|A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
41370467|NCT02892916|DRUG|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
41370468|NCT02892916|DRUG|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
41370469|NCT04657861|DRUG|APRIL CAR-T cells|Each subject receive APRIL CAR T-cells by intravenous infusion
41370470|NCT04290871|DRUG|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
41370471|NCT04290871|OTHER|The delivery system will be set up anyway without study gas administration|The delivery system will be set up anyway without study gas administration
41370472|NCT03005262|DRUG|MLN8237|
41370473|NCT04035707|DRUG|Rocuronium|using rocuronium as a relaxants during general anaesthesia
41370474|NCT04035707|DRUG|general volatile anaesthesia|method of anaesthesia
41370475|NCT03383276|DRUG|IL-1Ra|custom eye drop to be applied to the left eye.
41370476|NCT00202254|BEHAVIORAL|Physiotherapy|
41370477|NCT00202254|BEHAVIORAL|Occupational therapy|
41503248|NCT06469632|OTHER|Experimental: Experimental Group 2|"Multimodal physiotherapy treatment composed of:~Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain.~Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity.~Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique.~Non-ablative radiofrequency: using capacitive superficial electrodes and resistive superficial and intravaginal electrodes."
41503249|NCT05605015|BEHAVIORAL|ACTIVE-CR|The ACTIVE-CR intervention comprises three key components: a wrist-worn physical activity monitor, a web-based platform providing physical activity feedback, and three autonomy supportive online trainer sessions. Each component is grounded by multiple established behaviour change techniques consistent with the behaviour change taxonomy developed by Michie et al. (2013). The barriers to physical activity were identified in our previous work and are consistent with previous literature
41503250|NCT05744141|PROCEDURE|Relaxation Exercises|"Relaxation exercises consist of voluntary, rhythmic and regular stretching and relaxation of large and small muscle groups until the whole body relaxes. For this exercise application, the Relaxation Exercises CD prepared by the Turkish Psychological Association will be used. The CD consists of 30 minutes and relaxation exercises are explained with the sound of a stream accompanied by verbal instructions. This exercise includes rhythmic breathing, muscle relaxation exercises and music (stream sound)."
41030798|NCT00358046|DRUG|ILY101|
41030799|NCT02030977|DIETARY_SUPPLEMENT|Resveratrol|
41370478|NCT00202254|BEHAVIORAL|Speech pathology|
41370479|NCT01955824|DRUG|1% lignocaine|
41503251|NCT01097512|DRUG|AS703569/gemcitabine|"Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
41503252|NCT01097512|DRUG|AS703569/gemcitabine|"AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
41503253|NCT00865371|DRUG|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
41503254|NCT00865371|DRUG|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
41503255|NCT05927948|DEVICE|Laight therapy, NICE V3.1 device|Laight therapy is a non-invasive method of treatment for HS and acne developed in Germany which utilizes a combination of radiofrequency and intense pulsed light exposure. Three passes of the device, all coupled with radiofrequency, are used in the proposed treatment area. The first pass encompasses wavelengths between 420 nm and 1200 nm, the second between 510 nm and 1200 nm, and the third pass between 690 nm and 1200 nm.
41030800|NCT02030977|OTHER|placebo|
41370480|NCT01955824|DRUG|2% lignocaine|
41370481|NCT00002329|DRUG|Celgosivir hydrochloride|
41030801|NCT03613857|DRUG|Clopidogrel|8 tablets 75 mg clopidogrel loading dose before PCI
41030802|NCT03613857|DRUG|Ticagrelor 90mg|2 tablets 90 mg brilique before PCI
41030803|NCT04396951|DEVICE|Active external overheating with heating plate, Aragonia ® MTC 400|It is a heating device that is adjustable in height up to 50 cm from the patient and generates radiant heat at low temperature (up to 39 ◦C) distributed evenly. It is equipped with an adjustable 0-9 potentiometer and has a skin temperature probe as a control and safety mechanism Measure during 6 hours with indirect calorimetry in first week
41370482|NCT03269565|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody
41370483|NCT00238680|BEHAVIORAL|Bladder rehabilitation|
41370484|NCT00238680|BEHAVIORAL|Bladder rehabilitation with programmable timer|
41370485|NCT02403115|OTHER|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
41503256|NCT05739149|DIAGNOSTIC_TEST|Microvessel Ultrasound Examination|Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin
41370486|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.
41370487|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
41370488|NCT06406959|PROCEDURE|Transversus abdominal plane block (TAP block)|Unilateral US-guided TAP-block lateral approach with 20 ml 0,375% Levobupivacaine before incision
41370489|NCT03863821|DEVICE|HHHFNC|"HHHFNC setting:~1. Flow rate: 40L/min~2. FiO2: 0.4~HHHFNC will use immediately before 6MWT and remove at the end of 6MWT"
41370490|NCT06262009|OTHER|human faecal collection|collecting stools 6 times over a 90 days period and complete a questionnaire at the same times: D1, D7, D15, D30, D60 and D90
40847858|NCT02709876|BIOLOGICAL|Stem Cell Transplantation|Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
40847859|NCT05746208|DRUG|Lenvatinib|Given orally
40847860|NCT05746208|DRUG|Pembrolizumab|Given IV
40847861|NCT05746208|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
41370491|NCT06262009|OTHER|ancillary study|interviews and/or ethnographic observations for 50 volunteers
41370492|NCT02664974|DIETARY_SUPPLEMENT|Enteral nutrition|"Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.~Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.~Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate."
41503257|NCT05739149|PROCEDURE|Skin Biopsy|Dermatology will remove a small piece of skin from the affected ulcer area and control skin
41503258|NCT04976413|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) psychotherapy|Experimental arm will receive eight phase EMDR treatment using manualized standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12-14 weeks.
41503259|NCT04976413|BEHAVIORAL|Counselling as usual|Control arm will receive counseling as usual for 12-14 weeks
41030804|NCT04396951|DEVICE|Active external overheating with air blanket, Equator Level 1® de Smiths Medical|Composed of a unit that produces hot air and forced air adjustable from 38ºC to 43ºC. Sends hot forced air distributed by tubular blanket that convectively heats the patient by diffusing hot air directed at the patient through the textile pore of the air blanket Measure during 6 hours with indirect calorimetry in first week
41030805|NCT00276445|DRUG|beta-1,3-glucan|
41503260|NCT03494101|OTHER|Blood samples|Blood samples will be collected and analyzed at different study time points
41503261|NCT03494101|OTHER|Stool samples|Stool samples will be collected and analyzed at different study time points
41030806|NCT02370654|BEHAVIORAL|Tai chi|
41030807|NCT02370654|BEHAVIORAL|Conventional exercise|
41030808|NCT01476215|DRUG|Paracetamol fast dissolution suspension|
41503262|NCT03494101|OTHER|Clinical information|Clinical information will be collected at different study time points using questionnaires
41503263|NCT05146648|DEVICE|Gondola AMPS|One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
41503264|NCT02006329|DEVICE|acupuncture|
40847862|NCT06172478|DRUG|HER3-DXd|Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle
40847863|NCT01887847|DRUG|Nicotine (Pharmaceutical Productions Inc.)|An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
40847864|NCT01887847|DRUG|Nicotine (Pharmaceutical Productions Inc.)|A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
41030809|NCT01476215|DRUG|Paracetamol medium dissolution suspension|
41030810|NCT01476215|DRUG|Paracetamol slow dissolution suspension|
41030811|NCT01476215|DRUG|Paracetamol|
41503265|NCT06626464|DRUG|[14C]MK-8189|Oral administration
41030812|NCT01178853|DRUG|Warfarin|Warfarin 5 mg once daily
41370493|NCT02664974|OTHER|Dietary counseling|"Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.~Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported."
41370494|NCT00766727|DEVICE|GLYDe Dressing|Wound dressing intended to minimize scar formation
41370495|NCT04640168|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
41370496|NCT04640168|DRUG|Dexamethasone|Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.
41370497|NCT04640168|OTHER|Placebo|Placebo matching oral baricitinib or intravenous dexamethasone.
41370498|NCT04640168|DRUG|Remdesivir|Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
41370499|NCT03541408|OTHER|Control|Standard Of Care without Preventative Delirium Protocol
41503266|NCT05177302|OTHER|HAGOS-C|The subjects will be instructed to complete HAGOS-C at the initial contact and again after 1 week and 4 month for reliability and responsiveness test, respectively
41503267|NCT05177302|OTHER|SF-36v2|The subjects will be instructed to complete SF-36v2 at the initial contact to determine the validity of HAGOS-C
41503268|NCT05046743|OTHER|Colonic gas load|Colonic infusion of gas via an anal cannula
41503269|NCT05046743|OTHER|Sham load|Sham infusion of gas via an anal cannula
41503270|NCT05056623|BEHAVIORAL|Dyadic pain management program|"Face-to-face part: The DPM will start with 20-30 minutes of physical exercise supervised by research assistant, followed by 20-minutes of pain management education. Communication skills regarding the practice of various pain management techniques by the participants and their caregivers will be taught. At the end of the session, the caregiver and research assistant will help the older adults to make portfolio entries on the activities of the day, to help them recall the various pain-relief methods learned in each class.~Home-based part: An exercise book will be given to guide them in performing exercises at home. It is recommended to perform 30 minutes of exercise, 3 times a week, at home and the more frequent the exercise time, the better.~All participants will join a WhatsApp group to receive teaching materials and videos of the physical exercises learned, for practice at home. The team will produce compact disc (CD) with the exercise video clips to the dyads for revision."
41503271|NCT05056623|OTHER|Usual care and pain management pamphlet|Usual care and pain management pamphlet
41503272|NCT02443987|OTHER|Intravenous fluid|500ml infusion of 0.9% Sodium Chloride intravenously.
41503273|NCT00109408|DRUG|Methotrexate|7.5-20mg po weekly
41030813|NCT01178853|DRUG|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
41370500|NCT03541408|OTHER|Preventative Delirium Protocol|Preventative Delirium Protocol
41503274|NCT00109408|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
41503275|NCT04005612|DIETARY_SUPPLEMENT|vitamin D3|50,000 IU VD3 / week for 8 weeks
41030814|NCT01178853|DRUG|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
41370501|NCT02679560|DRUG|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
41370502|NCT02679560|DRUG|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
41030815|NCT02216331|DRUG|TMC207|"This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description."
41030816|NCT02216331|DRUG|rifapentine|
41030817|NCT02216331|DRUG|rifampicin|
41370503|NCT06158295|OTHER|Voluntary apnoea|Walking apneas at low lung volume
41370504|NCT03445663|DRUG|AMG 424|Subjects will receive IV infusions of AMG 424
41370505|NCT02353234|OTHER|Bread|In each arm subjects consume bread
41370506|NCT04233606|OTHER|Hypertonic Saline|Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin
41370507|NCT04233606|OTHER|Normal Saline|Infusion of normal saline to inhibit the secretion of the hormone vasopressin
41370508|NCT01773434|DRUG|MORAb-004|"MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1."
41370509|NCT04235959|DRUG|Tirzepatide|Administered SC
41370510|NCT04235959|DRUG|Placebo|Administered SC
41370511|NCT01741727|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion.
41370512|NCT03713112|OTHER|Weekly MDT deprescribing rounds for certain drugs|"* Weekly deprescribing round (from randomization to day of discharge)~* Conducted by a multidisciplinary team (non-ward doctors, pharmacist, ward nurse)~* Using the 5 steps of de-prescribing~* De-prescribing targets:~  1. Beer's list of potentially inappropriate medications (American Geriatric Society 2015 version)~ 2. Supplements of questionable benefits (glucosamine, chondroitin, vitamin B complex and multivitamins)~ 3. Symptomatic medications (laxatives, gastro-protectives, painkillers, anti-emetics and steroid creams) (Standardized verbal script to initiate de-prescribing by the team)~* On top of usual care"
41370513|NCT00750373|PROCEDURE|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
41370514|NCT02151552|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
41370515|NCT02151552|DRUG|[18F](+/-)NOS|7 mCi of \[18F\](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
41370516|NCT04469101|PROCEDURE|Lumbar Epidural|Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
41370517|NCT01785251|DEVICE|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
41370518|NCT01343329|DRUG|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
41370519|NCT01343329|DRUG|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
41370520|NCT00241566|DEVICE|implantation of stimulator|
41370521|NCT03635541|OTHER|observational group of NAFLD|there's no intervention for patients for it is a observational study
41370522|NCT02775409|PROCEDURE|Subcutaneous placement|The tissue expander will be placed above the muscle.
41370523|NCT02775409|PROCEDURE|Submuscular placement|The tissue expander will be placed below the muscle
41370524|NCT06084442|PROCEDURE|Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia|"Patients will be divided into 2 groups:~* Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~* Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique."
41370525|NCT01520038|RADIATION|Proton therapy|
41370526|NCT01520038|RADIATION|IMRT|
41370527|NCT02092207|DRUG|KL7016 900mg|oral administration, 150mg 3tab, bid
41370528|NCT02092207|DRUG|KL7016 600mg|oral administration, 150mg 3tab, bid
41370529|NCT02092207|DRUG|Placebo|oral administration, 150mg 3tab, bid
41370530|NCT00305292|DRUG|Modafinil-Alcohol Interactions|
41370531|NCT02347345|DRUG|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
41503276|NCT04005612|DIETARY_SUPPLEMENT|omega-3 fatty acid|300 mg of omega 3-FA once daily for 8 weeks
41370532|NCT00045565|DRUG|arsenic trioxide|Given IV
41370533|NCT00045565|RADIATION|radiation therapy|Undergo radiation therapy
41503277|NCT04005612|DIETARY_SUPPLEMENT|vitamin D3 and omega-3 fatty acid|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
41030818|NCT04119284|DEVICE|Anterior body tether (ABT)|To insert the ABT in patients to correct AIS.
41030819|NCT03503942|BEHAVIORAL|Lifestyle modification|Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
41266919|NCT02647151|DRUG|AMINOLEVULINIC ACID HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
41503278|NCT04005612|OTHER|control|no intervention
41503279|NCT02583958|DEVICE|Urgo 3103166|URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).
41503280|NCT02583958|DEVICE|Aquacel Extra|Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
41503281|NCT02391129|PROCEDURE|Operation for Periprosthetic fractures of the hip with stem loosening|
40847865|NCT03287427|DRUG|TetMYB Vaccine|Weekly intra-dermal injections of either 0.1mg, 0.5mg or 1.0mg on day 1 for week 1 to week 6.
40847866|NCT03287427|DRUG|BGB-A317|3 weekly IV injections of 200mg commencing from Week 4.
40847867|NCT02267161|OTHER|Psychometric scales for infants at 3 years of age|WPPSI-III, VINELAND, CBCL, NEPSY
41030820|NCT03503942|DRUG|Metformin|Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
41030821|NCT03503942|OTHER|Financial incentives|Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
41370534|NCT00439920|DRUG|High-dose anthracycline|
41503282|NCT04562155|DRUG|BAY1817080|Study drug BAY1817080 will be administered orally as tablet.
41370535|NCT04926337|DEVICE|Tight Fitting Facemask|Preoxygenation with tight facemask, 10 L/min, 100% oxygen.
41370536|NCT04926337|DEVICE|High Flow Nasal Oxygen (HFNO)|Preoxygenation with high flow nasal oxygen, 40-70 L/min, 100% oxygen.
41503283|NCT04562155|DRUG|Placebo|Matching Placebo for BAY1817080 will be administered orally as tablet.
41503284|NCT05333731|DRUG|Oxytocin|In the two groups, if spontaneous labor does not occur after PROM, they all receive the oxytocin for up to 24h.
41503285|NCT04060862|DRUG|Ipatasertib|Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
40847868|NCT01876693|PROCEDURE|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
40847869|NCT02421588|DRUG|Lurbinectedin (PM01183)|
40847870|NCT02421588|DRUG|Pegylated liposomal doxorubicin (PLD)|
40847871|NCT02421588|DRUG|Topotecan|
40847872|NCT02207218|DRUG|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
40847873|NCT04391803|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
40847874|NCT06354478|DRUG|Dexmedetomidine Hydrochloride 0.5 MG/ML|Will be used either alone or in combination of gabapentin
40847875|NCT06354478|DRUG|Gabapentin|Will be used either alone or in combination of Dexmedetomidine
40847876|NCT06438250|DRUG|68Ga-JH04|The dose will be 148-222 MBq given intravenously.
41030822|NCT02696005|OTHER|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
41030823|NCT01176253|PROCEDURE|Blood draw|Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
41030824|NCT04841057|PROCEDURE|50 cm BP limb length|50 cm biliopancreatic limb length
41030825|NCT04841057|PROCEDURE|100 cm BP limb length|100 cm biliopancreatic limb length
41030826|NCT04841057|PROCEDURE|150 cm BP limb length|150 cm BP limb length
41030827|NCT02491320|OTHER|Pre-treatment acupuncture|Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
41030828|NCT02491320|DRUG|Letrozole|Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
41030829|NCT03066531|BEHAVIORAL|ACT-based intervention|
41266920|NCT03588741|DRUG|Turoctocog alfa|"Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month."
41370537|NCT02615652|OTHER|no intervention|no intervention, observational study
40847877|NCT00208533|DRUG|Aripiprazole|Aripiprazole 5 mg to 30mg, individually titrated
40847878|NCT02725866|DRUG|Paritaprevir/ritonavir/ombitasvir|Co-formulated tablet
40847879|NCT02725866|DRUG|Dasabuvir|Tablet
40847880|NCT02725866|DRUG|Ribavirin|Tablet
41266921|NCT05187832|DRUG|AND019 PO QD|AND019 administrated as oral capsule once per day for 28 days for each cycle
41266922|NCT00619957|DRUG|Placebo tablet|one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
41266923|NCT00619957|DRUG|Risedronate|one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
41266924|NCT02185378|PROCEDURE|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
41370538|NCT04524351|DRUG|Posiphen|Solid oral dosage form, capsule
40847881|NCT02082600|OTHER|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
40847882|NCT02082600|OTHER|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
41030830|NCT03066531|BEHAVIORAL|CBT-based intervention|
41030831|NCT04377646|DRUG|Hydroxychloroquine|400 mg at day 1 and day 2, then 400 mg weekly up to 2 months
41030832|NCT04377646|DRUG|Hydroxychloroquine (placebo)|1 pill at day 1 and day 2, then 1 pill weekly up to 2 months
40847883|NCT05359601|PROCEDURE|Infusion set replacement intervals|24-hour or 96-hour infusion set replacement intervals
40847884|NCT04645589|DRUG|Myfortic|There is no treatment allocation. Patients administered Myfortic by prescription that have started before inclusion of the patient into the study will be enrolled.
41030833|NCT04377646|DRUG|Zinc|15 mg per day up to 2 months
41030834|NCT04377646|DRUG|Zinc (Placebo)|1 pill per day up to 2 months
41030835|NCT02693990|RADIATION|Intensity Modulated Proton Therapy (IMPT)|Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)
41030836|NCT00147186|DEVICE|Hylan G-F 20|
41030837|NCT05622981|BEHAVIORAL|Age-specific educational materials and monitoring|Subjects will receive age-specific behavioral modification and educational materials plus every 2-week monitoring for goals and progress at reducing BMI for 24 weeks in the pediatric primary care clinic.
41030838|NCT04837365|OTHER|Three dimensional gait analysis with eyetracking|An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.
41030839|NCT03096418|DRUG|Paclitaxel|Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
41030840|NCT04506970|DIAGNOSTIC_TEST|Comprehensive Doppler Ultrasound of the Placenta|Ultrasound measures to be collected include uterine artery (UtA) and umbilical artery (UA), systolic/diastolic (S/D) ratio, resistance index (RI), pulsatility index (PI) and presence of early diastolic notch.
41030841|NCT04506970|OTHER|Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging)|In addition, a Verasonics ultrasound scanner will be used for ultra-sensitive Doppler imaging. Data will be collected on vessel density, periphery-to-center vessel density ratio (VDR) and microvessel morphology.
41370539|NCT04524351|DRUG|Placebo|Solid oral dosage form, capsule
41370540|NCT06175468|DRUG|Formosa 1-Breath Free (NRICM101)|After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.
41370541|NCT06175468|DRUG|Placebo control drug|After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.
41370542|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets.|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
41370543|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
41370544|NCT02042807|DRUG|Placebo|
41370545|NCT02042807|DRUG|MCS®|
41370546|NCT05783011|PROCEDURE|Electroacupuncture|Electroacupuncture was applied bilaterally to the LI4, ST5 and ST6 acupuncture points before and after periodontal flap surgery
41370547|NCT05783011|PROCEDURE|periodontal flap surgery|periodontal flap surgery
40847885|NCT01426776|PROCEDURE|heart valve replacement|The patients with heart valve disease and CSR will be received heart valve replacement
40847886|NCT03291652|DIAGNOSTIC_TEST|DSA/3DRA|DSA/3DRA
41030842|NCT03976362|BIOLOGICAL|Pembrolizumab|IV infusion
41030843|NCT03976362|DRUG|Carboplatin|IV infusion
41030844|NCT03976362|DRUG|Paclitaxel|IV infusion
41030845|NCT03976362|DRUG|Nab-paclitaxel|IV infusion
41370548|NCT01070225|DRUG|Hydrocortisone/ Placebo and Propranolol|Hydrocortisone 400mcg Propranolol 10mg or 20 mg
41370549|NCT00681434|BEHAVIORAL|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
41370550|NCT00681434|BEHAVIORAL|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
41370551|NCT03539666|OTHER|diet|dietary patterns
41370552|NCT00015912|BIOLOGICAL|recombinant interferon alfa|Given IV
41030846|NCT03976362|DRUG|Olaparib|Tablets
41030847|NCT03976362|DRUG|Placebo|Placebo to olaparib, tablets
41030848|NCT00803634|DRUG|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
41370553|NCT00015912|DRUG|thalidomide|Given orally
41370554|NCT00015912|OTHER|laboratory biomarker analysis|Correlative studies
41503286|NCT04060862|DRUG|Placebo|Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
41370555|NCT03143075|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
41370556|NCT03093558|BEHAVIORAL|ECA/Kardia|Use of the ECA and Kardia daily for 30 days.
41370557|NCT01780948|DRUG|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
41370558|NCT01780948|DRUG|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
41370559|NCT03110367|BEHAVIORAL|Pain Reframing Intervention|Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).
41370560|NCT03110367|BEHAVIORAL|Attention Control Group|Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
41370561|NCT00002037|DRUG|Trifluridine|
41370562|NCT03585166|PROCEDURE|lpaparoscopic hepatectomy|laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
41370563|NCT03585166|PROCEDURE|open hepatectomy|open hepatectomy: open hepatectomy for hepatocellular carcinoma
41370564|NCT05915507|OTHER|pranayama plus acupoint stimulation by laser|"This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for eight weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )"
41370565|NCT05915507|OTHER|acupoint stimulation by laser|This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints, the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
41370566|NCT04002466|OTHER|Risk factors for anemia|Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
41370567|NCT00525499|DRUG|ASC-J9 cream|Topical application to the face twice daily for 12 weeks.
41370568|NCT00525499|DRUG|placebo|vehicle control applied topically twice daily for 12 weeks
41370569|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
41370570|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + collagen membrane|Minimally Invasive Surgery Technique (MIST) + collagen membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
41370571|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST)|Minimally Invasive Surgery Technique in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
41370572|NCT04149366|DEVICE|Retainer|Orthodontic retainer
41370573|NCT01314508|DRUG|Increlex|Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
41370574|NCT02351050|DEVICE|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
41370575|NCT02351050|OTHER|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
41370576|NCT05697406|DRUG|Hyperpolarized 13C-Pyruvate|Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
41370577|NCT02035891|DRUG|colchicine 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
41503287|NCT04060862|DRUG|Palbociclib|Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
41370578|NCT02035891|DRUG|placebo 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
41370579|NCT05385783|DRUG|CYB003|CYB003 is a synthetic psilocybin analog.
41370580|NCT05385783|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
41370581|NCT05385783|DRUG|Placebo|Placebo
40847887|NCT03473795|BEHAVIORAL|Questionnaire forms|The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
40847888|NCT03473795|OTHER|Bio-specimen samples|Samples can include tissue, blood, urine, saliva, hair and nail clipping.
41370582|NCT05385783|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
41370583|NCT03465215|DEVICE|Digital holographic microscopy|Tissue obtained from CD patients will be analyzed using digital holographic microscopy. Results will be compared between non-stenotic and stenotic tissue of the intestinal wall of CD patients.
41370584|NCT01694927|PROCEDURE|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
41370585|NCT04401462|PROCEDURE|Tension band wiring or plate fixation|Operative fixation of olecranon fracture with either of the methods mentioned in the intervention name
41370586|NCT04401462|BEHAVIORAL|Sling or a long-arm plaster|Non-operative treatment and progressive range of motion as tolerated. A long-arm plaster will be used, if necessary, for pain relief.
41503288|NCT04060862|DRUG|Fulvestrant|Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
41503289|NCT01769560|BEHAVIORAL|MeFirst Tailored Intervention|Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
41503290|NCT05910801|PROCEDURE|Biopsy|Undergo biopsy
41503291|NCT05910801|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41503292|NCT05910801|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41503293|NCT05910801|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41503294|NCT05910801|PROCEDURE|Computed Tomography|Undergo CT scan
41503295|NCT05910801|DRUG|Lenalidomide|Given PO
41503296|NCT05910801|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
41503297|NCT05910801|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41503298|NCT05910801|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
41503299|NCT05910801|BIOLOGICAL|Tafasitamab|Given IV
41503300|NCT05910801|DRUG|Venetoclax|Given PO
41503301|NCT04906421|DRUG|TVB-2640|Oral dose, tablet
41503302|NCT04906421|OTHER|Placebo|Oral dose, tablet
41162625|NCT01195740|BEHAVIORAL|Attachment Based Family Therapy|ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
41162626|NCT01195740|BEHAVIORAL|Enhanced Usual Care|"Belmont offers the Therapeutic Bridge Program, funded by the Pew Charitable Trusts, which helps adolescents make the transition from the hospital back to home, school and community behavioral health services. The program serves as a bridge between inpatient and outpatient care during the first 90 days after discharge, linking them to supportive services. Aftercare begins at the point of intake. Several discharge planning meetings are held with the adolescent and parents during the inpatient stay. The range of services are based on the patient and families' need, and may include meeting with school personnel , conducting home visits or making referrals to other community services agencies. The main objective is to secure outpatient mental health services for the patient. These services will be enhanced by the weekly research tracking, assessment and 24-hour crisis phone line which will call into a cell phone rotated among the licensed mental health professionals on the research team."
41162627|NCT02949076|BEHAVIORAL|Exercise|Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
41162628|NCT01878383|DEVICE|Genexpert assay|
41162629|NCT05266157|OTHER|Manual lymph drainage|Manual lymph drainage
41162630|NCT05266157|OTHER|Usual care|skin care, exercise and compression stocking
41162631|NCT01319864|DRUG|Plerixafor Dose Escalation|"Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy."
41162632|NCT04589390|DRUG|Selexipag|treatment with selexipag
41162633|NCT06539416|PROCEDURE|MitraClip implantation|The MitraClip is used to catch the leaky parts of the mitral valve, and it is tested to ensure the leak is reduced.
41162634|NCT04015596|DRUG|Naproxen Sodium|Dosed by weight (10mg/kg), twice daily, for 8 weeks
41503303|NCT01068262|DRUG|Odanacatib|Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
40847889|NCT02448589|DRUG|TAS-119|
40847890|NCT00005994|DRUG|ondansetron|
41503304|NCT01068262|DRUG|Comparator: Placebo|Oral Placebo tablet administered once weekly for 4 consecutive weeks
41503305|NCT05467696|DRUG|CTP-543|For each period, subjects will be dosed with CTP-543 12 mg (1 x 12 mg tablet)
41503306|NCT04348695|DRUG|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days"
41503307|NCT04348695|OTHER|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
41503308|NCT04657926|DRUG|APPA|APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) \& 2-hydroxy-4-methoxyacetophenone (2H4MA).
41503309|NCT04657926|DRUG|Placebo|Placebo capsules
41503310|NCT02642848|PROCEDURE|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
41503311|NCT02642848|PROCEDURE|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
41503312|NCT02642848|PROCEDURE|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
41503313|NCT01312571|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
41503314|NCT01312571|BEHAVIORAL|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
41503315|NCT02547090|PROCEDURE|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
41370587|NCT03330340|PROCEDURE|Percutaneous Vertebroplasty|The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.
41162635|NCT04015596|OTHER|Placebo|Participants take placebo pills twice daily, for 8 weeks.
41162636|NCT06379555|PROCEDURE|Walanpoigne|Intervention will combine WALANT anesthesia with arthroscopy to reduce a joint fracture of the wrist
41162637|NCT02760472|DRUG|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
41030849|NCT00803634|DRUG|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
41370588|NCT00857701|DEVICE|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
41370589|NCT03808415|DEVICE|EMG-driven|The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
41370590|NCT03321773|DRUG|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
41503316|NCT05873933|OTHER|Hemptress Oil|Full ingredient list of the test product: Rubus occidentalis (Black raspberry) seed oil\*, Carica papaya (Papaya) seed oil\*, Bixa orellana (Annatto) seed oil\*, Orbignya oleifera (Babassu) seed oil\*, Borago officinalis (Bourrache) seed oil\*, Daucus carota (Carrot) seed oil\*, Hibiscus sabdariffa (Hibiscus) seed oil\*, Aronia melanocarpa (Chokeberry) seed oil\*, Vaccinium macrocarpon (Cranberry) seed oil\*, Moringa oleifera (Moringa) seed oil\*\*, Persea americana (Avocado) oil\*, Ribes nigrum (Black currant) seed oil\*, Copaifera officinalis (Copaiba) resin\*, Canabis sativa (Hemp) seed oil\*, Moringa peregrina seed oil extract \& Caprylic/Capric Triglyceride\*\* (Moringa peregrina extract), Ascorbyl tetraisopalmitate (Vitamin C), Proprietary full-spectrum blend of Cannabis sativa (Hemp) extract, Silica (Algica), Ergocalciferol (Vitamin D2), Menaquinone (Vitamin K2), Tocopherol (Vitamin E)\* Organic Ingredient\* Wild Crafted/Regenerative\*\*
41503317|NCT05352347|DRUG|NuSepin® 0.2 mg/kg|NuSepin® 0.2 mg/kg in 100mL NS bid
41030850|NCT01381172|DEVICE|Optimizer System|The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
41030851|NCT01381172|OTHER|No intervention: Optimal medical therapy|The control group receives optimal medical therapy only.
41162638|NCT02760472|DRUG|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
41162639|NCT00655668|DRUG|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
41162640|NCT03529084|DRUG|EFG816|It will be administered orally daily.
41162641|NCT03529084|DRUG|erlotinib or gefitinib|"Investigator's choice between erlotinib or gefitinib. These will be locally sourced.~Erlotinib will be administered orally daily. Gefitinib will be administered orally daily."
41162642|NCT02275845|DRUG|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
41162643|NCT02275845|OTHER|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
41162644|NCT01001130|DRUG|fluticasone furoate group|patients who are administered fluticasone furoate at least once
41162645|NCT04770740|DIETARY_SUPPLEMENT|Vitamin K2 in the form of Menaquinone-7 (MK-7)|Patients will take three tablets of vitamin K2 menaquinone-7 (333mcg) per day. Patients taking vitamin K2 MK-7 will receive the total of 999mcg per day from day 1 until day 14 or discharge, whichever occurs earlier. All subjects can be treated with prophylactic or therapeutic heparin-based (heparin or any low-molecular weight heparin) anticoagulants, according to local hospital protocols. Provided by Kappa Bioscience.
41370591|NCT03321773|DRUG|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
41503318|NCT05352347|DRUG|NuSepin® 0.4 mg/kg|NuSepin® 0.4 mg/kg in 100mL NS bid
41503319|NCT05352347|DRUG|Placebo|Normal saline (NS) 100mL bid
41503320|NCT03795038|DEVICE|Lipoprotein Apheresis MONET and DALI|Three apheresis treatments assigned to one type of apheresis system of MONETand DALI
41162646|NCT04770740|DIETARY_SUPPLEMENT|Placebo|Patients will take three tablets of placebo containing only inactive ingredients per day, from day 1 until day 14 or until discharge, whichever occurs first. The placebo is provided by Kappa Bioscience.
41162647|NCT02108418|DRUG|TG-2349 as the original formulation|single oral dose under fed condition
41162648|NCT02108418|DRUG|TG-2349 as a new capsule formulation|single oral dose under fed condition
41370592|NCT00005990|DRUG|tipifarnib|
41370593|NCT00005990|DRUG|topotecan hydrochloride|
41370594|NCT06469333|BEHAVIORAL|Eye movements (EM)|The participant focuses on the intrusive thought and visually follows the horizontal movement of a white dot (Ø 1 cm) on the black computer screen 8 times for 24 seconds.
41370595|NCT06469333|BEHAVIORAL|Auditory stimulations|"The participant focuses on the intrusive thoughts and hears the auditory beeps through the headphones provided 8 times for 24 seconds."
41370596|NCT06469333|BEHAVIORAL|Tactile stimulations|The participant focuses on the intrusive thought and applies tactile self-stimulation 8 times for 24 seconds.
41030852|NCT01828502|BEHAVIORAL|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
41030853|NCT01828502|BEHAVIORAL|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
41370597|NCT00322517|DRUG|SU014813|100 mg capsule/day for 6 cycle of 21 days
41370598|NCT03710681|BIOLOGICAL|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
41370599|NCT05685446|OTHER|Ice water|Ingestion of 175 ml iced tap water 15 minutes prior to elective gastroscopy
41370600|NCT01699321|BEHAVIORAL|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
41370601|NCT01699321|OTHER|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
41370602|NCT02730975|DRUG|AA Reduced dose-normal diet (A)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
41370603|NCT02730975|DRUG|AA reduced dose-fat diet (B)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
41370604|NCT02730975|DRUG|AA normal dose-fasting conditions (C)|Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
41370605|NCT05861024|OTHER|Bladder Augmentation|Bladder Augmentation using bowel loop (ileal or sigmoid loop)
41503321|NCT03795038|DEVICE|Lipoprotein Apheresis DIAMED and DALI|Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI
41503322|NCT04521127|OTHER|Kinesio Taping|Taping will be performed on sitting position with contralateral lateral flexion and flexion of the neck, using muscle technique with I strip and stretching the head at the maximum level in order to benefit from the muscle release effect. Kinesio tape was applied directly on muscle with 0% stretching.
41503323|NCT04521127|OTHER|Dry needling|The trigger point on the taut band will be held with the thumb and forefinger from below and above. In the needling technique, a 0.25 \* 25-mm with nickel handle, disposable sterile steel acupuncture needle will be used. The needle tip will be inserted perpendicularly into the subcutaneous tissue and inserted into the muscle until the trigger point in the taut band was found. The same point will be pinned 8-10 times with fast needle movements inside and out. Then the needle tip will pulled back so that it did not come out of the skin, and the bottom, top and sides of the first entered point were also pinned. This procedure was applied to all trigger points in the trapeze muscle.
41503324|NCT02607267|OTHER|LSG and LRYGB|The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
41503325|NCT05358080|DRUG|Entelon Tab. 50mg|twice daily for 24months
41370606|NCT06175052|OTHER|Dietary Intervention|Four nutrition counselling sessions conducted over eight weeks, in conjunction with food items to assist in meal preparation and with weekly educational information messages sent via email.
41370607|NCT03659032|PROCEDURE|Pediatric Manual Therapy|
41370608|NCT03659032|PROCEDURE|Educational Physical Therapy|
41370609|NCT03961347|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
41370610|NCT03961347|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
41370611|NCT05849649|BEHAVIORAL|BumptUp|The app contains a number of evidence-based, expertly designed features to help women with healthier lifestyle habits during and after pregnancy.
41503326|NCT05358080|DRUG|Placebo|twice daily for 24months
41503327|NCT02837848|PROCEDURE|Coactivation Strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
41503328|NCT02837848|PROCEDURE|Regular Strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
41503329|NCT00912613|OTHER|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
41030854|NCT03400540|DIAGNOSTIC_TEST|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
41030855|NCT05865470|DRUG|Cannabis|smoked cannabis
41030856|NCT05865470|DRUG|Dronabinol|Oral delta-9-THC
41030857|NCT05865470|DRUG|Smoked Placebo|Placebo Cannabis
41030858|NCT05865470|DRUG|Oral Placebo|Oral Placebo
41162649|NCT02659384|DRUG|Bevacizumab|
41370612|NCT05849649|BEHAVIORAL|Educational Brochure|An evidence-based brochure on physical activity
41370613|NCT05244902|DRUG|5% Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
41370614|NCT06011668|DEVICE|video game playing, kaleidoscope and virtual reality glasses|This thesis study was conducted with randomized controlled methods for control in order to analyze the effect of drawing attention to different directions during intramuscular use in countries to what extent the methods of drawing attention to pain and anxiety.
41370615|NCT03741816|DRUG|Indirect pulp capping|Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
41370616|NCT01471652|DRUG|Nutraceutical supplements|"1. CoEnzyme Q10: oral gel capsule bid~2. Acetyl L-carnitine: oral capsule bid~3. Alpha Lipoic Acid: oral tablet qd~4. Docosahexaenoic acid: oral gel capsule bid"
41370617|NCT01471652|DRUG|Placebo|"Capsule form to imitate the following nutraceuticals:~1. Placebo 1: oral gel capsule bid~2. Placebo 2: oral capsule bid~3. Placebo 3: oral tablet qd~4. Placebo 4: oral gel capsule bid"
41370618|NCT02190604|DRUG|Placebo|Capsule- oral dose
41370619|NCT02190604|DRUG|QBW251|Capsule - oral dose
41370620|NCT02675881|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
41370621|NCT02675881|DEVICE|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
41370622|NCT02844829|OTHER|Prostate MRI|MRI of the prostate prior to prostate biobsy
41370623|NCT05090592|DEVICE|orthokeratology|orthokeratology wearing for myopia control
41370624|NCT05090592|DRUG|0.01 atropine|0.01% atropine eye drop prevent myopic progression
41370625|NCT05090111|DRUG|ALG-055009|Single or multiple doses of ALG-055009
41370626|NCT05090111|DRUG|Placebo|Single or multiple doses of Placebo
41370627|NCT01613209|DRUG|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
41370628|NCT01613209|DRUG|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
41162650|NCT02659384|DRUG|atezolizumab|
41162651|NCT02659384|DRUG|acetylsalicylic acid|
41162652|NCT02659384|DRUG|placebo|
41162653|NCT01062971|DRUG|dorzolamide-timolol-brimonidine|Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
41162654|NCT02702336|BEHAVIORAL|EYTO-kids|To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
41370629|NCT04249908|DRUG|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d.
41370630|NCT03179137|OTHER|Standard therapy|Patients with therapy prescribed independent of the study
41370631|NCT05541107|DRUG|MAT2203|oral lipid nanocrystal amphotericin B
41370632|NCT05541107|DRUG|Amphotericin B|Intravenous Amphotericin B
41370633|NCT04299958|OTHER|Patient diary|In the first visit they will be examined by a neurologist with experience in headache disorders and NH diagnosis will be reviewed. Patients will be invited to participate into the study and they will provide and sign informed consent form. They will be instructed and trained to complete the prospective headache diary during 14 days. A follow up visit will be done within 15 to 30 days to review the data and analyze possible sources of bias.
41370634|NCT04284241|BEHAVIORAL|Parents'Health-Education Handbook|We created a Parents' Health-Education Handbook to teach the newborns' parents to enhance their knowledge of pediatric stone, with a view to changing parents' cognition, attitude and behavior for preventing pediatric stone formation by this cluster randomized control trail.
41370635|NCT05005923|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
41162655|NCT05004311|DRUG|Cenerimod|A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions
41370636|NCT05839366|DRUG|Esketamine|"Load dose of 0.25 mg/kg, and the fixed infusion rate of 0.15 mg/kg/h.The load dose will be injected intravenously within 1-2 minutes.Maintain the infusion at a fixed rate of 0.15 mg/kg/h for 72 hours; after 72 hours, change to a fixed rate infusion of 0.06 mg/kg/h.~Preparation: 46ml of saline + 4ml of eskeamine."
41370637|NCT05839366|DRUG|Saline|As a placebo,normal saline at the same dose as esketamine.Saline is also administered intravenously.
41370638|NCT05839366|DRUG|Remifentanil + propofol|Remifentanil + propofol
41370639|NCT05839366|PROCEDURE|Pain and Sedation Assessment|"RASS Score:~After randomization success, a baseline Richmond Agitation-Sedation Scale (RASS) score is obtained before administering the investigational drug. Pain assessments are conducted every 1 hour within the first 6 hours after the initiation of the intravenous loading dose of the investigational drug, every 4 hours within the first 24 hours, and subsequently every 8 hours until the end of the study. In addition to the fixed time points mentioned above, researchers may conduct RASS scoring at any time based on the subject's actual condition (excessive or inadequate sedation). (No further RASS scoring is performed once the subject is fully awake.)~CPOT Score:~CPOT（Critical-Care Pain Observation Tool）Pain assessments are conducted concurrently with RASS scoring."
41370640|NCT01700218|OTHER|telemonitoring|
41370641|NCT01700218|OTHER|control|
41370642|NCT00938275|DRUG|0.5g SRT2104|"SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment."
41370643|NCT06426901|OTHER|Effects of Tan Tui Exercises on Strength and Performance of Football Players.|Tan Tui, Exercises Tan Tui, is a style of traditional Chinese martial art that emphasizes leg techniques, agility, and conditioning. Basic Kicking Drills. Stance Work. Forms (Taolu) Pattern Drills. Conditioning.Sparring (San Shou). This protocol will be implemented by District Physiotherapist who will visit the mentioned Football academies in group session.
41162656|NCT06210399|PROCEDURE|Extracorporeal Shockwave Therapy|3 to 6 shock wave treatment sessions will be performed (PiezoWave 2 Control Unit Generator, classification 93/42/EEC class IIb), with a frequency of two sessions per week.
41162657|NCT01916642|DRUG|Lidocaine 1mg/kg|The total dosage of Etomidate needed for induction of anesthesia is recorded at last.
41162658|NCT01916642|DRUG|Lidocaine 1.5mg/kg|same as other
41370644|NCT00645606|BIOLOGICAL|Rituximab|rituximab :500 mg/m² every 8 weeks during 2 years
40847891|NCT05184816|DRUG|Deferoxamine (DFO)|The accelerated single-patient dose escalation will apply to dosing cohorts 1 through 4 (10mg, 30mg, 60mg, 100mg) and will convert to a 3+3 dose escalation for cohorts 5 through 9 (150mg, 210mg, 280mg, 372mg, 495mg).
40847892|NCT03330470|BEHAVIORAL|exercise|participants will be subjected to 3 months supervised exercise intervention
40847893|NCT03330470|DIETARY_SUPPLEMENT|carnosine supplementation|participants will be instructed to take carnosine 2 times daily
40847894|NCT03330470|BEHAVIORAL|stretching|participants will be subjected to 3 months supervised stretching program
40847895|NCT03330470|DIETARY_SUPPLEMENT|supplementation with placebo|participants will be instructed to take placebo 2 times daily
40847896|NCT02085330|DEVICE|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
40847897|NCT00446173|DRUG|Busulfan|130 mg/m\^2 IV Daily Over 3 Hours x 4 Days
40847898|NCT00446173|DRUG|Cyclophosphamide|60 mg/kg IV Daily Over 4 Hours x 2 Days
40847899|NCT00446173|DRUG|G-CSF|10 mcg/kg Subcutaneously Once Daily
40847900|NCT00446173|DRUG|GM-CSF|250 mcg/kg Subcutaneously Once Daily
40847901|NCT06431269|OTHER|Screening for neurodevelopmental disorders by an advanced practice nurse|Screening for neurodevelopmental disorders by an advanced practice nurse with Ages \& Stages Questionnaires (ASQ-3) and Haute Autorité de Santé (HAS) identification scale
40847902|NCT02478528|DEVICE|Energy-Light lamp|Exposure of the subject, at 5am, to the light source of Energy-Light lamp (Philips)
40847903|NCT02478528|DEVICE|Luminettes lamp|Exposure of the subject, at 5am, to the light source of Luminettes lamp (Lucimed)
40847904|NCT02478528|OTHER|control condition|No exposure of the subject to any light sources (control condition)
40847905|NCT01217372|DIETARY_SUPPLEMENT|Lemon supplementation|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
40847906|NCT02635997|DRUG|antiresorptive therapy|
40847907|NCT02861599|OTHER|proprioceptive therapy|
40847908|NCT02861599|OTHER|speech therapy|
41370645|NCT00396357|DRUG|Vildagliptin|
41370646|NCT00396357|DRUG|metformin|
41370647|NCT00246675|DRUG|Frusemide|
41503330|NCT03279692|DRUG|Pembrolizumab|pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
40847909|NCT02696239|DEVICE|V-lock suture|
40847910|NCT02696239|DEVICE|Vicryl Suture|
40847911|NCT02696239|DEVICE|Lapra-Ty II|
41030859|NCT03082963|DEVICE|Electrogram Morphology Mapping (EMR)|Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium \& then the left atrium.
41503331|NCT00753662|DEVICE|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
41503332|NCT00753662|DEVICE|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
40847912|NCT01694836|BIOLOGICAL|s.c. injection|3 years of therapy followed by 2 years (seasons) of treatment-free observational period
40847913|NCT01324869|BIOLOGICAL|KH902|Intravitreal injection of 0.5mg/eye/time KH902
41030860|NCT05724186|DEVICE|Test myopia control lenses (CSL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
41503333|NCT00753662|DEVICE|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
40847914|NCT00004113|DRUG|temozolomide|
40847915|NCT01123707|DRUG|Aripiprazole|Aripiprazole oral capsules
40847916|NCT01123707|DRUG|Escitalopram|Escitalopram oral capsules
40847917|NCT03092635|DRUG|OPC|OPC is a derivative of grape seed extract
40847918|NCT04908865|DRUG|Belimumab|Belimumab will be administered.
40847919|NCT04908865|DRUG|Standard therapy|Standard therapy will be continued.
40847920|NCT05018104|OTHER|This is not an interventional study|This study utilizes data from the St. Paul's Hospital Peripheral Nerve Block Database.
40847921|NCT03087292|OTHER|Resistance training with vascular occlusion|Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
40847922|NCT03479710|BIOLOGICAL|FMT infusion|Fecal microbiota transplantation via OGD
40847923|NCT03678168|OTHER|Throat Pack|Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)
40847924|NCT03678168|OTHER|Pharyngeal Tampons|Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
40847925|NCT02356848|BEHAVIORAL|Tailored Intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.
40847926|NCT02356848|BEHAVIORAL|Current Practice (CP)|this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
41030861|NCT06529952|PROCEDURE|hysteroscopic surgery by resection and endocoagulation|resection of lower edge, resection of upper edge and endocoagulation
41030862|NCT06529952|PROCEDURE|hysteroscopic surgery by endocoagulation only|hysteroscopic endocoagulation to the base of the niche by roller ball
41030863|NCT06529952|DRUG|hormonal treatment|using 3rd generation contraceptive pills
41030864|NCT04078282|BEHAVIORAL|Intervention group|see above
41030865|NCT02609243|BEHAVIORAL|dietary consulting|dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
41370648|NCT04823494|DEVICE|Hearing aids|Earbud style hearing aids fit to both ears
41370649|NCT03056534|DEVICE|R3 Biolox Delta Ceramic Acetabular System|All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).
41162659|NCT01916642|DRUG|Lidocaine 2mg/kg|same as other
41503334|NCT06104943|OTHER|Heredity for cardiovascular disease|First degree relatives with a diagnosis of Cardiovascular disease.
41162660|NCT01916642|DRUG|Lidocaine 2.5mg/kg|same as other
41162661|NCT02253745|DRUG|V81444|V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14
41162662|NCT02253745|DRUG|Placebo|Capsules to match V81444 twice daily for 13 days and once on Day 14
41162663|NCT00084747|DRUG|bortezomib|
41162664|NCT00598286|DRUG|[18F]FMPEP-d2|
41162665|NCT05694936|DRUG|Sodium Valproate|Sodium valproate oral continuously in a twice daily dose (Initial dose of 600mg/d up-titrated to target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL); Refer to arm description.
41162666|NCT05694936|DRUG|Panitumumab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
41503335|NCT06104943|OTHER|Heredity for pancreatitis|First degree relatives with a diagnosis of pancreatitis.
41503336|NCT06104943|OTHER|Heredity for type 2 diabetes|First degree relatives with a diagnosis of type 2 diabetes.
41503337|NCT06104943|OTHER|Heredity for hypertriglyceridemia|First degree relatives with hypertriglyceridemia
41503338|NCT06249815|COMBINATION_PRODUCT|Misoprostol 200mcg Tab|ranscervical Foley catheter (silicone, size 20F with 30ml balloon)+Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
41030866|NCT06478784|OTHER|Resistance training|"The experimental group (ACTIVE GROUP) will perform a circuit-based muscular strength program at high intensity three days per week for 10 weeks.~Each session will last approximately 45 minutes.~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid."
41030867|NCT06478784|OTHER|Low aerobic training|"Patients assigned to this group will perform exercise in static bicycle during 45 minutes three days a week, with a duration of 10 weeks.~This second group, despite performing the aerobic exercise, is considered control, since they will perform low-intensity aerobic exercise (50% of the maximum power developed in cycloergometer)~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid."
41030868|NCT04602624|DRUG|SAGE-718|SAGE-718 oral tablets.
41030869|NCT01140035|OTHER|Administration of continuous insulin infusion for glycemic control in brain dead donors|As per protocol
41030870|NCT00620308|DRUG|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
41030871|NCT00620308|DRUG|Placebo|Dextrose 5% in water (the vehicle)
41030872|NCT02845908|DRUG|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
41030873|NCT02845908|DRUG|FOLFOX|Oxaliplatin plus Leucovorin plus 5-FU
41162667|NCT05694936|DRUG|Cetuximab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
41162668|NCT04532983|PROCEDURE|fixation of mesh prosthesis|in the first group mesh was fixed in position with laparoscopic tacks
41162669|NCT04532983|PROCEDURE|mesh placement without fixation|mesh placement in preperitoneal space without fixation
41162670|NCT01359878|DRUG|Fibrinogen Concentrate|2 gram intra venous
41162671|NCT01359878|DRUG|Isotonic Saline|Isotonic saline in equivalent volume - 100 ml
41162672|NCT01521689|DRUG|Rituximab|Low doses of sub cutaneaous rituximab
41162673|NCT05844033|OTHER|Screening|Blood tests
41162674|NCT03051529|OTHER|combined spinal epidural anesthesia|After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
41162675|NCT02548754|DEVICE|Parasym device|
41162676|NCT01802892|DRUG|Ronacaleret 100 mg|Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
41503339|NCT06249815|DRUG|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
41030874|NCT02845908|DRUG|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally PAC
41030875|NCT01857544|DRUG|Aflibercept|Monthly 2.0mg Aflibercept Intravitreal Injection
41030876|NCT04771169|OTHER|vestibular Training Group|this Group will receive vestibular Adaptation \& Balance exercises
41162677|NCT01802892|DRUG|Ronacaleret 400 mg|Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
41162678|NCT01802892|DRUG|Plerixafor|Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
41162679|NCT01124214|PROCEDURE|endomicroscopy|endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
41162680|NCT03459521|BIOLOGICAL|Fendrix or HBVAXPRO 40|To administer hepatitis B virus vaccines in patients with chronic liver disease that have not been previously vaccinated.
41162681|NCT02041221|DRUG|SPARC1316 Dose 1|The subjects will receive SPARC1316.
41162682|NCT02041221|DRUG|Placebo|
41162683|NCT02041221|DRUG|SPARC1316 Dose 2|
41162684|NCT02041221|DRUG|SPARC1316 Dose 3|
41162685|NCT02041221|DRUG|SPARC1316 Dose 4|
41162686|NCT02041221|DRUG|SPARC1316 Dose 5|
41162687|NCT03810287|DRUG|Domperidone|Domperidone will be prescribed for patients with upper GI symptoms at an initial dose of 10 mg up to 4 times a day (prior to each meal and at bedtime). It is possible that the dose of domperidone may be increased to 20 mg if symptoms are not adequately controlled on the initial dose.
41030877|NCT04771169|OTHER|Virtual Reality Group|This Group will receive Virtual Reality Training by using exergaming.
41030878|NCT04474184|PROCEDURE|Biospecimen Collection|Receive vaginal kit for biospecimen collection
41030879|NCT04474184|BEHAVIORAL|Focus Group|Attend focus group
41030880|NCT04474184|OTHER|Survey Administration|Ancillary studies
41370650|NCT01886105|DRUG|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg."
41370651|NCT01886105|OTHER|Autologous Stem Cell Infusion|"Administered 14 days after Treatment infusion of Samarium-153 EDTMP."
41370652|NCT01886105|RADIATION|External Beam Radiotherapy|"The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary."
41370653|NCT04523363|DRUG|Metformin|Maximum dosage of 500 mg tablets 2 times a day (with each meal)
41370654|NCT05152524|DEVICE|Tigertriever 13|patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO) will be treated with the Tigertriever 13 device.
41030881|NCT06627504|BEHAVIORAL|Sleep Health and Circadian Timing Intervention|Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.
41030882|NCT04015648|BIOLOGICAL|ChAdOx1 Zika|Single dose of ChAdOx1 Zika at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
41162688|NCT03769077|DEVICE|Exergaming|This study involves the use of multiplayer exercise video games or 'exergames' that incorporate an avatar powered by pedaling a recumbent stationary bicycle. The Liberi suite of exergames contains six mini-games, including a combination of cooperative games, competitive games and individual games designed to be fast-paced, action-oriented, and enjoyable for youth with special needs.
41370655|NCT02860650|BIOLOGICAL|Ad26.Filo|Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).
41030883|NCT04947111|DIAGNOSTIC_TEST|Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue|"Indirect IgG ELISA to estimate seroprevalence: The seropositivity will be evaluated with the Indirect IgG ELISA following the instructions of the Panbio E-DEN 01 G manufacturer, which has a specificity of 98% and a sensitivity of 100%. In brief, 10 microliters of participant serum will be used for each assay. Each kit provides a positive and negative control, as well as three calibrators, with the respective values for quality control. Samples will be classified as positive, negative or indeterminate according to the cut-off point for each ELISA kit.~Neutralizing antibody titers serotype-specific: To establish the type of humoral immunity that the selected city presents, the measurement of the neutralizing antibody titers will be carried out by means of the neutralization test by reducing the number of lytic plaques to 50% (PRNT50%) , using Vero cells and the following reference strains for each serotype: DENV-1 (HAWAI), DENV-2 (NEW GUINEA), DENV-3 (H-887) and DENV-4 (H-24)"
41162689|NCT04295850|DRUG|Aspirin 81 mg|Aspirin 81mg daily PO
41162690|NCT00618384|DRUG|Sorafenib|patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
41162691|NCT00465907|DRUG|Paclitaxel, Carboplatin and Irinotecan|Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
41370656|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).
41370657|NCT02860650|BIOLOGICAL|Ad26.ZEBOV|Ad26.ZEBOV intramuscular (IM) injection at a dose of 5\*10\^10 vp.
41162692|NCT01974934|DRUG|Desvenlafaxine Succinate|
41162693|NCT01912183|BEHAVIORAL|Communication through PHR outside clinic|
41162694|NCT01912183|BEHAVIORAL|Monitoring device in PHR|
41162695|NCT01912183|DEVICE|Physical activity and sleep monitor|
41162696|NCT01912183|OTHER|PHR|Access to their PHR
41162697|NCT04308213|DEVICE|Marrow Cellution System|The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.
41162698|NCT00212277|DRUG|Norethindrone,Ethinyl Estradiol|
41370658|NCT02860650|BIOLOGICAL|Placebo|IM injection of 0.9 percent saline.
41370659|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 1\*10\^8 Inf U.
41370660|NCT01361308|DRUG|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
41370661|NCT01361308|DRUG|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
41370662|NCT03218657|DRUG|levamisole hydrochloride|levamisole hydrochloride take orally 150mg qod
41370663|NCT03218657|DRUG|Androgens|Androgens take orally 80mg qd
41370664|NCT03218657|DRUG|Cyclosporins|Cyclosporines take orally 3-5mg/kg\*d qd
41503340|NCT03620045|BEHAVIORAL|Acute moderate physical activity|For 20 minutes, participants will walk on a treadmill at a moderate intensity based on a combination of evidence-based and pre-determined parameters, including ratings of perceived exertion and heart rate
41370665|NCT03186794|OTHER|Treadmill exercise training|30 minutes of continuous treadmill walking at a target intensity or use of an interval approach in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each session will last about 60 minutes but slightly longer if an interval approach is used.
41030884|NCT06512662|PROCEDURE|Consultations with paramedics|"Patients of experimental arm will beneficiate of supplemental consultations with paramedics intervenants at 1 month, 3 months and 6 months after surgery :~* dietetician~* speech therapist~* psychologist~* advanced practice nurse~During these consultations, several scales will be performed to assess the patient's condition (anxiety, nutritional status, psychological condition, speech therapy status)."
41030885|NCT04478279|DRUG|ST101|ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm
41370666|NCT04310241|BEHAVIORAL|Patching therapy, Glasses|Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
41370667|NCT04716205|OTHER|Mulligan Bent Leg Raise Technique|Participant will be in supine lying on a high couch with the resting on the shoulder. A distraction (longitudinal traction force along the long axis of femur) will be investigator in walk stand position lateral to the leg, which to be stretch. Hip and Knee of the side to be stretch will bent at 90˚- 90 ˚. Participant's flexed knee will be placed over the shoulder, the popliteal fossa of the knee applied at the lower end of femur and the participant will ask to push the shoulder with his or her leg followed by voluntary relaxation.The traction will maintained throughout the technique.
41370668|NCT04716205|OTHER|Static Stretching|It will be given in supine position by performing passive SLR and end range will hold in 30sec.
41370669|NCT05859594|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
41370670|NCT04435652|DRUG|QL1604|3mg/kg, D1,8,15,Q4w, IV infusion
41370671|NCT04435652|DRUG|Nab-paclitaxel|100mg/m2, D1,8,15,Q4w, IV infusion
41370672|NCT04435652|DRUG|Paclitaxel|80mg/m2, D1,8,15,Q4w, IV infusion
41370673|NCT01869959|DRUG|LY2405319|Administered SC
41370674|NCT01869959|DRUG|Placebo|Administered SC
41370675|NCT01813162|DRUG|Tenofovir 1% gel|
41370676|NCT01813162|DRUG|Vaginal product|
41370677|NCT06274281|DEVICE|Digital Telerehabilitation|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Wearable devices: each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for monitoring of movement data (i.e., activity level, number of steps, distance travelled) during daylife activities and rehabilitation sessions. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level."
41030886|NCT04478279|DRUG|Temozolomide|Temozolomide
41162699|NCT05074277|BEHAVIORAL|Simulated short term night shift work schedule|Participant sleep schedules (in the experimental arm) will be modified to simulate short-term (3 consecutive nights) night shift work schedule (kept awake at night and offered sleep opportunities during the day instead) in each of two inpatient stays.
41162700|NCT01574014|BEHAVIORAL|CBGT|Cognitive-behavioral group therapy
41370678|NCT06274281|OTHER|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
41370679|NCT00187005|DRUG|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
41370680|NCT00187005|DRUG|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
41370681|NCT00002600|BIOLOGICAL|filgrastim|
41370682|NCT00002600|DRUG|carboplatin|
41370683|NCT00002600|DRUG|cyclophosphamide|
41370684|NCT00002600|PROCEDURE|autologous bone marrow transplantation|
41370685|NCT00002600|PROCEDURE|peripheral blood stem cell transplantation|
41370686|NCT04656249|DRUG|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.
41030887|NCT04478279|RADIATION|Radiation|Radiation
41030888|NCT06410066|OTHER|no intervention|
41030889|NCT06632041|DIAGNOSTIC_TEST|Complete blood count|Study haemtological disturbances in neonates with necrotizing enterocolities
41030890|NCT06632041|OTHER|Complete blood count|Haemtological disturbances in neonates with necrotizing enterocolities
41162701|NCT01574014|DRUG|Hydrocortisone|3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
41162702|NCT01574014|DRUG|Placebo|Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
41162703|NCT00170417|BEHAVIORAL|Cognitive Behaviour Therapy|
41503341|NCT06222879|DRUG|HRS-8080; SHR-A1811|Participants will receive HRS-8080 and SHR-A1811
41503342|NCT06222879|DRUG|HRS-8080; SHR-A2009|Participants will receive HRS-8080 and SHR-A2009
41503343|NCT06222879|DRUG|SHR-A2009; SHR-1316|Participants will receive SHR-A2009 and SHR-1316
41370687|NCT00684658|BEHAVIORAL|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
41370688|NCT00684658|BEHAVIORAL|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
41370689|NCT02503215|DEVICE|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
41370690|NCT03445936|DEVICE|Parietene Macro|Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
41370691|NCT03445936|DEVICE|Permacol|Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
41370692|NCT00906776|DEVICE|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
41370693|NCT00906776|DEVICE|Autogenous bone|Autogenous bone application during periodontal surgery
41370694|NCT01711736|BIOLOGICAL|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
41370695|NCT01711736|BIOLOGICAL|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
41370696|NCT02837250|BEHAVIORAL|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
41370697|NCT02837250|BEHAVIORAL|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
41370698|NCT02301949|DRUG|Thalidomide|Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
41370699|NCT02301949|OTHER|Placebo|Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
41370700|NCT03414099|DRUG|Ketum|Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
41503344|NCT02849938|DEVICE|TytoCare Device|Tyto is a handheld, mobile device designed for capture and transmission of ear/throat/skin images and lung/heart auscultations. It may be used to perform non-invasive, medical examinations, either on a patient (by another person, most commonly a family member, or by a medical professional) or self-performed by the patient, for remote review by a medical practitioner. It is suitable for use on patients in both clinical and home environment.
40847927|NCT04058886|BEHAVIORAL|Telephone-delivered Mindfulness|The telephone-delivered mindfulness training intervention that will incorporate the following elements: 1) training for primary caregivers (CG) and their caregiving partner (CP) in a telephone-based mindfulness training intervention; 2) groups of up to eight participants (four CG-CP pairs) plus an instructor, on a shared telephone line; and 3) training in a 8-week, modified MBSR program, which places additional emphasis on training in the following: a) mindful experiencing, including mindfulness of feelings and body sensations; b) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking; and c) mindful compassion for self and others. Additionally, homework assignments will involve listening to exercises on a dial-in telephone line; and assignments for CG-CP dyads (e.g. mindful listening and communication practices) as well as CG mindfulness practices in the presence of care recipients (e.g. mindful eating, and mindful listening).
40847928|NCT02815423|BIOLOGICAL|UCMSCs|Transplatation of umbilical cord mesenchymal stem cells
41370701|NCT03414099|DRUG|Placebo|Placebo drink matched for taste and appereance
41370702|NCT00811499|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
41370703|NCT00811499|DRUG|Placebo; oral|matching placebo
41370704|NCT00811499|DRUG|Placebo; oral|multiple dose, single schedule
41370705|NCT04651569|OTHER|Observational study|none, Observational study
41370706|NCT01913613|DEVICE|IASD|IASD device implantation
41370707|NCT02127866|DRUG|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
41370708|NCT02127866|DRUG|Foster 100/6 µg|"Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
41503345|NCT00256399|DRUG|Alfuzosin 10 mg|
41503346|NCT02274831|OTHER|Email Reminder of need to follow up with primary physician|
41503347|NCT05640258|DIAGNOSTIC_TEST|rotatory chair testing in a velocity step protocol.|Tc was evaluated by the rotational velocity step test using the OtoaccessTM interface (Interacoustics Nydiag 200, Middlefart, Denmark). Subjects were seated on the rotatory chair wearing videonystagmography goggles with their heads supported and tilted 30° forward, thus bringing the horizontal semicircular canals plane perpendicular to the axis of rotation. Standard videonystagmography techniques were employed to record eye-movements. Subsequent to eye movements' calibration, the chair was accelerated about the yaw axis at 30°/sec2 to a maximal velocity of 90°/sec, followed by rotation at a constant velocity. After 57 seconds of constant velocity rotation, the chair was decelerated to zero velocity at 30°/sec2. The described velocity step was conducted both clockwise and counter-clockwise, giving a total run time of 4 minutes.
41503348|NCT02916667|OTHER|dietary guidelines|dietary guidelines will include chrono- nutrition diet plan
40847929|NCT02815423|BIOLOGICAL|Percutaneous|Percutaneous injection
41370709|NCT04996212|PROCEDURE|Walking APP Group|"The participants of this group will be explained their treatment plan by a physiotherapist who will contact them through a video call. This treatment will consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of aerobic exercise: walking.~Participants will consult their treatment plan through an application that will be installed on their mobile phone. They will start with 25 minutes of walking and will increase progressively until they reach 45 minutes.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.~Participants must perform the proposed exercises, 5 days a week, once a day In addition to the respiratory physiotherapy guideline, they will be given the health education manual."
41370710|NCT04996212|PROCEDURE|Functional APP group|"The participants of this group will be explained their treatment regimen by a physiotherapist who will contact them through a video call. This treatment planwill consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of functional exercise which involve the activation and performance of large muscle groups. Participants will consult their treatment plan through an application that will be installed on their mobile phone.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment."
41370711|NCT00968565|DRUG|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
41370712|NCT01077908|BIOLOGICAL|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
41370713|NCT01077908|DRUG|Best available antiviral drug therapy|"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
41370714|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
41370715|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
41370716|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
41370717|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
41266925|NCT02185378|PROCEDURE|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
41266926|NCT04461821|DIAGNOSTIC_TEST|Real-time SESI-MS breath analysis|Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.
40847930|NCT02122224|OTHER|High fiber breakfast|Breakfast will contain 10-11g fiber.
41266927|NCT04461821|DIAGNOSTIC_TEST|Off-line breath analysis|In young children below the age of 4 not capable of completing the on-line exhalation maneuvers, or in cases when the patient needs cannot approach the mass spectrometer, the sample will be collected off-line. They will be asked to exhale into a bag that will be transported to the lab and deflated into the mass spectrometer for analysis. Exhaled breath of patients under anesthesia will also collected using available ventilation system in the operation theatre.
41266928|NCT04461821|DIAGNOSTIC_TEST|Blood analysis|Blood analysis done in patients who undergo regular blood sampling needed for clinical routine laboratory controls. This includes i) children and adolescents receiving medications which require TDM ii) patients with acute diseases such as TD1 and pneumonia and iii) patients with chronic diseases such as asthma bronchiale. For those patients where a blood sample is drawn during the clinical routine, an additional blood sample consisting of only several blood drops will be collected using the same blood sampling line. No additional venous puncture for research purpose will be done.
41266929|NCT04461821|DIAGNOSTIC_TEST|Saliva analysis|During the diagnostic and therapeutic work-up of T1D patients, saliva samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
41266930|NCT04461821|DIAGNOSTIC_TEST|Urine analysis|During the diagnostic and therapeutic work-up of T1D patients, urine samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
41266931|NCT04713761|DRUG|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with MPM received surgical treatment (PD/EPP) after neoadjuvant therapy. Patients who were unable to operate or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
41266932|NCT02844790|DRUG|insulin degludec/insulin aspart|A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
41266933|NCT00522067|BIOLOGICAL|Adjuvanted influenza vaccine|Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
41266934|NCT00361738|DRUG|AVE2268|
41266935|NCT00382148|DRUG|omalizumab|SC repeating dose
41266936|NCT02908100|DRUG|GDC-0853|Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.
41266937|NCT02908100|DRUG|Placebo|Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
41266938|NCT05302323|OTHER|Disposable Drape|Disposable surgical drapes, consisting of 6 pieces, were used as a set during surgery
41266939|NCT05302323|OTHER|Reusable Drape|Reusable surgical drapes, consisting of 6 pieces, were used as a set during surgery
41503349|NCT01269931|PROCEDURE|EBUS-TBNA|Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
41370718|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
41503350|NCT04935359|DRUG|NIS793|Concentrate for solution infusion (Liquid in Vial)
41503351|NCT04935359|DRUG|Nab-paclitaxel|Per locally approved formulation
41503352|NCT04935359|DRUG|Gemcitabine|Per locally approved formulation
41503353|NCT04935359|DRUG|Placebo|Dextrose 5% in water (D5W) solution for infusion
41503354|NCT01178528|DRUG|ivabradine|7.5 mg bd
41503355|NCT01178528|DRUG|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
41503356|NCT01178528|DRUG|Carvedilol|25 mg bd
41503357|NCT01009502|DRUG|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
41503358|NCT03977714|DEVICE|Zirconia implants with G3-coated abutments (test implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
41503359|NCT03977714|DEVICE|Zirconia implants with control abutments (test implants, negative control abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
41370719|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
41370720|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
40847931|NCT02122224|OTHER|High Protein Breakfast|Breakfast will contain 19-20g of protein.
40847932|NCT02122224|OTHER|High Protein/High Fiber Breakfast|Breakfast will include 19-22g of protein and 10-12g of fiber.
40847933|NCT01605721|DEVICE|XIENCE PRIMETM everolimus-eluting coronary stent|"Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM"
40847934|NCT02997982|DRUG|Valaciclovir 500Mg Tablet|Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
41370721|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
41370722|NCT00984646|DRUG|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
41370723|NCT01400659|PROCEDURE|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
41162704|NCT01848262|PROCEDURE|ECALMIST|Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.
41370724|NCT01400659|PROCEDURE|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
41370725|NCT04365556|BEHAVIORAL|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
41370726|NCT01326312|DRUG|GTx-758 1000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
41370727|NCT01326312|DRUG|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
41370728|NCT01326312|DRUG|GTx-758 2000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
41370729|NCT02223637|BIOLOGICAL|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
41370730|NCT04329156|OTHER|Digitally Flip Technique|A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.
41370731|NCT04329156|OTHER|Stock Healing Abutment|After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
41370732|NCT03780920|PROCEDURE|manual therapy/osteopathy|"In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes"
41370733|NCT02905695|DRUG|Chirocaine|
41370734|NCT02905695|OTHER|Placebo|
41370735|NCT03358407|DRUG|GSK2983559|GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
41370736|NCT03358407|DRUG|Placebo|Placebo oral capsules matching GSK2983559 will be available for subjects.
41370737|NCT04822467|DEVICE|SQ53 Wipe|SQ53-based wipe to be used by the participant daily or upon dressing change
41370738|NCT04822467|DEVICE|Ethanol Wipe|Ethanol-based wipe to be used by the participant daily or upon dressing change
41503360|NCT03977714|DEVICE|Titanium implants with G3-coated abutments (control implants, test abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
41370739|NCT03371602|PROCEDURE|surgery|a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.
41370740|NCT03371602|PROCEDURE|multi-organ sampling|a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
41370741|NCT04235127|OTHER|sociodemographic variables, somatic conditions, mental disorders, treatment and drug use|"* sociodemographic variables~* history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.~* prescriptions for psychopharmacological products~* the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide"
41370742|NCT04155567|DRUG|TAK-123|TAK-123 infusion
41370743|NCT06235086|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
41370744|NCT06235086|DRUG|Dulaglutide|Dulaglutide, SC, once a week
41370745|NCT05059561|RADIATION|X-ray radiograghy|Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
41370746|NCT05056363|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
41503361|NCT03977714|DEVICE|Titanium implants with control abutments (negative control implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
41370747|NCT05056363|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
41370748|NCT00845351|DRUG|Bexarotene|bexarotene at 300 mg/m2/day
41370749|NCT03011385|BEHAVIORAL|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
41370750|NCT03011385|BEHAVIORAL|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning."
41370751|NCT03011385|BEHAVIORAL|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
41370752|NCT03011385|BEHAVIORAL|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
41370753|NCT04281095|DRUG|Botulinum toxin type A|Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
41370754|NCT03873662|DIAGNOSTIC_TEST|Blood sample|Biochemical markers will be recorded as follows: as soon as possible after the arrival of the patient and insertion of a intravenous line, blood will be drawn for the analysis of arterial blood gases, which are a standard test in patients admitted to emergency department. Blood will be analysed in a bed-side analyzer. Serum lactate and base-excess (BE) will be documented from this blood sample. Another blood sample will be drawn parallelly for biochemical tests which will be sent to the laboratory. These tests standard in patients admitted to emergency department. Serum concentration of NSE and S100B protein will be analysed and recorded from this sample. A sample of blood for the evaluation of the early dynamics of the serum concentration of NSE and S100B will be redrawn after 12 and 48/24 hours after admitting the patient.
41370755|NCT00131001|PROCEDURE|contrast-enhanced magnetic resonance angiography|
41370756|NCT04749901|OTHER|Psycho-emotional and semiological measures|Surveys, interviews and measures
41370757|NCT01969331|DIETARY_SUPPLEMENT|Normia|One capsule twice a day/14 days
41503362|NCT03977714|DEVICE|Zirconia implants and titanium implants, for histological and histomorphometric evaluation.|"6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth (non useful sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary."
40847935|NCT05894655|BEHAVIORAL|COVID-19 walk-up, on-site testing strategy|This strategy is a no-appointment, walk-up point-of-care PCR and rapid testing strategy for clinic patients and community members. It will be offered 5 days/week for 7 hours during the first 3 months of the trial at Clinic 1. The intensity will decrease over the trial ending with 1 SYH Medical Assistant overseeing the testing protocol. Bilingual research staff will be trained to oversee onsite testing.
41030891|NCT06246877|BEHAVIORAL|virtual reality applied group|"Before the K-wire is removed and dressed, the three-dimensional video that the child likes and wants to watch will be placed on virtual reality glasses and attached to the child.~During the procedure, the child will be allowed to watch videos through virtual reality glasses."
41370758|NCT01969331|DIETARY_SUPPLEMENT|Placebo|maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171)
41370759|NCT00000509|BEHAVIORAL|diet, sodium-restricted|
41370760|NCT00000509|BEHAVIORAL|diet, potassium-supplementation|
41370761|NCT03957343|DEVICE|Pacing and Planning App|Participants will download and use the Pacing and Planning app through mybrainpacer.ca. The app will be used to track and monitor their daily tasks and symptoms at any time, for as long as they would like to use the app. While using the app, participants will also fill out short assessments, including the Rivermead Post-Concussion Questionnaire once a month (to monitor symptoms) and an overall symptom question once a week (to rate how they feeling in general from a lot better to a lot worse).
41370762|NCT00138281|BIOLOGICAL|FluMist|
41370763|NCT00138281|BIOLOGICAL|Fluzone|
41370764|NCT01062529|DRUG|Somatostatin|4 h of 150 microgram infusion
41370765|NCT03358017|DRUG|Zoledronate|4 mg i.v. every 3/4 weeks for 6 months
41370766|NCT03358017|DRUG|Atorvastatin 80mg|80mg /die os for 6 months
41370767|NCT03358017|DRUG|Standard neoadjuvant cht|Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice
41370768|NCT06360159|OTHER|Intervention|As an intervention, the newborn will be massaged.
41370769|NCT06311981|RADIATION|carbon ion radiotherapy|The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.
41370770|NCT06311981|OTHER|targeted therapy|targeted therapy
41370771|NCT06311981|OTHER|single regimen chemotherapy in sequence with radiotherapy|single regimen chemotherapy in sequence with radiotherapy
41370772|NCT02046551|DRUG|Atomoxetine|
41370773|NCT02046551|DRUG|Placebo|
41370774|NCT01172860|DEVICE|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
41030892|NCT03542643|DIETARY_SUPPLEMENT|n-3 Polyunsaturated fatty acid|1g of Eicosapentaenoic acid (EPA)
41030893|NCT03542643|DIETARY_SUPPLEMENT|Placebo|Olive oil ethyl esters
41370775|NCT04037826|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
41370776|NCT04037826|DIETARY_SUPPLEMENT|Placebo|Placebo
41370777|NCT02008162|DRUG|Bronchodilators|Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
41370778|NCT01355380|DRUG|Inhaled iloprost (Ventavis, BAYQ6256)|Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
41370779|NCT03351426|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
41370780|NCT01196754|OTHER|sevoflurane|
41030894|NCT03085563|DRUG|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.
41030895|NCT03085563|DRUG|Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
41030896|NCT01060215|PROCEDURE|Normal saline|20 cc normal saline injection into the knee joint
41030897|NCT03668145|PROCEDURE|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
41030898|NCT05239091|DRUG|Dextrose solution|A total of 3 doses of dextrose prolotherapy will be administered with an interval of 2 weeks.
41030899|NCT05239091|DRUG|Lidocain|A total of 3 doses of lidocaine will be administered with an interval of 2 weeks.
41030900|NCT05995912|DRUG|etoricoxib-tramadol|Oral administration (with or without food)
41162705|NCT01848262|PROCEDURE|InSure|Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
41162706|NCT04306549|OTHER|Bulk-Fill and Microhybrid Composite Resins|Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias
41162707|NCT00202306|DRUG|lithium carbonate|
41370781|NCT01016366|DRUG|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
41370782|NCT01016366|DRUG|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
41370783|NCT03058549|BEHAVIORAL|Family Expectations|Relationship education and referral services for expectant couples.
41370784|NCT04465591|DIAGNOSTIC_TEST|troponin T fragmentation test|laboratory test from blood sample
41370785|NCT00201630|DRUG|Uroxatrol (drug)|
41370786|NCT03899038|PROCEDURE|spinal anesthesia|Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
41370787|NCT04731740|DRUG|Lenvatinib|PO
40847936|NCT05894655|BEHAVIORAL|Community Health Worker (CHW) leading testing navigation and general preventive care reminders|This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.
41030901|NCT05995912|DRUG|Naproxen|Oral administration (with or without food)
41030902|NCT05995912|DRUG|Tramadol|Oral administration (with or without food)
41030903|NCT03359980|DRUG|fecal microbiota transfer|transfer of fecal microbiota from healthy donors to the patients
41030904|NCT05820724|DIAGNOSTIC_TEST|PSMA PET scan|Subjects will undergo DCFPyL PET/CT imaging and mpMRI imaging prior to the prostate biopsy. The decision for biopsy targets will be made based on the combination of the findings of mpMRI and PSMA scans. The intervention includes a mpMRI, a PSMA PET scan, and a prostate biopsy.
41370788|NCT04731740|BIOLOGICAL|Pembrolizumab|IV
41370789|NCT04731740|DRUG|Chemotherapy|Investigators' choice
41370790|NCT02259777|DRUG|Telmisartan/Amlodipine|Fixed dose combination tablet
41370791|NCT02259777|OTHER|high fat, high caloric meal|
41370792|NCT03350529|DEVICE|MRI guided transurethral HIFU ablation of prostatic tissue|The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
41370793|NCT01711424|DRUG|OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
41370794|NCT00889928|DEVICE|NOTES GEN 1 Toolbox|"* Articulating Hook Knife~* Articulating Snare~* Articulating Needle Knife~* Articulating Graspers~* Articulating Biopsy Forceps~* Steerable Flex Trocar with Rotary Access Needle~* Flexible Bipolar Hemostasis Forceps~* Flexible Maryland Dissector"
41370795|NCT01733758|DRUG|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
41370796|NCT01733758|DRUG|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
41370797|NCT01733758|DRUG|Placebo|Albiglutide matching placebo will be available as a pen injector
41370798|NCT01733758|DRUG|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
41370799|NCT04856566|DRUG|Low Marijuana, Hash, THC, or Grass|Cannabis with low amount of THC
41370800|NCT04856566|DRUG|High Marijuana, Hash, THC, or Grass|Cannabis with high amount of THC
41370801|NCT04856566|DRUG|Placebo|Placebo drug with no THC
41370802|NCT04856566|DRUG|0.05 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.05
41162708|NCT01154465|PROCEDURE|Central Venous Catheter Insertion|"The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.~The patients' skin disinfection before catheter insertion and care will follow the protocol:~* Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).~* Rinse with sterile water and then drying.~* First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.~* Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.~After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed."
41370803|NCT04856566|DRUG|0.08 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.08
41370804|NCT04298307|OTHER|Intracoronary lithotripsy (ICL)|ICL using the Shockwave catheter.
41030905|NCT05820724|OTHER|No PSMA PET|Subjects will undergo mpMRI imaging prior to the prostate biopsy. These subjects do not undergo a PSMA PET scan prior to the prostate biopsy. The decision for biopsy targets will be made based on the findings of mpMRI. The intervention includes a mpMRI and a prostate biopsy.
41030906|NCT05820724|DRUG|18F- DCFPyl Injection|DCFPyL is a PSMA imaging ligand that was developed to enhance the detection of small lesions in the prostate or other pelvic areas. 18F- DCFPyl Injection will be administered prior to the PSMA PET/CT via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access under the direct supervision of study personnel.
41030907|NCT02758431|DRUG|Acyline|Acyline 300ug/kg injection will be administered on Day 0 and on day 14
41030908|NCT02758431|DRUG|Placebo Gel|Placebo gel packet applied daily for 28 days.
41030909|NCT02758431|DRUG|Placebo Tablet|Placebo oral tablet taken daily for 28 days.
41030910|NCT02758431|DRUG|Testosterone Gel|Testosterone Gel applied daily for 28 days
41030911|NCT02758431|DRUG|Arimidex|Arimidex Oral Tablet 1mg taken orally daily for 28 days
41030912|NCT03089424|DEVICE|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.
41030913|NCT03089424|DEVICE|PBMT active|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
41030914|NCT01269892|DIETARY_SUPPLEMENT|lactose-free milk|a milk without lactose
41030915|NCT01269892|DIETARY_SUPPLEMENT|conventional milk|a milk with lactose
41162709|NCT01154465|DEVICE|Ultrasound guidance|"The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.~A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method."
41162710|NCT00833183|DRUG|MAL|80 mg/g cream one administration with incubation for 90 minutes
41162711|NCT00087997|DRUG|STA-4783|
41162712|NCT00220597|BEHAVIORAL|Trauma-focused group therapy|
41370805|NCT01338311|DRUG|salbutamol|200mcg twice daily for a total of 7 doses
41370806|NCT01338311|DRUG|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
41370807|NCT03588494|COMBINATION_PRODUCT|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
41370808|NCT03588494|DRUG|Endostar for one cycle|Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
41370809|NCT03588494|DRUG|Endostar for two cycles|Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
41370810|NCT02184988|BIOLOGICAL|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
40847937|NCT05894655|BEHAVIORAL|No-cost self-testing kit vending machines|This strategy includes vending machines that will provide interactive instructions for accessing free self-testing COVID-19 kits located outside of clinics for patients and community members to use anytime. The vending machines will be available 24 hours/day, 7 days a week.
41030916|NCT02112526|DRUG|Acalabrutinib|
41370811|NCT04099901|DRUG|Anakinra|Subjects will be treated with a daily dose of 300 mg anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
41370812|NCT04099901|DRUG|Placebos|Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
41370813|NCT01825421|OTHER|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
41370814|NCT02337543|DRUG|NEO6860|NEO6860 is an NCE acting as a TRPV1 antagonist
41370815|NCT02337543|DRUG|Placebo|Placebo
41370816|NCT02402608|DIETARY_SUPPLEMENT|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
41370817|NCT02402608|DIETARY_SUPPLEMENT|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
41370818|NCT05179811|PROCEDURE|Hypnosis sessions|"* Physical examination~* Psychiatric Assessment~* VHI, SF-36, IPQ-R questionnaires~* Standardized voice recording~* 3 Standardized Hypnotherapy sessions~* CGI-I-Patient Questionnaire"
41370819|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
41370820|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
41370821|NCT01393652|DRUG|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
40847938|NCT02350738|OTHER|Period I MCET (8 wks)|MCET_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock_MCET group: mock-therapy (3 sessions/wk)
41162713|NCT01624298|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
40847939|NCT02350738|OTHER|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
40847940|NCT02350738|OTHER|Period II MCET (8 wks)|MCET_Mock group: mock therapy (MCET) (3 sessions/wk) Mock_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
40847941|NCT01750905|DRUG|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
40847942|NCT01750905|DRUG|Placebo|Vehicle (D5W) SQ
41162714|NCT04800133|BIOLOGICAL|Tozinameran|mRNA vaccine developed by BioNTech against COVID-19
41370822|NCT03551457|DIAGNOSTIC_TEST|Biopsy|Patient-derived xenograft treatment response phenotype.
41503363|NCT02290457|BEHAVIORAL|core strength training|"Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only."
41503364|NCT01544179|DRUG|Gefitinib|Investigational Drug
41162715|NCT04800133|BIOLOGICAL|CoronaVac|Inactivated virus vaccine developed by SinoVac against COVID-19, intramuscular
41370823|NCT03341559|DEVICE|Spatial Frequency Domain Imaging (SFDI)|Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS
41503365|NCT01544179|DRUG|Placebo|Matching placebo as comparator
41503366|NCT01544179|DRUG|Pemetrexed|Chemotherapy (concomitant therapy)
40847943|NCT03172156|GENETIC|ctDNA detection|To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
40847944|NCT03046225|DEVICE|Transcutaneous electrical nerve stimulation|TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
40847945|NCT03046225|DEVICE|Continuous passive movement device|CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
40847946|NCT03046225|OTHER|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
40847947|NCT03194438|BEHAVIORAL|Urban Zen Integrative Therapy (UZIT)|Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
40847948|NCT04113525|DEVICE|MyoRegulator™ System|Paired transcutaneous spinal and peripheral nerve stimulation
41162716|NCT04800133|BIOLOGICAL|CoronaVac, intradermal|Inactivated virus vaccine developed by SinoVac against COVID-19, intradermal
41162717|NCT01929577|DRUG|ASP015K|oral tablet
41370824|NCT04547829|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
40847949|NCT06584214|DIAGNOSTIC_TEST|Diagnostic test: Determine™ Syphilis Advanced test|The Determine™ Syphilis Advanced test is intended as an aid in detecting antibodies to Treponema pallidum in individuals with current or past infection.
40847950|NCT02469519|DRUG|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
40847951|NCT02469519|OTHER|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
41370825|NCT06371573|DIAGNOSTIC_TEST|ULTRASOUND EXAM AND MRI SCAN|Within two weeks from the US, each patient underwent an MRI of the upper abdomen to evaluate the splenic volume. MRI examinations were performed using a 3T Biograph mMR scanner (Siemens Healthcare, Erlangen, Germany) with 4-channel flex phased-array body coil. Routine clinical abdominal MRI acquisition includes coronal T2W Half-Fourier Acquisition Single-shot Turbo spin Echo imaging (HASTE), axial T1 Dual-echo FSE, axial T2 TSE Fat Sat, and an axial diffusion-weighted imaging (DWI).
41503367|NCT01544179|DRUG|Cisplatin|Chemotherapy (concomitant therapy)
41370826|NCT04537286|DRUG|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
41370827|NCT01826006|DEVICE|Excimer laser|
41370828|NCT01826006|DEVICE|Manual Thrombus Aspiration|
41370829|NCT00094146|DRUG|Sandostatin LAR Depot|
41370830|NCT02862743|OTHER|patients with metastatic melanoma|Blood sample to realize molecular characterization of melanoma
41370831|NCT02951143|DRUG|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
41370832|NCT02951143|DRUG|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
41370833|NCT02046993|BEHAVIORAL|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
41370834|NCT02046993|BEHAVIORAL|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
41370835|NCT01866605|DRUG|Midazolam|Intravenous midazolam 0.3 mg/kg
41370836|NCT01866605|DRUG|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
41503368|NCT04932161|PROCEDURE|Titanium Granules|After degranulation of the intrabony defect, titanium particles will be placed in the defect and will be sutured.
41503369|NCT04932161|PROCEDURE|Hydroxyapatite|After degranulation of the intrabony defect, hydroxyapatite will be placed in the defect and will be sutured.
41503370|NCT01657812|DRUG|dexmedetomidine|"Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery."
40847952|NCT04374058|OTHER|less-frequency hemodialysis|Patients of treatment group would be evaluated quarterly
40847953|NCT01032499|DRUG|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
40847954|NCT01032499|DRUG|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
41162718|NCT02811393|OTHER|Assess muscle function|Assess muscle function with hand grip test and sit and stand test
41370837|NCT01866605|DEVICE|Bair Hugger|Forced air warming
41370838|NCT02159872|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
41370839|NCT06269562|PROCEDURE|Serratus posterior superior intercostal plane block and clavipectoral plane block|The analgesic effectiveness achieved by the concurrent application of these two techniques was investigated.
41370840|NCT05805579|DIAGNOSTIC_TEST|Diaphragmatic echography|Diaphragmatic echography
40847955|NCT04556019|PROCEDURE|Hepatobiliopancreatic surgery|Different surgical techniques tailored to each patient´s pathology
40847956|NCT02741206|BEHAVIORAL|Bellevue ROSE Intervention|
41370841|NCT03127267|DRUG|Masitinib (6.0)|Masitinib (titration to 6.0 mg/kg/day)
41370842|NCT03127267|DRUG|Riluzole|Riluzole 50 mg tablet, treatment per os
41370843|NCT03127267|DRUG|Placebo|treatment per os
41370844|NCT03127267|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
41370845|NCT02190994|DRUG|Hydrocortisone|used intravenously
41370846|NCT02190994|DRUG|Prednisone|used as tablet form
41370847|NCT04877405|OTHER|No intervention|This observational study is not focused on therapeutic intervention
41370848|NCT00926146|BEHAVIORAL|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
41370849|NCT00926146|BEHAVIORAL|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
41370850|NCT01970020|DRUG|JNJ-38518168|Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
41370851|NCT04136509|PROCEDURE|sinus floor elevation|sinus floor elevation with the lateral technique
40847957|NCT02741206|BEHAVIORAL|Psycho-education session and usual, Standard of care Control|Psycho Education and usual, standard of care
41162719|NCT05131789|PROCEDURE|dementia case management information system|The investigators will develop an information system based on the data collected in our previous research, the content and method of dementia case management which will be established by the Delphi method, and then the dementia case management information system will be constructed accordingly.
41370852|NCT04136509|PROCEDURE|bone core biopsy|After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
41370853|NCT04136509|DEVICE|dental implant placement|During reentry after bone biopsy dental implants were placed.
41370854|NCT04136509|DIAGNOSTIC_TEST|Cone Beam Computed Tomography scans (CBCT)|Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
41370855|NCT01159652|DRUG|zaleplon|10 mg
41370856|NCT01159652|DRUG|zolpidem extended release|12.5 mg
41370857|NCT01159652|DRUG|bedtime placebo|placebo
41370858|NCT01159652|DRUG|middle of the night placebo|placebo
41370859|NCT04383652|OTHER|Biological sample and clinical data collection|Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
41370860|NCT02158949|BEHAVIORAL|mROAD|
41370861|NCT01489345|DRUG|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
41370862|NCT01489345|DRUG|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
41370863|NCT02189538|DIETARY_SUPPLEMENT|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
41503371|NCT03909880|OTHER|Kinesio tape|"Kinesio tape (kinesio taping; kinesio holding corporation,USA) was placed on the skin above muscle belly of finger flexor. There were three types of taping:~Taping20 condition - tape was pulled from the wrist to the proximal forearm. The two ends of the tape (\~5 cm) were held by the therapist and the middle area was pulled 20% additional tension.~TapingN condition - tape was pulled with neutral tension. Control condition - no taping."
40847958|NCT02741206|BEHAVIORAL|One Psycho-education session and usual, standard of care Control|
40847959|NCT00302757|DRUG|Radioimmunotherapy|
40847960|NCT00302757|PROCEDURE|allogeneic hematopoietic cell transplantation|
41370864|NCT02189538|DIETARY_SUPPLEMENT|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
41370865|NCT02538432|DRUG|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
41370866|NCT02538432|DRUG|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
41370867|NCT01359774|OTHER|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
41370868|NCT01359774|OTHER|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
41370869|NCT02956980|BIOLOGICAL|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
41370870|NCT05821166|DEVICE|moderate Whole Body Hyperthermia (mWBH)|Patients receiving 3-4 times mWBH
41370871|NCT01206296|DRUG|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
41370872|NCT02377258|OTHER|Non Interventional|
41370873|NCT06118216|PROCEDURE|rectus abdominis(RAM) and external oblique muscle(EOM) infiltration analgesia|After suturing the muscular fascia, an indwelling catheter was placed above the RAM and EOM and under the subcutaneous tissue and then sutured to the skin for fixation. Approximately 30 min before surgery completion, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter for IA. Additionally, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter every 12 h, starting 8 h postoperatively, injected four times.
41370874|NCT06118216|PROCEDURE|intravenous patient-controlled anesthesia|After completion of the operation, the anesthesiologist used the IPCA device; it was programmed with a background infusion rate of 2 mL/h, a bolus volume of 2 mL, and a lockout interval of 15 minutes. The 100 mL total volume of the PCA consisted of normal saline, 2.0 ug/kg sufentanil, and adjuvant antiemetic (tropisetron).
41503372|NCT03452137|DRUG|Atezolizumab|Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
41503373|NCT03452137|DRUG|Placebo|Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
40847961|NCT05419726|DRUG|Semaglutide Injectable Product (not provided by the study)|"Study Procedure:~Subjects that are to be started on semaglutide by their physician will be invited to participate in the study. If the subject is eligible and signs the consent form they will be enrolled in the study. There are three (3) study visits including Baseline/Visit 1 (prior to starting semaglutide), Visit 2 (at week 2-4) and Visit 3 (at week 18-20). The subjects undergo these tests at each visit: weight circumference measured, BMR testing, thermal imaging of BAT, and perform a 24 hour food recall."
40847962|NCT02823379|BEHAVIORAL|Physical Activity|A Smartphone delivered physical activity program
40847963|NCT02823379|BEHAVIORAL|Wellness|A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
40847964|NCT05335941|DRUG|Pemetrexed|Given by vein (IV)
40847965|NCT05335941|DRUG|Zimberelimab|Given by vein (IV)
40847966|NCT05335941|DRUG|Etrumadenant|Given by PO
40847967|NCT04518033|DEVICE|Various commercially available face coverings|Various commercially available face coverings
40847968|NCT05096949|OTHER|Home visit delivery strategy|A nurse will deliver and administer Cabenuva injection at patient's home
40847969|NCT00795080|PROCEDURE|Dynamic cervical MRI scans|Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
40847970|NCT03539575|OTHER|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
41370875|NCT04721431|DIAGNOSTIC_TEST|Myotonometric assessment|MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device
41370876|NCT02568501|BEHAVIORAL|Daily feedback|Daily feedback on glucose levels from wireless glucometers
41370877|NCT02568501|BEHAVIORAL|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
41370878|NCT01636102|BIOLOGICAL|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
41370879|NCT02822027|DRUG|human gamma globulin|human gamma globulin for preterm infants with encephalopathy of prematurities
41370880|NCT02822027|DRUG|non-human gamma globulin|Non-human gamma globulin for preterm infants with encephalopathy of prematurities
41370881|NCT04790214|OTHER|CHF Patients|Cardiac rehabilitation program on CHF patients on 06-08 weeks. Program will include: physical aerobic re-training, therapeutic education on CHF, psychological follow-up, nutritional education
41370882|NCT04179188|PROCEDURE|Bariatric surgery|Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)
40847971|NCT01185977|DRUG|Fluoxetine|one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
40847972|NCT01185977|DRUG|Placebo|One pill of PBO for 4 days then two pills of PBO thereafter
40847973|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
40847974|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
40847975|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
41370883|NCT00077870|DRUG|ocrelizumab|
41370884|NCT01934777|DRUG|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
41370885|NCT01934777|DRUG|placebo pearls|placebo
41503374|NCT02570594|OTHER|questionary|
41503375|NCT03698552|BIOLOGICAL|ADCT-602|Starting dose of ADCT-602: 30 μg/kg given by vein.
40847976|NCT01545440|DRUG|placebo|subcutaneous dose every 4 weeks
40847977|NCT06303245|OTHER|ABDOMINAL BINDERS|will be given abdominal binders along with basic physiotherapy care. Physiotherapy care will include sitting exercises such as deep breathing exercises, protected huffing technique will be performed to improve gases exchange and remove secretion. In supine exercises such as basic ROM, ankle pumps, pelvic rolling, leg sliding will be performed. Each exercise will be of 10 repetition. This exercise will be given for 2 days per week for 6 weeks. Along with these exercises education related postural management and breastfeeding positions will also be guided
41030917|NCT03348891|OTHER|Tumor biopsy specimens and blood samples|Tumor biopsy specimens (if feasible) and blood samples will be collected at Baseline, Week 6 Day 1 (blood sample only) and Week 12 Day 1.
41030918|NCT03239379|DRUG|BNZ132-1-40|Injectable peptide antagonist of IL-2, IL-9 and IL-15
41030919|NCT03239379|DRUG|Placebo|Normal Saline
41030920|NCT01278277|DIETARY_SUPPLEMENT|Saffron supplementation|Saffron supplementation 20 mg
41030921|NCT01278277|OTHER|placebo|placebo supplementation
41030922|NCT05111249|DRUG|Branaplam|messenger ribonucleic acid (RNA) splicing modifier
41030923|NCT05111249|DRUG|Placebo|Matching placebo oral solution once weekly
41030924|NCT06345105|DEVICE|Endoscreener QC|Artificial intelligence monitoring of effective withdrawal time
41030925|NCT00547560|DRUG|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
41030926|NCT01788683|PROCEDURE|Regenexx SD|stem cell treatment
41030927|NCT01788683|OTHER|Exercise Therapy|exercise therapy control
41030928|NCT05234138|OTHER|Blood Sample|Blood Sample
41030929|NCT03249623|DEVICE|Beacon Caresystem|The core of the system is a set of physiological models including pulmonary gas exchange, acid-base chemistry, lung mechanics, and respiratory drive. The Beacon Caresystem tunes these models to the individual patient such that they describe accurately current measurements. Once tuned, the models are used by the system to simulate the effects of changing ventilator settings. The results of these simulations are then used calculate the clinical benefit of changing ventilator settings by balancing the competing goals of mechanical ventilation.
41030930|NCT04287049|DRUG|Azithromycin|Azithromycin 250 mg PO daily
41030931|NCT01627093|OTHER|Medical Chart Review|Review of medical records
41030932|NCT01627093|OTHER|Questionnaire Administration|Complete questionnaires
41030933|NCT05481762|DEVICE|Aided read with contextflow DETECT Lung CT|Radiologists read chest CT scabs with and without the aid of contextflow DETECT Lung CT as a second reader
41030934|NCT00650468|DRUG|tacrolimus|Oral
41030935|NCT00650468|DRUG|CellCept|IV or Oral
41030936|NCT00650468|DRUG|steroids (methylprednisone or prednisone)|IV or Oral
41030937|NCT02405715|DRUG|Oxytocin nasal spray or placebo|
41030938|NCT05032703|DEVICE|Arm ergometer|"The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises."
41030939|NCT06635005|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41503376|NCT02568839|DRUG|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
41503377|NCT02568839|DRUG|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
41503378|NCT05189444|DRUG|Vonoprazan|20mg bid
41503379|NCT05189444|DRUG|Amoxicillin|0.75g tid
41503380|NCT05189444|DRUG|Esomeprazole|20mg bid
41503381|NCT05189444|DRUG|Amoxicillin|1.0g bid
40847978|NCT06303245|OTHER|TENS|will receive TENS with high frequency (F=100Hz and T=100μs), intensity according to patient's pain threshold, duration of 30 continuous minutes, 2 cm above and below incision, with electrodes transversally positioned and crossing the incision. Two treatment sessions will be done per week for the period of 6 weeks. This group will be given tens along with abdominal binders with basic physiotherapy care. (23) In this treatment female's abdomen will be measured by a standard inch tape, then, according to the abdominal circumference, the binder will be fastened for 6 weeks. The binder will be placed tightly at the lower abdominal level with the incision positioned at the middle part of the binder. Participants will be asked to note the time to record the duration of binder wearing before taking the break. The binder will be opened between 10 pm and 8 am. This group will be given abdominal binders along with basic physiotherapy care
41370886|NCT06071351|OTHER|motivational interviewing based training program|In addition to the informative brochure prepared by the researcher; A 6-session training program based on motivational interviewing, including nutrition, physical activity, smoking and alcohol use, will be held.
41370887|NCT06071351|OTHER|Routine practice|An informative brochure prepared by the researcher was given.
41370888|NCT01574924|OTHER|No intervention.|There are no interventions in this observational study.
40847979|NCT04557709|OTHER|Medical Chart Review|Review of medical charts
40847980|NCT01833572|DRUG|Gefitinib|Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
40847981|NCT01784718|DRUG|Buphenyl|
40847982|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
41370889|NCT03004898|BEHAVIORAL|multidisciplinary renal education|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
41370890|NCT05372991|DRUG|CBT-009|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
41370891|NCT05372991|DRUG|Vehicle|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
41370892|NCT05372991|DRUG|Atropine Sulfate|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
41370893|NCT04984304|BEHAVIORAL|Lifestyle modifications and Antireflux diet|Patients in Arm 1 - mild cough only slightly worsening the quality of life (VAS 1-3) will undergo treatment using lifestyle modifications and an Antireflux diet for 3 months.
41503382|NCT05189444|DRUG|Clarithromycin|0.5g bid
41503383|NCT05189444|DRUG|Bismuth potassium citrate|0.22g bid
41503384|NCT01777230|PROCEDURE|SPECT-CT sentinel node mapping|sentinel node localisation using the nuclear medicine technique SPECT-CT
41503385|NCT01777230|PROCEDURE|Magnetic Resonance Lymphangiography sentinel node mapping|Sentinel node localisation using Magnetic Resonance Lymphangiography
41503386|NCT01777230|PROCEDURE|Intra-operative sentinel node procedure|Open or (robot-assisted) laparoscopic sentinel node detection and resection.
41503387|NCT01655576|PROCEDURE|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
41503388|NCT01830790|DRUG|Sildenafil citrate|Single dose of 100mg Sildenafil citrate
41503389|NCT03516513|BEHAVIORAL|Problem Solving Therapy as Usual|Treatment as usual to deliver 6 weekly sessions to teach patients how to use the seven step process to solve problems.
41503390|NCT03516513|BEHAVIORAL|Assisted Problem Solving Therapy|Smart note assisted delivery of 6 weekly session to teach patients how to use the seven step process to solve problems
41503391|NCT03829787|DEVICE|Eye tracking|Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
41503392|NCT01509703|PROCEDURE|High flow therapy|Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
41503393|NCT02204228|DEVICE|TITAN™ Reverse Shoulder System (TRS)|All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
41503394|NCT00866879|DRUG|Sirolimus|Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
41370894|NCT04984304|DIAGNOSTIC_TEST|Extraesophageal reflux diagnostic|Patients in Arm 2 - moderate and severe cough that significantly worsen the quality of life (VAS 4-10) will undergo extraesophageal reflux diagnostics consisting of esophageal 24-hour pH/Impedance Reflux Monitoring and peptest study on fasting
41370895|NCT04271423|PROCEDURE|Ridge Preservation|Ridge Preservation using demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier.
41370896|NCT05979389|DRUG|Bicalutamide 50 mg|Bicalutamide capsules will be prepared from U.S. Pharmacopeia grade powder at a dose of 50 mg
41370897|NCT05979389|DRUG|Placebo|Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.
41370898|NCT01993290|DRUG|Ropivacaine|20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
41370899|NCT04334356|BEHAVIORAL|Mobile Web App|App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
41370900|NCT04567849|BEHAVIORAL|message|patient portal message
41370901|NCT04567849|BEHAVIORAL|provider|nudging calling the patient's provider
41370902|NCT04567849|BEHAVIORAL|tele-nurse|nudging calling the tele-nurse
41370903|NCT02950285|OTHER|Baseline alert|PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
41370904|NCT03292770|DEVICE|Flushing Catheter|A catheter will be used to performed a flushing of the cervical canal with culture media.
41370905|NCT00584610|DEVICE|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
41370906|NCT00584610|DEVICE|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
41370907|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test|self-collected direct anterior nares swab samples
41370908|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)|adult lay user collected anterior nares swab sample
41370909|NCT03044691|BEHAVIORAL|ResearchACTS software|screen patients for tobacco and nicotine product use (using the anticipate and ask components of the 6As) by having youth complete a tobacco and nicotine use screening tool using the ResearchACTS software.
41370910|NCT03674385|DIETARY_SUPPLEMENT|vitamin E|Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
41370911|NCT03674385|DRUG|Metformin|Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
41370912|NCT03674385|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
41370913|NCT02043002|PROCEDURE|18F-FDG-PET scan|
41370914|NCT00458133|BEHAVIORAL|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.
41370915|NCT00620126|OTHER|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
41370916|NCT00620126|OTHER|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
41370917|NCT06220929|DRUG|Mecobalamin|The drug Mecobalamin in the intervention group was divided into intravenous and oral formulations, with the intravenous formulation being used for the first 14 days of the experiment and the oral formulation for the second 14 days.
41503395|NCT00866879|OTHER|Demographic Data, Medical History, and Donor Data|Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
41503396|NCT00866879|PROCEDURE|Blood Draws for Control Group|Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
41503397|NCT00866879|PROCEDURE|Blood Draws for Experimental Group|This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
40847983|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
40847984|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
40847985|NCT05393024|DRUG|Belantamab mafodotin|MMRR patients included in Named Patient Program e Expanded Access Program
41370918|NCT06220929|DRUG|Ceftriaxone Sodium|Ceftriaxone sodium all intravenous formulations
41370919|NCT06220929|DRUG|Saline|The saline used in the control group was the same as the saline used in the experimental group to dispense the drug
41370920|NCT06220929|DRUG|Placebo|Placebo and Mecobalamin tablets look and smell the same.
41370921|NCT01269138|DRUG|plasma derived Factor VII|Treatment of bleeding episodes,treatment during surgery and prophylaxis
41370922|NCT01269138|DRUG|recombinant FVIIa|Treatment of bleeding episodes,treatment during surgery and prophylaxis
41370923|NCT01269138|DRUG|Fresh Frozen Plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
41370924|NCT01269138|DRUG|Activated Prothrombin Complex Concentrates|Treatment of bleeding episodes,treatment during surgery and prophylaxis
41370925|NCT01269138|DRUG|Virus Inactivated plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
41370926|NCT05480852|OTHER|Bis-GMA Free dental resin composite|Restorative Material
41370927|NCT04580875|PROCEDURE|Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children|
41370928|NCT04938869|OTHER|Educational Intervention|Receive basic diabetes mellitus education
41370929|NCT04938869|OTHER|Medical Device Usage and Evaluation|Use CGM device and app
41370930|NCT04938869|OTHER|Survey Administration|Ancillary studies
41370931|NCT01108861|DEVICE|GORE VIABAHN® Endoprosthesis|GORE VIABAHN® Endoprosthesis
41370932|NCT01108861|DEVICE|Plain old balloon angioplasty|Plain old balloon angioplasty
41503398|NCT00866879|PROCEDURE|Donor Blood Draws|Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
40847986|NCT06262243|OTHER|electric blankets|"While the patient is in surgery; An electric blanket will be placed under the bed mattress, and the bed will be placed on the electric blanket.~The bed sheet will be laid, and the blanket used in the clinic will be laid on top of the bed sheet.~-The electric blanket will be turned on at hot setting 20 minutes before the patient leaves the surgery. After the mother is placed in a heated bed, the electric blanket will be unplugged when the temperature reaches 36.5."
40847987|NCT03722524|DRUG|amlodipine / indapamide / perindopril arginine FDC|CCB / diuretic / ACE inhibitor
40847988|NCT02634827|DRUG|Decitabine|Given IV
40847989|NCT02634827|OTHER|Laboratory Biomarker Analysis|Correlative studies
40847990|NCT02634827|DRUG|Midostaurin|Given PO
40847991|NCT05347303|OTHER|Finding-oriented orthopedic manual therapy treatment combined with foam roller|Blind randomized controlled clinical trial, where a total of 87 people, men and women, of legal age, university athletes of collective disciplines will be evaluated. The experimental group will receive foam roller therapy and manual therapy guided by findings (n = 44) for 8 weeks.
40847992|NCT05347303|OTHER|Foam roller treatment|Subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
40847993|NCT01776723|DRUG|Ruxolitinib|In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
41030940|NCT06635005|OTHER|Dietary Intervention|Receive the Low-EDIH dietary pattern intervention
41030941|NCT06635005|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
41030942|NCT06635005|BEHAVIORAL|Motivational Interviewing|Undergo motivational interviews
41503399|NCT00866879|OTHER|Donor Information|Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
41503400|NCT00866879|PROCEDURE|Kidney Biopsy|Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
41030943|NCT06635005|OTHER|Nutritional Assessment|Participate in nutrition counseling
41030944|NCT06635005|OTHER|Questionnaire Administration|Ancillary studies
41503401|NCT06293469|PROCEDURE|Accelerated Flap Coverage Surgery|Timing of the flap surgery is with a goal of 72 hours from injury
41503402|NCT06293469|PROCEDURE|Standard of Care Flap Timing|Timing of the flap surgery is the standard of care flap timing for the participating institution.
41503403|NCT04766164|BEHAVIORAL|Survey|Data will be obtained via self-report from participants via a one-time Qualtrics survey.
41030945|NCT00489450|DRUG|SK3530|
41030946|NCT05273164|DEVICE|Computerized Cognitive Training|Participants will complete computerized cognitive training developed by Posit Science Corporation. For a description of the training paradigms please review arm descriptions.
41370933|NCT00984100|PROCEDURE|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
41370934|NCT01243853|DIETARY_SUPPLEMENT|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
41370935|NCT05474846|DRUG|Melatonin|Given by PO
41370936|NCT05474846|OTHER|Placebo for Melatonin|Given by PO
41370937|NCT05474846|DRUG|Melatonin|Given by PO
41370938|NCT05474846|DRUG|Methylphenidate|Given by PO
41370939|NCT03730259|OTHER|Web-based Tailored Intervention Preparation for Surgery|A Tailored Internet-based Preparation Program for Perioperative Anxiety and Pain (WebTIPS) is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent experience, and reduced resource utilization during the surgical episode. WebTIPS aims at reducing perioperative anxiety and pain in children via an internet-based platform with short message service (SMS) two-way communication between a healthcare provider and patient.
41370940|NCT03964142|OTHER|Cardiac rehabilitation|"Integrated cardiac rehabilitation program that includes supervised exercise training\*.~\* Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise)."
41370941|NCT01511367|DRUG|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
41370942|NCT01511367|DRUG|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
41370943|NCT01511367|DRUG|Flixotide|50ug 2 puffs twice daily
41370944|NCT01871870|DEVICE|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
41370945|NCT03273088|DRUG|Etanercept|A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
41370946|NCT05400434|BEHAVIORAL|Standard Parent-Child Interaction Therapy (PCIT)|PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.
41370947|NCT05400434|BEHAVIORAL|Natural Helpers (NH)|Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
41370948|NCT04295629|PROCEDURE|Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia|The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.
41370949|NCT04295629|PROCEDURE|Ilioinguinal nerve block|Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
41370950|NCT04980196|DIAGNOSTIC_TEST|urodynaemic studies|The Urodynamic studies carried out were : uroflowmetry and cystometry. The Uroflowmetry was performed by the gravimetric method Detrusor over activity was diagnosed when the patient has involuntary detrusor contractions during filling with or without leakage which may be spontaneous or provoked,
41370951|NCT05969626|BIOLOGICAL|5-dose group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
41370952|NCT05969626|BIOLOGICAL|5-dose group of control vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
41370953|NCT05969626|BIOLOGICAL|4-dose A group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14
41370954|NCT05969626|BIOLOGICAL|4-dose B group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 28
41370955|NCT03143465|DRUG|Calcitonin Gene-Related Peptide|
41370956|NCT03143465|DRUG|Sildenafil|
41370957|NCT03143465|DRUG|Placebo|
41370958|NCT00812968|DRUG|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
41370959|NCT00250666|PROCEDURE|PCT measurement|Peripheral blood samples were collected in the morning, using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, Allschwil, Switzerland). Circulating plasma PCT levels were measured with a time-resolved amplified cryptate emission technology assay (Kryptor PCT; Brahms AG, Hennigsdorf, Germany), with an assay sensitivity of 0.06 mg/L, approximately fourfold above mean normal levels. Measurements were performed 7 days a week.
41370960|NCT02598791|OTHER|IIGI+GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
41370961|NCT02598791|OTHER|IIGI+GLP-1|glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
41370962|NCT02598791|OTHER|IIGI+NaCl (placebo)|i.v. NaCl during isoglycemia
41370963|NCT02598791|OTHER|OGTT|50 g oral glucose tolerance test
41370964|NCT02598791|OTHER|IIGI+GIP+GLP-1|i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
41370965|NCT05963685|OTHER|standardized MT alarming system|Standardized alarming system via telephone loop in the primary thrombectomy centre triggered immediately after decision to mechanical thrombectomy in stroke patients admitted in primary stroke centers
41370966|NCT06297642|DRUG|TQB2928 injection|Anti-CD47 monoclonal antibody
41370967|NCT06297642|DRUG|Penpulimab|Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
41370968|NCT04427241|DRUG|Cerebrolysin|30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
41370969|NCT04427241|DRUG|Control|100 ml normal saline, days 4-17, once/day, IV
40847994|NCT02939768|OTHER|High-intensity interval training (HIIT)|The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit \~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed \~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
40847995|NCT02939768|OTHER|Strength training (ST)|ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
40847996|NCT02939768|OTHER|ST combined with HIIT (ST+HIIT)|Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
40847997|NCT05150938|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
40847998|NCT05150938|DRUG|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
40847999|NCT05150938|DRUG|vitamin K antagonist (VKA)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
40848000|NCT05150938|DRUG|other NOACs|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
41370970|NCT00021476|BEHAVIORAL|Behavioral treatments|
41370971|NCT00021476|BEHAVIORAL|Physical therapy|
41370972|NCT00081900|DRUG|DENSPM )|Each patient will receive DENSPM at an initial dose of 30mg/m\^2, then escalating to 120mg/m\^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
40848004|NCT05320393|DRUG|PrabotulinumtoxinA-Xvfs|One treatment of 40 units
40848005|NCT05320393|DRUG|OnabotulinumtoxinA|One treatment of 20 units
40848006|NCT05320393|DRUG|PrabotulinumtoxinA-Xvfs|One treatment of 20 units
40848007|NCT02332291|DRUG|Escitalopram|Escitalopram 10-20mg daily
40848008|NCT02332291|DRUG|Bupropion XL|Bupropion XL 150-450mg daily
40848009|NCT04832880|DRUG|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg die (2 mg for patients aged \> 75 years) for 10 days.
41370973|NCT02621528|DEVICE|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
41370974|NCT04231903|DEVICE|Aortic clamp|In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
41370975|NCT03081962|DRUG|Bundle|Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
40848010|NCT04832880|DRUG|Remdesivir|Intravenous remdesivir 200 mg on day 1, followed by remdesivir 100 mg die until day 10
40848011|NCT04832880|DRUG|Dexamethasone|Intravenous dexamethasone 6 mg for 10 days
40848012|NCT00642447|DRUG|helium:oxygen mixture|
41370976|NCT03081962|PROCEDURE|Standard care|Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
41370977|NCT01431599|RADIATION|short-course radiation|33Gy/10 fractions
41370978|NCT06186466|OTHER|Observational Survey and Analysis|This study does not involve a clinical or medical intervention. Instead, it employs an observational survey method to gather data from family members of patients who visited the Health Sciences University Van Training and Research Hospital's emergency department between December 1, 2023, and June 1, 2024. The study aims to use logistic regression analysis to identify factors influencing the intent of violence against healthcare professionals. The survey includes structured questionnaires and scales developed based on theoretical frameworks and previous research. The gathered data will be statistically analyzed using the G\*Power software to assess the significance and impact of various factors on the propensity for violence.
41370979|NCT02014428|DIETARY_SUPPLEMENT|Hyaluronic acid|
41370980|NCT02014428|DRUG|Placebo|
41370981|NCT01919437|DEVICE|Web-Enabled Cognitive Neuropsychological Evaluation System|
41370982|NCT03479957|BEHAVIORAL|REMOTE-CR|The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link. Remotely monitored exercise training sessions will be offered monday-friday 13.00-16.00.
40848013|NCT04591847|DRUG|Vitamin D 2|Vitamin D2 20000IU 1 tab oral weekly
40848014|NCT04591847|DRUG|Placebo drug|Placebo drugs 1 tab oral weekly
40848015|NCT00218972|BEHAVIORAL|Aerobic interval training|
40848016|NCT00218972|BEHAVIORAL|moderate intensity training|
40848017|NCT00218972|BEHAVIORAL|Recommendation of regular exercise|
40848018|NCT00238238|BIOLOGICAL|rituximab|Given IV
40848019|NCT00238238|DRUG|lenalidomide|Given orally
40848020|NCT04241302|DIAGNOSTIC_TEST|Pure Tone Audiogram|A Pure Tone Audiogram is done in a sound proof room in both cases of Free Field Voice Test and Free Field Click Tests to identify the Pure Tone Average (Hearing Threshold Average of 500Hz,1000Hz and 2000Hz).
40848021|NCT00733681|DEVICE|PFC Sigma RP TC3 Revision knee system|Orthopaedic implant system for revision total knee replacement
40848022|NCT01873651|DEVICE|Implantation of a Delta III Prosthesis|Implantation of a Delta III Prosthesis
40848023|NCT05804032|DRUG|Isatuximab|IV isatuximab will be administered weekly in the first cycle (Cycle 1) on days 1, 8, 15, 22, 29, and biweekly on the 2 subsequent cycles at days 1, 15 and 29, at the dose of 10 mg/kg.
41030947|NCT06299397|BEHAVIORAL|breastfeeding - humor training|Breastfeeding and humor-based practice will continue for 35-45 minutes, once a week for 2 weeks.
40848024|NCT05804032|DRUG|Isatuximab|SC isatuximab will be administered on days 1, 8, 15, 22, 29 of cycle 1, and on days 1, 15 and 29 of cycles 2-3, at the dose of 1400 mg
40848025|NCT05804032|DRUG|Lenalidomide|Both arms: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3
40848026|NCT05804032|DRUG|Bortezomib|Both arms: 1.3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
40848027|NCT05804032|DRUG|Dexamethasone|20 mg per os on day 1-2, 4-5, 8-9, 11-12, 15; and 22-23, 25-26, 29-30, 32-33 in induction cycles 1-3.
40848028|NCT02374567|DRUG|Phenobarbital|
40848029|NCT02374567|DRUG|Phenytoin|
40848030|NCT02374567|DRUG|Carbamazepine|
40848031|NCT02374567|DRUG|Oxcarbazepine|
40848032|NCT02374567|DRUG|Valproic Acid|
40848033|NCT02374567|DRUG|Lamotrigine|
40848034|NCT02374567|DRUG|Topiramate|
40848035|NCT02374567|DRUG|Gabapentin|
40848036|NCT02374567|DRUG|Levetiracetam|
40848037|NCT02374567|DRUG|Pregabalin|
40848038|NCT02374567|DRUG|Lacosamide|
40848039|NCT02374567|DRUG|Clonazepam|
40848040|NCT02374567|DRUG|Biperiden|
40848041|NCT02374567|DRUG|Levomepromazine|
40848042|NCT02374567|DRUG|Fluphenazine|
41030948|NCT06299397|OTHER|Control Group|After randomization, consent was obtained from the pregnant women determined that they agreed to participate in the study. The pregnant women in the control group were given a pre-test before starting the study, an interim test 1 month after the start, and a final test 3 months later.
41030949|NCT05498259|DRUG|Orelabrutinib|Orelabrutinib 150mg qd PO
40848043|NCT02374567|DRUG|Perphenazine|
41030950|NCT05498259|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle
41162720|NCT01603771|OTHER|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
41370983|NCT03479957|OTHER|Control|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care)
40848044|NCT02374567|DRUG|Perazine|
40848045|NCT02374567|DRUG|Thioridazine|
41162721|NCT03704571|DRUG|Polyethylene Glycol|"In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens."
41370984|NCT03821519|BIOLOGICAL|donor-derived CIK cells|Treatment plan will be based on three infusions of donor derived CIK cells given by 3 weeks intervals at increasing dose levels. No dose changes are allowed and the following planned dose levels will be administered to each patient enrolled: 5x106, 5x106 and 10x106 cells/Kg according to the dose escalating program
41370985|NCT01848769|DRUG|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
41370986|NCT01848769|DRUG|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
40848046|NCT02374567|DRUG|Haloperidol|
40848047|NCT02374567|DRUG|Melperone|
40848048|NCT02374567|DRUG|Pipamperone|
40848049|NCT02374567|DRUG|Bromperidol|
40848050|NCT02374567|DRUG|Benperidol|
40848051|NCT02374567|DRUG|Sertindole|
40848052|NCT02374567|DRUG|Ziprasidone|
40848053|NCT02374567|DRUG|Flupentixol|
40848054|NCT02374567|DRUG|Chlorprothixene|
40848055|NCT02374567|DRUG|Zuclopenthixol|
40848056|NCT02374567|DRUG|Fluspirilene|
40848057|NCT02374567|DRUG|Pimozide|
40848058|NCT02374567|DRUG|Clozapine|
40848059|NCT02374567|DRUG|Olanzapine|
40848060|NCT02374567|DRUG|Quetiapine|
40848061|NCT02374567|DRUG|Sulpiride|
40848062|NCT02374567|DRUG|Tiapride|
40848063|NCT02374567|DRUG|Amisulpride|
40848064|NCT02374567|DRUG|Prothipendyl|
40848065|NCT02374567|DRUG|Risperidone|
40848066|NCT02374567|DRUG|Aripiprazole|
40848067|NCT02374567|DRUG|Paliperidone|
40848068|NCT02374567|DRUG|Diazepam|
40848069|NCT02374567|DRUG|Oxazepam|
40848070|NCT02374567|DRUG|Lorazepam|
40848071|NCT02374567|DRUG|Bromazepam|
40848072|NCT02374567|DRUG|Clobazam|
40848073|NCT02374567|DRUG|Alprazolam|
40848074|NCT02374567|DRUG|Hydroxyzine|
40848075|NCT02374567|DRUG|Buspirone|
40848076|NCT02374567|DRUG|Chloral Hydrate|
40848077|NCT02374567|DRUG|Flurazepam|
40848078|NCT02374567|DRUG|Nitrazepam|
40848079|NCT02374567|DRUG|Triazolam|
40848080|NCT02374567|DRUG|Lormetazepam|
40848081|NCT02374567|DRUG|Temazepam|
40848082|NCT02374567|DRUG|Midazolam|
40848083|NCT02374567|DRUG|Brotizolam|
40848084|NCT02374567|DRUG|Zopiclone|
40848085|NCT02374567|DRUG|Zolpidem|
40848086|NCT02374567|DRUG|Zaleplon|
40848087|NCT02374567|DRUG|Melatonin|
40848088|NCT02374567|DRUG|Clomethiazole|
40848089|NCT02374567|DRUG|Diphenhydramine|
41030951|NCT05498259|DRUG|CHOP-like Regimen|cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
41030952|NCT03434925|GENETIC|Multi-targeted next generation sequencing|Study directed at finding molecular predictors of recurrent colorectal adenomas also taking into account the intrinsic level of heterogenity imprinted in the internal differences in molecular profiles
41030953|NCT04519229|BEHAVIORAL|Child-Parent Psychotherapy|Relationship-based trauma focused psychotherapy for Children 0-6 years old and their caregivers. The objective is to decrease symptoms of post-traumatic tress and re-establish a secure attachment for the child and good caregiving from the caregiver/s.
41030954|NCT03871647|DRUG|Beta blocker|perioperative beta blockers
41370987|NCT01848769|DRUG|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
41370988|NCT04418466|COMBINATION_PRODUCT|Risperidone|Risperidone Implant
41370989|NCT03527875|PROCEDURE|PTBD group|Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
41370990|NCT03527875|PROCEDURE|ENBD group|Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
41370991|NCT03527875|PROCEDURE|EBS group|Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
41370992|NCT04560543|PROCEDURE|McCall suture|Laparoscopic suture including the uterosacral ligaments and the peritoneum
41370993|NCT04560543|PROCEDURE|Standard cuff closure|Standard laparoscopic barbed suture of the vaginal cuff
41370994|NCT00511706|DRUG|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
41370995|NCT00511706|BIOLOGICAL|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
41370996|NCT00511706|OTHER|sham|Sham needle-less injection administered in the study eye at Day 1.
41370997|NCT02620826|PROCEDURE|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
41370998|NCT02620826|PROCEDURE|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
41370999|NCT00184730|DRUG|somatropin|
41371000|NCT02974023|DEVICE|Pain Gear|PainGear \[ActiPatch®\] (BioElectronics Corporation, MD, USA) has been recently introduced as an 'topical' analgesic for localized musculoskeletal pain. PainGear is a noninvasive, low power, easy to use, pulsed shortwave therapy device for localized musculo¬skeletal pain.
41371001|NCT06028191|OTHER|Kabat Technique along with baseline treatment|"Group A will receive Kabat Technique along with baseline treatment. Electrical muscle stimulation for 15 min which includes faradic current to the facial nerve trunks given by DL-2 electro pulse stimulator, Effleurage and Kneading for 5 min and resistive exercise for 5 min and facial expression exercises for 5 min, which included eye closure, eyebrow raise, frown, smile, snarl, pucker and pout as baseline treatment.~Kabat Technique is neurorehabilitation technique that uses diagonal and spiralpatterns for movement in conjunction with stretch and resistance and other PNF techniques to reinforce neuromuscular recruitment. It mainly concerns the stimulation of these muscles: Orbicularis occuli, ztgomaticus, Levator labii, nasalis, buccinator, frontalis, corrugator"
41371002|NCT06028191|DEVICE|Kabat Technique and LLLT along with baseline treatment|Group B will receive Kabat Technique and LLLT along with baselinetreatment. Kabat technique is same as mentioned in group A. Laser treatment will be administered to eight points of the affected side for 2 min at each point at a wavelength of 830 nm, output power of 100 Mw, and frequency of 1 KHz. Endo laser 422 is the model name and number of device which will be used in this study to administered low level laser therapy.
41371003|NCT03237910|DIAGNOSTIC_TEST|AMSA|A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
41371004|NCT03237910|PROCEDURE|Defibrillation|delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
41371005|NCT03237910|PROCEDURE|CPR|chest compressions and ventilations at a rate of 30:2
41371006|NCT02078141|DRUG|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
41371007|NCT01432743|PROCEDURE|NavX Fusion|Using NavX Fusion to guide catheter ablation
41371008|NCT01432743|PROCEDURE|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
41371009|NCT00792467|DRUG|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
41371010|NCT04554563|OTHER|Core stability training|20 sessions of specific core stability exercise with no external loading.
41371011|NCT05129358|DRUG|Dehydration|The subject is brought to mild dehydration (loss of approximately 1.5% of body weight) through intravenous injection of up to 40 ug Furosemide. The subject shall not ingest any fluid for the next 120 minutes.
41371012|NCT05129358|DIETARY_SUPPLEMENT|Rehydration|The subject is rehydrated by oral intake of 1.5 liters Resorb Sport (Nestlé). The subject is monitored for 60 minutes following intake.
41371013|NCT01339273|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
41371014|NCT01339273|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
41371015|NCT02120456|DRUG|LEO 43204|
41371016|NCT02120456|DRUG|Placebo|
41371017|NCT03495596|DEVICE|Videolaryngoscopy|Videolaryngoscopy device type
41371018|NCT00612300|BEHAVIORAL|Lokomat - Physical therapy|A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
41371019|NCT00612300|BEHAVIORAL|Physical therapy - Lokomat|"B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.~A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks."
41371020|NCT04004975|DRUG|Anlotinib|Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
41371021|NCT00006401|DRUG|iNO|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
41371022|NCT00006401|OTHER|Placebo|Inhaled Nitrogen
40848090|NCT02374567|DRUG|Promethazine|
40848091|NCT02374567|DRUG|Imipramine|
40848092|NCT02374567|DRUG|Clomipramine|
40848093|NCT02374567|DRUG|Opipramol|
40848094|NCT02374567|DRUG|Trimipramine|
41371023|NCT01698606|BEHAVIORAL|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
41371024|NCT02806206|DRUG|Prucalopride|A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
41371025|NCT02806206|DRUG|Placebo|A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
41371026|NCT03077581|DRUG|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
41371027|NCT03077581|DRUG|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
41371028|NCT03077581|DRUG|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
41371029|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|1 x 10\^ 7 TCID50 administered intramuscularly
41371030|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1|0.6 mg administered intramuscularly
41371031|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452) placebo|ALVAC placebo administered intramuscularly
41371032|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1 placebo|Alum placebo administered intramuscularly
41371033|NCT00230711|BEHAVIORAL|Physical activity counseling|
41371034|NCT01826929|OTHER|Therapeutic education|
41371035|NCT00193076|DRUG|Gemcitabine|Gemcitabine
41371036|NCT00193076|DRUG|Carboplatin|Carboplatin
41371037|NCT00193076|DRUG|Trastuzumab|Trastuzumab
41371038|NCT02780180|DRUG|QGC001|
41371039|NCT02780180|DRUG|Placebo|Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
41371040|NCT00636402|PROCEDURE|Cold Knife Tonsillectomy|Cold Knife Tonsillectomy (CKT) will be done on the other side.
41371041|NCT00636402|PROCEDURE|Vessel Sealing System Tonsillectomy|Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
41371042|NCT05406466|DRUG|Tislelizumab|a PD-1 immune check inhibitor
41371043|NCT05406466|DRUG|Lenvatinib|multitargeted receptor tyrosine kinase inhibitor
41371044|NCT05406466|DRUG|Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
41371045|NCT05417373|OTHER|calculated radscore|The development cohort is case_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
41371046|NCT00700466|DRUG|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
41371047|NCT03801863|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%|Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used.
40848095|NCT02374567|DRUG|Amitriptyline|
41371048|NCT03801863|DRUG|Ropivacaine|Using 0.375% Ropivacaine in the nerve block
41371049|NCT06378112|DRUG|GTO®|After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.
41371050|NCT02635906|OTHER|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
41371051|NCT02635906|OTHER|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
41371052|NCT02477462|OTHER|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
41371053|NCT02477462|OTHER|Baseline visit|Blood draw and quality of life surveys
41371054|NCT04940832|DEVICE|pulsed radiofrequency modulation|a percutaneous needle electrode to apply pulsed RF signals that modulate the activity of sensory nerves. The pulsing of the RF signal permits a maximum temperature to be achieved - usually 42 Celsius. This helps prevent collateral damage from occurring during the procedure and should help reduce procedural complications.
41371055|NCT03998527|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)|TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.
41371056|NCT06516289|DRUG|HRS-1167|a highly selective PARP1 inhibitor
41371057|NCT06516289|DRUG|Famitinib|a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
40848096|NCT02374567|DRUG|Nortriptyline|
40848097|NCT02374567|DRUG|Doxepin|
40848098|NCT02374567|DRUG|Maprotiline|
40848099|NCT02374567|DRUG|Amitriptyline oxide|
40848100|NCT02374567|DRUG|Fluoxetine|
40848101|NCT02374567|DRUG|Citalopram|
41371058|NCT06516289|DRUG|Camrelizumab|a humanised anti-programmed death-1 (anti PD-1) antibody
41371059|NCT05371262|DRUG|Levothyroxin|Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
41371060|NCT01694849|DRUG|GFT505 80mg|
41371061|NCT01694849|DRUG|GFT505 120mg|
41371062|NCT01694849|DRUG|Placebo|
41371063|NCT02545699|DEVICE|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
41371064|NCT02545699|DEVICE|Standard Colonoscopy|Standard Colonoscopy
41030955|NCT05034692|PROCEDURE|Total laparoscopic with intracorporeal anastomosis by overlap method|After the intestinal canal was dissociated and vascularized, the intestinal canal was nuded and cut off, and the distal and proximal intestinal canals were overlapped by 6 cm
41162722|NCT02054598|BEHAVIORAL|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
41162723|NCT02773121|BEHAVIORAL|Physical Activity|Trainer-guided at-home behavioral intervention
41162724|NCT06294483|DIAGNOSTIC_TEST|CBC|Is used to detect haematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and its relation to disease activity
41371065|NCT05142462|DEVICE|Hip arthroplasty|Hip prosthesis surgical implantation
41162725|NCT06294483|DIAGNOSTIC_TEST|Antinuclear Antibody tests (ANA)|To be tool in diagnosis of SLE
41162726|NCT06294483|DIAGNOSTIC_TEST|Rest of ANA profile|As tool of diagnosis of SLE
41162727|NCT06294483|DIAGNOSTIC_TEST|C3 and C4 complement level.|As method of detection of acute acivity of SLE
41162728|NCT06294483|DIAGNOSTIC_TEST|Anti phospholipid marker|To detect antiphospholipid syndrome if there is sign of thrombosis
41162729|NCT06294483|DIAGNOSTIC_TEST|Serum creatinine and Alb/create ratio|To detct complication of disease on kidney
41162730|NCT06294483|OTHER|2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.|Is criteria of diagnosis of SLE
41162731|NCT06294483|OTHER|SLEDAI scores|Is score to detect the activity of disease
41162732|NCT04770142|DEVICE|TIRA catheter|treat hypertrophic obstructive cardiomyopathy
41162733|NCT05947708|DEVICE|Dialysate Flow Rate|Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.
41162734|NCT02358213|PROCEDURE|Ultrasound|Ultrasound examinations are done 5 times
41162735|NCT03750305|OTHER|imagery-focused Cognitive Therapy|"In depth identification phase: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus.~Imagery interventions: The imagery intervention consists of metacognitive imagery rescripting or promoting positive imagery or competing tasks (or a combination of these).~Consolidation: Consist of fine tuning the strategies, relapse prevention using a video diary."
41162736|NCT03750305|OTHER|TAU|Psycho-education is offered in groups, using the format described by Honig (Postma, Honig, \& van Gent, 2008).
41371066|NCT04162756|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
41371067|NCT04162756|DRUG|Fludarabine|Administered per package insert
41371068|NCT04162756|DRUG|Cyclophosphamide|Administered per package insert
41371069|NCT04165850|DRUG|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
41371070|NCT06116357|DEVICE|External Ultrasonic Micro-bubble|The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble
41503404|NCT01857479|DRUG|Inhaled budesonide|The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
40848102|NCT02374567|DRUG|Paroxetine|
41162737|NCT04730076|PROCEDURE|Standard Balloon Dilation|The standard approach involves a gradual balloon dilation where the balloon is inflated then held at each balloon size for 30-60 seconds then inflated to the next largest balloon diameter size and repeated to the maximum diameter size of that catheter. The dilation session will be repeated as frequently and as many times as needed to achieve the balloon diameter size of 18mm at the discretion of the endoscopist.
41162738|NCT04730076|PROCEDURE|Progressive Balloon Dilation|In the progressive approach, the balloon is continuously inflated over the course of 3-5 minutes starting at the smallest to the largest balloon diameter depending of the balloon catheter used. The dilation will be repeated every 2-3 weeks (total of 2-3 sessions). At the next endoscopic procedure, the balloon diameter used will be the next size up based on previous session.
41162739|NCT02456675|DRUG|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
41162740|NCT02456675|DRUG|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
41162741|NCT02456675|DRUG|itacitinib|The dose of itacitinib will be given orally once daily (QD).
41162742|NCT02946307|DEVICE|Restore DEB（dimeter>2.00 mm）|
41162743|NCT02946307|DEVICE|Resolute DES|
41162744|NCT02946307|DEVICE|Restore DEB（dimeter:2.00 mm）|
41162745|NCT04678635|OTHER|Chronic transcranial direct current stimulation|Chronic transcranial direct current stimulation
41162746|NCT01560585|DRUG|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
41371071|NCT01340794|OTHER|Laboratory Biomarker Analysis|Correlative studies
41371072|NCT01340794|DRUG|Pazopanib Hydrochloride|Given PO
41371073|NCT05201898|OTHER|control:usual medical management|with regular doctor visits every 3 months
41371074|NCT05201898|BEHAVIORAL|intervention 1:usual medical management+individual dieting consultation|with regular doctor visits every 3 months and dietitian visits every 3 months
41371075|NCT05201898|BEHAVIORAL|intervention 2:usual medical management+individual dieting consultation+ daily tea drinking|with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
41371076|NCT06509217|BEHAVIORAL|Moderate-intensity Group|Water aerobics sessions involved exercises performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
40848103|NCT02374567|DRUG|Sertraline|
40848104|NCT02374567|DRUG|Fluvoxamine|
40848105|NCT02374567|DRUG|Escitalopram|
40848106|NCT02374567|DRUG|Tranylcypromine|
40848107|NCT02374567|DRUG|Moclobemide|
40848108|NCT02374567|DRUG|Mianserin|
40848109|NCT02374567|DRUG|Trazodone|
40848110|NCT02374567|DRUG|Mirtazapine|
40848111|NCT02374567|DRUG|Bupropion|
40848112|NCT02374567|DRUG|Venlafaxine|
40848113|NCT02374567|DRUG|Reboxetine|
40848114|NCT02374567|DRUG|Duloxetine|
40848115|NCT02374567|DRUG|Agomelatine|
40848116|NCT02374567|DRUG|Pyritinol|
40848117|NCT02374567|DRUG|Piracetam|
40848118|NCT02374567|DRUG|Donepezil|
40848119|NCT02374567|DRUG|Rivastigmine|
40848120|NCT02374567|DRUG|Galantamine|
40848121|NCT02374567|DRUG|Memantine|
40848122|NCT02374567|DRUG|Nicergoline|
40848123|NCT02374567|DRUG|Acamprosate|
40848124|NCT02374567|DRUG|Lithium|
40848125|NCT02969460|BEHAVIORAL|Neurotrack Virtual Cognitive Health Program|
40848126|NCT06084221|BEHAVIORAL|Data-Driven Decision Making (DDDM)|The intervention consists of providing real-time data on overdose touchpoints to OFRs and training in DDDM for continuous quality improvement cycles, leading to improved OFR recommendations and implementation of overdose prevention strategies.
41162747|NCT02109107|DEVICE|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
40848127|NCT06084221|BEHAVIORAL|Overdose-prevention strategies inventory|A list of overdose prevention and harm reduction strategies will be provided to OFRs for possible implementation, depending on local needs and final dashboard development.
40848128|NCT06246578|DEVICE|Continuos glucose monitoring and blood glucose measurement|The individuals who use Dexcom G 7 sensors for continous glucose monitoring is in addition applied a Libre 2 sensor and asked to wear both sensors for 14 days. In case of a Dexcom glucose value \< 5 mmol/l, the participants is aked to measure a blood glucose as well uising fingerprick and Contour Next One
40848129|NCT02556060|DRUG|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
40848130|NCT02556060|DRUG|Placebo|Same dosing schedule as study drug
40848131|NCT06242015|OTHER|Carbohydrate-first meal|Rice (150 grams) eaten first, followed by broccoli (150 grams) and chicken (100 grams)
40848132|NCT06242015|OTHER|Carbohydrate-last meal|Broccoli (150 grams) and chicken (100 grams) eaten first, followed by rice (150 grams)
40848133|NCT03813914|DIETARY_SUPPLEMENT|Sineos|glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day
41162748|NCT04205214|BEHAVIORAL|Integrative Cognitive Behavioural Therapy|This intervention involves the psychological intervention of Cognitive Behavioural Therapy. This intervention also includes third wave psychological interventions of Mindfulness and Narrative Therapy which has been found to be helpful for people with chronic health conditions and chronic skin conditions.
41162749|NCT01101464|DRUG|Asenapine 3x5mg followed by 1x15mg|Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
40848134|NCT02428764|DRUG|Nimotuzumab|Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
40848135|NCT02428764|DRUG|Gemcitabine|Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
40848136|NCT02428764|DRUG|Carboplatin|carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
40848137|NCT02428764|PROCEDURE|Surgery|Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
40848138|NCT05391256|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|"Totally n=6 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 12 months Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.~An interventional package directed to the dispatchers is distributed and consists of an e-learning program, an AED -trainer placed at the dispatch center. Within the dispatcher decision tool - there is information how to inform the caller to retrieve the AED. The HEMS-coordinator reminds the dispatcher during the call on operational information. Monthly information to staff of project progress is provided."
40848139|NCT06144047|DEVICE|EEG SubQ subcutaneous EEG device|2-channel subcutaneous EEG device
40848140|NCT01620762|DRUG|Cat-PAD|1 dose every 4 weeks
40848141|NCT01620762|DRUG|Placebo|1 dose every 4 weeks
40848142|NCT02923076|OTHER|CCR5 delta32/delta32 cord blood transplantation|
40848143|NCT06258408|DRUG|BB102 tablet|BB102 tablets will be administered orally once daily(QD).
40848144|NCT00444340|DRUG|Enbrel (Etanercept)|
40848145|NCT00695864|DRUG|Ondansetron and Placebo crossover|
40848146|NCT05066308|DRUG|CBD|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring. The drug is formulated from extracts prepared from Cannabis sativa L. plants that have a defined chemical profile and contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (\>95%) CBD that typically contains less than 0.5% (w/w) THC. Cannabidiol is the active ingredient in Epidiolex; inactive ingredients include dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose. Of note, CBD has no psychoactive properties.
40848147|NCT05066308|OTHER|Placebo|Placebo CBD will be identical to the active CBD, a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring, but with no CBD.
40848148|NCT04569357|DRUG|Prospekta|Oral administration.
40848149|NCT04569357|DRUG|Placebo|Oral administration.
40848150|NCT04070612|OTHER|Blood sample|A blood sample of 2 times 2 to 5 ml additional maximum
40848151|NCT05624749|DRUG|ianalumab|ianalumab s.c. monthly
40848152|NCT05624749|DRUG|placebo|placebo s.c. monthly
40848153|NCT03205527|OTHER|Overground slip perturbation training|Slips will be induced by a low-friction platform (65×30×0.6 cm, μ\<0.05) embedded side-by-side in the walking path, set nearly flush with the floor surround. The moveable platform, mounted on top of a pair of force platforms (AMTI, Newton, MA) for measuring ground reaction forces is firmly locked in a stationary position. An unannounced release occurs at heel strike of the perturbed, without the knowledge of subject, after which the platform is free to slide up to 150 cm. The mechanical release is controlled by the loading on the force platforms and the computer.
41503405|NCT01857479|DRUG|Inhaled amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\].~The first dose will be administered under direct supervision."
40848154|NCT02161757|BIOLOGICAL|Tralokinumab|Subcutaneous injection
41162750|NCT01101464|DRUG|Asenapine 1x15mg followed by 3x5mg|One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
41162751|NCT00610818|OTHER|Palifermin|day -14, -13, -12 before transplant and then day 0,1,2 after transplant
41371077|NCT06509217|BEHAVIORAL|High-intensity Group|Water aerobics sessions involved exercises performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
41162752|NCT02154477|DRUG|intranasal insulin|insulin
41371078|NCT03728166|BEHAVIORAL|Electronic alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
41503406|NCT02339662|DRUG|Gabapentin|muscles pain treatment
41503407|NCT02339662|DRUG|Amitriptyline|muscles pain treatment
41503408|NCT04787679|PROCEDURE|Hip replacement surgery|After hip replacement surgery the sponsor obtains femoral head samples for the study
41162753|NCT02154477|DRUG|placebo (intranasal saline)|saline
41162754|NCT00985634|DEVICE|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
41162755|NCT00985634|DEVICE|Control|Vessel loops
41162756|NCT03042858|OTHER|Infants with PPV|Data will be collected for up to 18 years to monitor for inguinal hernia.
41162757|NCT03042858|OTHER|Infants without PPV|Basic data will be collected regarding the surgery and the subject's study participation will be complete.
41162758|NCT06479226|DRUG|cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash|mouthrinse
41162759|NCT00935714|OTHER|Exercise|
40848155|NCT02161757|OTHER|Placebo|Subcutaneous injection
40848156|NCT01211821|DRUG|metoprolol|Tablets, Oral, 200 mg, once, 1 day
40848157|NCT01211821|DRUG|BMS-914392|Tablets, Oral, 60 mg, once daily, 7 days
40848158|NCT00148876|DRUG|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22
41162760|NCT00935714|OTHER|Exercise|
41162761|NCT06051968|BEHAVIORAL|Online hearing support for first-time hearing aid users|Participants get hearing rehabilitation according to common practice and the online hearing support consists of five chapters that aim to give information, support, and advice to the new hearing aid users. The participants are assigned a new chapter between each visit at the clinic.
41162762|NCT06051968|BEHAVIORAL|Hearing rehabilitation according to common practice.|Participants get hearing rehabilitation according to common practice.
41371079|NCT03326323|PROCEDURE|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
41371080|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
41371081|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340269A|Two intramuscular injections
41371082|NCT03186287|OTHER|Eccentric training|Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
41371083|NCT03186287|OTHER|Concentric training|Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
41371084|NCT03186287|OTHER|Standard physiotherapy|The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
41371085|NCT05791123|PROCEDURE|a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket|Extraction sockets were filled with minced PRF clots mixed with the bovine xenograft and covered by PRF membranes to seal the extraction sockets.
41371086|NCT04615338|OTHER|no intervension|no intervention needed just observation and description
41371087|NCT04678726|DIAGNOSTIC_TEST|Lung ultrasound assessment for ruling out pneumothorax|Patients who have undergone heart surgery and have decided to enroll in our study, will have the standard chest x-ray and an additional lung ultrasound. Within a maximum of two hours of the chest tube removal, the standard chest x-ray will be performed, and then a different nurse will perform the lung ultrasound to check for pneumothorax.
41371088|NCT04085926|DEVICE|Sealed therapeutic shoe|Off-the-shelf therapeutic shoe and custom-made insole
41371089|NCT04085926|DEVICE|Total contact cast|Custom-made total contact cast
41371090|NCT04624282|DIAGNOSTIC_TEST|different diseases|Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
40848159|NCT00148876|DRUG|Trastuzumab|Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
40848160|NCT04503824|DIAGNOSTIC_TEST|saliva samples|Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.
40848161|NCT04384523|DRUG|OsrHSA 20 mg/kg IV|A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
40848162|NCT04384523|DRUG|OsrHSA 40 mg/kg IV|A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
40848163|NCT04384523|DRUG|OsrHSA 80 mg/kg IV|A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
40848164|NCT04384523|DRUG|OsrHSA 140 mg/kg IV|A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
40848165|NCT04384523|DRUG|OsrHSA 200 mg/kg IV|A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
40848166|NCT04384523|OTHER|Placebo|Normal Saline (0.9% Sodium Chloride)
41371091|NCT01993238|DEVICE|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
40848167|NCT02277808|DRUG|500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)|
40848168|NCT02277808|DEVICE|Respirgard II|
40848169|NCT02277808|DEVICE|Isoneb®|
40848170|NCT03659136|DRUG|Xentuzumab|Intravenous infusion
40848171|NCT03659136|DRUG|Placebo|Intravenous infusion
40848172|NCT03659136|DRUG|Everolimus|Tablet
41371092|NCT01993238|DRUG|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
41371093|NCT02859025|BIOLOGICAL|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
41371094|NCT02859025|BIOLOGICAL|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
41371095|NCT02859025|BIOLOGICAL|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
41371096|NCT03688191|DRUG|Sirolimus|Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
41371097|NCT06212609|OTHER|transcranial electrical stimulation therapy|new procedure of non-invasive, individualized and optimized transcranial electrical stimulation therapy in the management of pharmaco-resistant focal epilepsies
41371098|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 10µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 10µg antigen
41371099|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 40µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 40µg antigen
41371100|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 100µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 100µg antigen
41371101|NCT02285673|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell|
41371102|NCT01015170|DRUG|bupropion HCl|150mg BID for up to 8 weeks + counseling
41371103|NCT01535209|RADIATION|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity \<2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity \>4cm in maximum diameter
41371104|NCT01535209|RADIATION|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
41371105|NCT01599091|OTHER|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
40848173|NCT03659136|DRUG|Exemestane|Tablet
41371106|NCT03233009|OTHER|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
41371107|NCT03233009|OTHER|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
41371108|NCT03233009|OTHER|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
41371109|NCT03233009|OTHER|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
41371110|NCT03233009|OTHER|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
41371111|NCT05570734|BEHAVIORAL|LUNA Care Coordination|Participants in this group will have 6 or more 30-minute care coordination sessions with the LUNA Care Coordinator. The LUNA Care Coordinator will assist with appointments and referrals, medications, and assist with accessing the health education videos. They will work closely with the participant's primary care provider and the LUNA Behavioral Health Provider.
41503409|NCT06216678|OTHER|Healthy Dietary Pattern with Cottonseed Oil|Cottonseed Oil
40848174|NCT06474403|PROCEDURE|standard Sugarbecker's operation|Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
40848175|NCT06474403|PROCEDURE|modified Sugarbecker's operation|Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
40848176|NCT04897763|DRUG|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
40848177|NCT01799824|BIOLOGICAL|ANT-1403|
40848178|NCT01799824|BIOLOGICAL|placebo|
40848179|NCT03534375|OTHER|The study is an observational cross sectional study|An intervention will not be performed
40848180|NCT05435417|RADIATION|CBCT radiation|CBCT scanning
41371112|NCT05570734|BEHAVIORAL|LUNA Behavioral Health|Participants in this group will have 6 or more 30-minute behavioral health sessions with the LUNA Behavioral Health Provider. The LUNA Behavioral Health Provider will screen and address life stressors, social support, and health care use. The purpose of these sessions is to check on participant's progress with their care plan. The behavioral health sessions will involve discussion of issues that may interfere with optimal diabetes self-management. The LUNA Behavioral Health Provider will help participants overcome any potential barriers to managing their diabetes by setting goals and helping to address life stress or other issues that may be interfering with their diabetes self-management.
41371113|NCT05570734|BEHAVIORAL|Health Education Videos|Participants in this group will have access to eight 20 to 30-minute health education video sessions with corresponding print material and activities to reinforce what they learn. The health education videos focus on medication adherence, self-monitoring, stress and coping, nutrition, physical activity and culturally driven beliefs and values.
41371114|NCT05570734|BEHAVIORAL|Virtual Integrated Visits|Participants in this group will have two virtual integrated visits with the LUNA care team. Through video conferencing, they will meet at the same time with the LUNA Care Coordinator, the LUNA Behavioral Health Provider, and their primary care provider to ensure an integrated care plan.
41371115|NCT05671042|OTHER|Patients with Upper excretory tract tumors|Standard of care for patients with Sezary Syndrome
41371116|NCT03583801|OTHER|Olfactory aromatherapy|2 drops of the essential oil choosed by the patient are applied on a compress placed next to his head from his arrival in the recovery room to his leaving from the operating theatre. The method of administration is the respiratory tract..
41371117|NCT03583801|OTHER|without aromatherapy|no intervention
41371118|NCT03681925|DIAGNOSTIC_TEST|Nutrition Literacy Assessment Instrument (NLit)|The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
41371119|NCT02147015|DRUG|Glucocorticoids|
41503410|NCT06216678|OTHER|Healthy Dietary Pattern with Fatty Acid-Matched Plant Oils|Plant oil blend fatty acid matched
40848181|NCT01764828|DRUG|Refametinib (BAY86-9766)|
40848182|NCT01764828|DRUG|Gemcitabine|
40848183|NCT05834348|DRUG|lorlatinib|As provided in real world practice
40848184|NCT05834348|DRUG|crizotinib|As provided in real world practice
40848185|NCT05834348|DRUG|brigatinib|As provided in real world practice
40848186|NCT05834348|DRUG|ceritinib|As provided in real world practice
40848187|NCT05834348|DRUG|alectinib|As provided in real world practice
41162763|NCT04091464|BEHAVIORAL|Backward Walking Training|Training will consist of BW training on both a treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline BW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes BW, backward stepping, and functional exercises that incorporate BW movements.
41371120|NCT02147015|DRUG|Antibiotics|
41371121|NCT02147015|DRUG|Inhaled corticosteroid (ICS)|
41371122|NCT02147015|DRUG|Long-Acting Muscarinic Antagonists(LAMA)|
41371123|NCT02147015|DRUG|Short-acting beta2-agonist (SABA)|
41371124|NCT02147015|OTHER|Physical treatments|
40848188|NCT05834348|DRUG|atezolizumab|As provided in real world practice
40848189|NCT05834348|DRUG|bevacizumab|As provided in real world practice
40848190|NCT05834348|DRUG|paclitaxel|As provided in real world practice
40848191|NCT05834348|DRUG|carboplatin|As provided in real world practice
40848192|NCT05834348|DRUG|docetaxel|As provided in real world practice
41371125|NCT02147015|DRUG|long-acting beta2-agonist (LABA)|
41371126|NCT02304484|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
41503411|NCT06216678|OTHER|Healthy Dietary Pattern with PUFA:SFA Ratio-Matched Plant Oil|Plant oil with matched PUFA to SFA ratio
41503412|NCT04410237|DEVICE|Med-Jet|"One half of each psoriasis plaque will be treated with a Med-Jet device and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using a conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
40848193|NCT05834348|DRUG|erlotinib|As provided in real world practice
40848194|NCT05834348|DRUG|gefitinib|As provided in real world practice
40848195|NCT05834348|DRUG|afatinib|As provided in real world practice
40848196|NCT05834348|DRUG|dacomitinib|As provided in real world practice
40848197|NCT05834348|DRUG|osimertinib|As provided in real world practice
40848198|NCT05834348|DRUG|pembrolizumab|As provided in real world practice
40848199|NCT05834348|DRUG|nivolumab|As provided in real world practice
40848200|NCT05834348|DRUG|entrectinib|As provided in real world practice
40848201|NCT04072263|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.
40848202|NCT04072263|DRUG|Interferon Alfa 2A|Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
40848203|NCT04072263|DRUG|Carboplatin|chemotherapy i.v.
40848204|NCT04072263|DRUG|Paclitaxel|Chemotherapy i.v.
40848205|NCT04797546|PROCEDURE|Adductor Canal Block|Continous peripheral nerve block
40848206|NCT04797546|DEVICE|Morphine Patient Controlled Analgesia|Morphine Patient Controlled Analgesia Delivery System
40848207|NCT04380805|BIOLOGICAL|AK104|All subjects will receive AK104 as a single agent at a dose of 6 mg/kg Q2W (Day 1 and Day 15 of each 28 day treatment cycle) via IV infusion.
41371127|NCT05653648|DIETARY_SUPPLEMENT|Potato starch|Participants will consume 24 grams (days 1-15) and 48 grams (days 16-30) of potato starch. Potato starch is a type 2 resistant starch that is available over the counter.
41371128|NCT03108664|DRUG|SYL1001 ophthalmic solution|1 drop in the affected eye
41371129|NCT03108664|DRUG|Vehicle opthalmic solution|1 drop in the affected eye
41371130|NCT01863108|BIOLOGICAL|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
41371131|NCT06325072|DIAGNOSTIC_TEST|Conclusive genetic testing|Patients will be referred for genetic counseling at the study coordinating center. This will lead to a conclusive genetic diagnosis.
41371132|NCT06325072|DIAGNOSTIC_TEST|Genotype-phenotype correlation for personalized diagnosis|Patients and their family members will undergo a thorough clinical reassessment at the study coordinating center to identify diagnostic handles of the suspected disease based on the genetic test result (reverse phenotyping). The clinical reassessment could include the performance of additional clinical and instrumental tests, as well as other specialized consultations. This will lead to a conclusive genetic diagnosis in a substantial proportion of cases, cases, who will then be provided with genetic counselling.
41371133|NCT06325072|DIAGNOSTIC_TEST|Personalized study of variants of uncertain clinical significance (VUS) through functional studies on 3D organ-on-a-chip|The investigators will perform functional assessment trough urine derived Renal Progenitor Cells (u-RPC) to establish the role of variants in determining the clinical phenotype.
41371134|NCT06372262|OTHER|ergometer test|2000meter rowing ergometer test
41371135|NCT00154674|DEVICE|ICY catheter, Thermoguard device|
41371136|NCT02715843|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
41503413|NCT04410237|OTHER|Traditional Syringe|"One half of each psoriasis plaque will be treated with a traditional syringe and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
41503414|NCT02182635|DRUG|Ba253BINEB|
41503415|NCT02113618|BEHAVIORAL|Cogmed training|Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity
41162764|NCT04091464|BEHAVIORAL|Forward Walking Training|Training will consist of FW training on both treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline FW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes FW, forward stepping, and functional exercises that incorporate FW movements.
41162765|NCT00596258|DRUG|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
41162766|NCT00554086|DRUG|Escalating dose of Casodex from 50mg daily to 150 mg daily|Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
41162767|NCT01202409|DRUG|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
41162768|NCT00506272|PROCEDURE|Self blood glucose monitoring and insulin administration|Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin
41503416|NCT02113618|BEHAVIORAL|Standard Training|Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level
40848208|NCT00600899|PROCEDURE|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
41162769|NCT00506272|PROCEDURE|Standard care|finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
41162770|NCT00676195|DRUG|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
41371137|NCT03164629|DEVICE|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
41371138|NCT02734290|DRUG|Pembrolizumab|Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle
41371139|NCT02734290|DRUG|Paclitaxel|Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle
41371140|NCT02734290|DRUG|Capecitabine|Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
41371141|NCT03755856|OTHER|Questionnaire|Health-related quality of life
41371142|NCT01429142|BEHAVIORAL|Treatment as usual|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
41503417|NCT05184881|OTHER|Retrolaminar block|2- Cervical retrolaminar block: will be performed on prone-positioned patients. Under fluoroscopic visualization, after identification of the lamina at the desired level, a 25-gauge, 3.5-inch spinal needle was introduced and when the needle tip will be confirmed at the posterior aspect of the cervical lamina corresponding to cervical facet arthropathy level. 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) will be injected.
40848209|NCT00600899|PROCEDURE|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
40848210|NCT02178696|OTHER|Placebo, identified as placebo to participants|White tablets
41503418|NCT05184881|OTHER|Medial Branch Block|1- Cervical medial branch block: will be performed on prone-positioned patients using a posterior approach. Under fluoroscopic visualization, after identification of the waists of the articular pillars at the desired levels, each medial branch block was administered with a 25-gauge, 3.5-inch spinal needle. When the place of the needle tip will be confirmed at the mid-point of the waists of articular pillars, 1 ml of the mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml) will be injected at each level.
41503419|NCT03744429|OTHER|Mediterranean Diet|Participants will be provided with meals that follow a Mediterranean meal plan.
41371143|NCT01429142|BEHAVIORAL|AIMS intervention|"The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo."
41371144|NCT05723406|DRUG|Sugammadex 100 MG/ML [Bridion]|8 mg/ml
41371145|NCT05723406|OTHER|Placebo|Sodium 0.9% 5 ml
41371146|NCT02726516|DIETARY_SUPPLEMENT|PRJ-205|1 sachet per day
41371147|NCT02726516|OTHER|Placebo|1 sachet per day
41371148|NCT03229902|BEHAVIORAL|mantra meditation|see study description
41371149|NCT02945566|PROCEDURE|Standard TME surgery|Total mesorectal excision
41371150|NCT02945566|DRUG|Long course concurrent chemoradiation with capecitabine and radiotherapy|Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
41371151|NCT02945566|RADIATION|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
41371152|NCT04099589|DRUG|Toripalimab|Gemcitabine/Cisplatin plus Toripalimab
41503420|NCT05855122|DRUG|Tocilizumab|Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
41162771|NCT05427019|PROCEDURE|Distal adductor canal block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.
41503421|NCT00905710|PROCEDURE|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
41503422|NCT01056042|DRUG|intramuscular depot medroxyprogesterone acetate|150 mg, Intramuscular, every 3 months
41503423|NCT01056042|DRUG|ethinyl estradiol 30 micrograms, gestodene 75 micrograms|one tablet orally, everyday
41162772|NCT05427019|PROCEDURE|Distal adductor canal block and Periarticular block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
41162773|NCT01218295|DEVICE|Spirotiger®|training session :10 minutes twice a day X 4 weeks
41162774|NCT00001666|DEVICE|Cadwell High-Speed Magnetoelectric Stimulator|
41162775|NCT00001666|DEVICE|Magpro High-Speed Magnetoelectric Stimulator|
41162776|NCT01039259|DEVICE|piercings of four different materials|randomly assigned sterile piercings are inserted for two weeks
41371153|NCT01459016|OTHER|PET scan using florbetapir|A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
41371154|NCT01459016|OTHER|MRI Scan|Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
41371155|NCT01748162|DRUG|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
41371156|NCT01748162|DRUG|Prednisolone IF needed|
41371157|NCT00003758|DRUG|cytarabine|
41371158|NCT00003758|DRUG|idarubicin|
41371159|NCT00003758|PROCEDURE|allogeneic bone marrow transplantation|
41371160|NCT00003758|PROCEDURE|autologous bone marrow transplantation|
41371161|NCT00003758|PROCEDURE|peripheral blood stem cell transplantation|
41371162|NCT02679300|OTHER|Virtual reality exercise group|
41371163|NCT02679300|OTHER|Conventional exercise group (control group)|
41371164|NCT02203604|BIOLOGICAL|aldesleukin|Given IV
41371165|NCT02203604|BIOLOGICAL|ipilimumab|Given IV
41371166|NCT02203604|OTHER|laboratory biomarker analysis|Correlative studies
41371167|NCT06309667|DRUG|PG-102(MG12)|GLP-1 and GLP-2 fusion protein
41371168|NCT06309667|DRUG|Placebo|Placebo drug of PG-102(MG12)
41371169|NCT00197691|PROCEDURE|blood draws, etc.|
41371170|NCT04158466|DEVICE|Kalifilcon A Daily Disposable Contact Lenses|Contact lens
41371171|NCT04158466|DEVICE|Biotrue ONEday Daily Disposable Contact Lenses|Contact lens
41371172|NCT06425822|DIAGNOSTIC_TEST|Left atrial electroanatomical mapping|Left atrial electroanatomical mapping (substrate and functional mapping)
41371173|NCT03625102|DRUG|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
41371174|NCT03625102|OTHER|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
41371175|NCT02684370|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
41371176|NCT02684370|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
41371177|NCT02684370|DRUG|ustekinumab|Ustekinumab administered by subcutaneous (SC) injection
41371178|NCT02684370|DRUG|placebo for ustekinumab|Placebo for ustekinumab administered by subcutaneous (SC) injection
41371179|NCT05072431|OTHER|SVVR training program|The SVVR training program is consisted of five scenarios with tasks. Before the SVVR training implementation, the research team provided 10-minute orientation session to introduce the purpose of the training. The 3D VR professional taught the participants how to wear the 3D VR helmets and select the VR scenes, so that the participants could practice multiple times.
41371180|NCT01898390|PROCEDURE|Transplant|Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
41371181|NCT00848302|DRUG|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
41503424|NCT06040151|DEVICE|Digizorg mobile app (quality evaluation study)|Erasmus Medical Center is developing a state-of-the-art, mobile-based patient portal that combines up-to-date medication lists from all healthcare providers involved in a patient's care. Other functionalities include: accessing health information, viewing and planning appointments, teleconsulting, sending messages, filling in questionnaires, reporting self-measurements, and reading background information on diseases, medication, and other interventions. The patient portal will primarily be implemented in Erasmus Medical Center, and is ultimately intended for every patient, regardless of underlying condition.
41503425|NCT00191165|DRUG|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
41503426|NCT00191165|DRUG|Somatropin|In-label dosage
41030956|NCT05034692|PROCEDURE|Laparoscopic-assisted colectomy with extracorporeal anastomosis|After the corresponding colon and blood vessels were dissociated and treated, the carbon dioxide pneumoperitoneum was removed. The appropriate length of the incision was cut at the corresponding position of the abdomen, and the incision protector was placed. The tumor was lifted together with the free intestinal canal to the outside of the abdomen. The intestinal canals at the quasi-dismembered sites on both sides of the tumor were nuded, and the colon-colon functional end-to-end anastomosis was performed.
41030957|NCT06395688|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one|AEF0117 soft capsules of 1mg
41030958|NCT06395688|DRUG|Placebo|Placebo soft capsules (identical to active compound)
41503427|NCT04244383|DIAGNOSTIC_TEST|interleukin IL-1beta and interleukin IL-18|pro-inflammatory cytokines measured in the serum
41503428|NCT03587116|DRUG|Standard of Care FIX Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
41503429|NCT03587116|DRUG|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
41503430|NCT00397514|PROCEDURE|Congenital Heart Surgery Patients|undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
41503431|NCT05329324|OTHER|Questionnaire for study group|Demographic features, Stage and Type, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
41503432|NCT05329324|OTHER|Questionnaire for control group|Demographic features, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
41030959|NCT00002026|DRUG|Acyclovir|
41162777|NCT05641714|OTHER|L test|The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.
41162778|NCT05641714|OTHER|Timed Up and Go test|The test requires the individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.
41371182|NCT02103894|DRUG|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
41371183|NCT02788890|PROCEDURE|Scaling without LA|The patient will undergo a supragingival scaling procedure without local anesthesia
41371184|NCT02788890|PROCEDURE|Simple restoration under LA|The patient will undergo a simple dental restoration procedure under local anesthesia
41371185|NCT02788890|PROCEDURE|Simple exodontia under LA|The patient will undergo a simple dental extraction procedure under local anesthesia
41371186|NCT05287581|BEHAVIORAL|MOVES|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
41030960|NCT01136291|OTHER|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care."
41030961|NCT04573920|DRUG|Atrasentan|Film-coated tablet
41030962|NCT04613414|OTHER|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
41371187|NCT06355518|DIETARY_SUPPLEMENT|Immunonutrition|This formula is enriched in arginine, nucleotides (RNA) and omega-3 fatty acids and provides, with the proposed therapeutic volume (2 units per day), 36 grams of protein and 682 kcal/day.
41371188|NCT06355518|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement|This formula provides 38 grams of protein and 500 kcal/day with the proposed therapeutic volume.
41371189|NCT04941833|DRUG|Desogestrel Oral Tablet|Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
41371190|NCT02260570|DRUG|Tolcapone|COMT Inhibitor
41371191|NCT02260570|DRUG|Placebo|A pill that contains no active ingredient
41371192|NCT03035175|OTHER|Video Laryngoscopy|Residents intubate using video laryngoscopy.
41371193|NCT03035175|OTHER|Traditional Laryngoscopy|Residents intubate without using video laryngoscopy.
41371194|NCT03539627|DRUG|Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]|patients are to receive azilsartan medoxomil
41371195|NCT03590158|BEHAVIORAL|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
41371196|NCT02198820|DRUG|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
41503433|NCT05134857|DRUG|Zonisamide|The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.
41503434|NCT05134857|DRUG|Placebo|The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
41030963|NCT02488486|DEVICE|Automated postoperative sedation|
41030964|NCT02488486|DRUG|propofol|
41030965|NCT02488486|DRUG|remifentanil|
41030966|NCT05016492|DEVICE|Visual-perceptual interactive game system|Subjects received 30-min interactive digital game training session per week. The game system contain 7 skills training, each of which was named according to the corresponding TVPS-3.
41030967|NCT05016492|BEHAVIORAL|standard rehabilitation|Subjects received the standard 4-week course of rehabilitation delivered in one 30-min session per week. The course of rehabilitation included: sensory integration therapy, cognitive function training and visual perception/auditory attention training.
41030968|NCT00418392|PROCEDURE|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
41030969|NCT00418392|PROCEDURE|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
41030970|NCT04148443|OTHER|Preoxygenation|participants will receive 3 minutes of preoxygenation before intubation
41371197|NCT02198820|DRUG|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
41371198|NCT05901376|DIAGNOSTIC_TEST|MicroRNA|MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
41371199|NCT04587362|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.
41371200|NCT06509438|DEVICE|Embella (Deoxycholic acid, produced by Espad Pharmed Co.)|2 milliliters of Embella injectable solution containing 20 milligrams of deoxycholic acid
41371201|NCT06374511|DIAGNOSTIC_TEST|Test for CMV reactivation|All enrolled patients are monitored for CMV reactivation and hepatic encephalopathy using regular clinical tests or library test
41371202|NCT02304770|DRUG|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
41371203|NCT01761565|DRUG|Single dose of SUF NT 15 mcg|
41371204|NCT01761565|DRUG|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
41371205|NCT03246152|DRUG|Bevacizumab|Repeated intravitreal injections of Bevacizumab monthly
41371206|NCT00762281|DEVICE|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
41371207|NCT00189917|BIOLOGICAL|IMVAMUNE (MVA-BN)|1x10E08 TCID50, subcutaneous vaccination
41371208|NCT06450990|DRUG|BGY-1601-VT|Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.
41371209|NCT06450990|OTHER|PLACEBO|Placebo
41371210|NCT04098003|DRUG|Rosuvastatin|rosuvastatin 20 mg daily or placebo for eight weeks
41371211|NCT04098003|DRUG|Placebo|Matched placebo control
41503435|NCT03390426|DRUG|Mepivacaine|An ultrasound guided injection of mepivacaine superomedially to the femoral artery.
41503436|NCT03390426|PROCEDURE|Perifemoral Injection of Local Anesthetic|An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
41503437|NCT03390426|DRUG|Saline|An ultrasound guided injection using a medication that does NOT numb any nerves called saline, or salt water.
41371212|NCT06045468|OTHER|Amputation-specialized rehabilitation|Study center; amputation-specialized unit within rehabilitation facility; fully practicing national guidelines
41371213|NCT06045468|OTHER|Non-amputation-specialized rehabilitation|Control clinics; treating some amputated patients each year but do not practice national guidelines or partially practicing national guidelines
41371214|NCT01222962|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
40848211|NCT02178696|DRUG|Celexa or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg
40848212|NCT02178696|OTHER|"Placebo, identifed to participants as Active medication"|Blue Capsule
40848213|NCT03078855|DIETARY_SUPPLEMENT|Vitamin D|vitamin D3 2,000 IU daily
40848214|NCT03078855|BIOLOGICAL|Rituximab|Administered weekly x 4
40848215|NCT03078855|OTHER|Placebo|methylcellulose
41162779|NCT05641714|OTHER|10 meter walk test|In the test, the clinician measures the time taken to walk a distance of 10 m from a standing position. Participants are asked to walk along a 14 m long walkway.
41371215|NCT04037540|PROCEDURE|Operational approach|Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.
41371216|NCT04037540|PROCEDURE|Conservative approach|Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
41371217|NCT02224495|BEHAVIORAL|Structured exercise training|
41371218|NCT03042338|BEHAVIORAL|CET: Central Executive Training|CET: Central Executive Training
41371219|NCT03042338|BEHAVIORAL|CET: Comparison Executive Training|CET: Comparison Executive Training
41371220|NCT05829746|DEVICE|Tubridge|Intracranial stent for wide-necked aneurysms
41371221|NCT05098678|DIETARY_SUPPLEMENT|Zinc gluconate|120 mg each tablet containing 30 mg elemental zinc
41371222|NCT05098678|DIETARY_SUPPLEMENT|Placebo|Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
41371223|NCT05921851|OTHER|no intervention|no intervention
41371224|NCT02549391|DRUG|KHK7580|Oral administration
41371225|NCT02549391|DRUG|KRN1493|Oral administration
41371226|NCT00003876|DRUG|polifeprosan 20 with carmustine implant|
40848216|NCT01248637|DRUG|Pimonidazole hydrochloride|Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 \<= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
40848217|NCT03776591|PROCEDURE|Open surgery|
40848218|NCT03776591|PROCEDURE|Right colectomy|
40848219|NCT03776591|PROCEDURE|Laparoscopic surgery|
40848220|NCT03776591|PROCEDURE|Central lymphadenectomy and vascular ligation|
40848221|NCT00923845|DRUG|Pentostatin|Pentostatin: 2- 4mg/m\^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
40848222|NCT00923845|DRUG|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
40848223|NCT00923845|DRUG|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
40848224|NCT00923845|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
40848225|NCT00923845|PROCEDURE|Th2 rapa cells|Th2 rapa cell Transplantation
40848226|NCT00923845|PROCEDURE|Donor Lymphocyte Harvest|Apheresis
40848227|NCT00923845|PROCEDURE|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
40848228|NCT00923845|PROCEDURE|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
41371227|NCT00003876|PROCEDURE|surgical procedure|
41371228|NCT00003876|RADIATION|iodine I 125|
41371229|NCT00101140|DRUG|anti-thymocyte globulin|
41371230|NCT00101140|DRUG|fludarabine phosphate|
41371231|NCT00101140|DRUG|thiotepa|
41371232|NCT00101140|PROCEDURE|biological therapy|
41371233|NCT00101140|PROCEDURE|bone marrow ablation with stem cell support|
41371234|NCT00101140|PROCEDURE|chemotherapy|
41371235|NCT00101140|PROCEDURE|non-specific immune-modulator therapy|
41371236|NCT00101140|PROCEDURE|peripheral blood stem cell transplantation|
41371237|NCT00101140|PROCEDURE|radiation therapy|
41371238|NCT01875900|OTHER|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
41371239|NCT01875900|OTHER|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
41371240|NCT00886977|DRUG|YAM80|Oral administration, 2 to 6 mg, once a day.
41371241|NCT04213001|DIAGNOSTIC_TEST|ultrasonographic measurement|ultrasonographic measurement- Subcutaneous ultrasound echogenicity (SEG) and Skin and subcutaneous thickness measurement
41371242|NCT00381680|DRUG|vincristine sulfate|Given IV
41371243|NCT00381680|DRUG|prednisone|Given PO
41371244|NCT00381680|DRUG|doxorubicin hydrochloride|Given IV
41371245|NCT00381680|DRUG|pegaspargase|Given IM
41371246|NCT00381680|DRUG|cytarabine|Given IT or IV
41371247|NCT00381680|DRUG|methotrexate|Given IT or IV
41371248|NCT00381680|DRUG|dexamethasone|Given PO
41371249|NCT00381680|DRUG|etoposide|Given IV
41371250|NCT00381680|DRUG|cyclophosphamide|Given IV
41371251|NCT00381680|DRUG|leucovorin calcium|Given IV or PO
41371252|NCT00381680|BIOLOGICAL|filgrastim|Given IV or SC
41371253|NCT00381680|DRUG|asparaginase|Given IM
41371254|NCT00381680|DRUG|mercaptopurine|Given PO
41371255|NCT04285957|OTHER|Questionnaire administration pre test|"Pre-test:~Two expert physicians/physical therapist shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI);"
41371256|NCT04285957|OTHER|Questionnaire administration - validation|Validation Two expert physicians shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI); In case the patient is unable to be interviewed due to aphasia cognitive or sensorial problems, a proxy would be interviewed both at T0 and at T1 (the same proxy would be interviewed both times)
40848229|NCT00923845|PROCEDURE|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
41503438|NCT03071939|OTHER|Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers|"This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services)."
41503439|NCT01221389|DRUG|Human Plasma|Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
41503440|NCT05368064|OTHER|observational|collection of phenotype data
41503441|NCT03155516|OTHER|Good pain management (GPM) procedure|"In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.~Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required."
41503442|NCT03155516|OTHER|Current practice procedure|Current practice clinical procedure for pain management
41503443|NCT06633835|BIOLOGICAL|protein subunit: Novavax COVID-19 vaccine|Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.
41503444|NCT06633835|BIOLOGICAL|Pfizer mRNA COVID-19 vaccine|Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.
41503445|NCT03247192|DIETARY_SUPPLEMENT|Whey protein-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
41030971|NCT04148443|OTHER|Preoxygenation (longer)|participants will receive 5 minutes of preoxygenation before intubation
41162780|NCT05641714|OTHER|Six Minute Walk Test|This test measures the distance (in m) that an individual is able to walk at a comfortable speed for 6 minutes. Starting from a standing position, participants walk continuously around two pylons placed 30 m apart for 6 minutes. The distance is recorded end of the test.
41162781|NCT05641714|OTHER|The timed 360° turn test|Each participant turns around in place in a standing position for both sides.
41162782|NCT05310058|DIETARY_SUPPLEMENT|C6 ketone di-ester|C6 ketone di-ester
41371257|NCT03935282|OTHER|AH-HA Tool in the EPIC EHR|The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
41371258|NCT03947632|DIAGNOSTIC_TEST|serum ferritin and hemoglobin test|Five milliliter of blood samples were collected in two tubes (ethylenediaminetetraacetic acid and gel) at Fatimid foundation by a trained phlebotomist prior to blood transfusion to determine hemoglobin and serum ferritin.
41371259|NCT06332677|DIAGNOSTIC_TEST|the main genes and expression by comparing the transcriptomic lipidomic profile|To identify the main genes and pathways differentially expressed and the main factors associ- ated in order to evaluate the role of SUV420H1/H2
41371260|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
41503446|NCT03247192|DIETARY_SUPPLEMENT|Placebo-whey protein|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
41503447|NCT03247192|DIETARY_SUPPLEMENT|Placebo-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
40848230|NCT06035848|PROCEDURE|Association of the components of metabolic derangement and paracentesis.|"In the intervention group were determined:~1. Components of metabolic derangement~2. Paracentesis. Determination of surgery: 3 positive points of the components of the metabolic derangement and a positive paracentesis.~The components of the metabolic derangement are the 7 parameters described by Tepas: positive blood culture, metabolic acidosis, neutropenia, bandemia, thrombocytopenia, hyponatremia and hypotension, being considered positive when 3 or more parameters are present.~Paracentesis was considered positive according to Kosloske's criteria: obtaining more than 0.5ml of serohematic fluid, Gram-positive fluid and obtaining fecal material.~Both groups had the same pre, trans and postoperative care."
40848231|NCT06035848|PROCEDURE|Bell's criteria: pneumoperitoneum|In the control group, the surgery was determined according to Bell's criteria, in the presence of radiographic pneumoperitoneum as an absolute indication for surgery.
40848232|NCT05908773|DRUG|TTX-MC138-NODAGA-Cu64|TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging.
41162783|NCT01880697|BIOLOGICAL|TIVc|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)
41371261|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
40848233|NCT03746041|DRUG|abaloparatide|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days.
41371262|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
41371263|NCT00835861|DRUG|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
41371264|NCT00835861|DRUG|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values \<90 and one hour post prandial values \<130.
41371265|NCT04961944|OTHER|Disease assessment|"A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed.~The association between endotypes and disease progression will be tested."
41371266|NCT00862667|DRUG|Treatment A|PF-00241939 300ug using Inhaler A
41371267|NCT00862667|DRUG|Treatment B|PF-00241939 300ug using Inhaler B
41371268|NCT00862667|DRUG|Treatment C|PF-00241939 300ug using Inhaler C
41371269|NCT04282551|OTHER|dietary intervention with oligosaccharides|intervention with oligosaccharide 1 or 2, or placebo, given once a day
41371270|NCT02862002|OTHER|"therapeutic education of type caratif"|"study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology"
41371271|NCT02862002|OTHER|Standard care|patients receiving standard care of cancer pain.
41371272|NCT05662982|DEVICE|Northwestern University Flexible Subischial Suction Socket (NU-FlexSIS)|A custom-made prosthetic socket for transfemoral amputation that consists of proximal trimlines that do not interact with the pelvis.
41371273|NCT06315634|DRUG|Dexmedetomidine|5 micrograms intrathecal dexmedetomidine
41371274|NCT06315634|DRUG|Midazolam|2 milligrams intrathecal midazolam
41371275|NCT06315634|DRUG|Bupivacain|12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
40848234|NCT03746041|DRUG|bevacizumab|In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
40848235|NCT01799434|OTHER|treadmill run|
41162784|NCT02673554|DRUG|GIP Bolus|bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
41162785|NCT02673554|DRUG|GIP Clamp|hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
41162786|NCT02673554|PROCEDURE|Oral glucose tolerance test (OGTT)|an oral glucose challenge (75 g)
40848236|NCT05551884|PROCEDURE|Metabolites and HVPG|"HVPG measurement are performed by well-trained interventional radiologists in accordance with standard operating procedures.~All enrolled patients were analyzed for potential differential metabolites using metabolomics."
40848237|NCT05018078|BIOLOGICAL|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
40848238|NCT02678455|BIOLOGICAL|TV005 vaccine|Delivered by subcutaneous injection; contains 10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31, and 10\^3 PFU of rDEN4Δ30.
40848239|NCT02678455|BIOLOGICAL|Placebo|Delivered by subcutaneous injection
40848240|NCT02249182|DRUG|LDV/SOF|LDV/SOF FDC administered orally once daily
41371276|NCT04231799|PROCEDURE|Bathing|Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
41371277|NCT01521975|DRUG|Telbivudine, Adefovir dipivoxil|All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
41030972|NCT04200066|DRUG|Temozolomide, Tamoxifen, Maprotiline|Subjects will receive a combination of temozolomide and tamoxifen for two weeks. After that, they will receive a combination of temozolomide, tamoxifen and maprotiline for the remainder of the study. All drugs are administered orally. Subjects will undergo visits at the beginning of week 3, week 5 and week 7 that will involve multiple blood draws and ECGs to evaluate for pharmacokinetics and drug interactions. Response will be assessed every two months with an MRI and patients will continue on study as long as their tumors are under control and they are tolerating the regimen.
41030973|NCT02925975|DRUG|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
41030974|NCT02925975|DEVICE|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
41030975|NCT02925975|PROCEDURE|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
41030976|NCT04154787|DRUG|LNP023|Investigation of LNP023
41030977|NCT04154787|DRUG|Rituximab|Comparison of rituximab dose
41030978|NCT06536283|OTHER|13-item Barriers Questionnaire (BQ-13)|Given by questionnaire
41030979|NCT06536283|OTHER|Four-item Medication Adherence Questionnaire|Given by questionnaire
41030980|NCT06536283|OTHER|14-item Hospital Anxiety and Depression Scale (HADS)|Given by questionnaire
41030981|NCT05809518|DRUG|Propofol injection|sedation after cardiac surgery
41030982|NCT05809518|DRUG|Dexmedetomidine injection|sedation after cardiac surgery
41030983|NCT05809518|DRUG|Dexmedetomidine and Propofol|sedation after cardiac surgery
41162787|NCT02673554|PROCEDURE|hyperglycemic clamp|a hyperglycemic clamp (capillary venous glucose concentration \~ 8.5 mmol/l)
41162788|NCT03433209|DEVICE|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy
41162789|NCT03433209|DEVICE|Articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy
41371278|NCT02620228|DEVICE|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
41503448|NCT00022282|DRUG|shark cartilage extract AE-941|
40848241|NCT02249182|DRUG|RBV|Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
41030984|NCT03305679|PROCEDURE|Direct provisional technique|The method of implantation will be accomplished directly.
41030985|NCT03305679|PROCEDURE|Indirect Provisional technique|The method of implantation will be accomplished indirectly.
41030986|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
41030987|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
41162790|NCT03209050|DEVICE|Central Venous Access Placement|Device inserted into the femoral vein to insert a central venous access catheter
41162791|NCT02551692|DRUG|Nicotine Patch|Participants will wear 21mg/day patches for days 1-14. After day 14, participants will make a quit attempt continue to wear the 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment. Participants will also take a placebo capsule. During days 8-14, participants will undergo 2 cue-exposure sessions.
41162792|NCT02551692|DRUG|Varenicline|Varenicline (VAR) will be administered by titrating to steady state levels over a 7 day induction period (.5 mg once daily in Days 1-3; .5 mg twice daily on Days 4-7 and 1 mg twice daily on Days 8-14). Participants will continue on 1mg twice daily until the end of treatment (days 15-84). Participants will also wear a placebo patch. During days 8-14, participants will undergo 2 cue-exposure sessions.
41162793|NCT02551692|DRUG|Placebo Nicotine Patch|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the VAR group, participants will wear a placebo patch while taking varenicline."
41371279|NCT03778021|BEHAVIORAL|Behavioral Gardening Exposure|Assistance provided with planting and maintaining the school garden
41371280|NCT03778021|BEHAVIORAL|Healthy Eating and Gardening Curriculum|14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
41371281|NCT00700115|DRUG|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
41030988|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
41030989|NCT05234944|BEHAVIORAL|Type 1 Diabetes and Life|Brief behavioral intervention, delivered remotely by certified diabetes care and education specialists, targeting diabetes-specific health-related quality of life for people with type 1 diabetes across the lifespan and for their parents and partners.
41030990|NCT00253864|PROCEDURE|Single row|Fixation type in arthroscopic rotator cuff repair.
41371282|NCT00700115|DRUG|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
41371283|NCT02293876|DEVICE|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
41503449|NCT04061148|DEVICE|NIRSIT|NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
41503450|NCT05627362|DRUG|Elafibranor 80 mg|Oral Tablet
41503451|NCT05627362|DRUG|Elafibranor 120 mg|Oral Tablet
41503452|NCT05627362|DRUG|Placebo Matched to Elafibranor 80 mg|Oral Tablet
41503453|NCT05627362|DRUG|Placebo Matched to Elafibranor 120 mg|Oral Tablet
40848242|NCT05271448|OTHER|Continue ACEI or ARBs ( Enalapril , Ramipril , Valsartan , Candesartan, Losartan )|Randomized to continue on prescribed ACE1 or ARBs ( Enalapril 5, 10, 20 mg // Ramipril 2.5 , 5 mg // Valsartan 80 , 160 mg // Candesartan 8, 16 mg // Losartan 50 mg )
40848243|NCT05271448|OTHER|Hold ACEI or ARBs|"Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-72 hours post-catheterization (after creatinine measurement)~Other Name: Includes all ACEI inhibitors or ARBs"
41162794|NCT02551692|DRUG|Placebo Capsule|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the NRT group, participants will take a placebo capsule while wearing nicotine patches."
41371284|NCT02293876|DEVICE|LIPOSIC®|Carbomer and Sorbitol based gel, used in the treatment of dry eye.
41371285|NCT02293876|DEVICE|Glad wrap|A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
41371286|NCT03959306|DIETARY_SUPPLEMENT|Black Seed Oil|Black seed oil soft gelatin capsule
41371287|NCT03959306|DRUG|Anti-Diabetics|standard anti-diabetic treatment prescribed for the patient
41371288|NCT02295124|DRUG|Oxycodone|Patients will receive oxycodone 10mg (5mg if \> 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
41371289|NCT02295124|DRUG|Hydromorphone|Patients will receive an initial dose of hydromorphone 2mg (1mg if \> 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
41371290|NCT05466916|BEHAVIORAL|Exercise and diet education and instruction|1:1 or small group sessions consisting of educational materials and exercise instruction.
41371291|NCT05239065|BEHAVIORAL|The basic intervention|The participants will receive a paper-printed booklet introducing stress and stress management strategies, regular exercise, deep breathing and mediation, etc, as well as a HUAWEI portable device at the recruitment. During the following 3-month intervention phase, there is not informational materials, portable device data feedback, online group discussion or interpersonal communications with the participants. The participants will only need to fill in a simplified questionnaire biweekly.
41371292|NCT05239065|BEHAVIORAL|The personalized interventions|The participants will receive a paper-printed booklet introducing stress and stress management strategies and a HUAWEI portable device at the recruitment. A neurologist will be the health educator to host an online group for free communications. The typical stress-relieving methods and the strategies of using portable device will be explained by providing small videos, online article links and nursing coaching in person. The health educator will give regular knowledge educations about the stress hazards, stress management necessities and skills on weekly basis. The weekly data of HUAWEI portable devices will be sent to the participants along with personalized suggestions by trained nurses. At certain occasions, gifts and rewards will be sent out for encouragement and keeping attachment to the program. The participants will be required to fill in the weekly questionnaires online for feedback.
41371293|NCT03881748|OTHER|Manual acupuncture|"Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes."
41371294|NCT03881748|OTHER|Electro-acupuncture|"Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied."
41371295|NCT03015662|OTHER|Dry Needling Therapy|Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).
41371296|NCT03015662|OTHER|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
40848244|NCT06463860|DEVICE|DermDx|DermDx is a computer-aided diagnosis (CADx) software product that uses an AI-based algorithm to evaluate non-invasively captured images of skin lesions obtained from any commercially available dermoscopes. DermDx uses state-of-the-art deep neural network models that have been trained on a large database of dermoscopy images. DermDx analyzes the image of a new skin lesion and provides an output.
41162795|NCT02690415|PROCEDURE|Antibiotics Given|Patients who's treating physician prescribed antibiotics
40848245|NCT01533142|PROCEDURE|Bariatric surgery|"Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass"
41371297|NCT01479777|DEVICE|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
40848246|NCT01533142|PROCEDURE|Bariatric surgery|Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
41030991|NCT00253864|PROCEDURE|Double row|Fixation type in arthroscopic rotator cuff repair.
41371298|NCT04647175|OTHER|Fermented aronia|Given twice daily for 8 weeks
41371299|NCT04647175|OTHER|Aronia|Given twice daily for 8 weeks
41503454|NCT05703360|DEVICE|Audiovisual Stimulation|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
41503455|NCT03909282|PROCEDURE|Lumpectomy|Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
41503456|NCT03909282|RADIATION|Partial breast irradiation prior to surgery|Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
41503457|NCT01404676|DRUG|Add Vildagliptin|Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
40848247|NCT01976143|DRUG|NKTR-102|
40848248|NCT06061835|OTHER|Non-contrast MRA in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: MRA scan Philips Ingenia 1.5 T (Royal Philips, Netherlands)~Preprocedural patient's preparation: the study was performed on an empty stomach (at least 8 hours of fasting).~Type of patient positioning. MRA scanning was performed in the prone position.~Additional devices. The investigators placed the patient on her abdomen on a special coordinate system mesh, for the most precise and convenient way of marking.~Scanning protocol. The investigators added T2 pulse sequence to increase the accuracy of muscle localization assessment and the point of vessel immersion into the muscle at TR and TE using a fat suppression program, wich allows receiving information from moving objects (including blood within the vascular lumen).~Scan viewer program. OsiriX 10.0 Release"
41371300|NCT04647175|OTHER|Placebo|Given twice daily for 8 weeks
41371301|NCT02973282|OTHER|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
41371302|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
41371303|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
41371304|NCT01399619|DRUG|BI201335|BI201335 for 12w
41503458|NCT01404676|DRUG|Add Glimepiride|Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
41503459|NCT02930759|DRUG|BAY987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-096)
41371305|NCT01399619|DRUG|BI201335 24W|BI201335 for 24w
41371306|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
41503460|NCT00801099|DRUG|Amoxicillin/Clavulanic Acid|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
41503461|NCT04952909|DEVICE|ShortCut™|Splitting bioprosthetic aortic valve leaflets
41503462|NCT06588855|DRUG|RO7790121|RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.
41030992|NCT02671487|BEHAVIORAL|Mind-Body Skills Groups|Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
41371307|NCT01399619|DRUG|Bi 201335|BI 201335 for 24 w
41371308|NCT02348671|OTHER|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
41503463|NCT06588855|DRUG|Placebo|Placebo matching IV RO7790121. Placebo matching SC RO7790121.
41503464|NCT05803421|DRUG|Orforglipron|Administered orally once daily
41503465|NCT05803421|DRUG|Insulin Glargine|Administered SC once daily
41503466|NCT01138982|BEHAVIORAL|Youth Mentoring program|
41503467|NCT02041065|DEVICE|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
41503468|NCT02041065|DEVICE|CUSA induced dissection|Ultrasound based destruction of the liver
41503469|NCT05966662|DEVICE|IVL with Shockwave C2+ 2Hz Coronary IVL Catheter|Lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.
41030993|NCT06047769|OTHER|Board Games|Participants will receive cognitive training in board games including Ludo, Chutes \& Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
41030994|NCT01354821|PROCEDURE|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
41503470|NCT00215280|DRUG|ivermectin and albendazole|
41503471|NCT05691517|PROCEDURE|Biopsy|Undergo tumor biopsy
41371309|NCT04233372|DRUG|Delstrigo|"Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil.~1 covered tablet for day .( will be administered 28 days maximum)"
41371310|NCT03075826|DRUG|SGI-110|subcutaneously at a dose of 60 mg/m2
41371311|NCT04269161|DEVICE|Automatic control of inspired oxygen|A device will be used to automatically adjust the blend of oxygen and air with the ability to return to manual control as needed.
41371312|NCT00295256|BEHAVIORAL|nurse case manager|
41371313|NCT01322061|DRUG|Ascorbic Acid|Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
41371314|NCT04705259|BEHAVIORAL|Antimicrobial Stewardship ENGAGEMENT bundle|"Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs \[7\], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~* Education and engagement of prescribers, nurses, pharmacists and residents and family members~* Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~* Guideline development specific to antibiotic use in RACF residents~* Antimicrobial stewardship team creation in RACF with GP involvement~* EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~* ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~* Telehealth support for key intervention components"
41371315|NCT00556140|DRUG|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
40848249|NCT06061835|OTHER|CTA with iodine contrast in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: Device: Toshiba Aquilion 64 CTA scan machine (Toshiba Medical Systems, Tokyo, Japan).~Preprocedural patient's preparation: A catheter was placed in the antecubital vein of one arm, and a bolus injection of 80 ml contrast medium (Omnipaque 300 mg/ml, GE Healthcare, Oslo, Norway, registration number P N015799/01 from July 31, 2003, international nonproprietary name is a Iohexol) was administered through a power injector (M. Schilling GmbH Medical Products, Germany) at 4 ml/s.~Type of patient positioning. CTA scanning was performed in the supine position.~Scan viewer program. OsiriX 10.0 Release"
40848250|NCT01078844|DRUG|memantine|memantine 5-20 mg daily
41371316|NCT02078557|DRUG|MK-8892|
41371317|NCT00040326|PROCEDURE|anteromesial temporal resection|surgical treatment for epilepsy
41371318|NCT00040326|DRUG|antiepileptic drugs|pharmacotherapy
41371319|NCT04434612|DEVICE|OXSIGHT smart glasses|OXSIGHT smart glasses are head-mounted electronic LVAs designed for LV patients with visual field loss.
40848251|NCT01078844|DRUG|Placebo|Look-alike placebo
41371320|NCT02180659|DRUG|sublingual buprenorphine tablets|
41371321|NCT02180659|DRUG|Buprenorphine implant|
41371322|NCT02180659|DRUG|placebo implants|
41503472|NCT05691517|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40848252|NCT06583772|DIAGNOSTIC_TEST|VR-based 9-hole peg test|The volunteers will first undergo a physical 9-hole peg test. After the physical test is completed, the VR-based 9-hole peg test will be performed.
40848253|NCT02807870|DRUG|Methylphenidate|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments).
40848254|NCT02807870|BEHAVIORAL|Parental training|Weekly parental training conducted by behavioral psychologists.
40848255|NCT02807870|OTHER|Psychoeducational groups for parents|Weekly psychoeducational groups conducted by educators.
40848256|NCT02807870|DRUG|Placebo pill|Placebo pill during 8 weeks.
41371323|NCT02180659|DRUG|sublingual placebo tablets|
40848257|NCT00013013|PROCEDURE|Systems Support|
41030995|NCT01354821|PROCEDURE|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
41371324|NCT02778893|DRUG|Conmana|125mg three times a day (TID) continuously
41371325|NCT02778893|DRUG|Thalidomide|100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
41371326|NCT02687724|DRUG|Golimumab (GLM)|GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
41371327|NCT00234533|DRUG|Somatropin (rDNA origin)|Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
41371328|NCT01568255|DRUG|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
40848258|NCT02689167|DRUG|Sunitinib|
41030996|NCT05846516|DRUG|VSV-GP154|Injection
41030997|NCT05846516|DRUG|ATP150|Injection
41503473|NCT05691517|PROCEDURE|Computed Tomography|Undergo CT scan
41503474|NCT05691517|DRUG|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
41030998|NCT05846516|DRUG|ATP152|Injection
41030999|NCT05846516|DRUG|Ezabenlimab|Infusion
41031000|NCT01985594|DRUG|utrogestan|Oral Tablet Utrogestan 400 mg daily for 2 days
41031001|NCT01985594|DRUG|Nifedipine|Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
41031002|NCT01373086|DRUG|LFF269|
41031003|NCT01373086|DRUG|Eplerenone|
41031004|NCT01373086|DRUG|Placebo|
41031005|NCT06086223|PROCEDURE|ankle arthroscopy with ORIF|we will go for fixation of the fracture with association of scope intervention pre and post fixation
41031006|NCT06086223|PROCEDURE|fracture ankle fixation without ankle arthroscopy|we will go for fixation of the fracture alone with no scope intervention
41031007|NCT06052852|DRUG|BDC-3042|Dectin-2 agonist antibody
40848259|NCT01399710|PROCEDURE|CT colonography|Participants were placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously if this was common practice in the participating center. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide, either manually by means of a balloon pump or with an automatic device, until maximum tolerance was reached. CT colonography was performed with the participant in supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 1.25 mm.
40848260|NCT01399710|PROCEDURE|colonoscopy|Colonoscopy was performed at least 3 hours after CT colonography. The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a lesion measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy
40848261|NCT01399710|DEVICE|CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy|Each CT colonography study was read in two phases. In the first phase the radiologist interpreted the examination without activating the CAD algorithm. This phase of reporting was defined as unassisted reading. Then the radiologist activated the CAD algorithm which pinpointed a series of colorectal lesion-like structures (i.e. lesion candidates) on both the prone and supine acquisition. All lesion candidates were examined. The second phase of reporting was defined as CAD-assisted reading.
40848262|NCT02211066|DRUG|Clopidogrel|
40848263|NCT02211066|DRUG|Ticagrelor|
40848264|NCT01531751|DEVICE|High Cut-off Hemodialysis|During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.
40848265|NCT01531751|DRUG|Chemotherapy|Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
40848266|NCT03363880|OTHER|trauma treatment team|Establishing the trauma management system included a trauma treatment team. The severe trauma treatment team will be composed by the physicians from departments of emergency, orthopedic trauma, urology, cardiothoracic surgery, neurosurgery, general surgery, anesthesiology, and ICU.
40848267|NCT03363880|OTHER|Basic experimental settings|Establishing the trauma management system without a trauma treatment team.
40848268|NCT01025830|DRUG|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
41371329|NCT01568255|DRUG|Placebo|placebo at 50,000IU for 8 weeks
41371330|NCT04120116|DRUG|FX-322 (One Dose)|Patients will receive one dose of FX-322.
41371331|NCT04120116|DRUG|FX-322 (Two Doses)|Patients will receive two doses of FX-322.
41371332|NCT04120116|DRUG|FX-322 (Four Doses)|Patients will receive four doses of FX-322.
41371333|NCT04120116|DRUG|Placebo|Patients will receive Placebo.
41371334|NCT02434640|DRUG|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
41371335|NCT02434640|DRUG|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
41371336|NCT02434640|DRUG|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
41371337|NCT04911569|DEVICE|Cryoneurolysis|Cryoneurolysis
41371338|NCT05797948|DRUG|Obinutuzumab|Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；
41371339|NCT05797948|DRUG|Zanubrutinib|Zanubrutinib 160mg (2 capsules) oral bid；
41371340|NCT05797948|DRUG|Lenalidomide|Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.
41371341|NCT05797948|DRUG|CD19/CD22 CAR-T|Targets of CAR-T cells are tandem CD19/CD22. 1 \* 10 \^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
41371342|NCT05797948|DRUG|Azacitidine For Injection|Azacitidine For Injection 100mg i.h. d1-d5;
41371343|NCT05797948|DRUG|Fludarabine|Fludarabine 300mg/m2 ivgtt d3-d5;
41371344|NCT05797948|DRUG|Cyclophosphamide|Cyclophosphamide 300mg/m2 ivgtt d3-d5.
41371345|NCT05665946|DIAGNOSTIC_TEST|Blood sample analysis|Analysis of proposed biomarkers.
41371346|NCT05033769|DRUG|Eribulin Injection [Halaven]|on days 1 and 8 q21d
41371347|NCT05033769|DRUG|Paclitaxel injection|on days 1, 8, and 15 q21d
41371348|NCT01166126|DRUG|temsirolimus|Given IV
41371349|NCT01166126|DRUG|selumetinib|Given orally
41371350|NCT01166126|OTHER|laboratory biomarker analysis|Correlative studies
41371351|NCT02032433|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®)
41371352|NCT02032433|DRUG|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone®)
41371353|NCT05681975|DIAGNOSTIC_TEST|Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions|Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.
41503475|NCT03450252|DEVICE|Active pacing|Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.
41503476|NCT03450252|DEVICE|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
41371354|NCT03274791|DIAGNOSTIC_TEST|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa."
41371355|NCT03274791|DIAGNOSTIC_TEST|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
41371356|NCT03274791|DIAGNOSTIC_TEST|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
41371357|NCT01634399|DRUG|Torrent's Quetiapine Fumarate Tablets|
41371358|NCT03172910|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
41371359|NCT03172910|DRUG|Placebo|Saline for injection
41371360|NCT03172910|DRUG|Rivaroxaban|Rivaroxaban 20 mg given once per day (QD) in the morning
41371361|NCT00175110|BEHAVIORAL|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
41371362|NCT02267421|BEHAVIORAL|Home based Aerobic exercise training|
41371363|NCT05123066|OTHER|Aquatic Exercises|"These 3 sets were the following:~Set 1: warming up exercise as floating exercise 24 Set 2: Standing education/training Set 3: Walking education/training~The exercises will be conducted taking in consideration safety measures as:~1. Each participant will use Noodles to ensure safety.~2. Each participant will train individually to ensure safety and avoid distraction.~3. Each participant will use special swimming suit in case of lack of bowel and/or bladder control."
41371364|NCT05123066|OTHER|Land Exercises|All participants were physical therapy intervention according to their level of functional impairment :
41371365|NCT04717986|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
41371366|NCT04717986|DRUG|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
41371367|NCT00058097|DRUG|tipifarnib|Given orally
41371368|NCT00058097|RADIATION|radiation therapy|Undergo radiation therapy
41371369|NCT01046617|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
41371370|NCT05865002|DRUG|AUR107|Once daily
41371371|NCT02618096|DRUG|Oxytocin|
41371372|NCT02618096|DRUG|Dinoprostone|
40848269|NCT01025830|DRUG|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
41371373|NCT02618096|PROCEDURE|Membrane sweeping|
41371374|NCT03199924|DRUG|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
40848270|NCT06584513|OTHER|Specific tapering plan for sleep medication, educational and cognitive behavioural therapy elements|The intervention consists of a patient-centred intervention to help patients in deprescribing BSHs and better managing their sleep problems. The material used consists of training modules, brochures, and self-monitoring tools. There are materials for physicians and for patients.
40848271|NCT00321633|DRUG|carboplatin|
40848272|NCT00321633|DRUG|docetaxel|
41031008|NCT06052852|DRUG|Cemiplimab|Drug which blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells
41371375|NCT03199924|DRUG|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
41371376|NCT03199924|DRUG|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
41371377|NCT00808769|DRUG|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
41371378|NCT00808769|DRUG|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
41371379|NCT04744935|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.
41371380|NCT06477731|BEHAVIORAL|total anesthetic consumption|total anesthetic consumption required to reach the optimal depth of anesthesia (BIS 50) depending on the anxiety of the waiting period in the preoperative waiting room and the degree of anxiety.
41503477|NCT06081179|DRUG|Psilocybin|Single dose of psilocybin (15mg), orally in form of capsules
41503478|NCT06081179|DRUG|3,4 Methylenedioxymethamphetamine|Single dose of MDMA (100mg), orally in form of capsules
41503479|NCT06081179|DRUG|Methylphenidate|Single dose of methylphenidate (60mg), orally in form of capsules
41503480|NCT02110784|DRUG|Eurartesim tablets|dosage bands: 24 to \<36 kg body weight: 2 tablets a day for three consecutive days 36 to \<75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
41503481|NCT05705076|DRUG|catheter induced thromboprophylaxis|Direct oral anticoagulation for catheter induced thromboprophylaxis
41503482|NCT03082144|DRUG|MTX|MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
41503483|NCT03082144|DRUG|Ara-C|Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
41371381|NCT02920866|BEHAVIORAL|Functional Strength Integration (FSI)|FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.
41371382|NCT02920866|BEHAVIORAL|Control Group (CON)|Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
41371383|NCT05180123|PROCEDURE|Anterior cruciate ligament reconstruction|Adolescent patients with confirmed full thickness ACL injury were operated arthroscopically with semitendinosus and gracilis autograft anatomical reconstruction.
41371384|NCT02770534|PROCEDURE|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
41371385|NCT00998621|OTHER|Adherence questionnaire|Adherence questionnaire
41503484|NCT03082144|RADIATION|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
41503485|NCT00459901|DRUG|Erlotinib and capecitabine|
41503486|NCT01168752|DRUG|Debio 0932|"Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met."
41503487|NCT02352688|PROCEDURE|Enhanced Colorectal Geriatric Care|
41503488|NCT01004744|DRUG|Anastrozole|1mg PO daily for two weeks prior to scheduled surgery
41503489|NCT04494984|DRUG|INM005|The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
41503490|NCT04494984|DRUG|Placebo|Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
40848273|NCT03025243|DEVICE|computer aided surgical guide|comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
41031009|NCT03913273|PROCEDURE|AMI transtibial amputation|Two Agonist-antagonist myoneural interfaces (AMIs) were surgically constructed during a modified transtibial amputation procedure. Each AMI was made of natively innervated and vascularized muscle segments - an agonist and antagonist - that were surgically connected in series within the amputated residuum. Tarsal tunnels, including segments of each tunnel's native tendon component, were procured from the amputated joint. The tunnels were affixed to the residual limb tibia and the AMIs were constructed by coaptation of an agonist and an antagonist muscle to either end of the tendon passing through the tunnel. Consequently, the force produced by one muscle stretches its partner such that the AMI can communicate signals from the mechanoreceptors in both muscles to the central nervous system.
41371386|NCT06404294|DEVICE|External Diaphragm Pacemaker treatment|On the basis of conventional treatment, the patients in this group were treated with external diaphragm pacemaker for 2 weeks or until extubation.The treatment process of external diaphragm pacemaker is as follows: Set parameters: pacing frequency: 5-9 times /min, generally starting from 5 times /min, and adjusted according to the tolerance of the child; Pulse frequency 30 hertz; The stimulation intensity generally starts from 2-3. If the respiratory waveform of the child on the machine is not disturbed, it indicates that the child can tolerate it and the intensity can be appropriately increased. Treatment time: generally starts from 5 minutes, the longest is not more than 20 minutes, the frequency of treatment: 1 time/day in the first week, 2 times/day in the second week.
41371387|NCT01254695|DEVICE|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
41371388|NCT05548270|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
41371389|NCT05548270|DRUG|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
41503491|NCT03332810|BEHAVIORAL|SME family based physical activity|"* One train-the-trainer workshop: to train the service providers from 8-15 NGO service units on the concept of SME, ways of conducting mental well-being activities and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder).~* Two SME family-based physical activities held by each NGO service unit: to organize enjoyable activities according to the needs of individual district as well as to promote positive psychology under the theme of SME. All these activities are organized by the NGO service providers in collaboration with District Healthy City Committee."
40848274|NCT05004220|PROCEDURE|Plasmapheresis|Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor.
41162796|NCT02690415|PROCEDURE|Antibiotics not given|Patients who's treating physician did not prescribed antibiotics
41371390|NCT02769182|DEVICE|Monitoring and training using the system|subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.
41371391|NCT02769182|BEHAVIORAL|Standard of care|Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
41371392|NCT01321086|BEHAVIORAL|Motivational Interviewing|9 sessions of MI from baseline to six months
41371393|NCT01321086|BEHAVIORAL|PACE|9 sessions of PACE delivered from baseline to six months
41371394|NCT00742404|DRUG|bortezomib|
41371395|NCT00742404|DRUG|dexamethasone|
41371396|NCT00742404|DRUG|pegylated liposomal doxorubicin hydrochloride|
41371397|NCT00742404|GENETIC|protein analysis|
41371398|NCT00742404|OTHER|immunologic technique|
41371399|NCT01335620|DRUG|Raltegravir|400 mg twice daily
41371400|NCT01335620|DRUG|Tenofovir|245 mg once daily
41371401|NCT01335620|DRUG|Emtricitabine|200mg once daily
41371402|NCT04853953|OTHER|Incidence of bleeding complications in ARDS patients on veno-venous ECMO|All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment
41371403|NCT00346775|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate
41371404|NCT00346775|DRUG|Flunisolide|Flunisolide
41371405|NCT01890876|OTHER|Walking uphill|ascending about 500 m
41371406|NCT01890876|OTHER|Walking downhill|descending about 500 m
40848275|NCT02929940|OTHER|No intervention|No Intervention, observational
41371407|NCT02257970|DRUG|Ketoprofen|
41371408|NCT02257970|DRUG|Placebo|Placebo to match ketoprofen.
41371409|NCT01831297|DEVICE|measurement of blood pressure|measurement of pulse wave velocity
41371410|NCT00382434|PROCEDURE|presence of an emergency pharmacist in the ED|
41371411|NCT02249065|DRUG|Brimonidine|
41371412|NCT02962440|DRUG|somapacitan|All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
41371413|NCT00495950|BEHAVIORAL|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
41371414|NCT05334576|OTHER|Crizanlizumab|Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months
41371415|NCT02032394|DRUG|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
41371416|NCT02032394|DRUG|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
41371417|NCT02032394|DRUG|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
41371418|NCT02900508|OTHER|Exergaming training|
40848276|NCT06169111|BIOLOGICAL|REGulatory T cells in Autism induced by maternal Immune activation|REGulatory T cells in Autism induced by maternal Immune activation
41162797|NCT04623359|DEVICE|High resolution manometry|High resolution manometry
41162798|NCT04258488|DRUG|Rivaroxaban Oral Tablet|For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects_creatinine clearance 15-49 mL/min, 15mg once daily
41162799|NCT04258488|DRUG|Vitamin K antagonist(warfarin)|For 12months, keep the international normalized ratio (INR) 1.7-3.0
41162800|NCT05450640|OTHER|satisfaction survey|1 eQuestionnaire per patient completed during study
41162801|NCT04136171|DRUG|Eplontersen|Eplontersen by subcutaneous injection
41371419|NCT02900508|OTHER|Physical therapy intervention|
41371420|NCT04740762|BEHAVIORAL|Intervention group|The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
41371421|NCT00722618|BEHAVIORAL|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
41371422|NCT00722618|OTHER|Written materials|2 written materials available on public website
41371423|NCT04585828|DEVICE|Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon|The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.
41371424|NCT04585828|DEVICE|Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm|The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
41503492|NCT03332810|BEHAVIORAL|Gathering activity|- Gathering activities will be held for control groups. However, SME concept or techniques will not be introduced during the activity. Physical activity will not be used as the intervention method.
41503493|NCT04251520|DIAGNOSTIC_TEST|Pharmacogenomics testing|Participants will undergo pharmacogenomics testing and will be asked to provide a one-time buccal scraping. These results will be utilized for clinical treatment decisions.
41503494|NCT04251520|OTHER|Pharmacist review|Participants will have their medical information, including patient demographics, problem list, medication list, allergies, and relevant lab work reviewed by a One Point pharmacist. The pharmacist will work with the Palliative Medicine team to make medication related recommendations to improve individual patient care. The pharmacist will call the patient roughly 48 hours following their outpatient consultation or hospital discharge to review the medication list and address any medication-related questions. The pharmacy will send refill reminders to the patients.
41503495|NCT01261091|PROCEDURE|Early Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
41503496|NCT01261091|PROCEDURE|Late Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
41503497|NCT01853800|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|
41503498|NCT03021863|BEHAVIORAL|Group A Reminder|Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)
41503499|NCT03021863|BEHAVIORAL|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)
41503500|NCT03021863|BEHAVIORAL|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
41503501|NCT03021863|BEHAVIORAL|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
40848277|NCT06576401|DRUG|[14C] HDM1002|Administered orally
40848278|NCT03533244|DRUG|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
41503502|NCT03021863|BEHAVIORAL|Group E Reminder|Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)
41031010|NCT03913273|PROCEDURE|Standard transtibial amputation|A standard transtibial amputation was performed according to traditional techniques. No surgical construction of agonist-antagonist myoneural interfaces (AMIs) was performed.
41503503|NCT03021863|BEHAVIORAL|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
41503504|NCT03021863|BEHAVIORAL|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
41503505|NCT03021863|BEHAVIORAL|Group H Reminder|Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)
41503506|NCT03021863|BEHAVIORAL|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
41503507|NCT05511311|PROCEDURE|Resistance Training|Resistance training developed by the researcher (SCR-RSCM) for 12 weeks
41503508|NCT05511311|PROCEDURE|Standard Therapy|Standard therapy for 12 weeks
40848279|NCT03533244|DRUG|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
40848280|NCT03533244|DRUG|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
41031011|NCT05459844|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Four administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
41503509|NCT03340974|DRUG|GC4419|90 mg Avasopasem (GC4419) per day daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
41031012|NCT05459844|DRUG|Octreotide LAR|60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
41031013|NCT06309147|DRUG|BMS-9894923|50 mg capsules, oral administration
41031014|NCT00959023|OTHER|laboratory biomarker analysis|
41031015|NCT00959023|OTHER|medical chart review|
41031016|NCT00959023|OTHER|questionnaire administration|
41031017|NCT05982743|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota fermented milk|Participants will take one bottle (65 ml) of Yakult® drink daily, containing at least 6.5 x 10\^9 CFU of Lactobacillus casei strain Shirota, for a period of 4 weeks. Subsequently, there will be a two-week follow-up period.
41031018|NCT06158633|DRUG|Prevora|"Prevora Stage 1, a topical, intra-oral solution of chlorhexidine acetate 100mg/ml followed immediately by Prevora Stage 2 which is a topical solution of polymethylmethacrylate. Prevora Stage 1 and Prevora Stage 2 are applied topically using a small brush and sequentially to the teeth and gum line of the patient/participant.~All subjects will receive at total 4 applications of Prevora 1 and 2. One on Day 1, 14 days, 3 months and 4 months."
41031019|NCT04724317|PROCEDURE|Steroid Group|Ultrasound guided shoulder intra-articular steroid injection
41031020|NCT04724317|PROCEDURE|Ozone Group|Ultrasound guided shoulder intra-articular Ozone injection
41031021|NCT04724317|PROCEDURE|PRF Group|Ultrasound guided shoulder intra-articular pulsed radiofrequency application
41031022|NCT05636540|DRUG|[18F]FluorThanatrace ([18F]FTT)|A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
41031023|NCT05360875|PROCEDURE|Endometrial scratching|An intrauterine procedure that causes mild endometrial injury
41031024|NCT02897544|BEHAVIORAL|Individualized Manualized Health Education Intervention|
41371425|NCT02009111|BEHAVIORAL|Couple CARE for Parents|Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).
41031025|NCT05956431|DRUG|Levosimendan Injection|The administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
41371426|NCT02847078|DEVICE|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
41371427|NCT02847078|DEVICE|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
41371428|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
41371429|NCT00682006|OTHER|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
41371430|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
41371431|NCT02237066|DEVICE|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
41371432|NCT02237066|DEVICE|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
41371433|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe|Evaluation of therapy of bempedoic acid with PCSK9 inhibitors and ezetimibe in reducing LDL-C in statin-intolerant patients.
41371434|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe|Evaluation of therapy of PCSK9 inhibitors with ezetimibe in reducing LDL-C in statin-intolerant patients.
41503510|NCT03340974|DRUG|Placebo|Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
40848281|NCT04371692|OTHER|self-administered questionnaire|Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
41371435|NCT04383925|BIOLOGICAL|BCG-Japan|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).
41371436|NCT04383925|BIOLOGICAL|BCG-Russia|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)
41162802|NCT04136171|DRUG|Placebo|Eplontersen-matching placebo by subcutaneous injection
41371437|NCT02723682|OTHER|Collect 24-hour urine specimen|A random half sample of NHANES participants 20-69 examined in the mobile examination center were asked to collect a 24-hour urine specimen.
41371438|NCT03948321|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
41371439|NCT06044168|DIETARY_SUPPLEMENT|Dietary Supplement: Leucine|150mg/kg body mass/day
41503511|NCT03340974|RADIATION|Stereotactic Radiation Therapy (SBRT) 50 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
41503512|NCT03340974|RADIATION|Stereotactic Radiation Therapy (SBRT) 55 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
41503513|NCT00683579|DRUG|Early Treatment with HAART|HAART with possibility of de-intensification
41503514|NCT00683579|OTHER|No treatment|No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.
41503515|NCT00683579|DRUG|HAART Treatment - standard care|Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA \>100,000 copies/ml
41503516|NCT02487303|DRUG|Acetaminophen Intravenous|IV 1 gram f3 doses over 24 hours
41503517|NCT02487303|DRUG|Acetaminophen Oral|Oral 1 gram 3 doses over 24 hours
41503518|NCT00616070|DRUG|Difluprednate|Difluprednate
41162803|NCT05885841|DRUG|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
41162804|NCT06090019|BEHAVIORAL|Routine PICU nursing care for children on mechanical ventilator.|Nursing interns students learned the routine PICU nursing care for the children on mechanical ventilator.
41162805|NCT06090019|BEHAVIORAL|Self-instructional module for VAP care bundle prevention|Nursing interns students learned about VAP care bundle prevention self-instructional module through assessment, preparation, implementation and evaluation phases.
41503519|NCT00616070|OTHER|Placebo|Vehicle
40848282|NCT04371692|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
41162806|NCT01083446|OTHER|Nutritional Intervention|Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)
41162807|NCT01083446|OTHER|Nutritional Intervention|Cognitive and executive functions during fast
41371440|NCT02319018|DRUG|Alisertib|Given PO
41503520|NCT01906515|DEVICE|Continuous non-invasive hemoglobin monitoring|Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
41503521|NCT06387524|PROCEDURE|McConnell Taping|Begin with the patient in supine lying with the knee slightly bent. The knee should be completely relaxed and a foam roller or rolled up towel under the knee. Start the tape in line with the middle of the knee cap at the outer aspect of the knee. Using your thumb on top of the sports tape, gently push the patella towards the inner aspect of the knee whilst simultaneously using your fingers to pull the skin at the inner aspect of the knee towards the patella. Finish this taping technique at the inner aspect of the knee ensuring you have created some wrinkling of the skin at the inner aspect of the knee.
40848283|NCT05816434|BEHAVIORAL|Sleep extension|\>1 hour additional time in bed per night for 1 week.
40848284|NCT01778101|DRUG|Lansoprazole|lansoprazole 1mg/kg twice a day for 14days
40848285|NCT05966051|BEHAVIORAL|Educational interventions|The educational interventions will consist in:
40848286|NCT00364741|DRUG|Oxygen|During and 2 hours after surgery
40848287|NCT04373746|DEVICE|NICCI|Non-invasive beat-to-beat blood pressure monitor capable of producing a waveform similar to an invasive arterial line.
40848288|NCT03052595|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
40848289|NCT03052595|DIAGNOSTIC_TEST|Testing of autonomous nervous system function|Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)
41162808|NCT00742014|DRUG|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
41162809|NCT00683397|OTHER|Blood sampling|Screening of thrombophilia
41162810|NCT00361842|DRUG|CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection|CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
41371441|NCT02319018|DRUG|Fluorouracil|Given IV
41371442|NCT02319018|OTHER|Laboratory Biomarker Analysis|Correlative studies
41371443|NCT02319018|DRUG|Leucovorin Calcium|Given IV
41371444|NCT02319018|DRUG|Oxaliplatin|Given IV
41371445|NCT03904602|DEVICE|Edema Wear fuzzy wale compression garment|net-like compression structure of Lycra spandex elastic yarn with longitudinal fuzzy wales (similar to corduroy fabric)
41371446|NCT05629260|DRUG|ATG|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
41371447|NCT05629260|DRUG|Post-transplantation cyclophosphamide|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
41371448|NCT02213627|DRUG|Corifollitropin alfa|
41371449|NCT02213627|DRUG|Recombinant FSH|
41371450|NCT02213627|DRUG|HP-hMG|
41371451|NCT00103389|DRUG|PI-88|PI-88+docetaxel
41371452|NCT00103389|DRUG|docetaxel|docetaxel only
41371453|NCT03792880|BEHAVIORAL|Telematic control and self-management program|"During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring."
41371454|NCT03792880|BEHAVIORAL|Habitual follow-up in Healthcare System|According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.
41371455|NCT04911361|DRUG|Dexamethasone|Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
41371456|NCT00824993|DRUG|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
41371457|NCT00824993|DRUG|Vitamin Supplements|"Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months"
41371458|NCT04034329|PROCEDURE|ASVAL|Ambulatory Selective Varices Ablation under Local Anesthesia
41371459|NCT04034329|PROCEDURE|EVLA|Endovenous Laser Ablation
41503522|NCT06387524|PROCEDURE|ECCENTRIC EXERCISES:|"Performed for 6 weeks, in 3 sets of 10-12 repetitions each day. Detailed protocol is as under:~Warm up phase (5 minutes) It will comprise of following components 5 minutes warm up exercise protocol: Marching in place while swinging your arm, rotating toe touching, walking jacks, leg swings, arm circles, shoulder shrugs Eccentric exercises: Each of the following exercise will be performed for 30 seconds, repetitions and hold time will increase with increasing weeks according to patient's stamina.~Straight leg raise, side lying hip abduction, single leg bridging, supported double leg squatting, hip hikes,supported single leg squatting Following is the detailed description of Cool down phase: Hip stretch, cat cow stretch, oblique stretch, lower back stretch, calf stretch, cross body shoulder stretch"
41503523|NCT03183167|OTHER|No intervention|
41503524|NCT06129305|OTHER|Comparison of the distance of the Erector Spina muscle from the skin at different thoracal levels and different posıtıons under ultrasonography|Comparison of the distance of the Erector Spina muscle from the skin at different thoracal levels and different posıtıons under ultrasonography
41162811|NCT01012596|BEHAVIORAL|Creighton Model System of Natural Family Planning|Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
41162812|NCT01174498|DEVICE|Cerbomed t-VNS® transcutaneous stimulation|Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
41503525|NCT06013748|BEHAVIORAL|VR-VOICES|7-10 individual VR assisted therapy for voice-hearing session and two booster sessions, in addition to TAU.
41503526|NCT06013748|OTHER|Treatment as usual|Treatment as usual as provided by the mental health centers
41503527|NCT06291415|DRUG|HMPL-523|Syk inhibitor
41503528|NCT04233073|DRUG|andexanet alfa|Andexanet is a recombinant version of human FXa
41162813|NCT01174498|DEVICE|t-VNS Sham stimulation|t-VNS Sham stimulation
41371460|NCT01419834|BIOLOGICAL|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over \~30 minutes
41503529|NCT04972110|DRUG|RP-3500 (camonsertib)|RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)
41503530|NCT02565212|DRUG|Montelukast,mometazon froat|
41503531|NCT06374797|DRUG|Auxora|1.25 mL/kg (2.0 mg/kg of zegocractin) intravenously (IV) over 4 hours at 0 hours, and then 1.0 mL/kg (1.6 mg/kg of zegocractin) IV over 4 hours at 24, 48, 72 and 96 hours for a total of 5 doses.
41371461|NCT06375902|BEHAVIORAL|PragmaCom|Cognitive behavioral intervention targeting the ability to understand metaphors
41371462|NCT06192407|DIETARY_SUPPLEMENT|High Oleic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is 100% hazelnut oil. They will be taught to consume the oil with each meal and mix it in with the food provided.
41371463|NCT06192407|DIETARY_SUPPLEMENT|High Palmitic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is palm oil-89%, peanut oil-6.75%, and virgin olive oil-4.25%; . They will be taught to consume the oil with each meal and mix it in with the food provided.
41371464|NCT05234073|BEHAVIORAL|SEE Learning Online Training|This intervention includes classes about socioemotional learning theory and practice, topics related to ethics and well-being practices
41371465|NCT05234073|BEHAVIORAL|Waiting list|This group will wait for one month to receive SEE Learning Online Training
41503532|NCT06374797|DRUG|Placebo|1.25 mL/kg IV over 4 hours at 0 hours and then 1.0 mL/kg IV over 4 hours at 24, 48, 72, and 96 hours for a total of 5 doses.
41371466|NCT06202898|OTHER|Baseline|At the baseline visits, all study participants will be complete an interviewer-assisted questionnaire using REDCap, and will also receive the SBIRT-T MI-based intervention. Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for strength sessions, and they will be provided with a schedule of strength session visits
41371467|NCT06202898|OTHER|ENTRUST|Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for economic strength sessions, group-based economic training through photovoice activities and adapted screening brief intervention and treatment (SBIRT-T) adapted for transgender women delivered by a facilitator or digitally.
41371468|NCT06202898|OTHER|Control|participants assigned to the control arm will have the option of participating in the four additional strength sessions.
41371469|NCT03132610|DRUG|andrographolide sulfonate|Conventional Therapy+Xiyanping injection
41371470|NCT03132610|DRUG|andrographolide sulfonate simulation|Conventional Therapy+Xiyanping injection simulation
41371471|NCT03068507|BEHAVIORAL|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
41371472|NCT04746170|OTHER|Labor Dance|Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
41371473|NCT03315442|OTHER|Caffeine versus Energy Drink|Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
41371474|NCT02049476|DRUG|Dexamethasone pellet|"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."
41371475|NCT00004107|BIOLOGICAL|filgrastim|as prescribed by physician
41371476|NCT00004107|PROCEDURE|autologous bone marrow transplantation|1-2 weeks before treatment
41371477|NCT00004107|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks before treatment
41371478|NCT00004107|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
41371479|NCT00004107|RADIATION|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
41371480|NCT04132817|BIOLOGICAL|Nivolumab|specified dose on specified days
41371481|NCT04132817|BIOLOGICAL|Ipilimumab|specified dose on specified days
41371482|NCT04132817|DRUG|Nab-paclitaxel|specified dose on specified days
41371483|NCT03603626|DRUG|Pregabalin 150mg|Preemptive pregabalin 150 mg administered 1 hour before surgery
41371484|NCT03603626|DRUG|Placebo oral capsule|Placebo administered 1 hour before surgery
41371485|NCT00194038|DRUG|Aripiprazole|Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
41371486|NCT04170023|DRUG|ALXN2050|Oral FD inhibitor
41371487|NCT04918251|PROCEDURE|128 electrode electroencephalography (EEG)|128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
41371488|NCT04918251|PROCEDURE|Transcranial magnetic stimulation (TMS)|Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions
41371489|NCT03353025|PROCEDURE|transsphenoidal surgery treatment|transsphenoidal surgery treatment
41371490|NCT03353025|DRUG|dopamine agonist treatment|Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
40848290|NCT03052595|DIAGNOSTIC_TEST|Stroop test|Stroop test will be used to test cognitive function
41371491|NCT05033795|DIETARY_SUPPLEMENT|Water A|2 L of water A per day
41371492|NCT05033795|DIETARY_SUPPLEMENT|Water B|2 L of water B per day
41371493|NCT01795534|DIETARY_SUPPLEMENT|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
41371494|NCT01795534|DIETARY_SUPPLEMENT|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
41371495|NCT01136317|DRUG|Omeprazole|
41371496|NCT01136317|DRUG|Rabeprazole|
41371497|NCT01136317|DRUG|Lactose|
41371498|NCT06515886|DIAGNOSTIC_TEST|Clinical Examination|Clinical examination of a dental implant
41371499|NCT06515886|PROCEDURE|Peri-implant crevicular fluid|Collection of a sample of peri-implant crevicular fluid
41371500|NCT00206700|DRUG|Sargramostim (Leukine)|Open Label, 8 week cycle
41371501|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (compact)|Circular cylindrical mirror modulated frame glasses (compact)
41371502|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (strong defocus)|Circular cylindrical mirror modulated frame glasses (strong defocus)
41371503|NCT05288335|DEVICE|single vision frame glasses|single vision frame glasses
41371504|NCT03732534|DRUG|NBI-98854|vesicular monoamine transporter 2 (VMAT2) inhibitor
41162814|NCT05494281|PROCEDURE|Serratus Anterior Plane Block with local anesthetic|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of 1% Lidocaine will be administered."
41503533|NCT04366687|BEHAVIORAL|Smart Parents - Safe and Healthy Kids|Smart Parents - Safe and Healthy Kids (SPHSK) is a module designed to be added to existing evidence-based parent education programs. Because the module builds off of the core parenting skills developed in existing parent education programs, the module can be delivered in one session. SPSHK is comprised of three key CSA-prevention components: healthy child sexual development, parent-child communication about sex and sexual behaviors, and CSA-specific safety strategies such as vetting a babysitter and monitoring one-on-one time with adults. Behaviorally based, the module presents developmentally comprehensive information to parents of children 0-13 and utilizes role-playing scenarios and activities to maximize parents' use of learned skills.
41371505|NCT04178330|RADIATION|tomotherapy|Whole brain radiation (WBRT) with 38-40Gy in 20 fractions and concurrent boost of 60-70Gy of the lesions. TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.
41371506|NCT02986048|OTHER|Proton Beam Therapy|Intervention is not assigned. Only patient data is being collected
41503534|NCT04366687|BEHAVIORAL|Parents as Teachers|Parents as Teachers (PAT) is a parent-support program delivered to parents of children under five and focuses on improving parenting skills through parent-child interactions, development centered parenting, and general well-being. PAT has demonstrated positive effects on child and parent outcomes related to school readiness.
41503535|NCT04181723|DRUG|Trofinetide|Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
41503536|NCT04181723|OTHER|Placebo|Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
41503537|NCT01638585|DRUG|urokinase|daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
41503538|NCT03173287|PROCEDURE|Quantification of liver fibrosis|Procedure MRI and liver biopsy
40848291|NCT03401671|DRUG|Lanadelumab|SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
41371507|NCT00627913|PROCEDURE|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
40848292|NCT00888342|DRUG|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 \< 90%. If SpO2 \< 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
40848293|NCT00888342|DRUG|zopiclone|5 mg sedative given approximately 1 hour before sleep
40848294|NCT00888342|OTHER|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
41371508|NCT00627913|PROCEDURE|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
41371509|NCT01263652|DRUG|Diclofenac hydroxyethylpyrrolidine|IM/PO
41371510|NCT01263652|DRUG|orphenadrine|IM/PO orphenadrine
41371511|NCT01263652|DRUG|Tramadol|IM/PO tramadol
41371512|NCT01263652|DRUG|Dipyrone|PO/IM Dipyrone
41371513|NCT01503229|DRUG|Abiraterone Acetate|Given by mouth
41371514|NCT01503229|OTHER|Laboratory Biomarker Analysis|Correlative studies
41371515|NCT01503229|OTHER|Pharmacological Study|Correlative studies
41371516|NCT01503229|DRUG|Prednisone|Given PO
41503539|NCT00002926|DRUG|cytarabine|
41371517|NCT04716816|PROCEDURE|Stripping massage|Stripping massage for rhomboid myofascial trigger points
41503540|NCT00002926|DRUG|etoposide|
41503541|NCT00002926|DRUG|idarubicin|
41503542|NCT00002926|PROCEDURE|allogeneic bone marrow transplantation|
41503543|NCT00002926|PROCEDURE|peripheral blood stem cell transplantation|
41503544|NCT05511779|DRUG|Brincidofovir|BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours
41503545|NCT02040441|DRUG|Spironolactone|
41503546|NCT02040441|DRUG|Placebo|
41503547|NCT02040441|DRUG|Standard care|Standard diabetes care
41503548|NCT05698225|OTHER|Streptococcus pneumoniae serotype 6B|A controlled concentration of streptococcus pneumoniae serotype 6B is placed in both nares of participants
41503549|NCT03016819|DRUG|AL3818|Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
41503550|NCT03016819|DRUG|Dacarbazine|Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
41503551|NCT03016819|DRUG|AL3818 or placebo|AL3818 or placebo 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
41503552|NCT04924257|DRUG|Esketamine nasal spray|Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS \<10).
41371518|NCT01182480|BEHAVIORAL|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:~* 7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.~* 3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
41371519|NCT03709342|DRUG|CM4620-IE|single IV infusion on Day 1 over 4 hours
41371520|NCT00994266|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
41371521|NCT00994266|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
41371522|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
41371523|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
41371524|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
41371525|NCT01396252|DRUG|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
41371526|NCT01396252|DRUG|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
41371527|NCT00372658|DRUG|1% Lidocaine intracervical injection|
41371528|NCT06060717|DEVICE|F&P Caramel|Nasal mask
41371529|NCT05784168|OTHER|Manual therapy|"6 weeks, 12 sessions in total, 2 times a week of manual therapy: spinal manipulation, specific mobilisations and stretches. Manual therapy treatments are carried out by a physiotherapist with more than 10 years of experience.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
41371530|NCT05784168|OTHER|Exercise therapy|"6 weeks, 12 sessions in total, 2 times a week therapeutic exercise programme under the supervision of a physiotherapist. The exercise programme consisted of muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
41371531|NCT04589793|BEHAVIORAL|Life Style|Life Style intervention including physical activity, diet, sleep and stress
41371532|NCT00863564|DIETARY_SUPPLEMENT|Caseine|
41371533|NCT00863564|DIETARY_SUPPLEMENT|Cod|
41371534|NCT00863564|DIETARY_SUPPLEMENT|Gluten|
41371535|NCT00863564|DIETARY_SUPPLEMENT|Whey Isolate|
41371536|NCT06516783|DEVICE|Full Body Blue GEN 1.0 device|Full body blue irradiation in the treatment of inflammatory skin diseases and chronic pruritus
41371537|NCT04468139|DRUG|Quercetin|Dietary Supplement: Quercetin Treatment a daily dose of quercetin (500 mg) will be taken orally by proven COVID-19 cases intervention
41371538|NCT04468139|DIETARY_SUPPLEMENT|bromelain|Dietary Supplement:Bromealin Treatment a daily dose of bromelain(500 mg) will be taken orally by proven COVID-19 cases intervention
41371539|NCT04468139|DRUG|Zinc|zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention
41371540|NCT04468139|DRUG|Vitamin C|vitamin c 1000 mg orally daily by proven COVID-19 cases intervention
41371541|NCT04778319|OTHER|occlusion of tubes|to occlude the fallopian tubes
41371542|NCT04778319|OTHER|non occlusion of tubes|not to occlude the tubes
41371543|NCT03646929|DIAGNOSTIC_TEST|MEP using standard facilitation technique|measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology
41371544|NCT03646929|DIAGNOSTIC_TEST|MEP using modified facilitation technique|measuring of MEP using modified facilitation technique (application of additional 8-12x magnetic stimuli for arms and legs)
40848295|NCT04202887|DRUG|Low Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
40848296|NCT04202887|DRUG|High Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
41371545|NCT06014515|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
41371546|NCT06014515|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
41371547|NCT05508360|DEVICE|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
41371548|NCT00777504|DRUG|usage oral angiogenesis inhibitor|see under 'study arms'
41371549|NCT00777504|DRUG|stop oral angiogenesis inhibitor|see under 'study arms'
41371550|NCT05428358|DIAGNOSTIC_TEST|Preoperative MRI|Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
41371551|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine placebo|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
41371552|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
41371553|NCT01992926|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
41503553|NCT04924257|PROCEDURE|Electroconvulsive therapy|Patients will receive three treatments per week for four weeks (maximum of 12 ECT treatments) or until clinical remission (MADRS \<10).
41503554|NCT06548815|DRUG|GZR4|Ascending single doses - 4 dose levels.
41503555|NCT06548815|DRUG|Placebo|Ascending single doses - 4 dose levels.
41503556|NCT00315887|DRUG|Buprenorphine transdermal delivery system|
41503557|NCT02740114|DRUG|Bupivacaine|150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
41162815|NCT05494281|PROCEDURE|Serratus Anterior Plane Block with saline solution|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of saline solution"
41162816|NCT01187407|DRUG|LY2216684|
41162817|NCT01187407|DRUG|Placebo|
41162818|NCT01187407|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
41162819|NCT03945097|BEHAVIORAL|preK|Subjects enter and education program that either focuses on learning letters and their corresponding sounds or on language comprehension skills.
41162820|NCT01490359|BEHAVIORAL|Men Making a Difference HIV/STD Risk Reduction Intervention|Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
41162821|NCT01490359|BEHAVIORAL|Health Promotion Control|The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
41162822|NCT03421600|DEVICE|blue laser imaging|blue laser imaging
41162823|NCT03421600|DEVICE|White light imaging|White light imaging
41162824|NCT03574493|PROCEDURE|TME with LAR|Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME
41162825|NCT02648113|PROCEDURE|Restrictive transfusion|Transfusions are withheld unless Hb is \<= 8 g/dL, with a target Hb of 8 to 10 g /dL
41162826|NCT02648113|PROCEDURE|Liberal transfusion|transfusions are allowed as soon as Hb \<= 10 g/dL with a target of 11 g /dL
41162827|NCT02648113|BIOLOGICAL|red blood transfusion|
41162828|NCT04878575|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
41162829|NCT04878575|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
41162830|NCT00553605|DRUG|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
41162831|NCT00553605|DRUG|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
41371554|NCT04940624|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
41503558|NCT02740114|DRUG|Liposomal Bupivacaine|266 mg injected on each side of the wound at the end of surgery before wound closure.
41503559|NCT02740114|DRUG|Oxycodone|1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
41503560|NCT02740114|BEHAVIORAL|Pill Diary|Participants complete a pill diary every day for 30 days after hospital discharge.
41503561|NCT02740114|BEHAVIORAL|Symptom Questionnaire|Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
41503562|NCT03827720|DEVICE|SENSE Device|Non-invasive radiofrequency (RF) sensor
41503563|NCT01922804|DIETARY_SUPPLEMENT|K2 vitamin|K2 vitamin tablet
41503564|NCT01922804|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
41503565|NCT01819610|DRUG|SPRIX|
41503566|NCT05695066|PROCEDURE|Preoperative fasting instruction|Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction
41503567|NCT03838497|BIOLOGICAL|Prevenar13|Prevenar13 for both arms
41503568|NCT05322109|DIAGNOSTIC_TEST|CMR|Clinically indicated cardiac magnetic resonance tomography executed according to international guideline recommendations.
41031026|NCT05956431|DRUG|physiological saline|The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
41031027|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
41031028|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
41503569|NCT04975191|BEHAVIORAL|Resources|Participants will be provided a list of resources available at VCU that are intended to support student success
41503570|NCT04975191|BEHAVIORAL|Personalized Feedback Program (PFP)|Participants will complete an interactive online program that explores their personality-related traits to provide personalized recommendations for success
41503571|NCT04975191|BEHAVIORAL|Substance Use Feedback Program (BMI)|Participants will complete an online program based on brief motivational intervention (BMI) content/principles that explores their current substance use patterns to make personalized recommendations for success
41503572|NCT04836897|DEVICE|PrizValve® valve and transapical delivery system|Transcatheter aortic valve replacement system
41503573|NCT00003911|RADIATION|stereotactic radiosurgery|
41503574|NCT04478812|DIAGNOSTIC_TEST|Single Group Assignment|Tbit™ System will detect S100B and GFAP concentrations with the blood specimen collected
41503575|NCT05231005|BIOLOGICAL|BNT162b2 vaccine|fourth dose of the BNT162b2 vaccine (30 microgram) adminstered IM
41503576|NCT01484327|DRUG|Carvedilol|Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
41503577|NCT01860352|DIETARY_SUPPLEMENT|Fish OIl|
41503578|NCT01776255|BEHAVIORAL|Healthy Children, Strong Families|"Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year."
41503579|NCT01776255|BEHAVIORAL|Child Safety|The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
41503580|NCT02332954|DRUG|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
41503581|NCT04880603|DEVICE|Restrata Graft|Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.
41503582|NCT04880603|PROCEDURE|Standard of Care Skin Graft|Standard of Care Skin Graft
41503583|NCT02506829|BEHAVIORAL|Smoking cessation counseling (Quitline)|
41503584|NCT02506829|BEHAVIORAL|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|
41503585|NCT02506829|BEHAVIORAL|Financial incentives|
41503586|NCT02012348|OTHER|Antibacterial soap with triclocarban|
41503587|NCT02012348|OTHER|Antibacterial soap + benzalkonium chloride|
41503588|NCT02012348|OTHER|Control soap|
41503589|NCT00086593|DRUG|lamotrigine|
41503590|NCT06633601|DEVICE|MR-Guided Focused Ultrasound Technology|MRI Guidance for use with High-intensity-focused ultrasound (HIFUS)
41503591|NCT06633601|DRUG|Definity Suspension for Injection|Microbubble contrast agents for ultrasound
41503592|NCT06633965|DEVICE|AIDANET|AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
41503593|NCT06633965|DEVICE|AIDANET|AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
41503594|NCT04563546|OTHER|Quality Improvement|A quality improvement intervention including reminders, care protocols, and text messages to improve care of myocardial infarction in the KCMC ED
41503595|NCT05063032|OTHER|Radiofrecuency ablation|Radiofrequency ablation to treat left atrial flutter, guided by high-density mapping versus linear ablation.
41503596|NCT00636389|DEVICE|Polyflux 210H dialyzer|Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
41371555|NCT04940624|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
41371556|NCT00314275|DEVICE|Coronary Artery Stenting|Drug eluting stent
41371557|NCT00314275|DEVICE|Endeavor|Drug eluting stent
41371558|NCT00658203|DEVICE|New Living CHF|PEA CRT optimization
41503597|NCT00636389|DEVICE|Polyflux HD-C4|Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
41503598|NCT02974712|DRUG|Fentanyl|
41503599|NCT02974712|DRUG|Saline|
41503600|NCT00000494|DRUG|indomethacin|
41371559|NCT00658203|DEVICE|New Living CHF|Standard optimized CRT.
41371560|NCT05894824|DRUG|T-Dxd(Trastuzmab deruxtecan), Ramucirumab|"Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4\~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~* Dosing Regimen~  * Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~ * Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle"
41371561|NCT01872663|PROCEDURE|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
41371562|NCT01872663|PROCEDURE|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
41371563|NCT01872663|PROCEDURE|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
41503601|NCT00000494|PROCEDURE|surgery, cardiovascular|
41503602|NCT02592317|DRUG|JNJ 56021927|JNJ 56021927 will be administered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
41503603|NCT02592317|DRUG|Drug Cocktail|Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.
41503604|NCT02592317|DRUG|Pioglitazone|Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.
41503605|NCT02592317|DRUG|Rosuvastatin|Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
41031029|NCT01016795|DRUG|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
41371564|NCT01872663|PROCEDURE|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
41371565|NCT01872663|PROCEDURE|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
41371566|NCT01872663|PROCEDURE|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
41503606|NCT01747746|DRUG|Rivaroxaban|Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
41503607|NCT01747746|DRUG|Warfarin and Enoxaparin|Historical Control
41503608|NCT04886609|DEVICE|ORISE gel|To establish if ORISE Gel an effective and feasible submucosal injecting solution during endoscopic resection of large colorectal polyps
41503609|NCT06500169|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41503610|NCT06500169|PROCEDURE|Discussion|Ancillary studies
41503611|NCT06500169|OTHER|Exercise Intervention|Complete golf related exercises
41503612|NCT06500169|OTHER|Interview|Ancillary studies
41371567|NCT02066909|DRUG|0.15 mg PF-06649751|Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
41371568|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
41371569|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
41371570|NCT02066909|DRUG|1.5 mg PF-06649751|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
41371571|NCT02066909|DRUG|1.5 mg PF-06649751 21 Days|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
41371572|NCT02066909|DRUG|3.0 mg PF-06649751|Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
41371573|NCT02066909|DRUG|5.0 mg PF-06649751|Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
41371574|NCT02066909|DRUG|8.0 mg PF-06649751|Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
41371575|NCT02066909|DRUG|1.5 mg PF-06649751 in healthy Japanese subjects|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
41371576|NCT05483569|OTHER|Complex Decongestive Physiotherapy|Complete or complex decongestive physiotherapy (CDP) is a treatment for lymphedema, a condition in which excess fluid (lymph) collects in a part of the body. Damage to the lymph nodes or vessels, or a blockage leading to chronic swelling, usually causes lymphedema.
41371577|NCT05483569|OTHER|Multidimensional Diaphragmatic Breathing Exercises|Diaphragmatic breathing is an exercising technique to help strengthen your diaphragm and fill your lungs with air more efficiently.
41371578|NCT05483569|OTHER|Facial Release Technique|Fascial release is a manual therapy method that is applied holistically to the muscles and surrounding fascia through mechanical stimulation. It is a comprehensive approach to the evaluation and treatment of the muscular and fascia system in the body.
41371579|NCT03214016|OTHER|Aerobic Exercise|1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
41371580|NCT03214016|OTHER|Pilates|1 hour of Mat Pilates, 2 times a week, during 8 weeks.
41503613|NCT06500169|OTHER|Medical Device Usage and Evaluation|Wear activity tracker
41503614|NCT06500169|PROCEDURE|Physical Examination|Ancillary studies
41371581|NCT06180993|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study
41371582|NCT00721513|BIOLOGICAL|cetuximab|
41371583|NCT00721513|DRUG|cisplatin|
41371584|NCT00721513|DRUG|docetaxel|
41371585|NCT00721513|DRUG|fluorouracil|
41371586|NCT00721513|PROCEDURE|computed tomography|
41031030|NCT06035133|DRUG|CapeOX + cetuximab|CapeOX + cetuximab for RAS wild-type patients and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
41031031|NCT06035133|DRUG|CapeOX + bevacizumab|CapeOX + bevacizumab for RAS mutant patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
41371587|NCT00721513|PROCEDURE|positron emission tomography|
41371588|NCT00721513|PROCEDURE|quality-of-life assessment|
41371589|NCT00721513|RADIATION|3-dimensional conformal radiation therapy|
41371590|NCT00721513|RADIATION|intensity-modulated radiation therapy|
41031032|NCT06035133|RADIATION|radiotherapy|radiotherapy
41371591|NCT01225601|BEHAVIORAL|Tabacco discontinuation|Tabacco discontinuation
41371592|NCT02027831|DRUG|Indocyanine Green|
41371593|NCT05169866|DRUG|Nifekalant|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours.
41371594|NCT05169866|DRUG|Amiodarone|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours.
41371595|NCT03851562|DRUG|Alprostadil 20 micrograms|Intravenous infusion of PGE1 (Days 0, +1 and +2)
41031033|NCT04034433|PROCEDURE|Handgrip exercise program|Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
41031034|NCT03790891|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
41031035|NCT03593668|DRUG|Metformin|"2-week dose adjustment period（0-2weeks）\[before meals\] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po."
41371596|NCT03851562|DRUG|Placebo|Intravenous infusion of physiological saline solution
41503615|NCT06500169|OTHER|Physical Performance Testing|Ancillary studies
41503616|NCT06500169|OTHER|Questionnaire Administration|Ancillary studies
41503617|NCT06500169|OTHER|Recreational Therapy|Participate in golf program
41503618|NCT01577940|PROCEDURE|Infusion of ropivacaine|TAP block with ropivacaine 20 ml 0,5%. Catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours on one side of the abdomen.
41371597|NCT03506334|DEVICE|AVBT using Dynesys System Components|Zimmer Biomet Tether System and Dynesys System components are intended to treat scoliosis in skeletally immature children.
41371598|NCT03506334|PROCEDURE|Spine fusion|Children with scoliosis undergoing fusion surgery will form the control arm
41371599|NCT04801017|DRUG|OT-101|TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
41371600|NCT04801017|DRUG|Artemisinin|Herbal Supplement/ Purified extract from Artemisia
41503619|NCT01577940|PROCEDURE|Infusion of saline|TAP block with ropivacaine 0,5% 20 ml. Catheter with infusion of saline 5 ml/h 24 hours.
41503620|NCT00255554|BEHAVIORAL|Dialectical Behavioral Therapy|
41503621|NCT00255554|DRUG|Escitalopram|
41503622|NCT04251572|OTHER|Blood sampling|Blood sampling
41503623|NCT04251572|OTHER|questionaires|Included participants will complete a baseline questionnaire at end of treatment (EOT) and a follow-up questionnaire throughout the follow-up period (Table 1). The questionnaires collect information on socio-demographics (age, gender, ethnicity, employment status, education level, housing status, incarceration, medical history and OST), injecting drug use (drugs injected, injection frequency and sharing of needle/syringe, cookers, cotton/filter or water). Details on the received DAA regime including mode of administration (direct observed therapy, pill box, etc.) and self-reported data on treatment adherence will also be recorded.
41503624|NCT05593497|DRUG|Capivasertib|400 mg (2 tablets) BID given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week (4 days on, 3 days off). Treatment will be given in combination with abiraterone for 16 weeks duration (+/- 1 week for surgery window).
41503625|NCT05593497|DRUG|abiraterone acetate|"Administered orally as tablets at a dosage of 1000 mg daily. To be administered with prednisone 5mg po daily.~Subjects will be on concurrent GNRH agonist therapy (leuprolide, administered as standard of care). Intensified androgen deprivation (iADT) consisting of abiraterone and leuprolide will be administered for a 4 week run-in prior to addition of capivasertib."
41503626|NCT00396643|DRUG|Omega 3 fatty acids|The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
41503627|NCT00717379|DRUG|Tacrolimus|oral
41503628|NCT00717379|DRUG|Mycophenolate Mofetil|oral
41503629|NCT00717379|DRUG|Methylprednisolone or equivalent|oral
41503630|NCT00717379|DRUG|Prednisone|oral
41371601|NCT04801017|DRUG|Placebo|0.9% sodium chloride injection
41031036|NCT03593668|DRUG|Benaglutide|"2-week dose adjustment period（0-2weeks） \[before meals\] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH"
41371602|NCT03720639|DEVICE|Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM|Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.
41371603|NCT03379038|OTHER|Progressive Physical Therapy|Stretching of the tight muscle, positioning, abdominal co activation; rolling etc to decrease muscle tone and functional independence.
41371604|NCT03379038|OTHER|Maintenance Physical Therapy|Same Physical therapy protocol but aim was to maintain current level of spasticity and functioning
41371605|NCT00066573|DRUG|anastrozole|Given orally
41371606|NCT00066573|DRUG|exemestane|Given orally
41371607|NCT05650255|OTHER|A Digital Twin for Exoskeleton Pilot|The purpose of this project is to establish a digital twin of this driving, which will perform the driving action in parallel, and calculate in parallel in the virtual environment the torque required to provide each joint torque to maintain stable walking without falling, and this torque can be used as a monitoring basis for the auxiliary torque of each axis for the exoskeleton. When the exoskeleton's movements are out of range of a stable gait, the controller can warn and attenuate the output of auxiliary forces, and on the other hand, it has the opportunity to analyze whether the intention of driving is to switch the movement mode - such as stopping, or sitting, squatting, etc.
41371608|NCT04269317|DEVICE|Tixel C|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide for dermal remodeling and collagen restructuring that promote acne scar appearance improvement.
41503631|NCT05503810|BEHAVIORAL|Social support|Contact ones a week with Informal caregiver or peer support
41503632|NCT02628886|BIOLOGICAL|13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid|pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
41503633|NCT02628886|BIOLOGICAL|placebo 0.9% sodium chloride plus tetanus toxoid|pregnant women will be given intramuscular saline injection between 28-34 weeks
41503634|NCT02628886|OTHER|tetanus toxoid|new born babies will be given PCV13 vaccine at birth
41503635|NCT06349590|DIETARY_SUPPLEMENT|High-fiber/low-fat meals|Meals with Low fat/High fiber
41503636|NCT01550575|DEVICE|Non Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc.
41503637|NCT01550575|DEVICE|Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc
41371609|NCT06420024|BEHAVIORAL|Acceptance and Commitment Therapy|See: https://link.springer.com/chapter/10.1007/0-306-48581-8_1
40848297|NCT04202887|DEVICE|Gastric Ultrasonography|"The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF."
40848298|NCT06434805|OTHER|sex workers and sexual minorities education workshop|The participants will receive a one-day workshop (four sessions). The generic content aims at enhancing the understanding of sexual orientation, gender identities, social stigma, sex work and sexual orientation and human rights (session 1), the lived experience of SWSM (session 2), the content specifically related to the medical and healthcare field, including be familiar with the professional and ethical obligations (session 3), the skills that can be adopted when providing services to SWSM (session 4).
40848299|NCT04785924|DRUG|Imipenem+Relebactam|Antibiotic treatment for KPC producing CRE-containing gram-negative infections
40848300|NCT05385744|BIOLOGICAL|BCD-132|anti-CD20 monoclonal antibody
40848301|NCT05385744|DRUG|Teriflunomide|Teriflunomide 14 mg
41031037|NCT00283504|DRUG|ANTI-IGE THERAPY (XOLAIR)|Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
41371610|NCT01061073|DRUG|Omexel|
41371611|NCT01061073|DRUG|spasfon|
41371612|NCT01043809|BEHAVIORAL|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
40848302|NCT03752658|DRUG|Tenofovir Alafenamide|The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents
40848303|NCT00245843|BEHAVIORAL|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
40848304|NCT04039217|DRUG|Biktarvy|Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
40848305|NCT02229409|BEHAVIORAL|Walkadoo|Walkadoo is a MeYou Health, LLC product.
41031038|NCT04775446|OTHER|Data collection|Data entered in a secure computer database
41031039|NCT05706727|DRUG|Intravenous bolus dose of Mephentermine and mephentermine|intravenous bolus dose of mephenteramine 6mg
41031040|NCT05706727|DRUG|intravenous bolus dose of phenylephrine 50 mcg|intravenous bolus dose of phenylephrine 50 mcg
41162832|NCT05566002|DIAGNOSTIC_TEST|Right heart catheterization|RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
41371613|NCT01043809|BEHAVIORAL|expanded school-based handwashing promotion|Procter \& Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
41371614|NCT06055452|DRUG|Empagliflozin 10 MG|Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
41371615|NCT06055452|DRUG|Placebo|Each participant in the placebo group takes matching placebo.
41371616|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
41371617|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
41371618|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
41371619|NCT01001195|DRUG|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
41503638|NCT02027428|DRUG|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
41503639|NCT02027428|DRUG|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
41503640|NCT02027428|DRUG|Abraxane (Maintenance)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
41371620|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with pattlar bone will used for grating
41371621|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH HAMSTRING TENDON GRAFT|Hamstring tendon with will used for grating
41371622|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without pattlar bone will used for grating
41503641|NCT02027428|OTHER|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
40848306|NCT05100446|DRUG|Amoxicillin - high dose dual therapy|Eradication with Amoxicillin 1000mg + 500 mg + 1000mg + 500mg, for 15 days.
40848307|NCT05100446|DRUG|Pylera|Eradication with Pylera, for 10 days.
40848308|NCT05100446|DRUG|Esomeprazole 40mg|Esomeprazole 40mg, twice a day.
40848309|NCT03287362|BEHAVIORAL|schema therapy|The intervention consists of a seven-week program of schema therapy, which is a further development of cognitive behavioral therapy, designed in a three-phase combined group and single session concept
40848310|NCT03287362|BEHAVIORAL|cognitive behavioral therapy|The intervention consists of a seven-week program of cognitive behavioral therapy, which is the current gold standard of treatment
40848311|NCT03287362|BEHAVIORAL|individualized supportive therapy|The intervention consists of a seven-week program of individualized supportive therapy, including different therapeutic offers from the clinic and a high frequency of physician contacts.
41371623|NCT04742868|OTHER|Rehabilitation protocol|All patients will receive six months rehabilitation program which aim to recover the strength and function
40848312|NCT06434467|DRUG|Nelarabine injection|Nelarabine is a prodrug of the nucleotide metabolism inhibitor deoxyguanosine analogue 9-β-arabinoguanine (ARA-G). Nelarabine undergoes catalytic transformation by adenosine deaminase (ADA), resulting in the removal of its methoxy group and conversion into ARA-G, Subsequently, ARA-G undergoes sequential monophosphorylation by deoxyguanosine kinase and deoxycytosine nucleoside kinase, yielding the active compound 5'-Guanosine triphosphate (GTP), ARA-GTP. This active compound accumulates within leukemic blast cells and binds to deoxyribonucleic acid (DNA), effectively inhibiting DNA synthesis and ultimately leading to cell death.
40848313|NCT04119011|BIOLOGICAL|Probiotic|(Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
40848314|NCT04119011|OTHER|Placebo|lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
41162833|NCT01486511|PROCEDURE|Liver resection|Hepatectomy including both minor and major.
41162834|NCT01486511|RADIATION|Computed Tomography|Computed Tomography +/- pulmonary angiography
41371624|NCT04227730|DIAGNOSTIC_TEST|culture and PCR for group B streptococcus|all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.
41371625|NCT00719706|DRUG|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
41371626|NCT00719706|DRUG|Placebo|Placebo
41371627|NCT00156624|DRUG|Balloon Angioplasty with or without drug administration|
41371628|NCT01750034|PROCEDURE|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
41371629|NCT01750034|PROCEDURE|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
41371630|NCT02727374|OTHER|Physiotherapy intervention|Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises
41371631|NCT02727374|BEHAVIORAL|Cognitive-behavioural Intervention|Psychological treatment consists of group talks to treat the fear to fall
41371632|NCT05128656|OTHER|serology|serology at M3 and serology at M6
41371633|NCT02772159|DRUG|TD-4208|One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.
41371634|NCT05694923|DRUG|Empagliflozin 10 MG|non fatty liver non alcoholic patients Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg
41371635|NCT04861766|DEVICE|STYLAGE® L|Injection in both NLFs
41371636|NCT04861766|DEVICE|Active Comparator|Injection in both NLFs
41503642|NCT02027428|DRUG|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
41503643|NCT02027428|DRUG|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
41503644|NCT02027428|OTHER|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
41503645|NCT05446259|OTHER|Standard clinical care procedures and outcome measurements.|Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.
41371637|NCT03301207|DRUG|Ibrutinib|Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
41371638|NCT03301207|DRUG|OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg|Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.
41371639|NCT03301207|DRUG|Bupropion|Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
41371640|NCT03301207|DRUG|Midazolam|Midazolam 2 mg (1 milliliter \[mL\]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
41503646|NCT04421300|BEHAVIORAL|smile exercise|"Launch the smile face recognition APP on smart phone, after user guidance and pretest, a smile exercise will display on the phone, while facing the front camera on the phone, participant will do an exercise emphasizing facial movements, as exaggerated as possible. The exercise last for 8 weeks and 4 times a day"
41503647|NCT04421300|DRUG|0.1% sodium hyaluronate eye drop|0.1% sodium hyaluronate, 4 times a day, the time is in the morning, lunchtime, afternoon and evening. the interval between two training time is 2 hours, 1 hour before and after can be added or subtracted by users, 8 weeks.
41503648|NCT05173441|BIOLOGICAL|Human COVID-19 immunoglobulin (pH4) for intravenous injection|The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.
41031041|NCT05511987|DEVICE|Madela THOPAZ Digital Device|Digital drainage systems use electronic sensors to measure changes in pressure and thus may allow for quantification of the degree of air leak continuously and provide a graphical representation of the trend over time. Data on intrapleural pressure are also provided by some units. Together, these data may lead to expedited chest tube removal and hospital discharge with obvious financial implications.
41031042|NCT05511987|DEVICE|Atrium Analog Device|Analog drainage systems contain a sequentially numbered series of columns in the water seal chamber. The degree of air leak is assessed by observing the highest numbered column in which bubbling occurs. This provides a qualitative assessment at a specific point in time. This assessment, however, is subject to interobserver variability and does not account for variation over time.
41031043|NCT04307823|OTHER|Treadmill training|"3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest\*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms"
41162835|NCT03449134|DRUG|Placebo|Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.
41371641|NCT02366026|BIOLOGICAL|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
41371642|NCT02476058|DRUG|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
41371643|NCT02476058|DRUG|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
40848315|NCT01238328|DRUG|Conditioning regimen|"For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2"
41371644|NCT02476058|DRUG|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
41371645|NCT01385839|PROCEDURE|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
40848316|NCT01238328|DRUG|Graft-versus-host disease (GVHD) prophylaxis|"* Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)"
41162836|NCT03449134|DRUG|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID during the 12-week main study period and during the 40-week extension period, according to randomization.
41371646|NCT01385839|PROCEDURE|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
41371647|NCT05471141|OTHER|Cognition ECHO|Cognition ECHO is the intervention designed to be used by the study participants who are primary care practitioners. No involvement of patients in this study. The panel will consist of the CI and Co-PIs of this study, a neurologist as a co-moderator, a medical specialist who is the expert on the subject, an occupational therapist, a psychologist, and a speech and language pathologist with experience and expertise in CI. A patient with CI and a caregiver, family member, or community representative who is not a healthcare professional will join the panel because CI is frequently observed with lived experience of family members and loved ones, as two non-clinician panelists. The five topics with the integration of related diagnoses for Cognition ECHO are listed in Table 4. The time allocated for the didactic will be 15-20 minutes and the de-identified case discussion will be 40 - 45 minutes.
41371648|NCT05921734|PROCEDURE|AF-termination Group|Each center completes the ablation according to the above ablation procedure. The choice of ablation strategy is not restricted, but efforts should be made to achieve termination of AF during the ablation procedure. If cannot terminate AF for safety or other reasons involving difficulties to remap AFEGM or creating a complete conduction block despite the operator's best efforts, then direct current conversion (DCCV) was performed.
41371649|NCT05921734|PROCEDURE|Prespecified-ablation Group|Each center completes the prespecified ablation according to the above ablation procedure. Although there is no restriction on the choice of ablation strategy, Ablation must be performed following the PVI plus strategy, which can be combined with one or more additional ablation procedures, but each ablation must achieve its own endpoints, such as bidirectional block of linear damage, posterior wall isolation, etc. After completing the preset ablation steps, DCCV will be performed. If AF is terminated after or during ablation, it is also considered the endpoint of ablation in this group, but the preset ablation steps must be completed.
41371650|NCT00344968|DRUG|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
41371651|NCT00344968|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
41371652|NCT00344968|PROCEDURE|Standard of care laser photocoagulation|Laser photocoagulation
41371653|NCT03302221|DRUG|0.5% ropivacaine paravertebral block|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block
41371654|NCT03302221|DRUG|0.25% ropivacaine epidural block|A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.
41371655|NCT03302221|DRUG|0.5% ropivacaine local anaesthesia|local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
41371656|NCT05716516|DRUG|Estradiol|Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
41371657|NCT06050031|DIETARY_SUPPLEMENT|Intake of antioxidant supplement|All participants will supplent oral antioxidants (individual or combined which can be obtained without prescription, and which are not regulated as a pharmaceutical drug) over three months.
41503649|NCT05173441|DRUG|Placebo|The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
41503650|NCT00589927|DRUG|cilostazol|cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
41162837|NCT02742792|OTHER|Resistance training|Twenty-four strength training sessions consisted in exercises of extension and flexion knees, lat pull-down, elbow extension and flexion, sitting bench press and hip abduction.
41162838|NCT02742792|OTHER|Advice on Lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
41162839|NCT00206505|DRUG|Taxotere|
41371658|NCT03030131|DRUG|Durvalumab|durvalumab 750 mg IV Day1, 15, 29
41371659|NCT01449474|DEVICE|Patient matched instruments|The patients undergo TKA with using patient matched instruments
41503651|NCT00589927|DRUG|placebo|placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
41503652|NCT05105009|DRUG|Furosemide|"* Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~* Oral creatinine load using 5 grams of creatinine"
41371660|NCT01449474|DEVICE|Jig based instruments|The patients undergo TKA with using jig based instruments
41371661|NCT02815007|DRUG|Chidamide with EGFR-TKI|Chidamide and EGFR-TKI, dosage described in arm description.
41371662|NCT01347931|DEVICE|NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
41371663|NCT01347931|DEVICE|Standard Oxygen Cannula|Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
41371664|NCT04385719|DRUG|Remdesivir|Remdesivir (GS-5734) is a nucleoside analogue with in vitro activity against filoviruses EBOV, SUDV, BDBV and MARV, in addition to arenaviruses and coronaviruses
41371665|NCT04343508|OTHER|Fortified rice|100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
41371666|NCT02277665|BEHAVIORAL|CUD Treatment|
41371667|NCT02277665|BEHAVIORAL|Tobacco Treatment|
41371668|NCT00990782|DIAGNOSTIC_TEST|PillCam ESO Capsule Endoscope|Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
41371669|NCT04366011|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT teaches a set of cognitive and somatic coping skills to manage panic and anxiety as patients conduct repeated exposure to feared situations and sensations.
41371670|NCT04366011|BEHAVIORAL|Capnometry Assisted Respiratory Training (CART)|CART has four major treatment components: educating patients about the etiology and maintenance of PD according to a hyperventilation centered rationale, directing patients' attention to potentially aberrant respiratory patterns, instructing patients in respiratory control techniques, and instructing patients in home breathing exercises.
41371671|NCT00909857|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
41371672|NCT00909857|DRUG|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
40848317|NCT01238328|PROCEDURE|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical"
41371673|NCT00909857|DRUG|Placebo Match to SH T00658ID|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
41371674|NCT00909857|DRUG|Placebo Match to SH D593B|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
41371675|NCT03626935|DEVICE|3D-printed customized guide plate|3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
41371676|NCT06401772|BEHAVIORAL|Intracranial Hypotension Targeted(IHT) Body Posture|IHT therapy requires CSDH patients to raise their lower limbs 30° higher over the horizontal level of their head.For patients with unilateral CSDH, the head should be tilted towards the hematoma affected side and opposite side lying should be avoided as much as possible. For patients with bilateral CSDH, there is no need for the head lateralization.To avoid food reflux and aspiration pneumonia, IHT therapy was strictly prohibited within 2 hours after each meal
41371677|NCT04918186|DRUG|Durvalumab|1500mg IV, 60 min day 1 every 4 weeks
41371678|NCT04918186|DRUG|BA3011|IV
41371679|NCT04918186|DRUG|BA3021|IV
41371680|NCT04918186|DRUG|To be determined|To be determined
41503653|NCT05977036|DEVICE|DiviTum® TKa assay|Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions
40848318|NCT01978223|PROCEDURE|Stool sample collection|Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
41031044|NCT04307823|OTHER|Treadmill protocol and Respiratory training|"Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks"
41371681|NCT04755491|DEVICE|Continuous veno-venous hemofiltration|Treatment of KDIGO stage 3 AKI by CVVH, in which renal replacement therapy is applied using a convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVH treatment.
41371682|NCT04755491|DEVICE|Continuous veno-venous hemodialysis|Treatment of KDIGO stage 3 AKI by CVVD, in which renal replacement therapy is applied using a diffusion technique (dialysis). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVD treatment.
41371683|NCT04755491|DEVICE|Continuous veno-venous hemodiafiltration|Treatment of KDIGO stage 3 AKI by CVVHDF, in which renal replacement therapy is applied using a combination of diffusion technique (dialysis) and convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVHDF treatment.
41371684|NCT04703465|DRUG|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25mg for 48 weeks will be delivered
41371685|NCT01619709|OTHER|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
41371686|NCT00650806|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
41371687|NCT00650806|DRUG|Placebo|One matching placebo capsule orally once daily for 12 weeks.
41371688|NCT04909879|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
41371689|NCT04909879|DRUG|Placebo|Excipient solution
41371690|NCT01553708|DRUG|Epidermal growth factor with silver sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
41371691|NCT01553708|DRUG|Silver zinc sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
41371692|NCT04868838|DRUG|Daratumumab|1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.
41371693|NCT04353570|OTHER|clinical interview|This interview can be carried out face to face or remotely. In the latter case, it is part of telemedicine, which is recognised by the health authorities in France.
40848319|NCT00665964|DEVICE|X-3 polyethylene|highly cross-linked polyethylene for knee arthroplasty
40848320|NCT00665964|DEVICE|N2Vac polethylene|conventional polyethylene
41371694|NCT00965458|BIOLOGICAL|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
41371695|NCT00965458|DRUG|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
41371696|NCT01932541|DRUG|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
41371697|NCT02182726|DRUG|MOBEC|
41371698|NCT02054351|DRUG|IMAB027|Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
41371699|NCT01726426|DIETARY_SUPPLEMENT|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
41371700|NCT03811899|DIAGNOSTIC_TEST|18F-DCFPyL|The purpose of this study is to determine whether HG SOC are 18F-DCFPyL (=GCP-II)-avid and to compare the performance of this PET to CT and findings at time of surgery.
41371701|NCT04825639|OTHER|No intervention|no intervention
41371702|NCT04704791|PROCEDURE|PA-LAA shunt|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
41371703|NCT03534934|DIAGNOSTIC_TEST|Vital signs|"Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight"
41371704|NCT03534934|DIAGNOSTIC_TEST|Urine Pregnancy Test|Urine pregnancy test done on woman of childbearing potential.
41371705|NCT03534934|OTHER|Questionnaires|Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey
41371706|NCT03534934|DIAGNOSTIC_TEST|Blood Test|Blood test for vitamin D level, Hemoglobin A1c, and creatinine level
41371707|NCT03534934|DIAGNOSTIC_TEST|Duel-energy X-ray absorptiometry scan|Bone density measurement
40848321|NCT05623657|OTHER|Trunk Stabilization Exercise Training Group|The adolescents in this group who are involved in archery sports will be given 40 minutes of exercise training 2 days a week for 8 weeks. Exercise training will be applied as 5-10 minutes warm-up, 15-30 minutes trunk stabilization exercises, 5-10 minutes cooling down, and stretching exercises. The number of repetitions and difficulty levels of the exercises will gradually increase in the 3rd and 6th weeks.
41371708|NCT03534934|DIAGNOSTIC_TEST|Multi-detector computed tomography|Hip and ankle CT scan
41371709|NCT03534934|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry scan|Vertebral fracture assessment
41371710|NCT03023358|DRUG|chidamide|30mg po twice a week
40848322|NCT05623657|OTHER|Game Based Exercise Program Group|At least 4 different games selected from Xbox 360 Kinect® games will be applied to adolescents practicing archery sports in this group for a total of 40 minutes with the physiotherapist. The games will be selected from games that include movement patterns similar to the exercises of the trunk stabilization exercise group. Game-based exercise training is planned to be performed twice a week for a total of 8 weeks.
41371711|NCT03023358|DRUG|cyclophosphamide|750mg/m2 iv on day 1
41371712|NCT03023358|DRUG|liposomal doxorubicin|30mg/m2 iv on day 1
41503654|NCT05977036|DRUG|CDK4/6 + Endocrine therapy|FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
41503655|NCT02971098|PROCEDURE|Reduced activity|Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
41503656|NCT05443178|DRUG|Nivaquine ® (Chloroquine)|dose escalation and extension trial
40848323|NCT03325595|DRUG|AEF0117|0.2, 0.6, 2, or 6mg of AEF0117
40848324|NCT03325595|DRUG|Placebo|Matching capsule placebo
40848325|NCT00496288|RADIATION|Prophylactic radiation to the contralateral breast|The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
40848326|NCT01252030|DEVICE|physical activity monitors|physical activity monitors
40848327|NCT01252030|OTHER|No physical activity monitors|No physical activity monitors
41371713|NCT03023358|DRUG|vincristine|1.4mg/m2 iv on day 1
41371714|NCT03023358|DRUG|prednisone|100mg/d po on day 1-5
41371715|NCT02945501|DEVICE|NeuroConn DC Stimulator PLUS|Prior to bedtime on the sleep restriction night, 4 transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will receive a one hour period of SO stimulation, for a total of approximately two hours of sleep.
41503657|NCT03086551|DEVICE|Active continuous theta burst stimulation (cTBS)|Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
40848328|NCT06469606|DEVICE|AI tool|"Both the arms will undergo the use of AI tool developed in the group. The tool will be trained to detect outcomes."
41371716|NCT02945501|DEVICE|SHAM TES|Prior to bedtime on the sleep restriction night, 4 placebo transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will sleep for approximately 2 hours without stimulation.
41371717|NCT01097174|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
41371718|NCT02007798|DRUG|dexmedetomidine|2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
41371719|NCT02007798|DRUG|normal saline|100 ml per bag
41371720|NCT04766346|OTHER|Fortified Cow's Milk-Based Oral Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form that provides the appropriate amount of energy and protein to promote growth in children.
41371721|NCT02502994|DRUG|GEN0101|
41503658|NCT03086551|DEVICE|Placebo (Sham) continuous theta burst stimulation|Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
41371722|NCT04657627|BEHAVIORAL|PACE plus calorie labelling information|The intervention group will be exposed to PACE plus calorie labelling information via Instagram and Twitter social media posts every day for 13 weeks.
41503659|NCT03086551|BEHAVIORAL|Motor Practice|Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
41503660|NCT05978947|DEVICE|ZyMōt Multi 850µL device|The ZyMōt Multi 850µL device is a laboratory tool designed for use in assisted reproductive technology (ART) procedures such as intrauterine insemination (IUI) and in vitro fertilization (IVF). It is a sperm preparation device that uses a proprietary patented technology to isolate and select motile sperm from semen samples for use in ART procedures.
41503661|NCT05978947|DEVICE|Density Gradient Centrifugation Method|Density gradient centrifugation is a laboratory technique used to separate and isolate different types of cells or particles based on their density. It is commonly used in various applications, including cell biology, immunology, and assisted reproductive technology (ART).
41503662|NCT04135326|OTHER|Quality-of-Life Assessment|Ancillary studies
41503663|NCT04135326|OTHER|Questionnaire Administration|Ancillary studies
41503664|NCT04135326|PROCEDURE|Transcranial Direct Current Stimulation|Undergo tDCS
41503665|NCT06398275|DRUG|Remimazolam 20 MG Injection [Byfavo]|Remimazolam 0.1 mg/kg intravenous injection
41503666|NCT06398275|DRUG|NaCl 0.9%|NaCl 0.9% 0.04 mL/kg
41371723|NCT04657627|BEHAVIORAL|Calorie-only labelling information|The comparator group will be exposed to calorie-only labelling information via Instagram and Twitter social media posts every day for 13 weeks.
41503667|NCT05191537|OTHER|Sustained Natural Apophyseal Glides|The patient sits well supported in a chair. The cervical spine and head are set in a neutral position. A painless passive posterior to anterior (PA) glide is applied in the plane of the facets on either the spinous process or the articular pillar/cervical lamina. While the glide is sustained the patient actively moves their neck in the direction that previously produced the symptoms. If symptom-free, the patient applies over-pressure further into the movement restriction. 3-6 repetitions are performed
41503668|NCT05191537|OTHER|shoulder Mobilization with arm movement|The patient is seated. The therapist contacts the length of the spinous process with the medial aspect of the thumb. A transverse glide is applied by the therapist's index finger against the thumb contacting the spinous process. The direction of the glide is to the contralateral side of the pain. While the mobilisation is sustained the patient moves their arm through a pain-free abduction range. 3-5 sets of 6-10 repetitions may be performed.
41503669|NCT03515590|OTHER|Emulsion with solid droplets|This will be a 500 mL beverage emulsion in which the droplets are crystalline. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
41503670|NCT03515590|OTHER|Emulsion with liquid droplets|This will be a 500 mL beverage emulsion in which the droplets are liquid. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
41503671|NCT03809962|DEVICE|Ostenil® Plus|Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation
41503672|NCT04107766|DEVICE|Microwave Ablation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) with the NEUWAVE Microwave Ablation System with or without Ablation Confirmation of at least one soft-tissue liver lesion, in accordance with the study site's standard-of-care (SOC) practices.
41503673|NCT02849483|DRUG|Ramosetron|Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.
41503674|NCT02849483|DRUG|Normal saline|Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
40848329|NCT04544579|DEVICE|Stent grafts anchored in different areas|Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
41371724|NCT03597126|DEVICE|Robot-assisted surgery|robot-assisted intersphincteric resection for low location rectal cancer(T=1\&2)
41371725|NCT03597126|DEVICE|Laparoscopic surgery|laparoscopic intersphincteric resection for low location rectal cancer(T=1\&2)
41371726|NCT05598502|DEVICE|REBOA, Resuscitative Endovascular Occlusion of the Aorta|The balloon catheter is inserted via the common femoral artery in the groin, accessed under ultrasound guidance due to weak femoral pulses, and the puncture is done by the Seldinger technique. The balloon is inserted along a guidewire 25-30 cm, safely below the renal arteries, to be in the right place to stop pelvic hemorrhage including life-threatening post-partum hemorrhage
41371727|NCT05598502|OTHER|National guidelines|Standard management of postpartum hemorrhage according to Uganda national guidelines
41371728|NCT04722627|DRUG|AT-752|Parallel Assignment
41371729|NCT04722627|DRUG|Placebo|Parallel Assignment
41503675|NCT06628804|DIETARY_SUPPLEMENT|Artemisia and green tea extracts|Artemisia and green tea extracts 700 mg/day for 8 weeks
41503676|NCT06628804|DIETARY_SUPPLEMENT|Placebo|Placebo 700 mg/day for 8 weeks
41503677|NCT00306930|DEVICE|Acetabular cup|Acetabular cup replacement
41371730|NCT03878108|DIETARY_SUPPLEMENT|LCHF diet|low-carbohydrate, high-fat (LCHF)diet
41371731|NCT03878108|DIETARY_SUPPLEMENT|LFHC diet|low-fat, high-carbohydrate (LFHC) diet
41371732|NCT00153751|DRUG|Traditional Chinese Medicine|They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
41371733|NCT00153751|DRUG|Holopon|holopon
41371734|NCT00153751|OTHER|placebo|placebo
41371735|NCT03922048|DRUG|HTX-011|Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
41371736|NCT03922048|DRUG|Bupivacaine HCl|Bupivacaine HCl 0.25% (without epinephrine) (total dose not to exceed 75 mg).
41371737|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1.
41371738|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohorts 1 and 2.
41371739|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1 Part A.
41371740|NCT03922048|DEVICE|Luer Lock Applicator|Applicator for instillation.
41371741|NCT03094923|OTHER|Inspiratory Muscle Training|"The inspiratory muscle training (IMT) will be carried out in the IG with Threshold® IMT (Respironics New Jersey, Inc) consisting of a unidirectional flow control valve which assures the constant resistance (linear load) between 7 and 41cmH20.~The IMT will be carried out in the sitting position with a load of 30% of the MIP during the two weeks preceding the surgery, seven days a week, twice daily in three series of ten repetitions with a 30 second interval between series, under the supervision of a physiotherapist. A load of 15% of the MIP was used only on the first day of training in order for the individual to adapt to the equipment. Subsequently, the 30% MIP load will be applied and readjusted according to the new MIP values determined every four days."
41371742|NCT02377674|DEVICE|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
41371743|NCT03143933|DRUG|Propofol|I.V propofol
41031045|NCT05976074|DEVICE|Apple Watch|The smartwatch will collect data including accelerometry, heart rate, activity, move time, exercise time, stand time, steps, walking and running distance, heart rate variability, respiratory rate, six-minute walk, and flights climbed. During sleep, the smartwatch will collect daily nighttime physiologic data such as time in bed, average sleep time, sleep efficiency, wake after sleep onset, nocturnal heart rate, and nocturnal respiratory rate.
41371744|NCT03143933|DRUG|Fentanyl|
40848330|NCT04313114|BEHAVIORAL|health literacy appropriate education and demonstration|If a patient chooses the Fecal Immunochemical Test (FIT), the Screening Coordinator (SC) will give the FIT kit, emphasize the necessity of annual completion, and distribute an additional plain language, literacy appropriate, actionable handout with simplified illustrated instructions on how to complete the test and mail to the central lab. The SC will review the handout and instructions with the patient and use the 'teach back' method to confirm understanding.
41031046|NCT05976074|OTHER|BrainRISE app|The app will play a prerecorded video, which will walk participants through tasks which include holding your arms in different postures, repeating different vowel sounds and phrases as prompted, and tracing different patterns on the phone screen. The tasks are video and audio recorded while being completed. Completing the tremor assessment tasks will take about 10 minutes.
41031047|NCT03661853|BEHAVIORAL|Control|60 minute psycho-education on alcohol and drugs.
41031048|NCT03661853|BEHAVIORAL|Functional Analysis|"Component of standard CBT that helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use."
41162840|NCT04598945|OTHER|Functionel MRI|During the activation fMRI sequences, the subject will perform target pointing tasks, that is to say that he will have to reach, by controlling a cursor using a non-magnetic joystick, targets projected onto a display screen. In each of the pointing tasks he will have to reach the target as quickly and as precisely as possible, and stay in the center of it for a long time times reached.
41162841|NCT01774019|DEVICE|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|
41162842|NCT00053352|PROCEDURE|conventional surgery|
41371745|NCT04058665|DEVICE|Floseal|Hemostatic agent
41371746|NCT04956068|COMBINATION_PRODUCT|PIPAC|A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.
41371747|NCT03224169|BEHAVIORAL|Directly observed hand hygiene|Directly observed hand hygiene to the residents and staff
41371748|NCT05100706|DRUG|Continuous adductor canal block (CACB)|Ropivacaine 0.2% infusion through adductor canal catheter
41371749|NCT05100706|DRUG|Sham continuous adductor canal block (ShACB).|NaCl 0.9% infusion through adductor canal catheter
41371750|NCT03364699|DIETARY_SUPPLEMENT|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
41371751|NCT03364699|OTHER|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, all participants were supplemented. Blood samples were collected before and after both half-marathon race.
41371752|NCT00051766|BEHAVIORAL|Computer-based Intervention|
41371753|NCT02874235|BEHAVIORAL|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
41371754|NCT02874235|BEHAVIORAL|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
41371755|NCT00753402|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
41371756|NCT00753402|BIOLOGICAL|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes/Epinephrine 30mcg/kg/min
41371757|NCT01333501|DRUG|Fingolimod|0.5 mg in capsules for oral administration once daily
40848331|NCT04313114|BEHAVIORAL|shared decision making|Screening Coordinator (SC) will give patients a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; using the low literacy handout as a teaching tool, the SC will briefly counsel patients on CRC screening options prior to seeing their healthcare provider, reviewing the benefits of each, as well as applicable costs. After reviewing the CRC screening pamphlets with a patient, the SC will use shared decision-making techniques using the study CRC materials to aid patients in selecting the test they prefer and that meets their needs - colonoscopy or FIT.
40848332|NCT04313114|BEHAVIORAL|automated call reminders or automated texts|"Colonoscopy year 1: Will receive an automated call recording by PCP 48 hours after the clinic visit to remind them of their choice of colonoscopy; then, one week before the test reminding them to pick up the preparation kit. Those who chose SMS will receive a text message from their PCP with content similar to the voice call. A 3rd reminder call/text will be sent 2 days prior to the test. If no colonoscopy with 3 months, the clinical manager (CCM) will call to determine if they want to switch screening options. The CCM will discuss barriers and option of choosing FIT for 3 years. If they opt to change, they will be mailed a FIT with simplified instructions and then follow the FIT follow-up protocol.~FIT year 1: Motivational reminders recorded by their PCP will be sent by automated call or text within 48 hours after the visit and again at 4, 8 and 12 weeks for those who have NOT completed the test. FIT will be mailed year 2 \& 3 - follow-up will follow same procedure as year 1."
41162843|NCT00053352|DRUG|cisplatin|Given IV
41371758|NCT01333501|DRUG|Interferon beta 1b|250 μg injected s.c. every other day
41371759|NCT03066466|DRUG|Atorvastatin|Oral medication given to prevent graft versus host disease in bone marrow transplant.
41371760|NCT03066466|DRUG|Methotrexate|IV medication given to prevent graft versus host disease in bone marrow transplant.
41371761|NCT03066466|DRUG|Tacrolimus|IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
41371762|NCT03564015|OTHER|Smartphone app|Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home
41371763|NCT03564015|OTHER|Paper handout|Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
41371764|NCT03065010|DRUG|BCD-115|Inhibitor of CDK8/19
41371765|NCT00077896|PROCEDURE|Direct Current Polarization|
41371766|NCT04837807|DRUG|Systane Hydration PF|This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
41371767|NCT01632007|DRUG|SYR-472|
41371768|NCT01632007|DRUG|Alogliptin 25 mg|
40848333|NCT01298765|DRUG|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
41371769|NCT01632007|DRUG|Placebo|
41503678|NCT01799369|BEHAVIORAL|Surgical Apgar Score|Post-operative care influenced by Surgical Apgar Score
41162844|NCT00053352|DRUG|etoposide|Given IV
41162845|NCT00053352|BIOLOGICAL|bleomycin sulfate|Given IV
41031049|NCT03661853|BEHAVIORAL|Cognitive Restructuring|CR is used to to help identify and change automatic, habituated thoughts that occur in response to alcohol triggers.
41371770|NCT01056458|OTHER|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
41371771|NCT01056458|OTHER|sham acupressure|use only tape without ear adhesive beads under the same ways
41371772|NCT06079606|OTHER|Antibiotic treatment|Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
41371773|NCT00379821|DRUG|Atovaquone-proguanil|Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
41371774|NCT00379821|DRUG|Artesunate|Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
41371775|NCT00379821|DRUG|Azithromycin|Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
41371776|NCT00379821|DRUG|Chloroquine|Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
41371777|NCT02311075|BIOLOGICAL|Blood samples|Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
41371778|NCT03851536|PROCEDURE|Transvaginal Ultrasound Guided ET|Use of TVUS to guide ET
41371779|NCT03851536|PROCEDURE|Transabdominal Ultrasound Guided ET|Use of TAUS to guide ET
41371780|NCT01441882|DRUG|Dasatinib|Given PO
41371781|NCT01441882|OTHER|Laboratory Biomarker Analysis|Correlative studies
41371782|NCT01441882|OTHER|Pharmacological Study|Correlative studies
41371783|NCT00604175|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
41371784|NCT01050998|BIOLOGICAL|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
41371785|NCT01050998|BIOLOGICAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
41371786|NCT01050998|BIOLOGICAL|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
41371787|NCT01050998|BIOLOGICAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
41371788|NCT01050998|OTHER|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
41371789|NCT03222180|BEHAVIORAL|Website|Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
41371790|NCT01263366|DRUG|Norepinephrine|Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
41371791|NCT01125449|DRUG|Ascorbic acid (vitamin C)|Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
41371792|NCT02463812|DRUG|Intralipid|
41371793|NCT02463812|DRUG|Saline|
41031050|NCT03661853|BEHAVIORAL|Dealing With Cravings|DC is used reduce cravings for alcohol by conjuring negative images associated with alcohol, teaching distraction techniques, and teaching breathing techniques to reduce physiological arousal.
41162846|NCT00053352|OTHER|laboratory biomarker analysis|Correlative studies
41371794|NCT01724723|DRUG|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
41371795|NCT01558466|DRUG|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
41371796|NCT01558466|DRUG|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
40848334|NCT01969032|DRUG|Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
41371797|NCT06521632|OTHER|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 2 hours.
41162847|NCT03135613|PROCEDURE|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot at self-selected gait speed.
40848335|NCT02770300|DEVICE|Arm Light Exoskeleton Rehab Station (ALEx RS)|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress.
41371798|NCT00666952|OTHER|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
41371799|NCT00666952|OTHER|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
41371800|NCT00830726|DRUG|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
41371801|NCT00830726|PROCEDURE|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
41371802|NCT00830726|PROCEDURE|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
41371803|NCT00830726|PROCEDURE|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
41371804|NCT05905354|BIOLOGICAL|NWRD08|Subjects in dose group 1 and 2 were intramuscularly injected with NWRD08 at week 0, week 4 and week 12 by electric pulse gene delivery instrument, respectively. Subjects in dose group 3 and 4 were intramuscularly injected NWRD08 at week 0, week 2, week 4 and week 12 by electric pulse gene delivery instrument, respectively.
41371805|NCT05158075|BEHAVIORAL|Approach-Avoidance Bias Modification|In this task participants must zoom in or zoom out a food image according to its format (vertical or horizontal) using their smartphone device. 90% of healthy food images will appear in the format to be approached (for example, vertical), while only 10% of unhealthy images will appear in that format (to ensure concentration on the task). The format to be approached will be counterbalanced. Participants will practice the task at home at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
41371806|NCT05158075|BEHAVIORAL|Inhibition Training|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone device. Some images are food, some non-foods. Participants can choose which food categories they would like to train to resist. The food-specific inhibition training condition included pictures of high-calorie foods always paired with the no-go signal. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
41371807|NCT05158075|BEHAVIORAL|Implementation of Intentions|"Participants establish one intention related to food and one related to exercise, and write when, where and how they will implement each one, possible inconveniences to do it, and how they will overcome them. Furthermore, motivational cues (why I eat) will be considered (negative emotions -I'm bored; social motives -eat a piece of cake you are offered in a party; politeness/conformity with others' expectations; pleasure). The implementation of intentions related to food will be written in format: if... then.... This format allows for the consideration of the health goals and medium and long-term objectives for each of the participants. The intention related to food will focus on unhealthy snacking habits whenever possible. Participants will read and visualized their implementation of intentions at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones."
41503679|NCT05520515|OTHER|Aquatic Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention is performed at the thermal pool sector of Clube Brilhante in Pelotas city. The pool water temperature is maintained between 30-32°C, with participants immersed in the depth level between the xiphoid process and shoulders. The aquatic training group performs the following water aerobics exercises: stationary running, frontal kick, cross-country skiing, and butt kick during the stimulus and jumping jacks during the active recovery. The training session is collective, with 3 to 6 participants, supervised by two experienced instructors, one outside and one inside the pool. The group also receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
41031051|NCT06218069|DRUG|Sasanlimab|6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.
41031052|NCT06218069|RADIATION|non-ablative radiotherapy|Patients will receive a total dose of 24Gy irradiation to the tumor, fractionated in 3 doses of 8Gy, on three consecutive days and starting on the day of first sasanlimab administration.
40848336|NCT02770300|DEVICE|Arm Light Exoskeleton Rehab Station (ALEx RS) - automatically personalized|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress. The movements to be performed by the patient are automatically decided by the exoskeleton.
40848337|NCT00745433|DRUG|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
40848338|NCT00745433|DRUG|metformin|Start dose and frequency at the discretion of the physician following clinical practice
41031053|NCT06218069|DRUG|[89Zr]Zr-crefmirlimab berdoxam|Prior to sasanlimab injection and prior to surgery, \[89Zr\]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.
41371808|NCT05158075|BEHAVIORAL|Episodic Future Thinking|Participants will decide health-related goals and anticipate positive future personal events at various time points (next month, 2-3 months and 4-6 months), from which contextual, temporal and emotional cues should be obtained. Goals and future events will be matched to generate episodic future thinking cues that include the necessary keys to facilitate their effectiveness. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
41371809|NCT05158075|BEHAVIORAL|Sham Approach-Avoidance Bias Modification|Participants must zoom in or zoom out a food image according to the format (vertical or horizontal) using their smartphone device. 50% of healthy food images and 50% of unhealthy food images will appear in the format to be approached (for example, vertical). The format to be approached will be counterbalanced. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
41371810|NCT05158075|BEHAVIORAL|Sham Inhibition Treatment|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone devices. Some images are food, some non-foods. Participants can choose which food categories they would like to resist. High-calorie and low-calorie foods will be paired with the go signal on 50% of trials and with the no-go signal on 50% of trials. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
41371811|NCT05158075|BEHAVIORAL|Setting Intentions|Participants will choose 10 items of healthy foods to eat whenever they want to eat unhealthy food. They will also order a list of physical activities that they could do to lose weight. Participants will read their lists (food and exercise) at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
40848339|NCT02406404|BEHAVIORAL|Incentive spirometer training|The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
40848340|NCT00442221|DRUG|Sumatriptan and Naproxen sodium|
40848341|NCT03916081|DRUG|Roflumilast Cream 0.05%|Roflumilast 0.05% cream for topical application
40848342|NCT03916081|DRUG|Roflumilast Cream 0.15%|Roflumilast 0.15% cream for topical application
40848343|NCT03916081|DRUG|Vehicle Cream|Inactive vehicle cream matched to roflumilast cream for topical application.
40848344|NCT00604890|DRUG|API 31510 3% Topical Cream|Topical treatment 3% active cream applied to the lesion
40848345|NCT00604890|DRUG|API 31510 1.5% Topical Cream|Topical treatment 1.5% active cream applied to the lesion
40848346|NCT00604890|OTHER|Placebo|Topical treatment placebo applied to the lesion
40848347|NCT03223376|COMBINATION_PRODUCT|fruquintinib +paclitaxel|treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
40848348|NCT03223376|COMBINATION_PRODUCT|fruquintinib placebo + paclitaxel|control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
40848349|NCT03511196|DRUG|Adaptive Androgen Deprivation Therapy (ADT)|ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.
40848350|NCT03511196|DRUG|Abiraterone|Prednisone 5 mg once a day with food.
40848351|NCT03511196|DRUG|Prednisone|Abiraterone 1000 mg daily with empty stomach.
41031054|NCT01502501|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
41371812|NCT05158075|BEHAVIORAL|Recent Episodic Thinking|Participants will match habits and positive recent past events (1 day ago, 2 days ago, 1 week ago), both unrelated to food or physical activity, to establish their cues. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
41371813|NCT05158075|BEHAVIORAL|Motivational Interviewing|Participants will assist a 90-minute group Motivational Interviewing session to maximize motivation and adherence to the program. The session will be guided through open questions and empathic reflections and affirmations to promote change talk. Participants will share their personal aims to reduce weight, improve their diet and increase their level of physical activity. Further, participants will talk about obstacles they have had on previous occasions, their expectations, and their motivations in regards to weight loss. When needed, information will be provided with the elicit-provide-elicit format. Sessions will end with an individual empathic summary for each participant's interventions.
41371814|NCT05158075|BEHAVIORAL|Nutritional intervention|Participants will maintain a 60-minute group session with a nutritionist and will watch a 20-minute video to match and complete relevant information on nutrition. The nutritionist will design a 6-week individualized diet that participants will receive after the initial assessment. When the 6-week diet ends, participants will assist another 60-minute group session with the nutritionist and will watch another video intended to teach them how to design their own healthy diet and maintain long-term healthy eating habits.
41371815|NCT05158075|BEHAVIORAL|Physical exercise intervention|Participants will maintain a 60-minute group session with a physical exercise professional and will watch a 20-minute video to match and complete relevant information on exercise. The physical exercise professional will design a 6-week physical exercise planning that participants will receive after the initial assessment. After those 6-weeks, participants will assist another 60-minute group session with the physical exercise professional and will watch another video intended to teach them how to design their own physical activity planning and maintain long-term healthy exercise habits.
41371816|NCT00038428|DRUG|TLK286|
41371817|NCT03705221|BEHAVIORAL|Healthy Parent Carers group programme|Peer-led group-based weekly programme.
41371818|NCT03705221|BEHAVIORAL|Healthy Parent Carers online resources|Online resources related to health and wellbeing
41503680|NCT05520515|OTHER|Land Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention occurs at the School of Physical Education, Federal University of Pelotas. Depending on weather conditions, the land training group will perform aerobic training with walking/running exercises in a flat outdoor environment or inside a multi-sport gym. The training session will be collective, with 3 to 6 participants, supervised by two experienced instructors, one at the starting point and the other following the movement of the participants. In addition, the group receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
41503681|NCT05520515|OTHER|Health Education|The intervention occurs at the School of Physical Education, Federal University of Pelotas. The intervention consists of an educational program with weekly lectures of approximately 30 min. The lectures are led by a qualified health professional, using expository and interactive approaches on topics that cover basic knowledge related to breast cancer and complementary therapies. Additionally, each participant receives a self-care booklet containing information about the topics addressed during the meetings. Qualified professionals give lectures on the following topics: 1) fatigue and quality of life; 2) anxiety and depressive symptoms; 3) body image and sexual function; 4) self-esteem; 5) self-care; 6) sleep; 7) cognitive function; 8) symptoms in the arm and breast; 9) pain and arthralgia; 10) body composition and bone health; 11) eating habits; 12) physical activity.
41503682|NCT01069874|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D/Vigantol oil)|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
41503683|NCT01069874|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
41503684|NCT01118065|DRUG|everolimus|
41503685|NCT02931929|DRUG|68Ga-NeoBOMB1, 2-vial kit|intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
41503686|NCT04609566|DRUG|brentuximab vedotin|1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks
41503687|NCT04609566|DRUG|pembrolizumab|200 mg given intravenously every 3 weeks
41503688|NCT06079320|DRUG|Sisunatovir|Participants will receive tablets from Day 1 to Day 5
41503689|NCT06079320|DRUG|Placebo|Participants will receive matching placebo tablets from Day 1 to Day 5
41503690|NCT00530218|DRUG|Ganciclovir|Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
40848352|NCT04283591|PROCEDURE|Acupuncture Treatment|Acupuncture Treatment Group will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points of the hemiplegic side and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week.
40848353|NCT04283591|OTHER|Conventional Rehabilitation Programme|They will continue to receive the conventional rehabilitation programme.
41371819|NCT03346109|RADIATION|medial group retropharyngeal node（MRLN） sparing|Patients in MRLN sparing group will not routinely receive MRLN irradiation; while patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr.
41503691|NCT02793505|DRUG|metformin|This is not an intervention but an observed exposure.
41503692|NCT02793505|DRUG|any drug not known as a major teratogen or major fetotoxicant|This is not an intervention but an observed exposure.
41503693|NCT02343783|OTHER|Allergic Skin Reaction (ASR) Testing and Skin Blister Induction|Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
41503694|NCT04752059|DRUG|Trastuzumab deruxtecan|Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death
41503695|NCT06435273|DRUG|AZD4604|Janus kinase 1 (JAK1) inhibitor
41503696|NCT06435273|DRUG|Placebo to AZD4604|Placebo to AZD4604
41503697|NCT04319198|DRUG|Sacituzumab Govitecan-hiy|Administered intravenously
41503698|NCT04648202|DRUG|FS120|Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
41503699|NCT06381713|BEHAVIORAL|High intensive combined phonetic-phonological intervention|"Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 5 times 30' per week for 2 times 4 weeks."
41503700|NCT06381713|BEHAVIORAL|Low intensive combined phonetic-phonological intervention|"Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 2 times 30' per week for 20 weeks."
41503701|NCT03168230|PROCEDURE|Portal vein embolization (PVE)|"Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.~An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.~This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.~Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx"
41371820|NCT03201601|DRUG|D-chiro-inositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
41371821|NCT03201601|DRUG|Myoinositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
41371822|NCT05225701|BEHAVIORAL|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists). The function of the psychological advisor is to motivate, guide and listen to the doubts and comments of each participant by providing a weekly session of one hour in individual online format, in addition to the review of the module in platform in self-suggestive format.
41371823|NCT05225701|BEHAVIORAL|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each module will include exercises and tasks for the practice of each technique. Automatic emails with notifications will be sent to access the program when participants have not entered in the last 15 days.
41371824|NCT03678649|DRUG|Capecitabine|1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
41371825|NCT00731094|BEHAVIORAL|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
41371826|NCT00212082|DRUG|doxorubicin, docetaxel|
41503702|NCT05658458|DRUG|Vericiguat (Verquvo, BAY1021189)|The recommended starting dose of vericiguat is 2.5 mg once daily, taken with food. The dose of vericiguat would be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the participant.
41371827|NCT04614480|GENETIC|Exome analysis|Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment
41371828|NCT01846442|DRUG|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
41371829|NCT01846442|DRUG|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
41371830|NCT01846442|DRUG|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
41371831|NCT01846442|DRUG|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
41371832|NCT03652129|PROCEDURE|Disinfection|Disinfection maneuver using LASER and nano irrigant
41371833|NCT05038085|BEHAVIORAL|progressive muscle relaxation exercise|"36-37 with pregnant women in the experimental group. There will be two online interviews starting from week one. Before the first interview, the PMRE video will be sent to the women, explained by the researcher. In the first meeting, basic information about postpartum depression and what to do to prevent postpartum depression and its treatment will be explained. The women will then be asked to describe the PKGE. Relaxation Exercises CD Audio Recordings belonging to the Turkish Psychological Association will be sent to women, and they will be asked to perform PMRE at least 3 days a week until delivery, accompanied by the instructions on the CD. In the second meeting; maternal attachment will be explained. In this interview, women will be asked to continue to do PMRE at least 3 days a week from the day they feel ready, starting at the latest 1 week after delivery."
41371834|NCT01484691|DRUG|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
41371835|NCT03032939|PROCEDURE|endotracheal intubation|standard endotracheal intubation of surgical patients after induction of anesthesia
41371836|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
41371837|NCT05832073|DRUG|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
41371838|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection placebo|Composition: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
41371839|NCT05832073|BIOLOGICAL|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
41371840|NCT01466309|DEVICE|Somnoguard oral appliances|wearing somnogaurd daily at bedtime
41371841|NCT05040295|DRUG|ritlecitinib|30 mg intact adult capsule
41371842|NCT05040295|DRUG|ritlecitinib|10 mg pediatric capsule
41371843|NCT05040295|DRUG|ritlecitinib|30 mg spray congealed beads
41503703|NCT06632405|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
41503704|NCT06632405|DRUG|Nab paclitaxel|Nab paclitaxel 100mg/m2 will be administered as an intravenous infusion every 4 weeks in d1,8,15until unacceptable toxic effects or disease progression or other termination criteria appeared.
41503705|NCT06632405|DRUG|Levocetirizine Hydrochloride|5mg daily, start 3 days before the 1st administration
41503706|NCT06632405|DRUG|Placebo|5mg daily, start 3 days before the 1st administration
41371844|NCT03509766|DEVICE|Histamine skin testing|skin testing using histamine
41371845|NCT01977066|BEHAVIORAL|Six months supervised resistance training|progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.
41371846|NCT01977066|BEHAVIORAL|Six months home-based exercise training|Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
41371847|NCT02349100|DEVICE|Nellix Endoprosthesis|Implantation of Nellix
41371848|NCT01024270|DRUG|Misoprostol|
41371849|NCT05070494|BIOLOGICAL|Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)|study of immunologic response to different dose and duration of Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)
41371850|NCT05499104|DEVICE|NovaDress|NovaDress is constructed of pure cellulose derived from tree pulp. The tree pulp is reconstructed into hydrated sheets wrapped in nonwoven viscose and irradiated.
41371851|NCT05499104|DEVICE|Mepilex Ag|Mepilex Ag is an antimicrobial foam dressing that absorbs low to moderate exudate and maintains a moist wound environment.
41503707|NCT01186484|DRUG|JNJ-212082|250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
41503708|NCT01982448|DRUG|Cisplatin|
41503709|NCT01982448|DRUG|Paclitaxel|
40848354|NCT01618149|RADIATION|dual energy x-ray absorptiometry|before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
40848355|NCT03936972|PROCEDURE|ilizarov circular frame and uni-planarexternal fixator|both are types of external fixators, but one is circular frame and other is uni-planar frame
40848356|NCT04965662|DRUG|Maraviroc|Maraviroc 300 mg, TWO tablets once daily.
40848357|NCT04965662|DRUG|Truvada|Truvada one tablet once daily
41371852|NCT05499104|DEVICE|Xeroform|Xeroform® Occlusive Dressing (XF) is a fine-mesh gauze impregnated with a petrolatum blend, 3% bismuth tribromophenate.
41371853|NCT02070718|DRUG|Standard Dose Kappa Agonist|
41371854|NCT02070718|DRUG|Half Dose Kappa Agonist|
41371855|NCT02070718|OTHER|Placebo|
41371856|NCT03628573|DEVICE|repetitive transcranial magnetic stimulation (MagPro X100).|accelerated rTMS.
41503710|NCT05823324|BEHAVIORAL|Therapeutic play group|The dramatization method with teddy bear, one of the TP methods, was applied during the PIVC intervention
41503711|NCT06084936|DRUG|Obinutuzumab|Participants will receive two 1000 mg pretreatments of intravenous (IV) obinutuzumab from Cycle 1 Day 1
40848358|NCT02842749|DRUG|everolimus|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
40848359|NCT04200144|DEVICE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)
40848360|NCT05382897|OTHER|Plant-based fasting-mimicking diet|Participants will be on a low caloric plant-based diet or a caloric-sufficient plant-based diet for 3 x 5 day cycle each month followed by 3 weeks of eating normally for a total period of 3 months.
41031055|NCT06635551|DIAGNOSTIC_TEST|Ultrasonographic evaluation of vascular catheter-related thrombosis after oncological surgery.|In patients who will undergo oncological surgery and have a central venous catheter, the presence of thrombosis, its duration of occurrence and its dimensions will be evaluated by ultrasonography.
41371857|NCT03628573|DEVICE|Intermittent Theta burst stimulation ( iTBS)|
41031056|NCT06635551|DIAGNOSTIC_TEST|Ultrasonographic evaluation of vascular catheter-related thrombosis after non-oncological surgery.|In patients who will undergo non-oncological surgery and have a central venous catheter, the presence of thrombosis, its duration of occurrence and its dimensions will be evaluated by ultrasonography.
41031057|NCT02882802|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
41031058|NCT02882802|BEHAVIORAL|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
41031059|NCT05846581|DEVICE|GORE® ACUSEAL Vascular Graft|"The device placement will be performed according to each participating site's standard practice. No specific procedures are required by the protocol.~At the time of the GORE® ACUSEAL Vascular Grafts implantation, procedural and adverse event information will be collected."
41031060|NCT02286089|BIOLOGICAL|OpRegen|Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space.
41371858|NCT02191033|BEHAVIORAL|Smoking counseling|
41031061|NCT05409014|OTHER|PFMT|The phase 1 of the protocol was awareness-raising, the athlete receives guidance from a physical therapist and learns the location of the PFM and the ability to contract them in isolation. The phase 2 is stabilization, consisting of 15 stabilization exercises, which are performed through pelvic floor contractions for 10 seconds and with the same relaxation time, repeating each group 10 times. The phase 3 is strength, the same exercises as the second phase are performed using 2 kg weights at the end of each leg and/or arm. There are eight groups of exercises and with changes in the time of slow contraction and relaxation. The phase 4 is power, in power exercises the training loads are increased and the sequence of movements is also increased. The phase 5 is to complement the power, this phase was the continuation of the previous one in the sense of potentiation of the results where ballistic movements, speed and impact fundamentally predominate.
41371859|NCT02191033|BEHAVIORAL|Text messaging|
41371860|NCT02191033|DRUG|Nicotine patch|
41371861|NCT05326958|DEVICE|HRT RCM|Imaging with HRT RCM done only at site 1 (on normal eyes of subjects without DM).
41371862|NCT05326958|DEVICE|HRT RCM-E|imaging done on eyes of all enrolled subjects at site 1 and site 2.
41371863|NCT01958619|DRUG|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
41371864|NCT01958619|DRUG|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
41371865|NCT01958619|DRUG|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
41371866|NCT01958619|DRUG|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
41371867|NCT00453076|DEVICE|Paclitaxel eluting covered metal stent and control covered metal stent|Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
41371868|NCT03082079|PROCEDURE|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
40848361|NCT06440551|BEHAVIORAL|TeleSalud Healthy Eating- Physical Activity/Sedentary Behavior (HE-PA/SB)|Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud HE-PA/SB Class, after which they will attend one maintenance meeting per month for 4 months. Weekly, Day 1 (Healthy Eating \& PA-SB Class): Participants will receive a 50-min. healthy eating class. Physical Activity- Sedentary Behavior (PA-SB) Class: By discussing barriers and strategies to overcome barriers, this will help to increase self-efficacy. We will engage in Latino-centered moderate impact (increasing to vigorous) aerobics with Latino or salsa movements and music for 45-50 minutes. Aspects of kickboxing aerobics will be integrated. Goal: Exercise a minimum of 150-250 min./ week of moderate intensity. Weekly, Day 2: PA-SB identical PA-SB to Day 1. Maintenance (Months 5-8): Meetings once/ month for 70 min. for HE/PA-SB class, including 25 min. to discuss diet and PA-SB barriers. Goal: Exercise a minimum of 150-250 min./week.
40848362|NCT06440551|BEHAVIORAL|TeleSalud General Health Intervention|Weekly: Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud General Heath Class, after which they will attend one maintenance meeting per month for 4 months. Participants will meet and discuss general health topics (not diet or PA). Examples of the general health topics are: Back Pain, Muscle Strains, Alcohol Use, Stress \& Coping, Oral and Dental Health, Safety Tips, Emergency Preparedness. The content is relevant to Latinos, and information is focused on Latino men. Maintenance (Months 5-8): Participants will meet via telehealth once/ month for 70 min. to discuss general health topics. To enhance motivation to complete the study and assessments, this group will receive a copy of the TeleSalud HE-PA/SB intervention manual and related materials after the maintenance period ends.
40848363|NCT01819350|OTHER|G1, G2 and G3|Nutritional, respiratory and endocrine group applicated 12 subjects
40848364|NCT01819350|OTHER|G4 and G5|Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
40848365|NCT00082199|DRUG|Aripiprazole|Tablets, Oral, 2-30mg, Once daily, 12 weeks.
40848366|NCT00082199|DRUG|Placebo|Tablets, Oral, Once daily, 12 weeks.
40848367|NCT04518683|DEVICE|Perineal rehabilitation with mobile applications for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. the sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home Program: The home program will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes. The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
40848368|NCT04518683|DEVICE|Classic perineal rehabilitation for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. The sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home program: The home program will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist."
40848369|NCT01920737|DRUG|Daunorubicin|In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
41031062|NCT02322944|BEHAVIORAL|Quality improvement strategies and tools|Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
41162848|NCT00946634|DRUG|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
41162849|NCT00946634|DRUG|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
41162850|NCT00946634|DRUG|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
41371869|NCT02816658|OTHER|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
40848370|NCT01920737|DRUG|Vincristine|
40848371|NCT01920737|DRUG|Prednisone|
40848372|NCT01920737|DRUG|PEG-Asparaginase|
40848373|NCT01920737|DRUG|Methotrexate|
40848374|NCT01920737|DRUG|6-MP (6-Mercaptopurine)|
40848375|NCT01920737|DRUG|Cyclophosphamide|
40848376|NCT01920737|DRUG|Cytarabine|
40848377|NCT01920737|DRUG|Leucovorin|
41162851|NCT04677933|DRUG|A: OLP-1002|10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002
41162852|NCT04677933|DRUG|B: OLP-1002|10 patients will receive 10 µg OLP-1002 BIW OLP-1002
41162853|NCT04677933|DRUG|C: Placebo|10 patients will receive Placebo BIW
41162854|NCT04570254|DRUG|Vitamin C|Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient. Protect from light at all times, as it is photosensitive.
41162855|NCT04570254|DRUG|Vitamin E|Vitamin E. 800 mg tablet. 800 mg dose every 24 hours. Dissolve the capsule in 30 ml of hot water. The administration of vitamin E is recommended during or after meals since its absorption depends on pancreatic enzymes' presence.
41503712|NCT06084936|DRUG|Glofitamab|Participants will receive IV glofitamab beginning Cycle 1 Day 8 for 12 cycles (cycle length = 21 days).
41371870|NCT02816658|OTHER|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
41371871|NCT02799576|DEVICE|Curved needle|In this arm, the curved block needle will be used for regional blockade
41371872|NCT02662140|BEHAVIORAL|Mobile Health Applictaion|"Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.~Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process"
41371873|NCT03573466|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
41162856|NCT04570254|DRUG|Melatonin|"Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast."
41371874|NCT03721614|DEVICE|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
41371875|NCT03721614|DEVICE|Xience family Everolimus Coronary Stent Systems|Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
41371876|NCT00556972|DEVICE|Fecal Incontinence Management System|The device is intended to remedy fecal incontinence.
41371877|NCT02584972|OTHER|no intervention required|no intervention required
41371878|NCT00032058|PROCEDURE|magnetic resonance imaging|
41371879|NCT00032058|PROCEDURE|magnetic resonance spectroscopic imaging|
41371880|NCT02210559|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm group description.
41371881|NCT02210559|DRUG|Gemcitabine|Gemcitabine will be administered per dose and schedule specified in the arm group description.
40848378|NCT01920737|DRUG|Dexamethasone|
40848379|NCT01920737|OTHER|Blood draw|
40848380|NCT01920737|DEVICE|CT/PET scans|PET or CT scan every 6 months for 3 years
41371882|NCT02210559|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
41371883|NCT00718809|DRUG|saracatinib|Given orally
41371884|NCT02871869|DRUG|vindesine|3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles
41371885|NCT02871869|DRUG|cyclophosphamide|750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
41371886|NCT02871869|DRUG|Epirubicin|60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
41371887|NCT02871869|DRUG|prednisone tablets|100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
41371888|NCT02871869|DRUG|Cinobufacini Tablets|0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
41371889|NCT02871869|DRUG|Rituximab|375mg/㎡,one day before CHOP protocol
41371890|NCT01393574|DRUG|Melatonin|3 mg for body weight \<40kg, 6 mg for body weight \>40kg, once a day 30-60 minutes before sleep
41371891|NCT01393574|DRUG|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
40848381|NCT02458443|OTHER|Isometric resistance training|Isometric handgrip exercise using a hand dynamometer
41162857|NCT04570254|DRUG|N-acetyl cysteine|N-acetylcysteine. Tablets, 600 mg. 600 mg dose every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient.
41503713|NCT06084936|DRUG|Rituximab|Participants will receive IV rituximab every 28 days for up to 6 cycles (when in combination with bendamustine), or until disease progression (when in combination with lenalidomide).
41503714|NCT06084936|DRUG|Bendamustine|Participants will receive IV bendamustine on Days 1 and 2 Q4W for 6 cycles (cycle length = 28 days).
40848382|NCT01577342|DRUG|Moxifloxacin 0.5%|1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
40848383|NCT05547308|DEVICE|3D myoelectric prosthetic device|All subjects will use the 3D Prosthetic device and complete a variety of quality of life questionnaires.
40848384|NCT05374629|BEHAVIORAL|Use different methods of teaching|Both groups will receive a smoking cessation education guideline and post-test three months after the intervention.
40848385|NCT01463202|DRUG|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
41162858|NCT04570254|DRUG|Pentoxifylline|Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours. The tablet is dissolved in 30 ml of water and is administered orally or nasogastric tube.
40848386|NCT01463202|DRUG|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
40848387|NCT01769820|DRUG|Dexamethasone|studies 1\&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
40848388|NCT01769820|DRUG|placebo|
40848389|NCT01088399|DRUG|Somatropin (rDNA origin)|Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
40848390|NCT03262636|DRUG|Indocyanine Green|Indocyanine Green
40848391|NCT02219074|DEVICE|Sebacia microparticle and laser treatment|
40848392|NCT02219074|DEVICE|Vehicle and laser treatment|
40848393|NCT04783077|BEHAVIORAL|WhatsApp|Participants assigned to the WhatsApp group will receive weekly messages developed by communication specialists aimed to motivate blood donation, be encouraged to discuss their blood donation experiences, and share their own motivations for donating blood in a moderated, closed group over a six-month duration. The moderator will provide guidelines on acceptable use of WhatsApp in the group, including images they can or cannot share. Participants will also receive standard NBSG communications for first-time donors.
40848394|NCT04783077|BEHAVIORAL|Control|Participants in this group will receive the standard NBSG communications for first-time donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to the second blood donation eligibility. The second blood donation eligibility is four months after the first donation.
40848395|NCT04783077|BEHAVIORAL|Docudrama|Participants will be exposed to a document-drama related to blood donation.
40848396|NCT05407155|COMBINATION_PRODUCT|bevacizumab plus nab-paclitaxel and platinum|Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.
40848397|NCT01321957|DRUG|Oxaliplatin, 5FU/LV, Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
41162859|NCT02878590|DEVICE|BONGO DEVICE|A device to be used for the treatment of mild to moderate obstructive sleep apnea
41371892|NCT05174312|DEVICE|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
41371893|NCT05174312|DRUG|Diuretic|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
41371894|NCT03891433|DRUG|Meropenem|Carbapenems group intervention.
41371895|NCT03891433|DRUG|Ertapenem 1000 MG|Carbapenems group intervention.
41503715|NCT06084936|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 Q4W until disease progression.
40848398|NCT01321957|DRUG|5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
40848399|NCT06389851|DIETARY_SUPPLEMENT|Experimental: Case Group - Tomato-free diet|Nutritional intervention without tomatoes and sauce
40848400|NCT06389851|DIETARY_SUPPLEMENT|Experimental: Case group - Diet enriched with tomatoes|Nutritional intervention enriched with tomatoes and souce
40848401|NCT00492336|DRUG|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
40848402|NCT00492336|DRUG|Placebo|Placebo 1 tablet each day
40848403|NCT06334068|OTHER|Short-term glycemic control group|Patients will be admitted to the hospital for 2-3 days before surgery. During this pilot study, patients will be admitted to the intermediate care unit to monitor and control preoperative blood glucose. We aim to maintain moderate glucose control (140-180 mg/dl) using the basal-bolus insulin protocol, plus correctional doses as needed.
40848404|NCT06334068|OTHER|Standard-of-care group|Patients will be admitted the day before surgery with the usual patient treatment.
40848405|NCT00459654|DRUG|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
41371896|NCT03891433|DRUG|Piperacillin, Tazobactam 4-0.5G Solution for Injection|Piperacillin/Tazobactam group intervention.
41371897|NCT00422058|DRUG|liraglutide|Injected s.c. (under the skin) once daily
41371898|NCT00422058|DRUG|orlistat|120 mg capsule. Administered thrice daily
41371899|NCT00422058|DRUG|placebo|Injected s.c. (under the skin) once daily
41371900|NCT02231502|OTHER|Vegetable-based convenience food|
41371901|NCT02231502|OTHER|Vegetable meal|
41371902|NCT02701907|OTHER|Blood sampling|
41371903|NCT00752063|DRUG|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
41503716|NCT06084936|DRUG|Tocilizumab|Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.
41503717|NCT06277232|OTHER|Nutrition care|Nutrition care is designed to include nutrition assessment (e.g., malnutrition screening, monitoring weight changes, etc.), optimization of individual dietary patterns, and evaluation. Through the Diet4painrelief platform, a dietician will follow up the progress of each participant in different timepoints and also plan meetings with other professionals in IPRP. A dietitian together with a physician in rehabilitation are responsible for the administration of the procedure.
41503718|NCT06277232|BEHAVIORAL|Dialogue and education (part of Interdisciplinary Pain Rehabilitation Program)|Dialogue and education consists of patient education, training in wellness and healthy living habits, meetings with families, video feedback, and couples therapy and self-training (e.g., home lessons, activity diary, physical self-training, reflection time, and self-analysis. . In addition, lectures in basic pain science and pain management are offered for both patients as well as for relatives, friends, and colleagues.
40848406|NCT00459654|DRUG|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
41162860|NCT05735119|DEVICE|Tapestry Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
41162861|NCT06104579|OTHER|Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection|Concordance between the two registers was analysed using Cohen´s Kappa.
41371904|NCT05206669|BEHAVIORAL|Health Messages|Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
41371905|NCT02272569|DEVICE|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
41371906|NCT05460312|DIAGNOSTIC_TEST|prostate biopsy|trans rectal ultrasound guided biopsies of prostate . Biopsy smaples will be referred to staining and western blot analysis.
41371907|NCT00902759|OTHER|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
41371908|NCT02553993|DEVICE|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
41371909|NCT02553993|DEVICE|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
41371910|NCT02553993|OTHER|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
41162862|NCT01855178|DEVICE|Emfit Movement Monitor|Factory settings
40848407|NCT04631965|BEHAVIORAL|Transition support service|The hospital-wide transition support service provides systematic care coordination for young patients prior to the transfer of care
40848408|NCT00855972|DRUG|Low Dose Naltrexone|
40848409|NCT06089512|PROCEDURE|paravertebral block group|Paravertebral block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
40848410|NCT06089512|PROCEDURE|Mid point transverse process block group|Mid point transverse process block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
40848411|NCT06089512|PROCEDURE|Control group|Only general anesthesia was applied to the patients.
40848412|NCT01735370|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
40848413|NCT01735370|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
40848414|NCT01600937|BEHAVIORAL|Theoretical & practical exercise counseling|2 sessions/ per wk for 1 month
40848415|NCT03515642|BEHAVIORAL|HIIT group|Physical Training
40848416|NCT01868334|BEHAVIORAL|Pillar 1: Convenient Vaccination Services|"Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap."
40848417|NCT01868334|BEHAVIORAL|Pillar 2: Patient notification|"Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media"
40848418|NCT01868334|BEHAVIORAL|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
40848419|NCT01868334|BEHAVIORAL|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
40848420|NCT00562991|DEVICE|measurement of exhaled NO is used to guide treatment|exhaled NO
40848421|NCT04398550|OTHER|Specific Carbohydrate Diet|Diet restricts all but simple carbohydrates and allows for inclusion of fresh fruits, vegetables, unprocessed meats, and homemade lactose-free cheese and yogurt.
40848422|NCT04398550|OTHER|Mediterranean Diet|Diet rich in whole vegetables, fruit, plant-based protein, and olive oil, with moderate amounts of seafood and dairy, and limited in sugar-sweetened goods, red meat, and nutrients like heme and sodium.
40848423|NCT04994678|OTHER|Virtual Reality Training|The Virtual reality based training group will receive a game based virtual reality training via XBOX 360or wii fit balance games. Player will be required to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week or 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
40848424|NCT04994678|OTHER|Moderate Aerobic Exercise Training|Moderate intensity continuous Aerobic exercises (Recombinant/Stationary cycling for 10-15 min with progression followed by treadmill walking for 10-15 min with progression, as well as stepping and Jogging). The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
41371911|NCT03284762|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
41371912|NCT00037908|PROCEDURE|Strength training|
41371913|NCT04698707|OTHER|Vascularized lymph node flap transfer|Patients who have received VLNT as their primary treatment but with minimal improvement
40848425|NCT05490004|OTHER|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
40848426|NCT02945813|DRUG|Metformin|850mg PO BID; 48 weeks
40848427|NCT02945813|RADIATION|Salvage Radiotherapy SRT|SRT 35 x 2Gy; 7 weeks
41031063|NCT02322944|BEHAVIORAL|Process optimization|Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
41371914|NCT04698707|OTHER|Patients without prior lymphedema surgery|Patients without prior lymphedema surgery
40848428|NCT06049303|OTHER|Paraffin wax bath therapy and Maitland joint mobilization techniques|"In group A Patients will be treated with paraffin wax bath 20 minutes (before any physical therapy treatment)~* (Apply a few drops of olive oil into the skin of the area. Dip/pour knee joint area into the wax and leave it in for a few seconds until a layer forms over the area. Wait for the wax to dry. Repeat this process until you have at least 10 layers of wax area to be treated.)~* Joint mobilization technique (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) will be given 4 times a week for 6 weeks (The patient will be positioned in supine lying with the knee slightly flexed and a prop placed under the distal femur. The stabilizing hand will be used to prop the distal femur and the mobilizing hand is placed over the proximal tibia just below the tibial tuberosity. The mobilization itself will be performed by a force perpendicular to the line of the tibia.)"
41371915|NCT00190294|DRUG|MIFEPRISTONE 200 mg and misoprostol 400 µg|MIFEPRISTONE 200 mg and misoprostol 400 µg
41371916|NCT02853825|BEHAVIORAL|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
40848429|NCT06049303|OTHER|Maitland knee joint mobilization|"Group B will have (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) 4 times a week for 6 weeks.~Mobilization procedure will be same as above"
40848430|NCT01359228|DRUG|Rifaximin (XIFAXAN)|Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
40848431|NCT01359228|DRUG|Placebo|Placebo 1 tablet three times a day for 14 days.
40848432|NCT04534881|DRUG|Progesterone 200 MG|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
40848433|NCT04534881|DRUG|Placebo|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
40848434|NCT05887531|OTHER|Prehabilitation|Patients will be included in a prehabilitation program
41371917|NCT00314262|DRUG|Erlotinib & Celecoxib|"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months."
41371918|NCT00594568|DRUG|LY450139|Administered orally once daily
41371919|NCT00594568|DRUG|Placebo|Administered orally once daily
41371920|NCT05287165|DRUG|IM96 CAR-T cells|treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
41371921|NCT00625768|DRUG|AS1409|Study drug
41371922|NCT06235177|COMBINATION_PRODUCT|Decompartmentalization Framework|"I will also be using mental imagery, consciousness, cognition, and cognitive psychology during this study to show the effectiveness of the conscious mind, and how the mind can influence behavior.~Decompartmentalize means to remove excessive compartmentalization; to restore from a compartmentalized state; to merge back together."
41371923|NCT06235177|DIETARY_SUPPLEMENT|Liquid Herbal TInctures|I will make and administer liquid herbal tinctures that will be made from all natural leafs, roots and flowers. I will focus on and track the participants' diagnosis, side effects, and how they feel before, during and after taking the liquid tincture.
41371924|NCT06235177|OTHER|Mental Imagery|I will have the participants focus on a particular shape, sound or image that they can see, think, or hear. This will allow the participant to have a clear mind, and release any negative thoughts, negative energy and boost their moods and their 5 senses.
40848435|NCT05972083|DRUG|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
40848436|NCT02653937|DRUG|Tsumura's shigyakusan|"Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne"
40848437|NCT05138887|DRUG|Tetrahydrobiopterin|The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
40848438|NCT03405818|DRUG|Tavaborole 5% Topical Solution|topical solution for application to toenails
40848439|NCT04775264|PROCEDURE|Pulsed Electric Field Ablation|Catheter ablation of Ganglionated Plexi (GP) structures on the epicardial surface of the heart during cardiothoracic surgery
41162863|NCT05286086|BEHAVIORAL|prehabilitation|Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery
41371925|NCT06235177|DIAGNOSTIC_TEST|Clinical Yoga|I will show the participants many different yoga positions that will give them a peace of mind, stretch their muscles and release any tension throughout their body, and have an overall well-being, as well as promoting mindfulness.
41371926|NCT06235177|DIETARY_SUPPLEMENT|Dietary Supplements|I will have the participants take an herbal supplement and/or vitamin that relates to the symptoms and current issues/diagnosis they have. The Dietary Supplements/Vitamins will enhance their capacity to overcome their health conditions, protect their body from unwanted germs and bacteria, and relieve the participants' mind and body from the symptoms they are experiencing based on their current condition.
41503719|NCT06277232|BEHAVIORAL|activity training (part of Interdisciplinary Pain Rehabilitation Program)|Activity training includes graded activity training, and exposure training, which are delivered by an interdisciplinary team (i.e., a physiotherapist, an occupational therapist, and a psychologist).
40848440|NCT03743701|DIAGNOSTIC_TEST|The method of transrectal ultrasound in В-mode|A linear transrectal ultrasonic sensor with a frequency of 9 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. In real time, the rectal wall and anatomical structures of the anal canal are evaluated using linear sections. The localization of the internal fistula opening, the course of the fistula relative to the fibers of the external sphincter and the presence or absence of cellular and wall plug is determined.
40848441|NCT03743701|DIAGNOSTIC_TEST|The method of transrectal ultrasound examination using three-dimensional image reconstruction.|A mechanical circular transrectal ultrasonic sensor with a frequency of 13 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. Within 30 seconds with a scan interval of 2 mm with a length of 10 cm, a circular recording of the anatomical structures of the rectum, surrounding tissue and anal canal takes place, obtaining an array of images in the form of a cube. The study was completed. After, at a convenient time for the researcher is working with a three-dimensional array of images. The resulting cube can be rotated 360 degrees in a circle of its axis, work with the sagittal, frontal and axial plane. To obtain a more visual representation of the exact localization of the internal fistula orifice, the course of the fistula relative to the fibers of the outer sphincter and to design volumetric cellular and wall plug.
40848442|NCT01211340|BEHAVIORAL|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
40848443|NCT03296150|BEHAVIORAL|PRESTAGE|PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.
40848444|NCT01894022|DRUG|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
40848445|NCT03771274|DEVICE|Tecnis ZLB00 & Symfony IOL|The Symfony IOL will be implanted in the dominant eye while the Tecnis ZLB00 will be implanted in the non-dominant eye.
40848446|NCT05648019|BIOLOGICAL|Anti-CD19 CAR T-cells|A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.
40848447|NCT03825016|DRUG|Lidocaine Hydrochloride|Lidocaine infusion on hystroscopic media during office hystroscopy
40848448|NCT03825016|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium
40848449|NCT00195156|DRUG|ATRA-IV|
40848450|NCT00195156|DRUG|Depakote|
40848451|NCT03580226|OTHER|No intervention|No intervention
40848452|NCT01105156|BEHAVIORAL|VEW Questionnaire|Patient Self reported questionnaire filled in.
40848453|NCT03263338|BEHAVIORAL|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
40848454|NCT01853878|BIOLOGICAL|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
40848455|NCT01853878|BIOLOGICAL|Placebo|Intramuscular administration
40848456|NCT00258934|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL single annual dose
40848457|NCT00258934|BIOLOGICAL|Inactivated, split-virion, influenza virus|0.5 mL single annual dose
40848458|NCT01105377|DRUG|entinostat|Given orally
40848459|NCT01105377|DRUG|azacitidine|Given SC
40848460|NCT01105377|OTHER|laboratory biomarker analysis|Correlative studies
40848461|NCT03908814|DRUG|Whole Human Anti-PD-L1 Antibody Injection (LDP)|Dose escalation study evaluating six dose levels (0.1, 0.3, 1, 3 , 10and 20 mg/kg) of LDP.
40848462|NCT04649684|DEVICE|Conventional robot-assisted gait training|They got conventional robot-assisted gait training, guidance force given equally to both limbs, and then gradually reduce the degree of guidance force to the extent that the patient is tolerable equally .during 4- week treatment session
40848463|NCT04649684|DEVICE|Lower CIMT robot-assisted gait training group|They got robot-assisted gait training based on CIMT concept; 100% guidance force is given on the unaffected side and then verbal ques are given not to contract unaffected muscle voluntarily as much as possible are provided, automatically according to the predetermined joint trajectory. In contrast at the affected side, gradually reduce the degree of guidance force to the extent that the patient is tolerable.
40848464|NCT04740216|BEHAVIORAL|exercise therapy plus jaw device|The mouth-opening rehabilitation exercise lasts for twelve weeks, five days a week, three times a day. Subjects can arrange to perform before or after meals according to personal eating time and preferences. The experimental group performs 30 minutes each time, including 20 minutes of stretching exercises. Ten-minute mouth expander assisted passive exercise.
40848465|NCT04740216|BEHAVIORAL|exercise therapy|the control group performed 20-minute stretching exercises each time.
41162864|NCT05762081|PROCEDURE|Disposable Wipes for wiping baths|A disposable wipe bath is a type of bath that is applied to bed-bound or unconscious patients and weak individuals by wiping the entire body.
41162865|NCT05762081|PROCEDURE|Traditional bed bath|Traditional bed bathing is a type of bathing applied to bed-bound or unconscious patients and weak individuals by wiping the entire body with soap and water.
41162866|NCT02709447|BEHAVIORAL|Date SMART|Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.
41162867|NCT02709447|BEHAVIORAL|Health Promotion|Psycho-educational group prevention program targeting knowledge and skills only
41371927|NCT06235177|BEHAVIORAL|Applied Relaxation|"Applied Relaxation is a specialized form of relaxation training that aims to teach the participant how to relax in common social situations.~Mindfulness training encourages participants to gain psychological distance from their worries and negative emotions, seeing them as an observer would see them. 2 types of mindfulness will be used, which is mindfulness-based stress reduction and mindfulness-based cognitive therapy. Treatment starts with general education about stress and social anxiety."
40848466|NCT05021575|OTHER|Data collection on outpatient care|"Outpatient data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Outpatient data related to cardiovascular diseases (CVD) were collected as described:~1. data on visits were collected using ICD-10 codes I00-I99 and other CVD related codes (e.g., certain Z, Q codes, J81.0, R57.0)~2. data were collected from CVD prevention program~3. data on interventional cardiology were collected from day care facility regardless of the diagnosis.~Date of the visit, patient age, sex and municipality, service level (primary, secondary or tertiary), type of service and main diagnosis were recorded."
40848467|NCT05021575|OTHER|Data collection on hospitalisation|"Hospitalisation data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Data on hospitalisation were collected if any of the diagnoses (principal or secondary) were in I00-I99 range. Hospitalisation data covered hospitalisation date, patient age, sex, municipality and outcome. Data on cardiovascular procedures performed during hospitalisations included date of the procedure and ACHI (Australian Classification of Health Interventions) code."
40848468|NCT05021575|OTHER|Data collection on cardiovascular mortality|Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.
40848469|NCT05021575|OTHER|Data collection of patients presenting to the tertiary care centre with acute coronary syndrome|Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.
40848470|NCT02439034|DRUG|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
40848471|NCT02439034|DRUG|Ketoprofen|Ketoprofen\* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
40848472|NCT02486965|DEVICE|thermode (TSA-II model)|thermal stimulation with test thermode
40848473|NCT02486965|OTHER|Adapted Physical Activity|
40848474|NCT02486965|OTHER|Physical activity|
40848475|NCT04248088|BEHAVIORAL|Gentle Stretching and Education|60 minutes of gentle stretching twice weekly for 6 months
40848476|NCT02650102|DRUG|Risperidone|a kind of antipsychotics
40848477|NCT02650102|DRUG|Olanzapine|a kind of antipsychotics
41162868|NCT04083937|RADIATION|Hypofractionated radiotherapy with photons|hypofractionated radiotherapy with photons (total dose 57.0 Gray in 19 fractions)
41371928|NCT06235177|BEHAVIORAL|Pain Relaxation Techniques|"Relaxation can reduce the feelings of stress, helping them to gain more control. Reduce pain by decreasing muscle tension, aches and pains. The body releases endorphins (the body's natural pain-killers) to relieve pain.~Yoga incorporates breath control, meditation, and gentle movements to stretch and strengthen muscles.~Mind-body techniques, which includes meditation, mindfulness, and breathing exercises help you restore a sense of control over your body and turn down the fight or flight response, which can worsen chronic muscle tension and pain."
40848478|NCT02650102|DRUG|Quetiapine|a kind of antipsychotics
41371929|NCT06235177|BEHAVIORAL|Comprehensive Theocentric Psychological Assessment|To enhance the lives of add to the lives of those who are well adjusted but know they have a greater potential within themselves to ring forth and live more fulfilling lives,
40848479|NCT02650102|DRUG|Aripiprazole|a kind of antipsychotics
40848480|NCT02650102|DRUG|Ziprasidone|a kind of antipsychotics
40848481|NCT05455931|DRUG|Poteligeo|Poteligeo treatment will be used as prescribed by the Investigator in accordance with the terms of the reimbursed indication within the relevant country. The assignment of the patient to a particular therapeutic strategy falls within current practice and the prescription of Poteligeo is clearly separated from the decision to include the patient in the study.
40848482|NCT06229327|BEHAVIORAL|THERAPEUTICGAMES|THERAPEUTICGAMES
40848483|NCT01651663|DRUG|Arbidol (Umifenovir)|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
40848484|NCT01651663|OTHER|placebo|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
41162869|NCT04083937|RADIATION|Hypofractionated radiotherapy with protons|hypofractionated radiotherapy with protons (total dose 57.0 Gray relative biological effectiveness (RBE) in 19 fractions)
41162870|NCT04083937|RADIATION|Normofractionated radiotherapy with photons|normofractionated radiotherapy with photons (total dose 70.0 Gray in 35 fractions)
41162871|NCT03743129|DRUG|Anlotinib|Anlotinib 12mg p.o, qd
41162872|NCT03292198|OTHER|20-30 mmHg compression sleeve and gauntlet|"Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists."
40848485|NCT01651663|DRUG|Arbidol (Umifenovir)|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
40848486|NCT01651663|OTHER|placebo|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
40848487|NCT03085745|OTHER|Transcranial Magnetic Stimulation (TMS)|TMS is a non invasive brain stimulation technique which allows to measure corticospinal excitability from peripheral muscles.
40848488|NCT01068158|DRUG|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
40848489|NCT01068158|DRUG|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
40848490|NCT03472144|DRUG|gel loaded with steroids (momentasone)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local corticosteroids (momentasone) after balloon sinuplasty for chronic sinusitis patients.
40848491|NCT03472144|DRUG|gel loaded with antibiotic (Levofloxacin)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
40848492|NCT03472144|DRUG|gel loaded with both steroids and antibiotic|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local both steroids (momentasone)and antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
40848493|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET|Prostate specific membrane antigen positron emission tomography
40848494|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET/MRI|Prostate specific membrane antigen positron emission tomography combined with magnetic resonance imaging
40848495|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET/CT|Prostate specific membrane antigen positron emission tomography combined with computed tomography imaging
40848496|NCT00687531|DRUG|Mometasone Furoate|Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
40848497|NCT06192680|DRUG|Liposomal irinotecan|70 mg/m² IV
41031064|NCT04289857|OTHER|Neurodynamic training|Starting from a sitting position on a stretcher, with dorsolumbar flexion, it is required to maintain that posture throughout the exercise. Sliding with the straight leg sitting consists of performing alternate movements. First, knee extension and dorsal ankle flexion will be performed, increasing neural tension, combined with cervical extension (to decrease neural tension) in the first instance. Subsequently, knee flexion and plantar ankle flexion (decreasing neural tension) combined with cervical flexion (increasing neural tension) will be performed. The dosage of the technique will be: two seconds for each movement, with 10 repetitions of each one. All sessions will be led by one of the group's researchers.
41162873|NCT03292198|OTHER|Manual Lymphatic Drainage|"Manual Lymphatic Drainage (MLD) is a gentle skin-stretch massage that stimulates the lymphatic system and assists in creating collateral drainage pathways out of non-intact (damaged) lymphatic territories. MLD is a critical part of Complete Decongestive Therapy (CDT), which is accepted as the international standard of care in the treatment of lymphedema.~The MLD sessions will be performed by 2 Certified Lymphedema Therapists, Megan Klote and Sarah Stolker, both trained through the Norton School of Lymphatic Therapy. The therapists have completed reliability meetings regarding MLD sequencing and techniques."
41371930|NCT02654405|DIETARY_SUPPLEMENT|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
40848498|NCT06192680|DRUG|Capecitabine|1000 mg/m² PO BID
41031065|NCT01015742|DRUG|Stem cell Transplantation|"Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant."
41371931|NCT02654405|OTHER|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
40848499|NCT06192680|DRUG|Bevacizumab|5mg/kg IV
40848500|NCT02714283|DRUG|inhaled corticosteroid therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
41162874|NCT04317105|PROCEDURE|Biopsy|Undergo a tumor biopsy
41371932|NCT01161212|OTHER|Physical education sessions|3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
41371933|NCT01161212|OTHER|Physical education sessions|1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
41371934|NCT05696665|OTHER|conventional therapy|Patients will be kept on conventional therapy and no added drugs will be given
41371935|NCT05696665|DRUG|Saffron and Chamomile|Patients will be given saffron and chamomile in capsule formulation twice daily
41371936|NCT05696665|DRUG|Crocin and Apigenin|Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
41371937|NCT03950934|OTHER|no intervention, observational study, perioperative survey|no intervention
41371938|NCT00924820|DRUG|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
41371939|NCT01476527|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
41371940|NCT05689801|OTHER|"Questionnaire recovery time after a dialysis session."|A very short questionnaire just after the dialysis session
41371941|NCT05689801|OTHER|SF-12 questionnaire|Questionnaire about quality of life of the patient
41371942|NCT05689801|OTHER|EQ-5D-5L Questionnaire|Questionnaire about quality of life of the patient
41371943|NCT05689801|OTHER|Pittman, John et McIntyre questionnaire|Questionnaire about quality of life of the patient under dialysis
41371944|NCT05689801|PROCEDURE|Conventional hemodialysis|patient on polyethersulfone membrane dialysis (Revaclear®, Baxter) with HemoControl™ for 12 weeks
41371945|NCT05689801|PROCEDURE|Optimized hemodialysis|patient on Medium Cut-Off membrane dialysis (Theranova®, Baxter) with HemoControl™ for 12 weeks.
41371946|NCT06004518|OTHER|sexual counselling with PLISSIT model|sexual counselling with PLISSIT model
41371947|NCT00253071|BEHAVIORAL|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
41383513|NCT06541938|DIETARY_SUPPLEMENT|Sorbitol Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~10g sachet of sorbitol is roughly equal to the amount of sorbitol present in 3 pears or 1 prune"
40848501|NCT02714283|DRUG|macrolide therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
41031066|NCT00035438|DRUG|St. John's Wort|
41031067|NCT00823719|DRUG|ofatumumab + ICE|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg~ICE regimen:~ifosfamide + mesna - 5 grams (g)/meters squared (m\^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m\^2 on days 1, 2 and 3 of dosing cycle."
41031068|NCT00823719|DRUG|ofatumumab + DHAP|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m\^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m\^2 q12 hrs (2 doses) on day 2 of dosing cycle."
41031069|NCT02751281|PROCEDURE|Pneumatic percutaneous nephrolithotomy|Pneumatic percutaneous nephrolithotomy is type of surgery that we use pneumatic lithotripter to treat kidney stone
41031070|NCT02751281|PROCEDURE|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery that we use ultra-sonic lithotripter to treat kidney stone
41031071|NCT00796718|RADIATION|Standard radiotherapy|Administered as prescribed according to normal clinical practice.
41031072|NCT00796718|DRUG|Capecitabine [Xeloda]|825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.
41503720|NCT06277232|BEHAVIORAL|meetings (part of Interdisciplinary Pain Rehabilitation Program)|The meetings consist of conferences with patients, rehabilitation team, vocational guidance, rehabilitation coordinator, goal-setting meetings, and meetings to check goal achievement.
41503721|NCT06277232|BEHAVIORAL|Cognitive behavioral therapy (part of Interdisciplinary Pain Rehabilitation Program)|Acceptance and Commitment Therapy (ACT, e.g., goal compass, training in ACT principles, and mindfulness) is mainly delivered by psychologist in a group-treatment (e.g., training in coping strategies). The cognitive behavioral principles are also used in physiotherapy, ergonomics, and education in pain management.
41503722|NCT06277232|BEHAVIORAL|Relaxation techniques (part of Interdisciplinary Pain Rehabilitation Program)|This group-treatment is mainly format by a physiotherapist and psychologist in an interdisciplinary team.
41031073|NCT03789240|BIOLOGICAL|Rituximab|Rituximab is administered at a dose of 375 mg/m2 via IV weekly for the first 4 weeks on Days 1, 8, 15, and 22 during cycle 1. With subsequent cycles (cycles 2-6), rituximab will be dosed only once on Day 1 of the cycle.
41503723|NCT06277232|BEHAVIORAL|Physical exercise (part of Interdisciplinary Pain Rehabilitation Program)|This group-treatment is mainly format by a physiotherapist in an interdisciplinary team.
41503724|NCT06508658|DRUG|Epcoritamab|Subcutaneous Injection
41503725|NCT06508658|DRUG|Rituximab|Intravenous (IV) Infusion
41503726|NCT06508658|DRUG|Lenalidomide|Oral Capsule
41503727|NCT06508658|DRUG|Oxaliplatin|IV Infusion
41503728|NCT06508658|DRUG|Gemcitabine|IV Infusion
41503729|NCT00557089|DRUG|rhDNAse|2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
40848502|NCT00562146|PROCEDURE|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
41503730|NCT00557089|OTHER|Placebo|2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
40848503|NCT05134480|PROCEDURE|Descemet membrane endothelial keratoplasty|cornea transplant procedure to replace dysfunctional endothelial cell layer
40848504|NCT04708860|BEHAVIORAL|Prolonged Nightly Fasting|Restriction of consumption of calorie-containing food/drinks after 8pm
40848505|NCT04708860|BEHAVIORAL|Exercise|Personalized moderate-intensity, aerobic exercise and strength training
41031074|NCT03789240|DRUG|Copanlisib|Copanlisib is administered at a fixed dose of 60 mg via IV weekly for the first 3 weeks on Days 1, 8, and 15 followed by a 1-week break (no infusion on Day 22)
41031075|NCT06503276|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm
41031076|NCT06503276|RADIATION|Ultra-low dose radiotherapy|2 Gy radiotherapy will be administerd twice in the first cycle
41031077|NCT00005633|BIOLOGICAL|OVA BiP peptide|
41031078|NCT00005633|BIOLOGICAL|gp209-2M antigen|
41162875|NCT04317105|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41162876|NCT04317105|PROCEDURE|Computed Tomography|Undergo a CT scan
41162877|NCT04317105|DRUG|Copanlisib Hydrochloride|Given IV
41162878|NCT04317105|PROCEDURE|Echocardiography|Undergo ECHO
41503731|NCT05258448|OTHER|Chemoradiotherapy|Cardiac Magnetic Resonance scan and ECG
41162879|NCT04317105|BIOLOGICAL|Ipilimumab|Given IV
41371948|NCT04869618|DEVICE|Raman spectroscopy based device (SPECTRA IMDx)|The SPECTRA IMDx system is developed on the basis of Raman spectroscopy. It comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx system also comprises a SPECTRA IMDx probe that can be connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal, which is then parsed through an analysis algorithm for diagnosis.
41031079|NCT00005633|BIOLOGICAL|recombinant 70-kD heat-shock protein|
41503732|NCT05805215|COMBINATION_PRODUCT|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the hippocampus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz."
41031080|NCT00005633|BIOLOGICAL|tyrosinase peptide|
41031081|NCT06388187|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
41031082|NCT06388187|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
41031083|NCT06388187|DRUG|Placebo|Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
41031084|NCT00008853|BIOLOGICAL|GBS III-TT-SSI|
41031085|NCT00008853|BIOLOGICAL|GBS III-TT-MPHL|
41031086|NCT01866410|DRUG|Cabozantinib S-malate|Given PO
41031087|NCT01866410|DRUG|Erlotinib Hydrochloride|Given PO
41031088|NCT01866410|OTHER|Laboratory Biomarker Analysis|Correlative studies
41031089|NCT06068413|DEVICE|CT image-assisted detection software|CT image-assisted detection software can help doctor to diagnosis the focal liver lesion
41031090|NCT01737112|DRUG|99mTc-3PRGD2|For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
41162880|NCT04317105|BIOLOGICAL|Nivolumab|Given IV
41031091|NCT01813500|OTHER|Blood and stool sample|Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
41162881|NCT04317105|PROCEDURE|X-Ray Imaging|Undergo an x-ray
41031092|NCT05574010|DRUG|Cohort 1 in Part A|Dose 1 KAN-101 Intravenous (IV) infusion
41031093|NCT05574010|DRUG|Cohort 2 in Part A|Dose 2 KAN-101 Intravenous (IV) infusion
41031094|NCT05574010|OTHER|Placebo: Group 1 in Part B and Part C|Placebo Intravenous (IV) infusion
41031095|NCT05574010|DRUG|Group 2 in Part B and Part C|Dose 3 KAN-101 Intravenous (IV) infusion
41031096|NCT05574010|DRUG|Group 3 in Part B and Part C|Dose 4 KAN-101 Intravenous (IV) infusion
41031097|NCT05574010|DRUG|Group 4 in Part B and Part C|Dose 5 KAN-101 Intravenous (IV) infusion
41031098|NCT05656573|DRUG|CART-PSMA cells|"This study consists of 2 parts:~Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer.~Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows:~cohort 1： CART-PSMA cells 1-3x10\^7 on Day 0;~cohort 2： CART-PSMA cells 1-3x10\^8 on Day 0;~cohort 3： CART-PSMA cells 1-3x10\^7 on Day 0,following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days;~cohort 4： CART-PSMA cells 1-3x10\^8 on Day 0,following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days;~Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation)."
41031099|NCT00499187|PROCEDURE|Blood Draws|A single whole blood sample was collected for genomic analysis.
41031100|NCT06343766|GENETIC|DNA collation and genotyping|"DNA collation and genotyping of specific genes ENAM rs3796703, AMBN rs4694075), TUFT1 rs78802584 and KLK4 rs2242670 through PCR and sequencing for various SNPs~Dental examinations by comparing dental covariates such as the number of DMF-T index, presence of biofilm, gingivitis, fluorosis, and detection of interproximal caries with caries progression."
41031101|NCT02123654|DRUG|Daclatasvir|
41031102|NCT02123654|DRUG|Asunaprevir|
41031103|NCT02123654|DRUG|DCV 3DAA|
41031104|NCT02123654|OTHER|Placebo for DCV 3DAA|
41031105|NCT02123654|OTHER|Placebo for Daclatasvir|
41031106|NCT02123654|OTHER|Placebo for Asunaprevir|
41031107|NCT06345443|DIETARY_SUPPLEMENT|Nicotinamide Riboside Malate|Active supplement.
41031108|NCT06345443|OTHER|Placebo|Placebo
41031109|NCT00000218|DRUG|Carbamazepine|
41031110|NCT06264921|DRUG|NKT3447|Oral CDK2 inhibitor
41162882|NCT03185845|DRUG|Warfarin|tailored dose according to international normalized ratio (INR) for 3 months
41162883|NCT04499014|DEVICE|ultrasound|5 days a week, a total of 10 sessions
40848506|NCT04651127|DRUG|Toripalimab + Chidamide|In combination dose finding phase, phase 1b will begin with Dose Level 1: chidamide 30 mg/day orally (twice a week) and toripalimab (240mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (chidamide 25 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously) and Dose Level 3 (chidamide 20 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously). If RP2D was reached in Part A, eligible patients would be enrolled and receive toripalimab (240mg q3w, intravenously) plus chidamide (RP2D, twice a week).
40848507|NCT01092910|DEVICE|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
40848508|NCT00180011|DRUG|Omalizumab|injectable medication
40848509|NCT00006158|DRUG|Testosterone|
40848510|NCT01336023|DRUG|insulin degludec/liraglutide|Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
40848511|NCT01336023|DRUG|insulin degludec|Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
40848512|NCT01336023|DRUG|liraglutide|Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
40848513|NCT02020408|DRUG|[11C]raclopride|1.\[11C\]raclopride -The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
40848514|NCT02020408|DRUG|[11C]DASB|BPND of \[11C\]DASB.
41503733|NCT05805215|COMBINATION_PRODUCT|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the Precuneus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz."
40848515|NCT02020408|DRUG|amphetamine|The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
40848516|NCT03491111|OTHER|Respiratory muscle training for EMT+IMT|2 times per day and 5 day per week, 6 weeks, training with breathing trainer.
40848517|NCT03491111|OTHER|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
40848518|NCT03491111|OTHER|Respiratory muscle training for EMT|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
40848519|NCT04602247|DIETARY_SUPPLEMENT|SIC|Sodium Iron Chlorophyllin, whose bioavailability is to be studied
41031111|NCT01745861|DIETARY_SUPPLEMENT|Lipidem (Omega-3 fish oil lipid emulsion)|Lipidem 200 mg/ml daily infusion for 7 days maximum
41503734|NCT05805215|COMBINATION_PRODUCT|High-frequency stimulation (placebo) with Face-name association training task|High-frequency (\>1 kHz) stimulation; Standardly used as a carrier frequency; Effects are expected to he high-pass filtered by neurons
41503735|NCT00735618|OTHER|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
41503736|NCT03143374|DRUG|18F-AV-1451|"The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain.~Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit.~The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania."
41031112|NCT01745861|DIETARY_SUPPLEMENT|Lipofundin® MCT/LCT 20%|Lipofundin® MCT/LCT 20% daily infusion for 7 days
41031113|NCT05961202|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg qd
41031114|NCT05961202|DRUG|Prednisolone|Prednisolone 20mg qd
41031115|NCT06635980|PROCEDURE|Biopsy of Breast|Undergo breast biopsy
41031116|NCT06635980|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41031117|NCT06635980|PROCEDURE|Breast Surgery|Undergo breast surgery
40848520|NCT04602247|DIETARY_SUPPLEMENT|SIC + AA combined|Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
40848521|NCT04602247|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate serves as a positive control, whose iron bioavailability is known
40848522|NCT04602247|DIETARY_SUPPLEMENT|FeSO4 + AA combined|Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability
40848523|NCT04602247|OTHER|EP + FeSO4 combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system
41031118|NCT06635980|DRUG|Chemotherapy|Receive SOC chemotherapy
41031119|NCT06635980|PROCEDURE|Computed Tomography|Undergo CT
41031120|NCT06635980|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CEDM
41031121|NCT06635980|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiotherapy
41031122|NCT06635980|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41031123|NCT06635980|PROCEDURE|Positron Emission Tomography|Undergo PET
41031124|NCT06635980|OTHER|Survey Administration|Ancillary studies
40848524|NCT04602247|OTHER|EP + FeSO4 + AA combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4
41371949|NCT04114474|DIAGNOSTIC_TEST|TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity
41371950|NCT01998165|DRUG|Remifentanil|After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
41371951|NCT05756166|PROCEDURE|Biopsy|Undergo tumor biopsy
41371952|NCT05756166|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41371953|NCT05756166|DRUG|Celecoxib|Given PO
41371954|NCT05756166|PROCEDURE|Computed Tomography|Undergo CT scan
41371955|NCT05756166|BIOLOGICAL|Interferon Alpha-2|Given IV
41503737|NCT05167799|DEVICE|Cardiac Contractility Modulation (CCM)|Patients will be implanted with CCM device according to indications, to improve Heart Failure symptoms and then enrolled in the Registry if they fullfil Inclusion and Exclusion Criteria (First of all if they are diagnosed with TTR Amyloidosis)
41503738|NCT00385008|DRUG|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
41503739|NCT00385008|DRUG|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
40848525|NCT02542787|DRUG|VSN16R|Small molecule
40848526|NCT02542787|OTHER|Placebo|dummy tablet
40848527|NCT05239767|DRUG|NSAID|We will administer oral NSAIDs
40848528|NCT04364152|BEHAVIORAL|Dual-task walking training|Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
40848529|NCT03915964|DRUG|Baricitinib|Administered orally.
40848530|NCT03915964|DRUG|TNF Inhibitor|Administered SC
40848531|NCT05407779|BIOLOGICAL|BCD-180, dose 1|anti-TRBV9 monoclonal antibody single infusion at dose 1
40848532|NCT05407779|BIOLOGICAL|BCD-180, dose 2|anti-TRBV9 monoclonal antibody, single infusion at dose 2
40848533|NCT05407779|BIOLOGICAL|BCD-180, dose 3|anti-TRBV9 monoclonal antibody, single infusion at dose 3
41503740|NCT02264912|DRUG|antiplatelet drugs - P2Y12 antagonists|
41503741|NCT01872286|DEVICE|AKE-1|
40848534|NCT05407779|BIOLOGICAL|BCD-180, dose 4|anti-TRBV9 monoclonal antibody, single infusion at dose 4
40848535|NCT05407779|BIOLOGICAL|BCD-180, dose 5|anti-TRBV9 monoclonal antibody, single infusion at dose 5
41371956|NCT05756166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40848536|NCT05407779|BIOLOGICAL|BCD-180, dose 6|anti-TRBV9 monoclonal antibody, single infusion at dose 6
40848537|NCT05407779|BIOLOGICAL|BCD-180, dose 7|anti-TRBV9 monoclonal antibody, single infusion at dose 7
40848538|NCT03302637|OTHER|16S rRNA gene sequencing assay|extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.
41371957|NCT05756166|BIOLOGICAL|Pembrolizumab|Given IV
41371958|NCT05756166|DRUG|Rintatolimod|Given IV
41371959|NCT05998304|DRUG|[14C] Yiqibuvir|600 mg suspension containing 100µCi of \[14C\] Yiqibuvir
41371960|NCT05587075|PROCEDURE|Filiform needle|A needle treatment: guide patients take lying or sitting, keep relaxed, select Jingjiaji Point, Fengchi Point, Jianjing Point, Tianzhu Point, Houxi point, Hegu Point, Waiguan Point, preoperative, marker points, conventional disinfection, application specification of 0.35mmx50mm disposable sterile acupuncture needle, in the marker quick needle subcutaneous, slow needle to feel acid swelling feeling, keep needle 30min, once a day, last 5d for 1 course, a total of 4 courses of treatment.
41503742|NCT01872286|DEVICE|Pillcam SB2|
41503743|NCT00555152|OTHER|Laboratory Biomarker Analysis|Correlative studies
41503744|NCT00555152|DRUG|Lapatinib Ditosylate|Given PO
41503745|NCT00555152|OTHER|Placebo|Given PO
41503746|NCT05264129|DRUG|Atogepant|Oral Tablet
40848539|NCT01705093|DIETARY_SUPPLEMENT|flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
40848540|NCT01705093|DIETARY_SUPPLEMENT|macronutrient-matched control powder|50g macronutrient-matched powder that will lack strawberry flavonoids
40848541|NCT02596945|DRUG|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
40848542|NCT05417087|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
41503747|NCT05264129|DRUG|Ubrogepant|Oral Tablet
41503748|NCT03352258|RADIATION|Low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
41503749|NCT03063918|OTHER|Informational Intervention|Receive a workbook
41503750|NCT03063918|OTHER|Quality-of-Life Assessment|Ancillary studies
41503751|NCT03063918|OTHER|Questionnaire Administration|Ancillary studies
41503752|NCT03063918|OTHER|Survey Administration|Ancillary studies
41503753|NCT03063918|BEHAVIORAL|Telephone-Based Intervention|Receive personalized dietary intervention
41371961|NCT05587075|PROCEDURE|Long round needle|Long round needle treatment: mark tendon lesions, take 3-5 tendon lesion points for needle point, after injection of 0.5% lidocaine 1mL, local anesthesia, to hold long round needle, slowly hierarchical detection to tendon lesion points, patients feel acid, hemp, swelling feeling is appropriate, to close method line knot treatment: straight to tendon lesions point surface, scraping, to remove the surface adhesion. Do not cross the superficial surface of the clavicle, sternocleidomastoid muscle deep surface, gentle action. After the needle was released, the pinhole was covered with a disposable dressing, bandaged for 2d, once a week, once for 1 course, and for a total of 4 courses of treatment.
41503754|NCT02950649|DEVICE|invasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards Lifesciences|Experimental: Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
41503755|NCT02950649|DEVICE|No Hemodynamic Monitored Guided Assesment|Arm: Active Comparator: No Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
41503756|NCT02129608|DEVICE|LLLT|The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
41503757|NCT02129608|DRUG|Lorcaserin|10 mg pills twice daily for 12 weeks.
41503758|NCT06148584|BEHAVIORAL|General, status-neutral HIV education|General, status-neutral HIV education
40848543|NCT05417087|DRUG|Vortioxetine Hydrobromide Tablets|Vortioxetine Hydrobromide Tablets 20mg
41503759|NCT06148584|DIAGNOSTIC_TEST|HIV self-test kits|HIV self-test kits
41503760|NCT06148584|OTHER|Information about where to receive HIV prevention services|Information about where to receive HIV prevention services
40848544|NCT00995995|DRUG|Rosiglitazone|Rosiglitazone
40848545|NCT02615340|DRUG|Melatonin|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
41031125|NCT06635980|PROCEDURE|Tissue Collection|Undergo tissue collection
41031126|NCT06635980|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
41031127|NCT02943746|DIETARY_SUPPLEMENT|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
41031128|NCT02943746|DIETARY_SUPPLEMENT|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
41031129|NCT02186951|DRUG|Amoxicillin - clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
41031130|NCT02186951|DRUG|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
41031131|NCT00090389|PROCEDURE|Chinese Acupuncture|
41031132|NCT04932304|DEVICE|Transcranial direct current stimulation (tDCS)|
41031133|NCT04932304|DEVICE|Sham Transcranial direct current stimulation (tDCS)|Sham Transcranial direct current stimulation (tDCS)
41031134|NCT03794089|BEHAVIORAL|Brief anxiety intervention|Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills
41031135|NCT03794089|BEHAVIORAL|Usual PC-MHI care|Anxiety treatment with mental health provider in local primary care clinic
41031136|NCT06485232|DRUG|Universal BCMA CAR-T|Universal BCMA CAR-T
41031137|NCT06485232|DRUG|Universal CD19 CAR-T|Universal CD19 CAR-T
41031138|NCT06485232|DRUG|Universal BCMA CAR-T; Universal CD19 CAR-T|Universal BCMA CAR-T; Universal CD19 CAR-T
41031139|NCT00127959|DRUG|tenofovir|
41031140|NCT00127959|DRUG|emtricitabine|
41031141|NCT00127959|DRUG|zidovudine|
41031142|NCT00127959|DRUG|efavirenz|
41031143|NCT03799562|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial. Placebo will be identical to the pregnenolone arm, except placebo will be dispensed.
41031144|NCT03799562|DRUG|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
41031145|NCT02469194|OTHER|Blood Draw|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques
41031146|NCT04166409|PROCEDURE|Biospecimen Collection|Correlative studies
41031147|NCT04166409|DRUG|Carboplatin|Given IV
41031148|NCT04166409|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41031149|NCT04166409|OTHER|Quality-of-Life Assessment|Ancillary studies
41031150|NCT04166409|OTHER|Questionnaire Administration|Ancillary studies
41031151|NCT04166409|DRUG|Selumetinib Sulfate|Given PO
41031152|NCT04166409|DRUG|Vincristine Sulfate|Given IV
41031153|NCT01186523|OTHER|Long Term Energy Balance|To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
41371962|NCT06282263|OTHER|"Awareness Development Program on Suicide Prevention for Oncology Nurses"|"While developing the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to the nurses in the experimental group, literature information on suicide risk management and suicide prevention in oncology was included in the study content by the researchers. Awareness Development Programme on Suicide Prevention for Oncology Nurses includes 3 sessions and the titles of the programme are as follows:~Session 1: Introduction to Understanding Suicide Awareness and Development Session 2: Assessing Suicide Risk Session 3: Management of Suicide Risk Communication and Referral The programme was submitted to the opinions of 5 experts before starting the study and the programme was finalised after the feedbacks."
41371963|NCT00314847|DEVICE|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
41371964|NCT01554917|DRUG|Iguratimod|taken orally, 2 tablets/day (bid)
41503761|NCT06148584|BEHAVIORAL|Barber-led peer support group education|Barber-led peer support group education
41503762|NCT06148584|BEHAVIORAL|Facility-based HIV risk reduction counseling|Facility-based HIV risk reduction counseling
41503763|NCT06148584|DIAGNOSTIC_TEST|Facility-based HIV testing|Facility-based HIV testing
41031154|NCT00244075|DIETARY_SUPPLEMENT|nutritional supplement|either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr
41031155|NCT00244075|DRUG|recombinant human growth hormone (rcGH)|subcutaneous administration of 75 micrograms/kg/day of rcGH for 3 consecutive days
41503764|NCT06148584|OTHER|Information about facility distributed HIV self-test kits|Information about facility distributed HIV self-test kits
41503765|NCT06148584|DIAGNOSTIC_TEST|STI testing|STI testing
41503766|NCT02045147|BEHAVIORAL|Grp 1a Low Cognition, Low Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation."
41031156|NCT00244075|BEHAVIORAL|exercise|either dual leg press (3 sets of 8-12 repetitions) beginning 30 minutes prior to hemodialysis, or modified stepper (minimum of 15 minutes up to a maximum of 90 minutes, depending upon the patient's tolerance) beginning 15 minutes post initiation of hemodialysis
41503767|NCT02045147|BEHAVIORAL|Grp 2a Low Cognition, High Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations."
41031157|NCT06040489|DRUG|Miltefosine 50mg|Oral Miltefosine 50mg bid
41503768|NCT02045147|BEHAVIORAL|Grp 3a Normal Cognition, Low Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The teach back method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals."
41503769|NCT02045147|BEHAVIORAL|Grp 4a Normal Cognition, High Activation Intervention|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
41503770|NCT00220831|DRUG|Natural source Vitamin E 400IU/day|
41503771|NCT02851693|DEVICE|Optical Coherence Tomography (OCT) with Vivosight|OCT used is Vivosight for diagnosis
41503772|NCT02851693|DEVICE|Optical Coherence Tomography (OCT) with Skintell|OCT used is Skintell for diagnosis
41031158|NCT06040489|DRUG|Pentoxifylline 400mg|Oral Pentoxifylline 400mg tid
40848546|NCT02615340|DRUG|Placebo|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
41031159|NCT06040489|DRUG|Liposomal Amphotericin B|Intravenous 25 to 40mg/kg
41031160|NCT05519839|DRUG|qNIV Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV vaccine given on Day 0 and Day 70 .
41371965|NCT06566937|OTHER|E-health video|"Length: The video is approximately 10-15 minutes long, making it concise and easy to watch in one sitting.~Visuals: Includes engaging visuals, such as animations, graphics, and real-life footage, to illustrate key concepts and keep viewers engaged.~Tone: The tone is supportive, empathetic, and empowering, aiming to create a positive and encouraging atmosphere."
41371966|NCT00557986|PROCEDURE|Primary surgery|Primary breast surgery before systemic therapy
41371967|NCT03130634|DRUG|Silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
41371968|NCT03857165|DRUG|SAP-001|SAP-001 or placebo treatment in a 3:1 randomization ratio.
41371969|NCT02798302|OTHER|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
41371970|NCT00735748|DRUG|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
41503773|NCT06525207|DEVICE|Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography|Global morpho-functional assessment of the anal sphincter complex using Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography
41503774|NCT00827437|OTHER|Parent Interview|To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
41371971|NCT00735748|DRUG|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
41371972|NCT05573425|DRUG|Tazarotene gel 0.1%|Tazarotene gel 0.1% applied daily on Acne Scars.
41371973|NCT05573425|DEVICE|Microneedling|Microneedling via dermaroller device performed on Acne Scars monthly.
41503775|NCT05673811|DRUG|Nab-paclitaxel|Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
41503776|NCT05673811|DRUG|Gemcitabine|Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
41503777|NCT05673811|GENETIC|VCN-01|VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.
40848547|NCT03834831|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10
40848548|NCT03834831|DIETARY_SUPPLEMENT|Selenium|Selenium
40848549|NCT04510896|OTHER|InheRET|Primary Appropriate Referral Rates 6-months pre-intervention vs post-intervention Compare appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention vs post- intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
40848550|NCT04510896|OTHER|Patient Acceptance|Acceptance by Patients Over the course of the study Acceptance measures will include completion rates and levels of ease of use of InheRET by the patient. Impact measures will include uptake of advised risk management interventions. We will qualitatively describe why patients do not follow up with their referral. We will explore patterns of acceptance and impact levels by demographic and clinical data using correlation, t- tests, ANOVA, or their non-parametric equivalents.
40848551|NCT04510896|OTHER|Physician Acceptance Survey|Secondary Acceptance by Physicians Over the course of the study Acceptance by physicians will measure the physician effort required to deploy and use InheRET in their respective clinics, and overall satisfaction. Impact measures will include appropriate referral rates and rates of genetic testing. We will qualitatively describe why patients are not referred for genetic counseling if indicated. We will explore patterns in acceptance and impact levels by demographic and clinical data using correlations, t-tests, ANOVA, or their non-parametric equivalents.
40848552|NCT03108417|DEVICE|continuous negative external pressure|continuous negative external pressure will be applied to the anterior neck at night
41371974|NCT02594566|DRUG|CyMVectin|CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
41371975|NCT01194765|OTHER|Distance-based Cognitive Behavioural Therapy|Participants will engage in cognitive behavioural therapy to treat high anxiety sensitivity. Treatment will be delivered over the telephone.
41371976|NCT01232764|OTHER|Exposure to multi-disciplinary wound care team|"Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting."
41503778|NCT00383305|DEVICE|Cool-Cap|
40848553|NCT04855656|DRUG|RP-6306|Oral PKMYT1 Inhibitor
40848554|NCT04855656|DRUG|RP-3500|Oral ATR Inhibitor
40848555|NCT04855656|DRUG|Debio0123|Oral WEE1 Inhibitor
40848556|NCT01351155|DEVICE|Skin protective dressing device|Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
41371977|NCT02842736|DEVICE|Cerene(R) Cryotherapy Device|
41031161|NCT05519839|DRUG|Influenza Vaccine|Intramuscular (deltoid) injections of Comparator influenza vaccine given on Day 0 and Day 70 (if applicable).
41371978|NCT00744029|BEHAVIORAL|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
41371979|NCT05988866|BEHAVIORAL|lipodia|Participants will receive access to the digital health intervention lipodia in addition to TAU.
41371980|NCT03370718|DRUG|Cabozantinib|Given PO
41371981|NCT03370718|OTHER|Pharmacogenomic Study|Correlative studies
41503779|NCT01954745|DRUG|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
41503780|NCT04934059|DRUG|Yuxuebi tablet|0.5g/ tablet
41503781|NCT04934059|DRUG|Placebo tablet|0.5g/ tablet
41503782|NCT00392912|DRUG|AndroGel (Solvay Pharmaceuticals)|Testosterone Replacement Therapy: AndroGel 1% 5g packets (Solvay Pharmaceuticals). Initial dosage: 5g daily (1 packet). Patients who do not achieve eugonadal levels of 400-600 mg/dL within 2 weeks will be raised to 10g daily.
40848557|NCT04611451|OTHER|classic lumbar home exercise|classic lumbar home exercise
41031162|NCT05519839|DRUG|CIC Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of co-formulated mix of various doses and formulations of CIC Vaccine given on Day 0 and Day 70
41031163|NCT05519839|OTHER|Placebo Comparator|Intramuscular (deltoid) injection of placebo given on Day 70.
41371982|NCT03370718|OTHER|Pharmacokinetic Study|Correlative studies
41371983|NCT03446157|DRUG|Cetuximab|Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib
41503783|NCT05491317|BIOLOGICAL|GEN1042|Intravenous
41503784|NCT05491317|DRUG|Pembrolizumab|Intravenous
41503785|NCT05491317|RADIATION|Radiotherapy|Radiotherapy
41371984|NCT03446157|DRUG|Palbociclib|125 mg taken orally once daily on days 1-21, then 7 days off
41371985|NCT01593761|DRUG|CG400549|960mg QD at fed state approx 1 hour after meal
41371986|NCT04689334|OTHER|Outcome|The number of surgeries
41371987|NCT05390060|DEVICE|Neuromonitoring|Multimodal neuromonitoring encompassing intracranial pressure, brain tissue oxygenation, microdialysis and cerebral blood flow monitoring
41371988|NCT00785252|DEVICE|Powered Intraosseous device (EZIO)|EZIO
41371989|NCT00785252|DEVICE|standard central line|placement of a central line
41371990|NCT03228615|OTHER|SDM Intervention|Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
40848558|NCT04611451|DEVICE|Whole body vibration|Whole body vibration (WBV), which is a new treatment method and applied through the device, is defined as mechanical repetitive motion or oscillatory motion occurring around a balance point
40848559|NCT04611451|OTHER|Whole body vibration exercise|Whole body vibration exercise
41503786|NCT06633861|DEVICE|spot-check measurement|Spot-check measurement: different Philips SpO2 sensors and Philips FAST pulse oximeter system, capnography
41503787|NCT06634004|OTHER|BOLD MRI|The study will utilize the MRI diagnostic reactivity test to evaluate cerebrovascular reactivity in patients with moyamoya and healthy controls. All participants (patients and controls) receive the same diagnostic scan, and there is no cross-over, factorial, or sequential nature to the study.
41371991|NCT00720668|PROCEDURE|radiofrequency ablation|radiofrequency ablation for HCC
41371992|NCT00039429|DRUG|atrasentan hydrochloride|
41371993|NCT04076982|DIETARY_SUPPLEMENT|mung bean protein|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
41503788|NCT01258712|DRUG|Tocilizumab + methotrexate(MTX)|Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
41503789|NCT01258712|DRUG|Tocilizumab placebo + methotrexate(MTX)|Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
41503790|NCT03429400|DRUG|Morphine Sulfate|Morphine every 4 hours as needed for up to a maximum of 5 days
41503791|NCT05523791|DIETARY_SUPPLEMENT|Fortiral|Twice a day, patients took 10 g of powder containing 92.5% whey protein with 2.7% cysteine; emulsifier: soy lecithin, lactose free to be reconstituted with 150-200 ml of water.
41503792|NCT05523791|DIETARY_SUPPLEMENT|Mg++|Twice a day, patients took 2.250g of magnesium pidolate (=184 mg of Magnesium++ ione) powder twice a day to be reconstituted with 150-200 ml of water
41503793|NCT03578575|DRUG|Danggui Buxue Tang|Danggui Buxue Tang is an extracted powder of traditional Chinese medicine formula.
41503794|NCT03578575|DRUG|Placebo|Placebo is a very low dose Danggui Buxue Tang powder.
41503795|NCT04800679|DRUG|receive 4 monthly IVB injections and then rescue IVB|IVB group that receive 4 monthly IVB injections and then rescue IVB
41503796|NCT04800679|DRUG|PRP group|PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
41371994|NCT04076982|OTHER|control biscuit|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
41371995|NCT01312363|DRUG|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
40848560|NCT03244163|DEVICE|Spyglass DS cholangioscope|The 1.8Fr holmium:YAG laser fiber (Lumenis, Yokneam, Israel) will be inserted into the cholangioscope's working channel for lithotripsy under direct visualization. An EHL probe may alternatively be used depending on availability. Lithotripsy is applied until fragments of the targeted stone are no longer lumen filling, and can be dispersed easily with fluid irrigation. Fragmented stones are then removed by a combination of conventional techniques. To confirm stone clearance, the Spyglass DS cholangioscope will be re-introduced, and the bile duct will be examined for residual stones from the confluence of the right and left intrahepatic ducts to the papillary opening
40848561|NCT03244163|DEVICE|BML|Biliary sphincterotomy with/without EPBD to the size of the lower bile duct with a limit of 15mm will be performed. Stones are removed by a combination of conventional BML, extraction balloon and/or baskets, without laser lithotripsy. An occlusion cholangiogram is performed to confirm stone clearance. In cases where stone clearance is incomplete, a plastic biliary stent bridging the stone will be inserted for temporary drainage until definitive management, usually within one month.
41371996|NCT02145949|DRUG|Essential Amino Acids (EAA)|Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
41371997|NCT02145949|DRUG|Placebo (Alanine)|Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
41371998|NCT04469712|PROCEDURE|SASI Bipartition|SASI Bipartition is performed with a sleeve gastrectomy over a 32 French gastric bougie and a 300 cm common limb. Side-to-side gastroileostomy with a diameter of approximately 2.5 cm at the anterior part of antrum, 6 cm proximal to pylorus.
41503797|NCT04800679|DRUG|IVB injections and a modified laser|Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser
41503798|NCT02191644|DIETARY_SUPPLEMENT|Dietary intervention-refined rice|Subjects in the control group maintained the usual refined-rice diet.
41503799|NCT02191644|DIETARY_SUPPLEMENT|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
41503800|NCT02558530|OTHER|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
41503801|NCT05517811|DIAGNOSTIC_TEST|TEG indices|Blood samples
41503802|NCT03545230|PROCEDURE|":Four Not Techniques"|":Four Not Techniques~1. Not enter posteriorly~2. Not too much dissection the muscle around the lateral condyle during surgery~3. Not perfect anatomical reduction~4. Not using bone graft."
41503803|NCT00890604|OTHER|Stepwise normothermia protocol|Use of standard care interventions in a protocolized/step-wise fashion instead of ad hoc based on nurse decision making which may include antipyretics, physical cooling measures.
41031164|NCT05519839|DRUG|SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of in-clinic mix of various doses of SARS-CoV-2 rS vaccine given on Day 0 and Day 70 .
41031165|NCT05126797|OTHER|Questionnaire Administration|Ancillary studies
41031166|NCT05126797|DEVICE|Stent Device|Wear customized 3D printed oral stent
41031167|NCT03926507|PROCEDURE|Computed Tomography|Undergo PET/CT scan
41031168|NCT03926507|OTHER|Fluciclovine F18|Given IV
41031169|NCT03926507|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
41371999|NCT04469712|PROCEDURE|Gastric bypass|A small gastric pouch (15 mL) is created, and the jejunum brought up as an antecolic and antegastric fashion. Routine limb lengths were 150 cm for the alimentary limb and 60 cm for the bilio-pancreatic limb. Both mesenteric defects are closed with the Endohernia® stapler.
41372000|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
41372001|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
41372002|NCT03145038|DRUG|Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
41372003|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|10 mg IR tablet, intact (fed; American breakfast)
41372004|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|10 mg IR tablet, crushed (fed; American breakfast)
41372005|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast|10 mg IR tablet, intact (fed; Continental breakfast)
41503804|NCT00890604|DRUG|Ibuprofen|It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
41503805|NCT00890604|DRUG|Acetominophen|It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
41503806|NCT04558918|DRUG|LNP023|Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral
41503807|NCT04558918|DRUG|Eculizumab|"Administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
41503808|NCT04558918|DRUG|Ravulizumab|"Administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
41503809|NCT05102227|DEVICE|Left bundle branch area pacing|A dual-chamber DF-1 defibrillator is implanted. Left bundle branch area pacing is performed for cardiac resynchronization therapy.
41372006|NCT00766129|DEVICE|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
41372007|NCT00766129|DEVICE|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
41372008|NCT05174208|OTHER|CTE examination|each patients should have undergone CTE examination
41372009|NCT05290636|OTHER|Teaching intervention program|Using an action research approach, The investigators designed a pair of geriatric nursing and practicum courses and recruited a class of in-service nursing students through convenience sampling in a college setting. The intervention was an 18-week course in geriatric nursing that meets once a week in the classroom and internship practice in settings used for training nursing students. The investigators collected data using quantitative indicators (attitude measurements) and qualitative textual analysis. The quantitative data were analyzed by paired t-testing using SPSS 21.0 software.
41372010|NCT06124859|OTHER|Functional capacity tests|"Maximal effort test on cycloergometer (1st visit)~Maximal effort test, 6-minute stepper test, 6-minute walk test, 5-times sit to stand test. A minimum rest period of 15 minutes must be observed between these tests (2nd Visit)"
41372011|NCT00271297|BEHAVIORAL|Pelvic floor muscle training|
41372012|NCT06405646|DIAGNOSTIC_TEST|Blood CB1, CB2, TRPV-1 concentration measurement|In each of the patients blood CB1, CB2, TRPV-1 concentration will be measure
41372013|NCT04132206|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
41372014|NCT05431673|DRUG|Doxycycline|Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
41372015|NCT05431673|DRUG|Ciprofloxacin|Ciprofloxacin 500mg/day for 4 weeks used as single or combination treatment for Rhinoscleroma
41031170|NCT05228613|BIOLOGICAL|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
41031171|NCT05228613|BIOLOGICAL|SARS-CoV-2 inactivated vaccine|active control manufactured by Sinovac Life Sciences Co.Ltd
41031172|NCT01149304|DRUG|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
41503810|NCT06624644|BIOLOGICAL|LNS8801|G protein-coupled estrogen receptor (GPER) agonist
41503811|NCT06624644|BIOLOGICAL|Pembrolizumab|Recombinant monoclonal antibody (anti-PD1)
41503812|NCT06624644|DRUG|Chemotherapy (dacarbazine or temozolomide)|chemotherapy (dacarbazine, temozolomide)
41503813|NCT06624644|BIOLOGICAL|Immunotherapy (Pembrolizumab)|pembrolizumab
41503814|NCT06624644|BIOLOGICAL|Immunotherapy (nivolumab and relatlimab)|nivolumab and relatlimab
41031173|NCT01149304|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
41031174|NCT01149304|DRUG|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
41031175|NCT04056806|DRUG|Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial|efficacy comparison between 2 days and 5 days
41031176|NCT01881451|DRUG|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
41031177|NCT01881451|PROCEDURE|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
41031178|NCT01752192|DEVICE|Telerehabilitation programme|Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
41031179|NCT03236103|OTHER|Clinical Recommendations|"The clinical recommendations will regard the following:~1. Avoidance of potentially nephrotoxic medications (e.g. NSAIDs, intravascular contrast, nephrotoxic antimicrobials)~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Optimizing hemodynamics (Mean arterial BP\>65mmHg)~5. Assessment of kidney function with serum creatinine and/or cystatin C~None of the suggestions will be experimental. All suggestions will be based on standard nephrology practice."
41031180|NCT01324492|DRUG|RAD001|
41503815|NCT06624644|BIOLOGICAL|Immunotherapy (ipilimumab and nivolumab)|ipilimumab and nivolumab
41031181|NCT01494051|BEHAVIORAL|Diet counseling|Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
41031182|NCT00337714|PROCEDURE|CVC impregnated with silver nanoparticles (AgTive®)|insertion of medicated silver nanoparticles CVC
41162884|NCT05540418|OTHER|lavender oil inhalation|Two drops of lavender (2%) essential oil were dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses. They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation. Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed.
41372016|NCT05431673|DRUG|Rifampin|Rifampin 600mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
41372017|NCT05354349|DRUG|PRA023 IV Low Dose|Drug
41372018|NCT05354349|DRUG|PRA023 SC|Drug
41372019|NCT05354349|DRUG|Placebo IV|Placebo
41372020|NCT05354349|DRUG|Placebo SC|Placebo
41372021|NCT05354349|DRUG|PRA023 IV High Dose|Drug
41372022|NCT05483816|COMBINATION_PRODUCT|VR+TENS|The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality
41372023|NCT01639625|DRUG|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
41372024|NCT04446182|DRUG|Itacitinib|All eligible patients will begin study therapy with approximately a week lead-in of itacitinib monotherapy at scheduled dose. Itacitinib will be taken daily at scheduled dose for a total of six cycles. Itacitinib may be tapered as deemed appropriate by the treating investigator. Patients will remain on study therapy as long as treatment discontinuation criteria are not met. Patients with Partial Response (PR) or better may continue itacitinib for up to 1 year.
41372025|NCT04446182|DEVICE|Extracorporeal Photopheresis (ECP)|ECP will begin after itacitinib lead in period. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule. Patients achieving PR or better after 6 cycles of itacitinib may continue treatment with itacitinib for up to 1 year. Thereafter, itacitinib may be tapered at the treating investigator's discretion.
41372026|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation Randomized)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.
41503816|NCT01589497|DRUG|Rifampicin|Participants with body weight \</= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight \>50kg were administered one 600 mg tablet orally once daily.
41031183|NCT00337714|PROCEDURE|CVC cannulation|placement of conventional trilumen CVCs
41031184|NCT03257462|DRUG|SPR001|SPR001 Capsules
41031185|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 14
41031186|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 23
41162885|NCT06183827|PROCEDURE|Emergency Medical Service intervention|"Facing an Acute Respiratory Failure, emergency medical service must rapidly choose between oxygen supply by face mask (15Liters/minutes), Mechanical Ventilation or non-invasive ventilation.~Mechanical Ventilation as non-invasive ventilation present interest and side arms as oxygen supply by face mask (15Liters/minutes) for hypoxemia control."
41372027|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation-Open Label)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 8 weeks using a non-invasive brainstem modulation device.
41372028|NCT03903575|PROCEDURE|En masse anterior teeth retraction|After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.
41372029|NCT03903575|PROCEDURE|Two-Step Retraction|After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
41372030|NCT05574673|OTHER|Standard of care|Patients receive standard of care treatment according to local and national guidelines
41503817|NCT01589497|DRUG|Isoniazid|Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
41503818|NCT01589497|DRUG|Pyrazinamide|Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
41503819|NCT01589497|DRUG|Ethambutol|Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
41503820|NCT01589497|DRUG|Moxifloxacin|Participants were administered one 400 mg tablet orally once a day.
41031187|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 8
41031188|NCT04783753|DRUG|Itraconazole|Subjects will receive itraconazole QD for 14 days
41031189|NCT04783753|DRUG|Carbamazepin|Subjects will receive carbamazepine BID for 23 days
41372031|NCT04661865|OTHER|Health Information Package Program (HIP program )|"Fifteen minutes PowerPoint presentation will be introduced to women to increase women's educational experience and raise their level of engagement and commitment.~The principal investigator will narrate the video record with PowerPoint slides and it was recorded as a video and will include information regarding the introduction to pregnancy, causes and predisposing factors of iron deficiency anemia during pregnancy, signs and symptoms, prevention, management of iron deficiency anemia during pregnancy that includes iron therapy, iron supplementation, dietary management. Content validity for the information in the video will be done by sending it to three experts in maternity nursing. Iron supplementation will be given to all participants who will start by sixteen weeks of pregnancy and they will receive information regarding the proper usage of iron supplements."
41372032|NCT03728101|DRUG|Simvastatin, Dabigatran Etexilate|The subjects receive dabigatran etexilate with and without simvastatin administration
41372033|NCT03500302|DRUG|Evolocumab|Evolocumab sq once a month for a total of two doses
41372034|NCT06347848|OTHER|Psychoeducation Focused on Reducing Internalized Stigma|"Participants will be randomized and divided into experimental and control groups. Initial measurements will be collected through a face-to-face meeting. While the control group will continue to receive routine Community Mental Health Center service, the experimental group will receive a psychoeducation program focused on reducing internalized stigma in addition to the routine Community Mental Health Center service. After the program is completed, final measurements of the experimental and control groups will be collected.~The program is planned to consist of 7 sessions, once a week, and approximately 60-90 minutes are expected to be allocated for each session. Sessions will be divided into two sessions: a 30-40 minute session and a 15 minute break."
41372035|NCT00161148|DRUG|Probiotics|
41372036|NCT01409382|BEHAVIORAL|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
41372037|NCT00236730|DRUG|topiramate|
41372038|NCT01766466|DRUG|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
41372039|NCT01766466|DRUG|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
41031190|NCT04783753|DRUG|Quinidine|Subjects will receive quinidine BID for 8 days
41372040|NCT00464308|DRUG|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
41372041|NCT00464308|DRUG|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
41372042|NCT00464308|DRUG|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
41372043|NCT03096457|DRUG|Paromomycin Sulfate|topical application 2 times a day during 20 days
41372044|NCT03096457|DRUG|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
41372045|NCT03096457|OTHER|Placebo|topical application 2 times a day during 20 days
41372046|NCT05308134|OTHER|Standard fortification|Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.
41372047|NCT05308134|OTHER|Target fortification|Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.
41372048|NCT05308134|OTHER|BUN adjustable fortification|BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
41372049|NCT03022526|PROCEDURE|CSE|
41031191|NCT04719585|DRUG|Duloxetine vs. Opioid|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
41503821|NCT01644617|DRUG|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
41031192|NCT04894253|BIOLOGICAL|SRAS-CoV-2 vaccination immunological response|"Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination.~Intervention includes immunological analysis on additional volume of blood collected as part of routine care."
41031193|NCT06634043|PROCEDURE|Coronally Advanced Tunel + ADM (Novomatrix®)|ADM (Novomatrix®) will be used alone
41031194|NCT06634043|PROCEDURE|Coronally Advanced Tunel + ADM (Novomatrix®) + L-PRF|ADM in combination with L-Prf will be applied
41372050|NCT03022526|PROCEDURE|Epidural|
41372051|NCT03022526|DRUG|Bupivacaine / fentaNYL|
41372052|NCT01133912|DRUG|paclitaxel, gemcitabine, lapatinib|Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
41372053|NCT04700592|OTHER|Gabapentin versus Ketamine|A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain
41503822|NCT01644617|DRUG|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
41503823|NCT01644617|DRUG|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
41503824|NCT06451211|DRUG|Tislelizumab|Tislelizumab 200 mg will be administered systemically on day 1 of each cycle in all participants
41372054|NCT04420975|PROCEDURE|Definitive Surgical Resection|Undergo definitive surgical resection
41372055|NCT04420975|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given intratumorally
41162886|NCT01470105|OTHER|blood sampling, the SF-36 questionnaire|"The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.~At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit"
41162887|NCT01860495|PROCEDURE|perforated membrane|perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration
41031195|NCT06626191|PROCEDURE|Interscalene brachial plexus block|"Interscalene brachial plexus block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
41503825|NCT06451211|DRUG|Oxaliplatin|Oxaliplatin 150 mg will be administered systemically on day 1 of each cycle in all participants
41162888|NCT01860495|PROCEDURE|G2|tradetional occlusive collagen membrane
41503826|NCT06451211|DRUG|S-1|S-1 40 mg will be administered orally on day 1-14 of each cycle in all participants
41503827|NCT06451211|DRUG|Capecitabine|Capecitabine 2500 mg will be administered orally on day 1-14 of each cycle in all participants
41503828|NCT03761940|OTHER|EQ5D questionnaire and a demographic questionnaire|questionnaires
40848562|NCT00965419|DRUG|Edivoxetine|0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ \[No NCT number\]) and (LNBF \[NCT00922636\]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
41031196|NCT06626191|PROCEDURE|Serratus posterior superior intercostal plane block|"Patients will undergo serratus posterior superior intercostal plane block using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
41031197|NCT06626191|PROCEDURE|Group without peripheral nerve block|In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
41031198|NCT03604250|DIETARY_SUPPLEMENT|Lifestyle plus prebiotic supplement|Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
41503829|NCT03111771|PROCEDURE|carcinological surgery|carcinological surgery for Group K +
41162889|NCT02986659|DRUG|Metformin|
41503830|NCT03111771|PROCEDURE|cervical surgery|cervical surgery for Group K-
41162890|NCT02986659|DRUG|Placebo|
41162891|NCT04151823|DRUG|Vitamin D3|2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN: 2 mL of product will give 1600 UI/die of VIT D3.
41372056|NCT04420975|BIOLOGICAL|Nivolumab|Given IV
41503831|NCT06632678|OTHER|behavior, procedure, diet, exercise, device, education, and any other|Any type of intervention except pharmacological interventions (drugs, biologicals, genetics)
41503832|NCT05186675|PROCEDURE|superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure
41503833|NCT05339334|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days
40848563|NCT00628745|OTHER|None. Observational Study.|
41372057|NCT04420975|RADIATION|Radiation Therapy|Undergo radiation therapy
41372058|NCT06230276|OTHER|enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast|Participants who are already treated by one of the HCL systems (MiniMed 780G, Tandem Control-IQ, Ypsomed CamAPS) will have a precisely defined amount of enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast during eight different days under predetermined conditions. They will administer premeal bolus only for half of these meals.
41503834|NCT06423807|DRUG|Ondansetron lozenge|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
41503835|NCT06022900|BEHAVIORAL|Online training group|online health education with video call
41503836|NCT06022900|BEHAVIORAL|Face-to-face training group|Face-to-face health education with home visit
41503837|NCT00990860|DRUG|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
41503838|NCT00990860|PROCEDURE|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
41503839|NCT01332292|DRUG|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
41503840|NCT01332292|DRUG|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
40848564|NCT01423266|PROCEDURE|12-week supervised weight loss intervention|Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
40848565|NCT00292539|DEVICE|Any pacemaker with right ventricular pacing option|
40848566|NCT04186871|DRUG|branebrutinib|Specified dose on specified days
40848567|NCT04186871|DRUG|abatacept|Specified dose on specified days
40848568|NCT04186871|DRUG|branebrutinib placebo|Specified dose on specified days
40848569|NCT05683002|DIETARY_SUPPLEMENT|Aronia supplementation|As described in experimental arm
40848570|NCT05683002|DIETARY_SUPPLEMENT|Cellulose supplementation|As described in placebo comparator arm
41372059|NCT04717323|DEVICE|mPAD (or TPAD) Pelvic Assist Device|Gait retraining device that applies pelvic forces and measures response
41372060|NCT04717323|DEVICE|No Intervention|Gait with no pelvic assistance
41372061|NCT02232191|BIOLOGICAL|Pneumovax-23|
41031199|NCT04954339|DRUG|Aatezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
40848571|NCT00158951|DEVICE|CONTAK RENEWAL 2/4/4HE CRT-D|
41162892|NCT04151823|DRUG|Immunofos|Postbiotics will be given at the dose of 80 mg/day. immunofos from Lactobacillus paracasei CNCM I-5220).
41372062|NCT04851509|PROCEDURE|Dynamic Rotational Locking|Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.
41372063|NCT04851509|PROCEDURE|Static Locking|Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the screw within the nail.
41372064|NCT02401217|OTHER|Phase 1- Arm 1 Infant Formula|Powder infant formula
41372065|NCT02401217|OTHER|Phase 2- Arm 2 Infant Formula|Powder infant formula
41503841|NCT03007992|DRUG|Vinorelbine|Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
40848572|NCT00158951|DEVICE|EASYTRAK 2 Lead|
40848573|NCT01392209|OTHER|Bevacizumab & Stereotactic Radiotherapy|Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
40848574|NCT02396368|DRUG|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
40848575|NCT02396368|RADIATION|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
40848576|NCT01596036|BEHAVIORAL|Early appointment (within 10 days)|Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
41162893|NCT04151823|OTHER|Promotion of physical activity|Promotion of physical activity will be encouraged at t0, t1, t2
41372066|NCT02401217|OTHER|Phase 2- Arm 3 Infant Formula|Powder infant formula
41372067|NCT03740152|DEVICE|Transcranial Light Therapy|Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
41372068|NCT06309069|OTHER|None, purely observational study|None, purely observational study
41372069|NCT00612963|DRUG|Frio Oral Rinse|Prescription Mouth Rinse
41372070|NCT00798902|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
41372071|NCT00798902|OTHER|Iliac crest autograft|autograft
41372072|NCT06159946|DEVICE|Access-H2O faucet|The assigned invention was developed to test the feasibility of the prototype of the Access-H2O faucet by assessing whether subjects can activate the faucet to control water outputs via the motion sensor, eye gaze, and a speech speaker. To activate the faucet via the motion sensor, each subject was asked to place his or her hand near the motion sensor. To activate the faucet via the eye gaze, each subject was asked to look directly at the eye gaze sensor. To activate the faucet via the speech speaker, each subject was asked to speak to the speaker. Each subject performed the same function three times. The water from the faucet was used for drinking, rinsing, and grooming.
41372073|NCT02000466|OTHER|Data collection|Initial and follow-up data will be collected using questionnaires
41372074|NCT02570945|PROCEDURE|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
41372075|NCT05383157|BEHAVIORAL|Brief mindfulness|Training in mindfulness focused on breathing and pain sensations to enhance decentering, meta-awareness, and interoceptive awareness.
40848577|NCT01596036|OTHER|Routine referral (at 5 weeks)|Standard Referral to Cardiac Rehabilitation
40848578|NCT01086943|DEVICE|LT2420|
40848579|NCT02292706|DRUG|Sofosbuvir|Exposure of interest for participants who received sofosbuvir in a previous Gilead study for chronic HCV infection.
41372076|NCT05383157|OTHER|Usual care|Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
41372077|NCT01734109|DEVICE|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
41372078|NCT01258010|DRUG|Tranexamic Acid|Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
41372079|NCT01258010|DRUG|Placebo|Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
41372080|NCT01719263|DEVICE|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
41372081|NCT01719263|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
41372082|NCT00629382|DEVICE|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
41503842|NCT05875311|DEVICE|telemonitoring|"The system consists of the following elements:~Professional website at the ambulatory centre, which allows:~To set up an individualised care plan To establish the patient's risk profile and targets for improvement. Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred Advise the patient on self-management strategies.~Mobile application software with the following functions:~Scheduled exercise sessions Medication reminder Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.) Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~Training monitor: guides the patient in the performance of their exercise. Access to certified health information for patients"
41503843|NCT05875311|OTHER|control follow-up|Patients are instructed to perform 150 minutes per week of moderate physical activity and follow healthy lifestyles
41503844|NCT04877457|DRUG|Ocrelizumab|The first course of ocrelizumab will be administered as two 300 mg infusions at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given as a single 600 mg infusion at Weeks 24 and 48.
40848580|NCT02292706|DRUG|Ribavirin|
40848581|NCT02292706|DRUG|LDV/SOF|Exposure of interest for participants who received LDV/SOF in a previous Gilead study for chronic HCV infection.
40848582|NCT02292706|DRUG|SOF/VEL|Exposure of interest for participants who received SOF/VEL in a previous Gilead study for chronic HCV infection.
40848583|NCT02292706|DRUG|SOF/VEL/VOX|Exposure of interest for participants who received SOF/VEL/VOX in a previous Gilead study for chronic HCV infection.
41372083|NCT00629382|OTHER|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
41503845|NCT04877457|OTHER|Placebo|Placebo will be administered at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given at Weeks 24 and 48.
41372084|NCT05821023|OTHER|messages|Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
41372085|NCT00021554|DRUG|Enfuvirtide|
41372086|NCT01024816|BEHAVIORAL|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
41372087|NCT01024816|BEHAVIORAL|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
41372088|NCT01128699|DRUG|Subconjunctival Avastin|Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
41372089|NCT01128699|DEVICE|Ahmed Valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
41372090|NCT01001091|DRUG|AL-38583 ophthalmic solution|
41372091|NCT01001091|DRUG|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
41372092|NCT01001091|DRUG|Dexamethasone ophthalmic suspension, 0.1%|
41503846|NCT03571386|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
41503847|NCT03571386|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|Standardized 8-week patient-centered educational approach which uses relatively intensive training in core meditation practices that teaches people how to take better care of themselves using mindfulness skills and live healthier and more adaptive lives.
41503848|NCT05360485|BEHAVIORAL|MOV'D (Move Often eVery Day)|The MOV'D intervention is a remotely-delivered, peer-supported intervention that delivers exercise snack (2-5 minutes of moderate to vigorous activity) and behavior change technique (BCT) videos to a private social media support group with the goal of interrupting prolonged sitting at work with MVPA minutes.
41503849|NCT05360485|BEHAVIORAL|Fitbit Self-Monitoring|All participants receive a Fitbit and are told to monitor their physical activity for the duration of the study period.
41503850|NCT06111352|DRUG|Pralidoxime|Inj. Pralidoxime 1 gm I/V will be given as first dose over 10-20 minutes. If no improvement of muscle weakness, then repeat the dose after one hour. Then 1 gram of Inj. Pralidoxime will be given at an 8-hour interval
41162894|NCT04151823|OTHER|Healthy food habits promotion|Promotion of healthy food habits will be encouraged at t0, t1, t2
41503851|NCT06111352|DRUG|Atropine|Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement
41503852|NCT04302636|DIETARY_SUPPLEMENT|Low glycemic index diet|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
41503853|NCT03466268|DRUG|Gumarontinib Tablets|Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
41503854|NCT04421235|BEHAVIORAL|Childbirth support|"There are 5 program components that women may receive as a part of childbirth support:~Prenatal education - consists of up to 8 sessions of education on pregnancy, childbirth, and postpartum health and wellness.~Support group - semi-structured group which provides time for women to process their pregnancy and postpartum-related experiences with other women facing similar challenges. Integrates mindfulness exercises, cognitive-behavioral skills, and special topics as requested by group members.~Lactation program - program for women who wish to provide breastmilk for infants from which they are separated.~Doula support program - 2 prenatal and 2 postnatal individual visits with a doula who will also provide continuous childbirth support and support during separation from infants.~Parenting classes - group classes focused on helping women learn parenting skills and (if applicable) meet state requirements for reunification with children"
41372093|NCT00198107|DRUG|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
41372094|NCT00198107|DRUG|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
40848584|NCT02292706|DRUG|Other SOF-Based Regimen|"The other SOF-based regimens may have included the following:~* BMS-790052 (Daclatasvir) + GS-7977 (SOF) with or without RBV~* LDV/SOF + GS-9669, GS-7977 (SOF) + with or without RBV + TMC-435 (Simeprevir)~* LDV/SOF + Vedroprevir (VDV), LDV/SOF + GS-9669 (250 mg and 500 mg)~* LDV/SOF + VDV + RBV~* Simeprevir + SOF~* TMC-435 (Simeprevir) + VEL/SOF"
40848585|NCT02292706|OTHER|Ineligible parent treatment|Participants were enrolled from ineligible parent treatment group.
40848586|NCT01868386|RADIATION|Hypofractionated therapy|Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
41372095|NCT00198107|DRUG|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
41372096|NCT02265991|PROCEDURE|Fibula Explantation|surgical harvest of an osteomyocutaenous transplant consisting of a part of the fibula and surrounding soft tissues
41372097|NCT02426164|DRUG|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
41372098|NCT02426164|DRUG|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
40848587|NCT04836884|PROCEDURE|Percutaneous Vascular Anomaly/Malformation Biopsy|US-guided percutaneous vascular anomaly core needle biopsy of up to 10 cores using an 18-gauge co-axial core needle biopsy device at the time of clinically indicated sclerotherapy, embolization or ablation treatment.
41031200|NCT04346758|PROCEDURE|lumbar plexus block|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
41372099|NCT00012350|DRUG|FTI|
41162895|NCT02517125|DEVICE|Transoral robotic-assisted surgery with Da Vinci Xi|
41372100|NCT06124716|OTHER|Enhanced COACH CDS Tool|CDS tool with features to promote high blood pressure management
41372101|NCT06124716|OTHER|Usual Care COACH CDS Tool|CDS tool with limited features to promote high blood pressure management
41372102|NCT02226380|DRUG|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
41372103|NCT02531074|BEHAVIORAL|Mobile Application|
41372104|NCT02531074|BEHAVIORAL|Food Journal|
41372105|NCT02531074|BEHAVIORAL|Usual Care|
41372106|NCT02926768|DRUG|CK-101|"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily"
40848588|NCT06315127|DIETARY_SUPPLEMENT|Human donor milk|The intervention will involve providing donor milk as required as a supplement to parent milk and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. All donor milk will be aliquoted into individualized syringes in the Rogers Hixon Ontario Human Milk Bank which is located in Sinai Health. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad. As this study follows a pragmatic approach, the clinical team will assess the need for supplementation based on the mother-infant dyad's condition.
41162896|NCT05172518|DRUG|Taxane plus Intermittent Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
41372107|NCT04499118|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
41372108|NCT04499118|DRUG|TP regimen|Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
41372109|NCT03568136|DRUG|Secukinumab 300 mg|Solution for injection in pre-filled syringe
41372110|NCT03568136|DRUG|Placebo|Solution for injection in pre-filled syringe
41372111|NCT02682966|RADIATION|Coronary Computed Tomography Angiography|Coronary Computed Tomography Angiography will be performed in all participants
41372112|NCT00877526|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
41372113|NCT05309317|OTHER|Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections|"A training on Prevention of CAUTI will be held for the experimental and control groups. The experimental group will be able to play a seven-day virtual simulation game devised by the researcher to prevent CAUTI."
41372114|NCT05309317|OTHER|Ongoing education|"Only a course on Prevention of CAUTI will be given to the control group."
41372115|NCT05513807|DRUG|Nicotinamide treatment|3g Nicotinamide orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
41372116|NCT05513807|DRUG|Placebo treatment|3g Placebo orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
41372117|NCT05897411|BEHAVIORAL|Unmasking previous conditioning procedure|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.
41372118|NCT05897411|BEHAVIORAL|No unmasking of previous conditioning|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
41372119|NCT03194594|DRUG|Ketamine Hydrochloride, dexamethasone, and combination of two drugs|After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
41372120|NCT06208670|BEHAVIORAL|Progressive muscle relaxation exercises|PMI is among the non-pharmacological methods nurses can offer caregivers (Yılmaz et al., 2019). Health professionals, especially nurses, should evaluate all women of reproductive age in terms of PMS, plan educational interventions that will increase their awareness of the issue and enable them to develop appropriate coping strategies, support the planned educational interventions through written or visual materials, provide effective and quality counseling services, and aim to improve women's decreased quality of life (Abay \& Kaplan 2019; Aksoy Derya et al. 2019; Akmalı et al. 2020). Women can be advised to do relaxation exercises such as walking, running, swimming, and yoga regularly (at least 30 minutes a day) as they reduce stress by increasing endorphin levels and improve heart rate, lung capacity, and general health (Penedo \& Dahn, 2005; ACOG, 2015; Khajehei 2015).
41372121|NCT06208670|BEHAVIORAL|Violent tendency Scale|Violent tendency Scale
41372122|NCT06023485|OTHER|stress ball use during subcutaneous injection|The effect of stress ball use on pain during subcutaneous injection
41372123|NCT03796572|DRUG|Ropivacaine|Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine
41372124|NCT03796572|OTHER|Puncture Wound and Dressing|No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
41372125|NCT00483717|DRUG|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
41372126|NCT00483717|DRUG|Placebo|Intranasal (IN) placebo
41372127|NCT02908191|DRUG|ABI-H0731|
41372128|NCT02908191|DRUG|Placebo for ABI-H0731|
41372129|NCT02908191|DRUG|Entecavir|Used to treat adults with chronic hepatitis B virus
41372130|NCT02908191|DRUG|Tenofovir disoproxil fumarate|Used to treat adults with chronic hepatitis B virus
41372131|NCT02908191|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
41372132|NCT02908191|DRUG|Nucleos(t)ide|Used to treat adults with chronic hepatitis B virus
41372133|NCT00281931|BIOLOGICAL|rituximab|
41372134|NCT00281931|DRUG|cyclophosphamide|
40848589|NCT06315127|DIETARY_SUPPLEMENT|Formula|The intervention will involve providing formula as required as a supplement to parent milk and as a standard of care, and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. The formula will be supplied from the hospital's inventory in accordance with the standard procedure followed by the well-baby unit to supplement infants. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad.
41372135|NCT00281931|DRUG|fludarabine phosphate|
40848590|NCT04209933|DRUG|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
40848591|NCT04209933|DRUG|Colloidal pectin bismuth capsules containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
40848592|NCT04209933|DRUG|Colloidal pectin bismuth particles A quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
40848593|NCT04209933|DRUG|Colloidal pectin bismuth particles B quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
40848594|NCT03579810|OTHER|Investigational|"The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity"
40848595|NCT03579810|OTHER|Control|The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
40848596|NCT03406117|DRUG|HAT1|All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.
40848597|NCT03406117|OTHER|Saline Solution|Only for CIT portion of the study. Participant will have product applied topically on site by the trained study staff.
40848598|NCT03872791|BIOLOGICAL|KN046|KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle
41031201|NCT06098521|BEHAVIORAL|CONSENT|The CONSENT program is a risk-, need- and responsivity (RNR) based CBT program primarily focused on reducing risk of sexual reoffending, that consists of 18-26 one-to-one sessions in correctional settings.
41031202|NCT04418882|OTHER|management and follow up of all open fractures|to evaluate the development of sepsis after an open fracture and then, if there is a development of a pseudarthrosis too.
41031203|NCT06283004|OTHER|Downhill walking training|For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
41031204|NCT06283004|OTHER|Level walking training|For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
41031205|NCT06283004|OTHER|Uphill walking training|For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
41031206|NCT00256789|PROCEDURE|Radiation|
41031207|NCT00256789|DRUG|Chemotherapy|
41031208|NCT00993447|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months
41031209|NCT00993447|BIOLOGICAL|Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis|NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
41031210|NCT05309161|DIETARY_SUPPLEMENT|Crassocephalum rabens extract|dosage: a capsule (180 mg)/day; duration: 1 month
41031211|NCT06534476|OTHER|Education|"Patients who agreed to participate in the study and met the inclusion criteria were interviewed face to face before the HD session and their verbal and written permissions were obtained by reading the voluntary consent form. The researcher interviewed the patients one-on-one and provided information about the purpose of the study and the training program. Then, scale forms were applied to the patients. In order not to interrupt the training and not to distract the patients in this group, a separate room in the Dialysis Unit was used during the training. The education booklet Living with Hemodialysis on hemodialysis management prepared in line with the literature was given to the patients by the researcher. The training of a patient lasted an average of 40-50 minutes. During and at the end of the training, the patients' questions were answered in the training room."
41031212|NCT01714219|PROCEDURE|Posterior reconstruction|
41372136|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA-compatible Related|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
41372137|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA Unrelated|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
41372138|NCT04992780|RADIATION|Hypo-Fractionation|62.5 Gy in 25 fractions of 2.5 Gy/fraction
41372139|NCT04992780|RADIATION|Standard-Fractionation|60 Gy in 30 fractions of 2 Gy/fraction
41372140|NCT03846960|DEVICE|using specially adapted VNscope|surfactant administration via thin catheter using a specially adapted VNscope
41372141|NCT03846960|DRUG|surfactant administration|surfactant administration via thin catheter using a specially adapted VNscope
40848599|NCT03872791|DRUG|Nab-paclitaxel|Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
41031213|NCT01006044|BIOLOGICAL|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
41372142|NCT03267199|DRUG|Thrombolytic|Thrombolytic therapy
41372143|NCT03267199|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention
41372144|NCT03267199|DIAGNOSTIC_TEST|Complete blood count|Blood sample for complete blood count
41503855|NCT05790603|DEVICE|Intervention group with PHD-Band|The initial compression pressure was systolic blood pressure plus 10mmHg. Pressure will be released by 20mmHg and 40mmHg 1 hour and 2 hours respectively after the surgery and then the band will be removed after 3 hours if no bleeding occurs. The compression will continue if bleeding occurs.
41503856|NCT05790603|DEVICE|Control group with TR-Band|TR-Band will be inflated with 15 mL of air The band will be deflated with 1 mL of air hourly for the following 2 hours after the procedure. After 3 hours, the band will be removed if no bleeding occurs. If rebleeding occurs, the band will be inflated with appropriate volume of air until bleeding stops .
41503857|NCT02665845|DRUG|5-ASA|5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).
41372145|NCT03267199|DIAGNOSTIC_TEST|Platelet function test|Blood sample for platelet function test
41503858|NCT02665845|DRUG|Corticosteroids|Corticosteroids will be given to all patients.
41503859|NCT00796107|DRUG|RG1507|R1507 was administered at a dose 16 mg/kg every 3 weeks.
41031214|NCT06193421|DRUG|Ambroxol Hydrochloride|75mg slow release (SR), X16/day or 300mg X4/day oral capsules.
41503860|NCT00796107|DRUG|Letrozole|Letrozole was administered orally at a dose 2.5 mg daily.
41031215|NCT03631186|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
41031216|NCT00680407|OTHER|Placebo|Placebo (5 pills, three times daily) for 48-50 week treatment period
41503861|NCT01559389|DRUG|Solifenacin|Women presenting with UUI symptoms receive 5 to 10 milligrams (mg) of daily solifenacin for up to 16 weeks
41503862|NCT01350570|OTHER|acupuncture|acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
41503863|NCT01350570|OTHER|acupuncture group2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
41503864|NCT01350570|OTHER|acupuncture group3|All acupoints used in acupuncture group1 and group2 will be used in this group.
41503865|NCT01350570|DRUG|Loperamide|Loperamide will be used in this group for a dose of 2mg a time, three time a day.
41503866|NCT04430894|DRUG|Carfilzomib|"* Induction: protocol determine dose,via IV on 3 days per cycle up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination~* Maintenance: protocol determine dose,via IV on 2 days per cycle- Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
40848600|NCT06172725|OTHER|Dietary and exercise intervention|"The healthy older adults will follow a twelve-week high-protein vegetarian diet or high-protein omnivorous diet both in combination with a resistance exercise program.~All participants will receive blended dietary counselling. Blended dietary counselling is based on tele-coaching and face-to-face coaching performed by dieticians."
41031217|NCT00680407|DRUG|Silymarin 700 mg|700 mg dose (5 pills, three times daily) for 48-50 week treatment period
41372146|NCT03267199|DIAGNOSTIC_TEST|ECG|Electrocardiogram
41372147|NCT02753582|DIETARY_SUPPLEMENT|SOD+Gliadin Capsule|
41372148|NCT02753582|DIETARY_SUPPLEMENT|Placebo|
41372149|NCT03123627|DRUG|New profilaxis|Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
41372150|NCT03123627|DRUG|Profilaxis recommended|Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ\> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
41372151|NCT01476891|OTHER|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
41372152|NCT01476891|OTHER|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
41372153|NCT00013910|DRUG|NNC 90-1170|
41372154|NCT05356260|DEVICE|URincontrol4men|The intervention is built as an app
41503867|NCT04430894|DRUG|Isatuximab|"* Induction: At predetermined dose, via IV up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination:~  -- Cycles 1 and 2 once per week, Cycles 3-4 every other week, Cycles 5 and 6 every other week, Cycles 7 and 8 once every 4 weeks.~* Maintenance: At predetermined dose, via IV, once per cycle, Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
41503868|NCT04430894|DRUG|Lenalidomide|- Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity
41503869|NCT04430894|DRUG|Dexamethasone|Induction: Predetermined dosage, oral, Predetermined times per cycle up to 8 cycles dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: orally or IV will be administered as a preinfusion medication prior to isatuximab dosing
41372155|NCT05356260|OTHER|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
41372156|NCT02350868|DRUG|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
41372157|NCT03054493|BEHAVIORAL|no intervention|no intervention
41503870|NCT02147964|DRUG|Testosterone 1% Gel|Testosterone 1% gel 5g daily for 4 months \[all subjects\]
41503871|NCT02147964|DRUG|Acyline|Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]
41503872|NCT02147964|DRUG|Dutasteride|Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
40848601|NCT06526533|OTHER|Liberal Transfusion|Liberal transfusion trigger group (patient receives RBC transfusion if Hb ≤ 90g/L).
40848602|NCT06526533|OTHER|Restrictive Transfusion|Restrictive transfusion trigger group (patient receives RBC transfusion if Hb≤70g/L).
40848603|NCT00713895|BEHAVIORAL|Expert System|an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
40848604|NCT00713895|BEHAVIORAL|Standard Self-Help|standard smoking cessation self-help manual
40848605|NCT00544427|DEVICE|Optical coherence tomography|Optical coherence tomography imaging
41372158|NCT01336647|DRUG|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
41372159|NCT01336647|DRUG|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
41372160|NCT01336647|DRUG|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
41372161|NCT00852657|PROCEDURE|Tendon repair with acromioplasty|Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
41372162|NCT00852657|PROCEDURE|Physiotherapy|According to a rehabilitation program which was established prior to study start.
41372163|NCT02163746|PROCEDURE|CO2 (carbon dioxide) laser|
41372164|NCT02163746|PROCEDURE|Surgical Deroofing|
41503873|NCT02147964|DRUG|Ketoconazole|ketoconazole 400 mg PO daily for 4 months
41503874|NCT02147964|DRUG|HCG|HCG 60 IU injection Subcutaneously, every other day for 4 months
40848606|NCT00639626|DRUG|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
40848607|NCT02222376|DRUG|Pirfenidone|Twice a day topical application
40848608|NCT02222376|PROCEDURE|Debridement|Weekly ulcer debridement
40848609|NCT00237016|DRUG|doxycycline treatment|
40848610|NCT04758923|PROCEDURE|Cholecystectomy|Under General anaesthesia cholecystectomy and CBD exploration
40848611|NCT03167528|BEHAVIORAL|Relaxation|Relaxation
40848612|NCT03167528|BEHAVIORAL|Hypnosis|Hypnosis
40848613|NCT03167528|BEHAVIORAL|Holistic gymnastics|holistic gymnastics
41503875|NCT02147964|DRUG|placebo dutasteride|placebo oral dutasteride PO daily for 4 months
40848614|NCT03167528|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS
40848615|NCT03167528|BEHAVIORAL|Sophrology|Sophrology
41372165|NCT04631432|DIAGNOSTIC_TEST|Pre-screening|Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
41503876|NCT02147964|DRUG|placebo ketoconazole|placebo ketoconazole daily for 4 months
41503877|NCT02932410|DRUG|Macitentan|Dispersible tablet; Oral use
41503878|NCT02932410|OTHER|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and IV/SC prostanoids.
41503879|NCT04751071|DRUG|Roflumilast 500Mcg Tab|Roflumilast 500µg tablet once daily for 6 weeks plus the standard therapy
41503880|NCT04751071|DRUG|Placebo|Placebo tablet once daily for 6 weeks plus the standard therapy
41503881|NCT05153525|DRUG|Intermittent boluses of Cisatracurium|Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
41372166|NCT04631432|BEHAVIORAL|Task session|"The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino \& Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)"
41503882|NCT05153525|DRUG|Intravenous infusion of Cisatracurium for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
41503883|NCT03632018|BEHAVIORAL|HEART-PLAY|Participants assigned to the HEART-PLAY intervention will receive standard CR. Additionally, they will receive pedometers, group education, and educational materials introduced by peer Health Coaches for 12 months. Before or after their regularly scheduled CR appointments, they will meet at the clinic as a group twice per week to receive Health Tips and participate in discussions. At 8 weeks in to the 12-week CR, they will begin to discuss with their peer Health Coaches the transition from the formal CR setting into community-based exercise. As part of this transition, peer Health Coaches will slowly introduce group community walks and train participants in the proper use of resistance bands. Health Coaches will have talk with their assigned participants about relapse prevention and sustaining exercise following the termination of formal CR.
41503884|NCT03632018|BEHAVIORAL|Standard Cardiac Rehabilitation|During the 12-week intervention period, the STANDARD intervention participants will receive standard of care by attending the 36 sessions of standard CR as prescribed by his/her physician and administered by the Step Clinic.
41503885|NCT04513366|DRUG|SEL-212 low-dose|IV infusion of SEL-212 low-dose every 28 days for a total of up to 12 infusions
41503886|NCT04513366|DRUG|SEL-212 high-dose|IV infusion of SEL-212 high-dose every 28 days for a total of up to 12 infusions
41503887|NCT04513366|OTHER|Normal Saline|IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
41503888|NCT05518188|BIOLOGICAL|MELPIDA|MELPIDA, a recombinant serotype 9 adeno-associated virus (AAV) encoding a codon-optimized human AP4M1 transgene
41503889|NCT00745550|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
41503890|NCT01957735|DRUG|BP31510 monotherapy|
41503891|NCT01957735|DRUG|BP31510 in combination with chemotherapy|
41503892|NCT00183911|DRUG|floxuridine, 5-Fluorouracil, leucovorin|
41503893|NCT00183911|PROCEDURE|External Beam Radiotherapy|
41503894|NCT00183911|PROCEDURE|Surgery|
41503895|NCT00755443|DEVICE|Drug eluting stent|Drug eluting stent implantation
41503896|NCT00755443|DEVICE|Bare metal stent|
41503897|NCT05424458|PROCEDURE|Anterior Implant Treatment|Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.
41503898|NCT00464438|DRUG|gatifloxacin|Day 1-6 = 1 drop of study medication three times a day
41503899|NCT00464438|DRUG|moxifloxacin 0.5% eye drops|Day 1-6 = 1 drop of study medication three times a day
41503900|NCT05446584|DEVICE|High Definition Transcranial Direct Current Stimulation|HD-tDCS for this study is not intended to be a treatment, and will be applied continuously for 30 minutes at sham (0 mA) or 2 mA for active conditions across 3 consecutive daily sessions to probe neural circuit integrity. This specific HD-tDCS device is completely computer driven, running on a laptop using specialized software. Circular electrodes (12-mm in diameter) filled with conductive gel will be placed in a 4x1 ring configuration with the central electrode being the anode surrounded by four cathodes.
41503901|NCT01739660|DRUG|Pegloticase|a single 8 mg iv (in the vein) dose before hemodialysis session
41503902|NCT00338455|DRUG|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
41503903|NCT00338455|DRUG|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
41503904|NCT01017796|DRUG|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
41503905|NCT05026827|OTHER|Iyengar Yoga|Participation in Iyengar Yoga classes
41503906|NCT05026827|OTHER|Socialization Control|Participation in socialization control group sessions
41503907|NCT04808180|OTHER|Biorepair Shock Treatment|Teeth from this group will undergo the application of Biorepair Toothpaste for the first 7 days of the month for 9 months (1 application per day that lasts 10 minutes).
41503908|NCT04808180|OTHER|No treatment|Teeth from this group will not be treated with the experimental toothpaste.
41503909|NCT06452095|DEVICE|Hyperbaric Oxygen therapy|The SECHRIST INDUSTRIES Models 3600 and 4100 (H/HR) Hyperbaric Chambers are Monoplace Pressure Chambers designed to administer oxygen at near 100% concentration as the hyperbaric treatment gas, up to 3.0 atmospheres absolute (ATA) of pressure (29.4 psig). This study will utilize the 3600 and 4100 (H/HR) Hyperbaric Chambers located at Toronto General Hospital, Rouge Valley Hyperbaric Medicine Unit and Restore Hyperbaric Oxygen \& Medical Centre.
41503910|NCT06632951|DRUG|Livmoniplimab|Intravenous (IV) Infusion
41372167|NCT04899362|DEVICE|BB-RIC-D1/LAPUL Medical Devices Co, Ltd, China|The RIC consisted of 4 cycles of extremities ischemia (5-minute blood pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm. This intervention was undertaken twice a day for 7 days.
41372168|NCT04899362|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 3ml four times (at baseline and the first, seventh and eighth day of the study).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
41372169|NCT04899362|DEVICE|dCA measurement|Serial measurements of dCA were performed at 10 days, baseline, 1st, 2ed, 4th, 7th, 8th, 10th, 14th, 21th and 35th of the study.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
41503911|NCT06632951|DRUG|Budigalimab|IV Infusion
41503912|NCT06632951|DRUG|Docetaxel|IV Infusion
41503913|NCT06632951|DRUG|Paclitaxel|IV Injection
41503914|NCT06632951|DRUG|Docetaxel|IV Injection
41031218|NCT00680407|DRUG|Silymarin 420 mg|420 mg dose (5 pills, three times daily) for 48-50 week treatment period
41372170|NCT00621309|DRUG|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
41372171|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (\~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
41503915|NCT06632951|DRUG|Paclitaxel|IV Infusion
41503916|NCT06632951|DRUG|Gemcitabine|IV Infusion
41503917|NCT04204473|DRUG|TY-9591(10mg,40mg) qd. po|Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
41503918|NCT01056315|DRUG|GRT3938Y|Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
41372172|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
41503919|NCT01056315|DRUG|Placebo|Overencapsulated tablets of placebo, 16 weeks treatment.
41503920|NCT02341898|OTHER|Educational programme for all nurses|
41503921|NCT02341898|OTHER|Training and structured support for nominated key nurses|
40848616|NCT06077032|DRUG|garlic extract (15%) solution|•Group 1: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with garlic extract (15%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
40848617|NCT06077032|DRUG|topical chlorhexidine (2%) solution|•Group 2: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with topical chlorhexidine (2%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
40848618|NCT06077032|DRUG|Saline|•Group 3: (control) will use normal saline 0.9% as a placebo (they will be treated later on after completion of the study using any of the standard therapies for non-genital warts).
40848619|NCT00360568|DRUG|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
41503922|NCT02341898|OTHER|Facultative train-the-trainer module for key nurses|
40848620|NCT00360568|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
41031219|NCT02287103|OTHER|Skipping Breakfast|NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
41503923|NCT02341898|OTHER|Printed study material|
41503924|NCT02341898|OTHER|Supportive material (poster, mugs etc.)|
41503925|NCT02645903|DRUG|Transversus Abdominis Plane Block|Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1
41031220|NCT02287103|OTHER|Eating Breakfast|YesB: will eat all three meals
41031221|NCT02213003|BIOLOGICAL|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
41031222|NCT00023673|DRUG|carboplatin|
41031223|NCT00023673|DRUG|paclitaxel|
41031224|NCT00023673|RADIATION|three-dimensional conformal radiation therapy|
41503926|NCT02645903|DRUG|standard general anesthesia|Cases to whom applied alone standard general anesthesia were determined as Group 2
41503927|NCT01335334|DRUG|bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole|Pylera capsule contains bismuth subcitrate potassium, 140 mg (q.i.d.), metronidazole, 125mg (q.i.d.), tetracycline hydrochloride, 125mg (q.i.d.). Generic omeprazole (20mg, b.i.d) tablets
41503928|NCT06170697|DRUG|Camrelizumab|200mg, iv, d1, q3w
41503929|NCT06170697|DRUG|Cisplatin|80-100mg/m2, iv, q3w, 2-3 cycles in total
41503930|NCT06170697|DRUG|Carboplatin|AUC 2, iv, q1w, 5-7 cycles in total
41503931|NCT06170697|DRUG|Lobaplatin|30mg/m2, iv, q3w, 2-3 cycles in total
41503932|NCT06170697|DRUG|Nedaplatin|25-30 mg/m2, iv, q1w, 5-7 cycles in total
41503933|NCT06170697|RADIATION|Radiotherapy|PGTVp/PGTVnd 66-70Gy/2-2.2Gy/30-35F；PTV1 60Gy/1.8-2.0Gy/30-33F；PTV2 50Gy/1.8-20Gy/25-28F；Start 1-2 weeks after the start of immunotherapy, 1 time before the start of simultaneous chemotherapy, up to 3 times during the concurrent chemoradiotherapy
41372173|NCT01211210|DRUG|fluorouracil|Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
41503934|NCT03577782|BIOLOGICAL|Entyvio (Vedolizumab)|"1. Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.~2. Entyvio (Vedolizumab) (300mg), 7 intravenous infusions at week 0 (baseline) (concomitant with ART onset), 4, 8, 12, 16, 20 and 24.~At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).~Patients will be followed up until week 48."
41372174|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
41372175|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
41372176|NCT03378024|DEVICE|oscillometric (Omron Colin co)|fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
41372177|NCT03422276|OTHER|Rehabilitation Discharge Plan|"CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~1. patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~2. written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~3. a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc."
40848621|NCT00360568|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
41503935|NCT05113433|OTHER|conventional physical therapy|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session."
41503936|NCT05113433|OTHER|standing frame.|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session. sanding on standing frame for different time period according to group with upper limb activities lie box and blocks , cones and theraputty ."
40848622|NCT00360568|DEVICE|J-tube|jejunal tube
41372178|NCT03422276|OTHER|Rehabilitation Transition Plan|"Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~1. Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~2. Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population."
40848623|NCT01915979|BIOLOGICAL|Plasma rich in growth factors (PRGF)|
40848624|NCT01915979|DRUG|Celestone cronodose (Bethametasone)|
41372179|NCT03876795|BIOLOGICAL|Bone Marrow Concentrate|Bone Marrow Concentrate injection
41372180|NCT05527249|DIETARY_SUPPLEMENT|Dietary Supplement|20g of protein powder + 650mg of pomegranate extracts
41372181|NCT05527249|OTHER|Placebo of the dietary supplement|20g of protein powder + 650mg of maltodextrin
41372182|NCT05921539|DRUG|steroid hydrodilatation|ultrasound-guided steroid hydrodilatation
40848625|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
40848626|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
40848627|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
40848628|NCT02790424|DEVICE|Imaging devices|technological adjustment tests
40848629|NCT02215304|DIETARY_SUPPLEMENT|Bifidobacterium longum ssp infantis R0033|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
40848630|NCT02215304|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
41031225|NCT03735550|DEVICE|Contact thermographic breast examination device|A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.
41031226|NCT02488434|DEVICE|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
41372183|NCT05921539|DRUG|axillary nerve injection|ultrasound-guided axillary nerve injection
41372184|NCT05862870|BEHAVIORAL|painTRAINER|patient self-administered pain management web application
41372185|NCT00462501|BIOLOGICAL|bevacizumab|
41372186|NCT00462501|DRUG|fluorouracil|
41372187|NCT00462501|DRUG|leucovorin calcium|
41372188|NCT00462501|DRUG|oxaliplatin|
40848631|NCT02215304|DIETARY_SUPPLEMENT|Bifidobacterium bifidum R0071|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
40848632|NCT02215304|DIETARY_SUPPLEMENT|Placebo|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
40848633|NCT00873184|BEHAVIORAL|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
40848634|NCT05784519|DRUG|MSCs eye drops|MSCs were used to prepare single-cell suspension, and 0.9% sodium chloride was added to balance PH value to prepare the effective, safe and stable eye drops. Giving the patient with 5×10\^5 /50μl in each eye, twice a day for 2 weeks.
40848635|NCT02728466|DIETARY_SUPPLEMENT|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
40848636|NCT02728466|DIETARY_SUPPLEMENT|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
40848637|NCT02728466|DIETARY_SUPPLEMENT|control supplement deprived of flavanols and procyanidins|Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
41031227|NCT02878993|DEVICE|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
41031228|NCT01700608|DRUG|plerixafor|plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
41031229|NCT02207829|DRUG|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
41031230|NCT02207829|DRUG|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
41031231|NCT02207829|DRUG|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
41031232|NCT02207829|DRUG|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
41031233|NCT01303627|DRUG|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
41031234|NCT03269474|PROCEDURE|Experimental Group|Subjects with EB diagnosis
41031235|NCT04035941|BEHAVIORAL|Cycle Nation Multicomponent Intervention|"This intervention group will receive 4 elements:~1. Practical skills programme: a workplace-based programme covering basic cycling skills, delivered by trained 'cycle champions' - HSBC staff members.~2. Cycle provision scheme: participants will have the opportunity to have their own bicycles serviced or obtain a loaned bike or e-bike from local bike shops before the start of the programme.~3. Cycle-friendly workplace culture: all offices taking part will have a minimum of secure bike parking facilities as part of an ongoing roll-out of cycle infrastructure across HSBC UK offices.~4. Our Cycle Hub app: an adapted version of an existing HSBC app including route planning, goal setting and practical skills videos, as well as supportive social interaction among participants."
41031236|NCT05802459|OTHER|EORTC QLQ-C30|central generic questionnaire associated with different disease specific modules
41031237|NCT05802459|OTHER|EORTC QLQ-OG25|module to assess the quality of life in patients with esophagogastric disease.
41031238|NCT05802459|OTHER|GIQLI|Gastrointestinal Quality of Life Index. It is a gastrointestinal quality of life scale.
41031239|NCT05802459|OTHER|SWAL QoL|Swallowing Quality of Life questionnaire. This is a quality of life and quality of attention questionnaire for patients with oropharyngeal dysphagia.
41031240|NCT05802459|PROCEDURE|Videofluoroscopy|It consists of 14 items that represent the oral and pharyngeal function observed in the VDF. It allows to quantify the severity of dysphagia.
41031241|NCT05635123|OTHER|No intervention|This is a prospective observational study with no intervention.
41031242|NCT05935501|DEVICE|Formaderm Young|Dermal filler injection to facial areas.
41031243|NCT05935501|DEVICE|Restylane|Dermal filler injection to facial areas.
41031244|NCT06111521|DRUG|LY3537982|Administered orally
41031245|NCT06111521|DRUG|Digoxin|Administered orally
41372189|NCT00462501|PROCEDURE|conventional surgery|
41372190|NCT00462501|RADIATION|radiation therapy|
41031246|NCT06111521|DRUG|Rosuvastatin|Administered orally
41031247|NCT06111521|DRUG|Midazolam|Administered orally
41031248|NCT06111521|DRUG|Midazolam|Administered IV
41031249|NCT04246034|PROCEDURE|Microvascular Breast Reconstruction with Vascularized Lymph Node Transfer|simultaneous free abdominal flaps with VLNT from groin are transferred on a single pedicle for breast reconstruction and postmastectomy lymphedema
41031250|NCT01031147|OTHER|Examination|3D-TOF-MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
41031251|NCT06124157|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
41031252|NCT06124157|BIOLOGICAL|Blinatumomab|Receive IV
41031253|NCT06124157|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41031254|NCT06124157|DRUG|Calaspargase Pegol|Receive IV
41031255|NCT06124157|DRUG|Cyclophosphamide|Receive IV
41031256|NCT06124157|DRUG|Cytarabine|Receive IV
41031257|NCT06124157|DRUG|Dasatinib|Receive PO or NG
41031258|NCT06124157|DRUG|Daunorubicin|Receive IV
41031259|NCT06124157|DRUG|Doxorubicin|Receive IV
41031260|NCT06124157|PROCEDURE|Echocardiography|Undergo ECHO
41031261|NCT06124157|DRUG|Leucovorin|Receive PO or IV
41031262|NCT06124157|DRUG|Mercaptopurine|Receive PO
41372191|NCT01646268|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period"
41372192|NCT01646268|DRUG|Placebo Patch|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches"
41372193|NCT01154530|OTHER|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
41372194|NCT00627094|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
41503937|NCT05599581|BEHAVIORAL|Tu'Washindi|"Tu'Washindi consists of 3 primary components:~1. PrEP Adherence Support Clubs: Eight 2-hour sessions that occur over the intervention period: twice per month for the first 2 months \& once per month for the remaining 4 months. Sessions will use structured \& unstructured activities designed to improve outcomes expectations, increase self-efficacy to use PrEP safely \& consistently, increase peer support for PrEP use, provide access to community IPV resources \& provide skills for healthy communication \& PrEP disclosure with male partners.~2. Community Male Sensitization conducted weekly over the first 3 months of the intervention period aimed to increase PrEP knowledge, reduce stigma, \& promote healthy relationship communication.~3. Buddy Days, which take place 3 months into the intervention period, designed to bring participants \& their male partners together to learn about PrEP, discuss community attitudes \& concerns regarding PrEP use, \& promote HIV prevention \& family well-being."
41031263|NCT06124157|DRUG|Methotrexate|Receive IT or IV
41372195|NCT00627094|DEVICE|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
41372196|NCT05152498|DRUG|Fu Zheng Jie Du Hua Yu therapy|Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
41372197|NCT02672748|OTHER|Garden|Two years of financial and technical home gardening support for new gardeners
41372198|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
41372199|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
41031264|NCT06124157|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41031265|NCT06124157|DRUG|Pegaspargase|Receive IV
41031266|NCT06124157|DRUG|Prednisolone|Receive PO
41031267|NCT06124157|DRUG|Prednisone|Receive PO
41372200|NCT00003576|DRUG|cisplatin|
41372201|NCT00003576|DRUG|fluorouracil|
41372202|NCT00003576|PROCEDURE|surgical procedure|
41372203|NCT00003576|RADIATION|radiation therapy|
41372204|NCT00186173|BEHAVIORAL|After school sports program|After school team sports intervention designed specifically for overweight and obese children
41372205|NCT00186173|BEHAVIORAL|After school health education|After school health and nutrition education program
41031268|NCT06124157|RADIATION|Radiation Therapy|Undergo radiation therapy
41031269|NCT06124157|DRUG|Thioguanine|Receive PO
41031270|NCT06124157|DRUG|Vincristine|Receive IV
41503938|NCT01653301|DRUG|XELAC RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
41503939|NCT01653301|DRUG|XELOX RT|"* Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~* Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
41031271|NCT04696068|OTHER|Porcelain plates|The patients will receive the same food in another presentation : porcelain plates instead of plastic trays
41372206|NCT02739711|DRUG|Glycoprotein IIb/IIIa inhibitors|Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
41503940|NCT04409314|DRUG|Fluorine F 18-fluoroazomycin Arabinoside|Given IV
41503941|NCT04409314|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41503942|NCT01040598|BIOLOGICAL|Omalizumab|Omalizumab, an anti-IgE monoclonal antibody is dosed on the basis of subject's weight and IgE levels. It is administered as a subcutaneous injection every 2 weeks or 4 weeks based on the total dose required.
41031272|NCT03344991|OTHER|Cardboard Cot Care|When ready to be weaned from radiant warmer, infant will be placed in a reflective film-lined cot for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
41031273|NCT03344991|OTHER|Open Crib|When ready to be weaned from radiant warmer, infant will be placed in a standard of care open crib for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
41372207|NCT00830011|BEHAVIORAL|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
41372208|NCT00830011|OTHER|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
41372209|NCT05726123|DEVICE|The Exopulse Mollii Suit on a Fibromyalgia patient|The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
41372210|NCT00006354|DIETARY_SUPPLEMENT|mistletoe extract|
41372211|NCT05735860|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Four VRET sessions of approx. one hour each session taking place in an individual setting accompanied by a therapist. The participants wear a head-mounted display showing different musical performance scenarios (i.e. audition in a concert hall/ recording studio/ in front of a professional jury/ an audience/ a class of music students) that are selected individually by a previously standardized, graded exposure procedure.
41372212|NCT05735860|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Four PMR sessions of approx. 45min each session taking place in an individual setting accompanied by a therapist. The sessions follow a previously standardized procedure.
41372213|NCT05630768|DRUG|Risedronate Sodium 35 MG [Actonel]|Risendronate Sodium Tab. 35mg, orally, once weekly
41372214|NCT05630768|DRUG|Calcium Vitamin D combination|orally, once daily for concomitant drug
41372215|NCT04910191|DIAGNOSTIC_TEST|Electronic stethoscope|Electronic stethoscope
41372216|NCT03131375|DRUG|Dexmedetomidine|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
41372217|NCT03131375|DRUG|Normal saline|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
41372218|NCT03131375|DEVICE|Bispectral index|Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
41372219|NCT03131375|DEVICE|Train of four ratio|Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
41162897|NCT05172518|DRUG|Utidelone plus Intermittent Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
41162898|NCT05172518|DRUG|Taxane plus Metronomic Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(For the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
41503943|NCT02305160|DRUG|Butantan|Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
41503944|NCT02305160|DRUG|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
41162899|NCT05172518|DRUG|Utidelone plus Metronomic Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
40848638|NCT06303323|OTHER|Qigong Exercise|"Baduanjin Exercise will be performed which consists of 8 standing postures. At least 30 minutes per time. 10-13 min for a set of Badaunjin.~In the first 2 weeks, two sets of Baduanjin will be performed. Total Duration: 6 weeks Frequency: for 3 days/week. (alternative days) Intensity: low-intensity exercise Total Time: 50 Minutes Type: aerobic training"
41162900|NCT02359578|DRUG|Indocyanine Green|Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
41162901|NCT02601105|OTHER|Placebo Vehicle Cream|Lipoderm Cream alone
41162902|NCT02601105|OTHER|Centella Asiatica Cream|1% Centella Asiatica in lipoderm
41162903|NCT03498885|PROCEDURE|Low ligation|Left colic artery (LCA) is identified, Tie the sigmoid artery and superior rectal artery, Apical lymph node dissection with the left colic artery preservation is performed.
41162904|NCT03498885|PROCEDURE|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apicallymph nodes dissection is performed.
41162905|NCT03528109|BEHAVIORAL|Exposure Therapy|A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety
41503945|NCT06546774|DIETARY_SUPPLEMENT|Melatonin|In the study group, patients will receive melatonin supplementation for at least two months prior to IVF cycles
41503946|NCT00197288|BIOLOGICAL|Influenza|
41503947|NCT03328975|DRUG|Dexamethasone|The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.
41503948|NCT03328975|OTHER|Placebo|the placebo group will not receive the corticosteroid medication in their injection to treat the inflammation and pain in their shoulder. Instead, they will receive an injection of 5 mL lidocaine only.
40848639|NCT06303323|OTHER|Wu Dang Tai Chi|"Wu Dang 13 form postures will be performed. Initially, each posture will be performed 3 times then progressively increase to more according to the patient's discomfort.~Total Duration: 6 weeks Frequency: 3 times/ week (alternative day ) Intensity: Low to Moderate Intensity Time: 50 Minutes Type: aerobic training"
40848640|NCT04854382|BEHAVIORAL|Tailored information|Tailored information about coronavirus for patients with chronic kidney disease by information videos followed by a teach back procedure
40848641|NCT00156871|BEHAVIORAL|exercise|
40848642|NCT03609411|PROCEDURE|Splenectomy|Splenectomy was performed after hepatectomy, in an extra-hilar manner with manual ligation of splenic vessels.
41162906|NCT01291043|OTHER|Shiatsu|8-week treatment with two Shiatsu sessions per week (50-minute duration)
41162907|NCT05736445|BEHAVIORAL|Wellness coaching plus app use|Participants will participate in wellness coaching and interact with apps on their smartphones
41503949|NCT02552732|DEVICE|NHF with or without Oxygen|NHF using myAIRVO™ 2 will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.
40848643|NCT05700032|DIAGNOSTIC_TEST|high MI impulses|patients will receive intermittent high MI impulses(\>1.0) in addition to low MI imaging. LVOT VTI will be measured at different times per protocol.
40848644|NCT05700032|DIAGNOSTIC_TEST|low MI impulses|patients will receive low MI imaging only. LVOT VTI will be measured at different times per protocol.
41503950|NCT05340829|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia
41503951|NCT06270186|DIAGNOSTIC_TEST|Type 1 myotonic dystrophy|"To compare classical neuropsychological test and on Good Diag NMD software in Type 1 myotonic dystrophy patients"
41503952|NCT00070200|BIOLOGICAL|filgrastim|
41503953|NCT00070200|DRUG|cisplatin|
41503954|NCT00070200|DRUG|cyclophosphamide|
41503955|NCT00070200|DRUG|doxorubicin hydrochloride|
41503956|NCT00070200|DRUG|etoposide|
41503957|NCT00070200|DRUG|isotretinoin|
41503958|NCT00070200|DRUG|melphalan|
41503959|NCT00070200|DRUG|topotecan hydrochloride|
41503960|NCT00070200|DRUG|vincristine sulfate|
41503961|NCT00070200|PROCEDURE|conventional surgery|
41503962|NCT00070200|PROCEDURE|peripheral blood stem cell transplantation|
41503963|NCT00070200|RADIATION|radiation therapy|
41503964|NCT05405582|COMBINATION_PRODUCT|Community-based differentiated HIV prevention incl.PrEP with SRH|Community-based model of care, that consists of social mobilisation by area-based peer-navigator into decentralised sexual reproductive health (SRH) and HIV care (incl. PrEP).
41503965|NCT05405582|OTHER|Primary Health Clinic based HIV prevention and care|Primary Health Clinic (PHC) based initiation and follow-up with HIV testing and standard HIV prevention and treatment package. Family planning support and syndromic management for STIs as per South African National Department of Health Guideline.
41503966|NCT04609826|DRUG|JNJ-74856665|JNJ-74856665 will be administered orally.
41503967|NCT04609826|DRUG|AZA|AZA will be administered IV infusion or SC injection.
41503968|NCT04609826|DRUG|VEN|VEN tablet will be administered orally.
41503969|NCT03398070|OTHER|Standard of Care|"The standard of care interventions for Functional Neurological Disorders (FND) include:~1. delivery of a rule-in diagnosis~2. providing educational materials~3. referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated~4. referring to FND-related cognitive behavioral therapy (CBT)~5. psychotropic medication management based on standard psychiatric care"
41503970|NCT01000558|OTHER|biologic sample preservation procedure|
41503971|NCT06453252|OTHER|we are aiming to develop a Scoring system based on certain variables derived from both groups|We are aiming to develop a Scoring system based on certain variables derived from both group
41162908|NCT01928407|DRUG|DARUNAVIR|The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
41503972|NCT03918460|DEVICE|ANEUFIX|ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
41503973|NCT01721317|DRUG|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
41503974|NCT01721317|DRUG|Placebo|Matching placebo will be available
41503975|NCT05326048|OTHER|cytof analysis|cytof analysis of biological samples of CIS patients. Genomic analysis
41503976|NCT06578143|OTHER|Placebo|Placebo is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
41503977|NCT06578143|OTHER|Synbiotics|Synbiotics is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
41503978|NCT06322602|PROCEDURE|Intracranial Catheter Placement|Undergo Ommaya reservoir placement
41503979|NCT06322602|PROCEDURE|Lumbar Puncture|Undergo LP
41503980|NCT06322602|PROCEDURE|Biopsy|Undergo biopsy
41503981|NCT06322602|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
41503982|NCT06322602|PROCEDURE|Computed Tomography|Undergo CT
41503983|NCT03645707|BEHAVIORAL|CAR Training and Psychoeducational Sessions|"Participation in the CAR Training Program, a 1-day training program developed by the J\&J Human Performance Institute (HPI). The CAR Training Program uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.~Participants will attend eight weekly follow-up psychoeducational group sessions facilitated by a licensed mental health counselor that will meet for 90 minutes. The themes of these sessions will be RISE - Resilience, Insight, Self-Compassion, and Empowerment. Due to limited time and flexibility in sessions, participants will practice skills through optional homework activities to facilitate learning between sessions."
41503984|NCT03155945|DRUG|Olorinab|Olorinab active treatment for 8 weeks.
41503985|NCT04105127|DEVICE|orthodontic - Anterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the palatal aspect of the upper central incisors. Both central incisors are customarily bonded to broadly distribute the occlusal forces. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
41503986|NCT04105127|DEVICE|orthodontic - Posterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the supporting cusps of first or second upper/lower molars. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
41503987|NCT02167854|DRUG|BYL719|
41503988|NCT02167854|DRUG|LJM716|
41503989|NCT02167854|DRUG|TRASTUZUMAB|
41503990|NCT04647903|DRUG|ADAIR 10 mg IR tablets|manipulated ADAIR 3x10mg
41503991|NCT04647903|DRUG|d-amphetamine sulfate|crushed d-amphetamine sulfate 3x10mg
41503992|NCT04647903|DRUG|Placebo|placebo for oral and intranasal administration
41503993|NCT00010426|DRUG|cysteamine hydrochloride|
40848645|NCT00420121|PROCEDURE|laboratory analysis|blood withdrawal for laboratory analysis
41162909|NCT01928407|DRUG|ATAZANAVIR|The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
41162910|NCT03207698|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
41372220|NCT00300261|BEHAVIORAL|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
41372221|NCT05920382|PROCEDURE|Radiofrequency ablation of peripheral nerves.|Randomized double-blind clinical trial where we will apply thermal radiofrequency to the sensory terminal branches of the femoral nerve in the knee, including the vasto medial nerve, vasto lateral nerve, vasto intermedio nerves, and the infrapatellar branch of the saphenous nerve.
41162911|NCT03207698|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
41162912|NCT03207698|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
41372222|NCT05075109|DEVICE|High Frequency TENS|30 minutes of high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
41372223|NCT05075109|DEVICE|Low Frequency TENS|30 minutes of low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks. And combined with 30 minutes of TRT.
41503994|NCT05577195|DEVICE|Impella|To provide active left ventricular unloading in the experimental arm
41503995|NCT05577195|DEVICE|VA-ECMO|To provide circulatory support in both arms
41503996|NCT03546127|GENETIC|Next Generation Sequencing (NGS): exome, RNA seq|"Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms.~For both sequencing configurations:~* Data from each cancer and normal genome will be analysed for the presence of somatic variants.~* DNA and RNA sequencing results will be integrated.~* Technical replication for the mutations / chromosome alterations / transcript fusions that most likely drive the tumour process will be performed via Target Resequencing of the genomic / coding regions of interest."
41503997|NCT06393517|DRUG|PF-06954522 IR (Formulation 1)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
41503998|NCT06393517|DRUG|PF-06954522 MR (Formulation 2)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
41503999|NCT06393517|DRUG|PF-06954522 MR (Formulation 3)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
41504000|NCT02257385|DRUG|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
41504001|NCT02257385|DRUG|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
41504002|NCT02257385|DRUG|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
41504003|NCT02257385|DRUG|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
41504004|NCT02257385|DRUG|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
41504005|NCT02257385|DRUG|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
41504006|NCT02257385|DRUG|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
40848650|NCT00958646|OTHER|Osteopathic Manipulation|Standardized rib raising protocol
40848651|NCT00958646|OTHER|Placebo|Light touch control procedure
40848652|NCT06423131|PROCEDURE|TCRαβ Depleted haploidentical HCT|Use the CliniMACS TCRα/β deplete from the mobilized peripheral blood stem cells of haploidentical donor in children
40848653|NCT04346849|PROCEDURE|Pulpotomy|Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration
40848654|NCT05593627|DRUG|Lithium Carbonate 250 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 250mg lithium carbonate
41162913|NCT02241278|DRUG|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision (a single dose).
40848655|NCT05593627|DRUG|Calcium Carbonate 500 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 500mg calcium carbonate
41031274|NCT04529213|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
41031275|NCT00353704|DRUG|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
41031276|NCT00353704|DRUG|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
41162914|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, patients receive clinically-optimized open loop DBS stimulation to the pallidum.
41372224|NCT05075109|OTHER|Task Related Training|"Each session of TRT would include:~1. postural control, 2. shoulder mobilization, 3. weight bearing exercises 4. Functional activities that will comprise of simple tasks to more advanced movement patterns as follows:~* Reaching activities~  1. Forward supported reach with cane on tabletop~ 2. Reaching against gravity~ 3. Reaching overhead with active wrist/hand movements~ 4. Dynamic reaching to target e.g. catch a ball~* Grasping, holding and release~  1. Grasp, hold and release objects with gravity minimized~ 2. Pick up and move/release small objects on table~ 3. Pick up and move/release large objects without proximal support~ 4. Incorporate pinch grips in hold and release including stacking, lifting and overhead activity~* Upper limb ADL~  1. Brushing hair, putting on scarf~ 2. Opening bottles, turning off water tap~ 3. Writing, drawing~ 4. Folding of towels, hanging towels and setting table~ 5. Self-feeding"
41372225|NCT00942110|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
41031277|NCT00353704|DRUG|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
41031278|NCT04071938|OTHER|Teaching to GPs|Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists
40848656|NCT05698953|OTHER|Reiki|Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
41031279|NCT04071938|OTHER|Site visits to GP practices|Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
41031280|NCT06630832|OTHER|Simulated work in the heat with no cooling during rest breaks|Young and older adults will not undergo cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
41031281|NCT06630832|OTHER|Simulated work in the heat with partial cooling during rest breaks|Young and older adults will not undergo partial cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
41031282|NCT06630832|OTHER|Simulated work in the heat with full cooling during rest breaks|Young and older adults will not undergo full cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
41031283|NCT00823082|DRUG|Antithrombin III|Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
41031284|NCT04525404|DIAGNOSTIC_TEST|MRI (heart, brain, lungs, liver)|MRI (heart, brain, lungs, liver)
41031285|NCT04525404|DIAGNOSTIC_TEST|Bloodwork|Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA
41031286|NCT04525404|OTHER|Cognitive testing|NIH toolbox Cognitive Measures
41031287|NCT04525404|OTHER|Olfaction testing|Brief Smell Identification Test (BSIT)
41031288|NCT04525404|DIAGNOSTIC_TEST|Spirometry|Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity
41031289|NCT04525404|OTHER|Walk Test|Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
41031290|NCT04852081|DRUG|Palbociclib|Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
41031291|NCT04852081|DRUG|Ribociclib|Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
40848657|NCT05698953|OTHER|Placebo|Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days by an independent nurse during the same application period.
41031292|NCT04852081|DRUG|Abemaciclib|Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
41031293|NCT04852081|DRUG|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
41031294|NCT04852081|DRUG|Anastrozole|Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
41031295|NCT04852081|DRUG|Tamoxifen|Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
41162915|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation at random time points. These random stimulation times will in total equal the total amount of time of active movement.
41162916|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of contralateral limb movement (e.g. left brain stimulation during right leg/arm movement).
41031296|NCT04852081|DRUG|Fulvestrant|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
41162917|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of no movement for the contralateral limb (e.g. left brain stimulation while right leg/arm is not moving).
41162918|NCT03758456|BIOLOGICAL|HAL-MRE1|HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.
41031297|NCT04852081|DRUG|Exemestane|Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
41031298|NCT04852081|DRUG|Alpelisib|Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
41031299|NCT04625803|DRUG|Camrelizumab , apatinib and chemotherapy|"Camrelizumab 200 mg, IV infusion on Days 1 each 14-day cycle~Apatinib 250mg oral administration once a day, for two months~mFOLFOX6 oxaliplatin 85 mg/m\^2 IV infusion on Day 1 of each14-day cycle. Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2. The loading dose is then followed by a 46-hour 5-fluorouracil infusion of 2,400 mg/m2 via a pump programmed to provide a constant drug infusion rate."
41031300|NCT02683538|DEVICE|Separable cluster electrode (Octopus®)|Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
41162919|NCT02325583|DRUG|30% Glucose|ORAL 30% GLUCOSE 0,5-2 ML
41162920|NCT02325583|DRUG|Midazolam|INTRAVENOUS 0.1 MG/KG MIDAZOLAM
41162921|NCT00822666|DRUG|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
41162922|NCT06380647|DRUG|Intravenous Acyclovir|Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.
41162923|NCT01661530|DIETARY_SUPPLEMENT|Vitamin E enhanced soup|vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
41162924|NCT01661530|DIETARY_SUPPLEMENT|Non-enhanced soups|Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
41162925|NCT00488228|BEHAVIORAL|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
41162926|NCT00255671|OTHER|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
41162927|NCT01088178|DEVICE|Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)|Placement of Mirena at given intervals during the postpartum period
41162928|NCT03650361|DRUG|Adapalene Gel 0.3%|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
40848658|NCT06470646|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body.By employing specialized catheters and devices,endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the targetsite,without the need for conventional open surgery.
41162929|NCT03650361|DRUG|Differin 0.3% Topical Gel|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
41162930|NCT03650361|DRUG|Adapalene Gel 0.3% Vehicle Placebo|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
41162931|NCT02413099|DRUG|KBMSI-2|The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
40848659|NCT00426543|DRUG|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
41162932|NCT03219255|DRUG|RELVAR 100 ELLIPTA|RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
41162933|NCT05392062|OTHER|Pathophysiology of gas exchange|Exploration of pathophysiology of gas exchange
41162934|NCT05625568|DRUG|VYNT-0126|Liquid for oral administration once daily
41162935|NCT05625568|DRUG|Placebo|Liquid for oral administration once daily
40848660|NCT00426543|DRUG|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
40848661|NCT01548066|DRUG|Valproic Acid|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
40848662|NCT01548066|DRUG|Control placebo|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
41162936|NCT04112875|DIETARY_SUPPLEMENT|L-arginine|Handled powdered supplement to be mixed with water, has orange flavor for oral use.
41162937|NCT04112875|DIETARY_SUPPLEMENT|Maltodextrin|hydrolysis of cornstarch or starch as a white powder to be mixed with water, has orange flavor for oral use.
41031301|NCT06534281|PROCEDURE|BAO-G|Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.
41031302|NCT02376907|PROCEDURE|Biliary drainage|EUS-BD or ERCP
41031303|NCT04242927|DRUG|Nicotinic acid +Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
41031304|NCT04242927|DRUG|Routine care|Routinely apply urea ointment and provide best supportive care.
41372226|NCT00665327|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
41372227|NCT00665327|DRUG|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
41372228|NCT01863160|DRUG|0.1% ZEP-3 cream|"Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~* Right arm, single treatment area - ZEP-3 (0.1%)~* Left arm, single treatment area - Placebo cream"
41372229|NCT01863160|DRUG|placebo|"Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream"
41372230|NCT02230332|DRUG|Alendronate|
40848663|NCT01401608|DEVICE|RF Ablation|Ablation of arrhythmogenic ventricular tissue
40848664|NCT05364021|DRUG|LP352|LP352 administered three times daily, orally or through G-tube
41162938|NCT03962517|DEVICE|with Gait Enhancing and Motivating System-Hip (GEMS-H)|"The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.~Assessments consist of gait function, cardiopulmonary metabolic energy cost, physical performance, balance, physical level, pain, fall efficacy, depression, quality of life and activities of daily living."
41162939|NCT03962517|OTHER|without Gait Enhancing and Motivating System-Hip (GEMS-H)|The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.
41372231|NCT02230332|DRUG|Placebo|
41372232|NCT01103076|DEVICE|Polyamide HD membrane|Single use polyamide membrane
41372233|NCT05784467|BEHAVIORAL|Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) study|Group behavioral intervention with 12 weekly sessions lasting 2 hours focusing on coping, resistance, and resilience.
41372234|NCT04179929|DRUG|Pediatric-type of chemotherapy|Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
41372235|NCT04179929|PROCEDURE|allogeneic HSCT|allogeneic HSCT
41372236|NCT02015312|DRUG|Epigallocatechin-3-gallate (EGCG)|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
41372237|NCT02015312|DRUG|Placebo|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
40848665|NCT05364021|DRUG|Placebo|Matching placebo for LP352 administered three times daily, orally or through G-tube
40848666|NCT00064051|DRUG|gemcitabine hydrochloride|
40848667|NCT00064051|DRUG|triapine|
40848668|NCT02578056|DEVICE|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
40848669|NCT02578056|PROCEDURE|Genital prolapse surgery|Surgical correction of genital prolapse
40848670|NCT06009328|OTHER|fundamental movement skills|measured by test of gross motor development
40848671|NCT00622388|DRUG|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
41372238|NCT05614544|DRUG|HSK3486|HSK3486 for induction of general anesthesia
41372239|NCT05614544|DRUG|Propofol|Propofol for induction of general anesthesia
41372240|NCT05614544|DRUG|Placebo|Intralipid
41372241|NCT04197856|OTHER|Standard care encouraging family-mediated disclosure of hereditary cancer risk|At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.
41372242|NCT04197856|OTHER|Offer of health-care assisted disclosure by sending direct letters to at-risk relatives|The participant is offered that the health care provider at the cancer genetic unit mail a direct letter with personalized family risk information to all at-risk relatives that participant approve contact with.
41372243|NCT01096017|DRUG|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
41372244|NCT01096017|DRUG|Salbutamol pMDI|200 μg, inhalation, single dose
41372245|NCT01096017|OTHER|pMDI placebo pMDI|Placebo pMDI 2 inhalations
41372246|NCT01096017|OTHER|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
41372247|NCT00912431|DRUG|ABT-126|ABT-126 administered on Day 1 of Period 1
40848672|NCT04672122|DEVICE|Transcranial direct current stimulation|Cathodal tDCS will be applied for 20 mins.
40848673|NCT01195324|DRUG|Canagliflozin/Warfarin|Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
41372248|NCT00912431|DRUG|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
41372249|NCT05942040|OTHER|Tailored Palliative Care Information|This study test feasibility and acceptability of implementing tailored informational materials into clinician's discussions about CBPC with MA plan members who are eligible for the service.
41504007|NCT03337958|DEVICE|Ventilatory re-education|The first day of intervention consisted primarily in ventilatory re-education. During the realization of the technique he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
40848674|NCT01195324|DRUG|Canagliflozin/Warfarin|Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
40848675|NCT04381650|DRUG|TAK-981|TAK-981 IV infusion.
40848676|NCT04381650|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
41031305|NCT03726034|BEHAVIORAL|Life Story Book|The protocol of life story book creation is validated in Hong Kong. The life story book would contain two elements: (1) the development of the older adults over the course of his/her lifetime (i.e. from childhood to old age); and (2) the psychosocial development and ways of life of the older adults (e.g. education, marriage, career, and hobbies). The product of the intervention will be a written story with pictures or other memorabilia that are meaningful to the older adults. There is no limitation on the number of words, pages, and pictures. Four to six 60-minute scheduled sessions will be needed for the older adult and the live-in migrant caregivers to discuss and produce the lifestory book at home.
41162940|NCT03591432|DEVICE|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.
41162941|NCT03591432|DEVICE|Facemask ventilation|Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
41162942|NCT01828593|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
41162943|NCT01828593|OTHER|Placebo|Matching placebo
41162944|NCT03158129|DRUG|Carboplatin|Given IV
41162945|NCT03158129|DRUG|Cisplatin|Given IV
41162946|NCT03158129|DRUG|Docetaxel|Given IV
41504008|NCT00501098|DRUG|Caspofungin|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
41504009|NCT06385548|DRUG|Lurbinectedin|participants will receive intravenous infusions of lurbinectedin at a dose of 2.6 mg/m², diluted in a minimum of 100 mL of either 5% glucose solution or 0.9% sodium chloride solution. The infusion will last for one hour and will be administered every three weeks.
40848677|NCT06584032|DRUG|fruquintinib|Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.
40848678|NCT06584032|BIOLOGICAL|sintilimab|Sintilimab will be intravenously administrated on Day 1 every three weeks.
40848679|NCT06584032|DRUG|paclitaxel|175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.
40848680|NCT06584032|DRUG|doxorubicin|60mg/m\^2 via IV infusion, on Day 1 every three weeks.
40848681|NCT01364025|PROCEDURE|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
41031306|NCT03726034|BEHAVIORAL|Self-selected social activities|To control the possible social interaction effects on the dyadic relationship and wellbeing, the caregivers of the control group will conduct self-selected social activities with older adult at home individually for four times weekly.
41162947|NCT03158129|BIOLOGICAL|Ipilimumab|Given IV
41162948|NCT03158129|BIOLOGICAL|Nivolumab|Given IV
41162949|NCT03158129|DRUG|Pemetrexed|Given IV
41162950|NCT01335321|DRUG|Hylan GF-20 alone|A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
41162951|NCT01335321|DRUG|Triamcinolone|A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
41162952|NCT04771962|DRUG|DESFLURANE AND SEVOFLURANE|COMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS
41162953|NCT02072278|DRUG|Vortioxetine 10 mg|
41162954|NCT02072278|DRUG|Vortioxetine 20 mg|
41162955|NCT02072278|DRUG|Escitalopram 15 mg|
41162956|NCT02072278|DRUG|Placebo|
41372250|NCT04198974|BEHAVIORAL|PreVenture Training (PTtT)|"PreVenture TtT model will involve identifying local expert trainers to be trained to train school-based professionals on the PreVenture program. Steps include:~1. PreVenture Facilitator certification: Trainers participate in training workshops and deliver the program to eligible youth in Cohort 1 and are rated on quality of implementation using the PIFA.~2. Reliable use of the PIFA: Each trainer demonstrates convergence with the Montreal Team's ratings on a set of previously-recorded PreVenture sessions.~3. PreVenture Training Workshop Certification: Trainers participate in a one-day TtT workshop to review the main aims and exercises of PreVenture Training. Trainers then record mock TtT sessions in which key components of the PreVenture Training Workshop are delivered to an audience of 4-10 individuals (e.g., class of graduate students). These sessions are rated by the Montreal Team the PreVenture Implementation Fidelity and Adherence-Trainer Scale (PIFA-T)."
41372251|NCT04198974|BEHAVIORAL|PreVenture Training+Implementation Facilitation|"PreVenture TtT model + Implementation Facilitation Package:~1. Youth advisors identified the role of older youth to support program implementation. Youth will help promote PreVenture to students and families and help Facilitators optimize attendance at sessions.~2. Trainer-led coaching sessions will focus on enhancing program fidelity and acceptability by Facilitators. 'Best practice' supervision elements from efficacy trials will be integrated. Fidelity and symptom monitoring will be conducted in real-time during program implementation.~3. Performance metrics have been developed based on youth qualitative feedback to PreVenture sessions in previous trials. Analysis indicates key responses that are predictive of students most likely to benefit from PreVenture on 12-month substance use outcomes and indicates the extent to which Facilitator's interventions are leaving students with impressions consistent with positive long-term outcomes."
41372252|NCT04698668|DEVICE|fusion imaging|To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
41372253|NCT00488098|DRUG|GSK372475|
41372254|NCT02826005|DEVICE|MRI|
41372255|NCT00082069|BIOLOGICAL|Shigella flexneri 2a Invaplex 50|
41372256|NCT01701180|DRUG|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
41372257|NCT01701180|DRUG|Placebo|
41372258|NCT02583854|DEVICE|RY-STOP hemostasis device|
41372259|NCT02583854|DEVICE|TR-Band, Terumo|
41372260|NCT02401724|OTHER|Transcranial direct current stimulation|
41372261|NCT02401724|OTHER|Action Training|
41372262|NCT03572348|PROCEDURE|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
41372263|NCT03572348|PROCEDURE|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
41372264|NCT02649127|BEHAVIORAL|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
41372265|NCT02649127|BEHAVIORAL|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity \[i. e., \>60% of oxygen uptake reserve (VO2R)\], and a time of 20-25 minutes each bout of training
41372266|NCT02649127|BEHAVIORAL|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
41372267|NCT00594009|DEVICE|Venovenous CO2 Removal (VVCO2R) in COPD|Patients who meet criteria will be placed on an extracorporeal circuit consisting of an oxygenator, centrifugal pump, tubing and indwelling double lumen venous catheter for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
41372268|NCT00937859|DRUG|SER120|SER120
41504010|NCT06385548|DRUG|Dostarlimab|participants will receive intravenous infusions of dostarlimab at a fixed dose of 500 mg, administered over 30 minutes on Day 1 of each three-week cycle.
41504011|NCT04147585|OTHER|Intermittent Reduced Calorie Diet (IRCD)|Three cycles of a 5-day Intermittent Reduced Calorie Diet over three months.
41504012|NCT05901597|DEVICE|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer
40848682|NCT06501612|OTHER|Continuous Glucose Monitor and Undermyfork App|Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices). Participants will also be instructed to download and use Undermyfork mobile application where they will have access to their history of their blood glucose responses to their meals in Undermyfork. A randomly selected number of participants in this group will be requested to complete a semi-structured qualitative interview to assess satisfaction with using Undermyfork application immediately following the intervention.
41504013|NCT03893097|DRUG|Praziquantel|40 mg/kg at baseline
41372269|NCT00937859|DRUG|Placebo|Placebo
41372270|NCT03423004|PROCEDURE|Biopsy|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
41372271|NCT01714726|DRUG|MEDI2070|1 iv infusion on Week 0 and Week 4
41372272|NCT01714726|DRUG|placebo|1 iv infusion on Week 0 and Week 4
41372273|NCT05116410|DRUG|HS-20094|Administrated SC
41372274|NCT05116410|DRUG|Placebo|Administrated SC
41372275|NCT06502002|DRUG|Dexmedetomidine Hydrochloride|Initial dexmedetomidine bolus of 1 mcg/kg over 30 min after induction, followed by an infusion rate of 0.3 mcg/kg/hr that will be stopped 30-45 minutes before the end of the surgery or once a maximum dose of 2mcg/kg has been achieved, whichever comes first.
41372276|NCT06502002|DRUG|Placebo|normal saline infusion
41372277|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma|Floroscopy guided by C-arm Intraarticular injection in Lumbar facet Joints
41504014|NCT03893097|DRUG|Artesunate + Mefloquine|4mg/kg artesunate and 8 mg/kg mefloquine at baseline (3 consecutive days) and repeated at Week 6 and Week 12
41504015|NCT01141205|BIOLOGICAL|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
41504016|NCT01141205|DRUG|Saline|1.2 ml saline intramuscularly
40848683|NCT06501612|OTHER|Continuous Glucose Monitor|Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices).
40848684|NCT02619032|DRUG|Remifentanil|Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
41031307|NCT05923281|DRUG|K-877 0.2 mg/day (once daily)|K-877 0.2mg tablet
41031308|NCT05923281|DRUG|K-877 0.4 mg/day (once daily)|K-877 0.2mg tablet
41031309|NCT05923281|DRUG|Placebo (once daily)|Placebo tablet
41031310|NCT04820764|DEVICE|CardioMech MVRS|CardioMech MVRS
41372278|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone|Lumbar Facet Joints intra-articular injection
41372279|NCT03096249|DRUG|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
41372280|NCT03096249|OTHER|Placebo|Placebo spray: single dose (3 puffs per nostril).
41372281|NCT03048175|PROCEDURE|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
41372282|NCT02184234|DRUG|Antistax film coated tablets|
41372283|NCT05853081|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.
41372284|NCT05005468|DRUG|Camrelizumab|Camrelizumab is given on the first day of each cycle, intravenous drip.
41372285|NCT05005468|DRUG|Famitinib|Famitinib is administered orally, once a day.
41372286|NCT04709640|OTHER|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
41372287|NCT01947010|BIOLOGICAL|Prevenar 13|
41372288|NCT01947010|BIOLOGICAL|Pneumovax|
41372289|NCT05842668|BEHAVIORAL|ESWL Group|Increasing comfort and reducing pain during ESWL
41372290|NCT00830310|BEHAVIORAL|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
41162957|NCT06171282|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
41372291|NCT00830310|BEHAVIORAL|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
41372292|NCT00830310|BEHAVIORAL|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
41372293|NCT00830310|BEHAVIORAL|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
40848685|NCT02619032|DRUG|Fentanyl|Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
41031311|NCT04584372|DIETARY_SUPPLEMENT|High-nitrate intervention|The 2×70 mL of nitrate-rich (i.e., 'high nitrate') beetroot juice contains 12.9 mmol nitrate (NO3-).
41031312|NCT04584372|DIETARY_SUPPLEMENT|Low-nitrate intervention|The 2×70 mL of nitrate-depleted (i.e., 'low nitrate') beetroot juice contains 0.04 mmol (or less) nitrate.
41031313|NCT02328326|OTHER|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
41031314|NCT02328326|OTHER|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
41031315|NCT06535685|DRUG|Romiplostim|Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months.
41162958|NCT03318783|DRUG|GSK2256294|GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
41372294|NCT04293601|OTHER|interventional nursing care|"The infants enrolled will receive different intervention according to a defined risk factor level:~Low:~* NCPAP duration \< 48 hours (h)~* Gestational Age (GA) \> 32 weeks (wks)~* Current weight \> 1500 g~Interventions:~* alternating mask or nasal prongs once per shift~* skin assessment (excoriation, erythema or skin breakdown) once per shift~Medium:~* NCPAP duration from 48 to 72 h~* GA from 32 to 28 wks~* Current weight from 1500 to 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) twice per shift~* repositioning of device once per shift~High:~* NCPAP duration \> 72 h~* GA \< 28 wks~* Current weight \< 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) every 3 h per shift~* repositioning of device every 3 h per shift"
41372295|NCT04293601|OTHER|Standard nursing care|"* Use of hydrocolloid as nasal barrier dressing~* Appropriate size of headbands, indicated by production company~* Appropriate size of mask or binasal prongs, indicated by production company~* Frequently assess skin integrity, every 4 hours~* Replace hydrocolloid if it's dirty or displaced~* Humidity and heat gases"
41504017|NCT04914455|DIAGNOSTIC_TEST|Echocardiography and transhepatic inferior vena cava assessment using ultrasound.|"For all participant :~* Inferior vena cava diameter will be measure before and after fluid expansion 'which administration will be decided by a physician other that the investigator).~* Stroke volume using primarily VTI in TTE or a cardiac output monitoring device (Swan ganz catheter (Edwards life science), EV 1000 (edwards life science), PiCCO(Getinge))~* Absence of significant pericardial effusion of hematoma~Whenever possible:~Subcostal measurement of IVC, ejection fraction, cardiac outcput, mitral E, A and E' waves, TAPSE, tricupid S' wave, Right ventricle fractional area change.~venous congestion assesment : hepatic vein, portal vein and renal vein Doppler to define the VEXUS Score;"
41504018|NCT05093764|DEVICE|VIV TAVR with BVF using TCEP|The insertion and retrieval of the SENTINEL device is performed at the time of the patients TAVR procedure in the same setting while they are sedated under moderate sedation or general anesthesia depending on the case. The device is inserted at the initiation of the procedure through 6F right radial artery access and the filters are positioned in the left common carotid artery and brachiocephalic artery. After deployment, the usual TAVR procedure is performed. At the conclusion of the procedure, the SENTINEL device is extracted and hemostasis is achieved at the radial access site in the usual fashion with patent hemostasis.
41504019|NCT02766283|DRUG|iodinated contrast agents|Intravascular application
41504020|NCT01590277|DRUG|Active Ethanol|Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
41504021|NCT01590277|DRUG|Active Iomazenil|Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.
41504022|NCT01590277|DRUG|Placebo|Control: no alcohol, administered for a total of 90 minutes.
41504023|NCT01590277|DRUG|Placebo|Control: no iomazenil, administered for a total of 10 minutes
41504024|NCT04521972|DEVICE|Room light/light bulb|Room light will be ON/OFF or red light used in the room. Reducing/eliminating light in the room in the evening and night is expected to allow the natural release of melatonin, which is thought to promote uterine contractions in late pregnancy.
41504025|NCT00338312|DRUG|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
41504026|NCT00338312|DRUG|Placebo patch|placebo patch changed twice a week for one year
41504027|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).
41504028|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 21 days (Cycle 1-6) and 28 days for Cycle 7 and beyond.
41504029|NCT04623541|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|R-CHOP will be administered intravenously in cycles of 21 days for the first 6 cycles.
41504030|NCT04623541|DRUG|Venetoclax|Venetoclax tablets will be administered orally once daily during the 5-week ramp up period and during Cycle 1-26 of 28 or 35 days each.
41504031|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
41504032|NCT04623541|DRUG|Lenalidomide|Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days up to 12 cycles.
41504033|NCT06434623|OTHER|patient record|using patient record to construct AI models
41504034|NCT05261295|DIAGNOSTIC_TEST|PEEP|PEEP of 7 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
41504035|NCT05261295|DIAGNOSTIC_TEST|ZEEP|PEEP of 0 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
41504036|NCT01338870|DRUG|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
41504037|NCT01338870|DRUG|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
41504038|NCT01338870|DRUG|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
41504039|NCT01338870|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
41504040|NCT01338870|DRUG|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
41162959|NCT03318783|DRUG|Placebo|Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
41372296|NCT06464471|OTHER|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
41372297|NCT05321342|BEHAVIORAL|Bullying Classroom Check-Up (BCCU)|BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, \& Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator \[developed at the University of Central Florida \[UCF\]; Dieker, Hynes, Hughes, \& Smith, 2008\], and self-monitoring) and utilizing motivational interviewing (Miller \& Rollnick, 2012) to empower teacher practice change.
41372298|NCT04260360|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
41372299|NCT05023499|DRUG|SYMPT-X Glutamine, Oral Powder for Reconstitution|erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
41372300|NCT00779857|DEVICE|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
41372301|NCT02088359|OTHER|Cycled light|We covered the incubator with blanket for darkness approximately 12 hours.
41372302|NCT02088359|OTHER|Continue near darkness|We covered the incubator with blanket all days.
41372303|NCT02689713|DRUG|Voriconazole (topical)|The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
41372304|NCT02689713|DRUG|Topical Sterile Water Placebo Group|Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
41504041|NCT01338870|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
41504042|NCT04385303|DRUG|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 m vehicle
41372305|NCT01821508|OTHER|Clinical Treatment|metabolic surgery for diabetes and weight control
41372306|NCT01821508|PROCEDURE|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
41372307|NCT05354401|OTHER|HHF|HHF is an integrated flow generator that delivers heated and humidified air or oxygen at high flow rates via a soft nasal cannula using an open circuit. HHF via the Fisher and Paykel myAIRVO 2 device will be initiated as per The Hospital for Sick Children's sleep laboratory standard protocol by a sleep technician or respiratory therapist (RT) during an overnight polysomnography. Nasal prongs will be selected that are less than fifty percent of the subject's nares. The lowest flow rate of HHF will be selected and titrated upwards until clinical effect is achieved, to a maximum flow of 60L/minute, as per standard clinical care.
41504043|NCT04385303|DRUG|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
41372308|NCT02909127|OTHER|SWALLOWING EVALUATION|Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
41504044|NCT04809233|DRUG|Tipifarnib|
41504045|NCT03976544|DRUG|Estradiol Valerate|Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
41504046|NCT03976544|DRUG|Micronized progesterone|If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
41504047|NCT02556229|DRUG|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
41504048|NCT04772157|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
41504049|NCT02359994|DEVICE|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.
41504050|NCT02359994|DEVICE|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
41504051|NCT03103841|PROCEDURE|Sleep studies [Polysomnography]|Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires
41504052|NCT05587348|BEHAVIORAL|Best Practice Advisory|Provider will get Best Practice Advisory or Message from DCE in intervention practices
41031316|NCT05260710|BEHAVIORAL|Telemedicine Intervention|"Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~+~Continuing education activities: video classes and discussions of complex cases."
41031317|NCT05255653|DRUG|Olaparib|300 mg twice daily for two years
41031318|NCT05255653|RADIATION|Pelvic external beam radiotherapy|45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
41031319|NCT05255653|DRUG|Chemotherapy|Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
41031320|NCT05255653|DRUG|Durvalumab|1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles) starting within the first week of radiotherapy,
41031321|NCT05255653|DRUG|Medroxyprogesterone Acetate|Oral medroxyprogesterone acetate for two years
41031322|NCT05255653|DRUG|Megestrol Acetate|Oral medroxyprogesterone acetate for two years
41031323|NCT05255653|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
41162960|NCT06276634|OTHER|Acute Intermittent Hypoxia|During each AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles: one with lower oxygen concentration (9-10% Oxygen) than that at sea level (\~21% Oxygen) lasting between 30 and 60 seconds, followed by a similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
41162961|NCT06276634|OTHER|Sham-Acute Intermittent Hypoxia|During each Sham-AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the Sham-AIH intervention. The Sham-AIH intervention involves alternating breathing cycles: both with oxygen concentrations of \~21% Oxygen lasting between 30 and 60 seconds, followed by another similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
41162962|NCT00114543|PROCEDURE|Aggressive Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.
41162963|NCT00114543|PROCEDURE|Aggressive Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.
41162964|NCT00114543|PROCEDURE|Conservative Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.
41162965|NCT00114543|PROCEDURE|Conservative Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
41162966|NCT01422083|PROCEDURE|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
41372309|NCT02909127|OTHER|The Functional Independence Measure|The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
41372310|NCT02909127|OTHER|The PEDI-EAT-10|The PEDI-EAT-10 will also be administered.
41031324|NCT05255653|OTHER|Observation|No adjuvant therapy
41031325|NCT03659552|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
41162967|NCT04792255|PROCEDURE|Carotid artery stenting with standard contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
41372311|NCT02475109|DRUG|PAN-90806 Ophthalmic Solution|
41372312|NCT00058994|DRUG|anecortave acetate|
41504053|NCT05587348|BEHAVIORAL|Peer Support|Patients referred to DSMES classes will be randomized to get a peer supporter
41504054|NCT06296082|DRUG|Botulinum toxin type A|Botulinum toxin type A injections are a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a chimical disruption of dysfunctional endplates.
41031326|NCT04661995|COMBINATION_PRODUCT|Hearing Aid and Notched Noise Therapy|Notched Noise Therapy involves presenting wide-band sound with the tinnitus frequency region notched out, referred to as notched noise, or notch therapy. This procedure may distribute lateral inhibition into the notched frequency region, suppressing tinnitus neural activity believed to be occurring there. This type of therapy is provided through a sound file that is streamed through hearing aids.
41031327|NCT04661995|COMBINATION_PRODUCT|Hearing Aid and Broadband Noise|"Broadband Noise, or white noise, is a common tinnitus sound therapy treatment option. It is also commonly used as a masker noise for individuals with tinnitus that like to enrich their environment with sound."
41031328|NCT04661995|DEVICE|Hearing Aid|A-O groups will use ear-level, self-contained devices (hearing aids) that (1) are capable of streaming shapeable broadband noise between 1-10 kHz; (2) allow for normal conversation; and (3) are comfortable, easy to use, and discrete. These criteria describe a behind-the-ear hearing aid with the capability of streaming custom sounds. Hearing aids are used to provide amplification to those with hearing loss and are fit by licensed audiologists. Sometimes, hearing aids can provide benefit to those with bothersome tinnitus.
41031329|NCT01063257|DRUG|Clofarabine|"The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:~DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).~The DLa will be the following:~DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation."
41031330|NCT06243653|DIAGNOSTIC_TEST|CMD test|Measured CFR and IMR
41372313|NCT02616107|OTHER|Managing Cancer Care: A Caregiver's Guide|"MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:~1. Becoming a Cancer Caregiver \[role, changes, challenges, adjusting, self-care\]~2. Basics of Cancer Caregiving \[physical, functional, emotional, social, \& spiritual support; treatment timeline worksheet\]~3. Caregiver's Role in Managing Patient Care \[who/what is involved; health care professionals worksheet\]~4. Managing Cancer Symptoms and Side Effects \[common symptoms/side effects; maintaining health; nutrition \& exercise; medication management worksheet\]~5. Care Options: \[information on curative, palliative and hospice care\]~6. Talking About Goals of Care \[information on goals of care conversations\]~7. Managing Transitions \[defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet\]"
41372314|NCT02616107|OTHER|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
41372315|NCT04281147|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow clinical administration
41372316|NCT04259398|DRUG|Propofol|propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
41372317|NCT04259398|DRUG|Sevoflurane|sevoflurane is administered for induction and maintenance of anesthesia
41372318|NCT04096716|DRUG|Tc-99m tilmanocept|Tc-99m tilmanocept is a radioactive diagnostic agent.
41372319|NCT02430155|DEVICE|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
41372320|NCT02430155|DEVICE|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
41372321|NCT00752206|DRUG|Saracatinib|Oral Agent
41372322|NCT00752206|DRUG|Placebo|Oral Agent
41504055|NCT06296082|OTHER|Dry Needling|Dry Needling is a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a mechanical disruption of dysfunctional endplates.
41372323|NCT06249087|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
40848686|NCT05712278|DRUG|SAR445419|Cell suspension, by intraveneous (IV) injection
41031331|NCT02861690|DRUG|Liposomal Paclitaxel|Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
41031332|NCT02861690|DRUG|Nedaplatin|Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
41031333|NCT04351438|DEVICE|Active Comparator: centrifuge TPE with citrate|Patients who received citrate-based anticoagulation with centrifuge TPE
41031334|NCT04351438|DEVICE|Active Comparator: Filter TPE with heparin|Patients who received heparin-based anticoagulation with filter TPE
41031335|NCT04351438|DRUG|Active comparator: Filter TPE with citrate|Patients who received citrate-based anticoagulation with filter TPE
41504056|NCT03300843|BIOLOGICAL|Peptide loaded dendritic cell vaccine|On days 0, 14 (+/- 5 days), 28 (+/- 5 days), and 42 (+/- 5 days). The vaccine will be administered as both an intravenous (IV) infusion and a subcutaneous (SQ) injection. The total dose will be divided equally between intravenous (IV) and SQ containing 1.0E7 to 8.0E7 cells per cycle depending upon the manufacturing yield.
41504057|NCT05772247|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound score was calculated by the results of lung ultrasound examination
41504058|NCT02988635|OTHER|Early Palliative Care|Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaire at 12 weeks after enrollment.
41504059|NCT04590235|DRUG|Selumetinib|"All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m\^2. After a washout period of 2 days, oral selumetinib 25 mg/m\^2 twice daily will be administered continuously. Subjects will continue to receive selumetinib until disease progression or unacceptable drug-related toxicity, whichever occurs first.~10 mg and 25 mg capsules strengths available."
41504060|NCT04538625|DRUG|Crofelemer 125 MG [Mytesi]|Randomized, Double-blind, Placebo-controlled, two arm trial
41504061|NCT04538625|DRUG|Placebo|Matching placebo tablets
41504062|NCT00126282|BEHAVIORAL|behavior therapy|
41504063|NCT00126282|DRUG|D-Cycloserine|
41031336|NCT00000893|DRUG|Nelfinavir mesylate|
41031337|NCT00000893|DRUG|Efavirenz|
41504064|NCT05092269|DRUG|Ustekinumab|Ustekinumab will be administered as a SC injection.
41162968|NCT04792255|PROCEDURE|Carotid artery stenting with reduced contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
41504065|NCT04962152|DRUG|Nalbuphine Sebacate or Sesame oil (placebo)|ultrasound-guided intramuscular injection after the induction of anesthesia immediately
41162969|NCT04792255|DIAGNOSTIC_TEST|Carotid Duplex Ultrasound|Pre- and postinterventional assessment of the treated internal carotid artery.
41162970|NCT00604513|OTHER|Ready. Set. ACTION! Protocol|"The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun \& Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception."
41504066|NCT03260725|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered in the clinic.
41504067|NCT03260725|BEHAVIORAL|Internet-delivered PCIT (I-PCIT)|I-PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered to families in their own home in real-time via videoconferencing over the Internet by a remote therapist.
41504068|NCT02195661|DIETARY_SUPPLEMENT|Melatonin|
41031338|NCT06334770|DEVICE|Roxolid implants|four Straumann BLX® roxolid implant 15% zirconium and 85% titanium), 3.7 mm in diameter, and 10 mm in length.implants were selected with the following criteria: tapered, self-tapping, aggressively threaded,were inserted with novalock attachments.
41031339|NCT06334770|DEVICE|Titanium implants|four conventional acid etched pure implants tapered, self-tapping, threaded, two-piece, with the 10 mm length and 3.7 mm diameter were inserted with Sphero flex attachments.
41031340|NCT00507793|DRUG|Sirolimus|
41031341|NCT00507793|DRUG|Cyclosporine|
41031342|NCT02814318|BIOLOGICAL|Vaginal and rectovaginal swab cultures|The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
41031343|NCT04976920|DIAGNOSTIC_TEST|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
40848687|NCT05712278|DRUG|fludarabine|Solution for injection , by IV injection
41031344|NCT00002934|PROCEDURE|long-term screening|
41031345|NCT04097132|DEVICE|echocardiography|echocardiography for left atrial diameter, size ,Ejection Fraction Holter for detection of paroxusmal AF
41031346|NCT06255223|RADIATION|High-dose Radiotherapy (HDRT)|SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).
41162971|NCT00604513|OTHER|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
41162972|NCT02956278|DRUG|Allopurinol|
41162973|NCT02956278|OTHER|Placebo|lactose placebo pill
41504069|NCT02195661|DRUG|Chloral Hydrate|
41504070|NCT01927198|DRUG|Placebo|
41504071|NCT01927198|DRUG|RDEA3170 5 mg|
41504072|NCT01927198|DRUG|RDEA3170 10 mg|
41504073|NCT01927198|DRUG|RDEA3170 12.5 mg|
41504074|NCT05858112|DIAGNOSTIC_TEST|SuperTROPO novel assay to measure the long forms of cTnT|SuperTROPO novel assay to measure the long forms of cTnT
41504075|NCT02481362|OTHER|CAKE|For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
41504076|NCT02481362|OTHER|APRICOTS|For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
41504077|NCT02602444|DRUG|ticagrelor|180 mg loading dose
41504078|NCT06632223|OTHER|Sensory motor training|Each session will be composed of 10 minutes of warm-up, followed by 50-60 minutes of sensory motor exercises, followed by 5-10 minutes of cool down.
41504079|NCT06632223|OTHER|Traditional physical therapy|traditional physical therapy program in form of stretching exercises, strengthening exercises, scar management, and gait training
40848688|NCT05712278|DRUG|cytarabine|Solution for injection, by IV injection
40848689|NCT06439303|DRUG|Cytisine 1,5 mg|Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious
40848690|NCT00802893|DRUG|6R-BH4|6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
41162974|NCT01705145|DRUG|Ivacaftor|
40848691|NCT00802893|OTHER|Placebo|placebo given BID for entire length of study
41372324|NCT06249087|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
41162975|NCT01916798|DRUG|Intralipid infusion|IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up \& another dose at the day of embryo Transfer.
41372325|NCT06249087|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
41372326|NCT01657591|DRUG|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
41372327|NCT01657591|DRUG|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
41372328|NCT06190860|OTHER|Autologous Leukocyte and platelet-rich fibrin|Participants will be treated with L-PRF plugs and membranes from autologous venous blood. Participants will have drawn blood after venipuncture (median cubital vein) into sterile, glass-coated plastic 9 mL tubes without anticoagulant. These tubes will be centrifuged at 2700 rpm for 12 min (Relative Centrifugal Forces-clot = 408 g). After tooth extraction, participants in the experimental group will be treated with L-PRF plugs and membranes.
41372329|NCT06190860|OTHER|Intraoral Scan|Intraoral scan will be taken in the treated zone after tooth extraction and after four months.
41372330|NCT06190860|RADIATION|Computed Tomography|Cone Beam Computed Tomography in the treated zone will be taken after tooth extraction and after four months.
41372331|NCT06190860|OTHER|Biopsy|Before dental implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.
41372332|NCT02736734|DRUG|CRH|CRH injection: 100 µg CRH powder for injection (CRH Ferring) dissolved in 1ml NaCl 0.9%, administration intravenously over the course of 1 minute to avoid side effects.
40848692|NCT01983774|DRUG|Esomeprazole|
40848693|NCT01983774|DRUG|Placebo|Sugar pill
40848694|NCT00888953|OTHER|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
40848695|NCT00888953|OTHER|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
40848696|NCT00202956|DRUG|Bugusan|
40848697|NCT01106235|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
40848698|NCT01106235|BIOLOGICAL|aldesleukin|Given SC
40848699|NCT01106235|DRUG|cyclophosphamide|Given IV
40848700|NCT01106235|PROCEDURE|biopsy|Optional correlative studies
41031347|NCT06255223|RADIATION|Low-dose Radiotherapy (LDRT)|Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.
41031348|NCT06255223|DRUG|Anti-PD-1 monoclonal antibody|At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.
41031349|NCT00427050|DRUG|PEP005|
41031350|NCT02007577|DRUG|salsalate|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
41031351|NCT02007577|DRUG|Placebo|Participants will take 3 tablets with breakfast and 4 tablets with dinner
41031352|NCT00280332|PROCEDURE|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
41031353|NCT06108622|DIAGNOSTIC_TEST|cbc ,u\s renalor hepatic function test if needed|just blood sample if the case needed
41031354|NCT05026957|DEVICE|SharedHeart|A smartphone application
41031355|NCT01329029|DRUG|Roflumilast|500 µg, once daily
41031356|NCT01329029|DRUG|Placebo|once daily
41031357|NCT00298428|PROCEDURE|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
41031358|NCT01217931|DRUG|Pazopanib|800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.
41031359|NCT01217931|DRUG|Bevacizumab|10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.
41031360|NCT01217931|DRUG|Everolimus|10 mg by mouth once daily. A cycle consists of 4 weeks.
41031361|NCT03177304|OTHER|Web based IPT Training|
41031362|NCT03022851|DEVICE|Occlutech AFR Device|Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
41031363|NCT00833989|DRUG|GSK249320|I.V. infusion
41031364|NCT00833989|DRUG|PLACEBO|Placebo
41031365|NCT04686448|DRUG|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
41162976|NCT03256370|PROCEDURE|milk collection|"* Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~* After completed informed consent, demographic data was collected and filled in case record form~* Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~1. Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~2. High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method"
41162977|NCT03140449|DRUG|Rapamycin|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
41162978|NCT03140449|DRUG|Calcitriol|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
41162979|NCT03140449|DRUG|Rapamycin-calcitriol combination|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
41162980|NCT06026826|DEVICE|transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
41162981|NCT06026826|DEVICE|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
41504080|NCT03008317|DEVICE|PEEK|a metallic denture base
41504081|NCT00936247|DRUG|HES 130/0.42 + electrolyte solution|Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component
41504082|NCT00936247|DRUG|Albumin + electrolyte solution|Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
41031366|NCT04686448|DRUG|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
41031367|NCT01674036|DRUG|Genz-682452|Capsules for oral administration.
41031368|NCT01674036|DRUG|Placebo|Placebo to Genz-682452
41031369|NCT02896855|DRUG|Docetaxel|Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
41031370|NCT02896855|DRUG|Pertuzumab|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
41031371|NCT02896855|DRUG|Placebo|Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
41031372|NCT02896855|DRUG|Trastuzumab|Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
41162982|NCT00586742|PROCEDURE|labral repair|labral repair with suture anchors
41162983|NCT00586742|PROCEDURE|biceps tenodesis|biceps tenodesis with suture anchor
41162984|NCT00586742|PROCEDURE|diagnostic arthroscopy|diagnostic arthroscopy
41162985|NCT02589418|PROCEDURE|Acupuncture|Needle insertion and manipulation at 4 acupuncture points (bilateral LI4, right ST6 and ST7).
41162986|NCT02589418|PROCEDURE|Sham-Acupuncture|Needle insertion and manipulation at 4 non-acupoints
41162987|NCT02589418|PROCEDURE|No Acupuncture|Control intervention: No needle insertion and manipulation
41162988|NCT06452927|PROCEDURE|Endoscopic enucleation of the prostate|"Endoscopic enucleation of the prostate, regardless of energy source.~Also see:~* Enucleation is enucleation is enucleation is enucleation~* PMID: 27585786 DOI: 10.1007/s00345-016-1922-3"
41162989|NCT00875615|DRUG|Carboplatin|Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
41504083|NCT06456853|OTHER|Pain assesment|We will ask patients about their pain and will try to asses their pain scores. Then we will ask them to which methot is more suitable for assesment.
41504084|NCT02694328|DRUG|ALKS 3831|Daily dosing
41031373|NCT04890002|DEVICE|Far-infrared emitting pyjamas|Clothing made in far infrared (FIR) - based textiles could be a sustainable way for alleviating sleep problems with many advantages. Firstly, the proposed far infrared textiles are made of man-made profiled fibers without the addition of chemicals such as ceramic additives or other related coatings.
41031374|NCT04890002|DEVICE|Sham-pyjamas|The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function.
41031375|NCT02279758|DRUG|Metformin|
41031376|NCT03669029|DRUG|Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg|Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.
41162990|NCT00875615|DRUG|Cisplatin|Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
40848701|NCT02097654|OTHER|SENATOR software generated pharmacotherapy advice report.|
41162991|NCT00875615|DRUG|Sorafenib|Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
41372333|NCT04804306|DEVICE|Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
41372334|NCT01147432|DRUG|PF-04427429|Single dose IV infusion up to 300mg
41372335|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
41372336|NCT01147432|DRUG|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
41372337|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
41372338|NCT01147432|OTHER|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
41372339|NCT03010475|DRUG|Furosemide|Oral administration A total of three single doses.
41162992|NCT04564859|DEVICE|Heated Humidified High-Flow Nasal Cannula|Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
41162993|NCT02934893|OTHER|Medication Management Clinic|referral to medication management clinic from primary care
41162994|NCT02934893|OTHER|Diabetes+Me plus connected glucometer|Use of software and medication modeling tool as add on to medication management standard of care
41162995|NCT05160597|PROCEDURE|Biopsy of Prostate|Undergo image-guided prostate biopsy
41372340|NCT03010475|DRUG|Rosuvastatin|Oral administration. A total of three single doses.
41372341|NCT03010475|DRUG|SNAC|Oral administration. A total of five single doses.
41504085|NCT02694328|DRUG|Olanzapine|Daily dosing
41372342|NCT03010475|DRUG|Semaglutide|Oral administration. Once daily.
41372343|NCT00493701|BEHAVIORAL|High Fat Diet|Daily eating
41372344|NCT00493701|BEHAVIORAL|Low Fat Diet|Life style eating habits
41372345|NCT00359866|RADIATION|IMRT with tomotherapy|
41504086|NCT00926783|PROCEDURE|CFAE ablation|CFAE ablation (targeted vs. generalized)
41031377|NCT03669029|DRUG|Golimumab treatment optimization.|Golimumab dosing will be optimized in patients without clinical response at week 6.
41372346|NCT03237000|DRUG|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~* Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~* Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
41372347|NCT02264925|DEVICE|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
41372348|NCT05538039|OTHER|Distract with play dough|Distract with play dough
41372349|NCT05538039|OTHER|Distract with play kaleidoscope|Distract with play kaleidoscope
41372350|NCT05538039|OTHER|Control group|Routine nursing care
41372351|NCT03676816|PROCEDURE|vaginal self sampling|This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
41504087|NCT00151346|DRUG|Bupivacaine and Fentanyl (for CSE)|Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
41504088|NCT00151346|DRUG|Bupivacaine and Fentanyl (for traditional epidural)|Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
41031378|NCT06326606|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
41031379|NCT06326606|DRUG|Placebo|Capsule with no active ingredients
41031380|NCT01248650|DRUG|nalfurafine hydrochloride|
41031381|NCT01195012|BEHAVIORAL|Helping HAND (Healthy Nutrition and Activity Directions)|6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
41372352|NCT03676816|PROCEDURE|provider-performed endocervical sampling|provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
41372353|NCT02382107|OTHER|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
41372354|NCT00160719|PROCEDURE|retrieve blood samples|blood samples obtain pre-op, 6 and 12 months post-op
41372355|NCT01761123|BIOLOGICAL|VXA-A1.1|
41504089|NCT06456905|BEHAVIORAL|Contingency Management|Participants in the contingent group will be rewarded on an incrementally increasing scale for submitting consecutive breathalyzer samples that are 0.00%. For every day this target is met, the participant will receive an increase in reward until a daily cap is reached. If a day contains at least one sample where the target is not met, the participant will not be paid for that day, and the amount will reset. The participant will have the opportunity to earn on this scale throughout the duration of the study.
41031382|NCT06634511|OTHER|core stability exercises|"Group A: core stability exercise group:15 Patients assigned to this group will undergo a core stability exercises ts.2times per week /8weeksin addition to conventional therapy (Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes~Group B:(aerobic exercise group) 15 patients will receive aerobic exercise in the form of treadmill for 30 minutes2 session per week/8 weeks~Group C(conventional group): 15 patients will receive Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes, Participants were treated twice weekly"
41162996|NCT05160597|OTHER|Gallium Ga 68 Gozetotide|Given IV
41162997|NCT05160597|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo standard of care TRUS
41162998|NCT00160979|PROCEDURE|Pre-treatment tumour oxygen measurements|Pre-treatment tumour oxygen measurements
41162999|NCT03630523|BIOLOGICAL|Influvac Tetra|Tetravalent seasonal flu vaccination 2018/2019
41163000|NCT06019845|DEVICE|MAGiC™|Robotic magnetic radiofrequency (RF) ablation catheter
41163001|NCT05243342|DRUG|XmAb24306|XmAb24306 will be given via intravenous (IV) infusion
41372356|NCT05942716|DRUG|Administration of a PET radiotracer|"A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic."
41372357|NCT04409509|BIOLOGICAL|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
41372358|NCT04409509|DRUG|Placebo|CSL312 diluent administered intravenously
41504090|NCT02212379|DRUG|raltegravir and etravirine|"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."
41504091|NCT01199016|PROCEDURE|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
41504092|NCT01199016|PROCEDURE|Nose/throat swab|To be performed at every study visit
41163002|NCT05243342|DRUG|Daratumumab|Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)
41372359|NCT04951596|OTHER|Investigate the current situation|Investigate the current situation of infusion treatment for acute and critical patients in 2 hospitals in the province
41372360|NCT04411030|DRUG|ASTX660|Form: capsule; Route of administration: oral
41372361|NCT04411030|DRUG|Midazolam|Form: syrup; Route of administration: oral
41372362|NCT04411030|DRUG|Itraconazole|Form: capsule; Route of administration: oral
41504093|NCT01199016|BIOLOGICAL|Observational|Observational Study Only
41504094|NCT05659212|DRUG|Dexmedetomidine|Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
40848702|NCT03939936|OTHER|Psoriatic measurements|Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
41372363|NCT04144140|DRUG|E7766|E7766, solution, intratumorally
41504095|NCT05659212|DRUG|Magnesium sulphate|Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
41504096|NCT05659212|DRUG|Lidocaine|Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
41504097|NCT06625775|DRUG|BBO-10203|Participants will receive assigned dose of BBO-10203 orally (PO) QD
41372364|NCT04975867|OTHER|Targeted therapeutic hypothermia|Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
41372365|NCT04975867|OTHER|Targeted therapeutic normothermia|Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
41372366|NCT02264340|BEHAVIORAL|Relaxation technique Autogenic Training|Autogenic Training
41504098|NCT06625775|DRUG|Trastuzumab|Participants will receive trastuzumab infusion (IV) or subcutaneous (SC)
41372367|NCT02264340|BEHAVIORAL|Combined treatment Autogenic Training + Cervical exercises and postural correction|Autogenic Training + Cervical exercises and postural correction
41372368|NCT03252652|RADIATION|vascular duplex ultrasound imaging|Duplex ultrasound is a non-invasive evaluation of blood flow through cranial arteries and veins.
41372369|NCT00152659|PROCEDURE|Tissue sample (procedure/screening)|Tissue sampling
41372370|NCT00389766|DRUG|iodine I 131 metaiodobenzylguanidine|
41372371|NCT00389766|DRUG|topotecan hydrochloride|
41372372|NCT00389766|PROCEDURE|chemotherapy|
41372373|NCT00389766|PROCEDURE|peripheral blood stem cell transplantation|
41372374|NCT00389766|PROCEDURE|radioisotope therapy|
41372375|NCT00389766|PROCEDURE|radionuclide imaging|
41372376|NCT00389766|PROCEDURE|radiosensitization|
41372377|NCT00389766|PROCEDURE|total-body irradiation|
41372378|NCT01976104|DRUG|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
41372379|NCT01976104|DRUG|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
41372380|NCT01976104|DRUG|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
41372381|NCT01976104|DRUG|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
41372382|NCT02848781|DEVICE|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
41372383|NCT02848781|PROCEDURE|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
41372384|NCT03297710|OTHER|Quality-of-Life Assessment|Ancillary studies
41372385|NCT03297710|RADIATION|Radiation Therapy|Undergo radiation therapy
41372386|NCT03297710|DRUG|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
41372387|NCT00010634|DRUG|Connective Tissue Nutrient Formula|
41372388|NCT00010634|DRUG|Adaptogenic herbs|
41372389|NCT00010634|DRUG|glutamine|
41372390|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|"Patient in lithotomy position (supine) with return plate at lumbar level.~Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.~Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all)."
41372391|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|Doctor uses sham sensor to reduce efficiency to zero.
41372392|NCT00869362|OTHER|Diabetes management team|MD evaluation followed by NP education and and medication titration
41372393|NCT03334201|OTHER|Western Diet|high fat (40%), high sugar (25%) and low fiber (15g/day)
41372394|NCT03334201|OTHER|Non-Western Diet|low fat (25%), low sugar (15%), high fiber (30g/day)
41372395|NCT03045926|DRUG|Diosmectite (Smecta®)|
41372396|NCT04238117|PROCEDURE|Laser acupuncture treatment|Laser acupuncture therapy (LAT) is a noninvasive technique that involves stimulation of traditional acupoints with low intensity, non thermal laser irradiation.
41372397|NCT05199714|DRUG|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
41504099|NCT00426361|BIOLOGICAL|Boostrix ® Polio|One dose of vaccine administered intramuscularly
41504100|NCT00426361|BIOLOGICAL|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
41504101|NCT00144157|DRUG|Nevirapine|
41504102|NCT00144157|DRUG|Zidovudine|
41504103|NCT00144157|DRUG|3TC|
41504104|NCT01582152|DRUG|TPI287|"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
41504105|NCT01582152|DRUG|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
41372398|NCT05199714|DEVICE|Artificial Pancreas|Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.
41372399|NCT05199714|DRUG|Pramlintide|Pramlintide delivered in a basal-bolus manner.
41372400|NCT05199714|DRUG|Aspart|Aspart insulin delivered in a basal-bolus manner.
41372401|NCT01138709|DEVICE|Vitala|Vitala™ Continence Control Device
41372402|NCT05071521|OTHER|The Body Project: A Dissonance-Based Eating Disorder Prevention Intervention|The Body Project is a a selective dissonance-based prevention program that targets women with body image concerns. It has been developed with University and similar populations in mind, making it appropriate to the current research.The Body Project is based on a protocol, and aims to create cognitive dissonance that encourages participants to reduce pursuit of the thin-ideal. It involves the use of a scripted manual, covering four interactive weekly sessions. These involve role play, behavioural, verbal and written exercises.
41372403|NCT00998166|DRUG|Pemetrexed|"1. Pre-hydration for 1-1/2 hours at 250 ml/hour~2. Pemetrexed 500 mg/m2 IV over 10 minutes~3. Return to hydration for 30 minutes at 250 ml/hour"
41372404|NCT00998166|DRUG|Cisplatin|4. Cisplatin 75mg/m2 IV over 60-120 minutes
41372405|NCT00998166|DRUG|Bevacizumab|5. Bevacizumab 15mg/kg IV over 90 minutes
41372406|NCT02254629|DRUG|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
41372407|NCT02254629|DRUG|Laxative Polyethylene Glycol|laxative：2000 ml.
41372408|NCT05392465|OTHER|Fascial mobilization group|Fascial mobilization+ conventional treatment (3 sessions per week). MFR is thought to work directly on restricted fascia; practitioners use knuckles or elbow to slowly sink into the fascia, and the pressure applied to contact the restricted fascia, apply tension, or stretch the fascia. MFR involves application of gentle stretch the pressure applied is a few grams of force, and the hands tend to follow the direction of fascial restriction, hold the stretch, and allow the fascia to release itself + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation).A total of 40-45 min session three times a week on alternate days for three weeks.
41372409|NCT05392465|OTHER|Conventional physical therapy|Conventional Therapy (3 sessions per week). In this treatment group conventional treatment for chronic neck pain will be given which includes hot pack, Neck Isometrics and Neck Stretches. Hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotators).A total of 40-45 min session three times a week on alternate days for three weeks On eligible participants baseline assessment was done,3 session were given per week.
41372410|NCT02020356|BEHAVIORAL|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
41372411|NCT02020356|BEHAVIORAL|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
41372412|NCT05429749|DRUG|Ferinject|Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
41372413|NCT05429749|DRUG|Normal saline|Normal saline 250ml is administered between the admission day and the surgery day.
41372414|NCT02231606|OTHER|Free Glasses|Provide free glasses
41372415|NCT02231606|OTHER|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
41372416|NCT02231606|OTHER|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
41372417|NCT01700894|BEHAVIORAL|Walking Program + Motivational Interviewing Calls|
41372418|NCT01700894|BEHAVIORAL|Walking Program + Automated Calls|
41372419|NCT01700894|BEHAVIORAL|Walking Program|
41372420|NCT03644966|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotics
41372421|NCT03644966|OTHER|Placebo|Sugar pill manufactured to mimic probiotic tablet
41372422|NCT03644966|DRUG|Antibiotics|Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
41372423|NCT05396326|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
41372424|NCT05396326|DRUG|Teysuno|Oral S-1, 40mg-60mg bid, day 1-14 for four 21-day cycles.
41372425|NCT05396326|PROCEDURE|Transarterial arterial chemoinfusion and embolism (TACiE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1, if applicable.
41372426|NCT02021019|PROCEDURE|Renal Denervation|Renal Denervation
41372427|NCT01273246|BIOLOGICAL|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
41372428|NCT01273246|BIOLOGICAL|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
41372429|NCT01273246|BIOLOGICAL|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
41372430|NCT01273246|BIOLOGICAL|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
41372431|NCT03260621|DIAGNOSTIC_TEST|stress CMR|additional stress CMR to the established clinical diagnostics
41372432|NCT00594334|DRUG|Risedronate|Weekly Risedronate
41372433|NCT02489682|OTHER|Long-form written Informed consent information|
41372434|NCT02489682|OTHER|Short-form written Informed consent information|
41031383|NCT06489548|DRUG|Foralumab TZLS-401 50 µg|Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 50 µg vs. placebo.
41031384|NCT06489548|DRUG|Foralumab TZLS-401 100 µg|Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 100 µg vs. placebo.
41031385|NCT01872260|DRUG|LEE011|LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.
41163003|NCT03605368|BEHAVIORAL|Virtual Reality Intervention|Floreo's Police Safety Module (PSM) offers a supervised VR experience for people with ASD. The software is an application that provides a 3D immersive scene for headset-compatible smartphones. The person with ASD will use a smartphone capable of running the application with a dedicated headset providing the virtual environment. The PSM provides an immersive story-based intervention that shows a fully realized and intricately detailed urban environment designed to engage the user in a virtual encounter with a law enforcement officer. The immersive VR environment engages the person with ASD as an actor in a virtual narrative, incorporating strategies from both story-based intervention and video modeling. The video demonstrates the approach and initial engagement efforts of two police officers in the virtual environment, from the perspective of the person wearing the headset. The PSM allows a monitoring therapist to use a tablet or phone to supervise the person's virtual world.
41163004|NCT03605368|BEHAVIORAL|Video Modeling Intervention|The video modeling intervention is a subset of the BE SAFE The Movie Curriculum Lessons (https://besafethemovie.com/curriculum/) that were selected to match Floreo PSM on length. The BE SAFE The Movie Curriculum consists of video-based instruction on police officer interaction expectations and safety. Within each of three sessions, participants will watch videos, complete worksheets, and discuss topics related to police safety knowledge and behaviors with the study administrator.
41163005|NCT03605368|BEHAVIORAL|No intervention|Participants will follow all study procedures with the exception of the VR-based intervention including assessments.
41163006|NCT01431950|DRUG|fluticasone furoate|Inhaled corticosteroid
41163007|NCT01431950|DRUG|albuterol/salbutamol|Provided as rescue relief of asthma symptoms
41163008|NCT02863913|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
41163009|NCT02863913|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
41163010|NCT02863913|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
41163011|NCT04832815|BEHAVIORAL|Equine Therapy|Aim 1: Six session equine interventions. Intervention will be provided one day per week for four weeks. During the first two weeks, each intervention day with consist of two sessions with a lunch break in between. Weeks four and five consist of one trail riding session per intervention day followed by lunch. Each session will be approximately 1.5 hours in length. Sessions 1-4 will occur at the USU Equine Education Center, and session 5-6 will occur on local trails. Optional transportation for participants will be provided from the VA to the intervention site.
41163012|NCT04832815|BEHAVIORAL|Therapeutic Horsemanship Program|Aim 2: Therapeutic Horsemanship program utilizes the USU Pathways to Horsemanship model and covers levels of equestrian training from basic groundwork to more advanced riding techniques. Training occurs in a three or six-session format with once weekly sessions over three or six weeks. Mindfulness and mindful self-compassion training may be included.
41163013|NCT05380388|BIOLOGICAL|Malaria Vaccine|blood stage Plasmodium vivax malaria vaccine
41163014|NCT05380388|BIOLOGICAL|HBV vaccine|HBV Vaccine
41163015|NCT02174614|BEHAVIORAL|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
41372435|NCT02489682|OTHER|Video Informed consent information|
41372436|NCT02010671|OTHER|Survey|Survey
41372437|NCT04822727|DEVICE|1 or more AndraTec devices (see description for list of devices)|1 or more AndraTec devices (Lokum L-Quest guidewire, Lokum Amplatz guidewire, Slider Hydrophilic Nitinol Guidewire, AltoSa-XL PTA Balloon, Alto-Sa-XL Gemini Balloon, Optimus-CoCr stent, Optimus-CVS PTFE covered stent)
41372438|NCT03704194|BEHAVIORAL|Adapted LiFE|The standardized components include presenting the Adapted LiFE user manual to participants, and teach participants to embed the exercise activities in their daily routine with the LiFE activity calendar.
41372439|NCT03704194|BEHAVIORAL|Attention control|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
41372440|NCT00387101|DEVICE|Dermal - Living Skin Replacement (Dermal - LSR)|
41372441|NCT03143712|DRUG|GLPG1690|Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
41031386|NCT01872260|DRUG|Letrozole|Letrozole 2.5 mg/day
41031387|NCT01872260|DRUG|BYL719|BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
41031388|NCT00804947|DRUG|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
41031389|NCT05854381|BIOLOGICAL|VIR-1388|VIR-1388 is given by subcutaneous injection
41031390|NCT05854381|BIOLOGICAL|Placebo|The HT Diluent Placebo is HT buffer (20 mM histidine, 10% trehalose-dihydrate, pH 7.2) and contains no active ingredient and will be administered by subcutaneous injection
41031391|NCT04486352|DRUG|Atezolizumab - 28 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.
41031392|NCT04486352|DRUG|Bevacizumab|Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.
41031393|NCT04486352|DRUG|Ipatasertib|Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.
41163016|NCT02174614|BEHAVIORAL|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
41031394|NCT04486352|DRUG|Talazoparib|Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.
41163017|NCT02174614|BEHAVIORAL|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
41163018|NCT04935918|DEVICE|ACT|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck. The ACT system is a permanent implant designed for the correction of incontinence in patients.
41163019|NCT03065205|DEVICE|Propeller Health device + asthma navigator|The patients will be monitored using the propeller health device for 6 months. The patients will be contacted at 2 month intervals by an asthma health educator to discuss barriers to adherence to asthma medications
41163020|NCT01580007|DRUG|Active Sodium Phenylbutyrate and active cholecalciferol|Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
41163021|NCT01580007|DRUG|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
41163022|NCT01580007|DRUG|Active Sodium Phenylbutyrate and placebo cholecalciferol|Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
41031395|NCT04486352|DRUG|Trastuzumab emtansine|Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.
41031396|NCT04486352|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.
41163023|NCT01580007|DRUG|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
41031397|NCT04486352|DRUG|Atezolizumab - 21 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.
41031398|NCT04486352|DRUG|Inavolisib|Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.
41163024|NCT01792583|DRUG|Modafinil/armodafinil|
41163025|NCT00418418|PROCEDURE|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
41163026|NCT00418418|PROCEDURE|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
41163027|NCT00418418|BIOLOGICAL|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
41163028|NCT00418418|BIOLOGICAL|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
41163029|NCT06332300|DRUG|Adebelimumab+Famitinib + FOLFIRI+Ariely|Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy
41163030|NCT02271659|RADIATION|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
41372442|NCT03142282|DRUG|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
41372443|NCT03142282|RADIATION|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
41372444|NCT05486975|BIOLOGICAL|CT0591CP Cells|CT0591CP cells
41372445|NCT02861248|PROCEDURE|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60-90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50-80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8-16 weeks.
41372446|NCT06343922|BEHAVIORAL|oral motor facilitation technique group|oral motor facilitation technique
41372447|NCT06343922|OTHER|traditional oral motor exercises group|traditional oral motor exercises
41372448|NCT03455400|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.
41372449|NCT04669275|BEHAVIORAL|Telephone Counselıng|Telephone counseling
41372450|NCT01173666|PROCEDURE|stenting angioplasty plus medical therapy|Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
41372451|NCT01173666|DRUG|Medical therapy|Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
40848703|NCT03939936|OTHER|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
40848704|NCT03939936|OTHER|saliva samples|Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
40848705|NCT02168608|OTHER|Remote ischemia precondition|Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.
41031399|NCT04486352|DRUG|Letrozole|Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.
41031400|NCT04486352|DRUG|Giredestrant|Giredestrant will be given orally at a dosage of 30 mg once daily for each day of the 28-day cycle.
41031401|NCT04486352|DRUG|Abemaciclib|Giredestrant will be given orally at a dosage of 150 mg twice daily for each day of the 28-day cycle.
41031402|NCT05733988|PROCEDURE|Bailout edge to edge|Edge to edge repair is the suture of the mitral valve leaflets in the regurgitant spot. It can be used as a bailout procedure when the first attempt of mitral valve repair with other surgical techniques is not satisfactory at intraoperative echo control. In this case, a second run of cardiopulmonary bypass is carried out, the heart is reopened and an edge-to-edge is performed.
41031403|NCT00690521|DRUG|Treatment of Furosemide + Hydrochlorothiazide|A randomized, double-blind, crossover study designed to compare the efficacy of hydrochlorothiazide in combination with stable doses of furosemide in congestive heart failure patients.
41031404|NCT00690521|DRUG|Treatment of Furosemide + Metolazone|A randomized, double-blind, crossover study designed to compare the efficacy of metolazone in combination with stable doses of furosemide in congestive heart failure patients.
41504106|NCT04769531|OTHER|Hip Joint Mobilizations|i. Anterior-posterior glide ii. Posterior-anterior glide iii. Caudal glide iv. Posterior-anterior glide with Abduction, flexion, and lateral rotation
40848706|NCT02168608|OTHER|None remote ischemia precondition|Placed an uninflated cuff on the right upper arm for 30 min.
40848707|NCT02146625|DRUG|CJ-40002|
40848708|NCT00017407|BIOLOGICAL|ISIS 3521|
40848709|NCT00017407|DRUG|carboplatin|
40848710|NCT00017407|DRUG|paclitaxel|
40848711|NCT03207633|PROCEDURE|Repetitive trans-magnetic stimulation (rTMS) on DLPFC|Repetitive trans-magnetic stimulation (rTMS) on DLPFC
40848712|NCT03207633|PROCEDURE|Repetitive trans-magnetic stimulation (rTMS) on OFC|Repetitive trans-magnetic stimulation (rTMS) on OFC
40848713|NCT03207633|PROCEDURE|Sham repetitive trans-magnetic stimulation (rTMS)|Sham repetitive trans-magnetic stimulation (rTMS)
40848714|NCT00408434|DRUG|CS-7017|CS-7017 0.05mg and 1.0mg tablets
40848715|NCT02731443|PROCEDURE|Epilepsy surgery|Epilepsy surgery is a procedure that removes an area of the brain where seizures originate.
40848716|NCT02731443|PROCEDURE|Depth electrodes insertion|Depth electrodes are inserted for monitoring/mapping the subsurface levels of the brain for the surgical treatment of epilepsy.
41031405|NCT06029907|OTHER|Smoking cessation and pain management intervention|Patients will receive a behavioral smoking cessation and pain management intervention
41031406|NCT06029907|DRUG|Varenicline|Patients will receive varenicline prescribed by their oncologist
41031407|NCT03579563|OTHER|AUD fitting|Prescription hearing aids will be fitted by audiologists using established procedures.
41031408|NCT03579563|OTHER|OTC+ fitting|Audiology professionals provide brief services to fit preset-based OTC hearing aids, which are simulated using prescription hearing aids.
41372452|NCT03006042|DRUG|Bupivacaine|
41372453|NCT02111473|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
41372454|NCT05416268|DIAGNOSTIC_TEST|Electroretinography|Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).
41372455|NCT00212446|DEVICE|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
41504107|NCT04769531|OTHER|Hip joint Muscle strength training|i. Hip abduction in side-lying ii. Hip extension in the prone position iii. Sideways walk iv. Hip abduction in stand up position v. Hip hitching
41504108|NCT04769531|OTHER|knee strengthening and flexibility exercises|"i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:"
41372456|NCT02201732|PROCEDURE|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
41372457|NCT02201732|PROCEDURE|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
41372458|NCT01578109|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
41372459|NCT01578109|DRUG|Sorafenib|Given PO
41372460|NCT01578109|DRUG|Sorafenib Tosylate|Given PO
41372461|NCT03142984|OTHER|Cosmetic Products|"Phase 1:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
41372462|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-Ib)|"Phase Ib:~- Ipilimumab will be administered in a 3 + 3 dose escalation design.~* The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).~* If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.~* The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.~* In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.~* Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual."
41372463|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-II)|"Phase II:~- Interleukin-2 \& Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D)."
41372464|NCT01891227|DRUG|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
41372465|NCT01891227|DRUG|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
41372466|NCT01150149|BEHAVIORAL|No face touch|
41031409|NCT03579563|OTHER|OTC fitting|In this group, preset-based OTC hearing aids, which are simulated using prescription hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
41031410|NCT03579563|DEVICE|High-end HA|High-end hearing aids will be used.
41372467|NCT01150149|DEVICE|Surgical face mask|
41031411|NCT03579563|DEVICE|Low-end HA|Low-end hearing aids will be used.
41031412|NCT03351374|OTHER|Software|multi-module system of web software tools
41031413|NCT03547661|OTHER|P-Dragees rosa Lichtenstein|Placebo dragées
41031414|NCT04543929|BEHAVIORAL|exercise|partially supervised and home-based exercise activity
41031415|NCT05515341|DEVICE|Commercially Approved Interventional Medical Device/Therapy for Chronic Pain|Commercially Approved Interventional Medical Device/Therapy
41031416|NCT05959551|DEVICE|high definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.
41031417|NCT04090307|BEHAVIORAL|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for \~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
41031418|NCT00324623|BIOLOGICAL|Melan-A VLP vaccine, IMP321 adjuvant|
41163031|NCT02271659|RADIATION|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
41163032|NCT05042713|OTHER|WaveOne Gold, One Curve, OneFlare|During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.
41163033|NCT01508832|DRUG|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
41163034|NCT01508832|DRUG|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
41031419|NCT00324623|BIOLOGICAL|adoptive immunotherapy|
41031420|NCT00324623|BIOLOGICAL|therapeutic autologous lymphocytes|
41031421|NCT00324623|DRUG|cyclophosphamide|
41031422|NCT00324623|DRUG|fludarabine phosphate|
41031423|NCT05859100|OTHER|≥ 2 eggs in addition to usual diet for 8 weeks|Participants are expected to consume≥ 2 eggs per day in addition to usual diet for 8 weeks in early intervention arm, beginning immediately post-treatment.
41031424|NCT05859100|OTHER|≥ 2 eggs in addition to usual diet for 4 weeks|Participants are expected to continue intake of regular diet beginning immediately at post-treatment recovery for a duration of 4 weeks, then crossover to nutritional intervention arm from weeks 5 to 8 of post-treatment recovery for a duration of 4 weeks.
41372468|NCT01150149|DEVICE|Surgical face mask + no face touch|
41372469|NCT04551612|RADIATION|Multislice computed tomography temporal bone|Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
41372470|NCT05229718|OTHER|Diabetes Collaborative Care Model for Young Adults|We designed a diabetes collaborative care model for young adults that incorporates a mental health provider alongside a diabetes care provider during joint office visits to facilitate screening and treatment of psychosocial determinants of diabetes management. The Massachusetts General Hospital (MGH) Diabetes Center will be piloting this model with a multi-disciplinary team of diabetologists, nurse practitioners, diabetes nurse educators, and mental health provider. Patients scheduled to be seen in the diabetes collaborative care model will continue to follow in the diabetes collaborative care model, with follow up visits every 3-4 months. All patients will receive routine diabetes care with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers.
41163035|NCT02652377|DRUG|EDP-494|10, 100 and 200 mg capsules
41163036|NCT02652377|DRUG|Placebo|placebo to match EDP-494
41372471|NCT05229718|OTHER|Usual Care Model|Patients enrolled in this arm will receive routine diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center, with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers. In the usual care model, behavioral/mental health and social work services are available on a referral basis and are not integrated into a patients' routine appointment. Screening and treatment of psychosocial determinants of diabetes management are at done at the discretion of the patients' provider. Frequency of follow up visits is at the discretion of the patients' provider.
41372472|NCT05186116|PROCEDURE|Living donor liver transplant, Split liver transplant, RAPID, DDLT|Transplantation of part of the liver from a living donor, or entire cadaveric graft
41372473|NCT02395757|DEVICE|MAIA™ (Centervue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|"An automatic microperimetry exam of the 10° central macular coverage expert test (customized grid) will be performed with the MAIA™ device at each semi-annual follow-up visit."
41372474|NCT06452420|OTHER|Traumatic dental injuries|The Degree of knowledge and Attitude of Medical Residents and Interns in Egypt regarding Emergency treatment of traumatic dental injuries.
41372475|NCT03452722|DRUG|intraventricual recombinant tissue plasminogen activator application|
41504109|NCT04743492|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.
40848717|NCT06136065|DIAGNOSTIC_TEST|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography scan
40848718|NCT04457492|OTHER|Application of FES to the Face|Functional electrical stimulation (FES) for facial paralysis is a technique in which muscles are electrically stimulated.
40848719|NCT05452304|BIOLOGICAL|AZD7798|Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.
41372476|NCT00577382|DRUG|Sunitinib|
41504110|NCT04035915|PROCEDURE|Limited driving pressure|Keep driving pressure \<15 cmH2O
41504111|NCT04035915|PROCEDURE|Conventional mechanical ventilation strategies|Keep tidalvolume \</= 8
41504112|NCT02354794|DIETARY_SUPPLEMENT|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
41504113|NCT02354794|DIETARY_SUPPLEMENT|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
41504114|NCT05321641|BEHAVIORAL|Mobile phone message reminders.|Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.
40848720|NCT05452304|BIOLOGICAL|Placebo|Subjects will receive placebo matching the AZD7798 dose as a single ascending dose or as a repeat dose.
40848721|NCT03866564|DIAGNOSTIC_TEST|Echocardiography|Cardiac ultrasound to measure left ventricular systolic function.
40848722|NCT03866564|DIAGNOSTIC_TEST|Neuropsychological Testing|Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.
40848723|NCT03866564|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Clinically accepted quantitative assessment of chronic pain burden.
41372477|NCT06015061|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in PPGL tumors.
41372478|NCT03456557|RADIATION|Perfusion computed tomography.|Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
41372479|NCT05151874|DRUG|Abobotulinum toxin A|To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.
41372480|NCT06418789|DRUG|High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )|"TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest. Leukapheresis will be performed starting on day 11 in case blood level of CD45+CD34+ above 20x10\^6/L is achieved.~CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m\^2 IV daily days -4 to -2, autlologous stemm cell transplantation \>=2\*10\^6/Kg at day 0, GCSF support from day 4 until the recovery of neutrophils above 1\*10\^9/L.~Patients will receive two cycles of TI followed by 3 cycles of CE in case at least 6\*10\^6 CD34+ stem cells will be harvested."
41504115|NCT05222698|PROCEDURE|Facial reanimation surgery by free muscle trasfer.|Muscle flap harvesting from the back or from the thigh to be insetted to the paralyzed side of the face with microvascular anastomosis of the muscle pedicle to facial artery and vein.
41504116|NCT04249869|DRUG|VGH-AD1|VGH-AD1 includes Yi-gan-san 3.0g, Huan-shao-dan 1.0g, Danshen(Radix et Rhizoma Salviae Miltiorrhizae) 0.75g, Tian-ma(Rhizoma Gastrodiae) 0.75g, Gou-teng(Ramulus Uncariae Cum Uneis) 0.375g, and Ba-ji-tian(Radix Morindae Officinalis) 0.375g, two times per day, each serving a small packet of 7.5 grams of concentrated granules.
40848724|NCT03866564|DIAGNOSTIC_TEST|Nocturnal Polysomnography|Routine overnight sleep study to measure apnea-hypopnea index.
41163037|NCT05212311|DEVICE|Chitosan Phonophoresis|Therapeutic pulsed ultrasound using EMS physio Ltd ultrasound device in presence of chitosan gel will be applied over the elbow. The following parameters will be used: US treatment was applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2.
41372481|NCT04908696|PROCEDURE|routines|"For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery (CO2 laser resection), open partial laryngectomy (vertical partial laryngectomy, cricohyoidoepiglottopexy, cricohyoidopexy, horizontal partial laryngectomy), partial hypopharyngectomy, radiotherapy, and transoral robotic surgery were performed for patients with proper indications (NCCN 2020).~For advanced stage laryngeal carcinoma and hypohparyngeal carcinoma (T3 and T4), surgical treatment ± postoperative adjuvant therapy, concurrent chemoradiotherapy, neoadjuvant therapy + radiotherapy/chemoradiotherapy, or neoadjuvant therapy + surgery + radiotherapy or chemoradiotherapy were performed for patients with proper indications (NCCN 2020)."
41372482|NCT01564680|OTHER|placebo|normal saline
41163038|NCT05212311|DEVICE|Therapeutic Ultrasound|US treatment will be applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2 using aquasonic gel.
41372483|NCT01564680|DRUG|Paracetamol|IV paracetamol infusion
41372484|NCT01564680|DRUG|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
41504117|NCT03996629|OTHER|Patient education and compliance|When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
41504118|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 1
41163039|NCT05212311|DEVICE|Splinting|"Splinting the elbow in comfortable flexion (40-70), forearm and wrist in neutral (slight forearm pronation and wrist flexion if symptoms are severe), can allow the nerve and surrounding supporting structures the rest and relief from compression and traction.~The elbow portion of the splint should be well padded or ''bubbled out'' to provide pressure relief for the area of the cubital tunnel. It may be necessary to splint the ulnar digits of the hand to prevent contracture, maintain passive and active range of motion, and improve hand function. If the motor branch of the nerve is sufficiently involved to cause muscle denervation, a hand-based intrinsic plus splint or the use of finger-based splints to prevent clawing of the ring and small fingers will provide balanced positioning of the affected structures."
41163040|NCT05212311|OTHER|Neural mobilization exercises of the ulnar nerve|Nerve mobilization exercises Inflammation or adhesions anywhere along the ulnar nerve path can cause the nerve to have limited mobility and essentially get stuck in one place. These exercises help stretch the ulnar nerve and encourage movement through the cubital tunnel
41163041|NCT06462612|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
41504119|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 2
41504120|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 3
41504121|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 4
41504122|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 5
41504123|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 6
41504124|NCT04187339|OTHER|Placebo|Placebo
41504125|NCT01193179|DRUG|OPC-262|Oral administration of tablets for 52 weeks
41504126|NCT03929991|OTHER|Observational|To record social and clinical characteristics
41163042|NCT06462612|DRUG|Placebo|Matching capsules administered orally, once daily
41163043|NCT00107081|DRUG|ciprofloxacin and amoxicillin|
41372485|NCT01165892|DRUG|Gadofosveset Triodium|Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
41372486|NCT03294811|DEVICE|Telemonitoring|The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
41372487|NCT01156129|DRUG|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
41504127|NCT06189976|DIAGNOSTIC_TEST|Rapid atrial pacing|Rapid atrial pacing after TAVI
41504128|NCT02735785|BEHAVIORAL|Harnessing Online Peer Education (HOPE) Social Media Intervention|
41504129|NCT04505956|DEVICE|Holmium laser lithotripsy with Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned on.
41504130|NCT04505956|DEVICE|Holmium laser lithotripsy without Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned off.
41504131|NCT03009773|OTHER|rehabilitation multitasking walking.|rehabilitation multitasking walking.
41504132|NCT03009773|OTHER|Traditional walking rehabilitation|Traditional walking rehabilitation
41504133|NCT04880473|DEVICE|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
41504134|NCT06065215|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that uses powerful magnets and radio waves to generate detailed images of the body's internal structures. The MRI intervention includes using a specialized MRI machine and lung imaging protocol.
41163044|NCT00107081|PROCEDURE|Outpatient management|
41163045|NCT00107081|DRUG|i.v. antibiotics|
41163046|NCT00107081|PROCEDURE|inpatient management|
41163047|NCT01565252|DIETARY_SUPPLEMENT|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
41163048|NCT06392919|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS intervention timing: rTMS is applied after the tracheal tube is removed in the PACU. Stimulation site: DLPFC (left dorsolateral prefrontal cortex); Stimulation intensity: 100% RMT; Stimulation frequency: 10Hz; Total number of stimulation pulses: 2000. Pulse characteristics: Each duration lasts 5 seconds, with a 25-second interval.
41163049|NCT04116242|OTHER|blood sampling for research purpose|blood sampling for research purpose (about 30ml) taken by venepuncture or from intravenous catheters if already in place
41163050|NCT04116242|OTHER|clinical data collection|clinical data collection in order to document the stage of disease, the presence of infection and existing complications of cirrhosis (ascites, hepatic encephalopathy, renal dysfunction, pulmonary dysfunction) and concomitant disease. These data will be collected for clinical reasons as highly important in the context of patients with cirrhosis and possible decompensation or liver failure and will therefore not require additional time
41163051|NCT04116242|OTHER|Health-related Questionnaires|Health-related Questionnaires (Questionnaire_CLD) regarding sleep characteristics (Pittsburgh sleep Quality index, PSQI), daytime sleepiness (Epworth sleepiness scale, ESS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS) and quality of life (EQ-5D-5L)
41163052|NCT04116242|OTHER|Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)|Other biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies) will only be investigated if sampled for clinical reasons and if excessive material is available that is not needed for clinical purpose.
41163053|NCT04719468|OTHER|Dance with ballet elements|Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.
41163054|NCT02306213|DRUG|Hydroxyethylstarch 6% 130/0.4|Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
41163055|NCT02306213|OTHER|standard volume therapy|
41163056|NCT06331533|DRUG|Botulinum toxin A|Intradermal botulinum toxin A was applied to the treatment side
41163057|NCT06331533|DRUG|Placebo|NaCl was injected into the placebo side
41163058|NCT04964778|DEVICE|SKED©|A SKED device is lightweight plastic stretcher used for moving patients through difficult terrain.
41163059|NCT00632723|DRUG|gefitinib (IRESSA™, ZD1839)|250 mg tablet; daily dose 500 mg daily
41163060|NCT00478998|DRUG|Tamsulosin|
41163061|NCT06320847|DIAGNOSTIC_TEST|rPPG|A pulse oximeter and blood pressure cuff will be applied on the study patient by the study team member (research coordinators). At the same time, vital signs from Nervotec's rPPG technology will be recorded via the laptop and webcam. Synchronous measurement process of heart rate, respiration rate, pulse oximetry, heart rate variability and blood pressure estimates using Nervotec rPPG technology will take place for a duration of 3 minutes.
41163062|NCT03626311|DIETARY_SUPPLEMENT|AKBM-3031|"Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction.~The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use."
41163063|NCT03626311|OTHER|Placebo|The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
41372488|NCT01156129|DEVICE|Arm B: Acupressure bracelet|Bioband
41372489|NCT01156129|DIETARY_SUPPLEMENT|sugar free gum|Orbit
41163064|NCT00825734|DRUG|Sorafenib|Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
41163065|NCT00825734|DRUG|Ixabepilone|Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)
41163066|NCT04653207|OTHER|Glucose Solution 1|50g glucose dissolve in 300ml of water
41163067|NCT04653207|OTHER|Glucose Solution 2|50g glucose dissolve in 300ml of water
41163068|NCT04653207|OTHER|Glucose Solution 3|50g glucose dissolve in 300ml of water
40848725|NCT05639530|BIOLOGICAL|IBI333|Intravitreal injection of IBI333
41163069|NCT04653207|OTHER|Sucrose/Isomaltulose 100:0|50g sucrose dissolve in 300ml of water
41163070|NCT04653207|OTHER|Sucrose/Isomaltulose 0:100|50g isomaltulose dissolve in 300ml of water
41372490|NCT02866721|BIOLOGICAL|Mesenchymal Stem Cells|"A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10\^6, 3 x 10\^6 or 5 x 10\^6 human mesenchymal stem cells per kilogram body weight (hMSCs/kg) during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic mesenchymal stem cells (MSCs) will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of cystic fibrosis lung infection and inflammation."
41163071|NCT04653207|OTHER|Sucrose/Isomaltulose 50:50|25g sucrose and 25g isomaltulose dissolve in 300ml of water
41031425|NCT05811338|BEHAVIORAL|Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement|The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.
41031426|NCT05811338|BEHAVIORAL|Project 2, Phase 2: Intelligent Adaptive System|An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.
41031427|NCT05811338|BEHAVIORAL|Project 3, Phase 3: Intelligent Decision Support Tool|An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
41031428|NCT04088097|BEHAVIORAL|Cognitive-Behavioral Therapy for Adolescent Binge/Loss-of-Control Eating|Cognitive-behavioral therapy (CBT) developed for adolescents with binge eating or loss-of-control eating.
41163072|NCT04653207|OTHER|Sucrose/Isomaltulose 60:40|30g sucrose and 20g isomaltulose dissolve in 300ml of water
41163073|NCT04653207|OTHER|Sucrose/Isomaltulose 70:30|35g sucrose and 15g isomaltulose dissolve in 300ml of water
41163074|NCT04653207|OTHER|Sucrose/Isomaltulose 80:20|40g sucrose and 10g isomaltulose dissolve in 300ml of water
41372491|NCT01878968|OTHER|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
41504135|NCT06065215|DIAGNOSTIC_TEST|Echocardiogram|"An echocardiogram, often called an echo, is a non-invasive medical test that uses high-frequency sound waves (ultrasound) to create real-time images of the heart's structure and function. It provides valuable information about the heart's size, shape, and function."
41031429|NCT04088097|OTHER|Control Condition|Educational and informational materials on adolescent health and nutrition.
41031430|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 1|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331) three times a day before meal.
41031431|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 2|Subjects take probiotics capsule(Lactobacillus reuteri,TSR332) three times a day before meal.
41031432|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 3|Subjects take probiotics capsule(Lactobacillus plantarum,TSP05) three times a day before meal.
41031433|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 4|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05) three times a day before meal.
41031434|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 5|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05+Postbiotics PE0401) three times a day before meal.
41031435|NCT06183801|DIETARY_SUPPLEMENT|Placebo 1|Subjects take capsule three times a day before meal.
41031436|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 6|After 1 month wash out, subjects take probiotics capsule(Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
41031437|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 7|After 1 month wash out, subjects take probiotics capsule(Lactobacillus rhamnosus, bv-77+Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
41031438|NCT06183801|DIETARY_SUPPLEMENT|Placebo 2|After 1 month wash out, subjects take capsule three times a day before meal.
41163075|NCT06419322|OTHER|Optimized rehabilitation program|Consisting of: goal-oriented rehabilitation, hands on physiotherapy sessions and home use of SMA approved rehabilitation device.
41163076|NCT01530477|DEVICE|Lunar Prodigy (GEHC)|Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements
41163077|NCT01530477|DEVICE|Lunar iDXA (GEHC)|Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements
41163078|NCT01530477|DEVICE|Discovery A (Hologic|Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements
41163079|NCT03925662|DRUG|Folfox with avastin|Folfox with avastin only
41163080|NCT03925662|DRUG|Mebendazole|Folfox with avastin with mebendazole
41163081|NCT04967586|OTHER|No intervention, questioner only|questioner only
41163082|NCT00644332|DRUG|Ranolazine|Oral dosage form.
41163083|NCT04041661|OTHER|Active tDCS plus gait training|Participants in experimental group will accept Active tDCS which combined with treadmill
41163084|NCT04041661|OTHER|Sham tDCS plus gait training|Participants in control group will accept Sham tDCS which combined with treadmill
41163085|NCT02754310|OTHER|Variation of scenarios|Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.
41163086|NCT02754310|OTHER|Repeated scenarios|The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
41163087|NCT02874248|DRUG|15 mg E4/3 mg DRSP|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
41372492|NCT01481480|PROCEDURE|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
41372493|NCT01481480|PROCEDURE|Arthroscopic repair|Arthroscopic repair
41504136|NCT06065215|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound is a non-invasive imaging technique that employs high-frequency sound waves (ultrasound) to visualize the structures and conditions of the lungs. It is particularly valuable for diagnosing and monitoring lung-related conditions, such as pneumonia, pleural effusions, and pulmonary edema. The lung ultrasound intervention involves using an ultrasound machine equipped with a specialized probe gently placed on the chest to capture detailed images of the lungs and adjacent structures.
41504137|NCT04585230|DRUG|CBD|CBD oil Roll-On Stick
41504138|NCT04585230|DRUG|Mineral Oil|Mineral Oil- Roll on Stick
40848726|NCT03348176|OTHER|Vegetable exposure|Repeated exposure to variety of vegetables
41163088|NCT02874248|DRUG|30 mg E4/6 mg DRSP|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
41163089|NCT02874248|DRUG|60 mg E4/12 mg DRSP|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
41163090|NCT02874248|DRUG|Visually matching placebo|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
41504139|NCT04585230|DRUG|Placebo|Roll- On stick with no CBD and no Mineral Oil
41031439|NCT04272450|DIAGNOSTIC_TEST|respiratory muscle strenght measurement|Maximum inspiratory pressure-maximum expiratory pressure. The mouth pressure measurement was performed with the Micro-RPM® instrument from SensorMEDIC. Patient placed a rubber mouthpiece with flanges, on the device, sealed their lips firmly around the mouthpiece, exhaled/inhaled slowly and completely and then tried to breath in as hard as possible. The patient was allowed to rest for about a minute and the maneuver was repeated.
41031440|NCT06432127|DRUG|Placebo|Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using normal saline 3 mL
41031441|NCT06432127|DRUG|Bupivacaine|Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using 0.5% Bupivacaine 3 mL
41031442|NCT06627283|DEVICE|IMT|Description: A pressure threshold loading device will be used: the POWERbreathe Medic (load range 10-90 cmH2O). Participants will be instructed to exhale passively during normal tidal breathing through the training device (until functional residual capacity) and to perform deep inspirations against the external load. The first week, the resistance will be fixed at 30% of the baseline measured maximal inspiratory pressure (MIP). Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
41031443|NCT06627283|DEVICE|EMT|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic (load range 10-90 cmH2O) or POWERbreathe Ex1 EMT MR (load range 35-175 cmH2O) depending on their baseline MEP measurement. Participants will be instructed to inhale quietly during normal tidal breathing through the training device and to perform rapid and deep exhalation against the external load. The first week, the resistance will be fixed at 30% of the baseline measured MEP. Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
41031444|NCT06627283|DEVICE|Sham|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic or MR, but with the resistance mechanism inside removed and replaced by a plastic ball. The same instructions will be given as for the EMT group, except that there will be no or minimal resistance (less than 6 cmH2O). There will be no change in resistance over the weeks.
41031445|NCT05542355|DRUG|EXL01|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
41031446|NCT05542355|DRUG|Placebo|Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
41031447|NCT05542355|OTHER|SoC corticosteroid - Induction Period|Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
41031448|NCT05542355|OTHER|SoC corticosteroid - Tapering|"Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop."
41031449|NCT06609239|DRUG|Lunsekimig|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
41031450|NCT02765529|PROCEDURE|Blood sampling|
41031451|NCT06634979|PROCEDURE|Selective lymph node dissection|For 0.5 \< CTR \< 1 and ≤ 2 cm diameter cT1N0M0 invasive non-small cell lung cancer patient sex for selective lymph node (lower mediastinal lymph nodes are not required to be cleared for upper lobe tumors and upper mediastinal lymph nodes are not required to be cleared for lower lobe tumors)
41031452|NCT00880932|BEHAVIORAL|Electronic Alert|
41031453|NCT04208022|OTHER|Respiratory evaluation|Hypermobility and Respiratory evaluation
41031454|NCT01072682|DEVICE|Selective cytopheretic device (SCD)|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
41031455|NCT01761747|DRUG|ponatinib|
41163091|NCT02874248|DRUG|75 mg E4/15 mg DRSP|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
41163092|NCT06255912|DRUG|LTC004 + MIL-97|Dose group 1：MIL97:0.2mg/kg,Day1,Q3W,LTC004:90ug/kg,Day3,Q3W Dose group 2:MIL97:0.2mg/kg,Day1,Q3W,LTC004:180ug/kg,Day3,Q3W Dose group -1:MIL97:0.2mg/kg,Day1,Q3W,LTC004:45ug/kg,Day3,Q3W
41163093|NCT06255912|DRUG|LTC004 + MIL-97+chemotherapy|LTC004 + MIL-97+chemotherapy
41163094|NCT01828398|DEVICE|real-tDCS + UE robot-assisted therapy|
41163095|NCT01828398|DEVICE|sham-tDCS + UE robot-assisted therapy|
41163096|NCT03787238|DEVICE|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation using the gammaCore Sapphire device
41163097|NCT05470361|PROCEDURE|stellate ganglion block (SGB)|The protocol for the SGB plus SCGB will be followed, wherein participants are given right-side procedures followed by left-side procedures on a different day if no initial improvement is seen. This procedure is carried out by injecting a local anesthetic into the neck to target the Stellate Ganglion and Superior Cervical Ganglion nerve bundles.
41031456|NCT02271386|BEHAVIORAL|Supporting Practice for ADHD (SPA)|"The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.~3) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period."
41504140|NCT06633978|DEVICE|MediTrain|Participants will engage with a digital meditation app for 30m/day for 6wks. MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
41504141|NCT06633978|DEVICE|wrist worn multi-sensor watches|Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
41504142|NCT06633978|DEVICE|Sleep monitor|Sleep Profiler devices are FDA-cleared reduced-montage EEG recording devices that will be used in accordance with its FDA clearance. They are completely non-invasive and are designed to be comfortable enough to wear all night without interfering with normal sleep. These devices enable quality sleep recordings in the comfort of people's homes, rather than required an overnight stay at a sleep lab at UCSF.
41504143|NCT01924559|OTHER|standard clothing|
41504144|NCT01924559|OTHER|Biohazard gear|
41504145|NCT01924559|DEVICE|Direct Laryngoscopy|
41504146|NCT01924559|DEVICE|Glidescope|
41504147|NCT01924559|DEVICE|Supraglottic Airway|
41504148|NCT05308082|BEHAVIORAL|Dance Movement Therapy (DMT)|The main Dance Movement Therapy (DMT) methods were dance-movement improvisations, body awareness exercises, and reflection through drawing/painting, writing, and verbalization. There was an orientation to personal space and body awareness, interaction in pairs, and interaction in the whole group. The themes included exploration of boundaries, somatic resources, symbols, pleasant and unpleasant emotions, mindfulness, and body awareness, enriched movement experiences, and safety and touch. In the present study, it consists of six sessions, including (1) Movement for Self-expression, (2) Movement for Emotional Health I, (3) Movement for Emotional Health II, (4) Movement for Connection \& Creativity, (5) Embracing your Dancing Child, and (6) Movement for Self-compassion.
41504149|NCT04263324|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care.
41504150|NCT04360538|OTHER|Quality of Life|Physical disability assessment tool
41504151|NCT04360538|OTHER|Impact Event Score|Psychological Sequelae assessment tool
41031457|NCT03320447|DRUG|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
41031458|NCT03320447|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
41031459|NCT03320447|DRUG|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
41031460|NCT03320447|DEVICE|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
41031461|NCT04855734|BEHAVIORAL|FAmily CEntered (FACE) pACP Intervention|The (approximately) weekly 3-session FACE-Rare intervention of approximately 45-60 minutes each is comprised of the CSNAT approach \[Sessions 1 \& 2\] and Respecting Choices \[Session 3\].
41031462|NCT02494284|DRUG|Clopidogrel|6-month DAPT followed by clopidogrel monotherapy
41031463|NCT02494284|DRUG|Aspirin plus clopidogrel|standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
41031464|NCT05155826|DEVICE|Virtual Reality Headset|The patient will benefit from the placement of Cook's balloon (standard care) with the placement of the virtual reality headset on the examination table with the launch of the software before the beginning of the procedure. The virtual reality helmet will be removed at the end of the procedure.
41031465|NCT02073084|DRUG|K-877 Low Dose|K-877 Low Dose
41504152|NCT04360538|OTHER|Hospital anxiety and depression scale|Psychological Sequelae assessment tool
41504153|NCT05478577|OTHER|Motor rehabilitation|Treatments for upper limb recovery (e.g. occupational therapy, technology devices, conventional therapy)
41504154|NCT03712878|RADIATION|Total-Body Irradiation|Undergo TBI
41504155|NCT03712878|PROCEDURE|Donor Lymphocyte Infusion|Given IV
41504156|NCT03712878|DRUG|Cyclophosphamide|Given IV
41504157|NCT03712878|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
41504158|NCT03712878|DRUG|Tacrolimus|Given IV
41504159|NCT03712878|DRUG|Mycophenolate Mofetil|Given IV
41031466|NCT02073084|DRUG|Moxifloxacin|
41031467|NCT02073084|OTHER|Placebo|
41031468|NCT02073084|DRUG|K-877 High Dose|K-877 High Dose
41031469|NCT05082090|PROCEDURE|Spinal Surgery|Implanted with Orthofix Spinal products
41031470|NCT01757769|DRUG|Silodosin|8 mg daily for 24 weeks
41031471|NCT06499870|PROCEDURE|Biopsy|Undergo biopsy
41031472|NCT06499870|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41031473|NCT06499870|PROCEDURE|Computed Tomography|Undergo CT
41372494|NCT04845451|OTHER|Minimal surgical exploration for a neuroma|Orientation marking of the trigger point by injectable sterile methylene blue dye 0.1ml. Marking a 2-3-centimeter long incision line 7 mm from the Neuroma marking on the skin. Local anesthesia using plain 2% lidocaine infiltration of the circumferential exploratory area. Sterile prep and drape in surgical fashion. Meticulous exploratory preparation of the subcutaneous tissue 20 mm at each side of the incision line. Appropriate visibility of the ZT nerve branches embedded in lipomatous and connective tissue over the temporal fascia. Exploratory visualization of the subcutaneous marked tissue by methylene blue using a binocular magnification eases visualization. Using an Adson tissue forceps with side grasping teeth, now an exploratory touch of the above and distal of the marking would deliver the hypersensitive painful Neuroma tissue for sharp excision using surgical scissors. Control of bleeding and skin closure. Sterile pressure dressing. Specimen be sent to pathologic examination.
41372495|NCT03090945|OTHER|This is an obsevational cohort study|no intervention
41372496|NCT01904266|PROCEDURE|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
41372497|NCT01904266|PROCEDURE|GA + sham block|Injection of 1 cc saline subcutaneously
41372498|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|treatment drug
41372499|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg|treatment drug
41372500|NCT06181552|DIAGNOSTIC_TEST|fundus photograpgy|All the participants will undergo fundus photography.
41031474|NCT06499870|DRUG|Enzalutamide|Given PO
41031475|NCT06499870|OTHER|Fluorine F 18 Piflufolastat|Undergo fluorine F 18 piflufolastat PET/MRI
41031476|NCT06499870|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
41031477|NCT06499870|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
41031478|NCT06499870|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
41031479|NCT06499870|OTHER|Questionnaire Administration|Ancillary studies
41031480|NCT06499870|DRUG|Relugolix|Given PO
41031481|NCT02848417|DRUG|Curcumin|Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
41031482|NCT02848417|DRUG|Glutathione|Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
41031483|NCT02848417|OTHER|Placebo|"Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions."
41031484|NCT01981135|OTHER|Clean Air|Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
41031485|NCT01981135|OTHER|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
41031486|NCT01194674|DRUG|Microplasmin|Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
41031487|NCT02980367|OTHER|Non-Surgical Management (Rehabilitation)|Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
41372501|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography|All the participants will undergo OCT examination.
41372502|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography angiography|All the participants will undergo OCT-A examination.
41372503|NCT02706015|DRUG|Cefaliv® & Placebo|02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
40848727|NCT03348176|BEHAVIORAL|VIPP-Feeding Infants|Promoting responsive feeding practices
40848728|NCT03348176|OTHER|Control|Phone calls with mother about development of child, no advice on complementary feeding
41372504|NCT02706015|DRUG|Neosaldina® & Placebo|02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
41031488|NCT02980367|PROCEDURE|Surgical Management (Reconstruction)|All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
41031489|NCT00216684|DRUG|fentanyl|
41031490|NCT05660746|DEVICE|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
41031491|NCT05660746|DRUG|Infliximab|"Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool."
41031492|NCT00302224|DRUG|2S, 4R Ketoconazole (DIO-902)|
41031493|NCT04414670|PROCEDURE|C/S|laparoscopic or robotic metroplasty
41031494|NCT00968669|BIOLOGICAL|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
41372505|NCT01707667|DRUG|prucalopride|One 2 mg tablet orally administered on Day 1
41372506|NCT01707667|DRUG|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
41372507|NCT05935449|DEVICE|Formaderm Lidocaine|Dermal filler injection to facial areas
41372508|NCT05935449|DEVICE|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
41504160|NCT04094727|DRUG|Presumptive treatment with Artemether-lumefantrine (AL)|All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.
41504161|NCT04094727|OTHER|Enhanced vector control|"The mop up indoor residual spraying (IRS) campaign will be targeted to farms and cattle posts/kraals in intervention areas in December 2019 to fill gaps from the routine spray campaign (September to November 2019) and utilize the same insecticides and protocols as the national campaign. The team will spray each unsprayed structure with the recommended solution of dichloro-diphenyl-trichloroethane (DDT) for traditional structures and/or Actellic for modern structures, tarps and tents.~Alternative vector control interventions, including LLINs (long-lasting insecticide treated bed nets), sprayed tents/tarps and topical repellents will be distributed to eligible HRPs between November and January 2020 during one round."
41504162|NCT04686552|DIETARY_SUPPLEMENT|cinnamon|6 g of ground cinnamon
41504163|NCT06353542|DIAGNOSTIC_TEST|Software analysis|The tested AI software analyzes the optic disc retinography to determine if the patient is healthy, a glaucoma suspect, or a glaucoma case
40848729|NCT00373945|DRUG|Observational Study|
41031495|NCT00968669|BIOLOGICAL|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
41031496|NCT00968669|BIOLOGICAL|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
41031497|NCT00968669|OTHER|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
41031498|NCT04481048|DRUG|N-Acetyl cysteine|Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC).
41031499|NCT04481048|OTHER|Placebo|Eight (8) weeks of treatment with placebo.
41031500|NCT01458574|DRUG|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
41031501|NCT01458574|DRUG|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
40848730|NCT01642108|DRUG|Sitagliptin|50 mg once per day
40848731|NCT00003354|PROCEDURE|conventional surgery|
41031502|NCT01458574|DRUG|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
41031503|NCT00628732|DRUG|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
41031504|NCT04848038|BEHAVIORAL|Exercise|Standard public health exercise recommendations
41163098|NCT06140914|DIAGNOSTIC_TEST|Proteomics, miRNA studies and studies of blood cells from blood samples|This is an observational study where we follow patients and save blood samples and biopsies for analysis as described above.
41372509|NCT01726556|DEVICE|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
41372510|NCT01726556|DEVICE|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
41372511|NCT01261299|DRUG|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
41031505|NCT03631979|OTHER|Intestinal lavage with normal saline|Specially trained pediatric surgeon will administer 10ml/kg pre-warmed (37oC) normal saline via a single-use rectal tube of size 6FR twice per day, aiming at a depth of maximum 10 cm/kg, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. However, the intervention will be applied at a maximum of 2 weeks from birth.
41031506|NCT03958344|DRUG|Prednisolone|Oral Tablet
41163099|NCT00399503|PROCEDURE|Spectral T Wave Alternans|
41372512|NCT05806658|OTHER|Visual arts-based intervention|This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
41372513|NCT04802421|PROCEDURE|alveolar recruitment manoeuver|alveolar recruitment manoeuver are recommended during general anesthesia to prevent pulmonary atelectasis
40848732|NCT00003354|PROCEDURE|laparoscopic surgery|
40848733|NCT02123368|DRUG|Hyaluronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
40848734|NCT02123368|BIOLOGICAL|10 million Bone marrow mesenchimal stem cells|10 million of Bone marrow mesenchimal stem cells
40848735|NCT02123368|BIOLOGICAL|100 million Bone marrow mesenchimal stem cells|100 million of Bone marrow mesenchimal stem cells
40848736|NCT04688554|DIAGNOSTIC_TEST|fMRI and DTI|Neurologic imaging correlates
40848737|NCT04688554|BEHAVIORAL|Behavioral questionnaires|RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam
40848738|NCT04688554|BEHAVIORAL|Disease-Specific Patient-Reported Outcomes|Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)
40848739|NCT04688554|BEHAVIORAL|Behavioral tests|Behavioral tests may include one or more of the following procedures: Upper extremity testing, Perdue Peg Board testing, Hand tactile detection and discrimination test, Temperature and pain threshold testing, Lower extremity Testing, Myomotion Inertial Motion Testing.
40848740|NCT04161001|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
41031507|NCT03958344|DRUG|Triamcinolone + Betamethason|A compound long acting and short acting injectable steroid
41163100|NCT00399503|PROCEDURE|Modified Moving Average T Wave Alternans|
41163101|NCT00399503|PROCEDURE|Baroreceptor Sensitivity|
41372514|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with Autograft|Single Dose Autograft Surgical Implantation
41372515|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
41372516|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
41163102|NCT00399503|PROCEDURE|Heart Rate Variability|
40848741|NCT04161001|DRUG|Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
40848742|NCT04161001|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
40848743|NCT02541734|DRUG|Gelofusine|Infusion of gelofusine
40848744|NCT02541734|RADIATION|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
40848745|NCT02541734|DRUG|Placebo|
40848746|NCT03792568|OTHER|ALK Inhibitor|Any ALK inhibitor like crizotinib, alectinib and so on.
40848747|NCT01707082|DRUG|PF-06282999|Tablet, 10 mg, every 8 hours, 14 days
40848748|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
41163103|NCT00399503|PROCEDURE|Heart Rate Turbulence|
41163104|NCT00399503|PROCEDURE|Deceleration Capacity|
41163105|NCT00399503|PROCEDURE|Signal Averaged ECG|
41163106|NCT02110511|OTHER|blended lentils|blended lentils burritto breakfast
41163107|NCT02110511|OTHER|whole lentils|whole lentils breakfast burritto
41163108|NCT02110511|OTHER|no lentils|No lentils control breakfast burritto
40848749|NCT01707082|DRUG|PF-06282999|Tablet, 30 mg, every 8 hours, 14 days
40848750|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
40848751|NCT01707082|DRUG|PF-06282999|Tablet, 100 mg, every 8 hours, 14 days
40848752|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
40848753|NCT01707082|DRUG|PF-06282999|Tablet, 250 mg, every 8 hours, 14 days
40848754|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
41163109|NCT00487513|PROCEDURE|Procurement of Follicular B Cell Lymphoma Cells|Participants will undergo the following procedure(s) that are appropriate for collecting their tissue: Blood collection, lymph node biopsy, drainage of an effusion, or bone marrow biopsy
41163110|NCT04003961|OTHER|STOP- BANG Questionnaire and Epworth sleepiness scale|STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
41163111|NCT05402618|OTHER|No intervention|This is an observational study without any intervention.
41163112|NCT02257918|DRUG|AZD0914|AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
41372517|NCT04416412|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
40848755|NCT01707082|DRUG|PF-06282999|Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
40848756|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 or 12 hours, 14 days
40848757|NCT01707082|DRUG|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
40848758|NCT01707082|DRUG|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
40848759|NCT01707082|DRUG|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
40848760|NCT01707082|DRUG|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
40848761|NCT03763136|BIOLOGICAL|hPSC-CM Therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
41031508|NCT04568538|OTHER|Training program|"A training program and booklet content for the education to be given to mothers includes the following topics.~* What is shaken baby syndrome and what is its cause?~* What are the harms caused by shaken baby syndrome?~* How is shaken baby syndrome understood?~* What problems can shaken baby syndrome cause?~* What are the measures to be taken? For the training and the content of the booklet, expert opinion was obtained from 10 academic members who are experts in the field of Child Health. An evaluation form was created for pre-test and post-test measurements. Expert opinions were also received for these forms.~Mothers of 2-4 months old babies who applied to Akdeniz University Hospital Pediatric Outpatient Clinic for check-up were randomized with a sealed envelope and accepted the study. In this way, intervention and control groups can be determined. After the pre-test is done in the intervention group, 2-month training, booklet and tele-consultancy services will be provided."
41163113|NCT02257918|DRUG|Ceftriaxone|Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
41163114|NCT02967809|DEVICE|echography|cardiac and pulmonary echography
41163115|NCT00578318|BEHAVIORAL|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
41163116|NCT02946450|DRUG|Other: Not applicable-observational study|
41163117|NCT00052325|DIETARY_SUPPLEMENT|mistletoe extract|
41372518|NCT06187207|DIAGNOSTIC_TEST|Hand acceleration time (HAT) measurement|Hand Duplex Ultrasound to measure the Hand Acceleration Time (HAT)
41372519|NCT02154152|DRUG|Homoeopathic Medicine causticum 200c|
41372520|NCT02026986|BEHAVIORAL|sleep deprivation|sleep deprivation for one night
41372521|NCT04139642|DEVICE|SimpleSway|"During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences."
41372522|NCT04753606|DRUG|Obicetrapib|tablets
41372523|NCT03830073|GENETIC|Measurement of VDR genetic polymorphism|VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.
41372524|NCT02713724|BEHAVIORAL|physical exercise|DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions
41372525|NCT02713724|BEHAVIORAL|limited physical exercise|The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
41372526|NCT02764229|DRUG|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
41504164|NCT06353542|DIAGNOSTIC_TEST|Ophthalmologist examination|The ophthalmologist (a glaucoma specialist) will analyze the tests and will examine the patient to determine if the patient is healthy, a glaucoma suspect or a glaucoma case
41504165|NCT02895828|OTHER|Core Stabilization Exercise|the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
40848762|NCT00246246|DRUG|risperidone|
40848763|NCT04976361|OTHER|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
41504166|NCT02895828|OTHER|General Strengthening Exercise|the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
41504167|NCT04837131|DRUG|Ixazomib|Ixazomib 4 mg capsule taken orally on days 1, 8, and 15 of a 28-day treatment cycle repeated for 6 cycles
40848764|NCT01002274|DRUG|MCS-2|2 soft-gel capsules Qd for 40 weeks
40848765|NCT02335424|BIOLOGICAL|pembrolizumab|IV infusion
40848766|NCT05443711|OTHER|No intervention, observational study|No intervention, observational study
40848767|NCT00432770|DRUG|ARC1779|
40848768|NCT02092025|DRUG|Azilsartan|Azilsartan tablets
40848769|NCT00122369|BEHAVIORAL|Self-hypnotic Relaxation|A research assistant read to the patient a self-hypnotic relaxation script while displaying empathic attention.
40848770|NCT00122369|BEHAVIORAL|Empathic Attention|A research assistant displayed defined behaviors of empathic attention.
40848771|NCT04685525|BEHAVIORAL|Mycobiome Supporting Diet|MSD takes combines elements from several diets (e.g., Paleo, low-carbohydrate, vegetarian, and Mediterranean) and excludes elements of these diets that have been specifically proven to increase pathogenic fungi in the human gut.
40848772|NCT04941846|DRUG|nimodipine and euvolemia|administered nimodipine to prevent vasospasm, and euvolemia was maintained via intravenous hydration
40848773|NCT03228212|DEVICE|CONTROL|ACUVUE OASYS
40848774|NCT03228212|DEVICE|TEST|senofilcon A with new UV blocker
40848775|NCT02514148|BEHAVIORAL|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
41372527|NCT00694226|BEHAVIORAL|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
41163118|NCT02053064|GENETIC|SAF-301|
41163119|NCT02290197|PROCEDURE|Surgery|Surgical reconstruction of all injured ligaments.
41163120|NCT02290197|DEVICE|Hinged External Fixator|Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.
41031509|NCT04890340|DIAGNOSTIC_TEST|ARNA Breast|Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI. Based on the results of these studies, a biopsy is prescribed to make a final diagnosis. Before a biopsy to diagnose the presence / absence of breast cancer, patients do the blood sampling one time. The blood is processed in the Sponsor's laboratory. The test results are compared with the data obtained from the biopsy. The evaluation of the effectiveness of the method will be determined on the basis of the obtained data on the sensitivity and specificity of the test in relation to the reference method
41031510|NCT04616326|DRUG|Galcanezumab|Administered SQ
41031511|NCT04616326|DRUG|Placebo|Administered SQ
41031512|NCT00448539|DRUG|Rufinamide|Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
41031513|NCT05224791|PROCEDURE|Roux-en-Y Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
41031514|NCT05224791|PROCEDURE|Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption"
41372528|NCT00694226|BEHAVIORAL|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
41031515|NCT02009176|PROCEDURE|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
41031516|NCT02009176|PROCEDURE|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
41031517|NCT02105506|DRUG|Tachosil patch|
41163121|NCT02290197|DEVICE|Cast Immobilization|Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
41163122|NCT05652699|OTHER|High Flow Nasal Oxygen|Flow 60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celsius.
41163123|NCT05652699|OTHER|Conventional Oxygen Therapy|Nasal Cannula, Venturi Mask or Non-rebreathing mask, according to local clinical protocols
41163124|NCT06006832|DRUG|Steroid Drug|Maintaining low-dose oral steroids
41163125|NCT06006832|OTHER|Withdraw all immunosuppresants|Withdraw all immunosuppresants
41372529|NCT01519635|DRUG|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
41372530|NCT01519635|DRUG|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
41163126|NCT05645809|DEVICE|MONOFIX® PGCL|An absorbable suture made of polyglycapron (PGCL) used for soft tissue suture.
41163127|NCT05645809|DEVICE|Quill Monoderm™|An absorbable suture made of polyglactin used for soft tissue suture.
41372531|NCT01620749|RADIATION|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
41372532|NCT04085562|DRUG|Bisoprolol Fumarate 5-10 mg|Bisoprolol as antihypertensive drug in patients on hemodialysis
41372533|NCT04085562|DRUG|Amlodipine 5-10 mg|Amlodipine as antihypertensive drug in patients on hemodialysis
41372534|NCT00145106|DRUG|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
41504168|NCT03905616|DEVICE|functional Magnetic Resonance Imaging|In a 2-hour session, the subject we be shown different control and experimental conditions (all being visual stimuli) in perceptive tasks.
41163128|NCT00993798|DRUG|SABER-Bupivacaine Treatment 1a|5.0 ml
41163129|NCT00993798|DRUG|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
41163130|NCT00993798|DRUG|Bupivacaine HCl Treatment 1c|20.0 ml
41163131|NCT00993798|DRUG|SABER-Bupivacaine Treatment 2a|7.5 ml
41163132|NCT00993798|DRUG|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
41163133|NCT00993798|DRUG|Bupivacaine HCl Treatment 2c|20.0 ml
41504169|NCT00099879|DRUG|BMS-275183|
41372535|NCT01559584|RADIATION|ultraviolet A (UVA)|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
41372536|NCT01559584|DRUG|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
41372537|NCT03494452|OTHER|No intervention|There is no intervention in this cross-sectional study
41372538|NCT05711459|DRUG|Bicyclol tablets|Take Bicyclol tablets for the treatment of liver injury.
41372539|NCT05868707|DRUG|OH2|Oncolytic Type 2 Herpes Simplex Virus
41372540|NCT05868707|DRUG|Salvage chemotherapy or best supportive care|single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
41372541|NCT00705471|BIOLOGICAL|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
41372542|NCT00186082|DRUG|Cefotetan or Cefoxitin vs placebo|"Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm."
40848776|NCT02514148|OTHER|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
40848777|NCT02514148|OTHER|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
40848778|NCT02514148|OTHER|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
40848779|NCT05494437|COMBINATION_PRODUCT|PP-01 High Dose|Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
40848780|NCT05494437|COMBINATION_PRODUCT|PP-01 Low Dose|CB1 partial agonist / GABAergic modulator
41504170|NCT02462291|OTHER|Ecological Environmental therapy|The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
41031519|NCT01308749|DRUG|Oxytocin|"Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU."
41031520|NCT01308749|DRUG|Placebo|Placebo Nasal Spray
41031521|NCT00497302|BEHAVIORAL|RBT|Contingency management and behavioral counseling including motivational interviewing
41372543|NCT00210366|DRUG|Idarubicin|
41372544|NCT04054531|BIOLOGICAL|KN046|IV infusion
41031522|NCT00497302|BEHAVIORAL|usual care|receives usual comprehensive care at Center for Addiction and Pregnancy
41031523|NCT02283866|DRUG|Administering desflurane according to the patient's BIS value|Administering desflurane according to the patient's BIS value
40848781|NCT05494437|DRUG|Placebo|Placebo comparator
40848782|NCT05494437|DRUG|Nabilone|CB1 receptor
40848783|NCT05494437|DRUG|Gabapentin|GABAergic modulator
40848784|NCT01188304|DRUG|aleglitazar|repeated daily doses
40848785|NCT01188304|DRUG|aspirin|repeated daily doses
41031524|NCT02283866|DRUG|Administering desflurane at 1 MAC|Administering desflurane at 1 MAC
41372545|NCT04054531|DRUG|Paclitaxel|IV infusion
41372546|NCT04054531|DRUG|Pemetrexed|IV infusion
41372547|NCT04054531|DRUG|Carboplatin|IV infusion
41372548|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
41372549|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
41372550|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
41372551|NCT02835664|DIETARY_SUPPLEMENT|Nicotinamide Riboside (Niagen)|
41372552|NCT02835664|DIETARY_SUPPLEMENT|Placebo|
40848786|NCT01188304|DRUG|placebo|repeated daily doses
40848787|NCT04008251|GENETIC|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
41504171|NCT06359639|BEHAVIORAL|Cognitive restructuring|Five 50-60-minute videoconferencing sessions of cognitive restructuring based on Mind Over Mood: Second Edition (MOM2) (Greenberger \& Padesky, 2016) and The Clinician's Guide to CBT Using MOM2 (Padesky \& Greenberger, 2019) as guides. The sessions will consist of understanding the cognitive model, filling in Thought Records, and complementary coping strategies of looking for evidence, action planning, and acceptance.
41504172|NCT06359639|BEHAVIORAL|Supportive counselling|Five 50-60-minute videoconferencing sessions of supportive counselling consisting of psychoeducation on breakup effects, validation of breakup experiences and emotions, introduction to deep breathing and progressive muscle relaxation, and identification of existing coping strategies.
41504173|NCT00150787|DRUG|LEVETIRACETAM|
41504174|NCT00476775|BEHAVIORAL|after school ethnic dance program - ballet folklorica|
40848788|NCT00128115|DRUG|MK0677|
41372553|NCT04100759|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg Oral Tablet
41372554|NCT04494334|PROCEDURE|Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis|Blood samples and Nasosorption sampling
41372555|NCT01920269|PROCEDURE|Trans-urethral resection|Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.
41504175|NCT00476775|BEHAVIORAL|culturally-tailored, home-based screen time reduction|
41504176|NCT00476775|BEHAVIORAL|culturally-tailored health and nutrition education|
40848789|NCT05431504|DRUG|Dalpiciclib in combination with endocrine therapy by Physicians choice|"Dalpiciclib 150 mg orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses"
41372556|NCT01920269|DRUG|intravesical passive diffusion mitomycin|A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.
40848791|NCT00876434|DRUG|Sirolimus|
41031525|NCT01126983|DEVICE|Suture|Suture (2.0 Mono-filament nylon suture) will be used to secure the leads to the skin. Benzoin and Steri-strips will also be used.
41031526|NCT01126983|DEVICE|Lead Anchor|Suture (2.0 Mono-filament Nylon suture) will be applied over the lead anchor(Lead Anchor St.Jude Medical Co, model-long, No# 1106) to the skin. Benzion and Steri-strips will also be used.
41372557|NCT01920269|DEVICE|intravesical electromotive mitomycin|A dose of 40 mg mitomycin dissolved in 100 ml water is instilled and retained in the bladder for 30 minutes with 20 mA pulsed electric current, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations with the same dose and methods of infusion as initial assigned treatment. Intravesical electromotive drug administration is given by a battery-powered generator delivering a controlled electric current that passes between the active intravesical electrode (integrated into a specific transurethral catheter) and dispersive ground electrodes (on skin of the lower abdomen). Operators set active electrode polarity and current intensity on the generator.
41372558|NCT02402556|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
41372559|NCT01462409|DEVICE|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
41372560|NCT01462409|DEVICE|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
41372561|NCT01462409|DEVICE|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
41372562|NCT02777554|DRUG|Apremilast IR|Apremilast immediate release tablet
40848792|NCT01496846|DRUG|IANB Articaine|IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.
41031527|NCT01156701|DRUG|Receiving a prescription of Relenza for prophylaxis|Receiving a prescription of Relenza for prophylaxis
41031528|NCT01156701|OTHER|No prophylaxis with Relenza|No prophylaxis with Relenza
41031529|NCT03998618|BEHAVIORAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, patients in the Acceptance and Commitment Therapy condition will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' cancer experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to fatigue. Participants will receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
41372563|NCT02777554|DRUG|Apremilast XL|Apremilast extended release formulation tablet
41372564|NCT05375942|DRUG|Inflectra|1. To describe the characteristics of patients newly initiated on Inflectra.
41504177|NCT02264860|DIETARY_SUPPLEMENT|Zinc and SAMe|The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
41504178|NCT05010616|DEVICE|Fixed orthodontic appliances|"Visual presentation of patient's predicted teeth alignment at the end of orthodontic treatment:~Presenting predicted teeth alignment after orthodontic treatment to patients before treatment starts, by using photos and videos of dental digital set-up.~Predicted teeth alignment can be described as: well-leveled and aligned patient's dental arches, well engaged posterior teeth and normal frontal teeth relationships."
40848793|NCT01496846|DRUG|SUP Articaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
40848794|NCT01496846|DRUG|SUP Lidocaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
41031530|NCT03998618|BEHAVIORAL|Education/Support|Across six weekly 50-minute sessions, patients in the education/support condition will discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist will direct patients to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center, education regarding common cancer-related symptoms and quality-of-life concerns, and an overview of resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts on session topics and will be asked to review them as homework.
40848795|NCT03963648|DIAGNOSTIC_TEST|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
40848796|NCT02588209|BEHAVIORAL|Strategic Memory Advanced Reasoning Training|SMART teaches strategies to improve the ability to process information.
41031531|NCT00645398|DRUG|Pregabalin|Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
41372565|NCT05375942|DRUG|Inflectra|2. To describe 6-month outcomes after initiating Inflectra, among patients who have 6 months follow-up information in the CorEvitas' RA Registry.
41372566|NCT03696420|OTHER|Coordinates of active plots and VIM landmarks calculation|Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
41372567|NCT00245492|PROCEDURE|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
41372568|NCT02492009|BEHAVIORAL|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
41031532|NCT00645398|DRUG|Pregabalin|Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
41504179|NCT03765788|DRUG|Secukinumab 300 mg, s.c.|Secukinumab 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
41504180|NCT03765788|DRUG|Prednisolone|Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)
41504181|NCT03765788|DRUG|Placebo|Placebo 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
41504182|NCT00750581|DRUG|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
41504183|NCT03677583|OTHER|Duckweed|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
41504184|NCT03677583|OTHER|Spinach|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
41031533|NCT00645398|DRUG|Pregabalin|Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
41031534|NCT00645398|DRUG|Placebo|Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
41031535|NCT06077396|PROCEDURE|radial artery cannulation|radial artery cannulation
41031536|NCT01380483|DRUG|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
41031537|NCT01380483|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
41031538|NCT01935817|DRUG|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|
41031539|NCT01935817|DRUG|Placebo|
41031540|NCT02417038|DEVICE|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
41031541|NCT01277965|OTHER|50%VO2maxTBR50|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
41031542|NCT01277965|OTHER|50%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
41031543|NCT01277965|OTHER|75%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%
41031544|NCT01277965|OTHER|75%VO2max TBR100|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
41031545|NCT01277965|OTHER|Rest|Patient will be in rest, basal insulin flow rate will not be change
41031546|NCT03380442|DRUG|Psilocybin|Psilocybin ingested orally
41031547|NCT03380442|DRUG|Ketamine (Ketalar)|Ketamine administered intranasally
41163134|NCT01708005|DRUG|Lecitone®Se-Vitamin D3|"Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.~Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study."
41163135|NCT01708005|DRUG|Placebo|The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
41372569|NCT02492009|BEHAVIORAL|Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
41372570|NCT01445015|BEHAVIORAL|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
41372571|NCT01445015|OTHER|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
41372572|NCT01667523|DIETARY_SUPPLEMENT|Capsaicin|1.5 mg capsaicin administered intraduodenally
41372573|NCT01667523|DIETARY_SUPPLEMENT|Cinnamaldehyde|70 mg per intervention administered intraduodenally
41031548|NCT03590301|BEHAVIORAL|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup aims to enable and inspire parents to improve their toddlers dietary intake and physical activity habits through authoritative parenting, structured feeding practices, and a healthy home environment. Playgroups will include open but structured experiential learning activities, free play, and instruction/discussion.
41031549|NCT03590301|BEHAVIORAL|Healthy Toddler Parent Group|The parent class will serve as our instruction only control group. Parents in this class will receive information about nutrition and activity recommendations regarding their toddler age children and will discuss it in a group with other parents. No experiential learning activities, information about parenting, or children will be involved in this class.
41031550|NCT05106257|BEHAVIORAL|Self-management education (short)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The short condition consists of two calls (30-45 minutes each) to introduce patient education topics and refer to the booklet for further information.
41031551|NCT05106257|BEHAVIORAL|Ground-based walking training|Participants randomized to this condition will be mailed a pedometer (3DFitBud Simple Step Counter) and instructed on its use to establish baseline steps/ day for 7 days. They will then receive a booklet with instructions to establish a walking program and three brief (10-15 minute), bi-weekly calls from a trained staff member to review step count values and engage in setting personal activity goals over the course of 6 weeks, following established exercise guidelines for individuals with COPD.
41031552|NCT05106257|BEHAVIORAL|Inhaler training|Participants randomized to this condition will receive two sessions of inhaler technique education using a virtual teach-to-goal (TTG) method in which individuals are observed using their inhaler, provided feedback, and then observed again.
41372574|NCT01667523|DIETARY_SUPPLEMENT|Placebo|Physiological saline
41372575|NCT05814380|RADIATION|99mTc-DPD scintigraphy|99mTc-DPD scintigraphy
41372576|NCT05814380|DIAGNOSTIC_TEST|Collection of blood samples and echocardiography|Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
41372577|NCT06235060|OTHER|Computer-assisted simulation technique training group|After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training.
41031553|NCT05106257|BEHAVIORAL|Caregiver support|Participants randomized to this condition will identify an informal caregiver who is involved in their healthcare (i.e., spouse, family member, or friend), who will receive a mailed copy of the Respiratory Health Association's COPD Caregiver's Toolkit, a comprehensive informational resource to support the care of the person living with COPD. Caregivers will receive two brief (10-15 minute) check-in calls from a trained staff member. The structured content of these sessions will include providing an overview of toolkit content, identifying goals for sections(s) to review and incorporate into caregiving activities, and addressing any questions.
41163136|NCT04303871|DIAGNOSTIC_TEST|Invasive blood pressure assessment by radial artery canulation|radial artery canula used to measure central blood pressure compared to non invasive automated device to measure BP in pregnant females
41372578|NCT06235060|OTHER|Imagery GROUP|After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training.
41372579|NCT01584050|DIETARY_SUPPLEMENT|L-5-methyltetrahydrofolate (Metafolin ®)|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
41372580|NCT01584050|DIETARY_SUPPLEMENT|folic acid|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
41372581|NCT01584050|DIETARY_SUPPLEMENT|Placebo|frequency: once daily, duration: 12 weeks
41504185|NCT03108885|OTHER|Blood and Tissue Collection|Blood DNA will be isolated from plasma. Tumor DNA will be purified with a kit and amplified regions of 10 genes discovered to by mutated in whole exome sequencing.
41504186|NCT03093116|DRUG|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005) capsules.
41504187|NCT02906358|BEHAVIORAL|Community-based pain self-management|
41504188|NCT02906358|BEHAVIORAL|Clinic-based pain self-management|
41504189|NCT05139810|DRUG|Donidalorsen|Donidalorsen will be administered by SC injection.
41504190|NCT05139810|DRUG|Placebo|Donidalorsen-matching placebo will be administered by SC injection.
41372582|NCT05957159|OTHER|Detoxification Program|Patients will begin inpatient or outpatient detoxification prior to completing imaging
41372583|NCT05957159|RADIATION|PKAB|90 PET Imaging Scan using \[11C\]LY2795050 (AKA \[11C\]PKAB)
41372584|NCT05957159|RADIATION|CFN|90 Pet Imaging Scan using \[11C\]-Carfentanil
41372585|NCT02119858|DRUG|indocyanine green solution|Given transperineally
41372586|NCT02119858|OTHER|diffuse optical imaging|Undergo near infrared fluorescence imaging
41372587|NCT02119858|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic radical prostatectomy
41372588|NCT02119858|PROCEDURE|therapeutic lymphadenectomy|Undergo lymphadenectomy
41372589|NCT00182208|DEVICE|Veno-device (Venowave)|
41504191|NCT02137876|PROCEDURE|Blood Draws|Patients will be asked to provide blood for immune tests.Patients will not take any study medications, all the research will be performed on blood donated for the study.Patients will donate about 20mls of blood (2 tbls)to be used to determine the subject's blood group and tissue typing (genetic).Results and the patient's contact information will be maintained in a database that is accessible only by the investigators and study personnel conducting the study.For the duration of this study, the investigator will contact patients by phone to request additional samples when needed. Study staff may ask patients donate more blood on short notice (1 day). This will consist of 60-120 ml (6-12 tbls) of blood.The frequency of blood collection will not exceed more than 2 times per week.The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups) within any eight week period throughout the two year timespan patients may be asked to participate in this study.
41504192|NCT03249831|DRUG|Cyclophosphamide|Orally daily
41504193|NCT03249831|DRUG|Pentostatin|Intravenous
41504194|NCT03249831|DRUG|Rabbit anti-thymocyte globulin|Intravenous
40848797|NCT02588209|BEHAVIORAL|Brain Health Workshop|Brain Health Workshop provides information about brain health in a seminar format. Topics include: sleep, nutrition, and exercise.
40848798|NCT03268291|OTHER|Standard outpatient observation|Outpatient management according to Ministry of health standards
41031554|NCT05106257|BEHAVIORAL|Self-management education (long)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The long condition consists of five, weekly calls (30-45 minutes each) following a structured curriculum of patient education topics.
40848799|NCT03268291|BEHAVIORAL|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
41031555|NCT06103981|OTHER|Acute Liver Injury|To evaluate the impact of acute liver injury in patients with pneumonia on hospital stay and outcome.
41372590|NCT05137431|OTHER|HFNO and NIV|"Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~* Respiratory parameters (respiratory rate)~* SpO2~* Ventilator settings~* Patient's tolerance (VAS; between 0-100)~* Arterial blood gas (HFNO and NIV at 1 hour)~* Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~* Loss of consciousness~* Agitation~* Persistent hypotension~* Need for fluid resuscitation~* Need for vasopressor~* Respiration rate ≥40/min~* SpO2 \<92~* pH\<7.30"
41504195|NCT03249831|DRUG|Tacrolimus|Initially IV. If patient tolerates, convert to oral.
41504196|NCT03249831|DRUG|Mycophenolate mofetil|IV or oral
41504197|NCT03249831|BIOLOGICAL|CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant|Infusion
41504198|NCT04592835|DRUG|DWRX2003|"Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites"
41504199|NCT00721227|PROCEDURE|Reduction Gastroplasty|"* Subjects will undergo reduction gastroplasty by gastric plication~* Subjects are followed for 12 months to evaluate outcomes and potential complications."
41504200|NCT05050110|OTHER|Fruits and Vegetable increase|Increase fruits and vegetable consumption in chronic Kidney Patients to maintain Normokalemia
40848800|NCT06438666|DEVICE|Anodic Transcranial Direct Current Stimulation|This study will apply the anodic transcranial direct current stimulation over 20 children between 14-18 years old. The protocol that it will follow is the next one: 3 days to value the outcome measures, 4 days (1 sessions per day of 17 minutes and 30 seconds) to apply the protocol of anodic transcranial direct current stimulation (0,6 mA of intensity). It will use the EPTE V07 Bipolar System by IONCLINICS ®; 3 days to value the outcome measures studying the effects produced at the affected upper limb. Another evaluation will be realized 3 weeks after the last sessions of anodic transcranial direct current stimulation to know if the effects obtained last at medium-long term.
41031556|NCT02293187|DIETARY_SUPPLEMENT|vitamin D3|Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level \<70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
41031557|NCT02293187|OTHER|Placebo|Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
41031558|NCT02997566|OTHER|Autonomic evaluation|
41031559|NCT04036916|OTHER|Virtual Reality Sensorimotor Training|Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
41031560|NCT04631822|PROCEDURE|Spinal anaesthesia|spinal anesthesia shall be conducted with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position.
41031561|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block + dexamethasone|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery. then, a 20-ml mixture of 0.25% bupivacaine, and 4 mg dexamethasone will be injected."
41372591|NCT04866602|DRUG|Atoguanil|Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
41504201|NCT04464707|DRUG|Fremanezumab|Dose A or Dose B subcutaneous
41504202|NCT04464707|DRUG|Placebo|Matching placebo
41504203|NCT06619769|BEHAVIORAL|eSense-Cancer CBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer|eSense-Cancer CBT is an online, cognitive behavioural therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer CBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
41504204|NCT06619769|BEHAVIORAL|Navigator support for eSense-Cancer|The eSense digital health tool has been previously tested alongside the support of treatment navigators - trained undergraduate students, not licensed therapists, who provide encouragement and answer any questions users may have as they work through eSense.
41372592|NCT04866602|DRUG|Malarone|Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets
41372593|NCT04518449|PROCEDURE|medial border along the left side of SMA|to place the medial border along the left side of SMA in laparoscopic D3 lymphadenectomy for right colon cancer
41372594|NCT04518449|PROCEDURE|medial border along the left side of SMV|to place the medial border along the left side of SMV in laparoscopic D3 lymphadenectomy for right colon cancer
41372595|NCT02396524|BEHAVIORAL|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
41372596|NCT04423289|OTHER|Farmalarm|Monitoring after COVID-19 discharge from hospital via Farmalarm app
41372597|NCT02469402|DIETARY_SUPPLEMENT|Standard infant formula|
41372598|NCT02469402|DIETARY_SUPPLEMENT|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
41504205|NCT06619769|BEHAVIORAL|Behavioral: eSense-Cancer MBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer|eSense-Cancer MBT is an online, mindfulness-based therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer MBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
41504206|NCT00200044|DEVICE|Gatekeeper Reflux Repair System|The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score \>15.
41504207|NCT00304837|GENETIC|pVGI.1 (VEGF-2)|
41504208|NCT00799825|BIOLOGICAL|GSK Biological's HPV vaccine GSK580299 (Cervarix™)|All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
41504209|NCT03197181|DEVICE|transcranial direct current stimulation|Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
41504210|NCT05602883|BEHAVIORAL|music therapy|Music is played for 30 minutes to the pregnant woman who is hospitalized due to the threat of premature birth.
40848801|NCT02051634|DRUG|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
40848802|NCT02051634|DRUG|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
40848803|NCT04580095|OTHER|AI algorithm for apical foreshortening in echocardiography|The algorithm is based on artificial intelligence, giving the sonographer performing the echocardiographic exam real-time feedback on left ventricular apical foreshortening.The algorithm is developed using deep learning techniques by technologists at the Department of Circulation and Medical Imaging, NTNU.
41031562|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block + dexmedetomedine|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine, and 0.5 Mg/kg dexmedetomidine will be injected."
41372599|NCT06152666|OTHER|None - qualitative interviews|These are qualitative interviews and involve no intervention
41372600|NCT00743873|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
41372601|NCT00743873|DRUG|placebo|injection of 6 cc of saline into injured area
41372602|NCT02708576|BIOLOGICAL|NGM313|
41372603|NCT02708576|OTHER|Placebo|
41372604|NCT05359146|DRUG|161Tb-DOTA-LM3|"161Tb-DOTA-LM3 is a therapeutic medicinal product with three main components, namely (a) Terbium-161 (161Tb), a beta minus-, gamma- and Auger-/conversion electron-emitting radionuclide with a half-life of 6.96 days; (b) DOTA, a chelator that allows stable complexation of 161Tb; and (c) LM3, an antagonistic SST analogue which binds to SST2 receptors (SST2 receptor antagonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
41372605|NCT05359146|DRUG|177Lu-DOTATOC|"177Lu-DOTATOC = 177Lu-edotreotide is a therapeutic medicinal product with three main components (a) Lutetium-177 (177Lu), a beta minus and gamma--emitting radionuclide with a half-life of 6.65 days; (b) DOTA, a chemical chelator that allows stable complexation of 177Lu; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to SST2 and much less to SST5 receptors (SST2 receptor agonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
41372606|NCT06246656|PROCEDURE|Maxillary Expansion|Palatal Expansion using a CAD/CAM appliance
41372607|NCT04478773|PROCEDURE|MRI|MRI with or without contrast
41372608|NCT02183168|DRUG|Meloxicam suppository|
41372609|NCT02183168|DRUG|Meloxicam tablet|
41372610|NCT02183168|DRUG|Indomethacin|
41504211|NCT03935438|OTHER|Cardiac rehabilitation|The training program of cardiac rehabilitation, depending on the results of the patient's medical qualification, will consist of the following: free active exercises, isometric exercises, active exercises in relief with resistance, isotonic exercises, isokinetic exercises, active breathing exercises, active breathing exercises with resistance, balance exercises, general exercises- individual and in groups, interval training on a treadmill or cycling cycloergometer, continuous training on a treadmill or cycling cycloergometer, circuit training, walking training, march training with accessories, autogenic training, walking. The training program will last an average 2 weeks.
41372611|NCT00498004|DRUG|Quetiapine, Risperidone|The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
41372612|NCT05180682|OTHER|Gait Training|"the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training"
41372613|NCT00442572|DRUG|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
41372614|NCT01172327|BEHAVIORAL|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
41372615|NCT01172327|BEHAVIORAL|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
41372616|NCT02997852|BEHAVIORAL|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
41504212|NCT02114385|BIOLOGICAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
41504213|NCT02114385|BIOLOGICAL|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
41504214|NCT06381557|DRUG|Zhengyuan Capsules|Zhengyuan capsules, 4 capsules at a time, 3 times per day;
41163137|NCT04950387|OTHER|Breathing exercises|Based in yoga, common load
41372617|NCT02439593|OTHER|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
41372618|NCT02439593|OTHER|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
41372619|NCT01334502|BIOLOGICAL|rituximab|PO
41372620|NCT01334502|DRUG|cyclophosphamide|IV
41372621|NCT01334502|DRUG|doxorubicin hydrochloride|IV
41372622|NCT01334502|DRUG|everolimus|PO
41372623|NCT01334502|DRUG|prednisone|PO
41372624|NCT01334502|DRUG|vincristine sulfate|IV
41372625|NCT00563706|DRUG|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
41372626|NCT00563706|DRUG|risperidone|
41372627|NCT00563706|OTHER|placebo|
41372628|NCT01367626|DRUG|letrozole|2.5 mg tablet
41372629|NCT01367626|DRUG|letrozole|2.5 mg tablet
41372630|NCT03818334|DRUG|Cyclophosphamide|Cyclophosphamide 1000 mg/flask
41372631|NCT03818334|DRUG|ATG|Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
41372632|NCT03253666|OTHER|Nutrient Intake|Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
41372633|NCT00373282|DRUG|Triamcinolone acetonide|
41372634|NCT02977052|DRUG|Ipilimumab|
41372635|NCT02977052|DRUG|Nivolumab|
41372636|NCT02977052|PROCEDURE|Surgery|Surgery will be done at 6 weeks
41372637|NCT02977052|PROCEDURE|Blood for PBMCs|Blood will be taken for translational research on PBMCs
41372638|NCT02977052|PROCEDURE|Biopsies|Biopsies will be taken during screening and at relapse.
41504215|NCT06381557|DRUG|Placebo contains 5%-10% Zhengyuan Capsule total mixed powder|Zhengyuan capsules simulator（Placebo contains 5%-10% Zhengyuan Capsule total mixed powder）, 4 capsules at a time, 3 times per day;
41504216|NCT02925104|DRUG|INC280|
41504217|NCT03179423|DRUG|GNbAC1|Monthly IV repeated dose
40848804|NCT02082704|BEHAVIORAL|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
41372639|NCT02818582|DRUG|GS-5734|Daily GS-5734 delivered intravenously (IV) for 5 days
41504218|NCT03179423|DRUG|Placebo|Monthly IV repeated dose
41504219|NCT01590303|DRUG|Vitamin C|Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
41372640|NCT02818582|OTHER|Placebo Comparator|Placebo delivered intravenously (IV) for 5 days.
41372641|NCT04679233|OTHER|Prescription aerobic exercise|high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
41372642|NCT04216992|DEVICE|Cone beam computed tomography|The contrast agent (Omnipaque, GE Healthcare, Ireland) was instilled to conﬁrm the epidural space. With use of a calibrated angiographic C-arm system and a postprocessing workstation, we acquired volume data sets from two dimensional digital projection images obtained to reconstruct the 3D-RE during a C-arm rotation around the patient axis.
41372643|NCT00589966|BEHAVIORAL|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
41372644|NCT00589966|BEHAVIORAL|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
41372645|NCT05455294|DRUG|Navitoclax|See Arm Description
41372646|NCT05455294|DRUG|Venetoclax|See Arm Description
41372647|NCT05455294|DRUG|Decitabine|See Arm Description
41372648|NCT05110300|DEVICE|Body weight support system control group|Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.
41372649|NCT05110300|DEVICE|Body weight support system with balance perturbations|Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
41372650|NCT00401414|DRUG|Warfarin|2 mg tablets take as directed by study staff (based on INR)
41372651|NCT04189666|DRUG|Rivastigmine Transdermal System [Exelon]|compare the ability of the drug in preventing postoperative delirium
41372652|NCT04189666|DRUG|Melatonin|compare the ability of the drug in preventing postoperative delirium
41372653|NCT02087865|DRUG|donepezil HCL|
41372654|NCT02087865|DRUG|Placebo|
41372655|NCT05623189|DRUG|HTD1801|HTD1801,1250 mg, BID
41372656|NCT05623189|DRUG|Placebo|Placebo, BID
41372657|NCT06455163|OTHER|Eerder Erbij|The intervention (Eerder Erbij, EE) is a person-centred, manual-based intervention consisting of education, information and a support group for persons in the early stage of dementia and their main informal caregiver (e.g. spouse, relative), who receive little or no formal care. The intervention will discuss the effects of dementia, and how to cope and adjust to those effects. It will take place in small group sessions led by a health care professional (e.g. casemanager) and is intended for both the person with dementia and the caregiver. The intervention will be personalised to meet needs, interests and strengths of the dyad by discussing the sessions content at the start of the intervention.
41372658|NCT02922231|BIOLOGICAL|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
41372659|NCT00994123|DRUG|MM-121|MM-121 (SAR256212) = intravenous solution
41372660|NCT00994123|DRUG|Erlotinib|erlotinib = daily oral tablet
41372661|NCT06089590|OTHER|Non-interventional|This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.
41372662|NCT05245461|OTHER|Assessments|Muscle Strength, Proprioception, Kinesiophobia
41372663|NCT05766280|BEHAVIORAL|iCareer Soft Skills Training for Employment|The telehealth iCareer intervention will be delivered during regular educational or vocational services (i.e., services from the Office of Disability Services (ODS) and/or from the school or college counseling center). Six modules of Soft Skills Training (SST), four group sessions for each module with 60 to 90 min for each session (depending on group size) will be delivered by trained project staff (graduate counseling student assistant or graduate counseling intern) via HIPAA-compliant Zoom videoconferencing. If participants are unable to join by Zoom videoconferencing, telephone (a format widely used in Cognitive Behavior Therapy (CBT) for Post Traumatic Stress Disorder (PTSD) treatment delivery and in CBT for depression) will be utilized. Ethical guidelines for providing telehealth over videoconferencing or phone will be followed.
41372664|NCT00117013|DRUG|Fluorine-19-Fluoroded Xyglucose|
41372665|NCT00117013|DRUG|Topotecan|
41372666|NCT05046145|BEHAVIORAL|speech therapy for chewing + real tDCS|participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.
41372667|NCT05079711|DEVICE|SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)|The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.
41372668|NCT01012609|OTHER|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
41372669|NCT06539793|OTHER|Aerobic Exercises|Treadmill 20 minutes including 5 minutes warm up and 5 minutes cool.
41372670|NCT06539793|OTHER|Transcutaneous electrical nerve stimulation|"will be applied for all patients, which uses an asymmetrical biphasic alternating current in the continuous mode (pulse duration 100 µs, low frequency). TENS intensity will increase slowly, and patients will be instructed to indicate sensory threshold (ST); then, the intensity are going to increase until the sensation perceived as strong but comfortable (SC1). The duration will be for 30 minutes, 3times/ week for 4 weeks"
41372671|NCT05946746|DIETARY_SUPPLEMENT|PeptiStrong|PeptiStrong is a protein hydrolysate derived from Vicia faba. It is a free-flowing powder, pale yellow in colour. For the purposes of the trial, PeptiStrong will be encapsulated in size '00' hydroxypropyl methylcellulose capsules.
41372672|NCT05946746|DIETARY_SUPPLEMENT|Placebo SMCC silicated micro-crystalline cellulose|Placebo - SMCC silicated microcrystalline cellulose (INCI name: MCC, cellulose gel), For the purposes of the trial, SMCC will be encapsulated in size '00' hydropropyl methylcellulose.
41372673|NCT03773159|BIOLOGICAL|Blood sampling|4 citrated/PPACK tubes and 1 EDTA tube maximum
41504220|NCT01590303|DRUG|placebo|placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
41504221|NCT04545320|BEHAVIORAL|Usual care control group|Health education
41504222|NCT04545320|BEHAVIORAL|HIIT group|Once-a-week HIIT
41504223|NCT04545320|BEHAVIORAL|MICT group|Once-a-week MICT
41504224|NCT03277755|DRUG|AL-335 800 mg|Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
41163138|NCT05294406|DRUG|Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine|Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)
41504225|NCT03277755|DRUG|ODV 25 mg|Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
41504226|NCT03277755|DRUG|SMV 75 mg|Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
41504227|NCT06330363|OTHER|Laser therapy|The Cube plus30 from Eltech K-Laser s.r.l. (Italy, www.k-laser.com) will be used for LLLT. The laser devices from Eltech K-Laser s.r.l. have been used in (clinical) studies with a variety in patient populations (38-41) and clinical practice (https://resources.k-laser.com.au/medical-laser-clinical-applications). The device is a registered medical device in the EU confirmed by Kiwa Cermet Italia.
41504228|NCT06330363|OTHER|Sham|The laser device has sham light option that will be used.
41504229|NCT02329626|DEVICE|PET CT 18 FDG|"Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography.~This intervention is required for the observational needs of the study."
41504230|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392103A|intramuscular vaccination according to protocol schedule
41372674|NCT03461393|DEVICE|Medical-Eye-Trainer (MET)|In order to provide a high contrast, dynamic visual stimulus to the patients, we developed an app that allowed the patients to regularly train with this stimulus. The app runs on Android (version 4.2 or later). The display of the screen is divided into 4 rows. In each row, a pattern of black and white squares is moving in one direction. The directions in subsequent rows are opposite to each other. Through the movement in the opposite direction a changing pattern is achieved in vertical and horizontal extension, the pattern alternates between continuous beams and a checkered pattern. The speed of the display on the monitor is 2 cm per second. In a comfortable viewing distance (ca. 40 cm), this leads to an angular velocity of approximately 3°/sec.
40848805|NCT02082704|BEHAVIORAL|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
40848806|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 1
40848807|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 2
40848808|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Tes Lens 3
40848809|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 4
40848810|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Control Lens
40848811|NCT04942782|OTHER|lumbopelvic stabilization exercises|the patients will receive lumbopelvic stabilization in the form of three parts: 1 Segmental control over primary stabilizers (mainly TrA, deep multifidus, pelvic floor and diaphragm) 2-Exercises in closed chain, with low velocity and low load 3-Exercises in open chain, with high velocity and load
40848812|NCT04942782|OTHER|pilates exercise|the patient will receive pilates exercise in the form of Breast stroke prep, Side leg lift series, One leg circle, Hundreds, Shoulder bridge, and Spine stretch forward
41031563|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine"
41031564|NCT00733317|DRUG|0.5 mg/ml budesonide nebules|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
41031565|NCT00733317|DRUG|Saline|Children will receive 2 ml of saline every 20 minutes for 3 times
41372675|NCT04089657|DRUG|Apatinib Mesylate|Apatinib 500mg qd, oral, taken half an hour after a meal
41372676|NCT04089657|DRUG|Sintilimab|Sintilimab 200mg intravenously on day 1
41372677|NCT00367224|PROCEDURE|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
41372678|NCT00367224|PROCEDURE|Skin biopsies|4 mm punch biopsies of the skin
41504231|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392105A|intramuscular vaccination according to protocol schedule
41504232|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392106A|intramuscular vaccination according to protocol schedule
41504233|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392019A|intramuscular vaccination according to protocol schedule
41504234|NCT01160172|DRUG|Saline placebo|intramuscular vaccination according to protocol schedule
41504235|NCT04362553|DEVICE|wearable vital signs sensor|vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization
41504236|NCT04801381|PROCEDURE|Aquablation therapy|Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA
41504237|NCT04801381|PROCEDURE|Transurethral laser enucleation|Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP).
41504238|NCT06426771|BEHAVIORAL|Dietary Inflammatory Index|The aim of this study was to compare the dietary habits of patients with PCOS and an AMH value of \>3.32 ng/ml, of patients with low ovarian reserve without PCOS and an AMH value of less than 1.2 ng/ml and of patients with normal AMH values (between 1.2-3.32 ng/ml) according to Dietary Nutrient Density according to Dietary Inflammatory Index, Dietary Phytochemical Index and Nutrient Rich Food Index.
41504239|NCT06426771|DIAGNOSTIC_TEST|hormone profile|In the routine practice of the PCOS clinic, about 7 ml of blood is taken in a vacuum gel tube for hormonal and biochemical analysis by medical staff. The blood samples are centrifuged by the researchers at 1000xg for 20 minutes. In the next step, the supernatant part is separated and transferred to 3 mL Ependorfs. These samples are used to determine the levels of anti-Müllerian hormone (AMH), oestradiol, LH and FSH, which are routinely determined at the PCOS clinic.
40848813|NCT04942782|OTHER|conventional therapy|Patients will received strengthening exercises for the abdominal, back, and hip muscles. The patients performed an average of three series of ten repetitions of each exercise. Increases in the number of exercises performed in each session (or load progression) occurred according to individual tolerance
40848814|NCT02372981|DEVICE|mucopexy +/- Doppler-guided haemorrhoidal artery ligation|Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
40848815|NCT03160820|BIOLOGICAL|Measles, mumps and rubella Combined Vaccine, Live|Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
40848816|NCT01850407|BEHAVIORAL|Education Counseling|
40848817|NCT03899987|DRUG|Aspirin|Given PO
40848818|NCT03899987|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
41504240|NCT02985216|DRUG|YHD1119|"YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO"
41504241|NCT02985216|DRUG|Lyrica|Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
40848819|NCT03899987|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
41031566|NCT05164822|OTHER|Necrotizing Vasculitis|"Pain scale Diagnosis of necrotizing vasculitis and peripheral neuropathy, Clinical characteristics of the disease, Biological analysis, Treatment and evolution of the disease,~Questionnaires :~Neuropathy Impairment Score (NIS) sensitive sub-questionnaire that measures extremity sensitivity.~MRC (Medical Research Council), which evaluates three motor functions on each member.~RODS questionnaire on the relationship between your daily activities and your health.~BVAS (Birmingham Vasculitis Activity Score) disease activity questionnaire. VDI (Vasculitis Damage Index) questionnaire evaluates the sequelae of the disease.~Rankin Score modified to measure the degree of disability~Two tests will be performed:~EMG (electromyogram) to evaluate the electrical activity of the muscles, Walking Test of 10 meters which aims to measure the time taken to travel 10 meters."
41031567|NCT04265755|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).
41031568|NCT03094689|OTHER|Cold water immersion|
41031569|NCT03094689|OTHER|Water immersion|
41372679|NCT03112759|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
41372680|NCT02582216|DEVICE|3D augmented reality|Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
41372681|NCT02729597|OTHER|medical history|The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.
41372682|NCT02729597|OTHER|neurological clinical examination|Neurological examination will be performed at baseline and follow-up.
41372683|NCT02729597|OTHER|neuropsychological testing|Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.
41372684|NCT02729597|OTHER|brain MRI|Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.
41372685|NCT05294133|BEHAVIORAL|physical activity|physical activity
41504242|NCT01181570|DRUG|Adalimumab|Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
41504243|NCT01181570|DRUG|Placebo|Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
40848820|NCT03899987|DRUG|Rintatolimod|Given IV
40848821|NCT02681315|DEVICE|HHHFNC 6 liter minute|Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
41031570|NCT06446037|DEVICE|Non-invasive EMG band instrumentation|The sensed EMG signals from the subjects will be decoded by Phantom X algorithm and used to drive various gestures in a desk-mounted hand prosthesis
41031571|NCT05162820|DIETARY_SUPPLEMENT|100 mg Solarplast|100 mg Solarplast delivered in capsules with the carrier of rice dextrin and medium chain triglycerides consumed daily at breakfast for 60 days
41031572|NCT05162820|DIETARY_SUPPLEMENT|Placebo|rice dextrin and medium chain triglycerides in capsules consumed daily at breakfast for 60 days
41031573|NCT01343368|DRUG|Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
41372686|NCT06520761|PROCEDURE|Injectable platelet rich fibrin|blood sample obtained from the participant, centrifuged at 700 rpm to produce injectable platelet rich fibrin, this will be injected around the upper canine
41372687|NCT06520761|DEVICE|Low Level LASER|Diode LASER device is used to apply Low Level LASER around the upper canine
41372688|NCT05473039|DIETARY_SUPPLEMENT|Seidivid Ferty4|The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
41372689|NCT05473039|OTHER|Placebo|The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
41372690|NCT02459756|OTHER|Beverage: Spray dried blackcurrant powder dissolved in water|
41372691|NCT02459756|OTHER|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
41372692|NCT02674568|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
41372693|NCT04066127|DEVICE|Non-ischemic heart preservation (NIHP)|The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
41372694|NCT04066127|DEVICE|Standard ischemic cold static storage (SCS)|The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
41504244|NCT05830344|DEVICE|Placebo Multi Radiance Medical® Super Pulsed Laser|Placebo, without therapeutic dose.
41504245|NCT05830344|DEVICE|Active Multi Radiance Medical® Super Pulsed Laser|Active with a dose of 8.02 J per site.
41504246|NCT04895982|BIOLOGICAL|BNT162b2|Intramuscular Injection
41504247|NCT03883802|DRUG|Foxy-5|Lyophilized powder for solution for intravenous infusion
41504248|NCT03883802|DRUG|FOLFOX regimen|6 months treatment regimen
41372695|NCT05597930|DEVICE|Wrist and Thumb orthosis|Custom 3D printed thumb and wrist orthosis
41372696|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
41372697|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
41372698|NCT02950727|DEVICE|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
41372699|NCT02950727|DEVICE|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
41372700|NCT02246244|DRUG|Escitalopram|
41372701|NCT02246244|OTHER|Placebo|
41372702|NCT04943536|DRUG|bicalutamide|localized anti-androgen therapy
41504249|NCT03883802|PROCEDURE|Tumour resection (colon cancer surgery)|Surgical removal of patients colon cancer
40848822|NCT02681315|DEVICE|HHHFNC 3 liters/min|Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
41031574|NCT01343368|BIOLOGICAL|hematopoietic cell transplant|Conventional bone marrow transplant regimen.
41031575|NCT01343368|BIOLOGICAL|reduced intensity allogeneic HCT|A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.
41372703|NCT04943536|RADIATION|Stereotactic body radiation therapy|localized radiation therapy
41372704|NCT01139138|DRUG|Panitumumab|Panitumumab 6mg/kg IV every 14 days
41372705|NCT01139138|DRUG|Irinotecan|Irinotecan 200mg/m2 IV every 14 days
41372706|NCT01139138|DRUG|Everolimus|Everolimus daily po (dosage varies with cohort)
41372707|NCT00465322|DRUG|fluvastatin|
41372708|NCT02513901|DRUG|Chidamide|Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
41372709|NCT05289921|BIOLOGICAL|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle
41372710|NCT02149277|DRUG|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
41372711|NCT05786027|BEHAVIORAL|PDI|A 12-week in-prison peer-driven intervention to increase the uptake of primary HIV prevention strategies (readiness to initiate addiction treatment (MMT or Atlantis), initiation of MMT/Atlantis, retention in MMT/Atlantis; or the use of SSP), and reduce the use of opioids and HIV risk behaviors, in HIV-negative PWID in prison.
40848823|NCT05144867|RADIATION|Stereotactic Radiosurgery|All patients to undergo planning CT simulation with 1mm slice thickness. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging. A Planning Target Volume (PTV) margin of 2-5 mm will be added. Organs at risk visible in the planning CT scan will be contoured. The doses will be prescribed to approximately 100% isodose level and 95% of the PTV should receive 95% of the prescription dose. Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
41372712|NCT01678391|PROCEDURE|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
41372713|NCT04780126|OTHER|Sarcopenia diagnosis|History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
41372714|NCT00509275|DRUG|W0027|capsule
41372715|NCT00509275|DRUG|Placebo|Placebo
41372716|NCT02525575|BEHAVIORAL|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
41372717|NCT02096406|DRUG|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
41372718|NCT02096406|DRUG|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
41372719|NCT05659082|DEVICE|Laser Interstitial Thermal Therapy|Ventral capsulotomy for OCD using laser interstitial thermal therapy
41372720|NCT01422876|DRUG|high dose FDC|once daily
41372721|NCT01422876|DRUG|BI 10773 high dose|once daily
41372722|NCT01422876|DRUG|high dose FDC placebo|once daily
41372723|NCT01422876|DRUG|low dose FDC placebo|once daily
41372724|NCT01422876|DRUG|high dose FDC placebo|once daily
41372725|NCT01422876|DRUG|high dose FDC placebo|once daily
41372726|NCT01422876|DRUG|low dose FDC placebo|once daily
41372727|NCT01422876|DRUG|low dose FDC placebo|once daily
41372728|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
41372729|NCT01422876|DRUG|low dose FDC|once daily
41504250|NCT04826692|DRUG|Metformin|Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
41504251|NCT04826692|DRUG|Placebo|425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
41504252|NCT00226174|DRUG|Curcuminoids|
41504253|NCT03430388|BIOLOGICAL|Yellow Fever vaccine (17D)|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
41504254|NCT03696953|BIOLOGICAL|Florajen3|Probiotic combination product One capsule daily by mouth.
40848824|NCT02574689|BEHAVIORAL|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
41372730|NCT01422876|DRUG|high dose FDC placebo|once daily
41372731|NCT01422876|DRUG|BI 10773 low dose|low dose once daily
41372732|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
41372733|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
41372734|NCT01422876|DRUG|linagliptin|once daily
41372735|NCT01422876|DRUG|low dose FDC placebo|once daily
41163139|NCT05436600|OTHER|Exercise Intervention|The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
40848825|NCT02574689|BEHAVIORAL|Wellness contact control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
40848826|NCT04006392|DEVICE|Erchonia FX-635|The Erchonia FX-635 has three independent 17 milliWatts (mW) 635 nanometer (nm) red laser diodes mounted in scanner devices.
40848827|NCT04006392|DEVICE|Placebo Laser|Non-therapeutic output.
40848828|NCT04029103|OTHER|knowledge, behaviour, self efficacy|Knowledge, behavior and self-efficacy of both groups were measured before and after the study.
40848829|NCT01571011|BEHAVIORAL|CURB|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
40848830|NCT04078152|DRUG|Durvalumab|IV infusion q4w with 1500mg durvalumab until progressive disease
40848831|NCT03997110|RADIATION|Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
41372736|NCT01422876|DRUG|linagliptin placebo|once daily
41372737|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
40848832|NCT03997110|RADIATION|Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
41372738|NCT01422876|DRUG|linagliptin placebo|once daily
41372739|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
41372740|NCT01422876|DRUG|linagliptin placebo|once daily
41372741|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
41372742|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
41372743|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
41372744|NCT01422876|DRUG|linagliptin placebo|once daily
41372745|NCT04249557|BEHAVIORAL|exercise is medicine|a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
41372746|NCT05260528|DRUG|Cytarabine and Idarubicin|"Induction 1: Cytarabine 200 mg/m2 i.v. (continuously) d1-7 + Idarubicin 12mg/m2 d1, 2, 3 i.v (60 min)~Induction 2: Cytarabine 1500 mg/m2 i.v. q12h d1-3~Consolidation: Cytarabine 1500 mg/m2 i.v. q12h d1-3"
41372747|NCT05260528|DRUG|CPX-315|"Induction 1:CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3,5~Induction 2: CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3~Consolidation therapy:CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine i.v. (90 min) d1,3"
41372748|NCT03226782|OTHER|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
40848833|NCT03401268|DRUG|subcutaneous immunoglobulin|24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
40848834|NCT05011266|DRUG|Buprenorphine/naloxone|5.7 mg buprenorphine/1.4 mg naloxone sub-lingual daily
41372749|NCT03226782|OTHER|Long intervention protocol|This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
40848835|NCT05011266|DRUG|Placebo|placebo sub-lingual tablet daily
40848836|NCT04533867|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape
41031576|NCT02465229|PROCEDURE|Multimodal tissue-sampling methods before and after stricture dilation|Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.
41031577|NCT01993810|DRUG|Carboplatin|Given IV
41031578|NCT01993810|DRUG|Cisplatin|Given IV
41031579|NCT01993810|BIOLOGICAL|Durvalumab|Given IV
41031580|NCT01993810|DRUG|Etoposide|Given IV
41031581|NCT01993810|DRUG|Paclitaxel|Given IV
41031582|NCT01993810|DRUG|Pemetrexed Disodium|Given IV
41031583|NCT01993810|RADIATION|Photon Beam Radiation Therapy|Undergo photon beam radiation therapy
41031584|NCT01993810|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
41031585|NCT01993810|OTHER|Quality-of-Life Assessment|Ancillary studies
41031586|NCT01993810|OTHER|Questionnaire Administration|Ancillary studies
41031587|NCT00207272|BEHAVIORAL|1170-1870 kcal/day liquid diet|
41031588|NCT00207272|PROCEDURE|Gastric bypass surgery|
41031589|NCT00207272|PROCEDURE|Biopsy.visceral adipose tissue|
41372750|NCT05473234|DRUG|Azithromycin|Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
41031590|NCT00207272|PROCEDURE|Biopsy.omental adipose tissue|
41031591|NCT00207272|PROCEDURE|Biopsy. subcutaneous abdominal adipose tissue|
41031592|NCT00207272|PROCEDURE|Blood sample|
41031593|NCT01863550|DRUG|Bortezomib|Given SC or IV
41372751|NCT05473234|DRUG|Amoxicillin|Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
40848837|NCT04533867|DRUG|Palonosetron 1mcg/kg|Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.
41031594|NCT01863550|DRUG|Carfilzomib|Given IV
41031595|NCT01863550|DRUG|Dexamethasone|Given PO
41031596|NCT01863550|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41031597|NCT01863550|DRUG|Lenalidomide|Given PO
41031598|NCT01863550|OTHER|Quality-of-Life Assessment|Ancillary studies
41031599|NCT02136173|DEVICE|Heliosphere bag (air filled balloon)|sequential balloons . Heliosphere bag (air filled balloon)
41031600|NCT05688904|DRUG|Imipramine|Topical 4% Imipramine
41031601|NCT05688904|OTHER|Vehicle|Vehicle
41031602|NCT05797168|DRUG|AZD5335|IV Antibody-drug conjugate
41031603|NCT05797168|DRUG|Saruparib (AZD5305)|Oral PARP inhibitor
41031604|NCT05797168|DRUG|Bevacizumab|IV Monoclonal antibody
41031605|NCT05797168|DRUG|Carboplatin|IV Alkylating agent
41031606|NCT04763122|OTHER|not applicable as it is a retrospective study|It is a retrospective study
41031607|NCT02961140|OTHER|Cardiac Output Maximization|According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
41031608|NCT02961140|OTHER|Cardiac Output Normalization|The investigator will administer intravenous fluids to keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation.
41031609|NCT05200923|DEVICE|Sacral Neuromodulation|Sacral neuromodulation delivers electrical stimulation to a sacral nerve
41031610|NCT02124642|DIETARY_SUPPLEMENT|Folic acid, 400 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
41031611|NCT02124642|DIETARY_SUPPLEMENT|Folic acid 800 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
41031612|NCT03220191|DRUG|Palbociclib|palbociclib tablet formulation
41031613|NCT03220191|DRUG|Rabeprazole|rabeprazole as PPI
41163140|NCT02973477|DRUG|Dapagliflozin|Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.
40848838|NCT04533867|DRUG|Ondansetron 1 mg/kg, max dose 8 mg|Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.
40848839|NCT04228367|DEVICE|JuggerStitch Meniscal Repair Device|Treatment of torn meniscus with JuggerStitch.
41372752|NCT06111976|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
40848840|NCT06299462|DRUG|ATG 5.0|ATG 2.5 mg/kg on days -2 and -1
40848841|NCT06299462|DRUG|Cyclophosphamide injection|Cyclophosphamide 50 mg/kg on days +3 and +4
40848842|NCT06299462|DRUG|ATG 2.5±1.5|ATG 2.5 mg/kg on day -1 ± 1.5 mg/kg on day -2
41031614|NCT05316038|DIAGNOSTIC_TEST|Oral glucose tolerance test|The test is performed on an empty stomach for at least 10 hours. The first blood sugar level is taken on an empty stomach. Then ingestion of 75g of sugar. A second blood test takes place 1 hour after the sugar intake and the third blood sugar test takes place 2 hours after the sugar intake.
40848843|NCT04266054|BEHAVIORAL|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
40848844|NCT06583993|DRUG|HNF4α srRNA|HNF4α srRNA will be administered intravenously for the treatment of ICC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.
40848845|NCT06284733|DEVICE|Whole-body vibration plus conservative care|Whole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform. This method was used in rehabilitation to improve muscle function, joint stability, balance control and to reduce the risk of falling.
40848846|NCT06284733|OTHER|conservative care|"1. Stretching and ROM exercises daily to make sure that the patient can straighten hip; this makes walking, and even lying in bed, more comfortable.~2. Resting hip on a pillow, as this promotes a hip flexion contracture~3. A pillow between legs, as this lengthens the inner thigh muscle that helps to keep legs together while walking, and shortens the outer thigh muscles so that walking and standing with feet apart.~4. Regular skin care.~5. Regular prosthetic care."
40848847|NCT04984382|BEHAVIORAL|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
41031615|NCT01244152|BEHAVIORAL|Intensive diabetes self-management education|18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
40848848|NCT01811186|DRUG|Oxycodone/naloxone|Oxycodone/naloxone titration
40848849|NCT02343809|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
40848850|NCT02343809|OTHER|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
40848851|NCT02343809|OTHER|Protocolized Physiotherapy|Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
40848852|NCT02065505|OTHER|Mat Pilates|
40848853|NCT02065505|OTHER|Water Pilates|
40848854|NCT04849715|DRUG|parsaclisib|parsaclisib will be administered orally once daily.
40848855|NCT04849715|DRUG|rituximab|rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.
41031616|NCT01244152|BEHAVIORAL|Enhanced standard diabetes education|2 3-hour diabetes education classes taught by a health educator at a local clinic
41031617|NCT06282627|OTHER|Observational study|No intervention. Observational study
41031618|NCT00139750|DRUG|CP-526,555 (varenicline)|
41031619|NCT00970502|DRUG|erlotinib + celecoxib|In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
41031620|NCT06471101|DIAGNOSTIC_TEST|clusters|clustering
40848856|NCT04849715|DRUG|bendamustine|bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.
40848857|NCT04849715|DRUG|Placebo|placebo will be administered orally once daily
40848858|NCT01996085|DRUG|lisinopril|"Angiotensin converting enzyme inhibitor recommended in case of:~1. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2)~2. hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~3. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~4. balanced profile"
40848859|NCT01996085|DRUG|Telmisartan|Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
40848860|NCT01996085|DRUG|Nebivolol|"Beta-blocker recommended in case of:~1.hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min)"
40848861|NCT01996085|DRUG|Indapamide/hydrochlorothiazide|"1. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm)~2. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)"
40848862|NCT01996085|DRUG|Amlodipine|1/ SVRI \> 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
40848863|NCT01996085|DRUG|lisinopril|Drug choice at the discretion of physician (blinded to ICG)
40848864|NCT01996085|DRUG|Telmisartan|Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
40848865|NCT01996085|DRUG|Nebivolol|Drug choice at the discretion of physician (blinded to ICG)
40848866|NCT01996085|DRUG|Indapamide/hydrochlorothiazide|Drug choice at the discretion of physician (blinded to ICG)
40848867|NCT01996085|DRUG|Amlodipine|Drug choice at the discretion of physician (blinded to ICG)
40848868|NCT06583486|BIOLOGICAL|Rcombinant botulinum neurotoxin type A for injection (YY001)|Five sites will be injected at 0.05 mL each, 2 sites in corrugator muscle of each side and 1 site in the procerus muscle, for a total dose of 20U.
40848869|NCT01019850|DRUG|Vorinostat|Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
40848870|NCT01019850|RADIATION|131- I Metaiodobenzylguanidine|Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).
40848871|NCT01019850|PROCEDURE|Peripheral Blood Stem Cell Infusion|Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.
40848872|NCT01019850|DRUG|Filgrastim|All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
40848873|NCT04842981|DRUG|Tocilizumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
40848874|NCT04842981|DRUG|Sarilumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
40848875|NCT03270891|DIAGNOSTIC_TEST|PGx test|A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
40848876|NCT01921764|BEHAVIORAL|Workplace physical exercise|
40848877|NCT01921764|BEHAVIORAL|Home physical exercise|
40848878|NCT03937414|DEVICE|The OSNA assay|SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.
40848879|NCT00695552|BEHAVIORAL|Aerobic exercise|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
41163141|NCT02973477|DRUG|Glimepiride|Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
40848880|NCT00695552|BEHAVIORAL|Low impact exercise|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
41163142|NCT00443677|DRUG|COPPEBVCAD vs BEACOPP vs ABVD|
41504255|NCT03987321|DEVICE|Infrarenal vena cava filter placement|Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups
41031621|NCT05870800|DRUG|Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2|Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPEOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)
41031622|NCT05870800|DRUG|Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
41031623|NCT05870800|DRUG|Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
41031624|NCT06533982|OTHER|High intensity interval exercise session|Physical activity session supervised and adapted on ergometer
41031625|NCT06533982|OTHER|Isometric neuromuscular exercise session|Physical activity session supervised and adapted with a handgrip
41372753|NCT06111976|PROCEDURE|Placebo|"sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
41372754|NCT04600531|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
41504256|NCT06130423|DRUG|Music intervention|Music therapy carried out with Music Care
41504257|NCT06130423|DRUG|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
41504258|NCT04058067|DRUG|Brolucizumab|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
41504259|NCT04058067|DRUG|Aflibercept|5 x every 4 weeks loading then every 8 weeks maintenance
41504260|NCT03485365|DRUG|GSK3858279 IV|GSK3858279 will be available as solution for injection to be administered via IV route.
41504261|NCT03485365|DRUG|GSK3858279 SC|GSK3858279 will be available as solution for injection to be administered via SC route.
41504262|NCT03485365|DRUG|Placebo matching to GSK3858279 (SC or IV)|Placebo will be available as sodium chloride solution to be administered via SC or IV route.
41504263|NCT03485365|DRUG|Placebo matching to GSK3858279 (SC)|Placebo will be available as sodium chloride solution to be administered via SC route.
41163143|NCT02847819|DEVICE|airway ultrasound for vocal cords movement assessment.|Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
41504264|NCT05548738|DRUG|medthylprednisolone|a type of steroids injected in epidural space
41504265|NCT05548738|DRUG|prolotherapy|a type of hypertonic glucose
41504266|NCT00264550|DRUG|Golimumab 100 mg|Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
41504267|NCT00264550|DRUG|Golimumab 50 mg|Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
40848881|NCT05730439|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40848882|NCT05730439|DRUG|Nicotine Oral Pouch|Receive ZYN brand NP
41031626|NCT05717127|BEHAVIORAL|Time restricted feeding|Restricted feeding with 20 hours of fasting and a 4 hour window of feeding (between 4 and 8 PM or between 5 to 9 PM).
41031627|NCT05717127|BEHAVIORAL|Standard lifestyle|Standard lifestyle recommendations
41031628|NCT01605617|DRUG|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
41031629|NCT01605617|DRUG|Placebo|PTNS + placebo for 12 weeks
41163144|NCT01032746|OTHER|educational intervention|
41163145|NCT01032746|OTHER|internet-based intervention|
41163146|NCT01032746|PROCEDURE|evaluation of cancer risk factors|
41504268|NCT00264550|DRUG|Methotrexate|Participants will receive methotrexate capsules weekly.
41504269|NCT00264550|DRUG|Placebo injection|Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
41504270|NCT00264550|DRUG|Placebo capsules|Participants will receive placebo capsules weekly
41504271|NCT02919592|DEVICE|MemoryShape® Breast Implants|MENTOR® MemoryShape™ Breast Implants are devices with shells constructed from medical grade silicone elastomer. The shell is filled with Mentor's proprietary formulation of medical grade silicone gel. The textured shell is constructed of successive crosslinked layers of silicone elastomer, and includes raised orientation marks on the anterior and posterior of the implant intended to help the physician orient the implant and ensure proper placement during implantation. Each MENTOR® MemoryShape™ Breast Implant is provided sterile. MemoryShape Breast Implants are available in sizes ranging from 120 cc-775 cc and 5 styles with various projection and height options.
40848883|NCT05730439|DRUG|Nicotine Oral Pouch|Receive Rogue brand NP
40848884|NCT05730439|OTHER|Questionnaire Administration|Ancillary studies
40848885|NCT05730439|DRUG|Smokeless Tobacco|Receive usual SLT
41163147|NCT01032746|PROCEDURE|fecal occult blood test|
41163148|NCT01032746|PROCEDURE|screening colonoscopy|
41372755|NCT04600531|DEVICE|4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)|"HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS)."
41372756|NCT02709980|BEHAVIORAL|Sleep Education|The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.
41031630|NCT01605617|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
41372757|NCT02709980|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
41372758|NCT04847427|OTHER|Core exercises training|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
41372759|NCT04847427|OTHER|Structural exercises training|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
41372760|NCT04847427|OTHER|Accentuated eccentric exercises training|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Bulgarian squat jumps, 4 sets of 5 repetitions at 30% BM"
41372761|NCT04847427|OTHER|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
41372762|NCT03744208|DRUG|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
41372763|NCT05151991|OTHER|Fixed orthodontic treatment with stainless steel brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy); brackets will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste will be removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). The following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS."
41031631|NCT06318676|DRUG|Mezigdomide|Specified dose on specified days
41031632|NCT04956718|OTHER|Cold Pressor Test (CPT)|Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.
41031633|NCT04956718|OTHER|Placebo NaCl Nasal spray|placebo nasal spray containing NaCl solution
41031634|NCT01689116|DRUG|Bardoxolone Methyl 20mg|Oral
41031635|NCT01689116|DRUG|Bardoxolone Methyl 80mg|Oral
41031636|NCT01689116|DRUG|Bardoxolone Methyl Placebo|Oral
41031637|NCT01689116|DRUG|Moxifloxacin 400mg|Oral
41031638|NCT01689116|DRUG|Moxifloxacin Placebo|Oral
41031639|NCT00120393|DRUG|atazanavir/ritonavir +2 NRTIs (immediate Switch Group)|Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
41031640|NCT00120393|DRUG|LPV/r +2 NRTIs (Delayed/optional Switch Group)|Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
41031641|NCT06636344|OTHER|Pseudoxanthoma Elasticum|Answer to the PSQ-18, patient care confidence score (likert scale) and SF-12 questionaries at each visit, for an estimated duration of 15 minutes.
41031642|NCT01897584|OTHER|inverse IE|in only one group changes of I:E ratio would be applied
41031643|NCT00417937|DRUG|azelaic acid 15% gel|15% gel, topically applied once daily for six weeks
41504272|NCT02919592|DEVICE|MemoryGel® Breast Implants|MENTOR® MemoryGel™ Breast Implants are round devices with shells constructed from medical grade silicone elastomer. The shell is filled with MemoryGel™, Mentor's proprietary formulation of medical grade silicone gel, and is constructed of successive cross-linked layers of silicone elastomer. There are two styles of shell: smooth and textured. Each MENTOR® MemoryGel™ Breast Implant is provided sterile. MemoryGel Breast Implants are available in sizes ranging from 100 cc-800 cc and 4 styles with various projection and height options.
41504273|NCT02919592|PROCEDURE|Other Aesthetic Surgery|Other aesthetic surgery procedures (for example, liposuction, rhinoplasty, brow lift, rhytidectomy, mentoplasty/genioplasty, otoplasty, or blepharoplasty; may not include silicone implants)
41504274|NCT01006018|DRUG|Sitagliptin + Pioglitazone PLACEBO|Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
41504275|NCT01006018|DRUG|Sitagliptin + Pioglitazone|Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
41372764|NCT05151991|OTHER|Fixed orthodontic treatment with ceramic brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of ceramic brackets; brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste is removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). Then, the following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS"
41504276|NCT01006018|DRUG|PLACEBO|Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
41031644|NCT00417937|DRUG|azelaic acid 15% gel|15% gel, topically applied twice daily for six weeks
41031645|NCT04612361|OTHER|insommnia severity index questionnaire|insomnia severity index questionnaire and scoring system
41031646|NCT02539264|OTHER|Smoking|Influence of smoking on parameters derived from overnight PSG
41504277|NCT00541879|BEHAVIORAL|Program ENERGY|Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented
41504278|NCT00541879|OTHER|comparison|
41504279|NCT00638053|GENETIC|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
41504280|NCT03458299|BEHAVIORAL|Motivational Interviewing|2 hours of motivational interviewing
41504281|NCT03458299|BEHAVIORAL|Psychoeducation|2 hours of DVD viewing and discussion
41504282|NCT02188186|DRUG|Initial triple combination|Initial triple combination arm
41504283|NCT02188186|DRUG|Conventional treatment|Conventioanl treament with dose escalation
41504284|NCT02011477|OTHER|Neural Glide|This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
41504285|NCT02011477|OTHER|Neural stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
41504286|NCT05468931|DEVICE|Prostate stimulator|Prostate stimulation device for sexual dysfunction
41504287|NCT00591981|BEHAVIORAL|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
41031647|NCT02539264|OTHER|Obesity|Influence of obesity on parameters derived from overnight PSG
41031648|NCT02539264|OTHER|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
41504288|NCT02198963|DRUG|Hypochlorous acid solution 106 mg/L|test product
41504289|NCT02198963|DRUG|0.1% (w/v) Sodium Lauryl Sulfate|positive control
41504290|NCT02198963|DRUG|0.9% Physiological Saline, USP|negative control
40848886|NCT01434251|OTHER|Anti-hypotensive treatment|Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
40848887|NCT00158691|DRUG|Ethyol|
41031649|NCT06377930|DRUG|RAP-219|RAP-219 oral tablet
41031650|NCT00604253|DRUG|insulin detemir|
41031651|NCT00604253|DRUG|insulin NPH|
41163149|NCT03022110|DEVICE|Endoscopic Ultrasound-guided Drainage|Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
41163150|NCT03565640|DEVICE|Capio Slim Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.
41504291|NCT05354739|DEVICE|The vibration cold device (BUZZY)|If the patient fulfils the inclusions criteria, the research nurse will obtain informed consent from a parent or legal guardian and assent form if the child is 7years or older. She will assess the ability of the child to use the Faces Pain Scale-Revised (FPS-R), as a pain assessment instrument used by the child. It is a six cartoon faces showing a normal facial expression if no pain, progressing into the facial expression with very severe pain. FPS-R is graded from zero to ten; the child will be asked to quantify the pain by: no hurt, hurt, or very much hurt. This scale is widely used not only in research but also in a routine bases in ours and other units by the nursing staff and are familiar with it. The research nurse is one of the nurses used the same scale during the routine work and will be trained further to ensure consistency, she will document the findings prior, during and after the procedure. This instrument was reliable, valid, and standardized
40848888|NCT03964688|DRUG|Vitamin C|vitamin C intravenous during hospitalization, after oral, total 6 weeks.
41504292|NCT00002678|DRUG|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
40848889|NCT03964688|DRUG|Placebos|placebo intravenous during hospitalization, after oral, total 6 weeks
40848890|NCT01323140|DRUG|testosterone matrix transdermal system|
40848891|NCT01727336|DRUG|Dalantercept and axitinib|
40848892|NCT01727336|DRUG|Placebo and axitinib|
40848893|NCT03945149|DIETARY_SUPPLEMENT|Turmipure Gold™|30 subjects will take 1000mg in 4 capsules (with 250ml water before breakfast , each day, during 5 weeks
40848894|NCT03945149|DIETARY_SUPPLEMENT|Placebo|30 subjects will take 4 capsules with 250ml water before breakfast , each day, during 5 weeks
40848895|NCT04314011|BIOLOGICAL|Human umbilical cord mesenchymal stem cells（HUC-MSCs）|Human umbilical cord mesenchymal stem cells（HUC-MSCs）
40848896|NCT04314011|BIOLOGICAL|Placebo|Placebo
40848897|NCT02126839|DRUG|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
40848898|NCT02126839|DRUG|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
40848899|NCT02126839|DRUG|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
40848900|NCT03824600|DIAGNOSTIC_TEST|Fractional Flow Reserve Motorized Pullback|A pullback device (Volcano R 100, San Diego CA, USA), adapted to grip the coronary pressure wire (PressureWire X, St Jude Medical, Minneapolis, USA), set at a speed of 1 mm/sec to pullback the pressure-wire until the tip of the guiding catheter during continued pressure recording.
41163151|NCT03565640|DEVICE|Anchorsure Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
41163152|NCT03703843|DEVICE|ARTUS MONO|Temporarily implant and activation of the medical device
41504293|NCT00002678|DRUG|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
41504294|NCT00002678|DRUG|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
41504295|NCT01455298|OTHER|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
41504296|NCT00001797|DRUG|Recombinant human interleukin-10|
41504297|NCT01208987|OTHER|Medication History was printed|
41504298|NCT03002701|BEHAVIORAL|UNDERPIN-ICU program|UNDERPIN-ICU consists of standardized protocols focusing on several modifiable risk factors for delirium, including cognitive impairment, sleep deprivation, immobility and visual and hearing impairment.
41504299|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^7 pfu /2mL administered in each deltoid
41504300|NCT00083603|BIOLOGICAL|rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)|Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
41504301|NCT00083603|BIOLOGICAL|Empty TBC-FPV|Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
41504302|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^8 pfu /2mL administered in each deltoid
41504303|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^9 pfu /2mL administered in each deltoid
41504304|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^7 pfu/2mL administered into each deltoid
41504305|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^8 pfu/2mL administered into each deltoid
41504306|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^9 pfu/2mL administered into each deltoid
41504307|NCT03502434|DRUG|SM04755|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
40848901|NCT05320003|DIAGNOSTIC_TEST|Inky foot analysis|Inky foot analysis to confirm the diagnosis of pes planus
40848902|NCT05320003|DIAGNOSTIC_TEST|Evaluation of plantar pressure with pedobarography|Evaluation of plantar pressure distribution by pedobarography in individuals with pes planus
40848903|NCT05320003|DIAGNOSTIC_TEST|Balance assessment with computerized posturography|Evaluation of fall risk with computerized posturography
40848904|NCT06510010|DRUG|Oxaliplatin With S-1 (SOX) Combined H. Pylori Eradication (Amoxicillin + clarithromycin + omeprazole + colloidal bismuth subcitrate)|"Oxaliplatin With S-1 (SOX) regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle.~H. pylori eradication regimen:~H. pylori eradication was performed using a quadruple regimen for 14 d. Omeprazole 20 mg bid+Colloidal bismuth subcitrate 220mg bid+Amoxicillin 1g bid+Clarithromycin 500mg bid."
40848905|NCT06510010|DRUG|Oxaliplatin With S-1 （SOX）|"Oxaliplatin With S-1 （SOX） regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle."
40848906|NCT04112394|OTHER|local anesthetic injection|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic mixture will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
40848907|NCT04112394|OTHER|Standard perioperative and postoperative analgesia protocol.|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive contramal 1 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
40848908|NCT00761826|DEVICE|MEL 80 Mixed Astigmatism Treatment|Treatment of Naturally Occuring Mixed Astigmatic corrections up to 6.0 D.
40848909|NCT05695144|DEVICE|tDCS active stimulation combined with rTMS sham stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
40848910|NCT05695144|DEVICE|rTMS active stimulation combined with tDCS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
40848911|NCT05695144|DEVICE|tDCS active stimulation combined with rTMS active stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
40848912|NCT05695144|DEVICE|tDCS sham stimulation combined with rTMS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
40848913|NCT04487652|OTHER|Gingival recession coverage|The Modified Coronally Advanced Tunnel technique in conjunction with a palatal subepithelial connective tissue graft will be performed.
40848914|NCT04487652|DRUG|with CoQ10 spray application|After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.
40848915|NCT04487652|DRUG|with placebo spray application|After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.
40848916|NCT04672915|DIAGNOSTIC_TEST|test of HBV DNA|Real time PCR or nested PCR to check
40848917|NCT00826670|DRUG|Decolonization|"Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days~plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days"
40848918|NCT00826670|DRUG|Placebo (Decolonization)|Placebo
40848919|NCT00439062|DRUG|Roxithromycin|
40848920|NCT02212769|DRUG|Losartan 50mg|Losartan 50mg once daily for 7 days
40848921|NCT02212769|DRUG|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
40848922|NCT02280317|DRUG|VAL201|VAL201-001 Sub-cutaneous injection.
40848923|NCT04739579|DIAGNOSTIC_TEST|C-Reactive Protein|C-Reactive Protein trend in post-operative course
40848924|NCT05329064|BIOLOGICAL|BNT162b2 Pfizer-BioNTech/Comirnaty|"The study will use 10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose.~Two doses will be given at 2 months apart between doses."
40848925|NCT05788497|DRUG|Hemorrane plus|Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine
40848926|NCT05788497|DRUG|Hemorrane|Hemorrane 10 mg/g rectal ointment
41163153|NCT02494453|PROCEDURE|Research Cardiac MRI|Cardiac MRI has increasing utility in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their treating physician. In this study, treatment will not be altered based on the data collected from these MRIs.
41163154|NCT02494453|PROCEDURE|Biomarkers|"Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However, we have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their treating physician. In this study, treatment will not be altered based upon the data collected from these samples."
41163155|NCT02515656|DRUG|POLYGYNAX®|
40848927|NCT05788497|DRUG|Placebo|Rectal ointment
40848928|NCT01201226|OTHER|Removal of half an ovary|Removal of half an ovary
41163156|NCT02515656|DRUG|GYNODAKTARIN®|
41163157|NCT02515656|DRUG|Placebo|
41163158|NCT02165397|DRUG|Ibrutinib|Participants will receive 420 mg of Ibrutinib orally.
40848929|NCT00854035|DRUG|MK-0431/ONO-5435|Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
40848930|NCT00854035|DRUG|MK-0431/ONO-5435|Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
40848931|NCT04770792|OTHER|2% chlorhexidine gluconate with mineral trioxide aggregate.|2% chlorhexidine gluconate with mineral trioxide aggregate.
40848932|NCT04770792|OTHER|Mineral trioxide aggregate.|Mineral trioxide aggregate.
40848933|NCT06429774|OTHER|Neurological function|Neurological function will be examined using Glasgow Coma Scale (GCS) and Extended Glasgow Outcome Scale (GOSE).The GOSE was created as an advancement from the original GOS. The GOSE score categorizes the prognosis of patients with traumatic brain injury into eight categories.The 8 categories are: Dead, Vegetative State, Lower Severe Disability, Upper Severe Disability, Lower Moderate Disability, Upper Moderate Disability, Lower Good Recovery, and Upper Good Recovery.
40848934|NCT06429774|OTHER|Mental State, cognitive function, and life quality assessment|Mental State, cognitive function, and life quality will be examined using the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9(PHQ-9), Rivermead post-concussion symptoms questionnaire(RPQ), PTSD Checklist-5 Version(PCL-5)，Six-Item Screener（SIS） and 12-Item Short-Form Health Survey version 2(SF-12v2).
40848935|NCT06429774|OTHER|Peripheral blood test|Collect peripheral blood samples from patients.
40848936|NCT06429774|OTHER|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
40848937|NCT02501525|DEVICE|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
40848938|NCT02501525|DEVICE|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
40848939|NCT05026203|DRUG|Ketamine Hydrochloride|Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days
40848940|NCT05026203|DRUG|Midazolam|Midazolam
40848941|NCT03600532|BEHAVIORAL|Teachable Moment Brief Intervention (TMBI)|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt.
40848942|NCT05873491|OTHER|Music therapy|The music therapy sessions will offer sensory workshops of immersive musical listening, digital and acoustic music creation and shared improvised music.
40848943|NCT01041820|BEHAVIORAL|Exercise|Children will be exposed to a 10-week exercise intervention
40848944|NCT04496011|OTHER|Aerobic training with cycle ergometer|Patients start with an initial warm-up of 2 minutes, with rotations per minute free, without load. Progressively, the load of the exercise cycle increases every minute up to the supported limit or up to 60% - 70% of maximum heart rate (HRmax). The training will be carried out for 20 continuous minutes, being interrupted whenever the heart rate (HR) reaches 90% of the maximum expected for the age and / or the loss of effort perceived in the BORG scale, above 8 on a scale of 0 to 10.
40848945|NCT03995706|DRUG|Sacituzumab Govitecan|All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
40848946|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects
40848947|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
41031652|NCT05410574|BEHAVIORAL|Family-based Behavioral Weight Loss Treatment|The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts
41031653|NCT05546281|OTHER|No intervention|No intervention
41031654|NCT00605241|DRUG|GSK598809|Drug
41031655|NCT00346008|GENETIC|mutation analysis|
41031656|NCT00346008|OTHER|high performance liquid chromatography|
40848948|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort C: Cohort C are healthy subjects, cohorts C and D, should be matched in terms of sex, age, and body mass index (BMI). On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
41031657|NCT00346008|OTHER|laboratory biomarker analysis|
40848949|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort D: were subjects with severe liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
41031658|NCT00346008|OTHER|questionnaire administration|
41031659|NCT04423965|DRUG|mFOLFOXIRI|irinotecan 165 mg/m² IV day 1+ oxaliplatin 85 mg/m² IV day 1 + leucovorin 400 mg/m² day 1, fluorouracil 1200mg/m²/day \*2 days (total 2400 mg/m² over 48 hours) continuous infusion starting on day 1 of each 2 weeks cycle
41031660|NCT04423965|COMBINATION_PRODUCT|Chemoradiotherapy|Capecitabine based chemoradiotherapy
41031661|NCT05824832|DRUG|Interscalene block with the addition of buprenorphine, clonidine, dexamethasone|Addition of the adjuvant buprenorphine, dexamethasone, and clonidine in the nerve block performed prior to shoulder arthroscopy surgery
41031662|NCT05824832|DRUG|Interscalene block with buprenorphine alone|Addition of the adjuvant buprenorphine alone the in nerve block performed prior to shoulder arthroscopy surgery
41031663|NCT01629329|DRUG|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
41031664|NCT01629329|DRUG|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
41031665|NCT01194141|BEHAVIORAL|Exercise training|aerobic exercise training, 45-60 minutes, 3x/week, 12 weeks (3-months)
41031666|NCT04313634|DRUG|Dasatinib|Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated
41031667|NCT04313634|DRUG|Quercetin|Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg
41163159|NCT02165397|DRUG|Placebo|Participants will receive placebo capsules orally.
41163160|NCT02165397|DRUG|Rituximab|Participants will receive rituximab 375 mg/m\^2 IV.
40848952|NCT04478448|DRUG|Flupirava|1 tablet contains 200 mg Favipiravir
40848953|NCT04478448|DRUG|Avigan|1 tablet contains 200 mg Favipiravir
40848954|NCT01534195|DRUG|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 8 days.
40848955|NCT01534195|DRUG|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 8 days
41031668|NCT04313634|DRUG|Fisetin|Fisetin will be supplied in 100 mg capsules to be administered orally
41504308|NCT03502434|OTHER|Vehicle|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
41504309|NCT03502434|OTHER|White Petrolatum|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
41031669|NCT00372463|BEHAVIORAL|6-week Online Diabetes Self-Management Educational Program|
41031670|NCT06634563|OTHER|mindfulness meditation|the patients will receive mindfulness meditation in the form of Attention-focusing technique (body scan, directing attention throughout the body in a relaxed, supine state) guided by audiotapes. Relaxing every part of the body by guided audiotape from head to toes and Sitting meditation (systematically directing attention to breath) guided by audiotapes. Relaxing deep rhythmic breathing with concentration on every breath.
40848956|NCT06393023|DEVICE|Continuous Positive Airway Pressure|Although this study is designed as an observational cohort study, where patients were not assigned to intervention or non-intervention groups, there is still an intervention project indicator present in the observational cohort. The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
40848957|NCT00245648|DRUG|fibrinolytic therapy or combination reduced fibrinolytic therapy|
40848958|NCT06551259|DRUG|Dexmedetomidine|Intravenous infusion of 0.6μg/kg load dose of dexmedetomidine within 10 minutes after intubation, followed by continuous infusion at a rate of 0.4 μg/kg/h until 30 minutes before the end of surgery
41504310|NCT03502434|OTHER|Sodium lauryl sulfate|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
40848959|NCT06551259|DRUG|physiological saline|physiological saline
40848960|NCT05009290|DRUG|SHR3680|"Treatment group: SHR3680 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
40848961|NCT05009290|DRUG|Placebo|"Treatment group ：Placebo 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
40848962|NCT00815893|DRUG|dexmedetomidine|dexmedetomidine 1.0 mcg/kg infusion for 10minutes
40848963|NCT00815893|DRUG|Normal Saline 0.9%|0.9% Normal Saline 0.25ml/kg infusion for 10minues
40848964|NCT00815893|DRUG|propofol 1%|"Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion."
41163161|NCT02338427|OTHER|Immunohistochemistry|
41163162|NCT02338427|OTHER|Proteomic analysis|
41504311|NCT05962762|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|"The trial was conducted sequentially from the low dose group to the high dose group, with 3-6 subjects enrolled in each dose group. The trial was conducted on a case-by-case basis in the high dose group, with each subject in the high dose group being enrolled in subsequent subjects only after completion of at least 7 days of post-dose safety observation. Each subject received only one corresponding dose. All subjects received experimental drugs and conventional treatment during the study period.~All subjects in each test dose group will complete a 4-week (28-day) dose-limiting toxicity (DLT) After the observational evaluation period, a decision will be made by the investigator and sponsor based on a discussion of relevant safety data whether to start the next dose group."
41504312|NCT04326621|OTHER|Pressure Release Technique (PRT)|A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
41504313|NCT04326621|OTHER|Control|exercises
41504314|NCT03590769|DRUG|18F-FDG|All subject will undergo PET/MRI scans pre-operatively, 1 day and 1 week post-operatively using FDG
41163163|NCT04308642|OTHER|blood test for renal biomarkers|blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)
41163164|NCT04308642|OTHER|urine test for renal biomarkers|urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)
41163165|NCT02107547|PROCEDURE|Biceps tenodesis|A biceps tenodesis involves cutting the tendon within the shoulder joint and reattached further down the arm.
41163166|NCT02107547|PROCEDURE|Labral repair|Repair of a Superior Labrum Anterior and Posterior lesion involves placing small anchors in the glenoid to re-attach the torn labrum.
40848965|NCT02816229|DEVICE|Insertion of endobronchial valve|One or more endobronchial one- way valves will be inserted into the appropriate lung regions
40848966|NCT04859374|BEHAVIORAL|Mindfullness|Behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
40848967|NCT04859374|DRUG|treatment as usual (TAU) (pharmacological)|Any pharmacological therapy used for managing chronic pain or chronic migraine
40848968|NCT03595527|DIAGNOSTIC_TEST|HIV and HCV screening|HIV test: ARCHITECT HIV Ag/Ab Combo, Abbott HCV test: ARCHITECT Anti-HCV, Abbott
40848969|NCT03803436|PROCEDURE|Liver transplant|Liver transplant from cadaveric donors
40848970|NCT03803436|DRUG|Chemotherapy|mFOLFOX
40848971|NCT03803436|DRUG|Chemotherapy|Panitumumab
40848972|NCT03786471|OTHER|Health System-based Dementia Care|Active comparator
40848973|NCT03786471|OTHER|Community-based Dementia Care|Active comparator
40848974|NCT03786471|OTHER|Usual Care|Control
40848975|NCT01050244|DIETARY_SUPPLEMENT|Whole soybean soymilk powder|
40848976|NCT01050244|DIETARY_SUPPLEMENT|Whole milk powder|
40848977|NCT00445770|DRUG|Etanercept|10 mg twice weekly, subcutaneous injection for 52 weeks
40848978|NCT00445770|DRUG|Etanercept|25 mg, twice weekly, subcutaneous injection for 52 weeks
40848979|NCT00445770|DRUG|Methotrexate|up to 8 mg per week, oral dosing for 52 weeks
40848980|NCT02889445|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
40848981|NCT05006482|OTHER|Best Practice|Receive usual follow-up survivorship care
40848982|NCT05006482|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessment
41031671|NCT06634563|OTHER|cognitive behavioral training|Training sessions will include three cognitive training tasks each of them target a particular core cognitive capability and are grouped into three categories by target domain: memory (working memory), attention (selective attention), and problem solving (logical reasoning) through these games (organic order and fuse clues for logical reasoning training, lost in migration, trouble brewing, assist ants and train of thought for attention training and memory match and memory match one drive for working memory training).
40848983|NCT05006482|OTHER|Educational Intervention|Participate in survivorship health education sessions
40848984|NCT05006482|OTHER|Exercise Intervention|Participate in EXCAP program
40848985|NCT05006482|OTHER|Questionnaire Administration|Ancillary studies
40848986|NCT05006482|PROCEDURE|Tailored Intervention|Participate in GEM consultation
40848987|NCT04702425|DRUG|VOB560|Powder for concentrate for solution for infusion
40848988|NCT04702425|DRUG|MIK665|Concentrate for solution for infusion
40848989|NCT00260416|PROCEDURE|Primary angioplasty with stent and abciximab|
40848990|NCT04488016|DRUG|Treatment A- Part 1|Subjects will receive 100 mg acalabrutinib capsule, fasted state;
40848991|NCT04488016|DRUG|Treatment B- Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
40848992|NCT04488016|DRUG|Treatment C - Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
40848993|NCT04488016|DRUG|Treatment D- Part 1|Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
40848994|NCT04488016|DRUG|Treatment A-Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
40848995|NCT04488016|DRUG|Treatment B - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
40848996|NCT04488016|DRUG|Treatment C - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
40848997|NCT04488016|DRUG|Treatment D - Part 2|Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
40848998|NCT04959305|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
40848999|NCT04959305|DRUG|RLD2003|Take it once daily for 8 weeks orally.
40849000|NCT04959305|DRUG|RLD2004|Take it once daily for 8 weeks orally.
40849001|NCT04959305|DRUG|RLD2005|Take it once daily for 8 weeks orally.
40849002|NCT04959305|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
40849003|NCT04959305|DRUG|HPP2005|Placebo drug. Take it once daily for 8 weeks orally.
40849004|NCT01895959|DRUG|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
40849005|NCT01895959|DEVICE|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
40849006|NCT00364143|DRUG|IHL-305 (irinotecan liposome injection)|
40849007|NCT01513122|DRUG|Lopinavir / ritonavir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily
40849008|NCT01513122|DRUG|2-3N(t)RTI|
40849009|NCT01513122|DRUG|raltegravir|raltegravir 400mg 1 tablet twice daily.
40849010|NCT01737216|DRUG|Zoledronic acid plus EP/TP|Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
41031672|NCT04305613|OTHER|Chemoradiation|Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
41031673|NCT06204731|OTHER|Exercise and environmental conditions|Participants will engage in interval training and will reside and sleep at different altitudes for a period of 4 weeks. Aerobic and anaerobic capacity tests and an eccentric exercise test will be performed before and after the training intervention. Before and after the training program, somatic measurements will also be taken. Before and after the first and last workout, blood will be drawn for biochemical analysis.
41031674|NCT02692248|DRUG|Ibrutinib|Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
41504315|NCT06449144|OTHER|Mindfulness education|The mindfulness-based stress reduction method was examined and a two-step mindfulness education is planned. To reveal the experience of pain: It was planned to conduct interviews with the participants to realize what they think about the pain they have experienced before or what they think about the pain they have experienced here and now, what emotions they have, and their experiences related to their coping processes with pain. Participants will be encouraged to notice negative thoughts that could impact their coping with pain negatively, and they will be provided with education on the benefits of managing the process of changing these negative thoughts. Attempts will be made to establish positive thinking. Attention: Recognizing the relationship between pain sensation and attention and encouraging its expression is included in the intervention. Information on distraction was given and two exercises we planned to increase the level of awareness.
41504316|NCT02870010|BIOLOGICAL|blood samples (5 ml) will be taken|blood samples (5 ml) will be taken
41504317|NCT02870010|RADIATION|Chemoembolization|Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
41504318|NCT01696058|DRUG|Tiotropium|marketed product
41504319|NCT01696058|DRUG|Placebo matching Olodaterol|one dose
41504320|NCT01696058|DRUG|Tiotropium|marketed product
41504321|NCT01696058|DRUG|Olodaterol|one dose
41504322|NCT05840679|DRUG|Irrigation Solution|Different concentrations of NaOCl are being used as the endodontic irrigant.
41504323|NCT04556851|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
41504324|NCT04556851|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
41504325|NCT04556851|DRUG|Placebo|Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
41504326|NCT02865460|DRUG|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
41504327|NCT02865460|DRUG|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
41504328|NCT01061476|DEVICE|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
41504329|NCT01061476|OTHER|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
41504330|NCT01061476|OTHER|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
41504331|NCT06550362|DRUG|iron sulfate|Oral iron administration
41504332|NCT00575887|DRUG|Temozolomide|100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
41372765|NCT04489862|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion，Cyclophosphamide 300 mg/m2/day IV infusion on days -5, -4 and -3. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
41504333|NCT05408585|OTHER|Regional Anesthesia Techniques|Fascial Plane Blocks
41504334|NCT02094911|BEHAVIORAL|Combined lifestyle intervention|"10-month intervention period with:~* weekly group-based sports lessons supervised by a physiotherapist~* individual dietary advice by a dietician~* case management by practice nurse~* maintenance programme to guide subjects to maintain lifestyle behaviour change"
41031675|NCT02692248|DRUG|Rituximab|Rituximab 375 mg/m2 IV day 1 during 4 cycles.
41163167|NCT01997437|DEVICE|Stem-cell seeded bioartificial tracheal scaffold|Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
41031676|NCT02692248|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
41031677|NCT02692248|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
41163168|NCT00352963|BIOLOGICAL|Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec|
41372766|NCT00053911|DRUG|anastrozole|
41504335|NCT02094911|OTHER|Usual care group|Written information on healthy lifestyle was provided at baseline, no individual advice or programme was provided. No additional appointments were scheduled, apart from the visits for follow-up measurements
41504336|NCT03132779|DRUG|Intralipid|Adose of intralipid given and rechecking NKcells activity
41031678|NCT02692248|DRUG|Dexamethasone|Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
41031679|NCT02653521|RADIATION|Dose adaptation|Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
41031680|NCT04236557|BEHAVIORAL|Music listening|Other than usual care, subjects will listen to a 30-min individualized playlists with preferred music genres sequenced by a registered music therapist according to the ISO-Principle when agitated.
41031681|NCT04236557|BEHAVIORAL|Audio Book Listening|Other than usual care, subjects will listen to to a 30-min audio-script of book reading in Cantonese (a common dialect in Hong Kong being spoken by most people) when agitated.
41031682|NCT03314987|DIETARY_SUPPLEMENT|L-carnosine|a naturally occurring di-peptide
41031683|NCT03314987|OTHER|placebo|an identically appearing supplement
41372767|NCT00053911|DRUG|cyclophosphamide|
41372768|NCT00053911|DRUG|docetaxel|
41372769|NCT00053911|DRUG|epirubicin hydrochloride|
41372770|NCT00053911|DRUG|fluorouracil|
41372771|NCT00053911|DRUG|goserelin acetate|
41372772|NCT00053911|DRUG|tamoxifen citrate|
41031684|NCT01197040|DRUG|Prednisone|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
41031685|NCT01197040|DRUG|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
41372773|NCT00053911|PROCEDURE|adjuvant therapy|
41372774|NCT01743495|BEHAVIORAL|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
41372775|NCT04480554|DRUG|Methadone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
41372776|NCT04480554|DRUG|Buprenorphine/naloxone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
41504337|NCT00920790|BIOLOGICAL|KW-0761|KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
41504338|NCT05419921|DIAGNOSTIC_TEST|Hysterosalpingo-lidocaine-foam-sonography combined with power doppler (HyLiFoSy-PD)|"Women in the reproductive age group between 18- and 40-years old presenting with primary or secondary infertility who underwent HSG in the previous 5 years as a part of their infertility work-up with availability of good-quality HSG images, \& did not get pregnant in this period, and gave no history of incidences that might affect their tubes, such as : abdominal surgery or laparoscopy, pelvic inflammatory disease, smoking, and intrauterine device insertion.~Women fitting these inclusion criteria and scheduled for LDT as part of their infertility work up will be considered. HyLiFoSy-PD will be carried out few days before the already scheduled LDT."
41372777|NCT04480554|DRUG|XR-Naltrexone|Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
41372778|NCT03155269|DIETARY_SUPPLEMENT|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
40849011|NCT01737216|DRUG|EP/TP|Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
41372779|NCT03155269|DIETARY_SUPPLEMENT|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
41372780|NCT04314115|OTHER|Mindfulness|Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.
41372781|NCT04314115|OTHER|Systemic therapy|Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.
41372782|NCT04314115|OTHER|Cognitive behavioral therapy and positive psychology|Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
41372783|NCT01483495|DEVICE|Diffuse optical spectroscopy|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
40849012|NCT01561053|BIOLOGICAL|Albumin 5%|Therapeutic plasma exchange with human albumin 5%
40849013|NCT01561053|BIOLOGICAL|Albumin 20%|Low volume plasma exchange with human albumin 5%
41031686|NCT05229289|OTHER|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
41031687|NCT05229289|OTHER|Fecal Microbiota Transplant|Fecal Microbiota Transplant
41372784|NCT02255045|DRUG|Meloxicam|1 Meloxicam Vaginal Ring (MVR) for 4-6 days
40849014|NCT01561053|BIOLOGICAL|Immunoglobulin|Intravenous human immunoglobulin 5%
40849015|NCT03592563|BEHAVIORAL|Neuro-QoL questionnaire|Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
41372785|NCT02255045|DRUG|Diclofenac Potassium|1 tablet 50 mg diclofenac every 12 hours for 4-6 days
41372786|NCT02255045|DRUG|Placebo Oral|1 placebo tablet every 12 hours for 4-6 days
41372787|NCT02255045|DRUG|Placebo Vaginal|1 placebo vaginal ring for 4-6 days
41163169|NCT02469077|BEHAVIORAL|6 week aerobic exercise intervention|"Participants randomly assigned to the 6 week aerobic exercise intervention will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks).~Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out."
41163170|NCT02469077|DRUG|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
41372788|NCT05609656|DEVICE|Irreversible electroporation|"Percutaneous ablation of a metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is CE approved for medical use."
41372789|NCT05609656|DEVICE|Calcium electroporation|"Just before the reversible electroporation, calcium chloride will be injected into the primary tumor. The electroporation will be delivered as at least four pulses and up to eight pulses. The device is repositioned after each pulse to ensure coverage of the entire surface area of the tumor.~The reversible electroporation regime will be delivered through the endoscopic device EndoVE®, while the ePORE® will be used for pulse generation, both CE approved."
41031688|NCT02635815|PROCEDURE|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
41031689|NCT00534729|DRUG|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
41031690|NCT05928026|BEHAVIORAL|Financial Support|A debit card will be loaded with $500 and can be used like a typical debit card.
41031691|NCT06149260|DRUG|Semaglutide Pen Injector|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.
41031692|NCT05575947|DEVICE|da Vinci Surgical System|da Vinci Surgical System
41031693|NCT05575947|PROCEDURE|laparoscopic bariatric surgery|laparoscopic bariatric surgery
41031694|NCT06465420|BIOLOGICAL|Haemophilus influenzae type a (Hia) glycoconjugate vaccine|0.5 mL intramuscular injection, given on days 0 and 28
41031695|NCT02256462|DRUG|Adalimumab|Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (\> 40kg 160/80/40 mg every 2 weeks or \< 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
41031696|NCT06095414|DIAGNOSTIC_TEST|MRI|MRI based assessment of tumor microenvironment in breast cancer mass
41031697|NCT06276855|OTHER|Sleep hygiene education|The sleep hygiene education booklet was prepared by the researchers by in line with the literature. The booklet contains information on the definition and benefits of sleep, sleep problems during insomnia, arrangements for regular sleep, and the principles of sleep hygiene. The principles of sleep hygiene include individual habits that facilitate sleep, proper arrangement of the physical environment, exercises before going to bed, and dietary habits. This educational content was applied to those in the experimental group. The education took an average of 30 minutes.
41031698|NCT04218968|DRUG|Carvedilol|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.
41031699|NCT02079805|DRUG|Azilsartan|Azilsartan tablets
41031700|NCT02079805|DRUG|Telmisartan|Telmisartan tablets
41031701|NCT00164437|BEHAVIORAL|educational CD-ROM|
41031702|NCT00401570|DRUG|Volociximab|Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
41031703|NCT00401570|DRUG|Gemcitabine|Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
41031704|NCT02532218|DRUG|ARI-3037MO|Lipid lowering treatment Statins
41031705|NCT01813799|DRUG|DA-9801 300mg|300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
41031706|NCT01813799|DRUG|DA-9801 600mg|600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
41163171|NCT02469077|DRUG|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
40849016|NCT03323177|DIETARY_SUPPLEMENT|Gender specific nutritional standardized formula|Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
40849017|NCT03323177|OTHER|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
41031707|NCT01813799|DRUG|DA-9801 900mg|900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
41372790|NCT05609656|DRUG|Pembrolizumab|"Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months~Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
41372791|NCT02736006|OTHER|20 meters air dive|"A dive in the depth of 20 m during 40 minutes. The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.~In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react."
41372792|NCT00501969|DRUG|Rotigotine|"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
41372793|NCT00939068|DRUG|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
41031708|NCT01813799|DRUG|Placebo|Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
41372794|NCT00939068|BIOLOGICAL|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
41372795|NCT00470301|DRUG|tipifarnib|Given orally
41504339|NCT01586793|DEVICE|Magstim Rapid2 Stimulator|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
41504340|NCT01586793|DEVICE|Magstim Rapid2 Stimulator|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
41504341|NCT04153903|OTHER|OCT, coronary angiography, FFR|Coronary images by OCT and angiography and FFR values will be registered.
40849018|NCT01918956|BIOLOGICAL|PURETHAL Birch, 20.000 AUM/ml|comparison of different up-dosing regimes
40849019|NCT04979494|OTHER|ultrasound examination|We conduct abdominal ultrasound examinations for each patient.
40849020|NCT00351507|DRUG|Vildagliptin|
41031709|NCT03013010|DRUG|Tegafur-Gimeracil-Oteracil Potassium|The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
41031710|NCT03013010|RADIATION|Chemoradiotherapy|"Chemotherapy: S-1 40-60mg/m2 orally, oral tablet twice daily, days 1-5 of each week of radiotherapy.~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
41163172|NCT02469077|DRUG|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
41372796|NCT00470301|DRUG|paclitaxel|Given IV
41372797|NCT00470301|DRUG|doxorubicin|Given IV
41031711|NCT03013010|PROCEDURE|Gastric resection|A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.
41372798|NCT00470301|DRUG|cyclophosphamide|Given IV
41372799|NCT05443776|OTHER|Biomaterial implantation|Implant a approved biomaterial by European Regulatory Agencies
41372800|NCT03661346|DRUG|Labetalol|"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"
41372801|NCT03661346|DRUG|Esmolol|"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"
41372802|NCT06102473|OTHER|Nutritional education|With prior authorization from the principals of the elementary schools, meetings will be held with parents to invite them to participate, and the aim, activities, and duration of the intervention will be explained to them. They will be invited to sign a consent and informed assent, clarifying that their participation is voluntary and they may not continue at any time they wish without affecting their activities at school.
41504342|NCT00839553|PROCEDURE|Intrapleural Minocycline application|
41504343|NCT03640286|DEVICE|VeSTAL|The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.
41504344|NCT03981692|OTHER|Consecutive dual task|8 weeks and 2 days per week, one session 45 min. Consecutive dual task creates the idea that it may provide more workable work without creating stress while doing secondary task during dual task.
41504345|NCT03981692|OTHER|Integrated dual task|8 weeks and 2 days per week, one session 45 min. Integrated dual task is a proven mode of work that has positive effects on geriatrics
41504346|NCT05350605|BEHAVIORAL|Breastfeeding position education with lactation simulation model|pregnant women will receive training with a lactation simulation model once in the last trimester.The pregnant woman will wear the lactation simulation model during the education period and show what she has learned practically on the model.Mothers who have given birth will be supported to practice the breastfeeding position in the postpartum service.
41372803|NCT04935528|BIOLOGICAL|serology and ELISPOT test|27 mL blood sample to study the humoral and the cellular immune response
41372804|NCT04935528|BIOLOGICAL|serology|7 mL blood sample to study the humoral response
41372805|NCT02875743|DRUG|Posaconazole|
41372806|NCT01052220|BEHAVIORAL|BP education and BP self-regulation|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
41031712|NCT03013010|DRUG|Oxaliplatin|The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
40849021|NCT04872660|DRUG|Gushen Antai Pill|The Gushen Antai Pill (GSATP, Z20030144) is composed of 10 herbs including radix-polygoni multiflori, radix rehmanniae praeparata, cistanche salsa, radix dipsaci, uncaria, semen cuscutae, rhizoma atractylodis macrocephalae, radix scutellariae, radix paeoniae lactiflorae. Its production follows GMP standards and takes the form of water honey pills, each bag of 6g.
40849022|NCT04872660|DRUG|Placebo pill|The placebo pill is produced by Beijing boran Pharmaceutical Co., Ltd. It can simulate the appearance, color and smell of GSATP formula, but it has no clinical effect because it has no active ingredients.
41031713|NCT03778736|OTHER|Cumulase denudation|Testing the effect of cumulase for women with poor oocyte yield due to poor ovarian reserve
41031714|NCT03829904|DRUG|VGH-BPH1|A scientific Chinese granule powder
41031715|NCT03829904|DRUG|Placebo (Corn starch pill manufactured to mimic VGH-BPH1)|Corn starch pill manufactured to mimic VGH-BPH1
41031716|NCT03517644|OTHER|DP|Participants are informed that they are about to receive an effective analgesic cream. They are instructed to apply the cream using a cotton pad.
41031717|NCT03517644|OTHER|OLP Hope|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. Therefore, participants are supposed to evaluate the subjective probability for a positive effect of the cream as rather low. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect for them because this placebo cream did have a positive among some former participants who were similar to the current participant. The emphasis of this similarity (regarding age and sex) aims to induce a feeling of connectedness to previous participants who reported positive effects of the placebo cream.
41031718|NCT03517644|OTHER|OLP Expectation|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, participants are told that placebos have been shown to contribute substantially to clinical outcomes such as pain intensity/unpleasantness. This positive effect of placebos is reasoned by explaining learning mechanisms such as classical conditioning. We anticipated that after hearing this instruction, participants would consider it to be likely that the placebo has a positive effect for them.
41031719|NCT03517644|OTHER|Placebo cream|The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).
41031720|NCT03517644|OTHER|Heat pain|Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
41031721|NCT00966316|DRUG|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
40849023|NCT01962870|DRUG|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
41031722|NCT04571619|BEHAVIORAL|Pain Coping Skills Training (PCST)|The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills. For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use. During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video). During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone. The telehealth component will consist of weekly sessions, each lasting 45-50 minutes. The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes. Both components of the intervention will be available in English and Spanish.
41372807|NCT01052220|BEHAVIORAL|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
41372808|NCT03480243|DRUG|Padsevonil (UCB0942)|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
41504347|NCT06158620|DRUG|intra-nasal ketorolac|Experimental group receiving intra-nasal ketorolac for management of post-operative pain following ureteroscopy for kidney stone, and associated ureter stent discomfort.
40849024|NCT01962870|DRUG|Placebo|
40849025|NCT02725229|PROCEDURE|parasternal block|parasternal block and PCA for sternotomy pain
40849026|NCT02725229|DEVICE|TENS group|TENS and PCA for sternotomy pain
41163173|NCT04145323|DIAGNOSTIC_TEST|ICG microangiography|Indocyanine Green (ICG) is a FDA approved dye which preferentially bind to exposed phospholipids in the membranes of necrotic cells, thus acting as a biomarker for necrotic tissue.
41163174|NCT00989898|OTHER|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
41504348|NCT06158620|DRUG|oral diclofenac|Control group to receive oral diclofenac, which is a comparable medication to intra-nasal ketorolac.
41163175|NCT01613807|DRUG|Insulin LISPRO|Humalog® Mix50/50™ \[50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)\], three times daily at mealtime. Dose determined by blood glucose history.
41504349|NCT03399825|DEVICE|OCT-A|"optical coherence tomography angiography~Imaging with optical coherence tomography angiography"
40849027|NCT02725229|DEVICE|control group|PCA for sternotomy pain
41372809|NCT03480243|DRUG|Erythromycin|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
41372810|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 7 days
41372811|NCT01205139|DRUG|TDF|300 mg tablet once daily for 7 days
41031723|NCT04571619|DRUG|Buprenorphine|At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
41372812|NCT01205139|DRUG|TMC435 + TDF|150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
41372813|NCT01205139|DRUG|TMC435 + TMC278|150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
41372814|NCT01205139|DRUG|TMC278|25 mg tablet once daily for 11 days
41372815|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 11 days
41372816|NCT01135251|DRUG|dimiracetam|400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
41031724|NCT00941603|DRUG|SCH 900271 15mg|oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks
41163176|NCT01613807|DRUG|Insulin, Long-Acting and Insulin|Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
41372817|NCT01135251|DRUG|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
41031725|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271 10 mg taken once daily for 8 weeks
41372818|NCT00030056|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)|
41372819|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a low dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
41031726|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks
41031727|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks
41163177|NCT00427297|DRUG|AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)|First line regimen
41163178|NCT00427297|DRUG|d4T/3TC/NVP (stavudine/lamivudine/nevirapine)|First line regimen
41163179|NCT00427297|DRUG|AZT/3TC/ABC (zidovudine/lamivudine/abacavir)|First line regimen
41163180|NCT00427297|DRUG|d4T/3TC/ABC (stavudine/lamivudine/abacavir)|First line regimen For children who have anaemia(Hb of\<8g/dl), AZT will be substituted for d4T.
41163181|NCT00427297|DRUG|ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)|Second line regimen
41163182|NCT00427297|DRUG|ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)|Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.
41163183|NCT00427297|DRUG|ABC/3TC/NVP (abacavir/lamivudine/nevirapine)|First line regimen
41372820|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a medium dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
41372821|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a high dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
41372822|NCT02406066|DRUG|Placebo|Each cohort will have 2 subjects receiving placebo
41372823|NCT02783976|DRUG|Sovaldi|Sovaldi 400 mg tablets administered orally once daily
41372824|NCT06353581|DRUG|Neulapeg|Participants will receive Neulapeg subcutaneously 24 hours after the end of modified FOLFIRINOX dosing. (Must be administered within a maximum of 72 hours; Neulapeg will only be given for up to 8 cycles).
41372825|NCT06353581|OTHER|Control|Patients assigned to the non-Neulapeg arm will be crossover to Neulapeg if they develop grade 3-4 neutropenia or neutropenic fever. Crossover subjects will receive up to 8 cycles of Neulapeg as a secondary treatment regardless of starting cycle.
41372826|NCT04944485|OTHER|(FIT SA F03, SHOFU, USA)|Self adhesive giomer containing nanohybrid flowable composite
41372827|NCT04944485|OTHER|(Neo Spectra™ ST, Dentsply, Sirona, USA)|Conventional technique using putty nanohybrid resin composite
41372828|NCT02025127|OTHER|Enteral nutrition|Enteral nutrition introduced via a feeding tube
41372829|NCT02765906|OTHER|Graphic card|A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics \& Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).
41372830|NCT02765906|OTHER|Video|This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
41372831|NCT06221852|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
41372832|NCT06221852|OTHER|Dietary Guidelines for Americans|Dietary Guidelines for Americans diet is a normo-caloric diet consisting of 3 meals a day plus snacks, emphasizing nutrient dense foods to meet food group needs (85% of calories), and limits foods and beverages higher in added sugars and saturated fat (15% of calories).
41031728|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks
41372833|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose 0|"Patients will receive oral ATRA 25 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.~If a dose limiting toxicity occurs at 25 mg/m2, then the dose will be reduced by 50% to 15 mg/sq m daily in two divided doses."
41031729|NCT00941603|DRUG|Placebo|oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
41163184|NCT02656745|DEVICE|Mobile Smoking Cessation Solution|"The intervention regimen is almost entirely user-directed; users will download the application on their iPhones \& engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program."
41163185|NCT04385940|DIETARY_SUPPLEMENT|Ddrops® products, 50,000 IU, Oral|Vitamin D3
41372834|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose -1|"Patients will receive oral ATRA 15 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study."
41504350|NCT06206135|DRUG|the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)|The initial dose of Nephoxil capsules for the subjects participating in this study shall be determined at the investigator's discretion, and subjects shall be classified into either the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) according to the initial dose. It will be conducted with 13 visits over 48 weeks.
41504351|NCT02724371|DEVICE|Mentor Larger Size MemoryGel Ultra High Profile Breast Implant|The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.
41504352|NCT00000693|DRUG|Zidovudine|
41504353|NCT00000693|DRUG|Acyclovir|
41163186|NCT04385940|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 1000IU
40849028|NCT00406536|DIETARY_SUPPLEMENT|Lym-X-Sorb powder|Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
40849029|NCT00406536|DIETARY_SUPPLEMENT|Placebo powder|The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is \>99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
40849030|NCT06379269|DEVICE|App healthcare|Self-developed app: includes home stretching and strengthening exercises, muscle release technique instruction.
40849031|NCT06379269|OTHER|Control|general education and home rehab program
41031730|NCT02620553|DRUG|Human Insulin|There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
41031731|NCT02620553|OTHER|Oral Placebo|Oral Placebo is given orally daily
41031732|NCT00502125|PROCEDURE|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
41031733|NCT05651477|DEVICE|Wearable Device (Smart Watch)|A smart watch refers to an embedded system portable watch equipped with improved functions than a general watch, and is almost always in the form of a wrist watch. The device we are using is the Samsung Galaxy 4 (SM-R860/870).
41031734|NCT05651477|DEVICE|Edge-Box|Edge-Box collects data such as air. The device we are using is the TDS Mfepc-4C2R.
41031735|NCT02796339|DIETARY_SUPPLEMENT|Mastiha|
41163187|NCT04866433|PROCEDURE|Real-time binaural sound|Play music with a frequency difference (real-time binaural sound) in each ear through headphones during sedation.
41163188|NCT04866433|PROCEDURE|Music|Play the same music in both ears through headphones during sedation
41163189|NCT04866433|PROCEDURE|Control|Just wear headphones during sedation
41372835|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose 1|"Patients will receive oral ATRA 45 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study."
41372836|NCT00003726|BIOLOGICAL|lepirudin|lepirudin
41372837|NCT02478216|PROCEDURE|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
40849032|NCT00637962|BIOLOGICAL|HIV glycoprotein CN54gp140 (vaccine)|vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
41163190|NCT06347029|PROCEDURE|Urine sampling|Urine sampling
41031736|NCT02796339|DIETARY_SUPPLEMENT|Placebo|
41031737|NCT01144312|DRUG|Fentanyl|an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
41031738|NCT00098124|DRUG|milnacipran hydrochloride|
41031739|NCT01954654|DEVICE|Custom-made compression sleeve and -gauntlet|Device: Compression garments worn for a minimum of six hours per day
41031740|NCT01954654|OTHER|Educational information, recommendation and instruction|Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
41163191|NCT06347029|PROCEDURE|Blood sampling|Blood sampling
41163192|NCT06347029|DEVICE|Flow mediated dilatation test|The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
41163193|NCT01282749|BEHAVIORAL|SisterTalk Hartford|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
41163194|NCT01282749|BEHAVIORAL|Attention control video series|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
41163195|NCT05441371|OTHER|Toothpaste; Paradontax|Comparison of Paradontax toothpaste anti-plaque abality versus regular toothpaste
41163196|NCT03767400|DEVICE|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.
41372838|NCT02335229|DEVICE|Axium DRG Neurostimulator|Implantation with Axium DRG Neurostimulator
40849033|NCT00637962|BIOLOGICAL|Carbopol 974|vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
40849034|NCT00680797|DRUG|Testosterone|Testosterone gel
40849035|NCT00680797|DRUG|Estrogen|Estrogen patch
41372839|NCT06439134|DIAGNOSTIC_TEST|Pulmonary Ultrasound, Respiratory Function Test|Volunteers underwent pulmonary ultrasound and respiratory function test
41372840|NCT06192875|OTHER|Non-Interventional Study|Non-interventional study
40849036|NCT05799794|BEHAVIORAL|Supervisor-led Implementation Coaching|Implementation coaching, support, or facilitation includes the support provided to supervisors and their organizations for successfully delivering an evidence-based practice (EBP). Implementation support can include consultation, supervision, and coaching.
40849037|NCT03190616|DRUG|apatinib|apatinib 500mg/qd, 28d/cycle
41372841|NCT03041818|BEHAVIORAL|Horseback riding therapy|Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
41372842|NCT05329012|DEVICE|DUL- Distal Ulna Locking PLate (I.T.S)|The patients are surgical treated with the Distal Ulna locking plate according to standard surgical procedures to treat the unstable distal ulna fractures.
41372843|NCT02668445|OTHER|Standard meal containing low or high carbohydrate content|
41372844|NCT03563729|DRUG|Pembrolizumab Injection [Keytruda]|Alone
41372845|NCT03563729|DRUG|Ipilimumab Injection [Yervoy]|In combination with nivolumab.
41372846|NCT03563729|DRUG|Nivolumab Injection [Opdivo]|In combination with ipilimumab.
41372847|NCT03563729|DRUG|Encorafenib|In combination with binimetinib
41372848|NCT03563729|DRUG|Binimetinib|In combination with encorafenib
41372849|NCT03563729|DRUG|Dabrafenib|In combination with dabrafenib
41372850|NCT03563729|DRUG|Trametinib|In combination with trametinib
41504354|NCT06632587|PROCEDURE|Early cranioplasty|Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Early cranioplasty is defined as being performed within 8 weeks following the decompressive hemicraniectomy.
40849038|NCT01032031|DIETARY_SUPPLEMENT|Green tea + vitamin C high dose|One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
40849039|NCT01032031|DIETARY_SUPPLEMENT|Placebo capsule|One capsule daily for 3 months
40849040|NCT04883814|DIAGNOSTIC_TEST|18F-fluoroestradiol PET/CT|Estrogen receptor targeted imaging
40849041|NCT05933343|PROCEDURE|Ethibond suture|An Ethibond™ 1 suture will be placed as a drainage seton for complex anal fistula
40849042|NCT05933343|PROCEDURE|Vessel loop|A vessel loop will be placed as a drainage seton for complex anal fistula
41031741|NCT04979819|OTHER|Upper extremity endurance test (UULEX)|Patients will lift 5 bars consecutively rhythmically until they feel fatigued. The bars will weigh 200 grs 500 gr 1kgs and 2 kgs respectively. The duration of the test will be measured to determine the endurance levels of the patients.
41031742|NCT01043874|DRUG|Nilotinib|400 mg BID
41031743|NCT04956393|BEHAVIORAL|Immediate 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
41372851|NCT04801069|DEVICE|Nocturnal Ventilation|AirCurve 10CS PaceWave (Resmed)
41372852|NCT00538434|BIOLOGICAL|Reslizumab|
41372853|NCT00538434|OTHER|Saline|
40849043|NCT01362387|OTHER|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
40849044|NCT05343572|DRUG|Plerixafor|A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing \>83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.
40849045|NCT06293768|DEVICE|continuous wireless monitoring system of Vital Signs (Win@Hospital) + continuous system for continuous monitoring of blood sugar (Dexcom G6)(only for diabetic patients)|Patients randomized to the experimental group on discharge or with transfer to the subacute ward will be connected to the system continuous monitoring of Vital Signs(Win@Hospital) continuous system for the continuous monitoring of blood sugar(Dexcom G6)(only for diabetic patients). The system, once applied, does not require the presence of a dedicated person and continuous monitoring in real time. It is set with alerts that are triggered both when the parameters they leave the normal ranges both if the data is not recorded due to technical problems. the data is transmitted in real time on mobile devices in the possession of a doctor and a nurse available 24 hours a day who guarantee the remote control system. Devices. Mobiles also contain the clinical information of each patient.
40849046|NCT03691662|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
40849047|NCT03691662|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
41031744|NCT04956393|BEHAVIORAL|Delayed 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
41031745|NCT05524194|DRUG|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
41031746|NCT04781153|PROCEDURE|Periodontal treatment|Periodontal treatment (scaling and rootplaning) with adjunctive chlorhexidine use
41031747|NCT03087266|PROCEDURE|FM-SRP|Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
41031748|NCT03087266|PROCEDURE|Q-SRP|Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
41031749|NCT01858662|PROCEDURE|Metastases Resection ( multiple steep surgery possible)|Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
41031750|NCT01858662|DRUG|5-Fluorouracile|5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
41031751|NCT01858662|DRUG|leucovorin L|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
41031752|NCT01858662|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
41031753|NCT01858662|DRUG|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
41031754|NCT01858662|DRUG|Cetuximab|Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
41031755|NCT00720954|PROCEDURE|Ct-guided pleural needle biopsy|Biopsy of pleura
41031756|NCT00720954|PROCEDURE|Thoracoscopy|Biopsy of pleura
41031757|NCT00673049|DRUG|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
41031758|NCT00673049|DRUG|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
41031759|NCT00673049|DRUG|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
41031760|NCT04711564|OTHER|Olive oil-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
41031761|NCT04711564|OTHER|Soybean-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
41031762|NCT03360461|DRUG|EMI-137|EMI-137 - a fluorescent c-Met receptor targeted peptide
41031763|NCT05006170|DRUG|DTG DT 20 mg|Give 2 tabs of MYLTEGA DT (10mg) PO once daily
41031764|NCT05006170|DRUG|DTG DT 25 mg|Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
41031765|NCT05598359|DIETARY_SUPPLEMENT|TA-65|TA-65 is a purified small molecule extracted from Astragalus root
41372854|NCT04409327|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 4 weeks
41031766|NCT05598359|OTHER|Placebo|Inactive formulation
41031767|NCT01359553|OTHER|Intra-articular ultrasound imaging of knee joint during arthroscopy|
41031768|NCT01359553|OTHER|Non-invasive ultrasound imaging of knee|
41031769|NCT01359553|OTHER|Quantitative MRI imaging of knee|
41031770|NCT01359553|OTHER|Contrast-enhanced CT imaging of knee|
41031771|NCT05881668|BIOLOGICAL|MSC-EV|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
41372855|NCT04409327|DRUG|Placebo|Oral matching placebo once daily for 4 weeks
41031772|NCT04257370|DEVICE|Kerecis™ Omega3 Wound|Kerecis™ Omega3 Wound is decellularised, intact fish skin from North Atlantic cod fish. Kerecis™ Omega3 Wound is FDA approved and EU cleared for the treatment of diabetic ulcers, chronic vascular ulcers, venous ulcers, trauma wounds (including abrasions, lacerations, and skin tears), acute surgical wounds (including debridement, amputation, and donor sites), surgical wounds (dehiscence or failed healing after surgery), imminent failure of STSG, and post-injection necrosis.
41031773|NCT04257370|OTHER|Standard of care|Standard of care wound treatment as defined by the local site, including debridement of the wound, standard wound dressing, and proper offloading of the wound site.
41372856|NCT05797142|OTHER|Virtual reality glasses|"Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes)."
41372857|NCT04476576|BEHAVIORAL|Aerobic exercise (experimental)|3 times per week, 30 minutes each time. Entrance in heat: 8-10 min of joint mobility and / or the aerobic exercise in the main part at light intensity (OMNI 3-4) Main part: minimum 30 minutes, maximun 60 minutes. Intensity: moderate, guided by Talk Test and effort perception scale 5-6 OMNI. Type: aerobic, cycling or walking at home using a treadmill or exercise bike and / or cycling and walking outdoors according to the patient's possibilities and preferences. Return to calm: 5 min of aerobic physical activity of main part at mild intensity (OMNI 3-4), then static stretching. Pictures with each type of exercise will be offered and detailed explained.
41372858|NCT04476576|BEHAVIORAL|Flexibility exercise (active comparator)|Entrance in heat: 10 min of joint mobility. Main part: Minimum 30 minutes. Frequency: 3 times por week Intensity: The patient should be able to slowly stretch the muscle to a position of mild discomfort. Type: Static Stretch Time: 15-30 seconds 2 repetitions of each stretch Number of exercises: 12 . Pictures with each muscle group to exercise will be offered and detailed explained.
41031774|NCT05282381|BEHAVIORAL|DRS : Decision Regret Scale|"The DRS is a self-administered questionnaire including 5 items assessing decisional regret in a score graduated between 0 and 100 (0 = no regret).This scale is associated with the ReTransQoL, a specific quality of life questionnaire.~Questionnaires are administrated at 1, 3, 6 and 12 months post-transplantation."
41031775|NCT06532708|OTHER|5x Oxycodone Oral Tablets|Participants will be prescribed 5 doses of 5mg tablets of oxycodone for postoperative pain relief.
41372859|NCT00302068|BEHAVIORAL|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
41372860|NCT00302068|DRUG|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
41372861|NCT00302068|DRUG|Placebo Pill.|Placebo pill, daily, for 16 weeks.
41372862|NCT01169623|OTHER|Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
41372863|NCT01927159|BIOLOGICAL|ID93 + GLA-SE|
41372864|NCT01927159|OTHER|Placebo|
41163197|NCT03767400|OTHER|Facial Cleanser|Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.
41372865|NCT05498545|BIOLOGICAL|LUCAR-B68 cells product|Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen
41372866|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
41372867|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
41372868|NCT01569074|DRUG|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
41372869|NCT01569074|DRUG|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
41372870|NCT01569074|DRUG|Placebo|Placebo twice daily for 12 weeks
41372871|NCT03235063|OTHER|routinely care- no intervention|routinely care- no intervention
41372872|NCT04092608|PROCEDURE|GDFT|The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable \< 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.
41372873|NCT04092608|PROCEDURE|LOW CVP (restrictive group)|Goal = CVP \< 7mmHg and only 2 ml/kg/h max during surgery.
41372874|NCT00145795|DRUG|Kaletra + Current Dual NRTI Backbone|
41372875|NCT00145795|DRUG|Current Regimen|
41372876|NCT01320826|PROCEDURE|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
41031776|NCT06532708|OTHER|16x Oxycodone Oral Tablets|Participants will be prescribed 16 doses of 5mg tablets of oxycodone for postoperative pain relief.
41372877|NCT00403962|DRUG|vestipitant/paroxetine|
41372878|NCT04375527|DRUG|Binimetinib|Given PO
41372879|NCT04375527|BIOLOGICAL|Nivolumab|Given IV
41372880|NCT04375527|OTHER|Questionnaire Administration|Ancillary studies
41372881|NCT02530086|PROCEDURE|Nasogastric tube placement|Placement of a Nasogastric tube
41372882|NCT02530086|PROCEDURE|No Nasogastric tube use|No placement of a Nasogastric tube
41031777|NCT03769532|DRUG|Pembrolizumab|Pembrolizumab (IMP): 200mg i.v. (fixed dose), every 3 weeks (Q3W), 8 doses
41031778|NCT03769532|DRUG|Azacitidine|Azacitidine (SOC): 75 mg/m2 s.c., day 1-7 every 4 weeks (Q4W), 6 cycles
41031779|NCT01834365|OTHER|Structured education|Formatted education about hypertension
41031780|NCT01834365|OTHER|Checklist|
41031781|NCT01834365|OTHER|Without structure education with checklist|
41031782|NCT03020420|OTHER|Cicatricell Cream|Cream to be applied 2 times a day for 8weeks to 6 months
41163198|NCT01717547|BEHAVIORAL|Yoga-based treatment|
41372883|NCT00065169|DRUG|Celecoxib|
41372884|NCT01863394|OTHER|Screening by mothers|
41372885|NCT01863394|OTHER|Active comparator: Screening by community health workers|
41031783|NCT01028209|DRUG|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.
41031784|NCT05923944|BEHAVIORAL|Eco-Rescue|Ecorescue is a gamified adaptation of the multiple object tracking task (MOT) combined with a detection task. It requires to track the spatial position of specific moving targets among visually similar moving distractors, while at the same time detecting briefly flashed events. It was designed to load on attentional control and visuo-spatial working memory. Additionally, targets may express various facial emotions (happy, angry or neutral) requiring some emotional control in addition to attentional control.
41031785|NCT05923944|BEHAVIORAL|Bejelewed 3|Bejeweled 3 is a commercially available puzzle video game developed and edited by PopCap Games. The main objective is to swap two adjacent gems of seven colors to create a line or row of 3 or more gems of the same type. When these gems are aligned, they disappear, and points are earned. The goal is to get as many points as possible until it is impossible to line up gems. Bejeweled 3 offers a variety of game modes that players can freely explore at their own pace, enhancing the overall enjoyment and providing increased variability during each gaming session. These game modes typically have shorter durations, with a single game usually lasting less than 5 minutes. Bejeweled 3 was chosen as it requires fewer attentional resources compared to Eco-Rescue and because it was reported to reduce stress and anxiety in adult samples (Russoniello et al. 2009, 2013).
41031786|NCT05213845|PROCEDURE|Spine flexion/extension active range of motion exercises|Five full active range of motion rehabilitation sessions will be scheduled. Four or the five following full active range of motion exercises will be performed during one rehabilitation session : spine flexion and extension (quadrupedic position), lumbar flexion and extension (sitting position), posterior and anterior pelvic tilt (sitting and standing position), lumbar flexion and extension (standing position) and Jefferson Curl exercise. All five rehabilitation sessions must be performed within 60 days
41031787|NCT06484062|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41031788|NCT06484062|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
41031789|NCT06484062|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
41031790|NCT06484062|DRUG|Cirtuvivint|Given PO
41031791|NCT06484062|DRUG|Decitabine and Cedazuridine|Given PO
41031792|NCT06484062|PROCEDURE|Echocardiography|Undergo ECHO
41031793|NCT06484062|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41031794|NCT06484062|DRUG|Venetoclax|Given PO
41031795|NCT06390410|DRUG|Simufilam|100 mg PTI-125
41031796|NCT01031823|BEHAVIORAL|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
41031797|NCT00814372|DRUG|MBX-102|capsule
41031798|NCT00814372|DRUG|Placebo|matching placebo
41031799|NCT00814372|DRUG|Actos|over-encapsulated to match MBX-102 and placebo
41031800|NCT00814372|DRUG|Metformin|greater than or equal to 1500 mg/kg day
41372886|NCT01530776|BEHAVIORAL|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
41372887|NCT00740129|DRUG|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
41031801|NCT04399629|BEHAVIORAL|PCIT-ED|12 sessions of PCIT-ED therapy
41031802|NCT04399629|BEHAVIORAL|Parenting Wisely|Teaches parents how to set more effective limits
41031803|NCT02663817|DEVICE|CT Scan|
41031804|NCT03719066|BIOLOGICAL|killed whole cell oral cholera vaccine|two week interval
41031805|NCT03421691|DEVICE|excel V Laser|excel V Laser Genesis procedure utilizing 1064 nm laser
41031806|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
41031807|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
41031808|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
41031809|NCT01388387|OTHER|Tacrolimus pharmacokinetics|tacrolimus pharmacokinetics over 12 hours
41031810|NCT00254254|DRUG|Exenatide - Exenatide - Placebo|Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
41031811|NCT00254254|DRUG|Exenatide - Placebo - Exenatide|Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
41031812|NCT00254254|DRUG|Placebo - Exenatide - Exenatide|Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
41031813|NCT02959060|DRUG|BMS-986177|Single dose of BMS-986177 and multiple doses of Rifampin
41031814|NCT02959060|DRUG|Rifampin|Single dose of BMS-986177 and multiple doses of Rifampin
41031815|NCT03060941|BEHAVIORAL|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
41031816|NCT03060941|BEHAVIORAL|Facility access|Participants will receive at 6 month membership to a local fitness facility.
41031817|NCT03060941|BEHAVIORAL|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
41372888|NCT02989922|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
41372889|NCT02188927|OTHER|Implementation of ANL|Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
41372890|NCT02188927|BEHAVIORAL|No included ANL|Sending Standard Invitation only six weeks before planned screening colonoscopy
41372891|NCT04507282|DRUG|LMWH|COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
41031818|NCT03060941|BEHAVIORAL|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
41031819|NCT03060941|BEHAVIORAL|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
41031820|NCT06312839|OTHER|Collecting data from the medical record|"Collecting data from the medical record:~* Gastroepiploic artery diameter before and after ischaemic preconditioning~* Postoperative mortality~* Complications related to embolisation and surgery~* Length of stay in intensive care unit and total length of hospital stay"
41031821|NCT00793208|BIOLOGICAL|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
41031822|NCT01930773|DEVICE|Genotyping|Patients harboring CYP2C19 \*2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
41031823|NCT01930773|DEVICE|Phenotyping|Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
41031824|NCT04306380|OTHER|no intervention, database study|data collection from EMR for database
41031825|NCT03551015|OTHER|Change in the timing of components of usual care|Bringing forward outpatient review, and cardiac rehabilitation after CABG by 3 and 4 weeks respectively.
41031826|NCT04757649|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
41031827|NCT06082180|PROCEDURE|prophylactic central neck dissection|prophylactic central neck dissection was performed for the ipsilateral lesion
41163199|NCT02966600|OTHER|Progressive resistance exercise|The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
41163200|NCT02966600|OTHER|Physical Activity|The control group followed its usual weekly physical activity routine
40849048|NCT00879528|OTHER|Patients with negative PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET:~PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells."
41031828|NCT02099734|BEHAVIORAL|Questionnaires|
41031829|NCT02099734|OTHER|sample of blood or saliva|A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
41031830|NCT02754635|OTHER|Induction of labour|Induction of labour
41031831|NCT02754635|OTHER|Expectant management|Expectant management
41163201|NCT04826926|PROCEDURE|Procedure/Surgery: Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
41163202|NCT00826371|DRUG|ranibizumab 0.5 mg|
41163203|NCT01747629|DRUG|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
41163204|NCT01747629|DRUG|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
41372892|NCT05518058|OTHER|device and exercises|device and exercises
41372893|NCT04720976|DRUG|JAB-3312|JAB-3312 will be administered orally, variable dose.
41372894|NCT04720976|DRUG|Binimetinib|Binimetinib will be administered orally.
40849049|NCT00879528|OTHER|Patients with positive PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET~PET positive, the consolidation therapy consists of 2 phases:~* phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells~* phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.~If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells."
41031832|NCT06272734|DEVICE|Reprieve System|"The study is broken into stages:~1. In Stage one, Subjects enrolled in the study received Reprieve System (RS) therapy, a hospital bedside fluid management system designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure. (complete, N=10)~2. In future Stages, Subjects enrolled in the study will receive RS therapy and will be given varying levels of water consumption to challenge the algorithm. Future Stages will also assess new RS hardware and software features."
41372895|NCT04720976|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous infusion.
41031833|NCT02626715|DRUG|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
41031834|NCT02626715|DRUG|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
41372896|NCT04720976|DRUG|Sotorasib|Sotorasib will be administered orally.
41372897|NCT04720976|DRUG|Osimertinib|Osimertinib will be administered orally.
41372898|NCT01881867|BIOLOGICAL|Glycosylated Recombinant Human Interleukin-7|Given SC
40849050|NCT06420180|PROCEDURE|hip arthroscopy|"CT rotational profile Will be used for measurement of LL rotational abnormality.~MRI will be evaluated for the presence of labral tears, chondral lesions, ligamentum teres pathology, and other soft-tissue disorders."
40849051|NCT05949632|DRUG|INCB099280|Administered as specified in the treatment arm description
40849052|NCT05949632|DRUG|axitinib|Administered as specified in the treatment arm description
41031835|NCT03223363|DIAGNOSTIC_TEST|2D and 3D ultrasonography|All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
41031836|NCT03771482|BEHAVIORAL|Quiztime modules|Text Messaging or Email system
41031837|NCT03408912|DIAGNOSTIC_TEST|FFR|FFR from CMR compared to invasive FFR
41031838|NCT03577002|OTHER|Serious Illness Care Program (SICP)|SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations
41372899|NCT01881867|OTHER|Laboratory Biomarker Analysis|Correlative studies
41372900|NCT05079984|BEHAVIORAL|Graded exposure treatment (GET)|Graded-exposure is a theory driven, individually tailored, and evidenced based behavioral intervention for individuals with chronic pain targeting pain-related impairment by exposing patients to previously feared and avoided activities.
41372901|NCT02837666|DIETARY_SUPPLEMENT|Supplementation with Spirulina maxima|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
41372902|NCT02837666|OTHER|Washout|2 weeks washout period to each study subject to avoid any possible carryover effect.
41372903|NCT02837666|OTHER|Supplementation with placebo|Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.
41372904|NCT02837666|OTHER|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks
41504355|NCT06632587|PROCEDURE|Standard-of-care cranioplasty|Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Standard-of-care cranioplasty is defined as being performed after 3 months following the decompressive hemicraniectomy.
41372905|NCT02837666|OTHER|Exercise program|Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
41372906|NCT01891669|DRUG|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
41372907|NCT01891669|DRUG|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
41031839|NCT04398524|DRUG|ISA101b|ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
41372908|NCT04701957|BEHAVIORAL|Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
41372909|NCT00859352|DRUG|AZD1981|oral tablets during 14 consecutive days.
40849053|NCT02634502|PROCEDURE|radiofrequency ablation|
41031840|NCT02484794|BEHAVIORAL|Standard Outpatient Treatment|Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
41372910|NCT00859352|DRUG|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
41372911|NCT02515175|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
41031841|NCT02484794|BEHAVIORAL|Smartphone App|The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
41163205|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
41372912|NCT02515175|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
41372913|NCT02515175|DRUG|Placebo|0.9% Normal Saline
41504356|NCT02197910|OTHER|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
41504357|NCT02197910|OTHER|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
41504358|NCT03983915|DRUG|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
41504359|NCT03983915|DRUG|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
40849054|NCT02634502|DRUG|S-1|
40849055|NCT06066008|DRUG|ZM-01-L|rAAV-hRS1 intravitreal injection of low dose
40849056|NCT06066008|DRUG|ZM-01-H|rAAV-hRS1 intravitreal injection of high dose
41372914|NCT00230113|DIETARY_SUPPLEMENT|Omega-3 fatty acid diet supplementation|4 gm fish oil per day
41031842|NCT02462746|DIETARY_SUPPLEMENT|L-Cysteine|The trade name is New Root Herbal Inc.
41031843|NCT05598333|DRUG|AB-1002|Intracoronary Infusion of AB-1002 or placebo
41031844|NCT02410395|PROCEDURE|Conventional|Two-layer technique with the first layer performed as an un-locked, continuous suture without inclusion of the endometrium and the second layer performed as an un-locked, continuous suture with the stitches placed superficially, horizontally along the first layer.
41031845|NCT02410395|PROCEDURE|Modified|The modified mattress suture is performed as a single-suture, double-layer technique with limited inclusion of the myometrium and broad inclusion of the serosal surface and myometrium, interchangeably
41031846|NCT00659269|DIETARY_SUPPLEMENT|Multivitamin (MV)|Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
41031847|NCT00659269|DIETARY_SUPPLEMENT|Multivitamin + Vitamin B12 + Vitamin B6|Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
41031848|NCT00659269|DRUG|Chemotherapy|"Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800"
41031849|NCT06636630|PROCEDURE|Quadruple scleral flap|Quadruple Flap Technique (Group B) A 360-degree peritomy will be performed to expose the underlying sclera. Following evisceration of the ocular contents, careful hemostasis will be achieved. Four muscular-tendinous flaps will be developed from the recti muscles. These flaps will be dissected under minimal tension to preserve their vascular supply. The prepared flaps will be draped over the implant in a manner that the edges slightly overlap, ensuring complete coverage. The flaps will be sutured together using silk sutures, securing the implant in place.The conjunctiva will be meticulously closed over the muscle flaps with continuous absorbable sutures to enhance the healing process and minimize postoperative discomfort.
41031850|NCT06636630|PROCEDURE|Double scleral flap|The double flap technique, which involves the creation of two scleral flaps to encase and secure the implant, has been a standard approach in many surgical settings. This method aims to cover the implant adequately, thereby minimizing exposure risks and enhancing the potential for implant motility.
41031851|NCT05043649|DRUG|Camsirubicin|The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
41031852|NCT00725166|OTHER|Skeletal muscle aging|"W1 - Blood test~* Maximal voluntary contraction of quadriceps~* Hydrostatic weighing~W2 - Maximal metabolic test using a cycloergometer~W3 - Muscular biopsy"
41031853|NCT00841581|DRUG|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
41031854|NCT04789421|DEVICE|Clinical, dermoscopy and Reflective confocal microscopy evaluations|Adjunctive reflective confocal microscopy to dermoscopy and clinical dermatological evaluation.
41031855|NCT04789421|DEVICE|Clinical, dermoscopy evaluations|Dermoscopy and clinical dermatological evaluation only
41163206|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)~* Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)"
41372915|NCT00230113|DIETARY_SUPPLEMENT|safflower oil|4 gm per day safflower oil
41372916|NCT04189224|DEVICE|JJV Investigational Multifocal Contact Lens|TEST
41372917|NCT04189224|DEVICE|1-Day Acuvue® Moist Brand Multifocal Contact Lens|CONTROL
41372918|NCT01763125|OTHER|Blood collection|Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
41372919|NCT00937430|OTHER|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
41372920|NCT00775827|DRUG|fenofibrate 160 mg tablets|
41372921|NCT06440044|OTHER|Data collection|A prospectively maintained database query of all patients with CRC and VTE was initially performed, and then each patient's electronic record was reviewed for inclusion criteria.
41372922|NCT02563366|OTHER|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
41372923|NCT02563366|OTHER|Saline|Saline is the placebo of MSCs in this study.
41372924|NCT00494234|DRUG|Olaparib|Participants will receive capsules of olaparib orally as stated in arm description.
41372925|NCT06207045|PROCEDURE|limb elevation|limb elevation more than 45 degrees
41372926|NCT02393404|OTHER|PT-FMT|Physiotherapeutic functional movement-power training
41372927|NCT02393404|OTHER|FMT alone|Physiotherapeutic power training
41372928|NCT03317925|PROCEDURE|Renal Transplantation|Kidney transplantation and biomarkers that can identify injury after transplant.
41372929|NCT00978120|BIOLOGICAL|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
41372930|NCT00978120|BIOLOGICAL|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
41504360|NCT03983915|DEVICE|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
41504361|NCT05954910|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.
41031856|NCT02595203|DRUG|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
41031857|NCT02595203|DRUG|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
41031858|NCT02824913|DRUG|P-321 Ophthalmic Solution|
41031859|NCT02824913|DRUG|P-321 Ophthalmic Solution placebo|
41031860|NCT05194397|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
41031861|NCT05194397|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
41031862|NCT05194397|OTHER|Exercise Intervention|The exercise program consists of at-home training sessions and will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strengthening over 16 weeks. For aerobic training, the eventual intensity and duration goal (adapted for each person as necessary) will be for persons to train at 70-80% of peak 2MSPT heart rate 20-45 minutes 3-5 days/week. For resistance exercises the goal will be a load/weight that results in fatigue after 3 sets of 10-12 repetitions on 8-10 exercises 2 days/week.
41372931|NCT06201676|DRUG|Ketorolac Injection|Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin Reference ID: 3281582 3 synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.
41372932|NCT06201676|OTHER|Normal Saline|0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+) 154 mEq; chloride (Cl-) 154 mEq. The osmolarity is 308 mOsmol/L (calc.).
41372933|NCT00514501|DRUG|Iodofiltic acid I 123|
41372934|NCT05672615|OTHER|Questionnaires|Participants will be given the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale to complete prior to each induction intravesical treatment and prior to 3-month follow-up appointments.
41372935|NCT05672615|OTHER|Daily Mood Diaries|Participants will be given daily mood diaries to complete during their 6-week induction intravesical treatment, 3-week maintenance treatment course, and between 3-month follow-up appointments.
41372936|NCT05672615|OTHER|Urine Specimen Collection|Urine collections from patients will occur prior to each induction intravesical treatment and at 3-month follow-up cystoscopy appointments. An at home urine collection may occur 6 hours post intravesical treatment.
41372937|NCT05672615|OTHER|Research Blood Draw|Blood collections will occur prior to first intravesical treatment, prior to fourth intravesical treatment, and each 3-month cystoscopy as indicated by the participant's treatment course.
41372938|NCT05672615|OTHER|Utilize excess tissue from a standard of care procedure|Participants may indicate permission to provide excess tissue from a clinically indicated procedure for research purposes.
41372939|NCT05069376|DEVICE|Ureteral Stent of 5-16 or 5-18|Boston Scientific Polaris™ Ultra Ureteral Stent
41372940|NCT05069376|DEVICE|Ureteral Stent of 5-22 or 5-24|Boston Scientific Polaris™ Ultra Ureteral Stent
41372941|NCT00762073|DRUG|budesonide|oral suspension
41372942|NCT00762073|DRUG|placebo|oral suspension matching budesonide
41372943|NCT00135811|DRUG|Cyclosporin|Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
41372944|NCT00135811|DRUG|MMF and Dexamethasone|"MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.~Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg"
41372945|NCT05643859|DIETARY_SUPPLEMENT|Dietary Fiber|Given PO
41372946|NCT05643859|PROCEDURE|Proctoscopy or anoscopy with Biopsy|Undergo proctoscopy or anoscopy
41372947|NCT05643859|PROCEDURE|Colonoscopy|Undergo Colonoscopy
41372948|NCT05643859|OTHER|Questionnaire Administration|Ancillary studies
41372949|NCT02641691|RADIATION|Radiation|
41372950|NCT02641691|DRUG|Oxaliplatin|
41372951|NCT02641691|DRUG|Leucovorin|
41372952|NCT02641691|DRUG|Fluorouracil|
41372953|NCT02513680|DEVICE|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
41372954|NCT02513680|DEVICE|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
41372955|NCT05361005|DRUG|BDB-001 injection|Intravenous injection
41372956|NCT05361005|DRUG|Placebo|Intravenous injection
41372957|NCT01195662|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
41372958|NCT01195662|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
41372959|NCT00100711|DRUG|Motexafin Gadolinium|
41163207|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)~* Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)"
41163208|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
41163209|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)~* Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)"
41163210|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)~* Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)"
41372960|NCT02992782|BEHAVIORAL|Standard Care|Home program of decongestive exercise and daily use of a compression sleeve
41372961|NCT02992782|BEHAVIORAL|Exercise and Compression Garment|Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve
41372962|NCT02992782|BEHAVIORAL|Exercise and Adjustable Compression Wrap|Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
41372963|NCT00006049|DRUG|carboplatin|
41372964|NCT00006049|DRUG|gefitinib|
41372965|NCT00006049|DRUG|paclitaxel|
41372966|NCT03788317|DRUG|Botulinum toxin type A|Injections to hypertonic muscles
41372967|NCT03482388|BEHAVIORAL|Crowdsourced materials|Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.
41372968|NCT03482388|OTHER|Control|Participants will not view any images or videos promoting HBV and HCV testing.
41372969|NCT02100215|OTHER|Common readings and educational handouts|Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
41031863|NCT04421144|PROCEDURE|orthognathic surgery|patients with maxillofacial disharmony will undergo orthognathic surgery using CAD/CAM Cutting Guides and Customized Titanium Plates.
41031864|NCT04258020|DEVICE|BiPAP|Bilevel Positive Airway Pressure (BiPAP) oxygen administration
41031865|NCT04258020|DEVICE|HFNC|Heated High Flow Nasal Cannula oxygen administration
41031866|NCT00733265|DRUG|AZD6140|single oral dose
41031867|NCT01103206|DRUG|cinacalcet|Intake of a single tablet of cinacalcet
41031868|NCT01103206|DRUG|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
41163211|NCT02713607|DRUG|Doxycycline|Given doxycycline to acne subjects
41163212|NCT04219917|OTHER|Kinesio Tape|Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.
41372970|NCT02100215|OTHER|Expert Modeling|70 minutes of expert modeling videos
41372971|NCT02100215|OTHER|Voice Over Power Point|60 minutes of Voice Over PowerPoint presentations
41372972|NCT03142230|OTHER|the laying of the gastric tube and a group using the holed baby bottle nipple, the feeding tube ideally positioned at the center of the intersection pharyngeal|The newborn then receives the care with the introduction of the gastric tube after randomization with holed baby bottle nipple
41372973|NCT03142230|OTHER|the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier|The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier
41372974|NCT01460979|DRUG|Temsirolimus|25mg weekly intravenous until progression
41372975|NCT00540982|DRUG|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
41372976|NCT00540982|DRUG|lidocaine|1 mg/kg will be administered to determine metabolic capacity
41372977|NCT00540982|DRUG|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
41372978|NCT00540982|OTHER|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
41372979|NCT00540982|OTHER|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
41372980|NCT00540982|OTHER|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
41372981|NCT00540982|OTHER|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
41031869|NCT01103206|DRUG|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
41031870|NCT04744480|PROCEDURE|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
41031871|NCT03579979|DRUG|Methylene Blue|Subcutaneous injection of injection point at the periphery of the areola or tumor, injecting 1% methylene blue 0.5ml at each point, a total of 2-3 points.
41031872|NCT03579979|DRUG|Indocyanine Green|Within 5 minutes after MB injection, 2.5mg/ml ICG 0.5ml was injected at each point, a total of 2-3 points. Methylene blue and ICG injection points do not coincide
41372982|NCT00540982|OTHER|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
41372983|NCT04490109|BIOLOGICAL|B244|B244 suspension
41372984|NCT04490109|BIOLOGICAL|Vehicle|Vehicle suspension
41372985|NCT02384590|BEHAVIORAL|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
41372986|NCT03188250|BEHAVIORAL|Chama cha Mamtoto|Chama cha Mamatoto is a community-based model of peer support group in pregnancy and infancy that combines health education, relationship building and a savings and loans program, led by community health workers
41372987|NCT01846039|DEVICE|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
41372988|NCT05143489|DRUG|Preservative Free Lidocaine|The patient will receive a 1mg/kg IV dose of lidocaine with a max dose of 40mg.
41504362|NCT04219826|DRUG|CK-3773274 (5 - 15 mg)|CK-3773274 tablets administered orally
41504363|NCT04219826|DRUG|CK-3773274 (10 - 30 mg)|CK-3773274 tablets administered orally
41504364|NCT04219826|DRUG|Placebo for CK-3773274|Placebo administered orally
41504365|NCT01290159|OTHER|heat tolerance test (HTT)|An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.
41504366|NCT03931525|DEVICE|Fractitional Radiofrecuency with Drug Delivery|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects and which will be complemented with a skin drug
41504367|NCT03931525|DEVICE|Fractitional Radiofrecuency|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects
41504368|NCT05547841|DEVICE|Echocardiography acquisition|Echocardiography examination of all participants using PHILIPS. Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), 6 weeks and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
41504369|NCT06148415|BEHAVIORAL|Fetal Heartbeat Monitoring Group|Fetal Heartbeat Monitoring Group
41504370|NCT01613313|DRUG|Collagenase Clostridium Histolyticum|This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
41504371|NCT04702308|OTHER|Clinical Decision Rule Alerts|The
41504372|NCT00613886|DEVICE|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
41504373|NCT00613886|BEHAVIORAL|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
41504374|NCT05373628|DIAGNOSTIC_TEST|Gradient and pulse imaging|A novel diffusion-based magnetic resonance imaging method
41031873|NCT04511689|DEVICE|gene-activated bone substitute mixed with autobone|gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
41031874|NCT05877001|DRUG|Tislelizumab|200mg, IV, Q3W
41031875|NCT05877001|DRUG|Regorafenib|80 mg once daily for the first 3 weeks of each 4-week cycle
41031876|NCT05877001|OTHER|HAIC|OXA 85mg/m2 IA 0-4h +5-Fu 2000mg/m2 IA 4-48h，CF 200mg/m2 IV 2-4h， Q3W
41372989|NCT05143489|DRUG|Saline|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
41372990|NCT05542212|DEVICE|Transcranial Magenetic Stimulation|Intermittent Theta Burst Stimulation (iTBS) treatment plan: iTBS treatment for the left dlPFC were used for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
41372991|NCT05542212|DEVICE|Sham Transcranial Magenetic Stimulation|Sham stimulation: The coil angle is set at 90° to the scalp for Sham stimulation of the left dlPFC for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
41372992|NCT04270331|OTHER|PADS protocol|Assessment and management per PADS protocol
41372993|NCT04264806|DRUG|Azacitidine|Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.
41372994|NCT04264806|DRUG|Cusatuzumab|Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
41504375|NCT02800642|DRUG|Aflibercept (Eylea, BAY86-5321)|The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.
41504376|NCT04416165|DIAGNOSTIC_TEST|18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
41504377|NCT05076019|DRUG|Atorvastatin 80mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
41504378|NCT05076019|DRUG|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
41372995|NCT02168569|DRUG|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
41372996|NCT02168569|DRUG|Coarsucam™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
41372997|NCT05741762|OTHER|Retrospective chart review|The retrospective chart review will be done for patient admitted into ICU between 01/06/2017 to 01/06/2022
41372998|NCT03490253|BEHAVIORAL|DIAMANTE Adaptive|In a three arm randomized controlled trial we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen by a reinforcement learning algorithm.
41372999|NCT03490253|BEHAVIORAL|DIAMANTE Static|The static intervention group receives health information text-messages, typical of existing text-messaging interventions for diabetes and depression.
41373000|NCT02259166|OTHER|EHFP+|Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
41373001|NCT05860452|OTHER|ropivacaine|single shot bilateral TAP block
41373002|NCT05860452|OTHER|normal saline|single shot bilateral TAP block
41373003|NCT05031975|DRUG|Irinotecan|Irinotecan 100 mg/smq intravenous infusion every 14 days
41373004|NCT05031975|DRUG|Temozolomide|Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
41373005|NCT03799237|OTHER|GOS trap and dengue NS1 antigen kit|The GOS trap lure and sticky surfaces to trap gravid Aedes mosquitoes. Three GOS traps will be placed on every 3 floors of the residential blocks. The traps will be changed weekly. Trapped Aedes mosquitoes will be identified to species. The mosquitoes will then be dissected, to remove the abdomen from the thorax. Five to seven abdomens of the same mosquito species will be pooled and tested for dengue NS1 antigen using the SD Biosensor Standard Q dengue NS1 antigen test kit. If the pool is tested positive for dengue NS1, the head and thorax of the respective abdomens will be subjected to the same procedure for dengue NS1 antigen test, individually. This may allow us to identify a focus where there could be dengue-infected individuals. Flyers/Posters will be disseminated besides, house-to-house approach to inform the residents of the findings and apartment blocks where these mosquitoes were found. The apartment management will also make use of social media disseminate this information.
41373006|NCT03764241|DRUG|Rivaroxaban|Rivaroxaban 15mg/QD will be applied for 3 months unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
41373007|NCT03764241|DRUG|Vitamin K Antagonist|warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
41373008|NCT02353273|DRUG|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
41373009|NCT03987581|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
41373010|NCT03987581|BEHAVIORAL|Mobile Contingency Management (mCM)|Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.
41373011|NCT03987581|BEHAVIORAL|Long-term incentive|This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
41373012|NCT01735136|DIETARY_SUPPLEMENT|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
41373013|NCT01735136|DIETARY_SUPPLEMENT|Placebo|Placebo (10g/day)
41373014|NCT00736216|OTHER|survey administration|Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases \[STDs\], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.
41373015|NCT02267616|DEVICE|Etonogestrel Implant|Subdermal arm implant
41373016|NCT04111666|BIOLOGICAL|AL101|Active dose of AL101
41373017|NCT04111666|OTHER|Placebo|Saline solution administered as a single and multiple infusion as placebo.
41373018|NCT05307926|DRUG|PD-1 inhibitors|For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.
41373019|NCT05307926|PROCEDURE|TACE|Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.
41504379|NCT06593639|OTHER|Prehabilitation before surgery|Prehabilitation multimodal program will start about 4 weeks before the surgery and will be continued until 2 weeks after the surgical intervention. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.
41031877|NCT06315218|BEHAVIORAL|iTHRIVE 365 HIV care intervention|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) with mHealth interventions, iTHRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. iTHRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. iTHRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of Black SGLM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
41031878|NCT00656838|BEHAVIORAL|Patients receives letter, phone call, office visit, educational materials|Behavioral
41031879|NCT00408369|DRUG|DB289|
41031880|NCT00949247|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
40849057|NCT05032885|OTHER|physiotherapy|"Patients in the intervention group will receive early physiotherapy treatment. This intervention will consist of exercises and physiotherapy techniques commonly used and aimed at improving the patient's respiratory and motor conditioning.~At the respiratory level: diaphragmatic and costal targeted ventilation, pursed-lip breathing and bronchial hygiene techniques if required.~At the motor level: passive, active-assisted kinesitherapy and analytical and global potentiation of the upper and lower limbs that will allow the maintenance and improvement of the articular pathway and will prevent muscle weakness; retraining of transfers and balance; gait reeducation."
40849058|NCT03891758|BIOLOGICAL|DPT-IPV-Hib|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
40849059|NCT03891758|BIOLOGICAL|Hib vaccine|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
40849060|NCT03891758|BIOLOGICAL|DPT-IPV|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
40849061|NCT02921087|DEVICE|Test Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
41031881|NCT00949247|BIOLOGICAL|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
41031882|NCT00949247|DRUG|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
41504380|NCT06593639|OTHER|Prehabilitation before and during CRT|Prehabilitation multimodal program will start about 4 weeks CRT and will be continued in parallel until 2 weeks after the end. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.
41504381|NCT04283604|DRUG|MPH|The treatment will include taking the patient's own medication by the patient himself in the treatment session 60-180 minutes before the beginning of the tests, according to their prescription given by their own physician. Participants must have consumed this medication at least 3 months before the first session as their regular treatment for ADHD. Note, we are not planning on giving the medication to the participant, rather he/she will consume their own prescribed MPH by them self.
41504382|NCT00387556|DRUG|Ondansetron|ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
40849062|NCT02921087|DEVICE|Control Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
40849063|NCT05409937|OTHER|Water-saturated Improved Hot Weather Combat Uniform|Water-saturated Improved Hot Weather Combat Uniform
40849064|NCT05409937|OTHER|Water-saturated Army Combat Uniform|Water-saturated Army Combat Uniform
40849065|NCT05409937|OTHER|Water-saturated Army Combat Uniform + Silk Weights|Water-saturated Army Combat Uniform + Silk Weights
40849066|NCT04667546|OTHER|Survey|Patients or their parents will complete a survey at D2, D5, D10 and D28 to assess the presence or absence of a symptom
40849067|NCT05196633|OTHER|radial extracorporeal shock wave therapy|rESWT (Endopuls 811; Enraf Nonius B.V. Va-reseweg 127, 3047 AT Rotterdam MedTech, Wessling, Germany) will be applied on the myotendinous junction of both the gastrocnemius and the soleus muscles in post-stroke spasticity patients. 2000 shots will be applied on the gastrocnemius and soleus myotendinous junction with a frequency of 10 Hz and energy density of 60 mJ (1 bar) within tolerable pain limits.
40849068|NCT05196633|OTHER|sham radial extracorporeal shock wave therapy|The control group will receive sound over the myotendinous junction of gastrocnemius and soleus with transducer-like contact.
40849069|NCT02238860|DRUG|Entacavir|Entacavir-0.5 mg ,OD,for
40849070|NCT02238860|DRUG|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
40849071|NCT01302197|OTHER|No intervention|longitudinal follow-up after stroke
40849072|NCT02021955|BEHAVIORAL|guideline treatment recommendations|Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
41373020|NCT02797600|BEHAVIORAL|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
41373021|NCT02797600|OTHER|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
41504383|NCT03587324|DRUG|Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).|"To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)"
41031883|NCT00949247|DRUG|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
41031884|NCT00949247|OTHER|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
41031885|NCT04442217|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
41031886|NCT04914572|OTHER|Therapeutic rainforest mindful walking|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by Mindfulness Practitioner who volunteered to be guides for this study.
41031887|NCT04914572|OTHER|Therapeutic rainforest walk|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by volunteer guides recruited by the research team.
41031888|NCT04914572|OTHER|Campus Green walk|A two-kilometer trail curated by the Office of Facility Management, NUS. The walk will be led by volunteer guides recruited by the research team.
41031889|NCT01201434|DIETARY_SUPPLEMENT|Bio-25 probiotic|2 tablets per day for 6 months
41373022|NCT05250739|OTHER|Strength training|Strength training was performed with resistance bands. The band was fastened to the unaffected ankle, while the participant was told to perform front and back pulls, as well as adduction and abduction movements with the affected ankle. They were told to control the ankle movement and to make it slow. Since the first day, they were told to perform the exercise pulling the band as if they wanted to make the resistance of 5 on a scale from 0 to 10.
41373023|NCT05250739|OTHER|Neuromuscular training|consisted in a multi-station training with 6 exercises, increasing the difficulty progressively as the participants controlled the execution. The exercises were all performed barefoot and with the injured foot. These were a combination of standing and jumping exercises involving the injured ankle. The participants did not start the next progression until they perform a complete circuit in the level before.
40849073|NCT03797300|DEVICE|Spry Loop Band|Loop band measures pulse oximetry and respiration rate
41031890|NCT03818373|PROCEDURE|polysomnography|Sleep examination strictly non-invasive with skin sensors. This exploration would allow for the detection of respiratory sleep disorders and consider of appropriate management for patients.
41031891|NCT00511004|DRUG|Albendazole|Comparing 400 mg to 800 mg dose
41031892|NCT00511004|DRUG|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
41031893|NCT05253898|PROCEDURE|Pelvic floor Physical Therapy|Purpose of pelvic floor muscle education program is reduce the symptoms of stress urinary incontinence and improving quality of life.
41031894|NCT05253898|PROCEDURE|Therapeutic Yoga Training|Purpose of this group show the effectiveness of yoga therapy on stress urinary incontinence and quality of life.
41031895|NCT02352064|PROCEDURE|PET (18-FDG)|Every patient will have a PET
41031896|NCT04381026|DIETARY_SUPPLEMENT|Botanical dry extracts combination|Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)
41031897|NCT04381026|DIETARY_SUPPLEMENT|Placebo|Filler agent
41031898|NCT02536508|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
40849074|NCT04416906|DRUG|Biktarvy|Once daily fixed dose combination regimen of Biktarvy will be evaluated as a rapid treatment strategy in newly HIV diagnosed patients HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit
41373024|NCT05434975|PROCEDURE|Interscalene brachial plexus block|"For single shot-ISBP block, 15 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine, a total of 25 ml of local anesthetic, will be administered to all patients.~For the block procedure, an imaginary horizontal line drawn from the thyroid cartilage to the sternocleidomastoid (SCM) muscle will followed and the lateral of the SCM muscle will be cleaned with povidine iodine. At the C6 level to be blocked, the nerve roots will be detected by ultrasound. 25 ml of local anesthetic will be injected around the plexus roots with a 22 G 80 mm echogenic needle. The distribution of the local anesthetic applied to the area, which expands the tissues and separates the nerve roots from other tissues, will be seen on ultrasound."
41373025|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
41373026|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
41373027|NCT00696332|OTHER|placebo|capsules, placebo, 3 times a day, for 52 weeks
41373028|NCT01297738|OTHER|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
41373029|NCT01297738|OTHER|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
41373030|NCT01297738|OTHER|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
41373031|NCT01297738|OTHER|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
41373032|NCT05275556|DEVICE|Computer-Assisted Detection (CADe) Device|The CADe Device uses artificial intelligence to aid in identifying colorectal polyps during High Definition White Light Endoscopy (HD-WLE) based colonoscopies. This device connects the Gastroenterologist's colonoscopy video output source to the main monitor and highlights the regions of interest where the device detects a potential lesion. The CADe Device overlays graphical markers onto video from the endoscope camera and does not perform further processing to the endoscope video signal. This device is not intended to replace clinical decision making.
41373033|NCT01585285|PROCEDURE|LIMA to SVG Bridge Technique|This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
41504384|NCT04182282|BEHAVIORAL|CARES Dementia-Friendly Hospitals Online Training and Certification Program|The CARES Dementia-Friendly Hospitals Online Training program is a 4-course, 16-module, video-based training program for hospital staff members. The CARES Dementia-Friendly Hospitals Online Certification Program is a 100-point certification exam evaluating knowledge from the online training protocol.
41504385|NCT00685776|DRUG|anacetrapib|Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
41504386|NCT00685776|DRUG|Comparator: placebo|Participants will receive one placebo tablet once daily for 76 weeks.
41504387|NCT06552013|OTHER|MERV 13 filter|This is an environmental intervention consisting of a low-cost box fan with a MERV 13 filter placed behind it. The company Lasko makes these fans and other environmental appliances.
41504388|NCT06552013|OTHER|Sham filter|This is an environmental intervention consisting of a low-cost box fan with a sham filter (MERV 1) placed behind it. The company Lasko makes these fans and other environmental appliances.
41504389|NCT02304133|OTHER|Education|
41504390|NCT02056912|GENETIC|Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene|
41504391|NCT02056912|BIOLOGICAL|Perform blood cells and fibroblasts biochemical and immuno-labeled investigations|Performed only in the two index patients enrolled in the sub-study
41031899|NCT02536508|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate
40849075|NCT01900808|DEVICE|Trained operator with M probe.|Trained operator with M probe: non-drug intervention, baseline comparator.
40849076|NCT01900808|DEVICE|Experienced operator with M probe.|Experienced operator with M probe: non-drug intervention, longitudinal comparator.
40849077|NCT01900808|DEVICE|Experienced operator with XL probe.|Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
40849078|NCT01140061|DRUG|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
41031900|NCT02536508|DRUG|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate
41031901|NCT05635214|PROCEDURE|real time remote tele mentored ultrasound exam|A patient will have a point of care ultrasound exam performed by a local provider with a remote expert guiding them through the exam using video conferencing.
41031902|NCT01151670|DRUG|pioglitazone|Pioglitazone 22.5 mg daily before, during and after radiation therapy.
41031903|NCT01151670|DRUG|Pioglitazone|Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
41373034|NCT01585285|PROCEDURE|Conventional CABG|Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
41373035|NCT05292248|BEHAVIORAL|Confidently Navigating Financial Decisions and Enhancing Financial Wellbeing in Dementia Caregiving|Multicomponent psychoeducational intervention focused on financial wellbeing
41373036|NCT04194138|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
40849079|NCT01140061|DRUG|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
40849080|NCT01140061|DRUG|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
40849081|NCT01140061|DRUG|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
41373037|NCT03248557|DIAGNOSTIC_TEST|Spectral analysis of ventricular fibrillation tracings|Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
41163213|NCT06407583|BEHAVIORAL|ProMIO2.0 program|"ProMIO2.0 is a lifestyle intervention carried out by physiotherapy and dietetics. They guide and encourage the participants to achieve the following behavioral goals:~* moderate/intensive exercise (e.g. walking) for 150-300 minutes per week~* Muscle-strengthening exercises 2x a week~* Supplemented with balance and flexibility exercises~* 1.2 grams of protein per kilogram of body weight per day (\~25-30 grams of protein per meal, 4x/day) The combination of consultations, information sessions and on-site training at the physiotherapist should ensure that participants acquire the necessary knowledge, awareness and skills to adopt the health behavior in daily life. Materials such as posters, pedometers and videos are used for support.~The intervention is divided into 2 phases, which indicate the degree of professional guidance:~1. intensive guidance (month 0 - 3)~2. average guidance (months 4 - 6)"
41163214|NCT06338293|DRUG|Inclisiran sodium|The patients in Inclisiran group were given drugs three times in total. The first needle was injected subcutaneously with 284mg(1.5ml solution) after entering the group, the second needle was injected three months later and the third needle was injected at the ninth month.
41163215|NCT06338293|DRUG|Rosuvastatin|Rosuvastatin
41373038|NCT03611452|PROCEDURE|Episiotomy|repair of perineal muscles and skin
41373039|NCT03740035|DEVICE|eHealth for Sedentary Behavior|Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
41373040|NCT03148912|DIAGNOSTIC_TEST|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
41373041|NCT03179462|DIETARY_SUPPLEMENT|Pork intake|Each participant will consume 2 ounces of cooked lean pork.
41373042|NCT03179462|DIETARY_SUPPLEMENT|Mixed nuts intake|Each participant will consume 1 ounce of mixed nuts.
40849082|NCT01140061|DRUG|Plain patch|Plain patch containing no MK-0873 or placebo
40849083|NCT00320424|DRUG|Fondaparinux|
40849084|NCT06478303|OTHER|Motor imagery|Participants were asked to imagine arm or foot movements.
40849085|NCT06478303|OTHER|Action reading|Participants were asked to read sentences involving arm or foot movements
40849086|NCT06478303|OTHER|Motor localizer|Participants were asked to perform arm or foot movements
40849087|NCT05628909|PROCEDURE|PPV with SO tamponade|Patients randomized into silicone oil group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
40849088|NCT05628909|PROCEDURE|PPV with fovea-sparing ILMP and gas tamponade|Patients randomized into gas group 1 were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.
40849089|NCT05628909|PROCEDURE|PPV with gas tamponade|Patients randomized into gas group 2 were received pars plana vitrectomy surgery without internal limiting membrane peeling and gas tamponade.
40849090|NCT06576128|DEVICE|ultrasound|In additional to local anesthesia, 10 ml lidocaine (2%) (Lidon, Onfarma, Turkey ), TAPB will be performed under ultrasound imaging..
40849091|NCT06576128|PROCEDURE|parenteral local anesthesia|As routine procedure; the cardiologist will palpate the right or left femoral artery under sterile conditions and apply approximately 10 ml lidocaine (2%) to this area as local anesthesia (Lidon, Onfarma, Turkey ). Then, a puncture will be made on the anterior wall of the femoral artery with an 18 G needle . Approximately 3-4 mm skin incision will be made with the number 11 scalpel tip and the Seldinger technique will be continued. 6F femoral sheath to be placed, cardiac The catheterization process will begin.
40849092|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (600 IU)|Daily oral dose for 12 months
40849093|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (2000 IU)|Daily oral dose for 12 months
41373043|NCT03179462|DIETARY_SUPPLEMENT|Tofu intake|Each participant will consume 2 ounces of tofu.
41373044|NCT02501642|BEHAVIORAL|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
41373045|NCT02501642|OTHER|Treatment as usual|Treatment as usual
41373046|NCT03331952|OTHER|Prospective study|To identify and characterise patients with culture proven invasive pneumococcal disease or probable bacterial meningitis over the first three years after PCV13 introduction in Cambodia in January 2015.
41373047|NCT03331952|OTHER|Prospective study|To identify and characterise patients hospitalised with clinical and/or radiologic pneumonia over the first three years after PCV13 introduction in Cambodia in January 2015
41373048|NCT03331952|OTHER|Cross-sectional surveys|Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees
41373049|NCT06536478|OTHER|exercise|50 minutes of exercise twice a week, including stretching, core exercises, gross motor movements and balance exercises for 5 weeks
41373050|NCT06536478|OTHER|education|The patient will be given a one-time exercise education session and a 50-minute video that included stretching, core exercises, gross motor movements and balance exercises that could be practiced at home.
41373051|NCT02934126|OTHER|breast cancer patients|semi structured face to face interviews
41373052|NCT01281475|DRUG|Levodopa|"Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
41373053|NCT01281475|DRUG|Placebo Oral Capsule|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
41373054|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at 3 minutes before the end of the surgery.
41373055|NCT05420402|DRUG|Propofol continuous infusion|1 mg/kg propofol was started by continuous infusion 3 minutes before the end of surgery, and the infusion time was 3 minutes.
41373056|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at the end of the surgery.
41373057|NCT01528839|DRUG|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
41373058|NCT01528839|DRUG|Placebo|
40849094|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (4000 IU)|Daily oral dose for 12 months
40849095|NCT01992263|OTHER|Placebo|Daily oral dose for 12 months
41163216|NCT06180902|DIAGNOSTIC_TEST|Inferior vena cava's diameter ratio|"In mechanical ventilation, the Inferior Vena Cava's maximum diameter (IVCmax) is measured at peak inspiration, and minimum diameter (IVCmin) at expiration's end. The Distensibility Index (IVCDI) is calculated as \[(IVCmax - IVCmin) / IVCmin\] × 100%. In spontaneous breathing, IVCmax is the diameter at expiration's end, and IVCmin at inspiration's end. The Collapse Index (IVCCI) is \[(IVCmax - IVCmin) / IVCmax\] × 100%.~Clinically, an IVCDI/IVCCI ≥ 18% indicates a 'responder'. Values \< 18% denote 'non-responders'."
41373059|NCT03361566|BEHAVIORAL|physical activity|3 different levels of physical activity
41373060|NCT03361566|BEHAVIORAL|energy intake|4 different types of energy intake
41373061|NCT01353209|DRUG|Letrozole|2.5 mg daily for twelve months
41373062|NCT01353209|DRUG|Placebo|placebo given daily for twelve months
40849096|NCT04735991|BEHAVIORAL|Kapok Initiative|"The detailed process is:~1. After randomization, the Kapok assistant will contact the patient's family~2. The family of the patient joins the Kapok Initiative. They will participate in a 60-minute training program for 27 days, which is taught online by experts; The contents of the lectures are as follows: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation."
41373063|NCT06205940|BEHAVIORAL|Audioguided Nature tour|Listening to audio instructions by an app while visiting nature. The instructions emphasize the connection between self and nature and direct attention to the present moment experience by guiding focus towards sensory experiences and specific natural elements.
41373064|NCT06205940|BEHAVIORAL|Non audio guided nature tour|Visiting nature without listening to audio instructions by an app
41373065|NCT04047316|DEVICE|Digital dermoscopy|Acquire skin images with a new digital dermatoscope
41373066|NCT06286878|DRUG|Placebo|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
41373067|NCT06286878|DRUG|Dapagliflozin|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
41373068|NCT05081115|DIAGNOSTIC_TEST|ABCDE-Stress Echo|Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.
41504392|NCT00620685|DRUG|Placebo|Tablet, once daily for 4 weeks
41504393|NCT00620685|DRUG|PH-797804|Tablet, 1 mg PH-797804, once daily for 4 weeks
40849097|NCT01626417|DEVICE|Tibion Bionic Leg|The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
40849098|NCT05938127|DEVICE|Inspiratory muscle strength training|High-resistance inspiratory muscle strength training (IMST) is a time-efficient (\~5 minutes/day) form of exercise that employs an affordable, handheld device which impedes inspiratory breathing to train the diaphragm and accessory respiratory muscles
40849099|NCT05938127|DEVICE|Sham Inspiratory muscle strength training|Low-resistance inspiratory muscle strength training
41504394|NCT00620685|DRUG|PH-797804|Tablet, 5 mg PH-797804, once daily for 4 weeks
41504395|NCT04036110|DIETARY_SUPPLEMENT|Vitamin C 500 mg|500 mg tablet taken orally with one meal daily
41504396|NCT04036110|DIETARY_SUPPLEMENT|Vitamin C 1000 mg|1000 mg tablet taken orally with one meal daily
41504397|NCT04036110|OTHER|Placebo|1 tablet taken orally with one meal daily
41504398|NCT05297578|BIOLOGICAL|24-Valent Pneumococcal Conjugate Vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
41504399|NCT05297578|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
41504400|NCT05524571|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
41504401|NCT05524571|DRUG|Placebo|Matching Placebo
41504402|NCT00812448|DIETARY_SUPPLEMENT|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
41504403|NCT06603831|PROCEDURE|patients treated using 3D technology and Patient-Specific Instrumentation|"3D Digital surgery includes:~* 3D Surgical Planning using biomedical engineering software; 3D visualization of the patients anatomy and surgical simulation.~* Use of personalized surgical guides created through additive manufacturing.~* Use of personalized implants created through additive manufacturing.~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis"
41504404|NCT06603831|PROCEDURE|Patients treated with conventional surgery, without using 3D technology|"Conventional surgery includes:~* 2D planning using TC and x-rays~* Free-hand surgery~* Use of generic, non-personalized implants~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis"
41504405|NCT01722422|DRUG|oxygen and saline|
41504406|NCT05353387|OTHER|Motivational Interviewing|Motivational Interviewing will be carried out in 3 different sessions, each to be conducted one week apart. 6 weeks after the last interview, first follow up would be conducted through phone communication and 6 weeks after the first follow up, a face-to-face interview would be conducted for the scales to be applied to the participants again.
41504407|NCT06505070|BEHAVIORAL|Recreational Games|"40 individuals in the intervention group were introduced to 15 games. Researchers conducted these sessions and provided participants with instructions and rules for the games. Then, they were asked to rate the games from 1 to 10. In this form, the elderly individuals evaluated the games by determining the minimum 1 and maximum 10 points according to their interest and willingness to play. Thus, it was ensured that individuals freely choose the games they want to play. As a result, bingo, matching pairs, word challenges and hot-cold games, which received the highest scores from the participants, were selected to be played."
41504408|NCT04141930|DRUG|Baloxavir Marboxil|Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset
41504409|NCT01242722|DEVICE|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
41504410|NCT04194294|DRUG|Lidocaine|Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.
41504411|NCT04194294|OTHER|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.
41504412|NCT02558348|DRUG|AL3818|Administered orally
41504413|NCT03426137|DRUG|Oxycodone|5mg Oxycodone in oral solution given every 3 hours
41504414|NCT03426137|DRUG|Ketorolac|toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
41504415|NCT03426137|OTHER|Placebo|Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
41504416|NCT02265926|DEVICE|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
41504417|NCT06370286|BEHAVIORAL|concurrent exercise (CE)|Participants in the concurrent exercise group engaged in 12-minutes of aerobic exercise (40%-59% of heart rate reserve \[HRR\]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
41504418|NCT06370286|BEHAVIORAL|aerobic exercise (AE)|Participants in the aerobic exercise (AE) group participated in 25 minutes of AE (40%-59% of heart rate reserve \[HRR\]). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
40849100|NCT00547521|DRUG|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
41504419|NCT02037386|DEVICE|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
41504420|NCT02794870|BIOLOGICAL|RSV LID ΔM2-2 1030s vaccine|10\^5.0 PFU; administered as nose drops
41504421|NCT02794870|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
41504422|NCT00610610|DRUG|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
41504423|NCT00610610|DRUG|Placebo|Same shape Placebo
41504424|NCT03277924|DRUG|Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
41504425|NCT03277924|DRUG|Nivolumab 100 MG/10 ML [Opdivo]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
41504426|NCT03277924|DRUG|Epirubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
40849101|NCT00547521|DRUG|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
41504427|NCT03277924|DRUG|Ifosfamide|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
41504428|NCT03277924|DRUG|Doxorubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
41504429|NCT03277924|DRUG|Dacarbazine|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
40849102|NCT05475236|BEHAVIORAL|Experimental: Locomotor Learning|Participants will undergo four sessions of locomotor and turn learning. Locomotor learning will involve practicing walking over different terrains (i.e., soft and firm mats) and obstacles at different walking speeds (slow or fast) and turning practice at each end of the walking course. The full cohort will undergo either transcranial direct current stimulation or sham stimulation.
41163217|NCT06180902|DIAGNOSTIC_TEST|Central venous pressure|"In our protocol, patients lie flat, connected to a saline-filled system for intravenous infusion via a central venous catheter. The system, starting from the subclavian catheter, extends to the 2nd to 3rd intercostal space at the mid-axillary line. The tube's end is raised perpendicular to the bed until saline flow stops, marking the liquid level. The height from the mid-axillary line to this point is measured in millimeters. If the liquid column falls below the mid-axillary line, indicating continuous flow, the CVP is negative, and the catheter is closed to block air entry. CVP readings are taken at exhalation's end.~CVP interpretation:~* CVP ≤ 12 mmHg (16.3 cm H2O) indicates a responder.~* CVP \> 12 mmHg (16.3 cm H2O) indicates a non-responder."
41504430|NCT03277924|DRUG|Cisplatin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
41504431|NCT03277924|DRUG|Methotrexate|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
41504432|NCT04474444|OTHER|attendance by ambulance crew|hear, attendance, convey
41504433|NCT00810511|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel contact lens
41504434|NCT00810511|DEVICE|Comfilcon A contact lens|Silicone hydrogel contact lens
41504435|NCT04391504|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
41504436|NCT03876262|DRUG|Moxidectin|2mg tablets, encapsulated for blinding
41504437|NCT03876262|DRUG|Ivermectin|3mg tablets, encapsulated for blinding
41504438|NCT06550284|OTHER|Physical Therapy|The intervention will be physical therapy standard care.
41504439|NCT05784441|DRUG|JNJ-90009530|JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20
41504440|NCT00916760|BIOLOGICAL|Depigoid Parietaria judaica 1000DPP/ml|Subcutaneous monthly treatment
41504441|NCT00916760|BIOLOGICAL|Placebo|Subcutaneous monthly treatment
41504442|NCT02765763|DRUG|2-Minute Reveal Masque|
41504443|NCT02765763|DRUG|24/7 Barrier Repair Cream|
40849103|NCT06198686|DRUG|Nalmefene|Opioid antagonist
41504444|NCT02765763|DRUG|8-in-1 BioSerum|
41504445|NCT02765763|DRUG|Null Formula 2-Minute Reveal Masque|
41504446|NCT02765763|DRUG|Null Formula 24/7 Barrier Repair Cream|
41504447|NCT02765763|DRUG|Null Formula 8-in-1 BioSerum|
41504448|NCT05227963|OTHER|soft tissue mobilization|In this group, each participants received 45-minutes long session that includes 25-minutes of soft tissue mobilization and 20-minutes of neck isometric strengthening exercises. In each session, patient was seated on chair and sustained pressure, direct oscillation, perpendicular mobilization, parallel mobilization, and friction massage was applied on the neck musculature for a minute followed by a release for 30 seconds. This protocol was repeated three times in each session. Each session was repeated four-times a week for two-weeks (a total eight sessions).
41504449|NCT05227963|OTHER|neck isometric strengthening exercises|In this group, each participant received 20-minutes long session. Each session started in seated position and participants were asked to perform flexion, extension, side bending and rotation against resistance. During flexion movement, therapist placed hand on forehead and asked patient to move the neck forward, while in extension, therapist hand was placed at back of the head and patient had to move neck in backward direction. However, in side bending and rotation- therapist hand was placed at lateral side of the head and asked patient to side bend the neck and look at shoulder in the same direction respectively. Each session was repeated four-times a week for two-weeks (a total eight sessions).
41504450|NCT06361121|PROCEDURE|mid-point transverse process to pleura (MTP) block|"the T1-T12 thoracic spinal levels will be sonographically identified using a high frequency linear US probe (HFL_50, 15_6MHz). Then the probe will be placed vertically and nearly 3 cm lateral to the spinous process at the thoracic level T4/T5. The paraspinal muscles (erector spinae, trapezius, rhomboid), transverse processes , superior costo-transverse ligament (SCTL) and parietal pleura will be all identified under parasagittal scanning.~In MTP block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the 2 transverse processes and advanced till it reaches the mid-point between the transverse process and pleura. After negative aspiration of blood or air, a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected superficial to the SCTL."
41504451|NCT06361121|PROCEDURE|Thoracic Paravertebral Block|In the TPV block group , the transverse process and the pleura will be identified and the needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards
41504452|NCT05373004|DRUG|Empagliflozin 25 MG|It is the experimental drug in this trial. this drug has an approved efficacy in delaying kidney deterioration based on the results of (the EMPA-REG OUTCOME) trial. it is also recommended based on the ADA/EASD 2019 consensus, as the SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent the progression of CKD. However, the previous trials where always add it to a patient already on an ACE inhibitor (in most cases). In this trial, it will be compared head to head with the gold standard treatment of CKD which is Enalapril 20 mg (ACE inhibitor).
41504453|NCT05373004|DRUG|Enalapril Maleate 20 mg|It is an ACE inhibitor, the active comparator in this trial, and is considered the gold standard for the treatment of diabetic kidney disease.
41504454|NCT03492086|DIETARY_SUPPLEMENT|Dietary supplementation with capsules containing rosemary and alkylglycerol|
41504455|NCT03492086|DIETARY_SUPPLEMENT|Dietary supplementation with control capsules|
40849104|NCT03973268|DEVICE|Arm 1, 2, 3 device interventions|MagPro 100 TMS Therapy System
40849105|NCT03973268|OTHER|Arm 2 Interventions|Placebo
40849106|NCT03973268|DRUG|Arm 1, 2, 3 drug Interventions|Ketamine
41373069|NCT05081115|DIAGNOSTIC_TEST|SE diastolic assessment|The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation, at intermediate load of exercise and/or 1- 2 min after the end of the exercise. We will also assess, at baseline, intermediate load (50 watts) and peak-post stress: end-diastolic left ventricular volume index; end-systolic left ventricular volume index; ejection fraction and both stroke volume and cardiac output (to assess conventional contractile reserve); mitral regurgitation and left ventricular outflow tract obstruction; pulmonary artery systolic pressure; B-lines; right ventricular free wall strain to assess the presence of right ventricular dysfunction; left atrial volume index; peak atrial longitudinal strain; and mitral inflow E velocity and mitral annulus e' tissue Doppler velocity; global longitudinal strain (GLS).
41031904|NCT01990053|BEHAVIORAL|Beating the Blues|The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
41373070|NCT05081115|DIAGNOSTIC_TEST|SE Right ventricular function assessment|Right ventricular function will be assessed at baseline and peak stress with variations of tricuspid annular plane systolic excursion, an index of right ventricular longitudinal function, and right ventricular fractional area change (a load-dependent index of right ventricular inlet function). To distinguish between genuine right ventricular dysfunction and/or pathological increases in pulmonary vascular load, we will combine systolic pulmonary artery pressure and right ventricular end-systolic area to calculate right ventricular end-systolic pressure-area relation. Peak systolic tricuspid annulus velocity and conventional indices of left ventricular systolic and diastolic function will also be measured at baseline and peak stress according to the standard ABCDE-FGLPR protocol. Right ventricular free wall strain combined with interventricular septum strain will be assessed. Left ventricular function, wall motion score index and E/e' at baseline and peak stress.
41373071|NCT05081115|DIAGNOSTIC_TEST|SE in heart donors|The examination of the heart starts with a resting transthoracic echocardiography. Exclusion criteria are: resting wall motion score index\>1.0; ejection fraction \<45%; diastolic dysfunction of grade 2 or more; hemodynamically significant (moderate or higher) valve regurgitation or stenosis; severe left ventricular hypertrophy (left ventricular mass index \>175 g/m2). A pharmacological SE with dipyridamole (0.84 mg/kg over 6 minutes) is recommended. The diagnostic end-points are stress-induced RWMA and abnormalities in global LVCR. All images will be analyzed as per guidelines similarly to the other projects, with emphasis on wall motion score index and LVCR based on ejection fraction and force. The hearts excluded from donation for RWMA or abnormal LVCR could however be collected for heart valve preparation and evaluated by coronary angiography and by pathological examination according to local facilities.
41373072|NCT01019746|DRUG|propofol|propofol administration
41373073|NCT00773201|DRUG|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
41031905|NCT00354354|DRUG|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
41504456|NCT06054165|OTHER|Clinical pathway|Evidence-based and expert-opinion-based clinical pathway regarding the diagnostic and treatment strategy
41504457|NCT04854044|DRUG|Akt/ERK Inhibitor ONC201|Given orally
41031906|NCT04320680|OTHER|description of a lupus patient cohort|description of a lupus patient cohort
41031907|NCT03806829|OTHER|Water|250 ml
41031908|NCT03806829|OTHER|Red Wine|250 ml
41031909|NCT03806829|OTHER|Green Tea|250 ml
41031910|NCT03806829|OTHER|Orange Juice|250 ml
41031911|NCT05561959|OTHER|topical glyceryl trinitrate gel|topical nitroglycerin medication were treated with 1 gr nitroglycerin 2% gel
41031912|NCT05561959|OTHER|Eccentric exercises|stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee).
41031913|NCT05665777|DRUG|Qingyan Lihou Decoction|Chinese medicine granules
41031914|NCT05665777|OTHER|Placebo|Placebo granules
41031915|NCT03328897|DRUG|Omalizumab|injection of 150mg or 300 mg
41031916|NCT03328897|DRUG|Placebo|Injection of placebo
40849107|NCT03973268|DRUG|Arm 1 and 2 Interventions|Perampanel
40849108|NCT04420403|OTHER|Manual Therapy|Cyriax's mobilization techniques will be applied as manual therapy. Before the mobilization, soft tissue mobilization techniques will be applied to relieve muscular spasm and preventing the patient' s anxiety. Bringing, manual traction, manual traction with rotation, manual traction with anterior-posterior gliding and lateral gliding mobilization techniques will be applied. Appropriate mobility techniques will be selected according to the complaints and symptoms of the patients. Cervical mobilization applications will take an average of 15-20 minutes.
41031917|NCT02727101|DRUG|perampanel|Each group of 6 patients will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. Perampanel will be titrated to 8-12 mg/day, with the final dose determined by side effects and tolerability of Perampanel at 8-12 mg/day doses. Titration will occur at the rate of 2 mg/week or two weeks, as tolerated.
41031918|NCT02890381|BIOLOGICAL|RSV LID cp ΔM2-2 Vaccine|10\^5 plaque-forming units (PFUs); administered as nose drops
41031919|NCT02890381|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
41031920|NCT04040127|BIOLOGICAL|Cord blood stem cells|Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.
41031921|NCT04040127|OTHER|Saline solution|saline solution used to rinse the canal.
41373074|NCT04456062|OTHER|Caring Contacts|Caring Contacts are brief email communications sent to the patient post-discharge. They convey messages of hope, support, promote a sense of belonging, and provide information on resources for care. They are not written uniquely for each patient but are purposefully crafted to intervene on those specific vulnerabilities that form the core of many patients' experiences with intense emotional distress and suicidal thoughts.
41373075|NCT06509425|PROCEDURE|salpingectomy during caesarean section|Salpingectomy will be done by clamping, division and ligation using adsorbable suture material (2-0 Vicryl) and excising the tube till it's isthmic part by scissors.
41373076|NCT06509425|PROCEDURE|tubal ligation during caesarean section|Tubal ligation will be done by Parkland technique. An opening is made in an avascular section of the mesosalpinx by electrocautery. Two absorbable suture ties (2-0 Vicryl) are passed through the opening and used to ligate the proximal and distal ends of the segment (at least 2 cm) which will get excised by scissors.
41504458|NCT04854044|RADIATION|Radiation Therapy|Undergo radiation therapy
41504459|NCT04854044|PROCEDURE|Resection|Undergo surgical resection
40849109|NCT04420403|OTHER|Cervical Stabilazation Exercise (CSE)|The CSE program aims to maintain a neutral spine position and activate deep cervical muscles during exercises. It is performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program will start with postural training and then the cervical bracing technique with the activation of deep neck flexors for CSE was performed. The patients will be asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises will be increased weekly. It will be carried out 2 days a week for 6 weeks (12 sessions) by the supervisor physiotherapist.
40849110|NCT02286557|DRUG|Methelphenidate|All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo
40849111|NCT02286557|DRUG|Placebo|
40849112|NCT03507738|BIOLOGICAL|MT-5625 low dose|Intramuscular injection
41031922|NCT05605470|BIOLOGICAL|ChulaCov19 BNA159 vaccine (50 mcg)|Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1
41031923|NCT05605470|BIOLOGICAL|Pfizer/BNT vaccine (30 mcg)|Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1
41031924|NCT05605470|BIOLOGICAL|COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)|Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1
41373077|NCT00978640|OTHER|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
41373078|NCT00978640|OTHER|exercise|exercise 1 h 50% VO2max
41373079|NCT01685320|PROCEDURE|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
41373080|NCT03005717|DRUG|LIPO-202|
41373081|NCT03005717|DRUG|Placebo for LIPO-202|Lyophile manufactured to mimic LIPO-202 lyophile.
41373082|NCT05583604|DRUG|secukinumab|The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by a maintenance dose of 300 mg every 2 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.
41373083|NCT01778296|DEVICE|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
41504460|NCT01475097|DRUG|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
40849113|NCT03507738|BIOLOGICAL|MT-5625 middle dose|Intramuscular injection
40849114|NCT03507738|BIOLOGICAL|MT-5625 high dose|Intramuscular injection
40849115|NCT03507738|BIOLOGICAL|Rotarix|Oral administration
40849116|NCT03507738|BIOLOGICAL|Placebo|Intramuscular injection
40849117|NCT05997212|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive high frequency 10 Hz stimulation at 100% of motor threshold over the dorsolateral prefrontal cortex (DLPFC) at 1500 pulses per session with 30 trains of 5 seconds and 0.5 ms stimuli and an inter-train distance of 15 seconds. In 2 daily sessions 4 days a week for 4 weeks."
40849118|NCT05997212|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive consistent treatment in 2 sessions a day for 20 consecutive business days for 4 weeks. The coil will be placed facing away from the skull to avoid an effect."
40849119|NCT05268952|OTHER|Liquid biopsies|Blood/urine sampling and scans are done at regular intervals
40849120|NCT05268952|OTHER|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
41504461|NCT01475097|DRUG|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
41504462|NCT03268707|DEVICE|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
41504463|NCT03268707|OTHER|Conventional follow up|Conventional follow up at physician practice
41504464|NCT05110742|DRUG|Fludarabine Phosphate|Given by IV
41504465|NCT05110742|DRUG|Cyclophosphamide|Given by IV
41504466|NCT05110742|DRUG|CAR.5/IL15-transduced CB-NK cells|Given by IV
41504467|NCT04268199|DRUG|Bortezomib Injection|Subcutaneous injection
41504468|NCT04605874|OTHER|Package Quantity (cigarillos)|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack.
41031925|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a phospholipid|A shake with 3000 mg choline added as a phospholipid
41031926|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a salt|A shake with 3000 mg choline added as a salt
41504469|NCT00620087|PROCEDURE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
41504470|NCT00620087|PROCEDURE|Screening Mammography|A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
41504471|NCT04731363|DIETARY_SUPPLEMENT|xylitol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of xylitol as a single oral dose.
41504472|NCT04731363|DIETARY_SUPPLEMENT|erythritol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of erythritol as a single oral dose.
41504473|NCT04731363|DIETARY_SUPPLEMENT|xylitol, 5g|Intervention is a drink consisting of 300mL of water containing 5g of xylitol as a single oral dose.
41504474|NCT04731363|DIETARY_SUPPLEMENT|glucose, 30g|Intervention is a drink consisting of 300mL of water containing 30g of glucose (dextrose) as a single oral dose.
40849121|NCT03687606|DRUG|Human Chorionic Gonadotropin|White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
40849122|NCT03687606|DRUG|human menopausal gonadotropin|White freeze-dried cake or powder with specification of 75IU.
40849123|NCT04597073|PROCEDURE|Initial Periodontal Therapy|Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator
40849124|NCT05439538|DIAGNOSTIC_TEST|SERUM NGAL|Study the sensitivity and the specificity of serum NGAL to detect AKI in myeloma
40849125|NCT00006400|DRUG|Hydroxyurea|Participants will receive hydroxyurea.
40849126|NCT00006400|DRUG|Placebo|Participants will receive placebo.
41031927|NCT05164510|GENETIC|ct-DNA guided therapy|treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
41031928|NCT04135053|BIOLOGICAL|Lyophilised Neisseria lactamica|Previously lyophilised Neisseria lactamica will be reconstituted and intranasally given to participants
41031929|NCT06209268|DRUG|Paricalcitol injection|5 μg intravenous paricalcitol (1 mL) per day in five consecutive days
41031930|NCT06209268|DRUG|Placebo|0.9% NaCl 1 ml per day in five consecutive days
41504475|NCT03287843|PROCEDURE|Total mesorectal excision before 56 days (4-8 weeks)|Low anterior resection or abdominoperineal resection
41504476|NCT03287843|PROCEDURE|Total mesorectal excision after 56 days (8-12 weeks)|Low anterior resection or abdominoperineal resection
41504477|NCT04790708|RADIATION|Lutetium-177 (177Lu)-DOTATOC|5 cycles of 3,7 e 5,55 gigabequerel (GBq) of 177Lu-DOTATOC every 8-10 weeks. Cumulative activity: 18,5 e 27,75 GBq
41504478|NCT04790708|RADIATION|Yttrium-90 (90Y)-DOTATOC|5 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks. Cumulative activity: 9,25 e 13,875 GBq
41163218|NCT06180902|DIAGNOSTIC_TEST|Passive leg raising test|"In our protocol, the patient starts flat for initial CVP measurement. Then, the bed is tilted to 45 degrees for the first measurements: Systolic/Diastolic Blood Pressure, Mean Arterial Pressure, and Pulse Pressure (Systolic - Diastolic). Next, the bed is adjusted to elevate the feet, creating a 135-degree angle between torso and legs. After 90 seconds, the second set of measurements, including CVP, is taken. The patient is then returned to the initial position.~Interpreting results:~A responder is indicated by:~* Over 10% Pulse Pressure (PP) increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) \> 1;~* Second measurement CVP ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* Less than 10% PP increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second measurement CVP \> 12 mmHg (16.3 cm H2O)."
41373084|NCT03882567|OTHER|Electro Neuro adaptative Regulator|The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance
41373085|NCT05673486|COMBINATION_PRODUCT|PENG Block|"With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer is then slid medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks.~Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 100 mg of ropivacaine is then deposited in this plane, lifting the psoas tendon."
41373086|NCT05673486|COMBINATION_PRODUCT|Multimodal analgesia|Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight \<60kg; 3mg if patient's weight \>60kg) + Paracetamol 1g/8h and Nefopam 20mg/8h. Frequency of morphine administration depends on the assessed pain.
41373087|NCT04025697|OTHER|Complete Denture|A conventional CD will be constructed
41373088|NCT04025697|OTHER|Rapid prototyped denture|A 3d printed complete denture will be constructed
41373089|NCT01111968|BIOLOGICAL|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
41373090|NCT01111968|BIOLOGICAL|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
41373091|NCT01111968|BIOLOGICAL|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
41373092|NCT01111968|BIOLOGICAL|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
41373093|NCT01111968|BIOLOGICAL|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
41373094|NCT01111968|BIOLOGICAL|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
41373095|NCT01111968|BIOLOGICAL|pandmeic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
41373096|NCT01111968|BIOLOGICAL|pandmeic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
41373097|NCT01111968|BIOLOGICAL|pandmic vaccine 13|15µg of A/H1N1 with no adjuvant
41373098|NCT01111968|BIOLOGICAL|placebo group 14|All elements of the vaccine but antigen and adjuvant
41373099|NCT04435431|DRUG|Mesdopetam|Oral use
41373100|NCT04435431|DRUG|Placebo|Oral use
41373101|NCT00661791|BEHAVIORAL|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
41373102|NCT00661791|BEHAVIORAL|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
41373103|NCT02860026|OTHER|Marketed cow's milk-based infant formula|
41373104|NCT02860026|OTHER|Cow's milk-based infant formula with added nutrients|
41373105|NCT03116958|DEVICE|CPAP + Standard care|CPAP device + Standard management at Sleep Unit. According to Spanish Respiratory Society guidelines during 6 months
41163219|NCT06180902|DIAGNOSTIC_TEST|Fluid challenge|"In our clinical procedure, patients start horizontally for initial measurements: Systolic, Diastolic, Mean Arterial, Pulse Blood Pressures, and Central Venous Pressure (CVP). Then, they receive a balanced crystalloid solution at 4 ml/kg body weight at maximum permissible infusion rate. After infusion, a second measurement set identical to the first is taken.~Interpretation:~A responder is indicated by:~* Pulse Pressure (PP) increase \> 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) \> 1;~* Second CVP measurement ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* PP increase \< 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second CVP measurement \> 12 mmHg (16.3 cm H2O)."
41163220|NCT06180902|PROCEDURE|Fluid infusion|After assessing infusion therapy responsiveness, patients receive balanced crystalloid solutions at 1000 ml, infused at 15 ml/kg/hour, accounting for any prior infusions. Effectiveness evaluation follows, involving cardiac output reassessment (initially measured upon study enrollment). Effectiveness is determined by a ≥10% increase in cardiac output in the second measurement compared to the first. This is quantified as: \[(CO(after) - CO(before)) / CO(before)\] × 100% ≥ 10%, where CO(after) is the post-infusion cardiac output and CO(before) the pre-infusion output.
41163221|NCT01961921|DRUG|ALN-TTR02 (patisiran) administered by intravenous (IV) infusion|
41163222|NCT00626613|DRUG|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
41163223|NCT00332488|DRUG|Technosphere Insulin|Inhalation, 15U/30U, prandial
41163224|NCT00332488|DRUG|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
41163225|NCT00332488|DRUG|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
41163226|NCT05501496|PROCEDURE|intramedullary nailing|Flexible intramedullary nailing using 2 nails
41163227|NCT05501496|PROCEDURE|casting|casting with long leg cast
41163228|NCT05125016|DRUG|REGN4336|Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion
41163229|NCT05125016|DRUG|Cemiplimab|Administered concomitantly every 3 weeks (Q3W) by IV infusion
41163230|NCT05125016|DRUG|REGN5678|Administered concomitantly QW by IV infusion
41163231|NCT05125016|DRUG|Sarilumab|Administered once by IV infusion as prophylaxis prior to REGN4336 IV
41163232|NCT00915785|DRUG|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
41373106|NCT03116958|DEVICE|CPAP + Telemedicine|CPAP+ telemedicine approach. Patients followed up at Sleep Unit according to Spanish Respiratory Society guidelines during 6 months.
41373107|NCT05731973|PROCEDURE|Intercostal nerve cryoablation|Intercostal nerve cryoablation is applied during Nuss procedure.
41163233|NCT03165578|OTHER|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
41163234|NCT03165578|OTHER|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
41163235|NCT02607345|DIETARY_SUPPLEMENT|Zusto|25gr
41163236|NCT02607345|DIETARY_SUPPLEMENT|Glucomedics®|25gr
41163237|NCT00770640|DRUG|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
41163238|NCT00770640|DRUG|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
41163239|NCT04360434|DRUG|NI006|NI006 will be administered intravenously
41373108|NCT05731973|DRUG|Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Thoracic epidural is placed prior to Nuss procedure
41373109|NCT05731973|DRUG|Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))|Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
41373110|NCT05731973|DRUG|Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)|Opioids
41373111|NCT04025866|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for femur fracture
41373112|NCT04025866|OTHER|Aerobic exercise|30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
41163240|NCT04360434|DRUG|Placebo|Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously
41163241|NCT02347969|DIETARY_SUPPLEMENT|X34|Dietary supplement named X34
41163242|NCT04858321|PROCEDURE|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature \~38.5 °C and \<39 °C) sessions over a period of 14 days.
41163243|NCT04114578|OTHER|Echocardiography|Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.
41163244|NCT06008340|DEVICE|Dual chamber Pacemaker|Anti bradycardia device implanted in patients with complete heart block, the device has 2 leads, one in the RT atrium and the other in RV. The RV lead positioned either apical or septal
41373113|NCT05749549|DRUG|BR1733|Subjects will receive oral administration of BR1733.
41373114|NCT02531958|OTHER|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
41373115|NCT04516291|DRUG|Vupanorsen|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
41373116|NCT04516291|DRUG|Placebo|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
41504479|NCT04790708|RADIATION|177Lu-DOTATOC + 90Y-DOTATOC|"3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC alternated with 2 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks.~Cumulative activity: 18,5 e 27,75 GBq of 177Lu-DOTATOC and 9,25 e 13,875 GBq of 90Y-DOTATOC"
41504480|NCT04790708|RADIATION|Re-treatment 177Lu-DOTATOC|3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC every 8-10weeks. Cumulative activity: 11,1 e 16,65 GBq of 177Lu-DOTATOC
41504481|NCT04790708|RADIATION|Re-treatment 90Y-DOTATOC|3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC
41504482|NCT05015452|DEVICE|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
41504483|NCT06206629|DIAGNOSTIC_TEST|blink reflex evaluation|A blink reflex evaluation will be performed in all subjects
41504484|NCT06381739|BIOLOGICAL|ChAd-triCoV/Mac|Clinical-grade, fully certified ChAd-triCoV/Mac produced according to current Good Manufacturing Principles (cGMP) will be provided. A single dose of ChAd-triCoV/Mac diluted in 0.5mL formulated buffer will be aerosolized and inhaled via a mouthpiece and tidal breathing over approximately 2 minutes using the AeroNeb Solo Mesh Nebulizer.
41504485|NCT06381739|OTHER|Control|A single dose of placebo (0.5mL formulated buffer) will be aerosolized and inhaled as the intervention vaccine.
41504486|NCT06053684|DEVICE|Standard Non-Invasive Mechanical Servo Ventilation|The active comparator arm will utilize a standard non-invasive mode to provide ventilation support
41504487|NCT06053684|DEVICE|Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation|The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support
41504488|NCT01062347|BIOLOGICAL|Zinc|
41504489|NCT05091190|OTHER|Blood draws|"Blood draws will be realized at the following time points:~C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration."
41504490|NCT02542605|DRUG|Erenumab|Administered once on day 1 of Part B of the study by intravenous infusion.
41163245|NCT02024477|DRUG|Saxagliptin|5 mg tablet once daily for 12 weeks
41163246|NCT02024477|DRUG|Placebo|1 tablet daily for 12 weeks
41163247|NCT02654613|OTHER|Quality Improvement Model of Care|"QI addresses the how of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context."
41504491|NCT02542605|DRUG|Placebo|Administered once on day 1 of Part B of the study by intravenous infusion.
41504492|NCT02542605|DRUG|PACAP-38 Challenge Agent|"Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack."
41163248|NCT03716947|PROCEDURE|Device: ZACK|Surgical procedure with total disc replacement using ZACK disc prostheses
41163249|NCT03716947|PROCEDURE|Device: ORBIT|Surgical procedure with total disc replacement using ORBIT disc prostheses
41163250|NCT03716947|PROCEDURE|Device: SASCA|Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
41163251|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
41504493|NCT04223557|DEVICE|focused power ultrasound treatment|Patients will be placed in the lateral decubitus position and receive treatment with sequential bilateral PRF ablation. Before the treatment, a professional sonographer will be responsible for the length, thickness, and width of PRF sac measurement and localisation, and utilise the ultrasonic diagnostic transducer to delineate the targeted region. The treatment will launch layer-by-layer. After confirming accurate localization of the treatment, layer-by-layer PRF ablation will be performed on the patients. The device generates and delivers a pattern of conic-shaped ultrasound energy to the PRF sac noninvasively. The treatment of FPU-mediated PRF ablation will be implemented once.
40849127|NCT05819320|OTHER|observe pattern of mucocutaneous manifestations in chronic kidney disease patients|"1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients .~2. Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease"
40849128|NCT05387668|DRUG|BGB-23339|Administered orally as a tablet.
40849129|NCT05387668|DRUG|Placebo|Administered orally as a tablet.
40849130|NCT04494126|DRUG|Tranexamic acid|Drug: Tranexamic Acid Injectable Solution the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia before incision.
41031931|NCT00158743|DRUG|Anti-digoxin antibody (FAB fragment)|intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
41163252|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
41163253|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
41373117|NCT05288621|DEVICE|electroacupuncture|"For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment."
41373118|NCT02735720|OTHER|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
41373119|NCT02735720|OTHER|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
41373120|NCT03508076|DEVICE|Vibrating Capsule|Patients in this group would be treated with Vibrating Capsule
41373121|NCT03508076|DEVICE|Sham Capsule|Capsules can't vibrate but look the same as Vibrating Capsule
41373122|NCT04734366|PROCEDURE|"Uterine closure with Baseball suture technique"|"A simple running (continuous) baseball suture is essentially an interrupted sutures. Applied as inside to outside/inside to outside of incision."
41373123|NCT04734366|PROCEDURE|Single Layer Continuous Locked|Suturing is continued by passing through the previous stitch.
41373124|NCT03976674|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|5 group sessions (2h30/session) before the surgery
41373125|NCT02097966|DRUG|Daclatasvir|
41373126|NCT02097966|DRUG|Sofosbuvir|
41373127|NCT02097966|DRUG|Ribavirin|
41373128|NCT03648073|DRUG|[68Ga]DOTATATE-PET/MRI|\[68Ga\]DOTATATE-PET/MRI
41373129|NCT05200975|DIAGNOSTIC_TEST|Venapunction|Three venapunctures within a period of 72 hours, containing a maximum of 18ml of venous blood in total.
41373130|NCT00011999|DRUG|cisplatin|
41504494|NCT04223557|DEVICE|Sham treatment|Participants will receive the same procedure as those in the FPU treatment including PRF ultrasonic measurement and localization and focused ultrasound treatment parameters setting, except that no energy will be delivered to the PRF.
40849131|NCT04494126|DRUG|Placebo|Other: Placebo (normal saline 0.9%) An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
40849132|NCT02919514|OTHER|Physical training on hard surface.|Physical training on hard surface.
41163254|NCT01476813|DRUG|Comparator|comparison of different dosages of drug versus comparator
41163255|NCT05341063|BEHAVIORAL|Online Education|"Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.~Two months after the training was completed, the current routine analysis results of the participants were taken again, and height and weight measurements were made with the same measurement tools. Participants were allowed to fill in the data collection forms again."
41373131|NCT00011999|DRUG|paclitaxel|
41373132|NCT00011999|PROCEDURE|conventional surgery|
41373133|NCT00011999|RADIATION|radiation therapy|
41373134|NCT04901182|DIAGNOSTIC_TEST|the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)|the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
41373135|NCT06449352|DRUG|Netarsudil|netarsudil 0.02%
40849133|NCT02919514|OTHER|Physical training on sand surface.|Physical training on sand surface.
41031932|NCT00158743|OTHER|sodium chloride|
41031933|NCT02660944|DRUG|RSLV-132|RNase-Fc fusion protein
41373136|NCT06449352|DRUG|Brimonidine|brimonidine 0.1%
41373137|NCT02209220|DEVICE|Positive airway pressure for the treatment of OSA|
41504495|NCT00559806|OTHER|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
41504496|NCT00559806|OTHER|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
40849134|NCT02919514|OTHER|Physical training on soft surface.|Physical training on soft surface.
40849135|NCT01076387|PROCEDURE|open radical cystectomy|Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.
41031934|NCT02660944|DRUG|Placebo|Saline placebo
41031935|NCT02575846|DIETARY_SUPPLEMENT|Enteral Intake - Human Milk|Comparing formula and human milk
41031936|NCT02575846|DIETARY_SUPPLEMENT|Enteral Intake - Formula|Comparing formula and human milk
41031937|NCT03686007|OTHER|Informational Intervention|Receive MSM intervention handbook
41031938|NCT03686007|OTHER|Informational Intervention|Receive MSM intervention research nurse coaching
40849136|NCT01076387|PROCEDURE|robotic-assisted radical cystectomy|Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
41373138|NCT02206256|DRUG|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
41373139|NCT02206256|BEHAVIORAL|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
41373140|NCT04973917|PROCEDURE|respiratory support|respirators for invasive mechanical ventilation
41373141|NCT00803582|PROCEDURE|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
41373142|NCT00803582|PROCEDURE|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
41504497|NCT05999487|DRUG|Dobutamine|"Patient randomization will be done by a computer based generation , serial enveloped numbers will be taken for the patients. Cardiac assessment will be done by a blinded pediatric cardiologist. If at any time the randomly assigned therapy considered to be failed or unsafe to continue, the treating physician will discontinue randomization and will continue with the appropriate medication according to the patients need.~Milrinone will start by 0.25 , 0.5 , 0.75 we can titrate up with time interval 3 hours after re-assessment.~Dobutamine will start by 5, 10 , 15, 20 we can titrate with time interval 15 mins after re-assesment."
41504498|NCT04641078|DRUG|Darolutamide|600 mg BID
41163256|NCT05341063|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
41373143|NCT05700526|DEVICE|Planning of multiplanar and/or multifocal osteotomies in children by using VSP, PSIs and customized structural bone allograft|Preoperative VSP is performed starting from 3D digital models obtained from DICOM data of CT-scan with a segmentation process. If applicable, a model of the contralateral limb is obtained and used as reference for the correction. The surgeon and the engineer together define the surgical strategy, establishing the correction, the design of Patient-Specific Instruments (PSIs) and the hardware to implant. Then, through VSP, an ideal model of the bone graft is designed.
41373144|NCT05700526|DEVICE|Routine preparation of bone graft according to standard protocols|The size dimensions obtained through VSP are used by the tissue bank to manually cut a structural bone graft according to the standard protocols.
41373145|NCT05700526|DEVICE|Preparation of bone graft with virtual bone-matching and GSIs|The best donor bone is identified by matching the 3D models provided by bone bank with the planned graft, considering not only the size but also the most suitable configuration of cortical and medullary bone. Then GSIs are designed and 3D printed to perform the exact cut on the donor bone according to the experimental protocol.
41373146|NCT05700526|PROCEDURE|Corrective osteotomy|The acute surgical correction is performed according to VSP using PSI and the customized bone graft. Preoperative variables (age, sex, disease, deformity), intraoperative variables (operation time, intraoperative complications, use of fluoroscopy, intraoperative bleeding) are registered.
41373147|NCT06421662|BEHAVIORAL|Attachment Training|"The study group was trained online by a psychologist on attachment in two sessions. In order to measure the level of attachment knowledge before and after the training, a test form prepared by the researcher based on the literature and expert opinion was used as pre-test and post-test. In the 8th week after delivery, Maternal Attachment Inventory  developed by Mary Muller in 1994 and Turkish validity and reliability study was conducted by Şirin and Kavlak."
41373148|NCT03619512|GENETIC|Whole exome sequencing.|Retrospective biological exploration of the samples, including tumoral DNA exploration.
41373149|NCT03619512|GENETIC|RNA sequencing|Characterization of tumor transcriptomic profile.
41373150|NCT03619512|OTHER|Mass spectrometry|Characterization of tumor proteomic profiles.
41373151|NCT02888782|OTHER|Pharmacist Consultation|
41373152|NCT03583931|PROCEDURE|VATS Decortication|Surgical procedure to unroof all located collections of the pleural space through a chest wall incision
41504499|NCT04641078|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
41504500|NCT00782405|DRUG|quetiapine|XR, 150-300mg
41504501|NCT00782405|DRUG|mirtazapine|30-45 mg
40849137|NCT06437977|RADIATION|SBRT|SBRT. 24Gy/3fractions Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
41163257|NCT03964922|BIOLOGICAL|blood sample|20 ml at inclusion, and 20ml at 1, 3, 6 and 12 months after allo HSCT
41373153|NCT03583931|DRUG|Fibrinolytic Therapy|Instillation of DNAse and tPA together through patient's chest tube already in placed to break down complex fluid collection in the pleural space. DNAse and tPA are are administered together only i.e. are not mutually exclusive.
41373154|NCT06342791|DEVICE|laser acupuncture|laser use to stimulate acupuncture points
41504502|NCT01920607|DEVICE|magnetic anal sphincter|
41504503|NCT01920607|DEVICE|sacral nerve stimulation|
41504504|NCT04803305|DRUG|PF-06946860|subcutaneous injection
41504505|NCT04803305|DRUG|Placebo for PF-06946860|subcutaneous injection
41504506|NCT05712798|OTHER|No intervention|No intervention
41163258|NCT03964922|BIOLOGICAL|bone marrow sample|3 ml at inclusion, and 3 ml at 1, 3, 6 and 12 months after allo HSCT
41373155|NCT03426735|OTHER|Dry heat|Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
41504507|NCT05955508|DRUG|Linvoseltamab|Administration by intravenous (IV) infusion
41163259|NCT04098393|DRUG|Busulfan 3.2 mg/kg/day|Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
41163260|NCT04098393|DRUG|Fludarabine|Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
41163261|NCT04098393|DRUG|Melphalan|Melphalan (70mg/m2/day) administered on days -6 and -5.
41163262|NCT04098393|DRUG|Antithymocyte globulin (ATG)|ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
41163263|NCT04098393|DRUG|Busulfan 0.8 mg/kg|Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
41163264|NCT04098393|PROCEDURE|Allogeneic hematopoietic cell transplantation (Allo-HCT)|Allogeneic hematopoietic cell transplantation following the conditioning regimen.
41373156|NCT03426735|OTHER|Dry cold|Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
41373157|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with feedback provided|Feedback about drug levels in blood provided to participant's site
41373158|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with no feedback provided|Testing drug levels in blood but feedback not provided to participant's site
41373159|NCT04115800|DRUG|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
41373160|NCT02850159|DEVICE|rTMS and tDCS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
41504508|NCT04840537|PROCEDURE|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage
41504509|NCT03815526|OTHER|Dynamic tape|Dynamic tape apply 1 time
41504510|NCT03815526|OTHER|Kinesio tape|Dynamic tape apply 1 time
41163265|NCT00793377|DRUG|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
41163266|NCT00793377|DRUG|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
41373161|NCT02850159|DEVICE|rTMS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and sham anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
41373162|NCT03384576|OTHER|Music intervention|Classical music to be played in the Emergency waiting room
41373163|NCT03384576|OTHER|No music|No music played in emergency waiting room
41504511|NCT03815526|OTHER|Sport tape|Dynamic tape apply 1 time
41504512|NCT01339338|PROCEDURE|warming the contrast media|warm the contrast media with 37℃ water-bathing
41163267|NCT02335398|DRUG|Methadone|The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
41163268|NCT00002519|DRUG|chemotherapy|
41163269|NCT00002519|DRUG|paclitaxel|
41163270|NCT00002519|RADIATION|radiation therapy|
41163271|NCT03744741|DIAGNOSTIC_TEST|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
41504513|NCT02315274|OTHER|Frequent remote contact between clinic visits.|Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
41504514|NCT01184079|BIOLOGICAL|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
41504515|NCT01184079|BIOLOGICAL|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
41504516|NCT03840369|DEVICE|Repetitive Transcranial Magnetic Stimulation to Right Dorsolateral Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
41031939|NCT03686007|OTHER|Informational Intervention|Receive ASCO print materials
41031940|NCT03686007|OTHER|Informational Intervention|Receive CRA assistance
41504517|NCT03840369|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|The sham TMS coil will make a similar sound to the real rTMS coil, but will not deliver a magnetic pulse. This is a no-treatment device.
41504518|NCT03840369|DEVICE|Repetitive Transcranial Magnetic Stimulation to Right Dorsomedial Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
41031941|NCT03686007|OTHER|Media Intervention|View the MSM intervention videos
41031942|NCT03686007|OTHER|Media Intervention|View ASCO Cancer.net videos
41031943|NCT03686007|OTHER|Quality-of-Life Assessment|Ancillary studies
41031944|NCT03686007|OTHER|Questionnaire Administration|Ancillary studies
41031945|NCT01316822|DRUG|ARRY-382, cFMS inhibitor; oral|multiple dose, escalating
41031946|NCT01870271|BEHAVIORAL|Developmentally adapted cognitive processing therapy|
41031947|NCT04887870|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
41031948|NCT04887870|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
41031949|NCT04887870|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
41163272|NCT03834818|BEHAVIORAL|COMPAS Participants|"The schedule of events for this study are as follows:~Day 1 Pre-Surgery:~* Download the Medable App~* Register to the study~* Validated Questionnaires~* Active Task~Every Day~* 9:00 a.m. Daily Questions~* 9:00 p.m. Daily Questions~Outcome Surveys and Active Task:~* Day 1 Pre-Surgery~* 1-Week Post Operation~* 2-Weeks Post Operation~* 1-Month Post Operation~* 3-Months Post Operation~* 6-Months Post Operation"
41163273|NCT00384098|DRUG|CTA018 cream|
41163274|NCT01093183|DRUG|lenalidomide|Given PO
41163275|NCT01093183|DRUG|cyclophosphamide|Given PO
41163276|NCT01093183|OTHER|laboratory biomarker analysis|Correlative studies
41373164|NCT03131466|DEVICE|High-voltage pulsed radiofrequency|The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.
41031950|NCT04887870|DRUG|Enfortumab Vedotin-Ejfv|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
41031951|NCT04887870|DRUG|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
41031952|NCT04463641|DEVICE|Implantation of the Axone 4LV Lead|Implantation of the Axone 4LV Lead
41031953|NCT04106999|DRUG|Dexmedetomidine|Drug infusion will be delivered intra-operatively
41504519|NCT06137625|BEHAVIORAL|With regular rhythm|All children learn one dance choreographie with regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
41031954|NCT04106999|DRUG|Placebos|Normal Saline will be infused as a control drug
41031955|NCT03205800|OTHER|Mini-screw|Placement of a mini-screw
41031956|NCT06028594|DRUG|Pozelimab|Subcutaneous (SC) administration
41031957|NCT06028594|DRUG|Cemdisiran|Subcutaneous (SC) administration
41031958|NCT00184860|PROCEDURE|PET-scan, MRI-scan|
41031959|NCT01286779|BIOLOGICAL|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
41163277|NCT01093183|OTHER|questionnaire administration|Ancillary studies
41163278|NCT01093183|OTHER|quality-of-life assessment|Ancillary studies
41163279|NCT00531063|DRUG|Everolimus (RAD001)|
41163280|NCT00125853|DRUG|Nebivolol|Nebivolol 2.5mg daily
41163281|NCT00125853|DRUG|Atenolol|Atenolol 25mg daily
41163282|NCT02721433|DRUG|Pamidronate|Bone-targeted agent as standard of care
41163283|NCT02721433|DRUG|Denosumab|Bone-targeted agent as standard of care
41163284|NCT02721433|DRUG|Zoledronate|Bone-targeted agent as standard of care
41163285|NCT01636830|DEVICE|Toothbrush type|Evaluate the use of toothbrushes with bristles soft and medium
41163286|NCT04960436|PROCEDURE|Meniscus Allograft Transplantation|patients received surgery of Meniscus Allograft Transplantation
41163287|NCT04960436|PROCEDURE|Meniscectomy|patients received surgery of Meniscectomy
41163288|NCT03456635|OTHER|guided antimicrobial prophylaxis|During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
41163289|NCT00286975|BEHAVIORAL|Leadership development program educational intervention|
41163290|NCT05955755|OTHER|butterfly vacuum blood collection set|Blood collection from the children in the experimental group will be performed with a butterfly vacuum blood collection set.
41163291|NCT00249171|DRUG|risperidone|
41163292|NCT06208800|OTHER|Blend Aromatherapy|Inhalation of a mixture of essential oils of peppermint, palmarosa for 10 minutes at 11:00 am during the day and vetiver, cedar, clary sage, musk sage, grapefruit and petitgrain for 10 minutes at 21:30 pm before bedtime for 4 weeks
41373165|NCT03131466|DRUG|Nerve block|The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
41373166|NCT03078504|DEVICE|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
41373167|NCT03668613|DRUG|secukinumab low dose|dose depends on the weight group
41504520|NCT06137625|BEHAVIORAL|Without regular rhythm|All children learn one dance choreographie without regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
41504521|NCT03041428|DEVICE|Ultraprotective ventilation|Adjusting ventilator parameters for 3 ml/kg of tidal volume in order to achieve the ultra protective strategy
41163293|NCT04168021|BEHAVIORAL|Leg ischemia|potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
41163294|NCT02206945|BEHAVIORAL|neurofeedback|Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
41163295|NCT02206945|BEHAVIORAL|control feedback|Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
41163296|NCT01702519|DRUG|nicotine|nicotine transdermal patch
41163297|NCT04530877|BIOLOGICAL|Infliximab|Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
41373168|NCT03668613|DRUG|secukinumab high dose|dose depends on the weight group
41373169|NCT03908229|PROCEDURE|Trainee colonoscopy|Colonoscopy performed by trainee
41373170|NCT03908229|PROCEDURE|Experienced physician colonoscopy|Experienced physician colonoscopy
40849138|NCT06437977|DRUG|Toripalimab|Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
41373171|NCT00739830|DRUG|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
40849139|NCT00543335|DRUG|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
40849140|NCT00543335|PROCEDURE|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
40849141|NCT06560905|DRUG|68Ga-PSMA|This is an imaging radionuclide tracer and is in chemical form. Up to 200 MBq. Route of administration is Intravenous.
40849142|NCT06583434|BEHAVIORAL|core-lower extremity Pilates Training Group|Participants in this group will engage in a stabilization-based Pilates exercise program focusing on core and lower extremity stabilization. The program consists of twice-weekly sessions, each lasting 50 minutes, over a period of 8 weeks. The primary goal of the intervention is to improve gait patterns and balance in women with flexible pes planus
40849143|NCT06583434|OTHER|Non-Training Group|Participants in this group will not receive any specific intervention during the study period. They will continue their usual activities without any additional exercises provided by the study.
40849144|NCT04439981|DIETARY_SUPPLEMENT|Ice cream|Curcumin extract was added into ice cream
40849145|NCT03802773|PROCEDURE|CB transplantation|Myeloablative conditioning with post-transplant cyclophosphamide in patients receiving a matched CB transplant for hematological malignancies.
40849146|NCT01160913|PROCEDURE|Continuous wound infusion|
40849147|NCT01160913|PROCEDURE|Continuous wound|
40849148|NCT06197620|OTHER|Thread embedding acupuncture and standard therapy|In the treatment, thread embedding acupuncture was performed using a needle containing polydioxanone (PDO) thread at the EX-B2 acupuncture point (12.5 mm lateral to the spinous process) at the level of the 1st lumbar vertebra with an insertion angle perpendicular to the skin surface. All patients are also given standard therapy after surgery in the form of intravenous Paracetamol 1000 mg, 3 times a day.
40849149|NCT03739346|BEHAVIORAL|Hypnosis|Therapeutic technique in which clinicians make suggestions to individuals who have undergone a procedure designed to relax them and focus their minds.
40849150|NCT03739346|BEHAVIORAL|Tell, show, do technique|The technique involves verbal explanations of procedures in phrases appropriate to the developmental level of the patient (tell); demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do). Tell-show-do technique is used with communication skills (verbal and nonverbal) and positive reinforcement.
40849151|NCT06457451|OTHER|DIAPASOM program|A program of adapted physical activity carried out remotely by a specialist instructor, combined with personalized dietetic care by a dietician for one year.
40849152|NCT00769509|OTHER|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
40849153|NCT00769509|OTHER|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
40849154|NCT04957368|DRUG|Nitrous Oxide 99 %|Nitrous oxide will be administered at an inspiratory concentration of 50% with concurrent intravenous saline (100ml) for one hour.
40849155|NCT04957368|DRUG|Oxygen + Midazolam|Oxygen will be administered at 50% with intravenous midazolam (0.02mg/kg in 100ml) for one hour
40849156|NCT05262647|DIAGNOSTIC_TEST|18F-FAPI|Patients with chronic liver disease underwent 18F-FAPI-04 PET/CT and percutaneous liver biopsy.
40849157|NCT01737853|DRUG|Ganforti|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
40849158|NCT01737853|DRUG|Krytantek|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
40849159|NCT00524615|DRUG|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
40849160|NCT05564585|OTHER|Kinesio Taping|Kinesio tape was applied over the calf muscle of either leg.
40849161|NCT05564585|OTHER|Sham Taping|The sham tape was applied over the calf muscle of either leg.
40849162|NCT01660620|DRUG|Betaxolol|
40849163|NCT01660620|DRUG|topical betaxolol|given topically
40849164|NCT03897595|DEVICE|MPact Cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
40849165|NCT01558050|DIETARY_SUPPLEMENT|red rice supplement|patricipants take a red rice supplement or placebo daily for 8 weeks
41031960|NCT04847635|DEVICE|Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)|The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.
41373172|NCT00739830|DRUG|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
41373173|NCT00739830|DRUG|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
41373174|NCT05557526|OTHER|Expectation optimization|A short (2-5 min) verbal intervention will be createad individually based on the expectation of the patient towards the procedure.
41373175|NCT02494882|DRUG|Ruxolitinib|
41163298|NCT04530877|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (\>110%-120% of the average requirement).
41373176|NCT02494882|DRUG|Dasatinib|
41373177|NCT02494882|DRUG|Dexamethasone|
41373178|NCT01700686|OTHER|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
41373179|NCT01305460|DRUG|Azacitidine|"Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.~* Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.~* Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.~* Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study."
41373180|NCT04869202|DIAGNOSTIC_TEST|COVID-19 test|Naso-pharyngeal swab test
41031961|NCT04847635|DEVICE|Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)|The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.
41031962|NCT00493766|DRUG|LBH589|
41373181|NCT00333437|DRUG|Mycophenolate mofetil|
41373182|NCT02592070|BEHAVIORAL|Walking|Participants will walk on the treadmill for 30 minutes at a moderate intensity.
41373183|NCT01048710|OTHER|No intervention|
41373184|NCT04800510|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
41373185|NCT01014104|DRUG|Methylprednisolone|Administration of Methylprednisolone
41373186|NCT01014104|DRUG|Control|Normal salin injection
41373187|NCT03479619|DEVICE|Lancing device A|Glucoject Dual Plus lancing device
41373188|NCT03479619|DEVICE|Lancing device B|Droplet lancing device
41373189|NCT03479619|DEVICE|Lancing device C|Commercially available lancing device
41373190|NCT03479619|DEVICE|28 G lancet|Droplet 28 G
41373191|NCT03479619|DEVICE|30 G lancet|Droplet personal lancet 30 G
41373192|NCT03479619|DEVICE|33 G lancet|Droplet personal lancet 33 G
41373193|NCT03479619|OTHER|Lancing depth setting (1)|The lowest depth setting (1)
41373194|NCT03479619|OTHER|Lancing depth setting (5)|The highest depth setting (5)
41373195|NCT02583594|DRUG|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
41373196|NCT02583594|DRUG|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
41373197|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
41373198|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
41373199|NCT02583594|DRUG|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
41373200|NCT02583594|DRUG|Loratadine|Pharmaceutical form:tablet Route of administration: oral
41373201|NCT02583594|DRUG|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
41373202|NCT02583594|DRUG|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
41373203|NCT03271580|DIAGNOSTIC_TEST|Finger prick test for HbA1c measurement|HbA1c measurement with finger prick method
41373204|NCT03271580|PROCEDURE|Punch Biopsy|Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
41031963|NCT03129334|BEHAVIORAL|LST Middle School Online|The adapted intervention will (1) utilize both online e-learning module (self-guided) and classroom-based sessions (facilitator led) to address PDA and concurrent ATOD abuse; (2) positively change social norms and challenge positive expectancies regarding PDA and ATOD abuse; (3) discourage diversion of prescription medications; (4) enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios; and (5) incorporate booster sessions.
41163299|NCT02435381|DRUG|Carisbamate|600mg Orally on days 2-4
41163300|NCT02435381|DRUG|Placebo|Placebo treatment only
41163301|NCT04897685|BEHAVIORAL|Flow with Nature|Nature-based intervention was facilitated by a health care professional and included 12 x 90 mins sessions within 12 weeks.
41163302|NCT03505918|OTHER|No referral for rehabilitation|Intervention is that some patients will not be refered for postoperative physiotherapy.
41373205|NCT03271580|OTHER|Vac Sponge Collection|NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
41373206|NCT03271580|OTHER|Ankle Brachial Index|Blood pressure test
41373207|NCT03367676|DRUG|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
41373208|NCT03367676|DRUG|Docetaxel|Docetaxel 100mg/m2，d1，iv，q3w\*4
41373209|NCT01987570|DRUG|Allopurinol|
41373210|NCT01987570|DRUG|Placebo|
41373211|NCT05472480|DIAGNOSTIC_TEST|anthropometric and psychosocial measurements|"Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ)."
41373212|NCT03300804|DRUG|20-herb formulation|Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
41373213|NCT03300804|DRUG|Placebo|Placebo herb formulation
40849166|NCT00268541|BEHAVIORAL|Physical activity|
41163303|NCT05451056|DRUG|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity.
40849167|NCT02493231|DRUG|Nefopam|
40849168|NCT02493231|DRUG|Ketamine|
40849169|NCT02493231|DRUG|Saline|
41163304|NCT01723514|DRUG|Erenumab|Administered by subcutaneous injection once a month
40849170|NCT03328351|OTHER|manual therapy|"1. Manual therapy: One of the following techniques was used for the treatment group based on the patients' response (i.e centralization and reduction of symptoms).~   1. Cervical postero-anterior vertebral mobilization glides:~      a central posteranterior (PA) or unilateral PA oscillatory pressure of grade III on the patient's most symptomatic level for 2 minute and 3 sets .~  2. Cervical lateral vertebral glides :at grade III for 1 minute and 3 sets.~2. Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times."
40849171|NCT03328351|OTHER|Superficial soft tissue massage|"1. Superficial soft tissue massage: The researcher applied a superficial effleurage massage without moving the deeper tissue for 2 minutes for 3 sets~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times"
40849172|NCT06584227|DRUG|Adebrelimab and Chidamide Combined with Gemcitabine and S1|Chidamide：20mg，po，biw，（d8、11、15、18）； Adebrelimab: 1200mg，d8，q3w； Gemcitabine：800-1000mg/m2，bid，d1、d8，q3w； S1：40mg/50mg，bid，d1-14，q3w.
40849173|NCT02973516|DRUG|P03277 at 0.1 mmol/kg|P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
40849174|NCT02973516|DRUG|P03277 at 0.05 mmol/kg|P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
40849175|NCT02436954|PROCEDURE|CO2 insufflation at intra-abdominal pressure 8 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 8 mmHg
40849176|NCT02436954|PROCEDURE|CO2 insufflation at intra-abdominal pressure 12 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 12 mmHg
40849177|NCT02655575|BEHAVIORAL|BI + VR + CBT|Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
40849178|NCT02655575|BEHAVIORAL|BI + phone calls|Brief intervention (information and advice). Patients are followed-up by phone calls
40849179|NCT03530501|OTHER|Diet|Very low calorie ketogenic diet followed by low calorie diet
40849180|NCT03530501|DIETARY_SUPPLEMENT|Synbiotic1|B. lactis, Lactobacillus rhamnosus, B. longum ES1 and prebiotics fiber
40849181|NCT03530501|DIETARY_SUPPLEMENT|Synbiotic2|B. animalis subsp. lactis and prebiotics fiber
40849182|NCT04316026|DEVICE|shock wave therapy|Shockwave therapy is a non-invasive treatment creating a series of low energy acoustic wave pulsations that are directly applied through the skin via a gel medium
40849183|NCT00005818|DRUG|irinotecan hydrochloride|Given IV
40849184|NCT00005818|DRUG|semaxanib|Given IV
40849185|NCT00005818|OTHER|laboratory biomarker analysis|Correlative studies
40849186|NCT00634062|DRUG|Lamotrigine|Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
40849187|NCT00634062|DRUG|Placebo|Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
41031964|NCT05558059|DEVICE|Handheld Optical Coherence Tomography with OCT Angiography|"OCT systems are in vivo optical imaging technology that allows non-contact imaging of early-stage ocular pathology. They create real-time, non-invasive images of ocular microstructure and have become standard-of-care instruments in ophthalmic imaging in clinics and operating rooms. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are analyzed for depth-resolved information and can also be stacked to create a volume and the stack may be summed up to create a retinal image.~OCT angiography (OCTA) is an extension of the OCT systems, by taking images at the same location over time to extract retinal vascular flow information. It has been utilized to assess the ocular blood flow in many adult and pediatric patients."
41163305|NCT01723514|DRUG|Placebo|Administered by subcutaneous injection once a month
41373214|NCT00194116|DRUG|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
41031965|NCT00365859|DRUG|Aripiprazole|Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
40849188|NCT03964402|DRUG|intervention treatment|intervention treatment (any)
40849189|NCT03618316|DRUG|Imeglimin|2 singles oral doses of imeglimin 1,500 mg (one at day 1 and one at day 8)
40849190|NCT03618316|DRUG|Cimetidine|400 mg of cimetidine bid from Day 5 to Day 10
41373215|NCT00194116|DRUG|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
40849191|NCT03154749|DRUG|DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)|All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).
41504522|NCT06083012|DEVICE|Cardiac mapping|"All patients enrolled are treated for their atrial fibrillation/tachycardia via a catheter ablation procedure using VX1/Volta AF-Xplorer/Volta AF-Xplorer II software (used in accordance with its approved indication as per of its IFU) during the mapping phase to identify areas of interest specific to the patient.~The ablation approach is free and chosen by the operator according to his standard practice. The two main phases of the ablation procedure are:~* 3D mapping of the atria and location of areas of interest;~* Catheter ablation at the operator\&amp;#39;s discretion."
41504523|NCT03364543|OTHER|Access to the Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs.
41504524|NCT03364543|OTHER|Access to social worker and a community worker|Access to social worker and a community worker, but no systematic process for addressing health-harming legal needs.
40849192|NCT04297605|DRUG|Pembrolizumab|Pembrolizumab 200 mg
40849193|NCT04297605|OTHER|Pemetrexed (Chemotherapy)|500 mg/m2 day 1 of 21 day cycle (for non-squamous only)
40849194|NCT04297605|OTHER|Nab-paclitaxel (Chemotherapy)|100 mg/m2 days 1,8 of 21 day cycle x 4 cycles
41373216|NCT03036540|DEVICE|application in midline catheter|The routine insertion of midline catheter for the patients admitted in hospital who needs peripheral venous approach for the period more than 5 days or with the insufficient peripheral veins system
41373217|NCT02575261|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
41373218|NCT03698058|DIETARY_SUPPLEMENT|Toddler milk|Commercially available toddler milk
41504525|NCT05881746|PROCEDURE|anatomical liver resection|Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
41504526|NCT05881746|PROCEDURE|nonanatomical liver resection|Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
41504527|NCT05080153|DIETARY_SUPPLEMENT|Ocufolin forte|start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)
41504528|NCT01866046|BEHAVIORAL|RESPECT-IPV|rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
41504529|NCT04665466|DEVICE|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
41504530|NCT00435760|DRUG|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
41504531|NCT00435760|DRUG|Placebo Tiotropium|1 puff once daily, 1 day treatment
40849195|NCT02083497|OTHER|rigid bandage|
40849196|NCT02083497|OTHER|elastic bands|
40849197|NCT02083497|OTHER|without the use of banding|
40849198|NCT05582941|OTHER|No intervention will be performed.|No intervention will be performed.
40849199|NCT02937766|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
40849200|NCT02937766|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
40849201|NCT01868477|DRUG|Deferasirox DFX, DT|provided as dispersible tablets for oral use in 125 and 250, 500 mg
41031966|NCT05772793|DEVICE|Telerehabilitation|The home visual telerehabilitation path using the EyeFitness software consisted of performing one visual training session per day, 5 days a week (from Monday to Friday) for a total of 6 weeks.
40849202|NCT01868477|DRUG|Erythropoietin alpha|
40849203|NCT01868477|DRUG|Deferasirox DFX, FCT|provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
40849204|NCT00959127|DRUG|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
40849205|NCT04219644|DEVICE|Breatheasy device|
40849206|NCT05090033|OTHER|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
41031967|NCT02580149|DRUG|Ticagrelor|"Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15)."
41031968|NCT02580149|DRUG|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
41031969|NCT00772174|DRUG|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
41031970|NCT00772174|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
41504532|NCT00435760|DRUG|Tiotropium|1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
41373219|NCT05772728|DRUG|Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen|CAM regimen (every 21 days as a treatment cycle). Cetapenem 20 mg orally twice weekly Azacitidine 75 mg/m2 subcutaneously d1-7 Mitoxantrone liposomes 20 mg/m2 intravenous d6
41373220|NCT02279082|DRUG|DFN-02|Active Experimental Drug
40849207|NCT06328309|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
41373221|NCT05246982|DRUG|HLX07+HLX10+oxaliplatin+capecitabine|HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
41373222|NCT05246982|DRUG|HLX07|HLX07 1500mg q3w
41373223|NCT02413710|OTHER|Soy protein containing foods|Daily consumption of 2 food products, each providing 15g of soy protein per day.
41373224|NCT02413710|BEHAVIORAL|Dietary Guidance|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
41373225|NCT00656669|DRUG|sunitinib alone|sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
41373226|NCT00656669|DRUG|sunitinib plus paclitaxel|sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
41373227|NCT00656669|DRUG|doxorubicin and cyclophosphamide|doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
41373228|NCT00892710|DRUG|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
41031971|NCT04629794|PROCEDURE|Posterolateral Lumbar Fusion with Demineralized Bone Fibers|Posterolateral Lumbar Fusion with Demimeralized Bone Fibers
41373229|NCT00892710|DRUG|Bevacizumab|15 mg/kg IV every 21 days
41373230|NCT00892710|DRUG|Carboplatin|AUC=5 IV every 21 days
41373231|NCT03446846|DRUG|MIN-117 5.0 mg|5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily
41373232|NCT03446846|DRUG|MIN-117 2.5 mg|2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily
41373233|NCT03446846|DRUG|Placebo|Placebo administered as two Placebo capsules as a single dose once daily
41373234|NCT01826201|DRUG|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
41373235|NCT01826201|DRUG|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
41373236|NCT01283659|OTHER|Standard Imaging|
41373237|NCT01283659|OTHER|Advanced Imaging|
41373238|NCT03962426|DEVICE|SocialVille Social Cognitive Training|"SocialVille exercises in this study include 4 exercises:~* Recognition: a speeded face matching task~* Face to Face: a speeded facial emotion matching task~* Gaze Match: a speeded gaze matching task~* Face Poke: a continuous performance task with facial expressions"
41373239|NCT05053594|DRUG|Neostigmine 10 mcg/kg|Once the third response to TOF is obtained, neostigmine 10 mcg/kg will be administered
41373240|NCT05053594|DRUG|Neostigmine 20 mcg/kg|Once the third response to TOF is obtained, neostigmine 20 mcg/kg will be administered
41373241|NCT05053594|DRUG|Neostigmine 30 mcg/kg|Once the third response to TOF is obtained, neostigmine 30 mcg/kg will be administered
41373242|NCT05053594|OTHER|Placebo|Once the third response to TOF is obtained, saline will be administered
41373243|NCT00292006|DEVICE|Computerized tomography|
41373244|NCT04243811|DEVICE|Diode Laser|LLLT with dental needle for local anesthesia during dental treatment
41373245|NCT04243811|OTHER|topical anesthesia|topical anesthesia with dental needle for local anesthesia during dental treatment
41373246|NCT03504956|DEVICE|Cardiac MRI|MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
41373247|NCT03504956|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
41373248|NCT03504956|DRUG|Beta blocker|Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
41373249|NCT04946669|DRUG|Abatacept|Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
41504533|NCT00435760|DRUG|Placebo LAS34273|1 puff, 1 dat treatment
41504534|NCT05998148|OTHER|virtual phone appointment visits|Patient will have post-operative appointments that place with telemedicine. The visits will will be virtual phone appointments scheduled at approximately 6 weeks, 12 weeks, and 6 months after surgery.
41373250|NCT04276532|PROCEDURE|sentinel lymph node sampling (SLN)|"Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN).~1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines；~2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted；~3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted."
41373251|NCT04276532|PROCEDURE|pelvic lymphonodectomy (PLN)|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
41373252|NCT01851824|DRUG|acenocoumarol|4 mg single oral doses on Days 1 and 23
41373253|NCT01851824|DRUG|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
41373254|NCT02844231|OTHER|Single-photon emission computed tomography|
41373255|NCT02471794|BEHAVIORAL|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
40849208|NCT06328309|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
40849209|NCT04267081|DRUG|Venetoclax|Ex vivo venetoclax sensitivity testing is used for patient selection.
40849210|NCT03821194|OTHER|Gua sha|Scrape the skin around the knee joint
40849211|NCT03821194|OTHER|hot pack|hot pack
40849212|NCT04411745|OTHER|No intervention, observational study|
40849213|NCT02012712|BEHAVIORAL|Personal Health Record (PHR)|"Iowa PHR is a Web-based application that features a tabbed interface design. Users can enter, view, and print their current and past medicines, allergies, health conditions, and health event tracking over time. An embedded tutorial video provides assistance with the system. The PHR was developed and refined using participatory design and focus group sessions as well as evaluation in a usability laboratory. The resulting design emphasizes the reduction of physical and cognitive demands on users, focusing on simplicity, readability, and quick navigation.~Iowa PHR displayed a message when a user entered a medication with an associated Assessing Care of Vulnerable Elders project (ACOVE-3) safety concern. This included 16 safety issues for 12 drugs or drug classes with safety concerns. We also adapted four general medication use patient safety indicators from the ACOVE project and displayed them to all users on a rotating basis upon login."
41373256|NCT02317796|DRUG|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
41373257|NCT02316704|DEVICE|THA with G7 PPS coted acetabular component|
41373258|NCT02316704|DEVICE|THA with G7 OsseoTi coted acetabular component|
41373259|NCT05804695|PROCEDURE|Arthroscopic TMJ disc repositioning under GA|a surgical procedure used to treat Tempro- mandibular disc displacement using arthroscope.
41373260|NCT03733665|OTHER|Patients admitted to hospital|Data is captured in HES for all patient interactions with the NHS (each episode) in England. All patients admitted for heart failure have data captured in the National Heart Failure Audit.
41373261|NCT03088566|PROCEDURE|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
41373262|NCT03088566|PROCEDURE|Conventional foot screening|The foot screening is performed with clinical conventional methods.
40849214|NCT06085924|DRUG|SoC|COVID-19 treatment as per government guidance
40849215|NCT06085924|OTHER|Disease description|No intervention
41504535|NCT06588842|OTHER|Cluster Set Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets and 15-second rests after repetitions three and six.
40849216|NCT01881568|DRUG|Tranexamic Acid|Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
40849217|NCT01881568|DRUG|Tranexamic Acid|Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
41504536|NCT06588842|OTHER|Traditional Set Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets.
41504537|NCT00771459|DRUG|Ropivacaine 0.5 %|Local infiltration analgesia
41373263|NCT05654116|BEHAVIORAL|Caregiver Interaction Profile (CIP) training|The CIP training aims to boost six interactive skills in daycare providers: sensitive responsiveness, respect for children's autonomy, structuring and limit setting, verbal communication, developmental stimulation, and fostering positive peer interactions. The training takes place with 1 or 2 daycare providers at a time, and consists of 5 or 6 weekly sessions, respectively. In individual trainings, sessions 1-3 focus on two skills each, session 4 is a recap of two skills the daycare provider chooses, and the final session is shared with a colleague. In pairwise sessions, session 1 focuses on the first two skills, sessions 2-5 each focus on one skill, and the last session serves as a recap of two skills the daycare providers choose. The training uses a video-feedback method: daycare providers are filmed in interactions with children in daycare, the CIP trainer preselects relevant fragments of video recordings to discuss with the daycare provider(s) during the training sessions.
41373264|NCT06217562|DRUG|Vasopressin|Intravenous vasopressin infusion added to first-line vasopressors. Recommended vasopressin dose is 1.8 units/hour (equivalent to 0.03 units/minute) at a fixed rate.
41504538|NCT00771459|DRUG|Isotonic NaCl|Local infiltration analgesia
40849218|NCT04266236|PROCEDURE|L3 LPB|ultrasound-guided L3 lumbar plexus block
41031972|NCT04629794|PROCEDURE|Posterolateral Lumbar Fusion with Bone Morphogenic Protein|Posterolateral Lumbar Fusion with Bone Morphogenic Protein
41504539|NCT04936035|DRUG|Placebo|Placebo administered by SC injection
41504540|NCT04936035|DRUG|ALN-AGT01|ALN-AGT01 administered by SC injection
41504541|NCT01738451|DRUG|GSK2118436 75 mg|Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
41504542|NCT01738451|DRUG|Placebo|Matching placebo capsules will be administered in Part 2 of the study.
41504543|NCT04694534|DIAGNOSTIC_TEST|Serious game|"The serious game is accessible via an online platform, on a tablet: 4 20-minutes activities sessions per week must be carried out.~The program format in the serious game form makes possible to simultaneously understand a large number of cognitive functions."
41504544|NCT04694534|DIAGNOSTIC_TEST|Usual HAS care|The control group patients will follow the care they need, according to the HAS recommendations. Non-specific cognitive activities notebooks will be provided to them. They will be instructed to perform the 4 20-minutes sessions per week for 4 months.
41504545|NCT06550700|PROCEDURE|laparoscopic hybrid surgery (LHS)|First performed the laparoscopic exploration of the entire abdominal-pelvic cavity to determine the resectability of the primary and metastatic lesions. After the blood vessel detachment and bowel detachment, the distal bowel of the tumor was severed and the pneumoperitoneum was closed. The liver metastases were then removed in both cohorts by open resection through the right subcostal incision.
41504546|NCT01354379|BIOLOGICAL|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
41504547|NCT01354379|BIOLOGICAL|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
41504548|NCT06634277|BEHAVIORAL|NavSTAR (Philly adaptation)|Patient Navigation
40849219|NCT04266236|PROCEDURE|L4 LPB|ultrasound-guided L4 lumbar plexus block
40849220|NCT04266236|PROCEDURE|T12 block|ultrasound-guided thoracic 12th segment nerve block
40849221|NCT04266236|PROCEDURE|L3 QLB|ultrasound-guided quadratus lumborum block at L3 level
40849222|NCT04266236|DRUG|0.375%ropivacaine 25 ml (Raropin)|0.375%ropivacaine (Raropin) 25ml will be given
40849223|NCT04266236|DRUG|0.375%ropivacaine 40 ml (Raropin)|0.375%ropivacaine (Raropin) 40ml will be given
40849224|NCT04266236|PROCEDURE|General anesthesia with tracheal intubation|General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation
41031973|NCT03906058|DRUG|Anlotinib|All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
41031974|NCT00325793|DRUG|Nicardipine|
41031975|NCT02159482|DRUG|Interferon Alfa-2a|
41031976|NCT05343871|BIOLOGICAL|Sinovac|"Sinovac inactivated COVID-19 vaccine:~● Full dose (0.5 ml)"
40849225|NCT02409342|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
41373265|NCT06217562|OTHER|Recommendation to use a lower initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.1 mcg/kg/min of norepinephrine (or equivalent)
40849226|NCT02409342|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.
40849227|NCT02409342|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m\^2) every 21 days for 4 or 6 cycles as per local standard of care.
40849228|NCT02409342|DRUG|Gemcitabine|Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m\^2 (in combination with cisplatin) or 1000 mg/m\^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.
40849229|NCT02409342|DRUG|Pemetrexed|Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m\^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
40849230|NCT04300036|DIETARY_SUPPLEMENT|longan syrup|Subjects will take 15 ml of longan syrup once a day for 3 months
40849231|NCT04300036|DIETARY_SUPPLEMENT|Placebo syrup|Subjects will take 15 ml of placebo syrup once a day for 3 months
40849232|NCT02476292|OTHER|online questionnaire|The online questionnaire includes questions about vasculitis, employment and work status before diagnosis and over the course of the disease, work capacity and the financial impact of vasculitis.
40849233|NCT00133224|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
40849234|NCT00133224|DRUG|Chemotherapy (docetaxel and prednisone)|Chemotherapy (docetaxel and prednisone)
40849235|NCT04667104|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.
40849236|NCT04667104|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
41373266|NCT06217562|OTHER|Recommendation to use a higher initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.4 mcg/kg/min of norepinephrine (or equivalent)
41373267|NCT00005658|DRUG|Glycine|
40849237|NCT04667104|DRUG|Tenofovir alafenamide (TAF)|TAF film-coated tablet will be administered orally once daily.
40849238|NCT04667104|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film-coated tablet will be administered orally once daily.
40849239|NCT04667104|DRUG|PegIFN-alpha2a|PegIFN-alpha2a injection will be administered subcutaneously once weekly.
40849240|NCT05266391|OTHER|subacromial corticosteroid injections|Patients with SAIS whose application of corticosteroid in their injections were the same in terms of type and dose (1 ml betamethasone dipropionate + betamethasone sodium phosphate).
41373268|NCT06283654|DEVICE|1-lead ECG|patient were handed out a 1 lead ECG device, they were free to use it anyway they wanted, even not at all
41373269|NCT01143129|DRUG|Dexamethasone|Single dose (1 mg/kg) at start of cardiac surgical procedure
41373270|NCT01143129|DRUG|Placebo|Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
40849241|NCT05158725|DEVICE|Standard Colonoscopy|In this arm, subjects will undergo colonoscopy using a standard colonoscope
40849242|NCT05158725|DEVICE|Discovery aided colonoscopy|the Discovery is a customized detection support software, developed utilizing AI deep learning technology to support endoscopic lesion detection in the colon. In this arm, a standard colonoscope is used with the Discovery.
40849243|NCT05158725|DEVICE|Discovery and G-EYE|The G-EYE® Endoscope is a standard colonoscope which is remanufactured by installing the G-EYE® balloon on the distal bending section of the colonoscope. in this arm, the G-EYE® Endoscope is used with the Discovery
40849244|NCT01258283|OTHER|Addional imaging|All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
40849245|NCT02013245|BIOLOGICAL|MTBVAC live vaccine|Live-attenuated Mycobacterium tuberculosis vaccine
40849246|NCT02013245|BIOLOGICAL|Commercially available BCG live vaccine|Live-attenuated Mycobacterium bovis vaccine
40849247|NCT05977088|DEVICE|Repetetive Transcranial Magnetic Stimulation|".Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group."
41031977|NCT05343871|BIOLOGICAL|AZD1222|"AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine:~* Full dose (0.5 ml)~* Half dose (0.25 ml)"
41031978|NCT05343871|BIOLOGICAL|BNT162b2|"Pfizer/BioNTech BNT162b2 mRNA vaccine:~* Full dose (30 micrograms)~* Half dose (15 micrograms)~* One-third dose (10 micrograms)"
41031979|NCT05307224|DEVICE|Mandala|Experimental group will paint mandala for 30 minutes/day in the evenings for six consecutive days. Six pre-selected mandalas were planned to be printed separately on A4 paper. Each patient will be given a new mandala each day. Additionally, At the beginning of the study, the experimental group will be given six colors (yellow, blue, green, red, purple, brown).
41031980|NCT02389543|DRUG|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
40849248|NCT05998382|BEHAVIORAL|Online group-based parent-mediated intervention program|The program is an online group-based parent-mediated intervention program implemented in 2 sessions of 2 hours once a week for 6 weeks. In the first part of the weekly sessions, the topic of that week is explained to the parents. In the second part, videos recorded by the parents are watched and feedback is given to the parents. At the end of the session, written materials about that week's practices and homework are sent to the parents
41373271|NCT02147574|PROCEDURE|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
41373272|NCT00990366|DEVICE|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
41373273|NCT03406286|DRUG|Tolvaptan|
41373274|NCT04698018|DRUG|Faster Aspart|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
40849249|NCT06584253|OTHER|Musculoskeletal System Health Questionnaire Scale|It is a 14-item scale that evaluates pain intensity, physical function, sleep, fatigue, emotional state, physical activity level, impact on work and social life, independence, self-management ability and general impact.
40849250|NCT06584253|OTHER|International Physical Activity Questionnaire (short form)|"International Physical Activity Questionnaire (short form) -~The IPAQ assesses a range of physical activities, including leisure-time physical activities, indoor and outdoor activities, work-related physical activities, and transportation-related physical activities."
40849251|NCT06584253|OTHER|Pittsburgh Sleep Quality Index|It is a questionnaire that evaluates sleep quality with questions asked under 7 main headings: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disorders, use of sleep aids and daytime functions.
41031981|NCT02389543|DRUG|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
41031982|NCT02389543|DRUG|Dexamethasone|"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."
41031983|NCT05970861|DIETARY_SUPPLEMENT|Freeze-dried Mare Milk (Saumal)|Freeze-dried Mare Milk (Saumal) is frequently reported for having therapeutic and dietary properties associated with specific chemical composition and certain physical properties of the product. It contains a total of about 40 biologically active components, the most important of them vitamins A, C, B1, B2, B6, and B12, amino acids, enzymes, and trace elements (low molecular weight peptides, lactalbumins, and globulins). Saumal will be administered to patients at a dose of 25 grams of dry powder per 200 ml of water, 2 times a day, 30 minutes before the meal, for 4 weeks.
41031984|NCT01129310|DRUG|Irinotecan-Capecitabine-Oxaliplatin|Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
41373275|NCT04698018|DRUG|Novo Rapid|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
41373276|NCT06415188|BEHAVIORAL|Video game with headset|Half an hour before the first treatment in the morning, the screens around the patients' beds were closed by the researcher. The child was asked to choose one of the introduced games and the game he/she chose from the tablet was turned on. Children were asked to wear headphones for sound isolation and the sound was adjusted at the appropriate decibel setting. Half an hour before the treatment, children were allowed to play the video game until the treatment without any different warning. Physiologic Parameter Assessment Form, Child Anxiety and Fear Scale, Child Pain Scale were filled by the researcher 1 minute before and 1 minute after the procedure. Finally, Parental Satisfaction Scale was completed at the end of the intervention.
41373277|NCT00260949|PROCEDURE|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
41373278|NCT00995462|BEHAVIORAL|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
41373279|NCT00122954|DRUG|Fish oil concentrate|fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
41373280|NCT00122954|DRUG|Placebo|soybean oil with 1% fish oil at a daily dose of 6 grams
41373281|NCT02513095|DRUG|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
40849252|NCT06584253|OTHER|Cognitive Failures Questionnaire|The questionnaire aims to measure daily cognitive errors. It assesses simple errors made over the last 6 weeks, as well as perception (e.g., are there times when you can't see something you need at the supermarket even though it's there?), memory (e.g., have you ever forgotten people's names?) and motor functioning (e.g., have you ever bumped into anyone?).
40849253|NCT06584253|OTHER|Jamar hand dynamometer|Jamar hand dynamometer - students will perform grip strength assessments with their dominant hand while seated. As recommended by the American Association of Hand Therapists protocol, students will sit in a comfortable chair with their shoulders neutrally rotated and adducted, elbow flexed to 90°, and wrist and forearm in neutral positions.
41373282|NCT04424186|OTHER|'Rehabilitation for Life'|An empowerment-oriented cross-sectorial program including vital sign measurement and systematic progressive rehabilitation combined with convenient access for collaboration among professionals.
41373283|NCT04424186|OTHER|Usual care and rehabilitation|The care and rehabilitation usual provided to patients after hip fracture surgery
41504549|NCT06487533|DEVICE|EmbracePlus Smartwatch|"The EmbracePlus is worn on the user's wrist and continuously collects raw data via specific sensors. These data can be wirelessly transmitted to a paired mobile device. The data received are analyzed by EmpaDSP, which computes the user physiological parameters. The Care App is responsible for transmitting raw data, device information, Care App-specific information, and computed physiological parameters to the Empatica Cloud. The device supports continuous data collection for monitoring of the following physiological parameters:~* Peripheral skin temperature~* Electrodermal activity~* Blood Oxygen Saturation under no motion conditions~* Activity associated with movement during sleep.~The EmbracePlus Watch has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements."
41504550|NCT06487533|DEVICE|Corti Sensor|"The Corti Wearable is a sweat sensor that is worn continuously measure cortisol, melatonin, tumor necrosis alpha interleukin-6 (IL-6) in the protein analytes in the sweat of participants via electrochemical impedance spectroscopy. The Corti Wearable comprises a plastic reader and a replaceable polymer sweat-sensing strip with zinc oxide (ZnO) coated electrodes that is worn on the participant's forearm. It is manufactured through a screen-printing technique that allows for an affinity-based interaction between a capture probe antibody and the target molecule generating electrochemical activity.~The Cort Wearable has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements."
41504551|NCT02296931|OTHER|Saline|Standard IV Saline Fluids
41504552|NCT02296931|DRUG|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
41504553|NCT02937389|DIAGNOSTIC_TEST|Patients after esophagectomy|Endoscopic examinations are performed at 1 and 8 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
41504554|NCT04204057|DRUG|Tenalisib|Tenalisib 800 mg BID, Orally
41504555|NCT02971020|OTHER|Observational/Cognitive Assessment|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
41504556|NCT06409208|BEHAVIORAL|mHealth intervention (video and reminder SMSs)|intervention includes educational video related to postnatal care and reminder SMSs related to postnatal visits, family planning adoption and exclusive breast feeding practice.
41504557|NCT06572111|DRUG|BI 1839100 (C-14) formulation 1|BI 1839100 (C-14) formulation 1
41504558|NCT06572111|DRUG|BI 1839100|BI 1839100
41373284|NCT02352831|DRUG|Tosedostat|
41373285|NCT02352831|DRUG|Capecitabine|
41373286|NCT02352831|PROCEDURE|Fresh tissue biopsy|Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
41373287|NCT04498975|OTHER|Rurality; Ethnicity; Exercise; Hopelessness|Observational study exploring rurality, ethnicity, exercise and hopelessness patterns cross-sectionally and longitudinally
41373288|NCT03651440|OTHER|PNF|PNF
41373289|NCT03651440|OTHER|lumbar stabilization training|lumbar stabilization training
41373290|NCT03651440|OTHER|Physical Therapy|Physical Therapy
41373291|NCT03651440|OTHER|Control|Control group
41373292|NCT01315626|OTHER|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
41373293|NCT02235207|BEHAVIORAL|Neuromuscular exercise|"Fustra20 Neck \& Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.~The main targets are to~* improve movement control in different posture and movements of the neck and back~* improve flexibility with active functional movements~* improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain~* improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities"
41373294|NCT06021769|OTHER|Observational only|No intervention
41373295|NCT05880069|OTHER|Pathogen resistant phenotype|Drug resistant phenotype of the target pathogen under study
41504559|NCT06572111|DRUG|BI 1839100 (C-14) formulation 2|BI 1839100 (C-14) formulation 2
41504560|NCT00000691|DRUG|Foscarnet sodium|
41504561|NCT02505308|OTHER|Glucose-Potentiated Arginine-Induced Insulin Secretion|Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
41031985|NCT02525133|DRUG|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
41163306|NCT05591378|OTHER|core stability exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~first week:Cat camel stretch, all fours stretch and lifting one leg, cobra pose, lying on your back and raising the legs/one leg, and hamstring stretch on chair second week:Straight Leg Crunch, with first week exercises third week:Crunch, bridge exercise,and lifting the legs/one leg straight out with first week exercises fourth week:lifting the legs/one leg to the opposite hand, with first week exercises fifth week:Reverse Crunch, bridge exercise without support with first week exercises sixth week:Hamstring stretch on the Floor with first week exercises seventh week:lifting one hand and one leg, with first week exercises eight week:Exercise Ball Crunch,and stability ball bridge with first week exercise"
41163307|NCT05591378|OTHER|otago exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~Walking forward with support, standing on heel with support, side walking with support, standing on one foot with support.Walking forward without support, standing on heel without support, side walking without support, standing on one foot without support.~Walking backward with support, walking on heel with support, walking and turning around, walking on heel with support.~Walking backward without support, walking on heel without support, walking and turning around, walking on heel without"
41504562|NCT01119365|OTHER|Bright light|Light is administered through a custom designed mask with LED lights.
41504563|NCT03005912|DEVICE|Conventional acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
41504564|NCT03005912|DEVICE|Conventional bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
41504565|NCT03005912|DEVICE|VoIP acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
41504566|NCT03005912|DEVICE|VoIP bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
41504567|NCT01492920|DIETARY_SUPPLEMENT|Acetyl-L-Carnitine Hydrochloride|Given orally
41504568|NCT01492920|OTHER|Placebo|Given orally
41504569|NCT01492920|OTHER|Questionnaire Administration|Ancillary studies
41504570|NCT01492920|OTHER|Quality-of-Life Assessment|Ancillary studies
41504571|NCT03670290|PROCEDURE|Fascia iliaca compartment catheter|Patient will evaluate and if VAS score \>3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
41504572|NCT03670290|PROCEDURE|epidural catheter|Patient will evaluate and if VAS score \>3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
41504573|NCT03670290|PROCEDURE|patient controlled analgesia|Patient will evaluate and if VAS score \>3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
41504574|NCT06593054|DRUG|Ceftibuten|Ceftibuten dihydrate, formulated in capsules
41504575|NCT06593054|DRUG|Avibactam prodrug|Avibactam prodrug, formulated in capsules
41504576|NCT06593054|DRUG|CTB-AVP in Tablet|ceftibuten and avibactam prodrug, in Tablet formulation
41504577|NCT06001593|DEVICE|YPS-201b|electrical stimulation device.
41504578|NCT06001593|DRUG|betahistine|Relieve symptoms of balance disorders or dizziness
41504579|NCT06001593|DEVICE|YPS-201b|sham electrical stimulation device.
41504580|NCT03796052|OTHER|Avena Sativa Skincare Regimen|Regimen consisting of 3 topical agents containing Avena Sativa (oat) kernel flour: a body wash (type = cosmetic), a body cream (type = cosmetic), and an anti-itch balm (type = OTC monograph drug with 0.5% Pramoxine HCl)
41504581|NCT06218576|OTHER|None, purely observational study|None, purely observational study
41504582|NCT03086759|PROCEDURE|platelet rich plasm|intra-articular infiltration with platelet rich plasm
41504583|NCT03086759|DRUG|Triamcinolone Hexacetonide|intra-articular infiltration withTriamcinolone Hexacetonide
41504584|NCT03086759|PROCEDURE|Isotonic Saline Solution|intra-articular infiltration with Isotonic Saline Solution
41504585|NCT06633614|DEVICE|Supervised prehabilitation programme|Participants will receive standard preoperative physiotherapy education along with a Fitbit Aspire 3 wearable device to track vital signs such as heart rate, physical activity, and sleep patterns. They will follow a personalized exercise program, supervised remotely by a physiotherapist via telemedicine twice a week. The program will include 20-minute sessions at least three times per week, focusing on strength training, aerobic exercises (at 40% of maximal heart rate), and flexibility exercises. Progress will be monitored through vital signs and workout data, with the physiotherapists adjusting the regimen as needed. Participants with low inspiratory pressure (MIP \&amp;lt;100 cmH₂O) will receive an Inspiratory Muscle Trainer (IMT). Additionally, some participants may be provided with a portable cycle pedometer featuring adjustable resistance. To ensure safety, both participants and caregivers will receive a safety briefing, and a 24-hour emergency hotline.
41031986|NCT02525133|OTHER|Placebo|Plain collagen implant (vehicle)
40849254|NCT06584253|OTHER|Depression Anxiety Stress Scale - 21 Short Form|DASÖ-21 consists of 3 subcategories (depression, anxiety and stress). Each category consists of 7 separate questions and a total of 21 questions.
41031987|NCT04616651|BEHAVIORAL|Online Survey|Participants respond to online survey questions either before or after using the Chatbot O2O intervention.
41504586|NCT03887494|DEVICE|Implantation|Implantation of Y-Strut + cementoplasty in the femoral neck
41504587|NCT00036192|DRUG|FK614|
41504588|NCT06633172|PROCEDURE|laparoscopic ventral mesh rectopexy|performing ventral mesh rectopexy via laparoscopic surgery to correct the anterior rectocele.
41504589|NCT06633172|PROCEDURE|Trans vaginal repair|performing repair of the rectocele through the recto vaginal septum repair.
40849255|NCT06584253|OTHER|Body Awareness Questionnaire|The questionnaire aims to determine the level of body composition sensitivity.
41163308|NCT00962221|PROCEDURE|laboratory analysis|laboratory analysis
41163309|NCT00202332|PROCEDURE|Coronary artery bypass|
40849256|NCT06584253|OTHER|SF-12|This questionnaire consists of two general components related to physical and mental function, consisting of 12 questions and 8 scales measuring physical function (2 questions), bodily pain (1 question), role limitations due to physical problems (2 questions), general health (1 question) vitality (40).
41031988|NCT04616651|BEHAVIORAL|Chatbot prototype|An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).
41163310|NCT05414006|DRUG|S-ketamine|S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively
41163311|NCT01177137|DEVICE|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
41163312|NCT01177137|DEVICE|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
41163313|NCT01177137|BEHAVIORAL|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
41163314|NCT01177137|BEHAVIORAL|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
40849257|NCT05917171|BEHAVIORAL|painTRAINER|painTRAINER is an 8 week online behavioral pain coping skills training program derived from cognitive behavioral therapy approaches, which includes 45 minute behavioral coping sessions to be completed over 8 weeks. Weekly sessions are guided by an automated coach that teaches skills for coping with pain.
40849258|NCT05969340|DIAGNOSTIC_TEST|ultra-high-resolution CT-scan|Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV
40849259|NCT00141128|DRUG|SS-RBX|
41031989|NCT04616651|BEHAVIORAL|Open to Options (O2O) Program|Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.
41031990|NCT01923727|BIOLOGICAL|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.
41031991|NCT04197947|DEVICE|Neuro Omega|"A neurophysiological navigation system NeuroOmegaTM (Alpha Omega. Israel) was implemented in our group and the operation of this system for aDBS experiment is proved to be successful (Fig 9, 10). This system was proved by both FDA and tFDA. The aDBS stimulation algorithm will be integrated with NeuroOmegaTM. The aDBS stimulation control will achieve through self-developed algorithms or built-in scripting of the system. We introduce NeuroOmega system to conduct the designed aDBS experiment for its multifunction and safety. Our group has established collaboration with Department of Eelectronic Engineering in Chang Gung University (Co-PI HL Chan) and BERTEC in National Ciao Tung University (Co-PI MD Ker). Three postdoctor fellows and one senior engineer have been working on the operation of this aDBS system.~All hardware and software problems could be sorted out in time."
41031992|NCT01407861|OTHER|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
41031993|NCT01407861|OTHER|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
40849260|NCT02068287|DRUG|Esmolol|After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate. This infusion is maintained for six hours.
40849261|NCT05687019|COMBINATION_PRODUCT|Intravesical instillations of Ialuril® Prefill|5 injections of Ialuril® Prefill on D0 or D1, D7, D14, D21 and D28 after Holmium laser surgery for prostate adenoma
40849262|NCT04267055|DEVICE|Valiant Navion Thoracic Stent Graft System|Placement of the Valiant Navion for endovascular repair of a dissection in the thoracic aorta.
41031994|NCT04483453|OTHER|EXPL feeding regimen|EXPL FUF (lower protein and 100% lactose) + EXPL IC (whole grains and legumes)
41031995|NCT04483453|OTHER|CTRL feeding regimen|CTRL FUF (standard protein content and carbohydrate profile) + CTRL IC (refined grains)
40849263|NCT04083157|BIOLOGICAL|Intradermal hepatitis B vaccine with imiquimod|Intradermal hepatitis B vaccine with topical imiquimod pretreatment
40849264|NCT04083157|BIOLOGICAL|Intramuscular hepatitis B vaccine with aqueous cream|Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
41031996|NCT02763384|DRUG|BL-8040|
41031997|NCT02763384|DRUG|Nelarabine|
41031998|NCT04977167|DRUG|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
40849265|NCT00284310|PROCEDURE|Anamnesis and clinical examination|Anamnesis and clinical examination to follow.
40849266|NCT00516165|DRUG|RAD001|Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
40849267|NCT01601665|DEVICE|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
40849268|NCT01601665|DEVICE|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
41031999|NCT04977167|DRUG|PD-(L)1 antibody|PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
41032000|NCT05157646|BEHAVIORAL|Fitness tracker|Participants will be asked to wear a Fitbit fitness tracker and report their fitness activity to the study team
41032001|NCT00649012|DRUG|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
41032002|NCT00649012|DRUG|Actos® Tablets 45 mg|45mg, single dose fed
40849269|NCT01601665|DEVICE|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
40849270|NCT01601665|DEVICE|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
40849271|NCT01601665|DEVICE|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
41032003|NCT04532697|OTHER|Uncaria Rhynchophylla (Gou-Teng)|Uncaria Rhynchophylla (Gou-Teng) is a kind of Chinese Medicine. All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
41163315|NCT01177137|BEHAVIORAL|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
41032004|NCT04532697|OTHER|Placebo|All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
41163316|NCT01570621|PROCEDURE|peroral endoscopic myotomy|A 3-cm incision is made into the mucosa after injection of saline and methylene blue. A submucosal tunnel is created from the mid-esophagus to the gastric cardia by a triangle-tip knife. The circular muscle fibers or full-thickness muscle are divided by the triangle-tip knife over a length of 6-20 cm on the esophagus, starting 3 cm below the initial mucosal incision, and extended 3-4cm onto the gastric cardia. The mucosal entry site is closed using standard endoscopic clips at last.
41163317|NCT04059887|DRUG|Atezolizumab Injection [Tecentriq]|Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
41163318|NCT02681445|DEVICE|Breath Collection|breath will be collected from patients in breath bag for analysis for observational study.
41163319|NCT00817336|DRUG|D Serine|60 mg/kg/day
41163320|NCT00817336|DRUG|Placebo|oral
41163321|NCT01936298|DEVICE|A-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
41163322|NCT01936298|DEVICE|P-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
41163323|NCT02805036|DEVICE|echocardiography|• Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).
41163324|NCT02805036|DEVICE|Arterial oximetry|measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
41032005|NCT05720611|BEHAVIORAL|Digitally delivered gardening and healthy eating course|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
41504590|NCT05980572|DRUG|Glenohumeral joint and subacromial space triamcinolone injections|"All patients will receive both glenohumeral joint and subacromial space injections. The injections will consist of a solution containing 1 ml of 40 mg/ml triamcinolone acetonide and 1 ml of 1% lidocaine in each site. The glenohumeral joint injection will be performed blindly using an anterior approach. The needle will be inserted medially to the head of the humerus, located approximately 1 cm lateral to the coracoid process, and directed posteriorly at a slight superior and lateral angle.~Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds."
40849272|NCT02872272|DRUG|Treatment with Amikacin|Aminoglycosides. Blood sampling for pharmacokinetic evaluation
41032006|NCT06535477|DEVICE|Fall risk assessment|"Assessing frailty in elderly patients using Fried Frailty and Short Emergency Geriatric Assessment scales combined with measurement - via the AbilyCare device - of the two markers of balance and gait"
41373296|NCT00253747|DRUG|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
41373297|NCT00253747|DRUG|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
41504591|NCT05980572|DEVICE|App-assisted exercise|Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds. Then the APP group will suggest performing the exercise from APP education The APP intervention group will be guided through the exercises using the mobile app, while the conventional group will be provided with a printed pamphlet illustrating the exercises.. Each set exercise will have 10 repetitions and investigators recommend 4 sessions per day.
41504592|NCT05980572|DRUG|Nonsteroidal anti-inflammatory drugs (aceclofenac)|All patients will be prescribed two weeks of nonsteroidal anti-inflammatory drugs (aceclofenac) .
41504593|NCT01630070|DEVICE|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
41504594|NCT05954286|DRUG|Upamostat|Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.
41504595|NCT05954286|DRUG|Placebo (PO)|Oral Capsules
41504596|NCT04223375|BEHAVIORAL|Nutrition Training|Postpartum women were educated on postpartum healthy and regular nutrition.
41504597|NCT00551018|DRUG|Vicriviroc|one 30 mg tablet QD
41504598|NCT00551018|DRUG|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
41504599|NCT03783429|DRUG|Digoxin|Digoxin tablets will be given orally
40849273|NCT01192568|DRUG|Oxybutynin|10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
40849274|NCT01192568|DRUG|Placebo|Topical gel
41032007|NCT04671862|DEVICE|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~* 1 Treatment 4J continuous prior to RT. (Within 14 days of RT start)~* 3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)"
41032008|NCT05669391|DIAGNOSTIC_TEST|Genomic analysis of antidepressants|Genomic analysis of all antidepressants. Tris EDTA anticoagulation and salting out were used to extract DNA. OD 260/280 was between 1.6-1.8 and the concentration was greater than 50 ng/ μ L。 Using the PCR gene chip detection method and the Asian Screening Array (ASA) chip detection technology of Illumina Company (this chip is the first whole genome SNP chip designed based on the whole genome sequencing data of 9000+East Asian populations, which contains 750000 markers, with 85% of the effective loci), we can obtain the genetic information of polymorphic loci related to the individual differences of drug effects of subjects.
41504600|NCT03783429|DRUG|Placebos|Placebo tablets will be given orally
41504601|NCT06050304|BEHAVIORAL|Observation of behavior and search of biomarkers with 3 blood tests.3 weeks wearing an actimeter|In the form of a small watch, which collects the level of motor activity throughout the day and night. Patients will be asked to indicate each moment of crack-cocaine use by pressing the button in the center of the watch. We want to know if certain uses lead to more behavioral problems (especially after periods of cessation).
41504602|NCT06050304|BIOLOGICAL|3 blood tests|We will try to identify biomarkers of BS: blood proteins, genetic markers passed on by your parents, or the expression of proteins in particular situations
41504603|NCT00364000|DRUG|Calcium acetate|Calcium acetate in 240 chronic HD patients
40849275|NCT02240602|DRUG|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
40849276|NCT02240602|DRUG|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
40849277|NCT02240602|DRUG|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
40849278|NCT04433065|DEVICE|Intrepid™ TTVR System|Device: Intrepid™ TTVR System
41032009|NCT01288482|DEVICE|AeroEclipse II breath-actuated nebulizer|The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.
41504604|NCT00364000|DRUG|Sevelamer|label sevelamer (RenagelR) 800 mg tablets
41504605|NCT05428566|DIETARY_SUPPLEMENT|Pulse-based diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine and chickpeas) will be used."
40849279|NCT01686282|DIETARY_SUPPLEMENT|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
40849280|NCT01686282|DIETARY_SUPPLEMENT|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
40849281|NCT05315089|OTHER|Virtual reality games +conventional exercises|Virtual reality games +conventional exercises
40849282|NCT05315089|OTHER|Conventional exercises|Conventional exercises
41373298|NCT06514508|DRUG|Motixafortide+G-CSF|Patients will receive the first dose of motixafortide (1.25 mg/kg) by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of motixafortide can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
41373299|NCT06514508|DRUG|Placebo+G-CSF|Patients will receive the first dose of placebo by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of placebo can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
41373300|NCT03984552|BEHAVIORAL|This was an observational study of medical devices (rapid tests) used for the HIV diagnosis in children up to 2 years|"These rapid tests are based on lateral flow immunochromatography technology, in which a nitrocellulose membrane is impregnated with the antigen of interest. The patient sample (blood, serum, plasma, oral fluid, etc.) is applied in this membrane which facilitates the interaction of antibodies in the sample with the antigens on the membrane. This reaction becomes visible to the naked eye thanks to a color developing revelator.~The entire testing process, from sample collection to result reading takes no more than 40 minutes and does not depend on laboratory facilities."
41373301|NCT03131791|DEVICE|Shock Wave|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
41504606|NCT05428566|DIETARY_SUPPLEMENT|TLC diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber."
41504607|NCT06633653|BEHAVIORAL|exercise intervention|Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
41504608|NCT06621446|OTHER|Comprehensive intervention model|A dry eye intervention strategy: including health education, the use of eye drops, and regular review.
41504609|NCT03020589|DRUG|Tacrolimus|See description in arm/group sections
41504610|NCT02003950|OTHER|Snack Condition Specification|Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
41504611|NCT05096650|PROCEDURE|mesotherapy of platelet rich plasma and platelet poor plasma|Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.
41504612|NCT01807247|PROCEDURE|Intensive lower limbs muscles strengthening|
41504613|NCT01839318|DEVICE|Nelfilcon A contact lenses|
41504614|NCT01839318|DEVICE|Omafilcon A contact lenses|
41504615|NCT01839318|DEVICE|Etafilcon A contact lenses|
41504616|NCT04205305|DRUG|conventional blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
40849283|NCT05709639|OTHER|Individualized counselling in nutrition|Individualized counselling in nutrition - collaborate on a nutrition plan
40849284|NCT01114438|DEVICE|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
40849285|NCT05582174|DRUG|Vonoprazan|Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
41504617|NCT04205305|DRUG|intensive blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.
41504618|NCT05102812|BEHAVIORAL|Breakfast Group Intervention|An actionable toolkit encompassing an assessment, a personalised care plan and a range of outcome measures.
40849286|NCT05582174|DRUG|esomeprazole|A high dose PPI infusion (esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours), and frorm day 4-30 oral esomeprazole daily
40849287|NCT04855383|DRUG|The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles|Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
40849288|NCT00001094|DRUG|Lamivudine/Zidovudine|
40849289|NCT00001094|DRUG|Nelfinavir mesylate|
40849290|NCT00001094|DRUG|Saquinavir|
40849291|NCT00001094|DRUG|Delavirdine mesylate|
41032010|NCT01288482|DEVICE|English-Wright continuous-mode nebulizer|The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
41373302|NCT03131791|DRUG|Botulinum toxin A|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
41373303|NCT04689126|PROCEDURE|surgical or nonsurgical endodontic treatment|Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
41373304|NCT02071472|OTHER|DP medication reconciliation|
41373305|NCT00381602|DRUG|GHRP-1/AG 70 mg depot in ESRD|
41032011|NCT02345057|DRUG|CS-3150|
41032012|NCT02345057|DRUG|placebo|
41032013|NCT03671603|DRUG|Iodixanol|Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
41163325|NCT04826497|DRUG|nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg nicorandil was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
41163326|NCT04826497|DRUG|Placebo（normal saline）|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
41163327|NCT01086618|DRUG|systemic chemotherapy|
41163328|NCT01086618|PROCEDURE|adjuvant therapy|
40849292|NCT04269876|DIETARY_SUPPLEMENT|Marine Lipid Oil Concentrate|Marine Lipid Oil Concentrate softgels
40849293|NCT04269876|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement capsules
40849294|NCT04269876|DIETARY_SUPPLEMENT|Placebo|Placebo softgels
40849295|NCT04269876|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
41032014|NCT04824313|DIAGNOSTIC_TEST|Chest CT|Chest CT without intravenous contrast material
41163329|NCT01086618|PROCEDURE|quality-of-life assessment|
41163330|NCT01086618|PROCEDURE|therapeutic conventional surgery|
41163331|NCT04101019|DRUG|Lidocaine|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of 5% lidocaine will be dripped into one or two nostrils.
41163332|NCT04101019|DRUG|Saline Solution|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of saline will be dripped into one or two nostrils.
41163333|NCT01939405|BEHAVIORAL|built environment use counseling|
41373306|NCT00381602|OTHER|Placebo|
40849296|NCT01209078|DRUG|GSK1322322|GSK1322322 1500mg BID
40849297|NCT01209078|DRUG|Linezolid|Linezolid 600mg
40849298|NCT01209078|DRUG|GSK1322322 placebo|Placebo
40849299|NCT01209078|DRUG|Linezolid placebo|placebo
41032015|NCT04824313|DIAGNOSTIC_TEST|Chest CTA|Chest CT with intravenous contrast material
41032016|NCT03049124|BEHAVIORAL|Exercise|Participants will engage in supervised exercise 3 times per week for 60-75 minutes/session for 12 weeks. Sessions will include a warm-up (aerobic activity less than \< 60% of heart rate reserve), aerobic training (30 minutes of exercise at 60-75% of heart rate reserve, using cycle ergometers/treadmills), strength training (8 exercises; upper body, lower body, and core), and a cool-down (aerobic activity less than \< 60% of heart rate reserve) component.
41373307|NCT02244385|OTHER|no intervention|
41373308|NCT03093129|DRUG|artesunate|"Artesunate (Trade name : Arinate®)~Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015)."
41373309|NCT03093129|OTHER|placebo|The matching placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and a magnesium stearate blend.
41504619|NCT04314895|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles within a well-characterized particle-size distribution. Following PCA, NanoPac is filled into a clear 60mL Type 1, USP, clear-glass vial (306 mg/vial) as a powder fill of nanoparticulate paclitaxel, closed with a bromobutyl rubber stopper and aluminum crimp seal, and sterilized by gamma irradiation. Prior to administration at the hospital/clinic, NanoPac will be reconstituted with 1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP, to form a suspension. The suspension will be further diluted with 0.9% Sodium Chloride for Injection, USP to achieve the final clinical formulation.
40849300|NCT02547168|DEVICE|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
40849301|NCT02978950|OTHER|Duplex ultrasound surveillance|bilateral lower extremity venous duplex
40849302|NCT02978950|OTHER|No ultrasound surveillance|will have daily exam and history as per normal clinical routine
40849303|NCT00478686|PROCEDURE|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
40849304|NCT04957056|PROCEDURE|Hospitalization|Hospitalization
40849305|NCT03080363|DRUG|Bupivacaine|10 ml %0.5 bupivacaine
40849306|NCT03080363|DRUG|Lidocaine|10 ml %2 lidocaine
40849307|NCT03634254|OTHER|Satisfaction survey of communication quality:|a conversation from phone call to survey primary caregivers of AAC users in New Taipei City who think the users communication quality
41373310|NCT01914107|PROCEDURE|real-time monitoring and instruction of cancer pain|as description in arm
41373311|NCT01914107|PROCEDURE|standard cancer pain care|as description in arm
40849308|NCT04480658|DRUG|Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)|"Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed.~Other Names:~Bryophyllum pinnatum/Kalanchoe"
40849309|NCT02545244|DIETARY_SUPPLEMENT|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
40849310|NCT02545244|DIETARY_SUPPLEMENT|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
40849311|NCT02545244|DRUG|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
40849312|NCT05293626|DRUG|NR082 Injection|"The starting dose is 1.5E9 vg, 0.05 mL eye/dose.~Dose Escalation:~If drug-related dose-limiting toxicity (DLT) events are observed in ≤ 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be escalated to 4.5E9 vg, 0.05 mL eye/dose (high dose) after approval by SRC.~Dose De-escalation： If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be de-escalated to 0.5E9 vg, 0.05 mL eye/dose (low dose) after approval by SRC.~If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects within 6 weeks after the dosing of NR082 at the high dose, the dose can be de-escalated to 3.0E9 vg, 0.05 mL eye/dose (intermediate dose) after the approval by SRC."
40849313|NCT05293626|DEVICE|Injection needle|"19G 1 1/2IN TW filter needle with filter element (BD 305200)，used to NR082 Intraocular injection solution dose preparation; 30G 1/2IN injection needle (BD 305106)，used to NR082 Intraocular injection solution administration;~1 ml screw top syringe (BD 309628),used to NR082 Intraocular injection solution dose preparation and administration."
40849314|NCT02622893|DRUG|Transperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
41373312|NCT02714413|DIETARY_SUPPLEMENT|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
41373313|NCT02714413|DIETARY_SUPPLEMENT|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
41504620|NCT01969786|OTHER|Corneal ulcer prevention program|The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
41032017|NCT05104606|OTHER|TEE|"The intervention within the framework of the protocol will consist, for the needs of the study, in performing 2 TEE and 5 TTE in 24 hours after~For TEE:~* The first TEE will allow us to evaluate the right ventricle, to look for the existence of a acute cor pulmonale, to evaluate the patient's blood volume as recommended during the management of ARDS. If the patient is included in the study, our intervention will consist in leaving this TEE in place in order to perform measurements at H0, 30min, H1 and H2 after iNO administration.~* The second TEE will be performed at H24 to performed new measurements."
41032018|NCT05104606|OTHER|TTE|"For TTE:~• The TTEs will allow us to evaluate the anatomy of the right ventricle, to estimate the systolic pulmonary artery pressure, to calculate the cardiac output and to measure the conventional parameters of the right ventricular systolic function. This noninvasive examination will be repeated at 30 min, H1, H2, and H24 after iNO administration"
41032019|NCT02084953|DRUG|BMS-791325|
41163334|NCT01849913|OTHER|Laser|The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
41373314|NCT02714413|OTHER|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
41032020|NCT02084953|DRUG|Moxifloxacin|
41032021|NCT02084953|DRUG|Placebo matching BMS-791325|
40849315|NCT02622893|DRUG|Retroperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
41032022|NCT02805569|DEVICE|articulating stylet|patient who intubated with articulating stylet
41032023|NCT02805569|DEVICE|conventional stylet|patient who intubated with conventional stylet
41032024|NCT05476224|BIOLOGICAL|Blood sample of 30 ml|The parameters analyzed on this blood sample: Fasting blood glucose, HbA1C, creatinine, creatinine clearance (MDRD), fasting lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
41032025|NCT05954897|DRUG|Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC|RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab
41032026|NCT04307186|DRUG|Gadoquatrane (BAY1747846)|Solution for IV injection, single dose
41032027|NCT04307186|DRUG|Gadobutrol (Gadovist/Gadavist)|Solution for IV injection, single dose
41032028|NCT02043782|DEVICE|Coloplast Test|Newly developed 1-piece convex ostomy product
41032029|NCT02043782|DEVICE|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
41032030|NCT02043782|DEVICE|Competitor soft convex|A commercially available soft convex product
41032031|NCT01265329|OTHER|Negative selection|Sperm selection to continue the treatment with healthy sperm
41032032|NCT02331992|BEHAVIORAL|Adherence program|Participants will receive supportive messages while enrolled in the program.
41032033|NCT01944046|DRUG|Double blind phase Placebo Nasal Spray|This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
41373315|NCT04895046|DRUG|Niraparib|300 mg taken orally (all cycles)
41032034|NCT01944046|DRUG|double Blind Oxytocin Nasal Spray|Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.
41032035|NCT01944046|DRUG|Open Label intranasal oxytocin|All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin
41032036|NCT05795725|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
41032037|NCT05795725|PROCEDURE|Colonoscopy|Colonoscopy procedure
41032038|NCT04745676|BEHAVIORAL|Telehealth|Telehealth ACP intervention advance care planning intervention
41373316|NCT04895046|DRUG|Dostarlimab|500 mg (cycles 1-4) intravenously
41373317|NCT04895046|DRUG|Dostarlimab|1000 mg (cycle 5+) intravenously
41373318|NCT00554268|DRUG|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
41373319|NCT05837884|DIAGNOSTIC_TEST|blood sampling|Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
41373320|NCT00856570|DRUG|warfarin|Oral
41373321|NCT00856570|DRUG|YM178|Oral
41373322|NCT00564382|PROCEDURE|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
41373323|NCT02654561|DRUG|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
41504621|NCT01249573|OTHER|fascia therapy or transcutaneous fibrolysis|fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
41373324|NCT02654561|DRUG|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
41373325|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with intraoperative periarticular injection|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
41504622|NCT00157924|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
40849316|NCT02677896|DRUG|Enzalutamide|Oral
40849317|NCT02677896|DRUG|Placebo|Oral
41032039|NCT04821596|OTHER|biological collection|"Six 5 mL heparinized tubes, approximately 24 mL of blood will be collected as per standard practice. The 5 tubes collected from a given individual will be transported directly to the laboratory. In the laboratory, peripheral blood mononuclear cells (PBMC) will be prepared for the various analyses.~However, in order to minimize the effect of agents other than CoA in MS patients, it is necessary that peripheral blood mononuclear cells are collected before treatment is given: for RR MS patients treated with first-line drugs (IFNβ, glatiramer acetate, teriflunomide and dimethyl fumarate, ...), RR MS patients treated with second-line drugs (natalizumab and fingolimod, ...) and RR MS patients treated with third-line drugs (alemtuzumab, ...)."
41032040|NCT04020510|DRUG|onaBoNT-A|Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
41032041|NCT02848508|DRUG|Metformin|
41032042|NCT06534788|OTHER|Reciprocal Inhibition MET|Reciprocal Inhibition MET will be applied to the shortened piriformis muscle in supine and prone positions with participants using 30-50% of their maximum voluntary isometric contraction. It will include 30-50% isometric contraction of the muscle opposite to the muscle to be stretched for 7-10 seconds, followed by inhalation, exhalation and rest period of 5 seconds and then a stretch (through the new barrier with patients' assistance) of 10-60 seconds hold. RI-MET group will receive 3-5 repetitions.
41032043|NCT06534788|OTHER|Post-facilitation MET|Post-facilitation stretch technique for shortened piriformis muscle in supine and prone positions will be applied with participants using 20% of their maximum voluntary isometric contraction. It will include 20% maximal isometric contraction of the muscle to be stretched for 6-10 seconds, followed by a rapid stretch (through the new barrier) of 15 seconds hold. After stretch, the muscle is allowed to relax in the midrange for up to 30 seconds. PFS-MET group will receive 3-5 repetitions.
41032044|NCT06534788|OTHER|Conventional physical therapy|"TENS and hot pack application to provide heating effect over the painful area (10 minutes) Both groups will receive conventional physical therapy which they will be taught as a home plan. Following exercises are guided to the patient as home plan.~* Resisted abduction with Thera/resistance band~* Resisted bridging with Thera/resistance band~* Resisted clam exercise with Thera/resistance band"
41032045|NCT01934218|DEVICE|Gel-One|
41032046|NCT01934218|DEVICE|PBS|
41032047|NCT06635798|BIOLOGICAL|GR2001|The packaging for GR2001 injection uses a borosilicate glass vial, a brominated halobutyl rubber stopper for injectable solutions and an aluminum-plastic combination cap for antibiotic vials as its primary packaging materials. The specification is 5mg/1ml per vial.
41504623|NCT00157924|DRUG|atorvastatin|atorvastatin 10mg
41504624|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
41504625|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day
40849318|NCT06526910|BEHAVIORAL|Swallowing exercises|Standard-of-care swallowing exercises include tongue exercise. The experimental part added in Phase 3 includes some participants completed standard-of-care exercises again and others completing standard-of-care exercises and motor imagery practice of those exercises.
40849319|NCT04054375|DRUG|Prednisone|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
40849320|NCT02197091|OTHER|questionnaire administration|Ancillary studies
40849321|NCT02197091|OTHER|medical chart review|Ancillary studies
41373326|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with non-injection of MMA drugs|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* 43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
41373327|NCT04985032|RADIATION|stereotactic body radiation therapy|Treatment technique used to deliver a highly focused and accurate radiation dose to a defined target volume outside the brain; the entire course of therapy delivered in five fractions or less
41373328|NCT02928562|OTHER|exercise|cyclic exercise, aerobic exercise and resistant training exercise
41373329|NCT00744068|BEHAVIORAL|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
41373330|NCT02583165|BIOLOGICAL|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
41373331|NCT06520488|DRUG|HRS-4642|Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904 Treatment group Part II: HRS-4642 combined with AG
41373332|NCT06174792|DRUG|Drospirenone 4 MG|Patients who met all inclusion criteria and had no exclusion criteria would receive one tablet of Drospirenone 4mg daily for 20 weeks, starting from day 2 to day 5 of their menstrual cycle.
41504626|NCT00506584|DIETARY_SUPPLEMENT|Human milk fortifier (bovine-based), pre-term formula|Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
41504627|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day
40849322|NCT02387554|DRUG|HGP0904|
41504628|NCT00506584|DIETARY_SUPPLEMENT|Pre-term/term formula|Bovine milk-derived nutrition formulated for very low birth weight infants
40849323|NCT02387554|DRUG|HGP0608|
40849324|NCT02387554|DRUG|HGP1405|
40849325|NCT00595816|OTHER|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
40849326|NCT04443309|DRUG|Camrelizumab|Camrelizumab 200mg,iv,d1,q2w
41032048|NCT06635798|BIOLOGICAL|HTIG|The HTIG is a Chinese licensed Human Tetanus Immunoglobulin produced by Tonglu-Bio, which are derived from human plasma, and then purified and filled in the injectable vial form.
41032049|NCT00695331|DRUG|Misoprostol|Titrated Misoprostol Solution
41032050|NCT00695331|DRUG|Oxytocin|Titrated Intravenous Oxytocin
41032051|NCT00444548|DRUG|[S,S]-Reboxetine|
41032052|NCT04159688|DRUG|Alcohol|Alcohol Challenge
41032053|NCT06634576|DEVICE|Smooth pursuit neck torsion test|Used custom-made system to stimulate the procedure of smooth pursuit neck torsion test in the current study, the multiple axis motion platform can adjust the neck postures to three different neck motion planes, seven different neck postures.
41032054|NCT06213883|OTHER|Biobehavioral Response to in-lab exposure to physical activity|ED severity, biological and affective markers of physical activity response, and both exercise-specific and general positive (reward) and negative (avoidance/escape) valence sensitivities associate with physical activity will be comprehensively examined.
41504629|NCT01560650|DEVICE|CRRT|Difference dose of CRRT
41504630|NCT02538380|PROCEDURE|EUS-B-FNA followed by EUS-FNA for LAG analysis|
41504631|NCT02143076|BEHAVIORAL|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
41504632|NCT02143076|BEHAVIORAL|Medical Adherence Measure Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
41504633|NCT02143076|BEHAVIORAL|Acceptability Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
41504634|NCT06377033|BEHAVIORAL|Behavioral nudge|Comparison of genetic rates among individuals for whom it may make a difference in their care across study arms.
41504635|NCT02184767|DRUG|ADASUVE®|ADASUVE® 2.5, 5, or 10 mg
41504636|NCT02022748|DRUG|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
40849327|NCT04443309|DRUG|Lenvatinib|Lenvatinib 8mg (\<60kg) or 12mg (≥60kg),po,d2,qd
41032055|NCT06114446|OTHER|simulation group|Participants will be educated with simulation manikin for postoperative nursing care of a patient who underwent colorectal surgery
41032056|NCT06114446|OTHER|immersive virtual reality|Participants will be educated with immersive virtual simulation f for postoperative nursing care of a patient who underwent colorectal surgery
41373333|NCT01286896|DRUG|Sunitinib|"Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses."
41373334|NCT02966366|DEVICE|Cochlear implant|
41373335|NCT03495167|DRUG|SyB C-1101|SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.
41373336|NCT00683670|DRUG|cyclophosphamide|
41373337|NCT00683670|BIOLOGICAL|Mature dendritic cell vaccine|
41373338|NCT05635929|COMBINATION_PRODUCT|Composition comprising olive oil, xylitol and betaine|Topical composition in the form of a gel.
41373339|NCT05214339|DRUG|Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab|The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day. The intervention is repeated every 3 weeks.
41373340|NCT00131937|DRUG|sorafenib tosylate|Given orally
41504637|NCT02022748|DRUG|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
41504638|NCT02022748|DRUG|ticagrelor|Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
41504639|NCT06629831|OTHER|group with complications|Complications in patients undergoing cytoreduction surgery for ovarian cancer
41504640|NCT06629831|OTHER|group without complications|Complications in patients undergoing cytoreduction surgery for ovarian cancer
41504641|NCT03069326|DRUG|Ruxolitinib|Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.
40849328|NCT04232111|DEVICE|Heat|Heat applied to hand
41373341|NCT00371748|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
41373342|NCT00371748|DEVICE|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
41373343|NCT00371748|DEVICE|Express2|Coronary Stent System
41504642|NCT03069326|DRUG|Thalidomide|Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
40849329|NCT04232111|DEVICE|Vacuum|vacuum applied to hand
41032057|NCT06114446|OTHER|observation|All participants who participate in simulation or immersive virtual arms will be observed to assess postoperative nursing care skills
41032058|NCT03832010|DRUG|Crisaborole|Participants will be instructed to apply crisaborole to affected areas with eczema.
41032059|NCT03832010|DRUG|Hydrocortisone Ointment|Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
41032060|NCT03832010|DRUG|Triamcinolone ointment|Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.
41032061|NCT03832010|DRUG|Aquaphor|Participants will be instructed to moisturize all over the body with Aquaphor.
41163335|NCT01849913|OTHER|Placebo|"To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy)."
41032062|NCT05307055|DEVICE|STN DBS - Theta Burst|200 Hz intraburst stimulation for 0.1 second repeated at intervals of 5hz with an existing device
41032063|NCT05307055|DEVICE|STN DBS - Gamma|Standard of care gamma stimulation with an existing device
41032064|NCT03920917|PROCEDURE|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
41373344|NCT03893279|BEHAVIORAL|Smell and Taste and questionnaire|The questionnaire must be completed before the antibiotic is taken, if a change of antibiotic is planned (stop of a treatment or addition of another treatment) and at the end of the antibiotic treatment.
41032065|NCT03920917|PROCEDURE|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~3. Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~4. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~5. Evaluated the procedure and radiofrequency ablation time.~6. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
41032066|NCT02363738|DRUG|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
41163336|NCT00420563|DRUG|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
41163337|NCT00420563|DRUG|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
41163338|NCT02096809|PROCEDURE|One week loading of Bone Anchored Hearing Aid (BAHA)|Patients in this arm will be fitted with the BAHA one week after surgery.
41163339|NCT02096809|DEVICE|Cochlear Baha BI300/BA400 Implant System|
41163340|NCT05188313|DRUG|Trastuzumab|Intravenous administration of study drug
41163341|NCT05188313|DRUG|Pertuzumab|Intravenous administration of study drug
41163342|NCT05188313|DRUG|Paclitaxel|Intravenous administration of study drug
41163343|NCT05188313|DRUG|Carboplatin|Intravenous administration of study drug
41163344|NCT02510404|BIOLOGICAL|mCTLs|The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
41163345|NCT00814645|DRUG|Sodium Nitrite Inhalation Solution|a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
41163346|NCT00814645|DRUG|Placebo and AIR001 Inhalation Solution (Expansion arm)|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
41163347|NCT01451697|BEHAVIORAL|Cognitive Remediation|A computerized cognitive remediation program focused on attentional training will be used.
41163348|NCT01451697|BEHAVIORAL|Control (Placebo)|The control condition will involve relaxation training.
41163349|NCT03644706|DRUG|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
41163350|NCT03644706|DRUG|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
41163351|NCT05809245|PROCEDURE|Corneal neurotization|Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
41373345|NCT05273801|DEVICE|Heart Rate Recording from Multiple Participants, No visual feedback|Heart rates are recorded from multiple participants during the group sessions. However during this intervention, it will not be cast to a TV for feedback to the participant or clinician.
40849330|NCT04232111|DEVICE|sham|neither heat nor vacuum
41373346|NCT05273801|DEVICE|Visual Feedback of Multiple Participant Heart Rates|Visual feedback of HR is provided through a TV monitor. Multiple heart rates can be displayed and recorded simultaneously allowing for group encouragement, continuous monitoring and adjustment of all participants to ensure reaching appropriate target intensity.
41383514|NCT06541938|DIETARY_SUPPLEMENT|Inulin Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~A 10g sachet of inulin is roughly equal to the amount of inulin present in 1 head of garlic"
41163352|NCT04915547|OTHER|Group-Based Exercise|"Each group session will consist of 10 to 18 participants and each exercise session will last 60 minutes and consist of four stages: (1) five minutes warm up (i.e. self-regulated walk); (2) twenty minutes of moderate intensity walking (3) thirty minutes of resistance training for the major muscles of the leg, trunk and arm and balance exercises that progress in difficulty; (4) five-minute cool down period (i.e. self-regulated walk). The exercise intensity will be assessed by one of the following criteria: 1) Resistance training - Point of volitional fatigue. Walking - Somewhat difficult (Borg at 3 to 4). The intensity will be increased according to the ACSM guideline.~The exercise was set up based on changes in instruments of evaluation of the older peoples as, Berg Balance Scale; Dynamic Gait Index and Timed Up and Go. In addition, exercises commonly used in primary health care groups. The protocol will take place in a gymnasium and will be supervised by a trained instructor."
41032067|NCT02363738|OTHER|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
41032068|NCT04378933|DEVICE|Amber Glasses|Half of the participants will be wearing the amber glasses to see if they can help with sleep onset.
41163353|NCT01889277|DRUG|MT-3995-Low|
41163354|NCT01889277|DRUG|MT-3995-High|
41163355|NCT01889277|DRUG|Placebo|
41163356|NCT01562483|DRUG|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
41163357|NCT01562483|DRUG|Placebo|Identical to the Namisol arm.
41163358|NCT02854839|BIOLOGICAL|MG4101|MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
41163359|NCT01381458|DRUG|FSC|fluticasone propionate / salmeterol xinofoate combination
41163360|NCT01381458|DRUG|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
41163361|NCT00212719|DRUG|ONO-5920|
41163362|NCT06247488|DRUG|Placebo|Participant will receive oral dose of placebo.
41163363|NCT06247488|DRUG|Oxycodone 20 mg|Participant will receive oral dose of oxycodone 20 mg.
41163364|NCT06247488|DRUG|GE-IR 200 mg|Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.
41373347|NCT05833269|BEHAVIORAL|Mindfulness and Compassion based Intercare program for parental burnout reduction (IBAP-BP)|The interventions is an adaptation of an 8-week program called Mindfulness and Compassion based Intercare program designed to reduce burnout. The adaptation includes a parental burnout risk and resource balance framework, focusing on factors such as parental perfectionism, low emotional intelligence, lack of parenting practices, excess parental responsibilities, lack of co-parental support, and lack of social support. The program consists of 8 modules with practical and theoretical activities and daily tasks that require 10-30 minutes. The modules cover topics such as mindfulness, coping with stress, empathy, and self-care. Formal meditation practices include body exploration, sitting, movement, walking, eating, acceptance, compassion, and gratitude. The program also includes descriptions and motivation for practices related to identifying values that promote parenting, time management, attentive parenting techniques, and emotional management.
41373348|NCT05833269|BEHAVIORAL|Educational material|On a weekly basis, participants will receive reminder emails highlighting specific risk factors associated with parental burnout. These risk factors include parental perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Each week, the reminder email will cover a different topic, providing participants with relevant information.
41032069|NCT04378933|DEVICE|Clear Lens Glasses|Half of the participants will be wearing the clear glasses to see if the glasses help with sleep onset.
41163365|NCT06247488|DRUG|GE-IR 450 mg|Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.
41163366|NCT00120822|DRUG|Folic acid|
41163367|NCT04528290|DRUG|Ozanimod|Ozanimod capsule formulation of 0.92mg
41373349|NCT05833269|BEHAVIORAL|Reminder by email|Every week, participants will receive two reminder emails: one with a list of activities to complete during the week and another containing information about parental burnout. This approach aims to support participants in staying engaged with the program.
41373350|NCT05833269|BEHAVIORAL|Whatsapp support group|The participants will have the option to join a WhatsApp group with 25 other members from the specific group to receive daily greetings, group support, and have general doubts resolved.
41383515|NCT06541938|DEVICE|AIRE-2 Portable breath analyzer|The AIRE-2 breath analyzer will capture hydrogen and methane at baseline and after every fodmap challenge
40849331|NCT01394913|DRUG|Reumatocept (etanercept)|50mg each week for 30 weeks
41163368|NCT04528290|DRUG|Ozanimod|Ozanimod, granule formulation of 0.92mg
41163369|NCT02007759|DEVICE|VitalStim|This group will receive active VitalStim treatment.
41163370|NCT02007759|DEVICE|Sham VitalStim|This group will receive a sham VitalStim intervention.
40849332|NCT01394913|DRUG|Enbrel (etanercept)|50mg each week for 30 weeks
41163371|NCT03158818|OTHER|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
41163372|NCT01592383|DRUG|erlotinib hydrochloride|Given PO
41163373|NCT03327077|OTHER|Live Preferential Music|Trained musicians will play live preferential music to ED patients who consent to participate.
41163374|NCT02382406|DRUG|Carboplatin|Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
41163375|NCT02382406|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
41163376|NCT02382406|DRUG|MK-3475 (Phase I)|"MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
41163377|NCT02382406|DRUG|MK-3475 (Phase II)|"MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
41163378|NCT05317221|OTHER|Not an extra intervention, tissue taken in routine practice will be used.|No extra intervention: using tumour tissue taken during surgery in standard of care.
40849333|NCT04319237|OTHER|Handgrip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles.
41032070|NCT05593835|DEVICE|METHIS Platform|The METHIS platform is a digital healthcare platform, supported by three databases using PostreSQL (based in relational SQL). One of the databases allows adequate internal testing before production. Another database of production (secured with unique access codes) will be created to retrieve data from the practices' and the last database for the research data, where pseudonymised production data can be analysed for research purposes. The platform is integrated (via FCCN Scientific Computation Unit of the Portuguese Fundação para a Ciência e a Tecnologia) with the Software Zoom® to allow encrypted teleconsultations, with a guarantee that each patient connection is unique. The digital platform is web-based, and it can be used in multiple devices.
41032071|NCT05593835|OTHER|Goal-Oriented Care Training Program|The training program will have three stages: initial face-to-face training, which will happen before the data collection, followed by remote, asynchronous training during a 12-month period, and a final seminar to discuss the results and inquire about the usability of the GOC model and the METHIS platform. The course will be offered to the intervention group one month before the start of patient recruitment, and for the control group at least one month after the end of data collection.
41032072|NCT01410448|DRUG|Everolimus|Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
41032073|NCT01410448|DRUG|Mycophenolate sodium|Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
41032074|NCT01410448|DRUG|Cyclosporine|Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
41032075|NCT01410448|DRUG|Steroids|Steroids were administered according to local clinical practice.
41032076|NCT03516318|BEHAVIORAL|SMART Connections|SMART Connections: Trained facilitators will deliver key informational messages and moderate online group discussions. The informational messages have been developed from key messages identified in each of the Positive Connections curriculum sessions. Each SMART Connections group will consist of approximately 15 to 20 YLHIV. Each online support group will begin with one in-person group meeting with the facilitator. During this meeting, participants meet one another and the facilitators. Facilitators will describe the intervention and set ground rules for participation. Ground rules will be discussed and accepted by the group members, but at a minimum, group members will be advised not to talk about what is discussed in the online group with people outside of the group.
41032077|NCT02627677|DRUG|Ponatinib 30 mg QD|Ponatinib 30 mg, taken orally once daily.
41032078|NCT02627677|DRUG|Ponatinib 15 mg QD|Ponatinib 15 mg, taken orally once daily.
41032079|NCT02627677|DRUG|Nilotinib 400 mg BID|Nilotinib 400 mg, taken orally twice daily.
41032080|NCT06013176|OTHER|Encounter-based PRO monitoring|This arm consists of usual practice plus the addition of patient reminders to complete PRO questionnaires and triage nurse alerts for severe symptoms. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
41032081|NCT06013176|OTHER|Remote PRO monitoring|This arm will consist of weekly PRO questionnaires administered via the patient portal, de-linked from clinical encounters. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
41032082|NCT00001048|DRUG|Filgrastim|
41032083|NCT00001048|DRUG|Cytarabine|
41373351|NCT05833269|BEHAVIORAL|Journaling|As part of the mindfulness intervention, participants are required to write in a journal every day with the purpose of cultivating awareness of bodily sensations, emotions, thoughts, and impulses. Each week, the journaling topic focuses on a different area, including pleasant experiences, unpleasant experiences, needs and resources, communication difficulties, and sharing resources. In contrast, the control group's journaling activity involves free writing about everyday issues, thoughts, and ideas.
41373352|NCT05833269|BEHAVIORAL|Guided relaxation excercise|Participants receive a 10 and 20-minute relaxation exercise guide called the Jacobson Progressive Relaxation, which they are expected to practice daily.
41373353|NCT00307775|DRUG|oestradiol|
41373354|NCT05419960|DIAGNOSTIC_TEST|Vestibular Assessment|"During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~* Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~* Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~* Video Head Impulse Test (vHIT)~* Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)"
41504643|NCT06197165|OTHER|Targeted Shiatsu|"demonstrate the beneficial impact targeted Shiatsu compared with a comfort Shiatsu"
41032084|NCT00001048|DRUG|Zidovudine|
41032085|NCT00001048|DRUG|Zalcitabine|
41032086|NCT00001048|DRUG|Didanosine|
41032087|NCT05659290|DRUG|Fruquintinib alternating with Bevacizumab plus Capecitabine|Maintenance therapy with Fruquintinib 5mg, orally, once daily, d1-14, 2 weeks on/ 1 week off, q3w, followed by Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 6 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
41032088|NCT05659290|DRUG|Bevacizumab plus Capecitabine|Maintenance therapy with Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 3 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
41032089|NCT05715580|OTHER|Nursing information with a Protocol|"The nursing intervention will consist of providing information to the patient with a kidney transplant.~To do this, a Committee of experts, made up of the 6 nurses from the kidney transplant Consultations of the Community of Madrid (Spain), will carry out an Information Protocol for adults with a kidney transplant, which will cover the healthy lifestyle habits described by the bibliography"
41163379|NCT03163836|PROCEDURE|double valve replacement|After median sternotomy, cardiopulmonary bypass was established via bicaval and aortic cannulation. After cross-clamping of the aorta and cardioplegia, mitral and aortic replacement were performed. Supplementary procedures such tricuspid annuloplasty, ascending aorta replacement and coronary artery bypass grafting were performed as required. The left atrial appendage was excised to avoid thrombus formation.
41163380|NCT03163836|PROCEDURE|surgical ablation|Both left and right atrial ablation were performed using a bi-polar radiofrequency ablation clamp.
41163381|NCT02357719|DEVICE|VistaO2 FLUX device|Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.
41163382|NCT06247618|DEVICE|visor|The treatment will have a duration of 4 weeks, with the execution of two sessions per week with the use of a viewer positioned on the head that allows users to navigate and interact in real time with a three-dimensional (3D) environment
41163383|NCT03415347|PROCEDURE|Abscess de-roofing and curettage|Abscess de-roofing and curettage
41163384|NCT03415347|PROCEDURE|Abscess wide local excision|Abscess wide local excision
41504644|NCT01352416|DRUG|Ranolazine|Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
41504645|NCT01352416|DRUG|Placebo|Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
41504646|NCT03510962|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice without any intervention.
41504647|NCT03510962|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
41163385|NCT00451555|DRUG|enzastaurin|1125 milligram (mg) loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
41163386|NCT00451555|DRUG|placebo|oral, daily
41163387|NCT00451555|DRUG|fulvestrant|500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
41163388|NCT02182583|DRUG|Ba253MDI|
41163389|NCT02182583|DRUG|Ba253BINEB|
41163390|NCT02287883|OTHER|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
41163391|NCT05460429|BIOLOGICAL|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.
41163392|NCT01091519|OTHER|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
41504648|NCT03510962|DRUG|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
41163393|NCT01091519|OTHER|Toviaz(fesoterodine) without educational materials|No educational materials
41032090|NCT05715580|OTHER|Usual clinical practice|Nursing information following the usual clinical practice
41032091|NCT03888573|OTHER|Stretching protocol|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms. Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
41032092|NCT00492349|DRUG|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
41032093|NCT00492349|DRUG|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
41032094|NCT02429128|OTHER|14 weeks exercise training|
41032095|NCT02283814|DRUG|BIA 2-093|
41032096|NCT02283814|DRUG|Topamax|
41032097|NCT02388386|DEVICE|PROTEUS-SENSOR|An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
41032098|NCT03619733|OTHER|no intervention|this is an observational study. no intervention is planned
41032099|NCT02337647|OTHER|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
41032100|NCT00305058|DRUG|Morphine|0.05 mg/kg Intravenous
41163394|NCT06105762|OTHER|Ketogenic Diet|The ketogenic diet intervention, administered as a Modified Atkins Diet, involves a significantly reduced daily carbohydrate intake, typically less than 20 grams of net carbs. This approach primarily relies on higher fat consumption to induce ketosis, a metabolic state characterized by elevated ketone body production, serving as an alternative brain fuel source.
41163395|NCT04466397|DEVICE|3D printed individualized porous implants|Use 3D printed individualized porous implants to reconstruct the large bone defects caused by tumor, infection or trauma.
41163396|NCT03377725|DRUG|Decitabine|20mg/m\^2,d1-5,ivgtt,28days as a duration
41163397|NCT03377725|DRUG|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
41163398|NCT05269303|DEVICE|Live With Wearable Monitoring Device program|The participants in the intervention group will receive a home visit by a Community Healthcare Worker in the first month, and biweekly motivational messages via Whats App in the second and third months.
41163399|NCT06400264|PROCEDURE|Biopsy|Undergo biopsy
41163400|NCT06400264|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41373355|NCT05419960|DIAGNOSTIC_TEST|Petrous bone Computed Tomography (CT)|"For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear."
41373356|NCT05419960|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings."
41373357|NCT01572012|DRUG|Ondansetron|Ondansetron solution 4 mg single administration
41373358|NCT01572012|DRUG|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
41373359|NCT01572012|DRUG|Zofran ODT|Zofran ODT (8 mg) single administration
41373360|NCT01572012|DRUG|Ondansetron solution|Ondansetron solution (4 mg) single administration
41373361|NCT00456027|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
41373362|NCT02067728|BEHAVIORAL|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
41373363|NCT02067728|BEHAVIORAL|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
41373364|NCT04380493|DIAGNOSTIC_TEST|hepatic transient elastography using S probe and M probe|
41373365|NCT02307695|DRUG|Saxagliptin|saxagliptin 5 mg p.o. qd, 24 week
41373366|NCT02307695|DRUG|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
41373367|NCT05092217|DRUG|Tirelizumab|Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
41373368|NCT05092217|PROCEDURE|salvage surgery|Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor
41373369|NCT04131452|OTHER|Filling out the forms including IDAS-II, BAI, SF-36 and FSFI|Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
41373370|NCT02129257|DRUG|AFLIBERCEPT|
41032101|NCT00305058|DRUG|Hydromorphone|0.0075 mg/kg intravenous
41032102|NCT04111081|OTHER|Auricular pressure|Select related auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
41163401|NCT06400264|PROCEDURE|Computed Tomography|Undergo CT scan
41163402|NCT06400264|PROCEDURE|Echocardiography|Undergo ECHO
41163403|NCT06400264|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41032103|NCT04111081|OTHER|Shame auricular pressure|Select unrelated auricular points: eye(LO5), occipital(AT3), tonsil(LO7,8,9), lower auricular root(R3), dorsum auricular kidney(P5) and dorsum auricular lung(P2). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
41032104|NCT00326378|DRUG|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
41032105|NCT00326378|DRUG|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
41163404|NCT06400264|BIOLOGICAL|Nivolumab|Given IV
41163405|NCT06400264|BIOLOGICAL|Relatlimab|Given IV
41373371|NCT02129257|DRUG|Irinotecan|
41373372|NCT02129257|DRUG|5-Fluorouracil|
41373373|NCT02129257|DRUG|Folinic Acid|
41373374|NCT04968873|PROCEDURE|Cholecystectomy and common bile duct exploration|During elective open cholecystectomy, a basal commcn dile duct (CBD) manometry was obtained immediately after cholecystectomy, with a 10 Fr. silicone T tube introduced into the cystic duct and connected to a glass manometer.
41373375|NCT04214145|DRUG|Phenylephrine|"Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg \* 5@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.42 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.21 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 3.33 μg/kg/min (=0.8 mL/kg/hr)"
41373376|NCT04214145|DRUG|Norepinephrine|"Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)"
41373377|NCT04214145|DRUG|Vasopressin|"Continuous infusion of Vasopressin 0.1 u/mL (=Vasopressin 20u \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.01 u/kg/hr (=0.1 mL/kg/hr)~2. Increment by 0.005 u/kg/hr (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.08 u/kg/hr (=0.8 mL/kg/hr)"
41373378|NCT05298124|DEVICE|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair
41373379|NCT05298124|OTHER|Medical therapy|Medical treatment in an intensive care unit
41373380|NCT00501748|DRUG|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
41373381|NCT01595399|DRUG|atropine|Atropine 0.02 mg/kg IV
41373382|NCT01595399|DRUG|Placebo|an equivalent volume of normal saline to atropine IV
41373383|NCT02980484|PROCEDURE|Active|Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
41373384|NCT02980484|PROCEDURE|Sham|Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
41373385|NCT04766788|OTHER|Wearable devices, saliva samples, survey measures|Provide a self-collected saliva sample, download and use the suite of apps (e.g., Fitbit, Social Rhythms, Roadmap 2.0), and answer online surveys.
41373386|NCT03405545|BEHAVIORAL|High-intenstiy interval training|High-intensity interval training is a training of 30 minutes involving 10 bouts of 1 minute high intensity cycling (80-90% of maximum heart rate) interspersed by 2 minutes rest.
41373387|NCT03441373|DRUG|XC8 20 mg|once daily during 5 days.
41373388|NCT03441373|DRUG|XC8 100 mg|once daily during 5 days.
41373389|NCT03441373|DRUG|XC8 200 mg|once daily during 5 days.
41373390|NCT03441373|DRUG|Placebo|once daily during 5 days.
41373391|NCT01454037|PROCEDURE|Prostate cryotherapy|cryoablate the prostate
41373392|NCT01454037|PROCEDURE|Radical prostatectomy|Remove prostate
41373393|NCT01454037|PROCEDURE|Radiation|Radiate prostate
41373394|NCT01613066|PROCEDURE|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
41373395|NCT00242645|BEHAVIORAL|Health Information|
41373396|NCT00242645|BEHAVIORAL|Preventive Services|
41373397|NCT00242645|BEHAVIORAL|Computer tailored information|
41373398|NCT06133465|PROCEDURE|Surgical wide local excision|Surgical excision of breast carcinoma
41373399|NCT06133465|PROCEDURE|Cavity shaving|Cavity shaving of resection margins to guarantee oncological safety
41504649|NCT03510962|OTHER|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
41373400|NCT06133465|PROCEDURE|Excision margin surgical clearance|Surgical clearance of involved and/or closed excision margins
41373401|NCT06133465|RADIATION|Adjuvant Radiotherapy|Adjuvant radiotherapy
41032106|NCT03483636|DRUG|Lemborexant|Film-coated oral tablet
41032107|NCT03483636|DRUG|Alcohol|0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot).
41373402|NCT06133465|BIOLOGICAL|Adjuvant Hormone Therapy|Adjuvant hormone therapy
41373403|NCT01193478|DRUG|GS-5885|tablet, oral, 3 mg once daily for 3 days
41373404|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
41373405|NCT01193478|DRUG|GS-5885|tablet, oral, 10 mg once daily for 3 days
41373406|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
41373407|NCT01193478|DRUG|GS-5885|tablet, oral, 30 mg once daily for 3 days
41373408|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
41373409|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
41373410|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
41373411|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
41373412|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
41373413|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
41373414|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
41373415|NCT06405048|OTHER|Mobile Weibo post screenshot with mock-up Chinese fact-checking extension|The intervention in this survey experiment involves mobile Weibo post screenshots equipped with a mock-up Chinese fact-checking browser extension. All screenshots are based on actual Weibo posts. The fact-checking content is generated by a Large Language Model (LLM), tailored to relevant knowledge and prompts, and subsequently validated by experts. The Weibo posts cover a range of popular topics known to contain misinformation, including infertility, safety, vaccine ingredients, high-risk cervical cancer types, regular check-ups, transmission routes, and others.
41373416|NCT02303977|DRUG|Abraxane|
41373417|NCT02303977|DRUG|Gemcitabine|
41373418|NCT05479734|BEHAVIORAL|mHealth Intervention|A smartphone app (mHealth app) will deliver daily tailored messages with tips on monitoring and promoting child development and positive parenting tips.
41373419|NCT06116903|GENETIC|Blood sampling|Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors
41373420|NCT04335760|COMBINATION_PRODUCT|Modified Bruce protocol on treadmill|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
41373421|NCT02959398|DEVICE|Standard mammography|Standard mammography
40849334|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)|"The Wechsler Test of Adult Reading (WTAR) is a neuropsychological assessment tool used to provide a measure of Intellectual function. Participants are presented with 50 irregularly spelled words and prompted to pronounce each; the irregular grapheme-to-phoneme translations (such as the gh in the word tough) in the prompts make it difficult to pronounce without having previously learned the word. A high WTAR score is correlated with higher general intelligence as measured by the Wechsler intelligence scales."
40849335|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)|The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of twelve subtests which give five scores, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, delayed memory).
41032108|NCT03483636|DRUG|Placebo|Film-coated oral tablet
40849336|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Color Trails|The Color Trails test measures sustained attention and sequencing. Numbered circles are printed with vivid pink or yellow backgrounds that are perceptible to color-blind individuals. Participants rapidly connect circles numbered 1-25 in sequence and rapidly connect numbered circles in sequence, but alternates between pink and yellow. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.
40849337|NCT04319237|BEHAVIORAL|Neuropsychological Assessment -Stroop Color and Word Test|The Stroop Color and Word Test is based on the observation that individuals can read words much faster than they can identify and name colors. The test-taker reads color words or names ink colors from different pages as quickly as possible within a time limit. The test yields three scores based on the number of items completed on each of the three stimulus sheets. An Interference score is useful in determining the individual's cognitive flexibility, creativity, and reaction to cognitive pressures.
41032109|NCT00836823|DRUG|Alfuzosin|Alfuzosin 10mg once daily for 12 months
40849338|NCT04319237|BEHAVIORAL|Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire|The PROMIS-29 questionnaire assesses each of 7 domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities). A higher score equals more of the concept being measured.
40849339|NCT04319237|BEHAVIORAL|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-3) and the add-on EORTC QLQ Non-Hodgkin's Lymphoma (EORTC QLQ-NHL-HG29) module. All scales range from 0-100, a high scale score represents a higher response level. For example, a high functional score represents a high level of functioning.
40849340|NCT04319237|BEHAVIORAL|Quality of Life (EQ-5D-5L) Questionnaire|The EQ-5D-5L questionnaire is a self assessed quality of life questionnaire. The scale measures quality of life on a 5 component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.
40849341|NCT04319237|BEHAVIORAL|PROMIS Cognitive Function 4a Questionnaire|The PROMIS measures function, symptoms, behavior and feelings.
40849342|NCT04319237|BEHAVIORAL|Comprehensive Score for Financial Toxicity (COST) measure|The COST is a questionnaire made up of 11 statements around topics including costs, concerns and resources and is designed to measure financial toxicity. The user answers questions about their concern over finances numbered from 0-4, with 0 being not at all and 4 being very much.
41032110|NCT06148129|DIAGNOSTIC_TEST|Tissue Biopsy|The Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM
41032111|NCT02360709|DEVICE|CRE8 sirolimus-eluting stent|The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
41032112|NCT04999202|DRUG|BAY2416964|Oral, twice or three times daily
41032113|NCT04999202|DRUG|BAY2416964|The highest dose determined safe in combination with pembrolizumab in the dose escalation part or a lower dose. More than one dose may be explored in the dose expansion.
41032114|NCT04999202|DRUG|Pembrolizumab|Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks
41373422|NCT02959398|DEVICE|Standard mammography and tomosynthesis|Standard mammography and tomosynthesis
41373423|NCT03879759|DRUG|NAC 2400mg/day|2400mg/day 2 x 600mg b.d
41032115|NCT05377177|DEVICE|Accelerated Theta Burst Stimulation|B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.
41032116|NCT00414752|DRUG|AFQ065|
41163406|NCT01189318|DRUG|Quetiapine Fumarate Extended Release|Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4\~28 50\~150mg (increments and deduction of 50mg are allowed)
41163407|NCT03462498|DRUG|1-months DAPT|1-month DAPT followed by 59-month monotherapy
41163408|NCT03462498|DRUG|12-month DAPT|12-month DAPT followed by 48-month monotherapy
41373424|NCT03879759|DRUG|Placebo|4 matched placebo tablets/day
41373425|NCT04081727|DEVICE|Zip-stitch(TM)|The assigned intervention is used to close the cuff following colpotomy.
41373426|NCT06459427|PROCEDURE|Robot-Assisted Stereotactic Brainstem Hematoma Puncture|Positioning and surgical procedures are carried out based on the use of robotic navigation equipment. Precise preoperative design is conducted using preoperative imaging data to create a preoperative three-dimensional visualization model. During surgery, robot-assisted stereotactic puncture is performed. First day, urokinase may be used as needed to assist in dissolving residual hematoma and adjusting the depth of the drainage tube. For every 10 mL of hematoma, 1 mL of 10,000 IU urokinase in 0.9% sodium chloride solution is injected, followed by flushing with 2 mL of 0.9% sodium chloride solution through the tube after closing it for 2 hours, and then reopening it. Urokinase injections into the drainage tube are used 1-2 times daily to facilitate hematoma drainage. Third day, if the residual hematoma volume is \<3 mL or if the drainage tube has been in place for \>5 days, the drainage tube is removed.
41373427|NCT06459427|DRUG|Conservative non-surgical treatment|Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
41373428|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (HQ)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
41373429|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (C1)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
41373430|NCT03927846|BEHAVIORAL|Nurse-guided Web-based Cognitive Behavioral Therapy|nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
41373431|NCT05535816|DIAGNOSTIC_TEST|Ultrasound|Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound instead of fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
41373432|NCT05508308|DEVICE|OxyMate|Automated Oxygen Control algorithm (VDL 1.1) coupled with Diamedica Baby CPAP device
41032117|NCT06470217|DRUG|tirilizumab with albumin-bound paclitaxel and cisplatin|tirilizumab administered by intravenous drip (no prophylaxis required) at a fixed dose of 200 mg. each infusion was given for 30 min (not less than 20 min and not more than 60 min) every 3 weeks, and 3 preoperative cycles of albumin-bound paclitaxel 260 mg/m2 and cisplatin 75 mg/m2 on d1, with 1 cycle every 21 days; 3 preoperative Cycles. After neoadjuvant therapy, patients underwent surgery and were stratified according to pathological conditions after surgery; if significant pathological remission (MPR) was achieved, 6 cycles of adjuvant therapy with tirilizumab monotherapy (concurrent radiochemotherapy was available for those with high-risk factors) were performed; if MPR was not achieved, concurrent radiochemotherapy was performed.
41373433|NCT05508308|OTHER|Manual oxygen control|Guidelines and training in FiO2 titration to achieve a target range of SpO2. Health workers instructed in responding to continuous pulse oximetry readings and alarms
41373434|NCT05144919|BEHAVIORAL|Promotion of a biodiverse diet|"Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~1. Where to locally source inputs and expected price~2. How/when to prepare plots using organic inputs~3. Planting and best-practice management practices~4. Seed saving and storage~5. Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices"
41373435|NCT04818866|DIAGNOSTIC_TEST|SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase|Biomarkers of inflammation
41373436|NCT05669612|DIETARY_SUPPLEMENT|Dairy based protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
41032118|NCT06470217|PROCEDURE|surgery|patients underwent direct surgical treatment, with postoperative radiotherapy or radiochemotherapy depending on the presence or absence of histological or pathological high-risk factors.
41032119|NCT03814447|DRUG|anti- MESO CAR-T cells|Autologous genetically modified anti- MESO CAR transduced T cells
41032120|NCT03814447|DRUG|Fludarabine|Dose: 30mg/m2/d
41032121|NCT03814447|DRUG|Cyclophosphamide|Dose: 300mg/m2/d
41032122|NCT00974857|DEVICE|BCM|Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.
41163409|NCT00312234|BEHAVIORAL|Aerobic exercise|
41163410|NCT00312234|BEHAVIORAL|Qigong exercise|
41163411|NCT05804981|OTHER|PRO-CS|4 questions about cognitive function added to annual wellness visit protocol
41163412|NCT00740298|OTHER|sucrose|sweet taste
41163413|NCT00740298|OTHER|warmth|warmth
41373437|NCT05669612|DIETARY_SUPPLEMENT|Mixed protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
41163414|NCT01009762|BIOLOGICAL|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
40849343|NCT05808413|BEHAVIORAL|Informational Video|This video emphasizes that vaccination against COVID-19 continues to be important, highlights the importance of seeking accurate information, and provides statistics about the estimated number of lives saved by vaccination and reported adverse events following vaccination in Canada.
41032123|NCT00974857|OTHER|control group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
41032124|NCT02617589|DRUG|Nivolumab|
41032125|NCT02617589|DRUG|Temozolomide|
41032126|NCT02617589|RADIATION|Radiotherapy|
41032127|NCT01915134|DRUG|Recombinant Human Endostatin plus gemcitabine and cisplatin|target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
41032128|NCT01915134|DRUG|Gemcitabine and cisplatin|only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
41032129|NCT02873624|PROCEDURE|Laparoscopic cholecystectomy|
41032130|NCT01735539|DIETARY_SUPPLEMENT|15g EAA bolus|Oral; in aqueous solution
41163415|NCT05188872|DIAGNOSTIC_TEST|68Ga-Pentixafor|Each patient receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT scan within specified time.
41163416|NCT05694533|DRUG|INDV-2000|Capsules administered orally twice a day
41373438|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 1|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
41373439|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 2|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
41373440|NCT04791410|PROCEDURE|microvascular decompression|Microvascular decompression of rostral ventrolateral medulla
41032131|NCT01735539|DIETARY_SUPPLEMENT|4 x 3.75g Mixed EAA Pulses|Oral; in aqueous solution
41373441|NCT05355506|DEVICE|Application|Knowledge \& record
40849344|NCT05808413|BEHAVIORAL|Altruistic Video|This video presents a vignette about a young adult woman who has many social interactions during her daily life. It shows that her decision to stay up-to-date on COVID-19 vaccination could help to protect those people she comes into contact with, who may be at greater risk from COVID-19 infection. Statistics are used to show that up to one-in-four people in Canada have underlying conditions that make them more vulnerable to COVID-19, and to quantify the number of surgeries that were delayed by pandemic-related disruptions.
41032132|NCT01735539|DIETARY_SUPPLEMENT|15g EAA Bolus supplemented with 3g Arginine|Oral; in aqueous solution
41032133|NCT04023006|DEVICE|Removable prostheses|Full dentures created by Additive manufacturing (Carbon Printers)
41032134|NCT02317458|BIOLOGICAL|Experimental|One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection
41032135|NCT02317458|BIOLOGICAL|Sham comparator|One arm with standard of care undergoing a sham procedure
41032136|NCT02618473|OTHER|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
41032137|NCT02127801|DRUG|REGN1908-1909|
41373442|NCT04180956|OTHER|Bias-reduction Intervention|A training for doctors
41032138|NCT02127801|DRUG|placebo|
41163417|NCT05694533|DRUG|Midazolam|Midazolam syrup administered orally on Days 1 and 15
41163418|NCT01113164|DRUG|Ondansetron and Sertraline|capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
41163419|NCT00103116|BIOLOGICAL|autologous dendritic cell cancer vaccine|"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."
41163420|NCT04577976|DEVICE|SMBG|Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months.
41163421|NCT05627583|OTHER|Rehabilitation|Hospitalized patients with AN under treatment for rehabilitation
41163422|NCT03116672|DRUG|one dose ketorolac 10 mg|Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
41163423|NCT03116672|DRUG|One dose Diclofenac|Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
41163424|NCT03116672|DRUG|Placebo oral capsule|Administration of Placebo, 15 minutes before the clinical procedure.
41163425|NCT00591604|DRUG|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
41373443|NCT03004612|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
41373444|NCT03004612|DRUG|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
41373445|NCT06276491|BIOLOGICAL|XmAb541|Monoclonal bispecific antibody
41373446|NCT00860756|OTHER|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
41373447|NCT02549612|DEVICE|Moniri Otovent|Please see arm description.
41373448|NCT04536818|PROCEDURE|Laparotomy|Exploratory laparotomy.
40849345|NCT05808413|BEHAVIORAL|Individualistic Video|This video presents a vignette about a young adult man who is very health-conscious. He is unsure about staying up-to-date on COVID-19 vaccination until he learns that COVID-19 infection can have serious and disruptive consequences even if someone is younger. Statistics are used to quantify the increased risk of severe symptoms in young adults who are not up-to-date on vaccination.
41163426|NCT00296023|BIOLOGICAL|anti-thymocyte globulin|
41163427|NCT00296023|BIOLOGICAL|filgrastim|
41373449|NCT01546701|DRUG|Buprenorphine|2 mg sublingual tablet
41373450|NCT01546701|DRUG|Morphine|0.1 mg/kg IV morphine
41373451|NCT04235725|OTHER|Harmonized Depression Outcome Measures|This is an observational study where retrospective data on previous disease status and patient characteristics will be collected and combined with longitudinal data from these data sources on outcomes during the study timeframe.
41373452|NCT04962191|DIAGNOSTIC_TEST|Idylla EGFR Mutation Test|This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
41373453|NCT03175809|OTHER|PFM training|The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.
41373454|NCT03175809|OTHER|Dry needling|The dry needling technique will be applied to the abdominal muscles (external oblique, rectus abdominis), lumbar spine (lumbar multifidus and erector spinae) and hip muscles (piriformis, gluteus medius, psoas major and adductors). Both active of latent myofascial trigger points will be treated with sterile stainless steel needles (0.25x0.4 mm or 0.2x0,7mm, DongBang, Korea). After diagnosis of the area of muscle pain, the tight band of the muscle will be palpated and the needle will be introduced subcutaneously. The second insertion will be toward the muscle point until a local twitch response (LTR) is elicited. Then the needle will be removed and the area will be compressed for 30 seconds.
41373455|NCT06443216|DEVICE|Auditory closed-loop stimulation|Auditory closed-loop suppression of slow wave sleep
41373456|NCT06443216|DEVICE|Sham stimulation|No auditory stimulation
41163428|NCT00296023|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41373457|NCT04846010|COMBINATION_PRODUCT|PurWet|(1) cang zhu (Atractylodis Rhizoma), bai (zhu Atractylodis macrocephalae Rhizoma), dang shen (Codonopsis Radix), huang qi (Astragali Radix), Fu ling (Poria), Zhu ling (polyporus), Ze xie (Alismatis Rhizoma), Yi yi ren (Coicis Semen), gan cao (Glycyrrhizae Radix),
41373458|NCT04846010|COMBINATION_PRODUCT|FurFat|(2).shan zha (Crataegi Fructus), Jue Ming Zi (Cassiae Semen), He ye (Nelumbinis Folium), Da huang (Rhei Radix et Rhizoma), Ze xie (Alismatis Rhizoma), dan shen ( Salviae miltiorrhizae Radix).
41373459|NCT04846010|COMBINATION_PRODUCT|PurApo|(3)Sheng Di Huang (Rehmanniae Radix), Xuan Shen (Scrophulariae Radix), mai men dong (Ophiopogonis Radix), shan zhu yu (Corni Fructus), shan yao (Dioscoreae Rhizoma), sha yuan zi (Astragali complanati Semen), ci ji li (Tribuli Fructus), nu zhen zi (Ligustri lucidi Fructus)
41373460|NCT04846010|COMBINATION_PRODUCT|PurPhl|(4) chen pi (Citri reticulatae Pericarpium), hua ju hong (Citri grandis Exocartium rubrum), zhi shi (Aurantii Fructus immaturu), zhi ban xia (Pinelliae Rhizoma preparatum), zhi tian nan xing (Arisaematis Rhizoma preparatum),sha ren (Amoni Fructus), Gua lou (Trichosanthis Fructus), Chuan bei mu ( Fritillatiae cirrhosae Bulbu), Fu ling ( Poria), Da huang ( Rhei Radix et Rhizoma).
41373461|NCT04846010|COMBINATION_PRODUCT|PurClo|(2) Dan shen (Salviae miltiorrhizae Radix), Yu jin (Curcumae Radix), chi shao (Paeoniae Radix rubra), tao ren (Persicae Semen), hong hua (Carthami Flos)
41373462|NCT04846010|COMBINATION_PRODUCT|PurInf|(1) lei gong teng (Tripterygii wilfordii Radix), Huang Qin (Scutellariae Radix), Huang Lian (Coptidis Rhizoma), Huang Bai (Phellodendri Cortex), Zhi Zi (Gardeniae Fructus).
41373463|NCT04846010|COMBINATION_PRODUCT|Smoliv|(2). Vagus never communicates with LES: yu jin (Curcumae Radix), Chai Hu (Bupleuri Radix), chi shao (Paeoniae Radix rubra), Mu Dan Pi (Moutan Cortex), chuan lian zi (Toosendan Fructus), long gu (Fossilia Ossis Mastodi), mu li (Ostreae Concha)
41373464|NCT01153659|DRUG|E3810|RAB ER 50 mg capsule once per day on Days 1-5
40849346|NCT04230213|DRUG|PF-06410293|SC injection
40849347|NCT04230213|DRUG|adalimumab|SC injection
41163429|NCT00296023|DRUG|busulfan|
41163430|NCT00296023|DRUG|fludarabine phosphate|
41163431|NCT00296023|DRUG|methotrexate|
41163432|NCT00296023|DRUG|tacrolimus|
41163433|NCT00296023|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
41163434|NCT00296023|PROCEDURE|peripheral blood stem cell transplantation|
41373465|NCT01153659|DRUG|Aciphex (rabeprazole)|Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
41163435|NCT05146661|DEVICE|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
41373466|NCT01153659|DRUG|Nexium (esomeprazole)|Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
41373467|NCT02088866|DRUG|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
41373468|NCT04780360|PROCEDURE|Cayanoacrylate tissue adhesives|Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains
41373469|NCT04780360|PROCEDURE|Silk suture|Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing
41373470|NCT04747691|DIAGNOSTIC_TEST|Bedside gastric ultrasound|Bedside ultrasound exam of the stomach
41373471|NCT05681676|OTHER|Blood samples before and after standard of care of polymyalgia rheumatica|Blood samples were taken before glucocorticoid treatment and three months after.
41373472|NCT02058459|DEVICE|Holaira™ Lung Denervation System with energy delivery|
41373473|NCT02058459|DEVICE|Holaira™ Lung Denervation System without energy delivery|
41373474|NCT03323021|OTHER|Dehydrated human amnion/chorion membrane|dehydrated human amnion/chorion membrane
41163436|NCT05578898|BEHAVIORAL|CLEAR Care Companion (CC) application|The CLEAR CC application is an EPIC-based, electronic application, downloaded to the patient's Smartphone or Tablet. The CLEAR CC leverages patient-reported symptoms assessment vis-a-vis push notifications to complete clinically meaningful questions and validated questionnaires pertaining to symptoms that serve as early indicators of readmission. The CLEAR CC application will send notifications beginning two days prior to surgery and continue until the 6 week post operative appointment.
41373475|NCT03323021|OTHER|Standard of Care|Standard of Care
41373476|NCT06137274|RADIATION|Intensity-modulated radiotherapy|All patients will be treated with intensity-modulated radiotherapy (IMRT) plans.
41373477|NCT06137274|OTHER|Magnetic Resonance Guidance|All patients will undergo combined CT and/or MR simulation and will be treated with a sequential-boost technique.
41373478|NCT04452994|DRUG|JNJ-68284528|JNJ-68284528 will be administered as a single intravenous (IV). The target dose will be the recommended Phase 2 dose (RP2D) of 0.75\*10\^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg) (range: 0.5 to 1.0\*10\^6 CAR-positive viable T cells/kg).
41373479|NCT05460195|DRUG|sintilimab combined with anlotinib|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab combined with anlotinib therapy repeats every 3 weeks until one year after surgery.
41373480|NCT05460195|DRUG|sintilimab monotherapy|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab monotherapy repeats every 3 weeks until one year after surgery.
41373481|NCT02071823|DRUG|BIA 9-1067|A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
41373482|NCT03842865|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
41373483|NCT04666935|OTHER|The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program|Sport Injury Prevention Program.
41373484|NCT04666935|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
41373485|NCT02156570|DRUG|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg \<75kg, 1200mg \>/= 75 kg) Treatment will be for 6 weeks in all participants.
41373486|NCT04250506|DRUG|Daridorexant|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
41163437|NCT04304313|DRUG|Sildenafil citrate tablets|0.1g/day for 14 days
41163438|NCT05301361|DRUG|Methylphenidate Oral Solution|The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).
41163439|NCT03557450|DEVICE|PET/CT Scan|PET/CT scanning with sodium fluoride
41373487|NCT04250506|DRUG|Placebo|Placebo administered as tablets for oral use.
41373488|NCT04250506|DRUG|Moxifloxacin|Moxifloxacin administered as film-coated tablets for oral use.
41373489|NCT01439308|DRUG|Placebo|SB-705498 placebo
41373490|NCT01439308|DRUG|SB-705498|12mg intranasal SB-705498
41373491|NCT03868956|DIAGNOSTIC_TEST|Colour doppler ultrasound with or without D-dimer test|"* Positive CDUS: anticoagulant treatment~* Negative CDUS: no anticoagulant treatment~* Non diagnostic CDUS : reference to routine D-dimer test~  * Negative test : no anticoagulant treatment~ * Positive test : second CDUS 7 days (±2) after first one~    * No change in CDUS : no anticoagulant treatment~   * Change in CDUS : anticoagulant treatment"
41373492|NCT04423107|DRUG|Acetaminophen, Ibuprofen|Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h
41373493|NCT04423107|DRUG|Acetaminophen, Ibuprofen, Oxycodone|Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
41373494|NCT04899531|OTHER|Longitudinal observation|No specific intervention, longitudinal (pre-post measurements) only
41373495|NCT03681912|BEHAVIORAL|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|"Coaching feedback will be triggered by a provider falling below the competency threshold on the standardized patient interaction. Everyone will receive coaching for two assessments in the month following training. After that, if mean scores fall below competency, then the provider will receive a 45-minute coaching session by the external Motivational Interviewing Network of Trainers (MINT) facilitator.~Feedback on two highest and two lowest ratings, review of the audio recording and interactive coaching activities (e.g., fidelity assessments) targeting the lowest ratings. While many aspects of this implementation strategy are adaptable, organizational leadership will review data on completion of coaching feedback sessions and will determine corrective action for suboptimal adherence."
41373496|NCT03681912|BEHAVIORAL|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity monitoring, and prevent drift. In addition to CoP, half the sites will be randomized to receive an internal facilitator who will be trained to continue quarterly fidelity monitoring and coaching feedback when scores fall below competency.
41373497|NCT03681912|BEHAVIORAL|CoP development without internal facilitation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity
41373498|NCT04723329|BEHAVIORAL|Web-based exercise training based on the transtheoretic model|Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
41373499|NCT02903849|BEHAVIORAL|Drafting Motivational Messages|Write down three motivating messages
41373500|NCT02903849|BEHAVIORAL|Control Reminders|Receive standard reminders at three points during the challenge
41373501|NCT02903849|BEHAVIORAL|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
41373502|NCT01388036|DRUG|esmolol|consecutive infusions of esmolol and normal saline (placebo)
41373503|NCT05463393|BIOLOGICAL|Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/|The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
41373504|NCT02608827|DEVICE|Resperate®-InterCure Ltda|The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
41373505|NCT02608827|OTHER|Music group (GC)|The patients in this arm will hear slow music - Music group (GC).
41373506|NCT05751824|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
41032139|NCT05699434|BEHAVIORAL|Obstetrics and Gynecology residents and experts'|Obstetrics and Gynecology residents and experts' knowledge of, attitudes toward, practice behaviors, and self-confidence levels of caring for lesbian, bisexual, and transgender (LBT+) patients in Turkey (Istanbul)
41373507|NCT05751824|OTHER|Manually remind the patients to review.|Medical staff remind patients to review by telephone.
41373508|NCT00282516|PROCEDURE|In-home telemonitoring of pediatric patients with persistent asthma|
41373509|NCT05077033|DRUG|phIL12 GET|intratumoral phIL12 gene electrotransfer
41032140|NCT03450031|OTHER|NAC (no drug/no device)|Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted
41032141|NCT03932565|BIOLOGICAL|CAR-T therapy for nectin4-positive malignant solid tumor|The Intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted the fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells and preventing recurrence.
41032142|NCT03711981|PROCEDURE|TAP Block|
41032143|NCT06481241|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
41032144|NCT06481241|DRUG|Venetoclax|VEN
41032145|NCT03034577|DRUG|Sugammadex|Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
41032146|NCT03034577|DRUG|Neostigmine|Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
41032147|NCT04896957|BEHAVIORAL|Interview|Face to face semi-directed interviews about perceptions, representations and experiences of Covid-19 vaccination, including six opened-questions
41032148|NCT04121104|OTHER|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
41032149|NCT04121104|OTHER|SCS is switched on|Spinal cord stimulator is on
41032150|NCT06261151|OTHER|Clinical data collection|Clinical data of elderly patients with gastric cancer who underwent open gastrectomy were collected and analyzed.
41032151|NCT03586609|DRUG|Azacitidine|Given SC or IV
41032152|NCT03586609|DRUG|Cladribine|Given IV
41032153|NCT03586609|DRUG|Cytarabine|Given SC
41373510|NCT04386798|OTHER|survey work|Bebeği Yenidoğan Yoğun Bakım Ünitesinde Yatan Annelerin Stres ve Anksiyete Düzeyleri anket yöntemi ile ölçülecektir.
41373511|NCT03418025|BEHAVIORAL|Exercise Intervention|Undergo Exercise Together intervention
40849351|NCT00788710|DRUG|etoricoxib (MK0663) 120 mg|120 mg of etoricoxib (MK0663) for a total of 5 days
40849352|NCT00788710|DRUG|Comparator: Placebo|Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
40849353|NCT00788710|DRUG|etoricoxib (MK0663) 90 mg|90 mg of etoricoxib (MK0663) for a total of 5 days
40849354|NCT02487030|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
40849355|NCT02487030|DRUG|RBV|Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
40849356|NCT06564896|DEVICE|CPAP Airsense 10 vs Air-Mini|Patients' satisfaction and CPAP efficacy
40849357|NCT03376685|BEHAVIORAL|Endurance Exercise Training (END)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 5 days a week for 30 minutes (Week 1-2); 35 minutes (Weeks 3-4); or 40 minutes (Weeks 5-6) at 60% VO2 peak.
40849358|NCT03376685|BEHAVIORAL|Sprint Exercise Training (SIT)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 3 days a week involving a 3-minute warm-up, followed up 4 repetitions (Week 1-2); 5 repetitions (Weeks 3-4); or 6 (Weeks 5-6) repetitions of 30 seconds at a maximal intensity with 2 minutes' rest in between. Exercise will conclude with a 2-minute cool-down.
40849359|NCT04833296|DRUG|Ropivacaine|all patients will receive interscalene block using same volume of ropivacaine but in different concentrations
40849360|NCT03392818|OTHER|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of Fiberoptic bronchoscope.
40849361|NCT03392818|OTHER|formula|Calculate the depth of intubation according to the formula of 0.1977\* patient's height - 4.2423
40849362|NCT03392818|DEVICE|Fiberoptic bronchoscope|The intubation of Uniblocker under the guidance of Fiberoptic bronchoscope
40849363|NCT00002458|BIOLOGICAL|monoclonal antibody 3F8|
40849364|NCT04790071|OTHER|Conventional physical therapy|Conventional physical therapy: The patients received physical therapy to the shoulder, transcutaneous electrical nerve stimulation, and stretching and strengthening exercises (5 days per week for three weeks in a total of 15 sessions).
40849365|NCT04790071|OTHER|Conventional physical therapy plus dry needling|Conventional physical therapy plus dry needling: The patients received physical therapy to the shoulder, including transcutaneous electrical nerve stimulation, stretching, and strengthening exercise (5 days per week for three weeks in a total of 15 sessions). And also, a total of 3 dry needling sessions were applied at 7-day intervals.
40849366|NCT01812265|DRUG|PF-06305591|single Dose
40849367|NCT01812265|DRUG|PF-06305591|single Dose
40849368|NCT01812265|DRUG|Placebo|Single Dose
40849369|NCT00087854|DRUG|Amonafide L-malate (drug)|
40849370|NCT01359501|DRUG|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
40849371|NCT01359501|DRUG|Placebo|Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
41032154|NCT03586609|DRUG|Venetoclax|Given PO
41032155|NCT00135954|DRUG|Cyclophosphamide and steroids|comparison of difference in time of start of therapy
41032156|NCT01384617|PROCEDURE|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
41032157|NCT01384617|PROCEDURE|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
41373512|NCT03418025|OTHER|Questionnaire Administration|Ancillary studies
41032158|NCT05508282|BEHAVIORAL|Reading Bees app and children's book to enhance parent-infant reading quality (0-2 month visit)|The reading intervention will be provided at the baseline clinic well-visit (0-2 months), and is based on the SHARE/STEP approach.
41373513|NCT03418025|OTHER|Survey Administration|Ancillary studies
41373514|NCT02687815|DRUG|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
41373515|NCT02687815|DRUG|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
41373516|NCT00138866|DRUG|Risedronate|
41373517|NCT02551874|DRUG|Saxagliptin, Onglyza|Tablets, Oral, 5mg , Once daily, 24 weeks
40849372|NCT03382808|BEHAVIORAL|SEE Training|Participants are first presented with a fixation cross which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a neutral and a fearful image (face) of the same model identity. The fearful expression is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with neutral and 75% fearful expressions only in the first session; the intensity of the fearful cue is successively decreased by 15% at every subsequent session.
40849373|NCT03382808|BEHAVIORAL|GAZE Training|Participants are first presented with a fixation cross, which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a direct gaze-image (neutral face) and an image of a neutral face (same model identity) displaying deviated gaze. The averted gaze-face is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with direct and 100% averted gaze images only in the first session; the intensity of the deviated gaze cue is successively decreased by 20% at every subsequent session.
40849374|NCT01099397|OTHER|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
40849375|NCT02366156|DIETARY_SUPPLEMENT|Placebo|Three placebo capsules consumed prior to breakfast each day for 4 weeks
41163440|NCT02611375|OTHER|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
40849376|NCT02366156|DIETARY_SUPPLEMENT|Low Dose Grape Blend|Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
40849377|NCT02366156|DIETARY_SUPPLEMENT|High Dose Grape Blend|Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
40849378|NCT03114384|OTHER|Creation and detection of patient-respirator asynchronies|The provocation of leaks on the Ventilation circuit and expiratory trigger modulation will generate a number of asynchronies between the subject and the respirator
40849379|NCT03794154|DRUG|Cymbalta capsule|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
40849380|NCT03794154|DRUG|Duloxetine hydrochloride capsule|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
40849381|NCT02564809|BEHAVIORAL|Fit Brains Training|These hourly classes will consist of cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individuals aim to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
40849382|NCT02564809|BEHAVIORAL|Exercise + Fit Brains Training|These classes combine aerobic training and cognitive training. The classes will consist of a 15-minute walk prior to cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individual aims to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
40849383|NCT02564809|BEHAVIORAL|Balanced And Tone|These classes will consist of hourly sham training class, hourly classes of sham exercise (e.g., balance, stretching, range of motion), and hourly educational classes.
40849384|NCT05981183|DEVICE|Transcutaneous electrical nerve stimulation unit (TENS)|The TENS unit will be applied to participants' right ear at the cymba conchae. The dose is dependent on which arm (Intervention A or Intervention B) the participant is assigned to. Participants will undergo 15 minutes of vagal nerve stimulation.
40849385|NCT04369625|BEHAVIORAL|CHIMPS-T|CHIMPS-T (Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.
41163441|NCT02611375|OTHER|peripheral nerve somatosensory stimulation|"Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation."
41163442|NCT02611375|OTHER|sham transcranial direct current stimulation|During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
41163443|NCT05915013|DRUG|Ketamine|Intravenous ketamine
41163444|NCT05915013|DRUG|Perampanel|Oral perampanel (6 mg)
41163445|NCT05915013|DRUG|Placebo|Oral placebo
41163446|NCT06161818|DRUG|FLOT-CROSS or CROSS-FLOT|Randomization between TNT FLOT-CROSS and TNT CROSS-FLOT
41373518|NCT02551874|DRUG|Dapagliflozin, Farxiga|Tablets, Oral, 10mg , Once daily, 24 weeks
41373519|NCT02551874|DRUG|Glargine insulin|100 Units/ml solution for injection in a prefilled SoloStar pen
41504650|NCT03510962|OTHER|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention."
40849386|NCT04369625|BEHAVIORAL|CHIMPS-P|CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention.
40849387|NCT04369625|BEHAVIORAL|CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families.
41373520|NCT02551874|DRUG|Metformin|Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
41373521|NCT01133366|DRUG|warfarin sodium|25 mg of warfarin oral (single dose)
40849388|NCT04369625|BEHAVIORAL|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
40849389|NCT00815594|DRUG|bevacizumab|0.05ml, 1.25mg
40849390|NCT02239315|OTHER|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
40849391|NCT00881816|DRUG|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
40849392|NCT00376896|DRUG|GW876008 200mcg|GW876008
40849393|NCT00376896|DRUG|GW876008 20mcg|GW876008 20mcg
40849394|NCT00376896|OTHER|Placebo|placebo
40849395|NCT00268970|DRUG|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
40849396|NCT05642299|DEVICE|MBCI-SR|Participants will be asked to wear and EEG+NIRS cap and a soft robotic glove on their stroke-impaired hand. The participant will be instructed to ask to imagine to picture moving the stroke-imparied hand in the mind. The brain signal (EEG and NIRS data) will be recorded as a reference. When the participant pictures this move again, upon detection of such imagined move by MBCI-SR system, the glove will be activated and assists the participants to perform a specific upper limb task based on individual ability. There are six different activities of daily living (ADL)-oriented tasks enacted through a virtual arm and virtual objects, which formed the visual feedback for the participants. These tasks include scanning goods, moving an object upward to a cabinet, using two hands to move a towel, pouring of water into a cup, eating action and fine motor movement of picking up a small block using two fingers. Training intensity is 1.5 hours for 3 times a week for 6 weeks, a total of 18 sessions.
40849397|NCT01207349|BEHAVIORAL|Secondary prevention intervention trial|Close follow-up by nurses, exercise physiologist and dieteticians
40849398|NCT01207349|BEHAVIORAL|standard follow up|
41032159|NCT05508282|BEHAVIORAL|Reading Bees app and children's book to encourage alternatives to digital media (6-month visit)|The digital media (screen time) intervention will be provided at the 6-month clinic well-visit and is based on Baby Unplugged materials (book and app content).
41032160|NCT04452708|DEVICE|HFNC|HFNV vs NIV vs conventional nasal cannula
41032161|NCT06111950|OTHER|Blood samples|Blood samples of 5 ml to 15 ml depending on their weight
41373522|NCT01133366|DRUG|mipomersen sodium; warfarin sodium|200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
41373523|NCT01343238|BEHAVIORAL|Diet|12 week diet behavior modification
41373524|NCT01343238|BEHAVIORAL|Exercise|12 week exercise behavioral intervention
41373525|NCT01343238|BEHAVIORAL|Diet and Exercise|12 week diet and exercise behavioral modification intervention
41504651|NCT03510962|OTHER|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
41032162|NCT06111950|OTHER|Skin biopsies|Biopsies of fragment of skin 2 to 3 mm long by 1 mm wide and 1 mm deep will preferably be taken on the inside of the arm, in the upper third, between the bend of the elbow and the hollow of the armpit under strict sterility conditions.
41163447|NCT02787759|OTHER|Hands-Free Walking|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything
41163448|NCT02787759|OTHER|Challenge Based plus Hands-Free'|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
41373526|NCT03444129|BEHAVIORAL|Healthy eating workshop and interactive health game|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
41373527|NCT03444129|BEHAVIORAL|Healthy eating workshop|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
41373528|NCT04503109|DEVICE|Nalu Neurostimulation System|The Nalu Neurostimulation System is a Spinal Cord Stimulation system
41373529|NCT01510340|BEHAVIORAL|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
41373530|NCT05477849|DRUG|Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection|"1. Dose level 1~2. Dose level 2~3. Dose level 3~4. Dose level 4~5. Dose level 5"
41373531|NCT05778682|PROCEDURE|Suctioning based protocol|cf. arm The necessity of suctioning will be assed continuously by the nurses, respiratory therapist and the medical team. If the patient require 2 or less aspiration each 8 hours for 24 hours straight, an attempt of decanalution will be done.
40849399|NCT06303297|OTHER|REFLEXOLOGY|will receive foot and hand reflexology and stretching. The researcher will administer foot and hand reflexology to the participant for a period of 3 weeks this last for a duration of 10 min on each hand and foot with total duration of 40 minutes. Foot reflexology include general foot massage, including the foot rotation, Achilles stretching, and the foot extension and stretching, will be performed for a minute on each foot. In the right foot, the bottom of the heel will be kept with the left hand, and the metatarsal arch of the same foot will be held with the other hand. Then, the foot will be rotated clockwise and counter clockwise three times each direction. The same technique will be performed on the left foot. On hand lubricated with moisturizer to the dorsal and plantar surface and apply pressure on for 10 minutes. Noninvasive and safe complementary therapy that involves a direct pressure on specific body points connecting specific organs.
40849400|NCT06303297|OTHER|GENERALIZED STRETCHING|will receive Stretching of upper and lower limbs. The stretching program lasts for 3 weeks with 60 min of stretching session 3 times a week. Extension of body include shoulder extension, torso rotation, hip extension, calf stretching (ankle pumps). ten stretches of 30 s each, with 15 s of rest between each stretch
41373532|NCT05778682|PROCEDURE|Usual Care|Usual care in our center is tolerance to a capping trial.
40849401|NCT00015808|DRUG|Idebenone|
40849402|NCT04801147|BIOLOGICAL|Dendritic Cells Vaccine|"Right after the surgical resection of the tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Immunotherapy will follow radiochemotherapy and will comprise 4 vaccinations every second week (injections I, II, III, IV), 2 further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) 2 months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only. In correspondence to the third vaccine injection (week 13), mTMZ will start.~Vaccine doses will be injected in the forearm of the patient."
40849403|NCT06547073|OTHER|Virtual reality exercise training|Beat saber
40849404|NCT06547073|OTHER|Traditional exercise training|Bench slides, supine active assisted flexion, pendulum exercise, seated active assisted external rotation
40849405|NCT02122367|OTHER|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
40849406|NCT00049660|DRUG|capecitabine|
40849407|NCT00049660|DRUG|vinorelbine tartrate|
40849408|NCT06010134|OTHER|Physical Therapy Program|Physical Therapy Program plus Whole Body Vibration
40849409|NCT00028236|DRUG|Gene-Transduced Autologous CD34+ Stem Cells|
40849410|NCT00003763|PROCEDURE|radionuclide imaging|
40849411|NCT00003763|RADIATION|indium In 111 folic acid|
41032163|NCT06111950|OTHER|Fetal samples|Skin, muscle, brain and bone biopsies will be collected from fetuses in the autopsy room after the medical termination of pregnancy or miscarriage
41032164|NCT00891566|PROCEDURE|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
41032165|NCT04345848|DRUG|Enoxaparin|Two different doses of anticoagulation
41032166|NCT06533241|PROCEDURE|renal biopsy|percutaneous renal biopsy procedure
41032167|NCT03346629|DRUG|Mifepristone + Misoprostol|A single dose of 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed 24-48 hours later with 400mcg misoprostol (buccal) at home. The participant will return to the hospital one to two hours after taking the initial dose of misoprostol to receive repeated doses of 400 mcg misoprostol until the abortion occurs.
41032168|NCT03178357|OTHER|Cardiac rehabilitation + standard therapy|Patients with HCM subjected to cardiological rehabilitation
41032169|NCT03178357|OTHER|Standard therapy|Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
40849412|NCT06372691|OTHER|Subparaneural Injection (Grup S), Block|Comparison of two different methods in terms of various features
40849413|NCT06372691|OTHER|Interneural Injection (Grup I), Block|Comparison of two different methods in terms of various features
40849414|NCT00039663|DRUG|Pravastatin|
40849415|NCT00039663|DRUG|Gemfibrozil|
40849416|NCT00039663|DRUG|Rosiglitazone|
40849417|NCT02927938|PROCEDURE|Allogeneic HCT|Allogeneic HCT
41032170|NCT06041724|DRUG|Envafolimab combined with recombinant human endostatin and first-line chemotherapy|"Envafolimab: 300mg day1, s.c. Q3W; Recombinant human endostatin: 210mg day1, Intravenous pump for 72 hours, Q3W; Temozolomide: 150 mg/m2 d1-5, i.v. Q3W; Cisplatin: 25 mg/m2 d1-3, i.v. Q3W.~All of the above drugs were used for 6 cycles, and then Envafolimab and recombinant human endostatin continued only in patients with no progression in the first stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 2 years."
41032171|NCT01477827|OTHER|None - observational study|
40849418|NCT02927938|DRUG|Consolidation chemotherapy|Cytarabine-based consolidation chemotherapy
40849419|NCT06012929|DRUG|ONC201|ONC201 is an oral medication given once per week
40849420|NCT06055309|DRUG|Cannabis (up to three doses)|a dose of cannabis will be baked into brownies
40849421|NCT02818049|PROCEDURE|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
41373533|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
41373534|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
41373535|NCT00814762|BIOLOGICAL|HIV Vaccine 732462|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
41373536|NCT00814762|BIOLOGICAL|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
41373537|NCT02095834|DRUG|Bendamustine Hydrochloride|Given IV
41373538|NCT02095834|DRUG|Carfilzomib|Given IV
41373539|NCT02095834|DRUG|Dexamethasone|Given PO or IV
41373540|NCT02095834|OTHER|Laboratory Biomarker Analysis|Correlative studies
41373541|NCT04121468|DRUG|Metformin|Each tablet contains 500mg of metformin hydrochloride
40849422|NCT02221388|DRUG|BI 671800 HEA, 200 mg tablets|
40849423|NCT02221388|DRUG|BI 671800 HEA EC, 200 mg tablets|
40849424|NCT02221388|DRUG|BI 671800 HEA, 50 mg tablets|
40849425|NCT02221388|DRUG|BI 671800 ED, 100 mg capsules|
40849426|NCT02221388|OTHER|Standard meal|
41373542|NCT04121468|OTHER|Placebo|Each tablet contains no active drug ingredient
41373543|NCT01001286|BEHAVIORAL|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
41032172|NCT02673658|BEHAVIORAL|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
40849427|NCT01496911|DRUG|Levocetirizine|a single oral dose of 5 mg
40849428|NCT01496911|DRUG|Hydroxyzine|a single oral dose of 50 mg
40849429|NCT01496911|DRUG|Placebo|a single oral dose
40849430|NCT01380834|DRUG|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
41504652|NCT02644005|DEVICE|Smart Vent Control|Smart Vent Control (SVC) was designed to automatically control the following ventilator settings: mechanical breathing frequency, inspiratory pressure, pressure support, inspiratory time, trigger sensitivity. SVC adjusts the ventilator settings with the aim to keep a patient stable in a target zone (TZ). Numerous predefined TZs exist that can be set according to the current therapeutic situation. All TZs are adoptable by the user for each individual patient and consist of upper and lower limits for tidal volume and for the partial pressure of end-tidal carbon dioxide (PetCO2). Based on these limits, the system classifies the current quality of ventilation, called Classification of Ventilation, and derives new ventilator settings accordingly. SVC is available as a software option on Zeus Infinity Empowered anesthesia machines (Drägerwerk AG \& Co. KGAa, Lübeck, Germany) and is approved as a medical product according to 93/42/European Economic Community.
41504653|NCT05879120|DRUG|Pembrolizumab|Given by IV (vein)
41504654|NCT05879120|DEVICE|Exablate MRgFUS + neoadjuvant pembolizumab|Given by IV (vein)
41373544|NCT04150107|DRUG|ORMD-0801 Treatment A|Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime
40849431|NCT01380834|DRUG|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
40849432|NCT01973725|DRUG|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
40849433|NCT05755984|DIAGNOSTIC_TEST|3D printed model|scan
40849434|NCT06021509|DEVICE|NovoClasp® transcatheter mitral valve clip and steerable guide catheter|The experimental device is a class III implanted valve device, which will be used to treat the mitral valve regurgitation via transcatheter edge-to-edge repair.
40849435|NCT06463054|BEHAVIORAL|Dialectical Behavior Therapy Skills Group Training|The investigators will employ Dialectical Behavior Therapy Skills Training in order to experimentally manipulate maternal emotion dysregulation, the targeted mechanism.
40849436|NCT06463054|BEHAVIORAL|Safety Planning Intervention|Safety Planning Intervention (SPI) or SPI only for 6 months, such that all mothers with history of suicidal behavior + ER difficulties will receive SPI.
40849437|NCT03029091|DRUG|Losartan Potassium|Losartan potassium
40849438|NCT03291990|DRUG|Temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
41373545|NCT04150107|DRUG|ORMD-0801 Treatment B|Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
41373546|NCT04150107|OTHER|Placebo|Fish oil capsule
41373547|NCT02900131|DRUG|Jaungo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.
41373548|NCT02900131|DRUG|Placebo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
41373549|NCT01156974|BEHAVIORAL|education and care guide|Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
41373550|NCT01156974|BEHAVIORAL|education only|patients receive education about care goals
41373551|NCT06542809|OTHER|Questionnaire|Recruitment will take place through routine paediatric endocrinology consultations with physicians registered with BELSPEED. These doctors will take the time to explain the questionnaire. And allow the patient to complete it.
41373552|NCT02786810|DRUG|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
41504655|NCT05233111|BEHAVIORAL|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes.
41504656|NCT05233111|BEHAVIORAL|Treatment as Usual|This may include an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months.
41504657|NCT00098358|DRUG|Zileuton|
41504658|NCT01616355|OTHER|Sodium hypochlorite immersion|Dentures daily immersion in a 0.5% sodium hypochlorite solution for 3 minutes.
41504659|NCT03571412|DEVICE|repetitive Transcranial Magnetic Stimulation|Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
41504660|NCT03145389|PROCEDURE|Epidural catheter placement|After explaining about the procedure an 18 Gauge epidural catheter was inserted into thoracic 11-12 inter vertebral space under strict asepsis. Before inserting the epidural needle same space was infiltrated with adequate amount of 2% Lignocaine with Adrenaline (1: 200,000) to make the procedure pain free. Epidural space was confirmed by loss of resistance technique.
41032173|NCT02673658|BEHAVIORAL|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
41373553|NCT01683786|DRUG|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day
40849439|NCT01725594|DRUG|CAT 2003|
40849440|NCT01725594|DRUG|Placebo|
40849441|NCT03370666|OTHER|HFNT|High flow nasal therapy
40849442|NCT03370666|OTHER|NIV|Noninvasive ventilation
40849443|NCT04180332|DIAGNOSTIC_TEST|Blood sample|5ml of venous blood was taken from the ante cubital vein from each of the study subjects
41032174|NCT00158379|DRUG|Paclitaxel|4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
41032175|NCT02451657|OTHER|No Intervention|No intervention was administered in this study
41373554|NCT00066586|DRUG|exemestane|exemestane 25 mg once daily x 1 year
41373555|NCT00066586|DRUG|Placebo|placebo once daily x 1 year
41373556|NCT02524262|DIETARY_SUPPLEMENT|Slow-release L-cysteine|Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
41373557|NCT02469558|DIETARY_SUPPLEMENT|Winclove 851 and 110|prebiotic and probiotic mixture
41373558|NCT02469558|DIETARY_SUPPLEMENT|Placebo|white powder without pro/probiotic
41163449|NCT03366545|DEVICE|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of routine care for CRT patients
41163450|NCT05196022|OTHER|Cochlear implant|G2 will receive a cochlear implant during the study
41163451|NCT00026013|DRUG|hypericum perforatum|
41163452|NCT03730311|DRUG|Elpida|elsulfavirine, capsules
41163453|NCT03730311|DRUG|placebo|placebo
41032176|NCT05658172|DIAGNOSTIC_TEST|Determination of tumormarkers (CA27.29, CEA, CA125)|CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
41373559|NCT02619565|OTHER|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
41032177|NCT05658172|DIAGNOSTIC_TEST|Determination of CTC levels|CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
41032178|NCT05658172|DIAGNOSTIC_TEST|Determination of ctDNA levels|Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
41032179|NCT05658172|OTHER|Biobanking of blood samples|To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.
41032180|NCT00803647|BIOLOGICAL|cetuximab|500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.
41032181|NCT00803647|DRUG|5-FU|3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
41163454|NCT02846935|DRUG|Decitabine|2-4 capsules depending on the weight of participant. Dec capsules are ingested \~60 minutes after THU capsules.
41163455|NCT02846935|DRUG|Tetrahydrouridine|2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
41163456|NCT03015181|BIOLOGICAL|VRC-HIVMAB075-00-AB|VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
41163457|NCT00690378|DRUG|NXL104/ceftazidime|125mg/500mg TID
41163458|NCT00690378|DRUG|Imipenem/Cilastatin|4 x daily
41163459|NCT01484314|DRUG|Eltrombopag|100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
41163460|NCT03133078|OTHER|Step-Down Test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
41163461|NCT03133078|OTHER|Side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
41163462|NCT00791102|DRUG|ASP-1001 nasal spray|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
41163463|NCT00791102|DRUG|Placebo for ASP-1001|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
40849444|NCT01770015|PROCEDURE|biological sampling|cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
41373560|NCT03226366|OTHER|Immediate evaluation by multidisciplinary team|Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
41373561|NCT05790252|DRUG|Buprenorphine Transdermal Matrix Patch|Buprenorphine transdermal patches will be applied at time of induction initiation and removed at 48 hours.
41373562|NCT05790252|OTHER|Sham patch|Bandage applied at time of induction initiation and removed at 48 hours.
40849445|NCT01770015|PROCEDURE|sampling blood|HLA DR antigen, cytokines (IL 6 and 10), B-glucan
40849446|NCT01770015|PROCEDURE|endotracheal aspiration|fungi and bacteria endotracheal aspiration
40849447|NCT04858412|DIETARY_SUPPLEMENT|β-hydroxy β-methyl butyrate (HMB) enriched amino acid|β-hydroxy β-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.
40849448|NCT04858412|DIETARY_SUPPLEMENT|Balanced amino acid|Balanced amino acid is the balanced mixture of the various essential amino acids.
40849449|NCT06118957|DRUG|Enoxaparin|Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.
40849450|NCT00285168|BEHAVIORAL|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
41373563|NCT00807859|DRUG|AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
41373564|NCT00807859|DRUG|AMG 386 30 mg/kg, Capecitabine and Lapatinib|AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
40849451|NCT06348628|BEHAVIORAL|Motivational Interview|4 Motivational interviews within first 6 months
41373565|NCT00807859|DRUG|AMG 386 10 mgkg, Paclitaxel and Trastuzumab|AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
41373566|NCT00807859|DRUG|AMG 386 10 mg/kg, Capecitabine and Lapatinib|AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
40849452|NCT06348628|BEHAVIORAL|Placebo|Advices on standard of care treatment of NAFLD within first 6 months
40849453|NCT03854461|BEHAVIORAL|Personalised dietary advice and educational material|As within arm/group description
40849454|NCT03854461|BEHAVIORAL|Educational material|As within arm/group description
41032182|NCT00803647|DRUG|oxaliplatin|85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
41032183|NCT00803647|DRUG|leucovorin|400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
41032184|NCT01985126|DRUG|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
41032185|NCT01985126|DRUG|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
41032186|NCT01985126|DRUG|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
41032187|NCT01985126|DRUG|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
41032188|NCT01985126|DRUG|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
41032189|NCT01985126|DRUG|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
41373567|NCT03055273|BEHAVIORAL|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
41373568|NCT03717441|DIAGNOSTIC_TEST|chromosome numeration of embryos|Use genomic technologies to analyze the discarded media drop for chromosome counting
41373569|NCT00536991|DIETARY_SUPPLEMENT|Calcitriol|Given PO
41373570|NCT00536991|DRUG|Ketoconazole|Given PO
41373571|NCT00536991|OTHER|Laboratory Biomarker Analysis|Correlative studies
41373572|NCT00536991|OTHER|Pharmacological Study|Correlative studies
41032190|NCT02326402|DEVICE|TandemHeart or LifeSPARC System|Percutaneous insertion of TandemHeart or LifeSPARC System
41032191|NCT01834820|DRUG|Epinephrine and Dexamethasone|
41373573|NCT00536991|DRUG|Therapeutic Hydrocortisone|Given PO
41373574|NCT02874820|RADIATION|[11C]BU99008|Baseline and blocked scans
41373575|NCT02874820|DRUG|Idazoxan|Idazoxan dose up to 80mg
41373576|NCT03158454|PROCEDURE|Capsula Closure|The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures
41373577|NCT03158454|PROCEDURE|Non-Capsula Closure|No capsular closure procedure is performed.
41373578|NCT01280760|OTHER|Device: Neurally Adjusted Ventilatory Assistance|"Device: Neurally Adjusted Ventilatory Assistance~In ICU following extubation NIV was performed as follows:~facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode"
41373579|NCT05195385|PROCEDURE|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
41373580|NCT03754400|BIOLOGICAL|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
41373581|NCT03754400|OTHER|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
41373582|NCT00483574|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
41373583|NCT00483574|BIOLOGICAL|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
41373584|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
41373585|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
41373586|NCT03711747|PROCEDURE|Osteochondral allograft ankle|Open osteochondral allograft to replace the cartilage that is grade four on the tibia and/or talus
41373587|NCT04553328|DEVICE|Us guided nerve blocks|The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
41032192|NCT01834820|DRUG|Hypertonic Saline|
41032193|NCT01834820|DRUG|Normal Saline|
41032194|NCT03839953|BEHAVIORAL|Supervised Exercise Program|This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.
41032195|NCT03839953|OTHER|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
41032196|NCT04644354|DRUG|Nifedipine 10 mg|For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
41163464|NCT03645005|BEHAVIORAL|"My Guide (psychoeducation & self-management program)"|"My Guide is a Smartphone application incorporating elements informed by the extant literature, designed to improve quality of life and symptom burden among Hispanic breast cancer survivors. My Guide components are designed to improve breast cancer knowledge, cancer-relevant self-efficacy, stress and symptom management skills, Both intervention and active comparator conditions are administered to participants for 8 weeks."
41163465|NCT03645005|BEHAVIORAL|"My Health (health education program)"|"My Health is a health promotion Smartphone application with health education content on nutrition, and general advice on lifestyle choices and prevention. The My Health control content was based on similar content tested in other psychosocial interventions with cancer survivors. Both intervention and active comparator conditions are administered to participants for 8 weeks."
41163466|NCT02728375|OTHER|computer game based rehabilitation protocol|Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
40849455|NCT06576206|OTHER|Bin therapy and finger gnosia|Schedule bin therapy sessions 2-3 times per week at first, increasing the frequency as participants get used to it. Data will be collected twice i.e., at the start of the study and after completion of 6 weeks of treatment by using outcome measure tools
41163467|NCT02728375|OTHER|Conventional therapy protocol|In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
41163468|NCT05498077|PROCEDURE|Body scan meditation|Subject is placed through a brief body scan meditation to determine whether this intervention affects a person's pain experience
41163469|NCT04165525|DEVICE|Ablation|comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.
40849456|NCT06576206|OTHER|conventional therapy|schedule conventional therapy with 20-50 minutes of each session with each set comprises of 10-12 repetitions of each exercise
41163470|NCT04389918|OTHER|Tality|Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.
40849457|NCT01100775|DRUG|Galantamine|A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
41032197|NCT03609827|DRUG|Melphalan|
41163471|NCT02720081|DRUG|MK-1029 150 mg|150 mg tablet administered orally, once a day (QD), at bedtime
41163472|NCT02720081|DRUG|MK-1029 Matching-image Placebo|Matching-image placebo tablet administered orally, QD, at bedtime
40849458|NCT01100775|DRUG|Placebo|Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
41032198|NCT05386160|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection of Ranibizumab；
41163473|NCT02720081|DRUG|Montelukast 10 mg|10 mg tablet administered orally, QD, at bedtime
41373588|NCT02602470|DRUG|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing
41373589|NCT02602470|DRUG|Azelaic Acid Cream|Azelaic Acid Cream 20%
41373590|NCT02602470|DRUG|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
41373591|NCT02602470|DRUG|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
41032199|NCT05386160|DEVICE|Phacoemulsification|Phacoemulsification
41373592|NCT02602470|DRUG|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
41373593|NCT02602470|DRUG|Metronidazole Lotion|Metronidazole Lotion 0,75%
41373594|NCT02602470|DRUG|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
41373595|NCT01697124|BEHAVIORAL|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
41032200|NCT00639717|PROCEDURE|stem cell transplant|reduced intensity, matched unrelated donor stem cell transplant
41163474|NCT02720081|DRUG|Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation|1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
41163475|NCT05114161|OTHER|Novel Care Pathway|The novel care pathway will follow a decision tree based on several criteria to stratify patients in an appropriate risk category. Patients with large radiographic lobar consolidation OR POC CRP \> 60mg/L will be deemed 'appreciable risk' while patients with CRP \< 20mg/L will be deemed 'low risk'. Patients with CRP between 20 - 60mg/L will be evaluated further, as follows: if they have an oxygen saturation of \<95%, they will be 'appreciable risk', and if not, there are further decision points: if they are not tachypneic, they will be 'low risk'; if they are tachypneic and less than 1 year of age, they will be 'appreciable risk'; if they are tachypneic, over 1 year of age, but with either complete PCV13 immunization OR detectable wheezing as per the ED clinician, they will be classified as 'low risk'. Appreciable-risk participants will be given a prescription for antibiotics at ED discharge.
41163476|NCT03132753|BEHAVIORAL|SUPPORT|SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with up to $700 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
41373596|NCT05352607|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"Put the patient in comfort position as long sitting on bed with a supported back and a pillow under the forearm, clean the skin by alcohol swab, setup the parameter, put a gel on electrodes then placed the negative electrode (black wire) over biceps belly and positive electrode (red wire) 3 cm distally from negative electrode , turn on TENS device .~With increase the intensity gradually until patient feel a tingling sensation (no muscle contraction) and every 10 minutes ask patient about the feeling until complete 30 minutes."
41373597|NCT05352607|OTHER|Conventional physiotherapy treatment|Application of a hot pack for 20 minutes to enhance muscle flexibility and get overall spastic muscle relaxation. Anti-spastic muscles (elbow extensors) facilitation: tapping followed by movements (three sets of 15 repetitions per session). Hand weight-bearing with bodyweight (two 5-minute per session). Passive stretching of tight muscles (elbow flexors) is used (this must be a slow and gradual stretch for 20 seconds, followed by 20 seconds of rest, five times per session). Upper-limb active exercises should be done gradually. include (finger flexion and extension exercises, elbow and shoulder (three sets of 20 reps for each session).
41373598|NCT04753931|OTHER|Sensory Training in addition to Bobath Training|Trunk-focused exercises will be applied for different senses (tactile, proprioceptive, etc.) in addition to Bobath exercises. Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
41373599|NCT04753931|OTHER|Bobath Training|Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
41373600|NCT03683264|OTHER|Ultrasound diagnosis of avulsion of the levator ani muscle|In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
41373601|NCT00564473|BEHAVIORAL|questionnaire|"* questionnaire of demographic and medical data, use of and attituded toward herbal medicine.~* Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
41373602|NCT02243709|DRUG|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
41373603|NCT02823223|DEVICE|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
41373604|NCT00395395|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
41373605|NCT04136717|OTHER|Washout period|During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.
41373606|NCT04136717|DEVICE|NIV - FreeO2|"During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes."
41373607|NCT04136717|DEVICE|Nasal High flow Oxygen therapy - FreeO2|During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.
41373608|NCT04136717|OTHER|CPAP - Oxygen constant flow|During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.
41373609|NCT04136717|OTHER|CPAP - FreeO2|During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
41373610|NCT00562874|DIETARY_SUPPLEMENT|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
41373611|NCT00562874|DIETARY_SUPPLEMENT|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
41163477|NCT01862185|OTHER|semi-quantitative procalcitonin|
40849459|NCT03012204|DEVICE|real LFrTMS at unaffected M1|"Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
40849460|NCT03012204|DEVICE|real primed LFrTMS at unaffected M1|"Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
41373612|NCT00562874|DIETARY_SUPPLEMENT|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
41373613|NCT03853226|PROCEDURE|All monitoring|For all patients, data from trans-esophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded at two predefined aortic locations: in the ascending aorta and in the descending thoracic aorta just in front of the esophageal Doppler probe.
41373614|NCT03054675|DIAGNOSTIC_TEST|Spirometry|Absolute FEV1 is measured in every patient using a handheld spirometer
41373615|NCT00625846|OTHER|Laboratory Biomarker Analysis|Correlative studies
41163478|NCT05195450|DRUG|Tenofovir alafenamide fumarate|• TAF 25 mg OD vs no treatment x 5 years and beyond
41163479|NCT02618863|DEVICE|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
41373616|NCT00625846|DRUG|Pazopanib Hydrochloride|Given PO
41373617|NCT02130648|OTHER|A sampling of blood|A sampling of blood de 14 ml
41373618|NCT04667793|DRUG|Toripalimab + Chemotherapy|"Toripalimab: 200mg, q3w, i.v., 2-4 cycles~Chemotherapy:~Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel"
41373619|NCT02681549|DRUG|Pembrolizumab plus Bevacizumab|Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.
41373620|NCT06325969|DIAGNOSTIC_TEST|Detect the immune function of peripheral blood samples|Flow cytometry was used to detect the immune function of peripheral blood samples of PCOS patients.
41373621|NCT04679116|PROCEDURE|Laparoscopic bilateral inguinal hernia repair|Laparoscopic bilateral inguinal hernia repair
41373622|NCT04679116|PROCEDURE|Open bilateral inguinal hernia repair|Open bilateral inguinal hernia repair
41373623|NCT05185791|OTHER|Pre-ERAS® phase (current clinical practice)|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
41373624|NCT05185791|OTHER|Post-ERAS® implementation phase|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
41373625|NCT01740297|DRUG|Talimogene laherparepvec|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
41373626|NCT01740297|DRUG|Ipilimumab|Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
41373627|NCT05978375|PROCEDURE|Posterior intra-articular distraction and fusion|Using reduction using posterior intra-articular distraction and fusion technique.
41373628|NCT05978375|PROCEDURE|Anterior transoral release and posterior cantilever reduction and fusion|Using anterior transoral release and posterior cantilever reduction and fusion technique.
40849461|NCT03012204|DEVICE|combined rTMS at both M1|"Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
40849462|NCT03012204|DEVICE|all sham stimulation|used as controls to eliminate the placebo effect of all kinds of combinated rTMS
41373629|NCT05978375|PROCEDURE|TARP|Using TARP technique.
41373630|NCT05638438|PROCEDURE|transarterial therapies|transarterial therapies combine with donafenib and Anti-PD-1 Antibody
41373631|NCT06470126|PROCEDURE|2.5% NaOCl group: The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|10 mL 2.5% NaOCl application followed the mechanical preparation. After 2 mL 0.9% saline application, the second samples were taken by placing a sterile cone in the largest canal of the tooth (distal canal for 60 seconds). The mesiobuccal and distobuccal canals were closed with a sterile cotton pellet while the samples were taken. After the application, the root canal filling was completed with a calcium hydroxide-containing paste (TgPex™, London, England), glass ionomer cement (Ionofil U, Voco, Cuxhaven, Germany) was placed, and the teeth were restored with a Stainless-Steel Crown (3M ESPE, Seefeld, Germany)
41373632|NCT06470126|PROCEDURE|0.9% sterile saline solution combined with 80 seconds: The OzonyTronX® interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The canals were irrigated with 10 mL 0.9% sterile saline. Ozone treatment (OzonyTronX with CA probe) was applied for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with 2.5% NaOCl, and the canal treatment was completed.
41373633|NCT06470126|PROCEDURE|2.5% NaOCl with 80 seconds OzonyTronX®:The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The disinfection of root canals was done using 10 mL, 2.5% NaOCl, and ozone treatment for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with %2.5 NaOCl, and the canal treatment was completed.
41383516|NCT03327935|DIETARY_SUPPLEMENT|Nutrition|150 Faroese surgical patients randomized to one of the following three arms 1) oral nutritional supplements and advice, 2) oral nutritional supplements and training exercise and 3) Standard hospital procedure. Primary outcome is loss of lean body mass
41383517|NCT01576731|DRUG|Tenofovir, Emtricitabine, Lopinavir/r|Combination drug
41032201|NCT00639717|DRUG|tacrolimus (standard GVHD prophylaxis)|"Tacrolimus(or cyclosporine when necessary)~Tacrolimus will begin on day -3, IV or oral.~Target trough level for tacrolimus is 8-12 ng/ml.~In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant"
41373634|NCT03933709|DIETARY_SUPPLEMENT|Nutritional Support System (NSS)|Envelope 1 4.9g of Spirulina, 100mg ascorbic acid, 5mg folic acid and 10mg of glutamine. Was to be added to shake 1 during the first 10 days. Envelope 2 1g PUFAs n-3 and was to be added to shake 2 which was given throughout the intervention. Envelope 3 4.9g of Spirulina Maximum, 100mg ascorbic acid, 5mg folic acid, 5.2g vegetable protein, 125mg nicotinic acid, 50mg zinc, 100 mcg selenium and 800 UI cholecalciferol. Was to be added to shake 1 from day 11 until the end of week 6, after which it was suspended for 10 days and substituted for envelope 5 and then to be retaken until the end of the intervention. Envelope 4. 1g arginine and was to be added to shake 3 from day 8 until the end of the intervention. Envelope 5 contained the same ingredients as envelope 3 with an additional 10mg glutamine and was to be added to shake 1 from the start of week 7 for 10 days, after which envelope 3 was restarted. Probiotic at a dosage of 200 mg every 12 hours for 3 days at the beginning and week 6
41373635|NCT03933709|OTHER|deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.
41032202|NCT00639717|DRUG|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
41032203|NCT00639717|DRUG|etanercept|Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
41032204|NCT00639717|DRUG|methoxsalen|"Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.~On day +70 post transplant ECP frequency will be given every other week.~On day +100 post transplant ECP will be given monthly until day +180 and stopped."
41373636|NCT03933709|OTHER|recommended diet|WHO Diet
41032205|NCT06201182|DRUG|FMT via rectal enema|50 grams of FMT via rectal enema
41032206|NCT06201182|DRUG|FMT capsules|FMT capsules given twice daily for 2 consecutive days
41032207|NCT06201182|DRUG|Placebo via rectal enema|Placebo via rectal enema
41373637|NCT00000518|PROCEDURE|electrophysiology|
41373638|NCT00000518|PROCEDURE|electrocardiography, ambulatory|
41373639|NCT00000518|DRUG|imipramine|
41032208|NCT06201182|DRUG|Placebo capsules|Placebo capsules given twice daily for 2 consecutive days
41373640|NCT00000518|DRUG|mexiletine|
41373641|NCT00000518|DRUG|procainamide|
41373642|NCT00000518|DRUG|quinidine|
41032209|NCT06500702|DRUG|frexalimab|frexalimab treatment
41373643|NCT00000518|DRUG|sotalol|
41373644|NCT00181051|DEVICE|Alaris AEP monitor|
41373645|NCT00939861|PROCEDURE|laparoscopy|colorectal resection
41373646|NCT00939861|PROCEDURE|laparotomy|colorectal resection
41163480|NCT04146285|DRUG|BAT4406F|"Open-label dose escalation starting from 20mg.~Route of administration: intravenous infusion."
41373647|NCT01132027|DRUG|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
41373648|NCT03187639|DIAGNOSTIC_TEST|FFRct|In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or \> 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.
41383518|NCT01576731|DRUG|Tenofovir, Emtricitabine, Raltegravir|Combination drug
41383519|NCT06567483|DEVICE|ELISIO21HX|Super-high flux dialyzers (ELISIO21HX) will be used. The blood flow rate and dialysate flow rate will be set as 400 and 800 ml/min respectively for 4 hours of dialysis.
40849463|NCT06153966|DRUG|ION717|ION717 will be administered by IT injection.
41032210|NCT06500702|DRUG|SAR442970|SAR442970 treatment
41032211|NCT06500702|DRUG|rilzabrutinib|rilzabrutinib treatment
41032212|NCT06500702|DRUG|placebo|placebo treatment
41032213|NCT03370887|DRUG|AZD8601|AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
41032214|NCT03370887|DRUG|Placebo|Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
41032215|NCT03216876|DRUG|Ursolic acid|Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
41032216|NCT02759159|PROCEDURE|true acupuncture|"acupuncture at the four-gateacupoints, three times per week and last for 6 months"
41032217|NCT02759159|PROCEDURE|sham acupuncture|"acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months"
41032218|NCT01432119|DEVICE|SIR-Spheres|100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
40849464|NCT06153966|DRUG|Placebo|Placebo-matching ION717 will be administered by IT injection.
40849465|NCT05367843|DRUG|PRIME-2-CoV_Beta|Intramuscular (IM) injection
40849466|NCT01742806|DEVICE|bio-absorbable felt(NEOVEIL®)|To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
40849467|NCT06236490|DIAGNOSTIC_TEST|Blood Oxygen Level Test|The study participants rested for 15 minutes before measuring the BOLT score. During this time they were carefully instructed on how to perform the measurement. It was underlined that we do not measure how long one can hold their breath, but the time it takes for the body to react to lack of air and feel the desire to breathe. After a few normal breaths through the nose, after the exhalation, the participants held their breath until they felt the first definite desire to breathe or felt the first involuntary contractions of the respiratory muscles. The first was assessed by the participants, the latter was also visually assessed by the researchers. The nose was closed with the fingers to prevent any gas exchange. The researchers measured the time with a Finis 3x300M stopwatch (FINIS USA, Livermore, CA, USA). Time in seconds, to one decimal place, was noted as a BOLT score. The visualisation of BOLT is presented in Figure 2.
40849468|NCT06236490|DIAGNOSTIC_TEST|Wingate Anaerobic Test|WAnT was conducted with Monark 874E Cycle Ergometer (Monark Exercise AB, Sweden). Before WAnT, the participants performed a 5-minute warm-up with resistance ranging from 0.8 to 1.2 W/kg. Next, the participants performed a maximal 6-second sprint, with the resistance adjusted to 7.5% of the individual body mass. After a rest interval of 2 to 5 minutes, the participants underwent a 30-second WAnT with resistance set at 7.5% of the individual body mass. They were instructed to attain the highest peak power output as quickly as possible and maintain the highest power output throughout the entire duration of the test. The participants received motivating and enthusiastic verbal support. The following indices were measured and included in the further analysis: peak power (Ppeak), total work (TW), WSSR. All the indices were calculated with the dedicated software (MCE 6.0, JBA Z. Staniak, Poland) linked to the cycle ergometer.
40849469|NCT06236490|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|CPET was performed with the Cortex Metamax B3 (Cortex Biophysik GmbH, Leipzig, Germany), breath-by-breath method, and Cyclus II Ergometer (RBM, Leipzig, Germany). Participants underwent an incremental ramp test, commencing at 55-70W and incrementally increasing the load by 0.17-0.28 W·sec-1, individually adjusted for body mass. The participants were instructed to continue the effort until total exhaustion. All the participants fulfilled the maximum effort criteria (Wiecha et al. 2023): 1) respiratory exchange ratio ≥ 1.10, (2) present VO2 plateau (growth \< 100 mL·min-1 in VO2 despite increased cycling power), (3) respiratory frequency ≥ 45 breaths·min-1, (4) declared subjective exertion intensity during CPET ≥ 18 according to the Borg Scale (Borg 1998), (5) blood lactate concentration ≥8 mmol·L-1, (6) peak heart rate ≥ 15 beats·min-1 below predicted maximal heart rate (HRmax) (Lach et al. 2021).
40849470|NCT05825560|DRUG|OFA multimodal analgesia|Multimodal opioid free analgesia
41032219|NCT01432119|DRUG|Cetuximab|Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
41163481|NCT05490147|PROCEDURE|conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|In the conventional tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 10\~12.
41032220|NCT01432119|DRUG|Erlotinib|Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
41032221|NCT01432119|PROCEDURE|Break-Through Scan|"Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
41163482|NCT05490147|PROCEDURE|low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume|In the low tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 6\~8.
41373649|NCT03187639|DIAGNOSTIC_TEST|Standard care|All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites... (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
41373650|NCT02530801|DRUG|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
41373651|NCT02530801|DRUG|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
41373652|NCT06496984|OTHER|Nutritional intervention|Diet changes with different dietary therapies, such as oral nutritional supports (ONS), extra nutritional cares, diet changes without supplements and artificial nutrition.
41373653|NCT04310904|OTHER|contrast assessment of cardiac output (CO)|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
41383520|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
40849471|NCT05825560|DRUG|Standard multimodal analgesia|Standard remifentanil analgesia
40849472|NCT00455143|DRUG|Precedex (Dexmedetomidine)|Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
40849473|NCT00455143|DRUG|Placebo|Matching placebo given prior to surgery and continued for 24 hours postoperatively
40849474|NCT03274518|DEVICE|Expanded Hemodialysis|"Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration"
40849475|NCT03274518|DEVICE|Online Hemodiafiltration|"Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis."
41373654|NCT04310904|OTHER|cardiac Doppler technique|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
41032222|NCT01260233|OTHER|Smoking cessation program|"Smoking cessation program includes:~* brief smoking cessation counselling by preadmission nurse (less than 5 minutes)~* smoking cessation brochures~* referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society~* free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day"
41032223|NCT00750789|DIETARY_SUPPLEMENT|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
41032224|NCT04517721|OTHER|Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)|The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
41032225|NCT03039673|DRUG|Riluzole|"All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.~Riluzole treatment is part of routine care for patients with ALS."
41032226|NCT03039673|DRUG|IL-2|"The dose of IL-2 to be used in this study will be 2.0 million IU/day.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.~In case of intolerance, a flexible dose-reduction schedule is available."
41373655|NCT06445517|DRUG|ISM8207|Pharmaceutical formulation: Capsules Mode of Administration: Oral
41373656|NCT02389621|DRUG|Lusutrombopag|Tablets for oral administration
41373657|NCT02389621|DRUG|Placebo|Tablets for oral administration
41373658|NCT03014570|BEHAVIORAL|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
41373659|NCT03014570|BEHAVIORAL|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
41373660|NCT02270021|OTHER|Provider Mobile Application (ProvAPP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
41373661|NCT02270021|OTHER|ProvAPP + Patient Educational Tool (Tab)|"Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
41373662|NCT03383302|RADIATION|Stereotactic body radiotherapy|Patients will receive a total of 54 Gy if delivered in 3 fractions, 55 Gy if delivered in 5 fractions or 60 Gy if delivered in 8 fractions.
41373663|NCT03383302|DRUG|Nivolumab|Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be administered intravenously at a flat dose of 240 mg q2w over 30 minutes for 13 cycles followed by 480mg q4w over 60 minutes for 7 cycles, until 20 cycles in total to complete (a minimum of 1 year of treatment if no delays are encountered).
41373664|NCT01847625|OTHER|simulator|
40849476|NCT05286216|BEHAVIORAL|effectiveness of education|"The education program will be prepared using power point presentations within the relevant scientific literature. The education program is planned to be given to each group as 1 session on 2 different days, between 09:30 and 13:00. Day 1 module 1; Module 2 will be shared on the 2nd day and all patients in the experimental group will participate in the education program. During and after the education, individuals will be provided with the opportunity to ask questions. In addition, after the education, the researcher's phone will be given and counseling will be provided by phone. The duration and subject of the telephone conversations will be recorded by the researcher.~In order to evaluate the training, all patients will be invited to the hospital on the day of the control at the end of 12 and 24 weeks, and evaluations will be made again with data collection tools."
40849477|NCT01543776|DRUG|abiraterone acetate|Given PO
41373665|NCT02938819|OTHER|Goal-oriented upper-limb intervention|The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
40849478|NCT00418327|DRUG|Tarceva (Erlotinib Hydrochloride)|tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily
41373666|NCT02938819|OTHER|Standard upper limb intervention|The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
40849479|NCT03851055|DRUG|Zinc|One arm will receive Zinc Second arm will receive placebo
40849480|NCT00048100|PROCEDURE|Apheresis|Apheresis for T-Cell collection
40849481|NCT00048100|BIOLOGICAL|Stem Cell Transplant|Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).
40849482|NCT03513627|PROCEDURE|Post-occlusive reactive hyperemia test (PORH test)|Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.
40849483|NCT02021903|OTHER|V1: HGPO + meal and V2: placebo + meal|"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
40849484|NCT02021903|OTHER|V1: placebo 75mg + meal and V2: HGPO 75mg + meal|"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
40849485|NCT04292743|BIOLOGICAL|Eryaspase|intravenous administration of Eryaspase, starting dose 75 units/kg, dose escalation to 100 units/kg, dose reduction 50 units/kg and 25 units/kg
40849486|NCT04292743|DRUG|FOLFIRINOX|intravenous administration of FOLFIRINOX
40849487|NCT00392990|DRUG|Regimen A|Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
41373667|NCT06060912|DEVICE|Left Atrial Appendage Occlusion|Left Atrial Appendage Occlusion will be performed according to current international standards by experienced operators under TOE and angiographic guidance. Either a LAmbre occlusion device (group A) or an AMPLATZER Amulet occlusion device (group B) will be implanted depending on treatment allocation.
41373668|NCT05434949|DIAGNOSTIC_TEST|Blood test|"Three blood samples to be taken at 08.00, 10.00 and 12.00 on day 1 of the study.~The following day, after an overnight fast, a blood sample will be taken at 8.00, followed by a standardized breakfast provided by the study team at 8.30, and then two further blood samples at 10.00 and 12.00."
41373669|NCT05434949|OTHER|Analyses of samples|C4 will be measured in surplus serum from 30 adult lipid patients before starting on lipid-lowering therapy (either statin of PCSK9 therapy) and then again 3 months after starting on therapy. Blood samples will be collected as part of routine lipid management, no additional samples are required.
41373670|NCT04535518|DRUG|IVIG|IVIG at a single dose of 2 g/kg
41373671|NCT04535518|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
41373672|NCT04535518|DRUG|Infliximab|Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
41383521|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
40849488|NCT00392990|DRUG|Regimen B|Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
40849489|NCT03647163|BIOLOGICAL|VSV-IFNβ-NIS|Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
40849490|NCT03647163|BIOLOGICAL|Pembrolizumab|Pembrolizumab
41383522|NCT03388528|DIETARY_SUPPLEMENT|Low Residue Diet Intervention|All patients will be provided with a LRD plan (\< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
40849491|NCT03647163|BIOLOGICAL|ipilimumab + nivolumab|Intravenous ipilimumab 1mg/kg in combination with nivolumab 360mg
40849492|NCT00244634|DRUG|candsartan cilexetil|
40849493|NCT00666965|DRUG|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
41032227|NCT03039673|DRUG|5% glucose water solution|"The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period."
41032228|NCT05262153|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
41032229|NCT02858739|DEVICE|BIOFREEDOM STENT|
41373673|NCT01201122|DRUG|Mesalamine|"Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- \<30 kg, 30-40kg, \>40kg.~For body wt. 15- \<20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- \<30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- \<40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening)."
41373674|NCT02953873|DRUG|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
41373675|NCT02953873|DRUG|Mycophenolate mofetil|≥500mg twice a day
41373676|NCT02953873|DRUG|Prednisone|goal dose 5mg daily
40849494|NCT04313478|BEHAVIORAL|Low Birth Weight and Normal Weight infants|This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.
41373677|NCT02953873|DRUG|Mycophenolate Sodium|≥360mg twice a day
41373678|NCT04209426|DEVICE|THA with SYMBOL CUP DMR HA|
41373679|NCT04209426|DEVICE|THA with SYMBOL CUP DM CEM|
41373680|NCT03225950|OTHER|In vitro stimulation of blood with periodontitis-associated- and control bacteria|Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
41373681|NCT03225950|DIAGNOSTIC_TEST|Anti-CCP- and anti-P.g.-antibodies titers|Anitbody titers will be measured in saliva and serum samples.
41373682|NCT03225950|GENETIC|Analysis of selected single nucleotide polymorphisms (SNPs)|DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
41373683|NCT03225950|DIAGNOSTIC_TEST|periodontitis-associated bacteria presence|Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
41373684|NCT05393570|BEHAVIORAL|Healthy Lifestyle Behavioral Intervention (MBS -supported intervention)|After patient/parent consent is completed, participants will begin the pre-MBS intervention phase. A minimum of 6 1- hour sessions will occur pre-MBS, and 26 will occur post-MBS.Dr. Klement, MBS coordinator and a diabetes educator will manage session delivery to adolescents/parents. All content will follow the Diabetes Prevention Program (DPP)-adapted curriculum flow. After that the research assistant will perform outreach, reminder calls, and follow-up for missed appointments. Pre-and post-MBS intervention delivery (based on adapted curriculum/model) may consist of a combination of 1-on-1 and group sessions (in-person or virtually), and online support tools, dependent upon adolescent/parent qualitative feedback on delivery method preference.
40849495|NCT04697732|OTHER|General anesthesia|Following emergence from general anesthesia, patients will be evaluated at 4 different timepoints; (a) One hour after emergence, (b) Twenty four hour after emergence (c) One week after emergence (d) One month after emergence. The first interview will be made face-to-face in the recovery unit, and other interviews will be made by phone.
41032230|NCT05739747|OTHER|Questionnaire|"All patients should complete the following questionnaires:~On the day of surgery:~* Patient registration.~* Complete medical history.~* Gendolcat scale (including the Spanish version of the SF-12 scale).~* Spanish version of the catastrophizing scale."
41032231|NCT05739747|OTHER|Questionnaire|The investigators should complete a questionnaire during the surgical procedure specifying the anesthetic technique used, drugs and doses used and record any incident during the surgical procedure
41032232|NCT05739747|OTHER|Questionnaire|The investigators should complete a questionnaire 24 hours after surgery to assess the possible presence of postoperative pain as well as the intensity and need for rescue analgesia.
41032233|NCT05739747|OTHER|Questionnaire via telephone call|At 3 months, patients will be called and a structured questionnaire will be completed to assess the presence of chronic postoperative pain.
41032234|NCT05739747|OTHER|Physical examination|Those women who, after the telephone call, are considered to have chronic post-surgical pain will undergo a physical examination to confirm it. The type of pain and its intensity will also be evaluated. The impact on their daily physical activity and quality of life will be evaluated by means of a questionnaire.
41032235|NCT02546752|OTHER|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
41032236|NCT02042482|DIETARY_SUPPLEMENT|Coenzyme Q10U, L-carnitine|
41032237|NCT04388293|OTHER|Exposure of interest|Very Low Birth Weight infants admitted to tertiary NICUs in Canada.
41032238|NCT01638923|DRUG|EV/DNG (Qlaira, Natazia, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
41032239|NCT01638923|DRUG|placebo|Matching placebo to be taken orally daily for 7 cycles of 28 days each.
41032240|NCT01600157|PROCEDURE|Ambulant laparoscopic nephrectomy|The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
41373685|NCT01789476|DRUG|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
41373686|NCT01789476|DRUG|Placebo|Matching placebo administered using same dosing algorithm as the active arm
41373687|NCT00330772|DRUG|Aspirin|
41373688|NCT00330772|DRUG|Clopidogrel|
41373689|NCT02181075|DRUG|ThermoDox® (LTLD)|ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
41373690|NCT02181075|DEVICE|Focused Ultrasound of Target Liver Tumour|Whilst the ThermoDox® was circulating in the blood stream, the JC200 Therapeutic Ultrasound device was used to induce mild hyperthermia in a single (region of) a target liver tumour.
40849496|NCT05179759|BEHAVIORAL|Tealeaf|Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
40849497|NCT05179759|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment
40849498|NCT04853238|OTHER|Prospective observational cohort study|Prospective observational cohort study
40849499|NCT01507480|DRUG|Bevacizumab|There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
40849500|NCT05876338|OTHER|CRCaSSM|The intervention group will receive face-to-face training, giving patient education booklet and telephone counseling based on the symptom management model. After the training, it is planned to provide telephone counseling for a total of 6 times, once every 2 weeks for 3 months.
40849501|NCT05894811|DIAGNOSTIC_TEST|oral glucose tolerance test|Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.
40849502|NCT05894811|DIAGNOSTIC_TEST|MRI|Using MRI to quantify of fat content in the liver and pancreas of the subjects
40849503|NCT06409494|BIOLOGICAL|EuHZV|Drug(injection)
40849504|NCT06409494|BIOLOGICAL|Shingrix|Drug(injection)
40849505|NCT04888169|DEVICE|SMART Mobile App - Attention Bias Modification|ABM involves placing the probe behind the neutral stimulus on 100% of the trials.
41032241|NCT05263388|DRUG|REKOVELLE (Follitropin Delta)|REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE is 15 μg fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose can be increased or decreased by 5 μg based on the subject's response. The minimum REKOVELLE dose is 5 μg and the maximum REKOVELLE is 20 μg. Subjects can be treated for a maximum of 20 days.
41373691|NCT02181075|DIAGNOSTIC_TEST|Pre-LTLD Biopsy of Target Liver Tumour|
40849506|NCT04888169|DEVICE|SMART Mobile App - Attention Control Training|ACT involves placing the probe behind the neutral stimulus on 50% of trials, and behind the threat stimulus on 50% of trials.
41373692|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD Biopsy of Target Liver Tumour|
41373693|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour|
41373694|NCT02181075|DEVICE|Thermometry of Target Tumour|A clinically approved thermistor or thermocouple was placed in the target liver tumour for real-time thermometry.
41373695|NCT02219477|DRUG|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
41373696|NCT02219477|DRUG|dasabuvir|tablet
40849507|NCT04888169|DEVICE|SMART Mobile App - Placebo Training|Placebo training only includes neutral stimuli.
40849508|NCT04888169|DEVICE|SMART Mobile App - Control|Participants will only answer questions.
41373697|NCT02219477|DRUG|ribavirin|tablet
41373698|NCT03304132|OTHER|Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach|The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.
41373699|NCT03304132|OTHER|Classification of Oral Microbiome Using taxonomic approach|The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
41373700|NCT04943601|OTHER|action observation therapy|The participants will be three meters from the screen onto which the videos will be projected. The initial posture will vary depending on each movement, lying down, sitting, or standing and ensuring a clear field of vision. The sessions will be performed in groups of three to four patients
41373701|NCT04943601|OTHER|conventional physical therapy|Verbal instructions will be given to perform and correct the movements requested. The sessions will be conducted in groups of three to four patients and all participants will have 3 to 4 assistants in the session, they will help them achieve their active-assisted range of motion requested in the exercises, when necessary.
41373702|NCT01973699|OTHER|visualization in shoulder arthroscopy|Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
41373703|NCT00987506|DEVICE|XIENCE V®|Participants with placement of a XIENCE V® EESS
41373704|NCT01696266|OTHER|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
40849509|NCT06303219|OTHER|RADITIONAL MODERATE INTENSITY TRAINING|"It consists of patients who will receive High-intensity interval training, including running as well as walking at 80% to 95% HR peak. Which is monitored by a smart watch. Before starting treatment, it follows a 10-minute warm-up exercise which includes basic stretches (Quads, Hams, and calf muscles) with a 30-second hold of both legs and same exercise will be pursued for the cool-down period. This intervention will be performed 5 days per week for 4 weeks.~The total duration of this session will be 50 minutes"
40849510|NCT06303219|OTHER|HIGH INTENSITY INTERVAL TRAINING|"It consists of patients who will receive Moderate-intensity interval training, including running as well as walking at 60% HR peak. Which is monitored by a smart watch. Before starting treatment, it follows a 10-minute warm-up exercise which includes basic stretches (Quads, Hams, and calf muscles) with a 30-second hold of both legs and same exercise will be pursued for the cool-down period. This intervention will be performed 5 days per week for 4 weeks.~The total duration of this session will be 50 minutes ("
40849511|NCT00941122|DEVICE|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
40849512|NCT03496805|DRUG|MGE|The patients will take 4 capsules by mouth BID (twice daily).
40849513|NCT03496805|OTHER|Placebo|The patients will take 4 capsules by mouth BID (twice daily).
40849514|NCT03496805|OTHER|ADT|Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
40849515|NCT02516592|DRUG|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
41163483|NCT04882033|DRUG|Concurrent chemoradiotherapy plus anlotinib|"Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy."
41373705|NCT05811507|DIAGNOSTIC_TEST|serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate|Venous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA
41373706|NCT05811507|DIAGNOSTIC_TEST|The Childhood Autism Rating Scale (CARS)|It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism
40849516|NCT02516592|DRUG|Salmeterol/fluticasone 50/500 microgrammes|Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device
40849517|NCT03492801|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
40849518|NCT03492801|OTHER|Laboratory Biomarker Analysis|Correlative studies
40849519|NCT01398748|DRUG|Intranasal glutathione - (in)GSH|Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
40849520|NCT01398748|DRUG|Intranasal glutathione - (in)GSH|Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
40849521|NCT01398748|DRUG|Saline Intranasal Delivery|Saline administration 1ml 3x/day 12 weeks in 15 participants
40849522|NCT04623840|OTHER|Tadalafil 5Mg Tab + continuous and interval exercise|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
41163484|NCT00153348|BEHAVIORAL|Women's health|
41163485|NCT00549861|PROCEDURE|Cardiac Magnetic Resonance study|Cardiac MRI study
41163486|NCT04159805|DRUG|TAK-079|TAK-079 subcutaneous injection
41163487|NCT04159805|DRUG|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection
41373707|NCT05811507|DIAGNOSTIC_TEST|DSM-5 Diagnostic Criteria for ASD|Persistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay.
41373708|NCT05811507|DIAGNOSTIC_TEST|Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):|"IQ Score ranges for the Stanford-Binet:~Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+"
41373709|NCT02454699|DRUG|MBX400|MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
41373710|NCT02454699|OTHER|Placebo|Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
41504661|NCT01769456|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
40849523|NCT04623840|DRUG|Tadalafil 5Mg Tab|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
40849524|NCT06203769|DRUG|14-day antibiotic therapy|The studied intervention will be 14-day antibiotic therapy after removal of infected material
40849525|NCT06203769|DRUG|28-day antibiotic therapy|The comparator arm will be 28-day antibiotic therapy after removal of infected material
40849526|NCT02536222|OTHER|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
40849527|NCT05751226|DRUG|BI 1820237|BI 1820237
40849528|NCT05751226|DRUG|semaglutide|semaglutide
40849529|NCT05751226|DRUG|Placebo|Placebo
40849530|NCT05751226|DRUG|BI 456906|BI 456906
40849531|NCT04932642|BEHAVIORAL|HIIT+RT experimental group|Each experimental group will be compared with their another contrast order session group
40849532|NCT04932642|BEHAVIORAL|RT+HIIT experimental group|Each experimental group will be compared with their another contrast order session group
40849533|NCT01320202|DRUG|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
40849534|NCT01320202|DEVICE|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
40849535|NCT03332667|RADIATION|131I-MIBG|Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration
41032242|NCT05263388|OTHER|GONAL-F (Follitropin Alfa)|GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F is 225 IU fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose may be adjusted by 75 IU based on the subject's response. The minimum GONAL-F dose is 75 IU and the maximum GONAL-F dose is 300 IU. Subjects can be treated for a maximum of 20 days.
41032243|NCT03646513|DEVICE|SMF Short Modular Femoral Hip System|Primary Total Hip Arthroplasty with SMF Short Modular Femoral Stem Hip System.
41373711|NCT01975129|DRUG|Vagitocin|
41373712|NCT01363531|OTHER|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
41373713|NCT05878496|PROCEDURE|fixation by plate and screws|reduction and fixation of pediatric fracture neck femur by plate and screws
41373714|NCT02616341|BEHAVIORAL|Team ERP (T-ERP) Intervention|
40849536|NCT03332667|DRUG|Dinutuximab|Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.
40849537|NCT03332667|DRUG|Vorinostat|Vorinostat will be given on day 0-13. Vorinostat dose will be based on the dose level assigned at the time of patient registration.
40849538|NCT03332667|DRUG|Sargramostim|Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2
41373715|NCT02616341|BEHAVIORAL|Treatment as Usual (TAU)|
41373716|NCT00665418|DRUG|sevoflurane|sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
41373717|NCT00313482|DRUG|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
41373718|NCT00313482|DRUG|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
41373719|NCT00313482|DRUG|Prednisone|5 mg orally BID on Day 1 continuously
41373720|NCT03436940|OTHER|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
41504662|NCT01769456|DRUG|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
40849539|NCT03332667|DRUG|Potassium Iodide|Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45
40849540|NCT02359513|DRUG|Antidepressants|bulimic patients are treated during 3 months
40849541|NCT02359513|DRUG|Positron Emission Tomography (PET)|PET scan using \[18F\]MPPF is performed before and after (3 months)antidepressant treatment
40849542|NCT03908918|OTHER|Mindfulness app|Mobile app-delivered mindfulness intervention delivered over 4 weeks.
41032244|NCT02504294|BIOLOGICAL|Epoetin Hospira Arm|Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
41032245|NCT02504294|OTHER|Standard of Care Arm|Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.
41032246|NCT02504294|DRUG|IV Iron|Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
41032247|NCT00137332|DRUG|GAP-486 (ZP-123)|
41032248|NCT00137332|DRUG|0.9% Sodium Chloride, USP|
41032249|NCT05942326|BEHAVIORAL|Sleep GOALS|Web-based interventions
41032250|NCT05942326|BEHAVIORAL|Education|Brochures from the American Academy of Sleep Medicine (e.g., sleep hygiene, sleep in women) and SNAP education connection (e.g., family-friendly activities, meal planning)
41032251|NCT04797858|BEHAVIORAL|COVID-19 self-test|5 COVID-19 self-test kits will be given to participants after they have been tested for COVID-19. Participants will be instructed to give test kits to others in their social networks who are symptomatic, exposed to COVID-19, or otherwise at high risk of COVID-19.
41032252|NCT04797858|BEHAVIORAL|COVID-19 test referral|5 test referral cards and text messages on how to obtain COVID-19 testing will be given to participants after they have been tested for COVID-19. These cards and text messages will have information on how to obtain free COVID-19 tests at local testing sites. Participants will be instructed to give out referral cards and text messages to others in their social networks to obtain testing.
41032253|NCT05456581|BEHAVIORAL|'Scotoma awareness' Training|In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.
41032254|NCT05456581|BEHAVIORAL|Control Training|The task will be performed in the control group without the visible scotoma.
41032255|NCT00004179|BIOLOGICAL|rituximab|
41032256|NCT00004179|DRUG|CHOP regimen|
41032257|NCT00004179|DRUG|cyclophosphamide|
41163488|NCT03553485|DEVICE|Transcutaneous vagus nerve stimulation|The transcutaneous auricular vagus nerve stimulator Parasym consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The patient can regulate and adapt the intensity of the stimulation (current intensity) according to his/her individual sensitivity, which can vary from day to day or even over the period of the therapy.
41032258|NCT00004179|DRUG|doxorubicin hydrochloride|
41504663|NCT05706883|PROCEDURE|Needle or forceps biopsy of cervical and/or supraclavicular lymph nodes|Patients with evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes suspected of being metastasis from lung cancer will be submitted to the biopsy from this location.
41032259|NCT00004179|DRUG|prednisone|
41032260|NCT00004179|DRUG|vincristine sulfate|
41032261|NCT06388343|OTHER|Evaluation of Children's Listening and Processing Skills|The Evaluation of Children's Listening \& Processing Skills (ECLiPS; (Barry \& Moore, 2021; Barry et al., 2015; Petley et al., 2021) is a caregiver-report outcome measure to profile auditory and cognitive real-world abilities important for successful listening and (auditory) processing.
41032262|NCT06388343|BEHAVIORAL|Multidisciplinary behavioral assessment|By collecting behavioral measures, the investigators wish to understand the functional implications of the presented problems. Children will complete various well-chosen tasks using a tablet, in the presence of a trained clinician. Tablets are used as they are ubiquitous, cost-effective, and have excellent quality audio output. The investigators will apply the concept of differential testing (Dillon \& Cameron, 2021; Lagacé et al., 2010) to narrow down the range of deficits that lead to deficient scores. The investigators distinguish four (partly overlapping) categories of behavioral measures: 1) auditory processing, 2) (nonsense) speech sound processing in quiet and in noise, excluding semantics, 3) meaningful speech in quiet and in noise, language processing, and 4) neurocognitive (including attention, memory, processing speed) processing.
41032263|NCT02365051|BEHAVIORAL|Care of Persons with Dementia in their Environments|In-home visits by occupational therapist and advanced practice nurse.
41032264|NCT03146169|BEHAVIORAL|Training group|"The training workshop includes four two-hour sessions:~Session one - a knowledge, self-efficacy, and motivation enhancement session at baseline; Session two - an interpersonal communication and leadership skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing session at three months"
41032265|NCT04020120|OTHER|questionnaires|answer questionnaires
41163489|NCT03553485|DEVICE|Sham|Sham Earclip electrodes are electrodes that appear identical to functioning electrodes, however do not deliver any stimulation due to removed wiring.
41163490|NCT03553485|RADIATION|Radiotherapy|Standard treatment for included patients
41163491|NCT00282828|DRUG|Sertraline|
41163492|NCT00282828|DRUG|Venlafaxine|
41163493|NCT00282828|DRUG|Placebo|
41163494|NCT00282828|DRUG|Clonazepam|
41163495|NCT01319825|DRUG|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
41504664|NCT05706883|PROCEDURE|Needle, forceps or surgical biopsy of any lesion other than cervical and/or supraclavicular lymph nodes|Patients without evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes will be submitted to the biopsy considered less invasive and effective based on imaging data and clinical health status.
41373721|NCT03436940|OTHER|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
40849543|NCT02661074|OTHER|Questionnaire|"A questionnaire will be completed in order to collect data on:~* Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~* Occupational and/or domestic exposure to fish."
40849553|NCT00317096|PROCEDURE|FCM|Active comparator: Chemotherapy
41163496|NCT05524415|DEVICE|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
41373722|NCT02883608|PROCEDURE|cap assisted forward-viewing endoscope|a cap fitted to the to top of the forward-viewing endoscope
41373723|NCT05750745|DRUG|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity \& Gum toothpaste is containing 0.454% w/w SnF2.
41373724|NCT05750745|DRUG|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million (ppm) fluoride as Sodium fluoride (NaF).
40849554|NCT00317096|PROCEDURE|R-FCM|experimental: Chemotherapy with additional rituximab
40849555|NCT00317096|DRUG|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
40849556|NCT00317096|OTHER|observation only|no Intervention after completion of FCM or R-FCM
40849557|NCT06583291|DRUG|Allogeneic dopaminergic neural precursor cell(iDAP)|Bilateral implantation
40849558|NCT01548196|PROCEDURE|Standard Percutaneous nephrolithotomy|Percutaneous nephrolithotomy
40849559|NCT05331794|BEHAVIORAL|Training on BIOFIT-Park|"Participant will perform one strength training session on the new line of outdoor fitness equipment BIOFIT-Park. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series."
40849560|NCT05331794|BEHAVIORAL|Training on gym park equipament|Participant will perform one strength training session on a gym park equipment. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series.
40849561|NCT06548607|DRUG|RD06-04 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
40849562|NCT06217588|OTHER|Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.|The study will collect extensive historical health data (retrospective), and at baseline will conduct an extensive characterization of the disease progression using the parameters described above.
40849563|NCT02199561|BIOLOGICAL|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donor
40849564|NCT05325333|BEHAVIORAL|Retrieval-based word learning|"Learning sessions: Novel nouns and their meanings are practiced on Day 1. In both conditions, retrieval trials will initially be immediate. In the expanding condition, the next two retrieval trials will each occur after 1 intervening word and then after 3 intervening words for the remainder of the session. In the standard condition, all remaining retrieval trials will occur after 3 intervening words. This practice schedule is repeated the next day (Day 2).~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word and its meaning twice. One week after Day 1, this recall test is completed again. At this time, the child will complete a recognition test: viewing sets of 4 pictures, the child will hear each novel noun and point to its referent in the array."
40849565|NCT03663335|BIOLOGICAL|CFZ533 - MMF - CS|Comparison with standard of care immunosuppression
41373725|NCT05750745|DRUG|Sensodyne Repair and Protect|Sensodyne Repair and Protect toothpaste is containing 5.0% w/w calcium sodium phosphosilicate (CSPS).
41373726|NCT05277909|OTHER|The expert assessment of shoulder impairments and individualised treatment plan|The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.
41373727|NCT05277909|OTHER|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.
41373728|NCT04942561|DEVICE|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
41383523|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
41504665|NCT02723747|OTHER|myocardial perfusion with magnetic resonance imaging|
41504666|NCT04079465|DEVICE|O2matic|O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.
41373729|NCT04942561|DEVICE|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
41373730|NCT02705534|DRUG|Sofosbuvir|400 mg, included in a combination pill with 90 mg ledipasvir
41504667|NCT05771844|DEVICE|Transcranial Electrical Stimulation|Oscillating electrical current
40849566|NCT03663335|DRUG|Tacrolimus - MMF - +/- corticosteroids|Standard of care immunosupprevive regimen
40849567|NCT02903732|OTHER|observational|registry
41032266|NCT05716581|DEVICE|Catheter ablation|Catheter ablation for atrial fibrillation will be done according to the current medical praxis. Pulmonary vein isolation using either radiofrequency or pulsed-field ablation will be done in all patients. In patients with non-paroxysmal AF, additional ablation lesions (posterior wall ablation, roof or mitral isthmus line, ablation of complex fractionated atrial electrograms) could be done based on the operator´s discretion
41373731|NCT02705534|DRUG|Ledipasvir|90 mg, included in a combination pill with 400 mg sofosbuvir
41032267|NCT05063344|DEVICE|Diagnostic Test: NOWDx Syphilis Test|For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.
41373732|NCT02705534|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
41504668|NCT02884570|OTHER|Auto-Questionnaires|Consents and questionnaires will be sent to the parental home or filled in an interview with an investigator (or telephone consultation).
41504669|NCT03933215|DRUG|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
41504670|NCT02655705|DRUG|Cyclosporine A|Male 200 mg/day, Female 150 mg/day for 16 weeks
41504671|NCT02655705|DRUG|Methotrexate|Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
41504672|NCT04881019|DEVICE|Continuous glucose monitoring|Continuous monitoring of blood sugar over a 10-day period.
41032268|NCT01692704|DRUG|Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin|"Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications."
41032269|NCT04612244|DEVICE|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
41373733|NCT01377857|BEHAVIORAL|Monetary Incentive|$1, $5, or $10 incentive
41373734|NCT01377857|BEHAVIORAL|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
41373735|NCT01377857|BEHAVIORAL|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
41373736|NCT00118209|BIOLOGICAL|rituximab|IV
41373737|NCT00118209|DRUG|cyclophosphamide|IV
41373738|NCT00118209|DRUG|doxorubicin|IV or CIVI
41373739|NCT00118209|DRUG|vincristine|IV or CIVI
41373740|NCT00118209|DRUG|prednisone|oral
41373741|NCT00118209|DRUG|etoposide|CIVI
41504673|NCT01406587|DRUG|PP4001|50 mg, 1 dose every 12 hours x 4 doses
41504674|NCT01406587|DRUG|PP4001|100 mg, 1 dose every 12 hours x 4 doses
41504675|NCT01406587|DRUG|PP4001|200 mg, 1 dose every 12 hours x 4 doses
41504676|NCT01406587|DRUG|Placebo|Placebo, 1 dose every 12 hours x 4 doses
41504677|NCT06633783|DRUG|Semaglutide|The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
41373742|NCT00118209|DRUG|filgrastim|IV
41373743|NCT00118209|DRUG|pegfilgrastim|IV
41373744|NCT01112969|BEHAVIORAL|Internet-based supportive coaching OSCAR|The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
41373745|NCT01112969|OTHER|Waiting-list control group (TAU)|Waiting-list control group (treatment as usual, TAU, no specific intervention)
41383524|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
41504678|NCT06633783|DRUG|Semaglutide|The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
41373746|NCT06231992|PROCEDURE|opioid anaesthesia|I.V Fentanyl (1-2ug/kg) before induction of general anesthesia with I.V propofol (1-2mg/kg), atracurium (0.5mg/kg). Intermittent boluses of fentanyl will be given intraoperatively when needed to maintain the change in hemodynamics within 20 % of the baseline.
41373747|NCT06231992|PROCEDURE|Opioid free anaesthesia|"* IV Ketamine (0.25-0.5 mg/kg) before induction of general anesthesia with I.V propofol (1-2 mg/kg), atracurium (0.5mg/kg) followed by(0.25mg /min) infusion of ketamine for maintenance~* Dexamethasone I.V (8 mg) will be given before induction of general anesthesia.~* magnesium sulphate (20 mg/kg)in 100ml saline within 10 mints Followed by infusion of magnesium sulphate at rate of (10mg/kg/h)."
41373748|NCT01920841|OTHER|Cream A applied to left thigh and Cream B to right thigh|Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh
41373749|NCT01920841|OTHER|Cream B applied to left thigh and Cream A to right thigh|Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
41032270|NCT04612244|DEVICE|RadioFrequency and Cryoballoon Ablation|Contact Force Enabled RF and Cryoballoon ablation catheters indicated for Paroxysmal Atrial Fibrillation
41032271|NCT02893215|OTHER|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
41032272|NCT00893659|DIETARY_SUPPLEMENT|wheat bread with beta-glucan|3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
41032273|NCT00893659|DIETARY_SUPPLEMENT|wheat bread without beta-glucan|Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
41032274|NCT00856401|DRUG|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
41032275|NCT03713762|DRUG|peribulbar block 1 lidocaine/bupivacaine|Peribulbar block: 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml.
41163497|NCT03284125|OTHER|Swallowing disorders evaluation|Self-administered questionnaires and non-invasive clinics tests
41163498|NCT05216393|OTHER|RecTech Match Website|Participants will have access to the Rectech Match website. These participants will receive 9 health coaching calls. Fitbit physical activity data will be collected on an ongoing basis during the intervention.
41163499|NCT01700114|DEVICE|MelaFind|The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
41373750|NCT03669627|BIOLOGICAL|aTIV Primer|MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart
41373751|NCT03669627|BIOLOGICAL|QIV Primer|Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart
41373752|NCT03669627|BIOLOGICAL|aTIV Booster|MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2
41373753|NCT03669627|BIOLOGICAL|QIV Booster|Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
41163500|NCT05854121|DIAGNOSTIC_TEST|Functional Electrical Stimulation|Functional Electrical Stimulation for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
41163501|NCT05854121|DIAGNOSTIC_TEST|Constrained Induced Movement Therapy|Constrained Induced Movement Therapy for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
41163502|NCT00785850|DRUG|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
41373754|NCT04530422|DRUG|Sofosbuvir plus Ledipasvir|"Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days."
41373755|NCT03401827|DRUG|Chemotherapy (Gemcitabine + nab-paclitaxel)|"Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15~Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15"
41373756|NCT01092286|OTHER|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
40849568|NCT06366230|DRUG|Urea in the dialysate|Adding urea to the dialysis fluid. Ure-Na 15 grams would be used. It would be added to the acid component of the dialysis fluid. The amount added would depend on the serum BUN concentration and is determined by a simple calculation. It would be available in powder form. Urea would be added just to the first 1-3 dialysis treatments as needed.
41504679|NCT02954991|DRUG|Glesatinib|Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
41504680|NCT02954991|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
41504681|NCT02954991|DRUG|Mocetinostat|Mocetinostat is an HDAC inhibitor.
41504682|NCT02954991|DRUG|Nivolumab|nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
41032276|NCT03713762|DRUG|peribulbar block 2 lidocaine/bupivacaine/fentanyl|Peribulbar block: 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
41032277|NCT05847218|DRUG|RHN-001 (one tablet 750mg)|Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
41032278|NCT05847218|DRUG|RHN-001 (750mg * 2 Tablets)|Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
41032279|NCT04104581|OTHER|Control Refined Grain Diet|Subjects will be fed the average American diet except it will be free of whole grains
41032280|NCT04104581|OTHER|Low Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain oats
41032281|NCT04104581|OTHER|High Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain oats
41163503|NCT00936754|DIETARY_SUPPLEMENT|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
41504683|NCT06534983|DRUG|Autogene Cevumeran|Autogene cevumeran will be administered as an IV infusion per the schedule in the specified arm.
41504684|NCT06534983|DRUG|Nivolumab|Nivolumab will be administered as an IV infusion per the schedule in the specified arm.
41504685|NCT06534983|DRUG|Saline|Saline solution for intravenous infusion
41373757|NCT05709392|PROCEDURE|Delayed cord clamping and early skin-to-skin contact|A new method for taking care of remature infants born in gestational weeks 30+0-34+6 will be introduced with delayed cord clamping and early skin-to-skin-contact with a parent. If the infant needs help with the breathing this can be given during the time when the cord is still intact.
41373758|NCT04898946|BIOLOGICAL|CoronaVac Vaccine|CoronaVac Vaccine
41373759|NCT04898946|BIOLOGICAL|BNT162b2 Vaccine|Covid-19 BNT162b2 Vaccine
41373760|NCT01882166|DRUG|fostimon|
41373761|NCT01882166|DRUG|puregon|
41032282|NCT04104581|OTHER|Low Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain wheat
41032283|NCT04104581|OTHER|High Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain wheat
41032284|NCT04410432|BIOLOGICAL|Blood sample collection|"Additional blood volumes taken during a routine care blood test:~* 1 dry tube 5 mL for isolation and freezing of serum~* 1 x 5 mL EDTA tube to isolate and freeze plasma~* 8 heparinized 6 mL tubes for flow cytometry study"
41373762|NCT03804060|DEVICE|Thermogard XP3|Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
41032285|NCT01660906|DRUG|Dasatinib|tablets, oral, 100 mg, Once daily, Up to12 months on study,
41032286|NCT01957189|DRUG|Dutasteride and Tamsulosin|0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
41032287|NCT00374842|BIOLOGICAL|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
41032288|NCT00374842|BIOLOGICAL|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
41032289|NCT00737841|DRUG|Bifidobacterium breve|1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
41032290|NCT00737841|DRUG|Placebo|1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
41032291|NCT02152267|DEVICE|tDCS|The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area
41032292|NCT06150664|DRUG|CTX-8371|Intravenous (IV) infusion (0.1-10.0 mg/kg) every two weeks.
41032293|NCT04108312|DIAGNOSTIC_TEST|Anatomical MRI Scan|T1-weighted (T1w) magnetization prepared rapid gradient echo (MPRAGE) sequence (TR=8.776 milliseconds, TE=3.656 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution) and T2-weighted (T2w) CUBE sequence (TR=61.803 milliseconds, TE=3200 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution)
41032294|NCT03129893|DEVICE|Cuffed tracheal tubes|Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
41032295|NCT02133846|DRUG|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
41032296|NCT02133846|DRUG|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
41373763|NCT03804060|PROCEDURE|Recanalization only|Standard of Care for recanalization
41373764|NCT02267343|DRUG|ONO-4538|
41373765|NCT02267343|DRUG|Placebo|
41373766|NCT03317691|DIAGNOSTIC_TEST|electrocardiogram diagnosed by artificial intelligence|According to coronary angiogram results, the accuracy of STEMI patients' electrocardiogram diagnosis by artificial intelligence was evaluated.
40849569|NCT00663403|DRUG|Daptomycin|Daptomcyin 8 mg/kg infused intravenously every 48 hours
40849570|NCT01494597|DRUG|isavuconazole|oral
41032297|NCT02133846|DRUG|Placebo|500mL 0.9% sodium chloride
41032298|NCT02133846|DRUG|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
41032299|NCT00901290|DRUG|monophasic oral contraceptive|mg, oral dose
41032300|NCT00901290|DRUG|AZD7325|mg, oral dose
41032301|NCT00270543|DRUG|Taxotere, Fluorouracil, Leucovorin|
41032302|NCT01732367|DRUG|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
41373767|NCT00165191|DRUG|Doxorubicin|
41373768|NCT00165191|DRUG|Cisplatin|
41373769|NCT00165191|DRUG|5-fluorouracil|
41373770|NCT02064231|DEVICE|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
41373771|NCT02064231|DEVICE|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
41373772|NCT02064231|DEVICE|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
41373773|NCT02064231|DEVICE|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
41373774|NCT02064231|DEVICE|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
41373775|NCT05673954|DIAGNOSTIC_TEST|C-Read test|C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
41373776|NCT06192069|OTHER|Sustainable Heat Strain Prevention Program for Agricultural Elderly Workers (SHiP-AEW)|The SHiP-AEW is a 4-week multifaceted intervention program focused on evidence-based heat strain prevention strategies for agricultural workers over 60 years old. Delivered through weekly 1-hour sessions, the program incorporates the following primary components:
40849571|NCT01494597|DRUG|cyclosporine|oral
40849572|NCT02255201|DIETARY_SUPPLEMENT|Master Performance Blend Dose 1|Caffeine content: 200 mg
41032303|NCT01732367|DRUG|Tenofovir|Tenofovir 300mg QD for 96 weeks
41373777|NCT02777866|DRUG|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
41373778|NCT02777866|DRUG|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
41373779|NCT04148027|OTHER|Treatment recommendation by emergency department physicians|Standard treatment after admission in the emergency department from a team of residents in internal medicine, neurology and general surgery.
41373780|NCT04148027|OTHER|Treatment recommendation by telemedical geriatric co-evaluation|Treatment recommendation from a board-certified geriatrician linked for co-evaluation by means of video transmission
41373781|NCT05358704|DRUG|combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)|To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
41373782|NCT05957939|DRUG|Alkaline Glucosodiene Molecules|Toxic chemotherapeutic nutrition of cancer cells by alkaline glucosodiene molecules via targeting metabolic of cancerous tumors: a promising treatment
41373783|NCT00752427|DRUG|Paliperidone ER OROS®|
41373784|NCT06448169|DRUG|PD-1 inhibitor|PD-1 inhibitor combined with neoadjuvant chemotherapy
41032304|NCT04090736|DRUG|Pevonedistat|Pevonedistat 20 mg/m2 intravenous on days 1, 3, and 5 (28-day cycles)
41032305|NCT04090736|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off \[weekend\]/2-on schedule (28-day cycle). Intravenous for patients who have non-tolerated local reactions
41032306|NCT00407537|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
41032307|NCT06270823|PROCEDURE|Knee-to-chest-flexion manoeuvre|The obstetrician will place one hand at the neck and shoulder of the baby and gently bend the infant into dorsiflexion while with the other hand bending the hips and knees against the abdomen and chest (squatting into fetal position). This holding position will be continued for 30 seconds, while compression of the umbilical cord is avoided to maintain an undisturbed umbilical circulation to and from the infant during KCF.
41032308|NCT04501861|DRUG|Norepinephrine|Hemodynamic effect of norepinephrine on the pulmonary circulation in cardiac surgery patients
41032309|NCT04501861|DRUG|Vasopressin|Hemodynamic effect of vasopressin on the pulmonary circulation in cardiac surgery patients
41032310|NCT00889213|PROCEDURE|Falciform patch and fibrin glue application|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.
41373785|NCT02010346|PROCEDURE|Early headgear treatment|The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
41373786|NCT01652040|DEVICE|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
41373787|NCT01652040|DRUG|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
41373788|NCT00329225|DRUG|rosiglitazone|
41373789|NCT04375566|OTHER|Patient Decision Aid|More than 20 IT specialists, 15 doctors and 15 patients
41373790|NCT03583840|BEHAVIORAL|ScreenMen website|An educational website that aims to improve evidence-based health screening uptake in men
41373791|NCT05041218|OTHER|Neural Interfaces Electroencephalogram measurement on Operators|Electroencephalogram based neural interfaces acquired during the interventional procedure and during alpha attenuation protocols (AAP) and psychometric questionnaires. AAP and psychometrics are acquired at the beginning of the shift, before and after each procedure performed.
40849573|NCT02255201|DIETARY_SUPPLEMENT|Master Performance Blend Dose 2|Caffeine content: 400 mg
40849574|NCT02255201|DIETARY_SUPPLEMENT|Performance Energy Blend|Caffeine content: 175 mg
40849575|NCT02255201|DIETARY_SUPPLEMENT|Energy Blend|Caffeine content: 200 mg
40849576|NCT02255201|DIETARY_SUPPLEMENT|Placebo|Caffeine content: 0 mg
41504686|NCT05593419|DEVICE|TIIC signature|Collect tumor tissue of 300 gastric cancer patients at treatment baseline, samples will be transferred to central lab to detect the density and spatial proximity of certain immune cells infiltrated in tumor by multi complex immunohistochemistry, and evaluate patients' TIIC signature.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastaticorgan ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
41504687|NCT06361719|OTHER|Experimental Group (EG)|Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
41373792|NCT02869373|BEHAVIORAL|spinal stabilizaton exercise|In Exercise group, spinal stabilization exercise program was carried out 3 days a week for 8 weeks.
41373793|NCT05493059|OTHER|Data collection|o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
41504688|NCT06361719|OTHER|Control Group (CG)|Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
41163504|NCT00936754|DIETARY_SUPPLEMENT|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
41373794|NCT05493059|OTHER|Questionnaires|"o Administration of two standardized questionnaires by telephone in prospective:~* Dermatology Life Quality Index (DLQI)~* Treatment Satisfaction Questionnaire for Medication (TSQM)"
41504689|NCT06185881|PROCEDURE|restoration of cervical carious teeth|restoration of carious cervical lesions by glass ionomer
41504690|NCT05101343|BEHAVIORAL|Breathing meditation|Daily, 5-minute breathing meditation for one week.
41373795|NCT00608127|DEVICE|LupusorbTM|Single treatment
41373796|NCT03735680|DRUG|ONM-100|A polymer micelle covalently conjugated to indocyanine green.
41373797|NCT00852267|OTHER|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
41373798|NCT00852267|OTHER|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
41504691|NCT03140371|DIETARY_SUPPLEMENT|High energy high protein peptide feed study|"Each patient will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
41504692|NCT03527381|DRUG|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
41373799|NCT00852267|OTHER|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
41373800|NCT05138510|BEHAVIORAL|Focus Group|"Providers with extensive training and expertise in the subject will lead the virtual focus groups over Zoom using a semi-structured guide. Topics will focus on education received from the health care team, information received from outside sources, and patient recommendations on the type and timing of information preferred.~We will create an analytic report based on the focus group findings, which will be used to inform the development of educational material.~Sexual well-being is currently measured longitudinally on a 0-100 point scale as a component of a validated patient-reported outcome measures (PROM) survey (BREAST-Q) distributed to all breast cancer patients. These scores will be analyzed in patients with and without educational interventions for comparison."
41373801|NCT06540690|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
41504693|NCT03527381|OTHER|Standard CPB|Standard CPB protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit during cardiac surgery.
41504694|NCT04463797|OTHER|Square-stepping exercise|The square-stepping exercise is a low-cost indoor program to improve lower extremities fitness and cognitive function.
41504695|NCT04463797|OTHER|Stretching and strengthening|whole-body stretching and upper extremity strengthening
41504696|NCT04614948|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
41504697|NCT04614948|OTHER|Placebo|Placebo will be administered as IM injection on Day 1 and Day 57.
41504698|NCT05873829|OTHER|Hand-foot exercises|Hand-foot exercise program consists of 5 hand and 5 foot exercises, and a total of 15 minutes of simple hand-foot exercises. The exercise program is applied 3 times a day, 3 days a week. The tennis ball and the towel that used in the exercise program, the booklet which containing the exercise explanations and the video link showing the implementation of the exercises were provided by the researcher.
41504699|NCT03086382|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
41504700|NCT03086382|DRUG|Lacosamide (LCM) syrup|Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
41163505|NCT01536613|DRUG|biphasic insulin aspart 30|The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
41504701|NCT04779554|DRUG|Mitomycin C, flat dose 40 mg|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.
41504702|NCT04779554|DRUG|Mitomycin C, weight-based dose 12.5 mg/m2|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.
41373802|NCT05422105|DRUG|18F-PSMA-1007|18F-PSMA-1007 PET/CT
41373803|NCT03194295|BEHAVIORAL|Community Support Intervention Group|This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
41504703|NCT05624398|DEVICE|Vivity IOL|Cataract surgery with implantation of the Vivity IOL along with concurrent implantation of the Hydrus Microstent
41504704|NCT01371812|DRUG|GSK2239633|Drug will be orally administered at the doses and time points detailed in the 'arms' section.
41504705|NCT01371812|DRUG|Placebo|Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
41504706|NCT00873457|DRUG|perifosine|Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
41504707|NCT00002231|BIOLOGICAL|APL 400-003|
40849577|NCT06267664|DRUG|Patients with migraine treated with triptans, Lasmiditan or Gepants|Patients will complete the study information in their smartphones, tablets or computers, using a QR code or a link that will redirect hem to the study questionnaires. RedCap will be used in the study.
41373804|NCT03194295|BEHAVIORAL|Substance Use Disorder Educational Group|This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
41373805|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310 Dose Level 1
41373806|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310 Dose Level 2
41504708|NCT05460481|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
41504709|NCT03580486|OTHER|The squares test|The squares test (ST) originally used in handedness is modified. The ST is a reliable, not time-consuming and easy to administer test for evaluated hand function.
41504710|NCT06121934|DRUG|Carica Papaya Leaf Extract|Active drug: CPLE 500mg 2 capsule t.i.d for 5 dayseive CPLE or placebo once daily for 5 days.
41504711|NCT06121934|DRUG|Placebo|Placebo: visually matched placebo 2 capsule t.i.d for 5 days
40849578|NCT01239823|OTHER|Whole Body Vibration Training|The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.
40849579|NCT01239823|OTHER|Exercise without vibration|Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
41373807|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310 at the selected dose
40849580|NCT03335280|DRUG|68Ga-citrate PET/MR|Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
41373808|NCT00635193|DRUG|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
41373809|NCT00635193|DRUG|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
41373810|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
41373811|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
41373812|NCT00402506|DRUG|(MC-1) Pyridoxal 5'-phosphate|
41373813|NCT00347776|DRUG|azithromycin|oral antibiotic
41373814|NCT00347776|DRUG|topical tetracycline|
41504712|NCT03609320|BEHAVIORAL|The STOP-HPV Trial 5: Bundle Intervention|This intervention will implement a 3-component bundle intervention (communication skills training, performance feedback and prompts) together in practices that previously received standard of care.
41504713|NCT03573830|BEHAVIORAL|Transport Canada material|The current Transport Canada booster seat education material focuses on imparting guidelines; that is, it describes, in plain language, the minimum and maximum ages, heights, and weights to determine when a child should use a booster seat, and when it is safe for a child to use only the seat belt. This material does not describe the principle of operation of seat belts (i.e., redirecting crash forces to the rib cage and pelvis), nor the principle of operation of booster seats (i.e., ensuring the seat belt is placed correctly across the chest and hips).
41163506|NCT05826405|OTHER|No intervention|No intervention, it's an observational study
41163507|NCT04037943|DIETARY_SUPPLEMENT|Walnuts 30 grams|Roasted walnuts without salt or sugar.
41163508|NCT04037943|DIETARY_SUPPLEMENT|Walnuts 60 grams|Roasted walnuts without salt or sugar.
41373815|NCT02012751|DEVICE|Nevus doctor program|The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
41383525|NCT05830123|DRUG|HS-20093|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
41383526|NCT03761121|OTHER|Wave-CAIPI|"wave-CAIPI technology, a data acquisition / reconstruction scheme designed to optimally exploit available information in modern multi-channel receivers and in multi-contrast/time-series data for improved image encoding"
41383527|NCT06224504|BEHAVIORAL|routine health education|guided the diet of patients, and introduced the knowledge of the disease in detail
41163509|NCT00583050|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
41383528|NCT06224504|BEHAVIORAL|psychological nursing|hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
40849581|NCT02841462|DEVICE|Intra-bursal thermal ablation|A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
40849582|NCT06136130|DEVICE|Tortoise Positioning Material Group|Preterm infants were placed in the nest with positioning material and placed in lateral and prone positions The positioning material and hand-face maneuver were applied together to the preterm infants in the Positioning Material Group 2, and they were given lateral and prone positions in this way
40849583|NCT05448391|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
40849584|NCT05655013|DRUG|Zoledronate|zoledronate 5 mg
40849585|NCT05655013|DRUG|Placebo|isotonic saline 100 mL
40849586|NCT05840536|DRUG|Furosemide plus Chlorothiazide|"Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs."
40849587|NCT05840536|DRUG|Furosemide|Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
40849588|NCT02703480|BIOLOGICAL|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
40849589|NCT02703480|BIOLOGICAL|Ti-mesh|Titanium mesh
40849590|NCT03088813|DRUG|Irinotecan liposome injection|IV
41373816|NCT03572621|OTHER|Therapeutic education|"Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid."
41373817|NCT03572621|OTHER|Collection of data concerning their sexuality|Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).
40849591|NCT03088813|DRUG|Topotecan|IV
40849592|NCT02364934|DRUG|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
40849593|NCT02364934|DRUG|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
40849594|NCT06108830|DRUG|Esketamine|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began
41163510|NCT05199441|DRUG|Dihydroxydibutylether group|This group takes 1.500 mg/day of dihydroxydibutylether for 8 weeks.
41373818|NCT03572621|OTHER|Participation|Participation in a therapeutic education day.
41373819|NCT00826878|DRUG|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
41373820|NCT04325191|DIETARY_SUPPLEMENT|Melatonin|Daily consumption of a high sodium diet and melatonin for 10 days
41373821|NCT04325191|OTHER|Placebo|aily consumption of a high sodium diet and placebo for 10 days
41373822|NCT00062829|BEHAVIORAL|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
41373823|NCT00622752|DRUG|EVT 302, 10 mg|2 X EVT 302, 5 mg tablets
41373824|NCT00622752|DRUG|placebo|2 X placebo tablets to match EVT 302 5 mg
41504714|NCT03573830|BEHAVIORAL|Enhanced material|Enhancements to the booster seat education material were developed based on the hypothesis that parents would better appreciate the additional injury risk reduction afforded by booster seats, if they understand that: (1) seat belts prevent injuries by redirecting crash forces to stronger parts of the body (i.e., rib cage and pelvis); and (2), without booster seats, children would wear the seat belt on their abdomen and neck, which directs crash forces to more vulnerable anatomical structures (i.e., internal organs and spine).
41373825|NCT00622752|DRUG|Nicotine replacement therapy (NRT)|NRT patch containing 21 mg of nicotine
41373826|NCT00622752|DEVICE|NRT placebo|Medically inert plaster cut to match the NRT plaster
41373827|NCT04051515|OTHER|Intradialysis exercise training|Combined exercise, aerobic and resistance training, implemented by nursing staff
41373828|NCT04051515|OTHER|Home-based exercise training|Combined exercise, aerobic and resistance training, implemented independently home
41504715|NCT00143247|DRUG|Exubera® (inhaled insulin)|Treatment of type 1 and type 2 diabetes with short-acting insulin
40849595|NCT06108830|DRUG|Remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
40849596|NCT06108830|DRUG|Esketamine and remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
40849597|NCT06108830|DRUG|normal saline|Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
41163511|NCT05199441|DRUG|Control group placebo|This group takes 1,500 mg/day of placebo for 8 weeks.
40849598|NCT01985425|DRUG|Colchicine 0.6 mg|
40849599|NCT01985425|DRUG|Placebo Colchicine|
40849600|NCT04560153|OTHER|karate kata|sessions of karate kata every week during 4 months
40849601|NCT03653728|DEVICE|Near infrared spectroscopy|"All patients would be receiving the same treatment including application of non-invasive monitoring with near-infrared spectroscopy (NIRS) together with the standard of care with interval CT Brain scan for all patients.~Non-invasive monitoring with near-infrared spectroscopy (NIRS) is very safe and is in current daily routine clinical use for intraoperative patients."
40849602|NCT02860572|OTHER|follow-up without intervention|
40849603|NCT02860572|OTHER|fluid bolus|
40849604|NCT02670668|OTHER|Mutation analysis|
40849605|NCT04720677|OTHER|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire
40849606|NCT06526065|OTHER|no intervention|no intervention
40849607|NCT03172130|DEVICE|Straight CPAP|
40849608|NCT03172130|DEVICE|Sham CPAP|
40849609|NCT02696759|OTHER|Blood & Fecal Collection|Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
40849610|NCT06481566|RADIATION|stereotactic ablative body radiotherapy|The residual primary lung lesions after first-line Almonertinib will be delivered stereotactic ablative body radiotherapy.
40849611|NCT02864160|BEHAVIORAL|Health Coaching|Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
40849612|NCT02864160|BEHAVIORAL|Comparison Group|Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
40849613|NCT04897178|DIAGNOSTIC_TEST|Ultrasound|Routine 2 dimensional Ultrasound used to screen fetuses for congenital anomalies
41032311|NCT00889213|PROCEDURE|standard pancreatic closure|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
41032312|NCT00355082|DRUG|lamotrigine, 300 mg/day|300 mg/day
41373829|NCT05423639|DEVICE|palodent|innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.
41373830|NCT05423639|DEVICE|optracontact|The instrument is used to achieve large and tight proximal contacts in posterior teeth.
41373831|NCT06032026|DRUG|11C-HY-2-15 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-HY-2-15
41373832|NCT06032026|DIAGNOSTIC_TEST|brain MRI|brain MRI scan
41373833|NCT06032026|DIAGNOSTIC_TEST|Amyloid PET scan|PET scan with Florbetaben F18 or 11C-PiB
40849614|NCT06282913|BEHAVIORAL|Mindfulness Meditation|Mindfulness Meditation application will be implemented online by the researcher in 20-minute group sessions once a week for 8 weeks. Participants will be asked to provide a quiet, ventilated, dimly lit environment for the practice. The researcher will start the application when the participants take their places as they feel comfortable. In the first stage, the researcher will teach physicians and nurses to take deep diaphragmatic breaths through the nose and out through the mouth.
40849615|NCT04928118|OTHER|Evaluate the blood flow and pressure into kidneys|"Renal artery pressure and flow measures will be obtained using dedicated equipment positioned into the renal artery under fluoroscopic guidance.~A pulmonary artery catheter will be used to measure the pressure inside participant's renal vein and to collect small blood samples to measure oxygen content."
40849616|NCT00044902|DRUG|epratuzumab|
40849617|NCT06284668|DRUG|normal Saline|Patients undergoing oocyte retrieval were given 5ml 0.9% saline before anesthesia and surgery
40849618|NCT06284668|DRUG|Esketamine|Patients undergoing oocyte retrieval were given esketamine 0.2mg/kg before anesthesia and surgery
40849619|NCT06284668|DRUG|Remimazolam|Patients undergoing oocyte retrieval were given remimazolam 0.2mg/kg before anesthesia and surgery
40849620|NCT04422704|BEHAVIORAL|Technology-based-Intervention|"The intervention is intended to address the concerns and needs that emerge from the participants' interviews. The intervention is based on the principles of the process of adaptation to retirement defined by Atchley and the Prochaska and Diclemente Model on the phases of preparation for retirement. The material to be used will be based on existing resources for retired people, awareness through multimedia material and knowledge of possible contributions of different technological devices to the retirement process.~The sessions consisted of showing different exercises and devices to perform physical activities, cognitive training, relaxation activities, counselling about healthy eating and leisure-time activities."
41032313|NCT00355082|DRUG|lamotrigine, 250 mg/day|250 mg/day
41032314|NCT01552044|DRUG|Spironolactone|25mg tablet once a day for 1 month
41032315|NCT01552044|DRUG|Placebo|one tablet once a day for 1 month
40849621|NCT05042284|DRUG|Non-enteric coated pancreatic enzyme preparation|The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
40849622|NCT06414577|DRUG|Irinotecan Liposomal combined With Nituzumab|Irinotecan liposomal: 70mg/m2, ivgtt, d1; Nituzumab: 400 mg, igvtt, d1 One treatment cycle every two weeks for up to 8 cycles, or until disease progression, intolerable toxicity, death, and investigator judgment of no further benefit
40849623|NCT06304779|DRUG|Lidocaine|"Lidocaine group receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively and Control group receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.~Both groups will receive the same anesthesia and postoperative analgesia protocols, lung-protective ventilation strategy, and fluid, transfusion, and warming strategies. The only difference is the intervention during surgery, with the lidocaine group receiving continuous intravenous lidocaine."
40849624|NCT06304779|DRUG|Placebo|atients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
40849625|NCT03524638|OTHER|Visbiome|Colorectal surgery plus administration of Visbiome on post-operative day 2.
40849626|NCT03524638|PROCEDURE|Colorectal Surgery|Colorectal surgery alone
40849627|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
40849628|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
40849629|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
40849630|NCT02698150|DEVICE|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
40849631|NCT01590160|DRUG|Ganetespib|IV, Using dose from Phase I
40849632|NCT05008198|OTHER|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
41373834|NCT06032026|BEHAVIORAL|Neurological assessments|Neurological assessments, including video interview
41373835|NCT04233255|DEVICE|Neuromuscular Ultrasound (US)|"Quantitative ultrasound measurements will be performed to studied muscles according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.The study will be performed using My lab 7 ultrasound system (Esaote company, Italy) that is equipped by 7-19 MHz linear array transducer and color and power Doppler.~Technique: evaluation of studied muscles for echo intensity (ECHO), quantitative assessments of echointensity, muscle perfusion, transverse and longitudinal sections of the muscle and its thickness at rest and during maximal voluntary contractions (MVC), overlying subcutaneous fat, cross-sectional area (CSA), and angled fibers of pennate muscles."
40849633|NCT04794127|DRUG|Trabectedin|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
41373836|NCT04233255|DEVICE|Electrophysiological studies|"Includes: Motor and sensory nerve conduction study, F-wave and H-reflex study to assess the proximal roots, Electromyography (EMG) of the studied muscles.~using machine: recordings will be performed with a Nihon Kohden equipment (model 7102) with the following parameters: sweep time 8 ms/D, sensitivity 0.5 mV/D, low frequency filter 2 Hz, high frequency filter 10 kHz, stimulation duration 0.1 ms and stimulation frequency 1 Hz."
41373837|NCT04233255|DIAGNOSTIC_TEST|Seum CPK, CK-MM levels, Lactate dehydrogenase and alanine aminotransferase.|measured in U/L using ELISA.
40849634|NCT04794127|DRUG|Pioglitazone Oral Product|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
40849635|NCT03265782|DRUG|ibuprofen|drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
40849636|NCT03265782|DRUG|paracetamol|drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
40849637|NCT05921799|PROCEDURE|Blood specimen collection|Routinely collect citrate blood and native blood from patients as required by their condition.
40849638|NCT03113981|DEVICE|Total Hip Arthroplasty|Implanting THA grafted with PolyNass or not
41032316|NCT01289067|DRUG|Satraplatin|Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
41373838|NCT05377541|PROCEDURE|Surgical treatment of femur fracture|Definitive surgical treatment of femur fracture.
41373839|NCT00556166|DEVICE|Enterra Therapy Gastric Stimulator|"The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.~The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control."
41032317|NCT03557437|DRUG|Esomeprazole|Proton pump inhibitor
41032318|NCT03557437|DRUG|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
41032319|NCT03557437|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
41032320|NCT05846724|DRUG|Pembrolizumab + Lenvatinib|single-arm study of pembrolizumab plus lenvatinib
41032321|NCT04619641|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
41373840|NCT04544748|BIOLOGICAL|GNR-051|Anti-PD1 monoclonal antibody
41373841|NCT04566965|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
41504716|NCT06148935|DRUG|Vericiguat (Verquvo, BAY1021189)|Following the manner of observational study, no intervention will be provided in the study. Participants follow locally approved label, without interference by the study initiator or study protocol
41373842|NCT00734318|DRUG|Flutiform 250/10 micrograms|
41373843|NCT00734318|DRUG|Flutiform 50/5 micrograms|
41373844|NCT00734318|DRUG|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
41163512|NCT02878460|OTHER|monitoring with ORI + SpO2|"If ORI is equal to 0.00, the FiO2 (or oxygen flow) is not changed. if ORI is ≥ 0.01, Nurses must decrease the FiO2 (or oxygen flow) by 10%, until ORI is =0.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
41373845|NCT00734318|DRUG|Flixotide pMDI 250 micrograms|
41373846|NCT05805072|DRUG|Selinexor|Selinexor 60 mg/day, orally on d1,4,8,11
41373847|NCT05805072|DRUG|Homoharringtonine|Homoharringtonine 1 mg/day intravenously on days 3 to 9
41504717|NCT00275119|DRUG|fluorouracil|
41504718|NCT00275119|DRUG|gemcitabine hydrochloride|
41504719|NCT00275119|DRUG|oxaliplatin|
41504720|NCT00275119|RADIATION|radiation therapy|
40849639|NCT01088620|DRUG|Panitumumab|"Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression."
40849640|NCT01088620|DRUG|Pemetrexed|Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
40849641|NCT01088620|DRUG|Cisplatin|Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
40849642|NCT05397639|DRUG|Masupirdine 50 mg|Tablet, Once Daily
40849643|NCT05397639|DRUG|Masupirdine 100 mg|Tablet, Once Daily
40849644|NCT05397639|DRUG|Placebo|Matching Placebo Tablet, Once Daily
40849645|NCT05595772|DRUG|Drug: Growth Factors (CGF)|Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant
40849646|NCT05595772|DRUG|Drug: Growth Factors (PRGF)|Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant
41032322|NCT04619641|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
41032323|NCT03219112|OTHER|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
41032324|NCT02707055|DRUG|PF-05190457|Ghrelin Receptor Inverse Agonist
41032325|NCT02707055|OTHER|Placebo|Placebo
41163513|NCT02878460|OTHER|monitoring with SpO2|"If SpO2 is below the upper individualized limit, the FiO2 (or oxygen flow) is not changed.~If SpO2 is equal or above this limit, Nurses must reduce the FiO2 (or oxygen flow) by 10% every 10 minutes until SpO2 is ≤ upper individualized limit, with FiO2≥25 %.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
41163514|NCT02917798|BEHAVIORAL|Assessments|
41163515|NCT03290937|BIOLOGICAL|Cetuximab|Given IV
41373848|NCT05805072|DRUG|Cytarabine|cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9
41373849|NCT05805072|DRUG|Aclacinomycin|aclacinomycin 10 mg/day intravenously on days 3 to 6
41373850|NCT05805072|DRUG|Granulocyte Colony-Stimulating Factor|granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,
41373851|NCT05805072|DRUG|Decitabine|Decitabine 20 mg/m2/day intravenously on days 1 to 5.
41373852|NCT05805072|DRUG|Azacitidine|Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7
41373853|NCT01472666|DIETARY_SUPPLEMENT|High content of MC-SFA|12 weeks dietary intervention
41373854|NCT01472666|DIETARY_SUPPLEMENT|Whey|12 weeks dietary intervention
41373855|NCT01472666|DIETARY_SUPPLEMENT|Low content of MC-SFA|12 weeks dietary intervention
41504721|NCT03348735|DRUG|Lidocaine patch 5%|Application of Lidocaine 5% patch for 12 hours.
41504722|NCT03348735|DRUG|Capsaicin 8% Patch|Application of Capsaicin 8% patch for
41504723|NCT03348735|DRUG|Pregabalin|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.
41504724|NCT05686226|BIOLOGICAL|E7 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
41504725|NCT05686226|DRUG|Aldesleukin|Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV every eight hours will be administered for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
41504726|NCT00002505|BIOLOGICAL|filgrastim|
41504727|NCT00002505|BIOLOGICAL|recombinant interferon gamma|
41504728|NCT00002505|BIOLOGICAL|tumor cell lysate vaccine therapy|
41504729|NCT04735978|BIOLOGICAL|RP3|Genetically modified HSV-1
41504730|NCT04735978|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
41504731|NCT03376061|DRUG|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
41504732|NCT03172195|PROCEDURE|rectosigmoidoscopy|A rectosigmoidoscopy will be realized and two fragments will be collected.
41504733|NCT03172195|BIOLOGICAL|biopsies|For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
41504734|NCT03172195|BIOLOGICAL|blood sample|Blood sample will be collected in more.
41504735|NCT05745597|OTHER|Follow up|Four samples of cervical exfoliated cells and fornix secretions were collected from all subjects at enrollment, 6 months, 12 months and 24 months for HPV integration status and vaginal microbiota diversity sequencing, and two additional samples of peripheral blood (whole blood + serum) were collected at enrollment.
41373856|NCT01472666|DIETARY_SUPPLEMENT|Casein|12 weeks dietary intervention
41504736|NCT05351801|DRUG|THC (Syndros)|Participants will receive a target dose of 10mg per day of THC (Syndros).
40849647|NCT05595772|PROCEDURE|Surgery: Dental Implant surgery|Immediate implant following extraction
40849648|NCT05595772|PROCEDURE|Tooth extraction|A Traumatic tooth extraction
40849649|NCT05595772|PROCEDURE|Xenogenic bone grafting|Application of bovine bone grafting over area of dehiscence around immediate implant
41373857|NCT05781204|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
40849650|NCT04499989|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide self inserted 12 hours before IUD insertion.
40849651|NCT04499989|DRUG|Placebo Comparator|3 vaginal tablet of Placebo Comparator self inserted 12 hours before IUD insertion
40849652|NCT00000470|PROCEDURE|cardiac surgical procedures|
40849653|NCT00000470|PROCEDURE|cardiopulmonary bypass|
41373858|NCT02027246|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
41373859|NCT00076544|DRUG|Ziconotide|
41373860|NCT05237960|PROCEDURE|Biopsy|Undergo biopsy
41504737|NCT05351801|DRUG|CBD (Epidolex)|Participants will receive a target dose of 800 mg per day of CBD (Epidolex).
40849654|NCT02861638|DEVICE|Experimental group|Video of the exercises
40849655|NCT02861638|DEVICE|Control group|video of nature scenes
40849656|NCT02861638|DEVICE|Conventional physiotherapy|Mobilization, exercises and transfer practice.
40849657|NCT01781559|DIETARY_SUPPLEMENT|phenolic acid|phenolic acid
40849658|NCT06268613|DRUG|SB27|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
41504738|NCT05351801|DRUG|THC + CBD (Nabiximols)|Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).
40849659|NCT06268613|DRUG|EU sourced Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
41163516|NCT03290937|DRUG|Irinotecan Hydrochloride|Given IV
40849660|NCT06268613|DRUG|US sourced Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
40849661|NCT03997825|DEVICE|Basivertebral Nerve (BVN) Ablation|Single follow-up visit of previously treated participants from the SMART trial.
41163517|NCT03290937|OTHER|Pharmacodynamic Study|Correlative studies
41504739|NCT05351801|DRUG|Placebo|Placebo
41504740|NCT04490616|OTHER|rTMS treatment|"A two-site rTMS stimulation delivered by a Magstim unit featuring a double 70 mm cooled coil will be applied.~MCI patients will be randomly assigned to one of the two study groups:~1. RR-Gr will receive 4 weeks of rTMS stimulation of the right temporo-parietal junction (RTPJ) and medial prefrontal cortex (MPFC);~2. PL-Gr will receive sham stimulation of the RTPJ and MPFC during the first 2 weeks followed by 2 weeks of real stimulation. Each week of rTMS treatment will consist of five sessions (50 min, one per day).~For each area target, a total of 2000 pulses at 20Hz, 3-s train duration, and 28-s inter-train interval at 100% motor threshold (MT) will be delivered per session. A fixed intensity of MT will ensure a more consistent spatial spread of TMS effects in subjects' brains not influenced by differences in individual MT. In the sham condition, a sham coil will be used.~Each session lasted for about 60 min including time for set up and 50 min of stimulation."
40849662|NCT01940627|DIETARY_SUPPLEMENT|Ubiquinol|Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
40849663|NCT01940627|DIETARY_SUPPLEMENT|Control|placebo capsules (two capsules (Breakfast and lunch)) for 14 days
40849664|NCT03308994|OTHER|Delay between MS onset and introduction of first line DMT|Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)
40849665|NCT03308994|OTHER|EDI|For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.
40849666|NCT01123395|DRUG|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
40849667|NCT01123395|DRUG|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
40849668|NCT00922714|DRUG|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
40849669|NCT00922714|DRUG|saline (placebo)|NaCl 0.9 g/L
41163518|NCT03290937|BIOLOGICAL|Utomilumab|Given IV
41373861|NCT05237960|PROCEDURE|Biospecimen Collection|Correlative studies
41373862|NCT05237960|DRUG|Extended Release Metformin Hydrochloride|Given PO
41373863|NCT05237960|DRUG|Placebo Administration|Given PO
41373864|NCT02288234|DRUG|Vibativ|This is an observational study for patients who were already prescribed Vibativ.
41383529|NCT06224504|BEHAVIORAL|MBSR therapy|Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans
40849670|NCT06574997|DRUG|OCU400|Participants will receive a subretinal injection of OCU400 modifier gene therapy product.
40849671|NCT04584242|DRUG|gluconon tab 15mg|frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST
40849672|NCT04584242|DRUG|suganon tab 5mg|frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
40849673|NCT05463016|DEVICE|Experimental Group 1: Color Correcting Lenses|Color Correcting Lenses
40849674|NCT05463016|DEVICE|Placebo Group 1: Placebo Lenses|Placebo Lenses
40849675|NCT05463016|DEVICE|Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses|Color Correcting Lenses
40849676|NCT05463016|DEVICE|Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses|Placebo Lenses
41032326|NCT02206503|DRUG|Cyclophosphamide|This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
41032327|NCT02206503|DRUG|Lenalidomide|
41032328|NCT02206503|DRUG|Dexamethasone|
41032329|NCT05800522|BEHAVIORAL|Behavioral parent or child directed intervention|Control group will include different behavioral interventions that may include caretakers or the target child, and thus may vary in scope and intensity.
41163519|NCT00364221|DRUG|Rosiglitazone|
41163520|NCT03821064|OTHER|Patient Navigation|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of clinic-based sessions of manualized PN to reduce barriers to care, increase HNC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months). The three in-person NDURE sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit. During the first session, the navigator will 1) elicit barriers and facilitators to timely PORT, 2) develop the personalized barrier reduction plan (BRP), review the BRP with the patient, caregiver, and provider, and 3) implement the BRP. At the two subsequent sessions, the navigator will review and update the BRP in an iterative, dynamic fashion, identifying new barriers and systematically tracking resolution of prior barriers until the start of PORT.
41163521|NCT04441827|OTHER|breathing exercise|Pranayama Group Breathing Exercises Step One:Focusing on breathing (1 minute) Step Two: Alternative nasal breathing (3 minutes) Step Three: Refreshing breath (3 minutes) Step Four: Humming bee breath (2 minutes) Step Five: Focusing on breathing (1 minute)
41163522|NCT03849521|DIAGNOSTIC_TEST|MRI|Enhanced carotid calcification presented by UTE MR.
41163523|NCT02299856|OTHER|Cardiac magnetic resonance scan|
41373865|NCT05319652|BEHAVIORAL|Pain self-management program|Each week for eight weeks, participants are invited to complete self-directed lessons on particular themes. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning. Through pain education, positive testimonials from individuals with CNCP applying the suggested strategies, reflective activities, goal setting and monitoring, and the gradual development of a personal plan, the program supports self-efficacy building to manage CNCP.
41163524|NCT04959825|DRUG|Melatonin 5 mg|study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain
41163525|NCT04959825|DRUG|Sugar Coated Tablets|the control group patients will receive placebo tablets one hour before induction of anesthesia
41163526|NCT02960256|DEVICE|ekocardiogram test|ekocardiogram test
41163527|NCT05734742|OTHER|Educational video|"There were two videos including the first video Sleep apnea Syndrome Driving Safety Picture Scroll and the second video Sleep apnea Syndrome and Traffic Accidents. The first video was approximately 3 minutes long. This video was suitable for all ages. It was an easy-to-understand video explaining the characteristics of OSA and its relationship with traffic accidents. The second video was the detailed video, which is approximately 20 minutes in duration. This video was suitable for those who desire to learn more about OSA. It can be used in various educational settings, including internal training and traffic safety workshops. Participants must watch at least the first video."
41373866|NCT00883831|PROCEDURE|Individualized manual acupuncture|Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
41373867|NCT04284176|OTHER|Mirror therapy and action-observation therapy|The mirror therapy and action-observation therapy group will receive for 20 days a daily therapy of 15 minutes at home of MT and 45 of AOT, whereas the action-observation therapy group will receive 60 minutes of AOT.
41373868|NCT02996838|DRUG|TQ-B3234|TQ-B3234 p.o. qd
41373869|NCT03737357|DEVICE|SLActive® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
41383530|NCT06224504|BEHAVIORAL|exercise therapy|Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day
41504741|NCT06338124|DIAGNOSTIC_TEST|Triglyceride glucose index|To evaluate the role of various laboratory biomarkers ( TyG , RAR , CAR, N\\L ratio, CRP, Serum lactate )in prediction of sepsis outcome.
41032330|NCT05800522|BEHAVIORAL|Supportive Parents - Coping Kids|Intervention group will receive the transdiagnostic parent intervention (SPARCK). SPARCK is designed to include up to 12 sessions with caretakers. If necessary and applicable, children can attend sessions. The starting point for the development of SPARCK has been the Social Interaction Learning model, which represents the behavioral management perspective. In addition, SPARCK consists of empirically supported components based on attachment theory, emotion socialization, CBT, and family accommodation. Thus, content and strategies have been collected from different theories to provide a diverse toolkit tailored to address transdiagnostic problems in families with externalizing, internalizing, and caregiver challenges. SPARCK content and target strategies are tailored to the needs of the families and children, and the manual explains the content and how the target strategies may be tailored and combined.
41032331|NCT03067441|DRUG|bempedoic acid|bempedoic acid 180 mg tablets taken orally, once per day.
41032332|NCT02759900|DEVICE|Non-thermal, atmospheric plasma to treat skin lesions and acne|Non-thermal, atmospheric plasma treatment of affected area or lesions using a nanosecond dielectric barrier discharge plasma device
41032333|NCT02759900|DEVICE|Indirect non-thermal, atmospheric plasma to treat hair loss and acne|A compound of non-thermal, atmospheric plasma and medium is delivered to or generated at the target area. Plasma is generated using either microsecond dielectric barrier discharge plasma device or PiezoBrush (a helium jet plasma). The medium is an aqueous alcohol solution
41032334|NCT04442555|DIETARY_SUPPLEMENT|HVMN Ketone Ester|Commercially available ketone supplement
41032335|NCT04442555|DIETARY_SUPPLEMENT|Maltodextrin|Commercially available maltodextrin supplement
41373870|NCT03737357|DEVICE|SLA® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
41373871|NCT00605969|PROCEDURE|Motion analysis|Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.
41373872|NCT00605969|DIAGNOSTIC_TEST|Computed Tomography|Participants will undergo computed tomography (CT) scan of their hip.
41373873|NCT04893915|BIOLOGICAL|Cytokine-induced memory-like NK cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core or another FACT-accredited cellular therapy production facility that can manufacture the product per the IND CMC.
41373874|NCT04893915|DRUG|Fludarabine|-Lymphodepleting regimen
41163528|NCT05264064|OTHER|The motor assessment to establish validation of the Polish version of the AIMS|The translation, cultural adaptation, and validation were conducted according to existing recommendations. The motor development of infants was assessed with the Polish scoresheet of the AlMS and the PDMS v.2. The examination was conducted by two peadiatric physiotherapists with a minimum 7 years of experience.The examination methodology was concordant with the recommendation of the authors of AIMS and PDMS-2.The intrarater reliability test included two assessments (with one-month interval) performed by one researcher (Rater A). For the second assessment, the videos of spontaneous motor performance of infants were recorded during the examination. The interrater reliability involved assessments by two researchers (Rater A, Rater B). The Gross Motor Scales of the PDMS v.2 was administered to estimate concurrent validity (participants at the age of 0-12 months).
41163529|NCT00823004|DRUG|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
41163530|NCT00823004|DRUG|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
41373875|NCT04893915|DRUG|Cyclophosphamide|-Lymphodepleting regimen
41163531|NCT00823004|DRUG|GnRH agonist (buserelin)|50 µg SC twice daily
41373876|NCT04893915|PROCEDURE|Donor Leukapheresis|-Apheresis will be performed via peripheral IVs or central line, as determined by the apheresis team.
41373877|NCT04893915|DRUG|Interleukin-2|-IL-2 will start approximately 2-4 hours after the NK cell infusions.
41373878|NCT05459012|OTHER|follow-up|Questionnaire of Quality of life
41373879|NCT02743182|DRUG|Pegylated interferon alfa-2a|
41373880|NCT06400719|BIOLOGICAL|AVT16|Single intravenous administration of 300mg of AVT16
41032336|NCT01479660|OTHER|Control|Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose
41373881|NCT05666765|DRUG|Isotretinoin ,silymarin|20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
41373882|NCT01511562|DRUG|carmustine|Given IV
41373883|NCT01511562|DRUG|cytarabine|Given IV
41373884|NCT01511562|DRUG|etoposide|Given IV
41504742|NCT04832022|OTHER|Biological samples|Serum and plasma samples. At baseline, 3, 6 and 12 months
41032337|NCT01479660|DRUG|Probiotic|Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
41163532|NCT00823004|DRUG|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
41163533|NCT00823004|DRUG|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
41373885|NCT01511562|DRUG|thiotepa|Given IV
41373886|NCT01511562|PROCEDURE|stem cell transplant|
41373887|NCT01511562|DRUG|G-CSF|
41373888|NCT01038076|BEHAVIORAL|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
41373889|NCT01605539|DRUG|Cannabidiol 400|Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
41373890|NCT01605539|DRUG|Cannabidiol 800|Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions
41373891|NCT01605539|DRUG|Control|Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
41373892|NCT03528265|DEVICE|Lateral flow immunoassay|Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis
41383531|NCT05482438|DEVICE|Polyethylene|Wear measurement
41373893|NCT04807816|DRUG|Association of berzosertib with gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~Berzosertib will be administered intravenously on days 2 and 9 every 3 weeks (210 mg/m²).~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
41373894|NCT04807816|DRUG|Gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
41373895|NCT06402825|BEHAVIORAL|Fit-for-Fertility program|Women in the intervention group had to delay fertility treatments for 6 months and were offered the interdisciplinary lifestyle intervention, which was provided for a maximum of 18 months or until the end of a pregnancy that occurred. The lifestyle intervention consisted of individual meetings with a dietitian and a kinesiologist trained in motivational interviewing, combined with 12 educational group sessions during the first 6 months. Details of the lifestyle intervention are presented in the previously published protocol (Duval et al., 2015).
41032338|NCT02449538|DRUG|everolimus|everolimus 10 mg qd daily one cycle is 28days.
41032339|NCT03347500|OTHER|use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.
41032340|NCT03043612|DEVICE|Cook Sof-Flex® Double Pigtail Ureteral Stent coextruded with doxazosin|Placement of drug-coated ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
41032341|NCT03043612|DEVICE|Cook Sof-Flex® Double Pigtail Ureteral Stent|Placement of a commercially available ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
41032342|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
41032343|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
41032344|NCT00613951|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme, injection s.c., twice daily
41163534|NCT01996397|PROCEDURE|Cardiac resynchronization therapy device implantation|
41373896|NCT04599543|DRUG|IL3 CAR T-cells|Each subject receive IL3 CAR T-cells by intravenous infusion
41373897|NCT00012766|BEHAVIORAL|Integrated team care|
41373898|NCT02341339|PROCEDURE|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
41373899|NCT02647632|DRUG|Grazoprevir/Elbasvir|
41373900|NCT02647632|DRUG|Sofosbuvir|
41373901|NCT02647632|DRUG|Ribavirin|
41373902|NCT01010724|DRUG|bIAP|
41373903|NCT01010724|DRUG|Placebo|
41373904|NCT00388713|PROCEDURE|carotid intima-media thickening ultrasound|
41032345|NCT00613951|DRUG|metformin|Tablets, 1500-2000 mg/daily
41032346|NCT02543359|BEHAVIORAL|Training Models of PCIT|Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.
41032347|NCT02543359|BEHAVIORAL|Training Models of PCIT|One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).
41032348|NCT02543359|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT) Treatment|Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
41032349|NCT03535818|PROCEDURE|Radiofrequency ablation|RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
41163535|NCT03771183|OTHER|Patients in long response during Halaven® treatment|Data collection
41373905|NCT06519201|DEVICE|SRT with SpineCare|Korean medicine doctors performed the treatment regimens.The TG underwent SRT with SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
41383532|NCT04854421|DEVICE|VBC|Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
41163536|NCT06360523|DIAGNOSTIC_TEST|AI modal|The MRI image will be reviewed by radiologist and AI model(s) respectively. The urologist will combine the results of the two approaches to optimize the biopsy strategy which is expected to result in more accurate diagnosis.
41163537|NCT02606097|DRUG|regorafenib|
41163538|NCT03467997|BEHAVIORAL|Trier social stress test|Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.
41163539|NCT03467997|OTHER|Diesel exhaust|Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).
41383533|NCT04672824|BIOLOGICAL|ChAdOx1 RVF|Single dose ChAdOx1 vectored vaccine
41383534|NCT04672824|OTHER|Saline|0.5ml saline placebo
41032350|NCT03073889|PROCEDURE|Scalp Nerve Block|A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
41373906|NCT06519201|DEVICE|SRT without SpineCare|Korean medicine doctors performed the treatment regimens. The CG underwent SRT without SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
41373907|NCT04984889|DRUG|TAK-662|Lyophilized, sterile concentrate of human protein C
41373908|NCT01782638|BEHAVIORAL|deep brain stimulation|
41373909|NCT05872282|DEVICE|ZIPPER aortic arch stentgraft system|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
41373910|NCT03961932|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
41373911|NCT04254926|BEHAVIORAL|Revie ⊕|Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
41373912|NCT01945866|DRUG|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
41373913|NCT01945866|DRUG|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
41373914|NCT01945866|PROCEDURE|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
41373915|NCT04642040|OTHER|Pulmonary Rehabilitation|Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
41373916|NCT05468866|GENETIC|Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR|detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping
41373917|NCT04711642|DRUG|The study will include three arms, one non interventional and 2 interventions. The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod)|All groups will receive a topical steroid-antibiotic for 3 weeks. The study groups will be also prescribed eye drops containing sodium hyaluronate 0.1% from the postoperative day 7 for 4 weeks.
41373918|NCT00061269|PROCEDURE|Videoscopic-Assisted Retroperitoneal Debridement (VARD)|
41373919|NCT03305926|OTHER|Conventional CVR programme|Programme in a CVR centre involving 20 sessions of reconditioning to effort, 3 times per week for roughly 7 weeks, as well as 14 sessions of therapeutic education in groups.
41373920|NCT03305926|OTHER|Connected CVR programme|First week in the CVR centre with 3 sessions combining reconditioning to effort, individual interviews and targeted therapeutic education, so as to define the objectives and methods of the connected CVR at home for the 6 following weeks.
41373921|NCT03305926|OTHER|Follow-up visit M2|Effort test and evaluation at the end of the CVR programme
40849677|NCT05463016|DEVICE|Color Correcting Lenses in Subjects with Normal Color Vision|Color Correcting Lenses
40849678|NCT00003066|DRUG|docetaxel|
40849679|NCT00003066|DRUG|estramustine phosphate sodium|
40849680|NCT00839761|DIETARY_SUPPLEMENT|iron fortified rice|
40849681|NCT00839761|DIETARY_SUPPLEMENT|iron drops|
40849682|NCT00366912|DEVICE|non-invasive ventilation|
40849683|NCT00695422|GENETIC|polymerase chain reaction|PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
40849684|NCT00695422|OTHER|cytology specimen collection procedure|Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
40849685|NCT00695422|OTHER|histological technique|Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
40849686|NCT00695422|PROCEDURE|colposcopic biopsy|Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
40849687|NCT02459678|BEHAVIORAL|Enhanced Adherence Package|The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
40849688|NCT02459678|OTHER|Standard of Care|Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
41373922|NCT03305926|OTHER|Follow-up vsit M8|Evaluation at 8 months following the CVR programme
41373923|NCT00732732|DIETARY_SUPPLEMENT|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
40849689|NCT02464514|OTHER|High carbohydrate meal|65% carbohydrate, 17% protein, and 18% fat
40849690|NCT02464514|OTHER|High fat meal|58% fat, 17% protein, and 25% carbohydrate
40849691|NCT04833595|BEHAVIORAL|Mindfulness practice|Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
40849692|NCT04407234|DRUG|Tirzepatide|Tirzepatide administered SC.
41373924|NCT00732732|OTHER|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
41373925|NCT04208061|DRUG|Dabigatran Etexilate|Participants will receive single dose of dabigatran etexilate orally.
41504743|NCT05277662|DIAGNOSTIC_TEST|cell and molecular diagnostics in accordance with functional test results|"Procedure: Anorectal manometry (ARM) Studies are performed in the left lateral position with the hips and knees of the subject flexed. Manometric sensor records circumferential pressure. The base of the rectal balloon attached to the ARM catheter is sited 3-5 cm above the upper border of the anal canal, to prevent the balloon impinging upon the anal canal during inflation. The most distal recording sensor is external to anal verge. If any pain or discomfort is experienced, the probe is immediately withdrawn.~Procedure: Rectal sensory test (RST) The test is also performed in the left lateral position with hips and knees flexed. Studies are conducted with either an integrated balloon on the manometric probe or with a separate system. Balloon capacity is no less than 400 mls and all components are latex-free. Insufflation is always performed with air. For ramp distension, the rate should be between 1 and 5 mL/s, and for phasic distension, inflation rate should be set at 10 mL/s (C1)."
40849693|NCT04407234|DRUG|Acetaminophen|Acetaminophen administered orally.
40849694|NCT05880173|DIAGNOSTIC_TEST|FIB4|"Diagnostic procedure :~FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography"
40849695|NCT03291860|PROCEDURE|Ovum retrievum|assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles
41163540|NCT06139159|OTHER|Outreach/navigator|"* Conduct outreach activities with people in the community who are hard to reach and with limited access to health care, conduct informal screening for symptoms of mental illnesses, encourage and refer individuals at-risk, suspected of having, or affected by mental health issues to clinics for triage.~* Document outreach, screening, and referral activities in LHW database"
41373926|NCT04208061|DRUG|DRV/COBI|Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).
40849696|NCT04010591|DEVICE|impedance measurement during urodynamic study|Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
41373927|NCT04208061|DRUG|Ritonavir|Participants will receive ritonavir orally.
41373928|NCT04208061|DRUG|Darunavir|Participants will receive Darunavir orally.
41373929|NCT01400607|BIOLOGICAL|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
41373930|NCT01400607|OTHER|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
41373931|NCT00942669|DEVICE|SleepStrip OTC(TM)|self contained SAS screening device
41373932|NCT02329951|PROCEDURE|Facet intervention|Diagnostic block of the nerves innervation the lumbar facet joint. If this block is positive (greater or equal to 50% relief), the participant will proceed to radiofrequency nerve ablation when the pain returns
41373933|NCT02329951|PROCEDURE|Sacroiliac joint injection|Injection of steroid and local anesthetic into SI joint
41373934|NCT02329951|PROCEDURE|Epidural steroid injection|Transforaminal or interlaminar injection of steroid epidurally
41373935|NCT00296777|DRUG|Escitalopram|8 weeks: up to 40 mg/day
41373936|NCT00296777|DRUG|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
41373937|NCT00296777|DRUG|Imipramine|"8 weeks: up to 300mg/day~\*if patient does not have contraindication."
41373938|NCT00071006|DRUG|AG-013736 (Axitinib)|patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
41373939|NCT06484816|DRUG|TGRX-1942|At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).
41373940|NCT05903781|DIAGNOSTIC_TEST|Prostate MRI|MRI of the prostate
41373941|NCT00100282|DRUG|PPI-1019 (APAN)|
40849697|NCT02913495|DRUG|Vaginal Progesterone|
40849698|NCT02913495|DRUG|Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)|
40849699|NCT03399474|DRUG|Lidocaine Hydrochloride 2%|Lidocaine Hydrochloride 2%
40849700|NCT03399474|DRUG|Dexmedetomidine 0.5 ug/kg|pecedex
40849701|NCT03399474|DRUG|Dexmedetomidine Injection 0.25 ug/kg|pecedex
40849702|NCT02537184|PROCEDURE|Oral Clinical conditions|caries incidence assessment dental anxiety assessment
40849703|NCT06260553|DRUG|tislelizumab and metronomic oral vinorelbine|tislelizumab 200mg intravenous drip once every three weeks; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
40849704|NCT01971385|DRUG|Squaric Acid solution|
40849705|NCT01971385|DRUG|Placebo solution|
40849706|NCT00861471|DRUG|Docetaxel|"One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days."
40849707|NCT00861471|DRUG|Imatinib Mesylate|"One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days."
40849708|NCT01616368|BEHAVIORAL|Mindful Eating and Living Course|An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
40849709|NCT01813448|DRUG|Fidaxomicin|oral
41373942|NCT02614352|DRUG|Atorvastatin + Candesartan|
41373943|NCT02614352|DRUG|AG1502|
41373944|NCT05890235|DRUG|Ningmitai Capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
41373945|NCT05890235|DRUG|Tamsulosin Hydrochloride|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
41373946|NCT03585595|OTHER|Blood pressure lowering strategy|The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
41373947|NCT02800317|PROCEDURE|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
41504744|NCT02379572|DEVICE|iMRI-guided surgery|For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
41504745|NCT02379572|DRUG|5-ALA-guided surgery|For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
41504746|NCT01898273|DRUG|I-124-CLR1404|single-dose, intravenous
40849710|NCT01813448|DRUG|Placebo|oral
40849711|NCT02808468|BEHAVIORAL|Brief Cognitive Therapy|Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
40849712|NCT01189643|DRUG|irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator|Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
40849713|NCT01942070|DEVICE|Bioresorbable vascular scaffold|
40849714|NCT01942070|DEVICE|Durable polymer everolimus-eluting metallic stent|
40849715|NCT00828750|DRUG|Eltrombopag oral tablets|Eltrombopag oral tablets once daily
40849716|NCT00064792|DRUG|Simvastatin Susp.|During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
41504747|NCT05465109|OTHER|TBI-AD/ADRD Caregiver Support Intervention (TACSI)|The TBI-AD/ADRD Caregiver Support Intervention (TACSI) incorporates psychosocial and psychoeducational approaches with the objective of: a) identifying stressors associated with caregiving for family members who have the dual diagnosis of traumatic brain injury and dementia; and b) supporting caregivers in developing more effective coping and communication strategies as well as enhanced caregiving self-efficacy. This intervention offers individual and family coaching and knowledge and skills to help manage stress and reduce caregiver burden.
41373948|NCT04957628|BEHAVIORAL|Harmful alcohol use treatment|Patients identified through routine hospital screening as having a potentially harmful alcohol use (AUDIT-C 4-6 points (men) / 3-5 points (women) will receive information about the possible harmful effects of their drinking and will be advised to reduce their consumption. Patients identified with more excessive drinking patterns (AUDIT-C \> 6 (men) / \> 5 (women) will be assessed with blood sample analysis of relevant alcohol biomarkers, psychological assessments for alcohol addiction and withdrawal symptoms, and if necessary referral to alcohol addiction treatment. Patients with severe withdrawal symptoms will be put in CIWA-Ar observation.
41373949|NCT04957628|BEHAVIORAL|Non-prescribed psychoactive medicinal use treatment|Patients with prescription on psychoactive medicinal drugs are pharmacologically assessed using serum sample analysis. Patients identified with discrepancy in prescribed doses and serum concentrations will have doses adjusted, or be referred to addiction treatment. Patients identified with psychoactive medicinal drugs other than those prescribed will be advised to quit those medications, or be referred to addiction treatment.
41504748|NCT04495335|DEVICE|photobiomodulation|Laser treatment will complete using Gallium-Aluminum-Arsenide (GaA1As) diode laser and application will complete by laser energy immediately and three times a week for just 15 days after surgery.
41504749|NCT04096040|DEVICE|μCor|μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.
40849717|NCT00064792|DRUG|OraPlus|During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
40849718|NCT00250276|BIOLOGICAL|Cervarix™|GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
41163541|NCT06139159|OTHER|Auxiliary to care|"* Arrange consultation for those at-risk, suspected, or affected individuals at clinics for triage.~* Introduce the patient to the clinical team via a warm hand-off and assist in scheduling a follow -up visit.~* Reviews care plan with patient and help reduce patient and system barriers impeding psychological wellbeing~* Support patients in achieving management goals; help patients address barriers through education, referral, and navigation to ancillary community services (SAVAME, legal, housing, economic, etc);~* Engage, activate, and empower patients to participate in the care process~* Frequent contact with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Assist with group sessions: affinity groups~* Identify community-based resources.~* Document outreach, screening, referral, and auxiliary care activities in LHW database"
41163542|NCT06139159|OTHER|Stepped care and task shifting|"* Support counselling initiated by the psychologist~* Reinforce patient education about depression, anxiety, trauma, and other syndemic conditions.~* Work with patients' families and peers to reduce stigma, address syndemic factors and social conditions.~* Contact frequency with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Co-lead group sessions: affinity groups~* Provide Mental Health First Aid to members of the community.~* Document outreach, screening, referral, auxiliary and stepped care activities in LHW database"
41163543|NCT04276636|DRUG|Caltrate Pill|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
41163544|NCT04335370|OTHER|Blood Draw|"Blood samples will be collected from enrolled patients at 5 time points during a single dosing interval:~1. Prior to start of infusion~2. End of infusion~3. One hour after end of infusion~4. Three hours after end of infusion~5. Eight hours after start of infusion"
41163545|NCT00932659|DEVICE|continuous cardiac monitoring device (REVEAL, Medtronic)|hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
41163546|NCT05193500|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
41504750|NCT04639804|DRUG|Tegoprazan|Tegoprazan 50 mg tablet
41504751|NCT04639804|DRUG|Naproxen|Naproxen 500 mg tablet
41163547|NCT05193500|BEHAVIORAL|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
41504752|NCT04639804|DRUG|Aceclofenac|Aceclofenac 100 mg tablet
41504753|NCT04639804|DRUG|Celecoxib|Celecoxib 200 mg capsule
41504754|NCT04397263|DRUG|Guselkumab|Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
41504755|NCT00138554|DRUG|vildagliptin|
41163548|NCT02172950|BIOLOGICAL|rVIII-SingleChain|Recombinant single-chain coagulation factor VIII
41504756|NCT00138554|DRUG|pioglitazone|pioglitazone 45 mg qd
41032351|NCT03073889|PROCEDURE|Scalp infiltration|Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
41032352|NCT03073889|DRUG|Ropivacaine|
41032353|NCT02455245|DRUG|Carboplatin|
41032354|NCT02455245|DRUG|Vincristine|
41032355|NCT05907668|DRUG|IMVT-1401 (batoclimab)|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
41032356|NCT03789422|DRUG|association of levocetirizine and tranexamic acid|levocetirizine 10 mg/day + tranexamic acid 2 g/day
41032357|NCT03789422|DRUG|Levocetirizine only|levocetirizine 20 mg/day
41373950|NCT00280839|DRUG|Topiramate|
41373951|NCT00280839|DRUG|Placebo|
41504757|NCT05912166|BEHAVIORAL|Wakeful Spanish|"Wakeful Spanish is the Spanish-language version of Wakeful, a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs. Wakeful makes one new class available to users each week for 9 weeks. Users receive weekly email notifications from Wakeful informing them when a new class is available. Estimated class duration is 1-1.5 hours.~With Wakeful, users can -~1. Write what they observed during meditations.~2. Be guided by videos/audios through breathing exercises and gentle stretching.~3. See what others experienced and their tips for overcoming challenges.~4. Access videos/audios that explain how mindfulness benefits the body and mind.~5. Receive suggestions on meditations to do during the week~6. Set an intention for the week based on class content."
41504758|NCT00516373|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
41504759|NCT06163391|DRUG|SOT201|intravenous infusion
41504760|NCT02353910|PROCEDURE|Ultrasound|
41504761|NCT02123446|DRUG|Cephalexin|Administered orally.
41504762|NCT05013437|DRUG|Evomela|16 mg/m\^2 Evomela administered one time via a central line
41504763|NCT05013437|DEVICE|Next Generation Sequencing|Next Generation Sequencing
41504764|NCT05013437|DRUG|Prochlorperazine|10mg once intravenous (IV) within 30 minutes before Evomela
41504765|NCT05013437|DRUG|Acetaminophen|650 mg once orally within 30 minutes before Evomela
40849719|NCT05669651|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from healthy people's feces into patients' intestines to rebuild new intestinal flora and achieve the treatment of intestinal and parenteral diseases. In this study, 100 patients with recurrent hepatic encephalopathy were randomly divided into 1:1 groups to receive FMT with different amounts of bacteria, observe the therapeutic effect and adverse reactions of hepatic encephalopathy, and evaluate the effectiveness and safety of the two groups of patients. At the same time, the blood and stool samples of patients with recurrent hepatic encephalopathy before and after FMT were collected clinically, the composition of bile acid and other metabolites in stool and serum samples was analyzed, and the effective core flora was identified to clarify the mechanism of intestinal bacteria transplantation for the treatment of recurrent hepatic encephalopathy.
40849720|NCT05278832|DRUG|QLS31905|QLS31905 injection
40849721|NCT04542031|OTHER|Questionnaire|Questionnaire to be completed at 6 and 12 months
40849722|NCT03878303|DRUG|AC0058TA|25 mg capsules
40849723|NCT03878303|DRUG|Placebo AC0058TA|equivalent dose of investigational product
41373952|NCT03349203|DRUG|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day by mouth for 8 weeks as neoadjuvant therapy before surgery and 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
41373953|NCT03329404|DEVICE|Mirasol Red Blood Cells (MIR RBCs)|Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.
41373954|NCT03329404|DEVICE|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
41504766|NCT05013437|DRUG|Diphenhydramine|50 mg once intravenously within 30 minutes before Evomela
41504767|NCT05634408|DEVICE|ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management (A1D)|TEST Lens
41504768|NCT03295682|DEVICE|Endovascular thoracoabdominal aneurysm repair|Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries
41504769|NCT06132932|DRUG|WX390|Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
41504770|NCT04113785|DEVICE|Klassic Knee System|At present, all TKA available for surgeons to use are asymmetric where there is a distinct femoral and tibial component for the left knee and a distinct femoral and tibial component for the right knee. The Klassic knee system is a symmetrical knee implant, where the same femoral and same tibial component can be used for either the right or left knee
41504771|NCT01119781|DRUG|BIIB017(peginterferon beta-1a)|peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
41504772|NCT00131495|DRUG|Testosterone (transdermal patches)|Testosterone patch (300mcg/day, changed twice a week for one year
41504773|NCT00131495|DRUG|Placebo patch|placebo patch changed twice a week for one year
41504774|NCT03532373|OTHER|Preference Elicitation tool|A preference elicitation tool for carpal tunnel syndrome
41504775|NCT02279108|DRUG|indocyanine green|One injection, 2.5 milligrams per patient, intradermal use
40849724|NCT03167021|OTHER|Survey|This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
40849725|NCT01496820|DIETARY_SUPPLEMENT|GO2KA1|GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks
40849726|NCT01496820|DIETARY_SUPPLEMENT|Placebo|placebo 1500mg/day for 12weeks
41032358|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
41373955|NCT00690846|DRUG|adalimumab|40 mg weekly adalimumab injection.
41373956|NCT02313246|BEHAVIORAL|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
41032359|NCT01306162|DRUG|Dabigatran etexilate|150 mg as single dose
41163549|NCT01232569|DRUG|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
41163550|NCT01232569|DRUG|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
41032360|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
41373957|NCT00993941|PROCEDURE|Autologous BMSCs transplantation|10 ml autologous BMSCs(7\~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
41373958|NCT00993941|DRUG|Conserved therapy|Oral or intravenous administration
41373959|NCT04125082|DRUG|Afrezza Inhalant Product|Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
41504776|NCT02279108|DRUG|isotope|One injection, 20 MBq techntium99, intradermal use
41504777|NCT05890534|DRUG|Pycnogenol®|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
41504778|NCT05890534|DRUG|Placebo|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
41504779|NCT04049136|DIAGNOSTIC_TEST|NT-proBNP|Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.
41504780|NCT03981913|BEHAVIORAL|Simon Task with high-density EEG recording|"The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected."
41504781|NCT01404078|DRUG|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
41504782|NCT01404078|DRUG|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
41504783|NCT03414476|OTHER|Hair follicles sampling|The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath
41032361|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
41032362|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
41163551|NCT02004132|DRUG|Axiron|Solution administered topically using pump and applicator
41163552|NCT06230133|BEHAVIORAL|MBSR intervention|In our study, it is the same to arm description.
41163553|NCT01031186|DRUG|GSK356278|GSK356278
41163554|NCT01031186|DRUG|PLACEBO|PLACEBO
41163555|NCT01165164|OTHER|FID 115958D (lubricant eye drop)|1 drop in each eye at bedtime
41163556|NCT00000236|DRUG|Buprenorphine/naloxone|
41163557|NCT02150083|PROCEDURE|OR retrograde fill|
41163558|NCT02603861|DRUG|LY3154207|LY3154207 administered orally.
41163559|NCT02603861|DRUG|Placebo|Placebo administered orally.
41373960|NCT04088617|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.
41373961|NCT04088617|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
41504784|NCT05753995|DIAGNOSTIC_TEST|PET imaging|The evaluation of PET imaging using PET ligand \[18F\]JNJ-64413739 or a \[18F\] labeled equivalent in vivo in patients.
41373962|NCT04739202|DRUG|Atezolizumab + Ipatasertib|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
41373963|NCT04739202|DRUG|Atezolizumab + Bevacizumab|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
41032363|NCT00329277|PROCEDURE|perimetry|
41032364|NCT05904847|BEHAVIORAL|Application of The Theory of Planned Behaviour for Diabetes|In the study, diabetes education consisting of a total of 4 sessions structured according to the Planned Behavior Theory will be applied to the intervention group, and a standard diabetes education consisting of a single session containing information about diabetes on the website of the Ministry of Health will be applied to the control group. The training will be given face-to-face in groups of 10-15 people. After the training, the participants will be monitored for 3 months. To increase patient empowerment and self-efficacy, the intervention group will be followed up by phone calls every 15 days to increase motivation and answer questions.
41032365|NCT04933747|DRUG|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants
41032366|NCT04933747|DRUG|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
41032367|NCT02640729|DRUG|Nelotanserin|once daily, oral, 20-mg tablets
41032368|NCT02640729|DRUG|Placebo|once daily, oral, matching tablets
41032369|NCT00841867|PROCEDURE|All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.|All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
41032370|NCT02732535|PROCEDURE|sleeve gastrectomy , roux-en-y gastric bypass|laparoscopic sleeve gastrectomy or laparoscopic gastric bypass
41032371|NCT01086657|BIOLOGICAL|VRC-AVIDNA036-00-VP|H5 DNA Vaccine
41032372|NCT01086657|BIOLOGICAL|Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine|Inactive H5N1 Vaccine
41032373|NCT06393062|DIAGNOSTIC_TEST|Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.|Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.
41163560|NCT02603861|DRUG|Modafinil|Modafinil administered orally.
41163561|NCT01357447|DRUG|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
41163562|NCT01357447|DRUG|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
41163563|NCT03888261|BEHAVIORAL|Mind-Body Approaches for Medical Conditions|"The intervention programme of the present trial is delivered in a group-based format (15 participants per group) and overall applies three therapeutic components:~1. Contemplative practices~2. Psychoeducation~3. Dialogue, including therapist-group dialogue as well as participant-participant dialogue."
41373964|NCT01891136|DRUG|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
41373965|NCT03096106|DEVICE||the investigators just observe the pressure time curve on the ventilation
41373966|NCT01527331|BEHAVIORAL|video decision aid|cpr video decision aid
41373967|NCT05100277|GENETIC|Oncotype DX® Assay|After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.
41032374|NCT00637221|DRUG|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
41032375|NCT01971398|BEHAVIORAL|Positive FASD education brochure|Exposure to a positive FASD education brochure
41032376|NCT01971398|BEHAVIORAL|Negative FASD education brochure|Exposure to a negative FASD education brochure
41032377|NCT01971398|BEHAVIORAL|Active comparator (a general women's health brochure)|Exposure to a general women's health brochure
41032378|NCT06141642|DEVICE|Self-adaptive serious game|A self-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
41032379|NCT06141642|DEVICE|Non-adaptive serious game|A non-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
41373968|NCT05100277|OTHER|Cost|Changes in treatment costs were estimated from Pérola Byington Hospital.
41373969|NCT01855607|DRUG|topical menthol|7.5% Methylsalicylate / 2% Menthol Lotion
41373970|NCT01855607|DRUG|placebo lotion|The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
41032380|NCT05399498|DRUG|Psilocybin|Psilocybin 25mg capsule
41032381|NCT02637297|PROCEDURE|Hypnotherapy|Undergo hypnotherapy
41032382|NCT02637297|OTHER|Questionnaire Administration|Ancillary studies
41163564|NCT02646189|DRUG|REP 2139-Ca|REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
41163565|NCT02646189|DRUG|Zadaxin|Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
41163566|NCT02646189|DRUG|Pegasys|Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
41163567|NCT06423677|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|The Serratus Posterior Superior Intercostal Plane Block will be performed under ultrasound guidance. During the block, a linear ultrasound probe will be placed parallel to the spine of the scapula on the surgical side and then slid medially. The block needle will be advanced under ultrasound guidance over the 3rd rib. After the needle touches the rib, it will be withdrawn by 1mm, and the block site will be confirmed by injecting sterile 0.9% NaCl. Subsequently, patients will be administered 50mg of bupivacaine and 100mg of lidocaine in a controlled manner.
41373971|NCT01305694|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
41373972|NCT01722058|DRUG|Peptide application|
41373973|NCT05227534|DEVICE|OverC multi-cancer detection blood test|Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
41373974|NCT01716546|DRUG|Pazopanib|
41373975|NCT05263245|OTHER|Light breakfast|Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.
41032383|NCT06146010|OTHER|No intervention|Once the patient or their legal guardian has given their written consent, a patient is included in the leptomeningeal disease register. Due to the rapid course of the disease and potential rapid deterioration, the documentation of the course of the disease of the individual patients is to be carried out retrospectively from the data recorded during the course of the clinical routine for the entire duration of the study or until the death of the participating patients after the written consent of the patients. The registry's data sources are the diagnostic findings made at the center and doctors' letters from routine clinical practice. The participating centers carry out the assessment of the participants' performance status so that the patients do not have to complete any study-related questionnaires.
41032384|NCT04266977|DRUG|Dexamethasone|restrictive use of DEX, based on standardized clinical and radiological criteria.
41032385|NCT02685254|BEHAVIORAL|Structural skills training group|Weekly 2-hours sessions for 14 weeks follow the Norwegian translation of the Swedish version of the ADHD skills training manual/workbook (Hesslinger 2010; Hirvikoski 2011; Morgensterns 2015) which is based on an adaption of Marsha Linehan's dialectical behavior therapy (DBT) for borderline personality disorder into a group-based skills training program for adults with ADHD (Hesslinger 2002; Philipsen 2007). The groups embrace 7 - 10 participants, and two group leaders trained in group therapy, cognitive-behavioral treatment or DBT. Each session contains an initial short repetition and feedback on the previous session, followed by review of the homework during the first hour. After a break, a new topic with exercises and homework for the following week is introduced.
41032386|NCT02685254|OTHER|Treatment as usual|Treatment as usual includes clinical management and/or medication, and or supportive counselling by physician or nurse
41032387|NCT01910519|BIOLOGICAL|H5N1 vaccine plus AS03 adjuvant|"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart."
41373976|NCT04357756|DRUG|YH001|YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
41032388|NCT01910519|BIOLOGICAL|H5N1 vaccine without adjuvant|"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart."
41032389|NCT02775383|OTHER|Therapeutic|Observational Study
41032390|NCT01564225|DRUG|EDI200|Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
41032391|NCT03119766|DRUG|Kolofort|Oral administration
41373977|NCT04357756|DRUG|Toripalimab|Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
41373978|NCT06097416|DRUG|Neoadjuvant Chemoradiotherapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period."
41032392|NCT03119766|DRUG|Placebo|Oral administration
41032393|NCT01175668|DRUG|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores \<8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
41373979|NCT06097416|DRUG|Total Neoadjuvant Therapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane with an oxalate ligand as a leaving group. Platinum content is 48.1% to 50.1%.~All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery."
41032394|NCT01175668|DRUG|Phenobarbital|"Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.~NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores."
41032395|NCT02132611|DEVICE|Diamondback 360® Coronary OAS Micro Crown|The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
41163568|NCT06423677|DEVICE|patient controlled analgesia|intravenous patient-controlled analgesia (PCA) with 4mg/ml Tramadol HCl in 100ml NaCl. There will be no basal infusion, with bolus doses of 20mg and a lockout period of 20 minutes, and a total dose limitation of 200mg over 4 hours
41163569|NCT02731456|OTHER|altitude exposure|altitude exposure
41163570|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
41163571|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
41163572|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
41163573|NCT04171921|PROCEDURE|Robotic ventral hernia repair|Laparoscopic robotically assisted trans-abdominal pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
41373980|NCT06363227|PROCEDURE|Standardized pain management|multimodal postoperative pain protocol
41373981|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort|For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
41373982|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort|For treatment of stenosis in the AV circuit
41373983|NCT02586909|DRUG|RVT-101 35 mg tablets|once daily, oral tablets
41383535|NCT02964910|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
41032396|NCT05071001|PROCEDURE|MRI|"This assessment will be planned in the year after the consent signAll patients will have one brain MRI performed in Henri Mondor Hospital on a 3T MR unit (Skyra, Siemens, Erlangen). The procedure will include:~1. a 3D-FLAIR imaging~2. a morphometric study based on a 3DT1 MPRAGE gradient echo sequence (TR / TI / TE = 2300/900 /2.9 ms)~3. an analysis of the anatomic connectivity of the patient's brain assessed using a 1.5mm isotopic DTI with a high number of directions (HARDI / 65 directions / b=1500s/mm2).~4. An evaluation of neuronal dysfunction using MR Spectroscopy. Spectroscopic data will be collected using a 2D CSI laser with a short TE technique.~5. Magnetization transfer imaging providing information about integrity of membranes."
41032397|NCT04812353|OTHER|Follow-up of Io-Fix type fixation|Follow-up of patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
41032398|NCT01404312|DRUG|Rifapentine (RPT)|"RPT dosing was be based on participants' weight:~Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets).~Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets).~Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets)."
41032399|NCT01404312|DRUG|Isoniazid (INH)|Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
41032400|NCT01404312|DIETARY_SUPPLEMENT|Pyridoxine (Vitamin B6)|"Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH."
41032401|NCT01385059|DRUG|axitinib|Given PO
41032402|NCT01385059|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy and pelvic lymph node dissection
41032403|NCT01385059|OTHER|enzyme-linked immunosorbent assay|Correlative studies
41032404|NCT01385059|OTHER|laboratory biomarker analysis|Correlative studies
41032405|NCT04838301|DRUG|Allopregnanolone|Allopregnanolone 4mg IV via 30-minute infusion, once per week.
41032406|NCT04838301|OTHER|Placebo|Normal saline solution IV via 30-minute infusion, once per week
41032407|NCT04122417|OTHER|The Effect Of Therapeutic Touch Training Given To Mothers With Preterm Babies On Attachment Level And The Responses The Baby|The study was carried out as randomized experiment to determine the effect of Yakson or Gentle Human Touch method practiced by mothers to preterm newborns on the maternal attachment level and the baby's responses.
41032408|NCT06081660|BEHAVIORAL|ACP-I Plan|ACP-I Plan consisting of education, counseling, decisional support, and patient navigation
41032409|NCT02910622|OTHER|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
41032410|NCT03331120|DEVICE|ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)|Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
41032411|NCT06227000|BEHAVIORAL|Living Longer and Stronger with SCI|Study staff will schedule a brief zoom training session with each person assigned to the intervention to ensure that they are able to download and use the Zoom platform. Once a weekly session day and time has been determined the 8-week LLS intervention program will begin. LLS group participants will participate in 2-hour weekly sessions co-facilitated by a study investigator and one of the study's senior advisors. Participants will be encouraged to set a health-oriented goal and complete weekly action plans. They will be provided with materials each week with health-related information and resources. Participants will also be asked to complete a short survey each week to rate the session. After completing the 8 sessions, a link to the post-test survey and some questions to evaluate the LLS program will be sent to the participants. Finally there will be follow up survey to be completed at 4 months post intervention.
41163574|NCT04171921|PROCEDURE|Open ventral hernia repair|Standard open pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
41373984|NCT02054507|BEHAVIORAL|Cognitive evaluation (Wechsler IV tests)|Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
41373985|NCT03742869|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
41373986|NCT01852669|PROCEDURE|Inversion|Patients inverted 30 degree head down in Trendelenburg position
41373987|NCT01852669|PROCEDURE|Shock Wave Lithotripsy|Shock wave lithotripsy
41373988|NCT01852669|DRUG|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
41373989|NCT00934518|RADIATION|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
41373990|NCT00934518|DRUG|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
41373991|NCT03296397|BIOLOGICAL|Vaccination with Gardasil|Vaccination with Gardasil in patients apparently cured of external genital warts
41373992|NCT03296397|BIOLOGICAL|Injection of Normal Saline|Injection of Normal Saline in patients apparently cured of external genital warts
41383536|NCT05919771|OTHER|rock climbing|Vertical ascent of a surface specifically designed to elicit the skills that might be required to scale a naturally occurring rock formation
41373993|NCT06127862|OTHER|Education group|Students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals.
41032412|NCT06227000|BEHAVIORAL|Control|Participants will be sent links to the three surveys at the same time as those assigned to the LLS group but they will not attend any of the zoom calls. They will be offered all study materials at the end of the study.
41504785|NCT00852722|OTHER|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
41032413|NCT01968213|DRUG|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
41032414|NCT01968213|DRUG|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
41032415|NCT04712526|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
41032416|NCT05284968|DRUG|Cell injection|All subjects will be treated with cell injection
41032417|NCT03152747|DEVICE|ultrasound, b-scan|Some selected centres will participate in a substudy. In the substudy population, if the vitreous cortex is not visible on OCT both in the study eye and the fellow eye, or if the OCT is of poor quality and most likely will not allow definite diagnosis, a B-scan ophthalmic ultrasound will be performed by an experienced examiner. The presence or absence of a PVD in the ultrasound measurement will be recorded in the case report form (CRF). If ultrasonography was not performed, allocation to the groups is based on the staging of the reading centre. Otherwise ultrasonography will be used for final diagnosis and group allocation if the reading centre classifies the OCT as not decisive.
41504786|NCT01403857|OTHER|Whole grain foods|Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
41504787|NCT01403857|OTHER|Refined grains|Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
41163575|NCT03191214|DEVICE|Intraoperative Forced Air Warming|As part of their standard care, patients undergoing surgery \>30 min in duration will receive forced air warming in the form of a Bair Hugger. This is a blanket covering their upper torso and arms into which warm air is blown.
41373994|NCT06127862|OTHER|No training was given|No training was given
41373995|NCT02424357|DRUG|5%povidone iodine ophthalmic solution|one drop of 5% povidone iodine instilled into the conjunctival fornix.
41373996|NCT02424357|DRUG|routine post-operative ophthalmic ointment|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
41504788|NCT00511823|DRUG|casopitant|The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
41504789|NCT00511823|DRUG|dolasetron|The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
41032418|NCT03778294|PROCEDURE|Computed Tomography|Undergo PET/CT
41373997|NCT03264573|BIOLOGICAL|Stem cell|after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells
41373998|NCT03264573|DEVICE|MSCs|manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
41373999|NCT01092676|DRUG|Ibuprofen Regular Dosing|Regular dosing
41504790|NCT00511823|DRUG|granisetron|The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
41032419|NCT03778294|OTHER|Fluorodopa F 18|Given IV
41032420|NCT03778294|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
41374000|NCT01092676|DRUG|PRN dosing Ibuprofen|PRN dosing Ibupofen
41374001|NCT06167759|OTHER|Opioid Use Agreement|This was previously developed specifically for surgical patients using a modified Delphi method with a group of experts (including surgeons, nurses, advanced practices providers, quality improvement experts, and patients).
41504791|NCT00511823|DRUG|rosiglitazone|The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
41504792|NCT04821622|DRUG|talazoparib plus enzalutamide|experimental arm
41504793|NCT04821622|DRUG|Placebo plus enzalutamide|Active comparator arm
41504794|NCT06413511|BIOLOGICAL|Belantamab|Belantamab will be administered.
41504795|NCT00549744|DRUG|GSK256066|
41032421|NCT03778294|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
41032422|NCT03778294|RADIATION|Proton Beam Radiation Therapy|Receive proton beam RT
41032423|NCT03778294|OTHER|Quality-of-Life Assessment|Ancillary studies
41032424|NCT03778294|OTHER|Questionnaire Administration|Ancillary studies
41032425|NCT03778294|DRUG|Temozolomide|Drug
41032426|NCT00762125|BEHAVIORAL|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
41032427|NCT00762125|BEHAVIORAL|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
41032428|NCT00762125|BEHAVIORAL|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
41032429|NCT02094703|DRUG|Levofloxacin|
41032430|NCT02094703|DRUG|Solifenacin succinate|
41032431|NCT02094703|DRUG|Placebo (for Solifenacin succinate)|
41504796|NCT04275986|PROCEDURE|Intensity modulated radiotherapy (IMRT)|Intensity-modulated radiation therapy (IMRT) with a total dose of 45Gy in 25 fractions
41374002|NCT06505473|BEHAVIORAL|music-CBT|notched relaxation music combined with personalized CBT
41374003|NCT00083356|PROCEDURE|Wisdom tooth extraction|
41374004|NCT06149494|DRUG|Vapendavir|Participants randomized to the experimental cohort will be administered Vapendavir.
41374005|NCT06149494|DRUG|Placebo|Participants randomized to the placebo cohort will be administered placebo.
41374006|NCT04105465|DEVICE|PlasmaJet|The PlasmaJet device is used following groin node dissection on the side randomised to receive it as per protocol specifications
41374007|NCT03256591|OTHER|HBB facilitators with simulation training|HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
41374008|NCT00960648|DEVICE|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
41374009|NCT00960648|DEVICE|Cypher|Retrospective historical controls that received sirolimus-eluting stent
41374010|NCT00779142|DRUG|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
41374011|NCT02340117|GENETIC|SGT-53|The dose of SGT-53 will be 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 2.4 mg, 1.2 mg or 0.6 mg DNA per infusion in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
41374012|NCT02340117|DRUG|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.
41374013|NCT02340117|DRUG|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
41374014|NCT05075551|DEVICE|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL23 is in the sacral region, in the second posterior sacral foramen; BL54 is in the fourth posterior sacral foramen, 3 cun beside the median sacral crest; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
41374015|NCT05075551|DEVICE|Sham acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.These volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23 and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35).The same equipment of fMRI scanner will be used.
41374016|NCT05075551|OTHER|fMRI scan|Both two group will get fMRI scan week 0 (before treatment), week 12 (after treatment) and week 36 (following up). The resting-state fMRI data will be obtained by using a 3.0T GE MR 750 MRI scanner with an eight-channel phase array head coil at the Huashan Hospital, Shanghai. The high resolution T1-weighted magnetic resonance images will be collected by a three-dimensional fast spoiled gradient-echo dual-echo sequence \[repetition time (TR) = 8100 ms; echo time (TE) = 3.1 ms; FA = 8 deg; matrix=256 × 256; field of view (FOV)=25.6× 25.6 cm2; slice thickness=1 mm; no gap and 156 slices\]. The whole resting state fMRI data will be acquired by using a gradient-recalled echo-planar imaging pulse sequence (TR/TE = 2,000/30 ms; FA = 90°; acquisition matrix = 64×64; FOV = 22×22 cm2; slice thickness= 4 mm; 43 slices and total 240 time points; no gap).
41374017|NCT00548340|DRUG|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
41504797|NCT04275986|DRUG|Chemotherapy|Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks
41504798|NCT00122759|DRUG|ketamine|
41504799|NCT00878176|PROCEDURE|First stage tined lead procedure|bilateral first stage tined lead placement
41504800|NCT02460679|DRUG|EPI-589|An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
41374018|NCT00548340|DRUG|Placebo|Placebo capsules, PO daily for five weeks
41374019|NCT00548340|DRUG|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
41504801|NCT01377012|BIOLOGICAL|Secukinumab (AIN457)|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
41504802|NCT01377012|BIOLOGICAL|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
41504803|NCT05848947|DRUG|99mTc-Macro Albumin Aggregate|Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.
41163576|NCT00141713|DRUG|Etanercept|Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
41374020|NCT02315651|DIETARY_SUPPLEMENT|Coenzyme Q10|A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
41374021|NCT02315651|DIETARY_SUPPLEMENT|Placebo|A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
41504804|NCT01114607|DRUG|GSK1605786 ChemoCentryx: formulation A|ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
41504805|NCT01114607|DRUG|GSK1605786 GSK: formulation B|GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
41504806|NCT01114607|DRUG|GSK1605786 GSK direct-fill: formulation C|GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
41374022|NCT02539472|OTHER|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
41374023|NCT01583699|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
41374024|NCT01583699|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
41374025|NCT03962751|BEHAVIORAL|Simultaneous Post Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
41032432|NCT00982462|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
41032433|NCT00982462|DIETARY_SUPPLEMENT|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
41032434|NCT05996068|DEVICE|arterial line|insert arterial line for patients who meet major trauma criteria
41504807|NCT01114607|DRUG|GSK1605786 GSK modified-process: formulation D|GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
41504808|NCT01114607|DRUG|GSK1605786 GSK tablet: formulation E|GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
41504809|NCT04528407|OTHER|Observation without intervention|This study is a follow-up study without intervention.
41504810|NCT04233996|DRUG|Piperacillin-Tazobactam 4 g-0.5 g|Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h
41032435|NCT03859323|DRUG|SHP681|Participants will receive SC injection of SHP681 in the abdomen.
41032436|NCT03859323|OTHER|Placebo|Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
41504811|NCT04233996|DRUG|Cefepime 2000 mg|Patients with FN who required empirical treatment with cefepime 2g/8h
41163577|NCT02210611|PROCEDURE|Intrauterine Insemination 36 hours|Intrauterine insemination 36 hours after ovulation induction
41504812|NCT04233996|DRUG|Meropenem 1000 mg|Patients with FN who required empirical treatment with meropenem 1g/8h
41504813|NCT05323279|DEVICE|artificial intelligence assistance system|The artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed and feedback the overspeed percentage.
41374026|NCT03962751|BEHAVIORAL|Sequential Post Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
41163578|NCT02210611|PROCEDURE|Intrauterine Insemination 42 hours|Intrauterine insemination 42 hours after ovulation induction
41163579|NCT01412632|DRUG|Remifentanil, propofol and citanest|iv remifentanil iv propofol im citanest
41163580|NCT00866827|OTHER|Protocols for Treatment|Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.
41504814|NCT04473066|PROCEDURE|Adenotonsillectomoy +/- turbinate reduction|Tonsillectomies were performed by bipolar electrocautery while adenoidectomies were done by monopolar suction diathermy. Turbinate reduction (by either submucosal bipolar diathermy or radiofrequency) would be offered if the subject had on-going history of allergic rhinitis and examination revealed at least grade II turbinate hypertrophy. (Grade I = no turbinate hypertrophy; Grade II = turbinate hypertrophy without touching the septum; Grade III = turbinate hypertrophy touching the septum).
41504815|NCT06469502|PROCEDURE|Stretching Exercises|Group 1 will be included in the program consisting of stretching exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of stretching exercises (3 times a week) under the supervision of a physiotherapist.
41163581|NCT03092245|DRUG|OctaplasLG|OctaplasLG is given as an infusion when resuscitation fluids are required.
41374027|NCT03962751|BEHAVIORAL|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking event
41374028|NCT00161031|DRUG|Atomoxetine|
41374029|NCT04061837|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
41374030|NCT04895904|OTHER|No intervention|Our study is an observational study and the main purpose of our study is to observe the efficacy of endoscopic hemostasis and drug therapy
41374031|NCT02224794|DEVICE|Ovation® Abdominal Stent Graft Platform|
41374032|NCT03693235|PROCEDURE|bending angle of a lightwand|For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
41032437|NCT05004623|DEVICE|Sentinel Lymph Node Biopsy|Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.
41032438|NCT03340051|BEHAVIORAL|Episodic Future Thinking (EFT)|EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
41032439|NCT03340051|BEHAVIORAL|Episodic Recent Thinking (ERT)|ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
41032440|NCT02909777|DRUG|CUDC-907|
41032441|NCT04419493|DRUG|Alteplase (from modified manufacturing process)|Alteplase, TPA-05
41032442|NCT04419493|DRUG|Alteplase (from current manufacturing process)|Alteplase, TPA-02
41032443|NCT04419493|DRUG|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
41032444|NCT00687037|DRUG|Cetylpyridinium chloride|
41032445|NCT05372445|BEHAVIORAL|Non-intensive intervention|"After an evaluation of 7 day initial food-recall, subjects will receive counseling in order to improve their dietary habits, according to the American Diabetes Association 2019 Guidelines. The goals of this intervention are (i) achieve a caloric restriction of 500 kcal from their habitual energy intake, (ii) prioritize natural, minimally processed foods with a low glycemic index and glycemic load, (iii) eat lean protein sources, both from plant and animal origin and (iv) gradual increments of fiber intake, to achieve at least the minimum recommendations for the general population.~The frequency of the follow-up appointments will be every 4 weeks, alternating between a clinical control and nutritional one. Therefore, the planned nutritional follow-up frequency will be every 2 months. In these appointments, the objective will be to achieve the mentioned energy intake reduction of 500 kcal, aiming to the nutritional goals previously mentioned, with the aid of the food-recalls."
41032446|NCT05372445|BEHAVIORAL|Intensive intervention|"People will have virtual education with food and nutrition coaching workshops, as well as weekly meetings in small groups as a support and follow-up groups. The frequency of the face-to-face follow-up appointments will be every 3 weeks.~The nutritional intervention will emphasize the consumption of mainly minimally processed food from plant origin. A vitamin b12 supplement per week will be provided. This intervention group will have 2 stages. First stage will have a duration of 3 months setting the nutritional bases going to a plant-based diet with basic considerations regarding fiber intake reducing meat consumption, and incorporating protein from vegetable sources, among other considerations. Second stage will progress to higher levels of fiber and others nutritional requeriments in order to intensify the nutritional plant-based intervention."
41163582|NCT03092245|DRUG|Ringer-Acetate|Ringer-acetate is given as an infusion when resuscitation fluids are required.
41374033|NCT02767908|OTHER|Intervention|Participants will receive a tailored support package which will include; Nicotine replacement products, behavioural support, including telephone support, Carbon dioxide measurements, home air quality measurements, signposting to support groups, and self-help materials.For participants who decline a home visit, the above support options will be offered as far as possible through telephone contact and delivered to the extent accepted by the participant. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation.
41374034|NCT02751658|OTHER|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
41374035|NCT01046175|PROCEDURE|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
41504816|NCT06469502|PROCEDURE|Strengthening Exercises|Group 2 will be included in the program consisting of strengthening exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of strengthening exercises (3 times a week) under the supervision of a physiotherapist.
41374036|NCT01046175|PROCEDURE|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
41374037|NCT05547516|DRUG|Standard infusion chemotherapy|standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50mL normal saline or glucose, intravesical infusion chemotherapy, retained for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery
41374038|NCT05547516|PROCEDURE|BL - 5 ala PDT|BL - 5 ala PDT - plan: 5ALA 1.5g (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd), dissolved in 50mL normal saline, was infused into the bladder for 2 hours before surgery and before each cystoscopy. Blue laser irradiation was performed under a flexible cystoscope at 30mW/cm2 for 21min. PDT was performed during the operation and at 3, 6, and 9 months after the operation.
41374039|NCT04551326|OTHER|manual hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
41374040|NCT06126185|DIETARY_SUPPLEMENT|12-week course of synbiotic|A 12-week-course of synbiotic, which contains containing 5 billion colony-forming unit (CFU) of a combination of 4 probiotic species belonging to the genus of Lactobacillus, Bifidobacterium and Streptococcus, and 3 prebiotics, will be given to participants to take daily through oral route.
41374041|NCT01884909|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
41374042|NCT01884909|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
41374043|NCT03811652|DRUG|MEDI7247|Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
41374044|NCT05789901|OTHER|MARVIN|Chatbot on Meta (Facebook) Messenger for HIV Patients
41374045|NCT05789901|OTHER|MARVIN-Pharma|Chatbot on Meta (Facebook) Messenger for community pharmacists
41374046|NCT05789901|OTHER|MARVINA|Chatbot on Meta (Facebook) Messenger for breast cancer patients
41374047|NCT05789901|OTHER|MARVIN-CHAMP|CHatbot to Assist the Management of Pediatric patients with infectious conditions (CHAMP)
41374048|NCT05341427|DEVICE|electromagnetic device|electromagnetic waves for burn wound
41374049|NCT02867748|PROCEDURE|TVT-Abbrevo|
41374050|NCT02867748|PROCEDURE|Serasis|
41374051|NCT00137306|PROCEDURE|Facilitate evidence-based treatment for depression|
41374052|NCT01006031|DRUG|Pegylated interferon alfa-2a and Ribavirin|"Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels."
41032447|NCT03887377|DRUG|Botulinum Toxins|We will be comparing botulinum toxin following breast reduction surgery to placebo injection. We will then compare photos of each breast reduction scar at set intervals following surgery.
41032448|NCT03887377|OTHER|Normal saline|Normal saline will serve as the placebo control on the contralateral breast
41374053|NCT00957840|PROCEDURE|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
41374054|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
41374055|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
41374056|NCT02334046|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
41374057|NCT01260064|PROCEDURE|Open appendectomy|The subjects will have traditional open appendectomy procedure.
41374058|NCT01260064|PROCEDURE|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
41374059|NCT01260064|PROCEDURE|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
41374060|NCT02226575|BEHAVIORAL|A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives|Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
41374061|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)|Huoxin Pill (concentrated pill) is composed of Radix Ginseng, Radix Aconiti Lateralis Preparata, Ganoderma, Flos Carthami, artificial Moschus, cultured calculus bovis in vitro, Fel Ursi, Margarita, Venenum Bufonis, and Borneolum Syntheticum. It has the effect of invigorating qi and promoting blood circulation. It has been marketed in China for more than 30 years. Clinical studies have shown that Huoxin Pill (concentrated pill) has significant clinical efficacy in improving the symptoms and prognosis of coronary heart disease and angina pectoris. Basic studies have also confirmed that Huoxin Pill (concentrated pill) can play a role in myocardial protection by dilating coronary arteries and promoting angiogenesis. It produced by Guangzhou yuekang biopharmaceuticals co., ltd.
41374062|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)simulant|Huoxin Pill (concentrated pill) simulant, a placebo-like simulation have no therapeutic effect. The shape, packaging and taste are the same as Huoxin Pill (concentrated pill), produced by Guangzhou yuekang biopharmaceuticals co., ltd.
41374063|NCT04833816|DRUG|Administration of drug|Administration of ketamin during the 48h after trauma
41374064|NCT03448562|PROCEDURE|CPVI|ablate around the pulmonary vein orifice
41374065|NCT03448562|PROCEDURE|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
41374066|NCT03091478|DRUG|Pembrolizumab|200mg every 3 weeks
41374067|NCT00707551|DRUG|Ketoconazole|Tablet, administered as repeated doses.
41374068|NCT00707551|DRUG|Verapamil|Extended Release tablet, administered as repeated doses.
41374069|NCT00707551|DRUG|AZD1305|Extended Release tablet, administered as a single dose.
41032449|NCT01664845|DRUG|metformin|metformin 500mg tid
41032450|NCT01664845|DRUG|pegylated-IFN|pegasys 180 mcg qw
41032451|NCT01664845|DRUG|ribavirin|ribavirin 800-1200 mg qd according to BW
41032452|NCT02584049|OTHER|Osteopathy|3 sessions of osteopathy during 60 minutes each
41504817|NCT04819763|OTHER|Physical therapy|"Coordination training for lateral movement of the mandible (spatula exercise):~1. A wooden spatula is loosely placed between the teeth of the upper and lower jaw; the head must be aligned with the body axis; the exercise should be performed in front of a mirror.~2. The lower jaw moves to the left and back to the center with little contact to the spatula~3. The lower jaw moves to the right and back to the center under contact with the spatula~Training of the left lateral pterygoid muscle:~1. The left palm is placed on the left temple region~2. Right hand forms a fist and is placed on the tip of the right chin~3. Both arms are aligned parallel to the surface of the floor~4. The lower jaw is moved to the right against a moderate resistance of the fist = concentric muscle work~5. With measured force of the fist, the lower jaw is brought back to the center = eccentric muscle work (Right lateral pterygoid muscle training with opposite hands.)"
41374070|NCT01374516|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
41374071|NCT01374516|BIOLOGICAL|Placebo: (NaCl) 0.9% solution|0.5 mL, Subcutaneous
41374072|NCT05562596|DIAGNOSTIC_TEST|Measurement of oxysterol profile, including 20 molecules, in liquor before and after surgery|Samples are quantitated by deuterium-labeled mass-spectrometry amalysis.
41374073|NCT03546270|BEHAVIORAL|Swimming|This group completed 20-weeks of swimming
41374074|NCT03371095|DRUG|Infliximab|Use of infliximab instead of cyclophosphamide
41374075|NCT03371095|DRUG|Cyclophosphamide|Use of cyclophosphamide
41032453|NCT02584049|OTHER|Sham osteopathy|3 sessions of sham osteopathy during 60 minutes each
41032454|NCT03089086|BIOLOGICAL|Licensed 4CMenB vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to \<3 months apart in adolescents.
41163583|NCT03756064|DRUG|Pyrotinib|Pyrotinib: 400mg orally daily
41374076|NCT04979325|OTHER||
41374077|NCT04395625|PROCEDURE|Direct bonding of Orthodontic brackets|Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding
41374078|NCT04395625|PROCEDURE|Indirect bonding of Orthodontic brackets|Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
41374079|NCT06149000|DEVICE|Avulux Lenses|Avulux lenses are specialized eyewear designed to reduce specific wavelengths of light to alleviate symptoms in individuals who experience light sensitivity and migraines
41374080|NCT06149000|DEVICE|Placebo Lenses|Lenses that will look identical to Avulux lenses without the medical benefits
41374081|NCT03471507|DRUG|Bonipar|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
41374082|NCT03471507|DRUG|Diclofenac sodium topical solution 1.5%|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
41163584|NCT03756064|DRUG|Trastuzumab|Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;
41163585|NCT03756064|DRUG|Docetaxel|Docetaxel: 75mg/m2 for a total of 6 cycles
41163586|NCT03756064|DRUG|Carboplatin|Carboplatin: AUC=5 for a total of 6 cycles
41374083|NCT05335161|DEVICE|Home-based leg heat therapy|The Aquilo system consists of a garment that contains an inner water-circulating pad that is compressed by air bladders. The volume of air inflating the air bladders is pressure-controlled so the garment automatically adjusts to the shape and size of all legs. The touch screen console contains pre-programmed settings for ease of use. After baseline characteristics are established, patients will be provided with the Aquilo device and will be instructed on how to operate the equipment and how to rapidly remove the system if the alarm sounds or if they have any unusual feeling. Patients in both groups will also receive a logbook to record their sessions. Patients will undergo daily home-based leg HT (90 min/day, 7 days/week) for 12 weeks. Water at 42ºC will be perfused through the water-circulating garment for 90 min, with the goal of increasing skin temperature in the calf to \~37ºC.
41374084|NCT00003977|BIOLOGICAL|human papillomavirus 16 E7 peptide|
41374085|NCT00003977|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
41374086|NCT05794126|DEVICE|Lens 1|Soft multifocal hydrogel contact lens for 15 minutes
41374087|NCT05794126|DEVICE|Lens 2|Soft multifocal silicone hydrogel contact lens for 15 minutes.
41374088|NCT04433858|DRUG|Psilocybin|open-label
41374089|NCT01961765|DRUG|cabozantinib|
41374090|NCT03080207|PROCEDURE|PRP method|It will first be placed on a 25 cc venous blood centrifuge in anticoagulated tubes containing acid citrate dextrose (ACD), and autologous venous blood will be centrifuged at 3200 rpm for 15 minutes. Using the PRP kit, the plasma rich in platelet volume of about 3 cc volume will be removed. This will be activated by the addition of platelet agonists such as thrombin, calcium gluconate or calcium chloride. Injections should be administered subcutaneously for 2-3 weeks, 3-4 times for inguinal, popliteal region and ankle for a total of 12 weeks. Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise).
41032455|NCT02504658|BEHAVIORAL|Lifestyle text messages|"Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website."
41163587|NCT03756064|DRUG|Placebo Oral Tablet|Placebo Oral Tablet: 400mg orally daily
41163588|NCT00349739|DRUG|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
41163589|NCT05324813|BEHAVIORAL|Domain-Specific Episodic Future Thinking|Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.
41163590|NCT03375840|BEHAVIORAL|Text-only PWL|Control condition
41163591|NCT03375840|BEHAVIORAL|Low-emot PWL|Pictorial warning
41163592|NCT03375840|BEHAVIORAL|High-emot PWL|Pictorial warning
41163593|NCT03375840|BEHAVIORAL|Immediate posttest|
41163594|NCT03375840|BEHAVIORAL|delay posttest|
41163595|NCT02306083|DRUG|Placebo three times a day|
41163596|NCT02306083|DRUG|glucosamine sulfate 1500 mg three times a day|
41374091|NCT03080207|PROCEDURE|Low Level Laser|"Low Density Laser treatment will be applied for the first 4 weeks every 12 weeks, the remaining 8 weeks 2 days / week. A total of 9 regions (6 point inguinal region and 3 points popliteal region) are to be applied by applying the laser head close to the skin (20000 Hz, 1.5 J / cm2) with the laser device and the regions where lymph nodes and lymph pathways are dense.~During the application, the patient will be in the supine position for the popliteal region, with the patient in the supine position for the inguinal region and the legs free in the abdomen.Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise)."
41374092|NCT03080207|PROCEDURE|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy (CDP) consists of four basic components and two phases. Four basic components; Manual lymph drainage (MLD), skin care, compression therapy and therapeutic exercise. Phase I (intense phase): It is also referred to as the phase of reducing the remission. In this phase, skin care and compression bandages are renewed after daily MLD application. The patient is taught how to bandage on his own. (Phase I, 4 weeks) The duration of phase I may vary according to the patient. In Phase II, MLD can be administered 2 or 3 times per week depending on the needs of the individual. In this case, the patient is followed by home program. Our cases will be treated in Phase I every day for 12 weeks in total and 2 days / week in Phase II according to KBF phases. All patients in this group have received only Complex Decongestive Physiotherapy.
41374093|NCT00591916|DRUG|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
41374094|NCT00591916|PROCEDURE|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
41374095|NCT00591916|PROCEDURE|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
41374096|NCT02566629|OTHER|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
41374097|NCT00090259|DRUG|Losartan 50 mg|50-mg losartan oral tablet
41374098|NCT00090259|DRUG|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
41374099|NCT01577082|DRUG|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
41374100|NCT01577082|DRUG|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
41374101|NCT06334627|BEHAVIORAL|Pre-Primary Intervention|School readiness intervention
41374102|NCT02854202|OTHER|Arm1: Whey protein|Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast
41374103|NCT02854202|OTHER|Arm 2 Breakfast- other proteins|Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast
41374104|NCT02854202|OTHER|Arm 3 Breakfast- low protein|Arm 3: Low protein' :The participants will consume 22 g protein at breakfast
41374105|NCT02228148|DEVICE|NFS|Cochlear Nucleus Fitting Software
41374106|NCT02228148|DEVICE|CSS|Cochlear Nucleus Custom SoundTM Suite
41374107|NCT05423665|OTHER|sample collection|blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth
41374108|NCT00701012|PROCEDURE|preservation of nerve fibers around IMA|low ligation
41374109|NCT00701012|PROCEDURE|resection of nerve fibers around IMA|high ligation
41374110|NCT02189928|DEVICE|Lower limb tourniquet|"Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations')."
41374111|NCT02189928|OTHER|Usual care|
40849727|NCT02682992|DEVICE|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
40849728|NCT00761722|DRUG|azacitidine|"Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
41374112|NCT06021873|PROCEDURE|SADI-S|Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
41374113|NCT04381117|DRUG|Previously Treated with EN3835|No treatment to be administered - Observational only
41374114|NCT03245359|DEVICE|Short-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)
41374115|NCT03245359|DEVICE|Short-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)
40849729|NCT02314832|PROCEDURE|adductor canal block|ultrasound guided saphenous nerve block in the adductor canal
41374116|NCT03245359|DRUG|Short-term ON-Q|Bupivacaine 0.125%
41374117|NCT03245359|DEVICE|Long-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative
41374118|NCT03245359|DEVICE|Long-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
41374119|NCT03245359|DRUG|Long-term ON-Q|Bupivacaine 0.125%
41374120|NCT00323362|DRUG|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
41374121|NCT00323362|DRUG|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
41374122|NCT03198819|DRUG|Local Rifampisin and İnrtravenous cefotaxime|
41374123|NCT03431688|DRUG|PAM|treatment with PPI, metonidazole, amoxicillin
41374124|NCT03431688|DRUG|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
41374125|NCT05863780|OTHER|Carpal bone mobilization|"Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest- 3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
41374126|NCT05863780|OTHER|Flexor retinaculum stretch|"Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time,-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
41374127|NCT05863780|OTHER|Carpal bone mobilization and flexor retinaculum stretch|"1. Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest.3 sessions on alternate days per week for 04 weeks.~2. Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
41374128|NCT05147311|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
41504818|NCT04819763|OTHER|Appliance therapy|"Upper and lower jaw impressions are registered by using an intraoral scanner. The arbitrary hinge axis position is determined using a face bow.~The stabilization appliance with anterior canine guidance is manufactured in the Lexmann laboratory in Dresden.~The stabilization appliance is incorporated by the dentist and the static and dynamic occlusion is checked. A tension-free fit of the appliance on the lower jaw is necessary. Additionally, equal contacts in the side teeth area and incisors guidance in the case of mandibular protrusion are checked visually and by using occlusion foil. During mandibular lateral movement only the canine guidance takes place and is also registered optically and by using occlusion foil.Interference contacts should be adjusted.~The patient is instructed to wear the stabilization appliance while sleeping. The wearing rhythm is described as intermittent. (three nights - wearing the appliance, one night - not wearing the appliance)."
41504819|NCT00457548|BEHAVIORAL|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
41504820|NCT05970666|DRUG|TACE with adebrelimab and bevacizumab|TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);
41504821|NCT01254383|DRUG|Sildenafil Tablet|Tablet, 50 mg, Single Dose
41504822|NCT01254383|DRUG|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
41504823|NCT01254383|DRUG|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
41374129|NCT06096909|DRUG|Tafolecimab|The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.
41374130|NCT06096909|DRUG|Cholesterol Absorption Inhibitor|Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.
41504824|NCT05579002|OTHER|Questionnaires and tests|"Application of three questionnaires:~1. Canadian Occupational Performance Measure (CORM),~2. a version of the Disabilities of the Arm Shoulder and Hand (DASH) modified for the child~3. a questionnaire developed by CEREFAM~   * Two analytical and functional tests:~1) the Action Research Arm Test (ARAT) 2) modified 400-point assessment."
41504825|NCT03245112|DRUG|Eribulin Mesylate|The patients received intravenous eribulin 1.4 mg/m2 over 2-5 minutes on days 1 and 8 of every 21 days.
41504826|NCT06114069|PROCEDURE|implant supported maxillary fixed prosthesis|Maxillary fixed prosthesis according to all on four or all on six concept
41374131|NCT06096909|DRUG|Statin|Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.
40849730|NCT02314832|PROCEDURE|femoral nerve block|ultrasound guided femoral nerve block
40849731|NCT06526104|DRUG|Tremelimumab|Priming dose of tremelimumab 300 mg IV once (Cycle 1, Day 1 only)
40849732|NCT06526104|DRUG|Durvalumab|Durvalumab 1500 mg IV on Day 1 of each 4-week cycle.
41374132|NCT01530152|PROCEDURE|Truwiev PCD laryngoscope|"The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.~The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made."
41374133|NCT01896518|DRUG|Nicotine polacrilex|
41374134|NCT01896518|DRUG|Tobacco lozenge|
41504827|NCT04040192|DRUG|Crisaborole 2%|Crisaborole ointment 2%
41504828|NCT04040192|DRUG|Vehicle|Vehicle ointment
41504829|NCT03301571|OTHER|Change in preload and afterload|Afterload: Three levels of positive end-expiratory pressure (PEEP) will be examined post-operatively: 0 cm H20, 5 cm H2O, 10 cm H2O Preload: Trendelenburg position for 5 minutes will be investigated
41504830|NCT03301571|OTHER|Inspired oxygen|Following fractions of inspired O2 will be investigated: 0.5 and 1.0 for 10 minutes respectively
41504831|NCT03301571|OTHER|Pacemaker mode|Following pacemaker settings will be investigated: Atrioventricular pacing 10 bpm over the patients' intrinsic rhythm, atrial pacing 10 bpm over the patients' intrinsic rhythm, ventricular pacing 10 bpm over the patients' intrinsic rhythm
40849733|NCT06583551|DRUG|Botulinum toxin|Botulinum toxin, produced by Clostridium botulinum, is a neurotoxin. Presently, there are 7 serotypes (A, B, C1, D, E, F, G). Botulinum neurotoxin A (BoNT-A) is the most frequently used variant in clinical applications.
41374135|NCT04451070|OTHER|Clinic First curriculum|"The Clinic First model was designed by the Association of Family Medicine Residency Directors (AFMRD) in collaboration with the University of California San Francisco's (UCSF) Center for Excellence in Primary Care. The components of the Clinic First model are summarized in the Association of American Medical Colleges' (AAMC) publication titled High-Functioning Primary Care Residency Clinics: Building Blocks for Providing Excellent Care and Training. Using the principles of Clinic First, the authors of this study drafted a Family Medicine residency curriculum to be implemented at David Grant Medical Center at the beginning of the 2020-2021 academic year."
41374136|NCT01060007|RADIATION|External beam radiation|
41374137|NCT01060007|DRUG|Oxaliplatin|
41374138|NCT01060007|DRUG|Leucovorin|
41374139|NCT01060007|DRUG|5-FU|
41374140|NCT01060007|DRUG|Capecitabine|
41374141|NCT01177865|OTHER|informational intervention|
41374142|NCT01177865|OTHER|questionnaire administration|
41374143|NCT06499272|PROCEDURE|Conventional occupational therapy sessions + NeuronUP|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
41374144|NCT06499272|PROCEDURE|Conventional occupational therapy sessions|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
41374145|NCT04360213|DEVICE|Advanced multimodal wireless vital signs monitor|Investigators have developed a lightweight, stretchable 'skin-like' membranes, called skin sensors. These small, paper-thin monitors were created by matching the mechanical properties of skin, and can be applied to the skin's surface without skin disturbance. Each patch is encapsulated using medical grade materials and applied using single use medical grade skin adhesive integrated with eco-fused fabric (moisture wicking layer between adhesives). The adhesive may be changed between uses, and the device itself can be cleaned with Super Sani-Cloth®, commonly used in the hospital setting.
41374146|NCT02980666|DRUG|Teduglutide|0.05 mg/kg/day SC injection once daily for 24 weeks.
41374147|NCT03564977|BIOLOGICAL|CD19-targeted CAR-T cells|MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
41374148|NCT02010359|DRUG|Lovaza|Lovaza 4 grams per day
41504832|NCT01410656|BEHAVIORAL|Telephone Implementation Intention|Telephone implementation intention counseling
41504833|NCT01410656|BEHAVIORAL|Self-completed implementation intention|Self-administered implementation intention intervention
40849734|NCT06583551|PROCEDURE|Dry needling|Dry needling (DN) is a type of acupuncture therapy, that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points (MTrPs) and muscular, and connective tissues.
41374149|NCT02010359|DRUG|Placebo|Placebo pill
41374150|NCT04898517|PROCEDURE|Pancreaticoduodenectomy with the CONDUCTJE-ST technique|"The termed technique connexion pancreatic duct to the jejunum stented (CONDUCTJE-ST) in pancreaticoduodenectomy is a novel technique, modification of the pre-existing ones, whose effectiveness lies in the fact that it is not an anastomosis in the strict sense but rather a simple connection for restoring pancreatic juice flow from the pancreatic remnant towards the intestine."
41374151|NCT04311814|DIAGNOSTIC_TEST|Maximum urethral closure pressure during Valsalva (v-MUCP)|v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
41374152|NCT03511391|DRUG|Nivolumab or Pembrolizumab or Atezolizumab|per national standard of care
41374153|NCT03511391|RADIATION|SBRT|Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.
41374154|NCT02070367|OTHER|Somatosensory rehabilitation|
41374155|NCT02070367|OTHER|Usual treatment: physiotherapy|
41374156|NCT03063931|DRUG|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
41374157|NCT03063931|DRUG|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
41374158|NCT06143176|BEHAVIORAL|VR-based occupational therapy|All patients will undergo 20 sessions of virtual reality based occupational therapy for 30 minutes a day, 5 days a week for 4weeks
41374159|NCT06246630|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
41504834|NCT03167463|PROCEDURE|flap|Repair choanal atresia with using flap during surgery
41504835|NCT01019668|DRUG|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
41504836|NCT01019668|DRUG|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
41504837|NCT03946852|DEVICE|Abdominal Regional Perfusion|Abdominal Regional Perfusion
41032456|NCT02504658|BEHAVIORAL|Attention Control Group|"Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over."
41032457|NCT00870805|PROCEDURE|bilateral ultrabrief ECT|Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
40849735|NCT06583551|DRUG|Myorel|Metacarbamol (380mg), paracetamol (300mg)
41032458|NCT00870805|PROCEDURE|bilateral standard ECT|Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
41374160|NCT06344676|OTHER|Cognitive|Tree 10 minutes individual sessions per week involving memory, attention and executive functions tasks.
41374161|NCT06344676|OTHER|Mobility|Two 30 minutes group session per week involving physical activity assisted by a social robot.
41032459|NCT00870805|PROCEDURE|right-unilateral ultrabrief ECT|Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
41032460|NCT00870805|PROCEDURE|right-unilateral standard ECT|Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
41374162|NCT06344676|OTHER|Social|One 60 minutes group session per month assisted by a social robot that facilitates talking about costumes and traditions.
41374163|NCT06344676|OTHER|Relational|Unrestricted individual interaction of the user with the Pepper robot to obtain information of interest for the user (menu, time, date, place and calendar of activities of the residential. center) and 1 individual monthly videoconference with the family of 10 minutes of duration.
41504838|NCT05055583|DRUG|Toripalimab in Combination With Platinum-based Chemotherapy|Toripalimab will be administered at a fixed dose of 80 mg (2ml)/vial, IV, D1, with a full dose of 240 mg at one time, every 3 weeks for 3-4 cycles. Squamous cell carcinoma will be combined with cisplatin/carboplatin and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles. Non-squamous cell carcinoma will be combined with cisplatin/carboplatin and Pemetrexed, cisplatin/carboplatin is the same as above, Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.
41504839|NCT05055583|PROCEDURE|Surgical treatment stage|After the last treatment (Day 21 of Cycle 4), surgery was performed within 4-6 weeks.
41504840|NCT05055583|DRUG|Adjuvant treatment stage|Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
41504841|NCT01051947|DRUG|Nebivolol|10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
41504842|NCT01051947|DRUG|Metoprolol|dosage prescribed prior to starting on study
41504843|NCT01406444|DRUG|rhIGF-1|Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
41504844|NCT01406444|DRUG|Risedronate|Risedronate 35mg PO one time weekly
41504845|NCT01406444|DRUG|Placebo|Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
41504846|NCT02713412|OTHER|Glucose|75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
41504847|NCT02713412|OTHER|Water|300ml water
41504848|NCT06453369|PROCEDURE|Y shaped Tunnel with Connective tissue graft|Sulcular incision followed by Micro-periosteal elevator will be used to elevate vertical full thickness tunnel starting coronally from the gingival sulcus and directed apically. CTG will be prepared and inserted into the coronal tunnel aperture using blunt instrument to facilitate intrusion of graft into tunnel. CTG insurted into the tunnel up to the apical level leaving a coronal part to completely cover the recession defect. Finally single interrupted suture will be used to secure the coronal exposed part of the CTG followed by sling suture fixation of the gingival flap with that of CTG. The donor CTG will be stabilized to the underlying connective tissue interproximally using 5.0 sutures.
41504849|NCT05332873|DEVICE|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
41504850|NCT04820660|OTHER|Task orientated strengthening training|"1. Standing and reaching in different directions for objects located beyond arm's length to promote loading of the lower limbs and activation of lower limb muscles;~2. Sit-to-stand from various chair heights to strengthen the lower limb extensor muscles;~3. Stepping forward and backward onto blocks of various heights to strengthen the lower limb muscles;~4. Stepping sideways onto blocks of various heights to strengthen the lower limb muscles;~5. forward step-up onto blocks of various heights to strengthen the lower limb muscles;~6. heel(s) raise and lower while maintaining in a standing posture to strengthen the plantar- flexor muscles.~Each workstation was 5 min in duration for each exercise class. Each subject participated in a one-to-one therapy."
41032461|NCT04153266|OTHER|No intervention is planned for this study|No intervention was/is planned for this study. The study is questionnaire-based (observational).
41032462|NCT02897804|BEHAVIORAL|Knowledge alone|Increase knowledge related STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing \& treatment services.
41374164|NCT06344676|OTHER|Usual Care|Attentions and treatments received by the persons before the enrollment in the study.
41374165|NCT03522025|DEVICE|Unicompartmental Knee Arthroplasty (UKA)|Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
41032463|NCT02897804|BEHAVIORAL|Self-efficacy alone|Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032464|NCT02897804|BEHAVIORAL|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
41374166|NCT05919875|BEHAVIORAL|Unguided Mindfulness-Based Cognitive Therapy|"The unguided iMBCT intervention is divided into six sessions. The sessions are an online adaptation of the regular MBCT. Subsequent sessions are unlocked gradually, once a week. The training consists of audio/video recordings and a workbook. Materials are recorded by a certified MBCT teacher and represent topics raised during regular courses:~1. Awareness and automatic pilot~2. Living in our heads~3. Being present in the body~4. Recognizing aversion~5. Allowing / Letting be~6. How can I best take care of myself?~The intervention requires daily commitment of about 30-40 minutes."
41032465|NCT02897804|BEHAVIORAL|Perceived benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032466|NCT02897804|BEHAVIORAL|Injunctive norms|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
41374167|NCT05919875|BEHAVIORAL|Guided Mindfulness-Based Cognitive Therapy|"The guided iMBCT intervention consists of six online meetings in groups of maximum 25 participants. The weekly meetings will be led by an experienced and certified MBCT teacher. The course of the meeting will represent thematically the unguided condition according to the agenda:~* Introduction to the topic~* Guided meditation~* Brief inquiry and discussion~* Setting tasks for the upcoming week~To reduce the number of differences between the conditions as much as possible and narrow it down to the active participation of the teacher, the meetings will be modified version of MBCT and will last maximum 90 minutes. Between the meetings participants will be ask to practice daily 30-40 minutes mindfulness exercises."
41504851|NCT04820660|OTHER|Balance training exercises|"1. Stepping forward, backward, and sideways on the exercise step;~2. Stepping over blocks of various heights;~3. Standing up from a chair, walking four steps forward, performing a bilateral stool touch and walking backwards to the chair;~4. Standing up from a chair, walking four steps forward, turning to the right, stepping over the exercise step, turning to the right again and walking forwards to the chair (repeat the exercise circuit in opposite direction);~5. From a sitting position on a 65-cm Swiss ball, performing a range of motion and balance exercises (forward and backward rolling of the~6. Arms; bending the trunk forward and side to side);~7. Performing double-legged stance for 10 s;~8. Performing tandem stance for 10 s;~9. Rising from a chair without the use of the arms;~10. Walking forward and backward with a tandem walking pattern (toes of one foot touching the heel of the foot in front);~11. Performing single- legged stance for 10 s."
41504852|NCT01547130|DRUG|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
41504853|NCT01547130|DRUG|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
41504854|NCT03311750|DRUG|Panitumumab|6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
41504855|NCT05547620|DEVICE|LIFUS Online Real|Stimulation using NeuroFUS device while standing
41504856|NCT05547620|DEVICE|LIFUS Online Sham|Stimulation using NeuroFUS device while standing
41504857|NCT05547620|DEVICE|LIFUS Offline|Stimulation using NeuroFUS device prior to standing
41504858|NCT04241926|DIAGNOSTIC_TEST|transpolmonary thermodilution|Thermodilution was attempted via PICC and via CICC in the same patient
41504859|NCT01137994|DRUG|Lapatinib|oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
41504860|NCT01137994|BIOLOGICAL|Trastuzumab|monoclonal antibody directed to HER2 receptor
41504861|NCT01137994|DRUG|Docetaxel|Taxane chemotherapy
41504862|NCT01137994|DRUG|Paclitaxel|Taxane chemotherapy
41504863|NCT01137994|DRUG|Vinorelbine|Vinka alkaloid
41504864|NCT01920022|DRUG|Mifepristone|Day one of medical abortion
41504865|NCT01920022|DRUG|etonorgestrel|
41504866|NCT02132793|BEHAVIORAL|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
41504867|NCT02132793|BEHAVIORAL|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
41504868|NCT04342455|OTHER|double-low scanning|a CT angiography protocol with low radiation and contrast agent exposure
41504869|NCT01843387|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 1 or Placebo
41504870|NCT01843387|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 2 or Placebo
41504871|NCT06050343|DRUG|Humulin® Regular|subcutaneous injection at a dose of 0.3 IU / kg
41504872|NCT06050343|DRUG|Rinsulin® R|subcutaneous injection at a dose of 0.3 IU / kg
41504873|NCT04284059|DRUG|Placebos|Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.
41504874|NCT04284059|DIETARY_SUPPLEMENT|vitamin AD|A vitamin AD capsule contains vitamin A 2000 IU and vitamin D 700 IU. The patients need to administrate 3 capsules once a day for 8 weeks.
41504875|NCT04284059|DIETARY_SUPPLEMENT|vitamin D|A vitamin D capsule contains vitamin D 400 IU. The patients need to asministrate 6 capsules/time, once a day for 2 weeks, then change to 5 capsules/time, once a day for 6 weeks.
41504876|NCT02535286|DRUG|Umbralisib|A once daily oral agent
41504877|NCT02535286|BIOLOGICAL|ublituximab|IV anti-CD20 monoclonal antibody
41504878|NCT02535286|BIOLOGICAL|TG-1501|IV immunotherapy for cancer
41032467|NCT02897804|BEHAVIORAL|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032468|NCT02897804|BEHAVIORAL|Injunctive norms and perceived benefits|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41504879|NCT05351658|DEVICE|KronoSafe® System|All patients included in the study will have a temporary pacemaker with active fixation leads, held by the KronoSafe® fixation system.
41504880|NCT06359028|DRUG|Stannous fluoride toothpaste|Toothpaste containing 0.454 % weight/weight (w/w) SnF2
41504881|NCT06359028|DRUG|Crest cavity protection toothpaste|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
40849736|NCT06583551|PROCEDURE|Manual therapy|Manual therapy (MT) entails the use of the hands to apply a force with a therapeutic intent, including techniques such as massage, joint mobilization/manipulation, myofascial release, nerve manipulation, strain/counterstrain, and acupressure.
40849737|NCT01832532|DRUG|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
40849738|NCT00289081|DEVICE|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee implant
40849739|NCT00289081|DEVICE|Total knee replacement|Rotating Platform (RP) Cruciate Substituting Knee implant.
40849740|NCT02760316|DRUG|AZD9567 10 mg|Oral suspension Multiple doses 5 days of treatment Once daily
40849741|NCT02760316|DRUG|AZD9567 20 mg|Oral suspension Multiple doses 5 days of treatment Once daily
40849742|NCT02760316|DRUG|AZD9567 40 mg|Oral suspension Multiple doses 5 days of treatment Once daily
41374168|NCT04812886|OTHER|Epidemiological study|Questionnaires (quality of life, gout, life habit, comorbidities) anthropometrics and health measures DNA analysis RNA analysis Metabolomic analysis
41374169|NCT00219024|DRUG|aliskiren|
41374170|NCT03062878|OTHER|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplesmography
41374171|NCT03062878|OTHER|Vascular Ultrasound|Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter
41374172|NCT03062878|OTHER|Venous blood sample|Evaluation of oxidative stress via serum lipid hydroperoxide
40849743|NCT02760316|DRUG|AZD9567 80 mg|Oral suspension Multiple doses 5 days of treatment Once daily
40849744|NCT02760316|DRUG|Prednisolone 20 mg|Oral Multiple doses 5 days of treatment Once daily
40849745|NCT02760316|DRUG|AZD9567 125 mg|Oral Multiple doses 5 days of treatment Once daily
41374173|NCT03062878|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
41374174|NCT02866201|OTHER|Rectal swab|
41374175|NCT01358266|DRUG|DE-109 44 ug|Low dose
41374176|NCT01358266|DRUG|DE-109 440 ug|Medium dose
41374177|NCT01358266|DRUG|DE-109 880 ug|High dose
40849746|NCT02760316|DRUG|AZD9567 155 mg|Oral Multiple doses 5 days of treatment Once daily
40849747|NCT02760316|DRUG|Prednisolone 5 mg|Oral Multiple doses 5 days of treatment Once daily
40849748|NCT02760316|DRUG|Prednisolone 40 mg|Oral Multiple doses 5 days of treatment Once daily
40849749|NCT00741442|DRUG|RDEA806|Uricosuric agent for the treatment of gout
40849750|NCT00741442|DRUG|Placebo|Matching Placebo.
41374178|NCT06260462|DRUG|dual-release hydrocortisone|Oral tablets 20-25-30-40 mg/day
41374179|NCT06260462|DRUG|Conventional glucocortidois|Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
41374180|NCT03381898|BEHAVIORAL|Telehealth Exercise, speech therapy, medication management|Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
41504882|NCT03001453|DRUG|Liposomal Bupivacaine|266mg liposomal bupivacaine
41504883|NCT03001453|DRUG|0.25% Bupivacaine with epinephrine|0.25% bupivacaine with epinephrine
41504884|NCT03001453|DRUG|Saline|Normal saline
41504885|NCT00478244|DRUG|busulfan|Day -9 through Day -6: 1.1 mg/kg if \< 12 kg IV every 6 hours; 0.8 mg/kg if \> 12 kg.
41504886|NCT00478244|DRUG|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
41504887|NCT00478244|DRUG|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
41504888|NCT00478244|PROCEDURE|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
41504889|NCT05503511|DRUG|NPT 2042 (bumetanide analog) or Matching Placebo|Soft gelatin capsules
41504890|NCT00230178|DRUG|Rasburicase (SR29142)|30-min IV infusion
41504891|NCT00230178|DRUG|Allopurinol|Oral administration
41504892|NCT03523299|PROCEDURE|Cryoablation|Cryoablation is a non-surgical, minimally invasive freezing procedure used to destroy tumors. In the breast, cryoablation is performed under ultrasound guidance. Due to the analgesic properties of freezing, no IV sedation or anesthesia is required. After administration of local anesthetic, the physician makes a 2-3 mm incision and inserts needle-like cryoprobes into the tumor, commencing a number of freeze-thaw cycles. Then the probe is removed, pressure is applied to the area, and a bandage is placed. The patient leaves the office without stitches and minimal, if any, pain. Any residual pain after the procedure is routinely treated with over the counter analgesics such as acetaminophen.
41504893|NCT03909269|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring five times over 17 weeks
41504894|NCT03909269|DIAGNOSTIC_TEST|Glycaemic markers|Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.
41504895|NCT03909269|RADIATION|Erythrocyte life span|Erythrocyte life span measured by Crom-51 labelling over 4 weeks
41504896|NCT03909269|DEVICE|Carbon monoxide (CO)-rebreathing method|Measurement of total blood volume, plasma volume and erythrocyte volume
41504897|NCT01507766|DRUG|early enteral nutrition|The enteral nutrition was started within 48h after admission
41504898|NCT01507766|DRUG|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
40849754|NCT03133351|DEVICE|PCM|A fresh whole blood sample will be tested by PCM to determine the reference range.
40849755|NCT02006849|DRUG|Acthar|FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.
41374181|NCT01014442|DRUG|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
41374182|NCT01510587|BEHAVIORAL|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
41374183|NCT01510587|BEHAVIORAL|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
41374184|NCT00117975|BIOLOGICAL|galiximab|given IV
41504899|NCT05759013|DEVICE|Breath synchronized abdominal NMES|Active abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), five days per week, for 28 days or ICU discharge, whichever comes first.
41504900|NCT05759013|DEVICE|Sham breath synchronized abdominal NMES|Sham abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), five days per week, for 28 days or ICU discharge, whichever comes first.
41504901|NCT06329427|OTHER|Dragon Ambient eXperience (DAX) Copilot|The tool (DAX) listens to the conversation between a clinician and patient/caregiver during their visit, provides transcriptions between different speakers for the clinician to review, edit, and included in the final EHR notes.
41504902|NCT01368315|DRUG|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
41504903|NCT01368315|DRUG|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
41504904|NCT01368315|DRUG|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
41504905|NCT01368315|DRUG|No intervention|No intervention to one out of four test fields marked on the patient's back.
41504906|NCT06172621|PROCEDURE|Spinal Cord Associative Plasticity (SCAP)|Paired non-invasive brain and spinal cord stimulation.
41504907|NCT06172621|PROCEDURE|Upper extremity task-oriented exercise|Participants will perform a range of exercises composed of tasks resembling daily home/community activities such as stacking and sorting small objects, manipulating writing utensils, keys, buttons, etc.
41504908|NCT02111603|DRUG|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
41504909|NCT03591042|DIAGNOSTIC_TEST|cervical length screening|transvaginal ultrasound cervical length
41032469|NCT02897804|BEHAVIORAL|Injunctive norms, perceived benefits, and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032470|NCT02897804|BEHAVIORAL|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
41032471|NCT02897804|BEHAVIORAL|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032472|NCT02897804|BEHAVIORAL|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
41032473|NCT02897804|BEHAVIORAL|Descriptive norms,perceived benefits,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032474|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
41032475|NCT02897804|BEHAVIORAL|Descriptive norms, injunctive norms,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032476|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms, benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
41032477|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms, benefits,efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032478|NCT02897804|BEHAVIORAL|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
41374185|NCT00117975|BIOLOGICAL|rituximab|Given IV
41374186|NCT01864746|DRUG|Palbociclib PD-0332991|palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
41374187|NCT01864746|DRUG|Placebo|Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
41374188|NCT05847023|BEHAVIORAL|LUNA|see description above
41374189|NCT05479617|OTHER|Deep learning model|Use of deep learning model to predict individual patients disease course
41374190|NCT01275118|DEVICE|Tecnis Multifocal IOL|Presbyopia correcting IOL
41374191|NCT01275118|DEVICE|crystalens Accommodating IOL|Presbyopia correcting IOL
41374192|NCT01934101|DRUG|CHR-5154|CHR-5154
41374193|NCT01934101|DRUG|Placebo|Placebo
41374194|NCT00859313|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
41374195|NCT01821131|OTHER|muffin|
41374196|NCT04809415|OTHER|Photobiomodulation|Photobiomodulation consists of irradiation by light in order to achieve photochemical and photophysical outcomes.
41374197|NCT04809415|OTHER|Sham|Simulation of the application of photobiomodulation therapy.
41374198|NCT05493748|OTHER|Bladder training|Bladder training for overactive bladder syndrome.
41374199|NCT02889627|DRUG|Fecal microbiota suspension|The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
41374200|NCT02825875|DRUG|18F DCFPyL- Radiopharmaceutica|
41374201|NCT04156438|DEVICE|Low tidal volume ventilation|Conventional ventilation strategy for patient with ARDS
41374202|NCT04156438|DEVICE|Airway pressure release ventilation|Experimental ventilation protocol for patients with ARDS
41374203|NCT04850170|PROCEDURE|manual therapy|"1. release and stretch the muscles and fascia around shoulder girdle、upper arm and forearm;~2. massage the masseter muscle and temporalis muscle;~3. mobilization of the temporomandibular joint, the thoracic and cervical spine, shoulder, and elbow."
41374204|NCT04850170|PROCEDURE|Speech therapy|include the stretching of the neck, facial and oral movement training, and swallowing training
41374205|NCT02774577|OTHER|whole body vibration training in vibrating platform in young|
41374206|NCT02774577|OTHER|whole body vibration training in vibrating platform in elderly|
41374207|NCT01535872|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
41374208|NCT03866811|BEHAVIORAL|Dr. Erica|The 10 week texting intervention contains the follow characteristics to increase engagement: (1) Dr. ERICA (Emergency Room Interventions to Improve the Care of Adolescents): The persona and brand of the intervention is Dr. Erica, a relatable, empathetic, straightforward and reliable female doctor; (2) Personalization: Information collected at baseline will be incorporated into each individualized program; (3) Interactivity: The majority of text message algorithms contain 3-4 two-way automated messaging conversations. (4) Feedback loops: The investigators will collect feedback from participants to prompt action; (5) Visual stimuli: Texts include emojis, memes, and other visual stimuli, similar to current teen texting behaviors; (6) Social media: The investigators designed sexual health comic strips posted as an Instagram story; (7) Links and role modeling: Texts contain links to testimonials, influencers, and evidence-based websites.
41374209|NCT05552898|DIETARY_SUPPLEMENT|Sleep Study Product Usage|Participants will use their Radicle Sleep study product as directed for a period of 4 weeks.
41374210|NCT04992091|OTHER|constructive debriefing|Constructive debriefing was applied to an interventional group Traditional debriefing was applied on noninterventional group
41374211|NCT06160258|BEHAVIORAL|Ready to Eat (RTE)|Participants will be provided precooked and individually packaged whole grains in the ready-to-eat (RTE) condition for reheating and consumption at home.
41374212|NCT06160258|BEHAVIORAL|Dried|Participants will be provided with dried whole grains for home preparation and consumption
41374213|NCT06396806|PROCEDURE|indocyanine green fluorescence imaging lymphatic tracing|At the end of routine operation, indocyanine green was used for lymph node tracing, and further lymph node dissection was performed according to the tracer results.
41374214|NCT05719701|DRUG|ICP-490|Several dose groups of ICP-490 are planned for the dose exploration.
41374215|NCT05719701|DRUG|Dexamethasone|Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.
41374216|NCT01980056|DRUG|Vosaroxin|Dose level 1: Vosaroxin 50 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg\^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
41374217|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
41374218|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
41374219|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
41374220|NCT02103608|DEVICE|Glide|6 facial hair reduction treatments with the Glide device, two weeks apart.
41374221|NCT01572610|DRUG|RTA 402|once a day, oral administration
41504910|NCT03451552|BEHAVIORAL|Patient Navigator|Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
41504911|NCT03507647|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"MBCT is a manualised group skills-training program (Segal, Williams \& Teasdale 2012) consisting of eight weekly sessions of 2.5 hours, plus one day of silent practice. The program includes both formal and informal meditation exercises. Cognitive techniques that are part of the program are education, monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan.~The MBCT treatment will be adapted to address the needs of patients with a bipolar disorder. A few examples of these adaptations are: (more) psychoeducation about manic symptoms in addition to the psychoeduction about depression; introducing the 3-minute breathing space earlier in the programme and more often during sessions, especially when strong emotions are present; repeatedly bringing the focus to self-care; and making use of the mindful movement (yoga) exercises more frequently."
41504912|NCT03507647|OTHER|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse). Usual care will not be restricted, except for proscribing high-frequency psychological interventions such as (group) cognitive behavioral therapy, for practical and methodological reasons.
41504913|NCT05382585|OTHER|Next generation Sequencing|Next generation sequencing for 161 genes
41504914|NCT00950365|DRUG|Erlotinib Hydrochloride|Given PO
41504915|NCT00950365|OTHER|Laboratory Biomarker Analysis|Correlative studies
41504916|NCT00950365|DRUG|Pemetrexed Disodium|Given IV
41504917|NCT02513212|DEVICE|Potassium Oxalate|Professionally applied liquid
40849756|NCT04129892|BEHAVIORAL|"In Favor of My Resilient Self Academic course"|Assessing the effect of an academic course on student's emotional resilience.
41032479|NCT02897804|BEHAVIORAL|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41374222|NCT01717300|DRUG|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
41374223|NCT01717300|DRUG|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
41374224|NCT01717300|DRUG|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
41374225|NCT01717300|DRUG|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
41374226|NCT02791906|DRUG|ISMN|
41374227|NCT02791906|DIETARY_SUPPLEMENT|Vitamin C|
41374228|NCT00323830|DRUG|Capecitabine, cisplatin, Radiotherapy (+/-)|Capecitabine, cisplatin + Radiotherapy (randomized)
41374229|NCT00277823|DRUG|DVS-SR 50 mg|
41374230|NCT00277823|DRUG|DVS-SR 100 mg|
41374231|NCT00277823|DRUG|Placebo|
41374232|NCT00350935|PROCEDURE|fMRI|One 30 minute session
41374233|NCT06538389|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41374234|NCT06538389|DRUG|BRC-001|Given PO
41374235|NCT06538389|DRUG|Placebo Administration|Given PO
41374236|NCT06538389|OTHER|Questionnaire Administration|Ancillary studies
41504918|NCT02513212|DRUG|Stannous fluoride paste|SnF2 Paste
41504919|NCT02513212|DEVICE|Manual toothbrush|Marketed manual toothbrush
41374237|NCT01077791|BEHAVIORAL|original cognitive therapy|12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
41032480|NCT02897804|BEHAVIORAL|Expectancies and Perceived Benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
41032481|NCT02897804|BEHAVIORAL|Expectancies, perceived benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41374238|NCT00814502|DRUG|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
41374239|NCT00814502|DRUG|Placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
41504920|NCT02513212|DEVICE|Power toothbrush|Marketed power toothbrush
41504921|NCT01179711|DEVICE|Glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
41504922|NCT01542879|PROCEDURE|WB-DW-MR scan|WB-DW-MR scans will be obtained on a 3T PET-MR system
41504923|NCT01542879|PROCEDURE|18-F-FDG PET scan|
41504924|NCT01542879|DRUG|Ferumoxytol|
41032482|NCT02897804|BEHAVIORAL|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
41032483|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032484|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
41163597|NCT05992662|BEHAVIORAL|Mindfulness-Based Training Programme in Bariatric Surgey Patients|"ACTION Conducting mindfulness-based 4-session training program Focus group discussion after the training Within the scope of mindfulness-based training: Mindful Eating practices; qigong exercises; meditation exercises; breathing exercises; training specific to the bariatric surgery process was given.~FOLLOW-UP PHASE (3rd MONTH/6.MONTH POSTOPERATIVE)~* Reminder of weekly practices~* Recording changes in mindful eating in participant experience diaries during the follow-up"
41374240|NCT02513732|DEVICE|XIENCE Xpedition 2.25 mm stent|Patients receiving XIENCE Xpedition 2.25 mm stent
41374241|NCT05076812|DIAGNOSTIC_TEST|measure plasma level of interleukin 38 by ELISA kit|draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
41504925|NCT01542879|PROCEDURE|18-F-FDG PET/MR scan|
41504926|NCT00408746|BEHAVIORAL|palatal development|Impressions of preterm and term palates.
41504927|NCT00754546|DRUG|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
41504928|NCT00754546|DRUG|Placebo: Normal Saline|Normal saline was nebulized.
41504929|NCT00754546|OTHER|Treadmill Exercise|
41504930|NCT00754546|OTHER|Cycle Exercise|
41504931|NCT01393886|PROCEDURE|Laparoscopic Greater Curvature Plication (LGCP)|This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
40849757|NCT00968877|DRUG|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
40849758|NCT03248089|DIAGNOSTIC_TEST|Guardant360|Cell-free circulating tumor DNA (cfDNA) targeted next-generation sequencing (NGS) panel.
40849759|NCT02400021|DRUG|Prometrium|
41374242|NCT05033691|RADIATION|Stereotactic surgery|At two month (8 weeks) post Osimertinib start, patients will be randomized into one of the two study arms. Arm A patients will be treated with stereotactic surgery (SRS). In both arms Osimertinib treatment will continue.
41374243|NCT00002074|DRUG|Fluconazole|
41374244|NCT00002074|DRUG|Amphotericin B|
41504932|NCT03769961|OTHER|No intervention|No interventions - Observational study
40849760|NCT04859816|OTHER|Metabolic test|Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
40849761|NCT04859816|OTHER|DXA-scan|Dual energy X-ray Absorptiometry scan of whole-body fat
41504933|NCT01733810|OTHER|Cessation of Acid Suppressing Medications|Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
41504934|NCT01708967|PROCEDURE|pretreatment method for transnasal endoscopy|"Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).~Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity."
41504935|NCT00199524|DEVICE|Navigator Ureteral Access Sheath|ureteral access sheath
41504936|NCT02483546|DEVICE|Laerdal®|simulation- based educational intervention
41374245|NCT03280472|BEHAVIORAL|Cognitive Bias Modification|"CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information"
41504937|NCT02483546|BEHAVIORAL|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
41374246|NCT03280472|BEHAVIORAL|Symptom tracking|Participants will track their symptoms
41374247|NCT01424631|PROCEDURE|single incision laparoscopic appendectomy|
41374248|NCT01424631|PROCEDURE|conventional laparoscopic appendectomy|
41374249|NCT03252665|DRUG|Alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
41374250|NCT03252665|DRUG|Nicorandil|Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
41374251|NCT03252665|DRUG|Nitroglycerin|Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
41374252|NCT05448469|PROCEDURE|ultrasound guided erector spinae plane block|patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.
41504938|NCT02483546|BEHAVIORAL|traditionally teaching|Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
40849762|NCT04859816|OTHER|MRS|Magnetic resonance spectroscopy of liver fat content
41374253|NCT05448469|PROCEDURE|ultrasound guided paravertebral block|patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.
41374254|NCT05448469|DRUG|conventional analgesia|patients will receive combined general anesthesia and conventional analgesia
40849763|NCT04859816|OTHER|Feces collection|4-day feces collection
40849764|NCT00153465|BEHAVIORAL|Motivational intervention, parent training|
40849765|NCT05580068|DEVICE|Hypertension therapy through iATROS medical device|"The intervention to be carried out in the treatment group is the use of the therapy support provided by the iATROS medical device for the treatment of arterial hypertension.~In particular, patients are guided through a structured digital therapy program that enables them to better manage their disease. Patient receive reminders for taking their medication, for performing vital parameter measurements, and receive educational content for them to learn how to manage their disease better."
41032485|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032486|NCT02897804|BEHAVIORAL|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
41163598|NCT02251340|BEHAVIORAL|Eczema Care Plan|
41374255|NCT03730623|BEHAVIORAL|Supervised exercise training|Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program
41374256|NCT05912192|DRUG|Elonide Nasal Spray|50mcg/dose One puff for each nostrils twice daily
41374257|NCT05912192|DRUG|Nasonex Nasal Spray|50mcg/dose One puff for each nostrils twice daily
41374258|NCT05912192|DRUG|Normal saline|50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
41374259|NCT00681876|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
41374260|NCT00681876|DRUG|Avastin|Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
41374261|NCT00681876|DRUG|Erbitux|Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
41374262|NCT01246193|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
41374263|NCT01246193|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
41374264|NCT05818046|DIAGNOSTIC_TEST|transcutaneous oxygen pressure|External proxe fixed to the skin and ultrasound examination.
41504939|NCT02603991|PROCEDURE|PINS Vagus Nerve Stimulator|The stimulators are implanted in the body,with the stimulation of the IPG
41504940|NCT02603991|DRUG|Levetiracetam|The best anti-epileptic drugs to patients who participate in this study，Levetiracetam，
41504941|NCT06633146|BEHAVIORAL|Therapies in nature|Therapeutic tasks in nature specifically designed for the study
41504942|NCT04693416|OTHER|Intrapersonal Stigma Reduction|Brief intervention for stigma reduction
41504943|NCT04693416|OTHER|Interpersonal Stigma Reduction|Brief intervention for support persons of intrapersonal intervention participants.
41504944|NCT03047629|DRUG|ENT-01|Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
41504945|NCT03047629|OTHER|Placebo|Daily dosing with a placebo
40849766|NCT02361008|DEVICE|TEE-guided perventricular device closure without CBP|Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
40849767|NCT02361008|PROCEDURE|Surgery repair with CBP|Traditional surgery repair under the CBP.
40849768|NCT03728179|COMBINATION_PRODUCT|Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib|"Low Dose Radiation (RT): RT will be administered as single fractions every 2 weeks (Q2W) from cycle C0 to cycle C4. RT will be delivered to a number of metastatic deposits visible by PET/CT, at the PI's discretion.~Cyclophosphamide: 200mg/m2 will be administered as intravenous infusion (IV) Q2W from cycle C0 to C4.~Nivolumab: 240 mg will be administered as IV Q2W from cycle C1 to C4.~Ipilimumab: 1mg/kg will be administered as IV every 6 weeks (Q6W) from cycle C1 to C4~Aspirin: 300mg will be administered orally daily from cycle C1 to C4. All subjects will receive mandatory gastric prophylaxis with an oral H2 antagonist.~Celecoxib: 200mg will be administered orally twice a day from cycle C1 to C4.~At the end of cycle C4, patients eligible for maintenance will be treated with nivolumab at 240mg Q2W until progression or excessive toxicity; celecoxib will be maintained if the drug is well tolerated"
40849769|NCT03815565|PROCEDURE|continuous femoral block|infusion of anesthetic by PCA pump
40849770|NCT06195410|OTHER|kangaroo care application|In the study, the mother applied kangaroo care to her premature baby for 65 minutes, and after a 24-72 hour washout period, the father applied kangaroo care for 65 minutes.
40849771|NCT01836926|PROCEDURE|Open intersphincteric resection|"laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum~Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.~laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description~intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach"
41374265|NCT05818046|PROCEDURE|Supervised Exercise therapy|Supervised exercise therapy consists of three exercise sessions per week for 3 months, combining treadmill walking, lower limb muscle strengthening and stretching exercises. It is considered highly effective for people with leg pain related to peripheral arterial disease and has shown statistically significant improvements in maximum walking distance and quality of life parameters.
40849772|NCT01836926|DEVICE|transanal minimally invasive intersphincteric resection|minimally invasive approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
40849773|NCT00344422|DRUG|Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)|
41504946|NCT03870165|BEHAVIORAL|Resistance exercise|Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
41163599|NCT06480578|BEHAVIORAL|ISS-SBDOH arm|Once the ID-Cap ISS system has identified a participant who has missed his/her prescribed ARVs for five (5) consecutive days, a member of the multidisciplinary team will be informed automatically by the system and reach out to the participant immediately. The team will work with the primary provider and the participant to evaluate and understand the patient's SBDOH profile and status and develop a coordinated plan that fits the patient's specific need to address the patient's particular challenges in SBDOH. This plan (all SBDOH interventions) is considered standard of care and would be initiated in the same manner regardless of participation. Participation in this study will not alter the planned interventions determined by the HIV Care team.
41163600|NCT04350983|BEHAVIORAL|Increased physical activity|PAP and enhanced individual support by physiotherapist to increase physical activity
41163601|NCT06479200|BEHAVIORAL|VR-guided mindfulness|The VR-guided mindfulness intervention is a 6-week home-based program delivered through an Oculus Quest 3 (or equivalent) headset. Participants practice 10-15 minutes of guided mindfulness exercises daily in immersive virtual environments. The program includes various mindfulness techniques such as body scans, breath awareness, and loving-kindness meditation, designed to reduce stress and improve well-being.
41163602|NCT06479200|OTHER|Sham VR|The sham VR intervention is a 6-week home-based program that involves viewing relaxing nature videos without any mindfulness content. Participants use the same VR headset as the experimental group and engage with the sham content for 10-15 minutes daily, matching the duration of the experimental intervention. This sham intervention controls for the effects of using VR technology and engaging in a relaxing activity.
41374266|NCT02381366|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"
41504947|NCT03870165|OTHER|Salmon|Participants will ingest salmon immediately after resistance exercise
41504948|NCT03870165|DIETARY_SUPPLEMENT|Isolated amino acids and fatty acids|Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise
41504949|NCT03478527|DIETARY_SUPPLEMENT|Vivomixx® powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
41504950|NCT03478527|OTHER|Placebo powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
41504951|NCT04705272|OTHER|Questionnaire|Pregnant women will be included in the study at the time of their first or second trimester ultrasound in the Hautepierre and CMCO ultrasound department. The period of inclusion should extend from 1 October 2020 to 31 October 2021 with a duration of participation of each subject of 9 months.
41504952|NCT05927597|DRUG|INS1007|Oral tablets.
41504953|NCT05927597|DRUG|Placebo|Oral tablets.
41504954|NCT05410587|DEVICE|Fracture Monitor (implantable device class III)|Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.
41504955|NCT04368351|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
41032487|NCT02897804|BEHAVIORAL|Expectancies, descriptive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032488|NCT02897804|BEHAVIORAL|Expectancies, descriptive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
41032489|NCT02897804|BEHAVIORAL|Expectancies,descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032490|NCT02897804|BEHAVIORAL|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
41032491|NCT02897804|BEHAVIORAL|Expectancies, descr& injun norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41374267|NCT02048527|OTHER|Global|Single medium for the culture of embryos from Day1 to Day 5
41374268|NCT02048527|OTHER|Origio|Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
41504956|NCT04368351|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
41504957|NCT04368351|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
41504958|NCT05766137|PROCEDURE|Alveolar ridge preservation|Socket preservation
41504959|NCT00117832|DRUG|Azelastine nasal spray|
41504960|NCT01509014|BEHAVIORAL|CPATCH intervention to support statin adherence|Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
41504961|NCT00303459|DRUG|bosentan|bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
41504962|NCT00303459|DRUG|placebo|Matching bosentan placebo/b.i.d.
41032492|NCT02897804|BEHAVIORAL|Expectancies, desc & injun norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
41032493|NCT02897804|BEHAVIORAL|Expectancies,desc & injun norms,benefits,efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
41032494|NCT00413153|DRUG|atazanavir/ritonavir|atazanavir 300mg + ritonavir 100mg once daily
41374269|NCT02360904|OTHER|Yoga|The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
41374270|NCT05182229|OTHER|Home-based (a hybrid model) CDT|Participants will be provided therapist-administered, in person complete decongestive therapy (CDT) two times per week for two weeks (4 sessions), followed by real-time, virtual CDT consultations two times per week for three weeks (7 sessions) and one in person follow-up visit.
41374271|NCT05182229|OTHER|Clinic-based CDT|Participants will be provided therapist administered, in-person CDT two times per week for six weeks (12 sessions).
41374272|NCT03136978|DIAGNOSTIC_TEST|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
41504963|NCT02691143|OTHER|TheraBand Kinesiology Tape|One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
41504964|NCT06064578|BEHAVIORAL|Project SOLVE|Project SOLVE is a \~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
41504965|NCT05435846|DRUG|Capmatinib|Given orally
41504966|NCT05435846|DRUG|Trametinib|Given orally
41504967|NCT04731792|OTHER|Virtual Reality|a bronchial fibroscopy with a virtual reality helmet
41504968|NCT03414684|DRUG|Carboplatin|Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
41504969|NCT03414684|DRUG|Nivolumab|Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
41504970|NCT05342779|PROCEDURE|stripping of great saphenous vein|"I will make 2 or 3 small cuts in your leg. The cuts are near the top, middle, and bottom of your damaged vein. One is in your groin. The other will be farther down your leg, either in your calf or ankle.~I will then thread a thin, flexible plastic wire into the vein through your groin and guide the wire through the vein toward the other cut farther down your leg.~The wire is then tied to the vein and pulled out through the lower cut, which pulls the vein out with it.~I will close the cuts with stitches. Patient will wear bandages and compression stockings on leg after the procedure."
41504971|NCT04082156|DEVICE|electrical stimulation|electrical stimulation
41504972|NCT04082156|DEVICE|Sham|no stimulation
41504973|NCT03842644|DEVICE|Tension reduction device|Continue using this device for 3 months post surgery.
41504974|NCT00309803|DEVICE|FiberNet Embolic Protection Device|
41504975|NCT06501430|OTHER|Heating Therapy|Heating Therapy will be performed on subjects along with PNF Exercises.
41032495|NCT00413153|DRUG|lopinavir/ritonavir|patient remains on their pre-study dose of lopinavir/ritonavir
41504976|NCT06501430|OTHER|Manual Soft tissue Release|Manual Soft tissue Release will be performed on subjects along with PNF Exercises.
41504977|NCT04641052|OTHER|Music listening|The music type will be chosen by the patients and researchers will not have any influence on their choices.
41032496|NCT05403489|PROCEDURE|Bronchoalveolar lavage|In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
41032497|NCT05403489|PROCEDURE|endotracheal aspirate culture|In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
41374273|NCT04510558|DEVICE|Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Application of an ULTRAPRO Advanced Mesh, Ethicon, Johnson \& Johnson, with +2cm on the edges, secured by 4 stiches of Maxon 2-0~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
41032498|NCT01303289|DIETARY_SUPPLEMENT|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
41032499|NCT01303289|DIETARY_SUPPLEMENT|Jevity|JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
41032500|NCT01510847|DRUG|Andriol Testocaps|Oral, 40mg, Twice a day, 30days
41032501|NCT03487250|DEVICE|TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
41163603|NCT06480604|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules once daily, for 6 months.
41374274|NCT04510558|PROCEDURE|Stoma closure without mesh|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
41374275|NCT02525367|BEHAVIORAL|Online cognitive training|The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
41032502|NCT03081455|DIAGNOSTIC_TEST|Diagnostic Test|Genetic Diagnostic Testing
41374276|NCT02525367|BEHAVIORAL|Active control condition|The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
41032503|NCT06042829|DEVICE|Intubation using aerosol box|Intubation time and ease of intubation using aerosol box
41032504|NCT06042829|DEVICE|Intubation without aerosol box|Intubation time and ease of intubation without aerosol box
41032505|NCT03408158|PROCEDURE|same type infusion of main HPA antigen|Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not
41163604|NCT06480604|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for for the duration of the study (6 months).
41163605|NCT02759887|PROCEDURE|biospecimen collection|Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
41163606|NCT02759887|OTHER|cognitive assessments|Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
41374277|NCT05554666|BIOLOGICAL|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
41374278|NCT00694330|BIOLOGICAL|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
41032506|NCT05393232|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
41032507|NCT05393232|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
41032508|NCT06617195|OTHER|Exercise|Young and older adults will perform a single bout of unaccustomed resistance exercise to evaluate molecular and cellular response in skeletal muscle
41032509|NCT01863680|DRUG|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent \[%\] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
41032510|NCT01863680|DRUG|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
41032511|NCT01863680|DRUG|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
41032512|NCT01863680|DRUG|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
41032513|NCT04405700|OTHER|Pharmacovigilance surveillance program|The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).
41032514|NCT03398538|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
41032515|NCT03398538|OTHER|Additional (outer) Dressing Application|Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
41032516|NCT03398538|OTHER|Mirragen Wound Matrix Dressing|Application of Mirragen to wound site along with standard of care treatment
41032517|NCT03398538|OTHER|Fibracol Wound Dressing|Application of Fibracol Alginate along with standard of care treatment
41032518|NCT01049906|PROCEDURE|Placement of nerve block catheter|Placement of nerve block catheter with nerve stimulator and ultrasound
41504978|NCT02028741|OTHER|Transverse vertebral pressures|Graded transverse mobilization directed to the thoracic spine
41504979|NCT02176785|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
41032519|NCT01049906|PROCEDURE|Placement of nerve block catheter|Placement of nerve block catheter with ultrasound only
41504980|NCT01171755|DRUG|Gemcitabine TS-1|Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA\<1.25 M2, 80 mg/day; 1.25 M2≤BSA\<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
40849774|NCT04591444|DRUG|Fluoride Varnish|Following the manufacturer's recommendations, it was not necessary to moisten or dry the treated surface beforehand or afterwards. The product was dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush, flowing into interproximal areas, and quickly adhering to the tooth surface in the presence of saliva.
41032520|NCT01201525|PROCEDURE|Pulsed dye laser treatment|Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.
41032521|NCT01201525|PROCEDURE|Control|Part 2 of the surgical scar will serve as a within patient control.
41032522|NCT00566228|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
41032523|NCT00566228|PROCEDURE|leukapheresis|Stem cells collected
41032524|NCT02332070|PROCEDURE|cardiac surgery|coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
41032525|NCT05932069|BEHAVIORAL|SPIN|Stationary cycling
41032526|NCT05932069|BEHAVIORAL|Non-aerobic, stretching/balance intervention Control|Balance and stretching exercise
41032527|NCT04116502|DRUG|Ruxolitinib|10mg of ruxolitinib twice daily (bd)
41032528|NCT04116502|DRUG|Hydroxycarbamide|Via standard hospital mechanisms
41032529|NCT04116502|DRUG|Interferon-Alpha|Any formulation, via standard hospital mechanisms
41032530|NCT06470932|DIAGNOSTIC_TEST|Follow-up consult|Patients will be ask to participate to a follow-up consult
41504981|NCT04093375|PROCEDURE|Radical Prostatectomy|Radical prostatectomy with or without androgen deprivation therapy
41032531|NCT05616533|OTHER|biopsy of tumor before treatment|samples obtained from biopsy will be used in the zebrafish PDX model
41032532|NCT03551938|BEHAVIORAL|Relationship skills session for YMSM partnered-individuals and couples|Relationship skills session as an addition to the current CTR and CHTC intervention for 15-24 year old YMSM and their partners.
41163607|NCT02759887|OTHER|caregiver questionnaire|
40849775|NCT04591444|DRUG|Glass Ionomer Sealant|Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
40849776|NCT04591444|OTHER|Placebo Group|4 weeks after the simulation of the treatment application, participants in the placebo group received DH treatment with the product that had the best effect in the first 4 weeks.
40849777|NCT02145065|DRUG|Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)|
40849778|NCT02145065|DEVICE|Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)|
40849779|NCT02675114|PROCEDURE|SAVR|SAVR with a commercially available bioprosthetic valve.
41032533|NCT06331221|OTHER|Muscle fatigue Protocol|Four experimental conditions consisting of different local muscle fatigue protocols performed in the isokinetic dynamometer in random order, with at least one week of interval between them.
41032534|NCT04393883|DRUG|A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;|(A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
41032535|NCT04393883|DRUG|B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;|(B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
41032536|NCT06635447|DRUG|Capivasertib|400 mg, oral, twice daily; 4 days on and 3 days off
41032537|NCT06635447|DRUG|Fulvestrant|Fulvestrant IV
41032538|NCT04365946|PROCEDURE|Gastroscopy|Upper GI endoscopy and biopsy
41032539|NCT01019655|DRUG|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
41032540|NCT03346668|DRUG|Topical gabapentin|topical gabapentin 6% solution
41032541|NCT06133894|BEHAVIORAL|Exercise program PERMANENTO inspired by developmental kinesiology|"The intervention is based on activation of reflexive movement patterns which ensures the original reflexive control of strength, mobility and stability. After birth, we cannot control our body movements - they are reflexes hard-wired into our brains and vitally important for proper development of our body (muscular system, vestibular system, sensory system, cardiovascular system or digestive system) as well as our brain and nervous systems. During early childhood, everything becomes integrated and works perfectly according to the original design. But this design is slowly abandoned due to for example sedentary lifestyle and replaced by compensatory movement patterns that are making us weaker and defective with all the consequences that are becoming more severe as we age. The aim is restore the original design and improve posture and other crucial components of functional fitness and move better and more."
40849780|NCT02675114|DEVICE|SAPIEN 3 THV|TAVR with the Edwards SAPIEN 3 Transcatheter Heart Valve and Edwards Commander Delivery System
40849781|NCT03449472|DRUG|Quetiapine|Patients are tested for their normal prescription quetiapine medication
40849782|NCT02883101|BEHAVIORAL|Pulmonary Rehabilitation|"The Rehabilitation Programme will include the following :~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
40849783|NCT04118595|BEHAVIORAL|Educational Video|Educational Video: Development of the original video was funded by the John A. Hartford Foundation and used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script was developed for a grade level 5.5 and will be shown to the patient within 24 hours of the acute care visit. A link to the video is emailed or texted to the patient.
40849784|NCT04118595|BEHAVIORAL|Telecare|Telecare will be provided via a protocol-guided phone call from a nurse care manager 48-72 hours after discharge from the ED or orthopedic urgent care. The call is designed to support patient decision-making regarding analgesics and behaviors following the content presented in the video. Topics covered in the call will include discussion of goals and priorities the patient has for their pain management, current prescriptions and analgesic use (and adjustments if needed), non-pharmacologic methods of pain management, warnings about potential side effects, current healthcare utilization, and open-ended questions to address additional patient care needs. Conversations will be guided by a shared decision making framework in which the nurse suggests pain management options, discusses their pros and cons, and actively elicits feedback from the patient. The telecare call is designed to last 15 minutes.
40849785|NCT04118595|BEHAVIORAL|Correspondence with Primary Care Provider|Following the telecare conversation, a note will be sent directly to the patient's primary care provider using a secure email or an electronic message that includes: 1) The date, time, location and reason for the index visit; (2) Results of diagnostics studies; (3) Discharge prescriptions/ recommendations; (4) A summary of and link to the video, explaining the emphasis on patient knowledge and SDM; (5) A summary of the telecare conversation; and (6) Encouragement for follow-up. PCPs will be asked to confirm receipt of this message.
41032542|NCT06635408|DIAGNOSTIC_TEST|cystatin c|a biomarker to assess renal function
41032543|NCT04055948|BEHAVIORAL|One-on-one teaching sessions|One-on-one teaching sessions with the caregiver during radiation treatments. (note - intervention sessions 2 \& 3 delivered by phone during COVID-19)
41032544|NCT04055948|BEHAVIORAL|Telephone booster contact|Telephone booster contact 2 weeks post-treatment.
41032545|NCT01267123|PROCEDURE|Trendelenburg position|The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination
41032546|NCT01267123|PROCEDURE|Standard care|The patient will be placed in the standard horizontal position
41032547|NCT05896306|OTHER|No intervention|No intervention
41163608|NCT02759887|PROCEDURE|Florbetapir F18 imaging|Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
41163609|NCT02759887|PROCEDURE|MRI|Magnetic resonance imaging of the head and brain.
41504982|NCT04093375|OTHER|Radical Radiotherapy|Radical Radiotherapy with adjuvant androgen deprivation therapy
41504983|NCT05127915|DEVICE|Adient absorbable filter + best practice VTE prophylaxis|Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
40849786|NCT06583356|BEHAVIORAL|Motivational interviewing|Participants will receive motivational interviewing intervention previously, delivered face-to-face at participants' home, 1 session, followed by 2 brief follow-up sessions. Each session is expected to last approximately 30 to 45 minutes.
40849787|NCT02484482|DRUG|CKD-519 200mg / Fasting, Standard Meal, High Fat Meal|
41504984|NCT05127915|DEVICE|best practice VTE prophylaxis|Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
41374279|NCT05727865|BEHAVIORAL|Online CBT following cardiac surgery|It will include psychoeducation, behavioral activation to address post-operative fatigue and depression, interoceptive exposure to reduce fear of cardiac-related symptoms and in-vivo exposure to reduce avoided situations, and activities to enhance physical activity and wellbeing. Labeling (i.e., describing post-operative and/or cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure and pain management
41374280|NCT00673868|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes|CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
41374281|NCT00004646|DRUG|prednisone|
41504985|NCT05412238|DIETARY_SUPPLEMENT|micro-and macro-nutrients fortified sachets|Every subject receives daily fortified sachets containing micro-and macronutrients for 6-9 months
41504986|NCT05178342|DRUG|CA-4948|"Patients will be treated orally with CA-4948 at 300 mg BID (2x200mg) over 4 cycles. One cycle consists of 28 days, 21 of which are treatment days, followed by 7 days off.~Patients with erythroid response (HI-E) after 4 cycles who tolerate CA-4948 may continue to receive CA-4948 until loss of HI-E response."
41504987|NCT04220424|DIAGNOSTIC_TEST|MR and Histopathology images based prediction of molecular pathology and patient survival|MR and Histopathology images based prediction of molecular pathology and patient survival in gliomas by leverage artificial intelligence algorithms
41504988|NCT02594670|OTHER|DU20 and HT7 combination|acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
41504989|NCT02594670|OTHER|DU20 and SP6 combination|acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
41504990|NCT02594670|OTHER|DU20 and SA combination|Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
40849788|NCT05150522|BIOLOGICAL|BCMA CAR-T cells|BCMA CAR-T cells infusion
40849789|NCT06160427|BIOLOGICAL|CTM Boost|Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue. It is considered a minimally-manipulated biologic by the FDA and is marketed as an allograft for repairing connective tissue. It is administered via injection.
40849790|NCT06160427|BIOLOGICAL|PRP|"PRP is derived by a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing.~At baseline, a blood draw of 60 milliliter (mL) will be obtained and concentrated in an Angel System to yield 5 cc of PRP and a supra-physiological concentration of white blood cells. All injections will be done under ultrasound guidance. A two-part injection process will be used. An advancing 20 gauge 1.5-inch needle first placed 3 mL of 1% xylocaine proximal to the tendinopathic area or tear. The needle will then be re-inserted at the proximal aspect of the lesion and slowly removed while infiltrating of 5 mL of PRP without activation with Calcium Chloride/thrombin at the lesion and surrounding tendon."
41032548|NCT02920905|DRUG|Lidocaine|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
41032549|NCT02920905|DRUG|atracurium|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
41163610|NCT02759887|PROCEDURE|Fludeoxyglucose F18 (FDG)|Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
41374282|NCT02568111|DRUG|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
41504991|NCT00462150|BEHAVIORAL|home-based emotional disclosure|
41504992|NCT00462150|BEHAVIORAL|time management control condition|
40849791|NCT03653676|OTHER|Exercise Test (CIIT)|The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
40849792|NCT02800083|DRUG|Pitolisant (BF2.649)|
40849793|NCT02800083|DRUG|Placebo|
40849794|NCT03263260|DEVICE|implant|coronary stent implantation
40849795|NCT05573126|DRUG|EP0062|EP0062 is an orally administered investigational selective androgen receptor modulator (SARM)
40849796|NCT02943421|PROCEDURE|Transverse B-Lynch suture|
40849797|NCT02979223|DRUG|sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid|"sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group"
41163611|NCT02759887|PROCEDURE|Tau Pet|Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
41163612|NCT02759887|PROCEDURE|Actigraphy|A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
41163613|NCT02604797|DRUG|Nalbuphine|patient-controlled intravenous analgesia
41163614|NCT02604797|DRUG|Sufentanil|patient-controlled intravenous analgesia
41163615|NCT02604797|DRUG|flurbiprofen axetil|patient-controlled intravenous analgesia
41163616|NCT02604797|DRUG|ramosetron|patient-controlled intravenous analgesia
41163617|NCT01318538|BEHAVIORAL|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
41163618|NCT01318538|BEHAVIORAL|Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
41163619|NCT04069429|RADIATION|Computerized Tomography scan|imaging scan from a person's eyes to their thighs
41504993|NCT01014793|DRUG|cabergoline|cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
40849798|NCT05458323|DEVICE|Free near and Distance Vision glasses|Intervention Description: All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction.Glasses will be provided at the time of enrolment in the study.
40849799|NCT03905850|DRUG|somapacitan|5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)
40849800|NCT00358969|DRUG|guanfacine (Tenex)|
40849801|NCT00999518|BIOLOGICAL|Tanezumab|1 mg dose given subcutaneously twice at an 8-week interval.
40849802|NCT00999518|BIOLOGICAL|Tanezumab|2.5 mg dose given subcutaneously twice at an 8-week interval.
40849803|NCT00999518|BIOLOGICAL|Tanezumab|10 mg dose given subcutaneously twice at an 8-week interval.
40849804|NCT00999518|BIOLOGICAL|Tanezumab|20 mg dose given subcutaneously twice at an 8-week interval.
41032550|NCT02920905|DRUG|Mg sulphate|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
41032551|NCT00093769|DRUG|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~* Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
41032552|NCT01279226|DEVICE|Auralevée device|Single treatment with Auralevée device.
41032553|NCT01018901|OTHER|Survey Administration|Patients complete survey
41032554|NCT00406575|DRUG|Placebo|Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
41032555|NCT00406575|DRUG|Recombinant human relaxin (rhRlx)|Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
41163620|NCT04069429|RADIATION|Single Photon Emission Computed Tomography scans|imaging scan taken during, and after, the administration of the radioactive agent
41163621|NCT04069429|DRUG|Technetium Tc 99M|subjects are administered radioactive heparin as part of study participation.
41163622|NCT04069429|RADIATION|Planar Images|2 dimensional imaging - whole body planar scans
41163623|NCT04069429|PROCEDURE|Esophagogastroduodenoscopy|esophagogastroduodenoscopy with tissue biopsies
41163624|NCT06460181|DIETARY_SUPPLEMENT|Astaxanthin|Manufactured by AstaReal Inc
41163625|NCT06460181|DIETARY_SUPPLEMENT|Placebo|Manufactured by AstaReal Inc
40849805|NCT00999518|OTHER|Placebo|Placebo dose given subcutaneously twice at an 8-week interval.
40849806|NCT06452043|OTHER|PARC program|Activities in nature such as walking, exercises (strengthening, mobility, balance), pedal boat, yoga, dance, mindfulness, meditation, forest bathing or Shinrin-Yoku, interpretation of nature
41504994|NCT05095571|DIETARY_SUPPLEMENT|EH301 (Nicotinamide Riboside/Pterostilbene)|For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
41504995|NCT01296997|DIETARY_SUPPLEMENT|calcium phosphate|the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
41163626|NCT03500263|DRUG|PTI-808|Active
41163627|NCT03500263|DRUG|Placebo|Placebo
41374283|NCT02568111|DRUG|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
41374284|NCT02568111|DRUG|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
41374285|NCT04595825|BIOLOGICAL|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
41504996|NCT01296997|OTHER|placebo|the subjects consumed a bread without pentacalcium phosphate
41504997|NCT04718948|DEVICE|Urinary Multimodal Fiber Optic Spectroscopy|"Approach based on a physical principle, mainly spectroscopy, which is rapid non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in urine samples.~It will be administered through a appositely designed device"
41504998|NCT04718948|DIAGNOSTIC_TEST|Urine Cytology|An expert cytopathologist will analyze urine samples to detect urinary tract cancer cells. It is the current golden standard to detect urothelial cancer in urine
41504999|NCT04718948|PROCEDURE|Surgery|It will provide a reliable information on the presence/absence of cancer in the urinary tract (from direct visualization to pathological analysis)
41374286|NCT04595825|OTHER|Placebo|Placebo - intravenous infusion
41374287|NCT00478504|DRUG|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
41032556|NCT06502171|DRUG|Cabozantinib Oral Tablet|"Cabozantinib will be taken once a day. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 20 mg.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events.~Cabozantinib may be taken simultaneously with selumetinib."
41163628|NCT03500263|DRUG|PTI-801|Active
41163629|NCT03500263|DRUG|PTI-428|Active
41163630|NCT03500263|DRUG|Placebo|Placebo
41505000|NCT00166582|DEVICE|electronic medication monitoring system|
41505001|NCT00166582|BEHAVIORAL|parent-adolescent communication and problem-solving skills|
41505002|NCT05940012|OTHER|Manual Therapy|Hands on treatments including manipulation, mobilization and soft-tissue mobilization with therapeutic intent.
41505003|NCT02366273|OTHER|PASI and HOMA index|
41163631|NCT05866341|DIETARY_SUPPLEMENT|nitrate-rich lettuce juice|Consumption of a daily dosage of 200 mg nitrate via the consumption of a 300mö of a nitrate-rich lettuce juice
41374288|NCT00478504|DRUG|Clomifene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
41505004|NCT00506701|DRUG|Tadalafil|40 mg tablet
41505005|NCT03391726|OTHER|CART-19 cells|CART-19 cells treat
41163632|NCT05866341|DIETARY_SUPPLEMENT|nitrate-depleted lettuce juice|Daily consumption of 300 ml of a nitrate-depleted lettuce juice
41163633|NCT02535962|BIOLOGICAL|Lactobacillus acidophilus and Bifidobacterium lactis|study product will be freeze dried and put into foil sachets
41163634|NCT02535962|OTHER|Placebo|Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
41163635|NCT04233333|DEVICE|method of fixation of the orogastric tube|Methods of fixation of the orogastric tube will be randomized
41163636|NCT01220856|DRUG|Reparixin|Reparixin + immunosuppression
41374289|NCT05737394|PROCEDURE|Laparoscopic-guided TAP Block|Laparoscopically-assisted placement of block
41374290|NCT05737394|PROCEDURE|Ultrasound-guided TAP Block|Ultrasound-assisted placement of block
41374291|NCT05718921|DRUG|YR001 Dose A on low body surface area|Part A: Single topical dose
41374292|NCT05718921|DRUG|YR001 Dose A on middle body surface area|Part A: Single topical dose
41374293|NCT05718921|DRUG|YR001 Dose A on high body surface area|Part A: Single topical dose
41374294|NCT05718921|DRUG|YR001 Dose B on low body surface area|Part A: Single topical dose
41374295|NCT05718921|DRUG|YR001 Dose B on middle body surface area|Part A: Single topical dose
41374296|NCT05718921|DRUG|YR001 Dose B on high body surface area|Part A: Single topical dose
41374297|NCT05718921|DRUG|Placebo on low body surface area|Part A: Single topical dose
41374298|NCT05718921|DRUG|Placebo on middle body surface area|Part A: Single topical dose
41374299|NCT05718921|DRUG|Placebo on high body surface area|Part A: Single topical dose
41505006|NCT00238355|DRUG|caspofungin acetate|70 mg iv x 1 on day 1 (loading dose), followed by 50 mg iv daily on day 2 through day 84.
41505007|NCT00238355|DRUG|voriconazole|6mg/kg iv q12 hours x 2 doses OR 400mg po q12hours on day 1 (loading doses. Maintenance doses on day 2 through day 84 may be either 4 mg/kg iv q12 hours, or 200 mg po q12 hours (at least one hour before or after meals).
41505008|NCT03107221|BEHAVIORAL|"Smart Eating internet-based self-help programme"|An internet-based self-help programme using cognitive behavioural therapy principles to treat individuals receiving input from a specialist eating disorders service. The programme takes 3 months to complete.
41505009|NCT04521387|PROCEDURE|injection therapy|The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.
41505010|NCT04521387|DRUG|Platelet Rich Plasma|Platelet rich plasma injection in the painful area of humeral epicondyle.
41505011|NCT04521387|DRUG|Corticosteroid Injection|Corticosteroid injection in the painful area of humeral epicondyle.
40849807|NCT03253328|DRUG|Active Arm N-acetyl cysteine (NAC)|N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
40849808|NCT03253328|DRUG|Placebo Arm|Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
40849809|NCT02166268|DRUG|AVANZ Phleum pratense 15,000 SQ+|
40849810|NCT02166268|DRUG|Placebo|
40849811|NCT02396589|BEHAVIORAL|Education Group|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
40849812|NCT02396589|BEHAVIORAL|Home Modifications Group|The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
41163637|NCT02262390|PROCEDURE|Partner Notification Reminders|"For all 3 arms, the following will be done:~* All participants will have an antenatal clinic visit every 4 weeks until delivery.~* All notification slips will be duplicate; one given to the mother and one held in the clinic. The study ID number will be documented on the slip. On partner return the slips will be matched and used to link mothers with male returning partners.~* Partner participant test result will be linked to the patient using the participant ID number in the lab. Partners will be tested using a rapid treponemal antibody test."
41505012|NCT04521387|DRUG|Hyaluronic Acid Injection|Hyaluronic acid injection in the painful area of humeral epicondyle.
41505013|NCT04521387|OTHER|Placebo Injection|Saline injection in the painful area of humeral epicondyle.
41505014|NCT03997279|DRUG|Saccharomyces boulardii|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week
40849813|NCT02457949|OTHER|Non-synchronized social assistance receipt|Social assistance disbursement outside government cheque issue week
40849814|NCT02457949|OTHER|cheque divided into two equal disbursements|Social assistance disbursement divided into two equal payments
41374300|NCT05718921|DRUG|YR001 Dose A on high body surface area twice daily|Part B: Multiple topical dose
41374301|NCT05718921|DRUG|YR001 Dose B on high body surface area twice daily|Part B: Multiple topical dose
41374302|NCT05718921|DRUG|Placebo on high body surface area twice daily|Part B: Multiple topical dose
41374303|NCT03495752|OTHER|Bruce Fatigue Protocol|Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
41374304|NCT05703009|DRUG|Sacrosidase Oral Solution|Study drug
41374305|NCT05703009|DRUG|Placebo|Placebo
41374306|NCT05896072|PROCEDURE|Erector Spinae Plane Block|"Application of ultrasound-guided erector spinae plane block for perioperative analgesia for elective inguinal hernia repair. Erector spinae plane block will be administered under general anesthesia before the surgery~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc)."
41374307|NCT05896072|PROCEDURE|Caudal Block|"Application of caudal block for perioperative analgesia for elective inguinal hernia repair. The caudal block will be administered under general anesthesia before the surgery.~Drug: Bupivacaine (Block Drug)~0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for block performances"
41374308|NCT05920057|BEHAVIORAL|constructive emotional management interventions|The Constructive emotional management interventions sessions were conducted in the activity rooms of the elderly clubs where the researchers met the participants. Participants completed a baseline evaluation of the outcome measures of the researched variables after being found to be eligible for the current study and indicating their willingness to participate willingly. After explaining the study's objectives to participants, the researchers themselves delivered the Constructive Emotional Management Interventions program, which had been vetted by experts in the field.
41374309|NCT00497822|PROCEDURE|Aerobic exercise training|
41374310|NCT06301126|OTHER|Virtual reality|The system included an Xbox 360® console, a sensor that detects motion (Kinect®), and a projector device with loudspeakers. The console, which was mounted on a table, reached 1 m tall. The Kinect® motion sensor was attached to the projector, which showed images onto a wall 2.5 metres distant from the playing field. The playing field was at least 1.8 m wide and 1.8 m long, with the Kinect® sensor situated 1.2 m away. The device was calibrated before each training session to accurately follow the motions of each subject.
41374311|NCT06301126|OTHER|conventional physical therapy exercise program|Participants will receive conventional physical therapy exercise program (Deep diaphragmatic, costal breathing exercises, bronchial hygiene techniques and assisted cough) for 45 minutes, 5 days/ week for 8 weeks.
41374312|NCT01250691|OTHER|ward-type ICU|frequency of hospital acquired pneumonia in the ICU
41374313|NCT05186376|PROCEDURE|bimaxillair osteotomy with maxillar segmentation|Patients who underwent bimaxillair osteotomy with maxillar segmentation
41374314|NCT01298362|DRUG|Aromatase Inhibitors|
41505015|NCT03997279|DRUG|Placebo|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week
40849815|NCT00934908|DIETARY_SUPPLEMENT|Green Tea|Green tea capsules taken twice a day.
40849816|NCT00934908|OTHER|Placebo|"Non-active sugar pill."
41374315|NCT01298362|DRUG|Chemotherapy|
41374316|NCT02951182|DRUG|TEZ|
41374317|NCT02951182|DRUG|IVA|
41374318|NCT02951182|DRUG|VX-440|
41374319|NCT02951182|DRUG|Matched Placebo|
41374320|NCT03495895|BEHAVIORAL|Minding the Baby|Visits are carried out on an alternating basis by a team made up of a nurse practitioner (NP) and social worker.
41374321|NCT03495895|BEHAVIORAL|Usual Care|Usual care condition
40849817|NCT00376857|DRUG|Surgery with and without the aid of Indocyanine Green (ICG)|
40849818|NCT03727906|OTHER|No pre-sleep arousal manipulation|As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.
41163638|NCT00931918|DRUG|Bortezomib|Bortezomib IV
41163639|NCT00931918|DRUG|Rituximab|Rituximab IV
41163640|NCT00931918|DRUG|Cyclophosphamide|Cyclophosphamide IV
41505016|NCT00702988|DRUG|Org 36286|single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
41505017|NCT00702988|DRUG|recFSH|150 IU recFSH daily (reference group administered under protocol 38826)
41505018|NCT03097991|BEHAVIORAL|Focused Coparenting Consultation|Six 90-minute sessions completed within 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
41505019|NCT05434637|OTHER|Physical Therapy|Individuals randomized to this intervention will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.
41505020|NCT05434637|OTHER|Sound-based Therapy|Individuals randomized to this intervention will receive sound-based therapy, consistent with an audiology-based standard of care treatment.
41505021|NCT05434637|OTHER|Combination Therapy|Individuals randomized to this intervention will receive both individualized physical therapy and sound-based therapy.
41505022|NCT06057402|DRUG|Elranatamab|Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
41374322|NCT01342809|BEHAVIORAL|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
41374323|NCT02409680|DRUG|Low dose aspirin|Daily administration of low dose (81 mg) aspirin \[also known as acetylsalicylic acid (ASA\], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
41374324|NCT02409680|DRUG|Placebo|Placebo
41374325|NCT00075101|DRUG|Dexamethosone|10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
41505023|NCT05343546|DEVICE|Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion|"Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion within seven days of giving Misoprostol Early insertion or 2-4 weeks after Misoprostol use Standard insertion"
41374326|NCT02992808|DRUG|recombinant gonadotropins|
41505024|NCT00005957|RADIATION|Standard Breast Irradiation|Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
41505025|NCT00005957|RADIATION|Breast Radiation plus Regional Radiation|Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
41505026|NCT01182376|DRUG|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
41505027|NCT01182376|DRUG|Placebo|Placebo will be administered by the patient's team according to established guidelines.
41505028|NCT04659603|DRUG|tusamitamab ravtansine|"Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion"
41505029|NCT04659603|DRUG|Gemcitabine|"Pharmaceutical form: Lyophilized powder for reconstitution or as a solution for infusion;~Route of administration: IV infusion"
41505030|NCT06328049|DRUG|Trilaciclib Injection|Patients with lung adenocarcinoma were given Trilaciclib combined with pemetrexed and carboplatin, Q3W; For patients with lung squamous cell carcinoma,Trilaciclib combined with paclitaxel/albumin-bound paclitaxel and carboplatin, Q3W. From cycle 2 onwards, patients chose whether to use trasylol with chemotherapy.
41505031|NCT05913505|BEHAVIORAL|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
41505032|NCT05913505|BEHAVIORAL|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
41374327|NCT02992808|DRUG|HP-HMG|
41374328|NCT02557191|OTHER|Observational study|
41374329|NCT04543747|DEVICE|HeartWare Ventricular Assist Device|The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
41374330|NCT02208466|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
41374331|NCT02208466|DRUG|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
41374332|NCT02208466|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
41374333|NCT02208466|DRUG|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
41374334|NCT06165575|DEVICE|Press needle|Press needle is a very small needles (1-3 mm long) that are 'pressed' onto acupuncture point and are held in place with a small, sterile surgical adhesive patch.
41374335|NCT06165575|DEVICE|Sham press needle|Sham press needle is a surgical adhesive patch placed on acupuncture points
41505033|NCT04831424|BEHAVIORAL|Trier social stress test|The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
41505034|NCT04148573|DRUG|NFX88 - 1|3 times a day
41505035|NCT04148573|DRUG|NFX88 - 2|3 times a day
41505036|NCT04148573|DRUG|NFX88 - 3|3 times a day
41505037|NCT04148573|DRUG|PLACEBO - 4|3 times a day
41505038|NCT00583388|DIETARY_SUPPLEMENT|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
41505039|NCT00583388|DEVICE|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
41505040|NCT00338728|DRUG|Imatinib Mesylate|Given PO
41505041|NCT00338728|DRUG|Letrozole|Given PO
41505042|NCT04939220|PROCEDURE|TEE with SGA|SGA Placement and maintenance with inhalational anesthetic or propofol
41505043|NCT04939220|PROCEDURE|TEE with Deep Sedation|Deep sedation with propofol and natural airway
41505044|NCT06257095|BEHAVIORAL|Stepped-care social and mental health engagement|Each student will be matched to an older adult and the students will make one call o the older adult which lasts upto 1 hour each week for 8 weeks. Ending each call, the student will assess symptoms of depression anxiety through questionnaires. If the participant responds yes on two consecutive calls to any of these questions, they will be asked if they would like to receive a call from the University of Texas Health Science Center Trauma and Resilience Center to discuss free counseling services.
41505045|NCT06257095|BEHAVIORAL|APS Usual care|Participants will receive a phone call for data collection. Then they will be offered to receive an abbreviated version of the stepped-care social and mental health engagement intervention, lasting only 6-weeks with the option to continue calls if agreeable between the student and older adult.
41505046|NCT04550923|COMBINATION_PRODUCT|Z-Brace interbody fusion device|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
41032557|NCT06502171|DRUG|Selumetinib Oral Capsule|"Selumetinib will be taken twice a day, at least 6 hours apart. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 15 mg twice a day.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events."
41032558|NCT06393452|DRUG|PP405 0.05% Topical Gel|PP405 is an inhibitor of mitochondrial pyruvate carrier (MPC)
41032559|NCT06393452|DRUG|PP405 Topical Vehicle Gel|PP405 Vehicle = placebo
41032560|NCT02863640|DEVICE|Color retinography|
41374336|NCT03726242|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
41374337|NCT03726242|DRUG|Saline|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
41374338|NCT05333861|DRUG|hetrombopag|According to prescription
41374339|NCT00790270|DRUG|Cyclobenzaprine|5 mg orally every 8 hours as needed
41374340|NCT00790270|DRUG|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
41374341|NCT00790270|DRUG|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
41505047|NCT04550923|COMBINATION_PRODUCT|PEEK interbody fusion device|Use rigid (PEEK) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
41032561|NCT02863640|DEVICE|Optical coherence tomography|
41032562|NCT02863640|DEVICE|Fundus autofluorescence imaging|
41032563|NCT04329104|BIOLOGICAL|VRC-MALMAB0100-00-AB (CIS43LS)|Administered via one-time IV infusion
41032564|NCT04329104|OTHER|Normal saline|Administered via one-time IV infusion
41032565|NCT03140748|OTHER|To evaluate the initial levels and kinetics of serum β-D-glucan|To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
41374342|NCT03309072|DEVICE|tDCS|active tDCS
41374343|NCT03309072|DEVICE|sham tDCS|sham tDCS
41374344|NCT02222168|DRUG|BI 409306|film-coated tablet
41374345|NCT02978729|OTHER|Two-way videoconference remote genetic counseling|
41374346|NCT02978729|OTHER|Telephone remote genetic counseling|
41374347|NCT02736331|DIETARY_SUPPLEMENT|Treatment 1|Treatment 1 Beverage
41374348|NCT02736331|DIETARY_SUPPLEMENT|Treatment 2|Treatment 2 Beverage
41374349|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
41374350|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
41505048|NCT02254434|DRUG|Eltrombopag|Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
41163641|NCT00931918|DRUG|Doxorubicin|Doxorubicin IV solution
41163642|NCT00931918|DRUG|Vincristine|Vincristine IV
41163643|NCT00931918|DRUG|Prednisone|Prednisone tablet
41163644|NCT00885326|DRUG|Bevacizumab|Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
41163645|NCT00885326|DRUG|cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
41163646|NCT00885326|DRUG|zoledronic acid|Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
40849819|NCT03727906|OTHER|pre-sleep arousal down-regulation|"On the low pre-sleep arousal night, about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process."
40849820|NCT03727906|OTHER|pre-sleep arousal up-regulation|"On the high pre-sleep arousal night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone)."
41032566|NCT03151733|PROCEDURE|single incision laparoscopic surgery|Patients undergo single incision laparoscopic surgery
41032567|NCT03151733|PROCEDURE|conventional laparoscopic surgery|Patients undergo conventional laparoscopic surgery
41032568|NCT03837652|OTHER|Use of bone-borne palatal expander & maxillary osteotomy|Application of bone-borne palatal expander in conjunction with maxillary osteotomy for expansion of constricted maxillae
41032569|NCT05230524|DEVICE|DiamondTemp™ Ablation System|Pulmonary vein isolation will be performed with the DiamondTemp™ Ablation System
41032570|NCT05263531|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to design pressure for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
41032571|NCT00326235|DRUG|Buspirone|
41032572|NCT02582905|DRUG|Placebo|Inactive ingredient matching the active comparators in appearance.
41163647|NCT02956083|OTHER|Systane Balance eye drops|Propylene Glycol 0.6% Over the counter lipid based artificial tears.
41163648|NCT02956083|OTHER|Systane Contacts eye drops|Hydroxypropyl methycellulose over the counter non-lipid based artificial tears
41163649|NCT02956083|OTHER|saline|Saline - no brand name
41163650|NCT00118703|DRUG|GW685698X|
41163651|NCT00961298|DRUG|Duloxetine|All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
41163652|NCT02674048|OTHER|Metvix|
41163653|NCT00520403|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
41163654|NCT00520403|DRUG|Interferon alfa-2a|3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
41163655|NCT00520403|DRUG|Vinblastine|0.1mg/kg iv every 3 weeks
41505049|NCT05299528|BEHAVIORAL|Direct Feedback|Procedure-specific direct feedback will be provided to surgeon participants through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
41505050|NCT03735004|DEVICE|Transcranial electrostimulation (TES)|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
41032573|NCT02582905|DIETARY_SUPPLEMENT|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
41032574|NCT02582905|DRUG|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
41032575|NCT00264615|DRUG|lamotrigine extended-release|
41032576|NCT03906331|DRUG|Selpercatinib|Open-label expanded access
41163656|NCT02301364|DRUG|Buparlisib (BKM120)|Buparlisib 100 mg once daily.
41163657|NCT01201915|DRUG|Vismodegib|Vismodegib was supplied in gelatin capsules.
41163658|NCT01121185|BIOLOGICAL|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
41163659|NCT01121185|OTHER|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
41163660|NCT01728207|DRUG|IMMU-114|hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
41374351|NCT01366846|OTHER|Avoidance of peanut|All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
41374352|NCT04281849|BEHAVIORAL|BAMS-HF Program|"BAMS-HF Program (intervention) arm will consist of 3 in-home sessions (45-60 min ea) per week for 12 weeks with the study physical therapist. The study physical therapist will transition appropriate participants to virtual in-home visits (i.e. telerehabilitation) for some visits. The study physical therapist will design individualized exercise programs first targeting strength, then mobility and balance, and finally, aerobic capacity. Exercises will be progressive, with the goal of an 8 repetition maximum for each strength component, 80% completion rate for balance/mobility components and targeting a moderate rate of perceived exertion for aerobic components.~Interviews: There will be a recorded interview after the last session of the study to get participants' opinion of the program, suggestions for improvement and description of any barriers to participating in the program fully."
41374353|NCT02036892|BEHAVIORAL|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
41374354|NCT02036892|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
41374355|NCT04352075|DRUG|Autologous biologic drug of innovative therapy /cell therapy drug|Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution
41374356|NCT01536522|DIETARY_SUPPLEMENT|Nutritional approach for asthma|participants will be provided a medium chain triglyceride supplement or placebo
41374357|NCT01536522|DIETARY_SUPPLEMENT|Low Caloric Shake|participants will be provided a low caloric dietary shake
41374358|NCT01536522|BIOLOGICAL|whole lung allergen challenge|inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation
41374359|NCT00467051|DRUG|Carboplatin|Given IV
41163661|NCT01746108|BIOLOGICAL|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
41374360|NCT00467051|BIOLOGICAL|Filgrastim|Given IV or subcutaneously
41374361|NCT00467051|DRUG|Ifosfamide|Given IV
41374362|NCT00467051|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41374363|NCT00467051|DRUG|Paclitaxel|Given IV
41374364|NCT03825887|DRUG|Nalbuphine|"Nalbuphine (Group B): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
41374365|NCT03825887|DRUG|Morphine|"morphine (Group A): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
41374366|NCT06231901|OTHER|CO-OP|With a task-specific and goal-focused CO-OP approach; it is aimed to increase one's skills, to teach to use self-generated cognitive strategies, and to encourage generalization and transfer to new situations and activities.
41374367|NCT06231901|OTHER|GDT|Goal-directed training included the active implementation of task-specific activities related to the child's functional goals. Focusing on motor learning, GDT is an activity-based approach to therapy that uses meaningful, self-selected goals to provide opportunities for problem solving and indirectly guide the movements necessary to successfully meet task demands
41374368|NCT06231901|OTHER|traditional occupational therapy|The program included functional one-handed and two-handed training and consisted of advice and treatment aimed at reducing spasticity, improving hand function and activities of daily living, and providing appropriate orthoses. It also includes techniques aimed at improving impairment (e.g., stretching, sensory stimulation) and strengthening activities (e.g., motor training, environmental modification, performing specific target activities) to help participants achieve their individual goals.
41374369|NCT00564876|DRUG|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
41374370|NCT05376540|PROCEDURE|Direct gallbladder injection of ICG intraoperatively|Patients randomized to this arm will have 2.5 mg ICG injected directly into the gallbladder intraoperatively.
40849821|NCT00512785|DRUG|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 52 weeks
40849822|NCT00512785|DRUG|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
41032577|NCT02829437|OTHER|Treatment for EST|Surgery and/or Chemotherapy and or/radiotherapy for EST treatment according to disease guidelines: no specific treatment is imposed by protocol (observational study)
41032578|NCT01704339|DRUG|QUTENZA|Single treatment with topical capsaicin 8%
41032579|NCT03851653|BEHAVIORAL|Lifestyle Intervention|Cognitive-behavioural intervention for weight loss and lifestyle change
41163662|NCT05436106|BEHAVIORAL|Adaptive Intervention Approach|"This is an adaptive intervention approach with 7 module-based sessions selected on the basis of post-session assessments of acceptability and satisfaction;~1. weekly group sessions will be co-led by a community member with expertise in working with transgender women and a public health nurse,~2. supplemental educational content will be available for individual consumption via an online portal or application (and tracked via participant click counts), and~3. additional social resources will be available through the online portal or app."
41032580|NCT04669704|OTHER|Experimental: Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology."
41163663|NCT06219681|BEHAVIORAL|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the repetitive negative thinking (RNT) related brain functional connectivity.
41163664|NCT06219681|BEHAVIORAL|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
41163665|NCT03271177|DEVICE|7F sheathless Guide Catheter|Transradial PCI will be performed with a 7F sheathless Guide Catheter
41374371|NCT05376540|PROCEDURE|Intravenous injection 2.5 mg|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prio to surgery
41374372|NCT05376540|PROCEDURE|Intravenous injection and direct gallbladder injection|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prior to surgery and another 2.5 mg ICG injected directly into the gallbladder, intraoperatively.
41374373|NCT05376540|PROCEDURE|Intravenous injection 5 mg|Patients randomized to this arm will have 5 mg ICG injected intravenously 0-8 hours prior to surgery
41374374|NCT03493477|OTHER|exposure will be abnormal skeletal jaw relations|Class II skeletal jaw relation or class III skeletal jaw relation based on lateral cephalometric radiograph
41374375|NCT00592137|DIETARY_SUPPLEMENT|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
41374376|NCT00592137|DIETARY_SUPPLEMENT|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
41374377|NCT00592137|DIETARY_SUPPLEMENT|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
41032581|NCT04669704|OTHER|Comparator: Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
41032582|NCT06038721|BEHAVIORAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children|The UP-C is administered in-person to parents and children over the course of up to 15 weekly group sessions, which last approximately 90 minutes each.
41374378|NCT03215602|OTHER|NEMEX and education + strength training|Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
41032583|NCT06038721|BEHAVIORAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents|The UP-A is administered to parents and teens over the course of approximately 15-24 weekly individual sessions, which last approximately 50 minutes each. Sessions can be administered in-person or online, with at least one session occurring in person.
41163666|NCT03271177|DEVICE|6F Sheath/Guide Catheter Combination|Transradial PCI will be performed with a 6F Sheath/Guide Catheter Combination
41032584|NCT00727272|DRUG|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered after an overnight fast of at least 10 hours.
41032585|NCT00727272|DRUG|Quinine Sulphate Tablets 300 mg|One 300 mg tablet administered after an overnight fast of at least 10 hours.
41032586|NCT00727272|DRUG|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
41032587|NCT00692172|DRUG|Alefacept|intramuscular injection (IM)
41374379|NCT03215602|OTHER|NEMEX and education|Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
41374380|NCT03397576|BEHAVIORAL|ATHENA|Adherence Through Home Education and Nursing Assessment (ATHENA), is an evidence-based ART adherence intervention delivered in the patient's home by nurses and peer educators working in teams.
41374381|NCT02618148|DRUG|ESTROGEN HERBALS 21|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
41374382|NCT02618148|DRUG|ESTROGEN HERBALS 28|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
41374383|NCT03696537|DRUG|Fludarabine|Fludarabine 30 mg/m2/day IV (total 5 doses) administered days -7 through -3 of conditioning regimen
41032588|NCT05567887|DRUG|maplirpacept (PF-07901801)|maplirpacept (PF-07901801)
41032589|NCT05190393|PROCEDURE|hemivertebra resection on convex side|Patients were used hemivertebra resection procedure to treat congenital cervical scoliosis.
41032590|NCT05190393|PROCEDURE|concave distraction group|Patients were used distraction and lateral opening procedure to treat congenital cervical scoliosis.
41032591|NCT03808506|DIAGNOSTIC_TEST|Fecal calprotectin|Stool test to look at baseline burden of inflammation
41032592|NCT06634654|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty is performed using conventional surgical techniques.
41032593|NCT06634654|DIAGNOSTIC_TEST|Multifaceted diagnostic assessments|Multifaceted diagnostic assessments involving genetic analysis, biomechanical data collection, radiographic imaging, and psychological evaluations.
41032594|NCT06634654|BEHAVIORAL|Follow-ups|Postoperative follow-up includes behavioral interventions, such as lifestyle counseling and rehabilitation programs, tailored based on AI-driven insights into individual patient recovery profiles.
41032595|NCT06634654|GENETIC|Genetic screening|Genetic screening and analysis, including whole exome sequencing, are conducted to identify genetic markers that might influence the outcomes of knee arthroplasty. This data is utilized within AI models to predict patient-specific surgical outcomes and recovery processes.
41032596|NCT01448746|DRUG|low molecular weight heparin|40mg 12 hours before surgery and 12 hours later surgery
41032597|NCT02078284|BIOLOGICAL|CPP|One unit of frozen CPP contains approximately 3.4 x 10\^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
41032598|NCT02078284|BIOLOGICAL|LSP|
41032599|NCT03087591|OTHER|Laboratory Biomarker Analysis|Correlative studies
41032600|NCT03087591|BIOLOGICAL|siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401|Given IV
41032601|NCT02548962|DRUG|Ibrutinib|
41032602|NCT02548962|DRUG|Pomalidomide|
41032603|NCT02548962|DRUG|Dexamethasone|
41032604|NCT02548962|DRUG|Placebo|
41032605|NCT00095264|DRUG|Darbepoetin Alfa|
41032606|NCT00142480|DRUG|Capecitabine|Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
41032607|NCT00142480|DRUG|Oxaliplatin|Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29
41032608|NCT00142480|DRUG|Bevacizumab|Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.
41032609|NCT00142480|PROCEDURE|Radiation therapy|Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
41032610|NCT03227770|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform at least once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
41032611|NCT03227770|DEVICE|hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
41374384|NCT03696537|RADIATION|Total Marrow Irradiation (TMI)|TMI will be delivered twice a day, at least 6 hours apart, on days -7 through -3 (total of 10 fractions) of conditioning regimen
41032612|NCT03848533|DRUG|melatonin|"The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)"
41032613|NCT03848533|DRUG|metformin|"For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)"
41032614|NCT03848533|DRUG|Placebo|"The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)"
41032615|NCT00393926|DEVICE|TheraDrive Assistive Device|
41032616|NCT00393926|PROCEDURE|Rote Therapy versus Fun Therapy|
41032617|NCT04851613|DRUG|Afuresertib|The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles
41032618|NCT04851613|DRUG|Afuresertib/placebo|afuresertib/placebo 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
41374385|NCT01467518|DRUG|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
41032619|NCT01573845|BEHAVIORAL|Healthy Eating + Eco-Friendly Campaign|"Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements"
41032620|NCT01573845|BEHAVIORAL|Healthy Eating Campaign|"Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements"
41032621|NCT04495374|DRUG|Pregabalin 300mg|Group P1 will receive a 300 mg tablet of pregabalin, 02h before the surgical procedure
41032622|NCT04495374|OTHER|Placebo|Group P0 will receive a placebo tablet, 02h before the surgical procedure
41032623|NCT05202561|BIOLOGICAL|RNA tumor vaccine|Subjects will receive single dose of RNA tumor vaccine injection on day 1, day 4, day 7, and day 14, each dose of 600 ng.
41032624|NCT05202561|BIOLOGICAL|RNA tumor vaccine+Navuliumab|RNA tumor vaccine+Navuliumab Subjects will receive maintenance therapy with a PD-1 inhibitor in addition to monotherapy with the RNA tumor vaccine injection. Subjects received a single dose of RNA vaccine injection on day 1, day 4, day 7, and day 14, with each dose of 600 ng. Inhibitors, accept the Navuliumab on day 14, the recommended dose is 3 mg/kg, intravenous injection every 2 weeks.
41032625|NCT00001601|PROCEDURE|Electrocardiogram|
41032626|NCT00001601|PROCEDURE|Biopsies|
41374386|NCT01467518|DRUG|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
40849823|NCT03460561|PROCEDURE|Thoracic epidural block (TEA)|Under complete aseptic precautions and before induction of GA, thoracic epidural catheter was inserted using a 17 gauge, Tuohy epidural needle by a midline approach. T9-T10 interspace was chosen for the injection after skin infiltration by 5 mL of lidocaine 1%. The epidural space was identified by the loss of resistance technique then the catheter was introduced 2 cm into the epidural space, and epidural test dose of 3 mL of lidocaine 2% with 1:200,000 adrenaline was injected to exclude vascular or subarachnoid position.
40849824|NCT03460561|PROCEDURE|Rectus sheath block (RSB)|"Under aseptic technique, the rectus muscle was imaged with the ultrasound probe, A broadband (5-12 MHz) linear array probe of Sonosite ™ 3000 ultrasound (FUJIFILM, Sonosite EDGE II -UAS) in a transverse orientation at or immediately above the level of the umbilicus, with an imaging depth of 4-6 cm.~Inserting the needle: An 18G Tuohy needle was introduced few millimeters from the probe using an in plane technique in an angle of 45 degrees to the skin. (posterior rectus sheath and fascia transversalis). Under direct vision, the needle tip was advanced to the desired position where 20 mL of (levo-bupivacaine 0.25% Fentanyl 30 μg) were injected causing hydro dissection of the rectus muscle away from the posterior rectus sheath. The technique is repeated on the opposite side."
41374387|NCT04327869|DEVICE|Magnetically controlled capsule endoscopy|The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.
41374388|NCT06257511|BEHAVIORAL|Simulation-Based Mastery Learning of the Non-technical skills|Participants will participate in a simulation-based mastery learning of the non-technical skills.
41374389|NCT04189536|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
41032627|NCT00001601|PROCEDURE|Diagnostic imaging|
41032628|NCT06184698|DRUG|liposomal irinotecan|liposomal irinotecan 70 mg/m²
41032629|NCT06184698|DRUG|5-FU|5-FU 2400 mg/m²
41032630|NCT06184698|DRUG|LV|5-FU 2400 mg/m²
41032631|NCT06184698|DRUG|Bevacizumab|bevacizumab 5 mg/kg
41032632|NCT03321019|DRUG|Capsaicin|Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
41032633|NCT03321019|DEVICE|Resistive respiratory loads|Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
41032634|NCT03321019|OTHER|Event-related evoked potential using electroencephalography (EEG).|The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
41032635|NCT03321019|PROCEDURE|Fluoroscopic swallow evaluation|Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
41032636|NCT03131648|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
41032637|NCT03131648|DRUG|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
41032638|NCT06436742|BIOLOGICAL|ARGX-119|Intravenous infusion of ARGX-119
41032639|NCT06436742|OTHER|Placebo|Intravenous infusion of placebo
41032640|NCT05800392|DRUG|DEC103|The intervention is composed by two medications: An active sublingual pill and an active oral one.
41032641|NCT05800392|DRUG|Placebo DEC103|The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.
41032642|NCT03016871|DRUG|Carboplatin|Given IV
41374390|NCT05238922|DRUG|INCB0123667|25 mg tablets
41374391|NCT03790475|OTHER|Offering a choice for colorectal cancer screening|Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.
41374392|NCT03790475|OTHER|Offering an alternative colorectal cancer screening method|Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
41032643|NCT03016871|DRUG|Etoposide|Given IV
41032644|NCT03016871|DRUG|Ifosfamide|Given IV
41032645|NCT03016871|OTHER|Laboratory Biomarker Analysis|Correlative studies
41032646|NCT03016871|BIOLOGICAL|Nivolumab|Given IV
41374393|NCT02983357|RADIATION|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
41032647|NCT03950232|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
41032648|NCT04974216|DRUG|Tafasitamab|Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
41032649|NCT04974216|DRUG|Lenalidomide|Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
41032650|NCT04974216|DRUG|Rituximab|Administration: IV at 375mg/m2 C1 to C6: D1
41032651|NCT03675386|OTHER|Interventional Group|The Transitional Pain Service Program enables targeted, mechanism-based, treatment innovations aimed at reducing the incidence and severity of chronic post-surgical pain, disability and enabling safe opioid prescribing/ weaning after major surgery. The investigator's TPSP intervention uses a variety of methods to support patients to manage pain and wean off opioids. This includes physician-guided opioid and non-opioid pharmacotherapy and tapering, and clinical psychology services specializing in pain education, Acceptance \& Commitment Therapy (ACT) and e-mobile self-management tools.
41374394|NCT02983357|OTHER|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
41374395|NCT02983357|OTHER|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
41374396|NCT06257849|OTHER|BPII 2.0|Banff Patella Instability Instrument 2.0 is a questionnaire developed for measuring outcome in patients with patella instability
41374397|NCT05276934|DIAGNOSTIC_TEST|Brain computed tomography|This study will use an established local protocol for DCI and intracranial arterial vasospastic stenosis screening, and follow-up to make sure that all patients have the same protocol and don't lose any chance of improvement and good outcome : CT perfusion at different time intervals
41374398|NCT02840019|DEVICE|Investigational MRI coil designed for pregnant women|The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
41374399|NCT02840019|PROCEDURE|MRI Scan|All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
41374400|NCT06422299|BEHAVIORAL|Online, couples-based intervention|During Phase 1 of the present study, the intervention will be iteratively developed using a rigorous, user-centered design approach through integration of knowledge gained from Phase 1 dyadic analyses and qualitative interviews, and existing gold-standard treatments for substance use among couples, including Integrative Behavioral Couples Therapy (IBCT; Christensen \& Doss, 2016) and Behavioral Couples Therapy for Alcohol (ABCT; McCrady et al, 1995) and substance use brief interventions for young adults (Halladay, et al., 2019; Tanner-Smith et al., 2015).
41374401|NCT03704285|DRUG|Propofol|Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
41374402|NCT03704285|DEVICE|BIS|GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
41374403|NCT03087227|DEVICE|NEUTROSIS|evaluate a shared health information system (NEUTROSIS) for home-hospital management of febrile neutropenia after anti-tumor chemotherapy
40849825|NCT02675530|DRUG|ketamine|"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia"
41374404|NCT04854928|DRUG|LTX-109 gel, 3%|A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
41374405|NCT04854928|DRUG|Placebo gel|A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
41374406|NCT02516462|DEVICE|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
41374407|NCT02516462|DRUG|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
41374408|NCT05254691|PROCEDURE|Sprinting|"The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing). This sprinting is performed on the theory that the respiratory muscles can be slowly trained to sustain complete spontaneous breathing. Also, theoretically this sprinting allows a better global and regional distribution of the tidal volume in the lung."
41374409|NCT05375110|DEVICE|NoYA™ Radiofrequency Interatrial Shunt System|NoYA™ Radiofrequency Interatrial Shunt System include Adjustable Interatrial Shunt System and Radiofrequency Ablation Generator.
41374410|NCT00733642|BIOLOGICAL|PF-04360365 1 mg/kg|PF-04360365 1 mg/kg infused as a single dose
41374411|NCT00733642|BIOLOGICAL|PF-04360365 3 mg/kg|PF-04360365 3 mg/kg infused as a single dose
41374412|NCT00733642|BIOLOGICAL|PF-04360365 5 mg/kg|PF-04360365 5 mg/kg infused as a single dose
40849826|NCT06485466|COMBINATION_PRODUCT|TACE plus camrelizumab and apatinib|"TACE plus camrelizumab and apatinib group:~Patients who were randomized to this group, TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) and oxaliplatin (50-150mg) are considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol (5-20ml) and other embolic agent( blank microspheres/ PVA/gelatin sponge particles) were determined by diameter and blood supply type of HCC. Within 1 week after first TACE treatment, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
41374413|NCT00733642|BIOLOGICAL|PF-04360365 10 mg/kg|PF-04360365 10 mg/kg infused as a single dose
41374414|NCT06059508|DRUG|SHR-5495 for injection|SHR-5495 for injection
41374415|NCT02267174|BEHAVIORAL|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
41374416|NCT04301401|OTHER|Vaginal swabs|On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
41374417|NCT04301401|OTHER|Stool samples|Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
41374418|NCT04301401|OTHER|Urine samples|Urine samples will also be taken before surgery and 6 weeks after surgery.
41374419|NCT04692974|DEVICE|Mobile phone application and smart watch|Mobile phone application prompts
41374420|NCT02696837|DEVICE|ETT|
41374421|NCT02696837|DEVICE|Proseal LMA|
41505051|NCT03526159|DRUG|Gentamicin Sulfate|Gentamicin (formulated as gentamicin sulfate) is a well-known, well-characterized antibiotic that has been used for four decades as a treatment against gram negative bacteria. It, like other aminoglycoside antibiotics, has the well documented added potential to facilitate readthrough of premature termination codons in eukaryotic cells and organisms.
40849827|NCT06485466|COMBINATION_PRODUCT|Camrelizumab and apatinib|"Camrelizumab and apatinib group:~Patients who were randomized to this group, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
41374422|NCT02696837|DRUG|Rocuronium|
41374423|NCT02696837|OTHER|No Muscle Relaxant|
41374424|NCT02696837|DRUG|Rocuronium|
41374425|NCT01608048|DEVICE|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
41374426|NCT03217916|DIAGNOSTIC_TEST|Elisa assay of podocyte glycoprotein in urine|"Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information."
41374427|NCT05334992|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Individual therapy 12 to 16 weeks
41374428|NCT05334992|BEHAVIORAL|Behavior Activation|Individual therapy 12 to 16 weeks
41374429|NCT03821805|OTHER|Foot reflexology massage|Foot reflexology technique of Father Josef was used as massage intervention
41374430|NCT03913429|PROCEDURE|Infiltration|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml"
41374431|NCT03913429|PROCEDURE|Maxillary nerve blockade|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side. Together with adrenaline infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 110ml SF."
41374432|NCT04773314|OTHER|PROPESS Cohort|Non-intervention
41505052|NCT01474200|DEVICE|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
41505053|NCT01474200|DRUG|IV Loop Diuretics (LD)|"IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial."
40849828|NCT01041287|DRUG|Nebivolol|Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is \>125/80 for the remaining 8 weeks
41374433|NCT03175068|BEHAVIORAL|CBT|CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
41374434|NCT03175068|BEHAVIORAL|ST|Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
41374435|NCT04890691|DEVICE|Feel Bright Light|During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
41374436|NCT04186637|DRUG|ALPN-202|Multiple dose levels and dose regimens of ALPN-202 will be administered
41374437|NCT00795886|DRUG|RAPAMYCIN|Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
41374438|NCT05947656|DEVICE|NaviFUS System|NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).
41374439|NCT00326625|DRUG|40 mg glatiramer acetate|parenteral drug
41374440|NCT00326625|DRUG|Placebo|
41374441|NCT00914511|DRUG|avanafil 200mg|single dose tablet of 200mg avanafil
41374442|NCT00914511|DRUG|avanafil 200mg|single tablet dose of 200mg avanafil
41374443|NCT05112224|BEHAVIORAL|Education program based on health belief model to improve oral health|Five weekly sessions each one lasted for one hour to encourage participants to follow healthy behaviors on oral health.
41374444|NCT06135272|DRUG|Resin infiltration|Icon Resin Infiltration as minimally invasive technique
41374445|NCT06135272|DRUG|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish as minimally invasive technique
41374446|NCT06135272|DRUG|Light cured giomer varnish|Light cured giomer varnish as minimally invasive technique
41505054|NCT04928768|OTHER|Questionnaire|A validated questionnaire (five-point Likert scale) through 10 items developed by Lee et al 2018 is employed to measure the level of orthodontic treatment satisfaction in 10 items; overall satisfaction, tooth alignment, facial appearance, eating and chewing, confident smile and self-image, retention state, treatment duration, treatment costs, intention to recommend, and relief of previous concerns. Total satisfaction is calculated by averaging the Likert scores from the 10 items
41505055|NCT01652989|BEHAVIORAL|Weight loss maintenance intervention face-to-face|
40849829|NCT01041287|DRUG|Metoprolol succinate|Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is \>125/80 for the remaining 8 weeks
41163667|NCT06124183|BEHAVIORAL|The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals|The program is based on the emotional intelligence skills model (Mayer \& Salovey, 1997; Salovey \& Mayer, 1990), which suggests that emotional intelligence consists of four hierarchical branches or components: (a) perception of emotions, (b) facilitating thinking using emotions, (c) understanding emotions, and (d) managing and handling emotions. The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals. The sessions follow a similar structure, involving session framing, motivation on the central theme, group activity for sharing ideas and experiences, individual activities, review, and task assignment. The first and second sections focus on analyzing the personal reality and current emotional conditions of the participants, while the final session is designed for both celebration and program evaluation. The remaining nine sessions address the four branches of the skill model.
41163668|NCT01579110|DRUG|levamisole|"Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months."
40849830|NCT03004235|DEVICE|Observational data collection|Observational data collection
40849831|NCT04683445|DRUG|Eribulin|Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
40849832|NCT04683445|DRUG|Trastuzumab|Trastuzumab，8mg/kg for the first dose，6mg/kg for the following dose，Intravenous infusion，3-week cycle
40849833|NCT04683445|DRUG|pertuzumab|Pertuzumab，，840mg for the first dose，420mg for the following dose，Intravenous infusion，3-week cycle
40849834|NCT04683445|DRUG|Pyrotinib|Pyrotinib，400mg，oral，every day
41374447|NCT00283517|DRUG|antipsychotics|as prescribed
41374448|NCT02305199|DRUG|Hartmann's solution|Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
40849835|NCT04683445|DRUG|Pembrolizumab|Pembrolizumab，200mg，Intravenous infusion，3-week cycle
40849836|NCT04683445|DRUG|Camerlizumab|Camerlizumab，200mg，Intravenous infusion，3-week cycle
40849837|NCT00267852|OTHER|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
41374449|NCT02305199|DRUG|Normal saline|Fluid containing Sodium chloride 9 g/L
41374450|NCT04785846|DEVICE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
41374451|NCT04504292|DRUG|SUPREP Bowel Prep Kit|Bowel prep prior to colonoscopy
41374452|NCT04504292|DRUG|Golytely Oral Product|Bowel prep prior to colonoscopy
41374453|NCT05246631|DRUG|Dexamethasone injection|Group A consisted of patients given 5 mg intravenous dexamethasone after induction.
41374454|NCT05246631|DRUG|Haloperidol Injection|Group B consisted of patients given 1 mg intravenous haloperidol one hour before the surgery ended
40849838|NCT06502808|OTHER|Hyperbaric oxygen therapy|Series of 30 HBOT sessions of 60 minutes at 2 ATA in the hyperbaric chamber for five consecutive days per week.
40849839|NCT05068219|PROCEDURE|Usual physical therapy|"Standard rehabilitation for diaphragmatic paresis~* EFA (Expiratory Flow Acceleration) at the upper thoracic level.~* PEP (Positive Expiratory Pressure).~* Expectoration if necessary (coughing up and spitting out)"
41374455|NCT06455930|DEVICE|Stand-on ride-on power mobility device|Children will receive the adapted toy car (individually-adapted stand-on PMD) to take home and use for three months. PMD will be used at their house and familiar environments to the family (e.g., neighborhood, parks, schools).
40849840|NCT05068219|PROCEDURE|Contract-Relax technique|"The diaphragmatic CR is done in a semi-sitting position.~The CR is composed of 4 steps :~* First maximum inspiration expiration with position of the hands of the physiotherapist on the last ribs and without resistance (Goal: taking rhythm).~* Second maximum inspiration expiration : Free inspiration, expiration with pressure on the last ribs to bring the diaphragm into internal stroke.~* Maximum inspiration against resistance, then maximum expiration with increased pressure.~* Maximum inspiration with dynamic release of resistance (Goal: hyperextension of the diaphragm) followed by maximum expiration with resistance to allow an increase in expiratory flow."
40849841|NCT03447847|OTHER|Water|1 liter of water in meals; 1 liter out of meals
40849842|NCT04338737|OTHER|timming of feeding|post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet
41032652|NCT03675386|OTHER|Control Intervention|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
41032653|NCT00936364|OTHER|Short-term fasting|No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).
41032654|NCT00936364|OTHER|Modified fast|Minimal caloric intake on days -2 and -1
41163669|NCT01579110|DRUG|Prednisone|Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
41163670|NCT00629551|DRUG|saredutant (SR48968)|oral administration,capsules
41374456|NCT03832907|DEVICE|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
41032655|NCT00936364|OTHER|Fasting|Day -1
41032656|NCT00936364|OTHER|Fasting|Days -2 and -1
41032657|NCT00936364|OTHER|Fasting|Days -3, -2, and -1
41032658|NCT00936364|OTHER|Fasting|48-hour fast with minimal caloric intake on days -2 and -1
41374457|NCT03832907|DIAGNOSTIC_TEST|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
41374458|NCT00054639|BIOLOGICAL|oblimersen sodium|Given IV
41374459|NCT00054639|BIOLOGICAL|rituximab|Given IV
41374460|NCT00054639|OTHER|laboratory biomarker analysis|Correlative studies
41374461|NCT01033110|BEHAVIORAL|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
41374462|NCT02422186|DRUG|Esketamine|All participants will start with first dose (Day 1 as 28 milligram \[mg\]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
41374463|NCT02422186|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
40849843|NCT00659230|DRUG|Nepicastat|100-800mg
40849844|NCT00659230|DRUG|Placebo|100-800mg placebo
40849845|NCT06332105|DIETARY_SUPPLEMENT|Glytactin|Glycomacropeptide based protein substitute for dietary treatment of PKU
40849846|NCT06332105|DIETARY_SUPPLEMENT|L-AA|Amino acid based protein substitute for dietary treatment of PKU
41032659|NCT01914796|DRUG|PF-06412562|Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
41032660|NCT01914796|DRUG|PF-06412562|It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
41032661|NCT00006325|DRUG|Peginterferon alfa-2b|
41163671|NCT00629551|DRUG|paroxetine|oral administration, capsules
41163672|NCT00629551|DRUG|placebo|oral administration, capsules
41163673|NCT06014502|DRUG|IMGS-001|Every 2 weeks
41163674|NCT06364891|OTHER|VMMC NEXUS Digital application|A handheld digital application which supports segmentation of potential VMMC Clients
41163675|NCT05869383|DRUG|Ophiochepalus striatus extract|Ophiochepalus striatus extract 2x5 grams
41163676|NCT05869383|DRUG|Placebo|Placebo 2x5 grams
41163677|NCT05687318|DEVICE|DeFrame|DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.
41163678|NCT00887185|OTHER|Simulator training for temporal bone surgery|Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
41374464|NCT02422186|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
41374465|NCT02422186|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
40849847|NCT03633266|PROCEDURE|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
41374466|NCT02422186|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
41032662|NCT01602848|OTHER|Intensive care management and coordination|Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
41032663|NCT05509829|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy using PICO14.
41032664|NCT05787418|DRUG|HH-120 Nasal Spray|HH-120 nasal spray 8 times per day for 7 consecutive days
41032665|NCT05787418|DRUG|Placebo|Placebo 8 times per day for 7 consecutive days
41032666|NCT04053764|DRUG|Crizanlizuamb|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
41032667|NCT04053764|DRUG|Standard of Care|HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
41032668|NCT01007591|DRUG|LEO 80190|Applied once daily
41032669|NCT01007591|DRUG|Hydrocortisone|Applied once daily
41163679|NCT05458830|BEHAVIORAL|Brief Barrier Reduction Intervention|After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.
41374467|NCT02422186|DRUG|Venlafaxine Extended Release (XR) (New Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
41374468|NCT04539106|DRUG|intravitreal injection of Ranibizumab|intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
41374469|NCT02022566|BEHAVIORAL|A supported self management of osteoarthritis program|Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
40849848|NCT03633266|PROCEDURE|PRP|vitreoretinal surgery combined with intraoperative PRP
40849849|NCT06524323|DRUG|5-fluorouracil Injection|The mixture contains 2mL of triamcinolone acetonide injection and 4mL of 5-fluorouracil injection, which is diluted with saline to 10mL.
40849850|NCT06524323|DRUG|Triamcinolone Acetonide|The mixture contains 2mL of triamcinolone acetonide injection which is diluted with saline to 10mL.
41032670|NCT06465329|DRUG|Cemiplimab|Intravenous (IV) infusion administration
41032671|NCT06465329|DRUG|Platinum-based chemotherapy|IV infusion
41032672|NCT06465329|DRUG|REGN7075|IV infusion
41032673|NCT02693873|BEHAVIORAL|GLA:D Canada (education and neuromuscular exercise program)|"EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.~EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions)."
41032674|NCT06119100|DIAGNOSTIC_TEST|Ultrasound characterization of stenotic lesion type|Target lesion type will be classified as restrictive, hyperplastic or mixed using high frequency Duplex ultrasound, before the angioplasty procedure and at 6 months follow up.
41163680|NCT05458830|BEHAVIORAL|Plain advisory text|Care as usual
41163681|NCT00735462|DRUG|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
41163682|NCT00735462|DRUG|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
41163683|NCT00735462|DRUG|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
41163684|NCT03277677|DRUG|Normal saline|for resuscitation in sepsis patients
41163685|NCT03277677|DRUG|Ringer's Acetate|for resuscitation in sepsis patients
41163686|NCT01431105|DRUG|Atorvastatin|Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
40849851|NCT03625999|BEHAVIORAL|video game training exercise|"The game, called The Silent Service and developed by our collaborators, is an online game with an underwater theme, and is comprised of 5 distinct mini-games, each of which demands auditory attention. The mission is to navigate an underwater scene, listening and responding to 'sonar' (e.g., an oddball in a stream of sounds). For example, participants may have to respond to an oddball sound stream to protect their submarine from a looming sea monster, while successfully ignoring a distractor sound stream (responses to the distractor sound stream allow the sea monster to damage the submarine). The five games share the same underlying framework of detecting oddballs while ignoring distractors but have unique artwork and 'backstories' to keep players interested. There is a hierarchical reward structure for 'leveling up' across the game that helps players to stay engaged and interested while playing."
40849852|NCT04320901|DEVICE|Ligasure|Ligasure™ Maryland Jaw Laparoscopic Sealer/Divider 37cm
41374470|NCT03077854|RADIATION|Functional Lung Avoidance Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
40849853|NCT04320901|DEVICE|Harmonic|Harmonic ACE 7+
41032675|NCT05080764|COMBINATION_PRODUCT|1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 1 hour. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
41163687|NCT04115956|DRUG|Melphalan-Flufenamide (Melflufen)|Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.
41163688|NCT04115956|DRUG|Dexamethasone|Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
41163689|NCT02344056|OTHER|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
41163690|NCT02344056|OTHER|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
41163691|NCT06222775|BEHAVIORAL|Group session 1|"This session will have 3 editions in which the 50 participants of the experimental group will be distributed, with about 16 to 17 participants per edition.~Its objective is to know the group and their expectations, in addition to providing basic knowledge about diabetes and a healthy lifestyle."
41163692|NCT06222775|BEHAVIORAL|Group session 2|"The sessions for the 5 groups will take place within 2 weeks. Two weeks after the 1st session, the 2nd session-workshop will be scheduled with no more than 10 participants. For this, 5 groups will be made. An attempt will be made to ensure that the participants in the groups remain stable.~Its objective is to pave the way for the change to a healthy eating lifestyle and provide patients with sufficient knowledge so that with theory they can prepare a daily group menu according to the caloric needs of each of the participants."
41163693|NCT06222775|BEHAVIORAL|Group session 3|Its general objective is to motivate the change towards healthy eating. And the specific ones develop a weekly menu according to calorie needs.
41163694|NCT06222775|BEHAVIORAL|Group session 4|Its general objective is to reinforce a healthy lifestyle-eating, and the specific ones are to learn to read labels, preparing a weekly menu in a group.
41163695|NCT06222775|BEHAVIORAL|Group session 5|Its general objective is to reinforce lifestyle-physical activity. And the specific objectives are to recognize that it is a moderate physical activity and the goal to achieve of recommended physical activity per week and plan a week of physical activity.
41163696|NCT06222775|BEHAVIORAL|Group session 6|Its general objective is to reinforce a lifestyle-healthy eating and physical activity. And the specific ones are to reinforce the concept of physical activity in diabetes, what to do with hypoglycemia and adjust diet and exercise to current weight and needs.
41163697|NCT06222775|BEHAVIORAL|Group session 7 to 8|The objective will be to maintain a healthy lifestyle and adjust menus and physical activity to current caloric needs, in addition to sharing experiences.
40849854|NCT00859937|DRUG|Dasatinib|Given PO
40849855|NCT00859937|OTHER|Laboratory Biomarker Analysis|Correlative studies
40849856|NCT00051922|BIOLOGICAL|PolyEnv1|Recombinant vaccinia virus vaccine
41163698|NCT06222775|BEHAVIORAL|Group session 9|"In the final session, a certificate of adherence to healthy living will be delivered, reminding you to continue with the acquired habits and attend scheduled consultations and tests.~The days of the sessions are indicative, but they must be held in the week when the specified period of time between session and session is met."
41163699|NCT06222775|BEHAVIORAL|Control Intervention 1|They will be given written information about the convenience of moderate physical activity and they will be informed of the importance of following an appropriate diet for diabetes and we will encourage weight loss.
41163700|NCT06222775|BEHAVIORAL|Control Intervention 2|Your controls will be carried out according to the usual diabetes protocol established in the individual scheduled diabetes consultation reviews.
41163701|NCT06222775|BEHAVIORAL|Control Intervention 3|These patients will also be given a written document about living with diabetes, advice on physical activity, and a pre-established diet will be given according to the number of calories needed previously calculated
41505056|NCT01652989|BEHAVIORAL|Weight loss maintenance intervention delivered via DVD|
40849857|NCT00620113|DRUG|Odanacatib|Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.
40849858|NCT00620113|DIETARY_SUPPLEMENT|Vitamin D3|Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.
40849859|NCT00620113|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.
40849860|NCT00620113|DRUG|Placebo|Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
40849861|NCT00829959|BEHAVIORAL|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
40849862|NCT05222906|DRUG|Venglustat|tablet; oral
40849863|NCT05222906|DRUG|imiglucerase|sterile lyophilized product; intravenous
41032676|NCT05080764|COMBINATION_PRODUCT|1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 1h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
40849864|NCT05899972|OTHER|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The contact is made with the hands on the shoulder blades of the volunteer for 6 minutes.
40849865|NCT05899972|OTHER|Suboccipital inhibition technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator starts by placing both hands under the patient's head in the occipital region. After palpating the suboccipital muscles, the investigator uses the second, third and fourth fingers of both hands flexed against the muscle belly and remains in this position.
40849866|NCT05899972|OTHER|Frontal lift technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions the tips of both index fingers on either side of the metopic suture while the third finger remains resting on the frontal bone so that the tips of the fourth fingers contact the zygomatic processes bilaterally. A slight pressure is applied with the index fingers and an anterior pressure is performed.
41032677|NCT05080764|COMBINATION_PRODUCT|3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 3 hours. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
41032678|NCT05080764|COMBINATION_PRODUCT|3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 3h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
41032679|NCT06496893|DIETARY_SUPPLEMENT|IP 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
40849867|NCT05899972|OTHER|Parietal lift technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator places the palms on the lateral edges of the parietal bones and the thumbs crossed at the sagittal suture. First, a medial pressure is administered with the second, third and fourth fingers and then a cephalic traction is performed.
40849868|NCT05899972|OTHER|IV ventricle technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions his hands in a shell and thumbs together at the level of the spinous apophyses of the patient's second or third cervical vertebra.
40849869|NCT04552288|DRUG|Benralizumab|All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.
40849870|NCT01704404|DRUG|TD-4208|
40849871|NCT01704404|DRUG|Placebo|
41032680|NCT06496893|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
41374471|NCT03077854|RADIATION|Standard Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
40849872|NCT01685021|DRUG|MOR00208 (formerly Xmab5574)|
40849873|NCT00490074|BIOLOGICAL|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
40849874|NCT00490074|BIOLOGICAL|NYVAC-C|NYVAC-C 1 ml IM
41032681|NCT06001177|DRUG|KAN-101|Dose KAN-101 Intravenous (IV) Infusion
41032682|NCT06001177|DRUG|Placebo|Placebo Intravenous (IV) Infusion
41032683|NCT00243724|DRUG|Esomeprazole|
41032684|NCT04718675|DRUG|KB-0742|Oral capsules
41163702|NCT06222775|BEHAVIORAL|Control Intervention 4|In addition to verbal recommendations. This document will be made after the act of assigning the control or experimental group.
41374472|NCT04209166|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
41374473|NCT04209166|DRUG|SSRIs/SNRIs+Mood Stabilizer|Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
41374474|NCT04209166|DRUG|SSRIs/SNRIs+Quetiapine|Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
41374475|NCT04209166|DRUG|Usual Treatment|Patients' treatment will be decided by the clinical doctor.
41374476|NCT01477775|DRUG|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
41374477|NCT01477775|DRUG|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
41374478|NCT00696826|DRUG|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
41374479|NCT05487859|DRUG|Acarbose Tablets|Acarbose Tablets PO ranging from 25 mg initially to 100 mg as tolerated
41374480|NCT05247606|DEVICE|Mobile application|Lifestyle intervention through web-based mobile application
41374481|NCT06332924|BEHAVIORAL|motivational discussion group|There will be 3 interviews with the motivational interview group, one week apart.
41032685|NCT01613248|DRUG|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
41032686|NCT01613248|DRUG|Placebo-matching MK-1602|Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
41032687|NCT01613248|DRUG|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded."
41032688|NCT06634745|PROCEDURE|Standard Needle Irrigation (SNI)|"Standard Needle Irrigation (SNI):~Utilizes standard needle irrigation techniques for activating the antimicrobial solution within the root canal."
41032689|NCT06634745|PROCEDURE|Passive Ultrasonic Irrigation (PUI|"Passive Ultrasonic Irrigation (PUI):~Employs ultrasonic energy to enhance the activation and effectiveness of the antimicrobial solution in the root canal."
41032690|NCT06634745|PROCEDURE|EndoActivator (EA)|"EndoActivator (EA):~Uses a sonic activation device to facilitate the distribution and activation of the antimicrobial solution in the root canal."
41032691|NCT06634745|PROCEDURE|EDDY|"EDDY:~Involves the use of a sonic activation device that operates at high frequency to activate the antimicrobial solution within the root canal.~These descriptions focus on the general method and purpose of each intervention without delving into the specific procedural details already covered in the arm/group descriptions."
41163703|NCT02168478|DRUG|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
41163704|NCT02168478|OTHER|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
41163705|NCT02168478|OTHER|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
41163706|NCT05492123|DRUG|Nivolumab 40 mg in 4 ml Injection|Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation
41163707|NCT05492123|DRUG|Ipilimumab 200 MG in 40 ML Injection|Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation
41163708|NCT05492123|RADIATION|Chemoradiation|Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w
41163709|NCT04202016|PROCEDURE|Piezocision Surgery|After a surgical cut using #15 surgical blade 2-3 mm distal to the canine a pizocision using piezo-surgery device is made.
40849875|NCT01564732|DEVICE|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
41163710|NCT02845713|DRUG|Ivermectin, Diethylcarbamazine Albendazole (IDA)|To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
41163711|NCT05262465|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|HLA-mismatched donor peripheral stem cell infusion
41163712|NCT05262465|DRUG|Azacitidine|azacytidine 50-75mg/m2
40849876|NCT01564732|DEVICE|Plicated-LAGB|"At the time of LAGB placement, plication sutures can be placed along the body \& greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss."
41032692|NCT05892679|OTHER|acupressure|"Acupressure will be formulated according to the standards of the World Health Organization and applied to the determined points in a certain order. Since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. Pressures will be applied manually by a single practitioner. A total of 8 points with parallel points will be studied, with four points in each lower extremity. There will be a total of 12 minutes of pressure on 8 points, with an average of 90 seconds on each point, and approximately 10-15 seconds of warming and preparatory scrubbing before pressing on the area where the points are located.~Considering the studies done, a person will be given acupressure three times a week for four weeks."
41032693|NCT02816671|DEVICE|Surgical Stapler|Patients in whom the MicroCutter stapler was used during a thoracic surgical procedure.
41163713|NCT05262465|DRUG|Venetoclax|Venetoclax 100-300mg/d ×3d，400mg 4-28d
41163714|NCT05765890|OTHER|No treatment given|No treatment given
41163715|NCT00510783|DRUG|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
41163716|NCT00510783|DRUG|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
41163717|NCT00510783|DRUG|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
41163718|NCT02920021|DRUG|Etokimab|Humanized monoclonal antibody, administered by intravenous infusion
41163719|NCT02920021|DRUG|Placebo|Administered by intravenous infusion
41374482|NCT01901952|BEHAVIORAL|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
41374483|NCT01901952|BEHAVIORAL|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
41374484|NCT06132711|OTHER|APRIL-BAFF-Bicephali CAR-T cells|Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
41374485|NCT04308356|BEHAVIORAL|Dedicated Discussions on Anticipating preferences of care in the event of Aggravation (DDA)|interview 2
41374486|NCT04308356|OTHER|Autonomy Preference Index (API ) questionnaire - Information|part of interview 1
41374487|NCT04308356|OTHER|anxiety and depression (HADS) questionnaire|part of interview 1
41374488|NCT06257459|PROCEDURE|subinguinal varicocelectomy|exision or preservation of spermatic cord lipoma during subinguinal varicocelectomy
41374489|NCT04555798|DRUG|Meropenem Injection|patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
41163720|NCT04632797|DEVICE|Hilotherm Chemo Care|Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.
41163721|NCT01997489|DRUG|Enzyme replacement|Observational study of current treatment and with no comparative groups
41163722|NCT02657759|DIETARY_SUPPLEMENT|CARDICHOL|
41374490|NCT04555798|DEVICE|A-V ECMO|Only patients of group B connected to A-V ECMO for two weeks
41374491|NCT00674882|OTHER|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
41032696|NCT02907021|DRUG|standard-of-care treatments for LV impairment|Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
41032697|NCT03627403|DRUG|Selinexor|"Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly."
41032698|NCT06034405|DIAGNOSTIC_TEST|Tc99-PYP or Tc99-HDMP Scan|Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.
41032699|NCT00481429|DRUG|Rosiglitazone|Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
41374492|NCT05681221|OTHER|Nano silver particles and calcium hydroxide|Combination of two materials that can possibly eradicate the mixed odontogenic infection in the periapical area and dentinal tubules in necrotic primary second molars.
41032700|NCT00740545|DRUG|enoxaparine 40 mg daily|Women inject ourselves every days with 40 mg of enoxaparine
41032701|NCT00740545|DRUG|placebo|Women inject ourselves every days with placebo
41032702|NCT01658787|DEVICE|Endovascular aortic repair|Treatment with Gore Endovascular Aortic Products.
41032703|NCT02173977|OTHER|ARM A- Agonist/Antagonist protocol|In vitro fertilization (IVF/ICSI)
41032704|NCT02173977|OTHER|ARM B- Antagonist protocol|In vitro fertilization (IVF/ICSI)
41032705|NCT04955639|OTHER|Control|Standard of Care - Control Smoking Cessation Program
41374493|NCT05681221|OTHER|TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
41374494|NCT06126107|BEHAVIORAL|Brief Normative Feedback|Once a participant has completed the assessment of their drinking during the baseline battery, the participant will receive brief normative feedback about how their drinking compares to their peers.
41374495|NCT06126107|BEHAVIORAL|Loss-framed Text-messaging|Daily text-messages on the consequence of hazardous drinking.
41374496|NCT06126107|BEHAVIORAL|Gain-framed Text-messaging|Daily text messages on the benefits of reducing drinking to safe guidelines.
41374497|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell (PBPC) transplant|Peripheral blood hematopoietic progenitor cell (PBPC) transplant
41374498|NCT00061568|DRUG|Alemtuzumab|Alemtuzumab
41374499|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell Apheresis|Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis
41374500|NCT00061568|DRUG|Sirolimus|Sirolimus
41374501|NCT06391047|OTHER|Mulligan's Squeeze Technique - manual therapy|This technique was introduced by Brian R. Mulligan. In this technique the therapist places thumb along the tender joint margin and applies force centrally. The patient actively flexes knee and therapist progressively enhances force and at end applies overpressure. This force is decreased as knee moves towards extension. This method helps to maintain the meniscus in its normal position and corrects the derangement of meniscus.
41374502|NCT06391047|OTHER|Conventional Physiotherapy|It includes stretching and strengthening exercises of muscles of the knee joint.
41374503|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
41374504|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
41374505|NCT02074982|DRUG|AIN457 300 mg|
41374506|NCT02074982|DRUG|ustekinumab 45/90 mg|
41374507|NCT02074982|DRUG|placebo secukinumab|Placebo
40849877|NCT06351254|PROCEDURE|Sine sound waves|Group A 8 participants will be given sine sound waves treatment with the frequency of 80 pulses on C1 vertebrae. Treatment session will be 6 session 3 times a week followed by 6 sessions 2 times a week.
41032706|NCT04955639|OTHER|Pivot|Pivot Program Smoking Cessation Program
41032707|NCT04026412|BIOLOGICAL|nivolumab|Specified dose on specified days
41163723|NCT02657759|DIETARY_SUPPLEMENT|PLACEBO|
41163724|NCT02921152|PROCEDURE|bone marrow aspiration /trephine biopsy|
41163725|NCT04231747|BIOLOGICAL|CC-97540|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.~During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy.~Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection."
41374508|NCT03047512|BEHAVIORAL|Experimental: Internet-based program|"* Adolescents who obtain a score between 2 and 4 on the PHQ-3 will be invited to use the information module, the psychoeducational material and the symptom monitoring with personalized automatic feedback.~* Adolescents who obtain a score between 5 and 6 on the PHQ-3 will be invited to use, in addition to the above, group forum activities (peer support moderated by mental health professionals) and the possibility of a chat (individualized support by mental health professionals).~* Adolescents who obtain a score greater than 6 on the PHQ-3 or that have suicidal thoughts will be invited to see the mental health counselor of the institution and the possibility of their reference to face-to-face professional attention will be considered."
41163726|NCT04035863|DEVICE|Low level laser therapy|"For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light."
41374509|NCT03193424|DRUG|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
41374510|NCT06269042|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances,
40849878|NCT06351254|PROCEDURE|Kinesthetic exercises|Kinesthetic exercises was conducted for GROUP 2 8 patients for 6 weeks. Before and after assessment was taken to track patient progress. Cervicocephalic kinesthetic sensibility tests were performed. The first test was Head-to-Neutral Head Position(NHP) repositioning test. In the second repositioning test is Head-toTarget repositioning tests.
40849879|NCT06351254|PROCEDURE|Sine sound waves plus kinesthetic exercises|Group C 8 was given combine treatment of sine sound waves and kinesthetic exercises before and after measurement was taken.
40849880|NCT01771445|DRUG|IL-1Ra|100mg, s.c, once only
40849881|NCT01771445|DRUG|Placebo|100mg, s.c., once only
41374511|NCT00363935|DRUG|Dexmedetomidine|
40849882|NCT02624531|DRUG|Taxane|NACT and Fertility-sparing Treatment Strategy
40849883|NCT02624531|PROCEDURE|radical trachelectomy|NACT and Fertility-sparing Treatment Strategy
40849884|NCT01122615|DRUG|Sunitinib|12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.
40849885|NCT01122615|DRUG|Temsirolimus|6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
40849886|NCT03114631|BIOLOGICAL|Dendritic cells pulsed with tumor lysate|
41032708|NCT04026412|BIOLOGICAL|ipilimumab|Specified dose on specified days
41032709|NCT04026412|BIOLOGICAL|durvalumab|Specified dose on specified days
41032710|NCT05954143|DRUG|BDC-1001|BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.
41032711|NCT05954143|DRUG|Pertuzumab|Pertuzumab is a monoclonal antibody that targets HER2 and prevents dimerization of HER2 with other members of the HER family (HER1, HER3, and HER4), thereby blocking ligand-activated downstream signaling.
41032712|NCT02038738|DRUG|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
41032713|NCT00023829|DRUG|bicalutamide|
41032714|NCT00023829|DRUG|flutamide|
40849887|NCT03114631|BIOLOGICAL|Dendritic cells pulsed with MUC-1/WT-1 peptides|
40849888|NCT00012168|DRUG|isosulfan blue|
40849889|NCT00012168|GENETIC|polymerase chain reaction|
41032715|NCT00023829|DRUG|releasing hormone agonist therapy|
41032716|NCT00023829|PROCEDURE|adjuvant therapy|
41032717|NCT00023829|RADIATION|radiation therapy|
41032718|NCT06615531|BEHAVIORAL|Advanced multi-component meditation practice|The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
41374512|NCT03449277|DRUG|Oral Tablet|oral labetalol tablets and oral nifedipine tablets
41374513|NCT05765994|DIAGNOSTIC_TEST|Modified hydrogen breath test|A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
40849890|NCT00012168|OTHER|immunohistochemistry staining method|
40849891|NCT00012168|PROCEDURE|lymphangiography|
40849892|NCT00012168|PROCEDURE|radionuclide imaging|
40849893|NCT00012168|PROCEDURE|sentinel lymph node biopsy|
40849894|NCT00012168|RADIATION|technetium Tc 99m sulfur colloid|
40849895|NCT05629468|DRUG|Azithromycin|antibiotic
40849896|NCT05629468|DRUG|Probiotic Formula|probiotics
40849897|NCT05629468|DRUG|Benzoyl Peroxide 4 % Topical Cream|topical cream
41374514|NCT06019169|OTHER|Yoga arm|Participation in YOGA classes performed by Mme Laura BOGANI from The Blue Fish LAB Association. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months. An attendance sheet will be completed at each session.
41374515|NCT06019169|OTHER|storytelling activities|Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months. An attendance sheet will be completed at each session.
41374516|NCT01471600|PROCEDURE|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
41374517|NCT02160184|DEVICE|Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)|
41374518|NCT03692767|BIOLOGICAL|Anti-CD22 CAR NK Cells|Anti-CD22 CAR NK Cells injection
40849898|NCT03508232|DRUG|Placebo|Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
40849899|NCT03508232|DRUG|Doxycycline Hyclate|Patients will receive doxycycline hyclate in a loading dose of two 100 mg capsules (200 mg total) initially followed by one 100 mg capsule every 12 hours for 7 days.
41374519|NCT03863925|DEVICE|Target controlled infusion, Schnider model|Target controlled infusion (TCI) is an intravenous drug delivery system estimating pharmacokinetics after input of patient's data, e.g. age, sex, body height, body weight. Schnider model is one of TCI model to deliver Propofol. After target concentration at effect site (e.g. the brain) is keyed in, the computerized infusion pump will calculate dosage of bolus and infusion rate for each individual, and calculated concentration of propofol at plasma and brain will be displayed. The clinicians should evaluate the patient's sedation level in response to calculated propofol concentration and titrate target concentration to achieve desired sedation level.
41374520|NCT03863925|BEHAVIORAL|Bolus injection of Propofol|Bolus intravenous injection is a traditional way to deliver anesthetic, and the dosage and amount of medication is based on clinical experience and patients' response.
40849900|NCT00162812|DRUG|Epirubicin|100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)
40849901|NCT02724709|PROCEDURE|Three-dimensional transoesophageal echocardiography|Three-dimensional transoesophageal echocardiography, analysed by eSie valve software (Siemens)
40849902|NCT02724709|PROCEDURE|Computed tomography|Computed tomography, analysed by Synovia Workstation (Siemens)
41374521|NCT06471023|DIETARY_SUPPLEMENT|TP1|Vitamin C formulation 1, 1000 mg
41374522|NCT06471023|DIETARY_SUPPLEMENT|TP2|Vitamin C formulation 2, 1000 mg
41374523|NCT06471023|DIETARY_SUPPLEMENT|TP3|Vitamin C formulation 3, 1000 mg
41374524|NCT06471023|DIETARY_SUPPLEMENT|TP4|regular Vitamin C, 3000 mg
41374525|NCT06471023|DIETARY_SUPPLEMENT|CP|Vitamin C formulation 4, 1000 mg
41374526|NCT06471023|DIETARY_SUPPLEMENT|RP|regular Vitamin C, 1000 mg
41374527|NCT00944528|RADIATION|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
41374528|NCT03061916|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon 20% will be given to participants after baseline collection of saliva
41374529|NCT03061916|DIETARY_SUPPLEMENT|Ginger|Ginger 20% will be given to participants after baseline collection of saliva
41374530|NCT03061916|DRUG|Chlorhexidine Gluconate|Chlorhexidine Gluconate will be given to participants after baseline collection of saliva
41374531|NCT00943826|DRUG|Bevacizumab|10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
41374532|NCT00943826|DRUG|Temozolomide|75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.
41374533|NCT00943826|RADIATION|Radiation therapy|30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
41374534|NCT00943826|DRUG|Placebo|Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
41374535|NCT05592704|DEVICE|Usage of a wearable heart rate monitor and a smartphone with the application for home-based exercises|Physical activity self-monitoring using a wearable heart rate monitor and a smartphone with specially designed application
41374536|NCT01801306|DEVICE|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
41374537|NCT05813730|OTHER|urinary creatinine excretion measurement|Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.
41374538|NCT04940091|DRUG|Epidural analgesia|Epidural analgesia is performed with a mixture of local anesthetics (ropivacaine) and opioids (sufentanil).
41374539|NCT04804579|BEHAVIORAL|Fall Prevention Intervention|The intervention will aim to reduce fall risk through weekly virtual group meetings and at-home exercise assignments to address physical and environmental factors that may put participants at a higher risk of experiencing a fall.
41374540|NCT03540485|DRUG|Melatonin|Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
41374541|NCT03540485|OTHER|Placebo|Daily administration of placebo orally, for 24 months between 10pm to 11pm
41374542|NCT05259059|OTHER|No intervention is involved|No intervention is involved
41374543|NCT00908375|DRUG|Pregabalin|One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
40849903|NCT05972681|DRUG|Bupivacaine|10 milliliters (ml) of bupivacaine 0.50% injected to the vaginal laceration site.
40849904|NCT05972681|DRUG|Epinephrine|Epinephrine (1:200,000) injected to the vaginal laceration site.
40849905|NCT05972681|OTHER|Sham normal saline arm|10 milliliter (ml) of normal saline injected to the vaginal laceration site.
40849906|NCT02797782|OTHER|Detection of anti HBs antibody titer|All samples will be analyzed for anti HBs antibody titer using ELISA kits.
40849907|NCT00558181|DRUG|rituximab, methylprednisolone|Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
40849908|NCT04929080|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
41374544|NCT00908375|DRUG|Sugar Pill|One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
41374545|NCT02500134|OTHER|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
41374546|NCT04585958|PROCEDURE|Biopsy|Undergo biopsy
41374547|NCT04585958|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41505057|NCT01205984|DRUG|methylprednisolone|Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
41505058|NCT03261492|BEHAVIORAL|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.
41163727|NCT03386214|DRUG|Pevonedistat|The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a \> 5% change in body weight from the weight used for the most recent BSA calculation.
41374548|NCT04585958|PROCEDURE|Computed Tomography|Undergo CT
41505059|NCT03261492|BEHAVIORAL|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
41505060|NCT01917916|DRUG|Placebo|Solution for subcutaneous (s.c.) injection.
41505061|NCT01917916|DRUG|BI 655064|Solution for subcutaneous (s.c.) injection.
41374549|NCT04585958|PROCEDURE|Echocardiography|Undergo echocardiography
41374550|NCT04585958|DRUG|Olaparib|Given PO
41374551|NCT04585958|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
41374552|NCT03253809|DEVICE|Biotronik Vision Guidewire|The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
41374553|NCT04800991|DEVICE|Rhexium Onco Nutrition|"The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body"
41374554|NCT00664066|DRUG|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
41374555|NCT01756586|DRUG|Dexamethasone|
41374556|NCT01756586|DRUG|Bupivacaine|Control
41374557|NCT02046655|DRUG|Corifollitropin alfa|
41374558|NCT02046655|DRUG|rFSH|
41374559|NCT05623774|DRUG|Imatinib Mesylate|400mg tablet
41505062|NCT04167540|BIOLOGICAL|AAV2-GDNF|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
41505063|NCT04190017|OTHER|Cranial MRI|Cranial MRI
41505064|NCT00656266|DRUG|mycophenolate mofetil|immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept
41505065|NCT00656266|OTHER|placebo medication|medication that looks like mycophenolate mofetil
41505066|NCT01184443|DRUG|Olanzapine|Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
41505067|NCT01413607|DEVICE|Quill knotless tissue-closure device|The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.
41505068|NCT01413607|DEVICE|2-0 absorbable vicryl suture|In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
40849909|NCT04929080|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|600mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
41163728|NCT03386214|DRUG|Ruxolitinib|-Standard of care outside of protocol
41374560|NCT05623774|DRUG|IkT-001Pro|100mg or 400mg tablet
41374561|NCT01002417|DRUG|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
41374562|NCT01002417|DRUG|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
41374563|NCT01002417|DRUG|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
41374564|NCT03938454|DRUG|crizanlizumab|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
41374565|NCT06108973|DEVICE|Capnography|To know the Co2 graph in COPD and Normal patients under General Anesthesia
41374566|NCT04177901|DEVICE|Near infrared spectroscopy|It is used for detection of tissue oxygenation
41374567|NCT06311331|DEVICE|Total Talus Replacement (TTR)|The restor3d patient-specific TTR Implant and Instrumentation System is designed to replace a native talus bone that has been affected by a disease state or injury. The implant is an additively manufactured Cobalt Chromium alloy (ASTM F3213) construct produced by laser powder bed fusion. The data-driven design of the implant enables the patient to salvage their joint while maintaining ankle range of motion, reducing pain and improving physical function.
41374568|NCT03582098|DRUG|Idelalisib|Tablets were administered in accordance with the marketing authorization.
41374569|NCT03582098|DRUG|Rituximab|Tablets were administered in accordance with the marketing authorization.
41505069|NCT05656872|PROCEDURE|Transverse Abdominis Plane Block|Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.
40849910|NCT04929080|BIOLOGICAL|JS001 and JS004|Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001
40849911|NCT06403436|DRUG|TT125-802|TT125-802 administered orally
40849912|NCT00371904|DRUG|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
41163729|NCT03386214|PROCEDURE|Peripheral blood draw|"* Baseline or Cycle 1 Day 1 (prior to study treatment administration)~* Cycle 2 Day 1 (prior to study treatment administration)~* Cycle 4 Day 1 (prior to study treatment administration)~* End of treatment"
41163730|NCT03386214|PROCEDURE|Skin biopsy|A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.
41374570|NCT04952610|DRUG|Etripamil NS 70 mg|Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
41374571|NCT04952610|DEVICE|Aptar Pharma Nasal Spray Bidose System|Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
41374572|NCT02043626|OTHER|DISTRICT WELLNESS COMMITTEE|Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
41374573|NCT02043626|OTHER|NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
41374574|NCT02043626|OTHER|HEALTH PROMOTION AND MARKETING|SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
41374575|NCT02043626|OTHER|OPPORTUNITIES FOR PHYSICAL ACTIVITY|District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
41374576|NCT03843866|OTHER|4-0 Monocryl|sutures and steri-strips
41374577|NCT03843866|OTHER|Adhesive Glue|Adhesive Glue
41374578|NCT01040624|RADIATION|< 15% risk of + LN|Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
41374579|NCT01040624|RADIATION|> 15% risk of + LN|Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
41374580|NCT00040209|DRUG|JP 1730|
41374581|NCT00040209|DRUG|IV Levodopa|
41374582|NCT00040209|DRUG|IV Apomorphine|
41374583|NCT00792142|DRUG|bortezomib|Given IV
41374584|NCT00792142|DRUG|dexamethasone|Given orally
41374585|NCT00792142|DRUG|melphalan|Given IV
41374586|NCT00792142|DRUG|thalidomide|Given orally
41374587|NCT00792142|GENETIC|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
40849913|NCT00371904|DRUG|Standard Care|Standard care
41374588|NCT00792142|GENETIC|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
41374589|NCT00792142|OTHER|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
41374590|NCT00792142|OTHER|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
41374591|NCT00792142|PROCEDURE|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
41374592|NCT00792142|PROCEDURE|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
40849914|NCT06023680|BEHAVIORAL|Continuous sedentary reduction intervention|"During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be gradually combined into one 30-minute bout over the course of 20 days."
41374593|NCT04017065|DEVICE|DePuy Synthes MAXFRAMETM system|Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
41374594|NCT05022121|BEHAVIORAL|Supported Biopsychosocial Self-Management (SBSM)|Participants receive training and instruction in skills to engage in healthy physical, psychological, and social self-management behaviors. This will be accomplished through 6-12 sessions with a trained chiropractor or physical therapist. Patients will receive training and instruction in exercises targeting posture, strength, stabilization, and mobility based on their individual needs. They will learn psychological strategies including problem solving and cognitive restructuring to address unhelpful thoughts and emotions. Social strategies include pleasant activity planning with a social focus, and communication techniques for navigating relationships to garner support for self-sufficiency. Other elements include providing key evidence based information about BRLP and spinal manipulation therapies (SMT). SMT will include manipulation, mobilization and soft-tissue treatment. Other intervention elements include enablement, persuasion, and resources and materials to support the patient.
41374595|NCT05022121|DRUG|Medical Care|Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
41374596|NCT00816062|DEVICE|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
40849915|NCT06023680|BEHAVIORAL|Bouted sedentary reduction intervention|"During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be maintained over the course of 20 days."
40849916|NCT05510336|PROCEDURE|Arthrocentesis|Injection of lactated ringer solution in the TMJ to wash out inflammatory mediators and help reducing anterior disc displacement with reduction
40849917|NCT05592678|OTHER|Donepezil|Donepezil is administered as a standard of care treatment by the subject's provider.
41374597|NCT02409225|DEVICE|Home Monitoring|Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
41374598|NCT02409225|DEVICE|no Home Monitoring|Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
41374599|NCT06505330|DIETARY_SUPPLEMENT|Probactiol Baby|Dietary Supplement: Probactiol Mini 6 droplets of Probactiol Mini daily intake for 13 months
41374600|NCT04056650|DRUG|L-theanine|up to 250 mg
41374601|NCT04056650|DIETARY_SUPPLEMENT|Caffeine supplement|50-400mg
41505070|NCT05656872|PROCEDURE|Ilioinguinal-iliohypogastric block|Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.
41505071|NCT01590797|DRUG|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks
41505072|NCT01590797|DRUG|Placebo|Matching placebo once daily for 24 weeks
41505073|NCT01590797|BIOLOGICAL|Insulin|Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
40849918|NCT02697435|OTHER|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain. Treatments may involve behavioral components, physical therapy, or medical treatments such as cortisone shots, depending on the patient's needs.
41374602|NCT04056650|DEVICE|N1 app|N1 App on mobile device
41374603|NCT01173380|OTHER|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
41374604|NCT01173380|OTHER|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
41505074|NCT01590797|DRUG|Metformin|At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
41374605|NCT05697445|OTHER|Mobilization Techniques|Combination of Cranial and Cervical Mobilization for Cervicogenic headache Patients treatment
41032719|NCT03335033|COMBINATION_PRODUCT|Contrast-enhanced ultrasound|Subjects will receive a low mechanical index (0.17-0.20) imaging during ultrasound contrast agent intravenous infusion. Real-time cine-loop including longitudinal and transverse images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the carotid artery will be acquired and digitally stored for offline analysis. Also use of a 3D ultrasound transducer to evaluate the feasibility of using US images with contrast to assess the residual diameter of the diseased vessel. Specifically, two 3D acquisitions of each lesion would be obtained after contrast has been injected.
41032720|NCT03335033|DEVICE|Shear Wave Elastography|Shear wave elastography will be performed with the General Electric Logiq E9 scanner acquiring images of each plaque in the longitudinal and transverse imaging planes. In each plane 10 measurements will be made and the in-phase/quadrature (IQ) data will be saved for further analysis. The plaque area in the imaging plane will be user-defined to extract the wave velocity values for a ROI analysis.
41374606|NCT05697445|OTHER|Conventional Treatment|Cervicogenic headache exercises
41374607|NCT02249546|DRUG|N-acetylcysteine + PPI-amoxicillin-clarithromycin|
41374608|NCT02249546|DRUG|PPI-amoxicillin-clarithromycin|Triple therapy
41374609|NCT00823875|DRUG|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
41374610|NCT00823875|DRUG|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
41374611|NCT00823875|DRUG|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
41505075|NCT00580515|BEHAVIORAL|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
41505076|NCT00580515|BEHAVIORAL|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
41032721|NCT03335033|DEVICE|Ultrasound Examination|A standard carotid US examination using Duplex imaging will performed using a linear array transducer to obtain longitudinal and transverse images. All ultrasound measurements will be made by a trained registered vascular technologist. Severity of stenosis of the plaque will be measured based on established protocol and guidelines.
41374612|NCT00823875|DRUG|control group|routine treatment
41374613|NCT05568888|DRUG|BE1116|4-Factor Prothrombin Complex administered by intravenous (IV) infusion
41374614|NCT05568888|DRUG|Placebo|Administered by IV infusion
41374615|NCT06442111|DRUG|The intravenous ferritin group|Administer intravenous ferritin approximately 3-7 days before surgery (0.9% normal saline 250ml + 1000 mg of ferric carboxymaltose \[Ferinject™, Vifor Pharma, Glattbrugg, Dwitzerland\], inject over 15 minutes)
41374616|NCT06442111|DRUG|The placebo group|Administer intravenous 10ml of normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) approximately 3-7 days before surgery
41374617|NCT01679691|OTHER|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
41374618|NCT01934062|PROCEDURE|Surgery|"All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 \& 7/31/2013.~--------------------------------------------------------------------------------"
41374619|NCT00136266|DRUG|Ferrous sulphate drops with vitamins A, D, and C|
41374620|NCT00136266|DRUG|Ferrous fumarate sprinkles with vitamins and minerals|
41374621|NCT04498260|DRUG|Local steroid - triamcinolone acetonide|(triamcinolone acetonide)
41374622|NCT04498260|DRUG|Oral steroid - predonisolone|(predonisolone)
41374623|NCT02869204|OTHER|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
41374624|NCT02869204|DIETARY_SUPPLEMENT|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
41374625|NCT02869204|DIETARY_SUPPLEMENT|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
41374626|NCT02869204|DIETARY_SUPPLEMENT|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
41374627|NCT04943523|DIETARY_SUPPLEMENT|Krill Oil|Krill oil supplements 4g/day
41374628|NCT04943523|DIETARY_SUPPLEMENT|Vegetable Oil|vegetable oil supplements 4g/day
41374629|NCT03377803|COMBINATION_PRODUCT|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
41374630|NCT03377803|COMBINATION_PRODUCT|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
41032722|NCT03391479|DRUG|Avelumab|Avelumab is a fully human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 isotype. Avelumab selectively binds to programmed death-ligand 1 (PD-L1) and competitively blocks its interaction with programmed death protein 1 (PD-1).
41374631|NCT04929795|BEHAVIORAL|Rhythmic auditory stimulation (RAS)|"The song named 'Sign of The Times' is played and recorded by the research personnel beforehand. The beat of the song will serve as RAS. The computer software Audacity will be used to adjust tempi of RAS. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo. For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Participants in the experimental groups are required to use their right hand to pick up beads from source bowls to the target bowl when listening to the song. The 3-week intervention program will include 21 40-minute daily training sessions."
41032723|NCT03391479|OTHER|Best Supportive Care|As required.
41374632|NCT04929795|BEHAVIORAL|no RAS|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
41374633|NCT02728141|OTHER|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
41374634|NCT02728141|OTHER|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
41374635|NCT04803032|PROCEDURE|Superficial parotidectomy|The parotid gland was exposed with its capsule by subplatysmal and SMAS flaps. Dissection was performed from the tragal cartilage until the bony anterior wall of the external auditory canal; from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle. ); it is the lower point of the landmark. The FNT is located in the region between these two structures. The dissection after identification of the main trunk of the facial nerve was similar to the routine parotidectomy. The surgical defect was closed over a removac suction drain using Vicryl materials; the skin was closed by 6-0 absorbable sutures. A dressing was applied to the surgical site. Then, a gauze was wrapped over the parotid area and secured around the forehead and neck.
41374636|NCT03362411|DRUG|BMS-986205|Single 100 mg dose on Day 1 and Day 15
41374637|NCT01952873|OTHER|Prolonged inflation|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.
41374638|NCT01952873|OTHER|Rapid inflation|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
41032724|NCT05369234|DIETARY_SUPPLEMENT|100% Aloe Vera Juice|George's 100% Aloe Vera Liquid Supplement
41374639|NCT01329562|DRUG|Treximet|Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
41374640|NCT01329562|DRUG|Placebo|A placebo tablet matching Treximet for oral administration.
41374641|NCT00905437|DRUG|Placebo|Placebo as an adjunct to standard of care
41374642|NCT00905437|DRUG|Pregabalin|75 mg BD for 14 days
41505077|NCT00580515|BEHAVIORAL|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
41505078|NCT03675061|OTHER|Current care|Tocolysis and a complete corticosteroid treatment.
41505079|NCT03675061|DEVICE|PartoSure Test negative|Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
41505080|NCT03675061|DEVICE|PartoSure Test positive|Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
41505081|NCT02925039|OTHER|Rehab with computer feedback|Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
41032725|NCT05369234|COMBINATION_PRODUCT|Magic Mouthwash|Magic Mouthwash
41032726|NCT05369234|COMBINATION_PRODUCT|Salt and Baking soda rinse|Mouth rinse made with salt and baking soda
41032727|NCT05369234|DRUG|Carafate|Carafate taken as a slurry
41032728|NCT04695834|PROCEDURE|Neurolysis peroneal nerve|The surgical approach for entrapment at the fibular head is usually through a curvilinear incision just distal to the fibular head. The subcutaneous tissue is bluntly dissected, and the common peroneal nerve is identified proximal to the peroneus longus muscle. The peroneal nerve is then released from the surrounding fibrous tissue and fascia. The nerve is decompressed distally as it dives under the peroneus longus muscle. The decompression at this site is essential. Certain authors state that an adequate decompression should extend beyond the bifurcation in the deep and superficial peroneal nerve and should involve cutting the intermuscular septa
41505082|NCT02925039|OTHER|Treatment as usual|Treatment as usual
41505083|NCT05857852|DEVICE|Low-Intensity Focused Ultrasound|Low-Intensity Focused Ultrasound administration to right dorsal anterior insula, in one of two sessions
41505084|NCT05857852|DEVICE|Sham LIFU device|Sham LIFU device administered in one of two sessions
41505085|NCT00487968|DRUG|eltrombopag|
41505086|NCT03513133|BEHAVIORAL|working memory training|Hierarchical cognitive training of the different components of working memory according to Baddeley model; 15 tasks are used addressing: the phonological loop (8 tasks), the visuospatial sketchpad (4 tasks) and the central executive 3 tasks). Task are given in a hierarchical order, according to each individual patient's deficits and improvement.
41032729|NCT04695834|OTHER|Maximal physiotherapy|Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule
41032730|NCT03563495|OTHER|tissue engineered group|cultured and bone marrow derived autologous mesenchymal stem cells, loaded on collagen matrix (Osteovit)
41163731|NCT05432700|OTHER|LactApp|"LactApp® provides personalised answers that can be arrived at through different pathways, which vary according to the profile of the user and the options she selects, allowing data sampling through an Ecological Momentary Assessment.~The app will remind of:~The first month: baby's breastfeeding position, frequency of feeds, number and consistency of stools, general breast care, average weight gain; in mothers who gave some supplementation, advice and support for them to try re-breastfeeding.~From the second to the third month: advice on expressing milk to create a reserve just in case they went back to work or had to be absent from home for a day, instructions on how to handle and preserve milk.~From the fourth to the sixth month: indications to use the stored milk (if it was created) and techniques for administering it to the infant, the importance of maintaining the EBF and the inadvisability of offering other types of milk or food."
41163732|NCT05235776|OTHER|observation|observation
41163733|NCT04313790|DRUG|Heparin Infusion|500 unit heparin infusion \\ hour for DVT prophylaxis experimental group (n=20)
41163734|NCT04313790|OTHER|subcutaneous heparin|5000 unit subcutaneous heparin /8 hours control group n=(20)
41163735|NCT00143598|DEVICE|Knee-length, graduated elastic compression stocking|Worn daily for 2 years, 30-40 mm Hg
41505087|NCT05379673|OTHER|Oxygen Gas for Inhalation|Oxyhemoglobin saturation (SpO2) higher than 96% vs SpO2 between 90% and 94%.
41505088|NCT00650208|DRUG|Lamotrigine Tablets 25 mg|2x25mg, single dose fasting
41032731|NCT03563495|PROCEDURE|autogenous bone graft group|
41032732|NCT00832923|BEHAVIORAL|PEPAC|"The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider."
41032733|NCT00114374|DRUG|Escitalopram|
41032734|NCT04108546|DEVICE|Electroacupuncture device|The technical characteristics of the device will be: power supply with alkaline batteries (4 pieces), 6V voltage, 6 independently regulated channels, symmetrical biphasic rectangular pulse, excitation from pen type electrode 0.48mA, with high 0.32mA + / -25% \& low 0.16mA +/- 25%. Three preset programs to avoid tolerance effect: program 1) 1-6Hz, program 2) 30-100Hz, program 3) 2-100Hz. Low frequencies (2Hz) cause release of endorphins in the brain and enkephalins in the spinal cord, high frequencies (30-100Hz) cause release of dynorphins in the spinal cord, while medium frequencies (15Hz) cause simultaneous release of endorphin and dynorphin. At low frequencies slow diffuse analgesia is achieved with a long duration of analgesic effect, while at high frequencies rapid local analgesic effect of short duration is achieved.
41032735|NCT04108546|DRUG|Epidural analgesia|Ropivacaine (Naropeine) 0.2%, 5-7% ml, and Fentanyl 25mcg
41032736|NCT04833023|DRUG|Haldol 2mg/ml oral solution|"Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
41032737|NCT04833023|DRUG|Olanzapine Actavis 5mg orodispersible tablet|"Starting dose: 2.5mg~Maximum Dose within 24 hours: 15mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
41032738|NCT04582630|DIETARY_SUPPLEMENT|omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
41032739|NCT01156753|DRUG|CDX-011|CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
41032740|NCT01156753|DRUG|"Investigator's Choice chemotherapy"|Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
41163736|NCT00143598|DEVICE|Knee-length, placebo stocking|Worn daily for two years
41505089|NCT00650208|DRUG|Lamictal® Tablets 25 mg|2x25mg, single dose fasting
41163737|NCT05280366|DEVICE|Streamline Surgical System|Completion of the Streamline Surgical System procedure
41163738|NCT05280366|DEVICE|iStent Inject W|Implantation of competitor device
41505090|NCT03700385|DEVICE|IOWA Approach Endocardial Ablation System|Endocardial ablation using the IOWA Approach Endocardial Ablation System
40849919|NCT02697435|OTHER|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
41032741|NCT03321981|DRUG|Zenocutuzumab|full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3
41032742|NCT03321981|DRUG|Trastuzumab|humanised IgG1 monoclonal antibody
41032743|NCT03321981|DRUG|Vinorelbine|antineoplastic drug of vinca alkaloid family
41505091|NCT02901977|DRUG|Ramipril|Antihypertensive therapy
41032744|NCT03321981|DRUG|Endocrine therapy|same endocrine therapy is administered as the last line of endocrine therapy
41505092|NCT02901977|DRUG|Doxazosin|Antihypertensive therapy
41505093|NCT03591497|OTHER|Virtual Reality|As described in Experimental arm description.
41505094|NCT01820975|DIETARY_SUPPLEMENT|High protein intake|
41032745|NCT05579353|OTHER|nothing|nothing
41032746|NCT06634667|DRUG|third-generation EGFR-TKI combined with anlotinib|third-generation EGFR-TKI combined with anlotinib as maintenance therapy following 4 to 6 cycles of chemotherapy and immunotherapy until progressive disease.
41374643|NCT04145739|OTHER|Rehabilitation protocol|The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
41374644|NCT06045910|DRUG|ALETA-001|ALETA-001 will be administered intravenously (IV) every two weeks.
41374645|NCT01643967|OTHER|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
41374646|NCT01643967|OTHER|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
41374647|NCT05917080|OTHER|Manual Therapy|"Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia \& applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time."
41374648|NCT04122339|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
41374649|NCT06318494|OTHER|jumping performance|"Patients suffering from chronic ankle instability symptomatic of recurrent subjective and objective instability will be considered. Patients will be compared to a control group of healthy volunteer subjects.~T0 Explanation of the study and written informed consent.~* Verification of inclusion/exclusion criteria and verification of previous or ongoing treatments.~* AOFAS Rating Scales,~* Tegner activity level~* Vertical Jump Test (CMJ) by foot pedal"
41374650|NCT05099744|BEHAVIORAL|Electrostimulation Therapy|During 20 minutes participants are connected to the handles and receive electrostimulation therapy.
41374651|NCT05099744|BEHAVIORAL|Relaxation|During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.
41374652|NCT05099744|BEHAVIORAL|Placebo|During 20 minutes participants will be connected to the handles but will not receive any frequency.
41374653|NCT01905631|DRUG|Aurstat Anti-Itch Hydrogel (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
41374654|NCT00306800|PROCEDURE|Photodynamic therapy with methyl aminolevulinate cream|
41374655|NCT02014909|BIOLOGICAL|KTN3379|Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
41032747|NCT04866264|DEVICE|eNutrition Optimizer|The eNutrition optimizer is based on the electronic food frequency questionnaire (FFQ) used in the multicentre randomized controlled trail DO-HEALTH \[56\] developed by the CAM. The FFQ is split up in sections of 33 food groups and contains 216 items. It asks the user on the relative frequency of consumption of the different foods showing a picture of the food in the portion size of interest. Within the eNutrition Optimizer, the FFQ will be extended to create an output of the user's adherence to the Mediterranean diet, the MIND diet and the adherence with the current dietary recommendations for micro- and macronutrients provided by the Swiss Society for Nutrition and the DACH-references, compare it to the DO-HEALTH population and give recommendations on how to improve the score.
41032748|NCT02740127|PROCEDURE|Caudal Nerve Block (CNB)|General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
41032749|NCT02740127|DRUG|Ropivacaine|Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
41032750|NCT02740127|DRUG|Epinephrine|Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
41032751|NCT02740127|DRUG|Decadron|Decadron 10 mg by bolus injection given by anesthesiologist in OR.
41032752|NCT02740127|DRUG|Clonidine|Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
41032753|NCT02740127|DRUG|Propofol|General anesthesia given in the OR using Propofol titrated for induction.
41374656|NCT06214429|DIAGNOSTIC_TEST|Vascular Ultrasound|Complete vascular ultrasound routine in B mode, color mode and Doppler.
40849920|NCT00675220|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40849921|NCT05652153|OTHER|Single-/paired-pulse transcranial magnetic stimulation|Single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) is a technique for noninvasive assessment of brain physiology by delivering single or paired magnetic stimuli to the scalp with an electromagnetic coil. This results in transient induction of cortical electrical activity, which can be measured as evoked potentials by electromyography (EMG) and electroencephalography (EEG). Note that sp/ppTMS is used for neurophysiologic measurements; it is distinct from other TMS applications such as repetitive TMS, which can be used as interventions.
40849922|NCT00555737|DEVICE|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
41032754|NCT02740127|BEHAVIORAL|Phone Call|Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
41374657|NCT06214429|DIAGNOSTIC_TEST|Shear Wave Elastography|Vascular ultrasound assisted shear wave elastography of the atherosclerotic plaque.
41374658|NCT06214429|DIAGNOSTIC_TEST|Greyscale Median|Vascular ultrasound assisted assessment of the plaque in B mode. The plaque image will be post-processed for the histogram median value for the plaque area.
40849923|NCT03298763|GENETIC|MSCTRAIL|"3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).~After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL."
40849924|NCT03298763|DRUG|Placebo|Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product
41374659|NCT06214429|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Assessment of the plaque and carotid residual lumen by magnetic resonance.
41374660|NCT06214429|DIAGNOSTIC_TEST|Histopathology|Histopathology findings for patients that undergo carotid endarterectomy.
41374661|NCT01207219|BEHAVIORAL|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
40849925|NCT00627055|DRUG|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
40849926|NCT00627055|DRUG|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
41032755|NCT05520905|OTHER|TelePrEP|HIV pre-exposure prophylaxis delivered via telemedicine.
41374662|NCT01207219|BEHAVIORAL|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
40849927|NCT00003968|DRUG|bryostatin 1|
40849928|NCT04180566|OTHER|Ultrasound Examination|Includes a regular growth ultrasound examination.
40849929|NCT04180566|OTHER|Antenatal Testing (biophysical profile)|Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
41032756|NCT02308033|DRUG|Metronidazole|
41032757|NCT02308033|DRUG|Gel vehicle|
41374663|NCT03848481|DRUG|CBDV Compound|CBDV is obtained from the Cannabis sativa L. plant and contains a negligible quantity (less than 0.2%) of THC
40849930|NCT02038075|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|
40849931|NCT02038075|BEHAVIORAL|Treatment As Usual (TAU)|
40849932|NCT00997594|PROCEDURE|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
40849933|NCT02724527|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
41374664|NCT03848481|DRUG|Placebo|Placebo oral solution contains matching excipients.
41374665|NCT00461591|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
41374666|NCT00461591|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
41374667|NCT00461591|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
41374668|NCT03056456|DRUG|LY900014|Administered subcutaneously (SC)
41374669|NCT03056456|DRUG|Insulin Lispro (Humalog)|Administered SC
41374670|NCT03115320|DRUG|Human chorionic gonadotropin|Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.
41374671|NCT03115320|OTHER|Home ovulation test|The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
41374672|NCT04284046|OTHER|CT score|CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
41374673|NCT01950052|DIETARY_SUPPLEMENT|Diet group 800 Kcal diet|Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
41374674|NCT01640964|DRUG|Terlipressin acetate|IV bolus injection
41505095|NCT01820975|OTHER|Placebo comparator|No protein intake
40849934|NCT02724527|DRUG|Placebo|Matched Placebo capsule
40849935|NCT03267888|BIOLOGICAL|Pembrolizumab|Given 200 mg IV.
40849936|NCT03267888|RADIATION|Radiation Therapy|Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
41374675|NCT01640964|DRUG|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
41374676|NCT00912756|DRUG|cilostazol|200 mg/day BID
41374677|NCT05242900|PROCEDURE|Complete decongestive therapy|The investigators will identify participants undergoing clinically-indicated interventions that they are already receiving for their routine clinical management (complete decongestive physical therapy). They will make no evaluation of the efficacy of these procedures, but rather will test fundamental hypotheses regarding lymphatic clearance of tissue sodium.
41374678|NCT05242900|OTHER|Standard imaging protocol|The standard imaging protocol entails noninvasive magnetic resonance imaging techniques including sodium and lymphatic angiography.
41374679|NCT05328999|DIETARY_SUPPLEMENT|Probiotics (Omnibiotic (R))|As intervention in the randomized placebo controlled double blind trial, 30 males will receive either probiotics or placebo once daily for 3 months. Sperm count and microbiome analysis before and after intervention will be performed.
41374680|NCT05671822|DRUG|SHR-A1811；SHR-1701；capecitabine；oxaliplatin|(Arm 1A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 1B) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1C) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1D) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
40849937|NCT00742729|BEHAVIORAL|Arm 1|Educational small group session with free FOBT kit
40849938|NCT00742729|BEHAVIORAL|Arm 2|Educational small group session with no FOBT kit
40849939|NCT00742729|BEHAVIORAL|Arm 3|Educational small group session, exercise
40849940|NCT02454062|DRUG|TAS-114|TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
40849941|NCT02454062|DRUG|S-1|S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
40849942|NCT04951700|OTHER|Other|This is not an intervention study
40849943|NCT03850574|DRUG|Tuspetinib|Daily (QD), continuous dosing
40849944|NCT03850574|DRUG|Venetoclax Oral Tablet|Venetoclax will be given to study participants in the Part C tuspetinib plus venetoclax combination treatment group either in 50 mg or 100 mg tablets
40849945|NCT03850574|DRUG|Azacitidine for Intravenous Infusion|Azacitidine will be given to study participants in Part D as intravenous infusion at a dose of 75 mg/m\^2
40849946|NCT06330207|BEHAVIORAL|Clinical decision support tool|The intervention involves two strategies. The first strategy is education where at baseline participants will complete the one-hour online Smiles for Life oral health educational module on acute dental problems, which includes NTDC management. This module can be completed in multiple sessions. Providers will be asked to share the certificate of completion that is provided to them via the website by passing a post knowledge test. The second strategy is CDST. Providers who completed NTDC module certificate will pilot test the CDST which is an algorithm that walks the ED provider thru patient's signs and symptoms and identifies guideline-recommended treatments available in the ED.
40849947|NCT05118373|BEHAVIORAL|BEHAVIOURAL CHANGE CAMPAIGN FOR COVID-19 PREVENTION IN ZAMBIA|The intervention is a mass media campaign using TV, radio, billboard and posters to disseminate the message. The content are well-produced videos and pictures emphasising the need to wash hands, wear a mask, maintain social distance and clean surfaces. The English version of the video can be viewed at this link: https://youtu.be/tcjaLAxy4Ms.
41374681|NCT05671822|DRUG|SHR-A1811；SHR-1701；capecitabine；oxaliplatin|(Arm 2A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 2B) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 2C) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
41374682|NCT01224600|OTHER|patients with newly diagnosed PAD (<1year)|patients with newly diagnosed PAD (\<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
41374683|NCT00956813|DIETARY_SUPPLEMENT|flaxseed|Given orally
41374684|NCT00956813|OTHER|placebo|Given orally
41374685|NCT02764606|BIOLOGICAL|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
41374686|NCT01440075|OTHER|Cardiac evaluation|"complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping"
41374687|NCT03855930|DIAGNOSTIC_TEST|functional MRI|During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).
41374688|NCT00124709|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
41374689|NCT00124709|DRUG|Corticosteroid|conventional corticosteroid-based treatment
40849948|NCT04090463|RADIATION|Intraoperative radiotherapy|"IORT will be delivered as follows:~1. Radical resection --\> delivery of 10-15 Gy to the tumor bed~2. Non radical resection --\> delivery of 15-20 Gy to the tumor in situ"
40849949|NCT00429533|DRUG|Dapsone|
40849950|NCT00319254|DRUG|SKI-606 (Bosutinib)|SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
40849951|NCT06524817|OTHER|transcranial magnetic stimulation|Neuronavigated Theta-Burst Transcranial Magnetic Stimulation
41374690|NCT00240331|DRUG|10mg Rosuvastatin|
41505096|NCT02018380|OTHER|Shock Absorbing Insole (SofSole Athletes Plus)|The shock absorbing insole used in this study was the SofSole Athletes Plus, (Implus Inc, Durham, NC), recommended by the manufacturer for repetitive activities such as running and walking. It is readily available in most athletic shoe stores, retailing for under $20.00. The insole is full-length with a curved last made of Implus XP that has a shore A durometer reading of 60 (0 = softest to 100 = hardest).
41032758|NCT06198569|OTHER|PNF EXERCISES|"Scapular PNF exercise training (6 Weeks) Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Scapular patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization"
41032759|NCT06198569|OTHER|strength exercises|"Upper limb exercise training (6 Weeks) 3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down~Upper extremity movements - Scapular retraction - Shoulder flexion - Shoulder extension - Shoulder abduction - Shoulder adduction Resistant exercise training with Theraband and weights"
41032760|NCT00162851|DRUG|alemtuzumab|
41032761|NCT04942171|PROCEDURE|Atrial fibrillation catheter ablation group|"1. Pulmonary vein isolation~2. Additional treatment for lesions caused by non-pulmonary veins~3. Esophageal temperature monitoring to prevent damage to the esophagus~4. Evaluation of procedure time and radiofrequency ablation time~5. Evaluation of complications after the procedure~6. Rhythm follow-up after the procedure is conducted in accordance with the above study design.~7. Conduct a survey on cognitive function and emotion before and 12 months after the procedure"
41032762|NCT04942171|DRUG|Medical therapy group|"1. Use of beta-blockers or calcium channel blockers for pulse rate control~2. Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.~3. If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.~4. To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.~5. Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure"
41032763|NCT04357028|DRUG|Measles-Mumps-Rubella Vaccine|Measles mumps Rubella vaccine is a weak attenuated life vaccine
41032764|NCT04357028|DRUG|Placebos|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
41032765|NCT03951467|OTHER|Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.|"Three interviews between the patient and a health advisor trained for the study: two times before discharge from hospital and a telephone reminder within 3 weeks after discharge.~First and second interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: within 3 weeks after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations.~Two interviews by phone with a clinical reseach assistant at 30 days et 90 days after discharge which consist of questionnaire."
41032766|NCT05153837|OTHER|saline intravenous administration|Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
41032767|NCT05153837|OTHER|oral water|500 ml oral water
41163739|NCT06096818|BEHAVIORAL|Experimental Group: Kegel exercises and abdominal exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6thweek+12th week). Each training: approx. 30 min.~First session:Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form,International Urinary Incontinence Consultation Questionnaire-Short Form,Pittsburgh Sleep Quality Scale) Information about stress urinary incontinence is given The woman is given kegel exercise and abdominal exercise training face to face by the researchers.~Kegel and abdominal exercise application chart is explained and given as homework.~Relevant brochure is provided. Second Session:Greeting-Kegel and abdominal exercise application chart is being checked Kegel and abdominal exercises are performed again under the supervision of the researcher.~Third session:Greeting-Kegel and abdominal exercise application chart is being checked Data collection tools are being refilled."
41505097|NCT06452901|OTHER|Progression and structured surgical training.|Participants will be exposed to different amounts of open vascular surgical training, but only group I will receive the complete structured and progressive training program. This ensures that all participants have access to the potential benefits derived from the intervention. Current evidence supports this approach, which supports the benefits of medical simulation in the training process of surgical residents.
40849952|NCT02310633|BEHAVIORAL|Memory Strategy Training|This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
40849953|NCT02310633|BEHAVIORAL|Errorless Learning|This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
40849954|NCT02310633|BEHAVIORAL|Retrieval Practice|This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
41505098|NCT04298268|DEVICE|CUSA Clarity Ultrasonic Surgical Aspirator System use|Assessment of the CUSA® Clarity Ultrasonic Surgical Aspirator System use during urological or general surgery for soft tissue removal
41032768|NCT00428454|DEVICE|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
41032769|NCT04757623|PROCEDURE|Purse string closure of Ileostomy|conventional proceedure
41374691|NCT00240331|DRUG|Placebo|
41505099|NCT01767324|DEVICE|Injection to deltoid|Deliver 0.5 milliliters of saline intradermally
40849955|NCT06526052|BEHAVIORAL|Mindfulness Program|Online, coached mindfulness training program
40849956|NCT06526052|BEHAVIORAL|Active Comparator|Remote meetings with a supportive coach
41374692|NCT03488537|DEVICE|AeonoseTM|Breath test
41374693|NCT04240782|BEHAVIORAL|Nutrition and hands on cooking classes for parents and their children|The adults and children will learn how to prepare the fresh produce during an age appropriate, evidence-based, family cooking school. The class will provide participants with a no-cost, low-risk incentive to try new vegetables, and will empower them to build healthier lives through nutrient-rich, locally sourced meals. Participants will also receive nutrition education and information on how they can integrate local produce into their food budget. One of the class sessions will focus solely on how to budget for healthy food, comparison shop, and make the most of their food dollars. Participants will learn how to use their SNAP benefits at local farmers markets.
41374694|NCT04240782|BEHAVIORAL|Produce allocations|Participants will also receive a produce allocation from a local farm during each session of the class.
41032770|NCT03646786|DEVICE|Virtual reality tests|"The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~1. 10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~2. 10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~3. Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe"
41374695|NCT00828009|BIOLOGICAL|bevacizumab|IV
41374696|NCT00828009|BIOLOGICAL|Tecemotide|
41374697|NCT00828009|DRUG|carboplatin|IV
41374698|NCT00828009|DRUG|cyclophosphamide|IV
41374699|NCT00828009|DRUG|paclitaxel|IV
41374700|NCT00828009|RADIATION|radiotherapy|radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
41374701|NCT05874921|DRUG|Jelmyto (mitomycin) for pyelocalyceal solution|"The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations."
41374702|NCT00593385|DEVICE|iCAST covered stent|Iliac stent implantation
41374703|NCT06276647|BEHAVIORAL|HOME|The study intervention consists of a patient education pamphlet and partner sheet (physically and virtually accessible) that will educate and prepare post-partum patients. The patient navigator will explain this pamphlet at postpartum discharge, then will follow-up with the patients up to 30 days in the postpartum period.
41374704|NCT04831255|DRUG|triamcinolone acetonide extended-release injectable suspension|ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
41374705|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
41374706|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
41374707|NCT03039829|DIETARY_SUPPLEMENT|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
41374708|NCT01744275|DIETARY_SUPPLEMENT|Omega 3 fatty acids|
41374709|NCT01744275|DIETARY_SUPPLEMENT|corn oil|Placebo
41032771|NCT01432366|OTHER|SC anti-TNF|Subcutaneous (SC) anti-TNF
41374710|NCT04885842|OTHER|injection I-PRF|injection I-PRF with brackets
41032772|NCT05152693|OTHER|Low variety|Meal components are mixed together on the plate
41032773|NCT05152693|OTHER|High Variety|Meal components are served separately on the plate
41032774|NCT05152693|OTHER|Small Portion Size|Small meal portion size
41032775|NCT05152693|OTHER|Large Portion Size|Large meal portion size
41374711|NCT03351348|DRUG|Bupivacaine|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
41374712|NCT03351348|BEHAVIORAL|patient-reported pain scores|Will be recorded by the nurse in the PACU as per usual practice. Patients will be given a follow-up Brief Pain Inventory (short form) 6 months and 1 year after surgery to assess their level of chronic pain. Patients may be discharged when table either on the day of surgery or post-operative day 1 (on pill diary for same-day discharge patients).
41374713|NCT03351348|OTHER|saline|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 ± 30 minutes hours postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
41374714|NCT03624049|OTHER|Exercise|Community based exercise programs held 2-3 times per week
41374715|NCT03624049|OTHER|Health Class|Community based health class held 1 time per week
41374716|NCT02008955|DIETARY_SUPPLEMENT|Lysine intake provided as a milkshake|There are 7 different lysine test levels ranging from 10 to 80 mg of lysine per kilogram body weight per day (10 - 80 mg/kg/d)
41032776|NCT05152693|OTHER|With Beverage|Meal served with water
41032777|NCT05152693|OTHER|Without Beverage|Meal served without water
41032778|NCT03221582|DRUG|EBR/GZR|Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
41032779|NCT05023252|OTHER|mobile application|VetThrive is a mobile smartphone application that monitors and transmits mobile sensor and utilization data. This app is deployed in Veteran patients who passively self-track their behaviors and psychiatric symptoms.
41032780|NCT03894449|COMBINATION_PRODUCT|Prebiotic + Iron Forificant|A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
41032781|NCT01494402|DRUG|D961S|Oral gelatine capsule
41032782|NCT01494402|DRUG|Esomeprazole|Oral HPMC capsule
41374717|NCT03911557|DRUG|Durvalumab and Tremelimumab|Durvalumab 1500mg + tremelimumab 75mg via IV infusion Q4W, starting on Week 1, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 2 years of total therapy.
41374718|NCT00941681|DRUG|CK-1827452|50 mg MR CK-1827452 BID for 10 days
41032783|NCT01494402|DRUG|Buffered acetylsalicylic acid|Tablet
41032784|NCT04304833|OTHER|Provider-Based Care Model Arm|The PI will be supplementing standard care by providing and training each patient in the use of an analog (not internet connected) vital sign kit for 6 months: weight scale, blood pressure cuff, pulse oximeter. A Log for recording their vital sign measures.
41374719|NCT00941681|DRUG|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
41374720|NCT00941681|DRUG|CK-1827452|100 mg MR CK-1827452 BID for 10 days
41374721|NCT04020822|DEVICE|Guardian Sensor (3)|Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
41374722|NCT06303024|OTHER|personalized combined physical and cognitive intervention|The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload. An incremental exercise test until exhaustion on a bicycle ergometer will be applied to determine directly measured VO2-max in order to customize and personalize the training on each patient. The progressive aerobic exercise (PAE) will last 12 weeks with two sessions per week. Continuous training will be alternated with interval training during the program. The intervention included two weekly training sessions. One session will involve continuous exercise initially commencing at 10 min and progressing towards 30 min/session. Ultimately, a computer based cognitive rehabilitation program will be carried out twice a week for 12 weeks, using the Rehacom software. Participants will begin at level 1 on each RehaCom module and advance through the program as dictated by their performance. Each session will be programmed to last 60 minutes.
41032785|NCT04304833|BEHAVIORAL|mHealth Model Arm|The PI will provide each patient with weight scale, blood pressure cuff, \& pulse oximeter kit connected to a Bluetooth-paired Android Health Tablet for 6 months. Daily vital sign readings will be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse Call Center will be automatically alerted and triaged.
41032786|NCT06459921|DRUG|SOX+Sintilimab|Patients would be allocated to the SOX+Sintilimab group.
41032787|NCT06459921|DRUG|FLOT+Sintilimab|Patients would be allocated to the FLOT+Sintilimab group.
41032788|NCT05815524|OTHER|Physical activity training|training on treadmill
41032789|NCT00519480|DRUG|GSK189075|GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
41032790|NCT00519480|DRUG|Metformin|Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
41032791|NCT00519480|DRUG|Placebo|Placebo will be available as an oral tablets.
41032792|NCT06635707|DRUG|Urapidil|"1. Control systolic blood pressure within 130-140mmHg using urapidil and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, positioning of the body, and other means to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the use of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants."
41032793|NCT06635707|DRUG|Urapidil and Esmolol|"1. Utilize both urapidil and esmolol to control systolic blood pressure within 130-140mmHg and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, strategic positioning of the body, and other measures to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the administration of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants."
41032794|NCT00001651|OTHER|[6,6-2H2]-glucose|\[6,6-2H2\]-glucose will be administered as a continuous IV infusion for one to five days.
41032795|NCT01808690|DRUG|Metformin|
41032796|NCT01808690|DRUG|Placebo|
41032797|NCT05981274|DIAGNOSTIC_TEST|serum biomarker.|serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)
41032798|NCT02188433|BEHAVIORAL|Quit immediately (QI) / cut down to quit (CDTQ)|Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence
41032799|NCT00999479|DRUG|Norethindrone acetate and ethinyl estradiol tablets, USP|"Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc."
41032800|NCT00999479|DRUG|ferrous fumarate (placebo) tablets|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
41032801|NCT03729219|BIOLOGICAL|E. coli ETVAX|Oral suspension Sterile water is added to dmLT . Vaccine is poured to the effervescent solution and needed amount of dmLT is added.
41032802|NCT03729219|OTHER|Placebo|Oral suspension
41032803|NCT01012869|DEVICE|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
41032804|NCT04247854|DIETARY_SUPPLEMENT|Bacillus subtilis probiotic|Bacillus probiotic which contains one confidential ingredient of Bacillus subtilis spores (2 x 1010 CFU/g). Over 5 days of interventional period, the patient receives one tablet (250 mg; 5 x 109 CFU) of probiotic per day.
41032805|NCT04247854|OTHER|Placebo|Over 5 days of interventional period, the patient receives 1 placebo tablet per day
41374723|NCT02325193|DEVICE|Minimed®640G system|Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)
41374724|NCT02284880|DRUG|BIA 2-093|MF - Marketed formulation
41374725|NCT02284880|DRUG|BIA 2-093|TBM - to-be-marketed
41374726|NCT01103908|DEVICE|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
41374727|NCT01164631|DEVICE|Bioajusta X Orthodontic treatment|Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
41505100|NCT01767324|DEVICE|Injection to forearm|Deliver 0.5 milliliters of saline intradermally
41505101|NCT01767324|DEVICE|Injection to thigh|Deliver 0.5 milliliters of saline intradermally
41505102|NCT04290195|DRUG|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Intravitreal injection of 1.25 mg of ziv aflibercept in patients
41374728|NCT04629209|DRUG|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
41374729|NCT01004822|DRUG|CVX-241|0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
41374730|NCT01004822|DRUG|CVX-241|1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
41032806|NCT05266911|BEHAVIORAL|high-intensity functional strength training|HIFST is an exercise program using an interval format: alternating periods of high intensity/'hard' exercise using everyday lower-extremity based strength-building movements (e.g., sit to stand) with periods of light/'easy' activity. High-intensity is individualized based on the use of a rating of perceived exertion (RPE) scale. The program includes a warm-up and cool-down and will be completed in participant's homes 3 days per week.
41032807|NCT05266911|BEHAVIORAL|Lower extremity stretching|Lower extremity stretching program to be completed by participants at home 3 days per week.
41032808|NCT01097135|DRUG|Duraprep Surgical Solution|
41374731|NCT01004822|DRUG|CVX-241|3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
41374732|NCT01004822|DRUG|CVX-241|6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
41374733|NCT01004822|DRUG|CVX-241|12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
41374734|NCT01004822|DRUG|CVX-241|15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
41374735|NCT01004822|DRUG|CVX-241|18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
41374736|NCT01004822|DRUG|CVX-241|25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
41374737|NCT05011162|DEVICE|Digital ACT|Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT).
41032809|NCT01973790|DRUG|Z-338|100mg TID
41032810|NCT03798860|DIAGNOSTIC_TEST|blood samples|For performing the Luminex solid phase assay (SPA) test, 7.5 ml of patient whole blood are collected from a peripheral vein.
41032811|NCT01939028|PROCEDURE|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
41032812|NCT01939028|PROCEDURE|sentinel lymph node biopsy|Undergo SLN biopsy
41032813|NCT01939028|DRUG|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
41032814|NCT01939028|DRUG|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
41374738|NCT05283655|BEHAVIORAL|Gut-directed hypnotherapy|hypnotherapy
41374739|NCT06452732|OTHER|MFC for the determination of leukemia stem cell|MFC for the determination of leukemia stem cell
41374740|NCT03667781|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Blood assay to evaluate for the presence of medications that the patient is prescribed. This is not being used for therapeutic purposes. It has already been validated in prior papers.
41374741|NCT06005077|OTHER|Perineal Massage Group|While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
41374742|NCT06005077|OTHER|Perineal Warm Compress Application Group|Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
41374743|NCT06005077|OTHER|Perineal Massage and Perineal Warm Compress Application Group|When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well .
41374744|NCT04330066|DIAGNOSTIC_TEST|Abdominal ultrasound measurement of the endometrial lining|On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.
41374745|NCT05732103|DRUG|CTX-712|CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
41374746|NCT00346970|DRUG|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
41374747|NCT00346970|DRUG|Placebo|Placebo tablets
41374748|NCT04281030|BEHAVIORAL|PMR (Progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
41374749|NCT04281030|BEHAVIORAL|Monitored Usual Care (MUC)|Subjects will be given basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
41374750|NCT04851704|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
41374751|NCT01961778|DEVICE|Radio-Frequency Ablation|
41374752|NCT01961778|DEVICE|Cryotherapy|
41374753|NCT00003582|DRUG|amifostine trihydrate|
41374754|NCT00003582|DRUG|cisplatin|
41374755|NCT00003582|DRUG|fluorouracil|
41374756|NCT00003582|DRUG|paclitaxel|
41374757|NCT00003582|PROCEDURE|quality-of-life assessment|
41374758|NCT00003582|RADIATION|radiation therapy|
41374759|NCT04216134|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
41374760|NCT04216134|PROCEDURE|Positron Emission Tomography|Undergo 68GA-PSMA-11 PET
41374761|NCT03390010|DRUG|Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine|medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
41374762|NCT03390010|DRUG|Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost|medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
41374763|NCT01967810|DRUG|ANG1005|ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks
41374764|NCT01967810|DRUG|Bevacizumab|For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
41374765|NCT04357431|OTHER|self-administered questionnaire|Data will be collected using Google online self-administered questionnaire disseminated in Arabic language
41374766|NCT00975000|DRUG|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
41374767|NCT00975000|DRUG|Placebo|Administered orally following the same dosing regimen as the experimental arm.
41374768|NCT06129500|BEHAVIORAL|Cognitive Behavioural Therapy for Problematic Impulsive Behaviours|Up to 12 sessions of Cognitive Behavioural Therapy adapted to focus on mood-driven impulsivity in adults with bipolar disorder.
41374769|NCT01296269|DRUG|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
41374770|NCT01296269|DRUG|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
41374771|NCT01296269|DRUG|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
41505103|NCT03624309|DRUG|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
41505104|NCT03624309|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1)
41505105|NCT06219278|DEVICE|Profound Matrix|The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks
40849957|NCT03064919|BEHAVIORAL|Curriculum Testing|An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
41374772|NCT00262483|DRUG|VX-950|
41374773|NCT00262483|DRUG|ribavirin|
41374774|NCT00262483|DRUG|peginterferon alfa-2a|
41374775|NCT02113904|DRUG|Adalimumab|6 injections (one every 15 days during 3 months)
41374776|NCT05511155|OTHER|Oxygen therapy|Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.
41374777|NCT02355366|BEHAVIORAL|Family-Focused Therapy|Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
41374778|NCT02355366|BEHAVIORAL|Brief Educational Treatment|Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
41505106|NCT06440005|DRUG|AGX101|Antibody Drug Conjugate
41505107|NCT03991676|BEHAVIORAL|Values-Based Behavioral Treatment|The values-based behavioral treatment will consist of a series of three, once-weekly weight loss workshops infused with techniques to elicit values clarification and awareness in moments of dietary decision-making, and to enhance autonomous motivation for behavior change.
41374779|NCT03429465|OTHER|EVO Cognitive Remediation Game|EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, \& Anguera, 2016; Journal of Medical Internet Research).
41374780|NCT03577665|RADIATION|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
41505108|NCT01886079|DRUG|dexmedetomidine|0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
41505109|NCT01886079|DRUG|Saline|0.4 mcg/kg/h, IV
41505110|NCT02755285|DEVICE|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
41374781|NCT01977703|OTHER|Ultra Conservative ICD Programming|
41374782|NCT01977703|OTHER|Traditional ICD Programming|
41374783|NCT04864704|OTHER|dry needling|Physical therapy
41374784|NCT06259825|OTHER|Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)|At least four portions of omega-3 PUFA enriched chicken-meat (whole chickens, breasts, thighs and drums) and at least four omega-3 PUFA enriched eggs will be consumed weekly for 4 months. The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland).
41374785|NCT06259825|OTHER|Control poultry foods (chicken-meat and eggs)|At least four portions of standard chicken-meat (whole chickens, breasts, thighs and drums) and at least four standard eggs will be consumed weekly for 4 months.
41374786|NCT02111265|DRUG|Remifentanil|"1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure"
41374787|NCT02111265|DRUG|Cisatracurium|"1. Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~2. Cisatracurium is stopped before skin closure."
41374788|NCT02111265|DRUG|Sufentanil|Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
41374789|NCT02111265|DEVICE|Bispectral index(BIS) monitor|BiS is maintained at 40-60 during anesthesia.
40849958|NCT05880498|BEHAVIORAL|Mindfulness Intervention|Self-guided mindfulness training using a customized version of the Healthy Minds app
40849959|NCT06054802|DEVICE|eCAP|eCap™ has the look and feel of a regular prescription bottle and records real-time adherence data, tracking each opening with the date and time.
40849960|NCT04956653|OTHER|Without additional intervention|Only patients' information was collected
41374790|NCT06296901|OTHER|Perineal Wipe|use of perineal wipe
41374791|NCT05493683|DRUG|Disitamab vedotin|2.0mg/kg，q2w
41374792|NCT05493683|DRUG|Tislelizumab|400mg，q6w
41374793|NCT03854799|DRUG|Avelumab|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
41374794|NCT03854799|DRUG|Capecitabine|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
41374795|NCT03854799|RADIATION|EXTERNAL---BEAM IRRADIATION 50.4 GY|Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
41374796|NCT04148469|PROCEDURE|Dry needling|Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.
41505111|NCT01360463|BEHAVIORAL|Behavioral Drug and Risk Counseling (BDRC)|"The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session."
41505112|NCT01360463|BEHAVIORAL|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
41505113|NCT02497638|DRUG|Metformin|One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
41505114|NCT02497638|DRUG|Atorvastatin|Atorvastatin 20 mg once daily until progression.
41505115|NCT02497638|DRUG|Placebo (corresponding to metformin)|One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
41505116|NCT02497638|DRUG|Placebo (corresponding to atorvastatin)|One placebo tablet (corresponding to atorvastatin) once daily until progression.
41505117|NCT00740012|OTHER|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
41505118|NCT00740012|OTHER|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
40849961|NCT05065151|OTHER|Stimulation on|Stimulation from Percept PC DBS will be on while the patient is playing a decision-making game on a computer-based application.
40849962|NCT05065151|OTHER|Stimulation off|Stimulation from Percept PC DBS will be off while the patient is playing a decision-making game on a computer-based application.
40849963|NCT05065151|BEHAVIORAL|Decision Making Task|Patients will be playing a decision making task through a computer-based application.
40849964|NCT03305978|DEVICE|Ultra low dose chest CT|An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.
40849965|NCT03305978|DEVICE|Low dose chest CT|standard diagnostic low dose chest CT
40849966|NCT01630291|DEVICE|Electrode device|Lacrimal gland stimulation
40849967|NCT05513053|BIOLOGICAL|Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH|Pharmaceutical form: Solution for injection Route of administration: intramuscular
41032815|NCT01939028|PROCEDURE|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
41032816|NCT01939028|PROCEDURE|lymphadenectomy|Undergo para-aortic lymphadenectomy
41374797|NCT04148469|PROCEDURE|Transcutaneous Nerve Stimulation.|Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.
41374798|NCT04148469|PROCEDURE|Placebo needling|No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
41374799|NCT06363552|DRUG|SC0191|The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.
41374800|NCT06363552|DRUG|SC0191 + Bevacizumab|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle."
41505119|NCT00740012|OTHER|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
41505120|NCT00740012|OTHER|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
41505121|NCT00740012|OTHER|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
41505122|NCT00740012|OTHER|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
40849968|NCT00653380|DRUG|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
40849969|NCT00653380|DRUG|Monodox|Capsules, 100 mg, single-dose
40849970|NCT03918525|OTHER|Sindhi families|It is an observational study and no intervention is involved
40849971|NCT01816867|DEVICE|Intramesh T1 implantation|
40849972|NCT06301932|PROCEDURE|Open liver resection|The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
41032817|NCT05435612|DEVICE|cochlear implant|Patients enrolled in the study undergo the cochlear implant surgery.
41032818|NCT04779801|BEHAVIORAL|Attachment-Based Family Therapy|16 weeks of Attachment-Based Family Therapy treatment.
41032819|NCT04013542|BIOLOGICAL|Ipilimumab|Given IV
41032820|NCT04013542|BIOLOGICAL|Nivolumab|Given IV
41032821|NCT04013542|RADIATION|Radiation Therapy|Undergo radiation therapy
41032822|NCT02235493|BIOLOGICAL|Retrospective Case Only|
41032823|NCT06635057|DRUG|Tirzepatide|Administered SC
41374801|NCT06363552|DRUG|SC0191 + 5-FU/LV|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Calcium folinate 400mg/m2 intravenous infusion (over 2 hours or more), on the first day, followed by 5-fluorouracil 400mg/m2 intravenous bolus injection, then continuous intravenous infusion of 1200mg/m2/day for 2 days."
41505123|NCT00125515|DRUG|Memantine|One arm receives 30 mg bid and the other arm receives receives 15mg bid
41505124|NCT00125515|DRUG|Naltrexone|Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
41374804|NCT03591666|DRUG|Anlotinib|Anlotinib p.o. qd
41374805|NCT02223624|OTHER|walking and light weights|
41374806|NCT02223624|OTHER|eccentric aerobic exercise|
41374807|NCT02223624|OTHER|concentric aerobic exercise|
41374808|NCT05437731|OTHER|Coated titanium mesh|patients will undergo repairing of defects or reconstruction using the titanium mesh coated with hydroxyapatite nanocrystals.
41374809|NCT05437731|OTHER|Uncoated titanium mesh|patients will undergo reconstruction using the conventional uncoated titanium mesh.
41374810|NCT01970423|DEVICE|CRT|The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.
41374811|NCT01970423|DEVICE|conventional right ventricular stimulation|
41374812|NCT01788969|DRUG|Lexapro|Agent + training vs Placebo + training
41374813|NCT01788969|DRUG|Placebo|Agent + training vs Placebo + training
41374814|NCT03602976|DRUG|Ursodeoxycholic Acid|weight-based dosing
41374815|NCT00259311|DRUG|LY2422347|
41374816|NCT00259311|DRUG|placebo|
41374817|NCT03375346|DEVICE|Whole body vibration|whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
41374818|NCT03375346|OTHER|Exercise|maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
41374819|NCT02473341|DRUG|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
41374820|NCT02473341|DRUG|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
41374821|NCT04723667|BEHAVIORAL|13-week multimodal intervention|The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.
41374822|NCT04723667|BEHAVIORAL|5-week health education programme|The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
41374823|NCT04328168|PROCEDURE|ROM exercises, stretching, positioning, gait training|
41374824|NCT04328168|PROCEDURE|by two physiotherapist under the supervision of a doctor|
41374825|NCT06465160|BIOLOGICAL|MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)|"The participant will undergo 5 days of mobilization by G-CSF administration (Neupogen) once a day during 5 days.~On the 5th day, and after receiving the last dose of Neupogen, the participant will undergo Apheresis to collect CD34+ cells.~MNV-201 consists of autologous CD34+ cells enriched with allogeneic placenta derived mitochondria. Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by apheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.~Each product package will consist of a ready-for-injection sterile infusion bag containing clinical grade MNV-201 product for IV infusion for a single specified (autologous) participant."
41374826|NCT04787575|PROCEDURE|Oxygen-ozone therapy|"Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas"
41374827|NCT03288428|DRUG|Nalbuphine|patient controlled analgesia with Nalbuphine
41374828|NCT03288428|DRUG|Morphine|patient controlled analgesia with Morphine
41374829|NCT04151316|PROCEDURE|crown preparation|includes tooth preparation
41374830|NCT04151316|PROCEDURE|vertical preparation|type of vertical preparation on the tooth that accepts the crown
41374831|NCT04151316|PROCEDURE|horizontal preparation|type of horizontal preparation on the tooth that accepts the crown
41374832|NCT00806806|DRUG|SKY0402|Local administration of SKY0402 followed by noxious stimulus
41374833|NCT00806806|DRUG|Placebo|Local administration of Placebo followed by noxious stimuli
41374834|NCT06407843|OTHER|Schroth Method|In addition to regular physical therapy, Group A will engage in Schroth exercises therapy (SET). These regular workouts will include breathing exercises, posture training, spinal flexibility exercises, and stretching activities (especially for the muscles on the concave side of the curve). Ten sessions total (30 minutes each, five days a week) will be conducted.
41505125|NCT03106987|DRUG|Active Comparator: Olaparib tablets|"Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
40849973|NCT05633173|PROCEDURE|Ultrasound-guided erector spinae plan block|Ultrasound-guided erector spina plan block was performed for patients in group E for postoperative analgesia. The patients were placed in the lateral decubitus position and the linear ultrasound probe was placed longitudinally into the sterilized area 1-2 cm lateral to the spinous process of the L1 vertebra. After visualizing the erector spina muscle and the transverse process, the transverse process was reached by pushing forward the 22 gauge, 50 mm needle in the direction from cranial to caudal. Hydrodissection was performed with 1 ml of saline for confirmation. 0.5 mL kg-1 dose of 0.25% bupivacaine was injected under the erector spina muscle at the level of the 1st lumbar vertebra by aspiration every 2 mL.
40849974|NCT05633173|PROCEDURE|Ultrasound-guided caudal block|The patients in group C underwent ultrasound guided caudal block for postoperative analgesia. By placing the patients in the lateral decubitus position, the linear ultrasound probe was placed longitudinally on the sterilized area on the midline of the sacrum, and access was provided with a 2.5 cm 22 gauge needle on the dorsal skin of the sacral hiatus at a 90° position. The sacrococcygeal ligament was crossed, the needle was oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. When it was understood that the sacral hiatus had been entered, 0.5 mL kg-1 0.25% bupivacaine was injected by aspirating every 2 mL after the location was confirmed with the negative aspiration method.
41374835|NCT06407843|OTHER|Regular Physical Therapy|Stretching exercises (especially for the muscles on the concave side of the curve) will be part of these regular workouts. Twice day, perform 10 repetitions of a 5-second hold while supine pelvic tilt, twice. Ten sessions total (30 minutes each, five days a week) will be conducted.
41374836|NCT04778397|DRUG|Magrolimab|Administered intravenously (IV).
41374837|NCT04778397|DRUG|Venetoclax|Administered orally at a dose of 100 milligrams (mg) on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle (Cycle=28 days).
41374838|NCT04778397|DRUG|Azacitidine|Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m\^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).
41374839|NCT04778397|DRUG|Cytarabine|"Induction: administered continuous infusion, 100 or 200 mg/m\^2 on Days 1-7 (7+3 induction) and if needed Days 1-5 (5+2 induction) during a cycle (Cycle=Up to 42 Days).~Consolidation: administered IV, 1500 or 3000 mg/m\^2 on Days 1, 3, and 5 once every 12 hours for up to 4 cycles."
41374840|NCT04778397|DRUG|Daunorubicin|Administered IV peripherally (IVP), 60 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
41374841|NCT04778397|DRUG|Idarubicin|Administered IV, 12 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
41374842|NCT04778397|DRUG|Steroidal Eye Drops|Administered per institutional standard during consolidation.
41374843|NCT00251680|DRUG|Lapaquistat acetate and lipid-lowering therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
41374844|NCT00251680|DRUG|Lipid-lowering therapy|Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
41374845|NCT05353920|OTHER|Cognitive training|cognitive related training bu virtual reality system
41374846|NCT02742415|BEHAVIORAL|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
41374847|NCT02713100|BEHAVIORAL|level of agitation|psychological pain
41374848|NCT01587807|DRUG|GSK1995057|inhaled dose (volume based on cohort)
41374849|NCT01587807|PROCEDURE|bronchoalveolar lavage|BAL
41374850|NCT01587807|DRUG|LPS|50 μg
41374851|NCT01587807|DRUG|Placebo|Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
41374852|NCT01683565|DRUG|LCPUFA oil supplement|"2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
41374853|NCT01683565|OTHER|Canola Oil Placebo|2.5mL per day for 90 days
40849975|NCT04598412|OTHER|No intervention|Cross-sectional
41505126|NCT03106987|DRUG|Placebo|"Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
40849976|NCT01223183|DRUG|hypertonic saline (7%)|single treatment by inhalation
40849977|NCT01223183|DRUG|isotonic saline|single treatment by inhalation
40849978|NCT05688020|DRUG|Tranexamic acid|Tranexamic acid will be injected as part of the injectate during endoscopic resection.
40849979|NCT05688020|DRUG|Epinephrine injection|Epinephrine will be injected as part of the standard injectate used during endoscopic resection.
41374854|NCT05078359|DIAGNOSTIC_TEST|Prostate Magnetic resonance Imaging|Magnetic resonance imaging (MRI) uses a magnetic field, radiofrequency pulses, and a computer to produce detailed pictures of the organ. Prostate MRI evaluate the presence and extent of prostate cancer and determine whether it has spread around the organ
41374855|NCT00917904|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
41374856|NCT00917904|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
41374857|NCT06038669|DEVICE|Dried blood spot device|Patients will be asked to provide a dried blood spot sample
41374858|NCT06038669|OTHER|Healthcare professional interviews|Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring
41374859|NCT01808508|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
41374860|NCT01808508|DEVICE|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
41374861|NCT02328170|OTHER|EUROIMMUN Allergy|Immunoblot assay
41374862|NCT02328170|OTHER|ImmunoCap|Fluoroallergosorbent test
41374863|NCT01283009|DRUG|Inactive Substance|Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
41163740|NCT06096818|BEHAVIORAL|Control Group: Kegel exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6th week+12th week). Each training: approx. 20 min.~First session: Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form, International Urinary Incontinence Consultation Questionnaire-Short Form, Pittsburgh Sleep Quality Scale).~Information about stress urinary incontinence is given The woman is given kegel exercise training face to face by the researchers. Kegel exercise application chart is explained and given as homework. Relevant brochure is provided. Second Session:Greeting-Kegel exercise application chart is being checked Kegel exercises are performed again under the supervision of the researcher. Third session:Greeting-Kegel exercise application chart is being checked Data collection tools are being refilled."
41163741|NCT01430208|PROCEDURE|resectoscopy|hysteroscopy for myomas G0 and/or polyps
41163742|NCT02512861|DRUG|Bupivacaine|"Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients \> 50 kgs"
41374864|NCT01283009|DRUG|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
41374865|NCT02514434|RADIATION|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
41374866|NCT02514434|RADIATION|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
41374867|NCT05278975|DRUG|RSO-021|A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.
41374868|NCT03495765|DRUG|Ranibizumab|Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
41374869|NCT01687127|DIETARY_SUPPLEMENT|Folic acid|Supplement
41374870|NCT01687127|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate, calcium salt|Supplement
41374871|NCT04485871|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)
41374872|NCT05111548|DEVICE|tDCS (Active)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the experimental arm will receive a steady current delivery through the device.
41374873|NCT05111548|BEHAVIORAL|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
41374874|NCT05111548|DEVICE|tDCS (Inactive)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the sham arm will wear the device but will not receive a steady current delivery.
41374875|NCT03152058|DRUG|Certolizumab Pegol|"Certolizumab \[400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter\] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
41374876|NCT01301248|OTHER|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
41374877|NCT01301248|OTHER|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
41374878|NCT05319509|DEVICE|gameChange|Staff will explain the rationale behind gameChange, and briefly explain the different scenarios: a doctor's office, a waiting room, a pub, a café, a grocery store, a public street and a bus. Each scenario contains five levels, each increasing with anxiety stimuli and certain tasks the participant must complete. The participant will put on the Oculus headset, and go through a preliminary orientation game. The headset will be casted to an external monitor. Once they start gameChange, it will take the participants to the virtual therapist's room. They will be asked to choose which scenario they would like to participate in first and will complete all five levels for one scenario. Research staff will be taking event sampling-style observations of the participant. After completion of the levels, the participant will return to the virtual therapist's room for debriefing, and then will be asked to exit the game.
41505127|NCT00295061|DRUG|Alpha-1 MP|alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
41374879|NCT05097261|DRUG|Ketamine|Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.
41374880|NCT05097261|DRUG|Placebo|Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
41374881|NCT05649709|DRUG|L-VA dual therapy|1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
41374882|NCT05649709|DRUG|H-VA dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
41505128|NCT00295061|DRUG|alpha-1 proteinase inhibitor (human)|Prolastin
41374883|NCT03289182|DRUG|MabThera|Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
41374884|NCT06012357|DIAGNOSTIC_TEST|Nociception Coma Scale-Revised|Nociception Coma Scale-Revised Recorded after personalized painful stimulus
41374885|NCT04045041|BEHAVIORAL|Acceptance and commitment therapy|An acceptance based intervention with focus on exposure.
41505129|NCT00001705|DRUG|GP100 peptide|
41505130|NCT00001705|DRUG|IL-2|
41374886|NCT01135147|BEHAVIORAL|Diet|Dietary therapy and physical education
41374887|NCT01135147|PROCEDURE|Surgery|Adenotonsillectomy along with diet and physical therapy
41505131|NCT03938285|OTHER|Theranova 400 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
41374888|NCT01692990|DIETARY_SUPPLEMENT|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
41374889|NCT05938413|DEVICE|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
41374890|NCT05938413|BEHAVIORAL|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
41374891|NCT05710367|DRUG|Dapagliflozin 10mg Tab|Forxiga® as an add-on treatment in patients with renal and/or cardiac association FD in an exploratory framework.
41374892|NCT05710367|DRUG|Placebo|matched oral drug. Placebo tablet will have the same color, taste, smell and package as the verum tablet
41374893|NCT01319994|DRUG|Metformin|Metformin 850mg TDS (12 weeks)
41374894|NCT01319994|DRUG|Placebo|Placebo 850mg TDS (12 weeks)
41374895|NCT00509223|DEVICE|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
41374896|NCT00509223|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
41374897|NCT01556490|DEVICE|TheraSphere|Yttrium 90 microspheres
41374898|NCT01294280|OTHER|Laboratory Biomarker Analysis|Correlative studies
41374899|NCT03454191|PROCEDURE|Erector spinae plane block|Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
41374900|NCT03454191|PROCEDURE|No injection|No injection
41374901|NCT00698009|DRUG|Fludarabine|25 mg/m\^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
41374902|NCT00698009|DRUG|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
41374903|NCT00698009|BIOLOGICAL|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
41374904|NCT00698009|DRUG|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
41374905|NCT00698009|DRUG|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
41374906|NCT02376582|BIOLOGICAL|DNA|DNA co-administered with protein at month 0, 1 and 6
41374907|NCT02376582|BIOLOGICAL|AIDSVAX B/E|Protein co-administered with DNA at month 0,1 and 6
41374908|NCT00589823|DRUG|Fentanyl citrate|nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
41374909|NCT00589823|DRUG|Immediate release morphine sulphate|drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
41374910|NCT03205046|DRUG|acalabrutinib|Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
41374911|NCT03205046|DRUG|vistusertib|Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
41374912|NCT02325414|DRUG|Zoledronic acid|Intravenous infusion of zoledronic acid 5 mg.
41374913|NCT02325414|DRUG|Placebo|Placebo (saline) infusion to match zoledronic acid
41374914|NCT05500729|OTHER|Hamstrings maximal voluntary isometric contraction.|Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
41374915|NCT05500729|OTHER|Quadriceps maximal voluntary isometric contraction|Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
41374916|NCT03620669|DRUG|Durvalumab|Durvalumab 1500mg q4W until progression or unacceptable toxicity
41374917|NCT05483062|OTHER|galla chinensis|toothpaste
41505132|NCT03938285|OTHER|FxCordiax 120 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
40849980|NCT03963427|PROCEDURE|Breast reconstruction|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap. Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
40849981|NCT05521789|DRUG|ESB Thoracic|Erector spinae thoracic block with bupivacaine
40849982|NCT00718692|DRUG|Sym001|Each cohort will receive one single dose of Sym001 according the assigned dose level.
41374918|NCT05483062|OTHER|Stannous fluoride|Toothpaste
41374919|NCT02810210|OTHER|fundus examination|"In cohort 3, a fundus examination will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
41374920|NCT02810210|OTHER|Head ultrasound|"In cohort 3, a head ultrasound will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
41505133|NCT01658501|DRUG|50 mg PB1023|
41374921|NCT02144142|BIOLOGICAL|Moisturizer with each subject's own antimicrobial bacteria|
41374922|NCT04114591|PROCEDURE|anterior resection|The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed
41374923|NCT00270400|DRUG|nesiritide|
41374924|NCT03808298|DRUG|Balovaptan therapeutic dose Treatment A|Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
41505134|NCT01658501|DRUG|70 mg PB1023|
41505135|NCT01658501|DRUG|100 mg PB1023|
41032824|NCT04639414|DRUG|Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.
40849983|NCT03588936|DRUG|Nivolumab (.25 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
40849984|NCT03588936|DRUG|Tocilizumab|Participants will receive 2 doses of tocilizumab
40849985|NCT03588936|DRUG|Nivolumab (.5 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
41032825|NCT04639414|DRUG|Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide|Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
41032826|NCT04639414|DRUG|Placebo matching empagliflozin and placebo pen injector matching semaglutide|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
41032827|NCT00579917|BEHAVIORAL|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
41032828|NCT00579917|BEHAVIORAL|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
41032829|NCT01843413|RADIATION|stereotactic radiosurgery|Undergo SRS
41032830|NCT01843413|PROCEDURE|quality-of-life assessment|Ancillary studies
41032831|NCT01843413|PROCEDURE|cognitive assessment|Ancillary studies
41032832|NCT04060394|DRUG|Phase I and Phase II: LAE001/prednisone + afuresertib|In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).
41032833|NCT00157326|DRUG|tadalafil|
41032834|NCT04855253|DRUG|E7777|E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
41032835|NCT02564575|BIOLOGICAL|HPIV3-EbovZ GP Vaccine|Administered intranasally by a VaxINator device
41032836|NCT04040985|PROCEDURE|Total Knee Arthroplasty using LEGION™ Total Knee System|Primary Total Knee Arthroscopy using LEGION™ Total Knee System
41032837|NCT02621606|DRUG|[11C]MK-6884|IV bolus dose of \~370 MBq \[11C\]MK-6884
41374925|NCT03808298|DRUG|Balovaptan supra-therapeutic dose Treatment B|Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
41374926|NCT03808298|DRUG|Active control [moxifloxacin] on Day 2 Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
41374927|NCT03808298|DRUG|Active control [Moxifloxacin] on Day 15 Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
41505136|NCT01658501|DRUG|Placebo (0.9% Sodium Chloride)|
40849986|NCT01623869|OTHER|Laboratory Biomarker Analysis|Correlative studies
40849987|NCT01623869|BIOLOGICAL|Trebananib|Given IV
40849988|NCT03666221|DRUG|Nimotuzumab|Drug: Nimotuzumab Radiation: Intensity Modulated Radiation Therapy
40849989|NCT05254249|DRUG|Lactobacillus Plantarum IS-10506|Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
40849990|NCT05254249|OTHER|Placebo|Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets
40849991|NCT02210975|DEVICE|LES-Stimulation Device|
40849992|NCT02859441|DRUG|Ranibizumab|Intravitreal injections of the commercially-available 10 mg/mL formulation of ranibizumab. Ranibizumab is formulated as a sterile solution (pH 5.5) with histidine, trehalose and polysorbate 20. The vial contains no preservative. Each vial contains 0.5 mL of 10 mg/mL ranibizumab aqueous solution. The intravitreal injection volume of ranibizumab is 50 microliter, which correlates to 0.5 mg of dry ranibizumab.
40849993|NCT02859441|DRUG|E10030|E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
41032838|NCT02624804|BIOLOGICAL|Stem Cell Educator Therapy|"Patients will receive apheresis and then have their own blood returned to them with the educated lymphocytes"
41032839|NCT02116465|DRUG|Levodopa Carbidopa immediate release tablets|oral administration
41032840|NCT06386484|DEVICE|PolarCap System|The PolarCap Coolant flows through a silicone-based head cap. An insulating neoprene cover is put on top of the cap to isolate the cold. Using PolarCap system to selective head and neck cooling for 45 minutes post fight in boxing.
41032841|NCT05015894|DRUG|NNC0480-0389|"A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).~Total duration of study participation for each participant is 38 to 66 days"
41163743|NCT02512861|DRUG|Placebo|"Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients \> 50 kgs"
41374928|NCT03808298|DRUG|Placebo for Balovaptan Treatment C|Days 1-14: Matching placebo for balovaptan for 14 days.
41374929|NCT03808298|DRUG|Placebo for Balovaptan Treatment D|Days 1-14: Matching placebo for balovaptan for 14 days.
41374930|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment A|Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
41505137|NCT01658501|DRUG|Victoza®|
41505138|NCT01658501|OTHER|Diet and Exercise|
41505139|NCT01658501|DRUG|Metformin|
41505140|NCT01658501|DRUG|Sulfonylurea|
41505141|NCT01658501|DRUG|Metformin and Sulfonylurea|
41505142|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One stick pack containing 500 mg acetylsalicylic acid dry powder
41374931|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment B|Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
41374932|NCT03808298|DRUG|Moxifloxacin Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
41374933|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment C|Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
40849994|NCT01999725|DRUG|EDP-788|EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses
41374934|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment D|Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
41374935|NCT03808298|DRUG|Moxifloxacin Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
41374936|NCT04984499|DEVICE|Dental implant|"The procedure used to accomplish its intended use is as follows :~The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level with a cover screw to allow the tissues healing. After this healing phase, the final prosthesis will be loaded on the implant."
41374937|NCT03204006|DRUG|Dexmedetomidine|Dexmedetomidine preinduction
41374938|NCT03204006|DRUG|sterile saline|normal saline preinduction
41374939|NCT02423564|DIETARY_SUPPLEMENT|Digesta Lac|
41374940|NCT02423564|OTHER|Placebo|
41374941|NCT00576667|DRUG|Rimonabant|Tablet, oral administration
41374942|NCT00576667|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
41374943|NCT01652807|BEHAVIORAL|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
41374944|NCT00322530|PROCEDURE|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
41374945|NCT02553486|OTHER|quality of life evaluation|
41374946|NCT01545375|BIOLOGICAL|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
41374947|NCT01545375|BIOLOGICAL|Placebo|4 doses administered intramuscularly
41374948|NCT01545375|BIOLOGICAL|Prevnar 13®|4 doses administered intramuscularly
41374949|NCT01545375|BIOLOGICAL|PedvaxHIB®|4 doses administered intramuscularly
41374950|NCT05773924|DEVICE|triLift system|To evaluate the efficacy of the triLift™ treatment
41374951|NCT02264886|RADIATION|MRI-guided stereotactive body radiation therapy|
41374952|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP)|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
41374953|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP) Sham|Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
41374954|NCT00312650|DRUG|liposomal doxorubicin and gemcitabine|
41163744|NCT06088797|OTHER|METRIC COMPARISON Tasks : Tactile PVSE test|"Tactile PVSE test The tests are presented in 6 independent booklets, each of which tests a distinct skill: comparison of lengths, comparison of sizes, comparison of obliques, perception of environments, comparison of relative positions in relation to a frame and comparison of relative positions with distractors.~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
41374955|NCT00403611|DRUG|Praziquantel 60 mg/kg|Praziquantel (Distocide) 60 mg/kg single oral dose
41374956|NCT00403611|DRUG|Praziquantel 40 mg/kg|Praziquantel (Distocide) 40 mg/kg single oral dose
41374957|NCT03896802|PROCEDURE|Physiological assesment|"1. Arterial and mixed venous blood gas analysis.~2. Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~3. Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~4. Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~5. Urine flow in 1h and determination of the fractional excretion of sodium and creatinine."
41374958|NCT06452862|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Both Diabetics and Healthy Volunteers will undergo MRI protocols including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE). For Diabetics, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, Diabetics will undergo a renal biopsy to assess the extent of kidney damage.
41374959|NCT02223520|DRUG|Mupirocin and Chlorhexidine|
41374960|NCT02223520|DRUG|Placebo ointment and placebo cloths|
41374961|NCT02556112|BEHAVIORAL|Group Lifestyle Balance|The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed
41505143|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One tablet containing 500 mg acetylsalicylic acid
41505144|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One effervescent tablet containing 500 mg acetylsalicylic acid
41505145|NCT01941498|DEVICE|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
41505146|NCT01941498|PROCEDURE|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
41505147|NCT05551663|OTHER|Isometric exercise training|Participants randomised to the intervention will perform a 4-week programme of isometric exercise training.
41505148|NCT04554446|PROCEDURE|T-MSAT(Motion style acupuncture treatment using traction)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. T-MSAT(Motion style acupuncture treatment using traction) is a kind of MSATs, and a treatment that improves musculoskeletal problems by pulling the patient's body through the device and giving instructions for walking while being acupuncture.
41505149|NCT04554446|PROCEDURE|Korean medicine treatment|acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
41505150|NCT03237507|DRUG|S-1|40-60mg/m\^2 bid, days 1-14, oral，every 3 weeks.
41505151|NCT03237507|DRUG|oxaliplatin|100mg/m\^2 days 1，intravenous infusion, every 3 weeks.
41505152|NCT03237507|DEVICE|Hyperthermic Intraperitoneal|hyperthermic intraperitoneal chemoperfusion
41505153|NCT03237507|DRUG|Paclitaxel|intraperitoneal perfusion
41374962|NCT02556112|BEHAVIORAL|Better Body Better Life|The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class
41374963|NCT02556112|BEHAVIORAL|Fitness Improvement Program|The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
41374964|NCT00620776|BEHAVIORAL|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
41374965|NCT00620776|DRUG|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
41374966|NCT04188613|DEVICE|Percutaneous tracheostomy|Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
41374967|NCT02689973|BEHAVIORAL|Self-Efficacy|"The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
41374968|NCT02689973|BEHAVIORAL|Planning|"The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
41374969|NCT02689973|BEHAVIORAL|Education|"Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools."
41374970|NCT06168084|DRUG|Vonoprazan|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
41374971|NCT06168084|DRUG|amoxicillin|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
41374972|NCT06168084|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
41374973|NCT06168084|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
41505154|NCT04368689|OTHER|Floatation-based reduced environmental stimulation therapy|Completion of 3 float session that can last for up to 90 minutes each session, each spaced approximately one week apart
41505155|NCT03148665|DEVICE|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
41505156|NCT04123626|DRUG|QR-1123|unilateral IVT injection
41505157|NCT04123626|OTHER|Sham procedure|Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
41505158|NCT04357080|PROCEDURE|Urethroplasty|Augmentation Anterior Urethroplasty Using Dorsal Onlay Buccal Mucosal Graft
41505159|NCT04201197|DRUG|Inje cocktail|Acute drug exposure
41505160|NCT04201197|DRUG|THC Cannabis extract|Acute drug exposure
41505161|NCT04201197|DRUG|THC/CBD Cannabis Extract|Acute drug exposure
41505162|NCT03729726|BEHAVIORAL|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model uses a placed-based collective impact framework to provide a comprehensive intervention model, including: academic support and college and career readiness services, evidence-based social emotional learning instruction to strengthen protective factors and promote healthy transitions to adulthood, and trauma-informed, medically accurate, and age appropriate sexual health education. Moreover, the 2.0 PREIS program model features a unique student advocacy component designed to ensure that youth and their families receive the wraparound supports necessary for their students to remain on track for school success.
41374974|NCT06168084|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
41374975|NCT06168084|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
41374976|NCT04639050|DRUG|RO7126209|RO7126209 will be administered intravenously as specified in each treatment arm.
41374977|NCT04639050|DRUG|Placebo|RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.
41374978|NCT06128109|DEVICE|Thioderm Strong|Test Device
41374979|NCT06128109|DEVICE|Juvéderm VOLUMA Lidocaine|Comparator Device
41374980|NCT02989701|DRUG|Plerixafor|Dose escalation of Plerixafor for Hematopoietic stem cell mobilization in patients with Sickle Cell Disease
41374981|NCT03396601|DRUG|Ketamine Hydrochloride|Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes
41374982|NCT03396601|DRUG|Placebo|Normal Saline placebo will be infused IV over 40 minutes
41374983|NCT04485026|RADIATION|Local consolidative radiation therapy|All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (\>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.
41374984|NCT04485026|DRUG|Standard of care radiation therapy|Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
41374985|NCT03813966|DIAGNOSTIC_TEST|Sofia Influenza A+B FIA|The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.
41374986|NCT01028274|DIETARY_SUPPLEMENT|Placebo|Two capsules, twice daily with meals for 12 weeks.
41374987|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
41374988|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
41374989|NCT06567444|OTHER|Working memory intervention|During the intervention, the participants in the ADHD group received five computerized working memory training sessions per week over five weeks, and each session lasted 20 minutes. This training paradigm is based on previous studies which show improvements in working memory capacities after a 5-week training period.
41374990|NCT00644527|OTHER|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
41505163|NCT01308801|DEVICE|active rTMS + rehabilitation exercise|14 weeks program of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
41374991|NCT00644527|OTHER|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
41374992|NCT01269346|DRUG|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
41374993|NCT02659657|DRUG|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
41374994|NCT03417245|DRUG|fitusiran|by SC injection
41374995|NCT03417245|DRUG|factor concentrates|by intravenous (IV) injection
41374996|NCT01994369|DRUG|EC17|
41374997|NCT04470856|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|An occlusion manoeuvre during the end of expiration for 20 seconds
41374998|NCT05074459|DRUG|Eptinezumab Mammalian Cell Line|Concentrate for solution for IV infusion
41374999|NCT05074459|DRUG|Eptinezumab Yeast Cell Line|Concentrate for solution for IV infusion
41375000|NCT05736549|DRUG|Bupivacaine-Liposomal Bupivacaine|A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
41375001|NCT05736549|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
41375002|NCT05199649|DRUG|SintilimabCombined With Chemotherapy|Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
41375003|NCT03680209|OTHER|Simulation|pre-training observation training post training observation
41375004|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake|6g protein per day for 8wk
41375005|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake + stickwater|6 g protein per day for 8 wk
41375006|NCT01894542|DIETARY_SUPPLEMENT|Control|
41375007|NCT04044404|DIAGNOSTIC_TEST|Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)|Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
41505164|NCT01308801|DEVICE|placebo rTMS+ rehabilitation exercise|14 week program of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
41505165|NCT03482115|RADIATION|PET examination with radiopharmaceutical drug [18F] DPA-714|Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection
41375008|NCT04575233|PROCEDURE|laparoscopic-assisted Transversus Abdominis Plane (TAP) block|"The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side."
41375009|NCT04575233|PROCEDURE|ultrasound-assisted Transversus Abdominis Plane (TAP) block|Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.
41375010|NCT04575233|DRUG|Ropivacaine|a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
41375011|NCT05969275|BIOLOGICAL|Allogeneic umbilical cord-derived human mesenchymal stromal cells|Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells
41375012|NCT05969275|OTHER|Placebo|Intravenous infusion of placebo, with excipients
41375013|NCT03874507|OTHER|Virtual Reality/Augmented Reality Headset|"A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view."
41375014|NCT02553291|BEHAVIORAL|SystemCHANGE|
41375015|NCT02553291|BEHAVIORAL|Control|
41375016|NCT02503696|DEVICE|Stool Collection Kit|Stool Collection Kit.
41375017|NCT04681859|DEVICE|High Flow Nasal Oxygen (HFNO) treatment|Administration of High Flow Nasal Oxygen (HFNO) to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). Adjust flow-rate and FiO2 as per standard HFNO treatment protocol.
41375018|NCT04681859|DEVICE|Continuous Positive Airway Pressure (CPAP) therapy using OxyJet|Administer CPAP to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). CPAP initiated with FiO2 at 40% and a 10cm PEEP. Titrate PEEP to 15 cm if required. Deliver additional oxygen via secondary port if a higher FiO2 is required.
41375019|NCT04746001|DIAGNOSTIC_TEST|Genomic sequencing|Sequencing data
41375020|NCT04746001|DIAGNOSTIC_TEST|Histological examination|Images for deep learning
41375021|NCT00226447|DRUG|Pegylated Interferon|
41375022|NCT00226447|DRUG|Lamivudine|
41375023|NCT06248866|OTHER|Extracorporeal Shock Wave Therapy|The affected hand or fingers will be positioned comfortably to ensure optimal access to the fibromatosis lesion. Gel or oil will be applied to the skin to enhance the transmission of shock waves. Shock wave therapy will be administered using the selected energy level and frequency settings. Energy level and frequency will be customized based on individual patient requirements. (1000-1500 shock/session, frequency between 5-12HZ, compression power of 1.5- 2.5 bars).and will receive traditional treatment
41505166|NCT03482115|DIAGNOSTIC_TEST|MRI examination|MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).
41505167|NCT03482115|BIOLOGICAL|Blood samples|Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity
41375024|NCT06248866|OTHER|traditional treatment|the patients will receive traditional treatment in the form of laser (A low-level laser device with a wavelength of 830 nm and power output of 50 mW will be used as one Of the pain relief methods), ultrasound (An ultrasound device with a frequency of 1 MHz and an intensity of 1.5 W/cm² will be used), stretching and strengthening exercise and splinting.
41505168|NCT06402760|OTHER|TCM comprehensive treatment|"1. Taodan Granules (TCM formulation for promoting blood circulation and removing blood stasis): The granules consist of the following herbal components: milkvetch, licorice, angelica, rhizoma chuanxiong, peach seed, Salvia miltiorrhiza, Curcuma zedoaria, Achyranthes bidentata, and sarsaparilla. Patients will take it orally in two divided doses after breakfast and dinner.~2. Fish Oil: Patients will take 1g of fish oil orally twice daily. Patients will be instructed to purchase fish oil under the guidance of the researchers.~3. Exercise Plan: Researchers will design an exercise plan for patients, who will be required to engage in at least 150 minutes of moderate-intensity aerobic exercise per week.~Patients will undergo a 16-week treatment period followed by a 24-week follow-up period. During the follow-up, patients will continue taking fish oil and adhering to the exercise regimen, while other treatment modalities will be unrestricted."
41505169|NCT06402760|DRUG|Western medicine|The treatment methods prescribed in the guidelines.
41505170|NCT05690230|OTHER|Virtual reality|Patients will be provided with a wireless virtual reality headset that contains a guided meditation application. The application allows users to select their preferred music, visual setting, and a topic for meditation.
41505171|NCT05690230|OTHER|Environmental changes|A nature themed wall mural decal will be installed in the procedure room and the in-room computer will play music from Pandora. A selection of suggested stations will be provided, with the option for outside selections.
41375025|NCT06515639|OTHER|Diet therapy for Classic IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants. The classic intermittent fasting diet was planned with a macronutrient distribution of 45-60% carbohydrates, 10-15% protein, and 25-30% fat. Additionally, total energy intake was reduced by 500-750 kcal.
41375026|NCT06515639|OTHER|Diet therapy for low carb-High fat IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants.The low carb-high fat intermittent fasting diet included 10-30% carbohydrates and 50-65% fat.Additionally, total energy intake was reduced by 500-750 kcal.
41375027|NCT05255939|PROCEDURE|distal TRA group|dTRA for PCI procedure to ACS patients.
41375028|NCT05255939|PROCEDURE|conventional TRA group|Conventional TRA for PCI procedure to ACS patients
41032842|NCT06635239|OTHER|Co-creation and assessment|"1. MOOC co-creation: development of a MOOC initially structured into modules consisting of a variety of downloadable educational resources such as videos, audios, infographics, texts, etc., covering several units related to Person-Centered Care (Shared Decision-Making, strategies for managing the clinical encounter, Patient Decision Aids, etc.) and Digital Health Literacy (skills, tools, etc.). These resources will serve as the central focus of the educational intervention, and may undergo appropriate adjustments established during the co-creation sessions.~2. MOOC acceptability and effectiveness: evaluation of the MOOC in terms of effectiveness (level of Health Literacy, Digital Health Literacy, and knowledge acquired) and acceptability (usability, areas for improvement, etc.)"
41375029|NCT04869475|DRUG|Arsenic trioxide|This is a single-arm study with all patients receiving arsenci trioxide.
41375030|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
41375031|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
40849995|NCT01999725|DRUG|Placebo|Matching placebo capsules or matching suspension
40849996|NCT03669237|PROCEDURE|different reconstruction methods|Different reconstruction methods should be performed after sphincter preservation surgery in two groups.The methods include end-to-end anastomosis or end-to-side anastomosis
41032843|NCT05216172|DRUG|AZD1656|active drug
41375032|NCT04260594|DRUG|Arbidol|Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
41375033|NCT04260594|OTHER|basic treatment|basic treatment
41375034|NCT03542175|DRUG|Rucaparib|one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
41375035|NCT03542175|RADIATION|Radiotherapy|50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician.
41375036|NCT06286995|PROCEDURE|Chemomechanical preparation for root canals|After working length determination ,root canal preparation was made by two different NiTi File systems to both group ( the first group using Trunatomy file and the second one using edgeendo x7 file) and assessment of pain was made preoperatively and postoperatively and also apical fluid samples
41163745|NCT06088797|OTHER|METRIC COMPARISON Tasks : Classic PVSE test|"Classic PVSE test Use of the standardized PVSE test printed on thick white paper in 6 separate booklets each containing a subtest (length, size, oblique, middle, relative position and relative position with distractor)~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
41375037|NCT05945368|DRUG|Eribulin mesylate injection、Pertuzumab、Trastuzumab|"* Eribulin mesylate, 1.4 mg /m², day 1 and day 8;~* Trastuzumab, 8 mg/kg load dose in the first cycle and 6 mg/kg in each subsequent cycle on day 1;~* Pertuzumab, 840 mg load dose in the first cycle and 420 mg in each subsequent cycle on day 1; There are four cycles in 21 days"
41375038|NCT02544607|DRUG|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
41375039|NCT02544607|OTHER|Magnetic Resonance Imaging (MRI)|MRI technology will be used before and after ketamine for patients with depression
41375040|NCT00150137|DRUG|Methimazole|
41375041|NCT05936775|OTHER|nano-hydroxy apatite coated titanium implants|titanium implants with surface treatment of nano-hydroxy apatite
41375042|NCT05936775|OTHER|sandblasted large acid itched coated titanium implant|titanium implants with SLA surface treatment
41375043|NCT06074666|BEHAVIORAL|CareMeds Intervention|3 parenting sessions will be offered during weeks 2 through 4 of the study period.
41375044|NCT06074666|BEHAVIORAL|Usual Care Group|3 parenting sessions will be offered during weeks 13 through 15 of the study period.
41375045|NCT01055184|BIOLOGICAL|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
41375046|NCT01450670|DIETARY_SUPPLEMENT|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
41375047|NCT06461273|BEHAVIORAL|Lifestyle Medicine Program|"Participants will engage in culinary and nutrition education for 6 weeks curated by a professional chef working in conjunction with the project team from community partner Ethos Farm to Health. Lessons will be adapted from the American College of Lifestyle Medicine (ACLM) Culinary Medicine Curriculum~Participants will engage in exercise sessions on weeks without culinary and nutrition instruction for a total of 6 weeks. Exercise sessions will include a variety of activities to include calisthenics, weight training, walking, running, dance, and games delivered by the Rutgers physical therapy team.~Urban Agriculture lessons will occur longitudinally throughout the 12-week course. Participants will learn to cultivate a variety of crops in limited spaces, emphasizing sustainable practices and the importance of local food systems in urban communities.~Additionally, this arm will receive a supplemental food box weekly consistent with the dietary pattern set forth by ACLM."
41375048|NCT06461273|BEHAVIORAL|Medically Tailored Groceries|"Participants in the Food is Medicine arm will receive a supplemental food box weekly curated by a registered dietician and dietetics students. Each food box will contain seasonally available fruit and vegetables and other items including protein, dairy/cheese, and legumes that may be available at the time of the food box delivery. Each box will contain approximately 8 pounds of food and all participants in this group will receive the same food items. Classes and educational materials provided will be tailored to the specific foods contained in the weekly food box and will include simple preparation methods, recipes, nutrition information and grocery shopping tips."
41375049|NCT05841862|DEVICE|2C-QD|Quantum Dot
41375050|NCT05841862|DEVICE|Sham 2C-QD|Sham Intravitreal Injection
41375051|NCT05557409|DRUG|AXS-05|AXS-05 tablets, taken twice daily
41375052|NCT05557409|DRUG|Placebo|Placebo tablets, taken twice daily
41375053|NCT01012531|BIOLOGICAL|Subcutaneous injections with highly polymerized allergen extract|cluster schedule
41375054|NCT01012531|BIOLOGICAL|Subcutaneous injection with placebo|cluster schedule
41375055|NCT06539078|OTHER|Maximal exercise test|Participants will undertake an incremental ramp test on a cycle ergometer to determine maximal oxygen uptake (V̇O2max) and the gas exchange threshold (GET). Throughout the exercise test, muscle oxygenation and deoxygenation will be monitored by NIRS.
41375056|NCT06539078|OTHER|3D Ultrasound|Muscle volume and morphological characteristics will be assessed via 3D ultrasound imaging.
41375057|NCT06539078|OTHER|Dynamometry|To determine the contractile properties of the knee extensors, participants will perform maximal isometric and isoinertial contractions of the knee extensors on a dynamometer.
41375058|NCT06539078|OTHER|Exercise test and occlusions|Participants will perform a series of moderate-intensity constant power output exercise bouts on a cycle ergometer following which the recovery rates of muscle V̇O2 will be determined via a series of intermittent arterial occlusions. Throughout all tests, pulmonary gas exchange and ventilation will be determined and muscle oxygenation and deoxygenation will be monitored by NIRS.
41375059|NCT06539078|OTHER|Exercise test in MRI|Exercise will be performed on a custom-built magnetic resonance-compatible cycle ergometer in supine position for determination of muscle phosphocreatine recovery kinetics using 31phosphorous magnetic resonance spectroscopy \[31P-MRS\].
41375060|NCT06539078|PROCEDURE|Muscle biopsy|A muscle biopsy will be obtained from the vastus lateralis using a modified Bergström needle technique with suction.
41375061|NCT06289959|DIAGNOSTIC_TEST|cfDNA|After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.
41375062|NCT04394572|BIOLOGICAL|Blood sample|All patients included in the study will have blood sample
41375063|NCT03605758|DRUG|Ivermectin|Ivermectin is an anti-parasitic
40849997|NCT01037738|PROCEDURE|ACL reconstructive surgery and ACS/ Orthokin application|ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
41375064|NCT03930524|BEHAVIORAL|Personalized Normative Feedback (PNF)|Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on prevalence of drinking, consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. Students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
41375065|NCT03930524|BEHAVIORAL|Self-Monitoring (SM)|Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
41505172|NCT03564392|BEHAVIORAL|Acceptance Based Behavioral Intervention|This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
41032844|NCT05216172|DRUG|Placebo|placebo
41032845|NCT00390052|DRUG|triapine|Given IV and orally
41032846|NCT00390052|OTHER|pharmacological study|correlative study
41032847|NCT00390052|PROCEDURE|laboratory biomarker analysis|Correlative study
41032848|NCT06636591|COMBINATION_PRODUCT|Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Epirubicin Drug: Cyclophosphamide|Drugs was given a few days after multimodal thermal therapy
41032849|NCT06636591|COMBINATION_PRODUCT|Device: Multimodal Tumor Thermal Therapy System Drug: SHR1316 Drug: Nab paclitaxel Drug: Carboplatin|Drugs was given a few days after multimodal thermal therapy
41032850|NCT05611801|DRUG|marstacimab|marstacimab
41032851|NCT05695365|BEHAVIORAL|Resistance Exercise Training|Participants will complete a 16-week, twice/week supervised resistance exercise training program to increase strength. Each session will last \~60 minutes and begin and end with a 5-minute aerobic warm-up/cool-down on a cycle ergometer, elliptical, treadmill, or walked laps. Training will begin with a 1-week standard familiarization process to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 10 Keiser resistance machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension, abdominal crunch), with a 1-minute rest time between each set. Workload will begin at 50% of the estimated 1-RMs and increase by 5-10% after any session in which a participant completes 12 repetitions in all 3 sets. The workload will be tailored based on progressive increases in strength.
41032852|NCT03023891|DRUG|Prednisone|Prednisone 60 mg tablet once
41032853|NCT05828511|DRUG|Linvoseltamab|Linvoseltamab will be administered by intravenous (IV) infusion
41032854|NCT02359396|DRUG|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
41032855|NCT00727857|DRUG|Pioglitazone and metformin|Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
41032856|NCT00727857|DRUG|Pioglitazone|Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
41032857|NCT00727857|DRUG|Metformin|Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
41032858|NCT03814889|DEVICE|Vibration pattern|Vibration patterns applied to the affected limb based on pilot study results.
41032859|NCT03814889|DEVICE|No vibration|These patients will wear a glove with a blinking light instead of feeling vibrations.
41032860|NCT05295498|DEVICE|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
41032861|NCT05295498|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
41032862|NCT03914157|DEVICE|Low-energy extracorporeal ultrasound shockwave therapy (SWT)|SWT delivers 10% energy of the traditional SWT used for clinically indicated lithotripsy, evokes neovascularization, and improves regional blood flow and function in various ischemic tissues.
41163746|NCT06088797|OTHER|Mental imagery task|This involves answering questions concerning the position or identity of 2 or 3 objects on the basis of the mental representation of a grid by auditory guidance. Each grid must be constructed mentally with the verbal description of the path and the objects encountered.
41375066|NCT03930524|BEHAVIORAL|Web-BASICS|Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for online use in studies conducted by Drs. Larimer and Lee (e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
41375067|NCT03930524|BEHAVIORAL|Health Promotion Consultation|A health promotion consultation via a campus clinic is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
41375068|NCT03930524|BEHAVIORAL|M-Bridge Online Health Coach|A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
41375069|NCT00167414|PROCEDURE|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
41375070|NCT00167414|RADIATION|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
41375071|NCT03662477|BIOLOGICAL|NK cells|"NK cells were generated in good manufacturing practice (GMP) condition. In brief, PBMCs were isolated from 50mL patient's blood with Ficoll-Hypaque(Morecell Biomedical Co. Ltd., Shenzhen, China). Then the Human NK Cell Culture Kit (Cat. No.~MCF-004, Morecell Biomedical Co. Ltd., Shenzhen, China) and Serum-free Medium for NK Cells (MCM-002, Morecell Biomedical Co. Ltd., Shenzhen, China) was used for induction of NK cells according to the manufacturer's instructions. Three days before NK cell transfusion, the NK cells were sampled and sent to detect the NK cell quality."
41375072|NCT03801200|DRUG|Apatinib|radiotherapy with Apatinib
41375073|NCT03496597|PROCEDURE|Retinal imaging assessment|"* OCT-angiography~* Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~* Eye fundus photography: macular image~* Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus"
41375074|NCT03496597|PROCEDURE|blood glucose holter|for 40 subjects, implantation of a blood glucose holter monitor for 7 days
41375075|NCT04136522|PROCEDURE|conventional pancreaticoduodenectomy|In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.
41375076|NCT04136522|PROCEDURE|total mesopancreas excision including superior mesenteric artery first approach|In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
41375077|NCT05931601|DRUG|Noradrenaline|See arm description
41375078|NCT04066101|GENETIC|high caries risk|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
41375079|NCT04066101|OTHER|caries activity|"Dental caries lesions of all patient scored as initial, moderate or advanced caries~Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed"
41375080|NCT04393987|BEHAVIORAL|Treatment Compliance Training|Treatment Compliance Training consist of: Introduction of Treatment Compliance Program and Information about the Disease, Therapies for Bipolar Disorder and Importance of Treatment Compliance, Drugs Used for Bipolar Disorder, Effects and Side effects, Strategies to Solve Treatment-Related Problems and Cope with Stress, Beliefs, Attitudes, and Stigmatization Towards Patient/Disease in Bipolar Disorder. The sessions were held in the form of PowerPoint presentations. In the Treatment Compliance Training, lecture, question-answer, homework, sharing experiences, video presentation, summarization were used.The day before each session, patients were phoned and reminded of the time of the session.
41375081|NCT02057549|DRUG|Haloperidol|Intravenous dose of haloperidol 5 mg.
41032863|NCT02734212|BEHAVIORAL|Ending Self Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
40849998|NCT05930184|PROCEDURE|peri-wound Transversus Abdominis Plane Block|0.25% bupivacaine 20ml was injected using no24 needle into a plane between internal oblique muscle and transversus abdominis muscle around every wound 2 cm. from wound opening. The procedure was confirmed by laparoscopic vision and the injection was done before removal of laparoscopic port.
41375082|NCT02057549|DRUG|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
41375083|NCT05181501|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|"CT103A is a customized, BCMA-targeted genetically modified autologous T cell immunotherapy, which can identify and eliminate malignant and normal cells expressing BCMA. CAR specifically recognizes BCMA with single chain fragment variable (ScFv), and promotes the activation, proliferation, cytokine secretion and target cell killing of CAR-T through the CD3ζ domain. And 4-1BB enhances the expansion and persistence of CT103A.~CT103A will be infused at 1.0×10\^6 /kg via intravenous drip within 24h to 72h after chemotherapy conditioning regimen at the recommended infusion rate of 3-5 mL/min."
41375084|NCT00794222|DEVICE|Mobile Tracking Young People's Experiences (mobiletype)|A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
41375085|NCT04518527|DEVICE|Tape|The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
41375086|NCT02291705|PROCEDURE|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
41375087|NCT02291705|DRUG|Tramadol|tramadol 1 mg/kg iv
41375088|NCT04001478|DIAGNOSTIC_TEST|Breath test|Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
41375089|NCT01275170|DRUG|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
41375090|NCT01275170|DRUG|Imipenem + Cilastatin|250 mg IV over 30 minutes as a single dose
41375091|NCT01275170|DRUG|Caffeine|Caffeine caplet, single 200 mg dose, orally
41375092|NCT01275170|DRUG|Midazolam|Midazolam hcl syrup single 2.0 mg dose by mouth.
41375093|NCT01275170|DRUG|Omeprazole|Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
41375094|NCT00408135|DRUG|telithromycin (HMR3647)|
41375095|NCT01695707|DRUG|Pioglitazone|see Arm Description
41375096|NCT01695707|DRUG|Placebo (for pioglitazone)|see Arm Description
41505173|NCT03190811|BIOLOGICAL|Anti-PD-1 plus DC-CIK|"Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.~DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible."
41032864|NCT02734212|OTHER|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
41375097|NCT00142961|DRUG|Atomoxetine|atomoxetine
41375098|NCT00142961|OTHER|placebo|
41375099|NCT03542864|DIETARY_SUPPLEMENT|Nasogastroduodenal Protocol|Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)
41375100|NCT03542864|OTHER|Control|Progress registration of body composition values
41375101|NCT03542864|OTHER|Data analysis|Statistical analysis of all data
41375102|NCT05543226|DRUG|PHGG-rich enteral nutrtiion|PHGG-rich enteral nutrition
41375103|NCT00370929|BEHAVIORAL|Meditation|
41375104|NCT03373825|BEHAVIORAL|Take home rapid drug test|The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).
41375105|NCT01285388|DRUG|MB12066|MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
41375106|NCT05602025|BIOLOGICAL|Depemokimab|Depemokimab will be administered via a SSD or autoinjector.
41375107|NCT05980013|DEVICE|Whole blood donation supine|Subjects will undergo a 1-unit whole blood donation in a supine position
41375108|NCT05980013|DEVICE|Whole blood donation reclined|Subjects will undergo a 1-unit whole blood donation in a reclined position
41375109|NCT05595460|DRUG|RYZ101 Dose Level 1|Dose Level 1
41375110|NCT05595460|DRUG|RYZ101 Dose Level 2|Dose Level 2
41375111|NCT05595460|DRUG|RYZ101 Dose Level 3|Dose Level 3
41375112|NCT05595460|DRUG|RYZ101 Dose Level -1|Dose Level -1
41375113|NCT05595460|DRUG|Atezolizumab|Atezolizumab
41375114|NCT05595460|DRUG|Carboplatin|Carboplatin
41375115|NCT05595460|DRUG|Etoposide|Etoposide
41375116|NCT01198327|DRUG|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
41375117|NCT01198327|OTHER|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
41375118|NCT03305159|DRUG|Povidone-Iodine|Patients will receive povidone iodine for the surgical preparation of the vagina.
41163747|NCT06088797|OTHER|Proprioceptive spatial representation tasks|"16 configurations of 3 objects with direct or indirect passive exploration of their relative positions.~Each grid is presented 3 times with the following 3 questions to which the subject answers yes or no by forced choice~a single measure of the number of correct answers which will be the sum of the correct answers obtained to each of the 3 questions in the direct vs indirect condition"
41032865|NCT05795595|BIOLOGICAL|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
41032866|NCT00189631|PROCEDURE|UFT/LV|
41163748|NCT06088797|OTHER|Tasks assessing number sense based on relative positions or lengths|"Pointing exercises on a digital line of 50 cm paper tape: the participant points with his finger to a position on the tape, according to the verbal request of the experimenter~Measures the intermanual gap during requests for evaluation of 5 times the wand, subtracting the length of a wand, then dividing this length by 2."
41163749|NCT06088797|OTHER|WISC V Similarity and Span Test|The Wechsler Intelligence Scale for Children - Fifth Edition, Australian Standard (WISC-V) is an individually administered and comprehensive clinical instrument used to assess the general thinking and reasoning skills of children aged six years to 16 years. Test results include a Full-Scale Intelligence Quotient (IQ) score as well as age-equivalent rankings and scores for Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory and Processing Speed composites
41163750|NCT06088797|OTHER|WISC V Arithmetic subtest|The WISC-V is an individually administered, comprehensive clinical instrument for assessing the intelligence of children. The primary and secondary subtests are on a scaled score metric with a mean of 10 and a standard deviation (SD) of 3. These subtest scores range from 1 to19, with scores between 8 and 12 typically considered average.
41163751|NCT00306956|BEHAVIORAL|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
41032867|NCT00189631|PROCEDURE|Observation|
41032868|NCT03801902|RADIATION|Accelerated Hypofractionated Radiation Therapy|160 Gy given as one 4 Gy fraction per day, 5 days per week for 15 fractions.
41032869|NCT03801902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41032870|NCT03801902|PROCEDURE|Computed Tomography|Undergo brain CT and chest CT
41032871|NCT03801902|BIOLOGICAL|Durvalumab|Administered intravenously (IV) as a 1500 mg fixed dose over 60 minutes for 13 cycles (1 cycle = 4 weeks), until disease progression or toxicity or death, whichever comes first.
41032872|NCT03801902|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo brain MRI
41032873|NCT03801902|BIOLOGICAL|Monalizumab|Administered IV as a 1500 mg fixed dose over 60 minutes (+/- 10 minutes)
41032874|NCT03801902|BIOLOGICAL|Oleclumab|Administered IV 3000 mg over 60 minutes (+/- 10 minutes)
41032875|NCT03801902|RADIATION|Radiation Therapy|60 gy given as one 2 Gy fraction per day, 5 days per week for 30 fractions
41163752|NCT00535795|RADIATION|Radiation Therapy|Radiation Therapy
41163753|NCT02591914|DRUG|Fovista™|Anti-PDGF-B pegylated aptamer
41163754|NCT02591914|DRUG|Lucentis®|Anti-VEGF
41163755|NCT02591914|DRUG|Avastin®|Anti-VEGF
41163756|NCT02591914|DRUG|Eylea®|Anti-VEGF
41163757|NCT05436652|DRUG|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
41163758|NCT05436652|DRUG|SPI-62 matched placebo|Inactive tablets identical in appearance to SPI-62 tablets
41163759|NCT05436652|DRUG|Prednisolone 10mg|Standard of care prednisolone
41163760|NCT05436652|DRUG|Additional prednisolone|Over encapsulated prednisolone
41163761|NCT05436652|DRUG|Additional prednisolone matched placebo|Inactive capsules identical in appearance to over encapsulated prednisolone
41163762|NCT05538637|DIAGNOSTIC_TEST|Echocardiography|"Mitral velocity time-integral variability measurement before and after passive leg raising.~Mitral velocity time-integral variability measurement after fluid loading in preload-responsiveness patients."
41163763|NCT00115336|DRUG|Intravenous Ketorolac|Intravenous ketorolac
41163764|NCT00115336|DRUG|Ibuprofen|Ibuprofen, taken orally
41032876|NCT04279808|PROCEDURE|dilator depth|For soft tissue dilation just after guidewire insertion in central venous catheterization through the right internal jugular vein, investigators will measure the distance between the skin puncture site and outside of anterior wall of the vein with real-time ultrasonography in the measured depth group. Next, practitioner will insert the dilator by the measured length and continue to insert the central venous catheter. For the conventional group as a control group, practitioner will perform the central venous catheterization with a manner used routinely by the practitioner.
41032877|NCT04294810|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
41032878|NCT04294810|DRUG|Tiragolumab|Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
41032879|NCT04294810|DRUG|Matching Placebo|Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
41032880|NCT05887193|DEVICE|Biothesiometry|Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.
41032881|NCT05887193|DEVICE|Near Infrared Spectroscopy|Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.
41032882|NCT05887193|DEVICE|Cycling on a home trainer|Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
41032883|NCT05887193|DEVICE|Bike Fitting|Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
41163765|NCT05436977|DIAGNOSTIC_TEST|coronary OCT|Intermediate coronary lesions will be evaluated by OCT
41163766|NCT05436977|DIAGNOSTIC_TEST|68GaDOTATATE PET/CTCA|Intermediate coronary lesions will be evaluated by68GaDOTATATE PET/CTCA
41163767|NCT00582114|DRUG|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
41375119|NCT03305159|DRUG|4% Chlorhexidine Gluconate|Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
41163768|NCT00582114|DRUG|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
41163769|NCT02615548|OTHER|community-based exercise class|This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.
41163770|NCT02615548|OTHER|self-directed physical activity|Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
41163771|NCT03495440|BEHAVIORAL|Center Sessions|Program to support relationships and communication between parents and typically developing adolescent siblings of individuals with intellectual and/or developmental disabilities.
41163772|NCT03495440|BEHAVIORAL|At-home|Self-study resources paired with regular contact with study personnel.
41163773|NCT00496626|BIOLOGICAL|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
41163774|NCT00496626|BIOLOGICAL|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
41163775|NCT02296203|DRUG|cetuximab|
41163776|NCT02296203|DRUG|irinotecan|
41163777|NCT04503837|PROCEDURE|Personalized Mobile Phone Video Recording|Subjects will be asked to perform inhaler technique while on video recording. The video will be shown to subjects immediately during technique education session and mistakes (if any) will be pointed out to subject.
41163778|NCT05610059|OTHER|Blood Pressure Technology System M|Participants will be provided the blood pressure technology system M. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
41163779|NCT05610059|OTHER|Blood Pressure Technology System E|Participants will be provided the blood pressure technology system E. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
41163780|NCT02520596|OTHER|Bioavailability of Raspberry polyphenols|
41163781|NCT03436030|OTHER|Simple breathing manuevers during brief echocardiographic imaging|Valsalva, Muller, light mask CPAP, leg raising, hand grip.
41163782|NCT04765540|BEHAVIORAL|Low Intensity Nudges|"A bundle of 'low-intensity' passive interventions, including:~Large Mirrors \& hand-shaped sign posts pointing to the station"
41375120|NCT00381667|DRUG|GW642444M|M salt
41375121|NCT00381667|DRUG|GW642444H|H salt
41375122|NCT00381667|OTHER|placebo|placebo
41375123|NCT02209272|DRUG|bacteriostatic saline|
41375124|NCT02209272|DRUG|buffered lidocaine|
41163783|NCT04765540|BEHAVIORAL|High Intensity Activities|"A bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks for handwashing station users, a community message board \& general encouragement"
41163784|NCT04765540|BEHAVIORAL|BRAC's business-as-usual|A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.
41375125|NCT06302075|OTHER|One Day Rehabilitation|Patient discharged at home the day after the operation and carrying out outpatient rehabilitation according to the clinical standard
41375126|NCT06302075|OTHER|Fast Rehabilitation|Patient discharged to the rehabilitation department of the Institute 48 hours after surgery which carries out rehabilitation during the hospital stay according to the clinical standard
41375127|NCT02738606|DRUG|Chemotherapy|
41375128|NCT02738606|OTHER|Laboratory Biomarker Analysis|Correlative studies
41375129|NCT02738606|PROCEDURE|Metastasectomy|Undergo lung metastasectomy
41375130|NCT02738606|OTHER|Quality-of-Life Assessment|Ancillary studies
41375131|NCT02738606|PROCEDURE|Therapeutic Conventional Surgery|Undergo hepatectomy
41375132|NCT03512704|OTHER|Collection of possible predictors from patient data|Collection of sociodemographic and clinical parameters, from medical records, and health related quality of life data, that may predict the outcomes of interest (mortality, complications, readmissions)
41375133|NCT03240809|BIOLOGICAL|Brodalumab|140 mg SC dose
41375134|NCT03240809|BIOLOGICAL|Brodalumab|70 mg SC dose
41375135|NCT03638479|OTHER|Data Capture|This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
41375136|NCT02510131|BEHAVIORAL|Exercises|To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
41375137|NCT02319642|DRUG|Certolizumab Pegol|Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
41375138|NCT06539845|BEHAVIORAL|Outbreak Preparedness Intervention for the Orang Asli|"The chosen villages will be given the intervention package, which includes a workshop, simulation exercises, and a card game, in addition to educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This entire package will be delivered once, during the workshop, after they have answered the survey at T0."
41375139|NCT06539845|BEHAVIORAL|Educational Brochures for the Orang Asli|"The chosen villages will be given educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This will be given once during the first encounter with the participant, after they have answered the survey at T0."
41375140|NCT02594254|DRUG|C16G2 Gel|Antimicrobial peptide
41375141|NCT02594254|OTHER|Placebo|Placebo
41375142|NCT03953391|OTHER|Tea|Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.
41375143|NCT03953391|OTHER|Water|150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.
41375144|NCT04520633|OTHER|biologic initiation|introduction or modification of biotherapy at M0
41375145|NCT06002425|OTHER|Clinician-Directed Treatment Plan|In this approach, clinicians do not employ any technological assistance and rely solely on their professional expertise and experience to formulate treatment plans for participants.
41375146|NCT06002425|OTHER|ChatGPT-Assisted Treatment Plan|In this approach, clinicians utilize the ChatGPT technological tool, formulating treatment plans for participants based on its suggestions and their own professional expertise.
41375147|NCT00845559|DRUG|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
41375148|NCT06045377|DIETARY_SUPPLEMENT|Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia|A prospective single center cohort study
41375149|NCT01545401|OTHER|EMPOWER-PAR Intervention|"Implementation process is conducted in 3 phases:~I. Phase 1: Formation and training of the CDM team~II. Phase 2: Distributions of the intervention tools~* Global CV Risks Self-Management Booklets~* CPG to aid clinical decision making~III. Phase 3: Facilitation and support to implement the intervention"
41163785|NCT03140878|DIETARY_SUPPLEMENT|LGG|LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)
41375150|NCT06046404|PROCEDURE|closed reduction|the intervention of closed fracture reduction widely known and part of daily practice. we test the eficacy of this intervention by not performing it in our test group.
41375151|NCT06046404|PROCEDURE|no closed reduction|no reduction will be performed
41375152|NCT03028077|DIETARY_SUPPLEMENT|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
41375153|NCT03028077|DIETARY_SUPPLEMENT|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
41375154|NCT03028077|DIETARY_SUPPLEMENT|Placebo|Placebo 1 g/day
41375155|NCT02047929|OTHER|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
41375156|NCT03775694|DEVICE|dMRI Scan|Data will be collected from cases where dMRI scans were obtained as part of the subject's previous treatment.
41375157|NCT05280886|PROCEDURE|therapeutic drug monitoring(TDM)|Based on this data, population pharmacokinetic models of antibiotics drugs that can be applicable to TDM will be developed.
41375158|NCT01360021|DRUG|Symbicort|Breath actuated metered dose inhaler
41375159|NCT01360021|DRUG|Symbicort|Actuation counter pressured metered dose inhaler
41163786|NCT03140878|DIETARY_SUPPLEMENT|Placebo|Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
41375160|NCT01360021|DRUG|Budesonide|Actuation counter pressured metered dose inhaler
41375161|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 1 initial treatment (W1\~W6). Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
41375162|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Consolidation continuation treatment (W7\~W22) . Prednisone 40mg/m2 d1-5 q3w (w7,10,13,16,19,22); VCR 1.5/m2 iv d1 q3w (w7,10,13,16,19,22); Cytarabine 100mg/m2 iv/IH d1-4 q3w (w7,10,13,16,19,22); 6-MP 50mg/m2/d,po,qn
41375163|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Maintenance continuation treatment (W25\~52) . Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w; Cytarabine 100mg/m2 iv/IH d1-4 q6w ×3 times (w25,31,37); 6-MP 50mg/m2/d,po,qn
41375164|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 2 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
41375165|NCT04773366|DRUG|Prednisone+vincristine+Mercaptopurine|Group 2 continuation treatment (W7\~W52) . Prednisone 40mg/m2 d1-5 q3w; VCR 1.5/m2 iv d1 q3w; 6-MP 50mg/m2/d,po,qn
41375166|NCT04773366|DRUG|Prednisone+vincristine|Group 3 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6
41375167|NCT04773366|DRUG|Prednisone+vincristine|. Group 3 Continuation treatment (W7\~W52)Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w
41375168|NCT04773366|OTHER|Local therapy|Local therapy/wait and see. Group 4
41375169|NCT00462241|PROCEDURE|chiropractic treatment|Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
41375170|NCT00462241|OTHER|Self-management|Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
41163787|NCT01393613|DRUG|OPC-34712|Higher dose tablet, once daily, for six weeks,
41163788|NCT01393613|DRUG|OPC-34712|Middle dose tablet, once daily, for six weeks
41375171|NCT00622622|BIOLOGICAL|VEGFR2-169 and gemcitabine|Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
41375172|NCT04000958|DRUG|PIRF measured by InCheck DIAL|Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
41375173|NCT04000958|DRUG|Regular treament|The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
41375174|NCT06561620|DRUG|Befotertinib|Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.
41375175|NCT05059470|DRUG|Pembrolizumab|Given by IV
41375176|NCT06176417|PROCEDURE|horizontal ridge augmentation by decompression technique.|Instead of a cover screw, a 2-mm healing abutment was used after implant insertion
41375177|NCT06176417|PROCEDURE|horizontal ridge augmentation by ridge splitting technique using piezosurgery.|horizontal ridge augmentation was done using piezosurgery tips and bone expanders
41375178|NCT06329765|BEHAVIORAL|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.
41375179|NCT01628159|DEVICE|Lutonix Drug Coated Balloon|balloon angioplasty with a drug coated balloon
41032884|NCT01310036|DRUG|Erlotinib|Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
41163789|NCT01393613|DRUG|OPC-34712|Lower dose tablet, once daily, for six weeks
41032885|NCT05814523|DRUG|Ganaxolone|Ganaxolone will be administered as IV solution.
41032886|NCT05814523|DRUG|Placebo|Placebo will be administered as IV solution.
41032887|NCT05814523|DRUG|Standard of care|A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
41032888|NCT04564833|DRUG|Low Dose RBT-1|intravenous administration
41032889|NCT04564833|DRUG|High Dose RBT-1|intravenous administration
41163790|NCT01393613|DRUG|Placebo|Placebo, once daily, for six weeks
41032890|NCT04564833|DRUG|Placebo|intravenous administration
41163791|NCT00104975|BIOLOGICAL|alemtuzumab|
41163792|NCT00104975|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41163793|NCT00104975|DRUG|fludarabine phosphate|
41163794|NCT00104975|DRUG|melphalan|
41163795|NCT00104975|DRUG|tacrolimus|
41163796|NCT00104975|DRUG|thiotepa|
41163797|NCT00104975|PROCEDURE|peripheral blood stem cell transplantation|
41163798|NCT05767814|OTHER|Phenotyping of synovial immune and stromal cells|Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.
41163799|NCT03248713|DRUG|Mifepristone|Mifepristone 600mg 2 tablets will be compared to the placebo
41163800|NCT03248713|DRUG|Placebo|Placebo sugar 2 tablets will be compared to mifepristone
41163801|NCT02003378|DEVICE|Pacemaker sensor set to MV|Pacemaker sensor set to minute ventilation
41163802|NCT02003378|DEVICE|Pacemaker sensor set to XL|Pacemaker sensor set to accelerometer
41032891|NCT05786924|DRUG|BDTX-4933|RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations
41032892|NCT00119509|PROCEDURE|HPV DNA testing|
40849999|NCT05930184|PROCEDURE|Local wound infiltration|0.25% bupivacaine 20ml was injected using no24 needle into subcutaneous tissue after the abdominal sheet was sutured.
41032893|NCT00119509|PROCEDURE|Conventional management (repeat Pap smear at 6 months)|
41032894|NCT00119509|PROCEDURE|Decision aid with choice of management|
41032895|NCT01367873|DRUG|Placebo|Oral, matching number of placebo capsule(s) with active arm
41032896|NCT01367873|DRUG|VIA-3196|Oral, capsule(s)
41032897|NCT06137391|PROCEDURE|Vital Pulp Therapy|The pulp is accessed after caries removal then the inflamed part of the pulp is excavated. After haemostasis is achieved, a pulpootmy medicament is used to coronally seal the remaining pulp tissue. In partial pulpotomy only part of the pulp chamber is excavated while in full pulpotomy the whole pulp chamber is excavated.
41032898|NCT04376021|BEHAVIORAL|Babywearing|Increase mother-infant physical contact through babywearing
41375180|NCT04540172|BEHAVIORAL|Music Therapy|"Mahur tune, one of the nonverbal instruments of the Traditional Turkish Music Authorities, was selected for the study with the opinion of a music therapy specialist."
41505174|NCT03190811|BIOLOGICAL|Anti-PD-1 alone|Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
40850000|NCT01005758|DRUG|cyclophosphamide|
40850001|NCT01005758|DRUG|cytarabine|
40850002|NCT01005758|DRUG|dexamethasone|
40850003|NCT01005758|DRUG|doxorubicin hydrochloride|
40850004|NCT01005758|DRUG|etoposide phosphate|
40850005|NCT01005758|DRUG|hydrocortisone sodium succinate|
40850006|NCT01005758|DRUG|imatinib mesylate|
40850007|NCT01005758|DRUG|mercaptopurine|
40850008|NCT01005758|DRUG|methotrexate|
40850009|NCT01005758|DRUG|methylprednisolone|
40850010|NCT01005758|DRUG|pegaspargase|
40850011|NCT01005758|DRUG|prednisolone|
40850012|NCT01005758|DRUG|prednisone|
40850013|NCT01005758|DRUG|vincristine sulfate|
40850014|NCT01005758|OTHER|laboratory biomarker analysis|
40850015|NCT01005758|RADIATION|radiation therapy|
40850016|NCT01818063|DRUG|Paclitaxel|Given IV
40850017|NCT01818063|DRUG|Carboplatin|Given IV
40850018|NCT01818063|DRUG|Doxorubicin|Given IV
40850019|NCT01818063|DRUG|Cyclophosphamide|Given IV
41032899|NCT02119351|DEVICE|ViaValve™ Safety IV Catheter|Safety peripheral IV catheter with a blood control feature
41032900|NCT02119351|DEVICE|ProtectIV® Plus Safety IV Catheter|Safety peripheral IV catheter with no blood control feature
41032901|NCT01311492|BEHAVIORAL|Healthy Lifestyle Program|"The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes."
41375181|NCT04540172|BEHAVIORAL|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercise were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association."
41505175|NCT04435184|DRUG|Crizanlizumab|Crizanlizumab 5.0 mg/kg in 100 ml IV once.
41505176|NCT04435184|OTHER|0.9% saline|0.9% saline 100 ml IV once.
41505177|NCT00682357|DRUG|Methylprednisolone and Lidocaine|Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
41163803|NCT05854771|OTHER|Single bout of yoga before eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend before the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition maximum of each participant will be calculated first, and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
40850020|NCT01818063|DRUG|Veliparib|Given PO
40850021|NCT03300921|DRUG|Paricalcitol|"Product: Paricalcitol~Dose/Route/Regimen:~Arm A: 50mcg IV weekly Arm B: 12mcg PO daily"
41032902|NCT01311492|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
41375182|NCT01473537|DRUG|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
41375183|NCT03205839|BEHAVIORAL|Acceptance-based self-help intervention|"Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.~A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.~In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video."
41375184|NCT05213065|OTHER|Sphenopalatine ganglion block with 0.5% bupivacaine|Repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device.
41375185|NCT05213065|OTHER|Sphenopalatine ganglion block with saline|Repetitive SPG blockade using saline delivered with the Tx360® device.
40850022|NCT03116256|DIETARY_SUPPLEMENT|Very low calorie diet (VLCD)|All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.
40850023|NCT03116256|OTHER|High intensity interval training (HIIT)|Participants in this group will be having HIIT session three times per week under close medical supervision. This involves 60 sec high intensity cycling at 95-125% Watt Max, with 90s recovery, repeated 5 times, with 2 minutes warm up and cool down.
40850024|NCT03116256|OTHER|Resistance exercise training (RET)|The exercise format will be 2 sets of 12 repetitions at 70% 1-RM for each resistance regime, with 1-2 minutes rest between sets after a prescribed warm-up 3 sessions/week. The resistance regimes are: (3 upper body)chest press, latissimus pull down, seated lever row; (3 lower body) leg extension, leg curl, leg press. Participants will be alternating between upper and lower body exercise during each training session.
41032903|NCT04108091|DRUG|Treatment for TTR amyloidosis|The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
41163804|NCT05854771|OTHER|Single bout of yoga after eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend after the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition of each participant will be calculated first and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
41163805|NCT03220659|DEVICE|Multi-point pacing|Pacing from more than one pole from the left ventricular lead
41163806|NCT03220659|DEVICE|Standard settings|Normal bipolar LV pacing
41375186|NCT02151565|DEVICE|HTEMS|
41375187|NCT02151565|DEVICE|TENS|
41375188|NCT02413723|DEVICE|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
41375189|NCT02413723|DEVICE|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
41505178|NCT00682357|DRUG|Methylprednisolone and Lidocaine|Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
40850025|NCT00847197|DRUG|MK1903|Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
40850026|NCT00847197|DRUG|Comparator: Placebo|Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
40850027|NCT03778502|DRUG|Direct Oral Anticoagulants|Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
40850028|NCT03867357|DRUG|GnRH agonist|Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.
40850029|NCT05160129|DEVICE|Selective focal stimulation of ALIC-pathways|DBS will be applied selectively to different electrode contacts/ segments to evaluate clinical, behavioral, and electrocortical responses of specific pathways within the ALIC.
41032904|NCT04108091|DRUG|Treatment for TTR amyloidosis|The usual adult dose is 61 mg of tafamidis orally once daily.
41505179|NCT00682357|DRUG|Placebo and Lidocaine|Placebo and lidocaine 20 mg
40850030|NCT02381340|DEVICE|ACE stapling procedure|Endoscopic trans-oral gastroplication
41375190|NCT05822388|PROCEDURE|Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care|Participants in this study will already be undergoing a DBS intervention, however, this is part of their standard clinical care. Pre-surgical DBS candidates that enroll in this study will consent to participate in 1) pre-operative neuroimaging including a high-resolution MRI scan, 2) collection of pre-operative neurocognitive data via chart review and 3) a 1-year postoperative neurocognitive assessment.
41375191|NCT03118401|OTHER|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
41375192|NCT03118401|OTHER|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
41375193|NCT03133208|PROCEDURE|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
41375194|NCT00513578|BIOLOGICAL|PR1 leukemia peptide vaccine|
41375195|NCT00513578|BIOLOGICAL|incomplete Freund's adjuvant|
41375196|NCT00513578|BIOLOGICAL|sargramostim|
41375197|NCT06468449|OTHER|Lower limb power output training|"Lower limb power output training content:~Half squat up squat: 70%1R (6 repetitions × 5sets) + 5 knees jumps × 5 sets with an interval of 90 seconds；"
41375198|NCT06468449|OTHER|Force Combined Speed training|"Lower limb Force Combined Speed training content:~Rapid half squat : Optimal load (6 sets × 7 repetitions). Rest intervals between sets range from 2 to 5 minutes."
41375199|NCT03644927|BEHAVIORAL|Progressive exercise training|The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
41375200|NCT03644927|BEHAVIORAL|Waitlist Control|Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
41375201|NCT02863588|BIOLOGICAL|seropositive for Toxoplasma gondii|blood sample
41375202|NCT03202329|OTHER|standard care|cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon
41375203|NCT03202329|OTHER|Nurse-based care|board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
41375204|NCT00912327|BIOLOGICAL|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
41375205|NCT01312948|DEVICE|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
41375206|NCT01721941|DRUG|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
41505180|NCT06035835|COMBINATION_PRODUCT|Lacticaseibacillus rhamnosus|Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day)
41505181|NCT06035835|COMBINATION_PRODUCT|Lactobacillus acidophilus + Bifidobacterium bifidum|Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h)
40850031|NCT06211257|OTHER|Dematerialized Personalized Care Plan (ePCP)|Post-treatment support with standard support combined with dematerialized support
40850032|NCT03478735|PROCEDURE|Ultrasound Guided Greater Occipital Nerve Block at C2|Ultrasound guided injection
40850033|NCT03478735|PROCEDURE|Landmark-Based Greater Occipital Nerve Block|Traditional landmark-guided technique at the superior nuchal line. This approach relies solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line.
40850034|NCT05236504|DIETARY_SUPPLEMENT|Melatonin and magnesium-containing pod|A 50-100mL hot water drink, obtained from a coffee pod machine, containing 1.9mg of melatonin and 200mg of magnesium in a powdered form, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
41375207|NCT01721941|DRUG|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
41505182|NCT06352827|BEHAVIORAL|Survey|All participants will complete a baseline survey and have medical information collected.
41505183|NCT04621019|DEVICE|BTL-785F|Treatment with study device.
41032905|NCT03671330|DRUG|Ribociclib Placebo|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
41505184|NCT05655130|DRUG|Dexamethasone|Intraoperative 10 mg IV Dose
41375208|NCT01721941|DRUG|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
41375209|NCT01721941|DRUG|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
41375210|NCT04672369|BIOLOGICAL|IBI939|IBI939 injection
41375211|NCT04672369|BIOLOGICAL|Sintilimab|Sintilimab injection
41375212|NCT02288949|OTHER|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
41375213|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|ultra sound guided injection into the rectus sheath
41375214|NCT03225313|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#5|injected into rectus sheath using ultrasound \& locally surrounding the hernia
41375215|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|locally surrounding the hernia
41375216|NCT03508466|BEHAVIORAL|hypersensitivity reaction|Previous hypersensitivity reaction
41375217|NCT04733807|BIOLOGICAL|BNT162b2 mRNA Covid-19 Vaccine|Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.
41375218|NCT04234516|DRUG|Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film|3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
41375219|NCT04234516|DRUG|Morphine Sulfate 30 mg|oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
41375220|NCT02464176|DRUG|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
41375221|NCT02464176|DRUG|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
41375222|NCT02464176|DRUG|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
41505185|NCT05655130|DRUG|Methylprednisolone|"The oral methylprednisolone taper course will begin on the day of surgery and will taper as noted below:~Day 1: 24 mg orally (8 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 2: 20 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 3: 16 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 4 mg at bedtime) Day 4: 12 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg at bedtime) Day 5: 8 mg orally (4 mg before breakfast; 4 mg at bedtime) Day 6: 4 mg orally (4 mg before breakfast)"
41505186|NCT05655130|OTHER|Standard of Care|standard of care surgery
41505187|NCT03293316|DEVICE|Transcranial Random Noise Stimulation|The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
40850035|NCT05236504|OTHER|Placebo comparator|A 50-100mL hot water drink of identical taste, obtained from an identical pod with the same ingredients except melatonin and magnesium, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
40850036|NCT00465647|DRUG|Hydromorphone|Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
41032906|NCT03671330|DRUG|Ribociclib|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
41163807|NCT03120299|DRUG|Omega-3 fatty acid|Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
41163808|NCT03120299|DRUG|Placebos|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
41375223|NCT02464176|PROCEDURE|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
41375224|NCT02464176|DRUG|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
41375225|NCT02684526|PROCEDURE|Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.
41375226|NCT02684526|PROCEDURE|Non Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
41375227|NCT02936349|OTHER|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
41375228|NCT00626067|DEVICE|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
41375229|NCT00626067|DEVICE|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
41375230|NCT00626067|DEVICE|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
41375231|NCT03381807|BIOLOGICAL|hAESCs|5\*10\^7 hAESCs is infused into uterine cavity with TCRA on Day0, Day7 and after the first menstruation
41375232|NCT02923557|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
41375233|NCT03486015|DRUG|Sterile water|2 ml of sterile water
41375234|NCT03486015|DRUG|30% glucose|2 ml of 30% glucose
41375235|NCT00684645|DRUG|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
41375236|NCT00761969|OTHER|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
40850037|NCT05176834|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
41505188|NCT02814890|PROCEDURE|Video-assisted Pneumonectomy|Video-assisted Pneumonectomy under general anesthesia.
41032907|NCT03671330|DRUG|NSAI: Letrozole or Anastrazole|"Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole."
41375237|NCT03730025|OTHER|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
41163809|NCT02844348|OTHER|Hypnosis session|
41505189|NCT02814890|PROCEDURE|Thoracic paravertebral block|The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
41375238|NCT03730025|OTHER|Auscultation without NeoTapAS|Auscultation without NeoTapAS
41375239|NCT05478356|DRUG|low-dose atropine eye drops|low-dose atropine eye drops
41375240|NCT05478356|DEVICE|orthokeratology|orthokeratology, ortho-K lenses
41375241|NCT00985127|DRUG|placebo|administered daily for 21 days
41375242|NCT00985127|DRUG|BCX4208|Administered daily for 21 days.
41375243|NCT03908840|BIOLOGICAL|TBI 302|TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)
41375244|NCT02921646|OTHER|Measure of resting energetic expenditure|measure of resting energetic expenditure
40850038|NCT05641922|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
40850039|NCT05726747|DIAGNOSTIC_TEST|Quality of Life surveys|QoL and sarcopenia assessments
40850040|NCT01162811|BEHAVIORAL|visualization together with structured behavioural attention.|visualization and relaxation exercises together with structured behavioural attention.
40850041|NCT04887896|DEVICE|GS500|Device: GS500
40850042|NCT04887896|DEVICE|Placebo|Device: Placebo
41032908|NCT03671330|DRUG|Letrozole|Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
41032909|NCT03671330|DRUG|Goserelin|Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
41375245|NCT01725204|DRUG|Dasatinib + PegIFN|
41375246|NCT00869726|DRUG|dirucotide|500mg, intravenous, dosed once every six months for 18 months
41375247|NCT00869726|DRUG|Placebo|intravenous, once every six months for 18 months
41375248|NCT02872584|DRUG|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
41375249|NCT06226064|DRUG|VES001|VES001 is an oral, blood brain barrier penetrating ligand of sortilin.
41375250|NCT06226064|DRUG|Placebo|A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.
41375251|NCT05564507|DIAGNOSTIC_TEST|TEE simulation-based training|"All participants of the TEE simulation-based training group received:~1. a traditional didactic training using e-learning with a national free-access online course;~2. two teaching sessions using a TEE simulator for 2 hours per session. The simulation session will involve standardized initial teaching of normal cardiac, including anatomy of mitral valve with some mitral regurgitation cases, aortic valve, tricuspid valve, interatrial septum, and left atrial appendage, and demonstration of image acquisition by the teacher (time duration: 30 min). The duration of each session was 2 h with a 6:1 student to instructor ratio. Each subject had a dedicated 20 min of hands-on to manipulate the probe and undertake a sequential TEE examination under the supervision of the teacher. Other participants could watch their colleagues working on the TEE simulator."
41375252|NCT01757795|DRUG|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
40850043|NCT06230939|OTHER|Examination|"Individual characteristics of the patients (gender, age, height, body weight, marital status, education level, dominant extremity, smoking and alcohol consumption habits, use and type of assistive device, how many years the assistive device has been used) and disease-related (year of diagnosis, disease duration Information (such as CV, family history, medications used, surgeries) will be questioned. HYE and UPDRS will be used for disease staging and grading. PFS-16 will be used to evaluate fatigue and MMSE will be used to evaluate sleep. In addition, Timed Up and Go (TUG) will be applied for lower extremity performance evaluation. All evaluations will be collected in a single meeting using the face-to-face interview method."
41375253|NCT01757795|DRUG|Placebo|Placebo will be intravenously administered
41375254|NCT00023426|DRUG|rifapentine|
41375255|NCT00245258|DRUG|Sildenafil Citrate|
41032910|NCT03157986|OTHER|Balance Training on a vibration platform|n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.
40850044|NCT00166530|DRUG|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
40850045|NCT00166530|DRUG|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
40850046|NCT00166530|DRUG|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
41032911|NCT03157986|OTHER|Conventional Balance training|n=24 patients with COPD, Exercises will be performed on a Balance pad
41032912|NCT04361357|OTHER|whey protein|whey protein powder was added on the basis of standardized enteral nutrition preparation.
41163810|NCT05651542|BEHAVIORAL|Comprehensive Self-Management Intervention|In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.
41163811|NCT05651542|OTHER|Control|The control group will receive standard care.
41163812|NCT03962478|DEVICE|biliary stent and high-intensity focused ultrasound ablation system|Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment
41163813|NCT03962478|DEVICE|biliary stent|Self-expandable biliary nitinol alloys stent
41375256|NCT00084188|BEHAVIORAL|Behavior Therapy|
41375257|NCT02793258|DEVICE|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
41375258|NCT00648739|DRUG|Samalizumab|Samalizumab is a humanized anti-CD200 monoclonal antibody.
41375259|NCT00421369|DRUG|sertraline|
41375260|NCT00421369|DRUG|triiodothyronine (T3)|
41375261|NCT00421369|DRUG|reboxetine|
41375262|NCT01187511|DRUG|GSK561679|Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.
41375263|NCT01187511|DRUG|Placebo|Placebo is an inactive tablet design to look exactly like GSK561679
41375264|NCT06382766|DIAGNOSTIC_TEST|Skeletal Muscle Ultrasonography|Skeletal Muscle Ultrasonography in Detection of Malnutrition and Prediction of The Outcome among critically ill children
41375265|NCT00578448|DRUG|Belatacept|IV infusion
41375266|NCT03165253|DRUG|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
41375267|NCT03165253|DRUG|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
41375268|NCT03165253|DRUG|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
41375269|NCT03165253|DRUG|Omeprazole|1 mg/kg/day
41375270|NCT02400697|OTHER|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
41375271|NCT04066894|PROCEDURE|Explantation|Undergo lead removal
41375272|NCT04066894|OTHER|Quality-of-Life Assessment|Ancillary studies
41375273|NCT04066894|OTHER|Questionnaire Administration|Ancillary studies
41375274|NCT04066894|DEVICE|Sacral Nerve Stimulator|Undergo sacral nerve stimulator implantation
41505190|NCT06468436|DRUG|Dexmedetomidine-Esketamine Combination|"For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1."
41163814|NCT06307964|PROCEDURE|Biological sampling|"* A fragment of the diagnostic transjugular liver biopsy (D0)~* Plasma samples at D0, and at 1 and 6 months after liver biopsy if possible~* Fecal samples at D0, and at 1 and 6 months after liver biopsy if possible"
41163815|NCT02856061|BEHAVIORAL|Pivotal Response Treatment|Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
41505191|NCT06468436|DRUG|Dexmedetomidine|"For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1."
41505192|NCT00627861|DRUG|Aliskiren|150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol.
41505193|NCT00627861|DRUG|Extended-release metoprolol|50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameters set by the protocol. Subjects will take metoprolol for a total of 2 weeks, then be tapered off of it over 5-7 days.
41505194|NCT05576246|DIAGNOSTIC_TEST|airway pressure occlusion measurement|Flow, airway pressure (Paw), and esophageal pressure (Pes) will be recorded for 10 minutes on different NIV settings: during each one, three end-expiratory airway occlusions will be applied at random intervals. Each occlusion was maintained for the duration of a single breath deflection in Paw from PEEP, confirmed by the return of Paw to baseline.
41505195|NCT06538415|OTHER|Pulse Diet|Participants will consume cooked pulse (112 calories -lentils, red kidney beans, black beans, and pinto beans) during 14 weeks.
41032913|NCT05978323|BEHAVIORAL|Brief intervention|Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
41032914|NCT03451838|DIAGNOSTIC_TEST|Ultrasound|Ultrasound will be done to every pregnant lady
41375275|NCT04066894|DEVICE|Sacral Nerve Stimulator Battery|Undergo sacral nerve stimulator battery implantation
41375276|NCT04066894|PROCEDURE|Therapeutic Conventional Surgery|Undergo sacral nerve stimulator implantation
41375277|NCT01301625|DEVICE|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
41375278|NCT01079572|OTHER|in-person|Follow-up appointments will be completed in-person as per usual
41375279|NCT01079572|OTHER|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
41505196|NCT06538415|OTHER|Control Rice Diet|Participants will consume cooked rice (112 calories) during 14 weeks.
41505197|NCT06604598|DRUG|IBU-PCT-DEX|Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.
41163816|NCT02830256|OTHER|NCS-I (Nociception Coma Scale adapted intubated patients)|Every included patient will be assessed by the 3 methods 3 times (before, during, after the procedure fo care) in 3 conditions. There will be 2 painful conditions usually performed in ICU (Nursing and bronchoaspiration) and a painless condition (RASS assessment).
41163817|NCT00557336|DRUG|somatropin|
41163818|NCT03982875|DEVICE|Alfred SmartBag|The Alfred SmartBag encompasses a pouch, a baseplate, and a hub, is intended to be used as a continuous ostomy monitoring system by tracking the volumetric filling of the pouch through integrated thermistor and capacitive sensors and potential leakage and skin irritation development through integrated thermistors in the wafer. The Alfred SmartBag system is indicated for daily use for both in-patient and out-patient settings to provide information to patient and medical professionals. The data is intended to aid patient self-management and to alert the clinical team to changes in the patient condition that may warrant specific intervention.
41163819|NCT04620031|DRUG|HSK3486|Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
41375280|NCT05378568|OTHER|the selection scheme of peripheral venous access devices|"Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations."
41375281|NCT05378568|OTHER|the existing nursing routine|To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
41375282|NCT01140815|DEVICE|Total Knee Replacement|Smith and Nephew Total Knee Replacement
41375283|NCT01140815|DEVICE|Deuce|Smith and Nephew Bicompartmental Knee Replacement
41375284|NCT06445725|BEHAVIORAL|Acceptance Based Coping (ABaCo)|The educational ABaCo protocol consists of core Acceptance \& Commitment Therapy (ACT) interventions, culturally and contextually-tailored for this population, and in accordance with clinician-led versions of ACT for diabetes to include (a) identification of patient values, (b) teaching acceptance and brief mindfulness skills, and (c) techniques for engaging in valued activities while coping with difficult experiences (e.g., sugar cravings, distress). It is delivered by a community health worker (promotor/a) over 6 consecutive weeks over the phone, followed by a booster call at week 10.
41375285|NCT02387723|BIOLOGICAL|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)
41375286|NCT06244134|PROCEDURE|ultrasound guided autologous blood injection|guided
41375287|NCT06244134|PROCEDURE|non guided autologous blood injection|non guided
41375288|NCT05950204|DIETARY_SUPPLEMENT|ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)|Intervention with 100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks. The other group of patients will receive only the same dose of VD and calcium.
41375289|NCT05582655|BEHAVIORAL|ONLINE|The ONLINE intervention applies the JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation: Kasari et al., 2021) social communication intervention for young children with autism. The JASPER approach has been tested in a caregiver-mediated format where caregivers are taught to use the JASPER strategies with their children during play and home routine (e.g., Kasari et al., 2010; Kasari et al., 2014). The JASPER intervention is being adapted in this study to include online web based materials.
41375290|NCT05582655|BEHAVIORAL|COACH|COACH includes live synchronous caregiver coaching in the JASPER intervention model. Coaching follows prior published JASPER caregiver coaching protocols (e.g., Shire, Shih, Barriault, \& Kasari, 2022). This implementation strategy has been tested in a pilot study when applied by community early intervention providers (Shire, Baker Worthman, \& Arbuckle, 2021).
41375291|NCT00206037|DEVICE|COLLOSS E|
41375292|NCT00206037|DEVICE|TomoFix Plate|
41375293|NCT00106613|DRUG|FK228 (romidepsin)|Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
41375294|NCT01600755|BIOLOGICAL|Iltamiocel|Single intrasphincteric injection of iltamiocel at a dose of 250 x 10\^6 cells
40850047|NCT02108314|BEHAVIORAL|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
40850048|NCT05246813|OTHER|Blood and bone marrow cell collection|Collection of blood and bone marrow
40850049|NCT00007891|BIOLOGICAL|filgrastim|
41163820|NCT04620031|DRUG|Propofol|"Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s~Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:~0.3-4 mg/kg/h"
41163821|NCT06276751|PROCEDURE|End-tidal CO2 monitor|Throughout the study, measurements were taken at 2 and 4 hours after tube thoracostomy was applied to every patient undergoing the procedure.
41375295|NCT05552391|DRUG|Bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
41375296|NCT05552391|DRUG|Ketamine Hydrochloride|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
41375297|NCT05552391|DRUG|Dexmedetomidine Hydrochloride|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
41375298|NCT00444665|DRUG|Travatan-Z|
40850050|NCT00007891|PROCEDURE|autologous bone marrow transplantation|
40850051|NCT00007891|PROCEDURE|peripheral blood stem cell transplantation|
40850052|NCT00007891|RADIATION|indium In 111 monoclonal antibody BrE-3|
41375299|NCT00405496|DRUG|Difluprednate Ophthalmic Emulsion|
41375300|NCT04928625|DRUG|SHR-A1904|SHR-A1904
41375301|NCT05980637|DRUG|Shaoyao Gancao Decoction with Addition|11g twice daily for 4 weeks
41375302|NCT05980637|OTHER|Placebo|11g twice daily for 4 weeks
41375303|NCT06337344|BEHAVIORAL|Baduanjin|The treatment group will individually perform single-session Baduanjin by following a video broadcasted the standardised BDJ protocol, which lasted for 12 minutes including 6 times of BDJ movements. Breathing rhythm is emphasised to be followed by participants.
41375304|NCT06337344|BEHAVIORAL|Exercise|The active control group will individually perform 8-sets of aerobic exercise movement by following a video selected by registered physiotherapist.
41505198|NCT06604598|DRUG|IBU-PCT-placebo|Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, and 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the IBU-PCT-placebo intervention
40850053|NCT00007891|RADIATION|yttrium Y 90 monoclonal antibody BrE-3|
41032915|NCT03451838|DIAGNOSTIC_TEST|HbA1c level in blood|a blood sample will be taken to measure HbA1c level
40850054|NCT02578186|DRUG|Diphenhydramine Hydrochloride|30 mL at bedtime
41032916|NCT06252376|DIAGNOSTIC_TEST|Head-up tilt table|Different versions of cognitive assessments will be administered in the supine and upright positions while the participant is on the tilt table.
41032917|NCT05898542|PROCEDURE|Nature-based therapy|Therapy sessions conducted outdoors
40850055|NCT02578186|DRUG|Placebo|30 mL at bedtime
40850056|NCT03057275|DEVICE|Abdominal fetal/maternal monitoring|A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
40850057|NCT01454765|OTHER|generation of stem cells|Collected germ cells will be cultured in medium. The germ cell cultures will be infected with reprograming factors. Rare colonies with characteristic stem cell morphologies will be expanded.
41375305|NCT06337344|BEHAVIORAL|Video Viewing|The control group will individually watch a 12-minute video with 6-minute introducing BDJ practice and 6 minute introducing aerobic exercise. This control group is used for controlling the effect of behavioural movement and brain activity generated by passive video viewing.
41375306|NCT01256086|DRUG|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
41032918|NCT05880095|OTHER|Unrestricted Mediterranean diet|Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.
41032919|NCT05880095|OTHER|Energy-reduced Mediterranean diet|Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.
41032920|NCT05880095|OTHER|Mediterranean diet with time-restricted eating|Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.
41163822|NCT00797511|BIOLOGICAL|TdcP-IPV vaccine|0.5 mL, Intramuscular
40850058|NCT05972746|DEVICE|Telemonitoring with electronic alerts|Patients assigned to this group will receive standard care plus a telemonitoring program.
40850059|NCT05972746|OTHER|Standard of care|Standard of care
41163823|NCT00000521|BEHAVIORAL|diet, sodium-restricted|
41375307|NCT01256086|DRUG|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
41375308|NCT01256086|DRUG|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
41375309|NCT01256086|DRUG|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
41505199|NCT06604598|DRUG|PCT-placebo-placebo|Paracetamol (Bernofarm) 2x1 gr iv, 2xplacebo (normal saline alike paracetamol), 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the PCT-placebo-placebo intervention.
40850060|NCT02804035|COMBINATION_PRODUCT|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
40850061|NCT04924153|OTHER|No Intervention|Administered as specified in the treatment arm.
41032921|NCT06636461|PROCEDURE|microfragmented adipose tissue loaded on allograft|microfragmented adipose tissue loaded on allograft on ridge preservation
41032922|NCT06636123|DRUG|Investigational Agent Administration|GZ17-6.02 will be taken orally with a high-fat meal at a fixed dose of 375 mg twice daily each day of a 28-day cycle, continuing until progression or intolerable toxicity
41163824|NCT00000521|BEHAVIORAL|diet, potassium-supplemented|
41163825|NCT04854213|DEVICE|Stereotactic Body Radiation Therapy (SBRT)|Radiation treatment
41163826|NCT02712164|DEVICE|Modified NPWT dressing|Use of negative pressure wound therapy on split-thickness skin graft (STSG) donor sites
41375310|NCT06456749|COMBINATION_PRODUCT|Integrated Disease Management|For COPD, they are encouraged to seek further cares and manage COPD on a regular basis. For smokers, they will be given a digital health intervention based on CBT. For participants with symptoms of depression or anxiety, another digital health intervention is provided. For abnormal BMI participants, a knowledge brochure will be provided and a medical worker from the township hospital will tell the harm of abnormal BMI. For hypertension and type 2 diabetes, we will actively include them into the National Essential Public Health program.
41375311|NCT04759352|OTHER|Post-test genetic counseling delivered by telephone|Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.
41375312|NCT05376657|DIETARY_SUPPLEMENT|Cherry collagen drink|consume 1 sachet per day
41375313|NCT05376657|DIETARY_SUPPLEMENT|Placebo drink|consume 1 sachet per day
41375314|NCT02302118|PROCEDURE|Esophagogastrectomy|Esophagogastrectomy
41505200|NCT04646005|DRUG|Cemiplimab|Administered intravenously (IV) every three weeks (Q3W)
41505201|NCT04646005|BIOLOGICAL|ISA101b|Administered by subcutaneous (SC) injection on day 1, day 29, and day 50
40850062|NCT06164704|DRUG|Verekitug (UPB-101)|Verekitug (UPB-101) 0.5 mL of formulated solution (100 mg verekitug \[UPB-101\])
41032923|NCT06383572|DRUG|Cyclophosphamide|Given by IV
40850063|NCT06164704|DRUG|Placebo|Verekitug (UPB-101) matching placebo
41032924|NCT06383572|DRUG|Fludarabine phosphate|Given by IV
41032925|NCT06383572|DRUG|Decitabine|Given by IV
41032926|NCT01255358|DRUG|Dexamethasone|"Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient).~The treatment has to be repeated at intervals of 30 days (±10 days)"
41032927|NCT02508311|DRUG|Oral Albuterol Extended Release|Subjects will receive extended release Albuterol, 4mg twice daily for the first week. The remaining 15 weeks subjects will receive extended release Albuterol, 8mg twice daily.
41032928|NCT02508311|DRUG|Placebo|Subjects will receive placebo tablets twice daily for 16 weeks.
41032929|NCT06500884|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
41032930|NCT06500884|DRUG|Prophylaxis A|Prophylaxis A will be administered orally.
41375315|NCT04368117|BEHAVIORAL|Physical Therapy|Directed and prescribe physical therapy program for severely burned patients
41032931|NCT06500884|DRUG|Prophylaxis B|Prophylaxis B will be administered orally.
41032932|NCT06500884|DRUG|Prophylaxis C|Prophylaxis C will be administered orally.
41032933|NCT06453486|DRUG|Induction chemotherapy with modified FOLFIRINOX (FFX) or gemcitabine and nab-paclitaxel (GnP)|"The study doctor will determine which of the two chemotherapy regimens a participant will receive:~Modified FOLFIRINOX (FFX) is a combination of four drugs called oxaliplatin, leucovorin, irinotecan, and 5-fluorouracil. Drugs will be administered through a vein in the arm on the first day of each cycle. Each cycle lasts 14 days.~Gemcitabine and nab-paclitaxel (GnP) will be administered through a vein in the arm on Day 1, 8, and 15 of each cycle. Each cycle lasts 28 days.~In both cases, chemotherapy treatment will last 4 to 6 months."
41032934|NCT06453486|RADIATION|High dose radiation therapy|"High dose radiation refers to the administration of a concentrated beam of radiation to target and treat the tumor. High dose radiation therapy typically involves delivering radiation in fractions over a set period. For instance, options such as:~* 50Gy/5Fx: 50 Gray delivered over 5 fractions, administered every other day over 2 weeks.~* 67.5Gy/15Fx: 67.5 Gray delivered over 15 fractions, administered once a day over 3 weeks.~* 75Gy/25Fx: 75 Gray delivered over 25 fractions, administered once a day over 5 weeks.~These numbers denote the total dose of radiation (in Gray, abbreviated as Gy) delivered over a specific number of fractions (abbreviated as Fx), and the respective time frames for administration. The selection of radiation therapy (RT) dose levels for participants is guided by the expertise and evaluation of the radiation oncologist."
41032935|NCT06360835|PROCEDURE|total hip arthroplasty|
41032936|NCT06034600|OTHER|taping|Taping will be applied to the exercise and taping group after the exercises with theraband. Other exercises that are not performed will be performed with the tape on the skin.The application will be repeated three days a week for eight weeks.
41032937|NCT06034600|OTHER|exercise|"Stretching and strengthening exercises will be applied to both groups three days a week for 8 weeks.The exercises performed with theraband will be performed in the same way in both groups. While the other exercises will be done after taping in the taping and exercise group, the exercise group will be done without taping."
41375316|NCT00286936|DRUG|Zolpidem|
41375317|NCT04135352|DRUG|200 mg of pembrolizumab|Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
40850064|NCT05664802|BEHAVIORAL|e-HERO: Ending the HIV Epidemic in Rural Oklahoma|A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.
40850065|NCT05050864|PROCEDURE|venous sinus stenting|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid
41032938|NCT06635096|DEVICE|Multimodal Tumor Thermal Therapy System (Shanghai MAaGI Medical Technology Co., Ltd.)|These patients will receive multimodal thermal therapy using Multimodal Tumor Thermal Therapy System.
41163827|NCT02712164|DEVICE|Tegaderm|Standard of care for STSG donor sites.
41163828|NCT05853692|DEVICE|Zinc Gluconate|Three times a day (spray)
41163829|NCT05853692|DEVICE|Sodium Bicarbonate|Five times a day (rinse)
41375318|NCT04135352|BIOLOGICAL|V938|Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.
41375319|NCT03176628|DIETARY_SUPPLEMENT|Basis|NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries
41375320|NCT03176628|DIETARY_SUPPLEMENT|Placebo|Placebo capsule(s)
41375321|NCT01212432|DRUG|Daptomycin|Daptomycin kinetics in CRRT
41375322|NCT00000459|BEHAVIORAL|diet, fat-restricted|
41375323|NCT03421873|OTHER|0h/1h hs-cTnT protocol|Implementation of a 0h/1h hs-cTnT protocol in routine care
41375324|NCT02220621|DEVICE|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
41375325|NCT02220621|DEVICE|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
41375326|NCT00805857|DRUG|Tipranavir|
40850066|NCT05050864|PROCEDURE|Neurosurgical internal ventricular shunt|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
40850067|NCT06206915|DRUG|XZ120 injection|in Part One：XZ120 monotherapy, IV, no less than 60min, Q3W dose escalation study: 4 dose group (0.75 mg/m2, 1.5 mg/m2, 2.25 mg/m2, 3.0 mg/m2) Dose expansion study: MTD dose
40850068|NCT00001317|DRUG|interferon-gamma|
40850069|NCT02652078|DEVICE|Extracorporeal shockwave therapy|Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
41032939|NCT06543979|DRUG|lubiprostone , single arm|laxative
41032940|NCT06543979|PROCEDURE|biofeed back sessions|Biofeedback for participants with dyssynergic defecation and participants with reduced rectal sensations
41032941|NCT06543979|PROCEDURE|botox injection|Botulinum toxin injection for participants suffering from elevated anal canal pressure
41032942|NCT01473654|BEHAVIORAL|ADAPT tool|Use of ADAPT shared goal setting tool in EMR
41032943|NCT06191848|DRUG|Tirzepatide|Participants will receive tirzepatide subcutaneously
41032944|NCT06191848|DRUG|Placebo|Participants will receive placebo subcutaneously
41032945|NCT05831332|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
41032946|NCT05878639|DRUG|3 bottles of Lactulose oral solution|Patients will take lactulose for bowel preparation.
41032947|NCT05878639|DRUG|3L-polyethylene glycol|Patients will take 3L-polyethylene glycol for bowel preparation.
41032948|NCT04834323|PROCEDURE|distal mesogastric fixation after sleeve gastrectomy|Investigators performed traditional laparoscopic sleeve gastrectomy then we fixed the greater omentum \& mesocolon that were cut during gastrectomy to the remaining gstric pouch along the new greater curvature as high as possible along the stable line then we plicated the remaining staple line till angle of His. (the greater omentum \& mesocolon not reach this part of staple line) , so the remaining gastric pouch remained tension free and was returned to original position and this may prevent the axial gastric rotation
41032949|NCT06634628|RADIATION|Radioligand [11C]CHDI-00491009|Intravenous injection of radioligand in the arm with PET imaging of the brain.
41032950|NCT06632990|DRUG|BMS-984923|oral capsules once or twice daily
41375327|NCT04016909|PROCEDURE|aerobic exercise plus calorie restriction|both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
41375328|NCT05069129|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm
41032951|NCT06632990|DRUG|Midazolam|midazolam, oral, 2mg administered before study drug and after study drug
41032952|NCT06632990|DRUG|Caffeine|Caffeine, oral, 100mg administered before study drug and after study drug
41032953|NCT06632990|DRUG|dextromethorphan|dextromethorphan, oral, 30mg administered before study drug and after study drug
41032954|NCT04094311|BIOLOGICAL|CTL019|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
41032955|NCT04965844|DEVICE|Oxygen close-loop|The Automatic FiO2 option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the Oxygen setting to keep the patient's SpO2 in the target range.
41032956|NCT04965844|DEVICE|No intervention|Manual FiO2 adjustment according to SpO2 values
41375329|NCT05069129|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
41375330|NCT05069129|BIOLOGICAL|3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm on 0，30，60 days
41375331|NCT04389008|OTHER|no interventions|no interventions
41505202|NCT03857269|OTHER|Acupoint Massage|The operators is trained for two weeks. At 9 o'clock in the morning, the elderly are organized by Nursing home to perform acupressure.Intervention frequency will be monday to saturday per week for 6 months.
41032957|NCT06635759|OTHER|Upper trapezius low-load endurance exercise|Participants in the EE group will perform the overhead shrug exercise for the affected side using a green Thera-Band Elastic Band. To perform this exercise, the subject will stand and place one arm of the affected side in an overhead position against the wall. The middle portion of the theraband will be placed on the floor, and the subject will stand on the middle portion of the theraband to fixate it in place with both feet shoulder-width apart. Then, the subject grasp both tails of the theraband and perform the shoulder shrug movement for the affected side with a 3-second elevation, hold at the end range for 5 seconds, and then return back to the starting position with a 3-second depression. The subject will perform this exercise for 20 repetitions per set, 3 sets a day with 1-minute rest between sets, 3 alternate days a week, for 5 weeks. They will be instructed to record all training sessions in a diary.
41032958|NCT06635759|OTHER|Upper trapezius stretching exercise|Participants in the SE group will perform static upper trapezius stretching exercise for the affected side. To perform the stretch, participants will be asked to sit upright on a chair and look straight ahead. To reduce scapular elevation and upward rotation, the ipsilateral hand should be placed below the buttock. The subject will then be asked to perform deep neck flexion, neck rotation towards the affected side, and contralateral side flexion using the opposite hand in a diagonal direction until the position of 'mild discomfort' is attained. They should maintain the deep neck flexion when performing the stretch. The stretch will be held for 30 seconds each set, 3 sets a day, daily for 5 weeks.
41032959|NCT00311077|DRUG|Insulin Glulisine|
41032960|NCT05396586|BEHAVIORAL|N-back|The training program is a personal device-based adaptive version of a visual N-back task, either devoid of game elements or embedded in a gamified platform game
41032961|NCT05396586|BEHAVIORAL|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
41375332|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 5mg/day for one year
41375333|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 40mg/day for one year
41032962|NCT05396586|BEHAVIORAL|Multisensory|The training program is a personal device-based adaptive version of an N-back task that features visual stimuli (Unisensory) or visual stimuli paired with unique sounds (Multisensory) and is devoid of game elements
41032963|NCT02534857|PROCEDURE|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
41375334|NCT01977924|DIETARY_SUPPLEMENT|one month polyphenols supplementation (600mg)|
41375335|NCT01977924|DIETARY_SUPPLEMENT|placebo (microcrystalline cellulose)|
41375336|NCT05725642|OTHER|Polysomnography|Polysomnography
41032964|NCT05973526|PROCEDURE|Percutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using needles.
41032965|NCT05973526|PROCEDURE|Transcutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using the surface electrodos.
41032966|NCT05924919|PROCEDURE|Whole-body Passive Heat Therapy (HT)|The whole-body passive heat therapy (HT) intervention will consist of an acute bout of infrared sauna for 25 minutes at 60°C. Participants will lie supine on a memory foam pad.
41032967|NCT05924919|PROCEDURE|Thermoneutral Control (CON)|Participants will remain in a room temperature environment (22°C) underneath the infrared domes for 25 minutes.
41032968|NCT04804319|OTHER|9-days habitual diet|9-days study with habitual diet including one standardized breakfast on a single day
41032969|NCT05595304|PROCEDURE|prosthetic refunctioning|Active treatment followed by regular interventions
41032970|NCT05595304|PROCEDURE|conventional prosthetic treatment|new prosthesis
41032971|NCT01140191|DRUG|WR 279,396|Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
41032972|NCT05480566|OTHER|Functional strength training|Functional strength training will include lower limb (e.g. rising from chair, heel rises) and upper limb (e.g. push-ups from the chair and against the wall) exercises for 15 min/day. Target levels of dyspnoea and/or perceived exertion will be 4 to 6 in the modified Borg scale.
41032973|NCT05480566|DEVICE|NMES|For neuromuscular electrical stimulation, electrodes will be placed longitudinally on the vastus intermedius and vastus medialis and a symmetric biphasic pulse waveform, with a pulse duration of 400ms, a frequency of 50Hz, in cycles of 8s of contraction and 20s of rest, will be used for 30min/day. The highest intensity tolerated by the patient will be used and intensity will be increased every time the patient feels comfortable with increasing the intensity. The device Compex Pro Rehab (CE-0473) will be used.
41375337|NCT00669110|DRUG|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"* tablet~* subjects randomly assigned to 10-200 mg/day by age group~* 6 month treatment period(\~182 days)"
41505203|NCT03857269|OTHER|lavender essential oil|Modulated by an international aroma therapist,The cotton ball containing essential oil is replaced by the operator at 9 am.Intervention frequency will be monday to saturday per week for 6 months.
41032974|NCT05480566|DRUG|Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine)|Patients will be treated with daily medication prescribed by the physician, which can include oxygen, medrol, duovent, azitromycine or other medications that physicians consider that are needed.
41032975|NCT05480566|OTHER|Routine physiotherapy|Daily sessions of approximately 15 minutes consisting of airway clearance techniques and breathing exercises upon indication, mobilization, and low-intensity daily walking/cycling exercise (5 to 10 minutes) according to patients' tolerance.
41032976|NCT05846659|DRUG|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
41375338|NCT05978817|DEVICE|Damon Ultima bracket|It is metal twin bracket with their recommended arch wire
41375339|NCT05393765|BEHAVIORAL|Yönetebilirim|"Yönetebilirim is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses."
41375340|NCT00928629|PROCEDURE|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
41375341|NCT00163527|DRUG|Roflumilast|
41375342|NCT02175472|DEVICE|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
41375343|NCT02175472|DEVICE|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
41375344|NCT05490160|DRUG|Tranexamic acid|During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
41383537|NCT02657746|OTHER|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
40850070|NCT00106353|DRUG|Torisel|60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
40850071|NCT03559647|DRUG|Atezolizumab|Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
40850072|NCT02197650|DRUG|suspension of erythrocytes encapsulating L-asparaginase|Erythrocytes encapsulating L-asparaginase
40850073|NCT05538143|OTHER|Comprehensive ED syncope/presyncope management tool|This is a data-only, prospective observational cohort study to validate the performance metrics of the Canadian Syncope Risk Score in a diverse population of patients evaluated in community EDs of a U.S. integrated health care system.
40850074|NCT01267526|DEVICE|Easypod™|Saizen (Somatotropin) administered by easypod™ as defined in SAIZEN® Canadian Product Monograph
40850075|NCT04077515|DRUG|Sirolimus(0.8mg/m2)|The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
40850076|NCT04077515|DRUG|Sirolimus(0.7mg/m2)|The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
41032977|NCT05846659|DRUG|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
41032978|NCT05846659|RADIATION|PULSAR|1st day of Cycles 1, 2 and 3.
41163830|NCT05334706|BIOLOGICAL|Nonavalent HPV vaccine (9vHPV/Gardasil-9™).|"Sterile suspension, 0.5 ml dose, intramuscular administration in a 3 dose-regimen (Day 1, Month 2, Month 6), prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein from 9 HPV types: 6/11/16/18/31/33/45/52/58.~9vHPV is currently indicated in the EU in individuals from 9 years of age for the prevention of diseases caused by vaccine's 9 HPV types: genital warts (HPV6 and 11) and premalignant lesions and cancers affecting the cervix, vulva, vagina and anus (HPV16, 18, 31, 22, 45, 52 and 58). It was authorized for marketing in the EU on June 9th, 2015."
41163831|NCT00700518|DRUG|placebo cream|placebo cream applied to 2 adjacent fingers of non-dominant hand one time
41163832|NCT00700518|DRUG|Glyceryl Trinitrate|0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
41163833|NCT00700518|DRUG|Glyceryl Trinitrate|1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
40850077|NCT03088943|OTHER|TTE Apical 4 Chamber View|We will measure a number of echocardiography parameters by TTE (apical 4 Chamber View) prior to and after induction
40850078|NCT03088943|OTHER|TEE dTG View|We will measure a number of echocardiography parameters by TEE (dTG View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
40850079|NCT03088943|OTHER|TEE ME 4C View|We will measure a number of echocardiography parameters by TEE (ME 4C View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
41163834|NCT00700518|DRUG|Glyceryl Trinitrate|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
41163835|NCT00700518|DRUG|Glyceryl Trinitrate|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
41163836|NCT02435797|DRUG|Nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
41163837|NCT02435797|DRUG|normal saline|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
41163838|NCT00953511|GENETIC|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
41383538|NCT01843660|DRUG|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram \[mg\] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
40850080|NCT01497301|BEHAVIORAL|Group Visits|"During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants."
40850081|NCT02109809|RADIATION|total nodal irradiation|Undergo TLI
41032979|NCT04531046|DRUG|axicabtagene ciloleucel|Patient-specific (autologous) product cryopreserved in cryostorage bag
41032980|NCT00905580|DRUG|Pregabalin|Pregabalin 150 mg orally
41032981|NCT00905580|DRUG|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
41163839|NCT04626271|DEVICE|"ACR | U.S. Urine Analysis Test System"|"Each study participant will test their urine sample using the ACR \| U.S. test device - a home-use device intended for the semi-quantitative measurement of ACR in the urine (albumin and creatinine ratio) and used to aid in the management of kidney health."
41163840|NCT04626271|DEVICE|URiSCAN Optima Urine Analyzer|"Upon completion of the test using the ACR \| U.S. device, each urine sample will be provided to a professional user for further urine analysis test using the comparator device, the URiSCAN Optima Urine Analyzer."
41163841|NCT05977673|DRUG|Tislelizumab|Tislelizumab 200mg IV day1
41163842|NCT04040283|PROCEDURE|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
41032982|NCT06146348|BEHAVIORAL|adapted DRAUP strategy bundle|DRAUP deimplementation strategy bundle includes: 1) education and training, 2) supervision and in-person decision support, and 3) audit and feedback to target capability. Opportunity is addressed by 4) algorithm development and 5) organizational support. Finally, 6) facilitators and 7) planned adaptation after interval program assessment address the motivations needed to change behavior.
41032983|NCT01601587|OTHER|A psychoeducational group intervention.|"The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:~1. What is mental health?~2. Treatment options: orientation about individual and group based treatment modalities.~3. Former patients experience with their own treatment, self-help and participation.~4. How to influence and participate actively in the treatment and patient rights.~5. What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?"
41163843|NCT06319274|DRUG|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
40850082|NCT02109809|OTHER|laboratory biomarker analysis|Correlative studies
40850083|NCT02109809|OTHER|questionnaire administration|Ancillary studies
40850084|NCT04352023|PROCEDURE|Patient-controlled analgesia|Intravenous patient-controlled analgesia Patient-controlled epidural analgesia
41032984|NCT06287775|BIOLOGICAL|Atezolizumab|Given IV
41032985|NCT06287775|PROCEDURE|Biopsy|Undergo optional tumor biopsy
41032986|NCT06287775|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41032987|NCT06287775|PROCEDURE|Computed Tomography|Undergo CT scan
41032988|NCT06287775|BIOLOGICAL|Durvalumab|Given IV
41032989|NCT06287775|PROCEDURE|Echocardiography|Undergo ECHO
41032990|NCT06287775|DRUG|Iadademstat|Given PO
41032991|NCT06287775|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41032992|NCT06287775|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41032993|NCT00366626|DRUG|Naltrexone|Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
41032994|NCT00366626|DRUG|Placebo|Placebo for 7 days matched to Naltrexone
41032995|NCT02747342|DRUG|SHR3680; SHR3162|"SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase."
41032996|NCT04074980|DIAGNOSTIC_TEST|Venous and Fingerstick blood draws|Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects
41032997|NCT04074980|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to collect blood samples from subjects
41032998|NCT05634707|DRUG|Fluoxetine|"Patients randomized to the experimental arm will receive fluoxetine 20mg/day for 5 days before escalation to a maintenance dose at day 6. On day 6, patients will start treatment with 50 mg/m2 TMZ daily for 7 days (Days 6-12)~* Arm 2A (n=10) - Escalate to maintenance 40mg/day fluoxetine on day 6~* Arm 2B (n=10) - This arm will be opened as long as there are less than 3/10 dose limiting toxicities in Arm 2A. Patients will escalate to maintenance 60mg/day fluoxetine on day 6"
41032999|NCT05634707|DRUG|Temozolomide|Patients randomized to the control arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
41163844|NCT06319274|DRUG|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
41163845|NCT01115283|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
41163846|NCT01115283|BEHAVIORAL|Video Games|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
41163847|NCT01115283|BEHAVIORAL|Occlusion therapy|Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
41383539|NCT05288452|BEHAVIORAL|Digital Health Coaching|The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.
41375345|NCT06355180|DRUG|Subanesthetic dose intravenous esketamine|"The study, lasting 12 weeks, includes a 2-week intervention and 10-week follow-up. Esketamine (0.2mg/kg) is given intravenously three times a week for two weeks. Dosage and sessions may adjust for safety and efficacy, with study treatments limited during follow-up.~Efficacy is evaluated via scales measuring suicidal ideation, depression, cognition, and social function. Adverse effects are tracked through vital signs, exams, events, and tests.~Biological samples (blood, urine, feces) are collected from some participants at baseline, post-first, and sixth treatments for omics analyses.~Brain imaging from some participants at baseline and post-sixth treatment aims to obtain high-resolution T1, T2 FLAIR, resting fMRI, and DTI images.~Electrophysiological data, including resting state EEG signals and task paradigms, are collected from some participants at baseline, after the first, and sixth treatments."
41505204|NCT03857269|OTHER|Acupoint Massage and lavender essential oil|At the same time as the acupressure, patients began to smell the essential oil.Intervention frequency will be monday to saturday per week for 6 months.
41505205|NCT06107803|DRUG|Roluperidone 64 mg|64 mg/day oral
41033000|NCT05918094|DRUG|Experimental dose: modified XELOX + sintilimab|The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.
41505206|NCT06107803|DRUG|Olanzapine 10 MG|10 mg/day oral
41505207|NCT01772797|DRUG|LDK378|LDK378 is a capsule to be taken daily by mouth.
41033001|NCT05918094|DRUG|Standard dose: standard XELOX + sintilimab|The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
41033002|NCT02267382|DRUG|VT-1161|
41033003|NCT02267382|DRUG|Placebo|
41033004|NCT06380751|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.
41033005|NCT06380751|DRUG|Camizestrant|Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .
41033006|NCT06380751|DRUG|Abemaciclib|CDK4/6 Inhibitor
41033007|NCT06380751|DRUG|Ribociclib|CDK4/6 Inhibitor
41505208|NCT01772797|DRUG|AUY922|AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
41505209|NCT04848727|OTHER|Detecting asymmetric lung disease like atelectasis or pneumothorax with electrical impedance tomography (EIT)|"The EIT system will be placed at the subject's bedside to collect EIT measurements: Ventilation distribution%, changes in regional aeration in arbitrary units (AU), dependent and non-dependent silent spaces. A data acquisition cart will also be placed at the subject's bedside to collect hemodynamic and respiratory parameters measurements including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices.~The LuMon belts for neonates are disposable single-patient use belts that are adhesive-free. EIT measurements and data will be collected on each timeperiods (t1 and t2) for approximately 15-30 minutes on invasive or non-invasive ventilatory support."
41505210|NCT06474273|DRUG|Methylprednisolone|IV Methylprednisolone
41505211|NCT06474273|DRUG|Prednisone|Oral prednisone augmentation
41505212|NCT05307692|DRUG|Seltorexant|Seltorexant 20 mg will be administered orally as a tablet.
41505213|NCT05307692|DRUG|Placebo|Matching placebo will be administered orally as a tablet.
41505214|NCT04611633|COMBINATION_PRODUCT|Trimbow|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
41505215|NCT04378738|BEHAVIORAL|survey|all people in the cohort
41505216|NCT06192056|BEHAVIORAL|RNT Focused Web- Based Self-Help Program|This 10 day long intervention contains psychoeducational contents, experimental exercises, monitoring behavior and committed action strategies. Each step of the intervention aims to develop a specific psychological flexibility skill like cognitive defusion etc.
41505217|NCT01639157|DRUG|Buspirone|Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
41505218|NCT01639157|DRUG|Placebo|Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
41505219|NCT04717557|DRUG|Hyperbaric Oxygen|Hyperbaric oxygen (HBO2) 1-2 times daily for up to 10 times after amputation
41505220|NCT02012426|BEHAVIORAL|Weight management program|
41033008|NCT06380751|DRUG|Palbociclib|CDK 4/6 Inhibitor
41033009|NCT06380751|DRUG|Fulvestrant|Endocrine Therapy
41033010|NCT06380751|DRUG|Letrozole|Endorcine Therapy
41033011|NCT06380751|DRUG|Anastrozole|Endocrine Therapy
41033012|NCT06380751|DRUG|Exemestane|Endocrine Therapy
41033013|NCT02794402|DRUG|Exenatide|Bydureon (Exenatide once weekly) injections s.c.
41163848|NCT05264298|OTHER|VIRTUAL|At the time of discharge, stroke survivors in the VIRTUAL arm will receive a package containing an iPad and a remote BP monitoring device that allows transmission of BP to the study team.The first telehealth visit will occur 7-14 days after discharge. Patient will be counseled on the importance of BP monitoring, salt reduction, and the importance of diet and exercise for stroke prevention. Medications, side effects and interactions will be reviewed. The social worker will refer the patient to specific resources according to social needs abd patient will be referred to a primary care provider if they do not have one. Subsequent video visits will be 1-month (30 days +/- 7) , 3 months (90 days +/- 14), and 5 months (150 days +/- 14) days after enrollment.
41505221|NCT03446807|DRUG|Droxidopa|Droxidopa in 100, 200, and 300mg capsules. Maximum dose to be used in this study is 600mg.
41505222|NCT03446807|DRUG|Placebo Oral Tablet|Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
41375346|NCT06355180|DEVICE|Modified electroconvulsive therapy|"The study, lasting 12 weeks, includes a 2-week intervention and 10-week follow-up. Modified electroconvulsive therapy (MECT) is given three times a week for two weeks. Sessions may adjust for safety and efficacy, with study treatments limited during follow-up.~Efficacy is evaluated via scales measuring suicidal ideation, depression, cognition, and social function. Adverse effects are tracked through vital signs, exams, events, and tests.~Biological samples (blood, urine, feces) are collected from some participants at baseline, post-first, and sixth treatments for omics analyses.~Brain imaging from some participants at baseline and post-sixth treatment aims to obtain high-resolution T1, T2 FLAIR, resting fMRI, and DTI images.~Electrophysiological data, including resting state EEG signals and task paradigms, are collected from some participants at baseline, after the first, and sixth treatments."
41375347|NCT03252236|BEHAVIORAL|Tai Chi|Modified 12-form Yang style Tai Chi.
41375348|NCT03252236|BEHAVIORAL|Conventional exercise|Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
41375349|NCT05668377|DEVICE|PulseAI ECG Platform|Cloud-based AI-enabled ECG analysis platform
41375350|NCT01061346|OTHER|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
41375351|NCT01061346|OTHER|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
41375352|NCT01061346|OTHER|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
41375353|NCT01610726|PROCEDURE|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
41375354|NCT02585193|BEHAVIORAL|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
41375355|NCT03472391|BEHAVIORAL|Physical Therapy|A 4-week (2 exercise session af week, of 40 minutes )tailored physiotherapeutic exercise program. The sessions are individually and supervised by physical therapist and tailored to patients with severe anorexia nervosa. The exercise program mainly consist of strength training exercises without any equipment other than a floor mat.
41375356|NCT02822729|DRUG|DE-117 ophthalmic solution|
41375357|NCT02822729|DRUG|Timolol ophthalmic solution|
41375358|NCT04899219|DRUG|ACT-1014-6470 40 mg|ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.
41375359|NCT02466776|DEVICE|Absorbable subcuticular suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean delivery (CD).
41375360|NCT02466776|DEVICE|Stainless steel staples|Patients will receive stainless steel staples for skin closure at time of cesarean delivery (CD).
41375361|NCT05184491|DRUG|Naïve patients - ACO therapy|Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
41375362|NCT05184491|DRUG|Naïve patients - LNDL therapy|Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
41375363|NCT05184491|DRUG|Naïve patients - MNDL therapy|Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
41375364|NCT05184491|DRUG|Treatment-experienced patients- LNDL therapy|Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
41375365|NCT05184491|DRUG|Treatment-experienced patients- MNDL therapy|Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
41375366|NCT01900353|OTHER|brushing methods|
41375367|NCT02437175|DIETARY_SUPPLEMENT|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
41505223|NCT06010186|OTHER|Ultrasound measurement of the diaphragm and intercostals|"The specific research procedures correspond to the addition of :~* Two additional ultrasound examinations, i.e. at discharge from intensive care and 3 months after hospital discharge: non-invasive examination (duration 20 minutes). Ultrasound is a risk-free, painless procedure involving the placement of an ultrasound probe on the body part under investigation, without the need for a radius or puncture.~* Questionnaires to assess quality of life (SF-36) and functional impact (LCADL) of dyspnea, carried out at discharge from hospital and at 3 months (duration 15 minutes)."
41375368|NCT02437175|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
41375369|NCT04936568|OTHER|Palliative Care Referral System - PCRS|Implementation of a system to help oncologists to identify criteria for referring patients to specialized outpatient palliative care (Palliative Care Referral System - PCRS)
41375370|NCT04518800|DRUG|Jin Youli(PEG-rhG-CSF)|Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle
41375371|NCT05252507|BEHAVIORAL|Paint Night|There will be 8 Sessions (4 paint nights and 4 educational sessions alternating weeks). For the painting sessions, participants will paint for 45 minutes and then participate in a combined presentation/discussion session (45 minutes). For the educational sessions, they will attend a 30-minute presentation presented by a researcher on heart health and then have the opportunity to discuss with the researcher and other members of the group (60 minutes).
41033014|NCT02794402|BEHAVIORAL|Placebo|Placebo once weekly injections sc
41033015|NCT06289673|DRUG|Dexamethasone|Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
41033016|NCT06289673|DRUG|Vincristine|Intravenously (IV) for 1 dose on Day 1 or 2
41375372|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W0, W4, W8 and W20|
41375373|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W4, W8 and W20|
41375374|NCT00219362|BIOLOGICAL|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
41033017|NCT06289673|DRUG|Daunorubicin|Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
41033018|NCT06289673|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
41033019|NCT06289673|DRUG|Methotrexate|Given IT as part of Intrathecal triple therapy.
41163849|NCT05264298|OTHER|Standard care|Participants randomized to standard care will receive an educational packet and a blood pressure monitor prior to hospital discharge. They will be contacted by a social worker to determine if they received their medications and appointments. The stroke practitioner will evaluate the patients at 7-14 days and then follow up according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities. The pharmacist will contact patients at 1-month (30 +/- 7 days) days over the telephone to review BP logs and will make recommendations to their primary care provider to adjust BP medications. Subsequent pharmacist calls will occur monthly until 6 months and recommendations for medication adjustments will be communicated to their primary care provider.
41163850|NCT03590717|BEHAVIORAL|BCC-Only|Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
40850085|NCT02363296|DEVICE|TMS|Paired associative stimulation and single pulse TMS
40850086|NCT04937283|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
40850087|NCT04937283|PROCEDURE|Lobectomy with hilar and mediastinal lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
41163851|NCT03590717|OTHER|Small-voucher|Households in the 'Small-voucher' arm receive a voucher (\~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
41163852|NCT03590717|OTHER|Large-voucher|Households in the 'Large-voucher' arm receive a larger voucher (\~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
41033020|NCT06289673|DRUG|Cytarabine|Given IT as part of Intrathecal triple therapy.
41033021|NCT00655187|OTHER|Collection of information|Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
41033022|NCT00655187|PROCEDURE|Collection of stool samples|Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
41033023|NCT04519840|OTHER|nill|nill
41033024|NCT00081367|BEHAVIORAL|CBT|Participants will receive ten weekly sessions of treatment. Suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed.
41033025|NCT00081367|BEHAVIORAL|Standard care alone|Participants will receive standard care for suicide prevention.
41375375|NCT04967599|BEHAVIORAL|Phenotype Feedback Intervention|Online session providing information on health-related risk associated with alcohol consumption and alcohol metabolism gene variations plus personalized feedback on flushing phenotype and associated risks.
41033026|NCT05408494|BEHAVIORAL|Gamified behavioral weight loss treatment|12-month mHealth fully-gamified version of the same program, comprised of a behavior change program with digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game
41375376|NCT04967599|BEHAVIORAL|Genotype Feedback Intervention|Online session providing personalized feedback on alcohol metabolism genotypes and associated health-related risks.
41375377|NCT03598075|OTHER|Amylin (Pramlintide)|Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
41375378|NCT03598075|OTHER|CGRP|CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.
41505224|NCT04556227|BEHAVIORAL|Simultaneous Cycle/Cognitive Training|Two weeks after discharge from the hospital the intervention group will complete recumbent cycle for 1 hour, 2x/wk. for 12 weeks (24 sessions). 10-minute cycle warm-up, 40-minute simultaneous cycling and cognitive training, 10-minute cool down. Cycling based on provider prescription and progression of physical recovery. Cognitive training program from Posit Science, Brain HQ (TM) progressive level of difficulty. Total duration of 60 minutes.
41505225|NCT03095638|DRUG|Conventional dolutegravir 10 mg tablet|Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
41505226|NCT03095638|DRUG|Conventional dolutegravir 50 mg tablet|Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
41033027|NCT05408494|BEHAVIORAL|mHealth behavioral weight loss treatment|a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining
41375379|NCT00201266|PROCEDURE|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
41033028|NCT04219748|BEHAVIORAL|Case Management|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes.~This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition.~The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system."
41033029|NCT03761602|OTHER|Not applicable (for observational studies)|This study is an observational study. No intervention will be administered for research purposes.
41375380|NCT03844802|OTHER|Local Dry needling and exercise|"Deep dry needling will be applied bilaterally in the locus of active or latent myofascial trigger points of several neck shoulder muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius). The presence of active or latent myofascial trigger points will be assessed according to the diagnostic procedures described by Travell and Simons. The dry needling intervention technique will be the fast in-fast out Hong technique, with a minimum of 3 to 6 local twitch responses to be elicited.~Patients will perform a home based therapeutic neck exercises program."
41383540|NCT05288452|DIETARY_SUPPLEMENT|Food Box Delivery|The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.
41505227|NCT03095638|DRUG|Dispersible dolutegravir 5 mg tablet|Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
41505228|NCT03095638|DRUG|Conventional dolutegravir 25 mg tablet|Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
41505229|NCT01910246|DRUG|Metformin|
40850088|NCT02401451|DEVICE|RhythmPadGP|ECG acquisition using a novel device RhythmPadGP
41033030|NCT04724655|OTHER|gastric lavage with paraffin oil and bicarbonate|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube
41033031|NCT04724655|OTHER|gastric lavage with coconut oil and bicarbonate|Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube
41033032|NCT04724655|DRUG|standard treatment|inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
41033033|NCT04724655|OTHER|gastric lavage with saline and bicarbonate|Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube
41033034|NCT04697758|DRUG|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye
41163853|NCT00799136|DRUG|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
41383541|NCT05288452|BEHAVIORAL|Remote Patient Monitoring (RPM)|The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.
41375381|NCT03844802|OTHER|Distal Dry needling and exercise|"Patients in this group will undergo deep dry needling at a remote spot from the locus of the myofascial trigger point. As a result no local twitch response should be elicited. As in the previous group, dry needling will be carried out in the same assessed muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points, according to the diagnostic procedures described by Travell and Simons. The intervention technique chosen for these participants will be to insert the needle in a location in the same muscle, but far away (at least 1 to 1.5 cm) from the location of the myofascial trigger point. Likewise, the needle will be inserted without the intention to evoke local twitch responses. Therefore, the entry and exit of the needle will be performed in a slower fashion.~Patients will perform a home based therapeutic neck exercises program."
41383542|NCT05288452|BEHAVIORAL|Diabetes Education Class|The diabetes education class will be administered by a certified diabetes educator.
41505230|NCT04210050|DEVICE|Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical.|"In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time.~For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring."
41505231|NCT04210050|DIAGNOSTIC_TEST|Arterial blood gas (ABG) and serum bicarbonate level|Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study
41505232|NCT04210050|DIAGNOSTIC_TEST|Overnight home oximetry and transcutaneous CO2 monitoring|will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
40850089|NCT00477152|DRUG|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
41505233|NCT05327673|OTHER|questionnaire|"* quality of life score: FACT-BMT~* decisional conflict scale~* Discreet Choice Experiment questionnaire"
41505234|NCT03305367|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil|Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.
41505235|NCT06448806|OTHER|mobile health lifestyle intervention|You will be asked to record all dietary and physical activity log for 12 months on an application. Mobile sms reminders will be sent to you on regular basis. At day 0, at 6th and 12 months you will be asked to provide 3 ml of blood for the methylation and advance glycation level testing and your weight and body fat percentage will be measured. During this period you will have to follow the lifestyle and diet chart provided to you by the researchers.
41505236|NCT04785755|DRUG|Oral standard diuretics therapy|Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
40850090|NCT04720742|DRUG|Analytical Treatment Interruption + bNAbs infusion|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
41505237|NCT04785755|DRUG|Hypertonic saline solution|Hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
41505238|NCT04785755|DRUG|Etilefrine|Etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
40850091|NCT05406102|DRUG|Remimazolam|Patients received an initial dose of 0.1mg/kg of remimazolam (add to 0.05 mg/kg top-ups doses to a total of up to five times within 15minutes).
40850092|NCT05406102|DRUG|Propofol group|Patients received an initial dose of 1.5mg/kg of propofol(add to 0.5 mg/kg top-ups doses to a total of up to five times within 15minutes).
40850093|NCT03877484|DEVICE|ALLEVYN Gentle border|ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
41033035|NCT04697758|DRUG|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye
41383543|NCT01527942|DRUG|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
41383544|NCT01527942|DRUG|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
41383545|NCT01382680|DEVICE|Guidewire|Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
41383546|NCT03029104|COMBINATION_PRODUCT|CXLO Corneal Strengthening Solution and UVA Illumination Device|CXLO Corneal Strengthening Solution
41375382|NCT03844802|OTHER|Sham dry needling and exercise|"Patients in this group will undergo sham-placebo dry needling. For that purpose, placebo dry needling will be carried out in the same muscles previously described (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points. The intervention technique will be carried out in the locus of the trigger point but using placebo needles. For this placebo group, a simulation needle procedure using a Dong Bang placebo needle, similar to the Streitberger needle, will be used. The placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.~Patients will perform a home based therapeutic neck exercises program."
41375383|NCT03844802|OTHER|Exercise|Patients will perform a home based therapeutic neck exercises program.
41375384|NCT01302639|DIETARY_SUPPLEMENT|Comparison of different combinations of polyphenols with respect to effects on fat oxidation|EGCG, resveratol and genistein
41375385|NCT02778269|DEVICE|12-lead ECG T-shirt|The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
41375386|NCT02778269|DEVICE|Dexcom G4-System|Continuous Glucose Monitoring
41375387|NCT01054209|DEVICE|Warming with warming mattress|"Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.~Inditherm Alpha systems, OTM1: 1900mm x 585mm"
41383547|NCT02539329|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
41383548|NCT05649059|DRUG|Cannabidiol|Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.
41505239|NCT03164538|BEHAVIORAL|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).
41505240|NCT03164538|BEHAVIORAL|Diabetes Education|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
41505241|NCT05864989|PROCEDURE|Non-incised papila surgical approach only|Reconstructive periodontal surgery
41505242|NCT05864989|PROCEDURE|Non-incised papila surgical approach with connective tissue grafting|Reconstructive periodontal surgery
41505243|NCT06006390|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
41505244|NCT06006390|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
41505245|NCT06509503|DRUG|Combined oral contraceptive|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are regular users of COCs and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
41505246|NCT06509503|DRUG|Vaginal Ring|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are users of mechanical contraceptive methods and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
41505247|NCT03169231|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
41505248|NCT03169231|OTHER|Placebo|Intravenously delivered
40850094|NCT06121024|PROCEDURE|Interventional Bronchoscopy|Bronchoscopy offers vital information when evaluating patients suffering from tracheal stenosis. It enables direct visualisation which identifies the lesion, determines its location and extent of airway involvement, highlights vascularity and fragility, allows for tissue diagnosis and enables the operator to assess the extent of mucosal infiltration and airway compression caused by the tumour. The technique facilitates assessment of stenosis diameter for suitable stent selection. In addition to enabling diagnostic bronchoscopy, rigid bronchoscopy offers therapeutic options such as dilatation, cryotherapy and stenting for tracheal stenosis patients. Our clinical setting employs rigid bronchoscopy for interventional procedures with both diagnostic and therapeutic aspects.
41033036|NCT04697758|DRUG|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye
41033037|NCT05752123|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
41033038|NCT06413693|DRUG|PF-07293893|A single dose of PF-07293893 administered orally as tablets
41033039|NCT06413693|DRUG|Placebo|A single dose of Placebo administered orally as tablets that look the same as PF-07293893
41375388|NCT03673137|DEVICE|Irreversible electroporation|During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
41375389|NCT03673137|DRUG|Gemcitabine|Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.
41375390|NCT02262507|DEVICE|Device Wearing|Q30 collar - collar designed to be worn around the neck to apply slight pressure to jugular veins. Each subject will undergo repeat oto-acoustic measures both wearing the device and not wearing the device
41375391|NCT00916773|DEVICE|continuous positive airway pressure (CPAP)|CPAP of optimal pressure used during sleep for 3 months
41375392|NCT02294565|DRUG|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
41375393|NCT02294565|DRUG|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
41375394|NCT01737203|DRUG|Viagra|50 mg tablet on Day 1 of each period
41375395|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
41375396|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
41375397|NCT05428306|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)|Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
41375398|NCT05428306|DRUG|A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)|A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
41375399|NCT05428306|DRUG|A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)|A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
41375400|NCT05681299|DRUG|growth hormone and lirglutide|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
41033040|NCT06636370|DIAGNOSTIC_TEST|Contrast-enhanced mammography (CEM)|This intervention group receives supplemental screening with CEM after a negative screening result within the Dutch National Breast Cancer Screening program
41033041|NCT06636370|DIAGNOSTIC_TEST|Abbreviated MRI (AB-MRI)|This intervention group receives supplemental screening with AB-MRI after a negative screening result within the Dutch National Breast Cancer Screening program
41375401|NCT05681299|DRUG|growth hormone|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.
41375402|NCT05681299|DRUG|liraglutide|Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
41375403|NCT05681299|DRUG|Placebo|Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
41375404|NCT04895748|DRUG|DFF332|Hif2alpha inhibitor
41375405|NCT04895748|DRUG|RAD001|mTOR inhibitor
41375406|NCT04895748|DRUG|PDR001|anti-PD-1
41375407|NCT04895748|DRUG|NIR178|Adenosine A2A antagonist receptor
41505249|NCT00153972|DRUG|Cabergoline|
41033042|NCT00920426|DRUG|GSK1265744 30mg|GSK1265744 30 mg
41033043|NCT00920426|DRUG|Placebo|Placebo to match GSK1265744
41033044|NCT00920426|DRUG|GSK1265744 5mg|GSK1265744 5mg
41033045|NCT05501860|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
41033046|NCT05501860|DRUG|Placebo|Placebo Sterile Topical Ophthalmic Solution
41033047|NCT00374322|DRUG|lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
41033048|NCT00374322|OTHER|placebo|6 tablets daily for 12 months
41033049|NCT03447769|DRUG|Canakinumab|200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
41375408|NCT06540937|DRUG|Leflunomide Pill|This is a single-arm, single-center, phase II clinical study. Primarily evaluated in advanced MEN-1 neuroendocrine tumors. The initial efficacy of leflunomide tablets in second-line treatment provided evidence for phase III clinical trials.
41375409|NCT01656850|OTHER|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
41033050|NCT03447769|DRUG|Placebo|Placebo administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Placebo solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
41375410|NCT01656850|OTHER|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
41375411|NCT03521674|DEVICE|pregnancy termination|Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done
41375412|NCT04060901|BEHAVIORAL|CCSH Intervention for Teams|"CCSH Interventions for Teams will be a six session intervention. The groups meet once per week for 60 minutes for 4 weeks, coupled with 2 booster sessions over the following 2 months. Participants will receive the CCSH interventional approach, adapted for a group setting, which follows four stages: 1) Preparing the care responder; 2) Attuning to the Relationship; 3) Accessing Compassion, and 4) Entrusting the Careseeker.~The CCSH approach will be used to assess group dynamics, individual member sources of distress, as well as existing resources for resilience and compassion. Through the intervention, resources will then be identified and accessed in order to respond to team (and individual) sources of distress with greater resilience and increased compassion toward self and others. CCSH clinicians will utilize group process skills to encourage team communication about work-related challenges, enhance team cohesion, and enable interpersonal support among members of the team."
41375413|NCT02714140|BEHAVIORAL|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
41033051|NCT05759598|OTHER|Rehabilitation protocol + guided spontaneous breathing exercises|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises
41033052|NCT05759598|OTHER|Rehabilitation protocol + specific respiratory muscle training program|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects
41033053|NCT01691261|BIOLOGICAL|PF-05206388|PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.
41033054|NCT03859843|COMBINATION_PRODUCT|PRP|Ten mL of venous blood will be drawn in a syringe fill with 1.5 mL of anticoagulant solution (anticoagulant citrate dextrose solution formula A, Baxter, Deerfield, IL). The blood will be centrifuged at 160 g for 10 minutes. After the first spin, the lower red blood cell portion will be discarded, and the supernatant will be centrifuged at 400 g for 10 minutes. The resulting pellet of platelets will be mixed with 1.5 mL of supernatant, which make 1.5 mL of PRP. One mL of 3% calcium chloride will be added to the PRP to induce platelet activation.
41163854|NCT05692323|OTHER|PREHAB|6-week supervised PREHAB program. Each week of the program consists of 3 x 1 hour supervised training sessions made up of moderate intensity aerobic training and resistance training. In addition to the supervised sessions, patients will be instructed to accumulate a total of 150 minutes per week of moderate aerobic training at home which is measured by a wrist worn FitBit device.
41375414|NCT02714140|BEHAVIORAL|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
41375415|NCT02714140|BEHAVIORAL|Economic incentive|Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
41375416|NCT02714140|BEHAVIORAL|PB-HCT ++|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
41375417|NCT02714140|BEHAVIORAL|SMS Reminder|Participants will receive an SMS reminder to test.
41375418|NCT02936466|BEHAVIORAL|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :~* At least one connection per week during 4 weeks~* Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
41375419|NCT01815372|PROCEDURE|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
41375420|NCT01815372|PROCEDURE|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
41383549|NCT05649059|DRUG|Placebo|Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.
41383550|NCT00423501|DRUG|Placebo|sc weekly
41383551|NCT00423501|DRUG|taspoglutide|20mg sc weekly
41505250|NCT00153972|DRUG|Levodopa|
41375421|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
41375422|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
41375423|NCT00446134|DRUG|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
41375424|NCT00446134|DRUG|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
41375425|NCT02760849|OTHER|Laboratory Biomarker Analysis|Correlative studies
41375426|NCT02760849|PROCEDURE|Oophorectomy|Undergo ISDO
41375427|NCT02760849|OTHER|Quality-of-Life Assessment|Ancillary studies
41375428|NCT02760849|PROCEDURE|Salpingectomy|Undergo ISDO
41375429|NCT02760849|PROCEDURE|Salpingo-Oophorectomy|Undergo RRSO
41375430|NCT03107715|BEHAVIORAL|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
41375431|NCT03107715|BEHAVIORAL|Positive Messaging|iPad based behavioral intervention facilitated by researcher
41375432|NCT00186875|DRUG|Etoposide, cytarabine, vincristine, dexamethasone|See Detailed Description section for details of treatment interventions.
41375433|NCT00186875|DRUG|methotrexate, teniposide, PEG-asparaginase|See Detailed Description section for details of treatment interventions.
41375434|NCT00186875|DRUG|mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine|See Detailed Description section for details of treatment interventions.
41375435|NCT00186875|DRUG|L-asparaginase, erwinia asparaginase|See Detailed Description section for details of treatment interventions.
41033055|NCT03859843|OTHER|Chemical peeling (Salycilic acid)|SA is a 2-hydroxybenzoic acid (from willow tree) used for superficial peeling due to its strong keratolytic and comedo- lytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum.19 These chemical properties explain its popularity and success in acne patients.It also has well- documented anti-inflammatory properties.
41033056|NCT03859843|OTHER|Chemical peeling (Jessener's solution)|is a superficial peeling agent used as adjuvant therapy for acne. it is generally proposed to break of the hydrogen bonds of keratin (keratolysis), disruption of cell membranes (cell death) and is bactericidal.
41033057|NCT03174223|DRUG|deep neuromuscular block|a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
41033058|NCT03735732|BEHAVIORAL|prime|groups be confronted with health or palatability aspects of food items
41375436|NCT00186875|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
41375437|NCT00186875|PROCEDURE|Hematopoietic Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
41375438|NCT00186875|PROCEDURE|Natural Killer (NK) Cell Transplant|See Detailed Description section for details of treatment interventions.
41033059|NCT04969523|PROCEDURE|lobectomy|Intravenous es-ketamine 0.5mg/kg or saline during lobectomy
41033060|NCT03507166|DRUG|RC48-ADC|2 mg/kg IV every 2 weeks
41033061|NCT05797285|DEVICE|human keratin graft|The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
41375439|NCT01370291|OTHER|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
40850095|NCT02461940|BEHAVIORAL|Adolescent Behavioral Intervention|Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
40850096|NCT01195480|GENETIC|donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|All patients will be treated at the same total dose level of 2 x 10\^8/m2
40850097|NCT01195480|BIOLOGICAL|Irradiated donor-derived Lymphoblastoid Cell Line|"The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in \> 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10\^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion."
41033062|NCT05062928|OTHER|Virtual coach|This group will be trained and assessed by the virtual coach.
41163855|NCT01222078|BIOLOGICAL|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
41163856|NCT06369857|PROCEDURE|Pectopexy|Suspension of apical organs
41383552|NCT00423501|DRUG|taspoglutide|10mg sc every 2 weeks
41383553|NCT00423501|DRUG|taspoglutide|5mg sc weekly
41163857|NCT02664025|PROCEDURE|vaginal examination simulator|
41505251|NCT03474458|DRUG|Doxycycline|Doxycycline
41505252|NCT03474458|DRUG|Standard of care therapy|Standard of care therapy
41163858|NCT01002911|DRUG|Cefazolin, Bacitracin, Cefalexin|Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
41375440|NCT01370291|OTHER|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
41375441|NCT01370291|OTHER|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
41375442|NCT04985825|DRUG|Imgatuzumab|Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
41375443|NCT03290131|DRUG|Arbaclofen|Arbaclofen Extended Release Tablet
41375444|NCT03290131|DRUG|Placebo|Placebo comparator
41505253|NCT04683679|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for 3 doses
41505254|NCT04683679|DRUG|Olaparib|Olaparib will be administered twice daily continuously without breaks on a 21-day (3 week) cycle length, for a total of 2 cycles. Olaparib tablets will be administered bid (2 x 150 mg tablets twice daily; total 600 mg daily) on continuous days without interruption for 2 cycles. Each 3 week period constitutes one cycle.
41505255|NCT04683679|RADIATION|Radiation|The dose of radiation will be 8-9 Gy x 3 fractions. Radiation therapy will begin on C1D2-7. For tumors that are too large for this schedule, an accomodation of 30 Gy in 6 Gy per fraction is allowed, a schedule commonly used at MSK.
41163859|NCT01002911|DRUG|Cefazolin|Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
41163860|NCT02274623|DRUG|CTAP101 Capsules|escalating doses
41375445|NCT04410627|OTHER|HoPE Website|Educational website focused on hospice care
41375446|NCT03158857|DRUG|Sofosbuvir 400 mg|These drugs are being offered as part of routine care
41375447|NCT02696304|OTHER|Adipose tissu repartition|absorptiometry,
41375448|NCT02696304|OTHER|Visceral and liver adipose tissue repartition|MRI,spectroscopy,
41375449|NCT02696304|OTHER|Preadipocyte quantification and adipose tissue inflamation|biopsy
41375450|NCT02696304|OTHER|Inflamation blood markers quantification|blood drawn,
41375451|NCT00375024|PROCEDURE|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
41375452|NCT00375024|PROCEDURE|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
41505256|NCT01111825|DRUG|Temsirolimus|"28 day treatment cycle Phase 1~* Weekly intravenously (IV) on days 1, 8, 15, and 22~* Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~* Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~* HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22"
41505257|NCT01111825|DRUG|Neratinib|"28 day treatment cycle~• 240 mg orally daily"
41375453|NCT06124001|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.
41375454|NCT06124001|DRUG|camrelizumab for Injection|Administered once at 3 mg/kg intravenously on Days 8 of each cycle.
41375455|NCT02133911|DRUG|Ranolazine|
41375456|NCT03372018|BEHAVIORAL|Promotora-led Intervention (PLI)|Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
41375457|NCT03372018|BEHAVIORAL|Usual care (UC)|Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.
41375458|NCT03277859|BEHAVIORAL|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
41505258|NCT01194063|DRUG|Omega-3 fish oil lipid emulsion|daily intravenous administration of Omegaven fish oil emulsion
41505259|NCT04419012|OTHER|observation|observation
41505260|NCT03123276|DRUG|Pembrolizumab|humanized IgG4 PD-1 blocking antibody
41163861|NCT05367752|OTHER|Myofascial release with TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
41163862|NCT05367752|OTHER|Myofascial release without TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
41375459|NCT03957161|OTHER|Continuation of ACEi and/or ARBs|Patients will continue or start taking ACEi and/or ARBs
41375460|NCT04034875|OTHER|Questionnaire|questionnaire
41375461|NCT02985515|BEHAVIORAL|Smell training|Participants will be provided with 4 vials of essential odors. Participants will sniff each scent for 20-30 seconds, twice daily, for 12 weeks. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
41375462|NCT00152594|DRUG|voriconazole|
41375463|NCT06518057|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
41375464|NCT06518057|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
41375465|NCT06518057|OTHER|Electronic Health Record Review|Ancillary studies
41163863|NCT05367752|OTHER|Conventional TENS|Two 40\*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
41163864|NCT05367752|OTHER|Sham TENS|Two 40\*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
41163865|NCT01417702|DEVICE|High-definition white light endoscopy and i-Scan|Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
41163866|NCT06043453|OTHER|revitalization|The main idea behind revitalization is to firstly disinfect the root canal and subsequently attract or transplant mesenchymal stem cells from the (remaining) dental pulp and apical papilla (in case of immature permanent teeth) into the root canal. More specifically, this therapy is not based on mechanical and (aggressive) chemical debridement as in conventional root canal treatment but is supported by the pillars of tissue engineering: stem cells, growth factors and a scaffold .
41163867|NCT01315197|OTHER|Massage|Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
41163868|NCT01990664|DEVICE|senofilcon A|
41163869|NCT01990664|DEVICE|senofilcon A for Astigmatism|
41375466|NCT06518057|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
41375467|NCT06518057|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41375468|NCT06518057|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41375469|NCT06518057|RADIATION|Proton Beam Craniospinal Irradiation|Undergo proton CSI
41375470|NCT06518057|OTHER|Survey Administration|Ancillary studies
41375471|NCT06518057|RADIATION|Volume Modulated Arc Therapy|Undergo photon VMAT CSI
41375472|NCT01064869|BEHAVIORAL|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~1. A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~2. Motivational interviewing based on stages of change model to encourage change and adherence~3. Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
41375473|NCT04392791|OTHER|balneotherapy|Balneotherapy, a medical remedy, with medically and legally recognized mineral waters for therapeutic and rehabilitation purposes
41375474|NCT03361839|DIAGNOSTIC_TEST|endometrial biopsy|endometrial biopsy for genetic study of endometrial receptivity
41375475|NCT03236337|BEHAVIORAL|MOVI intervention|MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
41375476|NCT00592007|DRUG|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
41375477|NCT05278624|DRUG|Roflumilast Cream|Topical Cream
41505261|NCT03123276|DRUG|Gemcitabine|Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
41375478|NCT06510114|DRUG|methylprednisolone(daily scheme)|0.5 g methylprednisolone i.v. daily for 5 consecutive days, followed by oral prednisone for 6 months. Oral prednisone started at 40 mg/day for 4 weeks and then the dose was tapered by 5 mg/day every 2-4 weeks.
41375479|NCT06510114|DRUG|methylprednisolone(weekly scheme)|0.5 g methylprednisolone i.v. weekly for 6 weeks and then the dose was tapered by 0.25 g/week over the following 6 weeks.
41375480|NCT02508649|DRUG|selepressin|
41375481|NCT02508649|DRUG|placebo|
41375482|NCT04216953|DRUG|Cobimetinib|"Adults: 20mg film coated tablet~Paediatrics:~i) powder for oral suspension containing 250mg of cobimetinib~ii) for pediatric patients ≥12 years-old and with a BW ≥60kg : 20mg film coated tablet same as adults"
41375483|NCT04216953|DRUG|Atezolizumab|20-mL glass vial containing 1200 mg of atezolizumab.
41375484|NCT04984694|BEHAVIORAL|Computerized virtual reality training programs group (Hot-Plus group)|"In this study, the investigators utilised interactive-video games called Xavix Hot Plus(Hot-plus, Shinsedai\[SSD\] Co. Ltd, Shiga Japan), which was designed specifically for rehabilitation and reported high participant motivation and enjoyment while playing."
41375485|NCT04984694|BEHAVIORAL|Social interaction group|The social interaction group will get together as a group for social interaction one hour weekly for 12 weeks.
41375486|NCT00953017|DRUG|Miralax (PEG 3350)|Miralax 255gm bottle
41375487|NCT00953017|DRUG|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
41375488|NCT00953017|DRUG|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
41375489|NCT00953017|DRUG|Golytely (polyethylene glycol)|Golytely 1 gallon
41033063|NCT05935540|OTHER|ACP-Family|"It consists of two sessions (45-60 mins) to be delivered within one month in a face-to-face format as long as the patient is still in the hospital. The treatment will be continued in the patient's home if he/she is discharged before the two sessions are completed.~The treatment will cover five elements in ACP, namely (1) patients' understanding of their illness, (2) patients' values and beliefs underpinning care preferences, (3) possible health conditions in the future, (4) introducing the idea of AD and its arrangement, and (5) construction of the role of substituted decision maker. A 3-min video on end-of-life treatment options will be shown to help patients and family members to clearly understand the related topic. However, there will be no restriction on the order of the five topics to be discussed during the intervention."
41033064|NCT04829838|DRUG|intravenous levetireacetam|phenytoin is considered as control drug in the study
41033065|NCT06177457|DRUG|PF-07293893|PF-07293893 will be administered as tablets every day (QD) over 14 days
41375490|NCT02676271|PROCEDURE|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
41375491|NCT06026969|OTHER|Neurodevelopmental assessments and follow-up|All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
41375492|NCT01018680|DRUG|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
41375493|NCT01018680|DRUG|Placebo|Taken by mouth, once daily for 10 weeks
41033066|NCT06177457|DRUG|Placebo|Placebo will be administered as tablets; QD over 14 days
41033067|NCT06177457|DRUG|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07293893
41375494|NCT03936946|BEHAVIORAL|Audio Content 1|\~30 minute daily audio recordings of content 1 for 28 days
41375495|NCT03936946|BEHAVIORAL|Audio Content 2|\~30 minute daily audio recordings of content 2 for 28 days
41033068|NCT05006625|OTHER|Collaborative Care Model|Use of the collaborative care model to screen and deliver care for depression in adolescents and young adults aged 15-24 years seeking HIV prevention and treatment services
41033069|NCT05272826|DRUG|Iberdomide|Available as formulated capsules and administered as oral medication
41375496|NCT04353115|DEVICE|Training with Serious game|training the gaze stability with a serious game, 20 minutes a day, 2 days a week for 5 weeks in the presence of a doctor or physiotherapist, at the hospital to avoid addiction at home.
41375497|NCT00437294|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease
41375498|NCT00437294|DRUG|placebo|oral, daily, 21-day cycles until progressive disease
41375499|NCT00437294|DRUG|capecitabine|1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease
41375500|NCT05417477|DEVICE|use of an e-health application|Use of the e-health application throughout the duration of the study combined with the usual management of the disease and 20 physiotherapy sessions.
41375501|NCT03232775|OTHER|Treatment: Physical Exam with Visual Pedagogy and Structure|Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
41375502|NCT03232775|OTHER|Control: Physical Exam without Visual Pedagogy and Structure|Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
41383554|NCT00423501|DRUG|taspoglutide|10mg sc weekly
41383555|NCT00423501|DRUG|taspoglutide|20mg sc every 2 weeks
41383556|NCT06567457|BIOLOGICAL|SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19|intramuscular injection
41375503|NCT03891602|BEHAVIORAL|Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)|Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
41375504|NCT03891602|BEHAVIORAL|Patient Trust in the Medical|"Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84."
41375505|NCT03891602|BEHAVIORAL|Decision Conflict Scale (DCS) - Lung Cancer Screening|"The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict."
41375506|NCT03891602|BEHAVIORAL|Shared Decision Making Questionnaire (SDM-Q)- Patient|"Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94."
41375507|NCT03891602|BEHAVIORAL|Stage of Readiness for Smoking Cessation - Contemplation Ladder|Among current smokers
41375508|NCT03891602|BEHAVIORAL|Primary Care Clinicians' Lung Cancer Screening Survey|Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
41375509|NCT01075126|DRUG|Depakote|
41375510|NCT01075126|DRUG|Lithium|
41375511|NCT05365776|BEHAVIORAL|Graded Exposure Therapy|Graded exposure therapy is delivered by a psychologist over 12 individual (1:1) secure videoconference sessions. The core active ingredient is graded situational exposure to foster habituation and challenge beliefs that the avoided activities are dangerous. Homework exercises involve planned exposure exercises in the home and community to support generalization.
41375512|NCT05365776|BEHAVIORAL|Prescribed aerobic exercise|Participants will be asked to complete 30 minutes of aerobic exercise on 5 days/week for a 12-week period. Participants select the mode (e.g., swimming, jogging, bicycling) and location of exercise (e.g., outdoors, a gym or community centre, at home). The initial exercise intensity target will be based on the Buffalo Concussion Bike Test. The target progression will be 3-5 beats per minute every two weeks.
41375513|NCT05365776|OTHER|Enhanced usual care|Usual care (education about concussion from the website: concussion.vch.ca/) will be enhanced through email message support.
41375514|NCT05866614|DRUG|Remsima IV|Patient will be treated with Remsima IV as per the SmPC or
41375515|NCT05866614|DRUG|Remsima SC|Patient will be treated with Remsima SC as per the SmPC
41375516|NCT05263869|DRUG|MRG002|Administrated intravenously
41375517|NCT05018533|DRUG|TAKC-02|Inhalation Solution
40850098|NCT05118334|DRUG|Sintilimab|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
41033070|NCT05272826|DRUG|Bortezomib|Administered as subcutaneous injection
41033071|NCT05272826|DRUG|Dexamethasone|Administered as oral medication
41033072|NCT05272826|DRUG|Isatuximab|Administered as subcutaneous injection
41033073|NCT03843918|DRUG|LAE001|LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
41033074|NCT02208180|BEHAVIORAL|Return of genomic results on cardiovascular disease risk|"Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study."
41375518|NCT05018533|DRUG|Placebo|Inhalation Solution
41375519|NCT01484717|BEHAVIORAL|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
41375520|NCT01484717|DRUG|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].
40850099|NCT05118334|DRUG|IBI310|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
41033075|NCT01408160|DRUG|Cytarabine|Given IV
41033076|NCT01408160|BIOLOGICAL|Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Given IV
41375521|NCT01484717|BEHAVIORAL|Telephone counseling|Participants receive brief twice weekly telephone counseling.
41375522|NCT01725100|DRUG|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
41375523|NCT01725100|DRUG|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
41505262|NCT00486031|DRUG|Balsalazide Disodium|
41033077|NCT01408160|OTHER|Laboratory Biomarker Analysis|Correlative studies
41033078|NCT01408160|OTHER|Pharmacological Study|Correlative studies
41033079|NCT03348254|DRUG|Single shot antibiotic prophylaxis|single shot preoperative antibiotic prophylaxis
41375524|NCT04190251|OTHER|Inteprofessional medication adherence support program (IMAP)|In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.
41375525|NCT00285012|DRUG|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
41375526|NCT00285012|DRUG|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
41375527|NCT02599298|DEVICE|Continuous Positive Airway Therapy|
41505263|NCT01823601|BEHAVIORAL|Behavioral Management Program|Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
41505264|NCT01823601|BEHAVIORAL|Seminars in Health|Volunteers that participate in 10 weekly sessions of seminars in health
41375528|NCT02599298|BEHAVIORAL|Sleep-Study Guided Multidisciplinary Therapy|
41375529|NCT03916055|BEHAVIORAL|Exposure and response prevention (ERP)|"The intervention consists of 10 modules/chapters for children/adolescents, delivered over 10. Each of the 10 modules includes age-appropriate texts, animations and exercises. The intervention is primarily based on ERP techniques. During the treatment, participants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their caregiver/parent, the participant is instructed to provoke premonitory urges (a sensation usually felt before a tic is expressed), while still suppressing tics, which is known as 'exposure'.~The parent is provided with her/his own separate login to the internet platform, which consists of 10 separate modules/chapters. The parent intervention consists mainly of information regarding parent coping strategies, social support and functional analysis relating to tics. Both the child/adolescent and the parent have individual access to the same therapist."
40850100|NCT00406679|DRUG|Paracetamol (acetaminophen) solution experimental|1 gm IV
41383557|NCT06567457|BIOLOGICAL|SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19|intramuscular injection
40850101|NCT00406679|DRUG|paracetamol (acetaminophen) solution commercial|1 gm IV
40850102|NCT00406679|DRUG|placebo|equivalent volume IV 0.9% sodium chloride (equivalent volume)
40850103|NCT01959438|DRUG|Sodium selenite (Introselen)|Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
40850104|NCT01959438|DRUG|Sodium selenite|Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
40850105|NCT04676035|DRUG|Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680|"* Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~* Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27"
41383558|NCT00897039|OTHER|flow cytometry|
40850106|NCT02333786|OTHER|Long-axis/in-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
40850107|NCT02333786|OTHER|Short-axis/out-of-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
40850108|NCT02237755|DRUG|Clomiphene citrate|clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
40850109|NCT02237755|DRUG|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
40850110|NCT05745519|OTHER|Pittsburgh sleep quality index (PSQI)|The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in general people.
40850111|NCT05745519|DEVICE|ANSWatch|Measure eight physiological parameters including heartbeat, systolic blood pressure, diastolic blood pressure, heart rhythm variability HRV, low frequency component LF, high frequency component HF, LF/HF low frequency high frequency component ratio, and irregular heartbeat within five minutes
41505265|NCT03203850|DRUG|Deferasirox FCT|Taken orally once per day (QD) as a film coated tablet (FCT)
40850112|NCT06584318|OTHER|Intermittent hypoxia intervention|The intermittent hypoxia protocol refers to 6 cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
40850113|NCT02505113|DRUG|Montelukast|Montelukast (10mg, q.d., p.o.)
41505266|NCT03203850|PROCEDURE|Phlebotomy|according to investigator's decision
41505267|NCT04274231|GENETIC|different effection|Analysis of the reasons for treatment
41505268|NCT00683345|DRUG|Anakinra|Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
41375530|NCT03916055|BEHAVIORAL|Education on tics|"The active comparator is designed to match the experimental intervention in all aspects except for the module content (same platform, same treatment length, same therapist support etc.). The intervention consists mainly of psychoeducational information about TD/PTD and common comorbid conditions, and reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors, strategies for describing tics to other people, among others. Problem-solving and development of expertise in tic disorders is emphasised. The intervention does not include any information on ERP or functional analysis and interventions.~As in the experimental intervention, the parent is provided with her/his own separate login to the internet platform. The parent intervention consists mainly of information regarding parent coping strategies and social support. Both the child and the parent have individual access to the same therapist."
41033080|NCT03348254|DRUG|Multiple shot antibiotic prophylaxis|Multiple shot perioperative antibiotic prophylaxis
41033081|NCT01089972|DEVICE|22 gauge catheter|radial artery cannulation using 22 gauge catheter
41375531|NCT03423914|BEHAVIORAL|Expressive writing|The emotional or expressive writing therapy developed by James Pennebaker has been used as a method of self-understanding in people with high levels of stress, chronic diseases, sexual and physical abuse, natural disasters and job loss, among others. Expressive writing allows and implies revealing the deepest thoughts and feelings of the person about a stressful or traumatic event in life translate emotions into words, and with that, reduce mental stress (decrease in levels of depression, stress and anxiety), strengthen self-esteem and even strengthen the immune system
40850114|NCT06347263|OTHER|Entire papilla preservation technique|Minimally invasive periodontal surgery
41033082|NCT01089972|DEVICE|20 gauge catheter|radial artery cannulation using 20 gauge catheter
41033083|NCT05467553|DRUG|Ursodeoxycholic acid|Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
41033084|NCT05467553|DRUG|Ropeginterferon alfa-2b|P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
41033085|NCT05467553|DRUG|Tenofovir Alafenamide|TAF 25 mg PO QD for 60 weeks
41033086|NCT03759873|BEHAVIORAL|Incentives|Patient earns financial incentives (gift cards) on an escalating schedule for completing cardiac rehabilitation sessions.
41033087|NCT03759873|BEHAVIORAL|Case Management|A case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as to provide advice about cardiac symptoms and healthy behavior change.
41033088|NCT06635720|DRUG|Prednisone|This study will compare two steroid dosing protocols for the treatment of childhood nephrotic syndrome relapses. The medications used for both intervention and control arms are oral prednisone 5mg tablets (DIN: 00312770) for children able to swallow or use crushed tablets, or oral prednisolone sodium phosphate 5mg base/5mL liquid (DIN: 02245532). Participants hospitalized after study enrollment will be permitted to switch to intravenous methylprednisolone sodium succinate (DIN: 02367955) at the same dose without being considered to have violated their treatment assignment.
41033089|NCT00467870|DRUG|Testosterone Undecanoate 750 mg|
41033090|NCT00467870|DRUG|Testosterone Undecanoate 1000 mg|
41375532|NCT03423914|OTHER|Only Writing|Participants write about knowledge related to infant care during four days
41505269|NCT00683345|DRUG|Placebo|Saline 0.67 ml daily subcutaneously as placebo drug.
41505270|NCT02382861|DEVICE|Neurally adjusted ventilatory assist|In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
41505271|NCT02382861|DEVICE|Noninvasive pressure support ventilation|In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
40850115|NCT04255641|OTHER|time lapse analysis|grading of the embryos before freezing using time lapse/
40850116|NCT01202630|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285® and Lactobacillus casei|2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
41033091|NCT00378417|BIOLOGICAL|7-valent pneumococcal-CRM197 conjugate vaccine|
41033092|NCT00378417|BIOLOGICAL|7-valent pneumococcal-OMPC conjugate vaccine|
41033093|NCT05207059|BEHAVIORAL|HELMS Lifestyle Intervention|The HELMS life-course Interventions, namely 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management'), are developed to deliver care throughout the journey from preconception to postpartum periods. Screening involves health and risk assessments through physical and biomarker measurements, as well as emotion and sleep evaluations for mother, and developmental assessment for children. Body Size management encompasses education on weight status awareness and mother-child health implications, both mother-child weight tracking, healthy eating and physical activity guidance. Supplementation includes multi-micronutrient, vitamin D, calcium and/or Docosahexaenoic acid (DHA) supplements, which is phase-specific for mother, and vitamin D drops supplement for child. Specific case management comprises preconception sexual health and function management, pregnancy symptoms management, postpartum recovery management, infant growth monitoring and feeding management.
41033094|NCT05929833|BEHAVIORAL|BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery)|The six components of BETTER include: 1) assessment of patient/family needs and referral to community-based resources; 2) patient goal setting and review of goals; 3) health care coordination; 4) availability of clinical interventionist to patient/family; 5) training on self- and family-management and brain injury coping skills; and 6) warm hand off/referral to the state-affiliated Brain Injury Association at the end of the intervention for additional resources.
41033095|NCT05929833|OTHER|Usual Care|Usual care discharge planning process and follow up (e.g., verbal and written discharge instructions, with guidance on medications, outpatient therapy, and follow-up appointments)
41033096|NCT01889537|BEHAVIORAL|Virtual Reality|The patient will receive virtual reality during a burn care procedure
41033097|NCT03358667|PROCEDURE|augmentation peri-implant soft tissue|the implant was cover with a 2 mm cover screw for a tent effect or with a dermal membrane after implant insertion
41033098|NCT05378399|DRUG|Descovy or Truvada|Descovy or Truvada prescribed with digital pills for PrEP
41033099|NCT05378399|DEVICE|ID-Cap System|Digital pills overencapsulating Descovy or Truvada for PrEP
41505272|NCT02121873|DEVICE|Nipple aspirator|The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.
41505273|NCT02121873|DEVICE|Ductal lavage microcatheter|Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.
41163870|NCT04420741|DRUG|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
41375533|NCT03296267|PROCEDURE|Gastroduodenoscopy|Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
41375534|NCT00924313|DRUG|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
41375535|NCT00860054|DIETARY_SUPPLEMENT|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
41375536|NCT04130477|DEVICE|Tunnel attachments and light Nickel Titanium wire|Tunnel attachments planned virtually and light Nickel Titanium wire
41375537|NCT04130477|DEVICE|Clear Aligner therapy|Clear Aligner therapy
41375538|NCT03117972|DRUG|FOLFOXIRI|12 cycles
41375539|NCT03117972|DRUG|FOLFOX|12 cycles
41375540|NCT03117972|DRUG|FOLFIRI|12 cycles
41505274|NCT02121873|DEVICE|Blood draw|Blood will be drawn and immediately processed for shipping to Covance for WGS.
41505275|NCT04701164|DRUG|ANX005|Solution for intravenous infusion
41375541|NCT03117972|DRUG|Bevacizumab|12 cycles
41375542|NCT03117972|DRUG|LV5FU2|Maintenance chemotherapy
41375543|NCT03117972|DRUG|Capecitabine|Maintenance chemotherapy
41375544|NCT01814917|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
41375545|NCT01814917|DRUG|CBPB|
41375546|NCT04555772|OTHER|factors evaluation|They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
40850117|NCT01202630|DIETARY_SUPPLEMENT|Placebo|2 capsules of placebo (no live cells), consumed once daily for 60 days
41375547|NCT01145573|DIETARY_SUPPLEMENT|Calcium or Placebo|Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
41375548|NCT01969201|DRUG|Urofollitrophin|
41375549|NCT01969201|DRUG|Follitrophin alpha|
41375550|NCT05981365|DRUG|Voxelotor|Drug drug interaction
41375551|NCT05981365|DRUG|Bupropion|Drug drug interaction
41505276|NCT04701164|DRUG|Placebo|Solution for intravenous infusion
40850118|NCT01557907|DEVICE|Subcutaneous delivery via Medtronic Quick-Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
41375552|NCT05981365|DRUG|Repaglinide|Drug drug interaction
41375553|NCT05981365|DRUG|Flurbiprofen|Drug drug interaction
40850119|NCT01557907|DEVICE|Intradermal delivery via the BD Research Catheter Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
41163871|NCT04420741|DRUG|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
41375554|NCT05981365|DRUG|Omeprazole|Drug drug interaction
41375555|NCT05981365|DRUG|Midazolam|Drug drug interaction
41375556|NCT05981365|DRUG|Metformin|Drug drug interaction
41375557|NCT05981365|DRUG|Furosemide|Drug drug interaction
41375558|NCT05981365|DRUG|Rosuvastatin|Drug drug interaction
41375559|NCT02027766|OTHER|Calf muscle stretching|
41375560|NCT03146819|DEVICE|iTotal PS Knee Replacement System|Total Knee Replacement systems (Patient Specific)
41375561|NCT03146819|DEVICE|Off-the-Shelf Knee Replacement System|Total Knee Replacement systems (Off-the-shelf)
41375562|NCT04859959|DIAGNOSTIC_TEST|Gallium-68 Pentixafor PET/CT|Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
41375563|NCT01081431|DRUG|Lenalidomide|10 mg d1-d21 of a 28-day cycle
41375564|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose A|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
41375565|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose B|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
41375566|NCT06264765|OTHER|scalp block|The scalp block will be performed by the anesthesiologist 10 minutes before the pin head holder application (PHHA). Supraorbital and supratrochlear nerves will be blocked bilaterally with 6 ml of 0.5% bupivacaine injected vertically into the skin above the eyebrow midline. Auriculotemporal nerves will be blocked bilaterally by injecting 4 ml of 0.5% bupivacaine 1.5 cm anterior to the ear at the tragus level. The needle will be inserted perpendicular to the skin and the fascia will be injected deeply and superficially while the needle is withdrawn. Postauricular branches of the greater auricular nerves will be blocked bilaterally with 2 ml of 0.5% bupivacaine injected 1 cm posterior to the ear, between the bone and skin, at the level of the tragus. The greater, lesser, and third occipital nerves run along the upper nuchal line approximately halfway between the occipital prominence and the mastoid prominence.
41375567|NCT06264765|OTHER|Incisional infiltration|Incisional infiltration: 20 ml of 0.5% bupivacaine will be infiltrated by the surgeon into the PHHA points and surgical incision areas 10 minutes before PHHA. Two
41375568|NCT06116799|DEVICE|Orthotic|Arch support orthotic
41383559|NCT00897039|OTHER|immunohistochemistry staining method|
41383560|NCT05672225|DRUG|Dexmedetomidine|Dexmedetomidine 0.2mcg/kg/hr (2ml/hr) administration via continuous channel in the experimental group
41505277|NCT01386983|DRUG|5ARI|Dutasteride or Finasteride
41505278|NCT01386983|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
41375569|NCT05965232|DIAGNOSTIC_TEST|Fibroscan|"Performing FibroScan :~The patient is positioned supine, with the right arm in maximum abduction to clear the intercostal spaces.The measurement itself is performed on the right lobe of the liver via the intercostal (intersection of the mid-axillary line and the xiphoid process) using a dedicated probe (3.5 MHz) after application of a conduction gel to the skin. FibroScan® examinations are carried out by personnel trained in the use of the device.This training is specific and validated by the device's manufacturer manufacturer, EchosensTM (Paris). Ten valid measurements at the same measurement point in the right liver must be be performed, with an interquartile range/median ratio ≤ 30 (required only if the elastometry value is \> 7.1 KPa."
41375570|NCT05090046|OTHER|Trauma exposure|Exposure to the Canterbury earthquake sequence and other relevant psychological trauma
41375571|NCT00561600|DEVICE|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
41375572|NCT00561600|DEVICE|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
41375573|NCT00453336|DRUG|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
41375574|NCT00453336|PROCEDURE|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
41375575|NCT04478994|BIOLOGICAL|TEPEZZA|TEPEZZA is a fully human anti-IGF-1R mAb. TEPEZZA will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of TEPEZZA must be reconstituted with 10 mL of water for injection. Reconstituted TEPEZZA solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. TEPEZZA will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
41375576|NCT04478994|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
41375577|NCT02619370|BEHAVIORAL|Conversation card game|
41375578|NCT02619370|BEHAVIORAL|Active Control|
41375579|NCT02702375|OTHER|Fructose-containing Sugars|
41375580|NCT02648646|OTHER|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
41505279|NCT02754856|BIOLOGICAL|Durvalumab|Given IV
41375581|NCT04785651|DRUG|Tibial osteotomy with Tranexamic acid|"Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure."
41375582|NCT04785651|PROCEDURE|Tibial osteotomy without Tranexamic acid|Patients in this arm will undergo to the tibial osteotomy procedure as by clinical practice
41375583|NCT00988039|DRUG|Aluvia + 2NRTIs|"Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy."
41375584|NCT00988039|DRUG|Aluvia + raltegravir|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily"
41375585|NCT00988039|DRUG|Aluvia monotherapy|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily for the first 12 weeks only"
41375586|NCT01082601|PROCEDURE|Pulmonary Vein Isolation (PVI)|Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
41375587|NCT04366115|DRUG|AVM0703|Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
41375588|NCT04366115|DRUG|Placebo|Single IV infusion in normal saline over 1 hour to patients.
41375589|NCT01246102|DRUG|AT13387|Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
41505280|NCT02754856|OTHER|Laboratory Biomarker Analysis|Correlative studies
41163872|NCT05510739|BEHAVIORAL|Motor-cognitive home exercise supported by eHealth technology|10-week, individualized and progressive exercise program targeting functional strength, cardiovascular fitness and physical activity levels. Cognitive exercises are incorporated with motor exercises as an adjunct to the intervention.
41505281|NCT02754856|PROCEDURE|Therapeutic Conventional Surgery|Undergo liver surgery
41505282|NCT02754856|BIOLOGICAL|Tremelimumab|Given IV
41505283|NCT05122559|DRUG|N-acetyl cysteine|N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.
41505284|NCT05122559|DRUG|Placebo|Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF
41505285|NCT02075307|DIETARY_SUPPLEMENT|Blueberry Powder|
41505286|NCT02075307|DIETARY_SUPPLEMENT|Placebo|
41505287|NCT05847829|DEVICE|T-REEX algorithm|Phase locked transcranial stimulation.
41505288|NCT03306446|DRUG|Start adalimumab in monotherapy|Discontinuation of Adalimumab in patients who achieved deep remission
40850120|NCT00855049|DRUG|Acetaminophen|Intranasal acetaminophen administration
40850121|NCT00855049|DRUG|Acetaminophen|Oral acetaminophen administration
41375590|NCT05368376|DRUG|Labetalol Hydrochloride Oral Tablet|Labetalol 200 mg
41375591|NCT05368376|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol 100 mg
40850122|NCT02483117|OTHER|Adaptation of the CIA|Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
40850123|NCT00441805|DEVICE|Radio Frequency|
40850124|NCT06523244|PROCEDURE|PHOTODYNAMIC THERAPY|Respective photosensitive dye solution is applied on to the surgical site, including all the root surfaces. Vacuum suction is used to remove the excess dye from the site and to prevent ingestion of the dye solution The dye is activated with 810nm diode laser with continuous wave frequency and power of 0.3 W with 400 µm fiber tip for 20 seconds/spot. After this, the area is irrigated with saline.
40850125|NCT01108198|DRUG|Mometasone furoate cream|Study cream was applicated once per day for 4-8 weeks.
40850126|NCT01108198|DRUG|moisturizing cream|study cream was applicated once per day for 4 to 8 weeks
40850127|NCT05557305|DEVICE|Videogame therapy|There will be 5 video game-type applications for virtual therapy, each with a specific therapeutic objective, which will be administered by trained personnel, depending on the characteristics of each patient.
40850128|NCT05557305|OTHER|Conventional therapy|Occupational therapy with different play materials
40850129|NCT05018663|OTHER|Artificial Intelligence software ROSE|Rapid on-site evaluation (ROSE) of Endoscopic Ultrasound (EUS) guided FNA/FNB (Fine Needle Aspirate/Fine Needle Biopsy) of pancreatic solid lesions (PSLs) has been shown in improve diagnostic yield. The availability and performance of ROSE at EUS performing centers is variable. With strides in Artificial Intelligence (AI) capabilities over the years, the University of Texas at Health Sciences Center at Houston in collaboration with Haystac is developing an artificial intelligence based proprietary system to analyze slides from EUS FNA/FNB samples at bedside.
40850130|NCT02848391|OTHER|Environmental|hypobaric flight simulation
40850131|NCT03752749|OTHER|Prednisolone + Acute Intermittent Hypoxia|Administration of oral prednisolone followed by 15, 60-second bouts of mild hypoxia
40850132|NCT03752749|OTHER|Placebo + Acute Intermittent Hypoxia|Administration of oral matching placebo followed by 15, 60-second bouts of mild hypoxia
40850133|NCT03637517|DRUG|DSM265-TPGS 34% SDD, 400 mg fasted|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.
40850134|NCT03637517|DRUG|DSM265-TPGS 34% SDD, 400 mg fed|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.
40850135|NCT03637517|DRUG|DSM265 25% SDD, 400 mg fasted|Reference formulation used in early clinical trials.
40850136|NCT00241592|DRUG|Cannabis|
40850137|NCT01112748|DRUG|Topical lidocaine patch|Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.
41033100|NCT05378399|DEVICE|Beiwe|Digital phenotyping app
41375592|NCT01261962|DIETARY_SUPPLEMENT|zinc|zinc sulfate, 35 mg twice daily for 4 months
41375593|NCT01261962|OTHER|Placebo|Placebo, One capsule, twice daily for 4 months
41375594|NCT02059681|OTHER|Autologous bone marrow derived-CD133+ cells|Cell therapy
41375595|NCT06107465|DRUG|Nitroglycerin|high dose Nitroglycerin
41375596|NCT04240665|BEHAVIORAL|Digital Memory Notebook (DMN) Application|Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
41375597|NCT01830712|DRUG|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
41375598|NCT03359499|DRUG|Bacillus clausii|Oral suspension administered BID
41375599|NCT03359499|DRUG|Trimebutine|One tablet of 200 mg of trimebutine administered BID
41375600|NCT04945226|DRUG|Finasteride 1mg Tablet|Propecia Tablet 1mg
41375601|NCT04945226|DRUG|IVL3001|Finasteride long acting injection
41375602|NCT06038370|BEHAVIORAL|Self-induced cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
41375603|NCT04067505|DRUG|Rivaroxaban|Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral
41375604|NCT04067505|DRUG|Warfarin|Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral
41375605|NCT04067505|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
41375606|NCT02879552|PROCEDURE|Traditional upper blepharoplasty|The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.
41375607|NCT02879552|PROCEDURE|Brassiere suture with blepharoplasty|"Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues."
41375608|NCT00363272|DRUG|ispinesib|Given IV
41505289|NCT06432374|BEHAVIORAL|WET|"The five weekly WET sessions were delivered online via Canvas. Five session modules were created, each containing writing instructions for the respective session and an assignment feature for participants to upload their narratives. All sessions included 30 minutes of writing. Following instructions, participants wrote about a specific work-related trauma event in detail and described the emotions and thoughts experienced during the event. While all sessions were self-paced, participants were advised to complete each subsequent session within one week. Participants had the option to self-administer sessions or participate in Zoom office hours for live writing sessions with a facilitator who had completed WET training providing the writing instructions."
41505290|NCT01059578|DRUG|GSK206136|GSK206136 2mg, 10mg, 50mg, 100mg capsule
41505291|NCT01059578|DRUG|PLACEBO|Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
40850138|NCT02624427|DEVICE|Measurement of intraocular pressure (IOP)|Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
41033101|NCT04757753|DEVICE|ready-to-use root canal sealer: PA1704|The participant will be treated with the ready-to-use root canal sealer (PA1704) in combination with gutta percha.
41033102|NCT04757753|DEVICE|root canal sealer: BioRoot™ RCS|The participant will be treated with BioRoot™ RCS sealer in combination with gutta percha.
41375609|NCT00363272|OTHER|laboratory biomarker analysis|Correlative studies
41375610|NCT00363272|OTHER|pharmacological study|Correlative studies
41375611|NCT00618800|BEHAVIORAL|Pharmaceutical Care|Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
41375612|NCT00618800|OTHER|Written Materials|Participants receive written information about falls prevention.
41375613|NCT05270772|BIOLOGICAL|CAR-T-19 Cells|T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10\^6/kg,1.5×10\^6/kg, 5.0×10\^6/kg CAR+ cells.
41375614|NCT04596618|DEVICE|Forearm cooling|forearm cooling will be performed for active cooling assessment.
41375615|NCT01905891|PROCEDURE|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
41375616|NCT04116307|DIETARY_SUPPLEMENT|Polymethylsiloxane|
41375617|NCT04116307|DIETARY_SUPPLEMENT|Lactobacillus reuteri|
41375618|NCT06428734|DIAGNOSTIC_TEST|hydrocephalus group|Diagnostic Test: high throughput sequencing and electromyography Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
41505292|NCT01059578|RADIATION|PET|Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
41505293|NCT02058329|OTHER|Home Visit|A geriatric fellow will conduct a comprehensive in hospital post discharge assessment of hip fracture patients discharged to home in the intervention group.Follow up home visits will occur at 1,3 and 6 months post discharge.Any problems will be referred to the patient's primary care physician.
41505294|NCT04284540|RADIATION|Adjuvant hypofractionation|15 fractions of 2.7 Gy per fraction daily over 3 weeks for a total of 40.5 Gy to the post-operative bed and/or necks.
41505295|NCT04284540|RADIATION|Definitive Hypofractionation|15 fractions of 3 Gy per fraction daily over 3 weeks for a total of 45 Gy to regions of gross disease. Elective areas can be treated to 37.5 Gy in 15 fractions.
41505296|NCT02460146|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
41505297|NCT02460146|OTHER|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
41505298|NCT03638726|DRUG|Atropine sulfate and epinephrine|Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.
41505299|NCT03638726|DRUG|Topical cyclopentolate and phenylephrine|Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.
41505300|NCT03551288|DRUG|SUVN-911|Tablet
40850139|NCT04186338|DEVICE|Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)|All participants were instructed to wear monitors for five consecutive days except during water-based activities. Data for each participant was collected to ensure included three valid weekdays. Daily activity energy expenditure (kcal/kg/min), and sedentary, light, moderate and vigorous levels (min) were examined using a software program.
40850140|NCT01521377|DRUG|Placebo Moxifloxacin|Single dose placebo oral tablet Moxifloxacin
40850141|NCT01521377|DRUG|Moxifloxacin|Single oral dose tablet Moxifloxacin (400mg)
40850142|NCT01521377|DRUG|GSK573719/Vilanterol 125/25mcg|Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
40850143|NCT01521377|DRUG|GSK573719|Single inhalation from GSK573719 500mcg DPI once daily
40850144|NCT01521377|DRUG|GSK573719/Vilanterol 500/100mcg|Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
40850145|NCT01521377|DRUG|Placebo DPI|Single Inhalation from matching Placebo DPI once daily
41375619|NCT06428734|OTHER|normal group|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
41375620|NCT01148875|BEHAVIORAL|Mammography appointment reminders; telephone counseling|Women randomly assigned to UCR, EAPR, ELR; repeated 4 times at yearly intervals. Using claims data, supplemented by self-report, verified if women had recent mammograms. Women who remained non-adherent after reminders received Barriers-Specific Telephone Counseling Call, or an enhanced call including focus on either positive or negative consequences of getting/not getting mammograms. Prior to calls, women in each of the three phone counseling groups received priming letters to prime them to process information in the call. Priming letters should prepare women to process information from subsequent counseling calls more deeply by focusing on the positive or negative consequences of getting/not getting mammograms or on identifying and overcoming their own barriers to being screened.
40850146|NCT04236739|DRUG|Instant MSC Product accompanying Autologous Chondron Transplantation|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) in the cartilage defect of the knee during one surgical procedure.
40850147|NCT06261359|DRUG|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
40850148|NCT06261359|DRUG|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
40850149|NCT06261359|DRUG|Nab paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
40850150|NCT05615740|DIAGNOSTIC_TEST|Optical coherence tomography (OCTA)|OCTA can detect the passage of individual blood elements (mostly erythrocytes) through capillaries and larger vessels in real-time
41375621|NCT00004454|GENETIC|lymphocyte gene therapy|
40850151|NCT02870530|PROCEDURE|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
40850152|NCT04487925|DRUG|A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation|CFA will be administered in combination with Follitropin beta.
40850153|NCT04487925|DRUG|Up to three modified natural cycles with Follitropin beta.|Follitropin beta in a low dose will be given.
40850154|NCT03265457|OTHER|Specular microscopy|Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group
40850155|NCT04536207|OTHER|Cryotherapy (apparatus)|Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
40850156|NCT02406105|RADIATION|Radiosurgical thalamotomy|Cybernetic microradiosurgery based thalamotomy
40850157|NCT02406105|DRUG|CyberKnife|
40850158|NCT02661867|BEHAVIORAL|delivery|delivery either vaginal or by cesarean section
40850159|NCT06402032|OTHER|Hesperidin|Hesperidin is a natural flavonoid with well-known of its anti-inflammatory properties in many disease. Hesperidin in previous studies has been documented to reduce inflammation as well as pain through suppression of cytokine production, NF-κB activity, and oxidative stress. Hesperidin, as a natural product, have been considered as a promising pulp capping material in several invitro and animal studies. However, the regenerative effect of hesperidin as pulp capping material in human teeth has not yet been reported.
41033103|NCT02709954|DRUG|Active inhaled delta-9-THC|"Low dose THC (\~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
41033104|NCT02709954|DRUG|Placebo|Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
41375622|NCT00886626|DRUG|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
41375623|NCT00625313|DEVICE|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
41375624|NCT04493255|DRUG|[14C]E7090|\[14C\]E7090, oral capsule.
41375625|NCT00572910|BIOLOGICAL|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
41375626|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
41375627|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
41375628|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
41375629|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
41375630|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
41375631|NCT04928924|PROCEDURE|Total Hip Arthroplasty|We will be observing patients who have undergone surgical replacement of arthritic hip with an implant.
41505301|NCT00366366|BIOLOGICAL|Infanrix-Hexa|
41505302|NCT01153295|PROCEDURE|Clinical diagnosis based on symptom criteria|The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
41505303|NCT01153295|PROCEDURE|Diagnosis of exclusion|The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
41505304|NCT02135471|DRUG|acellular dermal matrix graft|On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
41505305|NCT02135471|DRUG|enamel matrix derivative|On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
41505306|NCT03612349|BEHAVIORAL|Experimental Tobacco Marketplace Task|Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.
41505307|NCT06251245|PROCEDURE|Oral Injector|"* Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* • Experimental Group (Giving the medicine orally to the child with an Oral Injector)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2"
41505308|NCT06251245|PROCEDURE|Spoon|"* Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* Control Group (Giving the medicine orally to the child with an oral medication spoon)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2"
41505309|NCT04112186|BEHAVIORAL|Behavioral group therapy #1|Participants will participate in an 8-weeks of group therapy that uses psychological principles including mindfulness training, and could help decrease cravings for heroin and increase general well-being.
41505310|NCT04112186|BEHAVIORAL|Behavioral group therapy #2|Participants will participate in an 8-weeks of group therapy that uses psychological principles (but not including mindfulness training) and could help decrease craving for heroin and increase general well-being.
41505311|NCT00224471|BIOLOGICAL|GSK208141 vaccine|3 IM doses
41505312|NCT02068703|BEHAVIORAL|Sleep Education Presentation|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
41033105|NCT02709954|DRUG|Placebo|Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
41375632|NCT00727675|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
41375633|NCT00952432|DRUG|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
41033106|NCT02709954|DRUG|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
41033107|NCT05630274|DRUG|Selpercatinib|Administered orally
41033108|NCT05630274|DRUG|Moxifloxacin|Administered orally
41033109|NCT05630274|DRUG|Placebo|Administered orally.
41033110|NCT00505739|DRUG|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
41033111|NCT06413108|DRUG|TB31F|transmission-blocking monoclonal antibody TB31F
41375634|NCT00952432|PROCEDURE|Acupuncture|Acupuncture
41375635|NCT01292291|OTHER|biologic sample preservation procedure|
41375636|NCT01292291|OTHER|laboratory biomarker analysis|
41375637|NCT01292291|OTHER|study of socioeconomic and demographic variables|
41375638|NCT01292291|PROCEDURE|diffusion-weighted magnetic resonance imaging|
41375639|NCT01292291|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
41375640|NCT01292291|PROCEDURE|multiparametric magnetic resonance imaging|
41505313|NCT02068703|BEHAVIORAL|Sleep Tool Demonstration|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
41505314|NCT00022113|DRUG|cilengitide|Given IV
41505315|NCT00022113|OTHER|pharmacological study|Correlative studies
41505316|NCT00022113|OTHER|laboratory biomarker analysis|Correlative studies
41505317|NCT05018546|PROCEDURE|Irrigation force|RIRS with different irrigation force
41505318|NCT06632704|DEVICE|Colgate Toothbrush assist|toothbrush handle assignment to all subjects; subjects will have a choice between two brush heads
41505319|NCT06172634|DRUG|dentritic cell infusion and immunecheckpoint inhibitor|dentritic cell infusion and immunecheckpoint inhibitor
41505320|NCT03946280|PROCEDURE|conventional X-ray based Fluoroscopy|catheter tracking via conventional X-ray based Fluoroscopy
41505321|NCT03946280|PROCEDURE|low X-ray 3D navigation technique|catheter tracking via low X-ray 3D navigation technique
41505322|NCT05529446|DEVICE|Combination therapy (CT)|Two therapeutic modalities at the same site is described as combination therapy (CT). The most commonly used CT is US \& TENS where this approach was effective in pain modulation
41505323|NCT05645705|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
41375641|NCT01292291|PROCEDURE|quality-of-life assessment|
41505324|NCT05645705|OTHER|LISTERINE Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of LISTERINE Cool Mint Antiseptic Mouthwash for 30 seconds after brushing twice daily.
41505325|NCT05645705|OTHER|Listerine Advanced Gum Alcohol|Participants will use 20 mL of Listerine Advanced Gum Alcohol Rinse for 30 seconds after brushing twice daily.
41505326|NCT05645705|OTHER|Listerine Advanced Gum Zero|Participants will use 20 mL of Listerine Advanced Gum Zero Rinse for 30 seconds after brushing twice daily.
40850160|NCT06402032|OTHER|Mineral Trioxide Aggregate (MTA)|Mineral trioxide aggregate is a cementitious material having various advantages as it is biocompatible, bioactive, osteo-inductive, non-resorbable material with exciting clinical applications, stimulating reparative continuous dentin formation along with maintaining the integrity of the pulp. Moreover, mineral trioxide aggregate provides seal to tooth structure and is of high strength. It is considered the gold standard material for direct pulp capping.
41033112|NCT06413108|OTHER|Normal saline|normal saline as control (placebo)
41033113|NCT05894876|OTHER|No treatment is given|No treatment is provided to the participants as part of this study.
41375642|NCT01292291|PROCEDURE|transperineal prostate biopsy|
41375643|NCT01292291|PROCEDURE|transrectal prostate biopsy|
41505327|NCT05645705|OTHER|LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|Participants will use 20 mL of LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint Rinse for 30 seconds after brushing twice daily.
41505328|NCT06498440|DRUG|Ketorolac 0.5% Eye Drops|Participants in this arm will receive ketorolac 0.5% eye drops, administered twice daily for one week following Selective Laser Trabeculoplasty (SLT). Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX) enzymes, which play a key role in the inflammatory process. This intervention aims to reduce postoperative inflammation and pain, promoting patient comfort and potentially improving outcomes following SLT.
41505329|NCT06498440|DRUG|Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops|Participants in this arm will receive a combination of ketorolac 0.5% eye drops and fluorometholone 0.1% eye drops. Ketorolac will be administered twice daily and fluorometholone four times daily for one week following SLT. Fluorometholone is a corticosteroid that reduces inflammation by stabilizing capillary permeability and inhibiting inflammatory cell activation. The combination aims to maximize anti-inflammatory effects and enhance patient comfort, potentially leading to better postoperative outcomes compared to ketorolac alone or no treatment.
41505330|NCT02075515|BIOLOGICAL|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
41505331|NCT06633588|DRUG|Polyhexanide|Participants will apply Prontoderm® Nasal Gel and perform whole-body wash with Prontoderm® Foam daily for 5 days before surgery.
41375644|NCT01292291|PROCEDURE|ultrasound-guided prostate biopsy|
41375645|NCT03058081|DEVICE|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (\< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher\&Paykel)
41375646|NCT05531695|BEHAVIORAL|Exercise (either aerobic or flexibility)|
40850161|NCT01138501|DRUG|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
41033114|NCT05493280|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.
41033115|NCT04402177|DRUG|Methyl Prednisolonate|Corticosteroid treatment
41033116|NCT04181762|DRUG|secukinumab|STUDY DRUG
41033117|NCT04181762|DRUG|Placebo|Placebo
41033118|NCT00167544|DRUG|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
41033119|NCT00167544|DRUG|Placebo|Saline
41033120|NCT06196762|DRUG|XKH002 Injection|240 mg/4 mL/vial（60 mg/mL）
41033121|NCT01672801|DRUG|Placebo|oral administration
41375647|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
41375648|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
41375649|NCT05628818|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Real anodal tDCS over the left dorsolateral prefrontal cortex in acute stroke patients to improve dysexecutive syndrome. Intensity: 2 mA. Stimulation period: 20 minutes.
41375650|NCT05628818|DEVICE|Sham Transcranial Direct current Stimulation|Sham anodal tDCS over the left dorsolateral prefrontal cortex: anodal tDCS. Intensity: 2 mA. Stimulation period: 1 minute. Afterwards, the device will automatically shut down but the sham stimulation period will last a total of 20 minutes.
41375651|NCT03075215|DEVICE|Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The optimization during the standard of care visits in the first 12 months following implantation
41375652|NCT01985776|PROCEDURE|Exercise intervention|Functional stabilisation exercise for the trunk.
41033122|NCT01672801|DRUG|Nimodipine|oral administration
41033123|NCT01734668|DEVICE|In Vitro Diagnostic device to aid in diagnosis|
41033124|NCT04644328|BEHAVIORAL|Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday|Facebook ads to show a 15 second video clip recorded by MGH, Harvard and Lynn Community health center and other health care professionals. The ads will be shown before the Thanksgiving/Christmas holiday and will focus on staying safe - limiting travel and mask-wearing. The investigators will randomize exposure to the ad campaign at the ZIP code or county level.
41033125|NCT01069783|DRUG|A3309|A3309 in two different dosage levels
41033126|NCT01069783|DRUG|A3309|A3309 in two different dosage levels for the duration of the study
41033127|NCT01069783|DRUG|Placebo|Placebo comparator once daily for the duration of the trial
41375653|NCT01985776|PROCEDURE|Exercise and e-stim|Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
41375654|NCT00247416|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 intravenously over 30 minutes on days 5 and 12.
41375655|NCT00247416|DRUG|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
41375656|NCT00247416|DRUG|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
41375657|NCT02866370|DRUG|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
41375658|NCT02866370|DRUG|Paclitaxel|"Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days\* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
41375659|NCT02866370|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
40850162|NCT01138501|DRUG|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
41375660|NCT02866370|DRUG|Topotecan|"Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
41375661|NCT02866370|DRUG|Carboplatin|"Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
41375662|NCT02866370|DRUG|Doxorubicin|"Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
41375663|NCT00807040|PROCEDURE|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
41375664|NCT00807040|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
41375665|NCT02344212|BEHAVIORAL|ESENCIAL Para Vivir: a weight loss program for Latinas|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
41505332|NCT06633588|DRUG|Mupirocin and Chlorhexidine|Participants will apply Bactroban® Nasal ointment and perform whole-body wash with Lifo-Scrub® daily for 5 days before surgery.
40850163|NCT02415270|OTHER|Reduced Nicotine Cigarettes|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
41505333|NCT04185623|PROCEDURE|denudation time lag|The time between ovum pickup and denudation of oocyte
41505334|NCT00948324|DRUG|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
41033128|NCT06529588|RADIATION|Radiation|HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months
41505335|NCT04655001|BEHAVIORAL|MORPH|A 12-week movement and caloric restriction intervention meant to reduce pain and body weight.
41505336|NCT03598790|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
41033129|NCT05144997|DRUG|Lorlatinib|ALK-positive NSCL treatment
41033130|NCT06024304|DEVICE|Synthes TFNA|Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.
41033131|NCT06024304|DEVICE|Trigen InterTAN|Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.
41033132|NCT02672046|OTHER|Assessment at the Clinic of Sports Injuries|Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
41033133|NCT04523545|DEVICE|cardiac ablation|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation
41033134|NCT04596254|OTHER|Pomegranate Juice|Collection of Mother's milk before and after juice consumption
41033135|NCT06479629|DRUG|Piracetam|800mg oral tablet of Piracetam three times every day for 3 months
41033136|NCT06479629|DRUG|Placebo|starch tablet
41505337|NCT04590105|DEVICE|"Smartphone App SB Colonoscopy Prep"|We created a smartphone app that informs patients about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite.
41505338|NCT04590105|OTHER|Written Instruction|Written Instruction
41505339|NCT06304168|OTHER|Non-Interventional Study|Non-interventional study
41505340|NCT01871571|BIOLOGICAL|bevacizumab|Given IV
41505341|NCT01871571|DRUG|oxaliplatin|Given IV
41505342|NCT01871571|DRUG|leucovorin calcium|Given IV
41505343|NCT01871571|DRUG|fluorouracil|Given IV
41505344|NCT01871571|OTHER|laboratory biomarker analysis|Correlative studies
40850164|NCT02415270|OTHER|Reduced ROS/RNS|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
40850165|NCT02415270|OTHER|Control|Human topography data will show if smokers change the way they smoke due to being in a research study. Select biosamples of participants will be used to analyze how biomarkers differ among groups
41375666|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
41375667|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
41375668|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
41163873|NCT05510739|BEHAVIORAL|Individualized home exercise program|Individualised home exercise program leaflet involving one initial instruction session. Written instructions involving dose and exercise progression. No support during the 10 week period.
41375669|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
41505345|NCT02252406|DRUG|Ranolazine|Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
41505346|NCT02252406|OTHER|Placebo|Matching placebo tablets daily for 24 weeks.
40850166|NCT02769169|DRUG|Lucentis® (Raibizumab) double-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
40850167|NCT02769169|DRUG|Lucentis® (Raibizumab) regular-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
41505347|NCT05263830|OTHER|Quantitative assay of GlypicanPC-3|Quantitative assay of GlypicanPC-3 in human serum is performed by direct sandwich immunoassay ( CanAg Glypican3 EIA - Fujirebio ) on microplate using two mouse monoclonal antibodies against two epitopes of the Glypican-3 core protein
40850168|NCT02720406|DRUG|Intravenous ketamine0.5mg/kg|Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
40850169|NCT02720406|DRUG|Nebulized Ketamine 1mg/kg|Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.
41033137|NCT03904472|BEHAVIORAL|Web-based CBTI|Sessions comprise a range of cognitive and behavioral techniques and psychoeducation including sleep hygiene. During the intervention period the participant will complete daily online sleep diaries. Additionally, participants will be asked to complete multiple questionnaires.
41033138|NCT06103864|DRUG|Dato-DXd|Provided in 100mg vials. IV infusion. Experimental drug.
40850170|NCT02720406|DRUG|Nebulized Ketamine 2mg/kg|Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.
40850171|NCT02720406|DRUG|saline placebo|Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
40850172|NCT03897855|OTHER|Post Traumatic Stress Disorder|"The test Think / No-Think"
40850173|NCT03156283|BEHAVIORAL|SleepWell24 Application|An evidence-based behavioral change smartphone application designed to promote adherence to positive airway pressure (PAP) therapy
40850174|NCT03156283|OTHER|Usual Care Plus Activity Monitor|Participants will receive usual care at the Mayo Clinic Center for Sleep Medicine when first diagnosed with sleep apnea and prescribed positive airway pressure therapy. In addition, they will receive a commercial activity monitor with an associated smartphone application to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
41033139|NCT06103864|DRUG|Durvalumab|Provided in 500mg vials. IV infusion. Experimental drug.
41033140|NCT06103864|DRUG|Paclitaxel|IV infusion. Active comparator.
41033141|NCT06103864|DRUG|Nab-paclitaxel|IV infusion. Active comparator.
41033142|NCT06103864|DRUG|Gemcitabine|IV infusion. Active comparator.
41033143|NCT06103864|DRUG|Carboplatin|IV infusion. Active comparator.
41163874|NCT01265121|DEVICE|Continuous positive air pressure device (CPAP)|After titrating the air pressure during a polysomnography test, a CPAP device will be applied to the patient, during the night, for three months.
40850175|NCT02477189|PROCEDURE|Silicone Block|
40850176|NCT05567926|DIETARY_SUPPLEMENT|Beetroot juice concentrate (140 ml)|A beetroot juice concentrate (140 ml) will be administered to participants in experimental conditions.
41033144|NCT06103864|DRUG|Pembrolizumab|IV infusion. Active comparator.
41163875|NCT01265121|OTHER|External nasal dilator adhesive|An external nasal dilator adhesive will be given to patients. They will be applied on the nose and will be used for three months aiming to serve as a placebo for snoring and sleep apnea.
41375670|NCT02753777|OTHER|Questionnaires|
41375671|NCT01857011|DRUG|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
41375672|NCT01857011|DRUG|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
41375673|NCT00390091|DRUG|abetimus sodium (LJP 394)|
41375674|NCT06308965|PROCEDURE|Vessel technique|Vessel sparing vs Vessel ligation
41375675|NCT01389700|DRUG|SAR279356|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
41505348|NCT01374269|OTHER|Exercise program|Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
41505349|NCT01374269|DRUG|NSAID (Nonsteroidal anti-inflammatory drugs)|The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
41375676|NCT01389700|DRUG|placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
40850177|NCT05567926|DIETARY_SUPPLEMENT|Blackcurrant juice (placebo)|140 ml of blackcurrant juice with added appropriate amount of sugar to equalize the carbohydrate value and lemon juice fort the taste.
41375677|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go (TUG single-task)|The TUG test is a well-established clinical test of one mobility sequence: rising from an armchair, walking straight ahead, passing a line marked on the floor, turning around, walking back, and sitting down again.
41375678|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go dual-task (TUGdt)|Two dual-task tests including TUG (TUGdt) were carried out: TUGdt naming animals and TUGdt months backwards. The outcomes registered were: time scores for TUG single-task and both TUGdt tests, TUGdt costs (relative time difference between TUG single-task and TUGdt), number of different animals named, number of months recited in correct order, number of animals per 10 s, and number of months per 10 s.
41375679|NCT05893524|DIAGNOSTIC_TEST|Clinical functional assessment|The diagnostic procedure was part of the clinical routine for patients undergoing memory assessment and involved a geriatrician's careful evaluation of the patient's history and cognitive testing including Mini-Mental State Examination (MMSE), Clock Drawing Test, Verbal Fluency Test, and Trail Making Test A and B. In addition, all participants carried out short versions of the Geriatric Depression Scale and the General Motor Function Assessment Scale, as well as static balance according to the Bohannon Method, and hand grip strength using a dynamometer.
41375680|NCT06145399|DIAGNOSTIC_TEST|18F-FDG PET/CT|Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners
41375681|NCT06145399|DIAGNOSTIC_TEST|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
41375682|NCT06145399|DRUG|18F-FDHT|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
41505350|NCT02285374|DRUG|Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir|Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
41505351|NCT06633874|DIAGNOSTIC_TEST|TD Playing the Serious Game APSOU|After parents participate in informative meetings, they proceed with written consent, SmartSpeech enrollment, and child developmental history. Then, the child may interact with the Serious Game. Typically developed (TD) children engage under the clinician's face-to-face supervision with the serious game APSOU, which assesses developmental domains, including speech, language, psychomotor, cognitive, psychoemotional, and hearing abilities. The average time for TD children to play the whole game is estimated to be 45 minutes.
41033145|NCT03879798|DRUG|DS-3201b|100 mg daily
40850178|NCT00077649|DRUG|ribavirin [Copegus]|600mg po bid for 48 weeks
40850179|NCT00077649|DRUG|ribavirin [Copegus]|800mg po bid for 48 weeks
41033146|NCT03879798|DRUG|irinotecan|Irinotecan 125 mg/m\^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle.
41033147|NCT03524404|BEHAVIORAL|6 Week Intervention|Weekly interactive webinars based on the DPP curriculum at senior center.
41375683|NCT00539006|DRUG|FPNS|fluticasone propionate nasal spray
41375684|NCT00539006|DRUG|FFNS|fluticasone furoate nasal spray
41375685|NCT00539006|DRUG|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
41375686|NCT00539006|DRUG|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
41383561|NCT05672225|DRUG|Control|Normal saline 2ml/hr administration via continuous channel in the experimental group
40850180|NCT00077649|DRUG|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|180 micrograms sc weekly for 48 weeks
40850181|NCT00077649|DRUG|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|270 micrograms sc weekly for 48 weeks
40850182|NCT06579690|DRUG|8.4% sodium bicarbonate solution|Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose.
40850183|NCT06579690|OTHER|0.9% Normal Saline|The comparision group will receive 50 mls of 0.9% Normal Saline
41033148|NCT03153280|DRUG|Lithium|Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
41375687|NCT04481399|BEHAVIORAL|Family Strengthening Intervention for Early Childhood Development|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.
41505352|NCT06633874|DIAGNOSTIC_TEST|Non-TD Playing Serious Game|After parents participate in informative meetings, they proceed with written consent, SmartSpeech enrollment, and child developmental history. Then the child may interact with the serious game. Non-typically developed (non-TD) children engage under the clinician's face-to-face supervision with the serious game Apsou, which assesses developmental domains, including speech, language, psychomotor, cognitive, psychoemotional, and hearing abilities. The average time for non-TD children to play the whole game is estimated to be over an hour.
41505353|NCT05085262|DIAGNOSTIC_TEST|Bloodwork, Echocardiogram, PET/MRI|The study will use blood samples from COVID biobank at University Health Network. Samples will be collected at time of admission to ER in patients discharged after assessment and at three time points during admission in patients who are admitted for measurement of blood biomarkers. Echocardiography studies will be assessed for structural and functional abnormalities. All included patients will have prospective short-term follow-up (3-6 months) for assessment of clinical events and subclinical cardiovascular disease. 50 patients who had clinical cardiac MRI at our center within 5 years prior to COVID-19 (January 2015-January 2020) and have since tested positive for COVID-19 will be recruited for research cardiac MRI to compare changes between baseline (pre-COVID) and follow-up (post-COVID imaging). A subgroup of 50 patients will undergo cardiac PET/MRI at 1-3 months post COVID-19 diagnosis to evaluate for myocardial inflammation and other imaging markers of cardiac injury.
41505354|NCT05085262|DIAGNOSTIC_TEST|Bloodwork, Echocardiogram, MRI|The study will involve use of blood samples from the COVID biobank at UHN (University Health Network) for measurement of blood biomarkers. Echocardiography Studies will be systematically assessed for structural and functional abnormalities. All included patients assessment of clinical events and subclinical cardiovascular disease.
41505355|NCT04948892|OTHER|Prescence of the father during cesarean section in general anesthesia|The father is now present in the OR during cesarean section category 1, instead of waiting outside
41505356|NCT06206798|BEHAVIORAL|Resourcefulness Group|The content of the Resourcefulness intervention group includes 6 sessions such as session 1 to introduce resourcefulness skills; sessions 2-4 to discuss personal resourcefulness skills including planning daily activities, and positive self-talk; sessions 4-5 to discuss social resourcefulness skills including relying on family or friends, and seeking professional assistance.
41505357|NCT02201277|DEVICE|Filter Placed|
41505358|NCT01727726|DRUG|Brexpiprazole|tablet/capsule
41505359|NCT01727726|DRUG|Seroquel XR|tablet/capsule
41505360|NCT01727726|DRUG|Placebo|tablet/capsule
41505361|NCT00437918|DRUG|nateglinide|
41505362|NCT00437918|DRUG|acarbose|
41505363|NCT06550258|OTHER|Equine-assisted therapy|Hippotherapy is a therapeutic intervention applied by physiotherapists that aims to improve impaired body functions. Hippotherapy is a therapy in which the rider receives stimuli from the horse that stimulate the sensory, neuromotor and cognitive systems during riding and exercise on the back of a horse. Hippotherapy is effective on posture control, balance, gross motor functions and functional performance in children with cerebral palsy.
41505364|NCT06550258|OTHER|Traditional Pediatric Physiotherapy|In traditional pediatric physiotherapy, cushions of appropriate hardness were used for proprioceptive input. Stools of different heights were used for sitting, squatting, standing up by holding on and standing, Bobath balls and balance boards were used for balance reactions. Triangular and roll cushions of different hardness were used for weight transfer. Surfaces with different patterns were used for sensory input. The child's wishes and interests were taken into consideration in the selection of materials. The treatment was planned according to the activities that were difficult in daily life and the aim was to transfer the knowledge learned to daily life.
41505365|NCT05603403|DRUG|Probiatop|1 sachet orally, 2 times a day, for 42 days
41505366|NCT05603403|OTHER|Placebo|1 sachet orally, 2 times a day, for 42 days
41505367|NCT04839484|DEVICE|Study Product|up to 2cc per injection of filler placed into nasolabial fold.
41505368|NCT04839484|DEVICE|Active Control|up to 2cc per injection of filler placed into nasolabial fold.
41505369|NCT05482711|OTHER|Time Restricted Eating Intervention|All participants will be asked to adhere to suggested fasting and feeding periods throughout the 8 week study period. These participants will self-monitor eating and sleeping habits as well to present to study staff at checkpoints. Self-reported information will be used during group-mediated intervention sessions throughout the duration of the study, as well.
40850184|NCT01810497|PROCEDURE|Use of ear bandage|Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
41033149|NCT03153280|DRUG|Oxaliplatin|Dose as used in standard of care - 130 mg/m2.
41505370|NCT00600587|DRUG|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
40850185|NCT04541628|COMBINATION_PRODUCT|SIG-001|Laparoscopic administration of SIG-001 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce BDD-hFVIII.
41033150|NCT03153280|DRUG|Capecitabine|Dose as used in standard of care - 800 - 1000 mg/m2
41033151|NCT00344682|DRUG|memantine|memantine 5mg - 20mg PO daily
41033152|NCT00344682|DRUG|Placebo|5mg - 20mg PO daily over 8 weeks
41383562|NCT00552812|DEVICE|Stent therapy of aortic coarctation|Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
41163876|NCT02637856|DRUG|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
41375688|NCT04481399|OTHER|Community Health Worker Routine|Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
40850186|NCT01204216|BIOLOGICAL|re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month"
41163877|NCT02637856|DRUG|Ocrelizumab|Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
41163878|NCT05185297|OTHER|Recreational Futsal|Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
41375689|NCT02222246|DRUG|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
41375690|NCT02222246|DRUG|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
41375691|NCT02222246|DRUG|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
41375692|NCT02222246|DRUG|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
41375693|NCT02698319|BEHAVIORAL|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
41375694|NCT04246411|BEHAVIORAL|Ultrasound-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field.~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
41375695|NCT04246411|BEHAVIORAL|Auscultation-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
41375696|NCT00472004|DRUG|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
41375697|NCT00472004|DRUG|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
41375698|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|Usual CPAP treatment in sleep apnea patients
41375699|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|CPAP treatment with telemedicine system
41375700|NCT00104858|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
41375701|NCT00104858|DRUG|Cyclosporine|Given PO
41375702|NCT00104858|DRUG|Fludarabine Phosphate|Given IV
41375703|NCT00104858|OTHER|Laboratory Biomarker Analysis|Correlative studies
41375704|NCT00104858|DRUG|Mycophenolate Mofetil|Given PO
41375705|NCT00104858|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
41375706|NCT00104858|OTHER|Pharmacological Study|Correlative studies
41375707|NCT00104858|BIOLOGICAL|Rituximab|Given IV
41375708|NCT00104858|RADIATION|Total-Body Irradiation|Undergo TBI
41375709|NCT04387812|DEVICE|Xtrodes home PSG system|Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
41375710|NCT05163249|DRUG|Osimertinib|osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
41375711|NCT05163249|DRUG|Savolitinib|savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
41375712|NCT03403010|OTHER|Rehabilitation-specific gaming platform|The rehabilitation specific gaming software was developed as part of the ICT4rehab project with partners from the Vrije Universiteit Brussel and the University Libre de Bruxelles. The ICT4Rehab puts several ICT tools supporting 2/3D user interaction into place. The games can be controlled using a Kinect camera system (Microsoft(®) (Redmond, WA) Kinect™) or a Wii balance board (® NintendoTM, Japan), depending on the choice of the therapist and the needs of the child.
41375713|NCT03514823|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) are breathing exercises used to increase strength and endurance of the respiratory muscles.
41375714|NCT03514823|OTHER|No Inspiratory Muscle Training (IMT)|No inspiratory muscle training.
40850187|NCT01204216|BIOLOGICAL|Re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.~small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate."
41505371|NCT00600587|DRUG|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
40850188|NCT01204216|BEHAVIORAL|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
40850189|NCT05917054|OTHER|use of bipolar vascular sealing method on the renal allograft at the back-table stage|Ligation of small vessels and lymphatics of the renal graft at the back-table stage prior to transplantation to the recipient is a routine practice in kidney transplantation. Bipolar vascular sealing method will be used for this purpose in Group 1, while the conventional silk-tie method will be used in Group 2.
40850190|NCT04551950|DRUG|M7824|Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
41505372|NCT02191761|DRUG|SM04755|Escalating Doses
40850191|NCT04551950|DRUG|Carboplatin|Carboplatin was administered intravenously as per standard of care.
40850192|NCT04551950|DRUG|Paclitaxel|Paclitaxel was administered intravenously as per standard of care.
40850193|NCT04551950|DRUG|Bevacizumab|Bevacizumab was administrated as indicated for standard of care.
40850194|NCT04551950|DRUG|Cisplatin|Cisplatin was administered intravenously as per standard of care.
41033153|NCT06635876|BEHAVIORAL|Coaching Sessions|"The goals of coaching are two-fold:~1. To assist and guide the caregiver to establish a standby caregiver relationship~2. To assist and guide the caregiver as to how to use the EPT~These goals will be accomplished using motivational interviewing techniques, which include:~1. Expressing empathy~2. Developing discrepancy~3. Rolling with resistance~4. Supporting self-efficacy"
41033154|NCT03820661|DEVICE|Ultrasound|High resolution ultrasound pre-operatively and intra-operatively
41163879|NCT06320327|OTHER|Cannabidiol cream|Group 1 will be administered the recommended quantity of CBD cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
41375715|NCT06129851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41505373|NCT04704570|OTHER|Exercise|Spinal stabilization exercise
41033155|NCT03160027|DEVICE|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
41163880|NCT06320327|OTHER|Placebo cream|Group 2 will be administered the recommended quantity of placebo cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
41375716|NCT06129851|PROCEDURE|Bone Scan|Undergo bone scan
41375717|NCT06129851|RADIATION|Brachytherapy|Undergo brachytherapy
41375718|NCT06129851|PROCEDURE|Computed Tomography|Undergo CT
41375719|NCT06129851|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
40850195|NCT04551950|RADIATION|Radiotherapy|Participants received radiotherapy as per standard of care.
40850196|NCT04693286|BIOLOGICAL|novel oral polio type 2 vaccine (nOPV2)|• nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.
40850197|NCT04693286|OTHER|Placebo|Placebo contains no active ingradients, only sucrose in buffer
41033156|NCT04156607|OTHER|Kinesio taping|For the fascia technique, one part of the band which were divided by 4 fans is adhered on Achilles tendon to the heel with a 0% stretch. Then the plantar fascia was stretched by the examiner and the toes were extended (ankle dorsiflexion, toe extension) and the divided part of the band was applied toward the metatarsal heads with paper-off technique (5-15%).
41375720|NCT06129851|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
41375721|NCT06129851|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41375722|NCT06129851|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
41375723|NCT06129851|OTHER|Questionnaire Administration|Ancillary studies
41375724|NCT06129851|DRUG|Relugolix|Given PO
41375725|NCT03058159|OTHER|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
41375726|NCT06420726|BEHAVIORAL|Resistance Exercise|Supervised resistance exercise
41375727|NCT01058226|BIOLOGICAL|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
41383563|NCT05527288|DRUG|Drug: [18F]florbetaben|All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.
41033157|NCT04156607|OTHER|Sham taping|''I'' bant were cut from the middle point of the Achilles tendon to the metatarsal heads. The band was applied from the Achilles tendon to the metatarsal heads without any stretching of plantar fascia and band.
41033158|NCT04136951|OTHER|PREVENT clinical decision support|PREVENT clinical decision support tool consideres five patient risk factors as significant predictors of patient's priority for the first homecare nursing visit: (a) Presence of wounds (either surgical or pressure ulcers); (b) a documented comorbid condition of depression; (c) need for assistive equipment, assistive person, or both for toileting; (d) number of medications; and (e) number of comorbid conditions. Each risk factor was assigned a specific score based on the logistic regression weights. For instance, for a wound (e.g., pressure ulcer, vascular ulcer), the patient received a score of 15 points. For each additional co-morbid condition, one point was added to the final score. Summing the scores for the factors generated a cumulative score. The optimal cut-off point was established based on the regression model performance statistics, indicating that patients with a score greater than 26 points are a high priority for the first nursing visit.
41163881|NCT01104064|DEVICE|real rTMS combined with constraint induced therapy|10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
41163882|NCT01104064|DEVICE|sham rTMS combined with constraint induced therapy|10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
41163883|NCT04089839|OTHER|Non-Interventional|Non-Interventional
41163884|NCT01961674|DIETARY_SUPPLEMENT|Capsinoid/placebo and rice|The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
41163885|NCT01102387|DRUG|LAS41003|Once daily, topically
41163886|NCT01102387|DRUG|LAS189962|Once daily, topically
41163887|NCT01102387|DRUG|LAS189961|Once daily, topically
41163888|NCT03631654|DRUG|Ivabradine|Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily
40850198|NCT03422536|BIOLOGICAL|Cetuximab|Given IV
41163889|NCT03631654|DRUG|Placebos|Placebo
41163890|NCT05691283|DEVICE|trans cranial direct current stimulation (tDCS)|Three weeks of 20-minute tDCS stimulation
41163891|NCT05691283|DEVICE|Sham|Three weeks of sham stimulation
41163892|NCT04316520|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet 2:1
41163893|NCT01836016|DRUG|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
41163894|NCT01836016|DRUG|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
41163895|NCT01836016|DRUG|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
41163896|NCT01836016|DRUG|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
41163897|NCT01836016|DRUG|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
41163898|NCT01836016|DRUG|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
40850199|NCT03422536|DRUG|Ficlatuzumab|Given IV
41375728|NCT05946096|OTHER|Dynamic surface exercise training|Dynamic surface exercise training involves a set of exercises that are performed on various dynamic surfaces like gym ball and vestibular swing. All these exercise provide optimal arousal as they provide proprioceptive and vestibular stimulus. This group received a set of exercises on various dynamic surfaces.These exercises were implemented for 60 minutes for four days a week for two months.And it was observed how these exercises impacted gross motor function and trunk control of children with diplegic cerebral palsy of GMFCS level 3 and 4
41375729|NCT05946096|OTHER|conventional physical therapy|conventional physical therapy based on NDT involves a set of exercises that mostly include positioning exercises such as quadruped, side sitting, reaching sideways and overhead in sitting and catch and throw activities.
41375730|NCT01881711|DEVICE|ShuntCheck-Micro-Pumper (SCMP)|"ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck."
41505374|NCT04704570|OTHER|Remotely and face to face evaluation of Functional Capacity Level|Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.
41505375|NCT06174467|BEHAVIORAL|SEELearning Training|"This group will receive the Learning Training for Hearts and Minds and will be submitted to assessments and questionnaires that measure the improvement of well-being, reduction of stress and literacy in the contents and human values taught in the training.~The program aims to increase participants' awareness, compassion and engagement. Compassion refers to cultivating a way of relating to oneself, others and humanity through kindness, empathy and genuine care for the happiness and suffering of these individuals. Awareness refers to cultivating a detailed, first-person understanding of thoughts, feelings, and emotions."
41505376|NCT06174467|BEHAVIORAL|Waiting list group of the intervention|The group will remain on a waiting list and will respond to questionnaires about well-being and other items before receiving the training and, in the second semester, during the period in which it will receive the training
41163899|NCT01836016|DRUG|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
41505377|NCT00900835|OTHER|educational intervention|
41505378|NCT00900835|OTHER|questionnaire administration|
41505379|NCT00900835|OTHER|study of socioeconomic and demographic variables|
41505380|NCT00900835|PROCEDURE|assessment of therapy complications|
41505381|NCT00900835|PROCEDURE|fatigue assessment and management|
41505382|NCT00900835|PROCEDURE|quality-of-life assessment|
41505383|NCT00900835|PROCEDURE|standard follow-up care|
41505384|NCT02186288|OTHER|High-flow nasal cannula oxygen|
41033159|NCT00761839|BEHAVIORAL|After-care summary|"The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals."
41375731|NCT01881711|DEVICE|Imaging|Imaging of ventricle size
41375732|NCT00877799|DRUG|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
41375733|NCT00877799|DRUG|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
41375734|NCT00877799|DRUG|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
41505385|NCT03651882|DRUG|Oxytocin|Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.
41505386|NCT03651882|DRUG|Carbetocin|Carbetocin is given 0.1mg intravenously as a bolus after delivery.
41505387|NCT00822978|DRUG|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
41505388|NCT04214626|DRUG|Rituximab|"Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment for patients with CR after 6 cycles: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 3 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles (Total 8 cycles)."
41375735|NCT00877799|DRUG|Placebo|Matched placebo administered the day after surgery (Day 1)
41033160|NCT00761839|BEHAVIORAL|Control group|Patients in the control group will receive usual counseling for self-management.
41033161|NCT00149058|DRUG|Erythropoietin|
41505389|NCT04214626|DRUG|Lenalidomide|Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
41163900|NCT01836016|DRUG|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
41505390|NCT04214626|DRUG|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
41163901|NCT04052997|DRUG|Camidanlumab Tesirine|Intravenous Infusion
41163902|NCT03822377|DRUG|Ticagrelor orodispersible tablets|Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
41163903|NCT03822377|DRUG|Ticagrelor standard tablets|Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
41163904|NCT01984671|BEHAVIORAL|Mobile Pain Coping Skills Training|
41505391|NCT04214626|DRUG|Epirubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
41505392|NCT04214626|DRUG|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
41505393|NCT04214626|DRUG|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
41505394|NCT04214626|DRUG|Methotrexate|Induction Chemotherapy: 1g/m2, Intravenous administration on day 3 of each 3-week cycle from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
41505395|NCT06600425|DRUG|RCT1100|RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
41505396|NCT06048263|BEHAVIORAL|interpersonal psychotherapy (IPT)|The ROSE intervention is a five-session intervention developed to build communication skills, improve social support, and improve stress management. It is easy to learn and does not require a healthcare professional or mental health specialist to deliver. For this study, the investigators plan to deliver to individuals during inpatient visits, in-person appointments or via telemedicine (phone or videoconference), as appropriate or per participant preference. The first four sessions are approximately 60 minutes in length.
41505397|NCT06048263|DRUG|Ketamine|During the first four post-cesarean days, the investigators will administer subcutaneous ketamine (0.5 mg/kg) and a repeated dose of 0.5 or 0.7 mg/kg \~24 hours later (the second dose will be increased to 0.7 mg/kg if no severe adverse effects are reported after the first dose and the patient is in agreement with the dose escalation).
41505398|NCT01307748|OTHER|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
41505399|NCT05651607|DRUG|Cannabidiol|Oral solution, taken 3 times a day (morning, noon and evening), 5 mg/kg/day from day D0 to day D4. If not effective and well tolerated, dose increase : 10 mg/kg/day from day D5 to day D9, then 20 mg/kg/day from day D10 to day D29, maximum 800 mg/day
41505400|NCT05099250|DRUG|Bupivacain|local anesthetic agent
41505401|NCT05099250|DRUG|magnesium sulfate|In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines
41505402|NCT05099250|OTHER|saline|medical solution
41505403|NCT04981327|DRUG|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|Apixaban 5 MG BID versus Apixaban 2.5 MG BID
41505404|NCT00408083|DRUG|MultiHance|0.5 mmol/kg as a single dose administration
41505405|NCT00408083|DRUG|Magnevist|0.5 mmol/kg as a single dose administration
40850200|NCT04138290|DEVICE|Predictix Antidepressant Software tool|Predictix Antidepressant is a stand-alone software tool based on a patients' genetic panel, clinical, demographic and behavioral inputs, intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with Major Depressive Disorder.
41163905|NCT03819842|DIAGNOSTIC_TEST|Pseudophakic Measurement|standard aphakic measurements will be taken and then pseudophakic measurements will be taken after toric iol implantation. The data produced will aid the surgeon in proper placement of toric iol orientation
41163906|NCT06129045|BEHAVIORAL|One-time educational video|Sleep hygiene educational tips provided through a video participants watch on their own.
41163907|NCT06129045|BEHAVIORAL|Educational video plus repeated education|Sleep hygiene educational tips are provided first through a video participants watch on their own and then tips are repeated through daily automated text messaging for an additional 4 weeks.
41163908|NCT06192719|OTHER|None, observational study.|Epidemiological, clinical and dietary data will be collected along with blood, saliva, urine, bile, feces and gallbladder tissue samples.
41163909|NCT04529811|DRUG|Rifaximin Novel Formulation|Rifaximin Novel Formulation
41163910|NCT04529811|DRUG|Placebo|Placebo
41505406|NCT05327231|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
41505407|NCT05327231|DRUG|Docetaxel|Docetaxel 75mg/m2 every 21 days a cycle.
41505408|NCT02859142|DRUG|Chantix|Chantix given alongside standard smoking cessation treatment, and administered per manufacturer's instructions \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
41505409|NCT02859142|BEHAVIORAL|Behavioral Counseling Sessions|One-to-one behavioral counseling sessions with a trained therapist
41505410|NCT02859142|DRUG|NicodermCQ|Nicotine patches provided over 12 week participation
41505411|NCT02859142|DRUG|Placebo|Identical in appearance to varenicline \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
41505412|NCT01239108|DRUG|SGI-1776|SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.
40850201|NCT06447402|DRUG|Normal saline|5 mL of normal saline will be nebulised in the control arm
41375736|NCT00877799|DRUG|Placebo|Matched placebo administered immediately after surgery (Day 0)
41505413|NCT00641069|DEVICE|Automated load-distributing band device|Blood pressure recording before and after starting up the automated band device
41505414|NCT06487208|OTHER|Use of a digital cognitive aid in order to anticipate a critical situation|Use of a digital cognitive aid in order to anticipate a critical situation
41505415|NCT06487208|OTHER|Placebo|No intervention
41505416|NCT06526624|DRUG|HS-20093|Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.
41505417|NCT05096832|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|"Appearance: Creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5 mL) /vial Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg (0.5 mL) Immunization schedule: 1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).~Storage condition: Store at 2-8 °C protected from light Expiry date: 24 months temporarily"
41505418|NCT05096832|BIOLOGICAL|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
41505419|NCT00695305|DRUG|rilapladib|250 mg oral dose once daily
41505420|NCT00695305|DRUG|placebo|placebo
41505421|NCT00695305|OTHER|18F Fluorodeoxylucose (FDG)-PET|FDG-PET
40850202|NCT06447402|DRUG|Amphotericin B deoxycholate|2 mL of the above reconstituted amphotericin B solution will be obtained in a sterile syringe and transferred into the drug chamber of a nebulizer. Three mL of distilled water will be added to 2 mL of the reconstituted amphotericin B (5 mL liquid in the chamber ensures complete and easy nebulization of all the contents)
41163911|NCT00478322|DRUG|Placebo|Matching placebo of 100 mg BID
41505422|NCT05125965|OTHER|additional time for the MRI|3 additional minutes to perform the MRI
41505423|NCT05044559|OTHER|Continuous Positive Air Way Group|CPAP between 10 and 12 cmH2O
41505424|NCT05044559|OTHER|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
41505425|NCT03408171|DEVICE|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
41505426|NCT03408171|DEVICE|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
41163912|NCT00478322|DRUG|INCB013739|INCB013739 100 mg BID
40850203|NCT05984888|BEHAVIORAL|MIND Diet Intervention Group|Participants will receive individually tailored nutrition counseling on adopting the MIND diet pattern from a registered dietitian nutritionist (RDN) for a total of 8 sessions spanning 12 weeks. After completing the counseling sessions participants will be followed up 6 months later to collect additional questionnaires and assessments.
41163913|NCT05479747|DRUG|post operative analgesics|post-operative pain killer
41163914|NCT01092988|DEVICE|Exablate 2100|MR guided focused ultrasound
41375737|NCT06338280|OTHER|Sonara|Sonara virtual dosing window and engagement platform
41375738|NCT01800812|BIOLOGICAL|Injections of OM-174|
41375739|NCT05623826|OTHER|Cognitive- behavioral imagery-based training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and a repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
41383564|NCT04724070|GENETIC|NGS, PDO/PDX establishment|Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
41383565|NCT03888898|OTHER|Reusable respirator fit test and competency evaluation|Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
41505427|NCT05296863|COMBINATION_PRODUCT|Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|"Non-concentrated ADSC-CM is given during week 0, 2, 4, and 6 on the left side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
41505428|NCT05296863|COMBINATION_PRODUCT|Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|Intervention is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.
41505429|NCT05296863|COMBINATION_PRODUCT|Placebo and 5% Minoxidil|"Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
41505430|NCT01808573|DRUG|neratinib|
41505431|NCT01808573|DRUG|capecitabine|
41375740|NCT02003248|DEVICE|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
41505432|NCT01808573|DRUG|lapatinib|
41375741|NCT02322866|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day.
41375742|NCT02322866|DRUG|Placebo|Placebo-matching sarecycline tablets, taken orally at the same time each day.
41375743|NCT05284227|OTHER|Electronic Clinical Decision Support Application|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application, that calculates perioperative risks for the patient and informs the anaesthesiologist on indicated diagnostics and procedures according to clinical guidelines in real-time.
41505433|NCT06236841|DRUG|XH-S004 tablet|XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days.
41505434|NCT06236841|DRUG|XH-S004 placebo tablet|XH-S004 placebo tablet (matched) will be administered orally as per assigned treatment regimen on schedualed days.
41505435|NCT00055042|DRUG|Vitamin E|
41505436|NCT00554190|DEVICE|AdvaCoat sinus gel|A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
41505437|NCT00554190|DEVICE|Merogel Injectable|Bioresorbable hyaluronic acid product
41505438|NCT05232188|PROCEDURE|Percutaneous nephrolithotomy|percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.
41505439|NCT05631197|OTHER|Biorepair Total Protection Plus + desensitizing enamel-repair shock treatment|Domiciliary use twice a day
41163915|NCT04326153|DRUG|Sintilimab Injection|"Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total."
41505440|NCT05631197|OTHER|Sensodyne Repair & Protect|Domiciliary use twice a day
41505441|NCT03484546|PROCEDURE|laparoscopic endometrioma cyst excision|laparoscopic resection of ovarian endometrioma
41505442|NCT03527953|OTHER|Tetric EvoCeram Bulkfill|The preparation will be etched with 37% phosphoric acid. It will be then rinsed with an air-water spray and dried, leaving the dentin slightly moist. An etch-and-rinse adhesive, ExciTE F, will be applied and agitated on the prepared surfaces for at least 10 seconds. The adhesive will be air-thinned and light-cured for 20 seconds with an LED curing unit. The sectional matrix will be placed and fixed with wooden wedges. Then the bulk-fill resin composite, TBF, will be placed in bulk in about 4-mm thickness and then will be cured for 20 seconds.
41505443|NCT03527953|OTHER|Surefil SDR Flowable bulkfill|The preparation will be etched. A two-step etch-and-rinse adhesive, Prime\&Bond NT will be applied to all enamel/dentin surfaces, air-dried for 5 seconds, and will be light cured for 10 seconds. After the sectional matrix will be placed, the flowable bulk-fill resin composite, SureFil SDR™ flow (Dentsply Caulk, Milford, DE, USA), will be placed in a 4-mm bulk increment in the dentinal part cured for 20 seconds and will be followed by a covering layer of the nanohybrid resin composite, Ceram.X Mono that will be cured for 20 seconds.
41505444|NCT03527953|OTHER|everX fiber-reinforced resin|The enamel will be etched with 37% phosphoric acid for 10 seconds, then will be rinsed, and dried with an air/water syringe for at least 5 seconds. Self-etch adhesive, G-aenial Bond (GC Co., Tokyo, Japan), will be applied to all enamel/dentin surfaces and gently air thinned and then will be light cured for 10 seconds. After the matrix will be placed and wedged, mesial or distal walls will be built with 1-2-mm layers of G-aenial Posterior resin composite. The fiber-reinforced composite, everX Posterior, will be placed into the cavity in approximately 4-mm thickness. The last 2 mm of the cavity will be restored using the G-aenial Posterior composite as an overlay layer. Each increment will be light cured for 20 seconds using an LED unit.
41375744|NCT05284227|OTHER|Standard procedures of the hospital and Sham Clinical Decision Support Application|Preoperative anaesthesiological assessment using standard procedures of the hospital. In addition a sham clinical decision support application will be used. Information on perioperative risks and indicated diagnostic procedures according to clinical guidelines is not given to the physician.
41505445|NCT04187417|DRUG|topical tetracaine hydrochloride 1%|topical ophthalmologic anesthestic
41505446|NCT04187417|DRUG|Placebo|Placebo
41375745|NCT01819012|DRUG|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
41375746|NCT01819012|DRUG|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
41375747|NCT01819012|DRUG|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
41375748|NCT04588740|DRUG|concentrated beet root juice|On average, we will expect subjects to ingest the supplement for approximately 5 days minimum depending on their testing schedule. On each testing day subjects will be asked to consume the two bottles of either beetroot juice (BRJ) or Placebo 2.5 hours before testing time. Specifically, for female subjects, they will be asked to start their supplementation on day 1 of menses. On day 3-4 they will take the last 2 shots. Female subjects' wash-out period will go according to their menstrual cycle as we will be controlling for hormone fluctuation (low vs high estrogen phase) know to interact with nitric oxide physiology.
41375749|NCT04588740|DRUG|Placebo beet root juice|This will follow the same supplementation regime as explained above but this supplement taste and looks exactly the same as the nitrate-rich beet root juice. It is provided by the same company that produces the concentrated beet root juice shots (Beet It, UK)
41505447|NCT03560180|DIAGNOSTIC_TEST|Dutch score|leakage score (DUtch LeaKage, DULK), that consider several items (fever, heart rate, respiratory rate, urinary production, mental status, clinical conditions, signs of ileus, gastric retention, fascial dehiscence, abdominal pain, wound pain, leukocytosis, CRP, increase of urea or creatinine and nutrition status), to give a score
41505448|NCT03560180|DIAGNOSTIC_TEST|Serum C-reactive Protein|see study protocol
41505449|NCT03560180|DIAGNOSTIC_TEST|serum Procalcitonin|see study protocol
41505450|NCT06055829|DRUG|Insulin injection and blood glucose|The FreeStyle Libre sensor continuously measures glucose every minute and saves the glucose data. Scan the sensor at least every 8 hours for a full glycemic profile. The below data is displayed after a typical 1-second scan of the FreeStyle LibreLink app or FreeStyle Libre reader via the sensor:
41505451|NCT06142318|DRUG|Pirfenidone|Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
41163916|NCT05285956|BEHAVIORAL|Calm app|Calm is a popular, subscription-based, meditation app accessible across web-based and smartphone platforms (iOS and Android) with over 100 million downloads and four million subscribers. The app offers a range of content rooted in mindfulness principles to help users incorporate mindfulness into their lives and generally promote wellbeing (e.g., a large library of guided meditations including the 10-minute Daily Calm, Sleep Stories, educational courses, mindful movement, music, and nature scenes and sounds). Calm also teaches users the basics of mindfulness, includes components to remind users to meditate, track user activity, and allow users to share their status with others. The feasibility of the app and its efficacy for improving mental health outcomes (i.e., stress, anxiety, and depressive symptoms), mindfulness, and sleep have been previously tested in various populations providing evidence that using Calm may improve wellbeing.
41163917|NCT04984278|DRUG|Nabiximols|oromucosal spray
41163918|NCT04984278|DRUG|Placebo|oromucosal spray
41375750|NCT03243552|DRUG|L-DOPA versus Placebo|Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
41375751|NCT03243552|BEHAVIORAL|Social Skills Training|ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
41375752|NCT05542173|DRUG|BALI association|BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
41375753|NCT05542173|DRUG|Placebo|Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
41375754|NCT01736982|BEHAVIORAL|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
41375755|NCT01736982|OTHER|Standard of Care|Standard smoking cessation counseling
41375756|NCT01736982|OTHER|Standard of Care|transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\]
41375757|NCT01736982|OTHER|Standard of Care|Breath sample monitoring
41375758|NCT01592526|OTHER|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
41505452|NCT06142318|DRUG|Placebo|Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
40850204|NCT05984888|BEHAVIORAL|General Health Curriculum (GHC) Group|Participants will meet with trained study staff for 8 sessions spanning 12 weeks covering content on non-diet related health topics. After these sessions, participants will be followed up 6 months later to collect additional questionnaires and assessments. Once 6-month follow-up has been completed, participants will be offered to receive the MIND diet intervention offered in the MIND Diet Intervention Group.
41375759|NCT01592526|OTHER|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
41375760|NCT03087448|DRUG|Ceritinib|"ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~1. Ceritinib 300mg~2. Ceritinib 450mg~3. Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study"
41375761|NCT03087448|DRUG|Trametinib|"MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~1. Trametinib 1.5mg~2. Trametinib 1.5mg~3. Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study"
41375762|NCT01051076|DRUG|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
41505453|NCT04817020|OTHER|%2 Klorheksidin|Effect on phlebitis
40850205|NCT00053144|DRUG|cytarabine|
40850206|NCT00053144|DRUG|irinotecan hydrochloride|
41375763|NCT01715675|DIETARY_SUPPLEMENT|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
41375764|NCT01715675|DIETARY_SUPPLEMENT|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
41375765|NCT03189199|OTHER|a cohort using Dazhuhongjingtian injection|All patients will be measured and assessed at the time Dazhuhongjingtian Injection is administered to them until they discharge. Patients using Dazhuhongjingtian Injection will be registered on a registration form including disease background, Dazhuhongjingtian Injection's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Dazhuhongjingtian Injection.
41375766|NCT03128801|PROCEDURE|Global Stretching Program|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.
41375767|NCT03128801|PROCEDURE|Stabilization Exercises|The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
41375768|NCT06367751|DIAGNOSTIC_TEST|ctDNA measurement|Blood samples are collected as part of standard of care and ctDNA measurements will be performed on these samples.
41375769|NCT05696457|BEHAVIORAL|Passive music therapy|Patients included in the experimental group receive a 25 min passive music therapy session on a daily basis, which changes depending on their emotion.
41375770|NCT03279120|DRUG|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
41375771|NCT03279120|DRUG|Placebo|Used for 90 days (Continuous or Interrupted)
41375772|NCT04897724|OTHER|dental composite|clinical performance of composite restorations used for posterior teeth in patients with Amelogenesis Imperfecta
41375773|NCT01377207|PROCEDURE|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
41375774|NCT02290652|OTHER|Prospective - Factors affecting sexual function pre-THR|"A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.~Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.~Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI."
41375775|NCT02290652|OTHER|Retrospective- Factors affecting sexual function post-THR|"A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.~Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).~Maximum retrospective collection of data 12 months."
41375776|NCT05779059|DRUG|De-escalation to ticagrelor 60 mg at day 30|Change of P2Y12 receptor antagonist regimen to ticagrelor 60 mg bid at day 30.
41375777|NCT05779059|DRUG|De-escalation to prasugrel 5 mg at day 30|Change of P2Y12 receptor antagonist regimen to prasugrel 5 mg qd at day 30.
41375778|NCT05779059|DRUG|Switch to ticagrelor 60 mg at day 45|Switch to ticagrelor 60 mg bid at day 45.
41375779|NCT05779059|DRUG|Switch to prasugrel 5 mg at day 45|Switch to prasugrel 5 mg qd at day 45.
41375780|NCT06567496|OTHER|First Resort|First Resort is an 8-week, self-guided, at-home, virtual reality program designed to be used as an intervention to help manage stress, worry, and sadness. It is grounded on evidence-based cognitive behavioral therapy and acceptance and commitment therapy techniques, including psychoeducation, mindfulness, behavioral activation through values clarification and goal setting, and cognitive reframing to identify and reframe cognitive distortions.
41375781|NCT01146340|RADIATION|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
41375782|NCT05774782|DEVICE|Cerebral flow diverter|The surface-modified flow diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm.
41375783|NCT03586427|DRUG|AGN-241751|AGN-241751 administered orally as a single tablet
41375784|NCT03586427|DRUG|Placebo|Placebo administered orally as a single tablet
41375785|NCT01829659|DRUG|Ticagrelor|
41383566|NCT03888898|OTHER|Control fit test evaluation|control comparator for fit testing time threshold
41505454|NCT06632652|BEHAVIORAL|Health Education|"Provide 'Health Education' for acquisition of self-management skills, acquiring knowledge of both the disease and self-care. By making self-supported decisions, the patients are able to manage their diet, exercise and medication.~Patients will start implementing diabetes management right after the group education. Each patient will develop monthly goal settings (behavior change plan) related to their diabetes management, daily practice them, and record the results every day on the self-monitoring notebook. The nurses call each patient on the scheduled day, ask/evaluate his/her behavior changes and monitored data, then make step-up goals for the next month. In addition, based on his/her knowledge and practice level, the nurses provide education using the education booklet. Patients and the nurses repeat these activities during 6 months."
40850207|NCT01879943|DEVICE|PillCam Colon 2|PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.
40850208|NCT01879943|PROCEDURE|Colonoscopy|Standard colonoscopy is the standard against which capsule endoscopy is compared.
40850209|NCT05665296|OTHER|cervicothoracic mobilization|Each participant in study group will receive cervicothoracic mobilization (central PA and transverse Grade III or grade IV) with comprehensive corrective exercise. The duration will eight weeks three sessions per week.
41375786|NCT04638218|DEVICE|Rehabilitation Training System|The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
41375787|NCT02820324|DRUG|Oliceridine|
41375788|NCT02820324|DRUG|Placebo|
41375789|NCT02820324|DRUG|Morphine|
41375790|NCT01458535|DRUG|ABT-450|tablets
41375791|NCT01458535|DRUG|ABT-267|tablets
41375792|NCT01458535|DRUG|ribavirin|tablets
41375793|NCT01458535|DRUG|ritonavir|capsules
41033162|NCT05146674|DRUG|Tadalafil 5mg|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
41375794|NCT01428388|DRUG|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
41375795|NCT01428388|DRUG|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
41033163|NCT02487563|DRUG|Decitabine|Decitabine
41163919|NCT04902196|OTHER|high intensity cardiorespiratory exercise protocol|During the high intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, a high-intensity interval protocol is started, consisting of five one-minute bouts (110 reps/minute at 100% VO2max workload), separated by one minute of active rest (75 reps per minute at 50% VO2max workload).
41163920|NCT04902196|OTHER|moderate intensity cardiorespiratory exercise protocol|During the moderate intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, participants begin a moderately-intensive continuous 14-minute exercise protocol at a stable resistance (90 repetitions per minute at 60% VO2max workload).
41163921|NCT00151905|DRUG|3 % hypertonic saline|
41375796|NCT00566397|DRUG|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
41375797|NCT00566397|DRUG|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
41375798|NCT00566397|DRUG|Placebo|Placebo
41375799|NCT03716830|DEVICE|verum acupuncture|Participants will receive real acupuncture treatment.
41505455|NCT02627651|OTHER|cognitive and motor assignments|walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
41505456|NCT04069338|PROCEDURE|Lithotripter|Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines
41033164|NCT02487563|DRUG|rhTPO|rhTPO
41033165|NCT02487563|OTHER|Conventional Treatment|immunoglobulin, glucocorticoid etc
41033166|NCT01185574|DIETARY_SUPPLEMENT|Vitamin D supplementation|Vitamin D2 50,000 IU will be administered once a week for six months.
41163922|NCT02690493|PROCEDURE|Acupuncture|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.
41375800|NCT03716830|DEVICE|sham acupuncture|Participants will receive sham acupuncture treatment.
41375801|NCT03716830|DEVICE|real tDCS|Participants will receive real transcranial direct current stimulation.
41375802|NCT03716830|DEVICE|sham tDCS|Participants will receive sham transcranial direct current stimulation.
41375803|NCT04129866|BEHAVIORAL|M-IBM|"In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect."
41375804|NCT04129866|BEHAVIORAL|Control-IBM|Placebo IBM where sentences are not related to anxious threat meaning of cue word.
41375805|NCT01113073|OTHER|ventilatory protocol|Ventilatory protocol for short period with four different tidal volumes (12 min)
41375806|NCT01113073|OTHER|Elastic band|Placement of an elastic band around thorax to reduce thorax compliance
41375807|NCT01113073|OTHER|passive leg raising test|performing the passive leg raising test
41375808|NCT02365701|DRUG|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
41375809|NCT02365701|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
41505457|NCT05816538|PROCEDURE|Paravertebral nerve block (PVB)|PVB is a regional anesthetic technique applied at the thoracic (Th) level of Th2, Th3, and Th4 at a dose of 0.3ml/kg 0.5% levobupivacaine total, divided into levels. Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
41033167|NCT02091726|PROCEDURE|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
41375810|NCT03752424|DRUG|Silver nanoparticles|The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
41375811|NCT03752424|DRUG|Topical approved anti-microbial gel|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
41375812|NCT00689494|OTHER|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
41375813|NCT02910895|OTHER|tumor biopsy|biopsy
41375814|NCT00221416|DRUG|Aripiprazole|5-20 mg/day
41375815|NCT02183948|DRUG|Oxytocin|
41375816|NCT02183948|DRUG|Placebo|
41375817|NCT00131027|DRUG|Cyclophosphamide|
41375818|NCT00131027|DRUG|Daunorubicin|
41375819|NCT00131027|DRUG|Vincristine|
41375820|NCT00131027|DRUG|Prednisolone|
41375821|NCT00131027|DRUG|L-asparaginase|
41375822|NCT00131027|DRUG|Cytarabine|
41375823|NCT00131027|DRUG|Etoposide|
41375824|NCT00131027|DRUG|Dexamethasone|
41375825|NCT00131027|DRUG|Methotrexate|3 g/sqm (high dose)
41375826|NCT00131027|DRUG|Mercaptopurine|
41375827|NCT00131027|DRUG|Doxorubicin|
41375828|NCT00131027|DRUG|Methotrexate|0.5 g/sqm (intermediate dose)
41375829|NCT01752608|BEHAVIORAL|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
41375830|NCT05317923|OTHER|Flow Controlled Ventilation|Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
41375831|NCT01725217|BIOLOGICAL|MenACWY-CRM|1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
41375832|NCT05785273|DEVICE|Pupillometer|1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage
41505458|NCT05816538|PROCEDURE|Pectoralis and Serratus Plane Nerve Blocks (PECS 2)|Pectoralis and Serratus Plane Nerve blocks (PECS 2) is a regional anesthetic technique applied in the space between the large and small pectoral muscles (10 ml of 0.5% levobupivacaine), and in the space between the small pectoralis muscle and the serratus anterior muscle (with 15 ml of 0.5% levobupivacaine). Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
41033168|NCT05218005|DIAGNOSTIC_TEST|Research-based genetic test for Familial Hypercholesterolemia|Next-generation targeted sequencing assay to identify DNA variants in genes known to cause Familial Hypercholesterolemia
41033169|NCT06171737|BEHAVIORAL|Decision Aid|The American College of Cardiology decision aid: Treatment Options for Severe Aortic Stenosis for patients deciding between Tavi and Surgery
41033170|NCT06171737|BEHAVIORAL|Shared Decision Making Skills Training|60-minute online training session that will provide practical tips, interactive case studies and tools for conducting shared decision making conversations covering core competencies
41375833|NCT00774774|DEVICE|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
41505459|NCT05816538|DEVICE|Regional anesthetic technique with ultrasound guidance|The device that will be used is an ultrasound with an 8 Hz ultrasonic linear probe for both regional anesthetic techniques.
41505460|NCT05816538|DEVICE|Regional anesthetic technique with peripheral nerve stimulation.|The 22G neurostimulator needle (Stimuplex D®, B. Braun Melsungen AG)\], and neurostimulator (Stimuplex HNS 12, B. Braun, Melsungen AG, Germany) will be used for both regional anesthesias.
41033171|NCT05096338|OTHER|Social Determinants of Health|We will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
41033172|NCT04853004|DIAGNOSTIC_TEST|SARS-CoV2 antibody measurement|Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
41033173|NCT04272281|PROCEDURE|medical shared decision|The experimental group will use the share decision making tool during consultation to adapt antibiotherapy
41033174|NCT04272281|PROCEDURE|Standard medical care|control group will act as usual in their practice.
41375834|NCT00774774|DEVICE|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~* during the night,~* when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
41375835|NCT02628197|DIETARY_SUPPLEMENT|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
41375836|NCT02628197|PROCEDURE|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
41375837|NCT05141110|DRUG|NVP-1705|NVP-1705
41375838|NCT05141110|DRUG|NVP-1705-R|NVP-1705-R
41375839|NCT03526549|BIOLOGICAL|CCH-aaes|Administered to participants who qualified for, and opted for, retreatment.
41375840|NCT03526549|OTHER|Observation|No treatment administered during 180 days of observation.
41375841|NCT05031559|BEHAVIORAL|Episodic Future Thinking|Participants are invited to imagine themselves in a positive situation after COVID-19 public health restrictions and guidelines are lifted. They are then reminded that their actions are able to change how soon this future can be achieved.
41375842|NCT05031559|BEHAVIORAL|Compassion Training|Participants are invited to imagine themselves in someone else's situation, who is in a bad situation due to COVID-19 (e.g., ER nurse, family of someone in ICU). They are then reminded that their decisions have an impact on the occurrence of these situations.
41375843|NCT05031559|BEHAVIORAL|Sham|Participants are invited to reflect on some COVID-19 related news, and reminded that their actions have bearing on the COVID-19 situation.
41375844|NCT04122677|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw.
41375845|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily"
41375846|NCT00151775|DRUG|placebo|Cohorts A, B, C: placebo, once daily
41375847|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
41375848|NCT06215872|OTHER|Therapeutic Exercises|Participants who have inclusion criterias after DRF reconstrontion pos-op 4. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize or structered exercises pragram with telerehabilition during 4 weeks and 16 sessions. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
41033175|NCT00563199|BEHAVIORAL|nurse-delivered stage-matched smoking cessation counseling|
41375849|NCT05534698|PROCEDURE|PCI|Revascularization by PCI
41033176|NCT00395876|DRUG|placebo|2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
41505461|NCT05816538|DRUG|Levobupivacaine 0.5%|Local anesthetic levobupivacaine 0.5% will be used for regional anesthetic technique with ultrasound guidance and peripheral nerve stimulation. For the paravertebral block at a dose of 0.3ml/kg total, applied at the thoracic (Th) level of Th2, Th3, and Th4 and divided into levels. For the PECS 2 block levobupivacaine 0.5% 10 ml will be applied in the space between the large and small pectoral muscles and 15 ml in the space between the small pectoralis muscle and the serratus anterior muscle.
41505462|NCT05816538|PROCEDURE|General anesthesia|In both groups for induction of general anesthesia we will use 1% propofol 2 - 2.5 mg/kg (10 mg/ml, Fresenius), sufentanil (Sufentanil® Altamedics) 0.2 μg / kg, rocuronium \[Zemuron®, Schering - Plow\] 0.8 mg/kg. We will use a laryngeal mask (I - gel supraglottic airway) of appropriate sizes for airway maintenance. All subjects will be ventilated by controlled mechanical ventilation with a volume of 8 ml/kg, a frequency of about 12 breaths per min with a mixture of oxygen and air in a 40: 60% ratio. Maintenance of anesthesia and sedation in group 1 will be performed with continuous infusion of 1% propofol (10 mg / ml, Fresenius) (25 - 150 mcg / kg / min.) and rocuronium \[Zemuron®, Schering - Plow\] 0.01 mg / kg / min per perfusor.
41505463|NCT01270191|DRUG|Exenatide|They will be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months.
41505464|NCT01270191|DRUG|Humulin-N|The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
41033177|NCT00395876|DRUG|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
41033178|NCT01742767|DRUG|Cisplatinum|
41033179|NCT01742767|DRUG|Pemetrexed|
41033180|NCT00354523|DRUG|Capecitabine (Xeloda)|Starting Dose 500 mg/m\^2 twice a day Days 1-14 of 21 Day Cycle.
41375850|NCT05534698|PROCEDURE|CABG|Revascularization by CABG
41375851|NCT03596476|PROCEDURE|Upper gastrointestinal (GI) endoscopy|An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
41375852|NCT03596476|PROCEDURE|Wireless pH monitoring|Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
41375853|NCT03596476|PROCEDURE|Post prandial esophageal High Resolution Impedance Manometry|Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
41505465|NCT06550713|DRUG|TQB3455 tablet+Azacitidine for Injection|TQB3455 is a selective IDH2 mutant enzyme inhibitor. Azacitidine for injection is a cytosine nucleoside drug that is used for demethylation therapy.
41505466|NCT05950178|DIAGNOSTIC_TEST|Apnea test under high-flow oxygenation|Apnea test under high-flow oxygenation in patients with a confirmed clinical brain death by a standard apnea test (under standard oxygen therapy)
41505467|NCT02480348|DEVICE|Polymer-free DES (Drug Eluting Stent)|
41033181|NCT00354523|DRUG|DTIC-Dome (Dacarbazine)|Starting Dose 250 mg/m\^2 a day on Days 1-3 of 21 Day Cycle.
41033182|NCT00354523|DRUG|Gleevec (Imatinib Mesylate)|Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
41033183|NCT04183322|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|
41033184|NCT06631144|BEHAVIORAL|Spanish-language Caregiver-Enabled Care Program (CECP)|CECP is a nonmedical digital population health intervention to support and engage family caregivers of persons with dementia. CECP consists of digital content, including health education videos and tutorials, that is delivered to caregivers on a dedicated tablet based on their specific needs. Caregivers are supported by a proactive human coach who provides support, access to resources, and performs risk mitigation measures as necessary. Alerts are shared with providers and/or care management teams via a data hub that makes it easy to track, manage and resolve alerts. CECP is delivered over a 6-month period via a dedicated tablet that is shipped to the caregiver's home at no cost to the caregiver or person with dementia. This study's CECP is in Spanish.
41375854|NCT03596476|PROCEDURE|pH-impedance monitoring|24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
41505468|NCT03138590|DEVICE|Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS|Transcranial Direct Current Stimulation targeting the trigeminal nerve
41033185|NCT03353818|BEHAVIORAL|Golf|A free golf course and free membership for one year in a golf club will be given to participants.
41375855|NCT03632057|DEVICE|Fixed Tilt (65%)|This is the standard group, so device programming for shock energy is the default setting
41163923|NCT02690493|OTHER|Functional Taping|Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.
41163924|NCT02690493|OTHER|Acupuncture and Functional Taping|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
41375856|NCT03632057|DEVICE|Fixed Pulse Width|The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
41163925|NCT01834768|DRUG|Eplerenone|
41163926|NCT03285633|BEHAVIORAL|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
41505469|NCT05780476|BEHAVIORAL|Psychoeducation|6 sessions of 2 hours over 6 weeks
41505470|NCT05780476|BEHAVIORAL|Psychoeducation + virtual reality|6 sessions of 2 hours over 6 weeks. Virtual reality experience will be carry out in the last 30 minutes of each meeting. Virtual reality consists of 360-degree videos depicting everyday situations and allowing the caregivers to feel the specific symptoms of dementia (e.g., disorientation, agnosia, apraxia and memory loss).
41033186|NCT03353818|BEHAVIORAL|No intervention|Patients acting as controls will not be restricted in any ways.
41033187|NCT03787940|DRUG|Isoniazid|standard dose isoniazid or high dose isoniazid for participants with rapid acetylators
41033188|NCT01877447|DEVICE|Transcranial Direct Current Stimulation|Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
41033189|NCT05215574|DRUG|NGM831|Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
41375857|NCT03523676|DIAGNOSTIC_TEST|Red Cell Distribution Width|
41375858|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for Acquired AA|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
41375859|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
41375860|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)\*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0"
41033190|NCT05215574|DRUG|NGM831 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle."
41375861|NCT03466060|DEVICE|Opti-Free : RevitaLens / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
41375862|NCT03466060|DEVICE|Opti-Free : RevitaLens / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
41375863|NCT03466060|DEVICE|Clear Care : RevitaLens/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
41375864|NCT03466060|DEVICE|Clear Care : RevitaLens / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
41505471|NCT06349174|PROCEDURE|bronchoscopic lung volume reduction surgery using endobronchial valve|The patients would undergo bronchoscopic lung volume reduction surgery using the self developed endobronchial valve.
41505472|NCT04867174|BEHAVIORAL|Financial incentives|Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)
41505473|NCT04867174|BEHAVIORAL|Convenient scheduling link|In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).
41505474|NCT04867174|BEHAVIORAL|Race concordant|Randomized to a messenger who is race concordant with the participant
41375865|NCT03466060|DEVICE|RevitaLens : Clear Care/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
41505475|NCT04867174|BEHAVIORAL|Gender concordant|Randomized to a messenger who is gender concordant with the participant
41505476|NCT00281957|DRUG|sorafenib tosylate|Given orally
41505477|NCT00281957|DRUG|tipifarnib|Given orally
41505478|NCT00281957|DRUG|temsirolimus|Given IV
41505479|NCT04163510|BEHAVIORAL|Behavioral: Parent/Child Reading Program|A 9-week parent/child reading program will help parents to identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading. Three large-group sessions will be held in a central location, to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. Intervention sessions will be held once per week for 60-90 minute sessions.
41505480|NCT06412783|DIAGNOSTIC_TEST|blood test|performing blood tests on the participants for specific markers.
41505481|NCT01469078|DRUG|Monofer®|Single Bolus Injections
41505482|NCT04408235|DRUG|Enoxaparin|Low-Dose LMWH: enoxaparin 4000 IU daily; High dose LMWH: 70 IU/kg twice daily
41033191|NCT05215574|DRUG|NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle."
41033192|NCT02721238|BIOLOGICAL|20% Albumin|
41033193|NCT02721238|OTHER|Plasmalyte|
41033194|NCT06264440|DRUG|BIIB122|Administered as specified in the treatment arm.
41505483|NCT04623086|DRUG|Insulin Degludec|Insulin Degludec injection
41505484|NCT04623086|DRUG|Insulin Glargine|Insulin Glargine injection
41375866|NCT03466060|DEVICE|RevitaLens : Clear Care / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
41505485|NCT04623086|DRUG|Placebo|9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection
41505486|NCT01062711|DIETARY_SUPPLEMENT|Whey or soy protein|Whey and casein are isolated milk proteins
41505487|NCT05308628|DIAGNOSTIC_TEST|Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA etc.)|Liver biopsies will be performed at 3 months, 6 months and 12 months post-transplant. Fibrosis was evaluated using the liver allograft fibrosis score (LAFSc) staging system. Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA)or (FBLN3,YKL40,LECT2 etc.)
41505488|NCT01154361|DRUG|Icatibant (subcutaneous) and plazebo (intravenous)|
41505489|NCT01154361|DRUG|Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)|
41505490|NCT01324531|PROCEDURE|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
41505491|NCT01324531|PROCEDURE|Bankart repair|Bankart repair based on surgeon's preference
41033195|NCT06264440|DRUG|Rabeprazole|Administered as specified in the treatment arm.
41375867|NCT03466060|DEVICE|RevitaLens : Opti-Free / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
41375868|NCT03466060|DEVICE|RevitaLens : Opit-Free / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
40850210|NCT05665296|OTHER|CCE|"Each participant will receive comprehensive corrective exercise include three phases: Initial phase -Improvement phase and Maintenance phase.~The initial phase exercises progress in frequency and intensity during this phase, as long as participants are able to demonstrate good quality movement. The initial phase duration is 2 weeks and the exercises will be performed for seven sets of 10-s hold .~Improvement phase exercises are progressed by considering individual characteristics of each participant and by observing the overload principle and the progression in the number of repetitions of each set during the 4 weeks of the improvement phase. The exercises will be performed from five sets of ten repetitions to six sets of 15 repetitions .~Maintenance phase exercises:The exercises are the same as in the improvement phase without any progression in intensity and frequency. The maintenance phase duration is 2 weeks"
41033196|NCT04837248|OTHER|Active Comparator: Group 1. Conventional treatment|"Patients will be treated using a physiotherapy programme without digital support. A written document with exercises and recommendations will be given to them on the first day. This booklet will detail the exercises they can do depending on their surgery and the weeks elapsed, as well as the recommendations adapted according to the needs identified in the motivational interview (MI). This is the treatment that is currently being applied in the hospital.~The patient will carry out the treatment at home and will come back after 20 sessions for the corresponding assessment."
41033197|NCT04837248|OTHER|Experimental: Group 2. Experimental treatment.|"A digitally supported physiotherapy programme including:~* Group session: expectations, interests, experiences with regard to their health problem and the consequences on their life, joint exercise and discussion with subsequent debate will be held.~* Exercise session: each week, patients will find different exercise videos on the platform according to the phase of recovery in which each one of them is, having been previously evaluated in the group session.~* Relaxation session: this will be carried out by means of audio that will be posted on the platform and that the patient will be able to perform simultaneously.~* Empowerment session: audio sessions that will deal with those needs that frequently arise after breast surgery in their daily lives, focusing on limiting beliefs (e.g. fear of moving), positive thoughts and information extracted from the motivational interview that should be developed."
41375869|NCT03690375|DEVICE|Broad Band Light (BBL)|Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
41505492|NCT03668392|DRUG|Asparaginase|Measurement of serum Asparaginase activities during therapy, in terms of intensity and duration, as surrogate parameter for asparaginase depletion.
41505493|NCT02000765|DRUG|GSK2140944 for Injection|GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing \[14C\] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
41505494|NCT02000765|DRUG|GSK2140944 Capsule|GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing \[14C\] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
41505495|NCT05838196|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed during clinic appointment
41505496|NCT05510284|OTHER|Doula-coordinated, midwife-delivered postpartum care|A doula will coordinate all postpartum care and provide support to the participant. A midwife will be available on-site in the NICU to provide postpartum care.
41505497|NCT02558439|DRUG|CNTX-4975|
41505498|NCT02558439|OTHER|Placebo|
41505499|NCT00791895|DRUG|biphasic insulin aspart 30|Treat-to-target dose titration scheme
41505500|NCT03743155|BIOLOGICAL|mesenchymal cells|Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out. The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration
41505501|NCT03912545|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
41505502|NCT06548997|DRUG|GZR18|5 μg/kg-maximum tolerated dose (MTD), single dose or two doses
41375870|NCT03602846|DIETARY_SUPPLEMENT|Medical Nutrition Therapy|Only given medical nutrition therapy.
41375871|NCT03602846|DRUG|Insulin|Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
41375872|NCT03602846|DRUG|Oral Antidiabetics|Prescribed with all types of oral anti-diabetics.
41505503|NCT06548997|OTHER|Placebo|administered the same volume as GZR18
41505504|NCT02609074|PROCEDURE|Minimally invasive internal fixation surgeries|
41505505|NCT02609074|DEVICE|CPC/rhBMP-2 micro-scaffolds|
41505506|NCT02609074|DEVICE|CPC paste|
41505507|NCT04928079|PROCEDURE|deep brain stimulation|performing deep brain stimulation if needed
41505508|NCT04928079|DRUG|Anti-Parkinsonian Drugs|Using anti-parkinsonian drugs if needed
41505509|NCT02125721|DRUG|Tiopronin 1g per day|500mg PO BID x 7 days
41505510|NCT02125721|DRUG|Tiopronin 2g per day|1g PO BID x 7 days
41505511|NCT02125721|DRUG|Tiopronin 3g per day|1.5g PO BID x 7 days
41033198|NCT01826591|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
41375873|NCT00900276|OTHER|immunologic technique|
40850211|NCT03450733|DEVICE|Wright Medical Technology Metal-on-Metal Total Hip System|Subjects in Group 1 previously implanted prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 5 years, 6 years) using contiguous visit windows (number of years + 6 months). Subject data will be grouped in order to create cross-sectional epochs of ≤ 8 years and \> 8 years.
41033199|NCT01826591|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a low-fat diet.
41375874|NCT00900276|OTHER|laboratory biomarker analysis|
41375875|NCT00900276|OTHER|mass spectrometry|
41375876|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
41375877|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using escalating product prices
41375878|NCT01800500|OTHER|questionnaire administration|Ancillary studies
41505512|NCT04874805|OTHER|Measurement of oxygen saturation|Measurement of oxygen saturation by pulse oximetry once a day, at 6 a.m., for a minimum of 3 days, thanks to three pulse oximeters (1 measurement point per device/day), in parallel with a synchronous sampling, programmed as part of the usual care, of arterial gasometry.
41505513|NCT03548701|DIAGNOSTIC_TEST|Thromboelastometry testing|Thromboelastometry testing - a form of testing in whole blood for coagulation abnormalities
41033200|NCT01826591|BEHAVIORAL|Mobile App|Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
41505514|NCT05976126|OTHER|Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements|Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.
41505515|NCT00352417|DRUG|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
41505516|NCT00352417|DRUG|Placebo|oral dosing, 1 time daily for 12 weeks
41505517|NCT02029157|DRUG|ARQ197|
41505518|NCT02029157|DRUG|Placebo|
41505519|NCT03450044|BIOLOGICAL|Dendritic cells|Adoptive transfer of autologous DCs
41033201|NCT00513669|BIOLOGICAL|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
41033202|NCT00513669|BIOLOGICAL|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
40850212|NCT02982941|DRUG|Enoblituzumab|enoblituzumab administered IV weekly for up to 96 weeks
40850213|NCT02177682|DRUG|Afuresertib|Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
40850214|NCT04706728|OTHER|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first four weeks of their ECT treatment.
40850215|NCT04706728|OTHER|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first two weeks of their ECT treatment.
41033203|NCT00433069|DRUG|Pioglitazone|Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity
41033204|NCT00433069|DRUG|Interferon Alfa-2a|Standard of care for chronic hepatitis C
41033205|NCT00433069|DRUG|Ribavirin|Standard of care for chronic hepatitis C
41033206|NCT00423124|GENETIC|HSV-TK|Infusion of genetically modified lymphocytes (1x10\^6-1x10\^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
41375879|NCT01800500|OTHER|quality-of-life assessment|Ancillary studies
41033207|NCT05706805|DEVICE|Naviscore|Patients in whom treatment with (Naviscore) has been attempted
41033208|NCT00856050|DRUG|letrozole|Taken orally once a day continuously
41033209|NCT04749719|DEVICE|remotely supervised transcranial direct current stimulation|Low levels of electrical current are applied across the scalp to induce small changes in brain activity. This is done using remote supervision.
41375880|NCT01800500|OTHER|laboratory biomarker analysis|Correlative studies
41375881|NCT01800500|OTHER|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
41375882|NCT01800500|OTHER|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
41375883|NCT01976325|OTHER|Ottawa Malaria Decision Aid|The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
41375884|NCT01400191|DRUG|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
41505520|NCT05517538|DEVICE|Electromyography-Needle Intramuscular Drug guidance|EMG-guided needle neurotoxin injection
41505521|NCT05517538|DRUG|Botulinum toxin type A|Botulinum toxin type A injection into the Corrugator Supercilii muscle
41505522|NCT05489614|DRUG|Olpasiran|Participants will receive olpasiran by subcutaneous (SC) injection.
41505523|NCT00948532|BIOLOGICAL|biologic, Osteocel Plus|Osteocel® Plus
41505524|NCT04540796|DRUG|JNJ-75348780|Participants will receive JNJ-75348780 by subcutaneous (SC) administration.
41033210|NCT06459687|DRUG|Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab|"6\~8 cycles of Socazolimab (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with Socazolimab (5 mg/kg), Q3w."
41033211|NCT06459687|DRUG|Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab|"6\~8 cycles of placebo (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with placebo (5 mg/kg), Q3w."
41033212|NCT04148248|OTHER|No intervention|There is no intervention for this study
41033213|NCT00850616|BIOLOGICAL|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
41033214|NCT00850616|BIOLOGICAL|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
41033215|NCT04339231|PROCEDURE|sphenopalatine ganglion block|"The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa."
41033216|NCT00659633|DRUG|lidocaine|intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
41033217|NCT01176539|DEVICE|Non-Contact Respiratory Rate Monitor|"The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.~The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults."
41033218|NCT06635187|DIAGNOSTIC_TEST|Speech and swallowing assessment|This is an observational study in which post-stroke patients will undergo a series of assessments tapping oral-motor and speech functions. Both behavioral and instrumental examinations will be used. Their performance will be captured via an artificial intelligence(AI)-powered mobile health application. The relation between the oral/speech-motor movements captured by the app and their performance as measured via instruments/behavioral means will be investigated.
41033219|NCT02086357|PROCEDURE|SWUE|
41033220|NCT03152253|BEHAVIORAL|Text My Quit (TMQ)|Text messages designed to aid smoking cessation
41033221|NCT03152253|BEHAVIORAL|Peer Support|A group chat room for peer support
41033222|NCT03152253|OTHER|Motivational Messages|Generic motivational messages not related to smoking cessation
41033223|NCT03007927|DRUG|Bupivacaine-Dexamethasone|Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
41033224|NCT03007927|DRUG|Bupivacaine- physiological solution|Bupivacaine 1,5 mg/kg- physiological solution
41033225|NCT04922242|BEHAVIORAL|Welch Emotional Connection Screen for Neonatal Intensive Care Unit|The Welch Emotional Connection Screen (WECS) is an investigational developmental screening tool, developed to rate the quality of the emotional connection that formed between mother and child. The screen is administered in 2-3 minutes by observing a mother and child interact, and requires the rater to critically assess 4 sub-domains of emotional connection. The NICU WECS is a clinical tool adapted for use with neonates in the NICU. Reliability of NICU staff WECS scoring will be calculated via intra-class correlations with key scores. The WECS is scored on intervals of 0.5, with a minimum of 1 (rarely--low level of connection) and maximum of 3 (mostly--high connection). Scores are used to determine the level of need for intervention.
41375885|NCT02372786|DRUG|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
41375886|NCT02372786|DRUG|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
41505525|NCT00970827|PROCEDURE|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
41505526|NCT00562523|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
41505527|NCT04999891|OTHER|Neurocognitive tests|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, NuDESC, 3D-CAM.
41505528|NCT01649960|DRUG|Rapamycin|Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
41033226|NCT04922242|OTHER|NICU WECS Training|"WECS Training is an educational module consisting of an introduction of the concepts of emotional connection and autonomic co-regulation as studied by The Nurture Science Program, as well as an illustration of how these experiential constructs differ from traditional care plans that focus on educating parents to encourage bonding as opposed to autonomic emotional connection within the NICU. An introduction to the domains of the WECS screen as well as illustrations of these domains through video will augment the training designed for NICU staff."
41033227|NCT00990652|DRUG|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
41033228|NCT00990652|DRUG|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
41375887|NCT02372786|DEVICE|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
41505529|NCT06187805|DEVICE|OSSIX Volumax|OSSIX Volumax is used in combination with autogenous bone collected during preparation of the implant osteotomy.
41163927|NCT02591797|PROCEDURE|inferior alveolar and lingual nerve block procedure|"The needle is inserted laterally to the pterygomandibular pit at its deepest point without noticing any resistance. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution.~The application of anesthesia shall be in accordance with the following guidelines:~1. Topical Anesthetic: Benzocaine 20% (Hurricaine, Clarben Laboratories SA, Madrid, Spain).~2. Dental Needle: short needles (21mm/30g) (Octoplus, Clarben Laboratories SA, Madrid, Spain)~3. anesthetic: lidocaine hydrochloride 2% with epinephrine 1: 100,000 (2% XILOCAINE, Dentsply, Spain).~4. Syringe: carpule syringe-conventional harpoon with suction system."
41505530|NCT02077361|GENETIC|rAAV2.REP1 vector|No additional details needed.
41505531|NCT03762694|DEVICE|Acupuncture|Electroacupuncture (EA) and Auricular Acupuncture (AA)
41505532|NCT00073710|DRUG|Zemplar|
41505533|NCT00073710|PROCEDURE|42 Ca carbonate absorption via single tracer method|
41163928|NCT01907022|DEVICE|Left DLPFC Butterfly Coil|"High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.~Arms: Left DLPFC Butterfly Coil"
41163929|NCT04265911|BIOLOGICAL|ASP3772 (subcutaneous)|Subcutaneous injection
41163930|NCT04265911|BIOLOGICAL|ASP3772 (intramuscular)|Intramuscular injection
41163931|NCT04265911|BIOLOGICAL|PPSV23 (subcutaneous)|Subcutaneous injection
41375888|NCT02372786|DEVICE|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
41375889|NCT02279472|PROCEDURE|Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia|All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
41375890|NCT04912973|PROCEDURE|Robotically Assisted Total Knee Arthroplasty - Knee Replacement|Robotically Assisted Total Knee Arthroplasty with a particular alignment strategy
41163932|NCT04265911|BIOLOGICAL|PPSV23 (intramuscular)|Intramuscular injection
41163933|NCT02712190|DEVICE|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
41163934|NCT01100918|DEVICE|BiV ICD|Biventricular ICD
41163935|NCT01100918|DEVICE|ICD|Implantable Defibrillator
41163936|NCT04567797|DEVICE|Laevo 2|The Laevo V2 is a wearable chest and back support exoskeleton. The Laevo transfers the from its chest pad to the thighs while bending forward. The passive exoskeleton (works with gas springs, not motors) transfers part of the load away from the back muscles, reducing the pressure on the spinal column. It provides a dampening effect on the back, reducing the risk of sudden back muscle contractions that needlessly overcompress the spine.
41375891|NCT03740126|DIAGNOSTIC_TEST|Whole body 18F-FDG PET/CT|In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.
41375892|NCT06317701|DEVICE|Hypoglossal Nerve Stimulation (HGNS)|Alternative therapy for Obstructive Sleep Apnea
41375893|NCT01477541|OTHER|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
41375894|NCT05558735|OTHER|urine collection|urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
41505534|NCT00073710|DRUG|Calcijex|
41505535|NCT05314088|BEHAVIORAL|RISE+|The intervention includes psychoeducational videos and written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience.
41505536|NCT05314088|BEHAVIORAL|Stress Reduction Control|Placebo Comparator: Stress Reduction Control Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games.
41505537|NCT01555671|DRUG|Meperidine|0.5 ml meperidine injection intravenously injected in randomly selected patients
41505538|NCT01555671|DRUG|Saline|0.5 ml saline solution injection intravenously injected in randomly selected patients
41505539|NCT05550506|DRUG|Duloxetine|Patients who use duloxetine for chronic pain or fibromyalgia
41505540|NCT03296878|OTHER|Own-Price Elasticity|The price of eggs will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
41505541|NCT03296878|OTHER|Cross-Price Elasticity|The price of eggs will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
41505542|NCT02646761|DEVICE|InterACTION|InterACTION guided home exercise program paired with standard of care physical therapy
41505543|NCT02646761|OTHER|Standard of Care Physical Therapy|Physical therapy rehabilitation program
41505544|NCT05727826|DEVICE|Thrive MD-01 .|The experimental group received a 60 Hz vibration stimulation treatment using the SMV method three times per week for two weeks (EG).
41505545|NCT04414774|DEVICE|GG-Suicide-Ideation|GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.
41505546|NCT05052047|OTHER|Brisk Walking Group|Brisk Walk: 20 min/day (The researchers found, for most people, brisk walking could be defined as moving at a pace of 2.7 miles per hour or 100 steps per minute for adults under about age 60 or guidelines define brisk walking as occurring when individuals move at a pace that increases their heart rate to about 70% of their heart rate maximum) Patient will also perform breathing exercises as given to Control group, Positioning (lean forward when needed) Percussion coughing when needed
40850216|NCT04706728|OTHER|Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with sounds from nature one day prior to ECT procedures for the first two weeks of their ECT treatment
41375895|NCT05558735|OTHER|canine detection|urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
41375896|NCT05225324|DRUG|Equfina 50 mg|Equfina 50 mg tablets.
41375897|NCT03176576|BEHAVIORAL|Patient Navigator (PN)|Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
41375898|NCT03176576|OTHER|Baseline Questionnaire|Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
40850217|NCT01412788|PROCEDURE|peri-areolar incision|peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
40850218|NCT01412788|PROCEDURE|traditional incision|Traditional incision above tumor was used to carry out breast-conserving surgery.
40850219|NCT00982839|PROCEDURE|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
40850220|NCT00982839|PROCEDURE|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
41033229|NCT05123248|DEVICE|Blinded Group|Participants in the blinded group will be wearing the sensor for 14 days without a reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
41033230|NCT05123248|DEVICE|Unblinded group|Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
41033231|NCT04743908|OTHER|Social Network Strategy + COVID-19 messaging|Contextually adapted and theory-driven messages - misinformation correction and self-affirmation - to increase awareness, self-efficacy and community engagement in our adapted Social Network testing Strategy (SNS). SNS is an evidence-based testing intervention that has been widely used in multiple settings with marginalized individuals (ie substance-users) who facilitate the recruitment of their social contacts into testing services.
41033232|NCT01360606|RADIATION|Stereotactic Body Radiation Therapy|"SBRT:~Patients will receive one of the following radiation regimens:~* 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~* 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~* 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period."
41033233|NCT01775891|DRUG|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
41033234|NCT01775891|DRUG|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
41033235|NCT03407638|OTHER|PROUD Intervention|The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
41033236|NCT06377241|DEVICE|ScentAware|ScentAware is a smell test
41033237|NCT06377241|DEVICE|UPSIT|UPSIT is a smell test
41033238|NCT05745077|BEHAVIORAL|Telemedicine Consultation|Patients will be contacted by their surgeon over the phone to discuss surgical treatment.
41033239|NCT05745077|BEHAVIORAL|Traditional Care|Patients will proceed with their surgical consultation as per standard practice.
41033240|NCT05934734|OTHER|No intervention|This is an observational cross-sectional study. No intervention will be provided. Participants will be assessed and stratified into four cohorts based on self-reported symptom severity of thoracic outlet syndrome using a visual analog scale (VAS) to investigate the relationship between symptom severity and upper extremity function/neural integrity.
41033241|NCT01490177|DRUG|Food proteins|Oral ingestion of Food proteins
41033242|NCT04445805|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, cognitive therapy, and relaxation. Treatment will be delivered via telemedicine.
41505547|NCT05052047|OTHER|Conventional Breathing Exercise Group|"Breathing exercises: 20 min/day~Breathing Ex includes:~• Pursed lip breathing: Sit with your back straight, inhale through your nose for 2 seconds. Purse your lips like you rae blowing on hot food and then breath out slowly, take twice as long to exhale as you took to breath in 4-5 times a day~• Diaphragmatic breathing: Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs . breathe in slowly through your nose tighten your stomach, letting them fall inward as you exhale through your pursed lips. Practice these exercises 5-10 minutes about 3-4 times a day.~Positioning (lean forward when needed) Percussion coughing when needed"
40850221|NCT05170399|BIOLOGICAL|Fluzone|Annual Influenza Vaccine
40850222|NCT05170399|BIOLOGICAL|Shingrix|Recombinant, adjuvanted Zoster Vaccine (RZV)
41033243|NCT04445805|BEHAVIORAL|Perinatal-enhanced Behavioral Therapy for Insomnia|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, and metacognitive exercises. Treatment will be delivered via telemedicine.
41033244|NCT04445805|BEHAVIORAL|Attention Control|Will include education on sleep, circadian rhythms, and good sleep hygiene in addition to self-monitoring with sleep diaries.
40850223|NCT05170399|BIOLOGICAL|Flucelvax|Annual Influenza Vaccine
40850224|NCT05170399|BIOLOGICAL|Afluria|Annual Influenza Vaccine
40850225|NCT05170399|BIOLOGICAL|PREVNAR 13|Pneumococcal Conjugate Vaccine (PCV13)
40850226|NCT05170399|BIOLOGICAL|Heplisav -B|Recombinant, adjuvanted Hepatitis (HepB-CpG)
40850227|NCT05170399|BIOLOGICAL|Pfizer-COVID-19 Vaccine|COVID-19 Vaccine
40850228|NCT05170399|BIOLOGICAL|FluLaval|Annual Influenza Vaccine
40850229|NCT05170399|BIOLOGICAL|Fluarix|Annual Influenza Vaccine
40850230|NCT05170399|BIOLOGICAL|PNEUMOVAX 23|Pneumococcal Polysaccharide Vaccine (PPSV23)
40850231|NCT05170399|DRUG|PREVNAR 20|Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
40850232|NCT05170399|DRUG|AREXVY, ABRYSVO|Respiratory Syncytial Virus Vaccine
40850233|NCT00837850|DEVICE|Bone cement 1|Bone cement SmartSet® HV
40850234|NCT00837850|DEVICE|Bone cement 2|Bone cement Palacos R
40850235|NCT00668668|DRUG|Lactic acid (Dermacid)|
41033245|NCT04396067|DRUG|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
41033246|NCT04396067|DRUG|Aerosolized All trans retinoic acid|The infected patients will receive Aerosolized All trans retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled all trans retinoic acid therapy for 14 days
41033247|NCT04396067|OTHER|Placebo|Placebo is a pill or tablet that does not contain any study drug.
41033248|NCT05591352|DIETARY_SUPPLEMENT|Chenopodium formosanum extracts sachet|consume 1 sachet per day
41033249|NCT05591352|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
41033250|NCT06308159|DRUG|Vebeglogene autotemcel|Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.
41033251|NCT02843568|OTHER|Laboratory Biomarker Analysis|Correlative studies
41033252|NCT02843568|RADIATION|Standard fractionation|60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
41033253|NCT02843568|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
41033254|NCT02843568|PROCEDURE|Four Dimensional Computed Tomographic Imaging (4DCT)|Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
41033255|NCT04731649|BEHAVIORAL|Families Talking Together Plus (FTT +)|FTT + consists of three online intervention sessions of approximately 60-90 minutes each, that cover content from nine modules designed to teach parents effective communication skills, build parent-adolescent relationships, help parents develop successful monitoring strategies, and teach adolescents assertiveness, refusal skills, and how to use a condom correctly and every time.
41033256|NCT05781750|DRUG|zetomipzomib|Subcutaneous injection of zetomipzomib
41033257|NCT05781750|DRUG|placebo|Subcutaneous injection of placebo
41033258|NCT03030300|DRUG|Novolin 30R;Pioglitazone;Metformin|"* Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~* Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~* Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone."
41033259|NCT04989348|PROCEDURE|Gonadotrophin releasing hormone antagonist protocol|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger or
41033260|NCT04989348|PROCEDURE|Progestin-primed ovarian stimulation protocol|Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
41163937|NCT04567797|DEVICE|backX|"backX is a novel industrial exoskeleton that substantially augments its wearer and reduces the forces and torques on a wearer's lower back region (L5/S1 disc) by an average of 60% while the wearer is stooping, lifting objects, bending or reaching. backX augments the wearer's strength and can reduce the risk of back injuries among workers. It does not require external motors or power source. The mechanism of backX is similar to the first device Laevo 2."
41163938|NCT04567797|DEVICE|FLx ErgoSkeleton|The FLx ErgoSkeleton is a range limiting work vest for physical work use. The FLx naturally reminds the user of the correct posture and lifting techniques while on the job site.
41033261|NCT02233829|DRUG|Brain Dopamine Reactivity|IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.
41033262|NCT02233829|RADIATION|Brain Dopamine Receptor|The radiotracer \[11C\] raclopride is used for imaging dopamine receptors and dopamine release.
41033263|NCT02562755|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
41033264|NCT02562755|DRUG|Sorafenib|"Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease."
41033265|NCT04729803|BEHAVIORAL|Experimental: Attention Guidance + Exposure|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention guidance condition: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given target audience members to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target audience member for the whole response."
41033266|NCT04729803|BEHAVIORAL|Active Comparator: Exposure Alone|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial."
41375899|NCT03176576|OTHER|Follow-up Questionnaire|After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
41375900|NCT03176576|OTHER|Patient Navigator Satisfaction Survey|Evaluation of Patient Navigator intervention process.
41163939|NCT04567797|DEVICE|V22 ErgoSkeleton|"Similar to the FLx ErgoSkeleton, the V22 ErgoSkeleton keeps the position of the human body as to always stay within a safe body posture while lifting or moving heavy objects. The V22 ErgoSkeleton applies pressure to remind the user both during improper lifts and over rotation.~In addition, the V22 ErgoSkeleton comes with two clutch controlled cables to assist in lifting and moving. The cables transfer part of the weight of the object being held directly to the V22 ErgoSkeleton vest, similar to other arm and shoulder support exoskeletons."
41163940|NCT03198936|DIETARY_SUPPLEMENT|Cognizin® SynapsaTM|2 capsules to be taken twice a day with meals with a glassful of water
41163941|NCT03198936|DIETARY_SUPPLEMENT|Placebo|2 capsules to be taken twice a day with meals with glassful of water
41163942|NCT03123419|BEHAVIORAL|Appointment reminders|The purpose of the Gardasil study is to increase the rates of Gardasil vaccination in the Maternal Fetal Care Center. This will be done by reminding patients via text to come for their follow up vaccine appointments.
41163943|NCT06414759|DRUG|Acetazolamide|"Acetazolamide is a medication that belongs to the class of carbonic anhydrase inhibitors. It acts by reducing the reabsorption of sodium in the proximal tubules of the kidneys. When combined with loop diuretics, acetazolamide has the potential to enhance the effectiveness of diuretic therapy, thus aiding in the process of decongestion.~It will be given 500mg orally, once daily."
41163944|NCT06414759|DRUG|Metolazone|"Metolazone is a medication with properties like thiazide diuretics, prescribed for the management of congestive heart failure and hypertension. Its mechanism of action involves blocking the transport of sodium across the epithelium of renal tubules, predominantly in the distal tubules.~It will be given 5mg orally, once daily."
41163945|NCT06414759|DRUG|IV Loop Diuretics|IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.
41163946|NCT04318314|DIAGNOSTIC_TEST|COPAN swabbing and blood sample collection|COPAN swabbing of nostrils and/or oropharynx and blood sample collection
41163947|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
41163948|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
41163949|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
41163950|NCT01180790|DRUG|Placebo|Powder in capsule once daily
41163951|NCT01180790|DRUG|Pegylated Interferon alpha-2a|180 micrograms (ug) once a week by subcutaneous injection
41163952|NCT01180790|DRUG|Ribavirin|400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily
41163953|NCT03292497|PROCEDURE|Treatment Algorithm|Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle \>=25 degrees, or repaired if the posterior leaflet tethering angle \<25 degrees.
41163954|NCT03292497|PROCEDURE|No Treatment Algorithm|Patients will have their valve repaired or replaced at the discretion of their surgeon.
41163955|NCT01246219|DRUG|GH treatment (Genotropin)|4 years treatment with GH
41163956|NCT01246219|DRUG|1 year treatment with placebo followed by optional 3 years of GH treatment|1 year treatment with placebo followed by optional 3 years of GH treatment
41505548|NCT01554319|DRUG|SB010|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL."
41505549|NCT01554319|DRUG|Placebo (phosphate-buffered saline)|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board."
41505550|NCT03365557|PROCEDURE|Airway peak pressure|Air was injected into LMA cuff during expiration phase to make intracuff pressure achieve the level of airway peak pressure. If there's any leakage, increase 5 cmH2O every time till there's no air leakage from the mouth.
41163957|NCT05277818|PROCEDURE|Surgery lumbar disc herniation|Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation
41163958|NCT03505255|DRUG|Neostigmine|Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction
41163959|NCT03505255|OTHER|Normal saline|Normal saline 0.9 % is given in the control group
41163960|NCT04961983|BEHAVIORAL|Comprehensive Travel Health Education Model|"The comprehensive travel health education model consists of:~1. Online training: 10 hours (2 days) online education via Zoom. The topics that will be delivered during the training includes:~   * The potential roles of tour guides in tourists' health,~  * The importance of travel health information for tourists,~  * Assessment of tourist's health risks,~  * Prevention and first aid of various travel health problems Topics related to tour guides will be delivered by the tourism experts, while topics related to travel health will be provided by travel medicine experts, Faculty of Medicine, Udayana University. Participants will also receive a travel health guide book.~2. Weekly travel health Information sharing through WhatsApp group for 2 months."
41163961|NCT04593706|DRUG|Betamethasone acetate + Betamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
41163962|NCT04593706|DRUG|Dexamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
41163963|NCT04593706|DRUG|Methylprednisolone acetate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
41163964|NCT04593706|DRUG|Triamcinolone acetonide|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
41163965|NCT01532583|OTHER|Gynaecological examination, a supine stress test, questionnaires|Gynaecological examination, a supine stress test, questionnaires
41505551|NCT03190902|BEHAVIORAL|Attention Processing Training program (APT)|
40850236|NCT00766051|OTHER|The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)|This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
41033267|NCT04729803|BEHAVIORAL|Experimental: Attention Control + Exposure|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~   F~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. During each call participants will be prompted by one of the audience members.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention control condition: (1) the intervention rationale will include information about the importance of attention control; (2) participants will be given target at the center of the screen to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target for the whole response."
41163966|NCT00551135|DRUG|Pregabalin|150 mg BID
41163967|NCT00551135|DRUG|placebo|Placebo
41163968|NCT00551135|DRUG|Pregabalin|75 mg BID
41505552|NCT03190902|BEHAVIORAL|nonspecific computer training (n-ST)|
41505553|NCT05068154|DIAGNOSTIC_TEST|Myovista® WavECG™|The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired 12-lead ECG signal which is then analysed using artificial intelligence to provide information relating to left ventricular relaxation abnormalities
41505554|NCT02965586|DRUG|intrathecal|intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
41163969|NCT00551135|DRUG|Pregabalin|25 mg BID
41163970|NCT05172557|BEHAVIORAL|Wellness Program|Wellness Program involves participation in classes with topics involving resiliency, stress, physical activity, and nutrition to be completed within a few months of study participation
41163971|NCT05172557|BEHAVIORAL|Wellness Coaching|Wellness coaching sessions throughout 12 months of study participation
41163972|NCT05648318|DRUG|Lactulose oral solution|In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
41375901|NCT06103617|DRUG|Penicillamine|Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
41375902|NCT04456998|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
41163973|NCT05648318|DRUG|PEG|patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
41163974|NCT00961896|DRUG|Vehicle|Placebo cream
41375903|NCT04456998|DRUG|Placebo|Matching capsule containing placebo
41163975|NCT00961896|DRUG|LDE225 0.25%|
41375904|NCT04456998|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
41375905|NCT02127021|DRUG|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
41375906|NCT02127021|DRUG|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
41375907|NCT03133429|DEVICE|MER|carotid artery stenting
41375908|NCT03055286|DRUG|CWP232291|"For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion."
41163976|NCT00961896|DRUG|LDE225 0.75%|
41163977|NCT00005058|PROCEDURE|ultrasound imaging|
41163978|NCT01135030|PROCEDURE|Total knee|Primary Total knee
41163979|NCT01187810|DRUG|Fenretinide|925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.
41163980|NCT01187810|DRUG|Cytarabine|dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle
41375909|NCT03525769|DIAGNOSTIC_TEST|FibroTouch|"FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging."
41375910|NCT05375487|OTHER|Carbonated Natural Mineral Water|750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.
41375911|NCT05375487|OTHER|Low Mineral Water|750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
41375912|NCT02780817|OTHER|Error enhancement|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
41375913|NCT02780817|OTHER|Control group|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
40850237|NCT05964036|DEVICE|active TMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized target in the DMPFC will be generated using the pBFS method
40850238|NCT05964036|DEVICE|sham TMS|The parameters in the sham arm are the same as in the active stimulation group. Stimulation was delivered by the same device as the active group fitted with a sham coil
40850239|NCT03193710|DRUG|Propofol|Propofol will be used for anesthesia maintenance in the total intravenous anesthesia group.
40850240|NCT03193710|DRUG|Sevoflurane|Sevoflurane will be used for anesthesia maintenance in the inhalation anesthesia group.
40850241|NCT03193710|DRUG|Remifentanil|Remifentanil will be used for analgesia in both groups.
40850242|NCT04374006|DRUG|Dienogest|1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day
40850243|NCT04374006|DRUG|Propolis|The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment
40850244|NCT04374006|OTHER|placebo|we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
41163981|NCT01187810|DRUG|Methotrexate|Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
41163982|NCT06165536|BEHAVIORAL|Resonant voice therapy|Resonant voice therapy is a standard of care procedure for treating phonotraumatic vocal hyperfunction. The full standardized voice therapy program will have a duration of four weeks, each week with one 60-minute therapy session.
41163983|NCT02957162|DRUG|Atorvastatin|
41163984|NCT02957162|OTHER|Blood samples|3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
41375914|NCT01561573|DEVICE|Point of care ultrasound|A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
41375915|NCT03788239|OTHER|Staples versus sutures|"Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples."
41375916|NCT02826239|DEVICE|multiple breath washout test (MBW)|measured in upright and supine position
41375917|NCT02965027|DRUG|Prazosin|
41375918|NCT02965027|DRUG|Placebo|
41375919|NCT05749900|DRUG|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin|Phase Ib Nivolumab 360mg IV q 3weeks Gemcitabine 1000mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks Level -1 Nivolumab 360mg IV q 3weeks Gemcitabine 800mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks
41375920|NCT00632138|BEHAVIORAL|exercise intervention|
41375921|NCT00632138|OTHER|questionnaire administration|
41375922|NCT00632138|PROCEDURE|biofeedback|
41375923|NCT00632138|PROCEDURE|management of therapy complications|
41375924|NCT00632138|PROCEDURE|psychosocial assessment and care|
41375925|NCT00632138|PROCEDURE|quality-of-life assessment|
41375926|NCT05214976|DRUG|Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)|Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.
41375927|NCT03148873|DEVICE|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
41375928|NCT02364882|DRUG|Sildenafil|
41375929|NCT05696691|DRUG|Ketamine Hydrochloride|100mg IM ketamine to be administered in conjunction with CRP. The ketamine injection will be administered first. Participants will be observed and have vital signs monitored for the first 45 minutes after administering medication in the ED, observing for immediate reactions. Afterwards, participants will continue to be monitored for potential late-term side effects on the inpatient unit. Ketamine will be given only after initial standard of care (SOC) treatment and screening studies have been initiated.
41375930|NCT05696691|BEHAVIORAL|Crisis Response Plan|"Crisis Response Plan is a brief, empirically-validated, Cognitive-Behavioral Therapy-based one-time therapy, and its administration typically takes 30-60 minutes. It begins with a narrative assessment (allowing patients to tell their story) and concludes with collaboratively constructed plan that outlines strategies for the patient's self-management of future acute suicidal crises. Patients who engage in CRP are given an index card to keep with them that summarizes the emotional management strategies that they collaboratively generate with the CRP provider."
41375931|NCT05820880|DRUG|Fixed [Per/Ind/Aml]|Fixed Dose combination of Perindopril/Indapamide/Amlodipine
41375932|NCT05820880|DRUG|Free [Per/Ind + Aml]|Free dose combination of Perindopril/Indapamide and Amlodipine
40850245|NCT04519281|DRUG|IV of vitamin C|administration of high-dose of IV vitamin C perioperatively
40850246|NCT00004275|DRUG|growth hormone|
40850247|NCT00004275|DRUG|oxandrolone|
40850248|NCT05805891|DRUG|bortezomib|bortezomib 2mg/week subcutaneous injection
40850249|NCT03057860|OTHER|No study intervention|
40850250|NCT03471780|DIAGNOSTIC_TEST|ultrasound|Transperineal us are made to pregnant ladies in labour
40850251|NCT00180583|DEVICE|Guidant GALILEO Intravascular Radiotherapy System|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
40850252|NCT04826640|OTHER|Observational|Observational
40850253|NCT05705427|DRUG|Tenofovir Disoproxil Fumarate 300 MG|Pregnant women in the experimental arm will receive TDF daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
41033268|NCT03684629|BEHAVIORAL|the response of KPI and corresponding suggestion|Standardized templates of medical record, evidence-based clinical pathway, and written care protocols are applied in all hospitals.The KPI of the AIS patients who were admitted to a single hospital continuously at the time of hospitalization were studied. Feedback system of performance measures: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system since that month into the group. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the corresponding monthly KPI. The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Expert online consultation: based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month.
41033269|NCT00866840|DRUG|riluzole|100 mg orally twice daily
41033270|NCT03858205|OTHER|Quality-of-Life Assessment|Ancillary studies
41033271|NCT03858205|OTHER|Questionnaire Administration|Ancillary studies
41033272|NCT03858205|RADIATION|Radiation Therapy|Receive low-dose radiation therapy
41033273|NCT04681638|DRUG|Pathogen-Reduced Plasma|The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL\*kg\*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
41033274|NCT04681638|DRUG|Crystalloid Solutions|The control group will receive an additional infusion of LR based on the formula: hourly rate, mL/hr = (1mL\*kg\*TBSA)/24 hr. this infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
41033275|NCT03171298|PROCEDURE|Laparoscopic Assisted Transanal Total Mesorectal Excision|"* Abdominal approach with laparoscopic mobilization of the left colon~* Laparoscopic isolation and transection of inferior mesenteric vessels .~* Transabdominal dissection of the upper rectum and mesorectam.~* Insertion of transanal platform and the creation of pneumorectum.~* Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~* Transanal dissection of lower and mid mesorectam~* The specimen will be extracted transanally"
41033276|NCT00000216|DRUG|Buprenorphine|
41033277|NCT04969081|BEHAVIORAL|referral to work focused program|referral to Incentive Therapy or to Other Therapeutic and Supported Employment Services
41375933|NCT06282250|BEHAVIORAL|Bright light therapy + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: BLT will be administered for 30 minutes on five consecutive days, starting on Monday of the work week, between 7:30 AM and 10:00. The effect of the light therapy is evaluated by means of the Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). Further treatment strategy is determined on the basis of these results:~* If the patient has achieved remission (QIDS-SR \< 6), BLT has been successful and the patient can continue with PE and IMCT.~* If there is insufficient or no response (QIDS-SR of 6 or higher), BLT is extended with five more sessions the following week.~* If necessary, a third week is optional.~Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
41375934|NCT06282250|BEHAVIORAL|Blue-light blocking glasses + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: blue-light blocking glasses will be administered. Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
41033278|NCT04969081|OTHER|treatment as usual|usual treatment
41033279|NCT06415682|DEVICE|SMA+M1 Transcranial Magnetic Stimulation|"The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). For SMA stimulation, a 5s burst of 10Hz rTMS was repeated 20 times (1000 pulse, 20 minutes' duration).~Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex (M1) of the lower leg and supplementary motor area (SMA)."
41033280|NCT06415682|DEVICE|M1 Transcranial Magnetic Stimulation|The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). Patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral M1 of the lower leg.
41033281|NCT06415682|DEVICE|Sham Transcranial Magnetic Stimulation|Patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on M1 of the lower leg.
41033282|NCT03448146|DRUG|Para-Toluenesulfonamide|
41033283|NCT01753024|DIETARY_SUPPLEMENT|Enteral nutrition (EN)|All patients enrolled in this study must carry out nutritional support by enteral nutrition
41033284|NCT05400096|OTHER|Psychological therapy|The protocol for the group will be developed collaboratively between the chief researcher and the supervisor based in the weight management service. The protocol will contain Compassion Focused Therapy (CFT) based therapeutic approaches, but the group will integrate some Acceptance and Commitment Therapy (ACT) concepts.
41163985|NCT02629419|DRUG|Amphotericin B|Oral lipid nanocrystal formulation of amphotericin B
41375935|NCT06282250|BEHAVIORAL|Psycho-education + Imagery focused Cognitive Therapy|"Week 1: Psycho Education, 1 session.~Week 2-7: ImCT will follow, 6 sessions."
41375936|NCT01754012|DIETARY_SUPPLEMENT|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
41375937|NCT05432466|DRUG|ACER-002 (celiprolol) 200 mg BID|ACER-002 (celiprolol) 200 mg BID
41375938|NCT05432466|DRUG|Placebo BID|placebo for ACER-002
41375939|NCT00958659|OTHER|laboratory biomarker analysis|Correlative studies
41505555|NCT01761760|BEHAVIORAL|Videogame-based smoking cessation intervention|Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
41505556|NCT04207307|BEHAVIORAL|Multimodal exercise program|Multimodal exercise intervention (machine-based resistance, coordination and endurance training).
40850254|NCT05705427|BIOLOGICAL|Hepatitis B monovalent vaccine|All infants born to women in the study will receive a birth-dose hepatitis B vaccine.
40850255|NCT05705427|DRUG|Placebo|Pregnant women in the placebo arm will receive a placebo pill daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
41505557|NCT04207307|BEHAVIORAL|Usual Care|General recommendations for healthy ageing, no machine-based strength training intervention.
41505558|NCT00437359|DRUG|Toremifene citrate|Toremifene citrate: 40-mg tablets by mouth once daily.
41505559|NCT00437359|DRUG|Anastrozole|Anastrozole: 1-mg tablets by mouth once daily.
41033285|NCT05540236|OTHER|auricular acupressure|The experimental group were given therapeutic intervention of single ear auricular pellet acupressure at the stomach(CO4), cardia(CO3), liver(CO12), occiput(AT3), shenmen(TF4) and subcortex(AT4) acupuncture points
41033286|NCT05540236|OTHER|sham auricular acupressure|The control group were given sham intervention of single ear auricular pellet acupressure at the knee(AH4) and thoracic vertebrae(AH11) acupuncture points
41033287|NCT06328361|PROCEDURE|Nonoperative surveillance|Clinical and imaging surveillance with digital rectal examination and/or endoscopy, rectal MRI and body CT
41033288|NCT02521090|BIOLOGICAL|EGFRBi-Armed Autologous T Cells|Given IT and IV
41033289|NCT02521090|OTHER|Laboratory Biomarker Analysis|Correlative studies
41033290|NCT05982522|DRUG|IN10018|orally taken once daily
41033291|NCT05982522|DRUG|Nab-paclitaxel|125 mg/m2 D1, 8 Q3W, Intravenously
41033292|NCT05982522|DRUG|Tislelizumab|200mg Q3W, Intravenously
41375940|NCT04461912|DEVICE|Eye Scan Ultrasound System (ESUS)|"• For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved."
41505560|NCT05575609|OTHER|children with Diabetes Mellitus, Type 1|assessment of Relation between anthropometric measurements and balance in children with type 1 diabetes
41505561|NCT00348504|DRUG|levosimendan|
41033293|NCT04169841|DRUG|olaparib, durvalumab, tremelimumab|"STEP 1:~Olaparib 300 mg BID during 8 weeks. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food~STEP 2:~Olaparib 300 mg during 4 months as per same requirement as below. Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing."
41505562|NCT00348504|DRUG|dobutamine|
41505563|NCT06435442|DRUG|Epaminurad, Naproxen|Period 1: Epaminurad/ Period 2: Naproxen -\> Epaminurad+Naproxen
41033294|NCT00332748|DRUG|Oral Taxane|
41033295|NCT06152120|OTHER|Nurse-facilitated advance care planning intervention|"The intervention consists of two components:~Component 1. Palliative care needs assessment - The research nurse will conduct a palliative care needs assessment and also review related information from the medical chart, which will enable the nurse to provide tailored information on the patient's illness, prognosis, and palliative care needs during subsequent ACP consultations.~Component 2: Structured nurse-facilitated ACP consultations - The research nurse will conduct post-discharge ACP consultations with the family surrogate, with content that includes: assess readiness for discussions, introduce video decision aides to provide related ACP information and share examples of family surrogates with similar experiences."
41033296|NCT05637021|OTHER|Carbon dioxide insufflated during colonoscopy|Carbon dioxide is insufflated to dilate the bowel lumen during colonoscopy.Record the amount of gas insufflated during colonoscopy.
41033297|NCT06635382|OTHER|Universal single bond adhesive|Will be applied and light cured for 20 seconds.
41505564|NCT06435442|DRUG|Epaminurad|Epaminurad
41505565|NCT06435442|DRUG|Epaminurad placebo|Epaminurad placebo
41505566|NCT04766112|OTHER|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training
41033298|NCT06635382|OTHER|DMSO|DMSO application on tooth followed by active application of universal single bond adhesive and light cured for 20 seconds.
41505567|NCT04766112|OTHER|Group II|Group II will receive yang style Tai chi exercise which consist of 10 positions.
41505568|NCT05770895|BIOLOGICAL|GS-2829|Administered intramuscularly
41505569|NCT05770895|BIOLOGICAL|GS-6779|Administered intramuscularly
41505570|NCT05770895|BIOLOGICAL|Placebo for GS-2829|Administered intramuscularly
41163986|NCT06337240|OTHER|Pelvic floor on COPD patients|"Group A (study group) :~This group will include 30 COPD patients with urinary incontinence , who will receive pelvic floor exercise for 3 days a week for a total of 3 months."
41375941|NCT06539897|BEHAVIORAL|Sexual education|These sessions of the sexual education program aim to increase women's knowledge and awareness about their own bodies. Women are informed about their own bodies, their identities, and the stages of sexual response, aiming to make the process clearer and more understandable. They will be encouraged to discover what sexuality means to them, their knowledge about sexuality will be questioned, and sexual myths, if any, will be revealed, and correct information about sexual myths will be provided to normalize sexuality. In addition, discussions will be held on the meanings of being a woman and an older woman, and women's perspectives on themselves and their self-esteem will be emphasized. In the third session, participants will be taught effective communication techniques to improve their communication skills with their partners.
41375942|NCT00910000|DRUG|Vorinostat|
41375943|NCT00910000|DRUG|Carboplatin|
41375944|NCT00910000|DRUG|Gemcitabine|
40850256|NCT02518373|BIOLOGICAL|G17DT|G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.
41033299|NCT06247176|BEHAVIORAL|Sensory Habituation Protocol|"The first session continues with the Mock MRI, which lasts 10 minutes. Participant's comfort level in VR will be evaluated.~At the pre-exposure visit, participants complete an MRI scan on a 3 Tesla MRI, which takes approximately 1 hour \& 15 minutes. It consists of structural \& functional MRI scans. Structural scans require the participant to stay still with eyes closed. Functional scans will require the participant to lie with eyes closed or watch and listen to sensory stimulation.~VR exposure will occur across 3 1-hour sessions at most. Participants will be asked to complete a sensory habituation protocol, in which they will watch and listen to sensory stimuli in VR for an increasing amount of time. Between the sensory stimuli, the participant will watch a self-selected video.~Finally, the subject will be asked to do a post-exposure MRI visit, which is the same as the pre-exposure visit."
41033300|NCT06635512|OTHER|The Effect of Stress Ball Application After Transurethral Resection of the Prostate on Patients' Recovery Quality and Hospital Discharge Time|The effect of the stress ball applied after surgery on patients' recovery quality will be evaluated.
41033301|NCT02672904|DEVICE|CO2 laser|surgical removal of carcinoma from the vocal cords with CO2 laser
41033302|NCT02672904|DEVICE|KTP laser|surgical removal of carcinoma from the vocal cords with KTP laser
41033303|NCT02842060|BEHAVIORAL|myDEx|myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
41033304|NCT02842060|BEHAVIORAL|NTHP|The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
41033305|NCT04452461|DRUG|mFOLFIRINOX|mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
41033306|NCT04452461|DRUG|Gemcitabine / Nab-paclitaxel|Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
41163987|NCT06337240|OTHER|Pilates exercises on COPD patients|"Group B (study group):~This group will include 30 COPD patients with urinary incontinence , who will receive pilates for 3 days a week for a total 3 months."
41375945|NCT04401709|DRUG|Gemcitabine/Capecitabine|gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 \~ 21 days for 4 weeks
41375946|NCT04401709|DRUG|Capecitabine|total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 \~ 14 days for 3 weeks
41375947|NCT06364007|DRUG|HAIC+STRIDE+Len|patients will be administrated with STRIDE plus lenvatinib (8 mg or 12 mg) once daily plus HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h).
41375948|NCT03497000|PROCEDURE|OCTA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
41163988|NCT01269255|DRUG|TS-1 with Cisplatin|"SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)~* Step 1: Chemotherapy; TS-1/CDDP #2 cycles~* Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP~* Step 3: Surgery therapy"
41163989|NCT05806164|DRUG|Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]|The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
41163990|NCT05806164|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
41375949|NCT03497000|PROCEDURE|ICGA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
41375950|NCT01504152|BEHAVIORAL|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
40850257|NCT02518373|DRUG|Omeprazole|Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
41033307|NCT04790981|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
41033308|NCT04790981|OTHER|physical thertapy training|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern including.
41163991|NCT04059497|BEHAVIORAL|Exercise condition|Each participant in the intervention group can freely choose a handgrip of strength from 10 to 25kg which can be gripped with adequate grip strength. The PI will play the short video (5 minutes, www.youtube.com/watch?v=mZex2Wwy3fU) about the 10s-E for the participant, including (1) rapid grip-and-release the handgrip for at least 30 times in 10seconds in each hand, and (2) short-bout hand pushing and pulling exercises without handgrip. During the video, participants are asked to follow the 10s-E demonstrated by the medical professor. After the video, the PI will guide the participant to repeat the 10s-E for 5 times within the next 5 minutes. If participants feel pain in their hands, they can slow down the exercise. Between each exercise set, rest time for 10-20 seconds will be allowed. After practicing all these exercises, participants are asked to complete a post-intervention questionnaire
41163992|NCT04059497|BEHAVIORAL|Healthy diet condition|The control group will watch two videos on healthy diet (https://www.youtube.com/watch?v=w_u4BYV2Okc). Similar to the 10s-E condition, they will complete a post-intervention questionnaire after the two videos.
41375951|NCT02418338|OTHER|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
41375952|NCT05643807|DEVICE|Flexible cystoscopy|Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
40850258|NCT02300181|DIETARY_SUPPLEMENT|Placebo|
41375953|NCT05643807|DEVICE|Urinary catheter|Urinary cytology will be collected through a Ch14 urinary catheter after the cystoscopy
41375954|NCT02099929|OTHER|Coffee with Sugar|300mL of Coffee with 30g of Sugar
41375955|NCT02099929|OTHER|Coffee without Sugar|300mL of Coffee without Sugar
41375956|NCT02099929|OTHER|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
41375957|NCT02099929|OTHER|Water with Sugar|300mL of Water with 30g of Sugar
41375958|NCT02099929|OTHER|Water without Sugar|300mL of Water without Sugar
41375959|NCT00003104|RADIATION|radiation therapy|
41375960|NCT00620191|DRUG|Metformin|Metformin 1000 mg twice a day titrated from 500 mg once a day
41375961|NCT00620191|DRUG|Placebo|Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
40850259|NCT02300181|DIETARY_SUPPLEMENT|Bacillus subtilis var natto DC-15|
40850260|NCT01743040|DIAGNOSTIC_TEST|CADence|"Patients with chest pain and two or more coronary risk factors and who were already indicated for nuclear stress test were enrolled in the study. The CADence was performed prior to nuclear stress test. Patients underwent standard angiogram based upon normal clinical judgement. In all other patients a CT angiogram followed.~CADence is a handheld equipped with acoustic sensor technology, a patient booklet, remote algorithm and final report."
41163993|NCT02456298|BEHAVIORAL|Standard FA+FCT|Standard Functional Analysis and Functional Communication Training
40850261|NCT04723680|OTHER|Qualitative interview|Qualitative semi structured interview
41033309|NCT00451581|PROCEDURE|Endoscopic papillary balloon dilation-5 minutes|
41375962|NCT00519909|OTHER|Dairy calcium|Diets with different content of calcium and fat
41375963|NCT06374693|DEVICE|Transcutaneous Vagus Nerve Stimulation|"* Pulse width - 25ms~* Frequency - device default (20 or 25Hz)~* Intensity - below pain threshold.~* Frequency - 45 minutes twice daily. On the basis of similarity to other studies, practicalities on the ward and clinical scenario~We have chosen a duration of 5 days based on the usual clinical pathway of inpatient management at the Royal Hallamshire Hospital, and have chosen to deliver the treatment twice daily to optimise the dose. This is a pilot study with feasibility outcomes and as such we will be exploring the feasibility of this treatment regimen.~The Parasym Device will be applied to the left tragus (figure 1) as this is the most common site for tVNS delivery in neurological studies and is associated with few afferents to the heart."
41375964|NCT06374693|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|The active intervention will be compared to sham tVNS where the vagal nerve stimulator will be attached to the earlobe instead of the tragus, in keeping with evidence that this does not cause vagus nerve stimulation and is in line with sham methods used in other studies. We do not anticipate that patients will have the intervention long enough to become familiar with the common sensations associated with true tVNS intervention. At the end of the intervention period, participants will be asked if they thought they had received true of sham tVNS to understand the blinding ability of the sham.
41505571|NCT05770895|BIOLOGICAL|Placebo for GS-6779|Administered intramuscularly
41505572|NCT02460406|OTHER|traditional physiotherapy|We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching \& walking so on).
40850262|NCT03410303|DIAGNOSTIC_TEST|Intraoperative ultrasound and 2 months post-operative ultrasound ( ± 1 month)|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
40850263|NCT01822392|BEHAVIORAL|Online Parent Management Training (Interactive)|
40850264|NCT01822392|BEHAVIORAL|Online Parent Management Training (Recorded)|
40850265|NCT01150565|DRUG|LiRIS low dose and LiRIS high dose|Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
41033310|NCT00451581|PROCEDURE|Endoscopic papillary balloon dilation-1 minute|
41375965|NCT02163525|PROCEDURE|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
41375966|NCT02163525|PROCEDURE|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
41375967|NCT02163525|PROCEDURE|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
41375968|NCT05252273|OTHER|Observational, No intervention|Open-label observational study that will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
41505573|NCT02460406|OTHER|progressive functional strength training|"Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball \& heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
40850266|NCT02687581|DEVICE|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
40850267|NCT02687581|DEVICE|patch|6-hour of eye patch on the fellow eye
41505574|NCT06501586|DRUG|SGB-3908|SGB-3908 for sc injection
41505575|NCT06501586|OTHER|SGB-3908-Matching placebo|Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered
41505576|NCT05845502|BIOLOGICAL|SZ003 CAR-NK|Drug: SZ003 CAR-NK In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8 ,2.0×10\^8 and5.0×10\^8 cells. The infusion is given every 2 weeks.
41505577|NCT02497911|PROCEDURE|Adductor Canal Catheter|0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump
40850268|NCT00883441|OTHER|Insecticide treated curtains and insecticide treated covers|The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
40850269|NCT02854748|DRUG|Empagliflozin 25mg|Empagliflozin 25 mg QD for 5 days
40850270|NCT02854748|DRUG|Lobeglitazone 0.5mg|Lobeglitazone 0.5mg QD for 5 days
40850271|NCT02854748|DRUG|Empagliflozin 25mg/Lobeglitazone 0.5mg|Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
41505578|NCT02497911|PROCEDURE|Intraarticular Catheter|0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump
41505579|NCT02497911|DRUG|Ropivicaine|
41505580|NCT02497911|DRUG|Bupivicaine|
41505581|NCT03190031|OTHER|Endurance respiratory muscle training|Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea
41505582|NCT03190031|OTHER|Resistance inspiratory muscle training|Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
41505583|NCT03775044|DEVICE|Medherent Device|The Medherent Medication Management Device (MMD) is intended to enable patients to self-manage their medication at home when it may otherwise require assistance.
41505584|NCT05358509|DRUG|Ferric carboxymaltose|Pregnant participants randomized to intervention arm 1 will receive a single dose of ferric carboxymaltose having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
41505585|NCT05358509|DRUG|Iron isomaltoside|Pregnant participants randomized to intervention arm 1 will receive a single dose of iron isomaltoside having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
41505586|NCT05358509|DRUG|Ferric Sulfate|Pregnant participants randomized to the oral iron arm will be given 200 ferrous sulphate tablets with 60mg elemental iron each, immediately after randomization, and instructed to take two per day (one in the morning and one at night) throughout the remainder of their pregnancy.
41505587|NCT04206969|BEHAVIORAL|Transcultural psychotherapy|In addition to usual care, the participants receive transcultural psychotherapy
41505588|NCT03685201|DIETARY_SUPPLEMENT|Orange Juice1|100% Orange Juice
40850272|NCT02738424|OTHER|Calculate the ADC scores|The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.
40850273|NCT05137977|PROCEDURE|Intensive Care|Invasive ventilation more than 24hs.
40850274|NCT01366729|DEVICE|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
40850275|NCT01366729|DEVICE|Cane walking|All walking activities must take place with cane from waking until sleeping
40850276|NCT02782221|DRUG|Growth Hormone|Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
40850277|NCT02782221|DRUG|Pegisomant|One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
40850278|NCT06006403|BIOLOGICAL|CD123 targeted CAR-NK cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
41033311|NCT02277782|DRUG|Hydromorphone|
41505589|NCT03685201|DIETARY_SUPPLEMENT|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
41505590|NCT03685201|DIETARY_SUPPLEMENT|Raw Orange|Raw Orange
41033312|NCT02277782|DRUG|Hyperbaric bupivacaine|
41033313|NCT02277782|DRUG|Fentanyl|
41375969|NCT03504839|DEVICE|Subcutaneous ICD with same day discharge|Receiving a SICD and discharged the same day
41375970|NCT02060526|DRUG|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase \[rhHNS\]
40850279|NCT02513576|OTHER|physiotherapy exercises|Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
40850280|NCT01989806|DEVICE|Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)|
40850281|NCT01989806|DEVICE|Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)|
41033314|NCT06635343|OTHER|CPRP|In the CPRP group, a chest physiotherapy program was given by the physiotherapist 5 days a week, for 8 weeks, including respiratory control, diaphragmatic breathing, thoracic expansion exercises, and physical activity recommendations, to be applied once a day.
41163994|NCT02456298|BEHAVIORAL|Pragmatic FA+FCT|Pragmatic Functional Analysis and Functional Communication Training
41163995|NCT00003502|DRUG|antineoplaston A10|
41163996|NCT00003502|DRUG|antineoplaston AS2-1|
41163997|NCT00003502|PROCEDURE|alternative product therapy|
40850282|NCT02168218|OTHER|7-day overfeeding|7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
40850283|NCT02071069|DRUG|Cetuximab|400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
40850284|NCT02071069|DRUG|irinotecan|180 mg/m2 IV every 2 weeks
40850285|NCT02071069|DRUG|fluorouracil|400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
40850286|NCT00963794|OTHER|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
40850288|NCT03817268|DRUG|Capecitabine monotherapy|Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
41163998|NCT00003502|PROCEDURE|biological therapy|
41163999|NCT00003502|PROCEDURE|biologically based therapies|
41164000|NCT00003502|PROCEDURE|cancer prevention intervention|
41375971|NCT01991756|DEVICE|Altura Endograft System|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
41375972|NCT06361368|DIETARY_SUPPLEMENT|PS150|Participants took one capsule with PS150 after dinner for 30 days.
41375973|NCT06361368|DIETARY_SUPPLEMENT|Placebo|Participants took one capsule with placebo after dinner for 30 days.
41505591|NCT06398119|OTHER|Traditional Treatment Program|Traditional Treatment Program for improving hand function
41164001|NCT00003502|PROCEDURE|complementary and alternative therapy|
41505592|NCT06398119|OTHER|Virtual Reality Program|Virtual Reality Program for improving hand function
41505593|NCT02886624|DRUG|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
41505594|NCT03104478|PROCEDURE|Biological samples collection|In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.
41164002|NCT00003502|PROCEDURE|differentiation therapy|
41164003|NCT04180306|OTHER|pediatric early warning scoring system and resuscitation curriculum|teaching resuscitation to medical providers and implementing a scoring tool to help identify patients at risk for clinical deterioration in an inpatient setting
41164004|NCT01029678|DRUG|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
41164005|NCT01029678|DRUG|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
41164006|NCT01029678|RADIATION|Radiotherapy|66Gy, 33 fractions, 6 week
41505595|NCT02083068|BIOLOGICAL|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6
41505596|NCT02083068|BIOLOGICAL|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0
41164007|NCT05971277|DEVICE|Halo Wearable data device|A wrist-worn tracker with heart-rate monitor and pedometer (step counter), as well as a mobile app.
41164008|NCT05550597|DRUG|Fentanyl HCl|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia
41164009|NCT05550597|DRUG|Bupivacaine 0.25% Injectable Solution|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution
41164010|NCT05849571|OTHER|coconut oil|• The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Child Mucositis Evaluation Scale (ChIMES) on days 0, 7, and 14, and after each assessment, the frequency of oral care is determined and applied for 21 days. The final assessment is made on Day 21.
41164011|NCT02870751|BIOLOGICAL|TW11681 or TW10722|
41164012|NCT04723732|DRUG|Myrrh mouthwash|1% mouthwash solution of commiphora myrrha, made from Commiphora Myrrha resin extract.
41164013|NCT04723732|DRUG|Chlorhexidine mouthwash|0.2% mouthwash solution of chlorhexidine gluconate.
41164014|NCT04723732|DRUG|Normal saline|0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)
41375974|NCT05869604|BEHAVIORAL|HEALTHY AYA|8-session health lifestyle behavior intervention combining behavioral symptom management strategies with strategies to improve diet and increase physical activity.
41375975|NCT05869604|OTHER|Education Control|Participants will receive paper materials on topics of relevance to adolescent and young adult cancer survivors.
41033315|NCT06635343|OTHER|Experimental Inspiratuar Muscle Training|In the experimental group inspiratory muscle training was applied. Children in the experimental group started inspiratory muscle training at 30% of the measured intra-oral maximum inspiratory pressure (MIP) value with 30x2 breaths (1 minute rest between repetitions) for 5 days a week for 8 weeks. The training was carried out with MIP every week. The training was continued for a total of 8 weeks with 30% of the new value by re-measuring the MIP value every week The value was measured again and continued at 30% of the new value for a total of 8 weeks. During each inspiratory muscle training session, oxygen saturation data from the index finger were monitored with a pulse oximeter to prevent individuals from experiencing hypoxia
41164015|NCT03511378|DRUG|Lupin's Pegfilgrastim|Administration of Pegfilgrastim
41375976|NCT01269671|DRUG|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
41375977|NCT01269671|OTHER|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
41375978|NCT01463631|DRUG|LY3007113|Administered orally
41375979|NCT05002738|DRUG|Desogestrel and Ethinyl Estradiol Tablets|Combined oral contraceptive pill
41164016|NCT03511378|DRUG|Neulasta®|Administration of Neulasta®
41375980|NCT03223506|DRUG|Paracetamol|
41505597|NCT02083068|BIOLOGICAL|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
41505598|NCT04023227|DRUG|Sacubitril/valsartan|50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.
41033316|NCT06279221|DRUG|LITFULO|as provided in real world practice
41033317|NCT02421614|OTHER|high-protein low-carbohydrate diet with high olive oil|
41033318|NCT02421614|OTHER|high-protein low-carbohydrate diet with high sunflower oil|
41164017|NCT06433440|BIOLOGICAL|PVRV|Group-1 will receive PVRV ID on on the following days: Day0, Day3, Day7, while group-2 will receive PVRV IM on Day0, Day3, Day7, Day14, and Day28.
41164018|NCT05708313|BEHAVIORAL|lifestyle modification|Participants will undergo an exercise program designed by AHH
41164019|NCT04232800|DRUG|Riboflavin|The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
41164020|NCT04232800|OTHER|Placebo|An inert, standard placebo in identical capsules to primary intervention.
41375981|NCT02865616|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
41375982|NCT02865616|DRUG|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
41505599|NCT04023227|DRUG|Enalapril|5 mg and 10 mg will be available for dose adjustments.
41505600|NCT01015469|PROCEDURE|Conventional laparoscopic Roux-en-Y gastric bypass|Conventional laparoscopic Roux-en-Y gastric bypass
41505601|NCT01015469|PROCEDURE|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
41505602|NCT03640416|DEVICE|Fitbit® Charge HR smart watch|The Fitbit® Charge HR is a commercial product widely used worldwide, and data from the device is sent to a secured online server and can be accessed by each user to see only data collected from his own device. Data collected from the Fitbit® Charge HR is described earlier.
41505603|NCT05639075|OTHER|Peripheral vision|A gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
41375983|NCT04761926|DEVICE|Audiometry|"Audiometry: Thresholds from the audiogram obtained when Ponto 4 were fitted. Pure tone air conduction (AC) and bone conduction (BC) audiometry conducted at the visit.~Speech recognition in quiet: Speech intelligibility is measured in a soundproof room using the Matrix sentences presented from a loudspeaker. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. This test will be obtained both unaided and aided (with and without the Ponto 4(s)).~Sound field Audiometry: Detection of sound field thresholds presented from a loudspeaker. Thresholds will be obtained both unaided and aided and the test order will be balanced between subjects. During these measurements, the Ponto 4 will be programmed in omni-directional mode, with noise reduction and feedback management system turned off."
41033319|NCT04223453|DIAGNOSTIC_TEST|BIA and DXA|Patients with acute pneumonia measured simultaneously with DXA-scan and BIA-impedance
41033320|NCT04915963|DIETARY_SUPPLEMENT|Vitamin D supplementation|Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements
41033321|NCT06275646|OTHER|PRP layer|platelet rich plasma layer was applied in addition to dartos flap
41033322|NCT06275646|OTHER|dartos flap|dartos flap alone was used
41033323|NCT06252129|OTHER|Subjects undergoing a lung specimen lymph node dissection|"A lobectomy specimen's resection will undergo systematic lymph node dissection either by the patient's treating thoracic surgeon and/or by a member of the pathology team.~The protocol for a standardized lymph node dissection consists of a series of blunt peribronchial dissections starting from the hilum to the periphery, with particular attention to points of airway bifurcation where intrapulmonary lymph nodes aggregate. By emphasizing the intrapulmonary lymph node map and a standardized dissection, the team will remove more lymph nodes from the lobectomy specimen, resulting in an accurate N staging."
41033324|NCT06252129|OTHER|Control group|Control group
41033325|NCT02103439|DRUG|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
41033326|NCT02103439|DRUG|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
41375984|NCT01959217|BEHAVIORAL|PM Component Text Reminders|The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
41033327|NCT03190382|OTHER|Decision Support Tool|Patients enrolled in the study will receive the decision tool prior to the first PAD clinic visit and the medical decision making conversation with the provider.
41375985|NCT02723760|DRUG|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
41375986|NCT06565650|DRUG|Miebo|100% perfluorohexyloctane
41375987|NCT06565650|DRUG|Saline|0.6% sodium chloride solution
41033328|NCT04080973|DIAGNOSTIC_TEST|CT scan|non contrast spiral CT of the urinary tract including the bony structures of the spine and pelvis
41033329|NCT04080973|DIAGNOSTIC_TEST|24 hour urine collection|24 hours collection of urine and measurement of the concentration of calcium, phosphorous, uric acid, oxalate and citrate
41033330|NCT01781728|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) which included 5 consecutive fractions of 25 to 33 Gy, following 3 months of multiagent chemotherapy.
41033331|NCT03822299|DIETARY_SUPPLEMENT|healthy feces microbiota|Suspension of healthy feces microbiota in sterile saline solution
41164021|NCT06399341|DEVICE|Papilocare vaginal gel|Treatment with Papilocare® for 6 months (1 cannula/day for 21 days during first month + 1 cannula/alternate days for subsequent 5 months)
41033332|NCT04894604|DEVICE|Avance® Solo NPWT System|Application of the Avance® Solo NPWT System on up to 34 study Subjects, in accordance with the IfU for up to 14 days.
41033333|NCT06102902|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
41033334|NCT06102902|PROCEDURE|Biopsy|Undergo biopsy
41033335|NCT06102902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41033336|NCT06102902|BIOLOGICAL|Cetuximab|Given IV
41033337|NCT06102902|PROCEDURE|Computed Tomography|Undergo CT
41033338|NCT06102902|PROCEDURE|Echocardiography|Undergo ECHO
41033339|NCT06102902|DRUG|Encorafenib|Given PO
41033340|NCT06102902|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41033341|NCT06102902|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41164022|NCT04152395|OTHER|EVAR|Patients undergoing EVAR
41505604|NCT06223087|OTHER|winter swimming|Intervention involves bathing/swimming in cold water during the winter months in open waters
41375988|NCT02384031|DEVICE|Traumatic needle|Lumbar puncture is performed with a traumatic needle
41375989|NCT02384031|DEVICE|Atraumatic needle|Lumbar puncture is performed with an atraumatic needle
41375990|NCT04717934|DEVICE|GAL1906|hyaluronic acid dermal filler gel
41505605|NCT03466255|OTHER|Ultrasound|Contrast-enhanced ultrasound (CEUS)
41505606|NCT06388499|OTHER|TECC (Telerehabilitation and Exercise for Chronic Conditions)|"Exercise: Synchronous group exercise sessions will be delivered weekly via videoconferencing by a physiotherapist. Recordings of exercise sessions will be made available. Participants will be advised to perform additional exercise sessions at their own convenience to supplement the synchronous exercise sessions and facilitate adherence to physical activity guidelines.~Education: A synchronous educational webinar will be delivered each week. These will be delivered by relevant healthcare professionals and explore various aspects of self-management of health and well-being. Recordings of the webinars will be made available to participants.~Social component: At the end of each weekly synchronous group exercise session, participants will have the opportunity to engage in a 10-15-minute synchronous online social interaction with other participants in their exercise group via videoconferencing."
41505607|NCT04202055|OTHER|Biomarker analysis|Detection of biomarker in cerebrospinal fluid
41033342|NCT05935345|BEHAVIORAL|Addressing NSSI in schools|During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.
41375991|NCT04069208|DRUG|Idarubicin and cytarabine induction|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
41375992|NCT04087486|DIAGNOSTIC_TEST|Implementation of a behavioural test for patients with TBI|"The following data will be collected: (1) sociodemographic variables (2); clinical and psychological data; (3) functional tests (neuropsychological testing, TEM version CRR and TEM-PRO).~On day one, patients will undergo standard neuropsychological tests and questionnaires listed hereafter, which are commonly used in the clinical practice at the CRR.~* The Patient Competency Rating Scale (PCRS)~* TEM (Multiple errands test)~* GREFEX~* 5 POINTS TEST~* TAP 2.3~* Behavioral Assessment of the Dysexecutives Syndrome (BADS)~On day two, the patients will perform the TEM-PRO test ambulatory in our vocation rehabilitation unit.~Predictors variables will be collected before testing: Sociodemographic: age, sex, education, marital status, mother language, time since TBI, severity of the TBI (moderate or severe), type of lesion (contusion, diffuse axonal injury grade 1-3, ischemic or other complications), history of TBI, stroke or meningitis."
41033343|NCT05935345|OTHER|Control condition|Participating adolescents, parents, teachers and health care personnel receive no intervention during four months
41033344|NCT06092996|OTHER|Time of Sling Use|Standard sling worn for only three days post operatively
41033345|NCT06636474|OTHER|patients with mental disorders|administration of standardized questionnaires and scales, upon entering the research, then annually, and finally upon leaving the research
41033346|NCT06634472|OTHER|AI|AI-enabled skin perforator segmentation tool
41375993|NCT01068093|DRUG|Ezetimibe|10mg daily
41375994|NCT01758991|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
41375995|NCT06225674|DEVICE|Episealer Talus implant|This is an observational study, no intervention will be done. The aim for the clinical investigation is to collect data from approximately 25 adult subjects who were treated for focal osteochondral defect with Episealer Talus implant in 6 clinics (Sweden and Germany) since January 2020.
41375996|NCT01803464|DEVICE|Low-magnitude vibration|Children will receive a daily low-magnitude vibration treatment.
41505608|NCT04022408|DIAGNOSTIC_TEST|Liquid based cytology|Liquid based cytology
41505609|NCT04022408|DIAGNOSTIC_TEST|Conventional cytology|Conventional cytology
41505610|NCT01908907|DIETARY_SUPPLEMENT|DHA oil|Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
41505611|NCT01908907|DIETARY_SUPPLEMENT|(MCT) Control oil|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
41033347|NCT00744653|PROCEDURE|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
41033348|NCT02397395|DRUG|Simeprevir (SMV) 150 mg|Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
41033349|NCT02397395|DRUG|Daclatasvir (DCV) 60 mg|Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
41033350|NCT06635824|DRUG|Acasunlimab|IV infusion
41033351|NCT06635824|DRUG|Pembrolizumab|IV infusion
41033352|NCT06635824|DRUG|Docetaxel|IV infusion
41505612|NCT02171871|OTHER|exposed to a smoking environment|Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
41375997|NCT01803464|DRUG|Botox|Children who are candidates to receive Botox as part of their standard of care.
41375998|NCT00066417|DRUG|cyclophosphamide|
41375999|NCT00066417|DRUG|cyclosporine|
41376000|NCT00066417|DRUG|fludarabine phosphate|
41376001|NCT00066417|DRUG|methylprednisolone|
41376002|NCT00066417|DRUG|therapeutic allogeneic lymphocytes|
41376003|NCT00066417|DRUG|thiotepa|
41505613|NCT02490280|BEHAVIORAL|Trier Social Stress Test|The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
41505614|NCT04585880|OTHER|Virtual Collaborative Care Clinic|The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care. Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician. As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
41505615|NCT04376931|DRUG|Intravenous Solution|Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany, Austria, Sweden, and South Korea in dosages up to 20 mg.
41033353|NCT05857930|DRUG|OM-85|OM-85 capsule (3.5mg) contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
41033354|NCT05857930|DRUG|Placebo|Placebo capsule contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
41164023|NCT02599090|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
41376004|NCT00066417|PROCEDURE|allogeneic bone marrow transplantation|
41376005|NCT00066417|PROCEDURE|biological therapy|
41376006|NCT00066417|PROCEDURE|bone marrow ablation with stem cell support|
41376007|NCT00066417|PROCEDURE|bone marrow transplantation|
41376008|NCT00066417|PROCEDURE|chemotherapy|
41505616|NCT05088811|DIAGNOSTIC_TEST|WRAP53, UCA-1|Diagnostic value of UCA-1 and WRAP53 in HCC
41505617|NCT02031718|BEHAVIORAL|Virtual Counseling|
41505618|NCT00221377|DEVICE|Intubation using tracheal tubes with or without cuff|
41505619|NCT06222320|OTHER|Kinesiotaping|Kinesiotaping will be applied to patients in this group in addition to painkillers. Kinesiotaping is a physical therapy technique used to treat muscle pain. It is performed with kinesiotaping tapes attached to the skin. These bands are removed after 4-5 days.
41505620|NCT06222320|DRUG|Painkillers|Patients in this group will be treated with painkillers consisting of paracetamol and dexketoprofen.
41505621|NCT03714919|DRUG|Dextromethorphan|Preoperative oral dextromethorphan 1 mg/kg
41505622|NCT03714919|DRUG|Acetaminophen|Preoperative oral acetaminophen 15 mg/kg
41505623|NCT03714919|DRUG|Dexmedetomidine|Intraoperative intravenous dexmedetomidine 0.5 μg/kg
41164024|NCT02599090|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
41376009|NCT00066417|PROCEDURE|leukocyte therapy|
40850289|NCT04302545|PROCEDURE|Cystoinflation|Bladder retrofill with 300cc saline to distend the bladder to recognize bladder outline
41376010|NCT00066417|PROCEDURE|non-specific immune-modulator therapy|
41376011|NCT00066417|PROCEDURE|peripheral blood lymphocyte therapy|
41376012|NCT00066417|PROCEDURE|peripheral blood stem cell transplantation|
41376013|NCT00066417|PROCEDURE|radiation therapy|
41376014|NCT01285180|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
41376015|NCT03529539|DRUG|PSV|
41376016|NCT02590146|BEHAVIORAL|Non-pharmacologic pain control adjuncts|
41376017|NCT04129645|DEVICE|URS|"URS is a permanent ureteral stent made of nitinol and covered by a polymer, that is indicated to open strictures in the ureter.~Study patients who has strictures in the ureter, will be implanted with the URS for long term opening of the stricture."
41376018|NCT02769832|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle
41376019|NCT02769832|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
41376020|NCT04029766|DRUG|HSK3486|
41376021|NCT02262572|DRUG|Telmisartan /HCTZ - compression tablet (DC)|
41376022|NCT02262572|DRUG|Telmisartan /HCTZ - dry granulation tablet (DG)|
41376023|NCT02262572|DRUG|Telmisartan /HCTZ - present commercial formulation|
41376024|NCT02299661|DRUG|DS-1093a|DS-1093a, single oral doses up to 50 mg
41376025|NCT04288739|DIAGNOSTIC_TEST|flow cytometric immunophenotyping|Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).
41376026|NCT04288739|GENETIC|Xist gene by fluorescence insitu hybridization|"Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.~The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes."
41376027|NCT02623569|DRUG|Ivabradine|Not Provided
41376028|NCT02623569|DRUG|Atenolol|Not Provided
41376029|NCT01237704|BEHAVIORAL|Traditional rehabilitation (TR)|TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
41376030|NCT01237704|BEHAVIORAL|Transcutaneous electrical stimulation (ES)|Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
41376031|NCT02705664|DRUG|Loceryl Nail Lacquer|Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
41376032|NCT02705664|DRUG|Urea Ointment|Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
41376033|NCT02705664|DRUG|Bifonazole Cream|Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
41376034|NCT03148834|PROCEDURE|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
41505624|NCT03714919|DRUG|Ketamine|Intraoperative intravenous ketamine 0.5 mg/kg
41505625|NCT01272492|OTHER|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
41505626|NCT05721976|BEHAVIORAL|"With Love, Grandma (Con Cariño, Abuelita)"|"Cancer survivor-Daughter dyads will log in to a secured website to access intervention content over a period of 10-12 weeks. The intervention will be delivered primarily through smartphones and will include 8 modules with didactic content on healthy lifestyle behaviors for cancer prevention and control, family behavior change content for setting weekly goals and self-monitoring health behaviors, and family communication and positive parenting/grandparenting content, all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
41505627|NCT00939016|OTHER|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
41505628|NCT04812808|DRUG|Bazedoxifene 20 mg|"Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy.~Prophylactic rivaroxaban (Xarelto®) 10 mg per day orally will be added to avoid thromboembolic events."
41505629|NCT06501326|DRUG|Liraglutide|After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
41505630|NCT06501326|DRUG|Orlistat|After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
41376035|NCT01079000|BEHAVIORAL|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
41376036|NCT01079000|BEHAVIORAL|Involvement of a care manager|The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
41376037|NCT01079000|BEHAVIORAL|Usual care|Usual care provided to asthma patients when discharged from the ED
41376038|NCT04511923|DRUG|Nebulised heparin|Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
40850290|NCT06172075|BEHAVIORAL|Brief video intervention (Black Woman)|A brief social contact-based video. The video presented a young Black woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Black woman with depression and raising themes of recovery and hope.
41376039|NCT02423746|BEHAVIORAL|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
41376040|NCT02423746|BEHAVIORAL|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
41505631|NCT04977479|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)|mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.
41033355|NCT03834064|BEHAVIORAL|Oral health promotion strategy|The proposed intervention is comprised of four components : (a) planned action including a behavioral contract Activity 1) with caregivers and action planning for oral health (Activity 2), (b) caregiver capacity building with didactic training (Activity 3), observational learning and caregiver practice (Activity 4); (c) environmental adaptations with location of oral health activities and reminder posters - physical environment (Activity 5) and administrative oral health support- (social environment (Activity 6); and (d) reinforcement with caregiver coaching (Activity 7).
41033356|NCT00848679|DRUG|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
41033357|NCT00848679|DRUG|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
41033358|NCT06635967|DEVICE|frequency-specific rTMS|Patterned repetitive transcranial magnetic stimulation will be performed at specific frequencies and inter-train intervals
41033359|NCT06635967|DEVICE|1 Hz rTMS|Low-frequency rTMS will be performed at a frequency of 1Hz
41376041|NCT03187899|DRUG|Ropivacaine|0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.
41376042|NCT03187899|DRUG|Normal saline|5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
41376043|NCT01650142|OTHER|No intervention|No intervention
41376044|NCT00006292|DRUG|Infliximab|
41376045|NCT06357065|OTHER|Active transport educational program based on the ecological model|The intervention is structured according to the following units: Unit I: benefits of physical activity on health and healthy habits in schoolchildren; Unit II: Active Transportation: Experiences from other countries; Unit III: Analysis of the environmental characteristics of the school environment of each establishment; and Unit VI: Road safety for pedestrians and cyclists. This last topic will be broken down considering analysis and prevention of accidents with automobiles, pedestrian regulations, signaling, and cyclist safety. The sessions of the last month of intervention (November) will include practical walking activities in the school environment (outside the school). Depending on the possibilities of each school, cycling sessions will be included.
41376046|NCT01254357|OTHER|Questionnaire self report|Burn specific outcome measurement and global health measurement
41376047|NCT05952570|DIETARY_SUPPLEMENT|oral protein nutritional supplement (Fresubin protein powder)|50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) 1 hour before the start of the session (predialytic) for 3 months
41376048|NCT05952570|OTHER|routine nutrition regimen|50 patients will receive a routine nutrition regimen for 3 months. (control group)
41505632|NCT04977479|OTHER|Placebo|Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.
40850291|NCT06172075|BEHAVIORAL|Brief video intervention (Latinx Woman)|A brief social contact-based video. The video presented a young Latinx woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Latinx woman with depression and raising themes of recovery and hope.
40850292|NCT06172075|BEHAVIORAL|Brief video intervention (White Woman)|A brief social contact-based video. The video presented a young White woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a White woman with depression and raising themes of recovery and hope.
41033360|NCT01719952|DRUG|Carbetocin|"IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.~pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group."
41033361|NCT01719952|DRUG|Oxytocin|5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
41033362|NCT02691455|DEVICE|Baerveldt Glaucoma Implant 350-mm2 / BG101-350|
41376049|NCT05036486|GENETIC|next-generation sequencing|Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis
41505633|NCT04977479|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine, Bivalent|mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19. Single dose (0.3mL) via IM.
41505634|NCT01006798|OTHER|Placebo|enteric coated capsule containing no vaccine virus
41505635|NCT01006798|BIOLOGICAL|Ad4-H5-Vtn|a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
40850293|NCT06172075|BEHAVIORAL|Vignette Control|A brief vignette control condition with a script about a young woman who describes her struggles with depression and raises themes of recovery and hope.
41376050|NCT04761523|BEHAVIORAL|Dietary intervention: reduced fat diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
40850294|NCT00730548|BEHAVIORAL|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
40850295|NCT05262296|PROCEDURE|Laparoscopic Surgeon|Laparoscopic Arm This cohort of participants will have their procedure completed by a human surgeon.
41033363|NCT02691455|PROCEDURE|Transscleral Diode Laser Cyclophotocoagulation|Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
41376051|NCT04761523|BEHAVIORAL|Dietary intervention: standard healthy diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
41376052|NCT00925509|PROCEDURE|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.~Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.~Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.~A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
41376053|NCT04034524|DRUG|GLP-1 receptor agonist|any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
41376054|NCT04034524|DRUG|Insulin|glargine, detemir, neutral protamine Hagedorn (NPH), degludec
41376055|NCT01607580|DRUG|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
41376056|NCT04145804|DEVICE|Medtronic Minimed 670G insulin pump|It is an insulin pump to deliver insulin to the patient and associated with a sensor to monitor the glucose levels of the patient. The new feature in this device is the automode algorithm which regulates insulin delivery to the patient automatically to keep glucose levels within target.
41376057|NCT02724176|DRUG|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
41376058|NCT01682681|DRUG|Topiramate|This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
41376059|NCT02008487|OTHER|Wound powder application|Powder application to wound per protocol.
41376060|NCT04768881|DRUG|Selinexor|Dose and formulation: 80 mg (4 tablets of 20 mg)
41376061|NCT04768881|DRUG|Pembrolizumab|Dose and formulation: 400 mg (25 milligrams per milliliter \[mg/mL\]) Solution
41376062|NCT05692570|DRUG|PBI-200 Tablet|PBI-200 is a TRK inhibitor
41376063|NCT05692570|DRUG|Ritonavir Oral Tablet|Ritonavir is a potent CYP3A inhibitor
41376064|NCT05692570|DRUG|Cobicistat Oral Tablet|Cobicistat is a potent CYP3A inhibitor
41376065|NCT00678652|BIOLOGICAL|10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
41376066|NCT00678652|BIOLOGICAL|25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
41376067|NCT00678652|BIOLOGICAL|50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
41376068|NCT00678652|BIOLOGICAL|75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
41376069|NCT04707612|OTHER|No intervention.|No intervention.
40850296|NCT05262296|PROCEDURE|Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
40850297|NCT05684029|DEVICE|Near-infrared devices|This device can emit and collect near-infrared light of a specific wavelength. The parathyroid glands in the specimen appear as a high-brightness image in the device, to find the parathyroid gland that may be accidentally removed from the specimen.
40850298|NCT05684029|DIAGNOSTIC_TEST|PTH test strip|The PTH test strip is to detect the PTH in the specimen by immunocolloidal gold technology to determine whether it is parathyroid.
41033364|NCT02691455|DEVICE|Ahmed Model FP7 Flexible Plate|
41033365|NCT02691455|DEVICE|Baerveldt Glaucoma Implant 250-mm2 / BG103-250|
41033366|NCT04651452|BEHAVIORAL|Value Affirmation|Participants will complete writing tasks regarding their personal values.
41505636|NCT01006798|BIOLOGICAL|Sanofi Pasteur Influenza Virus Vaccine, H5N1|Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
41505637|NCT00925639|DRUG|Isoflavone|150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.
41505638|NCT00925639|DRUG|Placebo|Starch pill
41505639|NCT03874273|DRUG|Crizotinib|Crizotinib 280mg/m2 twice a day (for 24 months maximum)
41505640|NCT04391296|PROCEDURE|Arm I (Prepectoral), Arm II (Subpectoral)|"Arm I (Prepectoral)De-epithelialized skin flaps are made from the inferior pole of breast skin and soft tissue. The implant pocket is shaped by fixing a sufficiently large amount of ADM to the medial surface of the mastectomy pocket, the upper edge of the pectoralis major muscle and the de-epithelial skin flap. The implant is located in the prepectoral mastectomy pocket and the ADM anchored to the chest wall, serratus fascia, and de-epithelial skin flaps. The pectoralis major muscle is located in the anatomical location behind the ADM.~Arm II (Subpectoral)The pectoralis major muscle is dissected from the thorax to create sufficient space for the implant to be placed behind the pectoralis major muscle. Implant pockets are made by suturing the lower part of the elevated pectoralis major muscle to the top of the de-epithelial skin flap and the ADM patch to the skin flap, the pectoralis major muscle, and the lateral thoracic fascia."
41505641|NCT05755971|OTHER|Combination taping|Elastic and rigid tapes applied together for six weeks
41505642|NCT00006760|BIOLOGICAL|filgrastim|subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
41505643|NCT00006760|DRUG|ifosfamide|V over 24 hours on days 1-4
41505644|NCT00006760|DRUG|vinorelbine tartrate|IV over 6-10 minutes on days 1 and 5.
41505645|NCT06185530|DIAGNOSTIC_TEST|Detection of obstructive coronary disease|Detection of obstructive coronary disease
41505646|NCT01741168|OTHER|TLSO|Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.
41505647|NCT01741168|OTHER|No Orthosis|Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
41505648|NCT03742947|DIAGNOSTIC_TEST|peripartum haemostasis|Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
41505649|NCT06632509|DEVICE|BD SiteRite(TM) 9|Ultrasound-guided vascular access device placement procedure using the BD SiteRite(TM) 9.
41505650|NCT04860609|OTHER|Conventional Physiotherapy|"The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Bed Rest with lumbar Sacral Support~9. Home plan:~Exercises Posture Correction Precautions Contra indication"
41505651|NCT04860609|OTHER|Lumber Spinal Decompression|"The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Decompression therapy session lumbar spinal decompression therapy for 30 minutes.~9. Home plan:~Exercises Posture Correction Precautions Contra indication"
41033367|NCT04651452|BEHAVIORAL|Reflective Journaling|Participants will complete writing tasks regarding their least important values and discuss why they may be important to others. They will also describe aspects of daily life.
41376070|NCT02829229|BEHAVIORAL|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials \& 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
41376071|NCT04441437|BEHAVIORAL|Task-oriented training with a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
41376072|NCT04441437|BEHAVIORAL|Task-oriented training without a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
41376073|NCT01832896|DRUG|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
41376074|NCT01040468|PROCEDURE|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
41376075|NCT01040468|PROCEDURE|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
41033368|NCT06636292|DEVICE|Virtual Reality Distraction and Disassociation (VRDD) Stage 1|Participants wear a VR headset which plays VR content/material pre- endoscopy only.
41033369|NCT06636292|DEVICE|Virtual Reality Distraction and Disassociation (VRDD) Stage 1&2|Participants wear a VR headset which plays VR content/material pre- endoscopy and during endoscopy.
41033370|NCT00407992|DEVICE|Occipital nerve stimulation ON|Implant of an occipital nerve stimulator switched ON
41033371|NCT00407992|DEVICE|Occipital nerve stimulation off|Implant of an occipital nerve stimulator switched OFF
41164025|NCT02599090|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
41164026|NCT04185987|OTHER|Leone slide low friction elastomeric ligature|Leone slide low friction elastomeric ligature application
41164027|NCT04185987|OTHER|RMO tough - o energy elastomeric ligature|RMO tough - o energy elastomeric ligature application
41164028|NCT04185987|OTHER|Dentsply sili tie elastomeric ligature|Dentsply sili tie elastomeric ligature application
41164029|NCT04185987|OTHER|AO twisted ended ligature wire|AO twisted ended ligature wire application
41164030|NCT00562185|DRUG|carboplatin|
41164031|NCT00562185|DRUG|doxorubicin hydrochloride|
41164032|NCT01330992|OTHER|Ocular light or darkness exposure|Ocular light or darkness exposure
41164033|NCT00177385|BEHAVIORAL|Modest sleep deprivation with sleep hygiene education|
41164034|NCT04387422|OTHER|Experimental hyperglycemia|Experimental hyperglycemia with MRI
41164035|NCT03686241|PROCEDURE|Tibiotalocalcaneal (TTC) arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
41033372|NCT06630871|DRUG|Distitamab Vedotin in combination with Tislelizumab|On the day after the initial TURBt procedure, use trastuzumab (200mg)+ Distitamab Vedotin (120mg \[≤ 60Kg\] or 2.0mg/Kg \[\>60Kg\]) every 3 weeks (Q3W). Simultaneously arrange for the patient to complete a second TURBt within 6 weeks, and continue to use 3 courses of Trastuzumab+Vediximab (Q3W) after surgery until the endpoint of 3-year follow-up
41033373|NCT00583557|DRUG|belimumab|IV 10mg/kg Q28 days
41033374|NCT04972955|DEVICE|Freestyle Libre 2|Participants will wear a continuous glucose monitoring device, the Freestyle Libre 2, for two weeks following delivery.
41164036|NCT03686241|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
41164037|NCT03836170|PROCEDURE|Laparoscopic cholecystectomy|A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
41164038|NCT02205723|BEHAVIORAL|Asthma teaching in ER|Asthma teaching
41164039|NCT02205723|BEHAVIORAL|Smartphone Asthma Control|Smartphone Asthma Control
41164040|NCT03219307|COMBINATION_PRODUCT|NOVOCART 3D|Matrix associated autologous chondrocyte implant
41164041|NCT05157737|OTHER|Electrophysiological detection of KCNQ2 mutation|Electrophysiological detection of KCNQ2 mutation performed using patch clamp technique in an in vitro cell model. Analyze the association between phenotype and genotype.
41164042|NCT05157737|OTHER|Multi-modal brain image and EEG|Multi-modal brain image include brain magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). The electroencephalogram (EEG) incuding video electroencephalogram (VEEG) and sleep electroencephalogram (SEEG).
41164043|NCT05157737|OTHER|Omics testing|Omics testing include proteomics, metabolomics, transcriptomics.
41164044|NCT03397316|PROCEDURE|xenograft placement .|immediate implant placement in upper esthetic zone with xenograft placement between residual labial bone and implant surface.
41164045|NCT01046825|DRUG|COPAD|"Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
41164046|NCT01046825|DRUG|COP, COPD M3, CYM|"GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
41164047|NCT01046825|DRUG|COP, COPADM8, CYVE|"Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.~COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.~COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF.~Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.~Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.~Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications.~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
41164048|NCT00155883|DRUG|Taxteral|
41164049|NCT00155883|DRUG|5-Fluorouracil|
41164050|NCT00155883|DRUG|Leucovorin|
41383567|NCT04138173|BEHAVIORAL|Tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
41164051|NCT03465085|DRUG|Unfractionated heparin|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
41164052|NCT03465085|DRUG|Streptokinase|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
41164053|NCT05561985|DRUG|Itacitinib|
41164054|NCT04237519|BEHAVIORAL|SFL training|"The SFL training program comprises:~* Physical exercises: 50 video exercises to improve balance, muscle strength and physical capabilities in older adults;~* Cognitive exercises: Four ludic activities targeting problem solving (4 Images/ 1 word), memory (Quiz and Recall me), speed processing and divided attention (Attention!).~In addition, the SFL program includes a series of unique components:~* Chat rooms: to share views about topics of interest and tips for common real-life problems;~* Psycho-education content: to improve self-management and promoting cognitive transfer though 22 different topics (provide recommendations usually given in psychotherapy sessions);~* Virtual coach: to guide participants along the proposed exercises by giving them instructions, reminding them regularly to practice a variety of available activities repeatedly, providing appropriate and timely feedback on participant's performances and rewarding assiduity, perseverance and performance."
41376076|NCT01040468|BEHAVIORAL|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
41376077|NCT02084329|DEVICE|Weighted Compression Vest|
41376078|NCT04681001|DEVICE|nasal spray|application of nasal spray into nostrils and mouth
41505652|NCT06499324|DRUG|BTA group|It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment of a large anterior IH (width ≥ 10 cm) with open non absorbable mesh repair. The injection of BTA (XEOMIN®) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the BTA group, 3 vials of 100 equivalent IU of BTA (XEOMIN® 100U), diluted to 2 IU/mL with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of BTA solution (144 IU) will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
41505653|NCT06499324|DRUG|Placebo group|It consists of a blind injection of placebo of BTA (XEOMIN® 100U matching placebo) into the lateral muscles (18 injection sites, 8mL/injection site), 4 to 6 weeks before the treatment of a large IH (width \>= 10 cm) with open non absorbable mesh repair. The injection of placebo of BTA (XEOMIN® 100U matching placebo) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the control group, 3 vials of placebo of BTA (XEOMIN® 100U matching placebo), diluted with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of placebo of BTA solution will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
41505654|NCT06550570|BEHAVIORAL|QEVA questionnaire|QEVA questionnaire administered at 2 days pospartum (in hospital) and 4 weeks postpartum (phone call). (specific for the study)
41505655|NCT03259386|DEVICE|Microelectrode array|Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
41505656|NCT06588296|DRUG|Ixekizumab|Administered SC
41376079|NCT05371236|OTHER|Questionnaire|Phase I will use a descriptive qualitative approach to understand pediatric cancer patients' opinions related with spiritual issues and experience. The results of the qualitative study will be used to compare with the items of the original scale, and emerging themes will be used to generate new items. Phase Ⅱ will translates the original scale and validates the psychological properties of scale adapted for pediatric cancer patients.
41505657|NCT06588296|DRUG|Tirzepatide|Administered SC
41376080|NCT01998659|DRUG|Px-102|Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
41505658|NCT05379244|BEHAVIORAL|CBT-i|Behavioral intervention based on Cognitive Behavioral Therapy for insomnia, adjusted for psychiatric patients with anxiety disorders, affective disorders and trauma
41505659|NCT00933647|DIETARY_SUPPLEMENT|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
41376081|NCT01998659|DRUG|Placebo|Oral drinking solution
41376082|NCT01828164|DEVICE|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
41376083|NCT01828164|DEVICE|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
41376084|NCT05489952|DRUG|iron sucrose and ferrous lactate|The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.
41376085|NCT03073291|BEHAVIORAL|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
41376086|NCT03712462|BEHAVIORAL|Acceptance-Based Behavioral Weight Loss Therapy for BED|ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
41376087|NCT03712462|BEHAVIORAL|Standard Behavior Therapy|SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
41376088|NCT04867980|DRUG|ACP-196|Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.
41376089|NCT04867980|DRUG|Moxifloxacin 400 mg|Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.
41376090|NCT04867980|DRUG|Placebo|Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
41376091|NCT03297593|DRUG|nivolumab|240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter
41376092|NCT03297593|DRUG|ipilimumab|After 2 weeks 1mg/kg every 6 weeks
41505660|NCT00933647|DIETARY_SUPPLEMENT|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
41164055|NCT04237519|BEHAVIORAL|Active controlled training|"The active control training program is structured in the same manner as the SFL training program and will also offer different physical and cognitive activities:~* Physical exercises: 12 different exercises trains upper and lower extremity strength, mobility and balance offered through a computerized version of a health insurance company physical training program;~* Cognitive activities: Four commercially available leisure activities (Sudoku. Cross Words, Pac-Man and Countdown activities) that are appreciated by older adults but do not teach cognitive strategies and are were not designed to improve cognition per se.~No chat room, psycho-educational content or virtual coach were included in the active control training program."
41505661|NCT00933647|DIETARY_SUPPLEMENT|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
41505662|NCT04614415|DEVICE|Autocrosslinked Hyaluronic aid|IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA
41505663|NCT04614415|OTHER|placebo|The placebo consists in an isotonic saline solution (NaCl 0.9%)
41505664|NCT05734248|PROCEDURE|Facial filler injection|Hyaluronic acid will be injected on the cheek, based on the aesthetic evaluation of the face.
41505665|NCT04455165|PROCEDURE|Aortic valve replacement|Aortic valve replacement with or without associated cardiac surgery (coronary bypass, mitral valve surgery,...)
41033375|NCT04972955|DEVICE|Freestyle Libre 2|Participants will wear a second continuous glucose monitoring device, the Freestyle Libre 2, for two weeks at 4-6 months postpartum and before their standard of care postpartum bloodwork after having gestational diabetes.
41376093|NCT01626209|DRUG|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
41376094|NCT00604760|DRUG|MEM 3454|Capsule 5 mg once a day
41376095|NCT00604760|DRUG|MEM 3454|Capsule 15 mg once a day
41376096|NCT00604760|DRUG|MEM 3454|Capsule 50 mg once a day
41505666|NCT05076461|DRUG|Ondansetron|Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
41505667|NCT05065255|DEVICE|SpeediCath® catheters|Patients using SC catheters will be followed up in order to understand the major criteria in the choice of the catheter by the patients.
41505668|NCT02323828|DIETARY_SUPPLEMENT|High RS cookies|High RS cookies ingestion in healthy young adults
41505669|NCT02323828|DIETARY_SUPPLEMENT|Placebo|Placebo cookies ingestion in healthy young adults
41505670|NCT04892537|DEVICE|Coronary Sinus Reducer|Coronary Sinus Reducer implantation according to standard clinical protocols
41505671|NCT04892537|PROCEDURE|Placebo Procedure|A placebo procedure involving venous sheath implantation in the right internal jugular vein without proceeding to CSR implantation
41505672|NCT02008812|DEVICE|Ad sensor|"Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
41033376|NCT01818323|OTHER|Intra-tumoral T4 immunotherapy|Intra-tumoral administration of a single dose of T4-positive patient-derived T-cells (at five escalating dose levels) contained within 1-4 mL. Cohort 6 patients receive CAR T-cells (dose level 3) after lymphodepletion with fludarabine and cyclophosphamide. Cohort 7-8 patients receive T4 cells after lymphodepletion as above, combined with 4 doses of nivolumab.
41033377|NCT00290940|DRUG|CS-917|
41033378|NCT00290940|DRUG|metformin hydrochloride|
41033379|NCT00290940|DRUG|pioglitazone|
41505673|NCT05386940|OTHER|PKN1 level|different PKN1 level after on-pump cardiac surgery
40850299|NCT01483911|BIOLOGICAL|ALX-0171|Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
41033380|NCT01316367|BEHAVIORAL|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:~* Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~* Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~* Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
41376097|NCT00604760|DRUG|Placebo for MEM 3454|Capsule once a day
41376098|NCT04833569|BIOLOGICAL|ICG-PDT|An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients
41376099|NCT04833569|DEVICE|peri-implant mechanical debridement|The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
41376100|NCT04924465|OTHER|Follow-up|Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests
41376101|NCT05471375|OTHER|Database Entry|Database entries will contain wearable sensor, audio, and video data collected during rehabilitation-related movement assessments
41376102|NCT00931866|DRUG|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
41033381|NCT01316367|BEHAVIORAL|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
41033382|NCT06635577|BEHAVIORAL|Verbal Interference Task|"During the second half of the study, participants will undergo an interference task such as repetition of the word the; or shadowing a radio broadcast in order to increase cognitive load and disrupt the use of a mental workspace."
41164056|NCT00003185|BIOLOGICAL|autologous tumor cell vaccine|
41164057|NCT00003185|BIOLOGICAL|sargramostim|
41164058|NCT00003185|BIOLOGICAL|tumor-draining lymph node lymphocyte therapy|
41376103|NCT00931866|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
40850300|NCT01483911|BIOLOGICAL|Placebo|Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
40850301|NCT05316506|OTHER|Anticipated Discomfort Language|This language involves pain descriptors provided from physician to patient during procedure.
41376104|NCT02613559|BIOLOGICAL|TK001|Intravitreal Injection
41376105|NCT01600612|DRUG|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
41376106|NCT01600612|DRUG|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
41376107|NCT01600612|DRUG|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
41376108|NCT03599882|DEVICE|Fibroscan|Fibroscan with controlled attenuation parameter and transient elastography
41376109|NCT00783939|DRUG|Lactic Acid|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
41376110|NCT01717729|PROCEDURE|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
41376111|NCT01717729|RADIATION|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
41376112|NCT00738140|BEHAVIORAL|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
41376113|NCT04491773|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, for more than 6 months.
41376114|NCT05372211|OTHER|not use of any intervention|not use of any intervention
41376115|NCT02451631|OTHER|Traditional care with paper|Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.
41376116|NCT02451631|DEVICE|Health-on G App. + Physician Web|Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
41376117|NCT00270738|PROCEDURE|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
41033383|NCT00810134|PROCEDURE|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
41376118|NCT00270738|PROCEDURE|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
41376119|NCT00270738|PROCEDURE|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
41033384|NCT00810134|PROCEDURE|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
41033385|NCT01673932|BIOLOGICAL|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
41376120|NCT06062758|BEHAVIORAL|ECT Simulation Training|Simulation training will consist of three stages. The first stage is preliminary preparation. At this stage, students who review the resources identified and come prepared for the simulation scenario will be asked questions appropriate to the simulation objectives to help them remember the subject. In the second stage, the simulation will be realized. A high-fidelity mannequin/simulator will be used during the simulation, and the responsible faculty will give patient responses in the cabin. While the students taking roles during the simulation provide care to the patient, other group members will watch their teammates in the cabin or in a The simulation will be finalized by discussing the critical points of the case, the care to be given, communication skills and patient safety.
41376121|NCT06519539|BEHAVIORAL|PORTIONS-4 behaviour change strategies|The intervention includes 4 components, including: a portion control tool set previously developed and tested in our laboratory; a supporting guide (physical book) with dietary, activity and behavioural recommendations; a mobile application aligned with the guide; and biweekly telephone calls from the psychologist and/or dietitian.
41376122|NCT04675489|OTHER|Procedure: Vivity Toric IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
41505674|NCT03147625|BEHAVIORAL|SHAPE Intervention|SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
41376123|NCT03740854|OTHER|Pressure Controlled Ventilation|Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
41505675|NCT02432053|DRUG|Advagraf|
41505676|NCT05348447|DEVICE|cryoanalgesia|intraoperative intercostal nerve freezing for post-operative pain control
41505677|NCT05348447|OTHER|Standard of Care Pain Control|Standard of Care Pain Control Post-operatively
41505678|NCT06013826|OTHER|Telenursing|Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated.
41376124|NCT03740854|OTHER|Volume Controlled Ventilation|Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
41376125|NCT00959075|DIETARY_SUPPLEMENT|Vitamin B1|100 mg Twice a day
41376126|NCT00959075|DIETARY_SUPPLEMENT|Placebo|Sugar pill
41376127|NCT04871451|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
41505679|NCT01720888|OTHER|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
41505680|NCT05292365|BEHAVIORAL|RE-PACT Intervention|"* Create respiratory illness action plan~* Weekly mHealth text messages~* Monthly study assessments~* Action planning and JIT coaching"
41376128|NCT05170217|DRUG|THC|Inhaled cannabis containing 10mg THC
41376129|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 10mg CBD
41376130|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 20mg CBD
41376131|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 30mg CBD
41376132|NCT01225029|OTHER|Amount of total fluids|Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
41376133|NCT01165424|DRUG|mometasone furoate|"MFNS 50 μg spray device~* 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
41376134|NCT02395393|DEVICE|Alveoflex Confocal MiniprobeTM|-Alveolar imaging
41376135|NCT04354740|PROCEDURE|with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)|"II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:"
41376136|NCT04342130|DRUG|Morphine|30 mg oral tablet
41376137|NCT04113746|BEHAVIORAL|Better asthma self-management and incorporation of physical activity|Participants in the asthma and exercise lifestyle change arm will participate in 4 sessions focused on behavioral change and goal-setting education to teach them how to better incorporate exercise into their daily lives and better manage their asthma. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
41376138|NCT04113746|BEHAVIORAL|Asthma Education|General asthma education, but no discussion of the role of exercise and other lifestyle habits in asthma self-management. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
41376139|NCT00336531|DRUG|itraconazole|2.5 mg/kg twice daily for the first two days --\> once daily
41376140|NCT05311111|PROCEDURE|distal radial artery approach|Procedure: Use of radial artery for access for a coronary angiography or intervention After preparation and local anesthesia, the operator will puncture the distal radial artery in the dorsum of the hand or the anatomical snuff-box. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
41376141|NCT05311111|PROCEDURE|conventional radial artery approach|Procedure: conventional radial access for a percutaneous coronary intervention After preparation and local anesthesia, the operator will puncture the proximal radial artery at the conventional site in distal forearm. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
41505681|NCT00824343|DRUG|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
41033386|NCT01673932|PROCEDURE|surgery|
41033387|NCT00931073|DRUG|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
41033388|NCT00931073|DRUG|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
41033389|NCT00931073|DRUG|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
41033390|NCT02485470|OTHER|MPACT|Maintaining Physical Activity during Cancer Treatment
41164059|NCT00003185|DRUG|cyclophosphamide|
41164060|NCT00003185|PROCEDURE|conventional surgery|
41164061|NCT00338988|DRUG|Capecitabine|1500 mg/m\^2 PO twice daily x 14 days.
41164062|NCT00338988|DRUG|Oxaliplatin|130 mg/m\^2 IV over 2 hours on day 1 of cycle.
41164063|NCT01648985|OTHER|Diabetes in stroke/TIA|Mostly no intervention. A small Group of the patients recieved Yoga
41164064|NCT00246610|DRUG|Nelfinavir mesylate, 625 mg|Nelfinavir 625 mg \[dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)\] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
41376142|NCT05897931|OTHER|Connective tissue massage|Connective Tissue Massage will be applied by starting from the lumbosacral region, continuing from the lower thoracic region, and finishing by applying it to the scapular region, interscapular region, and cervico-occipital region.
41376143|NCT05897931|OTHER|Kinesio Tape Application|"Taping will be applied to the levator scapula and upper trapezius muscles in a Y shape, with 25% tension and while the participants were in an upright position. Again in the same position, this time the C shaped taping technique will be adhered with 50% tension from the middle fibers of the trapezium to the last rib."
41376144|NCT00138827|DRUG|Biotene (mouth care)|
41376145|NCT02008552|GENETIC|Sampling of blood|Sampling of blood was taken and analyse to research factor genetic
41376146|NCT00002680|BIOLOGICAL|filgrastim|
41376147|NCT00002680|DRUG|cyclophosphamide|
41376148|NCT00002680|DRUG|megestrol acetate|
41376149|NCT00002680|DRUG|melphalan|
41376150|NCT00002680|DRUG|tamoxifen citrate|
41376151|NCT00002680|DRUG|thiotepa|
41505682|NCT00869076|OTHER|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
41164065|NCT05738447|BIOLOGICAL|HBV mRNA vaccine|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.
41164066|NCT03683914|DRUG|Dinoprostone 3Mg Vaginal Tablet|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
41505683|NCT00869076|OTHER|Usual care|Patient was managed by their primary care physician as usual
41505684|NCT01364376|DRUG|S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium|"FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy"
41505685|NCT02068092|DRUG|Hydroxytyrosol|
41033391|NCT06245785|PROCEDURE|transarterial chemoembolisation|Before TACE, hepatic arteriography was performed to evaluate the vascular anatomy and tumour vascularity. During TACE, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function. Laboratory assessments were performed every four to six weeks. Radiological evaluation using contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) was recommended during weeks 4 and 8 after treatment and every 8 weeks thereafter. However, in clinical practice, the intensity of follow-up depends on an individual's baseline characteristics and response to the last treatment.
41033392|NCT02522533|OTHER|Physical Therapy|6 weeks of an exercise program.
41033393|NCT03713593|DRUG|lenvatinib|Administered orally once a day
41164067|NCT03683914|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
41376152|NCT00002680|PROCEDURE|conventional surgery|
41376153|NCT00002680|PROCEDURE|peripheral blood stem cell transplantation|
41376154|NCT00002680|RADIATION|radiation therapy|
41376155|NCT03156426|OTHER|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
41376156|NCT05867511|BEHAVIORAL|iPAL App|"The intervention will have a duration of eight weeks. It is theory-based, will be delivered to participants' smartphones via the study app (except components 5 and 6), and comprises the following components:~1. Theory-based individualized feedback.~2. Self-generated motivational messages.~3. Motivation for habit formation through push messages.~4. Motivational images and videos that participants handed in or selected will be sent to them through the app.~5. Study-specific social media groups. Participants will be offered the option to participate in study-specific social media groups.~6. Posting motivational stories. A story of a person, who successfully changed his or her lifestyle to be more physically active and/or less sedentary, will be posted once a week in the study-specific social media groups."
41376157|NCT01469416|DRUG|Rosuvastatin|Rosuvastatin 20 mg PO x 1
41376158|NCT01469416|DRUG|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
41376159|NCT01153971|DRUG|rituximab|1
41505686|NCT04876092|DRUG|JNJ-67856633|Participants will receive JNJ-67856633 orally.
41505687|NCT04876092|DRUG|Ibrutinib|Participants will receive Ibrutinib orally.
40850302|NCT05316506|OTHER|Objective Descriptive Language|This language involves neutral/objective descriptors provided from physician to patients during procedure.
41033394|NCT03713593|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 Q3W
41033395|NCT03713593|DRUG|saline placebo|Administered as an IV infusion on Day 1 Q3W
41033396|NCT05958342|DRUG|Calcium Gluconate|1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes
41033397|NCT05958342|DRUG|Vasopressin|4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours
41033398|NCT05958342|DRUG|saline placebo|saline placebo volume matched to prehospital or in hospital phase
41164068|NCT00018759|DRUG|paroxetine|
41164069|NCT00018759|BEHAVIORAL|ongoing psychological screening|
41164070|NCT01182181|DRUG|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
41164071|NCT01182181|DRUG|Anastrozole (Arimidex®)|1 mg Tablets
41376160|NCT05514327|RADIATION|ultra-fraction radiotherapy|the R/R DLBCL patients would receive ultra-fraction radiotherapy as bridging therapy before the CD19 CART cell infusion
41376161|NCT02259426|DRUG|Dihydroartemisinin-piperaquine combination (Artekin)|
41376162|NCT02259426|DRUG|Primaquine|Single-dose 0.25mg/kg
41376163|NCT00822237|BIOLOGICAL|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection \~6 weeks apart
41376164|NCT00822237|BIOLOGICAL|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection \~6 weeks apart
41376165|NCT00822237|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection \~6 weeks apart
41376166|NCT05598762|GENETIC|Tape strips|Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
41376167|NCT02988830|DEVICE|Subcutaneous Electric Lumbar Stimulation|
41376168|NCT05769348|DEVICE|HD-tDCS Active Protocol|non-invasive brain stimulation (active protocol)
41376169|NCT05769348|DEVICE|HD-tDCS Sham Protocol|non-invasive brain stimulation (sham protocol)
41376170|NCT02611076|BEHAVIORAL|Stop Smoking for Good Intervention in Spanish (SS-SP)|Assessments will occur at six-month intervals, through 24 months.
41376171|NCT02611076|BEHAVIORAL|Usual care (UC)|Assessments will occur at six-month intervals, through 24 months.
41505688|NCT04936711|DEVICE|Resteck Shiatsu Neck and Back Massager|back massager device sold on the market that can readily be purchased online or in store
41505689|NCT04936711|DRUG|Marcaine|Marcaine spray at incision site after closure
41505690|NCT00166647|PROCEDURE|Blood Sampling|
41505691|NCT02995408|BEHAVIORAL|Relaxation Response Resiliency Program for Parents of Children with ASD|
41376172|NCT02188667|OTHER|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
41505692|NCT04821193|DRUG|Skin antisepsis with 5% NaHCO3 water solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
41033399|NCT06466603|DIETARY_SUPPLEMENT|GABA Probiotic Dose 1|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
41033400|NCT06466603|DIETARY_SUPPLEMENT|GABA Probiotic Dose 2|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
41033401|NCT06466603|DIETARY_SUPPLEMENT|Placebo Group|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
41033402|NCT01792089|OTHER|fat+protein meal|cream+ whey protein
41033403|NCT01792089|OTHER|Fat + protein + 13C fructose meal|cream+ whey protein +13C fructose
41033404|NCT01792089|OTHER|Fat+protein+13C fructose+glucose meal|Cream + whey protein + glucose:13C fructose mixture
41033405|NCT01792089|OTHER|13C Fat + whey protein|cream labelled with 13C palmitate + whey protein
41376173|NCT02188667|OTHER|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
41376174|NCT03575806|COMBINATION_PRODUCT|TACE plus autologous Tcm immunotherapy|"TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro."
41376175|NCT03575806|PROCEDURE|TACE|TACE:transcatheter arterial chemoembolization.
41376176|NCT01157065|DRUG|AL-78898A|Investigational treatment
41376177|NCT01157065|DRUG|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
41505693|NCT04821193|DRUG|Skin antisepsis with 2% Chlorhexidine Gluconate solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
41033406|NCT01792089|OTHER|13C Fat + whey protein + glucose+ glucose meal|cream labelled with 13C palmitate + whey protein + glucose:fructose mixture
41033407|NCT02224729|DRUG|Bendamustine hydrochloride|Given IV
41033408|NCT02224729|DRUG|Bortezomib|Given SC
41033409|NCT02224729|DRUG|Dexamethasone|Given PO
41033410|NCT02570984|DRUG|Omalizumab|anti-ige injection
41033411|NCT02570984|DRUG|Placebo|placebo comparator arm, injection similar to active
41033412|NCT04700306|BEHAVIORAL|Sophrology|Patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology.
41033413|NCT01221597|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
41376178|NCT00139802|DEVICE|Coronary Stent Implantation|
41376179|NCT06538246|BEHAVIORAL|Blueprint|This is a mobile app-based adaptive coping skills intervention that lasts 1 month
41376180|NCT06538246|BEHAVIORAL|Education program|This is a mobile app-based education program that lasts 1 month
41376181|NCT02801201|DRUG|Midazolam|
41376182|NCT02801201|DRUG|Bupivacaine|
41376183|NCT01541644|DEVICE|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
41505694|NCT00212680|DRUG|ONO-1101|
41505695|NCT00356655|BEHAVIORAL|Psychoeducation|
41505696|NCT03752814|DEVICE|SYNOSTE Nitinail System|Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
41505697|NCT05624645|DEVICE|Pelex Upp|Patients were given the Pelex Upp is a non-invasive device that is designed to guide a user through personalized pelvic floor strengthening exercises. Patients used device for four weeks to treat stress urinary incontinence
41505698|NCT00073697|DRUG|Escitalopram|Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
41505699|NCT00073697|BEHAVIORAL|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
41033414|NCT01221597|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
41033415|NCT05445427|DEVICE|vagal nerve stimulator|Non-invasive vagus nerve stimulator
41033416|NCT03021187|DRUG|semaglutide|Oral semaglutide administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
41033417|NCT03021187|DRUG|semaglutide|Oral semaglutide (3 mg followed by 7 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
41033418|NCT03021187|DRUG|semaglutide|Oral semaglutide (3 mg followed by 7 mg and finally 14 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
41033419|NCT03021187|DRUG|placebo|Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
41033420|NCT05739981|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV
41033421|NCT05739981|DRUG|Carboplatin|Carboplatin AUC 5-6 IV
41033422|NCT05739981|DRUG|Bevacizumab|BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
41033423|NCT05739981|DRUG|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
41505700|NCT00073697|OTHER|Escitalopram plus IPT|Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
41505701|NCT02501018|BIOLOGICAL|CLBS12|Intramuscular transfusion of CLBS12.
41505702|NCT02501018|DRUG|SOC|Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
41505703|NCT02352012|OTHER|Autologous blood|Autologous blood was perfused to the target pulmonary segment
41505704|NCT02352012|DEVICE|Bronchial plug|Bronchial plug was placed to the target pulmonary segment
41505705|NCT02836314|OTHER|Anorganic Bovine Bone Mineral (ABBM)|In the control group, periodontal intrabony defects were treated with ABBM alone.
41505706|NCT02836314|OTHER|Anorganic Bovine Bone Mineral and Platelet Rich Fibrin (PRF)|In the test group, periodontal intrabony defects were treated with ABBM and PRF combination.
41505707|NCT03939715|BIOLOGICAL|DermaPure®|Surgical intervention using DermaPure®
41505708|NCT03939715|PROCEDURE|native tissue|Surgical intervention using native tissue
41505709|NCT04659759|OTHER|COVID-19 exposure|COVID-19 exposure during pregnancy
41505710|NCT04659759|BIOLOGICAL|COVID-19 vaccine|Receipt of any COVID-19 vaccine
41033424|NCT04993690|DRUG|LP-168 tablet|Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily
41033425|NCT06106477|BEHAVIORAL|Intermittent Fasting|"Participants will be asked to adhere to a six-month intermittent fasting intervention, a daily-recurring dietary plan consisting of:~* An approximately fourteen-hour nightly fasting period that is followed by~* An approximately ten-hour eating period with their last meal of the day occurring between 17:00 (5:00 PM) and 21:00 (9:00 PM)."
41033426|NCT06636097|DEVICE|Full arch|design
41033427|NCT06635863|DRUG|Prednisone 40mg|Prednisone 40mg x 8weeks
41033428|NCT04740294|DRUG|Magnesium Sulfate|Randomized to receive either magnesium sulfate or normal saline placebo.
41033429|NCT04408755|DRUG|AVP-786|oral capsules
41033430|NCT04408755|DRUG|Placebo|oral capsules
41033431|NCT05237466|BEHAVIORAL|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Each treatment session will involve a combination of motivational interviewing (MI) and sorting practice. The rationale behind the sorting practice is to develop the skill of sorting and the formation of a daily sorting routine. The MI portion of the initial session will involve an evaluation of client strengths and individual biopsychosocial goals. The initial and subsequent sessions will include a variety of MI techniques, including decisional balancing, developing discrepancy, personalized feedback, and reinforcement of responsibility of sense of self-efficacy.
41033432|NCT05237466|BEHAVIORAL|Sorting Practice|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Clinicians will encourage participants to sort objects during each session while refraining from use of any specific cognitive or motivational therapeutic techniques. Participants will be asked to record the frequency and duration of any sorting/ discarding they did during the previous week.
41376184|NCT05356546|OTHER|Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection|Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
41033433|NCT01615029|DRUG|Part 1 (Dose Escalation): Daratumumab|Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
41033434|NCT01615029|DRUG|Part 2 (Dose Expansion): Daratumumab|Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
41164072|NCT05726552|OTHER|Laughter therapy|"Laughter therapy will be applied for 50 minutes, 12 sessions, 3 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality.~The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
41164073|NCT05157568|BEHAVIORAL|Exercise Streaming (ES)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. No equipment is required. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
41376185|NCT05177328|BIOLOGICAL|S. hominis A 9 Product|Commensal staph species, phosphate buffered saline, and glycerol.
41033435|NCT01615029|DRUG|Lenalidomide|All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
41164074|NCT05157568|BEHAVIORAL|Exercise Streaming + Equipment (ES+E)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. Each participant will have a stationary exercise bike delivered to their home for use during their live classes. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
41164075|NCT05157568|BEHAVIORAL|Control|Participants will complete 8 weeks (1 class per week) of in-person supervised exercise.
41164076|NCT02161198|DIETARY_SUPPLEMENT|Y-75|Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package
41376186|NCT05177328|DRUG|Placebo|Phosphate buffered saline and glycerol
41376187|NCT03163823|OTHER|Proloquo2Go|Use of communication application Proloquo2Go modified for the ICU setting on an iPad device
41376188|NCT03163823|OTHER|Standard of Care|Standard of Care communication methods
41033436|NCT01615029|DRUG|Dexamethasone|All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously \[injection of a substance into a vein\]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index \[BMI\] less than \[\<\] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
41033437|NCT05911854|DEVICE|Multi-waved Locked System Laser|The M6 therapy laser is a robotized multi-target device designed to treat patients suffering pathologies affecting a wide area, and to perform automatic applications.
41033438|NCT05911854|DEVICE|Cold Compression therapy|The BioCryo Cold Compression System is a cold therapy pneumatic compression device that safely administers sequential, gradient pneumatic compression and CryoTherapy combined.
41033439|NCT05911854|OTHER|complete decongestive therapy|"Complete decongestive therapy consists of:~* Meticulous skin care with the use of emollients~* Using short stretch bandages or continuous wearing of a pressure garment~* Manual lymphatic drainage therapy~* Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)"
41033440|NCT01138332|GENETIC|western blotting|
41033441|NCT01138332|OTHER|laboratory biomarker analysis|
41164077|NCT02161198|DIETARY_SUPPLEMENT|Placebo|Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
41164078|NCT05558813|DIAGNOSTIC_TEST|Cardiac MRI|two cardiac MRIs with Gadolinum injection at 2-year intervals
41164079|NCT05558813|BIOLOGICAL|Blood assays|blood samples for the determination of blood biomarkers of heart failure (BNP, NTproBNP) and for the constitution of a biological collection
41164080|NCT03333083|DRUG|Raltegravir|Raltegravir (1200 mg once a day)
41164081|NCT03333083|DRUG|Lamivudine|Lamivudine (300 mg once a day)
41164082|NCT03831230|GENETIC|collection of blood, urine, tumor and ascite samples|collection of blood, urine, tumor and ascite samples during ovarian surgery
41376189|NCT03642158|DEVICE|repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
41376190|NCT02116309|DRUG|Rectal Indomethacin|
41376191|NCT02116309|DRUG|Epinephrine|
41505711|NCT01715571|DEVICE|Viberect|"Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.~Men will record device use and intercourse attempts after device use in a diary."
40850303|NCT06312319|DEVICE|Respiratory training|Respiratory training using the EMST 150 device to increase inspiratory and expiratory muscle strength.
41376192|NCT00638950|DIETARY_SUPPLEMENT|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
41376193|NCT00638950|DIETARY_SUPPLEMENT|Placebo|The placebo products were commercial dairy products with comparable fat contents.
41376194|NCT00457249|BIOLOGICAL|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
41376195|NCT00457249|BIOLOGICAL|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
41376196|NCT00198588|DRUG|argatroban|beginning dose: 0.7microgram/kg/H
41376197|NCT03807973|DRUG|[Zr-89]Oxine-labeled leukocytes PET/MRI|All study participants will undergo an investigational imaging study using autologous \[Zr-89\]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using \[Zr-89\]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
41376198|NCT03162016|PROCEDURE|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
41376199|NCT04080362|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
41376200|NCT04796259|DIETARY_SUPPLEMENT|Malt ingredient|Solution with malt-derived ingredient
41376201|NCT04796259|DIETARY_SUPPLEMENT|Non-alcoholic beer solids|Solution with non-alcoholic beer solids
41376202|NCT01504126|DRUG|Chemotherapy|Undergo standard chemotherapy
41376203|NCT01504126|DRUG|Propranolol Hydrochloride|Given PO
41505712|NCT06069115|RADIATION|Radiation therapy protocol for Breast cancer|Conformal 3D radiation therapy will be performed 4-12 weeks after surgical treatment of breast cancer on Electa Axesse linear gas pedal with 6 MeV energy in traditional fractionation mode. Different RT schemes will be used depending on the stage of the disease, type of surgical treatment, and morphological variant of the tumor. In organ-preserving surgeries the remaining breast will be irradiated with a single focal dose (FD) of 2 Gy, up to the total focal dose (TFD) of 50 Gy. In the presence of risk factors, irradiation of lymphatic outflow pathways will be performed: axillary, sub/adclavicular and parasternal lymph nodes areas (FD 2 Gy, up to TFD 44-46 Gy). In radical breast resection we'll use irradiation of the anterior chest wall in 2 Gy FD, up to 50 Gy FD, irradiation of lymphatic outflow pathways: axillary, sub/adclavicular and parasternal lymph nodes (2 Gy FD, up to 44-46 Gy FD).
41505713|NCT06069115|DIAGNOSTIC_TEST|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
41505714|NCT06069115|DIAGNOSTIC_TEST|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
41505715|NCT06069115|DIAGNOSTIC_TEST|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
41505716|NCT06069115|DIAGNOSTIC_TEST|SF-36 Quality of Life Questionnaire|Standard questionnaire for assessment quality of patient's life https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
41505717|NCT06069115|DIAGNOSTIC_TEST|Demographic and anthropometric measures|Age, sex, height. weight, body mass index (BMI)
41505718|NCT06069115|OTHER|Indicators characterizing the severity of the underlying disease|Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease) Medications taken.
41505719|NCT02856802|DRUG|Sumatriptan 10 mg Nasal Spray|100 μL nasal spray once
41033442|NCT01552213|OTHER|Minimum intervention control group|A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
41033443|NCT01552213|OTHER|Treatment for glucose intolerance|Diet, exercise glucose monitoring, insulin if necessary
41033444|NCT00096135|BIOLOGICAL|filgrastim|given subcutaneously (SC)
41033445|NCT00096135|DRUG|cyclophosphamide|IV over 15-30 minutes
41033446|NCT00096135|DRUG|cytarabine|IV over 3 hours twice daily
41033447|NCT00096135|DRUG|daunorubicin hydrochloride|IV over 15 minutes
41376204|NCT01504126|OTHER|Quality-of-Life Assessment|Ancillary studies
40850304|NCT06312319|OTHER|Orofacial exercises|The exercises will include activities to improve orofacial structures such as mobility, strength and coordination.
41033448|NCT00096135|DRUG|dexamethasone|oral twice daily
41033449|NCT00096135|DRUG|etoposide|IV over 1 hour
41033450|NCT00096135|DRUG|leucovorin calcium|rescue IV over 24 hours
41033451|NCT00096135|DRUG|mercaptopurine|oral
41033452|NCT00096135|DRUG|methotrexate|intramuscularly (IM)
41033453|NCT00096135|DRUG|pegaspargase|intramuscularly (IM)
41033454|NCT00096135|DRUG|therapeutic hydrocortisone|
41033455|NCT00096135|DRUG|vincristine sulfate|given IV
41376205|NCT01504126|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
41376206|NCT05388526|OTHER|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
41376207|NCT02875340|DRUG|VAL401|Risperidone formulated into a liquid lipid filled capsule
41376208|NCT03930615|DRUG|Letermovir|LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
41376209|NCT03930615|DRUG|Placebo|Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
41376210|NCT00399204|DRUG|Pioglitazone vs Metformin|
41376211|NCT02716415|DRUG|Calmoseptine Ointment|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
41376212|NCT02716415|DRUG|Destin Maximum Strength 40% Zinc|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
41505720|NCT02856802|OTHER|Sumatriptan Placebo Nasal Spray|100 μL nasal spray once
41033456|NCT00096135|RADIATION|radiation therapy|Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
41033457|NCT03607383|DRUG|Red Rice Yeast Extract|adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks
41164083|NCT03635840|DEVICE|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
41164084|NCT02766010|DEVICE|TensorTip|Non Invasive screening of various physiological and hematological parameters.
41164085|NCT02388932|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41164086|NCT02388932|DEVICE|Positron Emission Tomography|Undergo PET/CT
41376213|NCT00233675|DRUG|GABITRIL (tiagabine hydrochloride; CEP-6671)|
41376214|NCT04941014|BEHAVIORAL|Light Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
41376215|NCT04941014|BEHAVIORAL|Moderate Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
41376216|NCT04941014|BEHAVIORAL|Vigourous Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
41376217|NCT02743598|DRUG|Liraglutide|
41376218|NCT04760639|DIAGNOSTIC_TEST|Breath test|Participants provide a breath sample
41376219|NCT06134687|PROCEDURE|Endoscopic Submucosal Dissection|Removal of study eligible lesions per endoscopic submucosal dissection
41376220|NCT06134687|DEVICE|Novel Rigidizing Overtube|Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection
41376221|NCT01912469|DRUG|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
41376222|NCT01912469|DRUG|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
41376223|NCT03814824|DIAGNOSTIC_TEST|IRIS (Intelligent real-time image segmentation)|IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.
41376224|NCT03814824|DIAGNOSTIC_TEST|VLE (Volumetric laser endomicroscopy)|VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.
41164087|NCT02388932|DEVICE|Computed Tomography|Undergo PET/CT
41376225|NCT02984904|OTHER|survey|survey
41376226|NCT05922540|OTHER|Intravenous thrombolysis|Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
41376227|NCT00817427|OTHER|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
41376228|NCT00817427|OTHER|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
41376229|NCT02305069|DRUG|Pioglitazone|Described elsewhere
41376230|NCT02305069|DRUG|Insulin|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
41376231|NCT02305069|DRUG|Octreotide|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
41376232|NCT02305069|DRUG|Glucose|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
41376233|NCT02305069|DRUG|Mixed Amino Acids|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
41376234|NCT02305069|OTHER|[2H5]phenylalanine|Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
41376235|NCT02305069|OTHER|[1-13C]leucine|Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
41505721|NCT02644473|DRUG|Tranexamic Acid|
41505722|NCT02644473|DRUG|Normal saline|Control
41505723|NCT04546724|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
41505724|NCT04546724|BIOLOGICAL|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
41376236|NCT05571397|DEVICE|Dexcom G6|Continuous Glucose Monitor
41376237|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^6 cells/m2"
41376238|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^7 cells/m2"
41376239|NCT06567210|BEHAVIORAL|CBCTi|The program is composed of weekly online modules that include written information and interactive components such as schematics, images, videos, and questions. The content of the modules follows traditional and validated cognitive-behavioural therapy for insomnia protocols including sleep education, behavioural strategies (e.g., stimulus control, bedtime retraining, sleep hygiene), cognitive restructuration approaches (e.g., thought reappraisal, imagery, mindfulness), and relaxation practices (progressive muscle relaxation and autogenic training). In addition, further content aims to stabilize and amplify circadian rhythmicity through light exposure in the morning, daytime moderate physical activity, and evening time warm baths. Participants complete daily sleep diaries throughout the intervention.
41505725|NCT00896974|OTHER|Laboratory Biomarker Analysis|Correlative studies
41376240|NCT06567210|BEHAVIORAL|General sleep information|General sleep health information and access to daily sleep diaries during 8 weeks
41376241|NCT05248854|OTHER|Sensorimotor exercise training|The program included side stepping, tandem walking, perturbation exercise, overcoming mini obstacles, walking different surfaces and traditional hip and knee exercise. Participants applied these exercise as home program between postoperative second weeks and 8th weeks, 3-5 day /week , 20 25 min every session.
41376242|NCT05248854|OTHER|Core stabilization exercise training|Core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research.core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research
41376243|NCT02399410|DRUG|perioperative chemotherapy plus bevacizumab|preoperative and postoperative combination chemotherapy with bevacizumab
41376244|NCT02399410|PROCEDURE|cytoreductive surgery|complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
41376245|NCT02399410|DRUG|Intraperitoneal Oxaliplatin|Pump-driven intraperitoneal administration of oxaliplatin
41505726|NCT00896974|OTHER|Pharmacological Study|Correlative studies
41505727|NCT00896974|DRUG|Retinoid 9cUAB30|Given orally
41505728|NCT03068039|OTHER|Oats breakfast porridge|Isoenergetic and isovolumteric oats breakfast porridge
41505729|NCT03068039|OTHER|Pearl (bajra) breakfast porridge|Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
41505730|NCT04005365|DRUG|Propranolol|add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
41505731|NCT05171608|PROCEDURE|Ultrasound-based protocol based fluid therapy|"Protocol of the interventional group according to the ultrasonographic findings:~Ultrasound scan 2 hours before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate intravenous (IV) fluid therapy: 8 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.~A 2nd ultrasound scan at 30 minutes before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate further IV fluid therapy: 5 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy."
41505732|NCT06490185|OTHER|Clinical data collection|Clinical significance of peri-appendiceal abscess and phlegmon in acute complicated appendicitis patients undergoing emergency appendectomy
41505733|NCT05300828|DRUG|Genexl PM|Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
41505734|NCT06551519|OTHER|ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
41505735|NCT06551519|OTHER|DMT category 1|This is an observational study. There is no treatment allocation. The decision to continue their current DMT will be based solely on clinical judgement.
40850305|NCT02065817|OTHER|stable isotope of cholesterol|
41505736|NCT02939053|DEVICE|SOZO|The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.
41376246|NCT06032260|OTHER|Enriched panettone|Volunteers consumed 100 grams of panettone enriched with fiber (JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
41376247|NCT06032260|OTHER|Panettone standard|Volunteers consumed 100 grams of panettone standard
41376248|NCT04639570|OTHER|KneuroKnits|The KneuroKnits program will be based upon current knitting education practices and leading practices in facilitation of social participation for individuals with neurodevelopmental disorders, physical disabilities, and acquired brain injuries. The program will consist of 4 weekly sessions in which participants will learn knitting fundamentals and have opportunities to socialize over a shared occupation. The 4 weekly sessions of the KneuroKnits curriculum will include related knitting and social skills themes of the week. Each session will begin with a structured lesson on the knitting topic of the day, and will then continue into knitting practice and social interaction. Participants will be encouraged to practice their new skills (knitting and social) between sessions, and will be allowed to keep all materials that they use or create.
41376249|NCT00002738|DRUG|leucovorin calcium|
41376250|NCT00002738|DRUG|trimetrexate glucuronate|
41505737|NCT02735538|PROCEDURE|osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head will undergo total hip replacement.
41505738|NCT02735538|PROCEDURE|osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement.
41505739|NCT05852223|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab 200mg Q3W will be administered via IV infusion for 2 courses from the date of randomization until to the date of thyroidectomy.
41505740|NCT04169152|PROCEDURE|Cap-assisted endoscopic sclerotherapy|Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
41505741|NCT03691727|DRUG|tirofiban hydrochloride (AGGRASTAT®)|Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
41505742|NCT03691727|DIAGNOSTIC_TEST|MRI|Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
41505743|NCT03691727|DIAGNOSTIC_TEST|Neurological Exam|Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
41376251|NCT05700422|DRUG|Varenicline Nasal Spray|OC-01 (varenicline solution) 0.03 mg nasal spray
41376252|NCT00118560|BEHAVIORAL|Physical exercise|treadmill walking
41376253|NCT00118560|BEHAVIORAL|Physical walking|calf muscle exercise
41505744|NCT03691727|BEHAVIORAL|Questionnaires|Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
41505745|NCT03691727|DIAGNOSTIC_TEST|Vital Signs|Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
41505746|NCT03691727|OTHER|Standard of Care Treatment|Participants will receive standard of care treatment and will not receive study drug.
41505747|NCT00311324|BEHAVIORAL|Special Intervention|
41505748|NCT00311324|BEHAVIORAL|Delayed Intervention|
41505749|NCT04302012|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and/or after administration of mydriatic agent
41505750|NCT04302012|DRUG|Mydriatic Agent|Subjects may be administered mydriatic medication to dilate their pupils.
41505751|NCT00641615|BIOLOGICAL|RNF43-721|Doses of 0.5mg, 1.0mg, 3.0mg/body/week
41505752|NCT00000108|BEHAVIORAL|Exercise|
41505753|NCT02492659|PROCEDURE|femtosecond laser-assisted cataract surgery|the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.
41505754|NCT02492659|PROCEDURE|conventional phacoemulsification|continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
41505755|NCT03590054|DRUG|Abexinostat|Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
41505756|NCT03590054|BIOLOGICAL|Pembrolizumab|Given IV on day 1 of every 21 day cycle
41505757|NCT04150263|PROCEDURE|Intraocular lens (IOL) ab externo scleral suture fixation|traditional IOL scleral suture fixation
41505758|NCT04150263|PROCEDURE|Modified IOL ab externo scleral suture fixation|Modified IOL scleral suture fixation
40850306|NCT04325620|DRUG|HIP1601|HIP1601
40850307|NCT04325620|DRUG|HGP1805|Placebo of HIP1601
41376254|NCT05562739|DIETARY_SUPPLEMENT|Postbiotic|multistrain postbiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 6 weeks.
41376255|NCT05562739|DIETARY_SUPPLEMENT|Placebo|Matching placebo in a form of a capsule for 6 weeks.
41376256|NCT06338176|OTHER|OPTIMUS-SAB clinical care pathway|Activation of SAB clinical care pathway within EMR system.
41376257|NCT02768935|PROCEDURE|blood sample|blodd sample at 12 months
41376258|NCT06566833|DRUG|self assmbling peptide p11-4 combined with 0.05% fluoride|biomimetic remineralizing agent
41376259|NCT06566833|DRUG|Casein phosphopeptide amorphous calcium phosphate|remineralizing agents that acts as a fluoride booster
41376260|NCT06566833|DRUG|5% sodium fluoride varnish|remineralizing agent that is used as a gold standard for remineralization
41376261|NCT00731640|DEVICE|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
41376262|NCT04993937|OTHER|Intervention|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
41376263|NCT04993937|OTHER|Control Group|Control group will follow their daily routine activities and may involve in any other exercise program rather than plyometric exercises.
41376264|NCT02487459|BIOLOGICAL|BPX-501|T cells transduced with CaspaCIDe suicide gene
41376265|NCT02487459|DRUG|AP1903|dimerizer drug administered to treat GVHD
41376266|NCT04917406|DRUG|Application of lidocaine together with dexamethasone|Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
41376267|NCT04917406|DEVICE|Application of ultrasound as physical therapy|The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and a 1MZ head.
41376268|NCT03264001|BEHAVIORAL|Negative energy balance|20% and 40% reduction of daily energy needs for weight maintenance
41376269|NCT03803371|DRUG|Ultracet Tablets|Ultracet tablet (Janssen Cilag Farmacêutica Ltda) equivalent to Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg
41376270|NCT03803371|DRUG|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets (Pfizer)
41376271|NCT04998669|DRUG|Loncastuximab tesirine|"Induction Phase (Cycles 1 through 4):~* 150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~* 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 \& 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle."
41376272|NCT04998669|DRUG|Rituximab|"Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician."
41376273|NCT01873131|DRUG|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
41376274|NCT01873131|DEVICE|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
41505759|NCT04991207|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
41505760|NCT04991207|DRUG|bosentan|Oral Tracleer (bosentan) 125 mg film coated tablets
41505761|NCT01005147|DRUG|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
41505762|NCT01005147|OTHER|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
41505763|NCT05331807|DIETARY_SUPPLEMENT|Omega-3 FA|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA)
41505764|NCT05331807|DIETARY_SUPPLEMENT|Vitamin D|one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
41505765|NCT05331807|COMBINATION_PRODUCT|Combined Omega-3 and Vitamin D Supplementation|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA) and one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
41505766|NCT05545124|DRUG|Donafenib + Tislelizumab|Donafenib 100mg, BID+Tislelizumab 200mg, D1; q3w
41033458|NCT03607383|DRUG|Statin|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
41505767|NCT05198258|OTHER|Implementation strategy - experimental group|On-line theoretical education and three hours of practical training by the project leaders. Contact with the project team via e-mail, phone and on-line repetition of the education for remaining of the clinical examination, neck-specific program and the progression of exercises.
41505768|NCT05198258|OTHER|Implementation - control group|Physiotherapists in the control group will receive the same theoretical and practical training as the experimental group but without repetition of the education or support from the research team.
41505769|NCT03999229|DRUG|SNO|S-nitrosylating agent (SNO) Inhalation
41505770|NCT03999229|DRUG|Normal Saline|Normal Saline transfusion
41033459|NCT06042647|DRUG|0.01% Halobetasol|Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.
41033460|NCT06042647|DRUG|0.045% Tazarotene|Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.
41033461|NCT06042647|DRUG|0.05% Clobetasol Propionate|Drug to be applied to designated psoriatic plaque at bedtime.
41033462|NCT05462626|BEHAVIORAL|Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program|The intervention is comprised of the following sessions and themes; Session 1: Informed Consent and Pre-Testing; Session 2: Occupation and Healthy Aging; Session 3: Longevity and Thriving; Session 4: Movement Matters; Session 5: Thoughtful Eating; Session 6: Stress and Sleep; Session 7: Navigating Health Care; Session 8: Post-Testing and Discharge.
41376275|NCT03286530|DRUG|Ruxolitinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment."
41376276|NCT01465594|PROCEDURE|transurethral catheter after EERPE/ RALP|transurethral catheter after EERPE/ RALP
41376277|NCT01465594|PROCEDURE|suprapubic catheter after EERPE /RALP|suprapubic catheter after EERPE /RALP
41376278|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - Walking|30 minutes of walking or light jogging a day at a moderate intensity for 30 minutes a day, 5 days a week for 12 weeks
40850308|NCT04757545|OTHER|HM-PRO|"The intervention group will have a predetermined consultation appointment planned to assess medical status and symptom control. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients:~1. Worsening in symptoms results in a nurse-led telephone consultation within two days guided by the symptom management manual.~2. Minor changes in patient's symptom assessment result in a nurse-led telephone consultation within seven days using the symptom management manual.~3. Patients that are completely stable in the symptom assessment will receive an electronic answer via min-SP (electronic patient journal) regarding the results and a new appointment, including PRO-data prior to this."
40850309|NCT00429169|DRUG|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
41033463|NCT06495775|DEVICE|quickfact|fecal sampling
41033464|NCT03968653|DRUG|Debio 0123|Debio 0123 will be given as an oral capsule for 3 days during each 21-day cycle, except Cycle 1 which is of 24 days.
41033465|NCT03968653|DRUG|Carboplatin|Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 2 onwards in Group A.
41033466|NCT03968653|DRUG|Debio 0123|Debio 0123 will be given as an oral capsule for 3 or 6 days during each 21-day cycle.
41033467|NCT03968653|DRUG|Carboplatin|Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 1 onwards.
41033468|NCT04786262|BIOLOGICAL|VX-880|Infused into the hepatic portal vein.
41033469|NCT03099850|OTHER|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center responsible for monitoring protocol and regulatory compliance for consortium. CDMC responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.
41033470|NCT06636305|BEHAVIORAL|physical activity intervention|Women in the intervention group were instructed to obtain 10,000 steps per day and 150 minutes of MVPA (defined as physical activity that resulted in a heart rate in the range of 120-170 bmp) per week and were given a physical activity tracker (FitBit Charge HR 2, Fitbit, San Francisco, USA) to self-monitor progress.
41033471|NCT00633321|BIOLOGICAL|TA-NIC|TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
41033472|NCT00633321|BIOLOGICAL|Placebo|Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
41033473|NCT06045962|DEVICE|Ureteral stent|Used to open the ureter and help the kidney drain
41033474|NCT02192437|OTHER|Sulfur amino acid restricted diet|Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
41376279|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - HIIT Cycling|Four, 4 minute high intensity intervals of exercise, separated by 3 minutes of lower intensity exercise + a 10 minute warm up and 5 minute cool down for 40 minutes a day, 3 days a week for 12 weeks
41376280|NCT06539611|OTHER|Observational|This study is observationnal: Questionnaires to assess the endpoint
41376281|NCT02569502|DRUG|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
41376282|NCT03979339|PROCEDURE|Blood sample collection|A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
41505771|NCT03999229|DRUG|Red Blood Cell|Blood transfusion (RBCs)
41505772|NCT01970800|DRUG|Growth Hormone|Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
40850310|NCT00429169|DRUG|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
41033475|NCT04837482|DRUG|AGN-190584|Topical eyedrop
41033476|NCT04837482|DRUG|Vehicle|Topical eyedrop
41033477|NCT02044510|DRUG|Mirabegron|Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
41033478|NCT02044510|DRUG|Placebo|Matched placebo capsules to the intervention arm
41033479|NCT03388580|PROCEDURE|bronchoalveolar lavage (BAL)|clinically indicated, elective BAL
41033480|NCT00778466|DRUG|metformin hydrochloride 1000 mg tablets|
41033481|NCT04994626|DRUG|Ibrutinib Combined With Rituximab|"Drug: ibrutinib ibrutinib 560mg administered orally once daily. Other Name: Imbruvica~Drug: rituximab rituximab 375mg/m² administered intravenously (IV)"
41033482|NCT03809182|DRUG|Dexmedetomidine|A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.
41376283|NCT03140527|DRUG|PTI-801|Active
41376284|NCT03140527|DRUG|Placebo|Placebo
40850311|NCT06496854|DRUG|Lorazepam 1 mg|1 mg oral lorazepam, a sedative used to relieve anxiety
40850312|NCT06496854|DRUG|Ibuprofen 800 mg|800 mg ibuprofen, Nonsteroidal anti-inflammatory drug to treat pain
41376285|NCT03140527|DRUG|PTI-808|Active
41376286|NCT03140527|DRUG|Placebo|Placebo
41376287|NCT05409300|BIOLOGICAL|BBIBP-CorV|Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide
41376288|NCT00062075|DRUG|romidepsin|Given IV
41376289|NCT00623441|DEVICE|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
41376290|NCT05558709|OTHER|REALSOCOG|Patients will be asked to perform the REALSoCog serious game-type social cognition assessment task developed by the LMC2 laboratory (UR 7536). Their performance will be compared to those of control individuals recruited in parallel (independant clinical study: CER-U, IRB N°: 00012020-115). Participants will be asked to think about 16 social situations (6 control situations and 10 experimental situations) encountered in a virtual environment representing a city. REALSoCog can be used on a laptop computer, without any additional technical device.
41376291|NCT05558709|OTHER|BCS|Social-cognitive tasks from the BCS (Ehrlé et al., 2011) will also be offered to patients to test the concurrent validity of REALSoCog. This battery assesses social cognition. It includes paper-and-pencil tasks.
41376292|NCT05558709|OTHER|Hetero-questionnaires|Hetero-questionnaires assessing patients' social behavior will be transmitted to their relative or primary caregiver (Godefroy \& le GREFEX, 2008; Gury and Ehrlé, in progress of validation) in order to verify the concurrent validity of REALSoCog. These hetero-questionnaires aim to identify and quantify the presence of social skills and behaviour disorders.
41376293|NCT06330467|DIAGNOSTIC_TEST|psychometric assessment|Psychometric testing to assess trauma and dissociative disorders, and in particular dissociative identity disorder.
41376294|NCT06330467|DIAGNOSTIC_TEST|semi-structured clinical interview|Semi-structured interview for the assessment of dissociative disorders (SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders)
41376295|NCT03076710|DRUG|Opioids delivered through PCA|IV up to 1 mg. morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours
41376296|NCT03076710|DRUG|EXPAREL® infiltration|"22 gauge / 3.5 needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request"
41376297|NCT01771627|DRUG|varenicline|Given PO
41376298|NCT01771627|DRUG|nicotine patch|
41376299|NCT02341573|DRUG|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
41376300|NCT02341573|DRUG|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
41376301|NCT03635970|PROCEDURE|celular therapy|application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy
41376302|NCT03500029|RADIATION|Transcranial magnetic stimulation (TMS)|TMS treatment group is treated with TMS for 20-40 minutes a time, 5 times a week. The stimulation parameters were 20 Hz and 80% MT. Each stimulation continues for 2 seconds, and the interval time of stimulation is 58 seconds.
41376303|NCT03500029|DRUG|antidepressants|Medication group is treated with anti-depression for 6 weeks. The drugs and their doses belong to the first-line treatment for depression in the current guideline .
41376304|NCT03542825|DRUG|Lactoferrin|parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia
41376305|NCT03542825|DRUG|Iron Supplement|Iron Sulphate 150 mg once daily
40850313|NCT03252002|DRUG|BAY1101042|Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
41033483|NCT03809182|DRUG|0.9% Sodium-chloride|The same infusion rate used in the dexmedetomidine group.
41033484|NCT03809182|DRUG|Fentanyl|Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
41033485|NCT03809182|DRUG|Morphine Sulfate|Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.
41033486|NCT01868581|DRUG|insulin degludec|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
41033487|NCT01868581|DRUG|insulin degludec/insulin aspart|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
41033488|NCT06419179|DRUG|Durvalumab|1500 mg i.v. Q4W
41376306|NCT03542825|DRUG|Chelates, Iron|Amino acid chelated iron capsules contain 15 mg
41376307|NCT00008034|DRUG|capecitabine|
40850314|NCT03252002|DRUG|Placebo|Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
40850315|NCT06584461|DRUG|Lidocaine (drug)|IV lidocaine, administered once during the induction of anesthesia.
41033489|NCT06419179|DRUG|Olaparib|300 mg BID orally
41033490|NCT03815643|DRUG|Avelumab|Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).
41164088|NCT02388932|OTHER|Quality-of-Life Assessment|Ancillary studies
41376308|NCT00008034|DRUG|cyclophosphamide|
41376309|NCT00008034|DRUG|epirubicin hydrochloride|
41376310|NCT02592369|DEVICE|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
41376311|NCT03300726|DIAGNOSTIC_TEST|CSF analysis|CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
41376312|NCT03300726|RADIATION|Functional MRI|Functional MRI during resting state and semantic memory task activation
41376313|NCT02801149|PROCEDURE|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
41376314|NCT06566638|DEVICE|NucleoCapture device|100ml NucleoCapture selective DNA adsorber.
41376315|NCT00649714|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fed
41376316|NCT00649714|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fed
41376317|NCT01824095|DIETARY_SUPPLEMENT|Dietary supplement|
41376318|NCT03459066|DIAGNOSTIC_TEST|Institution-Group|"The study includes three measurement times:~* Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~* Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~* Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life."
41376319|NCT03312881|DIAGNOSTIC_TEST|quantitative sensory testing|multiple modality testing of generalized and localized changes in somatosensory perception
41376320|NCT03312881|DIAGNOSTIC_TEST|neuroimaging|magnetic resonance imaging (MRI)
41376321|NCT03312881|OTHER|Patient Reported Outcome Measures|neuropathic pain screening tool; validated questionnaires
41376322|NCT06457659|BEHAVIORAL|Early Rehab Group|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation. The basic theme was to check the physical psychological and QOL in early prostheic-fitted patients through WHO_QOL.
41376323|NCT06457659|OTHER|Delayed Rehab Group|The 2nd group of 25 patients was fitted with Prosthesis after 6 months after amputation. No physical rehab was done during this period including physiotherapy and prosthetic treatment. The main aim was to check the significant impact of delayed rehabilitation.
41376324|NCT00657176|DRUG|OPB-31121|"* 100mg tablet~* oral administration, Qd"
41376325|NCT04969991|DRUG|Varespladib|250 mg immediate-release oblong, white, film-coated tablet for oral administration
41376326|NCT04969991|DRUG|Placebo|Oral formulation matched to the oral varespladib tablet
41376327|NCT01392469|DRUG|Imatinib|Film coated tablets, oral administration
41376328|NCT01392469|DRUG|Sildenafil|Oral Administration
40850316|NCT06584461|DRUG|Saline (NaCl 0,9 %) (placebo)|IV placebo (normal saline), administered once during the induction of anesthesia.
40850317|NCT04090242|DEVICE|BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle|Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.
40850318|NCT01882530|DRUG|Paracetamol|
40850319|NCT01882530|DRUG|Nefopam|
40850320|NCT01882530|DRUG|Ketoprofen|
40850321|NCT01882530|DRUG|Morphine|
41033491|NCT05319327|OTHER|Nutritional intervention|"A nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.~Total intervention will last 6 months for both groups. During the intervention phase, a monthly interview with nutritionist/dietitian is scheduled. Face-to-face interviews will be carried out in months 2 and 4. Phone interviews will be carried out in months 1, 3 and 5. In the baseline and final visits (months 0 and 6) a sample and data collection will be performed."
41164089|NCT02867111|DEVICE|Sperm Selection Assay|Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.
41376329|NCT01392469|DRUG|Bosentan|Oral Administration
41033492|NCT05319327|OTHER|Control|General counseling to adhere to a healthy Mediterranean diet
41033493|NCT06576063|DEVICE|Lumoral Treatment|Home-use of photodynamic antibacterial dual-light device, used with a marker substance (indocyanine green)
41376330|NCT00658086|DRUG|ALN-RSV01|administered by nebulization once daily for 3 days
41376331|NCT00658086|DRUG|normal saline|administered by nebulization once daily for 3 days
41376332|NCT05068700|DEVICE|Integrated Pulmonary Index|Medtronic Capnostream 35p monitoring parameter
41376333|NCT05068700|DEVICE|Standard capnography monitoring|Medtronic Capnostream 35p monitoring parameter
41376334|NCT04103268|OTHER|sepsis|patients in the ICU with infection called sepsis
41376335|NCT00529165|PROCEDURE|injection-meal-interval|"The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~1. Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~2. Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks."
41376336|NCT03857425|DRUG|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3\*420mg,twice daily for 8 weeks
41376337|NCT03857425|DRUG|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
41376338|NCT03857425|DRUG|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
41376339|NCT01607398|DRUG|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
41376340|NCT01607398|DRUG|Placebo|Placebo inhalation, twice daily, from week0 -12.
41376341|NCT03576794|DRUG|Leflunomide 20 mg|During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
41376342|NCT03576794|DRUG|Prednisolone|Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
41376343|NCT01995604|OTHER|Application of Sterile 0.9% Saline Solution|Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
41376344|NCT01995604|OTHER|Application of dHACM|Application of dHACM to half of face after UltraPulse laser therapy.
41376345|NCT02570217|DEVICE|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
41376346|NCT02570217|DEVICE|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
41376347|NCT00389168|DRUG|Irbesartan|Titrated to 300 mg od, 48 weeks.
41376348|NCT00389168|DRUG|Atenolol|Titrated to 100 mg od, 48 weeks.
41376349|NCT05921370|DRUG|Silodosin 8 mg|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement"
41376350|NCT05921370|DRUG|Placebo|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery."
41376351|NCT00308555|DRUG|Cannabis|
40850322|NCT06426849|OTHER|Liuzijue Exercise|"LiuzijueExercise includes inhalation and exhalation through various mouth patterns to manage and control the rise and fall of the breath in the body. It is performed by delivering 6 distinct sounds, (xū,hē, hū sī, chuī, and xī) through termination along with comparing body activities.~The following are 6-8 vital parts of body movements:~1. Swaying and twisting~2. Hip rotations~3. Arm movements~4. Knee bends~5. Foot pivots~6. Spine elongation~7. Hand gestures~8. Breath synchronization Frequency: 1 session per day for a week Intensity:In first week 1 set of Luizijue exercise will be performed then progressively increase to 4 sets till 6th week .~Total Time for Session; 40 minutes Warm-up Time: 10 minutes with pursed lip breathing Cool Down Time: 10 minutes with upper body gentle stretching. Exercise Duration: 20 minutes for Luizijue Exercise."
41376352|NCT01151501|DEVICE|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) \>92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2\>92%.
41376353|NCT04472910|DRUG|Modified Folforinox (mFFX)|Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
41376354|NCT02256202|OTHER|Interview|Monitoring interviews to show medical and economic advantages of given therapy
41376355|NCT05340049|DIAGNOSTIC_TEST|Online questionnaire of children's backgrounds|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children.
41033494|NCT06576063|BEHAVIORAL|Standard oral hygiene methods|Best available standard oral self-care hygiene methods performed at home and instructed by oral healthcare professionals, supported by professional cleaning at the oral healthcare clinic
41033495|NCT04598477|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
41033496|NCT04598477|DRUG|prednisone|Oral prednisone tablets
41033497|NCT02003001|DRUG|Botulinum Toxin|
41033498|NCT02556021|DRUG|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
41376356|NCT05340049|OTHER|Academic behavioral intervention of teachers|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
41505773|NCT06140446|DEVICE|FeverApp|The (self-management) FeverApp contains evidence-based information about fever and how to deal with it, tailored (phase-oriented) fever advices, and the option to monitor the health status of the child during a fever episode. All information and advices are based on the clinical expertise of paediatricians and the most recent international literature on fever, and complement the Dutch national fever guidelines. It is expected that by letting the body fight the infection on its own in a safe way, less ABs are needed, and the immune system will get stronger leading to less future infections as well.
41376357|NCT05340049|PROCEDURE|Therapy sessions|"Seven sessions were given to each of the three groups according to their classification (placebo, TMR, TCS), being able to obtain a stable value in each of the treatments carried out. Before each session, the effect of the previous session was explored in order to evaluate its efficacy (from the second session onwards). Each of the therapies had the same number of sessions (1 per week for 7 weeks) in order to have equality in all the parameters evaluated.~The effectiveness values of the therapies were expressed as percentages of satisfaction with the classifications of 25% (apparent changes less than half of the sample in each therapy group), 50% (apparent changes in half of the sample plus one in each therapy group) and 75-100% (apparent changes in all or almost all of the sample in each therapy group)."
41376358|NCT05003752|RADIATION|External beam radiation therapy, High-dose-rate brachytherapy|Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)
41505774|NCT06140446|DEVICE|DMT App|The (self-care) DMT App is a decision making tool (DMT) that can be used by parents to choose a safe and effective herbal medicine (HM) product to reduce symptoms of mild, acute uncomplicated URTIs in their child. The advices that the DMT App provides, are based on a systematic review (SR) of SRs on effectiveness of HM for URTIs, a SR on working mechanisms of the most promising herbs, a prescription rates study of HM for URTIs in 6 European countries, and current EMA status of the included herbs. No prescription from a doctor is needed for these products.
41376359|NCT05003752|DRUG|Goserelin 10.8 mg|Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
41505775|NCT04926831|DRUG|capmatinib|150 mg and 200 mg tablets for oral administration
41505776|NCT01128179|DRUG|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
41505777|NCT01128179|DRUG|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
41505778|NCT04505254|DRUG|Acalabrutinib|Given PO
41505779|NCT04505254|BIOLOGICAL|Obinutuzumab|Given IV
41376360|NCT03892902|DRUG|ACT-541468|Film-coated tablet for oral use at a dose strength of 50 mg.
41376361|NCT03892902|DRUG|Zopiclone 7.5 mg|Over-encapsulated to maintain blinding.
41505780|NCT01197144|DRUG|adalimumab|Subcutaneous, 40 mg every other week for 4 weeks
41505781|NCT01197144|DRUG|Placebo|Subcutaneous, every other week for 4 weeks
41505782|NCT00381433|DRUG|AVI-4065 Injection|
41376362|NCT03892902|OTHER|Placebo|Matching to maintain blinding.
41376363|NCT00005607|DRUG|FOLFIRI regimen|
41376364|NCT00005607|DRUG|fluorouracil|
41505783|NCT04979351|OTHER|Abdominal Massage|Abdominal massage will be applied twice a day.
41505784|NCT04129671|GENETIC|No intervention was applied|No intervention was administered
41505785|NCT01662401|DRUG|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
41505786|NCT01662401|DRUG|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
41505787|NCT05237336|BEHAVIORAL|Mindfulness-based Cognitive Therapy|"MBCT is a relapse prevention program that is used to teach participants with chronic physical/mental ailment (used to their conditions):~* to manage early signs of distresses with compassionate awareness, and respond more effectively to mood and cognitive changes.~* To become aware of bodily sensations, feelings, and thoughts, from moment to moment.~* To help participants learn different ways of relating to sensations, thoughts and feelings- through mindful acceptance and acknowledgement of unwanted feelings and thoughts, rather than habitual, automatic, preprogrammed routines that tend to perpetuate difficulties.~* To help participants to be able to choose the most skilful response to any unpleasant thoughts, feelings or situations that they meet.~UK's NICE recommends MBCT for persons who are well and have had 3 or more episodes of depression. MBCT benefits persons whose distress is triggered by the way they process experiences."
41505788|NCT05237336|BEHAVIORAL|Counselling as usual|Control group, Counselling as usual
41505789|NCT04108624|OTHER|Screening Phase|This will identify subjects who are MRD (minimal residual disease) negative and eligible for the discontinuation phase.
41505790|NCT04108624|DEVICE|Discontinuation Phase|Patients will undergo discontinuation of their maintenance therapy if they are MRD negative by PET/CT (Positron Emission Tomography/Computed Tomography), flow cytometry and next generation sequencing
41505791|NCT01644383|BEHAVIORAL|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
41376365|NCT00005607|DRUG|irinotecan hydrochloride|
41376366|NCT00005607|DRUG|leucovorin calcium|
41376367|NCT00066859|DRUG|Zoloft 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
41376368|NCT00066859|DIETARY_SUPPLEMENT|St. John's Wort 600 mg|St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
41376369|NCT03762642|PROCEDURE|Mastectomy|Removal of the whole breast
41376370|NCT03762642|PROCEDURE|Breast-Conserving Surgery|Removal of the cancerous tissue only
41376371|NCT06106217|OTHER|bapne|An exercise program was created in the form of a movement sequence consisting of nine movement combinations.
41376372|NCT06106217|OTHER|qi gong|The exercise program, which was prepared in a 40-minute sequence, was arranged as 10 minutes of warm-up, 20 minutes of Qi Gong exercises, and 10 minutes of cool-down.
41505792|NCT01740726|BEHAVIORAL|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
41033499|NCT02556021|DRUG|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
41033500|NCT02556021|DRUG|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
41033501|NCT06387563|PROCEDURE|Abdominal activation using pressure biofeedback|"PBF assisted abdominal muscle activation training (30 min, 3x /week /4 weeks) Progressive Muscle Relaxation for 5 min Pressure biofeedback assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Progression criteria in training: Maintaining 3 - 5 mmHg pressure on PBF dial while performing abdominal muscle activation.~Exercises for Group For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
41376373|NCT00538473|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
41505793|NCT01740726|DRUG|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
41505794|NCT03656744|DRUG|HTD1801|HTD1801 tablets, 250mg
41505795|NCT03656744|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
41505796|NCT03476538|DRUG|Gabapentin|Patients are tested for their normal prescription gabapentin medication
41376374|NCT00538473|BIOLOGICAL|Fluarix™|Single dose, intramuscular injection
41505797|NCT01231204|PROCEDURE|Placebo (normal saline) Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
41505798|NCT01231204|PROCEDURE|Ropivicaine 0.4% Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
41505799|NCT02047734|DRUG|Ozanimod|Oral capsule, daily for 24 months
41505800|NCT02047734|DRUG|Ozanimod placebo|Oral capsule, daily for 24 months
41376375|NCT03861689|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
41376376|NCT05360017|DEVICE|litestepper single lower limb rehabilitation training robot|The experimental group adopts litestepper single lower limb rehabilitation training robot walking training on the basis of routine rehabilitation management of stroke patients with hemiplegia, walking training once a day, 40 ± 5 minutes each time; The control group was treated with routine rehabilitation management of stroke patients with hemiplegia. The trial was an open design. Both researchers and subjects knew the treatment allocation and conducted three evaluations within 21 days to evaluate the effectiveness and safety of litestepper single lower limb rehabilitation training robot in the training of lower limb motor function of stroke patients with hemiplegia.
41376377|NCT03081130|PROCEDURE|Intravenous laser irradiation treatment|control group
41376378|NCT06382324|BEHAVIORAL|mindfulness practice of body scan|Mindfulness intervention is one kind of psychological intervention. The founder of Mindfulness-Based Stress Reduction (MBSR), Jon Kabat-Zinn, described mindfulness as \&#34;awareness that arises through paying attention, on purpose, in the present moment, non-judgmentally\&#34; (Kabat-Zinn, 2003). Moreover, these attitudes can be nurtured through various practices such as body scan, meditation, yoga, mindful eating, and mindful walking. Mindfulness practices are recognized for their ability to alleviate stress among athletes and enhance their recovery capabilities (Li et al., 2019). Mindfulness practice has been shown to enhance athletes\&#39; performance (Chen et al., 2018)、 improve sleep quality (Rusch et al., 2019)，which in turn promotes emotional stability and physical recovery.
41376379|NCT06382324|BEHAVIORAL|listening to light music|listening to light music asa control
41505801|NCT02047734|DRUG|Interferon beta-1a|Intramuscular injection, 30 µg, weekly for 24 months
41505802|NCT02047734|DRUG|Interferon beta-1a placebo|Intramuscular injection, weekly for 24 months
41505803|NCT02051062|BIOLOGICAL|Blood sample collection|One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration but within a maximum of 32 hours after administration.
41505804|NCT06408506|PROCEDURE|Re-Entry Surgery|Re-entry surgery 4 months after the insertion of the implants to reveal implants after osseointegration
41505805|NCT06408506|PROCEDURE|Probing peri-implant bone|Probing peri-implant bone with Dental Probe during surgery
41376380|NCT04680390|BEHAVIORAL|Standard of care engagement practices|The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
41376381|NCT04680390|BEHAVIORAL|Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
41376382|NCT05925036|DRUG|Mesenchymal stem cells|Autologous bone marrow derived MSCs
41376383|NCT05925036|OTHER|Placebo|Controls
41376384|NCT01564810|DRUG|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
41376385|NCT01564810|DRUG|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
41505806|NCT06408506|PROCEDURE|Scanning peri-implant bone|Scanning peri-implant bone during surgery
41505807|NCT06408506|PROCEDURE|Conventional Impressions|Conventional Impressions during surgery
41505808|NCT06408506|PROCEDURE|Implant Surgery|Placement of 6 implants in the edentulous mandible
41505809|NCT06408506|PROCEDURE|Healing procedure|"All 6 Implants in all patients are let to heal for 4 Months under the same conditions:~The most distal implants are left submerged. The most mesial implants are left transgingival and the Implants in the middle are immediately loaded using gold bar retained dentures"
41505810|NCT01325844|PROCEDURE|Epidural anesthesia|0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
41505811|NCT05866419|DEVICE|ThecaFlex DRx System|The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
41505812|NCT04382287|PROCEDURE|Remin Pro® and MI Paste Plus®|Te toothastes were applied at home twice a day over the six anterior upper primary teeth
41033502|NCT06387563|PROCEDURE|Abdominal activation using SEMG biofeedback|"SEMG-BF assisted abdominal muscle activation training (30 min, 3x/ week/ 4 weeks) Progressive Muscle Relaxation for 5 min Surface EMG-BF assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Maintaining minimal volumetric contraction of abdominal muscle activation (as per person) on SEMG device with abdominal muscle activation for set frequency~Exercises for Group B For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
41164090|NCT02867111|OTHER|Attractant Substance|Capacitated spermatozoa may be oriented by following an increasing concentration gradient of an attractant molecule, a phenomenon called sperm chemotaxis. This is a guidance mechanism observed in vitro, which may transport and retain spermatozoa at the fertilization site. Though several molecules have been suggested to attract human spermatozoa, in the context of gamete interaction prior to fertilization, progesterone has biological importance for several reasons. After ovulation, this hormone is secreted by the cumulus cells that surround the oocyte, diffusing to form a molecular gradient toward the periphery of the cumulus and beyond. Notably, a gradient of very low concentrations (picomolar) of progesterone is sufficient to chemically attract capacitated human spermatozoa
41376386|NCT02332044|DRUG|Erdos|capsule, 300mg
41376387|NCT02332044|DRUG|Talion|tablet, 10mg
41376388|NCT02332044|DRUG|Erdos, Talion|capsule 300mg and tablet 10mg
41376389|NCT00296192|DRUG|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
41376390|NCT00296192|OTHER|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
41376391|NCT02048059|DRUG|ANG1005|
41376392|NCT06211504|DEVICE|ProStop, sinus tarsi implant (STI)|Insertion of a sinus tarsi implant (ProStop from Arthrex) in sinus tarsi
41505813|NCT06328179|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；|VHEA -Induction Phase Regimen/Consolidation therapy after remission
41505814|NCT02977897|DRUG|Octreotide Acetate|Octreotide 100mcg SC q12h for 5 days
41505815|NCT06223386|BEHAVIORAL|Designed on-line course A with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided at the beginning of the 3-month intervention. Participants can consult with the dietitian via the APP on their mobile phones during the intervention period. These materials will encompass dietary and physical activity guidelines by the government in Taiwan.
41505816|NCT06223386|BEHAVIORAL|Designed on-line course B with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education.
41376393|NCT06211504|PROCEDURE|Conventional surgery|MDCO - medial displacement calcaneal osteotomy FDL transfer - flexor digitorum longus tendon transfer to the navicular bone Spring ligament repair - reconstruction of the spring ligament Strayer's procedure - gastrocnemius recession (if necessary) Cotton osteotomy - medial cuneiform opening wedge osteotomy (if necessary)
41376394|NCT00636857|PROCEDURE|Fluid administration|Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
41376395|NCT00636857|PROCEDURE|Perioperative fluid management based on Lean Body Mass|Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
41376396|NCT02632448|DRUG|LY2880070|Capsules
41505817|NCT06223386|BEHAVIORAL|Designed on-line course B with 3-month consultation with the dietitians + 3-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 3 months.
41505818|NCT06223386|BEHAVIORAL|Designed on-line course B with 6-month consultation with the dietitians + 6-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 6-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 6 months.
41505819|NCT02623985|DEVICE|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
41505820|NCT02623985|DEVICE|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
41505821|NCT02623985|DEVICE|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
41505822|NCT04302038|DIETARY_SUPPLEMENT|Protein|Additional daily protein provided by potato protein.
40850323|NCT06426849|OTHER|Tai Chi Chuan Exercise|"Tai Chi Chuan Exercise combines deep diaphragmatic breathing and relaxation with many fundamental postures.~Names of the 10 Movements in Sequence~1. Commencing Form~2. Repulsing the Monkey~3. Brush Knee~4. Parting the Horse's Mane~5. Cloud Hands~6. Golden Cockerel Standing on the Left, then the Right~7. Kick Out Right, Kick Out Left~8. Grasping the Bird's Tail~9. Cross Hands or Embrace the Tiger~10. Closing Form Frequency: 3 sessions / week Intensity: Initially each posture will be performed 3 times then progressively leads to 6 or 10 reps according to patient tolorance.~Total Time for Session; 40 minutes Warm-up Time: 10 minutes with pursed lip breathing Cool Down Time: 10 minutes with upper body gentle stretching. Exercise Duration: 20 minutes for Tai Chi Chuan Exercise."
41505823|NCT04302038|DIETARY_SUPPLEMENT|Placebo control|No additional dietary protein (outside of 0.8 g/kg/day as provided by diet)
41505824|NCT02276807|BEHAVIORAL|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
41505825|NCT02276807|OTHER|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
41505826|NCT00426101|DRUG|Dexamethasone|"10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days"
41505827|NCT00426101|DRUG|Etoposide|"150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk"
40850324|NCT04866901|BEHAVIORAL|Slow-Paced Breathing (SPB)|see arm description
40850325|NCT04866901|BEHAVIORAL|Mindfulness (M)|see arm description
41376397|NCT02632448|DRUG|Gemcitabine|50 to 600 milligrams per square meter of body surface area (mg/m2)
41376398|NCT04649437|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.
41376399|NCT00031096|DRUG|Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
41376400|NCT00031096|DRUG|Vehicle gel (SH H 655 PBA)|Vehicle gel (SH H 655 PBA) applied topically two times per day.
41376401|NCT03359278|PROCEDURE|open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
41505828|NCT00426101|DRUG|Cyclosporin|"WK 1-8:~- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~- Aim for around 200 microgram/L. Monitor GFR."
41505829|NCT00426101|PROCEDURE|Intrathecal therapy|"If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: \<1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, \>3 yrs 12 mg. Prednisolone: \<1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, \>3 yrs 10 mg."
40850326|NCT04866901|BEHAVIORAL|Yogic Breathing (SPB+M)|see arm description
41376402|NCT03456986|BEHAVIORAL|PATH neurotraining|Tunes up the center of the motion discrimination (dorsal stream) working range
41376403|NCT03456986|BEHAVIORAL|Orientation Discrimination|Tunes up the ventral stream most sensitive to high contrast and colored patterns.
41376404|NCT05292313|PROCEDURE|Single distal femur implant|Single implant fixation
41376405|NCT05292313|PROCEDURE|Dual distal femur implants|Dual implant fixation
41376406|NCT04279002|OTHER|Brief 15-question questionnaire|Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
41505830|NCT00426101|PROCEDURE|Stem cell transplant|The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
41505831|NCT04600258|DIETARY_SUPPLEMENT|Dark Chocolate|The patients will receive 40g per day of dark chocolate for 2 months
40850327|NCT06537674|DRUG|Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection|Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection
40850328|NCT05492201|DRUG|LY3873862|Administered orally.
41376407|NCT04490772|DIAGNOSTIC_TEST|Laboratory tests|Laboratory tests such as CBC, Liver function and CRP
41505832|NCT02227446|DRUG|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
41505833|NCT03115216|PROCEDURE|FLA-CEIOL|Femtosecond laser-assisted cataract extraction and intraocular lens placement
41505834|NCT03115216|PROCEDURE|CEIOL|Manual cataract extraction and intraocular lens placement
41505835|NCT03387566|DRUG|HB002.1M|HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
41505836|NCT00438061|BEHAVIORAL|Weight loss by dietary restriction|
41505837|NCT05507736|OTHER|Acupuncture|13 Indwelling, sterile and disposable needles (SEIRIN NEW PYONEX® from 0.9 mm in length and 0.22 mm in diameter) on day 1 and 5 of the second cycle of irinotecan leaving them inserted for 4 days.
41505838|NCT03263897|DEVICE|insufflation|mobile interface driven insufflation of the ear canal
41505839|NCT03263897|DEVICE|placebo insufflation|mobile interface driven placebo insufflation of the ear canal
41505840|NCT00855907|OTHER|clinical evaluation|"Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.~Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography."
41505841|NCT03986411|OTHER|Phase 1: Qualitative interviews: Health care professionals|Semi-structured interviews of health care professionals to explore current management of urinary incontinence in the community
40850329|NCT05492201|DRUG|Placebo|Administered orally.
40850330|NCT03214042|DEVICE|K-rod dynamic stabilization system|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
40850331|NCT02673684|DEVICE|Experimental NSS|5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.
40850332|NCT02673684|DEVICE|Sham NSS|(5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
41505842|NCT03986411|OTHER|Phase 2: Physiotherapy for urinary incontinence|Tailored physiotherapy assessment and management for athletic women who self-report urinary incontinence
41505843|NCT03986411|OTHER|Phase 3: Qualitative Interviews: Participants|Semi-structured interviews of a purposeful selection of the participants from Phase 2 to explore reaction to the recruitment process and the intervention
41505844|NCT05019950|DRUG|NIM-1324|Once daily oral tablet
41505845|NCT05019950|DRUG|Placebo|Once daily oral tablet
41505846|NCT06430931|PROCEDURE|Minimal invasive abdominal prolapse surgery using Polypropylene mesh|All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).
41505847|NCT06430931|PROCEDURE|Minimal invasive abdominal prolapse surgery using OviTex 1S permanent mesh|All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).
41505848|NCT01279720|BIOLOGICAL|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
41505849|NCT00851435|BIOLOGICAL|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
41505850|NCT04951986|DRUG|Rifampin|Rifampicin up to 35 mg/kg/day for 14 days
41505851|NCT04951986|DRUG|Levofloxacin|Levofloxacin 750mg daily (for weight \<50kg) or 1 g daily (for weight \>50 kg) daily for 14 days
41505852|NCT04951986|DRUG|Rifampicin, Pyrazinamide, Ethambutol and Isoniazid|Rifampicin 10 mg/kg; Isoniazid 5 mg/kg; Pyrazinamide 15 mg/kg; Ethambutol15 mg/kg in fixed dose combination administered per weight band. Standard of care control arm
40850333|NCT04294836|DRUG|Curcumin|BCM-95® (CURCUGREEN®) is a 100 percent pure extract of turmeric with enhanced bio-availability and bio-efficacy. Its powerful health-promoting benefits are derived from the colorful and aromatic qualities of the Indian spice
40850334|NCT04294836|DRUG|Placebo oral tablet|PLACEBO Capsules 500mg
40850335|NCT00001644|DRUG|Indinavir|
40850336|NCT00001644|DRUG|Zidovudine|
40850337|NCT00001644|DRUG|Lamivudine|
40850338|NCT00001644|DRUG|Nevirapine|
41033503|NCT03749551|DIAGNOSTIC_TEST|cardiac magnetic resonance (CMR) post haemodialysis|patients will undergo a second CMR scan immediately after receiving haemodialysis (native CMR study)
41033504|NCT03515837|BIOLOGICAL|pembrolizumab|IV infusion
41033505|NCT03515837|DRUG|pemetrexed|IV infusion
41033506|NCT03515837|DRUG|carboplatin|IV infusion
41033507|NCT03515837|DRUG|cisplatin|IV infusion
40850339|NCT00001644|PROCEDURE|Blood testing|
40850340|NCT00001644|PROCEDURE|Lymph node biospy|
40850341|NCT00001644|PROCEDURE|Leukapheresis|
40850342|NCT04965532|DRUG|sevoflurane anesthesia|Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.
40850343|NCT04965532|DRUG|Propofol Injection|Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.
40850344|NCT03534622|DRUG|Delafloxacin|In this study, thirty subjects who meet the entry criteria will be assigned to 1 of 5 groups (A, B,C, D, or E) to receive 300 mg delafloxacin IV every 12 hours for a total of 7 doses over 4 days
40850345|NCT04930094|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg
40850346|NCT04930094|OTHER|Placebo|Placebo
40850347|NCT04930094|BIOLOGICAL|Secukinumab 150 mg|Secukinumab
40850348|NCT03991429|DIAGNOSTIC_TEST|Simultaneous functional MRI and urodynamic studies|"Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure."
40850349|NCT03991429|BEHAVIORAL|Questionnaires|Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
40850350|NCT03991429|OTHER|Post Void Residual (PVR), Uroflow and Bladder Diary|Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.
40850351|NCT03991429|DIAGNOSTIC_TEST|Urinalysis|Urine sample
40850352|NCT04115098|DRUG|Celecoxib|Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
40850353|NCT04115098|DRUG|Naproxen|Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
40850354|NCT04115098|DRUG|Meloxicam|Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
40850355|NCT00898833|OTHER|laboratory biomarker analysis|
41033508|NCT03515837|DRUG|saline solution|IV infusion
41033509|NCT06557265|DRUG|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK
41033510|NCT06557265|DRUG|Cyclophosphamide|Lymphodepletion
41033511|NCT05461872|OTHER|No intervention|No intervention
41033512|NCT04154124|DIAGNOSTIC_TEST|PET/MR scan|whole-body PET/CT scan and pelvic PET/MR scan (MR protocol will include three plane fast spin echo T2 weighted, DWI and dynamic contrast enhanced imaging). The ad interim assessment will use a pelvic PET/MR scan only (without PET/CT), to avoid the radiation associated with whole body CT. In the staging and post-nT assessment, the addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
41033513|NCT02352311|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg
41033514|NCT02352311|DRUG|AVODART|Dutasteride 0.5 mg
41033515|NCT02352311|DRUG|CIALIS|Tadalafil 5 mg
41164091|NCT02867111|PROCEDURE|ICSI|An in vitro fertilization procedure in which a single sperm is injected directly into an egg
40850356|NCT02853435|DRUG|Gepotidacin RC Tablet|The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
40850357|NCT02853435|DRUG|Gepotidacin HSWG Tablet|The tablet is an oval shape white film coated tablet with no identifying markings. This is an immediate release tablets containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
40850358|NCT02853435|DRUG|Gepotidacin Capsule|It is a pink gelatin size 00 capsule with no identifying markings containing slightly agglomerated pale yellow to grayish yellow to yellowish gray powder. This is an immediate release capsules containing gepotidacin 500 mg (mesylate salt) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing capsules.
40850359|NCT03482492|DRUG|Tramadol|Tramadol iv
41033516|NCT05131295|DRUG|Dapsone|Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect. It has an anti-inflammatory effect due to its inhibitory action on neutrophils. Neuroprotective effects have been found experimentally with the use of dapsone, predominantly through its glutamate receptors antagonistic effect; these are the main receptors involved in neuronal excitotoxicity.
41376408|NCT03949764|DRUG|Sofosbuvir/velpatasvir (Epclusa®)|The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
41505853|NCT04951986|DRUG|Prednisone|Prednisone 1.5mg/kg/day for 14 days
41033517|NCT05131295|DRUG|Aluminum Hydroxide Gel|Aluminum Hydroxide Gel is an antacid that works quickly to lower the acid in the stomach
41033518|NCT05978882|PROCEDURE|Laparoscopic sentinel navigation surgery using fluorescence|If the frozen biopsy of sentinel lymph nodes are all negative using fluorescence, stomach-preserving surgery is performed
41033519|NCT01361412|BIOLOGICAL|ToleroMune Ragweed|Intradermal administration 1x8 administrations, 2 weeks apart
41033520|NCT01361412|BIOLOGICAL|Placebo|Intradermal injection 1x8 administrations, 2 weeks apart
41033521|NCT04032899|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
41033522|NCT04032899|DIETARY_SUPPLEMENT|Maltodextrin|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
41033523|NCT05203419|DRUG|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
41033524|NCT05203419|DRUG|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
40850360|NCT03482492|DRUG|Paracetamol|Paracetamol iv
40850361|NCT01652131|OTHER|Tetrastarch (130/0.4)|
40850362|NCT03992443|DRUG|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
40850363|NCT00042991|DRUG|gefitinib|Given orally
40850364|NCT00042991|RADIATION|radiation therapy|Undergo standard brain irradiation
40850365|NCT00042991|OTHER|pharmacological study|Correlative studies
40850366|NCT00042991|OTHER|laboratory biomarker analysis|Correlative studies
41033525|NCT05631795|DRUG|Alpelisib|Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1
41033526|NCT05631795|DRUG|Fulvestrant|Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.
41376409|NCT05754359|BEHAVIORAL|I'm an Active Hero (IAAH) Intervention Program|"The I'm an Active Hero (IAAH) programme is a 10-week intervention aimed at increasing physical activity and decreasing sedentary behaviour in preschool-aged (aged 3-5 years) children. It is anticipated to begin in February 2023 to May 2023. Assessments will be conducted at baseline and immediately following the intervention. The IAAH-intervention will be implemented by the preschool teachers, who will have two teacher training sessions with the main researcher (myself). The IAAH-intervention involves environmental modifications (a classroom) to create areas with sufficient space for active play; classroom sessions these will be implemented for 10 weeks (a minimum of one hour per week); and parent involvement, such as the provision of parental-child interaction homework activities and written information (tip cards, posters, and newsletters). for parents on how to encourage their children to be active."
41376410|NCT06342661|DIAGNOSTIC_TEST|Neuropsychological testing|The primary outcomes were Mini-Mental State Examination and Montreal Cognitive Assessment scores for screening of cognitive decline, which are recommended by NINDS-AIREN. The secondary outcomes included the performance in five cognition domains: (1) verbal memory, Hopkins Verbal Learning Test ; (2) visual-spatial ability, Clock Drawing test; (3) executive function, Trail Making test (TMT) (B time); (4) attention, TMT (A time); and (5) language tests, Boston Naming test2 (BNT-2)
41505854|NCT04951986|DRUG|Placebo|Placebo identical to Prednisone
41505855|NCT04358952|DIAGNOSTIC_TEST|Global Longitudinal Strain|Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction
41033527|NCT06525623|OTHER|Recommendation: No Further Resuscitation|Treatment teams are encouraged not to administer any additional fluids
41033528|NCT06525623|OTHER|Recommendation: Resuscitation with Crystalloid|Treatment teams are encouraged to administer crystalloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
41033529|NCT06525623|OTHER|Recommendation: Resuscitation with Colloid|Treatment teams are encouraged to administer colloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
41033530|NCT06525623|OTHER|Recommendation: Standard of Care IV Albumin|Treatment teams are encouraged to administer 1 g/kg/d IV albumin (maximum 100 g/day) over 2 days
41033531|NCT00827034|DRUG|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
41164092|NCT02554552|DRUG|YY1201 2ml|YY1201 2ml
41164093|NCT02554552|DRUG|Placebo 2ml|phosphate buffered saline 2ml
41505856|NCT00003627|DRUG|cisplatin|
41505857|NCT00003627|DRUG|fluorouracil|
41505858|NCT00003627|RADIATION|radiation therapy|
41505859|NCT01697553|OTHER|home automation pack coupled to teleassistance service|
41505860|NCT01697553|OTHER|Home without automation pack coupled to teleassistance service|
41505861|NCT04167592|DRUG|Benzydamine Hydrochloride 0.15% Oral Rinse|Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
41505862|NCT04167592|DRUG|Water|Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
41505863|NCT02397876|OTHER|Partially Hydrolyzed Whey formula|Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
41505864|NCT06310304|DRUG|Ruxolitinib IR|Tablet
41505865|NCT06310304|DRUG|Ruxolitinib XR|Tablet
40850367|NCT02338700|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
40850368|NCT02338700|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
40850369|NCT06216548|OTHER|Usual Care and Enhanced Primary Care|"Usual Care: Interdisciplinary complex care teams help coordinate appointments, facilitate communication between the many specialist providers involved in the child's care, support families, assist with practical needs, and are available as a resource (as consultants) for Primary Care Physicians (PCPs) to care for Children with Medical Complexity (CMC). The complex care teams in tertiary care children's hospital is the focus for providing comprehensive care for CMC.~Enhanced Primary Care: The E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. A team of telehealth experts will help PCPs in using telehealth in their practice."
40850370|NCT06216548|OTHER|Enhanced Primary Care|The intervention has the following components: (A) The staff of the E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. (B) The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. (C) A team of telehealth experts will help PCPs in using telehealth in their practice.
40850371|NCT05131191|DIAGNOSTIC_TEST|CT-FFR measurement|Patients were scanned with ≥ 64 row CT according to standard operating specifications. The software obtains the coronary CT angiography image file through the data communication interface. Based on the image processing algorithm, the centerline and contour of the target vessel can be extracted, and then the target vessel can be reconstructed to obtain the three-dimensional size information of the vessel; Based on hydrodynamics calculation and analysis, the fractional flow reserve (FFR) of each position of the target vessel is measured.
40850372|NCT05131191|PROCEDURE|invasive FFR|Insert the pressure guide wire into the finger guide tube and push the pressure guide wire until the pressure sensor just comes out of the orifice of guiding catheter; Equalize PD and PA values;Push the pressure guide wire to the distal end of the lesion, and record the measured blood vessel and position;Record the resting Pd / PA of the pressure guide wire;Nitroglycerin and adenosine triphosphate were administered intravenously according to standard catheter laboratory specifications to achieve maximum hyperemia;Record the FFR value of the in-stent lesions.
40850373|NCT03027349|OTHER|No intervention are provided|
40850374|NCT03141632|DRUG|Dulaglutide|Evaluation visit with assessment of fluid intake
40850375|NCT03141632|OTHER|Placebo|Evaluation visit with assessment of fluid intake
40850376|NCT01603485|DRUG|Lersivirine Immediate-Release (fasted)|Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
40850377|NCT01603485|DRUG|Lersivirine Modified-Release #1 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #1
40850378|NCT01603485|DRUG|Lersivirine Modified-Release #2 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #2
40850379|NCT01603485|DRUG|Lersivirine Modified-Release #3 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #3
40850380|NCT01603485|DRUG|Lersivirine Modified-Release (fed)|Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
40850381|NCT01210586|BEHAVIORAL|Part 2|Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
40850382|NCT01000324|PROCEDURE|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
40850383|NCT01000324|BIOLOGICAL|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
40850384|NCT01000324|BIOLOGICAL|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
40850385|NCT02110264|DRUG|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
40850386|NCT02110264|BEHAVIORAL|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
40850387|NCT02110264|BEHAVIORAL|ETAU|Participants assigned to the ETAU group will receive drug education.
40850388|NCT05595733|DEVICE|Ventilator mode|Neurally Adjusted Ventilatory Assist (NAVA) mode is a new mode of ventilator, using electronic potential of diaphragm to adjust tidal volume. At the same time, this mode can trigger and cycle-off inspiratory time by high sensitivity of electronic potential of diaphragm, increase patient-ventilator synchrony, reduce sedative drug, improve oxygenation, shorten mechanical ventilation day and reduce the rate of diaphragm atrophy. It can improve survival rate and hospital day of patients. Both the animal and human experiment have the effect of lung and diaphragm protection.
40850389|NCT06023043|DRUG|Dexamethasone|Three (3) post operative intravenous dexamethasone injections at 8-hour intervals post-operatively. Dosing will be determined as 0.15 mg/kg per dose (WS)
40850390|NCT04520256|BEHAVIORAL|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
41376411|NCT00103376|DRUG|Velcade|"Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break"
41376412|NCT00103376|DRUG|LH-RH Agonist|given as a 3 month depo-injection
41376413|NCT00103376|DRUG|Androgen Receptor Antagonists|given orally daily for 3 months
41376414|NCT02808559|DEVICE|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
41376415|NCT02204709|OTHER|2N Trout|Diploid/2N trout source
41505866|NCT01263938|DRUG|Atorvastatin|"For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day."
41033532|NCT00827034|DRUG|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
40850391|NCT04520256|BEHAVIORAL|Virtual Reality for Behavioral Weight Loss Skills Training|This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
41033533|NCT00827034|DRUG|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
41505867|NCT03903211|DRUG|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
41505868|NCT04063150|BIOLOGICAL|fIPV (0.1 mL) ID|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.
40850392|NCT04520256|BEHAVIORAL|Tailored Interactive Video Feedback|Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
41033534|NCT05956340|BEHAVIORAL|Research interview|Research interview to capture speech data with high quality cardioid headset microphone
41505869|NCT04063150|BIOLOGICAL|fIPV (0.1mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
40850393|NCT04520256|BEHAVIORAL|Tailored Intervention for Structured Physical Activity|Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
41033535|NCT02001727|OTHER|13C-Urea breath test for Helicobacter Pylori|
41033536|NCT02001727|OTHER|Questionaire|
41164094|NCT02554552|DRUG|YY1201 3ml|YY1201 2ml
41164095|NCT02554552|DRUG|Placebo 3ml|phosphate buffered saline 3ml
41376416|NCT02204709|OTHER|3N Trout|Triploid/3N trout source
41376417|NCT02204709|OTHER|Tilapia|Tilapia/control fish source
41376418|NCT02002429|PROCEDURE|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
41376419|NCT02002429|PROCEDURE|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
41376420|NCT02002429|PROCEDURE|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
41376421|NCT05044910|DIETARY_SUPPLEMENT|Ready to Use supplementary food (RUSF)|Children with malnutrition will be given RUSF
41376422|NCT00183170|DRUG|Alcohol|Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.
41376423|NCT00183170|OTHER|Placebo|Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.
41376424|NCT06519422|DRUG|Tranexamic Acid 500 MG|Tablets
41376425|NCT06519422|OTHER|Matched placebo|Matched placebo tablets (inactive ingredients only, including microcrystalline cellulose, magnesium stearate BP and lactose)
41376426|NCT01905176|OTHER|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
41376427|NCT01905176|OTHER|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
41376428|NCT01905176|OTHER|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 \& 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 \& 2
41376429|NCT03409328|BEHAVIORAL|HIV and substance use prevention|The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
41376430|NCT04003103|DRUG|Islatravir|Islatravir 30 mg capsules taken by mouth.
41376431|NCT04003103|DRUG|Placebo|Placebo capsules taken by mouth.
41376432|NCT02320734|DRUG|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
41376433|NCT04527159|DRUG|Fluoraphat Pro / VivaSens|desensitizing agents for treatment of dentinal hypersensitivity
41505870|NCT04063150|BIOLOGICAL|fIPV (0.2mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.2 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
41376434|NCT06121986|BEHAVIORAL|Modified Mediterranean Ketogenic Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet in addition to titrating into a ketogenic macronutrient ratio across the first 5 weeks, starting at 50% fats/25% protein/25% net carbohydrates up to 70% fats/25% protein/5% net carbohydrates).
40850394|NCT04520256|BEHAVIORAL|Skills Training for Dysregulated Eating|Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
41376435|NCT06121986|BEHAVIORAL|Mediterranean Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet.
41376436|NCT02880709|DIETARY_SUPPLEMENT|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
41376437|NCT03325569|DIAGNOSTIC_TEST|oral glucose tolerance test|GLP1 response to oral glucose load during oral glucose tolerance test was assessed.
41376438|NCT05198414|OTHER|Focus group|Qualitative research methodology with healthcare workers
41376439|NCT02681991|DRUG|Renamezin capsule|
41376440|NCT04548336|BEHAVIORAL|Motor Imagery|Motor imagery group will have to imagine motor gestures of static and dynamic balance
41376441|NCT04548336|BEHAVIORAL|Action observation|Action observation group will have to observe static and dynamic equilibrium motor gestures
41376442|NCT04548336|BEHAVIORAL|Placebo group|This group will watch a video of nature without a human component.
41376443|NCT03250611|PROCEDURE|Occipital Condyle Screw|Occipito-Cervical Screw-Rod Fixation Technique
41376444|NCT04598815|DRUG|Sirolimus|"Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks.~Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g."
41376445|NCT06442774|OTHER|Mobile application|"The intervention that has been developed is a digital tool of a biopsychosocial nature based on the main cognitive-behavioral strategies: psychoeducation, reflection, self-observation, guided visualizations, mindfulness and progressive muscle relaxation.~The intervention consists of 3 main areas of work:~* Programs: Biopsychosocial programs in text and audio format.~* Community: Forum with directed questions and space to share experiences between mothers.~* Diary: Space to record mood and emotional record.~The entire tool works transversally in 4 dimensions: self-care, relationship with perinatal changes, relationship with the baby, social relationship.~The tool itself includes 3 mental health and well-being screening questionnaires: Whooley Questionnaire and the Edinburgh Postnatal Depression Scale (EPDS)."
41376446|NCT06442774|OTHER|Monitoring via wearable|Participants that own a wearable will connect it to monitor variables related to sleeping patterns, activity and stress (see variables section).
41376447|NCT01398540|BIOLOGICAL|IXIARO|2 immunizations (0,5ml) with a 28 day interval
41376448|NCT03984994|OTHER|Aerobic exercise training|3 months of center-based, supervised treadmill exercise
41376449|NCT03984994|OTHER|Strength training|3 months of center-based, supervise strength training
41376450|NCT04517630|DIAGNOSTIC_TEST|urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic|Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment
41376451|NCT04238494|DIAGNOSTIC_TEST|Nuclear magnetic resonance (NMR)|Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
41505871|NCT04063150|BIOLOGICAL|IPV|Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.
41505872|NCT02695537|DRUG|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
41505873|NCT02583490|DEVICE|spectrum 5000Q ECT device (RUL ECT)|
41505874|NCT02583490|DEVICE|spectrum 5000Q ECT device (RUL LAP ECT)|
41505875|NCT01919788|DRUG|Insulin (Insuman Rapid)|
41505876|NCT01919788|DRUG|Glucose|
41505877|NCT01919788|OTHER|Saline|
41505878|NCT06548945|DRUG|GZR18|5 mg-maximum tolerated dose (MTD), single dose
41505879|NCT06548945|OTHER|Placebo|administered the same volume as GZR18
41505880|NCT01711892|BEHAVIORAL|Soccer training|
41505881|NCT04309617|PROCEDURE|nephrectomy|Surgery performed within the study period
41505882|NCT05284266|PROCEDURE|Liposuction early|Liposuction 6-9 months after inclusion
41505883|NCT05284266|PROCEDURE|Liposuction late|Liposuction 18-21 months after inclusion
41505884|NCT05284266|OTHER|Standard conservative treatment|"Standard Conservative treatment consisiting of:~Physical therapy, including compression garment and exercise program, Self-care program"
41505885|NCT05284266|OTHER|Standard conservative treatment with Intermittent Pneumatic Compression (IPC)|Physical therapy, including compression garment and exercise program, Self-care program and Intermittent Pneumatic Compression (IPC)
41505886|NCT01740245|DEVICE|Chlorhexidine vaginal suppositories|
40850395|NCT04520256|BEHAVIORAL|Platform for Social Support & Friendly Competition|An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
41505887|NCT01740245|DEVICE|Polyhexamethylene biguanide vaginal suppositories|
41505888|NCT04109729|DRUG|Nivolumab|"Nivolumab 480mg IV every 4 weeks for up to 2 years~• Radium-223 55 kBq/kg IV q4 weeks for 6 cycles total"
41505889|NCT05144490|OTHER|Exercise|A single session of bodyweight exercise
41505890|NCT04228497|DEVICE|gastric ultrasound|Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.
41505891|NCT04228497|OTHER|the clear fluid intake|the clear fluid intake
41505892|NCT06550427|DIAGNOSTIC_TEST|ctDNA analyzed by phased variant|this observational cohort study is to investigate the correlation between ctDNA analyzed by phased variant and the early outcome of the disease.
41505893|NCT01125371|BEHAVIORAL|Computerized brief alcohol intervention + IVR booster calls|1) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
41505894|NCT01125371|BEHAVIORAL|Computerized brief alcohol intervention|Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
40850396|NCT04725500|DEVICE|Auto-Titrating EPAP|In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
40850397|NCT03865784|OTHER|Experimental|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done, proceed to ask the subject to lean forward applying the rest of the strip, except the distal edge, with a tension of between 15 and 25%, finally requesting the subject to rejoin straining the distal base without tension, on the twelfth dorsal spinous process.
40850398|NCT03865784|OTHER|Control|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. The objective of the application of the technique based on this type of exercise is to improve muscle strength, endurance and neuromuscular control. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done the tape will be placed without tension and sn movement of the subject.
40850399|NCT05113030|OTHER|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED|Test group(1st) enrollment criteria in PCOS group will be females of adolescent age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
40850400|NCT05113030|OTHER|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED|Test group(2 nd) enrollment criteria in PCOS group will be females of adult age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
40850401|NCT02331667|OTHER|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
40850402|NCT02331667|OTHER|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
41376452|NCT06538194|PROCEDURE|Mesotherapy|For 1. group, a solution containing 1 cc each of lidocaine, pentoxifylline, vitamin B complex diluted 1/10 with saline, thiocolchicoside, and meloxicam diluted 1/5 with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection. This injection will be applied once a week for a total of 4 sessions. Group 2 received dextrose prolotherapy: A 22 gauge syringe was used to apply a total of 5 cc of 15% dextrose solution (a combination of 3.75 ml 20% dextrose and 1.25 mg 2% lidocaine) to at least 5 most sensitive points of the lateral epicondyle. It was injected 3 times with 3 weeks intervals.
41376453|NCT04828551|DEVICE|Ultrasound based shear wave speed and fat quantification methods|Ultrasound based imaging parameters will be collected from all patients in two visits. These will include but may not be limited to SWE results, Quantitative ultrasound parameters,where available,including Attenuation Coefficient, Backscatter Coefficient, Shear Wave Dispersion, Speed of Sound, Ultrasound derived fat fraction Conventional Bmode (gray-scale) and Doppler ultrasound images,including An image of the liver and right kidney on the same image for hepatorenal index calculation Right liver lobe for skin to liver capsule distance calculation Portal vein Doppler for portal vein pulsatility index measurement VCTE and Controlled Attenuation Parameter measurements with the Fibroscan system
41376454|NCT04828551|DIAGNOSTIC_TEST|Blood collection|"Blood will be collected by trained phlebotomists at each site using routine methods and standard collection tubes.~Total volume is expected to be about 10 mL or less Blood collected at MGH will be analyzed by the MGH clinical laboratory. Blood collected at UCSD will be analyzed by the UCSD clinical laboratory. Blood results obtained within the 3-month interval prior to the screening visit at the MGH or UCSD laboratories will be considered acceptable for study analyses and may be used at PI discretion. For each laboratory, the normal ranges for each blood test will be recorded and filed"
41376455|NCT04828551|OTHER|Physical measurements|Height will be recorded at Screening. Weight and vital signs will be recorded at each visit. Body mass index will be calculated at each visit. All measurements will be made by trained coordinators using standard and calibrated instruments.
41505895|NCT01125371|BEHAVIORAL|Attention Control|Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
41505896|NCT06044012|PROCEDURE|Double layer of buccal myomucosal Flap and buccal pad of fat|The buccal myomucosal flap will be harvested from cheek below stenson papilla and will be sutured over buccal pad of fat which will be sutured at palatal mucosa after complete curettage of infected fistulous tract.
41505897|NCT02594865|DIETARY_SUPPLEMENT|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
41505898|NCT02594865|DIETARY_SUPPLEMENT|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
40850403|NCT05080530|DRUG|Cholecalciferol|Effect of Vitamin D on diabetic neuropathy symptoms
40850404|NCT05138315|DEVICE|Metamorphopsia quantification|Alleye App and M.chart examinations will be performed pre- and postsurgically.
41376456|NCT04828551|OTHER|Clinical history and medication reviews|"The following questionnaires will be administered at Screening:~Medical history questionnaire Medication use questionnaire Alcohol consumption questionnaire Physical activity questionnaire~The following questionnaires will be administered at Visit 1 and Visit 2:~Interim medical history questionnaire Change in medication use questionnaire Change in alcohol consumption will be recorded using a modified version of the alcohol use followback. Alcohol use for the 7 day period prior to Visit 1 and for all days between Visit 1 and Visit 2 will be recorded. Change in physical activity questionnaire"
41376457|NCT03839693|BIOLOGICAL|botulinum toxin, Type A|topical liniment
41033537|NCT04233099|PROCEDURE|Raman analysis of saliva with data collection and analysis|Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.
41376458|NCT03839693|BIOLOGICAL|Vehicle|Vehicle Formulation
41376459|NCT06294327|DEVICE|Reactive static air support surfaces|"* Repose® Mattress~* Repose® Cushion~* Repose® Wedge~* Repose® Foot Protectors"
41376460|NCT03962114|DIETARY_SUPPLEMENT|Vitamin B3|capsules with niagen
41376461|NCT05458791|DEVICE|Intra-arterial Perfusion|All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.
41376462|NCT05647395|BEHAVIORAL|Tracheal tube cuffs differ in deflation|When removing the endotracheal tube, the gas in the cuff is drawn at a uniform and slow pace
41376463|NCT03113201|BEHAVIORAL|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation and medication according to a stepped care model
41376464|NCT03113201|BEHAVIORAL|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
41376465|NCT03722459|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
41376466|NCT04887922|DEVICE|MIR Spirobank G|FDA-approved, Bluetooth digital spirometer
41376467|NCT04887922|DEVICE|ZEPHYRx®|ZEPHYRx® has developed a 1) digital Bluetooth-enabled IS that allows for the continuous and objective remote monitoring of patient compliance with pre- and postoperative IS via a smartphone app and online provider dashboard.
41376468|NCT04887922|DEVICE|Conventional spirometer|Will be provided to participants
41033538|NCT04026100|BIOLOGICAL|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10\^6), medium dose (2×10\^6), and high dose (3×10\^6).
41033539|NCT02504632|OTHER|test|"Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.~The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.~Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates."
41033540|NCT02504632|OTHER|control group|In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
41033541|NCT01597687|PROCEDURE|Blood collection|1 blood sample will be collected from each subject.
41033542|NCT01597687|OTHER|Data collection|Quality of Life and HE questionnaires.
41376469|NCT06397001|DRUG|nL-SAA1-01|Personalized antisense oligonucleotide
41376470|NCT00369798|PROCEDURE|PET scan|
41376471|NCT00369798|DRUG|Rolipram|
41376472|NCT03542929|DEVICE|whole body vibration|whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
41376473|NCT01534390|DEVICE|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
41376474|NCT06102070|OTHER|Blood samples drawing|10 ml of periferal blood
41376475|NCT06102070|OTHER|Skin biopsy|Skin biopsy only in some index cases depending of the pathology at the recruitment
41376476|NCT00726440|DEVICE|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
41376477|NCT00726440|DEVICE|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
41376478|NCT00726440|DEVICE|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
41376479|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 20 mg capsule
41376480|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 40 mg capsule.
41376481|NCT01369836|DRUG|Placebo|A single oral dose of matched placebo.
41376482|NCT05674747|DEVICE|Swift Microwave treatment - weekly x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
41033543|NCT06293235|OTHER|Lifestyle and metabolic indicators|Socio-demographics, health history, behavioural characteristics, environmental exposures, anthropometric measurements, body fat composition, metabolic and stress biomarkers, semen physical and molecular characteristics.
40850405|NCT00477646|BEHAVIORAL|Prevention Care Management|Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
40850406|NCT02980133|DRUG|Fluticasone Propionate|Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.
40850407|NCT02980133|DRUG|Fluticasone Propionate/Salmeterol|Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.
40850408|NCT02980133|DRUG|Placebo MDPI|Matching placebo was administered via MDPI per the schedule specified in the arm.
40850409|NCT00391924|DRUG|Dehydroepiandrosterone|
40850410|NCT03640221|DRUG|Ertugliflozin|The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. this arm will allow us to test our hypothesis.
41376483|NCT05674747|DEVICE|Swift Microwave treatment - Every other week x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
41376484|NCT05674747|DEVICE|Swift Microwave treatment - Every other week x 24wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
40850411|NCT03640221|DRUG|Hydrochlorothiazide 12.5mg|comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
40850412|NCT03640221|DEVICE|Microneurography|"Multiunit recordings of postganglionic sympathetic nerve activity will be obtained with unipolar tungsten microelectrodes inserted selectively into skeletal muscle nerve fascicles of the peroneal nerve. The nerve signals are amplified, filtered (bandwidth 700-2000 Hz), rectified and integrated to obtain a mean voltage display of sympathetic nerve activity. Sympathetic bursts are counted by inspection of the neurograms. A deflection on the mean voltage display is counted as a burst if it has a minimal signal to noise ratio of 2:1. The interobserver and intraobserver variations in identifying bursts are \<10% and \< 5%, respectively."
40850413|NCT03640221|OTHER|SKNA recordings|SKNA recordings will be captured by placing ECG electrodes on the chest wall. Recordings will be obtained simultaneously with microneurographic recording. The two techniques will undergo identical filtering and processing of the neurophysiologic inputs which are then displayed simultaneously using identical output functions.
41505899|NCT04602546|DEVICE|BIS Complete Monitoring System|The BIS™ EEG complete monitoring system is intended for use under the direct supervision of a licensed healthcare practitioner or by personnel trained in its proper use. The system and its associated parameters are intended for use on adult patients within a hospital or medical facility, providing patient care to monitor the state of the brain by data acquisition of EEG signals.
41505900|NCT00216138|DRUG|Docetaxel|Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
40850414|NCT03640221|OTHER|Static Handgrip|Subjects will perform static handgrip at 33% MVC for 2 minutes, using a Stoelting recording handgrip dynamometer. Force output will be recorded continuously and displayed on the computer screen in real time to provide the subject with visual feedback. MVC will be determined for each subject at the beginning of each experiment. Subjects will be instructed to avoid straining maneuvers, changes in breathing, and contraction of non-exercising muscles during the experimental protocols. Ratings of perceived exertion (RPE) will be obtained at the end of each exercise by using a 6- to 20-unit Borg scale. Static handgrip at 33% MVC is accompanied by reflex increases in muscle sympathetic nerve activity caused by activation of the acid-sensing unmyelinated muscle afferents.
41033544|NCT04254900|OTHER|evaluating energy availability|energy availability will be determined by measuring energy intake, exercise energy expenditure and fat-free mass and using the following formula: energy availability = (energy intake - exercise energy expenditure) / fat-free mass
41033545|NCT05952141|BEHAVIORAL|Clinic Outreach|A member of the pathology team will contact the referring clinic to communicate the readiness of results.
41033546|NCT05952141|BEHAVIORAL|Enhanced Outreach|A member of the pathology team will contact both the referring clinic and the patient directly to communicate the readiness of results.
41505901|NCT00216138|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
41505902|NCT00216138|DRUG|Premedication|Dexamethasone and antiemetic premedication
41505903|NCT06418516|DEVICE|Capsule-sponge|The capsule-sponge is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus.
41033547|NCT05952141|BEHAVIORAL|Low-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging.
41033548|NCT05952141|BEHAVIORAL|High-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging in combination with synchronous telephone-based patient navigation.
41033549|NCT01093794|DRUG|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
41505904|NCT01680107|DRUG|d-cycloserine|
41505905|NCT01680107|DRUG|placebo|
41033550|NCT01093794|DRUG|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
40850415|NCT03640221|OTHER|Post-handgrip forearm vascular occlusion|This will be performed by inflating a pneumatic cuff on the upper exercising arm to suprasystolic pressure (220 mmHg) beginning 10 seconds before the subject stops gripping and ending 2 minutes into the post-exercise period. The vascular occlusion maintains intramuscular acidosis and thus the stimulation of acid-sensing unmyelinated skeletal muscle afferents and their reflex increase in muscle sympathetic nerve activity and BP, while the muscular relaxation eliminates central command and the attendant increase in heart rate (which returns to the baseline level). As soon as the cuff is release and the forearm circulation is restored, muscle sympathetic nerve activity quickly returns to the baseline level and BP soon follows.
40850416|NCT03640221|OTHER|Testing of the Arterial Baroreflex Function|We will compare effects of Ertugliflozin vs. low-dose HCTZ on sinoaortic baroreflex function in hypertensive diabetic subjects during both spontaneous fluctuations in arterial pressure and during decreases and increases in arterial pressure induced by the Valsalva maneuver. The aim of this protocol is to determine if the sympathetic nerve, as well as the heart rate, component of the sinoaortic baroreflex can be augmented by the SGLT2 inhibitor. After obtaining stable baseline recordings, arterial pressure, heart rate, and muscle sympathetic nerve activity will recorded during spontaneous fluctuations in BP over 5 minutes and during both decreases in BP during phase III of the Valsavla maneuver and during the phase IV overshoot in BP upon its release. Frequent accurate measurement of arterial pressure will be obtained with a highly-rated oscillometric arm monitor that records 6 BP readings per minute (Welch Allyn Vital Signs Monitor).
40850417|NCT06583395|BEHAVIORAL|Advanced multi-component meditation practice|The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
40850418|NCT03759691|BEHAVIORAL|Structured interview|Interview contains questions about stroke knowledge and help-seeking behaviour on the day the stroke occured.
40850419|NCT01157026|DIETARY_SUPPLEMENT|Tocotrienol Rich Fraction (TRF)|Tocotrienol Rich Fraction (200mg), daily for five years
40850420|NCT01157026|OTHER|placebo plus tamoxifen|20mg tamoxifen daily
40850421|NCT05275036|DEVICE|early detection test|Blood collection and early detection testing
40850422|NCT05700227|RADIATION|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
40850423|NCT04180904|OTHER|Diet 1|Diet 1 will focus on which foods are eaten and the impact on disease outcomes.
40850424|NCT04180904|OTHER|Diet 2|This diet will limit the amount of food energy consumed each day and the impact on disease outcomes. This will be determined by factors including the subject's demographics (age, sex, weight, height).
40850425|NCT01903629|DEVICE|MCE|MCE first, followed by standard gastroscopy
41164096|NCT04993807|OTHER|Shared decision-making tool|Participants will use an interactive web page intended to aid patient decision-making (i.e., a decision aid) while undergoing consultation for atrial fibrillation ablation.
41164097|NCT04260399|OTHER|Lavender Aromatherapy|Participants in the experimental group will be passively exposed to lavender essential oil
41164098|NCT04260399|OTHER|Placebo Aromatherapy|Participants in the control group will be passively exposed to saline water aromatherapy
41164099|NCT02261298|DRUG|ONO-4538|
41164100|NCT00086021|PROCEDURE|Acupuncture|
41376485|NCT02425358|OTHER|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
41376486|NCT02425358|OTHER|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
41376487|NCT02425358|OTHER|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
41376488|NCT02425358|OTHER|PCI only|The saline was intracoronary infusion with the use of microtubular.
41505906|NCT01680107|BEHAVIORAL|cognitive-behaviour therapy|
41505907|NCT00735397|DRUG|perampanel|Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
40850426|NCT01903629|DEVICE|Standard gastroscopy|
40850427|NCT04090619|OTHER|Questionnaire Administration|Complete questionnaires
40850428|NCT02000297|PROCEDURE|Allogenic bone graft|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
40850429|NCT02000297|PROCEDURE|Synthetic bone substitute (geneX®)|Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
40850430|NCT01618825|DRUG|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
40850431|NCT01618825|DRUG|Lamotrigine|2 x 25 mg tablet once a day
40850432|NCT04239690|OTHER|Micromethods for blood sample analysis|Micromethods in the intervention arm are applied aiming to achieve a mean reduction of 50 % of sampled blood volume during the first two postnatal weeks as compared to standard clinical blood sampling analyses
40850433|NCT00988364|DRUG|Simvastatin|Simvastatin 20mg daily for 3 months.
40850434|NCT00988364|DRUG|Vytorin|Vytorin 20/10mg daily for 3 months.
40850435|NCT00988364|DRUG|Placebo|Placebo one tablet daily times 3 months.
40850436|NCT00988364|DRUG|Ezetimibe|Ezetimibe 10mg daily for 3 months.
40850437|NCT01240135|DEVICE|FID 114675A multi-purpose disinfecting solution (MPDS)|Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.
40850438|NCT01240135|DEVICE|renu fresh Multi-Purpose Solution (MPS)|Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.
40850439|NCT01240135|DEVICE|Galyfilcon A contact lenses (Acuvue Advance)|A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
40850440|NCT03309930|BEHAVIORAL|Comprehension Acquired Brain Injury|For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
40850441|NCT06380075|DEVICE|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
40850442|NCT06380075|DEVICE|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
40850443|NCT06380075|DEVICE|Clarus imaging|Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
40850444|NCT02815644|DRUG|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
40850445|NCT03471741|RADIATION|IMRT with concomitant boost|
40850446|NCT03471741|RADIATION|3D-RT with sequential boost|
41376489|NCT03487146|DEVICE|hemoperfusion(HP)|These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
41376490|NCT03654495|OTHER|Exergame training|"Training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.~FITT training principles are implemented; Frequency: three times per week, Intensity: individually adapted VG (allowing training progression), Type: combination of cognitive and motor training, and Time: 20 min training sessions. Training lasts 6 weeks (18 training sessions). Participants train 20 min, three times per week. Training includes one session of each VG (4 min) in a pre-defined order and short breaks (\~1 min) for game change."
41505908|NCT03283267|DRUG|Sodium Zirconium Cyclosilicate (ZS)|Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
40850447|NCT05216341|DRUG|OLP-1002|"Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection."
40850448|NCT04707300|DRUG|Human T Lymphoid Progenitor (HTLP) injection|The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
40850449|NCT03577678|PROCEDURE|Surgery to fix lateral half prosthesis for clavicle|Surgery to fix lateral half prosthesis for clavicle
40850450|NCT04705506|DRUG|Gemigliptin|We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
40850451|NCT01304537|DRUG|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
40850452|NCT01304537|DRUG|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
40850453|NCT01304537|DRUG|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
40850454|NCT05998577|DEVICE|ESM and Traqq|Two telephone applications: ESM is a psychosocial diary and Traqq is a food diary to measure abdominal pain as well as possible triggerfactors (i.e. diet, stress, anxiety)
40850455|NCT03319212|DEVICE|senofilcon A contact lenses|Senofilcon A Daily Disposable Contact Lenses
40850456|NCT00171847|DRUG|Letrozole|
40850457|NCT00171847|DRUG|Trastuzumab plus Letrozole|
40850458|NCT00171847|DRUG|Letrozole|
40850459|NCT01806909|BIOLOGICAL|Ad4-H5-Vtn|
40850460|NCT06348667|OTHER|Specific ankle stability exercises|Exercise program specifically designed to address ankle dorsiflexion and mediolateral displacement of the center of pressure, using the described device (BB). Done twice a week for 5 weeks.
40850461|NCT06348667|OTHER|Conventional physiotherapy exercises program|Conventional exercise program performed in the center twice a week, of which all participants are part.
41376491|NCT03654495|OTHER|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.
41376492|NCT03140813|DRUG|AZD7325 (High-Dose)|15mg PO BID
41376493|NCT03140813|DRUG|AZD7325 (Low-Dose)|5mg PO BID
41376494|NCT03140813|DRUG|Placebo oral capsule|Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
41376495|NCT06173882|BEHAVIORAL|Ordinary moxibustion volume group|Moxibustion for 10 minutes per acupoint
41376496|NCT06173882|BEHAVIORAL|First group of heavy moxibustion|Moxibustion for 20 minutes per acupoint
41376497|NCT06173882|BEHAVIORAL|Second groups of heavy moxibustion|Moxibustion for 30 minutes per acupoint
41376498|NCT05884866|DRUG|Dapagliflozin 10mg Tab|see arms
41376499|NCT05884866|DRUG|Balcinrenone 50mg Capsule|see arms
41376500|NCT05884866|DRUG|Balcinrenone 100mg Capsule|see arms
41376501|NCT05884866|DRUG|Dapagliflozin matching Placebo|see arms
41505909|NCT03254498|DEVICE|Endocuff|It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination
40850462|NCT05056506|PROCEDURE|EPLBD|Endoscopic papillary large balloon dilation for Choledocholithiasis
40850463|NCT05056506|PROCEDURE|ELPBD+ESD|Endoscopic papillary balloon dilation combined with limited endoscopic sphincterotomy for Choledocholithiasis
40850464|NCT03170193|DRUG|AMG 529|Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection
40850465|NCT03170193|DRUG|Placebo|Single doses of matching placebo by SC or IV injection
40850466|NCT02921711|DEVICE|LVIS®|Low-profile Visualized Intraluminal Support device
40850467|NCT02277912|DEVICE|navigated rTMS of motor cortex|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
40850468|NCT02277912|DEVICE|navigated rTMS of somatosensory cortex 2|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
40850469|NCT02277912|DEVICE|SHAM rTMS with SHAM block|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
40850470|NCT04091243|DRUG|Romosozumab|Experimental drug for the treatment of glucocorticoid induced osteoporosis
41376502|NCT05884866|DRUG|Balcinrenone 50mg matching Placebo|see arms
41376503|NCT05884866|DRUG|Balcinrenone 100mg matching Placebo|see arms
41376504|NCT04607772|DRUG|Selinexor|Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
41376505|NCT04607772|DRUG|Rituximab|Dose: 375 mg/m\^2
41376506|NCT04607772|DRUG|Bendamustine|Dose: 90 mg/m\^2
41376507|NCT04607772|DRUG|Polatuzumab Vedotin|Dose: 1.8 mg/kg
41376508|NCT04607772|DRUG|Ibrutinib|Dose: 420, 560 mg
41376509|NCT04607772|DRUG|Lenalidomide|Dose: 20, 25 mg
41376510|NCT04607772|DRUG|Tafasitamab|Dose: 12 mg/kg
41376511|NCT04607772|DRUG|Venetoclax|Dose: 200, 400, 600, 800 mg
41376512|NCT04607772|DRUG|Gemcitabine|Dose: 1000 mg/m\^2
41376513|NCT04607772|DRUG|Oxaliplatin|Dose: 100 mg/m\^2
41505910|NCT03254498|DEVICE|cap assisted colonoscopy (CAC)|cap assisted colonoscopy (CAC)
41505911|NCT00040131|DRUG|IL-10|
41505912|NCT04010474|PROCEDURE|Modified Surgical APGAR Score|"Four intraoperative factors~1. Lowest heart rate (HR),~2. Lowest mean arterial pressure (MAP)~3. Estimated blood loss~4. Operation time"
41505913|NCT02132858|OTHER|cytology specimen collection procedure|Correlative studies
40850471|NCT02160145|DRUG|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
40850472|NCT02160145|DRUG|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
40850473|NCT06453291|DRUG|NSAIDs (Nonsteroidal Anti-Inflammatory Drugs):|"Objective: To reduce pain and inflammation associated with chronic low back pain.~Medications: Ibuprofen, Naproxen, or Diclofenac.~Dosage:~Ibuprofen: 400-600 mg every 6-8 hours as needed. Naproxen: 250-500 mg twice daily as needed. Diclofenac: 50 mg three times daily as needed. Administration: Oral tablets. Duration: Daily use as prescribed, for the duration of the study. Monitoring: Regular follow-up visits to monitor pain levels, side effects, and adherence."
41376514|NCT03340246|PROCEDURE|Delayed sclerotherapy|See arm descriptions
41376515|NCT03340246|PROCEDURE|Immediate phlebectomy|See arm description
40850474|NCT06453291|PROCEDURE|Standard Physical Therapy|"Objective: To improve mobility, strength, and reduce pain.~Techniques:~Stretching exercises. Strengthening exercises for core and back muscles. Manual therapy techniques. Postural training. Frequency: Twice a week sessions. Duration: 45-60 minutes per session. Monitoring: Progress will be assessed during each session and adjusted as necessary"
40850475|NCT06453291|PROCEDURE|Neuromodulation via Dorsal Root Ganglion (DRG):|"Objective: To modulate excitatory pathways and reduce pain through targeted stimulation.~Procedure:~Placement of electrodes near the DRG. Application of pulsed radiofrequency (RF) at 42°C for 3-20 minutes.~Frequency:~Initial treatment: Once a week for the first month. Maintenance: Monthly sessions if needed. Duration: Each session lasts approximately 30-45 minutes. Monitoring: Pain levels and functional improvement will be assessed before and after each session."
40850476|NCT06453291|PROCEDURE|Platelet-Rich-Plasma Therapy|"Objective: To promote healing and reduce inflammation through the application of concentrated platelets.~Procedure:~Blood draw from the patient. Centrifugation to separate platelets. Injection of PRP into the affected area of the lower back.~Frequency:~Initial treatment: Once a week for the first three weeks. Follow-up: Additional injections may be given based on patient response and clinical judgment.~Duration: Each session lasts approximately 30-45 minutes. Monitoring: Pain levels, inflammation markers, and functional improvement will be assessed before and after each injection."
40850477|NCT04069754|BEHAVIORAL|Adapted Passport to Freedom|5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections.
40850478|NCT05665803|PROCEDURE|Pediatric rotary files|Mechanical preparation of primary tooth canals with pediatric rotary files
40850479|NCT05665803|PROCEDURE|Manual flare files|Mechanical preparation of primary tooth canals with manual flare files
41376516|NCT05843539|GENETIC|Biological and epigenetic measures|This study also includes an exploratory biological ancillary study that aims to identify the gene expression variations that are determinant in terms of vulnerability/protection (cytogenetic and transcriptome), through the measurement of the level of biological chronic stress and epigenetic methylations of the NR3C1 and FKBP5 genes, in relation to adversity in childhood And to show the convergence between self-reported measures related to the presence of ACEs and attachment disorders with assays of chronic stress and epigenetic biomarkers.
41376517|NCT00448110|DRUG|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
41376518|NCT00448110|DRUG|Intravenous Ketorolac|Intravenous Ketorolac
41376519|NCT00448110|DRUG|placebo|placebo
41376520|NCT06385821|BIOLOGICAL|Grippol Quadrivalent|Solution for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
40850480|NCT06148506|OTHER|Ribociclib|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with ribociclib+ET by prescription within the study enrollment timeline will be recruited.
40850481|NCT06148506|OTHER|Combination chemotherapy|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with CT by prescription within the study enrollment timeline will be recruited.
40850482|NCT00147004|DRUG|hydrocortisone sodium succinate|50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
41376521|NCT06385821|BIOLOGICAL|Grippol Plus|Suspension for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly, 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
41376522|NCT04706065|GENETIC|SHMT1 polymorphism|It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.
41376523|NCT02628067|BIOLOGICAL|pembrolizumab|intravenous infusion
41376524|NCT02628067|BIOLOGICAL|pembrolizumab|intravenous infusion
41505914|NCT02132858|OTHER|laboratory biomarker analysis|Correlative studies
40850483|NCT00147004|DRUG|Placebo|
40850484|NCT06031363|DRUG|Indomethacin Suppository|Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.
41376525|NCT04960137|DEVICE|button plates fixation system|The button plates fixation system consists of fixing plate, prefabricated mix, button and fuse. In the process of use, the fuse plays the role of guiding the fixed plate through, pulling the button and shortening the distance between the button and the fixed plate. The prefabricated mix is pre-worn between the button and the fixed plate, and the lead pulls the distance between the fixed plate and the button after tightening and fixing. Prefabricated mix, make mix tight and knot. Finish the preliminary work of fixing.
41376526|NCT04960137|DEVICE|Non-absorbable Suture Anchor|A conventional device used in surgery for shoulder dislocation.
41376527|NCT03296592|DIAGNOSTIC_TEST|MRI with DBSI technology|The MRI will be done with diffusion basis spectrum imaging
40850485|NCT00917488|OTHER|Standardization of allergenic extract (Gly. domesticus)|Allergenic extract for cutaneous prick-test
41376528|NCT02468167|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
41376529|NCT02468167|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
41376530|NCT02468167|DRUG|N-butyl-2-cyanoacrylate|
41376531|NCT02468167|DRUG|Lauromacrogol|
41505915|NCT04648800|DRUG|BCG-10 vaccine|"The BCG-10 anti-tuberculosis vaccine~* powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~* lyophilised BCG vaccine~* one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain."
41376532|NCT05385510|BIOLOGICAL|R21/Matrix-M™|Adjuvanted malaria vaccine
41376533|NCT03781817|DRUG|Intravenous Ketamine|Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
41376534|NCT03781817|DRUG|Intranasal Ketamine|Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
41376535|NCT00798161|DRUG|BI 1356|BI 1356 high dose tablet, once daily
41376536|NCT00798161|DRUG|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
41376537|NCT00798161|DRUG|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
41376538|NCT00798161|DRUG|Metformin|Metformin 500 mg tablet, twice daily
41376539|NCT00798161|DRUG|metformin|metformin 1000 mg tablet, twice daily
41376540|NCT00798161|DRUG|matching placebo|matching placebo
41376541|NCT05968469|DEVICE|Aerobic exercises with cycling ergometry|"A total of 20 sessions of high-intensity interval (HIIT) aerobic exercise program will be applied to the patients using a bicycle ergometer, five days a week and once a day for four weeks. And then, it was planned to perform stretching exercises for the cervical, thoracic and lumbar regions and posture exercises accompanied by a specialist physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
41376542|NCT05968469|OTHER|Stretching exercises|"Stretching exercises for the cervical, thoracic and lumbar regions and posture exercises were planned to be performed with the expert physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
41505916|NCT04648800|DRUG|0.9% saline|0.9% saline
41376543|NCT03727113|PROCEDURE|Optimization cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
41376544|NCT03727113|PROCEDURE|Control cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
41376545|NCT02392377|DRUG|Paclitaxel|Given IV or IVPB
41376546|NCT02392377|DRUG|Carboplatin|Given IV or IVPB
41376547|NCT02392377|DRUG|Oxaliplatin|Given IV
41376548|NCT02392377|DRUG|Leucovorin Calcium|Given IV
41376549|NCT02392377|DRUG|Fluorouracil|Given IV
41376550|NCT02392377|RADIATION|Radiation Therapy|Undergo radiation therapy
41376551|NCT02392377|PROCEDURE|Therapeutic Conventional Surgery|Undergo esophagectomy
41505917|NCT02423629|DEVICE|Agili-C™ implantation procedure|Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
41505918|NCT04760496|DRUG|Oxytocin 4 mIU/mL|Oxytocin at 4 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
41505919|NCT04760496|DRUG|Oxytocin 2 mIU/mL|Oxytocin at 2 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
41505920|NCT03541980|DRUG|Acetaminophen|Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
41505921|NCT03541980|DRUG|Normal saline|Normal saline volume equivalent
41505922|NCT00990925|BEHAVIORAL|Nutritional Lifestyle Modification Group|Manualized group treatment to educate about basic nutritional concepts to help improve eating choices with the goal of losing weight.
41505923|NCT00990925|OTHER|Usual Care|Care as usual
41505924|NCT05393479|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is a psychological treatment recommended by the World Health Organization for perinatal depression. The THP is based on the basic tenets of cognitive behavioural therapy (CBT) that aims to identify unhealthy thoughts and the vicious effects it has on the emotions and behaviour of a person and transform to healthy thinking style that ultimately impacts one's emotions and behaviour, too. The intervention aims to bring positive outcomes in three areas - a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. A randomized controlled trial (RCT) showed that the intervention was effective in reducing depressive symptoms and disability and improving functioning. Additionally, women receiving THP had higher rate of exclusive breastfeeding, and engaging more with their infants. Similarly, infants of these women were also less likely to have diarrhoeal episode and more likely to complete immunization.
41505925|NCT06060431|OTHER|Pain Science Education|The Pain Science Education program consists of two workshops, 90 and 60 minutes in length, one week apart. The content of the workshops aims to provide students with information about the contemporary pain paradigm and to re-conceptualize pain.
40850486|NCT01129661|BIOLOGICAL|CSL112 (reconstituted HDL)|Single escalating intravenous doses of CSL112
40850487|NCT01129661|BIOLOGICAL|normal saline (0.9%)|Single intravenous dose of normal saline (0.9%)
40850488|NCT04523883|RADIATION|postoperative radiotherapy|postoperative radiotherapy with a dose of 60-66Gy
41033551|NCT01093794|DRUG|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
41376552|NCT02392377|OTHER|Laboratory Biomarker Analysis|Correlative studies
41505926|NCT01593046|DRUG|GSK1265744 Oral|30mg tablet
41505927|NCT01593046|DRUG|GSK1265744 LAP 800mg intramuscular injection|800mg Loading dose given at month 1 dose
41505928|NCT01593046|DRUG|GSK1265744 LAP 200mg subcutaneous injection|200mg maintenance dose give at months 2 - 4
41505929|NCT01593046|DRUG|GSK1265744 LAP 200mg intramuscular injection|200mg maintenance dose given at months 2 - 4
41505930|NCT01593046|DRUG|GSK1265744 LAP 400mg intramuscular injection|400mg maintenance dose given at month 2 - 4
40850489|NCT04523883|DRUG|JS001|JS001 240mg every three week
40850490|NCT00557453|DRUG|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
40850491|NCT00557453|DRUG|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
40850492|NCT01907425|OTHER|Blood samples|
40850493|NCT01834352|DRUG|Walnut Protein Flour|Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
41033552|NCT01093794|DRUG|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
41033553|NCT05424419|PROCEDURE|Brace therapy|A Chêneau-type brace was made to be worn as a full-time brace or during daytime only (double-brace group), whereas the nighttime brace was produced according to the Charleston approach.
41376553|NCT00357734|DRUG|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
41376554|NCT02885831|DEVICE|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
41376555|NCT02646566|DRUG|APD421|
41376556|NCT02646566|DRUG|Placebo|
41376557|NCT06034301|DEVICE|Medication Reminder App|"If the participant is randomized to the intervention group, they will:~1. receive a brief education session and be handed a flyer about the importance of medication adherence.~2. get training on how to use the medication reminder app and participant will be given a user guide on how to use the app~3. demonstrate their understanding on an iPad using the teach back method~4. install and set up the medication reminder app on their phone~5. receive a MEMS cap and be given instructions on how to use it with their blood pressure medication. Study team members will use a participant ID to log into the MEMS cap application; no identifiable information will be entered."
41376558|NCT04054011|DRUG|Deoxycholic Acid|Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous
41505931|NCT01593046|DRUG|TMC278 LA 1200mg intramuscular injection|1200mg Loading dose given at month 3
40850494|NCT01834352|DRUG|Oat flour|Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
41033554|NCT00622167|DEVICE|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
41505932|NCT01593046|DRUG|TMC278 LA 600mg intramuscular injection|600mg Loading dose given at month 4
41505933|NCT01593046|DRUG|GSK1265744 LAP 800mg intramuscular injection|800mg dose given quarterly (once every) 12 weeks
41505934|NCT02571816|DRUG|ASP2215|oral
41505935|NCT00318877|BEHAVIORAL|After school team sports program|
41505936|NCT00318877|BEHAVIORAL|After school health education program|
41505937|NCT04204538|OTHER|Dietary habits|Data collected using food frequency questionnaire
41505938|NCT04204538|OTHER|Risk factors associated with metabolic syndrome|Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome
41505939|NCT06194760|PROCEDURE|Vitrectomy with ILM peeling|Vitrectomy with traditional internal limiting membrane (ILM) peeling technique is regarded as the gold standard treatment for MH; it works by completely relieving of the traction of the macula and increasing the flexibility of the retina
41505940|NCT06355102|OTHER|Conventional treatment and care|Conventional treatment and care
41505941|NCT00002200|DRUG|Abacavir sulfate|
41505942|NCT04054154|DEVICE|Shear Wave Elastography|Undergo shear wave elastography
41505943|NCT04054154|PROCEDURE|Tumor Interstitial Fluid Pressure Measurement|Undergo tumor pressure measurement
41505944|NCT05566795|DRUG|Tovorafenib|Oral type II RAF kinase inhibitor
41505945|NCT05566795|DRUG|Chemotherapeutic Agent|Intravenous solution for injection
41505946|NCT05243446|DRUG|Losartan|losartan treatment
41505947|NCT02467478|DRUG|Linagliptin|5 mg tablet once daily for 12 weeks
41505948|NCT02467478|DRUG|Placebo|1 tablet daily for 12 weeks
41505949|NCT03461731|DEVICE|Control|laser beam only
41505950|NCT03461731|DEVICE|800 nm laser|800 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
41505951|NCT03461731|DEVICE|combination laser|800 nm and 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
40850495|NCT03570801|OTHER|Expert Panel Review|There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
40850496|NCT02700828|DRUG|Hydrocortisone|4 \* 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
40850497|NCT02700828|DRUG|Placebo|4 \* 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
41505952|NCT03461731|DEVICE|905 nm laser|905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
41505953|NCT06324435|DRUG|Apremilast|60mg/day
41505954|NCT03518645|DEVICE|OPN strategy|Predilatation with OPN balloon will be performed as a lesion preparation for BVS Absorb implantation.
41505955|NCT03518645|DEVICE|standard strategy|Predilatation with standard balloon will be performed as a lesion preparation for BVS Absorb implantation.
41505956|NCT02224157|DRUG|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
41505957|NCT02224157|DRUG|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
41505958|NCT03779984|DEVICE|Red Rubber Catheter|Experimental group will be intubated with red rubber catheter guidance
41505959|NCT03779984|DEVICE|Standard nasal tracheal Intubation|Control group will be intubated with standard nasal tracheal tube without guidance
41505960|NCT05297773|BEHAVIORAL|Aerobic Training Group|The participants will perform continuous cycling at 30%-35% of their heart rate reserve for one month (phase 1: adaptive phase). Then, the intensity will increase every 4-5 weeks (± 5%) up to a maximum of 64% of heart rate reserve (moderate intensity), depending on the participant's tolerance. An individualized equation establishing the relationship between heart rate, oxygen consumption, and power output will be determined during the cardiorespiratory fitness assessment and used to determine exercise intensity.
41505961|NCT05297773|BEHAVIORAL|Resistance Training Group|Initially, and during the first two weeks of the adaptive phase (1-month), the resistance training group will perform one set of 8-12 repetitions (40%-repetition maximum) of 8 exercises for upper and lower body (squat, leg extension, leg curl, deadlift, plank, dead bug, seated row, shoulder press). Then, in the last two weeks, the participants will perform 2 sets of each exercise (45%-repetition maximum). After the adaptive phase, three sets of each exercise will be performed. The initial load will be 50% -repetition maximum increasing up to a maximum of 70%-repetition maximum at the end of the study. Every 4-5 weeks the load will be reviewed and adjusted according to individual.
41505962|NCT05297773|OTHER|Control group|The control group will perform a weekly stretching/relaxation session for 45 minutes.
41505963|NCT05528601|BEHAVIORAL|use of Endo App®|use of Endo App® smartphone application containing endometriosis relevant exercises and educational material
41505964|NCT01998841|DRUG|Crenezumab|Crenezumab will be administered as per the schedule specified in the treatment arm.
41505965|NCT01998841|DRUG|Placebo|Placebo will be administered as per the schedule specified in the treatment arm.
41505966|NCT04131348|PROCEDURE|botulinum toxin type A|From to December 2016 to December 2018, a single-center prospective comparative study was performed in 80 patients with LMIH at our tertiary center.
41505967|NCT05056038|PROCEDURE|Lateral Quadratus Lumborum block|Local anesthetic may spread to the T6-L1 spinal nerves and paravertebral area by spreading through the lateral QLB to the transversus abdominis plane, and posteriorly via the anterior thoracolumbar fascia.
41505968|NCT05056038|PROCEDURE|Posterior Quadratus Lumborum Block|In posterior QLB, the local anesthetic can spread on the anterior and lateral cutaneous branches of T4-L1 spinal nerves by administration of the agent to the lateral interfascial triangle.
41505969|NCT00323466|PROCEDURE|IMRT versus conventional radiotherapy|Comparing MRT versus conventional radiotherapy
41505970|NCT04428450|DEVICE|Deprexis|CBT-based, integrative online self-help program
41376559|NCT05025904|BEHAVIORAL|Real-time fMRI neurofeedback (rt-fMRI NFB)|Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.
41505971|NCT03423186|DRUG|SOBI003|Weekly i.v.infusion
41376560|NCT05025904|BEHAVIORAL|Сognitive behavioral therapy (CBT)|A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.
41376561|NCT05025904|BEHAVIORAL|EEG neurofeedback (EEG NFB)|EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.
41376562|NCT03717220|PROCEDURE|flap transferring|we use regional dorsal digital flaps for simultaneous reconstruction of multiple-digit soft-tissue defects
41505972|NCT06550765|DEVICE|Biodegradable Magnesium Metal Clips|The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
41505973|NCT00053183|PROCEDURE|conventional surgery|
41505974|NCT00053183|RADIATION|brachytherapy|
41033555|NCT00622167|DEVICE|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
41033556|NCT02615223|PROCEDURE|cryoablation|Cryoablation therapy
41033557|NCT02615223|DRUG|Bicalutamide|bicalutamide
41033558|NCT02615223|DRUG|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
41033559|NCT02513654|DRUG|Lamotrigine|Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
41376563|NCT05577975|DEVICE|The Aspara @ smart grower|The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention. The home-based program contains different horticultural, cognitive and multisensory stimulation activities such asking the PWD and the family caregiver to record the sense of touch and odor when taking care of the plant and the various changes of the plants by using the smart grower. Program evaluation will be conducted through focus groups with 15 participants with different levels of stress reduction after the intervention.
41376564|NCT00004123|DRUG|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
41505975|NCT00053183|RADIATION|radiation therapy|
41505976|NCT05755347|OTHER|General health survey questionnaires|Patient-reported outcome survey will be offered at baseline.
41505977|NCT05755347|OTHER|PROMIS Cancer Function Brief 3D profile questionnaires|Patient-reported outcome survey will be offered at baseline.
40850498|NCT05043389|OTHER|myofunctional therapy program|Exercise oral cavity muscle
41033560|NCT06635772|DRUG|HS-10390|HS-10390 will be administered daily
41505978|NCT05755347|OTHER|FACT-G questionnaires|Patient-reported outcome survey will be offered at baseline.
41033561|NCT06635772|DRUG|Irbesartan|Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg
41033562|NCT02755987|DRUG|ANG1005|
41033563|NCT05991154|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
41033564|NCT00451854|PROCEDURE|Random, no advanced notice drug and alcohol testing|
41033565|NCT02771951|BEHAVIORAL|"Lights of Change"|
41033566|NCT02771951|BEHAVIORAL|Usual Care|
41033567|NCT03911492|PROCEDURE|SCPP Management => 65 mmHg|A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.
41033568|NCT04992260|BIOLOGICAL|Inactivated COVID-19 Vaccine|The inactivated COVID-19 vaccine was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
41376565|NCT00004123|PROCEDURE|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
41376566|NCT00004123|RADIATION|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
41376567|NCT00004123|RADIATION|Radiation Therapy (RT)|5 days a week for 4 weeks
41376568|NCT05959174|DEVICE|3D printed mitchigen appliance|the process of appliance construction done by intra-oral scanning of the arch and 3d printing
41505979|NCT05755347|OTHER|Godin Leisure-Time Exercise Questionnaire|Patient-reported outcome survey will be offered at baseline.
41505980|NCT05755347|OTHER|REAP-S questionnaires|Patient-reported outcome survey will be offered at baseline.
41505981|NCT00186940|DRUG|Rasburicase|Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
41505982|NCT01661062|OTHER|Cone Beam Computed Tomography (CT) Scan|Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
41505983|NCT03543189|DRUG|Nivolumab|Treatment with nivolumab will begin four weeks prior to the first brachytherapy treatment. Nivolumab will be given through a vein every 2 weeks for 4 courses. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth.
40850499|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 400 to 500 calories|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie medium-fat lunch
40850500|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 600 to 750 calories|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie medium-fat lunch
41376569|NCT05959174|DEVICE|side chair appliance|the impresion will be taken to make a cast to reconstruct the appliance
41505984|NCT03543189|RADIATION|Brachytherapy|High dose rate (HDR) Brachytherapy involves the delivery of a high dose of radiation, internally, directly to the prostate. This procedure is completed in one day as an outpatient procedure.
41505985|NCT03543189|RADIATION|External Beam Radiation Therapy|External beam radiation therapy to the participant's prostate will be given once a day, five days a week (Monday-Friday), for a total of five weeks. External radiation therapy treatments are given as an outpatient procedure and take about 10-15 minutes each day.
41376570|NCT05704946|OTHER|THE EFFECT OF LAVENDER INHALATION ON SLEEP QUALITY IN INDIVIDUALS WITH CORONARY HEART DISEASE|The index includes 24 questions that evaluate the quality of sleep and the type and severity of sleep disorders experienced in the last 1 month period. The total score in the index takes a value between 0-21. If the total score is higher than 5, it is interpreted as poor sleep quality.
41505986|NCT03543189|DRUG|Androgen Deprivation Therapy|Standard of care.
41505987|NCT01307176|BEHAVIORAL|Home exercise program|The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
41505988|NCT00022334|BIOLOGICAL|AFP|Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
41505989|NCT05209165|DRUG|Semaglutide|weekly Semaglutide (increased from starting dose of 0.25 mg at four-week intervals (0.5 mg, 1.0 mg, 1.7 mg) to a target dose of 2.4 mg) for 52 weeks with intake visit for the VA MOVE program
41505990|NCT05209165|DRUG|Placebo|Matching placebo and intake visit for VA MOVE
41376571|NCT01412411|BEHAVIORAL|Nutritionl Education|to assess the change in behaviour
41376572|NCT01412411|DIETARY_SUPPLEMENT|Oral Iron Supplementation along with Nturition Eductaion|
41376573|NCT01412411|DIETARY_SUPPLEMENT|Multiple micronutrient fortification plus Nutrition Education|
40850501|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 800 to 1000 calories|A single oral dose of 330 mg controlled release tablet administered following an 800 to 1000 calorie medium-fat lunch
41376574|NCT04273763|DRUG|Bromhexine Hydrochloride Tablets|Bromhexine Hydrochloride Tablets
41376575|NCT04273763|DRUG|Arbidol Hydrochloride Granules|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.
41376576|NCT04273763|DRUG|Recombinant Human Interferon α2b Spray|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.
41376577|NCT03265483|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
41376578|NCT03265483|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
41376579|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
41376580|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
40850502|NCT01270815|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered fasted
40850503|NCT04454242|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
40850504|NCT03068767|DIETARY_SUPPLEMENT|Vitamin D|
41505991|NCT06229457|BEHAVIORAL|Girls PLAY program|Girls PLAY program (8-12 weeks) will include 1) a series of in-person sessions, led by Boys and Girls Clubs staff at the Boys and Girls Club sites, and 2) take-home activities. In-person sessions (60-75 min; 2-3x/week) will center around a different developmentally appropriate sport each week. Lesson plans will outline games/activities in which youth engage in fundamental, sport-specific movement skills. Lesson plans will be delivered by Boys and Girls Club leaders using acts of instruction derived from Self-Determination Theory. Take home activities will 1) summarize and add on to the week's in-person sessions and 2) be adapted for delivery by parents and/or self-guided participation by youth. Take-home activities will provide information for engaging in the past week's activities as well as additional activities that parents and youth can participate in together.
41505992|NCT03999749|DRUG|Ipilimumab|4 induction doses (during the 2 treatment cycles) at a dose of 1 mg/kg intravenously (IV) every 3 weeks, 4 times during the 12-week induction period, concurrent with nivolumab at 3 mg/kg administered at the same interval
41033569|NCT04992260|BIOLOGICAL|Controlled vaccine|The placebo was manufactured by Sinovac Research\& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
41505993|NCT03999749|DRUG|Nivolumab|Nivolumab (3 mg/kg) will be administered IV on Days 1 and 22 of each 42-day induction treatment cycle. Nivolumab will continue to be administered IV at 240 mg flat dose every 2 weeks; i.e., at Days 1, 15, 29, 43, 57, and 71 of the 84-day treatment cycle for the first maintenance cycle until week 24, then nivolumab will be administered at 480 mg flat dose every 4 weeks to a maximum of 2 years
41505994|NCT03999749|DRUG|Tocilizumab|Administered intravenously for each 42-day induction treatment cycle. After 12 weeks of therapy, starting at Week 13, subjects enter the maintenance phase. Tocilizumab will be administered intravenously every 6 weeks during the first 84 day maintenance treatment cycle only at 4 mg/kg
41505995|NCT03406754|BEHAVIORAL|rehabilitation programs|an 8-week multidisciplinary inpatient rehabilitation program
41505996|NCT05013307|OTHER|CASE|The Clinical Assessment for Sports Exertion (CASE) addresses the physical performance of athletes by quantifying physiological and symptomatic responses to dynamic exertion. It was developed by clinicians at the Baylor Scott and White Sports Concussion Program in an effort to identify specific system impairments in athletes who were unable to successfully demonstrate readiness for return to play protocols.
41505997|NCT02871544|OTHER|BNP and NGAL|
41505998|NCT05057806|DRUG|Empagliflozin 25 MG|Empagliflozin 25MG will be administered orally once per day for 3 months
41505999|NCT05057806|DRUG|Placebo|The placebo will be administered orally once per day for 3 months
41506000|NCT06109311|DRUG|Orforglipron|Administered orally.
41506001|NCT06109311|DRUG|Placebo|Administered orally.
41506002|NCT03136965|BIOLOGICAL|PRP|Injection of autologous platelet rich plasma (PRP)
41506003|NCT03136965|PROCEDURE|Dry Needling|This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.
41506004|NCT03136965|PROCEDURE|Dry Needling - Sham|This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.
41506005|NCT02352935|DEVICE|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
41506006|NCT06331767|BEHAVIORAL|mSYNC|mSYNC in an mHealth HIV prevention intervention to be initially delivered at point-of-care during a visit to the emergency department with continued on demand access to intervention app at home. Taking a behavioral medicine approach, mSYNC simulates hospital-based consultation \& liaison psychology service by intervening on interrelated health risk behaviors, mental health issues, and structural/treatment needs. The mHealth app includes modules with motivational interviewing for HIV/drug use risk behaviors, cognitive behavioral therapy for transdiagnostic psychological coping skills, referral system for needed hospital-based services (mental health/drug use treatment; HIV prevention; social services), and access to geolocated resources.
41506007|NCT00534404|DRUG|Nicotine patches|Participants will wear nicotine patches.
41506008|NCT00534404|BEHAVIORAL|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
41506009|NCT00534404|BEHAVIORAL|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
41506010|NCT06551766|DEVICE|Photosensitive hydrogel|In the photosensitive hydrogel group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by photosensitive hydrogel.
41506011|NCT06551766|DEVICE|6-0 absorbable stitches|In the suture fixation group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by two stitches using 6-0 absorbable wire.
41506012|NCT03174379|PROCEDURE|Standard of Care with no acupuncture|The control group will lie on a treatment table in the acupuncturist's office for the same amount of time that the treatment group did, but receive no acupuncture
41506013|NCT03174379|PROCEDURE|Acupuncture|The first set consists of core point selection, used in an MS Standard of Care (SOC). The second set of points will be individualized to the patient's needs as determined by the acupuncturist. SOC treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
40850505|NCT00681733|DRUG|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
40850506|NCT00681733|DRUG|Pioglitazone|30 mg OD
40850507|NCT00681733|DRUG|Pentoxifylline|1200 mg/d
41033570|NCT05721859|DEVICE|revision hip arthroplasty|revision hip arthroplasty
41033571|NCT05308862|BEHAVIORAL|Care process for assessements of risks|Intervention aiming to reduce the risk of pressure ulcers, malnutrition, poor oral health and falls among older persons in nursing homes, workshops will be conducted in collaboration with nurse aides, registered nurses and managers. Cluster randomization is going to take place via a computerized program prior to the workshops meaning that only those nurse aides, registered nurses and managers working in nursing homes allocated to the intervention group are going to develop an intervention together with the research group and then test it .
41033572|NCT00383435|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
41033573|NCT00383435|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
41033574|NCT00383435|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
40850508|NCT02400541|BEHAVIORAL|Cognitive remediation therapy|"Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.~Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients."
41033575|NCT00383435|DRUG|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
41033576|NCT00383435|DRUG|Placebo|Placebo MDI twice a day for 26 weeks
41033577|NCT06241326|OTHER|Immunotherapy-based Combination Therapies|immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
41033578|NCT00484705|PROCEDURE|Electroacupuncture|
41033579|NCT00484705|PROCEDURE|Physical exercise|
41376581|NCT03019666|BIOLOGICAL|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"* Cyclophosphamide 40 mg/kg x 1 day on Day -5~* Fludarabine 25 mg/m\^2 x 3 days (Day -5, Day -4, day-3)"
41376582|NCT05206279|DRUG|Ureteral injection of Indocyanine Green Powder (diluted)|The intervention we study is the intraureteral injection of ICG during a laparoscopic deep infiltrative endometriosis resection procedure. Cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
41376583|NCT04874415|BEHAVIORAL|1RLD|1RLD=One text per day, ramped goal, loss incentive, daily goal time period
41376584|NCT04874415|BEHAVIORAL|1RLW|1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
41376585|NCT04874415|BEHAVIORAL|1RGD|1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
40850509|NCT02400541|OTHER|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
40850510|NCT01659684|BIOLOGICAL|standard intravenous immunoglobulin|Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
41033580|NCT00484705|PROCEDURE|Untreated control|
41033581|NCT00396903|DEVICE|catheter|
41033582|NCT06636435|DRUG|CBA-1205|CBA-1205: 0.1, 0.3, 1, 3, 10, 20, 30 mg/kg (Intravenous solution)
41376586|NCT04874415|BEHAVIORAL|1RGW|One text per day, ramped goal, gain incentive, weekly goal time period.
41376587|NCT04874415|BEHAVIORAL|2RLD|Two texts per day, ramped goal, loss incentive, daily goal time period.
41376588|NCT04874415|BEHAVIORAL|2RLW|Two texts per day, ramped goal, loss incentive, weekly goal time period.
41376589|NCT04874415|BEHAVIORAL|2RGD|Two texts per day, ramped goal, gain incentive, daily goal time period.
41376590|NCT04874415|BEHAVIORAL|2RGW|Two texts per day, ramped goal, gain incentive, weekly goal time period.
41033583|NCT06636435|DRUG|CBA-1205|CBA-1205 : 20 mg/kg and 30 mg/kg (Intravenous solution)
41033584|NCT06636435|DRUG|CBA-1205|CBA-1205: 30 mg/kg (Intravenous solution)
41033585|NCT00125489|DRUG|chloroquine sulfate|
41033586|NCT00125489|DRUG|sulfadoxine/pyrimethamine|
41033587|NCT05818735|OTHER|electroacupuncture (EA) treatment|The regular acupuncture treatment will be applied at the acupoints including Baihui (GV20), Yintang (GV29), Guanyuan (RN4), Qihai (RN6), bilateral ZuSanli (ST36) and bilateral SanYinjiao (SP6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for 'De qi' sensation. Three pairs of electrodes of the electroacupuncture apparatus will be connected to the needles of GV20 and GV29, and bilateral ST36 and SP6 for 25 minutes, delivering a continuous wave with a frequency of 2-8Hz which is based on the tolerance of each patient. The selection of matching acupuncture points will be determined by the acupuncturist according to the patients' different syndrome patterns.
41376591|NCT04874415|BEHAVIORAL|1FLD|One text per day, fixed goal, loss incentive, daily weekly goal time period.
41376592|NCT04874415|BEHAVIORAL|1FLW|One text per day, fixed goal, loss incentive, weekly goal time period.
41376593|NCT04874415|BEHAVIORAL|1FGD|One text per day, fixed goal, gain incentive, daily goal time period.
41376594|NCT04874415|BEHAVIORAL|1FGW|One text per day, fixed goal, gain incentive, weekly goal time period.
41376595|NCT04874415|BEHAVIORAL|2FLD|Two texts per day, fixed goal, loss incentive, daily goal time period.
40850511|NCT05553392|DEVICE|StrataXRT|"StrataXRT is a full contact flexible wound dressing for the prevention and treatment of radiation dermatitis. StrataXRT is a semi-occlusive, self-drying and transparent gel.~When used as directed StrataXRT dries to form a protective layer that is gas permeable and waterproof which hydrates and protects compromised skin areas and superficial wounds from chemical and microbial invasion. StrataXRT may be directly applied to radiation dermatitis, compromised skin surfaces, superficial wounds and first and second degree burns."
40850512|NCT05553392|DRUG|Aquaphor|"Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc.~Aquaphor contains 41 percent petrolatum (or petroleum jelly), the active ingredient, temporarily protects minor cuts, scrapes, and burns; protects and helps relieve chapped or cracked skin and lips; helps protect from the drying effects of wind and cold weather."
41376596|NCT04874415|BEHAVIORAL|2FLW|Two texts per day, fixed goal, loss incentive, weekly goal time period.
40850513|NCT05861661|OTHER|The study do not include an intervention|The study do not include an intervention
40850514|NCT02471222|DRUG|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
40850515|NCT02471222|OTHER|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
40850516|NCT02487862|BEHAVIORAL|Stress Reduction Protocol|Stress Reduction Protocol
40850517|NCT00102427|BEHAVIORAL|Telephone-based collaborative care management|
40850518|NCT01548508|OTHER|Functionnal ElectroStimulation (FES)|Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
40850519|NCT01548508|OTHER|SHAM|SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
40850520|NCT00085449|BIOLOGICAL|alemtuzumab|
41033588|NCT05818735|OTHER|sham acupuncture (SA) treatment|The sham acpunture treatment will be applied at the same acupoints as the EA treatment with the Streitberger placebo needles. When the blunt needle tip of the placebo needles touches the skin, the patient will get a pricking sensation, but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set on the table beside the patients and two pairs of electrodes will be connected to the needles at bilateral ST36 and SP6. Acupuncturists will turn on the apparatus but all indicators will be set to '0'. Participants will be informed when needles are removed after 25 minutes. Acupuncturists will use dry cotton balls to press the skin around the acupoints when withdrawing the needles so that patients can feel the withdrawal of the 'needles'.
41033589|NCT05818735|DRUG|Escitalopram 10mg|Escitalopram will be used as the antidepressants for relieving patients' depressive mood. The dose of the drug will be the minimum clinical starting dose of 10 mg once daily, taken orally in the morning, for a period of 3 months. During the intervention period, patients will be allowed to increase the drug dose (up to 20 mg) according to their mental status. Patients will record the details of the drug dose, duration of dosing,responses and possible side effects on a drug dairy. Pateints will receive 7 tablets of escitalopram from an independent dispencer at a set time each week. They may receive additional dose of escitalopram once again during the week if necessary and it will be recorded by the dispenser.
41376597|NCT04874415|BEHAVIORAL|2FGD|Two texts per day, fixed goal, gain incentive, daily goal time period.
41376598|NCT04874415|BEHAVIORAL|2FGW|Two texts per day, fixed goal, gain incentive, weekly goal time period.
41376599|NCT04011891|PROCEDURE|Robotic Partial Nephrectomy|Robotic partial nephrectomy using da Vinci robot.
41376600|NCT04011891|PROCEDURE|Open Partial Nephrectomy|Standard open partial nephrectomy
41376601|NCT03217500|PROCEDURE|Corneal epithelial autograft|After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
41376602|NCT03217500|PROCEDURE|Limbal conjunctival autograft|After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.
41376603|NCT03217500|PROCEDURE|Simple removal|Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.
40850521|NCT00085449|DRUG|cyclosporine|
40850522|NCT00085449|DRUG|fludarabine phosphate|
40850523|NCT00085449|DRUG|melphalan|
40850524|NCT00085449|DRUG|mycophenolate mofetil|
41376604|NCT03217500|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
41376605|NCT03217500|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
41376606|NCT01529697|BEHAVIORAL|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
40850525|NCT00085449|PROCEDURE|peripheral blood stem cell transplantation|
40850526|NCT00085449|RADIATION|radiation therapy|
40850527|NCT04478604|OTHER|applied forms to pregnant women|
40850528|NCT00966212|BEHAVIORAL|parent education|Especially for Daughters audio-cd parent education
40850529|NCT00794885|DRUG|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
41376607|NCT04340739|OTHER|online patient education teach mindfulness based stress reduction|This is an online self management chronic pain curriculum that presents adapted Mindfulness Based Stress Reduction through videos, audios, and written materials
41376608|NCT05417685|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
41376609|NCT05417685|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
41376610|NCT05417685|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
41376611|NCT02544126|DEVICE|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
41376612|NCT02544126|BEHAVIORAL|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
41376613|NCT03660059|DRUG|Peficitinib|Oral
41376614|NCT03660059|DRUG|Plaebo|Oral
41376615|NCT03660059|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
41506014|NCT06495112|OTHER|Soft contact lens with lathe cut technique Lathe|athe cut technique Lathe cutting involves shaping a solid block of lens material into the desired form using precision machinery. This method allows for customized lens designs but may result in a less smooth surface compared to cast molding. Cast molding, on the other hand, uses a liquid monomer that is cured in a mold to form the lens. This technique typically results in a smoother and more uniform lens surface.
41506015|NCT06495112|DIAGNOSTIC_TEST|Soft contact lens with cast molding technique|Participants in this arm would receive Cast molding soft contact lenses and would wear them according to the study protocol, also likely for a specified duration.The cast molding technique for soft contact lenses involves creating lenses by polymerizing a liquid monomer mixture within a mold that forms the desired lens shape. Here's a brief overview of the steps involved in the cast molding process
41506016|NCT06550466|OTHER|Breakfast only|Participants will attend a breakfast-only arm without the exercise protocol.
41506017|NCT06550466|OTHER|FAST|Participants will be exercised for 90 minutes following a 12-hour overnight fast
41506018|NCT06550466|OTHER|FED|Participants will be exercised 90 minutes after a breakfast
41506019|NCT05070026|OTHER|uni-portal VATS group|patients received pulmonary lobectomy under general anesthesia by using uni-portal VATS method
41506020|NCT05070026|OTHER|three port VATS group|patients received pulmonary lobectomy under under general anesthesia by using three port VATS method
41506021|NCT05498181|DRUG|Sacubitril-valsartan|sacubitril/valsartan
41506022|NCT05498181|DRUG|Placebo|Placebo
41506023|NCT01346787|DRUG|CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE|Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
41506024|NCT05370469|OTHER|Sensus Smartwatch Application|Sensus is capable of administering ecological momentary assessments (EMAs) on a schedule, randomly, or using sensor-triggers. In this way, Sensus will capture both active (patient-initiated) and passive data streams from native smartphone sensors. Passive streams may include, but are not limited to, GPS, accelerometer, gyroscope, and pedometer data. Participants will be able to log data such as their activity, symptoms and medication adherence via user-initiated surveys within the Sensus app. Sensus will also prompt users to record their medication adherence, symptoms, or activity. This will be done either at fixed intervals (e.g., three times daily) or whenever the onboard sensors detect potential changes in a user's physiological state (e.g., shaking / moving around).
41506025|NCT05370469|DEVICE|RX Cap|The RXCap medication event monitoring device will be used to collect data on participant adherence to their TKI medication. A small computer chip is included in the top of a pill bottle. When the cap is taken off of the pill bottle by turning it or unscrewing it, the cap records the time and date that it was removed.
41376616|NCT05393635|BIOLOGICAL|ITIL-168|"ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion."
41164101|NCT04550286|BEHAVIORAL|Smartphone Use Reduction in Academic Context|"Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation). This refers to the behavior change techniques (BCT 4.1, instructions on how to perform the behavior; Michie et al.; 2013).~In the next step, participants in the intervention group complete planning sheets. Each student has to develop up to three action plans (BCT 1.4) including when, where, and for how long the smartphone will be put away during the daily exam preparation period (cf. Radtke et al., 2018). In addition, each participant should try to anticipate possible barriers to engaging in the planned behavior and plan what he or she could do to overcome these possible barriers (i.e., coping planning; BCT 1.2; Michie et al., 2013)."
41164102|NCT04550286|BEHAVIORAL|Control|Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation).
41164103|NCT00087477|DRUG|Pivanex|
41376617|NCT03754595|PROCEDURE|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
41376618|NCT03754595|PROCEDURE|2D Laparoscopic pancreatoduodenectomy|2D Laparoscopic pancreatoduodenectomy
41033590|NCT05818735|DRUG|Placebo|Placebo drugs are tablets of the same color and size as escitalopram tablets, consisting mainly of starch, and will be tested for safety before being used in the trial. The way the medication is dispensed, the details of how the medication is administered, the dosage, and the record of the drug diary are consistent with the application of the real drugs.
41033591|NCT06635460|OTHER|Motivational interviewing|This programme has been developed from the literature and structured according to expert opinion. It will consist of a total of 8 online sessions. The duration of the motivational interviewing sessions will be limited to 30-45 minutes, in line with the literature.
41164104|NCT04514692|DIAGNOSTIC_TEST|FDG PET/CT|Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)
41376619|NCT00919932|BEHAVIORAL|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
41033592|NCT06635460|OTHER|Social media-based patient monitoring|Blood glucose results, lowest and highest values, and reasons will be included in the content of the patient follow-up, which will be conducted at intervals on the WhatsApp platform. There will be a total of 10 follow-ups. Although the duration of the written dialog will vary among adolescents, it will be limited to an average of 2-10 minutes.
41033593|NCT03149783|DRUG|Ropivacaine HCL|Ropivacaine injected after placement of catheters, then infused during the operation
41033594|NCT03149783|DRUG|sodium chloride|Placebo
41164105|NCT04514692|DRUG|GCSF|Granulocyte Colony Stimulating Factor (GCSF)
41164106|NCT06039943|DEVICE|Wheeze measurement|Acoustic breath sounds will be measured during tidal breathing prior to spirometry and during a spirometry attempt.
41164107|NCT02456259|PROCEDURE|Neck cannula insertion|Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
41376620|NCT00919932|DEVICE|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
41506026|NCT05370469|DEVICE|Fitbit Sense|The Fitbit Sense smartwatch will be used to collect data including steps, calories burned, total distance travelled, sleep (e.g. time spent sleeping and quality of sleep), flights of stairs climbed, active minutes, exercise (e.g. minutes spent exercising at various intensities), and average heart rate.
41164108|NCT06435871|BEHAVIORAL|Expanded Prostate Cancer Index Composite and Decision Regret Scale|This comprehensive instrument measures urinary, sexual, and bowel symptoms in men treated for prostate cancer. It can provide a detailed view of the patient's quality of life post-treatment.
41506027|NCT05370469|OTHER|Surveys|Electronic and paper surveys will be administered throughout the study.
41506028|NCT03645863|DRUG|MT-6548|Oral tablet
41506029|NCT03645863|DRUG|Iron supplement A|Oral tablet
41506030|NCT03645863|DRUG|Iron supplement B|Oral tablet
41506031|NCT03645863|DRUG|Iron supplement C|Oral tablet
41376621|NCT02843490|DRUG|Ranibizumab|Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
41376622|NCT06466967|DEVICE|Advanced hybrid closed-loop CamAPS FX|Treatment with a strict programmed glucose target (80-99 mg/dL).
41376623|NCT06107413|DRUG|ABBV-400|Intravenous (IV) Infusion
41506032|NCT03645863|DRUG|Iron supplement D|Oral tablet
41506033|NCT03504683|BEHAVIORAL|Early TRE|Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)
41506034|NCT03504683|BEHAVIORAL|Mid-day TRE|Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)
41506035|NCT03504683|BEHAVIORAL|Control Schedule|Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
41506036|NCT02017015|DRUG|nab-paclitaxel|nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
41506037|NCT02017015|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
41506038|NCT02960490|DRUG|E6011|subcutaneous administration
41164109|NCT00977795|DRUG|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
41506039|NCT02960490|DRUG|Placebo|subcutaneous administration
41506040|NCT05998876|DEVICE|Remote Medication Monitor (RMM) - Prototype|Inserted Microneedle Electrode Array for assaying dermal interstitial fluid.
41506041|NCT05998876|DRUG|Daily Methadone Dose|patient takes their prescribed daily dose of methadone
41506042|NCT02304666|PROCEDURE|Colonoscopy for biopsies samples|
41376624|NCT06107413|DRUG|Bevacizumab|IV Infusion
41506043|NCT06633575|BEHAVIORAL|exercise intervention|Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
41506044|NCT04688385|BIOLOGICAL|Multipeptide Vaccine+ XS15|Peptide vaccination will take place in CLL patients that achieved at least a partial remission with detectable MRD after at least 6 and less than 9 months of an ibrutinib-based treatment regime. MRD will be determined by flow cytometry. MRD positivity is defined as \> 10-4 CLL cells in peripheral blood or bone marrow. Patients will receive either ibrutinib monotherapy or combinational therapy before study treatment. Vaccination will be done under ibrutinib monotherapy (i.e. after the end of e.g. anti-CD20 treatment, if applicable).
41506045|NCT01408043|DRUG|plerixafor|Given SC
41506046|NCT01408043|BIOLOGICAL|filgrastim|Given SC
41376625|NCT06107413|DRUG|Folinic Acid|IV Infusion
41506047|NCT01408043|DRUG|etoposide|Given IV
40850530|NCT00794885|DRUG|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
41376626|NCT06107413|DRUG|Fluorouracil|IV Infusion
41376627|NCT06107413|DRUG|Irinotecan|IV Infusion
41506048|NCT01408043|PROCEDURE|leukapheresis|Undergo apheresis
41506049|NCT03734939|OTHER|None intervention is planned.|None intervention is planned, just a survey.
41506050|NCT02600533|PROCEDURE|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
41506051|NCT05349045|DRUG|an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor|This is an observational study
41506052|NCT02006225|DRUG|Plerixafor|
41506053|NCT05778903|OTHER|Nerve block|Suprazygomatic maxillary nerve block
41506054|NCT05782881|BEHAVIORAL|phone calls and encouraging patients' lifestyle change and medication adherence|Use some methods to strictly intervene blood glucose , blood pressure and blood lipids for protocol treatment group people.
41506055|NCT05782881|DRUG|Statin|Treatment and management according to the guidelines
41506056|NCT01131468|DRUG|N-acetylcysteine|N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
41506057|NCT01724450|DRUG|Carvedilol|50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
41506058|NCT01724450|DRUG|Placebo|Placebo similar to the carvedilol up titration but wit no active drug.
41506059|NCT01912378|DRUG|Oxytocin|
41506060|NCT01912378|DRUG|Placebo nasal spray|
41506061|NCT02292173|DRUG|Trametinib|"Dose Escalation:~Level 1: 1 mg daily. Level 2: 1.5 mg daily. Level 3: 1.5 mg daily. Level 4: 2 mg daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
40850531|NCT00231413|BIOLOGICAL|HPV 16/18 L1 AS04|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
41376628|NCT00545493|DRUG|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
41376629|NCT00545493|DRUG|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
41376630|NCT03476395|OTHER|shoulder range of motion in IR/ER, strength of the IR/ER muscles and Scapular Dyskinesis Test. Core endurance test.|Passive shoulder range of motion using a digital application Clinometer. Isometric strength of the shoulder IR/ER using a HHD measured. Scapular Dyskinesis Test uses a visual scoring system. Core Endurance is teste by measuring the time (s).
41376631|NCT03733379|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
41376632|NCT03733379|DRUG|Metronidazole and Amoxicillin placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
41376633|NCT03733379|DRUG|Metronidazole|Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
41376634|NCT03733379|DRUG|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
41376635|NCT03733379|DIETARY_SUPPLEMENT|Probiotic|The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
41376636|NCT03733379|DIETARY_SUPPLEMENT|Probiotic placebo|The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
41376637|NCT04381793|DIETARY_SUPPLEMENT|Recovery Factors|Porcine serum amino acid/peptide
41376638|NCT01095458|BEHAVIORAL|Phone versus Clinic Weight Management Programs|To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
41376639|NCT03917654|BIOLOGICAL|Pfs230D1M-EPA/AS01|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
40850532|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 1|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
41376640|NCT03917654|BIOLOGICAL|HAVRIX|HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
41376641|NCT03917654|BIOLOGICAL|TYPHIM Vi (Salmonella typhi vaccine)|TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
41376642|NCT03917654|BIOLOGICAL|Menactra|Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
41376643|NCT03917654|BIOLOGICAL|AVAXIM|AVAXIM - Pediatric \[Hepatitis A Vaccine Inactivated\] is a sterile, whitish, cloudy suspension. The active ingredient is a purified and formaldehyde-inactivated hepatitis A virus (HAV) obtained from the GBM strain, cultured on MRC-5 human diploid cells. HAV is adsorbed onto aluminum.
41376644|NCT01798056|BIOLOGICAL|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
41376645|NCT01798056|DRUG|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
41376646|NCT00294190|DRUG|Topotecan|Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
41376647|NCT04772456|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
41033595|NCT05874479|DEVICE|Active PAC|The active PAC will contain HEPA filters inside the device.
41376648|NCT05863325|DRUG|HB1801|HB1801 will be administered by intravenous (IV) injections on the first day of each cycle.
41376649|NCT05863325|DRUG|Taxotere|Taxotere will be administered by intravenous (IV) injections on the first day of each cycle.
41376650|NCT05794555|BEHAVIORAL|Enhanced Usual Care|Patients will be provided and counseled on two methods which will enhance care. The first is a handout on nutrition recommendations and protein supplementation. This will include the recommendation of both high protein snacks during the daytime (e.g., protein bars) and a high-protein night-time snack (e.g., peanut butter and crackers). The second will be to counsel participants on falls prevention methods that can be enacted in day-to-day life. All participants will be provided with a standard hand-out of Centers for Disease Control and Prevention (CDC)-endorsed fall-risk reduction measures.
41376651|NCT05794555|DRUG|Lactulose|"Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2."
41376652|NCT05794555|BEHAVIORAL|Investigator recommended exercise|Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.
41376653|NCT05794555|BEHAVIORAL|TeleTai-Chi (virtual)|TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables and other device specific equipment to connect devices to televisions will be provided.
41376654|NCT00049010|GENETIC|comparative genomic hybridization|
41376655|NCT00049010|GENETIC|cytogenetic analysis|
41376656|NCT00049010|GENETIC|fluorescence in situ hybridization|
41376657|NCT00049010|OTHER|immunohistochemistry staining method|
41376658|NCT03605277|DRUG|Asciminib|40 mg single dose
41376659|NCT03741543|OTHER|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
41506062|NCT02292173|DRUG|Sorafenib|"Dose Escalation:~Level 1: 200 mg twice daily. Level 2: 200 mg twice daily. Level 3: 400 mg twice daily. Level 4: 400 mg twice daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
41033596|NCT05874479|DEVICE|Sham PAC|The sham PAC will contain no HEPA filters inside the device.
41033597|NCT00987467|DRUG|Cyclosporin 0.05% ophthalmic|Cyclosporine 0.05% ophthalmic solution, 1 drop 6 times in both eyes daily for first month, then 1 drop 4 times in both eyes daily for next month, then dosage was adjusted based on clinical disease by investigator.
41376660|NCT03514446|DRUG|Antibiotic therapy duration for 7 days|Antibiotic therapy for seven days
41033598|NCT06635733|BEHAVIORAL|Rhapsode Capable™ Platform (Intervention Group)|Participants in the intervention group will use the Rhapsode Capable™ platform to facilitate In-Person Skills Practice (ISP) sessions. The platform allows for scheduling ISP sessions, providing real-time performance feedback, and tracking progress. The platform integrates with the PACE adaptive learning modules, which cover pediatric acute care topics. The goal is to improve skills retention and performance in pediatric care through a blended learning approach.
41033599|NCT06635733|BEHAVIORAL|Paper-based ISP (Control Group)|Participants in the control group will also receive In-Person Skills Practice (ISP) sessions facilitated by clinical champions, but without the use of the digital platform. The ISP sessions will be tracked and scheduled using paper-based assessments. Feedback will be provided verbally or manually, and progress will be documented using paper forms. Both groups will receive the same PACE adaptive learning modules, but the method of ISP implementation differs between the groups.
41376661|NCT05819411|BEHAVIORAL|Project iSTRIVE|This intervention includes 6 face-to-face therapy sessions with a trained clinician to develop skills to counter internalized stigma and shame as barriers to HIV self-care. Both the intervention group and the active control group will also receive a mobile app-based iDOT intervention.
41506063|NCT06611280|OTHER|No Interventions|No delivered intervention.
41506064|NCT00660907|DRUG|dapagliflozin|Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
41506065|NCT00660907|DRUG|glipizide|Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
41506066|NCT00660907|DRUG|metformin hydrochloride|Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
41506067|NCT00243412|DRUG|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
41506068|NCT00243412|DRUG|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
41506069|NCT00243412|DRUG|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
41506070|NCT00243412|DRUG|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
41506071|NCT00243412|DRUG|Rituximab|500 mg or 1000 mg IV\*2.
41033600|NCT05153434|DRUG|ARD-101|Twice Daily, Oral Administration
41376662|NCT05819411|BEHAVIORAL|incentivized Directly Observed Therapy (iDOT)|Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.
41376663|NCT00256256|DRUG|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
41376664|NCT05184894|BEHAVIORAL|AKI in Care Transitions (ACT) program|Multicomponent transitional support bundle that includes consultation from nurse educators before discharge to deliver kidney health education and coordination of appointments post-discharge.
41376665|NCT03504501|DRUG|Lovastatin|oral application prior to transcranial magnetic stimulation intervention
41376666|NCT03504501|DRUG|Lamotrigine|oral application prior to transcranial magnetic stimulation intervention
41376667|NCT06329375|OTHER|Nutrition program|Nutrition program with twice daily meal delivery up to 90 days post-discharge and food and diet education at discharge.
41376668|NCT04768504|DRUG|Tofacitinib 10 mg|Tofacitinib 10 mg PO BID for 30 days
41376669|NCT02175927|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
41376670|NCT02175927|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
41376671|NCT02175927|DRUG|Metronidazole|antibiotic of each quadruple therapy
41376672|NCT02175927|DRUG|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
41376673|NCT02175927|DRUG|Tetracycline|antibiotic of classical quadruple therapy
41376674|NCT04434534|DIETARY_SUPPLEMENT|Hipocaloric Diet with Açaí Juçara|Daily consumption of Açaí Juçara pulp (200g) and nutritional adequacy of meals in individualized diet plans calculated for each participant.
41376675|NCT04434534|OTHER|Hipocaloric Diet|Nutritional adequacy of meals in individualized diet plans calculated for each participant.
41376676|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
41506072|NCT02764151|DRUG|PF-06840003|Daily Oral PF-06840003
41506073|NCT03150407|DEVICE|VR101 Device (Efficacy)|Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days
41506074|NCT03150407|OTHER|Sham Control Ring|Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days
41506075|NCT03150407|DEVICE|VR101 Device (Safety)|Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.
41506076|NCT06273501|DRUG|Magtrace|Patients will receive superficial and interstitial injection with a 23 G needle with of a total volume of 0.1 - 1 ml Magtrace at four sites in or near the tumor in vulva, the same localization as the injections of Technetium99m and Patent blue for tracing SLNs performed at the surgery. The injection is performed by one of the gynecologic cancer surgeons participating in this study.The time of migration of SPIO to the groin nodes is not known for vulvar cancer. Transportation by dynamic MRI, with selective sequences repeated during a time span of 1- 60 minutes after the injection.
41506077|NCT04642404|DRUG|Epidiolex 100 mg/mL Oral Solution|Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain
41506078|NCT04642404|DRUG|Placebo|Placebo drug will be a solution with the same taste, texture and color as the drug.
41376677|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
41376678|NCT05324254|DEVICE|Weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
41376679|NCT00352664|DRUG|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
41033601|NCT02143830|DRUG|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
41376680|NCT00352664|DRUG|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
41376681|NCT04492488|DRUG|MRG002|Administrated intravenously
41376682|NCT06549439|RADIATION|Electron FLASH radiotherapy|A nominal electron energy of 9 MeV will be used for both Flash-RT and Conv-RT, which guarantees ≥ 90% dose coverage up to a depth of 2.8 cm. Shallower lesions will be treated with the same electron energy and with a bolus. In order to treat these patients, field sizes between 2x2cm2 and 10x10cm2 will be used, which can be delivered with sufficient flatness (\<5%) and symmetry (\<2%) by the FlashTrueBeam v2.7.5.
41376683|NCT02361801|DRUG|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
40850533|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 2|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
40850534|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 3|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
41164110|NCT03562897|DIETARY_SUPPLEMENT|Ocoxin-Viusid|Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
41376684|NCT02361801|DRUG|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output \< 2 mL/Kg/h despite adequate fluid replacement.
41376685|NCT04985877|DIETARY_SUPPLEMENT|Yakult light 300|2 bottles of fermented Milk containing Lactobacillus casei Strain Shirota per day, Intervention for 12 weeks.
40850535|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 4|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
41376686|NCT05211284|DRUG|Saroglitazar Magnesium 4 mg|Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of study (24 weeks).
40850536|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 5|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
40850537|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 6|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
40850538|NCT03614299|OTHER|Ecological symptom measurements using a webapp|A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)
41033602|NCT02143830|DRUG|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
41033603|NCT02143830|DRUG|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
41033604|NCT02143830|DRUG|rabbit ATG|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
41033605|NCT02143830|DRUG|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
41033606|NCT02143830|BIOLOGICAL|Peripheral blood stem cell|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
41033607|NCT04695327|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
41033608|NCT03862404|DRUG|Bupivacaine-epinephrine|See previous description
41033609|NCT03862404|DRUG|Normal saline|See previous descreption
41033610|NCT06059716|BEHAVIORAL|Gluten detection technology|Portable technology to sense gluten after ingestion
41033611|NCT06059716|BEHAVIORAL|Continuous telemedicine monitoring|Regular follow-up with an expert dietitian
41033612|NCT01559402|PROCEDURE|CPAP and 100% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
41376687|NCT05211284|DRUG|Placebo|Subjects randomized to Placebo arm will receive Placebo treatment until the duration of study (24 weeks).
41506079|NCT02194348|DRUG|BIBN 4096 BS - in single rising doses|
40850539|NCT03614299|DIAGNOSTIC_TEST|Interferometry|Evaluation of the mebomian function using the LipiView methodology
40850540|NCT00983385|DRUG|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
40850541|NCT00983385|OTHER|Observation period|Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
41033613|NCT01559402|PROCEDURE|CPAP and 31% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
41033614|NCT01559402|PROCEDURE|No CPAP and 100% oxygen|This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
41164111|NCT03471897|DIAGNOSTIC_TEST|Glycosaminoglycan plasma score|A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.
41164112|NCT05243537|OTHER|ECG (diagnostic)|ECG collection (once, at rest), in both cases and controls
41376688|NCT00552422|DRUG|domperidone|10mg orally four times per day
41376689|NCT03832426|DRUG|Narlaprevir|100 mg film-coated tablets
41376690|NCT03832426|DRUG|Ritonavir|100 mg film-coated tablets
41376691|NCT04892875|DRUG|Zimberelimab|Zimberelimab will be administered at a dose of 360 mg IV on Day 1 of each 21-day cycle for up to 11 cycles.
41376692|NCT04892875|DRUG|Etrumadenant|Etrumadenant will be administered at a dose of 150 mg by mouth once daily on days 1-21 of each 21-day cycle for up to 11 cycles.
41506080|NCT02194348|DRUG|Placebo|
41506081|NCT00696787|DRUG|Desvenlafaxine Sustained Release (DVS SR)|
41506082|NCT00696787|DRUG|Lyrica® (Pregabalin)|
41506083|NCT00696787|DRUG|Placebo|
41506084|NCT05329662|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency|"* Patients in the two groups will receive two autologous AD-MSC administrations: the group A on day 0 and day 90 ± 7; the group B on day 180 ± 14 and day 270 ± 14.~* Dose: 1.0 x 106 cells/kg patient bodyweight.~* Route: intravenous infusion~ADSCs were collected after the third passage. On the day of transplantation, the ADSCs were harvested, washed twice with NaCl 0.9%, counted and resuspended in NaCl 0.9% in a total volume of 20 ml. Each participant received a dose of 1x10\^6 cells/kg body weight infused through the intravenous route within 30 minutes before being discharged after 24 hours"
41506085|NCT04539652|DRUG|Experimental|Experimental group are treated with TenofoBell®
41506086|NCT05968118|DRUG|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
41506087|NCT05968118|DRUG|Placebo|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections ) Other Name: Placebo
41506088|NCT03760185|DRUG|Brimonidine Tartrate|All subjects will apply brimonidine tartrate to one eye (right eye) only for the duration of study participation.
41506089|NCT03509857|DEVICE|BUZZY(tm)|"Risks associated with the BUZZY(tm) device The intervention group will receive vibration only, with application of the BUZZY device just proximal to the intravenous infusion site immediately before and during propofol infusion.~There are no known risks for the use of the BUZZY(tm) device, which is registered as an FDA class III device (therapeutic massager)."
41506090|NCT03509857|OTHER|No Intervention|No intervention
41506091|NCT06623474|DIAGNOSTIC_TEST|diagnosed by traditional diagnostic markers（such as AFP or CT etc.）|A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).
41506092|NCT01146756|DRUG|AZD6244|MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
41506093|NCT05847803|OTHER|No intervention, questionnaire survey|No intervention, questionnaire survey
41506094|NCT00481117|DRUG|LY2405319|
41506095|NCT00481117|DRUG|Placebo|
41506096|NCT02630979|BEHAVIORAL|Measuring satisfaction, knowledge and bias|Questionnaire based assessment.
41376693|NCT04892875|DRUG|Cisplatin|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
41376694|NCT04892875|RADIATION|Radiation|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
41376695|NCT04536480|BEHAVIORAL|Time Limited Eating|The TLE intervention arm will involve instructing participants to consume their usual kind and amount of food and beverages (all calories) within a pre-specified 8-hour period, fasting for the remaining 16-hours. They will be free to divide their food and beverage intake into as many meals or snacks as desired during the 8-hour period. Participants will be allowed to consume non-caloric beverages (water, tea, coffee) during the fasting period. No energy restriction will be required.
41376696|NCT04536480|BEHAVIORAL|Components Common to All Study Arms.|All participants will receive two hours of standard nutrition counseling recommended for adolescents living with T2D. No specific caloric restriction will be recommended. All participants will maintain their usual lifestyle, including physical activity and sleep patterns. Physical activity and sleep recommendations consistent with the American Academy of Pediatrics guidelines for adolescents will be encouraged but not formally prescribed.
41376697|NCT04536480|BEHAVIORAL|Control|Participants assigned to the control arm will be instructed to consume food over a 12-h or more eating window. No energy restriction will be required.
41506097|NCT05990985|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection (18 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
41506098|NCT05990985|DRUG|RiTUXimab Injection|RiTUXimab Injection (375 mg/m\^2) will be administered by intravenous infusion on day 0 in a 3-week treatment cycle.
41506099|NCT05990985|DRUG|Cyclophosphamid|Cyclophosphamid (750 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
41506100|NCT05990985|DRUG|Vincristine|Vincristine (1.4 mg/m\^2，maximum dose 2mg ) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
41506101|NCT05990985|DRUG|Prednisolone|Prednisolone (100mg/d) will be administered by intravenous infusion on day 1-5 in a 3-week treatment cycle.
41506102|NCT05019443|DEVICE|Wedge Scoring Balloon|Scoring balloon
41506103|NCT05019443|DEVICE|Conventional Balloon|Conventional balloon
41506104|NCT04277962|DEVICE|Triton L and D system for estimation of blood loss at time of vaginal delivery|The Triton L\&D system (Gauss Surgical, Inc., Menlo Park, CA) is an FDA-cleared mobile application on a tablet computer (iPad) that facilitates quantification of blood loss (QBL) by providing an easy to use process and user interface. Dry weights of all potential blood containing substrates are built-in to the device allowing batch weighing with automatic subtraction of dry weights. There is also a V-drape simulator accounting for collected fluids with automatic subtraction of a measured amount of amniotic fluid.
41506105|NCT01284946|DRUG|Exjade|Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
41376698|NCT04536480|DEVICE|Continuous Glucose Monitor|All participants will be trained to wear a blinded continuous glucose monitor sensor using manufacturer educational materials under the supervision of research staff. Participants will be asked to wear the CGM for the duration of the study. During each study visit, the CGM reader will be connected to the site database to create an individual participant report. Participants will be provided enough sensors to replace the sensor every 14 days. The participants and guardians will be educated on how to use the CGM and receive 1:1 coaching on how to change the sensor, which will be completed either independently or under study team guidance. At each weekly phone meeting, study staff will monitor any challenges related to CGM wear, including participant discomfort, skin adherence, and other issues.
41506106|NCT03417635|BEHAVIORAL|Guided focused attention|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The focused attention practice itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
41506107|NCT03417635|BEHAVIORAL|Acoustic music|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The acoustic music track itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
41506108|NCT01328379|DRUG|Dalfampridine-ER 5mg|5mg, twice daily
41506109|NCT01328379|DRUG|Dalfampridine-ER 10mg|10mg, twice daily
41506110|NCT01328379|OTHER|Placebo|placebo, twice daily
41506111|NCT05931978|OTHER|CKD dashboard|Online dashboard that visualizes patients' individual PROM- and clinical data related to their kidney disease.
41033615|NCT00898118|GENETIC|polymerase chain reaction|
41033616|NCT00898118|OTHER|flow cytometry|
41376699|NCT04575415|DRUG|Bevacizumab|Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle
41376700|NCT04575415|DRUG|Erlotinib|Erlotinib 150mg, orally once a day
41376701|NCT04575415|DRUG|Gefitinib|Gefitinib 250mg, orally once a day
41376702|NCT04575415|DRUG|Icotinib|Icotinib 125mg three times a day
41376703|NCT04575415|DRUG|Afatinib|Afatinib 40 mg or clinical routine dose once daily
41376704|NCT04575415|DRUG|Dacomitinib|Dacomitinib 45mg or clinical routine dose once daily
41376705|NCT04575415|DRUG|Osimertinib|Osimertinib 80 mg once daily
41376706|NCT05732025|DEVICE|Electrohydraulic shock wave lithotripsy|Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
41376707|NCT05732025|DEVICE|Rotary atherectomy|Pre-treatment of severe calcified coronary lesions with rotary atherectomy
41376708|NCT06491433|DEVICE|H2-BP|"The patient will have the test device applied to one wrist to measure blood pressure and the control device applied to the upper arm of the same arm to measure blood pressure.~1. H2-BP: The test device is placed on the wrist and presses a button to start pressurising. When the measurement is complete, the systolic and diastolic blood pressure is displayed on the screen.~2. big ben® Sphygmomanometer: The cuff is placed on the upper arm and the pump is pressed manually to inflate. 2 measurers will measure systolic and diastolic blood pressure by connecting 2 stethoscopes separately to one cuff.~Due to the external nature of the study medical device, it is not possible to blind subjects and investigators, so that subjects and measurers are aware of the allocation. Therefore, blinding of subjects and measurers will not be used in this study."
41376709|NCT03621566|OTHER|No intervention|Routine care (registry)
41376710|NCT02900157|BIOLOGICAL|MEDI9090|MEDI9090 will be administered by IV infusion
41376711|NCT02900157|BIOLOGICAL|Durvalumab|Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
41376712|NCT00026156|DRUG|docetaxel|
41376713|NCT00026156|DRUG|vinorelbine tartrate|
41376714|NCT05228990|DEVICE|warm acupunctrue|"The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes."
41033617|NCT00898118|OTHER|laboratory biomarker analysis|
41033618|NCT00898118|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
41376715|NCT04272411|DEVICE|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
41376716|NCT04272411|DEVICE|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
41376717|NCT04272411|DEVICE|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
41376718|NCT00747110|DRUG|budesonide|3x 3mg budesonide capsules once daily
41376719|NCT00747110|DRUG|mesalazine|3x 1000mg mesalazine onc daily
41376720|NCT03014427|OTHER|Biological Database|Biological Database
41376721|NCT04749173|DRUG|DWRX2003, 96mg|Drug: Placebo Intramuscularly injection at predefined injection sites
41506112|NCT06198166|OTHER|Cuevas Medek|Group A: will receive Cuevas Medek (CME) In a following procedure: supporting the patient in balance at the leg level and with slight posterior support. Then, once kept in the air for few seconds, slight up and down oscillations will make. The materials that will be used consists of three wooden boxes with the same dimensions (20cm x 40cm x 60cm), a bigger box, a wooden plate and two planks with the same dimensions (17cm x 80cm). Boxes
41164113|NCT02311985|OTHER|Coagulogram-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR \>1.5 or PTT \>50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen \<150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).
41376722|NCT04749173|DRUG|DWRX2003, 432mg|Drug: Placebo Intramuscularly injection at predefined injection sites
41506113|NCT06198166|OTHER|Standard kinetic programs|Group B: will receive standard kinetic programs consisting of stretching (2 sets 15 repetitions with 5 seconds hold) , passive mobilizations (2 sets of 20 repetitions), orthosis( for 6 hours). These techniques and orthotics devices typically focus on tight muscles, maintain proper foot alignment and to address sensory processing difficulties and promote relaxation. Stretching will focus on the hamstrings and calf muscles tightness.
41506114|NCT00000620|DRUG|Anti-hyperglycemic Agents|Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).
41506115|NCT00000620|DRUG|Anti-hypertensive Agents|Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).
41506116|NCT00000620|DRUG|Blinded fenofibrate or placebo plus simvastatin|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
41506117|NCT01611779|DEVICE|Encore Tongue Suspension System|The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
41376723|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
41376724|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
41376725|NCT05847621|BEHAVIORAL|Peer recovery coaching with linkage to recovery resources|Peer recovery coach (PRC) assessment of the participant's state of change, engage in motivational interviewing techniques, and link the participant to community-based recovery resources according to the needs of the participant. They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.
41376726|NCT05847621|BEHAVIORAL|Usual Care|Participants will be provided with a list of community recovery resources.
41376727|NCT01118949|DRUG|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
41506118|NCT05163392|DEVICE|Silverlon|SIlver-plated biopatch
41506119|NCT05163392|DEVICE|Control|Tegaderm without biopatch
41506120|NCT01795911|BIOLOGICAL|Pegylated Interferon Lambda|
41506121|NCT01795911|DRUG|Ribasphere|
41506122|NCT01795911|DRUG|Daclatasvir|
40850542|NCT00983385|DRUG|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
41506123|NCT02227511|DIETARY_SUPPLEMENT|Fruits|Randomization to extra fruit or nuts as snacks
41506124|NCT02227511|DIETARY_SUPPLEMENT|Nuts|
41506125|NCT00769938|DEVICE|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
40850543|NCT06583746|OTHER|Group1|30 children with DCP were included. The lower extremity evaluations of these cases were made according to ICF. Modified Ashworth Scale (MAS) was used for body structure and functions, Gillette Functional Assessment Questionnaire (FAQ) was used for activity and Pediatric Functional Independence Measure (WeeFIM) was used for participation.
41506126|NCT04589663|DRUG|Mometasone furoate|Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
41506127|NCT04589663|DRUG|QMF149|Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9
41506128|NCT04589663|DRUG|Standard of Care (Soc)|Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)
41506129|NCT01531439|DRUG|Naloxone|Naloxone infusion 0.5 mcg/kg/hr
41506130|NCT01531439|DRUG|Naloxone|Naloxone infusion 2.5 mcg/kg/hr
41506131|NCT00493415|DRUG|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
41506132|NCT00493415|DRUG|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
40850544|NCT02419820|DRUG|APD791|Temanogrel
40850545|NCT02419820|DRUG|Clopidogrel|Clopidogrel
41376728|NCT02103985|DRUG|JNJ-39823277|Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
40850546|NCT02419820|DRUG|Aspirin|Aspirin
40850547|NCT02419820|DRUG|Placebo for APD791|Placebo for APD791
41033619|NCT05403723|DRUG|Durvalumab 50 MG/1 ML Intravenous Solution|Durvalumab (1500 mg durvalumab via IV infusion) in combination with platinum doublet chemotherapy will be administered to patients once every 3 weeks for up to 4 cycles plus SBRT (platinum resistant group) or without SBRT (platinum sensitive group). Each 3-week of chemoimmunotherapy interval is considered a cycle. Patients with platinum sensitive disease will receive the combination of durvalumab and chemotherapy (total of four cycles) while those with platinum resistant SCLC will receive SBRT and continue to receive up to two additional cycles of treatment with durvalumab along with platinum/etoposide (not to exceed a total of four6 cycles of chemoimmunotherapy including 2 cycles obtained prior to SBRT). Following completion of 4-6 cycles of combination therapy, patients in both groups will continue with maintenance durvalumab (1500 mg) in q4w cycles until disease progression.
41376729|NCT02384980|DEVICE|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
41376730|NCT04104152|OTHER|CSD1902-11|A 2.4% nicotine ENDS product
41033620|NCT05403723|DRUG|Etoposide Injection|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
41033621|NCT05403723|DRUG|Cisplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
41376731|NCT04104152|OTHER|CSD1902-12|A 2.4% nicotine ENDS product
41376732|NCT04104152|OTHER|CSD1902-13|A 2.4% nicotine ENDS product
41376733|NCT04104152|OTHER|CSD1902-14|A 2.4% nicotine ENDS product
41376734|NCT04104152|OTHER|CSD1902-21|A 5.0% nicotine ENDS product
41376735|NCT04104152|OTHER|CSD1902-22|A 5.0% nicotine ENDS product
41376736|NCT04104152|OTHER|CSD1902-23|A 5.0% nicotine ENDS product
41376737|NCT04104152|OTHER|CSD1902-24|A 5.0% nicotine ENDS product
41376738|NCT05924009|PROCEDURE|Transcranial Magnetic Stimulation, TMS|"The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in the dominant hand and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are used as reference to determine the best location and stimulation parameters to evoke GEPs.~After identification of the GEP hot-spot, a water load test is administered to determine whether satiety shapes GEP responses.~In subsequent study visits, the water load test is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GEP hotspot."
41376739|NCT03337373|DRUG|cisatracurium|A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
41376740|NCT06033924|BEHAVIORAL|Walking Program: Internet-based|Internet pages allow participants to see step-count goals, progress over time and access to walking tips for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
41376741|NCT06033924|BEHAVIORAL|Walking Program: Telehealth-based|Telehealth sessions allow participants review step-count goals, progress over time and access to walking tips with the study coordinator for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
41376742|NCT03413618|DRUG|Rivaroxaban|15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
41376743|NCT03413618|DRUG|Diosmin|600 mg q.d. for 12 month
41376744|NCT03413618|OTHER|compression stockings|above knee stocking for 12 month
41376745|NCT00544778|BIOLOGICAL|filgrastim|
41376746|NCT00544778|DRUG|dexrazoxane hydrochloride|
41376747|NCT00544778|DRUG|doxorubicin hydrochloride|
41376748|NCT00544778|DRUG|ifosfamide|
41376749|NCT00544778|DRUG|irinotecan hydrochloride|
41376750|NCT00544778|GENETIC|protein expression analysis|
41376751|NCT00544778|OTHER|immunoenzyme technique|
41376752|NCT00544778|PROCEDURE|adjuvant therapy|
41376753|NCT00544778|PROCEDURE|conventional surgery|
41376754|NCT00544778|PROCEDURE|neoadjuvant therapy|
41376755|NCT00544778|RADIATION|radiation therapy|
41506133|NCT03103516|PROCEDURE|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
41376756|NCT02769962|DRUG|EP0057|"EP0057 IV Q 2weeks Day 1 and Day 15, administered in 28 day cycles, until disease progression or development of intolerable side effects~Plus olaparib (PO days 3-13\* and days 17-26\*) administered in 28 day cycles, until disease progression or development of intolerable side effects. P1: Dose Escalation P2: RP2D~(\* On days 13 and 26, only one dose of olaparib will be administered in the morning)"
41376757|NCT02769962|DRUG|olaparib|olaparib (PO days 3-13\* and days 17-26\* administered in 28 day cycles, until disease progression or development of intolerable side effects Plus EP0057 (IV Q 2weeks, Day 1 and Day 15) administered in 28 day cycles, until disease progression or development of intolerable side effects P1: Dose Escalation P2: RP2D (\* On days 13 and 26, only one dose of olaparib will be administered in the morning)
41376758|NCT00190476|DRUG|Weekly docetaxel alone|
41033622|NCT05403723|DRUG|Carboplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
41033623|NCT05403723|DEVICE|Stereotactic Body Radiotherapy|Patients will receive palliative radiation to the primary tumor site up to 30 Gy for 1 week given as 5 daily fractions of 6 Gy each or 27 Gy as 3 fractions of 9 Gy administered every other day.
41033624|NCT00604981|BEHAVIORAL|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
41033625|NCT00604981|BEHAVIORAL|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
41033626|NCT02628054|BIOLOGICAL|Typhoid Vaccine|Typhoid Vaccine injection given 7 days apart
41033627|NCT02628054|BIOLOGICAL|Placebo|Saline injection given 7 days apart
41033628|NCT04434040|DRUG|Atezolizumab|Atezolizumab is a type of antibody and is administered intravenously.
41033629|NCT04434040|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously
41033630|NCT01332877|BEHAVIORAL|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
41033631|NCT01332877|BEHAVIORAL|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
41033632|NCT03562221|OTHER|Gluten free diet|Controlled gluten free diet
41033633|NCT03562221|DIETARY_SUPPLEMENT|Probiotics|Capsules
41033634|NCT03562221|DIETARY_SUPPLEMENT|Placebo|Capsules
41033635|NCT00475059|DRUG|cimetidine arrow|patients who received cimétidine
41033636|NCT04278053|DIETARY_SUPPLEMENT|inositol-stabilized arginine silicate|Participants were asked to complete the experimental protocol in a 2-hour fasted state. Each participant's brachial artery FMD was assessed twice during each trial, once before supplement ingestion, and again 60 minutes post-ingestion. Male participants were required to wait for a minimum of seven days between trials as a supplement washout period. Female participants reported for supplement trials outside of their follicular phase of the menstrual cycle so that results were not confounded by changes in serum estradiol, which can significantly attenuate flow-mediated dilation. Sixty minutes after supplement consumption, each participant was asked which supplement they thought they had consumed. Participants were also asked whether they experienced any adverse side effects.
41033637|NCT05897099|BEHAVIORAL|Comprehensive Tele-harm Reduction|Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.
41033638|NCT05897099|BEHAVIORAL|Off-site Linkage to HIV Prevention|The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
41033639|NCT01496976|DRUG|High Dose Methylprednisolone (HDMP)|HDMP will be administered at 1 gm/m\^2 IV over 90 minutes daily with ofatumumab infusions 1-8.
41033640|NCT01496976|DRUG|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP.
41033641|NCT01496976|DRUG|Lenalidomide|The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
41376759|NCT00190476|DRUG|Weekly docetaxel + cisplatin combination|
41376760|NCT03079648|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
41376761|NCT03079648|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
41376762|NCT01680757|DEVICE|LARIAT Suture Delivery Device and Accessories|
41376763|NCT03590691|OTHER|Vietnam National Hypertension Program|A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
41506134|NCT03103516|PROCEDURE|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
41506135|NCT06505798|PROCEDURE|Catheter Ablation|Participants randomised to the catheter ablation arm will undergo Pulmonary Vein Isolation (PVI) which is the essential ablation intervention. The technique used will be at the discretion of the treating physician but may include Cryoballoon (Medtronic/Boston Scientific), Radiofrequency: CARTO (Biosense), pulsed field radiofrequency ablation, or Precision (Abbott Medical) electro-anatomical mapping systems. Additional ablation lesions may be delivered as preferred by the operator and will be documented. Electro-anatomical voltage maps will be collected (in SR/AF) and stored for later analysis.
41506136|NCT05054504|DEVICE|Butterfly iQ|The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.
41033642|NCT03790176|DRUG|Intravenous Infusion|see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN
41033643|NCT00384228|DRUG|Nilotinib|
41033644|NCT06318026|BEHAVIORAL|Centralized Intervention|A centralized intervention by a social worker or counselor, added to usual care that systematically offers outreach and shared decision-making for symptoms due to alcohol use
41033645|NCT06318026|OTHER|Primary Care Intervention|A primary care intervention added to usual care that uses state-of-the-art implementation interventions to systematically encourage primary care providers to offer routine shared decision-making for symptoms due to alcohol use.
41033646|NCT01201629|DEVICE|t DC stimulation|tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.
41033647|NCT01201629|DEVICE|tDCStimulation|1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
41033648|NCT04297540|DEVICE|Active-tDCS group|Active anodal-tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 1.5mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
41033649|NCT04297540|DEVICE|Sham-tDCS group|Sham -tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA but the current will be applied for 30 sec. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 0mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
41376764|NCT03590691|OTHER|Expanded community health worker services|A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.
41376765|NCT03590691|BEHAVIORAL|Storytelling intervention|The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.
41376766|NCT03590691|BEHAVIORAL|Home blood pressure self-monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
41376767|NCT02804659|OTHER|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
41506137|NCT01121562|DRUG|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
41506138|NCT02845193|DEVICE|Modified Nasoalveolar molding|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is routine step in Grayson's nasoalveolar molding technique).
40850548|NCT04678947|BEHAVIORAL|Baxter Retching Faces (BARF) scale|"* Pictorial scale that was developed for use by pediatric patients in self-reported assessments of nausea severity~* A patient will respond by choosing a picture or a number on the scale that best represents how they feel. The patient may speak or simply point to their response. While the numbers 0-2-4-6-8-10 are listed alongside the pictures, patients are also allowed to choose in between or odd numbers. If a patient is unwilling to participate, the patient's parent or guardian may serve as their proxy and choose a number for them, based off of their symptoms.~* The BARF scale has 6 faces with assigned scores ranging from 0 to 10 with a score difference of 2 between each face (a higher score indicates more nausea)."
41033650|NCT05741593|OTHER|Analysis of the verbatim from the transcription of the recorded interviews.|recorded semi-structured interviews between the patients and the pharmacist
41033651|NCT00071487|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
41033652|NCT00071487|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
41033653|NCT00071487|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
41033654|NCT00071487|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
41033655|NCT04215029|BEHAVIORAL|Exercise Intervention|Receive exercise plan
41033656|NCT04215029|OTHER|Informational Intervention|Receive printed exercise materials
41033657|NCT04215029|OTHER|Informational Intervention|Receive physical activity and healthy eating information/materials
41033658|NCT04215029|OTHER|Interview|Participate in interview
41033659|NCT04215029|OTHER|Nutritional Assessment|Complete nutrition counseling sessions
41033660|NCT04215029|OTHER|Questionnaire Administration|Ancillary studies
40850549|NCT00573014|OTHER|Cervical Spine Clearance|All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
41033661|NCT04215029|BEHAVIORAL|Telephone-Based Intervention|Receive coaching calls
41033662|NCT04216108|DEVICE|Vitrectomy (23G gauge needle)|Vitrectomy surgery with 23G gauge needle technique
41033663|NCT04216108|DEVICE|Vitrectomy (27G gauge needle)|Vitrectomy surgery with 27G gauge needle technique
41033664|NCT05806801|BEHAVIORAL|MICT Exercise|Subjects randomized into this group will complete a moderate intensity continuous exercise 4 days/week.
41506139|NCT02845193|DEVICE|Taping|Infants will receive a tape only on the upper lip segments to mold it to touch each other.
41033665|NCT05806801|BEHAVIORAL|No Exercise (Control)|Subjects randomized into this group will remain sedentary throughout the duration of the study.
41033666|NCT05017740|PROCEDURE|ICSI|In ICSI, the sperm is chosen based on motility and gross morphology to be inseminated directly into the cytoplasm of the oocyte.
41033667|NCT05017740|PROCEDURE|PICSI|In PICSI, the sperm is selected via hyaluronic binding before insemination into the cytoplasm of the oocyte.
41033668|NCT00781976|DRUG|AZD7295|700mg per day maximum
41033669|NCT00781976|DRUG|Placebo|matched placebo
41033670|NCT02446561|DRUG|MRXXX|
41033671|NCT02446561|DRUG|MR1XXX|
41033672|NCT02446561|DRUG|MR2XXX|
41033673|NCT02446561|DRUG|MR3XXX|
41033674|NCT06628921|DRUG|Eptinezumab 100 or 300 mg ev|Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.
41033675|NCT01159496|DRUG|PF-05212377 (SAM-760)|Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
41033676|NCT01159496|DRUG|Placebo|Oral capsule, once daily for 14 days
41033677|NCT06030609|DRUG|Ringer's Lactate Crystalloid Solutions|The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
41033678|NCT06030609|DRUG|Normal saline|The patient will receive NSS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
41033679|NCT01904812|OTHER|Questionnaire about quality of life and satisfaction|
41033680|NCT04133610|DIAGNOSTIC_TEST|Self-sampling using digene HC2 DNA Collection Device|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
41033681|NCT04133610|DIAGNOSTIC_TEST|Self-sampling using Evalyn Brush|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
41033682|NCT03529604|OTHER|Saliva sampling|Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
41506140|NCT02845193|DEVICE|CAD/NAM|computer aided design NAM
40850550|NCT01894243|DRUG|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
40850551|NCT02697188|DRUG|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
40850552|NCT02697188|DRUG|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
40850553|NCT02957968|DRUG|Doxorubicin|60 mg/m2 once every 2 weeks for 4 cycles.
40850554|NCT02957968|DRUG|Cyclophosphamide|cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
40850555|NCT02957968|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.
41033683|NCT03529604|DIAGNOSTIC_TEST|ELISA|Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
41033684|NCT03529604|DIAGNOSTIC_TEST|HPLC|High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
41033685|NCT06237972|PROCEDURE|4-week Perturbation-based balance training|Participants will be asked to walk over a six by two meters computer-controlled movable platform at a self-selected speed. Slip-like perturbations will be induced by the device software that moves the platform 12 inches forward at 0.46 m/s with an acceleration of 9.4 m/s2. Participants will be secured in a safety harness which will be attached to the overhead arch of the platform. Participants will be asked to go to the experimental study cite 11 times. A baseline screening, 8 training sessions, a post-training screening, and a 2 months folow up screening
41033686|NCT06237972|DEVICE|Neuromuscular electrical stimulation|NMES will be applied on tibialis anterior and quadriceps muscles during perturbation-based balance training.
41164114|NCT02311985|OTHER|Thromboelastometry-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex \<80 sec. and A10ex \>40 mm, then no blood transfusion is performed; when CTex \>80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex \<40 mm or A10fib \>10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex \<40 mm or A10fib \<10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).
41164115|NCT02311985|OTHER|Restrictive strategy|The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR \>5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
41164116|NCT05546736|BEHAVIORAL|iCanWork Intervention|Participants will receive RTW support from the VRC and OT.
41164117|NCT03719378|OTHER|Pre Operative Oral Fluids|Patients will be self hydrating prior to their total knee replacement.
41164118|NCT03277560|OTHER|No Intervention as it is an observational study|No Intervention as it is an observational study
41376768|NCT02596009|DEVICE|Breezhaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
41376769|NCT02596009|DEVICE|Ellipta®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
41376770|NCT02596009|DEVICE|Handihaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
41376771|NCT06353217|OTHER|Patient Group (Hypoglycemia Prevention Program)|"The Hypoglycemia Prevention Program:~The patient hypoglycemia profile - this is a set of survey questions about hypoglycemia and related aspects of diabetes care. The questions will be administered as an Epic MyChart message sent to the patient in the week prior to the clinic visit, and in the clinic waiting room on a tablet immediately prior to the patient's primary care provider visit."
41376772|NCT06353217|OTHER|Primary Care Physician Group|The provider hypoglycemia toolkit - this is the report from the patient hypoglycemia profile, which triggers a set of hypoglycemia prevention tools and patient education materials as appropriate. Primary Care Providers will not be exposed to the intervention until all of their patients have completed the Baseline Clinic Visit.
41376773|NCT06353217|OTHER|Clinic Staff Group|Clinic staff will provide the tablet to the participant immediately prior to the patient's primary care provider visit.
41506141|NCT05150847|OTHER|Oxygenation|Oxygenation will be calculated as PaO2/ FiO2 ratio.Static compliance will be calculated as tidal volume divided driving pressure.The potential for lung recruitment will be assessed by means of the R/I ratio (10).
41506142|NCT01308424|DRUG|BTL TML HSV|Sublingual micro-dosing for 7 days
41506143|NCT01308424|DRUG|Matching placebo|sublingual dosing for 7 days
41506144|NCT01499459|GENETIC|autologous mesenchymal stem cell transplantation|Every patient is given 1x106 MSCs per kg infused via peripheral vein.
40850556|NCT02957968|DRUG|Carboplatin|carboplatin IV 1.5 area under curve (AUC) once weekly for 12 weeks.
40850557|NCT02957968|DRUG|Decitabine|Given IV
40850558|NCT02957968|DRUG|Pembrolizumab|Given IV
40850559|NCT03104257|DRUG|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
40850560|NCT03015935|PROCEDURE|visual-assisted entry|First trocar entry will be performed with visual-assisted trocar
40850561|NCT03015935|PROCEDURE|Veress entry|First trocar entry will be performed with Veress
40850562|NCT04000581|OTHER|Best Practice|Receive standard of care
40850563|NCT04000581|OTHER|Physical Activity|Walk for minimum 30 minutes per day
41164119|NCT00523549|DRUG|valsartan|160 mg or 320 mg tablets once a day
41164120|NCT00523549|DRUG|amlodipine|5 mg or 10 mg tablets once a day
41164121|NCT00373022|BEHAVIORAL|exercise intervention|
41506145|NCT02650843|OTHER|DAT SPECT imaging|
41376774|NCT06497595|BEHAVIORAL|Wegovy (2.4 Mg Dose) + exercise & nutrition|Participants will participate in a 26-week, tri-weekly, exercise program. One 45-minute exercise session will be provided via a virtual meeting platform each week and recorded. The participants will be asked to independently repeat each recorded session twice on separate, non-consecutive days of the week without supervision. The program will focus on progressive resistance exercises using body weight, a resistance band and various household items. A weekly follow-up call will be conducted to gather feedback and monitor adherence along with a personal exercise diary that each participant will fill out and bring to each on-site visit. Each exercise session will be performed in small groups and will be administered by a fitness specialist. In addition, participants will receive personal individualized nutritional counseling which will be administered every 2-4 weeks online via ZOOM. A certified dietitian will conduct all diet sessions.
41376775|NCT06497595|OTHER|Wegovy (2.4 Mg Dose) + usual care|Participants will receive dietary guidance as customary among patients with type 2 diabetes (T2D) and obesity monitored in a diabetes clinic. Additionally, general recommendations for physical activity (PA) according to the medical guidelines for PA for T2D will be given. Guidelines recommend 150 minutes or more of moderate to vigorous-intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training (for more physically fit individuals). Incorporate 2-3 sessions/week of resistance exercise on nonconsecutive days, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. Participants in the GHRG will be requested to fill out an exercise diary (report on unsupervised training days) and a 2-day food diary for periodic monitoring which they will bring with them to each on-site visit.
41376776|NCT05298527|BEHAVIORAL|Back Massage|The woman lies face down and a pillow is placed under her forehead. Massage begins with effleurage. Petrissage is started from the sacrum and the hands are lifted up to the nape and repeated 4 times. After the petrissage movement is completed, effusion is applied to the area once. Friction is applied. After rubbing, tapotement is applied to the entire back.
41376777|NCT02072707|PROCEDURE|Epicardial VT ablation|Combined Epicardial and Endocardial VT Ablation
41376778|NCT02072707|PROCEDURE|Endocardial VT Ablation|Endocardial Only VT ablation
41164122|NCT00373022|OTHER|flow cytometry|
41164123|NCT00373022|OTHER|laboratory biomarker analysis|
41164124|NCT00373022|PROCEDURE|management of therapy complications|
41164125|NCT00373022|PROCEDURE|psychosocial assessment and care|
41164126|NCT00373022|PROCEDURE|quality-of-life assessment|
41164127|NCT03477825|DIETARY_SUPPLEMENT|Placebo Oral Tablet|"Group A: Placebo group (n = 10)~* Supplement appearing similar to Herbal formulations~* Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~* Dose: subjects in this group will take 4 placebo tablets per day"
41164128|NCT03477825|DIETARY_SUPPLEMENT|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~* 2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~* Each tablet contains 500 mg of R. cordifolia per tablet."
41164129|NCT03477825|DIETARY_SUPPLEMENT|Triphala|"Group C: Triphala group (n= 10)~* Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~* Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~* Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
41164130|NCT01059526|DRUG|ecallantide|30 mg SC
41164131|NCT03189641|DEVICE|Cilostazol eluting stent system (CES-1)|Implantation of drug eluting stent
41164132|NCT05857514|DRUG|Rectal Indomethacin|Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis
41164133|NCT05857514|PROCEDURE|Prophylactic Pancreatic duct stenting|Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis
41164134|NCT05080842|DRUG|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
41164135|NCT00630136|BEHAVIORAL|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
41164136|NCT00566839|PROCEDURE|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
41164137|NCT00566839|PROCEDURE|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
41164138|NCT03519477|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples
41164139|NCT00033189|DRUG|Coenzyme Q10|
41506146|NCT02268968|DRUG|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
40850564|NCT04000581|OTHER|Questionnaire Administration|Ancillary studies
41164140|NCT05431725|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|The influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.15 μg hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride,disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region.
41033687|NCT06404034|DRUG|Gallium Maltolate|GaM will be provided as 500 mg capsules and will be self-administered once daily by mouth at the assigned dose level on a 28-day cycle (one cycle is 28 days) on an empty stomach. GaM should be taken at least 60 minutes before a meal and at least two hours after a meal. Liquids are allowed
41033688|NCT00747799|DRUG|Sorafenib plus Cisplatin and 5-fluorouracil|"Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~* Sorafenib 400 mg bid per daily . Every 21-day cycles.~* Cisplatin 80 mg/m2 day d1, every 21 days cycle.~* 5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles"
41033689|NCT02807948|DEVICE|Pacemaker, ICD, or CRT device|MRI Scans on SJM device implanted subjects for clinical purpose
41033690|NCT00670774|DRUG|Eculizumab|"* Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.~* Patients will be given 900 mg of eculizumab on Day 1 post-transplant.~* Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant~* At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.~* In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period"
41033691|NCT03726346|DEVICE|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
41033692|NCT02169674|BIOLOGICAL|EngerixB, GlaxoSmithKline Vaccines|
41164141|NCT05431725|BIOLOGICAL|Control Quadrivalent influenza virus vaccine|The Control Quadrivalent influenza virus vaccines are manufactured by Sanofi and are purchased by Pontifical Catholic University of Chile.15μg HA of each of the four influenza strains in 0.5 mL of solution per injection.The routine of administration is intramuscular injection into deltoid region.
41033693|NCT03267680|DRUG|Cyclophosphamide|Given IV
41033694|NCT03267680|DRUG|Indomethacin|Given PO
41033695|NCT03267680|BIOLOGICAL|IRX-2|Given via submucosal injection or SC
41033696|NCT03267680|OTHER|Laboratory Biomarker Analysis|Correlative studies
41033697|NCT03267680|DIETARY_SUPPLEMENT|Multivitamin|Given zinc-containing multivitamin PO
41164142|NCT05666271|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation will be performed by using the Octopus MP electrodes. It is a method of directly measuring the temperature near the surrounding tissue of the target tumor using the Octopus MP electrode, and stopping ablation when the temperature rises above 60 degrees to prevent adjacent organ (gallbladder, gastrointestinal tracts, diaphragm, and heart). If the shape of the tumor is elliptical or irregular rather than circular, using an adjustable tip that can change the length of the active tip of the electrode according to the size of the tumor has the advantage of tailoring the ablation zone.
41164143|NCT05098756|OTHER|Art therapy|The art therapy in this study is once a week, 90 minutes each section for a total of 8-week, and using theme-oriented group art therapy. Each section has one theme, and the researcher guides the elderly to make artistic creations. Each section includes a warm-up phase is 15 minutes, the creative phase is 60 minutes, and sharing phase is 15 minutes.
41164144|NCT00515697|BIOLOGICAL|Ramucirumab|Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
41164145|NCT03497221|BEHAVIORAL|Education intervention|The same description of arm Education intervention.
41164146|NCT03497221|BEHAVIORAL|Visual identity campaign|The same description of arm Visual identity campaign.
41376779|NCT01723371|DRUG|Carvedilol|Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
41376780|NCT05990608|OTHER|Peabody Developmental Motor Scales-2, PDMS|"The Peabody Developmental Engine Scales-2, PDMS, is a standardized norm-referenced test used to determine the motor skill level of children aged 0 to 6, identify delays in engine development, and determine individual needs and challenges. The 2 scalar, which allows children to evaluate rough and thin motor skills, consists of 6 sub-tests and 249 articles. The rough motor scale contains 4 sub-tests and 151 items, including reflex, equilibrium, locomotion and object manipulation. The slim motor scale consists of 2 sub-tests and 98 items, including cognition and visual-motor integration. Using the age-appropriate normal value ranges in the test manual to determine developmental stress risk and level, the coarse motor skills, slim motor skills, and general motor development are categorized as very low, low, below average, above average, high, very high."
41506147|NCT03624907|RADIATION|Daily Stereotactic Body Radiotherapy|After randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion.
41033698|NCT03267680|DRUG|Omeprazole|Given PO
41033699|NCT03267680|OTHER|Placebo|Given via submucosal injections or SC
41033700|NCT03267680|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
41033701|NCT05680103|RADIATION|lateral cephalometry|lateral x-ray beam to capture lateral cephalometry of patients
41033702|NCT05834608|BEHAVIORAL|Mechanical ventilator-assisted ventilation|After the intravenous anesthesia induction, mechanical ventilator-assisted ventilation with AutoFlow mode of the anesthesia machine (Draeger-Perseus) will be applied before intubation.
41033703|NCT01612403|DIETARY_SUPPLEMENT|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
41033704|NCT06635993|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient\&#39;s weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
41376781|NCT04715321|OTHER|CT perfusion examination|CT perfusion was performed with a 64-section multidetector CT scanner. The following CT parameters were used to acquire dynamic data: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability-surface area product (PS), hepatic artery ejection fraction (HAF), hepatic artery perfusion (HAP), and hepatic portal vein perfusion (PVP). And we used these parameters to predict the vascular pattern.
41376782|NCT03638648|DRUG|Capecitabine|Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
41376783|NCT04649931|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
41376784|NCT05361200|BEHAVIORAL|Dynamic high-cadence cycling|Resistance settings will be changed based on entropy of cadence every 3 sessions. Cadence will be set at 80RPM for both groups
41376785|NCT05011357|DRUG|Phenylephrine|Phenylephrine will be administered as an infusion
41376786|NCT05011357|DRUG|Saline Control|Saline infusion
41376787|NCT04131439|DIAGNOSTIC_TEST|Computed Tomography and Magnetic resonance imaging|Preoperative imaging for patients undergoing cochlear implants
41376788|NCT01988194|PROCEDURE|Acupuncture|Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
41376789|NCT00252668|DRUG|Etanercept|
41376790|NCT00252668|DRUG|Methotrexate|
41376791|NCT06174922|DRUG|Prednisolone|Prednisolone for 4 months
41376792|NCT06174922|DRUG|Itraconazole|SUBA-itraconazole for 4 months
41033705|NCT03143218|BIOLOGICAL|RABIPUR®|Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)
41164147|NCT06234813|OTHER|Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen|"TTAS (single measurements)~Clot formation in whole blood under flow (2000 s-1) in a microfluidic flow chamber coated with tissue factor and collagen (T-TAS with AR chip)~1. 500 µL of whole blood for each point;~2. 7 points for each condition;~3. Around 4 mL of whole blood will be needed for each patient or healthy subject;~4. Values for Area Under the Curve (Aritrary Unit), Occlusion Starting Time (min), Occlusion Time (min.) will be reported."
41376793|NCT04221100|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
41376794|NCT01997060|BEHAVIORAL|Intensive Lifestyle Intervention|
41376795|NCT02073591|OTHER|Ceradan Cream|
41376796|NCT02073591|OTHER|Ceradan Wash|
41376797|NCT00007332|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
41376798|NCT00007332|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
41376799|NCT06538493|BEHAVIORAL|JUMPSTART-ANAI|"Patient questionnaire about experiences, preferences, and concerns regarding ACP followed by feedback form with tips for initiating ACP conversation with provider at next clinical visit."
41376800|NCT04707833|DIAGNOSTIC_TEST|Serological testing for COVID-19 infection|"The tests used will be the following:~EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)"
41376801|NCT01017965|DEVICE|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
41506148|NCT03624907|RADIATION|Non-Daily Stereotactic Body Radiotherapy|After randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion.
40850565|NCT05831605|PROCEDURE|venipuncture with near-infrared light|with near-infrared light to locate the veins
41033706|NCT03143218|BIOLOGICAL|RTS,S/AS01|Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)
41033707|NCT03143218|DRUG|SMC with SP+AQ|Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
41033708|NCT03143218|DRUG|SMC placebo|Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
41376802|NCT03352804|OTHER|Screening of MDR Bacteriae|questionnaire will be filled by every patient
41376803|NCT01674010|DRUG|ELND005|
41376804|NCT01674010|DRUG|Lamotrigine|
41376805|NCT01674010|DRUG|Valproic acid|
41376806|NCT01674010|DRUG|Placebo|
41376807|NCT00276458|DRUG|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
41376808|NCT00276458|DRUG|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
41376809|NCT00276458|DRUG|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
41376810|NCT00276458|DRUG|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
41376811|NCT04424732|RADIATION|Stereotactic Body Radiotherapy|This is a prospective study of breast bone only oligometastases (up to three sites). Following systemic treatment and primary tumor control, patients will receive SBRT to all metastatic sites. Data on toxicities and oncological outcomes will be collected for future analysis. There will be no change in the standard systemic therapy nor the local therapy of the primary tumor.
41506149|NCT03430765|BEHAVIORAL|Acceptance and Commitment Therapy|Single 2-hour individual Acceptance and Commitment Therapy coping skills session.
41506150|NCT02072603|OTHER|HITSystem|"Online, automated program designed to overcome current EID barriers by providing efficient prospective tracking of HIV-exposed infants and triggering electronic action alerts for both EID providers and lab technicians when time sensitive interventions are overdue for specific infants."
41506151|NCT02072603|OTHER|Standard of Care|current procedures that follow Kenyan National EID guidelines to diagnose and manage HIV infection among HIV-exposed infants.
41506152|NCT00579566|OTHER|Specimen protocol|The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
41376812|NCT06103162|DEVICE|flexible feeding plate|One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
41376813|NCT03572049|DRUG|SUBA itraconazole|SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
41376814|NCT03572049|DRUG|Conventional itraconazole|Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
41506153|NCT04986384|DRUG|Atoderm SOS spray Aerosol 200ml|A bottle of 200ml topical spray was used on the eczematous skin lesions for itch relief.
41506154|NCT05251610|DRUG|20mg oral propranolol and oxytocin|Participants will receive 20mg of oral propranolol 10minutes prior to initiation of augmentation or induction of labor with oxytocin
41506155|NCT05251610|DRUG|Oxytocin only|Participants will have outright augmentation or induction of labor with oxytocin
41506156|NCT03848390|BEHAVIORAL|Conventional diet|The conventional diet arm will be asked to consume a hypocaloric diet, and they will be allowed to eat at any time of the day with no time restriction.
41506157|NCT03848390|BEHAVIORAL|Modified Time-restricted Feeding|The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.
41506158|NCT03848390|BEHAVIORAL|Physical activity|At least 30 minutes of physical activity per day 5 times per week.
41506159|NCT03848390|BEHAVIORAL|Restricted consumption of sweetened beverages|Restricted consumption of juice, soda, and other sweetened beverages.
41506160|NCT01228578|DIETARY_SUPPLEMENT|Multivitamin supplements B,C and E|One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
41506161|NCT05574608|BIOLOGICAL|CD123-CAR-NK cells|CD123-CAR-NK is an allogenic CD123-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
41376815|NCT00290511|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
41506162|NCT01226407|DRUG|CG200745|Multiple administration (IV) over the cycles untile MTD/LTD
41506163|NCT02351141|OTHER|Hyperpolarized Noble Gas MRI|"Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
41506164|NCT04445597|OTHER|Sampling of tissue|In all groups of participants, tissue from the nasal cavity and olfactory system will be surgically removed
41506165|NCT05437315|BIOLOGICAL|bi-4SCAR GD2/PSMA T cells|Infusion of bi-4SCAR GD2/PSMA T cells at 10\^6 cells/kg body weight via IV
41376816|NCT00290511|DRUG|Mitoxantrone|10 mg/m\^2 IV over 5-30 minutes on Day 2.
41506166|NCT02346266|OTHER|SMART Education|
41376817|NCT00290511|DRUG|Rituximab|375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
41376818|NCT00290511|DRUG|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
41376819|NCT00290511|DRUG|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
41376820|NCT06390280|PROCEDURE|intraoperative Fraction of Inspired Oxygen|Group I intraoperative Fraction of Inspired Oxygen 30%, Group II intraoperative Fraction of Inspired Oxygen 80% applied group.
41376821|NCT03312764|BEHAVIORAL|Online diabetes prevention program|Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
41506167|NCT03101865|DEVICE|FlorenceM|The automated closed loop system (FlorenceM) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
41506168|NCT05629975|DIETARY_SUPPLEMENT|Oral Nutritional Supplements|"Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum\& bifidobacterium (500 mg) every day for 7 days."
41506169|NCT06191835|BEHAVIORAL|myCare Start|The service consists of 2 times 10-minutes semi-structured pharmaceutical interventions between community pharmacist and patient, tailored to the patient's needs, positioned as partner, during the first 6 weeks after treatment initiation.
41506170|NCT03555383|DIAGNOSTIC_TEST|Coagulation factor levels|The minimal functional hemostasis reserve capacity are defined by triggers as hematocrit: 27%, platelets: 30 G/l, Fibrinogen (FI): 1g/l, FII-FV-FVII-FX: 30%, Antithrombin III: 40%, FXIII: 60% levels. The estimate blood volume methodology is used for to determine the amount of allowable blood loss in volume (ml) that does not require replacement based on current and trigger levels. The individualized pyramid of intervention defined as hemostasis reserve capacity are followed at every studied patient. All measurements and calculations are performed before liver transplantation (T1), at arrival on Intensive Care Unit (T2) and 12-24-48 hours after liver transplantation (T3-4-5).
41506171|NCT01577771|BIOLOGICAL|Prevnar13 (manufactured by Pfizer)|Prevnar13 administered IM in the antero-lateral thigh
41506172|NCT02349867|DRUG|Gemcitabine|Given IV
41506173|NCT02349867|DRUG|Sorafenib|Given PO
41506174|NCT02349867|DRUG|Vorinostat|Given PO
41506175|NCT02349867|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
41506176|NCT02349867|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41376822|NCT03312764|BEHAVIORAL|Standard Care|One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
41506177|NCT02349867|OTHER|RosetteSep|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
41506178|NCT02349867|OTHER|DEPfff|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
41506179|NCT03531138|OTHER|Pulmonary Rehabilitation|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week and fill out the exercise follow-up form. Supervised exercise sessions consist of aerobic(treadmill walking, bicycle training, arm ergometer training) and strengthening training(free weights). A 6-min walk test, a 10-meter walking speed test and a 5 times sit to stand test will be performed to determine the exercise capacity of the patient. The tests will be carried out at the beginning and end of rehabilitation. At each testing session, the tests will be performed sequentially by the same physiotherapist, giving 20 minute rest periods within the same day.
41376823|NCT05776407|DRUG|ThisCART19A|Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.
41376824|NCT05776407|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
41376825|NCT05776407|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
41376826|NCT05776407|DRUG|Etoposide|Etoposide is used for lymphodepletion.
41376827|NCT01797068|BEHAVIORAL|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
41376828|NCT01797068|OTHER|Standard of Care|Patients in the standard of care group will experience the usual intake process in the ED setting.
41376829|NCT03857308|BEHAVIORAL|Mindfulness Training|"This stress reduction training will last 14 days and teach participants skills in concentration, monitoring of present-moment bodily experience, and acceptance of experience. Participants are encouraged to mentally welcome all physical and emotional experience. Each day will consist of approximately 25 to 30 minutes of training.~A full explanation of the mindfulness training compared to the reappraisal training could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
41376830|NCT03857308|BEHAVIORAL|Reappraisal Training|"This stress reduction training will last 14-days. Each day consists of 25 to 30 minutes of daily practice in Coping control. Participants are encouraged to reframe and reappraise life events, both past and present, and encouraged to solve personal problems through active change.~A full explanation of the reappraisal stress reduction program compared to the mindfulness program could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
41376831|NCT03209154|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Therapeutic drug monitoring will be performed.
41506180|NCT06550453|DRUG|Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)|"Pabolizumab is an lgG4 subclass monoclonal antibody humanized against PD-l molecules thatblocks the immune escape mechanism of cancer cells by inhibiting the PD-l receptor oflymphocytes, thereby allowing the immune system to destroy them.~In the single-arm study, all enrolled patients received a combination of chemotherapy and immunotherapy, as outlined below:~Pembrolizumab:~Day 1：Pembrolizumab injection 200mg was administered once and repeated every 21 days, expected to last 2-4 cycles. Two vials (200 mg) of pembrolizumab injection should be diluted into 100-200 mL of saline, and the infusion time should be more than 30 minutes.~Chemotherapy (CapeOX regimen):~Day 2: Bevacizumab (7.5 mg/kg) + Oxaliplatin (135 mg/m2) + Capecitabine (1 g/m2, did, d1-d14). Treatment repeated every 3 weeks (q3w) until disease progression or intolerable toxicity."
41506181|NCT03953326|BEHAVIORAL|HeartPhone app|Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)
41376832|NCT03209154|DEVICE|Home blood pressure monitoring|Patients will perform home blood pressure monitoring at home.
41376833|NCT06063980|PROCEDURE|Conventional sinus lift surgery|After graft reflection, sinus membrane is separated from bone or oral mucosa and then bone graft is inserted in between the two structures.
41376834|NCT06063980|PROCEDURE|Two-stage-sinus-lift procedure|Procedure is performed in two stages with the purpose of stage one to separate the oral mucosa from the sinus membrane using a small amount of bone graft and stage two as actual sinus augmentation, which is performed similar to that of conventional sinus lift procedure.
41376835|NCT06037148|BIOLOGICAL|DM-101PX|subcutaneous injection of DM-101PX
41376836|NCT06037148|BIOLOGICAL|Placebo to Match DM-101PX|Placebo to match DM-101PX administered subcutaneously
41376837|NCT02863874|DEVICE|VicrylPlus®|Suture
41506182|NCT03953326|DRUG|Acetylcholine|Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
41506183|NCT03953326|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor
41506184|NCT03953326|DRUG|L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester|This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
41506185|NCT05385549|DRUG|Imatinib Mesylate|Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)
41506186|NCT02908087|DRUG|Victoza® (liraglutide)|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
41506187|NCT02908087|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
41506188|NCT00786409|BIOLOGICAL|Gardasil|0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
41506189|NCT01902225|DRUG|Istodax|
41506190|NCT01902225|DRUG|Doxil|
41506191|NCT00815360|DRUG|intravitreal injection of ranibizumab|intravitreal injection of 0.5 mg ranibizumab
41506192|NCT00815360|PROCEDURE|peripheral laser|ultra-widefield fluorescein angiography guided peripheral laser
41376838|NCT02863874|DEVICE|Vicryl®|Suture
41506193|NCT00815360|DRUG|intravitreal injection of triamcinolone acetonide|intravitreal injection of 4.0 mg triamcinolone acetonide
41506194|NCT00815360|PROCEDURE|macular laser|macular laser to areas of retinal thickening or leakage
40850566|NCT05825976|DIETARY_SUPPLEMENT|Omega-3 Fatty ACids|Intervention consists of two different doses of omega-3: high concentration (Intervention group 1) and low concentration (Intervention group 2).
41376839|NCT02325739|DRUG|FGF401|FGF401 is a FGFR4 inhibitor.
41376840|NCT02325739|BIOLOGICAL|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
41376841|NCT04020614|OTHER|Survey|A survey with 13 questions will be applied to the patients
41376842|NCT03686488|DRUG|TAS 102|TAS 102 35 mg will be administered orally twice daily every 2 weeks.
41376843|NCT03686488|DRUG|Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]|Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
41376844|NCT00351611|DRUG|Lyrica (pregabalin)|150 mg twice a day, oral administration
41376845|NCT00351611|DRUG|placebo|Twice a day, oral administration
41376846|NCT00619658|OTHER|telephone follow-up|subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
41376847|NCT04666870|OTHER|myopia or not myopia|visual acuity, IOL master biometry, the anterior segment with slit lamp, dilated fundus examination and refraction.
41376848|NCT03582657|DEVICE|dental implant (KONTACT N)|Implant-supported prosthetic restoration
41376849|NCT05173025|DRUG|Fimasartan|- Fimasartan group: fimasartan, 60 mg once a day, oral administration
41376850|NCT00306124|DRUG|Levodopa|
41376851|NCT04094402|OTHER|None. It is an observational study|None. It is an observational study
41376852|NCT05761171|PROCEDURE|Biospecimen Collection|Undergo collection of blood and CSF samples
41376853|NCT05761171|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41376854|NCT05761171|DRUG|Calaspargase Pegol|Given IV
41376855|NCT05761171|DRUG|Cytarabine|Given IV and IT
41506195|NCT06282146|PROCEDURE|transcranial magnetic stimulation|non-invasive form of brain stimulation
41506196|NCT02698033|DRUG|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
41376856|NCT05761171|PROCEDURE|Echocardiography|Undergo ECHO
41506197|NCT02698033|OTHER|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
41376857|NCT05761171|DRUG|Fludarabine Phosphate|Given IV
41376858|NCT05761171|DRUG|Hydrocortisone Sodium Succinate|Given IT
41506198|NCT01783886|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
41506199|NCT01783886|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
41506200|NCT01783886|PROCEDURE|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
41506201|NCT03403647|DIETARY_SUPPLEMENT|Vitamin D|Oral daily vitamin D
41506202|NCT00978614|DRUG|Neramexane|"Dosage form:~25 mg immediate release \[IR\] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)"
41506203|NCT05795322|OTHER|Sound healing with tuning forks|"Over the course of a half-hour virtual session, a specially developed triple OM track created by tuning forks was played."
41033709|NCT06636604|OTHER|DSA(Decision Support Algorithm)|Intramuscular injection will be given to 30 volunteer patients using the decision support algorithm.
41506204|NCT05443815|DEVICE|HaemoCer-PLUS|HaemoCer-PLUS
41506205|NCT06297954|DRUG|Metoclopramide|Patients will receive metoclopramide 20 mg IV in a single dose prior to randomization.
41506206|NCT06297954|DRUG|Placebo|Patients will receive placebo 10 ml IV in a single dose prior to randomization.
41506207|NCT02990780|RADIATION|Conventionally fractionated concurrent chemo-radiotherapy|5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.
41506208|NCT02990780|RADIATION|Accelerated hypofractionated concurrent chemo-radiotherapy|5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.
41506209|NCT05577221|DEVICE|High Flow Nasal Air|Administration of air at high flow by using a high flow nasal oxygenation (FiO2 21%) device
41506210|NCT03906552|OTHER|nonpharmalogocial methods|neonates received acupressure (acupressure group) or massage (massage group) before heel lancing procedure
40850567|NCT05825976|OTHER|Control|Supplementation with extra virgin olive oil as a for of positive placebo control.
41033710|NCT01730937|DRUG|Sorafenib|By mouth (PO)
41033711|NCT01730937|RADIATION|stereotactic body radiation therapy|Intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy are allowed.
41376859|NCT05761171|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
41376860|NCT05761171|DRUG|Methotrexate|Given IT
41376861|NCT05761171|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
41376862|NCT05761171|DRUG|Prednisolone|Given PO or via NG, NJ, ND or G-tube
41376863|NCT05761171|DRUG|Prednisone|Given PO or via NG, NJ, ND or G-tube
41033712|NCT02703883|DEVICE|BWST|BWST (six weeks, 3 times/week)
41376864|NCT05761171|DRUG|Revumenib|Given PO or via NG, NJ, ND or G-tube
41376865|NCT05761171|DRUG|Vincristine Sulfate|Given IV
41376866|NCT02612649|DRUG|Ramosetron|Oral
41376867|NCT00054275|DRUG|docetaxel|Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.
41376868|NCT00054275|DRUG|erlotinib hydrochloride|OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
41376869|NCT06422949|DEVICE|Hilotherm® Cooling treatment|Patient will receive cooling treatment with Hilotherm® at hands and feet level from half an hour before taxol treatment start until half an hour after treatment end
41506211|NCT06632314|DIETARY_SUPPLEMENT|Enteral feeding|Enteral feeding will be withheld or continued in very low birthweight neonates during packed red blood cell transfusion. Regional cerebral and splanchnic oxygenation will be measured using near-infrared spectroscopy (NIRS) for 48 hours. Cerebral and splanchnic oxygenation parameters, including cerebral regional oxygen saturation (crSO2), splanchnic regional oxygen saturation (srSO2), the ratio of crSO2 to srSO2 (CSOR), cerebral fractionated tissue oxygen saturation (cFTOE) and splanchnic fractionated tissue oxygen saturation (sFTOE) will be measured immediately before PRBCT (baseline) and at the first, sixth, 12th, 24th, and 48th hours after PRBCT using near-infrared spectroscopy.
41506212|NCT01774708|DEVICE|Pressure sensitive pad|"The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.~This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient."
41506213|NCT01461447|BIOLOGICAL|Modified Vaccinia Ankara|Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
41506214|NCT06633055|DRUG|JH013 injection|JH013 injection is a BAFF-R inhibitor monoclonal antibody
41506215|NCT06633055|DRUG|Placebo|JH013 injections placebo
41376870|NCT05990946|DEVICE|ePRO based Remote Symptom Management provide by a mobile phone app|"Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management. This is facilitated through the Shuyu mobile application, which serves as the platform for monitoring symptoms and communication."
41506216|NCT01065402|DIETARY_SUPPLEMENT|PPB-R-203-Based Meal|PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
41376871|NCT00112086|DRUG|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|
41506217|NCT01065402|DIETARY_SUPPLEMENT|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
41506218|NCT06239857|PROCEDURE|Epidural pulsed radiofrequency|The radiofrequency treatment is applied under sterile conditions in the operating room environment. The target epidural area is reached under fluoroscopy guidance using a radiofrequency needle. After control of the needle position, radiofrequency treatment is given. Radiofrequency parameters are set as maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
41506219|NCT00005195|PROCEDURE|Catheter ablation|
41506220|NCT02072304|BEHAVIORAL|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
41506221|NCT02072304|BEHAVIORAL|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
41506222|NCT03161340|DRUG|Rapamycin|Patients will take Rapamycin 2 days before IVF until 15 days after IVF
41506223|NCT00627510|OTHER|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
41506224|NCT05959252|DRUG|Unfractionated heparin|Unfractionated Heparin protocol with target anti-Xa of 0.3-0.5 IU/mL
41506225|NCT05959252|DRUG|Bivalirudin|Bivalirudin protocol with target aPTT 50-70 seconds
41506226|NCT05018312|BEHAVIORAL|Modified Collaborative Assessment (MCA)|The Modified Collaborative Assessment (MCA) will be assessment of the patients that Is more thoroughly-done, and which will be inspired by the school of Therapeutic Assessment and Collaborative Assessment. It will include the EASE, SCID-interview, PSE, ADOS and SCIP-interviews.
41506227|NCT05018312|BEHAVIORAL|Assessment as Usual (AAU)|Assessment as usual is the standard assessment the patients will receive in the clinic. It includes one or more interviews with a mental health professional in the clinic.
41506228|NCT02715570|DRUG|PC945 - single doses|Safety and tolerability of single doses
41506229|NCT02715570|DRUG|Placebo - single doses|Safety and tolerability of single doses
41506230|NCT02715570|DRUG|PC945 - repeat doses|Safety and tolerability of repeat doses
41376872|NCT00843817|DRUG|Pulmozyme|Pulmozyme® 2.5mg by inhalation
41376873|NCT03334227|DEVICE|High-Flow nasal cannula (HFNC)|The patient will receive HFNC adjusted for SatO2 \> 92% and with, at least, 30 liters of total flow.
41376874|NCT02189200|DIETARY_SUPPLEMENT|oat bran - 40g|oat bran - 40g per day
41506231|NCT02715570|DRUG|Placebo - repeat doses|Safety and tolerability of repeat doses
41506232|NCT06287138|DRUG|ciprofol|Ciprofol will be infused at 0.3，0.4，0.5，0.6，0.7，0.8 mg/kg/h in sequence for 30 minutes at each dose.
41376875|NCT02189200|DIETARY_SUPPLEMENT|refined rice flour- 40g|refined rice flour - 40g per day
40850568|NCT06388798|OTHER|Education|Psychoeducational training
41033713|NCT02649868|PROCEDURE|Transarterial embolization (TAE)|Transarterial embolization
41376876|NCT02848859|BEHAVIORAL|Go! to Sleep|This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.
41376877|NCT02848859|BEHAVIORAL|General Sleep Education|Providing patients information on healthy sleep and habits to promote healthy sleep.
41376878|NCT01876927|OTHER|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
41376879|NCT01876927|OTHER|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
41376880|NCT04404192|DRUG|PH94B|Intranasal administration of 100 microliters to each nostril 4 times a day
41376881|NCT04404192|DRUG|Placebo|Intranasal administration of 100 microliters to each nostril 4 times a day.
41376882|NCT04552223|DRUG|Nivolumab|Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.
41376883|NCT04552223|DRUG|Relatlimab|Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.
41376884|NCT04895436|DRUG|Venetoclax|Oral tablet
41376885|NCT04895436|DRUG|Obinutuzumab|Intravenous (IV) infusion
41376886|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
41506233|NCT03121287|OTHER|Imaging Biomarkers|Whole lung volumetric CT scans
41506234|NCT03121287|OTHER|Pulmonary|Pulmonary Function Tests \& 6 minute hall walk
41506235|NCT03121287|OTHER|Imaging|Cardiac MRI
41506236|NCT03121287|OTHER|Specimen Collection|Blood draw
41506237|NCT04363827|DRUG|Hydroxychloroquine|Hydroxychloroquine
41506238|NCT00256113|DRUG|Saredutant succinate (SR48968C)|
41506239|NCT05489666|DIETARY_SUPPLEMENT|Nature Made Vitamin D3 5,000 IU, 125mcg|Taking a 5,000 IU oral supplement of Vitamin D3, daily, for 8 weeks, may improve strength performance in women who have and are continuing a resistance trained workout regimen. After blood vitamin D levels have been raised to an optimal range, a lower dosage may be assigned as needed from 5,000 IU per day to 1,000-2,000 IU per day.
41506240|NCT05489666|DIETARY_SUPPLEMENT|Placebo|Resistance trained women may not improve their strength performance with low levels of vitamin D in the blood.
41376887|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
40850569|NCT04600583|DEVICE|Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)|All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.
40850570|NCT05248477|OTHER|Premex Protocol|"This protocol presupposes stages during which staff are informed and trained. It is based on the following principles:~* Administration of corticosteroid therapy to all eligible women, independent of the decision about active or palliative care~* A prognostic evaluation in a non-emergency meeting of the obstetricians and neonatologists/pediatricians involved, no longer based only on gestational age, and enabling the team to provide consistent, consensual, and individualized information to parents;~* A joint decision about the obstetric and neonatal (active or palliative) care to be proposed to parents at the end of this evaluation;~* An interview with parents, also on non-emergency basis, to give them information about the child's prognosis and the management proposed, to answer their questions, and to obtain their opinion;~* Management at birth consistent with that decided in consultation with the parents."
41376888|NCT05879341|OTHER|High intensitiy interval training|The participants will perform HIIT at 85% of their heart rate reserve. There will be 8 cycles of high intensity with four minutes of rest intervals in between.
41376889|NCT04700813|DIAGNOSTIC_TEST|search for rare pathogenic mutations|search for rare pathogenic mutations causing diabetes type 2
41376890|NCT00825669|DRUG|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
41376891|NCT00825669|PROCEDURE|Laser ablation|Laser ablation is given to the PVTT.
41376892|NCT04324814|DRUG|SHR-1701|Anti-PD-L1/TGFβ fusion protein
41376893|NCT01284413|DRUG|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
41376894|NCT05828030|PROCEDURE|high flow nasal cannula|the patient receives HFNC after randomization. All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
41376895|NCT05828030|PROCEDURE|Oxygen mask|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
41376896|NCT02720796|OTHER|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
41376897|NCT02333175|OTHER|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
41376898|NCT02535312|DRUG|Cisplatin|Given IV
41376899|NCT02535312|DRUG|Methoxyamine|Given PO
41376900|NCT02535312|DRUG|Pemetrexed Disodium|Given IV
40850571|NCT00461084|DRUG|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
41033714|NCT02649868|DEVICE|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
41376901|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 1|5.0 e5/ kg CD19-BCMA CAR-T positive T cells
41376902|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|1.5 e6/ kg CD19-BCMA CAR-T positive T cells
41376903|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|5 e6/ kg CD19-BCMA CAR-T positive T cells
41376904|NCT00991146|DRUG|canakinumab|canakinumab
41376905|NCT01300741|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
41376906|NCT01300741|DEVICE|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
41376907|NCT01300741|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
41376908|NCT03986216|DEVICE|ReIn-Hand device assisted home-based practice|Practice reach-grasp-retrieve-release at home with the aid of ReIn-hand device
41376909|NCT04939337|DRUG|TH-SC01|Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
41376910|NCT04929834|OTHER|Hydrating emollient + body lotion for immunotherapy-related side effects|Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
41376911|NCT02185027|OTHER|complications and compliance with GIHP recommendations|Description of complications, compliance, major bleeding events, treatments, reversal strategies.
41376912|NCT06323265|DRUG|Adebrelimab + chemotherapy|Adebrelimab: 1200mg, d1, iv (30-60min), Q3W ,up to progressive disease or toxicity intolerable Chemotherapy: etoposide 100mg/m2，d1-3，iv；carboplatin AUC=5-6，d1，iv；or cisplatin 75mg/m2，d1，iv，Q3W，4 cycles；
41376913|NCT06323265|RADIATION|±chest radiotherapy|Chest radiotherapy: 3Gy/15f-18f or 2Gy/20f-25f
41376914|NCT03504527|DRUG|triple combinations|inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
41376915|NCT03504527|DRUG|double combinations|inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
41376916|NCT02378870|DRUG|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
41376917|NCT02378870|DRUG|Placebo|
41376918|NCT04162301|DRUG|CS3002|CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
41376919|NCT05802147|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact
41376920|NCT06515847|OTHER|End of Life Nursing Care Plan|the patients of experimental group were cared according to the nursing care plan based on Kolcaba's comfort theory,
41376921|NCT00327080|PROCEDURE|MRI|
41376922|NCT00327080|DRUG|L-NMMA|
41376923|NCT00327080|DRUG|Acetylcholine|
41376924|NCT00902265|DRUG|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
41506241|NCT06414226|DIETARY_SUPPLEMENT|Krill and Fish Oil vs. Placebo|Participants were prescribed to take a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at an appropriate temperature during the 8-week treatment period. The patients were informed to take 2 of the capsules in the bottle to be taken orally daily in the morning before breakfast and the other 2 capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil or placebo (empty capsule) capsules. The daily intake of EPA+DHA from krill and fish oil was determined as 520 mg and 600 mg, respectively. Krill and fish oil were obtained from Aniqnaturals Superba and Orzax Ocean company, respectively.
41506242|NCT02454855|DRUG|melatonin|"Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg."
40850572|NCT00461084|DRUG|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
40850573|NCT03060200|OTHER|Self-administered online CBT plus therapist check in|The app being tested is comprised of courses, exercises and a behavioural activation component. Courses represent the psycho-educational background of the program, comprising topics such as: information on depression, what is CBT, healthy/unhealthy negative emotions, rational/irrational thoughts, behaviour, social support, relaxation techniques, sleep hygiene, relapse prevention, treatment adherence, and suicide prevention plan. Exercises use the information presented in the courses and follow the structure of a regular therapy session/ therapeutic homework. The following exercises are included in the app: Emotional Pulse, Find Irrational Thoughts, and Change Irrational Thoughts. The behavioural activation component consists in two main exercises: My goals and My Activities.
40850574|NCT03060200|OTHER|Sham self-administered online CBT plus therapist check in|The active placebo intervention will be delivered via the same platform and largely in the same format as the tested app: it will include the same sections and features as the original app, except for the complete exercises. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense psychological well being aspects.
41033715|NCT06257758|DRUG|VIO-01|"VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly. Dosing will be according to body surface area. Based on emerging PK and PD data, alternative dosing schedules may be investigated during the Phase 1 part of the trial. If an alternative schedule is evaluated, the dose and schedule may not exceed the total dose already tested and cleared during the dose escalation.~In Phase 2, participants will receive VIO-01 by intravenous infusion at RP2D and schedule determined during the phase 1 part of the study."
41033716|NCT06634706|DEVICE|RefleXion X1 Radiotherapy System [Imaging Only]|kVCT and FDG-PET imaging using the RefleXion X1 Radiotherapy System in different anatomical regions
41033717|NCT06311214|PROCEDURE|Biopsy|Undergo biopsy
41033718|NCT06311214|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41033719|NCT06311214|PROCEDURE|Computed Tomography|Undergo CT
41033720|NCT06311214|PROCEDURE|Echocardiography|Undergo ECHO
41376925|NCT02871921|BEHAVIORAL|Conversational Engagement|Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
41376926|NCT04420559|OTHER|Intramuscular Injection|Intramuscular Benzathine Penicillin Injection Procedure
41033721|NCT06311214|OTHER|Electronic Health Record Review|Undergo review of SOC RNA testing results
41033722|NCT06311214|DRUG|Enfortumab Vedotin|Given IV
41033723|NCT06311214|OTHER|Immunohistochemistry Staining Method|Undergo IHC assay
41033724|NCT06311214|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41376927|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
41376928|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
41376929|NCT04951895|DIAGNOSTIC_TEST|MRI|MRI of TMJ
41033725|NCT06311214|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41033726|NCT06311214|BIOLOGICAL|Sacituzumab Govitecan|Given IV
41033727|NCT06311214|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
41376930|NCT05825417|DRUG|Selexipag|If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
41376931|NCT05825417|DRUG|Riociguat|If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
41506243|NCT02454855|DRUG|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
41506244|NCT06160219|DRUG|Hydroxycobalamin|prophylactic use of hydroxycobalamin in vasoplegia in high risk patients undergoing cardiac surgeries
41033728|NCT06511791|DRUG|FE 999302|Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
41376932|NCT05825417|DEVICE|CardioMEMS pulmonary artery pressure monitor|Implantation and remote monitoring established with patient initiated daily readings
41376933|NCT05825417|DEVICE|Confirm Rx|Implantation and remote monitoring established with automated daily readings / downloads
41376934|NCT00406497|DRUG|Difluprednate Ophthalmic Emulsion|
41376935|NCT06354127|DRUG|DWP450|The test drug or control drug is injected on the day of administration.
41376936|NCT06354127|DRUG|Botox®|The test drug or control drug is injected on the day of administration.
41376937|NCT00674440|DRUG|F-DOPA|0.08-0.16 mCi/kg once
41376938|NCT00674440|RADIATION|PET scan|
41376939|NCT00646282|DRUG|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH\>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH \<300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
41506245|NCT04795596|PROCEDURE|secondary cytoreductive surgery|resection of isolated recurrent ovarian carcinoma in platinum resistant disease
41506246|NCT04795596|DRUG|Chemotherapy|second line chemotherapy according to investigator's choice
41506247|NCT03132233|DIETARY_SUPPLEMENT|Beta-hydroxybutyrate calcium and magnesium salt|Exogenous ketone body in mineral salt form.
41506248|NCT03132233|OTHER|placebo powder|matched placebo powder to the IMP.
41506249|NCT00071292|BEHAVIORAL|stress reduction program|
41033729|NCT06511791|DRUG|Follitropin delta|The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
41033730|NCT06511791|DRUG|Placebo FE 999302|No active ingredient, subcutaneous injection.
41033731|NCT03447418|PROCEDURE|Multiple breath nitrogen washout|Lung Clearance Index (LCI) will be performed in healthy volunteers with a multiple breath nitrogen washout device.
41033732|NCT02804542|OTHER|Observational|
41376940|NCT00036556|DRUG|Atrasentan|
41376941|NCT06182410|DRUG|Defibrotide|Given intravenously (IV)
41506250|NCT00071292|BEHAVIORAL|meditation|
41506251|NCT02390024|DEVICE|Invasive Mechanical Ventilation|"Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:~Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840"
41506252|NCT03616145|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Experimental Condition
41506253|NCT03616145|OTHER|Light Touch|Comparator Arm
40850575|NCT00848783|DRUG|Irinotecan|
40850576|NCT00848783|DRUG|Cisplatin|
40850577|NCT00848783|PROCEDURE|Surgery|
41033733|NCT02804542|OTHER|Retrospective review|
41033734|NCT04657146|OTHER|Biorepository|"Tumor collection (\> 1cm3): Intraoperatively~Peripheral blood collection:~* Intraoperatively (60mL)~* Post-resection (30mL)~* Post- standard of care treatment (30mL)~Bone marrow aspiration:~* Intraoperatively (10mL)~* Post-resection (5mL)~* Post- standard of care treatment (5mL)"
41033735|NCT00818948|DRUG|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
41033736|NCT00741234|DRUG|SB939|SB939 taken orally in a 4-week cycle.
41376942|NCT00665366|DRUG|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
41376943|NCT00665366|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
41376944|NCT00665366|DRUG|Lithium|Participant's ongoing dose
41376945|NCT00665366|DRUG|Valproate|Participant's ongoing dose
41376946|NCT01441622|DEVICE|AL539 (SRETT)|recording data with AL539 (SRETT)
41376947|NCT02137031|DEVICE|Mini Link REAL-Time Transmitter|Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
41376948|NCT04219046|DRUG|Naloxégol oxalate|Oral administration once daily
41376949|NCT04219046|DRUG|Placebo oral tablet|Oral administration once daily
41506254|NCT05366140|OTHER|Prospective follow-up of patients who have received instrumented lumbar arthrodesis supplemented the Implanet Jazz System(TM)|To assess the clinical outcomes of patients receiving standard of care Implanet Jazz System(TM) at the time of their instrumented lumbar arthrodesis.
40850578|NCT00848783|DRUG|Floxuridine|
40850579|NCT00848783|DRUG|Capecitabine|
41506255|NCT06416046|DEVICE|Gemini laser|Photobiomodulation (810 + 980 nm, 15s/point, 11.8J/cm²) to evaluate healing and pain relief in recurrent aphthous stomatitis. A 0.7mm intraoral tip will be used - spot 0.38cm2 on the extent of the lesion.
41506256|NCT06416046|OTHER|Placebo|Examination and follow-up until the lesion heals spontaneously. The laser will not be activated.
41506257|NCT04807400|DRUG|Inclisiran|Inclisiran Sodium 300mg on Day 1 and Day 90 by subcutaneous injection
41506258|NCT04807400|BEHAVIORAL|Behavioural Support|Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.
41506259|NCT04807400|DRUG|Background lipid lowering therapy|lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
41506260|NCT04264676|DRUG|Metronidazole Oral Tablet|Supplement of metronidazole 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
41376950|NCT01102166|OTHER|Acapella with nebulization|"1. st Phase In this phase the jet nebulizer was connected to the branch end of the Acapella according to manufacturer's recommendations.~   The volunteer did the radio-aerosol inhalation to obtain images of the lung fields scintigraphy static during the period of 300 seconds using an array of at 256x256x16 incidence later, as that encompasses most incidence of lung volume.~2. nd Phase The experimental procedure of this phase was similar to the 1st stage, but what differed was it made an adjustment by placing a pipe T between the mouthpiece and the device Acapella so that the aerosol would be inhaled not pass through the device.~Stage 3 This stage was considered phase control since the aerosol inhalation was performed through the mouthpiece connected directly to the nebulizer as is routinely used in clinical practice as illustrated. The procedure of this phase followed the same protocol of previous phases."
41376951|NCT01456351|DRUG|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
41376952|NCT01456351|DRUG|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
41376953|NCT05136482|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a constant pressure of 25 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). Depending on the condition, the temperature of the water being pumped through the device will be either 6, 8, 10, or 12℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
41376954|NCT04379232|BIOLOGICAL|Screening test for covid ( RT PCR and CT Chest)|Each patient was screened before surgery with RT PCR and CT Chest. Post operatively, if symptoms, patients are tested with RT PCR and CT Chest
41376955|NCT02424851|DRUG|Bortezomib|"1.3 mg/m2 subcutaneously\* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~\*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
41376956|NCT02424851|DRUG|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
41376957|NCT02424851|DRUG|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
41376958|NCT02424851|DRUG|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
41376959|NCT00383929|DRUG|Candesartan cilexetil|32mg oral
41376960|NCT00383929|DRUG|Hydrochlorothiazide|12.5 mg oral
41376961|NCT00383929|DRUG|Hydrochlorothiazide|25 mg oral
41376962|NCT03686085|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
41376963|NCT03686085|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
41376964|NCT06542393|DRUG|Erythropoietin|"* Treatment regimen for hospitalized patients awaiting non-urgent surgeries: Administer EPO 600 IU/kg/week via subcutaneous (SC) or intravenous (IV) route, followed by 300 IU/kg/day via SC or IV 10 days before surgery. If ferritin \< 100 ng/dL, supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 1000 mg/week).~* Treatment regimen for hospitalized patients awaiting non-urgent surgeries with less than 5 days until surgery: Administer 40000 UI of EPO intravenous (IV) attack and supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 2000 mg/week), then 300UI/Kg/day IV or SC of EPO until day of surgery."
41376965|NCT06542393|PROCEDURE|blood transfusion|"After surgery, this group will receive one unit of RBC at the moment of ICU admission.~Hb \> 8 g/dl: 1 unit of RBC. HB \< 8 g/dl: 2 units of RBC."
41376966|NCT04931875|DEVICE|Total body PET/CT (uExplorer)|A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.
41376967|NCT03330977|DEVICE|Compression garments|"Patients will wear the compression garments since 4 months after inclusion in order to have a comparison before and after use.~Usual practice would give to the patient the compression garments at inclusion."
41376968|NCT00870415|PROCEDURE|quality-of-life assessment|
41376969|NCT00870415|PROCEDURE|therapeutic conventional surgery|
41506261|NCT04264676|DRUG|Placebo oral tablet|Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
41376970|NCT00843739|DEVICE|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
41376971|NCT00843739|DEVICE|sham EMST|Four week sham device training program
41376972|NCT04380662|OTHER|Risk factors|"The studied potential risk factors will be the following:~* Socio-demographic: age, sex, place of residence, CSP and income.~* Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc.~* Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain...~* Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA...)"
41506262|NCT02295540|RADIATION|hypofractionated radiation therapy|Undergo hypofractionated IMRT
41506263|NCT02295540|RADIATION|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
41506264|NCT02295540|PROCEDURE|therapeutic conventional surgery|Undergo surgery
41376973|NCT00490399|DRUG|gemcitabine|
41506265|NCT02295540|OTHER|laboratory biomarker analysis|Correlative studies
41506266|NCT03152734|PROCEDURE|Surgical or non-surgical intervention|Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
41506267|NCT05738044|OTHER|No intervention|No intervention
40850580|NCT00011622|DEVICE|Continuous ambulatory subcutaneous glucose monitor|
41376974|NCT00490399|DRUG|cisplatin|
41376975|NCT05046275|OTHER|Data analysis|No intervention, data analysis only
41376976|NCT00582634|DRUG|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
41376977|NCT02524366|DEVICE|Artificial Urinary Sphincter|
41376978|NCT00209560|DRUG|fospropofol disodium|
41376979|NCT03856632|DRUG|Liraglutide|Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
41376980|NCT03856632|OTHER|RFM|The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
41376981|NCT03856632|DRUG|Anti Arrhythmics|The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
41376982|NCT03856632|PROCEDURE|Afib Catheter Ablation|The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
41376983|NCT06178276|DIAGNOSTIC_TEST|behavior|behavioral measurements will be performed during the oral comprehension testing
41376984|NCT06178276|DIAGNOSTIC_TEST|physiology|physiologic (autonomic) measurements will be performed during the oral comprehension testing
41376985|NCT06178276|DIAGNOSTIC_TEST|imaging|central (brain) measurements will be performed during the oral comprehension testing
41376986|NCT02797951|DRUG|Galcanezumab|Administered SC
41376987|NCT04389294|DIAGNOSTIC_TEST|SARS-CoV2 serum antibody testing|Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.
41376988|NCT01412307|DRUG|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
41376989|NCT01412307|DRUG|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
41376990|NCT01412307|OTHER|Bio-specimen Retention|Samples with DNA and without DNA
41376991|NCT05549986|OTHER|Observational|Observational
41376992|NCT02325401|DRUG|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
41376993|NCT02325401|DRUG|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
41376994|NCT02325401|RADIATION|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
41376995|NCT03810027|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary
41506268|NCT05957744|PROCEDURE|Colorectal surgery|Right hemicolectomy, left colectomy, total colectomy, anterior resection
41506269|NCT04726176|BIOLOGICAL|Exposure to COVID-19|To study the exposure of COVID-19 on the brain and executive functioning
41506270|NCT05274555|OTHER|Assessment|"The Upper Limb Short Questionnaire was administered by the researcher in face-to-face sessions with the children and their caregivers.~The lower extremity functions and ambulation levels of the children were evaluated by the researcher using the Vignos Scale.~The Brooke Upper Extremity Functional Rating Scale and ABILHAND-Kids were used to evaluate children's upper extremity functions."
41376996|NCT04176068|COMBINATION_PRODUCT|calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)|Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.
41376997|NCT04612465|BIOLOGICAL|ASC|"Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.~The ASC injection dose is about 1x10\^7 cells of ASC per 1cm\^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu."
41376998|NCT04612465|DRUG|Fibringlue|Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.
41376999|NCT04299126|DEVICE|high absorption pad for blood and pus|High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
40850581|NCT04600934|DEVICE|Shockwave|Shockwave Medical, Inc. Peripheral Lithoplasty® System
41377000|NCT04299126|DEVICE|commercial wound dressing|Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
41377001|NCT00709904|DRUG|Open-label Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery"
41377002|NCT00709904|DRUG|Placebo (for Semuloparin sodium)|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily"
41033737|NCT00741234|DRUG|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
41377003|NCT00709904|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily"
41377004|NCT02823782|OTHER|MRI|MRI and neuropsychological assessment planned for the study for patient and volunteers
40850582|NCT04600934|DEVICE|Plain old balloon angioplasty|POBA
40850583|NCT03777319|DRUG|Spironolactone|Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.
40850584|NCT03777319|DRUG|Prednisolone|Prednisolone will be prescribed for 6 months as the clinical standard of care.
40850585|NCT00767819|DRUG|Everolimus|2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients
40850586|NCT01748721|BIOLOGICAL|anti-endosialin/TEM1 monoclonal antibody MORAb-004|Given IV
40850587|NCT01748721|OTHER|pharmacological study|Correlative studies
40850588|NCT01748721|OTHER|laboratory biomarker analysis|Optional correlative studies
40850589|NCT06288074|DIAGNOSTIC_TEST|Multi-omics tests|Biological sample collection for Multi-omics tests
40850590|NCT03672058|OTHER|Fitness tracker with goal setting and text message feedback|Participants provided with a Fitbit and this will also be linked to Fitabase. The physiotherapist will discuss the participants' baseline physical activity levels and individual patient centred short and long-term goals will be set with each participant. Every week participants will be contacted via text message by their CF physiotherapist. The physiotherapist will review their online data and will provide feedback and encouragement on their progress. Goals will be reviewed for each participant.
40850591|NCT03672058|OTHER|Fitness Tracker only|"Participants will be provided with the Fitbit and educated on how to use it. This will be linked to Fitabase, an online monitoring system for data collection purposes, with the consent of the participants. However no goal setting will be completed and no feedback will be provided to the participants on their physical activity levels"
40850592|NCT00900029|BIOLOGICAL|No HP802 Treatment|
40850593|NCT00900029|OTHER|No HP802 Vehicle Treatment|
41033738|NCT05808725|DRUG|Amlodipine Freeze-Dried Powder for Oral Solution 5 mg|Amlodipine Oral Solution 5 mg is given to T1 Fasting and T2 Fed
41377005|NCT02823782|OTHER|neuropsychological assessment|
41377006|NCT00608075|DRUG|lithium|600 mg - 1800 mg per day
41377007|NCT00608075|DRUG|Lithium|600 - 1800 mg
41377008|NCT03611595|DRUG|Cabozantinib|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
41377009|NCT03611595|DRUG|13-cis-retinoic acid|13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
41377010|NCT04130555|DEVICE|CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
41506271|NCT06124937|DRUG|Empagliflozin 10 MG|The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
41377011|NCT05476809|BEHAVIORAL|smart-cloth assisted home nursing|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
41377012|NCT03083457|DRUG|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
41377013|NCT03083457|DRUG|General anesthetic|Total intravenous anesthesia with a standard protocol
41506272|NCT06124937|DRUG|Placebo|The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital.
41506273|NCT06076460|OTHER|Early Total Enteral Feeding|This group will receive enteral feeding volumes at a rate of 80 ml/kg/day starting within the first two hours after birth. Volumes will increased by 20 ml/kg/day till day 4 (total 140 ml/kg/d) and then 150ml/kg/day on day 5.
41506274|NCT06076460|OTHER|Conventional Enteral Feeding|This group will receive enteral feeding volumes at a rate of 20 ml/kg/day starting within the first two hours after birth and rest of the daily requirement as Total parenteral nutrition. Volumes will be increased by 20 ml/kg/day till day 3 and thereafter by 30 ml/kg/d till 150ml/kg/day on day 6.
41506275|NCT00576446|BIOLOGICAL|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
41506276|NCT02709291|BEHAVIORAL|behavioral parent training|Parents receive up to 6 sessions of the Family Check-Up program
41506277|NCT02709291|BEHAVIORAL|interventionist training|Interventionists are trained in the delivery of the Family Check-Up program and deliver sessions to families in their community
41506278|NCT05418504|DRUG|Dental anesthesia|Dental anesthesia, used to do any dental procedure
41506279|NCT05341830|BEHAVIORAL|Recovery housing|Recovery housing provides housing and other services to individuals who are recovering from substance-use disorders. They provide a substance-free living environment, as well as services to assist residents with life in recovery. These services include connections to employment and educational opportunities, help obtaining documentation such as a driver's license, connection to mutual aid, and assistance building life skills.
41506280|NCT01708018|PROCEDURE|WATSU|"WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.~The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's energy-flow in the so called meridians (energy-channels) of Traditional Chinese Medicine. These meridians are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.~During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4)."
41506281|NCT01696279|DRUG|Lanthanum Carbonate|Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.
41506282|NCT01696279|DRUG|Calcium Carbonate|Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
41506283|NCT03597919|BIOLOGICAL|Sabin IPV|We select one Sabin IPV product, produced by Kunming Bio institute, which is available for China's National Immunization Program in the selected study sites.
41164148|NCT06234813|OTHER|: PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM|"ROTEM (single measurements)~1. ROTEM cups will be added~   * 20 µL calcium reagent (STARTEM)~  * 20 µL of 2,940-fold prediluted r-ExTEM reagent (50,000 fold dilution relative to 340 µL in the cup) added~  * 300 µL spiked PRP at 250 G/L (2.5 mL of PRP/patient)~2. Values for clot time (CT sec, clot formation time (CFT) sec, maximum clot formation (mm) will be reported."
41377014|NCT03083457|DRUG|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
41377015|NCT03083457|PROCEDURE|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
41377016|NCT03083457|PROCEDURE|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
41377017|NCT01073176|OTHER|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
41377018|NCT06466369|DRUG|Tadalafil|tadalafil 2.5 mg, 5 mg
41377019|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
40850594|NCT03665272|PROCEDURE|deepithelialized gingival graft fixation|one group's deepithelialized gingival graft fixed by sutures and other one's by tissue adhesive.
41377020|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
41506284|NCT04174612|DRUG|Cytarabine|100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7
41377021|NCT00692601|DIETARY_SUPPLEMENT|Acute ingestion of identical placebo capsules|10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
41377022|NCT02689505|DRUG|BI 836880|
41506285|NCT04174612|DRUG|Daunorubicin|60 mg/m2/die day 1-3
41506286|NCT04174612|DRUG|Midostaurin|50 mg/bid day 8-21
41377023|NCT02273349|DEVICE|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
41377024|NCT02918318|DRUG|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
41506287|NCT04174612|DRUG|Cytarabine HD|100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7
41506288|NCT04114487|OTHER|dual task balance training|The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
40850595|NCT02713828|DRUG|Phase I: Glembatumumab Vedotin|"Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).~Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs."
40850596|NCT02713828|DRUG|Phase II: Glembatumumab Vedotin|In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response \[PR\] or Complete Response \[CR\]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
41033739|NCT05808725|DRUG|Norvasc 5 mg tablets of Pfizer Labs|Norvasc 5 mg is given to R Fasting
41377025|NCT02918318|DRUG|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
41377026|NCT02918318|DRUG|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
41506289|NCT00802932|DEVICE|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
41506290|NCT00802932|DEVICE|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
41506291|NCT02473926|BEHAVIORAL|Physical Activity|Physical Activity Program Intervention
41506292|NCT02473926|BEHAVIORAL|Questionnaires|Participants in the usual care arm will receive three mailings during the intervention phase.
41506293|NCT02833337|RADIATION|Cone-beam computed topography|This study used a retrospective database of preexisting data that included patients treated as part of routine periodontal and oral surgery therapy for each patient's needs. All the patients signed an inform consent approving using their radiographic data for research purposes.
41506294|NCT03789929|BEHAVIORAL|The Emotional Backpack|In this 4 weeks course participants learn how to process difficult emotions that has been overwhelming in the past. They learn how they can use the support of other people and support other people in the processing emotions within a simple and easy to learn setting.
41033740|NCT05044572|OTHER|Open chain kinetic exercises|Group A will perform open chain kinetic exercises Before the intervention all the participants will perform 20 minutes of warm up and 10 minutes of cool down. The Open kinematic chain exercises(Three sets of each exercise while one set of each exercise will be performed at the setup and remaining two sets will be guided to the patient as a home plan)-:Blackburn exercises ( 20 repetitions ) , Dynamic hug( 10 repetitions), W exercise(10 repetitions), lunges with dumbbells-forward(10 repetitions with half kg dumbbell), upward and diagonal, and Pectoralis minor stretching(3 to 5 stretches)will be performed
41377027|NCT02918318|DRUG|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
41506295|NCT03789929|BEHAVIORAL|Feelings as Powers|In this 3 months course participants learn about the empowering potential of their feelings as well as the difficult aspects of them. In addition to that they learn techniques how to deal with difficult emotions.
41506296|NCT00000812|DRUG|Thalidomide|
41506297|NCT03629197|BEHAVIORAL|Communication skills training|Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient
41506298|NCT03629197|OTHER|Attention control|Physician will review materials based on CDC opioid prescribing guidelines.
41377028|NCT00888472|PROCEDURE|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
41377029|NCT02346071|BEHAVIORAL|Acceptance and Commitment Therapy|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy."
41506299|NCT02404766|OTHER|C0-C1 dorsal glide manual mobilization|
41506300|NCT02404766|OTHER|C7-T1 ventral cranial glide manual mobilization|
41506301|NCT04414618|DRUG|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
41506302|NCT04414618|DRUG|Placebo|Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
41506303|NCT06516211|DEVICE|Clara Pregnancy Test|Multi-Level Pregnancy Test
40850597|NCT05673291|OTHER|No intervention|Volunteers who will be included in the research will be informed about the research and an informed consent form will be signed. Questionnaire evaluating sociodemographic characteristics and working positions; The Extended Nordic Musculoskeletal Questionnaire (7) and measurements made with the Spinal Mouse device for posture analysis will be applied when individuals feel comfortable. Questionnaires and device and posture analysis will be carried out after the purpose of the research is explained to the individuals and their consent is obtained. The data will be analyzed in the SSPS program. Number, percentage, standard deviation and mean from descriptive statistics will be used in the evaluation of the data. The relationship between posture and musculoskeletal pain will be evaluated by correlation analysis. The confidence interval of the research will be 95% and the significance level will be considered as p\<0.05.
40850598|NCT04994301|DIAGNOSTIC_TEST|Lung T1 MRI|Evaluation of lung T1 MRI to Assess Lung Disease
40850599|NCT04150952|OTHER|HRV-based training|Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.
40850600|NCT04150952|OTHER|TRAD training|Traditional endurance training
40850601|NCT03100058|DRUG|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally.
40850602|NCT03100058|DRUG|Placebo|Placebo
40850603|NCT04438291|OTHER|MDL-SHPVP|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
41033741|NCT05044572|OTHER|Forward head posture correction exercises|PatienGroup B participants will perform forward head correction exercise(22) Chin tuck Patient will Stand with upper back against a wall, feet shoulder-width apart. • Face forward, tuck your chin down, and pull head back until it meets the wall. • t
41033742|NCT03872349|OTHER|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
41033743|NCT03872349|OTHER|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in saturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
41033744|NCT00005776|DRUG|Inhaled nitric oxide|Inhaled Nitric oxide at a concentration of 20 ppm
41164149|NCT06234813|OTHER|Thrombin Generation Assay (TGA) in PRP using TF trigger|"TGA (single measurements)~1. The following will be added to well:~   * 20 uL of PRP-Reagent~  * 80 uL of spiked PRP (600 µL/patient at 100 G/L)~  * 20 uL FluCa~2. Values for thrombin activity versus time and the derived parameters incl. lag-time (min), time to peak (min), time to peak (min), ETP (Arbitrary Unit) will be reported."
41377030|NCT02346071|OTHER|Enhanced Usual Care (EUC)|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services."
41377031|NCT00250965|DRUG|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
41377032|NCT03746249|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
41377033|NCT03746249|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
41377034|NCT03673124|DRUG|Ribociclib|600 mg by mouth daily for 21 days followed by 7 days off treatment
41033745|NCT00005776|DRUG|Placebo|100% Oxygen
41033746|NCT05924152|DRUG|Adagrasib|Adagrasib
41033747|NCT05924152|DRUG|Eltrombopag + adagrasib|Eltrombopag + adagrasib
40850604|NCT04438291|OTHER|30-minute educational video|A 30-minute education video (DVD) on HPV, cervical cancer and the HPV vaccine that is designed to enhance HPV vaccine acceptance
41033748|NCT03981458|DEVICE|Hyalofemme|Gel made with hyaluronic acid to be applied vaginally to treat atrophic vaginitis.
41033749|NCT03981458|DEVICE|Ialuril|Bladder instillation of hyaluronic acid to treat recurrent UTI.
41033750|NCT02438618|PROCEDURE|Surgery for Ponto bone anchored hearing aids|
41377035|NCT03673124|DRUG|Letrozole|2.5 mg by mouth daily
41506304|NCT06516211|DEVICE|Professional Marketed Pregnancy Test|Early Pregnancy Test
41506305|NCT02419781|PROCEDURE|Rescue endovascular therapy|endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
41506306|NCT02419781|PROCEDURE|No endovascular therapy|
41506307|NCT00098618|DRUG|sorafenib tosylate|Given orally
41506308|NCT00098618|BIOLOGICAL|recombinant interferon alfa|Given orally
41506309|NCT00098618|OTHER|laboratory biomarker analysis|Correlative studies
41506310|NCT01843738|RADIATION|Radiation therapy|Per standard of care
41506311|NCT01843738|DRUG|Vemurafenib|The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
41506312|NCT03506256|DRUG|Norfloxacin 400 MG|Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
41506313|NCT01700231|PROCEDURE|Liver resection|Liver resection of patient with neoplastic hepatic tumors
41506314|NCT02032680|BEHAVIORAL|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
41033751|NCT06538090|BEHAVIORAL|Early Movers|The intervention includes: 1) an educational resource (i.e., hard-copy handout) developed for this study on the 24-Hour Movement Guidelines provided to parents at 2-month immunization appointments by public health nurses, who will answer any questions, followed by a discussion with research staff. 2) Follow-up support via access to a digital app with evidence-based information and support through an online toolkit, an anonymous forum, as well as weekly text messages that include tips and supportive messaging related to the guidelines.
41377036|NCT02314130|DIETARY_SUPPLEMENT|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
41377037|NCT06565975|DRUG|Oral azacitidine|As per product label, prescribed by treating physician
41377038|NCT02996942|BIOLOGICAL|Factor VIII replacement|Patients receive their usual treatment
41377039|NCT04945980|DIETARY_SUPPLEMENT|Ground beef|Ground beef naturally low in monounsaturated fatty acids or naturally high in monounsaturated fatty acids
41377040|NCT05243472|DIETARY_SUPPLEMENT|Protein nutritional supplement|Participants in the intervention group will receive protein-enriched soups (24-30g of protein). Protein may come from either soy, bean or milk products.
41377041|NCT06465459|PROCEDURE|LAMBRE device implantation|LAMBRE device implantation
41377042|NCT01301157|DRUG|M518101|Proper quantity twice a day
41377043|NCT01301157|DRUG|placebo|Proper quantity twice a day
41377044|NCT01301157|DRUG|Dovonex|Proper quantity twice a day
41377045|NCT04100369|DIAGNOSTIC_TEST|laboratory|Arm
41377046|NCT00940446|DEVICE|Insorb staples|absorbable staples required for wound closure
41377047|NCT00940446|DEVICE|metal staples (Ethicon metal stapler)|wound closure with metal staples
41377048|NCT00823680|DRUG|Placebo|po bid for 4 weeks
41377049|NCT00823680|DRUG|RO5027838|200mg po qd for 4 weeks
41377050|NCT00823680|DRUG|RO5027838|50mg po bid for 4 weeks
41377051|NCT00823680|DRUG|RO5093151|400mg po bid for 4 weeks
41506315|NCT02032680|BEHAVIORAL|In-persons Multi-Family Group Psycho-Education treatment|This intervention will provide the VA's evidence-based MFG. This intervention is delivered to Veterans and their families or other supporters using an in-person format.
41164150|NCT06234813|OTHER|Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis|Global fibrinolytic capacity (Lysis Timer) in 100 µL of PRP (250 G/L) using reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA). Around 1 mL of PRP in total Lysis time in min
41377052|NCT00823680|DRUG|RO5093151|10mg po bid for 4 weeks
41377053|NCT00855634|PROCEDURE|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
41377054|NCT00855634|PROCEDURE|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
41506316|NCT02032680|OTHER|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
41506317|NCT04793594|OTHER|Berg Balance Test|Patients evaluate with Berg Balance Test for balance
41164151|NCT06234813|OTHER|Concizumab|Thrombin generation assay (TGA), microchip flow-chamber assay (T-TAS, rotational thromboelastometry and global fibrinolytic capacity to investigate and compare the effects of mixing concizumab (200, 1000 and 4000 ng/mL) with the main bleed treatment options for persons with GT
41164152|NCT00413075|DRUG|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
41377055|NCT04655365|DRUG|Enzalutamide capsule|160 mg po id
41377056|NCT00840762|OTHER|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
41377057|NCT00840762|OTHER|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
41377058|NCT02912507|DEVICE|Cutera enlighten laser|high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
41377059|NCT02912507|DEVICE|CynoSure PicoSure 755nm laser|high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
41377060|NCT02504060|DRUG|Starch Placebo|
41377061|NCT02504060|DRUG|N-acetyl-D-glucosamine|
41377062|NCT05263024|DEVICE|atrial appendage clip|During cardiac surgery, atrial fibrillation patients were treated with atrial appendage clipping
41377063|NCT02350114|PROCEDURE|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
41506318|NCT04793594|OTHER|Tinetti Balance And Gait Test|Patients evaluate with Tinetti Balance And Gait Test for balance
41506319|NCT04793594|OTHER|Time Up And Go Test|Patients evaluate with Time Up And Go Test for balance
41506320|NCT02067962|BIOLOGICAL|Blood sample|Blood sample
41506321|NCT05166616|PROCEDURE|Biopsy|Correlative studies
41506322|NCT05166616|DRUG|Osimertinib|Given PO
41506323|NCT05166616|DRUG|Triptolide Analog|Given PO
41506324|NCT01557517|DRUG|Clobetasol Oral Rinse|Cycle= up to 4 weeks Patients will rinse oral cavity with 10cc of clobetasol 0.05% oral rinse for 2 minutes 3 times a day.
41506325|NCT01557517|DRUG|Placebo oral rinse|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
41377064|NCT06326723|DRUG|Daridorexant|"25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.)."
41377065|NCT04973670|DRUG|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h for 1-7 days
41377066|NCT04973670|DRUG|Placebo|The same amount of NS containing only sivelestat sodium excipients
41506326|NCT05321004|OTHER|Semi-structured interviews will be conducted - there will be no intervention.|The use of semi structured interviews and questionnaires
41506327|NCT06292221|OTHER|A mobile Health (mHealth) tool called 'DepWatch'|The mobile Health (mHealth) tool 'DepWatch' developed by the study team consists of the DepWatch app that is uploaded on participant's smart phones with their consent and a Fitbit provided to the participants
41377067|NCT01469845|DEVICE|3% hypertonic saline|4 ml dose to be administered every 6 hours
41377068|NCT01583465|DEVICE|Aquamantys|Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
41506328|NCT00118326|BIOLOGICAL|filgrastim|
41377069|NCT01583465|DEVICE|standard electrocautery (Bovie)|Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
41506329|NCT00118326|PROCEDURE|allogeneic bone marrow transplantation|
41506330|NCT03923647|DEVICE|Laparoscopy|Laparoscopic insertion with carbon dioxide via open technique at the umbilicus
41033752|NCT06636487|BEHAVIORAL|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 3 - 5 patients who exercise at home and communicate via tablet-camera. Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks.~Specific exercises are evidence-based; been used in several intervention studies on patients with CRD (eg. COPD). Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations. The education sessions consist of dialogue, reflections around empowerment and better living with CRD. Every sixth education session consists of 25 min Mindfulness exercises developed for CRD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period"
41506331|NCT05012826|OTHER|Osteopathic Manipulative Treatment in addition to Physiotherapy|Participants in this group will receive OMT in addition to the same interventions of PT group. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).
41506332|NCT05012826|OTHER|Physiotherapy|Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 8 weeks. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council.
41506333|NCT00357253|DRUG|capecitabine|This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
41506334|NCT00357253|RADIATION|radiation therapy|Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
41506335|NCT03266939|DRUG|Lorcaserin|10 mg acute administration of lorcasein
41506336|NCT03266939|DRUG|Placebo Oral Tablet|Placebo
41506337|NCT05785884|BEHAVIORAL|Low-carbohydrate diet|A 6 week randomized diet low in carbohydrates
41506338|NCT05785884|BEHAVIORAL|USDA Diet|A 6 week randomized diet aligned with USDA recommendations
41506339|NCT02643667|DRUG|Ibrutinib|-Ibrutinib will be supplied by Pharmacyclics Inc.
41506340|NCT02643667|PROCEDURE|Radical prostatectomy|-Standard of care
41506341|NCT05860114|DRUG|Givinostat|Drug: ITF2357 Givinostat 10mg/mL Dose: 10mg/mL; Dosage form: oral suspension
41164153|NCT01032356|DEVICE|Wrist Extension Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
41164154|NCT02136342|DRUG|chlorogenic acid|
41033753|NCT06636487|BEHAVIORAL|Home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle endurance based exercise; 3-days/weekly for 10-weeks. Exercises are evidence based; used in several intervention studies on patients with CRD (eg. COPD) and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of access to mindfulness exercises and an educationbook. The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to CRD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period"
41033754|NCT06636487|BEHAVIORAL|Control|Receive usual care; medication, scheduled follow up visit and possible phone contact with GP and the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered. If a patient changes their decision and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation).
41164155|NCT01128140|BEHAVIORAL|Motivational Enhancement Therapy|MET, a 30-60 minute telephone session, seeks to increase motivation for change by highlighting inconsistencies between substance use behaviors and beliefs and negative consequences experienced as a result of the behaviors. The counselor will guide the participant in reviewing the Personal Feedback Report (PFR), using MI strategies to elicit the participant's reactions and foster motivation for change. The PFR will show the participant's self-reported alcohol and drug use behavior, consequences of SA, and the participant's perceived and actual descriptive norms for SA behavior. The second phase will target strengthening commitment to change. Counselors will explore with participants the pros and cons of seeking treatment. As the participant verbalizes potential benefits of learning more about treatment, the counselor will use MI skills to encourage elaboration of his/her thinking with the goal of tipping the scale toward a decision to consider taking steps toward treatment.
41164156|NCT01128140|BEHAVIORAL|Education|Participants will receive educational information on the health, psychological, social, and legal consequences of substance abuse. Included in the session will be: legal and behavioral definitions of SA, the social and legal consequences of SA, impact of SA on military duty, a review of the policies on substance use in the military, and treatment resources. The session will be conducted via the telephone and will last from 30-60 minutes. Counselors will present information in a didactic manner and will avoid the use of Motivational Interviewing skills (reflective listening, developing discrepancy, reinforcing participant statements regarding change).
41164157|NCT00001383|DRUG|PSC 833|
41164158|NCT00001383|DRUG|paclitaxel|
41164159|NCT01837797|DRUG|Placebo|Once daily, tablets, orally
41164160|NCT01837797|DRUG|Brexpiprazole 1 mg|once daily dose, tablets, orally
41164161|NCT01837797|DRUG|Brexpiprazole 3 mg|once daily dose, tablets, orally
41164162|NCT04137978|DRUG|ADV7103|Patients receive ADV7103 twice a day at optimal dose.
41164163|NCT04137978|DRUG|Standard of Care|Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
41164164|NCT00566345|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
41164165|NCT00566345|OTHER|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
41164166|NCT00292981|DRUG|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
41377070|NCT06567600|DRUG|Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody|"Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met."
41506342|NCT03636685|DRUG|Anlotinib combined with pemetrexed and carboplatin, phase I|"Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
41506343|NCT03636685|DRUG|Anlotinib combined with paclitaxel and carboplatin, phase I|"Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
41506344|NCT03636685|DRUG|Anlotinib combined with pemetrexed and carboplatin, phase II|Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
41164167|NCT03993496|DIAGNOSTIC_TEST|Abdominal Aortic Aneurysm Sac Pulsatility|"Measurements of aortic wall pulsatility will be performed using trans-abdominal ultrasound through the non-sterile field of the upper abdomen, while the surgeons operate through the groins. The pulsatilty of the aneurysm will then be measured using transverse views in 'M-Mode' of the ultrasound, and measures the aneurysm wall displacement during a cardiac cycle; the minimum diameter (diastole) and maximum diameter (systole) will be measured. These measurements will occur during surgery:~1. Prior to EVAR deployment~2. After EVAR deployment, but before balloon affixation to the aortic wall~3. After EVAR deployment and after affixation"
41377071|NCT02339246|DRUG|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
41377072|NCT02339246|DRUG|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
41377073|NCT03682211|DRUG|Fentanyl Citrate|50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
41377074|NCT03682211|DRUG|Morphine sulphate|10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
41377075|NCT00710008|OTHER|exercise training|3 bouts of exercise at 90%RCP during one week
41377076|NCT06330480|OTHER|Intervention group|Subjects will be invited for a home-based screening (phase 1) that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement for detection of atrial fibrillation. Both home-based tests will be performed with CE-marked medical devices used according to their intended use. A subset of the population will also receive a short questionnaire. Depending on the results of the home-based tests, subjects might be invited for further screening in a diagnostic screening facility (phase 2), that includes collection of physical data, blood, and urine for the assessment of parameters that are indicative of cardiovascular disease, chronic kidney disease, diabetes type 2 or their risk factors. Participants will also receive a questionnaire. Based on the results of the diagnostic screening, participants may be referred to their GP for appropriate treatment according to the prevailing guidelines (phase 3)
41377077|NCT05128552|DEVICE|Lung volume recruitment technique|A self inflating Ambu bag with one way valve , augmentation volume of air within 3 to 4 successive breaths and holding few seconds then coughing
41377078|NCT05128552|OTHER|Traditional chest physiotherapy|Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
41377079|NCT05646342|OTHER|Measure of CO by ECHocardiac Machine|we will realise ETT before and after PLR in all women that eligible of crieria inclusion , in obstetric consultation
41377080|NCT03955016|OTHER|Pulmonary rehabilitation|"Rehabilitation program consisting of 2 weeks inpatient (supervised training 5 times per week), 2 weeks outpatient (supervised sessions 3 times per week) and 11 weeks home-based exercise training (weekly phone call).~During the inpatient phase, patients will receive on top of the supervised training sessions a consultation of the dietitian, PH psychologist, social worker and specialized nurse. During the ambulatory rehabilitation phase patients will have 2 session with the occupational therapist.~Every supervised training session contains:~1. Interval training on a cyclo-ergometer~2. Strength training of the upper and lower extremities~3. Guided walks"
41377081|NCT04757896|PROCEDURE|Lateral costoclavicular approach|USG guided lateral costoclavicular approach for brachial plexus block
41377082|NCT04757896|PROCEDURE|Medial costoclavicular approach|USG guided medial costoclavicular approach for brachial plexus block
41377083|NCT02135276|DRUG|eravacycline|All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
41377084|NCT00734188|DRUG|PTI-6D2|monoclonal antibody
41377085|NCT00241059|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
41377086|NCT04212624|OTHER|Human retinal pigment epithelial (HuRPE) cell injection|Human retinal pigment epithelial cell injection Dosage form and specifications: injection; 600,000 cells / branch (200μl), 1 million cells / branch (200μl), 2 million cells / branch (200μl) Transportation and storage: sealed, stored at 2-8 ° C, valid for 6 hours
41377087|NCT00833391|DRUG|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
41377088|NCT00390338|BIOLOGICAL|polarized dendritic cells|
41377089|NCT00390338|BIOLOGICAL|non-polarized dendritic cells|
41377090|NCT05019872|BEHAVIORAL|(Components of) pasta meal|Samples will be provided one by one in cups labeled with an unique code.
41377091|NCT00632866|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
41377092|NCT00632866|DRUG|Placebo|Placebo : 2cp/ day since 24 weeks
41377093|NCT05562232|DIETARY_SUPPLEMENT|Creatine Monohydrate|Follows
41377094|NCT00717808|DRUG|Tranilast|Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
41033755|NCT04719793|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
41377095|NCT00717808|DRUG|Placebo comparator|The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
41377096|NCT06417853|BIOLOGICAL|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) Injection
41377097|NCT06417853|COMBINATION_PRODUCT|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA)|12 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
41377098|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA)|25 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
41377099|NCT06417853|BIOLOGICAL|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) with MF59® Injection
41506345|NCT03636685|DRUG|Anlotinib combined with paclitaxel and carboplatin, phase II|"Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent"
41506346|NCT02524457|OTHER|This is an observational study. There are no interventions|
41506347|NCT06551584|DRUG|ORCA-T|On Day 0, participants will receive an infusion of Orca-T HSPCs and Orca-T Tregs. On Day +2 or +3 (between approximately 48 to 72 hours of Day 0), patients will receive an infusion of the Orca-T Tcons. There is no dose escalation or de-escalation planned for the Orca-T investigational product.
41506348|NCT00775125|DRUG|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
41506349|NCT01722201|DRUG|Risperidone Tablet 1 mg|1 mg tablet once a day
41506350|NCT01722201|DRUG|Risperidone|1 mg tablet once a day
41506351|NCT01783912|BEHAVIORAL|Cognitive / Motivational Individual Sessions|Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
41033756|NCT04672551|BEHAVIORAL|EMDR Treatment|Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
41033757|NCT01184066|BEHAVIORAL|ACTS Intervention|ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence.
41377100|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant)|12 mcg Influenza A (H7N9) with 4 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
41377101|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant)|12 mcg Influenza A (H7N9) with 8 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
41377102|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant)|20 mcg Influenza A (H7N9) with 3.3 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
41377103|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant)|20 mcg Influenza A (H7N9) with 6.7 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
41377104|NCT06417853|DEVICE|Microarray Patch Delivery System|Vaccine free Microarray Patch Delivery System (VXS-1219U)
41377105|NCT03106701|PROCEDURE|Ablation|Epicardial Radiofrequency ablation
41377106|NCT01164280|OTHER|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
41506352|NCT01783912|BEHAVIORAL|Attention Control Individual Sessions|Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
41506353|NCT01783912|DRUG|Nicotine Patch|Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
41506354|NCT01783912|BEHAVIORAL|Group Curriculum|Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
41506355|NCT03399708|DRUG|Apremilast 30mg|Apremilast will used in line with its license. This includes the standard dose titration scheme (see section 6) and then the usual maintenance dose of 30 mg twice daily orally.
41506356|NCT00373633|PROCEDURE|Thoracic Epidural|Gold standard for post thoracotomy pain
41506357|NCT00373633|PROCEDURE|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
41033758|NCT01184066|BEHAVIORAL|Usual Care|Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics.
41506358|NCT00612664|DRUG|Anti-CD137 (4-1BB) (BMS-663513)|IV solution, IV, until PD or toxicity
41033759|NCT02979262|BEHAVIORAL|Fathers for Change|
41033760|NCT02979262|BEHAVIORAL|Parent Education|
41033761|NCT00177229|BEHAVIORAL|Family-based treatment|20 weekly group contacts with individual coaching over first 6 months, brief monthly contacts over next 6 months, no contacts over last 6 months. Medical monitoring throughout study period.
41033762|NCT04066114|BIOLOGICAL|lulizumab pegol|25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)
41164168|NCT04068285|OTHER|Aerobic Exercise|Participants will be making aerobic exercise
41164169|NCT00554944|PROCEDURE|Esophageal probe|Near-infrared spectroscopy (NIRS) sensor, polarographic-type tissue oxygen sensor (Licox®, esophageal probe
41164170|NCT03453203|OTHER|Osteopathic Manipulative Treatment Using Counterstrain|Described in arm/group descriptions
41164171|NCT06401785|DIETARY_SUPPLEMENT|Hydrogen capsules|In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks.
41377107|NCT06567886|DEVICE|Light Therapy|"Participants will self-administer the daily light therapy within a few minutes of their assigned wake up time for one hour.~Researchers will provide a light log to note light on/off times, any interruptions to light therapy, and primary activity during light therapy."
41377108|NCT06567886|BEHAVIORAL|Sleep Stabilization|All participants will be asked to follow a fixed sleep schedule.
41506359|NCT03229200|DRUG|Ibrutinib|Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
41506360|NCT03951324|OTHER|Interobserver agreement or Interrater agreement|Interobserver agreement or Interrater agreement using 9 visual criteria for diagnosing VLE clips that feature indeterminate biliary or pancreatic duct strictures
41377109|NCT06493110|PROCEDURE|Gastric ultrasound|To compare gastric volumes in standard fasting state before surgery in diabetic and non-diabetic pregnant women by evaluating the gastric antrum with ultrasound.
41506361|NCT05501990|BEHAVIORAL|Health intervention based on intelligent applet|Patients are jointly managed by a MDT team based on the applet. The supportive intervention based on the applet mainly includes three parts: Nutrition, psychology, and patient management which includes four main parts: Cancer patient education, self-management, patient community, and real-time communication.
41506362|NCT04462432|OTHER|no intervention|This is an observation study, with no intervention.
41506363|NCT03062384|DIETARY_SUPPLEMENT|AT-001|
41033763|NCT04066114|BIOLOGICAL|antithymocyte globulin (rabbit)|Study participants are administered four doses of rabbit anti-thymocyte globulin, total dose 6 mg/kg given in divided doses on the day of transplantation and days 1-3.
41033764|NCT04066114|DRUG|methylprednisolone|500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
41033765|NCT04066114|BIOLOGICAL|tocilizumab|8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)
41033766|NCT04066114|DRUG|Prednisone|"Beginning on Day 3 post transplantation, taken orally: 60 mg daily~* Days 4 through 10: 30 mg daily~* Days 11 through 17: 20 mg daily~* Days 18 through 24: 10 mg daily~* After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol"
41033767|NCT04066114|DRUG|everolimus|Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.
41033768|NCT04066114|BIOLOGICAL|belatacept|5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)
41033769|NCT04066114|DRUG|mycophenolate mofetil|mycophenolate mofetil is started no later than one day after transplant at 1000mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do no tolerate everolimus can stay on or switch back to mycophenolate mofetil 1000 mg twice daily and remain in trial.
41033770|NCT04066114|DRUG|mycophenolic acid|mycophenolic acid is started no later than one day after transplant at 720mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do not tolerate everolimus can stay on or switch back to 720 mg twice daily of mycophenolic acid and remain in trial.
41033771|NCT04571398|OTHER|ApricityRx mobile application|AE detection and monitoring software
41033772|NCT00941187|OTHER|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
41033773|NCT04639453|DIAGNOSTIC_TEST|Trunk strength with hand-held dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various trunk muscle groups in flexion, extension, and lateral (N).
41033774|NCT04639453|DIAGNOSTIC_TEST|Balance Assessment in Sitting and Standing test (BASS)|"The BASS is a test to assess static and dynamic sitting and standing balance, which has been validated for post-stroke hemiparetic patients. Each test is evaluated by a score from 0 (patient needs external support) to 4 (stable without external help) for static condition and from 0 (no possibility to pick up objects) to 3 (objects picked up without external help) for dynamic condition. The maximal score (sitting, standing, static and dynamic) is 14 points."
41033775|NCT04639453|DIAGNOSTIC_TEST|Timed Up and Go test|The participant sits on a chair, gets up, walks 3m, makes a half turn in 1m2, walks 3m and comes back to sit on the chair. The time (s) to complete the task is measured.
41033776|NCT04639453|DIAGNOSTIC_TEST|Modified Functional Reach Test (MFRT)|The MFRT is a dynamic seated balance test that measures the trunk's ability to move forward, to the paretic and non paretic side (cm).
41033777|NCT04639453|DIAGNOSTIC_TEST|Joint Position sense test (trunk)|The joint positional sense test of the trunk consists in evaluating the positional error of the trunk in the sagittal plane (mm) and in the frontal plane (mm) during a trunk flexion posture (target position).
41033778|NCT04639453|DIAGNOSTIC_TEST|Unstable sitting in a seesaw|This test evaluates the balance capacities of the subject in an unstable sitting position on a seesaw (mediolateral or anteroposterior instability) with forceplate and phone application using center of pressure variables: total displacement (mm), area (mm2), deltas (mm), mean velocity (mm/s) et maximal velocity (mm/s).
41033779|NCT06442436|DRUG|Nemtabrutinib|25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.
41033780|NCT05440864|DRUG|Tremelimumab|Pre-operatively Tremelimumab will be administered first for 1 hour; the Durvalumab infusion (1hr) will start approximately 1 hour (maximum 2 hours) after the end of the Tremelimumab infusion. Post-operatively patients will receive Durvalumab Q4W to complete up to 12 months of treatment or a maximum of 11 cycles of adjuvant Durvalumab
41033781|NCT03550313|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
41033782|NCT03550313|BIOLOGICAL|Prevnar 13|Pneumococcal conjugate vaccine
41377110|NCT06123624|DRUG|Desflurane Inhalation Solution|Keeping the anesthesia using desflurane inhalation solution as 1 minimal alveolar concentration
41033783|NCT02953626|BEHAVIORAL|Mother Matters Online Postpartum Support Group|"Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared."
41033784|NCT00021762|BIOLOGICAL|HIV-1 Immunogen|
41033785|NCT00021762|PROCEDURE|Structured Treatment Interruption|
41377111|NCT06123624|DRUG|Sevoflurane Inhalation Solution|Keeping the anesthesia using sevoflurane inhalation solution as 1 minimal alveolar concentration
41377112|NCT05852106|OTHER|"Surgical Simulation with 3D Heart Model and Parental Education with Congenital Heart Disease Parent Education Booklet and tailored 3D Heart Modeling"|The first step in the modeling process is masking. For this study, the average minimum value for masking ventricles and large vessels was set between 80 and 200 HU (Brüning et al., 2022). Threshold values of min 216 HU - max 1502 HU are used. At these HU values, the blood in the heart and great vessels is masked and the outline of the heart is revealed. Lowering the minimum HU value is necessary to make the heart walls more visible. However, this results in masking unwanted soft tissues other than the heart, such as muscle and fat. The masked unnecessary surrounding tissues are removed first with the cropping mask and then manually by marking along the contours of the heart and great vessels. Thus, a model containing only the heart and the desired large vessels will be created and cleaned from the surrounding tissues. With this mask, 3D reconstruction will be performed, and the model will be ready for printing.
41377113|NCT03818542|DRUG|ABBV-181|intravenous infusion
41377114|NCT03818542|DRUG|ABBV-368|intravenous infusion
41377115|NCT03818542|DRUG|ABBV-927|intravenous infusion
41033786|NCT02510495|PROCEDURE|"30 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
41377116|NCT03818542|DRUG|ABBV-927|intratumoral injection
41377117|NCT03356470|OTHER|F-FDG PET/CT|F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
41506364|NCT03062384|DIETARY_SUPPLEMENT|Placebo|
41506365|NCT04767438|OTHER|Pregnant women|All pregnant women that present to the 12-week scan in the Obstetrics Unit
41506366|NCT02461251|DEVICE|Rotational Thromboelastometry (ROTEM)|A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
41506367|NCT01194167|DRUG|Eltrombopag|75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
41164172|NCT01495234|DEVICE|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
41164173|NCT01495234|DEVICE|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
41506368|NCT06552039|OTHER|Polyherbal Hair Oil|Apply oil with the help of fingertips on your scalp and massage it gently enabling it to penetrate into the roots (follicle) of your hair. Don't apply with your palms and never rub it vigorously as it may uproot weak hair. Let the oil gradually seep into follicle of your hair \& nourish them for the whole night. The oil may be removed in the morning by washing of hair with Ayurvedic Shampoo. Dosage form: liquid frequency: Three times a week Route of Administration: Topical
41164174|NCT03749148|DRUG|Dupilumab|anti-IL4-Receptor alpha
41506369|NCT06552039|OTHER|Minoxidil Herbal Hair Oil + Minoxidil 5 (%) Hair Serum|"First, apply the herbal hair oil generously to your scalp and hair, ensuring thorough coverage. Gently massage it in with your fingertips to promote circulation and absorption. After the oil application, follow the instructions provided for the application of the minoxidil hair serum. Apply the serum to the areas of your scalp where you desire hair growth, using the dropper provided or as directed. Massage it gently into your scalp to ensure even distribution and absorption. Leave the serum on without rinsing.~Dosage form: liquid Frequency : For Minoxidil - Daily Night Application For Herbal Hair Oil- Thrice a week.~Route of Administration: Topical"
41506370|NCT06552039|OTHER|Minoxidil Hair Serum|Apply the amount prescribed to the area of the scalp being treated, beginning in the center of the area. Dosage form: liquid Frequency : Daily night Application of Minoxidil Route of Administration: Topical
41164175|NCT03749148|DRUG|Placebo|Placebo
41164176|NCT02645773|DEVICE|non-ablative laser|non-abaltive laser pre, immediate and post wounding
41164177|NCT00978783|DEVICE|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
41377118|NCT02195271|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
41377119|NCT02195271|DRUG|Melatonin|
41377120|NCT00584831|DEVICE|senofilcon A|toric contact lens
41377121|NCT00584831|DEVICE|balafilcon A|toric contact lens
41377122|NCT00584831|DEVICE|omafilcon A|toric contact lens
41377123|NCT00584831|DEVICE|lotrafilcon B|toric contact lens
41377124|NCT02724215|DEVICE|Sleep Apnea Screening (Out of Center Polysomnography Device)|
41377125|NCT00144859|DRUG|SB681323|
41377126|NCT04144309|PROCEDURE|Electroacupuncture (EA) and Auricular Acupressure (AA)|"EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments."
41033787|NCT02510495|PROCEDURE|"60 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
41033788|NCT02510495|PROCEDURE|"180 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
41033789|NCT02510495|PROCEDURE|"300 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
41033790|NCT05008354|DRUG|Pyridoxine|Pyridoxine tablet 40mg once daily
41033791|NCT05008354|DRUG|Placebo|Placebo tablet once daily
41033792|NCT06631586|BIOLOGICAL|MTP-101C|MTP-101C composed of double-encapsulated freeze-dried healthy donor microbiota. The fecal microbiota is frozen in the presence of a lyoprotectant (trehalose), freeze-dried, and double encapsulated into hypromellose capsules (Lonza, Morristown, NJ). Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
41033793|NCT06631586|BIOLOGICAL|MTP-101S|MTP-101S contains identical healthy donor microbiota double encapsulated in VCaps Plus (Lonza). These capsules are also composed of hypromellose but disintegrate in the proximal small bowel. Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
41033794|NCT04347681|OTHER|convalescent plasma from recovered COVID 19 donor|After obtaining informed consent, Eligible Patients who have severe COVID-19 and have not recovered yet will be infused with the donated convalescent plasma (10-15 ml/kg body weight of recipient)19 at least once \& if possible, daily, for up to 5 sessions.
41033795|NCT06636162|DRUG|DSP-0390|DSP-0390 will be administered orally with preferably 200 mL of water, or approximately one-half cup water. The patient will take DSP-0390 after a minimum of a 6-hour fast and will fast for 1 hour after taking the dose.
41033796|NCT04094454|DEVICE|special tampon with a diameter of 28mm|patients will use a special tampon with extended vaginal dilatation (diameter 28mm) during radiotherapy
41033797|NCT04094454|DEVICE|standard tampon with a diameter of 12-13mm|patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
41033798|NCT02170168|OTHER|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
41033799|NCT04401579|OTHER|Placebo|The matching Baricitinib placebo contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating for the placebo tablet is identical to that of the corresponding active tablet.
41033800|NCT04401579|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
41033801|NCT04401579|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
41033802|NCT00244504|DRUG|moxonidine|moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
41033803|NCT06515912|OTHER|Ketogenic Diet|A ketogenic diet with 5% carbohydrate, 18% protein, and 77% fat by percent kcal.
41164178|NCT00978783|DEVICE|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
41164179|NCT06195878|DEVICE|CPAP Therapy|Continuous positive airway pressure (CPAP) therapy in the management of moderate-to-severe sleep-related breathing disorders (SRBDs)/sleep apnea.
41164180|NCT02899819|OTHER|meconium|The meconium will be sampled in the first 2 days of life
41377127|NCT04144309|PROCEDURE|Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)|"SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure."
41164181|NCT02570256|BEHAVIORAL|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
41377128|NCT05109169|COMBINATION_PRODUCT|FINGER 2.0 multidomain lifestyle-based intervention|"Multimodal lifestyle-based precision prevention intervention, including:~* Optimized FINGER multidomain lifestyle intervention (diet, physical activity, cognitive training and cardiovascular/metabolic risk monitoring and social interaction)~* Metformin (Glucophage® XR)"
41377129|NCT05109169|OTHER|Self-guided multidomain lifestyle intervention|Participants build their own healthy lifestyle program based on standard healthy lifestyle advice on diet, physical activity, cognitive training and cardiovascular/metabolic risk
41506371|NCT05733273|OTHER|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
41506372|NCT05733273|OTHER|Single leg bridge exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
41506373|NCT05733273|OTHER|Hamstring razor curl|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
41506374|NCT01632657|DRUG|Sumatriptan|Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
41506375|NCT01632657|OTHER|Placebo|Single injection saline 0.5ml subcutaneously in recovery
41506376|NCT04380597|DRUG|Calcipotriene and betamethasone dipropionate aerosol foam|Prescribed according to clinical practice and following Product Data Sheet instructions
41506377|NCT02441660|DRUG|Capsaicin 8% Patch|Applied topically for 1 hour
41506378|NCT02441660|DRUG|Low Dose Capsaicin 0.025% Well Patch|
41033804|NCT06435234|BEHAVIORAL|risky sexual behavior intervention|Intervening in risky sexual behaviors among college students
41164182|NCT02570256|BEHAVIORAL|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
41164183|NCT02570256|BEHAVIORAL|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
41164184|NCT02004106|DRUG|RO6895882|Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
41377130|NCT04782973|OTHER|AMAZE (TM) Disease Management Platform|Providing patients with smartphone app that will integrate with provider facing dashboard within electronic medical record.
41506379|NCT02220062|PROCEDURE|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5\~10cc ethanol would be performed as bilateral injections at the celiac trunk.
41506380|NCT02220062|PROCEDURE|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2\~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
41033805|NCT06052410|OTHER|Early Intervention|Based on the principles of the Goal, Activity and Motor Enrichment (GAME) approach, which is an evidence-based early intervention approach for children at risk of developmental delay between 24-36 months, activity-based training is aimed at the development of sensory and cognitive skills in addition to the training of motor skills, which are intensively discussed in the content of the approach. Individualized early occupational therapy intervention including strategies was implemented.
41377131|NCT03503565|PROCEDURE|intraoperative neuromuscular blockade|The intensity of intraoperative neuromuscular blockade
41506381|NCT00970593|DRUG|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
41506382|NCT00970593|DRUG|placebo comparator|Group 1 \& 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
41164185|NCT01011127|DRUG|pravastatin, rosuvastatin|
41164186|NCT00598117|BEHAVIORAL|Questionnaires|"Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~* Initial QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS"
41377132|NCT04218175|OTHER|neuromobilization exercises|Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
41377133|NCT01584804|DRUG|Su-Huang antitussive capsule|Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
41377134|NCT01584804|DRUG|Sugar pill|Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
41377135|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin|Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
41377136|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), placebo|Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
41377137|NCT04190056|BIOLOGICAL|Pembrolizumab|Given IV
41377138|NCT04190056|DRUG|Tamoxifen|Given PO
41377139|NCT04190056|DRUG|Vorinostat|Given PO
41377140|NCT06149351|DIAGNOSTIC_TEST|Bio-fluid analysis for the implementation of a diagnostic test for sport related concussion|Saliva of participants will be sampled for analysis of biomarkers of interest (nucleic acids and proteins). The nucleic acids biomarkers will be quantified by reverse transcription followed by amplification (RT-PCR) and Next Generation Sequencing (NGS) techniques while enzymatic assay methods (ELISA) methods will be used to quantify protein biomarkers.
41377141|NCT02020421|DEVICE|rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
41377142|NCT02020421|DEVICE|tDCS|2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
41377143|NCT02020421|DEVICE|Sham rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
41377144|NCT02020421|DEVICE|Sham tDCS|Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
41377145|NCT00595946|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
41377146|NCT00595946|DRUG|Placebo|0 mcg capsules twice daily (BID)
41377147|NCT06569147|DRUG|Elranatamab|Elranatamab administered subcutaneously for 6 cycles of treatment with 28 days in a treatment cycle
41377148|NCT01953523|PROCEDURE|Administration of autologous adipose derived SVF|Intra-venous, intra-articular, and soft tissue injection delivery of SVF
41506383|NCT06038162|PROCEDURE|Parallel connection|The RRT machine is connected on a separate vascular access (dialysis catheter).
41164187|NCT02720198|DRUG|Levomilnacipran|treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
41164188|NCT02720198|DRUG|Quetiapine|Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
41164189|NCT04747821|BIOLOGICAL|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
41377149|NCT04065997|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
41377150|NCT05891288|OTHER|BioCoat® by Premier®|Bioactive pits and fissure sealant
41377151|NCT05891288|OTHER|3M™ Clinpro™ Sealant.|Fluoride releasing pits and fissure sealant
41377152|NCT01079169|DIETARY_SUPPLEMENT|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
41506384|NCT06038162|PROCEDURE|Integrated connection|A connection of the RRT machine with the input and output lines directly on the ECMO circuit.
41164190|NCT05008263|DIAGNOSTIC_TEST|Liver elastography (2D-SWE)|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
41164191|NCT05008263|DIAGNOSTIC_TEST|Liver scintigraphy with 99mTc-mebrofenin|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
41033806|NCT06052410|OTHER|Home Programme|For the control group, evaluation tests were first applied to the babies selected by simple random sampling method. An individualized home program was given according to the evaluation results. Home programs include activities for every skill area and were prepared together with the parents, taking into account the criteria suggested for the success of the home program. Based on these criteria, it was checked whether the family had received another home program, and while preparing the program, care was taken not to overload the parents, importance was given to the family's willingness to receive the home program, activities and goals were decided in cooperation with the parent, thus facilitating the applicability of the activities in daily life, ensuring that the number of activities was 6. Care was taken to ensure that the activity was not too much, the parent was given the necessary time to implement the program, and a phone call was made to the parent every 3 weeks.
41164192|NCT02628964|DEVICE|e-cigarettes|Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
41164193|NCT04617262|BEHAVIORAL|Remote Problem Management Plus|Five sessions of low-intensity, trans-diagnostic psychological intervention including the teaching and practice of the following strategies: stress management, problem solving, behavioral activation, and strengthening social support
41377153|NCT06199518|PROCEDURE|transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)|extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures
41033807|NCT03674229|OTHER|Informational Intervention|Receive information about weight management programs
41033808|NCT03674229|OTHER|Questionnaire Administration|Ancillary studies
41033809|NCT03674229|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls from an assigned patient navigator
41033810|NCT04620473|DRUG|Anlotinib+Capeox|to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
41033811|NCT04620473|DRUG|Capeox|to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer
41033812|NCT00414700|DRUG|ChondroCelect implantation|"10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm²."
41033813|NCT00414700|PROCEDURE|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
41377154|NCT00000254|DRUG|40% Nitrous oxide|Used as pain assay positive control
41377155|NCT00000254|OTHER|Sham comparator|0% isoflurane in oxygen
41506385|NCT05444894|GENETIC|EDIT-301|Administered by intravenous infusion after myeloablative conditioning with busulfan.
41506386|NCT05645952|OTHER|Clinical follow up of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
41506387|NCT05441501|DRUG|JNJ-80038114|JNJ-80038114 will be administered.
41506388|NCT01235481|DEVICE|Exercise DVD|Exercise DVD added to usual care during maintenance phase of pulmonary rehabilitation
41506389|NCT01235481|BEHAVIORAL|Usual Care|Usual care during maintenance phase post pulmonary rehabilitation
41506390|NCT02976987|DRUG|Cidofovir|
41506391|NCT05210010|DEVICE|CA-4F|"The study intervention is the CA-4F algorithm developed by Ensho Health.~The algorithm is a process for converting input parameters to a CA-4F Risk Score intended to facilitate clinical prioritization of patients suitable for follow-up investigation for ATTR-CM.~The algorithm is applied using the CA-4F Likelihood Estimator which encodes it in software and records its outputs. The CA-4F Likelihood Estimator is controlled through a graphical user interface called the CA-4F Controller.~The CA-4F Likelihood Estimator and its Controller are Class I medical devices in Canada registered under the Medical Device Establishment License of Ensho Health (license 16208)."
41033814|NCT05345015|DEVICE|Radiofrequency Energy Transfer|"Radiofrequency Electrical Currents (TECAR) will be delivered using a winback system (Winback, Villeneuve-Loubet, France) propagating radiofrequency waves of 448 kHz using metallic electrodes via a coupling medium. Radiofrequencies will be used in the capacitive mode , which aims to treat superficial /soft tissues in the area. The active plate will be applied sequentially on the skin in the injured or painful region. The base plate will be located to the other side of the injured body region (for back thigh muscle injuries, for example, the base plate will be located on the frontal thigh area, to close the current circuit. Therapy will be applied for 20 minutes, with a target intensity of 40% and a frequency of 0.5Mhz."
41164194|NCT05381181|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
41164195|NCT02106637|DRUG|Varenicline|drug will be initiated during hospitalization and continued for 12 weeks following discharge
41377156|NCT00000254|DRUG|0.2% isoflurane|
41377157|NCT00000254|DRUG|0.4% isoflurane|
41377158|NCT00000254|DRUG|0.6% isoflurane|
41377159|NCT04051658|DEVICE|Transcranial direct current stimulation|tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
41377160|NCT04966117|BEHAVIORAL|Risk-Guided DMP|"Patients will be assigned a cardiac nurse to help manage their heart condition who will:~1. develop a care plan and communicate with the patients' General Practitioner (GP) and cardiologist about management, particularly medications to help control risk factors.~2. provide health coaching at pre-specified times over 12 months via telehealth (phone or video call) to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~3. facilitate cardiac rehabilitation via a smart phone or tablet app (called SmartCR). This app monitors health and physical activity, has prompted tasks to do and delivers education via video, audio and written articles. The information from this app can be used by the cardiac nurse during telehealth follow-up.~4. invite participation to a supervised 6-week group exercise program which will require using our on-site gym."
41377161|NCT04966117|BEHAVIORAL|Usual Care|Usual care patients will receive standard cardiology care as scheduled that includes adherence to guideline-based care (medications and physical activity), education (self-care), a treatment plan to manage co-morbidities, early post-discharge follow-up/support and routine preventative care.
41377162|NCT03931902|DEVICE|intubation with Endotracheal tube|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
41377163|NCT03931902|DEVICE|intubation with laryngeal mask airway|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
41377164|NCT06289010|BEHAVIORAL|Family-Focused Treatment for Childhood-Depression (FFT-CD)|"This intervention includes 12 one-hour, in-person sessions. FFT-CD was designed to help families gain skills to combat depression and create ways of interacting that protect the child from the negative sequelae of stress. Within a broad psychoeducational framework, interpersonal factors impacting youth depression and the interplay of mood and interpersonal interactions are emphasized. Participants are taught to identify Upward Spirals - positive interactions fueling positive moods leading further upward - and Downward Spirals - negative interactions fueling negative moods leading further downward. The treatment rationale is to stop downward spirals and to start upward spirals; this idea provides a foundation for skills building to help the child and family better navigate stress. Handouts, role-playing, behavioral rehearsal, and homework assignments are all used to help shape behaviors."
41377165|NCT02604849|DRUG|Neomycin|
41377166|NCT02604849|DRUG|Streptomycin|
41377167|NCT02604849|DRUG|Gentamicins|
41377168|NCT06540352|DRUG|4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride|The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.
41377169|NCT06540352|DRUG|Mannitol|Placebo in tablets
41377170|NCT04571164|DRUG|LY03003(Rotigotine,extended-release microspheres)|During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
41377171|NCT04571164|DRUG|Placebo,extended-release microspheres|During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
41377172|NCT02641730|DRUG|Guselkumab|Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.
41377173|NCT02641730|DRUG|Placebo|Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
41506392|NCT02214537|OTHER|MACS|
41164196|NCT02106637|DRUG|placebo|placebo
41164197|NCT03660917|DRUG|Riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
41033815|NCT05345015|DEVICE|Transcutaneous Nerve Stimulation|Transcutaneous nerve stimulation (TENS) will be delivered using a Chattanooga Intellect Advanced Combo system (Chattanooga, Hixson, TN 3 7343, USA). Two electrodes will be placed on the skin at a distance so that they cover the entire painful area. The TENS asymmetric biphasic mode (phase 300 ms, frequency 80Hz, continuous cycle) will be applied. The intensity will be adjusted between 0 and 110A, such that it is tolerable by the participant. The total application time will be 20 minutes or equal to that applied for the TECAR group.
41033816|NCT03517774|DEVICE|3D Printed Socket|Twenty participants will be fitted with a 3D Printed socket created using 3DPrintAbility hardware and software. To do this, a 3D model of the participants residual limb will be generated which will be used to create the 3D printed sockets. These 20 participants will also receive standard care for prosthetic fitting at SJR. The fittings will be done by one prosthetist. Our team will compare the feasibility, function, quality and stability of the prosthetics through quantitative, economic and qualitative analyses. All fittings will be done under the supervision of a qualified Sunnybrook prosthetist who has previous experience with using 3D printed technologies for creation of prosthetics.
41506393|NCT04218578|DIAGNOSTIC_TEST|speckle tracking analysis of transthoracic echocardiogram|analysis at workstation with 2D strain-Speckle tracking echocardiography of transthoracic cardiac echo at baseline and one-year follow up examination
41033817|NCT00122512|DRUG|Tenofovir Disoproxil Fumarate|
41033818|NCT00536003|DRUG|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
41033819|NCT00536003|DRUG|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
41033820|NCT01435577|DRUG|Tapentadol|30 mg per administration, maximum 12 administrations over 48 hours
41033821|NCT01435577|DRUG|Matching Placebo|Maximum 12 administrations over 48 hours
41033822|NCT04182490|BIOLOGICAL|LMN-101|VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass
41033823|NCT04182490|DRUG|Placebo|Identical appearing placebo
41033824|NCT05577429|OTHER|Low-moderate intensity exercise under normoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 20.9%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
41164198|NCT03660917|DRUG|Placebo|Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
41164199|NCT05771597|OTHER|Home Biofeedback therapy|"Patients will be given home biofeedback device to take home and practice biofeedback exercises at least twice a day for six weeks of therapy.~1. HBT for patients with constipation and dyssynergic defecation:~   Patients will attend one session of training on how to use the device followed by daily sessions at home for 6 weeks. After placing a probe into rectum, the patient sits on a commode, activates the smart phone app and follow the voice-guided instructions to perform diaphragmatic breathing exercises and push maneuvers with/without balloon distension.~2. HBT for patients with FI:~   Subject will receive training on how to use the home-trainer device and probe placement. The patient will be asked to follow a series of voice guided instructions consisting of performing short and long duration squeeze maneuvers over 25 minutes.~3. HBT for patients with UI:~The instructions protocol as written above for patients with FI will be followed for UI patients as well."
41164200|NCT05771597|OTHER|Office biofeedback therapy|"Patients will receive traditional office biofeedback, once weekly, over six weeks.~1. OBT for patients with constipation and dyssynergic defecation:~   The patient will receive instructions on the diaphragmatic breathing techniques. Then the patient sits on a commode, coordination between push effort and the anal and pelvic floor relaxation is corrected by the therapist. The patients will receive visual and verbal feedback instructions from the therapist.~2. OBT for patients with FI:~   Patients will be taught Kegels and abdominal muscle exercises. Visual and verbal feedback techniques are used to reinforce the maneuvers. The patient is instructed to squeeze and to maintain this squeeze for as long as possible.~3. OBT for patients with UI:~Biofeedback training is performed using the protocol and objectives as described above for FI training."
41164201|NCT04020198|OTHER|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.
41164202|NCT00581841|OTHER|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
41377179|NCT05243810|DEVICE|EPC Silver Wound Gel|Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
41377180|NCT00586677|BEHAVIORAL|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
41377181|NCT00586677|BEHAVIORAL|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
41506394|NCT05100160|DRUG|Gabapentin|Given by PO
41506395|NCT05100160|OTHER|Placebo|Given by PO
41377182|NCT00586677|BEHAVIORAL|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
41164203|NCT05781997|DIAGNOSTIC_TEST|cycloplegic refraction|Cycloplegic autorefraction will be attempted on all children using a table-mounted autorefractor . Cycloplegia will be achieved with three drops of 1% cyclopentolate administered 5 min apart and autorefractive measurements will be performed 30 min after the instillation of the last drop. Auto refraction readings of three consecutive measurements will be obtained and the average will be computed automatically in each eye. Each child will be reexamined until three measurements fell within 0.50 diopters (D) if any two measurements varied by \>0.50D.
41377183|NCT02701660|DEVICE|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
41377184|NCT04406363|OTHER|non interventional|non interventional
41377185|NCT00517868|DRUG|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
41377186|NCT00517868|DRUG|Placebo|Liquid formulation without active URG101 drug components
41033825|NCT05577429|OTHER|Low-moderate intensity exercise under moderate hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 16.5%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
41033826|NCT05577429|OTHER|Low-moderate intensity exercise under high hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 14.8%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
41033827|NCT03955393|OTHER|18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
41033828|NCT03574168|BIOLOGICAL|CD19-CAR-T Cells|T cells purified from the PBMC of subjects or subjects' relatives which depends on their conditions, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
41033829|NCT04950699|GENETIC|Single-nucleotide Polymorphism of genes related with Dyslipidemia|This study is an observational study to study the effect of different genotypes on the incidence of myocardial infarction
41033830|NCT04179032|COMBINATION_PRODUCT|Belimumab|Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.
41033831|NCT06273852|DRUG|PBA-0405|Intratumoral microdose injection by the CIVO device.
41033832|NCT05654623|DRUG|ARV-471|orally, once daily on a 28-day continuous dosing schedule
41033833|NCT05654623|DRUG|Fulvestrant|intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
41164204|NCT02764177|DIETARY_SUPPLEMENT|Protein drink|The protein drink was administered during this trial
41164205|NCT02764177|DIETARY_SUPPLEMENT|Carbohydrate drink|The carbohydrate drink was administered in this trial
41164206|NCT02872818|DRUG|17β estradiol hemihydrate|4mg/kg/day for 20 days
41164207|NCT02872818|DRUG|Metformin|50 mg/kg/day last 10 days
41033834|NCT05889247|OTHER|Circulating tumor DNA treatment monitoring|A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)
41033835|NCT06316986|DIAGNOSTIC_TEST|pH indication with NGPOD|"The NGPOD sensor is inserted into the naso- or oro-gastric tube, then reconnected to the NGPOD handheld device, and the pH measurement is taken within 15 seconds.~When the 15 seconds have elapsed, the pH button is pressed. If the green LED lights up and the pH indicates a value \< 5.5, the sensor tip is in a pH environment associated with the stomach.~If the red LED lights up, the sensor tip is in a pH environment NOT associated with the stomach."
41164208|NCT02872818|DRUG|medroxyprogesterone acetate|1mg/kg/day last 10 days
41164209|NCT03471390|OTHER|ProQuaS 2 Intervention|Training and implementation of facility pain champions, comprehensive training of all care workers in pain assessment and management, implementation of pain management policies
41164210|NCT01940289|DEVICE|Algometric meter readings for perception of pain|
41164211|NCT01145417|DRUG|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
41164212|NCT00945451|DEVICE|CK|Cyberknife Irradiation
41164213|NCT03161223|DRUG|Durvalumab|"Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).~Starting dose: 1500 mg"
41377187|NCT06172569|DEVICE|Spartan Stem, World Acetabular Cup and World Liner|"The Spartan Stem is a wedge-shaped fit and fill design stem with Titanium Plasma Spray(TPS) and Hydroxyapatite (HA) coating.~The World Acetabular cup is Porous coated and mated with cross-linked polyethylene World Liner"
41377188|NCT03035500|OTHER|Educational Intervention|Receive health education
41377189|NCT03035500|OTHER|Laboratory Biomarker Analysis|Correlative studies
41377190|NCT03035500|OTHER|Long-term Follow-up|Undergo long-term follow-up using survivorship care plan
41377191|NCT03035500|OTHER|Quality-of-Life Assessment|Ancillary studies
41377192|NCT03035500|OTHER|Questionnaire Administration|Ancillary studies
41377193|NCT02393066|DRUG|Propofol|Sedation
41377194|NCT02393066|DRUG|Dexmedetomidine|Sedation
41377195|NCT01065545|DRUG|Clofarabine|dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
41377196|NCT01984970|DEVICE|videolaryngoscope|McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
41377197|NCT00179101|PROCEDURE|Deep Brain Stimulation|
41377198|NCT05725473|DEVICE|Eso-Flip|Dilatation with Eso-FLIP
40850605|NCT05496556|OTHER|Test Leeds Food Preference Questionnaire (LFQP-France)|"The version of this questionnaire has been adapted to French eating habits. and based on the presentation of food photos, each representing one of the four categories below : salty-high in fat / salty-low fat / sugary-high fat / sweet-low fat The answers given to the LFQP predict a more or less caloric food intake. This tool makes it possible to objectify changes in eating behavior according to the nutritional status and protein status of patients.~The implied wanting score for salty-high-fat, salty-low-fat, sweet-high-fat, and sweet-low-fat foods is calculated based on the frequency and speed of choice for one food type out of 150 combinations.~For each of the food modalities, the software will return a score with its standard deviation. The modality preferred by the patient is the one with the highest score"
40850606|NCT01297725|PROCEDURE|Blunt right, sharp left|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
40850607|NCT01297725|PROCEDURE|Blunt left, sharp right|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
40850608|NCT01184417|DRUG|10 mg/kg IV phenobarbital in 100 ml saline|10 mg/kg IV phenobarbital in 100 ml saline
40850609|NCT01184417|DRUG|placebo|100 m l saline
40850610|NCT04474015|DEVICE|transcranial electric stimulation|NeuroConn® DC Plus stimulator: the NeuroConn® stimulator can be programmed with specific frequencies of stimulation ranging from 0.5 to 500 Hz. This device is therefore appropriate for the present study to stimulate only at 0.75 or 3.0 Hz. Also, the NeuroConn only allows low current intensities to be chosen. The maximum current intensity that can be delivered with this stimulator is 5 milliamps.
40850611|NCT00915707|OTHER|Baseline|Subjects are allowed time in bed for sleep as their usual time at home.
40850612|NCT00915707|OTHER|Sleep restriction|Subjects sleep is reduced to 4.5 hours in bed for 4 nights.
40850613|NCT00915707|OTHER|Reduced Sleep Quality|Subjects sleep quality is reduced for 4 nights.
40850614|NCT00065845|PROCEDURE|Burch urethropexy at time of sacrocolpopexy|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
40850615|NCT05791240|BEHAVIORAL|Family Initiated Interpretation|Interpreter tablet will be given to families so they can contact an interpreter themselves.
41377199|NCT04207359|DIETARY_SUPPLEMENT|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
41377200|NCT02796365|OTHER|Exercise|Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
41377201|NCT04205864|DRUG|Thrombi-Gel|Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy
41377202|NCT04205864|PROCEDURE|Conventional Pelvic lymphadenectomy|Conventional Pelvic lymphadenectomy
41377203|NCT01687777|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
40850616|NCT05677009|DEVICE|BUFEO system|In the BUFEO Condition, the subject will receive oxygen through the BUFEO system.
41377204|NCT01687777|BIOLOGICAL|OrthADAPT|
41377205|NCT01199510|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care|Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
41377206|NCT01199510|OTHER|Standard of Care|Post Cataract Surgery Standard of Care
41377207|NCT01035112|PROCEDURE|MRI|
41377208|NCT05158907|OTHER|Patient reported Adverse event scale|Participants will be given a patient reported AE scale with numbers from 0 to 10 before start of each chemotherapy cycle. The PRAE scale will be like a Visual Analogue Scale and the patients will be given instructions how to record AEs that they experience after each chemotherapy cycle, until the first radiological assessment is done (palliative settings) or after 4 cycles of chemotherapy in adjuvant settings. Participants will take scale home to record the adverse effects and give it a number. Only the most severe will be analyzed. When patient reports for the next cycle of chemotherapy they will be asked to deposit the scale before meeting the physician. The physician will ask patient about the AEs experienced with the chemotherapy and record them using CTCAE grade. The study participants, at the start of chemotherapy cycle, will be informed, as a standard practice, to report to the emergency or contact nearest local clinic/hospital if the AE is severe or can't be managed at home.
41377209|NCT06538402|PROCEDURE|10 cm pouch|A 10 cm pouch will be constructed
41377210|NCT06538402|PROCEDURE|15 cm pouch|A 15 cm pouch will be constructed
41377211|NCT06542822|DRUG|Ferric derisomaltose|See group descriptions
41377212|NCT04165824|DRUG|MT-1186|"* An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period~* Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks."
41377213|NCT06035094|BEHAVIORAL|Exercise Intervention to improve overall Brain Health|"During each exercise session, the participant will be assigned to the HIIT or MIT exercise group and asked to ride the stationary bicycle for approximately 30-40 minutes, while wearing the heart rate monitor and recording the session on their smart phone application. For each exercise session, the Polar Beat application will record the time in each of four intensity zones. The participant will receive training on how to use the outlined schedule during the initial supervised training session."
40850617|NCT05677009|OTHER|Standard of Care|Standard Condition is the baseline apparatus utilized by the subject at the time of enrollment in the study. In the hospital setting, the supplemental oxygen delivery may come from compressed oxygen cylinders or liquid oxygen and is often delivered through a port in the facility wall at the bedside.
40850618|NCT04305847|OTHER|perioperative satisfaction assessment|Satisfaction assessment at 24 and 48 hours post operatively by self-administered survey questionnaire based on different scales: Evan-LR, Net Promotor Score, Satisfaction score.
40850619|NCT04692532|OTHER|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
41377214|NCT06008470|OTHER|observational tests|"Respiratory Muscle Strength Measurement In our study, respiratory muscle strength will be measured using a portable, electronic mouth pressure measuring device (MEC Pocket Spiro MPM100, Belgium). Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurement is one of the most commonly used non-invasive methods to evaluate respiratory muscles.~6 Minute Walk Test (6MWT): It has been used to assess physical activity and functional capacity in many pulmonary rehabilitation programs for patients with chronic pulmonary disease and limited respiratory capacity"
41377215|NCT06520839|DRUG|Tadalafil 5mg|We will include in the study 90 patients with diabetes and erectile dysfunction. We will use the IIEF-5 questionnaire to confirm the diagnosis of erectile dysfunction. Patients between the ages of 40 and 65 who score 21 points or less on the IIEF-5 scale will be included in the study. Each patient will receive drug tadalafil 5 mg every day for three months.
40850620|NCT04692532|OTHER|Calorie restriction|25% energy restriction every day
40850621|NCT01711450|PROCEDURE|Paravertebral block|Injection of local anaesthesia into paravertebral space to provide analgesia
41377216|NCT01853969|OTHER|Typing assessment|
41377217|NCT03441620|DIETARY_SUPPLEMENT|strawberries|Freeze-dried strawberry powder
41377218|NCT03441620|OTHER|Control powder|Control powder matched for fiber and strawberries
41377219|NCT02988310|OTHER|No intervention|
41377220|NCT04794595|PROCEDURE|CBP|continuous blood purification can prevent or treat fluid overload in children with septic shock or other sepsis-associated organ dysfunction who are unresponsive to fluid restriction and diuretic therapy management of septic AKI patients, particularly those with hemodynamic instability or fluid overload. Also, it can remove cytokines
41377221|NCT06411002|DRUG|DAXXIFY|Intramuscular injection of daxibotulintoxinA-lanm
41377222|NCT06515925|BEHAVIORAL|Our Whole Lives (OWL)|"OWL is a nine-session, web-accessible, self-paced mindfulness curriculum that has interactive components of self-monitoring and social support (online community). Our Whole Lives (OWL) online curriculum of self-management topics such as mindfulness, mind-body practices, education about chronic pain therapies, stress reduction, sleep, and nutrition.~Once a week for 9 weeks participants will attend a 1.5 -2-hour online group session via Zoom or Google Meets, accessing it through GEMINI platform."
41506396|NCT04392427|DRUG|Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :|"Target population: any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.~* Sample size: will depends on sequential analysis until a significant effect will be detected with a maximum of 100 subjects in each arm.~* Randomization: subjects will be allocated to either arm by block randomization method with sealed opaque envelops. Each block will include 10 subjects (to be allocated randomly as 5 in each group)~* Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days"
41506397|NCT01014377|DEVICE|VascuActive|
41506398|NCT00760734|DRUG|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
41506399|NCT00760734|DRUG|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
41506400|NCT02655783|OTHER|5% dextrose|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution + 5% dextrose
41506401|NCT02655783|OTHER|normal saline|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
40850622|NCT01711450|PROCEDURE|Control sham procedure|Injection of Normal saline into the paravertebral space
41506402|NCT01753557|DRUG|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
40850623|NCT05150717|DRUG|[14C]-Jaktinib|Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.
40850624|NCT02702414|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
40850625|NCT01768195|DRUG|Entecavir prophylaxis|"Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.~In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(\>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis."
40850626|NCT02748928|DEVICE|UltraShape Power|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
40850627|NCT03087903|DIETARY_SUPPLEMENT|Grape Seed Extract|Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
41164214|NCT03161223|DRUG|Pralatrexate|"Pralatrexate is an antimetabolite drug. Pralatrexate alone is FDA-approved for the treatment of PTCL. Given intravenously (through the vein).~Starting dose: 25 mg/m2"
41506403|NCT01753557|DRUG|RBV|RBV: 600 - 1000 mg/day based on body weight for 24 weeks
41506404|NCT01753557|DRUG|PEG-IFN alfa-2a|PEG-IFN alfa-2a: 180mcg/week for 24 weeks
40850628|NCT04379401|DEVICE|Cardiac Resynchronization Therapy (ON vs. OFF)|This study involves study participants, who already received cardiac resynchronisation therapy implantation for clinical reasons. CRT is authorized for medical use by Swissmedic in Switzerland and all implanted devices are CE-approved.
41377223|NCT06515925|BEHAVIORAL|Low Dose Mindfulness Training|The GEMINI platform will facilitate the delivery of a low-dose version of Our Whole Lives program. OWL in this arm is a nine-session, web-accessible, self-paced curriculum, self-monitoring. Participants will interface with the GEMINI platform's static content.
41033836|NCT06636058|BEHAVIORAL|vCare Intervention (6-month active treatment followed by 6-month maintenance)|"During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.~During the maintenance period, participants in the early vCare intervention arm will be able to interact with Lumen for PST coaching when they need to, i.e., on demand, although they will receive reminders to do so at least once a month. Participants may watch any of the 12 GLB videos again and will receive GLB-themed reinforcement and motivational messages by email every 2 weeks."
41033837|NCT06636058|BEHAVIORAL|vCare Intervention (active treatment after 6 months)|During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.
41033838|NCT02816580|OTHER|Blood collection|
41033839|NCT06635915|DIAGNOSTIC_TEST|Postoperative ultrasound|Ultrasound will be performed to both groups in the postoperative period to assess the normoposition or the absence of nasogastric tube.
41033840|NCT01056224|DRUG|Remifentanil|A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
41033841|NCT05625048|OTHER|Transperinal ultrasound guided instruction in pelvic floor muscle training|The physiotherapists uses transperinal ultrasound as a biofeedback or pedagogical tool to improve the muscle contractions and visualize the muscle work.
41033842|NCT06634849|DRUG|PTT-4256|Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohort 1-3 will receive 10mg, 20mg \& 40mg.
41033843|NCT01153646|GENETIC|pHIV7-shI-TAR-CCR5RZ treated CD4 cells|Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
41033844|NCT00628771|BEHAVIORAL|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
41033845|NCT00628771|BEHAVIORAL|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
41033846|NCT05893342|DIAGNOSTIC_TEST|Preoperative frailty diagnostic|The preoperative evaluation of the patient will be carried out through the application of different scales that evaluate frailty (Edmonton frailty test, Barthel Index, Mini-mental test, Charlson Index) and a postoperative follow-up will be carried out for the diagnosis of complications during the first 90 postoperative days.
41377224|NCT03933046|DIAGNOSTIC_TEST|PSG|polysomnography and urine analaysis for protein levels
41033847|NCT05807711|DRUG|L-Methyl Folate and methylcobalamine|Dietary supplement labeled to contain methylfolate 800 micrograms and methylcobalamine 1000 micrograms
41377225|NCT05039931|DRUG|GNC-035|Administration by intravenous infusion.
41377226|NCT03128775|BEHAVIORAL|Nudge|"School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~1. arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~2. Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment."
41377227|NCT03128775|BEHAVIORAL|Primary prevention|Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
41506405|NCT06370481|OTHER|Telemedicine|Routine care administered via telemedicine
41506406|NCT06370481|OTHER|Standard of care|Standard of care, as received in HIV clinic settings
41506407|NCT03955458|DRUG|EXPAREL|FICB with EXPAREL + Bupivacaine HCL (single dose)
41506408|NCT03955458|DRUG|Ropivacaine|FICB with continuous infusion of ropivacaine
41506409|NCT03955458|DRUG|Bupivacaine Hydrochloride|FICB with EXPAREL + Bupivacaine HCL (Single dose)
40850629|NCT05688332|DRUG|Voglibose + Metformin|"In treatment group B, 59 participants will also be randomly assigned to the voglibose 0.2/0.3mg TDS + metformin 500mg BD treatment combination to be taken orally daily, during or immediately after meals with dose titration at day 6 and 12 if the average fasting blood glucose (FBG) level is ≥7 mmol/L (126 mg/dL) and then dosage will be maintained for the remainder of the treatment period Participants in the intervention group initially receiving voglibose 0.2mg + metformin 500mg BD will be dose-titrated to voglibose 0.3mg +metformin 1g BD.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint."
41377228|NCT03128775|BEHAVIORAL|Primary prevention + nudge|This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
41377229|NCT06568289|DRUG|Lignocaine|A perineal infiltration of a 5-ml of the drug (100 mg of lignocaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
40850630|NCT05688332|DRUG|Glibenclamide + Metformin|"The drugs (glibenclamide + metformin), in the control or comparator group will also be taken orally, glibenclamide once a day (OD) before meals, and metformin twice a day (BD) also before meals. These drugs will also be taken with a dose-titration at days 6 and 12 if the average is FBG level will be ≥ 7 mmol/L and the dose will be maintained for the remainder of the study period.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint. In this group, participants will initially receive glibenclamide 5mg once daily (OD) + metformin 500mg BD then will be dose-titrated to glibenclamide 10mg OD + metformin 1g BD."
40850631|NCT00293618|DEVICE|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
40850632|NCT00293618|OTHER|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
40850633|NCT00293618|OTHER|Feedback|Feedback about the physician's personal performance on prevention of PONV
41033848|NCT06497439|DRUG|Silfamin|2 tablets of Silfamin 150 mg twice daily
41033849|NCT06497439|DRUG|Placebo tablet of Silfamin|2 tablets of Silfamin Placebo twice daily
41506410|NCT05408975|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
41506411|NCT05408975|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
41506412|NCT01398046|DRUG|Dasatinib|dasatinib (100mg) PO x1
41033850|NCT05193994|DRUG|Dolutegravir, Abacavir and Lamivudine|Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.
41033851|NCT05193994|DRUG|Placebo|Matching placebo.
41033852|NCT02599194|DRUG|18F-FSPG|Administered intravenously (IV)
41506413|NCT01398046|DRUG|Dasatinib plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
41506414|NCT01398046|DRUG|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
41506415|NCT00001605|BIOLOGICAL|Nontypeable Haemophilus influenzae|
41033853|NCT02599194|DRUG|18F-FDG|Administered intravenously (IV)
41033854|NCT05178628|DRUG|Innohep|Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
41033855|NCT05178628|DRUG|Chemotherapy: Gemcitabine + Nab-Paclitaxel|All patients will receive chemotherapy per clinical practice
41033856|NCT05062239|DRUG|Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative|Discontinuance of prior statin therapy
41033857|NCT05062239|DRUG|No-intervention.|Continuance of prior statin therapy
41377230|NCT06568289|DRUG|Bupivacaine|A perineal infiltration of a 5-ml of the study drug (20 mg of Bupivacaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
41377231|NCT00989365|OTHER|Aerobic training|Treadmill training
41377232|NCT00908362|DRUG|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
41506416|NCT06344585|OTHER|Drop out patients who had their first access in 2021 were additionally asked to answer to a phone -call questionnaire to assess their motivation of discontinuation|"A prospective comprehensive analysis of the data contained within patient charts, encompassing personal histories and demographic details, was extracted from the internal database of the Humanitas Fertility Center. This analysis aimed at elucidating the individual reasons for treatment discontinuation after the initial clinical visit throughout the year 2021. Additionally a tailored questionnaire was administered to patients via telephone by a member of Humanitas Fertility Center staff in July 2023.~The questionnaire was submitted to the patients via a phone call. The questionnaire comprised nine questions with response limited to 'Yes' and 'No' options for all queries."
41377233|NCT00908362|DRUG|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
40850634|NCT02085304|PROCEDURE|Gross total resection and Gliadel(R) wafers implanted|Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
41506417|NCT04794036|OTHER|Asynchronous telerehabilitation programme|Home-based physical rehabilitation programme using a telerehabilitation platform
40850635|NCT02085304|RADIATION|GammaKnife(R) stereotactic Radiosurgery|GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin
41506418|NCT04794036|OTHER|Rehabilitation programme|Home-based physical rehabilitation programme by means of an explanatory booklet
40850636|NCT02085304|RADIATION|Standard fractionated radiation therapy|standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)
41377234|NCT00908362|DRUG|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
41377235|NCT04977375|DRUG|Pembrolizumab|Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks
41377236|NCT04977375|RADIATION|Stereotactic Radiation Therapy|Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7
41506419|NCT06356857|DIAGNOSTIC_TEST|Myocardial perfusion imaging (MPI) using [O15]H2O-PET-CT|Re-scan for comparison with initial scan
41506420|NCT05696899|OTHER|STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents|A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
40850637|NCT02085304|DRUG|Temozolomide|temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
40850638|NCT04390841|DEVICE|Cardiac Stimulator|The subjects will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
41377237|NCT04977375|PROCEDURE|Surgical Resection|Standard of care surgical resection of tumor on Day 10-28
41377238|NCT02181127|DEVICE|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
41377239|NCT03185949|DEVICE|Endobar Infusion Catheter System|Bariatric embolization with microspheres using Endobar Infusion Catheter System
41377240|NCT03185949|BEHAVIORAL|Behavioral therapy|Healthy diet and exercise
41377241|NCT01965600|DRUG|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
41506421|NCT02286258|DRUG|Calcium EDTA|"Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
41506422|NCT02286258|DRUG|Gd-DOTA|"Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
41506423|NCT01935518|DRUG|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
40850639|NCT00588354|DRUG|Clonidine|200 or 400 micrograms clonidine
40850640|NCT00588354|DRUG|Triamcinolone hexacetonide|40 or 80 milligrams triamcinolone
40850641|NCT00588354|DRUG|Lidocaine HCl|1 ml 2% lidocaine (20 mg/mL)
40850642|NCT04652635|PROCEDURE|Nail plate removal, nail bed repair|Injection of local anesthetic, removal of nail plate, inspection of nail bed, repair of nail bed with suture and/or adhesive
41033858|NCT04722965|PROCEDURE|Fistulotomy with marsupialization|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. Wound edges are sutured to the bottom of the fistula using interrupted sutures of vicryl 3-0 completing the marsupialization.
40850643|NCT04374045|OTHER|ECG-Holter|Patient will have a ECG-Holter recording during all their hospitalization.
41377242|NCT01965600|DRUG|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
41377243|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
41377244|NCT01965600|DRUG|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
41033859|NCT04722965|PROCEDURE|Fistulotomy with open wound|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. The wound is left open.
41164215|NCT03161223|DRUG|Romidepsin|"Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).~Starting dose: 12 mg/m2"
41164216|NCT03161223|DRUG|5-Azacitidine|"Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).~Starting dose: 300 mg daily"
41164217|NCT00989313|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
41164218|NCT03900429|DRUG|MGL-3196|Tablet
41164219|NCT03900429|DRUG|Placebo|Matching Tablets
41164220|NCT03900429|PROCEDURE|Liver Biopsy|A procedure in which a needle is inserted into the liver to collect a tissue sample
41164221|NCT01370018|BIOLOGICAL|alpha-1-Proteinase Inhibitor|Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.
41164222|NCT02546778|DEVICE|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
41164223|NCT00260676|PROCEDURE|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
41164224|NCT00093132|DRUG|Satraplatin|Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
41164225|NCT00546078|BIOLOGICAL|Cervarix™|Intramuscular injection, one or three doses
41164226|NCT03672071|OTHER|Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)|If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups
41164227|NCT00086723|BIOLOGICAL|recombinant tissue plasminogen activator|
41506424|NCT03364842|DRUG|Furosemide|Administering furosemide
41506425|NCT05517083|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
40850644|NCT02489669|DEVICE|RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)|Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
40850645|NCT00486824|DRUG|Indomethacin|One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
40850646|NCT00486824|DRUG|Nifedipine|Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
41506426|NCT05052476|DIETARY_SUPPLEMENT|Bactecal® D Liquid|The patients will be randomized into two arms, A and B, in function of the intervention dose
40850647|NCT01303198|DEVICE|APAP - Therapy|automatic positive pressure therapy
40850648|NCT05942599|BIOLOGICAL|Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg. BECAR33 Total duration of treatment: 28 days follow up: 12 months
41033860|NCT03174977|DRUG|18F-Raltegravir|A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
40850649|NCT00370565|DRUG|Inhaled Human Insulin|
40850650|NCT03455816|DEVICE|Social Diabetes App|"Social diabetes is an app for diabetes, free with CE mark, that by means of the incorporation of a glucometer (glucomen Areo) allows through NFC technology the automatic introduction of data in the application"
41164228|NCT00086723|DRUG|captopril|
41164229|NCT01297699|DRUG|Tocilizumab (RoActemra®)|Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.
41164230|NCT01297699|DRUG|Sterile 0.9% Sodium Chloride|Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
41164231|NCT01439997|DRUG|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
41164232|NCT03023852|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
41164233|NCT03023852|DRUG|Oseltamivir|Participants will receive Oseltamivir 75 mg (1\*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
41164234|NCT03033758|OTHER|Budesonide/Formoterol treated patients|patients who are eligible to start their treatment with budesonide/formoterol therapy
41164235|NCT02669134|OTHER|Device programming|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
41164236|NCT00815347|DRUG|bosentan|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
41377245|NCT01965600|DRUG|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
40850651|NCT03455816|DEVICE|Usual clinical monitoring group (Control group)|Active Comparator: Usual clinical monitoring group (control group) This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
41377246|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
41377247|NCT00002949|DRUG|paclitaxel|Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
41377248|NCT00002949|DRUG|vinorelbine tartrate|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
41377249|NCT00002949|RADIATION|radiation therapy|Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
41377250|NCT05879796|DRUG|cis-platinum|chemotherapeutics
41377251|NCT05879796|RADIATION|radiation|"External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
41377252|NCT05879796|DRUG|Envafolimab Injection|PD-L1 antibody
41377253|NCT05879796|DRUG|Recombinant Human Endostatin Injection|angiogenesis inhibitors
41377254|NCT00136565|DRUG|Velcade|1.5 mg/m², D1, D5, 4 cycles
41377255|NCT00136565|DRUG|Doxorubicin|75 mg/m², D1, 4 cycles
41377256|NCT00136565|DRUG|Prednisone|60 mg/m², D1-D5, 4 cycles
41377257|NCT00136565|DRUG|Cyclophosphamide|1200 mg/m², D1, 4 cycles
41377258|NCT00136565|DRUG|Vindesine|2 mg/m², D1, D5, 4 cycles
41377259|NCT00136565|DRUG|Bleomycin|10 mg, D1, D5, 4 cycles
41377260|NCT03217474|PROCEDURE|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
41377261|NCT03217474|DRUG|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
40850652|NCT02767661|DRUG|Capecitabine|Capecitabine, 500mg, orally three times daily (continuously)
41164237|NCT00815347|DRUG|placebo|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
41164238|NCT02068196|PROCEDURE|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
41377262|NCT03217474|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
41377263|NCT03053102|DRUG|Danicopan|Danicopan was administered as multiple oral doses over a period of at least 28 days.
41377264|NCT06566144|OTHER|Standard treatment|The treatment to be used in the study is in accordance with the latest guidelines for chronic LBP \[George et al., 2021; Owen, et al., 2020\]. A warm-up will be performed by walking on a treadmill for 10 minutes, followed by 3 sets of 10 to 15 repetitions of exercise: bridge, cat, abdominal, straight leg raising, and oyster, and 3 sets of 30 to 60 seconds of each isometric exercise (front plank and side plank), where the therapist will assess the optimal amount of repetitions for each individual. The rest period between sets will be 40 seconds, and the rest period between exercises will be 1 minute. The total duration of the session will be 40 minutes \[Sipaviciene et al., 2020; Kim et al, 2020\].
41377265|NCT06566144|OTHER|Osteopathy treatment|The osteopathy treatment group (OTG) will receive the same standard treatment for low back pain as the STG, which will be applied twice a week and osteopathy treatment every 15 days for 8 weeks, totaling 4 sessions. The duration of the osteopathy sessions
41377266|NCT02448212|DRUG|TS-121|Oral
41377267|NCT02448212|DRUG|[11C]TASP0410699|Intravenous radiotracer
41377268|NCT02448212|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
41377269|NCT00398476|DRUG|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
41377270|NCT00398476|DRUG|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
41377271|NCT03122327|OTHER|Questionaires|Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
41377272|NCT00728273|DIETARY_SUPPLEMENT|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
41506427|NCT00445146|DRUG|EVG|Elvitegravir (EVG) tablet administered orally once daily with food
41164239|NCT02068196|DRUG|Ipilimumab|
41164240|NCT05012943|BIOLOGICAL|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
41377273|NCT05831475|BEHAVIORAL|Intergenerational Virtual Paired Exercise|Participants will be paired with someone older/ younger and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
41377274|NCT05831475|BEHAVIORAL|Peer Virtual Paired Exercise|Participants will be paired with someone of the same age group and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
41377275|NCT04755426|BEHAVIORAL|AVITA--Aortic Valve Improved Treatment Approaches|AVITA is an interactive shared decision making tool that helps patients clarify their treatment goals and preferences and communicate those preferences to their valve specialist.
41377276|NCT06041100|DEVICE|Exoskeleton|Use a passive assistive hip exoskeleton (alQ, Imasen Electrical Industrial Co., Ltd.) for 30 minutes daily during moderate to intensive activities over a period of 12-weeks. The exoskeleton is designed to aid hip flexion and as such its primary role is to improve gait by increasing step length and improving speed. The amount of time the exoskeleton has been used will be weekly monitored through phone calls and two gait sessions will be conducted to measure the development.
41377277|NCT03994991|DEVICE|active TMS|Transcranial magnetic stimulation
41377278|NCT03994991|DEVICE|sham TMS|Sham transcranial magnetic stimulation
41377279|NCT05769465|DRUG|disease modifying treatments|Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
41377280|NCT05848518|OTHER|Rehabilitation program|The participants will be randomly assigned to the experimental groups: supervised endurance rehabilitation program (SEG, n = 30), supervised strength rehabilitation program (SSG, n = 30), supervised concurrent rehabilitation program (SCG, n = 30), and control group (CG, n = 30)
41377281|NCT04241081|BEHAVIORAL|Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia|This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.
41377282|NCT04155775|OTHER|Computer electronic health record alert (Best Practice Alert - BPA)|Upon ordering platelets in patients with recent platelet count \>50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
41377283|NCT05688137|PROCEDURE|Abdominal drainage|The patients with intervention will take an abdominal drainage.
41377284|NCT01211158|DRUG|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
41377285|NCT01211158|DRUG|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS\<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
41377286|NCT04237831|DRUG|BMS-986259|Specified Dose on Specified Days
41377287|NCT00230217|DRUG|Rasburicase (SR29142)|
41377288|NCT04187937|DEVICE|Stereotactic image-guided resection|Stereotactic image-guided resection with an ultrasound-based image-guidance system.
41377289|NCT03162276|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
41377290|NCT03162276|BEHAVIORAL|Control|At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
41377291|NCT03465982|PROCEDURE|Surgery after 8 weeks from chemoradiation treatment|Minimally invasive surgery after 8 weeks from chemoradiation treatment
41506428|NCT00445146|DRUG|RTV|Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
41164241|NCT05012943|OTHER|Placebo (normal saline)|Normal saline with the same volume as of ARCT-154
41164242|NCT05012943|BIOLOGICAL|Astra Zeneca COVID-19 vaccine|Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)
40850653|NCT02767661|DRUG|Aromatase Inhibitor|Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
40850654|NCT03028779|PROCEDURE|Fast-track Total Hip and knee arthroplasty|To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
40850655|NCT04185389|OTHER|HPV and cytology co-testing (via Liquid based collection device)|Liquid-based cytology co-testing is a procedure in which that a cervical sample is taken, and can be co-tested for HPV and standard cytology at the same time. It is collected in the same way that a traditional Pap is collected
40850656|NCT00286871|DRUG|Neoral|
40850657|NCT00286871|DRUG|Tacrolimus|
40850658|NCT00002138|DRUG|Tecogalan sodium|
41377292|NCT03465982|PROCEDURE|Surgery after 12 weeks from chemoradiation treatment|Minimally invasive surgery after 12 weeks from chemoradiation treatment
41377293|NCT00014300|DRUG|glufosfamide|
41377294|NCT03562923|DRUG|Test Product|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
41377295|NCT03562923|DRUG|Reference Product|ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)
41377296|NCT03562923|DRUG|Placebo|Placebo Product
41377297|NCT01238861|BIOLOGICAL|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
41377298|NCT01238861|BIOLOGICAL|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
41377299|NCT01238861|BIOLOGICAL|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
41377300|NCT01238861|OTHER|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
41377301|NCT03878056|DEVICE|Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific|Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
41377302|NCT02511587|BIOLOGICAL|FSME-Immune vaccination|booster vaccination with FSME-Immune
41377303|NCT02415634|OTHER|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~* Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~* Part 2: A rehabilitation goal setting care plan~* Part 3: A patient communication forum~* Part 4: Useful supports and contact information~* Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
41377304|NCT02415634|OTHER|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
41377305|NCT03299439|OTHER|acupuncture|a stimulation of the body or auricular points
41377306|NCT04166188|PROCEDURE|Lumbar erector spinae plane block|Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
41377307|NCT01928810|BEHAVIORAL|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
41377308|NCT04712058|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]|Biktarvy will be administered on the same day of diagnosis. The daily dosing will be continued for 48 weeks.
41377309|NCT04706494|DIETARY_SUPPLEMENT|AlphaWave® LTheanine|200 mg of AlphaWave® LTheanine
41377310|NCT04706494|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
41377311|NCT04283513|DRUG|Virazole|Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
41377312|NCT01466907|OTHER|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
41377313|NCT01466907|OTHER|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
41377314|NCT05717075|BEHAVIORAL|Parents Round|The intervention carried out in this study is called Family Round. The Family Round is an additional medical round, aiming to involve parents in the discussion. The basic attitude of the healthcare staff is to make decisions collaboratively with parents or other family members based on the parents' observations of their infant and parents' opinions. As our daily medical round is carried out in the morning between 8 and 10 a.m. and we offer no accommodation for parents in the NICU, the Family Round will be carried out separately in the afternoon. One neonatologist who is in charge of the infant or taking care of the infant on that day will be a facilitator and proceed with the Parent Round according to the protocol. Other healthcare staff are also encouraged to participate, although the number of participants is limited.
41377315|NCT04756167|OTHER|Conventional Treatment|Hotpack, TENS, ultrasound and exercise
41377316|NCT04756167|OTHER|Myofascial Release Treatment|Hotpack, TENS, ultrasound, exercise and myofascial release therapy for subscapularis and serratus anterior muscles
41377317|NCT05463978|DEVICE|Sculptra Aesthetic|Sculptra Aesthetic in non-facial areas
41377318|NCT06565897|DRUG|Test regimen|toothpaste \& manual toothbrush
41377319|NCT06565897|DRUG|Control regimen|toothpaste \& manual toothbrush
41377320|NCT02206984|DRUG|Tamoxifen|
41164243|NCT06465992|DRUG|Exparel 266 MG Per 20 ML Injection|20 mL Liposomal bupivacaine (Exparel, 266 mg) will be administered in the popliteal and saphenous block
41377321|NCT02206984|DRUG|Anastrozole|
41377322|NCT02206984|DRUG|Fulvestrant|
41164244|NCT06465992|DRUG|Bupivacaine Hcl 0.75% Inj|10 mL of 0.75% bupivacaine will be administered in popliteal and saphenous block
41377323|NCT00088504|DRUG|Merimepodib|
41377324|NCT00088504|DRUG|PEG-Interferon-alpha 2a (Pegasys®)|
41377325|NCT00088504|DRUG|Ribavirin (Copegus®)|
41377326|NCT01042691|DRUG|Oxaliplatin|The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
41377327|NCT02325206|DRUG|dapagliflozin|one administration in the morning
41377328|NCT02325206|DRUG|Placebo|one administration in the morning
41377329|NCT05390086|OTHER|Standard of care|The study is being implemented among children who are seeking care at collaborating hospitals for signs and symptoms suggestive of TDD. All children will be treated by the hospital physicians following the usual hospital procedures. The study will not interfere in any with the administration of required treatments and interventions.
41377330|NCT04983628|OTHER|Tumor molecular profiling|targeted DNA NGS
41377331|NCT05601414|DEVICE|BIO-Z|a novel cuffless continuous BP wrist monitor
41377332|NCT05601414|DEVICE|Finapres Nova|a cuffless continuous BP monitor
41377333|NCT03885349|BEHAVIORAL|SBIP+ ADAPs-IMP|Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
41377334|NCT03885349|BEHAVIORAL|SBIP+IMP|Standard batterer intervention program plus Individualized Motivational Plans. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
41377335|NCT05416346|BEHAVIORAL|Digital Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-i) has been showed to be effective in reducing insomnia symptoms and insomnia-related symptoms, including sleepiness, dysfunctional beliefs and attitudes about sleep, anxiety and depressive symptoms
41377336|NCT05416346|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE group received sleep hygiene education delivered in text form, and the same intervention as the dCBT-i group did after four weeks.
41377337|NCT02861404|GENETIC|skin flakes collection|viral status assessment of skin flakes
41506429|NCT00445146|DRUG|ARV regimen|The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
41506430|NCT04098510|DIETARY_SUPPLEMENT|MitoQ|Subjects ingest 8x20 mg MitoQ capsules
41506431|NCT01897805|DRUG|Heart-protecting Musk Pill|
41506432|NCT01897805|DRUG|Placebo|
41033861|NCT01193803|PROCEDURE|Microbiological cultures and Molecular biology|"Biological/Vaccine: Microbiological cultures and Molecular Biology Bacteriological procedures: All solid specimens will be crushed using a mechanic apparatus. Direct examination and cultures will be performed according to the guidelines applied for osteoarticular infections. Cultures and subcultures will be incubated for 15 days to 3 months for Mycobacteria.~Molecular procedures: DNA extraction will be based on Boom's method (QIAGEN kit and EZ1 BioRobot). Detections of bacteria will be performed by amplification and sequencing of the 16S rRNA gene. Some specific detections as the detection of Staphylococcus sp. and Mycobacterium tuberculosis will be added to this protocol."
41033862|NCT04014660|DIETARY_SUPPLEMENT|Probiotic|The probiotic product consists of two different bacterial strains, L.plantarum Heal 9 and L.paracasei 8700:2
41033863|NCT04014660|DIETARY_SUPPLEMENT|Placebo|The placebo supplement consists of corn starch only.
41033864|NCT01314118|DRUG|abiraterone acetate in combination with prednisone|Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
41033865|NCT01767116|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
41033866|NCT01767116|DRUG|Ribavirin|Capsule
41033867|NCT01767116|DRUG|Placebo for ribavirin|Capsule
41506433|NCT06202729|OTHER|Questionnaire|GAD-7, VAS-A, NRS
41506434|NCT06083519|BEHAVIORAL|White Noise|This is the control condition. Listening to white noise -- participants listen to white noise for 24 minutes
41506435|NCT06083519|BEHAVIORAL|Music and Auditory Beat Stimulation|Listening to music and auditory beat stimulation. The VIBE app (LUCID) incorporates theta-band (4 Hz) auditory beat stimulation and an auditory music recommendation system. Participants will listen to this music with theta auditory beat stimulation for 24 minutes.
41506436|NCT04004416|OTHER|Placebo and fMRI|A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
41033868|NCT06634914|DIETARY_SUPPLEMENT|Moonbrew|A blend of adaptogens with Chamomile, Rose, and Magnesium in a powdered form, designed to be mixed in liquid and consumed 2-3 hours before bed.
41033870|NCT04634201|DIETARY_SUPPLEMENT|Oral probiotics (L. reuteri)|administration of probiotic containing tablets twice daily after tooth brushing for 3 months
41033871|NCT04634201|DIETARY_SUPPLEMENT|Placebo|administration of a placebo twice daily after tooth brushing for 3 months
41377338|NCT03160092|OTHER|Intervention|"The intervention aims to:~* Support the participant to explore their unusual experiences~* Reduce the distress or anxiety participants feel in response to their unusual experiences, through:~  * Helping them to recognise how common these unusual experience~ * Supporting them to make sense of their unusual experiences~ * Supporting them to understand why they may be experiencing these symptoms~ * Challenging any unhelpful beliefs they hold about their symptoms~* Help the participant to recognise the triggers to their unusual experiences~* Support the participant to increase their activities and socialisation~The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms."
41377339|NCT02384239|DRUG|Palbociclib|Given orally (PO)
41377340|NCT02384239|DRUG|Tamoxifen|Given orally (PO)
41377341|NCT02384239|DRUG|Fulvestrant|Given by intramuscular (IM) injection.
41377342|NCT05882656|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period).
41377343|NCT04210882|BEHAVIORAL|Moderate-Intensity Exercise|See description of study arm.
40850659|NCT04085757|DRUG|long interval dinoprostone|A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
41377344|NCT03292731|DRUG|17-Hydroxyprogesterone caproate 250mg or 500 mg.|For the pharmacodynamic study, subjects receiving either 250mg or 500 mg dose will be studied to relate the plasma concentration at 26-30 to the rate of sPTB. For the safety study, subjects will be randomized to either the 250mg or 500 mg dose.
41377345|NCT03292731|DRUG|Safety study of 500 mg dose.|Subjects randomized to 250 mg or 500 mg dose
41377346|NCT02006810|BEHAVIORAL|Induction of endothelial function variations|
41377347|NCT01922635|OTHER|Valadation of the metrological properties of questionnaire of quality of life|
41377348|NCT01058707|DRUG|MLN0128|MLN0128 capsules
41377349|NCT03612830|PROCEDURE|Laparoscopy endoscopy cooperated surgery|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
40850660|NCT04085757|DRUG|short interval dinoprostone|A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
40850661|NCT00514371|DRUG|tanespimycin|High dose
40850662|NCT00514371|DRUG|Bortezomib|Mid dose, and low dose
40850663|NCT05854342|OTHER|bicarbonate-calcium water|water with high content of bicarbonate and calcium, low sodium
40850666|NCT02948738|BEHAVIORAL|Interactive Asthma Education|Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
41164245|NCT06465992|DRUG|Dexamethasone|1 mL of 10 mg Dexamethasone will be administered in the popliteal and saphenous block
41164246|NCT02216578|DRUG|cabozantinib|Oral
41377350|NCT03612830|PROCEDURE|Dan Vinchi robot endoscopy cooperated surgery|RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
41377351|NCT03042975|OTHER|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
41377352|NCT03042975|PROCEDURE|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies.
41377353|NCT04453475|BEHAVIORAL|Training session adressing information and health literacy|The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19
41377354|NCT00474370|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
41377355|NCT00474370|DRUG|Placebo|One tablet of placebo once daily.
41377356|NCT00616889|DRUG|Seroquel|The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
41377357|NCT02404675|DRUG|icotinib|
41377358|NCT01829490|BIOLOGICAL|ChAdOx1 85A|Intramuscular injection
41377359|NCT01829490|BIOLOGICAL|MVA85A|Intramuscular injection
41377360|NCT03520582|DEVICE|Tube placement|Placement of enteral feeding tubes
41377361|NCT01797809|DRUG|EV/DNG (Qlaira, BAY86-5027)|Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
41377362|NCT01327066|DRUG|Droxidopa|600 mg, single oral dose
41377363|NCT01327066|DRUG|Droxidopa|2000 mg, single oral dose
41377364|NCT01327066|DRUG|Moxifloxacin|400 mg, single oral dose
41377365|NCT01327066|DRUG|Placebo|Placebo matching Droxidopa or Moxifloxacin
41377366|NCT03106740|DRUG|Minocycline Hydrochloride 100mg Capsule|Minocycline 100mg will be administered by mouth daily for 2 weeks
41377367|NCT03106740|DIAGNOSTIC_TEST|Magnetic Resonance-Positron Emission Tomography Imaging|Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
41377368|NCT03106740|OTHER|Placebo Capsule|1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
41377369|NCT04635956|DRUG|Drug therapy|6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
41377370|NCT03628781|OTHER|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
41377371|NCT03628781|OTHER|mehealth for ADHD|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
41377372|NCT01736527|DRUG|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
41377373|NCT06369077|DRUG|dorzolamide/timolol|Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing. Compare also to timolol/brimonidine/dorzolamide/bimatoprost
41377374|NCT06041802|BIOLOGICAL|MK-3475A|MK-3475A is a fixed-dose formulation of pembrolizumab and MK-5180 for SC administration.
41377375|NCT01728935|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
41377376|NCT02064374|DRUG|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
41506437|NCT04004416|DRUG|Lorazepam and fMRI|A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
41506438|NCT03046641|OTHER|Continuous training|Study group I (42 participants) received the continuous training.
41506439|NCT03046641|OTHER|The interval training|Study group II (40 participants) received the interval training.
41506440|NCT04974203|DEVICE|AptameX|DNA aptamer-based test using patient's saliva
41506441|NCT02750826|OTHER|Health Education Program|
41506442|NCT02750826|OTHER|Weight Loss Intervention|
41506443|NCT06421298|DRUG|Tafolecimab|450mg Q4W ≤6cycle
41506444|NCT06421298|DRUG|Sintilimab|200mg Q3W ≤2years
41506445|NCT06421298|DRUG|Nab paclitaxel|130mg/m² Q3W 4-6cycles
41506446|NCT06421298|DRUG|Docetaxel|75mg/m² Q3W 4-6cycles
41506447|NCT06421298|DRUG|Gemcitabine|1250mg/m² Q3W 4-6cycles
41506448|NCT04905940|DRUG|Turmeric mouthwash|Turmeric mouthwash evaluation in controlling halitosis
41506449|NCT01342757|DRUG|vorinostat|Given orally
41506450|NCT01342757|DRUG|temozolomide|Given orally
41506451|NCT01342757|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo MRI
41506452|NCT01342757|OTHER|survey administration|Ancillary studies
41506453|NCT03762044|OTHER|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|"* Health education / patient empowerment.~* Neurodynamic activities oriented to ADL.~* Proprioceptive neuromuscular facilitation exercises oriented to ADL.~* Self-adherent self-adhesive antiedema of low compression."
41506454|NCT03762044|OTHER|Complete Decongestive Therapy (CDT)|"* Skin care.~* Kinesitherapy~* Manual lymphatic drainage (MLD)~* Multilayer bandage.~The maintenance phase is based on self-care and the use of compression garments."
41506455|NCT06157190|OTHER|Unsupervised monitoring|"This study introduces technology-assisted rehabilitation for patients post-total hip or knee arthroplasty, utilizing wearable sensors and mobile health tech. The intervention includes:~Technology-Assisted Rehabilitation: Utilizing wearable sensors and mobile health technologies, the intervention promotes unsupervised, real-world assessments after total hip or knee replacement. It shifts from traditional supervised clinical assessments. The moveUP digital therapies platform, featuring a dedicated mobile app, acts as the primary interface for patients in rehabilitation.~Digital Biomarkers: The intervention involves gathering digital biomarkers from wearable sensors and mobile health tech. These biomarkers offer continuous, objective measurements of patients' biological and physiological data. Examples include mobility and activity level data."
41506456|NCT00226291|OTHER|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
41506457|NCT05908175|OTHER|FES-assisted gait training|The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.
40850667|NCT02948738|BEHAVIORAL|Standard Asthma Education|Basic review of asthma action plan and inhaler use
41506458|NCT00394563|DRUG|RN624 (PF-04383119)|10 mcg/kg
41506459|NCT00394563|DRUG|RN624 (PF-04383119)|25 mcg/kg
41506460|NCT00394563|DRUG|RN624 (PF-04383119)|50 mcg/kg
41506461|NCT00394563|DRUG|RN624 (PF-04383119)|100 mcg/kg
41506462|NCT00394563|DRUG|RN624 (PF-04383119)|200 mcg/kg
41506463|NCT00394563|DRUG|placebo|
41506464|NCT02986477|OTHER|Contrast Ultrasound|For diagnostic purposes, intravesicle administration of contrast ultrasound agent will be performed to study vesicoureteral reflux.
41377377|NCT02064374|DRUG|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
41377378|NCT02064374|DRUG|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
41377379|NCT01907516|DEVICE|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
41506465|NCT04134338|OTHER|To evaluate the effect of wound infection on costs|the degree of costs that is required for trating wound infection
41506466|NCT00195455|DRUG|Trimegestone|
41506467|NCT00195455|DRUG|17b Estradiol|
41506468|NCT03915405|DRUG|KHK2455|orally, once daily.
41506469|NCT03915405|DRUG|Avelumab|IV Administration
41506470|NCT04142112|DEVICE|Ohana IVF Sperm Preparation Kit (OHB035)|The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.
41033872|NCT01703364|DRUG|Lenalidomide|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
41506471|NCT04142112|DEVICE|Standard IVF Preparation Kit (OHB037)|The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
41506472|NCT01546454|DRUG|Ethinyl Estradiol-Levonorgestrel combination|0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
41506473|NCT01546454|DRUG|leuprolide acetate|single 22.5 mg subcutaneous depot suspension
41506474|NCT01546454|DRUG|Estradiol|0.05 to 0.3 mg transdermal daily for 26 days
41506475|NCT01546454|DRUG|Progesterone|50 to 100 mg vaginal suppositories twice daily for 13 days
41506476|NCT00794339|DRUG|64Cu-ATSM|
41506477|NCT00794339|DRUG|FDG|
41506478|NCT04502420|DIAGNOSTIC_TEST|Lung function before and after surgery|A diagnostic test
41506479|NCT02523300|PROCEDURE|TEVAR|The patients will be undertaken TEVAR
41033873|NCT02352948|DRUG|MEDI4736 (durvalumab)|MEDI4736 (durvalumab) treatment by intravenous infusion
41033874|NCT02352948|DRUG|Vinorelbine|Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
41033875|NCT02352948|DRUG|Gemcitabine|Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
41033876|NCT02352948|DRUG|Erlotinib|Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
41033877|NCT02352948|DRUG|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
41377380|NCT01907516|BEHAVIORAL|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
41377381|NCT03949634|DRUG|PLD|pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
41506480|NCT02523300|DRUG|Glucocorticoids|About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
41506481|NCT02523300|DRUG|saline|The other 120 patients will be given saline as control group
41377382|NCT03949634|DRUG|CTX|cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
41377383|NCT03949634|DRUG|Docetaxel|docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
41377384|NCT03949634|DRUG|Paclitaxel|paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
41506482|NCT00115427|DRUG|Liatermin (r-metHuGDNF)|
41506483|NCT01357148|DRUG|Sitagliptin Phosphate/Metformin HCl (JANUMET®)|Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
41506484|NCT03916705|OTHER|High Velocity Low amplitude spinal manipulation (HVLA-SM)|HVLA-SM is a commonly used spinal manipulation treatment for patients with chronic low back pain.
41377385|NCT03949634|DRUG|Doxorubicin|doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
41506485|NCT04994405|PROCEDURE|Tourniquet Pressure|"The procedural intervention will be inflation of a pneumatic tourniquet to a lower than standard pressure as determined by the patient's SBP in hand and upper extremity surgery. The control will be inflation of a pneumatic tourniquet at a standard pressure of 250 mmHg in hand and upper extremity surgery.~The tourniquet used will be the standard tourniquet used for hand and upper extremity surgery at our institutions - a tourniquet 18 inches in length and 3 inches in width manufactured by Stryker (Kalamazoo, MI) used in conjunction with a protective sleeve matched to the size of the tourniquet cuff which is provided by the manufacturer. Both pieces are supplied in a sterile packaging. No other tourniquets will be used."
41506486|NCT00625872|DRUG|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
41506487|NCT00625872|DRUG|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
41506488|NCT06253806|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 1% mepivacaine will be injected near the stellate ganglion.
41506489|NCT06253806|DRUG|Placebo Sham Injection|The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 0.9% saline will be injected near the stellate ganglion.
41506490|NCT00875797|DIETARY_SUPPLEMENT|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
41377386|NCT03047889|DRUG|standard therapy|standard therapy for advanced/metastatic breast cancer
41377387|NCT00708656|DRUG|mesalazine (Asacol®)|800 mg tablets
41506491|NCT00875797|DIETARY_SUPPLEMENT|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
41506492|NCT03683290|OTHER|Image acquisition and analysis|Oocyte image obtention and analysis prior to intracytoplasmic sperm injection
41506493|NCT02989909|DEVICE|CATS tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
41506494|NCT02989909|DEVICE|Goldmann tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
41506495|NCT05850598|DEVICE|sham rTMS|The coil was held while disconnected from the stimulator, and rTMS noise was presented with computer loudspeakers with recorded sound from a real stimulation (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
41506496|NCT05850598|DEVICE|active rTMS|Low-frequency (1 Hz) rTMS at with a stimulation intensity of 95% of the motor threshold will be delivered over the bilateral cerebellum for patients with Parkinson's disease (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
41506497|NCT03108378|PROCEDURE|Surgery|hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
41506498|NCT05190692|DEVICE|Use simulators in Obstetrics vaginal examination|"Two simulators will be used in the study:~(1st ) : PROMPT Flex Birthing Simulator Advanced - Light (PRODUCT NO. 80106).UK, 2020 .~2nd): PROMPT Flex Cervical Dilatation \& Effacement Module -Light (PRODUCT NO. 80102),Uk,2020.~Both will be used to perform obstetric vaginal examination before examination of patients"
41506499|NCT05175703|DEVICE|Passeo-18 Lux Paclitaxel releasing Balloon Catheter|collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
41506500|NCT00001526|DRUG|Daclizumab (Zenapax)|
41506501|NCT02786225|BEHAVIORAL|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a VUMC perinatologist and a VUSN nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
41033878|NCT02352948|DRUG|tremelimumab (anti-CTLA4)|tremelimumab (anti-CTLA4) treatment by intravenous infusion
41506502|NCT02786225|BEHAVIORAL|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
41506503|NCT02348255|PROCEDURE|Electric Field Therapy|Undergo NovoTTF-100A
41033879|NCT03419169|DEVICE|Light load BFR resistance training|A novel training light load resistance training modality.
41377388|NCT04355767|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma with neutralizing SARS-CoV2 antibodies titers of ≥1:160 administered via intravenous (IV) infusion.
41377389|NCT04355767|BIOLOGICAL|Saline|Saline with multivitamin administered via intravenous (IV) infusion..
41506504|NCT02348255|BIOLOGICAL|Bevacizumab|Given IV
41506505|NCT02348255|DRUG|Carmustine|Given IV
41506506|NCT02348255|OTHER|Quality-of-Life Assessment|Ancillary studies
41506507|NCT03548727|DIAGNOSTIC_TEST|PET/CT Imaging|PET/CT Imaging of tumor hypoxia and proliferation
41506508|NCT01776931|DIETARY_SUPPLEMENT|Lysine intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
41506509|NCT01884038|DRUG|treprostinil sodium|"A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative"
41506510|NCT01884038|DRUG|Placebo|
41506511|NCT03338725|OTHER|Clinical pharmacy model|Patients who are being monitored by a clinical pharmacy model
41033880|NCT03419169|PROCEDURE|Heavy load resistance training|A common form of resistance training used for rehabilitation within the National Health Service.
41164247|NCT05596149|OTHER|Toothpaste without fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste without fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
41164248|NCT05596149|OTHER|Toothpaste with sodium fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
41164249|NCT05596149|OTHER|Toothpaste with sodium monofluorophosphate|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium monofluorophosphate and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
41164250|NCT05596149|OTHER|Toothpaste with amine fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with amine fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
41164251|NCT03806413|OTHER|Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
41164252|NCT05027880|BEHAVIORAL|Web-based single-session growth mindset intervention for adolescent anxiety|This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.
41164253|NCT04126122|DIAGNOSTIC_TEST|Ultrasonography to assess fetus and mother|to assess fetal growth and maternal outcome
41164254|NCT01583738|DRUG|V0251|single dose
41164255|NCT01583738|DRUG|placebo|single dose
41164256|NCT00221702|DRUG|PegIntron|100 mcg SC/week for 36 months
41164257|NCT00221702|DRUG|intron A|3mui TIWW SC for 18 months
41164258|NCT06448936|OTHER|Patient-reported outcome measures (PROMs)|Administration of questionnaires investigating the impact of facial difficult-to-treat basal cell carcinoma treated by surgery on patient's quality of life over the course of one year. The questionnaires will be submitted at baseline (i.e., before surgery) and at 3-months follow up.
41164259|NCT01209286|BIOLOGICAL|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
41164260|NCT04058236|OTHER|human albumin 5%|Human Albumin 5% will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
41377390|NCT04275375|OTHER|observation study about the autonomic response after spinal anesthesia|ECG waveforms were continuously recorded using a multichannel polygraphic system (Embla N7000, Natus, Pleasanton, CA). The data were saved at a rate of 1024 Hz directly to a memory card within the device for offline analysis of heart rate variability (HRV) and PPG. All data included in the analysis were obtained from continuous artifact-free ECG recordings for analysis of the immediate effects of spinal anesthesia.
41377391|NCT01924572|PROCEDURE|cord clamping at 2 minutes|
41377392|NCT01924572|PROCEDURE|cord clamping at 5 minutes|
41377393|NCT01924572|PROCEDURE|cord milking|
41377394|NCT04156009|OTHER|Activated Lavender Elequil aromatabs® (#372)|Activated Lavender aromatherapy tablets wrapped in tape
41377395|NCT04156009|OTHER|Unactivated Lavender Elequil aromatabs® (#372)|Unactivated Lavender aromatherapy tablets wrapped in tape
40850668|NCT04193592|DRUG|Pirfenidone|Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
41377396|NCT03775265|DRUG|Atezolizumab|Given IV
41377397|NCT03775265|PROCEDURE|Biopsy of Bladder|Undergo a bladder biopsy
41377398|NCT03775265|DRUG|Cisplatin|Given IV
41377399|NCT03775265|PROCEDURE|Computed Tomography|Undergo CT or MRI
41377400|NCT03775265|PROCEDURE|Cystoscopy|Undergo a cystoscopy
41377401|NCT03775265|DRUG|Fluorouracil|Given IV
41377402|NCT03775265|DRUG|Gemcitabine|Given IV
41377403|NCT03775265|PROCEDURE|Magnetic Resonance Imaging|Undergo CT or MRI
41377404|NCT03775265|DRUG|Mitomycin|Given IV
41377405|NCT03775265|OTHER|Quality-of-Life Assessment|Ancillary studies
41377406|NCT03775265|RADIATION|Radiation Therapy|Undergo 3DCRT or IMRT
41377407|NCT03775265|OTHER|Survey Administration|Ancillary studies
41377408|NCT03775265|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo a TURBT
41377409|NCT05039632|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally
41377410|NCT05039632|RADIATION|Radiation Therapy|Undergo Abscopal radiation therapy
41377411|NCT05039632|RADIATION|Radiation Therapy|Undergo RadScopal radiation therapy
40850669|NCT04218539|DRUG|Psilocybin|10mg Psilocybin
40850670|NCT04218539|DRUG|Placebo|25mg Diphenhydramine
41377412|NCT01065246|DRUG|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
40850671|NCT06291285|DRUG|Decitabine-THU|Orally administered immediate release tablets.
40850672|NCT06291285|DRUG|Decitabine-THU|Orally administered delayed release capsules.
40850673|NCT06165263|BEHAVIORAL|Mobile earthquake education|The mobile earthquake education application was developed to increase high school students\&#39; knowledge about earthquakes through videos, activities or games. In the mobile earthquake education application, there are 4 modules that provide general information about the earthquake and what to do before, during and after the earthquake.
41377413|NCT02943369|DRUG|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
41377414|NCT02943369|DRUG|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
41377415|NCT02894060|OTHER|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
40850674|NCT06136611|DEVICE|TTFields|TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
40850675|NCT02022163|BIOLOGICAL|Low dose of H7 VLP vaccine + Alhydrogel|Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
40850676|NCT02022163|BIOLOGICAL|Med dose of H7 VLP vaccine + Alhydrogel|Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
40850677|NCT02022163|BIOLOGICAL|High dose of H7 VLP vaccine + Alhydrogel|High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
40850678|NCT02022163|BIOLOGICAL|High dose of H7 VLP vaccine|High dose of H7 VLP vaccine, 2 doses given 21 days apart
40850679|NCT02022163|BIOLOGICAL|Placebo|Placebo, 2 doses given 21 days apart
41033881|NCT06349161|PROCEDURE|One-trocar-assisted pyeloplasty|Positioned in a full lateral decubitus posture. A 12mm incision was made below the 12th rib, followed by a muscle-sparing technique to access and open the Gerota's fascia. A 10mm balloon trocar was inserted, and CO2 was insufflated to a pressure of 12 mmHg at a flow rate of 3L. An operative scope with dual channels was introduced for retroperitoneal dissection, utilizing a peanut to expand the working space. The proximal ureter, UPJ, and renal pelvis were visualized, and the UPJ was mobilized and exteriorized under direct visualization to prevent torsion. Anderson-Hynes dismembered pyeloplasty was performed using a 6/0 PDS suture, with possible enlargement of the incision if necessary. A 4 French double J ureteral stent was inserted antegradely before completing the anastomosis, verified by methylene blue presence at the anastomotic site. A final retroperitoneoscopic assessment ensured proper alignment of the anastomosis, with closure of the incision site without drain placement.
41033882|NCT00497380|DIETARY_SUPPLEMENT|Arginine|Oral nutritional supplement
41033883|NCT06370598|BIOLOGICAL|TP-122A|Bacteriophage cocktail targeting Psa
41377416|NCT06566196|PROCEDURE|Cardiac Cath|Patient will undergo standard of care Cardiac Cath and in addition invasive CPET (Cardiopulmonary exercise testing) will be performed during the procedure.
41033884|NCT04986657|DEVICE|ChromoSeq|Novel, streamlined whole genome sequencing approach
40850680|NCT02485704|DRUG|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
40850681|NCT02485704|OTHER|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
40850682|NCT01289366|DEVICE|Endocytoscopy|Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy are prospectively included in this study. Methylene blue or toluidine blue is topically applied to enable EC (XEC-120-U, Olympus, Tokyo, Japan). Data are digitally saved and analyzed independently from each other by two gastroenterologists and one pathologist who are blinded to clinical and endoscopic data.
40850683|NCT04869306|DEVICE|Hyaluronic acid gel|After lower third molar removal, the test group 1 will additionally receive hyaluronic acid gel prior to wound closure.
40850684|NCT04869306|DEVICE|Hyaluronic acid gel + carrier|After lower third molar removal, the test group 2 will additionally receive hyaluronic acid gel with a collagen carrier prior to wound closure.
40850685|NCT02599779|DRUG|Pembrolizumab|200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
40850686|NCT02599779|RADIATION|Stereotactic Body Radiation Therapy|Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
40850687|NCT02429791|DRUG|DTG 50 mg|Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
41033885|NCT05641688|DRUG|[18F]PI-2620|The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%
41033886|NCT05038735|DRUG|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
41033887|NCT05038735|DRUG|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).
41033888|NCT05038735|DRUG|Alpelisib-matching placebo|Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
41033889|NCT04576091|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41033890|NCT04576091|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT scan
41033891|NCT04576091|DRUG|Elimusertib|Given PO
41033892|NCT04576091|BIOLOGICAL|Pembrolizumab|Given IV
41033893|NCT04576091|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
41033894|NCT04576091|OTHER|Quality-of-Life Assessment|Ancillary studies
41033895|NCT04576091|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41033896|NCT04576169|PROCEDURE|Arthroscopic Debridement|Wrist arthroscopy can be performed with or without irrigation. In the debridement arm, a central or radial TFCC tear found during arthroscopy is debrided with a shaver. Portals are closed either with sutures or with medical tape. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
41164261|NCT04058236|OTHER|gelofusine.|Gelofusine will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
41377417|NCT04271241|OTHER|Passive stretching (PS) training|PSBil and PSMono underwent 12 weeks of PS training, 3 sessions per week (36 sessions in total). In PSBil, each session lasted 40 min and included two maneuvers for both the knee extensor and plantar flexor muscles with the following protocol: 45 s elongation and 15 s recovery in the resting position, all the cycle repeated for five times 7. In PSMono, exercises were performed only on the right limb and each session had a duration of 20 min. Ctrl did not underwent any PS exercise throughout the study. To promote participants' compliance, daily classes were held at different day time (morning and afternoon) at the University Sports Centre gym. Each class was supervised by an expert operator, which monitored the attendance, the correct exercise execution and the intensity exerted during the exercise (80% of the point of discomfort). The participants not attending at least the 80% of classes were excluded from the study, and a new participant was recruited to substitute the drop out.
41377418|NCT04232761|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug administration as determined by treating physician
41377419|NCT00615927|DRUG|Imatinib Mesylate & Hydroxyurea|"Imatinib administered orally on daily. Imatinib is local irritant \& must be taken in sitting position; mini of 2hrs should be allowed between last drug intake \& going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/\> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 \& continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts."
41377420|NCT03611920|PROCEDURE|Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
41377421|NCT03611920|PROCEDURE|Dexamethasone|Teeth were soaked in topical dexamethasone (60μ ml-1) for 20 minutes before replantation
41377422|NCT06543056|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 24 months.
41377423|NCT04217239|PROCEDURE|MIE Ivor- Lewis|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
41377424|NCT04217239|PROCEDURE|MIE McKeown|minimally invasive esophagectomy (MIE) with cervical anastomosis
41506512|NCT05505045|BEHAVIORAL|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
41506513|NCT05505045|BEHAVIORAL|Attention Control Procedures|Individuals in the attention control group will have dose-equivalent, weekly virtual contact through the Zoom platform for 12-weeks with a a trained interventionist not involved in CO-OP treatment. The control group will control for interpersonal interaction, maturation effects, and testing effects. The focus of each session will include: (1) social interaction characterized by warmth/empathy and (2) provision of usual care CRCI educational resources (e.g. exercise, using memory aids, minimizing distractions) from MD Anderson Cancer Center. These recommendations will be provided without further instruction. Any questions that arise regarding CRCI the subject is experiencing will be answered. The therapist will debrief with the subject on any changes in CRCI symptoms. The content and duration of each call will be tracked. Each session will be recorded with two randomly selected and reviewed for fidelity.
41506514|NCT05088785|DRUG|FES|\[18F\]FES PET imaging.
41506515|NCT00451945|PROCEDURE|biopsy|
41506516|NCT00451945|DEVICE|3d-ultrasound and fusion of UL and PET/CT|
41506517|NCT06551181|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.
41506518|NCT06551181|DRUG|Placebo|One dose of placebo is administered intramuscularly at Day 1.
41506519|NCT01740050|DIETARY_SUPPLEMENT|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
41506520|NCT01740050|PROCEDURE|RYGB|
41506521|NCT01740050|PROCEDURE|LAGB|
41377425|NCT02494804|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
41377426|NCT02494804|BIOLOGICAL|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
40850688|NCT02429791|DRUG|RPV 25 mg|Participants received one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
41377427|NCT04170569|BEHAVIORAL|Yoga|Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
41377428|NCT05660135|DRUG|Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca|Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
40850689|NCT02429791|DRUG|CAR|CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
40850690|NCT05063682|BIOLOGICAL|EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes|ICV administration
40850691|NCT00564213|DRUG|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
40850692|NCT02466009|DRUG|Regorafenib|Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
40850693|NCT00117260|DRUG|Seasonale (levonorgestrel and ethinyl estradiol)|
40850694|NCT05672550|DRUG|Bayesian based dose adjustment of enoxaparin|"A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours.~Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7."
40850695|NCT05672550|DRUG|Usual dose adjustment of enoxaparin|A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
40850696|NCT01487889|OTHER|Fatty acid composition of complementary food|Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
40850697|NCT04336033|OTHER|Counseling|Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
40850698|NCT04336033|OTHER|Renal Diet App|Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.
40850699|NCT04336033|OTHER|Printed Nutrition Pamphlet|"After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose.~Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions."
40850700|NCT05345717|DRUG|Belatacept Injection|Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy
40850701|NCT04286815|DEVICE|Lentiviral Vector Gene Therapy|Lentiviral vector to transfer IL2RG complementary DNA to patients'bone marrow stem cells
41164262|NCT02134613|OTHER|99mTc-anti-TNF-alpha Scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
41164263|NCT01978236|DRUG|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
41164264|NCT01978236|DRUG|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
41377429|NCT04715880|PROCEDURE|Paravertebral block/Intercostal Block (PVB/ICB) group|A paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
41377430|NCT04715880|PROCEDURE|Paravertebral Block (PVB) group|A paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity. The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour
41377431|NCT05215509|BEHAVIORAL|Exercise|Supervised high-intensity interval training for 12 weeks three times per week. The supervision may be physical or online supervision
41377432|NCT05215509|BEHAVIORAL|No exercise|Control group, therefore no supervised exercise regime
41377433|NCT03489239|DRUG|Tenofovir Alafenamide|subjects switching from Entecavir to single arm TAF 25mg
41377434|NCT00609115|DEVICE|AMES device (test)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
41506522|NCT03567928|DEVICE|Sedation with Gastro Cuff Pilot Laryngeal Mask|This specific type of laryngeal mask allows to separate the gastric and respiratory tract and allows the anesthesiologist to support patient's ventilation as (and only if) necessary.
41506523|NCT03567928|DRUG|Propofol|Target controlled infusion (TCI) with propofol
41506524|NCT06155695|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be administered using the Starstim system. We will use the freely available Simulation of Non-Invasive Brain Stimulation (SimNIBS) software to optimally target the rVLPFC and left TPJ in each subject. Finite element models will be generated using T1 and T2 scans. We will generate multiple models to maximize on-target stimulation and minimize off-target stimulation, as determined by ratio of the summed current density within and beyond target regions of interest (ROIs). tDCS current in the active stimulation condition will be maintained at 2.0 milliamps (mA) for the first 45 minutes of each one-hour training session. Sham stimulation the same current, only the current will be ramped down to 0 mA after 30 seconds. Our previous research has shown this method to produce indistinguishable skin sensation. During tDCS, patients will be monitored for possible negative side effects.
41506525|NCT06155695|BEHAVIORAL|Auditory Cognitive Control Training (ACCT)|ACCT incorporates a subset of components from Cognitive Enhancement Therapy found to have early benefits on the cognitive deficits of interest to the proposed studies and can be conducted more time-efficiently to achieve our specific goals. ACCT involves approximately 3 hours of computerized neurocognitive training using cognitive control and processing speed training software developed by Ben-Yishay and colleagues. Deficits in cognitive control are addressed with computer training exercises containing simple stimuli with little inherent emotional or motivational salience. ACCT requires individuals to be vigilant, inhibit irrelevant stimuli, and shift attention between auditory and visual modalities. Computer training exercises facilitate reaction time in a temporal mode using auditory cues (The Attention Reaction Conditioner), spatial focusing with visual cues (the Zero Accuracy Conditioner), and temporal vigilance with auditory and visual cues (Time Estimates).
41506526|NCT06484686|BIOLOGICAL|Live Attenuated Varicella Vaccine|lyophilized powder, subcutaneous injection
41164265|NCT06454318|DIAGNOSTIC_TEST|Wellue O2 ring|Wellue O2 ring wore when doing the polysomnography
41164266|NCT04865783|PROCEDURE|Saline spray|The saline spray will be applied twice for 1-2 seconds.
41164267|NCT04865783|PROCEDURE|Cryospray|The cryospray will be applied twice for 1-2 seconds.
41164268|NCT00495872|DRUG|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
41164269|NCT00495872|DRUG|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
41377435|NCT00609115|DEVICE|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
41377436|NCT00609115|DEVICE|AMES device (crossover)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
41377437|NCT01851343|OTHER|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
41377438|NCT04121832|DEVICE|Biofeedback training treatment in Fibromyalgia, a pilot study|The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks
41377439|NCT04121832|OTHER|Control (treatment as usual)|The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
41164270|NCT00495872|DRUG|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
41164271|NCT00495872|DRUG|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
41164272|NCT00495872|DRUG|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
41164273|NCT00495872|DRUG|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
41164274|NCT00495872|DRUG|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
41164275|NCT01384383|DRUG|GS-5885|GS-5885 30 mg tablet administered orally once daily
41377440|NCT04604353|DIAGNOSTIC_TEST|Polygenic Risk Score|Risk description to patient based on PRS
41377441|NCT04604353|DIAGNOSTIC_TEST|Coronary Calcium Score|Risk description to patient based on CCS
41377442|NCT02861729|OTHER|Vita Suprinity|zirconia reinforced lithium silicate partial coverage restorations
41377443|NCT02861729|OTHER|IPS e.max|lithium disilicate partial coverage restorations
41377444|NCT04836832|DRUG|Acalabrutinib|Given PO
41377445|NCT04836832|DRUG|Duvelisib|Given PO
41377446|NCT04837586|OTHER|Standard Care|Individuals will receive standard care for their obesity through the Pediatric Weight Management Clinic.
41377447|NCT04837586|DEVICE|Simple Scale|Individuals will be encouraged to perform daily weighing at home on a simple scale.
41164276|NCT01384383|DRUG|GS-9451|GS-9451 200 mg tablet administered orally once daily
41164277|NCT01384383|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
41164278|NCT01384383|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
41164279|NCT00000398|BEHAVIORAL|Coping skills training|
41377448|NCT04837586|DEVICE|EHR-Connected Scale|Individuals will be encouraged to perform daily weighing at home on a Smart scale that connects to the EHR. Clinic staff will review weight entries in the EHR and provide feedback.
41377449|NCT02253849|DRUG|Carbamazepine|
41164280|NCT00000398|BEHAVIORAL|Physical exercise training|
41377450|NCT02253849|DRUG|Tipranavir|
41377451|NCT02253849|DRUG|Ritonavir|
41377452|NCT02086734|OTHER|Perfusion-CT|"1. Baseline Perfusion CT-Scan (before AAT)~2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT~3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"
41377453|NCT01406327|DRUG|Ambrisentan|Ambrisentan
41377454|NCT04029142|DIAGNOSTIC_TEST|Review of routine lab data|Review of routine lab data from pregnant women (first trimester)
41377455|NCT04714710|DRUG|IV Potassium Canrenoate|"Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room"
41377456|NCT04714710|DRUG|IV Sodium Chloride 0.9 %|"Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room."
41164281|NCT00000398|BEHAVIORAL|Coping skills training plus physical exercise training|
41164282|NCT01792596|OTHER|Pasta with protein|Pasta with Protein
41164283|NCT01792596|OTHER|Pasta with Fiber|Pasta with Fiber
41164284|NCT01792596|OTHER|Pasta|Pasta
41164285|NCT01778647|DIETARY_SUPPLEMENT|Stimulants plus Lovaza|Patients randomized to stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. Conners and CGI scales filled out by parents, teachers and evaluators on each visit
41164286|NCT01778647|DRUG|Stimulants plus placebo|Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
41164287|NCT02105727|BEHAVIORAL|Community-based salt reduction|
41164288|NCT01603342|DRUG|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
41164289|NCT01603342|DRUG|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
41033897|NCT04576169|PROCEDURE|Placebo surgery|Diagnostic wrist arthroscopy can be performed with or without irrigation. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed either with sutures or with medical tape. The procedure is performed in general or regional anesthesia in operating room. Participants are not able to see to the operation area or monitor. They will listen to music with noise-cancelling headphones throughout the operation. The operative time will be matched, with the surgeon simulating a debridement procedure. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
41033898|NCT04576169|PROCEDURE|Arthroscopic or Open Repair|An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.
41033899|NCT04576169|PROCEDURE|Physiotherapy|An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
41033900|NCT06050460|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
41033901|NCT06050460|OTHER|Placebo for SA55 injection|Placebo for Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
41033902|NCT03264989|DRUG|crizanlizumab|Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days
41033903|NCT05369585|DIETARY_SUPPLEMENT|TOTUM-63|5-g per day dose of TOTUM-63 supplement, a mix of 5 plant extracts. Daily dose for 8 weeks followed by a 4 weeks follow-up period without supplementation.
41377457|NCT04324957|OTHER|Neonatal cardio-pulmonary outcome measure used to assess cardio-pulmonary status|Neonatal cardio-pulmonary outcome measure will be used to assess overall status of pulmonaryand cardio-vascular system
41033904|NCT03336619|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
41033905|NCT03336619|DRUG|Placebo|Placebo administered orally twice daily for five days
41033906|NCT03877523|DIETARY_SUPPLEMENT|Cocarnit|a metabolic complex
41164290|NCT01084239|RADIATION|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
41164291|NCT01304108|OTHER|VTE-P Tollgate|Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system
41164292|NCT01304108|OTHER|BLAZE Pop up|Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.
41033907|NCT02478294|PROCEDURE|Thoracoscopic LAA Excision plus AF Ablation|In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.
41033908|NCT02478294|DRUG|Warfarin or Novel Oral Anticoagulants|In this group, patients receive warfarin or novel oral anticoagulants
41033909|NCT06262035|OTHER|Periodontitis and Peri-implantitis|Defined periodontitis at ≤ 2 non-adjacent teeth AND Defined peri-implantitis at ≤ 1 implant, in function of at least 1 year.
41164293|NCT01304108|OTHER|Usual Care|No addition to the baseline system for care
41164294|NCT04669002|DRUG|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
41164295|NCT04669002|DRUG|Olaparib tablets|Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor)
41377458|NCT04846907|OTHER|Web-based survey|Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
41377459|NCT00295919|DRUG|fenretinide lipid matrix|
41164296|NCT04877249|BEHAVIORAL|Split-belt treadmill training|1. Split-belt gait training without or with any resistance, 2. Facilitating the knee extension during the terminal swing phase of gait cycle to identify the impact on the propulsive force generation of paretic leg
41164297|NCT03838978|DEVICE|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
41164298|NCT04977297|BEHAVIORAL|Move to Music Intervention (M2M)|The move to music (M2M) intervention pairs exercise with only music (no video), providing only audio stimulation. The intervention will be provided via an audio playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
41164299|NCT04977297|BEHAVIORAL|Move to Music -Video (M2M-V) Intervention|The move to music video (M2M-V) intervention pairs exercise with both music and video, thus providing both audio and visual stimulation. The intervention will be provided via an audio and video playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
41164300|NCT04733053|OTHER|Diet plus exercise|"The diet program has two phases: 1) intensive weight loss through a ketogenic very low calorie diet VLCD, and 2) transition from ketogenic VLCD onto a healthy eating plan for weight maintenance. Meal replacements will be provided to participants free of charge from the start of the trial to a maximum of 14 weeks (12 weeks for the ketogenic diet and 2 weeks for transition). If a participant does not wish to transition off the ketogenic diet after 14 weeks but wants to continue or if they wish to recommence the ketogenic diet any time after week 14 they will need to purchase meal replacements themselves at their own cost.~Participants will be encouraged to aim to lose at least 10% body weight."
41377460|NCT00295919|DRUG|ketoconazole|
41377461|NCT00295919|OTHER|laboratory biomarker analysis|
41377462|NCT00295919|OTHER|pharmacological study|
41377463|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
41377464|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
41377465|NCT04562766|DRUG|Rilzabrutinib|400mg Caplet
41377466|NCT04562766|DRUG|Placebo|400mg Caplet
41377467|NCT04800159|DRUG|THC Cannabis|Vaporization of cannabis
41377468|NCT04800159|DRUG|CBD Cannabis|Vaporization of cannabis
41377469|NCT04800159|DRUG|Placebo|Vaporization of placebo
41377470|NCT05686928|DRUG|Cetaphil Healing Ointment|Topical ointment application twice daily
41377471|NCT04125498|OTHER|Osteopathic treatment|Manual treatment that aims to release myofascial tensions
41377472|NCT04125498|OTHER|Placebo treatment|Similar to OMT without pressure
41377473|NCT04125498|OTHER|Self-massage|Women will be instructed to perform self-massage at home once a day for 5 minutes.
41377474|NCT00761566|OTHER|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
41377475|NCT00761566|OTHER|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
41377476|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening.
41377477|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening. They will also receive text messages to remind them to have their lab completed as well as a link to schedule the lab and inform them of walk-in hours.
40850702|NCT02036008|OTHER|Liver MRI with Gdfos|"Participants will receive Gdfos at a dose of 10 mL of 0.25mmol/mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase.~This study will be performed within 4 weeks of the MRI study with EcGd."
40850703|NCT02036008|OTHER|Liver MRI with EcGd|"Participants will receive a liver MRI with EcGd as per clinical institutional protocol.~Participants will receive EcGd at a dose of 0.1 mL/kg body mass up to 10 mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase. Additional noncontrast images will be obtained as per institutional protocol, including diffusion weighted imaging, in/out of phase imaging, and T2 weighted imaging."
41377478|NCT04511975|DRUG|IBI188|IBI188: 100 mg/mL, intravenous infusion once a week
41377479|NCT04511975|DRUG|Azacitidine|Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle
41377480|NCT06507059|DRUG|cabotegravir/rilpivirine (600mg/ 900mg)|Immediate switch from oral antiretroviral to long-acting injectables
41506527|NCT04884373|DIAGNOSTIC_TEST|Gastric ultrasound|An ultrasound exam will be performed before induction of anaesthesia. GUS results from selected patients will be systematically acquired and assessed following an algorithm (Appendix Ia). The ultrasound results will be collected on a standardized form (Appendix IIa). The technique is performed in the supine and right lateral decubitus position (Appendix Ib) and only by anesthesiologists with sufficient experience with ultrasound and the technique. The patient will be asked to indicate his/her satiety on a predetermined ten-point scale.
40850704|NCT03212534|OTHER|Patient mortality prediction|Healthcare provider is notified of patient mortality prediction.
41377481|NCT06507059|DRUG|Antiretroviral Combinations|Standard all-oral antiretroviral combinations
41377482|NCT00470249|DRUG|Carboplatin|At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
41377483|NCT00470249|DRUG|Gemcitabine Hydrochloride|1500 mg/m2 on day 2 of every 2-week cycle
41377484|NCT05635682|OTHER|Observational and anthropometric assesments|Plantar sensation, foot reaction time, head and trunk proprioceptions, posture, balance and gait assesments
41377485|NCT06330506|OTHER|Pressure ulcer prevention pack|The pressure ulcer prevention package to be prepared by the researchers will be applied
41377486|NCT05814224|DIAGNOSTIC_TEST|Liquid biopsy and CT scan|"CT scan and liquid biopsy blood sample are performed at baseline, after 8 weeks from baseline and, then, every 12 weeks.~Between two subsequent CT scan another liquid biopsy blood sample is performed.~CEA and CA 15.3 will be performed at baseline and then concomitantly to the radiological evaluation"
41377487|NCT06568042|DRUG|LY3848575|Administered SC
41377488|NCT06568042|DRUG|Placebo|Administered SC
41377489|NCT03207607|OTHER|Control snack|Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
41377490|NCT03207607|OTHER|Maltodextrin snack|Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
41377491|NCT03207607|OTHER|Whey protein snack|Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
41506528|NCT02104115|OTHER|MRI scanners|
41506529|NCT02104115|OTHER|VAS Symptom scores|
41506530|NCT04243031|DEVICE|QFT Access|Measure of Interferon Gamma
41506531|NCT02317029|DEVICE|Cardioversion with a pulsed biphasic waveform|Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
41377492|NCT03207607|OTHER|Oat snack|Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
41377493|NCT03207607|OTHER|Coconut oil snack|Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
41377494|NCT03207607|OTHER|Snack skipping|no snack
40850705|NCT02717052|DRUG|(S)-ketamine (Main study)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
41033910|NCT05150730|OTHER|Multi professional care|Participants were instructed to respect their pain threshold during body practice and the evolution of the participants happened gradually and individually. Associated with the practice of exercise, workers received information about their disease, chronic pain, guidelines for daily activities, and the importance of physical exercise. In the second hour, the responsible psychologist addressed issues such as the repercussions of illnesses on the individual's social and affective life, self-esteem, self-image, conformism, and self-indulgence after the illness and prospects for the future. Throughout the program, participants also received informative lectures from other professionals, such as social workers, nurses, and dentists.
41033911|NCT03821376|DRUG|Contrast enhanced ultrasound with Lumason|Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
41033912|NCT01244048|DIETARY_SUPPLEMENT|n3 long chain polyunsaturated fatty acids|Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)
41377495|NCT02452775|BIOLOGICAL|OC-L|
41377496|NCT02452775|OTHER|Montanide|
41377497|NCT02452775|OTHER|poly-ICLC (Hiltonol),|
41377498|NCT05277987|DRUG|HEC-016(0.5×10^6 CAR-T Cells)|The initial dose is set to 0.5 × 10\^6 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group. DLT was observed within 28 days after cell infusion.
41377499|NCT05277987|DRUG|HEC-016(0.5×10^6.5 CAR-T Cells)|The Second dose is set 0.5 × 10\^6.5 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
41377500|NCT05277987|DRUG|HEC-016(0.5×10^7 CAR-T Cells)|The Third dose is set 0.5 × 10\^7 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
41377501|NCT01407627|DIETARY_SUPPLEMENT|Fructose|"Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d"
41033913|NCT06632184|DRUG|Ondansetron (ODT) + Bicarbnate solution|This intervention involves the administration of an intraperitoneal solution of ondansetron combined with bicarbonate during laparoscopic cholecystectomy. The addition of bicarbonate is intended to enhance the analgesic properties of ondansetron by increasing its pH, which may improve its efficacy in controlling postoperative pain. This formulation is being compared to ondansetron in saline to determine its superiority in reducing pain, as well as the need for rescue analgesia and postoperative nausea and vomiting (PONV). The intervention is administered once intraoperatively.
41377502|NCT03953157|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary intervention
41377503|NCT03953157|BEHAVIORAL|Exercise Intervention|Receive exercise intervention
41377504|NCT03953157|OTHER|Questionnaire Administration|Ancillary studies
41377505|NCT06546735|DRUG|N0728|1 tablet of the test drug (N0728) and 1 tablet of placebo of Vesomni®.
41377506|NCT06546735|DRUG|Vesomni®|1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.
41377507|NCT05584241|BEHAVIORAL|Diagnostic Disclosure Protocol|Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.
41377508|NCT05584241|BEHAVIORAL|Biomarker Disclosure Protocol|Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.
41377509|NCT04045054|BEHAVIORAL|Link Team|A VA home care Link Team (clinical pharmacist, social worker, physical activity trainer) provides the intervention based on a conceptual model of home care as a bridge between hospital and home, in which three interconnected domains determine short-term and long-term outcomes: medical complexity (e.g., medication management), social complexity (e.g., caregiving, environment), and functional impairment (e.g., mobility, physical activity). The Link Team provides support and assessment for each domain, and will use tablet technology and wearable sensors in the home to gather patient data and facilitate communication. At the end of formal home care services, the Link Team provides patient-centered care in: 1) support for the the Veteran and caregiver in the event of changes in medical condition or medications and social or caregiver stressors; and 2) coaching to the Veteran and the caregiver during this transition period to optimize functional mobility and physical activity.
41377510|NCT00998231|BIOLOGICAL|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
41377511|NCT03273816|BEHAVIORAL|sessions of sophrology|10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
40850706|NCT02717052|DRUG|(S)-ketamine (Pilot II)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes."
40850707|NCT02717052|DRUG|(R,S)-ketamine (Pilot II)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes."
40850708|NCT02717052|DRUG|Placebo|0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
40850709|NCT02717052|OTHER|PILOT Study II: PET1|\[11C\]DASB PET
40850710|NCT02717052|OTHER|PILOT Study II: PET2|\[11C\]DASB PET
40850711|NCT02717052|OTHER|Main Study: PET1|\[11C\]DASB PET
41164301|NCT04733053|OTHER|Exercise|The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.
41164302|NCT00305097|DIETARY_SUPPLEMENT|Decaffeinated coffee|5 cups per day for 8 weeks
41164303|NCT00305097|DIETARY_SUPPLEMENT|Caffeinated coffee|5 cups per day for 8 weeks
41377512|NCT03870061|BEHAVIORAL|All Babies Are Equal Initiative (conditional cash transfer program)|New Incentives, an NGO, offers cash incentives to caregivers for bringing their child to clinics for the first five visits of the Nigerian Routine Immunization schedule. These small cash transfers can provide some material benefit to new caregivers from poor communities. At a minimum, they help offset time and transport costs. The following vaccines are directly incentivized by the New Incentives' program: tuberculosis (BCG vaccine); diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae Type B (Pentavalent Vaccine), pneumococcal bacteria (PCV vaccine), measles vaccine.
41164304|NCT00305097|DIETARY_SUPPLEMENT|No coffee|
41164305|NCT04106453|PROCEDURE|navigated microwave ablation|the laparoscopic microwave ablation in the pig liver is performed with the CasOne-Spot system
41164306|NCT04106453|PROCEDURE|ultrasound guided navigation|the laparoscopic microwave ablation iin the pic liver is performed with ultrasound guidance
41164307|NCT04210024|OTHER|Diabetes Empowerment Education Program|Individuals identified as Community Health Workers will participate in the Diabetes Empowerment Education Program (DEEP™). DEEP, is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
41164308|NCT02678364|DIETARY_SUPPLEMENT|Control eggs|Control eggs containing no additional vitamin D beyond norm
41164309|NCT02678364|DIETARY_SUPPLEMENT|Vitamin D3 eggs|Vitamin D3-biofortified eggs
41164310|NCT02678364|DIETARY_SUPPLEMENT|25-Hydroxyvitamin D3 eggs|25-Hydroxyvitamin D3-biofortified eggs
40850712|NCT02717052|OTHER|Main Study: PET2|\[11C\]DASB PET
40850713|NCT02717052|OTHER|PILOT Study I: PET1|\[11C\]DASB PET
40850714|NCT02717052|OTHER|PILOT Study I: PET2|\[11C\]DASB PET
40850715|NCT02717052|DRUG|(R,S)-ketamine (Pilot I)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
40850716|NCT02717052|DRUG|(R,S)-ketamine (Pilot III)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50"
41164311|NCT01355822|DRUG|PETN|Pentaerythrithyltetranitrate: 80 mg orally twice a day
41164312|NCT01355822|DRUG|Placebo control|orally, twice daily
41164313|NCT05903677|OTHER|magnesium levels|Detection of the relationship between cardiac surgery associated AKI and preoperative magnesium levels.
41164314|NCT03928678|PROCEDURE|enhanced recovery after surgery program in colorectal cancer surgery|to determine the feasibility of implementation of the ERAS protocol in our institute and its impact on hospital length of stay and outcome of surgery.
40850717|NCT02717052|OTHER|PILOT Study III: PET1|\[11C\]DASB PET
40850718|NCT02717052|OTHER|PILOT Study III: PET2|\[11C\]DASB PET
41377513|NCT03251443|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
41377514|NCT02946515|BEHAVIORAL|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
41033914|NCT06632184|DRUG|Ondansetron (ODT) + Saline Solution|This intervention involves the administration of ondansetron in saline solution, serving as the control arm in the study. Like the bicarbonate formulation, this solution is administered intraperitoneally during laparoscopic cholecystectomy. Ondansetron is a standard antiemetic used to prevent nausea and vomiting. This formulation will serve to evaluate whether adding bicarbonate enhances pain control compared to the saline solution.
41506532|NCT02317029|PROCEDURE|Normoxia during cardioversion|Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
41033915|NCT06536114|OTHER|CRISP: Criteria-Based Approach for the Rehabilitation for Non-Operative Shoulder Injuries|The CRISP group will undergo physical therapy treatment, directed by a research physical therapist, including both supervised physical therapy and a guided home exercise program. This approach has three phases: stabilization, to facilitate joint protection; strength and endurance, to optimize functional capacity; and power, to prepare the Service member for returning to previous level of duty.
41506533|NCT02317029|DEVICE|Cardioversion with a biphasic truncated exponential waveform|Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
41506534|NCT02317029|PROCEDURE|Hyperoxia during cardioversion|Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
41506535|NCT02015845|DEVICE|Accuvein|
41506536|NCT02015845|DEVICE|Routine technique|Placement of peripheral intravenous catheters using the routine technique
41506537|NCT03097146|OTHER|comprehensive multidisciplinary stroke care|"Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies."
41506538|NCT04975295|DRUG|LY3361237|Administered SC
41033916|NCT06536114|OTHER|Standard of Care|The Standard of Care group will serve as the control arm and complete a period of physical rehabilitation under the supervision of a Military Health System physical therapist without study-specific guidance or interventions.
41033917|NCT02837744|DEVICE|Axiostat®|Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
41033918|NCT00748046|DRUG|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
41033919|NCT04782323|DRUG|aQII-1|Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
41506539|NCT04975295|DRUG|Placebo|Administered SC
41506540|NCT01876225|BEHAVIORAL|Forced coughing during cervical punch biopsy|
41033920|NCT04782323|DRUG|aQII-3 Investigational|Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
41033921|NCT04782323|DRUG|aQII-6 Investigational|Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
41164315|NCT01435798|DRUG|Dextromethorphan|0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
41377515|NCT02946515|BEHAVIORAL|Wait List Control|Access to the online simulation training after the follow-up measurement visit is complete
41377516|NCT06335394|OTHER|NVD003|Autologous osteogenic implant NVD-003 for bone reconstruction
41377517|NCT02996604|OTHER|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
41377518|NCT00421746|DRUG|Piboserod|
41506541|NCT03145415|PROCEDURE|Caudal block|1 cc per kg of 0.2% ropivicaine in the caudal space given before the start of surgery.
41506542|NCT03145415|PROCEDURE|Bilateral Pudendal block|0.5 cc per kg of 0.2% ropivicaine. Half of the volume given as a right pudendal block and the remaining volume given on the left pudendal nerve block given prior to the start of surgery
41506543|NCT02897245|OTHER|No intervention|
41506544|NCT04868500|DEVICE|AMAZE™ Application|Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
41506545|NCT04868500|DEVICE|AMAZE™ Dashboard|Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.
41506546|NCT04030715|DRUG|bismuth-containing quadral therapy based on antibiotic susceptibility|the different mucosal pathology graded by New Sydney System
41033922|NCT04782323|OTHER|aQII-7 Investigational|Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
41033923|NCT04782323|DRUG|aQII-9 Investigational|Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
41033924|NCT04782323|DRUG|aQII-10 Investigational|Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
41164316|NCT04377412|OTHER|Pandemic control measures|Population of different countries are exposed to different pandemic control measures, and everyday lives of pregnant women are affected on different levels. Investigators will measure influence their influence on mental health.
41033925|NCT04782323|DRUG|aQII-11 Investigational|Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
41033926|NCT04782323|DRUG|Licensed QII Active Comparator|Biological/Vaccine: Licensed QII Licensed Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
41033927|NCT00679003|BEHAVIORAL|SLCBT|Social learning and cognitive behavioral therapy
41033928|NCT00679003|BEHAVIORAL|ES|Education and support (information about nutrition and gastrointestinal system)
41033929|NCT02311179|DEVICE|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
41033930|NCT02311179|DEVICE|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
41033931|NCT00063947|DRUG|erlotinib hydrochloride|Given orally
41033932|NCT00063947|DRUG|gemcitabine hydrochloride|Given IV
41033933|NCT00063947|RADIATION|radiation therapy|Undergo radiotherapy
41033934|NCT00063947|OTHER|laboratory biomarker analysis|Correlative studies
41033935|NCT06110923|DRUG|CKD-846|once administration of Investigational Product
41033936|NCT06110923|DRUG|D091|once administration of Investigational Product per day
41033937|NCT02795442|OTHER|Even protein|5 day intake of even protein 3 day rotating menu.
41033938|NCT02795442|OTHER|Skewed protein|5 day intake of skewed protein 3 day rotating menu.
41033939|NCT06161844|DRUG|semaglutide injection (HD1916)|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916
41033940|NCT06161844|DRUG|Ozempic®|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product
41377519|NCT05087576|BEHAVIORAL|Expressive Helping|Expressive helping integrates two distinct areas of research showing that emotional disclosure over writing and support giving improves psychological well-being among healthy and clinical populations. Participants write 4 brief structured writing sessions.
41033941|NCT01627249|DRUG|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
41033942|NCT01627249|DRUG|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
41033943|NCT01627249|DRUG|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
41164317|NCT05143879|DIETARY_SUPPLEMENT|Citrulline|3 g/day during 9 weeks
41506547|NCT03065946|OTHER|Early wakening|By using an intravascular device to administer mild TH for 24 hours, patients can safely have their medically induced coma reversed early at 12 hours, allowing an accurate neurological assessment to be performed
41164318|NCT05143879|DIETARY_SUPPLEMENT|Nitrate|300 mg/day during 9 weeks
41164319|NCT05143879|DIETARY_SUPPLEMENT|Nitrate plus Citrulline|3 g/day of citrulline and 300 mg/day of nitrate during 9 weeks
41164320|NCT05143879|DIETARY_SUPPLEMENT|Placebo|3 g/day during 9 weeks
41164321|NCT03643497|DRUG|anti-infective drugs|According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
41164322|NCT00347737|DRUG|teriparatide|Teriparatide
41377520|NCT05087576|BEHAVIORAL|Caregiving Fact writing|Factual Writing has been used with in other writing-based interventions (e.g., expressive writing). It is also completed in 4 brief structured writing sessions.
41377521|NCT01067729|DEVICE|AWBAT Wound Dressing|
41377522|NCT01067729|DEVICE|AWBAT™, Biobrane®|Comparison of burn dressings on randomized body sites using patient as own control
41377523|NCT05144971|DIAGNOSTIC_TEST|Glucose, Creatinine|Compare diagnostic tests to reference methods
41377524|NCT05880758|BEHAVIORAL|Intermittent Short Sleep (ISS)|Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.
41377525|NCT05880758|BEHAVIORAL|Social Jetlag (SJL)|2-hour delayed sleep timing.
40850719|NCT06525142|BEHAVIORAL|Audiovisual Intervention|"【Group 1】During the first three days, the researchers will provide a storybook to the father of the premature infant, and the researchers assist in recording the father's voice of the storybook in the form of MP4 recording. At the fourth day, one hour after the baby feeding, the father's voice will be played by the player to the baby, for 2 consecutive days, 2 times/day, 10 minutes/time. The baby's heartbeat, breathing and blood oxygen changes will be recorded and monitored with a physiological monitor. The recording files will be kept by the researcher.~【Group 2】 The intervention will be the same with Group 1 except the following intervention: on the 4th-6th day of the baby's birth, sleeping in the incubator, the baby's reaction behavior will be taken with a mobile phone, 1 time/day, 5 minutes/time, for 3 consecutive days, the image feedback is delivered to the father in person."
41377526|NCT05880758|BEHAVIORAL|Sustained Adequate Sleep (SAS)|Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
41377527|NCT02944344|BEHAVIORAL|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
41377528|NCT01856348|DRUG|Vitamin D|
41377529|NCT04054934|BEHAVIORAL|Reversed Circadian Rhythm|Revered day/ night sleep cycle
41377530|NCT04054934|BEHAVIORAL|Normal Circadian Rhythm|Normal day/ night sleep cycle
41377531|NCT00718627|BIOLOGICAL|Human Heterologous Liver Cells|Multiple applications of liver cell suspension for infusion
41377532|NCT04595617|BIOLOGICAL|Antibodies screening|All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.
40850720|NCT02567019|OTHER|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
40850721|NCT01824433|DRUG|venlafaxine|venlafaxine 75-225mg qd
41377533|NCT01443676|DRUG|Bevacizumab|Bevacizumab will be added to radiotherapy
41377534|NCT01443676|RADIATION|Radiation therapy|Radiation therapy
41377535|NCT02434029|DRUG|Budesonide 1mg orodispersible tablet twice daily|
41377536|NCT02434029|DRUG|Placebo orodispersible tablet twice daily|
41377537|NCT05259748|BEHAVIORAL|Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors|Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
41377538|NCT03780101|DIAGNOSTIC_TEST|Multi-parametric renal MRI|Multi-parametric functional magnetic resonance imaging of a transplant kidney including sequences for T1, T2, diffusion-weighted imaging, diffusion tensor imaging and arterial spin labelling.
41377539|NCT00616304|DRUG|L-arginine hydrochloride|Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
41377540|NCT00616304|OTHER|Normal saline|Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
41377541|NCT05340309|BIOLOGICAL|Atezolizumab and Recombinant Human Hyaluronidase|Given SC
41377542|NCT05340309|OTHER|Survey Administration|Ancillary studies
40850722|NCT01824433|DRUG|fluoxetine|fluoxetine 20-60mg qd
41377543|NCT00001080|BIOLOGICAL|Influenza Virus Vaccine|
41377544|NCT00001080|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
41377545|NCT00001080|DRUG|Lamivudine|
40850723|NCT04706156|BIOLOGICAL|COVID-19 Vaccine|Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine
41377546|NCT02164084|DRUG|SB204|SB204 Gel with hydrogel
41377547|NCT02164084|DRUG|Vehicle Gel|Vehicle Gel with hydrogel
41377548|NCT01902992|DRUG|Depiquick Birch (DPG103)|
41377549|NCT01902992|DRUG|Placebo|
41377550|NCT05677412|BEHAVIORAL|suggestive relaxation|suggestive story before sleep onset
41377551|NCT05677412|BEHAVIORAL|Neutral story|neutral story before sleep
41377552|NCT00000868|BIOLOGICAL|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
41377553|NCT00000868|BIOLOGICAL|Aluminum hydroxide|
41377554|NCT00000868|BIOLOGICAL|MF59|
41377555|NCT00000868|BIOLOGICAL|rgp120/HIV-1MN|
41506548|NCT01517958|OTHER|Respiratory Distress Group|Diagnostic lung ultrasound.
41033944|NCT05509439|OTHER|Home Transfusion Program Components|The Home Transfusion Program will include trained transfusion nurse(s) who will administer transfusions in the home setting. The transfusion nurse, who is part of the study team, will work closely with the DFCI/BWH Blood Bank and the hospice agency (Care Dimensions Inc.) that all study patients are enrolled in. The transfusion nurse will administer home transfusions using safe home transfusion practices endorsed by the AABB. The home transfusion program has 4 key aspects Initial home visit, (2) subsequent contact, (3) home transfusion assessment \& administration, (4) usual elements of hospice
41377556|NCT06474780|DEVICE|Weight: 414g Size: 19.5cm x 14cm x 11cm Compatibility: Android and iOS VR Box 3.0 3D Virtual Reality Glasses Has the Feature of Fixation with Headband It has a lens mechanism tha|Patients in the experimental group were fitted with virtual reality glasses for 3 cycles and were allowed to watch videos of city tours, walks in the forest, and nature walks for 15 minutes, depending on their choice.
41033945|NCT03506971|OTHER|Psychologist's evaluation|The research coordinator psychologist will evaluate: the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.
41164323|NCT05259436|BEHAVIORAL|Caregiver-child Intervention|"Intervention Groups:~1. Resilience Clinic (Benioff Oakland): 6 weekly interactive group-based visits in primary care that draws from the evidence-based Circle of Security Parenting along with the principles of mindfulness;~2. ABC Intervention (Lifelong): 10 weekly home visiting sessions. ABC is an empirically supported parenting program that focuses on improving maternal sensitivity;~   and,~3. Resiliency Family Program (Santa Barbara Neighborhood Clinic): 4 primary-care-based visits, every 2-3 weeks, that include psycho-education materials drawing from the culturally-responsive, evidence-based program, Madres a Madres."
41164324|NCT05259436|BEHAVIORAL|Enhanced Primary Care|Enhanced Primary Care (control group): This includes care coordination services for community resources in addition to usual care. Participants will be asked about any unmet social needs, e.g. food insecurity, financial strain, safe places to play. Those who endorse need will be offered navigational services to link to community resources.
41377557|NCT03573843|OTHER|Prevention software|All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.
41377558|NCT03573843|OTHER|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
41164325|NCT06076798|DEVICE|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
41377559|NCT04330677|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
41377560|NCT04330677|DRUG|Placebo nasal spray|The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
41377561|NCT04330677|DRUG|Estrogen Gel|Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
41377562|NCT04330677|DRUG|Placebo Gel|Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
41377563|NCT03544697|PROCEDURE|Skin expansion and repair with flaps|
41377564|NCT01284842|OTHER|24-Hour-Call|one 24-Hour-Call within the regular surgical schedule
41377565|NCT03906929|DEVICE|buried intramedullary K-wire|Using of buried kirschner wire in pediatric forearm fixation
41377566|NCT03906929|DEVICE|exposed intramedullary K-wire|Using of exposed kirschner wire in pediatric forearm fixation
41377567|NCT06326476|DRUG|Siplizumab|40 mg doses
41377568|NCT04741945|DRUG|Metformin|2000 mg/day metformin for 12 months (1000 mg b.i.d.) with a slow up-titration six weeks prior to full dose treatment.
41164326|NCT04294524|OTHER|Sleep apnea treatment|Sleep apnea treatment as decided according to routine practice. This may be Continuous positive airway pressure (CPAP) or wearing a mandibular advancement device (MAD).
41377569|NCT02801734|OTHER|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
41377570|NCT06563661|OTHER|The 21-style specific dance exercises|The 21 dance styles (dance in a group), chosen and modified from seven dance styles, including cha-cha, jive, rumba, salsa, waltz, tango, and macarena, were developed by a group of experienced dance and rehabilitation experts and have been previously practised by a group of older adults in our pilot work, demonstrating good feasibility and positive participants' feedback.
41377571|NCT02442739|DRUG|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
41377572|NCT02442739|OTHER|Placebo|Placebo syrup will be given by mouth once a week for 12 weeks.
41506549|NCT01517958|OTHER|Control Group|Lung ultrasound
40850724|NCT05432986|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow.
41164327|NCT04024514|OTHER|low dose CT contrast media|CT contrast media (Ioversol 320mgI/kg) is administrated at a dose of 300mgI/kg in low dose group
41506550|NCT04771975|BEHAVIORAL|Exercise Counselling|Phase 1: See previous description for MatchQEP (Intervention) group. Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants had the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner. The 8-week program was open to all participants from Phase 1 who choose to continue in the study, regardless of initial randomization status. Behavioural and exercise counselling were offered to phase 2 participants.
40850725|NCT04388163|DRUG|Gentian Violet|Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration.
40850726|NCT06024668|DEVICE|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
41377573|NCT04768283|OTHER|Additional balance and resistance training - 1|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises to improve static as well as dynamic balance ability, for 15-20 minutes.~The resistance training included exercises with weights (0,5, 1 or 2 kg), elastic resistance rubbers, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets."
41377574|NCT04768283|OTHER|Additional balance and resistance training - 2|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises with static and dynamic balance training device Biodex Balance System TM SD, for 15-20 minutes. Exercises are performed with the following programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training.~The resistance training included exercises with HUR strength training machines, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets. Strength training was performed with the following exercises: Leg press, leg extension, leg abduction, leg adduction."
41377575|NCT05036876|DRUG|Degludec|Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
41377576|NCT05036876|DRUG|Glargine U300|Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
41377577|NCT00703261|DRUG|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
41377578|NCT00703261|DRUG|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
41033946|NCT03506971|OTHER|Pediatric Nurse's interventions|"Pediatrics nurses perform preventive home visits that are based on : joint observation with the parents of the baby, play with the baby and his parents, interview with the parents on their parenthood~Rhythm of home visits:~* 1 every month from birth to 1 year~* 1 every 2 months from 1 year to 2 years~* 1 every 3 months from 2 years to 4 years"
41377579|NCT01171794|DRUG|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
41506551|NCT04771975|BEHAVIORAL|Partner Matching|"Phase 1: All participants will be matched with another participant (fellow BCS) and will facilitate / support exercise with their partner for the duration of the study.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants were rematched with different partner for this phase of the trial.~Participants will be matched based on personal and cancer-related characteristics."
41377580|NCT01171794|DRUG|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
41033947|NCT03506971|OTHER|Joint home visits|"Coordinating psychologist and the referent pediatric nurse will perform home visits. During this time, the psychologist evaluate : the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.~Rhythm of joint home visits:~* 1 at 4 months~* 1 at 24 months"
41033948|NCT04387084|DRUG|Atezolizumab|Given IV
41033949|NCT04387084|DRUG|Avelumab|Given IV
41377581|NCT03209973|DRUG|Tislelizumab|Administered as specified in the treatment arm
41377582|NCT04457323|DRUG|Metoprolol|S-Metoprolol XR 25 mg and 50 mg Film Coated Tablets
41377583|NCT04457323|DRUG|Metoprolol|Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets
41377584|NCT03537625|DIETARY_SUPPLEMENT|Green tea|We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
41377585|NCT00981565|PROCEDURE|open carpal tunnel release|surgery to release the carpal tunnel
41377586|NCT00981565|OTHER|Night-cast|individual night time splinting
41033950|NCT04387084|BIOLOGICAL|Cemiplimab|Given IV
41164328|NCT04024514|OTHER|Standard dose CT contrast media|CT contrast media (Ioversol 350mgI/kg) is administrated at a dose of 525mgI/kg in standard dose group.
41164329|NCT00174798|DRUG|SSR240600C|once daily
41164330|NCT00174798|DRUG|Placebo|oral
41377587|NCT02799485|OTHER|Laboratory Biomarker Analysis|Correlative studies
40850727|NCT02008773|DRUG|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
40850728|NCT02008773|DRUG|placebo|placebo capsules 6/day oral for 16 weeks
41164331|NCT00174798|DRUG|Tolterodine|once daily
41377588|NCT02799485|OTHER|Pharmacological Study|Correlative studies
41377589|NCT02799485|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
41377590|NCT02799485|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
41377591|NCT00448929|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
41377592|NCT04402580|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
41377593|NCT04402580|DRUG|Mycophenolate Mofetil|1,200 mg/1,73 sqm orally divided in 2 daily doses
41506552|NCT04771975|BEHAVIORAL|Resistance training sessions led by a QEP|Phase 2: participants were offered the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner.
40850729|NCT06583330|DRUG|Low Molecular Weight Heparin (dalteparin)|All patients initiated low molecular weight heparin for drug prevention within 24 hours after surgery. The prevention course for the experimental group patients was 14 days, while the prevention course for the control group patients was 28 days. Low molecular weight heparin is administered subcutaneously once daily at a dose of 0.3ml.
40850730|NCT04250207|DRUG|K-321 Solution|K-321 solution drops
40850731|NCT04250207|DRUG|Placebo Solution|Placebo solution drops for K-321
40850732|NCT03975387|DRUG|ASTX295|ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
40850733|NCT02941224|DEVICE|SELUTION DCB (sirolimus coated balloon)|
41377594|NCT05411848|DIETARY_SUPPLEMENT|2kcal HP PlantBased|Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.
40850734|NCT05279950|DEVICE|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
40850735|NCT05279950|DEVICE|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
40850736|NCT02834247|DRUG|TAK-659|TAK-659 Tablets.
41033951|NCT04387084|BIOLOGICAL|Durvalumab|Given IV
41033952|NCT04387084|BIOLOGICAL|Nivolumab|Given IV
41377595|NCT03713515|BEHAVIORAL|ALTA|The study will involve each site starting with the usual care phase, followed by a period of 6 months during which practice facilitators will conduct the pre-implementation evaluation (e.g., workflow analysis, environmental scan), refine the practice facilitation strategies that will be used in the implementation phase, and train staff in the Advancing Medication Adherence for Latinos with Hypertension through a Team-based Care Approach (ALTA) intervention model. ALTA is an efficacious systems-level intervention designed to help patients improve their ability to take their high blood pressure medications and control their blood pressure. Practices and the Project ALTA team will work together to implement the ALTA model into routine care to improve blood pressure control and medication adherence in Latinx patients.
40850737|NCT02834247|DRUG|Nivolumab|Nivolumab intravenous infusion.
40850738|NCT06462781|DRUG|Lidocaine hydrochloride|Intra-arterial injection of 40mg lidocaine per middle meningeal artery (total 2 arteries) administered one time
41033953|NCT04387084|BIOLOGICAL|Pembrolizumab|Given IV
41033954|NCT04387084|OTHER|Quality-of-Life Assessment|Ancillary studies
41033955|NCT04387084|OTHER|Short-Term Fasting|Undergo STF
41033956|NCT04121728|DRUG|Ginkgo biloba extract|Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.
41033957|NCT04121728|DRUG|Placebo|The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
41377596|NCT06265376|BEHAVIORAL|Educational Video|A recorded educational video will be presented to the patient prior to meeting with the provider at the presurgical meeting
41506553|NCT02108093|PROCEDURE|retrograde autologous priming|Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
41506554|NCT05972369|OTHER|12-Week Tailored Exercise Intervention|12-week individually tailored exercise therapy program based on patient presentation. Supervised physiotherapy plus home exercise
40850739|NCT06462781|DRUG|Methylprednisolone sodium succinate|Intra-arterial injection of 20mg methylprednisolone per middle meningeal artery (total 2 arteries) administered one time
40850740|NCT06462781|OTHER|Standard of Care|Acute and/or preventative therapeutic approaches currently used in practice
40850741|NCT06412198|DRUG|Cetuximab|Given by IV
40850742|NCT06412198|DRUG|Cemiplimab|Given by IV
40850743|NCT06412198|DRUG|Adagrasib|Given by PO
41506555|NCT05373199|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
40850744|NCT03937960|OTHER|Carbohydrate restricted group|Prescribed low carbohydrate diet with set recipes
40850745|NCT03937960|OTHER|Standard low fat diet|Diet with less than 20% total calorie intake from dietary fats
40850746|NCT06217003|DRUG|Trilaciclib|Preoperative application of trilaciclib during perioperative chemotherapy
40850747|NCT02776254|OTHER|START|Point of care testing for rapid ART initiation
40850748|NCT02776254|OTHER|CAG|Community Adherence Group
41506556|NCT05373199|DRUG|Euglycemic clamp with Lantus®|Administration of a single dose of Lantus® during an euglycemic clamp procedure.
41506557|NCT05373199|DRUG|Euglycemic clamp with Humalog®|Administration of a single dose of Humalog® during an euglycemic clamp procedure.
40850749|NCT02776254|OTHER|UAG|Urban Adherence Group
40850750|NCT02776254|OTHER|FAST-TRACK|Prescription refill only
40850751|NCT04443166|COMBINATION_PRODUCT|A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program|a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)
40850752|NCT06000410|BIOLOGICAL|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
40850753|NCT06000410|DRUG|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
41033958|NCT01998373|BEHAVIORAL|training leaflet and oral training|The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
41033959|NCT06636513|DIETARY_SUPPLEMENT|SMT04 (M3XTRA)|This is a pilot prospective single-arm, open-label clinical trial to assess the effect of the probiotic SMT04 (M3XTRA) on the gut microbiome and relief of IBS symptoms.
41506558|NCT04010552|DRUG|NALRINOX combination|NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
41033960|NCT01640691|BIOLOGICAL|Pandemic Influenza Vaccine (H5N1)|"Inactivated whole-virion vaccine~1. Administration route: Intramuscular Injection~2. Dosing schedule: 2 injections - at Day 1 and Day 22 separately~3. Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"
41033961|NCT04863066|BIOLOGICAL|CAR-T cells|The presence of latent infected cells remains a key barrier to HIV-1 functional cure. Current approach to reducing the latent HIV reservoir is to reactivate virus-containing cells to make them be detected and eliminated by host defense. Endogenous cytotoxic T-lymphocytes (CTL) may not be adequate because of cellular exhaustion and immune escape of virus. We have designed a kind of CAR-T cell based on CTL engineered to express a scFv of a broadly neutralizing anti-HIV antibody. According to our preclinical studies, CAR-T cells strongly eradicated HIV-1-infected target cells making them a particularly suitable candidate to reach a functional HIV cure. In this clinical trial, we mainly intend to evaluate the safety of CAR-T-Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after antiviral therapy.
41506559|NCT01563497|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
41506560|NCT01563497|DRUG|PF-05089771|Tablets TS formulation- fasted
40850754|NCT03137329|BEHAVIORAL|Exercise program|Physical therapy for aerobic and resistance training exercises
40850755|NCT03137329|DIETARY_SUPPLEMENT|Nutrition|Nutrition supplementation via HMR for lifestyle arm only
40850756|NCT03137329|PROCEDURE|WLS|Weight loss surgery as planned
40850757|NCT00417963|DEVICE|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
41033962|NCT04488536|DIAGNOSTIC_TEST|Clinical Frailty Scale|Frailty assessment
41164332|NCT05615480|OTHER|Controlled hypotension guided by cerebral oxygen saturation monitoring|In this group, intraoperative monitoring of cerebral oxygen saturation will be used. When the cerebral oxygen saturation decreased by 20% \~ 25% compared with the baseline for 300 seconds without improvement, or the cerebral oxygen saturation decreased by 25% \~ 30% compared with the baseline for 180 seconds without improvement, intervention would be carried out. When the cerebral oxygen saturation decreased by 30% compared with the baseline, immediate intervention would be carried out. The intervention measures were intravenous administration of deoxyepinephrine 50 \~ 100 μg or ephedrine 5 \~ 10mg, which can be administered multiple times until the cerebral oxygen saturation reaches more than 80% of the baseline.
41377597|NCT00611780|RADIATION|tube voltage|standard 120 kV
41506561|NCT01563497|DRUG|PF-05089771|Tablets TS formulation- fed
41506562|NCT05432635|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
41506563|NCT05432635|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHSCT
40850758|NCT00699660|BEHAVIORAL|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
40850759|NCT00699660|BEHAVIORAL|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
41033963|NCT04116931|DRUG|Switch ticagrelor to clopidogrel|Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
41033964|NCT03935386|PROCEDURE|Standard Multi-layered Compression dressing|Compression therapy with a multi-layered compression dressing for the treatment of venous leg ulceration
41506564|NCT05432635|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
41506565|NCT05432635|PROCEDURE|Myeloablative Conditioning|Given standard conditioning regimen
41506566|NCT00515918|DIETARY_SUPPLEMENT|iron|
41506567|NCT05503576|DEVICE|reminder mobile application|After thyroidectomy, patients will be reminded of medication and control appointments. In addition, patients will be able to access up-to-date and short trainings.
40850760|NCT06437470|OTHER|blood flow restriction technique|"All participants in the control group will receive the conventional physical therapy program with the use non-inflated cuff as a sham treatment during exercising.~All participants in the intervention group will receive the conventional physical therapy program combined to blood flow restriction to 80% of limb occlusive pressure by using blood flow restriction cuff."
40850761|NCT00683839|BEHAVIORAL|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
40850762|NCT06112834|BIOLOGICAL|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
40850763|NCT00465777|BEHAVIORAL|Guideline adherence and financial incentive|
41033965|NCT03935386|PROCEDURE|Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)|Application of a cryopreserved skin allograft (TheraSkin) beneath compression therapy with a multi-layered compression dressing.
41033966|NCT04093622|GENETIC|Genetically engineered NK cells|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered NK Cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
41377598|NCT00611780|RADIATION|tube voltage|reduced voltage of 100 kV
41506568|NCT01000961|DRUG|Cystagon® (Cysteamine Bitartrate)|"Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used"
41506569|NCT01000961|DRUG|Cysteamine Bitartrate Delayed-release Capsules (RP103)|"Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks"
41506570|NCT04160624|PROCEDURE|transcatheter aortic valve replacement|Use Venus-A valve or J-Valve to perform TAVR procedure. Use cardiopulmonary bypass or cardiopulmonary bypass to provide ECLS
41506571|NCT05904002|DRUG|pulmicort inhaler|Each woman in both groups (A\&B) will receive pulmicort inhaler on needs.
41506572|NCT05904002|DEVICE|Incentive spirometer treatment|Each patient in group B will be instructed about the effects of incentive spirometer to gain their cooperation during the study course.
41506573|NCT05865548|DRUG|Aspirin 150 mg|Aspirin 150 mg PO daily
41506574|NCT05865548|PROCEDURE|Standard of care|Surgery with or without radiation, palliative chemo as per investigators choice
41033967|NCT06635317|DRUG|Aspirin|100 mg/day orally for 25 days
41033968|NCT06635317|DRUG|enoxaparin|40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².
41506575|NCT04812522|BEHAVIORAL|Clean Cut program|Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis
41506576|NCT04038138|DIAGNOSTIC_TEST|Validation of new COA for FSHD patients|Monitoring of commonly used and news COA in patients with facioscapulohumeral muscular dystrophy
40850764|NCT05678257|DRUG|Fosifloxuridine Nafalbenamide|Intravenous infusion
41033969|NCT02995603|DEVICE|Nano-X patient rotation|Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.
41033970|NCT05867446|BEHAVIORAL|pecha kucha|pecha kucha training
41033971|NCT04177758|DRUG|Vitamin D|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
41033972|NCT04177758|DRUG|Control|Patients randomized to the control will receive a placebo
41033973|NCT00458328|DRUG|Z-338|
41033974|NCT03408717|OTHER|Questionnaires|Questionnaires including Pain catastrophizing scale (PCS), Central Sensitisation Inventory (CSI), Coping Strategies Questionnaire-Revised (CSQ-R), Brief Symptom Inventory-18 (BSI-18), Perceived Stress Scale (PSS), EQ-5D-3L and Eysenck Personality Questionnaire (EPQ) will be administered to the patient.
41033975|NCT03408717|OTHER|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
41506577|NCT02376673|OTHER|Children's Book|A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
40850765|NCT05678257|DRUG|Leucovorin|Intravenous infusion
40850766|NCT05678257|DRUG|Irinotecan|Intravenous infusion
41033976|NCT03408717|OTHER|Pain threshold assessment|Pressure is applied 90 degree straight down force on the subject's right/left centre of the trapezius muscle using an algometer, with a speed of pressure \~ 1kgf/s. The above procedure is then repeated 3 times at each site (left/right) which is indicated on the pressure mark with each time having the reading recorded. When patient shows no response ≥ 6kgf, the threshold is recorded as 6kgf. The patient upon feeling pain will say stop or raise the hand to terminate the test. The mean value is obtained by averaging the readings and will then be recorded as the threshold estimate.
41164333|NCT06379698|OTHER|personalized 3D model pré-opérative education|Before surgery, during a preoperative therapeutic education consultation, a personalized 3D models will be presented to the patients according to the allocated study group
41164334|NCT06379698|OTHER|generic 3D model pré-opérative education|Before surgery, during a preoperative therapeutic education consultation, a generic 3D models will be presented to the patients according to the allocated study group
41164335|NCT04514172|DEVICE|Passive industrial exoskeleton for back support|The goal is to compare the human response to the simulated industrial tasks
41164336|NCT04514172|OTHER|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
41506578|NCT02376673|OTHER|Standard Brochures|An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
41506579|NCT03101176|DRUG|SonoVue|The ultrasound contrast agent used for the CEUS specific ultrasound mode
41506580|NCT00785148|DRUG|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
41506581|NCT03718650|DRUG|Pimonidazole|Patients will take a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral pimonidazole HCI 16 to 24 hours prior to surgery.
40850767|NCT05678257|BIOLOGICAL|Bevacizumab|Intravenous infusion
40850768|NCT05678257|DRUG|5-FU|Intravenous infusion
41033977|NCT06395597|DIAGNOSTIC_TEST|Nine Hole Peg Test|3 attempts of each subtest of the Nine Hole Peg Test performed according to the Czech Extended Version of Manual for the Nine Hole Peg Test; questionnaire
41033978|NCT01631032|DRUG|Qi-tonifying Chinese herbal products|Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
41033979|NCT04357626|OTHER|Inpatient Rehabilitation|Observational electronic records review study during inpatient rehabilitation
41033980|NCT03449030|DRUG|TAK-164|TAK-164 intravenous infusion.
41033981|NCT03449030|DRUG|89Zr-TAK-164|89Zr-TAK-164 intravenous infusion
41164337|NCT04815785|DEVICE|TaurusOne® transcatheter aortic valve replacement system|The TaurusOne® Transcatheter Aortic Valve System consists of an aortic valve, an associated delivery catheter and a loading system. The aortic valve consists of a self-expanding nitinol frame, a sealing skirt and valve leaflets, which are made of bovine pericardium. The delivery system is mainly composed of conical head, opacity ring, inner tube, top ring, middle tube, outer tube, booster rod, stress diffusion catheter, handle, etc. The outflow end of the aortic valve is provided with three fixing holes evenly distributed on the circumference on the top ring of the delivery catheter, so as to facilitate the installation, delivery and release of the aortic valve. Before the operation, the aortic valve needs to be installed into the sheath of the delivery catheter as required.
41164338|NCT03430050|DRUG|Progesterone|Progesterone capsule
41164339|NCT03430050|DRUG|Placebo|Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
41164340|NCT01172639|DRUG|Methotrexate|Methotrexate tablet
41164341|NCT01172639|DRUG|Sulfasalazine|Sulfasalazine tablet
41164342|NCT01172639|DRUG|Leflunomide|Leflunomide tablet
41164343|NCT01172639|DRUG|Prednisone|Prednisone tablet
41164344|NCT06437054|DRUG|Dexamethasone|Dexamethasone 5mg/ml
41164345|NCT06437054|DRUG|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
41164346|NCT06437054|OTHER|Indocyanine green(ICG)|ICG 25mg
41164347|NCT02368899|OTHER|Computerized Alcohol Misuse Intervention|Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.
41164348|NCT02368899|OTHER|Attention Control (AC)|These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
41164349|NCT06266468|BEHAVIORAL|Nutricity|Nutricity is a bilingual (English/Spanish) mobile website supplemented by an automated text-messaging system.
41164350|NCT03443063|DRUG|Lemborexant|oral tablet
41164351|NCT05147649|DIAGNOSTIC_TEST|functional magnetic resonance imaging|functional magnetic resonance imaging
41164352|NCT03391583|OTHER|Education|Participants in the education arm of the study will be provided with three PowerPoint presentations. Material for these slides has been adapted from material developed by the Ontario Neurotrauma Foundation. Topics to be addressed will surround post-traumatic headache and will include information regarding common symptoms, timeline for improvement, red- flags and when to seek medical attention
41164353|NCT02780739|BEHAVIORAL|Cognitive Training - 48 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
41164354|NCT02780739|BEHAVIORAL|Fitness|Based on high intensity cardiovascular resistance training (HICRT), this intervention includes a combination of aerobic and strength training. Sessions are conducted in a group of ≤20 participants per class, with ≤5 participants per trainer. This intervention includes 28 70-min sessions (32.67 hrs) completed over 16 weeks: 3/wk weeks 1-4, 2/wk weeks 5-8, 1/wk weeks 9-16. At the first and last session, participants complete the Army Physical Readiness Test. All other sessions consist of: Warm-up; Walk/Run; 2 HICRT circuits with 3 sets of 3-4 exercises; 1-2 min jump rope and 4-min power series between HICRT segments; Drills \& Skills; and Cool-down/stretch.
41164355|NCT02780739|BEHAVIORAL|Active Control|The active control condition consists of 2 tasks (change detection and visual search) with 3 variants each. This intervention includes 48 70-min sessions (56 hrs) completed over 16 weeks: 3/wk. The 6 tasks are played in random order for 10 min each session.
41164356|NCT02780739|DEVICE|active tDCS|Active HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants receive 2.0 mA current for 30 min, split over the 2 anodal electrodes, each drawing ≤1.0 mA. Stimulation is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period.
41164357|NCT02780739|DEVICE|sham tDCS|Sham HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants do not receive sustained stimulation; it is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period to elicit the sensation of simulation and make the sham condition more convincing.
41164358|NCT02780739|BEHAVIORAL|Cognitive Training - 20 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
41164359|NCT03442140|OTHER|Harmonica playing|Patients will play the harmonica for up to 6 months
41164360|NCT00796614|DRUG|tamsulosin hydrochloride|Oral
40850769|NCT02682082|PROCEDURE|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
40850770|NCT02682082|DRUG|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
40850771|NCT02687100|DRUG|Beclomethasone|beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning
40850772|NCT02687100|DRUG|Placebo|patients will receive 8 mL of saline without any drug
40850773|NCT02868229|DRUG|COR-001|
40850774|NCT02868229|OTHER|Placebo|
40850775|NCT01586221|OTHER|Music & Physical Therapy|Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
40850776|NCT02128412|DEVICE|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
40850777|NCT02128412|DEVICE|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
40850778|NCT00773773|OTHER|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
40850779|NCT01710631|DRUG|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
40850780|NCT01710631|DRUG|placebo|placebo
40850781|NCT02815592|DRUG|BMS-986012|
40850782|NCT02815592|DRUG|Cisplatin|
41377599|NCT04619134|OTHER|NCSR Program|flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session
41377600|NCT04619134|OTHER|conventional physical therapy|hot pack,flexibility training,strengthening exercise.
41377601|NCT05649865|DIAGNOSTIC_TEST|Blood sample|Blood samples for analysis of circulating tumour HPVDNA
40850783|NCT02815592|DRUG|Etoposide|
40850784|NCT02815592|DRUG|Platinum|
40850785|NCT02815592|DRUG|Carboplatin|
40850786|NCT04659525|DRUG|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
40850787|NCT04659525|DRUG|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
40850788|NCT04659525|DRUG|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
41377602|NCT04865536|DRUG|1800 mg TBI-223|3 x 600 mg SR1 tablets
41377603|NCT04865536|DRUG|2400mg TBI-223|3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
41377604|NCT04865536|DRUG|3000mg TBI-223|4 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
41377605|NCT04865536|DRUG|TBI-223 Placebo|3 x Placebo tablets
40850789|NCT03618862|BIOLOGICAL|Blood sampling|Peripheral venous blood collection of 56 mL during a sampling required by routine monitoring of human immunodeficiency virus infection.
40850790|NCT01512992|PROCEDURE|Home telehealth|"Patients receive tailored intervention according to their clinical complexity.~All patients in the intervention group receive:~* Personalised care plan~* Education on self-management~* Access to a personalized online health folder~* Access to Call center~* Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).~Patients with LOW complexity additionally receive:~* Daily videoconferences for the 1st week after discharge~* Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.~Patients with HIGH complexity additionally receive:~* Videoconferences for at least 1 month after discharge, scheduled on an individual basis.~* Remote monitoring for respiratory parameters.~* One monthly phone call from the call centre to promote and assess patient self-management."
40850791|NCT02721095|OTHER|KCl plus 0.9%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
40850792|NCT02721095|OTHER|KCl plus 0.45%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
40850793|NCT05964413|DRUG|vilobelimab|vilobelimab infusion
40850794|NCT05964413|DRUG|Placebo|Placebo Infusion
40850795|NCT06051864|DEVICE|Modius Mood Active Device|Battery powered non-invasive neurostimulation device
40850796|NCT06051864|DEVICE|Sham Device|Placebo comparator sham device (no active stimulation)
40850797|NCT02346617|BIOLOGICAL|IFN-γ positive selected T-cells|No intervention
40850798|NCT04752358|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
40850799|NCT03084601|DRUG|Calcium Hydroxide, Iodoform, paste|mixture of calcium hydroxide and iodoform
40850800|NCT03084601|DRUG|3-mixtatin|3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
41377606|NCT04865536|DRUG|TBI-223 Placebo|4 x Placebo tablets
41377607|NCT04865536|DRUG|TBI-223 Placebo|5 x Placebo tablets
41377608|NCT03294382|DRUG|Botulinum toxin type A|5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
41377609|NCT03294382|DRUG|Placebo|0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
41377610|NCT01457690|DRUG|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
41377611|NCT01457690|DRUG|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
41377612|NCT01457690|DRUG|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
41377613|NCT00407966|DRUG|alvocidib|Given IV
41377614|NCT00407966|DRUG|cytarabine|Given IV
41506582|NCT03718650|PROCEDURE|Surgical Resection|Patients will undergo Pancreaticoduodenectomy or Whipple procedure, which involves the resection of the pancreatic head, duodenum, gallbladder, and a portion of the stomach, 16 to 24 hours after consuming oral pimonidazole.
41506583|NCT00479960|BEHAVIORAL|commercially available omega-3 fatty acids supplementation|
41506584|NCT02581722|DEVICE|PrePex Device|The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
41506585|NCT00550030|RADIATION|UVB-311nm radiation|UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
41506586|NCT00550030|OTHER|No treatment|no UV exposure
41506587|NCT05435937|BEHAVIORAL|Partnering for change (P4C-Swe)|"P4C focuses on the collaboration and a intersectional partnership between teachers and occupational therapists/special educators to create physical, social and learning environments that facilitate successful participation for all pupils. The intervention tiered model provides interventions in a school context in levels; class, group, and individual level to students with participation restrictions.~Dynamic Performance Analysis (DPA), which focuses on pupils' occupational performance, is used in P4C model to identify and analyze were and why pupils' occupational performance is breaking down in school-based occupations in the natural context, followed by collaboration and coaching between the occupational therapist and teacher in setting up goals, planning, implementing and monitoring intervention at the different intervention levels, to support participation."
41506588|NCT05435937|BEHAVIORAL|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
41506589|NCT01243112|DRUG|1% Lidocaine with Epinephrine (1:100,000)|0.2ml Intradermal injection once.
41377615|NCT00407966|DRUG|mitoxantrone hydrochloride|Given IV
41506590|NCT01243112|DRUG|0.25% Bupivacaine with Epinephrine (1:200,000)|0.2ml Intradermal injection once.
41506591|NCT01243112|DRUG|0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)|0.2ml Intradermal injection once.
41506592|NCT01243112|DRUG|1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)|0.2ml Intradermal injection once.
41377616|NCT05666648|OTHER|Sitz Bath|Individual patients were randomized to either receive 'sitz baths' or 'no sitz baths' treatment for 4 weeks. Patients were asked to have 'sitz bath' once in morning and again at bedtime, after each week pain scores and healing of fissure were assessed. Main outcome measures were validated
41377617|NCT02203773|DRUG|Posaconazole|Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
41377618|NCT02203773|DRUG|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
41506593|NCT03649347|BEHAVIORAL|Augmented reality exposure therapy|Exposure therapy via utilization of augmented reality. Virtual objects will be placed on the patient's real environment for exposure therapy.
40850801|NCT03800511|DIAGNOSTIC_TEST|sliding test|ultrasound detected sliding test before doing repeated caesarean section
41377619|NCT02203773|DRUG|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
41377620|NCT02203773|DRUG|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
41377621|NCT01412294|DRUG|Capecitabine, Cisplatin|"Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
41377622|NCT04707014|BEHAVIORAL|Hypnosis|Rapid conversational hypnosis
41506594|NCT06259097|DRUG|Misoprostol|25 mcg vaginally every 6 hours
41506595|NCT06259097|DRUG|Pitocin|3-6 mL intravenously every hour
41506596|NCT02624180|DRUG|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
41506597|NCT02624180|DRUG|Placebo|A substance containing no medication
41506598|NCT03304301|BEHAVIORAL|sunlight exposure|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months
41506599|NCT00001946|PROCEDURE|Magnetic resonance angiography|
41506600|NCT05896644|OTHER|Eat Well|A program offered by Reinvestment Partners giving clients gift/debit cards that allow the purchase of WIC approved fruits and vegetables.
41506601|NCT00843895|BIOLOGICAL|pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases
41377623|NCT04707014|BEHAVIORAL|Attention-distracting techniques|i-pad with movies, games and music
41506602|NCT02833987|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
41506603|NCT02833987|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
41506604|NCT02833987|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
40850802|NCT01628965|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
40850803|NCT00857857|DRUG|GW870086X|Investigational product
40850804|NCT00857857|DRUG|FP|Positive control
40850805|NCT00857857|DRUG|Placebo|Placebo control
40850806|NCT03719911|BEHAVIORAL|Live diabetes coaching program|Live diabetes coaching program
40850807|NCT01448499|DRUG|Clozapine|escalating dose of clozapine up to 900 mg/day
41164361|NCT00796614|DRUG|Placebo|Oral
41377624|NCT03910309|DEVICE|TLIF with Titan TT/TO interbody cage|fusion surgery
41506605|NCT02833987|DRUG|Warfarin (ATC B01AA03)|Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
41506606|NCT03003650|DEVICE|ACURATE TF™|ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
41377625|NCT06520787|COMBINATION_PRODUCT|ACDP® and Semaglutide|Families of children with obesity willing to join a combined intervention (ACDP® and Semaglutide). After the recruitment, the family will join Adhera Caring Digital Program® for 13 months. Semaglutide treatment will start one month after joining the digital intervention. The combined intervention (digital and pharmacological intervention) will last one year. Once the Semaglutide treatment is finished, there will be a 4-month follow-up. During the whole study (16 months, from recruiting to the end of follow-up) participants will wear a smartwatch (Fitbit or similar).
41377626|NCT05049902|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
41377627|NCT05049902|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
41377628|NCT05049902|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
41377629|NCT05049902|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
41377630|NCT05049902|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
41377631|NCT05049902|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
41377632|NCT05049902|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
41377633|NCT00925795|OTHER|consumption 1. EVOO; 2. ROO|EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days
41377634|NCT00925795|OTHER|consumption 1. ROO; 2. EVOO|ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
41377635|NCT03545568|OTHER|Neu5Ac supplementation|Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
41377636|NCT04027634|OTHER|Baduanjin program|This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
41377637|NCT00741026|DRUG|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
41377638|NCT00741026|DRUG|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
41377639|NCT05129527|DEVICE|InspirerMundi app|"Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period."
41377640|NCT05129527|OTHER|Usual care|Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
41377641|NCT04494191|DRUG|Flibanserin 100Mg Tab|One tablet contains 100 mg Flibanserin
41377642|NCT04494191|DRUG|Flibanserin 100 MG [Addyi]|One tablet contains 100 mg Flibanserin
41377643|NCT00973167|DEVICE|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
41506607|NCT03412799|DRUG|SBP-101|Administered as subcutaneous (SC) injection, escalating dose cohorts
40850808|NCT01448499|DRUG|Amisulpride|escalating dose of amisulpride up to 800 mg/day
41377644|NCT01654211|DRUG|danoprevir|single iv infusion
41377645|NCT01654211|DRUG|danoprevir|single oral dose
41377646|NCT01654211|DRUG|placebo|single iv infusion
41377647|NCT01654211|DRUG|ritonavir|oral doses
41377648|NCT04698252|RADIATION|Radiotherapy|Radiation therapy for oligometastatic sites
41377649|NCT04698252|PROCEDURE|Surgery|Surgery for oligometastatic sites
41377650|NCT04698252|OTHER|Radiofrequency ablation|Radiofrequency ablation for oligometastatic sites
41377651|NCT05457829|DRUG|Doxorubicin Hydrochloride Liposome+Irinotecan|Q3W, 2 cycles.
41377652|NCT05457829|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 2 cycles.
41377653|NCT02046720|DRUG|Propofol induced sedation|"Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.~The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)"
41377654|NCT00111007|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
41506608|NCT03412799|DRUG|nab-paclitaxel|Administered as intravenous (IV) infusion
41506609|NCT03412799|DRUG|Gemcitabine Injection|Administered as intravenous (IV) infusion
41506610|NCT01876446|OTHER|Laboratory Biomarker Analysis|Correlative studies
41506611|NCT01876446|DRUG|Pegylated Irinotecan|Given IV
41506612|NCT01876446|OTHER|Pharmacological Study|Correlative studies
41164362|NCT04295018|DRUG|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
41164363|NCT04486079|DIETARY_SUPPLEMENT|Nutricia PreOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
41164364|NCT00548002|DRUG|trovafloxacin and levofloxacin|Trovafloxacin: \<60 kg 200 mg iv/orally once daily and \>60 kg 300 mg iv/orally once daily Levofloxacin: \< 60 kg 500 mg iv/orally once daily and \>60 kg 500 mg iv/orally bid
41164365|NCT00802438|BIOLOGICAL|mepolizumab|up to three monthly doses of 750mg i.v. mepolizumab
41164366|NCT01591655|DRUG|Mapracorat|1 drop of study medication into the study eye four times daily (QID) for 14 days
41164367|NCT01591655|DRUG|Vehicle|1 drop of vehicle into the study eye QID for 14 days.
41164368|NCT04137302|DRUG|Hydrocortisone administration|Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
41164369|NCT04372537|BEHAVIORAL|hypnosis|use of hypnosis.
41164370|NCT04372537|BEHAVIORAL|standard care|standard clinical procedure
41164371|NCT05611723|OTHER|Exposure to disability|Disability status assessed by functional measures
41164372|NCT00723918|DRUG|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
41164373|NCT00723918|DRUG|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
41164374|NCT00723918|DRUG|SAB placebo|an inactive substance
41377655|NCT00111007|DRUG|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m\^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
41377656|NCT00111007|DRUG|Placebo|Placebo, 2 tablets bid Study Days 2-19
41377657|NCT06538376|DIAGNOSTIC_TEST|Portable Dynamic Digital Radiography (DDR)|"(DDR imaging has already been described in the arm/group description). Each patient in the study will receive at least one set of DDR images, which consists of one 7-second scan in which the patient breaths normally, and a second 7-second scan in which the patient holds their breath (or for ventilated patients, an inspiratory pause is placed by the care team).~If the patient's conditions warrant it, up to two sets of follow-up scans may be acquired. For instance, in a patient with diaphragmatic dysfunction, imaging may be completed pre- and post- diaphragmatic plication."
40850809|NCT01448499|DRUG|Clozapine+Amisulpride|augmentation of clozapine with amisulpride
41033982|NCT00855517|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
41033983|NCT05251753|DEVICE|K-Lock|Patients will be randomized to either A) left side K-Lock with right side suture-based technique or B) right side K-Lock with left side suture-based technique.
41033984|NCT01718769|OTHER|questionnaire STAMP|Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
41164375|NCT00723918|DRUG|Methadone placebo|Methadone placebo
41164376|NCT04970693|DRUG|Furmonertinib|The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.
41164377|NCT04560777|OTHER|CO-OP intervention|"The general structure of the intervention will follow the original key principles of CO-OP, with some adjustments to adapt it to the specificities of the ABI population (14 CO-OP sessions vs 10 in the original protocol).~The global strategy will be taught to the participant at the first session. The following sessions will be consisted of an process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the participant will be experiencing when performing the self-selected tasks. In addition, homework will be assigned to encourage the application and practice of the cognitive strategies discovered during the intervention sessions. Parents will be invited to attend the sessions if it will be possible for them. In any case, the global strategy, as well as the progress of the child, will be explained to the parents."
41033985|NCT04757116|DEVICE|iTind|The iTind is implemented for 5-7 days
41164378|NCT00302497|DRUG|basiliximab|
41164379|NCT06028217|OTHER|prognosis status|observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
41164380|NCT06102226|DIAGNOSTIC_TEST|coronary artery imaging (coronary CTA or coronary angiography)|In order to obtain the gold standard labeling for coronary heart disease, this topic will form a panel of experts on labeling, and the diagnosis will be based on coronary angiography, defined as a lesion with a stenosis of at least 50% in at least one coronary artery
41164381|NCT02122549|DEVICE|HWD1000|Wearable cardioverter-defibrillator designed for inpatient use
41164382|NCT03776162|PROCEDURE|ACL Reconstruction (Bone Patellar Tendon Bone Graft)|Standard of care procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
41164383|NCT03776162|DEVICE|Bridge Enhanced ACL Restoration (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR implant) between the torn ends of the ACL, providing a sponge for the ligament ends to group into.
41164384|NCT04815473|PROCEDURE|Valvulotomy|Valvulotomy of the venous valves
41164385|NCT02587013|PROCEDURE|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
41164386|NCT02587013|PROCEDURE|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
41377658|NCT05180994|DRUG|Topical infliximab|Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.
41377659|NCT05180994|OTHER|No topical infliximab|No treatment with infliximab.
41377660|NCT00623688|DEVICE|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
41377661|NCT00623688|DEVICE|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
41377662|NCT02098434|BEHAVIORAL|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
41377663|NCT05391607|DRUG|Hyperoncotic Albumin 20%|Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
41377664|NCT05391607|DRUG|Isooncotic Albumin 5%|Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
41377665|NCT05391607|DRUG|Ringer's Lactate Crystalloid Solutions (control group)|Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
41377666|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 2sites|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
41377667|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1 site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
41377668|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
41377669|NCT00297063|DRUG|Rosiglitazone|
41377670|NCT03949946|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan uses radio waves in a magnetic field to obtain images of the breast. It is non-invasive and participants will not be exposed to harmful radiation. An image contrast agent will be used to enhance image clarity. Participants will be scanned lying face-down on a specially-designed bed and ear protectors will be provided to screen out background noise.
40850810|NCT06525701|OTHER|Execise Group|SCORE workout: eight exercises done sequentially: bicycles, balancing dog, windshield wipers, three-point plank, kayaker, super push-ups, bridge, and side plank. These workouts are modified from the core regimen recommended by Steve House and Scott Johnston in their book Training for the New Alpinism: A Manual for the Climber as Athlete (House 2014). Each exercise is done until fatigue: when the individual is no longer able to complete the exercise with good form. The participant then rests for approximately thirty to sixty seconds before beginning the next exercise. Passive stretching can be performed during the rest periods. The workout is complete at twenty minutes. Those individuals who complete all eight exercises in less than twenty minutes begin again with the first exercise (bicycles) and continue until reaching twenty minutes. The workout is thus adaptive-seamlessly increasing in repetitions as an individual's strength and endurance increase.
41033986|NCT04757116|PROCEDURE|UroLift|UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.
41377671|NCT06103656|DRUG|Drug: Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT.
41377672|NCT06103656|DRUG|Drug: Placebo|Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
41506613|NCT05439967|OTHER|Augmented and Virtual Reality Gait and balanceTraining|C-Mill VR+ device used for training. The training was carried out 3 days a week for 6 weeks, with each exercise session lasting approximately 1.5 hours, accompanied by a physiotherapist. Training started with conventional exercises, continued with C-Mill VR+ training, and ended with stretching and relaxation exercises. The patients in the intervention group were applied the exercises with the same principles with conventional training, except the exercises performed in standing and walking. Patients performed 10 exercises in AR and VR gait training for 4 minutes and resting the individuals by sitting for 1 minute between exercises.
40850811|NCT06525701|OTHER|Control Group|No additional exercises or tasks are requested of control participants. Control group participants will perform or not perform exercise as they otherwise would outside of the study.
41377673|NCT06103656|DRUG|Drug: Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
40850812|NCT00147121|DRUG|Rituximab + Standard CHOP|Rituximab + Standard CHOP
41377674|NCT05012813|OTHER|Aromatherapy with Essential Oils|Participate in SFIT this is one intervention with aroma therapy with essential Forest oils
41377675|NCT00163371|DRUG|Ciclesonide|
41377676|NCT03609970|DIETARY_SUPPLEMENT|Vitamin D|Daily 4X 1000IU cholecalciferol
41377677|NCT03609970|RADIATION|UVR (Solar simulated radiation)|1.25 SED Solar simulated radiation twice weekly
40850813|NCT00147121|DRUG|Rituximab + Bi-weekly CHOP|Rituximab + Bi-weekly CHOP
40850814|NCT02302391|OTHER|PK analysis|Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
41033987|NCT06138574|DRUG|Dexmedetomidine|After the induction of general anesthesia, one group (Group: 1) will be administered dexmedotomidin infizyon and group (Group :2)remifentanil
41033988|NCT06138574|DRUG|Remifentanil|Remifentanil
41164387|NCT00002971|DRUG|O6-benzylguanine|
41377678|NCT05952154|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricular end-diastolic volume and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient enlargement of left ventricular end-diastolic volume and improvement of mitral regurgitation, while preventing iatrogenic injuries.
41164388|NCT01052389|DRUG|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
41377679|NCT01738282|DRUG|Baclofen|
41377680|NCT01738282|DRUG|Placebo (for baclofen)|
41377681|NCT05272267|OTHER|AI-assisted models providing diagnosis and prognostic information|AI-assisted models providing diagnosis and prognostic information in the ED, including triage, ICD coding, chest x ray alerts, critical event alerts, readmission prediction, and post-cardiac arrest prognostication.
41377682|NCT05272267|PROCEDURE|Critical treatment|Critical treatment of the emergency room
41506614|NCT05439967|OTHER|Conventional Training|Conventional training was applied to the patients in the control group. Conventional training was planned taking into account the following goals: increasing mobility by improving the impaired kinesthetic sensation; improving axial rotation, coordination, flexibility of soft tissues, mobility in and out of bed; increasing body image perception by improving upright and proper posture; and improving balance and gait. The training was applied 3 days a week for 6 weeks, with each exercise session lasting 40-50 minutes, accompanied by a physiotherapist. Each of the exercises was done in 2 sets of 10 repetitions. In gait training, each exercise was performed for 4 minutes.
41377683|NCT02014194|BEHAVIORAL|attentional bias modification treatment|The attentional bias modification treatment is a behavioral computerized program (software e-prime)
41506615|NCT05800158|DIAGNOSTIC_TEST|Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit|A reverse transcription, real-time polymerase chain reaction (RT-qPCR) test for the qualitative detection of SARS-CoV-2.
41377684|NCT05764629|DIAGNOSTIC_TEST|blood test|Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.
41377685|NCT05764629|DRUG|pharmacologic approaches to glycemic treatment|documenting the change of glycemic treatment during the follow-up period
41377686|NCT01042288|DRUG|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
41377687|NCT01042288|DRUG|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
41377688|NCT01042288|DRUG|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
41377689|NCT03448380|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
41377690|NCT02080624|DRUG|Drug: Topical Rapamycin|"After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment."
41377691|NCT05518409|BIOLOGICAL|Detection of cytof in peripheral PBMC|Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.
41377692|NCT05518409|DRUG|Donepezil for patients with AD and DLB|The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
41377693|NCT02461147|PROCEDURE|Cholecystectomy with intraoperative cholangiogram|cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
41377694|NCT00790972|DRUG|Sinofresh|two sprays in each nostril three times daily for one week
41377695|NCT00790972|DRUG|Placebo|two sprays in each nostril three times daily for one week
41377696|NCT02663999|DRUG|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
41377697|NCT02399046|DEVICE|Total Knee System made in China (Sigama, CoCr, PFC)|SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
41377698|NCT02399046|DEVICE|Total Knee System made outside of China (Sigama, NP, PFC)|SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
41377699|NCT01448070|DRUG|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
41164389|NCT01052389|DRUG|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
41506616|NCT03449446|DRUG|SEL|18 mg tablet administered orally once daily without regard to food
41506617|NCT03449446|DRUG|FIR|20 mg tablet administered orally once daily without regard to food
40850815|NCT00061633|DRUG|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
40850816|NCT00061633|DRUG|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
41164390|NCT01052389|DRUG|Haloperidol|"Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day)."
41377700|NCT04089150|RADIATION|Stereotactic Radiotherapy (SBRT)|40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction
40850817|NCT02491606|DRUG|Tafenoquine|Tafenoquine 200mg and 400 mg
40850818|NCT02491606|OTHER|Placebo|Placebo
41377701|NCT04089150|DRUG|mFOLFIRINOX|"* Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles"
41377702|NCT04089150|DRUG|Gemcitabine + Nab-paclitaxel|"* Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~* 28-day cycle, 3 cycles"
41377703|NCT04089150|DRUG|Gemcitabine + Capecitabine|"* Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles"
41377704|NCT04089150|PROCEDURE|Pancreatoduodenectomy (Whipple procedure)|R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
41377705|NCT03128931|DEVICE|Pediatric SedLine forehead EEG sensor|Pediatric EEG sensor.
40850819|NCT03828851|OTHER|Domiciliary care - Activities of Daily Living|Home-based ADL training.
40850820|NCT02240264|DIETARY_SUPPLEMENT|Krill oil capsules|1 year supplementation with Krill oil provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
40850821|NCT02240264|DIETARY_SUPPLEMENT|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
40850822|NCT01506999|BIOLOGICAL|MULTIGENE SCREENING FOR SINGLE SNPS|DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
41377706|NCT02673827|OTHER|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
41377707|NCT05772104|DRUG|Shugan Jieyu Capsules|Oral, 4 Capsules, BID
41377708|NCT05772104|DRUG|Shugan Jieyu Capsules+Placebo|"Drug: Shugan Jieyu Capsules, Oral，3 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID"
41377709|NCT05772104|DRUG|Placebo|Oral，4 capsules，BID
41377710|NCT05158972|DRUG|Dymista|1 spray per nostril twice daily up to four weeks
41377711|NCT05079204|OTHER|Intra oral scan|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions Intervention consists in an 3D intra oral representation of the oral cavity.
41377712|NCT05079204|OTHER|No intervention|No intervention
41377713|NCT01282879|DRUG|Itraconazole|200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
40850823|NCT05231018|OTHER|Psychotherapy|8-sessions psychotherapy
41033989|NCT01412008|DRUG|Botox (botulinum toxin)|A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
41033990|NCT02811562|DEVICE|manikin|
41377714|NCT05252169|OTHER|Proprioceptive training|"Proprioceptive Training will include some active exercises such as stair climbing up and down,one leg standing,Walking heel to toes,rising from a standard chair.~And swiss ball training will be applied passively by therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation,Trunk rotation will be performed with stabilized pelvis and hip."
41377715|NCT05252169|OTHER|Routine Physical therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
41377716|NCT01353586|DEVICE|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
41377717|NCT05354999|DIETARY_SUPPLEMENT|Sodium bicarbonate and caffeine|On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
41377718|NCT05996601|BEHAVIORAL|Educational intervention|Educational materials would be given to all the participants. They would also be followed up by pharmacist.
41377719|NCT03427827|DRUG|Camrelizumab|Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
41377720|NCT04708834|DRUG|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily for following 46 weeks
41377721|NCT06542679|BEHAVIORAL|Mobile Application|A mobile health application based on Social Cognitive Theory (SCT) and the Information-Motivation-Behavioral Skills (IMB) model has been developed. The design of the mobile health application is grounded in SCT, the IMB model, and behavioral change interventions and techniques. The content of the mobile application is based on the 'Healthy Weight Gain Guide for Pregnancy.' The application offers a comprehensive program that provides evidence-based recommendations using self-monitoring, feedback, shaping information, goal setting, planning, and reward techniques for healthy nutrition, physical activity, and optimal gestational weight gain for pregnant women.
41506618|NCT03449446|DRUG|CILO|30 mg tablet administered orally once daily without regard to food
40850824|NCT03245775|BEHAVIORAL|iChoose|12 bi-weekly sessions \& 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
40850825|NCT03245775|BEHAVIORAL|Family Connections|2 in-person sessions spaced one week apart \& 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
40850826|NCT06547255|DRUG|Bupivacaine liposome injectable suspension|At the end of the third molar extraction surgical procedure performed under general anesthesia and at least fifteen minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine nerve block (routine for this procedure), all patients will receive bilateral infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel) OR with 3mL of 0.5% bupivacaine with 1:200,000 epinephrine while they are still under general anesthesia.
41033991|NCT02811562|DEVICE|fiberoptic bronchoscope|
41033992|NCT02811562|DEVICE|pentax-airwayscope|
41033993|NCT03719105|DRUG|Methotrexate|Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.
41377722|NCT05770362|OTHER|lifestyle questionnaire|The changes in lifestyle by lifestyle questionnaire during and after home isolation
41377723|NCT06276348|GENETIC|Whole genome sequencing|Standard diagnostic whole genome sequencing will be performed.
41033994|NCT03719105|DRUG|pralatraxate,|Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
41377724|NCT06276348|GENETIC|BeginNGS test|Genomic sequencing that screens for 434 genetic diseases.
41506619|NCT03449446|DRUG|Placebo to match FIR|Tablet administered orally once daily without regard to food
40850827|NCT01975597|PROCEDURE|Bone marrow aspirates and biopsy|
41377725|NCT06276348|GENETIC|WES|Whole exome sequencing will be performed.
41377726|NCT00659945|DRUG|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
41377727|NCT00659945|DRUG|Ondansetron plus placebo|Ondansetron plus placebo
41377728|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RPF knee implant.|Total knee replacement
41377729|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RP knee implant|Total knee replacement
41377730|NCT02552329|OTHER|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
41506620|NCT03449446|DRUG|Placebo to match CILO|Tablet administered orally once daily without regard to food
41506621|NCT03449446|DRUG|Placebo to match SEL|Tablet administered orally once daily without regard to food
41506622|NCT03308812|BEHAVIORAL|Health360x|Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
41506623|NCT03308812|BEHAVIORAL|Health Coach|Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
41506624|NCT00004263|DRUG|7-hydroxystaurosporine (UCN-01)|20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
41033995|NCT03719105|DRUG|Ifosfamide|Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
41033996|NCT03719105|DRUG|Dexamethasone|Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
41506625|NCT00004263|DRUG|Cytarabine (Ara-C)|Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
41033997|NCT03719105|DRUG|Etoposide|Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
41506626|NCT05102747|RADIATION|Hypofractionated SRT (stereotactic radiotherapy)|3\*10Gy over 1 week
41377731|NCT05101057|DEVICE|SpinalogicTM Bone Graft Stimulator|The SpinalogicTM is a portable, battery-powered, microprocessor-controlled, non-invasive bone growth stimulator. The device is currently approved and commercially indicated as an adjunct electrical treatment to primary lumbar spinal fusion surgery for one or two levels.
41506627|NCT05102747|RADIATION|Historical single-dose SRS (stereotactic radiosurgery)|20 to 25Gy/1 fraction
41506628|NCT05443568|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
41377732|NCT03500237|BEHAVIORAL|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will respond within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
41377733|NCT03500237|BEHAVIORAL|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychoeducational support will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
41506629|NCT05114278|DRUG|Ferinject|Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
41506630|NCT05114278|DRUG|oral iron|All patients will receive an oral iron supplementation (100mg/day).
41506631|NCT03385850|OTHER|enteral nutrition|early enteral nutrition group or delayed enteral nutrition group
41506632|NCT06191588|PROCEDURE|INFANT CIMT/BIT|Constraint induced movement therapy (CIMT) and Bimanual Intensive therapy (BIT)
40850828|NCT02464410|BEHAVIORAL|Motivational intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.
41033998|NCT03719105|DRUG|calaspargase pegol|Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
41033999|NCT03719105|DRUG|cyclophosphamide|Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
41034000|NCT03719105|DRUG|Doxorubicin|Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
41034001|NCT03719105|DRUG|Prednisone|Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
41377734|NCT05847309|OTHER|Delayed extubation|Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
41377735|NCT05847309|OTHER|Early extubation|Patients randomized to early extubation, will be extubated \< 6 hours after endovascular treatment under general anesthesia.
41377736|NCT03126175|DEVICE|Below elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb.
41377737|NCT03126175|DEVICE|Above elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
41377738|NCT04516356|OTHER|Korean hand acupressure|According to the working principle of Korean hand acupressure; There are active points and areas in the hands and feet that fit the whole body. The active points on the hands and feet are properly matched to reflect the anatomy of the whole organism. Areas in the body and systems suitable for them are in constant contact. In the patient, the signal wave moves from the damaged point or area and reaches the appropriate point immediately. Thus, changes such as severe pain, skin discoloration, hardening, thickening and thinning in some parts of the skin occur at that point. With the stimulation of the effective point, a treatment wave occurs that heals the sick organ.
41377739|NCT03948646|DRUG|Sofpironium Bromide, 15%|Active
41377740|NCT03948646|DRUG|Vehicle|Vehicle gel
41377741|NCT06344650|PROCEDURE|Blood sample|Collection of blood serum for molecular and biochemical tests
41506633|NCT03106389|DRUG|Misoprostol|400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
40850829|NCT02464410|BEHAVIORAL|Psycho-educational control|The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.
40850830|NCT02464410|OTHER|Long-term opioid therapy informed consent|The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
40850831|NCT02843828|DEVICE|gait rehabilitation with Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
40850832|NCT02843828|OTHER|gait rehabilitation without Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
40850833|NCT00940498|DRUG|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
40850834|NCT04161261|PROCEDURE|Electrical Stimulation|To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli
41034002|NCT03719105|DRUG|Brentuximab Vedotin|Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
41034003|NCT00460889|PROCEDURE|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
41034004|NCT01276587|DRUG|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
41034005|NCT00114686|DRUG|Quetiapine fumarate|
41034006|NCT00114686|DRUG|lithium|
41034007|NCT00114686|DRUG|divalproex|
41034008|NCT06533176|DEVICE|Personalized brain state-dependent single-pulse TMS|Single-pulse TMS will be applied to the lesioned hemisphere during brain activity patterns associated with strong residual corticospinal tract activation and random brain activity patterns.
41034009|NCT06181162|OTHER|Social and/or physical environmental interventions|To be determined in the co-creation groups on the four sites (Denmark, the Netherlands, Nigeria, South Africa)
41034010|NCT06569173|DEVICE|LaiKai anti-reflux ureteral stent|Ureteral stents are serving to support the ureter and facilitate urine drainage with an anti-reflux valve.
41034011|NCT06569173|DEVICE|LaiKai Ureteral Stent|Ureteral stents are serving to support the ureter and facilitate urine drainage.
41034012|NCT06451068|DEVICE|Peripheral retina robotically aligned optical coherence tomography (OCT) system|To visualize the full 360° of the retinal periphery (from equator to the more anterior ora serrata), investigators developed and redesigned a conical mirror contact lens and our non-contact robotically aligning platform to deliver OCT to the peripheral retina. The peripheral retina robotically aligned OCT (PR-RAOCT) system is built around a 6-axis cooperative robot (UR5e, Universal Robots), using our previously developed RAOCT control software.
41034013|NCT06451068|OTHER|Likert Scales|Survey evaluating relative comfort with each type of peripheral exam (scleral depression vs. PR-RAOCT). Participants will rate 3 items on a 1 (non) to 5 (maximum) Likert scale: overall discomfort, physical pain, and photophobia for each exam.
41034014|NCT03548844|PROCEDURE|local excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .
41034015|NCT03548844|PROCEDURE|total mesorectal excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
41377742|NCT06344650|DIAGNOSTIC_TEST|Radiological tests|Performance of radiological tests (DXA, VFA, TBS, BSi, HR-pQCT) and DXA morphometry
41377743|NCT06344650|OTHER|Questionnaires|Compilation of questionnaires (AcroQol, SF-36)
41377744|NCT05316376|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)
41377745|NCT05316376|DRUG|paclitaxel|paclitaxel (175 mg/m2, day 1, every 3 weeks) combined with carboplatin (AUC=6, day1, every 3 weeks)
41506634|NCT03106389|DEVICE|Misoprostol/Transcervical catheter|Foleys' catheter introduced into the cervix and inflated with 30 ml. of fluid; weighted traction applied by using a 1000 ml fluid-filled bag
41506635|NCT04428814|BIOLOGICAL|CT-P43|45mg single dose
41506636|NCT04428814|BIOLOGICAL|EU-approved Stelara|45mg single dose
41506637|NCT04428814|BIOLOGICAL|US-licensed Stelara|45mg single dose
41506638|NCT02653833|DRUG|Tadalafil 20 MG|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
41506639|NCT02653833|OTHER|beetroot juice extract|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
41506640|NCT02959424|OTHER|Spanish Northwestern Esophageal Quality of Life questionnaire|
41506641|NCT04316793|OTHER|Dry needling|Intramuscular insertion of an OPTIMED 40mm x 0.3mm acupuncture needle in a trigger point of the infraspinatus muscle
41506642|NCT04316793|OTHER|Sham needling (SN)|Intradermal insertion of an OPTIMED 40mm x 0.3mm acupuncture needle over the infraspinatus region
41034016|NCT06636383|OTHER|No Intervention|No investigational/study product will be administered in this DMP.
41034017|NCT02416791|DEVICE|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
41377746|NCT04220723|OTHER|Frailty Assessment|"Liver Frailty Index measurements:~1. Grip strength: the average of three trials, measured in the subject's dominant hand using a hand dynamometer~2. Timed chair stands: measured as the number of seconds it takes to do five chair stands with the subject's arms folded across the chest~3. Balance testing: measured as the number of seconds that the subject can balance in three positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each."
41377747|NCT04220723|OTHER|Functional Capacity Assessment|Shuttle Walk Test: The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases. The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends. The number of shuttles is recorded. Each shuttle represents a distance of ten metres (i.e each time the patient reaches a cone is 1 shuttle).
41034018|NCT02416791|DEVICE|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
41034019|NCT02416791|DEVICE|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
41506643|NCT02210624|BIOLOGICAL|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
41506644|NCT00266539|DRUG|E-TRANS Fentanyl hydrochloride; Morphine|
41506645|NCT06334224|DEVICE|Low load resistance training with blood flow restriction|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
41506646|NCT06334224|OTHER|Low load resistance training|Leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
41506647|NCT03398603|PROCEDURE|blood sample and ultrasound|When included in the study blood samples and ultrasound are taken every second day of the first and third menstrual cycle after inclusion.
41506648|NCT01944111|DEVICE|Plication|Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
41034020|NCT02416791|OTHER|Physical Therapy|Physical therapy will be administered for 40 minutes.
41034021|NCT02416791|OTHER|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
41034022|NCT03176680|PROCEDURE|Fluid therapy optimization|colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
41034023|NCT05934344|OTHER|Action observation training|The activities proposed will be based on items from the FMA scale (Voluntary movement within synergies, voluntary movement mixing synergies, voluntary movement with little or no synergy, grip, coordination/speed, passive joint movement), and the exercises for the lower limbs will be designed by the authors of the study, based on Vivifrail (32), a multicomponent physical training program for the prevention of deconditioning and falls in older adults. These exercises will be progressive each week, focusing on strengthening, balance, and functional exercises to improve gait. The sessions will last between 20 and 30 minutes, with a frequency of three days per week. The intervention will last for 5 weeks.
41034024|NCT06177639|DEVICE|WiSLO|Imaging with the research WiSLO device in non-contact mode (4 images from each eye)
41034025|NCT06177639|DEVICE|Volk Pictor Plus™|Imaging with the commercial handheld fundus camera, Volk Pictor Plus™ (4 images from each eye)
41034026|NCT06636279|PROCEDURE|Gas bubble technique|Inject the sterile air into the anterior chamber after the conventional cataract surgery to reduce corneal endothelial damage
41034027|NCT03343262|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
41034028|NCT03343262|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
41034029|NCT03525353|OTHER|Endoscopic retrograde cholangiopancreatography - No Intervention have been used other than standard of care|No intervention has been used and this is an observational study
41034030|NCT06500442|DRUG|NEU-111|Oral Doses
41034031|NCT06500442|DRUG|Placebo|Oral Doses
41377748|NCT03029754|PROCEDURE|Passive leg raise|A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
41377749|NCT05624515|DEVICE|dry needling|Active trigger point puncture of the angularis scapulae muscle
41377750|NCT05624515|OTHER|Ischaemic compression|Ischaemic compression at the active trigger point of the angularis scapulae muscle
41506649|NCT02888730|DRUG|Tobramycin nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition."
41034032|NCT06634758|BEHAVIORAL|Nursing interventions based on the Watson Human Caring Model|In the literature review, it was noticed that nursing care based on the Watson Human Caring Model was applied to various patient groups but not to patients with MS.
41034033|NCT00820768|DRUG|ABI-010|17-AAG and ABI-007
41034034|NCT01817972|BIOLOGICAL|Certolizumab pegol|Subcutaneous injection
41034035|NCT01817972|DRUG|Azathioprine|50mg tablets
41034036|NCT04327414|BEHAVIORAL|Intervention group|Standing desks
41034037|NCT05469321|OTHER|None, pure observationnal study|None, pure observational study following the usual management of the patients
41034038|NCT03116919|OTHER|Potato|Participants will be given an extra serving of potato a day
41377751|NCT04334122|OTHER|Instrument-assisted soft tisue mobilization|"All patients in the experimental group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~In addition to the traditional physiotherapy program, the patients in the experimental group were subjected to tool-assisted soft tissue mobilization 3 times a week (12 sessions with 1 day interval).~All evaluations were repeated to all patients in the experimental and control groups after four weeks."
41377752|NCT04334122|OTHER|Traditional physiotherapy|All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.
41377753|NCT06327204|DEVICE|940-nm diode laser / one session|laser therapy using a 940-nm diode laser / one session per week
41377754|NCT06327204|DEVICE|940-nm diode laser / two session|laser therapy using a 940-nm diode laser / two session per week
41377755|NCT06327204|DEVICE|940-nm diode laser/ three session|laser therapy using a 940-nm diode laser / three session per week
41377756|NCT04480502|BIOLOGICAL|Envafolimab|PD-L1 single domain antibody for subcutaneous injection.
41377757|NCT04480502|DRUG|Ipilimumab|CTLA-4 monoclonal antibody
41034039|NCT03116919|OTHER|Non-starchy vegetable|Participants will be given an extra serving of a non-starchy vegetable
41377758|NCT02677337|OTHER|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
41377759|NCT02677337|OTHER|Educational Program|
41034042|NCT04957719|COMBINATION_PRODUCT|Selatogrel|"Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer 16 mg of selatogrel subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
41034043|NCT04957719|COMBINATION_PRODUCT|Placebo|"Placebo will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer placebo subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
41034044|NCT01060761|BEHAVIORAL|Rehabilitation program|"Patient and their relative receive three supportive, structured conversation with a trained nurse.~Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities"
41377760|NCT05031780|DRUG|Mitapivat|Mitapivat tablets
41377761|NCT05031780|OTHER|Mitapivat-matching placebo|Placebo to match 50 mg or 100 mg tablets
41377762|NCT05031780|OTHER|Mitapivat-matching placebo|Placebo to match 100 mg tablets
41377763|NCT00596973|PROCEDURE|Surgical Treatment|Ileal transposition with sleeve gastrectomy
41377764|NCT05688527|OTHER|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
41377765|NCT05688527|OTHER|Toning Essence|DermResults Advanced Toning Essence w/ Mineral Booster twice daily
41377766|NCT05688527|OTHER|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
41377767|NCT05688527|OTHER|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
41377768|NCT05688527|OTHER|Eye Cream|DermResults Advanced Eye Cream w/ Hyaluronic Acid twice daily
40850835|NCT06485388|DRUG|Propofol|Venous blood samples will be taken from the patients included in the study and incubated with propofol (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
41164391|NCT05655234|BEHAVIORAL|Music Breathing|"The MB programme consists of four stages: 1. Silent breathing for grounding (SB), 2. Music breathing for grounding (MBG), 3. Music breathing for modulation (MM), 4. Music breathing for working (MW).~After completing the silent breathing and music breathing practices, the participants will draw pictures of their body images of breathing space and centre. The form of the imagined breathing space expressed in the drawing and the meaning and content of the experience will be explored through a process facilitated by the therapist. The therapist's understanding of the participants' difficulties and progress will guide the next step, particularly the selection of music for the next sessions. The whole session takes about 2 hours. Weekly home practice is advised."
41164392|NCT05655234|BEHAVIORAL|Control condition|The control condition consists of 30-min mental health education programme with topics on stress management, music playing, and breathing exercise provided in the first and 6th weeks. A take-home kit which consists of the fact sheet information of the health talk and the video link of the breathing exercise and musical pieces will be provided to the participants after the first meeting. They are instructed to practice the breathing exercise and listening to the musical pieces at home.
41164393|NCT02960126|DRUG|Aspirin|
41164394|NCT02960126|DRUG|Clopidogrel|
41164395|NCT02450617|BEHAVIORAL|Conventional individual treatment|Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
41164396|NCT02450617|BEHAVIORAL|Stabilizing group treatment for PTSD|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
41164397|NCT02450617|BEHAVIORAL|Stabilizing group treatment for Dissociative disorders|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
41164398|NCT04103086|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
41164399|NCT04103086|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy
41164400|NCT02929719|DRUG|Test.|gel
40850836|NCT06485388|DRUG|Thiopental|Venous blood samples will be taken from the patients included in the study and incubated with thiopental (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
40850837|NCT04051502|DRUG|Method 1: Indocyanine green dye|Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
41034045|NCT06226376|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes."
41034046|NCT06296173|OTHER|"Protective open-lung extubation"|Emergence using 50% FiO2, semi-sitting position with pressure support ventilation and preserved PEEP
41034047|NCT06296173|OTHER|Conventional extubation|Emergence using 100% FiO2, dorsal decubitus position with manual bag ventilation without PEEP
41034048|NCT00748436|DRUG|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
41034049|NCT00748436|DRUG|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
41034050|NCT00748436|DRUG|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
41164401|NCT02929719|DRUG|Aczone Gel 5%|gel
41164402|NCT02929719|DRUG|Placebo|gel
41164403|NCT01935596|DRUG|ropivacaïne|spinal anesthesia.
41164404|NCT01935596|DRUG|lévobupivacaïne|
41164405|NCT05306522|OTHER|Spinal stabilization exercise|The effects of telerehabilitation based spinal stabilization exercise in chronic stroke patients will be investigated.
41164406|NCT05739643|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
41164407|NCT00937456|PROCEDURE|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
41164408|NCT00087555|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
41164409|NCT00087555|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
41164410|NCT00087555|DRUG|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
41164411|NCT00938990|DRUG|Etomidate|
41164412|NCT00938990|DRUG|Midazolam|
41164413|NCT06435741|DIAGNOSTIC_TEST|99mTc-3PRGD2 Spect-CT scan|Before the operation，SPECT-CT imaging of lymph nodes was performed by integrin αvβ3-specific 99mTc-3PRGD2 probe. The locations of 99mTc-3PRGD2 SPECT-CT were determined by preoperative CT scan. During the operation, D2 lymph node dissection of gastric cancer was performed under the guidance of fluorescent laparoscopy。
41164414|NCT05522777|OTHER|Drink one bottle of Yakult a day|Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota
41164415|NCT06471907|PROCEDURE|erector spinae plane block|fascial plane injection using ultrasound
41377769|NCT06035328|OTHER|Wheat (Four times per week)|Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
41377770|NCT02892435|DEVICE|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
41506650|NCT02888730|DRUG|Physiologic serum nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin"
41034051|NCT03568994|DRUG|Atovaquone|"Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations."
41506651|NCT05731193|OTHER|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.|After 3 days students will take 3 tests with different levels of white noise pollution added ( signal-to-noise ratio (SNR) 20, 40 and none added)
41506652|NCT05133674|DRUG|Tamoxifen 20 mg|i) a self-testing capillary kit, the rhelise™ kit for measuring the concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen and ii) a patient interactive digital tool (app) mBraze to collect data about symptoms and guide breast cancer patients on adjuvant tamoxifen.
41506653|NCT01890863|DRUG|Fluticasone Propionate / Salmeterol Xinafoate DISKUS|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.
41506654|NCT01890863|DRUG|Fluticasone Propionate / Salmeterol Xinafoate ROTACAP|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.
41506655|NCT00002897|DRUG|cisplatin|
41506656|NCT00002897|DRUG|fluorouracil|
41506657|NCT00002897|PROCEDURE|conventional surgery|
41506658|NCT01044108|DRUG|NNC 0070-0002-0453|Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
41506659|NCT01044108|DRUG|'2-0453|Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
41034052|NCT03568994|DRUG|Cytarabine|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
41034053|NCT03568994|DRUG|Daunorubicin|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
41034054|NCT03568994|DRUG|Etoposide|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
41034055|NCT03568994|DRUG|Gemtuzumab Ozogamicin|As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
41034056|NCT05610553|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries to help to reduce intra-operative radiation, puncture time, etc..
41164416|NCT01304771|BIOLOGICAL|Synbiotic AKSB|AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide \[FOS\], NutraFlora®).
41164417|NCT04208347|DRUG|Apatinib 250mg|Apatinib 250mg
41164418|NCT04208347|DRUG|Camrelizumab|Camrelizumab 200mg
41164419|NCT04208347|DRUG|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
41377771|NCT02892435|DEVICE|conventional dressing|positioning conventional dressing
41377772|NCT01729546|DEVICE|7 Blood glucose monitoring systems|
41506660|NCT01044108|DRUG|placebo|Placebo will be administered as a comparator at each dose level.
41506661|NCT04859205|BEHAVIORAL|Intervention|"Participants will have access to the SUPPORT-Pro self-guided online training platform addressing many aspects of type 1 diabetes care. The SUPPORT-Pro content was developped by a team of health professionals specialized in type 1 diabetes as well as patient partners. It's content is regularly updated, evidence-based and divided into 6 categories (medication, blood glucose monitoring, diet, physical activity, hypo and hyperglycemia, health and other particularities). In each category, users can pick between 3 levels (beginner, intermediate and advanced) according to their level of confidence and knowledge.~Participants will be asked to fill out questionnaires at baseline, 3-month, and 12-month of the intervention which include the following: Eligibility assessment, identification, background, confidence, platform satisfaction."
41377773|NCT02980939|OTHER|iv fluid infusion|Intravenous isotonic saline infusion
41034057|NCT05610553|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
41164420|NCT04208347|DRUG|Apatinib 500mg|Apatinib 500mg
41164421|NCT00913783|DRUG|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)|
41164422|NCT00913783|DRUG|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)|
41377774|NCT02974270|DRUG|Leuprolide|
41506662|NCT02658760|DRUG|Dexmedetomidine|dexmedetomidine plus placebo
40850838|NCT04051502|DRUG|Method 2: Indocyanine green dye|"1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~* Dorsal side of the IP ligament~* Ventral side of the IP ligament~* Dorsal side of the utero-ovarian ligament~* Ventral side of the utero-ovarian ligament"
40850839|NCT04051502|DRUG|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
40850840|NCT04051502|DRUG|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.
41034058|NCT05018611|BEHAVIORAL|LifeSkills Mobile|A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.
41034059|NCT02264067|DRUG|Talsaclidine|
41164423|NCT03539133|OTHER|collection of clinical data|prospectively and systematically collection of clinical research data from STEMI patients
41506663|NCT02658760|DRUG|Bupivacaine|dexmedetomidine and Bupivacaine
41506664|NCT06549946|BIOLOGICAL|Ixovex-1|Ixovex-1 is a novel oncolytic human adenovirus serotype 5.
41506665|NCT06549946|BIOLOGICAL|Pembrolizumab|Humanised antibody
41034060|NCT02264067|DRUG|Placebo|
41034061|NCT04984044|DIETARY_SUPPLEMENT|Vitamin D3|"Dietary supplement:Vitamin D3~1 capsule of Vitamin D3 (40,000IU) weekly for 8 weeks with antidiabetic drug"
41034062|NCT04984044|DIETARY_SUPPLEMENT|Placebo|1 capsule weekly for 8 weeks with antidiabetic drug
41034063|NCT00388687|DRUG|18F Fluoroazomycin Arabinoside (FAZA)|
41164424|NCT00503217|DRUG|Tryptorelin|
41164425|NCT06043700|OTHER|No Intervention|No treatment intervention will be administered.
41164426|NCT04921553|OTHER|Data collection and quality of life questionnaire|"* Data collection from the medical file~* Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months"
41164427|NCT03157492|BEHAVIORAL|Aural Rehabilitation Group|Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.
41164428|NCT03157492|BEHAVIORAL|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
41164429|NCT06088810|OTHER|CoMPoSER intervention group|Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.
41506666|NCT02040077|BEHAVIORAL|Computer + Fluency|
41506667|NCT02040077|BEHAVIORAL|Computer Only|
41506668|NCT02040077|BEHAVIORAL|Treatment as Usual|
41377775|NCT03676439|DEVICE|Magnetic Spinal Stimulation|"Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited."
41377776|NCT06539962|DIAGNOSTIC_TEST|Krebs von den Lungen-6 (KL-6)|Krebs von den Lungen-6 (KL-6) will be evaluated for ability to predict cardiovascular comorbidities among IPF patients
41506669|NCT01447043|DRUG|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
41506670|NCT01523002|DRUG|Metoprolol and pyronaridine-artesunate|"On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with pyronaridine-artesunate at the above dose.~On Days 98 - 100, subjects will receive pyronaridine-artesunate once daily at the same dose described above. Followed by a 40 day follow-up period."
41506671|NCT01523002|DRUG|pyronaridine-artesunate|"On Days 1 to 3, subjects will receive 3 days of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Days 61 to 63, subjects will be redosed with a 3 day course of pyronaridine-artesunate at the above dose.~Followed by a 40 day follow-up period."
41506672|NCT00626561|DRUG|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
41506673|NCT00626561|DRUG|Paclitaxel|60 mg/m\^2 IV weekly on days 1, 8, 15, and 22.
41164430|NCT06088810|OTHER|Sleep Education|Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.
41164431|NCT04212897|OTHER|Music Therapy|"Participants in the intervention arm will be asked to practice a rhythmic auditory synchronous finger tapping intervention task at home for a total of 25 minutes split between two ten-minute sets with a five-minute break between the sets every day for 8-weeks. During training sessions participants must listen to the instrumental of a pre-selected well-known Chinese melody, Moonlight over the Lotus Pond by Phoenix Legend, whose melody duration is 259s. This song was selected for its strong beat and familiarity to the participants. Participants must follow the beats of the melody and tap their right index finger simultaneously to the beats. A visual cue will be displayed to indicate the beats, identical to the one in the assessment. The training session will be conducted once daily after patients have taken their medication. Participants' primary caretaker will be asked to monitor and record completion of sessions."
41506674|NCT00641446|DRUG|budesonide|
40850841|NCT02340910|PROCEDURE|Short Duration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
41034064|NCT04320888|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, and/or CT/MRI
41034065|NCT04320888|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
41034066|NCT04320888|PROCEDURE|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
41034067|NCT04320888|PROCEDURE|Radionuclide Imaging|Undergo scintigraphy
41034068|NCT04320888|DRUG|Selpercatinib|Given PO
41034069|NCT04320888|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
41164432|NCT01128777|BEHAVIORAL|Cognitive Behavioral Group Therapy|The CBT group therapy protocol will teach adolescents coping, cognitive restructuring, and affect regulation skills to remediate skills deficits that underlie depression, anxiety, and behavior problems associated with the deployment cycle. Parents will also learn stress management and parenting skills in their own group therapy sessions that occur as the same time as the adolescent group.
41164433|NCT01128777|BEHAVIORAL|Nondirective supportive group therapy|Patient initiated discussions form the basis for the intervention for both the adolescent group and the parent group
41164434|NCT06048939|OTHER|moderate intensity aerobic training and body weight resistance training|"Bodyweight Resistance exercises Frequency: twice a week Intensity: moderate Time: 40 Minutes Warm up: 10mins Rotations and Dynamic stretches Body weight resistance Exercises: 20mins Calf raises (1 x 10-15 Reps) Squats (1 x 10-15 Reps) Lunges (1 x 10-15 Reps on each side) Modified push-ups (1 x 10-15 Reps) Bridging (1 x 10-15 Reps) Plank hold (10 Seconds) Side planks (10 Seconds each side) Cool down: 10 mins Slow marching and static stretches for next 6 weeks progression will be made by adding one more set of same exercises Aerobic training: Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Exercise Protocol Warm up: 10mins Rotations and Dynamic stretches~Aerobic exercises will be same as given to control group"
40850842|NCT02340910|PROCEDURE|Long Duration|"During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks ."
41034070|NCT06502821|OTHER|questtionnaire|questionnaire regarding workplace preferences and the factors influencing choosing a career in physiotherapy
41034071|NCT01951430|DRUG|Antibiotic and antifungal drugs|
41034072|NCT06153173|DRUG|Mirdametinib|Mirdametinib is administered at a dose of 2 mg/m2, twice a day (BID) with a maximum dose of 4 mg BID on a continuous daily schedule. Consecutive doses should be separated by minimum 6 hours and maximum 14 hours.
41034073|NCT02166008|DRUG|Repamipide|
41164435|NCT06048939|OTHER|moderate intensity aerobic training|"Aerobic Exercises Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Warm up: 10mins Rotations and Dynamic stretches Aerobic exercises: 25 mins~(1 minute of each exercise with 60 seconds rest and repeating the same sequence for 1 minute.) Exercises will be performed at slow pace Marching, Single step touch, Step touches front and back, Double step touch, V step, knee lift, leg curl , forward walk, reach outs, lunge side and back, L Step, jumping jacks Cool down: 10 mins Slow marching and static stretches for next 6weeks progression will be made by increasing speed of same exercises"
41034074|NCT02166008|DRUG|Placebo|
41377777|NCT05054088|DEVICE|T-Detect COVID test|• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.
41377778|NCT04686305|DRUG|T-DXd|T-DXd: administered as an IV infusion
41377779|NCT04686305|BIOLOGICAL|Durvalumab|Durvalumab: administered as an IV infusion
41377780|NCT04686305|DRUG|Cisplatin|Cisplatin: administered as an IV infusion
41164436|NCT01553227|DEVICE|ventilator|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
41164437|NCT02747719|BEHAVIORAL|Light and exercise|Exposure to light and exercise
41164438|NCT05808062|PROCEDURE|Root canal obturation|Root canal dryness
41164439|NCT03882996|DRUG|Ezetimibe|Ezetimibe 10 mg daily in the morning
41377781|NCT04686305|DRUG|Carboplatin|Carboplatin: administered as an IV infusion
40850843|NCT01960517|DEVICE|ACS Catheter|
40850844|NCT03021772|DRUG|Neostigmine|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
40850845|NCT03021772|DRUG|Dexamethasone|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
41377782|NCT04686305|DRUG|Pemetrexed|Pemetrexed: administered as an IV infusion (drug not used)
41377783|NCT04686305|DRUG|Volrustomig|Volrustomig: administered as an IV infusion
41377784|NCT04686305|DRUG|Rilvegostomig|Rilvegostomig: administered as an IV infusion
41377785|NCT06522828|DRUG|SSGJ-707|SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
41377786|NCT06522828|DRUG|carboplatin|chemotherapy
41506675|NCT00641446|DRUG|varicella zoster virus|
41506676|NCT03915418|PROCEDURE|Connected tools|At home, parents will record their child's sleep for 1night Then, on the date scheduled for the inclusion of the children and after the recording of the 1 night at home, the child will spend a night in a hospital environment to carry out the recording by polysomnography and tools connected simultaneously.
41506677|NCT00997204|DRUG|Icatibant|Single subcutaneous injection of icatibant, 30 mg
40850846|NCT06584448|OTHER|Deuterium Metabolic Imaging with deuterated acetate tracer|Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.
40850847|NCT00665548|RADIATION|X-ray; magnetic resonance imaging|"Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.~3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences."
40850848|NCT05192655|OTHER|Observation|Observation Study
41034075|NCT06635044|OTHER|intradialytic exercise|HD men came to the HD unit three times weekly to receive their dialysis session which consumed 3-4 hours. During the first two hours of the men's dialysis session, a pedal exerciser (RTL10273 Deluxe Folding Pedal Exerciser, Drive Medical Co. MPN) was utilized in performing leg cycling exercises while men were sitting. Before starting the session of intradialytic cycling, a 5-minute stretching of the lower limbs was performed as a warming up. Also, as cooling down, the same period of lower limbs' stretching was performed after ending intradialytic cycling
41034076|NCT01218438|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
41034077|NCT01218438|DRUG|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
41034078|NCT04995380|PROCEDURE|Early Cholecystectomy|Cholecystectomy performed within 10 days from onset of symptoms
41377787|NCT06522828|DRUG|paclitaxel|chemotherapy
41034079|NCT03732287|DEVICE|Cooling Anesthesia|Application of cooling anesthesia device prior to intravitreal injection
41034080|NCT00463190|DRUG|Biothree|
41034081|NCT00438516|BEHAVIORAL|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
41034082|NCT02875587|DRUG|Cabergoline|Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
41034083|NCT02875587|DRUG|Calcium gluconate|Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
41034084|NCT05905328|DRUG|CTO1681 10 μg|Administered 3 times daily for 15 days (initial cohort).
41034085|NCT05905328|DRUG|CTO1681 20 μg|Administered 3 times daily for 15 days (successive cohort).
41034086|NCT05905328|DRUG|CTO1681 30 μg|Administered 3 times daily for 15 days (successive cohort).
41034087|NCT03806985|DRUG|Placebo oral capsule|microcrystalline cellulose capsule
41034088|NCT03806985|DRUG|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
41034089|NCT03806985|DRUG|High Dose Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
41034090|NCT03526900|DRUG|Atezolizumab|"* Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~* Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2."
41034091|NCT06457542|OTHER|Active Release Technique|Active Release Therapy, which involves instructing the patient to sit and then positioning their shoulder in 90-degree abduction. The therapist will provide assistance to the patient's arm and then examine the supraspinous fossa by applying pressure with a finger. The patient will be instructed to gradually bring the arm towards the body as the therapist manipulates the muscle plane. This procedure should be repeated for a duration of 10 minutes, 3 times per week, over a duration of four weeks.
41034092|NCT06457542|OTHER|Soft Tissue Mobilization|Soft Tissue Mobilization (STM) targeting the subscapularis muscle. The participants will be placed in a position where their upper arm bone (humerus) is raised at a 45° angle, with the elbow bent at a 90° angle. Additionally, the humerus will be rotated outward to a position that is normally around 20° to 25° of external rotation. The subscapularis muscle remained examined by touch in the armpit area to locate regions of limited mobility due to myofascial limitations, trigger points or tense bands. The identified limitations remained addressed with STM, which included applying prolonged manual pressure and slow deep stroke to the subscapularis myofascial. This treatment was performed for a period of 7 minutes, three times a week, over a period of four weeks.
41034093|NCT06565663|BEHAVIORAL|MaPGAS Decision Aid|This intervention involves a novel, web-based decision aid tool specifically designed to support transgender and non-binary individuals assigned female at birth in making informed decisions about Metoidioplasty and Phalloplasty Gender Affirming Surgeries (MaPGAS). The tool includes comprehensive information on surgical options, risks, benefits, and medical illustrations to aid in aligning surgical decisions with the individual's personal values and goals.
41034094|NCT05013450|DRUG|Dupilumab|three q3w cycles
41034095|NCT05013450|DRUG|PD-1/PD-L1 blockade|SOC immunotherapy with PD-1/PD-L1 blockade
41034096|NCT05013450|DRUG|Anakinra|100 mg daily injection for Three q3w cycles
41034097|NCT04132609|BEHAVIORAL|Cognitive bias modification|: In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.
41034098|NCT04132609|BEHAVIORAL|Standard attentional bias|"the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language."
41034099|NCT00386906|PROCEDURE|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
41034100|NCT04826354|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin Versus Rosuvastatin plus Ezetimibe
41034101|NCT04826354|DRUG|Rosuvastatin|Rosuvastatin
41377788|NCT02921607|OTHER|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
41377789|NCT01819467|DEVICE|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
41377790|NCT03744494|PROCEDURE|Bilateral simple orchidectomy (BSO)|
41377791|NCT03744494|PROCEDURE|Bilateral Subcapsular Orchidectomy|
41377792|NCT03744494|PROCEDURE|Bilateral Epididymal-sparing Orchidectomy|
41377793|NCT01920698|DEVICE|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
41377794|NCT01920698|OTHER|control|
41164440|NCT03882996|DRUG|Atorvastatin|Atorvastatin 10 mg daily in the morning. Atorvastatin dose could be titrated up (by doubling the dose up to a maximum of 80 mg daily) to achieve the target low-density-lipoprotein cholesterol (LDL-C) level of 100 mg/dL (2.59 mmol/L) after a minimum of 4 weeks of treatment.
41377795|NCT03669874|DEVICE|Endoscopic fundoplication|"Endoscopic fundoplication is a less invasive alternative to the traditional surgical fundoplication.~The MUSE device is similar to an endoscope, so the whole procedure can be done by a single operator. The device is composed of a shaft with a distal rigid part which is placed in the esophagus 3 cm proximal to the esophago-gastric junction containing a cartridge holding five B-shaped titanium surgical Staples and a tip which is retroflexed and contains an ultrasonic transducer which defines the correct tissue thickness for stapling the fundus against the esophagus. The device must be extracted to be reloaded with 5 more staples at a time for creation of a 180° anterior fundoplication."
41034102|NCT05846594|DIAGNOSTIC_TEST|FoundationOne® Liquid CDx Assay|Participants will undergo liquid biopsy (FoundationOne® Liquid CDx) on blood samples collected once they have a clinical diagnosis of advanced cancer (as per label). Blood samples will be tested using the FoundationOne® Liquid CDx assay at a central laboratory. Results of the FoundationOne® Liquid CDx assay will be provided to the investigator to be used in accordance with professional guidelines in oncology for patients with malignant neoplasms.
41164441|NCT04209998|DIAGNOSTIC_TEST|transcutaneous oximetry|Analysis of transcutaneous oximetry (Tcpo2) in terme of variability at rest and of response to oxygen inhalation
41164442|NCT01742234|PROCEDURE|Organ Donation|People in this study will donate either a lung or kidney
41164443|NCT02990364|DRUG|Sucrose|Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
41377796|NCT03182972|OTHER|Medication reconciliation|Pre-post intervention
41377797|NCT02416505|BEHAVIORAL|Verbal+Anatomic Model|
41506678|NCT02843984|DRUG|Lactoferrin|
41506679|NCT02732171|OTHER|Research Blood Collection|Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)
41506680|NCT05538078|DRUG|Ozone gel|application of Ozone gel after scaling by ultrasonic scaler in the bottom of periodontal pocket
41506681|NCT06423378|DEVICE|OSSIOfiber® Trimmable Fixation Nails|"Subjects will be treated with cannulated nails before or after arthroscopic management of their concomitant pathology at the discretion of the investigator. Technique described below. Following nail placement, tissue layers will be closed in standard fashion.~1. Preop MRI views used to estimate the proper depth \& location of nail placement on the femur and/or tibia~2. Exposure is gained to medial tibia~3. 1.4 mm K-Wire is placed through medial tibia parallel to the articular joint surface \~ 1 cm distal to the articular joint line~4. A depth gauge is placed over K-Wire to determine required length of cannulated nail~5. A 4.0 mm cannulated drill bit used over K-Wire to prepare the pilot hole~6. Tamp is used to insert pre-trimmed 4.0 mm cannulated nail into the pilot hole and K-Wire is subsequently removed~7. Intraop fluoroscopy can confirm adequate nail placement prior to removing K-wire~8. Repeat steps for additional nails"
41506682|NCT01654016|DRUG|Detralex|Detralex 500 mg twice daily for three month prior to surgery
41506683|NCT01798316|DRUG|IV Acetaminophen|Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen
41506684|NCT01798316|DRUG|Standard of Care|Standard of care pain management regimen, no IV Acetaminophen,
41506685|NCT00683657|DRUG|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
41506686|NCT00683657|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
41506687|NCT06390709|OTHER|Lab Collection Only|2 Paxgene and 1 SST tubes will be collected at 2 timepoints throughout the study.
41506688|NCT02487225|DRUG|Pentoxifylline|Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors
41164444|NCT02990364|DRUG|Lidocaine|Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
41164445|NCT02990364|DRUG|EMLA Topical Product|EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
41164446|NCT01317706|OTHER|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
41164447|NCT04038671|DEVICE|Activated Carbon Cloth Dressing|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
41164448|NCT04038671|DEVICE|Knitted Cellulose Acetate Mesh|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
41164449|NCT04038671|DEVICE|Antimicrobial Alginate Dressing with Silver|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
41377798|NCT02416505|BEHAVIORAL|Verbal+Video|
41164450|NCT02271685|OTHER|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
41164451|NCT02271685|OTHER|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
41164452|NCT02271685|OTHER|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
41164453|NCT02271685|OTHER|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
41164454|NCT04838964|DRUG|MRG003|Administrated intravenously
41164455|NCT02956356|DIETARY_SUPPLEMENT|Control treatment + oral glucose|Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
41164456|NCT02956356|DIETARY_SUPPLEMENT|SATIOSTAT treatment + oral glucose|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
41377799|NCT03716440|OTHER|Nature exposure|Participants will view images of nature.
41377800|NCT03716440|OTHER|Non-nature exposure|Participants will view non-nature images.
41377801|NCT02025400|OTHER|eRehab|"Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders."
41377802|NCT02025400|OTHER|Formal Physical Therapy|This intervention involves referral to a licensed physical therapist or supervised ATC-L.
41377803|NCT03843723|OTHER|Pre-flight evaluation|All the participants receive the interventions as part of their routine medical care during their annual visit for CF follow-up. Oxygen saturation are measured by pulse oximetry. Exercise testing is performed by 6MWT and CPET. Pre-flight evaluation is performed by HAST.
41377804|NCT03718221|OTHER|Usual Care FIT Screening Strategy|Patients in usual care neighborhoods will receive FIT kits randomly throughout the year.
41377805|NCT03718221|OTHER|GeoMail FIT Screening Strategy|Patients in treated neighborhoods will receive kits at the same time.
41377806|NCT05032573|DIETARY_SUPPLEMENT|Olive oil and Dietary Guideline recommendations|60 mL of olive oil and healthy diet recommendations
41506689|NCT02487225|DRUG|Placebo|A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
41506690|NCT05513391|BIOLOGICAL|Recombinant influenza vaccine (RIV4)|Pharmaceutical form: solution for injection Route of administration: intramuscular
41506691|NCT05513391|BIOLOGICAL|Quadrivalent influenza vaccine (IIV4)|Pharmaceutical form: suspension for injection Route of administration: intramuscular
41164457|NCT02956356|DIETARY_SUPPLEMENT|Control treatment + meal intake|Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
41164458|NCT02956356|DIETARY_SUPPLEMENT|SATIOSTAT treatment + meal intake|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
41164459|NCT00439647|DRUG|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
41164460|NCT00439647|DRUG|Placebo|Placebo intravenous (i.v.) once a year
41164461|NCT05384236|OTHER|kinesiology taping|To apply kinesiology taping in plantar fascia
41164462|NCT05384236|OTHER|taping or Low-dye taping|To apply taping or Low-dye taping in plantar fascia
41164463|NCT01601717|DRUG|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
41164464|NCT01601717|DRUG|Placebo|Matching placebo pill administered once per day for 10 days.
41164465|NCT03897361|GENETIC|"CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)"|Peripheral blood autologous CD34+ enriched cell fraction transduced with lentiviral vector, pCCL-CTNS or pCDY.EFS.CTNS.T260I, that contains the human CTNS complementary deoxyribonucleic acid (cDNA) sequence.
41164466|NCT00402636|DEVICE|rapamycin plus 17beta estradiolvalerat-eluting stent|rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
41164467|NCT00402636|DEVICE|rapamycin-eluting stent|rapamycin-eluting stent was implanted due to randomisation
41164468|NCT01028755|DRUG|BAY79-4620|BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
41164469|NCT04301700|BEHAVIORAL|mindfullness and relaxation|three arms: mindfullness and relaxation
41164470|NCT05561582|OTHER|Seated knee extension exercise|Participants will be seated in a resistance exercise machine. Weight corresponding to the assigned group will be added to the machine. Participants will extend the dominant knee for 3 sets of 10 repetitions.
41164471|NCT02600598|DRUG|LEO 43204 Gel, 0.037%|
41164472|NCT02600598|DRUG|LEO 43204 Gel, 0.037%|
41377807|NCT05032573|OTHER|Dietary Guideline recommendations|healthy diet recommendations
41377808|NCT00883129|DRUG|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
41377809|NCT00883129|DRUG|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
41506692|NCT03861455|DRUG|Dupilumab|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
41506693|NCT03861455|DRUG|placebo|patient receive placebo
41506694|NCT06006377|OTHER|conventional physiotherapy|hotpack electrotherapy ultrasound exercises
41506695|NCT06006377|OTHER|Backup therapy|The backup spine health device is in the form of a mat and provides segmental electrical stimulation to the spines. At the same time, the mat can heat up to 40 degrees during the treatment process. Backup spine health device is very effective in both reducing pain and strengthening the muscles with electrical stimulations by reaching even the deep muscles around the spine. Sessions consist of 30 minutes
41506696|NCT02049970|DRUG|dexmedetomidine|1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
41506697|NCT02049970|DRUG|bupivacaine|30 ml 0.25 % bupivacaine is applied around brachial plexus
41506698|NCT01305044|BEHAVIORAL|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
41506699|NCT01305044|BEHAVIORAL|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
41506700|NCT00002638|BIOLOGICAL|filgrastim|
41506701|NCT00002638|BIOLOGICAL|sargramostim|
41506702|NCT00002638|DRUG|carmustine|
41506703|NCT00002638|DRUG|cyclophosphamide|
41377810|NCT00883129|DRUG|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
41506704|NCT00002638|DRUG|cytarabine|
41506705|NCT00002638|DRUG|etoposide|
41506706|NCT00002638|PROCEDURE|peripheral blood stem cell transplantation|
41506707|NCT00002638|RADIATION|radiation therapy|
41506708|NCT03335514|DIAGNOSTIC_TEST|expression of GALNT4|Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.
41506709|NCT04087434|DEVICE|Brain Gauge Prospective and Healthy Control|The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.
41164473|NCT02723513|OTHER|Hyperpolarized Xenon-129|"Hyperpolarized Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
41164474|NCT04278495|DRUG|Cozaar (Losartan Potassium 25mg)|Cozaar (Losartan Potassium 25mg)
41164475|NCT04278495|DRUG|Placebo|Placebo
41377811|NCT05392920|OTHER|assessment study|there is no intervention in this study
41164476|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
41164477|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
41164478|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
41164479|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
41377812|NCT06044922|DEVICE|24-hour Holter monitoring|Holter monitor is fitted within 2h of ICU admission to acquire a 24-hour electrocardiogram recording
41506710|NCT04533997|DRUG|Hypertonic saline solution plus intravenous furosemide|"Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide \> 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.4%, Na+ 135-145: 2.6%"
41506711|NCT04533997|DRUG|Intravenous furosemide|"Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide \> 160 mg"
41506712|NCT00316758|DRUG|GK Activator (2)|Escalating doses bid
41506713|NCT00316758|DRUG|Metformin|As prescribed, in patients who were in study BM18249
41506714|NCT06482073|OTHER|Non-Interventional Study|Non-interventional study
41506715|NCT04851847|DEVICE|Guided Tissue Regeneration (GTR)|Use of resorbable collagen membrane to treat periodontal intrabony defects.
41506716|NCT06552091|OTHER|self-hypnosis sessions|3 self-hypnosis sessions over 3 weeks, one session per week to be practiced daily
41506717|NCT03366012|DEVICE|Cytosponge|The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
41506718|NCT01869855|PROCEDURE|Subdural Drainage|
41506719|NCT01869855|PROCEDURE|Subperiosteal Drainage|
41506720|NCT06061068|PROCEDURE|Hernia belt compression|Use the hernia belt to compress the inguinal region
41506721|NCT03016975|DEVICE|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System
41506722|NCT03016975|DRUG|Guideline Directed Medical Therapy|GDMT Only
41164480|NCT01046422|DRUG|Placebo|Capsule, Oral, 0mg, Daily, 28 days
41506723|NCT04891003|DIAGNOSTIC_TEST|Ultrasonography|The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.
41506724|NCT02370524|DRUG|[18F]T807|All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
41506725|NCT03921593|PROCEDURE|Solid Organ Pancreas Transplantation with or without Kidney Transplantation|Deceased donor pancreas transplantation
40850849|NCT04241263|DEVICE|Wireless vital sign monitoring - comparative|Participants who currently have vital sign monitoring will, in addition, have the wireless system attached. We will then collect up to 24 hours of vital sign data from both systems, which will allow us to make direct comparisons between them.
41034103|NCT05846594|DIAGNOSTIC_TEST|Standard of Care Diagnostic Pathway|Participants will undergo the local standard of care diagnostic pathway including tissue biopsy/standard of care (if tissue not available), pathology workup, and molecular workup, according to ESMO guidelines or national guidelines for each tumor type included in this study.
41034104|NCT00977262|OTHER|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
41034105|NCT00977262|OTHER|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
41034106|NCT00977262|OTHER|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
41034107|NCT03432624|DIAGNOSTIC_TEST|Serum MicroRNA-25 detection|The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.
41034108|NCT04011150|DEVICE|Epidural infusion pump|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
41034109|NCT04011150|DRUG|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
41034110|NCT04011150|DRUG|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
41034111|NCT04239313|BIOLOGICAL|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose vaccine.
41034112|NCT04239313|BIOLOGICAL|Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose adjuvant.
41034113|NCT04239313|BIOLOGICAL|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.
41034114|NCT01243333|RADIATION|[F-18]fluorodeoxyglucose|Undergo PET scans with \[F-18\]fluorodeoxyglucose
41034115|NCT01243333|RADIATION|[F-18]fluorothymidine|Undergo PET scans with fluorine \[F-18\]fluorothymidine
41034116|NCT01243333|PROCEDURE|Positron Emission Tomography|Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)
41034117|NCT01243333|RADIATION|Water O-15|Undergo PET scans with water O-15 tracers
41506726|NCT01118975|DRUG|Vorinostat|"300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off."
41506727|NCT01118975|DRUG|Lapatinib|1,250 mg once daily
41506728|NCT05377060|BEHAVIORAL|Plasma p-tau risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, MMSE score, and plasma p-tau results.
41506729|NCT05377060|BEHAVIORAL|Standard risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, and MMSE score.
41506730|NCT02393352|OTHER|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
41506731|NCT02393352|OTHER|Electrical Stimulation Therapy|
41034118|NCT01308216|PROCEDURE|low level laser therapy procedure|Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
41034119|NCT04465006|OTHER|Hippotherapy Simulator|Patients in the hippotherapy simulator group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 45 minutes of Neurodevelopmental treatment exercises and 15 minutes of hippotherapy simulation exercise program were applied to the participants in this group.
41034120|NCT04465006|OTHER|Conventional Exercise|Patients in the conventionnal exercise group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 60 minutes of Neurodevelopmental treatment exercises were applied to the participants in this group.
41034121|NCT03807362|DRUG|CC-11050|CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
41034122|NCT04992715|DIAGNOSTIC_TEST|[99mTc]-NM01 SPECT/CT|Technetium-99m radiolabelled anti-PD-L1 single-domain antibody (NM01) single-photon emission computed tomography (SPECT)/computed tomography (CT)
41164481|NCT01046422|DRUG|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
41164482|NCT05715736|DRUG|APB-R3|APB-R3 is formulated as a sterile solution containing APB-R3 as the active substance administered intravenously.
41164483|NCT05715736|DRUG|Placebo|0.90% Normal Saline only
41506732|NCT00360087|DRUG|Bosentan|
41506733|NCT04274712|DIAGNOSTIC_TEST|INNOGRAFT Heart Suite|Liquid biopsy to identify acute rejection
41506734|NCT03203681|DRUG|Natesto|4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.
41506735|NCT03309527|BEHAVIORAL|e-aid Cognitive Behavior Therapy|e-aid Cognitive Behavior Therapy
41506736|NCT03309527|BEHAVIORAL|e-aid Sleep Hygiene Education|e-aid Sleep Hygiene Education
41506737|NCT03647085|DEVICE|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
41506738|NCT01711515|DRUG|Cisplatin|Given IV
41506739|NCT01711515|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
40850850|NCT04241263|DEVICE|Wireless vital sign monitoring - usability|Babies will be recruited who do not currently require vital sign monitoring. The wireless system will be attached to these babies by nurses who have been trained in its use. A parent will then be asked to perform Kangaroo Care for as long as they feel comfortable. After the baby is placed back in its cot, and the sensors have been removed, we will conduct (separate) interviews with the nurse and the parent on the neonatal intensive care unit (NICU).
40850851|NCT05846555|PROCEDURE|urologic surgery|surgery
41377813|NCT03900481|PROCEDURE|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive.
41377814|NCT04095975|DIETARY_SUPPLEMENT|Baking Soda|Standard baking soda that can be bought from stores.
41377815|NCT04095975|DIETARY_SUPPLEMENT|LithoLyte|LithoLyte is considered a medical food and consists of: potassium citrate, magnesium citrate, sodium bicarbonate, and erythritol.
41377816|NCT00211575|BEHAVIORAL|Disease Management Assessment|
41377817|NCT03922984|PROCEDURE|MRI with Arterial Spin Labeling (ASL)|Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
41377818|NCT03026894|RADIATION|Panoramic Radiograph|Measurement of bone resorption
41377819|NCT03026894|DEVICE|T-Scan III occlusal system|Recording percentage of force in maximum intercuspation
41377820|NCT03718559|DRUG|Edoxaban Monotherapy|Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
41377821|NCT03718559|DRUG|Edoxaban plus Single Antiplatelet Agent|Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.
41377822|NCT01482442|DRUG|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
41377823|NCT01482442|DRUG|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
41377824|NCT05958979|OTHER|Control Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
41506740|NCT01711515|RADIATION|Internal Radiation Therapy|Undergo intracavitary brachytherapy
41506741|NCT01711515|BIOLOGICAL|Ipilimumab|Given IV
41506742|NCT01711515|OTHER|Laboratory Biomarker Analysis|Correlative studies
41506743|NCT03804814|BEHAVIORAL|Motivational Interviewing Training|"Motivational Interviewing is a directive, client-centered counselling style intended to elicit behavior change by helping patients reach health goals through their own desires and actions.~A certified and experienced Motivational Interviewing trainer will develop and deliver the curriculum to healthcare providers."
41506744|NCT02940431|OTHER|High Autonomy|Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
41506745|NCT02940431|OTHER|Low Autonomy|Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
41506746|NCT03977142|DIAGNOSTIC_TEST|Radical 7 Masimo Hemoglobin pulse co-oximeter non invasive monitor|Measure hemoglobin levels non invasively by pulse co-oximeter
41034123|NCT04724460|DRUG|Long DOAC|Administration of Rivaroxaban for 18 months
41034124|NCT04724460|DRUG|Short DOAC|Administration of Rivaroxaban for 6 months
41377825|NCT05958979|OTHER|Experimental Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
41377826|NCT03353415|DEVICE|Dexcom CGM masked|"The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
41377827|NCT03353415|DEVICE|Dexcom CGM unmasked|"During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
41377828|NCT04587856|OTHER|bone marrow withdrawal|bone marrow samples evaluation
41506747|NCT05154825|OTHER|Imaging-Observational|Preoperative standing and supine, intraoperative pre- and post-correction, and postoperative standing imaging as well as imaging collected during follow-up exams for a year following surgery
41506748|NCT01940991|DRUG|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
41034125|NCT01257295|DIETARY_SUPPLEMENT|control: no fiber addition|liquid breakfast without addition of fiber
41034126|NCT01257295|DIETARY_SUPPLEMENT|breakfast with low viscous, low gelling pectin|10g of low viscous, low gelling pectin dissolved in a liquid breakfast
41377829|NCT04413357|OTHER|Balanced Nutritional Drink|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as Supplemental Nutrition.
41377830|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink (DMA)|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition available in retail setting.
41377831|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink DMB|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition.
41377832|NCT00310869|BEHAVIORAL|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
41377833|NCT05739942|DRUG|[177Lu]Lu-NeoB|Radiopharmaceutical solution for infusion
41377834|NCT05739942|DRUG|[68Ga]Ga-NeoB|Either provided as Kit for the radiopharmaceutical preparation of \[68Ga\]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
41377835|NCT05739942|OTHER|Temozolomide|Capsules/ lyophilized powder in single-dose vial for reconstitution.
41377836|NCT06650397|OTHER|Biofortified maize|Maize that has been grown to have higher amounts of iron and zinc.
41377837|NCT06650397|OTHER|Placebo|Traditional maize
41377838|NCT05359861|DRUG|SRF388|SRF388 will be administered by intravenous injection (IV)
41377839|NCT05359861|DRUG|Atezolizumab|Azezolizumab will be administered by IV
41377840|NCT05359861|DRUG|Bevacizumab|Bevacizumab will be administered by IV
41377841|NCT05359861|DRUG|Placebo|Placebo will be administered by IV
41377842|NCT04279483|BEHAVIORAL|7-11|Assigned to make a small (\~$3.00) purchase from any 7-11 store(s) using a study-provided debit card during each retail environment visit
41377843|NCT04279483|BEHAVIORAL|CVS|Assigned to make a small (\~$3.00) purchase from any CVS store(s) using a study-provided debit card during each retail environment visit.
41377844|NCT00070499|DRUG|Dasatinib|Given PO
41377845|NCT00070499|DRUG|Imatinib Mesylate|Given PO
41377846|NCT00070499|OTHER|Laboratory Biomarker Analysis|Correlative studies
41377847|NCT03285152|OTHER|Ketogenic Diet (KD)|specially-formulated very low carbohydrate meals (KD)
41377848|NCT03285152|OTHER|Standard Diet (SD)|counseling on maintaining adequate nutritional intake from a normal diet (SD)
41377849|NCT00682097|DRUG|RO4998452|Escalating oral doses
41377850|NCT00682097|DRUG|placebo|Oral doses
41377851|NCT00160446|DRUG|Asoprisnil|5mg Tablet, oral Daily for 12 weeks
41377852|NCT00160446|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
41377853|NCT00160446|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
41377854|NCT00160446|DRUG|Placebo|Tablet, oral Daily for 12 weeks
41377855|NCT06445127|DEVICE|MRI|A non-invasive, non-contrast, renal MRI will be performed.
41506749|NCT01940991|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
41506750|NCT03267901|OTHER|food|45 g of walnut / iso-caloric white bread
41377856|NCT01554696|DRUG|peficitinib|oral
41377857|NCT01554696|DRUG|Placebo|oral
41377858|NCT01554696|DRUG|methotrexate|oral
41377859|NCT03733418|DRUG|540,000 IU vitamin D3|This intervention was administered as part of VIOLET parent study. A single dose of 540,000 IU vitamin D3 was administered within 2 hours of randomization time.
41377860|NCT03733418|DRUG|Placebo|Placebo that matched the vitamin D3 color was provided.
41034127|NCT01257295|DIETARY_SUPPLEMENT|high viscous, low gelling pectin|10g of high viscous, low gelling pectin dissolved in a liquid breakfast
41377861|NCT05264623|DEVICE|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser use for refractive surgery
41506751|NCT03281395|PROCEDURE|Rapid ventricular pacing (RVP)|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short period of time during dissection of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. RVP technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations and can be lifesaving in the case of an intraoperative bleeding or rupture.
40850852|NCT01385241|BEHAVIORAL|Ipod video|This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
41034128|NCT01257295|DIETARY_SUPPLEMENT|low viscous, high gelling pectin|10g of low viscous, high gelling pectin dissolved in a liquid breakfast
41034129|NCT01257295|DIETARY_SUPPLEMENT|high viscous, high gelling pectin|10g of high viscous, high gelling pectin dissolved in a liquid breakfast
41377862|NCT04593589|OTHER|Submandibular Gland Stem Cell Transplantation|Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
41377863|NCT06651320|OTHER|The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery|"The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery and discharge. How to prepare for the procedure, what to expect during and after the procedure and what are the possible follow up scenarios.~In order to overcome language berries videos would be available in basic 6th grader language and translated into English, Arabic and Russian for the non-Hebrew speaking population.~There would be one staff member aware of the patient's allocation the international Vs nonintervention arm while the rest of the staff would be masked to the research arm the patient was allocated to.~Once they have watched the video they would be asked to fill up a questionnaire their anxiety level concerning the procedure (STAI-S)."
41377864|NCT06108297|DIETARY_SUPPLEMENT|Lithium|Elemental lithium as lithium aspartate.
41377865|NCT04567680|BEHAVIORAL|Acceptance and Commitment Therapy to Improve Social Support for Veterans with PTSD|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
41377866|NCT04567680|BEHAVIORAL|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
41377867|NCT05789316|OTHER|Ototoxicity Screening Protocol|The ototoxicity screening protocol contains a functional and objective component. The functional component is the Hearing Handicap Inventory for the Elderly - Screening Version (HHIE-S). The objective component will be pure tone audiometry. A 2 kHz tone at 40 dB will play through over-the-ear headphones and subjects will indicate whether they heard it.
41377868|NCT06251765|OTHER|Clinical scores|Clinical scores will be administered to patients
41377869|NCT06251765|OTHER|Range of Motion|Evalutation of knee mobility
41034130|NCT01257295|DIETARY_SUPPLEMENT|pectin supplement|10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
41377870|NCT04566666|DRUG|Placebo|Placebo of SCD-044 product
41377871|NCT04566666|DRUG|SCD-044_Dose 1|SCD-044 tablets in Dose 1.
41377872|NCT04566666|DRUG|SCD-044_Dose 2|SCD-044 tablets in Dose 2
41506752|NCT03281395|PROCEDURE|No rapid ventricular pacing|
41506753|NCT03988686|PROCEDURE|Radical prostatectomy plus standard care|To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer
41506754|NCT03988686|DRUG|Standard of care for metastatic prostate cancer|androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
41506755|NCT02850185|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
41506756|NCT02850185|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
41506757|NCT02850185|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
41034131|NCT06031246|PROCEDURE|Selective Lymph Node Dissection|For patients with NSCLC with CTR\>0.5 located in the apical segment, the inferior mediastinal lymph node was not need to dissected
41164484|NCT04675762|DRUG|Fingolimod|Patients randomized to fingolimod will also receive fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
40850853|NCT01089205|DRUG|Metformin|
41164485|NCT04675762|OTHER|Placebo|Patients randomized to fingolimod will also receive placebo once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
41164486|NCT01046591|PROCEDURE|Polysomnography|Overnight sleep studies will be performed on all children.
41377873|NCT04566666|DRUG|SCD-044_Dose 3|SCD-044 in Dose 3
41377874|NCT01299428|DEVICE|INVOS 5100|INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
41377875|NCT05966142|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
41377876|NCT05966142|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
41377877|NCT06280391|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
41377878|NCT06280391|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
41506758|NCT01998945|BEHAVIORAL|Exposure-based Cognitive Behavioral Therapy|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.
41506759|NCT01998945|BEHAVIORAL|Relaxation Training|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
41034132|NCT06204549|OTHER|Screening and management of cormobidities|"During the routine care assessment and as part of the research, patients will :~* Fill in cardiovascular risk assessment score: Life's simple 7~* Provide an additional blood sample (1 dry tube of 7 mL and 1 heparin tube of 7 mL) during their biological testing. These samples will be used for lipoprotein (a) testing and biological collection.~After hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior to this contact, patients will have biological tests as prescribed just before hospital discharge (including blood ionogram, creatinine, liver assessment, lipid assessment (LDL, HDL, triglycerides), fasting blood sugar test, A1C test, urinary albumin/creatinine ratio, protein/ urinary creatinine ratio). They will weigh themselves and take blood pressure self-measurements over 3 days."
41034133|NCT04287023|OTHER|individual physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - individual
41034134|NCT04287023|OTHER|group physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - groups of 10 patients
41034135|NCT03556657|OTHER|Music Therapy|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
41034136|NCT00826891|DRUG|Cisplatin Combined With Topotecan|"Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).~Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.~Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2~Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2"
41034137|NCT00882947|DRUG|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
41034138|NCT02602301|DRUG|Oxytocin|different oxytocin diluents and effect on fetal bilirubin\&sodium levels.
41034139|NCT06088654|DRUG|IPH6501|phase 1 (dose finding) and phase 2 (dose expansion)
41034140|NCT04298567|DRUG|Rivaroxaban (Xarelto,Bay 59-7939)|Rivaroxaban (2.5 mg \[BID\])
40850854|NCT06077942|DEVICE|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
41034141|NCT04298567|DRUG|Acetylsalicylic acid(ASA)|ASA (75mg \[QD\]; dose according to local label.
41034142|NCT01694537|DRUG|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
41034143|NCT01694537|DRUG|placebo|Placebo is made with same size and shape with study drug.
41034144|NCT06060691|DRUG|Kaempferol|Kaempferol
41034145|NCT03238937|DEVICE|Phrenic nerve stimulator|Implantation of phrenic nerve stimulator
41034146|NCT02116634|BIOLOGICAL|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
41164487|NCT04302051|DIAGNOSTIC_TEST|Thermo-acuostic image acquisition of liver|Estimation of hepatic fat content with thermo-acoustic device
41164488|NCT04302051|DIAGNOSTIC_TEST|MRI-PDFF estimation of hepatic fat|Estimation of hepatic fat content with MRI
41377879|NCT06651190|OTHER|Pain Caregiver Resource (PainCaRe)|The purpose of the PainCaRe mobile health app is to support parents of young children with cancer (between the ages of 2-11 years) to manage their cancer-related pain at home. The app will ask caregivers to completed a brief 6-question pain assessment once daily and complete ad hoc assessments as needed. Based on the results of the pain assessment, real-time, evidence-based pain management suggestions, including will be provided to parents. The purpose of the pilot randomized controlled trial (RCT) is to evaluate the feasibility of implementing PainCaRe in a future RCT. Please find attached the study protocol for reference.
41377880|NCT06468046|BEHAVIORAL|Mama Empoderada [Mom Power]|'Mamá Empoderada' \[Mom Power\] is a theory-based, trauma-informed group intervention to promote mental health and positive parenting among mothers with young children (0-5 years). It has been adapted for migrant mothers, and will conduct a pilot randomized controlled trial (RCT) of the intervention with migrant mothers with young children (MMC). The intervention group (IG) will receive 10 group and 3 individual sessions addressing attachment theory, hands-on parenting skills, linkage to resources (e.g., food, shelter), social support, and self-care and resilience.
41377881|NCT05297604|RADIATION|Vascular photobiomodulation (VPBM)|The participants received a 20-minute single session of VPBM. This noninvasive method involves the use of low-power laser coupled to a bracelet designed to transport the light beam transcutaneously over the radial artery. The laser device (DMC Therapy Ec) delivered irradiation with a power of 100 ± 20 mW, wavelength of 660 ± 10 nm (red light) and energy of 120 J applied continuously, with irradiance of 35 W/cm².
40850855|NCT00195663|BIOLOGICAL|Adalimumab|
40850856|NCT00195663|DRUG|Methotrexate|
41506760|NCT02777398|PROCEDURE|Trans-Quadrant Channel Surgery|Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
41506761|NCT02777398|PROCEDURE|Conventional Open Surgery|Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
41377882|NCT05297604|RADIATION|Sham group (simulated vascular photobiomodulation)|Simulated radiation. The participants received a single session.
41377883|NCT05560802|OTHER|WHOs Labour care guide|Guidelines for monitoring labor progress, the WHOs LCG
41506762|NCT01093092|DIETARY_SUPPLEMENT|Calcitriol|Given PO
41506763|NCT01093092|DRUG|Cisplatin|Given IV
41377884|NCT06622083|OTHER|Education|Students in both groups will be given 40 minutes of both theoretical and practical training on the anatomy of the pelvic floor, its contraction mechanism, function and dysfunctions, evaluation and physiotherapy and rehabilitation. Theoretical training will be given through presentation and question-answer techniques containing this information, and practical training will be given through a pelvic model and gynecological examination simulator.
41377885|NCT06622083|OTHER|Education and Aerobic exercise|Participants in the exercise group will undergo an aerobic exercise program using the Monark 938E Nova Ergometer and software before the training session. The bike operates with its computer software integrated with the ECG system. The aerobic exercise program will consist of 3-5 minutes of warm-up, 20 minutes of exercise, and 3-5 minutes of cool-down, performed at a moderate intensity. During the exercise session, heart rate will be recorded every 5 minutes using a Polar ECG sensor connected via Bluetooth to the 938E Nova Ergometer, while perceived exertion will be measured using Borg's 6-20 rating scale
41377886|NCT05132543|DEVICE|High density micro-electrocorticography for neural speech prothesis|ECoG electrodes are thin, high-density, flexible electrode arrays used for recording electrophysiological signals from the brain.
41506764|NCT01093092|DRUG|Gemcitabine Hydrochloride|Given IV
41506765|NCT01093092|OTHER|Pharmacological Study|Correlative studies
41506766|NCT01128543|DRUG|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
41506767|NCT00789243|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
40850857|NCT00195663|BIOLOGICAL|Adalimumab placebo|
40850858|NCT00195663|DRUG|Methotrexate placebo|
41506768|NCT03510598|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting machine will be used to perform the treatments.
41506769|NCT03510598|DRUG|Kybella 20 MG in 2 ML Injection|Injectable drug called KYBELLA® (deoxycholic acid)
41506770|NCT02290223|BEHAVIORAL|Behavioral Based Treatment Model|Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
41506771|NCT02089607|DEVICE|Thoracoabdominal Aortic Aneurysm Arm|"The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches). The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches."
41506772|NCT02089607|DEVICE|Aortic Arch Aneurysm Arm|The endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively. The main aortic endovascular graft will be connected into the innominate artery, left common carotid artery and left subclavian artery using additional stents into the branch vessels.
41377887|NCT06651593|DRUG|SAR444881|Given by IV
41377888|NCT06651593|DRUG|Cemiplimab|Given by Iv
41506773|NCT04987476|BIOLOGICAL|analyzes in singles cells|genome expression analyzes in single cells
41506774|NCT02939625|DEVICE|muscle training|
41506775|NCT02939625|DEVICE|Continue Positive Airway Pressure|
41506776|NCT02939625|DEVICE|bilevel positive airway pressure|
41506777|NCT02091466|DEVICE|pre-warming|warming patients 30 minutes prior to anesthesia
41506778|NCT06467799|DRUG|Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1|Patients will first receive two cycles of FOLFOX-HAIC combined with tislelizumab as neoadjuvant therapy, with a 3-week interval between cycles. Two weeks after completing the neoadjuvant therapy, imaging assessments will be conducted to evaluate treatment efficacy and surgical feasibility. Surgical resection should be performed within two weeks following the imaging assessment. Four weeks post-resection, patients will undergo a follow-up evaluation to assess postoperative recovery and determine the presence of any residual tumor. If no residual or recurrent tumor is detected, adjuvant therapy with tislelizumab will commence (every three weeks, for a total of four cycles).
41506779|NCT06395805|DIAGNOSTIC_TEST|BREF, ADL, AIS.|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL) -BREF~2. scale I - ADL according to Lawton~3. the AIS questionnaire~4. the Zimet Multidimensional Scale of Perceived Social Support - the original version of the MSPSS"
41506780|NCT05319210|PROCEDURE|Venous catheter application|To examine the effect of virtual reality glasses and buzzy application on pain management during venous catheter insertion in children.
41506781|NCT02004015|DRUG|injection of placebo|0.5 mg/kg milligram(s)/kilogram
41506782|NCT02004015|DRUG|injection of NMBA|
41506783|NCT02202707|DRUG|Gabapentin|Study medication, gabapentin, will be distributed to all study participants and participants will be instructed as to how to take and titrate the medication dose. Participants will take gabapentin daily for up to six weeks.
41506784|NCT00051935|DRUG|Alglucosidase alfa|20 mg/kg (qow); intravenous
41506785|NCT04679701|DEVICE|Amparo Confidence Socket|"The Amparo Confidence Socket technology takes a different approach by starting with a prefabricated socket (https://www.amparo.world/confidence-socket-en). The socket is made from a moldable thermoplastic and has the attachment point pre-assembled. This prefabricated socket is essentially an off-the-shelf product that can be heated, then molded directly to the patient's residual limb. This removes many of the intermediate steps in traditional socket fabrication. The product's molding temperature is between 60-70 ˚C but the insulation of a silicone liner between the plastic and limb ensures safe temperatures for the patient. This process is currently used in several workshops in Europe and with approximately 50 patients currently using the product. In general, it has been shown to be safe and effective in creating below-knee prosthesis."
41506786|NCT01644630|PROCEDURE|Cemented crowns|"The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.~- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection."
41164489|NCT06176053|OTHER|Homebased stretching exercise and app supervision|The intervention group will perform a self-administered, home-based stretching program (a total of 6 minutes per day) and maintain their daily activities as identified at baseline. Exercises are to be performed daily for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.
41164490|NCT04842409|RADIATION|Whole breast irradiation|Whole breast irradiation using an ultra-hypofractionated schedule (26 Gy in 5 fractions)
41377889|NCT06411288|DRUG|AOC 1001 (del-desiran)|Del-desiran will be administered by intravenous (IV) infusion.
41377890|NCT06411288|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
41377891|NCT03564678|DIETARY_SUPPLEMENT|Levocarnitine|Given IV
41377892|NCT03564678|DRUG|Vitamin B Complex|Given PO
41377893|NCT06389825|OTHER|Healthy diet|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
41377894|NCT06351501|DRUG|hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months|4 years of follow up (FU) with evaluation at T0 (14 years old +/- 6 months), T1 (16 years old +/-6 months) and T2 (18 years old+/- 6 months) with eather ANDROGEL® 16.2 mg/g, gel (testostérone) or ESTREVA® 0.1 %, gel ou 1.3 PROVAMES® 1 mg, cp (oestrogenes)
41377895|NCT06351501|DRUG|Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +/- 6 months|2 years of hormonal treatment from 16 to 18 years old.
41164491|NCT03223714|DRUG|Conbercept Ophthalmic Injection|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)."
41377896|NCT05570175|BEHAVIORAL|Mobile application RA joint protection and activity self-management program|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks. The program was based on self-efficacy theory and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
41377897|NCT06457503|DRUG|Toripalimab|Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.
41377898|NCT06457503|DRUG|Cisplatin|Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
41377899|NCT06457503|DRUG|Gemcitabine|Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.
41377900|NCT06457503|DRUG|Carboplatin|In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
41377901|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
41377902|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
41377903|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
41377904|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
41377905|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
41377906|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
41377907|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 80min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 80 minutes on Days (D) 1 and 15 of each 28-day cycle.
41377908|NCT06475105|DRUG|Oral Acetazolamide|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
41377909|NCT06475105|DRUG|Placebo|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
41377910|NCT01513759|DRUG|recombinant tissue plasminogen activator|Participants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
41377911|NCT01513759|DEVICE|EKOS EkoSonic Endovascular System|24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
41377912|NCT04998188|PROCEDURE|Collagen|Patients will be treated with a single injection of collagen (2 ml) in the knee joint affected by osteoarthritis
41377913|NCT04998188|PROCEDURE|Placebo (saline solution)|Patients will be treated with a single injections of saline solution (2 ml) in the knee joint affected by osteoarthritis
41377914|NCT06373159|OTHER|No study intervention|Retrospective observational study using Real World Data (RWD) in Japan without study intervention
41377915|NCT06651229|DRUG|JNJ-90189892|JNJ-90189892 will be administered.
41377916|NCT06279468|PROCEDURE|intervertebral disc release|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. The intervertebral discs on the convex side of the scoliosis, situated between the vertebrae that have undergone Ponte osteotomy, will be approached and incised parallel to the intervertebral space. The intervertebral disc and endplate cartilage were incised and separated using reamers. Subsequently, the intervertebral space was expanded and irrigated, and the fragments of the intervertebral disc were extracted using nucleus pulposus forceps. Impacting bone graft into the intervertebral space, thus sustaining the optimal height of intervertebral space.
41377917|NCT06279468|PROCEDURE|Ponte osteotomy|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. Subsequent corrective procedures can be performed immediately following Ponte osteotomy completion. The deformity was corrected using the bilateral rod rotation and segmental derotation technique after inserting rods. Under fluoroscopic guidance, compression, distraction, and in situ bending maneuvers were implemented as needed. Allograft bone material was utilized for the purpose of bone fusion
41377918|NCT06058598|OTHER|Exercise Training|6-months supervised exercise training + 6 months unsupervised exercise training
41377919|NCT06058598|OTHER|Lifestyle Counselling|12-months of lifestyle counselling
41377920|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg|Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg
41377921|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
41377922|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
41377923|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple palatal micro connective tissue grafts|The connective tissue graft will be harvested from the palate.
41506787|NCT01644630|PROCEDURE|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
41377924|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple tuberosity micro connective tissue grafts|The connective tissue graft will be harvested from the maxillary tuberosity.
41377925|NCT06642350|OTHER|Whole-body electrostimulation|10 weeks of WB-EMS 1.5x 20 min/week
41377926|NCT06642350|OTHER|Medical Training Therapy|10 weeks of MTT 2x 45 min/week
41377927|NCT04143477|DRUG|peficitinib|Oral
41377928|NCT04924738|BEHAVIORAL|Monitoring and lifestyle|Dietary and lifestyle modification recommended for pregnant women with hyperglycemia detected in pregnancy.
41377929|NCT06650085|PROCEDURE|Loop ileostomy|Patient undergoing anterior rectal resection will receive loop ileostomy
41377930|NCT06650085|PROCEDURE|Loop colostomy|Patient undergoing anterior rectal resection will receive loop colostomy
41377931|NCT06541314|DRUG|Fluzoparib|Fluzoparib (50mg per capsule) 150mg po bid. Take Fluzoparib for 3 weeks, then stop for 1 week, constituting a 28-day cycle. Administer 2 cycles in total.
41377932|NCT05268003|DRUG|Ponatinib|Given by PO
41377933|NCT05268003|DRUG|Venetoclax|Given by PO
41377934|NCT05268003|DRUG|Mini-hyper CVD|Given by IV (vein)
41377935|NCT06582680|OTHER|Ambient Heat|Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.
41377936|NCT04856488|DRUG|Iodine-Potassium Iodide 5%-10% Oral and Topical Solution|Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
41377937|NCT05242406|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
41377938|NCT04795713|DRUG|MT-6402|Experimental Treatment
41377939|NCT00554788|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
41377940|NCT00554788|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
41377941|NCT00554788|DRUG|Carboplatin|Given IV
41377942|NCT00554788|DRUG|Cisplatin|Given IV
41377943|NCT00554788|DRUG|Cyclophosphamide|Given IV
41377944|NCT00554788|DRUG|Etoposide|Given IV
41377945|NCT00554788|BIOLOGICAL|Filgrastim|Given SC
41377946|NCT00554788|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
41377947|NCT00554788|RADIATION|Radiation Therapy|Undergo radiotherapy
41377948|NCT00554788|DRUG|Thiotepa|Given IV
41377949|NCT00554788|DRUG|Vincristine Sulfate|Given IV
41377950|NCT02476916|DRUG|AG-348|Participants with PK deficiency were randomized to either receive AG-348, 50 or 300 mg, as initial doses, BID for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses, however, over the course of the core period were treated across a range of doses due to treatment emergent adverse events (AEs) and hemoglobin (Hb) levels exceeding mid-point of sex-adjusted ranges.
41377951|NCT01310725|PROCEDURE|Coronary artery bypass grafting|Bypass of stenoses in coronary arteries using different types os vessels as conduit.
41377952|NCT00564486|DRUG|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
41377953|NCT00564486|DRUG|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
41377954|NCT00564486|DRUG|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
41377955|NCT00564486|DRUG|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
41377956|NCT04912804|OTHER|Questionnaires|SF-12, GHQ-12 and HAQ
41377957|NCT02205281|BEHAVIORAL|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
41377958|NCT02160054|DRUG|Graceptor®|oral
41377959|NCT03601923|DRUG|Niraparib|"Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial."
41377960|NCT01959282|DRUG|Placebo|Participants will receive placebo once daily
41506788|NCT05097365|DIETARY_SUPPLEMENT|Vitamin B12 + folic acid supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.
41506789|NCT05097365|DIETARY_SUPPLEMENT|Placebo supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.
41506790|NCT05509075|DIETARY_SUPPLEMENT|nutraceuticals|antioxidants
41034147|NCT06635278|BEHAVIORAL|Mindfulness meditation|"The experimental group received eight 60-minute weekly sessions of mindfulness meditation over eight weeks in a private and quiet room at the hospital, according to Smith's (2005) recommendation. The study intervention was an audio based MBI sent to them by the WhatsApp application. It is a free, self-paced program developed by a study researcher based on the Smith's (2005) protocol.~The theory-based program (Smith, 2005) includes the ABC standardized versions of MBI (Smith, 2005), described as follows:~* Meditation of the body (Body sense meditation)~* Meditation of the body (Rocking meditation)~* Meditation of the body (Breathing meditation)~* Meditation of mind (Mentra meditation)~* Meditation of mind (visual Image)~* Meditation of sense (External image)~* Meditation of the senses (A sound)~* Open monitoring (Mindfulness)"
41034148|NCT00153777|DRUG|Cellulose Sulfate gel (6%)|
41034149|NCT05896774|DRUG|Maplirpacept|Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.
41034150|NCT05790733|OTHER|Standard intubation|This involves the use of 5% Xylocaine nebulizer spray and a single-use cannula. The nurse checks its expiry date and that the quantity is sufficient to practice the 7 instillations in one nostril and the other 7 in the mouth. A waiting time is respected and the installation of the NGS can begin. She will also set up a fast for 2 hours after this local anesthesia.
41377961|NCT01959282|DRUG|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
41506791|NCT04317079|DIETARY_SUPPLEMENT|Hydroxytyrosol|Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
41164492|NCT03223714|DRUG|sham injection|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)."
41164493|NCT00468507|DIETARY_SUPPLEMENT|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
41164494|NCT00508534|DRUG|SB-751689|
41506792|NCT04317079|OTHER|Diet|Consultation by a dietitian was offered to all participants
41506793|NCT00000139|BEHAVIORAL|Stress|
41506794|NCT00000139|DRUG|Acyclovir|
41506795|NCT00002031|DRUG|Dinitrochlorobenzene|
40850859|NCT05670418|DEVICE|Quantitative Electroencephalography|Each qEEG examination of one person lasted about 20 minutes and included two stages: the first-recording of brain waves with eyes closed (5 min), the other with eyes open (5 min)
40850860|NCT03304873|DRUG|Retapamulin|Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
40850861|NCT03304873|DRUG|Placebo Ointment|The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
40850862|NCT00032357|PROCEDURE|Ferritin reduction to 25 ng/ml by phlebotomy|
40850863|NCT01344083|DRUG|T1210|2 drops T1210 once a day
40850864|NCT01344083|DRUG|Olopatadine hydrochloride|2 drops once a day Olopatadine
40850865|NCT01817959|DRUG|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.The Investigational Product (IP) were to be administered as an add-on treatment for the immunosuppressant regimen.
40850866|NCT01817959|DRUG|Placebo|Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
40850867|NCT06123143|OTHER|Standardized/structured CPAP weaning protocol|Standardized/structured CPAP weaning protocol up to 32 or 34 weeks gestational age (GA) (based on GA at birth) for infants born at less than 30 weeks GA.
41034151|NCT05790733|OTHER|Hypnosis|"Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or somnambulism without sharing all the characteristics.~As part of the treatment, hypnosis is widely used for pain control. The adverse effects reported are nil. One of its main benefits is improved patient comfort. Another benefit is the reduction of exposure to anesthetic products.~The installation of the NGS with hypnosis will be carried out according to the protocol set out in appendix 4."
41034152|NCT06030726|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
41034153|NCT02610439|OTHER|Laboratory Biomarker Analysis|Correlative studies
41377962|NCT01959282|DRUG|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
40850868|NCT00903305|OTHER|medical chart review|
40850869|NCT00903305|OTHER|questionnaire administration|
40850870|NCT00903305|PROCEDURE|fatigue assessment and management|
40850871|NCT00903305|PROCEDURE|psychosocial assessment and care|
40850872|NCT00903305|PROCEDURE|quality-of-life assessment|
40850873|NCT01786252|DRUG|human chorionic gonadotropin (hCG)|"500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)"
40850874|NCT01786252|DRUG|Placebo Comparator (for hCG)|"50ul of IVF medium (Global-trademark) to mimic hCG infusion"
40850875|NCT04673539|DIAGNOSTIC_TEST|Spanish version of the Brief-BESTest in stroke patients|Adaptation and validation of the Spanish version of the Brief-BESTest in stroke Patients
40850876|NCT01912339|DEVICE|Rezum System|"The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death."
40850877|NCT01912339|PROCEDURE|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
41506796|NCT01261923|DRUG|Alitretinoin|30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
41506797|NCT00467324|DEVICE|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
41506798|NCT03887312|BEHAVIORAL|t-CETA|Cognitive Behavioural Therapy (CBT) based approach delivered over the telephone. Components are available for common problems, including anxiety, depression, PTSD, conduct problems, substance abuse, and safety issues (including self-harm or suicidal ideation), and a tailored treatment package is produced for each child based on the presenting problem(s) and response to treatment. There are components for use with both child and caregiver.
41506799|NCT03887312|BEHAVIORAL|Médecins du Monde treatment as usual|Case manager-led care, with referral to a psychotherapist or psychiatrist as necessary. Médecins du Monde's approach is based on a joint collaboration between mental health trained case managers (who undergo extensive training by experts in the field on topics including Psychological First Aid, Child Protection, Gender Based Violence, etc.) and psychotherapists from different schools (providing Eye Movement Desensitization and Reprocessing \[EMDR\] for trauma, Interpersonal Therapy \[IPT\] for depression, Cognitive Behavioural Therapy \[CBT\], motivational counselling, familial or systemic therapy, and integrative approaches). Thus the number and content of sessions, and the person delivering treatment (case manager, psychotherapist, psychiatrist) vary.
41506800|NCT03778073|DRUG|Cosibelimab|Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle
41034154|NCT06107686|DRUG|YL202 should be intravenously infused|For each patient, YL202 should be intravenously infused over 60±10 min.
41034155|NCT01178151|DRUG|Everolimus|10mg daily orally
41034156|NCT03844763|DRUG|Avelumab|Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity
41034157|NCT03844763|DRUG|CTX|CTX: 50 mg Daily untill PD or major toxicity
41034158|NCT03844763|RADIATION|RT|RT: 8 Gy single shot day 8
41034159|NCT03567538|PROCEDURE|Thoracic surgery|Thoracic surgery, pulmonary resection, minimally invasive thoracic surgery, video assisted thoracic surgery (VATS)
41034160|NCT06143618|BEHAVIORAL|escape room games|The escape room game will include a patient scenario of four female patients who are victims of violence and apply to different clinics. Necessary equipment and materials will be provided and stations will be established where four female patients who are victims of violence will be evaluated. In the game, each student will contact the patient at only one station and evaluate signs and symptoms of violence. The activities at the stations will be carried out together as a group. The group, which completes the tasks and activities and collects the puzzle pieces that will lead to the code of the lock, will complete the puzzle and enter the number codes on it into the key of the locked box on the table (4 numerical codes received), open the box and get the message 'you can escape'. The group with the most time left at the end of the game will come first and will be rewarded.
41164495|NCT00643435|BEHAVIORAL|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
41377963|NCT01959282|DRUG|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
41506801|NCT03778073|DRUG|Cosibelimab + Ublituximab + Bendamustine combination|"Cosibelimab (Intravenous infusion):~Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2."
41377964|NCT01959282|DRUG|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
41506802|NCT03778073|DRUG|Cosibelimab + Ublituximab + Bendamustine combination|"Cosibelimab (Intravenous infusion):~Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2."
41506803|NCT02637531|DRUG|IPI-549 (eganelisib)|IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)
41506804|NCT02637531|DRUG|Nivolumab|Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
41034161|NCT06143618|BEHAVIORAL|role playing|In the role play application, there will be scenarios of four female patients who are victims of violence and apply to different clinics. Before the role play activities, students will be asked to form groups of 4-5 people, and each week, a group will be asked to choose one of the four scenarios given by lot and improvise the case-based role play activity within 40 minutes. Before the role play application, the materials that may be required for the students (clothes, materials, etc.) and the preparation of the environment (hospital, polyclinic, etc.) will be provided by the researchers in accordance with the activity to be enacted. At the end of the role play activities, students will be able to express, evaluate and discuss their feelings and thoughts within and between groups.
41034162|NCT04389840|DRUG|Dociparstat sodium|Dociparstat is a glycosaminoglycan derived from porcine heparin.
41034163|NCT04389840|DRUG|Placebo|0.9% Normal Saline
41377965|NCT06551987|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6 weekly, 50-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
41377966|NCT06551987|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|4 weekly, 30-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
41377967|NCT01114126|DRUG|Neu-P11|comparison of different dosages of drug
41377968|NCT01114126|DRUG|Neu-P11 placebo|comparison of different dosages
41377969|NCT05859464|DRUG|ZL-1218|ZL-1218 dose escalation
41377970|NCT05859464|DRUG|Pembrolizumab|Combination treatment with ZL-1218
41377971|NCT06492291|DRUG|Enlicitide Decanoate|Oral tablet
41377972|NCT03025360|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
41506805|NCT03613233|PROCEDURE|Glaucoma surgery|phacoemulsification
41506806|NCT06551870|OTHER|Physical activity|The complexity of the games will increase as the levels of the sports games advance, which leads to faster movements with greater demands to progress in the sequence of the games, which allows reaching increases in intensity.
41506807|NCT01450683|DRUG|Itraconazole|"600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-\[4-(4-{\[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl\]methoxy}phenyl)piperazin-1-yl\]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one"
41506808|NCT03390855|OTHER|Broccoli sprouts|
41506809|NCT02631889|DEVICE|Transcollation technology|The use transcollation technology for dissection during lung surgery
41506810|NCT02631889|DEVICE|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
41506811|NCT01512160|DRUG|PF-04531083|2000 mg oral solution
40850878|NCT03190278|BIOLOGICAL|UCART123v1.2|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab
41506812|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
41034164|NCT04017026|DEVICE|Implantation|Implantation of 6 mm short implants
41034165|NCT04829643|DIAGNOSTIC_TEST|PET/MRI|A consecutive cohort of 247 patients with early BC and no suspicious nodes at both clinical and A-US evaluations and candidates to upfront surgery and SNB will be recruited
41034166|NCT01365000|DRUG|NKTR118 Formulation 1|Oral dose, 25 mg
41034167|NCT01365000|DRUG|NKTR118 Formulation 2|Oral dose, 25 mg
41034168|NCT01365000|DRUG|NKTR118 Formulation 3|Oral dose, 25 mg
41034169|NCT01365000|DRUG|NKTR118 Formulation 1a|Oral dose, 25 mg
41034170|NCT01365000|DRUG|NKTR118 Formulation 3a|Oral dose, 25 mg
41377973|NCT03469882|DIETARY_SUPPLEMENT|High protein nutrition|Patients in the HPE group will be submitted to nutritional support preferably through the enteral route. Energy expenditure will be determined by indirect calorimetry. They will receive 2.0 to 2.2 grams/kg/day of protein.
41377974|NCT03469882|DEVICE|Cycle ergometry exercise|Patients will be submitted to two daily sessions of exercise (cycle ergometry) 15 minutes duration each, during the 7 days of the week. The intervention will be maintained exclusively duting the patient's stay in the ICU. The cycle ergometer will be the MotoMed Letto II (Reck Technik, Germany).
41377975|NCT03469882|OTHER|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise.
41377976|NCT03890380|DEVICE|Magneto Wire|Patients will be treated with Magneto Wire
41377977|NCT06652139|DRUG|selinexor combined with BEAM regimen|Selinexor: 60mg po D-10, D-7 and D-4 Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
41377978|NCT06652139|DRUG|BEAM regimen|Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
41506813|NCT01512160|DRUG|PF-04531083|1000 mg oral solution
41506814|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
41506815|NCT01512160|DRUG|Ibuprofen|2 x 200 mg tablets
41506816|NCT01512160|OTHER|Placebo|Placebo solution for PF-04531083
41506817|NCT01512160|OTHER|Placebo|Placebo solution for PF-04531083
41506818|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
40850879|NCT01509911|DRUG|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
41034171|NCT01452269|BEHAVIORAL|Deaf Weight Wise program|"Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program."
41164496|NCT00643435|BEHAVIORAL|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
41377979|NCT06650007|DRUG|HRS9531 Injection|HRS9531 Injection
41377980|NCT06650007|DRUG|HRS9531 Placebo Injection|HRS9531 Placebo Injection
41377981|NCT06651788|OTHER|Ethyl Chloride|Topical anesthetic that rapidly cools the skin and underlying tissues
41377982|NCT06651788|OTHER|Cold Saline Spray|placebo application of cold saline spray
41377983|NCT05828069|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41377984|NCT05828069|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41377985|NCT05828069|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41377986|NCT05828069|PROCEDURE|Computed Tomography|Undergo CT
41377987|NCT05828069|PROCEDURE|Echocardiography|Undergo ECHO
41377988|NCT05828069|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|Undergo FDG-PET imaging
41377989|NCT05828069|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
41377990|NCT05828069|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41377991|NCT05828069|DRUG|Tovorafenib|Given PO
41377992|NCT04926857|OTHER|Non-Interventional|Non-Interventional
41377993|NCT03503201|DIETARY_SUPPLEMENT|Chromium|chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) daily for 2 months before ICSI cycle
41377994|NCT01778309|DIETARY_SUPPLEMENT|n-acetylcysteine supplementation|"n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise"
41377995|NCT06504407|BEHAVIORAL|Bingo Educational Game|The intervention involves Bingo games designed to educate African American/Black community members about cancer and clinical trials. During each game, educational facts are shared, and prizes promoting healthy lifestyles are awarded. Led by a Diversity Navigator, the sessions include pre- and post-test surveys to assess knowledge gain and engagement. The intervention also connects participants with needed medical services.
41377996|NCT06234969|DEVICE|Continuous Theta Burst Stimulation to the Intraparietal Sulcus|Continuous Theta Burst Stimulation delivered to the Intraparietal Sulcus
41377997|NCT06234969|DEVICE|Sham Continuous Theta Burst Stimulation|Sham Continuous Theta Burst Stimulation
41377998|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
41377999|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen A+|Hypoallergenic formula without lactobacillus
41378000|NCT01357382|OTHER|Low carbohydrate diet|restrict carbohydrate consumption to \< 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
41378001|NCT04514224|OTHER|Gabby implementation|Iimplement an evidence-based preconception care intervention, Gabby, into community-based health settings
40850880|NCT01509911|DRUG|Gemcitabine|Monthly cycles of 3 weekly treatments a month and one week off of treatment
41378002|NCT04514224|OTHER|Evaluate the Gabby implementation|Assess implementation outcomes using the Proctor Implementation Outcomes Framework
41378003|NCT06005740|DRUG|TORL-4-500|antibody drug conjugate
41378004|NCT02916056|DRUG|Azeliragon 5mg|
41378005|NCT05344417|PROCEDURE|Pneumoperitoneum Pressure|"Low Pneumoperitoneum Pressure: defined as an intrabdominal pressure between 8-12 mmHg during the laparoscopic procedure.~High Pneumoperitoneum pressure: defined as an intrabdominal pressure of 15 mmHg or more during the laparoscopic procedure.~Note: surgeons will set the pneumoperitoneum at the lowest value they are comfortable with based on their surgical criteria"
41378006|NCT05344417|PROCEDURE|Neuromuscular blockade|"Moderate neuromuscular blockade: defined as the presence of 1 or 2 responses after train-of-four stimulation.~Deep neuromuscular blockade: defined as no response to train-of-four stimulation and 1 or less responses after post-tetanic count stimulation."
41378007|NCT05344417|DEVICE|Pneumoperitoneum insufflation device|"AirSeal® device or Olympus standard of care insufflation device. Both devices are approved for use in laparoscopic gastrointestinal surgeries."
41164497|NCT03271918|DRUG|Cabergoline|
41164498|NCT01741311|BEHAVIORAL|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
41164499|NCT01741311|BEHAVIORAL|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
41378008|NCT05344417|DRUG|Neuromuscular blockade reversal|"Neostigmine: for Arm 1 only (standard use).~Sugammadex: will be used for the other arms in the study.~All drugs used in our randomized trial (neuromuscular blockade with rocuronium and reversal with neostigmine or sugammadex) are standard of care and approved for use by our institutional Institutional Review Board (IRB) Ethics Committee for this trial."
41034172|NCT01541228|DEVICE|Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.~Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval."
41164500|NCT03045055|DEVICE|Remote ischemic conditioning.|The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
41164501|NCT03045055|PROCEDURE|Endovascular treatment.|Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
41164502|NCT03045055|DEVICE|Sham remote ischemic conditioning|The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
41164503|NCT03015870|BEHAVIORAL|Vocal exercise with real-time feedback|The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
41164504|NCT03015870|BEHAVIORAL|Vocal exercise with recording|The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
41164505|NCT04250688|DEVICE|Ekso Training with FES|
41378009|NCT01852786|OTHER|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
41378010|NCT01852786|OTHER|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
41378011|NCT05885711|OTHER|self-management|self-managing a pessary: removing, cleaning and inserting
41034173|NCT01541228|PROCEDURE|Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval."
41034174|NCT04773587|DRUG|Roflumilast Cream 0.15%|Roflumilast Cream 0.15% - Active
41034175|NCT04773587|DRUG|Vehicle Cream|Cream - Vehicle
41164506|NCT02991703|DEVICE|pOpmètre®|the pOpmètre® uses saturation sensors,
41164507|NCT02991703|DEVICE|Sphygmocor|the Sphygmocor uses applanation tonometry
41164508|NCT02907450|DEVICE|TwiCare®.|
41164509|NCT04865614|DRUG|Etomidate|Use of etomidate
41164510|NCT04865614|DRUG|Sevoflurane|Use of sevoflurane
41164511|NCT06127940|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT is delivered using institutional standard dosing while sotorasib is withheld during radiation.
41034176|NCT01699594|DRUG|Mannitol|Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
41164512|NCT06127940|DRUG|Temporary Stopping|Temporary stop of sotorasib during SBRT
41378012|NCT02834013|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41378013|NCT02834013|PROCEDURE|Computed Tomography|Undergo CT
41378014|NCT02834013|PROCEDURE|Echocardiography|Undergo ECHO
41378015|NCT02834013|BIOLOGICAL|Ipilimumab|Given IV
41378016|NCT02834013|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41378017|NCT02834013|BIOLOGICAL|Nivolumab|Given IV
41378018|NCT03024359|DIETARY_SUPPLEMENT|Extra virgin olive oil|2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
41378019|NCT01495104|DRUG|RO4917838|Multiple doses
41378020|NCT01495104|DRUG|valproate|Multiple doses
41378021|NCT03707145|BEHAVIORAL|Consultation|The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
41378022|NCT03707145|BEHAVIORAL|Online Support|The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.
41164513|NCT05772481|OTHER|PET-MRI|"Each patient will have a pre-treatment PET-MRI (PET-MRI 1) within 21 days before the start of treatment.~Induction chemotherapy may be performed at another center than the investigating center.~After 3 cycles of induction chemotherapy and before the 4th cycle, a second PET MRI (PET MRI 2) will be performed. In patients who have received less than 3 cycles of induction chemotherapy, this mid-therapy PET-MRI will not be performed.~A 3rd PET-MRI will be performed prior to radiation therapy (PET-MRI 3). A final MRI PET (MRI PET 4) will take place before surgery.~A total of 4 PET MRI scans will be performed."
41164514|NCT01980524|DRUG|acipimox|
41378023|NCT03707145|BEHAVIORAL|Empowered|The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
41378024|NCT06219148|BEHAVIORAL|Music Therapy Telehealth|Music Therapy: delivered via Zoom by a board-certified music therapist (MT-BC) 30-min 2x/week for 4 weeks (8 sessions total); follows the Clinical Practice Model, which guides customizations of various music experiences (e.g., singing, songwriting, movement, relaxation, lyric discussion, improvisation, instrument play, etc.) per participants' strengths, interests, preferences, culture, and momentary responses. Each participant works with the same MT-BC throughout the study.
41378025|NCT06219148|BEHAVIORAL|Non-Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed social worker (SW) or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. SWs operate independently from MT-BCs to identify possible participant service referral needs using the Aging and Memory Quality of Life Survey (AMQoL), baseline data, SW session interactions, and SW Referral Worksheet. Each participant works with the same SW throughout the study.
41034177|NCT01699594|DRUG|Methacholine Chloride|Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
41378026|NCT06219148|BEHAVIORAL|Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed SW or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. In addition to the AMQoL, baseline data, SW session interactions, and the SW Referral Worksheet, SWs collaborate fully with MT-BCs, have full access MT session notes, and can discuss participants' needs with MT-BC to identify possible participant service referral needs. Each participant works with the same SW throughout the study.
41378027|NCT04583072|DIAGNOSTIC_TEST|The Stockholm3 test|Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.
41034178|NCT06559397|OTHER|Assessment of cervical proprioception|Cervical proprioception will be assessed using the 'head position error test' in both right and left rotation directions with the CROM device. Participants will be then divided into two groups based on the presence of proprioceptive errors (\>5°).
41034179|NCT06636526|GENETIC|The i4i PRODICT™ test.|The i4i PRODICT™ test combining both common and rare genetic variants into one saliva-based DNA test to estimate a person's future risk of prostate cancer. This test will be offered to all participants in Part 1 of the study. Participants will be classified into high-risk or population risk based on the results of the i4i PRODICT™ test. Those classified as high-risk due to either falling within the high polygenic risk score category, and/or having a rare variant in a gene in the test will be offered targeted prostate cancer screening.
41378028|NCT03323034|DRUG|Irinotecan|Given IV
41378029|NCT03323034|DRUG|Pevonedistat|Given IV
41378030|NCT03323034|DRUG|Temozolomide|Given PO
41378031|NCT02876185|OTHER|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
41378034|NCT03811015|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41378035|NCT03811015|DRUG|Cisplatin|Given IV
41506819|NCT03900052|DEVICE|Haptic cane|• A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.
41506820|NCT03900052|DEVICE|typical cane|Typical training cane loading training
41506821|NCT00897910|OTHER|flow cytometry|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
41164515|NCT01980524|DRUG|Placebo Oral Capsule|
41164516|NCT03508934|DEVICE|GTS (Continuous Glucose Monitoring)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)
41164517|NCT03508934|OTHER|POC (Point of Care)|Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
41164518|NCT00145483|DRUG|Sildenafil|
41164519|NCT05682885|PROCEDURE|Lymphatic Bypass Supermicrosurgery|Axillary Lymph Node Dissection with Lymphatic Bypass Supermicrosurgery
41164520|NCT00183183|BEHAVIORAL|Screening and Brief Intervention|
41164521|NCT05566353|OTHER|Remote Check|Remote Check is a remote monitoring tool which permits patients with Cochlear Nucleus CP1000 or CP1150 processors to complete hearing tests (pure-tone and speech-in-voice audiometry, electrode impedance measures, implant functioning assessment) at home,
41164522|NCT03167047|PROCEDURE|Caudal block|Caudal epidural
41164523|NCT03167047|PROCEDURE|Nerve Block|Peripheral nerve block
41378036|NCT03811015|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41378037|NCT03811015|PROCEDURE|Echocardiography|Undergo ECHO
41378038|NCT03811015|OTHER|Fludeoxyglucose F-18|Receive FDG
41378039|NCT03811015|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41378040|NCT03811015|BIOLOGICAL|Nivolumab|Given IV
41378041|NCT03811015|OTHER|Patient Observation|Undergo observation
41378042|NCT03811015|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41378043|NCT02772341|DEVICE|Salt room with halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.
41378044|NCT02772341|OTHER|Salt room without halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
41378045|NCT03684018|BIOLOGICAL|IgPro10|Normal human immunoglobulin G administered intravenously
41378046|NCT06213441|OTHER|pecha kucha education|"Pecha kucha training to be given to the experimental arm will be given by the researcher.~The training content will be created in line with the literature and will be given before the patient is discharged."
41378047|NCT06385509|DRUG|Jatenzo|237 mg JATENZO twice daily
41378048|NCT04533750|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41378049|NCT04533750|OTHER|Fludeoxyglucose F-18|Given IV
41378050|NCT04533750|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41378051|NCT04533750|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41378052|NCT04533750|DRUG|Peposertib|Given PO
41378053|NCT04533750|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41506822|NCT00897910|OTHER|immunoenzyme technique|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
41506823|NCT00897910|OTHER|laboratory biomarker analysis|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
41506824|NCT01241747|BEHAVIORAL|Walking Exercise|3 times per week for 3 months
41506825|NCT01241747|BEHAVIORAL|Control|Resistance training 3 times per week for 3 months
41506826|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)|6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
41506827|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (12 µg)|12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
41506828|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (25 µg)|25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
41378054|NCT03125642|DRUG|Etoposide|"BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4"
41378055|NCT03125642|DRUG|BCNU|BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6
41378056|NCT03125642|DRUG|AraC|BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
41378057|NCT03125642|DRUG|Melphalan|BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1
41378058|NCT03125642|PROCEDURE|Peripheral blood stem cell transplantation|All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
41378059|NCT03125642|BIOLOGICAL|G-CSF|All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3
41378060|NCT03125642|DRUG|Cyclophosphamide|"CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6"
41378061|NCT03125642|RADIATION|Total Body Irradiation|CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
41378062|NCT06554678|PROCEDURE|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）
41378063|NCT06554678|PROCEDURE|conventional oxygen mask|conventional oxygen mask
41378064|NCT06650150|DIAGNOSTIC_TEST|maximal inspiratory pressure|maximal inspiratory pressure (mip) will be measured with a specific device
41378065|NCT06650150|DIAGNOSTIC_TEST|maximal expiratory pressure|MEP will be measured with a specific device
41378066|NCT06650150|DIAGNOSTIC_TEST|6 minute walk test|6mwt will be done by a phsyotherapist
41378067|NCT05607056|DIETARY_SUPPLEMENT|Sinquanon|"This probiotic food supplement includes fourteen probiotic bacterial strains of Lactobacillus Spp, Bifidobacterium Spp., Bacillus coagulans, Saccharomyces boulardii, three prebiotics and Vitamin-B complex - B1, B2, B3, B6, B7, B9 in an enterosolvent cellulose capsule. The product includes supplementary substances: maltodextrin and magnesium stearate.~2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing."
41378068|NCT05607056|DIETARY_SUPPLEMENT|Placebo|The placebo product will have the same appearance as the active product and the same composition but without the live bacteria, prebiotics, and vitamin-B complex. 2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing.
41378069|NCT01897480|BIOLOGICAL|LY2875358|Administered IV
41378070|NCT01897480|DRUG|Erlotinib|Administered Orally
41378073|NCT06514365|DRUG|IPACK block with Bupivacaine 0.25% with adrenaline|The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.
41378074|NCT06378528|DRUG|Ketamine|3 Intravenous ketamine administrations (0.5mg/kg, not to exceed 40mg dose) immediately prior to a psychotherapy session over the span of 6 weeks
41506829|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)|The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
41378075|NCT06378528|DEVICE|SmartSleep EEG recording headband|Participants will complete 7 nights of at-home sleep recordings for exploratory analysis
41378076|NCT06649760|BEHAVIORAL|Gain and loss framed mobile text messages|To assess the effect of message framing on enhancing oral health practices in a group of refugees
41378077|NCT05771480|BIOLOGICAL|Durvalumab|Participants will receive 1500 mg every 3 weeks, or every 4 weeks (in combination with chemotherapy every 3 weeks, or every 2 weeks, respectively) from cycle 1 to cycle 8 of chemotherapy. Upon completion, participants will receive 1500 mg every 4 weeks (as monotherapy)
41378078|NCT05771480|DRUG|Gemcitabine monotherapy|Gemcitabine monotherapy as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
41378079|NCT05771480|DRUG|Gemcitabine + cisplatin|Gemcitabine plus cisplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab) for WHO/ECOG PS 2 participants only
41378080|NCT05771480|DRUG|Gemcitabine + oxaliplatin|Gemcitabine + oxaliplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
41378081|NCT05771480|DRUG|Gemcitabine + carboplatin|Gemcitabine + carboplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
41378082|NCT05771480|DRUG|Gemcitabine + cisplatin + S-1|Gemcitabine + cisplatin + S-1 as background gemcitabine-based chemotherapy every 2 weeks (i.e, 4 cycles of durvalumab)
41378083|NCT05771480|DRUG|Gemcitabine + S-1|Gemcitabine + S-1 as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
41378084|NCT05771480|DRUG|Gemcitabine + cisplatin + albumin-bound paclitaxel|Gemcitabine + cisplatin + albumin-bound paclitaxel as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
41378085|NCT05159713|BEHAVIORAL|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation."
41378086|NCT05159713|BEHAVIORAL|Treatment as Usual|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
41378087|NCT05958238|DEVICE|AR/VR oral care training system|Students simulated the treatment of the elderly with different physical and oral conditions using virtual situations and employed suitable oral care methods depending on each situation through VR. They learned the Bass brushing technique, the interdental brush cleaning method, and the soft tissue cleaning method through AR.
41378088|NCT05958238|OTHER|Traditional classroom teaching|The well-trained oral hygienist provided traditional oral care instruction with the same teaching content in the AR/VR-based training system.
41378089|NCT02279888|DEVICE|CardioMEMS HF System|Pulmonary artery pressure sensor
41378090|NCT01068418|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|cholecalciferol 15,000 IU daily for 30 days
41378091|NCT05537259|OTHER|Observation Group|No intervention; this is an observational study.
41378092|NCT03393039|BEHAVIORAL|Negative Affect Task|fMRI stress task
41378093|NCT06650410|OTHER|Virtual Intervention for Vertebral Fractures (VIVA)|VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. An exercise professional leads 1:1 once-weekly sessions (in person or virtual) over eight weeks. Sessions start with brief education on a topic, followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. The exercise professional prescribes resources using an app or that can be emailed or mailed. Exercises are tailored to the participant's abilities, and target balance, muscle strength, and endurance of back extensor muscles and scapular stabilizers.
41378094|NCT05295459|DRUG|LYR-210|LYR-210 drug matrix (mometasone furoate)
41378095|NCT05295459|DRUG|Sham procedure control|Sham procedure control
41378096|NCT05295459|OTHER|Background therapy|Daily Saline Irrigation
41378097|NCT06000007|DEVICE|2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app|2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.
41378098|NCT06000007|OTHER|Treatment as usual|Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.
41378099|NCT06651424|DIETARY_SUPPLEMENT|Combination of Lactobacillus probiotics (no comercial)|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
41378100|NCT06651424|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
41378101|NCT03819465|DRUG|Durvalumab|Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
41378102|NCT03819465|DRUG|Danvatirsen|Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
41378103|NCT03819465|DRUG|Oleclumab|Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
41506830|NCT03981952|OTHER|Placebo|0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
41378104|NCT03819465|DRUG|MEDI5752|MEDI5752 IV Every 3 weeks (q3w)
40850881|NCT01918059|PROCEDURE|Tissue Adhesive skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
41378105|NCT03819465|DRUG|Pemetrexed|Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
40850882|NCT01918059|PROCEDURE|Absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
40850883|NCT01918059|PROCEDURE|Non-absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
40850884|NCT05899374|BEHAVIORAL|KindMap|The KindMap is a stand-alone, cost-free e-mental health tool presenting a low-intensive psychological intervention adapted from the MBPI to fit a web app format. KindMap is to be used at users' own time and pace, and includes ten modules addressing psychoeducation, mindfulness and compassion guided practices, and ACT-based experiential exercises. These components are delivered through text, videos, audio, experiential exercises, and interactive contents.
40850885|NCT04611828|DEVICE|Philips SmartSleep|closed-loop auditory stimulation
40850886|NCT05124132|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction
40850887|NCT05124132|BEHAVIORAL|Exercise|Exercise
40850888|NCT05124132|BEHAVIORAL|Mindfulness-Based Stress Reduction + Exercise|Mindfulness-Based Stress Reduction + Exercise
40850889|NCT05124132|BEHAVIORAL|Health Education|Health Education
40850890|NCT04558359|OTHER|Standard of Care|These patients will receive standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
41034180|NCT06636526|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all participants identified as high risk from the i4i PRODICT™ test for three years in order to track development of cancer in the future.
41034181|NCT06636526|PROCEDURE|MRI Scan|MRI scan will be offered to participants identified in the high-risk category of the i4i PRODICT™ test depending on their PSA test results. Where PSA is above age-specific threshold (\&gt;2.5ug/L for people with prostates (PwPs) aged 40-50 years and \&gt;3.5ug/L for PwPs aged 50-55 years), those with raised PSA levels will be referred for multiparametric MRI at The Royal Marsden Hospital.
41034182|NCT06636526|PROCEDURE|Prostate Biopsy|Transperineal prostate biopsy under local anaesthetic will be offered to to participants identified in the high-risk category of the i4i PRODICT™ test depending on their MRI results. Where a lesion is visible on MRI (defined as a PIRAD score ≥3) onward referral will be made for a transperineal targeted prostate biopsy (or current gold standard NHS practice).
41034183|NCT04433767|DRUG|Transdermal Nicotine patch|"Participants will begin a 12- week open label trial of transdermal nicotine patch during the day and remove it at night (16 hours). Dose titration starting at 3.5 mg patch/daily to maximum of 21mg patch/daily.~After week 12 , dose will be slowly tapered over 3 weeks."
41378106|NCT03819465|DRUG|Carboplatin|Carboplatin IV Day 1 of each 21-day cycle
41378107|NCT03819465|DRUG|Gemcitabine|Gemcitabine IV Days 1 and 8 of each 21-day cycle
40850891|NCT04558359|DRUG|Angiotensin II|These patients will receive angiotensin II in addition to standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
40850892|NCT02389400|DRUG|methotrexate|Single Group Assignment
40850893|NCT06198517|OTHER|Moxibustion|The experimental group received moxibustion of Zhongji, Guanyuan, and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation, while treated conventionally.
40850894|NCT06198517|OTHER|Symptomatic treatment|The control group received conventional symptomatic treatment.
40850895|NCT00716846|DRUG|simvastatin|10mg, 2 weeks
40850896|NCT00716846|DRUG|atorvastatin|10mg
40850897|NCT00716846|DRUG|pitavastatin|2mg
40850898|NCT04098861|DRUG|Latanoprost/Timolol|Latanoprost/Timolol Fixed Combination
40850899|NCT02973308|OTHER|Observer|Observer A and observer B
41378108|NCT03819465|DRUG|Cisplatin|Cisplatin IV Day 1 of each 21-day cycle
40850900|NCT02728388|DRUG|aminolevulinic acid|"Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements"
41034184|NCT06634888|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|After the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
41378109|NCT03819465|DRUG|Nab-paclitaxel|Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
41378110|NCT03819465|DRUG|AZD2936|AZD2936 IV
41378111|NCT03752866|DEVICE|Portico™ Valve, Portico Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system.
41378112|NCT03752866|DEVICE|Portico™ Valve, FlexNav Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems.
40850901|NCT04317989|OTHER|Practice Facilitation|"1. Implementing evidence-based protocols and the use of clinical algorithms (for screening, counseling, referral, and MAT) to engage the entire clinical team in a high standard delivery of care.~2. Promoting a strong use of decision support tools and templates to support the practice workflow.~3. Optimizing the use of the electronic health record (EHR) to pull clinical data on a monthly basis to guide the change process.~4. Developing patient registries (e.g., for those identified to have AUD) to identify needed care~5. Proactive, team-based care with assigned roles and responsibilities to prepare the clinical team to develop needed care and engage patients throughout the entire visit process.~6. Enhancing the understanding of available counseling and referral resources to ensure that practices are confident that they have appropriate evidence-based intervention options."
41378113|NCT05843253|DRUG|Ribociclib|Ribociclib PO qd on days 1-21
40850902|NCT03402828|DRUG|Any topical drug treatment|Any treatment strategy used to prevent relapse of psoriasis symptoms
40850903|NCT01776866|PROCEDURE|Coronary Angiography|Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
41034185|NCT06634888|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
41378114|NCT05843253|DRUG|Everolimus|Everolimus PO qd on days 1-28
41378115|NCT00997269|DIETARY_SUPPLEMENT|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
41034186|NCT01556113|OTHER|Omega diet|Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
41164524|NCT03167047|DRUG|Standarising intraoperative pain relief|All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
41164525|NCT06008106|DRUG|tunlametinib|12mg BID
41164526|NCT06008106|DRUG|paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin|according to investigators' suggestion
41164527|NCT05191836|BEHAVIORAL|Evaluation of the effectiveness of Video Game Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during watching video game.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
41378116|NCT00997269|DIETARY_SUPPLEMENT|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
41034187|NCT02176135|DRUG|Auranofin|3 mg tablets
41034188|NCT05403762|OTHER|ESENTA™ Skin Barrier Spray (ConvaTec, UK)|The skin protectant will be applied on clean and dry skin exposed to urine and stool. After application, the solvent evaporates leaving a silicone film on the skin surface.
41378117|NCT03074916|DEVICE|DIP arthroplasty or arthrodesis|Arthroplasty of the DIP Joint or arthrodesis of the DIP joint
41378118|NCT06650891|DRUG|Quercetin|oral quercetin prior to surgery
41378119|NCT06650891|OTHER|Placebo|capsule identical looking to quercetin
41378120|NCT06650969|OTHER|Naturalistic observation|Naturalistic observation
41378121|NCT06169176|BIOLOGICAL|RAPA-501 Autologous T cells|Experimental: Intermediate size expanded access cohort. Single-agent RAPA-501 T cells, (80 x 106 cells per infusion; acceptable dose range of RAPA-501 is 20-to-80 x 106 cells per infusion, depending on manufacturing yield)
41378122|NCT05907746|DRUG|Mycophenolate Mofetil|15 mg/kg IV three times per day starting on day +5 until approximately day +30 (+/- 2 days)
41378123|NCT05907746|DRUG|Tacrolimus|0.02 mg/kg IV daily starting on day +5
41378124|NCT05907746|DRUG|Post-Transplant Cyclophosphamide|50 mg/kg IV daily on days +3 and +4
41378125|NCT05907746|RADIATION|Total Body Irradiation|200cGy on day -1
41378126|NCT05907746|PROCEDURE|Hematopoietic Cell Transplant|stem cell transplant on day 0
41378127|NCT05907746|DRUG|JSP191|Single 0.6 mg/kg IV infusion administered between days -13 and day -10
41378128|NCT05907746|DRUG|Cyclophosphamide|14.5 mg/kg IV daily on days -6 and -5; for 7/8 Unrelated or Haploidentical Donor, prior to transplant.
41378129|NCT05907746|DRUG|Fludarabine|30 mg/m2 IV over 30 minutes daily. For 8/8 Matched Related or Unrelated Donor, fludarabine dose will be on days -4, -3, and -2. For 7/8 Unrelated or Haploidentical Donor, fludarabine dose will be on days -6, -5, -4, -3, and -2.
41378130|NCT03079739|DIAGNOSTIC_TEST|fractional flow reserve|assessment with FFR in at least one coronary lesion
41378131|NCT06095089|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
41378132|NCT06095089|DRUG|JNJ-87189401|JNJ-87189401 will be administered.
41378133|NCT06372392|DEVICE|Universal meal coefficient utilization|Usage of universal fixed meal bolus coefficients for the control of postprandial hyperglycemia compared to individualized coefficients n the users of Medtronic Minimed 780G pumps
41378134|NCT04466371|OTHER|Questionnaire|A questionnaire to assess satisfaction with online learning and knowledge about COVID-19
41378135|NCT01030055|DRUG|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
41378136|NCT02825979|PROCEDURE|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
41378137|NCT02825979|DRUG|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
41378138|NCT03467373|DRUG|Glofitamab|Glofitamab will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.
41378139|NCT03467373|DRUG|Obinutuzumab (G)|Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only
41378140|NCT03467373|DRUG|Rituximab (R)|Rituximab will be administered as an IV infusion at a dose of 375 mg/m\^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).
41378141|NCT03467373|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.
41378142|NCT03467373|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 administered IV on Day 1 of each 21-day cycle
41378143|NCT03467373|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle
41378144|NCT03467373|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg
41378145|NCT03467373|DRUG|Prednisone|Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle
41378146|NCT03467373|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg administered IV on Day 1 of each 21-day cycle
41378147|NCT00759226|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
41378148|NCT00759226|DRUG|Cisplatin|Cisplatin 30 mg/m2 (90 min)
41378149|NCT00759226|DRUG|5-FU|5-FU 750 mg/m2 (24h CI)
41034189|NCT05403762|OTHER|Hydrophobes Basisgel DAC|The skin protectant will be applied on clean and dry skin. It contains 95% paraffin oil and creates a hydrophobic layer on the skin surface.
41034190|NCT05496504|OTHER|Holter ECG|
41034191|NCT04642638|DRUG|INO-4800|INO-4800 was administered ID on Day 0 and Day 28.
41378150|NCT00759226|DRUG|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
41378151|NCT06616753|BIOLOGICAL|vaccination status|knowledge of own vaccination status
41378152|NCT06651216|OTHER|Stool analysis|Analysis of infant fecal microbiota
41378153|NCT06651216|OTHER|breast milk analysis|Analysis of the effect of breast milk miRNAs on infant fecal microbiota
41378154|NCT02954874|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41378155|NCT02954874|OTHER|Laboratory Biomarker Analysis|Correlative studies
41378156|NCT02954874|OTHER|Patient Observation|Undergo standard monitoring
41378157|NCT02954874|BIOLOGICAL|Pembrolizumab|Given IV
41378158|NCT02954874|OTHER|Quality-of-Life Assessment|Ancillary studies
41378159|NCT02954874|OTHER|Questionnaire Administration|Ancillary studies
41378160|NCT02954874|RADIATION|Radiation Therapy|Undergo radiation therapy
41378161|NCT05032183|DRUG|Cyclophosphamide|Given IV
41378162|NCT05032183|DRUG|Cytarabine|Given IT
41378163|NCT05032183|DRUG|Dexamethasone|Given IV or PO
41378164|NCT05032183|BIOLOGICAL|Filgrastim-sndz|Given SC
41378165|NCT05032183|DRUG|Leucovorin|Given IV
41378166|NCT05032183|DRUG|Mercaptopurine|Given PO
41378167|NCT05032183|DRUG|Mesna|Give IV
41378168|NCT05032183|DRUG|Methotrexate|Given IT
41378169|NCT05032183|BIOLOGICAL|Pegfilgrastim|Given SC
41378170|NCT05032183|DRUG|Prednisone|Given PO
41378171|NCT05032183|BIOLOGICAL|Rituximab|Given IV
41378172|NCT05032183|BIOLOGICAL|Tagraxofusp-erzs|Given IV
41378173|NCT05032183|DRUG|Vincristine|Given IV
41378174|NCT06652906|DRUG|Sodium phosphate powder|After admission, the patient underwent comprehensive renal function and electrolyte tests. The first medication was taken at 7pm the day before the examination. One bag of sodium phosphate powder was diluted with 800ml or more of warm and cool water before taking. The second dose of medication should be taken at 7am on the day of operation or examination (or at least 3 hours before the examination), with the same usage as the first dose, with a 12 hour interval between each dose. The standard dose for each dose is 1 bag, until clear water like stool appears.
41378175|NCT06652906|DRUG|Polyethylene glycol electrolyte dispersion|After admission, the patient underwent comprehensive renal function and electrolyte examination. The evening before the intestinal examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken, 250ml every 10-15 minutes, and it was taken within 2 hours. On the day of examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken 3-4 hours in advance until clear water like stool appeared.
41034192|NCT04642638|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.
41378176|NCT06561711|DRUG|Vonoprazan|Potassium competitive acid blocker
41378177|NCT06561711|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
41378178|NCT06561711|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
41378179|NCT06561711|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
41378180|NCT03478813|BEHAVIORAL|Voiding school|Children are educated on the kidneys, bladder and bowel function, the importance of regular voiding and drinking habits, and avoidance of constipation. Balloons, books, videos, animations, the pictures of a satisfied and irritated bladder and a poo-cars formula track are used to exemplify the function of urinary and defecation systems. During toilet visits children are given advise about an adequate and relaxed toilet posture with the help of little bench under the feet if needed. Each child also make their own timetable for peeing, pooing, and water drinking times, which they then should learn to follow in day-care, pre-school and at home. At the end of each session child, parent and public health nurse/urotherapist discuss any individual advice and the homework for the next time.
41378184|NCT06650956|OTHER|Integrated HPV and SRH Service Package|"1. Integrated Service Package combines HPV vaccination with sexual and reproductive health (SRH) education. The vaccine in the intervention package is a single dose of recombinant Human Papilloma virus quadrivalent types, 6, 11, 16, and 18.;~2. The package will be delivered through multiple touch-points such as school-based programs, health facility services, and community outreach. i) In school, the intervention incorporates Comprehensive Sexuality Education, empowering boys and girls with knowledge about their bodies, health, and rights. This goes beyond simply providing information about HPV and vaccination. ii) At health facilities, the intervention package will also be delivered in adolescent-friendly ways, ensuring that boys and girls feel comfortable accessing SRH information. iii) Since not all boys and girls attend school, the intervention includes community outreach that ensures wider reach and accessibility for adolescents aged 10-13, including those not enrolled in school."
41378185|NCT06650956|BIOLOGICAL|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|The vaccine itself is not the intervention of interest as this is delivered in both intervention and comparison arms. The vaccine is a single dose of recombinant Human Papilloma Virus Quadrivalent (Types 6, 11, 16, and 18). The administration of the vaccine is an intramuscular injection of 0.5 mili liter of suspension form.
41378186|NCT06651073|OTHER|Observational|There is no intervention involved in the study. It is purely observational.
41378187|NCT06636019|DEVICE|Myopia control contact lens|Myopia control contact lens is placed on the study eye.
41378188|NCT06483334|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion at different dose levels
41378189|NCT06483334|BIOLOGICAL|Enfortumab Vedotin|IV infusion at different dose levels
41378190|NCT06483334|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
40850904|NCT06183333|BEHAVIORAL|Heidelberg Emotion Regulation Training|The four-week intervention program is specifically designed to enhance the participants' emotion regulation. It focuses on developing their skills in accurately recognizing various emotions and effectively applying diverse emotion regulation strategies. To achieve this, the program includes video-based psychoeducation sessions. Alongside these sessions, the program incorporates daily short exercises, each lasting approximately five minutes. These exercises are crafted to help participants practically integrate the concepts and strategies learned from the psychoeducation sessions into their everyday lives. All components of the intervention are accessible through an online platform, ensuring ease of access and flexibility for participants.
40850905|NCT03143504|DIAGNOSTIC_TEST|Skin Testing for Atopic eczema|"FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.~Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.~Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.~Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.~Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema."
40850906|NCT03144986|DEVICE|Deep Insula-coil rTMS|Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
41034193|NCT04642638|DRUG|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.
41034194|NCT04642638|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
41034195|NCT01100164|DRUG|Eszopiclone|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
41034196|NCT01100164|DRUG|Zopiclone|Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
41034197|NCT06307613|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
41034198|NCT06307613|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
41506831|NCT06235827|DIETARY_SUPPLEMENT|Green tean group|Patients in Group A will have to consume two cups (250ml for each cup) of hot green tea, five days per week for 6 months. A tea bag is brewed in 250ml hot water for 3 minutes. They are only allowed to consume as hot drink, not for iced tea. Any sweetener or sugar is not allowed to mix in the drink. The green tea bag will be distributed to patient at beginning of research and at every visit. Patient will be reminded weekly using text messages or phone call by a research assistant for green tea consumption.
40850907|NCT02249039|DRUG|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
40850908|NCT03878758|DEVICE|BD Nano™ PRO|Insulin Pen needle
40850909|NCT03878758|DEVICE|33G Artsana Insupen Extr3me|Insulin Pen Needle
41378191|NCT04629534|DRUG|High dose Cholecalciferol|Mothers in experimental group will receive 6,000 IU of vitamin D in addition to their prenatal vitamin, daily for 3 months. Infants in this group will receive placebo vitamin D drops
40850910|NCT03878758|DEVICE|34G Artsana Insupen Extr3me|Insulin Pen Needle
40850911|NCT03878758|DEVICE|Simple Diagnostics Comfort EZ™|Insulin Pen Needle
40850912|NCT00862056|PROCEDURE|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
41378192|NCT04629534|DRUG|Cholecalciferol|Mothers in placebo control group will receive 600 IU of vitamin D in the form of their prenatal vitamin along with placebo vitamin D. Infants of the mothers in this group will receive standard 400 IU of vitamin D
41378193|NCT03888651|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
41506832|NCT06235827|DIETARY_SUPPLEMENT|Control group|Patients in Group B will not be consuming green tea during 6 months of study period.
40850913|NCT05820984|OTHER|SPIRIT checklist plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (12) Sample size (14) Recruitment (15) Allocation implementation (16 c) Blinding (17 a) Data collection methods (18 a) Data collection methods - retention (18 b) Statistical methods (20 a) Population analysed (20 c) Access to data (29)"
40850914|NCT05820984|OTHER|Usual practice|Peer review as it is usual practice at the journal
40850915|NCT05034250|DIAGNOSTIC_TEST|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, the iron status is determined.
40850916|NCT05268172|DRUG|IFN-γ and CIK cells, Tcm cells or CAR T cells|A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
40850917|NCT05463250|DEVICE|Smartwatch|Wearing a smartwatch and having access to its data
40850918|NCT05722223|COMBINATION_PRODUCT|Trimodal prehabilitation|Pancreatic cancer patients (not stage 4) will undergo trimodal prehabilitation: nutrition, psychological, and exercise support.
41378194|NCT03888651|OTHER|Questionnaire Administration|Complete questionnaire
40850919|NCT01069705|DRUG|Tobramycin inhalation powder|Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.
40850920|NCT04999345|OTHER|Rehabilitation|Progressive resistance exercise and graded aerobic exercise will be provided for those in the experimental group.
40850921|NCT04999345|OTHER|Health education|Health education and gross joint range of motion exercise for bilateral upper and lower extremities will be provided for those in the control group.
40850922|NCT04792411|BEHAVIORAL|Prehabilitation|Multimodal, tailored prehabilitation programme
40850923|NCT05185414|DIAGNOSTIC_TEST|Venipuncture and skin biopsy for RNA extraction|"* Blood sampling (standard venipuncture)~* Skin biopsy (fibroblasts)"
41378195|NCT03835312|PROCEDURE|Sequential transplantation|After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
41378196|NCT02975882|DRUG|Irinotecan Hydrochloride|Given PO
41378197|NCT02975882|OTHER|Laboratory Biomarker Analysis|Correlative studies
41378198|NCT02975882|OTHER|Pharmacological Study|Correlative studies
41378199|NCT02975882|DRUG|Sirolimus Albumin-bound Nanoparticles|Given IV
41378200|NCT02975882|DRUG|Temozolomide|Given PO
41378201|NCT01905813|DRUG|INCB040093|Escalating doses starting at 100 mg every day (QD)
41378202|NCT01905813|DRUG|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
41378203|NCT06085586|OTHER|Early Weight Bearing|Full weight bearing (100%) initiated at 4 weeks postoperatively
41378204|NCT06085586|OTHER|Normal Weight Bearing|Full weight bearing (100%) initiated at 6 weeks postoperatively
41506833|NCT05884944|PROCEDURE|Sham- Light touch, not reaching restrictive barrier|Sham- Light touch, not reaching restrictive barrier For the control group, the subjects hip, knee, and ankle joints will be moved bilaterally 3 times into each plane to mimic the OMM muscle energy treatment. The joint will be moved in each plane of motion without reaching the joint barrier. The hip joint will be moved into adduction, extension, and flexion, the knee joint will be moved into extension and flexion, and the ankle will be moved into plantarflexion and dorsiflexion 3 times in each direction without reaching the barrier passively.
41506834|NCT05884944|PROCEDURE|Experimental: Interventional Group- OMM- Muscle energy|The interventional group will received Osteopathic Manipulative Medicine, specifically Muscle energy treatment. An osteopathic manipulative treatment protocol will be applied to the lower extremity joints bilaterally. Muscle energy technique (MET) will be applied to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated. Muscle energy is a direct active treatment asking the subject to move their joint in a direction against a counterforce by the treatment provider for 3 times for 3 seconds and repeating the procedure 3 times and afterwards a passive stretch to the joint is applied by the provider.
41506835|NCT02016924|DRUG|ATV|Capsules administered once daily according to dosing recommendations per product monograph
41506836|NCT02016924|DRUG|DRV|Tablets administered once daily according to dosing recommendations per product monograph
41506837|NCT02016924|DRUG|Cobicistat|Tablets administered orally once daily with food
40850926|NCT02671097|DRUG|Rosuvastatin|5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
40850927|NCT02671097|DRUG|BAY1841788 (ODM-201)|600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
41164528|NCT05191836|BEHAVIORAL|Evaluation of the effectiveness of Audio Video Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during audio video distraction.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
41378205|NCT05552183|DRUG|oral dose of 200 mg pacritinib twice daily (BID)|Subjects will receive 200 mg BID pacritinib for 14 days.
41378206|NCT04975997|DRUG|Dexamethasone|Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
41378207|NCT04975997|DRUG|Daratumumab|Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7 of a 28-day cycle
41378208|NCT04975997|DRUG|Bortezomib|Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
41378209|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
41378210|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
41378211|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
41378212|NCT06650436|DIAGNOSTIC_TEST|EEG|The phase lag index will be used to assess functional connectivity between time series based on the consistency with which one signal is leading or lagging with respect to another signal.The PLI characterizes the asymmetry in the distribution of instantaneous phase differences between signals. If such an asymmetry is present, a phase coupling is assumed between signals, reflecting synchronized activity. Importantly, zero-phase coupling is discarded in the PLI as this may represent activity from common sources picked up at different electrodes. Based on the MST, network measures can be calculated. It is a measure of network efficiency. Leaf fraction quantifies the fraction of nodes in the whole network that have only one connecting edge, which is a measure of network integration.
41506838|NCT02016924|DRUG|BR|Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).
41506839|NCT02016924|DRUG|F/TAF|Tablets administered orally once daily
41506840|NCT02016924|DRUG|LPV/r|Solution administered orally
41506841|NCT02016924|DRUG|Third Unboosted Drug|ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
41506842|NCT02016924|DRUG|Cobicistat TOS|Tablets for oral suspension
41506843|NCT02016924|DRUG|F/TAF TOS|Tablets for oral suspension
41034199|NCT05819749|BEHAVIORAL|Diabetes Homelessness Medication Support Program in Spanish|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief diabetes education as needed.
41034200|NCT03473886|BEHAVIORAL|Intervention arm: PP-MI|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
41034201|NCT04336215|OTHER|Non-Interventional|This non-interventional study poses no additional risks to people with pre-existing conditions.
41378213|NCT06650436|DIAGNOSTIC_TEST|MRI|"Manual segmentation of the acute ischemic lesion will be performed on MRI of the brain. Support vector regression-based lesion symptom mapping (SVR-LSM) will be performed to determine the association between AIL location and PSD. We will also perform an assumption-free region of interest (ROI)-based analysis by using support vector regression. The ROIs will be determined by the AAL atlas and ICBM-DTI-81 white matter tract atlas in MNI-152 space.~The MRI's will be performed within 72 hours of the stroke onset with a follow-up of 12 months."
41378214|NCT06650436|DIAGNOSTIC_TEST|Depression screening and neuropsychological tests|"Screening post-stroke delirium (during first 72hours after stroke symptom onset):~4AT test score: 0-12 (\>/= 4: diagnosis of (post-stroke) delirium) RASS score: from -5 until +4 Screening post-stroke cognitive impairment (3months, 12 months): MOCA score: 0-30~Screening post-stroke depression:~Patient Health Questionnaire-2: score 0-6 Hospital Anxiety and Depression Scale: score 0-21Anxiety and 0-21Depression"
41378215|NCT06336629|DRUG|Winlevi (clascoterone) 1% & Duac gel|Participants will use Winlevi (clascoterone) 1% and Duac gel as per label
41378216|NCT06465316|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
41378217|NCT06465316|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
41378218|NCT06465316|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
41378219|NCT06465316|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41378220|NCT06465316|DRUG|Iberdomide|Given PO
41378221|NCT06465316|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41378222|NCT06465316|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41378223|NCT06465316|DRUG|Teclistamab|Given SC
41378224|NCT04949256|BIOLOGICAL|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
41378225|NCT04949256|DRUG|Lenvatinib|8 mg QD (induction) or 20 mg QD (consolidation) via oral capsule.
41378226|NCT04949256|DRUG|Cisplatin|80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 75 mg/m\^2 Q3W via infusion, as part of investigator's choice TP chemotherapy.
41506844|NCT02268578|DEVICE|Transcranial Direct Current Stimulation|2mA tDCS
41506845|NCT02268578|PROCEDURE|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
41506846|NCT04220255|DEVICE|Liberty677MY Multifocal IOL|multifocal intraocular lens (IOL)
41378227|NCT04949256|DRUG|5-FU|4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
41378228|NCT04949256|DRUG|Oxaliplatin|85 mg/m\^2 Q2W via IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
41378229|NCT04949256|DRUG|Leucovorin|400 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
41378230|NCT04949256|DRUG|Levoleucovorin|200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
40850928|NCT05691647|BEHAVIORAL|Chronotherapy|Chronotherapy involves three different interventions. Sleep deprivation/wake therapy will be conducted for 34 hours. To assist wake and to ensure that the participants adhere to the sleep deprivation, they will be admitted to a one-night stay at the inpatient ward that is connected to the outpatient clinic at Nidaros DPS. Upon discharge, participants are encouraged to adhere to the sleep schedule which presents the sleep-wake phase advancement and later stabilization of the sleep-wake phase. Light therapy is provided for half an hour every day from day four in the study. In addition to the chronotherapeutic interventions, the participants will receive treatment as usual (TAU) with their assigned therapist.
40850929|NCT05691647|BEHAVIORAL|Treatment as usual|Participants allocated to receive TAU alone, will receive standard treatment for a depressive episode in the outpatient clinic. This study will not give restrictions or guidelines on how this treatment should be performed. The TAU-group will receive the treatment the responsible therapist considers and evaluate best fitting in the situation. Typical interventions administered in therapy for a depressive episode includes medication, cognitive behavioral therapy, and other psychotherapies.
40850930|NCT02577016|DRUG|Sitagliptin|50 mg tablet administered orally
41034202|NCT05198232|BEHAVIORAL|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
41034203|NCT05198232|BEHAVIORAL|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
41034204|NCT00959517|DRUG|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
41378231|NCT04949256|DRUG|Paclitaxel|175 mg/m\^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.
41378232|NCT06649682|DRUG|68Ga-NYM096 PET/CT and 177Lu-NYM096|Patients recruited in this study will undergo 68Ga-NYM096 PET/CT to evaluate the expression of carbonic anhydrase 9. Those with high CA9 expression will undergo 177Lu-NYM096 treatment, starting from 50mCi and increasing to 100mCi, 150mCi, 200mCi at most using a 3+3 design.
41378233|NCT06577090|BIOLOGICAL|Nimacimab injection|Nimacimab injection 200 mg
41378234|NCT06577090|BIOLOGICAL|Nimacimab placebo injection|matching nimacimab placebo injection
41378235|NCT06577090|COMBINATION_PRODUCT|semaglutide injection|semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
41378236|NCT03899220|BEHAVIORAL|Project Matter|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.
41378237|NCT06288932|DRUG|Mycophenolate Mofetil (MMF) Treatment|The addition of Mycophenolate Mofetil to the first line treatment of Immune thrombocytopenia purpura resulted in substantial response and a lower risk of refractory ITP with decreased financial burden and improved outcome.
41378238|NCT06531395|DRUG|Abiprubart|humanized monoclonal antibody
41378239|NCT06531395|DRUG|Placebo|sterile preservative-free solution
41378240|NCT06242262|OTHER|Deep neuromuscular block|Patients will receive deep neuromuscular block by using cis-atracurium. After tracheal intubation for 15 min, a cis-atracurium pump will be started, and its rate will be adjusted to maintain a post-tetanic count (PTC) in the 1-2 range.
41378241|NCT06242262|OTHER|Moderate neuromuscular block|Patients will receive moderate neuromuscular block by using cis-atracurium. Pump delivery of cis-atracurium will be started when the TOF count returned to 2. The TOF count is maintained between 1 and 3 by adjusting the pump rate
41378242|NCT06177626|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day
40850931|NCT02577016|DRUG|Placebo|Placebo to sitagliptin administered orally
41378243|NCT06177626|BEHAVIORAL|Balance Training|Training 5x a week for 30 minutes. Standard of care.
40850932|NCT02577016|DRUG|Ipragliflozin|50 mg tablet administered orally as background medication
41034205|NCT00959517|DRUG|sulphadoxine-pyrimethamine (SP)|
41034206|NCT00959517|DRUG|Chloroquine (CQ)|
41378244|NCT06651463|OTHER|Videorecording|Two cameras will be used to make the recordings: a classic camera placed on a stand 1 meter from your head, outside the sterile area and the color camera of the microscope used for the surgery.
41034207|NCT00959517|DRUG|primaquine (PQ)|
41034208|NCT01734512|DRUG|Everolimus|Everolimus tablet will be taken daily by mouth with water. All patients will be given a dose of 5 mg/m2/dose daily.
40850933|NCT06141291|DIETARY_SUPPLEMENT|High protein diet|Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects.
40850934|NCT06141291|DIAGNOSTIC_TEST|OGTT|Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
41034209|NCT01118208|OTHER|Blister packaging medications|Dispensing prescription medications on pre-filled blister package cards.
41378245|NCT03799445|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41378246|NCT03799445|BIOLOGICAL|Ipilimumab|Given IV
41378247|NCT03799445|BIOLOGICAL|Nivolumab|Given IV
41506847|NCT03514966|BEHAVIORAL|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
41378248|NCT03799445|OTHER|Quality-of-Life Assessment|Ancillary studies
41378249|NCT03799445|OTHER|Questionnaire Administration|Ancillary studies
41506848|NCT03580473|DRUG|SATURNO II association|opthalmic solution, 4 times a day
41506849|NCT03580473|DRUG|Vigadexa®|opthalmic solution, 4 times a day
41506850|NCT00309686|DRUG|Paliperidone ER|
41506851|NCT00847964|DEVICE|Algisyl-LVR|method of left ventricular restoration in patients with dilated cardiomyopathy
40850935|NCT05597553|OTHER|Premixed MTA|The premixed Bio-ceramic putty during setting become hard and expand slightly providing a superior long-term seal
41034210|NCT01118208|OTHER|Dispense as usual|Dispensing prescription medications in standard pill bottles.
41164529|NCT05191836|OTHER|Evaluation of the anxiety in pediatric patients during dental treatment without using any type of distraction aids|"The child will be provided dental treatment without using any type of distraction aids.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
41164530|NCT02825277|DEVICE|Doppler|acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
41164531|NCT04069533|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
41378250|NCT01754805|DRUG|peficitinib|oral
41378251|NCT01754805|DRUG|methotrexate|oral
41378252|NCT06649851|DRUG|Granulocyte Colony Stimulating Factor (G-CSF)|Subcutaneously injected study drug; target dose of 5-7 µg/kg/d.
41506852|NCT01653717|PROCEDURE|Leukapheresis|Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
41506853|NCT01653717|DRUG|Fludarabine|25 mg/m2 by vein on Days -5 to Day -3.
41506854|NCT01653717|DRUG|Cyclophosphamide|250 mg/kg by vein on Days -5 to -3.
41506855|NCT01653717|PROCEDURE|T-cell Infusion|Beginning dose of genetically modified cells is \> 5x10\^7/m2 but less than or equal to 5 x10\^8/m2 infused on Day 0.
40850936|NCT05597553|OTHER|Powder/liquid MTA|Mineral trioxide aggregate (MTA) is a silicate material that is said to aid in faster bridge formation with fewer tunnel defects, less pulpal inflammation, and the maintenance of pulpal integrity. It is widely used in pediatric dentistry due to its excellent sealing properties.
40850937|NCT02583555|BEHAVIORAL|Interview followed by frequent telephone support|Interview followed by telephone support
41378253|NCT06649851|RADIATION|Radiation Therapy + Temozolomide|Standard of care chemoradiation is radiation therapy + Temozolomide (TMZ). Chemoradiation (chemo-RT) includes an initial 6-week cycle, followed by a 4-week break, and up to 6 additional cycles of TMZ.
41378254|NCT05967351|GENETIC|delandistrogene moxeparvovec|No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.
41378255|NCT06456827|OTHER|Bite force and Gcf|"change in bite force will be measured by bite force measuring device at, T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval.~Changes in the following parameters - changes in change in levels of bone turnover markers CTX and BALP using ELISA at T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval"
41506856|NCT04577664|PROCEDURE|total thyroidectomy|a total thyroidectomy (TT) in which the entire gland is removed
41506857|NCT04577664|PROCEDURE|subtotal thyroidectomy|subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams.
41506858|NCT04712279|DRUG|Ivermectin 0.6mg/kg/day|Use of ivermectin 0.6m/kg/day q.d.for 05 days
41506859|NCT04712279|DRUG|Ivermectin 1.0mg/kg/day|Ivermectin 1.0mg/kg/day q.d. for 05 days
41506860|NCT04712279|DRUG|Placebo|Placebo q.d.for 05 days
41506861|NCT04712279|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg/day q.d. for 05 days
41506862|NCT00101283|DRUG|pemetrexed disodium|500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
41506863|NCT00101283|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
41506864|NCT00101283|DRUG|carboplatin|Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
41378256|NCT06650813|OTHER|Drépa-FACETS Program|Drépa-FACETS Program for Sickle Cell Disease
41378257|NCT06649786|PROCEDURE|Endoscopic superior rectal mucosal ligation|The patient takes the left side decubitus position, the endoscope is connected with 6 serial ligators, the cup of the sleeve is pointed at the upper edge of the straight anal line and the rectal mucosa is continuously aspirated under negative pressure. The mucosa enters the sleeve and sees a full-screen red sign. The sensing loop is successfully triggered, indicating that the loop is complete.
41378258|NCT06649786|PROCEDURE|Endoscopic hemorrhoid ligation|The patient takes the left side decubitus position,the endoscope is connected with 6 serial ligators,the cup the sleeve is aligned with the base of the hemorrhoid (above the dentate line) for continuous negative pressure suction.The hemorrhoid enters the sleeve and sees a full-screen red sign. Turn the handle of the sleeve clockwise and feel that the loop is successfully triggered, the ligature is completed.
41378259|NCT04303169|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
41378260|NCT04303169|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
41378261|NCT04303169|BIOLOGICAL|Gebasaxturev|Administered via IT injection at a specified dose on specified days
41378262|NCT04303169|BIOLOGICAL|MK-4830|Administered via IV infusion at a specified dose on specified days
41378263|NCT04303169|BIOLOGICAL|Favezelimab + Pembrolizumab|Administered via IV infusion at a specified dose on specified days
41378264|NCT04303169|DRUG|ATRA|Administered via oral capsules at a specified dose on specified days
41378265|NCT06335173|DRUG|sabirnetug|Intravenous sabirnetug
41378266|NCT06335173|DRUG|Placebo|Intravenous Placebo
41378267|NCT06513312|DRUG|Lenacapavir Injection|Administered subcutaneously
41378268|NCT06513312|DRUG|Lenacapavir Tablet|Administered orally
41378269|NCT06513312|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
41378270|NCT06113237|DRUG|Epidiolex|Oral solution
41378271|NCT05117242|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV)
41378272|NCT05117242|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV
41506865|NCT03697031|DRUG|Follitropin Delta|"The Intervention (solution for injection) is delivered with an injection pen. For women with AMH \<15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH ≥15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms.~For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms."
41506866|NCT04619212|DEVICE|breast pumping as per SoC but on new software for the pump|breast pumping as per SoC but on new software for the pump
40850938|NCT05878951|DRUG|OnabotulinumtoxinA|Intra-detrusor OnabotulinumtoxinA is commonly known as botox
40850939|NCT04294147|DRUG|Galcanezumab|Administered SC
41378273|NCT05946629|DEVICE|PCI with SELUTION SLR DCB|After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.
41378274|NCT05946629|DEVICE|"PCI with FDA approved -limus DES"|"For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.~The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain \< 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B."
41378275|NCT03635021|DRUG|FOLFOX regimen|oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
41378276|NCT03635021|DRUG|Panitumumab|6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle
41378277|NCT03635021|DRUG|Bevacizumab|5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle
40850940|NCT04294147|DRUG|Erenumab|Administered SC
40850941|NCT04338971|DEVICE|IpsiHand Therapy|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of hometherapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
40850942|NCT06393179|OTHER|pressure-volume curve with a low-flow insufflation of 5 L/min|The patient undergoes a pressure-volume curve with a low-flow insufflation of 5 L/min while in a state of analgesia, sedation, and absence of spontaneous breathing.
40850943|NCT05663957|DRUG|Evusheld|EVUSHELD users
40850944|NCT00407303|DRUG|Obatoclax mesylate|30 mg, 45 mg
40850945|NCT00407303|DRUG|Bortezomib|1.0mg/m2, 1.3 mg/m2
40850946|NCT04794075|OTHER|Therapeutic Education and Nursing Support Program for Supportive Care|"In addition to the conventional oncology follow-up, patients will participate in an initial educational assessment day within 15 days before or after their first dose of hormone therapy.~A discussion between the patient and the pivot nurse will then make it possible to define personalized objectives, thus guiding the choice of workshops in the outpatient educational program."
41378278|NCT03635021|DRUG|FOLFIRI regimen|irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
41378279|NCT06649214|DRUG|Olanzapine-samidorphan；|orally once daily, tablet, 10mg/10mg、15mg/10mg or 20mg/10mg，duration of 24 weeks.
41378280|NCT06649214|DRUG|Olanzapine|orally once daily, tablet, 10mg、15mg or 20mg，duration of 24 weeks.
41378281|NCT06650865|OTHER|Traditional Exercise Group|"It is important for the therapist to organize a exercise program to provide pain control. The exercise program should be specific and clear to the patient.~Exercises will be applied to this group. The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
41378282|NCT06650865|OTHER|Baduanjin Exercise Group|"In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
41378283|NCT06650865|OTHER|Telerehabilitation Group|"Baduanjin exercise will be applied simultaneously with the telerehabilitation method. In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
41378284|NCT05551936|DRUG|Bendamustine|90 mg/m\^2 IV Days 1-2, Cycles 1-3
41378285|NCT05551936|DRUG|Rituximab|375 mg/m\^2 IV Day 1 Cycles 1-6
41378286|NCT05551936|DRUG|Tazemetostat|RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6
41378287|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 3Gy per day for up to four days and as little as one day
41378288|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
41378289|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.
41378290|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
41378291|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 6Gy per day for up to four days and as little as one day
41378292|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
41378293|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days
41378294|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
41378295|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 9Gy per day for up to four days and as little as one day
41378296|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
41378297|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days
41378298|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
41378299|NCT06522360|DRUG|Brigatinib|Given by mouth
41378300|NCT06522360|DRUG|Carboplatin|Given by mouth
41378301|NCT06522360|DRUG|Pemetrexed|Given by vein
41378302|NCT01321970|PROCEDURE|Stress ultrasound|Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
41378303|NCT01321970|PROCEDURE|Scintigraphy|Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
41378304|NCT01321970|PROCEDURE|Coronary angiography|"Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:~* Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)~* Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)~* Circumflex (proximal, middle and distal) and collateral (first and second marginal)"
41378305|NCT05879315|OTHER|Fall risk prevention in hospital|All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
41378306|NCT04891445|BEHAVIORAL|Nursing monitoring program|A clinical pathway will be activate that allows all the necessary interventions, once the person is diagnosed, to be carried out on the same day, and a mental health nursing team will monitor the entire process.
41506867|NCT05536999|OTHER|Blood sample taking , like to measure hormonal level like LH, FSH, Perlakan ,in a follicular fluid after the oocyte retrival|Blood test measure basal FSH, follicular fluid testing
41506868|NCT02035358|BIOLOGICAL|HyperAcute®-Renal (HAR) Immunotherapy|"HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.~Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization."
41034211|NCT06205511|DIAGNOSTIC_TEST|Oral HPV Sample|The study participant will be asked to provide an oral swish and spit sample. This sample collection will follow the procedure published by (Herrero et al 2013). The specimen is collected by a 15-second rinse followed by a 15-second gargle using 15 ml of an alcohol-based mouth wash such as a commercially available product, Scope. The 15-ml samples will then be stored at -20 and then shipped on dry ice to Dr. Anna Giuliano's laboratory in Tampa Florida for HPV testing. At present Dr. Giuliano's laboratory is using the DDL SPF10 LiPA assay for sample analysis. An oral exam will be performed for each patient by the Vivent Dentist within 30 days of the collection of the HPV sample. If a referral is needed to an oral surgeon or Ears, Nose, and Throat specialist this will be done within 60 days of the dentist visit. The HPV results will not be shared with the participants as these are research study results and not part of standard of care.
41034212|NCT02658643|PROCEDURE|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
41034213|NCT02658643|PROCEDURE|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
41506869|NCT02132806|PROCEDURE|Piezosurgery with biomaterial mp3 + bracket|
41506870|NCT02132806|PROCEDURE|Piezosurgery with biomaterial mp3|
41506871|NCT02132806|PROCEDURE|Piezosurgery|
41506872|NCT00324220|DRUG|MGCD0103|MGCD0103 Oral administration 3 times per week.
41506873|NCT04683016|OTHER|Questionnaires|"Patients will be asked two sets of questions:~* questionnaire about their perception of periodontal disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire.~All these two sets of questions will be asked before and after non surgical periodontal therapy"
41506874|NCT05164783|COMBINATION_PRODUCT|Sanacoach Parkinson (SCP)|A web-based monitoring tool for patients with PD, using questionnaires. It includes nine parts: 1) A 89-question, quarterly questionnaire about PD-symptoms. 2) Questionnaire responses are converted to scores on 16 PD-related domains. Both the current score and the score's change compared to the previous questionnaire are visible. 3) An interim evaluation is sent after 6 weeks with questions on any domains where a patient indicated problems. 4) A medication monitor can be initialized by the treating physician to evaluate the effect of a therapeutic change. 5) A consultation preparation module allows patients to indicate which topics they want to discuss during an outpatient visit. 6) Patients can ask for 'calling advise' if they are unsure whether to contact their physician. 7) Patients and healthcare providers can send each other text messages. 8) Interactive learning modules about PD. 9) Annual evaluation regarding patient satisfaction, self-management and healthcare consumption.
41506875|NCT04402840|PROCEDURE|Stellate Ganglion Block|The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.
41506876|NCT02108912|OTHER|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
41506877|NCT02108912|OTHER|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
41506878|NCT05022212|DRUG|LACTIN-V|administered vaginally
41506879|NCT05022212|DRUG|Placebo|administered vaginally
40850947|NCT05986773|DRUG|Furosemide|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
40850948|NCT05986773|DRUG|Metolazone|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
41034214|NCT02165150|OTHER|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
41034215|NCT00658346|DRUG|Treatment initiation for HIV-1 group O infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
41164532|NCT01795521|RADIATION|Stereotactic Body Radiotherapy (SBRT)|A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
41506880|NCT03498495|BEHAVIORAL|Self-Monitoring Activity-restriction and Relaxation Training (SMART)|SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
41034216|NCT00658346|DRUG|Treatment initiation for HIV-1 group M infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
41378307|NCT04891445|BEHAVIORAL|As usual|Referral to the family doctor for a request for follow-up by the gastroenterologist. The specialist prescribes the tests for the definitive diagnosis that will take place in other units (with their corresponding appointments). After this, the patient will return to the specialist to establish the treatment to follow. Pharmacological treatment will be dispensed at the hospital pharmacy (collected once a month until completion of treatment and confirmation of cure). This last step of the treatment will be done in a new consultation at the gastroenterology service after blood tests to verify the disappearance of the viral load.
41378308|NCT05546515|DRUG|Suvorexant (dual orexin receptor antagonist)|Participants will be prescribed up to 30 days of SUVO.
41378309|NCT05546515|DRUG|Placebo|Participants will be prescribed up to 30 days of placebo medication.
41378310|NCT06340750|BIOLOGICAL|LMY-920|CAR T Therapy
41378311|NCT06649370|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|If the patients' mean arterial pressure falls below 60 mmHg or 20% below the preoperative value, ephedrine will be administered.
41378312|NCT04114461|DRUG|HL-TOF tab. 5mg|HL-TOF
41378313|NCT04114461|DRUG|Xeljanz tab. 5mg|Xeljanz
41378314|NCT03174457|DRUG|Micafungin|Intravenous
41378315|NCT06336603|DRUG|Winlevi (clascoterone) 1% & Adapalene 0.3% gel|Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD)
41378316|NCT04512105|DRUG|Pitavastatin|Given PO
41378317|NCT04512105|DRUG|Venetoclax|Given PO
41378318|NCT05467748|DRUG|Tulmimetostat|combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer
41378319|NCT00338377|BIOLOGICAL|Dendritic Cell Immunization|1x10\^7 to 2.5x10\^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
41378320|NCT00338377|DRUG|Cyclophosphamide|60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
41378321|NCT00338377|DRUG|Fludarabine|25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
41378322|NCT00338377|BIOLOGICAL|T-Cells|On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.
41378323|NCT00338377|BIOLOGICAL|Interleukin-2|12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
41034217|NCT04780204|DRUG|Treatment|Tenofovir Alafenamide 25 mg oral once daily
41034218|NCT03808662|RADIATION|Sterotactic Body Radiotherapy/SBRT|In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
41378324|NCT00338377|DRUG|Mesna|60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
41378325|NCT00338377|BIOLOGICAL|Intrathecal T-Cells|5.0x10\^9 T-cells administered on Day 1, and 10x10\^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.
41378326|NCT00338377|BIOLOGICAL|Intrathecal Interleukin-2|1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
41034219|NCT03808662|DRUG|Standard of care|Standard of care per physician discretion
41034220|NCT06635395|OTHER|Scale validity and reliability|The aim of this study is to adapt the Baltimore Orthopedic Subscapularis Score (BOSS) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 5 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
41034221|NCT02486224|DIETARY_SUPPLEMENT|Kona Deep|Subjects will receive Kona Deep post exercise
41034222|NCT02486224|DIETARY_SUPPLEMENT|Spring Water|Subjects will receive Spring Water post exercise
41034223|NCT02486224|DIETARY_SUPPLEMENT|Sports Drink|Subjects will receive Sports Drink post exercise
41378327|NCT05248919|DRUG|Epclusa (nucleotide HCV NS5B polymerase inhibitors).|Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
41378328|NCT06487182|OTHER|reiki|reiki
41378329|NCT06487182|OTHER|placebo reiki|placebo reiki
41378330|NCT05901636|BIOLOGICAL|INFLUENZA G1 mHA|INFLUENZA G1 mHA will be administered intramuscularly.
41034224|NCT06038565|DEVICE|RAM cannula ventilator CPAP|RAM cannula ventilator CPAP
41378331|NCT05901636|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly.
41378332|NCT05901636|BIOLOGICAL|Al(OH)3|Al(OH)3 will be administered intramuscularly.
41378333|NCT06370884|DRUG|IMT|a feeding tube placed at the time of surgery and receive IMT solution on postoperative day 2-3 (at least 48 hours following IV antibiotics) with the subsequent removal of the feeding tube.
41378334|NCT03233191|PROCEDURE|Digital Mammography|Undergo DM
41378335|NCT03233191|PROCEDURE|Digital Tomosynthesis Mammography|Undergo TM
41378336|NCT03233191|OTHER|Laboratory Biomarker Analysis|Correlative studies
41378337|NCT06395103|BIOLOGICAL|Zilovertamab vedotin|Administered via IV infusion
41378338|NCT06650241|OTHER|Behavioral therapy|
41378339|NCT06650241|OTHER|Lip Bumper Therapy|
41378340|NCT06650241|OTHER|Modified Twin-Block Therapy|
41378341|NCT06466187|DRUG|SGN-MesoC2|Given into the vein (IV; intravenously)
41378342|NCT04754529|OTHER|Quality-of-Life Assessment|Ancillary studies
41378343|NCT04754529|OTHER|Survey Administration|Ancillary studies
41378344|NCT04754529|OTHER|Yoga|Receive yoga intervention
41378345|NCT03958045|COMBINATION_PRODUCT|Rucaparib and Nivolumab|Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
41034225|NCT06038565|DEVICE|Occlusive interface bubble CPAP|Occlusive interface bubble CPAP
41034226|NCT06157931|BEHAVIORAL|Resilient Student Training intervention (ReST)|ReST consists of one individual 60-minute session and two 90-minute group-based sessions.
41378346|NCT04396860|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced brain MRI
41506881|NCT03830372|DEVICE|VR Tier One|"10 sessions of 20 minutes virtual terapeutic game~Thanks to using VR googles and the phenomenon of total immersion VR Tier One terapy game allows to completely separate the patient from the hospital environment and provides an intense visual, auditory and kinesthetic stimulation. Depending on the stage of therapy it can have a calming and mood-improving effect or it can motivate and cognitively activate the patient. The additional aim of the game is to help the patients regain their emotional balance, let them recognize their resources in order to bring them to power in the rehabilitation process and trigger the natural recovery mechanisms."
41506882|NCT03830372|OTHER|Control|10 sessions of 20 minutes of Schultz Autogenic Training
41506883|NCT03006302|DRUG|Epacadostat|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.
41506884|NCT03006302|DRUG|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.
41506885|NCT03006302|BIOLOGICAL|CRS-207|CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.
41506886|NCT03006302|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m\^2) will be administered IV on day 1 of Cycles 1 and 2.
41506887|NCT03006302|BIOLOGICAL|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). GVAX will be administered on Day 2 of Cycles 1 and 2.
41378347|NCT04396860|BIOLOGICAL|Ipilimumab|Given IV
41378348|NCT04396860|BIOLOGICAL|Nivolumab|Given IV
41378349|NCT04396860|DEVICE|NovoTTF-100A Device|Wear Optune device
41506888|NCT04474990|DRUG|Tradipitant|NK-1 Receptor antagonist
41506889|NCT02433314|DRUG|SAGE-547|
41506890|NCT00996892|DRUG|Cobimetinib|Repeated oral dosing.
41506891|NCT00996892|DRUG|Pictilisib|Repeated oral dosing.
41506892|NCT02682927|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
41506893|NCT02682927|DRUG|Matching Placebo|Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
41506894|NCT05704751|DEVICE|spinal cord stimulation|EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients
41506895|NCT02972190|PROCEDURE|Bilateral decompression with TLIF|Bilateral decompression of neural elements combined with TLIF
41506896|NCT02972190|PROCEDURE|laminectomy with PLIF|Decompression of neural elements using laminectomy combined with PLIF
41506897|NCT02972190|DEVICE|Pedicle screw and interbody cage|Pedicle screw and interbody cage
41164533|NCT05850182|BEHAVIORAL|Lifestyle intervention|12-week lifestyle intervention including adherence to a personalized balanced dietary regimen (low total fat, low saturated fat, high ω3 fatty acids, optimized protein content, low simple sugars) combined with regular physical activity (including physiotherapy sessions and self-training).
41378350|NCT04396860|OTHER|Quality-of-Life Assessment|Ancillary studies
41378351|NCT04396860|OTHER|Questionnaire Administration|Ancillary studies
41378352|NCT04396860|RADIATION|Radiation Therapy|Undergo radiation therapy
41378353|NCT04396860|DRUG|Temozolomide|Given PO
41378354|NCT06500975|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Continuously motion-modulated stimulation delivered by a vestibular implant already implanted under a prior study protocol (Labyrinth Devices MVI™ Multichannel Vestibular Implant System)
41378355|NCT00139243|DRUG|Taxotere|
41378356|NCT00139243|DRUG|Cisplatin|
41378357|NCT00139243|DRUG|5-Fluorouracil|
41506898|NCT00028977|DRUG|herba scutellaria barbata|
41506899|NCT00028977|OTHER|herba scutellaria Barbatae (HSB)|
41378358|NCT00139243|DRUG|Leucovorin|
41034227|NCT03111927|OTHER|Infant Formula: enriched level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
41034228|NCT03111927|OTHER|Infant formula: standard level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
41378359|NCT06650917|BEHAVIORAL|the experiment group were treated acupoint massage combined with ear point pressing beans|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~Patients in the experiment group were treated with auricular point pressing on basis if the treatment of the control group. Selecting 10 acupoints including Tanzhong, Tiantu, Dingchuan(both sides), Feishu(both sides), Yuji(both sides), and Lieque(both sides), and massage each acupoint for about 3 minutes. Acupoint massage once a day from Monday to Friday, lasting for 30 minutes each time. Selecting the Fengxi(both sides), Lung(both sides), Bronchial(both sides), and Shenmen(both sides) acupoints on the ear for ear point pressing beans. The operator rubs the above acupoints with their hands for about 5 minutes, and then performs ear point pressing beans on these 4 acupoints. The ear point pressing beans is performed once a day from Monday to Friday."
41378360|NCT06650917|BEHAVIORAL|the control group were treated with acupoint massage|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~On this basis, patients in the control group were treated with acupoint massage."
41378361|NCT06650839|DEVICE|NIUT|Treatment of moderate aortic stenosis using non-invasive ultrasound therapy delivered by Valvosoft
41378362|NCT06405152|OTHER|Chart review|Retrospective Chart Review
41378363|NCT05874544|DRUG|Vonoprazan|Proton pump inhibitor
41378364|NCT05874544|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
41378365|NCT05874544|DRUG|Tetracycline|Antibiotics for H. pylori eradication
41378366|NCT05874544|DRUG|Metronidazole|Antibiotics for H. pylori eradication
41378367|NCT05874544|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
40850949|NCT05986773|DRUG|Acetazolamide|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
40850950|NCT03845738|DEVICE|OsseoSpeed EV implant|The investigational product (OsseoSpeed EV implant) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
41034229|NCT01292603|DRUG|Cyclophosphamide|Days 1-3 or Days 1-5 of cycles 1-6
41034230|NCT01292603|DRUG|Fludarabine|Days 1-3 or Days 1-5 of cycles 1-6
41378368|NCT05874544|DRUG|Rifabutin|Antibiotics for H. pylori eradication
41378369|NCT06649812|PROCEDURE|Biopsy|Undergo optional tumor biopsy
41378370|NCT06649812|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41378371|NCT06649812|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
41378372|NCT06649812|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
41378373|NCT06649812|PROCEDURE|Computed Tomography|Undergo CT
41378374|NCT06649812|DRUG|Ibrutinib|Given PO
41378375|NCT06649812|DRUG|Lenalidomide|Given PO
41378376|NCT06649812|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41506900|NCT01613430|BEHAVIORAL|Coach Training (COACH)|"Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening."
41506901|NCT01613430|BEHAVIORAL|Printed Educational Materials (PEM)|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
41034231|NCT01292603|DRUG|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
41034232|NCT01292603|DRUG|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
41034233|NCT01292603|DRUG|rituximab [MabThera]|6 cycles of intravenous MabThera
41378377|NCT06649812|BIOLOGICAL|Obinutuzumab|Given IV
41378378|NCT06649812|PROCEDURE|Positron Emission Tomography|Undergo PET
41506902|NCT02204085|DRUG|GO-203-2c|
41034234|NCT01808157|DRUG|CT327 ointment|
41034235|NCT01808157|DRUG|placebo|
41378379|NCT06649812|DRUG|Prednisone|Given PO
41378380|NCT06649812|DRUG|Venetoclax|Given PO
41378381|NCT05477953|DRUG|Nifurtimox (BAYA2502)|At least 1 dose of nifurtimox
41378382|NCT04708782|DRUG|Placebo|Placebo administered QID
41378383|NCT04708782|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
41378384|NCT04708782|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
41506903|NCT02204085|DRUG|GO-203-2c + Decitabine|
41506904|NCT02369302|DRUG|DWC20141|Tablet
41506905|NCT02369302|DRUG|DWC20142|Tablet
41506906|NCT02369302|DRUG|DWC20141, DWC20142|Tablet
41034236|NCT02341716|PROCEDURE|WA|Walk advice with Nordic Poles and best medical treatment
41034237|NCT02341716|PROCEDURE|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
41034238|NCT02341716|PROCEDURE|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
41034239|NCT01237639|OTHER|Red blood cell Transfusion|Transfusion of Red blood cells to based on daily complete blood count
41034240|NCT01141192|DIETARY_SUPPLEMENT|vitamin D3, cholecalciferol|1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
41034241|NCT01141192|DIETARY_SUPPLEMENT|Inactive comparator|The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
41034242|NCT03667053|DRUG|dasiglucagon|glucagon analog
41034243|NCT03667053|DRUG|placebo|placebo for dasiglucagon
41034244|NCT03667053|DRUG|GlucaGen HypoKit|native glucagon
41164534|NCT05940714|BEHAVIORAL|Video participants|Showing a video of oral hygiene intructions
41378385|NCT03387423|DRUG|Tofacitinib|Patients who are started on Tofacitinib treatment according to the drug label
41378386|NCT06650904|OTHER|simulation based training|Simulation practice enables the acquisition of realistic skills. Semi-structured scenarios used in the training allow nurses to demonstrate their real communication skills.
40850951|NCT04358965|DRUG|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
41378387|NCT03914625|DRUG|Asparaginase Erwinia chrysanthemi|Given IV or IM
41378388|NCT03914625|BIOLOGICAL|Blinatumomab|Given IV
41378389|NCT03914625|DRUG|Cyclophosphamide|Given IV
41378390|NCT03914625|DRUG|Cytarabine|Given IT or IV
41034245|NCT05306327|DIAGNOSTIC_TEST|electroencephalography (EEG)|"1. brain cortical activity using full scalp~2. cerebral blood flow velocity~3. during the dying process following planned withdrawal of life sustaining measures (WLSM)"
41164535|NCT04262778|DIAGNOSTIC_TEST|electrochemical skin conductance measurement|electrochemical skin conductance measurement
41378391|NCT03914625|DRUG|Dexamethasone|Given PO or IV
41378392|NCT03914625|DRUG|Doxorubicin Hydrochloride|Given IV
41378393|NCT03914625|DRUG|Leucovorin Calcium|Given PO or IV
41378394|NCT03914625|DRUG|Mercaptopurine|Given PO
41506907|NCT05608473|OTHER|Posture Exercises|A 10-minute video consisted of 14 cervical and thoracal postural exercises was uploaded to the computers of the participants. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
40850952|NCT04358965|DRUG|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
40850953|NCT04358965|DRUG|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
41034246|NCT00003011|DRUG|marimastat|10 mg PO BID
41034247|NCT00003011|DRUG|Placebo|10 mg PO BID
41164536|NCT05426447|OTHER|Dietary intervention of reduced protein intake|6-wk dietary intervention of reduced protein intake
41378395|NCT03914625|DRUG|Mercaptopurine Oral Suspension|Given PO
40850954|NCT01718444|DRUG|Progestin|
40850955|NCT01718444|DRUG|Clomiphene Citrate|
40850956|NCT02116088|BEHAVIORAL|Teacher Coaching|
40850957|NCT00556816|BEHAVIORAL|on demand clinic|Outpatient on demand clinic
40850958|NCT00556816|BEHAVIORAL|Control|conventional outpatient clinic
40850959|NCT06575374|DRUG|Letermovir|Given by mouth or intravenously
40850960|NCT00255528|DRUG|metoprolol succinate|
40850961|NCT03368846|DRUG|Varlitinib|\[14C\]-Varlitinib
41378396|NCT03914625|DRUG|Methotrexate|Given IT or IV
41378397|NCT03914625|DRUG|Pegaspargase|Given IV or IM
41378398|NCT03914625|DRUG|Prednisolone|Given PO or IV
41378399|NCT03914625|DRUG|Prednisone|Given PO or IV
41378400|NCT03914625|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
41378401|NCT03914625|RADIATION|Radiation Therapy|Undergo testicular radiation therapy
41378402|NCT03914625|DRUG|Thioguanine|Given PO
41378403|NCT03914625|DRUG|Vincristine Sulfate|Given IV
41506908|NCT00537511|DRUG|Pomalidomide|
40850962|NCT04988009|OTHER|Electronic Health Record Review|Review of medical chart
40850963|NCT04988009|OTHER|Survey Administration|Complete survey
41034248|NCT03921268|DRUG|AZD1402|AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
41034249|NCT05864794|DIAGNOSTIC_TEST|MRI|MRI scan of the brain
41034250|NCT01839734|DRUG|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
41378404|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via open contest|PrEP campaign messages will be developed via an open contest in Baltimore.
41378405|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via social marketing approach|PrEP campaign messages developed with a traditional social marketing approach.
41378406|NCT04387656|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41378407|NCT04387656|OTHER|Data Collection|Undergo collection of medical information and imaging
41378408|NCT04387656|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
41378409|NCT04387656|OTHER|Questionnaire Administration|Complete quality of life questionnaires
41378410|NCT04111939|OTHER|Communities That HEAL|The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
41378411|NCT04111939|OTHER|Wait-list control|Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
40850964|NCT05463523|DEVICE|A Real-time Augmented Reality Device with Artificial Intelligence Integration|Patients are diagnosed and treated with the assistance of artificial intelligence, augmented reality and new optical imaging technology, which is different from traditional model.
41164537|NCT05426447|OTHER|Dietary intervention of normal protein intake|6-wk dietary intervention of normal protein intake
41164538|NCT03065478|DIETARY_SUPPLEMENT|OnLife|Daily dosing of dietary supplement OnLife
41164539|NCT00381888|DRUG|fondaparinux sodium|Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
41164540|NCT03781947|DRUG|teverelix TFA|A single s.c. or i.m. injection of teverelix TFA administered on Day 1
41164541|NCT01037413|DRUG|EXC 001|Multiple intradermal injections of EXC 001 and placebo
41164542|NCT01037413|DRUG|Placebo|Multiple intradermal injections of EXC 001 and placebo
41164543|NCT00668785|DRUG|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
41164544|NCT06173232|DEVICE|Camera Imaging|Camera Imaging
41164545|NCT03100136|DRUG|[11C]PF-06809247|PET Tracer
41378412|NCT04637815|BEHAVIORAL|Motivational Network Intervention|Every 2 weeks, residents attend meetings with their case manager. These meetings are customized to the needs of the resident at the time of the meeting. Participants randomized into the Motivational Network Intervention arm are offered an additional discussion about their social networks. Case managers ask participants to answer a series of standardized questions about people they know. After these questions are answered, case managers show participants a series of images representing these answers. While showing these images, case mangers engage the participant in discussions about what they notice using Motivational Interviewing techniques. The goal is to discuss what the participant wants to change and state strategies about achieving these changes.
41378413|NCT04637815|OTHER|Usual Care|Residents attend regular case management meetings with their case managers as a condition of their residency in the housing program. These sessions are customized do the needs of the resident at the time of the meeting. Participants randomized into the usual care arm will be offered these sessions every 2 weeks.
41378414|NCT00526929|DRUG|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
41378415|NCT05322200|RADIATION|A computerized tomography (CT) coronary angiogram|Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.
40850965|NCT04341948|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
41378416|NCT05322200|PROCEDURE|Vicorder (Skidmore medical, UK)|Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.
41378417|NCT05322200|OTHER|Blood tests for inflammation and oxidative stress markers|All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
41378418|NCT06653556|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
41378419|NCT05468489|DRUG|Serplulimab + chemotherapy (carboplatin-etoposide)|"Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~Drug: carboplatin and etoposide chemotherapeutics"
41378420|NCT05468489|DRUG|Atezolizumab + chemotherapy (carboplatin-etoposide)|"Drug: Atezolizumab is a monoclonal antibody targeting PD-L1，developed by Roche Pharma AG.~Drug: carboplatin and etoposide chemotherapeutics"
40850966|NCT06514404|OTHER|observational study|Observational study of the effects on anxiety and empathy of personality the situation of start academic year in health sciences
41164546|NCT03228953|OTHER|Pharmacogenomic testing|Pharmacogenomic testing is delivered to treating providers of patients with major depressive disorder
41378421|NCT02930538|OTHER|Survey|Completing a survey on RedCap
41506909|NCT00537511|DRUG|Cisplatin|
41034251|NCT05509413|DEVICE|DEFLAGYN vaginal gel|DEFLAGYN is a vaginal gel, classified as a medical device, containing silica and citric acid, which binds pathogens, inhibits their spread and exerts an antioxidant effect. It is applied intravaginally (through an applicator) and used for 3 months.
41506910|NCT00537511|DRUG|Etoposide|
40850967|NCT06577415|DRUG|RAY1225|Administered SC
40850968|NCT01023672|DRUG|Armodafinil|150-250 mg armodafinil by mouth daily
41034252|NCT00010218|DRUG|karenitecin|
41034253|NCT06636552|DRUG|Daratumumab (Subcutaneously)|"D-PAD (21-Day Cycles 1, 3 and 5):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycles 1 and 3) 1,800 mg (Q3W) SC on day 1 (for Cycle 5)~D-CVD (21-Day Cycles 2, 4, 6, 7 and 8):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycle 2) 1,800 mg (Q3W) SC on day 1 (for Cycles 4, 6, 7 and 8)~Daratumumab monotherapy (28-Day Cycles 9 to 32):~1,800 mg (Q4W) SC on day 1"
41034254|NCT01932164|PROCEDURE|maxillary alveolar graft by tissue engineering|Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells;
41034255|NCT01932164|PROCEDURE|Bone tissue engineering using mesenchymal stem cells|Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.
41034256|NCT05773859|BIOLOGICAL|XP-DC vaccinations|Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH
41034257|NCT01438866|OTHER|Fissure sealant|Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
40850969|NCT03631017|DRUG|[18F]- PARPi|injection of a microdose (\< 100 ug) of \[18F\]- PARPi
40850970|NCT03631017|DIAGNOSTIC_TEST|PET/CT Scans|"Patients will be injected with approximately 10 mCi of \[18F\]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use ultra -low dose CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings."
41378422|NCT03330275|DEVICE|Investigational Contact Lens|JJVC senofilcon A-based contact lens with new UV-blocker
41378423|NCT03330275|DEVICE|Commercial ACUVUE OASYS|senofilcon A
41378424|NCT03330275|DEVICE|Commercial ACUVUE OASYS and Spectacles|Senofilcon A and Spectacles
41378425|NCT06650488|DRUG|Clopidogrel|Patients will change from aspirin to clopidogrel (without loading dose)
41034258|NCT01438866|OTHER|Fissure sealants and fluoride varnish|Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
41378426|NCT06650488|DRUG|Aspirin|Patients will continue their existing aspirin.
41378427|NCT01389856|DRUG|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
41034259|NCT02872259|DRUG|BGB324+pembrolizumab|Combination
41378428|NCT01389856|DRUG|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
41378429|NCT05980949|DRUG|KarXT|KarXT 20/2 mg TID (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
41378430|NCT06541756|PROCEDURE|Fibrine Clot-augmented Meniscal Repair|The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The fibrin clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.
41378431|NCT06541756|PROCEDURE|Conventional Meniscal Repair|Patients in the standard repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures.
41506911|NCT04581330|DEVICE|DEKA SmartXide C02 laser|One pass with a 1-mm spot density and a 60 micron depth will be performed followed by a 1-mm spot density and a 200 micron depth will be used
41506912|NCT04740697|OTHER|Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.|"Each included patient will be referred to the health care staff for a blood sample:~* for the determination of the residual plasma concentration of tamoxifen and its active metabolites,~* for the constitution of a biobank.~Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...)."
41378432|NCT06641271|DEVICE|Closed Loop Trans-Auricular Vagus Nerve Stimulation System|A closed loop system that delivers stimulation to the vagus nerve via the ear non-invasively following a trigger event.
41378433|NCT06641271|DEVICE|Placebo|A closed-loop vagus nerve stimulation device that can deliver sham stimulation to the ear to simulate stimulation of the vagus nerve.
40850971|NCT05651815|DEVICE|Graphene spectrum light wave therapy room|Undergo 30-min of graphene adjuvant therapy every day for 7 d.
41378434|NCT02903095|DRUG|TD-1439|
41378435|NCT02903095|DRUG|Placebo|
41378436|NCT06652633|GENETIC|GLPG CAR T-cell therapy|No investigational products will be administered to participants in this study.
41378437|NCT03533829|DEVICE|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
41506913|NCT03959111|OTHER|Stimulation at Location 1|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
40850972|NCT03333629|BEHAVIORAL|Enhanced early detection|standardized screening
40850973|NCT00996983|DRUG|ziconotide|intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
41034260|NCT02872259|DRUG|BGB324+dabrafenib and trametinib|Combination
41034261|NCT02872259|DRUG|pembrolizumab|Monotherapy
41034262|NCT02872259|DRUG|dabrafenib and trametinib|Combination
41034263|NCT03386123|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia|Continuous maintenance of sleep diary, cognitive behaviour therapy, including cognitive restructuring, and behavioural change focusing on sleep restriction and safety behaviours.
41164547|NCT05757778|PROCEDURE|Sensory Nerve Coaptation|Nerve reconstruction will employ an off-the-shelf nerve graft coapted to the donor anterior intercostal nerve branch laterally and medially at the underside of the nipple. The anterior intercostal nerve branch and nerve graft coaptation will be performed in a standard fashion with a 1 mm gap between the ends of the graft and the donor nerve. Medially, the nerve graft will be inset into the underside of the preserved nipple-areola complex using 8-0 or 9-0 epineural stitches from the nerve allograft. All nerve coaptations will be performed under loupe magnification as is standardly performed.
41378438|NCT03533829|BEHAVIORAL|Music|Music will be selected and listened to as a distraction before and during vaccination.
41378439|NCT04179578|PROCEDURE|Crura plastic|Closure of hiatus with a running suture
41378440|NCT04883892|PROCEDURE|BMAC|"patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months.~During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability"
41378441|NCT04883892|PROCEDURE|HA|patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.
41378442|NCT02452008|DRUG|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
41506914|NCT03959111|OTHER|Stimulation at Location 2|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
41506915|NCT02934243|DEVICE|laryngeal mask insertion|airway management with laryngeal mask
41506916|NCT00259233|DRUG|peripheral Peptide YY administration|
41506917|NCT00321178|DRUG|SR4 - switch to CR4|switch to oral treatment after 4 weeks SR 'standard' therapy
40850974|NCT04688229|DEVICE|Hummingbird hand training device plus standard of care rehabilitation|The Hummingbird is a comprehensive hardware and software platform that isolates the hand, wrist, and forearm in a neutral and comfortable position, allowing linear force and angular torque to be measured at the finger-tips between 0-10 Newtons at milli-newton resolution at 100 Hz per digit, in 5 degrees of freedom simultaneously, in real-time, for all 5 digits. The platform allows isolating and characterizing fine resolution forces with sufficient sensitivity and resolution to record data in severe paralysis. The platform also comprises therapeutic software to train exploratory, individuated, and inter-digit complex finger movements by coupling force and torque output to NeuroAnimation physics-based virtual interface in engaging therapeutic experiences.
40850975|NCT04688229|OTHER|Comparison (sham) intervention|During each hour of sham therapy the therapist will select cognitive tasks (e.g. puzzles and games) targeted to a level of difficulty based on the subjects ability. No grasping or object manipulation using the target upper limb will be included in this intervention. Rather, the participant will use either the unaffected limb (or non-targeted limb for SCI subjects) as needed for any particular puzzle or game.
40850976|NCT05800912|OTHER|Narrative photography|"Students were shown real-life written stories, audio, and videos using a private online platform. The training activity included four modules: i) heart transplantation waiting list; ii) life expectancy, fear of death, and organ rejection; iii) post-transplant physical and functional limitations; and iv) lack of knowledge of physical exercise patients can perform.~The students were encouraged to think about how they would feel if they had undergone heart transplantation. Afterward, they had to communicate these feelings using up to three photographs and reflective explanatory text.~Two weeks later, the students met a heart transplantation expert patient followed by an educator-guided debate. Students' images were shared and discussed. Moreover, students were encouraged to explain their feelings and their acquired skills (two hours)."
41034264|NCT03386123|BEHAVIORAL|Standard Audiological Care|Maintenance of sleep diary at key times. Psycho-education, provision of bedside sound generator.
41506918|NCT06501677|BEHAVIORAL|WBI|"The WBI will comprise of four sessions focusing on CRAFT principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to the DP (PPR; i.e., actively listening, showing understanding, expressing interest in what their DP is thinking and feeling, and trying to see where the DPs is coming from), (3) understanding the DP's drinking reinforcers, and (4) supporting the DP if they want help and engaging in positive, healthy activities with the DP. ' partner.~Each module will take \~20-30 minutes and each session will: (1) instill optimism in CPs, (2) be solution-focused, (3) emphasize that the CP is not responsible for the DP's behaviors, and (4) use a nonjudgmental, non-confrontational, empathetic style. The WBI intervention is focused on reduced drinking in the DP and improved CP wellness."
41506919|NCT02447146|OTHER|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
41034265|NCT03386123|BEHAVIORAL|Sleep Support Group|Maintenance of sleep diary at key times. Social support focused on tinnitus and sleep problems.
41034266|NCT00146952|DEVICE|Vibrotactile feedback|
41034267|NCT01782989|DRUG|ORACEA®|ORACEA® (40mg doxycycline) capsule daily for 24 months
41034268|NCT01782989|DRUG|Placebo|Placebo capsule daily for 24 months
41164548|NCT05207098|OTHER|Neurocognitive Tests|Baseline only: WRAT Reading Test, WMS-IV Logical Memory Subtest, Hopkins Verbal Learning Test (HVLT), Oral Trailmaking - Part A and B, NAB Digit Span, Category Fluency Test, Oral Symbol Digit Modalities Test, Brief Test of Attention, FAS - Controlled Oral Word Association Test (COWAT), Verbal Naming, Enformia Cogsuite Battery
41378443|NCT02452008|DRUG|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
41034269|NCT06636500|DRUG|CG001419|Oral doses
41034270|NCT06636500|DRUG|Placebo|Oral doses
41378444|NCT04358822|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after specific time intervals
41378445|NCT02998372|PROCEDURE|patellar stabilization|surgery to either alter soft tissues around the patella or reorient the patellar tendon to restore patellar stability
41378446|NCT04842448|DRUG|Hyperbaric oxygen|Hyperbaric oxygen 240 kPa for 90 minutes (with 10 min compression time, 2 air bakes and 10 minutes decompression time).
41378447|NCT04842448|PROCEDURE|Sham treatment|Sham treatment 134-120 kPa Air (with 5 min compression time, and 5 min decompression to 120 kPa, two air brakes will be reported to the subjects)
41378448|NCT06260358|OTHER|Survey|"MRI examinations will be performed on 1.5T or 3T scanners, with protocol according to ESUR guidelines.The contextual structured report will be generated by the investigators in consensus.~In every centre, one report (structured or narrative) will be generated from various radiologists experienced in gynaecologic imaging during clinical practice. Two radiologists in consensus, will develop the second version (narrative or structured report)."
41378449|NCT05156866|DRUG|TORL-2-307-ADC|antibody drug conjugate
41378450|NCT04843891|DRUG|[64]Cu Macrin|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
41378451|NCT00795210|DRUG|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
41378452|NCT00795210|DRUG|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
41378453|NCT06136403|DRUG|deucravacitinib|treatment by deucravacitinib in two phases of challenge
40850977|NCT05800912|OTHER|Traditional learning|"A participatory lecture was carried out, in which cardiac rehabilitation in heart transplantation patients was explained. Then, there was an educator-guided debate about protocols and actions (one hour).~Second, the students autonomously prepared clinical cases on physical limitations, physical exercise, risk factors, and life after transplantation (two hours).~Two weeks later, the clinical session was held among students (2 hours). They adopted the roles of physical therapists or transplant patients to work on: i) post-transplant physical and functional limitations; ii) lack of knowledge of the physical exercise the patient can perform; iii) control of cardiovascular risk factors; iv) life post-transplant."
41378454|NCT01142388|BIOLOGICAL|Cixutumumab|Given IV
41378455|NCT01142388|OTHER|Laboratory Biomarker Analysis|Correlative studies
41378456|NCT01142388|DRUG|Paclitaxel|Given IV
41378457|NCT01142388|OTHER|Pharmacological Study|Correlative studies
41378458|NCT00940329|DRUG|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
41378459|NCT00940329|DRUG|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
41378460|NCT02435875|OTHER|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
41378461|NCT03519152|DRUG|low dose diclofenac|it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
41506920|NCT02447146|OTHER|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
41506921|NCT05870618|BIOLOGICAL|vaccinate with DTap|vaccinate with DTap
40850978|NCT01068769|DRUG|regorafenib|Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
40850979|NCT06578065|DEVICE|Echelon Circular™ Powered Stapler|Echelon Circular™ Powered Stapler will be used in colorectal anastomosis.
41378462|NCT05427214|DEVICE|Halcyon 4.0 system|During each of the 1 or more imaging sessions, no more than 6 images total will be acquired. Only 5 images total across all of the imaging sessions will be used toward the study endpoint.
41378463|NCT04619758|OTHER|Emollient (sunflower oil)|In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
41378464|NCT03699722|BEHAVIORAL|Education + Activities|Format:Video; discussion; information handouts; facilitated referral
41378465|NCT03699722|BEHAVIORAL|Information|Format: Information handouts
41378466|NCT04785027|DRUG|PSORI-CM01 formula|PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
41378467|NCT04785027|DRUG|Gu Ben Hua Yu formula|Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
41378468|NCT04785027|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg
40850980|NCT06578065|DEVICE|2-row circular staplers manual|2-row circular staplers manual will be used in colorectal anastomosis.
40850981|NCT02783599|DRUG|Olaratumab|Administered IV
40850982|NCT02783599|DRUG|Doxorubicin|Administered IV
40850983|NCT02783599|RADIATION|External Beam Radiotherapy|
41378469|NCT04450316|DRUG|Naltrexone|4.5mg tab (low-dose) nightly
41378470|NCT04450316|DRUG|Placebo|1 tab nightly
41378471|NCT02261558|OTHER|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
41378472|NCT02261558|OTHER|Clinical Vocal Improvisation|\* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
41378473|NCT03879135|BIOLOGICAL|rVWF|Recombinant von Willebrand factor
41378474|NCT03879135|BIOLOGICAL|rFVIII|Recombinant Factor VIII
41378475|NCT06467305|DEVICE|continuous theta-burst stimulation (cTBS)|Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.
41378476|NCT06467305|BEHAVIORAL|Adaptation|Auditory adaptation in speech
41378477|NCT05014139|DRUG|Enfortumab vedotin|Given into the bladder (intravesically)
41378478|NCT05966155|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
41378479|NCT05966155|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
41378480|NCT06650644|OTHER|Placebo of Lactococcus lactis KD10|"* Food Name: Placebo of Lactococcus lactis KD10~* Ingredients: Natural pigment enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Dosage period and route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
41506922|NCT05870618|BIOLOGICAL|vaccinate with DT|vaccinate with DT
41506923|NCT05019287|BIOLOGICAL|Allogeneic human menstrual blood stem cells secretome|This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.
41506924|NCT05019287|OTHER|Intravenous saline injection|Intravenous saline injection in addition to standard care
41506925|NCT05607420|BIOLOGICAL|UCART20x22|Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
41506926|NCT05607420|BIOLOGICAL|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
41506927|NCT03490578|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The gait robot provides an auditory feedback according to gait cycle and a visual feedback on the patient's active participation. If the patient can tolerate, the gait robot may control the walking speed automatically according to the patient's participation. The treatment time per session is 45 minutes including don and doff time. Total 12 sessions are provided for 4 weeks.
41506928|NCT03490578|DEVICE|Intensive treadmill training|Patients exercise on the treadmill. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The therapist provides appropriate visual and auditory instructions to allow the patient to participate in the treadmill training. The treatment time per session is 45 minutes including warm-up and cool-down. Total 12 sessions are provided for 4 weeks.
40850984|NCT06238804|PROCEDURE|KL, Iliofemoral, Ilioinguinal, Iliac fossa and combined approaches|A3.1, A3.2, A3.3
40850985|NCT06010511|OTHER|3T MRI scan|Conventional (3T) brain MRI scans will be used to determine global and functional markers of cerebral SVD, like WMH volume and presence of lacunes, microbleeds and superficial siderosis (3D T1, 3D FLAIR, SWI, DWI), hemodynamics (arterial spin labelling \& flow territory mapping) and white matter structural integrity (diffusion tensor imaging (DTI)). Furthermore, we want to measure structural integrity with a novel MR fingerprinting sequence and an inhomogeneous magnetization transfer (ihMT) MRI scan. We also want to apply a fMRI scan technique to measure CSF fluctuations in the 4th ventricle as a measure of brain glymphatics. Also the flow-territory mapping sequence is a non-standard sequence. Heart rate and respiratory signal will be measured during the scans (3T and 7T MRI) with standard vendor-supplied equipment.
41378481|NCT06650644|DIETARY_SUPPLEMENT|Lactococcus lactis KD10 (health food)|"* Food Name: Lactococcus lactis KD10 (health food)~* Ingredients: Freeze-dried Lactococcus lactis enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Administration Period and Route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
41378482|NCT03382561|DRUG|Carboplatin|Given IV
41378483|NCT03382561|DRUG|Cisplatin|Given IV
41378484|NCT03382561|DRUG|Etoposide|Given IV
41378485|NCT03382561|BIOLOGICAL|Nivolumab|Given IV
41378486|NCT06217822|DRUG|225Ac-PSMA-Trillium (BAY3563254)|Intravenous slow injection on Day 1 of a 6 week treatment cycle.
41506929|NCT03299582|DEVICE|Hypothermia|Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
40850986|NCT06010511|OTHER|7T MRI scan|Ultra-high field (7T) brain MRI scans will be used to determine WMH shape and other markers of cerebral SVD in or surrounding the WMH, like local enlarged perivascular spaces, (cortical) microinfarcts and microbleeds (T1, T2, FLAIR and T2\*) and vascular pulsatility (phase contrast MRI). Moreover, a recently implemented MRI technique to measure glymphatic flow in perivascular spaces will be used.
41378487|NCT06217822|DRUG|Tris-POC (BAY2688901)|0.5 mg/mL (7.5 mg/vial), i.v slow injection, Tris-POC will be administered approximately 15 minutes prior to the second dose of the 111In-PSMA-Trillium imaging agent.
41378488|NCT06217822|DRUG|111In-PSMA-Trillium (BAY3632687)|111In dose of 185 MBq (5 mCi) ± 10% and PSMA-Trillium-DOTA peptide dose of approximately 0.05 to 0.08 mg (approximately 0.04 mg if dosed the day after manufacture), slow intravenous injection bolus followed by 10 mL flush of normal saline
41378489|NCT02439801|PROCEDURE|PEEP 0|0 cmH2O positive end expiratory pressure
41378490|NCT02439801|PROCEDURE|PEEP 5|5 cmH2O positive end expiratory pressure
41378491|NCT02439801|PROCEDURE|PEEP 8|8 cmH2O positive end expiratory pressure
41506930|NCT03299582|DEVICE|Cryocompression|Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
40850987|NCT06010511|BEHAVIORAL|Neuropsychological assessment|"* Mini-mental state examination~* Clock drawing~* 15-Word Verbal Learning Test, immediate and delayed~* Visual Association Test~* Stroop Color Word Test, 40 item version~* Trail Making Test A\&B~* Letter Digit Substitution Test~* Animal fluency test~* Hospital anxiety and depression scale~* Informant Questionnaire on Cognitive Decline in the Elderly"
41378492|NCT01262391|DRUG|Solifenacin succinate suspension 2.5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.
41378493|NCT01262391|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
41378494|NCT01262391|DRUG|Solifenacin succinate suspension 10 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.
41378495|NCT06001736|PROCEDURE|Contralateral C7 root transfer for the treatment of spastic hemiparesis.|Performing surgery to transfer the C7 nerve to treat stroke patients experiencing spastic hemiparesis.
41378496|NCT06651060|BEHAVIORAL|Menu label|Participants will view a sample of items from a restaurant menu, displayed with labels
41378497|NCT00433511|BIOLOGICAL|Bevacizumab|Given IV
41378498|NCT00433511|DRUG|Cyclophosphamide|Given IV
41378499|NCT00433511|DRUG|Doxorubicin Hydrochloride|Given IV
41378500|NCT00433511|OTHER|Laboratory Biomarker Analysis|Correlative studies
41378501|NCT00433511|DRUG|Paclitaxel|Given IV
41378502|NCT00433511|OTHER|Placebo Administration|Given IV
41378503|NCT00433511|OTHER|Quality-of-Life Assessment|Ancillary studies (closed as of 5/28/10)
41378504|NCT06063954|OTHER|electroacupuncture|Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin.
41506931|NCT02488954|OTHER|Probiotics in the form of cheese portion|
41506932|NCT02695784|DIETARY_SUPPLEMENT|Probiotic Continuation|This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
41378505|NCT06650020|OTHER|synchronous online learning|Each participant in this cohort selected a suitable and peaceful learning environment, characterized by ample lighting and strong network connectivity. Equipped with laptops, participants logged into the Tencet conference software ten minutes prior to the session, entered their authentic names, completed the sign-in process five minutes before the course started, and kept their cameras activated throughout the session. During the instructional phase, both the teacher and control group were physically present. While the teacher instructed the control group, screen sharing through Tencet conference software allowed trainees in the experimental group to have clear visual access to instructional materials while audibly receiving instruction through microphones.
41378506|NCT06650020|OTHER|the traditional offline model of centralized training|The control group adhered to the traditional offline model of centralized training, which involved a training facility spanning 100 square meters and accommodating seating for 150 participants. The front section of the training room was equipped with various amenities, such as a projection screen, podium, computer, and microphone, all available for use by the instructors. Throughout the training period, the lecturer provided in-person instruction on-site, allowing trainees to engage in real-time interaction by raising their queries.
41378507|NCT06650592|OTHER|All patients who were candidates for immediate lymphatic reconstruction (ILR)|All patients who were candidates for immediate lymphatic reconstruction (ILR)
41378508|NCT04756466|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
41378509|NCT04756466|DIETARY_SUPPLEMENT|Lactobacillus|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
41378510|NCT03984448|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41378511|NCT03984448|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41378512|NCT03984448|PROCEDURE|Computed Tomography|Undergo CT scan
41378513|NCT03984448|DRUG|Cyclophosphamide|Given IV
41378514|NCT03984448|DRUG|Doxorubicin Hydrochloride|Given IV
41378515|NCT03984448|DRUG|Etoposide|Given IV
41506933|NCT05788432|DEVICE|Sequent Please Neo|Patients in whom treatment with (Sequent Please Neo) has been attempted
41506934|NCT04774497|OTHER|Oxygen inhalation treatment group|Oxygen inhalation group: oxygen inhalation was started on the first day of chemotherapy, and the oxygen inhalation volume was 2 L / min, 8 hours / day for 3 consecutive days.
41378516|NCT03984448|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
41378517|NCT03984448|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41378518|NCT03984448|DRUG|Prednisone|Given PO
41378519|NCT03984448|BIOLOGICAL|Rituximab|Given IV
41378520|NCT03984448|DRUG|Venetoclax|Given PO
41378521|NCT03984448|DRUG|Vincristine Sulfate|Given IV
41378522|NCT06426316|BIOLOGICAL|Blood test|1 blood test of maximum 40 millilitres per patient
41378523|NCT05365581|DRUG|ASP2138|Intravenously or Subcutaneously
41506935|NCT04774497|OTHER|Control group|The control group was not given oxygen inhalation.
41506936|NCT02569190|DEVICE|Walkbot|Robot assisted gait training
41506937|NCT02796638|DEVICE|Adaptive Servo-Ventilation|A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.
41506938|NCT05676515|OTHER|culture media|spliting of biological material and use of three culture media
41378524|NCT05365581|DRUG|Pembrolizumab|Intravenously
41506939|NCT02645331|BEHAVIORAL|Remind-to-move|
41506940|NCT02645331|BEHAVIORAL|Modified constraint induced movement therapy|
41506941|NCT02645331|BEHAVIORAL|Conventional rehabilitation|
41506942|NCT02193217|DRUG|MT-1303-Low|
41506943|NCT02193217|DRUG|MT-1303-High|
41506944|NCT02193217|DRUG|Fingolimod|
41506945|NCT02193217|DRUG|Placebo|
41506946|NCT02564887|DEVICE|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
41506947|NCT01970774|OTHER|MTM with PGx|Patients will attend MTM sessions and receive PGx testing
41506948|NCT03552848|BIOLOGICAL|MSC|MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times
41378525|NCT05365581|DRUG|Oxaliplatin|Intravenously
41378526|NCT05365581|DRUG|Leucovorin|Intravenously
41378527|NCT05365581|DRUG|Fluorouracil|Intravenously
41378528|NCT05365581|DRUG|Ramucirumab|Intravenously
41378529|NCT05365581|DRUG|Paclitaxel|Intravenously
41378530|NCT05365581|DRUG|Irinotecan|Intravenously
41378531|NCT05677763|DRUG|OM-85|Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)
41378532|NCT05677763|DRUG|Placebo|Subjects will be administered Placebo once daily. (10 days per month)
41506949|NCT01772485|BEHAVIORAL|Cognitive Training|The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.
41506950|NCT01772485|BEHAVIORAL|Active Control|Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
41506951|NCT02892929|BEHAVIORAL|Motivational interviewing|"The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change."
41506952|NCT02892929|BEHAVIORAL|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
41506953|NCT03127514|DRUG|AMX0035|AMX0035
41034271|NCT04553952|OTHER|Measurement of gingival display|"All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all."
41378533|NCT06649175|OTHER|Exercise|"Close kinetic chain (CKC) exercises :~1. Supine wall push exercise: Start position: supine with the both leg against wall, other limb straight. Exercise action: push against wall for thirty seconds.~2. Wall push against Swiss ball exercise: Start position: Supine with a Swiss ball between patient's legs and the wall. Exercise action: push against the wall for thirty seconds.~3. Supine half bridging exercise: Start position: Lying on back, knees bent Exercise action: keeping spine neutral and hinging up from the hips, move into a bridge."
41034272|NCT01495767|OTHER|Filling in a psychometric questionnaire|Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
41034273|NCT03808675|BEHAVIORAL|Aerobic walking|The investigators will use self-administered continuous walking exercise at a moderate intensity level, defined as 40-59% of heart rate reserve or 64-77% of heart rate at gas exchange threshold (HRGET) by ACSM as in the investigators' preliminary study (PMID: 24991037 PMCID: PMC4132568). The HRGET will be determined as the heart rate at VO2max during graded cycle ergometry. The total duration of the exercises will be 150 min/week per 2008 Physical Activity Guidelines for Americans and American Heart Association recommendations, conducted in three 50 min sessions. The aerobic walking intervention will take place outdoors (e.g., trails, sidewalks, parks) or indoors (e.g., track in a local gym or a mall) depending on the preferences of the subject and weather. Session duration will be 20 min the first week and will be advanced by 5 min per week over 6 weeks.
41034274|NCT03808675|BEHAVIORAL|Usual care with PD specific health education|"In this study, patients will receive their usual medical treatment for motor and non-motor symptoms from their~primary neurologist. The investigators will use a streamlined form of PD specific health education prepared by the VA: My Parkinson's Story, which consists of a series of short videos prepared by the VA PADRECCs addressing various aspects of PD. These 6-12 minutes long videos are freely available on YouTube. The investigators can also provide them on a CD if subjects desire. They start with a patient testimony about the topic of the episode, followed by comments of experts in the field. The title of the episodes are: Early Parkinson's, Medications, Exercise, Memory, Visual Disturbances, Depression, Sleep, Speech and Swallowing, Impulsive Behaviors, Driving, Pain, Dyskinesias, Deep Brain Stimulation, Advanced Parkinson's Disease, Falls, The Caregiver, Hospitalization, Genetics, Environmental Exposure, Atypical Parkinsonism"
41378534|NCT06649175|OTHER|Exercise|"Control Group (A): will receive the traditional physical therapy (PT) , the traditional physical therapy program will include the following:~* Stretching exercise for shortening muscle of lower limbs (LL) mainly (hip flexors, adductors, knee flexors and ankle planter flexors).~* Balance training from standing while giving perturbations.~* Balance board training.~* Step ups: repeated stepping anteriorly and laterally onto a step with both legs alternatively, progressing to higher step and decreasing upper extremity support.~* Forward and backward walking (with or without handheld mobility devices).~* Side walking (with or without handheld mobility devices).~* Walking in astride line (with or without handheld mobility devices)."
41378535|NCT06642662|DIAGNOSTIC_TEST|Somascan 5.0|This observational study will test patient plasma using the SomaScan platform, a highly multiplexed proteomic tool that uses SOMAmers (Slow Off-rate Modified Aptamers) to bind with high specificity and affinity to preselected proteins to quantify levels. SomaScan v5.0 quantifies 10,778 clinically relevant human proteins, with several thousand proteins linked to inflammation and immune system functions, across a wide range of concentrations (\>10 logs) with high sensitivity (\<1 pg/mL) and reproducibility (median coefficient of variation \< 5%). Individual protein concentrations are transformed into a corresponding SOMAmer concentration and quantified using a DNA microarray read-out.
41378536|NCT06647693|BEHAVIORAL|Motor Synchrony Games (MSG)|"The motor synchrony games (MSG) intervention uses fun but progressively more challenging gross motor and imitation games to promote behavioral self-regulation. Primary activities include: songs and fingerplays, stop and go games, and imitation games. These games get progressively more challenging over time by varying signal/modality. For example, going from a verbal and gestural paired stop and go signal to only a gestural stop signal. A fidelity checklist is used to ensure the intervention is appropriately used with the following criteria (uses \>10 imitation trials, \>10 Stop \& Go games, \>3 trials/min on average with \>5 trials/min preferred, use of progressive challenge, opportunities for Child Choice, environmental arrangement, and therapeutic strategies such as modeling)."
41378537|NCT00018343|DRUG|estrogen|
41378538|NCT05614102|DRUG|BAY2965501|Daily oral application
41506954|NCT03127514|OTHER|Placebo|Matching Placebo Comparator
41506955|NCT01180426|DRUG|CHR-2797|120mg once daily oral for 48 weeks
41034275|NCT01640158|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 65 hours
41034276|NCT01640158|OTHER|Commercially available computerized training|Commercially available computerized training, up to 65 hours
41378539|NCT05614102|DRUG|Pembrolizumab|In combination group 200mg as infusion every 3 weeks
41378540|NCT05396833|DRUG|Tuvusertib|Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
41378541|NCT05396833|DRUG|Lartesertib|Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
41506956|NCT01422980|OTHER|1- Test dairy product containing specific ingredients|
41506957|NCT01422980|OTHER|2- Control dairy product without specific ingredients|
41506958|NCT03608397|BIOLOGICAL|DaxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
41506959|NCT03608397|BIOLOGICAL|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
41034277|NCT00223418|DRUG|aripiprazole|
40850988|NCT06010511|OTHER|General baseline data|"Baseline data, such as age, sex, psychiatric comorbidity and medication lists will be extracted from the patient files.~Age (Year of birth); Years of education; BMI (height \& weight); Sex; Verhage scale (education); Smoking status; Blood values; Sleep habits; Waste-hip ratio; Blood pressure; Current/general cardiovascular health; Psychiatric comorbidity; medical history related to cardiovascular health."
40850989|NCT03316703|PROCEDURE|Conventional open surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the conventional open approach (group A)."
40850990|NCT03316703|PROCEDURE|Minimally invasive percutaneous surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the minimally invasive percutaneous approach (group B) according to allocation after randomization."
40850991|NCT03938506|OTHER|cuff pressure of the endotracheal tube|The endotracheal intubation will be performed after the anesthetic induction. The cuff will be inflated using the air by the palpation method. The cuff pressure of the endotracheal tube will be measured using the manometer.
40850992|NCT02523573|PROCEDURE|Adult ARF ICU patients needing BAL with HFNC|bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
40850993|NCT03219684|DIAGNOSTIC_TEST|serum protein ,kidney function ,liver function.,serum cholesterol|monthly review of serum protein kidney function ,liver function and serum cholesterol in all patients
40850994|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
41164549|NCT05207098|OTHER|Questionnaires|Sociodemographics, Computerized Cognitive Training Programs Questionnaire, CDC Behavioral Risk Factor (Smoking Assessment), Alcohol Consumption CDC, Current Health Rating (KPS), OARS Physical Health section, COVID Medical History, Hospital Anxiety and Depression Scale (HADS), Fatigue Symptom Inventory (FSI), Functional Assessment of Cancer Therapy-General (FACT-G V4), Functional Assessment of Cancer Therapy-Cognition (FACT-Cog V3), Sensory Gating Inventory (SGI)
41164550|NCT02552810|DEVICE|Steam clean|Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).
41164551|NCT02552810|DEVICE|Plasma of Argon|Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
41164552|NCT02617433|DEVICE|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
41506960|NCT06435910|BIOLOGICAL|DC vaccines|Antigen-presenting and immune modifying DCvacs to treat MM
40850995|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
40850996|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
40850997|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
40850998|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
41164553|NCT05101083|DEVICE|New Receiver-in-Canal Device|Successor of previous device generation
41164554|NCT05101083|DEVICE|Legacy Receiver-in-Canal Device|Receiver-in-canal device available on the market
41164555|NCT01820221|PROCEDURE|Suture vs. staples closure method after c-section in obese women.|Random card draw to either suture skin closure or staple skin closure arm of study.
41164556|NCT02191527|DEVICE|PIMA® for quantitative analysis of CD4-count|
41164557|NCT02191527|DEVICE|Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|
41164558|NCT02191527|DEVICE|SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis|
41164559|NCT04279756|OTHER|Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch|Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
41164560|NCT03545178|BEHAVIORAL|glucose control (Substudy A)|Comparison of glucose values during days 0 - 3 with days 4 - 28 and 0 - 7 with days 8 - 28 before a medical consultation at the diabetes clinic in patients suffering from diabetes and wearing a continuous glucose monitoring and/or flash glucose monitoring device
41164561|NCT03545178|DIAGNOSTIC_TEST|hypoglycemia prediction (Substudy B)|Use of CGM/FGM data to develop and evaluate a neural network based hypoglycemia prediction model
41164562|NCT04241887|PROCEDURE|thoracic paravertebral blockade|Anesthesia was performed under the ultrasound guidance: the Th8 spinous process was identified, then a probe was moved lateral to medial until two adjacent transverse processes and the pleura were visible. After anaesthetising the skin with 2ml of 1% lignocaine (Lignocainum hydrochlorici, WZF 1%), the Touhy needle 22G (Smith Medical)was introduced under the real time guidance. Once in the paravertebral space, 20ml of 0,25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa Warsaw SA) was injected with an end point of a characteristic pleural displacement.
41164563|NCT04241887|PROCEDURE|local anaesthesia|Local infiltration anaesthesia with 0.5% lignocaine 5ml (Lignocainum hydrochlorici, WZF 1%) was applied to the skin and the potential needle path of ablation.
41164564|NCT02380638|DEVICE|Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.|
41164565|NCT02692287|DEVICE|The PPH Butterfly|The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
41378542|NCT05396833|DRUG|Avelumab|Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
41164566|NCT01713998|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
41378543|NCT05712603|DIAGNOSTIC_TEST|FIB4-score|A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
41378544|NCT05712603|DIAGNOSTIC_TEST|Vibration controlled transient elastography|VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
40850999|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
40851000|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
40851001|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
40851002|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
40851003|NCT06560151|BIOLOGICAL|3.75 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
40851004|NCT06560151|BIOLOGICAL|7.5 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
40851005|NCT06560151|BIOLOGICAL|15 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
41164567|NCT04546659|OTHER|Retrowalking|Treatment of retro-walking including supervised 10 min retro-walking training with 5 min of warm-up and cool down on a flat surface at their comfortable speed
40851006|NCT03964324|DIAGNOSTIC_TEST|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
40851007|NCT06379776|OTHER|Education through a 3D model|Training through a 3D model of the spine fractures
40851008|NCT06379776|OTHER|Education through a traditional pedagogical support|Training through a traditional pedagogical support
41164568|NCT04546659|OTHER|Conventional Therapy|Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
41164569|NCT01998997|BEHAVIORAL|Family educational intervention|The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
41164570|NCT04584216|OTHER|Steam Eye Mask with acupoints stimulation|A participant needs to use SEM with acupoints stimulation once a day for 10 days and use hands to massage the acupoints on the eyebrows for the first 3 minutes, total application time at least for 20 minutes.
41164571|NCT04584216|OTHER|Steam Eye Mask|A participant needs to use SEM once a day for 10 days, total application time at least for 20 minutes.
41164572|NCT06478108|DEVICE|IRSW-MIM|IRSW-MIM collects patient's data and outputs a therapeutical strategy for treating advanced solid tumors.
41164573|NCT02954796|DRUG|SGN-CD352A|On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
41164574|NCT00618917|GENETIC|Manganese Superoxide Dismutase Plasmid Liposome|15 ml of liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
41164575|NCT00618917|DRUG|carboplatin|Chemotherapy to stop the growth of tumor cells.
41164576|NCT00618917|DRUG|paclitaxel|Chemotherapy to stop the growth of tumor cells. This drug kills tumor cells by inducing multipolar divisions. Cells entering mitosis in the presence of concentrations of paclitaxel equivalent to those in human breast tumors form abnormal spindles that contain additional spindle poles.
41164577|NCT00618917|RADIATION|Radiation Therapy|1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
41164578|NCT00218998|BEHAVIORAL|exercise training|
41164579|NCT02090998|PROCEDURE|SPG Block with 5% Lidocaine gel|cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia
41164580|NCT02090998|DRUG|Amitriptyline|The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
41164581|NCT04700566|BIOLOGICAL|Renuva Allograft Adipose Matrix|Injection of Renuva Allograft adipose Matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
41164582|NCT05155709|DRUG|siremadlin|Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
41164583|NCT05155709|DRUG|venetoclax|Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
40851009|NCT06289218|DEVICE|interferential current|IFC plus exercise
40851010|NCT06289218|OTHER|kinesio taping|KT plus exercise
40851011|NCT06289218|OTHER|exercise|exercise only
40851012|NCT05400304|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
40851013|NCT04964739|BEHAVIORAL|Cognitive Behavioral Therapy (CBT4CBT)|Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
41164584|NCT05155709|DRUG|azacitidine|Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
41164585|NCT01658956|DRUG|GCSF administration on days 8 and 12 after chemotherapy|
41034278|NCT05152979|BEHAVIORAL|Verb Network Strengthening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.
41034279|NCT06635902|DRUG|L-citrulline|Intravenous L-citrulline (50 mg/kg + 9mg/kg/hr.) for 16 hours
41034280|NCT06635902|OTHER|Placebo|Isotonic normal saline
41034281|NCT06635902|DRUG|L-citrulline|Intravenous L-citrulline (25 mg/kg + 9mg/kg/hr.) for 16 hours
41034282|NCT02369029|DRUG|BAY 1238097|Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
41034283|NCT05799495|DRUG|PF-07817883|Arm 1: low dose Arm 2: medium dose Arm 3: high dose
41034284|NCT05799495|DRUG|Placebo|Placebo
41034285|NCT04993924|DRUG|Cetrorelix Acetate, Ganerelix Acetate|3-6 days of 0.25 mg starting on day 2-3 of the menstrual cycle
41034286|NCT01093352|PROCEDURE|Alveolar-decortication.|Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
41034287|NCT02462876|DEVICE|GORE® VIABAHN® Endoprosthesis|Treatment of Popliteal Artery Aneurysm with the GORE® VIABAHN® Endoprosthesis.
41164586|NCT02413606|OTHER|Reduced follow-up schedule|In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
41034288|NCT01308580|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous"
41034289|NCT01308580|DRUG|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet~Route of administration: Oral"
41378545|NCT05712603|DIAGNOSTIC_TEST|Enhanced Liver Fibrosis test|The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
41378546|NCT04876482|PROCEDURE|transoral robotic surgery|transoral robotic surgery (TORS) which remove the extra soft tissue of the base of the tongue and soft palate in this study
41378547|NCT04876482|DEVICE|oral appliance|It is a kind of treatment for the participants who refuse surgeries and choose to use other kinds of conservative treatment. The conservative treatments included oral appliance, losing weights and using continuous positive airway pressure. The oral appliance would be wore only at night and it would press the soft palate and protrude the jaw.
41378548|NCT04876482|DEVICE|using continuous positive airway pressure|The participants only used CPAP at night. The device composed of a main machine, pipe and mask. The participants would instruct to wore the mask. The main machine would give positive airway pressure to open the airway and avoid collapsing.
41378549|NCT04876482|BEHAVIORAL|losing weights|The participants would ask to lose weight by changing their diets and exercising, without using drugs and surgeries.
41378550|NCT04876482|COMBINATION_PRODUCT|oropharyngeal rehabilitation|OPR included exercise for soft palate, tongue and oropharynx. There are 13 movements in OPR. The movements would be teach by a physical therapist.
41378551|NCT05612971|BEHAVIORAL|iAmHealthy Parents First|iAmHealthy Parents first is a 3-month adult obesity treatment program targeting the unique needs of adults with school-age children. Following the iAmHealthy Parents First program, these dyads will take part in a 6-month family-based healthy lifestyles program.
41378552|NCT05612971|BEHAVIORAL|iAmHealthy|The iAmHealthy group will receive newsletters for three months. Following this period, these dyads will take part in a 6-month family-based healthy lifestyles program.
41034290|NCT06389084|BEHAVIORAL|Parents Together parenting course|parenting course and coaching calls
41034291|NCT06082050|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1。
41034292|NCT02005471|DRUG|Bendamustine|Bendamustine will be administered at a dose of 70 mg/m\^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
41034293|NCT02005471|DRUG|Venetoclax|"Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy."
41034294|NCT02005471|DRUG|Rituximab|"Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle."
41034295|NCT01811550|OTHER|Glycemic Control|
41034296|NCT00650546|DRUG|Exenatide|5 mcg twice a day titrated to 10 mcg twice a day
41164587|NCT03935932|DEVICE|nasal delivery of heated and humidified air|Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
41378553|NCT06653881|OTHER|ARCHWIRE|Alignment efficiency of the archwires will be compared using little's irregularity index between the two groups
41378554|NCT06651489|DRUG|Guselkumab|Subcutaneous injection of 100 mg at Weeks 0, 4, 12, and 20
41378555|NCT06298916|COMBINATION_PRODUCT|64Cu-LNTH-1363S|64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,
40851014|NCT06187077|BEHAVIORAL|DHA-Enhanced FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Weekly educational modules provide information on components of cardiovascular health (CVH). Participants are given a Fitbit to track physical activity, which will automatically synch to the app and will be asked to track their daily fruit and vegetable intake on the app. DHAs will promote CVH and digital health readiness as peer mentors by guiding participants through the educational modules and encouraging use of the additional interactive app features. During the guided intervention phase, they will facilitate weekly visits with participants in their church, which will follow the FAITH! App modules and integrate a digital health topic. Following the 11-week guided intervention, participants will have a 12-month maintenance phase with access to use the app as they wish.
40851015|NCT06187077|BEHAVIORAL|FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Each week, an educational module is completed in the app, which provides information on a component of cardiovascular health. Participants will be given a Fitbit to track their physical activity, which will automatically synch to the app, and will be asked to track their daily fruit and vegetable intake on the app as well. Following the 11-week guided intervention, participants will have a 12-month maintenance phase in which they will have access to use the app as they wish.
40851016|NCT01631396|DRUG|Sugammadex vs. Neostigmine|"* Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~* Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body."
40851017|NCT01447186|BEHAVIORAL|Post-Test Questionnaire|Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
40851018|NCT01447186|BEHAVIORAL|Interviews|Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
40851019|NCT01447186|BEHAVIORAL|Focus Groups|Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
40851020|NCT02699710|DRUG|Folic Acid|Folic acid will be administered orally as tablet at a single dose of 5 mg.
40851021|NCT02699710|DRUG|GDC-0853|GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
40851022|NCT02699710|DRUG|Methotrexate|Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
40851023|NCT02699710|DRUG|Rabeprazole|Rabeprazole will be administered orally as tablet at a dose of 20 mg.
41378556|NCT05071846|BIOLOGICAL|MVX-ONCO-2|"One administration of MVX-ONCO-2 (or vaccination) consists of the implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10\^6 lethally irradiated autologous tumor cells. Tumor cells will have prealably been harvested from the participant through a surgical procedure.~A full treatment course with MVX-ONCO-2 consists of a total of 6 vaccinations: 4 vaccinations 1 week apart, followed by 2 boosters 2 weeks apart. Capsules are removed 1 week after implantation."
41378557|NCT06422806|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41378558|NCT06422806|PROCEDURE|Diagnostic Imaging|Undergo standard imaging scans
41378559|NCT06422806|DRUG|Doxorubicin|Given IV
41378560|NCT06422806|PROCEDURE|Echocardiography|Undergo ECHO
41378561|NCT06422806|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
40851024|NCT02172404|DEVICE|Placebo capsule administered via the HandiHaler®|
40851025|NCT02172404|DEVICE|Ipratropium metered dose inhaler (MDI)|
40851026|NCT01079494|OTHER|pharmaceutical care services|Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
40851027|NCT02188849|OTHER|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
40851028|NCT02188849|DRUG|Creatine|Creatine powder 5 g day
40851029|NCT05186506|DRUG|Ensatinib|225 mg administered once daily orally for two years.
41034297|NCT03453606|OTHER|Home respiratory rehabilitation|Home care is individual (often with the spouse or the carer), during 1h30, one visit per week for 8 weeks, after completion of the educational diagnosis, under direct supervision of a member of the team, with continued physical activities in autonomy the others days of the week, according to a personalized action plan. No visit is scheduled in the pulmonologist, the general practitioner or in the rehabilitation center. The team includes pulmonologist, nurses, dietician, socio-medical beautician and a administrative assistant.
41034298|NCT03453606|OTHER|Center respiratory rehabilitation|"In an outpatient setting, the course is performed in groups of 6 to 8 patients, during sessions from 3 to 7 am, under the direction of health professionals, 3 to 5 times a week, for 4 to 6 weeks, for a total of 20 to 24 sessions. Internally, patients come to complete hospitalization for 4 weeks. This duration can be modulated according to the evolution of the patients.~Supervision is carried out by the entire team including pulmonologists, nurses, physiotherapists, psychologists, activity professors adapted physicists, dietician"
41034299|NCT00746837|DRUG|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
41034300|NCT00746837|DRUG|AZD5672|50 mg od, 12 days
41034301|NCT00746837|DRUG|AZD5672|150mg od, 12 days
41034302|NCT03282448|BEHAVIORAL|family therapy|The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus \& Miller, 2014).
41378562|NCT06422806|BIOLOGICAL|Pembrolizumab|Given IV
41378563|NCT05476926|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
41378564|NCT05476926|COMBINATION_PRODUCT|Port Delivery System with Ranibizumab|The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
41378565|NCT06286397|DRUG|1% Clascoterone|Application of 1% clascoterone cream twice daily to affected area for 12 weeks.
40851030|NCT05186506|DRUG|chemotherapy|"Pemetrexed : Participants will receive 500 mg/m\^2, day 1 , Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Cisplatin :Participants will receive 75 mg/m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Paclitaxel: Participants will receive 175 mg/ m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~carboplatin AUC= 5 mg/ mL/min, intravenously guttae, day 1 ,Q21D ，until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
41506961|NCT03957850|BEHAVIORAL|Cognitive Reappraisal Training|The training procedure is adapted from a study by Denny \& Ochsner (2014). Before the task, participants are instructed that they will be presented pictures and that these pictures will be preceded by a condition specific cue signaling the appropriate strategy during picture viewing. Participants are instructed to indicate their affective response to the image on a rating scale. The task involves 4 conditions: 1) Negative-decrease: participants are asked to view negative pictures and to decrease their affective response by reappraising the negative event. 2) Negative-attend/ 3) Neutral-attend/ 4) Positive-attend: participants are asked to view pictures and to respond naturally to them without trying to alter their affective response. The training task will be repeated over 4 training sessions.
41378566|NCT06286397|DRUG|Vehicle Cream|Application of a vehicle cream to the natal cleft twice daily for 12 weeks
40851031|NCT05409898|DEVICE|smart wearable device|screening masked hypertension with smart wearable devices
40851032|NCT05898763|DRUG|TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)|Patients will receive three rounds of vaccination three weeks apart via one subcutaneous (SC) injection in an alternating limb. Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI).These patients will receive three rounds of combination treatment with TEIPP24 vaccination and pembrolizumab every three weeks. Pembrolizumab will be administered as per standard of care.
40851033|NCT02420236|BEHAVIORAL|High-intensity resistance training|
40851034|NCT02420236|BEHAVIORAL|General physical activity|
40851035|NCT02420236|BEHAVIORAL|Multidisciplinary rehabilitation program|
41378567|NCT03974607|BEHAVIORAL|Physical Activity Program (PAP)|A Physical Activity Program (PAP) will be carried out. Previously an initial measure will be made to know the little active adolescents. At the end of the PAF a retention measure will be carried out to know the scope and persistence of the variables analyzed. The PAF will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where we will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all. During the sessions, basic physical abilities and motor skills will be worked on with playful proposals focused on the improvement of physical and psychosocial parameters. They will always have the same monitor Graduate in Physical Activity and Sports Sciences, which will be responsible for developing the PAF.
41506962|NCT03957850|BEHAVIORAL|Control Training|The task in the control group is implemented to account for unspecific effects and is as similar as possible to the CR task except that it involves no negative-decrease (i.e., no reappraisal) condition. Instead, the control task only involves the three attend conditions (negative- attend, neutral-attend, positive-attend).
41506963|NCT00626808|DRUG|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
41034303|NCT03207529|DRUG|Alpelisib|Given PO
40851036|NCT06524622|DEVICE|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) measurements will be performed for all participants
40851037|NCT05906459|DIAGNOSTIC_TEST|Anti-HCV antibody and HCV core antigen testing|"HCV antibody screening were carried out with rapid diagnostic testings (RDTs) by colloidal gold method, using fingertip blood or residual blood from other testings.~For samples with positive HCV antibody RDTs screening results, HCV core antigen detection will be carried out subsequently as diagnostic test. HCV core antigen detection will be conducted with chemiluminescent particle immunoassay using residual blood from other testings."
41034304|NCT03207529|DRUG|Enzalutamide|Given PO
41034305|NCT00648232|BEHAVIORAL|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
41034306|NCT00648232|BEHAVIORAL|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
41164588|NCT05933122|OTHER|sexologist consult|"in the cohort called here, after the diagnosis of rectal cancer, patients will be seen by a sexologist before any kind of treatment for rectal cancer. Sexual dysfunctions will be assessed by a sexologist. After the surgery of rectal cancer, the sexologist will see them again to assess sexual dysfunctions after such a management of rectal cancer. If there is any discovery of a sexual dysfunction or aggravation of a previous one or alteration of sexual life, the sexologist will help the patients to improve their sexual quality of life."
41164589|NCT05933122|OTHER|standart of care|"in the cohort called elsewhere , patients will be treated according to standards of care, without specific care by a sexologist"
41378568|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
41378569|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
41378570|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
41378571|NCT04481087|DEVICE|Clearfil SE Bond|Adhesive systems
41378572|NCT04481087|DEVICE|Tetric N-Bond|Adhesive systems
41378573|NCT06234683|OTHER|Web-based educational video on pneumococcal vaccination|Participants will receive a link to view a short video on pneumococcal vaccination.
40851038|NCT03054779|OTHER|Canola Oil|Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
41378574|NCT06234683|OTHER|Reminder email to be vaccinated|Participants will receive a reminder email to be vaccinated.
41034307|NCT00648232|BEHAVIORAL|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
41034308|NCT00648232|BEHAVIORAL|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
41034309|NCT00293839|DRUG|oxybutynin chloride|
41034310|NCT05484674|PROCEDURE|Deroofing and laser|Deroofing and laser to axilla
41034311|NCT04367675|DRUG|INO-5401|INO-5401 contains genes which are active in human cancers (hTERT, PMSA, and WNT1) and are felt to be good targets for the immune system both people who have had cancer or for those at increased risk of getting cancer.
41164590|NCT01376050|DEVICE|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
41164591|NCT01376050|DEVICE|Placebo Laser|Placebo Laser has no therapeutic output emitted.
41164592|NCT00641836|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
41164593|NCT02881021|OTHER|Rehabilitation program|Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.
41164594|NCT02881021|DEVICE|Kinesiotaping|Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
41164595|NCT05132530|BEHAVIORAL|yoga|yoga practice will be done two days a week for 10 weeks.
41378575|NCT03791567|BIOLOGICAL|Donislecel (allogeneic islets of Langerhans for transplant)|Intervention Description: The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium bicarbonate and supplemented with human albumin).
41378576|NCT05533697|BIOLOGICAL|mRNA-4359|Intramuscular Injection
41378577|NCT05533697|BIOLOGICAL|Pembrolizumab|Intravenous infusion
41378578|NCT06481397|DEVICE|ONCObind (Onco-Seraph) 100 Filter|"The ONCObind (Onco-Seraph) 100 Microbind® Affinity Blood Filter (Onco-Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Onco-Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins.~Literature search yielded over 45 publications and 370 treated patients with Seraph platform technology for pathogen removals without significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of Onco-Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Onco-Seraph 100, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use."
41378579|NCT06652971|DRUG|CKD-379|QD, PO
41378580|NCT05459077|BEHAVIORAL|Hypertension control through education and monitoring|Enrollment of 60 PLWH ≥18 years old receiving care at the Duke ID clinic who have achieved HIV viral suppression who take antihypertensive medication and have uncontrolled blood pressure. Subjects will have be given educational materials, blood pressure monitors to use and report findings, follow up with study coordinator and communication with subject's HIV provider in order to maximize blood pressure control..
41378581|NCT05568875|OTHER|e-self-management intervention (Happy Hands app)|"The 12-week intervention consists of 30 short informational videos addressing the themes prioritized by the patient research partners. These themes are further operationalized into the following categories: Information on hand OA, Hand exercises, Use of assistive devices and orthoses, Medication and surgical alternatives, and Self-management of the disease. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The intervention group will additionally receive treatment as usual."
41378582|NCT05568875|OTHER|Treatment as usual|Treatment as usual may vary from no treatment at all to referral to a patient education group program, or occupational therapy.
41378583|NCT05784311|DRUG|Cefuroxime|1500mg IV cefuroxime thrice daily during five days.
41378584|NCT05784311|DRUG|Metronidazole|500mg IV metronidazole thrice daily during five days.
41378585|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
41378586|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: EPP|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
41378587|NCT06561048|DRUG|Soquelitinib|Soquelitinib 200 mg tablets will be taken by mouth two times a day
41378588|NCT06561048|DRUG|Belinostat|Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle
41378589|NCT06561048|DRUG|Pralatrexate|Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle
41378590|NCT06649695|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
41378591|NCT03687580|DEVICE|B-Cure Laser Pro|The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min
41034312|NCT04367675|DRUG|INO-9012|INO-9012 contains the gene for IL12, a part of your body's immune system. It is possible that adding this to INO-5401 will increase the immune response to the vaccine.
41378592|NCT03687580|DEVICE|Sham laser|The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
41506964|NCT05301595|PROCEDURE|TAP block|Please see description of TAP block group.
41506965|NCT05301595|PROCEDURE|QL Block|Please see description of QL block group.
41506966|NCT01609023|DRUG|Rituximab|Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
41506967|NCT00337337|BEHAVIORAL|Multiple grain|
41506968|NCT00337337|BEHAVIORAL|Ordinary Asian- rice|
41378593|NCT05829265|BEHAVIORAL|A digital social intervention by primary care clinicians.|"The intervention in this study will involve a structured consultation with a primary care clinician (e.g. a general practitioner (GP) or practice nurse) to promote online peer support, followed by engagement with the OHC of the Asthma + Lung UK (ALUK) charity. The intervention will either be delivered in person (in the general practices) or virtually. The aim is for the intervention to involve a face-to-face, one-off consultation, lasting approximately 30 minutes, during which a primary care clinician will:~* Signpost and sign patients up to the ALUK OHC, by thoroughly explaining terms of conditions of use and providing log in details.~* Introduce norms and values for passive (just reading) and active (writing OHC posts) participation.~* Encourage seeking and offering self-management information and support, by emphasising that the OHC could be used ad hoc (e.g. when feeling unwell, or when there are information or emotional needs)."
41378594|NCT04935866|OTHER|Near-infrared spectroscopy (NIRS)|Non invasive brain oxygenation monitoring with Near-Infrared Spectroscopy (NIRS) technology. Patients enrolled in the NeurO2 study will have bilateral NIRS sensors applied to the forehead according to manufacturer recommendations. Data will be monitored continuously throughout the study intervention in the parent trials (HEMOTION and SAHaRA trials) in the neurocritical care unit. Data will be extracted from the device at the end of the study period.
41378595|NCT06374459|DRUG|Zumsemetinib|Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.
41378596|NCT06374459|DRUG|Capecitabine|Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.
41378597|NCT06374459|DRUG|Zoledronic acid|Standard of care. Will receive zoledronic acid or denosumab.
41378598|NCT06374459|DRUG|Denosumab|Standard of care. Will receive zoledronic acid or denosumab.
41506969|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery
40851039|NCT03054779|OTHER|High oleic acid canola oil|High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
40851040|NCT03054779|OTHER|Western diet oil combination|"A typical Western diet fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily"
41034313|NCT04367675|DEVICE|Cellectra 2000|The device will deliver a small electric charge through 5 needles to increase the amount of the study vaccine taken up by the muscle.
41034314|NCT02529774|DRUG|Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1"
41378599|NCT06362707|DRUG|Fasudil|A ROCK inhibitor approved for treating vasospasms following subarachnoidal bleeding in Japan and China. Dosage: Participants will undergo a 2-week titration period at 60 mg daily before escalating to a maintenance dose of 120 mg daily.
41378600|NCT06362707|DRUG|Placebo|Placebo tablets that look identical to the fasudil tablets and will follow the same dosing schedule as participants receiving fasudil.
41378601|NCT05567172|DEVICE|Left atrial appendage closure device WM FLX Pro|Left atrial appendage closure
41378602|NCT03461653|OTHER|Telemedicine counselling|women on web counselling
41378603|NCT04688489|DIETARY_SUPPLEMENT|Carbloading and maltodextrin|The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
41378604|NCT06647069|DRUG|DR-0201|DR-0201 is a bispecific antibody
41378605|NCT03065335|DRUG|Ketamine|N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
41378606|NCT03065335|OTHER|Placebo|Placebo comparator
41378607|NCT03065335|DEVICE|Cobot TS MV robotic arm for TMS|TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil
41378608|NCT03065335|DEVICE|NeurOptics PLRTM-30000 Pupillometer|The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
41378609|NCT05190562|DRUG|Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet|Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
41378610|NCT03940898|DEVICE|repetitive transcranial magnetic stimulation|"There are two types of stimulation equipment, one is the transcranial magnetic stimulator model Magpro X100 produced by Danish Medtronic, and the other is the CCY-I TMS stimulator produced by Wuhan Eride, model B9076. The stimulating magnetic head uses an 8 shaped coil, and the stimulation site is the cerebellar vermis (ie, 1 cm below the occipital bulge), and the stimulation intensity is 100% of the motor threshold.The base frequency of the iTBS mode is 5 Hz, and one short burst stimulus occurs every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and each 10 short burst stimulation intervals are 8 seconds, for a total of 200 short burst stimulations. The total number of stimulation pulses is 600 per day.It takes 3 minutes and 20 seconds to complete one intervention. All participants were intervened once a day for 5 times a week for 2 weeks for a total of 10 times."
41378611|NCT02526017|BIOLOGICAL|Cabiralizumab|Solution for IV administration
41378612|NCT02526017|BIOLOGICAL|Nivolumab|Solution for IV administration
41378613|NCT06450197|DRUG|AZD7798|AZD7798
41378614|NCT06450197|OTHER|Placebo|Placebo
41378615|NCT06651138|RADIATION|Fluoroscopy|Pulsed or Continuous fluoroscopy during MILD procedure
41378616|NCT06542653|PROCEDURE|PCI|successful percutaneous coronary intervention (PCI) in Coronary chronic total occlusions (CTOs) patients
41378617|NCT06542653|DRUG|OMT|optimal medical therapy (OMT) in CTO patients, such as aspirin 1td, ACEI/ARB 1td, β blocker 1td, statin 1td.
41378618|NCT06649734|OTHER|Delphi Study|A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
41378619|NCT03843775|DRUG|Binimetinib|Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
41378620|NCT03843775|DRUG|Encorafenib|encorafenib 450 mg oral QD
41378621|NCT04938102|DRUG|Botulinum Toxin Type A Injection [Botox]|Injection of 100 units of botulinum toxin into the lower esophageal sphincter (25 units in each quadrant).
41378622|NCT04331769|DEVICE|AccuCinch Ventricular Restoration System|AccuCinch Ventricular Restoration System
41506970|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general Uro surgery
41506971|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general colorectal surgery
41506972|NCT01085357|PROCEDURE|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
41506973|NCT01085357|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
41378623|NCT04331769|DRUG|Guideline-Directed Medical Therapy|Guideline-Directed Medical Therapy
41378624|NCT06549725|DEVICE|software Lipidica|"The investigational medical device software (MDSW) Lipidica processes and analyses data inputs from the analysis of lipid profile in human plasma using an in-house in vitro diagnostic medical device."
41378625|NCT06549725|PROCEDURE|endoscopic ultrasonography|Endoscopic ultrasonography - maximum frequency: 3 times during the participation
41378626|NCT06549725|PROCEDURE|magnetic resonance|Magnetic resonance - maximum frequency: 3 times during the participation
41378627|NCT06549725|DIAGNOSTIC_TEST|laboratory examination|Lipidomic analysis, CA 19-9, CEA, HbA1c and hCG levels assessment (hCG only in women of childbearing potential in Arm 2)
41378628|NCT06549725|PROCEDURE|computed tomography|computed tomography - maximum frequency: 3 times during the participation
41378629|NCT06651437|OTHER|Experimental|At the end of the baseline examination, the Experimental group received a brief dietary education on the health damage due to excess salt consumption and on behavioural methods to gradually reduce dietary intake, for example at home, reduce the consumption of processed foods, do not bring salt shaker on the table, limit the use of condiments with a high sodium content; out of home, both when eating and when shopping, reduce the consumption of processed foods, check nutritional labels and choose products with lower salt content. In addition, written information was provided. All participants will be clinically followed every month, with potential titration of the antihypertensive therapy. After 3 months of follow-up, the baseline measurements will be carried out again. During the entire study period, subjects will be asked to maintain their lifestyle and report using additional medications.
41378630|NCT03592680|DIETARY_SUPPLEMENT|Vitamin C|1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
41378631|NCT03592680|OTHER|Placebo|1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
41378632|NCT05413395|OTHER|topical colloidal oatmeal formulation with a modified plant oil|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO). The AO contains proprietary blends of plant oils that have selective antimicrobial properties."
41164596|NCT05863013|OTHER|ADL-Glittre Test|They will receive standard care described plus perioperative pulmonary rehabilitation, with 20 preoperative sessions and 60 postoperative sessions. Preoperative sessions will be held 2X/week, in addition to home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and training of inspiratory and respiratory muscles. home will last 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at 60-80% of maximum HR intensity. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
41164597|NCT00801086|DRUG|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
41164598|NCT00801086|DRUG|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
41164599|NCT03206476|BEHAVIORAL|Nutritional intervention based on the SCT and the TM|Nutritional workshop based on the Cognitive Social Theory and the Transtheorical Model: twelve group sessions (one per week) lasting 40 minutes each, aimed at adolescents; With delivery of printed material to work at home (workbook); And two sessions (every month and a half) addressed to parents.
41164600|NCT03206476|BEHAVIORAL|Nutritional information|Three informative sessions of 25 minutes (one each month) on healthy eating habits and delivery of educational material to adolescents.
41164601|NCT03053115|DRUG|Liothyronine|Cases will take liothyronine drops in the morning and two hours after dinner
41164602|NCT03053115|DRUG|Levothyroxin|Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
41164603|NCT03053115|DRUG|Placebos|Controls will take placebo two hours after dinner
41164604|NCT01334762|DRUG|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
41164605|NCT01334762|DRUG|CC/IUI|Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
41164606|NCT00747045|OTHER|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
41164607|NCT02316847|DRUG|diazepam nasal spray|
41378633|NCT05413395|OTHER|topical colloidal oatmeal formulation|Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation
41378634|NCT05543629|BIOLOGICAL|BMS-986442|Specified dose on specified days
41378635|NCT05543629|BIOLOGICAL|Nivolumab|Specified dose on specified days
41378636|NCT05543629|DRUG|Docetaxel|Specified dose on specified days
41378637|NCT05543629|DRUG|Carboplatin|Specified dose on specified days
41378638|NCT05543629|DRUG|Pemexetred|Specified dose on specified days
41378639|NCT05543629|DRUG|Paclitaxel|Specified dose on specified days
41378640|NCT05798325|OTHER|2MWT|Two minutes walk tests.
41164608|NCT03212950|DRUG|Fast-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
41164609|NCT03212950|DRUG|Regular-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
41378641|NCT05798325|OTHER|MFM32|Motor Function Measurement (MFM) is a quantitative scale created to measure global motor functional abilities in a person with neuromuscular disease.
41506974|NCT03054584|OTHER|Collecting Nevi|Will be collecting Nevi and completing a DNA analysis, no intervention will be made.
41164610|NCT06360705|DEVICE|StrataMGT|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
41164611|NCT02779283|DRUG|Cyclophosphamide|Given IV
41378642|NCT05798325|OTHER|MyoGrip|The MyoGrip is a dynamometer for measuring grip strength.
41378643|NCT05798325|OTHER|QOL-gNMD|"The Quality of Life in genetic Neuromuscular Disease questionnaire (QoL-gNMD) is a patient reported outcome measure (PROM) tool specifically designed for patients with a lowly progressive neuromuscular disease with genetically predominant muscular damage"
41378644|NCT05798325|DIAGNOSTIC_TEST|Spirometry|Forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) will be measured in the hospital with the local hospital device (e.g. Vitalograph) under the supervision of the clinical evaluator, and at home with a portable device.
41378645|NCT05798325|DEVICE|Acceleromerty|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
41378646|NCT05798325|OTHER|10mWT|10 meters walking Test.
41378647|NCT05798325|OTHER|PUL|The Performance of the Upper Limb (PUL) is a functional scale specifically designed for assessing upper limb function in Duchenne muscular dystrophy.
41378648|NCT05798325|OTHER|NSAA|The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy.
41378649|NCT05798325|OTHER|NSAD|The NSAD was developed to measure motor performance in ambulant and non-ambulant subjects as part of the clinical outcome study of dysferlinopathy.
41378650|NCT05798325|OTHER|TANS|This scale is derived from the North Star Ambulatory Assessment and several items from the Egan Klassifikation Scale (EK2).
41378651|NCT05798325|OTHER|MyoPinch|The MyoPinch is a high-precision dynamometer that allows the evaluation of key pinch strength.
41378652|NCT05798325|OTHER|MyoQuad|The MyoQuad is a high-precision dynamometer that allows the evaluation of knee extension strength.
41164612|NCT02779283|DRUG|Cytarabine|Given IV
41378653|NCT05798325|OTHER|ACTIVLIM|Activity limitations, as measured by ACTIVLIM, is defined as the difficulties a patient may have in executing daily activities, whatever the strategies involved.
41378654|NCT05798325|OTHER|PREM|This questionnaire is made up of simple questions relating to the assessments and assessment tools that were used during the study.
41378655|NCT05798325|OTHER|SF-MPQ|The main component of the SF-MPQ consists of 15 descriptors (11 sensories; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
41378656|NCT05798325|OTHER|FSS|The Fatigue Severity Scale is used to assess the severity of fatigue and its impact on daily living. The patient responds on a Likert-type scale ranging from 1 to 7.
41378657|NCT05798325|OTHER|IPAQ|This questionnaire assesses overall physical activity and the level of sedentary lifestyle during the last seven days.
41378658|NCT05798325|OTHER|Rang of motion|The EasyAngle® is a digital goniometer improving long established goniometric functionality with rotation, inclination, and scoliosis measurement capabilities.
41378659|NCT05798325|DEVICE|Goniometry|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
41378660|NCT05798325|OTHER|Video captured monitoring|"Once every four weeks, while wearing the Yumen electronic goniometers (Links Sensor System), the patients will be asked to record on video three tasks related to:~1. Upper limbs: hands to head~2. Lower limbs: Sit to stand with or without the help of a person~3. Self-defined important task: A task of the patient's choice, from a list of tasks, representative of his/her motor difficulties or hindrance to autonomy."
41506975|NCT00313079|DRUG|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
41506976|NCT00313079|DRUG|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
41506977|NCT06243276|PROCEDURE|One stage implant surgery|It is a technique in which the healing cap is connected to the implant at the stage of implant placement.
41506978|NCT06243276|PROCEDURE|Two stage implant surgery|It is a technique in which the healing cap is connected to the implant three months after the implant is placed.
41506979|NCT01119664|DRUG|SCH 721015|
41506980|NCT03366441|OTHER|Telephone call|From 20 October to 10 November 2016, telephone calls were given to the donors in the phone call group
41506981|NCT03366441|OTHER|SMS|Text messages were sent to an equal number of donors in the SMS group
41164613|NCT02779283|DRUG|Dasatinib|Given PO
41164614|NCT02779283|DRUG|Dexamethasone|Given PO
41164615|NCT02779283|DRUG|Doxorubicin Hydrochloride|Given IV
41164616|NCT02779283|DRUG|Idarubicin|Given IV
41164617|NCT02779283|DRUG|Idelalisib|Given PO
41164618|NCT02779283|DEVICE|In Vitro Kinase Inhibitor Assay|Correlative studies
41164619|NCT02779283|DRUG|Leucovorin Calcium|Given IV
41164620|NCT02779283|DRUG|Methotrexate|Given IV
41034315|NCT02529774|DRUG|Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1"
41034316|NCT03380962|DRUG|Clazakizumab|All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
41506982|NCT04587726|BEHAVIORAL|Girl's room video|"Girls Room, a body image mini-series, developed in collaboration with Lena Waithe, Dove and CAR.~Video content was informed by empirical evidence related to body image prevention and intervention. The series consists of five, 3-minute videos.~The videos follow the lives of a 5 best friends, and each video targets a key risk factor for body image:~1. Appearance comparison~2. Body appreciation~3. Body talk~4. Body functionality~5. Appearance teasing \& bullying~6. Appearance focus~The five videos aired on Instagram TV (IGTV) in March 2020."
41506983|NCT04587726|OTHER|Control video - Chicken Girls|Chicken Girl's Episode - appearance neutral episode matched for target audience and video length
40851041|NCT04356235|PROCEDURE|A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
40851042|NCT04356235|PROCEDURE|B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
41034317|NCT06397469|DEVICE|MediTrain|MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
41034318|NCT06397469|DEVICE|Worder|Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
41506984|NCT05607745|OTHER|FMT and placebo|Similar healthy diet counseling is given to all participants in both FMT and placebo group. FMT to placebo is given in 2:1.
41506985|NCT05775133|DEVICE|ICG|"Patient will receive a standard dose of indocyanine green (ICG) 45 minutes prior to surgery. ActivSight will be used during laparoscopic cholecystectomy - the surgeon will perform the procedure in their standard fashion.~Video data will be analyzed in real-time by Activ Surgical's ActivInsight surgical artificial intelligence platform to identify anatomic structures and surgical phase. The surgeon will be blinded to this information, and will see the standard screens and information they do when performing the procedure in a non-study setting."
40851043|NCT04356235|PROCEDURE|C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
41034319|NCT06046573|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
41034320|NCT06046573|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
41034321|NCT06046573|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
41164621|NCT02779283|DRUG|Methylprednisolone Sodium Succinate|Given IV
41506986|NCT03438292|DIETARY_SUPPLEMENT|Berberine|Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
41506987|NCT03438292|DIETARY_SUPPLEMENT|TPGS emulsified berberine|Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
41506988|NCT03438292|DIETARY_SUPPLEMENT|Quillaja extract emulsified berberine|Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
40851044|NCT04356235|PROCEDURE|D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
40851045|NCT04356235|PROCEDURE|E: unilateral simple mastectomy|unilateral simple mastectomy
40851046|NCT04356235|PROCEDURE|F: after bilateral SSM, ASM, NSM, expander-implant exchange|after bilateral SSM, ASM, NSM, expander-implant exchange
40851047|NCT04020497|BEHAVIORAL|Ensemble programme|Ensemble is a individualized programme to address informal caregiver's specific unmet needs, emotions and social resources, in order to offer a targeted support in five sessions.
41034322|NCT06046573|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
41034323|NCT00634608|OTHER|Health Information Prescription|The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
41164622|NCT02779283|DRUG|Ponatinib Hydrochloride|Given PO
41164623|NCT02779283|BIOLOGICAL|Rituximab|Given IV
41506989|NCT01998763|DIETARY_SUPPLEMENT|Placebo|placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,
41378661|NCT05798325|DEVICE|Activity monitoring|Wearable devices (connected watch) will collect health-related data on a 24/7 basis remotely as patients go through their daily routines at home and work.
41378662|NCT06649773|DRUG|Noiiglutide Injection|Experimental group
41378663|NCT06649773|DRUG|Noiiglutide Placebo|Placebo Comparator group
40851048|NCT04020497|OTHER|SAU|"Informal caregivers have often to manage the situation in usual different ways. Support as usual (SAU) alone consists of an informal support by patient's clinical team. Specific psychoeducational programs depending on patient's illnes (like Profamille for schizophrenia) or peer-support depending to the voluntary work of families' associations. Some general professional services focused on informal caregivers or relatives in order to inform and orient them if they are avaible in the study area. No attempts have been made to standardize this treatement as SAU depend to informal caregiver's need and knowledge of the health system, also her/his capacity or possibility to be in contact with patient's clinical team."
40851049|NCT06006624|DRUG|Exparel 30 mL|30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block
40851050|NCT06006624|DRUG|0.5% bupivacaine|5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal
40851051|NCT06006624|DRUG|Dexamethasone|10 mg preservative free Dexamethasone evenly distributed and administered in adductor canal
40851052|NCT06006624|DRUG|iPACK block|iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block
40851053|NCT01663012|DRUG|Etirinotecan pegol|
40851054|NCT01601262|DEVICE|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
40851055|NCT05411484|DRUG|NanoDOX® Hydrogel|NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin
40851056|NCT05411484|DEVICE|CO2 Ablative Fractional Laser|CO2 Ablative Fractional Laser will be applied to healthy skin areas
40851057|NCT05485285|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
40851058|NCT00356343|DEVICE|NMES Strength Training|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
40851059|NCT00356343|OTHER|Volitional Strength Training|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
40851060|NCT01091012|DRUG|Sildenafil 20mg oral vs Sildenafil 10mg intravenous|2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
40851061|NCT05826847|PROCEDURE|Prone Positioning|Prone positioning will be performed according to ICU local protocol with trained provider teams.
40851062|NCT05826847|PROCEDURE|Thoracoabdominal Binding|Thoracoabdominal binding will be used in semi-recumbent position (supine at 45º) and titrated to obtain a 20-30% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing
40851063|NCT05826847|PROCEDURE|Control|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
41378664|NCT00207025|DRUG|BMS-275183|
41378665|NCT04827576|DRUG|Magrolimab|Administered intravenously
41378666|NCT04827576|DRUG|Docetaxel|Administered intravenously, 75 mg/m\^2 on Day 1 of each cycle
41378667|NCT06084013|OTHER|Non-Interventional Study|Non-interventional study
41506990|NCT01998763|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 2000 IU per day
40851064|NCT05805813|COMBINATION_PRODUCT|peritoneal rest|Change continuous ambulatory peritoneal dialysis to intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month. In this way, give a chance of peritoneum rest.
41034324|NCT05851404|PROCEDURE|Thyroidectomy|Total thyroidectomy or lobectomy
41034325|NCT04566029|BIOLOGICAL|Blood test|The patients' blood will be collected in four 5mL heparinized tubes
41034326|NCT04566029|BIOLOGICAL|Stool sample|The patients' stools will be collected at home
41034327|NCT04566029|OTHER|Questionnaires|At each visit, the following questionnaires will be collected: QLQ-C30 and EQ5D-5L Appendix 16.2 and PRO CTCAE
41034328|NCT00974168|RADIATION|Cumulative BED ≤ 100|Radiation
41034329|NCT00974168|RADIATION|Cumulative BED ≤ 130 Gy2|Radiation
41034330|NCT02501343|DRUG|Sodium Bicarbonate Oral Capsule|Sodium bicarbonate 1680 mg will be administered prior to the meal
41378668|NCT02585375|DRUG|Preservative-free latanoprost 50µg/ml|
41378669|NCT02585375|DRUG|Preserved latanoprost 0.005%|
41378670|NCT02459470|PROCEDURE|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
41378671|NCT06603077|DRUG|AVTX-009 Regimen 1|AVTX-009 will be administered as a subcutaneous injection every 4 weeks.
41506991|NCT02420912|DRUG|Ibrutinib|Given PO
41506992|NCT02420912|OTHER|Laboratory Biomarker Analysis|Correlative studies
41378672|NCT06603077|DRUG|AVTX-009 Regimen 2|AVTX-009 will be administered as a subcutaneous injection every 2 weeks.
41378673|NCT06603077|DRUG|Placebo|Matching placebo will be administered as a subcutaneous injection every 2 weeks.
41378674|NCT06049355|OTHER|Exercise Intervention|Undergo Exercise Together exercise program
41378675|NCT06049355|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41378676|NCT06049355|OTHER|Educational Intervention|Receive educational materials
41378677|NCT03804372|DRUG|Rituximab|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
41378678|NCT03804372|DRUG|Chemotherapy|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
41506993|NCT02420912|BIOLOGICAL|Nivolumab|Given IV
41506994|NCT02233439|DIETARY_SUPPLEMENT|Herbal galactagogue|
41506995|NCT02233439|DIETARY_SUPPLEMENT|Placebo|
41164624|NCT02779283|DRUG|Ruxolitinib Phosphate|Given PO
41164625|NCT02779283|DRUG|Sorafenib Tosylate|Given PO
41164626|NCT02779283|DRUG|Sunitinib Malate|Given PO
41378679|NCT03804372|DRUG|Tenofovir alafenamide|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
41378680|NCT04683874|DEVICE|3D printed tray|3D printed tray
41378681|NCT04529941|DEVICE|Device Implant with Active Treatment|ScNS at 3.5mA output for 2 weeks
40851065|NCT02558777|OTHER|Multicomponent nurse-led intervention|"Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs."
40851066|NCT01246336|OTHER|collection of exhaled breath|no intervention
40851067|NCT03223259|BEHAVIORAL|Injury Prevention Workshops|Each workshop will last 90 minutes and consist of approximately 20-30 minutes of lecture, 30 minutes of movement, no more than 20 minutes for a pre-test (workshop 1) or post-test (workshop 2), and remaining time for Q\&A.
41164627|NCT02779283|DRUG|Vincristine Sulfate|Given IV
41378682|NCT04529941|DEVICE|Device Implant without Active Treatment|No device output for 2 weeks
41378683|NCT05918211|DRUG|Udenafil|Active drug
41378684|NCT05918211|DRUG|Placebo|Matching Placebo
41378685|NCT06269705|DRUG|ZILRETTA|IA injection of 32 mg ZILRETTA
41378686|NCT06269705|DRUG|TCA-IR|IA injection of 40 mg TCA-IR
41378687|NCT06269705|OTHER|Placebo|IA injection of placebo (normal saline)
41378688|NCT05744388|DEVICE|Gliderite® shape modification|The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis.
41378689|NCT03793179|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41378690|NCT03793179|DRUG|Carboplatin|Given IV
41378691|NCT03793179|PROCEDURE|Computed Tomography|Undergo CT scan
40851068|NCT00056953|BEHAVIORAL|Peer mentoring program|
41164628|NCT06345547|OTHER|ultrasound|"Ultrasound of m. quadriceps and m. thenar All ultrasound measurements will be performed in triplicate, with the average of the scores used in final analyses. Four parameters will be evaluated: muscle thickness, muscle cross sectional area, pennation angle and echo intensity (gain, depth and frequency will be kept constant).~Hand grip strength measurement: measurement by an electronic hand dynamometer DynEx1TM (MD Systems, Inc. Ohio, USA). The recommendations for the handgrip strength test of the American Society of Hand Therapists will be followed: The maximum of the three values will be considered for analysis."
41378692|NCT03793179|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41378693|NCT03793179|BIOLOGICAL|Pembrolizumab|Given IV
41378694|NCT03793179|DRUG|Pemetrexed|Given IV
41378695|NCT03793179|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41164629|NCT04130581|OTHER|Transcranial Magnetic Stimulation (TMS)|TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
41378696|NCT04296331|DIAGNOSTIC_TEST|POC|DC DOC's current testing practice offers opt-out POC testing with the INSTI® finger stick test at entry
41378697|NCT04296331|DIAGNOSTIC_TEST|Ag/Ab|The DC DOC will transition from offering their current POC testing upon entry to offering opt-out HIV testing with Ag/Ab: ARCHITECT® laboratory-based test.
41378698|NCT04296331|DIAGNOSTIC_TEST|POC + Ag/Ab|As the DC DOC transitions to utilizing the Ag/Ab: ARCHITECT® laboratory-based test from their current POC testing, jail nurses will offer new entrants op-out testing with the two methods
41164630|NCT03553849|DIETARY_SUPPLEMENT|Very low calorie diet|The VLCD is a prescribed diet with well-balanced macro and micronutrients. It is intended for significant weight loss in a short period of time, is intended only for the extremely obese, and must be completed under the supervision of a trained physician.
41378699|NCT05326997|DEVICE|Photobiomodulation group|Participants will have their face sanitized with micellar water (a cosmetic product for cleaning and makeup remover), followed by cleaning with soap. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light. After the session the face will receive sunscreen. A placebo cosmetic will be given to the participant to be applied twice a day and daily sunscreen.
41378700|NCT05326997|OTHER|Group control (Tranexamic acid)|Participants will have their face sanitized with micellar water. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light sham. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same places described for the PBM group, however, the equipment will be kept off. After the session the face will receive sunscreen. Will be delivered to patients, liposomal tranexamic acid with use 2 x a day home care and daily sunscreen.
41378701|NCT05320926|DRUG|Clopidogrel monotherapy|Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
41378702|NCT05320926|DRUG|Aspirin monotherapy|Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
41378703|NCT05320926|DEVICE|zotarolimus-eluting stent (Resolute Onyx ®)|zotarolimus-eluting stent (Resolute Onyx ®)
41378704|NCT04103593|BEHAVIORAL|exercise training|12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
41378705|NCT06647446|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software of digital physiotherapy and telerehabilitation TRAK. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
41378706|NCT06647446|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
41378707|NCT03492489|DRUG|cemiplimab|Intravenous (IV) administration
41378708|NCT03673111|DRUG|Y14|Gut hormone analogue
41378709|NCT03673111|DRUG|Placebo|0.9% saline
41378710|NCT06652672|PROCEDURE|Organ-sparing surgery|Endoscopy-assisted laparoscopic/robotic wedge resection and sentinel lymph node biopsy using submucosal injection of ICG.
41378711|NCT06652672|PROCEDURE|Standard of care segmental resection|Standard of care segmental resection of the affected part of the colon including removal of regional lymph nodes.
41378714|NCT05662319|DRUG|Fitusiran|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)
41034331|NCT02501343|DRUG|Placebo|Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
41034332|NCT04231812|DEVICE|Laparoscopic Tissue Morcellation working space (bag)|"The LapBox is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy"
41034333|NCT03125304|OTHER|acupuncture|They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
41034334|NCT04536636|DRUG|Docohexanoic acid|Patients received 650 mg DHA/3 times/wk/post-HD session
41034335|NCT04536636|DRUG|Control-No drug|Patients received usual medical care with no DHA
41034336|NCT04000906|DRUG|Nab paclitaxel|Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)
41034337|NCT04000906|DRUG|Cisplatin|10.5 mg/m2
41164631|NCT03408223|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
41506996|NCT04291625|PROCEDURE|Levator muscle resection|"Surgery was performed under general anaesthesia. Two milliliters of 2% lidocaine with 1:100 000 epinephrine is injected subcutaneously. After the upper eyelid incision at the desired crease line, the orbital septum was opened and the preaponeurotic fat was identified and dissected off the levator aponeurosis. The aponeurosis was disinserted from the tarsus, and the complex of levator aponeurosis and Muller muscle was dissected free from the conjunctiva. The desired eyelid height was determined from the proposed formula.~Satisfactory Intraoperative lagophthalmos was defined as a difference of less than 1 mm between recommended by the formula and actual intraoperative lagophthalmos.~After permanent fixation, a caliper was used for precise measurement of lagophthalmos in a supine position. Additional sutures were placed on the medial and lateral sides for satisfactory eyelid contour. The redundant levator complex was excised. Eyelid crease was made by placing three interrupted sutures"
40851069|NCT00619307|DRUG|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
40851070|NCT00619307|DRUG|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
41164632|NCT03408223|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12-20 Gy TMLI (fraction size of 4 Gy given once a day).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
41164633|NCT03432650|DRUG|Bupivacaine + dexamethasone|Anesthetic that will help treat pain and sensation after hip arthroscopy
41164634|NCT03432650|DEVICE|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the nerve block
41164635|NCT00518583|DRUG|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
41164636|NCT05167513|DRUG|Metformin / Sitagliptin Oral Tablet|"Metformin and sitagliptin are oral diabetes medicines that help control blood sugar levels.~Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Sitagliptin works by regulating the levels of insulin your body produces after eating.~Metformin and sitagliptin is a combination medicine that is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. metformin and sitagliptin is not for treating type 1 diabetes."
41164637|NCT05999019|PROCEDURE|robotic surgery|robotic surgery
41378715|NCT05662319|DRUG|Clotting factor concentrates (CFC) or bypassing agents (BPA)|"* Coagulation factor VIII (ATC code: B02BD02)~* Coagulation factor IX (ATC code: B02BD04)~* Coagulation factor VIIa (ATC code: B02BD08)~* Factor VIII inhibitor bypassing activity (ATC code: B02BD03)~Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)"
41378716|NCT05662319|DRUG|Antithrombin concentrate (ATIIIC)|Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
41506997|NCT05919615|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
41506998|NCT05919615|DRUG|Normal saline|0.9% sodium chloride normal saline
41506999|NCT03389815|DRUG|WX-0593 Tablets|tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
41507000|NCT02017470|OTHER|Gender-tailored women's heart health outpatient programme|
41507001|NCT00079430|PROCEDURE|adjuvant therapy|
41507002|NCT00079430|DRUG|paclitaxel|Given IV
41507003|NCT00079430|DRUG|carboplatin|Given intraperitoneally
41507004|NCT00079430|BIOLOGICAL|bevacizumab|Given IV
41034338|NCT03334123|OTHER|Functional training and cycling|"First 8 weeks: patients will perform 20 minutes of functional training before their dialysis procedure. The exercise program will be run by kinesiologists, who will also teach patients how to perform exercises on their own at home. During intradialysis cycling 3 times weekly participants will cycle on adapted ergometer. Participants will start with 10 - 15 minutes of cycling and then gradually increase time and intensity up to 45 minutes of duration.~Second phase of 8 weeks: participants will no longer perform functional training before dialysis but will be motivated, monitored and advised to perform functional exercise at home on non-dialysis days for 20-30 minutes and continue with cycling sessions during the dialysis procedures three times weekly."
41034339|NCT03334123|OTHER|Cycling|"First 8 weeks: cycling on an adapted ergometer during dialysis; starting with 10 - 15 minutes of cycling and then gradually increasing time and intensity up to 45 minutes of duration.~Second 8 weeks: continue with cycling at the target duration and intensity during dialysis."
41034340|NCT06313762|DEVICE|Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet|They will experience in first person the two and a half minute graphic adventure, called Leia\&amp;amp;amp;amp;#39;s World, during the administration of the vaccines.
41034341|NCT06313762|BEHAVIORAL|Traditional Distractors|The control group participants will receive traditional distractors, such as being held by the parent or guardian who accompanies them to the appointment, receiving stickers at the end of the appointment, or receiving rewards that the parent or guardian has prepared from home, during the administration of the vaccines.
41034342|NCT06313762|BIOLOGICAL|Triple Viral + Varicella Vaccine at 3 years of age|Administration of vaccines in 3-year-old children, as appropriate according to the vaccination schedule
41034343|NCT06313762|BIOLOGICAL|Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age.|Administration of vaccines in 6-year-old children, as appropriate according to the vaccination schedule.
41034344|NCT03564912|DRUG|Capecitabine Oral Tablet [Xeloda]|2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
41034345|NCT02167828|BEHAVIORAL|Social Support|
41034346|NCT04111627|BEHAVIORAL|Aerobic exercise|Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.
41034347|NCT04111627|DRUG|Duloxetine|Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
41034348|NCT05064969|BEHAVIORAL|Blended intervention based in acceptance and commitment therapy|"Blended intervention includes completing 9 e-modules consist of written material, videos, and assignments (one e-module per week) that can be completed over 9 to 12 weeks AND 9 (to 12 ) coaching sessions (telephone call). Weekly coaching will be offered by a motivational coach based in Maastricht University.~After the post-intervention assessments, individuals will receive monthly calls from the motivational coach as booster sessions. Booster sessions will be received on monthly basis for a period of 6 months (one session per month) and until the last follow-up assessment. Communication with participants will take place online or via telephone."
41034349|NCT01989650|OTHER|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
41034350|NCT01989650|OTHER|No break|No break will be provided
41034351|NCT05253625|OTHER|Listening to a recorded lullaby.|A lullaby will be played from the MP4 player on the outer foot of an empty incubator, and a decibel meter (dB) will be placed in the empty incubator, so that the maximum level of the decibel meter does not exceed 50-60 dB (45-65 dB according to APA). ) (American Academy of Pediatrics. ACOG.2007) (Guidelines for Pediatrics Care. 7th edition) sound adjustment will be made. The lullaby with the mother's voice (first arm newborn mothers) adn with an unfamiliar female voice (second arm newborns) will be recorded in MP4 beforehand. The lullabies of groups A and B are lullabies performed in approximately 4 minutes and will be played repeatedly for the specified periods.
41034352|NCT01693432|DRUG|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14"
41034353|NCT04391049|DRUG|Carboplatin|Given IV
41034354|NCT04391049|DRUG|Paclitaxel|Given IV
41034355|NCT04391049|RADIATION|Radiation Therapy|Undergo radiation therapy
41034356|NCT04391049|BIOLOGICAL|Telomerase-specific Type 5 Adenovirus OBP-301|Given by intratumoral injection
41164638|NCT00634049|DRUG|isavuconazole|Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
41378717|NCT06565741|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
41378718|NCT06565741|PROCEDURE|ThuFLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
41378719|NCT05124912|PROCEDURE|Radiation Therapy|Post-op hypofractionated therapy or no radiation therapy
41378720|NCT05124912|DRUG|Steroid Therapy|Best medical management with steroid therapy
41378721|NCT05124912|PROCEDURE|Laser Interstitial Thermal Therapy|Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
40851071|NCT00133666|BEHAVIORAL|Asthma Communication Education|
40851072|NCT00133666|BEHAVIORAL|Standard Asthma Education|
40851073|NCT01045694|DRUG|Botulinum Toxin Type A|One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
40851074|NCT01045694|DRUG|Steroid - Triamcinolone Acetonide|Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
40851075|NCT01045694|DRUG|Lidocaine|Single injection of 1 - 3 mL of 2% Lidocaine
41378722|NCT04882514|BIOLOGICAL|p*17-K4S2|Administer p\*17-K4S2 25 μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
41378723|NCT04882514|BIOLOGICAL|J8-K4S2|Administer a vaccination schedule of J8-K4S2 50μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
41378724|NCT04882514|BIOLOGICAL|Rabavert vaccine|Administer the standard Rabavert vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly. The Rabavert vaccine will be used as a control comparator as it has a similar approved dosing schedule to the investigational vaccines.
41378725|NCT06652100|DIAGNOSTIC_TEST|ProNephro AKI (NGAL)|ProNephro AKI™ (NGAL) is an immunoassay for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine.
41034357|NCT04450589|DIETARY_SUPPLEMENT|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
41378726|NCT06017362|DRUG|Insulin|Topical insulin 1UI/ml 4 times a day
41378727|NCT06017362|DRUG|Artificial tear|Artificial tears 4 times a day
41378728|NCT06650657|BEHAVIORAL|touchpoint method|Touchpoint is a quality approach that can be applied to increase the sense of personal connection with the instructor, ensure that students are making satisfactory progress, increase instructor-student and student-instructor interactions, and increase student satisfaction, unlike traditional learning models.
41378729|NCT06558799|DEVICE|NovoTTF-200T|The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields exert electric forces intended to disrupt cancer cell division and induce immunogenic cell death.
41378730|NCT06558799|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
41378731|NCT04667507|DRUG|Dexamethasone Ophthalmic implant|Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use
41378732|NCT04070157|DRUG|Lofexidine|Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
41378733|NCT04070157|DRUG|Placebo|Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
41378734|NCT06036836|BIOLOGICAL|favezelimab/pembrolizumab|IV infusion
41378735|NCT06036836|BIOLOGICAL|pembrolizumab|IV infusion
41378736|NCT06036836|DRUG|lenvatinib|Oral administration of capsule
41378737|NCT01134614|BIOLOGICAL|Ipilimumab|Given IV
41378738|NCT01134614|BIOLOGICAL|Sargramostim|Given SC
41378739|NCT03361540|DRUG|ASP8302|ASP8302 will be administered orally.
41378740|NCT03361540|DRUG|Placebo|Placebo will be administered orally.
41378741|NCT06643481|BIOLOGICAL|VHB937|VHB937 solution for infusion
41378742|NCT06643481|OTHER|Placebo|Solution for infusion
41378743|NCT00838175|PROCEDURE|suture mediated closure|Suture mediated closure of femoral venous access
41378744|NCT04491474|DRUG|Lidocaine Hydrochloride|While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
41378745|NCT04491474|DRUG|Placebo|There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
40851076|NCT03653988|PROCEDURE|PEC I/II blocks by anesthesiologist - pre-operative|PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
41378746|NCT04688034|DRUG|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724.
41378747|NCT06489197|DRUG|Ivonescimab combined with albumin paclitaxel and cisplatin|Ivonescimab (20mg/kg, intravenous infusion, d1, Q3W) combined with albumin paclitaxel (220mg/m2, intravenous infusion, d1, Q3W) and cisplatin (75mg/m2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months.
41378748|NCT02577094|DRUG|90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
41378749|NCT02577094|DRUG|Busulfan|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
41378750|NCT02577094|BIOLOGICAL|allogeneic stem cell transplantation.|At Day 0
41378751|NCT02577094|DRUG|Fludarabine|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
41378752|NCT02577094|BIOLOGICAL|Thymoglobulines|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
41378753|NCT00381186|BEHAVIORAL|diet- and exercise intervention|
41378754|NCT05182840|DRUG|BI 690517|Film-coated tablets
41378755|NCT05182840|DRUG|Placebo to BI 690517|Film-coated tablets
41378756|NCT05182840|DRUG|Empagliflozin|Empagliflozin
41378757|NCT05182840|DRUG|Placebo to empagliflozin|Placebo to empagliflozin
41378758|NCT06237309|DRUG|REGN5381|Single dose intravenous (IV) infusion
41378759|NCT06237309|DRUG|Placebo|Single dose IV infusion
41378760|NCT02507531|DEVICE|NeXsys Embolization System|Woven metallic mesh placed in aneurysm fundus
41378761|NCT05252585|DRUG|Everolimus|"Everolimus tablets for oral use. The recommended everolimus starting dose will be 10 mg orally taken once daily for all patients, except for those with impaired liver function, for whom the everolimus dose will be:~* Child-Pugh grade A: 7.5 mg once daily (for patients with mild hepatic impairment)~* Child-Pugh grade B: 5.0 mg once daily (for patients with moderate hepatic impairment)"
41034358|NCT04450589|OTHER|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
41164639|NCT04772313|BIOLOGICAL|Pegloticase|Participants will receive pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
41378762|NCT06430385|DRUG|ION440|ION440 will be administered by intrathecal bolus (ITB) injection.
41164640|NCT04772313|DRUG|Methotrexate (MTX)|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
41507005|NCT06501716|PROCEDURE|Indocyanine Green|"Tumor resection, direct visualization of the chiasm and both optic nerves and ICG administration will be provided as it is recommended by the standard of care. ICG will be administered by an injection of 5 mg of ICG diluted in a 10 mL syringe performed in the line closest to the heart followed by a 10-mL saline bolus. Using near-infrared lighting, the investigators will determine the time between anterior cerebral arteries (ACA) peak luminescence to the peak luminescence of the superior hypophyseal arteries enveloping the optic chiasm (ACA to chiasm time). Because luminescence of large vessels precedes small arterial penetration, signal from the ACAs was considered as time 0 to account for possible differences in the arm-brain time between patients. In addition, the investigators will analyze the proportion of superior hypophyseal branches on the chiasm that luminesced from ICG."
41507006|NCT03076775|OTHER|Maternal glycemic control|Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
41507007|NCT03196245|OTHER|There is no intervention.|There is no intervention. This is a purely observational study. We enrolled pregnant women as they received a vaccine as part of their regular medical care; we did not administer the vaccine. We also enrolled pregnant women acutely infected with influenza.
41507008|NCT02203409|PROCEDURE|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
41507009|NCT04479644|DRUG|BRII-198|BRII-198 given intravenously
41507010|NCT04479644|DRUG|Placebo|Placebo given intravenously
41164641|NCT03299127|BEHAVIORAL|imagery rescripting|"The long version of the manual contained 4,959 words, the brief version had 3,369 words. Individuals were encouraged patients to time travel to negative personal events, enter the scene and protect or comfort their younger-ego. The participant should bring the negative event to a happy end. This could also be a fictive, compassionate person and may violate the laws of physics (e.g., a person may fly). Readers were encouraged to embellish the scenes as much as possible so that it competed with the original scene. This technique was then applied to future events. For the last technique, patients were asked to seek a corresponding mood-congruent metaphor, creature or symbol; for example, a small bird that has fallen out of its nest. Using their mind's eye, these images may be transformed into something of beauty or pride."
41378763|NCT06430385|PROCEDURE|Sham procedure|An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.
41378764|NCT06650124|DRUG|Mycophenolate Mofetil + Prednisolone Participants will receive mycophenolate mofetil in combination.|Participants in this arm will receive mycophenolate mofetil (MMF) starting at 1,000 mg/day for the first two weeks, increasing to 2,000 mg/day thereafter. This will be combined with prednisolone, beginning at 40-60 mg/day, with a tapering dose to 5-10 mg/day after 4-8 weeks, depending on the patient's response. MMF works by inhibiting inosine monophosphate dehydrogenase, which decreases lymphocyte proliferation, thereby reducing immune-mediated liver damage in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the induction phase of treatment. This intervention lasts for 24 weeks, with monitoring for biochemical remission (normalization of liver enzymes and IgG levels) and adverse events to assess the treatment's safety and efficacy.
41507011|NCT02445534|BIOLOGICAL|Autologous stem cell therapy|All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.
41507012|NCT00685386|OTHER|CO2 insufflation|The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
41507013|NCT00685386|OTHER|Room air insufflation|During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
41378765|NCT06650124|DRUG|Azathioprine + Prednisolone|In this arm, participants will receive azathioprine (AZA) starting at 50 mg/day for the first two weeks, followed by an increase to 100 mg/day. This dose will be combined with prednisolone, starting at 40-60 mg/day, with the dosage tapering to 5-10 mg/day after 4-8 weeks, depending on patient response. Azathioprine works as an immunosuppressive agent by inhibiting DNA synthesis in rapidly dividing immune cells, thereby reducing liver inflammation in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the initial treatment phase. The intervention lasts for 24 weeks with regular monitoring for biochemical remission, defined as normalization of liver enzymes (AST, ALT) and IgG levels, as well as the occurrence of adverse events to assess safety and tolerability.
41378766|NCT06561698|DRUG|Vonoprazan|Potassium competitive acid blocker
41378767|NCT06561698|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
41378768|NCT06561698|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
41378769|NCT06561698|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
41507014|NCT05361915|DRUG|Abivertinib|Abivertinib is a small molecule inhibitor
41507015|NCT05361915|DRUG|Abiraterone|Hormone-based chemotherapy
41507016|NCT00796055|DRUG|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
41507017|NCT00905671|DEVICE|LipiScan Coronary Imaging Catheter|Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
41507018|NCT02389231|DRUG|Interleukine-2|"Four courses of IL2 ( \[Proleukin, Novartis\]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out."
40851077|NCT03653988|PROCEDURE|PEC I/II blocks by surgeon - intra-operative|PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
41034359|NCT04450589|OTHER|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
41034360|NCT04450589|OTHER|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
41034361|NCT04450589|DIETARY_SUPPLEMENT|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
41034362|NCT04450589|OTHER|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
41034363|NCT04450589|OTHER|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
41034364|NCT04450589|OTHER|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
41034365|NCT00388414|DRUG|duloxetine|30-60mg of duloxetine daily
41034366|NCT00388414|DRUG|Placebo|Placebo pill once daily
41378770|NCT06650046|PROCEDURE|Topping-off Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
41507019|NCT00693043|DRUG|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
41507020|NCT04420494|OTHER|Umbilical Cord Blood|The diagnosis is definitely immune cytopenia (IRC), including autoimmune hemolytic anemia (AIHA, Hgb \<100g / L, acquired pure red aplastic anemia (PRCA, Hgb \<100g / L, EVANS syndrome , Hgb \<100g / L and / or platelet count \<30 × 109 / L, or blood cell reduction secondary to immune diseases (the same as the treatment indications, or neutrophils \<0.5 × 109 / L), at least after hormone therapy Patients who are ineffective (did not reach PR after 4 weeks of hormone therapy) or who have not achieved PR after 3-5 mg / kg / d of cyclosporine. These patients would be treated with umbilical cord blood.
41507021|NCT05317338|BEHAVIORAL|Group-based exercise training during hospitalization|Multicomponent exercises for 5-7 days with acutely hospitalized older.
41507022|NCT03915509|DEVICE|Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis|Lasak Impladent Implants (sandblasted)
41507023|NCT03960125|DEVICE|Photodynamic Therapy|Blue Light Therapy Exposure
40851078|NCT05169606|OTHER|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
40851079|NCT05169606|OTHER|Active Isolated Stretch|"AIS is a specific stretching program developed by Aaron Mattes. This technique is based on these four basic principles:~Isolate the muscle to be stretched. Repeat the stretch eight to 10 times. Hold each stretch for no more than two seconds. Exhale on the stretch; inhale on the release."
40851080|NCT05169606|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients
40851081|NCT05846373|DRUG|Nicotinic Acid 500 MG Extended Release Oral Tablet|Nicotinic acid 500 mg for 12 weeks
40851082|NCT05846373|DRUG|Nicotinic Acid 1000 MG Extended Release Oral Tablet|Nicotinic acid 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
41034367|NCT01597544|PROCEDURE|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
41034368|NCT01892748|DRUG|Cholecalciferol|All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
41378771|NCT06650046|PROCEDURE|Fusion Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
41378772|NCT06487390|BEHAVIORAL|PrEP Pro training intervention|Training intervention adapted from evidence-based HIV epidemiology, sexual history taking, and PrEP prescription curricula.
41378773|NCT04059484|DRUG|Amcenestrant|"Pharmaceutical form: Capsule~Route of administration: Oral"
41378774|NCT04059484|DRUG|Fulvestrant|"Pharmaceutical form: Solution for injection~Route of administration: Intramuscular"
41034369|NCT01892748|DRUG|Placebo|The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
41034370|NCT03317704|BEHAVIORAL|Speed endurance training|Speed endurance training
41034371|NCT03649022|DEVICE|Catheter ablation|Ventricular Tachycardia ablation, that will be performed per clinical practice, by using EnSite Precision mapping system with the Flexability catheter (St.Jude, now Abbott)
41034372|NCT05663047|OTHER|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
41378775|NCT04059484|DRUG|Anastrozole|"Pharmaceutical form:Tablets or capsules~Route of administration: Oral"
41378776|NCT04059484|DRUG|Letrozole|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
41378777|NCT04059484|DRUG|Exemestane|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
41378778|NCT04059484|DRUG|Tamoxifen|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
41378779|NCT00759369|OTHER|Water prescription|Water prescription in 12 to 16 equally divided doses
41378780|NCT05891795|DRUG|Clascoterone 1% Top Cream|Apply a thin layer to the affected area twice daily.
41378781|NCT05891795|DRUG|Vehicle|Apply a thin layer to the affected area twice daily.
41378782|NCT06018363|BIOLOGICAL|Allogenic B7H3 CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^7 cells) , dose 2 (3 × 10\^7 cells), dose 3 (1× 10\^8 cells); Phase 2 : dose of RP2D.
41378783|NCT06650761|DRUG|CDX-622|Up to 3 infusions of one of seven dosages of CDX-622
41378784|NCT06650761|DRUG|Normal Saline|Up to 3 infusions of Normal Saline
41378785|NCT05552157|DRUG|Remternetug (SC)|Administered subcutaneously every 12 weeks
41378786|NCT05552157|DRUG|Matching Placebo (Remternetug)|Administered as subcutaneous injection of placebo every 12 weeks
41378787|NCT05308446|BIOLOGICAL|Cetuximab|Given IV
41378788|NCT05308446|DRUG|Encorafenib|Given PO
41378789|NCT05308446|BIOLOGICAL|Nivolumab|Given IV
41378790|NCT03581500|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
41378791|NCT03581500|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
41378792|NCT05488067|DRUG|atorvastatin|Oral atorvastatin treatment for ALGS children with xanthoma
41378793|NCT05678101|DEVICE|transcutaneous electrical nerve stimulation (TENS)|Chattanooga Physio TENS (DJO Global, Vista, CA)
41378794|NCT05678101|DEVICE|Sham transcutaneous electrical nerve stimulation (TENS)|Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
41378795|NCT04757402|OTHER|Counselling with NSQIP Surgical risk calculator|Use of NSQIP surgical risk calculator to check for patient satisfaction regarding pre operative counseling.
41378796|NCT05400590|PROCEDURE|Peripheral venous blood sample|2.5% of body weight
41378797|NCT05400590|PROCEDURE|Conjunctival impression|Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
41507024|NCT03960125|DRUG|4% Imipramine|A tricyclic antidepressant (TCA) medication. Though it is usually taken orally, topical preparations (4%) has use in topical anesthetics and anti-pain medicaments.
40851083|NCT05846373|OTHER|Placebo|Placebo 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
40851084|NCT01153724|DRUG|BI 1744|10 mcg solution for oral inhalation
40851085|NCT01153724|DRUG|Fluconazole|400 mg capsule
41507025|NCT03960125|DRUG|Base Cream|Control to 4% Imipramine
41507026|NCT06490978|RADIATION|CT Brain|Patient needs follow up ct brain , cbc , CRP
41507027|NCT04007653|OTHER|Observation|No intervention
41507028|NCT03742791|DRUG|TS-134|5 mg to 80 mg oral solution
41507029|NCT03742791|DRUG|Placebo|Matched Placebo oral solution
40851086|NCT05395351|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
40851087|NCT01505816|DEVICE|Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)|Multifocal IOL implantation
40851088|NCT03683953|OTHER|mesenchymal stem cells therapy|mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group
41378798|NCT05858515|DRUG|Baricitinib 4 MG|Nonproprietary name: Baricitinib
41507030|NCT02439970|DRUG|Brincidofovir|
41507031|NCT02439970|DRUG|Valganciclovir|
41507032|NCT05092984|DRUG|Spironolactone|"77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
40851089|NCT03683953|DRUG|0.9% sodium chloride|0.9% sodium chloride in control group
40851090|NCT06137599|OTHER|Capillary analysis|Samples taken between 2 and 6 months after the presumed events. A pre-analytical treatment of the hair (washing, fragmentation), followed by detection by high-resolution mass spectrometry is carried out by an expert laboratory to search for both GHB and psychoactive drugs.
41034373|NCT05663047|OTHER|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
41034374|NCT06462144|DRUG|IMPT-514 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
41507033|NCT05092984|DRUG|Placebo|"77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
41507034|NCT05076448|PROCEDURE|Gonadal veins resection|"Gonadal veins resection (GVR) was performed open, transperitoneal and retroperitoneal endoscopic methods under general anesthesia.~Open GVR was performed in the Trendelenburg position, on the back with the operating table rotating 30° The retroperitoneal approach was employed in the left and/or right iliac region. The GV was mobilized for 10-12 cm and the vein was resected..~Transperitoneal GVR was performed with 3 ports were placed: one 10-mm port in the umbilical region, one 5-mm port in the left or right iliac region, and one 5-mm port 5 cm below the umbilicus. The GV was mobilized over a length of 10-12 cm and the vessel was resected.~Retroperitoneal GVR was performed with the patient in a lateral position and in the reverse Trendelenburg position. A 10-mm camera port was installed in the lumbar region between the posterior superior iliac spine and the lower edge of the XII rib. The GV was mobilized over a length of 10-12 cm and the vessel was resected."
40851091|NCT03416452|DEVICE|vibratory cueing device|ankle brace with vibrator that provides electric stimulus
40851092|NCT03416452|DEVICE|Mobile Gait Trainer|standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
40851093|NCT01569048|DRUG|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
40851094|NCT01569048|DRUG|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
40851095|NCT05966948|DRUG|Dextrose Solution|Prolotherapy is a regenerative tissue therapy that is considered efficacious for reducing the symptoms and morbidity of Knee Osteoarthritis (KOA) using hypertonic dextrose as an injectable substance. Treatment will be given two times, on day 1st and 30th day.
40851096|NCT05966948|DRUG|Normal Saline|Normal Saline will be intra-articular injected and given two times, on day 1st and 30th day.
40851097|NCT05577624|DRUG|AMG 510|Oral tablet
40851098|NCT05577624|DRUG|Rifampin|Oral capsule
40851099|NCT03213834|PROCEDURE|Chest thoracoscopy|Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction
40851100|NCT03213834|PROCEDURE|Chest fibrinolytic therapy|A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
40851101|NCT03213834|DRUG|tPA|tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
41034375|NCT06028269|DEVICE|Smartphone playing a sound|A sound will be played from a portable device (smartphone) during movement
41034376|NCT04016597|DEVICE|Jaeger Masterscreen TM|Single-breath nitric oxide lung diffusing capacity
41034377|NCT04016597|DEVICE|HypAir Medisoft|Single-breath nitric oxide lung diffusing capacity
41378799|NCT05858515|DRUG|Placebo|Placebo
41507035|NCT05076448|PROCEDURE|Gonadal vein embolization with coils|"Procedure was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The vein puncture was performed under ultrasound guidance. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
41507036|NCT05076448|PROCEDURE|Endovascular stenting of the common iliac vein (CIV)|"After providing local anesthesia, the left common femoral vein was punctured, a 0.035 guidewire was inserted into the inferior vena cava (IVC), and then a 10F introducer was installed. A balloon catheter was introduced over the guidewire in the left CIV (XXL balloon, Boston Scientific, diameter 14-18, length 40-60 mm), and double balloon dilation of the vessel was performed with a pressure of 6-8 atm. Then, a delivery system was advanced to the area of stenosis in the left CIV, and stent was deployed at the level of confluence of the left CIV and inferior vena cava (IVC) or with a protrusion in the IVC of no more than 1 cm. For better fixation of stent in the venous lumen and prevention of its displacements and migration, a balloon post-dilatation of the stented vessel was performed. In case of residual stenosis, the balloon angioplasty was performed."
41507037|NCT05642845|DRUG|Atorvastatin film-coated tablet 40 mg|Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.
41378800|NCT03184402|DRUG|DWJ1252|tablet
41378801|NCT03184402|DRUG|Gasmotin|tablet
41378802|NCT03184402|DRUG|Placebo of Gasmotin|tablet
41378803|NCT03184402|DRUG|Placebo of DWJ1252|tablet
41378804|NCT04387227|DRUG|Carboplatin|Given IV
41378805|NCT04387227|BIOLOGICAL|Pembrolizumab|Given IV
41378806|NCT04387227|PROCEDURE|Computed Tomography|Undergo CT
41378807|NCT04387227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41378808|NCT04387227|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41378809|NCT00602641|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41378810|NCT00602641|DRUG|Lenalidomide|Given PO
41378811|NCT00602641|DRUG|Melphalan|Given PO
41378812|NCT00602641|DRUG|Prednisone|Given PO
41378813|NCT00602641|OTHER|Quality-of-Life Assessment|Ancillary studies
41378814|NCT00602641|DRUG|Thalidomide|Given PO
41378815|NCT03587740|DRUG|T-DM1|T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
41378816|NCT06637332|DRUG|Daptomycin for Injection|Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg
41378817|NCT06637332|DRUG|Vancomycin (IV)|Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care
41378818|NCT04059861|DIAGNOSTIC_TEST|Ultrasound|enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
41378819|NCT06636682|BIOLOGICAL|FK-PC101|Up to 7 doses of FK-PC101 will be administered intradermally between Day 1 and Day 180. The immune adjuvant Bacillus Calmette Guérin (BCG) will be given concurrently with Dose 1 (day 1) and Dose 2 (day 8).
41378820|NCT06636682|BIOLOGICAL|Standard of Care (SOC)|Subject receives Investigator-defined standard of care, excluding adjuvant therapy. If prostate cancer recurs before 12 months after radical prostatectomy, subjects are eligible to receive up to 7 doses of intradermal FK-PC101 vaccine (first 2 given concurrently with BCG).
41378821|NCT00408005|DRUG|Asparaginase|Given IM or IV
41378822|NCT00408005|DRUG|Cyclophosphamide|Given IV
41378823|NCT00408005|DRUG|Cytarabine|Given IT, IV, or SC
41378824|NCT00408005|DRUG|Daunorubicin Hydrochloride|Given IV
41378825|NCT00408005|DRUG|Dexamethasone|Given IV or PO
41378826|NCT00408005|DRUG|Doxorubicin Hydrochloride|Given IV
41378827|NCT00408005|OTHER|Laboratory Biomarker Analysis|Correlative studies
41378828|NCT00408005|DRUG|Leucovorin Calcium|Given PO
41378829|NCT00408005|DRUG|Mercaptopurine|Given PO
41378830|NCT00408005|DRUG|Methotrexate|Given IT or PO
41378831|NCT00408005|DRUG|Nelarabine|Given IV
41378832|NCT00408005|DRUG|Pegaspargase|Given IM or IV
41378833|NCT00408005|DRUG|Prednisone|Given IV or PO
41378834|NCT00408005|RADIATION|Radiation Therapy|Some patients undergo testicular and/or prophylactic cranial RT
41378835|NCT00408005|DRUG|Thioguanine|Given PO
41378836|NCT00408005|DRUG|Vincristine Sulfate|Given IV
41378837|NCT04928599|OTHER|Electronic Health Record Review|Review of medical records
41378838|NCT04928599|OTHER|Interview|Complete interview
41378839|NCT04928599|OTHER|Survey Administration|Complete survey
41378840|NCT06650735|PROCEDURE|BMR resection|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose medial rectus muscle. Area that will be resected will be marked using calipers. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle.~The muscle then excised anterior to the sutures and the stump cut flush to the sclera.~The muscle will be sutured again to the original insertion by scleral sutures which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
41378841|NCT06650735|PROCEDURE|BLR recession|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose lateral rectus muscle. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle close to the insertion.~The muscle will then be cut anterior to the sutures flush with the sclera. Calipers will used to mark the new insertion on sclera measured from the stump. The muscle will be sutured again to the new insertion by scleral sutures, which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
41378842|NCT06596694|BIOLOGICAL|Patritumab deruxtecan|Administered via intravenous (IV) infusion
41034378|NCT06633640|COMBINATION_PRODUCT|Conventional flap with algae-based substitute (AlgOss) combined with collagen membrane.|The graft material will be prepared following the manufacturer instruction, transferred into a sterile cup than the mixture is condensed without overfilling in the intrabony defect to the level of the surrounding bony walls. The filled site will be than covered with collagen membrane.
41034379|NCT00884481|OTHER|Natalizumab|Participants treated with Tysabri
41378843|NCT05427370|PROCEDURE|Revascularization by PCI|"Contemporary, State-of-the-art PCI techniques will be encouraged in STICH3C, based on the most recent evidence and clinical practice guidelines recommendations. The best practices to be followed include the use of physiological and intravascular guidance, new-generation drug-eluting stents or scaffolds, rotational or orbital atherectomy for extensive calcifications, recommended bifurcation techniques, chronic total occlusion for viable segments by experienced operators, and trans-radial access.Planned temporary ventricular support is permitted by experienced operators when deemed indicated."
41378844|NCT05427370|PROCEDURE|Revascularization by CABG|The surgical revascularization strategy will be tailored according to the individual patient's coronary anatomy, left ventricular remodeling, aortic atherosclerosis, co-morbidities, local expertise, and surgical judgement. An internal thoracic artery will be used to graft the left anterior descending in all cases. Multi-arterial grafting may be considered in patients without significant co-morbidities and with expected limited vasopressor use, or in patients without saphenous conduits. Choice of on- vs. off-pump surgery is influenced by LV size, associated valvular disease, and aortic atherosclerosis, as well as surgeon experience, but on-pump surgery is recommended routinely. The use of adjunctive intra-aortic balloon support or other cardiac support is not routinely recommended in stable patients; the intra-aortic balloon support is the first line mechanical support.
41378845|NCT06542666|OTHER|Cognitive Functional Therapy|"The intervention focuses on addressing the maladaptive cognitive, physical, and lifestyle behaviors related to the disorder.~Cognitive functional therapy will focus on factors considered to contribute to the pain disorder, addressing the following topics:~1. The multidimensional nature of persistent pain, beliefs, emotions, and behaviors (movement and lifestyle) that can reinforce a vicious cycle of pain sensitization and disability.~2. Specific functional training designed to normalize maladaptive and provocative postural and movement behaviors as directed by the individual's presentation.~3. Targeted functional integration into daily activities that are avoided and/or provocative for the patient.~4. Counseling on physical activity and lifestyle, which will include promoting a gradual increase in physical activity based on the individual's preference and availability, advice on sleep hygiene, stress management strategies, and social re-engagement"
41378846|NCT06542666|OTHER|Exercises|"Individuals allocated to this group will perform stretching and strengthening exercises. The self-stretching exercises will target the upper trapezius and posterior shoulder region. Each stretching exercise will be performed for 3 repetitions of 30 seconds, with an interval of 10 seconds between repetitions.~The strengthening exercises will be performed using resistance elastic bands. Three sets of 10 repetitions will be performed for each strengthening exercise, with 1 minute of rest between sets. The strengthening exercises will target the lower and middle trapezius, anterior serratus, and the external and internal rotators of the shoulder."
41378847|NCT05154487|DRUG|Alpelisib Pill|Kinase inhibitor
41378848|NCT05154487|DRUG|Fulvestrant injection|estrogen receptor agonist
41378849|NCT06611085|OTHER|cold application group|The index finger of the child will be used in the cold application group. In this group, cold application will be performed by placing the index finger of the designated hand on a 10 x 10 cm ice pack for 30 seconds and then removing the ice pack immediately.
41378850|NCT06611085|OTHER|vibration group|The middle finger of the child will be used in the vibration group. In this group, vibration was applied by targeting the tip of the middle finger area using a vibrator device measuring 2x1x3 cm. The insertion of the needle will coincide with the application of the vibration stimulation.
41378851|NCT06611085|OTHER|vibration and ice group|In the vibration and ice group, cold and vibration stimulation will be applied to the child simultaneously. The ring finger of the designated hand was placed on a 10x10 cm ice pack for 30 seconds and subjected to cold application. Simultaneously, vibration stimulation will be applied to the tip of the middle finger area using a vibrator device with dimensions of 3x1 cm and 2x1 cm. After 30 seconds, the ice bag will be removed and the lancet pen will be adjusted for drilling from the fingertip while vibration stimulation continues.
41378852|NCT03712605|OTHER|Best Practice|Receive standard of care observation
41378853|NCT03712605|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41378854|NCT03712605|PROCEDURE|Computed Tomography|Undergo PET-CT or CT
41378855|NCT03712605|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41378856|NCT03712605|BIOLOGICAL|Pembrolizumab|Given IV
41378857|NCT03712605|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
41378858|NCT03712605|RADIATION|Radiation Therapy|Undergo radiation therapy
40851102|NCT03213834|DRUG|DNase|DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
41034380|NCT05497284|DRUG|LTP001|LTP001 will be administered once daily in the morning
41034381|NCT05497284|DRUG|Placebo|Placebo to LTP001 will be administered once daily in the morning
41034382|NCT05497284|DRUG|Standard of Care (SoC)|nintedanib, pirfenidone, or neither
41034383|NCT04194190|DRUG|Individual Patient TCR-Transduced PBL|
41034384|NCT04239989|DRUG|Itacitinib|Given PO
41034385|NCT04239989|DRUG|Itacitinib Adipate|Given PO
41034386|NCT00311272|BIOLOGICAL|MelCancerVac|
41507038|NCT05642845|DRUG|Liprimar® film-coated tablet 40 mg|"Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin."
41378859|NCT05813392|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia|a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
41507039|NCT05170282|DIAGNOSTIC_TEST|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
41507040|NCT06101160|DRUG|onaBoNT-A|injection under ultrasonography
41507041|NCT06070558|DEVICE|MRI with Real Time MRI Rapid Flash sequence|MRI examination of temporomandibular joint with Real Time MRI Rapid Flash sequence
41507042|NCT06467396|DEVICE|Large Vessel Occlusion Biomarkers Test|Duplex Point of Care test to measure the concentration of blood biomarkers (FABP+NT-proBNP) associated to Large Vessel Occlusion in blood samples used in combination with an APP.
41507043|NCT03994822|DEVICE|Mechanical Thrombectomy using the pRESET Thrombectomy device|Clot removal using the pRESET Thrombectomy device
41507044|NCT03994822|DEVICE|Mechanical Thrombectomy using the Solitaire Revascularization Device|Clot removal using the Solitaire Revascularization Device
41507045|NCT02171780|DRUG|BI 1744 CL|
41507046|NCT02171780|DRUG|Placebo|
41507047|NCT04792424|OTHER|Regional citrate anticoagulation|Starting RCA 4 mmol/L (adjust the rate by BFR)
41507048|NCT04792424|DRUG|Vasopressor|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
41378860|NCT06598800|DRUG|Drug: BG-T187|Intravenous administration
41378861|NCT04781309|DRUG|NT-I7|NT-I7 is a recombinant human interleukin-7 fused to a hybrid fragment crystallizable region of a human antibody (hyFc). NT-I6 has a molecular weight of 104 kD. The active moiety of NT-I7 is recombinant human interleukin-7 (rhIL-7), containing human IL-7 (amino acids 4 through 155) and exhibiting all known functions of endogenous human IL-7.
41378862|NCT05026424|OTHER|Balance oral nutritional drink - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
41507049|NCT04792424|DRUG|Antibiotic|Antibacterial agents deemed appropriate by physicians in the ICU
41507050|NCT04792424|DEVICE|Dialysis with continuous renal replacement therapy|Prismaflex
41507051|NCT02023294|PROCEDURE|Convetional laparoscopic Sleeve Gastrectomy|Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall
41507052|NCT02023294|PROCEDURE|SILS Sleeve gastrectomy|Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
41507053|NCT02303821|DRUG|Carfilzomib|
41507054|NCT02303821|DRUG|Dexamethasone|
41507055|NCT02303821|DRUG|Mitoxantrone|
41507056|NCT02303821|DRUG|PEG-asparaginase|
40851103|NCT05492786|BEHAVIORAL|Alert|Non-interruptive best practice alert in the electronic health record
40851104|NCT05492786|BEHAVIORAL|Salient alert features|Larger alert header and body font size, use of different font colors and boldface
40851105|NCT05492786|BEHAVIORAL|High-risk Text|Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)
41378863|NCT05026424|OTHER|Balance oral nutritional drink - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
41378864|NCT03213704|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41378865|NCT03213704|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
41378866|NCT03213704|PROCEDURE|Bone Scan|Undergo a bone scan
41378867|NCT03213704|PROCEDURE|Computed Tomography|Undergo a CT scan
41507057|NCT02303821|DRUG|Vincristine|
41507058|NCT02303821|DRUG|Intrathecal (IT) Methotrexate|
41507059|NCT02303821|DRUG|Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|
41507060|NCT02303821|DRUG|6-Mercaptopurine|
41507061|NCT02303821|DRUG|Cyclophosphamide|
41507062|NCT02303821|DRUG|Cytarabine|
41378868|NCT03213704|DRUG|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
41378869|NCT03213704|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41378870|NCT03213704|PROCEDURE|Radionuclide Imaging|Undergo a MIBG scintigraphy
41507063|NCT02303821|DRUG|Daunorubicin|
41507064|NCT04223193|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.
41507065|NCT04223193|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
41507066|NCT06283732|DIETARY_SUPPLEMENT|Greens powder|Participants are to consume one scoop (8.5 g) of the greens powder mixed in 8-10 oz of water every morning before breakfast for two weeks.
41507067|NCT05952674|DEVICE|Vagus Nerve Stimulation (VNS)|The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250μs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.
41507068|NCT05952674|OTHER|Best Medical Treatment|Best Medical Treatment for resistant depression.
41507069|NCT05035277|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
41507070|NCT05035277|DRUG|Apixaban|Standard dose apixaban will be one of the options for the patients in the experimental arm.
41507071|NCT05035277|DRUG|Rivaroxaban|Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
41034387|NCT04256551|OTHER|Heali mobile application + Registered Dietitian|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. RDs employed by Heali provide real-time messaging to users. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
41164642|NCT04647318|BEHAVIORAL|Compassion focused imagery, relaxation imagery and control task|Participants will engage in three tasks (control task, relaxation imagery, and CFI) every three days on a total of 3-4 occasions. Audio-recordings of scripts will be used for both relaxation and compassion imagery. The 4-minute relaxation imagery will involve the following components (i) breathing deeply and bringing mindful awareness to the breath, (ii) relaxing the body, (iii) multisensory mental imagery of a beach or a forest, (iv) noticing feelings that arise. The 4-minute self-compassion imagery scripts will involve the following components: (i) informing participants that showing ourselves self-compassion is an effective emotional-regulation tool, (ii) breathing deeply and attending mindfully to the breath, (iii) imagining oneself embodying the four characteristics of compassion according to Gilbert5, (iv) imagine wishing oneself free of suffering using a warm voice tone and (v) noticing feelings that arise. The control task will involve reading a local city culture magazine.
41164643|NCT00582959|OTHER|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
41164644|NCT00197119|BIOLOGICAL|Twinrix™ Adult|Intramuscular administration in the deltoid region (2 doses).
41378871|NCT03213704|PROCEDURE|X-Ray Imaging|Undergo an x-ray
41378872|NCT02902107|DEVICE|CivaSheet|
41378873|NCT02902107|RADIATION|Brachytherapy|
41378874|NCT02902107|PROCEDURE|surgical resection|
41378875|NCT06649825|DRUG|Vitamin B1|Vitamin B1 tablets, 100mg bid, taken orally for one year
41507072|NCT05035277|DRUG|Edoxaban|Standard dose edoxaban will be one of the options for the patients in the experimental arm.
41507073|NCT06149429|BEHAVIORAL|Personalized virtual reality experience|"The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to go to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset."
40851106|NCT05492786|BEHAVIORAL|Risk factors|Alert body indicates the top 3 factors contributing to the high risk
41034388|NCT04256551|OTHER|Heali mobile application|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
41164645|NCT00197119|BIOLOGICAL|Twinrix™ Junior|Intramuscular administration in the deltoid region (3 doses).
41378876|NCT05492578|DRUG|Amlitelimab|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
41378877|NCT05492578|DRUG|Topical corticosteroids|Pharmaceutical form: Topical Route of administration: Topical
41378878|NCT05492578|DRUG|Topical calcineurin inhibitors|Pharmaceutical form: Topical Route of administration: Topical
41378879|NCT05492578|DRUG|Oral corticosteroids|Pharmaceutical form: Oral Route of administration: Oral
41378880|NCT06179888|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41378881|NCT06179888|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
41378882|NCT06179888|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41378883|NCT06179888|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
41378884|NCT06179888|DRUG|Iberdomide|Given PO
41378885|NCT06179888|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41378886|NCT06179888|PROCEDURE|Patient Monitoring|Undergo disease monitoring
41378887|NCT06179888|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41378888|NCT06179888|PROCEDURE|Skeletal Survey X-Ray|Undergo skeletal survey x-ray
41378889|NCT04401995|DRUG|Vidutolimod (CMP-001)|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
41378890|NCT04401995|BIOLOGICAL|Nivolumab|a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
41378891|NCT04401995|OTHER|[18F]F-AraG PET/CT|\[18F\]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional \[18F\] and existing small molecule PET agents being investigated for immuno-monitoring. \[18F\]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.
41507074|NCT01960023|DRUG|Cetuximab|400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
41507075|NCT01960023|DRUG|Neratinib|"Phase I portion of the study:~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Phase II portion of the study: The recommended dose determined in the Phase I portion of the study."
41034389|NCT04256551|OTHER|Standard Dietary Education|An educational guide to the implementation of the elimination and reintroduction phases of the diet, a suitable/unsuitable food guide, 19 substitutes for unsuitable foods, a guide of example meals (i.e., breakfast-6 recipes, lunch-8 recipes, dinner-12 recipes, and snacks/beverages-13 recipes), and tips for reading labels and eating a balanced diet while following the LFD. The website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System.
41034390|NCT04378244|DRUG|DeltaRex-G|"This is an open label, dose-seeking phase 1/2 study using escalating doses of DeltaRex-G given intravenously for 7 days in a hospital setting.~The study will employ the standard Cohort of Three design (Storer, 1989). Three patients are treated at each dose level with expansion to six patients per cohort if DLT is observed in one of the three initially-enrolled patients at each dose level. If no DLT occurs in 3 patients, escalation to the next dose level will be permitted. The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced DLT, with the next higher dose level having at least two patients who experienced DLT. No intra-patient dose escalation will take place. Patients who do not complete the 7-day treatment will be replaced."
41378892|NCT06011499|OTHER|Internet-Based Exercise Intervention|Participate in online supervised, group resistance training sessions (iLIVE)
41378893|NCT06011499|OTHER|Internet-Based Diet Intervention|Receive online access to an interactive website with a series of weekly self-directed and interactive sessions on various topics associated with diet and weight loss (iLIVE)
41378894|NCT06011499|OTHER|Education Intervention|Receive usual care receiving educational information about diet and exercise for cancer survivors
41378895|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application.|"* An interactive mobile based application will be developed with the following features to assist in monitoring and preventing relapse.~* Purpose of the Mobile based application: The mobile application will be an interactive tool designed to assist in monitoring and preventing relapse of alcohol use disorder. It will provide various features to support users in their journey to sobriety, including personalized recovery plans, goal setting, progress tracking, stress and craving management tools, educational resources, daily reflection prompts, emergency assistance, personalized reminders, progress reports, and psychoeducational videos.~* The Target population: 40 Male patients selected through randomized sampling, aged between 18 and 59 years, who have participated in Nurse-Conducted Brief Intervention (NCBI) for AUD in the Gastroenterology ward with diagnosis of alcohol dependence use disorder based on ICD-10 who have access to smartphone application and have the ability to use it."
41507076|NCT04786587|DIAGNOSTIC_TEST|blood test|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~the blood test for dosage of phosphatidylethanol will be offered to all eligible pregnant women in each maternity clinic of the study during the recruitment period. There will not be different arms in this study."
41507077|NCT04786587|OTHER|self-administered questionnaire|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~A self-report, including the T-ACE, is the usual prenatal consultation procedure in the three maternities of the study. The specific procedure for the study is to perform a blood test for dosage of phosphatidylethanol in eligible pregnant women after informed consent."
41507078|NCT02088697|DRUG|Placebo|
41034391|NCT06495801|BEHAVIORAL|Frendie PRO mobile application|Frendie PRO mobile application offers employees an environment to manage their social relationships, organize leisure activities, and discuss personal or work-related matters.
41034392|NCT02566031|DRUG|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
41034393|NCT02566031|DRUG|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
41034394|NCT01270451|OTHER|Lifestyle intervention to prevent weight regain|To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
41034395|NCT00371891|PROCEDURE|Multidetector Computed Tomography Coronary Angiography|1 Multidetector Computed Tomography Coronary Angiography
41034396|NCT03655353|DIAGNOSTIC_TEST|ABY-PET|Diagnostic PET for HER2 expression
41034397|NCT05978765|DEVICE|Dry Cupping|treated by using dynamic cupping. Heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and a cup will be placed, a vacuum will be created by using vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes.
41164646|NCT04459221|DRUG|Gardasil 9, 9-Valent Intramuscular Suspension|access to HPV vaccination near the college in a health bus
41507079|NCT02088697|DRUG|ASC-01|
41507080|NCT05567510|DRUG|BMS-986369|Specified dose on specified days
41507081|NCT05944146|BEHAVIORAL|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
41507082|NCT05944146|DRUG|Dobutamine|infusion dobutamine
41507083|NCT00442455|DRUG|Erlotinib chlorhydrate|150 mg/day for 7 weeks
41507084|NCT00442455|DRUG|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
41507085|NCT00442455|PROCEDURE|Radiation therapy|63 Gy, five days a week, for 7 weeks
41507086|NCT03170063|PROCEDURE|Procedure/Surgery: Biofluid samplings|Biofluid samplings (blood and cerebrospinal fluid (CSF))
41507087|NCT06500325|PROCEDURE|retrograde titanium elastic nails for fixation of proximal third tibial shaft fractures in children|Two TENs were used in all cases using the double-C construct in most cases to gain three point of fixation. The starting point for nail insertion is 1.5-2.0 cm proximal to the physis of distal tibia. Both nails are then inserted through the entry holes and advanced to pass the level of the fracture site to achieve fixation. The two incisions for nail entry are closed in a layered fashion, and the wounds are well padded with gauze.
41507088|NCT02051348|BIOLOGICAL|Pylopass|Pylopass
41507089|NCT02051348|BIOLOGICAL|Placebo|Placebo
40851107|NCT06579911|DEVICE|High-frequency micro-ultrasound target biopsy|"1. High-frequency micro-ultrasound (transrectal ultrasound, 29 Hz, ExactVu) of the prostate. If suspicious lesions (PRIMUS \>= 3) other than those already detected in multiparametric MRI are found, target biopsy will be performed. Maximum of four cores per lesion.~2. Multiparametric MRI target biopsy (PI-RADS \>= 3) of the prostate (transrectal ultrasound, 29 Hz, ExactVu). Maximum of four cores per lesion.~3. Systematic biopsy (twelve cores) of the prostate"
41378896|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI)|"* Nurse-Conducted Brief Intervention (NCBI) is a feasible and acceptable model of care for males diagnosed with Alcohol Use Disorders (AUDs) in gastroenterology settings. The study found that the Nurse-Conducted Brief Intervention (NCBI) had a positive impact on promoting abstinence in patients with AUDs, and the preliminary findings demonstrate probable good outcomes. \[21\].~* It consists of a trained Nurse delivering three individual sessions with the patient over a span of two to three days (15 to 20 mins each) during their period of admission in the ward and one session with the family members."
41378897|NCT06652984|OTHER|Exercise 1|Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
41378898|NCT06652984|OTHER|Exercise 2|Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
41378899|NCT05047250|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
41378900|NCT04009681|DRUG|THOR-707|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
41378901|NCT04009681|DRUG|Checkpoint inhibitor|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
40851108|NCT06579911|DEVICE|conventional Multiparametric MRT target biopsy|"1. Multiparametric MRT target biopsy (PI-RADS \>= 3) of the prostate (conventional transrectal ultrasound, 8-10 Hz). Maximum of four cores per lesion.~2. Systematic biopsy (twelve cores) of the prostate"
40851109|NCT04962646|PROCEDURE|Carbon dioxide flooding|Once the thoracic cavity is opened a flow of carbon dioxide of 5L/min will be initiated into the surgical wound and proceed until there is no connection between the cardiac or aortic cavity and surrounding air.
41034398|NCT05978765|OTHER|Myofascial Release|e treated by soft tissue myofascial release. Heating pad will be applied for 10 minutes as a base treatment,petroleum jelly will be applied to the area follow by soft tissue myofascial release technique for 5 minutes either criss cross, along the fiber or in figure of 8
41034399|NCT05084872|DRUG|Hydroxychloroquine|Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
41034400|NCT03024073|PROCEDURE|BB-Phaco|Phacoemulsification with bilateral bifocal lenses implantation
41034401|NCT01906294|DRUG|antidiabetic treatment (ATC A10B)|
41034402|NCT06495008|OTHER|no intervention, only questionnaires, saliva collection and taste/smell tests|no intervention, only questionnaires, saliva collection and taste/smell tests
41034403|NCT06309953|DRUG|Miebo|Miebo treatment
41034404|NCT02106468|DRUG|Prednisone tablet 5mg|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
41034405|NCT02106468|DRUG|Omega-3 soft capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
41034406|NCT01417312|DIETARY_SUPPLEMENT|Capsules with 160 mg Teavigo (at least 94% EGCG)|Daily intake of 600 mg EGCG for 3 months
41034407|NCT01417312|DIETARY_SUPPLEMENT|Placebo|Daily intake of placebo capsules for 3 months
41034408|NCT02827877|RADIATION|Copper Cu 64-DOTA-Trastuzumab|Given IV
41034409|NCT02827877|OTHER|Laboratory Biomarker Analysis|Correlative studies
41034410|NCT02827877|BIOLOGICAL|Pertuzumab|Given IV
41034411|NCT02827877|PROCEDURE|Positron Emission Tomography|Undergo PET
41034412|NCT02827877|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41034413|NCT02827877|BIOLOGICAL|Trastuzumab|Given IV
41034414|NCT01133652|DEVICE|Veinviewer|Veinviewer machine
41034415|NCT01133652|DEVICE|Ultrasound|Ultrasound
41378902|NCT04009681|DRUG|anti-EGFR antibody|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
41378903|NCT06171165|DIAGNOSTIC_TEST|Yale Swallow Protocol|"All the participants will receive the two swallow screenings, i.e., Yale Swallow Protocol and Speech-language therapist, to classify the participants into either try swallow or NPO status."
41378904|NCT00335816|DRUG|fluorouracil|Given IV
41034416|NCT01133652|OTHER|Conventional technique|Conventional IV placement by nurses
41034417|NCT02101892|DRUG|Amitriptyline|per os, daily, evening
41034418|NCT02101892|DRUG|placebo|per os, daily, evening
41034419|NCT02568527|DEVICE|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
41034420|NCT05641493|COMBINATION_PRODUCT|HLX208+HLX10|HLX208 is a BRAF V600E inhibitor ,and HLX10 is an anti-PD-1 monoclonal antibody.
41034421|NCT00252642|DRUG|Peginterferon Alpha-2a|
41164647|NCT04749641|BIOLOGICAL|Histone H3.3-K27M Neoantigen Vaccine Therapy|"The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a 6+3 dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC."
41378905|NCT00335816|DRUG|leucovorin calcium|Given IV
41378906|NCT00335816|DRUG|oxaliplatin|Given IV
41378907|NCT00335816|PROCEDURE|conventional surgery|Patients undergo surgery
41507090|NCT01049646|DRUG|Angiotensin II|Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
41507091|NCT01049646|DRUG|Saline|Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
41507092|NCT03089710|OTHER|Mini-fluid challenge|Mini-fluid challenge test with 100mL colloid infusion in 1 min
41507093|NCT05860673|PROCEDURE|mini invasive scoliosis surgery|"The minimally invasive technique, involves two small median skin incisions that allow the deep structures to be exposed. The muscle fibers are separated from the bony insertion by the process of subperiosteal skeletonization. The Investigators then proceed with the arthrectomy of the levels to be instrumented and the infiltration of pedicle screw pairs of the appropriate caliber according to the free-hand technique. After amplioscopic control of proper screw placement, osteotomies of the posterior elements are performed to facilitate correction of the metameres."
41507094|NCT05860673|PROCEDURE|posterior spinal fusion technique|"The standard open technique involves a longitudinal incision along the midline extended along the entire thoracolumbar spine, the paravertebral muscles are incised and spread apart to expose the posterior vertebral structures, in a stretch extending more than 30 cm. The series of facetectomies are performed first, and then pairs of pedicle screws are infixed freehand.~After performing the osteotomies necessary to mobilize the vertebral metameres at the apex of the deformity, correction by derotation maneuvers is continued, and the obtained correction is fixed with pre-shaped bars that are then connected to the screws and tightened to the nuts by dynamometric technique. Almost all vertebral levels of the thoracolumbar tract are included in the arthrodesis"
41507095|NCT01144715|DEVICE|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
41507096|NCT01144715|DEVICE|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
41507097|NCT00061932|DRUG|bortezomib|Given IV
41507098|NCT00061932|DRUG|irinotecan|Given IV
41507099|NCT00716794|DRUG|HE3235|HE3235 will be administered orally in 28 day cycles.
40851110|NCT06576219|BEHAVIORAL|Group Music Therapy|My Life Is Music group therapy model
40851111|NCT02504580|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) by injection.
41507100|NCT00995774|DEVICE|robotic therapy|12 sessions of robot therapy for arm and hand function
41507101|NCT00995774|OTHER|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
41507102|NCT00995774|DEVICE|robotic therapy|12 sessions of robot therapy for arm and hand function
41507103|NCT00995774|OTHER|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
40851112|NCT02504580|DRUG|Placebo|Saline placebo by injection.
41507104|NCT01810757|RADIATION|Standard planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
41507105|NCT01810757|RADIATION|Adaptive planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
41507106|NCT05015257|DIETARY_SUPPLEMENT|Standard F100|100 kcal and 3 g protein per 100 ml
41507107|NCT05015257|DIETARY_SUPPLEMENT|Standard F75 + Plumpynut|Standard F75 with ready to-use therapeutic food (Plumpynut)
41507108|NCT05015257|DIETARY_SUPPLEMENT|Alternative F75 with CMV + Plumpynut|Alternative F75 containing CMV with ready to-use therapeutic food (Plumpynut)
41507109|NCT05015257|DIETARY_SUPPLEMENT|Alternative F75 without CMV + Plumpynut|Alternative F75 with no CMV with ready to-use therapeutic food (Plumpynut)
41507110|NCT03493256|OTHER|exposure to type 2 neurological complications|exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
40851113|NCT02504580|DRUG|HTX-002|HTX-002, by injection or instillation (pooled).
41378908|NCT00335816|RADIATION|radiation therapy|Patients undergo radiotherapy
40851114|NCT02504580|DRUG|Bupivacaine HCI (Marcaine)|Bupivacaine HCI (Marcaine) by injection.
40851115|NCT02504580|DRUG|HTX-011A|HTX-011A (bupivacaine/meloxicam) by injection.
40851116|NCT02504580|DRUG|HTX-011B|HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.
40851117|NCT02504580|DRUG|HTX-009|HTX-009 by injection and instillation (combination).
40851118|NCT01840345|DRUG|N-acetyl-l-cysteine|1200 mg BID x 4 weeks
40851119|NCT03345537|OTHER|Non interventional study|Non interventional study - only data collected and one blood sample additional
40851120|NCT03508700|DRUG|TNX-102 SL 5.6 mg|cyclobenzaprine HCl sublingual tablets
40851121|NCT00759421|DRUG|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
40851122|NCT00759421|DRUG|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
41378909|NCT00335816|OTHER|laboratory biomarker analysis|Correlative studies
41378910|NCT00335816|GENETIC|DNA analysis|Correlative studies
41378911|NCT00335816|GENETIC|polymerase chain reaction|Correlative studies
41378912|NCT00335816|OTHER|immunohistochemistry staining method|Correlative studies
41378913|NCT06525506|BIOLOGICAL|IBI311 (20 mg)|Arm 4: 10 mg/kg IBI311 on Day 1, followed by 20 mg/kg IBI311 from week 3 to week 21, Q3W.
41378914|NCT06525506|BIOLOGICAL|IBI311 (3-20 mg)|Arm 2: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 20 mg/kg IBI311 from week 12 to week 21, Q3W.
41378915|NCT06525506|BIOLOGICAL|IBI311 (10 mg)|Arm 3: 10 mg/kg IBI311 from day 1 to week 21, Q3W.
41378916|NCT06525506|BIOLOGICAL|IBI311 (3-10mg/kg)|Arm 1: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 10 mg/kg IBI311 from week 12 to week 21, Q3W.
41034422|NCT06276192|OTHER|Digital Physiotherapy (diSAID)|"The diSAID is developed by the research group and is a modified version of a previously tested exercise program for patients with subacromial pain. The diSAID is distributed in three stages with; Information about subacromial pain, effects of exercise, pain management and ergonomics in everyday living and at work. The training includes exercises for the rotator cuff and scapular stabilizers as well as posterior shoulder stretch. The exercises are performed 1 time/day during twelve weeks with a progression of dose, load and complexity continuously. Pain while performing the exercise program is accepted up until NRS 5 out of 10.~During ongoing treatment, there is the opportunity for counselling, individualization of exercises, adjustment of dose and load based on stated instructions from the treating physiotherapist.~Adherence, levels of pain and function is reported continuously by the patient via the digital platform."
41034423|NCT06276192|OTHER|Traditional Physiotherapy|Patients in the active control group are offered the usual treatment practice that is currently offered by physiotherapists in primary care. No predetermined directives for the active control group are defined prior to the study and can contain; home exercise programs, manual therapy and other techniques. The treating physiotherapists in this group are not involved in the digital treatment. The choice of interventions, amounts of visits and adherence is checked retrospectively via patient data and medical records.
41034424|NCT05268146|BEHAVIORAL|Lifestyles|Co-creation process and participatory research; lifestyles
41034425|NCT04058769|DEVICE|Premedication Guide|Software with guidelines recommendations for preoperative assessment
41034426|NCT06525181|OTHER|Generative Artificial Intelligence|Gen AI assisted symptom intake summarization
41034427|NCT06525181|OTHER|Standard weekly symptom intake|Standard weekly symptom intake performed by a physician
41034428|NCT04993326|BEHAVIORAL|emPOWERed To Change Program|Online Diabetes Self-Management Education and Support along with COVID-19 prevention and protection (vaccination) education and resource information
41034429|NCT04768322|DEVICE|HeartMate 3 TM Left Ventricular Assist System|The HeartMate 3 TM Left Ventricular Assist System will be implanted within 21 days of randomization.
41034430|NCT04768322|OTHER|Guideline Directed Medical Therapy|Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists and Sodium-GLucose co-Transporter-2 (SGLT2) inhibitors if tolerated.
41034431|NCT03013114|DRUG|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
41034432|NCT00607451|DRUG|Neu-120|Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
41034433|NCT04952545|DRUG|ALXN2050|Oral tablet.
41034434|NCT04952545|DRUG|Placebo|Oral tablet.
41164648|NCT01623206|DRUG|Desmopressin|"Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion."
41164649|NCT02205047|DRUG|Cisplatin|
41164650|NCT02205047|DRUG|5-fluorouracil or Capecitabine|
41164651|NCT02205047|DRUG|Trastuzumab|
41164652|NCT02205047|DRUG|Pertuzumab|
41164653|NCT02205047|PROCEDURE|gastrectomy|D2 gastrectomy
41164654|NCT01730547|BIOLOGICAL|Autologous mesenchymal stem cells|
41164655|NCT04648852|OTHER|Heart failure risk estimation|Evaluation by heart failure risk score
41164656|NCT03847480|RADIATION|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
41164657|NCT02587897|OTHER|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
41164658|NCT02587897|OTHER|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
41164659|NCT03290222|OTHER|TRACK questionnaire|TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
41164660|NCT01359683|DEVICE|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
41164661|NCT04228900|DIETARY_SUPPLEMENT|Individualized plan for improvement of nutrition|For each participant we will make a plan, describing different items the can improve their nutritional status: enrichment of food, dental care,
41164662|NCT04228900|DRUG|Systematic drug review|Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
41164663|NCT03856398|DEVICE|C- MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
41164664|NCT04160429|PROCEDURE|Biospecimen Collection|Undergo collection of sweat, saliva, and blood samples
41378917|NCT06652698|OTHER|Cow's milk formula [CMF]|At least 10 ml daily of cow's milk formula (Bebiko 1 NUTRIFlor Expert®, Nutricia; formula with galactooligosaccharides and without probiotics); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
41378918|NCT06652698|OTHER|Amino-acid formula [AAF]|At least 10 ml daily of amino-acid formula (Nutramigen Pureamino®, Reckitt Benckiser Group PLC); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
41034435|NCT04171700|DRUG|Rucaparib|Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
41378919|NCT06652698|OTHER|Donor human milk [DHM]|At least 10 ml daily of donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
41378920|NCT06652698|OTHER|"High-pressure processed pascalized donor human milk [DHM-P]"|"At least 10 ml daily of high-pressure processed pascalized donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided."
41378921|NCT04870645|PROCEDURE|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
41378922|NCT04870645|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo conventional MRI
41378923|NCT04870645|DRUG|Gadolinium-Chelate|Contrast agent
41378924|NCT04870645|DRUG|Iopamidol|Contrast agent
41378925|NCT06581146|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
41378926|NCT05112965|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
41378927|NCT05112965|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
41378928|NCT05112965|DRUG|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
41378929|NCT05112965|DRUG|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
41378930|NCT05112965|DRUG|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
41378931|NCT06650462|BEHAVIORAL|Community-led discussion|Participants engage in weekly community-led small group discussions about health related topics
41034436|NCT01436903|DEVICE|Thermal Balloon Endometrial Ablation|Thermal Balloon Endometrial Ablation for 10 minutes after curettage
41034437|NCT05157893|DEVICE|Virtual reality based analgesic therapy|The intervention is a single 15 min VR therapy. The VR therapy is consisted of VR device and software. The model of VR device used is Pico Neo 3 Pro. The software run on the VR device delivers two types of contents: 1) A 7min of computer-generated 360 video of underwater scene with therapeutic music to distract patients' attention on pain and make patients passively relax. 2) An 8min guided relaxation in which patients are transported to seaside with narrative to achieve image and breathing relaxation.
41034438|NCT03389802|BIOLOGICAL|APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|"APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the maximum tolerated dose (MTD) is reached or until dose level 3 (0.6 mg/kg) is complete without the MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
41034439|NCT03389802|BIOLOGICAL|APX005M treatment for newly diagnosed DIPG patients|"The starting dose of APX005M for the DIPG patients will be one dose level below the recommended phase II dose (RP2D) determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
41034440|NCT06147102|PROCEDURE|Surgery|Surgical treatment for the unruptured intracranial aneurysm
41034441|NCT06147102|PROCEDURE|Endovascular|Endovascular treatment for the unruptured intracranial aneurysm
41034442|NCT01022814|DEVICE|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
41034443|NCT06477445|DEVICE|Visual feedback balance training system|Using an visual feedback balance training system to provide a dynamic balance training platform for patients to perform balance training based on visual feedback.
41034444|NCT06477445|OTHER|repetitive facilitative exercise|Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
41034445|NCT06477445|OTHER|conventional therapy|Basic training, including passive joint movement and activities of daily living exercise.
41034446|NCT02045758|DEVICE|Fingerstick|
41164665|NCT04160429|OTHER|Medical Chart Review|Review of medical chart
41164666|NCT04160429|OTHER|Questionnaire Administration|Complete questionnaire
41378932|NCT06650449|OTHER|Mobile App-Based Mental Health Support|This intervention uses a mobile application designed to deliver Cognitive Behavioral Therapy (CBT) techniques. The app provides 12 weekly tasks aimed at reducing emotional distress and depressive symptoms in healthcare workers. Tasks include exercises on emotional regulation, coping strategies, and mindfulness. Participants receive notifications to encourage task completion, and the app tracks progress over the 3-month period. At the start and end of the study, participants will complete the PHQ-9 and GHQ-12 questionnaires to assess their mental health status.
41378933|NCT06641245|DIETARY_SUPPLEMENT|Folic Acid|folic acid (0.6 mg)
41164667|NCT02846597|PROCEDURE|Sustained lung inflation in preterms (SLI).|Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time
41164668|NCT05082623|OTHER|Music|Music medicine
41164669|NCT05082623|OTHER|Earplug|Earplug with noise cancelling
41507111|NCT06551818|OTHER|SesZen-Bio Low Dose 1 (350 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
41164670|NCT00631397|DEVICE|Ultrasound machine|Weekly Bone Density measurements using the Sonometer
41378934|NCT06641245|DIETARY_SUPPLEMENT|5-MTHF (5-methyltetrahydrofolate)|0.625 mg/d (6S)-5-MTHF
41034447|NCT02045758|DEVICE|TAP20-C|
41034448|NCT00277264|DRUG|Tiotropium (Spiriva®)|
41034449|NCT02656797|DRUG|Topical Amphotericin-B 0.4% liposomal gel|Topical Amphotericin-B 0.4% liposomal gel
41034450|NCT00150631|DRUG|Candesartan|placebo controlled double blind
41034451|NCT05734846|DEVICE|Control Lenses (control fitting approach)|Daily wear multifocal lenses for 1 week
41034452|NCT05734846|DEVICE|Test Lenses (test fitting approach)|Daily wear multifocal lenses for 1 week
41034453|NCT06483750|DEVICE|Systane iLux Treatment|The Systane iLux is an approved thermal pulsation device to treat dry eye disease. The application of heat and compression to both eyelids melts meibum in the obstructed glands to restore the secretion and production of meibum to the eye. The Systane iLux will only be administered to the eye to undergo cataract surgery.
41034454|NCT00872144|DRUG|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
41034455|NCT03314415|DEVICE|Aldebaraan Nao H25|The Aldebaraan Nao H25 is a humanoid robot with the capability to interact with people through small movements, gestures, and speech. It does not physically touch the participant at any time.
41034456|NCT06558318|OTHER|Assessment of temporomandibular dysfunction|TMJ dysfunction will be measured using the Fonseca Amnestic Index. The Fonseca Amnestic Index is used to assess the severity of temporomandibular joint (TMJ) dysfunction. The index consists of 10 questions, with each question scored as 0, 5, or 10 points, depending on the severity of symptoms. The maximum total score is 100, where a higher score indicates a more severe level of TMJ dysfunction. Therefore, patients with higher scores on the Fonseca Amnestic Index are considered to have more significant TMJ issues. Based on Fonseca scores, two groups will be formed: those with scores over 20 will be labeled 'with TMJ dysfunction,' and the others 'without TMJ dysfunction.
41034457|NCT05614297|DIAGNOSTIC_TEST|Knee joint laxity test|Patients seen in an outpatient clinic in connection with an ACL injury or in connection with short or long-term follow-up after ACL surgery, will undergo a clinical assessment of their knee injury as part of standard care. This includes an assessment of knee joint laxity using both the Rolimeter and the Lachmeter, to allow for an assessment of agreement between the two methods.
41378935|NCT04998396|BIOLOGICAL|AAV9 BBP-812|Sterile solution for injection for 1-time use via volumetric infusion pump
41378936|NCT04745572|BEHAVIORAL|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
41034458|NCT06535594|OTHER|Laser acupuncture|Laser acupuncture therapy will be performed five times a week for 4 weeks using laser beam. The acupoints on the ear that will be treated with laser acupuncture therapy are Zhouliao (LI12), Chize (LU5), Quchi (LI11), Shousanli (LI10) and Ashi.
41378937|NCT04745572|BEHAVIORAL|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
41507112|NCT06551818|OTHER|SesZen-Bio Low Dose 1 (150 mg liposomal)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
40851123|NCT00488696|DEVICE|Endovascular Bifurcated Stent-Graft|Treatment of Aneurysm involving the proximal aortic arch with endovascular bifurcated stent-graft.
40851124|NCT04510103|DRUG|Moisturizer A, F#9155-005|OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
40851125|NCT04510103|OTHER|Moisturizer B, F#E1387-004|Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.
40851126|NCT04510103|PROCEDURE|Regression|2 week regression period after 6 weeks of moisturizer use.
40851127|NCT04510103|PROCEDURE|Non-Regression|Physical insult (tape stripping) on the lower leg after 6 weeks of moisturizer use.
41034459|NCT06535594|OTHER|Physical therapy|Physical therapy method involved six elbow joint exercises. Patients performed the six exercises sequentially under guidance, each exercise performed five times, three times a day, gradually increasing weight until the movement was effective but below the pain threshold.
41034460|NCT00688636|DRUG|infliximab|5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
41034461|NCT00688636|DRUG|placebo|placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
41034462|NCT05083247|DRUG|mFOLFIRINOX or Gemcitabine nab-paclitaxel|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel
41034463|NCT05083247|RADIATION|Isotoxic High-Dose (iHD)-SBRT|Radiation therapy
41034464|NCT05083247|PROCEDURE|Surgery|Surgery
41034465|NCT05518929|DRUG|Ciprofol|The sedation of gastrointestinal endoscopy with Ciprofol
41378938|NCT01096862|DRUG|peficitinib|oral
41378939|NCT01096862|DRUG|Placebo|oral
40851128|NCT06083298|PROCEDURE|control group|patients will be operated under general anesthesia
40851129|NCT06083298|PROCEDURE|MCP group|patients will receive ultrasound-guided MCP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
40851130|NCT06083298|PROCEDURE|ISP group|patients will receive ultrasound-guided ISP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
41034466|NCT05518929|DRUG|Propofol|The sedation of gastrointestinal endoscopy with Propofol
41034467|NCT02864082|DRUG|PAT-001, 0.1%|PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
41034468|NCT02864082|DRUG|PAT-001, 0.2%|PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
41034469|NCT02864082|DRUG|Vehicle for PAT-001 0.1%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
41034470|NCT02864082|DRUG|Vehicle for PAT-001 0.2%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
41378940|NCT05782907|DRUG|Upadacitinib|Oral Solution/ Tablets
41378941|NCT03728257|BEHAVIORAL|LTGO-Home Based Exercise|The LTGO intervention consists of two phases: Phase 1. Intensive home-based exercise training and behavioral coaching via a telerehabilitation platform, Versatile and Integrated System for Tele-Rehabilitation (VISYTER)/two-way video communication system. Interactive intervention sessions will be delivered to the home via real time video conferencing (up to 12 sessions and a behavioral contract plan to prepare for phase 2); and Phase 2. Transition to self-management. Three telephone sessions (3 monthly counseling sessions) will be delivered over 12 weeks to provide behavioral coaching and exercise reinforcement
41378942|NCT03728257|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
41378943|NCT06531343|PROCEDURE|LDCT scan and simultaneous [18F]FDG PET/CT on new-generation long axial field of view scanner|"18F\]FDG will be injected intravenously, and PET/CT images will be acquired after 60 minutes (± 10 minutes). PET/CT images will be first analysed with the lung window to detect any findings suggestive of a lung tumour.~Whole-body PET/CT images will be then analysed to detect any incidental finding in the chest as well as other anatomical areas included in the field of view. PET/CT images will be considered positive if there is at least one non-calcified lung nodule or any suspicious finding on CT scan characterised by focal \[18F\]FDG uptake deviating from physiological distribution or above physiological background activity."
41378944|NCT06531343|PROCEDURE|LDTC only|The LDCT scan will be performed in single deep inspiratory breath hold. No intravenous contrast will be administered.
41378945|NCT06162624|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT: Therapy that builds in traditional cognitive behavioral therapy principles but emphasizes different processes in behavior change. Delivered over 8 weeks of self-guided study and homework assignments.
41378946|NCT06162624|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"As control condition, CBT book Feeling Good Self-Help Book will be used"
41378947|NCT03066011|DRUG|Isavuconazonium sulfate|Oral and Intravenous
41378948|NCT03066011|DRUG|Voriconazole|Oral and Intravenous
41378949|NCT03066011|DRUG|Posaconazole|Oral and intravenous
41378950|NCT06153758|DRUG|Danuglipron|Danuglipron oral tablets
41034471|NCT06405373|BEHAVIORAL|ReCharge|ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
41034472|NCT06405373|BEHAVIORAL|TakeCharge|TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
41378951|NCT02981628|DRUG|Asparaginase Erwinia chrysanthemi|Given Asparaginase Erwinia chrysanthemi
41378952|NCT02981628|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41378953|NCT02981628|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
41378954|NCT02981628|DRUG|Calaspargase Pegol|Given IV
41378955|NCT02981628|DRUG|Cyclophosphamide|Given IV
41378956|NCT02981628|DRUG|Cytarabine|Given IV or SC
41378957|NCT02981628|PROCEDURE|Diagnostic Imaging|Undergo imaging
41378958|NCT02981628|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
41378959|NCT02981628|DRUG|Leucovorin Calcium|Given PO or IV
41378960|NCT02981628|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
41378961|NCT02981628|DRUG|Methotrexate|Given IT
41378962|NCT02981628|DRUG|Pegaspargase|Given IV or IM
41378963|NCT02981628|DRUG|Vincristine|Given IV
40851131|NCT02253485|DRUG|telbivudine|"in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.~in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV."
40851132|NCT06583811|DRUG|Remifentanil|to compare remifentanil and remimazolam to limit patient movement during long-eye surgeries under local anesthesia.
40851133|NCT06490042|BEHAVIORAL|Questionnaire|A questionnaire about helmet use and attitude towards helmet use.
40851134|NCT00604695|DRUG|Tenecteplase|Intracoronary injection of IV tenecteplase.
40851135|NCT00604695|DRUG|Sterile Saline|Intracoronary injection of IV sterile saline
40851136|NCT00685789|DEVICE|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
41378964|NCT00319488|DRUG|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
41378965|NCT00319488|DRUG|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
41378966|NCT00319488|DRUG|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
41378967|NCT05604235|OTHER|Therapeutic upper limb strength exercise treatment|A treatment with therapeutic strength exercises, twice a week, for two months, with a total of 10 exercises, with 20 repetitions each, aimed at improving the strength of the trapezius and sternocleidomastoid muscles mainly, as well as improving mobility in flexion, abduction and rotation of the affected upper limb. It will take approximately 30 minutes.
41378968|NCT05604235|OTHER|Treatment with passive and active mobilization of the upper limb.|A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulo-humeral complex and neurodynamics, where mobilizations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
41378969|NCT00029159|DRUG|estrogen|Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
41378970|NCT00029159|DRUG|androgen|Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
41378971|NCT00029159|OTHER|placebo|an inactive substance
41378972|NCT06651645|OTHER|COVID-19 Surge|Impact of COVID-19 pandemic on hospital care delivery
41378973|NCT04402788|DRUG|Atezolizumab|Given IV
41507113|NCT06551818|OTHER|SesZen-Bio High Dose 1 (500 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
40851137|NCT00685789|DEVICE|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
41034473|NCT05291208|COMBINATION_PRODUCT|Combined tACS and Cognitive Training Program|The program contemplates 12 WM training sessions based on tasks of storage and manipulation of verbal and visuospatial information, with a frequency of twice a week during six weeks (total of 12 sessions). Patients will receive real electrical stimulation for 10 minutes during verbal working memory task. This includes 10s periods of phase-in and 10 s of phase-out and will be done in parallel with the cognitive intervention program in sessions 3, 4, 5, 6, 7, 8, 9, and 11. The electrical stimulation will be applied with two 3x1 arrays of electrodes. The central stimulation electrodes will be positioned in F3 and CP3 (10-20 system). The AC stimulation will be one mA from the baseline to the stimulation peak. The stimulation will have a gamma sine waveform (80Hz) over the positive phase of the theta oscillation (between 4 and 8 Hz, adjusted by each subject, Reinhart et al, 2019) phase-locked between arrays with impedances always under 10 kOhm.
41164671|NCT06190184|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
41378974|NCT04402788|PROCEDURE|Biospecimen Collection|Undergo blood and tissue collection
41378975|NCT04402788|PROCEDURE|Computed Tomography|Undergo CT
41378976|NCT04402788|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41378977|NCT04402788|PROCEDURE|Positron Emission Tomography|Undergo PET
41378978|NCT04402788|RADIATION|Radiation Therapy|Undergo radiation therapy
40851138|NCT06039618|OTHER|Referral to Centre of Higher Organizational Level|Referral to Centre of Higher Organizational Level. This means referral from a primary neonatal care center to a secondary one, or from the secondary to the tertiary center.
41378979|NCT06653543|OTHER|Mulligan mobilization with arm movement|mulligan mobilization applied on cervical spine with arm movement
41378980|NCT06653543|OTHER|conventional therapy of cevical radiculopathy|hot pack for 10 minutes, active ranges of motion (AROMs) with 3 sets of 10 repetitions and isometrics for each movement repeated 20 times with the hold of 6 to 10 seconds in each repetition
41378981|NCT05636618|DRUG|[212Pb]VMT-α-NET|Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered every 8 weeks for a maximum of four doses
41378982|NCT05636618|DRUG|[212Pb]VMT-α-NET|Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered at the RPh2D and schedule determined in Phase I dose escalation
41034474|NCT05291208|BEHAVIORAL|Traditional Cognitive Training Program|Participants will start a cognitive intervention program identical to the intervention group. Still, unlike the intervention group, they will receive placebo electrical stimulation, i.e., an electrical current will be applied for a short period at the beginning of the session (30 seconds), and then the stimulation will be stopped. This procedure induces a sensation in the skin similar to the real stimulation without generating a detectable impact on the brain state. They will be performed in parallel to the cognitive intervention program in sessions 1, 2, 3, 4, 5, 7, 9, and 10.
41034475|NCT05487599|GENETIC|LY3884961|• LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
41034476|NCT00803465|DRUG|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
41034477|NCT00803465|DRUG|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
41164672|NCT06190184|OTHER|Control arm|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and/or supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
41164673|NCT01967719|OTHER|mTHS 2.2|Single use of mTHS 2.2
41378983|NCT06653712|DIAGNOSTIC_TEST|Diagnostic Test|"The following clinical data sources are used:~* Personal interview (anamnesis)~* Physical examination~* Questionnaires~* Functional assessment~* Imaging techniques~The following biological materials are used:~• Max. 30 ml of blood"
41378984|NCT00359359|DRUG|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
41378985|NCT00359359|DRUG|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
41507114|NCT06551818|OTHER|Placebo|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
41507115|NCT03495921|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
41507116|NCT03495921|DRUG|Irinotecan|Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.
41507117|NCT03495921|DRUG|Temozolomide|Dose: 100 mg/m2 daily, oral Schedule: Days 1-5, every 21 days Administered at least 1 hour before Irinotecan.
41507118|NCT01080183|OTHER|Patient feedback form|patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
41507119|NCT02468856|DRUG|armodafinil|Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
41507120|NCT02468856|DRUG|Placebo (for armodafinil)|Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
41507121|NCT00238758|DRUG|Omega-3 Polyunsaturated Fatty Acids|
40918481|NCT03892278|BEHAVIORAL|Water-based aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and \<85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and \<85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
41507122|NCT01832571|DRUG|Once daily Truvada®|At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
41507123|NCT03044626|DRUG|Radiotherapy|"Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
41507124|NCT03044626|DRUG|Nivolumab|Nivolumab 240 mg fixed dose (q2w)
41034478|NCT02107521|OTHER|Intracytoplasmic morphologically selected sperm injection|Sperm selection for injection will be performed at 6600x magnification
41034479|NCT02107521|OTHER|Intracytoplasmic sperm injection|sperm selection for injection will be performed under 400x magnification
41034480|NCT01134029|BEHAVIORAL|Stepped Care|This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
41164674|NCT01967719|OTHER|mCC|Single use of subject's own mCC
41164675|NCT01967719|OTHER|NNS|Single administration of 1 mg of nicotine
41507125|NCT00686361|DRUG|Choline supplementation|Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
40851139|NCT06583499|BEHAVIORAL|Sustainable nutrition education based on the transtheoretical model|"Before the intervention begins, the Sustainable Nutrition Behaviour Change Stage Survey will be administered to determine participants' training stage. In addition, the Transtheoretical Model (TTM) Based Sustainable Nutrition Scales will be administered to evaluate the effectiveness of the training programme.~TTM Based Nutrition Training Programme consists of 11 modules developed according to the stages of the model.The methodology and tools used are aligned with the objectives of the training programme.The training modules are offered twice a week, with each session lasting a maximum of 40 minutes and continues for a total of 5 weeks. Participants may attend more than one training session in order to develop behaviours that increase adherence to a sustainable diet. At the end of the training programme, data from the Transtheoretical Model-Based Sustainable Nutrition Behaviour Scale will be collected again and evaluated by comparison with the baseline data set.."
40851140|NCT01555333|DRUG|arbaclofen|A flexible dose titration will be utilized. Orally disintegrating tablets
40851141|NCT03985371|DRUG|EDTA Eye Drops|One drop in the Band Keratopathy affected eye only, two times per day for six months.
40851142|NCT03523702|DRUG|PembroRT|Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.
40851143|NCT03523702|DRUG|ChemoRT|Patients whose tumors are found to have low (\< 50%) PD-L1 expression will automatically be placed in the ChemoRT group. These patients will receive radiotherapy over a course of four to seven weeks. During radiotherapy, patients will also receive two standard chemotherapy agents (carboplatin and paclitaxel) once each week. Following completion of chemotherapy and radiotherapy, patients may receive additional treatments with chemotherapy or immunotherapy as part of routine care. These treatments are optional and are not required by this clinical trial.
40851144|NCT03747640|DEVICE|Self Transcranial Direct Current Stimulation (tDCS)|tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., New York; 6.5 inches long, 3 inches wide, 0.7 inches thick) with headgear and 5x7 cm saline-soaked surface sponge electrodes.
41034481|NCT05656729|DIETARY_SUPPLEMENT|DefensePlus|Multistrain probiotic:L. plantarum PBS077, L. acidophilus PBS066, B. lactis BL050, Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
41034482|NCT05656729|DIETARY_SUPPLEMENT|Placebo|Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
41034483|NCT04567537|DEVICE|Laser Treatment|Patients will receive three laser treatments at one-month intervals.
41034484|NCT01511952|OTHER|Music Intervention|Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
41034485|NCT01511952|OTHER|Music|Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
41034486|NCT01704417|DRUG|insulin degludec|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
41034487|NCT01704417|DRUG|insulin glargine|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
41034488|NCT02535065|DEVICE|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
41164676|NCT04635085|BEHAVIORAL|Empowerment-based Cognitive behavioral therapy for insomnia for MCI|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups. In total, six face-to-face sessions (90 minutes/session) will be conducted in a small group format with 6-8 participants in a group.
41164677|NCT00153556|BIOLOGICAL|Hib conjugate vaccine (HbOC, Wyeth Vaccines)|
41164678|NCT00791297|DRUG|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
41164679|NCT03565692|BIOLOGICAL|the lung mycobiota and microbiota profile|"All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~* Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~* Separation of the pellet and supernatant, stored at -20 ° C until testing~* Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~* Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~* Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~* Pseudomonas aeruginosa load measured by qPCR"
41378986|NCT04431960|DRUG|blackcurrant (BC) extract|A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
41507126|NCT01699958|BEHAVIORAL|Problem-solving intervention|Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
41034489|NCT00986167|DRUG|Quetiapine XR|The daily dose of oral Quetiapine XR at the start of therapy is 300 mg on Day 1, 600 mg on Day 2 and up to 800 mg after Day 2. The dose will be adjusted within the usual effective dose range of 400 to 800 mg/day, depending on the clinical response and tolerability of the individual patient.
41378987|NCT03589729|DRUG|Cladribine|Given IV
41378988|NCT03589729|DRUG|Cytarabine|Given IV
41164680|NCT03565692|BIOLOGICAL|the gut mycobiota and microbiota profile|All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
41164681|NCT03851614|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
41164682|NCT03851614|DRUG|Olaparib|Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.
41164683|NCT03851614|DRUG|Cediranib|Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.
41378989|NCT03589729|DRUG|Dexrazoxane Hydrochloride|Given IV
41378990|NCT03589729|DRUG|Gemtuzumab Ozogamicin|Given IV
41378991|NCT03589729|DRUG|Idarubicin|Given IV
41378992|NCT04365127|DRUG|Progesterone 100 MG|Subcutaneous administration twice daily
41507127|NCT04766645|DEVICE|Robotic assisted intervention|Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
41507128|NCT04766645|GENETIC|epigenetic analyses|Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
41507129|NCT04766645|DIAGNOSTIC_TEST|biochemical analyses|Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
41507130|NCT04962386|DRUG|Hormone replacement therapy|HRT women were treated with an estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV, Weesp, the Netherlands).Take this medicine once a day.A course of treatment was defined as 28 days of continuous treatment.One white tablet containing 1mg of estradiol was taken daily for the first 14 days and one gray tablet containing 1mg of estradiol and 10 mg of dynamic progesterone was taken daily for the remaining 14 days.
41034490|NCT04590703|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
41034491|NCT04590703|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
41034492|NCT04838574|OTHER|15 years Follow-up group|Phone recruitment, screening interview and eligibility questionnaire. Patient inclusion during rheumatologic evaluation : questionnaire, examination and data collection in one of the 4 study hospital centers.
41034493|NCT00000457|DRUG|bupropion (Wellbutrin)|"1 pill in the am of 150 mg of Bupropion~1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks."
41034494|NCT00000457|DRUG|Placebo|placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
41034495|NCT02465593|DRUG|PEP503|The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
41034496|NCT02465593|DRUG|5-fluorouracil|225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
41034497|NCT02465593|DRUG|capecitabine|825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
41034498|NCT02465593|PROCEDURE|surgical resection|Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
41034499|NCT02465593|RADIATION|Radiotherapy|Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
41034500|NCT01765634|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) each week, four times for a cycle.
41378993|NCT05691465|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41378994|NCT05691465|PROCEDURE|Computed Tomography|Undergo CT scan
41378995|NCT05691465|RADIATION|Gallium Ga 68-DOTATATE|Given IV
41378996|NCT05691465|DRUG|Lutetium Lu 177 Dotatate|Given IV
41378997|NCT05691465|PROCEDURE|Positron Emission Tomography|Undergo PET
41378998|NCT06047964|DEVICE|DCB|Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
41378999|NCT06047964|DEVICE|POBA|Intracranial PTA balloon catheter
41379000|NCT05903092|DRUG|Durvalumab|1500mg IV on Day 1 of every Cycle
41379001|NCT05903092|DRUG|Monalizumab|1500mg IV on Day 1 of every Cycle
41507131|NCT04196881|OTHER|Knowledge Improvement Program about ADHD|This training program will cover an overview of ADHD, prevalence, causes, symptoms, risk factors, associated impairment, prognosis, and treatment options including behavioral interventions and medication.
41507132|NCT06425965|OTHER|Advanced life support training with high reality simulator|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out with a high reality simulator in line with the information (15 min), scenario implementation (15 min) and debriefing sessions (30 min), respectively.
40851145|NCT03747640|BEHAVIORAL|mindfulness-based meditation|The meditation intervention will be delivered by a recorded device that participants will be given together with the tDCS. All meditation instruction recordings will be done by an experienced mind-body intervention specialist and installed in a user-friendly MP3 player.
41034501|NCT01765634|BIOLOGICAL|Non-mesenchymal stem cells|Other second line drugs are taken.
41034502|NCT02999776|DEVICE|Laser microporation alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
41034503|NCT02999776|DRUG|Standard of care-daily administration of Daivobet|The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
41034504|NCT02999776|DRUG|Laser microporation + topical application of Etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
41034505|NCT03151265|DEVICE|ThermaCare Low Back Heat Wrap|The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.
41034506|NCT02359526|DRUG|IlUVIEN|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
41034507|NCT01949480|PROCEDURE|Thoracotomy|
41034508|NCT01949480|PROCEDURE|Video-Assisted Thoracoscopic Surgery (VATS)|
41034509|NCT00421499|DRUG|dark chocolate|
41034510|NCT05283174|OTHER|Blood sampling to test drug level|To collect blood sample during acute stroke and measure NOAC concentration.
41034511|NCT02459574|PROCEDURE|AVATAR-AF ablation|Experimental ablation protocol
41034512|NCT02459574|DRUG|Anti-Arrhythmic therapy|"Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed."
41034513|NCT02459574|PROCEDURE|Conventional AF ablation|Conventional ablation procedure
41034514|NCT03007823|BIOLOGICAL|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
41034515|NCT05585723|BEHAVIORAL|Questionnaires completion|Prospective, qualitative, observational, single-center study. 1) Two independent translations of the original questionnaires into French, 2) Back-translation of the consensus version into English by a professional bilingual translator 3) We will submit this final version to two opinion leaders in France. 4) Evaluation of the clarity, comprehension and acceptability of the translation of the questionnaire.
41034516|NCT04046874|DRUG|Usual Care|Pain Medication, imaging, referrals to other health services, other health care appointments
41034517|NCT04046874|OTHER|SPLIT Stratified Model of Care|Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
41034518|NCT03822013|DRUG|Miglustat|Treatment with Zavesca regimen based on body surface area as follows: SQRT \[Height (cm) × Weight (kg)\] / 3600 \<1.25 : 200mg TDS 0.88- 1.25: 200mg BID 0.73- 0.88: 100 mg TDS 0.47- 0.73: 100 mg BID \<0.47: 100 mg Daily
41034519|NCT00121238|DRUG|cilengitide|Given IV
41034520|NCT03564379|DRUG|JNJ-42165279|25 mg JNJ-42165279 tablet will be administered orally.
41034521|NCT03564379|DRUG|Placebo|Matching placebo tablet will be administered orally.
41034522|NCT00003951|DRUG|exatecan mesylate|
41034523|NCT00873795|DRUG|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
41034524|NCT02361853|OTHER|Exposure: abundance of Immature Myeloid Cells counts in blood samples|
41034525|NCT02361853|OTHER|Exposure: abundance of Immature Dentritic Cells counts in blood samples|
41034526|NCT02361853|OTHER|Exposure: abundance of Immature monocytes counts in blood samples|
41034527|NCT02361853|OTHER|Exposure: abundance of Immature neutrophils counts in blood samples|
41034528|NCT01369342|DRUG|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
41034529|NCT01369342|DRUG|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
41034530|NCT01369342|DRUG|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
41379002|NCT05903092|DRUG|Carboplatin or Cisplatin|"On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2"
41379003|NCT05903092|DRUG|Etoposide|80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4
41379004|NCT01892813|DRUG|Nicotine replacement therapy - Transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
41379005|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
41379006|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
41379007|NCT01892813|DRUG|Bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
41379008|NCT01892813|DRUG|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
41379009|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
41379010|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
40851146|NCT03747640|DEVICE|Sham Self Transcranial Direct Current Stimulation (tDCS)|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
41034531|NCT03523533|PROCEDURE|Angiocatheter|Placement of angiocatheter in internal jugular vein
41034532|NCT03948776|DIAGNOSTIC_TEST|BodyMetrix body composition ultrasound|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.
41034533|NCT03948776|DIAGNOSTIC_TEST|BodyMetrix body composition ultrasound only|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
41034534|NCT06293729|DRUG|NGGT006|Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).
41034535|NCT05631067|BEHAVIORAL|Remote blood pressure monitoring|Participants will receive a blood pressure monitor to check daily BPs for two weeks post partum
41034536|NCT05631067|DIAGNOSTIC_TEST|NT proBNP assessment|Participants will have biomarker assessment at 0-2 days postpartum
41164684|NCT04010383|DIAGNOSTIC_TEST|virtual reality perimeter|Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.
41164685|NCT03592823|DRUG|Hydroxychloroquine Sulfate 200 Mg Tablet|200 mg, bidpo.
41164686|NCT00522470|DRUG|rosiglitazone|
41379011|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
41379012|NCT01892813|BEHAVIORAL|Tobacco quitline referral|Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
41379013|NCT01892813|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
41379014|NCT01892813|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
41379015|NCT01892813|BEHAVIORAL|Behavioral activation for depressive symptoms|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
41379016|NCT01892813|BEHAVIORAL|Behavioral management of postcessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
41379017|NCT06652555|OTHER|Group 1|without Intervention
41379018|NCT01903213|DRUG|bixalomer|Oral
41379019|NCT06651515|BIOLOGICAL|Allogeneic Pancreatic Endocrine Cell Clusters|Allogeneic Pancreatic Endocrine Cell Clusters
41379020|NCT05728359|OTHER|Observational study|Blood sampling and clinical data collection
41379021|NCT03816319|DRUG|UAE Inhibitor TAK-243|Given IV
41379022|NCT00761735|BIOLOGICAL|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m\^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
41379023|NCT00761735|DRUG|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
41379024|NCT05323253|DEVICE|DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.
41034537|NCT05373251|DIAGNOSTIC_TEST|Whole genomic DNA/RNA tumour sequencing|"All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.~Participants with recurrence will have biopsy and subsequently will undergo rapid sequencing of RNA and DNA followed by bioinformatic analysis to identify somatic mutations or other abnormalities that might be drivers of an individual's cancer or predict response to therapies. These data will be compared to the literature and to a comprehensive database of drugs with the aim of identifying drugs most likely to target individual tumors based on the presence of mutated or abnormally expressed genes in the tumor. Any palliative systemic therapy treatment would be closely monitored for tolerability and response, as part of the general clinical care of someone on systemic therapy. The choice of systemic therapy will be up to the treating medical oncologist and the patient."
41379025|NCT03911700|DEVICE|Phasix™ Mesh|Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).
41379026|NCT05797246|DRUG|Bevacizumab|10 mg/kg IV every three weeks for 3 cycles and then every 6 weeks for a total treatment course of 11 cycles for approximately 1 year total.
41379027|NCT06609252|OTHER|Breast milk odour|On the day of the study, the mothers of the babies will be contacted and fresh breast milk will be obtained from the mother of each baby. In the study, a sterile sponge will be used to smell the breast milk to the baby. Breast milk will be taken as 2 ml, dripped onto a sterile sponge and held 10 cm away from the baby's nose and sniffed 2 minutes before the examination.
41379028|NCT06609252|OTHER|Mother voice|Mothers of premature babies in the mother voice group will be given a voice recorder on the day of the study and will be encouraged to express their feelings and thoughts and say what they want to say to their babies and will be asked to talk to their babies as they wish. The mother's voice, which is recorded 2 minutes before the procedure, will be placed approximately 30 cm away from the baby's ear and a loudspeaker will be placed at the foot end so that the baby can listen to the sound.
41379029|NCT06649604|DEVICE|Vibration Anesthesia Device|The intervention arm of this study is distinguished by way of the use of the Vibration Anesthesia Device
41379030|NCT06649604|PROCEDURE|Panretinal Photocoagulation|Laser treatment for diabetic retinopathy done in a standard fashion
41379031|NCT06379984|DRUG|Buprenorphine|Sublingual buprenorphine
41379032|NCT06652568|DEVICE|ThinkSono System|The ThinkSono Guidance System is a guidance software expected to help non-radiology specialist healthcare professionals produce compression ultrasound image data that meet or exceed the minimal image quality criteria for a remote diagnosis by an expert (e.g. radiologist).
41379033|NCT06650982|OTHER|Pecha Kucha presentation on MDPRI|Students in the experimental arm will be given training on MDRPI.
41379034|NCT05042128|DRUG|LSTA1|LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
41379035|NCT05042128|DRUG|Gemcitabine Injection|Chemotherapy drug provided as solution to be administered via IV infusion.
41379036|NCT05042128|DRUG|Nab paclitaxel|Chemotherapy drug provided as solution to be administered via IV infusion.
41379037|NCT02587117|DRUG|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
41379038|NCT02587117|DRUG|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
41507133|NCT06425965|OTHER|Advanced life support training with web-based simulation|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out by web-based simulation method. Students participate in the web-based simulation application developed by the researcher.
41034538|NCT01518868|DEVICE|Investigational contact lens|Worn on a daily wear basis for one week.
41034539|NCT01518868|DEVICE|PureVision contact lens|Worn on a daily wear basis for one week
41034540|NCT04502329|OTHER|Diet|Energy Restriction Intermittent Fasting Diet
41034541|NCT05967572|OTHER|Research processes;|"1. Before Inspection: information will be obtained and premature babies will be monitored by wearing a pulse oximeter device and their heart rate and oxygen saturation value will be recorded for control purposes. By making video recordings of each premature baby; PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded 3 minutes before the ROP examination. Babies will be fed and changed at least half an hour before the examination.~2. Inspection Sequence: PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded and evaluated from the video recording that continues with the start of the examination.~3. End of Inspection: Infants whose both eye examinations are completed and whose monitoring and video recording continue will be recorded and evaluated 3 minutes after the end of the examination, with PIPP pain score, PBIC comfort score, control oxygen saturation and heart rate values."
41034542|NCT03989804|BEHAVIORAL|Targeted follow-up|2 phone calls and 1 e-mail delivered over 6-8 weeks after enrollment aiming to help and support members to get started using the fitness center and its services.
41034543|NCT04273633|DEVICE|Monopolar 448 kilohertz radiofrequency stimulation|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant shoulder
41034544|NCT04273633|DEVICE|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the dominant shoulder
41164687|NCT05481398|OTHER|Negative Pressure Wound Therapy|The wound is dressed using negative pressure wound therapy comprising of a single layer of sterile gauze followed by placement of a 18 Fr nelaton catheter and the wound further covered with 4 more layers of sterile gauze over the nelaton catheter. The wound is then covered with opsite dressing making it airtight. The nelaton catheter is attached to the wall suction port once the patient is shifted to the bed with pressure set at - 25 mm Hg.
41034545|NCT02388633|PROCEDURE|Plasmapharesis|Clinically-indicated LDL apheresis
41164688|NCT00528710|DIETARY_SUPPLEMENT|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
41164689|NCT02813213|PROCEDURE|Skin micro Grafts|0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)
41164690|NCT02813213|PROCEDURE|Standard skin graft|Standard split thickness (0.3-0.5mm) skin graft
41164691|NCT05729945|BEHAVIORAL|home visiting|The intervention is a three year program that serves families and their first born children through home visiting using paraprofessionals to deliver a hybrid curriculum using the Partners for a Healthy Baby curriculum developed by Florida State University in January 2015.
41164692|NCT00449436|DRUG|TRIZIVIR|TRIZIVIR
41164693|NCT00449436|DRUG|Non-nucleoside reverse transcriptase inhibitor|Non-nucleoside reverse transcriptase inhibitor
41164694|NCT00449436|DRUG|Boosted Protease Inhibitor|Boosted Protease Inhibitor
41164695|NCT03918447|DRUG|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
41164696|NCT03918447|DRUG|Placebo oral capsule|Capsule containing an inert placebo
41164697|NCT02867241|BEHAVIORAL|Behavioral Early|Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
41164698|NCT02867241|BEHAVIORAL|Behavioral Late|After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
41164699|NCT00547183|DRUG|tadalafil|2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
41164700|NCT00547183|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
41164701|NCT00547183|DRUG|placebo|Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
41164702|NCT01982071|DRUG|Micafungin|Intravenous (IV)
41164703|NCT03011905|DRUG|Dexamethasone|4 ml DexaGalen 4 mg/ml
41164704|NCT03011905|DRUG|NaCl (Control)|4 ml NaCl 9 mg/ml
41164705|NCT03011905|DRUG|Paracetamol|Premedication and as needed after operation
41164706|NCT03011905|DRUG|EtoriCoxib|Premedication and first 2 postoperative days.
41164707|NCT03011905|DRUG|Oxycodone|Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
41034546|NCT04545541|DRUG|Nebulised unfractionated heparin (UFH)|Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days.
41034547|NCT03985618|PROCEDURE|Caesarean section|Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
41034548|NCT03985618|PROCEDURE|Induction of Labour|Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
41034549|NCT05147818|OTHER|CBC ,renal function tests , fundus Examination|Laboratory investigations
41164708|NCT03011905|DRUG|Ropivacaine|In brachial plexus block
41164709|NCT00730821|DRUG|BIBW 2992|
41034550|NCT03726905|OTHER|respiratory muscles training|4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time
41164710|NCT00730821|DRUG|BIBF 1120|
41164711|NCT01649505|DRUG|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
41164712|NCT01649505|PROCEDURE|breast reconstruction|Undergo sharp dissection technique
41164713|NCT01649505|PROCEDURE|breast reconstruction|Undergo electrocoagulation dissection technique
41164714|NCT01016223|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
41164715|NCT01016223|DRUG|placebo|Matched placebo swallowed two puffs twice daily
41164716|NCT06187597|DRUG|S-1|Patients received S-1 administration, 70mg/m2 per day, orally on days 1 to 14 and 29 to 42 during radiotherapy.
41164717|NCT06187597|DRUG|Toripalimab|Patients received toripalimab 240 mg every 3 weeks for up to 16 cycles.
41164718|NCT06187597|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 54 Gy in 27 fractions over 5-6 weeks.
41164719|NCT03331432|DIETARY_SUPPLEMENT|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
41164720|NCT03331432|DIETARY_SUPPLEMENT|Placebo|Taking daily placebo capsules for 4 weeks.
41164721|NCT04940780|OTHER|Acupuncture|Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms
41164722|NCT04940780|OTHER|Touch Therapies|Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch
41164723|NCT04868253|DRUG|EMB-01|EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).
41164724|NCT05692271|DRUG|Propranolol|40 mg teva-propranolol taken twice daily for 12 weeks
41164725|NCT05692271|DRUG|Placebo|Matching placebo
41164726|NCT05213325|DIAGNOSTIC_TEST|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits)
41164727|NCT02493881|DEVICE|intraoperative neuromonitoring|NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).
41379039|NCT02431507|DEVICE|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
41379040|NCT00249600|BEHAVIORAL|Contingency management|
41379041|NCT06650202|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
41379042|NCT06650696|BEHAVIORAL|PCE promotion|The intervention requires parents to complete a weekly parent-child interaction task online designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.
41379043|NCT06650696|BEHAVIORAL|Psychoeducation|Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
41379044|NCT06650696|BEHAVIORAL|Emotiaonl skill enhancement|This intervention combines online material with practical, emotion-focused activities. Participants will receive training online on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
41507134|NCT06425965|OTHER|Advanced life support training with hybrid simulation|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out with the hybrid simulation method in which high reality simulator and web-based simulation method are applied together. Students first apply the web-based simulation developed by the researcher. Then they perform the practice on the high reality simulator.
41507135|NCT02042456|DEVICE|Digital Breast Tomosynthesis|digital breast tomosynthesis technology
41034551|NCT03726905|OTHER|sham respiratory muscles training|4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
41034552|NCT03726905|OTHER|aerobic training|12 weeks treadmill walking
41164728|NCT04841070|OTHER|Ages & Stages Questionnaires®, Third Edition (ASQ3)|Investigators will propose to parents of children hospitalized for the treatment of persistent pulmonary hypertension of the newborn a hetero-evaluation via the validated ASQ questionnaire to analyze neuro-psychomotor development.
41164729|NCT04747210|BEHAVIORAL|contextual one-on-one coaching|Training workshop and coaching one-on-one
41379045|NCT06642441|DRUG|Chemotherapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive a 10 mg dose of vitamin D2 injection until adjuvant chemotherapy is completed. They will receive a standard adjuvant chemotherapy regimen, which includes 10 mg of vitamin D2 injections per cycle during treatment. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
41379046|NCT06642441|DRUG|Chemotherapy|Participants will receive a standard adjuvant chemotherapy treatment regimen for each adjuvant chemotherapy cycle. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
41507136|NCT02042456|DEVICE|Automated Whole Breast Ultrasound|Automated Whole Breast Ultrasound
41507137|NCT02042456|DEVICE|Full Field Digital Mammography|
41507138|NCT01185197|DRUG|Myfortic plus low-dose steroid|Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
41507139|NCT01185197|DRUG|Prednisolone|1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
41507140|NCT02310256|OTHER|Five plus exercise training|calf raise exercise
41034553|NCT03796624|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted"
41164730|NCT04747210|BEHAVIORAL|Trainig workshop|Ten-hour training workshop.
41034554|NCT03796624|DEVICE|PODEYE|"Implantation of intraocular lens (IOL). Name: PODEYE It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3."
41034555|NCT04604587|DRUG|1. amyloid PET；2. T807 PET|"1. Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807"
41164731|NCT05573347|PROCEDURE|Rotator Cuff Repair|Surgical repair of one or more ligament(s) that form the rotator cuff shoulder complex (supraspinatus, infraspinatus, subscapularis, and teres minor)
41164732|NCT05573347|PROCEDURE|Bone Marrow Harvest|Procedure in which bone marrow cells are extracted, or harvested, from a given location in the body
41164733|NCT00873678|BIOLOGICAL|Whole blood sample|Whole blood sample (10 ml)
41379047|NCT06651086|BEHAVIORAL|Unstuck and On Target|Unstuck and on Target (Unstuck; Cannon et al., 2021) is a cognitive-behavioral, intervention designed to be feasibly delivered by teachers and school staff in the elementary school setting. It was adapted for and pilot-tested in outpatient mental health. Unstuck targets key executive functions, including flexibility, goal-setting, planning, and coping. Sessions include prescribed content and activities to facilitate guided practice and home extension activities to aid generalization beyond the therapeutic session. It includes both child- and caregiver-directed strategies. It has been shown effective for youth with autism and attention-deficit/hyperactivity disorder.
41379048|NCT06651086|BEHAVIORAL|Unified Protocol for Children|Unified Protocol for Children is a transdiagnostic, cognitive-behaviorally based treatment targeting shared core dysfunctions underlying emotional disorders, including distress intolerance and emotional dysregulation. It was developed by integrating cognitive-behavioral and mindfulness strategies and includes prescribed activities, in-vivo experiments, and home-extension components to promote generalization. It includes both child- and caregiver-directed strategies. In addition to its effectiveness for youth with emotional disorders, recent work supports its efficacy for youth with additional non-emotional disorders (e.g., externalizing challenges, irritability).
41379049|NCT04520087|PROCEDURE|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
41379050|NCT06007378|OTHER|Bupivacaine and ketamine|Bilateral erector spinae plane block (bupivacaine and ketamine)
41379051|NCT06007378|OTHER|Bupivacaine and transdermal fentanyl patch|Bilateral erector spinae plane block (bupivacaine) and transdermal fentanyl patch
41379052|NCT06007378|OTHER|Bupivacain|Bilateral erector spinae plane block (bupivacaine)
41379053|NCT06650111|OTHER|Rereading of biopsies|Rereading of biopsies, blinded to the final diagnosis, by a pathologist specializing in nephropathology. This review includes: an optical microscopy study on a fragment fixed with routine staining, an optical microscopy study on a frozen fragment, an immunohistochemical study on a frozen fragment if available.
41034556|NCT06344312|DRUG|Yangxue Qingnao Granules|When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.
41034557|NCT04614389|OTHER|Contrast-enhanced ultrasound|Non Invasive Imaging Technique. CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion informatio
41034558|NCT04614389|OTHER|Shear Wave Elastography|Non Ivasive Imaging Technique. Shear Wave Elastography (SWE) is a recently developed technique that uses ultrasound to noninvasively assess the mechanical stiffness of tissue by measuring tissue distortion in ponse to an acoustic radiation force impulse from a focused ultrasound beam.
41034559|NCT04614389|DEVICE|Sequoia System|UltraSound System Cleared by FDA 510 (k) K180067
41034560|NCT00202163|DRUG|DHEA|
41379054|NCT06650111|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The clinical data of the care of patients at whom the biopsies belong will be analyzed until the date of the patient's last follow-up (before 12/31/2021).
41379055|NCT05388760|DRUG|Tralokinumab|A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.
41379056|NCT04690946|BEHAVIORAL|Cognitive Behavioral Therapy|14-18 sessions of CBT
41379057|NCT04690946|BEHAVIORAL|Emotion-Focused Therapy|14-18 sessions of EFT
41379058|NCT02407483|DEVICE|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
41379059|NCT02407483|DEVICE|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
41379060|NCT03183739|DRUG|ASP8062|ASP8062 will be administered orally.
41034561|NCT00202163|DRUG|Testosterone|
41034562|NCT03297840|BEHAVIORAL|Dialectical Behavioural Therapy (DBT)|Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
41034563|NCT04786444|BIOLOGICAL|Biological Vaccine VLA1553|Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate
41034564|NCT05222191|DRUG|Spironolactone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
41164734|NCT00751205|DRUG|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
41379061|NCT03183739|DRUG|Placebo|Placebo will be administered orally.
41379062|NCT04903288|GENETIC|Eladocagene Exuparvovec|Four 0.08 milliliters (mL) infusions at a dose of 0.45×10\^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10\^11 vg and a total volume of 320 μl per participant.
41379063|NCT06230705|OTHER|Guided management|Guided Management
41379064|NCT06230705|OTHER|Self management|Self management
41507141|NCT03768362|PROCEDURE|Plication strabismus surgery|The technique was the same as resection up to muscle suturing, in the next step, the sutures were passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures. At the end, conjunctiva was repaired by vicryl 8/0.
41507142|NCT03768362|PROCEDURE|Resection strabismus surgery|resection strabismus surgery
41034565|NCT05222191|DRUG|Chlorthalidone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
41379065|NCT05444361|DEVICE|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.
41379066|NCT05444361|DEVICE|Sham Comparator|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
41379067|NCT04785989|OTHER|[U-13C]glucose|\[U-13C\]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
41379068|NCT04785989|OTHER|[13C5]glutamine|6mg/kg of body weight of \[13C5\]glutamine will be administered as a bolus over 10 minutes (± 1 minute) followed by 6mg/kg/hr body weight continuous infusion for 2 hours through a peripheral IV catheter/line. This infusion rate will allow glutamine tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
41507143|NCT04968184|DRUG|Placebo|Participants will orally receive placebo matching to KBP-5074 tablets QD.
41034566|NCT05222191|DRUG|Placebo|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
41034567|NCT04073043|BEHAVIORAL|Telephone Coaching|Access to Telephone Coaching for a period of 12 weeks
41034568|NCT01049425|DRUG|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
41034569|NCT01049425|DRUG|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
41034570|NCT01049425|DRUG|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
41034571|NCT01049425|DRUG|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
41034572|NCT01049425|DRUG|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
41034573|NCT01637012|PROCEDURE|Implantation|index angioplasty with ALEX stent implatation
41034574|NCT02937545|OTHER|Medication Therapy Management|Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
41034575|NCT02937545|OTHER|Pharmacogenetic testing|Community pharmacist will provide pharmacogenetic testing.
41034576|NCT05088213|PROCEDURE|suction mini percutaneous nephrolithotomy|18Fr suction sheath (Weili, China) was inserted, and 12Fr mini-nephroscope was used, kidney stones was fragmented by pneumatic lithotriptor (LithoClast Master, Switzerland) or Ho:YAG laser（0.8-1.0W\*20-30Hz）, and stone fragments was sucked out with the suction sheath.
41034577|NCT05088213|PROCEDURE|standard percutaneous nephrolithotomy|24-30Fr sheath was inserted, and 20Fr nephroscope (Richard Wolf, Germany) was used, kidney stones was disintegrated and sucked out by ultrasonic-lithotripter (LithoClast Master, EMS, Switzerland or ShockPluse-SE, Olympus).
41034578|NCT02614976|DEVICE|Padding|"Padding webrill (Covidian) TM 6"
41034579|NCT03137511|OTHER|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
41034580|NCT06634966|PROCEDURE|Segmentectomy|The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
41507144|NCT04968184|DRUG|KBP-5074|Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
41034581|NCT05499741|DEVICE|Forehead Temperature-Regulating Therapy|A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.
41034582|NCT01412944|DRUG|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
41034583|NCT01412944|DRUG|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
41034584|NCT04015193|PROCEDURE|Single-port thoracoscopic sympathicotomy (patient care)|Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure
41034585|NCT04166019|BEHAVIORAL|Peer-led self-management program|The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being.
41034586|NCT04166019|BEHAVIORAL|Psycho-education group|The psycho-education group program is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
41034587|NCT04166019|BEHAVIORAL|Usual care|Routine care services consist of monthly psychiatric consultation and treatments prescribed by psychiatrist, nursing advice on community care, brief education (1-2 hourly sessions) about mental illness/treatments by psychiatric nurses, home visits by case managers, and/or referrals to community/welfare services.
41034588|NCT02039050|DRUG|Tiotropium|
41034589|NCT02039050|DRUG|Aclidinium|
41379069|NCT06650826|DIAGNOSTIC_TEST|Determination of anti-platelet factor 4 antibodies in the blood|"The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed."
41034590|NCT06635421|OTHER|Model of care delivery for long-acting injectable ART|This study is assessing a novel model of care delivery, i.e. pharmacist administered long-acting cabotegravir + rilpivirine (CAB+RPV LA). In phase 2 and 3, no medication will be provided by the study. The decision to initiate CAB+RPV LA will be at the discretion of the patient and their provider in accordance with both standard of care and local prescribing practices. This will occur independent of study participation. The study intervention is the model of care for CAB+RPV LA administration. The models of care being studied include (1) pharmacist administered CAB+RPV LA in MetroHealth satellite pharmacy setting (novel model of care); (2) nurse administered CAB+RPV LA in the Infectious Diseases clinic at MetroHealth main campus (current standard of care).
41034591|NCT05209282|OTHER|Video Based Action Observation|Individuals in this group will receive video-based action observation training in addition to the conventional physiotherapy program.
41379070|NCT06032546|DRUG|Budigalimab|Intravenous (IV) Infusion
41379071|NCT06032546|DRUG|Placebo for Budigalimab|IV Infusion
41379072|NCT06032546|DRUG|ABBV-382|IV Infusion
41379073|NCT06032546|DRUG|Placebo for ABBV-382|IV Infusion
41379074|NCT06032546|DRUG|Budigalimab|Subcutaneous (SC) Injection
41379075|NCT06649708|DRUG|HX044|Conventional dose-escalation design with 3+3 cohort size. All administered on a Q3 weekly basis. Dose escalation will be based on the absence of DLTs during the 21-day DLT evaluation after a review of safety data by the Safety Review Escalation Committee. Subjects will continue on study treatment until the subject develops an intolerable toxicity, withdraws consent, develops progression of disease, death, lost to follow-up, start of new anticancer treatment or up to study treatment duration of 24 months, whichever comes first.
41379076|NCT05910840|OTHER|Support-t|Support-t plus usual diabetes care for 18 months
41034592|NCT05209282|OTHER|Live Action Observation|Individuals in this group will receive live action observation training in addition to the conventional physiotherapy program.
41034593|NCT05209282|OTHER|Conventional physiotherapy program|Individuals in this group will only receive a conventional physiotherapy program.
41164735|NCT00751205|DRUG|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
41164736|NCT01781013|OTHER|Technology-supported care|The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
41379077|NCT04557293|DEVICE|Continuous Positive Airway Pressure (CPAP) treatment|Treatment of Obstructive sleep apnoea syndrome with CPAP
41379078|NCT04905238|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure
41379079|NCT05975476|BEHAVIORAL|Physical Activity|Participants will be asked to continuously move at a moderate pace along a park trail for 30 minutes, with limited rest periods. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
41379080|NCT05975476|BEHAVIORAL|Sensory Engagement|Participants will be asked to stay within a specific area of the park, relax and enjoy the scenery and engage their senses (see, touch, smell, and listen to nature). In addition, the participant will be told they can engage in meditation, mindfulness, and daydreaming. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
41379081|NCT06651580|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, urine or stool samples
41379082|NCT06651580|OTHER|Quality-of-Life Assessment|Complete QoL assessment
41379083|NCT06651580|OTHER|Questionnaire Administration|Complete questionnaire
41034594|NCT00465413|DEVICE|Small volume spacer and/or Rinsing the mouth with water|
41034595|NCT04666272|DRUG|dabrafenib|There is no treatment allocation. Patients administered dabrafenib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
41164737|NCT01272323|BIOLOGICAL|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
41164738|NCT01272323|BIOLOGICAL|Cat-PAD Dose 1|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
41379084|NCT03690206|DRUG|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
41379085|NCT03690206|DRUG|Placebo|Placebo for glepaglutide
41379093|NCT06652490|PROCEDURE|Short-axis/out-of-plane approach versus oblique- axis approach for ultrasound-guided internal jugular venous catheter.|"In the group A, The US probe will be placed perpendicular to the venous anatomy in the SAX approach.~In the group B, The US probe will be aligned at 45° angulation with the venous anatomy, and combined with an in plane needle insertion technique. The needle will be advanced from lateral to medial."
41379094|NCT06450522|OTHER|Pharmacist co-management of HF medication optimization|"In addition to usual care, participants with an initial Post-Discharge Medicine Clinic visit randomized to the intervention arm will receive pharmacist co-management of their medications, with the intent of to achieve rapid, maximum-tolerated pharmacotherapy for HFrEF as outlined by the 2021 CCS HF guidelines, and for HFmrEF/HFpEF as outlined by the 2022 ACC/AHA HF guidelines. This intervention will be delivered by a staff pharmacist at the St. Paul's Hospital, using the standard procedures outlined below:~For HFrEF: Where possible, a patient will be prescribed the combination of an ARNI, evidence-based beta-blocker, MRA, and SGLT2i at target HFrEF doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines.~For HFmrEF: We will target ACEI/ARB/ARNI+BB+MRA+SGLT2i. For HFpEF: We will target SGLT2i+MRA +/- ACEI/ARB/ARNI. The intervention will incorporate key components identified in a systematic review of observational studies of pharmacist-led optimization of HF."
41379095|NCT06450522|OTHER|Usual care|Usual care
40851147|NCT03747640|BEHAVIORAL|sham meditation|For sham meditation, the participants will be instructed, approximately every 2-3 minutes, to take deep breaths as we sit in meditation. Time spent giving instructions in the sham meditation intervention will be matched to time spent in the mindfulness intervention.
40851148|NCT06153472|DEVICE|VR-based intervention|The Virtual Reality-based sensory stimulation intervention will last for up to fourteen days, with all interventions administered by a research team. The primary outcomes will include delirium incidence, duration, and severity. The secondary outcomes will encompass patients' psychological well-being (post-traumatic stress disorder, sleep quality, and ICU memory), patients' clinical outcomes, and other outcomes (quality of life, independence, and cognitive function).
40851149|NCT01887353|DRUG|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
41164739|NCT01272323|BIOLOGICAL|Cat-PAD Dose 2|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
41164740|NCT02383238|DRUG|Dapagliflozin|10 mg, oral for 6 weeks
41164741|NCT02383238|DRUG|Placebo|oral for 6 weeks
41379096|NCT00636922|DRUG|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
41379097|NCT01950325|BIOLOGICAL|VRC-HIVMAB060-00-AB|VRC01 Human Monoclonal Antibody
41379098|NCT06415305|DRUG|Winlevi (clascoterone) 1% cream|Dosed twice daily (BID)
41379099|NCT04054323|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.
41379100|NCT06065748|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
41379101|NCT06065748|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.
41379102|NCT06065748|DRUG|Abemaciclib|If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
40851150|NCT01887353|DRUG|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
41164742|NCT04120662|PROCEDURE|Intramedullary screw fixation|A Kirschner wire was introduced in the proximal tuberosity under anteroposterior and lateral fluoroscopic control, following the bone axis and passing through the fracture line; a cannulated compressor screw in a diameter between 45 - 55 mm in the more satisfactory position to achieve the optimal fragments compression.
40851151|NCT05244551|DRUG|ABSK061|In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
40851152|NCT00411814|DRUG|GSK679586|Active Drug
41164743|NCT04120662|DEVICE|Focused Shock Wave Treatment|3 weekly session, one per week, of focused shock waves, using an electrohydraulic device.
41164744|NCT01448382|DEVICE|PillCam® capsule with Given PillCam® Platform|capsule endoscopy
41164745|NCT00297778|DRUG|Pramipexole|Dopamine agonist
41164746|NCT00297778|OTHER|Placebo|
41379103|NCT06065748|DRUG|Palbociclib|If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
40851153|NCT00411814|DRUG|Placebo|Saline
41034596|NCT04666272|DRUG|trametinib|There is no treatment allocation. Patients administered trametinib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
41034597|NCT03708939|DIETARY_SUPPLEMENT|Glucose|Daily consumption of 5g of glucose, for 14 days.
41379104|NCT06065748|DRUG|Ribociclib|If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
41379105|NCT06065748|DRUG|LHRH Agonist|Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.
40851154|NCT05348239|DRUG|Sodium Copper Chlorophyllin|Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.
40851155|NCT02023684|DRUG|control saline|Surgical bed irrigation with saline 40ml
40851156|NCT02023684|DRUG|Lidocaine|surgical bed Irrigation Lidocaine 0.5%, 40ml
40851157|NCT02023684|DRUG|Ropivacaine|surgical bed Irrigation Ropivacaine 0.2%, 40ml
40851158|NCT05777512|PROCEDURE|Gastric Feeds|The participant will receive nutrition via a nasogastric tube. Gastric feedings will be administered as bolus feeds every 3 hours over 1 hour. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
40851159|NCT05777512|PROCEDURE|Jejunal Feeds|The participant will receive nutrition via a nasojejunal tube. Postpyloric feedings will be administered continuously into the jejunum. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
40851160|NCT04371666|DRUG|Pamrevlumab|Pamrevlumab per dose and schedule specified in the arm description
40851161|NCT04371666|DRUG|Placebo|Matching placebo per schedule specified in the arm description
40851162|NCT04371666|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
40851163|NCT04897880|DRUG|Panobinostat|Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day
41164747|NCT01123512|DEVICE|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
41164748|NCT02996318|DEVICE|Paclitaxel coated balloon (SeQuent Please)|Paclitaxel coated balloon (SeQuent Please)
41379106|NCT06065748|DIAGNOSTIC_TEST|FoundationOne Liquid CDx Assay (F1LCDx)|F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).
41507145|NCT04427072|DRUG|Capmatinib|400mg of capmatinib tablets administered orally twice daily
41507146|NCT04427072|DRUG|Docetaxel|Docetaxel 75 mg/m2 by intravenous infusion every 21 days
40851164|NCT05526287|OTHER|Dual-Task Training|"Dual-task training sessions include; walking on treadmill for 10-30 minutes and half of this walking period participants will perform cognitive tasks, cognitive tasks will be repeated on tandem stance position and single leg stance position other half of the session consists of motor-motor dual task activities and gait training on firm and soft surfaces.~Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week."
41034598|NCT03708939|DIETARY_SUPPLEMENT|Aspartame|Daily consumption of six commercially available sachets containing aspartame and glucose as bulking agent (1g each sachet), for 14 days.
41034599|NCT03708939|DIETARY_SUPPLEMENT|Sucralose|Daily consumption of six commercially available sachets containing sucralose and glucose as bulking agent (1g each sachet), for 14 days.
41034600|NCT03708939|DIETARY_SUPPLEMENT|Saccharin|Daily consumption of six commercially available sachets containing saccharine and glucose as bulking agent (1g each sachet), for 14 days.
41034601|NCT03708939|DIETARY_SUPPLEMENT|Stevia|Daily consumption of six commercially available sachets containing Stevia and glucose as bulking agent (1g each sachet), for 14 days.
41034602|NCT03708939|OTHER|No Supplement|Follow up without any dietary supplementation.
41034603|NCT05073133|GENETIC|OAV101|A single Gene Therapy IV infusion at 1.1e14 vector genome (vg)/kg over approximately 60 minutes
41034604|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|Follow-up appointment needs/plans
41034605|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|Laboratory follow-up needs
41034606|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|New medications
41164749|NCT02996318|DEVICE|Sirolimus coated balloon|Sirolimus coated balloon
41164750|NCT05514197|DRUG|Ascorbic acid 5000mg|Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
41164751|NCT05514197|DRUG|Control Rx|Intravenous loading 100ml normal saline
41164752|NCT05955547|OTHER|Prognosis Scoring|To determine the prognosis of patients admitted to ICU with a scoring system that includes inflammation and nutritional status
41164753|NCT01879085|DRUG|Docetaxel|75 mg/m2 IV given over 60 minutes on day 8 every 21 days (1 cycle)
41379107|NCT06649617|OTHER|Control Group (Standard Procedure)|Before the application of nursing interventions ( Intramuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Then , information was given about the nursing intervention to be performed as a standard procedure . The nursing intervention was applied. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary for the patients ( Intramuscular , Intravenous , Subcutaneous Injection), that application was applied. No unnecessary procedure was applied. .
41379108|NCT06649617|OTHER|Music Therapy Group|Before the application of nursing interventions ( intramuscular , intravenous , subcutaneous injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients were made to listen to Büzürk makam, a Turkish musical makam. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( intramuscular , intravenous , subcutaneous injection), that application was performed on the patients . No unnecessary procedure was performed.
41379109|NCT06649617|OTHER|Virtual Reality Group|Before the application of nursing interventions ( Intamuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients watched 3D videos with relaxation effect with virtual glasses. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( Intamuscular , Intravenous , Subcutaneous Injection), that application was performed on the patients . No unnecessary procedure was performed.
41379110|NCT06576752|OTHER|Digital follow-up and uptitration of medications at home after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
41507147|NCT05575232|BEHAVIORAL|Application Group (GA)|The main focus of the application is to assist in the treatment of patients with SAH. The application will address the components of adherence to medication use, blood pressure monitoring and promotion/monitoring of physical activity. In addition, health education tips will be provided, including guidelines for reducing sodium consumption, adopting an adequate and healthy diet, controlling body weight, moderate alcohol consumption and stress management, in accordance with the recommendations of the main guidelines related to the theme¹ ³. The intervention will last eight weeks.
41507148|NCT00956072|DRUG|imatinib mesylate|Patients receive imatinib mesylate
41507149|NCT00956072|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
41507150|NCT03905720|PROCEDURE|Acupuncture|A licensed acupuncturist will assess participants' symptoms and administer acupuncture needles in accordance with traditional Chinese medicine principles and the study protocol. Treatments will provided daily for up to four hospital days.
41507151|NCT03905720|BEHAVIORAL|Pain Counseling|Participants will receive sessions with a counselor trained in pain management. The pain counselor will explain, review, and discuss the contents of a Pain Control booklet. Sessions will include pain assessment, pain education, and coping skills, provided daily for up to four hospital days.
41507152|NCT04134195|DEVICE|Transcranial direct current stimulation|2mA stimulation for 20 minutes
41507153|NCT01122186|BEHAVIORAL|Motivational Interviewing + Cognitive Behavioral Skills Training|The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.
41507154|NCT01122186|BEHAVIORAL|Education Attention Control|"During the first two sessions participants watch the documentary Rock bottom to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary Meth which highlights issues of methamphetamine use through interviews with men in various stages of recovery."
41507155|NCT02018965|DRUG|Niacin|"• Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
41164754|NCT01879085|DRUG|Gemcitabine|given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, given over 67.5 minutes at 10 mg/m2/min
40851165|NCT05526287|OTHER|Home Exercise Program|Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week.
40851166|NCT01714401|DRUG|Salbutamol 2,5 mg|20 min nebulization of 2.5 mg of salbutamol
41379111|NCT06576752|OTHER|Follow-up and uptitration of medications at the hospital outpatient-clinic after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
40851167|NCT01714401|DRUG|Salbutamol 5mg|20 min nebulization of 5 mg of salbutamol
40851168|NCT02157077|DRUG|Aflibercept|Intravitreal Injection
40851169|NCT02371603|DRUG|GSK1278863 25 mg Tablet|A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
40851170|NCT02371603|DRUG|Pioglitazone 15 mg Tablet|"White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning"
40851171|NCT02371603|DRUG|Rosuvastatin 10 mg Tablet|"Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning"
40851172|NCT02371603|DRUG|Trimethoprim 100 mg Tablet|"White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening"
40851173|NCT00627341|BEHAVIORAL|Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP)|AN-EX/RP will consist of in-session exposures to feared eating situations without using avoidance behaviors as well as formal motivational interviewing techniques.
40851174|NCT00627341|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT for anorexia nervosa sessions will focus on behaviorally normalizing eating patterns throughout the day and on cognitively addressing dysfunctional thinking that promotes disordered eating.
40851175|NCT04730531|PROCEDURE|Local infiltration with 0.25% bupivacaine and epinephrine|The local infiltration will occur in 2 stages, separated by 30 minutes. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
40851176|NCT04730531|PROCEDURE|Placebo of equal volume injectable saline|An equal volume of injectable saline will be used in the exact 2 stages as the treatment group. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
40851177|NCT03042884|BEHAVIORAL|Questionnaires|"Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.~Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.~Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.~At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete."
40918482|NCT03892278|BEHAVIORAL|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
41164755|NCT01879085|DRUG|Vorinostat|given orally at the specified dose levels (either 300 mg/daily or 200 mg twice per day) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle)
41164756|NCT01879085|DRUG|Pegfilgrastim|administered on day 9 subcutaneously at 6 mg
41507156|NCT02018965|DRUG|Niacin|"• Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
41507157|NCT03741426|DRUG|Olaparib|Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5
41507158|NCT03741426|DRUG|Cediranib|Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3
41507159|NCT03741426|DRUG|Durvalumab|Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
41164757|NCT05033899|OTHER|ERAS protocol|to compare between Enhanced Recovery After Surgery (ERAS) protocol and conventional care in non-insulin dependent diabetic patients undergoing lumbar spine surgery.
41379112|NCT00685074|BEHAVIORAL|Computer-based Motivational Interviewing|The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.
41507160|NCT01987479|DRUG|Non-Biologic DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
41507161|NCT01987479|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
41507162|NCT01987479|DRUG|Methotrexate|Methotrexate will be administered per investigator's discretion.
41507163|NCT02321033|DIETARY_SUPPLEMENT|soft drinks|soft drinks with palatinose and maltodextrin
40851178|NCT03042884|DEVICE|Wearable Exercise Tracker Watch|"Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.~Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit."
41164758|NCT05245305|OTHER|Mindfulness Based Stress Reduction Program|The intervention was structured as 11 weeks, taking into account the group. The program takes 2-2.5 hours per week. The program includes raisin exercise, body scanning meditation, breath awareness meditation, sitting meditation, mindfull movement, walking meditation, vision meditation, compassion meditation,mindfulness communication and day of silence.
41164759|NCT05183477|OTHER|fast track|short cut for the request of xrays directly at triage
41164760|NCT05183477|OTHER|normal pathway|x-ray would be required according to doctor's clinical evaluation.
41164761|NCT04676633|DRUG|STP705|Investigational Product
41164762|NCT05291806|OTHER|Reference Product|This intervention is based on white rice.
41164763|NCT05291806|OTHER|Wholegrain product Dose A|This wholegrain intervention contains whole cereal kernels.
41164764|NCT05291806|OTHER|Wholegrain product Dose B|This wholegrain intervention contains whole cereal kernels.
41164765|NCT05291806|OTHER|Wholegrain product Dose A, cut kernels|This wholegrain intervention contains cut cereal kernels.
41164766|NCT00988117|DRUG|Rivastigmine Patch 9.5 cm2|Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.
41379113|NCT00685074|BEHAVIORAL|Time control|A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
41379114|NCT02297438|DRUG|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
41379115|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
41379116|NCT02297438|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
41379117|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
41379118|NCT04185025|DRUG|Ceramides|"On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected."
41379119|NCT05232318|OTHER|Leveling and alignment|Root resorption comparison through the use of CBCT
41379120|NCT00337727|DRUG|aprepitant|aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
41379121|NCT00337727|DRUG|Comparator: ondansetron|Ondansetron 8 mg capsule Three day treatment period.
41379122|NCT00337727|DRUG|Comparator: dexamethasone|dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
41379123|NCT00337727|DRUG|Comparator: fosaprepitant dimeglumine|fosaprepitant dimeglumine 115 mg
41379124|NCT00337727|DRUG|Comparator; Placebo (unspecified)|dexamethasone 12mg Pbo tablets.
41379125|NCT00337727|DRUG|Comparator; Placebo (unspecified)|Aprepitant 80 mg \& 125 mg Pbo capsules.
41164767|NCT00990262|RADIATION|Cardiac Computed Tomography|"1. Localization of the heart position in a projectional topographic scan of the chest.~2. Determination of contrast agent transit time: 10 ml contrast agent.~3. CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds."
41164768|NCT00841607|PROCEDURE|pancreaticojejunostomy vs pancreaticogastrostomy|
41164769|NCT06347770|DRUG|Probiotic Blend Oral Tablet|In our study, forty pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered four tablets three times a day (2 g/d) for seven days before surgery until the fourth day after surgery.
40851179|NCT02762214|DEVICE|Clermont-Ferrand Uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1).~After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
41379126|NCT04176354|DRUG|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
41379127|NCT04176354|DRUG|Palbociclib + Letrozole|Palbociclib + Letrozole therapy
41379128|NCT04176354|DRUG|Letrozole|Letrozole monotherapy
41379129|NCT04423211|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
41379130|NCT04423211|DRUG|Apalutamide|Given PO
41379131|NCT04423211|PROCEDURE|Computed Tomography|Undergo PET/CT
41379132|NCT04423211|DRUG|Degarelix|Given SC
41379133|NCT04423211|RADIATION|External Beam Radiation Therapy|Undergo EBRT
41379134|NCT04423211|OTHER|Fluciclovine F18|Given IV
41379135|NCT04423211|DRUG|Goserelin Acetate|Given SC
41379136|NCT04423211|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
41379137|NCT04423211|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41379138|NCT04423211|DRUG|Leuprolide Acetate|Given IM
41379139|NCT04423211|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR
41379140|NCT04423211|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MR
41379141|NCT04423211|OTHER|Quality-of-Life Assessment|Ancillary studies
41379142|NCT04423211|OTHER|Questionnaire Administration|Ancillary studies
41379143|NCT04423211|DRUG|Relugolix|Given PO
41379144|NCT04423211|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41379145|NCT04423211|DRUG|Triptorelin|Given IM
41379146|NCT04423211|RADIATION|Volume Modulated Arc Therapy|Undergo VMAT
41507164|NCT04736225|OTHER|Insulin Self-Titration Education Program|The program contents of instruction included blood glucose self-monitoring, types of insulin, insulin self-administration, insulin dose titration, hyperglycemia or hypoglycemia self-management, diet, and exercise.a 20-min one-on-one training session from a nurse on how to self-titrate the insulin dose. The participants were taught to monitor their before-breakfast and before-dinner blood glucose levels at home and adjust their insulin doses accordingly.
41507165|NCT05250297|OTHER|no intervention|standard prenatal care
41507166|NCT00005553|PROCEDURE|Catheter Ablation|
41507167|NCT05961917|OTHER|5 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 5 cmH2O
41379147|NCT05793060|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine 50 Mcg
41379148|NCT05793060|DRUG|Dexamethasone Phosphate|Dexamethasone 4 mg
41379149|NCT04705896|BIOLOGICAL|20-25% Albumin fluid (100 mL)|"Participants will be randomized to receive albumin (20-25%) during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (i.e. for SLED sessions, at 0 and 4 hours; for IHD sessions, at 0 and 2 hours)."
41379150|NCT04705896|OTHER|0.9% Normal Saline (100 mL)|"Participants will be randomized to receive normal saline 100 mL boluses during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (e.g. for 8 hour SLED sessions, at 0 and 4 hours; for 4 hour IHD sessions, at 0 and 2 hours; for CRRT, after starting/randomization then every 12 hours while continuing on CRRT)."
41379151|NCT05456321|DEVICE|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS)
41379152|NCT05456321|BEHAVIORAL|Cognitive Training|Computerized Cognitive Training
41379153|NCT05456321|DEVICE|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS)
41379154|NCT06615635|DEVICE|DaRT seeds|Diffusing Alpha emitters Radiation (DaRT) treatment to be delivered through radioactive sources inserted into malignant cutaneous squamous cell carcinoma of Immunocompromised Patients
41379155|NCT06652711|BEHAVIORAL|2-month access to mental health app|Participants will have access to the well-being app for two months.
41379156|NCT06652711|BEHAVIORAL|Direct incentive|A $10 gift card are given to participants at the end of the study if they used the app sufficiently.
41507168|NCT05961917|OTHER|10 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 10 cmH2O
41507169|NCT00640315|DRUG|Riociguat (Adempas, BAY63-2521) 1.0 mg|1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
41164770|NCT02778334|OTHER|survey|"Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~1. patients who return home and~2. patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3)."
41164771|NCT04319614|DRUG|Tranexamic Acid Injectable Product|A single dose of tranexamic acid, corresponding to 20 mg/kg in 100 ml saline, will be administered in the beginning of procedure.
41164772|NCT04319614|DRUG|Placebos|100 ml of saline will be administered in the beginning of the procedure.
41164773|NCT05183321|PROCEDURE|periodontal therapy|periodontal cleaning
41379157|NCT06652711|BEHAVIORAL|4-month access to mental health app|Participants will have access to the well-being app for four months.
41379158|NCT06652711|BEHAVIORAL|Lottery incentive|Participants can participate in a draw of $150 gift cards at the end of the study if they used the app sufficiently.
41379159|NCT06308523|DRUG|AP303 150 μg|AP303 Tablet 150 μg QD
41379160|NCT06308523|DRUG|Placebo 150 μg|Placebo Tablet 150 μg QD
41379161|NCT06308523|DRUG|AP303 300 μg|AP303 Tablet 300 μg QD
41379162|NCT06308523|DRUG|Placebo 300 μg|Placebo Tablet 300 μg QD
41379163|NCT01251861|DRUG|Akt Inhibitor MK2206|Given PO
41507170|NCT00640315|DRUG|Riociguat (Adempas, BAY63-2521) 2.5 mg|2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
41164774|NCT02737202|DRUG|saracatinib|Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
41379164|NCT01251861|DRUG|Bicalutamide|Given PO
41379165|NCT01251861|OTHER|Clinical Observation|Undergo clinical observation
41379166|NCT01251861|OTHER|Laboratory Biomarker Analysis|Correlative studies
41379167|NCT05144724|PROCEDURE|Volume targeted ventilation|Positive pressure ventilation will be provided using a set tidal volume
41379168|NCT05144724|PROCEDURE|Pressure targeted ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
41379169|NCT04792073|DRUG|Avelumab|Avelumab 800 mg given intravenously over 60 minutes (+20 minutes / -10 minutes) every 2 weeks (+/- 3 days)
41379170|NCT04792073|RADIATION|Comprehensive Ablative Radiation Therapy|Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days
41379171|NCT06652529|DRUG|AROG4-01|AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.
41507171|NCT03104855|DRUG|d6-25-hydroxyvitamin D3|intravenous administration of stable isotope-labeled D6-25(OH)D3
41507172|NCT02795247|PROCEDURE|Anterior Cruciate Ligament Reconstruction|
41379172|NCT06652529|DRUG|AROG4-01|"AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.~This study is an open label, Phase 1 dose escalation trial with two expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 8 to 20 patients in total will be enrolled in part A, covering up to 6 dose levels.~* Part B: At the dose expansion phase, AROG4-01 two cohorts of ten patients with advanced solid tumor each will be recruited. One cohort of patients with advanced MPM (cohort 1) and a second cohort of patients with other solid tumors (cohort 2)."
41379173|NCT06653829|DEVICE|SPARK|A gamified augmented reality activity to recapitulate the beginning activation and engagement phase of each recovery-oriented cognitive therapy (CT-R) session
41507173|NCT01559883|OTHER|no intervention is being made|This is a Non-Interventional Study (NIS)
41379174|NCT05850260|DEVICE|Macintosh laryngoscope|During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option
41034607|NCT05246423|DIAGNOSTIC_TEST|Observation group|Patients with paroxysmal atrial fibrillation undergo cardiopulmonary exercise testing, echocardiography, 24-hour ambulatory electrocardiographic monitoring and plasma biomarkers' measurement
41379175|NCT05850260|DEVICE|Videolaryngoscope|During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option.
41034608|NCT02370212|DIETARY_SUPPLEMENT|Creatine|
41379176|NCT05554341|PROCEDURE|Biopsy|Undergo biopsy
41379177|NCT05554341|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41379178|NCT05554341|PROCEDURE|Computed Tomography|Undergo CT
41379179|NCT05554341|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41379180|NCT05554341|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO
41379181|NCT05554341|DRUG|Paclitaxel|Given IV
41379182|NCT06402513|DRUG|Ravagalimab|Subcutaneous Injection
41379183|NCT03323944|BIOLOGICAL|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.
41379184|NCT05971732|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
41379185|NCT05971732|DRUG|Placebo|In the placebo group, patients will receive the equivalent number of normal saline injections.
41507174|NCT05706857|BEHAVIORAL|Ultra Fast-track|Patients are extubated in the operating room
41034609|NCT02370212|DIETARY_SUPPLEMENT|Placebo|
41379186|NCT05333458|BIOLOGICAL|Atezolizumab|Given IV
41379187|NCT05333458|PROCEDURE|Biopsy|Undergo biopsy
41379188|NCT05333458|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41379189|NCT05333458|PROCEDURE|Computed Tomography|Undergo CT
41379190|NCT05333458|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41507175|NCT02939794|DRUG|Ferinject|1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
41034610|NCT02370212|OTHER|High intensity interval training|
41034611|NCT03701750|DRUG|Low Molecular Weight Heparin (enoxaparin sodium)|enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
41034612|NCT05652374|DEVICE|Ialuril 50ml Prefill|Bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 1 year
41379191|NCT05333458|DRUG|Selinexor|Given PO
41507176|NCT02939794|DRUG|Placebo|Saline (normal saline, sodium chloride)
41507177|NCT05873790|DRUG|Serplulimab plus chemotherapy|"Serplulimab: 4.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle. Chemotherapy drugs: etoposide + carboplatin/cisplatin Etoposide: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Carboplatin: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles."
41507178|NCT00004757|DRUG|acyclovir|
41507179|NCT00663026|DRUG|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
41507180|NCT00663026|DRUG|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
41034613|NCT05652374|DRUG|Nitrofurantoin|100mg daily (1dd100mg or 2dd50mg) for 1 year. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
41034614|NCT02001480|DEVICE|12 lead Holter|12 lead Holter measurements will be performed for 7 days
41034615|NCT02001480|DEVICE|CGM Continuous Glucose Monitoring|CGM will be performed continously for 7 days
41034616|NCT01709019|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
41034617|NCT01709019|BIOLOGICAL|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)|0.5mL IM injections
41034618|NCT01709019|BIOLOGICAL|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
41379192|NCT06483100|DRUG|Elrantamab|"- Elranatamab will be dosed in 28-day cycles as follows:~* C1D1: 12 mg SC priming dose~* C1D4: 32 mg SC priming dose~* C1D8, C1D15, C1D22: 76 mg SC~* Cycle 2 and all subsequent cycles: 76 mg SC on D1 and D15"
41379193|NCT06483100|DEVICE|clonoSEQ|FDA approved MRD testing
41379194|NCT05753592|DRUG|Part 1; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
41379195|NCT05753592|DRUG|Part 2; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
41379196|NCT06648473|DIAGNOSTIC_TEST|MRI Scan|Subjects will begin the MRI with T1-pre, T2w, and volumetric 3D FLAIR images being obtained. The subject will be brought out of the MRI magnet and moved into a seated position and will then have a standard Brain Tumor Imaging Protocol MRI scan.
41379197|NCT02860039|BIOLOGICAL|Trivalent Influenza Vaccine|High dose Trivalent Influenza Vaccine given intramuscular
41379198|NCT02860039|BIOLOGICAL|Quadrivalent Influenza Vaccine|Standard dose Quadrivalent Influenza Vaccine given intramuscular
41379199|NCT02860039|OTHER|Laboratory Biomarker Analysis|Correlative studies
41507181|NCT00663026|DRUG|placebo|Placebo subcutaneous injection once per week for 6 months
41379200|NCT01539707|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
41379201|NCT06148077|OTHER|Manual Therapy|3 times a week, for 6 weeks.
41379202|NCT06148077|OTHER|Motor control exercises|3 times a week, for 6 weeks.
41379203|NCT02842086|DRUG|F/TAF|200/25 mg tablet administered orally once daily
41507182|NCT02180737|DRUG|Dexmeditomedine|
41379204|NCT02842086|DRUG|F/TDF|200/300 mg tablet administered orally once daily
41507183|NCT03377257|DRUG|zolmitriptan by sublingual administration|Experimental group
41507184|NCT03377257|DRUG|zolmitriptan by oral|Active group
41507185|NCT02246114|DEVICE|piCO+ Smokerlyzer® monitor|
41507186|NCT02246114|OTHER|Text messages|
41507187|NCT00440349|DRUG|Tamoxifen|
41507188|NCT00440349|DRUG|Prednisone|
41507189|NCT01391897|BEHAVIORAL|psychotherapy|"multimodal complex psychotherapy"
41507190|NCT06434974|OTHER|Interview|Interviewer administered questionnaire
41379205|NCT02842086|DRUG|F/TAF Placebo|Tablet administered orally once daily
41379206|NCT02842086|DRUG|F/TDF Placebo|Tablet administered orally once daily
41034619|NCT01709019|BIOLOGICAL|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
41034620|NCT01709019|BIOLOGICAL|Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)|0.5mL IM Injections
41034621|NCT02493127|OTHER|Standard PCS|Subject completes the standard version of the PCS Questionnaire
41034622|NCT02493127|OTHER|Grip Strength|Research Assistant takes Grip Strength Measurements
41034623|NCT02493127|OTHER|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
41034624|NCT06299501|PROCEDURE|Routine questions|The routine group of nurses receive training and supervision and will ask questions about family violence to everyone, disregarding if they suspect family violence or not.
41379207|NCT03375320|DRUG|Cabozantinib S-malate|Given PO
41379208|NCT03375320|PROCEDURE|Computed Tomography|Undergo CT
41379209|NCT03375320|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41379210|NCT03375320|OTHER|Placebo Administration|Given PO
41379211|NCT03375320|OTHER|Quality-of-Life Assessment|Ancillary studies
41379212|NCT03375320|PROCEDURE|X-Ray Imaging|Undergo x-ray
41507191|NCT01867203|OTHER|Genotyping|DNA extraction from blood
41507192|NCT02943135|DRUG|lidocaine in-situ gel|lidocaine in-situ gel
41507193|NCT02943135|DRUG|placebo in-situ gel|placebo in-situ gel
41507194|NCT01148615|DRUG|Aflibercept (AVE0005)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
41507195|NCT01148615|DRUG|Docetaxel (XRP6976)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
41507196|NCT01973595|DIETARY_SUPPLEMENT|Almonds, Then no almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
41507197|NCT01973595|OTHER|No Almonds, Then almonds|No almonds will be consumed by participants for 3 weeks.
41507198|NCT04263181|PROCEDURE|Peripheral blood draw|"* All cohorts will have peripheral blood drawn at baseline no more than 4 days prior to the first dose of chemotherapy and must also occur before the first dose of chemotherapy~* Cohort 0 or 1 - peripheral blood draw on Day 2~* Cohorts 0, 2, 3, 4 and 5 - peripheral blood draw on Day 3~* Cohort 0 or 1 - peripheral blood draw on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - peripheral blood draw on Cycles 2 or 3 and 4 or 5, Day 28"
41507199|NCT04263181|PROCEDURE|Bone marrow aspirate|"* Cohort 0 or 1 - bone marrow aspirate on Day 14~* Cohort 0 or 1 - bone marrow aspirate on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - bone marrow aspirate on Cycles 2 or 3 and 4 or 5, Day 28"
41507200|NCT04263181|PROCEDURE|Buccal swab|"* Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28"
41507201|NCT00577603|PROCEDURE|mesh reinforcement of stoma|Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
41507202|NCT00577603|OTHER|no intervention|
41507203|NCT03490656|DIAGNOSTIC_TEST|MRI Scan - in addition to standard of care|Up to 3 Tesla (T) MRI
41507204|NCT03490656|DIAGNOSTIC_TEST|MRI Scan - not in addition to standard of care|Up to 3 Tesla (T) MRI
41507205|NCT05493501|DRUG|Aumolertinib monotherapy|Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
41507206|NCT05493501|DRUG|Osimertinib monotherapy|80 mg tablet administered orally, once daily
41507207|NCT05493501|DRUG|Pemetrexed|Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
41507208|NCT05493501|DRUG|Cisplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
41507209|NCT05493501|DRUG|Carboplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
41379213|NCT06594289|PROCEDURE|In laparoscopic hepatectomy, the subhepatic inferior vena cava was restricted and the patient was given non-restricted intraoperative fluid intake|"The specific steps of IVC blocking were performed by the principal physician under laparoscopic operation: slightly incision of the posterior peritoneum on both sides of the inferior vena cava above the level of the renal vein. The blood vessel blocking band is passed behind the inferior vena cava on the left or right side of the inferior vena cava. According to the intraoperative situation, the blocking band (flow limiting blocking/incomplete blocking of subhepatic inferior vena cava) was tightened to control the bleeding from hepatic vein on the liver section. Patients in this group did not use vasoactive drugs/underuse means to control CVP, so they need to strictly communicate with the anesthesiologist, and take the fluid intake based on the physiological requirements and fluid loss of individual patients (cancel the restriction of fluid intake)."
41379214|NCT05350969|DRUG|CDR132L|CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
41507210|NCT05493501|DRUG|Paclitaxel|Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
41507211|NCT05493501|DRUG|Nab paclitaxel|Administered by IV Infusion given over 4 fixed cycles per prescribing information.
41507212|NCT05493501|DRUG|Gemcitabine|Administered by IV Infusion over 4 fixed cycles per prescribing information.
41507213|NCT03876626|OTHER|PositiveLinks RX Mobile App|A mobile app designed with tools to facilitate patient self-monitoring, patient-provider communication, medication refills, and social support.
41507214|NCT03876626|OTHER|PositiveLinks RX Portal|An online portal that interacts with the mobile app to enable users to engage with participants though messaging and medication refill tracking.
41507215|NCT01266031|DRUG|vorinostat|Vorinostat 400mg/day will be administered on day 1 to 7 and day 15 to 21 orally on a 28 day cycle in the arm with combination of vorinostat and bevacizumab. Vorinostat will be administered orally. Vorinostat capsules should not be opened or crushed and must be administered whole.
41507216|NCT01266031|DRUG|bevacizumab|Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day cycle in both arms.
41507217|NCT00732485|DRUG|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
41507218|NCT00732485|DRUG|placebo|Placebo, sugar pill, from admission to 6 months post burn
41507219|NCT04637555|DRUG|sacubitril/valsartan|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
41507220|NCT05558566|OTHER|Neurofeedback from the SMA|Feedback is provided regarding activity in the SMA and participant attempts to control SMA activity using the feedback as a training signal
41507221|NCT05558566|OTHER|Neurofeedback from control region|Feedback is provided regarding activity in a control region and participant attempts to control activity in that region using the feedback as a training signal.
41379215|NCT05350969|DRUG|Placebo to CDR132L|Placebo to CDR132L
41507222|NCT05906524|DRUG|KD6001|KD6001 will be administered intravenously.
41034625|NCT06299501|PROCEDURE|Questions on evidence based indication|The group of nurses will receive training and supervision and will ask questions on evidence based indication
41034626|NCT06299501|PROCEDURE|Treatment as usual|The group of nurses will ask questions when suspecting ongoing violence in the family
41379216|NCT06650540|DRUG|Levofloxacin Plus Metronidazole Suppositories|Administer a two-week course of Levofloxacin Plus Metronidazole Suppositories to patients diagnosed with chronic endometritis.
41507223|NCT05906524|DRUG|Tislelizumab|Tislelizumab will be administered intravenously.
41507224|NCT05906524|DRUG|Bevacizumab|Bevacizumab will be administered intravenously.
41507225|NCT04613492|BIOLOGICAL|MEDI9253|Participants will receive either Single dose MEDI9253 or Multiple Dose MEDI9253; sequentially or concurrent with Durvalumab
41507226|NCT04613492|BIOLOGICAL|Durvalumab|Durvalumab treatment will be started sequentially or concurrently with MEDI9253
41507227|NCT03062046|DEVICE|RF ablation|RF ablation
41507228|NCT02171195|DRUG|BIA 2-093|BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
41507229|NCT02171195|DRUG|Placebo|Identical placebo administered as oral tablets with 200 ml potable water.
41507230|NCT05555485|DEVICE|transcutaneous Auricular neurostimulation - Active|Active auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved
41507231|NCT05555485|DEVICE|transcutaneous auricular neurostimulation - Sham|Sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX) but will not deliver prolonged stimulation.
41379217|NCT06650540|BIOLOGICAL|Levofloxacin co-administered with Metronidazole tablets|Administer a two-week course of Levofloxacin in combination with Metronidazole tablets to patients diagnosed with chronic endometritis.
41379218|NCT06333041|DRUG|Epidiolex|Epidiolex (cannabidiol) oral solution is a clear, colorless to yellow liquid containing cannabidiol at a concentration of 100 mg/mL. Inactive ingredients include dehydrated alcohol (7.9% w/v), sesame seed oil, strawberry flavor, and sucralose.
41034627|NCT04730297|DRUG|paracetamol 500 mg plus codeine 30 mg preoperative administration|each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg
41034628|NCT04730297|DRUG|ibuprofen 400 mg preoperative administration|each patient 30 minutes before surgery received ibuprofen 400 mg
41034629|NCT04730297|DRUG|Placebo oral tablet preoperative administration|each patient 30 minutes before surgery received placebo
41507232|NCT05372965|OTHER|experimental-periodontitis-mirna-223-gingival tissue-saliva samples|Non-surgical periodontal treatment will be applied to individuals with periodontitis, gingival samples will be collected during the treatment, clinical measurements and saliva collection will be repeated 6 weeks after the treatment. MiRNA-223 gene expression analysis will be performed by real-time PCR (Polymerase Chain Reaction) method in saliva and gingival samples of individuals. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
41507233|NCT05372965|OTHER|control-clinical healthy mirna-223-gingival tissue-saliva samples|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample will be collected from the clinically healthy group. A tissue sample will be collected during the clinical crown lengthening operation.
41164775|NCT04196829|DRUG|silver diamine fluoride ⁄ potassium Iodide|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption . Then after SDF application KI will be applied using a separate microbrush which will be saturated by the solution and will be used to paint solution over carious lesion , no rinse will be performed and special instructions will be given following application
41164776|NCT04196829|DRUG|Silver Diamine Fluoride|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption .
41379219|NCT06333041|DRUG|Placebo|Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring
41379220|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on Days 1, 8, and 15 of every 21-day cycle.
41379221|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on Days 1 and 8 of every 21-day cycle.
41379222|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on days 1, 8 +/- 15 schedule of every 21-day cycle.
41379223|NCT06225596|DRUG|Pembrolizumab|Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the BT8009 infusion.
41379224|NCT06225596|DRUG|Gemcitabine + cisplatin Or carboplatin|Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.
41379225|NCT06225596|DRUG|Avelumab|After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.
41379226|NCT02901184|DRUG|Spironolactone|Treatment with Spironolactone tablets on top of standard care
41379227|NCT02901184|OTHER|Standard care|Standard care does not involve Spironolactone
41379228|NCT05264818|PROCEDURE|Glycocheck|Assessment of the sublingual microvascularization
41507234|NCT03044821|PROCEDURE|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
41507235|NCT01384903|DRUG|KW-3357|Intravenous infusion once a day
41034630|NCT06319053|DEVICE|Turbine-based insufflator|The use of a turbine-based insufflator instead of a conventional insufflator
41034631|NCT06626828|DEVICE|Electroacupuncture|Disposable sterilized needles are inserted into selected acupoints at a depth of approximately 17-25 mm and an angle of 15-30° along the scalp. Acupoints are then stimulated by the SDZ-II electroacupuncture device, with a dilatational wave pattern at 4/20 Hz. The intensity of the stimulation was adjusted to the patient\&#39;s tolerance.
41034632|NCT00022464|DRUG|temsirolimus|
41034633|NCT04507191|DIAGNOSTIC_TEST|immunohistochemical staining|immunohistochemical staining of programmed death-ligand 1 (PDL1) marker
41034634|NCT02543346|DRUG|Cetirizine|Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
41034635|NCT02543346|OTHER|Placebo|Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
41034636|NCT00273117|PROCEDURE|transnasal gastroscopy|
41034637|NCT03114254|DRUG|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days."
41034638|NCT00919243|DRUG|prednisone|1 mg/kg/day with a maximum dose of 60 mg/day given orally
41379229|NCT05264818|PROCEDURE|Ophthalmological examinations|"Description :~Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)"
41379230|NCT05051384|DIAGNOSTIC_TEST|Doppler technology|The study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors
41379231|NCT02603328|DRUG|Atorvastatin|40-80 mg OD
41379232|NCT02603328|OTHER|Placebo|inactive
41379233|NCT04942964|DRUG|Bocidelpar|Oral
41379234|NCT06253585|OTHER|Algorithm Alarm- Crystalloids|"The study uses an algorithm implemented within the Electronic Health Record (EHR). This algorithm identifies patients who belong to a sepsis subphenotype known as Group D, in whom published data has shown a mortality benefit from balanced crystalloids compared to normal saline.~The intervention is an EHR alert when clinicians order normal saline on Group D patients randomized to intervention. In the intervention arm, if a clinician orders normal saline in a patient classified as Group D, there will be an EHR alert to change the order to balanced crystalloids (i.e., Lactated Ringer or Plasma-Lyte solution)."
41379235|NCT06253585|OTHER|Standard of Care|Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to usual care. In the usual care arm, the clinicians will not have any feedback from the algorithm and will not know the Group classification of their patient or the recommended fluid type.
41379236|NCT04964960|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that can help fight certain cancers.
41379237|NCT04964960|DRUG|Nab paclitaxel|Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.
41507236|NCT01384903|DRUG|Plasma-derived antithrombin|Intravenous infusion once a day
40851180|NCT02762214|OTHER|No uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.~Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
41034639|NCT00919243|DRUG|allopurinol|allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
41034640|NCT02942199|OTHER|MySafeRx|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
41034641|NCT06473987|OTHER|Personalized cognitive-sensorimotor VR/AR training|Thinking task integrated walking and balance training program
41034642|NCT06473987|OTHER|Traditional dual-task training|Walking and balance training similar to standard of care group but will also perform additional thinking tasks during training
41379238|NCT04964960|DRUG|Paclitaxel|Paclitaxel is a taxane derivative that promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication.
41379239|NCT04964960|DRUG|Pemetrexed|Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.
41379240|NCT04964960|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA and interferes with the function of DNA by producing interstrand DNA cross-links.
41379241|NCT04014296|BEHAVIORAL|High Protein Diet|16 week group-based weight loss program with high protein diet. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine the HP diet with supervised resistance training counseling (2 days per week) or add a protein supplement.
41379242|NCT04014296|BEHAVIORAL|Resistance Training|16 week weight loss program with normal protein diet and resistance training counseling. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:20%:26%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine resistance training with HP/protein supplement or add supervised sessions with a personal trainer (2 days per week) to the resistance training regimen.
41379243|NCT06210516|DEVICE|PowerBreathe|"Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index"
41379244|NCT06210516|OTHER|Conventional Physiotherapy|"Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index"
41034643|NCT06473987|OTHER|Standard of Care|Standard walking and balance training
41379245|NCT05292586|DRUG|Beclomethasone Dipropionate/Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF 200/6 µg
41379246|NCT05292586|DRUG|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP 100 µg
41507237|NCT03491657|BEHAVIORAL|virtual reality distraction (Yes VR)|
41507238|NCT03491657|BEHAVIORAL|music distraction (No VR)|
41507239|NCT01106014|DRUG|Selexipag|Selexipag 200 µg tablets
41507240|NCT01106014|DRUG|Placebo|Placebo tablets matching selexipag
41507241|NCT04004585|BEHAVIORAL|Get Up For Your Health|"The intervention is a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour. The intervention consists of one individualized face-to-face session and 3 subsequent weekly points of contact (face-to-face meetings or phone calls).~Behaviour change techniques will be provided including education, verbal persuasion, environmental restructuring and goal-setting."
41507242|NCT01291394|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
40851181|NCT05208814|DRUG|TPN171H single dose|10 mg TPN171H taken once
41379247|NCT01946204|DRUG|Apalutamide|240 mg tablets administered by mouth on a continuous once daily dosing regimen
41379248|NCT01946204|DRUG|Placebo|Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
41379249|NCT06254131|DRUG|Ondansetron lozenge (Ondalenz ©)|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
41379250|NCT06254131|DRUG|Ondansetron IV|Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
41507243|NCT03636997|PROCEDURE|Draining seton|Number 1 silk suture was passed through the fistula track and tied as loose seton
41507244|NCT03636997|PROCEDURE|Rerouting of track|The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
41507245|NCT05585021|DIETARY_SUPPLEMENT|Wonderlab Kids instant probiotics|"During study intervention, subjects are required to take the randomly assigned product based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period."
41379251|NCT04895709|DRUG|BMS-986340|Specified dose on specified days
41507246|NCT05585021|DIETARY_SUPPLEMENT|Instant probiotic placebo|"Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal.~1 bottle a day. Lasting for 24 weeks intervention period."
41507247|NCT00048737|DRUG|Zevalin Radioimmunotherapy|Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
41507248|NCT00048737|DRUG|Rituximab|250 mg/m\^2 on day 1 and day 8
41507249|NCT00048737|DRUG|Fludarabine|30 mg/m\^2/day for 3 days
41034644|NCT06053749|DRUG|Avonex (IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
41379252|NCT04895709|DRUG|BMS-936558-01|Specified dose on specified days
41379253|NCT04895709|DRUG|Docetaxel|Specified dose on specified days
41379254|NCT05714085|DRUG|Vericiguat tablet|2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
41379255|NCT05714085|DRUG|Vericiguat suspension|0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
41379256|NCT05714085|DRUG|Placebo tablet|Placebo for vericiguat administered orally once daily in tablet form
41379257|NCT05714085|DRUG|Placebo suspension|Placebo for vericiguat administered orally once daily in suspension form
41379258|NCT06150872|DEVICE|DurVena Photochemical Tissue Passivation|Treatment of a saphenous vein graft with the DurVena Photochemical Tissue Passivation device.
41379259|NCT06649357|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
41379260|NCT06649357|PROCEDURE|BiTURP|Patients with an indication for surgery for BPH viaEEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
41379261|NCT06650605|DRUG|123I-ATT001|123I-ATT001
41379262|NCT06649721|DRUG|bedaquiline|400 milligrams (mg) daily for 2 weeks(w), then 200mg three times a week for 22 weeks (w)
41379263|NCT06649721|DRUG|delamanid|"* for participants weighing up to 33.9 kilograms (kg): 50mg two times a day for 24w~* for participants weighing 34kg or above: 100mg two times a day for 8w, then 200mg daily for 16w"
41379264|NCT06649721|DRUG|linezolid|"* for participants weighing up to 33.9kg: 450mg daily;~* for participants weighing 34kg or above: 600mg daily; for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
41507250|NCT00048737|DRUG|Cyclophosphamide|750 mg/m\^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
41507251|NCT00048737|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation 2 days after chemotherapy
41507252|NCT05679271|DEVICE|Venous stenting|venous stenting associated to antiaggregation protocol
41507253|NCT05679271|OTHER|Standard of care|observation: no treatment
41507254|NCT03554434|BIOLOGICAL|AM0010|AM0010
41507255|NCT00436865|BEHAVIORAL|Weight loss|
41379265|NCT06649721|DRUG|Levofloxacin|"Only for participants with confirmed fluoroquinolone-susceptible TB or unknown fluoroquinolone susceptibility:~* for participants weighing up to 33.9kg: 500mg daily~* for participants weighing 34kg to 49.9kg: 750 daily~* for participants weighing 50kg or above: 1000mg daily for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
41379266|NCT06649721|DRUG|Clofazimine|"Only for participants with confirmed fluoroquinolone-resistant TB or unknown fluoroquinolone susceptibility:~100mg daily, for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
41379267|NCT06651255|PROCEDURE|Optimized management|systematic gastrointestinal and nasal endoscopic exploration, local endoscopic treatment whenever applicable,prophylaxis with stepwise dose escalation of VWF concentrate and use of antiangiogenic drugs in patients with severe GI angiodysplasia-related bleeding
41379268|NCT06651255|PROCEDURE|Standard of care management|Standard of care management
41379269|NCT05485961|DRUG|CSL300|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
41379270|NCT05485961|DRUG|Placebo|0.9% w/v NaCl
41379271|NCT05485961|DRUG|Placebo|Part 2 (Phase 3): Matching the excipient content and concentration of the CSL300 product, minus the active ingredient
41379272|NCT00944125|DEVICE|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
41379273|NCT00944125|DEVICE|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
41379274|NCT02736669|BEHAVIORAL|Energy Reduction|
41034645|NCT06053749|DRUG|Rebif (IFNβ-1-a, Merck Europe B.V.)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
41164777|NCT05644535|DIAGNOSTIC_TEST|Cerebrospinal fluid densitometry|After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.
41164778|NCT05644535|DIAGNOSTIC_TEST|blood routine examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.
41164779|NCT05644535|DIAGNOSTIC_TEST|Blood electrolyte examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.
41164780|NCT01628341|DRUG|insulin|Patients will be asked to complete 2 self-assessment questionnaires
41164781|NCT00748488|OTHER|Physical therapy aimed to move safely|"Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes"
41164782|NCT00748488|OTHER|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
41034646|NCT06053749|DRUG|Extavia (IFNβ-1-b, Novartis Europharm Limited)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
41034647|NCT06053749|DRUG|Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
41034648|NCT06053749|DRUG|Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
41034649|NCT06053749|DRUG|MS disease modifying drugs (MSDMDs)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
41034650|NCT00497653|DRUG|DCI|D-chiro-inositol 1200mg twicely daily for 6 weeks
41379275|NCT01686607|DRUG|Parenteral micafungin application|Parenteral
41379276|NCT01686607|DRUG|Other parenteral antifungal drugs|Parenteral
41379277|NCT06650163|PROCEDURE|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
41379278|NCT06650163|PROCEDURE|Brain Surgery|Undergo brain surgery
41379279|NCT06650163|OTHER|Electronic Health Record Review|Ancillary studies
41379280|NCT06650163|PROCEDURE|Immuno-Positron Emission Tomography Scan|Undergo immuno-PET
41507256|NCT01774162|DEVICE|Fine needle biopsy using ProCore needle for histology.|EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
41034651|NCT00497653|DRUG|Placebo|Placebo, twice daily for 6 weeks
41034652|NCT01899976|DEVICE|X-Suit NIR Covered Biliary Stent|
41034653|NCT06075810|DRUG|MBQ-167|MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
41034654|NCT00087074|DRUG|temsirolimus|Given IV
41379281|NCT06650163|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41379282|NCT06650163|PROCEDURE|Stereotactic Biopsy|Undergo stereotactic image-guided biopsy
41379283|NCT06650163|DIAGNOSTIC_TEST|Zirconium Zr 89 Crefmirlimab Berdoxam|Undergo Zirconium Zr 89 Crefmirlimab Berdoxam PET
41379284|NCT06465186|COMBINATION_PRODUCT|Efinopegdutide|Efinopegdutide is given as a subcutaneous injection using a single-use prefilled syringe, once per week for 28 weeks
41379285|NCT06465186|COMBINATION_PRODUCT|Placebo|Placebo is given as a subcutaneous injection using a single-use prefilled syringe once per week for 28 weeks.
41379286|NCT06650475|PROCEDURE|Using low or standart pressure|Written consent will be obtained before the randomized study. Randomization will be done on the computer using a software program. Participants will be divided into two groups. Patients in Group S will undergo laparoscopy under standard pressures (12-16 mmHg) in laparoscopic surgery, while patients in Group L will undergo laparoscopy under low pressure (8-10 mm Hg).
41379287|NCT06455670|DRUG|Sanhan Huayin recipe, Qingre Huatan recipe or Zaoshi Huatan recipe|On the basis of conventional treatment of western medicine,the experimental group will be given Sanhan Huayin granule , Qingre Huatan granule or Zaoshi Huatan granule based on CM syndrome differentiation.Take 1 dose daily for 10 days.
41379288|NCT06455670|DRUG|Sanhan Huayin recipe placebo, Qingre Huatan recipe placebo or Zaoshi Huatan recipe placebo|On the basis of conventional treatment of western medicine, in the experimental group 5% of the placebo drug, color, smell, taste, appearance, weight, similar to the experimental drug, drug packaging and test group. One dose was given daily for 10 days.
41379289|NCT04244162|DIAGNOSTIC_TEST|Brain Imaging|Magnetic resonance imaging (MRI) using diffusion tensor imaging (DTI)-based mean diffusivity (MD) measures.
41379290|NCT04244162|DIAGNOSTIC_TEST|Cognitive testing|Wide Range Assessment of Memory and Learning (WRAML2), Montreal Cognitive Assessment (MoCA), and Confusion Assessment Method for the ICU -severity (CAM-ICU S) tests.
41379291|NCT04244162|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory markers
41379292|NCT05692739|DRUG|Insulin|see arm description
41379293|NCT05692739|DRUG|Cyclosporins|see arm description
41379294|NCT05692739|DRUG|Artificial tears|see arm description
41379295|NCT06272942|OTHER|An ICU admission and a temporally related ARDS diagnosis|"This is a disease study to learn more about the morbidity after an ICU admission and a temporally related ARDS diagnosis.~ARDS stands for acute respiratory distress syndrome."
41379296|NCT06650332|DRUG|cadonilimab|Cohort 1:10 mg/kg, iv, Q3W, D1; Cohort 2/3:6 mg/kg, iv, Q2W, D1
41034655|NCT00087074|OTHER|laboratory biomarker analysis|Optional correlative studies
41034656|NCT03712917|PROCEDURE|Greater Occipital Nerve Block|An enjection to paralyze the occipital nerve.
41379297|NCT06650332|DRUG|Trastuzumab|loading dose 8 mg/kg, iv, Q3W, D1; maintenance dose 6 mg/kg, iv, Q3W, D1
41379298|NCT06650332|DRUG|XELOX|Oxaliplatin: 130 mg/m\\(\^2\\), IV, D1; Capecitabine: 1000 mg/m\\(\^2\\), oral (PO), twice daily, D1-14.
41379299|NCT06650332|DRUG|Disitamab Vedotin|1.5、2.0、2.5mg/kg，IV，D1，Q2W
41379300|NCT06650332|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m\\(\^2\\), IV, d1; Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1; 5-FU 400 mg/m\\(\^2\\), IV, d1, followed by 2400 mg/m\\(\^2\\), continuous intravenous infusion over 46 hours.
41379301|NCT04505592|DRUG|Tenecteplase|First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
41379302|NCT04505592|DRUG|Placebo|Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
41379303|NCT02616458|OTHER|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
41507257|NCT01774162|DEVICE|Fine needle aspiration using conventional FNA for cytology|EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
41034657|NCT03712917|DRUG|Topiramate|An antiepileptic agent used for migraine prophylaxis.
41379304|NCT02616458|OTHER|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
41379305|NCT05508867|BIOLOGICAL|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
41379306|NCT05508867|DRUG|bendamustine|IV infusion
41379307|NCT05508867|DRUG|gemcitabine|IV infusion
41379308|NCT04214262|DRUG|Atezolizumab|Given IV
41379309|NCT04214262|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41379310|NCT04214262|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41379311|NCT04214262|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
41379312|NCT04214262|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41379313|NCT04214262|OTHER|Quality-of-Life Assessment|Ancillary studies
41379314|NCT04214262|OTHER|Questionnaire Administration|Ancillary studies
41379315|NCT04214262|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41379316|NCT03902600|RADIATION|Moderately Hypofractionated RT|Patients will be treated with moderately hypofractionated radiation treatment
41379317|NCT05168657|DEVICE|Bionic Pancreas|14 days using the insulin-only configuration of the iLet Bionic Pancreas (Beta Bionics, Inc.), which automates insulin delivery, as the only intended mode of insulin delivery.
41379318|NCT05168657|OTHER|Usual Care|14 days of the participant's usual care of their type 1 diabetes
41379319|NCT05645562|BEHAVIORAL|Pain neuroscience education program|"1. Types of pain (peripherical and central pain)~2. Pain as information.~3. Benign and harmful pain~4. Psychological factors and pain in sport (Injuries, catastrophizing and pain)"
41379320|NCT05645562|BEHAVIORAL|Self-care education program|"1. The importance of resting~2. Nutritional habits~3. Recovery techniques for athletes~4. Principles of stretching, strengthening and endurance training"
41034658|NCT03712917|DRUG|Flunarizine|A calcium overload blocker agent used for migraine prophylaxis.
41034659|NCT06627933|OTHER|No intervention|No intervention
41034660|NCT00511576|DRUG|MGCD0103 & Docetaxel|"In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.~In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.~There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks."
41164783|NCT05923502|DRUG|Duvelisib|This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
41164784|NCT02960334|DEVICE|MyDiagnostick|The MyDiagnostick is a compact hand-held device that registers and stores I-lead ECG strips. In one minute, t analyses the rhythm for the presence of AF. It distinguishes AF from normal cardiac rhythms by measuring RR-irregularity.
41164785|NCT04855136|BIOLOGICAL|BB2121|CAR T Cell Therapy
41164786|NCT04855136|DRUG|CC-220|Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)
41164787|NCT04855136|DRUG|BMS-986405|gamma secretase inhibitor (GSI)
41164788|NCT02880124|DIETARY_SUPPLEMENT|Solution ingestion|Subjects will be required to ingest 2 litres of the experimental solution, spread over the 2 hours of exercise. A first ingestion of 572 mL of solution will be made at rest, 30 minutes before starting exercise, and 286 mL will be ingested immediately before the start of exercise and every 30 minutes during the exercise period.
41164789|NCT02880124|BEHAVIORAL|Constant load cycling|Subjects will be required to perform 2 hours of cycling exercise at a power output eliciting 60% of VO2max.
41164790|NCT02880124|PROCEDURE|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
41164791|NCT02880124|PROCEDURE|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
41164792|NCT02880124|OTHER|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
41164793|NCT02880124|OTHER|Gastrointestinal|At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
41379321|NCT06649799|DEVICE|LenSx|The patients in Group 1 conduct FLACS under LenSx
41379322|NCT06649799|DEVICE|Z8|The patients in Group 1 conducted FLACS using Z8
41379323|NCT00032825|DRUG|Ketaconazole|
41379324|NCT00032825|DRUG|Docetaxel|
41164794|NCT02880124|PROCEDURE|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
41164795|NCT02880124|BEHAVIORAL|Time trial|Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
41164796|NCT02720185|DRUG|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
41164797|NCT02720185|PROCEDURE|Conventional Surgery|Undergo surgery
41379325|NCT03941860|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41379326|NCT03941860|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
41034661|NCT04972513|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41034662|NCT04972513|PROCEDURE|Nitric Oxide Breath Test|Undergo nitric oxide breath testing
41034663|NCT04972513|PROCEDURE|Oscillometry|Undergo airwave oscillometry
41034664|NCT04972513|PROCEDURE|Spirometry|Undergo spirometry
41034665|NCT04972513|OTHER|Survey Administration|Complete survey
41164798|NCT02720185|OTHER|Laboratory Biomarker Analysis|Correlative studies
41379327|NCT03941860|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41379328|NCT03941860|PROCEDURE|Computed Tomography|Undergo CT scan
41379329|NCT03941860|DRUG|Ixazomib Citrate|Given PO
41379330|NCT03941860|DRUG|Lenalidomide|Given PO
41379331|NCT03941860|OTHER|Placebo Administration|Given PO
41379332|NCT03941860|PROCEDURE|Positron Emission Tomography|Undergo PET scan
41379333|NCT03941860|OTHER|Quality-of-Life Assessment|Ancillary studies
41379334|NCT03941860|OTHER|Questionnaire Administration|Ancillary studies
41379335|NCT05964400|BEHAVIORAL|duoABLE|Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
41379336|NCT05526248|DRUG|Darolutamide(BAY1841788, Nubeqa)|tablet, oral
41379337|NCT05526248|DRUG|Enzalutamide|tablet, oral
41379338|NCT06650306|OTHER|This study does not involve any interventions|This study does not involve any interventions
41379339|NCT04253028|DEVICE|NERv's Inline Device|NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.
41379340|NCT06641141|PROCEDURE|Induction of Labour|"Induction of Labour (IOL) will occur between 38+0 weeks and 38+6 weeks. All participating sites will follow an evidence-based approach for IOL, which may include any of the following: use of prostaglandins, oxytocin, amniotomy, or intracervical balloon catheters with and without extra-amniotic saline infusion for the intervention arm. Participants who are induced in either the intervention or control arms will be managed by their delivery care provider to ensure sufficient time to labour and determine when to proceed to Cesarean delivery. What constitutes a failed IOL will be dictated by local clinical practice guidelines and will be informed by the time since IOL (24-48 hours) and/or physician diagnosis of labour dystocia."
41379341|NCT06617546|DRUG|FTX-101|Lyophilized powder for subcutaneous or intravenous injection
41379342|NCT06617546|DRUG|Placebo|Lyophilized powder for subcutaneous or intravenous injection
41379343|NCT05257109|OTHER|Water Concentration 1|E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.
41379344|NCT05257109|OTHER|Water Concentration 2|E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.
41379345|NCT05257109|OTHER|Water Concentration 3|E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.
41379346|NCT05257109|OTHER|Water Concentration 4|E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.
41379353|NCT00110084|DRUG|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
41379354|NCT00110084|DRUG|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
41379355|NCT00040001|DRUG|DTI-0009|
41379356|NCT06649656|DRUG|TQB2252 injection|TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.
41379357|NCT06647043|DIETARY_SUPPLEMENT|SMT04 Pro|Consists of a blend of food-grade Bifidobacterium as active probiotics
41379358|NCT06128564|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
41379359|NCT05705349|DRUG|DOR/ISL|Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
41379360|NCT05705349|DRUG|BIC/FTC/TAF|Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.
41379361|NCT05705349|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL tablet taken by mouth.
41379362|NCT05705349|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.
41379363|NCT05041179|DIETARY_SUPPLEMENT|Pruvin R|Combination of N-acetylcysteine an glycine
41379364|NCT05041179|OTHER|Isomaltulose|Placebo as comparator to intervention
41379365|NCT06088290|DRUG|Lurbinectedin|Intravenous Infusion
41507258|NCT06550557|BEHAVIORAL|counselling sessions|the counselling sessions were adopted from the health belief model with the cues of action depending on mobile phones as muting notifications, removing social media and using computers instead if possible.
41507259|NCT01061268|DRUG|No topical artificial tear|40 patients randomized to not using a topical artificial tear.
41507260|NCT01061268|DRUG|Blink® Tears Lubricant Eye Drops|Blink® Tears Lubricant Eye Drops
41507261|NCT05258903|PROCEDURE|Ulnar artery cannulation|Ulnar artery will be cannulated under USG guidance
41034666|NCT04972513|PROCEDURE|Endothelial function|Endothelial function will be assessed with the EndoPAT device, which measures changes in pressure from sensors placed on the fingertip
41379366|NCT06088290|DRUG|Doxorubicin|Short intravenous push or bolus (according to label)
41379367|NCT06149520|DRUG|BAY3018250|Dose 1 or dose 2 of BAY3018250
41379368|NCT06149520|DRUG|Placebo to BAY3018250|Matching placebo to BAY3018250
41379369|NCT04534296|OTHER|early mobilization|Early mobilization is a kind of rehabilitation strategy. When the safe standards are met, early mobilization will be performed on subjects randomized in EM group for 30 minutes each time, twice a day, from Monday to Friday. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily, corresponding to their clinical conditions, developmental maturity, strength and endurance.
41379370|NCT04534296|OTHER|routine care|In this arm, no additional early rehabilitation interventions will be performed except for the routine clinical care, including the ventilation management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
41379371|NCT06644729|PROCEDURE|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
41507262|NCT05258903|PROCEDURE|Radial artery cannulation|Radial artery will be cannulated under USG guidance
41379372|NCT04186234|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
41379373|NCT04486573|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
41379374|NCT06649955|DEVICE|Multi-site direct current stimulation (DCS)|The MyoRegulator® treatment is a non-invasive intervention that suppresses motor neuron hyperexcitability and activates protein degradation pathways through the use of multi-site direct current stimulation (multi-site DCS).
41379375|NCT06537336|DEVICE|QoL|QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).
41379376|NCT06537336|DEVICE|lung function|lung function tests using spirometry
41379377|NCT04512716|DRUG|131-I Apamistamab|Patients will receive 131-I apamistamab 5-7 days prior to a single infusion of 1x10\^6 19-28z CAR T-cells/kg for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL. 131-I apamistamab may be administered inpatient or outpatient at the discretion and judgment of the treating investigators.
41379378|NCT04512716|BIOLOGICAL|CAR T-cell|19-28z CAR T-cells will be administered inpatient as a single infusion of 1x10\^6 19-28z CAR T-cells/kg, for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL cohort. Patients will be observed inpatient for a minimum of 7 days (longer as clinically indicated and at the discretion of the treating physician).
41379379|NCT02570399|RADIATION|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
41379380|NCT05239741|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
41379381|NCT05239741|DRUG|Oxaliplatin|85 mg/m\^2 given as an intravenous infusion (IV) on Day 1 in each 14-day cycle (Q2W) as part of the mFOLFOX6 regimen
41379382|NCT05239741|DRUG|Leucovorin|400 mg/m\^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
41379383|NCT05239741|DRUG|5-fluorouracil|400 mg/m\^2 given as an IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for a total dose of 2400 mg/m\^2 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
41379384|NCT05239741|DRUG|Irinotecan|180 mg/m\^2 IV on Day 1 Q2W as part of the FOLFIRI regimen
41379385|NCT05239741|BIOLOGICAL|Bevacizumab|IV infusion
41379386|NCT05239741|BIOLOGICAL|Cetuximab|IV infusion
41379387|NCT02959372|OTHER|lung ultrasound|
41379388|NCT02959372|OTHER|placebo|lung ultrasound. The attending physician will not know the result
41379389|NCT05101473|OTHER|Exercise Therapy|The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
41379390|NCT03176927|DIAGNOSTIC_TEST|magnetogastrogram|
41379391|NCT06651034|OTHER|Platelet Rich Plasma|Under aseptic measures, a phlebotomist obtained the blood in vacutainers. Vacutainers was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. The patient received intralesional injection
41379392|NCT06453616|BEHAVIORAL|Hello bundle|"Hello Bundle comprises : posters, email reminders, morning huddles, hello jar, hello board and a led example.~Participants will have to fill out a questionnaire before and after the intervention.~The main components of the questionnaire include respondent's characteristics, visitation policies, team-family interactions, family-centeredness (VAS), and practices at the end of life. ICU-conflicts (VAS), symptoms of burnout, and a VAS to rank the ethical climate, satisfaction with work, and intent to leave the job. Symptoms of burnout will be measured using the validated version of the 22-item Maslach Burnout Inventory (MBI, Human Services version)"
41379393|NCT05876039|DRUG|Initial remifentanil effect-site concentration|Different initial remifentanil effect-site concentration
41379394|NCT01148628|DRUG|RAD 001 in combination with Caelyx|RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
41379395|NCT04711135|DRUG|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
41379396|NCT06271109|PROCEDURE|Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically based on surgical anatomical segmentation of the liver
41379397|NCT06271109|PROCEDURE|Non-Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically not based on surgical anatomical segmentation of the liver
41164799|NCT06117202|OTHER|music therapy|The research is a thesis study aimed at determining the stress and anxiety levels of patients seeking in vitro fertilization, investigating influencing factors, and revealing the impact of pre-procedural music listening on these stress and anxiety levels.
41379398|NCT01029769|DRUG|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
41379399|NCT02000089|DRUG|Secretin|inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
41379400|NCT02000089|DIAGNOSTIC_TEST|MRI|MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
41379401|NCT02000089|OTHER|Tumor marker gene test with CA19-9|A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
41379402|NCT03352544|BEHAVIORAL|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week)
41379403|NCT00967707|DRUG|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added."
41379404|NCT00967707|DRUG|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added."
41507263|NCT03270878|DRUG|Glasdegib Oral Tablet|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
41507264|NCT03270878|DRUG|Glasdegib IV infusion|Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
41034667|NCT02523313|DRUG|Nivolumab + Placebo|Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.
41164800|NCT00192322|BIOLOGICAL|CAIV-T 10^7|a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)
41164801|NCT00192322|BIOLOGICAL|CAIVT 10^5|a single intranasal 0.2 mL dose of CAIV-T \<10\^5
41164802|NCT00192322|BIOLOGICAL|Placebo|a single intranasal 0.2 mL dose of placebo
41164803|NCT00192322|BIOLOGICAL|TIV|commercially available TIV injected intramuscularly
41164804|NCT00614588|DEVICE|Body temperature thermometers|Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
41164805|NCT05082285|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and study Part II.
41379405|NCT03717298|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|"An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.~The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously from the inclusion of the patient in the study, up to one year."
41034668|NCT02523313|DRUG|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
41034669|NCT02523313|DRUG|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
41034670|NCT01204151|BEHAVIORAL|discrete-trial training|
41034671|NCT01048528|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
41034672|NCT02486926|OTHER|Sevoflurane|Anesthesia of patients was maintained only with sevoflurane.
41034673|NCT02486926|DRUG|Remifentanil|Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
41034674|NCT02486926|DRUG|Alfentanil|Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
41164806|NCT05082285|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 2 and study Part II.
41164807|NCT05082285|COMBINATION_PRODUCT|MenABCWY-1Gen vaccine|MenABCWY-1Gen vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part II.
41164808|NCT05082285|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
41164809|NCT05082285|COMBINATION_PRODUCT|MenACWY-TT vaccine|MenACWY-TT vaccine is administered intramuscularly in the lower thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
41164810|NCT00384865|DRUG|Simvastatin|Simvastatin 40 mg, taken orally, once a day for 6 months
41164811|NCT00384865|DRUG|Aspirin|Aspirin 81 mg, taken orally, once a day for 6 months
41164812|NCT00384865|DRUG|Placebo|Placebo, taken orally, once a day for 6 months
41164813|NCT01989949|DRUG|TP-434 (Eravacycline) reconstituted and administered via an IV infusion|
41164814|NCT05478681|DEVICE|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
41164815|NCT05190471|DRUG|BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide|Dose escalation of BP1002 monotherapy
41164816|NCT05190471|DRUG|Decitabine (in combination with BP1002)|Dose expansion of BP1002 in combination with decitabine
41379406|NCT04143568|OTHER|Observation|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
41379407|NCT05433376|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) System C2|lithotripsy-enabled, low-pressure dilatation balloon to modify severely calcified lesions
41034675|NCT02486926|DRUG|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
41507265|NCT00609180|BEHAVIORAL|Minimal (Trophic) Feeding|Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
41379408|NCT00879762|BIOLOGICAL|IMVAMUNE® High Dose|IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10\^8 TCID50 (5×10\^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
41379409|NCT00879762|DRUG|Placebo|0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
41379410|NCT00879762|BIOLOGICAL|IMVAMUNE® Standard Dose|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route on Day 0 and 28 at standard dose (diluted with saline by study pharmacist to (1×10\^8 tissue culture infectious dose 50 \[TCID50\] per 0.5 mL dose)
41507266|NCT00609180|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
41379411|NCT06580041|DRUG|Pramipexole|CAU plan modified to include a trial of pramipexole.
41379412|NCT06580041|DRUG|Methylphenidate|CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).
41379413|NCT06580041|DRUG|Phenelzine|CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).
41379414|NCT06580041|BEHAVIORAL|Mindfulness-based Stress Sensitivity Therapy (MBSST)|CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.
41379415|NCT06580041|BEHAVIORAL|Complicated Grief Treatment (CGT)|CAU plan modified to include a trial of CGT.
41379416|NCT06580041|OTHER|Care as usual (CAU) plan|Unmodified CAU plan.
41379417|NCT00256841|DRUG|Chemotherapy|
41379418|NCT00256841|PROCEDURE|Radiation Therapy|
41379419|NCT03412448|OTHER|observation|Observation,
41379420|NCT06648603|BEHAVIORAL|Community-based larval source management|This project will foster active engagement with community stakeholders, including healthcare workers, community leaders, and other key informants, through participatory meetings aimed at co-creating and developing larval source reduction measures tailored to community's needs. This method emphasizes a participatory framework, ensuring that interventions are both community-informed and culturally relevant.
41379421|NCT06648603|DEVICE|Enhanced Aedes adults trapping (BG-GAT)|Furthermore, the project intends to determine whether the addition of cost-effective, gravid female mosquito-targeting traps, specifically two Biogents Gravid Aedes Traps (BG-GAT) per household, can improve the overall success of these community-based intervention.
41379422|NCT06648603|COMBINATION_PRODUCT|Community-based larval source management with Enhanced Aedes adults trapping (BG-GAT)|The community-based interventions and the BG-GAT deployment will be evaluated in combination to assess their individual and synergistic effects on vector control. This dual strategy combines local participation and practical, evidence-based solutions to address mosquito-borne illness transmission.
41379423|NCT04443426|DIETARY_SUPPLEMENT|Oral 3-hydroxybutyrate salts|Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.
41379424|NCT04443426|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.
41379425|NCT04443426|DIETARY_SUPPLEMENT|Ketone Monoester|Commercially available ketone monoester in a dosage isocaloric to 3-OHB salts.
41379426|NCT06325722|OTHER|Low-carbohydrate Diet|Consisting of 15 percent protein, 75 percent fat, and 10 percent carbohydrate
41379427|NCT06325722|OTHER|Low-fat Diet|Consisting of 15 percent protein, 10 percent fat, and 75 percent carbohydrate
41379428|NCT06249438|BIOLOGICAL|CD20/BCMA-directed CAR-T cells|Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously
41379429|NCT06650501|DRUG|Dabigatran|Patients will be assigned to change to dabigatran at the monograph approved dose for their indication, bleeding risk, and renal function.
41379430|NCT06650501|DRUG|Apixaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
41379431|NCT06650501|DRUG|edoxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
41379432|NCT06650501|DRUG|Rivaroxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
41379433|NCT05010915|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
41379434|NCT02244086|DRUG|bupivacaine|At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
41379435|NCT03350880|OTHER|Flexibility training|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
41507267|NCT00609180|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids and Antioxidant Supplements|Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
41034676|NCT02486926|DRUG|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
41034677|NCT06496152|OTHER|questionnaire|online form used to collect all information used in questionnaire
41034678|NCT02273141|DRUG|NER1006, Day Before-Only Dosing|The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
41379436|NCT06427382|DEVICE|Perfusion index|Perfusion index determination using non-invasive pulse oximetry
41379437|NCT04024527|DRUG|Esomeprazole|Proton pump inhibitor
41379438|NCT04024527|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
41379439|NCT04024527|DRUG|Metronidazole|Antibiotic for H. pylori eradication
41379440|NCT01810575|DRUG|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
41034679|NCT02273141|DRUG|SP+MS, Day Before-Only Dosing|The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
41379441|NCT01810575|DRUG|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
41379442|NCT01810575|DRUG|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
41379443|NCT05612035|DRUG|MK-5475|MK-5475 380 µg administered as dry powder inhalation once daily.
41379444|NCT05612035|DRUG|Placebo|Placebo administered as dry powder inhalation once daily.
41379445|NCT00719407|DRUG|erythropoietin|250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
41379446|NCT00583427|DRUG|Sulodexide|200 mg per day in an oral gelcap form
41379447|NCT00353392|DEVICE|Laser Therapy|
41379448|NCT05927532|DEVICE|Argyle Safety Fistula Cannula with Anti-Reflux Valve|The Argyle Safety Fistula Cannula with Anti-reflux Valve will be used 3x a week for 12 weeks in subjects with an arteriovenous fistulae (AVF) fistula
41379449|NCT01190202|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick
41379450|NCT01190202|PROCEDURE|Assessment of body temperature|Assessment of axial body temperature with a digital thermometer
41379451|NCT03890133|BEHAVIORAL|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful movements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
41379452|NCT03890133|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
41379453|NCT01541410|DEVICE|Vascutek Hybrid Graft|Single Group Assignment
41379454|NCT05384184|PROCEDURE|Tumor /metastases removal|Tumor /metastases removal
41379455|NCT06396247|BEHAVIORAL|Functional Activity Strength Training|FAST consists of five exercises (stepping on a step, chair stands, push-ups, rows, walking), for 30 seconds each, performed daily, with 30 seconds of rest between.
41379456|NCT06550076|DRUG|TAK-279|TAK-279 oral tablet
41507268|NCT00609180|DIETARY_SUPPLEMENT|Placebo|The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
41034680|NCT04825457|PROCEDURE|Anchoring-tip vs. Conventional|"Anchoring-tip: the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. At the final step of both conventional and Tip-in EMR, the lesion was resected.~Conventional: After injection of normal saline solution mix, snaring was tried for polyp resection."
41034681|NCT05466318|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
41379457|NCT05007938|DRUG|Icotinib|Icotinib is a EGFR ihibitior.
41379458|NCT05007938|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
41034682|NCT05466318|DRUG|Cladribine|6 mg/m2 intravenously once daily @ Day -7 \~ -3
41379459|NCT04449354|DEVICE|HidraWear Ax|An adhesive free wound dressing fixation device for people living with Hidradenitis Suppurativa (HS), Hidrawear AX, designed to make dressing changes quick and easy for subjects. The unique features of the product completely remove the use of adhesives on the skin.The body conforming garment acts as a second skin and incorporates largely perforated panels over wound affected areas, minimising skin contact and aerating the area. The main function of the perforated is to act as a retaining device for the wound pads. The garment facilitates easy insertion, removal, precise positioning and adjustment of a non- adhesive wound dressing onto the effected wound space. The perforated section of the garment sits on the outer surface of the dressing providing provisional fixation. Next, an outer patch is placed on the outside of the garment on the footprint of the dressing. Through a hook and loop mechanism the dressing is now fully secured in place.
41379460|NCT01248000|PROCEDURE|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
41507269|NCT04607057|DRUG|Parenteral Nutrition Solutions|"* Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + crystalloid fluid~* POD#3 : Semifluid diet (SFD) + PN~* POD#4-7: Soft blended diet (SBD) + PN"
41034683|NCT05466318|DRUG|Gemcitabine|2500 mg/m2 intravenously @ Day -7, -3
41034684|NCT05466318|DRUG|Busulfan|3.2 mg/kg intravenously once daily @ Day -7 \~ -4
41034685|NCT05466318|DRUG|Carmustine|300 mg/m2 intravenously @ Day -8
41034686|NCT05466318|DRUG|Etoposide|200 mg/m2 intravenously once daily @ Day -7 \~ -4
41379461|NCT05744635|DRUG|Tacrolimus|Tacrolimus received as part of routine clinical care
41379462|NCT06575348|DEVICE|YouControl-A-Fib mHealth Application|Participants will use the app for 3 months, includes 1 month phone call with Health Coach
41034687|NCT05466318|DRUG|Cytarabine|400 mg/m2 intravenously once daily @ Day -7 \~ -4
41379463|NCT02016027|DRUG|Carica folia|
41379464|NCT05639894|BIOLOGICAL|RSV vaccine candiate formulation 1|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
41379465|NCT05639894|BIOLOGICAL|RSV vaccine candidate formulation 2|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
41379466|NCT05639894|OTHER|Placebo|Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection
41379467|NCT05025267|OTHER|Medical Food: Peptide-Based Enteral Formula|Will be fed exclusively the study peptide-based, high protein enteral formula via a feeding tube
41379468|NCT00000667|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
41379469|NCT06246643|DRUG|Regorafenib (Stivarga, BAY73-4506)|Participants will be treated with the regorafenib dose taken during the last cycle of the feeder study. Adult participants will receive either 60, 80, 90, 120, or 160 mg orally (p.o.) once daily (qd) for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off). Pediatric participants will receive 82 mg/m\^2 p.o. qd for 14 days, in a 14 days on/7 days off schedule (21-day cycle).
41379470|NCT06646003|OTHER|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke.
41379471|NCT03741335|OTHER|Resistance Training|Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.
41379472|NCT03741335|OTHER|Stretching|Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session
41379473|NCT03741335|OTHER|Tai Chi|Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
41379474|NCT05948826|DRUG|TORL-3-600|antibody drug conjugate
41379475|NCT05672277|OTHER|TENS 1|Parasacral TENS will be applied for 30 minutes 3 days a week during 6 weeks.
41379476|NCT05672277|OTHER|TENS 2|Parasacral TENS will be applied for 30 minutes one day a week during 6 weeks.
41379477|NCT05104450|BEHAVIORAL|lifestyle intervention|Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
41379478|NCT04174443|PROCEDURE|High-voltage pulsed radiofrequency|2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
41379479|NCT04174443|PROCEDURE|Low-temperature continuous radiofrequency|Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.
41379480|NCT03623217|BEHAVIORAL|Qualitative interviews with participants|For the development and validation of a questionnaire.
41379481|NCT06566469|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 µg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
41379482|NCT06566469|DRUG|Esketamine|Esketamine 0.2 mg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
41379483|NCT06566469|DRUG|Normal saline|Normal saline at the same volume is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
41379484|NCT01596088|DRUG|Dexrazoxane|
41379485|NCT06509542|BEHAVIORAL|Objective assessment of upper limb use during activities in ecological situation|Twenty-five patients will be recorded performing three activities during their rehabilitation: getting dressed, preparing a meal, and eating a meal. The movements of their upper limbs will be tracked using wrist-worn accelerometers and video cameras.
41034688|NCT05466318|DRUG|Melphalan|140 mg/m2 intravenously @ Day -3
41034689|NCT05466318|PROCEDURE|Autologous hematopoietic stem cell transplant|autologous hematopoietic stem cells infusion after ChiCGB or BEAM chemotherapy
41379486|NCT04401046|OTHER|Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later|The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
41379487|NCT01076140|DRUG|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
41379488|NCT01076140|DRUG|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
41379489|NCT04158739|DRUG|Cytarabine|Given IT
41379490|NCT04158739|BIOLOGICAL|Flotetuzumab|Given IV
41379491|NCT05146609|BEHAVIORAL|Screening HCV. HR-HOSPITAL|Screening HCV in high risk population by themselves or at referral hospital.
41379492|NCT05146609|BEHAVIORAL|Screening HCV. HR-DDP|Screening HCV in high risk population by themselves or at drug dependence center.
41507270|NCT05389644|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of repetitive TMS. TMS is a form of non-invasive brain stimulation. In this modality, a current is rapidly passed through a TMS coil. This coil is placed on a subject's scalp. The rapidly discharging current creates a magnetic field perpendicular to the plane of the coil. This magnetic field diffuses through the subject's scalp and skull until it reaches the brain parenchyma. There, it causes focal neuronal depolarization.
41507271|NCT03584087|DRUG|Normal Saline|TG 0 (0Hr)
41034690|NCT02180646|OTHER|High protein breakfast|a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
41034691|NCT02180646|OTHER|High carb breakfast|a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
41034692|NCT05554237|DRUG|Placebo|Placebo
41034693|NCT05554237|DRUG|PF-07612577|PF-07612577
41034694|NCT05554237|DRUG|PF-06264006|PF-06264006
41034695|NCT00833638|DRUG|Placebo|One tablet orally daily
41034696|NCT00833638|DRUG|Tadalafil|Orally once daily
41034697|NCT03001648|PROCEDURE|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)
41034698|NCT05623150|DIAGNOSTIC_TEST|Liver biopsy|Liver biopsy planned as part of routine care. Clinical-biological characterisation with bio collections.
41034699|NCT06322472|OTHER|The Turkish Early Language Development Test (TEDIL)|The Turkish Early Language Development Test (TEDIL) is a test that measures the receptive and expressive language skills of children between the ages of 2 and 7 years and 11 months.
41507272|NCT03584087|DRUG|Terlipressin|Duration of Terlipressin after EVL
41507273|NCT01446328|DRUG|Amisulpride|Tablets, dose range 50-1200 mg/ day
41507274|NCT01446328|DRUG|Aripiprazole|Tablets, dose range 5-30 mg/ day
41507275|NCT01446328|DRUG|Olanzapine|Tablets, dose range 2.5-20 mg/ day
41507276|NCT03372291|OTHER|Usual Care|Usual leukemia care with all the supportive care measures instituted by the leukemia team
41164817|NCT04366518|DRUG|Rivastigmine Transdermal System|Rivastigmine doses will be administered transdermally using 9.5 mg/24 hr transdermal patches. Participants will be randomized to two treatments with oral rivastigmine vs. placebo separated by a 15-hour washout period (\>5 half-lives to eliminate any residual effects). This will require three separate visits: a baseline visit, a visit for the first transdermal treatment and a visit for the second transdermal treatment. All visits include fMRI scans. The first transdermal patch will be administered 8-14 hours before the scan. After the washout period, the second transdermal patch will be administered 8-14 hours before the scan. No study team member except for the unblinded team member will know which capsule the participant receives first. Because we are interested in rivastigmine as a probe for a pre-identified computational/physiological abnormality, we will median-split groups post-hoc for the purposes of analysis.
40851182|NCT00778908|RADIATION|Late-course accelerated hyperfractionated IMRT|"1. IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease~2. IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately."
41034700|NCT06322472|OTHER|The Family Literacy Scale|The Family Literacy Scale, which is a reliable and valid measurement scale, was developed by Kılıç, Doğan, and Özden (Kılıç, Doğan, and Özden 2017). The items of the scale consist of questions about parental literacy, child literacy, and early literacy. Parental Literacy Scale to identify and analyse situations such as the use of literacy skills, role modelling for children, performing simple literacy activities at home, on the street, etc. and generally helping children to learn to read and write.
41034701|NCT06322472|OTHER|The Early Childhood Phonological Sensitivity Scale (PASECP)|The Early Childhood Phonological Sensitivity Scale (PASECP), developed by Sarı and Aktan Acar (2013), measures the phonological awareness of children aged 60-72 months (Sari and Aktan Acar 2013).
41034702|NCT06322472|OTHER|The Early Literacy Home Environment Scale (ELHES)|The Early Literacy Home Environment Scale (ELHES) developed by Karaahmetoğlu and Turan is a reliable and valid questionnaire for assessing the early literacy home environment of families with children aged 0-6 years (Karaahmetoğlu and Turan 2020)
41034703|NCT06322472|OTHER|Demographic Questionaries|The demographic survey was prepared by the researchers. The demographic survey includes questions about educational status and family's socio-economic status.
41034704|NCT04412395|DIETARY_SUPPLEMENT|Lactoferrin (Apolactoferrin)|Apolactoferrin is an iron-free Lactoferrin (with very low iron saturation). Lactoferrin (Lf) is a natural glycoprotein that is found predominantly in milk. Lf represents a known component of the innate immune system present in neutrophil-specific granules and broadly distributed within the body fluids and exocrine secretions.
41507277|NCT03372291|OTHER|Psychological intervention|Psychological intervention is focused on educating patients about leukemia and how to cope with its treatment
41507278|NCT01654315|DEVICE|Myomo Robotic Arm|"Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion."
41034705|NCT04412395|DRUG|Placebo of excipient(s) will be administered|Placebo of the equivalent excipient will be administered to placebo group
41507279|NCT01654315|BEHAVIORAL|RTP Standard Therapy|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
41507280|NCT05931653|OTHER|Multimodal Physical therapy|• Multimodal Physical therapy: Hot pack for 15 mins, TENS for 15 mins, Ultrasound at 1.5 W/cm2 intensity for 5 mins, Soft tissue release for \<5-15 mins as per need, HVLA, PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets, Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets). 03 days/week for 06 weeks.
40851183|NCT00778908|DRUG|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
41034706|NCT06444282|OTHER|Emergency Care Action Plan|An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in a patient's electronic health record for access by providers in an emergency. Patients/families will have digital access to the ECAP and be given a paper copy. The patient's care team and caregiver(s) (parent/legal guardian) will collaborate to create an individualized ECAP containing the following content: caregiver contact information, patient summary, anticipated emergency presentations with suggested management, problem list (emergency relevant only), medication list, technology dependence, baseline important physical exam findings, baseline vital signs, allergies, advance directive information, contact information for established care providers, and other important information.
41164818|NCT04366518|DRUG|Scopolamine|The authors have chosen to use scopolamine to determine the effects of cholinergic antagonism, as treatment with scopolamine demonstrates a dose-related increase in propensity toward conditioned hallucinations and in doses much higher than those proposed here, can cause spontaneous hallucinations. At the proposed dose, scopolamine has an excellent safety profile and has been used routinely for nearly 20 years for treatment of nausea due to surgery or motion sickness in adults and children. Scopolamine is available in the US only as a 1mg / 72 hours transdermal patch, and peak plasma levels are reached within 24 hours. This standard dosage level is very well tolerated in the general population.
41379493|NCT05146609|BEHAVIORAL|Screening HCV. GP-HOSPITAL|Screening HCV in general population by themselves or at referral hospital.
41379494|NCT05146609|BEHAVIORAL|Screening HCV. GP-PCC|Screening HCV in general population by themselves or at primary care center.
41379495|NCT02351297|DIETARY_SUPPLEMENT|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
41379496|NCT02351297|DIETARY_SUPPLEMENT|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
41164819|NCT04366518|DRUG|Placebo Patch|Participants in Aim 2 will receive a placebo patch versus rivastigmine patch.
41379497|NCT02351297|DIETARY_SUPPLEMENT|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
41379498|NCT03914209|OTHER|EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
41379499|NCT06650800|DRUG|Psilocybin|Single-dose psilocybin administration: oral ingestion of one 25 mg capsule
41379500|NCT06650800|OTHER|MRI|1.5 hour brain MRI before and after psilocybin administration
41379501|NCT05846152|DEVICE|Intervention|"Patient wounds will be examined:~* by eye by the principal investigator~* using a ruler by the principal investigator~* by WoundCare algorithms (AKA WoundTrack) using smartphone photography by the principal investigator~* by eye by a second investigator~* using a ruler by a second investigator~* by WoundCare (AKA WoundTrack) algorithms using smartphone photography by a second investigator."
41379502|NCT02098707|OTHER|Stabilometric Platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
41379503|NCT06016231|DEVICE|Light Adjustable Lens|The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.
41379504|NCT05945927|DRUG|Trastuzumab emtansine|Trastuzumab emtansine will be administered as per local clinical practice and local labeling.
41379505|NCT06650995|OTHER|Exercise training|exercise intervention will consist of supervised, home-based, combined training with elements of endurance, resistance and respiratory training
41379506|NCT00477620|BEHAVIORAL|Wearing of reading glasses during prolonged near work|
41379507|NCT06647940|DRUG|Orelabrutinib Oral Tablet|Orelabrutinib (150 mg po D1-D21) is added from the second cycle of R-CHOP regimen
41379508|NCT06647940|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
41507281|NCT05931653|OTHER|Proprioceptive training along with and Multimodal Physical therapy|"* Multimodal Physical Therapy: Hot pack-5 mins, TENS-5 mins, U.S (1.5 W/cm2)-5 mins, Soft tissue release-\<5-15 mins, HVLA, PA Glides (Central and Transverse)-10 sec each 5 sets, Lumbar facet gapping-10 sec 3 sets and Lumbar rotational facet gapping-10 sec 3 sets. 3 days/week for 6 weeks.~* Proprioceptive Training:1. Trunk Balance (15 mins). In sitting, kneeling, quadruped, and supine positions for 30 seconds to 2 minutes. Progression to more challenging. Each will be performed for 2-3 mins. In case of pain exercise will be interrupted and substituted with another one.~  2. PNF Training (10-12 mins). Each PNF training-1 set of 15 reps with 30s rest between and 60s after 15 reps. Week 1-2 alternate full isometrics of trunk flexors and extensors for 10s in sitting. Week 3-4, 5s resisted concentric, 5s eccentric and 5s isometrics contractions in forward and backward bending. Week 5-6, alternate chop and lift movement patterns of upper extremities in diagonal and spiral directions for 10s."
41379509|NCT05901194|DRUG|Lenvatinib|Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight \< or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
41507282|NCT05792111|DRUG|Trigger point injection (lidocaine)|trigger point injection will be added to the gluteus medius and minimus muscles in addition to caudal epidural steroid injection.
41379510|NCT04340570|BEHAVIORAL|Medication management via televisit to home|Pharmacist led home based televisit for medication management
41379511|NCT06551506|BIOLOGICAL|Abrysvo|A maternal RSV vaccine based on the prefusion F protein administered during pregnancy
41379512|NCT06551506|BIOLOGICAL|Beyfortus|A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants
40851184|NCT00778908|RADIATION|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
41164820|NCT04366518|DRUG|Placebo Patch|Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
41379513|NCT06110338|DRUG|placebo|placebo iv. once.
41379514|NCT06110338|DRUG|IBI355|IBI355 iv. once.
41379515|NCT06650943|BEHAVIORAL|Nursing Consultation in Weight Management and Metabolic syndrome|Based on the Carbohydrate-insulin Theory
41379516|NCT06065631|DEVICE|Eyeglasses|Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.
41379517|NCT06065631|OTHER|Prescription slip|Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial
41379518|NCT02245997|RADIATION|External beam radiotherapy|
41379519|NCT02245997|RADIATION|proton beam RT|
41379520|NCT06040099|DRUG|Durvalumab|Durvalumab IV (intravenous)
41379521|NCT06040099|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
41379522|NCT06040099|PROCEDURE|Transarterial Radioembolization (TARE)|Yttrium 90 glass microspheres will be administered
41379523|NCT06222502|OTHER|Planning, Reminders, and Micro-Incentives|Participants will schedule planned walks during weekly phone calls with study staff. Participants will receive reminders for planned walks and receive micro-incentives after completion.
41379524|NCT06222502|OTHER|Health Education|"Participants in this group will receive health education tips during weekly phone calls with study staff."
41379525|NCT06399289|BIOLOGICAL|Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)|Lyophilized powder for solution for intravenous injection
41379526|NCT06469944|BIOLOGICAL|Pembrolizumab|Administered via intravenous (IV) infusion.
41379527|NCT06469944|BIOLOGICAL|Sacituzumab Tirumotecan|Administered via IV infusion.
41379528|NCT06469944|DRUG|Capecitabine|Administered via oral tablet.
41379529|NCT06469944|DRUG|Leucovorin|Administered via IV infusion.
41034707|NCT00644722|DEVICE|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
41379530|NCT06469944|DRUG|Levoleucovorin|Administered via IV infusion.
41379531|NCT06469944|DRUG|5-FU|Administered via IV infusion
41379532|NCT05773053|DRUG|NT 201|Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.
41379533|NCT05773053|DRUG|NT 201 Placebo|NT 201 Matching-placebo.
41379534|NCT02195921|OTHER|single point Zhongwan(CV12) plus antiemetic drug|"All participants were supine in the hospital bed. A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1 cm above the CV12 acupoints of the stimulation point, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
41379535|NCT02195921|OTHER|single point Zusanli(ST36) plus antiemetic drug|"A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1cm below ST36 acupoints of the stimulation point, respectively, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
41034708|NCT00644722|DEVICE|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
41034709|NCT05624996|DRUG|Carboplatin|Given IV
41034710|NCT05624996|DRUG|Cisplatin|Given IV
41034711|NCT05624996|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
41034712|NCT05624996|BIOLOGICAL|Durvalumab|Given IV
41379536|NCT02195921|OTHER|Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug|Stimulating both Zusanli(ST36)and Zhongwan(CV12)
41379537|NCT02195921|DRUG|only antiemetic drug|received routine antiemetic treatment
41034713|NCT05624996|DRUG|Etoposide|Given IV
41034714|NCT05624996|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
41034715|NCT05624996|DRUG|Paclitaxel|Given IV
41034716|NCT05624996|DRUG|Pemetrexed|Given IV
41379538|NCT01124500|DRUG|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
41164821|NCT03326050|DRUG|Gemifloxacin|Gemifloxacin 320Mg Oral Tablet once daily
41164822|NCT03326050|DRUG|Ciprofloxacin|cipro 750 tablet twice daily
41164823|NCT03326050|DRUG|Rifampicin|Rifampicin 150Mg Capsule twice daily
41164824|NCT05184621|OTHER|Eyesing Redlight Instrument|Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.
41164825|NCT02081118|DRUG|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
41164826|NCT02081118|DRUG|Placebo|Placebo for HM11260C
41164827|NCT03282578|DEVICE|Sternalock 360 sternal plating system|The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.
41164828|NCT03282578|DEVICE|Sternal Wires|"Stainless steel wires are applied in a figure of 8 configuration to close the sternum"
41164829|NCT05964751|DIAGNOSTIC_TEST|lipid profile|measuerments of lipid profile parameters to detect hyperlipidemia
41164830|NCT05964751|DIAGNOSTIC_TEST|fasting blood suger|measurment of fasting blood suger to detect hyprerglicemia
41164831|NCT04320810|OTHER|no intervention|It's only observational study. No interventions.
41164832|NCT04316221|DIETARY_SUPPLEMENT|Eggs plus standard of care|Eggs will be secured locally and delivered to families weekly.
41379539|NCT05941845|DRUG|Peginterferon Alfa-2A 180 MCG/ML Injectable Solution|"Injections will be carried out on the Nephrology day hospitalization ward. The injections follows a personalized administration schedule: all enrolled patients will receive an injection of Pegasys® at Week 0.~Patients with a persistent Th17 profile (cytokine profile showing IL-17A levels greater than 73 pg/ml) at Week 2 will receive a new dose of Pegasys®, followed by a monthly cytokine profile. In the case of a persistent Th17 profile, 2 injections will be given two weeks apart.~In patients with no Th17 profile at Week 2, no Pegasys® injections will be performed at this time. Cytokine profiles will be performed monthly, and in the case of a persistent Th17 profile, 1 injection will be performed.~In total, patients will receive a minimum of one injection and a maximum of 13 injections of 180 µg (1 injection every two weeks for 24 weeks)."
41379540|NCT03157934|OTHER|not applicable (observational study)|Observational study without study related intervention
41379541|NCT03940742|DRUG|Tirzepatide|Administered SC
41379542|NCT05037968|DEVICE|MagnetOs Flex Matrix|Procedure: Instrumented Posterolateral Lumbar Fusion
41379543|NCT00094900|DRUG|IL-1 Trap|
41034717|NCT05624996|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41034718|NCT05624996|OTHER|Quality-of-Life Assessment|Ancillary studies
41034719|NCT05624996|OTHER|Questionnaire Administration|Ancillary studies
41034720|NCT05624996|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41034721|NCT04276545|DRUG|IV administration of DEX to investigate the effects for functional nasal endoscopic surgery|IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
41034722|NCT04276545|DRUG|IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery|IV administration of midazolam (0.05mg/kg) after induction.
41034723|NCT06634485|DEVICE|ultrasound, spirometry|"Ultrasound assessment of~1. diaphragmatic excursion:-the probe will be angled medially ,cranially , and dorsally so that the ultrasound beam reaches the posterior third of the diaphragm, in B-mode.Then, then M-mode exploration line will be placed perpendicular to the diaphragmatic dome to obtain maximum excursion .~2. (Tdi) will be measured using a high-frequency linear probe (10 MHz) placed on (ZA).The probe will be angled perpendicular to the lateral chest wall and placed between the midaxillary and anterior axillary lines at the eighth or ninth intercostal space.~3. Quadricep\|rectus femoris muscle assessment will be done by placing the transducer perpendicular to the long axis of the thigh.~   * Spirometry:-will be performed thrice by experienced technicians at our pulmonary function laboratory. Patients will be asked to take a maximal inspiration and then to forcefully expel air for as long and as quickly as possible."
41034724|NCT01865591|DEVICE|Ultrasound-based Renal Denervation|
41034725|NCT03564496|DEVICE|tDCS Administration during MRI|All participants including healthy controls and MS patients will be given approximately 15 minutes of active tDCS during MRI. The simultaneous tDCS will be performed up to 2 mA dose intensity to determine CMRO2 changes from when the tDCS is on to when the tDCS is off. The stimulation consists of 15-min up to 2 mA tDCS using 5x5 cm electrode sponges with \~30s ramp-up and ramp-down periods.
41164833|NCT04316221|OTHER|Standar of care|frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
41164834|NCT04248036|BEHAVIORAL|Circle of Security - Parenting, COS-P|Circle of Security - Parenting is a manual-based, psychoeducational intervention program in group that includes 8 group sessions of 90 minutes each.
41164835|NCT01558778|PROCEDURE|management of therapy complications|Undergo mechanical stimulation
41164836|NCT01558778|PROCEDURE|musculoskeletal complications management/prevention|Undergo mechanical stimulation
41164837|NCT04588519|DEVICE|Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System|Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA.
41164838|NCT01525641|DRUG|Mirapex LA|Pramipexole Hydrochloride Hydrate
41164839|NCT00419419|DRUG|Topical AmphiMatrix with nitroglycerin (MQX-503)|
41164840|NCT00957996|DRUG|Peramivir|300 mg twice daily
41164841|NCT00957996|DRUG|Peramivir|600 mg once daily
41164842|NCT06211218|DIAGNOSTIC_TEST|Cornea diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose cornea diseases from slit-lamp images.
41164843|NCT04207697|BIOLOGICAL|Beltavac® Polymerized with cat dander|Adminstration of Beltavac® Polymerized with cat dander according to the routine clinical practice
41164844|NCT05773027|BEHAVIORAL|SAFE|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
41164845|NCT05773027|BEHAVIORAL|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
41379544|NCT02007512|DRUG|Enzalutamide|160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
41379545|NCT02007512|DRUG|exemestane|25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
41379546|NCT02007512|DRUG|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
41379547|NCT02007512|DRUG|exemestane|50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
41379548|NCT06327048|OTHER|Individual cognitive rehabilitation training based on Remind strategy was given|This training educates and learns patients from the aspects of assessment of cognitive function and strategic compensation for the impact of cognitive impairment on patients, and then conducts attention, memory and executive function training and attention retraining based on patients' cognitive function to improve patients' cognitive function
41379549|NCT03505320|DRUG|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
41379550|NCT03505320|DRUG|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
41379551|NCT03505320|DRUG|leucovorin|Leucovorin will be administered as a 2-hour IV infusion.
41379552|NCT03505320|DRUG|fluorouracil|Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
41379553|NCT03505320|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes.
41379554|NCT03505320|DRUG|folinic acid|Folnic acid will be administered as a 2-hour IV infusion.
41379555|NCT03505320|DRUG|nivolumab|Nivolumab will be administered intravenously according to institutional standards.
41164846|NCT02913170|DIETARY_SUPPLEMENT|Nattokinase|
41379556|NCT03505320|DRUG|Docetaxel|Docetaxel will be administered as a 1-hour IV infusion.
41379557|NCT04335292|DRUG|Osimertinib First-Line|Osimertinib, 80 mg, oral, daily
41379558|NCT04335292|DRUG|Platinum + Pemetrexed Chemotherapy Second-Line|Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
41379559|NCT04335292|DRUG|Osimertinib Third-Line|Rechallenge with osimertinib, 80 mg, oral, daily
41379560|NCT02633462|PROCEDURE|scaling and root planing , Myo-inositol|scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
41164847|NCT02913170|DIETARY_SUPPLEMENT|Placebo|
41379561|NCT02633462|DRUG|Myo-inositol|only provided treatment with Myo-inositol supplementation (1 gm twice a day)
41164848|NCT02222961|DRUG|BIIR 561 CL|
41164849|NCT02222961|DRUG|Placebo|
41164850|NCT06172998|DRUG|Phentolamine Injection|Under patient safety, Phentolamine will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent sympathetic overactivity. Under patient safety, Nitroglycerin will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent endothelial dysfunction.
41164851|NCT00675038|PROCEDURE|Liver Biopsy and MRI T2* MRI|Evaluation of iron overload with liver biopsy vs. MRI T2\* MRI
41379562|NCT06651242|OTHER|Decision-making information aids|Provide a decision-making information aids to assist patients and their parents in treatment decision making.
41379563|NCT06651242|OTHER|Routine care|Routine care
41379564|NCT01901393|DRUG|IV ibuprofen|
41379565|NCT01901393|DRUG|Ketorolac|
41379566|NCT05425550|DEVICE|medidux™ app|Use of the regular medidux™ application for 12 (maximum 16) weeks
41379567|NCT06576479|DIETARY_SUPPLEMENT|Nutritious Shake|Powder 70 g/d diluted in 237 ml natural water
41379568|NCT06576479|BEHAVIORAL|Nutritional counseling|Specialized nutritional recommendations for CKD
41379569|NCT06648395|BEHAVIORAL|CBT Text Messages|CBT text messages will be sent 3 times per week for 4 weeks
41379570|NCT06648395|BEHAVIORAL|Supportive Messages|Supportive text messages will be sent 3 times per week for 4 weeks
41379571|NCT05006313|DEVICE|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
41379572|NCT05123040|DRUG|Ruxolitinib 10 MG Oral Tablet|By mouth twice daily through day 56, then tapered
41379573|NCT05123040|DRUG|hCG|2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses
41379574|NCT05123040|DRUG|Corticosteroids|"Dose level 1 (starting dose) = 1 mg/kg~* Dose level 2 = 0.5 mg/kg~* Dose level 3 = 0.25 mg/kg~* Dose level 4 = 0.1 mg/kg~* Dose level 5 = 0 mg/kg~  • If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~* Dose level -1 = 1.5 mg/kg~* Dose level -2 = 2 mg/kg"
41379575|NCT00816166|DEVICE|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
41379576|NCT00816166|DRUG|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
41379577|NCT03768414|DRUG|Cisplatin|Given IV
41379578|NCT03768414|DRUG|Gemcitabine Hydrochloride|Given IV
41379579|NCT03768414|DRUG|Nab-paclitaxel|Given IV
41379580|NCT00663039|DRUG|Oxytocin|24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)
41379581|NCT00663039|DRUG|Placebo|Single dose (plus a booster dose) drug probe study using intranasal placebo
41379582|NCT06364410|DRUG|Azenosertib|Given PO
41379583|NCT06364410|PROCEDURE|Biopsy|Undergo biopsy
41379584|NCT06364410|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41379585|NCT06364410|PROCEDURE|Computed Tomography|Undergo CT
41379586|NCT06364410|PROCEDURE|Echocardiography|Undergo ECHO
41379587|NCT06364410|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41379588|NCT06364410|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41379589|NCT06364410|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
41379590|NCT05485506|OTHER|Multimodal exercise program|"Running technical drills: pogo, askip, dribble, scissor, etc. Exercises for lumbopelvic stabilization: mobility exercises, hip thrust, dead lift, lunge to skip.~Resisted sprints by using a sled: resistance leading to a 60% and 30% of optimal load (previously calculated)"
41379591|NCT06493188|OTHER|High-fidelity interprofessional simulation|Students will participate in realistic (high-fidelity) interprofessional simulation scenarios to practice and interpret ABG procedures
41379592|NCT06493188|OTHER|Low-fidelity interprofessional simulation|Students will take part in low-fidelity interprofessional simulation scenarios. Cases will be discussed, and reflection on ABG execution and interpretation will be guided using paper descriptions and clinical files
41507283|NCT05792111|DRUG|Caudal epidural Group (bupivacaine + triamcinolone + NaCl)|It will be advanced towards the sacral hiatus and local anesthesia of the skin and subcutaneous tissue will be provided with 2% lidocaine. The caudal epidural space will be entered by puncturing the sacrococcygeal ligament with the tip of a 22 G black needle from the appropriate area and taking a pop sensation. It will be confirmed that there is no bleeding or cerebrospinal fluid in this area by applying saline in real-time sonography and after the caudal epidural spread is observed, aspiration is performed. Afterward, a 10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space
40851185|NCT02173587|DIETARY_SUPPLEMENT|Mussel oil capsules|Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
40851186|NCT02173587|DIETARY_SUPPLEMENT|Corn oil capsules|Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
40851187|NCT04421248|DRUG|Methylphenidate|In ADHD participants only: blinded, randomized, placebo-controlled single dose, crossover on separate days separated by at least one week.
40851188|NCT04421248|DRUG|Placebo|In ADHD participants only: blinded, randomized, placebo-controlled, single dose, crossover on separate days separated by at least one week.
40851189|NCT03853564|BEHAVIORAL|Video-Feedback Intervention|Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
40851190|NCT03853564|OTHER|Phone-Call Intervention|Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
40851191|NCT05938673|OTHER|Active stimulation- intermittent theta-burst (iTBS) stimulation|During active stimulation, patients will receive intermittent theta-burst (iTBS) stimulation in T2-T3 toracic region while seated using a circular magnetic coil positioned at 90º, handle facing to the right, connected to a magnetic stimulator.Each participant will receive a total of 1,200 rTsMS pulses at 120% of resting motor threshold, determined by abdominal muscle contractions. In 3 minutes and 58 seconds, 20 trains with 20 bursts and each burst with 3 pulses at 50 Hz repeated at 5Hz with an intertrain interval of 8 seconds will be applied.Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
40851192|NCT05938673|OTHER|Sham stimulation|During sham stimulation, a circular magnetic coil will be positioned in the T2-T3 toracic region disconnected to the stimulation device and the active coil will be positioned about 15 cm behind the patient, away from his field of vision, to provide sound stimulus. To create a sensation of muscle contraction and impression of active stimulation, the group will be submitted to the sensory effect of transcutaneous electrical neurostimulation (TENS) for 5 minutes, with surface electrodes placed in parallel at the T2-T3, with the parameters (80Hz,150ms, 60 mA).Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
40851193|NCT03536234|DRUG|Triptorelin acetate depot|3.75 mg triptorelin depot (monthly injections). 3 doses in total
40851194|NCT05477797|DRUG|Ixazomib DX/Lenalidomide DX|After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
40851195|NCT01971008|DEVICE|Elastic abdominal binder|
40851196|NCT01971008|DEVICE|Placebo binder|
40851197|NCT03704909|DRUG|Adrenaline|i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg
40851198|NCT03704909|DRUG|Ephedrine|i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
40851199|NCT02103777|DRUG|Caffeine citrate|Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
41164852|NCT02738957|BEHAVIORAL|Prenatal Counseling Group|"Specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one of the two midwives involved in the study. The information provided include the following: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models."
41379593|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in POMS|The demographic information of the patients will be taken with the form prepared for the people in this group. Patients will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
41507284|NCT00749892|DRUG|Erlotinib Hydrochloride|Given PO
41507285|NCT01213277|OTHER|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
41507286|NCT01213277|OTHER|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
41379594|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in healthy controls|The demographic information of the healthy controls will be taken. Healthy controls will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
41379595|NCT05218096|DRUG|ALXN2050|Oral tablet.
41379596|NCT05218096|DRUG|Placebo|Oral tablet.
41379597|NCT03515681|BEHAVIORAL|Text messages|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
41507287|NCT01709539|PROCEDURE|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
41507288|NCT05326243|BIOLOGICAL|CD19-targeted chimeric antigen receptor T-cell|"Drug: Fludarabine~patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Drug: Cyclophosphamide~patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Biological: CD19 CAR-T~CD19 CAR-T cells will be administered using as a single dose at 0.1-9\*10\^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis."
41507289|NCT02458859|DEVICE|PICO (single use portable negative pressure wound therapy)|Single use portable negative pressure wound therapy
41507290|NCT00074828|DRUG|LY517717|
41507291|NCT00074828|DRUG|enoxaparin|
41034726|NCT03564496|DEVICE|Remotely-supervised Daily tDCS Administration|"While the first tDCS session will be performed at clinic under the full supervision, remaining sessions 2-20 (\~ 1 month) will be completed at home with remote monitoring by the study technician. Participants in the HC subgroup who opt-in to the additional 15 minutes of imaging +tDCS may complete the first session remotely.~For at-home tDCS administration, participants will be given the specially-designed tDCS device and headset, study laptop computer for secure video monitoring with study technician (must have internet access) and access to the cognitive training program, a detailed reference manual, and a training video. The device will produce up to 2.0 mA stimulation for around 20 minutes, and will not operate without the correct headset placement. The device will also automatically abort the session if optimal conditions are not maintained. It reports and records a completion code for each session."
41034727|NCT03564496|DEVICE|Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA|Participants in the healthy control subgroup who are willing may have an additional 15 minutes of imaging combined with 10 minutes of simultaneous tDCS of up to 4.0mA added at the end of their baseline scan. In this case, after the initial imaging and tDCS portion is complete, the participant will remain on the scanner for an additional 15 minutes during which brain imaging will continue and will be combined with 10 minutes of simultaneous tDCS up to 4.0mA. This will be a one-time add-on and will not be required at follow-up.
41034728|NCT01230476|DRUG|Cetuximab|Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.
41034729|NCT03694548|BEHAVIORAL|Part A Survey|Survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
41164853|NCT02199249|DEVICE|Open reduction Tightrope fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
41164854|NCT02199249|DEVICE|open reduction screw fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
41379598|NCT01638416|OTHER|Blood transfusion|Blood transfusion in ICU patients aged 18 and over.
41379599|NCT02942537|DEVICE|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
41379600|NCT02942537|PROCEDURE|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
41379601|NCT05694026|DEVICE|Intense pulsed light|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
41379602|NCT05694026|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
41379603|NCT03585894|OTHER|Sumatriptan|Receive intravenous infusion of sumatriptan
41379604|NCT03585894|OTHER|Ketorolac|Receive intravenous infusion of ketorolac
41507292|NCT06409819|DRUG|phage therapy|phage therapy will consist of an individualized combination of lytic phages that are active against the participant's E. coli/K. pneumoniae isolates and will be administered intravenously twice daily for 7 days.
41507293|NCT06409819|DRUG|control|Participants assigned to the control arm will start a 7-day course of intravenous sterile normal saline (placebo) administered twice daily.
41507294|NCT03624920|DRUG|THN102 Dosage A|THN102 Dosages A: placebo
41507295|NCT03624920|DRUG|THN102 Dosage B|THN102 Dosage B : 200mg/2mg
41507296|NCT03624920|DRUG|THN102 Dosage C|THN102 Dosage C: 200mg/18mg
41507297|NCT01467440|DEVICE|Selective Laser Trabeculoplasty|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
41507298|NCT02760745|OTHER|Ancillary tests|Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
41383568|NCT05345418|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency|Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.
41507299|NCT00792350|DRUG|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
41507300|NCT06550180|DRUG|Spinal anaesthesia group (S)|Spinal anaesthesia is given to all patients in S group. They will receive 20 mg of 0.5% hyperbaric bupivacaine plus 25 microgram fentanyl
41507301|NCT06550180|DRUG|Subcostal TAP block and spinal anesthesia group (STAP)|patient receive Subcostal TAP block before spinal anesthesia. Patients in STAP group will receive 20 ml of 0.25% isobaric bupivacaine for each side before spinal anesthesia
41507302|NCT06312566|DRUG|brivaracetam (BRV) tablet|Study participants will receive multiple-doses of brivaracetam tablet (reference - Treatment A) administered orally.
41507303|NCT06312566|DRUG|brivaracetam (BRV) dry syrup|Study participants will receive multiple-doses of brivaracetam dry syrup (test - Treatment B) administered orally.
41507304|NCT06548178|DRUG|T-DXd|T-DXd (5.4 mg/kg Q3W on Day 1) ×6 cycles.
41507305|NCT06548178|DRUG|THP|Docetaxel (75 mg/m2 Q3W on Day 1) concurrent with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg Q3W on Day 1) and pertuzumab (840 mg loading dose followed by 420 mg Q3W on Day 1) × 6 cycles.
41507306|NCT04898530|OTHER|NO INTERVENTION|There is no intervention for this study.
41507307|NCT03585920|BEHAVIORAL|Expanded Corn Snack|A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
41507308|NCT04575311|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
41507309|NCT04575311|OTHER|Placebo|Matching Placebo
41507310|NCT05016609|DEVICE|OraQuick HCV Antibody test (OraSure Technologies, Inc)|The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.
41034730|NCT03694548|BEHAVIORAL|Part B Yoga Program|Eight in-person instructor-led group yoga sessions.
41507311|NCT05016609|DEVICE|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|Xpert® HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Only participants who return a reactive OraQuick HCV Antibody test will be offered the Xpert® HCV VL Fingerstick test. Appropriate pre- and post-test counselling will be provided to participants.
41034731|NCT04667455|DIAGNOSTIC_TEST|Biomarker analysis at enrolment|Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
41034732|NCT04667455|DIAGNOSTIC_TEST|Biomarker analyses throughout the study|Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
41034733|NCT05271617|DIAGNOSTIC_TEST|VIDAS® NEPHROCLEAR™ CCL14|Measurement of CCL14 in sample aliquots after being subjected to different testing conditions
41034734|NCT05331352|BEHAVIORAL|Semi-structured interviews|Interview
41034735|NCT05331352|BEHAVIORAL|Projective methode|Rorschach + thematic aperception test
41507312|NCT05016609|DRUG|Sofosbuvir/Velpatasvir (Gilead)|Participants with a detectable HCV antibody will be offered treatment with sofosbuvir/velpatasvir.
41507313|NCT04198259|PROCEDURE|interventional devascularization|Interventional devascularization (BRTO and its variations) is a procedure for treatment of fundal varices associated with a large gastro-/splenorenal collateral.
41507314|NCT04198259|PROCEDURE|TIPS|TIPS is very effective in the treatment of bleeding GV, with more than a 90% success rate for initial hemostasis. It frequently requires additional embolization of spontaneous collaterals feeding the varices. The incidence of encephalopathy was higher after TIPS.
41507315|NCT01850251|DIETARY_SUPPLEMENT|Supplement with HMB and vitamin D|High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
41507316|NCT01850251|DIETARY_SUPPLEMENT|Standard nutritional supplement|High protein, high calorie nutritional supplement.
41507317|NCT05326282|DIAGNOSTIC_TEST|Multi-parametric ultrasound|Diagnostic ultrasound parameters used to evaluate the prostate. Transrectal scans will be performed
41507318|NCT01109147|OTHER|Imagery|All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
41507319|NCT01109147|GENETIC|pharmacogenetic sampling|A pharmacogenetic sample will be done with an additional consentment.
41034736|NCT05331352|BEHAVIORAL|Selfreported|RSQ - PBI - RFQ - QSCPGS - SSQ6 - ÉCHELLES DE CUNGI - STAI - PCL-S - IES-R
41034737|NCT04965675|DRUG|Eptinezumab|Eptinezumab will be administered per dose and schedule specified in the arm.
41034738|NCT04965675|DRUG|Placebo|Placebo matching to eptinezumab will be administered per schedule specified in the arm.
41034739|NCT02975167|OTHER|Outpatient Cervical Ripening|The experimental arm of the study will be subjects randomized to the outpatient group. Once randomized, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with outpatient induction of labor. Following placement of the Foley catheter, the subjects will be given detailed instructions for which to return to the hospital, as well as provided a 24 hour phone number to call if they have questions. They will be instructed to return to the hospital once the catheter falls out or if 24 hours has passed since its placement. Upon returning to the hospital, subjects will complete another survey assessing their satisfaction with their induction process.
41164855|NCT03159325|BEHAVIORAL|Healing Circles|See description in the arm description.
41507320|NCT03244644|DRUG|RBX2660|RBX2660 is a rectally administered microbiota suspension
41507321|NCT03244644|DRUG|Placebo|Placebo is normal saline solution administered rectally
41507322|NCT03244644|DRUG|Open label RBX2660 (only for confirmed CDI recurrence)|RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
40851200|NCT04383054|BEHAVIORAL|'More minutes' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
41379605|NCT06650176|BEHAVIORAL|Lifestyle Management|The Metrikamind intervention features a unique digital ecosystem designed to manage mental health specifically in workplace contexts, with a focus on aiding recovery and facilitating the return to work for employees on sick leave. This innovative tool employs bifactor models to enhance the accuracy of self-reported data, effectively countering potential faking behaviors. Through continuous, real-time data collection on a user-friendly platform, Metrikamind tracks and assesses various mental health conditions, including stress, anxiety, and depression. The intervention\&amp;#39;s advanced analytics enable personalized feedback and targeted interventions, improving the detection, management, and ultimately, the mitigation of mental health issues. By focusing on individuals currently unable to work due to mental health challenges, Metrikamind aims to support their recovery and accelerate their readiness to return to work, thus addressing both immediate and long-term recovery trajectories.
41383569|NCT05786131|PROCEDURE|Culprit-lesion revascularization|Percutaneous coronary intervention of culprit-lesion
41383570|NCT05786131|PROCEDURE|Non-culprit-lesion revascularization|Complete percutaneous coronary intervention of all angiographically significant non-culprit lesions
41507323|NCT02304497|OTHER|Platelet Rich Fibrin|Procedure: Platelet Rich Fibrin obtained
41507324|NCT03377491|DEVICE|NovoTTF-200T|Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
41507325|NCT03377491|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
41507326|NCT03377491|DRUG|nab paclitaxel|nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
41507327|NCT00553735|DRUG|Cyclosporine A 0.05%|Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.
41507328|NCT00553735|DRUG|Arificial Tear|Artificial Tear - three times a day for 18 months.
41507329|NCT03062761|OTHER|Infant Formula with prebiotics|Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
41507330|NCT03062761|OTHER|Standard Infant Formula|Control group: Intact cow's milk protein based infant formula containing prebiotics
41507331|NCT03716362|DEVICE|Otoacoustic emissions device|as a screening tool for Auditory brainstem response
41507332|NCT02547532|OTHER|collection of sputum|
41507333|NCT05689957|DRUG|Deep neuromuscular block using intravenous rocuronium induction at 1.2mg/kg and maintainance of 8-12mcg/kg/min for deep neuromuscular block|both arm are using low pressure pneumoperitoneum in laparoscopic surgery, moderate and deep neuromuscular block are monitor with neuromuscular monitoring. if surgical condition is inadequate, surgeon are allowed to increase intraabdominal pressure as per standard care
41507334|NCT00967460|BEHAVIORAL|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
41507335|NCT06200051|DIAGNOSTIC_TEST|Prediction of high risk of cancer|This initiative is aimed at comprehending the incidence rates of these four types of cancers, including lung cancer (LCA), liver cancer (LC), upper gastrointestinal cancer (UGIC), and CRC, to provide a theoretical foundation for the implementation of more practical and effective cancer screening strategies.
40851201|NCT04383054|BEHAVIORAL|'one minute' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
41164856|NCT04017897|DRUG|The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)|Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
41507336|NCT00060983|PROCEDURE|Body weight supported locomotor training|
41383571|NCT03549143|OTHER|IBS|No intervention, description of routine practice only
41507337|NCT00060983|PROCEDURE|Functional electrical stimulation|
41507338|NCT01161134|DRUG|Meloxicam|Meloxicam Tablets 15 mg
41507339|NCT02690987|DRUG|Exenatide|"Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.~The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of \~130-190 pg/mL."
41507340|NCT02690987|BIOLOGICAL|Desacyl ghrelin|"Ghrelin is a 28 amino acid stomach-derived peptide hormone, with the desacyl ghrelin (DAG) form inactive at the GHSR1a receptor. Good Manufacturing Practice (GMP)-grade DAG is obtained from Clinalfa (Bachem AG, Bubendorf, Switzerland).~The planned intravenous DAG infusion dose is expected to be 4.0 mcg/kg/hour aiming for maintenance plasma concentrations of \~13-19 ng/mL."
40851202|NCT04007419|BEHAVIORAL|Health Promoters and Organ Donation|Promotoras de Donación is a highly engaging and interactive online learning experience, that accommodates multiple learning styles by incorporating a variety of pedagogic approaches. The module consists of two components: a didactic educational component and a skills-based communication component. The didactic component provides basic information about organ donation and transplantation and the need for donors in the Hispanic community, and addresses concerns about donation commonly held by older Latina. The skills-based component provides instruction on the key communication skills needed to effectively engage small groups in discussions about organ donation. This component is intended to build communication self-efficacy or confidence opening the discussion about donation, addressing concerns raised by mature and older women participating in the small group sessions, and promoting the act of donor registration using persuasive, but non-coercive language.
40851203|NCT06529861|DIAGNOSTIC_TEST|[15O]H2O-PET Imaging|This imaging technique will be used to measure myocardial blood flow (MBF) and myocardial blood flow reserve (MBFR) in patients. The PET-CT scan involves the use of the radioactive tracer \[15O\]H2O to visualize blood flow in the heart, providing crucial data on coronary microvascular function.
40851204|NCT02112864|DRUG|Dexamethasone|10 mg (2.5 ml)
40851205|NCT02112864|DRUG|Normal Saline|2.5 mL normal saline
40851206|NCT01192308|DRUG|Tamoxifen 40mg QD|Tamoxifen 40mg QD during 4 weeks
40851207|NCT01196832|PROCEDURE|blood sample|blood sample for fibrocytes analysis
40851208|NCT01196832|PROCEDURE|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
40851209|NCT01452581|OTHER|Red blood cell transfusion|Maximal 2 units of packed red blood cells given one at a time on the first postoperative day. Evaluation of primary outcome is done after administration of each unit.
40851210|NCT01452581|DRUG|Voluven|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
40851211|NCT04207060|DRUG|Indomethacin|One capsule of 50 mg of indomethacin will be taken orally twice a day for a total of 28 days.
40851212|NCT04207060|DRUG|Placebo|One capsule of lactose not containing active study drug will be taken orally twice a day for a total of 28 days.
40851213|NCT04207060|PROCEDURE|Endoscopy for Pancreatic Function Testing|All subjects in the study (regardless of which treatment arm they are randomized to) will undergo an upper endoscopy during which they will receive an endoscopic pancreatic function test. An upper endoscopy will be performed during the baseline visit and at the follow-up visit at day 28 of the treatment (2 endoscopies total per each subject). Specifically, during the upper endoscopy, secretin will be administered intravenously at a weight-based dose of 0.2 mcg/kg over 1 minute. Fluid will be aspirated from the duodenum through the endoscope from 0-10 minutes and 10-20 minutes following secretin administration. The collected fluid will then be sent to the laboratory for analysis.
40851214|NCT05914207|BEHAVIORAL|Lifestyle modifications|Written suggestions on lifestyle modifications including duration of sleep, meal frequency, reduce screen time, exercise duration, food to avoid.
41034740|NCT02975167|OTHER|Inpatient Cervical Ripening|Once randomized to this group, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with inpatient induction of labor. Following placement of the Foley catheter, the subjects will undergo normal labor monitoring until their Foley catheter either falls out or is removed at 24 hours. At this time subjects will complete another survey assessing their satisfaction with their induction process.
41034741|NCT02975167|PROCEDURE|Foley catheter placement|Subjects randomized to both the inpatient and the outpatient arms will receive this intervention following completion of a survey. A Bard(TM) 16G two-way 5cc silicone-coated latex Foley catheter will be placed by a physician-member of the research team using a sterile metal speculum and ring forceps, or by hand, depending on physician preference. Once placed within the cervical canal, the Foley will be filled with 60cc of saline
41034742|NCT02975167|BEHAVIORAL|Pre-Foley Questionnaire|Prior to randomization into inpatient or outpatient arms, all subjects will complete a questionnaire assessing their attitudes, opinions, fears and anxiety regarding induction of labor.
41034743|NCT02975167|BEHAVIORAL|Post-Foley Questionnaire|Following removal of the Foley catheter (either by a physician at 24 hours or spontaneously), all subjects will complete the same questionnaire as prior assessing their attitudes, opinions, fears and anxiety regarding their induction of labor.
41164857|NCT03698617|DRUG|HSK3486|For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
40851215|NCT05914207|OTHER|Vestibular rehabilitation exercise|Each participant will be taught simple home-based vestibular rehabilitation exercise, which needs to be repeated
40851216|NCT04414514|DRUG|Ruxolitinib 1.5% Cream|Topical Ruxolitinib 1.5% Cream
40851217|NCT01041521|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
41164858|NCT03698617|DRUG|Propofol|For induction of general anesthesia
40851218|NCT05860465|DRUG|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
40851219|NCT05860465|DRUG|SPH4336 Tablets Placebo|SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
40851220|NCT06349668|DRUG|spinal analgesia with morphine and bupivacaine|single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery
40851221|NCT06349668|DRUG|lidocaine infusion|intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t (Ideal Body Weight)
40851222|NCT05416736|PROCEDURE|The bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins. Maneuvers will be performed by the researcher. Infants in both groups will be held under the armpit by a parent, male infants will be held in the drooping legs, and female infants will be held in the hip flexion position.
40851223|NCT05416736|PROCEDURE|Steril urine bag|Steril urine bag are attached to the genital area to collect urine samples
41379606|NCT04807881|DRUG|Keynatinib|All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is \> 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.
41379607|NCT01220037|BEHAVIORAL|Adhere to a specific standardized diet for 4 days|24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
41379608|NCT06648213|OTHER|Physiotherapy|Therapy group: In addition to routine care, they will be arranged according to the needs of the baby in the form of positioning, hand contacts, passive and active movement of the arms and legs for the development of movement, sensory stimuli around the mouth for oral motor organisation. Neurodevelopmental-based application will be applied three days a week, once a day for 10-15 minutes, from the 34th week until 36th week when vital signs are stable.
40851224|NCT05621174|DRUG|Dexamfetamine|Magisterial Dexamfetamine
40851225|NCT05621174|DRUG|Dexamfetamine|Tentin
40851226|NCT03515564|BEHAVIORAL|Dance/Movement Therapy, Art Therapy, Mindful Yoga|Utilizing deep breathing, exercise modalities, and social support in all settings
40851227|NCT00853138|BEHAVIORAL|cognitive-behavioral therapy|"In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week."
40851228|NCT04309708|DEVICE|Nimodipine pump infusion|Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
40851229|NCT04731272|DRUG|Dulaglutide 0.75Mg/0.5Ml Inj Pen|Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.
40851230|NCT02112292|DRUG|tetrahydrocannabinol|
40851231|NCT02112292|DRUG|cannabidiol|
40851232|NCT02112292|DRUG|Placebo|
40851233|NCT04356716|DRUG|Sildenafil|Initial Sildenafil dosage will be weight dependent. Participants will start at 40 mg daily (20mg in the morning, 20 mg in the evening) or 60 mg daily (40mg in the morning and 20 mg in the evening). Sildenafil dosage may be increased to up to 80mg daily (20-40mg in the morning and 20-40mg in the evening) based on the response to lower doses. If the participant has not had improvement after initial treatment, the dose may be increased, at the discretion of the study physician.
40851234|NCT04356716|OTHER|Standard of Care Sildenafil|Medical record review of participants that receive Sildenafil as part of standard of care.
40851235|NCT04356716|DIAGNOSTIC_TEST|Ocular Coherence Tomography-Angiography (OCT-A)|Retinal photographs will be taken at each study visit.
40851236|NCT04356716|OTHER|Visual Acuity (VA)|Visual acuity will be measured with Snellen Eye Chart at each study visit.
41034744|NCT02975167|PROCEDURE|Fetal Non-Stress Test|Following placement of the Foley catheter, all subjects, regardless of arm they are randomized to, will undergo a 20-minute NST. The NST will be read by a physician-member of the research team. If the NST is considered to be suspicious based on the physician's evaluation, subjects randomized to the outpatient arm will be moved to the inpatient arm, but evaluated as part of the outpatient arm on an intent-to-treat basis. All subjects randomized to the inpatient arm will be placed on continuous fetal heart rate monitoring, regardless of physician evaluation of the NST.
40851237|NCT04590716|OTHER|Data Collection|This is a non-interventional study conducted on the participant's smartphones to record MG related symptoms and conditions.
41034745|NCT05281562|DRUG|Lovaza|Daily dose of 1.68grams omega-3 fatty acids, 2 Lovaza pills per day.
41034746|NCT05281562|DRUG|L-Arginine Powder|Daily dose of 4.5 grams L-Arginine, powder form.
41034747|NCT05281562|DRUG|Vitamin C|Daily dose of 500 mg Vitamin C, powder form.
40851238|NCT01376414|OTHER|Urea Breath Test (UBT) for H. pylori infection|13C UBT to detect H. pylori infection. Single bedside test that determines infection in about ten minutes. Test machine is a product of Exalenz bioscience.
40851239|NCT04326049|DEVICE|LLETZ with videocolposcope|Loop procedure using a videocolposcope in order to see and remove the abnormal cervical tissue
40851240|NCT04326049|DEVICE|LLETZ with binocular colposcope|Loop procedure using a binocular colposcope in order to see and remove the abnormal cervical tissue
40851241|NCT04378114|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when C sensor algorithm is used.
41379609|NCT02628821|OTHER|Preterm Infants treated with non-invasive ventilation.|
41379610|NCT05965323|BEHAVIORAL|Health Education|Health education with comic books and videos
41034748|NCT03825380|DRUG|Bimatoprost|Eyedrops
41034749|NCT03825380|DRUG|Lumigan®|Eyedrops
41034750|NCT01445899|DRUG|PF-04523655 (Stratum I)|PF-04523655 (a small interfering RNA) - a single IVT injection
41034751|NCT01445899|DRUG|ranibizumab|6 monthly IVT injections of ranibizumab (Stratum II)
41164859|NCT05434715|PROCEDURE|Thyroidectomy|removal of the thyroid gland
41164860|NCT05537519|BIOLOGICAL|Phage Therapy|3-phage cocktail comprised of HP3, HP3.1 and ES19
41164861|NCT01975636|DRUG|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
41164862|NCT05635955|DRUG|Remimazolam|"Total intravenous anaesthesia will be induced with 0.3mg/kg remimazolam and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.2 mg/kg remimazolam (IV) will be administrated."
41379611|NCT05451849|BIOLOGICAL|TC-510|TC-510
41379612|NCT05451849|DRUG|Fludarabine|Fludarabine
41379613|NCT05451849|DRUG|Cyclophosphamide|Cyclophosphamide
41379614|NCT05497219|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VF)|A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.
41379615|NCT05661578|DRUG|Tiragolumab and Atezolizumab IV FDC|Intravenous fixed dose combination (IV FDC) of tiragolumab 600 mg and atezolizumab 1200 mg once every 3 weeks (Q3W).
41379616|NCT04943510|OTHER|Physical exercices|"surface EMG: surface electrodes will be positioned on the muscles to evaluate the level of muscle activation~non invasive muscular neurostimulations : application of a percutaneous electrical stimulation of the motor nerve of the considered muscle and a direct electrical stimulation of the muscle"
41379617|NCT03253159|BEHAVIORAL|Hypnosis|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room.
41379618|NCT06540430|BEHAVIORAL|The Use of a Mobile Application for Stoma Self-Care|The intervention group will use a mobile application where patients input their stoma condition, allowing healthcare professionals to monitor and manage their care. The app provides patients with information on diet, physical activity, stoma care, emotional support, and daily living needs.
41379619|NCT06536595|OTHER|Scales|Participants were asked to complete the HAnDE-T, MHISS, SF-36 and HAQ when they first came. After 1 week, they were asked to complete HAnDE-T for re-test.
41379620|NCT05934305|BEHAVIORAL|Matter Intervention|This 5-session text-enhanced intervention is designed to mitigate the negative behavioral consequences of internalized stigma and shame among MSM and gender minority individuals with SUDs that perpetuate sub-optimal engagement in HIV self-care and consequently inconsistent viral suppression. The intervention involves five virtually delivered one-on-one therapy sessions focused on behavioral goal setting skill development and related self-efficacy, increasing meta-cognitive awareness(i.e.,non-judgmental awareness of emotions and cognitions), and teaching and reinforcing compassionate self-restructuring (i.e., self-compassion). Participants also receive daily text messages querying emotions during the one-on-one portion of the intervention. For eight weeks after the one-on-one portion, participants receive their compassionate self-statements via text in response to their indicated emotions. Participants will also receive phone-based resource navigation, as needed.
41034752|NCT01445899|DRUG|PF-04523655 (Stratum II)|6 monthly IVT injections of PF-04523655 (a small interfering RNA)
41034753|NCT03264872|BEHAVIORAL|Peer-Enhanced Motivational Interviewing|Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.
41164863|NCT05635955|DRUG|Propofol|"Total intravenous anaesthesia will be induced with 2mg/kg propofol and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.25 mg/kg propofol (IV) will be administrated."
41164864|NCT05635955|DRUG|Esketamine|0.3mg/kg esketamine will be co-administrated in both arms
41164865|NCT03646695|PROCEDURE|ILM flap transposition|during ILM flap Transposition, an ILM flap is placed on the macular hole
41164866|NCT03646695|PROCEDURE|ILM peeling|during ILM Peeling the ILM is removed around the macular hole
41379621|NCT05934305|BEHAVIORAL|Control Condition|The control condition will involve five sessions of prerecorded asynchronous content related to local resources (e.g., information related to substance use treatment and other ancillary services).
41379622|NCT00581334|PROCEDURE|Robotic-assisted laparoscopic sacrocolpopexy|4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
41379623|NCT00581334|PROCEDURE|Open sacrocolpopexy|mesh augmented repair for post-hysterectomy prolapse performed via open laparotomy
41379624|NCT06079398|DRUG|Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg Navepegritide
41034754|NCT03264872|OTHER|Waitlist Control|After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
41034755|NCT06114823|PROCEDURE|carpal tunnel release mini-incision|Patients were subjected to a longitudinal mini-incision started just above the proximal flexor wrist crease and then extended for 1.5 - 2 cm in a proximal direction
41034756|NCT06114823|PROCEDURE|carpal tunnel release conventional incision|Patients were subjected a longitudinal incision which was created between the thenar and hypothenar eminences along the longitudinal axis of the ring finger. Then, it was extended to the proximal flexor wrist crease.
41034757|NCT04325659|DEVICE|Bridge Device|An FDA-cleared neuromodulator medical device, marketed for the treatment of opioid withdrawal
41034758|NCT04325659|DRUG|Lofexidine|FDA-approved medication for the treatment of opioid withdrawal. Participants will receive capsules 4 times daily for 7 days. The active dose is 0.72 mg four times daily for Days 1-5, for a total daily dose of 2.88 mg. Doses on Days 6 and 7 will be 1.44 (2 active, 2 placebo capsules) and 0.72 mg (1 active, 3 placebo capsules), respectively.
41034759|NCT04325659|DRUG|Placebo|Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
41164867|NCT06357936|PROCEDURE|nano-fat grafting in chronic limb ischaemia|The nano fat grafting procedure in the clinical trial involves the collection of adipose tissue under tumescent anesthesia, which is a technique to swell and firm the targeted area, through a separate puncture in the anterior abdominal wall. Following the collection, the adipose tissue undergoes a process of cannulation to prepare the nano fat. This prepared material is then injected into the tissues of the foot and leg using standard intramuscular injection needles. The injections are performed in various directions to ensure proper distribution of the nano fat. This method does not require additional drug therapy. It leverages the natural growth factors and stem cells present in adipose tissue, aiming to improve blood flow and tissue regeneration in limbs affected by critical ischemia. The unique aspect of this treatment is its focus on using autologous materials, minimizing the risk of rejection and side effects associated with foreign substances.
41164868|NCT06357936|PROCEDURE|sham comparator|For the clinical trial, a sham procedure would be designed to mimic the nano fat grafting without providing the actual therapeutic intervention. This involve the patient undergoing a similar process with tumescent anesthesia and making a puncture on the anterior abdominal wall. However, instead of harvesting adipose tissue and preparing nano fat, a placebo solution (such as saline) would be injected using the same intramuscular injection technique. The aim of this sham comparator is to assess the psychological and physiological effects of the nano fat grafting procedure itself, by eliminating the potential therapeutic benefits of the nano fat.
41164869|NCT05321381|OTHER|Resilience In Stressful Events (RISE) peer support team|Availability of peer support team to health care workers who experience stressful work-related events or situations
41164870|NCT03018847|DEVICE|COPD Co-Pilot|The COPD Co-Pilot is a system that guides a patient through a software application (web or mobile app) to collect, track, and trend daily symptoms related to Chronic Obstructive Pulmonary Disease (COPD). The system is intended to be used by patients as a support tool to track COPD symptoms as part of their personal disease management plan. The COPD Co-Pilot allows health care providers to view and triage subject symptoms via the provider web-based application. Health care providers also have the ability to send responses to subjects, like medication recommendations, through preset forms in the system.
41164871|NCT06183619|PROCEDURE|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
41034760|NCT04325659|DEVICE|Sham Bridge Device|Inactive Bridge Device which is applied and looks identical to the active Bridge Device
41034761|NCT02268838|DRUG|E6007|
41164872|NCT06183619|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation only
41034762|NCT02268838|DRUG|E6007 matching placebo|
41379625|NCT06079398|DRUG|Placebo for Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
41383572|NCT01243866|OTHER|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
41507341|NCT02690987|BIOLOGICAL|Saline|The placebo visit will involve an intravenous infusion of normal saline.
41507342|NCT03910985|DRUG|Duovent HFA|bronchodilation
41034763|NCT01360151|DRUG|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
41034764|NCT05515159|OTHER|electroconvulsive therapy|electrical stimulation of the brain while the patient is under anesthesia.
41034765|NCT06118372|DRUG|Recombinant von Willebrand Factor|Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
41507343|NCT01589718|DRUG|Macugen|one intravitreal injection of Macugen prior to vitrectomy surgery
41034766|NCT06635681|DRUG|combined chemotherapy|"Induction therapy(1 cycle):~Daunorubicin 60mg/m2/d d1-3 Cytarabine 100mg/m2/d d1-7 Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7 If the first course of treatment did not result in CR, patients with therapeutic target could be treated with targeted drugs, and the patients without targets would be treated with HAV regimen: Cytarabine 100mg/m2/d, d1-5, Homoharringtonine 2mg/m2 d1-5, Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7.~Consolidation therapy(3 cycles):~Cytarabine 2g/m2 q12h d1-3 Venetoclax 400mg d1-7 For patients with CBF and CEBPA dual mutations, the dose of cytarabine is 3g/m2.~Maintenance treatment(6 cycles):~Azacitidine 75mg/m2/d d1-5 Venetoclax 400mg d1-7~Allogeneic hematopoietic stem cell transplantation is recommended for high-risk groups and intermediate-risk with positive measurable residual disease."
41379626|NCT06648226|BEHAVIORAL|Health swaps|"Participants will view health grade labels on all products in the online grocery store indicating their healthfulness as estimated by United Kingdom Ofcom Nutrient Profiling Model scores. The health score labels will mimic Nutri-Score labels, a labeling system used in some European countries, showing a color-coded grade of A (green) through F (red) on each product. Products with A and B labels will meet the United Kingdom's cutoff for products that can be marketed to children and C, D and F labels products are less healthy than this cutoff (based on tertiles of Ofcom scores within each food group). When participants attempt to add a less healthy product to their cart (e.g., C, D or F health label), the store will automatically suggest a healthier product from the same category (e.g., with a A or B health label)."
41379627|NCT06648226|BEHAVIORAL|Environment swaps|"Participants will view climate grade labels on all products indicating their climate impact. The climate impact is calculated as the greenhouse gas emissions associated with producing the product in carbon dioxide equivalents (CO2-eq) per 100g (i.e., carbon footprint). Labels will be applied based on quintiles of carbon footprints in each food group. When participants attempt to add a high-climate-impact product to their cart (e.g., with a C, D, or F climate label), the store will automatically offer them swaps to more environmentally sustainable products (e.g., with a A or B climate label)."
41383573|NCT01243866|OTHER|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
41383574|NCT04048616|DIETARY_SUPPLEMENT|whey protein isolate|one 15-25 gm (based on body weight) protein packet three times a day with each meal
41507344|NCT01589718|DRUG|Sham|The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
40851242|NCT04378114|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when Zeus sensor algorithm is used.
40851243|NCT04378114|DRUG|Acetominophen|One time administration of acetaminophen.
40851244|NCT05373342|DEVICE|iCount system assembled with swabs|Designed as single use. Intended purpose - To be used to count swabs and tampons after childbirth in an objective manner. This is intended to be used in women during and after childbirth.
40851245|NCT00116116|DRUG|efavirenz, stavudine extended release, lamivudine|
40851246|NCT06247904|DEVICE|Active rTMS|The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be determined from individual MRI-modeled e-field, to achieve approximately motor threshold in the target area.
40851247|NCT06247904|DEVICE|sham rTMS|The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be close to zero (negligible) since sham coil will be used for the intervention
40851248|NCT03644667|BIOLOGICAL|tocilizumab|6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
40851249|NCT03644667|BIOLOGICAL|Placebo|The placebo is 0.9% sterile normal saline. 6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
40851250|NCT03644667|DRUG|Standard of Care Triple IS|"Standard of care triple maintenance IS includes:~1. A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.~   Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.~2. An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.~   Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.~3. Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol."
40851251|NCT03709394|PROCEDURE|Full utrasound guidance|The target vein is directly identified by portable ultrasound device and the complete procedure of peripheral venous cathether insertion is controlled by ultrasound guidance in real time
40851252|NCT03709394|PROCEDURE|Partial ultrasound guidance|The target vein is directly identified by ultrasound but the procedure of peripheral venous cathether insertion is performed conventionally, without ultrasound guidance
40851253|NCT03709394|PROCEDURE|No ultrasound guidance|The target vein is identified and peripheral venous catheter is inserted by conventional approach without use of any guiding devices
40851254|NCT00989963|DRUG|Beraprost Sodium Modified Release|60µg Tablets, twice a day for 12 weeks
41379628|NCT06648226|BEHAVIORAL|Combined health and environment swaps|"Participants will view both the health and climate grade labels on all products in the online grocery store. When participants attempt to select a product with a C, D, or F label on either dimension to their cart, the store will automatically offer them swaps to products that offer improvement over the original food on at least 1 dimension (health or environmental sustainability) and were at least as good or better on the other dimension, with the additional guardrail that the store never suggests products with a C, D or F label on either dimension."
41379629|NCT06648226|BEHAVIORAL|Control|Participants will not view any extra labels or be offered any swaps in the online grocery store.
41379630|NCT03257800|DRUG|Ketamine|Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
41379631|NCT03257800|DRUG|placebo|The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
40851255|NCT05784298|DEVICE|low-intensity rTMS|40 hz, 150 gauss, 1 session that lasts 45 minutes.
40851256|NCT02373644|OTHER|HVLA Thrust Manipulation and DN|HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
41379632|NCT01210625|DIETARY_SUPPLEMENT|Nutrabiotix|Fiber supplement: 9mg or 12mg
40851257|NCT02373644|OTHER|Conventional Physical Therapy|Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
40851258|NCT02745028|DIETARY_SUPPLEMENT|Monosodium glutamate|A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
40851259|NCT00724204|DIETARY_SUPPLEMENT|follow on formula without probiotics|A follow on formula without probiotics
40851260|NCT00724204|DIETARY_SUPPLEMENT|follow on formula with Lactobacillus salivarius CECT5713|follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day
41034767|NCT02125526|DEVICE|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
41034768|NCT03975348|DEVICE|High flow nasal cannula|High flow of warm and humidified oxygen/air mixture delivered through nasal cannula
41034769|NCT03975348|DEVICE|Continuous positive airway pressure|Positive airway pressure applied through a sealed face mask
40851261|NCT01249547|DRUG|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
41034770|NCT03975348|DEVICE|Facemask|Oxygen therapy through a conventional facemask
41034771|NCT02187757|DIETARY_SUPPLEMENT|Study Dietary Supplement (Prelipid 500 mg capsules)|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.
41034772|NCT02187757|DIETARY_SUPPLEMENT|Placebo|
41034773|NCT01319448|DRUG|Proguanil|Proguanil tablets, 1.5mg/kg/day
41034774|NCT01319448|DRUG|mefloquine plus artesunate|This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
41034775|NCT01319448|DRUG|Sulfadoxine-pyrimethamine plus amodiaquine|amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
41034776|NCT04175977|BEHAVIORAL|Aliviado Dementia Care-Hospice Edition QAPI program|Multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
41034777|NCT04175977|BEHAVIORAL|Usual Care|Usual care as provided by the hospice agency
41034778|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine|Subjects will be coadministered with inactivated SARS-CoV-2 vaccine and varicella vaccine.
41034779|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine coadministered with MMR|Subjects will be coadministered with SARS-CoV-2 vaccine and MMR.
41379633|NCT01210625|DIETARY_SUPPLEMENT|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
41383575|NCT04048616|DIETARY_SUPPLEMENT|potassium bicarbonate (KHCO3)|two 13.5 mmol capsules three times a day with each meal
41383576|NCT04048616|OTHER|microcrystalline cellulose|identical placebo capsule
41383577|NCT04048616|OTHER|maltodextrin powder|isocaloric placebo powder
40851262|NCT06049030|DRUG|HS-10516|Oral HIF-2α inhibitor
40851263|NCT02263443|PROCEDURE|Soap suds enema (S.S.E.)|Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
40851264|NCT02263443|PROCEDURE|sodium chloride enema|Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
40851265|NCT02263443|PROCEDURE|No enema|Patients NPO groups will NPO and no bowel preparation.
41379634|NCT06650098|OTHER|artificial intelligence-supported mobile application|It is aimed that an artificial intelligence-based mobile application that includes information, nutrition, exercise programs, complications and medication tracking, personalized suggestions, alarms and reminders, which will enable diabetic individuals to follow their glucose targets, support patients in their diabetes education, awareness and disease management to continue more actively. In addition, it is aimed that patients can easily access information, prevent acute and chronic complications, present physical activity and nutrition suggestions in accordance with the person\&#39;s lifestyle, follow up on medications with alarms and reminders, prevent the negative results of complications in advance, and improve individuals\&#39; diabetes-specific knowledge levels, compliance with treatment, self-management and care with information and guidance about foot care to reduce the risk of diabetic feet, which is particularly risky for diabetic patients.
41379635|NCT06650098|OTHER|WEB based application|The content plan for the web-based mobile application group will be prepared with technical support as specified. Patients will be able to log in to the mobile application with a username and password that will be defined specifically for them. Patients will be informed about how the website is used during the first meeting. They will be able to access all the information they need about diabetes with the web-based mobile application. Statistical data such as the frequency of individuals visiting the site, which sections they use more often and how much time they spend will be calculated.
41379636|NCT03273257|DRUG|Riociguat|"Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
41379637|NCT03273257|DRUG|Placebo|Placebo will be given analogue to riociguat with matching tablets.
41379638|NCT03273257|PROCEDURE|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
41507345|NCT04941326|OTHER|Diaphragmatic stimulation treatment with PNF techniques|Thumbs and palms are placed along the cartilage edges of the lower ribs. At the end of the expiration, pressure and stretching are given as far into the chest and upwards as possible and a deep inspiration is requested immediately after the pressure. Both sides can be stimulated by repeated contraction technique. Hand holding positions may differ according to the patient's preference. If the patient's physical condition is not suitable, the application can be done with the thumbs, the thumb of the left hand for the right rib, and the thumb of the right hand for the left rib in the same lying position. The patient will be asked to do the application 2 times in a day with 10 repetitions for 4 weeks.
41507346|NCT04941326|OTHER|Costal mobilization|In the supine position, the individual will place both hands around the 10-12th ribs and alternately apply an oblique push from the right and left sides to the opposite side. The exercise will be taught to the patient as training, and he will be asked to apply it 2 times a day with 20 repetitions for 4 weeks.
41507347|NCT04941326|OTHER|Breathing exercises|It is done to increase the diaphragm activity of the individual and to suppress chest breathing. While lying in the supine position, the legs are placed in a hooked position, with one hand on the abdomen and the other on the chest, and the deep breath that is taken from the nose in 2 seconds is asked to exhale through the mouth in 4 seconds, while revealing as little movement in the chest as possible, the main movement is requested to be around the abdomen. The application will be given to the patient as a home program and he will be asked to do it 2 times a day with 5 repetitions for 4 weeks.
40851266|NCT00656435|DRUG|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
40851267|NCT03274856|DRUG|GLWL-01|Oral administration of 3 capsules, twice a day
40851268|NCT03274856|DRUG|Placebo|Oral administration of 3 capsules, twice a day
40851269|NCT02772627|DRUG|Nebicapone|Nebicapone 100 mg tablets; oral route.
40851270|NCT02772627|DRUG|Placebo|Placebo tablets; oral route.
40851271|NCT05159115|OTHER|Low-FODMAP diet|4 weeks of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)
41034780|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine administered alone|Subjects will be immunized with inactivated SARS-CoV-2 vaccine alone
41034781|NCT04490746|OTHER|with no intervention, Collect samples|only with observation,there is no need to intervene
40851272|NCT05159115|OTHER|Starch- and Sucrose Reduced Diet (SSRD)|4 weeks of a diet low in starch and sucrose
40851273|NCT04627207|DRUG|CKD-330 1 Tab. and D085 1 Tab.|Other names: Reference
40851274|NCT04627207|DRUG|CKD-333 1 Tab|Other names: Test
40851275|NCT02621294|OTHER|Measuring protein requirement|a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-\[1-13C\] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
41034782|NCT01999504|OTHER|PAL-2|meal
41034783|NCT01999504|OTHER|TFH-1|Meal
40851276|NCT04359485|PROCEDURE|Glycolic acids peel 70%|Glycolic acid peel 70% applied in 3 coats medium depth
40851277|NCT04359485|OTHER|Saline|Sodium chloride
40851278|NCT00902707|DRUG|Mucinex 1200mg|Compared to Placebo
40851279|NCT00902707|DRUG|Placebo|Compare to active Mucinex
40851280|NCT05122299|PROCEDURE|Negative control group|No intervention after extraction then delayed implant insertion at the site of extraction after three months
40851281|NCT05122299|PROCEDURE|Postive control|Application of collagen only in the socket after extraction then delayed implant insertion at the site of extraction after three months.
40851282|NCT05122299|PROCEDURE|Study group|Application of acombination of CoQ10 and collagen hydrogel in the socket after extraction then delayed implant insertion at the site of extraction after three months.
40851283|NCT00545896|PROCEDURE|Extracorporeal shockwave therapy|Extracorporeal application of shockwaves on the surface of chronic wounds.
40851284|NCT00206713|DRUG|Sargramostim (Leukine)|6 μg/kg sargramostim administered SC once daily for 8 weeks
41034784|NCT01999504|OTHER|Reference|Meal
41379639|NCT06278532|DIAGNOSTIC_TEST|Brief Negative Symptoms Scale|The Lithuanian Brief Negative Symptoms scale (BNSS) version will be used and validated. BNSS is used as a modern tool for the evaluation of negative symptoms of schizophrenia. Older tools used for negative symptoms evaluation often include symptoms from other dimensions of symptoms of schizophrenia, and BNSS evaluates negative symptoms specifically. BNSS is a semi-structured interview made of 13 items. There are six subscales: anhedonia (3 items), lack of normal distress (1 item), asociality (2 items), avolition (2 items), blunted affect (3 items) and alogia (2 items).
41379640|NCT06278532|DIAGNOSTIC_TEST|The Calgary Depression Scale for Schizophrenia|The Lithuanian version of the CDSS will be used and validated. CDSS is a tool used to evaluate depressive symptoms, specifically for patients with schizophrenia. Often, distinguishing between depressive and negative symptoms of schizophrenia is difficult. Therefore, it is recommended to use tools designed specifically for patients with schizophrenia. CDSS is the only depression scale designed to assess depression in people with a schizophrenia syndrome disorder. It is a semi-structured interview consisting of 9 items.
41379641|NCT06278532|DIAGNOSTIC_TEST|The Schizophrenia Cognition Rating Scale|The Lithuanian version of the SCoRS will be used and validated. SCoRS is a 20-item interview-based assessment tool that evaluates cognitive deficits and the degree to which these deficits impair specifically in patients with schizophrenia.
41379642|NCT04472273|PROCEDURE|high-flow nasal cannula / classic nasal cannula|The oxygen given with nasal cannula cannot be humidified, causing drying in mucous membranes at high flow rates of more than 4L/min and problems in patient compliance.This situation prevents us to increase the oxygen FiO2 rate applied to the patient above 40%.According to the nasal cannula high-flow nasal cannula where heated and humidified oxygen can be delivered, oxygen therapy can be applied at a flow rate of 25L/min.It provides high flows easily, prevents the airway epithelium from drying out and improves mucus cleansing, causing a decrease in anatomical dead space.It provides discharge of expired air in the upper airways.It increases alveolar ventilation.It offers a stream adjusted to all children.Flow and titration can be adjusted according to the child's weight and effect.
40851285|NCT00206713|DRUG|Placebo|Placebo administered SC once daily during the randomized retreatment phase.
41379643|NCT00116545|DRUG|troglitazone|
41379644|NCT04513665|DRUG|ZW25|ZW25 at 20mg/kg intravenously (IV) every two weeks.
41507348|NCT04941326|OTHER|Spinal mobilization|T12 vertebrae will be found by following the 12th rib in the prone position of the individual and spinous of L1 and L2 vertebrae will be determined with this reference. Then, small amplitude rotational movements in the vertebrae will be revealed by pushing in the anterior direction over the transverse processes. This application will be applied once a week for an average of 10 minutes for 4 weeks.
40851286|NCT03384641|DRUG|Bedaquiline 200 mg|Participants will receive bedaquiline 200 mg (2\*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.
40851287|NCT03657849|DEVICE|EBUS TBNA|All patients undergo EBUS TBNA with two needle sizes
40851288|NCT03433352|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
40851289|NCT03433352|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
40851290|NCT05282433|DRUG|Surufatinib|Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
40851291|NCT02465203|DRUG|Previous treatment in DEB025 study|Follow-up after DEB025 active study
40851292|NCT05108558|DRUG|CCH administration|Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
41165786|NCT05749939|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. A goal of ACT is to help people develop psychological flexibility, meaning they can experience and live with difficult thoughts and emotions, and still pursue what matters to them. The current project is an online, self-guided, 6-session intervention. Each session is expected to take about 30 minutes each, and the entire course will take approximately 3-4 weeks to complete, as users are encouraged to take a few days in between sessions. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and care- specific vignettes, and apply ACT concepts to their own lives and care situations. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
41379645|NCT03878069|BIOLOGICAL|elapegademase-lvlr|"Patients transitioning from Adagen: For patients currently receiving Adagen at ≤ 30 U/kg/wk or an unknown Adagen dose, the suggested dosage of Revcovi is 0.2 mg/kg/wk IM. For patients currently receiving Adagen at \> 30 U/kg/wk the suggested equivalent Revcovi dosage (mg/kg/wk) is the Adagen dosage in U/kg/wk divided by 150.~At the investigator's discretion, the total weekly dose may be divided and administered in multiple IM injections, increased by 0.033 mg/kg/wk if trough ADA activity is \< 30 mmol/hr/L, dAXP is \> 0.02 mmol/L, and/or the immune reconstitution is inadequate.~Adagen-naïve patients: The suggested starting Revcovi dosage is 0.2 mg/kg twice weekly IM based on ideal body weight, for a minimum of 12 to 24 weeks until immune reconstitution is achieved. At the investigator's discretion, the dosage may be gradually increased to maintain trough ADA activity \> 30 mmol/hr/L, dAXP \< 0.02 mmol/L, and/or to maintain adequate immune reconstitution."
41379646|NCT06119581|DRUG|LY3537982|Administered orally.
41507349|NCT04941326|OTHER|Sham mobilization|Sham pressures will be applied to the lumbar region of the patient, away from the vertebrae. This application will be applied once a week for an average of 10 minutes for 4 weeks.
41507350|NCT00168935|DRUG|Fresubin protein energy Drink (CAVE! nutritional intervention)|
41507351|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
41507352|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
40851293|NCT05108558|DRUG|Control - Crossover to CCH|Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
40851294|NCT05108558|DEVICE|RestoreX|Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
40851295|NCT02653547|OTHER|standard multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
40851296|NCT02653547|OTHER|high-frequency multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
40851297|NCT02653547|OTHER|standard multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
40851298|NCT02653547|OTHER|high-frequency multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
40851299|NCT06480318|DEVICE|TENS|The device is portable and battery-powered to preserve the patient functional activity. The device has two channels and the parameters of each channel can be adjusted independently of the other. The device contains a power supply, amplifier and electrodes to give a warning. The power supply and amplifier are located within the TENS device. Electrodes are connected to the device via cables. The current produced in the power supply is increased in the amplifier and reaches the electrodes. The device is self-gel to facilitate the transmission of current between the electrodes made of carbon silicon alloy and the skin surface. In the research, a dual-channel, four-electrode (5 cm x 5cm) TENS device will be used. TENS application will be applied every 12 hours, twice and for 20 minutes, 24 hours after the surgery.
41507353|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
41507354|NCT03132155|DRUG|AMG 337|6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
41507355|NCT01437488|DRUG|Cabazitaxel|"* Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~* Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~* Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator"
41507356|NCT01437488|DRUG|Neulasta|6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
41507357|NCT01437488|PROCEDURE|CT Scan|CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)
41507358|NCT01437488|BIOLOGICAL|Blood Draw|Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
41507359|NCT01792687|DRUG|ARN-509|Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily
41507360|NCT01792687|DRUG|Abiraterone acetate|1,000 mg, oral, daily
41507361|NCT01792687|DRUG|Prednisone|5 mg, oral, daily
41507362|NCT05235516|DRUG|AK104|q3w iv
41507363|NCT05235516|RADIATION|EBRT|45-50.4Gy
41507364|NCT05235516|RADIATION|BT|≥80Gy
41034785|NCT05385016|BEHAVIORAL|Cooking Skills|This session will consist of a hands-on cooking demonstration in a demo kitchen. Skills addressed in this portion of the session will include proper kitchen utensil and appliance use, measuring dry and wet ingredients, following/reading a recipe, preparing ingredients, cooking a meal, etc. The participant will follow a visual recipe that provides a breakdown of each skill needed to complete each step of the recipe. Additionally, during the cooking session investigators will address nutrition topics related to food/kitchen safety, basic nutrition education (i.e., portion sizes, food groups, reading food labels, meal planning etc.) in a discussion format.
41034786|NCT05385016|BEHAVIORAL|Physical Activity|This session will consist of a group functional fitness class. Each session will include a warm-up (\~5 min) moderate-to-vigorous intensity aerobic and resistance exercise (\~20 min) and cool-down/stretching (\~5 min). Exercises may be accompanied by music and will include walking/jogging, dancing, imitating animal movements, vertical/horizontal jumps, squats, hurdles, walking on balance beam etc. Thera-Band, kettle bells, free weights, and medicine balls will be used during strength exercises for major muscle groups. These sessions will be led by certified personal trainers with experience in adaptive physical activity.
41034787|NCT03791125|DRUG|Salvianolic Acid A|4 anticipated doses are 30 mg, 90 mg, 180 mg and 270 mg, respectively. All of these are single-dose study.
41034788|NCT03791125|DRUG|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
41034789|NCT01138904|DRUG|irinotecan, oxaliplatin|"OXIR: FOLFOX -\> FOLFIRI~IROX: FOLFIRI -\> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
41034790|NCT01138904|DRUG|oxaliplatin, irinotecan|"FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
41034791|NCT04913363|OTHER|Green space|Green space in which activities take place
41034792|NCT04740918|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
41165787|NCT03987490|BEHAVIORAL|Text Message|Vaccine reminder notification sent via text
41507365|NCT05235516|DRUG|cisplatin|qw iv
41507366|NCT05235516|DRUG|Placebo|q3w iv
41507367|NCT02293980|DRUG|MK-3795|Oral administration
41507368|NCT02293980|DRUG|Nivolumab|IV infusion
41507369|NCT02293980|DRUG|Cabozantinib|Oral administration
41507370|NCT02293980|DRUG|Bezlutifan|Oral administration
41507371|NCT06032000|BIOLOGICAL|LEM-mR203|mRNA vaccine using Lemonex's Drug Delivery System (DDS), DegradaBALL
41034793|NCT04740918|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion
41034794|NCT04740918|OTHER|Placebo|Placebo matched to atezolizumab
41034795|NCT03853629|OTHER|None. Not applicable|None. Not applicable
41507372|NCT06032000|BIOLOGICAL|Placebo|0.9% Sodium Chloride Solution
41507373|NCT03660306|PROCEDURE|opioid anesthesia|opioid anesthesia means using sufentanil during surgery
41507374|NCT03660306|PROCEDURE|opioid free anesthesia|opioid free anesthesia means giving no opioids during surgery
41507375|NCT02922738|OTHER|VisualDx|VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
41507376|NCT00987779|DRUG|Gabapentin|Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
41379647|NCT06119581|DRUG|Pembrolizumab|Administered IV.
41379648|NCT06119581|DRUG|Placebo|Administered orally.
41507377|NCT00987779|DRUG|Gabapentin|Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
41165788|NCT03987490|BEHAVIORAL|PostCard|Vaccine reminder notification sent via standard mail
41165789|NCT03987490|BEHAVIORAL|Standard of Care|No additional information given to parents
41379649|NCT06119581|DRUG|Cisplatin|Administered IV.
41379650|NCT06119581|DRUG|Carboplatin|Administered IV.
41379651|NCT06119581|DRUG|Pemetrexed|Administered IV.
41379652|NCT06467292|DEVICE|continuous theta-burst stimulation (cTBS)|cTBS stimulation will be applied to different areas of the brain following learning. Stimulation will take place following learning in order to block motor memory retention.
41507378|NCT01870440|DRUG|Ozurdex Intravitreal Injection (0.7 mg)|Intravitreal Injection
41507379|NCT06228534|PROCEDURE|Root coverage with tunneling technique|THIS IS THE INTERVENTION GROUP THE RECIPIENT AREA OF THE CONNECTIVE GRAFT IS PREPARED.
41507380|NCT04200027|PROCEDURE|total mesorectal excision|Total Mesorectal Excision Total Mesorectal Excision is currently the standard technique for surgical treatment of RC. It was first described in 1982 by Bill Heald, and relies on the excision of the whole mesorectum within an intact mesorectal fascia, with the contained lymphatic system along with the tumour bearing bowel segment Total mesorectal excision
41034796|NCT04831736|DRUG|Ketamine|Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
41034797|NCT04831736|DRUG|Placebo|Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
41034798|NCT05616650|DRUG|18F-DCFPyL|Each participant will receive a single IV dose of 18F-DCFPyL by bolus injection. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi; dose variations will be in accordance with the Nuclear Regulatory Commission (NRC) standard dose variation (i.e., 20%) permitted for diagnostic clinical studies.
41034799|NCT05616650|RADIATION|Stereotactic Body Radiation Therapy|Intensity modulated radiotherapy will be delivered to a dose of 26Gy in two fractions with the second fraction performed within 8 days of the first session.
41034800|NCT03179228|DEVICE|Prostate Embolization|Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
41379653|NCT06467292|BEHAVIORAL|Adaptation|Auditory adaptation in speech
41379654|NCT06467292|DEVICE|Single pulse Transcranial magnetic stimulation (TMS)|TMS will be delivered 10 times in each motor evoked potentials (MEP) recording block.
41379655|NCT06467292|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
41379656|NCT02525380|PROCEDURE|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
41379657|NCT04491188|DIETARY_SUPPLEMENT|Bacillus subtilis DE111|1 x10-9 CFU Bacillus subtilis DE111 probiotic
41165790|NCT03987490|BEHAVIORAL|Motivational Interview|Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
41165791|NCT03811834|DRUG|Mobocertinib|Mobocertinib capsule, \[14C\]-Mobocertinib intravenous infusion, \[14C\]-Mobocertinib oral solution.
41165792|NCT01855477|PROCEDURE|Histological biopsy procedure|
41379658|NCT04491188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
41379659|NCT03910439|BIOLOGICAL|Avelumab|Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle
41379660|NCT03910439|RADIATION|External beam radiotherapy|5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
41379661|NCT03313388|DIETARY_SUPPLEMENT|Drink|Beverage to be consumed
41379662|NCT06643975|OTHER|One-piece zirconia dental implants|One-piece zirconia dental implants with zirconia ball attachments, these implants are metal free made of oxide ceramics with cutting-edge Selective laser melting(SLM) surface treatment technology
41379663|NCT06643975|OTHER|One-piece titanium dental implants|One-piece Titanium dental implants with titanium ball attachments, these implants are gold standard compatible implants
41379664|NCT01607866|PROCEDURE|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
41379665|NCT01607866|PROCEDURE|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
41379666|NCT05940558|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
41507381|NCT05548387|DRUG|HCP2202|Take it once per period.
41507382|NCT05548387|DRUG|RLD2202|Take it once per period.
41507383|NCT05548387|DRUG|RLD2203|Take it once per period.
41379667|NCT05670912|DRUG|Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
41164873|NCT04678765|PROCEDURE|Ultrasound-guided distal peripheral nerve block|"To localize the median nerve, the ultrasound transducer will be placed in a transverse orientation proximally to the wrist cease at mid-forearm level, with a slight tilt distally towards the hand. An in-plane ultrasound-guided medial-to-lateral puncture will be made and 3ml of 2% lidocaine was injected within the fascia that envelopes the median nerve.~To perform the ulnar block, an ultrasound transducer will be placed in a transverse orientation over the ulnar side of the distal forearm. An in-plane ultrasound-guided medial-to-lateral or proximal-to distal puncture will be made and 3 ml of 2% lidocaine will be infiltrated into the fascial plane to block the ulnar nerve. Finally, we will apply a circumferential subcutaneous infiltration of 4 ml 2% lidocaine at the radial side of the wrist, 2cm proximal to the styloid process of the radius to block the terminal sensory branches of the radial, musculocutaneous, and medial antebrachial cutaneous nerves that may reach the palmar crease."
41164874|NCT04678765|PROCEDURE|Ultrasound-guided quadruple-injection axillary nerve block|"The US probe will be applied in the axilla to obtain a short-axis view of the axillary artery. The following 4 nerves will be identified as hyperechoic structures: the median, ulnar, and radial nerve surrounding the axillary artery and the musculocutaneous nerve in the fascial layers between the biceps and coracobrachialis muscles.~A total volume of 20 mL lidocaine 2% will be administered divided over 4 locations. The needle is inserted in-plane from the anterior aspect of the axillary artery and directed toward the posterior aspect of the axillary artery to first anesthetize the radial nerve. The posteriorly located radial nerve is surrounded with 8 mL of local anesthetic. Afterward, the needle is withdrawn and redirected to the median and ulnar nerves, after which another 8 mL of local anesthetic is deposited. In the end, the needle is withdrawn and redirected toward the musculocutaneous nerve where another 4 mL of local anesthetic is deposited."
41164875|NCT00215722|DRUG|Cetuximab|
41164876|NCT05665413|DEVICE|TENS|strocking technique, HOT PACK and Ergon instrument
41164877|NCT00210678|BEHAVIORAL|No intervention|No treatment is given to the patients as this is an observational study.
41164878|NCT00574600|BIOLOGICAL|SAAVI DNA-C2 vaccine|DNA vaccine
41164879|NCT00574600|BIOLOGICAL|SAAVI MVA-C vaccine|Boost vaccine
41164880|NCT00574600|BIOLOGICAL|Placebo|Placebo vaccine
41164881|NCT03378778|PROCEDURE|Root canal treatment|Root Canal Treatment followed by Ceramic Onlay restoration
41164882|NCT03616236|DRUG|Buprenorphine/Naloxone|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
41379668|NCT05670912|DRUG|Placebo Comparator of Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
41379669|NCT04765501|OTHER|Survey study|Headache Impact Questionnaire (HIQ) will be applied.
41379670|NCT06188923|DRUG|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
41379671|NCT06188923|DRUG|Placebo|Same as active comparator, except placebo dispensed
41379672|NCT04310007|PROCEDURE|Biospecimen Collection|Undergo blood collection
41379673|NCT04310007|DRUG|Cabozantinib S-malate|Given PO
41379674|NCT04310007|PROCEDURE|Computed Tomography|Undergo CT
41379675|NCT04310007|DRUG|Docetaxel|Given IV
41379676|NCT04310007|PROCEDURE|Echocardiography|Undergo ECHO
41379677|NCT04310007|DRUG|Gemcitabine Hydrochloride|Given PO
41379678|NCT04310007|DRUG|Nab-paclitaxel|Given IV
41379679|NCT04310007|BIOLOGICAL|Nivolumab|Given IV
41379680|NCT04310007|DRUG|Paclitaxel|Given IV
41379681|NCT04310007|BIOLOGICAL|Ramucirumab|Given IV
41379682|NCT06649916|BEHAVIORAL|Parentese Speech|Novel words are introduced in parentese, a type of speech that is typically characterized by greater pitch variation, longer duration, and louder volume
41379683|NCT06649916|BEHAVIORAL|Adult Registered Speech|Novel words are introduced in standard adult register.
41164883|NCT03616236|OTHER|Treatment as usual|Participants will receive a referral to buprenorphine treatment in the community
41379684|NCT00002767|BIOLOGICAL|Detox-B adjuvant|
41379685|NCT00002767|BIOLOGICAL|recombinant interferon alfa|
41379686|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using laryngeal mask
41379687|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using endotracheal tube
41379688|NCT04311723|PROCEDURE|Bronchoscopy|Undergo standard of care bronchoscopy
41379689|NCT03434873|OTHER|magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks
41379690|NCT06412380|PROCEDURE|Implant insertion|All patients received a single Tapered Screw implant (Bioinnovation Dental®, Brazil). The implants were placed according to the manufacturer's instructions by using the appropriate burs with a final master drill of 3.5 or 4.5 mm in diameter by one senior oral surgeon. These implants were multi-threaded, and their surfaces were both sandblasted and acid etched. Of the 230 participants, 172 received a single 5 x 10-mm implant, and 58 received a 4 x 10-mm implant.
41379691|NCT01036594|DRUG|Ketoconazole|200mg during first week of study (run-in phase), then 400mg po tid
41379692|NCT01036594|DRUG|Hydrocortisone|"Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has \<30% PSA decline, patient goes off study."
41379693|NCT01036594|DRUG|Dexamethasone|"Dexamethasone 0.5mg po bid~If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
41379694|NCT05567562|COMBINATION_PRODUCT|dual anti-platelet therapy|dual anti-platelet therapy
41379695|NCT05567562|DRUG|Placebo|Placebo
41507384|NCT03229135|DEVICE|other antibacterial agents，breathing machine|If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
41379696|NCT05991622|DRUG|Combined LAI Treatment: Cabenuva and Sublocade|A preliminary test of the combined LAI treatment will be conducted with a total of 40 individuals diagnosed with HIV and OUD that meet all other study inclusion criteria. Treatment will take place primarily at TMH IC (n=30), however, about one-quarter of participants will undergo the pilot test at the RIDOC (n=10). Participants will complete a baseline interview, receive the combined LAI treatment (described below), and complete follow-up assessments at 1-, 3-, and 6-months following initiation of injectable medication. Of the 40 participants, 25 will be purposefully selected to engage in qualitative interviews to assess the strengths and limitations of the clinical protocol and combined treatment as well as describe their reasons for LAI uptake or discontinuation. We will also elicit feedback from clinic staff and other key stakeholders regarding the delivery of the clinical protocol and other implementation factors
41379697|NCT06648486|DEVICE|With the assistance of wearable isokinetic training robot|A child with SMA will use a wearable isokinetic training robot to train the knee joint for 20 sessions.
41379698|NCT06643962|DRUG|Venetoclax|Venetoclax in the EPBCRlow cohort will be added to the ongoing 3+7 regimen. In the first induction cycle: venetoclax needs to be ramped up: 100 mg on day 5, 200mg on day 6, and 400mg on days 7-14, orally once daily. In the second induction (if required), venetoclax 400mg will be administered orally once daily on days 5-14 without a dose ramp-up schedule. Venetoclax in the EPBCRlow cohort during consolidation therapy: 400mg on days 1-7, orally once daily, along with the consolidation chemotherapy.
41379699|NCT06643962|DRUG|Idarubincin|Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).
41379700|NCT06643962|DRUG|Cytarabine|During induction therapy: 100mg/m2/d on days 1-7, IV. During consolidation therapy: intermediate-dose cytarabine for age \>55 years old: 1.0g/m\^2 q12h on days 1-3, high-dose cytarabine for age ≦55 years old: 2g/m2 q12h on days 1-3.
41379701|NCT03978806|BEHAVIORAL|Active Comparator: peer navigator|The intervention is aimed to provide support with social challenges and adherence. The peer navigator will meet with patients to provide support with social challenges and use motivational interviewing to provide support with adherence.
41379702|NCT03978806|OTHER|Placebo Comparator: Control Arm (standard of care)|Control patients will have met the same inclusion and exclusion criteria as intervention patients.
41379703|NCT06411756|BEHAVIORAL|Narrative videos|Culturally targeted narrative videos will be sent via email.
41379704|NCT06411756|BEHAVIORAL|A Fitbit activity tracker|A Fitbit activity tracker is a wireless wearable device that monitors physical fitness activity.
41379705|NCT06411756|OTHER|Daily text message|A daily adaptive step goal that will be sent via text message with a short positive message.
41379706|NCT06411756|OTHER|Monthly Zoom meeting|Monthly Zoom meetings, led by the research team, to discuss physical activity with other study subjects.
41379707|NCT06411756|OTHER|Website access|Access to Physical Activity Centers Empowerment (PACE) website.
41379708|NCT06411756|OTHER|Printed materials|"Printed materials from the American College of Sport's Medicine's Moving through Cancer campaign."
41379709|NCT06411756|BEHAVIORAL|Printed materials|"Printed materials from the American College of Sports Medicine's Moving through Cancer campaign."
41507385|NCT00961402|BEHAVIORAL|Wellness Control|6-month wellness control
41379710|NCT04308759|OTHER|Experimental Smoking Cessation Program|Participate in Quitbot experimental cessation program
41379711|NCT04308759|OTHER|Control Smoking Cessation Program|Participate in Quitbot control cessation program
41379712|NCT05217901|DRUG|14C-labeled ASP0367|Oral
41379713|NCT04024722|PROCEDURE|In Vitro Fertilization|Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
41379714|NCT05935930|DRUG|Propofol 10 MG/ML Injection|Propofol infusion
41379715|NCT05935930|DRUG|Sevoflurane Inhalation Liquid|Sevoflurane inhalation
41379716|NCT00594581|DRUG|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
41379717|NCT00104962|DRUG|lenalidomide|Given orally
41379718|NCT05326412|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
41507386|NCT00961402|BEHAVIORAL|Exercise Intervention|6 month exercise intervention
41507387|NCT01453179|DRUG|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
41507388|NCT01453179|DRUG|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
41507389|NCT03375177|OTHER|Natural history of disease|registry plan
41164884|NCT01274559|DRUG|Extended-release niacin/laropiprant (ERN/LRPT)|1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
41164885|NCT01274559|DRUG|Placebo|1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
40851300|NCT06341569|OTHER|Respiratory breathing techniques group|"Target group: subjects in the respiratory breathing techniques group. Program duration: the program lasts for 14 weeks.~Breathing techniques: the program includes various breathing exercises, including:~Diaphragmatic breathing teaches participants to breathe deeply, engaging the diaphragm muscle, which can improve lung capacity and relaxation.~Pursed-lips breathing: this technique involves inhaling through the nose and exhaling slowly through pursed lips, which can help slow down breathing and manage shortness of breath.~Alternate nostril breathing: this technique involves closing one nostril while inhaling and exhaling through the other nostril alternately.~Relaxation techniques: the program incorporates progressive muscle relaxation techniques. This involves progressively tensing and relaxing different muscle groups.~Medical education: topics like the anatomy of the respiratory system, the importance of proper breathing, potential benefits of specific breathing exercises."
41034801|NCT06310252|DIAGNOSTIC_TEST|Opthalmic assessments|"The participants will undergo the following assessments:~1. Pupil size measurement~2. Manifest refraction (no autorefraction)~3. Monocular in both eyes and binocular uncorrected visual acuity (photopic):~   * Distance (4 m)~  * Intermediate (80 cm)~  * Near (40 cm)~4. Monocular best corrected visual acuity (photopic):~   * Distance (4 m)~  * Near (40 cm)~  * Distance-corrected near (40 cm)~5. Monocular and binocular mesopic (with and without glare) and photopic (without glare) contrast sensitivity testing (subgroup)~6. Slit lamp examination~7. Tear breakup time~8. Placido Corneal topography, keratometry and pachymetry~9. Optical coherence tomography including epithelium mapping (subgroup)~10. Applanation intraocular pressure~11. Cycloplegic refraction~12. Dilated fundus examination~13. Wavefront aberrometry (subgroup)~14. Adverse events"
41034802|NCT04880304|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
41164886|NCT03426553|BIOLOGICAL|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
41164887|NCT03426553|BIOLOGICAL|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
41164888|NCT00826228|DRUG|teriparatide|teriparatide 20ug daily sc for 6 months
41164889|NCT00826228|OTHER|weight-bearing|device assisted walking
41164890|NCT01704066|OTHER|Training and education|
41164891|NCT03955861|BIOLOGICAL|adalimumab|Subcutaneous injection
41379719|NCT06412666|DRUG|Aficamten|Oral Tablet
41379720|NCT06412666|DRUG|Placebo|Oral Tablet
41164892|NCT03955861|BIOLOGICAL|Certolizumab|Subcutaneous injection
41164893|NCT03955861|BIOLOGICAL|Etanercept|Subcutaneous injection
41164894|NCT03955861|BIOLOGICAL|Golimumab|Subcutaneous injection
41164895|NCT03955861|BIOLOGICAL|Secukinumab|Subcutaneous injection
41164896|NCT05951439|DIETARY_SUPPLEMENT|CRE + HMB|3 g/day of CRE and 3 g/day of HMB
41164897|NCT05951439|DIETARY_SUPPLEMENT|CRE + GAA|3 g/day of CRE and 3 g/day of GAA
41164898|NCT05951439|DIETARY_SUPPLEMENT|Placebo|6 g/day of inulin
41164899|NCT05950776|BIOLOGICAL|MVA-SARS-2-S|Vaccination with MVA-SARS-2-S
41164900|NCT05950776|OTHER|Placebo|Placebo
41164901|NCT01510002|PROCEDURE|Total thyroidectomy|Extracapsular total thyroidectomy
41164902|NCT01510002|PROCEDURE|Total thyroidectomy + prophylactic central neck dissection|Extracapsular total thyroidectomy plus prophylactic central neck dissection
41164903|NCT06157619|PROCEDURE|Oocyte Vitrification /Warming|In Vitro matured oocytes will be randomly assigned to any of the two Vitrification protocols
41164904|NCT06479122|DRUG|Acetaminophen|1g acetaminophen is administered during skin closure (end of operation).
41164905|NCT06479122|DRUG|Acetaminophen/Ibuprofen|A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)
41164906|NCT06479122|DRUG|Acetaminophen|1g acetaminophen is administered 6 hours after the first administration.
41164907|NCT06479122|DRUG|Acetaminophen/Ibuprofen|A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.
41164908|NCT03478410|PROCEDURE|Epicardial fat biopsy|A 1 cm (\~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery
41164909|NCT06050083|BEHAVIORAL|Hypnosis audio recordings|Hypnosis recordings created by the investigators that guide participants through using hypnosis to manage chronic pain.
41379721|NCT06647498|DRUG|Remternetug|Administered subcutaneously every 12 weeks
41379722|NCT06647498|DRUG|Matching Placebo (Remternetug)|Administered as subcutaneous injection of placebo every 12 weeks
41379723|NCT06143891|DRUG|Belumosudil|Pharmaceutical form:Tablet-Route of administration:oral
41379724|NCT06143891|DRUG|Placebo|Pharmaceutical form:Table-Route of administration:oral
41379725|NCT06143891|DRUG|Prednisone|Pharmaceutical form:Tablet-Route of administration:oral
41379726|NCT06143891|DRUG|Prednisolone|Pharmaceutical form:Tablet-Route of administration:oral
41379727|NCT01077167|DRUG|Omecamtiv mecarbil|Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
41379728|NCT02037594|BEHAVIORAL|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
41379729|NCT02037594|BEHAVIORAL|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
41379730|NCT02037594|BEHAVIORAL|PrEP Information (Active Control)|Standard of Care Information about PrEP
41379731|NCT02037594|BEHAVIORAL|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
41379732|NCT05566730|BEHAVIORAL|CT-MICART App|App designed with the goal of treating CUD in African American adults
41379733|NCT05566730|BEHAVIORAL|Control|App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
41379734|NCT05755399|DEVICE|Brain imaging using transcranial focused ultrasound (tFUS)|All enrolled patients will be imaged using the MRI as standard of care. The patient will additionally be imaged using the tFUS system, ICC HIFU Synthesizer. Total imaging time will be limited to 15 minutes. Following image acquisition by the ultrasound, the standard of care surgery will be performed.
41379735|NCT01958502|GENETIC|surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold|
41379736|NCT00891527|DRUG|Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)|"Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.~Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated."
41379737|NCT06650358|DEVICE|Light Adjustable Lens+|The Light Adjustable Lens+ (LAL+) is a posterior chamber, UV absorbing, three-piece, foldable, photo reactive silicone intraocular lens with a squared-posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure to the implanted LAL+ using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change postoperatively. A subsequent lock-in exposure is delivered to the implanted LAL+ to stabilize the lens power. The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
41379738|NCT06650137|DIAGNOSTIC_TEST|diaphragmatic ultrasound|"The examination is performed with a phased array probe, also known as a cardiac probe. The technique used will be that described and validated in anterior studies: the patient is in the Fowler position: half-seated, at an angle of around 45 degrees. The patient is ventilating spontaneously, and no participation is required. The probe is positioned in the sub-costal region between the mid-clavicular and anterior axillary line on the right, and between the anterior and middle axillary line in the sub- or intercostal region on the left. The liver is used as an acoustic window for the right hemi-diaphragm. The probe is oriented medially, cranially and dorsally.~The operator switches to time-motion (TM) mode when an angle of over 70° is achieved between the upper part of the diaphragm and the analysis axis in the most cephalic part of the diaphragm. The image is frozen when 6 respiratory cycles have been measured."
41379739|NCT03076307|BEHAVIORAL|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
41379740|NCT04613310|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
41379741|NCT04670510|OTHER|On-site AE|"Participants will attend on-site supervised AE sessions 3 times per week for the first 6 weeks, twice weekly for weeks 7-12; once weekly for weeks 13-18.~All supervised sessions will start and end with 5-minute warm-up and cool-down and will involve exercise on the treadmill, elliptical, and/or bike. During AE sessions, participants will exercise so that their heart rate is approximately 65% of their peak heart rate and gradually increase the intensity of exercise so that their heart rate is between 70 and 85% of their peak heart rate. All participants will wear heart rate monitors and encouraged to exercise in their target heart rate zone. Supervised AE sessions will gradually increase to 50-minutes per session"
41379742|NCT04670510|OTHER|At-home AE|Participants will increase at-home AE during the 6-month intervention period with weeks 19-26 occurring entirely at-home. As participants transition to home-based exercise, they will be equipped with a polar heart rate monitor and will be instructed to use this to record average heart rate during each exercise session. On a log sheet, they will record both average heart rate during exercise and average subjective rating of perceived exertion (RPE) during each exercise session.
41507390|NCT03864887|PROCEDURE|Oxygen supply of high-low-high procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).
40851301|NCT04353778|DRUG|Pyridostigmine|Eight weeks of low-dose pyridostigmine
40851302|NCT04353778|DRUG|Placebos|matching placebo x 8 weeks
40851303|NCT04353778|PROCEDURE|non-invasive vagal nerve stimulation|stimulation of the vagus nerve
40851304|NCT06416410|DRUG|JAB-21822|JAB-21822 administered orally as a tablet
40851305|NCT06416410|DRUG|Tislelizumab|Tislelizumab administered as an intravenous (IV) infusion
40851306|NCT06416410|DRUG|JAB-3312|JAB-3312 administered orally as a tablet or capsule
40851307|NCT06416410|DRUG|Pemetrexed|Pemetrexed administered as an intravenous (IV) infusion
40851308|NCT06416410|DRUG|Carboplatin|Carboplatin administered as an intravenous (IV) infusion
40851309|NCT02646813|PROCEDURE|Intraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed intraluminally
40851310|NCT02646813|PROCEDURE|Extraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed extraluminally
41034803|NCT04880304|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
41034804|NCT06636032|DRUG|AdMSC (CellReady®)|At day 0, patients will have AdMSC injections. Patients will be followed-up for 6 months
41379743|NCT04670510|OTHER|Social Engagement (SE)|To control for the social component of the AE intervention participants in the SE group will be invited to attend at total of 25 group meetings over the course of the 6-month study period.
41379744|NCT04827446|OTHER|Wearable Sensor|Patient is given a wearable device to wear for 12 weeks.
41379745|NCT04827446|OTHER|Blue-blocking glasses|Patient is given blue-blocking glasses to wear at instructed times.
21587754|NCT06578130|DEVICE|StypCel™ Absorbable Hemostat|The StypCel™ Absorbable Hemostat is used during neurosurgery to control bleeding. It is applied directly to the bleeding site to achieve hemostasis within a few minutes. The study will observe its effectiveness and any related complications during and after surgery.
41379746|NCT04827446|OTHER|Clear glasses|Patient is given glasses that block no visible light.
41379747|NCT04827446|OTHER|Full SYNC app|Patient downloads the SYNC app and is given light interventions designed to have a targeted, personalized effect on the circadian clock.
41379748|NCT04827446|OTHER|"Dummy SYNC app"|Patient downloads the SYNC app and is given light interventions designed to have minimal impact on the circadian clock.
41379749|NCT05041868|OTHER|Treatment|After a physical therapy evaluation, the patient underwent a booklet-guided physical exercise program that lasted three months (3 times per week with a duration of 60 minutes per session). Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit. The patient was evaluated at 2 different timepoints (baseline and after treatment). The physiotherapist contacted the patient by phone weekly to follow the progression of the treatment.
41379750|NCT01211873|DRUG|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
41379751|NCT01211873|DRUG|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
41379752|NCT00864084|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
41379753|NCT03505606|DIAGNOSTIC_TEST|Visual acuity tests|Participants to have visual acuity tested with the three modified vision tests.
41379754|NCT05285527|DEVICE|MiSight 1 Day|Subjects will wear MiSight 1 day lenses for three years.
41379755|NCT03759509|BEHAVIORAL|aerobic exercise|the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
41379756|NCT04937452|DRUG|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
41379757|NCT04937452|DRUG|Rotigotine 6Mg/24Hrs Patch|Rotigotine 6 mg/24Hrs administration for 24 weeks
41379758|NCT04937452|DRUG|Placebo|Placebo administration for 24 weeks
41379759|NCT00027573|BIOLOGICAL|filgrastim|
41379760|NCT00027573|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41379761|NCT00027573|DRUG|cyclophosphamide|
41379762|NCT00027573|DRUG|fludarabine phosphate|
41379763|NCT00027573|DRUG|methotrexate|
41379764|NCT00027573|DRUG|tacrolimus|
41379765|NCT00027573|PROCEDURE|peripheral blood stem cell transplantation|
41379766|NCT04905589|DIETARY_SUPPLEMENT|BetaQuik™|MCT (Medium chain triglycerides)
41164910|NCT04825834|OTHER|Blood Sample Collection|Subjects enrolled in the DELFI-L101 will have blood specimens collected (\~40 mL) at enrollment.
41379767|NCT04905589|DIETARY_SUPPLEMENT|WheyBasics|Whey Protein Isolate
41379768|NCT04905589|OTHER|Iso-voluminous water|Iso-voluminous Water as comparitor to Betaquik or WheyBasics
41507391|NCT03864887|PROCEDURE|Oxygen supply of low-high-low procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).
41507392|NCT03864887|DEVICE|Optical monitor for hemodynamic parameter.|Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.
41379769|NCT03125239|DRUG|Merestinib|Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)
41379770|NCT03125239|DRUG|LY2874455|This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
41379771|NCT05866159|OTHER|Kinesiotape using Rocktape®|Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
41379772|NCT05866159|OTHER|Sham taping|sham taping with Rocktape®, with no tension.
41379773|NCT06651177|DRUG|Tirzepatide|Tirzepatide is available in single dose vials at six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg/0.5 mL. A study MC will administer the once-weekly SQ dose of tirzepatide. Consistent with tirzepatide's prescribing guidelines, participants will be initiated at a once-weekly SQ dose of 2.5 mg/week with a dose increase to 5mg/week at week 5. Consistent with tirzepatide's prescribing information, once the participant has received 5 mg/week for 4 weeks they are eligible for a dose increase if needed
41379774|NCT06651177|OTHER|Placebo|"A matched placebo (containing saline) will be created for use in the trial. A study MC will administer the once-weekly SQ dose of saline. The process for deciding on dose increases will be the same for placebo and tirzepatide."
41379775|NCT01901939|OTHER|exercise|daily tailored low level pedaling exercise at bedside
41379776|NCT05963022|DRUG|Tirzepatide|Administered SC
41379777|NCT05963022|DRUG|Placebo|Administered SC
41379778|NCT00088400|DRUG|TransMID|
41379779|NCT01612988|DRUG|BOMP|"Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3"
41379780|NCT06571955|DEVICE|Implantation of LARS artificial grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial grafted ligament.
41379781|NCT06571955|DEVICE|Implantation of LARS artificial non-grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial non-grafted ligaments.
41379782|NCT04444921|DRUG|Carboplatin|Given IV
41379783|NCT04444921|BIOLOGICAL|Nivolumab|Given IV
41379784|NCT04444921|DRUG|Paclitaxel|Given IV
41379785|NCT06650852|BIOLOGICAL|BRII-179|BRII-179 will be given via intramuscular injection
41034805|NCT01258114|OTHER|SPA treatment (ST)|"Drug: spa treatment soon after randomization :~Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;~* nutritional counseling (french nutritional recommendations booklet) ;~* caloric restriction and physical training on demand (non mandatory)."
41034806|NCT01258114|OTHER|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
41034807|NCT03722251|BEHAVIORAL|Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing|
41034808|NCT05584215|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis Groups|Groups based on cognitive behavioural therapy for psychosis
41034809|NCT03607448|DEVICE|Freestyle Libre Flash Glucose Monitoring System|Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
41034810|NCT06634446|DEVICE|a mobile application for cognitive training|"Personalized cognitive training (PCT) HappyNeuronwill be delivered via a tablet or mobile application for 24 hours within 12 weeks, with a weekly supervision-call to reinforce their motivation.~HappyNeuron Pro is a digital therapy tool designed for clinicians to provide engaging cognitive therapy via a web-based platform. It is compatible with PC, Mac, iPad, and Android devices and is available in multiple languages. The tool features exercises from established cognitive remediation programs.~Functionality: The program offers 22 cognitive exercises targeting seven key functions outlined in the MATRICS framework: Processing Speed, Selective Attention, Reasoning and Working Memory, Verbal Memory, Visual Memory, and Auditory Memory. Exercises are customizable to meet individual patient needs, facilitating personalized cognitive training.~User Experience: Each session comprises brief, self-administered exercises, with the order and difficulty adjusted by clinicians."
41034811|NCT06634446|DEVICE|video games|Patients in the control group will use video games with no prominent cognitive involvement no prominent cognitive involvement
41034812|NCT01127178|DRUG|E7016 + TMZ|Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
41034813|NCT04139317|DRUG|Capmatinib|INC280 tablets were administered orally at 400 mg on a continuous twice daily (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle.
41034814|NCT04139317|BIOLOGICAL|Pembrolizumab|Pembrolizumab was administered by intravenous infusion at 200 mg once every 3 weeks (Q3W).
41034815|NCT04065438|DEVICE|LIPOSORBER® LA-15|"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."
41034816|NCT04820673|DRUG|Sarecycline|Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.
41034817|NCT02542748|DRUG|Norepinephrine|norepinephrine injection
41034818|NCT02542748|DRUG|Ephedrine|Ephedrine injection
41034819|NCT02071134|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
41379786|NCT06650852|DRUG|BRII-835 (VIR-2218)|BRII-835 will be given via subcutaneous injection
41379787|NCT06650852|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
41379788|NCT06650852|DRUG|Placebo of BRII-179|Placebo of BRII-179 will be given via intramuscular injection
41379789|NCT06650852|DRUG|Placebo of BRII-835|Placebo of BRII-835 will be given via subcutaneous injection
41507393|NCT01682811|DRUG|Part 1 Levulan injection|Control or treatment lesions will be injected with Levulan vehicle only or active drug and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
41507394|NCT01682811|DRUG|Part 1 Levulan surface application|Control or treatment lesions will be painted with Levulan vehicle only or active drug, allowed to dry, and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
41164911|NCT04037306|BEHAVIORAL|Butyrate Feedback|Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.
41164912|NCT04037306|BEHAVIORAL|Fiber Feedback|Estimated fiber consumption from menu records of weight loss facility.
41164913|NCT00857298|BEHAVIORAL|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be \~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
41164914|NCT05323188|OTHER|Tryptase dosage|Collection of biological waste from a blood test for complete blood count (CBC) of care. Centrifugation to recover the plasma, then dosage of the tryptase.
41164915|NCT01065207|BIOLOGICAL|blood test at day one|"Epidemiological, clinical, virological, and immunological data will be collected.~Clinical events as neoplasia will be collected"
41164916|NCT03269513|BEHAVIORAL|Physical Exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
41034820|NCT03497923|DRUG|Magnesium Sulfate|After reversal the obention of a TOF ratio of 0.9 is avaited. 10 minutes later patients will receive a perfusion of magnesium 60 mg kg-1 over 5 minutes.
41034821|NCT00919269|OTHER|Cytology Specimen Collection Procedure|Correlative studies
41034822|NCT00919269|OTHER|Laboratory Biomarker Analysis|Correlative studies
41164917|NCT01938898|OTHER|Invitation letter randomisation|"There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:~1. Male \& Study \& Confidentiality~2. Male \& Study~3. Male \& Project \& Confidentiality~4. Male \& Project~5. Female \& Project \& Confidentiality~6. Female \& Project~7. Female \& Study \& Confidentiality~8. Female \& Study~9. Neutral \& Study \& Confidentiality~10. Neutral \& Study~11. Neutral \& Project \& Confidentiality~12. Neutral \& Project"
41164918|NCT04054453|COMBINATION_PRODUCT|Intra-partum care bundle invoking 4 elements|Care bundle involving all the 4 elements
41034823|NCT03989947|DRUG|Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.|Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
41164919|NCT02001077|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
41164920|NCT02001077|BEHAVIORAL|Cognitive Behavioral Therapy for Pain (CBT-P)|
41164921|NCT00935259|DRUG|Simvastatin|40 mg once daily for 2 weeks
41164922|NCT00935259|DRUG|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
41164923|NCT02183077|DRUG|Meloxicam gel|
41164924|NCT02183077|DRUG|Meloxicam tablet|
41379790|NCT06576167|BEHAVIORAL|IMPROVE|IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.
41164925|NCT01878136|DRUG|Tissue Plasminogen Activator|Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
41164926|NCT00252018|BEHAVIORAL|Daily intake of broccoli sprouts|
41164927|NCT01530087|DEVICE|CASTLE barrier|Prototype barrier to be used in place of current two piece device
41164928|NCT04651556|DRUG|Magnesium Sulfate & bupivacaine|intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine
41034824|NCT05652751|DRUG|nerve growth factor|The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
41034825|NCT05652751|DRUG|physiological saline|Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
41164929|NCT04651556|DRUG|paracetamol & ketorolac|parenteral analgesics
41164930|NCT02475005|BEHAVIORAL|pain self management app on smartphone|
41164931|NCT00188825|OTHER|placebo|
41164932|NCT00188825|DRUG|basiliximab|
41164933|NCT01347177|PROCEDURE|Zirconia-based adhesive bridge|Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
41164934|NCT01347177|PROCEDURE|Metal-based adhesive bridge|The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
41164935|NCT02555488|DEVICE|diode laser|MB and diode
40851311|NCT00882960|DRUG|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
41164936|NCT02555488|DEVICE|diode laser|diode laser
41164937|NCT02555488|DRUG|Methylene blue|Methylene blue and diode laser was used
41165793|NCT01920178|DEVICE|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
41507395|NCT01682811|DRUG|Part 1 Levulan surface application twice|Control or treatment lesions will be painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 3 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
41507396|NCT01682811|DRUG|Part 1 Levulan surface application twice with microneedling|Control or treatment lesions will be prepared with microneedling, painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 24 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
41507397|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 8 minutes to achieve a dose of 50 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
41507398|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 16 minutes to achieve a dose of 100 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
41507399|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 32 minutes to achieve a dose of 200 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
41165794|NCT05271318|BIOLOGICAL|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
41379791|NCT06111781|DRUG|Relugolix 120 MG [Orgovyx]|ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
41379792|NCT06111781|RADIATION|SBRT standard of care radiotherapy treatment|SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.
41507400|NCT04412278|OTHER|Online Survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess physical activity level (International Physical Actvity Questionairre) and Exercise Benefits and Barriers (Exercise Benefits and Barriers Scale).
41507401|NCT04248829|DRUG|Lazertinib 240 mg/160 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
41507402|NCT04248829|DRUG|Gefitinib 250 mg|The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose
41507403|NCT04248829|DRUG|Lazertinib-matching placebo 240 mg/160 mg|The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances
41379793|NCT06650514|DRUG|OMO-103|OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).
41379794|NCT06067191|DRUG|RV299|Oral Suspension
41379795|NCT06067191|DRUG|Placebo|matching placebo
41379796|NCT05899933|PROCEDURE|Non-surgical peri-implant therapy|"2 weeks after baseline examination, non surgical therapy will be applied in implants diagnosed with peri-implantitis prior to enrollment in surgical therapy.~Firstly, participants will be instructed in oral hygiene. Professional supragingival and subgingival debridement of implants/ teeth, including the selected for the study implants, will be performed. Local anesthesia will be performed, when needed. Targeted implants will be treated with PEEK-coating ultrasonic tips (Instrument PI; EMS), titanium curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), rubber cup and polishing paste. Possible adjustments to implant-borne prostheses will be considered, whenever possible. Re-evaluation of non-surgical therapy will be performed after 6 weeks.~At the 6-week reevaluation, participants with peri-implant probing pocket depth ≥5 mm and bleeding on probing and/or suppuration in patients with full mouth plaque score ≤20% will proceed to surgical therapy."
41507404|NCT04248829|DRUG|Gefitinib-matching placebo 250 mg|The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
41507405|NCT01885195|DRUG|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
41507406|NCT02567877|PROCEDURE|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
40851312|NCT00882960|DRUG|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
40851313|NCT00820716|OTHER|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
41165795|NCT05271318|BIOLOGICAL|pembrolizumab|pembrolizumab, a monoclonal antibody binding PD-1
40851314|NCT05842681|DRUG|Azithromycin|A single daily oral dose of Azithromycin tablet 500 mg for five days
41507407|NCT02567877|DRUG|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
41034826|NCT05652751|DEVICE|EA|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
41034827|NCT05652751|DEVICE|sham EA|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
41034828|NCT03441425|OTHER|Unexpected death|
41034829|NCT03821311|RADIATION|Computed tomography|End-inspiratory/end-expiratory CT is repeated 3 times corresponding to the 3 studied conditions: At baseline, through expiratory resistive loading using an adjustable PEP mask, and after 5 min of nasal high flow therapy at 25 L/min.
41034830|NCT04674358|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
41034831|NCT04674358|DRUG|Vehicle Opthalmic Solution|Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
41379797|NCT05899933|PROCEDURE|Implantoplasty|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy) and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implantoplasty will be applied using tungsten carbide burs of various shapes and sizes (Peri-implantitis Kit; Meisinger) followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
41379798|NCT05899933|PROCEDURE|Erythritol Air-abrasive device|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implant surface decontamination with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS) will be applied followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
41379799|NCT05899933|PROCEDURE|Prophylaxis|Supramucosal biofilm removal of implants/ teeth will be performed at, 3, 6, 9 and 12 months after surgical therapy for the Implantoplasty group and the Erythritol Air-abrasive device group and at 2 weeks, 3, 6, 9 and 12 months after baseline examination for the control group. Targeted implants will be treated with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS). During these appointments, patients will be re-motivated and re-instructed to oral-hygiene measures.
41379800|NCT04277442|DRUG|Decitabine|Given IV
41379801|NCT04277442|BIOLOGICAL|Nivolumab|Given IV
41379802|NCT04277442|DRUG|Venetoclax|Given PO
41379803|NCT06648850|DRUG|DA-001|Allantoin + Topical Alpha 1 Agonist (GRAS) + TAAR Agonist (GRAS)
41507408|NCT05721911|GENETIC|whole genome sequencing|Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
41507409|NCT03939663|DRUG|misoprostol|misoprostol 2 tablets
41507410|NCT03939663|DRUG|Placebo|starch pills manufactured to mimic misoprostol 200 mg tablets
41507411|NCT03443271|PROCEDURE|TAP Block with Bupivicaine|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.25 % Bupivicaine on each side.
41507412|NCT03443271|PROCEDURE|TAP Block with Placebo drug|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.9% Saline on each side.
41507413|NCT05314101|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
41507414|NCT05314101|DRUG|bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
41507415|NCT05314101|DRUG|TAS-102|Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks
41034832|NCT03727191|OTHER|Control Group (education, guidelines, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.
41034833|NCT03727191|OTHER|Experimental Group (education, guidelines, 2 pckts diet, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
41034834|NCT06052332|RADIATION|Short course radiotherapy|Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.
41034835|NCT06052332|DRUG|Adjuvant chemotherapy (optional)|The choice of the adjuvant chemotherapy is to the investigator's discretion.
41165796|NCT05271318|DRUG|pegylated liposomal doxorubicin|Pegylated Liposomal Doxorubicin is a chemotherapy and a pegylated liposomal form of the anthracycline topoisomerase inhibitor, doxorubicin.
40851315|NCT05842681|DRUG|Methylprednisolone|methylprednisolone 500 mg single intra-venous daily dose for three days
41164938|NCT05278013|OTHER|Dermabond|High viscosity Dermabond is a sterile, liquid topical skin adhesive containing monomeric (2-OCA) formulation and the colorant D \& C Violet # 2. The product has a syrup-like in viscosity and polymerizes within minutes when applied to the skin. 2-OCA is an effective barrier against microbial penetration by Gram-positive (inc. methicillin-resistant Staphylococcus aureus) and Gram-negative motile and nonmotile species as long the as the film is intact (11-13). The high viscosity of Dermabond is intended to reduce the risk of unintended placement of the adhesive during the application process to other body parts, patient's clothing or in between the skin layers in the wound, which can result in delayed wound healing.
41379804|NCT06648850|OTHER|Placebo Topical Solution|Allantoin
41379805|NCT06638866|DIAGNOSTIC_TEST|Pancreatic imaging AI model|Subjects identified with pancreatic lesions by the AI model, which include PDAC and non-PDAC subtypes, will be required to undergo questionnaire, blood tests (including CA19-9, CA125, CEA, etc.) and further imaging examinations (including contrast CT, MRI, EUS, etc.) to confirm the final status of the pancreatic lesion.
41379806|NCT04078568|DRUG|IVIG|IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
41379807|NCT04078568|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
41379808|NCT04078568|DRUG|Prednisolone|Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
41379809|NCT04882085|DRUG|Zavicefta, Ceftazidime-Avibactam|CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.
41379810|NCT04882085|DRUG|Best Available Treatment|main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem
41379811|NCT06087640|BIOLOGICAL|aQIV or aTIV|Participants receive a 0.5-mL intramuscular dose of aQIV or aTIV on Day 1. A 0.5 mL dose of aQIV contains nominally 15 µg of hemagglutinin (HA) of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 µg HA). A 0.5 mL dose of aTIV contains nominally 15 µg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 µg HA). The strain composition of aQIV and aTIV is that recommended by the World Health Organization (WHO) for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
41379812|NCT06087640|BIOLOGICAL|QIV or TIV|Participants receive a 0.5-mL intramuscular dose of the non-adjuvanted QIV or TIV on Day 1. A 0.5 mL dose of QIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 μg HA). A 0.5 mL dose of TIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 μg HA). The strain composition of QIV and TIV is that recommended by the WHO for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
41379813|NCT06649890|DEVICE|Xperience™ Advanced Surgical Irrigation|Xperience™ solution will be applied twice during reconstruction procedures: first after achieving hemostasis and second just before implant introduction. The solution will be warmed to body temperature before use. Both tissue expanders/implants and mastectomy pockets will be soaked with Xperience™, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of Xperience™ will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout, and no rinsing will occur post-irrigation. Surgical site closure will follow standard procedures.
41379814|NCT06649890|DEVICE|Dilute Povidone-Iodine|5% dilute povidone-iodine solution will be prepared by mixing povidone-iodine solution and normal saline at the appropriate ratio. Both tissue expanders/implants and mastectomy pockets will be soaked with dilute povidone-iodine, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of dilute povidone-iodine will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout. Surgeon discretion will determine rinsing after irrigation. Surgical site closure will follow standard procedures.
41379815|NCT02976389|OTHER|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
41379816|NCT02976389|OTHER|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
41507416|NCT02836691|DEVICE|EKG (electrocardiogram)|Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.
41034836|NCT06052332|PROCEDURE|Total mesorectal excision|"Surgery must be performed according to the principles of total mesorectal excision. A watch \& wait approach is allowed for those subjects who have clinical complete response according to the local assessment."
41164939|NCT00000701|DRUG|Zidovudine|
41165797|NCT04591964|COMBINATION_PRODUCT|"mobile application M-Cardio based on android"|"Mobile apllication M-Cardio (android) for remote monitoring of patients with CHF developed on algorithms of clinical indicators, that's give us to evaluate current condition of patient, depends from quantity points of abnormals higher or lower threshold values, with automatically notification for doctor and patient for timely medical service."
41034837|NCT06052332|COMBINATION_PRODUCT|Total neoadjuvant therapy|"The choice of the TNT is left to the investigator's discretion.~If RAPIDO:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If RAPIDO light:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If OPRA with induction chemotherapy:~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~If OPRA with consolidation chemotherapy:~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine) followed by~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)"
41164940|NCT06478225|DRUG|BGT007H Cell Injection|"Intervention roughly goes through 3 phases (the day of cell infusion is defined as day 0, d0):~1. Apheresis and baseline period: Eligible subjects are enrolled for leukapheresis to prepare BGT007H cell injection solution, and baseline assessment is performed from after apheresis to before preconditioning.~2. Preconditioning (d-5\~d-3): Patients begin preconditioning (FC regimen) 5 days before BGT007H cell administration. A 2-day rest and observation period is conducted after preconditioning.~   The FC regimen is as follows:~  * Fludarabine: 25\~30mg/m2/d, intravenous infusion, once a day, for 3 consecutive days;~  * Cyclophosphamide: 250\~350mg/m2/d, intravenous infusion, once a day, for 3 consecutive days.~3. Cell infusion (d0) and DLT observation period (d0\~d28)."
41164941|NCT02274051|DIETARY_SUPPLEMENT|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
41379817|NCT02976389|OTHER|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
41379818|NCT02861573|BIOLOGICAL|Pembrolizumab 200 mg|IV Q3W
41379819|NCT02861573|DRUG|Olaparib 400 mg|Eight 50-mg capsules PO BID
41379820|NCT02861573|DRUG|Docetaxel 75 mg/m^2|IV Q3W
41034838|NCT05192525|DEVICE|mChemotherapy|"The intervention is composed of one core intervention mChemotherapy, one pre-chemotherapy consultation, and two app follow-up visits. mChemotherapy will be specifically utilized to facilitate symptom self-management for intervention group covering chemotherapy for six weeks. The mChemotherapy includes six components: (i) self-monitoring, (ii) alerts, (iii) reminder, (iv) consultation, (v) my prescription, (vi) knowledge base. Intervention group participants will be given an individual username and password to log in to the mChemotherapy platform. The intervention nurses will deliver the intervention and contact patients through this platform."
41164942|NCT06478810|OTHER|Domomedicine and dedicated nursing care for a close and secure monitoring after an ambulatory hepatectomy|For patient who need a minor hepatectomy under laparoscopy for the standard of care, the follow-up will be an ambulatory follow-up. This ambulatory follow-up will be made possible thanks to the integration of Domomedicine and dedicated nursing care for a close and secure monitoring.
41164943|NCT00984698|BEHAVIORAL|Cognitive Behavioral Social Rhythm Group Therapy|12 weeks, 2h structured group therapy
41379821|NCT02861573|DRUG|Prednisone 5 mg|One 5-mg tablet PO BID
41379822|NCT02861573|DRUG|Enzalutamide 160 mg|Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
41379823|NCT02861573|OTHER|Dexamethasone 8 mg|Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
41379824|NCT02861573|DRUG|Olaparib 300 mg|Two 150-mg tablets PO BID
41507417|NCT04669561|DRUG|Lifitegrast 5% Ophthalmic Solution|Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
41507418|NCT00231543|PROCEDURE|Laparoscopic fundoplication|
41034839|NCT05947344|DRUG|STI-8591|Seven dosing cohorts will be evaluated in the dose escalation phase: 20mg, 40mg,80mg,120mg, 160mg, 200mg, 240mg.Expansion is planned in three dose groups of 120mg, 160mg, and 200mg.
41034840|NCT04679467|DIETARY_SUPPLEMENT|PKU sphere|"TYR sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP); Docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
41034841|NCT00342316|PROCEDURE|Reduced Intensity Conditioning Stem Cell Transplantation|"One of the following conditioning regimens:~1. Busulphan (orally or IV), fludarabine~2. Fludarabine, carmustine, melfalan~3. Cyclophosphamide, fludarabine"
41034842|NCT00089440|DRUG|Aripiprazole|
41034843|NCT01076569|OTHER|laboratory biomarker analysis|Correlative studies
41164944|NCT00984698|BEHAVIORAL|Present Centered Group Therapy|12 weeks, 2h relatively unstructured group therapy
41379825|NCT02861573|DRUG|Abiraterone acetate 1000 mg|Two 500-mg or four 250-mg tablets PO QD
41379826|NCT02861573|DRUG|Lenvatinib|20 mg PO QD
41379827|NCT02861573|BIOLOGICAL|Pembrolizumab/Vibostolimab coformulation|IV Q3W
41379828|NCT02861573|DRUG|Carboplatin|IV Q3W
41379829|NCT02861573|DRUG|Etoposide|IV on Days 1, 2 and 3 of each cycle
41379830|NCT02861573|BIOLOGICAL|Belzutifan 120mg|PO QD
41379831|NCT06384170|DEVICE|Spinal Cord Stimulation- Closed loop|This is a percutaneously placed epidural electrode that is connected to a battery-powered impulse generator for power. The electrical delivery is monitored in real-time with the measurement of evoked compound action potentials and adjusted to provide titration of therapeutic stimulation delivery.
41379832|NCT01356290|DRUG|Bevacizumab|10mg/kg, intravenous (iv), biweekly, 1 year
41379833|NCT01356290|DRUG|Thalidomide|3mg/kg, oral, daily, 1 year
41379834|NCT01356290|DRUG|Celecoxib|50-400mg, oral bid, daily, 1 year
41379835|NCT01356290|DRUG|Fenofibric acid|90mg/m2, oral, daily, 1 year
41507419|NCT00231543|PROCEDURE|open Nissen fundoplication|
41379836|NCT01356290|DRUG|Etoposide|35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
41379837|NCT01356290|DRUG|Cyclophosphamide|2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
41379838|NCT01356290|DRUG|Etoposide phosphate|0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
41379839|NCT01356290|DRUG|Cytarabine|16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
41379840|NCT06653738|DRUG|Empagliflozin 25 MG|Once daily per os for 3 years
41379841|NCT06653738|DRUG|Placebo|Once daily per os for 3 years
41379842|NCT06653738|BEHAVIORAL|Personalized dietary counseling|Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years
41379843|NCT06653738|BEHAVIORAL|Generic dietary counseling|Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
41034844|NCT03165526|DEVICE|AMPLATZER™ Post-infarct Muscular VSD Occluder|The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.
41379844|NCT02152631|DRUG|Abemaciclib|Administered orally
41507420|NCT01690702|DRUG|Epirubicin|
41507421|NCT01690702|DRUG|nab-Paclitaxel|
41034845|NCT05014594|DRUG|Dapagliflozin (10Mg Tab) along with standard medical therapy|Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
41034846|NCT05014594|DRUG|Placebo of dapaglifozin along with standard medical therapy|Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
41034847|NCT05690841|DRUG|Focal Mass Drug Administration (fMDA)|"Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by 9-11 month intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for \>= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for \<16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for \>= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for \<16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, PQ age-based dosing)."
41034848|NCT01752491|DRUG|Ascorbate|Intravenous infusion of high-dose ascorbate
41034849|NCT01752491|DRUG|Temozolomide|Oral chemotherapeutic
41034850|NCT01752491|RADIATION|Radiation therapy|External beam radiation therapy
41034851|NCT06383975|PROCEDURE|Pulsed field ablation with posterior wall isolation|Extended pulmonary vein isolation including posterior wall isolation using pulsed field ablation
41165798|NCT01228721|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
41165799|NCT02999932|OTHER|SpO2 directed oxygen therapy|Oxygen therapy was administered to achieve targeted SpO2.
41379845|NCT02152631|DRUG|Erlotinib|Administered orally
41379846|NCT06653192|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
41379847|NCT06653192|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~Size: 10x40mm or 10x60mm or 10x80mm."
41379848|NCT06653192|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm. DPPS size: 7Fr x 3-7cm."
41379849|NCT05795361|DRUG|Idursulfase-IT|Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 \[NCT01506141\] or SHP609-302 \[NCT02412787\] study \[10mg or 30mg\] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.
41379850|NCT03170271|DRUG|Benralizumab (Medi-563)|30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
41379851|NCT03170271|DRUG|Placebo|Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
41379852|NCT06649864|DRUG|Autologous adipose derived mesenchymal stromal cells (AMSC)|Adipose derived autologous mesenchymal stromal cells; \[\~500,000 cells/cm2\] will be applied once to the biliary anastomosis using approximately 3-5 million cells in 5ml Lactated Ringer solution.
41507422|NCT01690702|DRUG|Cyclophosphamide|
41507423|NCT01690702|DRUG|Docetaxel|
41507424|NCT01786889|BIOLOGICAL|blood and urine|Blood collection and urine collection after consent of the patient
41507425|NCT01786889|BEHAVIORAL|Questionnaire|The patient complete the questionnaire alone at home
41507426|NCT01786889|BEHAVIORAL|Telephone interview|The patient will be contacted by the CRA for a telephone interview of around one hour
41507427|NCT06116630|DIAGNOSTIC_TEST|DCE-MRI|Both groups will undergo DCE-MRIs.
41507428|NCT00240565|DRUG|Tositumomab 450 mg|Unlabeled TST
41507429|NCT00240565|DRUG|Tositumomab 35 mg|TST labeled with 185 megaBecqueral (mbq) of iodine 131
41507430|NCT04015908|DRUG|Celecoxib|Celecoxib 100mg
41507431|NCT04015908|DRUG|Acetaminophen|Acetaminophen 325mg
41507432|NCT04015908|DRUG|Pregabalin|Pregabalin 50 mg
41507433|NCT04015908|DRUG|Oxycodone|oxycodone 5-10 mg
41507434|NCT04015908|DRUG|Percocet|Percocet (oxycodone 5mg/acetaminophen 325 mg)
41507435|NCT06296485|BEHAVIORAL|SAGE Group Sessions|Participants enroll in 3 educational group sessions and receive CGMs
41379853|NCT04736199|DRUG|Darolutamide (Nubeqa, BAY1841788)|Coated tablet, oral administration
41379854|NCT04736199|DRUG|Placebo|Coated tablet matching Darolutamide in appearance, oral administration
41379855|NCT04736199|OTHER|Androgen deprivation therapy (ADT)|Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
41379856|NCT05753085|DEVICE|Conavi Medical Novasight Hybrid System intervention|Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care
41379857|NCT06579105|DRUG|Placebo (placebo matching AZD5004 film-coated tablet)|Placebo film-coated tablet (matching AZD5004)
41379858|NCT06579105|DRUG|AZD5004|AZD5004 film-coated tablet, once daily during 26 weeks
41379859|NCT06579105|DRUG|Semaglutide|3-14 mg tablets of Semaglutide
41379860|NCT03797378|OTHER|eM2M|The eM2M intervention involves three 60-minute sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. The intervention uses combinations of movement patterns that target range of motion, muscle strength, cardiorespiratory fitness, balance, and breathing. Each session consists of movement routines choreographed to music, and every routine can be adapted to participants' functional ability.
41379861|NCT06640387|DIAGNOSTIC_TEST|Daily Influenza, RSV or SARS-CoV-2 PCR testing for 10 days|Each participant will undergo daily PCR testing for Influenza, RSV or SARS-CoV-2 to assess viral dynamics
41379862|NCT05072977|PROCEDURE|TransPRK|A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.
41379863|NCT05072977|PROCEDURE|Alcohol PRK|A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.
41379864|NCT06651372|BIOLOGICAL|The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons|Serological tests detecting IgM and IgG
41379865|NCT03233711|PROCEDURE|Biopsy|Undergo biopsy
41379866|NCT03233711|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41379867|NCT03233711|PROCEDURE|Colonoscopy|Undergo colonoscopy
41379868|NCT03233711|PROCEDURE|Computed Tomography|Undergo CT scan
41379869|NCT03233711|PROCEDURE|Digital Rectal Examination|Undergo digital rectal examination
41379870|NCT03233711|PROCEDURE|High Resolution Anoscopy|Undergo anoscopy
41379871|NCT03233711|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41379872|NCT03233711|BIOLOGICAL|Nivolumab|Given IV
41379873|NCT03233711|OTHER|Patient Observation|Undergo observation
41165800|NCT01800539|BEHAVIORAL|Provider Education Model (PEM)|Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
41379874|NCT03233711|PROCEDURE|Proctoscopy|Undergo proctoscopy
41379875|NCT03233711|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
41379876|NCT03233711|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
41379877|NCT06651125|OTHER|Adapted Physical Activity|Patients in the Adapted Physical Activity arm realized a 12-weeks supervised exercise program. The supervised PA intervention consisted of two sessions per week. Each session lasted one hour and was divided into 30 minutes of aerobic exercise using an ergometer (treadmill and/or bicycle), followed by 30 minutes of resistance exercises involving major muscle groups, with or without small equipment such as dumbbells, resistance bands, and balls. The exercise regimen was carried out at an intensity ranging from 50% to 70% of the heart rate reserve, with a rate of perceived exertion (RPE) set at 4 on a Borg scale of 0 to 10. A total of 24 sessions were planned. There was also the option to incorporate a 45-minute session of moderate-intensity water aerobics into the weekly routine.
41379878|NCT05348785|DRUG|BIIB122|Administered as specified in the treatment arm
41379879|NCT05348785|DRUG|BIIB122-Matching Placebo|Administered as specified in the treatment arm
41379880|NCT05744219|DRUG|Ferric carboxymaltose|Active drug
41379881|NCT05744219|DRUG|Placebo|Placebo
41379882|NCT02806700|BEHAVIORAL|Twitter Diabetes Intervention|This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
41379883|NCT05735717|DRUG|Fludarabine|Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
41379884|NCT05735717|DRUG|Busulfan|Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5
41379885|NCT05735717|DRUG|Melphalan|Melphalan 50 mg/m2 IV on days -4 to -2
41164945|NCT04857775|BEHAVIORAL|Attachment and Child Health (ATTACH) Parenting Program|ATTACH™ provides parent training to address Reflective Function (RF) of parents affected by a broad array of toxic stressors. RF, defined as the ability to have insight into one's own and one's child's mental states, feelings, thoughts and intentions, underpins parental sensitivity and responsiveness and is undermined by the experience of current or past stress. Parents require high RF to respond sensitively/appropriately to their children and thus promote secure parent-child attachments, essential for child MEB health. ATTACH™ consists of 10-12 \~45-minute clinic visits with dyadic (mother and infant) and triadic (mother, infant, and co-parent) elements, with a trained facilitator, who may be a nurse, social worker or other allied health professional.
41164946|NCT01540903|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
41164947|NCT01540903|BIOLOGICAL|Saline|Saline
41164948|NCT05362760|DRUG|Abemaciclib + Aromatase Inhibitor|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
41164949|NCT05362760|DRUG|Abemaciclib + Fulvestrant|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
41164950|NCT00000636|DRUG|Isoniazid|
41164951|NCT00000636|DRUG|Pyrazinamide|
41164952|NCT00000636|DRUG|Pyridoxine hydrochloride|
41164953|NCT00000636|DRUG|Rifampin|
41164954|NCT05684965|DRUG|XTX301|XTX301 monotherapy
41164955|NCT01759238|DRUG|Capecitabine|825mg/m2 per os bid
41379886|NCT05735717|DRUG|Rituximab|200 mg/m2 intravenous given once on day-1
41379887|NCT05735717|DRUG|Levetiracetam|As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
41379888|NCT05886049|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41379889|NCT05886049|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
41379890|NCT05886049|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
41379891|NCT05886049|DRUG|Cytarabine|Given IV
41379892|NCT05886049|DRUG|Daunorubicin|Given IV
41379893|NCT05886049|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41164956|NCT01759238|DRUG|Bevacizumab|7.5 mg/kg
41164957|NCT01759238|RADIATION|Radiotherapy|(conventional or intensity-modulated and image-guided radiotherapy)
41379894|NCT05886049|DRUG|Revumenib|Given PO
41379895|NCT05886049|PROCEDURE|Transthoracic Echocardiography|Undergo transthoracic ECHO
41164958|NCT00325546|DRUG|Rimonabant (SR141716)|
41164959|NCT00325546|DRUG|Placebo|
41164960|NCT00037661|DRUG|INS365 Ophthalmic Solution|
41164961|NCT06544421|OTHER|Assigned Interventions|Assigned Interventions
41164962|NCT00245440|DRUG|Azithromycin|250 mg tablets; 2 tablets once daily (500 mg) for 3 days
41164963|NCT00245440|DRUG|Telithromycin|400 mg tablets; 2 tablets once daily (800 mg) for 5 days
41164964|NCT04737005|PROCEDURE|Nano-ceramic hybrid (Grandio Blocs) Endo-crown|Nano-ceramic hybrid
41164965|NCT04469452|DEVICE|Apollo Device|Comparisons will be made between the Apollo EE Device (Sable Systems International, Las Vegas, NV) and the TrueOne 2400 metabolic cart (Parvo Medics, Salt Lake City, UT)
41164966|NCT04016350|BEHAVIORAL|Exercise training with Inulin Propionate Ester|Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.
41164967|NCT04016350|BEHAVIORAL|Exercise training with placebo|Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
41164968|NCT02017132|DIETARY_SUPPLEMENT|Pomegranate extract|
41164969|NCT04675905|OTHER|no intervention (cohort study)|Explanatory variables include preoperative comorbidities, baseline disability, surgical risk, postoperative complications, sex, rural/urban area of residency, Oslo Social Support Scale; Clinical Frailty Scale in patients aged \>= 65 years
41164970|NCT04343859|DRUG|IMMH-010|After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
41164971|NCT02287740|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
41164972|NCT02287740|BEHAVIORAL|Multimodal Exercise|The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
41164973|NCT02287740|BEHAVIORAL|Stretching|The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
41164974|NCT06368856|DRUG|Mupirocin (50 mg)|50 mg de mupirocin
41164975|NCT06368856|DRUG|Mupirocin (500 mg)|500 mg de mupirocin
41164976|NCT06368856|BIOLOGICAL|blood samples after Single dose part|3 blood samples will be performed sampling time ater application of mupirocin (single dose part): 00h30, 1h00, 02h00
41164977|NCT06368856|DIAGNOSTIC_TEST|nasal swab after Single dose part|7 nasal swab for the detection of S. aureus (type Swab) will be performed after application of mupirocin (single dose part): 00h00, 1h00, 02h00, 04h00, 06h00, 08h00, 12h00
41164978|NCT06368856|OTHER|Collection of urine after Single dose part|Collection of urine during 12 hours after the application of mupirocin (Single dose part)
41379896|NCT01503086|PROCEDURE|Cognitive Assessment|Ancillary studies
41379897|NCT01503086|OTHER|Computer-Assisted Cognitive Training|Receive computer-assisted cognitive training
41379898|NCT01503086|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
41379899|NCT01503086|OTHER|Quality-of-Life Assessment|Ancillary studies
41379900|NCT01503086|OTHER|Questionnaire Administration|Ancillary studies
41379901|NCT04780776|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention
41379902|NCT04780776|DEVICE|Sham comparator|5+16 weeks of visible light exposure
41507436|NCT06296485|OTHER|Usual Care|Participants continue to receive usual care (Control Arm)
41379903|NCT06652321|PROCEDURE|Endothelial Side Up Femtosecond Laser Assisted DSAEK|"The Femto LDV Z8 laser system will be set to create a 100 μm thick graft with a 7.5 mm diameter.~The graft will be inverted, placed endothelial side up in the anterior chamber, and coated with Viscoat. A fixation ring will center the graft by holding the scleral rim with forceps.~After cutting, the cornea should remain endothelium-up, stained with Trypan Blue, and dissected using a blunt spatula. The graft will be placed on a Busin glide and coated with Viscoat.~A 3-4 mm corneal incision will be made, and Descemet's membrane will be marked and stripped. The graft will be inserted using the Busin glide, spreading automatically. A small air bubble will fill the anterior chamber to compress the graft for 10 minutes."
41379904|NCT06652204|OTHER|questionnaire|Caregivers must reply to the French version of the QASCI questionnaire, the ZBI (Zarit Burden Interview) questionnaire, HADS (Hospital Anxiety and Depression Scale), and WHOQOL-Bref (World Health Organization Quality of Life Instrument - Short Form). After 15 days, they wil reply to the French version of the QASCI questionnaire (to asse the reliability).
41379905|NCT06045689|DRUG|Luspatercept|Specified dose on specified days.
41379906|NCT02666768|DRUG|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
41379907|NCT02127788|DRUG|Micafungin|intravenous
41379908|NCT01569594|DEVICE|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
41379909|NCT06025292|OTHER|Lean Pork vs Plant-Based Protein|Participants will eat prepared study meals for three days that have either protein sourced from lean pork or plant-based sources.
41379910|NCT00506558|PROCEDURE|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
41034852|NCT06383975|PROCEDURE|Radiofrequency ablation and vein of Marshall ethanolization|Radiofrequency pulmonary vein re-isolation (when necessary), vein of Marshall ethanol infusion with roof and mitral lines
41379911|NCT00506558|PROCEDURE|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
41379912|NCT05103410|DRUG|ARIPiprazole 30 MG|Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
41379913|NCT05103410|DRUG|Placebo|Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery
41379914|NCT05429112|DEVICE|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
41379915|NCT05429112|DEVICE|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
41379916|NCT06651892|DRUG|Enema Phosphates Sodium|oral diluted phosphate enema containing as a repletion strategy to replace phosphate in critically ill patients with acute hypophosphatemia.
41379917|NCT06651892|DRUG|Glycophos Injectable Product|intravenous sodium glycerophosphate as the standard of care or active control
41379918|NCT06653842|DRUG|QTORIN 3.9% rapamycin anhydrous gel|QTORIN 3.9% Rapamycin Anhydrous Gel
41379919|NCT06652789|BEHAVIORAL|Sleep hygiene|"The intervention will be conducted over 6 weeks, and consist of engaging patients (and caregivers) in two 60-minute face to face sessions 3 weeks apart, and twice weekly telephonic follow ups lasting for 20 minutes each during the 6-week period.~The 2 Direct face to face sessions in local language will focus on health education about sleep. (After taking consent)~1. st session (60 mins) Information will be given about lifestyles that can affect sleep positively or negatively- adequate sleep time required for health, healthy and unhealthy sleep habits~2. nd session Participants will be asked to indicate how many of the sleep hygiene techniques they were able to successfully implement since the previous session Successes and barriers will be discussed. provide solutions for standard difficulties faced Twice a week telephone calls. The participants will be followed up through telephonic conversation twice weekly with a gap of three to four days in between each call."
41379920|NCT05163548|DEVICE|PerQseal Plus Device|Percutaneous closure of femoral artery access site created by 14 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing Percutaneous Transcatheter procedures.
41379921|NCT04352621|DRUG|intranasal ketamine|Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
41507437|NCT01117493|BEHAVIORAL|Expert Patient Programme|Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
41034853|NCT01429259|DRUG|meropenem|meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
41034854|NCT00223860|DRUG|Human chorionic gonadotropin (hCG)|
41034855|NCT00223860|DRUG|Luteinizing hormone releasing hormone (LHRH)|
41034856|NCT03882684|DIAGNOSTIC_TEST|In-situ imprinting detection|The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.
41034857|NCT06284876|DRUG|Ilaprazole|Ilaprazole 10 mg
41034858|NCT06284876|DRUG|Lansoprazole|Lansoprazole 15 mg
41034859|NCT06284876|DRUG|Ilaprazole Placebo|Placebo of Ilaprazole 10 mg
41034860|NCT06284876|DRUG|Lansoprazole Placebo|Placebo of Lansoprazole 15 mg
41034861|NCT00062933|PROCEDURE|Laparotomy|
41379922|NCT04352621|DEVICE|rTMS treatment|patients will begin the open label trial of rTMS per the FDA-approved method on day 1 (the day after the Baseline Visit).
41379923|NCT05103683|DRUG|TORL-1-23|antibody drug conjugate (ADC)
41034862|NCT05712291|PROCEDURE|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
41379924|NCT06283485|DEVICE|ultrasound examination|"Phase 1 1: Taking ultrasound images from healthy volunteers (150 volunteers) to produce artificial intelligence - How to take PENG and Suprainguinal Fascia Iliaca Block sonoanatomical images is as follows.~Phase 2: In the second phase of the study, Smart Alfa Teknoloji San. and Tic. Inc. Artificial intelligence technology called Nerveblox, which was developed with the data received in the first stage with the support of the company, will be used. It is the validation and accuracy study of the artificial intelligence technology developed in the first stage. The accuracy study will be conducted on 40 healthy volunteers. 20 men and 20 women will be included in the study."
41379925|NCT05707806|DEVICE|MRI|Enables the use of custom pulse sequence
41379926|NCT00026312|BIOLOGICAL|Aldesleukin|Given IV
41034863|NCT05712291|DEVICE|TSolution One TCAT, and system for planning TPlan|the active robotic surgical system TSolution One TCAT, and system for planning TPlan
41034864|NCT05712291|PROCEDURE|total knee arthroplasty using the standard manual technic|total knee arthroplasty using the standard manual technic
41034865|NCT03992755|DRUG|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
41034866|NCT00607555|DEVICE|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
41034868|NCT01845610|DIETARY_SUPPLEMENT|Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese|Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
41034869|NCT01845610|DIETARY_SUPPLEMENT|Fortified fat-based paste with essential fatty acids|Complementary food supplement fortified with micronutrients and essential fatty acids
41379927|NCT00026312|BIOLOGICAL|Dinutuximab|Given IV
41379928|NCT00026312|DRUG|Isotretinoin|Given PO
41379929|NCT00026312|OTHER|Laboratory Biomarker Analysis|Correlative studies
41379930|NCT00026312|OTHER|Pharmacological Study|Correlative studies
41507438|NCT01117493|BEHAVIORAL|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
41034870|NCT04545268|DEVICE|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of heating and hitch. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation will start from the second day after the admission to preoperative department and will carried out during the entire preoperative period (about 10 days)."
41034871|NCT04545268|DEVICE|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same site, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
41034872|NCT00107419|DRUG|pemetrexed disodium|pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression
41034873|NCT04575428|DRUG|Splanchnic nerve block|Percutaneous splanchnic nerve block
41164979|NCT06368856|DIAGNOSTIC_TEST|nasal swab during Repeated dose part|5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
41164980|NCT06368856|OTHER|Collection of urine during Repeated dose part|5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
41164981|NCT06368856|OTHER|nasal swab after Repeated dose part|2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)
41379931|NCT00026312|OTHER|Quality-of-Life Assessment|Ancillary studies
41379932|NCT00026312|BIOLOGICAL|Sargramostim|Given IV or SC
41379933|NCT06147856|DRUG|mRNA-3210|IV infusion
41379934|NCT06226571|DRUG|SNDX-5613|Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
41379935|NCT06226571|DRUG|Chemotherapy Regimen|Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
41379936|NCT06226571|DRUG|HiDAC|Consolidation: Participants will receive HiDAC IV.
41379937|NCT06651554|BEHAVIORAL|Digital Platform Intervention|Key features of the digital platform include mental health self-help tools, a customizable safety plan, links to online counseling services, and gamification elements. Youth will be able to access the digital platform as often as they like during their assigned 3-month intervention period.
41379938|NCT02194959|BEHAVIORAL|Peer PN|Navigation by Peer Patient Navigators
41379939|NCT02194959|BEHAVIORAL|Pro PN|Navigation by Standard Hospital Navigators
41379940|NCT00168766|DRUG|Interferon-beta-1a (Avonex) plus methylprednisolone|oral administration given on 3 consecutive days, monthly as described in protocol.
41379941|NCT05698693|BEHAVIORAL|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor.
41379942|NCT05698693|BEHAVIORAL|Contact Control|This is healthy homes intervention.The program provides education on healthy homes, provide advice on specific healthy homes problems, and recommend actions to be taken by families, landlords, and community members.
41379943|NCT05444114|BEHAVIORAL|Mental Exercise|Participants perform a 10 minute mental exercise that is either mindful breathing or listening to a story
41379944|NCT06652880|DEVICE|Digital technology|The digital app is a customized comprehensive self-management platform designed to provide recovery and parenting support for individuals with substance use disorders.
41379945|NCT06652880|OTHER|Bibliotherapy|Bibliotherapy control group will receive parenting book what to expect the first year.
41379946|NCT04079972|BEHAVIORAL|personalized lifestyle intervention|Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.
41507439|NCT04037709|PROCEDURE|scaling and root planing (SRP) + PDT placebo|Patientes will receive periodontal treatment (scaling and root planing - SRP) with the ultrasound. The SRP will be done in one session. The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application.
41507440|NCT04037709|PROCEDURE|scaling and root planing (SRP) + PDT|patients will receive the same scaling and root planing treatment that placebo group.However the PDT will be done only on one side of mouth using methylene blue 0.005% .The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pockets.
41507441|NCT04325932|DRUG|Urinary Kallikrein|
41034874|NCT05558657|OTHER|Home-based, acupressure combined with nursing education|"The intervention group will focus on 11 acupoints on the abdomen (RN12, RN4, ST25), back (BL20, BL21, BL22, BL23, BL24, BL25), and limbs (LI4, ST36). The participants or their caregivers can perform acupressure 30 minutes after meals and twice a day. Participants can choose between two sets of acupressure: (1) Acupressure of the abdominal and back acupoints in a seated position, or (2) Acupressure of the abdominal and limb acupoints in a supine position. Each session lasts approximately 15 minutes.~Besides, the intervention group will also receive nursing education on the basis of receiving acupressure intervention including (1) dietary guidance: help patients to formulate a reasonable diet plan, (2) cultivate regular defecation habits, (3) understand appropriate defecation environments and postures, and (4) Moderate exercise to increase gastrointestinal motility."
41034875|NCT05558657|OTHER|Home-based, manual light touch of the abdomen combined with nursing education|Control group or their caregivers will apply the manual light touch to the abdomen in any direction or body position at home. In keeping consistent with the intervention group, abdomen touching will also be administered twice daily for approximately 15 minutes each for 10 days. Participants will also receive nursing education.
41034876|NCT05427786|DRUG|Nicorandil|Administer 8cc or more of the prescribed drug according to randomization into the coronary artery before starting balloon therapy. The stent treatment method follows the standard treatment method.
41034877|NCT04635722|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
41034878|NCT06465849|PROCEDURE|Dentin Etching time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 5 seconds in the etch-and-rinse application strategy.
41034879|NCT06465849|DEVICE|Scotchbond Universal Plus; 3M|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Scotchbond Universal Plus; 3M).
41034880|NCT06465849|DEVICE|Gluma Universal Bond; Kulzer|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Gluma Universal Bond; Kulzer).
41034881|NCT06465849|PROCEDURE|Dentin Etching time for 15 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 15 seconds in the etch-and-rinse application strategy.
41034882|NCT00648076|DRUG|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
41034883|NCT00648076|DRUG|Depakote ER® Tablets 500 mg|500mg, single dose fed
41034884|NCT06369350|DRUG|Vitamin B6 25 MG|Vitamin B6 25 mg/day will be given for up to 31 days.
41379947|NCT04079972|BEHAVIORAL|general lifestyle intervention|Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
41379948|NCT04855201|DRUG|Bocidelpar|Oral
41379949|NCT04855201|DRUG|Placebo|Oral
41379950|NCT06641687|OTHER|24% Sucrose|Participants will be given either sugar water (24% sucrose) randomly
41379951|NCT06641687|OTHER|Sterile water|Participants will be given sterile water randomly
41379952|NCT04619004|DRUG|Patritumab Deruxtecan (Fixed dose)|Patritumab deruxtecan will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
41379953|NCT04619004|DRUG|Patritumab Deruxtecan (Up-Titration)|Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.
41379954|NCT06415344|DRUG|GTX-102|Antisense Oligonucleotide
41507442|NCT04102189|DRUG|Semaglutide|Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks
41507443|NCT04102189|OTHER|Placebo|Participants will receive semaglutide placebo s.c. once weekly for a total of 68 weeks
41507444|NCT02336646|DRUG|Allogenic MSC|Hypoxia-cultured human bone marrow derived mesenchymal stem cells
41507445|NCT02336646|DRUG|Normal saline|
41507446|NCT04584762|DEVICE|Automated Variable Pressure Insufflation|Acute migraine treatment
41507447|NCT03486366|OTHER|non interventional trial|other
41507448|NCT02009592|DRUG|Rifaximin|Both arms receive Rifaximin
41507449|NCT01449370|DRUG|TAK-117|oral administration of TAK-117, daily and intermittent schedules.
40851316|NCT01640444|DRUG|FOLFIRI + bevacizumab|"* Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 400 mg/m2 iv bolus, followed by~* 5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
41034885|NCT06369350|DRUG|Vitamin B6 50 MG|Vitamin B6 50 mg/day will be given for up to 31 days.
41034886|NCT06369350|DRUG|Vitamin B6 100 MG|Vitamin B6 100 mg/day will be given for up to 31 days.
41164982|NCT05550714|DRUG|general anesthesia|The patients did not use any preoperative sedative drugs and were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction. After the patients were unconscious, oral endotracheal intubation was performed. Anesthesiologists should continuously monitor PetCO2 and maintain PetCO2 at 30-35 mmHg. During the operation, patients are treated with remifentanil, cisatracurium, and desflurane inhalation at 0.5-1.0 minimum alveolar concentration (MAC). In the MER process, the desflurane concentration is adjusted to maintain 0.5-0.6 MAC. If the desflurane concentration needs to be adjusted to less than 0.5 MAC during MER for various reasons, remedial measures will be implemented.
41379956|NCT04909177|OTHER|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
41379957|NCT03724305|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|Mindfulness-based therapy for insomnia (MBTI) will use mindfulness-based stress reduction techniques to specifically target cognitive-emotional arousal associated with non-refractory insomnia.
41379958|NCT03868917|PROCEDURE|thoracic paravertebral block using pressure measurement technique|The continuous thoracic paravertebral block using ultrasound machine is combined with pressure measurement during needle advancement.
41379959|NCT04130594|BIOLOGICAL|BVRS-GamVac|a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
41379960|NCT04130594|OTHER|placebo|placebo
41379961|NCT00417820|DRUG|BCT194|
41379962|NCT00502749|BEHAVIORAL|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
41379963|NCT00502749|BEHAVIORAL|Questionnaires|Questionnaires taking 15 minutes to complete.
41379964|NCT02181673|DRUG|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
41379965|NCT02181673|DRUG|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
41379966|NCT02057224|PROCEDURE|Renal denervation using Medtronic Symplicity System (mono-electrode)|Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
41379967|NCT03172715|PROCEDURE|Locking plate|Osteosynthesis
41507450|NCT04640415|DEVICE|Active Alarms|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds for more than a set duration. Continuous vital sign data will also be available to clinical staff.
41507451|NCT03524170|DRUG|Bintrafusp Alfa|Given IV
41507452|NCT03524170|RADIATION|Radiation Therapy|Undergo radiation therapy
40851317|NCT01640444|DRUG|FOLFIRI + cetuximab|"* Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~* FOLFIRI:~  * Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~ * Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle)."
40851318|NCT05305963|RADIATION|Mammogram|mammogram
41379968|NCT03172715|PROCEDURE|TKR|Total knee arthroplasty
41379969|NCT04359758|BEHAVIORAL|Proactive Streamlined Genetic Education and Testing|This intervention consists of the proactive delivery of genetic education print materials followed by streamlined and facilitated access to genetic testing.
41379970|NCT04359758|BEHAVIORAL|Usual Care|This intervention consists of a standard genetic referral letter that notified the participant that he qualified for genetic referral, recommends the scheduling of a genetic counseling session and provides a telephone number for scheduling.
41507453|NCT01396915|DIETARY_SUPPLEMENT|Dietary Protein Intake|Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
41507454|NCT00387777|DRUG|Patch with centrally acting analgesic|
40851319|NCT00774982|DRUG|Delayed Release 6 mercaptopurine|oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
41034887|NCT06369350|DRUG|Placebo|Placebo capsule will be given for up to 31 days.
41507455|NCT00387777|DRUG|Transtec(R) PRO (buprenorphine)|
41507456|NCT05012189|DRUG|Oseltamivir|Nursing home residents and staff 18 years and older are allocated to receive oseltamivir for treatment and chemoprophylaxis for influenza.
41507457|NCT05012189|DRUG|Baloxavir|Nursing home residents and staff 18 years and older are allocated to receive baloxavir for treatment and chemoprophylaxis for influenza.
41507458|NCT04141982|DIAGNOSTIC_TEST|T-Cell SelectTM Kit|The T-Cell Select kit is intended for the isolation of mononuclear immune cells from whole blood, using positive selection via a magnetic bead-based cell separation system, for use in the T-SPOT.TB assay.
41379971|NCT03506724|DRUG|Nifedipine|Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.
41379972|NCT03506724|DRUG|Labetalol|Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.
41379973|NCT01836094|DRUG|Methylene Blue (USP grade, 280mg oral)|
41379974|NCT01836094|DRUG|Placebo|oral, one time
40851320|NCT00774982|DRUG|6 Mercaptopurine|Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
41379975|NCT05507671|BIOLOGICAL|BCG (Bacillus Calmette-Guérin) vaccine|Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
41379976|NCT05507671|OTHER|Placebo|Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion
41379977|NCT00138801|DRUG|Ceftriaxone|
41379978|NCT00138801|DRUG|Doxycycline|
40851321|NCT05504005|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
40851322|NCT03662516|DRUG|PF-04965842|Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.
41379979|NCT06651398|BEHAVIORAL|Lenient diet|The interventional goup receives the lenient diet instructions and will eat a light meal until 18h on the day before the colonoscopy. The first dose of Plenvu will be started at 20h. All the other bowel preparation instructions will be the same as in the control group.
41379980|NCT00152386|DRUG|Certolizumab pegol (CDP870)|
40851323|NCT03662516|DRUG|Ethinyl estradiol (EE) and levonorgestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
40851324|NCT02961946|DRUG|Nitroglycerin|Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
40851325|NCT02913950|OTHER|validation of pediatric stool scale|validation of pediatric stool scale
40851326|NCT01646606|PROCEDURE|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
40851327|NCT01646606|PROCEDURE|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
41379981|NCT02122939|DRUG|Escitalopram|
41379982|NCT02505841|OTHER|TAP block with Ropivacaine|Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
41379983|NCT02505841|DRUG|Curare|Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
41507459|NCT06226181|PROCEDURE|Dacryocystorhinostomy and amniotic membrane|Dacryocystorhinostomy surgery with amniotic membrane placement on the osteotomy site.
41507460|NCT06226181|PROCEDURE|Conventional dacryocystorhinostomy|Conventional dacryocystorhinostomy surgery without adding amniotic membrane
41507461|NCT00533312|DRUG|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
41507462|NCT00533312|DRUG|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
41507463|NCT00533312|DRUG|Comparator : niacin / Duraton of Treatment: 4 Weeks|
41034888|NCT06634537|DEVICE|Active Comparator: insoles hard, soft and barefoot|"Primary Outcome Measure:~1. Stabilometry The measurements were conducted University. To assess participants' balance, the anthropometric position of the protocol proposed by the International Society for the Advancement of Cineatropometry (ISAK) was assigned: participants placed their mi Frankfort; the upper limbs remained relaxed throughout the body, with palms facing forward and thumbs separated from the rest of the toes, and were barefoot with feet externally rotated f 30 degrees and with a heel distance of 4cm.~The children were wearing sports costumes to contribute their free movement. For stabilometry data collection will use an inertial measurement instrument called Gyko® It is a state-of-the-art device that allows to measure an objective assessment of acceleration, angular velocity and with an acquisition frequency of 100Hz \[Time Frame: pre intervention, 3 months post intervention, 6 months post intervention\]"
41034889|NCT06295562|DRUG|Atomoxetine 80mg combined with oxybutynin 5mg|Atomoxetine 80mg combined with oxybutynin 5mg
41034890|NCT06295562|DRUG|Venlafaxine 37.5mg|Venlafaxine 37.5mg
41034891|NCT06295562|DRUG|Atomoxetine 80mg combined with trazodone 100mg|Atomoxetine 80mg combined with trazodone 100mg
41034892|NCT06295562|DRUG|Placebo|Placebo tablet
41034893|NCT00550225|DRUG|GSK961081|GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
41034894|NCT00550225|DRUG|GSK961081 matching placebo|GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
41034895|NCT05450432|DRUG|Ketamine|Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.
41034896|NCT05450432|DRUG|Esketamine|After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.
41034897|NCT01735123|DIETARY_SUPPLEMENT|dietary intervention|hydrolyzed vs. nonhydrolyzed infant formula
41034898|NCT03620942|DRUG|Phenylephrine|"Phenylephrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 25mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 25 to 75mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min."
41034899|NCT03620942|DRUG|Ephedrine|"Ephedrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 2mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 2 to 6mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min."
41034900|NCT03620942|DEVICE|ADIVA System|"1. When systolic blood pressure (SBP) is 100-110% of baseline, 25mcg phenylephrine (infusion) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion) is given if heart rate \< 60 beats/min;~2. When SBP is 90-100% of baseline, 25mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min;~3. When SBP is 80-90% of baseline, 50mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 4mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min;~4. When SBP \< 80% of baseline, 75mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 6mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min."
41034901|NCT03620942|DEVICE|DIVA System|"DIVA system works as below:~1. When systolic blood pressure is between 90 to 100% of baseline, 25mcg phenylephrine (bolus) will be given if heart rate ≥ 60 beats/min, whereas 2mg ephedrine (bolus) will be given if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 50mcg phenylephrine (infusion or bolus) will be given if heart rate ≥ 60 beats/min, whereas 4mg ephedrine (infusion or bolus) will be given if heart rate \< 60 beats/min."
41034902|NCT06636045|OTHER|Not applicable- observational study|No intervention. Observational study.
41034903|NCT00868023|DRUG|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
41034904|NCT00868023|DRUG|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
41034905|NCT00868023|DRUG|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
41034906|NCT00868023|DRUG|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
41034907|NCT00868023|DRUG|Placebo|Placebo
41034908|NCT00093301|DRUG|Levosimendan|
41034909|NCT00093301|DRUG|Dobutamine|
41379984|NCT01421524|DRUG|CC-122|CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are \> 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
41034910|NCT06378346|DRUG|Glycyrrhizin|75mg orally daily
41034911|NCT06378346|OTHER|Glycyrrhizin|150mg orally daily
41034912|NCT06378346|OTHER|Observation|Participants will not receive any Glycyrrhizin
41034913|NCT04099823|OTHER|MRI screening form|Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
41034914|NCT04099823|DIAGNOSTIC_TEST|Urine pregnancy test|Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
41507464|NCT05353530|BIOLOGICAL|Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells|Single dose of 8R-70CAR T cells administered IV
41379985|NCT01421524|DRUG|CC-122|One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
41379986|NCT01421524|DRUG|CC-122|Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .
40851328|NCT03779087|DRUG|10d TL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.
40851329|NCT03779087|DRUG|10d AL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
40851330|NCT00889642|DEVICE|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
40851331|NCT00889642|DEVICE|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
40851332|NCT00269854|DRUG|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
40851333|NCT00269854|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
40851334|NCT00269854|DRUG|Infliximab 20 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
41379987|NCT01421524|DRUG|CC-122|Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
41379988|NCT02658578|PROCEDURE|PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
40851335|NCT00269854|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
40851336|NCT06464562|BEHAVIORAL|LiveWell: Adapted Dialectical Behavioral Therapy Skills Training|An adapted dialectical behavioral therapy skills training intervention
40851337|NCT02937558|DRUG|Glucagon|Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
40851338|NCT02937558|OTHER|Placebo|Isotonic saline
40851339|NCT05623241|DIAGNOSTIC_TEST|Liquid Biopsy|Venous blood sampling for liquid biopsy in breast cancer patients after segmentation of the lesion on mammography
40851340|NCT00615992|DRUG|Tiotropium|
40851341|NCT02566694|PROCEDURE|Implant|orthopaedic implant
40851342|NCT05862311|DIAGNOSTIC_TEST|ELISA|ELISA(enzyme-linked immunosorbent assay)
40851343|NCT00822536|DRUG|Aspirin and Clopidogrel|Aspirin \<= 325 mg/j Clopidogrel = 75 mg /j
40851344|NCT00822536|DRUG|Aspirin|Aspirin : \<= 325 mg/j
40851345|NCT01954108|DEVICE|hyaluronic acid sodium salt|
40851346|NCT01954108|DEVICE|ESWT|
40851347|NCT00546949|PROCEDURE|Minimal invasive decompression|foraminotomy, laminotomy, microscopic decompression
40851348|NCT00546949|PROCEDURE|Interspinous Process Decompression (IPD)|Interspinous device
40851349|NCT05797597|DRUG|Aspirin 300 Mg Oral Tablet|8-week treatment of aspirin, then after 2-weeks washout the next treatment arm is placebo for 8 weeks
40851350|NCT05797597|DRUG|Placebo|8-week treatment of placebo, then after 2-weeks washout the next treatment arm is aspirin for 8 weeks
40851351|NCT05963997|DRUG|Samuraciclib|Samuraciclib capsules by mouth once a day
40851352|NCT05963997|DRUG|Elacestrant Dihydrochloride|Elacestrant tablets by mouth once a day
40851353|NCT02560012|DRUG|Sunitinib|One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
40851354|NCT02560012|DRUG|Temsirolimus|25 mg by an IV infusion over 30-60 minutes, once a week
40851355|NCT02560012|DRUG|Sorafenib|400 mg (2 tablets) orally twice daily without food
40851356|NCT02560012|DRUG|Pazopanib|800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
40851357|NCT02560012|DRUG|Everolimus|10 mg orally once daily with or without food
40851358|NCT02560012|DRUG|Axitinib|5 mg orally twice daily
40851359|NCT04292314|DRUG|Omega 3|Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
40851360|NCT04292314|DRUG|Nigella Sativa Oil|Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
40851361|NCT04292314|DRUG|Hydroxyurea|hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
40851362|NCT04292314|DRUG|Honey|Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
40851363|NCT04292314|DRUG|Deferoxamine|deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
40851364|NCT04292314|PROCEDURE|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
40851365|NCT05913024|BIOLOGICAL|Enterovirus Type 71 Vaccine|Participants received two doses of the vaccine, 28 days apart
40851366|NCT00030862|DRUG|cisplatin|
40851367|NCT00030862|DRUG|irinotecan hydrochloride|
40851368|NCT01659099|DRUG|GA101|in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)
40851369|NCT01659099|DRUG|Rituximab|in R-ACBVP or in R-CHOP 375 mg/m² on D1
40851370|NCT01659099|DRUG|Doxorubicin|in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
40851371|NCT01659099|DRUG|Cyclophosphamide|in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
40851372|NCT01659099|DRUG|Prednisone|in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
40851373|NCT01659099|DRUG|Bleomycin|in ACBVP 10 mg from D1 to D5
40851374|NCT01659099|DRUG|Vindesin|in ACBVP 2 mg/m² from D1 to D5
40851375|NCT01659099|DRUG|Vincristine|in CHOP 1,4 mg/m² on D1
40851376|NCT06584175|BEHAVIORAL|Internet Delivered Cognitive Behavioural Therapy|The tinnitus ICBT program consists of 1) an overview of tinnitus, depression, and anxiety; 2) managing unhelpful thoughts and learning problem solving strategies association with pain, anxiety, depression, and disability; 3) management of common symptoms associated with tinnitus, anxiety, and depression; 4) developing strategies to maintain activities while minimizing fatigue; and 5) strategies to improve quality of life through effective goal setting. Supplementary lessons can be accessed at any time (e.g., sleep, communication, problem solving, assertiveness training). Materials are presented in a didactic (i.e., text-based and audio with visual images) and case-enhanced learning format (i.e., stories demonstrate the application of skills). Case vignettes that specifically reflect the experiences of those with tinnitus are included.
40851377|NCT05933707|BEHAVIORAL|People with Metabolically Unhealthy Obesity - Low Calorie Diet|Consumption of a low-calorie diet with caloric intake reduced by \~25% to achieve \~10% weight loss in about 4 to 5 months.
40851378|NCT02349685|PROCEDURE|H. pylori culture and antimicrobial susceptibility test|Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute \[amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC \> 1.0 μ g / ml; metronidazole (MET), MIC \> 8 μ g / ml; tetracycline (TC), MIC \> 4 μ g / ml; and moxifloxacin (MOX), MIC \> 1 μ g / ml).
40851379|NCT02349685|DRUG|14 day PBMT group|Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]
40851380|NCT02349685|DRUG|14 day MEA group|Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
41379989|NCT05007652|DRUG|KRN125(pegfilgrastim), PLR001(plerixafor)|7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
41379990|NCT05007652|DRUG|KRN8601(filgrastim), PLR001(plerixafor)|400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
41379991|NCT06593574|PROCEDURE|Robotic laminectomy|Surgical robots are used to assist with laminectomy
41379992|NCT06593574|PROCEDURE|Traditional laminectomy|Instead of relying on a surgical robot, doctors perform the laminectomy themselves with an ultrasonic osteotome
41379993|NCT01895829|PROCEDURE|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
40851381|NCT02451462|DRUG|Zoledronic acid|
40851382|NCT02500446|DRUG|dolutegravir|Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
40851383|NCT02500446|OTHER|Placebo|A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
40851384|NCT05504993|OTHER|Frequency of AECOPD|No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
41164983|NCT05550714|DRUG|Conscious sedation|A loading dose of DEX 0.5 µg/kg was infused intravenously at a constant speed within 15 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.2-0.5 µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. Maintain the BIS value at 60-80.
41164984|NCT06114134|DIETARY_SUPPLEMENT|Fenobet|receiving fenugreek extract (3 capsules of 500 mg, 1 capsule half an hour before meals)
41379994|NCT01895829|DRUG|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
41379995|NCT06652763|OTHER|Minnesota Living with Heart Failure Questionnaire|Self-administered, validated questionnaire to assess symptoms of heart failure
41379996|NCT06652763|DIAGNOSTIC_TEST|Echocardiogram|Resting transthoracic echocardiogram to exclude valvular pathology and the assess indices of systolic and diastolic function and speckle tracking for strain
41379997|NCT06652763|DIAGNOSTIC_TEST|Six-minute walk test|Standardised, objective assessment of exercise capacity
40851385|NCT02609789|DRUG|JNJ-55920839|JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
40851386|NCT02609789|DRUG|Placebo|0.9 percent (%) normal saline.
40851387|NCT01325805|BEHAVIORAL|Structured Weight Loss Program|Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
40851388|NCT01325805|BEHAVIORAL|Routine Weight Loss Counseling|Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
40851389|NCT05942443|PROCEDURE|Pre-treatment|The custom MCP blocking orthosis was made of a 1.6-mm-thick thermoplastic material that extends from the palm over the MCP joint and includes a ring around the proximal phalanx. It is designed to block the MCP joint in flexion of 10°-20° while allowing full range of motion of the proximal and distal interphalangeal joints.
41164985|NCT06114134|DIETARY_SUPPLEMENT|Placebo|Placebo
41507465|NCT00003198|DRUG|ifosfamide|
41379998|NCT06652763|DIAGNOSTIC_TEST|Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy|Using a 3-Tesla scanner, 31P magnetic resonance spectroscopy will be performed to obtain information regarding cardiac energetics. An intravenous infusion of manganese dipyridoxyl diphosphate (mangafodipir, MnDPDP) will be commenced at a rate of 1mL/min using a dose of 5µmol/kg (0.1mL/kg).
41379999|NCT06652763|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance scan|Scan including adenosine stress perfusion
41380000|NCT06652763|DIAGNOSTIC_TEST|Blood tests|Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses
41380001|NCT04583592|DRUG|Camostat Mesilate|Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
41380002|NCT04583592|DRUG|Placebo|Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
41380003|NCT03107780|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
41380004|NCT03107780|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41380005|NCT03107780|DRUG|Navtemadlin|Given PO
41380006|NCT03107780|RADIATION|Radiation Therapy|Undergo radiation therapy
41380007|NCT06578078|DRUG|Sodium Zirconium Cyclosilicate|Use of sodium zirconium cyclosilicate to optimize RAASi therapy, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines
41380008|NCT06578078|DRUG|Standard of care treatment (RAASi therapy)|Standard of care treatment (RAASi therapy) without use of sodium zirconium cyclosilicate
41380009|NCT05925478|PROCEDURE|Ptergyopalatine Fossa Block|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
41380010|NCT05925478|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
41380011|NCT03147209|BEHAVIORAL|Health Coaching|This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
41380012|NCT06652750|OTHER|Routine Management|Conducting routine in-office follow-up for CIED paitents
41380013|NCT06652750|DEVICE|5G Cloud Follow-up|This study employed a 5G-cloud follow-up platform, a research tool that allows a device specialist to test, and program CIEDs in real-time from a remote location via an internet connection or mobile wireless network. Consistent with of the 5G remote support terminal externally connected to the programmer, a PAD was installed with a 5G-cloud follow-up app. The onsite medical staff began the cloud follow-up session by contacting the remote device specialist via video call. The connection to the CIED was made by the medical staff through the use of a standard programmer. He was in charge of turning on the programmer and applying the programmer wand to the patient's device. After an initial introduction, communication was established and continued via the wand connection. The remote device specialist logged into the 5G-cloud follow-up app with two-step verification. The remote device specialist then had complete control of the programmer to check and reprogram the device as needed.
41380014|NCT02353572|DRUG|Melphalan|Given IV
41380015|NCT02353572|DRUG|Bortezomib|Given IV
41507466|NCT00003198|DRUG|topotecan hydrochloride|
40851390|NCT05942443|PROCEDURE|Post-treatment|The RME orthosis was fabricated from 3.2-mm-thick thermoplastic material with the affected finger positioned at an extension of approximately 10°-20° relative to the adjacent fingers.
41380016|NCT02353572|DRUG|Dexamethasone|Given IV
40851391|NCT00151476|DRUG|Celecoxib|800 mg total daily dosing
40851392|NCT00151476|OTHER|Routine Medical Care|
41164986|NCT05643313|DEVICE|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
41380017|NCT02353572|PROCEDURE|Autologous Transplant|Undergo autologous hematopoietic stem cell transplant
41380018|NCT06653634|DRUG|Methotrexate|Gradual withdrawal of the medication
41380019|NCT06653634|DRUG|TNF Inhibitor|Gradual withdrawal of the medication
41380020|NCT01015118|DRUG|Placebo|comparator to BIBF 1120
41380021|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
41507467|NCT01855828|DRUG|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
40851393|NCT06128603|PROCEDURE|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy was performed for periampullary benign and malignant diseases. Besides, the surgical video was recorded.
41380022|NCT01015118|DRUG|BIBF 1120|comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
41380023|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
41380024|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
41380025|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
41507468|NCT01855828|DRUG|Trastuzumab|"For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total)."
41507469|NCT01855828|DRUG|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
41507470|NCT01855828|DRUG|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
41507471|NCT01855828|DRUG|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
41380026|NCT05809999|PROCEDURE|Standard colonoscopy with targeted biopsies|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
40851394|NCT03676907|PROCEDURE|double layer suturation technique|in our clinic uterine incision is sutured by single layer suturation technique routinely. in this arm, we will use double layer suturation technique which is also accepted as valid suturation technique in obstetrics and gynecology textbooks
41380027|NCT06653491|OTHER|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure in a supine position
41380028|NCT06653491|OTHER|simulated ankle technique|simulated ankle technique in a supine position
41380029|NCT05156060|DRUG|Gabapentin|Taken by mouth 3 times per day
41380030|NCT05156060|DRUG|Ketamine|Administered intranasally 3 times per day
41380031|NCT06214780|DEVICE|advanced hybrid closed-loop|"An advanced hybrid closed-loop system is a type of insulin delivery system that uses an algorithm to automatically adjust insulin delivery based on glucose levels. It combines an insulin pump with a continuous glucose monitor (CGM) and uses a closed-loop algorithm to adjust insulin doses based on real-time glucose readings. The hybrid aspect refers to the fact that the system still requires some user input, such as entering meal information, but the algorithm takes over the majority of insulin dosing decisions."
41380032|NCT01281176|DRUG|Carboplatin|Given IV
41380033|NCT01281176|OTHER|Laboratory Biomarker Analysis|Correlative studies
41380034|NCT01281176|DRUG|Paclitaxel|Given IV
41380035|NCT01281176|OTHER|Pharmacological Study|Correlative studies
41380036|NCT01281176|DRUG|Vorinostat|Given PO
41507472|NCT01855828|DRUG|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
41507473|NCT02668588|DRUG|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
41507474|NCT02668588|DRUG|extended release of placebo|1 intramuscular injection of extended release of placebo
41507475|NCT05322122|DEVICE|Side-to-side anastomosis duodeno-ileostomy diversion procedure|Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnetic Anastomosis System (The MAGNET System) to Achieve Duodeno-Ileostomy Diversion.
41507476|NCT02096744|DRUG|Catapres-TTS-1|Catapres-TTS-1 Oppanol
41507477|NCT02096744|DRUG|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
41507478|NCT02096744|DRUG|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
41507479|NCT02096744|DRUG|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
40851395|NCT05400772|OTHER|electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
41380037|NCT01351194|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
41380038|NCT01351194|PROCEDURE|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
41380039|NCT06122779|DRUG|BMS-986435|Specified dose on specified days
41380040|NCT06122779|OTHER|Placebo|Specified dose on specified days
41380041|NCT05045339|PROCEDURE|Ball Exercises|Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed. Exercises were performed with 55 and 65 inch gym ball and a small regular plastic ball.
41380042|NCT05127044|DEVICE|Diffuse Reflectance Spectroscopy|DRS will be used as a non-invasive optical spectroscopy method to collect key biological information from neonatal skin including skin maturity, blood oxygenation, and bilirubin content.
41380043|NCT05127044|DIAGNOSTIC_TEST|BiliChek|BiliChek will be used as a control for determining bilirubin content.
41507480|NCT02096744|DRUG|Catapres-TTS-1|Catapres-TTS-1 Vistanex
41507481|NCT02096744|DRUG|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
41507482|NCT02646605|OTHER|depression screening|Patient Health Questionnaire
41507483|NCT00656552|DRUG|Escitalopram|Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during breakfast (n=50) or placebo (n=50) for four weeks.
41507484|NCT03960463|DEVICE|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
41507485|NCT04604795|DRUG|GSK3915393 Capsules|GSK3915393 capsules will be given orally.
41507486|NCT04604795|DRUG|GSK3915393 Solution for Infusion|GSK3915393 solution for infusion will be administered intravenously.
41507487|NCT04604795|DRUG|Placebo capsules|Placebo matching GSK3915393 capsules will be given orally.
41507488|NCT04604795|DRUG|Itraconazole|Participants will be administered with GSK3915393 along with ITZ orally
41507489|NCT04604795|OTHER|Water|Participants will be administered with GSK3915393 along with water orally
41507490|NCT04604795|OTHER|Grape fruit juice|Participants will be administered with GSK3915393 along with GFJ orally
41507491|NCT01608061|DEVICE|DBS-f on|deep brain stimulation of the fornix
41507492|NCT01608061|DEVICE|DBS-f off|deep brain stimulation of the fornix turned off
41507493|NCT02551484|DEVICE|Measurements using NIRS|
41507494|NCT02551484|DEVICE|TCPO2 measurements|
41507495|NCT02551484|OTHER|2-minute walk test|
41380044|NCT03890159|BEHAVIORAL|Computer Assited Cognitive rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.
41380045|NCT03890159|BEHAVIORAL|Conventional Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests. The total duration of intervention will be 1 month.
41380046|NCT03486873|DRUG|Pembrolizumab|200 or 400 mg IV infusion
41380047|NCT03486873|DRUG|Standard of Care (SOC)|IV infusion or oral tablets
41380048|NCT03486873|DRUG|Lenvatinib|Oral capsules
41380049|NCT06432725|BEHAVIORAL|JUNTOS|HIV test counselor and Latino MSM participants will be given access to the JUNTOS website/app, which shows information about local HIV and ancillary services. HIV test counselor participants will also be given access to a training video explaining how to use the JUNTOS website/app. HIV test counselors are encouraged to use the website/app for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the website/app to locate HIV and ancillary services as needed.
41380050|NCT06432725|BEHAVIORAL|Referral Sheet|HIV test counselor and Latino MSM participants will be given access to referral sheet, which is a list of local HIV and ancillary services. HIV test counselors are encouraged to use the referral sheet for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the referral sheet to locate HIV and ancillary services as needed.
41380051|NCT06220916|BEHAVIORAL|Dance training in Classical Ballet and Contemporary Dance|Classes, Rehearsals, and Performances of classical ballet and contemporary dance.
41380052|NCT02484209|DRUG|Metformin|Metformin 1500 mg daily for 16 weeks
41380053|NCT02484209|DRUG|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
41380054|NCT02484209|DRUG|Metformin|metformin 1500 mg daily for 16 weeks
41380055|NCT03872908|DEVICE|Chilled gloves|Chilled glove for non-dominant hand (patients treated with paclitaxel)
41380056|NCT03872908|DEVICE|Surgical gloves|Surgical gloves (patients treated with oxaliplatine)
41380057|NCT04554225|DRUG|Oxygen gas|Oxygen administered to a patient using ambulatory oxygen
41380058|NCT03788785|BEHAVIORAL|Experimental arm|The specific tobacco cessation intervention will be based on meeting with trained nurses : three 1/2 hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days tops.
41380059|NCT03788785|OTHER|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
41380060|NCT06479148|DEVICE|enVista® Aspire™|Eyes will receive enVista® Aspire™ lenses
41380061|NCT06479148|DEVICE|An IOL with a slightly extended depth of focus|Eyes will receive lenses with a slightly extended depth of focus
41380062|NCT06479148|DEVICE|MX60E|Eyes will receive MX60E lenses
41380063|NCT06652607|DRUG|Enzalutamide|The objective of the study is to assess survival in patients treated with Enzalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
40851396|NCT05284344|DRUG|Anti-Diabetics|The anti-diabetic treatments include insulin glargine, insulin aspart, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, metformin, sulfonylureas and/or gliclazide. Therapeutic dose of each drug follows recommendation by the treating doctor.
40851397|NCT00724633|OTHER|Lowering the dialysate sodium|Please see above
40851398|NCT03273309|OTHER|Vibratory Perineal Stimulus|Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
41380064|NCT06652607|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|The objective of the study is to assess survival in patients treated with Apalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
41380065|NCT06652607|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|The objective of the study is to assess survival in patients treated with Darolutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
41380066|NCT06652607|DRUG|Taxotere (docetaxel)|The objective of the study is to assess survival in patients treated with Taxotere according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
41380067|NCT06652607|DRUG|Abiraterone acetate + Prednisone or Prednisolone|The objective of the study is to assess survival in patients treated with Abiraterone according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
41380068|NCT05744713|OTHER|Observational|Observational
41380069|NCT04839835|OTHER|waiting room enriched with music, paintings and artificial plants|waiting room enriched with music, paintings and artificial plants
41380070|NCT05378269|DRUG|Tamoxifen|Tamoxifen vaginal insert
41380071|NCT05378269|OTHER|Placebo|Placebo vaginal insert
41380072|NCT04045405|DRUG|CDR132L|i.v. administration
41380073|NCT06005974|DRUG|REC-4881|REC-4881 4mg capsules
41380074|NCT06417775|DRUG|Ubrogepant|Oral Tablets
41380075|NCT06417775|DRUG|Placebo for Ubrogepant|Oral Tablets
41380076|NCT05153629|DEVICE|TENS|TENS device used four times a day for 60 minutes each time
41380077|NCT00702975|DRUG|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
41380078|NCT04962958|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
41380079|NCT04962958|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
41380080|NCT04962958|DRUG|Donafenib|administration of Donafenib
41380081|NCT03731117|DRUG|Furosemide|"Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period"
41380082|NCT03952377|DRUG|SX600|Transforaminal Epidural Injection
41380083|NCT03952377|DRUG|Placebo|Transforaminal Epidural Injection
41380084|NCT06450509|BEHAVIORAL|Babble Boot Camp|Caregivers are coached by a pediatric speech-language pathologist to implement activities and routines into their daily home lives with the intent to foster and boost their child's precursor and earliest speech and language skills. The intervention will be conducted entirely via telehealth.
41380085|NCT00278473|BEHAVIORAL|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
41380086|NCT00278473|BEHAVIORAL|Supportive Therapy|Social Support Problem-Solving Group Treatment
41380087|NCT02352116|OTHER|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
41380088|NCT02352116|OTHER|Standard of care management|Current standard of care at a major U.S. teaching hospital.
41380089|NCT01966185|OTHER|Tutor function on|The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
40851399|NCT03273309|OTHER|Transvaginal Electrical Stimulation|The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
40851400|NCT00995423|DEVICE|CoroflexTM Please|highly flexible CoroflexTM Please-Stent
41380090|NCT05117307|DRUG|Bupivacaine 0.25% Injectable Solution|Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side
41380091|NCT02504463|DRUG|Samidorphan IV|Single IV administration
41380092|NCT02504463|DRUG|[14c]-Samidorphan sublingual|Single sublingual administration containing radiolabel
41380093|NCT02504463|DRUG|[14c]-Samidorphan oral|Single oral administration containing radiolabel
41380094|NCT04625907|DRUG|Irinotecan|antineoplastic enzyme inhibitor
41380095|NCT04625907|DRUG|Actinomycin D|Antineoplastic agent that is a polypeptide antibiotic
41380096|NCT04625907|DRUG|Doxorubicin|An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
40851401|NCT00995423|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent
41380097|NCT04625907|DRUG|Ifosfamide|chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide
41380098|NCT04625907|DRUG|Vincristine|anti neoplastic vinca alkaloid agent
41380099|NCT04625907|DRUG|Vinorelbine|vinca alkaloid with a role as an antineoplastic agent
41380100|NCT04625907|DRUG|Cyclophosphamide|Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
41380101|NCT04625907|DRUG|Temozolomide|oral antineoplastic alkylating agent
41380102|NCT04625907|RADIATION|radiotherapy|Ionising radiation
41380103|NCT04625907|DRUG|Regorafenib|Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).
41380104|NCT02973789|DEVICE|NovoTTF-200T|"Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel"
41380105|NCT02973789|DRUG|Immune checkpoint inhibitors or docetaxel|Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
41507496|NCT05354921|DEVICE|Indwelling Catheter|Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (\>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
41380106|NCT06556576|DEVICE|IMPROVA Platform|"Adolescents, teachers, school staff, and parents will have access to a variety of content aimed at promoting the mental health and well-being of adolescents that can be accessed through the IMPROVA platform, an innovative eHealth solution that can be accessed via app and website.~Students: around 20 modules that can be grouped in five categories: Me and My Emotions, Me and My Body, Me and My Relationships, School and Free time, and Finding my Strengths.~Teachers and other school staff: 1) pedagogical and health-related modules to support their students and teaching practices; 2) modules to manage their own health; 3) tutoring sessions: resources (lessons plans) for tutors (teachers or other school staff) for carrying out a discussion with students in topics related to the students' health and wellbeing.~Parents: contents on promoting positive relationships, emotional and social skills, positive behaviour, behaviours to support wellbeing, and family-school collaboration."
41380107|NCT02894541|DRUG|CKD-519 100mg|
41507497|NCT05354921|DEVICE|Intermittent Catheterization|"Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR\>400 mL, an intermittent catheter will be used. If PVR\> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.~It is expected that a small percentage of patients in either group will not have a PVR\>400 mL preoperatively.~These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR\>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR\>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time."
41380108|NCT02894541|DRUG|CKD-519 200mg|
41380109|NCT02894541|DRUG|CKD-519 100mg|
41380110|NCT02894541|DRUG|CKD-519 200mg|
41380111|NCT02771340|BIOLOGICAL|ICON-1|Intravitreal injection of ICON-1
41380112|NCT05053737|DRUG|Atezolizumab|One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.
41380113|NCT05053737|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.
41380114|NCT06096246|PROCEDURE|Pulmonary vein isolation|The catheter ablation (with a CE \[Conformité Européenne\] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
41380115|NCT06096246|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
41507498|NCT04799197|BEHAVIORAL|Kicking it with the Gurlz|The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
41507499|NCT05456230|DRUG|Midazolam|Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
41507500|NCT02928055|DEVICE|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
41507501|NCT04492592|BEHAVIORAL|Workshop|Workshop
41380116|NCT06096246|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
41380117|NCT06096246|PROCEDURE|Femoral sheath insertion|Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
41380118|NCT04515940|DIETARY_SUPPLEMENT|acceptability, tolerance and palatability study|prospective acceptability study
41380119|NCT05871853|BEHAVIORAL|Improved breastfeeding support|Cross-sectoral intervention to improve breastfeeding support among women giving birth at Slagelse Hospital, Region Zealand, Denmark
41380120|NCT06652373|BEHAVIORAL|Behavioural change through education|The content of the perinatal grief counselling training to be used in the study will be created in 8 modules and will be applied to midwives. The planned perinatal grief counselling training for midwives will be carried out online and it is aimed that midwives gain perinatal grief counselling skills and competence and increase their competence to cope with the problems they may encounter in the counselling process.
41380121|NCT06652620|OTHER|Cola|regular Coca-Cola (Coca-Cola company, Atlanta, GA) or Pesi-cola (PepsiCo, Inc.New York, NY)
41380122|NCT02217397|DEVICE|OA, CPAP, combination therapy|
41380123|NCT05516927|DIAGNOSTIC_TEST|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
41380124|NCT01556659|DRUG|Absence of vitamin K antagonist|Dual anti-platelet therapy
41380125|NCT06651203|OTHER|Follow-up|Clinical evaluation Blood sample Skin biopsy
41507502|NCT04492592|BEHAVIORAL|SMS/Texting|SMS/Texting
41507503|NCT03355612|DRUG|Apatinib|Apatinib: 500 mg, qd, po, last 180 days
41380126|NCT06652009|OTHER|Radical nephroureterectomy|Radical nephroureterectomy
41380127|NCT06652009|RADIATION|Radical radiotherapy|Radical radiotherapy with stereotactic body radiation therapy (SBRT) or moderately segmented radiotherapy
41380128|NCT06285591|DIETARY_SUPPLEMENT|Lactobacillus Reuteri Tablets|Lactobacillus Reuteri lozenges (NOW Foods, Sweden) contained no less than 2×10\^8 CFU viable cells of Lactobacillus Reuteri as the active ingredient.
41380129|NCT06285591|DIETARY_SUPPLEMENT|Placebo-containing tablets|Starch preparations that look and taste like Lactobacillus Reuteri
41380130|NCT06285591|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
41380131|NCT06653374|BEHAVIORAL|Infant, Premature|This intervention is distinct as it focuses specifically on observational monitoring and evaluation of neonatal outcomes without applying a therapeutic or procedural treatment. Unlike other interventional studies, the emphasis is on analyzing standard care practices, risk factor exposures (e.g., prematurity, maternal complications), and their impact on neonatal morbidity and mortality. The intervention involves systematic data collection and longitudinal follow-up to identify patterns and associations, rather than introducing new clinical techniques or treatment
41380132|NCT05940571|DRUG|MBF-362|Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
41380133|NCT04936334|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET Scan|Patients will undergo injection of 68Ga-PSMA-11 at the time of their pre treatment PSMA PET scan and followed until 12 months post surgery.
41034915|NCT04099823|DIAGNOSTIC_TEST|MR brain|"You will be asked to lie down on the bed of the MRI scanner. Then a MRI coil/antenna will be placed over your head. This will allow us to get clearer pictures of the tissue of interest. The MRI machine makes loud knocking sounds. Because of this you will be asked to wear earplugs. You will receive a squeeze ball alarm in case you need urgent help. We will be able to talk with you and hear you during the MRI exam. The entire MRI scan will last about 45-60 minutes. The MR exam will include standard clinical images as well as the CSF flow imaging."
41380134|NCT04192747|DEVICE|Percutaneous Coronary Intervention|Percutaneous coronary intervention of de novo native coronary artery lesions
41380135|NCT05970848|DEVICE|Washing Pipe With a Spray Nozzle|Administration of topical airway anesthesia via a washing pipe with a spray nozzle using the spray-as-you-go technique
41380136|NCT04130997|BIOLOGICAL|Ublituximab|Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
41380137|NCT06648915|DIAGNOSTIC_TEST|Lipoprotein(a)|Measurement of Lp(a) was performed at the time of entry to the registry. Lp(a) level was measured using immunenephelometric assay
41380138|NCT06652282|OTHER|Pilates exercises|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
41034916|NCT03960190|DEVICE|Using Eureka Breast Pump with Expression Kit|Each subject will undergo two expression sessions for single and double electric pumping in randomized order to reduce the variation.
41034917|NCT00652665|DRUG|Leflunomide|Tablets, 20mg, single-dose
41034918|NCT00652665|DRUG|ARAVA|Tablets, 20mg,single-dose
41034919|NCT00288587|DRUG|IV loop diuretic|Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
41034920|NCT00288587|DEVICE|NxStage System One|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
41380139|NCT06652282|OTHER|proprioceptive neuromuscular facilitation|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
41380140|NCT06652282|OTHER|The conventional program|Each patient was in the supine position and will receive stretching exercise for the flexors and adductors, and strengthening for the extensors, abductors and scapular stabilizers of the affected shoulder
41380141|NCT03743571|DEVICE|transcranial direct current stimulation|tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
41380142|NCT03743571|BEHAVIORAL|exposure therapy|participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
41380143|NCT03166969|PROCEDURE|Holter 21 days|
41380144|NCT01267227|DRUG|Pterostilbene 50 mg twice daily|Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
41034921|NCT01713218|DRUG|gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
41034922|NCT01713218|DRUG|Vismodegib|150 mg capsule, oral, once daily
41034923|NCT01713218|PROCEDURE|Neoadjuvant chemotherapy|Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
41034924|NCT04336254|BIOLOGICAL|allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19
41034925|NCT04336254|OTHER|Intravenous saline injection (Placebo)|Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19
41164987|NCT00280709|DEVICE|"Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)"|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
41164988|NCT06504212|OTHER||
41164989|NCT00291239|BEHAVIORAL|partial sleep deprivation|
41164990|NCT03665753|DRUG|Ketorolac|Subject will receive 10, 20, and 30mg of Ketorolac.
41380145|NCT01267227|DRUG|Placebo|Matching placebo by mouth twice daily for 6 to 8 weeks
41380146|NCT01267227|DRUG|Grape Extract|Grape extract 100 mg twice daily for 6-8 weeks
41380147|NCT01267227|DRUG|Pterostilbene 125 mg twice daily|Pterostilbene 125 mg twice daily for 6-8 weeks
40851402|NCT01024842|BIOLOGICAL|MVA.HIVconsv low dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10\^8 pfu at week 0, 4 and 12.
41034926|NCT02076009|DRUG|Daratumumab|Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.
41380148|NCT05283109|BIOLOGICAL|Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine|Vaccine that includes 3 peptides (EphA2 linked to P30 peptide, pp65 linked to P30 peptide, and Survivin linked to P30 peptide)
41380149|NCT05283109|DRUG|Hiltonol|Hiltonol® is made up of synthetic (manmade) RNA (ribonucleic acid) and is used as an adjuvant to the vaccine, meaning it is used with the vaccine to stimulate or enhance the activation of your immune system.
41380150|NCT06051617|DRUG|Seladelpar|"* Seladelpar 10 mg one capsule daily for up to 36 months in participants with CP-A cirrhosis or~* Seladelpar 5 mg one capsule daily for up to 36 months in participants with CP-B cirrhosis."
40851403|NCT01024842|OTHER|Placebo low dose|Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
41380151|NCT06051617|DRUG|Placebo|One capsule daily for up to 36 months.
41380152|NCT05584202|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
40851404|NCT01024842|BIOLOGICAL|MVA.HIVconsv high dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10\^8 pfu at week 0, 4 and 12.
40851405|NCT01024842|OTHER|Placebo high dose|Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
41380153|NCT05584202|OTHER|Placebo|0.9% sodium chloride
40851406|NCT02965430|DEVICE|AL-SENSE|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis
40851407|NCT03050320|OTHER|Exercise|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
40851408|NCT03050320|OTHER|No Exercise|A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
40851409|NCT05510674|DIAGNOSTIC_TEST|OWL-EVO1|EVOC probe
40851410|NCT03249987|OTHER|bladder diary|electronic diary to be completed for 3 days before crossover onto paper diary for 3 days
41380154|NCT00660101|BIOLOGICAL|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
40851411|NCT04629690|OTHER|SOLAR|The participants will obtain a multidisciplinary assessment regarding their medical conditions, medication review, cognitive assessment, functional assessment, gait and balance assessment by senior clinicians and a management plan will be implemented.
40851412|NCT06518486|OTHER|Foot-ankle exercise|Foot-ankle exercise group will receive usual care provide by public health center and intervention through health education, leaflets, and videos about foot-ankle exercise. At the first meeting, participants will be taught how to do foot exercises and practice them in front of the instructor. Afterwards, participants will practice foot exercises independently without supervision for 12 weeks. One foot exercise session takes 10-15 minutes, while the physical activity target is for participants to fulfil a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do foot exercises for 2-3 sessions every day. The minimum duration of each session is 10 minutes, and two consecutive days without foot exercise are not allowed. Participants are asked to document all foot exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for a minimum of 5 minutes
40851413|NCT06518486|OTHER|Walking exercise|Participants in the walking exercise group will receive usual care provide by public health center and intervention through health education and leaflets about walking exercise. Participants will practice walking exercises independently without supervision for 12 weeks. Participants walked at the same speed as they did every day. The physical activity target to be achieved is for participants to be able to engage in a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do walking exercises with a minimum duration of 10 minutes for each session. Two consecutive days without walking exercise are not allowed, and a minimum of 150 minutes/week is allowed. Participants are asked to document all walking exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for a minimum of 5 minutes.
40851414|NCT06518486|OTHER|Usual care and health education|Participants in the control group will receive the usual care provided by the community health center and intervention in the form of health education about DM in general.
40851415|NCT06551935|BEHAVIORAL|Habitual sleep habits without intervention|Sleep habits maintenance
41034927|NCT02076009|DRUG|Lenalidomide|Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
41034928|NCT02076009|DRUG|Dexamethasone|Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).
41034929|NCT05432791|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41034930|NCT05432791|PROCEDURE|Bone Scan|Undergo bone scan
41034931|NCT05432791|PROCEDURE|Computed Tomography|Undergo CT scan
41034932|NCT05432791|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41380155|NCT02457780|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
41507504|NCT03355612|DRUG|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
41380156|NCT02457780|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
41380157|NCT00585468|DRUG|Myfortic|Myfortic 720 mg orally twice daily
41380158|NCT03814213|OTHER|CGA|Multi-level Health assessment
41380159|NCT03814213|OTHER|tailored care|Tailored care based on problems identified by CGA
41380160|NCT06566586|DRUG|TQB3702 tablets+Chemotherapy regimen|"TQB3702 tablets: Tyrosine kinase inhibitor；~Chemotherapy regimen：inhibiting tumor cell proliferation, suppressing DNA synthesis, inducing cell apoptosis, enhancing immune system function, and inhibiting angiogenesis；"
41380161|NCT03073642|OTHER|Pain Education|Together with hydrotherapy, patients will receive pain therapeutic education
41380162|NCT03073642|OTHER|Hydrotherapy|Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
41380163|NCT06653348|DRUG|Ticagrelor 60 + Aspirin|Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 3.
41380164|NCT06653348|DRUG|Ticagrelor 90 + aspirin|ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.
41380165|NCT06540833|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
41380166|NCT06540833|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
41380167|NCT06592924|DRUG|Abiraterone|Assigned prior to enrollment
40851416|NCT06551935|BEHAVIORAL|Sleep extension and sleep hygiene|Players will extend their time in bed by 25%, based on their baseline sleep, and adopt sleep hygiene behaviors: relatively fixed sleep schedule; do not lie in bed awake for long periods of time; no caffeine and no alcohol prior to bedtime; avoid heavy meals close to bedtime; sleep environment cool, dark and quiet; low exposure to screen lights before bedtime, only with nightshift mode and low luminosity (avoid high cognitive demanded activities, like gaming); low luminosity near to bedtime; ensure adequate exposure to light in the morning.
40851417|NCT05029739|DEVICE|A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease|See description of the e-intervention group as above.
41380168|NCT06592924|DRUG|Enzalutamide|Assigned prior to enrollment
41380169|NCT06592924|DRUG|Apalutamide|Assigned prior to enrollment
41380170|NCT06592924|DRUG|Darolutamide (BAY 1841788)|Assigned prior to enrollment
41380171|NCT06592924|DRUG|Docetaxel|Assigned at enrollment
41380172|NCT06592924|DRUG|ADT|Physician's choice. Assigned prior to enrollment
41380173|NCT06480786|DEVICE|Spinal cord stimulation|active spinal cord stimulation
41380174|NCT06480786|DEVICE|Sham stimulation|Sham stimulation
41380175|NCT04532827|BEHAVIORAL|Case formulation with web-program|"The first meeting includes an interview to establish understanding on the participant´s symptomatology and current life situation, a case formulation (CF) will be build based on it. The CF is presented in the second session and modifications can be made to ensure acceptability for the participant. Goals for web program (WB) are set based on the CF and understanding of the factors contributing to the participant´s wellbeing.~WB modules are instructed to complete during the week. Modules include psychoeducation, experiential exercises and training aimed at improving wellbeing and psychological flexibility. Web-therapist will offer written feedback. The participants can contact the therapist via the WB and al messages will be replied within one week. Automatic reminders will be sent if a participant has not been active in the WB, the therapists will call participants who have discontinued using the WB."
41380176|NCT00770809|OTHER|Laboratory Biomarker Analysis|Correlative studies
41380177|NCT00770809|DRUG|Lapatinib Ditosylate|Given PO
41380178|NCT00770809|DRUG|Paclitaxel|Given IV
41380179|NCT00770809|BIOLOGICAL|Trastuzumab|Given IV
40851418|NCT01458015|DRUG|tapentadol, oxycodone|tapentadol pr 100-500 mg oxycodone cr 20-120mg
41380180|NCT06468007|DRUG|Methylprednisolone Tablet|Patients receiving equipotent doses of methylprednisolone or prednisolone . Dosages will be determined at the discretion of the treating physician, customized for the specific clinical need in accordance with local guidelines.
41380181|NCT06650033|RADIATION|Adaptive radiotherapy +/- margin reduction|Radiotherapy using adaptive technology to recontour and re-plan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
41380182|NCT06650033|RADIATION|Image guided radiotherapy|Standard radiation treatment used in the department of radiation oncology for cancer in pelvic area
41380183|NCT05993299|DRUG|Letetresgene autoleucel|Letetresgene autoleucel will be administered.
41380184|NCT05993299|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
41380185|NCT05993299|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
41380186|NCT02912559|DRUG|Atezolizumab|Given IV
41380187|NCT02912559|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41380188|NCT02912559|PROCEDURE|Computed Tomography|Undergo CT
41034933|NCT05432791|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41034934|NCT05432791|DRUG|Olaparib|Given PO
41380189|NCT02912559|DRUG|Fluorouracil|Given IV
41380190|NCT02912559|DRUG|Leucovorin Calcium|Given IV
41380191|NCT02912559|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41380192|NCT02912559|DRUG|Oxaliplatin|Given IV
41380193|NCT02912559|OTHER|Quality-of-Life Assessment|Ancillary studies
41380194|NCT03460977|DRUG|Mervometostat (PF-06821497)|Oral continuous
41380195|NCT03460977|DRUG|Enzalutamide|Oral continuous
40851419|NCT05652712|DRUG|Toripalimab|"Toripalimab injection, recommended dose is 3 mg/kg, intravenous infusion every 2 weeks or 240 mg fixed dose, intravenous infusion every 3 weeks.~Other treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients."
40851420|NCT04093440|OTHER|lifestyle modification|nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
40851421|NCT03075709|OTHER|Clinical Pathway (CPW)|CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
40851422|NCT06455501|PROCEDURE|Ventral mesh rectopexy|Ventral mesh rectopexy is performed with a superficial peritoneal incision from the right side of the sacral promontory, extended over the right outer border of the mesorectum, towards the deepest part of pouch of Douglas, sparing the right hypogastric nerve. In women, the vagina is retracted anteriorly and a dissection of the rectovaginal septum is performed down to the pelvic floor. A strip of mesh is attached to the ventral part of distal rectum and then fixed upon the sacral promontory.
40851423|NCT04922307|PROCEDURE|Blood Sparing Protocol|Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass
40851424|NCT04922307|PROCEDURE|Standard Blood Replacement|Allogenic blood transfusion as determined intra-operatively
40851425|NCT04079075|OTHER|Cognitive training|"This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will."
40851426|NCT04079075|BEHAVIORAL|Physical activity|This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.
40851427|NCT04079075|BEHAVIORAL|Nutrition education|"This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared."
40851428|NCT04079075|BEHAVIORAL|Adaption to memory loss|This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.
40851429|NCT04079075|DIAGNOSTIC_TEST|Diagnosis of hearing impairment|Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
40851430|NCT04718493|PROCEDURE|Self-expandable metal stent|Endoscopic stenting of intestinal stricture related to Crohn´s disease
40851431|NCT04718493|PROCEDURE|Balloon dilatation|Endoscopic balloon dilatation of intestinal stricture related to Crohn´s disease
40851432|NCT03350906|DRUG|n3-PUFA|The DHA/EPA softgels will each contain \~465mg of EPA and \~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (\~381 mg) and poloxamer 237, NF (\~8.8 mg).
41034935|NCT05432791|DRUG|Pazopanib|Given PO
41034936|NCT05432791|DRUG|Temozolomide|Given PO
41034937|NCT05432791|DRUG|Trabectedin|Given IV
41034938|NCT05432791|PROCEDURE|Transthoracic Echocardiography|Undergo TTE
41034939|NCT00000974|DRUG|Pentamidine isethionate|
41380196|NCT02257736|DRUG|Apalutamide|Participants will receive 240 mg (4\*60 mg tablets) of apalutamide once daily orally.
41380197|NCT02257736|DRUG|Abiraterone acetate|Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.
41380198|NCT02257736|DRUG|Prednisone|Participants will receive 5 mg tablet of prednisone twice daily orally.
41380199|NCT02257736|DRUG|Placebo|Participants will receive matching placebo to apalutamide once daily orally.
41380200|NCT04888377|DRUG|Aspirin|Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.
41034940|NCT01495065|DRUG|GSK2251052 750 mg|Treatment A: 750 mg IV GSK2251052 single dose
41380201|NCT04888377|DRUG|Placebo|Participant's mothers were administered placebo throughout their pregnancy with the participant.
41380202|NCT00835133|OTHER|biologic sample preservation procedure|one blood sample
41380203|NCT00835133|OTHER|medical chart review|confirmation of cancer diagnosis
41380204|NCT00835133|OTHER|survey administration|at baseline enrollment and 12 months post-enrollment
41507505|NCT04009707|OTHER|MoCA (Montreal Cognitive Assessment) test|the MoCA questionnaire is used to assess cognitive disorders
41507506|NCT04009707|OTHER|BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test|This questionnaire is used to assess cognitive disorders
41507507|NCT02521272|OTHER|Breathing in the simulated avalanche snow.|Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
41507508|NCT02521272|DEVICE|air pocket|Zero air pocket or one-liter air pocket in the snow.
41034941|NCT01495065|DRUG|GSK2251052 1500 mg|Treatment B: 1500 mg IV GSK2251052 single dose
41034942|NCT01495065|DRUG|GSK2251052 1500 mg BID|Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
41034943|NCT01495065|DRUG|GSK2251052 2250 mg|Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
41034944|NCT01495065|DRUG|GSK2251052 3000 mg|Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
41034945|NCT01495065|DRUG|GSK2251052 0.9% saline|Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
41034946|NCT02142049|DRUG|Ibrutinib|Ibrutinib
41034947|NCT02142049|DRUG|DA-EPOCH-R|Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
40851433|NCT03350906|DRUG|Placebo|Looks exactly like the study drug but contains soybean oil with no active ingredient.
40851434|NCT03350906|PROCEDURE|Biopsy|Two muscle biopsies from the upper part of one leg. A small (\~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.
40851435|NCT03350906|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
40851436|NCT05583084|OTHER|Investigation|
40851437|NCT02337881|DRUG|nifedipen|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
40851438|NCT02337881|DRUG|Sildenafil|sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
40851439|NCT04949074|OTHER|saliva sampling|when the patient goes to the laboratory for a covid 19 diagnostic from a routine nasopharingeal sample, an additionnal sample of saliva is asked
41164991|NCT05974683|DRUG|placebo|Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
41164992|NCT05974683|DRUG|mycophenolate mofetil|Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
41164993|NCT04119440|BIOLOGICAL|MVA-MERS-S_DF1 - Low Dose|Administrations of the low dose via the intramuscular route
41164994|NCT04119440|BIOLOGICAL|MVA-MERS-S_DF1 - High Dose|Administrations of the high dose via the intramuscular route
41164995|NCT04119440|OTHER|Placebo|Administrations of placebo via the intramuscular route
40851440|NCT04474821|OTHER|Educational Intervention|Receive educational materials on HPV
40851441|NCT04474821|OTHER|Survey Administration|Ancillary studies
40851442|NCT04028141|DRUG|Procedural sedation with ketofol in a 1 on 4 ratio|"The participant was brought to a zone where advanced life support could be optimally administered and where all necessary drugs and materials for treatment of complications are present. Oxygen saturation, continuous electrocardiogram, intermittent blood pressure measurement (every 2 minutes) and capnography were applied. A 20 gauge intravenous line was inserted. The participant was placed in semi-recumbent position and was given oxygen for at least 3 minutes through a non-rebreather mask unless contra-indications applied.~Ketofol 1 on 4 was prepared by mixing 1ml of ketamine (50mg) and 20ml of propofol (200mg) in a single syringe. It was administrated as a loading dose of 1ml/10kg, corresponding to 0,952mg/kg propofol and 0,238mg/kg ketamine, and followed by titration in aliquots of 0,5ml/10kg every 1 to 2 minutes until desired depth of sedation was achieved, and then every 3-5 minutes to retain the desired depth of sedation. The loading dose was halved if above 65 years."
40851443|NCT04025229|BEHAVIORAL|HIIT exercise|High intensity interval training (4 to 6 sessions) prior to surgery
40851444|NCT04751188|DRUG|Bezafibrate 200 MG Oral Tablet|Bezafibrate one tablet every 12 hours for six months.
40851445|NCT04751188|DRUG|Placebo|Placebo one tablet every 12 hours for six months.
40851446|NCT04751188|DRUG|Ursodeoxycholic Acid|At a dose of 13 to 15 mg per Kg per day.
40851447|NCT04649177|DEVICE|Ocular surface optical coherence tomography|EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices
40851448|NCT05152576|DRUG|OnabotulinumtoxinA X|Intramuscular Injection
40851449|NCT05152576|DRUG|Placebo|Intramuscular Injection
40851450|NCT02846441|PROCEDURE|hepatobiliary scintigraphy|99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)
41164996|NCT06319547|PROCEDURE|Thoracocentasis|patients will be submitted to diagnostic pleural fluid study, chest x-ray, liver function and blood picture
41164997|NCT01476124|DRUG|morphine Placebo|Morphine Placebo
41164998|NCT01476124|DRUG|GEn 600 mg|Gabapentin enacarbil 600 mg
41164999|NCT01476124|DRUG|Morphine|morphine extended release 60 mg
41165000|NCT01476124|DRUG|GEn Placebo|Gabapentin enacarbil placebo
41165001|NCT06383429|OTHER|forward head posture by using mobile application. And patients will fill out headache disability index.|forward head posture by using mobile application. And patients will fill out headache disability index.
41165002|NCT02873325|OTHER|antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV
41380205|NCT04991116|DRUG|TILD sub-cutaneous (SC) injection|1 mL injection of study medication
41380206|NCT06649981|DIETARY_SUPPLEMENT|FMT capsule|"A lyophilized gut microbiota capsule derived from a rigorously screened, healthy, and physically active donor, free of gastrointestinal diseases, antibiotic use, and chronic conditions. The donor\&#39;s diverse microbiome is supported by a nutrient-rich diet and active lifestyle. The lyophilization process preserves microbial integrity, offering a high-potency dose aimed at restoring and optimizing the gut microbiome of older adults.~This intervention is specifically designed for older adults to enhance resilience to stress, cognitive function, muscular strength, and metabolic health. It is part of a controlled clinical study with follow-up assessments at weeks 1, 4, 8, and 20 post-intervention. This targeted approach distinguishes it from other microbiome-based therapies by focusing on comprehensive health benefits for an aging population."
41507509|NCT06064305|OTHER|No study-specific interventions|Septic AKI patients, post-cardiothoracic AKI patients and non-AKI patients undergoing routine nephrectomy. Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians and the respective specialists.
41165003|NCT06468267|DRUG|Thiotepa|The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).
41165801|NCT00241969|BEHAVIORAL|Behavioral and Nutrition Treatment|This intervention will combine individualized nutrition counseling that targets increasing energy and fat intake and parent training of effective behavioral child management skills. The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
41165802|NCT00241969|BEHAVIORAL|Education and Attention Control|This intervention will provide information about a number of aspects of their child's CF care and also provides anticipatory guidance for preschoolers.The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
41165803|NCT03311269|DEVICE|ClariVein RES|ClariVein system
41380207|NCT06649981|DIETARY_SUPPLEMENT|Placebo Capsule(s)|"A placebo capsule will be used in this study to serve as a control, allowing us to objectively assess the true effects of the lyophilized gut microbiota intervention. The use of a placebo is essential to eliminate bias and ensure that any observed outcomes can be confidently attributed to the actual intervention rather than to psychological or other non-specific effects.~The placebo capsule will be identical in appearance, size, shape, and color to the interventional capsule to maintain blinding for both participants and researchers. This ensures that neither group knows which capsule is being administered, thereby preserving the study's integrity and validity by preventing any expectations or beliefs from influencing the results."
41380208|NCT05285553|DEVICE|MiSight 1 Day|Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.
41380209|NCT05285553|DEVICE|Proclear 1 day|"Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years.~Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year."
41380210|NCT06161038|DEVICE|LASER|LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
41380211|NCT06161038|DEVICE|Ultrasound|1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.
41380212|NCT06161038|DRUG|Prolotherapy|Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
41380213|NCT06411782|DEVICE|Foam roller|In foam roller application, a partitioned FR from the Trigger Point Grid 2.0 brand, measuring 33x14 cm and weighing 0.9 kg, with an inner part made of polyvinylchloride (PVC), will be used. Participants will roll the segmented FR with slight flexion-extension by placing the FR on the SCM muscle to apply FR from the starting point to the end point of that muscle region for the selected SCM muscle, with the person in the side stance position against the wall. This action will consist of 3 sets of 1 minute each, with a 30-second rest period between each set. It will be applied once for each region, including the right and left SCM muscle.
41380214|NCT06411782|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths.
41380215|NCT06651359|BEHAVIORAL|Surveys for Quality of Life|This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL).
41380216|NCT06651359|BEHAVIORAL|Surveys and mHealth App access|"This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL). Additionally, they will have a brief initial study visit, in-person or virtually, to review the app use. This arm of participants will use the mobile application at home for 12 months. During the first 12 weeks, the application will send daily surveys about symptoms, dietary and physical activities, weekly surveys about their mood, and an assessment of their overall QoL every 3 months. The app will provide tailored educational content, including short readings, videos, and audio recordings, to help users learn more about managing symptoms and improving their functioning. After 12 months of app use, an interview will be conducted to gather feedback about their experiences with the app. The information collected from these interviews will be analyzed to further enhance and improve the app's functionality."
40851451|NCT02673502|DIETARY_SUPPLEMENT|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
41034948|NCT02142049|DRUG|Lenalidomide|Lenalidomide
41034949|NCT05916690|DRUG|Electrochemotherapy with bleomycin or cisplatin|Combination of drug delivery platform (electroporation) and drug (bleomycin)
41034950|NCT01517802|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
41165804|NCT03311269|DRUG|Sodium Tetradecyl Sulfate 1% Injection|Sodium Tetradecyl Sulfate STS 1% Injection
41507510|NCT01313585|DRUG|Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
41507511|NCT01313585|DRUG|Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device|
41507512|NCT01313585|DRUG|Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
40851452|NCT02673502|DIETARY_SUPPLEMENT|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
40851453|NCT05297513|DRUG|ActiveMatrix|All patients will receive weight based prophylactic antibiotics i.e. Ancef, vancomycin, or clindamycin. Drains will be used in fusion cases only. Intrawound vancomycin will be used for all instrumented cases.No negative pressure devices will be used. Anatomic layers will be closed in similar, standard fashion for all cases. For those randomized to the treatment group, the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia. Those in the control group, will forgo this step.
40851454|NCT04532905|OTHER|Strength Training Exercises Therapy|Five type of exercises: dumbbell bent row over, deadlift, lunge, shoulder press, and squat with each three sets and 10 repetitions. Between each set there will be 2-3 minute rest period and 8-10 minute rest period among each exercise type.
41034951|NCT01517802|DRUG|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
41034952|NCT01571362|DRUG|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
41165805|NCT03311269|DRUG|Sodium Tetradecyl Sulfate 3% Injection|Sodium Tetradecyl Sulfate 3% Injection
41507513|NCT01313585|DRUG|Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI|
41034953|NCT01571362|DRUG|Placebo|oral placebo, divided into symmetric doses and administered twice daily
41034954|NCT03506516|DIETARY_SUPPLEMENT|Mixing alcohol|Alcoholic beverages, different types
41034955|NCT03506516|DIETARY_SUPPLEMENT|Single type alcohol|Alcoholic beverages, different types
41165806|NCT02792647|DRUG|Placebo|Administered orally
41165807|NCT02792647|DRUG|IX-01|Administered orally
41034956|NCT03362255|OTHER|thoracic epidural catheterization|thoracic epidural catheterization with different speed of injection
41034957|NCT05861674|BIOLOGICAL|HH-003(20mg/kg)|20 mg/kg Q2W intravenously for 48 weeks
41380217|NCT05278208|DRUG|LUTATHERA® (Lutetium Lu 177 dotatate)|Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
41380218|NCT05480904|OTHER|Neurocognitive (Thinking) Testing|"Intelligence: WASI-II 20 min; Sustained Attention:~Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min."
41380219|NCT05480904|DIAGNOSTIC_TEST|CNS Vital Signs (Thinking) Testing|Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins
41380220|NCT05480904|OTHER|Health Questionnaires, Sleep Surveys & Sleep Diary|The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.
41380221|NCT05480904|DIAGNOSTIC_TEST|Echocardiography/EKG|All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography
41034958|NCT05861674|BIOLOGICAL|HH-003(10mg/kg)|10 mg/kg Q2W intravenously for 48 weeks
41380222|NCT05480904|DIAGNOSTIC_TEST|Pulmonary Function|PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).
41380223|NCT05480904|DEVICE|Remote Polysomnography|The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.
41380224|NCT05480904|DIAGNOSTIC_TEST|Physical Function|This is a test of how your heart and lungs respond to exercise.
41034959|NCT05861674|DRUG|TAF|TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
41034960|NCT03080129|DIETARY_SUPPLEMENT|Fresubin energy|dietary protein energy supplement
41165004|NCT05802914|DEVICE|Back Exosuit|The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.
41165005|NCT06276205|DRUG|Vitamin D|"if Vitamin D level suboptimal, 50,000 IU/week for 8 weeks followed by 2000 IU/d~if optimal Vitamin D level, 2000 IU/d"
41165006|NCT06276205|DRUG|Levothyroxin|commenced at a dose of 1.6mcg/kg/day and will be titrated 8 weekly according to response
41380225|NCT02392312|DRUG|ATF-Fresenius S|intravenous
41380226|NCT06650059|OTHER|Questionnaire|Self-questionnaire intended to each patient with sickle cell disease seen in consultation in one of the three reference centers participating in the study. Patients will complete the questionnaire once, on site.
41380227|NCT06647576|DEVICE|Spinal Cord Stimulation - In Clinic|Control Group Intervention: In-Person SCS therapy. Device settings, such as pulse width and frequency, will be adjusted during regular clinic visits. Follow-up assessments for pain relief, quality of life, and therapy effectiveness will occur at 1, 3, and 6-month intervals over a 6-month period.
41380228|NCT06647576|DEVICE|Spinal Cord Stimulation - Neurosphere|Test Group Intervention: Test group participants will receive remote monitoring and therapy adjustments through the Neurosphere™ virtual clinic platform. Participants in test group will have trial and end of trial phases in clinic, but further SCS therapy will be performed through Neurosphere. Clinicians will adjust the SCS device settings, including pulse width and burst frequency, remotely. This intervention allows patients to avoid in-person visits while receiving continuous, personalized care, with follow-up assessments at 1, 3, and 6 months over a 6-month period.
41380229|NCT06590558|PROCEDURE|Biopsy|Undergo tissue biopsy
41380230|NCT06590558|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41034961|NCT03259035|DRUG|Folfox Protocol|6 cycles of q2weekly FOLFOX, or
41034962|NCT03259035|DRUG|Capox|4 cycles of q3weekly CAPOX
41034963|NCT06007092|BIOLOGICAL|HPVDC injection level dose 1|patient receive 3 injections of vaccine at the same level dose
41034964|NCT06007092|BIOLOGICAL|placebo injection level dose 1|patient receive 3 injections of vaccine at the same level dose
41034965|NCT06007092|BIOLOGICAL|HPVDC injection level dose 2|patient receive 3 injections of vaccine at the same level dose
41034966|NCT06007092|BIOLOGICAL|placebo injection level dose 2|patient receive 3 injections of vaccine at the same level dose
41034967|NCT06336096|DRUG|Suzetrigine|Tablet(s) for oral administration.
41034968|NCT06336096|DRUG|Suzetrigine|Tablet(s) and Suspension for oral administration.
41034969|NCT02943148|OTHER|Davey score for striae gravidarum|
41034970|NCT04833829|BEHAVIORAL|CHIMES Intervention|"There are six components to the intervention:~1. Posters and other print materials to prompt providers and patients to discuss MH care engagement.~2. Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~3. Expanded MH screening procedures, including at initial intake.~4. Case management, emphasizing MH care engagement.~5. Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~6. Regular case review meetings."
41034971|NCT04833829|BEHAVIORAL|Standard of Care|The standard of care practices of referring patients to mental health services of the clinic during Months 1 - 12 of the study.
41034972|NCT01108081|BEHAVIORAL|Physical activity|Moderate-intensity physical activity
41380231|NCT06590558|PROCEDURE|Computed Tomography|Undergo CT
41380232|NCT06590558|DRUG|Eribulin Mesylate|Given IV
41380233|NCT06590558|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40851455|NCT00151372|BEHAVIORAL|Treatment Adherence Intervention|The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.
40851456|NCT00151372|BEHAVIORAL|Enhanced Care|For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
40851457|NCT01345669|DRUG|Placebo|Once daily
40851458|NCT01345669|DRUG|Afatinib|Once daily
40851459|NCT05352425|DEVICE|MobiusHD|The MobiusHD® device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
40851460|NCT03364738|BIOLOGICAL|rhPTH(1-84)|Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.
40851461|NCT00461279|BEHAVIORAL|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
40851462|NCT00461279|BEHAVIORAL|Interpersonal Psychotherapy|Established psychotherapy for depression
40851463|NCT01990612|PROCEDURE|Elective Induction of Labor|Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score \< 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
40851464|NCT01511081|RADIATION|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
40851465|NCT01511081|RADIATION|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
41165007|NCT01457833|DEVICE|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
41380234|NCT06590558|DRUG|Tolinapant|Given PO
40851466|NCT03073993|PROCEDURE|feeding tube insertion|Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
40851467|NCT05747534|DRUG|Larazotide Acetate|AT1001 (Larazotide) is a locally acting, non-systemic, octapeptide inhibitor of the zonulin receptor that has shown efficacy in a large variety of animal models of inflammation. The effectiveness of AT1001 in controlling paracellular permeability as a tight junction regulator has been widely demonstrated in animal models both in vitro and in vivo. In MIS-C, prolonged presence of SARS-CoV-2 in the GI tract leads to release of zonulin, a biomarker of intestinal permeability, with subsequent trafficking of SARS-CoV-2 antigens into the bloodstream, leading to hyperinflammation (Yonker, et. al. 2021). Five children treated with AT1001 (through an Emergency Investigational New Drug request authorized by the FDA) displayed a decrease in plasma SARS-CoV-2 Spike antigen levels, inflammatory markers, and symptom improvement superior to that achieved with the current standard of treatment for MIS-C (ie. immunoglobulin, systemic steroids) (Yonker, et. al. 2021) (Yonker, et. al. 2022)
40851468|NCT05747534|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to participants in the placebo arm.
41380235|NCT06590558|PROCEDURE|X-Ray Imaging|Undergo chest X-ray
40851469|NCT03102060|OTHER|Dietary Intervention|Undergo gluten free diet
41165808|NCT02494752|PROCEDURE|Fat graft enriched with ex vivo expanded stem cells|Fat graft will be enriched with ex vivo expanded stem cells
41165809|NCT02494752|PROCEDURE|Fat graft not enriched with ex vivo expanded stem cells|Fat graft will not be enriched with ex vivo expanded stem cells
41165810|NCT05215418|DRUG|VI-0521|Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
41380236|NCT06532162|DRUG|1% Lidocaine Paracervical Block|"A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 4 and 10 o'clock. The injection is continuous from superficial to deep (3 cm)."
41380237|NCT06532162|DRUG|Normal Saline Paracervical Injection|A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 4 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
40851470|NCT03102060|OTHER|Laboratory Biomarker Analysis|Correlative studies
40851471|NCT01397942|OTHER|Diet intervention|The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
40851472|NCT02669992|PROCEDURE|Stapled or Hand-sewn anastomosis|Randomization between stapled or hand-sewn anastomosis
40851473|NCT02669992|PROCEDURE|Mesh or suture stoma site closure|Randomization between suture or Mesh closure of the stoma site
40851474|NCT03190460|OTHER|Cognitive Training|Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
40851475|NCT03190460|OTHER|Technology-based Education|Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
40851476|NCT03113695|DRUG|Obinutuzumab|obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
40851477|NCT03113695|DRUG|lenalidomide|lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
40851478|NCT03113695|DRUG|HDMP|methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
40851479|NCT02593825|BEHAVIORAL|START-Play intervention|The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill.
40851480|NCT02593825|BEHAVIORAL|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
40851481|NCT01674777|DRUG|ASP1941|oral
40851482|NCT02757118|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
40851483|NCT02757118|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
40851484|NCT00147316|DRUG|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
40851485|NCT06095609|OTHER|Early mobilization plus chest physiotherapy|"Early mobilization:early mobilization has been confirmed its positive effectiveness on cutting down the MV use days and mortality rate, attenuating the side effect such as muscle strength loss and functional activity dysfunction resulting from ICU acquired weakness among the patients with mechanical ventilation.~Chest physiotherapy:a common technique to reduce the respiratory complications in ICU, has been proved certain positive influence on airway clearance and hospital lengths of stay."
41380238|NCT05668962|DRUG|Selpercatinib|Selpercatinib Oral, twice daily during initial treatment period (28 Days). A second course of selpercatinib if the participant is demonstrating clinical benefit to the initial course selpercatinib and deemed clinically appropriate by the treating investigator
40851486|NCT01805557|DRUG|R-DHAP|"* Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy"
41380239|NCT05668962|DRUG|Sodium Iodine I-131|I-131 NaI, oral, is a standard treatment for all types of follicular-derived thyroid cancers, except anaplastic thyroid cancer
41507514|NCT05449860|PROCEDURE|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Twin Cooled-Wet electrodes|Radiofrequency ablation will be performed by using twin cooled-wet electrodes. Two electrodes will be places on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will be delivered by using the 200 watts single generator.
41507515|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
41507516|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
41507517|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
40851487|NCT01805557|DRUG|BR-DHAP|"* Rituximab 375 mg/sqm iv day 0 or 1~* Bortezomib SC 1.5 mg/sqm day 1, day 4~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days."
40851488|NCT03483545|COMBINATION_PRODUCT|Follitropin delta and HP-hMG|Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg
40851489|NCT03137225|DEVICE|Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
41034973|NCT01108081|BEHAVIORAL|Diet|Dietary weight loss
41380240|NCT05668962|DRUG|rhTSH|"RhTSH injection, dosage per protocol, timing per protocol during the initial treatment period per standard of care.~Participants may receive a second course of rhTSH if the participant is demonstrating clinical benefit to the initial course rhTSH and deemed clinically appropriate by the treating investigator."
41380241|NCT06422507|DRUG|8 mg aflibercept (BAY 86-5321) (High Dose)|High-dose (HD) aflibercept is the sponsor's study intervention under investigation. Dose formulation: solution in vial. Unit dose strength: 114.3 mg/mL, Dosage Level: 8 mg (70 µL), Route of Administration: Intravitreal (IVT) injection every 16 weeks following 3 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 3 mL glass vials. Each vial will be labeled as required per country requirement.
41507518|NCT01012310|DRUG|PF-04531083 or Placebo|A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
41507519|NCT02523261|PROCEDURE|direct aspiration procedure|Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
41507520|NCT02523261|PROCEDURE|stent retriever procedure|Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
41034974|NCT01108081|BEHAVIORAL|Health education|Attention control intervention
41034975|NCT06636565|OTHER|No intervention|No intervention
41034976|NCT06434701|DIAGNOSTIC_TEST|Nasopharyngeal swab sampling for COVID-19|The healthcare provider will gently insert the swab a short distance (1-1.5 cm for young children) into one nostril, reaching the back of the nasal cavity. The swab will then be gently rotated and rubbed for a few seconds to collect a sample of mucus. The same process may be repeated in the other nostril.
40851490|NCT03137225|DEVICE|Nasal Intermittent Positive Pressure Ventilation|Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
40851491|NCT05769049|BIOLOGICAL|REC610|administered as 2 intramuscular (IM) injections in healthy adults aged 40 years and older
40851492|NCT05769049|BIOLOGICAL|Shingrix|Shingrix
41165008|NCT01457833|DEVICE|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
41165009|NCT04009720|DEVICE|Lotus Edge Device|The LOTUS Edge Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] \<1.0 cm2 or AVA index \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
41165010|NCT04056741|COMBINATION_PRODUCT|surfactant airway device|Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
41165011|NCT02036255|DRUG|Taurolidine Urokinase|
41165012|NCT02036255|DRUG|Taurolidine Heparin|
41165013|NCT01162564|DEVICE|NG-TSM|Flexible Composite Next Generation Tissue Separating Mesh
41165014|NCT05268822|OTHER|Home exercise|Movement control exercise with or without specific breathing techniques
40851493|NCT01012544|DRUG|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
40851494|NCT04629651|DRUG|Captopril|Oral, to be administered per the dose escalation scheme.
41507521|NCT05566184|DEVICE|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure, and the data will be collected. In the application of vascular access to children, a) before the procedure (20 minutes before), b) just before the procedure (20. minutes), c) during the procedure (between 20.-40. minutes), and d) 20 minutes after the procedure (40. minutes). Physiological variables that will be evaluated four times, once for each application, will be observed on the monitor, the FLACC Pain Assessment Scale will be recorded by the researcher and salivary cortisol level will be measured.
40851495|NCT04385134|OTHER|No intervention|No intervention
41034977|NCT01765140|DRUG|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)
41165015|NCT02604485|DRUG|Cohort 1|XOMA 358 single dose level A administered by an intravenous infusion
41165016|NCT02604485|DRUG|Cohort 2|XOMA 358 single dose level B administered by an intravenous infusion
41034978|NCT02320604|DRUG|Administration of study drug|i.v. administration of Ambisome in two different dossages
41165017|NCT02604485|DRUG|Cohort 3|XOMA 358 single dose level C administered by an intravenous infusion
41034979|NCT05359523|DEVICE|Ultrasonographic measurements of the trapezius and rhomboid muscle and fascia|B mode measurements Trapezius and rhomboid muscle thickness and fascial thickness measurement M mode measurements Abduction at 90 and 180 degrees Forward flexion at 90 and 180 degrees
41034980|NCT03425149|BIOLOGICAL|VLA1601|purified inactivated ZIKV vaccine candidate adsorbed on alum
41165811|NCT05215418|DRUG|Phentermine|Phentermine 30 mg capsule
41507522|NCT05860855|PROCEDURE|Augmentative craniotomy|Expansion of the skull
41507523|NCT05860855|PROCEDURE|Decompressive craniotomy|Standard hemicraniectomy
40851496|NCT04342117|DRUG|duvelisib|25 mg BID, 15 mg BID
40851497|NCT04342117|DRUG|PI3K inhibitor|FDA approved PI3K inhibitors
40851498|NCT02371031|DRUG|6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|
40851499|NCT02371031|DEVICE|PET/MRI|
40851500|NCT02371031|PROCEDURE|Surgical resection (standard of care)|
40851501|NCT01199562|PROCEDURE|infection prophylaxis and management|Undergo infection prophylaxis and management
40851502|NCT01199562|OTHER|laboratory biomarker analysis|Correlative studies
40851503|NCT01199562|OTHER|flow cytometry|Correlative studies
40851504|NCT01199562|GENETIC|DNA analysis|Correlative studies
41034981|NCT03425149|BIOLOGICAL|Placebo|Phosphate buffered saline (PBS)
41034982|NCT02014116|DRUG|LY3009120 capsule|Administered orally.
41034983|NCT04540107|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
41034984|NCT04540107|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41034985|NCT04540107|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
41034986|NCT05519254|DIETARY_SUPPLEMENT|Lactoferrin|Caregivers of children will be instructed to provide 1.5g of lactoferrin with 40g of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
41034987|NCT05519254|DIETARY_SUPPLEMENT|Lysozyme|Caregivers of children will be instructed to provide 41.5g of Lysosure daily mixed with 125 mL of porridge or other complimentary food.
40851505|NCT01199562|GENETIC|RNA analysis|Correlative studies
40851506|NCT01199562|PROCEDURE|management of therapy complications|undergo infection prophylaxis and management
40851507|NCT01199562|DRUG|ganciclovir|Given IV
40851508|NCT01199562|DRUG|valganciclovir|Given orally
40851509|NCT01199562|DRUG|foscarnet sodium|Given orally
40851510|NCT01199562|PROCEDURE|antiviral therapy|undergo infection prophylaxis and management
41034988|NCT05519254|COMBINATION_PRODUCT|Lactoferrin + Lysozyme|Caregivers of children will be instructed to provide 40g of Lysosure with 1.5 grams of lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
41380242|NCT06422507|DRUG|2 mg aflibercept (EYLEA, BAY 86-5321)|"Aflibercept 2 mg is the sponsor's active comparator. Dose formulation: solution in vial. Unit dose strength: 40 mg/mL, Dosage Level: 2 mg (50 µL), Route of Administration: Intravitreal (IVT) injection every 8 weeks following 5 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 2 mL glass vials. Each vial will be labeled as required per country requirement. Aflibercept 2 mg for the non-study fellow eye treatment is considered an auxiliary medicinal product (AxMP) in this study. Fellow eye treatment will be allowed with 2 mg aflibercept, at the investigator's discretion for indications approved by governing authorities. The treated fellow eye will not be considered an additional study eye."
41380243|NCT06422507|OTHER|Sham|"To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56. Sham kits will be assigned for visits requiring sham injections. The sham kits are empty but should be handled in the same way as the active study intervention kits.~Sham injections will be given on visits when an active injection is not planned. During the study treatment period all participants will receive either an active injection (8 mg or 2 mg aflibercept) or a sham injection (for masking purposes) following their assigned treatment group and eligibility for Dose regimen modification (DRM)."
41380244|NCT05673759|DEVICE|Electroencephalogram (EEG) system|An FDA 510(k) approved EEG/ERP device designed by G-Tec ™ intended for the acquisition, display, analysis, storage, reporting and management of EEG and auditory evoked potentials (AEP) information and uses Bluetooth technology to securely transmit EEG signals to a computer. The device is patient-friendly, and no serious adverse events have occurred to-date in any research or clinical study or in clinical use.
40851511|NCT01199562|GENETIC|polymerase chain reaction|Correlative studies
41507524|NCT06498167|DRUG|Upadacitinib|Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).
41507525|NCT03409237|DRUG|Mannitol|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
40851512|NCT01199562|GENETIC|protein expression analysis|Correlative studies
40851513|NCT03554447|DRUG|Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet|Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
40851514|NCT03554447|DRUG|Escitalopram 20 mg tablet + Placebo|Selective serotonin reuptake inhibitor plus placebo
40851515|NCT05850338|DEVICE|cold pad pillow|cold pad pillow application when women have vasomotor symptoms for 8 weeks
40851516|NCT05850338|BEHAVIORAL|autogenic training|Autogenic relaxation for three times a day for eight weeks
40851517|NCT05433597|DRUG|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
40851518|NCT05433597|DRUG|Cisplatin|Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle.
40851519|NCT05433597|RADIATION|Radiotherapy|Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy . GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.
40851520|NCT05433597|DRUG|TNF|TNF (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA\<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intramuscular, QD, 30 days in the first and third months, once a day.
41034989|NCT05519254|OTHER|Placebo|Caregivers of children will be instructed to provide 41.5 grams of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
41034990|NCT05794464|PROCEDURE|Catheter ablation and/or electrical cardioversion|Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
41034991|NCT04798781|DRUG|Telatinib|900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent
41034992|NCT04798781|DRUG|Keytruda|200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent
41165018|NCT02604485|DRUG|Cohort 4|XOMA 358 single dose level D administered by an intravenous infusion
40851521|NCT05433597|DRUG|Placebo|Placebo: 1-2ml normal saline, intramuscular injection, QD, once a day, 30 days in the first and third months.
40851522|NCT04059120|OTHER|Experimental group whit specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced with specific exercises of stretching and with it the factors that determine the syndrome of overtraining
40851523|NCT04059120|OTHER|Control group whit out specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced less than specific exercises of stretching and with it the factors that determine the syndrome of overtraining
40851524|NCT01154426|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
40851525|NCT01154426|DRUG|Gemcitabine Hydrochloride|Given IV
40851526|NCT01154426|OTHER|Pharmacological Study|Correlative studies
40851527|NCT01154426|DRUG|Veliparib|Given orally
40851528|NCT03162081|DIAGNOSTIC_TEST|Substance misuse screening|Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)
40851529|NCT03162081|DIAGNOSTIC_TEST|EQ-5D|Health related Quality of life
41380245|NCT05673759|BEHAVIORAL|Standard Neuropsychological Testing|Prior to the EEG session, neuropsychological testing will be done to establish a baseline measurement. We administer a full standard neuropsychological battery (45 mins) for all participants which includes the following tests: MOCA (only for older participants), MMSE, CERAD, Phonemic Test and the Category Fluency test, Trails Making Test A and B, BNT, BAI, BDI, PANAS, Ishihara Color Blindness test, and the Snellen Eye Chart.
41380246|NCT05673759|BEHAVIORAL|Additional neuropsychological tests|Younger participants will receive additional testing along with the standard neuropsychological battery including Pittsburgh Sleep Quality Index (PSQI) \[37\] for sleep quality measures, the Test of Memory Malingering (TOMM) for effort measure, Ohio State Traumatic Brain Injury Identification Method questionnaire (OSU-TBI) \[38\] to gather lifetime TBI history, and the Neurobehavioral Symptom Inventory (NBSI) \[39\] for post-concussive symptoms. These additional tests will add an extra fifteen minutes, making the total time for neuropsychological questionnaires 1 hour in younger participants.
41380247|NCT02139969|DEVICE|GreenLight XPS Laser System|
41380248|NCT06008015|DRUG|BR1015|One tablet administered alone
41380249|NCT06008015|DRUG|BR1015-1|One tablet administered alone
41380250|NCT06008015|DRUG|BR1015-2|One tablet administered alone
40851530|NCT03162081|DIAGNOSTIC_TEST|Impulsivity screening|Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test
40851531|NCT03162081|DIAGNOSTIC_TEST|Cognitive screening|Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test
41034993|NCT06359587|BEHAVIORAL|Laboratory test overuse (LTO) Bundle|"Key Components of the LTO Bundle:~Educational materials, including an online module, clinical decision support tool, provision of lab utilization (Audit and Feedback) reports for healthcare providers.~Patient engagement tools, such as videos and educational infographics. System level implementation tools adapted to the local context, including EMR-based tools and order set changes, etc."
41034994|NCT01023100|DRUG|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
41034995|NCT02161744|BIOLOGICAL|ADSCs administration|100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
41034996|NCT06634641|BIOLOGICAL|blood test|Only carrying out additional immunological assays during blood tests before initiation of treatment, six months after initiation of treatment and then one year after initiation of treatment.
41380251|NCT06652022|RADIATION|Systematic therapy combined with radiotherapy|Systematic medical therapy is same as the systematic treatment group. SBRT radiotherapy or conventional fractionated radiotherapy can be used according to the extent and size of the metastatic foci. SBRT radiotherapy is preferred, and a higher dose should be given as far as possible when the normal tissues permit, with a preferred single dose of ≥5Gy.
41507526|NCT03409237|DRUG|Hypertonic saline solution|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
41507527|NCT05537974|PROCEDURE|Endotracheal aspiration|Clearance of endotracheal secretions via a catheter.
41507528|NCT02057887|DRUG|HM10660A|
41507529|NCT02057887|DRUG|Pegasys|180 mcg Pegasys SC once weekly
41507530|NCT01686230|OTHER|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
41507531|NCT01686230|DRUG|Basic treatment|"Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn."
41507532|NCT02847871|BEHAVIORAL|PRISME-3P program|"PRISM-3P program will consist on a visit in the geriatric centre:~* Consultation with the geriatrician to rule a condition associated with loss of mobility and not known until now.~* Perform a nutritional assessment by a dietician followed by appropriate care management.~* Educational activity based on exercises and physical activity and balance: MAPA teaches exercises to develop strength and balance; gives tips to increase time spent on non-sedentary activities and enhance endurance followed by a monthly phone coaching.~* At 3 months, in case of no improvement of the SPPB score of 1 point, a training of 10 weeks with two sessions per week will be perform by the MAPA individually or in small patients groups;~* Implementation of a information exchange processing (mail, phone and book binding) between the various stakeholders."
41507533|NCT04825340|BIOLOGICAL|Nasal Spray Lyophilized Live Attenuated Influenza Vaccine|0.2 ml/vial, 0.2ml/dose/per person
40851532|NCT03162081|DIAGNOSTIC_TEST|Functional tests|Timed up and go (TUG), Single leg balancing test (SLB)
40851533|NCT03162081|DIAGNOSTIC_TEST|Cognistat|Assessment of cognitive domains
40851534|NCT03162081|DIAGNOSTIC_TEST|Neuropsychological profiling|Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test
40851535|NCT03162081|OTHER|Clinical interview|Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale
41034997|NCT01921569|BEHAVIORAL|Standard of Care Therapy|Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
41034998|NCT01921569|OTHER|dHACM Injection|Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
41034999|NCT01921569|OTHER|Normal Saline Injection|Injection into affected area with 1.0 cc normal saline solution instead of active agent.
41035000|NCT03102398|DRUG|TR-399 (5% Vardenafil HCl·3H2O, topical gel)|5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
41165019|NCT06009263|OTHER|Conventional treatment|"Application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
41380252|NCT06652022|DRUG|Systematic drug treatment|The choice of first-line treatment is based on the guidelines, and may include chemotherapy or immune checkpoint inhibitors, or a combination of therapies. For patients who can tolerate cisplatin, chemotherapy is given with the gemcitabine-cisplatin regimen, as follows: gemcitabine 1000mg/m2 d1,8; cisplatin 70 mg/m2, avoiding light, intravenous drip d2; 3 weeks for 1 cycle. For intolerant patients, the gemcitabine-carboplatin regimen is given as follows: gemcitabine 1000 mg/m2 d1,8, IV, carboplatin (4.5×\[GFR+25\]) mg, IV, d1; 3 weeks as 1 cycle. Immune checkpoint inhibitors and targeted agents may be administered if the patient does not tolerate chemotherapy; either in combination with chemotherapy or directly as first line.
41380253|NCT01231880|DRUG|Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Given every 4 months (once a school term)
41380254|NCT01231880|DRUG|Monthly IPT using DP|Given every month
41380255|NCT01231880|DRUG|Placebo given every month|No active ingredient
41380256|NCT01649999|DRUG|peficitinib|oral
41380257|NCT01649999|DRUG|Placebo|oral
41380258|NCT02085798|OTHER|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
41380259|NCT01410747|DRUG|Tacrolimus|oral
41380260|NCT06156631|BEHAVIORAL|DASH-ExMAMI|The DASH-ExMAMI consists of ten counseling and health education sessions that each last from 20 to 60 minutes over 10 weeks. The DASH domain will address the following subjects: getting started on DASH, making the move to DASH, tips to reduce salt and sodium, and a week with the DASH eating plan. The Exercise component consists of brisk walking for 30 minutes every day, five days a week. The medication adherence domain is based on the participant's Hill-Bone Compliance to High Blood Pressure Therapy Scale items and their scores. All domains of the intervention are stages and processes of change-matched ones and are provided through 10 motivational interviewing and counseling sessions.
41380261|NCT00270205|BIOLOGICAL|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
41380262|NCT00270205|BIOLOGICAL|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
41380263|NCT00270205|BIOLOGICAL|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
40851536|NCT03162081|OTHER|Medication use|Detailed screen of used medications, interactions, side effects in electronic patient registry
40851537|NCT03162081|OTHER|Comorbidity|Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry
40851538|NCT05290116|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD."
40851539|NCT01815840|DRUG|Vismodegib|Vismodegib 150 mg hard gelatin capsule orally once daily
40851540|NCT01815840|DRUG|Placebo|Vismodegib placebo orally once daily
41165020|NCT06009263|OTHER|Open chain segmental control|"Application of open chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
41165021|NCT06009263|OTHER|Closed chain segmental control|"Application of closed chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
41165022|NCT00511797|DRUG|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
41380264|NCT00778193|DRUG|Naproxen|1 tablet 500mg BID for 8 days
40851541|NCT05041140|DEVICE|29-XeMRI imaging|129-XeMRI scan
40851542|NCT06388603|DEVICE|Bioactive Glass|Bonalive Granules and Bonalive Putty will be used (according to their IFU and CE certification) to fill the bone void after the debridment of infected tissue as they have osteoconductive and osteostimulative properties that allow bone rigeneration. Moreover, Bonalive Granules also present some bacteria growth inhibiting properties to combact bone infection propoer of Ostemyelitis.
40851543|NCT06388603|OTHER|Standard of Care|The investigators are left free to proceed according to the normal standar procedure they normally use. The procedures can vary according to investigator judgment also depending on the state of Osteomylitis.
41165023|NCT00511797|DRUG|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
41380265|NCT00778193|DRUG|Aspirin|1 tablet 81mg QD for 8 days
41380266|NCT00778193|DRUG|Celecoxib|1 capsule 200mg QD for 8 days
41380267|NCT00778193|DRUG|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
41380268|NCT00778193|DRUG|Placebo|1 capsule BID for 8 days
41380269|NCT06182748|OTHER|Training on eccentric ergocycle|Subjects will train on eccentric ergocycles. In eccentric cycling, pedals push against the user's feet in the opposite direction, user has to slow down pedals and quadriceps muscles lengthen during contraction.
41380270|NCT06182748|OTHER|Training on concentric ergocycle|Subjects will train on regular concentric ergocycles. In concentric cycling, quadriceps contract to push pedals.
41380271|NCT05997316|BEHAVIORAL|Time restricted eating|Participants will work with a psychologist towards achieving a 16 hour fasting period, 2-3 days per week. The intervention will last 12 weeks, with different intervention materials gradually introduced over the course of the 12 weeks.
41380272|NCT05643118|GENETIC|OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)|Clear colorless solution dissolved in 1X PBS and injected intravitreally
41380273|NCT03843905|OTHER|no intervention|The aim of this translational research project is to study the impact of these new prognostic tools on surgical and oncologic results in a prospective cohort of patients who underwent CRC surgery at the Digestive Surgery Department of the University Hospital of Clermont-Ferrand (France)
41380274|NCT02730039|BEHAVIORAL|workshop|
41380275|NCT02730039|BEHAVIORAL|follow-up calls & webinars|
41380276|NCT02730039|BEHAVIORAL|assessments|
41380277|NCT04274426|DRUG|Carboplatin|Carboplatin will administered by intravenous route
41380278|NCT04274426|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered by intravenous route
41380279|NCT04274426|DRUG|Gemcitabine|Gemcitabine will be administered by intravenous route
41507534|NCT02802904|OTHER|Diet: Palm olein IV64|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
40851544|NCT01271374|DRUG|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
40851545|NCT01271374|DRUG|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
40851546|NCT00646399|DRUG|Placebo|Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
40851547|NCT00646399|DRUG|Pagibaximab 50 mg/mL|Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
40851548|NCT01054001|DRUG|sildenafil 100mg|sildenafil 100mg per oral twice a week
40851549|NCT06428370|PROCEDURE|Damage Control Surgery|Simple resection, drop, and open abdomen in case of Hinchey III-IV
40851550|NCT02870608|OTHER|lung and liver elastography measurement of fetus|
40851551|NCT06204081|DEVICE|CSO_without cueing|The sole is worn without using the cueing application
40851552|NCT06204081|DEVICE|CSO_cueing|The sole is worn with using the cueing application
40851553|NCT06583616|DIAGNOSTIC_TEST|Anion Gap|Patient with acute pulmonary embolism who not survive after hospitalization
40851554|NCT06414447|DIAGNOSTIC_TEST|Huxley Medical|diagnostic
40851555|NCT05340790|DRUG|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
40851556|NCT05340790|DRUG|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
41035001|NCT04214132|OTHER|Virtual Counselling Application using Artificial Intelligence|Intervention comprises of four Virtual Patients scenarios that aimed to improve nursing undergraduates communication skills in a clinical setting. These scenarios are based on authentic clinical cases (adapted from the real-life clinical case studies) focusing mainly on the communication aspects. Scenarios included 1) a middle-aged pregnant woman in her third trimester experiencing pain, 2) a middle-aged lorry driver who self-admitted to the hospital due to relapse of depressive symptoms, 3) changing a bloody dressing of a middle-aged male patient who had an operation 3 days ago, and 4) communicating with a fellow stressed student during their final preregistration clinical posting period.
40851557|NCT00053872|DRUG|cisplatin|
41380280|NCT04274426|DRUG|Paclitaxel|Paclitaxel will be administered by intravenous route
41380281|NCT04274426|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered by intravenous route
41380282|NCT06507709|PROCEDURE|Low volume CBCT|3-D imaging used during dental practice
41380283|NCT05245292|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30 mg/kg
41380284|NCT05245292|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 10 mg/kg
41380285|NCT05245292|DRUG|N803|Subcutaneous injections of N803 at 6 mcg/kg
41380286|NCT00960232|DRUG|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
41380287|NCT00960232|DRUG|placebo|placebo
41380288|NCT04440761|OTHER|Observation only|Observation only
41380289|NCT05419687|BEHAVIORAL|Training in de-escalating violence|"* Individual educational component through a de-escalating violence training for health care workers (verbal and non-verbal de-escalating techniques)~* Refreshment training in the form of collaborative learning"
41380290|NCT05419687|BEHAVIORAL|Code of conduct delivered via a warning board|A publicly displayed code of conduct (a co-designed set of rules) for both HCWs and clients, delivered via a warning board at the level of the health facilities and secondary hospitals
41380291|NCT04305054|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
41380292|NCT04305054|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
40851558|NCT00053872|DRUG|lomustine|
40851559|NCT00053872|DRUG|vincristine sulfate|
40851560|NCT00053872|PROCEDURE|adjuvant therapy|
40851561|NCT00053872|RADIATION|radiation therapy|
40851562|NCT05696821|DIAGNOSTIC_TEST|Educational intervention|The educational intervention includes a 3-months training program in the use of point-of-care ultrasound tailored to meet the educational needs of general practitioners. The training programs consists of three teaching seminars over a three month time period, a curriculum of 10 POCUS applications, and an online learning platform providing educational support before, during and after the teaching sessions.
40851563|NCT03006874|DRUG|CJ-12420 100mg QD|CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
40851564|NCT03006874|DRUG|Esomeprazole 40mg|Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.
40851565|NCT03006874|DRUG|CJ-12420 50mg QD|CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
41380293|NCT04305054|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
41380294|NCT04305054|DRUG|Lenvatinib|Administered via oral capsule at a specified dose on specified days
41380295|NCT04305054|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a specified dose on specified days
41380296|NCT04305054|DRUG|ATRA|Administered via oral capsule at a specified dose on specified days
41380297|NCT06653673|BEHAVIORAL|ChatGPT supported Online Guided Self-Help Program (GSHP)|"Guided Self-Help Program (GSHP)~The Guided Self-Help Program (GSHP) was developed by Fairburn and Carter for patients with binge eating disorder and later adapted to address various eating behaviors, forming an intervention protocol. GSHP modules consist of:~Starting self-monitoring, Establishing regular eating patterns, Applying the mindful eating rule and developing alternatives to emotional eating, Practicing problem-solving exercises, Addressing diet-related issues and body image, and Termination modules.~Session Structure:~Session 1 focuses on tracking eating patterns and raising self-awareness about eating habits. Individuals are asked to maintain a daily record via a shared Google Forms link. This food diary is later processed through ChatGPT, and personalized feedback is provided.~Session 2 provides psychoeducation on developing regular eating patterns. It emphasizes recognizing hunger and satiety cycles and reducing triggers. Participants are asked to log their meals daily"
41380298|NCT03707938|DRUG|Brigatinib|Given PO
41380299|NCT03707938|PROCEDURE|Local Consolidation Therapy|Undergo local consolidative therapy
41380300|NCT06586658|BIOLOGICAL|anti-CD70-CAR-T cells|The subjects received infusions of anti-CD70 CART cells following completion of lymphodepleting preconditioning chemotherapy. Dosage: 3×10\^6 cells/Kg; 1×10\^7 cells/Kg; 2×10\^7 cells/Kg.
41380301|NCT06652087|DRUG|Rifaximin|Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days
41380302|NCT06652087|OTHER|Standard HFpEF treatment|diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor
41380303|NCT04507646|OTHER|True auricular acupuncture|The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.
41380304|NCT04507646|OTHER|sham auricular acupuncture|The participant in control group will receive acupuncture on ineffective point at ear.
41380305|NCT05753215|DRUG|Omadacycline Pill|Omadacycline will be administered 300 mg orally daily without the loading dose.
41380306|NCT05753215|DRUG|Standard of Care|Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
41380307|NCT06002828|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41380308|NCT06002828|OTHER|Quality-of-Life Assessment|Complete questionnaires
41380309|NCT06002828|OTHER|Questionnaire Administration|Complete questionnaires
41380310|NCT03296904|DEVICE|CLs++|Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
41380311|NCT02288650|OTHER|early refeeding|
41380312|NCT02288650|OTHER|refeeding only in the recovery room (usual practice).|
41380313|NCT05564533|BEHAVIORAL|Heart-Smile Training Intensive Introduction Program (HST-IIP)|"Heart-Smile Training (HST) is an interoceptive compassion program designed to develop the qualities of compassion, empathy, and kindness for oneself and others with a focus on interoceptive awareness. It is unique from other compassion trainings in its focus on 1) embodiment of warmth and tenderness of compassionate feeling with a compassionate body scan meditation, 2) development of an authentic presence, characterized by a warm feeling of loosened attachment to ego-based self, and 3) cultivation of joy triggered by genuine smile to oneself. HST-IIP is a 3-day/4-week/1-day interoceptive compassion program that shares the same core elements and practices as HST 3-day intensive program. Unlike HST, the format of the HST-IIP has an extended duration to develop self-regulation through the cultivation of emotional and behavioral regulation."
41380314|NCT04993287|OTHER|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and HF care team
41380315|NCT04993287|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
41035002|NCT05660265|DRUG|GSK4172239D|Different strength of GSK4172239D will be administered in different cohorts.
41380316|NCT06464536|OTHER|Compression|conventional surgical gloves that are commonly used in hospitals will be used for compression therapy of both hands
40851566|NCT04072887|DRUG|QBW251|QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks
41035003|NCT05660265|OTHER|Placebo|Matching placebo will be administered.
40851567|NCT04072887|DRUG|Placebo|Placebo oral capsules administered twice a day for 24 weeks
40851568|NCT04072887|DRUG|COPD maintenance background therapy|Combination of fluticasone furoate, vilanterol and umeclidinium bromide
40851569|NCT02376803|DRUG|Warfarin|Morning vs Evening administration
40851570|NCT01497249|DIETARY_SUPPLEMENT|A dietary fiber (FCHO)|15 g twice per day in beverage
40851571|NCT01497249|DIETARY_SUPPLEMENT|Placebo|Placebo drink
41035004|NCT00017381|BIOLOGICAL|rituximab|Given IV
41035005|NCT00017381|DRUG|cyclophosphamide|Given IV
41035006|NCT00017381|BIOLOGICAL|filgrastim|Given SC
41035007|NCT00017381|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
41035008|NCT00017381|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
41035009|NCT05934045|BIOLOGICAL|RNAseq|there is no intervention done.
41035010|NCT02048384|DRUG|metformin alone (Arm A)|metformin alone
41035011|NCT02048384|DRUG|metformin (Arm B)|rapamycin + metformin
41035012|NCT02048384|DRUG|rapamycin (Arm B)|rapamycin + metformin
41035013|NCT00450827|BIOLOGICAL|bevacizumab|
41035014|NCT00450827|BIOLOGICAL|filgrastim|
41380317|NCT06653699|DRUG|2 DOSES OF DEXAMETHASONE AND TRANEXAMIC ACID|In group B, 2 doses of 10 mg intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
41380318|NCT06653699|DRUG|1 DOSE OF DEXAMETHASONE AND TRANEXAMIC ACID|In group A, 1 dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
41380319|NCT00078273|BEHAVIORAL|Personalized Feedback Intervention|Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
41380320|NCT00078273|BEHAVIORAL|Cognitive Behavioral Intervention|Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
41380321|NCT02359409|DEVICE|goggle balloon|Colonoscopy will be performed using the water immersion technique.
41380322|NCT02359409|OTHER|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
41380323|NCT03394404|DEVICE|ECG-I mapping and PVI|ECG-I mapping and PVI
41507535|NCT02802904|OTHER|Diet: Cocoa butter|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
41507536|NCT02802904|OTHER|Diet: Virgin olive oil|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
41507537|NCT01108783|DRUG|Bilastine|20 mg (encapsulated) tablets QD/14 days
41507538|NCT01108783|DRUG|Desloratadine|5 mg (encapsulated) tablets QD/14 days
41507539|NCT01108783|DRUG|Placebo|(encapsulated) Tablets QD/14 days
41380324|NCT03291249|DRUG|Foralumab|Anti CD3 mAb
41380325|NCT03291249|OTHER|placebo|Placebo oral solution
41380326|NCT03291249|DRUG|Omeprazole 20mg|Omeprazole is a proton pump inhibitor used to neutralize stomach PH
41507540|NCT04725851|PROCEDURE|High concentration Oxygen therapy|FiO2 \>80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)
41035015|NCT00450827|PROCEDURE|autologous hematopoietic stem cell transplantation|
41035016|NCT00450827|RADIATION|iodine I 131 monoclonal antibody 3F8|
41165024|NCT00511797|DRUG|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
41507541|NCT04725851|PROCEDURE|Control: Room Air or Low concentration Oxygen|FiO2 \<30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
41507542|NCT00753311|DRUG|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
41507543|NCT02944773|PROCEDURE|Facilitated tucking device|20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
41507544|NCT06516003|DEVICE|Immersive Virtual Reality Goggles|Immersive Virtual Reality goggles are a head mounted device placed over a patient's head and eyes that allows them to play in a virtual reality game.
41507545|NCT06516003|BEHAVIORAL|Standard of Care|Distraction techniques like tablet, phone, television, parent, child life specialist
41507546|NCT00643812|OTHER|Installation of gun locker in household|Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.
41507547|NCT00643812|OTHER|Installation of gun locker in household|"Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Late arm received the gun locker 12 months after baseline."
41507548|NCT05141617|PROCEDURE|Endoscopic treatment|Patients in the endoscopic treatment receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices
41507549|NCT05141617|PROCEDURE|TIPS|Patients in the TIPS group receive Transjugular Intrahepatic Portosystemic Shunt
41380327|NCT00397293|DRUG|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
41507550|NCT01480362|DEVICE|Negative Pressure Wound Therapy|"Used therapy systems:~KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations."
41507551|NCT01480362|OTHER|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
41380328|NCT00397293|DRUG|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
41380329|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen (LtSTA)|Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.
41380330|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen Placebo (Placebo)|Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
41380331|NCT01114386|PROCEDURE|Lung function testing, echocardiography, blood sampling|"All patients will undergo to:~* physical examination~* 6' Minute Walk test~* pulmonary function testing (spirometry + volumes and reversibility testing)~* carbon monoxide diffusing capacity (DLCO) with single-breathe technique~* ECG~* echocardiography"
41380332|NCT06118086|DRUG|REM-422|"* REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~* REM-422 will be administered orally once daily"
41380333|NCT05940402|DRUG|Emraclidine|Oral tablets
41380334|NCT06652841|DEVICE|transShield Embolic Protection System|Patient undergoing TAVR procedure will receive the transShield EPS with the intent to capture and remove debris dislodged during the interventional procedure.
41507552|NCT01427608|DRUG|Sertraline + Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
41507553|NCT01427608|DRUG|Sertraline + Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
41507554|NCT06006429|OTHER|Numerical dental impression by intraoral scanner|Intervention consists in an 3D intra oral representation of the oral cavity
41507555|NCT06210022|DIAGNOSTIC_TEST|Neuropsychological Assessment|Cognitive evaluation and clinical monitoring of seizure frequency
40851572|NCT04934644|PROCEDURE|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment 90 min from start to start of decompression. The chamber is pressurized to 2,4 ATA and the patients will be breathing 100% oxygen. Treatments will be given once daily, five days a week (no treatments on weekends and holidays).
40851573|NCT01500902|OTHER|EndoPAT testing (non invasive device)|Using the EndoPAT device, we will assess endothelial function.
40851574|NCT01500902|OTHER|WatchPAT testing (non-invasive device)|Using the WATCHPAT device we will assess sleep apnea.
40851575|NCT03151187|OTHER|Teaching intervention|Two two hour teaching modules on the diagnosis and treatment of disruptive behaviour disorders in children and youth
41380335|NCT04980066|PROCEDURE|Sticky bone and EDTA|treatment using Sticky bone after EDTA root surface biomodification
41507556|NCT06338462|DEVICE|Chatbot|The chatbot is a WhatsApp-based, artificial-intelligence powered customer service agent adapted for TB outreach. The objective of the Chatbot is to facilitate information gathering, education, and support throughout TB contact evaluation, ensuring accessible assistance on-demand during and after contact tracing procedures. It operates in a secure data environment that includes end-to-end encryption and has been reviewed and approved by the data protection team within the information technology unit at the Cali Secretariat of Public Health (SoPH) for the study purposes.
41507557|NCT06338462|DIAGNOSTIC_TEST|Oral testing|Oral testing involves collection of a saliva sample or use of a nylon swab to collect material from the tongue and oral mucosa that is then tested with a molecular test for Mycobacterium tuberculosis
41380336|NCT04980066|PROCEDURE|Sticky bone|treatment using Sticky bone
41380337|NCT06652659|OTHER|Non-union|Observational study looking prospectively at many different factors that may affect non-union of midshaft clavicle fractures.
41380338|NCT06081894|DRUG|Aficamten|Oral Tablet
41380339|NCT06081894|DRUG|Placebo|Oral Tablet
41380340|NCT05299359|BIOLOGICAL|TAK-019|TAK-019 intramuscular injection
41380341|NCT03367741|PROCEDURE|Biopsy|Undergo tumor biopsy
41380342|NCT03367741|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41380343|NCT03367741|DRUG|Cabozantinib S-malate|Given PO
41380344|NCT03367741|PROCEDURE|Computed Tomography|Undergo CT scan
41380345|NCT03367741|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41507558|NCT03672253|DRUG|CAR-T Re-treatment|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.
41507559|NCT03059797|DRUG|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
41507560|NCT03059797|DRUG|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
40851576|NCT04165629|DRUG|Aspirin 300mg and Clopidogrel 300mg|Aspirin 300mg and Clopidogrel 300mg on the day of the PTA
41380346|NCT03367741|BIOLOGICAL|Nivolumab|Given IV
41380347|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
41380348|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
41380349|NCT05774080|OTHER|Observational|Observational
41380350|NCT04552158|DIETARY_SUPPLEMENT|Mediterranean diet|The Mediterranean diet (MedDiet) is a nutritional model inspired by the traditional dietary pattern of some of the countries of the Mediterranean basin. Mediterranean dietary pattern (MDP) gather the following characteristics: abundant consumption of olive oil and high consumption of fruits, vegetables, cereals (preferably as whole grain), legumes, nuts and seeds. The MDP also includes moderate consumption of fish and shellfish, white meat, eggs, and fermented dairy products (cheese and yogurt), as well as relatively small amounts of red meat, processed meats, and foods rich in sugars. Frequent but moderate intake of wine, especially red wine with meals is also recommended
41380351|NCT03413722|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
41380352|NCT03413722|DRUG|Everolimus|The patient's physician will prescribe drug according to standard practice.
41380353|NCT06650683|BEHAVIORAL|Pediatric HAH|Pediatric HAH nursing support for home nursery care provided by parents as part of their child's disease.
41380354|NCT03701282|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41380355|NCT03701282|PROCEDURE|Bone Marrow Biopsy|Undergo biopsy
41380356|NCT03701282|PROCEDURE|Computed Tomography|Undergo CT
41380357|NCT03701282|DRUG|Ibrutinib|Given PO
41380358|NCT03701282|BIOLOGICAL|Obinutuzumab|Given IV
41380359|NCT03701282|OTHER|Quality-of-Life Assessment|Ancillary studies
41380360|NCT03701282|DRUG|Venetoclax|Given PO
41380361|NCT06236438|DRUG|Livmoniplimab|Intravenously (IV) Infusion
41380362|NCT06236438|DRUG|Budigalimab|IV Infusion
41380363|NCT06236438|DRUG|Pembrolizumab|IV Infusion
41380364|NCT06236438|DRUG|Pemetrexed|IV Infusion
41380365|NCT06236438|DRUG|Cisplatin|IV Infusion
41380366|NCT06236438|DRUG|Carboplatin|IV Injection
41380367|NCT06236438|DRUG|Carboplatin|IV Infusion
41507561|NCT04045483|OTHER|Virtual reality based cognitive training|The VR-based cognitive training consists of a three-dimensional simulation of home, a mart, bus stop, and street. It provides an integrative cognitive training experience where participants are required to accomplish some common ADL's in three frequently visited places: home, a supermarket, and bus stop.
41507562|NCT06035978|DRUG|Nebivolol|Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
41165025|NCT00511797|DRUG|Placebo|Placebo
41035017|NCT02278601|DEVICE|epidural delivery system|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
41035018|NCT02278601|DRUG|Ropivacaine|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
41035019|NCT02278601|DRUG|Fentanyl|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
41035020|NCT05255640|PROCEDURE|operation of ischemia of the lower limbs|The intervention technique is left to the judgment of the investigator to treat the ischemia
41035021|NCT05897593|DEVICE|GlenXRose Augmented Reality Acquired Brian Injury Therapies|Rehabilitation therapies for ABI have been developed for augmented reality implementation. These include various games to interact within an augmented environment while conducting rehabilitation therapy.
41035022|NCT05312879|DRUG|VX-147|Tablets for oral administration.
41165026|NCT06039592|DRUG|Captopril Tablets|0.3mg/kg, tid
41380368|NCT03771391|DIETARY_SUPPLEMENT|PKU Sphere|PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.
41380369|NCT06653686|OTHER|Hyperthermia combined with oral febuxostat.|Extracorporeal high-frequency hyperthermia combined with oral febuxostat
41165027|NCT06039592|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
41380370|NCT06653686|DRUG|Febuxostat|The control group subjects were administered oral febuxostat.
41380371|NCT04700072|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
41380372|NCT04700072|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
41380373|NCT04700072|DRUG|Lenvatinib|Administered via oral capsule at a specified dose on specified days
41380374|NCT05443256|DEVICE|Transcranial Magnetic Stimulation|Figure 8 coil stimulation
41380375|NCT05181553|OTHER|Canada's Food Guide principles (CFG diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
41380376|NCT05181553|OTHER|Standard North American diet (NAD diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the eating habits of Canadians.
41380377|NCT05140473|BEHAVIORAL|perceived workload|Perceived workload takes into account the acts and care performed but also the pressure felt of having been efficient in its task, the efforts made and the level of frustration felt.
41380378|NCT06428409|BIOLOGICAL|Sacituzumab tirumotecan|Given by IV infusion every 2 weeks (Day 1 and Day 15 of every 4-week cycle)
41380379|NCT06428409|DRUG|Fluorouracil (5-FU)|5-FU is administered by IV infusion over 46 to 48 hours every 2 weeks
41380380|NCT06428409|DRUG|Leucovorin (LV) or levoleucovorin|LV or levoleucovorin is administered by IV infusion every 2 weeks
41380381|NCT06428409|DRUG|Rescue medication|Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
41380382|NCT06428409|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents.
41380383|NCT06509984|DRUG|Apremilast treatment|treatment of apremilast
41380384|NCT06651502|DEVICE|dental implant placement and immediate provisionalization|dental implant placement and immediate temporization
41380385|NCT06163898|DRUG|Alnuctamab|Specified dose on specified days
41380386|NCT06163898|DRUG|Mezigdomide|Specified dose on specified days
41380387|NCT06163898|DRUG|Dexamethasone|Specified dose on specified days
41380388|NCT05469776|PROCEDURE|bicruciate-retaining total knee arthroplasty|
41380389|NCT05469776|PROCEDURE|posterior-stabilized total knee arthroplasty|
41507563|NCT06035978|DRUG|Valsartan and Sacubitril|Valsartan and Sacubitril (Entresto) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
41507564|NCT06035978|DRUG|Carvedilol|Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
41507565|NCT06035978|DRUG|Bisoprolol|Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
41507566|NCT06035978|DRUG|Metoprolol|Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
40851577|NCT02999412|PROCEDURE|Comprehensive medication review|"* A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.~* The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature \[4\]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.~* Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record."
41380390|NCT05904886|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
41035023|NCT05312879|DRUG|Placebo|Tablets for oral administration.
41165028|NCT06039592|DRUG|Spironolactone Tablets|2-4mg/kg, bid
41165029|NCT06039592|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
41380391|NCT05904886|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
41380392|NCT05904886|DRUG|Tiragolumab|Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
41380393|NCT05904886|OTHER|Placebo|Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
41380394|NCT06652126|OTHER|Microbiological examinations.|"* BMR testing by rectal swab (combined with nasal swab in some centers) on admission to the ICU and weekly as part of routine care.~* Microbiological samples (blood cultures, respiratory and urinary samples, etc.) as part of routine care at the request of the clinicians in charge of the patient."
41380398|NCT05741788|DEVICE|Various Stimulation Patterns|Participants will undergo a structured optimization evaluating existing types of stimulation (tonic, burst, and multistim). Each participant will try out all types of available stimulation but be blinded to the type. Over the course of four months, each participant will evaluate each type of stimulation by reporting daily pain scores. Participants will follow up routinely to collect laboratory, behavioral, and survey responses to test for the feasibility of obtaining data explaining pain phenotype.
41507567|NCT06035978|DRUG|Spironolactone|Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
41507568|NCT05176444|BEHAVIORAL|Music therapy|Individual music therapy sessions across 12-weeks with people with cognitive impairment/dementia. Music therapy training for care home staff at four time points across 12-weeks.
41507569|NCT01111318|DRUG|BI 10773|2 tablets BI 10773 25 mg single dose
41380399|NCT06646536|OTHER|Anti-gravity treadmill training|Patients will participate to anti-gravity treadmill (Alter G) walking program in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
41380400|NCT06646536|OTHER|Conventional treadmill training|Patients will participate to walking program on a standard treadmill in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
41380401|NCT06646536|OTHER|Standard physiotherapy and rehabilitation program|Patients will participate to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
41380402|NCT04984161|OTHER|education|The aim of this project is to examine the effect of stoma care education on the knowledge and skill levels of pediatric surgery nurses about stoma care.
41380403|NCT05007106|BIOLOGICAL|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
41380404|NCT05007106|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered via IV infusion Q3W.
41380405|NCT05007106|DRUG|Lenvatinib|Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
41380406|NCT05007106|DRUG|5-Fluorouracil|5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
41380407|NCT05007106|DRUG|Cisplatin|Cisplatin administered via IV infusion
41380408|NCT05007106|DRUG|Paclitaxel|Paclitaxel administered via IV infusion at investigator's choice of dose
41380409|NCT05007106|DRUG|Gemcitabine|Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity
41380410|NCT05007106|DRUG|Carboplatin|Carboplatin administered via IV infusion at investigator's choice of dose and frequency
41035024|NCT05672992|OTHER|Spatial-frequency domain imaging (SFDI)|SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
41035025|NCT02015117|OTHER|Laboratory Biomarker Analysis|Correlative studies
41035026|NCT02015117|OTHER|Pharmacological Study|Correlative studies
41035027|NCT02015117|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of the tumor
41035028|NCT02015117|DRUG|Trametinib|Given PO
41035029|NCT02015117|RADIATION|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
41035030|NCT01431677|PROCEDURE|Muscle Biopsy|
41035031|NCT06635031|PROCEDURE|Oral surgery|The patients were undergone routine oral surgeries. Surgical procedures included an incision on the oral mucosa and full-thickness flap reflection, and the primary wound closure was achieved by polyglactin absorbable sutures.
41380411|NCT05007106|DRUG|Docetaxel|For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles
41035032|NCT04634604|DRUG|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
41035033|NCT04634604|PROCEDURE|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by OSHA and facility standards, will be followed.
41035034|NCT05709730|DIAGNOSTIC_TEST|HPV genotyping|"HPV genotyping of samples classified that were positive for other HPV"
41165030|NCT06039592|DRUG|Potassium citrate powder|0.06g/kg, tid
41035035|NCT01958151|OTHER|State-Trait Anxiety Inventory Scores|Patients are evaluated before the procedure with State-Trait Anxiety Inventory scores to determine the anxiety level.
41165031|NCT05959863|DIAGNOSTIC_TEST|Captopril Challenge Test|Patients received 50 mg captopril orally in the morning after sitting or standing for at least two hours. PAC and PRC were measured using mass spectrometry two hours after administration of capopril.
41165032|NCT03718819|OTHER|exercise|Pilates and aquaplyometric exercises will be done combinedly.
41165033|NCT02970786|DRUG|Injection of 68Ga-NODAGA-E(c[RGDyK])2|Following one injection of 68Ga-NODAGA-E(c\[RGDyK\])2 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
41165812|NCT05215418|DRUG|Placebo|Inactive oral capsule
41165813|NCT00766142|BIOLOGICAL|cetuximab|
41165814|NCT00766142|DRUG|fluorouracil|
41380412|NCT05007106|DRUG|Bevacizumab|Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles
41380413|NCT05007106|DRUG|Capecitabine|Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
41380414|NCT05007106|DRUG|Oxaliplatin|Oxaliplatin administered via IV infusion Q3W up to 35 cycles
41380415|NCT06647862|DRUG|IMM01|IV infusion
41380416|NCT06647862|DRUG|Azacitidine|subcutaneous injection
41380417|NCT06647862|DRUG|Placebo|IV infusion
41380418|NCT04782258|DRUG|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age.
40851578|NCT02999412|PROCEDURE|Comprehensive medication review with active follow-up|"The same as I1 but with the following additions:~* In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.~* A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.~* A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost."
40851579|NCT02999412|PROCEDURE|Usual Care|The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
40851580|NCT06478563|DRUG|NNC0487-0111 (formulation D)|Participants will receive NNC0487-0111 (formulation D) tablet once daily.
40851581|NCT06478563|DRUG|NNC0487-0111 (formulation C)|Participants will receive NNC0487-0111 (formulation C) tablet once daily.
40851582|NCT00296140|BEHAVIORAL|self management of PSD symptoms|
40851583|NCT00296140|PROCEDURE|screening and treatment of PSD|
40851584|NCT04241406|DEVICE|Transcutaneous spinal cord stimulation|Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequentl
40851585|NCT00332228|DRUG|depot naltrexone|long-acting depot parenteral formulation of naltrexone
40851586|NCT00332228|BEHAVIORAL|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
40851587|NCT00332228|DRUG|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
40851588|NCT03546114|OTHER|Gender Questionnaire|13-items questionnaire including demographics questions (gender, age, education; naive to osteopathic treatment or not; general gender preferences; specific gender preference in case of low back pain, neck pain, gastrointestinal disorders, musculoskeletal disorders of upper and lower limbs pain; headache; urogenital disorders
41035036|NCT05406687|OTHER|Health Navigator Model|The Health Navigator Model will be a longitudinal, person-centered and community-based intervention focused on addressing both primary and secondary cancer prevention, as well as reducing wider barriers to healthcare. Health Navigators (HNs) will be professionals who have a background in social care and an understanding of the local user population, and will be embedded in settings familiar and accessible to people experiencing homelessness. The primary aspects of the HN role will be to identify the health needs and barriers of users, promote cancer awareness and education, facilitate timely access to healthcare services and cancer screening, provide practical assistance, delivered through regular in-person meetings, and utilize wider stakeholders, including healthcare professionals, to deliver the intervention. A comprehensive training package will be delivered to the HNs, covering population specific knowledge, interpersonal skills, cancer education and local resources.
41035037|NCT03223298|DRUG|Botulinum toxin type A|37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle
41035038|NCT03223298|DRUG|0.9% Sodium Chloride Injection|1cc syringe
41035039|NCT01159938|DRUG|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
41165034|NCT06477250|BEHAVIORAL|Empathy-based socio-emotional mental training|The goal of the EmCo dyad practice is to enhance coping with difficult emotions, empathic and compassionate listening, social sharing, acceptance, and gratitude. It involves a daily partner-based practice and weekly coaching sessions with expert teachers.
41165035|NCT02101983|DRUG|Cytosine Arabinoside|
41165036|NCT03447977|OTHER|cervical|cervical spine manual therapy
41165037|NCT03447977|OTHER|thoracic|thoracic spine manual therapy
41165038|NCT03447977|OTHER|exercises|exercises for pain
41165039|NCT06123364|DRUG|mirabegron 50 mg daily|Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.
41165815|NCT00766142|DRUG|leucovorin calcium|
41380419|NCT04782258|DRUG|Tolvaptan Tablets|Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
41380420|NCT02989467|DRUG|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
41380421|NCT02989467|DRUG|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
41165816|NCT00766142|DRUG|oxaliplatin|
41380422|NCT06653231|DRUG|local delivery of Curcumin gel|The test site will be completely undiluted curcumin gel through a 2 mL disposable syringe was placed in the test site and isolated with cotton rolls (not to contaminate the medication with saliva) Patients were recalled after a week for refrained from using any other oral hygiene measures in the observation period, recalled after a month for follow-up.
41380423|NCT02603341|RADIATION|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
41380424|NCT02603341|RADIATION|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
41380425|NCT06445972|BIOLOGICAL|Ramucirumab|8 mg/kg IV Infusion
41380426|NCT06445972|DRUG|Paclitaxel|80 mg/M\^2 IV infusion
41380427|NCT06445972|BIOLOGICAL|MK-2870|3 mg/kg or 4 mg/kg IV Infusion
41380428|NCT02304302|DRUG|Memantine|Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
41380429|NCT02304302|DRUG|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
41380430|NCT06650384|DRUG|Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin|Group2 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice /day
41507570|NCT05668546|DEVICE|isokinetic testing CSMI HUMAC NORM instrument|The strength (PT) of the bilateral knee flexors and extensors were tested with isokinetic test. Tests were performed under the guidance of a rehabilitation medicine specialist, and the system was calibrated prior to their commencement. The patients were seated in upright position and were fixed with pelvic and thigh belts. Concentric extension (PT_E) and concentric flexion (PT_F) were measured between the 0° and 90° knee ranges at angular velocities of 60°/s and 180°/s (60 PT_E, 60 PT_F, 180 PT_E, and 180 PT_F, respectively) The tests were repeated five times at each velocity, and the highest PTs were selected for statistical analysis. The participants performed repeated trials before sets, while a 20-second rest was provided between sets.
41507571|NCT05560165|PROCEDURE|F-18 sodium fluoride PET/CT guided robotic arm assisted injection of combination of local anesthetic and steroids|A surgical aseptic approach will be followed for the procedure. Local anesthesia of the skin and soft tissue at the entry site will be achieved by 1% lignocaine. A 23G lumbar puncture needle will be introduced and the real-time final placement of the needle will be confirmed with low dose CT (40 mA) fused with pre-procedure PET images. After confirming the real-time position, the local anesthetic and steroid injection (0.5ml of 0.5% Bupivacaine per joint and a total dose of 80mg of Methylprednisolone acetate divided equally based on the number of joints to be injected) will be injected intraarticularly and periarticularly around the target joint through the lumbar puncture needle. The skin entry site will be compressed manually to achieve hemostasis. The same procedure will be repeated if multiple joints are to be injected. After the procedure, patient vitals will be observed for thirty minutes in the recovery area and discharged in stable condition.
41507572|NCT02768831|OTHER|CPAP|Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.
41035040|NCT06550401|OTHER|BREAST-Q Physical Well-Being|This BREAST-Q domain measures pain or tightness and difficulty with mobility, such as lifting arms or running. The preoperative survey contains 10 items, whereas the postoperative survey contains 11 items. Values for BREAST-Q subscales are converted to summary scores, ranging from 0 to 100, via Q-Score software. Higher scores correlate with better patient quality of life. 37 This survey is administered as part of standard care for all patients.
41035041|NCT06550401|OTHER|QuickDASH|QuickDASH, also known as the Arm and Shoulder Range of Motion survey within MSK Engage is an 11-item survey that measures physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb. It is currently standard of care for breast cancer surgery patients. It is a valid, reliable, and responsible survey that can be used for clinical and/or research purposes. Higher scores indicate greater disability.
41165040|NCT06123364|DEVICE|Extracorporeal magnetic innervation (active treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive sham stimulation.
41165041|NCT06123364|DEVICE|Extracorporeal magnetic innervation (sham treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive placebo stimulation.
41165042|NCT01328808|DRUG|Acetaminophen/APAP|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute"
41380431|NCT06650384|DRUG|Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin|Group3 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice/day
41380432|NCT06651021|DRUG|balcinrenone/dapagliflozin|"Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition.~Each participant will be involved in the study for up to 35 days."
41380433|NCT06241313|DRUG|Atogepant|Oral Tablet
41380434|NCT06241313|DRUG|Placebo for Atogepant|Oral Tablet
41380435|NCT00003452|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41380436|NCT06533449|DEVICE|Couplet Care Bassinet|Couplet Care Bassinet
41380437|NCT06533449|DEVICE|Standard Bassinet|Standard Bassinet
41380438|NCT06106828|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
41380439|NCT06106828|DRUG|Placebo|Placebo will be administered by SC injection
41380440|NCT06415669|DRUG|Paclitaxel for injection (albumin-bound)|100 mg/m2, day 1, day 8, every 21 days for a cycle.
41380441|NCT06415669|DRUG|Adebrelimab|20mg/kg or 1200mg, the first day, every 21 days as a cycle.
41380442|NCT06415669|DRUG|Apatinib mesylate|250mg once a day for 5 consecutive days and discontinue for 2 days
41035042|NCT01947946|BIOLOGICAL|Benralizumab|"Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive."
41035043|NCT01947946|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
41035044|NCT02532660|DRUG|Escitalopram 10mg|Escitalopram 10mg (1 pill once a day)
41035045|NCT02532660|DRUG|LABCAT TCJUSS|LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
41035046|NCT02532660|DRUG|LABCAT TCJUSS Placebo|LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
41035047|NCT02532660|DRUG|Escitalopram Placebo|Escitalopram Placebo (1 pill once a day)
41035048|NCT06284811|BEHAVIORAL|Exercise program focusing on quadriceps|Participants will be asked to perform the exercise program that focusing on quadriceps muscle
41035049|NCT01434602|DRUG|everolimus|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation: 5mg to 10mg daily.
41165043|NCT06406998|OTHER|Pre-existing atherosclerotic cardiovascular disease|Presence of pre-existing atherosclerotic cardiovascular disease
41165044|NCT05895968|PROCEDURE|posterior cervical surgery|The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.
41165045|NCT05674383|PROCEDURE|Axillary plexus nerve block|Axillary plexus nerve block: an ultrasound-guided axillary plexus nerve block with a single injection of lidocaine 1%.
41165046|NCT05674383|PROCEDURE|Fracture hematoma block|Fracture hematoma block: a blinded single injection into the fracture with lidocaine 1%.
41165047|NCT00814632|DRUG|CC-10004|CC-10004 20 mg. twice a day for 12 weeks
41380443|NCT06566092|BIOLOGICAL|LN-145/LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
41507573|NCT02768831|OTHER|Tidal volume|The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
41507574|NCT03409354|BEHAVIORAL|Tele-rehabilitation|There are five different categories of exercise in the rehabilitation program, which combines both physiotherapy (Category 1 to 4) and occupational therapy components (Category 5). Each tele-therapy session could cover all five categories of exercises. Progression of levels within each exercise within each category should be determined by the tele-therapist and in consultation with the participant.
41507575|NCT03409354|BEHAVIORAL|Usual care|Usual rehabilitation care (e.g., PT, OT and ST), prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
41507576|NCT00346983|DRUG|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
41507577|NCT00346983|DRUG|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
41507578|NCT01919021|OTHER|Magnetic Resonance Imaging MRI|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
41507579|NCT01919021|OTHER|Gamma Scintigraphy|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
41035050|NCT01434602|DRUG|sorafenib|Patients will be treated with sorafenib in combination with everolimus (days 1-28); There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation 400mg-600mg twice a day (bid) or 400mg-800mg twice a day, 7 days on and 7 days off.
41035051|NCT02951104|DEVICE|Ultrasonic Cardiac Output Monitor (USCOM) system|
41035052|NCT03923959|DRUG|Tranexamic Acid Injectable Solution|100 cc normal saline mixed with 1g of tranexamic acid in solution
41035053|NCT03923959|OTHER|Placebo|100 cc normal saline
41035054|NCT06635525|BIOLOGICAL|Influenza vaccination|Single-dose
41165048|NCT05297253|DEVICE|telescopic overdenture|fixed implant retained prostheses
41035055|NCT06635525|BIOLOGICAL|SARS-CoV-2 vaccine|Single-dose
41035056|NCT04618354|OTHER|No interventions|This clinical study is a retrospective study, and no interventions have been implemented for patients.
41035057|NCT03579745|PROCEDURE|Lingual orthodontics|A coil spring will be attached from the lever arm to the first molar tube
41035058|NCT06636071|BIOLOGICAL|setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
41035059|NCT04210687|PROCEDURE|trapeziometacarpal limited excision|Narrow pseudarthrosis CMC1
41035060|NCT04210687|PROCEDURE|Trapeziectomy|Simple trapeziectomy
41165049|NCT01520844|BIOLOGICAL|blood sampling|blood sampling
41165817|NCT00766142|PROCEDURE|adjuvant therapy|
41165818|NCT00766142|PROCEDURE|therapeutic conventional surgery|
41165819|NCT01176318|DRUG|Erdosteine|capsule 300mg twice daily for 10 days
41165820|NCT01176318|DRUG|Placebo|placebo capsule, twice daily for 10 days
41165821|NCT02807961|DRUG|ELX-02|Synthetic aminoglycoside
41380444|NCT05966129|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
41380445|NCT05966129|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
41380446|NCT06649643|DIAGNOSTIC_TEST|Inborn errors of immunity|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6. Complement assay (CH"
41165822|NCT02807961|DRUG|Placebo|Placebo comparator
41165823|NCT04846855|DRUG|local anaesthetic injection|Realization by the anesthesiologist of the local anesthesia by single dose of ropivacaine 0.35% in perinervous under ultrasound with distraction by a tablette.
41380447|NCT06649643|DIAGNOSTIC_TEST|A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4. Inflamatory marker ESR, CRP B.Immunology 1-Immunoglobulins IgG, IgM, IgA, IgE 2-Flow cytometric assessment: B|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6. Complement assay (CH"
41380448|NCT05925803|COMBINATION_PRODUCT|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
41380449|NCT05925803|DRUG|Placebo (blinded)|matched placebo delivered subcutaneously, once weekly for 52 weeks
41380450|NCT05925803|COMBINATION_PRODUCT|Anifrolumab (unblinded, open label)|At Week 52, all patients will receive Anifrolumab subcutaneously once weekly for 52 weeks
41380451|NCT06111235|DRUG|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
41380452|NCT06111235|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
41507580|NCT01919021|PROCEDURE|Assessment of Gastric motor and sensory function|
41507581|NCT04890912|RADIATION|Conventional Fractionation|Dose prescribed is 45 Gy in 25 fractions (1.8 Gy per fraction) delivered daily over 5 weeks.
41507582|NCT04890912|RADIATION|Hypofractionation|Dose prescribed is 30 Gy in 5 fractions (6 Gy per fraction) delivered every other day over 11 days. There will be a minimum of 36 hours and maximum of 96 hours between fractions. The entire course of treatment should be completed within no less than 10 days.
41507583|NCT04795947|BEHAVIORAL|Behavioral|There is no intervention in this study
40851589|NCT03960892|BEHAVIORAL|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialists, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
40851590|NCT02006979|OTHER|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
40851591|NCT05126849|OTHER|Allogenic transplantation|"1. Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~2. Stem cell source Bone Marrow~3. GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
40851592|NCT06130462|DIAGNOSTIC_TEST|Aluminum|Different concentrations of aluminium added to the blood test in vitro
40851593|NCT06130462|DIAGNOSTIC_TEST|Tetanus toxoid|Used as control substance
41507584|NCT03637387|DRUG|BIIB074|Administered as specified in the treatment arm
41507585|NCT03637387|DRUG|Placebo|Administered as specified in the treatment arm.
40851594|NCT05006027|PROCEDURE|Percutaneous coronary intervention via the distal radial approach|Percutaneous coronary intervention using a 7-Fr thin walled sheath (Prelude IDeal, MERIT MEDICAL, South Jordan, UT, USA) via the distal radial approach
40851595|NCT00411632|DRUG|Bexarotene|400 mg/m\^2 by mouth daily x 28 Days
40851596|NCT00411632|DRUG|Erlotinib|150 mg by mouth daily x 28 Days
40851597|NCT06284512|DIAGNOSTIC_TEST|Sonography, color fundus photography|Patients will undergo routine diagnostic imaging (Sonography, color fundus photography)
41507586|NCT03146429|DIAGNOSTIC_TEST|I-123 FP-CIT Single photon emission tomography|Brain scan for dopamine transporter
41507587|NCT02123810|OTHER|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
41507588|NCT04874831|DRUG|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
41507589|NCT00365313|DRUG|celecoxib, esomeprazole|
40851598|NCT01439594|DEVICE|MGH OFDI Imaging|Imaging of Esophagus with OFDI system
40851599|NCT02997059|DRUG|Fluconazole|200 mg/ day
41380453|NCT06034860|DRUG|MT-8421|Experimental treatment with MT-8421
41380454|NCT06034860|DRUG|Nivolumab|480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts
41380455|NCT04649151|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
41507590|NCT02892552|RADIATION|Cone Beam Computed Tomography (CBCT)|Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
41507591|NCT02892552|RADIATION|Multiple Detector Computed Tomography (MDCT)|Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
41507592|NCT02881697|OTHER|Adipose tissue sampling|
41380456|NCT04649151|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
41507593|NCT04811937|DIAGNOSTIC_TEST|Computer-aided polypectomy decision support by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedbackwill be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp and the information to help the polypectomy.
40851600|NCT02997059|OTHER|Placebo|
40851601|NCT04581551|PROCEDURE|SWE assessor 1|"SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
40851602|NCT04581551|PROCEDURE|SWE assessor 2|"SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
40851603|NCT04581551|PROCEDURE|Stretch intervention|Transversal stretch of pectoralis major muscle on the hemiplegic side.
40851604|NCT04581551|PROCEDURE|No stretch intervention|Passive mobilisation of the hemiplegic hand.
40851605|NCT05848427|OTHER|LUSZ P|LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.
40851606|NCT06069635|OTHER|Fatigue protocol (repeated sprint ability)|The test performed on an outdoor field (artificial grass carpet) in the form of 6 repetitions of maximal 2× 15 m shuttle sprints interspersed with 20 seconds of passive recovery , Before the RSA protocol, all players perform a brief standardized warm-up (approximately 20 minutes long), in 1at submaximal speed (followed by 40 seconds of passive recovery The fatigue index (FI) used to characterize the RSA performance was calculated in terms of percentage decrement score At the end of the RSA protocol , usually the time elapsed between the end of the last sprint and the beginning of the measurements was no more than 20 seconds, to avoid masking effects related to progressive recovery from fatigue.
40851607|NCT06069635|OTHER|Sham Comparator: Control group|approximately 20 minutes long), which consisted of : 6 minutes of incremental running from 60% to 80% of maximal aerobic speed; 6 minutes of dynamic flexibility exercises; 2 minutes of forward, backward, and lateral jogging and high-knee and ''butt-kick'' runs; 2 minutes of shuttle sprints (5 m in 1 direction and 5 m in the opposite direction, repeated for 2 minutes) at submaximal speed (followed by 40 seconds of passive recovery); and 2 minutes of RSA protocol simulation at submaximal speed (2 repetitions), again followed by 40 seconds of passive recovery. take apenalty of water and rest
40851608|NCT04845763|OTHER|FQoR-15 questionnaire|The FQoR-15 questionnaire (French version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. In the case of ambulatory surgery, the patient is contacted by telephone to answer the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
40851609|NCT01047982|DIETARY_SUPPLEMENT|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
40851610|NCT01047982|OTHER|folic acid 400 mcg|2 pills a day
41035061|NCT04829344|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
41380457|NCT04649151|BIOLOGICAL|mRNA-1273.222|Sterile solution for injection
41380458|NCT06036914|DRUG|Bumetanide|Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.
41380459|NCT06036914|DRUG|Furosemide|"Furosemide will be administered via intravenous (IV) infusion at usual doses (twice the home dose of oral daily diuretic in furosemide equivalents) administered as 2 doses total within 24 hours.~Furosemide equivalents will be considered as follows (40 mg of intravenous furosemide = 1 mg oral bumetanide or 40 mg of torsemide or 80 mg of oral furosemide consistent with prior literature). The lowest dose of furosemide administered during the study will be 40 mg IV two times a day (BID) and the maximum dose will be 100 mg IV BID."
41380460|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation|"In addition to standard touch-up of pulmonary vein isolation, subjects receive targeted source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 25%) are considered significant and targeted with radiofrequency ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold."
41380461|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping (no ablation)|"In addition to standard pulmonary vein isolation (PVI), subjects receive Electrographic Flow™ (EGF) mapping. PVI may be performed using any commercially available platform/catheter.~EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 25%) are marked as relevant; however, no EGF-guided ablations are performed during this index procedure. If subjects have AF recurrence after the 90-day blanking period, they may undergo a recurrence procedure and EGF-guided ablation."
41380462|NCT05268718|DRUG|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel was excited by NIR laser to release functional silver ions, copper ions and ROS.
41380463|NCT05268718|DRUG|Voriconazole eye drops|Voriconazole eye drops (1%) were administrated to infectious eye very frequently (once half an hour)
41380464|NCT05268718|OTHER|Normal saline|To be placebo, normal saline were administrated to infectious eye
41380465|NCT06243510|OTHER|apixaban|Participants will be randomized to receive a prescription for prophylactic apixaban
41380466|NCT06243510|OTHER|enoxaparin|Participants will be randomized to receive a prescription for prophylactic enoxaparin
40851611|NCT05293158|DRUG|Hepatect CP 50 I.E./ml infusion solution|"Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection."
40851612|NCT01802125|OTHER|laboratory biomarker analysis|Correlative studies
40851613|NCT02597387|DRUG|Mitoxantrone HCL Liposome Injection|
41035062|NCT04829344|DRUG|Placebo|Placebo Topical Ophthalmic Solution
41507594|NCT05812274|OTHER|Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation|"The Apricity CARE program for Cancer Adverse events Rapid Evaluation is a cloud-based 24/7 on-demand clinical coverage service, delivered exclusively via the ApricityRx digital care platform by certified and licensed healthcare professionals who are trained to monitor patient's symptoms and conduct standardized triage following guideline-based or protocol-specified pathways with 3 parts:~* ApricityCare™ Mobile Application - to collect health data (PGHD) on biometrics and self-reported symptoms (PRO) of symptoms and potential side effects at home, in between doctors' visits, and offers educational content in video.~* ApricityOncology™ Web-based Application - to provide authorized healthcare providers an organized, longitudinal and summarized view of a patient's pertinent cancer history and real world PGHD for purpose of symptom monitoring.~* ApricityManage™ Dashboard - a dashboard intended for administrators, sponsors or funders to track program status."
41507595|NCT03936595|OTHER|Core exercises protocol|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
41507596|NCT03936595|OTHER|Structural exercises protocol|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
41507597|NCT03936595|OTHER|Accentuated eccentric load exercises protocol|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Hip thrusts, 4 sets of 5 repetitions at 30% BM"
41507598|NCT03936595|OTHER|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
41507599|NCT01840306|OTHER|Biomarker Analysis|
41507600|NCT05949411|OTHER|Screening visit|Subjects will be invited to perform the screening visit to sign the informed consent and then to ensure that they are able to participate in this study.
41507601|NCT05949411|OTHER|Lactulose test|Fasted subjects (at least 10 hours) will receive on oral load of 10 g of lactulose. Then, exhaled H2 will be measured every 30 minutes during 4 hours.
41507602|NCT05949411|OTHER|Administration of standardized meals with characterized dietary fiber content|Subjects will receive standardized breakfasts and lunches characterized in terms of dietary fiber content. Urine, saliva, feces samples will be collected. Breath test and gastrointestinal symptoms will be followed during maximum 8h. Subjects will also complete SF36 questionnaire, food diary and stool/transit questionnaire.
41507603|NCT00727597|DRUG|Efavirenz 600mg|"QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
41507604|NCT00727597|DRUG|Boosted Lexiva|"Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
41507605|NCT04859452|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
41507606|NCT04859452|DRUG|Metformin hydrochloride tablets|Drug: Metformin hydrochloride, tablet, oral
41507607|NCT04859452|DRUG|Glibenclamide tablets|Drug: Glibenclamide, tablet, oral
41507608|NCT04859452|DRUG|Valsartan Capsules|Drug: Valsartan, capsule, oral
41507609|NCT04859452|DRUG|Simvastatin tablets|Drug: Simvastatin, tablet, oral
41507610|NCT01679509|PROCEDURE|Single-port laparoscopic adnexal surgery|
41507611|NCT01679509|PROCEDURE|Three-port laparoscopic adnexal surgery|
40851614|NCT06583889|DRUG|Heparin|The patients randomized to standard medical care will receive (or continue) either any type of body-weight adjusted low molecular weight heparin in therapeutic dose, or intravenous adjusted dose unfractionated heparin (aPTT value kept within 1 time the normal value), according to the existing international guidelines.
41380467|NCT03173937|BIOLOGICAL|Omidubicel (former CordIn)|Stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic umbilical/unrelated cord blood (UCB) cells. CordIn (TM) comprises: 1) cord blood-derived ex vivo expanded CD133+ cells (CordIn (TM) cultured fraction (CF)); and 2) the non-cultured cell fraction (CD133-) of the same CBU (CordIn (TM) Non-cultured Fraction (NF)). Both fractions, i.e. CordIn(TM) CF and CordIn(TM) NF are kept frozen until they are infused on the day of transplantation.
41507612|NCT00237653|DRUG|Valganciclovir|
41507613|NCT05741229|DRUG|Nebulized nitroglycerine as adjunctive therapy|Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy
40851615|NCT06583889|PROCEDURE|Endovascular treatment|Standard endovascular techniques to mechanically remove clot material, such as mechanical thrombectomy and/or balloon angioplasty and/or local application of alteplase or urokinase within the thrombosed sinuses.
41380468|NCT03173937|DEVICE|Miltenyi CliniMACS(R) CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device system that is designed for the in vitro enrichment of CD34+ target cells from heterogeneous hematologic cell populations. The process of CD34+ cell selection results in simultaneous passive depletion of donor lymphocytes, potentially obviating the need for immunosuppressive drugs to prevent GVHD.
41507614|NCT05741229|DRUG|conventional therapy for PPHN|patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.
41507615|NCT04297319|PROCEDURE|Laser diiodo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks It is an outpatient procedure, not anesthesia required.
41507616|NCT04297319|PROCEDURE|Laser Placebo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks. It is an outpatient procedure, not anesthesia required.
41380469|NCT03731325|BEHAVIORAL|Episodic Future Thinking Group|"Participants in the Episodic Future Thinking (EFT) Group will train with EFT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are descriptions of future events the participant can vividly imagine as happening right now.~Participants will be instructed to think about the EFT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their EFT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision."
41035063|NCT05677334|DRUG|Henagliflozin|Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
41380470|NCT06567834|DEVICE|Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric (Models ZXR00V/ZXW150)|Multifocal IOL with violet light filtration and high-resolution lathing
41380471|NCT06567834|DEVICE|Tecnis Symfony/Tecnis Symfony Toric (Models ZXR00/ZXT150)|Multifocal IOL with ultraviolet filtration
41380472|NCT05775341|OTHER|No Intervention|This is purely an observational study.
41380473|NCT03664388|DRUG|Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
41380474|NCT06055985|OTHER|Placebo|Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.
41380475|NCT06055985|DRUG|UCB0022|Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
41380476|NCT04695210|BEHAVIORAL|Virtual peer-to-peer support|See arm description
41380477|NCT02495974|DRUG|enzalutamide|oral
41380478|NCT05301894|DRUG|NBI-827104|T-type calcium channel blocker.
41380479|NCT04024254|DRUG|Folic Acid Tablet|Folic Acid 1 mg by mouth daily
41380480|NCT04374136|DRUG|AL001|Administered via intravenous (IV) infusion
41380481|NCT04374136|DRUG|Placebo|Administered via intravenous (IV) infusion
41380482|NCT04374136|DRUG|Open label - AL001|Administered via intravenous (IV) infusion
41380483|NCT06652997|DRUG|SPH3348|Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions
41035064|NCT05677334|DEVICE|Continuous Subcutaneous Insulin Infusion|Continuous Subcutaneous Insulin Infusion therapy alone
41035065|NCT04854291|OTHER|Administration of donor FMT|Intracaecal infusion of FMT
41380484|NCT06526585|BEHAVIORAL|Cyclic Sighing Breathing|"Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing practice during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the cyclic sighing during the 2 MRI assessments.~The cyclic sighing protocol consists of a breathing pattern that involves inhaling deeply, starting abdominally, inhaling through the nose until lungs feel comfortably filled, immediately followed by a second shorter inhale, also through the nose, to maximally inflate the lungs. Then participants are instructed to slowly exhale through the mouth until their lungs feel empty. This cycle is repeated for 10 minutes."
41380485|NCT06526585|BEHAVIORAL|Box Breathing|"Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the box breathing during the 2 MRI assessments.~The CO2 tolerance test is done at baseline to determine their comfort level with the duration of each side of the box during box breathing.~The box breathing protocol consists of a four-part breathing technique. The practice involves breathing through the nose in four equally timed parts: inhale, hold, exhale, and hold again, forming a 'box' of breaths (e.g. 4 sec inhale, 4 sec hold, 4 sec exhale, 4 sec hold).This cycle is repeated for 10 minutes."
41380486|NCT06526585|BEHAVIORAL|Hypnosis|Participants are instructed to sit comfortably or lie down during the 28 day at home practice (Participants will be lying down in the scanner during the 2 MRIs). Then participants are asked to look up, slowly close their eyes, take a deep breath, slowly exhale, and let their body float, and then to imagine floating in a bath, a lake, a hot tub, or floating in space. Participants are then asked to picture an imaginary screen and visualize a place where it would naturally feel comfortable and relaxed. The participants then divide the screen in half and picture on the left side one thing that is causing them stress, with the rule that no matter what the participant picture, to keep their body comfortable and relaxed. Then on the right side of the screen the participants are asked to picture one thing that can be done about the problem on the left. At the end the participant will be guided to come out of the state of hypnosis. This exercise will take 10 minutes.
41380487|NCT06526585|BEHAVIORAL|Audiobook|Participants are instructed to be seated or lying down, and can keep eyes open or closed throughout the 10 minutes of listening to the audiobook during the 28 days. Participants are instructed to keep their eyes closed during the 2 MRI assessments.
41035066|NCT04854291|OTHER|Administration of placebo|Intracaecal infusion of carrier solution
41035067|NCT05290558|DRUG|Bu Shen Yi Jing Pill|"Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
41035068|NCT05290558|DRUG|Placebo Drug|"Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
41507617|NCT03933566|PROCEDURE|Ultrasound-Guided Superficial Cervical Plexus Block|Ultrasound-Guided Superficial Cervical Plexus Block
41507618|NCT03933566|PROCEDURE|Landmark-Based Superficial Cervical Plexus Block|Landmark-Based Superficial Cervical Plexus Block
41380488|NCT03931707|GENETIC|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
41380489|NCT06112756|DRUG|Elinzanetant|Oral
41380490|NCT06112756|OTHER|Placebo|Oral
41380491|NCT00679042|BIOLOGICAL|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
41380492|NCT05777993|DRUG|Mitapivat|Tablets
41380493|NCT06381115|BEHAVIORAL|SleepWell24 Application|The SleepWell24 application will use connections with a Shelly smart plug and a Fitbit Charge 4 along with weekly questionnaires to monitor CPAP usage.
41380494|NCT03971422|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
41380495|NCT03971422|OTHER|Placebo|Subjects will receive placebo at pre-specified time points.
41380496|NCT06565585|PROCEDURE|Glans-sparing surgery|Patients who underwent glans-sparing surgery
41380497|NCT03538314|DRUG|UV1|UV1 (300 microgram)
41380498|NCT03538314|DRUG|GM-CSF|GM-CSF (37,5 or 75 microgram)
41380499|NCT06149988|DRUG|THC/CBD S.E powder|A single dose of THC/CBD S.E powder- 500 mg, given orally.
41380500|NCT06149988|DRUG|THC/CBD oil|Followed by a 30-day washout- A single dose of THC/CBD oil- 8 mg, given orally (equivalent dose to the powder).
41380501|NCT02676232|BEHAVIORAL|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
41380502|NCT06653582|OTHER|Postural reeducation|The program will include postural awareness, stretching, McKenzie's method, and manual therapy for 12 weeks.
41380503|NCT06653582|OTHER|Pelvic floor exercises|The program will include pelvic floor exercises for 12 weeks. Three sets of 10 long contractions will be performed, each sustained for 6-8 seconds, three times a day. After each contraction, participants will be asked to rest for the same period. Two series of 10 fast contractions will be recommended, consisting of short, quick exercises of 1- to 2-second contractions, followed by long, sustained exercises lasting 5-10 seconds.
41507619|NCT04515381|OTHER|Therapeutic Touch|Therapeutic Touch
41507620|NCT04515381|OTHER|Control group|Making measurements at the beginning of the research and 4 weeks
41507621|NCT04515381|OTHER|Sham Therapeutic Touch|Sham Therapeutic Touch
41507622|NCT05937737|BEHAVIORAL|Type 2 Diabetes Diet Modification|A 12-week dietary intervention model was prescribed to the patients in accordance with their needs.
41507623|NCT00948155|DRUG|Varenicline|Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
41507624|NCT05273346|BEHAVIORAL|Traditional Chinese medicinal ointment|The Group1 will be treated using the Comprehensive Conservative TCM Treatment Group protocol.The special TCM ointment will be applied to the waist, and then Tuina, in order to play the comprehensive therapeutic role of Tuina and medicine, promoting blood circulation and removing stasis, warming and dispersing cold, strengthening tendons and strengthening bones, regulating qi and blood. The method of ointment is generally used with rubbing method, rubbing method, flat pushing method and kneading method. Treatment time: 7 minutes.
40851616|NCT02085278|DEVICE|Apollo Micro Catheter device|Detachable Tip Micro catheter
41035069|NCT06300307|DRUG|ATX-01|Solution for infusion
41380504|NCT06652477|DIAGNOSTIC_TEST|ELISA|ElISA kit to detect autoantibodies against desmoglein 3 in tissues of oral lichen planus lesions
41380505|NCT06506669|PROCEDURE|Oral sedation|Oral medication for anxiolysis administered in the preoperative setting
41380506|NCT06506669|PROCEDURE|Placebo|A placebo pill with no active ingredients administered in the preoperative setting
41380507|NCT05345171|GENETIC|DTX301|non-replicating, self-complementary recombinant adeno-associated virus serotype 8 (AAV8) vector
41380508|NCT05345171|OTHER|Placebo|normal saline infusion
41380509|NCT05345171|DRUG|Oral Corticosteroids|Participants who receive DTX301 solution will receive oral corticosteroids.
41380510|NCT05345171|DRUG|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind
41380511|NCT05345171|DRUG|Sodium Acetate|A tracer for the Ureagenesis Rate Test (URT)
41380512|NCT03901339|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
41507625|NCT05273346|BEHAVIORAL|Acupotomy|It is in the special acupoints or Ashixue for cutting, stripping and other different stimulation, in order to reduce the tension of soft tissue outside the spinal canal, reduce the trend of dynamic and static spinal canal stenosis, to achieve the purpose of relieving pain and removing disease, opening points and collaterals. Acupotomy can separate the adhesive tissue, which can improve the blood circulation of the local tissue and promote the absorption of inflammation. Most acupotomy points are tenderness points or induration points, such as yaojiaji and Shenshu. Treatment time: 3 minutes.
41380513|NCT03901339|DRUG|Eribulin|Administered intravenously per NCCN guidelines
41380514|NCT03901339|DRUG|Capecitabine|Administered orally per NCCN guidelines
41380515|NCT03901339|DRUG|Gemcitabine|Administered intravenously per NCCN guidelines
41380516|NCT03901339|DRUG|Vinorelbine|Administered intravenously per NCCN guidelines
41380517|NCT06207656|DRUG|EBC|"Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice."
41380518|NCT03239340|DRUG|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
40851617|NCT03209466|DRUG|Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
40851618|NCT03209466|DRUG|Placebo Comparator with physiological saline sterile solution|Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
41507626|NCT05273346|BEHAVIORAL|Cupping therapy with bamboo cup|Put the bamboo cup with the thickness of the thumb into the cup and boil it, then find the meridian and select the acupoint, Pierce the skin with a needle at the appropriate acupoint, and remove the heated bamboo cup from the cup while it is hot. When the temperature of the steam in the bamboo cup is reduced, steam will condense into water quickly, which produces strong negative pressure. Through the medicinal force, heat and the suction of the bamboo cup, the blood stasis in the affected area is smoothly discharged, so that qi and blood can be unblocked and pain can be eliminated. Treatment time: 20 minutes.
41035070|NCT06300307|DRUG|Placebo|Solution for infusion
41035071|NCT00235976|DRUG|Gantacurium Chloride for Injection (AV430A)|
41035072|NCT05715047|BEHAVIORAL|CBT for Fatigue|10, individualized counseling sessions with a behavioral health counselor via Zoom platform.
41380519|NCT05232929|DRUG|Risdiplam|Participants will receive risdiplam orally.
41380520|NCT01350609|DRUG|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
41380521|NCT01350609|DRUG|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
41380522|NCT01271465|PROCEDURE|Kidney Biopsy|biopsy of transplant kidney
41380523|NCT05993481|DIAGNOSTIC_TEST|Blood Pressure Measurement|"NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program."
41507627|NCT05273346|OTHER|Oral Chinese medicine granules|Oral Chinese medicine granules use to nourish liver and kidney, improve qi and blood. Patients voluntarily take it when they think it is necessary.
41035073|NCT05715047|BEHAVIORAL|Usual Care|Standard transplant care.
41380524|NCT01815983|OTHER|Videolaryngoscopy review.|Review of video recordings.
40851619|NCT04638426|DRUG|HL237 tablet|Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
41380525|NCT05925764|DIAGNOSTIC_TEST|Whole Slide Image based Deep Learning|Whole Slide Image Based Deep Learning for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
41380526|NCT06144645|DEVICE|tVNS, intermittent stimulation|transcutaneous vagus nerve stimulation, intermittent stimulation
41380527|NCT06144645|DEVICE|tVNS, continuous stimulation|transcutaneous vagus nerve stimulation, continuous stimulation
41380528|NCT02416089|DEVICE|Tampostat|
40851620|NCT04638426|DRUG|Placebo of HL237 tablet|Placebo of HL237, twice a day
40851621|NCT05854979|DIAGNOSTIC_TEST|Gastric Ultrasound|A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.
40851622|NCT02707328|DRUG|Gemcitabine|
40851623|NCT02707328|DRUG|nab-paclitaxel|
40851624|NCT02707328|RADIATION|CyberKnife|
41035074|NCT02684422|OTHER|Intervention N/A. Observational study|There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.
41035075|NCT00270218|BIOLOGICAL|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
41035076|NCT00270218|BIOLOGICAL|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
41035077|NCT00270218|BIOLOGICAL|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
41035078|NCT00270218|BIOLOGICAL|PBS|phosphate buffered saline
41380529|NCT02416089|DEVICE|Condom catheter tamponade|
41035079|NCT03913611|OTHER|Accelerated rehabilitation protocol|Patients in this group will undergo an accelerated rehabilitation protocol, without movement restrictions. Movement restriction will instead be governed by patient comfort.
41035080|NCT03913611|OTHER|Traditional rehabilitation protocol|Patients in this group will undergo a traditional rehabilitation protocol, with movement restrictions and sling use for 6 weeks following surgery.
41035081|NCT06634927|DRUG|Ozempic®|Participants will be given Ozempic ® injection 0.25mg abdominal subcutaneous injection.
41035082|NCT06634927|DRUG|HDG1901|Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.
41380530|NCT03988049|DEVICE|1,550 fracionated photothermolysis laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
41380531|NCT03988049|DEVICE|755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
41507628|NCT05273346|BEHAVIORAL|Epidural Steroid Injections (ESIs)|The Group2 will be treated using the Modern Medicine Conservative Treatment Program Group protocol.All Epidural Steroid Injections(ESIs) will be performed by a physician in an outpatient surgical setting(a sterile operating room),the patient will be in prone position,while monitored the vital signs. After aseptic treatment, 1mg non-granular betamethasone plus 5mL 0.9% sodium chloride solution will be injected. Patients will repeat ESIs up to four times within three months after randomization, depending on the response to the previous ESIs, when the degree of pain increases or the degree of relief is less than 50%.
41507629|NCT05273346|BEHAVIORAL|Interferential current therapy|The 30-50cm padded electrode will be properly fixed on the left and right sides of the lumbar spinal stenosis, and the two groups of current will be crossed at the lesion. Constant frequency output 90Hz, frequency conversion output 90-100Hz, the current intensity is generally suitable for patient tolerance, each treatment for 10min, a total of 20 minutes. Twice a week for 3 months.
41507630|NCT05273346|BEHAVIORAL|Thermal therapy|After the interferential current therapy, the patient will receive Bohm light for 5 minutes at the site of lumbar spinal stenosis and massage for 5 minutes at low back. Twice a week for 3 months.
41507631|NCT05273346|OTHER|Oral painkillers|NSAID drugs, if necessary.
41507632|NCT00019240|DRUG|cidofovir|
41507633|NCT03596138|OTHER|Evaluate the reliability and reproductibility of the automated angular measurement by the Gazelab|Compare the results of the Gazelab to the alternate occlusion by prism bar (standard gold) examiners.
41507634|NCT03925259|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a 'third wave' behaviour therapy delivered on a one to one basis.
41507635|NCT01174043|DRUG|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
41035083|NCT04039113|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
41035084|NCT04039113|OTHER|Placebo|Placebo subcutaneous injection
41507636|NCT02248883|DRUG|TPV low|
41507637|NCT02248883|DRUG|Placebo|
41507638|NCT02248883|DRUG|Moxifloxacin|
41507639|NCT02248883|DRUG|TPV high|
41507640|NCT02248883|DRUG|RTV|
41507641|NCT02499484|DRUG|glyceryl trinitrate|Topical GTN will be used daily in combination with a eccentric home exercise program
41507642|NCT02499484|OTHER|Placebo ointment|Topical placebo ointment will be used in combination with a eccentric home exercise program
41507643|NCT02499484|OTHER|Eccentric exercise program|All participants will complete the eccentric exercise program as a home exercise program daily.
41507644|NCT04887155|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Group-based transdiagnostic cognitive-behavioral treatment
41507645|NCT03882229|DEVICE|MED-EL CI systems|• Cochlear Implant (CI) and external audio processor
41507646|NCT04902937|RADIATION|Adjuvant radiotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
41035085|NCT04327466|DEVICE|Osciflow|Osciflow is a non-invasive high frequency oscillatory ventilation support delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
41035086|NCT04327466|DEVICE|Highflow|Standard highflow therapy without oscillations delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
41035087|NCT06635928|DEVICE|Bright light therapy|30min daily of 10.000 lux bright light therapy
41035088|NCT05343702|DRUG|priming with rocuronium|Following induction (paralysis after onset of the induction effect) in routine rapid sequence intubation protocols While paralysis is applied, it is aimed to shorten the half-life of rocuronium by administering a subparalytic dose of rocuronium approximately 3-5 minutes before induction in the priming technique
41035089|NCT03730051|DRUG|Gadoterate meglumine|Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
41035090|NCT03730051|DRUG|Gadobutrol|Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
41380532|NCT05762588|DEVICE|Juggerknot with Broadband tape|The JuggerKnot system is comprised of a coreless sleeve structure and suture. The anchors are intended for use in soft tissue to bone fixation by bunching against the bone when deployed. The anchor sleeve material is polyester. Suture materials are ultra-high molecular weight polyethylene. The device has 510K FDA clearance.
41380533|NCT03985293|DRUG|Placebo|4 matching placebo tablets taken twice a day (BID)
41380534|NCT03985293|DRUG|PF-06882961|Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
41507647|NCT04902937|DRUG|neoadjuvant and adjuvant chemotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
41507648|NCT02864355|DEVICE|Goal Directed Therapy|Participants in this group will have a FloTrac monitor attached to their arterial line and the Goal Directed Therapy algorithm will be followed to manage blood pressures.
41507649|NCT00747032|DRUG|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
41380535|NCT04071925|PROCEDURE|Urethroplasty|Open reconstructive surgery to restore urethral patency in case of urethral stricture disease.
41380536|NCT03733301|DRUG|Baricitinib|Administered orally.
41380537|NCT03733301|DRUG|Topical corticosteroid|Administered as standard-of-care.
41380538|NCT03733301|DRUG|Placebo|Administered orally.
41380539|NCT04232696|DEVICE|Neuspera Implantable Sacral Nerve Stimulation System|Stimulation of the Sacral Nerve.
41380540|NCT02303275|BEHAVIORAL|Lifestyle Change|"Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes."
41380541|NCT02303275|BEHAVIORAL|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
41380542|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
41380543|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural injection|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
41380544|NCT03151707|DRUG|Nicotinamide Riboside|Nicotinamide riboside 2g/day for a 2 week duration
41380545|NCT06559163|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRllb, resulting in down regulation of B cell activity.
41380546|NCT06559163|DRUG|Placebo|Placebo
41380547|NCT03464110|BEHAVIORAL|Communication Intervention|. The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
41380548|NCT05000931|DEVICE|Osia 2 System|Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.
41380549|NCT02911610|DEVICE|arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
41380550|NCT02911610|DEVICE|Volar plate|surgery of wrist fractures with volar plate
41380551|NCT06650930|DRUG|Oral calcium carbonate|All participants receive a single, open-label dose of oral calcium carbonate 3000mg
41380552|NCT01265875|DRUG|Human Secretin|Dose Escalation
41380553|NCT06396208|DRUG|Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2)|Completing a pack (28 pills) of Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2), starting on day 7-9 of menstrual cycle
41380554|NCT06396208|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
41380555|NCT02660489|DRUG|OC459|
41380556|NCT02660489|DRUG|Placebo|
41380557|NCT02660489|OTHER|Rhinovirus|Inoculation with rhinovirus serotype 16
41380558|NCT06039293|BEHAVIORAL|Cognitive behavioral therapy and physical activity sessions|The intervention group will receive 10 sessions of cognitive behavioral therapy (CBT) and 6 physical activity sessions over the 12-week period. All Program AACTIVE CBT sessions and exercise sessions will run concurrently and take place virtually using Master of Social Work (MSW) trainees and Movement Science Master of Science students from the University of Michigan.
41380559|NCT06039293|BEHAVIORAL|Enhanced Usual Care + Diabetes Basics Web Series|"Participants will receive the American Diabetes Association Diabetes Basics web series (one video per week for 10 weeks) or Diabetes Basics handouts sent via mail."
41380560|NCT04243655|DEVICE|HA 330-II|One unit for 2-4 hours treatment, for 3 consecutive days
41380561|NCT04243655|DRUG|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
41380562|NCT01308762|BIOLOGICAL|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
41380563|NCT01308762|BIOLOGICAL|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
41380564|NCT01308762|BIOLOGICAL|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
41380565|NCT04116359|DRUG|Cisplatin|Given IV
41507650|NCT00747032|DRUG|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
41380566|NCT04116359|DRUG|Etoposide|Given IV
41380567|NCT04116359|DRUG|Etoposide Phosphate|Given IV
41380568|NCT04116359|DRUG|Molibresib|Given PO
41380569|NCT04116359|DRUG|Molibresib Besylate|Given PO
41380570|NCT06538311|DEVICE|Active rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
41380571|NCT06538311|DEVICE|Sham rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
41380572|NCT03083639|DRUG|Esomeprazole Capsule|Esomeprazole Capsule
41380573|NCT03083639|DRUG|Esomeprazole Tablet|Esomeprazole Tablet
41380574|NCT00000227|DRUG|Buprenorphine|
41380575|NCT00670527|PROCEDURE|[18F] Fluorocholine PET/CT|"The patients fast 6 hours before the \[18F\]Fluorocholine PET/CT scan. \[18F\]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.~The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark."
41380576|NCT02190968|BEHAVIORAL|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
40851625|NCT03413709|OTHER|Family Formation Program|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour FFP program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships, and economic stability and mobility.
41380577|NCT02190968|BEHAVIORAL|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
41380578|NCT05263804|OTHER|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection|No intervention. Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
40851626|NCT02893696|OTHER|Various sitting time|Various sitting time
40851627|NCT02870634|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
40851628|NCT05704790|OTHER|Cognitive Compensatory Training|The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
40851629|NCT03659071|OTHER|questionnaire VSP-A|VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
41380579|NCT05263804|OTHER|Cardiac MRI with gadolinium injection - Ancillary Study|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection. 100 patients are expected in this group, for each of them, specific cardiac MRI with gadolinium injection will be done at day 6. Moreover, those 100 patients will follow the same visit schedule as the patients in the cohort group.
41380580|NCT04538716|PROCEDURE|transconjunctival lower blepharoplasty|transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
41380581|NCT03725358|BEHAVIORAL|Training|Health facilities assigned to this group will receive a two-week training intervention on modern contraceptive methods and counseling techniques - aimed at nurses conducting family planning services. This new curriculum was developed by a large group of experts convened by the Ministry of Health in February 2018. The cascade training that is developed by the national government (cascading down to regions, districts, and finally health facilities) is a 15-day training module that targets family planning nurses, covering theory, practical knowledge (practicing administrations and removals), and counseling of clients.
41507651|NCT02290444|DRUG|Adrenocorticotropic Hormone|Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
41507652|NCT00194701|BEHAVIORAL|Walking exercise|
41507653|NCT00380744|DRUG|LY2189102|
41507654|NCT00380744|DRUG|placebo|
41507655|NCT04525937|OTHER|Patient Questionnaire|Patient Questionnaire
41507656|NCT04525937|OTHER|Provider Questionnaire|Provider Questionnaire
41507657|NCT05106608|DEVICE|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
41507658|NCT05106608|DEVICE|Energy density photobiomodulation (3)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
41507659|NCT05106608|DEVICE|Sham placebo|In addition, a mobile health application (LAXER) will be provided.
41035091|NCT04413890|DRUG|Dinoprostone vaginal gel|Prostaglandin gel 0.5, 1 or 2 mg
41507660|NCT02687217|DRUG|oxygen|"Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.~Received 6L/min of oxygen through venturimask upto 2 hours in post operative period.~Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery."
41035092|NCT02797925|OTHER|Training|Long slow strength training of the tendon for 3 months to improve function
41035093|NCT06500481|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
41035094|NCT06500481|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41380582|NCT03725358|BEHAVIORAL|App|"Health facilities assigned to this group will receive the same programming as the facilities in S1, but they will also be provided with tablets equipped with the job aid, which subsumes the basic data collection software used by the remaining facilities. They will also receive additional training on the use of the tablet-based job aid.~The app is a tablet-based decision-support tool, which is designed for use by the family planning nurse conducting counseling sessions and records the answers to a series of questions that elicit the client's life goals, fertility plans, needs, and preferences regarding contraceptive methods, as well as her medical eligibility (birth history, pregnancy check, breastfeeding status, blood pressure, medications, etc.)."
41380583|NCT03725358|BEHAVIORAL|Control|The comparison group includes facilities that continue business as usual (no FP training or tablet-based job aid). Each facility in this group will receive a tablet equipped with basic data collection software and a one-day training to use the tablets.
41380584|NCT06455475|OTHER|Derm-Maxx|Derm-Maxx™ Dermal Matrix is an acellular human dermis graft sterilized using the Tutoplast® Tissue Sterilization Process.
41380585|NCT04626635|DRUG|REGN7075|Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)
41380586|NCT04626635|DRUG|cemiplimab|administered concomitantly Q3W by IV infusion or SC injection
41380587|NCT04626635|DRUG|Platinum-based doublet chemotherapy|administered IV Q3W
41380588|NCT06014008|OTHER|Test product consumption group|Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
41380589|NCT06006169|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
41380590|NCT06006169|DRUG|SI-B003|SI-B003 was administered intravenously every 3 weeks (Q3W).
41380591|NCT06558682|DRUG|Disitamab Vedotin and Cisplatin|Disitamab Vedotin: 2mg/Kg,ivdrip, 3 weeks/cycle,3 cycles. Cisplatin: 75-80mg/m2, ivdrip, 3 weeks/cycle,3 cycles.
41380592|NCT06415032|PROCEDURE|Mastectomy with Quilting sutures without drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After the mastectomy, the skin flaps are sutured onto the pectoral muscle using polyfilament absorbable sutures (e.g. Stratafix PDS® 1 CT needle) placed at 4- to 5-cm intervals in two or three rows depending on the extent of the skin flaps. Care is taken to prevent dimpling of the skin. The axillary region is also approximated. Care is taken to prevent damage to nerves and blood vessels. No suction drains are placed. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference.
41380593|NCT06415032|PROCEDURE|Mastectomy with Conventional sutures with drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After mastectomy no flap fixation is performed. The skin is closed in a conventional manner using an absorbable skin suture. One or two suction drains are placed before skin closure. The drains are placed in the mastectomy gutter lateral to the pectoral muscle and/or in the prepectoral area. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference. Drain output is recorded daily. Drain removal policy varies among participating centres. In some centres drain removal is based on volume of drained fluids while in other centres it depends on the postoperative time
41380594|NCT06538779|DIAGNOSTIC_TEST|elastography,usg|Patients' general pain will be assessed with Visual Analog Scale (Global Pain), symptom severity and functional status will be assessed with Boston Carpal Tunnel Questionnaire, hand grip strength will be measured with dynamometer. Patient hand diagram will be marked according to patient's sensory symptoms. Median nerve cross-sectional area measurement at pisiform level with ultrasound, distal motor latency and sensory nerve conduction velocity with emg will be performed and recorded. Median nerve stiffness will be assessed with real-time elastography.
41380595|NCT04094818|DIAGNOSTIC_TEST|TriVerity|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection and sputum/ BAL sample collection
41507661|NCT05696379|OTHER|Angiography derived index of micro-circulatory resistance (Angio-IMR)|Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.
41035095|NCT06500481|RADIATION|Involved-Field Radiation Therapy|Undergo IFRT
41035096|NCT06500481|PROCEDURE|Lumbar Puncture|Undergo LP
41507662|NCT05123430|PROCEDURE|Monitoring of the pressure of the middle left atrium|During the MitraClip surgery, additional catheter is installed in order to monitoring the ppressure of the middle left atrium
40851630|NCT00066027|DRUG|20 mg doxycycline hyclate|Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
40851631|NCT00066027|DRUG|Placebo|Subjects in the placebo group took a placebo look-alike twice daily for two years.
40851632|NCT01262534|OTHER|Clinical profile of patients|Comorbidities and associated type of treatments will be collected.
40851633|NCT01262534|OTHER|Patient Preferences about treatment|Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
41035097|NCT06500481|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41035098|NCT06500481|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41035099|NCT06500481|RADIATION|Proton Beam Craniospinal Irradiation|Undergo pCSI
41035100|NCT06500481|OTHER|Quality-of-Life Assessment|Ancillary studies
41035101|NCT00006154|DRUG|Indinavir sulfate|400 mg tablets equaling 1600 mg daily
41035102|NCT00006154|DRUG|Ritonavir|100 mg liquid capsules equaling 400 mg daily
41035103|NCT00006154|DRUG|Abacavir sulfate|300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
41035104|NCT00006154|DRUG|Efavirenz|200 mg capsules equaling 600 mg daily
41035105|NCT00006154|DRUG|Stavudine|30-40 mg capsules equaling 60 or 80 mg daily
41035106|NCT00006154|DRUG|Didanosine|250-400 mg E.coated tablets equaling 250 or 400 mg daily
40851634|NCT01262534|OTHER|Quality of Life|The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
41380596|NCT06653270|OTHER|Virtual reality simulator|A in-house developed immersive virtual simulation of a normal vaginal delivery developed using a Unity Engine and installed in Oculus® Quest 2 head-mounted device
40851635|NCT02012660|OTHER|Seasonality|The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
41035107|NCT00006154|DRUG|Aldesleukin|Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
41035108|NCT05579860|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
41035109|NCT03782155|DRUG|glutamine supplementation|powder 14g
41380597|NCT06653270|OTHER|Mannequin-based simulator|Legacy PROMPT Flex® mannequin
41380598|NCT03242707|BIOLOGICAL|Autologous adipose tissue injection|"20ml to 40ml of subcutaneous adipose tissue will be aspirated from the abdomen. Adipose tissue will be processed using the Lipogems device, a closed-loop processing device used in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue.~The resulting fat product will be delivered locally via ultrasound-guided, intra-articular injection."
41035110|NCT03782155|DRUG|HMB|powder 3g
41035111|NCT03782155|DRUG|Placebo|powder 17g
41380599|NCT03242707|DRUG|Hyaluronic Acid|Synvisc-One® is a high molecular weight sodium hyaluronate.
41380600|NCT01338909|DRUG|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
41380601|NCT01338909|DRUG|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
41380602|NCT06313697|BIOLOGICAL|GR2102 injection|single dose
41380603|NCT06313697|BIOLOGICAL|placebo|single dose
41380604|NCT05809440|OTHER|20-minute mindful breathing session|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
41380605|NCT05571618|DRUG|ADC|Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
41380606|NCT05117294|DRUG|Bocidelpar|Oral
41380607|NCT00329758|DRUG|rosuvastatin|20 mg oral, during 10 days
41380608|NCT00329758|DRUG|Placebo|
41380609|NCT04966702|DRUG|Albendazole Pill|Using a MDA approach, fieldworkers will administer albendazole using directly observed treatment methodology to participants
41380610|NCT04966702|DRUG|Ivermectin Pill|Using a MDA approach, fieldworkers will administer ivermectin using directly observed treatment methodology to participants
41035112|NCT04027153|OTHER|Fee based delivery|Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
41035113|NCT06060171|PROCEDURE|Aortic valve intervention|Surgical or transcatheter aortic valve intervention
41380611|NCT04966702|DRUG|Ivermectin Injectable Product|Veterinary ivermectin injectable will be given to livestock in the relevant cluster
41380612|NCT03842202|DRUG|Semaglutide|Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
41380613|NCT03842202|DRUG|Placebo|Participants will receive once weekly injections of semaglutide matched placebo.
41380614|NCT04359888|OTHER|Multi-Modality Balance Intervention|Three one-hour training sessions 2-3x per week for six weeks in Multi-Modality Balance Intervention (MMBI). (See Study Design)
41380615|NCT04359888|OTHER|Balanced Reach Training (BRT)|One-hour training sessions 2-3x per week for six weeks in the Balanced Reach Training Protocol (BRTP) (See Study Design).
41380616|NCT04192799|BEHAVIORAL|Direct admission|Process of pediatric admission is through admission directly into the pediatric hospital medicine unit
41380617|NCT04192799|BEHAVIORAL|ED admission|Process of pediatric admission is through the emergency department
41380618|NCT00421486|PROCEDURE|Oral swabs for HPV-typing and high-risk HPV-determination|Oral swabs for HPV-typing and high-risk HPV-determination
41380619|NCT05477368|DIETARY_SUPPLEMENT|D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
41507663|NCT05736055|DIAGNOSTIC_TEST|Cambodia Version Five Minutes Hearing Test|The FMHT was developed by American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). The FMHT is composed of 15 questions. Each answer is scored as 0, 1, 2 or 3 according to the frequency of experience. If they answered 'never', the score was 0. The answer 'occasionally' scored 1, the answer 'half the time' scored 2, and the answer 'almost always' scored 3. Furthermore, it has shown more aspects, more reliability, and more assessments of the hearing impairment of the patients. is a standard hearing questionnaire. So, we plan to translate the FMHT into Cambodian language and validate by comparing its result with those of audiometry.
41507664|NCT02613182|DRUG|NEOD001|NEOD001
41380620|NCT05477368|OTHER|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
41035114|NCT01535404|DEVICE|Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead
41035115|NCT01535404|DEVICE|Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
41035116|NCT00444782|BIOLOGICAL|GV1001|
41035117|NCT04535401|PROCEDURE|Biopsy|Undergo tumor biopsy
41035118|NCT04535401|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41035119|NCT04535401|PROCEDURE|Diagnostic Imaging|Undergo imaging
41035120|NCT04535401|DRUG|Elimusertib|Given PO
41035121|NCT04535401|DRUG|Fluorouracil|Given IV
41035122|NCT04535401|DRUG|Irinotecan Hydrochloride|Given IV
41035123|NCT04535401|DRUG|Leucovorin Calcium|Given IV
41035124|NCT04195503|PROCEDURE|Liver Transplantation|Surgical removal of liver containing tumor(s) and transplantation of new healthy liver graft
41035125|NCT02221934|DEVICE|Altius|Electrical signal
41035126|NCT00593372|BEHAVIORAL|Spaced Retrieval Training|Increasing time to remember important information.
41035127|NCT04099069|PROCEDURE|anesthesia|patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
41380621|NCT05181176|DIETARY_SUPPLEMENT|Coffee|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
41380622|NCT05181176|DIETARY_SUPPLEMENT|Green tea|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
41380623|NCT05181176|DIETARY_SUPPLEMENT|Herbal tea (placebo)|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
41380624|NCT03563716|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
41380625|NCT03563716|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
41380626|NCT03563716|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
41380627|NCT05218915|DRUG|Dulaglutide|Dulaglutide once weekly subcutaneous
41380628|NCT05218915|DRUG|Insulin Degludec|Insulin degludec once daily
41380629|NCT05218915|DEVICE|Continuous glucose monitor|Dexcom G6 CGM system
41507665|NCT00447876|BIOLOGICAL|Botulinum toxin type A|Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
41035128|NCT06517316|DEVICE|Nelfilcon A plano cosmetic contact lenses|Commercially approved colored contact lenses worn to alter or enhance the apparent color of the eye. Plano contact lenses do not contain visual correction and are worn for cosmetic purposes only.
41380630|NCT03451474|PROCEDURE|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
41380631|NCT05679193|DRUG|Propranolol|"Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily"
41380632|NCT05651373|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
41380633|NCT05651373|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
41380634|NCT05651373|DRUG|CertolizumabPegol injection|200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
41380635|NCT04074356|OTHER|Clinical measure questionnaires|Collection of patient reported symptoms and perception of health
41380636|NCT04074356|DIAGNOSTIC_TEST|EESG|Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings
41380637|NCT04074356|DIAGNOSTIC_TEST|MESG|MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution
41380638|NCT04074356|DIAGNOSTIC_TEST|High resolution manometry (HRM)|Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms
41380639|NCT00132600|DRUG|bacitracin (allergen)|
41380640|NCT00838760|DRUG|TMC558445; TMC310911; Darunavir; Placebo|
41380641|NCT04195867|DRUG|Salmeterol Xinafoate|Subjects receive a daily inhaled dose of 200 μg (4 inhalations of 50 μg each).
41380642|NCT03889405|DEVICE|INVU™|The subject will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) for 30 to 60 min using INVU™.
41380643|NCT03889405|DEVICE|IUPC|The study participants will undergo continuous recording of the uterine contractions by IUPC.
41380644|NCT03889405|DEVICE|TOCO|Some of the study participants will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) by TOCO as well.
41380645|NCT01326611|DRUG|Clarithromycin|
41380646|NCT01326611|DRUG|Dextrose|
41380647|NCT04999137|DRUG|Vitamin C|Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses
41380648|NCT04999137|DRUG|Vitamin B1|Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
41380649|NCT03231709|DRUG|Trelagliptin|Trelagliptin tablets
41380650|NCT03231709|DRUG|Alogliptin|Alogliptin tablets
41380651|NCT06566339|DEVICE|Robotically Aligned Eye Imaging System|Robotically Aligned Eye Imaging System is a non-contact, micrometer scale imaging technique that provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D. The study team will develop hardware systems and software algorithms necessary for acquiring ocular anterior segment images for those seeking eye care in emergency department settings.
41380652|NCT02682069|DEVICE|MolecuLight i:X Imaging Device|The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
41035131|NCT06010589|DRUG|DWJ1558|DWJ1558
41380653|NCT06650319|BIOLOGICAL|intravenous LY-M003|The study was a single intravenous infusion of LY-M003 at a rate of 1 mL per minute.
41380654|NCT04561973|BEHAVIORAL|numerical rating scale|Patients seen for routine planned visits complete a self-administered retrospective questionnaire about pain during the last 3 months, and a prospective diary during the two weeks following the visit.
41380655|NCT03677973|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
41380656|NCT03677973|OTHER|Placebo|Matching Placebo
41380657|NCT04300049|DRUG|Glucagon Infusion|Study participants will receive glucagon infusion (6ug/kg/min for 12 hours) 12 hours.
41380658|NCT04300049|OTHER|Saline|Study participants will receive saline infusion for 12 hours.
41380659|NCT04587635|DIETARY_SUPPLEMENT|PHGG|PHGG
41507666|NCT00447876|DRUG|Placebo|0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
41507667|NCT02125864|PROCEDURE|intravitreal injection|collecting blood samples
41507668|NCT03593538|DRUG|Metformin|Metformin capsule
41507669|NCT03593538|DRUG|Placebo|Sucrose filler in gel capsules
41507670|NCT05976165|OTHER|Breath Testing|Subjects drink a small carbohydrate solution, and then provide a breath sample every 15 minutes for one hour, and then every 30 minutes for the next two hours
41380660|NCT04587635|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
41035132|NCT06010589|DRUG|DWC202310 and DWC202311|Co-administration of DWC202310 and DWC202311
41165824|NCT02010398|OTHER|Cross-Training healthy subjects|The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
41507671|NCT00437697|DRUG|dalteparin|
41380661|NCT05580432|BEHAVIORAL|Parenting with Positive Behavior Interventions|"Parenting with Positive Behavior Interventions is a 5 month packaged intervention. The curriculum and each element of the training and coaching program is described in detail below.~Each month, participants will participate in the following five activities:~1. Didactic Training: Participants will view a presentation~2. Workbook/Homework: Participants will complete a guided worksheet~3. Coaching Meeting - Planning: Participants will meet with a coach who is an expert in autism and behavior~4. Coaching - Observation/ Feedback: The coach will observe parent implementing the strategy, then provide feedback and direction regarding use of technique~5. Virtual Parent Community of Support Meeting: Attend parent led community support meeting to network, share experiences and information, and exchange ideas"
41380662|NCT04775953|DRUG|Cefazolin|Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
41380663|NCT04775953|DRUG|Dalbavancin|A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
41380664|NCT04775953|DRUG|Daptomycin|Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
41380665|NCT04775953|DRUG|Nafcillin|Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
41380666|NCT04775953|DRUG|Oxacillin|Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
41380667|NCT04775953|DRUG|Vancomycin|Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
41380668|NCT06652594|BEHAVIORAL|Eye Education Intervention|Doctors and nurses will educate parents about eye health in response to theirchild's myopia progression at baseline, 1 month, 3 months, 6 months.
41380669|NCT06652594|BEHAVIORAL|Control|Parents in the control group will not receive eye health education informationfrom doctors and nurses.
41507672|NCT03336528|DRUG|Degludec|Degludec is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner blood glucose (BG) between 100 mg/dL and 180 mg/dL.
41507673|NCT03336528|DRUG|Glargine|Glargine is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dL and 180 mg/dL.
41507674|NCT03336528|DRUG|Aspart|Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
41035133|NCT05679492|BIOLOGICAL|Meplazumab foe injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
41035134|NCT05679492|OTHER|Normal saline|Normal saline
41035135|NCT04295733|BIOLOGICAL|4CMenB (Bexsero®) vaccine|Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart
41165825|NCT02010398|OTHER|Cross-Training multiple sclerosis|The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
41380670|NCT04812548|DRUG|sabatolimab|Sabatolimab was administered at a low dose (Safety run-in (Part 1) cohort 1) or a high dose (Safety run-in (Part 1) cohort 2) via i.v. infusion over 30 minutes on Day 8 of every treatment cycle. Cycle = 28 days
41380671|NCT04812548|DRUG|azacitidine|A standard dose of azacitidine was given subcutaneously or intravenously every day for seven consecutive days on days 1-7 of a confirmed treatment cycle. In keeping with standard clinical practice, the alternative schedules for five consecutive days on days 1-5, followed by a two day break, then two consecutive days on days 8-9 was permitted (alternative schedule).
41380672|NCT04812548|DRUG|venetoclax|Venetoclax film-coated tablets was administered at a dose of 400 mg orally or corresponding reduced dose for concomitant use with P-gp inhibitors or moderate or strong CYP3A4 inhibitors, once a day, from C1D1 to C1D14 during the treatment cycle. No ramp-up for venetoclax was necessary.
41165050|NCT05643898|BEHAVIORAL|Mamá, te entiendo (Mom, I get you)|"Mamá, te entiendo is a guided 8-week cognitive-behavioral app-based intervention that targets postpartum women with minor and major depression. The development of the intervention followed the CeHRes Roadmap. It includes some elements from attachment and mentalization theories.~The intervention consists of six main sequential modules and three optional modules. All modules except the two psychoeducational ones include homework. Participants will receive feedback from an e-coach. They also can contact the e-coach to solve doubts about the app content and exercises. Other sections of the app include infographics about other relevant topics (for example, How to strengthen the couple relationship), a shareable document with reading about how to support a loved one struggling with depression and a resources section with links to websites and documents of interest."
41380673|NCT02772003|BIOLOGICAL|Electroporation-Mediated Plasmid DNA Vaccine Therapy|Undergo electroporation
41380674|NCT02772003|BIOLOGICAL|HCV DNA Vaccine INO-8000|Given IM
41380675|NCT02772003|OTHER|Laboratory Biomarker Analysis|Correlative studies
41380676|NCT02772003|OTHER|Quality-of-Life Assessment|Ancillary studies
41380677|NCT02772003|BIOLOGICAL|Rocakinogene Sifuplasmid|Given IM
41380678|NCT05819645|BEHAVIORAL|Fluid intake not as per standard guidlines|The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
41380679|NCT03456401|DRUG|Sorafenib or Sunitinib|After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
41380680|NCT00285259|BIOLOGICAL|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
41380681|NCT00285259|OTHER|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
41380682|NCT06653244|DRUG|Injection|dexmedimidine infusion
41380683|NCT03150433|BEHAVIORAL|Behavioral symptom management|Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
41380684|NCT03150433|OTHER|Sickle cell disease management|Individual sessions focused on understanding and managing sickle cell disease
41380685|NCT05762796|DEVICE|tDCS in Youth with mild traumatic brain injury|The safety and tolerability of tDCS have been established in children with mTBI (1). A recent study of 13-18 year youths post-mTBI showed that three sessions of 1.5 mA anodal tDCS over the left DLPFC, positively influenced prolonged working memory deficits. (2) Additionally, rodent studies show the effectiveness of tDCS in improving cognitive-motor (motor planning and balance/gait) function in rats with mTBI. (3)
41380686|NCT06138041|DRUG|intravenous lidocaine infusion|Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
41507675|NCT04526847|BEHAVIORAL|Intermittent energy restriction (IER) : 5:2 diet pattern|Participants in the IER group will be provided menus on fasting day that provide \~25% of the individual energy requirement (400 kcal/day for females and 600 kcal/day for males) that means \~75% energy restriction per week (Sundfør et al., 2018; Svendsen, 2018; Templeman, Gonzalez, Thompson, \& Betts, 2020). The recommended fasting day may be on two non-consecutive days (Mondays and Thursdays) per week and remaining five days of the week will be based on the usual diet plan. All participants will be instructed to complete all food by 12 pm and then fast until 8 am the following day (Svendsen, 2018).Thus, the weekly average calorie intake will correspond to \~75% of the normal energy requirements. They will receive a diet plan that recommended \~50 gm protein/day from chicken breast, lean meat, lean fish, fat-free yogurt, cottage cheese, egg or legumes, and vegetables to increase satiety on fasting days.
41507676|NCT04526847|BEHAVIORAL|Continuous energy restricted (CER) group|Participants in the CER group will be advised to reduce total energy intake to 1200-1550 kcal in all seven days a week. They will be provided diet plan calculated in relation to each person's estimated energy requirements. Menus will be divided into breakfast, lunch, dinner, and snacks in line with their individualized energy recommendations. They will be requested to consume \~75% of the individual energy requirements daily (25% energy restriction of calculated baseline energy requirements daily) over six months. Thus, the overall energy restriction will similar between the groups at an estimated reduction of 25% of requirements. Participants will be randomized in a 1:1 ratio, and assigned to an intermittent or continuous energy restriction group randomly.
41507677|NCT00863772|BIOLOGICAL|tanezumab|5 mg dose Intravenously every 8 weeks for duration of study
41165051|NCT02413554|DRUG|Rivastigmine patch|acetylcholine esterase inhibitor
41507678|NCT00863772|BIOLOGICAL|tanezumab|10 mg dose Intravenously every 8 weeks for duration of study
41507679|NCT00863772|OTHER|Placebo|Placebo, Intravenously, every 8 weeks for duration of study
41507680|NCT02671747|BEHAVIORAL|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
41507681|NCT00003183|BIOLOGICAL|filgrastim|
41507682|NCT00003183|DRUG|mitoxantrone hydrochloride|
41165052|NCT01077622|DRUG|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
41165826|NCT02010398|OTHER|Standard-training multiple sclerosis|The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
41165827|NCT03028259|OTHER|lab results|Comparison of lab results
41380687|NCT06138041|DRUG|Saline|Same volume of normal saline in bolus and continuous infusion as lidocaine group.
41380688|NCT01898884|DRUG|VP 20629|
41380689|NCT01898884|DRUG|Placebo|
41380690|NCT04936009|BEHAVIORAL|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
41380691|NCT05035706|PROCEDURE|Biopsy|Undergo biopsy
41380692|NCT05035706|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
41380693|NCT05035706|OTHER|Electronic Health Record Review|Medical records reviewed
41380694|NCT05035706|OTHER|Photography|Photographs taken
41380695|NCT04182412|PROCEDURE|ARD|surgical reconstruction with laparoscopic technique
41380696|NCT06649747|DRUG|AFA-281|A small molecule, orally available
40851636|NCT00794950|DRUG|Sunitinib|"Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.~Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy."
41165053|NCT05475496|OTHER|Measurements of quality of life and burnout|"WHOQOL-Bref questionnaire to assess the health related quality of life of the elderly cardiac patients. WHOQOL-Bref assesses Physical health (7 items), Psychological health (6 items), Social relationships (3 items) and the environment ( 8 items ), in addition to two items asking about overall perception of life and general health. Items are rated on a 5 point ordinal scale, domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life).~Maslach Burnout Inventory questionnaire to measure burnout among caregivers, it includes 3 components: emotional exhaustion (9 items), depersonalization(5items) and personal accomplishment(8 items)."
41380697|NCT04188678|OTHER|Bone Marrow Transplant (BMT)|Bone marrow transplantation will be conducted according to the investigators' institution's standard of care, or else according to research protocol (if applicable).Study visits that include the performance of assessments will occur prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. All dates are +/- 7 days. The initial study visit will take place during standard of care pre-transplant evaluations, which typically span 3-4 days. The post-BMT visits will take place before or after regularly-scheduled BMT follow up.
41380698|NCT06054750|DRUG|Ropivacaine|800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)
41380699|NCT06054750|DRUG|Normal saline|400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)
41380700|NCT04177472|BEHAVIORAL|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
41380701|NCT04177472|BEHAVIORAL|Obesity Prevention Group + Food Boxes|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options. Parents will also be provided with grocery items (fruits, vegetables, meat) prior to each intervention visit to facilitate a healthy family diet.
41380702|NCT04177472|BEHAVIORAL|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
41380703|NCT05329155|DRUG|Heparin Sodium Injection|Heparin Sodium Injection (100U/Kg body weight)
41380704|NCT06651918|BEHAVIORAL|yoga practise|For the experimental study, the researcher will contact the participants to be included in the study and the intervention (yoga group) and control groups will be randomly created. The participants will be informed about the study by the researcher and their voluntary consent will be obtained. The researcher will provide information about the Identifying Characteristics Form for Children Diagnosed with Cancer and Their Families, the Quality of Life Scale for Children (PedsQL) and the Memorial Symptom Assessment Scale to be used in the study. The survey and scales will be applied to each participant individually one day before yoga. Then, the Yoga Group will be applied 3 sessions per week, 3 weeks in a row, each session will be 30 minutes. The researcher will repeat the survey and scale questions that he asked the participants before they started yoga at the end of the 3 weeks.
41380705|NCT06653452|DIAGNOSTIC_TEST|18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan|Patients with Locally Advanced Rectal Cancer underwent 68Ga-FAPI-04 PET/CT and PET/MR scan after injection of 0.02 to 0.04 mCi/Kg×patient weight (Kg). Within 1 week before and after the examination, 18F-FDG PET/CT and PET/MR is completed.
41380706|NCT06653036|PROCEDURE|Dural puncture epidural|The Dural puncture epidural technique is done by assessing the epidural space using the Touhy needle and puncturing the dura matter with a finer needle.
41380707|NCT06653036|PROCEDURE|Standard Epidural Technique|The Standard Epidural Technique is usually performed by identifying the epidural space using the loss of resistance technique and threading the epidural catheter in the epidural space for administration of analgesic drugs.
41380708|NCT06653101|DIETARY_SUPPLEMENT|Probiotic|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8, week 12)
41380709|NCT06653101|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8, week 12)
41380710|NCT05808699|DEVICE|handheld fundus camera|Fundus camera
41380711|NCT05123807|OTHER|Cytoreductive surgery|(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy
41380712|NCT05999747|DRUG|pudexacianinium chloride|Intravenous
41380713|NCT06013462|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK (Descemet Membrane Endothelial Keratoplasty) is a surgical technique used to treat primary or secondary corneal endothelial decompensation.
41380714|NCT04770779|DRUG|Placebo Matching Mitapivat|Tablets
41380715|NCT04770779|DRUG|Mitapivat|Tablets
41507683|NCT04019626|OTHER|Continue-smoking|Ad-libitum use of subjects' usual brand combustible cigarette
41507684|NCT04019626|OTHER|myblu Tobacco 2.5%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 2.5% nicotine
41507685|NCT04019626|OTHER|myblu Tobacco 4.0%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 4.0% nicotine
41507686|NCT04019626|OTHER|myblu Honeymoon 2.5%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine
41507687|NCT04019626|OTHER|myblu Honeymoon 4.0%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine
41380716|NCT06650254|OTHER|Breastfeeding Support Program Structured According to Kolcaba's Comfort Theory|"Stage 1: The Postpartum Breastfeeding Comfort Scale will be applied to mothers before they are admitted to the support program. On the 0th day postpartum, the researcher will go to the mother, baby and father and provide mother-baby skin-to-skin contact and breastfeeding support (Module 1).~Stage 2: The videos aimed at increasing breastfeeding comfort, which were shot for Modules 2, 3, 4 and 5 and transferred to the website, will be watched by mothers and fathers/relatives after discharge. At the same time, online counseling will be provided through the website and support will be provided for applications that will increase breastfeeding comfort.~Stage 3: Mothers who have participated in at least 70% of the breastfeeding support structured according to Kolcaba's Comfort Theory will be called after 6-8 weeks and the Postpartum Breastfeeding Comfort Scale will be applied again and their final tests will be performed."
41380717|NCT04300478|BEHAVIORAL|REx Condition First|REx condition: Participants will complete a whole-body REx workout consisting of 1-set to failure (e.g. RPE of 9-10 on 10-point scale on final reps) on 12 exercises in the Exercise Research Laboratory (located in the CTRC), with a 3-minute rest between exercises. Participants will complete the following exercises: leg press; leg extension; leg curl; hip abduction; hip adduction; chest press; overhead press; seated row; overheard pulldowns and assisted triceps dips on Cybex resistance equipment; barbell calf raises on a Smith machine; and dumbbell biceps curls. Resistance for the REx trial will be determined based on the exercise familiarization session. Specifically, we will target a resistance level needed for each participant to complete \~12-15 repetitions per exercise, using proper form, with an RPE of 9-10 on a 10-point scale on final reps. This protocol eliminates the need for max testing in order to set an exercise protocol off of a specific intensity based on % of 1RM.
41380718|NCT04300478|BEHAVIORAL|Sedentary Control Condition First|Sedentary control condition: Participants will sit quietly in a seated position for the entire duration of this condition.
41380719|NCT06019611|DEVICE|Percutaneous epidural stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
41380720|NCT06358157|DEVICE|Ladera LBC System|Use of the Ladera LBC System to close the femoral arteriotomy
41380721|NCT06307652|DRUG|balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
41380722|NCT06307652|DRUG|balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
41380723|NCT06307652|DRUG|dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin|1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
41380724|NCT04692103|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
41380725|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
41380726|NCT04692103|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
41380727|NCT04692103|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
41380728|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
41380729|NCT04692103|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
41380730|NCT04692103|OTHER|Laboratory Biomarker Analysis|Correlative studies
41380731|NCT06213961|OTHER|pecha kucha education|Basic life support training to be given to students will be given by the pecha kucha presentation method.
41380732|NCT02867592|DRUG|Cabozantinib|Given PO
41380733|NCT02867592|DRUG|Cabozantinib S-malate|"Given PO~Note: Capsule formulation (Cometriq) not used in this trial."
41380734|NCT02867592|OTHER|Pharmacological Study|Correlative studies
41380735|NCT05861453|DRUG|Epeleuton|Participants will receive 2000mg Epeleuton (DS102) capsules twice daily.
41380736|NCT06651528|BEHAVIORAL|TBRI|The adapted TBRI WRA (Prison Only Component) will consist of an individual introductory module (1 hour) and a series of group modules (a minimum of 4 sessions, approximately 1-2 hours in length, delivered over the course of 3 months, with the final number and frequency to be determined in R61) focused on the core components of TBRI. The original TBRI approach includes a focus on group skills training; similarly, it is anticipated that R61 phase adaptations will meet the need for tailored skills training reflected by anticipated differences in the target population of women - including how their early attachment and trauma histories influence their current self-image and behavior (which likely has a tremendous impact on their relational attachments as adults). Group sessions will provide opportunities to build skills for regulating emotions and building healthy connections.
41380737|NCT06651528|BEHAVIORAL|TAU + TBRI + Re-entry Recovery Support|This condition includes the proposed adapted TBRI as well as on-going re-entry recovery support with the Safe Support Person (SPP). The SSP will be identified by the study participant as someone who will provide prosocial support during re-entry (e.g., support towards abstinence, establishing healthy recovery support relationships, rebuilding relationships with family and children) and in most cases will involve a close family member (mother, grandmother) or friend at the woman's identified home placement. This individual will be identified by the study participant as someone who is not involved in active substance use nor has a current legal system status (e.g., on probation).
41507688|NCT04019626|OTHER|JUUL 5%|Ad-libitum use of JUUL 5% e-cigarette
41507689|NCT03680612|DRUG|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Experimental drug
41507690|NCT03680612|DRUG|cefepime 1 g or cefepime 2 g|cefepime monotherapy
40851637|NCT05767060|DRUG|BAT7104 injection|According to the protocol, each dose group is given intravenous infusion at the rate of mg/kg, and the recommended infusion time is ≥ 60 minutes. Once every two weeks (Q2W), on the first day of each cycle.
41165054|NCT00931008|DRUG|SID530, Taxotere|75mg/m2
41035136|NCT03322865|DRUG|Obinutuzumab|"Induction:~Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15\*~\*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.~Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance~Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:~Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity"
40851638|NCT04924270|BIOLOGICAL|Faecal microbiota transplantation|The capsule FMT transplant consists of faeces obtained from a thoroughly screened, unpaid, anonymous stool donor. Each FMT product is made from 50g faeces diluted in sterile saline (0.9% NaCl) and glycerol, blended, centrifuged and filtered to remove particulate material before transfer to double-layered capsules. The FMT capsules will be stored at - 80 ⁰C until use. On the day of the FMT, the FMT capsules will be thawed to room temperature before treatment.
41035137|NCT00127075|DRUG|nomegestrol acetate|10 mg/day
41035138|NCT00127075|DRUG|estradiol|75 mcg, once a week
41035139|NCT00127075|DRUG|placebo|matching placebo treatments
41035140|NCT01228162|PROCEDURE|effect of muscle relaxation on muscle trauma, control group without relaxation|effect of muscle relaxation on muscle trauma, control group without relaxation
41035141|NCT03776136|DRUG|lenvatinib|Administered orally once a day during each 21-day cycle.
41035142|NCT03776136|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
41035143|NCT06436404|OTHER|Hammock intervention|It is a hammock made of 100% cotton fabric that prevents heat loss and has an internal apparatus to support the position, which can be adapted to the incubator by the researchers.
41035144|NCT06436404|OTHER|Kangaroo care intervention|In the clinic, the baby will receive kangaroo care with his mother in a quiet room with reduced lighting.
41035145|NCT01817049|BEHAVIORAL|HAPA-based coach education workshop|A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
41035146|NCT01817049|BEHAVIORAL|placebo attention control|
41380738|NCT06651528|OTHER|Treatment as Usual (TAU)|Women in the TAU condition will not receive TBRI intervention services, but will receive traditional in-prison SUD treatment over 6 months as usual in the four targeted prison sites. The programs are separate units with the prisons and emphasize participation by all program members in the overall goal of addressing substance use and criminal thinking. Although trauma and violence are addressed as part of the holistic group process approach in these programs, these topics are not addressed from an on-going systematic or relational perspective and are not specifically addressed as part of re-entry planning.
41380739|NCT06006416|DRUG|Fenugreek Fibre|Daily dose of 2 x 10g per day with/in food
41380740|NCT06649903|BEHAVIORAL|Chiropractic|high speed low amplitude neck manipulation
41380741|NCT06649903|BEHAVIORAL|Osteopathy|the stomach and liver technique was applied
41380742|NCT06574386|DIAGNOSTIC_TEST|Neurodevelopmental assessment|Neurodevelopmental assessment
41507691|NCT04306536|DIETARY_SUPPLEMENT|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
40851639|NCT04924270|OTHER|Placebo|Placebo capsules consist of NaCl (0.9%) and glycerol added brown food colouring.
40851640|NCT00520156|DEVICE|Continuous positive airway pressure (CPAP)|Patients diagnosed with obstructive sleep apnea (OSA) will be offered standard of care treatment of CPAP (patients given oral appliances for OSA are excluded from our study). Note: our study is a survey-based and observational study following patients who are being evaluated for sleep disorders. Those patients diagnosed with OSA would be offered CPAP or possibly an oral appliance regardless of whether they are entered into our study or not.
40851641|NCT03203434|DIAGNOSTIC_TEST|Urinary volatile organic compound analysis|
40851642|NCT01609881|DRUG|Acuvail|Dosing of drug 3 days prior to surgery
40851643|NCT01609881|OTHER|Placebo|Artificial tears qid for 3 days preoperatively
40851644|NCT03010280|DIETARY_SUPPLEMENT|Immunonutrition|Balanced high-protein formula enriched with Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
40851645|NCT03010280|DIETARY_SUPPLEMENT|Balanced high-protein formula|Balanced high-protein formula, without Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
41035147|NCT06634797|BIOLOGICAL|mRNA-1273.712|Intramuscular (IM) injection.
41035148|NCT06634797|BIOLOGICAL|Placebo|Sodium chloride for IM injection.
41035149|NCT02247505|DRUG|Harnal-D Cap. 0.2mg|
41035150|NCT02247505|DRUG|Cialis Tab. 5mg|
41035151|NCT03972488|DRUG|Lutathera|Lutathera is a sterile radiopharmaceutical supplied as a ready-to-use solution for infusion containing 177Lu-DOTA0-Tyr3-octreotate as a drug substance with a volumetric activity of 370 MBq/mL at reference date and time (calibration time). Each Lutathera infusion continued for 30 min.
41165828|NCT01127321|OTHER|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
41165829|NCT01127321|BIOLOGICAL|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
41165830|NCT01127321|BIOLOGICAL|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
41165831|NCT01127321|BIOLOGICAL|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
41380743|NCT06620016|DIAGNOSTIC_TEST|Circulating microRNAs.|Pre and post-surgery evaluation of peripheral blood circulating microRNAs levels.
41507692|NCT04036838|COMBINATION_PRODUCT|PyloPlus UBT System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
41380744|NCT01175408|OTHER|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
41035152|NCT03972488|DRUG|30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)|"Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes."
41165055|NCT02928809|DEVICE|low-level laser therapy|Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
40851646|NCT03191045|DIAGNOSTIC_TEST|MRI and concomitant perfused manometry of bowel motility|We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.
40851647|NCT00601549|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery
40851648|NCT00601549|PROCEDURE|Traditional open surgery|Open surgery
40851649|NCT01266590|DRUG|LY2216684|Administered orally
41165832|NCT01127321|BIOLOGICAL|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
40851650|NCT01266590|DRUG|Digoxin|Administered orally
40851651|NCT02241343|DEVICE|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
40851652|NCT02562859|DRUG|500 mg GLPG1837 as oral suspension|A single dose of 500 mg GLPG1837 administered as oral suspension
40851653|NCT02562859|DRUG|500 mg GLPG1837 as oral tablet|A single dose of 500 mg GLPG1837 administered as oral tablet
40851654|NCT00214916|DRUG|intensive insulin therapy (Actrapid IV to normoglycemia)|intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
40851655|NCT00214916|DRUG|conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)|conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
41035153|NCT03972488|DRUG|2.5% Lys-Arg sterile amino acid solution|Participants who received Lutathera were administered a concomitant 2.5% Lys-Arg solution for kidney protection, with each Lutathera dose. The 2.5% Lys-Arg solution was administered intravenously for 4 hours (infusion rate: 250 ml/h); the infusion was to start 30 minutes prior to the start of the Lutathera infusion and continue during (30 min) and up to at least 3 hours after the Lutathera infusion.
41507693|NCT04036838|DIAGNOSTIC_TEST|Histology|Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist
40851656|NCT04264364|PROCEDURE|Laparoscopic sleeve gastrectomy|Bariatric surgical intervention
40851657|NCT04264364|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic bariatric procedure
40851658|NCT05467176|DRUG|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
41380745|NCT01175408|OTHER|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
41380746|NCT01175408|OTHER|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
41507694|NCT04036838|DIAGNOSTIC_TEST|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
41507695|NCT04036838|DIAGNOSTIC_TEST|H.pylori Culture|Biopsy specimen obtained and sent to lab for culture analysis
41507696|NCT04682925|OTHER|skin care arm of where evidence-based practices in the implementation guide|"1. The nasal mucosa and nasal skin under the nasogastric tube will be cleaned and dried twice a day with a pH-compatible cleanser.~2. A water-based moisturizing cream will be applied to the nasal skin under the nasogastric tube twice a day, after care with a pH-compatible cleanser.~3. Spray skin barrier will be applied twice a day after applying water-based moisturizing cream to the nasal skin under the nasogastric tube.~4. The nasal mucosa and nasal skin under the nasogastric tube will be evaluated twice daily for signs of pressure-related injury. All these care interventions applied to the skin care arm will be applied together with the doctor and nurse responsible for the treatment and care of the patient."
41507697|NCT04682925|DEVICE|hydrocolloid (Convatec Granuflex-extra thin) dressing|The nasal skin of the patients and the surrounding skin will be cleaned with a pH-compatible cleaner, dried and a new hydrocolloid cover will be applied once a day. All these care interventions applied to the hydrocolloid dressing arm will be applied together with the physician and nurse responsible for the treatment and care of the patient.
41380747|NCT01175408|OTHER|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
41507698|NCT04682925|OTHER|control|In routine care, the skin under the nasogastric tube is evaluated once a day for redness and wound formation by the nurse responsible for the patient's care and is cleaned and dried with appropriate cleaners.
41507699|NCT00581165|DRUG|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
41507700|NCT03083652|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus
41507701|NCT03083652|OTHER|Sham|Conventional physiotherapy with NMES device NOT activated
41507702|NCT00817518|DRUG|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
41507703|NCT00817518|DRUG|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
41507704|NCT05509517|DIAGNOSTIC_TEST|Photoplethysmography based smartphone application for heart rhythm analysis (FibriCheck™)|Heart Rhythm assessment using the FibriCheck™ application with the patient's proprietary smartphone, three times daily, from discharge until follow-up consultation (day 21-91 after discharge).
41507705|NCT01601340|DRUG|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
41507706|NCT01601340|DRUG|Placebo|Placebo tablets, twice daily for 48 weeks
41507707|NCT06353347|DRUG|HTD1801|HTD1801 1000 mg administered orally BID as four capsules
41507708|NCT06353347|DRUG|Placebo|Matching placebo administered orally BID as four capsules
41507709|NCT00399633|DRUG|sumatriptan|
41507710|NCT03051477|DRUG|Helixor® M|3-hour IV infusion on Monday, Wednesday, and Friday of each week.
40851659|NCT04541511|DIAGNOSTIC_TEST|6-minutes walking test on a corridor|6-minutes walking test on a corridor : patient will be asked to achieve the longest possible distance without running. He/she will be allowed to take breaks if he/she feels the need to do so.
40851660|NCT04541511|DIAGNOSTIC_TEST|6-minutes walking test on a treadmill|6-minutes walking test on a treadmill : patient will be asked to achieve the longest possible distance without running on the treadmill. He/she will be allowed to take breaks if he/she feels the need to do so.
41165056|NCT02928809|OTHER|Placebo comparator|The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
41380748|NCT03729830|DEVICE|Boston Scientific Open Irrigated Ablation Catheters|The BSC Open-Irrigated catheters are designed to deliver RF energy to catheter tip electrode for cardiac ablation. The BSC OI catheters incorporate an open-irrigated cooling mechanism through a tip that is partitioned into two chambers. The proximal chamber circulates normal saline (0.9 %) within the tip to cool the proximal electrode and mitigate overheating while the distal chamber allows the fluid to flow through six irrigation holes into the patient's vasculature, thereby cooling the tip/tissue interface.
41380749|NCT03197506|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
41380750|NCT03197506|OTHER|Laboratory Biomarker Analysis|Correlative studies
41507711|NCT04191850|PROCEDURE|Single Port Video-Assisted Thoracoscopic Surgery|Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
41507712|NCT01105793|DRUG|Danazol|High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
41380751|NCT03197506|BIOLOGICAL|Pembrolizumab|Given IV
41380752|NCT03197506|RADIATION|Radiation Therapy|Undergo radiation therapy
41380753|NCT03197506|DRUG|Temozolomide|Given PO
41380754|NCT03197506|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41507713|NCT03098082|DEVICE|Actim Pancreatitis|Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
41507714|NCT04898452|OTHER|A new model of interaction across health services with use of welfare technology and telemedicine|Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
41507715|NCT05456490|DRUG|Liposomal Bupivacaine 13.3|Injection into the Intrathecal space
41380755|NCT04512976|OTHER|Control (no cooling modalities)|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.
41380756|NCT04512976|OTHER|Water Spray Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the skin wetting modality.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
41380757|NCT04512976|OTHER|Fan Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the fan cooling modality.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout."
41380758|NCT04512976|OTHER|Water Spray and Fan|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
41380759|NCT06652113|DRUG|hydroxychloroquine and levothyroxine|Hydroxychloroquine sulfate tablets (Fenle, 0.1g) will be given at a total daily dose of 0.2g to 0.4g based on individual weight as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
41380760|NCT06652113|DRUG|Levothyroxine|Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
41380761|NCT06465368|DRUG|PF-07220060|PF-07220060 given as tablet by mouth twice a day for 14 days.
41380762|NCT06465368|DRUG|letrozole|Letrozole given as tablet by mouth once a day for 14 days
41380763|NCT06653725|DIETARY_SUPPLEMENT|1,3-butanediol|1,3-butanediol (Ketone-IQ®) 118 mL (33 g) servings trice daily
41380764|NCT06653725|DIETARY_SUPPLEMENT|Placebo|Taste-matched placebo (isovolumic, isoviscous water with stevia) 118 mL servings trice daily
41380765|NCT03795298|DEVICE|WATCHMAN FLX Implant|Left atrial appendage closure with the WATCHMAN FLX device
41380766|NCT03795298|DRUG|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
41380767|NCT01565655|DRUG|peficitinib|oral
40851661|NCT02843672|PROCEDURE|Triple Weil´s Osteotomy|"A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.~Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture."
41035154|NCT03972488|DRUG|High dose 60 mg octreotide long-acting repeatable|"Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes."
41380768|NCT01565655|DRUG|Placebo|oral
41380769|NCT05870566|DEVICE|Corneal Crosslinking|"Riboflavin isotonic, 0,1 % Vitamin B2, with Dextran 20,0%, for epi-off procedure or Riboflavin isotonic 0,1% (Vitamin B2), 1,1% HPMC without Dextran for epi-off) 0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2. This dose, mode and scheme of the intervention follows the internationally recognized accelerated CXL protocol (Elbaz et al. 2014). The data existing shows equivalent outcome regarding efficacy and safety compared to the standard protocol. To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device (with maximal diameter of 11 mm) will be used. Furthermore, the limbal area will additionally be protected by a custom-cut LSC protection shield. (Protocol V04_0 Page 45-46)"
41380770|NCT06572449|DRUG|KarXT|Specified dose on specified days
41380771|NCT01898117|DRUG|Carbo/cyclo|
41507716|NCT05456490|DRUG|Bupivacaine|Injection into the Intrathecal space
41507717|NCT05456490|OTHER|Placebo|Injection into the Intrathecal space
41507718|NCT04627428|BIOLOGICAL|RPESC-RPE-4W|RPESC-RPE-4W
41507719|NCT05105152|BIOLOGICAL|SC-DARIC33|Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration
41507720|NCT01362543|OTHER|Cognitive behavioural therapy (stress management)|Following a manual
41507721|NCT01362543|OTHER|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
41507722|NCT05391386|PROCEDURE|modified bonding technique|adding a layer of compomer adhesive at the molar/tube interface.
41165057|NCT02369588|OTHER|Food portion size|
41165058|NCT00726388|DRUG|DIC075V (intravenous diclofenac sodium)|multiple doses up to 5 days
41380772|NCT01898117|DRUG|Carbo/cyclo + atezolizumab|
41380773|NCT01898117|DRUG|Paclitaxel|
41507723|NCT01162707|DEVICE|CardioMEMS HF Pressure Measurement System|Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure
41507724|NCT06468241|OTHER|Progressive relaxation exercise|For the progressive relaxation exercise group, a progressive relaxation exercise session will be applied to the participants 3 times a week for four weeks.
41507725|NCT06468241|OTHER|Listening to music|"For the music listening group, the participants will listen to the Turkish music makams (uşşak and rast) three times a week for four weeks."
41507726|NCT02255383|DEVICE|Zimmer Persona Total Knee System|Primary Total Knee Arthroplasty
41507727|NCT01932866|OTHER|diabetic risk score|
41507728|NCT02770898|BEHAVIORAL|Family Holistic Health|Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).
41507729|NCT03022097|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
41380774|NCT01898117|DRUG|Paclitaxel + Atezolizumab|
41380775|NCT05312801|DRUG|BAFF CAR-T|Autologous CAR-T cell therapy expressing the BAFF-ligand.
41380776|NCT05227937|DRUG|Amikacin|patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients \>120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
41380777|NCT04753879|DRUG|Nab-paclitaxel|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Abraxane"
41380778|NCT04753879|DRUG|Gemcitabine|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Gemzar"
41380779|NCT04753879|DRUG|Cisplatin|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
41380780|NCT04753879|DRUG|Irinotecan|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
41380781|NCT04753879|DRUG|Capecitabine|"1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~3. Other Name: Xeloda"
41380782|NCT04753879|DRUG|Pembrolizumab|"1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~3. Other Name: MK-3475; Keytruda"
41380783|NCT04753879|DRUG|Olaparib|"1. Patients will receive treatment on Days 1-21 during the maintenance phase.~2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~3. Other Name: Lynparza"
41380784|NCT04175912|DRUG|Carboplatin|Given IV
41380785|NCT04175912|DRUG|Paclitaxel|Given IV
41380786|NCT04175912|DRUG|Pevonedistat|Given IV
41380787|NCT04007393|BEHAVIORAL|Lifestyle Modification Therapy (LSMT)|LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase. Each session will last 30-60 minutes. A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction. Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
41380788|NCT04007393|DRUG|Phentermine Pill|Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment. Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss. Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
41380789|NCT04007393|DRUG|Topiramate Pill|Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48. At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
41035155|NCT06489613|DIAGNOSTIC_TEST|M protein detection by iMS-LC Assay|"iMS-LC Assay (intact M-protein Screening-Light Chain Assay) technology is a new method for the specific identification of M-proteins in peripheral blood, based on mass spectrometry recognition of intact clonal immunoglobulin light chains. Combined with AI algorithm models, M-proteins can be easily distinguished from the polyclonal background, enabling automated identification and quantitative analysis of M-proteins.~Previous studies have shown that the detection limit of the iMS-LC Assay is several times higher than that of IFE. Additionally, the iMS-LC Assay requires only 5 μL of peripheral blood serum for detection, offering advantages over traditional methods in terms of higher sensitivity, non-invasiveness, lower sample volume requirements, reduced detection costs, and higher throughput."
41035156|NCT06389604|OTHER|Heat acclimation|Daily repeated heat exposure to assess the effects of combined passive and active heat acclimation
41035157|NCT05727605|BEHAVIORAL|Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test|"Primary brain tumour patients will be evaluated longitudinally at the following timepoints: baseline (minimal 4 weeks after surgery, before radiotherapy), three months after end of radiotherapy, 1 year after end of radiotherapy and 2 years after end of radiotherapy. At each visit, neurocognitive testing, a self-report inventory and/or advanced MR imaging will take place.~Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy"
41035158|NCT05727605|DIAGNOSTIC_TEST|MRI|"Advanced MRI: all participants will be scanned on a 3T Siemens of Philips MR scanner (multicenter protocol): MPRAGE, FLAIR, T2, DWI, rsfMRI, SWI \& ASL~Time points: baseline, 3 months post-radiotherapy and 12 months post-radiotherapy"
41035159|NCT05727605|BEHAVIORAL|Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI|Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy
41035160|NCT05727605|OTHER|Toxicity scoring|During and after radiotherapy and at at the end of the study, adverse events will be monitored using CTCAEv5.0.
41380790|NCT02435615|DEVICE|SaniSal Oral Fluid Collector|SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
41380791|NCT06592794|BIOLOGICAL|mRNA-1403|Intramuscular (IM) injection.
41380792|NCT06592794|BIOLOGICAL|Placebo|0.9% sodium chloride solution by IM injection.
41507730|NCT03022097|DRUG|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
41507731|NCT03022097|DRUG|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
41507732|NCT03022097|DRUG|Placebo|Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
41507733|NCT00269984|DRUG|Epoetin alfa|
41035161|NCT06636240|DIETARY_SUPPLEMENT|Mulberry fruit juice|Mulberry fruit juice 200ml/day plus standard therapy for atopic dermatitis including Fluticasone and Prednisolone
41507734|NCT02845700|BEHAVIORAL|Perceptual Retraining Treatment|"Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor)."
41507735|NCT02845700|BEHAVIORAL|Sham Neutral training|Control condition using systematic presentation of diluted neutral-neutral odor pairs.
41507736|NCT04108026|DRUG|Durvalumab|1500 mg IV every 4 weeks
41507737|NCT00766779|PROCEDURE|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
41507738|NCT00766779|DRUG|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
41507739|NCT00596076|BEHAVIORAL|Back School|"All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month."
41507740|NCT01288404|DRUG|Fluorometholone|topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
41507741|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 1.25 mg/0.05mL
41507742|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 2.5 mg/0.1mL
41507743|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 3.75 mg/0.15mL
41507744|NCT03689465|DRUG|ATG|In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
41507745|NCT03689465|DRUG|CTX|In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
41035162|NCT06636240|OTHER|Fluticasone|Standard therapy for atopic dermatitis including Fluticasone and Prednisolone
41035163|NCT00179465|DRUG|Tiagabine|Up to 36 mg daily
41035164|NCT00179465|DRUG|Placebo|Placebo
41035165|NCT06634992|OTHER|Oral immunotherapy|Clinical Follow up
41035166|NCT03273439|DEVICE|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
41035167|NCT03273439|DEVICE|Sham rTMS|Sham rTMS, without stimulation
41035168|NCT04520984|OTHER|Integrated ambulatory palliative and nephrology care|"Monthly ambulatory care visits with the kidney palliative care team in the intervention group for three months.~The intervention in this study is addition of a palliative care team to the care team of the subject. This intervention will not change or impact their regular nephrology care. The subjects in the intervention arm will be seen by the palliative care team three times over the 12-week study period (once per month).The intervention will be delivered by a physician trained in both palliative care and nephrology, the PI of the study."
41035169|NCT04520984|OTHER|Standard nephrology care|Standard nephrology care
41035170|NCT05222919|DIETARY_SUPPLEMENT|Bare performance supplement|dietary supplement
41507746|NCT03689465|DRUG|Mycophenolate Mofetil|In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.
41035171|NCT05222919|DIETARY_SUPPLEMENT|Placebo|Placebo
41035172|NCT05053087|DRUG|Ropivacaine Continuous Infusion|0.2% continuous infusion 6mL/hr
41035173|NCT05053087|DRUG|Ropivacaine Intermittent Bolus|0.2% intermittent bolus infusion 8mL every 2 hours
41035174|NCT05053087|DRUG|Placebo|Saline filled catheter
41035175|NCT03876067|DRUG|Ozone|"Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:~50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).~At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution"
41035176|NCT03876067|DRUG|Cardioplegic Solutions|in which in which only cold blood cardioplegia
41035177|NCT06283550|DRUG|Abrocitinib 200 mg|Abrocitinib will be available in 100 mg strength tablet
41035178|NCT06283550|DRUG|Abrocitinib 100 mg|Abrocitinib will be available in 100 mg strength tablet
41035179|NCT06283550|DRUG|Placebo|Placebo tablet
41165833|NCT04257747|OTHER|MRI acquisitions|MRI acquisitions will be performed on the ACHIEVA 3T TX DStream Philips® Research MRI of the GIE Faire Faces.
41507747|NCT03689465|DRUG|Ciclosporin A (CsA)|In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.
41507748|NCT03689465|DRUG|methotrexate (MTX)|In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.
41507749|NCT04379791|OTHER|Data collection from routine medical records|Data collection from routine medical records for criteria for fracture related infections (FRI) and for wound complications. Data collection from routine medical records for risk factors.
41507750|NCT00997867|PROCEDURE|Sciatic catheter left 0-1cm past needle tip vs. 5-6cm past needle tip|Patients undergoing orthopedic surgery who are getting a perineural catheter will be randomized to one of two groups: catheter tip placed 0-1cm past needle tip or catheter tip placed 5-6cm past needle tip. Patients will be called by research staff the day following surgery to assess their post-surgical pain using a numeric rating scale.
41507751|NCT04899544|BEHAVIORAL|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|Pivotal Response Treatment in autism center.
41507752|NCT04899544|BEHAVIORAL|Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)|Pivotal Response Treatment in home environment.
41507753|NCT03357744|OTHER|distress barometer|not applicable, observational study
41507754|NCT02964572|DRUG|Glimepiride|In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
41507755|NCT02964572|DRUG|Empagliflozin|Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.
41507756|NCT01437930|DIETARY_SUPPLEMENT|n-3 PUFA|"products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder~1. linseed oil (20g/d)(PPM, Magdeburg)~2. echium oil (20g/d) (HARKE Nutrition)~3. microalgae powder(12g/d)(HARKE Nutrition)"
41507757|NCT03555110|BEHAVIORAL|Personality Factor Battery Test (PFB Test)|Psychological instrument built for personality evaluation from the model of the Five Great Factors (FGF), that includes the following dimensions: Neuroticism, Extroversion, Socialization, Effort / Commitment), focusing on the component of the aspects of Neuroticism.
41507758|NCT03555110|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy (EMDR)|"It is a psychotherapeutic approach effective on treatment for trauma and post-traumatic stress disorder. It is an intervention that allows the desensitization of negative emotions from traumatic experiences.This therapy modifies memories that have been processed non-adaptively and become painful and dysfunctional memories. During the procedure, the patient is encouraged to move the eyes from side to side, associating these movements with a target situation, previously defined at the beginning of the session. The ocular movements can be replaced by tactile or sonorous stimuli. The series of stimuli must continue until the memory of the traumatic event can be reprocessed adaptively, that is, without the emotional, negative or painful process associated with that memory."
41507759|NCT06547996|DEVICE|tES-tDCS group|2mA/20mins/session
41507760|NCT06547996|DEVICE|tES-tACS group|2mA/40Hz/20mins/session
41507761|NCT06547996|DEVICE|tES-sham group|0mA/20mins/session
41507762|NCT03364946|OTHER|No intervention|No intervention, observational study
41507763|NCT05551871|DRUG|Simvastatin|the patient will receive Simvastatin for 7 days
41035180|NCT02286544|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi®)|A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
41380797|NCT06048198|OTHER|No intervention|No intervention
41380798|NCT06306573|DEVICE|CardioMEMS HF System|The CardioMEMS HF System provides pulmonary artery (PA) hemodynamic data to monitor and manage HF subjects. The CardioMEMS HF System measures PA pressure which clinicians use to initiate or modify HF treatment.
41380799|NCT06651710|OTHER|Zynamite|Two doses of Mangifera indica leaf extract in its soluble form, Zynamite® S, 100 mg of which 60 mg is mangiferin and 150 mg of which 90 mg is mangiferin, will be tested against a placebo. On the day of the test, the supplements will be administered 30 minutes before the start of the test. The supplements or placebo will be administered in cellulose capsules or similar and accompanied by a glass of water.
41380800|NCT06652360|DEVICE|Chemical Debridement|The chemical debridement is a dehydrating agent in a gel shape that will dry out the woundbed and biofilm.
41380801|NCT06652360|DEVICE|Curettage debridement|The use of a currette will clean the wound bed. Debridement by mechanically removing the necrotic tissue and biofilm. This is performed confrom the standard of care standards.
41507764|NCT05551871|DRUG|Placebo drug|the patient will receive Placebo drug for 7 days
41507765|NCT06038318|BEHAVIORAL|PRISM Program Video Coach|A 6-session, skills-based, manualized resilience education program delivered via video coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by a HIPAA compliant videoconferencing platform, Zoom, approximately every 1-2 weeks based on participant preference. For participants who do not have smartphones, temporary equipment will be provided.
41507766|NCT06038318|BEHAVIORAL|PRISM Program Text Coach|A 6-session, skills-based, manualized, resilience education program delivered via text coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by HIPAA compliant SMS text-messaging service, Zoom, approximately every other week. For participants who do not have smartphones, temporary equipment will be provided.
41380802|NCT06470087|DEVICE|SOC and Type-I Collagen-based Skin Substitute|Arm 1 -The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
41035181|NCT02286544|DRUG|Oxygen (Oxymask®)|"As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry.~Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended."
41380803|NCT06470087|OTHER|SOC and Human Amnion/Chorion Membrane|Arm 2: The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
41380804|NCT06418932|DEVICE|UrgoK2 / UrgoK2 Lite|Multicomponent compressive bandage system consisting of an internal bandage of short traction and an external cohesive bandage of long traction, with pressure indicators on both bandages, which provides a sustained ankle pressure of \~20/40mmHg.
41380805|NCT06418932|OTHER|Controll|Administration of parenteral diuretics only
41380806|NCT05308654|DRUG|ABBV-453|Oral; Tablet
41380807|NCT05308654|DRUG|Dexamethasone|Oral Tablet
41380808|NCT05308654|DRUG|Daratumumab|Subcutaneous Injection
41380809|NCT05308654|DRUG|Lenalidomide|Oral Capsule
41380810|NCT01371981|DRUG|Asparaginase|Given IM
41380811|NCT01371981|DRUG|Bortezomib|Given IV
41380812|NCT01371981|DRUG|Cytarabine|Given IT or IV
41380813|NCT01371981|DRUG|Daunorubicin Hydrochloride|Given IV
41380814|NCT01371981|DRUG|Etoposide|Given IV
41380815|NCT01371981|OTHER|Laboratory Biomarker Analysis|Correlative studies
41507767|NCT06038318|BEHAVIORAL|mPRISM Program App|6 static modules to practice skills-based, manualized, resilience education program delivered via PRISM Program mobile app. For participants who do not have smartphones, temporary equipment will be provided.
41507768|NCT06550232|DRUG|Papaverine|Within 30-minutes prior to catheter insertion, women in the intervention group will receive IV-papaverine 80 mg in 100 ml 0.9% saline
41507769|NCT06550232|OTHER|placebo|I.V Sallne
41507770|NCT04258462|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
41507771|NCT04258462|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41507772|NCT04258462|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
41507773|NCT00080873|DRUG|Traumeel S|
41165834|NCT04257747|OTHER|Doppler ultrasound procedure|The Doppler ultrasound procedure will be conducted in the traditional way in the Vascular Medicine Department of the Amiens-Picardie University Hospital
41507774|NCT00080873|OTHER|Placebo|
41507775|NCT06304246|OTHER|Measurement Pain Threshold|Measurement Pain Threshold: Manual dolorimetry will be used to assess the pain threshold in the non-dominant hand of patients in the preoperative waiting room prior to spinal anesthesia. The dolorimeter head will be placed vertically on the wrist of the non-dominant hand, and pressure will be applied with increments of 1 kg/cm2/s. The pressure applied when the patient perceives pain will be recorded in kg/cm2. The measurement will be repeated three times for each patient, and the average will be recorded as the pain threshold value.
41165835|NCT01673295|DRUG|RTX infusions|RTX + Standard of Care
41165836|NCT01673295|OTHER|Standard of Care|Standard of Care only
41380816|NCT01371981|DRUG|Mitoxantrone Hydrochloride|Given IV
41380817|NCT01371981|OTHER|Pharmacological Study|Correlative studies
41380818|NCT01371981|OTHER|Quality-of-Life Assessment|Ancillary studies
41380819|NCT01371981|OTHER|Questionnaire Administration|Ancillary studies
41380820|NCT01371981|DRUG|Sorafenib Tosylate|Given PO
41380821|NCT06652724|BEHAVIORAL|Dynamic interpersonal therapy (DIT)|"Dynamic interpersonal therapy (DIT) is a dynamically oriented brief psychotherapeutic intervention based on attachment and mentalization theory that views symptoms of depression and anxiety as responses to interpersonal difficulties.~This intervention helps patients to understand the connection between their symptoms and their relationships by identifying a core, non-conscious, repetitive pattern of relating. Previous studies have shown positive results: significant reductions have been observed for the variables somatic symptom severity, depression, anxiety, and general psychiatric symptoms.~It consists of 16 sessions (one per week) for a total of 4 months."
41380822|NCT06652724|BEHAVIORAL|technique of expressive writing (TSE)|"The expressive writing technique created by Pennebaker has shown beneficial health effects in different contexts since, through writing, it is possible to mentally reorganize a difficult event, allowing the mind to find meaning to what has happened or is happening. This technique can be a resource that can promote activation from the ability to recognize, express, and process the unspoken emotional, psychological, and relational, helping to achieve emotional and physiological feedback. Although the application of expressive writing in patients with fibromyalgia is an under-explored area of investigation in the international literature, several studies have shown its effectiveness in some chronic syndromes.~It consists of 8 meetings (one every fortnight) for a total of 4 months."
41380823|NCT06652724|OTHER|Treatment as Usual (TAU)|The usual treatment involves two contacts by a rheumatologist/neurologist (depending on the clinical condition of the patient) during a four-month period, lasting about 10-15 minutes each, in which patients will be followed up medically. This treatment represents the active control group, planned to monitor specific aspects of the psychotherapeutic intervention, which aims to equate a good standard of primary care.
41380824|NCT04739059|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
41380825|NCT06653530|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed using polyglycolic acido thread. Needles have a gauge size of 23G, a shaft length of 60mm, and a thread length of 50mm, folded in half, and are applied to fourteen acupoints, including Zhongwan (CV12), Qihai (CV6), bilateral Tianshu (ST 25), bilateral Wailing (ST 26), bilateral Daheng (SP 15), bilateral Zusanli (ST 36), bilateral Pishu (BL 20), and bilateral Weishu (BL 21). After the thread is inserted into the body, the needle will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
41380826|NCT06653530|OTHER|Sham thread embedding acupuncture|The protocol includes the same duration and frequency of sessions as for thread embedding acupuncture, but the treatment will be delivered superficially at non-acupuncture points 10mm from the lateral of the corresponding acupuncture and not above a meridian line. Needles without threads have a gauge size of 23G, and a shaft length of 60mm will be used. After the needle is inserted into the body, it will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
41380827|NCT05371093|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
41380828|NCT05371093|DRUG|Cyclophosphamide|Administered intravenously
41380829|NCT05371093|DRUG|Fludarabine|Administered intravenously
40851662|NCT02843672|PROCEDURE|Distal metatarsal minimally invasive osteotomy|A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.
41380830|NCT05371093|DRUG|Lenalidomide|Administered orally
41380831|NCT05371093|DRUG|Rituximab|Administered intravenously
41380832|NCT05371093|DRUG|Doxorubicin|Administered intravenously
41507776|NCT06304246|OTHER|Measurement of Serum Asprosin|Measurement of Serum Asprosin: For serum asprosin measurements, blood will be drawn in the preoperative waiting room before the application of spinal anesthesia. The blood samples will be centrifuged, and the serum will be stored at -20°C to measure serum asprosin levels. After all patient blood is collected, serum asprosin will be evaluated with a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
40851663|NCT03680183|DRUG|Entecavir 1Mg Oral Tablet|The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
40851664|NCT01913002|DRUG|LX4211 800 mg|
41507777|NCT04385121|OTHER|Questionnary|Family member's will answer the questionnaires by phone
41507778|NCT05432661|DEVICE|HİGH-FLOW NASAL OXYGEN USE (HFNO)|It is aimed to show that the use of HFNO can improve oxygenation compared to the use of nasal cannula in ERCP procedures performed under sedation in the prone position.
41380833|NCT05371093|DRUG|Vincristine|Administered intravenously
41380834|NCT05371093|DRUG|Prednisone|Administered orally
40851665|NCT01913002|DRUG|LX4211 2000 mg|
40851666|NCT01913002|DRUG|moxifloxacin 400 mg|
40851667|NCT01913002|DRUG|LX4211 Placebo|
40851668|NCT02328027|DRUG|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
40851669|NCT02955537|OTHER|MI-BP|MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.
41165837|NCT06107049|DIETARY_SUPPLEMENT|BLa80|During the experiment, the subjects took a packet of probiotics every day, and the sleep condition, anxiety level and memory level of the subjects were evaluated by questionnaires and ability tests. The questionnaire included PSQI Pittsburgh Sleep Quality Index scale, ISI Insomnia Severity Index Scale and GSRS gastrointestinal symptom Score scale.
41380835|NCT05371093|DRUG|Bendamustine|Administered intravenously
41507779|NCT04063085|DEVICE|PROTAHERE Absorbable Adhesion Barrier|40 mg/ml (4%) cross-linked hyaluronan
41380836|NCT05146999|BIOLOGICAL|QM1114-DP|QM1114-DP
41380837|NCT05146999|BIOLOGICAL|Placebo|Placebo
41380838|NCT06415279|DRUG|Winlevi (clascoterone) 1% cream|Twice daily (BID) dosing
41380839|NCT06132087|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
41380840|NCT06132087|PROCEDURE|Computed Tomography|Undergo CT
41380841|NCT06132087|PROCEDURE|Distal Pancreatectomy|Undergo distal pancreatectomy
41380842|NCT06132087|PROCEDURE|Laparoscopy|Undergo laparoscopy
41380843|NCT06132087|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41380844|NCT06132087|PROCEDURE|Pancreaticoduodenectomy|Undergo pancreaticoduodenectomy
41380845|NCT06132087|OTHER|Questionnaire Administration|Ancillary studies
41380846|NCT06132087|PROCEDURE|Surgical Procedure|Undergo surgical resection
41380847|NCT06132087|PROCEDURE|Total Pancreatectomy|Undergo total pancreatectomy
41380848|NCT05887752|OTHER|Standard rehabilitation|"Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~* physiotherapy;~* occupational therapy;~* sports rehabilitation."
40851670|NCT00870545|BEHAVIORAL|Telephone support groups|There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
41380849|NCT05887752|DEVICE|Hunova® rehabilitation|Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.
41380850|NCT06061848|DRUG|SLIT Grazax ALK Nordic 75 000 SQ-T|Daily sublingual grass allergen tablets
41380851|NCT06061848|DRUG|ILIT + Vitamin D|1 mL of Vicotrat D3, Heyl Pharma, 100 000 IU/mL, as intramuscular injection. Followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
41380852|NCT06061848|DRUG|ILIT + placebo|1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
41380853|NCT06651658|PROCEDURE|Pleural embolisation|Administration of pleural blood patch with tandem needle technique
40851671|NCT01581060|DRUG|WX-554|Capsules of WX-554
40851672|NCT00550693|DEVICE|Chlorhexidine-impregnated foam dressing|Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
40851673|NCT06272110|OTHER|System level Language Access (LA) intervention|Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.
40851674|NCT05118399|DRUG|Bupivacaine Injection [Marcaine]|Bupivacaine injection \[Marcaine\] is the standard treatment used in our hospital.
40851675|NCT05118399|DRUG|Bupivacaine Liposome 13.3 MG/ML [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
40851676|NCT02307578|DRUG|Perampanel|Perampanel will be available in 2-milligrams (mg), 4-mg and 8-mg tablets and as 0.5 milligram per milliliter (mg/mL) oral suspension. Participants will start this EAP with the dose that they were receiving at the end of their participation in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401. Doses of perampanel can be adjusted based on clinical judgment.
41035182|NCT02286544|DRUG|Atorvastatin|As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry. A single dose of Atorvastatin 80 mg will be given immediately prior to start of oxygen. Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
41035183|NCT00777725|DEVICE|FibroScan|Liver scan, similar to an ultrasound.
41380854|NCT06337097|DIAGNOSTIC_TEST|Troponin surveillance|Troponin will be monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy.
41380855|NCT06337097|OTHER|Standard of care|Standard of care if symptoms arise then evaluation with cardiac biomarkers and/or further cardiac testing.
41380856|NCT05420064|BEHAVIORAL|Intervention Arm At-risk Relative/ARR Contacts|Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
41380857|NCT05420064|BEHAVIORAL|MyGene Portal|Through the MyGene Portal, participants will be able to continually access their genetic test results, personalized medical management recommendations from the MSK CGS care team, an interactive pedigree for personal/family history updates, and tailored educational materials for patients with a VUS in an effort to promote sustained engagement and transparency.
41380858|NCT05420064|BEHAVIORAL|Standard of Care|Participants will received appropriate clinical care as outline by standard of care guidelines
40851677|NCT04369950|DRUG|2% lidocaine with 1:200,000 epinephrine and epidural morphine|Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
41380859|NCT02554331|RADIATION|FP-CIT single-photon emission computed tomography|FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
41507780|NCT04063085|DEVICE|Hyalobarrier Gel|Laparotomy: 40 mg/ml (4%) cross-linked hyaluronan Endoscopy: 30 mg/ml (3%) cross-linked hyaluronan
41380860|NCT02554331|BEHAVIORAL|neuropsychological evaluation|"Assessment of:~* overall cognitive function~* executive functions~* visuospatial functions~* Nonverbal memory~* verbal memory~* Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~* Beck Depression Inventory"
41035184|NCT06412120|DRUG|Niraparib|Niraparib will be administered orally (PO) daily as tablets at one of three possible dose levels, 100mg/day, 200mg/day or 300mg/day, based upon participant weight, platelet count, and certain drug combinations and conditions assessed at baseline.
41035185|NCT06630455|DIETARY_SUPPLEMENT|Meu-cinn|Meu-cinn 250 mg/day for 8 weeks
41035186|NCT06630455|DIETARY_SUPPLEMENT|Placebo|Placebo 250 mg/day for 8 weeks
41035187|NCT01640756|DEVICE|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
41035188|NCT04333667|BEHAVIORAL|Intervention group|The intervention consists of 8 modules. Each week participants get access to a new module. Each module consists of psychoeducation and exercise parts. Most of the exercises are based on audio records. The content of the modules includes such themes as awareness and nonjudgement of senses, emotions, and thoughts. Participants can reach a psychologist on demand.
41035189|NCT05303987|DRUG|Propofol sedation|"After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given."
41035190|NCT05303987|DRUG|Dexmedetomidine sedation|"After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given."
41035191|NCT01413451|DRUG|Amatuximab (MORab-009)|
41035192|NCT00599326|DRUG|Deferasirox|250 mg of deferasirox once daily for 6 months
41035193|NCT03512223|DRUG|Dexamethasone|Intravenous and Perineural Dexamethasone for Brachial Plexus Block
41035194|NCT00477191|DRUG|Etanercept|TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
41035195|NCT06583096|BEHAVIORAL|Surveys|Participants (in both arms) will complete surveys once per week and participants in the intervention arm will also complete additional 1-minute surveys daily. Study participation will be completed at the conclusion of the final follow-up survey administered 6-weeks after study enrollment.
41035196|NCT06583096|BEHAVIORAL|Supportive Text messages|Text messages will be sent Mondays-Sunday if participants are randomized to receive them in a given week, with a daily 50:50 send/no-send randomization. A bank of 25 text messages will be used for the study, providing tips/strategies across a range of topics, including managing time and academic stressors, recommendations for self-care and mood management, and messages geared towards fostering social connections and support. Some messages will contain links to videos, websites, or articles for more information on a topic.
41035197|NCT06583096|BEHAVIORAL|Personalized Feedback (PF) Report|For individuals that are randomized to receive a Personalized Feedback Report, the study team will send participants a text on a Monday with the feedback from the prior survey (baseline survey in the first week, weekly survey in the next five weeks). There will be graphs for depression, anxiety, stress, and flourishing.
41035198|NCT03750318|DEVICE|Vital sign monitoring|Each patient will be set up for monitoring on admission. Duration of opioid therapy for post-operative in-patients may range from 1-3 days. Once opioid therapy is no longer required, Aingeal monitoring will be ended and each patient would be encouraged to have at least 1 day Aingeal monitoring to be recorded during the study. De-identified log files will be extracted from the Surveillance Station and reprocessed to produce counts of the number of alarms raised during monitoring. A sample of the data will be reviewed to determine whether cardiac and respiratory alarms are defined as True or False, with an overall Alarm Rate per patient per day and False Positive Alarm Rate per patient per day derived. Vital sign trend graphs for each patient will be produced.
41035199|NCT05027165|OTHER|Non-interventional|No intervention
41035200|NCT03021226|BEHAVIORAL|Fatherhood Development|Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.
41035201|NCT03021226|BEHAVIORAL|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.
41035202|NCT03021226|BEHAVIORAL|Financial Literacy|Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
41035203|NCT00496665|DRUG|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
41035204|NCT00496665|DRUG|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
41035205|NCT00496665|DRUG|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
41380861|NCT02554331|OTHER|Gait recording with sensors|Gait recording with sensors
41380862|NCT02559778|DRUG|Ceritinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
41507781|NCT04063085|OTHER|No treatment|No anti-adhesion agent applied
41380863|NCT02559778|DRUG|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
41380864|NCT02559778|DRUG|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
41380865|NCT02559778|DRUG|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
41380866|NCT02559778|DRUG|DFMO|DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
41380867|NCT03479515|DEVICE|Ultrasound|Ultrasound, ADP, bioimpedance measurements
41507782|NCT04063085|DEVICE|Seprafilm Adhesion Barrier|a hyaluronate carboxymethylcellulose-based bioresorbable membrane
41507783|NCT04063085|DEVICE|Gynecare Interceed (TC7) Absorbable Adhesion Barrier|an oxidized regenerated cellulose absorbable membrane
41507784|NCT03685812|DIAGNOSTIC_TEST|Autocad software|The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
41380868|NCT03070327|BIOLOGICAL|EGFRt/BCMA-41BBz CAR T cell|Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10\^6, 3x10\^6, and 1x10\^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10\^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
41035206|NCT06541964|OTHER|Parent-Provide Distraction|The children will be asked riddles by their parents for 5 seconds before and during the blood collection procedure.
41380869|NCT03070327|DRUG|Cyclophosphamide|Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
41380870|NCT03070327|DRUG|Lenalidomide.|A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
41380871|NCT00683462|DRUG|Placebo|
41380872|NCT00683462|DRUG|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
41380873|NCT00683462|DRUG|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
41380874|NCT00199095|DRUG|Adriamycin|
41380875|NCT00199095|DRUG|Cyclophosphamide|
41380876|NCT00199095|DRUG|Cytarabine|
41035207|NCT06541964|OTHER|Windmill Toy Blowing|The children will blow on the windmill toy for 5 seconds before and during the blood collection procedure.
41035208|NCT06541964|OTHER|Control|No intervention will make on the children.
41380877|NCT00199095|DRUG|Dexamethasone|
41380878|NCT00199095|DRUG|Idarubicin|
41380879|NCT00199095|DRUG|Ifosfamide|
41380880|NCT00199095|DRUG|Methotrexate|
41380881|NCT00199095|DRUG|Mercaptopurine|
41380882|NCT00199095|DRUG|VM26|
41035209|NCT05619614|DEVICE|eye-tracking glasses|endoscopists wear eye-tracking glasses during real-time colonoscopy
41035210|NCT06215274|OTHER|Relationship of the cognitive leisure activity levels, cognitive function, and MRI characteristics.|The cognitive leisure activity levels, cognitive function, and MRI characteristics in people in the preclinical stage of Alzheimer's Disease (AD).
41380883|NCT00199095|DRUG|Vincristine|
41507785|NCT05644197|OTHER|Multidisciplinary program|"Multidisciplinary program:~* APA interventions: 12 weeks Each week at home, cardio-respiratory endurance sessions for muscle strengthening and balance work from the Autohome interface (Neuradom) and one week supervised by an APA teacher.~* Nutrition interventions: A group nutrition workshop at the Hôpital Privé de Provence.~* Psychological intervention:~  5 sessions of 1h30 in group, the first session will take place at the Private Hospital of Provence and the others by videoconference.~An individual session the week following the last group session.~-Visit with the urologist, 5 weeks after the prostatectomy."
41035211|NCT05424068|BEHAVIORAL|In-person rehabilitaiton group|participants who have chosen to complete the study intervention by coming in for their 8 week education and exercise sessions.
41035212|NCT05424068|BEHAVIORAL|Virtual rehabilitation group|Participants who have chosen to complete the study virtually instead of in-person sessions.
41035213|NCT05794867|DIAGNOSTIC_TEST|clinical weaning criteria|Xray chest and calculation of thr rapid shallow breathing rate
41035214|NCT03103555|DRUG|Bortezomib|Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
41035215|NCT03103555|DRUG|Cyclophosphamide|Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
41035216|NCT06636617|DRUG|3.70 GBq (100 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.
41035217|NCT06636617|DRUG|5.55 GBq (150 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04
41035218|NCT06636617|DRUG|7.40 GBq (200 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04
41035219|NCT04198662|DEVICE|Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas)|The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
40851678|NCT04369950|DRUG|3% 2-chloroprocaine and epidural morphine|Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
40851679|NCT00913926|DRUG|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara according to local drug information.
40851680|NCT05297188|DEVICE|ergonomic sleep mask|Ergonomic sleep mask; It is a material that covers the eye and ear completely and can be adjusted according to the patient, can be washed and reused at 30 degrees after use, 95% cotton, 5% polyester structure and 100% light proof properties.
40851681|NCT03477838|DEVICE|FreeStyle LibrePro CGM|a professional CGM device will be worn by the participant for up to 14 days
40851682|NCT00810992|BEHAVIORAL|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
40851683|NCT00810992|BEHAVIORAL|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
40851684|NCT05686291|BEHAVIORAL|Hybrid volunteer training programme|The volunteer training will consist of a 6-module online course, followed by 5 face-to-face courses, incorporating the key volunteer training components, including Keyes theory, bio-psycho-social model, stress bucket model, recovery model and CHIME model.
40851685|NCT01546688|DRUG|Zonisamide at targeted daily doses of 100-500 mg/day|Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
40851686|NCT01546688|DRUG|Placebo administered to match targeted daily doses of 100-500 mg/day|matching placebo
40851687|NCT01059318|DRUG|Everolimus|Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
40851688|NCT04410406|DRUG|Ivermectin|Ivermectin (IVM) 200 µg/kg
40851689|NCT04410406|DRUG|Diethylcarbamazine|Diethylcarbamazine (DEC) 6mg/kg
41380884|NCT01728376|DRUG|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
40851690|NCT04410406|DRUG|Albendazole|Albendazole (ABZ) 400 mg
40851691|NCT04410406|DRUG|Moxidectin|Moxidectin (Mox) 8 mg
41035220|NCT04198662|DRUG|Intercostal nerve block ropivacaine with epinephrine|3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block(s)
41165059|NCT01891656|BEHAVIORAL|Motivational Interviewing|"MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller \& Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment."
41380885|NCT01728376|DRUG|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
41380886|NCT04462354|PROCEDURE|Blumgart Anastomosis|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Blumgart anastomosis
40851692|NCT02303028|DRUG|Topotecan and Pazopanib|Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
41035221|NCT04198662|DEVICE|Sham cryoneurolysis with a Painblocker|The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
41035222|NCT04198662|DRUG|Placebo intercostal nerve block with normal saline|3 mL of normal saline will be injected perineurally to provide placebo intercostal nerve blocks
41035223|NCT05872633|BEHAVIORAL|Online self-management intervention|
41035224|NCT05872633|OTHER|Care-as-usual|
41035225|NCT00592995|DRUG|Creatine monohydrate|10 to 30 grams daily
41035226|NCT00592995|DRUG|Placebo|10 to 30 grams daily
41380887|NCT04462354|PROCEDURE|Pancreatogastric anastomosis.|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Pancreatogastric anastomosis.
41380888|NCT02355314|OTHER|Doppler-based renal|Doppler-based renal : day 0 and day 3
41380889|NCT02355314|BIOLOGICAL|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
40851693|NCT00793325|DRUG|Somatropin|"Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
40851694|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
40851695|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
40851696|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
40851697|NCT04371601|DRUG|Oseltamivir|Oseltamivir capsules
41035227|NCT00175851|DRUG|Seletracetam (ucb 44212)|
41035228|NCT03305016|DRUG|TransCon hGH|Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
41035229|NCT05130658|DEVICE|Virtual reality treadmill training|C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.
41035230|NCT05130658|OTHER|Treadmill Training|Conventional gait and balance training using treadmill.
41035231|NCT03034148|DIAGNOSTIC_TEST|Platelet Acetyl Coenzyme A Carboxylase analysis in CAD|
41035232|NCT01986257|BEHAVIORAL|Emotion Regulation Group Therapy (ERGT).|
41035233|NCT02541929|DIETARY_SUPPLEMENT|Docosahexaenoic acid|
41035234|NCT03335553|DRUG|BMS-986235|Specified dose on specified days
41035235|NCT03335553|OTHER|Placebo|Specified dose on specified days
41035236|NCT06130059|DRUG|Low Dose Colchicine|Colchicine has been demonstrated to improve cardiovascular outcomes among patients with cardiovascular disease. In the COLCOT trial, the use of low-dose colchicine resulted in a reduction of major adverse cardiovascular events among participants with recent MI. The trial demonstrated the utility of anti-inflammatory therapies in improving cardiovascular outcomes. Colchicine has been widely used for decades and its safety profile is well established.
41035237|NCT06130059|DRUG|Placebo|Placebo
41035238|NCT02171468|DRUG|Dabigatran high dose|
41035239|NCT02171468|DRUG|Dabigatran low dose|
41035240|NCT06634810|BEHAVIORAL|Self-Management Support|The intervention will be delivered by CHWs in person and supplemented with telephone or video encounters over 6 months. The intervention comprises six core elements: engagement, intake, self-management assessment, barrier screening, actions to address identified barriers, and follow-up/maintenance support.
41035241|NCT06634810|BEHAVIORAL|COPD Education|The attention control is where CHWs will provide COPD education using the COPD 1-2-3 booklet. The attention control will consist of 6 CHW visits (approximately 1 per month) with the patient and care giver in their home or via video conference, per patient preference.
41035242|NCT04565457|DEVICE|Research CBCT|Each study participant will receive one additional CBCT scan, with 2D antiscatter grid in place. This is the only intervention in the study, referred as research CBCT scan, and it will be performed on one of the days during the participant's radiation treatment course. This additional research CBCT scan will be used strictly for the objectives of this study. It will not be used as part of the standard clinical care, such as imaging guidance of participant's radiation treatment or diagnostic purposes. To deliver participant's radiation treatment under CBCT guidance, a standard clinical CBCT scan will be acquired, as in standard clinical care protocols.
41035243|NCT04111445|DRUG|ADG116|IV infusion at Day 1 of each cycle
41035244|NCT05966441|DIETARY_SUPPLEMENT|Curcumin|"The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders.~Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress.~Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily"
41035245|NCT05966441|DRUG|Paclitaxel|"Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV..~Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV."
41035246|NCT06454630|DRUG|REGN7508|Administered by single intravenous (IV) dose
41035247|NCT06454630|DRUG|Enoxaparin|Administered by subcutaneous (SC) dose daily through the time of venography (or day 12, whichever is earlier)
41035248|NCT04271930|BEHAVIORAL|Mindfulness Awareness Practices for Insomnia|MAP-I is a curriculum-based intervention that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
41035249|NCT04271930|BEHAVIORAL|Sleep Health Information|A video SHE seminar will serve as active comparator for nonspecific treatment elements that pose rival explanations for the effectiveness of MAP-I.
41035250|NCT06635174|OTHER|Dextrose|we are using 2ml of 50% dextrose
40851698|NCT04371601|DRUG|hormones|a moderate amount of hormone
40851699|NCT04371601|DEVICE|oxygen therapy|oxygen therapy,mechanical ventilation and other supportive therapies
40851700|NCT04371601|PROCEDURE|mesenchymal stem cells|mesenchymal stem cells
40851701|NCT04771676|DRUG|Oncorine (H101)|A modified human recombinant type 5 adenovirus with genetic modifications.
41035251|NCT06635174|OTHER|normal water|patient will receive 2ml of normal water
41035252|NCT00002334|DRUG|Saquinavir|
41035253|NCT00002334|DRUG|Zidovudine|
41035254|NCT00002334|DRUG|Zalcitabine|
41035255|NCT01038908|OTHER|Isosulfan Blue (Patent Blue Dye V)|"1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is identified~3. Inject blue dye into patient's arm~4. Complete procedure (SLNB and/or ALND)"
41035256|NCT01038908|OTHER|Isosulfan Blue (Patent Blue Dye V)|"1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is not identified (No localization)~3. Inject blue dye into breast (nothing in arm)~i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)"
41380890|NCT01995409|BEHAVIORAL|No smoking material provided in households with newborn infants|
41035257|NCT06635564|DIAGNOSTIC_TEST|Viscoelastic testing|viscoelasting testing refers to a global hemostatic assay,that quantifies the viscoelastic properties of citrated whole blood
41380891|NCT03287908|DRUG|AMG 701|Subjects will receive IV infusions of AMG 701.
40851702|NCT00112125|DEVICE|OPTIMIZER System|
40851703|NCT00236236|DEVICE|Cardiac Resynchronization Therapy|
40851704|NCT05235542|DRUG|AK104|IV infusion,Specified dose on specified days
40851705|NCT05235542|DRUG|AK117|IV infusion,Specified dose on specified days
40851706|NCT05235542|DRUG|Capecitabine tablets|Oral,Specified dose on specified days
40851707|NCT05235542|DRUG|Oxaliplatin|IV infusion,Specified dose on specified days
40851708|NCT05235542|DRUG|Cisplatin|IV infusion,Specified dose on specified days
40851709|NCT05235542|DRUG|Paclitaxel|IV infusion,Specified dose on specified days
40851710|NCT05235542|DRUG|Irinotecan|IV infusion,Specified dose on specified days
40851711|NCT05235542|DRUG|Docetaxel|IV infusion,Specified dose on specified days
40851712|NCT05235542|DRUG|5-FU|IV infusion,Specified dose on specified days
40851713|NCT06384365|BEHAVIORAL|Physical activity|The control and the athletic group differ in the degree of physical acitvity
40851714|NCT03475589|DRUG|apatinib|Patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer will be included in this study to receive apatinib treaetment starting from 250 mg Qd and closely monitored for ADRs during apatinib treatment, with dosage adjustment performed as needed to make the treatment tolerable to the patients.
41035258|NCT02446132|DRUG|AVP-786|
41035259|NCT06425354|DEVICE|Mechanical ventilation|Mechanical ventilatiom
41035260|NCT03772080|OTHER|Early counseling of prematurity in high-risk pregnancies.|Standardized information regarding prematurity, including associated complications and ways to decrease chances of preterm birth using web-based educational platform.
41035261|NCT01754831|DEVICE|Fluoride varnish|Topical application of fluoride varnish on present teeth
41035262|NCT00734227|PROCEDURE|Emergency portacaval shunt|
41035263|NCT00734227|OTHER|Emergency TIPS|
41035264|NCT06463015|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
41380892|NCT03287908|DRUG|Pomalidomide|Subjects will receive oral capsules of pomalidomide.
41380893|NCT03287908|DRUG|Dexamethasone|Subjects will receive IV injections or oral dexamethasone.
41507786|NCT03791047|OTHER|Balance Analysis|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
40851715|NCT02176161|DRUG|Metformin Hydrochloride Extended Release 750mg|Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
40851716|NCT02259894|DRUG|BIRT 2584 XX|
40851717|NCT02259894|DRUG|Placebo|
40851718|NCT01499615|DEVICE|cardiac monitor|All children receive the same intervention which is the application of the 4 ekg electrodes
40851719|NCT04386694|DEVICE|Active PBMT/sMF|The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
40851720|NCT04386694|DEVICE|Placebo PBMT/sMF|The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
40851721|NCT00761527|DRUG|Desloratadine Syrup|"Desloratadine (Aerius) Syrup;~Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:~* Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg \[milligrams\] of desloratadine)~* Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)~* Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)"
40851722|NCT02211430|BEHAVIORAL|Cognitive-Behavioral Counseling (CBC)|Participants of CBC were educated about the effects of smoking on their personal health and their pregnancy during session 1 (45 minutes counseling), and were encouraged to explore their risk perceptions and emotions, for themselves and their unborn child. During session 2, the 15-minute counseling segment highlighted the cognitive and emotion barriers undermining the participant's motivation to quit and the self-regulatory techniques for resisting personal smoking triggers. Session 3 (45 minutes counseling) involved reviewing smoking status and smoking history over the course of the pregnancy, as well as the effects of smoking on both their health and the health of their infant. Booster session was held by phone for 15 min.
40851723|NCT02211430|BEHAVIORAL|Best Practice (BC) Control|"For ethical considerations, and consistent with practice guidelines for treating tobacco addiction (Fiore et al., 2000) which mandates that every pregnant smoker be offered smoking cessation treatment, the control group has been designed to be comparable to the current best practice guidelines for smoking cessation treatments. This condition, devised from a review of the current literature, will include one brief (5-15 minutes) prenatal individual session (session 1) consisting of smoking cessation education and advice, on-site brochure pick up (session 2), and a second brief postpartum individual session (session 3) followed by receipt of a newsletter (session 4)."
40851724|NCT06507488|DRUG|Daphnetin Capsule|Daphnetin, chemically known as 7,8-dihydroxycoumarin, also known as ZuShiMaJiaSu, is a class of coumarin derivatives derived from different Daphnetin genus plant .
41035265|NCT06239844|OTHER|Experimental: Nav-Team|Participants in this arm will receive additional assistance related to asthma, log encounters, complete surveys.
41035266|NCT00246636|DRUG|Antara (fenofibrate) + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
41035267|NCT00246636|DRUG|Antara (fenofibrate)|Antara (fenofibrate) + placebo
41035268|NCT01316926|DRUG|Test formulation|Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
41380894|NCT03280563|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
40851725|NCT06507488|DRUG|Placebo|The placebo is a Daphnetin Capsule simulants
40851726|NCT03970291|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
41035269|NCT01316926|DRUG|Reference formulation|Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
41035270|NCT05613660|DIETARY_SUPPLEMENT|Veg Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
41035271|NCT05613660|DIETARY_SUPPLEMENT|Bovine Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
41035272|NCT05613660|DIETARY_SUPPLEMENT|"Fish | Marine Collagen Peptide"|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
41035273|NCT05613660|DIETARY_SUPPLEMENT|Chicken Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
41035274|NCT01681589|DEVICE|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
41035275|NCT01681589|DEVICE|Control Group|This group will receive Sham TDCS
41035276|NCT01681589|OTHER|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
41035277|NCT03939286|OTHER|Clinical-neurological and neuropsychological tests|The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.
41035278|NCT03939286|DIAGNOSTIC_TEST|Blood sampling|Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.
41165838|NCT00427778|DEVICE|incontinence ring|"Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra."
41380895|NCT03280563|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
41380896|NCT03280563|DRUG|Entinostat|Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.
41380897|NCT03280563|DRUG|Exemestane|Exemestane will be given as 25 mg orally QD in each 21-day cycle.
41380898|NCT03280563|DRUG|Fulvestrant|Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
41380899|NCT03280563|DRUG|Ipatasertib|Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
41380900|NCT03280563|DRUG|Tamoxifen|Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
41380901|NCT03280563|DRUG|Abemaciclib|Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
41507787|NCT01080560|DRUG|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
40851727|NCT03117478|OTHER|Magneto-encephalography (MEG)|Magneto-encephalography
40851728|NCT03117478|OTHER|Electro-encephalography (EEG)|Electro-encephalography
40851729|NCT03117478|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging
40851730|NCT03117478|OTHER|Anatomical Magnetic Resonance Imaging (aMRI)|Anatomical Magnetic Resonance Imaging
40851731|NCT03117478|OTHER|Meditation|Meditation
40851732|NCT01378468|OTHER|"oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)"|see Ebinger et al., IJS, 2010
41035279|NCT03939286|OTHER|Assessment of physical activity via fitness tracker/diary|All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.
41165839|NCT02941419|BIOLOGICAL|Platelet lysate|Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
41165840|NCT02190552|DEVICE|EmboTrap® Revascularization Device|
41165841|NCT00335374|DRUG|Pardoprunox|12 -42 mg
41380902|NCT06653049|DEVICE|Reinforcement Learning (RL) Personalised Exercise Prescription via i80 BPM App|This intervention involved the use of a smartphone app, i80 BPM, which delivered personalised exercise prescriptions using a reinforcement learning (RL) model. The RL algorithm tailored the exercise sessions by adapting variables such as intensity, duration, and exercise type based on individual user preferences, real-time feedback, and performance data. This dynamic personalisation was designed to enhance user satisfaction and engagement over the 12-week study period. Participants completed three exercise sessions per week.
41507788|NCT02593292|BEHAVIORAL|PROSPERO|"The intervention is carried out in 3 steps:~1. At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~2. During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~3. The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives."
40851733|NCT03779815|DRUG|[18F]Florbetaben|"* Drug: \[18F\]Florbetaben~* \[18F\]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma~* Other name: Neuraceq~* Amount: 300 MBq ± 20% bolus, 10mL intravenously"
41507789|NCT02593292|OTHER|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
40851734|NCT02267538|DRUG|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery."
40851735|NCT02267538|DRUG|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation after surgery."
40851736|NCT02283788|DRUG|BIA 2-093|
40851737|NCT02283788|DRUG|Moxifloxacin|
40851738|NCT02283788|DRUG|Placebo|
40851739|NCT00603122|BEHAVIORAL|ascent protocol|ascent protocol for the two groups has different acclimatization time
40851740|NCT01371734|DRUG|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
40851741|NCT01371734|DRUG|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
40851742|NCT01371734|DRUG|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
41165060|NCT01891656|BEHAVIORAL|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere \& Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman \& Massey, 2008). As discussed by Hester \& Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
40851743|NCT06455865|OTHER|TPACK-Based Blended Learning Instruction|The control group employed traditional in-person teaching methods, including face-to-face classroom instruction, reading from printed textbooks, and completing homework assignments. The curriculum covered the fundamental theories and skills related to information resource retrieval and usage but did not specifically utilize the TPACK framework. Students primarily received lectures and guidance from the instructor during class and completed assignments and learning tasks independently after class.
41165061|NCT03098797|DRUG|Elamipretide|40 mg daily subcutaneous injection for 12 weeks
41165062|NCT03098797|DRUG|Placebo|daily subcutaneous injection for 12 weeks
41165842|NCT01233271|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
41165843|NCT00567983|DRUG|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
41380903|NCT06653049|DEVICE|Generic Non-Personalised Exercise Prescription via i80 BPM App|This intervention used the same i80 BPM smartphone app to deliver generic, pre-designed exercise sessions that did not adapt based on user preferences or feedback. The exercise sessions were standardised for all participants, with no customisation. The control arm served as a comparator to evaluate the impact of personalised, RL-driven exercise prescriptions. Participants completed three exercise sessions per week.
41507790|NCT04352868|DEVICE|Intelliwave multifocal, toric, soft contact lens|This is a quarterly disposable, multifocal, toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
41380904|NCT06631235|OTHER|orthopedic appliance|appliances are used to correct skeletal class II due to mandibular deficiency
41507791|NCT04352868|DEVICE|Intelliwave toric, soft contact lens|This is a quarterly disposable toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
41507792|NCT02552121|DRUG|Tisotumab vedotin (HuMax-TF-ADC)|
41380905|NCT06631235|OTHER|aesthetic orthopedic appliance|aesthetic appliances are used to correct skeletal class II due to mandibular deficiency
41165063|NCT02142998|OTHER|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
41165064|NCT02142998|OTHER|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
41035280|NCT03939286|OTHER|MRI-examinations|Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI
41035281|NCT06139523|DEVICE|Investigational contact OCT system|Theia imaging is developing handheld OCT systems bring state of the art OCT to the infant bedside. The Theia 1 widefield imaging system is a light weight, high speed (300 kHz), wide field of view (110°) OCT system that address the limitations of current commercial OCT systems. The system is cart mounted, enabling portable, bedside imaging. The system uses a 300 kHz swept source laser operating in 1060nm regime. The Theia system follows the same safety standards as all applicable laser safety standards (ANSI z80.36 or ISO 15004) as the currently approved prior OCT devices. This nearly 10-fold increase in acquisition speed dramatically reduces imaging time and enables acquisition of full retinal volumes in infants. The 110° field of view is provided via a re-usable contact lens that can be sterilized between imaging sessions.
41035282|NCT06139523|DEVICE|Investigational noncontact OCT system:|"The investigational noncontact handheld OCT systems in this study is developed at Duke University as the result of collaboration between the Departments of Ophthalmology (Cynthia Toth, MD) and Biomedical Engineering (Joseph Izatt, PhD). This investigational device was previously reviewed and approved for use in adults, children, and neonates in nursery by:~* Intraoperative OCT Guidance of Intraocular Surgery study's (Pro00016827) Data Safety and Monitoring Board Plus (DSMB+) (PI: Toth and Izatt)~* The Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care study (Pro00069721) Data Safety and Monitoring Committee (DSMC) (PI: Toth) The systems were declared non-significant risk by the Duke University Health System (DUHS) Institutional Review Board under Pro00016827. Staff from the DUHS Clinical Engineering Department evaluated the systems and found that they meet the accepted hospital standards for electrical safety."
41035283|NCT03892772|DRUG|SAS0421a|treatment will be given for 3 days
41035284|NCT03892772|DRUG|SAS0421b|treatment will be given for 3 days
41035285|NCT03892772|DRUG|SAS0421c|treatment will be given for 3 days
41035286|NCT03892772|DRUG|placebo|placebo will be given for 3 days
41035287|NCT05713318|DRUG|HH-120 nasal spray|Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.
41035288|NCT05713318|DRUG|HH-120 nasal spray|Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.
41035289|NCT05713318|DRUG|Placebo Comparator|Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.
41035290|NCT05713318|DRUG|Placebo Comparator|Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.
41035291|NCT03136614|DEVICE|Arteriograph|
41035292|NCT06613347|OTHER|whitening maintenance|whitening maintenance regimen
41035293|NCT06613347|OTHER|whitening maintenance MW|maintenance MW
41165065|NCT03927677|DRUG|Xanthine Oxidase Inhibitor|LC350189 200mg qd
41165066|NCT05259397|DRUG|PF-07225570|PF-07225570 given IVe in a 28-day cycle (as induction and maintenance regimen). Multiple dose levels will be evaluated.
41165067|NCT05259397|DRUG|sasanlimab|Sasanlimab will be administered SQ on day 1 of each 28 day cycle.
41165068|NCT05743673|DEVICE|Shape II|cardiopulmonary exercise testing apparatus
40851744|NCT00681928|DRUG|anastrozole|As determined by the subject's physician
40851745|NCT00681928|DRUG|letrozole|As determined by the subject's physician
41035294|NCT06613347|OTHER|negative control|negative control
41035295|NCT05778305|DRUG|Dexmedetomidine|a central sympatholytic drug
41035296|NCT05778305|OTHER|normal saline|saline is given to control group
41035297|NCT05639738|OTHER|Clinical and instrumental measurements|"* Clinical evaluations~* Non-invasive instrumental measurements~* Subject's evaluations"
41035298|NCT01235208|OTHER|"The Dr. Fedon Lindbergs Vektcoach Treatment"|Diet and lifestyle treatment
41035299|NCT05740462|BEHAVIORAL|Recipes consumption|Participants will eat two recipes a day for 17 weeks
41035300|NCT05740462|BEHAVIORAL|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
41035301|NCT05240014|DEVICE|Modular powered orthosis|This study will investigate modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. The central hypothesis is that high-torque, low-inertia motor systems controlled with energetic objectives will enable modular powered orthoses to partially assist the joints. High-torque electric motors combined with minimal transmissions can be freely rotated (i.e., backdriven) by human joints, allowing the use of an emerging torque control method called energy shaping to reduce the perceived weight/inertia of the body during any motion. By mounting these modular actuators to commercial orthoses, this technology will be easily prescribed/configured by clinicians.
41035302|NCT05354700|DRUG|HLX07|HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
41035303|NCT05354700|DRUG|HLX10|HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
41035304|NCT05354700|DRUG|carboplatin and etoposide|chemotherapeutics
41035305|NCT05997004|DRUG|Normal Saline|After surgical creation of umbilical port Control group received injection normal saline 1ml.
40851746|NCT00681928|OTHER|questionnaire administration|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
40851747|NCT00681928|PROCEDURE|cognitive assessment|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
40851748|NCT00681928|PROCEDURE|psychosocial assessment and care|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
40851749|NCT03772665|DRUG|Emixustat|Once daily oral tablet taken for 24 months
40851750|NCT03772665|DRUG|Placebo|Once daily oral tablet taken for 24 months
41035306|NCT05997004|DRUG|Glycopyrrolate|After surgical creation of umbilical port Group II received injection Glycopyrrolate 1ml=0.2mg
41035307|NCT04695223|DRUG|Arsenic Trioxide|Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)
41035308|NCT01669122|DRUG|nicotine|4 mg nicotine lozenge experimental
41035309|NCT05457946|BIOLOGICAL|LBVD (Hexavalent vaccine)|Injection within the muscle into the front area of the thigh
41035310|NCT05457946|BIOLOGICAL|Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)|Injection within the muscle into the front area of the thigh
41035311|NCT00297752|DRUG|ceriumnitrate silversulfadiazine (flammacerium)|treatment of patients with facial burns with CE-SSD
41035312|NCT00297752|DRUG|silversulfadiazine (flammazine)|treatment of patients with facial burns with SSD
41035313|NCT05990062|DEVICE|K-Socket-Harness|"A transradial socket and harness design that offers a hybrid polymer and textile-based design derived from advanced athletic shoe technology. The KSH integrated socket, frame, and wrist, the variable compliance prosthetic socket with breathable matrix, creates a dynamic and secure attachment with a combination of two lacing systems. The lacing systems lengthen and shorten six flexible hinges at the elbow, maintaining a secure attachment throughout the range of motion and accounting for volume changes in the soft tissue of the elbow that would otherwise restrict range of motion or cause the socket to separate from the residual limb."
41165069|NCT01593436|BEHAVIORAL|mindfulness training|mindfulness interventions for 8 weeks for a group of menopausal insomniacs
40851751|NCT04771702|DEVICE|Edmon|Exhaled air will be analyzed for propofol
41035314|NCT04885686|DEVICE|Endomethasone N RCS|Root canal sealer
41035315|NCT04885686|DEVICE|Endomethasone SP RCS|Root canal sealer
41165070|NCT01765452|DRUG|Closone|75mg/100mg, 8weeks, PO
41165071|NCT01765452|DRUG|Plavix with Astrix|75mg, 100mg a day, 8weeks, PO
41165072|NCT03765515|DEVICE|Twinfix Ti|The purpose is to evaluate the safety and efficacy of Q-Fix in patients requiring the repair of soft tissue of shoulder who receive the arthroscopic repair of soft tissue using Q-Fix, when compared with the patients receiving the treatment with Twinfix Ti Suture Anchor. The result of this trial will be used for the Q-Fix All-suture Anchor registration in China.
41165073|NCT03765515|DEVICE|Q-Fix|Q-Fix
40851752|NCT04864951|DIAGNOSTIC_TEST|Colli-Pee urine collection device|first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.
40851753|NCT04864951|OTHER|Survey|Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking
40851754|NCT01900743|DRUG|Regorafenib|Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
40851755|NCT01900743|DRUG|Placebo|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
41035316|NCT01146236|DEVICE|Sutures|Orthopedic surgical wounds closed with sutures
41035317|NCT01146236|DEVICE|Staples|Orthopedic surgical wounds closed with metallic staples
41035318|NCT05008679|DRUG|Oseltamivir|at a dose of 75 mg twice daily
41165074|NCT06455332|OTHER|Optic nerve MRI sequence|Systematic optic nerve MRI sequence during the CIS diagnosis work-up. This sequence is not done systematically and not recommended for now (except in case of acute ON). The interventional nature of the study remains minimal
41165844|NCT00567983|DRUG|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
41165845|NCT01586429|OTHER|Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)|
41165846|NCT03696888|BEHAVIORAL|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
40851756|NCT05532280|DRUG|Etoricoxib 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
40851757|NCT05532280|DRUG|Arcoxia 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
40851758|NCT00185224|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
40851759|NCT00185224|DRUG|SH D00264A (Triquilar)|7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
40851760|NCT03452709|BEHAVIORAL|therapeutic exercise|The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week. physical activity programmed by an instructor in patient with high risk of cardiovascular.
40851761|NCT03452709|DEVICE|ABPM ambulatory blood pressure monitoring|Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
40851762|NCT02800980|PROCEDURE|Drainage and sclerotherapy.|Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.
40851763|NCT02800980|PROCEDURE|Drainage alone.|Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
40851764|NCT03193736|DEVICE|MINIject implant|"MINIject implant is used to reduce intra-ocular pressure (IOP) in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
40851765|NCT00811174|DRUG|Octagam 10%|300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
40851766|NCT04439318|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
41035319|NCT00857324|DRUG|Vorinostat|"Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~* Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~* In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4"
41035320|NCT04899349|DRUG|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.
41035321|NCT04899349|DRUG|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
41035322|NCT04899349|DRUG|Metformin XR|Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
41035323|NCT04899349|DRUG|Dapagliflozin + metformin XR|Dapagliflozin + metformin XR administered as a single tablet combination at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg dapagliflozin + 500 mg metformin XR orally once daily to 10 mg dapagliflozin + 2000 mg metformin XR once daily
41035324|NCT04899349|DRUG|Dapagliflozin|Dapagliflozin (tablet) at a starting dose of 5mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg to 10 mg once daily
41035325|NCT02246998|DRUG|STB|150/150/200/300 mg fixed dose combination (FDC) tablet administered orally once daily with food
41035326|NCT02246998|DRUG|TVD|200/300 mg FDC tablet administered orally once daily with food
41035327|NCT02246998|DRUG|ATR|600/200/300 mg FDC tablet administered orally once daily on an empty stomach at bedtime
41035328|NCT02246998|DRUG|RTV|100 mg tablet administered orally once daily with food
41035329|NCT02246998|DRUG|ATV|300 mg capsule administered orally once daily with food
41035330|NCT02246998|DRUG|ABC/3TC|600/300 mg FDC tablet administered orally once daily with food
41035331|NCT02246998|DRUG|Iohexol|1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
41035332|NCT06288984|DEVICE|active rTMS|The magnetic stimulation coil was tangent to the scalp and kept parallel for 10 minutes a day, 5 days a week for 4 weeks
41035333|NCT06288984|DEVICE|sham rTMS|The magnetic stimulation coil was tangent to the scalp and kept perpendicular for 10 minutes a day, 5 days a week for 4 weeks
41035334|NCT00698568|BIOLOGICAL|Herpes simplex candidate vaccine- adjuvanted GSK 208141|Intramuscular injection, 3 doses
41035335|NCT00698568|BIOLOGICAL|Placebo|Intramuscular injection, 3 doses
41165847|NCT03696888|BEHAVIORAL|TeleCoach control|A web-app providing information about the health-related consequences of alcohol consumption.
40851767|NCT04766008|DRUG|Metformin|Diabetic patients treated with metformin undergoing coronary angiography will not suspend metformin before and after PCI.
40851768|NCT00147303|DRUG|MCI-9042|
40851769|NCT05536076|OTHER|Hypercapnia treatment|Intermittent hypercapnia treatment five days per week for two weeks.
41165848|NCT00745121|DEVICE|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
40851770|NCT02503501|DRUG|Insulin glulisine|
40851771|NCT02503501|DRUG|Placebo|Bacteriostatic 0.9% Sodium Chloride
40851772|NCT01406977|DRUG|BPS804|
41035336|NCT02921997|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
41035337|NCT02921997|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
41035338|NCT02921997|BIOLOGICAL|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
41165075|NCT06255236|DEVICE|Bispectral index (BIS)|"* All patient will receive standard monitoring (EKG, Blood pressure, pulse oximetry), and BIS transducer placement at standard frontal area before anesthesia.~* Sedative medication can be given as appropriate.~* Anesthesia induction by inhalation induction with sevoflurane (if intravenous line not presented) or intravenous induction with thiopental 5-6 mg/kg IV~* Other medication including fentanyl 1 mcg/kg IV and cisatracurium 0.1-0.2 mg/kg IV will be given and the patient will be intubated.~* The second BIS will be installed on the bridge of the nose and temporal on the same side as frontal BIS.~* The patient will be maintained with sevoflurane and other anesthetic drugs as appropriate, adjusted per frontal BIS (40-60).~* The frontal BIS and the nasal BIS will be measured until the endotracheal tube is being removed. If the patient has moved until it was impossible to measure the BIS or has any necessity to cancel the BIS measurement. The BIS measurement can be stopped."
41165076|NCT04204811|OTHER|Prehabilitation|A program of personalized independent home exercises are outline for participants to complete daily. Prehabilitation coaching will continue weekly until admission for surgical tumor debulking or termination of neoadjuvant treatment for any reason.
41165077|NCT01018797|PROCEDURE|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
41165078|NCT04793581|DEVICE|Atherectomy|Directional atherectomy of lesions below the knee.
40851775|NCT04836845|DEVICE|Focus extracorporeal shock wave therapy|Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
40851776|NCT04836845|DEVICE|Radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
41165079|NCT03847922|DRUG|Nitrous Oxide + Oxygen Gas (Product)|Self-administered 50% nitrous oxide / 50% oxygen mixture will be given to the intervention group, starting just before the beginning of the urethral bulking procedure.
41165080|NCT03847922|DRUG|lidocaine gel 2%|6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.
41165081|NCT03847922|OTHER|Room air|Room air will be administered via the Pro-Nox machine to participants in the control group, starting just before the beginning of the urethral bulking procedure.
41165082|NCT06306677|DIAGNOSTIC_TEST|AI-clincial-based hybrid system for radiographic image analysis|The Index test is a novel AI-clinical-based hybrid system for radiographic image analysis. Its diagnostic performance will be compared to the reference represented by a panel of experts.
41380906|NCT03265808|DRUG|allogeneic human mesenchymal stem cells (allo-hMSCs)|Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
40851777|NCT04836845|DEVICE|Sham extracorporeal shock wave therapy|Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
41165083|NCT04168996|BEHAVIORAL|Individualized discharge planning|Discharge planning is designed to ensure healthcare continuity, avoid preventable poor outcomes among at-risk populations, and promote the safe and timely transfer of patient care. The individualized discharge planning is characterized to take into account the preferences, interests and clinical profile of each patient.
41380907|NCT03265808|DRUG|Placebo|Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
40851778|NCT01366885|DRUG|Vitamin D3|5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
40851779|NCT01753089|BIOLOGICAL|WDVAX|
41165084|NCT04067271|OTHER|Analyze changes in intestinal microbiome|Descriptive Analysis
41165085|NCT02657421|PROCEDURE|Oblique Lateral Interbody Fusion|The oblique lateral interbody fusion (OLIF) procedures at L2-L5 (OLIF25™) and L5-S1 (OLIF51™) is a minimally invasive surgical option for degenerative lumbar disease. This approach allows for psoas-preserving access to the lumbar spine and minimizes the need to reposition the patient during surgery for accessing additional spinal levels for the interbody fusion portion of the procedure
41165086|NCT00046683|DRUG|alemtuzumab|
41165087|NCT03038945|OTHER|2/0 barbed suture|Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
41165088|NCT03038945|OTHER|0/0 Vicryl suture|Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
41165089|NCT05959161|PROCEDURE|DBS|We observed the prognostic changes of patients after DBS surgery
41380908|NCT02159651|DRUG|tacrolimus|oral
41380909|NCT03784755|RADIATION|Ablative Radiation Therapy|Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).
41380910|NCT03784755|OTHER|Standard of care|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
41380911|NCT02185560|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients treated by Physician with Nexavar under approved local prescriptions
41380912|NCT06630858|PROCEDURE|Subcostal Anterior Quadratus Lumborum Block|S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.
41380913|NCT06630858|PROCEDURE|Intrathecal Morphine|Intrathecal morphine will be performed (a total of 0.2 mg of morphine sulfate + 7.5 mg isobaric bupivacaine).
41380914|NCT06630858|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine-PCA will be applied postoperatively for 24 hours . IV-PCA: The requested dose will be 1mg morphine, the lock-in time will be 6 minutes, the 4-hour limit will be 20 mg morphine.
41507793|NCT00031148|DRUG|Recombinant Human Keratinocyte Growth Factor (rHuKGF)|
41507794|NCT00655343|DRUG|ATG-Fresenius S|"20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution~20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation"
41507795|NCT00300690|DEVICE|6 mm Uni-graft® (B-Braun)|
41507796|NCT00300690|DEVICE|6 mm Gore-Tex® (WL Gore)|
41507797|NCT05113784|DRUG|Meplazumab for Injection|humanized antibody target CD147
40851780|NCT00320515|DRUG|pemetrexed|"Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression~Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression"
40851781|NCT00320515|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
40851782|NCT06100913|BIOLOGICAL|Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)|The study vaccine is an FDA-approved recombinant vesicular stomatitis virus (rVSV) expressing the envelope glycoprotein of Ebola virus Zaire (rVSV∆G-ZEBOV-GP). The dose of rVSV∆G-ZEBOV-GP vaccine has been chosen for this study as per package insert recommendations and based on clinical data. Participants receive 1.0 milliliter (mL) of the study vaccine administered intramuscularly in the deltoid muscle of the non-dominant arm.
40851783|NCT03512379|DEVICE|TIANJI Robot|A robotic system for spinal surgery
40851784|NCT03512379|DEVICE|Fluoroscopy|For fluoroscopy-based free hand surgery
40851785|NCT03512379|DEVICE|Navigation|For navigation-assisted spinal surgery
40851786|NCT01180296|DRUG|oral micronized progesterone|oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
40851787|NCT01180296|DRUG|Identical Placebo tablet|Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
40851788|NCT01205971|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.
40851789|NCT01205971|BEHAVIORAL|Dental Preventive Services|Written oral health educational materials
41035339|NCT02508480|BEHAVIORAL|Photovoice|"The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.~In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination."
41507798|NCT05113784|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
40851790|NCT04729335|DIAGNOSTIC_TEST|phonocardiac spectrometry|Detection and application of organic disease with phonocardiac spectrometry
40851791|NCT04408040|BIOLOGICAL|Convalescent Plasma|200-425mL convalescent plasma donated by patients previously positive for COVID-19
40851792|NCT01356446|PROCEDURE|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implemented
40851793|NCT05755672|DRUG|Chemotherapy|Neo-adjuvant and adjuvant chemotherapy with curative intent, according to the current clinical practice guidelines
40851794|NCT05755672|PROCEDURE|Resection of the primary tumor|Surgical resection of the primary tumour, according to the current clinical practice guidelines
41165090|NCT01395849|DRUG|Salmeterol and Fluticasone|
41165091|NCT02624505|DRUG|90 mcg Reference Product|Drug: 90 mcg Reference Product
41165092|NCT02624505|DRUG|180 mcg Reference Product|Drug: 180 mcg of Reference Product
41165093|NCT02624505|DRUG|90 mcg Test Product|Drug: 90 mcg of Test Product
41380915|NCT03901352|DRUG|Placebo|Matching placebo tablets for oral administration
41507799|NCT00993421|DRUG|LY377604|Given daily, orally for 24 weeks
41507800|NCT00993421|DRUG|Sibutramine|given daily, orally for 24 weeks
41507801|NCT00993421|DRUG|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
41165094|NCT02624505|DRUG|Placebo|Placebo Product
41165095|NCT03068221|OTHER|anaerobic exercise|assessing anaerobic exercise status
41380916|NCT03901352|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
41380917|NCT06414408|DRUG|Doxycycline Pill|200mg Dose
41380918|NCT03072927|DEVICE|MILD|MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
41380919|NCT03072927|DEVICE|Interspinous Process Decompression|Interspinous Process Decompression
41507802|NCT00993421|DRUG|Placebo sibutramine|given daily, orally for 24 weeks
41507803|NCT00993421|DRUG|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
41507804|NCT00993421|DRUG|Placebo LY377604|given daily, orally for 24 weeks
41380920|NCT05040386|BEHAVIORAL|EPIC|Participants randomized to the intervention arm receive usual COPD care + EPIC. EPIC is informed by the ENABLE model or early palliative care. ENABLE (Educate, Nurture, Advise, Before Life Ends) is a theory-based, rigorously tested, and multicomponent early palliative care model that improved quality of life and emotional symptoms in patients with advanced cancer. The PI adapted ENABLE to meet the specific needs of patients with COPD and their care partners through EPIC. EPIC includes a series of weekly telephone-based, nurse coach-led sessions for patients (six) and their care partners (four) aided by a manualized curriculum. Participants also complete activities geared to solving problems and making difficult decisions, attend a Supportive Care clinic visit, and complete advance directives.
41380921|NCT05040386|OTHER|Usual COPD Care|Participants randomized to this arm receive standard of care for COPD. This includes routine clinic visits with their clinician, medications, inhalers, vaccinations, tobacco cessation counseling, illness education, cardiopulmonary rehabilitation, specialist referrals, and other COPD therapies deemed appropriate by their clinician.
41507805|NCT04556071|DRUG|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight\<77 kg and/or basal platelet count \<150,000/μL will take 200 mg daily.
41507806|NCT04556071|DRUG|Bevacizumab|The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.
41507807|NCT04168879|DRUG|Bupivacaine 0.5% Preservative-Free Injectable Solution|1.5 ml of Bupivacaine 0.5% Preservative-Free Injectable Solution used to block the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
40851795|NCT05755672|PROCEDURE|Resection of tumour metastases|Surgical resection of tumour metastases, according to the current clinical practice guidelines
41035340|NCT02508480|BEHAVIORAL|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
41035341|NCT00737087|DEVICE|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
41380922|NCT05570214|OTHER|Virtual Reality|Virtual reality device will be viewing calming narrated scenarios with relaxing music of walking through a forest, along a beach, through a Chinese garden, a winter landscape or taking off in a spaceship or snorkeling through a reef
41380923|NCT06137729|DRUG|PF-07899895|Participants will receive oral ascending doses.
41380924|NCT06137729|DRUG|Placebo|Participants will receive matching placebo.
41380925|NCT06623006|BEHAVIORAL|mobile health (mhealth)|The intervention will include a text-based mhealth component, designed using a behaviour change framework (Behaviour Change Wheel). The development process will be further informed by a formative research exploring perspectives of both health service providers and users on use of text based mhealth for supporting self-management in people with type 2 diabetes.
41507808|NCT04168879|DRUG|normal saline|1.5 ml of normal saline is delivered to the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
41507809|NCT02720497|BEHAVIORAL|60-minute Prolonged Exposure Therapy|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
41507810|NCT02720497|BEHAVIORAL|90-minute Prolonged Exposure Therapy|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
41507811|NCT01862484|DIETARY_SUPPLEMENT|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
41507812|NCT01862484|DIETARY_SUPPLEMENT|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
41507813|NCT02166658|DRUG|Cabazitaxel|Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
41507814|NCT04940637|DRUG|niraparib and dostarlimab|niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
41507815|NCT04272424|PROCEDURE|laparoscopic mesh fixation|laparoscopic mesh fixation by non fixation,tacker and histoacryl
41507816|NCT02677350|DRUG|Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)|Peri-fistula injections
41507817|NCT01159561|BIOLOGICAL|Western Equine Encephalitis Vaccine|Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
41507818|NCT03248973|DRUG|Ampicillin Injection|Ampicillin injection 2 g q4h for 3 weeks
41507819|NCT00327756|DRUG|Coenzyme Q10|
40851796|NCT05755672|PROCEDURE|Blood sampling during chemotherapy|Drawing of blood samples several times during patient visits for chemotherapy regimen
40851797|NCT03850535|DRUG|Idasanutlin|Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
41165096|NCT01136798|DRUG|Exenatide|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
41380926|NCT06634680|PROCEDURE|Procedure: Selection of parent(mother or father) according to children preference|Children will choose the parent who will accompany them.
41380927|NCT06634680|PROCEDURE|Procedure: Both parents will accompany the children.|Both parents will accompany the children.
41507820|NCT04927234|DEVICE|geko™ therapy|Neuro-muscular electrical stimulation of the peroneal nerve
41507821|NCT05637736|BEHAVIORAL|Mindfulness-based Stress Reduction by Therapeutic VR|Therapeutic VR+MBT was provided using a head-mounted display which designed to enclose eyes and block external stimuli almost entirely. Patients can see immersive natural scenes through VR devices and hear stereo sounds through headphones. We uploaded a programme, which was designed to induce recordings of guided meditations (The same as the MBT), musics for meditation and consists of meditation-videos of 40 minutes. We will guide patients to choose their favorite meditation videos, such as forest, seaside, lake, snow mountain, field and so on.
41507822|NCT05637736|BEHAVIORAL|Mindfulness-based Stress Reduction|39 participates randomized and allocated to this group. MBT was conducted as an 8-week group intervention. Sessions typically began with formal mindfulness meditations that include breathing exercises, prolonged expiratory relaxation, body scan, and meditation. MBT was delivered by the first author, who has specialized training in mindfulness meditation.
41507823|NCT05948176|OTHER|The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition|It is a standardized measure of fine and gross motor skills in children and youth aged 4-21 years
41507824|NCT04684043|DEVICE|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
41507825|NCT00003302|PROCEDURE|biopsy|
41507826|NCT00003302|DIAGNOSTIC_TEST|magnetic resonance imaging|
41507827|NCT00003302|DIAGNOSTIC_TEST|mammography|
41507828|NCT05440318|DEVICE|Wireless wearable digital devices|Wireless wearable digital devices (including a small patch, modified watch, and datahub smartphone with electronic Patient Reported Outcomes \[ePRO\] capability) will be provided to each participant enrolled in the study.
40851798|NCT03850535|DRUG|Cytarabine|Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m\^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m\^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
40851799|NCT03850535|DRUG|Daunorubicin|Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m\^2 QD as IV infusion.
40851800|NCT03850535|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)|After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.
40851801|NCT03625336|DIAGNOSTIC_TEST|MRI|An MRI will be obtained utilizing 3 different MRI sequences
40851802|NCT03320720|OTHER|Home Treatment|Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
40851803|NCT03320720|OTHER|Treatment-as-usual|Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
40851804|NCT05100576|DEVICE|Telemedicine system users|Telemonitoring by medical devices connected to a software system with a router.
41507829|NCT02587091|BEHAVIORAL|Portable obstetric ultrasound|This intervention was advertised at the cluster level
41507830|NCT00484640|DRUG|Coumadin|
40851805|NCT00487292|BEHAVIORAL|naps and pulses of bright light|
40851806|NCT05385055|OTHER|THS use|N/A: No intervention was assigned.
40851807|NCT05385055|OTHER|Cigarette smoking|N/A: No intervention was assigned.
40851808|NCT05385055|OTHER|Smoking abstinence|N/A: No intervention was assigned.
40851809|NCT01399320|PROCEDURE|cyanoacrylate|excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
40851810|NCT06470503|BEHAVIORAL|Exercise Program|8-week program and four-week short maintenance period.
40851811|NCT06160492|DRUG|5-aminolevulinic acid|Patients were randomly assigned to 5-aminolevulinic acid (20 mg/kg bodyweight）Those randomly allocated to 5-aminolevulinic acid were scheduled to receive freshly prepared solutions of 5-aminolevulinic acid orally 3 h (range 2-4) before induction of anaesthesia. Solutions were prepared by dissolving the contents of a vial (1·5 g) in 50 mL of drinking water.
40851812|NCT04784624|BEHAVIORAL|Lifestyle program|The cardiometabolic and weight loss program is based on The Wellness Institute clinically validated lifestyle medicine program and will be delivered virtually using a digital platform and artificial intelligence that is supported by a health coach. The program focuses on building individual's self-efficacy, motivation and importance to make and sustain healthy choices. The 16-week program begins with a health risk assessment and a personalized wellness plan. The plan includes a personalized exercise plan and nutrition strategy. Each user will regularly check-in with their personal health coach whose role is to provide expert advice and also empower, support and help make the user accountable as they build a healthy lifestyle. Coaching includes identifying obstacles to changing behaviors and how to develop new behaviors that will become the norm.
40851813|NCT00039858|DRUG|Argatroban|
40851814|NCT02528786|OTHER|No Intervention|No study drug will be administered in this study.
40851815|NCT04979611|DRUG|68Ga-NOTA-exendin-4|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously
40851816|NCT02745808|BIOLOGICAL|HUC-MSCs|The subjects will receive intracavernous injection of HUCMSC.
41035342|NCT06470672|DRUG|SHR-A1921|Anti-TROP-2 ADC
41035343|NCT06470672|DRUG|Adebrelimab|PD-L1 inhibitor
41035344|NCT00175682|DRUG|Prazosin HCL|See Detailed Description
41035345|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire between diagnostic annoucement and first line treatement
41035346|NCT05267041|BIOLOGICAL|Blood sample|One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
41035347|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire 6 months later after first line treatment
41035348|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire before second line treatment
41380928|NCT05279807|DRUG|Zofenopril|Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
41380929|NCT05279807|DRUG|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
41380930|NCT05792020|DEVICE|Focused Ultrasound Stimulation|This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.
41380931|NCT06651671|PROCEDURE|Myofascial release|THe treatment group was instructed to lay prone on the treatment table such that the skin on their upper back was visible. Participants then received direct and indirect myofascial release for 30 seconds each, performed by the same osteopathic physician.
41380932|NCT06651671|PROCEDURE|Sham (No Treatment)|The medical student gently placed their hands on the patients back for 60 seconds without manipulating the tissue in any way.
41380933|NCT06357208|OTHER|Breathing Control and Retention|4 appointments with training of Breathing Control and Retention
41380934|NCT05629741|DRUG|CMTX-101|Administered as specified in the treatment arm
41380935|NCT05629741|DRUG|Placebo|Administered as specified in the treatment arm
41380936|NCT03554759|DRUG|Avatrombopag|Avatrombopag dosing will be determined by the treating physician in conjunction with the FDA-approved package insert.
41380937|NCT04650178|OTHER|Quality-of-Life Assessment|Ancillary studies
41380938|NCT04650178|OTHER|Questionnaire Administration|Complete questionnaire
41380939|NCT06652230|OTHER|Smile Arc Marginal Ridge Approach (SAMRA)|Smile Arc Marginal Ridge Approach (SAMRA) is a new orthodontic bonding technique proposed by Dr. Dalia El Bokle where she stated that it provides more accurate orthodontic results and less time and effort needed during finished. No randomized clinical trials are done on this new approach yet so our study is the first one to test it. 0.018-inch MBT brackets will be used in our study.
41380940|NCT06652230|OTHER|MBT Chart Method|For our comparator group MBT Chart Method will be used. Using charts during orthodontic bonding procedures is considered the gold standard. 0.018-inch brackets will be used.
41380941|NCT04896697|DRUG|vilastobart (XTX101)|vilastobart (XTX101) monotherapy
41380942|NCT04896697|DRUG|Atezolizumab|1200 mg administered every 3 weeks in combination with vilastobart (XTX101)
41380943|NCT04896697|DRUG|vilastobart (XTX101)|In combination with Atezolizumab
41380944|NCT06239207|BIOLOGICAL|Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%)|Exosomes used are GFC CELL, consist of Leuco exo 97% having GFC CELL EXO SCALP 9700 powder and EXO SCALP Pep9 solution
41380945|NCT06239207|BIOLOGICAL|Platelet Rich Plasma|PRP is prepared under aseptic precautions, around 10ml of blood is collected in PRP tubes which are rotated in a centrifuge machine at 1500 RPM for 10 minutes. Which separates the blood into 2 layers: the lower RBC layer; the upper acellular plasma layer. The buffy coat along with the plasma was collected with a pipette and transferred into another test tube underwent 2nd spin at 4000 RPM for 10 min. This PRP was collected in another clean tube to be used as plasma
41380946|NCT06197698|DIAGNOSTIC_TEST|F18-FDG, Tc-99m TRODAT-1|In this project, 18F-FDG PET is used as an imaging marker of gut microbiota composition evaluation in PD patients, and the nigrostriatal dopamine system is assessed by Tc-99m TRODAT-1 SPECT.
41380947|NCT05062044|DIETARY_SUPPLEMENT|Multivitamins (Elevit, BAY987808)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
41380948|NCT05062044|DIETARY_SUPPLEMENT|Multivitamins (Elevit, BAY2906300)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
41380949|NCT05062044|DRUG|Multivitamins (Elevit, BAY987386)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
40851817|NCT02745808|BIOLOGICAL|Injectable Collagen Scaffold + HUC-MSCs|The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
40851818|NCT00002847|BIOLOGICAL|aldesleukin|
40851819|NCT00002847|BIOLOGICAL|recombinant interferon alfa|
40851820|NCT00002847|PROCEDURE|conventional surgery|
41035349|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire 6 months later after second line treatment
41380950|NCT05062044|DIETARY_SUPPLEMENT|Folic acid|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
41380951|NCT02150889|BEHAVIORAL|Running Program|16 week supervised running program
41380952|NCT02150889|BEHAVIORAL|Yoga Program|once weekly supervised yoga
41380953|NCT05925309|DRUG|Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem|Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.
41165097|NCT01136798|DRUG|Placebo|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
40851821|NCT04254094|OTHER|Neuropsychological scales|Basic Activity of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD), Clinical Dementia Rating Scale (CDR) and defining dementia criteria. Also as part of this study, an MRI examination at baseline and at 18 months follow-up will be performed in the Bordeaux center
41165098|NCT06462118|DRUG|Astegolimab|Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.
41165099|NCT03416621|BEHAVIORAL|Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
41380954|NCT05925309|DRUG|Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor|Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
41380955|NCT05319730|DRUG|Paclitaxel|80-100 mg/m2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
41380956|NCT05319730|DRUG|Irinotecan|180 mg/m2 IV infusion, administered on day 1 of every 14-day cycle.
41507831|NCT04011605|PROCEDURE|Biological Sample of Carious Dentin|Dental patient volunteers will have either areas of decayed tooth structure or recurrent caries defective fillings removed using conventional, routine procedures, which will include: local anesthesia; tooth isolation using rubber dam; removal of superficial decay, weakened tooth structure or defective filling materials with rotary tooth cutting instruments; and then removal of softened dentin using sterile sharp spoon excavators, by hand. The limit of dentin removal will be determined by the clinician's estimate of tooth hardness, that is, using present conventional and ethical practice.
41507832|NCT01869985|DRUG|HCP1104 / Mulex Tab. and Airtal Tab.|HCP1104 / Eperisone plus Aceclofenac
41507833|NCT02794246|BIOLOGICAL|CART-19 cells|
41507834|NCT03483363|DRUG|topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)|Fractures will be irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.
41507835|NCT03483363|DRUG|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure.
41507836|NCT03483363|DRUG|intravenous (IV) prophylactic antibiotic|All arms with receive standard parenteral (IV) prophylactic antibiotic.
41507837|NCT02498041|PROCEDURE|Transnasal Endoscopy|Experimental procedure with transnasal endoscopy for the first 80% of the patients (n=90). The examination is limited to the esophagus and the proximal stomach.
41507838|NCT02498041|DEVICE|Office-based disposable transnasal endoscopy Endosheath|Experimental procedure with portable, disposable transnasal endoscopy for the last 20% of patients only (n=25). The examination is limited to the esophagus and the proximal stomach.
41507839|NCT02498041|DEVICE|Standard upper GI endoscopy|Upper GI endoscopy with standard gastroscope.
41507840|NCT02498041|PROCEDURE|Esophageal biopsies|2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
41507841|NCT02713919|BEHAVIORAL|Adapted German PRO-SELF© Plus Pain Control Program|Two in-home visits (60 minutes) with at least weekly follow-up (visit or telephone call according to algorithm): Structured and tailored components; review of pain diary with participant, provision of information on pain medication, nurse coaching regarding pain self-management, detailed side-effect management plan, if distressing side-effects arise, re-evaluation together with participant at each subsequent visit.
41507842|NCT00668694|BEHAVIORAL|Stimulation|Stimulation given to the child by mother
41507843|NCT06319300|DEVICE|AI-assisted insulin dose adjustment model|We use an artificial intelligence-assisted insulin dose adjustment system to adjust insulin doses in hospitalised patients
41507844|NCT06319300|OTHER|doctor's insulin dose adjustment|participants' insulin doses are adjusted by doctors
41507845|NCT05823012|DRUG|levothyroxine sodium|Levothyroxine sodium 10 mg/mL
40851822|NCT00744107|DEVICE|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
40851823|NCT05977062|OTHER|Self screening|Score ISI (Index de Sévérité de l'Insomnie)
40851824|NCT05977062|OTHER|Phone call|Phone call at the beginning of the program and at the middle and at the end.
41165100|NCT03416621|BEHAVIORAL|Counseling and placebo drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
41165101|NCT03416621|DRUG|Counseling and active drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
41165102|NCT03450148|OTHER|Pavlok wristband with electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs
41165103|NCT03450148|OTHER|Pavlok wristband without electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
41165106|NCT03246399|DRUG|SM04690|suspension formulation of SM04690, delivered via intradiscal injection (single injection)
41380957|NCT05319730|BIOLOGICAL|Pembrolizumab|200 mg IV infusion, administered every Q3W.
41380958|NCT05319730|BIOLOGICAL|MK-4830|800 mg IV infusion, administered Q3W up to 35 infusions.
41380959|NCT05319730|DRUG|Lenvatinib|20 mg oral administration every day.
41380960|NCT05319730|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.
41380961|NCT05319730|DRUG|Antihistamine|Administered per product label.
41380962|NCT05319730|DRUG|H2 Receptor Antagonist|Administered per product label.
41380963|NCT05319730|DRUG|Acetaminophen (or equivalent)|Administered per product label.
41380964|NCT05319730|DRUG|Dexamethasone (or equivalent)|Administered per product label.
41380965|NCT04968912|OTHER|Placebo|Placebo infusion will be administered intravenously.
41380966|NCT04968912|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
41035350|NCT03006250|DRUG|Desflurane|Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
41035351|NCT03006250|DRUG|Sevoflurane|Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
41035352|NCT01844804|BIOLOGICAL|PF-06438179|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
41035353|NCT01844804|BIOLOGICAL|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
41035354|NCT01844804|BIOLOGICAL|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
41165107|NCT02880332|OTHER|Usual care|During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
41165108|NCT02880332|OTHER|Pain Neuroscience education|"This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well."
41165109|NCT02880332|OTHER|Extra care|During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
41165110|NCT03364478|PROCEDURE|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach.
41165111|NCT03364478|PROCEDURE|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach.
41380967|NCT04968912|DRUG|Standard of Care Treatment|Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
41380968|NCT01915498|DRUG|Enasidenib|Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
41380969|NCT03681561|DRUG|Ruxolitinib|"Phase I: Ruxolitinib at assigned dose\* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~* Dose Levels:~  1. (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop."
41380970|NCT03681561|DRUG|Nivolumab|Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
41380971|NCT06653296|DRUG|ENX-102|Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
41380972|NCT06653296|DRUG|Placebo|Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period
41380973|NCT06652945|OTHER|Uterine artery embolization|Uterine artery embolization under fluoroscopy
41380974|NCT00326339|DRUG|R788|R788 50 mg, 100 mg, or 150 mg PO bid
41380975|NCT00326339|DRUG|Placebo|Placebo PO bid
41507846|NCT02997748|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
41507847|NCT03996811|OTHER|Exercise education|weekly telephone consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
41507848|NCT04201184|BEHAVIORAL|Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules|Caregivers will receive 12 lessons, weekly, over a period of 12 weeks. Full curriculum contains: 4 lessons on cultural connection and traditions, 4 lessons on parenting adapted from Family Spirit intervention, and 4 lessons on stress and trauma adapted from CETA. modules
41507849|NCT04201184|BEHAVIORAL|Active nutrition control|The active control condition will receive nutrition information, weekly food boxes and recipes. Recipes will be developed based on seasonal foods and a shopping list for making future meals will be included.
41507850|NCT06257251|OTHER|Histological slides digitization|Histological slides of the capsule samples taken during surgery will be collected for analysis and digitized. Using the NDPview2 software, the investigators will manually count the silicone particles present in the peri-prosthetic capsule and measure the surface area of the capsule to estimate the silicone particle density.
41035355|NCT02433353|DRUG|Venlafaxine XR|Serotonin norepinephrine reuptake inhibitor
41035356|NCT02433353|BEHAVIORAL|EMDR|psychotherapy
41035357|NCT02433353|DRUG|Placebo|Look-alike venlafaxine XR tablets containing no active drug
41035358|NCT06635473|BEHAVIORAL|Information support|The experimental group was given intervention measures. According to the general data survey, discharge readiness and self-efficacy assessment, parents were divided into low, middle and high discharge readiness groups and low, middle and high self-efficacy groups, respectively, using WeChat mini programs to push different content.
41380976|NCT04463992|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
41380977|NCT04463992|OTHER|Usual Care|Usual care as provided by local oncologists
41380978|NCT06008756|DRUG|Enlicitide Decanoate|Enlicitide Decanoate 20 mg tablet taken by mouth.
41380979|NCT06008756|DRUG|Placebo|Placebo tablet matched to enlicitide decanoate taken by mouth.
41380980|NCT06649630|DRUG|NNC0442-0344 A|"SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally."
41380981|NCT06649630|DRUG|Placebo|"SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally."
41380982|NCT03725436|DRUG|MDM2/MDMX Inhibitor ALRN-6924|Given IV
41380983|NCT03725436|DRUG|Paclitaxel|Given IV
41380984|NCT06152653|DRUG|n-acetylcystine (NAC)+ albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
41380985|NCT06152653|DEVICE|AeroEclipse-VersaPAP System|The AeroEclipse-VersaPAP System combine continuous positive inspiratory pressure and nebulizer in one system.
41380986|NCT03382691|DEVICE|blood pressure check|Check blood pressure using new device and conventional device alternatively. Compare blood pressure measured with new device and conventional device.
41380987|NCT04633434|BEHAVIORAL|The Talk Parenting Skill for Alexa|In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
41507851|NCT03464630|BEHAVIORAL|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
41035359|NCT06635473|BEHAVIORAL|Stress and coping|According to the results of self-efficacy and anxiety assessment, different interventions were based on different scores. Give encouragement and affirmation to parents with low anxiety and high self-efficacy. Parents with high anxiety and low self-efficacy should push stress relief methods such as mindfulness relaxation therapy in time. And through the wechat mini program to provide parents to respond to the pressure of the problem, the medical staff to give timely feedback.
41380988|NCT00249327|BEHAVIORAL|education|
41507852|NCT03464630|BEHAVIORAL|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
41507853|NCT03617783|DRUG|Prebiotin|Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)
41507854|NCT03617783|DRUG|Placebo|placebo-OEI
41507855|NCT05270408|DEVICE|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 1mA to the scalp.
41507856|NCT05270408|DEVICE|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 2mA to the scalp.
41507857|NCT05270408|DEVICE|Sham Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver no current to the scalp.
41507858|NCT00006348|DRUG|ondansetron|
41035360|NCT06635473|BEHAVIORAL|Specialist guidance|Carry out offline science popularization education and specialized training, and highly qualified specialist doctors and nurses will train parents, and parents will be assessed after training, and personalized guidance will be given according to the weak points of each parent\&#39;s assessment.
41035361|NCT06635473|OTHER|Social support and interaction|Support and encouragement for parents continue from admission to discharge, so that parents feel that even after discharge, there are people to accompany and support them.
41035362|NCT06635473|BEHAVIORAL|Parentage development|Since parents and children are separated during the hospitalization of preterm infants, we will create an environment where parents still play the role of parents, and stimulate parental competence through kangaroo care, parental touch, and breastfeeding.
41035363|NCT02076152|DEVICE|FMISO PET|
41165112|NCT02168621|PROCEDURE|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score \<30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument.
41380989|NCT03861533|OTHER|survey|Cross-Reference
41380990|NCT01042379|DRUG|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
41380991|NCT01042379|DRUG|AMG 386 with or without Trastuzumab|Arm is closed.
41380992|NCT01042379|DRUG|AMG 479 (Ganitumab) plus Metformin|Arm is closed.
41380993|NCT01042379|DRUG|MK-2206 with or without Trastuzumab|Arm is closed.
41380994|NCT01042379|DRUG|AMG 386 and Trastuzumab|Arm is closed.
41380995|NCT01042379|DRUG|T-DM1 and Pertuzumab|Arm is closed.
41507859|NCT00006348|OTHER|placebo|
41507860|NCT00199147|DRUG|Cytarabine|
41507861|NCT00199147|DRUG|Etoposide|
41507862|NCT00199147|DRUG|Idarubicin|
41507863|NCT00199147|DRUG|G-CSF|
41507864|NCT00199147|DRUG|Fludarabine|
41507865|NCT00199147|PROCEDURE|Stem cell apheresis|
41507866|NCT00199147|PROCEDURE|Stem cell transplantation|
41507867|NCT02358239|PROCEDURE|acupuncture|Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
41507868|NCT01105624|DRUG|azithromycin ophthalmic solution, 1%|1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
41380996|NCT01042379|DRUG|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
41380997|NCT01042379|DRUG|Ganetespib|Arm is closed.
41380998|NCT01042379|DRUG|ABT-888|Arm is closed.
41380999|NCT01042379|DRUG|Neratinib|Arm is closed.
41381000|NCT01042379|DRUG|PLX3397|Arm is closed.
41381001|NCT01042379|DRUG|Pembrolizumab - 4 cycle|Arm is closed.
41381002|NCT01042379|DRUG|Talazoparib plus Irinotecan|Arm is closed.
41381003|NCT01042379|DRUG|Patritumab and Trastuzumab|Arm is closed.
41381004|NCT01042379|DRUG|Pembrolizumab - 8 cycle|Arm is closed.
41381005|NCT01042379|DRUG|SGN-LIV1A|Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
41381006|NCT01042379|DRUG|Durvalumab plus Olaparib|Arm is closed.
41381007|NCT01042379|DRUG|SD-101 + Pembrolizumab|Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for \>T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
41507869|NCT01105624|DRUG|Visine® for Contacts®|1-2 drops QID for the treatment period (29 ± 1 day)
41507870|NCT01822366|BEHAVIORAL|Trauma-focused Cognitive Behavioral Therapy|
41507871|NCT04935229|DRUG|SD-101|SD-101 doses will be delivered via hepatic artery infusion using pressure enabled drug delivery using the TriNav device
41507872|NCT04935229|BIOLOGICAL|Nivolumab|During Cohort B, nivolumab will be administered together with SD-101 and during Cohort C, it will be administered with ipilimumab and SD-101
41507873|NCT04935229|BIOLOGICAL|Ipilimumab|During Cohort C, ipilimumab will be administered together with nivolumab and SD-101
41507874|NCT04935229|BIOLOGICAL|Nivolumab and Relatlimab|During optional Cohort C1, nivolumab and relatlimab will be administered with SD-101
41507875|NCT02784561|DRUG|Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)|busulfan (3.2 mg/kg/day intravenously \[i.v.\], days -10 to -8)
41507876|NCT02784561|DRUG|Cytarabine(Actavis Italy S.p.A)|cytarabine (1.6 g/m2/day, days -7 to -3)
41507877|NCT02784561|DRUG|Fludarabine (Bayer)|fludarabine (30 mg/m2, day -7 to -3),
41507878|NCT02784561|DRUG|granulocyte colony-stimulating factor (KirinKunpeng)|granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)
41381008|NCT01042379|DRUG|Tucatinib plus trastuzumab and pertuzumab|Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
41507879|NCT02784561|DRUG|rabbit ATG（Sanofi/Genzyme）|ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
41507880|NCT01555697|DRUG|Memantine|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
41381009|NCT01042379|DRUG|Cemiplimab|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
41381010|NCT01042379|DRUG|Cemiplimab plus REGN3767|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
41381011|NCT01042379|DRUG|Trilaciclib with or without trastuzumab + pertuzumab|"Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles~For HER2+:~Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization"
41381012|NCT01042379|DRUG|SYD985 ([vic-]trastuzumab duocarmazine)|SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
41381013|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
41507881|NCT01555697|DRUG|Placebo|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
41507882|NCT03776916|OTHER|Simethicone administration 20-30 min before the procedure|Patients intake simethicone 20-30 min before the procedure
41507883|NCT03776916|OTHER|Simethicone administration 31-60 min before the procedure|Patients intake simethicone administration 31-60 min before the procedure.
41507884|NCT03776916|OTHER|Simethicone administration > 60 min before the procedure|Patients intake simethicone administration \> 60 min before the procedure.
41381014|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
41507885|NCT02989324|DRUG|MisoprostoL|Vaginal MisoprostoL
41507886|NCT02989324|DEVICE|Foley Catheter|Misoprostol Plus Foley Catheter
41507887|NCT00143871|DRUG|Rituximab|
40851825|NCT05977062|OTHER|Online questionnaires|To be completed at week 1, 6, 12 and 24.
40851826|NCT02587819|DRUG|Treatment with BSCT|"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."
40851827|NCT06224803|DIETARY_SUPPLEMENT|Compound plant extracts|Total supplement including bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder.
40851828|NCT06224803|DIETARY_SUPPLEMENT|Indigestible dextrin|Indigestible dextrin as placebo intervention
41035364|NCT02076152|DEVICE|MRI|"MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2\*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
41035365|NCT02076152|DRUG|Bevacizumab|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
41035366|NCT02076152|DRUG|CCNU|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
41035367|NCT04023695|DRUG|Corticosteroid with lidocaine with epinephrine|Trigger finger injection
41035368|NCT04023695|DRUG|Corticosteroid with normal saline|Trigger finger injection
41035369|NCT06636448|PROCEDURE|the effect of body mass index during low-flow anesthesia|The investigator planned to evaluate the effect of body mass index on patient outcomes during low-flow anesthesia in patients undergoing gynecologic cancer surgery.
41035370|NCT03811067|PROCEDURE|Transversus abdominis plane block|Transversus abdominis plane block will be performed bilaterally after the surgery.
41035371|NCT03811067|PROCEDURE|Rectus sheath block|Rectus sheath block will be performed bilaterally after the surgery.
41165113|NCT02168621|PROCEDURE|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval.
41381015|NCT01042379|DRUG|Amcenestrant|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks
41381016|NCT01042379|DRUG|Amcenestrant + Abemaciclib|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
41381017|NCT01042379|DRUG|Amcenestrant + Letrozole|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
40851829|NCT01867086|BIOLOGICAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
40851830|NCT01867086|DRUG|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
41381018|NCT01042379|DRUG|ARX788|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
41381019|NCT01042379|DRUG|ARX788 + Cemiplimab|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
41381020|NCT01042379|DRUG|VV1 + Cemiplimab|VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
41381021|NCT01042379|DRUG|Datopotamab deruxtecan|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
41381022|NCT01042379|DRUG|Datopotamab deruxtecan + Durvalumab|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
41507888|NCT03928210|DRUG|Digoxin|Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
41507889|NCT02443597|OTHER|ultrasound|trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
40851831|NCT01867086|DRUG|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
40851832|NCT04477655|PROCEDURE|Awake prone positioning|Patients will be asked to remain in prone position or lateral decubitus throughout the day as long as possible.
40851833|NCT04477655|PROCEDURE|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%
40851834|NCT06186258|DEVICE|percutaneous pulmonary valve implantation (PPVI)|The only inclusion criterion is a successful PPVI to treat RVOT dysfunction. Procedural techniques were at each operator's discretion as well as post-procedure treatments and patient's follow-up. As we sought to assess IE incidence during follow-up, patients who underwent catheterization for intended PPVI but who did not had a successful valve implantation were not included. Successful PPVI was defined as patient discharged alive without valve surgery after successful valve implantation in the RVOT.
40851835|NCT03662594|OTHER|ECMO|In this project, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control. These characteristic clear accounts of the high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility.
40851836|NCT02358226|BEHAVIORAL|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
40851837|NCT02358226|BEHAVIORAL|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
40851838|NCT06438432|OTHER|RAIT|The RAIT program focuses on improving postural control and balance of the entire body, including the trunk and other affected muscles, through autonomous actions in intermediate postures. This approach uses fundamental automatic control of postural support and balance to enhance the use of affected muscles during all postural and locomotor tasks. The child controls their balance during various voluntary actions from intermediate postures like alternating between four-legged and cobra postures, or swinging from the camel posture. These actions, less difficult than standing and walking, are expected to benefit the latter. The child also performs more challenging trunk movements, requiring dissociation of scapular and pelvic girdle movements or reducing lumbar lordosis.
40851839|NCT00004050|BIOLOGICAL|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
41035372|NCT03372226|BEHAVIORAL|Online self-help program|The program consists of 10 modules with many interactional exercises and homework-sheets. Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse.
41381023|NCT01042379|DRUG|Zanidatamab|Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks
41381024|NCT01042379|DRUG|Lasofoxifene|Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
41381025|NCT01042379|DRUG|Z-endoxifen|Z-endoxifen: 10 mg QD, p.o., for 24 weeks
41381026|NCT01042379|DRUG|ARV-471|ARV-471: 200 mg QD, p.o, for 24 weeks
41381027|NCT01042379|DRUG|ARV-471 + Letrozole|ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
41381028|NCT01042379|DRUG|ARV-471 + Abemaciclib|ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks
41381029|NCT01042379|DRUG|Endoxifen + Abemaciclib|Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks
41381030|NCT01042379|DRUG|Rilvegostomig + TDXd|Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks
41381031|NCT01042379|DRUG|Dan222 + Niraparib|DAN222: 8mg/m2 IV QW for 12 weeks Niraparib: 200mg QD p.p., 12 weeks
41381032|NCT01042379|DRUG|Sarilumab + Cemiplimab + Paclitaxel|Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks
41381033|NCT02252172|DRUG|Daratumumab IV|Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
41381034|NCT02252172|DRUG|Lenalidomide|Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
41381035|NCT02252172|DRUG|Dexamethasone|Dexamethasone 40 mg orally or intravenously once in a week.
41381036|NCT02252172|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
41381037|NCT06604806|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed transversely over the anterior superior iliac spine (ASIS). After identifying the ASIS, the transducer is aligned with the pubic ramus and rotated approximately 45 degrees to become parallel to the inguinal crease. The transducer is moved medially until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and psoas tendon are clearly visualized as anatomical landmarks. After confirming the correct location with saline injection, 50 mg of 0.25% bupivacaine will be administered.
41381038|NCT06604806|PROCEDURE|Quadro-Iliac plane block|With the patient in the prone position, a low-frequency convex transducer (2-6 MHz) and a 22G x 100 mm peripheral nerve block needle (Stimuplex® Ultra 360®, B-Braun) will be used. The transducer will be placed transversely at the L3 level to identify the spinal processes, followed by lateral movement to visualize the transverse process within the erector spinae muscle. The transducer will then be rotated parasagittally and moved caudally to locate where the Quadratus Lumborum muscle (QLM) attaches to the iliac crest. After confirming the location with saline, 50 mg of 0.25% bupivacaine will be administered under the fascia of the QLM.
41381039|NCT06651632|DEVICE|Aquablation Therapy|The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy.
41381040|NCT06651632|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is a surgery that is performed through an incision in the lower abdomen or perineum, or with a laparoscope or robotic system to remove the entire prostate gland.
41381041|NCT01256229|DEVICE|cochlear implantation|This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
41381042|NCT01256229|DEVICE|hearing aids|This is the conventional therapy for deaf children with developmental delays.
41381043|NCT06651333|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.
41035373|NCT00906672|DEVICE|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
41035374|NCT00906672|PROCEDURE|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
41507890|NCT05705037|OTHER|CPP-ACPF|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
41035375|NCT05726929|OTHER|Osteopathic treatment|Osteopathic Manual Treatment
41381044|NCT03225339|DIETARY_SUPPLEMENT|Low Energy Diet|Low Energy Diet
41381045|NCT05636475|OTHER|Manual hand massage after laparoscopic cholecystectomy surgery|Manual hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
41381046|NCT05636475|OTHER|Machine-based hand massage after laparoscopic cholecystectomy surgery|Machine-based hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
41035376|NCT05726929|OTHER|Capsaicin QUTENZA Patch (TAU)|Capsaicin QUTENZA Patch is the treatment as usual (TAU) delivered in the medical algology service
41381047|NCT03007615|OTHER|Intimate Lubricant Gel|
41381048|NCT04527406|PROCEDURE|posterior hemivertebra resection|The subjects in early surgical group are arranged to be admitted to for surgical treatment very soon. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
41035377|NCT00650832|DRUG|TMC114; darunavir; Prezista|
41035378|NCT00004129|RADIATION|brachytherapy|
41035379|NCT00004129|RADIATION|phosphorus P32|
41035380|NCT02669823|OTHER|None, treatment as actual best practice|
41035381|NCT02638662|OTHER|Observational|Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
41035382|NCT02995772|DRUG|Aromatase Inhibitors (Arimidex)|Comparison of efficacy with chemotherapy
41035383|NCT02995772|DRUG|Tamoxifen|Comparison of efficacy with chemotherapy
41035384|NCT02995772|PROCEDURE|SOB|Comparison of efficacy with chemotherapy
41035385|NCT02995772|DRUG|FAC|Comparison of efficacy with hormonal therapy
41035386|NCT02995772|DRUG|Aromatase Inhibitors (Femara)|Comparison of efficacy with chemotherapy
41035387|NCT02995772|DRUG|Aromatase Inhibitors (Aromasin)|Comparison of efficacy with chemotherapy
41035388|NCT02747134|BEHAVIORAL|Emotion Regulation and Mindfulness skills|
41035389|NCT03496038|PROCEDURE|L-PRF|The use of the L-PRF as graft material for sinus augmentation procedure will be analysed
41035390|NCT03496038|PROCEDURE|DBBM|The use of bovine xenograft as graft material for sinus augmentation procedure will be analysed
41035391|NCT05467644|PROCEDURE|Treatment of Fracture Related Infection|Observational Retrospective Study. Only one group. Patients diagnosed with fracture-related infection and submitted to surgical treatment
41165114|NCT05388695|BIOLOGICAL|Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells|Single or sequential injection of CD19, CD20 and CD22 CAR T cells.
40851840|NCT01093391|DEVICE|DRUG ELUTING STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
40851841|NCT01093391|DEVICE|BARE METAL STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
40851842|NCT05325840|OTHER|music terapy|The aim of this study was to examine the effects of the music concert applied during the nonstress test procedure on the health of the fetus, the anxiety level of the pregnant woman and blood pressure.
40851843|NCT01180010|PROCEDURE|Low Dose CT|"A chest CT uses special radiographic equipment using x-rays to capture images of the chest, and with the aid of a computer, processes the images to create cross-sectional pictures or slices of the areas of interest. The images can then be printed out or examined on a monitor. The CT scanner is a large unit with a hole running directly through its center, giving the appearance of a doughnut. During the scanning, patients will lie flat on their back on a table, and they are periodically asked to hold their breath. The table will first move through the scanner to determine the correct starting position. The rest of the scans are made as the table moves more slowly through the cavity in the scanner."
40851844|NCT01393639|DRUG|PF-04171327|1 mg tablet once daily (QD) for 8 weeks
40851845|NCT01393639|DRUG|PF-04171327|5 mg tablet once daily (QD) for 8 weeks
40851846|NCT01393639|DRUG|PF-04171327|10 mg tablet once daily (QD) for 8 weeks
40851847|NCT01393639|DRUG|PF-04171327|15 mg tablet once daily (QD) for 8 weeks
40851848|NCT01393639|DRUG|prednisone|5 mg capsule once daily for 8 weeks
40851849|NCT01393639|OTHER|prednisone|10 mg capsule once daily for 8 weeks
40851850|NCT01393639|OTHER|placebo|placebo (tablet or capsule) once daily (QD) for 8 weeks
40851851|NCT01707901|DRUG|ONO-8539|Treatment
40851852|NCT01707901|OTHER|Placebo|Placebo
40851853|NCT02595255|OTHER|No intervention|No intervention
41035392|NCT04024618|PROCEDURE|Parenteral Nutrition/Enteral Nutrition|Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.
41035393|NCT02559674|BIOLOGICAL|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
41035394|NCT02559674|BIOLOGICAL|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
41035395|NCT02559674|BIOLOGICAL|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
41035396|NCT01821664|DEVICE|Prosthetic vascular graft|Implantation of a prosthetic vascular graft
41381049|NCT04527406|PROCEDURE|conservative treatment+ delayed posterior hemivertebra resection|In traditional surgical group, subjects received conservative treatment firstly with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5. The operation choice is identical with early surgical group. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
41381050|NCT06650631|DEVICE|Knee Heatwraps|To treat the painful knee joint in patients with osteoarthritis without acute flares or inflammation. The investigational device will be used in accordance with the Instructions for Use.
41381051|NCT05888818|OTHER|Cold application|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
41381052|NCT00677170|DRUG|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
41381053|NCT01516060|DRUG|Efavirenz|400mg qd; 2 x 200mg
41381054|NCT01516060|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
41381055|NCT03660007|PROCEDURE|Fresh or frozen embryo transfer IVF|
41507891|NCT05705037|OTHER|PBMT|A placebo mousse (Elmex Junior®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
41381056|NCT02965716|BIOLOGICAL|Pembrolizumab|Given IV
41381057|NCT02965716|BIOLOGICAL|Talimogene Laherparepvec|Given IL
41381058|NCT04928794|PROCEDURE|Erector Spinae Plane Block|Regional anesthesia with injected local anesthetic solution, placed in space underlying erector spinae muscles
41381059|NCT04928794|PROCEDURE|Paravertebral Block|Regional anesthesia with injected local anesthetic solution, placed in space adjacent to vertebrae
41381060|NCT06653478|OTHER|No Intervention|No Intervention
41381061|NCT03244384|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41035397|NCT01673802|DRUG|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
41035398|NCT02706158|DIETARY_SUPPLEMENT|1500 mg Calcium and 1200 IU Vitamin D for 2 months|1500 mg Calcium and 1200 IU Vitamin D for 2 months
41035399|NCT02706158|BEHAVIORAL|balanced diet|participants will get a balanced diet according to pregnancy stage
41035400|NCT05659602|BIOLOGICAL|HH-120 Nasal Spray|HH-120 Nasal Spray 8-10 times per day for 6 consecutive days
41035401|NCT05110196|DRUG|Capmatinib 150 mg|Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
41035402|NCT05110196|DRUG|Capmatinib 200 mg|Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
41035403|NCT01155947|DRUG|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
41035404|NCT04210453|DRUG|Vitamin C|"Participants in Vitamin C group are administered IV vitamin C diluted in 100 cc normal saline 1 day before surgery, at rewarming during surgery, 3 hours after surgery, and every 6 hours thereafter until postoperative 24 hours."
41035405|NCT04210453|DRUG|Control (Normal saline)|"Participants in Control group are administered IV 100cc normal saline at the same timepoint as above."
41035406|NCT00000831|DRUG|Lamivudine|
41035407|NCT00000831|DRUG|Stavudine|
41035408|NCT00000831|DRUG|Zidovudine|
41035409|NCT00000831|DRUG|Didanosine|
41035410|NCT00938873|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
41381062|NCT03244384|OTHER|Clinical Observation|Undergo observation
41381063|NCT03244384|PROCEDURE|Computed Tomography|Undergo a CT scan
41381064|NCT03244384|PROCEDURE|CT Urography|Undergo a CT urography
41381065|NCT03244384|PROCEDURE|Cystoscopy|Undergo a cystoscopy
41381066|NCT03244384|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
41381067|NCT03244384|BIOLOGICAL|Pembrolizumab|Given IV
41381068|NCT03244384|OTHER|Pharmacological Study|Correlative studies
41035411|NCT06497478|DIAGNOSTIC_TEST|Ultrasonographic examination|"Ultrasonographic examination will be performed using a high-resolution (Epiq Elite Philips Medical Systems, Monza, Italia) and a linear 12-9 MHz transducer.~The patients will be placed in a supine position. Starting with the probe at the base of the neck, the common carotid artery will be explored on the transverse plane and then on the sagittal one, continuing in a cranial sense up to the carotid bifurcation. The medium-intimal thickness will be measured, defined as distance from the first hyperechoic line to the second hyperechoic line.~The femoropopliteal and run-off segments will be continuously scanned from the subinguinal region to the paramalleolar region with axial and sagittal scans. All segments will be examined for the presence of vessel wall calcifications and/or atherosclerotic plaques. In addition, flow velocity measurements will be obtained using spectral Doppler imaging and color Doppler imaging."
41035412|NCT00375687|DRUG|Triptorelin|
41035413|NCT02605057|DRUG|LEO 80185 gel|
41035414|NCT02605057|DRUG|Dovobet(r) Ointment|
41035415|NCT06635265|DEVICE|Target Stimulation (HGN, AC, GG, Strap muscles)|Simulation of a combination of: HGN, AC, GG or strap muscles
41035416|NCT00158938|DEVICE|EASYTRAK 3 left ventricular pacing lead|
41035417|NCT01298791|BEHAVIORAL|Sitting|Providers will sit during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain seated while communicating with the patient and caregiver.
41035418|NCT01298791|BEHAVIORAL|Standing|Providers will stand during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain standing while communicating with the patient and caregiver.
41035419|NCT02960529|PROCEDURE|extra-peritoneal high ligation of hernia|
41381069|NCT03244384|OTHER|Quality-of-Life Assessment|Ancillary studies
41381070|NCT03244384|OTHER|Questionnaire Administration|Ancillary studies
41381071|NCT06652516|PROCEDURE|plasma exchange|"comparison between the 2 methods of plasma exchange as regards efficacy, performance and adverse events.~Procedure of therapeutic plasma exchange (TPE) :~mTPE will be done by bellco hemodialysis machine (Formula 2000), while cTPE will be done by Nigale Plasma Collector (XJC 2000). The vascular access used for both types of plasma exchange will be central venous catheter inserted into the internal jugular vein, subclavian or femoral vein.~Prescription of TPE The amount of plasma to be treated is usually equivalent to the patient's estimated plasma volume (EPV).~Estimated plasma volume will be calculated using the following formula (Kaplan formula) in litres:~* EPV = 0.07 x wt (kg) x (1 - hematocrit) in males.~* EPV = 0.065 x wt (kg) x (1 - hematocrit) in females."
41507892|NCT05705037|OTHER|CPP-ACPF+PBMT|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2.
41381072|NCT06653335|BEHAVIORAL|Education Support Programme via Text Message|All students to be included in the study will be pre-tested via Google Form's. After the pre-test, the students in the experimental group will be sent images created by the researchers via text message for 4 weeks (22 days) and consisting of the information given in the Basic Principles and Practices in Midwifery Course. Each visual will contain one piece of information. The researchers will send 6 visuals to the students in the experimental group via text message every day for 4 weeks, except Saturdays and Sundays. The post-test will be applied immediately after the end of the implementation process. The messages will be short and contain a single piece of information.
41507893|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
41507894|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
41035420|NCT02960529|PROCEDURE|intraabdominal high ligation of hernia|
41381073|NCT06651970|DRUG|Acalabrutinib|Acalabrutinib Monotherapy
41381074|NCT06651970|OTHER|Investigator's choice of treatment|control arm treatment type will be defined by the PI prior to randomisation
41381075|NCT06060210|DRUG|normal Saline|50-ml Saline
41381076|NCT06060210|DRUG|Ketamine|50-ml volumes, and the ketamine concentration is 1 mg/ml
41381077|NCT03848000|OTHER|Exercise Programme|Two sessions per week for 12 consecutive weeks. 30 minute education talks covering topics regarding the physical and mental health benefits of exercise and behaviour change. The following 30-60 minute exercise sessions will utilise pad-boxing, football, body-weight training and circuit training.
41381078|NCT03848000|BEHAVIORAL|NHS Standard Care|Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
41381079|NCT03882034|DRUG|Pegvisomant|A fixed dose of pegvisomant 10-mg started on Day 1 of intervention and continued daily afterwards, will be administered subcutaneously according to manufacturer's recommendations. Adjustment of the dose will occur as per protocol.
41381080|NCT06634420|BIOLOGICAL|NTLA-2002|CRISPR/Cas9 gene editing system delivered by lipid nanoparticle (LNP) for intravenous (IV) administration
41381081|NCT06634420|BIOLOGICAL|Normal Saline IV Administration|The administration of intravenous (IV) normal saline
41035421|NCT06081309|DEVICE|EEG-based personalized TMS|Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
41165849|NCT03016949|BIOLOGICAL|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
41381082|NCT06550440|BEHAVIORAL|family integrated care|Trained NICU nurses give effective education to parents of children, and regard parents as a part of NICU team, so that they can actively provide positive care for babies instead of passive caregivers. Parents mainly participate in nursing care such as bottle feeding, changing diapers, skin contact and so on.
41381083|NCT06652217|DEVICE|Digitally manufactured occlusal splint.|digitally manfactured occlusal splint using intra oral scanner and jaw traccking device for data acqusition and 3d printing for manfacturing of the device
41381084|NCT06652217|DEVICE|conventionally manufactured occlusal splint|the occlusal device will be manufactured conventionally using impression and and anterior deprogramer with bite registeration material for data aquesition and usual construction method using clear acrylic.
41381085|NCT04495296|DRUG|TST001|TST001 will be administered by specified doses on specified day
41507895|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
41507896|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
41507897|NCT03904108|DRUG|Ramucirumab|platinum doublets chemotherapy plus ramucirumab, intravenously(IV)
41507898|NCT01527409|BEHAVIORAL|Tailored health partnership program|"When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).~Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.~The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement."
41381086|NCT04495296|DRUG|Oxaliplatin|Oxaliplatin will be administered by specified doses on specified day
40851854|NCT03154437|BIOLOGICAL|Emicizumab|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) per week subcutaneously (SC) for 4 weeks, followed by a maintenance dose of 1.5 mg/kg per week SC thereafter. Treatment with emicizumab will continue until unacceptable toxicity, withdrawal of consent, participant or physician decision to discontinue treatment, death, the participant is able to obtain commercial drug after emicizumab becomes commercially available, or the sponsor decides to discontinue emicizumab clinical development, whichever occurs first.
41381087|NCT04495296|DRUG|Capecitabine|Capecitabine will be administered by specified doses on specified day
41381088|NCT04495296|DRUG|Paclitaxel|Paclitaxel will be administered by specified doses on specified day
41381089|NCT04495296|DRUG|Gemcitabine|Gemcitabine will be administered by specified doses on specified day
41381090|NCT04495296|DRUG|Cisplatin|Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
41381091|NCT04495296|DRUG|Nivolumab|Nivolumab will be administered by specified doses on specified day
41381092|NCT05731128|DRUG|Dupilumab|injection solution subcutaneous
41381093|NCT05731128|DRUG|Placebo|injection solution subcutaneous
41381094|NCT06395389|BEHAVIORAL|Health Education (HealthEdu)|The Health Education condition is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session focuses on providing in-depth information on good sleep hygiene and habits to improve sleep and information on positive eating habits, nutrition, and physical activity/functional exercise. The second session focuses on providing information about stress and social connection.
41381095|NCT06395389|BEHAVIORAL|Values in Action (VIA)|VIA is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session encourages participants to ask themselves what is important to them. This discussion emphasizes identifying values and ways to live in line with their values, as well as why they use cannabis and providing personalized feedback related to their reasons for use. The second session asks participants to reflect on information from session one and consider what they would like to do next to live in line with their values.
41381096|NCT04469465|DRUG|Danicopan|Oral tablet
41381097|NCT04469465|DRUG|Placebo|Oral tablet
41381098|NCT04469465|DRUG|C5 Inhibitor|Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
41507899|NCT01527409|BEHAVIORAL|Usual care and health education workshop|"While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.~Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group."
41381099|NCT03907488|PROCEDURE|Biospecimen Collection|Undergo peripheral blood collection
41381100|NCT03907488|DRUG|Brentuximab Vedotin|Given IV
41381101|NCT03907488|PROCEDURE|Computed Tomography|Undergo PET/CT or CT scan
41381102|NCT03907488|DRUG|Dacarbazine|Given IV
41381103|NCT03907488|DRUG|Doxorubicin Hydrochloride|Given IV
41381104|NCT03907488|BIOLOGICAL|Filgrastim|Given SC or IV
41381105|NCT03907488|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41381106|NCT03907488|BIOLOGICAL|Nivolumab|Given IV
41381107|NCT03907488|BIOLOGICAL|Pegfilgrastim|Given SC
41381108|NCT03907488|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
41507900|NCT04617912|DEVICE|Long AFOV PennPET Explorer|A long-axial field-of-view (LAFOV) time-of-flight PET scanner, developed at the University of Pennsylvania, being tested for real-world applications.
41507901|NCT01533012|PROCEDURE|Pressure difference|Peak inspiratory pressures difference between two lungs
41507902|NCT00644930|DEVICE|the application of NPPV|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
41507903|NCT00644930|DEVICE|invasive ventilation|Standard therapy group (invasive ventilation). Patients in need of endotracheal intubation were mechanically ventilated with Amadeus (Hamilton, Via Nova, Switzerland) and Esprit (Respironics, PA, USA) ventilators in the assist-control or synchronized intermittent mandatory ventilation (SIMV) mode.
41507904|NCT02616302|DRUG|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
41507905|NCT06038487|PROCEDURE|Immediate loading of maxillary implant overdenture|The denture will be immediately connected to the implants. The abutment screw will be torqued at 15 Ncm. The Novaloc cap attachments will be picked up intra-orally using cold curing resin. To avoid contact of the resin with the surgical wound, a circular portion of a sterile rubber dam sheet will be adapted on the cap attachment once placed on the abutment during the pickup procedure. Occlusion is then checked and adjusted if necessary as well as the adaptation on the residual ridges and the patient dismissed. The patients in the test group will be instructed not to remove the prosthesis for one week.
41507906|NCT06038487|PROCEDURE|Delayed loading of maxillary implant overdenture|A cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as described for the test group. The abutment screw will be torqued at 35 Ncm. As post-surgical instructions, the patients will be asked not to brush the operated areas and to rinse instead with 0,12% chlorhexidine solution twice a day for 1 minute for 14 days. Pain control is provided with 400 mg ibuprofen, as needed. Soft diet is recommended for 2 weeks. The patients in the control group will be asked not to wear the denture for 7 days.
41507907|NCT00573261|DRUG|Pregabalin|Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
41507908|NCT00573261|DRUG|Placebo|Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
41507909|NCT05196308|DRUG|Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)|"Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator."
41507910|NCT05196308|DRUG|Placebo administration|"For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator."
41507911|NCT01864395|PROCEDURE|Centrifugation Method|Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
41507912|NCT01864395|PROCEDURE|Online MUF|Hemofilter is used online while the heart-lung machine is connected to the patient.
41507913|NCT01864395|PROCEDURE|Offline MUF|Hemofilter is used offline when the heart-lung machine is not connected to the patient.
41507914|NCT01141855|DRUG|Champix|"Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days~1mb b.d. for 70 days (full course 3 months)"
41507915|NCT01141855|BEHAVIORAL|Counselling alone|Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
41507916|NCT04631536|DRUG|Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol|active Comparator: Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc). Treatment to be continued until 14 days or discharge/death whichever occurs first. It includes: Nebivolol 5 mg PO daily, Sigmart 10 mg PO twice daily, Atorvastatin 40 mg PO daily, Folic Acid 5 mg PO daily, L-arginine 1000 mg PO 3 times daily.
41507917|NCT04631536|DRUG|Placebo|Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
41381109|NCT03907488|OTHER|Quality-of-Life Assessment|Ancillary studies
41381110|NCT03907488|OTHER|Questionnaire Administration|Ancillary studies
41507918|NCT00736632|DRUG|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
41507919|NCT00736632|DRUG|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
41507920|NCT02166710|DEVICE|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
40851855|NCT02080299|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.
41381111|NCT03907488|RADIATION|Radiation Therapy|Receive radiation therapy
41381112|NCT03907488|DRUG|Vinblastine Sulfate|Given IV
41381113|NCT05546385|DEVICE|Partial Rebreathing Device|Partial Rebreathing Device
41381114|NCT05546385|DEVICE|Sham breathing device|Sham breathing device
41381115|NCT03153319|DRUG|Adalimumab Injection [Humira]|Investigational Drug
41381116|NCT03153319|DRUG|Saline Solution for Injection|Placebo Comparator
41035422|NCT00400010|BEHAVIORAL|Expert System Intervention|Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
41381117|NCT05233397|DRUG|Tocilizumab|For \< 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks
41507921|NCT02166710|DEVICE|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
41381118|NCT05146700|DRUG|Restrictive oxygen|Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
41507922|NCT05326035|DRUG|WJ05129|WJ05129:Twice daily (except for single dose), 12 hours apart, fixed time is recommended
41035423|NCT04440553|BEHAVIORAL|Uniform random message delivery|The uniform random intervention group receives feedback and motivational messages chosen from the messaging banks with equal probabilities.
41035424|NCT04440553|BEHAVIORAL|Reinforcement learning message delivery|The adaptive intervention group receives messages chosen from the messaging banks by a reinforcement learning algorithm.
41035425|NCT03500874|DRUG|FUDR|Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.
41035426|NCT03500874|DRUG|Oxaliplatin|Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.
41035427|NCT03500874|DRUG|Leucovorin|Leucovorin 200mg/m2 ivd over 2 hours on Day 1
41035428|NCT03500874|DRUG|5FU|5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
41035429|NCT03500874|DRUG|Irinotecan|Irinotecan 180mg/m2
41035430|NCT04003649|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given ITV/ITC
41035431|NCT04003649|BIOLOGICAL|Ipilimumab|Given IV
41035432|NCT04003649|BIOLOGICAL|Nivolumab|Given IV
41507923|NCT05581381|BEHAVIORAL|empathy training program|Empathy training, a total of 8 weeks of training (1 time a week, 1 hour each time)
41035433|NCT04003649|OTHER|Quality-of-Life Assessment|Ancillary studies
41035434|NCT04003649|OTHER|Questionnaire Administration|Ancillary studies
41035435|NCT04429490|OTHER|Adipose tissue sampling during surgery and urine sampling|Adipose tissue sampling during surgery and urine sampling
41035436|NCT06100042|DRUG|BDP/FF/G|"BDP/FF/G is an extrafine single inhaler triple therapy available in two dosage strengths:~* Medium strength (MS) containing 100 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide);~* High strength (HS) containing 200 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide)."
41035437|NCT04086745|DRUG|Baricitinib|Administered orally.
41381119|NCT05146700|DRUG|Liberal oxygen|15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
41507924|NCT00258128|DRUG|Salsalate|Active
41507925|NCT00258128|DRUG|Placebo|Placebo for salslate, used only in the third trial
41035438|NCT04086745|DRUG|TNF Inhibitor|Administered SC
41035439|NCT03266588|DRUG|Rimegepant|75 mg oral tablet
40851856|NCT02080299|PROCEDURE|Placebo|Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
41035440|NCT00399477|DRUG|rasagiline mesylate|Azilect®
41035441|NCT00399477|DRUG|Rasagiline mesylate plus Mirapex|Mirapex, Azilect®
41035442|NCT00399477|DRUG|Rasagiline mesylate with Levodopa|Azilect®, Levodopa
41035443|NCT00399477|DRUG|Rasagiline mesylate with Requip|Azilect®, Requip
41035444|NCT00723775|DRUG|GSK706769 & KALETRA|GSK706769 alone and GSK706769 + Kaletra
41035445|NCT06556927|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
41035446|NCT03725982|DEVICE|Laevo ®|A passive exoskeleton supporting the lower back during bending and lifting tasks (for more information, visit the manufacturer's website: http://en.laevo.nl/).
41035447|NCT03725982|DEVICE|No Laevo ®|The subjects will not wear any supporting device to perform the experiment, which serves as the control condition.
40851857|NCT05084092|RADIATION|Intraoperative Radiotherapy (IORT)|If biopsy is positive, local treatment with IORT will be performed. After IORT (15,40 Gray at 2 mm dept), the applicator will be removed and surgery will be continued in a standard fashion.
40851858|NCT05084092|PROCEDURE|Brain surgery|Surgery should be performed according to the local standard of care, preferentially as image-(neuronavigation) guided surgery. To establish the diagnosis of a metastasis and to exclude primary CNS tumors, lymphomas, SCLCs or germinomas it will be performed a peroperative biopsy
40851859|NCT00667849|DEVICE|Exogen 4000+|Low-intensity pulsed ultrasound (LIPUS)
41381120|NCT05390853|PROCEDURE|Active tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Active stimulation is carried out with a current intensity of 2 milliAmpere. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
41035448|NCT01714128|DRUG|Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))|FES-PET/CT imaging
41035449|NCT01094080|OTHER|standard infant formula|infants are fed a commercial formula
41381121|NCT05390853|PROCEDURE|Sham tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Sham stimulation is carried out through a dedicated program, which increases the current for several seconds up to the target intensity and then decreases it gradually in a few seconds, so that subjects experience the same itching and tingling experience as in active stimulation, but they do not receive any significant therapeutic currents.~Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
41035450|NCT01094080|OTHER|modified infant formula|the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added
41035451|NCT01094080|OTHER|breast milk|infants are breast fed
41035452|NCT04458610|BIOLOGICAL|Rituximab|Given IV
41035453|NCT04458610|DRUG|Zanubrutinib|Given PO
41035454|NCT02037347|DRUG|Palifermin|
41035455|NCT06015776|OTHER|Gender|Differences between men and women will be observed
41381122|NCT05454488|OTHER|Focal Cryoablation|Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
41381123|NCT05454488|OTHER|Standard of Care|Participants will receive a prostate biopsy.
41381124|NCT05454488|OTHER|Quality-of-life Questionnaires|Participants will fill out questionnaires.
41035456|NCT05892354|DIETARY_SUPPLEMENT|Enteral immunonutrition|Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.
41035457|NCT05892354|DIETARY_SUPPLEMENT|Standard enteral nutrition|Isocaloric standard enteral nutrition formula (ENSURE®)， 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).
41035458|NCT00969033|DRUG|CS-1008|CS-1008
41165850|NCT03016949|BIOLOGICAL|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
41381125|NCT01137643|OTHER|biologic sample preservation procedure|All samples collected during routine clinical care.
40851860|NCT00667849|DEVICE|Sham|sham device identical to active device with the exception of administration of ultrasound
40851861|NCT03018977|OTHER|The sedative weaning protocol group|After physician decide to wean sedative or analgesic drugs. We divided to 2 groups including high risk group and low risk group. The sedative weaning protocol were used in these patients which rely on the high risk or low risk group.
41381126|NCT01137643|OTHER|cytology specimen collection procedure|All Samples collected during routine clinical care.
41381127|NCT06504290|DRUG|VV119 Placebo （in healthy adult subjects）|"VV119 0.5 mg Group:2 subjects will receive VV119 Placebo 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:2 subjects will receive VV119 Placebo 1 mg, orally once daily for 14 days.~VV119 2 mg Group:2 subjects will receive VV119 Placebo 2 mg, orally once daily for 14 days.~VV119 4 mg Group:2 subjects will receive VV119 Placebo 4 mg, orally once daily for 14 days."
40851862|NCT03018977|OTHER|The usual group|After physician decide to wean sedative or analgesic drugs. The sedative/analgesic drugs were weaned depend on physician
40851863|NCT02059603|PROCEDURE|Electroacupuncture|
41035459|NCT00969033|DRUG|irinotecan|irinotecan
41035460|NCT03463902|DEVICE|left IFG anodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
41035461|NCT03463902|DEVICE|left IFG cathodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
41035462|NCT03463902|DEVICE|left IPL anodal|Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
41035463|NCT03463902|DEVICE|left IPL cathodal|Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
41035464|NCT03463902|DEVICE|Placebo|Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
41035465|NCT04597853|DIAGNOSTIC_TEST|Assessment of lung mechanics and heart-lung interactions|Impedance tomography, right-heart catheterization, oesophageal pressure measurements, indirect calorimetry and classic mechanical ventilation parameters
41381128|NCT06504290|DRUG|VV119 （in healthy adult subjects）|"VV119 0.5 mg Group:6 subjects will receive VV119 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:6 subjects will receive VV119 1 mg, orally once daily for 14 days.~VV119 2 mg Group:6 subjects will receive VV119 2 mg, orally once daily for 14 days.~VV119 4 mg Group:6 subjects will receive VV119 4 mg, orally once daily for 14 days."
41381129|NCT06504290|DRUG|VV119(in adult patients with schizophrenia)|VV119 2 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, then take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the seventh day , then 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily.
41507926|NCT06581562|DRUG|AB-101|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
40851864|NCT02059603|PROCEDURE|Fast-track program|
40851865|NCT05171712|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of patients with severe aortic stenosis
40851866|NCT00002812|DRUG|asparaginase|Given IV
40851867|NCT00002812|DRUG|cyclophosphamide|Given IV
41035466|NCT02625623|DRUG|Avelumab|Avelumab was administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
41035467|NCT02625623|DRUG|Irinotecan|Irinotecan was administered at a dose of 150 mg/m \^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
41035468|NCT02625623|DRUG|Paclitaxel|Paclitaxel was administered at a dose of 80 mg/m\^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
41507927|NCT06581562|DRUG|Rituximab|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
41507928|NCT06581562|DRUG|Cyclophosphamide|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
41507929|NCT06581562|DRUG|Fludarabine|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
41507930|NCT03210792|DEVICE|Application of Rib Splint|Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
41381130|NCT06504290|DRUG|VV119 Placebo （in adult patients with schizophrenia）|VV119 2 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, then take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the seventh day , then 2 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily.
41381131|NCT05898022|DRUG|Furosemide (plus potassium chloride)|Furosemide is a loop diuretic that inhibits the reabsorption of sodium and chloride in the proximal and distal tubules as well as the loop of Henle. Participants will receive 2 mg/kg enteral furosemide daily during treatment periods when they receive study drug. To prevent hypokalemia and hypochloremia associated with furosemide use, participants will also receive 1 mg/kg of potassium chloride enterally twice per day when receiving furosemide. Each patient will have 14 days of total exposure to furosemide over the 28-day N-of-1 trial.
41507931|NCT06490679|PROCEDURE|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥7 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
41381132|NCT05898022|DRUG|Placebo (plus placebo electrolyte solution)|During treatment periods when participants receive placebo, they will receive a volume of sterile water equivalent to the study drug dose. Participants will also receive a placebo electrolyte solution equivalent to the volume of potassium chloride that would be given.
41381133|NCT05555745|DEVICE|Audio-based behavioral activation intervention|Access to audio-based behavioral activation intervention
41035469|NCT02625623|OTHER|Best Supportive Care (BSC)|BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC was administered once every 3 weeks.
41381134|NCT05555745|DEVICE|Audio-based self-monitoring intervention|Access to audio-based self-monitoring intervention
41381135|NCT06145451|BEHAVIORAL|Family Success Network|The Family Success Network (FSN) is a community-based maltreatment prevention program that is being piloted to serve caregivers of children aged between 0-18 in the Trumbull, Mahoning, and Columbiana Counties in Ohio. FSN is a comprehensive multi-tier program providing information and referrals to community resources at Tier I (i.e., the initial contact stage), caregiver education, and financial literacy program along with concrete support at Tier II (i.e., enrollment in family coaching services in FSN), and a life skills program and monthly home visits for families with more intensive needs at tier III (most intensive level of FSN services).
41381136|NCT04945460|DRUG|Sotatercept 0.3 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
41381137|NCT04945460|DRUG|Placebo|Administered by subcutaneous injection
40851868|NCT00002812|DRUG|cytarabine|Given IV
40851869|NCT00002812|DRUG|daunorubicin hydrochloride|Given IV
40851870|NCT00002812|DRUG|dexamethasone|Given IV
40851871|NCT00002812|DRUG|doxorubicin hydrochloride|Given IV
40851872|NCT00002812|DRUG|idarubicin|Given IV
40851873|NCT00002812|DRUG|mercaptopurine|Given IV
40851874|NCT00002812|DRUG|methotrexate|Given PO
41035470|NCT04313803|DEVICE|CGM|Dexcom CGM system
40851875|NCT00002812|DRUG|pegaspargase|Given IV
40851876|NCT00002812|DRUG|prednisone|Given PO
40851877|NCT00002812|DRUG|thioguanine|Given IV
41035471|NCT05268523|BEHAVIORAL|Education and Strategies Intervention|Sessions will be led by registered therapists and clinicians in the fields of psychology, rheumatology, cardiology and neurology. The sessions will be comprised of educational presentations on the nature of persisting symptoms after COVID-19 and associated recommendations for self-management.
41507932|NCT06490679|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"(a) Disclosure of biofilm with erythrosine, (b) Removal of supragingival and subgingival (up to 10 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS-Dental, Nyon Switzerland).~(c) Supra- and sub-gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
41507933|NCT02975778|DEVICE|Pain Monitor™|Pain measured by Pain Monitor™
41507934|NCT03008174|OTHER|Early one-way speaking valve (OWSV) assessment|The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
41507935|NCT03223701|COMBINATION_PRODUCT|Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion|The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).
41507936|NCT00233948|DRUG|nelfinavir mesylate|Given orally
41507937|NCT00233948|PROCEDURE|biopsy|Correlative studies
41507938|NCT00233948|OTHER|laboratory biomarker analysis|Correlative studies
41507939|NCT00233948|OTHER|pharmacological study|Correlative studies
41507940|NCT00233948|GENETIC|gene expression analysis|Correlative studies
41507941|NCT00233948|GENETIC|western blotting|Correlative studies
41507942|NCT00233948|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
41507943|NCT00233948|OTHER|immunoenzyme technique|Correlative studies
41507944|NCT05368116|OTHER|Video Assisted Self Management Program|"The main aim of this intervention is to educate the cancer patients receiving chemotherapy regarding the management of chemotherapy related side effects.~It will be one to one teaching session of 10-20 minutes conducted by the principal researcher with the help of a video on self management of chemotherapy related side effects and the video will focus on the self management of selected side effects of chemotherapy including nausea vomiting , Diarrhea , Fever , Mucositis , Skin changes , and Alopecia related distress.~The participants were given video when they comes to the Oncology day care and researcher instructs the participants to watch the video and at the same time the doubts asked by the participants were cleared by the researcher."
41507945|NCT05368116|OTHER|Standard of care|Standard of care
41507946|NCT04292288|DIAGNOSTIC_TEST|Biochemical observational|no intervention - observational
41507947|NCT01471730|DRUG|Fibrinogen|All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[m\] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
41507948|NCT01471730|DRUG|Saline solution|Normal saline will be administered to control patients.
40851878|NCT00002812|DRUG|vincristine sulfate|Given IV
40851879|NCT00002812|RADIATION|radiation therapy|
41507949|NCT01471730|DRUG|Prothrombin complex|After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds \[M1\] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
41507950|NCT02638025|DEVICE|OCT|Anterior Segment Spectral-domain Optical Coherence Tomography
41507951|NCT03865927|OTHER|Placebo Oral Tablet|see Arm/Group description
41507952|NCT03865927|DRUG|GKT137831|GKT137831 is a NOX enzyme inhibitor
41381138|NCT04945460|DRUG|Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
41381139|NCT06428383|DRUG|Vericiguat tablet|Vericiguat tablet at doses 2.5 mg, 5 mg, or 10 mg taken orally once daily
41381140|NCT06428383|DRUG|Vericiguat suspension|"Vericiguat suspension at doses 0.2 mg/mL,~1 mg/mL taken orally once daily"
41381141|NCT04758715|OTHER|Food provided from a commercial meal service provider for a week|Meals from a commercial meal service provider provide for a week to participant
41381142|NCT05273554|DRUG|Pembrolizumab|Given by IV
41381143|NCT05273554|DRUG|lenvatinib|Given by PO
41381144|NCT05025774|OTHER|Physical activity|Participant Reported Physical Activity and Outcomes (completed via REDCap or on paper)
41381145|NCT06589154|DIAGNOSTIC_TEST|Prostatic or Pelvic MR|Participants are required to undergo prostatic or pelvic MR according to the investigators.
41381146|NCT06589154|DIAGNOSTIC_TEST|Prostatic Biopsy|Participants are required to undergo prostatic biopsy according to the clinical indication and investigators.
41381147|NCT06652061|DIAGNOSTIC_TEST|Dual Energy X-Ray Absorptiometry Scan (DEXA Scan)|"A DEXA scan, or Dual-Energy X-ray Absorptiometry, is a specialized imaging technique used to measure Bone Mineral Density (BMD). It is commonly employed to diagnose osteoporosis and assess the risk of fractures, especially in areas prone to bone density loss, such as the spine, hip, and forearm. The scan works by using two low-energy X-ray beams that pass through the bone, allowing it to differentiate between bone and soft tissue and calculate the bone's density. DEXA is considered the gold standard for osteoporosis diagnosis due to its high accuracy and precision.~The DEXA scan is a non-invasive, out-patient and painless procedure. Patients lie on an examination table while the scanner passes over the targeted area, typically the hip and spine. The entire procedure is straightforward, taking around 10 to 30 minutes depending on the areas being scanned."
41381148|NCT06652061|DIAGNOSTIC_TEST|X-Ray (Hip and Spine)|Hip and spine X-rays are specific types of radiographic imaging used primarily to evaluate bone health, joint integrity, and alignment in these crucial areas. In the context of osteoporosis assessment, hip and spine X-rays can reveal signs of bone thinning or fractures, serving as an initial screening tool before more detailed imaging like a DEXA scan. During a hip X-ray, the patient typically lies on an examination table with the hip positioned for a clear view of the pelvis and femur. In a spine X-ray, the patient's posture may vary, often lying on the table in either a supine or lateral position to capture views of the vertebrae in the lower back (lumbar spine). Patients may be asked to remain very still, or even hold their breath momentarily, to prevent motion blur, which can obscure important details. Both hip and spine X-rays are quick and painless, generally taking only a few minutes, with the X-ray exposure itself lasting less than a second.
41381149|NCT06651762|PROCEDURE|unilateral Radiofrequency|unilateral genicular nerve cooled radio frequency ablation pre-operative
41381150|NCT06651762|PROCEDURE|bilateral Radiofrequency|bilateral genicular nerve cooled radio frequency ablation pre-operative
41381151|NCT06651762|PROCEDURE|Epidural|Patients will receive epidural anesthesia intra operative and epidural analgesia post-operative
41381152|NCT06652958|BIOLOGICAL|VH4527079|VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
41381153|NCT06652386|OTHER|Telemedicine Group|"* Nursing-led lactation support via secure video conferencing platforms (e.g., Zoom for Healthcare).~* Scheduled sessions at postpartum days 1, 3, 7, and 14.~* Additional support available upon request."
41507953|NCT00002397|DRUG|Nelfinavir mesylate|
41507954|NCT00002397|DRUG|Saquinavir|
41507955|NCT00002397|DRUG|Lamivudine|
41507956|NCT00002397|DRUG|Stavudine|
41507957|NCT02475928|DIETARY_SUPPLEMENT|zinc gluconate|Zinc supplementation plus nutritional education
41507958|NCT02475928|DIETARY_SUPPLEMENT|Placebo|
41035472|NCT05268523|BEHAVIORAL|Mindfulness Skills Intervention|The Mindfulness Skills Intervention is an 8-week program designed to provide an introduction to some basic mindfulness skills. Each session begins with a brief breath focus practice followed by discussion of the experience and sharing/discussion of the previous week including participants' experiences. Each session also includes some didactics, and a new, related mindfulness skill is introduced and practiced, followed by another discussion.
41507959|NCT02475928|BEHAVIORAL|Nutritional education|
41507960|NCT00858182|DRUG|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
41507961|NCT00858182|DRUG|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
41507962|NCT05237323|DRUG|mycophenolate mofetil 2 g per day|mycophenolate mofetil 2 g per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
41507963|NCT05237323|DRUG|azathioprine of 150 [75; 150] mg per day|azathioprine at an average dose of 150 \[75; 150\] mg per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
41035473|NCT00328419|DEVICE|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
41035474|NCT00328419|DEVICE|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
41507964|NCT05094661|PROCEDURE|BiPAP|The patient recives respiratory support with bilevel positive airway pressure system until treatment improves or fails (needs intubation/dies).
41507965|NCT05094661|PROCEDURE|CPAP|The patient recives respiratory support with continuous positive airway pressure system until treatment improves or fails (needs intubation/dies).
40851880|NCT03878901|COMBINATION_PRODUCT|high risk warm|Bair HuggerTM Forced-air Warming System to 30min pre- and entire operation warming, combined fluid warming
41035475|NCT04278144|DRUG|BDC-1001|Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
41165115|NCT01156402|BEHAVIORAL|Healthy Families-Childhood Obesity Prevention and Oral Health|The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
41381154|NCT06653127|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients. Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence.
41381155|NCT06401317|DRUG|Saline Hypertonic Solution|Ultrasound-guided intra-articular injection of 0.25ml of 0.9% saline solution.
41035476|NCT04278144|DRUG|Nivolumab|Programmed death receptor-1 (PD 1)-blocking antibody
41035477|NCT02244944|DRUG|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
41035478|NCT00710047|DRUG|ZD4054|one single 10mg dose
41035479|NCT05160922|DRUG|crizotinib|crizotinib oral treatment
41035480|NCT02869217|DRUG|Cyclophosphamide|
41035481|NCT02869217|BIOLOGICAL|TBI-1301|
41035482|NCT02869217|DRUG|Fludarabine|
41035483|NCT03876652|DEVICE|Pacemaker with Closed Loop Stimulation (CLS)|In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
41035484|NCT04405596|DRUG|Ambroxol Hydrochloride|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
41165116|NCT06278753|DIAGNOSTIC_TEST|carbon dioxide cystoscopy|Using carbon dioxide medium for filling bladder
41165851|NCT02987998|DRUG|Cisplatin|Cisplatin (50mg/m2 IV D1, 8, 29, 36)
41381156|NCT06401317|DRUG|Triamcinolone Acetonide|Ultrasound-guided intra-articular injection 0.25ml (10 mg) of triamcinolone.
41035485|NCT04405596|OTHER|Placebo|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
41035486|NCT02431039|DEVICE|NEOSORB PLUS|Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
41035487|NCT02431039|DEVICE|NEOSORB|Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
41035488|NCT00908479|BEHAVIORAL|Leg Exercise Program|Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.
41035489|NCT00908479|BEHAVIORAL|Leg Management group|Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
41035490|NCT06454357|DRUG|B007|B007：high dose/low dose: Subcutaneous injection was administered on days 1 and 15
41035491|NCT00736242|BIOLOGICAL|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
41035492|NCT00736242|DRUG|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
41035493|NCT05930327|OTHER|Unconditional Cash Transfer (High-Value)|Monthly, Unconditional Cash Transfer ($325) for 4-months
41035494|NCT05930327|OTHER|Unconditional Cash Transfer (Low-Value)|Monthly, Unconditional Cash Transfer ($25) for 4-months
41165117|NCT00997932|DRUG|Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration|Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
41165118|NCT01481519|DRUG|dexamethasone 0.1%/povidone-iodine 0.4%|dexamethasone 0.1%/povidone-iodine 0.4%
41165119|NCT01481519|DRUG|Artificial Tears|artificial tears 1 drop, 4 times per day
41165120|NCT01340040|DRUG|MEDI-573|MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
41165121|NCT05160311|DRUG|Optimized Medical Treatment (OMT)|Optimized Medical Drug Treatment
41165122|NCT05160311|DEVICE|Drug Eluting Stent (DES) Coronary Angioplasty|Percutaneous Angioplasty with DES
41165123|NCT02901483|DRUG|PEP503|PEP503 will be administered by intratumoral route as slow injection
41165124|NCT02901483|DRUG|Cisplatin|The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 or tri-weekly 100 mg/m2, depending on which dose level patients are in, with a minimum of accumulated 200 mg/m2 during the 7\~8 weeks' radiation period.
41165125|NCT02901483|RADIATION|Radiotherapy|Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7\~8 weeks.
41165126|NCT00812838|DRUG|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
41165127|NCT00812838|OTHER|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
41165128|NCT00812838|DRUG|100 units Botulinum Toxin A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
41165129|NCT05286008|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
41381157|NCT04408625|BIOLOGICAL|LY3884963|Participants will receive a single dose of LY3884963, administered intra cisterna magna
41035495|NCT02032472|OTHER|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
41035496|NCT04701398|OTHER|Multimodal prehabilitation|Exercise + nutritional supplementation + psychological advice
41035497|NCT03362905|DRUG|Lidocaine topical|Local anesthetic for reduction of IUD associated pain
41035498|NCT00389662|DEVICE|"Wearing the Nike Free shoe"|
41035499|NCT04667117|BIOLOGICAL|Quadrivalent influenza vaccine|2020-2021, 2021-2022, or 2022-2023 inactivated quadrivalent influenza vaccine. Participants received the vaccine within 9 calendar days after the Screening Visit, before the Week 0 Visit occurred.
41165130|NCT05286008|DRUG|Ropivacaine at high concentration|Before the induction of anesthesia,0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
41165131|NCT05286008|DRUG|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
41165132|NCT06250478|DIAGNOSTIC_TEST|Dynamic ultrasound of the calf muscles|Dynamic changes of the calf muscles during walking will be assessed in persons after stroke and compared to healthy controls
41165133|NCT00298337|DRUG|Mixture of probiotic bacteria and prebiotic oligosaccharide|
41165134|NCT00702546|DRUG|corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
41165135|NCT00702546|BIOLOGICAL|recFSH (follitropin alfa)|Daily recFSH administered under protocol P05690
41165136|NCT00702546|DRUG|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
41165137|NCT00702546|DRUG|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
41165138|NCT00702546|BIOLOGICAL|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
41165139|NCT00702546|DRUG|placebo-recFSH (follitropin alfa)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
41165140|NCT00702546|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
41165852|NCT02987998|DRUG|Etoposide|Etoposide (50mg/m2 IV D1-5, 29-33)
41507966|NCT02470845|DRUG|herbal patches of Tian Jiu group|The formula of herbal patch consists of BaiJieZi (Sinapis Semen), Yan Hu Suo（CorydulisRhizoma）、ZhiGan Sui (Kansui Radix)、Xi Xin (Asari Radix et rhizama) and Rengong She xiang(Moschus Artifactus) . The four herbs will be ground into powder, mixed thoroughlywith 20% BaiJieZi (Sinapis Semen), 25% Yan Hu Suo（CorydulisRhizoma), 15% ZhiGan Sui (Kansui Radix), and 40% Xi Xin (Asari Radix et rhizama), and the mixed powder will mix with fresh ginger juice in the ratio of 20g to 25 ml. The mixture will be made to a patch weighted as 2g and 1cm\*1cm round size. 0.02g artificial She Xiang (Moschus Artifactus) will be added on top of each patch. Each patch will be applied on one acupoint.
41507967|NCT02470845|DRUG|placebo patches of placebo-control group|The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm\*1cm round size.Each patch will be applied on one acupoint.
41507968|NCT01887171|DRUG|Tacrolimus|1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
41507969|NCT04590352|PROCEDURE|nasopharyngeal and throat swab|diagnostic specimens via nasopharyngeal swab and throat swab were collected following the current standard operating procedures.
41507970|NCT04590352|PROCEDURE|collection of mucosal lining fluid|MLF will be collected via nasal absorption at the inclusion visit by study staff and four more time points by the parents or by the children themselves. Nasal absorption is performed by maneuvering a strip of synthetic absorptive matrices (SAM) into the lumen of the nostril, avoiding rubbing against the nasal mucosa. The outside of the nose is then pressed with a finger to cause apposition of the SAM against the mucosa.
41035500|NCT04667117|DRUG|Ofatumumab|"Auto-injector containing 20 mg ofatumumab (20 mg/0.4mL) for subcutaneous (s.c.) administration.~* Participants in Cohort 1 received loading doses of 20 mg ofatumumab s.c. at Weeks 2, 3, and 4 in the Investigational Period. In the open-label Extension Period, they administered the first dose of ofatumumab at Week 6 and continued monthly dosing until the final dose at Week 26. Novartis supplied participants in Cohort 1 with ofatumumab treatment.~* Participants in Cohort 2 continued on their commercially prescribed ofatumumab treatment during the Investigational Period. In the open-label Extension Period, they continued to administer ofatumumab monthly until the final dose at Week 28. Cohort 2 participants in the extension could have either remained on their prescribed ofatumumab or switched to study supplied ofatumumab."
41035501|NCT04667117|DRUG|iDMT|Participants in Cohort 3 continued on their commercially prescribed injectable disease modifying therapy (iDMT) during the Investigational Period.
41165141|NCT00702546|BIOLOGICAL|open-label recFSH|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
41165142|NCT05305677|DIETARY_SUPPLEMENT|NMN intervention|NMN capsules (total of 600mg/day) for 8 weeks
41165143|NCT05305677|OTHER|Placebo|NMN-free placebo capsules for 8 weeks
41165144|NCT05404126|OTHER|exercise|• Static exercises and dynamic exercises to group 2; Hearing impaired children in group 3 will be given motor-motor double-task and motor-cognitive double-task exercises in addition to conventional balance exercises.
41165145|NCT02245750|DEVICE|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
41165146|NCT00435981|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
41165147|NCT02618564|DRUG|Sennosides|Each group will be assigned different doses of sennosides and varying times of administration
41381158|NCT04408625|DRUG|Methylprednisolone|IV pulses every 2 weeks in the first 3 months.
41381159|NCT04408625|DRUG|Optional Sirolimus|At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
41381160|NCT04408625|DRUG|Optional Prednisone|If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen
41381161|NCT06533579|GENETIC|Dose Level 1, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
41381162|NCT06533579|GENETIC|Dose Level 2, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
41381163|NCT06533579|GENETIC|Dose Level 3, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
41381164|NCT06533579|GENETIC|Dose Level 4, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
41381165|NCT06487559|DRUG|Livmoniplimab|Intravenous infusion
40851881|NCT03878901|COMBINATION_PRODUCT|moderate risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System cotton blanket warming and fluid warming through operation
40851882|NCT03878901|COMBINATION_PRODUCT|low risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System and cotton blanket warming through operation
41165148|NCT06271564|DRUG|Magnetite ZnO Composite Nanoparticles|Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell
41381166|NCT06487559|DRUG|Budigalimab|Intravenous infusion
41507971|NCT04590352|PROCEDURE|blood collection via fingerprick|Participants will be asked to wash their hands with soap and warm water. The procedure involves cleaning the ball of the fingertip with an alcohol swab, then using a sterile disposable lancet to pierce the skin (BD Microtainer Lancet or similar). The lancet is placed in a spring-loaded device, which propels the lancet a fixed distance (a few mm) into the skin when the trigger is pressed. Approximately 10-20 drops of blood (0.3 ml) will then be collected with a sterile capillary tube. The participant is given a cotton wool pad to mop up any extra blood, and an elastoplast-type bandage is placed over the finger if necessary. Fingerprick blood samples will only be collected from participants older than 6 months at 28-32 days after the first home visit (d0). Lancet length will be adjusted for age (2.0 mm for participants 8 years and older, 1.5 mm for participants older than 6 months and younger than 8 years).
41507972|NCT06091670|OTHER|No intervention|There is no intervention. The research is cross-sectional-descriptive type.
41507973|NCT04221230|DRUG|BTRX-335140|Active Drug
41035502|NCT05477355|BEHAVIORAL|Group Problem Management Plus (PM+)|Group PM+ is a low-intensity, trans-diagnostic, brief psychological intervention developed by the WHO. Group PM+ consists of five sessions delivered in five consecutive weeks and includes strategies that are aimed towards decreasing symptoms of depression, anxiety, general distress, and other related conditions. Group PM+ is designed to be delivered by non-specialists, persons without a formal education and licensure in psychology or mental health.
41035503|NCT01666002|DEVICE|Laser Treatment (Pulsed Nd:YAG 1064 nm Laser)|0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
41035504|NCT04942106|OTHER|Arm 1 - Side-lying position followed by Supine position|Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
41035505|NCT04942106|OTHER|Arm 2 - Supine position followed by Side-lying position|Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
41035506|NCT06630039|OTHER|Scale validity and reliability|The aim of this study is to adapt the Short-Western Ontario Rotator Cuff Disability Index (SHORTWORC) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 7 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
41035507|NCT01075074|PROCEDURE|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
41035508|NCT03812796|DRUG|Domatinostat|"Domatinostat is an oral tablet which will be given at a variable dose during the Phase IIA safety run in phase of the trial.~During the Phase IIB efficacy phase of the trial patients will be treated with domatinostat at the safe and tolerated combination dose identified during the Phase IIA safety run in phase."
41035509|NCT03812796|DRUG|Avelumab|Avelumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 10mg/kg every two weeks on the first day of a two week cycle. (Day 1 q 14d) from Cycle 2 onwards.
41035510|NCT03537924|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
41381167|NCT05726409|OTHER|Mobile application|Participants will use the meal planner function on the mobile application to plan and cook at least 3 meals a week for 12 weeks.
41381168|NCT05254041|OTHER|Menstrual Cup Removal|Participants will be asked to remove Menstrual cup by breaking the seal.
41381169|NCT04184882|DRUG|Bocidelpar|Oral
41381170|NCT04184882|DRUG|Placebo|Oral
41381171|NCT06651801|BEHAVIORAL|Group Medical Visits|Group medical visits occur every 2 weeks virtually (via Zoom) for 6 months. Each group consists of 45 minutes of group time and 5 minute individual check-in appointments. The group time consists of psychoeducation, group support, and medication follow-up.
41381172|NCT06651879|DIAGNOSTIC_TEST|techniques of ultrasound examination of the airway|two different techniques of ultrasound. The techniques are the two views and the five views
41381173|NCT05558007|DRUG|Tadalafil 5mg|Daily oral administration of tadalafil 5mg
41381174|NCT05558007|DRUG|BZ371A|Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
41507974|NCT04221230|DRUG|Placebo|Placebo
41381175|NCT05558007|DRUG|Oral Placebo|Oral administration of a placebo pill
41381176|NCT05558007|DRUG|Topical Placebo|Topical application of 1.5 mL of placebo
41381177|NCT05863351|PROCEDURE|Computed Tomography|Undergo CT
41381178|NCT05863351|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41507975|NCT03951220|OTHER|Diffusion Weighted Magnetic Resonance Imaging (DWMRI)|Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), we will test a single protocol which combines three emerging experimental imaging sequences into a simple, non-invasive whole body imaging protocol to quantify disease burden and bone disease. To our knowledge, this has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer-induced bone disease in response to therapy.
41507976|NCT03951220|OTHER|DXA scan|Used to assess bone density
41507977|NCT03951220|OTHER|Bloods and urine|Samples will be taken to assess bone biomarkers
41507978|NCT02445963|BIOLOGICAL|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
41507979|NCT00900822|DEVICE|Straumann Bone Ceramic|Granules applied once during surgery
40851883|NCT03878901|OTHER|passive warming|cotton blanket warming through operation
40851884|NCT01966835|BEHAVIORAL|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
40851885|NCT03829722|DRUG|Nivolumab|Given intravenously (IV), 240 mg every 2 weeks for 4 doses concurrent with radiation therapy (RT). Following completion of RT, 480 mg given every 4 weeks for 4 doses.
40851886|NCT03829722|DRUG|Carboplatin|Given IV once per week during radiation therapy (AUC=1).
41035511|NCT03537924|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
41035512|NCT02046330|DEVICE|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
41035513|NCT06569056|DRUG|HRS-8427|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
41035514|NCT06569056|DRUG|Imipenem and Cilastatin Sodium|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
41035515|NCT06569056|DRUG|HRS-8427 placebo|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
41381179|NCT05863351|OTHER|Questionnaire Administration|Ancillary studies
41381180|NCT05863351|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SAbR
41381181|NCT05863351|PROCEDURE|Systemic Therapy|Given standard of care systemic therapy
41381182|NCT05640999|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids
41381183|NCT05640999|RADIATION|Adjuvant radiotherapy (EBRT +/- brachytherapy)|Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.
41381184|NCT05640999|OTHER|Observation|Observation
41381185|NCT06533410|DIAGNOSTIC_TEST|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
41381186|NCT04914559|OTHER|Oral nutrition supplement - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
41381187|NCT04914559|OTHER|Oral nutrition supplement - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
40851887|NCT03829722|DRUG|Paclitaxel|Given IV once per week during radiation therapy (30mg/m\^2)
40851888|NCT03829722|RADIATION|Radiation Therapy|Given 5 days/week for a total of 35 doses (70 gray total).
40851889|NCT00005120|DRUG|Calanolide A|
41035516|NCT06569056|DRUG|Imipenem and Cilastatin Sodium placebo|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
41035517|NCT00605800|OTHER|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
41035518|NCT00605800|OTHER|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
41165853|NCT02987998|DRUG|Pembrolizumab|Pembrolizumab (200mg IV D1, 21, 42)
41381188|NCT06026449|DIETARY_SUPPLEMENT|Gluten-free diet|After initial fase of habitual diet (6 months), patients will start Gluten-free diet for a period of 12 months
41381189|NCT06351540|DRUG|Cannabis|cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
41381190|NCT06179186|DEVICE|Intense Pulsed Light|The axilla will be treated with intense pulsed light, being right or left, depending upon randomization.
41165149|NCT06271564|DRUG|Topical Placebo Gel|Topical placebo gel containing water, glycerin and Hydroxypropyl methylcellulose will be applied 3 times daily for 6 weeks as a positive control group
41381191|NCT06179186|DEVICE|Diode Laser|The axilla will be treated with diode laser, being right or left, depending upon randomization.
41381192|NCT06304688|OTHER|Yoga and Mediterranean Diet intervention|"It will last 12 weeks with a frequency of 2 sessions per week and each lasting 50 minutes.~* Warm-up phase (10 minutes): Conscious and gentle breathing. Gentle movements of the neck, shoulders, arms and legs to increase blood circulation and flexibility.~* Training phase (30 minutes): Series of gentle postures adapted to the needs of older adults. Includes standing, sitting and lying postures for relaxation and stretching. It will begin with basic postures and breathing techniques and will gradually advance as participants gain confidence.~* Return to calm (10 minutes): Deep relaxation in a lying position to integrate the benefits of the practice and promote total relaxation of the body and mind.~The Mediterranean diet consisted of: i) carbohydrates constitute 50% of the daily intake; ii) fats represented 35%; and iii) proteins represented 15%."
41507980|NCT00900822|DEVICE|BioOss|Granules that are applied once during surgery
41165150|NCT04479514|OTHER|Warm Baths or Showers|Daily warm baths or showers
41507981|NCT03232671|DIAGNOSTIC_TEST|MIF ELISA|Blood sample
41507982|NCT00004212|BIOLOGICAL|filgrastim|
40851890|NCT06183073|PROCEDURE|caudal block|bupivacaine 0.25% in a dose of (1 ml / kg)
41381193|NCT04092257|PROCEDURE|VIA and thermocoagulation|Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
41381194|NCT03668379|BEHAVIORAL|Augment w/mHealth|"Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention."
41381195|NCT03668379|BEHAVIORAL|Maintenance|"Responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment."
41381196|NCT03668379|BEHAVIORAL|Switch to CBT & mHealth|"Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used."
41507983|NCT00004212|DRUG|exatecan mesylate|
41507984|NCT01859910|PROCEDURE|compression and scrub of lid margin|compression and scrub of lid margin for 5 circles before cataract surgery
41507985|NCT01859910|PROCEDURE|routine preparation for cataract|
41507986|NCT05357066|DRUG|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
40851891|NCT06183073|DRUG|Dexmedetomidine|dexmedetomidine 1μg/ kg.
41165151|NCT04479514|OTHER|Moisturizer|moisturizers applied daily immediately after bathing
41165152|NCT04479514|DRUG|SPF 30 or Higher Suncreen|Mineral based sunscreen of SPF 30 or higher applied on a daily basis on all sun exposed areas.
41165153|NCT04479514|OTHER|Sun Protective Clothing|Sun protective clothing worn when outdoors
40851892|NCT06183073|PROCEDURE|TAP|analgesia
40851893|NCT06183073|DRUG|Bupivacain|bupivacaine 0.25% in a dose of (0.5 ml / kg
40851894|NCT03222401|DRUG|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
41165154|NCT04479514|BEHAVIORAL|Limited Sun Exposure|Limit sun exposure during peak hours of 10am-4pm
41165155|NCT04479514|OTHER|Dilute bleach baths|Warm 10-15 minute dilute bleach baths every other day
41165156|NCT05270473|PROCEDURE|uterine compressive sutures|uterine compression sutures comaprison
40851895|NCT03222401|DRUG|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
40851896|NCT03222401|DRUG|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
41035519|NCT05085600|OTHER|Exercise|"Patients will begin performing the cervical stabilization exercise, and will taught to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine.~In addition, progress will continued in the exercise of the contraction of deep neck flexor muscles in other positions.~The progression of the exercises will be adapted to each patient, depending on their evolution. Firstly, exercises will undertaken in the supine and standing positions; once these positions will mastered, the exercises progressed to asymmetric positions with cervical bending and/or rotation toward each patient's most symptomatic side."
41035520|NCT05085600|OTHER|Manual Therapy + Exercise|20-minute session. In the first 5 minutes, muscle techniques will be performed to prepare the tissue of the upper cervical spine before applying joint techniques. In the next 15 minutes, manipulation and / or mobilization techniques of the upper cervical spine, including the C2-3 segment, will be combined with cervical exercise
41381197|NCT03668379|BEHAVIORAL|Augment w/BAT & mHealth|"Non-responders to the BAT \& mHealth intervention may be re-randomized to receive an additional dose of BAT \& mHealth in the form of an additional session of BAT."
41381198|NCT06115707|OTHER|The lying flat (0°-10°) head position for 72 hours|The lying flat (0°-10°) head position for 72 hours after endovascular therapy.
41381199|NCT06115707|OTHER|The The head elevation (30°-40°) position for 72 hours|The head elevoatin (30°-40°) position for 72 hours after endovascular therapy.
41381200|NCT05864846|DRUG|Cannabidiol Oral Solution [Epidiolex]|100 mg/ml Cannabidiol Oral solution
41381201|NCT06623032|OTHER|Medium-Chain Fatty Acid (MCFA)|The participants will consume Medium-Chain Fatty Acid (MCFA) followed by Long-Chain Fatty Acid (LCFA)
41381202|NCT06623032|OTHER|Long-Chain Fatty Acid (LCFA)|The participants will consume Long-Chain Fatty Acid (LCFA) followed by Medium-Chain Fatty Acid (MCFA).
41381203|NCT06164886|OTHER|Waiting list|patient on the waiting list for scheduled surgical admissions
41381204|NCT06652828|OTHER|Conventional Treadmill Walking|The Conventional Treadmill Walking intervention serves as a comparison to PBT. It involves standard treadmill walking without perturbations. This intervention is conducted over the same defined period as PBT, with a matched frequency and exercise time compared to the PBT group for consistency. Regular treadmill walking safety protocols are applied to ensure participant safety.
40851897|NCT03139344|OTHER|Low-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.
41381205|NCT06652828|OTHER|Perturbation-Based Balance Training (PBT)|Overall, there are 9 training sessions with different objectives and progressions regarding perturbation directions, predictability, and intensity. In the initial sessions, the focus is on familiarizing participants with the treadmill and establishing their individual walking pace. This pace can be individually adjusted in each training session. Task-specific safety protocols are in place to ensure participant well-being.
41381206|NCT04800913|DIAGNOSTIC_TEST|Multimodal imaging|Preoperative 2D/3D TOE and MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
41381207|NCT04800913|DIAGNOSTIC_TEST|Standard imaging|Preoperative MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
41381208|NCT06305962|DRUG|177Lu-RAD204|177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses
41381209|NCT03269669|DRUG|Bendamustine Hydrochloride|Given IV
41381210|NCT03269669|PROCEDURE|Biopsy|Undergo biopsy
41381211|NCT03269669|PROCEDURE|Biospecimen Collection|Undergo collection of blood
41507987|NCT05357066|DRUG|Placebo|Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
41035521|NCT05843942|OTHER|Questionnaire|A food frequency questionnaire that was designed to assess folate, iron, and vitamin B12 intake will be administered. Furthermore a 24-hour recall food record will be administered and a complete blood count will be collected. Food frequency questionnaire data will be compared to recall food records and blood count data.
41165157|NCT06408922|OTHER|prp injection|intraarticular prp
41165158|NCT02893358|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
41165159|NCT02893358|DRUG|Placebo|Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
41165160|NCT00000370|BEHAVIORAL|Cognitive behavior therapy|
41165161|NCT00000370|BEHAVIORAL|Performance-based exposure therapy|
41165162|NCT00000370|BEHAVIORAL|Psychosocial intervention|
41165163|NCT05848453|DRUG|BAP5191|Placebo
41165164|NCT03694119|DRUG|Phenelzine|Phenelzine
41165165|NCT03694119|DRUG|Tyramine|Tyramine
41165166|NCT03694119|DRUG|Phenelzine placebo|Phenelzine placebo
41507988|NCT03405922|DRUG|Placebo 40 mL Saline 0.9%|Injection of 40 mL 0.9% saline
41507989|NCT03405922|DRUG|40 mL Ropivacain 0.5%|Ropivacaine Hcl 0.5% Injection 40 mL
41507990|NCT02256436|BIOLOGICAL|pembrolizumab|IV infusion
41507991|NCT02256436|DRUG|paclitaxel|IV infusion
40851898|NCT03139344|OTHER|High-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.
41035522|NCT06533748|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
41165167|NCT03694119|DRUG|ozanimod placebo|ozanimod placebo
41507992|NCT02256436|DRUG|vinflunine|IV infusion
41507993|NCT02256436|DRUG|docetaxel|IV infusion
41507994|NCT02130115|DEVICE|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
41507995|NCT00618332|DRUG|mometasone furoate nasal spray|2 puffs in each nostril once a day for 2 weeks
41507996|NCT00618332|DRUG|placebo|2 puffs in each nostril once a day for 2 weeks
41507997|NCT03874728|OTHER|Minimal shoes|A minimal shoe (Vivobarefoot Ltd., London, UK) will be used.
41507998|NCT03874728|OTHER|Standardised conventional shoes|The Go Walk 4.0-Pursuit shoe for women (Skechers USA, Inc.) and the Superior 2.0-Jeveno shoe for men (Skechers USA, Inc) will be used.
41507999|NCT03874728|OTHER|Barefoot|Participants will conduct the assessments barefoot.
40851899|NCT04165603|PROCEDURE|Preoperative Infusion of Indocyanine Green|preoperatively infuse indocyanine green through peripheral vein
40851900|NCT05091125|DIAGNOSTIC_TEST|Diagnostic performance of the S100B protein dosage|Dosage of the S100B protein in patients with mild head trauma with complication risks
40851901|NCT04991129|DRUG|WJ01024|5mg QD: WJ01024, Q4W, once per day
41508000|NCT03874728|OTHER|"Smart shoe insoles"|Arion pressure-measuring insoles (Eindhoven, The Netherlands) will be used in the study.
40851902|NCT04991129|DRUG|WJ01024|5mg BID: WJ01024, Q4W, twice per day
40851903|NCT04991129|DRUG|WJ01024|10mg BID: WJ01024, Q4W, twice per day
41035523|NCT06533748|DRUG|Vincristine|Given IV.
41035524|NCT06533748|DRUG|Inotuzumab|Given IV.
41035525|NCT06533748|DRUG|Blinatumomab|Given IV.
41035526|NCT06533748|DRUG|Dasatinib|Given PO.
41035527|NCT06533748|PROCEDURE|IT MHA|Given Intrathecal (IT), Age adjusted.
41035528|NCT06533748|DRUG|Cyclophosphamide|Given IV.
41165168|NCT03694119|DRUG|ozanimod|ozanimod
41165169|NCT06178198|PROCEDURE|Ablative radioembolization using Yttrium-90 resin microspheres|Based on 99mTc-MAA mapping, a partition model (multi-compartment MIRD) is employed to plan for a radiation dose of 400 (± 30%) to the tumor. If delivering this dose to the tumor is challenging due to lung dose limitations, the maximum feasible dose is administered to the tumor while maintaining the estimated lung dose below 15 Gy. While treating the entire tumor with a single high-dose radioembolization session is preferred, if necessary due to considerations like estimated lung dose, the treatment can be divided into two sessions, keeping the cumulative lung dose below 25 Gy. For any methods not covered in this discussion, refer to the SIR-Sphere user manual by Sirtex.
41165170|NCT04899401|DIETARY_SUPPLEMENT|Standard of care + PediaFlù®|Standard of care: Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. PediaFlù®: During the 6 days of the clinical investigation, the subjects will administer PediaFlù® 5ml x3 times per day for children below 6 years and 10mlx3 times per day for children above 6 years.
41165854|NCT02987998|DRUG|Radiation|Radiation (1.8Gy/D to 45Gy in 25 fractions)
41165855|NCT05061069|DIAGNOSTIC_TEST|cervical vestibular evoked myogenic potentials (cVEMP)|cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.
41165856|NCT00169949|DRUG|aripiprazole|
41165857|NCT03396211|DRUG|Apatinib|Apatinib tablets
41508001|NCT03928067|BEHAVIORAL|PNF + SAF|Personalized normative feedback (PNF) to correct misperceived peer drinking norms abroad + sojourner adjustment feedback (SAF) to promote cultural engagement abroad.
41508002|NCT00934024|DRUG|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
41508003|NCT00292890|DEVICE|insulin needle|
41035529|NCT06533748|DRUG|Cytarabine|Given IV or IT.
41035530|NCT06533748|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
41035531|NCT06533748|DRUG|6-Mercaptopurine|Given PO.
41035532|NCT06533748|DRUG|Calaspargase|Given IV.
41035533|NCT06533748|DRUG|Daunorubicin|Given IV.
41035534|NCT06533748|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
41035535|NCT04291963|PROCEDURE|DGG + TUN|In the DGG group, CTG was obtained at palatal mucosa by means of intra-oral de-epithelialization of the FGG using a 2.3 mm diameter diamond burr (801G/023, EMS, Aldrich Co., USA) with NaCL 0.9% saline irrigation
41035536|NCT04291963|PROCEDURE|SCTG + TUN|In SCTG group, graft was harvested through the single-incision approach at palatal mucosa
41035537|NCT00620477|DRUG|injection in the knee joint with 20 ml of chirocaine 0.125%|injection in the knee joint with 20 ml of chirocaine 0.125%
41035538|NCT00620477|DRUG|injection in the knee joint with 20 ml of physiological fluid|injection in the knee joint with 20 ml of physiological fluid
41035539|NCT06054724|OTHER|Yoga-Based Respiration Training|The selected asanas, believed to be beneficial for urinary incontinence, will be practiced with a focus on breath. After the assessment session, participants will engage in three days of face-to-face yoga sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
41035540|NCT06054724|OTHER|Pilates-Based Respiration Training|Before starting the 6-week practice protocol, participants will be taught the transversus abdominis muscle activation and centering, pilates-specific lateral costal breathing and other key elements of pilates. Pilates exercises chosen as beneficial for urinary incontinence will be performed with a focus on breath. After the assessment session, participants will engage in three days of face-to-face pilates sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
41035541|NCT06223828|DRUG|Azithromycin|10mg/kg/dose (max dose 500mg) once daily for 3 days
41035542|NCT00373334|DRUG|nizatidine (axid)|nizatidine (axid)
41035543|NCT00373334|DRUG|nizatidine (axid)|nizatidine (axid)
41035544|NCT00373334|DRUG|placebo|placebo
41035545|NCT05132699|DRUG|Cannabidiol (CBD) oral solution|An oral strawberry flavored liquid, taken as a 2.5ml (250mg) dose twice a day
41035546|NCT05132699|DRUG|Placebo|An inert strawberry flavored oral solution, taken as a 2.5ml dose twice a day
41381212|NCT03269669|PROCEDURE|Computed Tomography|Undergo PET/CT scans
41381213|NCT03269669|DRUG|Cyclophosphamide|Given IV
40851904|NCT04991129|DRUG|WJ01024|40mg BIW: WJ01024, Q4W, twice per week
41381214|NCT03269669|DRUG|Doxorubicin Hydrochloride|Given IV
40851905|NCT04991129|DRUG|WJ01024|60mg BIW: WJ01024, Q4W, twice per week
40851906|NCT04991129|DRUG|WJ01024|80mg BIW: WJ01024, Q4W, twice per week
40851907|NCT04991129|DRUG|WJ01024|60mg QW: WJ01024, Q4W, once per week
40851908|NCT04991129|DRUG|WJ01024|80mg QW: WJ01024, Q4W, once per week
40851909|NCT04991129|DRUG|WJ01024|50mg QW: WJ01024, Q4W, once per week
40851910|NCT04991129|DRUG|WJ01024|40mg QW: WJ01024, Q4W, once per week
41035547|NCT05132699|BEHAVIORAL|Massed Prolonged Exposure (mPE)|mPE, delivered daily Monday through Friday over two weeks, utilizes exposure-based interventions to target psychological mechanisms (i.e., experiential and behavioral avoidance; maladaptive cognitive changes) that are thought to maintain trauma-related symptoms.
40851911|NCT05003596|DRUG|Methylprednisolone Tablet|Subjects will take a quantity 21 4mg tablets over a 6 week taper.
41035548|NCT00251810|DEVICE|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
41035549|NCT04489446|DRUG|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
41035550|NCT04489446|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
41035551|NCT03355079|DRUG|SmofKabiven® E|In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
41035552|NCT06480773|DRUG|standard of care chemotherapy|intravenous Paclitaxel or the combination of Bleomycin and Vincristine.
41381215|NCT03269669|PROCEDURE|Echocardiography|Undergo ECHO
41381216|NCT03269669|DRUG|Lenalidomide|Given PO
41381217|NCT03269669|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41381218|NCT03269669|BIOLOGICAL|Obinutuzumab|Given IV
41381219|NCT03269669|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
41381220|NCT03269669|DRUG|Prednisone|Given PO
41381221|NCT03269669|DRUG|Umbralisib|Given PO
41381222|NCT03269669|DRUG|Vincristine Sulfate|Given IV
41381223|NCT06651996|DEVICE|one session of face-to-face telerehabilitation tutorial (OST)|The first group participated in a face-to-face tele-rehabilitation session in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
41381224|NCT06651996|DEVICE|Three session of face-to-face telerehabilitation tutorials (TST)|The second group participated in three face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
41381225|NCT06651996|DEVICE|Six session of face-to-face telerehabilitation tutorials (SST)|The third group participated in six face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
41381226|NCT06572228|DRUG|dupilumab|Administered by subcutaneous (SC) injection
41381227|NCT06572228|DRUG|Matching Placebo|Administered by SC injection
41381228|NCT06572228|DRUG|ICS/LABA|Administered at a blinded doses
41381229|NCT05439135|OTHER|washed microbiota transplantation|Each patient will receive washed microbiota transplantation each day for three consecutive days. After WMT, participants will receive free diet plus home enteral nutrition (solution at a 750ml daily dosage that provides 750 kcal energy) at home for 8 weeks.
41035553|NCT04479813|DRUG|Moxonidine 0.2 MG|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
41381230|NCT04793958|DRUG|MRTX849|28 Day Cycle
41381231|NCT04793958|BIOLOGICAL|Cetuximab|28 Day Cycle
41381232|NCT04793958|DRUG|mFOLFOX6 Regimen|"* Fluorouracil~* Oxaliplatin~* Folinic acid"
41381233|NCT04793958|DRUG|FOLFIRI Regimen|"* Fluorouracil~* Irinotecan~* Folinic acid"
41035554|NCT04479813|OTHER|placebo|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
41035555|NCT06628206|DRUG|LPX-TI641|Oral solution administered QD for 28 consecutive days
41381234|NCT05909904|DRUG|Tislelizumab|Administered intravenously
41381235|NCT05909904|DRUG|BGB-A425|Administered intravenously
41381236|NCT05909904|DRUG|LBL-007|Administered intravenously
41381237|NCT04522271|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
41381238|NCT04522271|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
41381239|NCT06622824|DRUG|KX-826 0.5% BID|0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
41381240|NCT06622824|DRUG|KX-826 1.0% BID|1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
41381241|NCT06622824|DRUG|Vehicle (Placebo) applied BID|Matching placebo applied topically to scalp twice daily for 24 weeks
41381242|NCT01286272|DRUG|Bendamustine Hydrochloride|Given IV
41381243|NCT01286272|DRUG|Bortezomib|Given IV or SC
41381244|NCT01286272|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET
41381245|NCT01286272|OTHER|Laboratory Biomarker Analysis|Correlative studies
41035556|NCT06628206|DRUG|Placebo|Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.
41035557|NCT02220972|DRUG|Perampanel|
41381246|NCT01286272|BIOLOGICAL|Ofatumumab|Given IV
41381247|NCT01286272|PROCEDURE|Positron Emission Tomography with Radiolabeled Targeting Agent|Undergo FDG-PET
41381248|NCT06105697|OTHER|Blood flow restriction Running on Treadmill|Soccer players included in experimental group I will carry out this program for 6 weeks, setting the blood pressure to \~ 60% of limb occlusion pressure (AOP). They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
41381249|NCT06105697|OTHER|Running on Treadmill|Soccer players included in experimental group II will carry out the program for 6 weeks without occlude the blood pressure. They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
41381250|NCT05237674|BEHAVIORAL|The TEACHOUT intervention|"The core component of the Intervention is a two-day training course on EOtC given to elementary school teachers followed by the teachers committing to apply EOtC for at least five hours a week, delivered in 1-2 weekly sessions for one school year (in this study, August 2022 to June 2023).~In the training course knowledge and understanding of the practice and theory of EOtC is facilitated in presentations and talks supplemented by illustrative examples in workshops and plenum discussions on local implementation. The 1-2 weekly EOtC sessions during the school year 2022-2023 may be delivered by one or more teachers simultaneously in various school subjects, at various places outside the school buildings."
41381251|NCT04293562|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
41381252|NCT04293562|DRUG|Asparaginase|Given IM or IV
41381253|NCT04293562|DRUG|Asparaginase Erwinia chrysanthemi|Given IM or IV
40851912|NCT05003596|OTHER|Standard Mobilization Treatment|standard treatment of hand injuries with focus on mobilization. No anti-inflammatory medications. Pain management via Tylenol or narcotics if deemed necessary.
41035558|NCT02220972|DRUG|Placebo|
41035559|NCT05878197|BEHAVIORAL|Straw phonation|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, straw phonation on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, straw phonation on word and sentence level, pitch variations Day 4: straw phonation in spontaneous speech, combination exercises"
41035560|NCT05878197|BEHAVIORAL|Resonant voice therapy|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, resonant voice therapy on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, resonant voice therapy on word and sentence level, pitch variations Day 4: resonant voice therapy in spontaneous speech, combination exercises"
41035561|NCT05878197|BEHAVIORAL|Vocal Hygiene|"Participants of the control group will receive a sham treatment, including the exact same games, drawing assignments, etc. as in the experimental groups. However, no SOVT or other active vocal techniques will be practiced. Vocal hygiene guidelines (e.g. avoid screaming, imitating voices, sufficient hydration etc.) will be kept equally in the four groups. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations Day 3: breathing exercises, vocal hygiene recommendations Day 4: combination exercises"
41165171|NCT04899401|OTHER|Standard of care|Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. Standard of care Nasopharyngeal liberation through hydration with drinking fluids to support body fluid excretion, aspiration of secretions, NaCl solution for nasal irrigation, Nasal sprays with sea water, nasal spray with active compound (to be used only at special indication of the medical doctor) Throat spray with Benzydamine hydrochloride (Tantum Verde®), Pediatric use: children over 6 and below 12: 4 sprays 2 - 6 times a day. Children (under 6 years): 1 spray per 4 kg of body weight, a maximum of 4 sprays at once, 2-6 times a day according to the leaflet. Each spray equals 0.17 ml of solution. Acetaminophen (Paracetamol) per os: at need, as antipyretic (\>38,5C), 10 mg/kg/dose, per need every 6-8 hours or according to the leaflet, maximum dosage 80 mg / kg / day. A dosage of over 30 mg/Kg/dose will result in an IP failure;
41165172|NCT06196073|OTHER|Osteopathic manual therapy|Bilateral oscillation therapy to the T10-L2 region for the regulation of sympathetic tone, suboccipital release technique for the regulation of parasympathetic tone, sacrum mobilization, celiac, mesenteric superior and inferior ganglion mobilizations, colon peristalsis and ileocecal valve mobilization for the treatment of functional dysfunctions, ascending colon mobilization, transverse colon. mobilization, descending colon fascia mobilization and sigmoid colon mobilization, peritoneal mobilization
41508004|NCT01932918|DRUG|Patient controlled analgesia|"1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients."
41165173|NCT06196073|DIETARY_SUPPLEMENT|conservative treatment|Nutritional recommendations and necessary nutritional supplements to facilitate digestion and defecation
41165174|NCT05352971|OTHER|Biomarker quantification|Patient blood samples will be tested on 2 different platforms
41165175|NCT02123277|DEVICE|Balloon catheter for the Eustachian tube|Balloon catheter is inserted in the Eustachian tube to dilate it.
41165176|NCT03844178|PROCEDURE|The option for compensation of Pupil centroid shift was ON|The option for compensation of Pupil centroid shift was ON
41381254|NCT04293562|PROCEDURE|Biospecimen Collection|Correlative studies
41381255|NCT04293562|PROCEDURE|Bone Marrow Aspiration|Undergo BM aspiration
41381256|NCT04293562|PROCEDURE|Bone Marrow Biopsy|BM biopsy
41381257|NCT04293562|BEHAVIORAL|Cogstate Assessment Battery|Ancillary studies
41381258|NCT04293562|PROCEDURE|Computed Tomography|Undergo CT
41381259|NCT04293562|DRUG|Cytarabine|Given IV or IT
41381260|NCT04293562|DRUG|Daunorubicin Hydrochloride|Given IV
41381261|NCT04293562|DRUG|Dexrazoxane Hydrochloride|Given IV
41381262|NCT04293562|DRUG|Etoposide|Given IV
41508005|NCT02026687|DRUG|Epidural|
41508006|NCT02026687|DRUG|Intrathecal|
41508007|NCT03886883|OTHER|Exercise induced hypoalgesia (EIH)|An EIH response was induced by a 3-minute isometric contraction of the hand flexor muscles at 25% of maximal voluntary contraction (MVC).
40851913|NCT05501743|DRUG|Intra-articular injection of microfat and PRP|The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
41381263|NCT04293562|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
41381264|NCT04293562|DRUG|Gemtuzumab Ozogamicin|Given IV
41381265|NCT04293562|DRUG|Gilteritinib Fumarate|Given PO/NG/G-tube
41381266|NCT04293562|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
41508008|NCT03886883|OTHER|Static stretch (SS)|Two bouts of 30 seconds of static stretching (SS) of the knee flexors.
41508009|NCT03886883|OTHER|Rest|The participants rested in a seated position for 10 minutes
41508010|NCT03886883|OTHER|Conditioned pain modulation (CPM)|A CPM response was induced by way of the cold pressor test.
41508011|NCT03785327|DEVICE|tDCS|Participants either complete active and sham tDCS sessions one week apart or an autism training program.
41508012|NCT03785327|BEHAVIORAL|Autism Training|Autism Information Presentation developed by Dr. Grace Iarocci's Autism \& Developmental Disorders Lab at Simon Fraser University
41508013|NCT01298414|GENETIC|RNA analysis|
41508014|NCT01298414|OTHER|laboratory biomarker analysis|
41508015|NCT03907657|DRUG|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
41508016|NCT03907657|DRUG|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
41508017|NCT02541968|BEHAVIORAL|Cognitive-behavioral therapy (face-to-face)|
41165177|NCT03844178|PROCEDURE|The option for compensation of Pupil centroid shift was OFF|The option for compensation of Pupil centroid shift was OFF
41165178|NCT03844178|DRUG|installation of Tetracaine 1%|installation of Tetracaine 1%
41165858|NCT03396211|DRUG|Nivolumab|Fixed dose of nivolumab given intravenously every 2 weeks
41381267|NCT04293562|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41381268|NCT04293562|DRUG|Methotrexate|Given IT
41381269|NCT04293562|DRUG|Mitoxantrone Hydrochloride|Given IV
41381270|NCT04293562|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
41381271|NCT04293562|DRUG|Therapeutic Hydrocortisone|Given IT
41381272|NCT06557772|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
41381273|NCT06557772|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: SC injection
41381274|NCT06557772|DIETARY_SUPPLEMENT|SIGE|Pharmaceutical form: Capsule Route of administration: Oral
41165179|NCT03844178|PROCEDURE|Photorefractive keratectomy (PRK)|periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA)
41508018|NCT02541968|BEHAVIORAL|Internet-based Cognitive-behavioral therapy|With therapist support
41508019|NCT02541968|BEHAVIORAL|Internet-based Cognitive-behavioral therapy without therapist support|
41508020|NCT06363903|DIAGNOSTIC_TEST|mesh allergy test|a 5 mm\^2 part of polypropylene mesh will be dissolved in 1 mL Methyl ethyl ketone (MEK), 25 microliters of this solution will be topically applied in a Finn chamber, and a reaction to the topical applicant will be assessed within 48 hours after application.
41508021|NCT06363903|DIAGNOSTIC_TEST|blood tests|Blood tests for diagnosis of autoimmune diseases will be performed
41508022|NCT06363903|PROCEDURE|Mesh removal|If wish for mesh removal persists, this procedure can be performed after separate informed consent (within the study), as standard practice of care.
41508023|NCT02153983|DRUG|Colchicine 0.6Mg Cap|Colchicine 0.6 mg given twice daily
41508024|NCT02153983|DRUG|Placebo capsules given|Placebo capsules given twice daily
41508025|NCT02153983|DRUG|Colchicine 0.6Mg Tab|Open-label colchicine
41508026|NCT04152863|BIOLOGICAL|Gebasaxturev IV|Administered as an IV infusion of 1 X 10\^9 TCID50
41508027|NCT04152863|BIOLOGICAL|Gebasaxturev ITu|Administered as an ITu injection of 3 X 10\^8 TCID50
41508028|NCT04152863|DRUG|Pembrolizumab|Administered as an IV infusion of 200 mg
41508029|NCT02872428|DRUG|Valproic Acid|By infusion over 1 hour
41508030|NCT02872428|DRUG|Isotonic saline solution|By infusion over 1 hour
41508031|NCT01252277|DRUG|Lovaza™|4 capsules daily for 6 months
41508032|NCT04805515|BEHAVIORAL|Nicotine Corrective Messages|Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.
41508033|NCT03460080|DIAGNOSTIC_TEST|AFP-L3 and PIVKA-II in HCC|"Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI"
41165180|NCT05238363|DRUG|HLX07|HLX07 1500mg ivgtt Q3W
41508034|NCT05233852|OTHER|"Do not do recommendation"|A drug prescription or procedure included in 'do not do' recommendations
41508035|NCT03561324|DEVICE|Imaging Beta Probe (IBP)|Using IBP for imaging of PET positive lymph nodes
41508036|NCT05776927|DRUG|QVM149|QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®
41508037|NCT05776927|DRUG|Salmeterol Xinafoate / Fluticasone Propionate|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
41508038|NCT05776927|DRUG|Placebo to QVM149|Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®
41165181|NCT04857047|DRUG|BR9003 2mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003 tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it.
41165182|NCT04857047|DRUG|BR9003A 1mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003A tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it. Another BR9003A tablet will be administered orally with water 150mL around 20:30 after dinner between 18-19:00.
41165183|NCT06104384|BEHAVIORAL|Behavioral and supportive therapy|Behavioral and supportive therapy
41165184|NCT02705625|DRUG|MIV-711|MIV-711 administered orally once daily
41165185|NCT02705625|DRUG|Placebo|Placebo manufactured to mimic MIV-711 capsule.
41165186|NCT01820637|DEVICE|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
41165187|NCT00185796|PROCEDURE|Total Lymphoid Irradiation (TLI)|TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1
41381275|NCT06557772|DIETARY_SUPPLEMENT|Gluten-free product (GFP)|Pharmaceutical form: Capsule Route of administration: Oral
41381276|NCT06652269|OTHER|Psychopharmacology intervention|Psychotherapy with horses
41508039|NCT05776927|DRUG|Placebo to Salmeterol Xinafoate / Fluticasone Propionate|Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
41508040|NCT05776927|DRUG|Run-In Medication|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
41508041|NCT05776927|DRUG|Rescue Medication|Salbutamol 100μg / Albuterol 90μg
41508042|NCT05776927|DEVICE|Concept 1 Device|Concept1 (Breezhaler) used for QVM149 and placebo delivery
41508043|NCT05776927|DEVICE|Girohaler|Girohaler for Comparator and Placebo delivery.
41508044|NCT01709929|DRUG|insulin detemir|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
41508045|NCT01936506|BEHAVIORAL|Cognitive Training A|
41508046|NCT01936506|BEHAVIORAL|Cognitive Training B|
41508047|NCT05741177|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound score
41508048|NCT03822104|DIETARY_SUPPLEMENT|Bovine Colostrum|Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants start with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5 if the infants only receive DM. The intervention lasts until the infants reach postmenstrual age (PMA) 35+6 weeks or in no-need of fortification due to sufficient growth, whichever comes first.
41381277|NCT03302130|BEHAVIORAL|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
41381278|NCT03302130|DEVICE|Arterial spin labeling MRI|Single PLD PCASL
41508049|NCT03822104|DIETARY_SUPPLEMENT|FM85|Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed until discharge.
41165188|NCT00185796|PROCEDURE|Anti-Thymocyte Globulin as Conditioning (ATG)|Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
41508050|NCT04684472|BIOLOGICAL|Modified anti-CD19 CAR T cells|intravenous infusion
41508051|NCT06318312|OTHER|Hypoxia|Hypoxic exposure: FiO2 = 11% Hypoxic exposure: FiO2 = 13% Hypoxic exposure: FiO2 = 15% Hypoxic exposure / placebo: FiO2 = 21%
41508052|NCT00003131|DRUG|chemotherapy|
41508053|NCT00003131|DRUG|gemtuzumab ozogamicin|
41508054|NCT02784041|DRUG|single adductor-canal-block|Single adductor-canal-block is performed before the surgery. A 12Hz linear ultrasound transducer is placed on the medial part of the thigh with the leg slightly externally rotated. The femoral artery was identified in short axis in the adductor canal, underneath the sartorius muscle. After skin disinfection , an 18-gauge needle (B.Braun Medical, Melsungen, Germany) is inserted in-plane from the lateral side of the transducer. The needle tip was placed underneath the sartorius muscle, just lateral to the artery and saphenous nerve, using 2-3 ml of saline to ensure correct placement. 25 ml of 0.35% ropivacaine is slowly injected with repeated aspiration.
41508055|NCT02784041|DRUG|periarticular infiltration|The periarticular infiltration of multimodal agents will involve the preparation of a mixture of 100 ml solution. The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to a total volume of 100ml. 50 ml of mixture will be injected into the anterior, medial and lateral soft tissues after the implantation of the joint prostheses. The remaining 50 ml of mixture will be injected into intraarticular space after the closure of articular capsule.
41508056|NCT03378752|PROCEDURE|HFJV|On High frequency jet ventilation, Every 15 minutes, after induction of general anaesthesia, a computed tomography of the lower part of the lungs are taken (10 cm volume, with the top of the right diaphragm as the lower border)
41508057|NCT00451646|DRUG|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
41508058|NCT00191126|DRUG|gemcitabine|1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
41508059|NCT00191126|DRUG|Cisplatin|75 mg/m2, IV, q 21 days x 3 cycles
41508060|NCT00191126|PROCEDURE|surgery|surgery
41508061|NCT01831102|OTHER|none- observational study|
41508062|NCT00911300|DRUG|fondaparinux|Comparison of different drugs
41508063|NCT00911300|DRUG|unfractionated heparin|Comparison of different drugs
41508064|NCT00911300|DRUG|Vitamin-K-Antagonist|Comparison of different drugs
41508065|NCT04593576|OTHER|Physical activity protocol/out door sports|"Warm up exercise will be administered for 10 minutes, then one-to-five small group of instruction based activity will be administered for 15 minutes. After this whole group will be engaged in ball exercise and cooperative ball games for 20 minutes. At the end cool down and reward activity will be done with participants for 15v minutes.~Total 1 hour physical activity protocol will be administered twice a week."
40851914|NCT05501743|PROCEDURE|Total denervation of the wrist|The surgical treatment by total denervation of the wrist will be performed during a one-day outpatient stay in the hand and limb surgery department at the Hôpital de la Timone. It will be performed under loco-regional anesthesia by axillary plexus block.
40851915|NCT05495867|PROCEDURE|implant placement|implant placement in edentulous area
41165859|NCT06442163|DEVICE|AVAPS study was performed within 1 week of the CPAP titration attempt failure, using the auto-titrating EPAP (AE), the OmniLab Advanced +, System One device (Philips Respironics, Murrysville, PA, U.S.|"After attending an educational session (in the presence of a family member) with hands-on training, the AVAP -AE devices were provided to the patients.~During the study, one month after AVAPS -AE initiation, patients had direct immediate access to medical and technical support through phone contact during daytime working hours."
41381279|NCT03302130|DEVICE|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
41381280|NCT05910450|DRUG|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
41381281|NCT05910450|DRUG|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
41381282|NCT05742607|DRUG|IPH5201 + durvalumab + standard chemotherapy|"Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab."
40851916|NCT04205617|OTHER|produce prescription and nutrition education|Participants will receive diabetic appropriate groceries, diabetes education classes led by volunteer doctors and nurses, cooking demonstrations, shared meals, 1:1 and group coaching by dietitians.
40851917|NCT03505528|DRUG|Nanoparticle albumin-bound paclitaxel|Abraxane is administered intravenous at a constant dose of 100mg/m2
41381283|NCT01139242|BEHAVIORAL|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
41165189|NCT04523298|PROCEDURE|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia(24)) with SMOOTH mode setting, which enables non-ablative, thermal-only operation(25). The parameters are selected based on extensive preclinical and clinical studies(26,27,28).~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
41165190|NCT04523298|OTHER|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
41381284|NCT01139242|BEHAVIORAL|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
41381285|NCT06652165|DRUG|zanubrutinib combined with BEAM|zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
41165191|NCT01691547|DRUG|UMEC /VI|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
41165192|NCT01691547|DRUG|UMEC|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
41165193|NCT01691547|DRUG|VI|Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
41381286|NCT06652165|DRUG|BEAM|camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
41381287|NCT06286813|OTHER|Plant (natural) oils|Using 10 ml of plant(natural) oil once a day for daily skin care of newborns
41381288|NCT03099655|DEVICE|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
41381289|NCT05671991|DRUG|Empagliflozin 25 mg vs Placebo|Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
41508066|NCT04593576|OTHER|Intensive table teaching speech therapy|Control group participants will be given speech therapy session based on intensive table teaching for 30 minutes twice a week.
41508067|NCT04993066|DEVICE|GentleMax Pro Plus|The GentleMax Pro Plus laser system to be used in this study received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) under K201111 on May 26, 2020
41508068|NCT03420586|DRUG|Nitrous Oxide|The nitrous oxide group (GN2O) will receive 70% N2O in 30% O2 at the end of surgery.
41508069|NCT05006547|OTHER|Electromyograph Biofeedback training of the peroneal muscle|The exercise will be performed with the subject sitting in front of a computer monitor, on an elevated chair, and his feet will be in the air. The examiner will ask the subject to perform a maximum contraction of the paronal muscles, in an open kinematic chain. After reference, the subject will begin a five-minute practice. The practice will be divided into rounds of: eight seconds of muscle work and 15 seconds rest.
41508070|NCT02206360|PROCEDURE|Endoscopic Ultrasound|
41508071|NCT02206360|PROCEDURE|Magnetic Resonance Imaging (MRI)|
41508072|NCT06239727|DRUG|PD-1 blocking antibody|"1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1."
41508073|NCT06239727|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
41508074|NCT06239727|DRUG|Cisplatin (80 mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
41381290|NCT05671991|DRUG|Empagliflozin 10 MG|Chronic Study- Empagliflozin 10 mg for 8 weeks
41508075|NCT06239727|RADIATION|Reduced-dose Intensity-modulated radiotherapy|"1. Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F."
41381291|NCT04637217|DIAGNOSTIC_TEST|Optical Coherence Tomography|Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
41381292|NCT01699100|OTHER|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure \> 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
41381293|NCT04130009|PROCEDURE|Tourniquet use|Use of Tourniquet in The TKA
41381294|NCT05436834|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
41508076|NCT06239727|RADIATION|Conventional-dose Intensity-modulated radiotherapy|"1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F."
41508077|NCT06239727|DRUG|Cisplatin (100 mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
41508078|NCT06239727|DRUG|Capecitabine|Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
41508079|NCT04269525|BIOLOGICAL|UC-MSCs|After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.
40851918|NCT03505528|DRUG|Phenelzine Sulfate|Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d
41508080|NCT04768660|OTHER|gum|Other: Chewing gum ChiczaTM organic chewing gum 6 pieces a day Other: Glucose 12ml glucose solution (13,6g) per day
41381295|NCT05436834|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
41381296|NCT06647966|DIAGNOSTIC_TEST|PET/CT|\[11C\]CH PET/CT
41381297|NCT03231423|OTHER|Drainage|Using drain after operation
41381298|NCT05168943|DEVICE|Nylon (Polyamide) Epidural Catheter|Nylon (Polyamide) Epidural Catheter
41381299|NCT05168943|DEVICE|Polyurethane Epidural Catheter|Polyurethane Epidural Catheter
41381300|NCT06411431|PROCEDURE|Early Chest Tube Removal|"Subjects within the Early Removal group will have their chest tube removed if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
41381301|NCT06411431|PROCEDURE|Standard Chest Tube Removal|"Subjects within the Standard Removal group will have their chest tube removal on POD#2 if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
41381302|NCT06411431|DEVICE|Apical Chest Tube|A single apical chest tube will be placed and connected to a suction device at least -20 mmHg suction.
41381303|NCT05465044|OTHER|Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule|50% of the eligible participants will be assigned to twice-weekly hemodialysis for up to 12 months with incremental crossover to thrice-weekly hemodialysis as indicated.
41381304|NCT05465044|OTHER|Thrice-Weekly Hemodialysis|50% of the eligible participants will be assigned to outright thrice-weekly hemodialysis, which will be continuation of the initial thrice-weekly schedule during the run-in period, without the option to switch to less frequent dialysis schedule representing the standard of care.
41381305|NCT05809596|DEVICE|WATCHMAN FLX Pro LAAC Device|Treatment with a WATCHMAN FLX Pro Left Atrial Appendage Closure Device
41381306|NCT06652191|PROCEDURE|Direct catheterization with non-dilation|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, place the catheter into the vessel directly along the guide wire without using an dilator to expand the skin
41381307|NCT06652191|PROCEDURE|Catheterization after expanding the skin with a dilator|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, after the skin is expanded with a dilator, the catheter is inserted into the vessel along the guide wire
41381308|NCT06652425|OTHER|Low temperature (16°C) group|The exposure group will be exposed to low temperature (16°C) in a chamber for about 2 hours, resting during the whole periods.
41381309|NCT06652425|OTHER|Moderate temperature (22°C) group|The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
41508081|NCT05044702|OTHER|Retro walking|Retro walking will be performed on treadmill for 15 min per day for 3 days per week for 4 weeks at self-paced speed.
41508082|NCT05044702|OTHER|conventional physical therapy|"hot pack for 10 mints and conventional exercise program Conventional physiotherapeutic exercise program which consist of exercises such as~* prone leg extension~* prone lying chest elevation~* prone extension with alternate arm and leg lift~* supine bridging, bridging with one leg lift Each exercise will be performed as 2 sets of 12 repetitions of each exercise, each exercise position maintained for 10 s, and a rest of 1 min between the sets will be perform. No external load/resistance will be provided for the exercises, and the participants will be perform the exercise within their available range of motion"
41508083|NCT04539327|DRUG|Rucaparib|Participating local sites (GEICO-associated hospitals with expertise in gynecological cancer management) will enter clinical data of those patients who have previously participated in the rucaparib access program (RAP) in Spain and have given their consent.
41508084|NCT01161485|BEHAVIORAL|HIV Testing and Counseling|A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
41165194|NCT01691547|DRUG|FF|Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
41165195|NCT01488838|DRUG|Cisplatin: 40 mg/m2 weekly during radiation|Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
41165196|NCT01488838|RADIATION|Radiation: 60-66 Gy in 2 Gy daily fractions|Radiation: 60-66 Gy in 2 Gy daily fractions
41381310|NCT05552092|DEVICE|Esophageal temperature monitoring according to the depth|"Core temperatures will be measured with a tympanic thermometer as a reference. When the tympanic membrane (TM) temperature is constant after measuring three consecutive times at 10 seconds intervals, the temperature will be assumed as the core body temperature.~Initially, the esophageal stethoscope (ES) will be inserted to a depth of 45 cm from the incisor. After 30 minutes of monitoring, when the changes in the body temperatures stabilized, initial temperatures of the TM and ES thermistor will be assessed.~After 5 minutes, ES will be taken out 2 cm back, and the temperatures of each site will be measured when the temperature change of the ES thermistor stabilized below 0.1°C. Eventually, the depth of ES will be changed from 45 to 27 cm with a 2 cm interval, and the temperature at each position will be measured."
41381311|NCT05552092|OTHER|Anatomical landmark|For the further evaluation of the optimal insertion depth of GDT, anatomical landmarks such as distance from the cricoid cartilage to the carina (CCD) and distance from the carina to the intervertebral disc between T8 and T9 (CDD) will be measured using an electronic caliper on a preoperative chest X-ray.
41381312|NCT05695456|OTHER|personalized exclusion diet based on CLE|personalized exclusion diet based on CLE
41381313|NCT05695456|OTHER|empiric exclusion diet|exclusion diet with milk or gluten-containing grains
41381314|NCT06651697|RADIATION|Radiation therapy|Radiation therapy with full bladder or empty bladder protocols
41381315|NCT05226013|DRUG|Polyglycol lated urate oxidase for injection|Single dose escalation
41381316|NCT05226013|DRUG|Placebo|Placebo
41381317|NCT00886873|DRUG|Mifepristone|
41381318|NCT04647448|DIAGNOSTIC_TEST|Application of sensor patch|Application of sensor patch to chest to record acoustic signals due to disturbed blood flow.
41381321|NCT06649591|BEHAVIORAL|Survey|The intervention is an email based survey as described in the study description.
41381322|NCT03595124|DRUG|Axitinib|Given PO
41381323|NCT03595124|BIOLOGICAL|Nivolumab|Given IV
41381324|NCT06652334|PROCEDURE|Spinal anesthesia|20 patients undergoing spinal anesthesia
41381325|NCT06652334|PROCEDURE|Erector spinae plane block|20 patients undergoing erector spinae plane block
41035562|NCT01646476|DEVICE|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
41381326|NCT02783300|DRUG|GSK3326595|GSK3326595 will be administered with and without food, in tablet and capsule formulation.
41381327|NCT02783300|DRUG|Pembrolizumab|Pembrolizumab will be administered.
41381328|NCT03394274|OTHER|restrictive and liberal transfusion|hemoglobin threshold value was accepted 8g/dl. restrictive blood transfusion group was defined that if perioperative transfusion was started equal or under hemoglobin level 8 g / dL. Liberal blood transfusion group was defined as perioperative transfusion was started over hemoglobin level 8 g / dL .
41508085|NCT01161485|BEHAVIORAL|Contingency Management|In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
41508086|NCT01161485|BEHAVIORAL|Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
41508087|NCT06256523|DRUG|GZR18|0.5mg-13mg
41508088|NCT06256523|OTHER|Placebo|administered the same volume as GZR18
41508089|NCT03394157|OTHER|metabolic surgery|operation to cure type2 diabetes
41381329|NCT04546737|OTHER|Magnetic Resonance Spectroscopy (MRS).|This is a Nuclear Magnetic Resonance (NMR) technique which can detect the NMR signal allowing to measure under curves areas, amplitudes, ratios and concentrations of various metabolites contained in a biological tissue, in addition to water and lipids. This offers the possibility, in addition to the contribution of MRI imaging, to better characterize pathological processes (inflammatory, infectious, etc.) through spectral and metabolic changes that can be quantitatively evaluated. Spectroscopic measurements will be carried out with a mono-voxel spectroscopy using a PRESS \[Point RESolved Spectroscopy\] sequence with a short Echo Time (TE) of 35 ms, an intermediate TE of 144 ms and a long TE of 288 ms.
41381330|NCT05805293|DEVICE|High-Velocity Nasal Insufflation Therapy|"Parameter settings for the HVNI apparatus are as follows:~1. The flow of HVNI will initially be set at 30-40 L/min, and inspiratory flow rate could be increased to 45-60 L/min.~2. FIO2 will be adjusted to maintain a SaO2 more than 90 % and relative humidity of 30-34%.~3. Temperature range of 35-37°C."
41381331|NCT05805293|DEVICE|Non-Invasive Ventilation|Patients will be put on inspiratory/expiratory pressure 10/5 cmH2O (11). The inspiratory and expiratory pressures will be titrated with increments of 2 cmH2O based on improvement of oxygen saturation by continuous pulse oximetry and arterial blood gases values, alleviation of dyspnea and a decrease of respiratory rate and heart rate. The maximum allowed inspiratory pressure was 20 cm H2O. The maximum allowed expiratory pressure was 10 cm H2O.
41381332|NCT00449761|DRUG|LBH589|
41381333|NCT00761085|DRUG|Morphine|Standard of care for pain management of acute episode of pain
41381334|NCT00761085|DRUG|Methadone|Compare to standard of care for pain management of acute episode of pain
41381335|NCT06652737|BIOLOGICAL|PfSPZ-LARC2 Vaccine|The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)
41381336|NCT06652737|BIOLOGICAL|Normal Saline (Placebo)|Normal Saline Placebo
41381337|NCT04725214|DRUG|Anlotinib|Anlotinib With STUPP Regimen
41381338|NCT02204527|DIETARY_SUPPLEMENT|supplementation of 100.000 IU of vitamin D3|supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
41381339|NCT02204527|DIETARY_SUPPLEMENT|placebo pill|Placebo
41381340|NCT03016988|DRUG|Bortezomib|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;
41381341|NCT03016988|DRUG|Fludarabine|Fludarabine(F) 25mg/m2, intravenously day 1-3;
41381342|NCT03016988|DRUG|Cytarabine|Cytarabine(A) 500mg/m2 for 3 days(day1-3)
41381343|NCT04478188|OTHER|Measuring Pressure Volume Loop Pre and Post Device Placement|To measure simultaneous pressure and volume of the heart (pressure volumes loops) before and after ventricular assist device placement for cardiogenic shock (a severe form of heart failure) and before and after device removal.
40851919|NCT05340842|OTHER|simulation training group|In this study, applied breastfeeding training with Lactation Simulation Model was given to pregnant women in the intervention group (simulation training group, n=64) during antenatal period
40851920|NCT06584201|PROCEDURE|Erector Spinae Plane Block (ESP)|The ESP block will be administered before the VATS procedure, aiming to manage postoperative pain and minimize the impact on early lung function test (SFT) parameters. The block will be performed using standard techniques under ultrasound guidance to ensure accurate placement.
41508090|NCT06257381|OTHER|VO2max|"Overall design 16 non-smoking individuals with COPD and 16 controls (non-smokers) matched for age and sex on a group level will be included in the study. The study consists of two study days. Separation between the study days are at least 48 hours and maximum 10 days.~Before entering the study: Informed written and oral consent.~Study day 1: Medical examination, full lung function testing (dynamic spirometry, whole-body plethysmography, diffusion capacity) followed by a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 3h).~Study day 2: Participants will undergo a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 1,5h)."
41035563|NCT01646476|DEVICE|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
41381344|NCT05424939|PROCEDURE|Colectomy|Colon resection
40851921|NCT06584201|PROCEDURE|Paravertebral Block (PVB)|The PVB will be administered prior to the VATS procedure, with the objective of managing postoperative pain and assessing its impact on early postoperative lung function (SFT) parameters. This block will also be performed using standard techniques and ultrasound guidance for precision.
40851922|NCT00004932|DRUG|imatinib mesylate|
40851923|NCT01958359|BEHAVIORAL|Short IVR|IVR-based alcohol diary with feedback
40851924|NCT01958359|BEHAVIORAL|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
41035564|NCT05853913|BEHAVIORAL|Exercise|Exercise will be walking/jogging at a medium to hard intensity for 1 hour.
41381345|NCT05424939|PROCEDURE|Stoma procedures|Any type of colostomy or ileostomy with or without bowel resection
41381346|NCT05424939|PROCEDURE|By-pass/laparotomy/laparoscopy/biopsy|Any palliative surgery without bowel resection
41381347|NCT06651749|DRUG|Propofol injection|hemodynamic changes of a high dose versus low dose propofol during induction of anethesia.
41381348|NCT01554059|DRUG|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
41381349|NCT01554059|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly \* 6 doses 3-4 weeks after radical resection
41381350|NCT01554059|DRUG|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly\*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
41381351|NCT01554059|RADIATION|Radiotherapy|2GY daily \*20次
41381352|NCT06651814|BEHAVIORAL|Supervised Exercise Group|A supervised exercise program will consists of 10 sessions. The 1st exercise station will be a 5-minute warming up of the jaw with a heat lamp. The 2nd station will involve jaw opening-closing movements (TMJ rotation) with the mandible in a slightly protruded position for 6 minutes. The 3rd and 4th exercise stations will comprised of jaw opening and jaw protrusion, respectively, against resistance for 4 minutes each. Measurements will be done before the trial started and after 3 months.
41381353|NCT06651814|BEHAVIORAL|Home Exercise Group|Patients will received a home regime of jaw exercises. They will be instructed to do two different trainings. The 1st type of exercise will be jaw opening and closing movements daily for 5 minutes after each meal with the mandible and the head of the TMJ in a slightly protruded position. This exercise should not produce any clicking sounds. The 2nd type of exercise will be isometric exercises; this entailed jaw opening and jaw protrusion against resistance with their hand for 10 seconds with 10 repetitions each daily. All the patients will receive a training brochure with photos of the exercises and detailed information on frequency and exercise time. The brochure will include a diary. After 6 weeks, the subject and the assistant will check the performance of the exercise and the diary
41508091|NCT00430066|DRUG|Imatinib Mesylate|400 mg/die for 6 months
40851925|NCT02919527|OTHER|Self-Myofascial-Release|Self-Myofascial-Release performed at the anterior thigh
40851926|NCT02919527|OTHER|Stretching|Static Stretching performed at the anterior thigh
40851927|NCT00648557|DRUG|Levothyroxine Sodium Tablets 200 mg|3x200mcg, single dose fasting
40851928|NCT00648557|DRUG|Synthroid Tablets 200 mg|3x200mcg, single dose fasting
40851929|NCT03300063|OTHER|Low flow nocturnal oxygen|Nocturnal low-flow oxygen via nasal cannula
41381354|NCT04732884|DEVICE|Smartsens, Gelenic AG; with biofeedback|The Smartsens is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.
41035565|NCT01131312|DEVICE|Thinprep|Pap test
41381355|NCT04732884|DEVICE|Smartsens, Gelenic AG; without biofeedback|Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
41381356|NCT05743244|DRUG|Abrocitinib 200 MG Oral Tablet|Abrocitinib
41381357|NCT05743244|DRUG|Ritlecitinib|Ritlecitinib
41381358|NCT05743244|DRUG|Placebo|Placebo for Abrocitinib or Ritlecitinib
41381359|NCT05053750|DRUG|Paclitaxel/Bev (control)|Given by PO
41381360|NCT05053750|DRUG|Paclitaxel/Bev + ZA (experimental)|Given by PO
41381361|NCT05959564|BEHAVIORAL|Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are tailored to their personalities.
41381362|NCT05959564|BEHAVIORAL|Non-Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are not tailored to their personalities.
41381363|NCT05959564|BEHAVIORAL|No Chatbot Control|In this intervention, participants will see a standard CDC HPV vaccine message only and will not interact with any chatbot.
41381364|NCT06566352|PROCEDURE|Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine|intramyometrial injection of epinephrine 1mg diluted in 200mg of NaCl solution
41381365|NCT06566352|PROCEDURE|traditional laparoscopic myomectomy|traditional laparoscopic myomectomy
41381366|NCT06566352|PROCEDURE|laparoscopic myomectomy with temporary bilateral uterine artery occlusion|Experimental: laparoscopic myomectomy with temporary bilateral uterine artery occlusion
41381367|NCT06566352|DRUG|injection of epinephrine 1mg diluted in 200mg of NaCl|injection of epinephrine 1mg diluted in 200mg of NaCl
41508092|NCT05885984|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) plus health education|Session 1: Reviewing experiences on struggles with CRF, realising consequence of controlling, introducing acceptance as an alternative, adopting virtual mindfulness. Education (patient): epidemiologic features of advanced lung cancer. Session 2: Separate thoughts/feelings related to CRF. Education (patient): treatments and symptoms of advanced lung cancer. Session 3: Reviewing caregiver's experiences of struggling with caregiving burden,introducing acceptance as an alternative. Education (caregiver): epidemiologic features of advanced lung cancer. Session 4: Separate caregivers' thoughts/feelings related to caregiving burden. Education (caregiver): treatments and symptoms of advanced lung cancer. Session 5:Understand the importance of values and clarifying personal values for dyads. Education (dyads): eating suggestions. Session 6: Emphasise ongoing value-based goals and commitment to actions for a meaningful cancer life for dyads. Education (dyads): exercising suggestions.
41508093|NCT05885984|OTHER|Health education|Session 1: health education on the epidemiologic features of advanced lung cancer will be taught to patients. Session 2: health education on treatments and related symptoms of advanced lung cancer will be taught to patients. Session 3: health education on the epidemiologic features of advanced lung cancer will be taught to caregivers. Session 4: health education on treatments and related symptoms of advanced lung cancer will be taught to caregivers. Session 5: health education on eating suggestions for advanced lung cancer patients and caregivers will be taught. Session 6: health education on exercising suggestions for advanced lung cancer patients and caregivers will be taught.
41508094|NCT01391715|DRUG|rabeprazole|rabeprazole 20mg bid per day for 2 weeks
41508095|NCT01391715|DRUG|standard dose rabeprazole|rabeprazole 20mg qd per day for 2 weeks
41381368|NCT06650787|OTHER|Ultrasound was used to locate the end of the gastric tube|"1. Inform the family of the purpose and method of using bedside ultrasound to guide the placement of the gastric tube, and determine the position of the end of the tube.~2. The ultrasound machine was connected to the power supply and placed on the right side of the patient.~3. Select the appropriate type of gastric tube and measure the length of the indwelling gastric tube by nursing staff before inserting the tube.~4. Nurses who had been trained in ultrasound performed ultrasound judgment on the neck and abdomen of the children. Sonographers, intensive care physicians and nursing staff jointly judged the ultrasound images.~5. Conventional judgment method was used to determine the position of gastric tube~6. Bedside chest radiography, with results obtained by a radiologist.~7. Keep your child safe at all times."
41035566|NCT01131312|DEVICE|Hybrid capture 2|Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
41035567|NCT01131312|PROCEDURE|Colposcopy|Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
41035568|NCT02461121|GENETIC|HLA mismatched stem cell|HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy
41035569|NCT02461121|GENETIC|HLA matched stem cell|HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
41165197|NCT03413540|OTHER|Jump|Drop jump from step
41381369|NCT06650787|OTHER|Conventional placing nasogastric tube group|"1. Choose the appropriate type of gastric tube, and measure the length of the indwelling gastric tube by the nursing staff before the tube insertion.~2. The gastric tube was inserted by the conventional blind insertion method.~3. The conventional judgment method was used to determine the position of the gastric tube.~4. Bedside chest radiography, with results obtained by a radiologist.~5. Keep your child safe at all times."
41381370|NCT03811002|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
41381371|NCT03811002|DRUG|Atezolizumab|Given IV
41381372|NCT03811002|PROCEDURE|Biospecimen Collection|Correlative studies
41381373|NCT03811002|DRUG|Carboplatin|Given IV
41381374|NCT03811002|DRUG|Cisplatin|Given IV
41381375|NCT03811002|DRUG|Etoposide|Given IV
41381376|NCT03811002|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41381377|NCT03811002|OTHER|Quality-of-Life Assessment|Ancillary studies
41381378|NCT03811002|OTHER|Questionnaire Administration|Ancillary studies
41381379|NCT06116292|DEVICE|The mobile application ESTOI for Asthmatic patients|"The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs:~1. SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities.~2. RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms.~3. YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan.~4. PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home.~5. NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs.~6. MESSAGING, it is a bidirectional contact area."
41381380|NCT05726110|DRUG|Selinexor|Given PO
41381381|NCT05726110|DRUG|Homoharringtonine|Given per standard of care
41381382|NCT05726110|DRUG|Daunorubicin|Given per standard of care
41381383|NCT05726110|DRUG|Cytarabine|Given per standard of care
41381384|NCT05726110|DRUG|Granulocyte Colony-Stimulating Factor|Given per standard of care
41381385|NCT05726110|DRUG|Aclacinomycin|Given per standard of care
41381386|NCT06652295|OTHER|Complex decongestive physiotherapy (CDP)|CDP consists of patient education, manual lymph drainage, short traction bandaging, skin/nail care and exercise. The applications of all modalities of the CDP programme were performed by the physiotherapist.
41381387|NCT06652295|OTHER|Self-administered Complex Decongestive Physiotherapy (CDP)|The self-administered CDP programme consisted of patient education, self-manual lymph drainage, self-short traction bandage application, self-skin/nail care and exercise. Participants were given one session of patient education before the self-administered CDP programme and patients were given practical information about all applications. Additionally, each component of the self-administered CDP programme was presented to the participants with a patient booklet and a video prepared by the researchers. Patients in the self-CDP group were followed up once a week with a patient follow-up diary.
41381388|NCT03713125|BEHAVIORAL|Reading Tutoring|20 hours of 1:1 reading tutoring intervention over 6 weeks
41381389|NCT05186974|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
41381390|NCT05186974|DRUG|Pembrolizumab|Administered intravenously
41165198|NCT02243761|OTHER|DBT Based Skills Groups for Families|12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
41165860|NCT02794714|DRUG|Deep neuromuscular blockade|Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
41381391|NCT05186974|DRUG|Carboplatin|Administered intravenously
41381392|NCT05186974|DRUG|Cisplatin|Administered intravenously
41381393|NCT06652503|BEHAVIORAL|online mental health coaching|SWAG-R Program: A 6-week Coaching Program Designed for NSU Undergraduate Students to Decrease Anxiety, Depression, and Stress and Improve Mental Health, Quality of Life, and Resiliency
41381394|NCT06635889|DRUG|Bupivacaine|The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.
41381395|NCT06635889|OTHER|Normal saline|Placebo of 50 ml of Normal Saline
41381396|NCT05621317|BIOLOGICAL|PVX-108|PVX108 comprises a mixture of peptides that represent sequences from peanut allergens
41381397|NCT05621317|BIOLOGICAL|Placebo|Matching placebo comprises the formulation vehicle without peptides
41381398|NCT02180867|DRUG|Doxorubicin|Given IV
41381399|NCT02180867|DRUG|Doxorubicin Hydrochloride|Given IV
41381400|NCT02180867|DRUG|Ifosfamide|Given IV
41381401|NCT02180867|DRUG|Pazopanib|Given PO
41381402|NCT02180867|DRUG|Pazopanib Hydrochloride|Given PO
41381403|NCT02180867|RADIATION|Radiation Therapy|Undergo radiation therapy
41381404|NCT02180867|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41381405|NCT06275919|DRUG|Regorafenib 40 MG Oral Tablet|REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
41381406|NCT06275919|DRUG|Local Standard of Care|In this setting there are not drugs with indication. Every site will treat patients as per their experience.
41381407|NCT06651164|DIAGNOSTIC_TEST|psychosocial risk screening|"* combined tablet-based screening questionnaire for psychosomatic screening and social service screening~* in case of positive psychosomatic or social service screening subsequent psychosomatic and / or social service consultation"
41381408|NCT06651307|DEVICE|Lifting with elbow sleeves|Lifting with elbow sleeves
41381409|NCT05330182|DRUG|LMN-201|"LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism"
41381410|NCT05330182|DRUG|Placebo|Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.
41381411|NCT06463886|BEHAVIORAL|STEP-AD|This in-person STEP-AD intervention will consist of 10 sessions. Session 1: Life Steps Adherence Session 2: Psychoeducation on the treatment model Session 3: Substance Use and Enhancing Resilience Session 4: Trauma Impact Session 5: Cognitive Restructuring Session 6: Racial Discrimination Impact and Coping Session 7: HIV Stigma Impact and Coping Session 8: Gender-related Stressors and Coping Session 9: Body Image and Healthy Relationships Session 10: Practice, Review, and Relapse Prevention. Each session lasts for about 40 to 60 minutes.
41381412|NCT06463886|BEHAVIORAL|Enhanced treatment as usual (E-TAU)|Participants assigned to the E-TAU condition will receive 10 in person sessions to ensure comparable contact time with study staff and identical incentives. The first session will consist of a session on healthy living with HIV (CDC content on HIV 101 \[highlights importance of engaging in care, adhering to medication, finding support\], nutrition, and physical activity. The remaining 9 sessions will consist of neutral (daily events) writing. Women will be asked to write a description of their plans for the next 24 hours.
41381413|NCT05915299|DEVICE|OCS Heart|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
41381414|NCT04914234|DRUG|Atenolol Succinate Oral Tablet|Atenolol 50 mg
41381415|NCT04914234|DRUG|Metoprolol Succinate Oral Tablet|Metoprolol 100 mg
41381416|NCT05119556|BEHAVIORAL|Video Telehealth Pulmonary Rehabilitation|Participant will be asked to exercise 3 times a week at their home for 60 minutes each session, via live two-way videoconferencing using a data-enabled smart phone or similar device. A total of 36 sessions will be administered over 13 weeks post-discharge. Sessions will be administered by exercise physiologists located at the University of Alabama at Birmingham. Each session will be scheduled with up to three other participants at a time to mimic group sessions as delivered at center-based pulmonary rehabilitation programs. Exercise sessions will include aerobics, strength or resistance training, breathing exercises, and education sessions. The exercise plans will be tailored according to the participants' baseline exercise tolerance as determined by an initial six minute walk test and their answers to the questionnaires at the baseline visit.
41381417|NCT06118099|DRUG|Amlitelimab|Injection solution SC injection
41381418|NCT06118099|DRUG|Placebo|Injection solution SC injection
41381419|NCT04840602|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41381420|NCT04840602|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
41381421|NCT04840602|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
41381422|NCT04840602|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
41381423|NCT04840602|DRUG|Ibrutinib|Given PO
41381424|NCT04840602|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41381425|NCT04840602|BIOLOGICAL|Rituximab|Given IV
41381426|NCT04840602|DRUG|Venetoclax|Given PO
41381427|NCT06099886|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate 30-45mg/day
41381428|NCT06653517|DRUG|Dabrafenib|"Dosage: 150 mg orally, twice daily (total daily dose of 300 mg) Administration: Administer at approximately 12 hours apart. Take at the same time each day. If a dose is missed and less than 6 hours remain until the next dose, skip the missed dose. Do not open, crush, or break the capsules.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
41381429|NCT06653517|DRUG|Trametinib|"Dosage: 2 mg orally, once daily Administration: Administer at least 1 hour before or 2 hours after a meal. Take at the same time each day. If a dose is missed, it should be taken no later than 12 hours before the next scheduled dose; otherwise, skip the missed dose.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
40851930|NCT03408964|OTHER|biological samples collection and analysis|Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
41381430|NCT06562985|DRUG|BAY3018250 Dose 1|Infusion, single dose
41381431|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, infusion
41381432|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, injection
41381433|NCT06562985|DRUG|BAY3018250 Dose 2 infusion|Infusion, single dose
40851931|NCT01930721|PROCEDURE|episiotomy|incision angle of episiotomy will be 60 degrees.
40851932|NCT01930721|PROCEDURE|episiotomy|incision angle of episiotomy will be 40 degree before cutting.
41381434|NCT06562985|DRUG|BAY3018250 Dose 2 injection|Injection, single dose
41381435|NCT06652685|DRUG|D5-PBCR(-) IA arm|"Induction: IA Drug: idarubicin, intravenously, 10 mg/m\^2 on D1-3 Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group with favorable/intermediate risk and MRD negetive, will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses. Subjects in the group with adverse risk or MRD positive will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
41381436|NCT06652685|DRUG|D5-PBCR(+) IA+Venetoclax arm|"Induction: IA+Ven Drug: idarubicin, intravenously, 10 mg/m\^2, on D1-3, Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7 For D5-PBCR (+) patients, Venetoclax will be combined. Drug: Venetoclax. Orally once daily, on D6-14. A 3-day dose ramp-up is required for the first induction (100mg D6, 200mg D7, 400mg D8-14) If a second induction is needed, the dose of IA is the same as the first cycle, and dose ramp-up of venetoclax is not required.~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
41381437|NCT03143205|BEHAVIORAL|AWARENESS for Sexual Minorities|9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
41381438|NCT03143205|BEHAVIORAL|Writing tasks|Writing sessions to explore daily activities.
41381439|NCT06651294|DIETARY_SUPPLEMENT|Neorenal Forte|This specialized formulation of phytotherapeutic extracts consists of proprietary Betula pendula leaves dry extract, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens. The product contains supplementary ingredients: microcrystalline cellulose, povidone, magnesium stearate, colorant film (brilliant blue FCF, iron dioxide).
41381440|NCT06651294|DIETARY_SUPPLEMENT|Placebo|The placebo product will be identical to the active form and will have the same composition but without the proprietary extract from Betula pendula, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens.
41381441|NCT05538663|DRUG|Gemcitabine|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
40851933|NCT05419544|BEHAVIORAL|Holy Quran Recital effect|The intervention group, listened to holy Quran recitation for 10 minutes twice a day 4 hours a part (10 am and 2 pm) for 2 consecutive days (usually the 2nd and the 3rd day post-operative) after extubation and gaining alertness. We have chosen Surah Al-Rehman because it is considered as the most rhythmic surah of the Quran and the recitation of Qari Abdul Basit is very soothing and effective as he has recited from the deep of the heart. The listing was by a disposable head phones for an I pad for each hospital. The control group received usual care by their nurses.
40851934|NCT02290977|RADIATION|Scheduled interval TACE - RT|RT will be administered at 2 weeks after TACE in HCC combined PVTT
40851935|NCT03314272|DEVICE|Space Glucose Control|Development of a closed loop control system via Space Glucose Control that automatically infuses insulin on the basis of an automated algorithm, which integrates a continuous glucose signal, could help overcome these obstacles and permit strict glycemic control without increasing the workload.
40851936|NCT04858295|DEVICE|Texting|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail, voice), self-administered surveys, and secure data capture for research purposes. Way to Health has been used successfully in prior behavior intervention studies.
40851937|NCT04858295|DEVICE|mHealth app|Omron Connect app available on a participant's smartphone connects to the participant's home Omron blood pressure monitor via bluetooth technology. The Omron Connect app, which stores the blood pressure readings and provides reminders to the participant via push notifications also communicates with the Way to Health research platform via Internet connection.
41381442|NCT05538663|DRUG|Docetaxel|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
41381443|NCT05538663|DRUG|Bacillus Calmette Guerin|intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
41381444|NCT06238466|DRUG|AZD1705|Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.
41381445|NCT06238466|OTHER|Placebo|Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.
41165861|NCT02794714|DRUG|Moderate neuromuscular blockade|Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
41381446|NCT06597760|DRUG|Enlicitide|Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.
41381447|NCT06597760|DRUG|Digoxin|Participants will receive 0.25 mg digoxin orally on Day 1 Period 1 in Arm A and Day 1 Period 2 in Arm B. They also receive Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B coadministered with oral 20 mg enlicitide/180 mg sodium caprate.
41381448|NCT06650267|BEHAVIORAL|Fathers for Change (F4C)|Defining features of F4C delivered over 18 sessions: 1) focus on the fathers model of fatherhood as a motivator for change, 2) focus on understanding and identifying feelings, teaching skills to identify and change emotional dysregulation that lead to both SU and FV, 3) co-parent communication skills to reduce stress and improve problem solving, 4) restorative parenting (see Table 1 and figure 1)127. F4C focuses on reflective understanding of emotional experiences, how that impacts thoughts and behaviors related to SU, FV, co-parenting/parenting each session. Through greater self-awareness, the father is better able to apply coping, communication and parenting skills introduced to reduce SU and FV.
41381449|NCT06650267|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC is an individual evidence-based SU treatment84 that incorporates two elements: endorsement of the disease model and the spiritual dimensions of recovery. These elements differentiate the approach from F4C. IDC is influenced by 12-step recovery philosophy and participation in 12-step groups like NA are encouraged. The model places focus on the individual in recovery without a focus on fatherhood or co-parenting. IDC will be offered in an 18-session format.
41381450|NCT06576375|DRUG|Dapagliflozin|oral Dapagliflozin
41381451|NCT06576375|DRUG|Metformin|oral metformin
41381452|NCT05134740|BIOLOGICAL|TAA-specific CTLs|"Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dose level:~2 x 10\^7/m2"
41381453|NCT00980460|DRUG|Cisplatin|Given IV
41381454|NCT00980460|DRUG|Dexrazoxane|Given IV
41381455|NCT00980460|DRUG|Doxorubicin Hydrochloride|Given IV
41381456|NCT00980460|DRUG|Fluorouracil|Given IV
41508096|NCT04521894|DEVICE|Positron emission tomography/computerized tomography (PET/CT)|"1. Genetic factors and age:~   Epidemiological studies have shown that if an immediate family member (brother or father) suffers from prostate cancer, the risk of prostate cancer will be more than doubled. Age is a relatively strong risk factor for PCa.~2. Prostatitis: Prostatitis is related to PCa. Cancer is usually found in the tissues where inflammation is found.~3. Obesity: Research has found that obese patients have a low grade of PCa, but their risk of developing aggressive cancer is higher.~4. Infection:~5. Exercise: Most studies have found that exercise does not reduce the risk of prostate cancer, but some studies have shown that.~6. Daily diet: The corrective mechanism of diet in PCa is not very clear.~7. Drinking history:"
41508097|NCT04538183|OTHER|WO 5000|WO 5000
41508098|NCT04538183|OTHER|WO 5001|WO 5001
41508099|NCT02905188|GENETIC|GLYCAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
41165862|NCT03713697|BEHAVIORAL|Pap testing|Un/underscreened women received a home visit by a Community Health Worker and were scheduled an appointment for a Pap testing at the Basic Health Unit
41381457|NCT00980460|DRUG|Irinotecan Hydrochloride|Given IV
41381458|NCT00980460|OTHER|Laboratory Biomarker Analysis|Correlative studies
41508100|NCT02905188|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
41508101|NCT02905188|DRUG|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
41508102|NCT05543798|DEVICE|Vision-MR Ablation Catheter 2.0|Catheter ablation of ventricular tachycardia
41508103|NCT02100488|DEVICE|Closed-loop insulin infusion system|"Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
41508104|NCT02100488|OTHER|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
41508105|NCT03513991|OTHER|Infant formula|
41508106|NCT06173856|OTHER|LED phototherapy|LED phototherapy (430-470nm) alone will be applied.
41381459|NCT00980460|PROCEDURE|Liver Transplantation|Undergo liver transplant
41381460|NCT00980460|DRUG|Temsirolimus|Given IV
41381461|NCT00980460|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41381462|NCT00980460|DRUG|Vincristine Sulfate|Given IV
41381463|NCT06429033|DRUG|PEP (Purified Exosome Product)|Injection of PEP into hypodermis of abdomen
41381464|NCT06455774|DEVICE|Wearable Postural Feedback Device|The postural feedback wearable device we will use in the study is programmed to vibrate when hunched postures are detected (based on changes in the curvature and curvature of the spine), alerting users to changes in their body position.
41381465|NCT06455774|OTHER|Exercise|Trapezius, Sternocleidomastoid (SCM), Scalene, pectoral muscles will be targeted for stretching exercises and deep neck flexors, Trapezius, Levator Scapula, Rhomboids will be targeted for strengthening exercises. The intensity of the exercises will be increased according to the weeks. Stretching exercises will be performed as a single set at the pain limit, maintaining the position of the muscle groups in the longest tolerable position for 30 seconds. In strengthening exercises, participants will hold the position for 5-10 seconds at the end of the movement. Moderate resistance elastic bands and free weights will be used for resistance exercises. In the following weeks, progression will be made in all exercises according to the patient's condition.
41165863|NCT03713697|BEHAVIORAL|Self-collection for HPV testing|Un/underscreened women received a home visit by a Community Health Worker and were given a kit to self-collect their own sampling for HPV testing at home
41381466|NCT05267639|DEVICE|Power Knee|Newest version of the commercially-available Power Knee developed by Ossur.
41381467|NCT06650345|OTHER|supervised aerobic exercise|In this training program, the participants exercised for 45-60 minutes through intervals on a treadmill, bike, or stair climber, three times a week for 12 weeks.
41381468|NCT02143479|DRUG|Tacrolimus|oral
41381469|NCT05841875|OTHER|C reactive protein|The attending physicians will be instructed to follow a flowchart created by the research team that uses clinical variables and the serum CRP value to guide the prescription and the duration of antibiotic therapy. This flowchart will be available in the application for mobile devices developed specifically for this study. CRP levels will be collected on a daily basis. Antibiotic suspension will be encouraged when CRP value is \< 35mg/L and after a minimal duration of 3 days (if peak CRP is below 100mg/L), or when CRP value reduces by 50% and after a minimal duration of 5 days (if peak CRP is above 100mg/L or if the patient fills the criteria for sepsis or septic shock). Before suspension, the physician will be instructed to make sure the patient is in clinical improvement, without any signs of persistent infectious focus and if the SOFA score is stable or in decrease.
41381470|NCT01711814|DRUG|peficitinib|oral
41381471|NCT06653920|OTHER|Chiropractic|SM used by the practitioner was the chiropractic side posture pisiform contact push move with a P-A thrust isolated to the lumbosacral joints and applied to the side of primary back and/or leg pain. Patients presenting with spondylolisthesis received a side posture distraction type maneuver instead of a P-A thrust. As pain began to subside during subsequent visits patients were transitioned to bilateral application of SM, rather than continuing treatment only on the side of back pain or radiculopathy.
41381472|NCT06653920|OTHER|Exercise|Core spine stretch and strength training throughout the course of care.
41381473|NCT06653920|OTHER|Cryotherapy|Therefore, during each treatment session when patients reported pain they received pretreatment with cryotherapy using a reusable ice pack (Polar Ice, Pelton/Shepherd Industries, Stockton, California) wrapped in 2 layers of headrest paper, but otherwise applied directly to the skin vertically along the lumbosacral spine, for 5 minutes.
41381474|NCT06653920|DEVICE|Spinalator|When patients no longer reported leg pain, spinalator intersegmental traction at \~10 lb/F, while the patient was lying supine with an ice pack between the traction table and the lumbar spine, was permitted as a pretreatment to side posture lumbar manipulation.
41381475|NCT06653790|BEHAVIORAL|Psychosocial stimulations|The psychosocial stimulation will be offered in two phases: in-patient (at stabilization unit) and after discharge patient will be referred to out-patient (at outpatient therapeutic centre) and developmental out-patient. The sessions with development paediatrician and team will be held every week lasting for about 20-40 min in the presence of the caregiver. The intervention includes auditory, tactile and visual stimulation, hand-eye coordination, and different types of sensory-motor training that included fine and gross motor activities. The guiding principle will be to enhance a child's holistic development-cognitive, language, physical, and social-in an integrated manner by using age-appropriate play materials, cultural tools, and resources.
41381476|NCT02626273|RADIATION|weight loss|
41508107|NCT03428711|DRUG|Mesoglycan Oral Tablet|"Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months."
41508108|NCT03428711|DRUG|Placebo Oral Tablet|Indistinguible placebo tablet
41508109|NCT03862924|DEVICE|Standardized Research Electronic Cigarette|Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
41508110|NCT00030472|DRUG|pegylated liposomal doxorubicin hydrochloride|
41381477|NCT06653660|OTHER|Clinical examination|For the aim of the present study, we will follow-up children born alive in the TIMOUN cohort at peripubertal age. Questionnaires will be administered to parents on the child's health and lifestyle. Stature-weight anthropometric and cardio-dynamic measurements of the child will be obtained. Scores on three cognitive tests will be obtained. Furthermore, steroid hormones and chlordecone in the child's peripheral blood will be determined.
41381478|NCT06652815|BEHAVIORAL|Suicide ideation or suicide attempt|Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study. socio- demographics details will also be gathered. Following this Depression, Anxiety and Stress Scale (DASS-21), Wisconsin Card Sorting Test (WCST), Metacognitions Scale (MCQ-30) and Stigma of Suicide Scale (SOSS) will be administered.
41381479|NCT03607552|DEVICE|Non-contrast DWI|Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium.
41381480|NCT03607552|DEVICE|Non-contrast MRI|Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.
41381481|NCT05644977|DRUG|Emraclidine|Oral tablets
41381482|NCT05644977|DRUG|Placebo|Oral tablets
41381483|NCT06162117|DIAGNOSTIC_TEST|2- Minute Step Test|2- Minute Step Test will be administered to patients with traumatic meniscus tear
41381484|NCT04800822|DRUG|PF-07284892|PF-07284892
41381485|NCT04800822|DRUG|lorlatinib|lorlatinib
41381486|NCT04800822|DRUG|binimetinib|binimetinib
41381487|NCT04800822|BIOLOGICAL|cetuximab|cetuximab
41381488|NCT04800822|DRUG|encorafenib|encorafenib
41381489|NCT06652776|OTHER|Pharmacological treatment|"Pharmacological and non pharmacological treatments will be assessed and monitored during the retrospective and prospective phase, and will include:~* bronchodilators, inhaled steroids and their combinations~* mucolytics~* biologic therapies for COPD~* roflumilast~* pulmonary rehabilitation"
41035570|NCT02461121|DRUG|cyclosporine A|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
41035571|NCT02461121|DRUG|Mycophenolate mofetil|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
41035572|NCT02461121|DRUG|Ara-C|2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
41035573|NCT02461121|DRUG|fludarabine|30 mg/m2/d for 5days
41381490|NCT06652776|OTHER|Pharmacological treatment|"All pharmacological and non pharmacological treatments for COPD will be assessed and monitored during the retrospective and prospective phase of the study, and will include:~* inhaled bronchodilators (long term beta-2 agonists and cholinergic antagonists), inhaled corticosteroids and their combinations~* mucolytics~* biologics for COPD (monoclonal antibodies)~* roflumilast~* chronic oral azythromicin~* pulmonary rehabilitation~* oxygen therapy~* non invasive/invasive ventilation"
41381491|NCT04798430|DRUG|lerodalcibep|PCSK9 inhibitor
41381492|NCT06633757|DRUG|RCT1100|mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
41381493|NCT06597487|PROCEDURE|Full pulpotomy|"The patients will receive full pulpotomy as follows:~-Under rubber dam isolation, the operator will perform caries removal, complete the access cavity preparation, achieve hemostasis from all canals, and apply the bioceramic material. The operator will seal the cavity with glass ionomer restoration."
41381494|NCT06597487|PROCEDURE|Conventional root canal treatment|The patients will receive conventional root canal treatment, which is the gold standard treatment protocol in cases with irreversible pulpitis.
41381495|NCT06650371|DRUG|Fentanyl infusion|opioid based anesthesia analgesia will be offered by fentanyl in induction and maintenance according to Ideal Body Weight (IBW).
41035574|NCT02461121|DRUG|anti-lymphocyte globulin|1.5-2 mg/kg/d for 4 days
41035575|NCT02461121|DRUG|cyclophosphamide|40 mg/kg/d for 2 days
41035576|NCT06025526|OTHER|aktivplan|"The aktivplan digital intervention consists of a digital planning calendar for regular heart-healthy physical activity Towards the end of rehabilitation phase II, health professionals introduce aktivplan and plan a personalised physical activity plan together with their patients using shared decision-making. The physical activity plan is devised for the time after discharge from cardiac rehabilitation.~In the aktivplan smatphone app, the patient can view their personalised physical activity plan, check off completed activities, enter additional unplanned activities, and open short videos with exercise instructions.~Additional functions of aktivplan include patient-centered goal-setting, automated messages to the patient (motivational messages and reminders), and the possibility for health professionals to monitor all their patients' adherence to the physical activity plan and to contact individual patients directly via the app."
41381496|NCT06650371|DRUG|Dexamedomedine and ketamine infusion|Analgesia will be offered by syringe containing ketamine and Dexmedetomidine in induction and maintenance according to IBW.
41381497|NCT05911763|DRUG|Efanesoctocog Alfa BIVV001|Given per investigator's discretion
41035577|NCT06025526|OTHER|Usual care|Usual care (standard of care) according to international and national cardiac rehabilitation guidelines.
41165864|NCT03713697|BEHAVIORAL|Choice|Un/underscreened women received a home visit by a Community Health Worker and were given a choice between scheduling an appointment for a Pap testing at the Basic Health Unit or self-collect their own sampling for HPV testing at home
41381498|NCT03366142|DRUG|Ustekinumab|0.75 mg/kg or 45 or 90 mg via subcutaneous injection for 5 doses (second dose 4 weeks after first, subsequent doses every 12 weeks thereafter).
41381499|NCT06029972|DRUG|Tilpisertib Fosmecarbil|Tablets administered orally
41381500|NCT06029972|DRUG|Placebo|Tablets administered orally
41381501|NCT05855967|DRUG|Ixekizumab|Administered SC
41381502|NCT05488340|DRUG|LBP-EC01 0.1 x IV dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
41035578|NCT03069482|DEVICE|Learn to Quit App|A smartphone app designed for individuals with serious mental illness. The main intervention components of the app are skills based on an intervention called Acceptance and Commitment Therapy that will (a) teach smoking cessation skills and (b) help cope with mental health symptoms. The app incorporates gaming features to keep users engaged, and a tracking component to record smoking habits and moods.
41035579|NCT03069482|DRUG|Nicotine patch|Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
41165199|NCT00680147|BEHAVIORAL|brief informational intervention to promote HPV vaccine acceptance|Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
41165200|NCT03867552|PROCEDURE|Altered gas (86% CO2, 10% N2O, 4% O2)|Assessment of pain degree after laparoscopic surgery with the altered gas (86% CO2, 10% N2O, 4% O2)
41165201|NCT03867552|PROCEDURE|Standardized gas (100% CO2)|Assessement of pain degree after laparoscopic surgery with the standardized gas (100% CO2)
41165202|NCT05439525|OTHER|mulligan technique|The patient will be in sitting and the therapist stands on the contralateral side of pain, stabilizing the scapula posteriorly with one hand. The head of the humerus is translated posteriorly and laterally with the other hand, along the plane of the glenoid fossa. While the glide is sustained, the patient actively elevates their arm through the plane of abduction or scaption (elevation). Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session the perform mobilization on acromioclavicular and sternoclavicular joint
41165203|NCT05439525|OTHER|conventional therapy|"1. Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~2. Strengthen the rotator cuff and scapular stabilizers.~3. Improve upper-quarter postural awareness"
41165204|NCT02292485|BEHAVIORAL|Survey|Physicians complete survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
41165205|NCT02383407|DEVICE|Medtronic Deep Brain Stimulation|
41165206|NCT04515628|DRUG|Rosuvastatin|Specified dose on specified days
41165207|NCT04515628|DRUG|Branebrutinib|Specified dose on specified days
41165208|NCT03436550|PROCEDURE|mpMRI|Multiparametric MRI
41165209|NCT03436550|PROCEDURE|ARFI US|Acoustic radiation force impulse is a type of ultrasound elastography
41165210|NCT05555615|DRUG|Pimavanserin|Pimavanserin given once daily, as capsule of 10, 20, or 34 mg dose strength, respectively, according to the patient's age
41165211|NCT01527903|DRUG|Propofol infusion|IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
41165212|NCT01527903|DRUG|Midazolam infusion|midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
41165213|NCT03891641|BEHAVIORAL|Treadwell Tredlr|Complete treadling exercise 3x per week (15 min sessions) for 6 weeks.
41165214|NCT04137757|OTHER|Lower Body Negative Pressure|Lower body negative pressure will be applied.
41165215|NCT04137757|OTHER|Sham Pressure|Noise will be turned on but no pressure will be applied.
41165216|NCT06479330|OTHER|Milk Chocolate|Acute intake
41165217|NCT02716857|DRUG|Oxycodone extended-release|
41165218|NCT02716857|DRUG|Placebo of oxycodone extended-release|
41165219|NCT05241054|DRUG|Bupivacaine|With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
41165220|NCT05241054|DRUG|Nitroglycerine|This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
41165221|NCT05241054|DRUG|Propofol|General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
41165222|NCT05241054|DRUG|Fentanyl|fentanyl 1 microgram.kg
41165223|NCT05241054|DRUG|Atracurium Besylate|Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
41381503|NCT05488340|DRUG|LBP-EC01 0.01x IV Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
41381504|NCT05488340|DRUG|LBP-EC01 IV Infusion Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
41381505|NCT05488340|DRUG|Placebo|Dose regimen selected from Part 1 of placebo (Tris buffer).
41165224|NCT05241054|PROCEDURE|Mechanical ventilation|Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg
41165225|NCT05241054|DRUG|Sevoflurane|Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
41165226|NCT05241054|DRUG|Lactated Ringers|Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
41165227|NCT05241054|OTHER|Head-up tilt|The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site
41165228|NCT05241054|DRUG|Paracetamol|paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
41165229|NCT05268497|DRUG|Esketamine|Esketamine will be self-administered as nasal spray.
41381506|NCT05488340|DRUG|LBP-EC01|Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.
41381507|NCT05488340|DRUG|TMP/SMX|TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
41381508|NCT06653400|PROCEDURE|paracervical block|paracervical block with office hysteroscopy
41381509|NCT06653400|DRUG|Lidocaine|Dosage: 20 mL of 1% lidocaine
41381510|NCT06653400|DRUG|ketorolac|Dosage: 2 mL (30 mg) of ketorolac
41381511|NCT06653088|BEHAVIORAL|Physical Education program|"A four-month intervention will be implemented, led by the PE teacher, with three sessions per week. These sessions will last 45 minutes each (Koolwikh et al., 2023), divided into 5 minutes of warm-up, 35 minutes of intervention content, and 5 minutes of return to calm.~The program content of the intervention group will contemplate a warm-up with several activities, such as dancing or games. The intervention part will be composed of circuit-based exercises with several stations and games involving locomotion skills, namely run, gallop, slide, skip, jump, hop, etc.; games that integrate manipulative skills, such as throwing, catching, kicking, punting, striking, rolling and bouncing/dribbling; balance games involving swinging, turning, pulling, etc. Games involving perceptual motor skills, such as body schema, laterality, temporality, and spatiality, and games focused on PA. The return to calm will include activities such as yoga, meditation, and flexibility."
41508111|NCT02711878|BEHAVIORAL|Let's Move Program|Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
41508112|NCT02711878|BEHAVIORAL|Let's Flex Program|Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
41508113|NCT02711878|BEHAVIORAL|Group Motivational Interviewing|Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
41381512|NCT06605157|BEHAVIORAL|AMUSED|Delivered live by a board-certified music therapist (MT-BC) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. A Multimodal mUSic therapy intervention for Engaging persons with severe Dementia (AMUSED) uses live participant-preferred music and progressively layers singing, touch, and rhythmic instrument playing concurrent with participant behavioral responses. Follows the Clinical Practice Model for Persons with Dementia and implementation strategies that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. Each small group works with the same music therapist throughout the study.
41381513|NCT06605157|BEHAVIORAL|Reading Aloud|"Delivered live by a trained research assistant (interventionist) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. The interventionist will read aloud from age-appropriate books (Chicken Soup for the Golden Soul by Jack Canfield; World of Wonders by Aimee Nezhukumatathil) selected to have sufficient material for all sessions, contain short stories to accommodate for attention span and session length, and offer choice. Follows implementation strategies identical to the music therapy arm (i.e., within the Clinical Practice Model for Persons with Dementia) that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. However, no music (including musical references) is used. Each small group works with the same reading interventionist throughout the study."
40851938|NCT02152319|DEVICE|KHV reporting|Clinicians will view the KHV motor symptom severity reports and use KHV to videoconference with subjects to titrate medications.
40851939|NCT02152319|PROCEDURE|Standard care|Subjects will receive the same disease management as if they were not participating in this study.
40851940|NCT02716623|OTHER|CR diet|Diet consists of meals lower in carbohydrates but does not restrict the number of calories that participants can consume.
40851941|NCT02716623|BEHAVIORAL|Exercise|Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
41165230|NCT05268497|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Clinician-directed CBT supplemented by the Mindset app will be administered.
40851942|NCT00033553|DRUG|carboplatin|Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles
40851943|NCT00033553|DRUG|gemcitabine hydrochloride|1000 mg/sq m IV over 30 min days 1 \& 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks
40851944|NCT00033553|DRUG|paclitaxel|225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks
40851945|NCT00033553|RADIATION|radiation therapy|3-D XRT 7400 cGy total after induction (during cycles 3-9)
40851946|NCT05945251|OTHER|Internet-delivered cognitive behavioral therapy|Ten weekly modules for children and ten weekly modules for parents. Exposure-based cognitive behavioral therapy delivered online with asynchronous support via text messages from psychologists.
40851947|NCT02205242|DRUG|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
40851948|NCT02205242|DEVICE|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
40851949|NCT02205242|DRUG|Placebo|
41165231|NCT05268497|DRUG|Antidepressant|Antidepressant will be administered orally.
41165232|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
41165233|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
41165234|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM FLU-A low dose, Intramuscular
41165235|NCT00819013|BIOLOGICAL|Saline placebo|0.5 mL, Intramuscular
41381514|NCT06621511|BEHAVIORAL|OurSleepKit|OurSleepKit is developed as an app including a patient version and a partner version, to be downloaded on the patient's or partner's mobile devices at home. The goal of OurSleepKit is to coach mutual engagement and model positive partner involvement in CPAP treatment, thus motivating greater CPAP adherence. Using OurSleepKit, both the patient and partner will complete periodic assessments tracking various aspects of their sleep and CPAP use. The assessment data are then processed by OurSleepKit to provide customized and dynamically updated support content consisting of brief story-telling videos featuring real-life couples' experiences emphasizing positive dyadic coping and problem-solving strategies. OurSleepKit delivers timely tailored prompts through push notifications on the users' mobile devices' screens, linked to relevant support content, to facilitate positive conversation in the dyad and offer in-the-moment support for CPAP use.
41381515|NCT06650553|PROCEDURE|Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.|This clinical trial is divided into three stages: the screening phase, the treatment phase, and the follow-up phase. During the screening phase, patient enrollment must be completed, and baseline conditions must be recorded. In the treatment phase, the transplantation treatment process for patients in the HLA-matched HSCT group and the umbilical cord blood-supported haplo-HSCT group must be completed, and treatment conditions must be recorded. In the follow-up phase, outcome evaluation indicators must be collected according to the follow-up plan, ensuring data quality.
41381516|NCT06604442|DRUG|Flotufolastat (18F)|Positron emission tomography (PET)
41381517|NCT06604442|DRUG|piflufolastat (18F)|Positron emission tomography (PET)
41381518|NCT04092283|DRUG|Carboplatin|Given IV
41381519|NCT04092283|DRUG|Cisplatin|Given IV
41381520|NCT04092283|BIOLOGICAL|Durvalumab|Given IV
41381521|NCT04092283|DRUG|Etoposide|Given IV
41381522|NCT04092283|DRUG|Paclitaxel|Given IV
41381523|NCT04092283|DRUG|Pemetrexed Disodium|Given IV
40851950|NCT02772185|DEVICE|active tDCS|Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus
40851951|NCT02772185|DEVICE|sham tDCS|The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.
40851952|NCT02772185|BEHAVIORAL|real CT|Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).
40851953|NCT02772185|BEHAVIORAL|placebo CT|Videos (short films) will be presented during the neurostimulation
40851954|NCT01743820|DRUG|dihydroartemisinin-piperaquine|
40851955|NCT01743820|DRUG|0.125 mg/kg Primaquine|
41035580|NCT03069482|DRUG|Nicotine lozenge|Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
41381524|NCT03747939|DRUG|Apremilast (CC-10004)|"Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles."
40851956|NCT01743820|DRUG|0.5 mg/kg Primaquine|
40851957|NCT01743820|DRUG|0.25 mg/kg Primaquine|
41381525|NCT03747939|OTHER|Apremilast (CC-10004) Placebo|"Subjects randomized to placebo will receive dummy dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles"
40851958|NCT01743820|DRUG|0.0625 mg/kg Primaquine|
40851959|NCT03016091|DRUG|Pembrolizumab|anti PD-L1
40851960|NCT03935750|PROCEDURE|Anterior cruciate ligament reconstruction (ACLR)|All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.
40851961|NCT03935750|PROCEDURE|Lateral extra-articular tenodesis (LET)|Participants randomized to the BPTB or QT arms will be randomized a second time to a LET procedure or no additional surgery.
40851962|NCT06506825|DIAGNOSTIC_TEST|Gastric Cancer AI-driven Data Integration Genomic Analysis Biomarker|Enter the clinical and related test, examination and treatment information of all gastric cancer patients, and find risk factors that affect the prognosis
40851963|NCT01802710|BEHAVIORAL|Psychological support|
40851964|NCT01802710|OTHER|No intervention|
40851965|NCT02860104|DEVICE|microwave ablation|ultrasound guided percutaneous microwave ablation for breast lesions
40851966|NCT01061502|DEVICE|Procellera (Bioelectric Wound Dressing)|Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed
40851967|NCT01061502|DEVICE|Opsite (Transparent Adhesive Dressing)|Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
40851968|NCT00927238|DEVICE|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
40851969|NCT00927238|OTHER|Lumbar fusion surgery|Lumbar fusion surgery
40851970|NCT03122782|DRUG|Topical application Tranexamic acid|Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
40851971|NCT03122782|DRUG|Placebo (Normal saline)|5ml of normal saline will be added to every 500 ml of distension media
41035581|NCT03069482|BEHAVIORAL|Technical Coaching|Coaching to assist the user on the use of each assigned smartphone app. This coaching will be delivered by research staff following a coaching procedure. These in-person coaching meetings will be brief (\~15 minutes), done on a weekly basis for 4 weeks, and will have a focus on providing technical assistance.
41165236|NCT04311385|DIAGNOSTIC_TEST|CT imaging|CT scan reported as 1-2 pericolic bubbles, but no free distant bubbles in the abdomen or abscess.
41165237|NCT00741468|DRUG|Proellex|2, 25 mg Proellex capsules administered daily
41165238|NCT00741468|DRUG|CYP1A2 probe|Caffeine (200 mg)
40851972|NCT03647267|DEVICE|Pneumatic Vitreolysis (C3F8 injection)|Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
40851973|NCT03647267|OTHER|Observation|No intervention; sham injection only
40851974|NCT01622387|PROCEDURE|Coronary artery bypass (CABG) surgery using a radial arterial conduit|Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
40851975|NCT01622387|PROCEDURE|Coronary artery bypass surgery using a long saphenous vein conduit|Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
41381526|NCT04286438|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration.~In subjects with potential drug interaction from recent concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36g infusion.~In patients presenting with intracranial hemorrhage (ICH), brain imaging within 2 hours of initiation of study drug and at least one follow-up brain imaging performed 12-24 hours post completion of PB2452."
41381527|NCT06026514|BIOLOGICAL|B/HPIV3/S-6P|Intranasal vaccine.
41381528|NCT06626568|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|gluteal injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4
41381529|NCT06626568|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|ultrasound-guided subacromial injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4.
41381530|NCT06626568|OTHER|Normal Saline as Placebo (ultrasound-guided subacromial injection)|ultrasound-guided subacromial injection of 5 ml of normal saline at week 0,2,4.
41381531|NCT06626568|OTHER|Normal Saline as Placebo (gluteal muscle inection)|gluteal injection of 5 ml normal saline at week 0,2,4.
41381532|NCT06626568|BEHAVIORAL|home exercise|The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session.
41381533|NCT06652347|OTHER|Cancer care delivery|Early vs. delayed sharing of GA and OFS diagnostic results and how that sharing affects patient preferences, decision- making, and satisfaction in the context of participants' cancer care.
41381534|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with a Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with a connective tissue graft harvested from the palate.
41381535|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with micro Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with multiple micro connective tissue graft harvested from the palate.
41381536|NCT06030947|DEVICE|Division of the Connective Tissue Graft into multiple micro Connective Tissue Grafts|The harvested connective tissue graft is divided in multiple micro connective tissue grafts with a scalpel blade before being placed on the recipient site.
41381537|NCT03620201|DRUG|Bintrafusp Alfa|Given IV
40851976|NCT00264264|PROCEDURE|Closure Device|
41381538|NCT06653595|OTHER|Programme to Support Breastfeeding|The intervention consists of active support for breastfeeding by a lactation expert and IBCLC until the premature baby is 6 months old. The intervention includes: 1 face-to-face pre-discharge session, 8 home sessions up to 4 months and 3 telephone sessions up to 6 months.
41381539|NCT06652048|DRUG|Furmonertinib 160mg QD|All patients enrolled into this group will receive furmonertinib 160mg p.o qd.
41381540|NCT06652048|DRUG|Furmonertinib 240mg QD|All patients enrolled into this group will receive furmonertinib 240mg p.o qd.
41381541|NCT06652048|DRUG|Furmonertinib 160mg QD plus Chemotherapy|All patients enrolled into this group will receive furmonertinib 160mg furmonertinib p.o qd plus chemotherapy\[(carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2) every 21 days ×4 cycles + pemetrexed 500mg/m2 every 21 days maintenance\]
41508114|NCT06551792|OTHER|Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection|Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection
41508115|NCT02404116|OTHER|Metacognitive Therapy|Participants will receive treatment which focus's on helping reduce excessive thinking about health,
41508116|NCT02404116|OTHER|Wait List|Individuals are on a waiting list
41508117|NCT02018575|DIETARY_SUPPLEMENT|Crystalline Lysine Amino Acid Mix|Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
41508118|NCT02018575|DIETARY_SUPPLEMENT|White corn meal porridge|A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
40851977|NCT00264264|PROCEDURE|Direct Compression|
40851978|NCT01957410|DRUG|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
41035582|NCT03069482|DEVICE|NCI QuitGuide App|A smartphone app developed by the National Cancer Institute which uses recommendations contained in the US DHHS Clinical Practice Guidelines and smokefree.gov. NCI QuitGuide has the following intervention components: (a) psycho-education about the impact of smoking in health, (b) tracking of smoking habits, and (c) Tips for quitting (e.g., distraction strategies).
41035583|NCT03830034|DRUG|Amino Acid chelated iron tab 15 mg|"Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
41035584|NCT03830034|DRUG|Ferrous Fumarate tab 350 mg( 115 mg elemental iron)|"75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb\<9g/dl) this dose can be doubled as recommended by the company of the product.~Some instructions will be given to all the pregnant women included in our study as follow: Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
41035585|NCT01792011|DEVICE|PVI-guided fluid management|In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
41035586|NCT04691765|DRUG|Kineret|escalating doses of drug will be administered to 3 groups of 4 patients for 7 months
41035587|NCT05725538|DEVICE|COVIDReApp Group|"The COVIDReApp group will be required to complete an exercise program guided by an m-health system for three times per week during 24 weeks. A 60-minute program, following the recommendations of the American College of Sports Medicine. The daily session will be divided into:~* Warm-up: 5 min. walking so that the patient can hold a conversation , monopodial balance exercise, core exercise and other respiratory and joint mobility exercises.~* Aerobic training: Walking for 10 to 20 min. so that the patient can maintain a conversation, but having to stop to breathe from time to time.~* Strengthening: It will focus on 7 exercises. a) squats, b) dead weight with stiff legs, c) lateral pull-ups, d) inverted flies, e) flies, f) unilateral rowing and g) lateral raises.~* Cool down: It will consist of stretching exercises. a) shoulders, b) triceps, c) chest, d) quadriceps, e) hamstrings, and f) back."
41035588|NCT05725538|OTHER|Control Group|Participants will receive the same intervention in the traditional way, they will receive the exercise program in paper format. They will receive a document with photos and descriptions of the exercises to be performed. Their doctors will determine if the patients will be able to exercise regularly and they will perform them for 24 weeks.
41035589|NCT00864032|DRUG|Sorafenib|400mg twice daily
41035590|NCT06316362|DRUG|SMOF lipid 20%|SMOF 20%; a blend of (soybean oil, medium chain triglycerides, olive and fish oil) is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
41165239|NCT00741468|DRUG|CYP2C9 probe|Tolbutamide (250 mg)
41165240|NCT00741468|DRUG|CYP2C19 probe|Omeprazole (20 mg)
41165241|NCT00741468|DRUG|CYP2D6 probe|Dextromethorphan (30 mg)
41165242|NCT00741468|DRUG|CYP3A4 probe|Midazolam (2mg)
41381542|NCT06585150|DRUG|Obeldesivir|Tablet administered orally
41381543|NCT06585150|DRUG|Obeldesivir Placebo|Tablet administered orally
41381544|NCT06653322|DRUG|HR-1703|HR-1703 will be administered by SC injection.
41381545|NCT06653322|DRUG|Placebo|Matching Placebo will be administered by the SC injection.
41381546|NCT04476654|BEHAVIORAL|YouTube Video Arm|Participants (n=25) will watch a 20 minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a culturally relevant format. Participants will complete pre and post assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to a patient navigator who will navigate participants to identified no cost or low cost services.
41381547|NCT06437522|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
41381548|NCT06437522|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
41381549|NCT01757418|DRUG|Immune Globulin Intravenous (IVIG)|A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
41381550|NCT01757418|OTHER|Normal saline|A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
41381551|NCT04057898|DRUG|MN-166|Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.
41381552|NCT04057898|DRUG|placebo|Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.
41381553|NCT03737994|DRUG|Alectinib|Given PO
41035591|NCT06316362|OTHER|Standard treatment for carbamazepine toxicity|"Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg).~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube"
41035592|NCT06373263|OTHER|Plain-language summary|Participants will receive information about a research study via a plain-language summary. The comparator will be a plain-language summary, since plain-language summaries are commonly used and more easily developed than other tools. The summary will be designed based on Canadian government and other key recommendations, including from the Cochrane Collaboration. It will include Background and Objectives, Methods, Results, Limitations, and Key Message for Patients sections and include information on how evidence informs knowledge or health care options. Abstract will be 275-300 words long and use short, positive, active-voice sentence structures and everyday words. Reading level will be between 8th and 9th grade based on Flesch-Kincaid Grade Level and readability score between 60 and 70 based on Flesch Reading Ease.
41035593|NCT06373263|OTHER|Dissemination Tool (Infographic)|The infographic will be developed based on key principles including clearly defining the audience and purpose; sharing a story, rather than just facts, with brief, clear messaging; highlighting main ideas; using an attractive title and images; and following principles of good graphic design.
41035594|NCT01466998|OTHER|Paced Respiration|Practice paced respiration 15 minutes per day for a total of 12 weeks.
41035595|NCT01466998|OTHER|Music Therapy|Practice music therapy for 15 minutes per day for a total of 12 weeks.
41035596|NCT04717596|OTHER|BC4Teens Care|Healthcare providers will be trained in contraceptive counseling and provision.
41035597|NCT03879720|PROCEDURE|Endoscope assisted endotracheal intubation [EAEI]|Endoscope assisted endotracheal intubation \[EAEI\] performed by anesthesiologist with endoscopist assistance.
41035598|NCT04333394|DIETARY_SUPPLEMENT|Probiotic|The probiotic capsules will be administrated once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with probiotic supplementation.
41035599|NCT04333394|OTHER|Placebo|The placebo capsules will be administered once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with placebo supplementation.
41035600|NCT03524222|OTHER|Home Hospitalization|See above
41035601|NCT05142267|DRUG|Placebo|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
41035602|NCT05142267|DRUG|Oxycodone|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
41035603|NCT05142267|DRUG|Naloxone|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
41035604|NCT04323436|DRUG|Spartalizumab|Concentrate for solution for infusion
41035605|NCT04323436|DRUG|Capmatinib|Film-coated tablet
41035606|NCT04323436|DRUG|spartalizumab placebo|dextrose 5% in water (D5W) for infusion
41035607|NCT03131518|BEHAVIORAL|Access to an e-bicycle with trailer|Participants will be provided with an e-bike with trailer for 3 months.
41381554|NCT03737994|DRUG|Brigatinib|Given PO
41381555|NCT03737994|DRUG|Carboplatin|Given IV
41381556|NCT03737994|DRUG|Ceritinib|Given PO
41381557|NCT03737994|DRUG|Cisplatin|Given IV
41381558|NCT03737994|DRUG|Crizotinib|Given PO
41381559|NCT03737994|DRUG|Ensartinib|Given PO
41381560|NCT03737994|DRUG|Lorlatinib|Given PO
41381561|NCT03737994|DRUG|Pemetrexed|Given IV
41035608|NCT03131518|BEHAVIORAL|Access to a longtail bicycle|Participants will be provided with a longtail bike for 3 months.
41381562|NCT06607692|DRUG|Olaparib; 177Lu-DOTATATE|7Lu-DOTATATE will be administered intravenously, on day 1, every 8 weeks, at a fixed dose of 200 mCi (7.4 GBq) for children \&gt;= 12 years old infused intravenously over a period of 30 minutes. For children younger than 12 years old, the dose that will be administered is 200 MBq per kilogram of body weight (maximum 7.4 GBq) infused intravenously over a period of 30 minutes. Concomitant to 177Lu-DOTATATE, patients will receive IV fluids and an IV infusion of amino acid solution for renal protection23. Patients will receive four infusions every 8 weeks (maximum cumulative radioactivity, 29.6 GBq \[800 mCi\]). Olaparib will be administered PO, BID, days 2-29, every 8 weeks at a fixed dose of 187.5mg/m2 twice daily (BID).
41508119|NCT04816071|DRUG|Essential amino acids|Dietary Supplement
41508120|NCT04816071|DIETARY_SUPPLEMENT|Maltodextrin|Control
41508121|NCT04727801|DEVICE|Verily Patch|The Verily Patch is an investigational wearable temperature sensor that consists of a Patch (Verily Patch), with swappable adhesives, as well as an app (Verily Patch app).
40851979|NCT01957410|DRUG|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
40851980|NCT02474953|DIETARY_SUPPLEMENT|Proprietary Curcumin Formulation|
40851981|NCT02474953|DIETARY_SUPPLEMENT|Unformulated Comparator Curcumin Product|
40851982|NCT03123016|DRUG|Apremilast|Apremilast 30 mg orally, twice daily. (oral tablet)
41381563|NCT06653062|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|"Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients.~Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence."
40851983|NCT03123016|PROCEDURE|NB-UVB phototherapy|treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
40851984|NCT00139555|DRUG|amlodipine/benazepril|
40851985|NCT05391633|BEHAVIORAL|Recorded Maternal Voice|60-minute looped recording of maternal voice, played once daily for 14 total days.
40851986|NCT05391633|BEHAVIORAL|Placebo Recording|60-minute blank recording played once daily for 14 total days.
41381564|NCT05637515|BIOLOGICAL|Humira 40 MG in Prefilled Syringe|Humira (40 mg every other week)
40851987|NCT05383716|DRUG|Pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.
41035609|NCT03131518|BEHAVIORAL|Access to a traditional bike with trailer|Participants will be provided with a traditional bicycle with trailer for 3 months.
41035610|NCT06635746|DRUG|Vinpocetine|Increasing doses of vinpocetine to assess tolerability.
41381565|NCT05637515|BIOLOGICAL|Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe|"• Subjects will receive Humira (initial dose of 80 mg \[2 × 40 mg\]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Hulio (40 mg every other week) at Week 12 and Week 14~* Humira (40 mg every other week) at Week 16 and Week 18, and~* Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
41035611|NCT02882568|BIOLOGICAL|blood analysis|Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
40851988|NCT03902834|OTHER|Fitbit|Use the wearable technology (Fitbit) and proven behavioural change techniques to precondition patients prior to lung cancer surgery
40851989|NCT03057782|DEVICE|Waveguard (TM) EEG cap|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp at the time points in the study listed in the protocol.
41035612|NCT01351285|DRUG|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
41035613|NCT05634395|DEVICE|Activity tracker|"Participants will receive a Withings Steel activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the GrannyFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure GrannyFit space."
41035614|NCT05916742|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions
40851990|NCT03057782|DEVICE|Micro Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor breathing and movement in children; the device is not used for validation purposes.
40851991|NCT03057782|DEVICE|Pico Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor respiration rate and gross body movement in children. The device will not be used for validation purposes.
41035615|NCT05916742|PROCEDURE|i-PRF|Blood-derived biomaterial. Two sterile plastic tubes (Process for PRF, Nice, France) with a volume of 10 ml will be used to generate fluid blood concentrate. After blood collection, the tubes will be centrifuged using a Duo centrifuge (Process for PRF, Nice, France) (fixed angle rotor with a radius of 110 mm) following the protocol proposed by Choukroun et al. (2018) (600 rpm; 8 min).
41035616|NCT05916742|DEVICE|VCMX|Porcine derived collagen matrix.
41035617|NCT05916742|DRUG|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
41035618|NCT05916742|DRUG|Chlorhexidine rinse|All participants will be instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
41035619|NCT05916742|DRUG|Amoxicillin 500mg|Participants enrolled in the CAF+VCMX and CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
41035620|NCT06160206|BIOLOGICAL|Bevacizumab|Given IV
41035621|NCT06160206|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41035622|NCT06160206|PROCEDURE|Computed Tomography|Undergo CT
41381566|NCT04223622|BIOLOGICAL|ASC secretome|The osteochondral explants isolated from arthroplasty patients will be induced to an OA phenotype and treated with ASC secretome (either complete conditioned medium or extracellular vesicles) in order to investigate its therapeutic potential.
41381567|NCT04121169|DRUG|IM-01|Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
41381568|NCT01971099|DRUG|tribulus terrestris|patients will use 750mg/day of tribulus terrestris
41381569|NCT01971099|OTHER|Placebo|patients will take one pill a day (the same shape of the drug)
41381570|NCT00954694|DEVICE|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
41381571|NCT00887965|DRUG|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
41381572|NCT05338671|DRUG|Local anesthetic|Patients will receive inferior alveolar nerve block injection following endodontic treatment.
41381573|NCT06649877|BIOLOGICAL|MK-6194|single injected dose
41035623|NCT06160206|OTHER|Electronic Health Record Review|Ancillary studies
41035624|NCT06160206|RADIATION|Hypofractionated Radiation Therapy|Undergo radiation therapy
41035625|NCT06160206|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41035626|NCT06160206|BIOLOGICAL|Retifanlimab|Given IV
41035627|NCT05624242|PROCEDURE|cardiac magnetic resonance imaging|all patients had magnetic resonance imaging at baseline and during follow-up.
41035628|NCT05796570|DRUG|Decitabine|Nucleoside metabolic inhibitor, via IV infusion.
41035629|NCT05796570|DRUG|Filgrastim|Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
41165243|NCT03258502|DRUG|RV521|RV521 drug in capsules
41165244|NCT03258502|DRUG|Placebo|Placebo in capsules
41381574|NCT05804123|DRUG|0.9% NaCl physiological saline Nasal-spraying|0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
41381575|NCT05804123|COMBINATION_PRODUCT|LiveSpo Navax®|In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016
41381576|NCT05804123|DRUG|Augmentin 500Mg Tablet|Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
41381577|NCT05804123|DRUG|Acetylcysteine|Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
41381578|NCT05804123|DRUG|Xylometazoline Nasal|Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
41165245|NCT05135923|DIETARY_SUPPLEMENT|Randomized, controlled trial (RCT) with parallel arms and double blinded|Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).
41165246|NCT03788122|OTHER|In-depth interview|The 'intervention' administered to this group of participants are two or three in-depth interviews (average 30-60 m minutes per interview) on their experiences, views, feelings and thoughts (perceptions) regarding acceptability of the fetal surgery.
41165247|NCT01904136|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
41165248|NCT01904136|PROCEDURE|Bone Marrow Transplantation|Undergo allogeneic PBSC or bone marrow transplant
41165249|NCT01904136|DRUG|Cyclophosphamide|Given IV
41165250|NCT01904136|DRUG|Fludarabine|Given IV
41165251|NCT01904136|OTHER|Laboratory Biomarker Analysis|Correlative studies
41165252|NCT01904136|DRUG|Melphalan|Given IV
41165253|NCT01904136|DRUG|Mycophenolate Mofetil|Given PO
41165254|NCT01904136|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
41381579|NCT05804123|DRUG|Cefotaxime|Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
41165255|NCT01904136|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
41381580|NCT05804123|DRUG|Ciprofloxacin|Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
41381581|NCT02660775|BEHAVIORAL|schizophrenia|"The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task (TREF)~* for theory of mind : Movie for the assessment of social cognition ( MASC-VF)~* for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia~* for self assessment : Self - assessment of social cognition (ACSo)"
41381582|NCT02660775|BEHAVIORAL|Autism|"The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels~* for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type~* for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy : Empathy quotient (EQ)~* for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes"
41508122|NCT06429293|BEHAVIORAL|Cognitive processing therapy|The active intervention is Cognitive Processing Therapy (CPT) is a gold-standard cognitive behavioral therapy for PTSD. The CPT intervention consists of 12 60-minute sessions teaching skills to challenge trauma-relevant cognitions that are distorted or unhelpful. Trauma-relevant cognitions fall into five themes that are highlighted during treatment: safety, trust, power/control, esteem, and intimacy. The empirical base for CPT is strong with numerous studies demonstrating that it results in significant reduction of PTSD symptoms regardless of trauma type and that it is 89% more effective than control treatment. CPT has been successfully implemented in virtual formats with comparable efficacy levels to that of in-person CPT. CPT sessions for this study will be conducted virtually by a CPT-trained clinician
41381583|NCT02660775|BEHAVIORAL|Healthy controls|only social cognitive measures
41508123|NCT03912935|OTHER|comparison between two different intubating position|Comparing to different position (sniffing and BUHE) in endotracheal intubation for rapid sequence induction in simulated emergency cases
41508124|NCT05662839|DEVICE|Cytological Brushing|All participants will undergo cytological brushing to collect cell samples for analysis
41508125|NCT04290143|OTHER|Colored healing water|Patients will be treated with colored healing water for 20 minutes.
41508126|NCT04290143|OTHER|Placebo treatment (colored tap water)|Patients will be treated with colored tap water for 20 minutes.
41165256|NCT01904136|DRUG|Tacrolimus|Given IV and PO
41165257|NCT01904136|RADIATION|Total-Body Irradiation|Undergo TBI
41165258|NCT01512914|DRUG|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
41165259|NCT01512914|DRUG|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
41508127|NCT05209529|DRUG|olaparib|olaparib 300 mg per os BID
41508128|NCT05209529|DRUG|Durvalumab|durvalumab 1500 mg IV Q4 weeks
41508129|NCT01287026|PROCEDURE|Cardiac Real-time MRI RHC (Right Heart Catheterization)|
41508130|NCT03555123|DRUG|Simdax|Levosimendan2.5mg/ml
41508131|NCT03810326|DEVICE|CTR device (tradename named Xtend)|Non invasive active splint
41508132|NCT00481403|BEHAVIORAL|Microarray analysis|Microarray analysis
41508133|NCT00481403|BEHAVIORAL|Microarray|Microarray
41165260|NCT01512914|DRUG|Ropivacaine 100 mg|preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
41165261|NCT01512914|DRUG|saline|preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
41165262|NCT06074445|OTHER|No intervention|No intervention
41165263|NCT04498143|OTHER|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|Internet-based, 30-minute single session intervention targeting NSSI via decreasing urge to act on self-punishment/self-harm thoughts/urges.
41165264|NCT04498143|OTHER|"Active Comparator: Supportive Therapy (Share Your Feelings) SSI"|Internet-based, 30-minute single session intervention to increase feelings disclosure.
41165265|NCT04545476|DEVICE|Participants in this group will receive the experimental APIS Biomaterial on the Head.|One layer of APIS® will be applied to the post-operative wound on the head covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
41165266|NCT04545476|DEVICE|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities.|One layer of APIS® will be applied to the post-operative wound on the lower extremities covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
40851992|NCT03057782|DEVICE|QS Piezostimulator|This device is not FDA approved. This device is used for research purposes by neurologists and physiologists. It is a mechanical tactile stimulator for use in functional imaging experiments like MEG, fMRI or EEG. The stimulation is realized by using several different pin matrices. In this study, the device is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
40851993|NCT03057782|DEVICE|tactileTM sensory evaluator|This device is not FDA approved. This device is used for clinical and research purposes by neurologists and physiologists. It is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
40851994|NCT03295617|PROCEDURE|Thoracoscopy|Thoracoscopy surgery
40851995|NCT04086914|PROCEDURE|Nerve Block|This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
40851996|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 10mg/kg intravenously (IV) every 2-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
41381584|NCT06651736|BEHAVIORAL|Low Vision Rehabilitation (LVR)|"The initial session will be with an LVR specialist that will recommend vision-enhancing devices and techniques to improve participant's vision and mobility functionality depending on needs. The devices will be given at no cost and include, but are not limited to: magnifiers that participants can hold or wear, glasses attachments that help filter out light to see better, or items that help with glare or seeing color. This session will be followed by at least one session with an occupational therapist, that will train participants to use the devices (take home and use) and recommend/teach ways to achieve functional goals.~Most participants will be asked to attend 2-4 visits, but additional visits may be needed depending on needs and progress toward functional goals. Additional visits if orientation and mobility training is also recommended. Participants will be asked to share experiences approximately 1-week after all visits."
40851997|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 15mg/kg intravenously (IV) every 3-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
40851998|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 10mg/kg Q3W plus anlotinib 1-14days of every 3-week cycle until progression.
40851999|NCT03424603|DRUG|STRO-001|intravenous antibody drug conjugate
40852000|NCT02317978|PROCEDURE|ICSI|records of women who had ICSI will be reviewed and analysed for determining FSI
40852001|NCT06040762|OTHER|Best Practice|Receive SOC educational materials
41165267|NCT04545476|OTHER|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
41165268|NCT04545476|OTHER|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
41381585|NCT06651736|BEHAVIORAL|Emotion Regulation Therapy (ERT)|There will be ten 1-hour weekly sessions of specialized psychotherapy with an ERT-trained therapist. These are typically done virtually but may be able to provide in-person sessions to those where this is needed. At the beginning of each session, the therapist will give participant's several questionnaires to learn about participant's experience with ERT. Questionnaires will also be completed after all sessions are completed.
41381586|NCT04969263|BIOLOGICAL|BNT162b2 vaccine (Pfizer/BioNTech)|30 microgram dose
41165269|NCT00521443|PROCEDURE|Cryopreservation, thawing and blastocyst culture|Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
41165270|NCT00001440|PROCEDURE|Autologous T cells|
41381587|NCT04969263|BIOLOGICAL|mRNA-1273 vaccine (Moderna)|100 microgram dose
41381588|NCT02250157|DRUG|Oratecan|
41381589|NCT06650280|OTHER|Hyaluronic Acid (HA)|hyaluronic acid coated implants will be placed in posterior maxilla to evaluate rapid osseointegration
41381590|NCT06650280|OTHER|nano-hydroxyapatite|nano-hydroxyapatite coated implants will be placed in posterior maxilla to assess rapid osseointegration
41381591|NCT06650280|OTHER|sandblasted acid etched|SLA coated implants will be placed in posterior maxilla and implant stability will be evaluated
41381592|NCT06650293|DRUG|Vitamin D|Vitamin D supplementation as vitamin D, 2 drops i.e., 800 IU daily for 5 days.
40852002|NCT06040762|OTHER|Exercise Intervention|Receive (P)REHAB exercise program
40852003|NCT06040762|OTHER|App-Based Intervention|Use ExerciseRx app
40852004|NCT06040762|OTHER|App-Based Intervention|Use FitBit app
41165271|NCT00001440|DRUG|Interleukin-2|
41165272|NCT02212483|OTHER|First home intervention with advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.
40852005|NCT06040762|OTHER|Interview|Ancillary studies
40852006|NCT06040762|OTHER|Wearable Activity Tracker|Wear FitBit
40852007|NCT06040762|OTHER|Physical Performance Testing|Ancillary studies
40852008|NCT06040762|OTHER|Questionnaire Administration|Ancillary studies
40852009|NCT06223126|OTHER|Combined oral contraception|Women, who want to start taking birth control pills will get a prescription for oral contraception at the discretion of their own attending physician
40852010|NCT06223126|OTHER|Discontinuation of a combined oral contraception|Cessation of the use of combined oral contraceptives
40852011|NCT04479202|DRUG|Berberine|Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.
40852012|NCT04479202|DRUG|Montmorrillonite|Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.
40852013|NCT02741427|OTHER|Conventional toothpaste|The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.
40852014|NCT02741427|OTHER|Whitening toothpaste|The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.
40852015|NCT02741427|OTHER|10% carbamide peroxide|"The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen"
40852016|NCT00390039|DRUG|Intranasal Morphine|MNS075 7.5mg q1h PRN
40852017|NCT00390039|DRUG|Placebo|IN Placebo q1h PRN
40852018|NCT00390039|DRUG|IV morphine|IV morphine 7.5mg q3h PRN
40852019|NCT00390039|DRUG|Placebo|IV Placebo q3h PRN
40852020|NCT00390039|DRUG|Intranasal morphine|MNS075 15mg q3h PRN
40852021|NCT00390039|DRUG|Placebo|IN Placebo q3h PRN
40852022|NCT06119191|DEVICE|Control Lenses (comfilcon A with current process)|Daily wear lenses for 4 weeks
41165273|NCT02212483|OTHER|First home intervention without any advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.
40852023|NCT06119191|DEVICE|Test Lenses (comfilcon A with novel process)|Daily wear lenses for 4 weeks
40852024|NCT01893775|BIOLOGICAL|Hu-Mik- Beta-1|Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
40852025|NCT04499287|OTHER|15-minute walk at preferred walking speed.|
40852026|NCT04499287|DIETARY_SUPPLEMENT|Fiber|9 grams soluble fiber
40852027|NCT04499287|OTHER|control|control
40852028|NCT05247281|DIAGNOSTIC_TEST|Culture-based treatment|Medications to treat prosthetic joint infection will be chosen based on results of traditional cultures alone
41381593|NCT02139930|BEHAVIORAL|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
41381594|NCT02139930|BEHAVIORAL|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
41381595|NCT02139930|BEHAVIORAL|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
41381596|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.
40852029|NCT05247281|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS) with Culture|Medications to treat prosthetic joint infection will be chosen based results of NGS and culture
41381597|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Three capsules for 6 weeks, followed by one capsule for 6 weeks.
41381598|NCT06247930|BEHAVIORAL|Mental health education|The mental health education consists of providing a brochure with information about mental health problems. Additionally, participants will receive a set of 5 educational mental health videos regarding depression. Each of these videos is 15 minutes long.
41381599|NCT06650189|OTHER|Music intervention|Recorded music created by a certified music therapist
41381600|NCT06651723|DEVICE|Toothbrush type|The participants will use either an electric soft brush (test) and soft manual brush (control).
41381601|NCT04692753|OTHER|Training and education|Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
41381602|NCT04274101|OTHER|Clinical Manifestations|Clinical manifestations in patients treated with Nifurtimox and Benznidazole
41381603|NCT04274101|DIAGNOSTIC_TEST|Serologic response|Serologic response in patients treated with Nifurtimox and Benznidazole
41508134|NCT00251121|OTHER|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
40852030|NCT03406897|DRUG|Cholecalciferol|Oral Administration
40852031|NCT03406897|DRUG|Omega 3 fatty acid|Oral Administration
40852032|NCT01589393|DRUG|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
40852033|NCT01589393|OTHER|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
41381604|NCT04274101|DIAGNOSTIC_TEST|Direct method|Direct method tests in patients treated with Nifurtimox and Benznidazole
40852034|NCT04689789|DIAGNOSTIC_TEST|optical coherence tomography angiography|optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network
41165274|NCT02212483|OTHER|Final home visit|"Final home visit at the end of the study after 12 months, with sampling and home audit.~For the intervention group, checking of the advice compliance. For the both comparative groups, delivery of advices."
40852035|NCT02779647|BEHAVIORAL|The intervention consisted of physical activity based on play|The intervention consisted of physical activity based on play, with four 90-minute sessions per week for nine months (the school year). The total of sessions was 144, the minimum number of sessions to consider valid that a child has completed the intervention was 115 (80%) in order to perform the minimum level of physical activity recommended for their ages. In parallel, twice-monthly theoretical and practical sessions of nutritional advice were given to the children and their families. The study group performed the physical activity and received the nutritional advice, while the control group received only the theoretical and practical sessions on nutrition.
40852036|NCT01251835|DRUG|Sitaxsentan alone|Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
40852037|NCT01251835|DRUG|Sitaxsentan|Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
41381605|NCT04274101|BEHAVIORAL|Adverse events|Adverse events in patients treated with Nifurtimox and Benznidazole
41508135|NCT00251121|OTHER|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
40852038|NCT01251835|DRUG|Rifampin|Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
40852039|NCT02846701|DRUG|duloxetine|The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
41381606|NCT04429633|DRUG|Candesartan|If GLS decreased less than 18% or LVEF decreased to 45-50% during the treatment of adjuvant trastuzumab, start candesartan medication.
41381607|NCT05131893|DRUG|Tamoxifen|endocrine therapy
41035630|NCT05788549|BEHAVIORAL|Progressive Muscle Relaxation|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. The first application was done face to face with the researcher. Individuals were asked to perform subsequent applications at home.Educational booklet describing the progressive relaxation exercises with pictures was given to individuals, and a video prepared by the researcher was uploaded to their mobile phones. Individuals were asked to practice progressive relaxation exercises every day, at least once a day, in a quiet and peaceful environment for 30-minute sessions. The researcher sent reminder SMS messages to individuals twice a week for eight weeks to encourage regular practice of the progressive relaxation exercises. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed
41035631|NCT05788549|BEHAVIORAL|Relaxative Music|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. Individuals were asked to perform subsequent applications at home.Individuals were provided with a relaxing music file prepared by the researcher and were asked to listen to it at least once a day for 30 minutes in a quiet and calm environment. The researcher also sent reminder SMS messages twice a week for eight weeks to remind individuals. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed to listen to the relaxing music regularly. At 4 and 8 weeks after the first meeting, the researcher transferred the forms to an online environment via Google Forms and asked individuals to fill them out by accessing the link sent to them via WhatsApp Messenger
41381608|NCT05131893|DRUG|Goserelin|endocrine therapy
41381609|NCT05131893|DRUG|Letrozole 2.5Mg Tab|endocrine therapy
41381610|NCT05131893|DRUG|Epirubicin|chemotherapy
41381611|NCT05131893|DRUG|cyclophosphamide|chemotherapy
41381612|NCT05131893|DRUG|Docetaxel|chemotherapy
40852040|NCT02193308|DRUG|Telmisartan/Amlodipine FDC|
41381613|NCT05131893|DRUG|paclitaxel|chemotherapy
41381614|NCT05131893|DRUG|trastuzumab|biological treatment
41381615|NCT05131893|DRUG|pertuzumab|biological treatment
41381616|NCT05131893|DRUG|Capecitabine|chemotherapy
41381617|NCT04060927|DEVICE|SGRT|Surface Guided Radiation Therapy
41381618|NCT02198209|DRUG|Liraglutide|"1. acute study: one injection of 0.6 mg s.c. before IVGTT~2. chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
40852041|NCT02193308|DRUG|Telmisartan|
40852042|NCT02193308|DRUG|Amlodipine|
40852043|NCT03151330|OTHER|Screened Arm|Woman who are identified as high risk will be advised of potential interventions which will include support through care link(nurse education), cervical surveillance, consider vaginal progesterone, low dose aspirin if not already taking.
40852044|NCT01058629|DEVICE|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
40852045|NCT03856827|DRUG|IW-6463|IW-6463 Tablet
40852046|NCT03856827|DRUG|Matching Placebo|Matching Placebo Tablet
40852047|NCT05581953|OTHER|Omnivorous|Pork-added plant-forward diet
40852048|NCT05581953|OTHER|Vegetarian|Plant-forward lacto-ovo-vegetarian diet
41381619|NCT06566053|OTHER|Observation|Observation
41381620|NCT06242275|DIAGNOSTIC_TEST|Salivary Alpha-amylase|"Saliva samples will be obtained using a saliva collection system and salivary Alpha-amylase (SAA) level will be measured preoperatively, immediately postoperative, at the end of the 1st, 2nd, and 3rd postoperative days. For sampling, the swab will be placed into the patient's mouth for 2-5min by a specially trained nurse.~A minimum of 0.2mL of saliva will be needed as per the manufacturer's recommendations to saturate the swab. The samples will be then stored at -70°C until analysis."
41381621|NCT06566235|BEHAVIORAL|Culturally adapted DBT-A-ST group|"The culturally adapted DBT-A-ST consists of 15 weekly group sessions, each lasting 120 minutes, including a 10-minute break. It maintains the core elements of standard DBT-A, including its philosophical foundation and treatment strategies.~Therapists focus on teaching DBT skills through various methods such as modeling, structured behavioral rehearsals, and feedback. Each session begins with a 40-minute group mindfulness exercise and homework review, followed by 60 minutes dedicated to skill-specific didactics and experiential activities, concluding with a 10-minute homework assignment. Two group leaders facilitate the sessions, and participants track their skill usage daily with diary cards, which are reviewed weekly."
41381622|NCT06566235|BEHAVIORAL|Activities-based support group (ASG)|ASG, based on principles of client-centered supportive therapy, is widely used by occupational therapists in mental health settings. ASG therapists aim to foster a sense of belongingness, maintain unconditional positive regard, provide empathy, psychoeducational and a treatment structure. Two group leaders held the sessions, teaching DBT skills and using cognitive behavioral strategies are prohibited. Each session starts with a review of their experiences over the last week (30 min), a support-building activity (30 min), and ends with an open group discussion about topics participants choose each week (50 min). For homework, participants will be asked to think about issues discussed and to track daily social support on diary cards.
41508136|NCT03608527|BEHAVIORAL|Voluntary-based upper limb motor rehabilitation|Exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, mainly including task-oriented movements with the goal to improve activities of daily living. Both proximal and distal muscles are involved, in actions such as grasping wooden cubes of different sizes, pinching, reaching targets displayed in front of the patient, and doing patchwork or paper mandala.
41508137|NCT03608527|BEHAVIORAL|Passive upper limb mobilization|Passive mobilization delivered by a physical therapist of shoulder, elbow, wrist and fingers without detectable muscle activity.
41508138|NCT03278626|DRUG|Nivolimumab+Carboplatin/paclitaxel+Radiation|In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).
40852049|NCT03052049|DEVICE|Prostate Artery Embolization|The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
40852050|NCT00475189|DRUG|loestrin 24/4 vs loestrin 1/20|One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
40852051|NCT00475189|DRUG|loestrin 1/20|loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
40852052|NCT05775731|DIAGNOSTIC_TEST|Tests for markers of inflammation and activated hemostasis|Volunteers who do not have exclusion criteria, are invited to complete the three questionnaires and to choose a date for blood drawing based on whether they are shift workers or not. Blood is immediately processed for platelet markers, and stored for inflammation and coagulation markers
40852053|NCT01278797|DRUG|Telmisartan/Amlodipine Combination Tablet|Combination Tablet
40852054|NCT01278797|DRUG|Amlodipine Monocomponent|Active Comparator
40852055|NCT03095729|OTHER|Neuropsychological tests|A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
40852056|NCT03320135|PROCEDURE|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.
40852057|NCT03320135|PROCEDURE|Open Flap debridement|Open flap debridement will be performed to decontaminate the proximal furcation involvements.
41035632|NCT00249925|BEHAVIORAL|Home-Based Intervention|
41035633|NCT00249925|BEHAVIORAL|Multi-component home-based intervention|
40852058|NCT05599243|DRUG|Dutasteride|The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).
41035634|NCT06122610|DEVICE|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after first cycle of Lutathera® treatment
41035635|NCT06122610|DEVICE|Photon Emission Tomography / CT (PET/CT)|PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
41035636|NCT06122610|DRUG|64Cu-Dotatate|Standard of care administration of radioactive drug for PET/CT
41035637|NCT06122610|DRUG|177Lu-Dotatate|Standard of care administration of radioactive drug for PET/CT and SPECT/CT
41035638|NCT05133557|OTHER|Chewing gum containing xylitol and blackberry extract (BBE)|On the day of gum chewing, four pieces of gum were provided per the assigned group, and each volunteer was requested to chew the gum four times daily (i.e., at 9 am, 11 am, 1 pm and 3 pm). Each gum chewing interval was for 20 minutes.
41035639|NCT06636357|DRUG|50% N2O plus 50% O2|Inhalation of 50% N2O plus 50% O2 for 45 min
41165275|NCT04817033|PROCEDURE|Spinal anesthesia with intraoperative dexmedetomidine sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
40852059|NCT05599243|OTHER|Placebo|Vehicle excipient
40852060|NCT03063268|BEHAVIORAL|Trust-Enhanced Messaging on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
41381623|NCT05258500|OTHER|Ghostly app|For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.
41035640|NCT06636357|DRUG|Oxygen (O2)|50% O2 plus 50% air for 45 min
41035641|NCT06443879|OTHER|Axillary brachial plexus nerve block: loss and return of sensation|Evaluating loss and return of sensation after axillary brachial plexus nerve block
41035642|NCT06636539|DEVICE|CEM Exam in Investigational Device|All subjects enrolled in this study will undergo a CEM exam using Investigational Device.
41165276|NCT04817033|PROCEDURE|Spinal anesthesia with intraoperative midazolam sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
41165277|NCT04817033|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
41165278|NCT04817033|DRUG|Midazolam|Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
41165279|NCT02971995|DEVICE|PET Scan ou TEP-TDM|Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
41165280|NCT02971995|DEVICE|mpMRI|Performance of the mpMRI in order to determine the place where to take the biopsy
41381624|NCT05258500|OTHER|Blood flow restriction|Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.
41381625|NCT05258500|OTHER|Leaflet|This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
41381626|NCT06652243|BIOLOGICAL|SN301A|"SN301A is an investigational off-the-shelf CAR NK cell therapy, armed with calibrated release (cr)IL15, designed to selectively target and treat GPC3 expressing advanced hepatocellular carcinoma.~Subjects will receive lymphodepletion pretreatment (Fludarabine/Cyclophosphamide), three SN301A intravenous infusions in a cycle (D0, D7, D14), with each subject receiving a maximum of 3 cycles."
41035643|NCT00126516|DRUG|Angiotensin II Receptor Antagonists|any dosage, frequency, and duration
41035644|NCT00126516|DRUG|Angiotensin-converting Enzyme Inhibitors|any dosage, frequency, and duration
41165281|NCT02453477|GENETIC|Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene|Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
41165282|NCT06041178|DRUG|2.5% flurbiprofen|Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)
41381627|NCT04484805|DEVICE|ICE Condition|Experimental socket integrated with a heat spreader. An ICE Unit (includes TEC) is attached to the socket.
41381628|NCT04484805|DEVICE|Sham Condition|Experimental socket integrated with a heat spreader. A Sham Unit (excludes TEC) is attached to the socket.
41381629|NCT01249625|DEVICE|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
41508139|NCT00564330|DRUG|Esomeprazole|20mg bid
41508140|NCT00564330|DRUG|Placebo|Placebo bid
41035645|NCT01615731|DRUG|Mifepristone|200mg Mifepristone orally
41035646|NCT01615731|OTHER|Hygroscopic cervical dilators|Dilapan-S osmostic cervical dilators inserted through the internal os
41035647|NCT01615731|DRUG|Misoprostol|400mcg buccal misoprostol 90 minutes pre-op
41035648|NCT01615731|DRUG|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically \~24 hours pre-op
41035649|NCT06296719|OTHER|Chit-Chat|Participants will receive the 2 sessions of the Chit-Chat intervention on a weekly basis.
41035650|NCT03850769|DRUG|nab-paclitaxel and S-1|Nab-Paclitaxel: 120 mg/m2 d1, 8, S-1: Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 \< 1.50 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14;
41035651|NCT06218017|DEVICE|High flow nasal oxygen fist|Patients in the two study group first underwent a 10-minute session of high-flow nasal oxygen (50 L/min) followed by the utilization of the standard low-flow nasal oxygen (4 L/min) or underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min).
41035652|NCT06218017|DEVICE|High flow nasal oxygen later|Patient in this group underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min)
41035653|NCT03812146|BEHAVIORAL|PC-TIME|PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
41381630|NCT01249625|DEVICE|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
41381631|NCT04384887|BEHAVIORAL|covid-19 positive pregnant women|"It is planned to receive pregnant women who are admitted to the clinic or outpatient clinic and who are offered inpatient follow-up and treatment with the diagnosis of COVID-19.~Pregnant women who do not have covid-19 disease as a control group and who do not have a comorbid disease at similar gestational week will be included in the study. As a control group, covid-19 pcr negative patients will be admitted to our clinic in the same period."
41381632|NCT06625047|BEHAVIORAL|Assessment|Complete in-person assessment visits
41381633|NCT06625047|OTHER|Questionnaire Administration|Ancillary studies
41381634|NCT06625047|OTHER|Telemedicine Visit|Complete telehealth assessment visits
41381635|NCT06625047|DRUG|Temozolomide|Given PO
41381636|NCT06634407|PROCEDURE|transcatheter closure|using transcatheter closure of PDA to detect outcome of patients with PDA
41381637|NCT05173922|BEHAVIORAL|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.
41381638|NCT05254002|DRUG|Finerenone (BAY94-8862 ) 10 mg|oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2
41381639|NCT05254002|DRUG|Empagliflozin|oral administration, once daily
41381640|NCT05254002|DRUG|Empagliflozin Placebo|Matching placebo to empagliflozin oral administration, once daily
41381641|NCT05254002|DRUG|Finerenone (BAY94-8862 ) 20 mg|oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2
41381642|NCT05254002|DRUG|Finerenone Placebo|Matching Placebo to Finerenone oral administration once daily
41035654|NCT03812146|BEHAVIORAL|PC-TAU|PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
41165283|NCT06041178|DRUG|98% aloe vera|the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)
41165284|NCT06041178|OTHER|Placebo|saline
41381643|NCT02980029|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
41381644|NCT02980029|OTHER|Placebo|Placebo
41381645|NCT06491264|DEVICE|Transcranial electrical stimulation|We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.
41381646|NCT05635643|DRUG|CHS-114|CHS-114
41381647|NCT05635643|DRUG|toripaliamab|toripalimab-tpzi
41381648|NCT06603506|OTHER|tumour and blood samples|Tumour and blood samples
41381649|NCT06652581|PROCEDURE|Modified Thorachoabdominal Nerve Block Perichondrial Approach(M-TAPA|USG Guided Bilateral Modified Thorachoabdominal Nerve Block Perichondrial Approach (M-TAPA) using 20 ml Bupivacaine 0,25%.
41381650|NCT06652581|DEVICE|Opioid Intravena|Opioid Intravenous post Surgery without M-TAPA Block delivered with PCA Machine
41381651|NCT05152147|DRUG|Zanidatamab|Administered IV
41381652|NCT05152147|DRUG|Tislelizumab|Administered IV
41381653|NCT05152147|DRUG|Trastuzumab|Administered intravenously (IV)
41381654|NCT05152147|DRUG|Capecitabine|Administered orally (PO bid)
41381655|NCT05152147|DRUG|Oxaliplatin|Administered IV
41381656|NCT05152147|DRUG|Cisplatin|Administered IV
41381657|NCT05152147|DRUG|5-Fluorouracil|Administered IV
41381658|NCT05309993|DEVICE|PTNS|See arm description
41381659|NCT05309993|DEVICE|TENS|See arm description
41381660|NCT05859269|DRUG|Methylprednisolone|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone followed with a 6-day oral methylprednisolone taper course.~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
40852061|NCT03063268|BEHAVIORAL|Interactive features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
40852062|NCT03063268|BEHAVIORAL|Standard E-Consent|Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
40852063|NCT02817243|DRUG|SP2086|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
40852064|NCT02817243|DRUG|Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
40852065|NCT05160376|OTHER|Self-help CBT with email reminder and text message|"An online transdiagnostic self-help intervention that is delivered through an online mental health platform.~Email reminder and text message will be sent to remind participant to complete the module"
40852066|NCT05160376|OTHER|Feedback calls on participants' progress|Feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor
40852067|NCT04125277|OTHER|FES-PET scan, and possibly one additional visit for an FDG-PET|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
40852068|NCT04807049|OTHER|Observational|Observational
40852069|NCT02218008|DRUG|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
40852070|NCT02218008|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
41035655|NCT04317820|BEHAVIORAL|Deep Brain Reorienting (DBR)|Trauma processing through DBR involves bringing up a traumatic memory and encouraging the client to focus on tensions arising in the muscles of the shoulders, neck, head and face (i.e., those involved in orienting toward a threatening person/event). The rationale is as follows: Physiologically, orienting to a stimulus, whether external or in the mind's eye, comes before any affective response to it. Here, it is hypothesized that there is activity in certain midbrain structures , i.e.,Superior Colliculi (SC) and Periaqueductal Gray (PAG). The deep layers of the SC bring on a brief (orienting) tension in the neck as well as preparing for eye movements, which is later followed by the processing of raw affect in the PAG. In session, if we can attend to this tension - even if we have to backtrack from the emotion that follows - we can establish an anchor in the body that precedes the affect and is hypothesized to protect against emotional overwhelm.
41381661|NCT05859269|OTHER|Standard of Care|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
41381662|NCT06653868|PROCEDURE|dental implant with bone augmentation|gap distance augmentation with bone graft
41381663|NCT04098666|DRUG|Placebo oral tablet|Placebo tablet identical to metformin, up to 4 tablets a day
41381664|NCT04098666|DRUG|extended release metformin|Metformin extended release 500 mg tablets, up to 4 tablets a day
41381665|NCT04475731|DRUG|Ponatinib|"Ponatinib 45 mg/day x 4 weeks x 3 courses.~+/- chemotherapy:~* vincristine or~* L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)"
41381666|NCT00474994|DRUG|sunitinib malate|
40852071|NCT04742114|DEVICE|use the face mask with Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
40852072|NCT04742114|DEVICE|use the face mask without Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
40852073|NCT05787925|DRUG|Topical corticosteroid and Vitamin E|"26 patients who will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase \* three times daily for 8 weeks applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application. In addition to one capsule of 400 mg oral systemic vitamin E supplement\* will be prescribed once daily at the morning"
40852074|NCT05787925|DRUG|Topical corticosteroid|"26 patients will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase three times daily for 8 week that will be applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application"
41381667|NCT00326118|BIOLOGICAL|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
41381668|NCT00326118|BIOLOGICAL|Priorix™|One subcutaneous dose at 12-18 months of age
41381669|NCT00326118|BIOLOGICAL|Hiberix™|One intramuscular dose at 12-18 months of age.
41381670|NCT00326118|BIOLOGICAL|Meningitec™|One intramuscular dose at 12-18 months of age
41508141|NCT02522923|OTHER|Physical Therapist|The participant will receive an evaluation and intervention from a physical therapist. The patient will be referred onward to other providers as needed.
41508142|NCT02522923|OTHER|Primary Care Provider|The participant will receive an evaluation and intervention from a primary care provider. The patient will be referred onward to other providers as needed.
41381671|NCT04035993|OTHER|Controlled hypoglycaemic state while driving with a driving simulator|"Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes."
41381672|NCT06436690|BEHAVIORAL|Diagnosis Mandate and Feedback|The intervention consists of: a) a Refresher Training on AMR, (b) a Diagnosis Mandate, and (c) an Individualized Feedback.
41508143|NCT01366625|DEVICE|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
41508144|NCT06019884|DEVICE|Caries detection method: Intraoral camera|A specialized intraoral camera (C50) with fluorescence signal and selective chromatic amplification will be used to record intraoral structures in the form of videos and/or photos. The camera has four modes (Daylight, Daylight+, Perio and Caries modes) which can differentiate the color of tissues to provide a reliable diagnosis. The camera will be used in a systemic sequence to video record and capture photos of intraoral conditions in both arches. The intraoral camera will be connected to a laptop screen, and the captured videos and/ or photos will be transferred to an electronic platform.
41508145|NCT06019884|DEVICE|Caries detection method: Smartphone camera|This is a low-cost electronic system consisting of a smartphone positioned in front of the oral cavity to scan the upper and lower jaws from the cheek then the tongue sides. The smartphone camera resolution should be sensitive enough to capture the intraoral structures (at least 1000 pixels). The focus will be adjusted, and the inbuilt flash will be used to obtain clear and sharp images. The photos will be transferred to the electronic platform.
41508146|NCT06019884|OTHER|Referral pathway: User fee removal|The child's parent/ legal guardian will receive financial incentives. These a are designed to cover the costs of treatment and transportation and are tied to attending the preventive dental visit. The child will receive complete dental care.
41508147|NCT06019884|OTHER|Referral pathway: Conventional referral|Children will be referred without providing financial incentives following the current standard of care in dental clinics in the public sector in Egypt. Care is planned by the receiving/ treating dentist, based on available resources, and hospital/ clinic policies. The screening/ sending dentist will inform the family about the oral health condition/s and planned treatment costs for which the child needs care and of available public and private facilities that offer the required care.
41508148|NCT03936803|BEHAVIORAL|aerobic interval training exercise .|Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with HR at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum HR. The exercise session was terminated by 5 minutes cool-down
41508149|NCT03936803|DEVICE|electro acupuncture|"electroacupuncture (EA) of (2 Hz, 4 mA) was applied at points of:liver 3 LR3,liver 14 LR 14, gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks"
41508150|NCT02033031|DRUG|Lucentis intravitreal injection|Lucentis intravitreal injection
41508151|NCT02033031|DRUG|Avastin intravitreal injection|Avastin intravitreal injection
41508152|NCT01822106|OTHER|Placebo|
41508153|NCT03852537|DRUG|Methylprednisolone|Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.
41508154|NCT03852537|OTHER|Usual Care|Usual care as determined by the patients treatment team.
41508155|NCT00161863|BIOLOGICAL|FSME-IMMUN NEW 0.25 ml|
41508156|NCT06222931|DEVICE|Triplanar vibrating platform|Mechanical vibration emitted by triplanar vibrating platforms
41508157|NCT06222931|DEVICE|Side-alternating vibrating platform|Mechanical vibration emitted by side-alternating vibrating platforms
41508158|NCT06222931|OTHER|Sham vibration|Simulated vibration
41508159|NCT00679133|DRUG|MGCD265|Oral daily administration; 7 days on / 7 days off
41508160|NCT02044913|BEHAVIORAL|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
41508161|NCT04623892|DRUG|TQB2618 injection|TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
41508162|NCT06418347|DRUG|Alpha lipoic acid|"Alpha-lipoic acid (ALA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic acid, is found in the mitochondria. It acts as an enzymatic cofactor for various enzymes in the Kreb's cycle. ALA has many beneficial properties making it a potential candidate for various clinical disorders. It is considered the universal or ideal antioxidant as it is both water-soluble and fat-soluble facilitating its passage across membran. ALA has direct as well as indirect anti-inflammatory effects. Being a potent antioxidant leads to a reduction in oxidative stress which in turn reduces inflammation, meaning ALA indirectly has anti-inflammatory effects. To add to ALA's benefits, it has anti-inflammatory properties that are independent of its antioxidant effects."
41508163|NCT06418347|DRUG|Letrozole|Letrozole is an aromatase inhibitor that controls the conversion of androgen to estrogen and increases ovarian androgens. The administration of letrozole in the follicular phase removes the effect of negative estrogen feedback on the pituitary and hypothalamus, thus increasing the gonadotropins\]. When Letrozole blocks estrogen production, it encourages the body to produce more follicle-stimulating hormone (FSH).The additional FSH stimulates egg development and increases the likelihood of ovulation. Kar, S. Found that letrozole has excellent pregnancy rates compared to clomiphene citrate, Letrozole should be considered at par with clomiphene citrate as first-line drug for ovulation induction in infertile PCOS women.
41035656|NCT02909972|DRUG|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
40852075|NCT03799276|OTHER|Opticare study|"Each patient will be evaluated by~* An HIV physician~* A nurse~* A social worker~* A psychological therapist~* A cultural mediator/member of patients community if needed for migrants~Following these interviews and visits, a multisciplinary team will define for each patient an individualized OPTICARE program based on the following items: clinical, psychological/psychiatric, social status and follow up visits will be planned with the patient.~Regular (Day 15 and monthly) phone calls will be set up during the first six months of the OPTICARE program, to assess the clinical status and ART adherence.~Patients will have their medical, biological and social status assessed through visits at W4, W12, W24, W36 (medical and social status only) and W 48 with all members of the OPTICARE team."
40852076|NCT04168099|DRUG|Cefotaxime|Cefotaxime IV
40852077|NCT04168099|DRUG|Gemifloxacin|Gemifloxacin oral
40852078|NCT05460143|OTHER|Near-infrared Spectroscopy scan|Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.
40852079|NCT05460143|OTHER|Magnetic Resonance Imaging scan|Magnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.
40852080|NCT04440657|BEHAVIORAL|Self-Assured Parenting program|Parents will receive parenting education for 10 weeks
41035657|NCT02909972|DRUG|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
41381673|NCT05070507|DIETARY_SUPPLEMENT|Enzyme containing lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
41381674|NCT05070507|DIETARY_SUPPLEMENT|Placebo lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
41381675|NCT06565598|PROCEDURE|Single-layer robot-assisted transperitoneal retroperitoneal tubeless radical nephrectomy|Free through the single layer of the posterior abdominal cavity
41381676|NCT03895827|BEHAVIORAL|Recovery Initiation and Management after Overdose (RIMO)|RIMO uses motivational interviewing and linkage assistance techniques to get people who have had a recent opioid overdose reversal to go to medication-assisted treatment (MAT), stay in MAT, and, if they drop out, go back to MAT treatment.
41381677|NCT03895827|OTHER|Passive Referral to Treatment Control|Currently neither first responders or emergency department staff regularly refer people to any kind of substance use after an opioid overdose reversal. In the passive referral condition they will at least get a brochure with information on recently expanded and publicly-funded medication-assisted treatment in their community.
41381678|NCT00191256|DRUG|Gemcitabine|
41381679|NCT00191256|DRUG|Carboplatin|
41381680|NCT00191256|DRUG|Paclitaxel|
41381681|NCT05250609|OTHER|"Endocrown composite."|It is a type of restoration has been shown a great success in adult and recently has been suggested for children
41381682|NCT03779282|DRUG|Dexmedetomidine|see descriptions
41381683|NCT04013373|DEVICE|SOZO Bioimpedance Spectroscopy Device|Bioimpedance spectroscopy measurements for assessment of fluid status
41381684|NCT03166670|DIAGNOSTIC_TEST|stool examination|collection of stool specimen and microscopic examination for parasites
41381685|NCT03166670|DIAGNOSTIC_TEST|real time polymerase chain reaction|evaluation of genotype of cryptosporidium in stool specimen
41381686|NCT04082533|DRUG|Hydrocortisone|Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
41381687|NCT04082533|DRUG|Dextrose 5% in water (D5W)|Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
41381688|NCT00679094|DRUG|Bowman-Birk inhibitor concentrate|Given orally
41381689|NCT00679094|OTHER|placebo|Given orally
41381690|NCT00679094|OTHER|pharmacological study|Correlative studies
41381691|NCT00679094|OTHER|laboratory biomarker analysis|Correlative studies
41381692|NCT01761617|BEHAVIORAL|Yoga class once per week|"The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio."
41381693|NCT01761617|BEHAVIORAL|Yoga class twice per week|"The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio."
41381694|NCT01959984|OTHER|100g Standard Noodles|Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
41381695|NCT01959984|OTHER|75g Oral Glucose|Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
40852081|NCT02075892|DIETARY_SUPPLEMENT|Mushroom Blend|Scivation
40852082|NCT02075892|DIETARY_SUPPLEMENT|Placebo|
41035658|NCT04962464|DIETARY_SUPPLEMENT|Peak Human Labs calorie mimetic supplement|Supplement
41035659|NCT04962464|BEHAVIORAL|Fasting Mimicking Diet|Diet
41035660|NCT06635252|DRUG|STA 4783|Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date
41035661|NCT00647712|DRUG|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fasting
41381696|NCT00845377|BEHAVIORAL|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
41381697|NCT06567977|OTHER|Trimbow|Trimbow® is a fixed triple therapy containing a long-acting muscarinic antago-nist (LAMA, Glycopyrronium), a long-acting beta-adrenergic agonist (LABA, Formoterol) and an inhaled corticosteroid (ICS, beclomethasone). Trimbow® has an extra-fine formulation delivered as a controlled dosage aerosol. Trim-bow® is to be applied in accordance with its current marketing authorisation and the guidance specified in the summary of product characteristics (SmPC) in each country.
41381698|NCT05661825|OTHER|phase II cardiac rehabilitation|Phase II cardiac rehabilitation was provided in the the department of physical medicine and rehabilitation in Wan Fang Hospital. The programs are two times a week, one session for 30 minutes (30 sessions in total). The training programs are focused on aerobic training with bicycles. The training intensity is calculated with 40% to 80% oxygen consumption reserve from the result of cardiopulmonary exercise test. In case of safety, heart rate, blood pressure, EKG and rate of perceived exertion will be monitored during training.
41381699|NCT01659762|BIOLOGICAL|autologous mesenchymal stromal cell|
41381700|NCT05156164|DEVICE|Kinesio Tape Group|The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder
41381701|NCT05156164|DEVICE|Control Group|KT application on the deltoid but without support function
41381702|NCT06565169|BEHAVIORAL|Primary Care Team Advance Care Planning With People with Alzheimer's Disease or a Related Dementia Training|Included in arm/group descriptions
41381703|NCT06565169|BEHAVIORAL|Care as Usual|Included in arm/group descriptions
41383578|NCT06436469|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) Program|The intervention involves participation in a structured Mindfulness-Based Stress Reduction (MBSR) program. Participants engage in a series of sessions over a four week period. During these sessions, participants learn and practice mindfulness techniques such as deep breathing and body scans. The program is designed to enhance participants' awareness of their thoughts, emotions, and bodily sensations in the present moment, promoting a nonjudgmental acceptance of their experiences. By cultivating mindfulness skills, participants aim to reduce stress, enhance emotional regulation, and develop resilience in coping with the challenges of their work environment.
40852083|NCT04213716|COMBINATION_PRODUCT|silver nano particulate solution mixed with calcium hydroxide powder|1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
40852084|NCT04213716|COMBINATION_PRODUCT|conventional calcium hydroxide|1ml of distilled water mixed with 100 mg of calcium hydroxide powder and used as intracanal medication after root canal retreatment
40852085|NCT01659749|BEHAVIORAL|Metabolic camp|To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
40852086|NCT01001793|DEVICE|Levacor Ventricular Assist Device|Surgical procedure
40852087|NCT04304872|BEHAVIORAL|Gamification|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
40852088|NCT04304872|BEHAVIORAL|Loss-Framed Financial Incentives|Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
40852089|NCT05084898|OTHER|Far-UVC light as an additional method of disinfection|Far-UVC light is a form of ultraviolet light with an extremely short wavelength (222 nm)
41035662|NCT00647712|DRUG|Depakote ER® Tablets 500 mg|500mg, single dose fasting
41035663|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.36 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"
41165285|NCT06240377|DEVICE|Transcranial direct current stimulation (tDCS)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
41165286|NCT06240377|DEVICE|Ultrasound-guided percutaneous neuromodulation (NMP)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
41165287|NCT01161628|DRUG|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
41165288|NCT04236414|DRUG|Olaparib|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 25 and 100 mg tablet strengths available for ages ≥3 to \<18 years. AAF available for ≥0.5 to \<6 years; The AAF is a sprinkle capsule formulation, available in dose strengths of 15 mg and 19.5 mg. The sprinkle capsules contain 1.5 mg granules which are to be dispersed onto a food vehicle prior to dosing.
41165289|NCT02264964|DEVICE|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.
41165290|NCT02264964|PROCEDURE|Arteriovenous fistula creation|500 patients will undergo AVF creation in either arm for femoral vein catheterization group.
41165291|NCT02264964|DEVICE|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.
41165292|NCT02264964|PROCEDURE|Arteriovenous fistula creation|900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
41508164|NCT03595007|BEHAVIORAL|Kids Kicking Cancer program|Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.
40852090|NCT05084898|OTHER|Placebo fluorescent light|"Inactive fluorescent light (no additional disinfection)"
40852091|NCT04638114|PROCEDURE|Mini-open DAA|Direct anterior approach hip
41165293|NCT04005456|DIETARY_SUPPLEMENT|Supplements and/or medical foods|Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)
41165294|NCT04005456|BEHAVIORAL|Behavioral change support program|Program to implement lifestyle and behavioral change according to individuals' need.
41165295|NCT04005456|OTHER|Food plan|Personalized food plan (e.g., basic wellness food plan, cardiometabolic food plan, high protein high phytonutrient food plan, ketogenic food plan, detoxification food plan, anti-inflammatory food plan, neuro food plan)
41165296|NCT06480877|DIAGNOSTIC_TEST|Taking a swab from periodontal pockets or gingival sulci|Swabs for next generation sequencing were taken with paper points as described earlier.
41165297|NCT06086119|DIAGNOSTIC_TEST|to assess the voice perception of the patient undergoing phonatory prosthesis placement surgery by evaluating the optimal score (>30) in terms of VHI.|Prospective, multicenter observational study involving patients who will undergo total laryngectomy surgery and placement of phonatory prosthesis
41165298|NCT05255198|PROCEDURE|Anterior versus lateral approach to hip joint|
41165299|NCT04358614|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib+antiviral therapy administration for 2 weeks
41165300|NCT04882189|DIAGNOSTIC_TEST|Imaging|Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.
41381704|NCT05234619|DRUG|Group one ( lidocaine or control LE ) Early deflation|"This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction"
41381705|NCT05234619|DRUG|Group two ( lidocaine , ketorolac LKE ) Early deflation|As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia
41508165|NCT00979641|DRUG|Docetaxel|
41508166|NCT04446923|DRUG|Hand antisepsis by scrub|Surgical Hand scrubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
41508167|NCT04446923|DRUG|Hand antisepsis by scrub|Surgical Hand rubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
40852092|NCT04638114|PROCEDURE|Hip arthroscopy|arthroscopic treatment of hip pathology
40852093|NCT01108523|DEVICE|HP828-101|
41381706|NCT05234619|DRUG|Group three ( lidocaine or control LL ) Late deflation|As the first intervention this will be conducted on group three but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine for IVRA .
41508168|NCT05742035|PROCEDURE|Venipuncture|Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
41508169|NCT00402116|DRUG|enzastaurin|"Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles~Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles"
41381707|NCT05234619|DRUG|Group four ( lidocaine , ketorolac LKL ) Late deflation|As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
41508170|NCT00402116|DRUG|temozolomide|75 milligrams per meter squared (mg/m\^2), oral, daily, 6 weeks then 200 mg/m\^2, oral, daily, twelve 28 day cycles
41508171|NCT00402116|RADIATION|radiation therapy|1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
41508172|NCT03594760|DIAGNOSTIC_TEST|18F-DCFPyL IV injection|Patient will receive one injection of 18F-DCFPyL and undergo PET-CT imaging
41508173|NCT01666769|DRUG|Micafungin|4 mg/kg/day
41508174|NCT01666769|DRUG|Micafungin|8 mg/kg/day
41508175|NCT01666769|DRUG|Micafungin|Standard of care Dosing
41508176|NCT00271193|BEHAVIORAL|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
41508177|NCT01612065|DRUG|Misoprostol|200 ug
41508178|NCT01612065|DRUG|Misoprostol|Misoprostol vaginally, 400 ug
41381708|NCT00540735|PROCEDURE|photodynamic therapy|
40852094|NCT00321867|PROCEDURE|Graft augmented posterior repair|Posterior repair with graft
40852095|NCT00321867|PROCEDURE|Control|Native tissue repair
41035664|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.24 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
41381709|NCT02575807|BIOLOGICAL|CRS-207|via IV infusion
41381710|NCT02575807|DRUG|Epacadostat|PO BID
41381711|NCT02575807|BIOLOGICAL|Pembrolizumab|via IV infusion
41381712|NCT02388659|DEVICE|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
41381713|NCT04163328|DRUG|HydroEye®|This is an omega-3 fatty acids supplement.
41381714|NCT04703647|OTHER|Administration of questionnaires for prospective group|Questionnaires: administration at T0, T1,T2,T3 and T4 of Short Form Health Survey (SF-36),Brief Pain Inventory (BPI),Disabilities of the Arm, Shoulder and Hand (DASH) for upper limb,Foot and Ankle Ability Measure (FAAM) for lower limb,Hospital Anxiety And Depression Scale (HADS),Tampa Scale of Kinesiophobia (TSK),Pain Catastrophizing Scale (PCS),Pattern Of Activity Measure - Pain (POAM-P) .
41381715|NCT04703647|OTHER|Blood samples for prospective group|Blood samples at T0,T1,T2 and T3.
40852096|NCT04016077|DRUG|PF-06651600 30 mg|PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
40852097|NCT00907504|DRUG|CP-751,871|CP-751,871 20mg/kg every 3 weeks
40852098|NCT00907504|DRUG|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
40852099|NCT00907504|DRUG|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
40852100|NCT00907504|DRUG|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
41381716|NCT04703647|OTHER|Blood samples for control group|Blood samples just one time
41381717|NCT04633187|DRUG|EDP-938|"EDP-938 800mg~Dose adjustments were made for subjects taking azole antifungals."
41381718|NCT04633187|DRUG|Placebo|Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
41381719|NCT05153655|PROCEDURE|Local ischemic post-conditioning|"Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0  1  2  3  4  5 min."
41508179|NCT05209607|OTHER|Mobile Medical and bundle management|Based on the current follow-up management platform of respiratory disease, the WeChat official account will be designed and used to provide health education for patients, such as smoking cessation, reasonable diet, appropriate exercise, etc., and monitor some physiological indicators (such as body temperature, weight, the score of mMRC, etc.) and guide patients to standardize medication and pulmonary rehabilitation.
41508180|NCT05209607|OTHER|Mobile Medical and standard of care|Based on the mobile medical, participants will receive advice on standard medication only.
41508181|NCT05682651|PROCEDURE|tracheal stenosis follow-up file|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
41508182|NCT01653912|DRUG|GSK2110183 in combination with carboplatin and paclitaxel|Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
41508183|NCT05644925|DEVICE|PiCSO Impulse System|The PiCSO Impulse System is intended to reduce infarct size by intermittently occluding the coronary sinus outflow in patients undergoing a percutaneous coronary interventional procedure for myocardial infarction and presenting with Thrombolysis in myocardial infarction (TIMI) flow of 0 or 1.
41508184|NCT05644925|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Minimally invasive procedures used to open clogged coronary arteries
41508185|NCT02806115|PROCEDURE|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
41381720|NCT04898790|BEHAVIORAL|CHAMPS-II adapted to adults 60+ years in HCT setting|CHAMPS-II is an evidence-based physical activity program designed to increase physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. Participants will engage in progressive, light to moderate-intensity physical activity throughout the HCT process, with the support of physical therapists, physical activity counselors, and their care-partner. They will take part in supervised exercise sessions; unsupervised exercise sessions; counseling sessions to address barriers, motivators, goals, and safety; and receive telephone support. Walking is the primary mode of aerobic activity, with training in flexibility, strengthening and balance exercises also included. An exercise kit will be provided, consisting of an intervention workbook, therapeutic resistance bands, and activity logs.
41381721|NCT05434767|DEVICE|Mobile application|Participants will be instructed on the installation and use of the mobile application on their personal mobile phones. Participants will then have to perform the assigned exercises using the mobile application 3 times daily. Physiotherapists will still perform the required assessment/review, education, and intervention.
41508186|NCT02806115|DRUG|Acetic Acid|The concentration of acetic acid used in this study is 1.5%.
41508187|NCT02806115|DEVICE|endoscope|This study using an EG-29-i10 endoscope (Pentax, Tokyo, Japan) and an EPK-i7010 processor (Pentax, Tokyo, Japan).
41508188|NCT01707264|DRUG|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
41508189|NCT03860857|RADIATION|Amyloid PET scan|Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
41508190|NCT03860857|DRUG|Tau PET scan using MK-6240|Tau Positron Emission Tomography scan using radio tracer MK-6240
41508191|NCT03860857|BEHAVIORAL|Neurocognitive testing|A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
41381722|NCT05434767|OTHER|Standard rehabilitation program|All participants will be seen by physiotherapists in the ward post-TKR surgery and undergo standard inpatient rehabilitation. Patients will be given instructions to perform assigned exercises 3 times daily. Physiotherapists will perform the required assessment/review, education, and intervention.
41508192|NCT03860857|OTHER|MRI|High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
41508193|NCT06143852|BEHAVIORAL|Mindfulness|12 minute daily guided meditation
41508194|NCT06143852|BEHAVIORAL|Social Media Reduction + Exercise|Reduce social media use at least 30 minutes daily and exercise instead
41508195|NCT06034782|DIAGNOSTIC_TEST|Fine Needle Aspiration|Fine Needle Aspiration of a salivary gland tumor
41508196|NCT06034782|PROCEDURE|Histologic Examination|Histologic examination of resected salivary tumor
41508197|NCT05454189|DEVICE|Reduced IPD Flush Schedule|IPD flush every 12 weeks
41508198|NCT05454189|DEVICE|Standard IPD Flush Schedule|IPD flush every 4 weeks
41508199|NCT00789997|DRUG|Prednisone|prednisone 40 mg daily for 10 days or placebo prednisone
41508200|NCT00789997|DRUG|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection
41508201|NCT00789997|DRUG|levofloxacin|Levofloxacin 750 mg daily for 10 days.
41508202|NCT01426074|DRUG|Bevacizumab 5 mg/kg|Intravenously every two weeks
41508203|NCT05376644|DRUG|99mTc-ADAPT6|One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.
41508204|NCT05376644|DRUG|99mTc-DARPinG3|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.
40852101|NCT00907504|DRUG|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
41508205|NCT02827695|BEHAVIORAL|SMASK|Medication adherence and BP monitoring
41508206|NCT02827695|BEHAVIORAL|EnhancedSC|Standard care without med reminder functions with healthy lifestyle texts
41508207|NCT00477633|DRUG|Norethindrone/ethinyl estradiol|1 tablet per day
41508208|NCT01753180|BIOLOGICAL|collagenase|Local intra-coronary administration of MZ-004 at or into the CTO
41508209|NCT01753180|DRUG|saline|Local intra-coronary administration of saline at or into the CTO
41508210|NCT03846583|DRUG|Tucatinib|Tucatinib is a drug that inhibits human epidermal growth factor receptor 2 (HER-2) protein, which is a protein expressed in the cancer cells. By inhibiting this protein, tucatinib may help stop or reduce the growth of the tumor
41508211|NCT03846583|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
41508212|NCT03846583|DRUG|Trastuzumab|"• Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When Trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system."
41508213|NCT03846583|DRUG|Aromatase Inhibitor|These drugs act by lowering the amount of estrogen produced by the body by blocking an enzyme called aromatase
41508214|NCT00493896|DRUG|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
41508215|NCT00493896|DRUG|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
41508216|NCT05975528|DRUG|SGLT2 inhibitor|"For the SGLT2 inhibitor group, total drug adminstration days are 180 days, but non-SGLT2 inhibitor administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.~For the SGLT2 inhibitor group, empagliflozin 10mg or dapagliflozin 10mg once daily is administered."
41508217|NCT05975528|DRUG|Glimepiride|For non-SGLT2 inhibitor (glimepiride) administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.
41508218|NCT03855982|DRUG|Drug inducing myocarditis|Drugs susceptible to induce myocarditis
41035665|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.12 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"
41381723|NCT03208218|DRUG|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
41381724|NCT03208218|DRUG|Revlimid cap|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)
41381725|NCT03628872|PROCEDURE|Scaling and root planing|"A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis."
41381726|NCT03628872|DEVICE|Er:YAG Laser|This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.
41381727|NCT03628872|DEVICE|Hand instruments|11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
41381728|NCT06567756|PROCEDURE|CSPO|The distal rectum is freed to the entrance of the internal and external sphincter space, and then an oblique resection line is designed under direct vision according to the tumor site and shape, ensuring that the distal and lateral margins are not less than 1 cm, and preserving the contralateral dentate line and the intestinal wall as much as possible, and the anastomosis is completed manually or with instruments.
41381729|NCT06567756|PROCEDURE|ISR|Partial, subtotal, or total excision of the internal sphincter and/or a portion of the longitudinal rectal muscle, expansion of the distal rectal excision margin into the anal canal or to the anal verge, and completion of the colo-anal anastomosis manually or instrumentally.
41381730|NCT05188274|DIETARY_SUPPLEMENT|T92|T92 granules (5g/sachet) will be taken BID for 8 weeks, the dosage will be calculated by individual's body weight.
41381731|NCT05188274|DIETARY_SUPPLEMENT|Placebo|The placebo matched to T92 granules will be taken BID for 8 weeks.
41381732|NCT00962013|DEVICE|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
41381733|NCT04160273|DIAGNOSTIC_TEST|patient questionnaire and telephone follow-up|PDI scale is filled in before returning home and follow-up at one month and one year thanks to a telephone call during which the patient answers the PCL-S questionnaire
41381734|NCT00348049|PROCEDURE|Laser in Situ Keratomileusis (LASIK)|
40852102|NCT04934657|OTHER|no intervention|no intervention
41035666|NCT02082054|DRUG|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
41381735|NCT00348049|PROCEDURE|Photorefractive Keratectomy (PRK)|
41381736|NCT05262894|OTHER|extreme hypercapnia induced by ventilation insufficiency|Re-breathing of gas by breathing into the simulated avalanche snow
41381737|NCT05564494|PROCEDURE|Bankart Repair|Patients Randomized to Bankart Repair Group
41381738|NCT05564494|PROCEDURE|Anatomic Glenoid Reconstruction|Patients Randomized to Anatomic Glenoid Reconstruction Group
41381739|NCT04259905|BEHAVIORAL|Active video game teleconference support group|12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device
41381740|NCT04259905|BEHAVIORAL|Standard support group + pedometer|3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
41381741|NCT02006901|PROCEDURE|microdecompression|a minimal invasive surgical technique
41381742|NCT02006901|PROCEDURE|laminectomy|The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
41508219|NCT02614274|DIETARY_SUPPLEMENT|Nutraceutical joint health formulation|A Proprietary Blend
41508220|NCT03026998|PROCEDURE|MRI|MRI will be performed each year during 10 years.
40852103|NCT00979771|DRUG|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
40852104|NCT00979771|DRUG|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
40852105|NCT01302028|DRUG|ASP1941|Oral
41035667|NCT02082054|DRUG|Atropine 0.24 mg|"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
41035668|NCT01443962|OTHER|PEEP|applying PEEP 0 cmH2O during pneumoperitoneum continuously
41035669|NCT01443962|OTHER|ZEEP|applying PEEP 10 cmH2O during pneumoperitoneum continuously
41035670|NCT01741623|DRUG|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
41035671|NCT01741623|DRUG|Bisoprolol|10 mg tablet once a day
41035672|NCT05709743|BEHAVIORAL|Experimental: Within-Subjects Attentional Information|Behavioral: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
41035673|NCT05115630|DRUG|Cyclophosphamide|Given by IV
41035674|NCT05115630|DRUG|Mesna|Given by IV
41035675|NCT05115630|DRUG|Filgrastim|Given by IV
41035676|NCT05115630|DRUG|Melphalan|Given by IV
41381743|NCT04690959|OTHER|neural mobilization|Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
41381744|NCT04690959|OTHER|Sham intervention|it is faked neural mobilization that mimic the neural mobilization treatment but believed not to stress the neural tissues in the upper extremity.
41381745|NCT06564961|DRUG|Clomiphene Citrate|50 mg tab once daily
41381746|NCT06564961|DRUG|Placebo|1 tab once daily
41381747|NCT03632837|DEVICE|Hemoadsorption|see arm description
41381748|NCT00265460|DRUG|Oliwer Twist smokeless tobacco (tobacco)|
41381749|NCT05620849|BEHAVIORAL|Online program|The online program is 4 weeks and focused on topics such as alcohol and sexual health
41381750|NCT03637270|DIETARY_SUPPLEMENT|Dietary supplementation|Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
41381751|NCT03637270|OTHER|Exercise training|Including aerobic cycling training and progressive resisted exercise
41381752|NCT05920031|OTHER|Cross-education|Participants will perform resistance exercises at 60% of their 1 repetition maximum (1RM) with the less affected limb. The intervention will be performed three times per week for 8 weeks. Each session will consist of three sets of 15 repetitions of bicep curls, tricep extensions, and wrist flexion/extension exercises with a 1-minute rest period between sets. The exercises will be performed in a seated position, with the participant's forearm resting on a table and the therapist providing manual resistance. The therapist will be positioned in front of the participant.
41381753|NCT05920031|OTHER|Mirror therapy|Participants will perform bilateral upper limb movements while observing the reflection of the less affected limb in a mirror. The intervention will be performed three times per week for 8 weeks. Each session will consist of 10 minutes of mirror therapy, with the participant seated in front of a mirror. The participant will perform various upper limb movements, such as reaching and grasping, while observing the mirror reflection of the less affected limb. The therapist will be positioned beside the participant, providing verbal cues and feedback as necessary.
41381754|NCT05920031|OTHER|Conventional Physical Therapy|articipants will receive conventional rehabilitation for post-stroke upper limb motor impairments, which may include exercises such as range of motion, stretching, and strengthening of the affected limb, as well as other therapies such as electrical stimulation or constraint-induced movement therapy. The intervention will be individualized for each participant and will be performed three times per week for 8 weeks. The frequency, duration, and intensity of the exercises will be gradually increased over the course of the intervention, based on the participant's progress. The exercises may be performed in a seated or standing position, depending on the participant's ability and preference. The therapist will be positioned in front of or beside the participant, providing verbal cues and feedback as necessary.
41381755|NCT02102529|PROCEDURE|laparoscopic colonic surgery|women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
41508221|NCT01188512|BIOLOGICAL|BPZE1|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
41035677|NCT05115630|DRUG|Fludarabine phosphate|Given by IV
41035678|NCT05115630|DRUG|Tacrolimus|Given by IV
41508222|NCT01188512|BIOLOGICAL|Placebo|Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).
41508223|NCT05149326|DRUG|KN046|KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
41508224|NCT05149326|DRUG|placebo|placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.
41508225|NCT02678208|DRUG|Tranexamic Acid|
41508226|NCT02678208|DRUG|5% glucose|
41508227|NCT02208804|DEVICE|Holmium-166-poly (L-lactic acid) microspheres|
41508228|NCT00511641|BEHAVIORAL|Questionnaire|Questionnaires lasting up to 30 minutes.
41508229|NCT01872923|DRUG|Amphinex|Photosensitiser
41508230|NCT01872923|DRUG|Bleomycin|Anticancer agent
41508231|NCT01872923|DEVICE|Laser|Laser that emits red light at 652 nm.
41035679|NCT05115630|DRUG|Mycophenolate mofetil|Given by IV
41035680|NCT05115630|DRUG|Total Body Irradiation One Dose|Given by IV
41035681|NCT04251585|DRUG|Regular Novolin R|Intranasal insulin
41035682|NCT04251585|DRUG|Placebo|Intranasal placebo (0.9% saline)
41035683|NCT00144339|DRUG|tiotropium|
41508232|NCT00398866|DRUG|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
41508233|NCT00398866|DRUG|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
41508234|NCT00398866|DRUG|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
41035684|NCT00144339|DRUG|placebo|
41508235|NCT05461326|PROCEDURE|Quad tendon|quadriceps tendon autograft
41508236|NCT05461326|PROCEDURE|BTB|patellar tendon autograft
41508237|NCT06141343|DIETARY_SUPPLEMENT|Veillonella atypica FB0054|Veillonella contains Veillonella atypica FB0054 as the active ingredient with microcrystalline cellulose and hypromellose as excipients. The two doses are 15 billion cfu (high dose) and 7.5 billion cfu (low dose). Placebo capsules contain microcrystalline cellulose and hypromellose. Both Veillonella and placebo are encapsulated in acid-resistant capsules to improve delivery to the large intestine, which participants will take orally at home on a daily basis for four weeks.
41035685|NCT04073953|DRUG|RPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
41035686|NCT04073953|DRUG|SPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
41035687|NCT04073953|DRUG|Placebo|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
41035688|NCT05499923|DEVICE|Debonding|Debonding of orthodontic brackets with wing or base method with a conventional debonding plier
41035689|NCT04519918|BEHAVIORAL|AOA|AOA represents an invasive non-physiological technique.
41381756|NCT05471518|OTHER|No intervention|No intervention
40852106|NCT02161055|DRUG|Insulin|"Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2"
40852107|NCT01898429|DEVICE|SCC DBS|Deep Brain Stimulator
40852108|NCT00727155|BEHAVIORAL|Adjusting to Chronic Conditions Using Education Support and Skills|This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
40852109|NCT00158041|DRUG|Amifostine administered subcutaneously|
40852110|NCT03420833|DEVICE|Cardiac resynchronization therapy pacemaker (CRT-P)|A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
40852111|NCT03323801|DRUG|13-cis retinoic acid|Accutane is used for the treatment of severe acne
41381757|NCT05752396|OTHER|Conditioned Pain Modulation|Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.
41381758|NCT05752396|OTHER|Offset Analgesia|Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.
41381759|NCT05752396|OTHER|Spatial Summation|Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.
41381760|NCT05752396|OTHER|Temporal Summation|Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.
41381761|NCT02080273|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
40852112|NCT02481245|DRUG|Bezafibrate|30 patients with Bipolar I or Bipolar II disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.
40852113|NCT00383942|DRUG|Misoprostol|Misoprostol,25 micrograms every 4 hours.
40852114|NCT00383942|DEVICE|Catheter|A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
40852115|NCT04384939|DEVICE|magnetic-end Double-J ureteral stent|"* Inserting the ureteral stent with magnet (same process as classic ureteral stent)~* Removing the ureteral stent with magnet without general anaesthesia. Usually, the classic ureteral stent removed during a general anaesthesia."
41381762|NCT02080273|DRUG|Colgate Total toothpaste|0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
41381763|NCT02080273|DRUG|Parodontax toothpaste|1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
41381764|NCT00374465|DRUG|Verapamil|
41381765|NCT00374465|DRUG|Carvedilol|
41381766|NCT04771273|DRUG|BI 456906|BI 456906
41381767|NCT04771273|DRUG|Placebo|Placebo
41381768|NCT02105207|OTHER|Lung Ultrasound|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
41381769|NCT02105207|OTHER|Chest Radiography|Chest Radiography is performed after clinical evaluation without using ultrasound assessment
40852116|NCT00152308|DEVICE|2% rapamycin-eluting YUKONdes PEARL-stent|
41035690|NCT05720806|OTHER|Weight Bearing as tolerated (WBAT) immediately following surgery.|Subject will be provided standard of care physical therapy following surgical intervention, except will be able to self-select weight bearing based on pain and confidence.
41381770|NCT00274664|DEVICE|6 hours occlusion by patching|
41381771|NCT00274664|DEVICE|12 hours occlusion by patching|
41381772|NCT04859699|BEHAVIORAL|COVID-19 Health Education Comic Books and Videos|Comic books and videos will be shared with intervention students and their parents to provide education on COVID-19 topics such as masking, social distancing and COVID-19 testing
41381773|NCT04983823|OTHER|Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
41381774|NCT04983823|OTHER|Usual care|This will be provided by participants' usual healthcare professional(s).
40852117|NCT00152308|DEVICE|1% rapamycin-eluting YUKONdes PEARL-stent|
40852118|NCT00152308|DEVICE|YUKONdes PEARL-stent coated with placebo (ethanol)|
40852119|NCT01315444|DRUG|Stop PPI gradually|
40852120|NCT01315444|DRUG|Stop PPI gradually|
40852121|NCT02929459|DIETARY_SUPPLEMENT|Riboflavin Dose 1|
40852122|NCT02929459|DIETARY_SUPPLEMENT|Riboflavin Dose 2|
40852123|NCT02929459|OTHER|Placebo|
40852124|NCT04561440|DIAGNOSTIC_TEST|molecular karyotyping|performed by NGS or CMA chip
40852125|NCT01575314|DEVICE|stapling device|Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
40852126|NCT06583408|OTHER|Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)|Subjects will complete the ASA food diary for 2 weekdays and 1 weekend day
40852127|NCT06583408|OTHER|REVEAL Questionnaire|Subjects will complete the REVEAL questionnaire form. This form includes questions about current and past medical history, including reproductive history, lifestyle specifics, and assessment of current health status.
40852128|NCT03275038|BEHAVIORAL|Tai-Chi exercise|Behavioral: Tai-Chi exercise
40852129|NCT03275038|BEHAVIORAL|Aerobic exercise|Behavioral: Aerobic exercise
41381775|NCT01432600|DRUG|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
41381776|NCT01432600|DRUG|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
41508238|NCT06141343|OTHER|Placebo|Placebo will be given as the non-active study control
41508239|NCT05748951|DEVICE|Canalicular occlusion device|Occlusive device is inserted into the tear duct to block tear drainage
41381777|NCT01432600|DRUG|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
41381778|NCT06243016|BEHAVIORAL|High-Intensity Interval Training (HIIT) Breaks to Sitting|HIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min HIIT Breaks. During sitting participants will engage in standardized sedentary activities. Each 6-min HIIT break comprises a one-minute warm-up, followed by a 2-minute high-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2 minutes at high intensity.
41381779|NCT06243016|BEHAVIORAL|Light-Intensity Interval Training (LIIT) Breaks to Sitting|LIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min LIIT Breaks. Each 6-min LIIT break comprises a one-minute warm-up, followed by a 2-minute light-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2-minute light-intensity interval.
41381780|NCT03280628|PROCEDURE|Absorbable Sutures|The patient's doctor will close the patient's laceration with absorbable sutures.
41381781|NCT03280628|PROCEDURE|Steri-Strips|The patient's doctor will close the patient's laceration with Steri-Strips.
41381782|NCT03280628|PROCEDURE|Dermabond|The patient's doctor will close the patient's laceration with Dermabond.
41381783|NCT05281328|DRUG|CAM2029|SC injection using a pre-filled pen
41381784|NCT05281328|DRUG|Placebo|SC injection using a pre-filled pen
41381785|NCT04275830|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
41381786|NCT04275830|BEHAVIORAL|Heart rate variability biofeedback|"Participants randomized to the intervention arm will receive exactly the same four digital stories via REDCap, a standardized HRV sensor and accompanying smart phone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be given a take-home manual and specifically asked to practice their HRVB skills at home for 5 minutes prior to viewing stories once each week and upload a log of their time practiced to the cloud. The main purpose of adding HRVB practice as a priming experience (i.e., to teach participants to practice HRV prior to viewing stories) is to optimize results by focusing patients' and caregivers' skills and experience on HRV as a mechanism of improved emotion regulation, and then combine this achieved coherent pattern with DS intervention."
41381787|NCT04275830|BEHAVIORAL|Heart rate variability waitlist and Digital storytelling Control intervention|Four Digital Stories Intervention (4 patient stories about hematopoietic cell transplantation (HCT) over the course of 2 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each). The 4 digital stories patients produced contained the following content: (1) a leukemia patient expressed and controlled her depression and anxiety and described how she dealt with the intensive treatment and recovery through a positive attitude and active coping; (2) a mother of 3 children, who was experiencing severe pain due to MS, coped with HCT through family support and positive reframing; (3) a lymphoma patient coped with the HCT procedures by praying during the treatment; and (4) a father of young twins had a HCT twice, and his wife helped him cope with emotional distress through open communication and expressing emotions.Participants will receive a 30-minute HRVB training session at T2.
41381788|NCT04950673|DEVICE|Cognivue|Computerized Cognitive Assessment Device
41381789|NCT04762212|PROCEDURE|Mobilization with movement and stretching, stretching or control|The participants will receive a therapist performed mobilization with movement and then instructed in a stretching program to be followed for one week or only receive instruction in a stretching program to be followed for one week on the hip with the greatest limitation in motion. The hip with the least amount of limitation will not receive an intervention.
41381790|NCT05201547|DRUG|Carboplatin-Paclitaxel|Chemotherapy will be administered by intravenous infusion. Carboplatin AUC 5-6 + Pacltaxel 175 mg/m² every 3 weeks. Total duration of treatment: 6 cycles
41381791|NCT05201547|DRUG|Dostarlimab|Dostarlimab will be administered through a 30-minute infusion at a dose of 500 mg Q3W from Cycle 1 through Cycle 4 and at a dose of 1,000 mg Q6W thereafter, beginning at Cycle 5 Day 1 up to a maximum of 2 years.
41381792|NCT02058264|DRUG|BBI-4000|
41381793|NCT06313294|OTHER|Tracking application app|An app will be implemented for mobile monitoring in patients who use continuous postoperative ambulatory regional analgesia.
41381794|NCT06313294|OTHER|Telephone interview|Patients who use continuous postoperative outpatient regional analgesia will be followed up using the current traditional method of post-discharge telephone call.
41035691|NCT05720806|OTHER|Flat foot weight bearing (FFWB) immediately following surgery|Subject will be provided standard of care physcial therapy following surgical intervention except
41035692|NCT05475951|DIAGNOSTIC_TEST|Biomarker measurement of pannexin-1 and gasdermin-D|These biomarkers were measured in the placental and adipose tissues of the participants.
41381795|NCT01170767|DRUG|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
41381796|NCT01170767|DRUG|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
40852130|NCT00411255|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|Three arms on three different days 180 stimuli will be delivered to the AC with a sham coil, with the H-coil and with a standard circular coil in separate sessions.
40852131|NCT01012778|BEHAVIORAL|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
40852132|NCT03934853|DEVICE|Dynamic Dental Navigation|Aid in dental implant placement in humans
40852133|NCT01357252|DRUG|vildagliptin|
40852134|NCT01357252|DRUG|Placebo|
40852135|NCT00255788|DRUG|everolimus|
40852136|NCT04148742|DRUG|DZD9008|Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
41035693|NCT03649828|DIETARY_SUPPLEMENT|probiotic milk fermented with kefir grains|Participants received probiotic milk fermented with kefir grains for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
41381797|NCT00939367|DRUG|Zolpidem Tartrate Tablets 10 mg|
41381798|NCT00939367|DRUG|'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg|
41381799|NCT02495636|DRUG|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
41381800|NCT02495636|DRUG|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
41381801|NCT02493023|DEVICE|navigated bronchoscopy|
41381802|NCT01708252|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
41381803|NCT01278381|PROCEDURE|Pancreaticoduodenectomy|Resection of pancreatic lesion
41381804|NCT05738083|DIAGNOSTIC_TEST|Machine Leaning Models|"Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance.~Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made.~Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes.~Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model.~Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model."
41381805|NCT05238701|DRUG|LPM3770164 sustained release tablet|LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
41381806|NCT05238701|DRUG|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
41381807|NCT04824612|DEVICE|Photobiomodulation with blue led|Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month. blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J).
41381808|NCT04824612|DRUG|Triamcinolone Hexacetonide|intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
40852137|NCT05804318|DEVICE|Daily adaptive SBRT with urethral sparing|The radiation plan for each daily fraction is adapted from the initial plan based on cone beam CT imaging acquired while the participant is laying on the treatment machine.
40852138|NCT04741490|DRUG|Camrelizumab|PD-1antibodies，200mg ivgtt Q3W
40852139|NCT04741490|RADIATION|radiotherapy|45-55Gy/1.8～2.0Gy
40852140|NCT06180642|OTHER|Assessment of soft tissue properties|Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
40852141|NCT06180642|OTHER|Retest assessment of soft tissue properties|Retest Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
40852142|NCT01463306|DRUG|Pregabalin|Pregabalin administered as either capsule or liquid oral formulations. Subjects \<4 years of age at Visit 1 will receive study medication 3 times daily (TID) in equally divided doses. Subjects who are ≥4 years of age at Visit 1 will receive study medication twice daily (BID) in equally divided doses. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
40852143|NCT03182907|BIOLOGICAL|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
40852144|NCT03182907|DRUG|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
40852145|NCT03182907|DRUG|Antibacterial drug treatment (ABD)|ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
40852146|NCT00801398|DRUG|Oxymorphone IR|Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
40852147|NCT00933465|DRUG|Imodium (Loperamide Hydrochloride) syrup|"syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most."
41381809|NCT04824612|DEVICE|Sham LED|A blue LED without power and biologic effect.
41381810|NCT02873195|DRUG|Atezolizumab|Given IV
41381811|NCT02873195|BIOLOGICAL|Bevacizumab|Given IV
41381812|NCT02873195|DRUG|Capecitabine|Given PO
41508240|NCT02521805|OTHER|Animal protein|
40852148|NCT00933465|DRUG|Imodium (Loperamide hydrochloride) tablets|"tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most"
40852149|NCT02572622|OTHER|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
40852150|NCT02572622|OTHER|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
41381813|NCT02873195|OTHER|Laboratory Biomarker Analysis|Correlative studies
40852151|NCT02572622|OTHER|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
40852152|NCT02572622|OTHER|exercise|special lumbar stabilization exercises were applied in advanced protocol.
40852153|NCT00235716|DRUG|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
40852154|NCT00235716|DRUG|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
40852155|NCT00235716|DRUG|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
40852156|NCT00235716|DRUG|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
40852157|NCT00235716|DRUG|Placebo|Matching placebos for dl-alpha-tocopherol and memantine.
40852158|NCT00854841|DRUG|Dasatinib and Imatinib|"Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.~Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted."
40852159|NCT06479941|OTHER|antibiotic treatment|AT: Mother-infant cohort with antibiotic treatment group CS: Mother-infant cohort (Prophylactic antibiotics therapy) ND: Mother-infant cohort (Natural delivery)
41381814|NCT02873195|OTHER|Placebo|Given IV
41381815|NCT00268385|OTHER|Laboratory Biomarker Analysis|Correlative studies
41381816|NCT00268385|OTHER|Pharmacological Study|Correlative studies
40852160|NCT02413489|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
40852161|NCT05462418|PROCEDURE|electrosurgery|incisions completed using use the unipolar diathermy from Whiteline till we reach the parietal peritoneum (cutting the Whiteline then coagulation till reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
41381817|NCT00268385|DRUG|Temozolomide|Given orally
40852162|NCT05462418|PROCEDURE|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
40852163|NCT05365126|BEHAVIORAL|Complete Vocal Technique Voice Therapy|A Complete Vocal Technique (CVT) Practitioner will assess the patient's voice and voice problems using the CVT framework and then apply CVT therapy, a form of voice therapy
40852164|NCT05749328|DIETARY_SUPPLEMENT|Carbohydrate|To ensure the safety of the trial, preoperative gastric ultrasound measurements will be performed on all patients to assess their gastric volume. See above for other details
41381818|NCT00268385|DRUG|Vorinostat|Given orally
41381819|NCT06283056|DEVICE|Device treatment|InMode RF system with Morpheus8 Body (up to 7mm depth) Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion..each subject is approximately 9 months (including screening, two treatments (2 months apart) and 3 follow-up visits at 1 month, 3 months, and 6 months post treatment.
41381820|NCT04137926|DIAGNOSTIC_TEST|MicRNAs battery|for MCI due to AD diagnosis
41381821|NCT06566365|OTHER|Subcostal Transversus Abdominis Plane Block|After ensuring airway safety under general anesthesia, a bilateral Transversus Abdominis Plane Block using 20 cc of 0.25% bupivacaine with a subcostal approach under ultrasound guidance will be administered
40852165|NCT02922426|DRUG|ALKS 3831|Daily dosing for 21 consecutive days
40852166|NCT02922426|DRUG|Olanzapine|Daily dosing for 21 consecutive days
40852167|NCT02922426|DRUG|Placebo|Daily dosing for 21 consecutive days
40852168|NCT01523509|DEVICE|Radiographic contrast agent. Sodium Iodide.|Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
40852169|NCT03612765|BEHAVIORAL|Push-Pull-Hold Program|Developed based on concepts of motivational interviewing, temporal framing, empowerment. It is tailored to Singaporean patients and includes contextual self-care information and tips.
40852170|NCT05519007|OTHER|No-Rinse Solution (NS)|The surgical site will be irrigated with NS prior to closure,
41381822|NCT04836637|DIETARY_SUPPLEMENT|Maltodextrin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
40852171|NCT05519007|OTHER|Saline irrigation|The surgical site will be irrigated with Saline
40852172|NCT00483938|DRUG|Pegylated-interferon Alfa-2a|Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
40852173|NCT00483938|DRUG|Ribavirin|Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
40852174|NCT03214406|DRUG|Arm & Hammer Advance White Brilliant Sparkle (Test product)|20% sodium bicarbonate
41381823|NCT04836637|DIETARY_SUPPLEMENT|Calcium-carbonate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
41381824|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
41381825|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate with Inulin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
41381826|NCT02716519|BIOLOGICAL|Santyl|Collagenase ointment applied topically once per day for up to six weeks
41381827|NCT02716519|OTHER|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
41381828|NCT05167994|DRUG|Anlotinib hydrochloride|Anlotinib 12mgQD, from D1 of pre-operative IMRT to 1 month after end of IMRT
40852175|NCT03214406|DRUG|Crest Cavity Protection Regular Toothpaste (Negative Control)|Negative control
40852176|NCT03686475|OTHER|Biodentine|pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month
40852177|NCT03686475|OTHER|MTA pulpotomy|MTA pulpotomy
40852178|NCT00930228|DRUG|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
40852179|NCT00930228|DRUG|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
40852180|NCT05186168|DEVICE|MiniHip Stem|The MiniHip stem is a titanium femoral stem (Ti-6Al-4V) coated with a layer of hydroxyapatite applied over a layer of pure titanium
41381829|NCT01592968|OTHER|Cognitive Assessment|Ancillary studies
41381830|NCT01592968|OTHER|Quality-of-Life Assessment|Ancillary studies
41381831|NCT01592968|RADIATION|Stereotactic Radiosurgery|Undergo SRS
41381832|NCT01592968|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
41381833|NCT04748549|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
41381834|NCT04748549|OTHER|Immersive Audio Experience|A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient.
41381835|NCT04748549|OTHER|Sham Virtual Reality Experience|Subjects will wear VR headsets and headphones but will not view any content or listen to any audible content.
41381836|NCT00258310|DRUG|capecitabine|Capecitabine 1000mg/day for one year
41381837|NCT00258310|PROCEDURE|Surgery, chemotherapy and/or radiotherapy|Surgery, chemotherapy and/or radiotherapy
40852181|NCT05186168|DEVICE|Trinity Acetabular Cup System|The Trinity Acetabular System is a modular acetabular cup system consisting of a press fit, titanium alloy shell
40852182|NCT05403450|DRUG|Tolinapant|Capsule for oral administration
40852183|NCT05403450|DRUG|Decitabine + Cedazuridine|Tablet for oral administration
40852184|NCT00621140|DRUG|linagliptin|active
40852185|NCT00621140|DRUG|placebo|placebo
40852186|NCT00718705|DRUG|Josamycin|josamycin with posology of 2 grams per day by oral way during 10 days
40852187|NCT00718705|DRUG|Placebo|Placebo with posology of 2 grams per day by oral way during 10 days
40852188|NCT05660317|OTHER|Tip control score|Scoring of endoscopist's tip control performing snare tip soft coagulation to the margins of a endoscopic mucosal resection (EMR) defect
40852189|NCT04360876|DRUG|Dexamethasone injection|Dexamethasone intravenous 20mg daily for 5 days followed by 10mg daily for 5 days
40852190|NCT04360876|DRUG|Placebos|Placebo delivered intravenously on the same dosing schedule as dexamethasone
40852191|NCT06448624|DRUG|Ampicillin sulbactam 3 days|Ampicillin sulbactam 1.5 gram IV TID for 3 days after CIED implantation
40852192|NCT06448624|DRUG|Placebo 3 days|Placebo for 3 days after CIED implantation
40852193|NCT03920930|PROCEDURE|Late local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
41381838|NCT03015207|DRUG|NNC0194-0499|
41381839|NCT03015207|DRUG|Placebo|
41508241|NCT02521805|OTHER|Vegetable protein|
41508242|NCT02521805|OTHER|Dietary fiber (cereal food matrice)|
40852194|NCT03920930|PROCEDURE|Early local infiltration analgesia|The local infiltration analgesia is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached.
40852195|NCT03809494|DEVICE|HemaTrate™ Blood Filtration system|Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.
40852196|NCT03809494|OTHER|Saline|Normal (0.9%) saline
40852197|NCT01651325|DRUG|Isavuconazole|oral
40852198|NCT01651325|DRUG|dextromethorphan|oral
41381840|NCT02609932|DRUG|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
41381841|NCT02326337|DEVICE|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
41381842|NCT02326337|DEVICE|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
41381843|NCT04494113|PROCEDURE|Biopsy|Undergo biopsy
41381844|NCT04494113|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
41381845|NCT04494113|PROCEDURE|Resection|Undergo surgical resection
41381846|NCT04494113|DRUG|Triapine|Given IV
41381847|NCT03672201|BEHAVIORAL|Non-Pharmacological Intervention|The behavioural intervention will be a structured implementation of individualized activities to be followed and customized as per the needs of the participant.
41381848|NCT03672201|OTHER|Pharmacological Intervention|The medication algorithm provides recommendations to the treatment team about algorithmic treatment and assessments as per the ICP but ultimately the decision to prescribe any particular intervention will be the treatment team's decision and the recommendations of the research team for ICP arm will not be binding for the treatment team.
41381849|NCT06385873|DRUG|RC48|RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);
41381850|NCT06385873|DRUG|Adebrelimab|Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);
41381851|NCT06385873|DRUG|Apatinib|Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);
41381852|NCT06385873|DRUG|S-1|S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);
41381853|NCT05808907|OTHER|Questionnaire|A novel TAVI PROMs questionnaire will be created by us and used for this study.
41381854|NCT04273659|DIETARY_SUPPLEMENT|Pulses and cereals|Dietary intervention. Ingestion of pulses with cereals and gastrointestinal health.
41381855|NCT04375033|DRUG|Sublingual buprenorphine with naloxone|The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit.
41381856|NCT04375033|DRUG|Injectable subcutaneous buprenorphine|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit.
41381857|NCT00421811|DRUG|ADH-1|4 gm IV Days 1 and 8
41381858|NCT00421811|DRUG|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
41381859|NCT05560230|DRUG|Clonidine|A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation
41381860|NCT05560230|DRUG|Isotonic saline|A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
40852199|NCT06222528|BEHAVIORAL|Brief video intervention (Black Girl)|A brief social contact-based video. The video presented a young Black girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
40852200|NCT06222528|BEHAVIORAL|Brief video intervention (Black Boy)|A brief social contact-based video. The video presented a young Black boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
40852201|NCT06222528|BEHAVIORAL|Brief video intervention (Latinx Girl)|A brief social contact-based video. The video presented a young Latinx girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
40852202|NCT06222528|BEHAVIORAL|Brief video intervention (Latinx Boy)|A brief social contact-based video. The video presented a young Latinx boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
40852203|NCT06222528|BEHAVIORAL|Brief video intervention (White Girl)|A brief social contact-based video. The video presented a young White girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
40852204|NCT06222528|BEHAVIORAL|Brief video intervention (White Boy)|A brief social contact-based video. The video presented a young White boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
41381861|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 1|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
40852205|NCT06222528|BEHAVIORAL|Brief video intervention (Nonbinary or transgender)|A brief social contact-based video. The video presented a young nonbinary or transgender adolescent, a professional actor, sharing their scripted personal story of struggles with depression and raising themes of recovery and hope.
40852206|NCT06222528|BEHAVIORAL|Control Condition|A video that will provide information about depression and how to seek help but does not include a personal story.
41035694|NCT03649828|DIETARY_SUPPLEMENT|curd|Participants received the curd for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
41035695|NCT04503265|DRUG|AMXI-5001:Dose Escalation Phase I|Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
41035696|NCT04503265|DRUG|AMXI-5001:Dose Expansion Phase II|Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
41035697|NCT05371184|DRUG|L-Glutamine, Oral Powder for Reconstitution|Glutamine is an essential amino acid. It will be provided in a powder form. It will be dissolved in at least 8 ounces of hot or cold liquid. It can also be mixed with a soft food such as pudding, applesauce, or yogurt. Then it will be Stirred and then eaten or drunken The Glutamine will be as an add on to the Standard of care
41035698|NCT05371184|OTHER|Standard of care|Hydroxyurea 15-25 mg per kg per day and/ or blood transfusion therapy
41035699|NCT04158947|DRUG|Afatinib|"Dose-escalation Phase (Phase I) - Afatinib Dose-escalation will proceed on the basis of dose limiting toxicity (DLT) during Cycle 1 starting at 20 mg/day.~Dose level 1: 20 mg/day; Dose level 2: 30 mg/day; Dose level 3: 40 mg/day; Dose level 4: 50 mg/day.~Dose-evaluation Phase (Phase II) - Patients will receive the highest dose of Afatinib with T-DM1 found in Phase I as study therapy"
40852207|NCT06015087|OTHER|fasting diet|A total of 50 patients with breast cancer will be randomly devided in intervention and control group. Intervention group will follow a 60 hours fasting diet (36h prior and 24h after chemotherapy infusion), low in calories, mainly plant based, and the Mediterranean Diet in the meantime between chemotherapy cycles. Control group will receive only standard of care. Nutritional counseling and dietary records will be performed by registered dietitian. Adherence to the Mediterranean Diet will be estimated with MedDietScore. Grade of toxicity will be estimated by using the National Cancer Institute Common Terminology Criteria for Adverse Events. All participants will be encourange to continue usual physical activity.
40852208|NCT05797636|DEVICE|transcranial magnetic stimulation|"The study intervention is modulation of cortical excitation to inhibition (E/I) balance in the dorsolateral prefrontal cortex (dlPFC) by means of 2 trains of spaced continuous theta burst stimulation (cTBS) using a transcranial magnetic stimulation device. As prior work (Huang et al 2005; Chung et al. 2018) has shown that cTBS reliably decreases the cortical E/I ratio with diverse cortical targets, the Investigators expect to replicate a reduction in E/I balance when applied. The mechanism of action is thought to be an increase in inhibitory neurotransmission across diverse timescales. The endpoint of this stimulation will be a decrease in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2018).~In separate sessions, all participants will receive stimulation to either the dorsolateral prefrontal cortex (dlPFC) or to the angular gyrus (AG). The Investigators will contrast the effects of dlPFC cTBS with control cTBS to the AG."
41035700|NCT04158947|DRUG|T-DM1|"Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
41035701|NCT01910129|DEVICE|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
41035702|NCT02601313|BIOLOGICAL|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
41035703|NCT02601313|DRUG|Cyclophosphamide|Administered intravenously
41035704|NCT02601313|DRUG|Fludarabine|Administered intravenously
41035705|NCT02601313|DRUG|Axicabtagene Ciloleucel|A single infusion of axicabtagene ciloleucel anti-CD 19 CAR T cells
41035706|NCT06636409|OTHER|Collection of medical data|A randomised selection of files to be analyzed will be conducted in each center to constitute a representative sample of liver transplanted patients. This represents 20% of the number of transplanted patients over the period 2008-2013 in the center, allowing a more in-depth analysis of the patients' medical records.
41035707|NCT01088451|DRUG|Combined prandial insulin therapy (CPIT)|Combined prandial insulin therapy (CPIT) applies individual combination of rapid insulin analogue and human insulin according subject's individual estimation of the type of carbohydrates in concrete mixed-meal, based on thorough education. In this study subjects use two applicators, giving two injections before main meals as per basal-bolus therapy. Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.
41381862|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 2|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
41381863|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 3|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
41381864|NCT04798027|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: Liquid Route of administration: Intramuscular injection
41381865|NCT03114527|DRUG|Ribociclib|Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
41381866|NCT03114527|DRUG|Everolimus|mTOR inhibitor
41381867|NCT06566547|DRUG|GR1803 injection|D1 given at a dose of 30ug/kg, D4 given at a dose of 90ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks
41381868|NCT02591602|OTHER|Teleradiology Service|Teleradiology Service at home or in nursing homes
41381869|NCT06417749|BEHAVIORAL|Control arm|Participants will receive a copy of the Chinese Dietary Guidelines leaflet at baseline.
41508243|NCT02521805|OTHER|Dietary fiber (meat food matrice)|
41508244|NCT02521805|OTHER|Dietary fiber (vegetable food matrice)|
40852209|NCT05454124|BEHAVIORAL|Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
40852210|NCT05454124|BEHAVIORAL|Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision, this condition combines elements of training visual sensitivity, spatial integration, and spatial attention.
40852211|NCT00004052|BIOLOGICAL|QS21|
40852212|NCT00004052|BIOLOGICAL|bcr-abl peptide vaccine|
40852213|NCT06197763|DRUG|Colesevelam|625 mg tablets - 3 tables twice per day of Colesevelam or placebo for 6 weeks (crossover), interspersed by 8 week of washout time.
40852214|NCT06197763|OTHER|Control Arm|No Treatment: baseline assessment only
40852215|NCT05222386|OTHER|Parkinson Disease Standard Care|Under usual care, community providers will deliver their usual care and center coordinators will collect data on our outcomes every 3 months. After one year of baseline data collection, eight practices will be randomized to the intervention, which will include clinician training and coaching as well as access to online services for their patients. Per the stepped-wedge design an additional eight practices will be randomized 18 months into the data collection period, and the final eight will enter the intervention 24 months into the data collection period to allow for 12 months intervention recruitment for all practices.
40852216|NCT05222386|OTHER|Online Community-Supported Palliative Care|"Neurologist Teleconferences: Training and coaching in palliative care will be provided using the Extension for Community Healthcare Outcomes (ECHO) model augmented by a Community of Inquiry Framework to address a desire for greater peer connection, enhance self-efficacy, and to address potential weaknesses in the ECHO model for more complex interventions such as palliative care.~Additional support services provided to carepartners and patients will be through the Family Caregiver Alliance's CareNav platform, including tailored educational materials, support groups and social support."
40852217|NCT04588116|BEHAVIORAL|Strategies Empowering activities in Everyday life (SEE 1.0)|"The patients are provided a person-centered activity-based intervention on the web aiming at facilitating the level of engagement in a variety of activities, at different places in society, together with other people to support an active life. In the long-term, the change to an active life will be reflected in a healthy and balanced pattern of activities.~The program provide the patients with tools to see their activities in everyday life in a new light and, also, tools to identify activity-based strategies that can empower them to take an active role to prevent and overcome challenging situations in everyday life."
40852218|NCT05712954|OTHER|music group|music
40852219|NCT05712954|OTHER|video group|video
40852220|NCT00635882|DRUG|mometasone furoate/formoterol 100/10 mcg|mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
41381870|NCT06417749|BEHAVIORAL|Intervention arm|Participants will be given three MIND diet education videos on different topics at baseline and during follow-up. In addition, each participant will receive a MIND diet education brochure at baseline and some food supply during follow-up.
41508245|NCT05158543|OTHER|conventional therapy|The conventional group will receive active and passive range of motion exercises, balance, and strength training for upper and lower limbs. One session per day, three sessions/week for total of 12 weeks.
40852221|NCT00635882|DRUG|mometasone furoate/formoterol 200/10 mcg|mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
40852222|NCT00635882|DRUG|mometasone furoate/formoterol 400/10 mcg|mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
40852223|NCT00635882|DRUG|MF DPI 200 mcg|MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
40852224|NCT00635882|DRUG|MF MDI 200 mcg|MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
40852225|NCT00635882|DRUG|Placebo|MF/F MDI placebo twice daily (BID) (2 inhalations)
40852226|NCT01031173|BIOLOGICAL|agalsidase alfa|0.2 mg/kg body weight, administered by an intravenous infusion over 40 minutes, every other week.
41381871|NCT00398632|DRUG|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
41381872|NCT03310606|OTHER|Dosage of serum and peritoneal of the B lactam used for antibiotic treatment|Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
41381873|NCT05229783|PROCEDURE|Electronic chromoendoscopy|Inspection of the Barrett's esophagus using the electronic chromoendoscopy modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions.
41381874|NCT05229783|PROCEDURE|White light endoscopy with Seattle protocol|Inspection of the Barrett's esophagus using the white light modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
41381875|NCT05615428|DIAGNOSTIC_TEST|LS-ratio|Included infants will have a gastric aspirate sampled via an NG tube at birth. This sample will be analyzed to determine the LS-ratio The LS-ratio will retrospectively be compared to RDS development and need for surfactant treatment to establish the cut-off ratio for LS-ratio with respect to surfactant treatment.
41381876|NCT05774431|OTHER|There was no intervention necessary.|There was no intervention necessary.
41381877|NCT05929040|BEHAVIORAL|mindful cognitive intervention|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
41381878|NCT01021696|DRUG|Paracetamol|Paracetamol Max. dose: 3g/d
41381879|NCT01021696|DRUG|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
41381880|NCT01021696|DRUG|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
41381881|NCT01021696|DRUG|Pregabalin|25mgx1/d; max 300mg/d
40852227|NCT05802615|BEHAVIORAL|PARITY|The PARITY program reinforces strengths through consistent, community-based Black doula support and protective asset (personal strengths) focused messaging. PARITY promotes wellness-related behaviors (nutrition, physical activity, sleep, and healthcare adherence) and promotes and builds empowered strengths (self-efficacy, social support, motivation, resilience, problem-solving, and self-regulation) through mobile technology and doula support.
40852228|NCT05802615|OTHER|Usual Care|Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
41035708|NCT04247620|BEHAVIORAL|DiaBetter Together|Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult, including (a) teaching and modeling strengths-based skills for goal-setting, problem-solving, and stress management; (b) guiding participants in obtaining support from their social support network (e.g., family, friends); (c) developing a plan for accountability around diabetes management and follow-up in adult care; (d) sharing his/her transition experiences and strategies for successfully navigating the adult healthcare system; (e) discussing how to prioritize diabetes self-care; and (f) assisting them in accessing diabetes-related resources (e.g., local diabetes groups, apps, social media). Contact will be in-person, by phone, email, text message, and/or video, approximately weekly for first 3 mos, approximately biweekly for next 3 mos, and approximately monthly for last 6 mos (while COVID-19 safety recommendations are in place, in-person meetings will not occur).
41035709|NCT04247620|BEHAVIORAL|Peer Mentor Delivery|Peer Mentors deliver the intervention to multiple young adult participants, each for 12 months. Peer Mentors may take on one or more participants at a time, and Peer Mentors may stay in their role in the study (delivering the intervention) for 1-3 years.
41165301|NCT05789550|DIAGNOSTIC_TEST|ALL PATIENT DIABETIC IN THIS PERIOD WILL BE INCLUDED IN THE STUDY|"1. Full clinical history with detailed history about T2DM (its duration and treatment).~2. Full medical examination, including BMI using the formula: weight (kg)/height (m2).~3. Laboratory investigation, including the following:~   1. Complete blood picture.~  2. Fasting blood sugar (FBS).~  3. Postprandial blood sugar (PP-BS) (2 h after 75 g glucose orally).~  4. HbA1c.~  5. Kidney function tests (serum creatinine and blood urea).~  6. Liver function tests (serum albumin, ALT, and AST).~  7. Lipid profile, which include cholesterol and triglyceride. 4)H PYLORI Ag IN Stool"
41165302|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein|Amount provided is based on the fat-free mass of subject
41381882|NCT02341794|DRUG|Rosuvastatin|Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
41381883|NCT03911817|DRUG|Midodrine|The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge
41381884|NCT02896621|DRUG|Chlorthalidone plus amiloride|A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
41381885|NCT02896621|DRUG|Amlodipine|A capsule of amlodipine was taken once daily in the morning for eight weeks.
41381886|NCT06218030|DRUG|L-methylfolate|Oral administration of L-methylfolate 15 mg per day for 8 weeks. The study drug will be given in addition to the standard of care (SOC) for GAD.
41381887|NCT05724875|DEVICE|FLASH RT|For T1 (small) lesions: 22 Gy single dose FLASH RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose FLASH RT
41381888|NCT05724875|DEVICE|Conventional RT|For T1 (small) lesions: 22 Gy single dose conventional RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose conventional RT
41381889|NCT05730335|DEVICE|Rapid Acoustic Pulse|Transdermal Rapid Acoustic Pulse Treatments
41165303|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject
41381890|NCT04216537|DIAGNOSTIC_TEST|Glioma groups based on molecular pathology or genetic variation|Patients with newly diagnosed glioma that receive tumor resection
41381891|NCT00308230|PROCEDURE|Six minute walk test|
41381892|NCT00308230|BEHAVIORAL|Minnesota Living with Heart Failure Questionnaire|
41381893|NCT02601326|PROCEDURE|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
40852229|NCT06548932|DRUG|GZR33 Injection|A single dose
41381894|NCT02601326|PROCEDURE|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
41381895|NCT04865887|DRUG|Pembrolizumab|200mg, every 3 weeks, IV infusion
41381896|NCT04865887|DRUG|Lenvatinib|20 mg (2 capsules x10mg), daily, orally
40852230|NCT06548932|DRUG|GZR101 Injection|A single dose
40852231|NCT06548932|DRUG|Placebo|A single dose
40852232|NCT01611194|DRUG|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
40852233|NCT01611194|DRUG|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
41381897|NCT04101721|DRUG|aflibercept|Administered IVT
41381898|NCT04101721|PROCEDURE|laser photocoagulation|Transpupillary conventional laser will be administered according to standard local procedures.
41381899|NCT02297607|DIETARY_SUPPLEMENT|Tube Feeding|
41381900|NCT02271100|DEVICE|ultrasound guidance|use of ultrasound for entry position estimation
41381901|NCT02271100|DEVICE|palpation guidance|use of palpation for position estimation
41381902|NCT05270629|OTHER|Antegrade and retrograde anastomoses|Patients who had received both antegrade and retrograde anastomoses.
41381903|NCT05270629|OTHER|Antegrade-only anastomoses|Patients who had received antegrade-only anastomoses.
41381904|NCT03179488|DEVICE|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
41381905|NCT03179488|DEVICE|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
40852234|NCT03147443|DRUG|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
40852235|NCT03147443|DRUG|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
40852236|NCT03147443|DRUG|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
40852237|NCT02356289|DRUG|Placebo|
40852238|NCT02356289|DRUG|MYK-461|
41381906|NCT06184373|DEVICE|Dexcom G6/G7 CGM|CGMs will be worn for a maximum of 10 days at 6-8 weeks postpartum.
40852239|NCT02151890|BIOLOGICAL|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
40852240|NCT00863005|DRUG|K201|Cream
41381907|NCT06184373|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|At 10-12 weeks postpartum, participants will complete an oral glucose tolerance test, which involves drinking a glucose substance and having glucose levels measured a maximum of 3 times.
41381908|NCT06184373|DIAGNOSTIC_TEST|Hemoglobin A1c|At 11-14 months postpartum, participants will be asked to have their blood drawn to check their hemoglobin A1c to look for signs of developed insulin resistance
41381909|NCT05496634|BEHAVIORAL|Sedantary|An informative presentation
41381910|NCT05496634|BEHAVIORAL|Exercise therapy|Pilates exercise therapy
41381911|NCT05927194|BEHAVIORAL|Using the Connect|Using the Connect (UTC) is an innovative, game-based intervention for youth to develop skills in adulthood preparation topics such as communication, decision making and accessing information.
40852241|NCT00863005|DRUG|K201|
40852242|NCT04831177|PROCEDURE|Laser in situ keratomileusis|Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
40852243|NCT00470925|DRUG|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
41165304|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
41165305|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + carbohydrates + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
41165306|NCT01734473|DIETARY_SUPPLEMENT|4 levels of hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
41381912|NCT02790619|DEVICE|tDCS via Chattanooga Ionto Iontophoresis System-Phoresor|Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
41381913|NCT02790619|DEVICE|Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor|Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
41381914|NCT05409157|DRUG|BMS-986166|Specified dose on specified days
41381915|NCT05409157|DRUG|Bisacodyl|Specified dose on specified days
41381916|NCT06565884|DEVICE|Home radiofrequency skin treatment instrument|Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
41381917|NCT06565884|OTHER|Ultrasonic coupler for medical purposes|In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
40852244|NCT02050087|DEVICE|Simple sling.|
40852245|NCT02050087|DEVICE|Neutral brace|
40852246|NCT00901121|DEVICE|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
40852247|NCT00901121|DEVICE|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
40852248|NCT00599755|RADIATION|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
41165307|NCT02597036|DRUG|LY3127804|Administered IV
41165308|NCT02597036|DRUG|Ramucirumab|Administered IV
41165309|NCT02597036|DRUG|Paclitaxel|Administered IV
41381918|NCT04361006|DEVICE|Radiofrequency (RF)|Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
40852249|NCT00599755|DRUG|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m\^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m\^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
40852250|NCT06186986|DRUG|Brentuximab vedotin|5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
41381919|NCT04361006|DEVICE|Cryotherapy (CRYO)|Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
40852251|NCT02955342|OTHER|no intervention|no intervention
41381920|NCT00312936|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|8 week program
40852252|NCT00003917|DRUG|topotecan hydrochloride|
40852253|NCT04995549|DEVICE|Cutiscan® CS 100|Repeated measures on healthy volunteers skin (forearm) are performed using Cutiscan® CS 100 device
40852254|NCT05244083|OTHER|Mirror Therapy|Therapy consisting of perfoming bimanual activities with a mirror placed on the patient's sagital plane, so it creates the brain illusion that the impaired limb moves the same way and quality that the unimpaired does.
40852255|NCT05244083|OTHER|Program without Mirror Therapy|Bimanual exercises performed with both upper limbs.
40852256|NCT03445689|OTHER|Assessment of oxygenation instability|Recordings of SpO2 and heart rate will be analyzed by dedicated software to obtain frequency, duration and severity of episodes of hypoxemia and hyperoxemia.
40852257|NCT03445689|OTHER|Determination of mechanisms of hypoxemia episodes|Recordings of SpO2, heart rate, esophageal pressure, tidal volume, minute volume, respiratory rate and transcutaneous PCO2 will be analyzed to determine the prevalence, severity and duration of hypoxemia episodes produced by the different mechanisms.
40852258|NCT03445689|OTHER|Assessment of respiratory instability|Recordings of tidal volume, minute volume and respiratory rate will be analyzed to determine frequency of apnea, periodic breathing, distribution of inter-breath intervals.
40852259|NCT03445689|OTHER|apneic threshold of CO2|In mechanically ventilated infants the apneic threshold of CO2 will be measured by transcutaneous PCO2 following a step wise increase in ventilator rate until spontaneous breathing ceases transiently. In spontaneously breathing infants the apnea threshold of CO2 will be measured during episodes central apnea.
40852260|NCT03445689|OTHER|Assessment of peripheral chemoreceptor function|The Dejours test will be used to assess peripheral chemoreceptor function by measuring the immediate ventilatory response to high-inspired oxygen.
41035710|NCT01223313|DEVICE|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
41035711|NCT03043664|DRUG|Lanreotide|Somatuline depot (lanreotide) 90 mg SQ every 3 weeks
41381921|NCT05959824|DEVICE|OR-AT0222|Topical viscous gel containing tamarind seed polysaccharide and isolated pea proteins will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
41381922|NCT05959824|OTHER|Placebo|Topical placebo viscous gel will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
41381923|NCT05873075|OTHER|Intravascular laser irradiation of blood|Intravascular laser irradiation of blood via an intravenous catheter for irradiation of the blood under a period of 60 minutes daily for 20 days
41381924|NCT00380575|DRUG|YM087|
41508246|NCT05158543|OTHER|Task oriented training (moderate intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Single session/day, 4 sessions/week for 12 weeks.
40852261|NCT03445689|OTHER|Assessment of central chemo-receptor function|Central chemo-receptor function will be assessed by measuring the ventilatory response to inspired CO2.
41508247|NCT05158543|OTHER|Task oriented training (high intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Two sessions/day, 5 sessions/week for 12 weeks.
40852262|NCT05327972|DRUG|The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).|Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance.
40852263|NCT05327972|OTHER|PLACEBO|Two milliliters of a saline solution containing an inactive lyophilisate will be once injected in the supra-spinatus muscle using ultrasonography guidance.
40852264|NCT06583967|OTHER|Physical Training|Group 1 - Elliptical Trainer Group 2 - Treadmill
41035712|NCT03043664|DRUG|Pembrolizumab|Keytruda (pembrolizumab) 200 mg IV every 3 weeks
41035713|NCT04732962|DEVICE|AposHealth|"AposHealth is comprised of a unique footwear (Apos device) and uses two convex pods called Pertupods, which are screwed into the plantar surface of the sole so that a person walks on these pods. A trained Apos therapist calibrates the devices. The location of the pods is adjusted according to the treatment methodology, depending on the needed effect on unloading the knee and with the purpose of potentially alleviating pain immediately."
41381925|NCT00910065|DRUG|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
41381926|NCT00910065|DRUG|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
41381927|NCT00910065|DRUG|Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet|Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
40852265|NCT01808235|BEHAVIORAL|Oral Health Intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
40852266|NCT01810718|DRUG|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are\>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond \>600 or \<200mg/die The MTD will be used for phase II
40852267|NCT02744638|OTHER|probiotic yoghurt|verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
40852268|NCT02744638|OTHER|chemically acidified milk|Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
41381928|NCT01153685|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
41381929|NCT05353816|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of the Corheart 6 Left Ventricular Assist Device for mechanical circulatory support.
40852269|NCT02744638|DRUG|Arilin|2 tablets Arilin 500mg for 7 days
40852270|NCT00627133|DRUG|levetiracetam|2 gram iv load, 500mg bid
40852271|NCT00538070|DIETARY_SUPPLEMENT|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
41381930|NCT06535828|DEVICE|AI and mechanic modeling|The data collected from research tests on your blood and tumor samples will be used to develop an AI model for treatment selection.
40852272|NCT02119663|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
40852273|NCT02119663|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth twice daily (BID)
40852274|NCT02119663|DRUG|Capecitabine|150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
41381931|NCT03544567|DRUG|Oraxol|oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
40852275|NCT06096662|BEHAVIORAL|Verb Network Strenghtening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, to drive) orally and in writing. The participants are first asked to name someone who may perform a given activity (an agent/subject, for example a chauffeur), then to name an object which the named activity can pe performed with (a patient/object, for example a limousine). Several types of semantic cues and assistance are given if the participant has difficulties finding adequate nouns). This procedure is repeated for three different agents and objects related to the given verb. The participants is then asked to choose one of the three sentences participants have created and expand on it by telling where, when and why the agents are performing the activity. After this, the participants are given sentences (with several foils) including the activity as well as agents and objects/patients, and are asked to indicate whether the sentences are plausible or not.
40852276|NCT04282525|OTHER|ECMO for hemodynamic or respiratory indication|ECMO for hemodynamic or respiratory indication
41035714|NCT04732962|PROCEDURE|Total Knee Replacement (TKR)|A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.
41381932|NCT06346080|OTHER|Survey|Discrete choice survey
41381933|NCT03979586|OTHER|Laser-assisted hyaluronic acid delivery|The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
41381934|NCT03337776|OTHER|WhatsApp message|WhatsApp message will be sent to invite subjects to participate in CRC screening
41381935|NCT03337776|OTHER|Telephone call|Telephone call will be made to invite subjects to participate in CRC screening
41381936|NCT05514496|DRUG|NX-019|NX-019 will be administered orally.
41381937|NCT01615822|DRUG|OZ439 100mg|OZ439 100mg oral suspension, single dose
41381938|NCT01615822|DRUG|OZ439 400mg|OZ439 400mg oral suspension, single dose
41381939|NCT01615822|DRUG|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
41381940|NCT01615822|DRUG|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
41381941|NCT01615822|DRUG|Placebo|
41381942|NCT05849129|DRUG|Ascorbic acid|High dose ascorbic acid delivered intravenously
41381943|NCT05849129|OTHER|Normal Saline|0.9% NaCl solution
40852277|NCT04301544|BEHAVIORAL|INDAK (Improving Neurocognition through Dance and Kinesthetics)|INDAK (Improving Neurocognition through DAnce and Kinesthetics) is a structured modular dance consisting of 8 types of ballroom dances (Reggae, Cha-cha, Samba, Merengue, Bachata, Swing, Tango and Salsa) with increasing complexity. The intervention group will receive dance intervention from a dance teacher two times a week, one hour each time, for 12 months. Each 60-minute session has 3 parts: 10 minutes warm-up/ stretching, 40 minutes dance proper and 10 minutes cool down. This dance intervention will last for 12 months.
40852278|NCT04301544|BEHAVIORAL|Nutrition Counseling|The dietary advice will follow Filipino Nutrition Research Institute (FNRI) recommendation called Pinggang Pinoy or Filipino Plate, which is a picture of a nine-inch plate with foods proportionally distributed among the food groups to provide approximately 1,200 to 1,500 calories per day. It is advised that half of the plate is composed of green leafy vegetables and one serving of fruit per meal. For fruits, 4 to 6 servings are encouraged per day. In general, affordable nutritious food is recommended: high consumption of local fruits and vegetables, brown/purple rice instead of white rice, coconut oil and other vegetable oils, and fish. Participants will be asked to use structured 3-day meal diary for diet monitoring. Individual counseling sessions depending on identified vascular risks based on FNRI recommendations will also be conducted. This is followed-up by study nutritionists every 3-month of intervention period.
40852279|NCT04301544|BEHAVIORAL|Standardized Vascular Care|The management advice for hypertension, diabetes, and dyslipidemia will be based on Filipino standard clinical practice guidelines. This is followed-up by study physicians every 3-month of intervention period
40852280|NCT00384332|DRUG|orally-disintegrating olanzapine|5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
40852281|NCT00384332|DRUG|regular olanzapine|5-20 mg. olanzapine daily for approximately 8 weeks.
40852282|NCT06330259|DIAGNOSTIC_TEST|menstrual cycle monitoring|frequent serum sampling and 3D ultrasound
40852283|NCT06583460|OTHER|Early and systematic oncosexological supporting care|"Each patient included in the study will be cared by an anthropologist and a sexologist.~This therapeutic support care will be based on :~* 2 qualitative semi-directive interviews (Baseline and M18),~* 2 individual consultations with questionnaires (Baseline and M18).~The qualitative semi-structured interviews will be conducted with the anthropologist, and the individual consultations with the sexologist.~At the end of the first oncosexology consultation, patients will be given the opportunity to decide whether or not to accept further systematic oncosexology support care, which will be based on :~* 3 individual and/or couple consultations,~* 3 group workshops.~Patients are under no obligation to accept this additional oncosexology support care."
40852284|NCT03396575|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
40852285|NCT03396575|BIOLOGICAL|TTRNA-xALT|During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.
40852286|NCT03396575|DRUG|Cyclophosphamide + Fludarabine Lymphodepletive Conditioning|Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.
41035715|NCT04100746|PROCEDURE|supramalleolar osteotomy|surgical intervention by using low tibial osteotomy
41381944|NCT04997018|RADIATION|Radiation Therapy|"Patients enrolled in this study will undergo ultra-hypofractionated radiation utilizing MR guided, daily online adaptive planning. Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously-delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm, as determined on the pretreatment diagnostic T2 MRI imaging. In the setting of two similarly-sized dominant lesions, both will be boosted."
41381945|NCT03793309|DRUG|Vitamin D|Oral vitamin D
41381946|NCT03465072|OTHER|Exercise training|8 weeks, 3 times per week, 30-40 minutes
41381947|NCT00986609|BIOLOGICAL|MUC-1 peptide vaccine|Given subcutaneously
41381948|NCT00986609|BIOLOGICAL|poly ICLC|Given intramuscularly
41381949|NCT00986609|BIOLOGICAL|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
41381950|NCT00986609|OTHER|laboratory biomarker analysis|Correlative studies
41381951|NCT00986609|OTHER|enzyme-linked immunosorbent assay|Correlative studies
41381952|NCT00986609|OTHER|flow cytometry|Correlative studies
41381953|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol|Ergocalciferol 50000 international units once a week for 12 weeks
41381954|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol placebo|Ergocalciferol placebo once a week for 12 weeks
41381955|NCT05823194|PROCEDURE|Fertility sparing surgery|Sparing the uterus and/or ovaries of the patients suffering from gynecologic malignancies to keep the patients' fertility
41381956|NCT03540446|DEVICE|First Relief Treatment|To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
41381957|NCT04365907|DRUG|Zafatek tablets|Once weekly new anti-diabetic drug approved only in Japan
41381958|NCT05087173|DEVICE|Chatbot|An interactive chatbot for patient decision aid A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.
41381959|NCT04057118|DRUG|SKI-O-703|Oral administration, twice per day
41381960|NCT04057118|DRUG|Placebo|Oral administration, twice per day
41381961|NCT05570058|DRUG|RXC007|RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.
41381962|NCT05570058|DRUG|Placebo|The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD
40852287|NCT03396575|DRUG|Dose-Intensified TMZ|After chemoradiation, subjects in Group A will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
41508248|NCT02798588|RADIATION|PET-MRI|18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)-\>8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
41508249|NCT04258033|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
41508250|NCT00016081|DRUG|ribavirin|
41508251|NCT05809479|OTHER|No intervention|No intervention
40852288|NCT03396575|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
41035716|NCT01230593|DRUG|Hot Compress plus Tobramycin Drops and Ointment|In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
41035717|NCT01230593|DRUG|Hot compress plus Tobramycin/Dexamethasone Drops and Ointment|In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
41381963|NCT01500434|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
41381964|NCT01500434|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
41381965|NCT01500434|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
41381966|NCT01100398|PROCEDURE|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
41381967|NCT05591404|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to the TSST arm will experience the Trier Social Stress Test.
41381968|NCT04242901|DIAGNOSTIC_TEST|Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo|Quantitative Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
41508252|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
41508253|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
41035718|NCT01230593|OTHER|Hot Compresses|Hot compresses 3x/day to eyelids
41035719|NCT03641482|DRUG|NBF|Once the molar is extracted, the socket is cleaned with water, NBF gel is introduced, and the flap is closed. Then, the patients are instructed to apply NBF Gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
41035720|NCT03641482|DEVICE|Placebo|Once the molar is extracted, the socket is cleaned with water, placebo gel is introduced, and the flap is closed. Then, the patients are instructed to apply placebo gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
41035721|NCT05035719|DEVICE|non-invasive cardiac output monitor|Equivalence of Caretaker cardiac output reading to reference standard
41035722|NCT05829161|BEHAVIORAL|no intervention|no intervention
41035723|NCT03690869|DRUG|cemiplimab (monotherapy)|To be administered intravenously as monotherapy in Phase 1
40852289|NCT03396575|BIOLOGICAL|Autologous Hematopoietic Stem Cells (HSC)|During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.
40852290|NCT03415438|DIAGNOSTIC_TEST|Visual Analogue Scale|intensity of pain perception patients feel
40852291|NCT03415438|DIAGNOSTIC_TEST|posterior capsule tightness|tape measurement for posterior capsule tightness with patients lying at side and horizontally adducting their shoulder.
40852292|NCT03415438|DIAGNOSTIC_TEST|shortness tests for lumbar movements|tape measurement for lumbar movements
40852293|NCT03415438|DIAGNOSTIC_TEST|range of motion tests for lumbar movements|range of motion measurements for lumbar flexion, extension and lateral flexion with goniometer.
41035724|NCT03690869|DRUG|cemiplimab (maintenance)|To be administered intravenously in combination with radiation and then used as maintenance therapy
41035725|NCT03690869|RADIATION|Conventional or hypofractionated|Combined with cemiplimab IV administration
40852294|NCT03415438|DIAGNOSTIC_TEST|The thoracolumbar fascia length test|patient sitting straight with shoulders at horizontal plane, both the arms are asked to rotated with primarily spinal rotation. the degree of rotation gives idea about the thoracolumbar fascia length
40852295|NCT03415438|DIAGNOSTIC_TEST|Modify Schober test|tape measurement of spinal flexion between designated regions
41165310|NCT04157218|DEVICE|HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)|The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .
40852296|NCT00551603|DRUG|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
40852297|NCT00551603|DRUG|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
41035726|NCT03690869|RADIATION|Re-irradiation|Combined with cemiplimab IV administration
41035727|NCT00110617|DRUG|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
41035728|NCT00110617|DRUG|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
41035729|NCT01756092|PROCEDURE|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
41035730|NCT03676062|OTHER|exercise|All exercises programs applied three sessions per week, totally six week.
41035731|NCT01863277|DRUG|Melatonin|
41035732|NCT01863277|DRUG|placebo|
41035733|NCT05001100|OTHER|rehabilitation|rehabilitation
41165311|NCT04157218|DEVICE|Threads used in this study are absorbable Aptos|The threads will be inserted to the cheeks
41165312|NCT04306913|DRUG|Esmolol|esmolol 250 mg in cardioplegia solution every 25 minutes
41165313|NCT04306913|DRUG|Potassium Cardioplegic Solution|15 meq potassium added to cardioplegia solution
41381969|NCT04303065|DRUG|Dexamethasone Oral|It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
41381970|NCT04303065|DRUG|Placebo oral tablet|The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
41165314|NCT03556540|OTHER|physical exercise|Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis.
41165315|NCT03535077|OTHER|Diagnostic Test|Imaging of the suspicious lesion after application of ORL-1 dye prior to biopsy
41165316|NCT01839383|OTHER|different dialysate calcium concentration|
41165317|NCT05239598|DRUG|Mouth rinse|Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
41381971|NCT05275855|DRUG|EDI048|Oral Liquid
41381972|NCT05275855|OTHER|Placebo|Oral Liquid
40852298|NCT05198843|DRUG|Dasatinib|Given PO
40852299|NCT05198843|DIETARY_SUPPLEMENT|Icosapent Ethyl|Given PO
41035734|NCT02198027|DRUG|Bupivacaine|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
41165318|NCT06144788|DRUG|SGLT2 inhibitor|SGLT 1/2 dual inhibitor
41165319|NCT03069014|DRUG|400mg LM11A-31-BHS|1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning \& evening) for 26 weeks
41165320|NCT03069014|DRUG|800mg LM11A-31-BHS|2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning \& evening) for 26 weeks
41165321|NCT03069014|DRUG|Placebos|2 Oral Capsules (200mg of Placebo) twice daily (morning \& evening) for 26 weeks
40852300|NCT01301859|BEHAVIORAL|TIP|Treatment visits as usual with MD
40852301|NCT00002609|BIOLOGICAL|lintuzumab|
41381973|NCT02248428|DRUG|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
41381974|NCT02248428|DRUG|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
41381975|NCT02248428|DRUG|Cyclophosphamide|300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days
41381976|NCT02248428|DRUG|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
40852302|NCT00002609|DRUG|cytarabine|
40852303|NCT00002609|DRUG|idarubicin|
41035735|NCT02198027|OTHER|Normal saline infiltration|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
41035736|NCT01750268|BEHAVIORAL|Medical Management Counseling|Brief alcohol and medication counseling
41381977|NCT01991600|DIETARY_SUPPLEMENT|ferrous sulphate|
41381978|NCT01991600|DIETARY_SUPPLEMENT|ferric iron oxide-organic acid (Fe-OA)|
40852304|NCT00068302|DRUG|sirolimus|3-6 subjects will be enrolled into each dose level
40852305|NCT02956187|BEHAVIORAL|Biofeedback|Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
40852306|NCT02956187|DIETARY_SUPPLEMENT|Fiber supplement|3.5 g plantago ovata per day will be administered for 4 weeks.
40852307|NCT01670435|DRUG|Ciprofloxacin (BAYQ3939)|Patient treated with Ciproxan as a first line treatment in daily clinical practice
40852308|NCT04673578|DRUG|Celecoxib|Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
40852309|NCT04673578|OTHER|Placebo|Microcrystalline cellulose
41035737|NCT01750268|DRUG|Topiramate|Experimental medication
41035738|NCT01750268|DRUG|Placebo|Placebo comparator
41035739|NCT01367327|BEHAVIORAL|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
41165322|NCT01250847|DRUG|Quetiapine(Seroquel-XR) 50~800mg a day|The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.
41165323|NCT03834155|OTHER|Hospital-based CR + Movn Application|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application.
41165324|NCT03834155|OTHER|Choice of Hospital or home-based CR + Movn Application|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application.
41165325|NCT03834155|OTHER|Hospital-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages.
41165326|NCT03834155|OTHER|Choice of Hospital or home-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, plus encouraging nudge messages.
41165327|NCT01300078|DRUG|MF101|MF101 10 g/day MF101 15 g/day
41165328|NCT00097708|DRUG|experimental anti-anxiety drug|
41165329|NCT00321321|DRUG|Sulfonylurea|
41165330|NCT05958784|DIETARY_SUPPLEMENT|L-Phenylalanine|100 mg/kg
41165331|NCT05127590|DRUG|RBN-2397|Continuous oral dosing with the RP2D of RBN-2397 (outpatient basis). Pembrolizumab IV infusion over 30 minutes in clinic on Day 1 of each cycle.
41165332|NCT00716066|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
41165333|NCT00716066|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
41165334|NCT00716066|DRUG|Carmustine|Given IV
41381979|NCT01544465|BEHAVIORAL|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
41381980|NCT01544465|BEHAVIORAL|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
41381981|NCT01849029|BEHAVIORAL|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
40852310|NCT05574842|BEHAVIORAL|Double duty interventions using nutrition behavior change communication approach|The packages of the double-duty interventions were modified and adapted from the 2017 WHO policy brief report and Hawkes et al., 2020. These interventions are optimized strong education and nutrition behavior change communication focused on promotion of healthy diets (adequate adolescent nutrition, dietary diversity), physical activity (doing moderate intensity physical exercise, avoiding sitting for log time), prevent undue harm from energy-dense foods (avoiding Junk processed foods, avoiding fizzy sweetened drinks, street fast foods, chips, salt, sugar, fats etc.), and regulations on marketing foods from the customer side (e.g., buying of packed foods frequently).
41383579|NCT06172361|DRUG|Prednisone+Tofacitinib|"Withdrawal of prednisone (or equivalent dose of methylprednisolone) within 4 weeks: 5mg tid for 2 weeks, 5mg bid for 1 week, 5mg qd for 1 week, then discontinue.~Take Tofacitinib 10mg/d for 3 months, then 7.5mg/d for 2 months, followed by 5mg qd for 2 months, then 5mg qod for 2 months, and finally 5mg every 3 days for 2 months, discontinue the Tofacitinib for 1 month. If there is a relapse during the dose reduction process, resume Tofacitinib at the original dosage."
40852311|NCT03941626|BIOLOGICAL|CAR-T/TCR-T cells immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
41165335|NCT00716066|DRUG|Cytarabine|Given IV
41165336|NCT00716066|DRUG|Etoposide|Given IV
41165337|NCT00716066|OTHER|Laboratory Biomarker Analysis|Correlative studies
41165338|NCT00716066|DRUG|Melphalan|Given IV
41165339|NCT00716066|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
41165340|NCT00716066|DRUG|Prednisone|Given PO
41165341|NCT00716066|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo syngeneic bone marrow transplantation
41165342|NCT01627470|DEVICE|CNAP-Monitor|Continuous non-invasive arterial blood pressure recording
40852312|NCT00525096|DRUG|placebo|2 tablets twice a day per os
40852313|NCT00525096|DRUG|Celecoxib|2\*200 mg tablets twice a day per os
40852314|NCT00525096|DRUG|Exemestane|Exemestane 25 mg per day per os
41165343|NCT04440059|DRUG|ICP-022|ICP-022 at a dose of 150mg PO QD
40852315|NCT03781778|OTHER|Dietary Intervention (resistant starch)|Eat foods with resistant starch
40852316|NCT03781778|OTHER|Dietary Intervention (regular starch)|Eat foods with regular corn starch
40852317|NCT03781778|OTHER|Questionnaire Administration|Ancillary studies
40852318|NCT05240001|DEVICE|Thulium Fibre Laser|Participants will undergo treatment using the TFL
41165344|NCT03919318|OTHER|Root Canal Filling Sealers|Root Canal Obturation
41165345|NCT03028012|DRUG|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
41165346|NCT03028012|DRUG|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
41165347|NCT03028012|DRUG|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
41165348|NCT02303002|BIOLOGICAL|Botulinum Toxin Type A|Intramuscular injection (IM)
41165349|NCT02303002|BIOLOGICAL|Active Comparator botulinum toxin|IM injection
41165350|NCT02303002|BIOLOGICAL|Placebo Comparator|IM injection
41165351|NCT01260207|OTHER|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
41165352|NCT03216941|DRUG|Ketamine|"study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication."
40852319|NCT05240001|DEVICE|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
41381982|NCT06569017|OTHER|1) Artificial intelligence supported working group|Pregnant women will be a personal information form, breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa infant nutrition attitude scale and Edinburgh postpartum depression scale. Pregnant women in the artificial intelligence-supported study group were aged 32-37. Starting from the first week of pregnancy, a mobile breastfeeding consultancy application supported by IOS and Android will be installed on smart phones. Pregnant women will be expected to use this application actively until birth and submit their questions about breastfeeding to this artificial intelligence-supported mobile application and receive instant answers. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
41381983|NCT06569017|OTHER|Online breastfeeding counseling group led by a nurse|The forms that will be applied to pregnant women in all three groups at the first meeting will also be applied to this group. 32-37 in the nurse-led online breastfeeding counseling group. Primiparous pregnant women at the gestational age will be offered 1.5 hours of breastfeeding counseling by one of the researchers, between the 32nd and 37th weeks of pregnancy, with the participation of small groups of five pregnant women in each interactive session. Pregnant women in this group will receive only one session of breastfeeding training. These trainings, which will be given by the nurse, will be carried out online via video call via WhatsApp application. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
41381984|NCT00834288|DRUG|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
41381985|NCT00834288|DRUG|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
41381986|NCT05494151|DIAGNOSTIC_TEST|Investigation of the metabolic substrate|A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
40852320|NCT03993522|OTHER|Symptom limited cardiopulmonary exercise test & Sub-maximal cardiopulmonary exercise test|Exercise tests on cycle ergometer for the purpose of collecting expired breath gasses
40852321|NCT05090852|DEVICE|Hi-VNI|Hi-VNI used instead of or along with endotracheal intubation or jet ventilation to provide oxygen to patients during upper airway surgery
40852322|NCT06435923|DRUG|[14C]-darigabat|Oral capsule
41381987|NCT03867825|DEVICE|Non-invasive hemodynamic monitoring|Impedance cardiography
41381988|NCT00034593|DRUG|ALIMTA|
41381989|NCT00034593|DRUG|gemcitabine|
41381990|NCT02765139|BEHAVIORAL|Engaging Men through Accountable Practice|Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
41381991|NCT02765139|OTHER|Alternative intervention|Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
41381992|NCT06043102|DEVICE|TheraClearX|TheraClear®X combines vacuum pressure with a broadband light source (500 nm to 1,200 nm) to treat facial acne.
41381993|NCT00713713|PROCEDURE|Mechanical ventilation with low and high tidal volume|Tidal volume of 6 or 12 ml.kg-1, calculated on ideal body weight
40852323|NCT03676140|DRUG|Albendazole on Day 1|Albendazole 400 mg oral tablet Single Dose Treatment on D1
40852324|NCT03676140|DRUG|Ivermectin on Day 1|Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
40852325|NCT03676140|DRUG|Diethylcarbamazine on day 1|Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
40852326|NCT03676140|DRUG|Azithromycin on Day 1|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
40852327|NCT03676140|DRUG|Azithromycin on Day 8|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
40852328|NCT05921253|DEVICE|PARASYM neuromodulation device|Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
40852329|NCT05921253|DEVICE|PARASYM neuromodulation device|"Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study."
40852330|NCT06124391|OTHER|Long-term follow-up|Participants diagnosed with PCOS were not subjected to any specific intervention post-diagnosis. Instead, they were followed up after 6.5 years to assess various outcomes related to PCOS and associated conditions.
40852331|NCT05926830|DEVICE|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue. The process is then repeated in a stepwise fashion.
40852332|NCT03833414|PROCEDURE|triceps lifting and olecranon osteotomy approaches|two different surgical approaches for distal humerus fracture
41035740|NCT01367327|BEHAVIORAL|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
41035741|NCT01941862|BEHAVIORAL|Psychoeducation and Cognitive Bias Modification|
41381994|NCT05909007|PROCEDURE|thoracic epidural insertion|thoracic epidural for pain relief after major thoracic surgery and lung transplantation
40852333|NCT04441255|DRUG|TAK-788|TAK-788 Capsule.
40852334|NCT00745043|DRUG|bronchodilator response|
40852335|NCT04770948|DEVICE|19 gauge needle|EBUS-TBNA performed using 19G needle
40852336|NCT04770948|DEVICE|22 gauge needle|EBUS-TBNA performed using 22G needle
40852337|NCT01357551|BEHAVIORAL|Maintenance intervention|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
40852338|NCT05036967|DRUG|HF medication|Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
40852339|NCT06038422|DRUG|GTP regimen|Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)
40852340|NCT00842543|DIETARY_SUPPLEMENT|Fruit and Vegetable Juice Concentrate (FVJC)|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
40852341|NCT00842543|DIETARY_SUPPLEMENT|Placebo|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
40852342|NCT01226576|DEVICE|MRgFUS Treatment|Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
40852343|NCT03100773|OTHER|Oral health educational strategy|Oral health educational strategy consisted of four consecutive sessions (once a week) about etiological factors of caries (using visual aids), oral hygiene instructions (using models), supervised toothbrushing and explanation of atraumatic restorative treatment (indications and stages).
41381995|NCT03184467|DRUG|Normal Saline 0.9%|Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
41381996|NCT03184467|DRUG|GV1001 0.56 mg|GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
40852344|NCT03100773|PROCEDURE|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment was performed using hand instruments for opening and cleaning the cavities and a high-viscosity glass-ionomer for restoration.
41035742|NCT02353793|DEVICE|ReadyHeat® blanket|Using ReadyHeat® blanket for patient warming
41035743|NCT02353793|DEVICE|Cotton wool blanket|Using cotton wool blanket for patient warming
41035744|NCT05234892|DEVICE|ALTO endograft implantation|Implantantion of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
41035745|NCT06259968|DEVICE|Neuromuscular electrical stimulation|Patients in the neuromuscular electrical stimulation group will receive neuromuscular electrical stimulation without the concomitant execution of voluntary quadriceps contraction
41381997|NCT03184467|DRUG|GV1001 1.12 mg|GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
41381998|NCT03431285|DRUG|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.
41381999|NCT03431285|DRUG|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration
40852345|NCT00006208|DRUG|Efavirenz|
40852346|NCT00006208|DRUG|Emtricitabine|
40852347|NCT00006208|DRUG|Stavudine|
41035746|NCT06259968|DEVICE|Neuromuscular electrical stimulation with superimposed voluntary contraction|Patients will be instructed to perform maximum voluntary contractions superimposed on neuromuscular electrical stimulation
41035747|NCT03624504|DEVICE|Micra Transcatheter Pacing System (TPS)|Treatment of subjects eligible for the single chamber ventricular pacemaker per study requirements
41035748|NCT01846130|DIETARY_SUPPLEMENT|Leucine|
41035749|NCT01846130|BEHAVIORAL|Exercise|
41035750|NCT01846130|DIETARY_SUPPLEMENT|Whey protein|
41035751|NCT06352853|OTHER|Skin incision in Cesarean Section by Diathermy|Skin incision by diathermy
41035752|NCT06352853|OTHER|Skin incision in Cesarean Section by Scalpel|Skin incision by scalpel
41035753|NCT04952324|OTHER|Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP|Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP
41165353|NCT03911908|COMBINATION_PRODUCT|Cerebral oximetry (near infrared) based CPR-Algorithm|If NIRS values do not increase over time until ROSC (target: \>40 % after 10 min), interventions are suggested in a modified CPR/NIRS algorithm.
41165354|NCT00329017|PROCEDURE|Fine needle aspiration|Fine needle aspiration
41382000|NCT03431285|OTHER|standard IV hydration|IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)
40852348|NCT00006208|DRUG|Didanosine|
40852349|NCT02639520|DRUG|Canephron® N|2 tablets 3 times a day for 7 days
40852350|NCT02639520|DRUG|Fosfomycin trometamol|1 sachet of 8 g of granules; one single dose on Day 1
40852351|NCT02639520|DRUG|Canephron® N-placebo|2 tablets 3 times a day for 7 days
40852352|NCT02639520|DRUG|Fosfomycin trometamol-placebo|1 sachet of 8 g of granules; one single dose on Day 1
40852353|NCT05252663|PROCEDURE|Quake device training|In Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds. The patient had the mouthpiece firmly sealed to the lips and were asked to inhale and exhale completely
40852354|NCT05252663|PROCEDURE|Traditional chest physiotherapy|postural drainage - percussion
40852355|NCT05747183|PROCEDURE|ProTaper Ultimate|Root canal preparation using ProTaper Ultimate files.
40852356|NCT05747183|PROCEDURE|ProTaper Gold|Root canal preparation using ProTaper Gold files.
40852357|NCT03180125|DRUG|Sodium Hyaluronate|median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound
40852358|NCT03180125|DEVICE|ultrasound|ultrasound guided injection
41382001|NCT01330407|PROCEDURE|cryopreserved skin allografts.|
41382002|NCT01330407|PROCEDURE|Cultured Epidermal Autografts|
41382003|NCT00357708|DRUG|decitabine|Given IV
41382004|NCT00357708|DRUG|vorinostat|Given orally
40852359|NCT03180125|DRUG|Sodium Hyaluronate and 1% lidocain|injection in the carpal tunnel
40852360|NCT03180125|DRUG|Corticosteroid and 1%lidocain|injection in the carpal tunnel
40852361|NCT04205721|BEHAVIORAL|School-based sexuality and HIV prevention scripted lesson plans|The revised life orientation content and implementation approach were designed to address gaps in prior implementation of the sexuality and HIV education content. By using scripted lesson plans and training teachers to use these, it was thought that students would get better information and lessons on the material important for HIV prevention.
40852362|NCT05191108|BEHAVIORAL|mindfulness stres reduction programe|Complaints about PMS and sharing information about these complaints, Practice of breathing focused meditation, mplementation of mindful eating exercises,Raising awareness in daily activities,Teaching the body scanning exercise and repeating this practice during the week with the audio recordings given.Ensuring environmental awareness Ensuring that you live by being aware of the moments experienced during the week, 20 minutes of sitting breathing focused sitting meditation Coping with stress Sharing the experiences of the previous week Implementation of mindful vision practices Explaining the relationship between stress and experienced events.Eating exercises Mindful breathing Ensuring environmental awareness Explaining the importance of thinking about the relationship between stress and their reactions and accepting them without judgment, and sharing the experiences at the end of the day of silence.
41035754|NCT04207723|OTHER|Transcutaneous posterior tibial nerve stimulation|Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.
41035755|NCT04207723|DRUG|Paroxetine|paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
41035756|NCT04383496|BEHAVIORAL|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
41035757|NCT05083091|BEHAVIORAL|Mindfulness and Attention Training|Guided mindfulness meditation with attention monitoring and acceptance skills training
41035758|NCT05083091|BEHAVIORAL|Mindfulness training|Guided mindfulness meditation, no attention monitoring or acceptance skills training
40852363|NCT04243733|OTHER|CEM and MTA|Pulpotomy agent
40852364|NCT04243733|OTHER|MTA and CEM|Pulpotomy agent
40852365|NCT04198077|DRUG|Oxygen|Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0
40852366|NCT01998308|DRUG|Crespine gel|50 Knees will have single injection of Crespine gel
40852367|NCT01998308|DRUG|Intragel|50 Knees will have single injection of 2 ampules of Intragel
40852368|NCT01998308|DRUG|Crespine plus gel|50 Knees will have single injection of Crespine Plus Gel
40852369|NCT01998308|DRUG|Monovisc|50 Knees will have single injection of Monovisc
41035759|NCT05083091|BEHAVIORAL|Coping Condition|Guided training focused on coping effectiveness strategies, no monitoring or acceptance instruction
41035760|NCT05321524|DRUG|OCA 0.1mg|Tablets administered orally once daily.
41035761|NCT05321524|DRUG|OCA 1.5mg|Tablets administered orally once daily.
41035762|NCT05321524|DRUG|OCA 5mg|Tablets administered orally once daily.
41382005|NCT00357708|OTHER|laboratory biomarker analysis|Correlative studies
41035763|NCT05996159|DEVICE|QDOT MicroTM catheter|Novel high power-short duration ablation catheter for atrial fibrillation
41035764|NCT05996159|DEVICE|AI-guided ablation only for PVI|Ablation is the removal or destruction of something from an object by vaporization, chipping, erosive processes, or by other means.
41035765|NCT04799015|DRUG|Dexamethasone|Dexamethasone 10mg IV
41035766|NCT04799015|DRUG|Metoclopramide 10mg|Metoclopramide 10mg IV
41382006|NCT00357708|OTHER|pharmacological study|Correlative studies
41035767|NCT04447404|DRUG|DUR-928|IV infusion
41035768|NCT04447404|DRUG|Placebo|IV infusion
41382007|NCT05732012|BEHAVIORAL|Sexual Health Psychoeducation Program|"62 adolescents were included in the study. Adolescents were assigned to intervention and control groups by randomization using simple numbers table. The intervention group was divided into 3 groups of 10 and included in a six-week psychoeducation program that lasted for one hour once a week, and 55 adolescents completed the program. The data on the sociodemographic characteristics of the adolescents constituting the sample were collected with the Participant Information Form. Data on the effectiveness of the psychoeducation program on sexual health knowledge and attitudes were collected with the Sexual Health Knowledge and Attitude Inventory before the psychoeducation, at the end of the training and at the 3rd month of follow-up."
41382008|NCT05560594|DEVICE|Coloplast SpeediCath CH12 standard male intermittent catheter|Drainage of the bladder through the urethra when using the SpeediCath standard male intermittent catheter.
41382009|NCT05056740|BIOLOGICAL|Data analysis|Analysis of the data from routine care at the end of the diagnostic work-up
41382010|NCT04028297|OTHER|Focus cardiac ultrasound (FoCUS)|
40852370|NCT00325390|DRUG|clopidogrel (SR25990C)|
40852371|NCT00005030|DRUG|SCH 66336|
40852372|NCT00005030|PROCEDURE|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
40852373|NCT01092052|DRUG|NMS-1116354|Oral daily administration for 14 consecutive days followed by 7 days of rest
40852374|NCT02820025|DRUG|doxapram|
40852375|NCT02820025|OTHER|saline|
40852376|NCT02712528|DRUG|remifentanil-based|
40852377|NCT02712528|DRUG|sevoflurane-sufentanil balanced|
40852378|NCT04530864|DRUG|Dextenza 0.4Mg Ophthalmic Insert|All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
40852379|NCT03394586|DRUG|Exposure to golimumab|retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
40852380|NCT03501940|PROCEDURE|Computed Tomography|Undergo 18F-DCFPyL PET/CT
40852381|NCT03501940|RADIATION|Fluorine F 18 DCFPyL|Given IV
40852382|NCT03501940|OTHER|Laboratory Biomarker Analysis|Correlative studies
40852383|NCT03501940|PROCEDURE|Positron Emission Tomography|Undergo 18F-DCFPyL PET/CT
40852384|NCT05407350|DIAGNOSTIC_TEST|Ultrasound, Colonoscopy, MRE|After the initiation of an established treatment of known efficacy for CD (biologic agents including infliximab, adalimumab, ustekinumab or vedolizumab either with or without corticosteroids), repeat IC and MRE will occur at Week 30 (± 6 weeks) (6-9 months); the IUS, IC, and MRE examinations will occur within a 4-week window and with no intervening change in medical therapy. All imaging data will be captured electronically (IUS and MRE with Digital Imaging and Communications in Medicine \[DICOM\] images, and IC with video recordings) for central, blinded reading. Two biopsies will be collected from each segment of the bowel (rectum, sigmoid, descending, transverse, ascending and terminal ileum) during IC, fixed in formalin collection containers, and shipped for histopathology processing and evaluation.
40852385|NCT04995861|PROCEDURE|Adductor canal block and IPACK block|Peripheral nerve blocks
40852386|NCT03392649|DEVICE|Parasym|Tragus stimulation was done using the Parasym device.
40852387|NCT05405101|PROCEDURE|Thermal ablation of aldosterone producing adenoma.|"On the left side, Radiofrequency ablation of aldosterone producing adenoma(s) will be undertaken via the stomach (endoscopically), under transgastric ultrasound guidance.~On the right side, either Radiofrequency or Microwave Ablation of aldosterone producing adenoma(s) will be performed via a percutaneous approach, under CT guidance."
40852388|NCT05405101|PROCEDURE|Unilateral adrenalectomy|Unilateral total adrenalectomy for aldosterone producing adenoma. This will be laparoscopic in the vast majority of patients, with open conversion if surgically indicated (unlikely in \>1-2 patients)
41035769|NCT06635161|DEVICE|Trancranial pulse stimulation (without a stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). No stand-off device will be used to target dorsal anteior cingulate cortex.
41165355|NCT00654615|DEVICE|Intramedullary Radius Fixation (Micronail)|After adequate anesthesia was obtained and the patient was prepared for surgery, distraction was applied to the fracture site and preliminary reduction of the distal radius fracture was performed under fluoroscopic guidance. A pin was inserted to maintain the fracture reduction, then the Micronail was inserted inside the radius. The metaphyseal defect created by the fracture was filled using allograft or autograft bone material. Limited incisions at either the radial or ulnar columns was performed to achieve acceptable reduction of the fracture. Radiographic parameters were used to evaluate the results of the surgical management with intramedullary nailing.
41165356|NCT00654615|PROCEDURE|Volar Plate Fixation|After adequate anesthesia, longitudinal traction of the wrist was applied. Based on the fracture pattern, fragments were reduced and stabilized using either one 2.4mm titanium pre-contoured locking plate or a combination of locking plates. Arthrotomy was performed to verify that the fracture fragments were reduced. Plates were contoured to fit boney contours as needed. Allograft or autograft was placed in the fracture repair site as necessary. Radiographic landmarks were evaluated. Care was taken to ensure that plates were covered with periosteum or retinaculum to reduce the incidence of possible soft tissue irritation caused by the plate on the bone. The skin incision was closed; a removable splint applied.
41165357|NCT06260241|PROCEDURE|Traction Dressing|Traction dressing will be applied to one group for 24 hours and simple dressing to the other group.
41165358|NCT06260241|OTHER|Without Traction Dressing|Without Traction Dressing
41165359|NCT02889783|OTHER|record of urethral pain sensation during urodynamics study|Record of pain using a VAS scale during the first catheterizing of urodynamics study, at every centimeter
41382011|NCT02566460|OTHER|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
41382012|NCT04513925|DRUG|Atezolizumab|Atezolizumab 1680 mg every 4 weeks (Q4W) will be administered IV on Day 1 of each 28-day cycle.
41382013|NCT04513925|DRUG|Tiragolumab|Tiragolumab 840 mg Q4W will be administered IV on Day 1 of each 28-day cycle.
40852389|NCT02403232|PROCEDURE|ASCs injection|"In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.~The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.~The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.~Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue."
41035770|NCT06635161|DEVICE|Transcranial pulse stimulation (with Neurology stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A Neurology stand-off device will be used to target the anterior insula cortex.
41035771|NCT06635161|DEVICE|Transcranial pulse stimulation (with a sham stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A sham stand-off device will be used to target vertex.
41035772|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
41165360|NCT01181219|PROCEDURE|CXL without epithelial removal|UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
41165361|NCT01181219|PROCEDURE|CXL with epithelial removal|UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
41382014|NCT04513925|DRUG|Durvalumab|Durvalumab will be administered based on weight at 10 mg/kg IV every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle, or will be administered at a fixed dose of 1500 mg IV every 4 weeks (Q4W) (for participants whose weight \>/= 30 kg) on Day 1 of each 28-day cycle.
41382015|NCT03469141|DEVICE|Pressure Relief Monitoring System|Biofeedback provided to the intervention group via the smartphone app will include: Visual (e.g., phone notification bar) and auditory reminders if PR (pressure relief) is not performed as scheduled, Real-time feedback during performance of PR maneuvers to ensure adequate PR (e.g., the app will indicate if the duration of PR is sufficient), and Aggregate counts of daily PR activity.
41382016|NCT06566391|DRUG|Ipilimumab|Nivolumab and Ipilimumab (sequential) for a total of four doses followed by Nivolumab
40852390|NCT02403232|DEVICE|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
40852391|NCT02403232|DEVICE|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
40852392|NCT05762406|DEVICE|Respiratory protective mask|"Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask.~During the exercises, oxygen consumption, ventilation and other cardiorespiratory parameters will be assessed using a portable device (K5, Cosmed)"
40852393|NCT05164614|COMBINATION_PRODUCT|RT-102 (80 μg)|RaniPill capsule containing PTH with doses of 20 and 80 μg
40852394|NCT05164614|DRUG|Forteo|A commercial formulation of PTH for SC control (20 µg)
40852395|NCT05164614|COMBINATION_PRODUCT|RT-102 (20 μg)|RaniPill capsule containing PTH with dose of 20μg
40852396|NCT04222660|DIETARY_SUPPLEMENT|Blackmores Omega Daily (4 1g capsules per day)|Subjects enrolled in phase two of the study will be instructed to take 4 capsules per day (2 in the morning and 2 in the evening). Each capsule contains 1000 mg of triglyceride; 35% eicosapentaenoic acid and 25% docosahexaenoic acid.
40852397|NCT04918732|DIAGNOSTIC_TEST|FibroScan|The FibroScan device developed by Echosens (France) measures the liver stifness and steatosis based on a pulse of sound waves that goes through the liver.
40852398|NCT05339126|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
40852399|NCT05845853|OTHER|scapular PNF technique|"PNF Technique is based on movement patterns to facilitate and correct sensory-motor function,then correct the impaired impulses emerging from proprioceptive receptors in the muscle. Therefore, it decreases pain and improve the strength of muscles.~PNF position renders a greater amount of sensory input coming from the periphery than that in the neutral position ."
40852400|NCT05607862|OTHER|Home Physiotherapy Group|The intervention group will receive 2 sessions per week for 8 weeks supervised and assisted by a physiotherapist at the patient's home. Muscle strengthening exercises of the lower and upper limbs, stretching, coordination and balance exercises, gait re-education with the relevant technical aids, a pattern of exercises to be performed daily by the patient and health education guidelines will be carried out.
40852401|NCT05607862|OTHER|Control Group|The control group will be given health education guidelines and will continue with their usual medical-pharmacological treatment. All patients included in this study will receive physiotherapy treatment, and those in the control group will be treated once the intervention and the post-intervention assessment have been completed.
40852402|NCT03485170|DIAGNOSTIC_TEST|18F-FDG PET/CT|glucose analogue fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography scan
41035773|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
41035774|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
41035775|NCT00760864|DRUG|Methotrexate|TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
41035776|NCT02870790|DRUG|TDF/FTC|one pill daily
40852403|NCT03656991|OTHER|Bicycle intervention|
40852404|NCT01518842|BIOLOGICAL|Intravitreal Bone Marrow Stem Cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
41035777|NCT04883671|OTHER|Standard of Care|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
41035778|NCT04883671|RADIATION|SBRT|SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer
41035779|NCT04298593|DEVICE|Cardiostat|This is a prospective observational study including patients accepted by the heart team for a TAVI procedure. There will be no restriction regarding the type of valve and approach used for the TAVI procedure. Following the TAVI procedure, the patients will be under telemetry until hospital discharge and, at hospital discharge, they will be monitorized up to 4 more weeks using the CardioSTAT® device.
41035780|NCT05300724|OTHER|No intervention|No intervention will be administered in this study.
41035781|NCT01643694|BEHAVIORAL|Electronic intervention suggesting behavioral activity|3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
41035782|NCT06073574|DIAGNOSTIC_TEST|Cardiac MRI|MRI Scans as specified in the corresponding arm group.
41035783|NCT05080400|DIETARY_SUPPLEMENT|White rice|Jasmine rice 179g of cooked weight
41035784|NCT05080400|DIETARY_SUPPLEMENT|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
41035785|NCT04383912|DRUG|Botox Injectable Product|The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
41165362|NCT04590950|OTHER|Non interventional study|Non interventional study
41165363|NCT05132088|DRUG|semaglutide 50 mg|"Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg."
41165364|NCT05132088|DRUG|placebo (semaglutide)|Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
41382017|NCT03976817|PROCEDURE|aortic valve replacement|After median sternotomy, cardiopulmonary bypass (CPB) was established between the ascending aorta and the right atrium. The aorta was cross-clamped and a high potassium warm cardioplegia was infused and repeated every 15 minutes. The aortotomy was made above the sinuses and the aortic valve was removed. The prosthesis was chosen one size larger than the maximal sizer that could be inserted, which was also used to determine the appropriate height for insertion of the sutures along the wall of the non-coronary sinus.
41382018|NCT01294709|DRUG|telcagepant|
41382019|NCT01294709|DRUG|Placebo to telcagepant|
41382020|NCT01948011|DRUG|Racecadotril suspension|Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
41382021|NCT01948011|DRUG|Racecadotril granules|Racecadotril granules at 60mg. Single oral dose.
40852405|NCT06445816|DRUG|chemotherapy|"* Parents whose consent was obtained will be asked to fill out the Mother and Child Information Collection Form and Psychological Resilience Scale, respectively.~* Immediately after receiving chemotherapy, the pain levels of the children will be measured with the Facial Expressions Pain Scale - Faces Pain Scale-Revised (FPS-R).~* The psychological resilience scale will be applied to mothers."
40852406|NCT05740332|DRUG|Alcohol hand sanitizer foam|"1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)"
40852407|NCT00187447|DRUG|indomethacin (two different dosing regimens)|
40852408|NCT01618006|DRUG|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
41382022|NCT02830646|OTHER|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC.
40852409|NCT01618006|DRUG|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
40852410|NCT01618006|DRUG|Aspirin|Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
40852411|NCT05175742|BIOLOGICAL|PTX-COVID19-B|Sterile solution for injection
40852412|NCT05175742|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Sterile solution for injection
41035786|NCT04383912|OTHER|No intervention (placebo)|This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.
41382023|NCT06064110|BEHAVIORAL|Pictou County Person Empowerment Program|The 6 month home-based program focuses on aerobic and strength training, meditation/relaxation techniques, social connection, and overall healthy lifestyle practices supported with daily email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily, the meditation/relaxation practice is 10 minutes daily, the intimacy and connection component consists of engaging in at least one form of intimacy practice prescribed, per day. Optional social connection components will be offered, such as pairing participants up with peers from the study, monthly Zoom videoconferences, and monthly in-person events in Pictou County to further promote healthy lifestyle habits.
41382024|NCT05589246|DEVICE|regional analgesia with cryolesia|The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves
41382025|NCT03372265|DRUG|Ropivacaine 0.2%|Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
41382026|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
41382027|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
41382028|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
41508254|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
41035787|NCT06534632|OTHER|Mother's colostrum|Oropharyngeal administration of mother's colostrum
41035788|NCT06534632|OTHER|Placebo|Oropharyngeal administration of sterile water
40852413|NCT05175742|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
40852414|NCT03682913|BEHAVIORAL|P-CIT protocol|Personalized inhibitory control training for one week.
40852415|NCT03682913|BEHAVIORAL|Placebo|without personalized inhibitory control training for one week.
40852416|NCT03120715|DRUG|estrogen|The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.
41035789|NCT01691300|OTHER|ACT PET/CT|Old tracer but new indication
41165365|NCT01625949|PROCEDURE|Intracoronary stem cells injection|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
40852417|NCT03120715|DRUG|Low Molecular Weight Heparin|If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
40852418|NCT03120715|DRUG|hCG|If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
40852419|NCT03120715|DRUG|progesterone|on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
41165366|NCT01625949|PROCEDURE|coronary dilatation and stenting|coronary dilatation and stenting
41035790|NCT06328647|DEVICE|POC Quantra QPlus System|The POC Quantra QPlus System will be located in the operating room. Samples will be processed by trained (certified for POC testing) personnel and interpreted by the primary anesthesia team. The anesthesia team will perform a baseline hemostatic assessment , approximately 15 min prior to separation from CPB, and again 10-20 min following protamine administration using the Quantra POC hemostasis monitor. If persistent bleeding occurs despite clinical management, coagulation will be rechecked by a repeated Quantra assessment and treated as necessary. A Quantra device will be placed in the ICU for assessment for the first 6 hours following surgery.
41382029|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
41382030|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
41382031|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
41382032|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
41382033|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
41382034|NCT01939834|DEVICE|Overnight CLC|Overnight Closed-Loop Control (CLC) is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the CLC and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.
41382035|NCT01939834|DEVICE|Sensor-Augmented Pump Therapy (SAP)|The subject will be on their home insulin pump (UVA) or study pump (Italy) and using a CGM per their usual care.
41382036|NCT04547712|DEVICE|Adaptive DBS|Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS
41508255|NCT05015686|BIOLOGICAL|Placebo|Sodium chloride and distilled water
41035791|NCT06328647|OTHER|Routine care|Blood and blood component transfusions will be determined by provider preference based on clinical findings. The anesthesia caregiver will perform laboratory testing for coagulation management at his/her discretion. Usual laboratory testing may include assessment of TEG with heparinase, platelet count, fibrinogen concentration at approximately 30-40 min prior to separation from cardiopulmonary bypass. Another set of laboratory tests may be sent post-CPB including TEG, platelet count, fibrinogen concentration, PT/aPTT, INR. Anesthesia caregiver will treat clinical bleeding and coagulopathy at his/her discretion.
41035792|NCT06635018|OTHER|Resting conditions|The volunteer's hands are at rest and PI readings are taken for six minutes. After two minutes, there is always a randomized rotation of the sensors between the fingers.
41035793|NCT06635018|OTHER|Movement artifacts|The volunteer periodically spreads his/her fingers and clenches them into a fist, and PI readings are taken for six minutes. After two minutes there is always a randomized rotation of sensors between the fingers.
41035794|NCT06635018|OTHER|Circulation constriction|The volunteer's arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize, the sensors are randomly rotated, and the measurement is repeated.
41035795|NCT04310826|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary magnesium intervention
41035796|NCT04310826|OTHER|Media Intervention|Undergo video interviews
41035797|NCT04310826|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls
41035798|NCT05523167|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
41035799|NCT05523167|OTHER|PBO|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
41035800|NCT00290823|DRUG|Albendazole|400 mg tablet taken orally twice daily
41508256|NCT00862732|BEHAVIORAL|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
40852420|NCT04260945|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
41035801|NCT00290823|DRUG|Dexamethasone|6mg or 8mg taken daily
41035802|NCT00290823|DRUG|Omeprazole|20 mg tablet taken orally daily
41035803|NCT06635083|OTHER|Telerehabilitation|A video conference software system will be installed on the subjects' laptops or tablets. Then, via video conference, strengthening/stretching exercises and breathing exercises will be performed for the areas affected by the deformity with the physiotherapist three times a week.
41165367|NCT05664230|OTHER|osteopathy|five osteopathy sessions
41382037|NCT00489008|PROCEDURE|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
40852421|NCT04225793|DRUG|Eziklen®|"The Eziclen solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure."
41382038|NCT06425718|PROCEDURE|Postoperative Pain Management Technique|Patients who will undergo cesarean section under spinal anesthesia will be included. Comparing postoperative pain and opioid consumption in groups
40852422|NCT04225793|DRUG|MoviPrep|"The Moviprep® solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Moviprep® solution should be completed at least 2 hours and no later than 4 hours before the procedure."
40852423|NCT06471075|BEHAVIORAL|Mindful Pain Management|The mindfulness intervention will involve a 2-minute introduction to mindfulness as a technique for pain management followed by a 5-minute, audio-guided, mindful breathing practice.
40852424|NCT06471075|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be provided timematched information about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
40852425|NCT00856297|BIOLOGICAL|MenACWY-CRM conjugate vaccine|
40852426|NCT00856297|BIOLOGICAL|Licensed comparator|
40852427|NCT04255303|OTHER|Integrated clinical prediction rule (iCPR) system (iCPR)|"The iCPR tool consists of an electronic calculator that can be used to determine whether the patient is at low, intermediate or high risk for having the diagnosis and a bundled order set (called a Smartset). The iCPR tool will be made available directly within the Electronic Health Record (EHR) for Registered Nurses (RNs) who are seeing patients fall into the study categories. The iCPR tool through the use of order sets will guide the RN in the patient's care. The order set for patients at low risk for these diseases will recommend supportive care including over the counter cold remedies and pain relievers. The order set for patients at intermediate or high risk of these disease will recommend diagnostic tests (rapid strep antigen or CXR) to help determine if they have the disease. Based on the results of the diagnostic tests new order sets will recommend antibiotics or supportive care"
40852428|NCT03238833|OTHER|luteal ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.
40852429|NCT03238833|OTHER|follicular ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.
40852430|NCT00715767|BEHAVIORAL|Assessment|"Cognitive Assessment:~Knowledge base and critical thinking will be evaluated by a 50-question BLS multiple-choice examination. At the designated 4 cognitive assessments in the study (pre-course, immediately post course, 3 months and 6 months) 50 equivalent questions will be used to cover all core BLS objectives. Technical Skills Assessment:~Primary outcome measures of adequacy of chest compressions and ventilations as well as key actions for each of the 3standardized basic life support skill tests during 3-minute testing scenarios. Video review by 2independent experts will be utilized for objective assessment of time and order dependent skills, and manikin output will be utilized to assess qualitative effectiveness of skills (adequate ventilation, compression, and defibrillation).~Survey Instrument for Barriers to Acute Medicine Education:~A survey tool will be used to identify barriers to acute medicine education implementation and efficacy."
40852431|NCT05641636|DIAGNOSTIC_TEST|12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis|Echocardiography - standart protocol. Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH). CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance.
41035804|NCT02907333|BEHAVIORAL|Advice to use condoms|
41035805|NCT00716872|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|"SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive Cores of information. As they progress through the program, users receive tailored instructions for how to improve their sleep."
41035806|NCT00716872|BEHAVIORAL|Hypnosis recordings|Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.
41035807|NCT04134260|DRUG|Apalutamide|Given PO
41035808|NCT04134260|DRUG|Hormone Therapy|Receive hormone therapy
41382039|NCT00819091|DRUG|BI 1356|5mg orally (po) tablet qd
41382040|NCT00819091|DRUG|Placebo|Placebo matching BI 1356 5mg one tablet daily
41035809|NCT04134260|OTHER|Quality-of-Life Assessment|Ancillary studies
41035810|NCT04134260|OTHER|Questionnaire Administration|Ancillary studies
41035811|NCT04134260|RADIATION|Radiation Therapy|Undergo pelvis and prostate bed radiation therapy
41035812|NCT03710915|DRUG|HG146|HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.
41382041|NCT05665816|DEVICE|Stent PULSAR® -18 T3,|"Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and/or popliteal artery, primarily as salvage, in a population of patients residing in Spain and in real life conditions."
41382042|NCT05898009|GENETIC|blood sample for BRCA2 mutation detection|blood sample
41508257|NCT00862732|OTHER|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
41035813|NCT02535208|OTHER|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR \< 0.73.
40852432|NCT05566561|DRUG|Postoperative analgesia management|Intravenous 0.5 mg/kg tramadol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, and 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
40852433|NCT06334666|OTHER|Encourage using pedometer|MASLD patient used pedometer recording actively with encourage by care provider or investigator
41035814|NCT02535208|OTHER|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
41382043|NCT06255275|OTHER|neurocognitifs tests + pedestrian crossign whith virtual reality|Neurocognitive tests (attention, executive functions, reaction to difficulty). Assessment of anxiety and impulsivity + pedestrian crossign with virtual reality + post-crossing questionnaire
41382044|NCT03622775|BIOLOGICAL|Daratumumab|Given IV
40852434|NCT03691571|DEVICE|Esophageal Cooling|The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.
41035815|NCT06429020|BIOLOGICAL|the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine.|record the condition of vaccination
41382045|NCT00080925|BIOLOGICAL|filgrastim|
41165368|NCT04755023|DRUG|Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide|Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
41382046|NCT00080925|BIOLOGICAL|graft-versus-tumor induction therapy|
40852435|NCT03691571|DEVICE|Control|Standard of care involves standard temperature probe monitoring.
40852436|NCT01250041|PROCEDURE|continuous femoral nerve block|ultrasound guided femoral nerve catheter insertion.
41382047|NCT00080925|BIOLOGICAL|rituximab|
41382048|NCT00080925|BIOLOGICAL|therapeutic allogeneic lymphocytes|
41382049|NCT00080925|DRUG|cyclophosphamide|
40852437|NCT01250041|PROCEDURE|continuous saphenous nerve block|ultrasound guided saphenous nerve catheter insertion
41382050|NCT00080925|DRUG|cyclosporine|
41382051|NCT00080925|DRUG|cytarabine|
41382052|NCT00080925|DRUG|doxorubicin hydrochloride|
40852438|NCT01849419|DRUG|Within-subjects (MDMA)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received a single dose of MDMA (0.75, 1.5 mg/kg) on two session, oxytocin (20 IU) as an active control on one session (see second Intervention), and placebo one session (see third intervention).
40852439|NCT01849419|DRUG|Within-subjects (oxytocin)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received oxytocin (20 IU) on one session, MDMA on two sessions (see first Intervention), and placebo on one session (see third Intervention).
40852440|NCT01849419|DRUG|Within-subjects (placebo)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
40852441|NCT06410456|OTHER|Exercise therapy|Schroth exercises
40852442|NCT01800136|DEVICE|Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
41035816|NCT05278273|DEVICE|NeurotrackerX|At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group.
41035817|NCT02270450|PROCEDURE|therapeutic conventional surgery|Undergo abdominal surgery
41035818|NCT02270450|PROCEDURE|gastrointestinal complications management/prevention|Undergo non-surgical management
40852443|NCT01964638|PROCEDURE|Targeted Biopsy|
41035819|NCT02270450|OTHER|quality-of-life assessment|Ancillary studies
41165369|NCT06010550|RADIATION|Magnetic resonance imaging|Brain magnetic resonance imaging
41382053|NCT00080925|DRUG|etoposide|
41382054|NCT00080925|DRUG|fludarabine phosphate|
41382055|NCT00080925|DRUG|prednisone|
41382056|NCT00080925|DRUG|vincristine sulfate|
41382057|NCT00080925|PROCEDURE|peripheral blood stem cell transplantation|
41382058|NCT04513873|DEVICE|Equipment to divert the focus of children|The equipment was placed in an area where the children would be able to see easily during the blood collection process. It was turned on as soon as the children sat on to the chair where the process would take place to divert the focus of the children at the equipment.
41382059|NCT01102881|DIETARY_SUPPLEMENT|Glucose polymer fiber|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
41382060|NCT01102881|DIETARY_SUPPLEMENT|Fiber made from corn starch|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
41382061|NCT01102881|DIETARY_SUPPLEMENT|placebo|low fiber breakfast cereal and muffin
41382062|NCT04916067|DEVICE|Mesh Implantation|Implantation of Phasix™ Soft Mesh - a knitted monofilament mesh scaffold using Poly-4-hydroxybutyrate (P4HB), a biologically derived material - to prevent hernia formation
41382063|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in Magdeburg|intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
41382064|NCT02460861|PROCEDURE|RPVE|Open Radical prostatovesiculectomy in Magdeburg
41382065|NCT02460861|PROCEDURE|ETRARP|Robotassisted Radical prostatovesiculectomy in Gronau
41382066|NCT02460861|PROCEDURE|CE|Open cystectomy in Magdeburg/Gronau
41382067|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in gronau|intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
41035820|NCT05035901|OTHER|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
41035821|NCT01628276|BEHAVIORAL|Cog Rehab|Cognitive rehab for MS patients
40852444|NCT06584123|DIAGNOSTIC_TEST|18F-Fluoro-ethyl-tyrosine (FET) PET|18F-Fluoro-ethyl-tyrosine PET study of the pituitary
41165370|NCT05062837|DRUG|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
41165371|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 1|"On the intervention day, the volunteers will consume the Quinoa Variety 1.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
41165372|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 2|"On the intervention day, the volunteers will consume the Quinoa Variety 2.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
41165373|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 3|"On the intervention day, the volunteers will consume the Quinoa Variety 3.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
41165374|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 4|"On the intervention day, the volunteers will consume the Quinoa Variety 4.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
41165375|NCT02621502|DIETARY_SUPPLEMENT|Anhydrous Glucose|"On the intervention day, the volunteers will consume the control product.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
40852445|NCT02564224|PROCEDURE|Pursestring Wound Closure|Procedure: Pursestring Wound Closure
41035822|NCT02941783|DRUG|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)|Treatment parameters following the physician's decision based on the summary of product characteristics.
41035823|NCT03447782|DRUG|Naltrexone HCl (Bulk) Powder|For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder
41035824|NCT03576547|DRUG|Dexamethasone|Given PO or IV
41165376|NCT05300997|DIAGNOSTIC_TEST|Biomarker blood draw and saliva collection|Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)
41165377|NCT05867550|DRUG|Rifaximin 550 MG|Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
41165378|NCT05867550|DRUG|Mebeverine 135 MG|Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
41165379|NCT05867550|DRUG|Psyllium Husk|Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
41165380|NCT05867550|DRUG|Amitriptyline Hydrochloride 25 MG|Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
41165381|NCT00698555|BIOLOGICAL|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
41165382|NCT00698555|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
41165383|NCT03361618|DIETARY_SUPPLEMENT|Zinc Sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
41165384|NCT01171183|DRUG|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
41165385|NCT01171183|DRUG|Placebo|Placebo
41382068|NCT02822612|DEVICE|Binocular OCT prototype|Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
40852446|NCT02564224|PROCEDURE|Conventional Wound Closure|Procedure: Conventional Wound Closure
40852447|NCT02564224|DEVICE|prolene|
41035825|NCT03576547|DRUG|Ponatinib Hydrochloride|Given PO
41035826|NCT03576547|BIOLOGICAL|Rituximab|Given IV
41382069|NCT00120380|DRUG|Aerosolized iloprost|
41382070|NCT00120380|DRUG|Placebo|
41382071|NCT05401773|OTHER|Real-time Quaking-Induced Conversion (RT-QuIC)|RT-QuIC is increasingly used as diagnostic tools in synucleinopathies and has shown high sensitivity and specificity for the detection of α-synuclein seeds in CSF and tissue samples, including the olfactory mucosa in different patients' cohorts including Parkinson's patientients, patients with REM sleep behavior disorder (RBD), and patients with dementia with Lewy bodies.
41382072|NCT06242977|DRUG|Eutectic mixture of local anesthetics (EMLA; Astra Pharmaceutical Products Inc., Westborough, MA)|The intervention is the utilization of EMLA cream, a topical anesthetic to determine if this reduces pain with local anesthesia infiltration, and for overall procedural pain
41035827|NCT03576547|DRUG|Venetoclax|Given PO
41035828|NCT06419374|BIOLOGICAL|Pegozafermin|Subcutaneous injection
41035829|NCT06419374|DRUG|Placebo|Subcutaneous injection
41035830|NCT04458948|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg BID, on day 1 and then 200 mg BID day 2 through 7 IV or po for 5 days. If the condition of the patient does not allow for oral therapy, HCQ can be given via a feeding or NG tube. Azithromycin can be given intravenously.
41035831|NCT04458948|DRUG|Azithromycin|Azithromycin 500 mg, IV or po for 5 days
41382073|NCT06242977|OTHER|Control cream|This intervention will be for the control group, a simple lotion cream.
40852448|NCT03536507|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
40852449|NCT03536507|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
40852450|NCT05049109|BEHAVIORAL|Integrated Telehealth After Stroke Care|"• 3 week and 8 week follow up visits with pharmacy through telehealth~Patients will provide home blood pressure monitoring kits at discharge for the first three months. The telemonitor that can send blood pressure readings, wirelessly or through telephone, to a secure server where study staff can look at the readings. Any blood pressure readings that are not within normal range will trigger an alert to be sent to study staff who will then follow up with the patient. A trained staff member will show the patient how to use the blood pressure monitor. Patients will be asked to take blood pressure at least 3 days per week and transmit the readings to study staff.~Patients will also be asked to wear an activity monitor starting at 4 weeks."
40852451|NCT05049109|BEHAVIORAL|Usual post-stroke follow-up care|"* 1-2 weeks follow up visit with primary care.~* 4-6 week and 12 week follow up visit with stroke practitioner~* At the end of the study, patients will be asked questions regarding their experience with the telehealth visits, health, medication taking and quality of life"
40852452|NCT01984918|OTHER|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
40852453|NCT01984918|OTHER|Non-SMS reminder|No Stext message reminder via Short Message Service (SMS) will be sent
40852454|NCT02146001|OTHER|Reducing sedentary behavior group|This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
40852455|NCT02146001|OTHER|Moderate-to-vigorous activity group|This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
40852456|NCT02966561|BEHAVIORAL|Pedometer-based activity promotion|"The central components of the 2 x 45 minutes lasting pedometer-based physical activity behaviour change intervention BCI are the following behaviour change techniques (BCTs):~* Instruction on how, where and when to perform the behaviour~* Prompt goal setting for physical activity~* Prompt self-monitoring of behaviour~* Feedback on behaviour. Participants receive a pedometer and a booklet with a physical activity diary and associated information on the importance of goal setting and keeping a physical activity diary, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
41382074|NCT06474260|BEHAVIORAL|"One All Intervention"|"One-all is a Three-year curriculum targeted at specific outcomes for each yearfacilitated by young people from the community. The facilitators are inducted througha rigorous facilitators programme of three to five months' length. The facilitators areencouraged to adapt the program to their needs and provide the programme incustomized forms appropriate and as required for the communities. The interventionhas thus far been provided to the fishermen communities in Chennai and anecdotalfield evidence suggest, gains in the intended goals. After these experiences theintervention was being tried amongst the tribal adolescents in Gudalur. One-alltargets to provide the undermentioned skills to achieve the mentioned Goals andSkills:~* self-management • understanding feelings~* social awareness • conflict resolution~* relationship skills • empathy building~* self-awareness Skills •nurturing interpersonal relationships~* identity building • awareness about gender stereotypes"
41382075|NCT02181634|DRUG|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
41382076|NCT06565767|OTHER|cardiopulmonary resuscitation quality|variability in compression depth among different age groups, taking into account physical attributes, through an active learning approach and game-based learning framework
41382077|NCT02765958|DEVICE|portable ECG devise|
41382078|NCT00692198|DRUG|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
41382079|NCT03299088|BIOLOGICAL|Pembrolizumab|Given IV
41035832|NCT04729855|DIAGNOSTIC_TEST|PBMCs and Tissue expression of HOTTIP ,EIF4EBP1 and serum SNP HOTTIP rs1859168|5 ml fresh blood sample, normal and CRC tissue
41035833|NCT04686903|PROCEDURE|Epiduroscopy treatment|Device Epiduroscop, procedure mecahnical lysis, laser, radiofrequency + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline) Follow-up: before procedure, 6 months and 12 months after procedure
41035834|NCT04686903|PROCEDURE|Racz catheter epidural procedure|"Device Racz catheter, two procedures during clinical trial observation~* First procedure after enrolment into the study mechanical lysis and drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 6 months mechanical lysis + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)"
41382080|NCT03299088|DRUG|Trametinib|Given PO
41382081|NCT05888649|BEHAVIORAL|Community Clusters|Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
41382082|NCT00568516|DRUG|ASP3550|subcutaneous administration
41382083|NCT04259307|DRUG|Omapone Peri 724mL or Winuf Peri 654mL|Additional intravenous nutrition of 500 kcal per day for 3 weeks
41383580|NCT06172361|DRUG|Prednisone|Prednisone 15mg (or equivalent dose of methylprednisolone) was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-10 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 6-8 weeks. Once relapse occurred, the dose increased to the pre-relapse dose. If reducing pred dosage is difficult, Methotrexate (MTX) 10mg qw can be added after 24 weeks.
40852457|NCT02966561|BEHAVIORAL|Short patient education and exercise|"The central components of the 2 x 45 minutes lasting intervention are revisions of knowledge of the pulmonary rehabilitation (standard care) in combination with related exercises:~* Revision of knowledge on exercise recommendations~* Revision of knowledge on possibilities of self-regulation of endurance training exercise intensity with the rate of perceived exertion (BORG-Scale)~* Revision of self-regulation of endurance exercise intensity~* Revision of strengthening activities consistent with the exercise recommendations.~Participants receive a booklet with information on the rate of perceived exertion, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
40852458|NCT02966561|OTHER|Pulmonary rehabilitation (Standard care)|Standard care is an in-patient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention based on a patient assessment followed by a combination of patient-tailored therapies. PR lasts on average 25 days. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current COPD-guidelines; physical training (4-5 units/week endurance training \[45 min\] and 3 units/week of strength training \[45 min\] per week, 7 units/week whole body vibration muscle training/week); structured COPD-patient education (6 hours patient education COPD + 1 hour device training); respiratory physiotherapy in groups \[2-4 units/week with 45 min\]. PR is implemented by an interdisciplinary rehabilitation team.
40852459|NCT02335593|DIETARY_SUPPLEMENT|Zinc Sulphate|Zinc Sulphate Hard Gel capsules 110mg
40852460|NCT02335593|OTHER|Corn Starch filled Hard Gel Capsules|Corn Starch filled Hard Gel Capsules
40852461|NCT02335593|DRUG|Epoetin alfa 2000-4000 IU solution for injection|Epoetin alfa 2000-4000 IU solution for injection
41382084|NCT06398561|BEHAVIORAL|Active Patient Program|"The Active Patient Program is a peer-leader intervention that consist of training patients with a chronic disease or mental health illness for improve the symptoms of that pathology.~Training is carried out in groups of about 12-15 patients and usually has 2 patient trainers. These patients lead the sessions through the theoretical content they have integrated, motivation, group leadership, exchange of experiences and promotion of communication. In this way they favor problem-solving by the patients who attend the sessions, thus improving their self-management and self-efficacy.~In the group formed by patients who are trainers and patients who benefit from the sessions, a climate of trust is created that favors the expression of emotions on both sides, empathy and assertiveness. In addition to fostering socio-affective bonds between the participants and increasing perceived social and emotional support."
40852462|NCT02335593|DRUG|Iron Hydroxide Saccharate Complex Solution for injection|Iron Hydroxide Saccharate Complex Solution for injection
40852463|NCT03242356|OTHER|Questionnaire to assess of the application of the current French guidelines as to fasting during labor.|"Questionnaire focuses on :~* oral intake of clear fluid during the labor~* oral intake of solid meal during the labor~* fasting duration for solid and liquids~* instruction received as to fasting during labor, nature of these instructions, and who given the instruction (midwife, nurse anesthetist, ...)~* discomfort related to thirst during labor~* discomfort related to hunger during labor~We will also record several medical data as to the course of pregnancy and delivery, analgesia technique, history and characteristics of the parturient."
40852464|NCT00349778|DRUG|Cyclophosphamide|Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in \~250 mL of saline or D5W and infused IV over 2 hours
40852465|NCT00349778|DRUG|Etoposide|100 mg etoposide as 5 mL solution in clear ampules for injection.
40852466|NCT00349778|DRUG|Melphalan|Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
40852467|NCT00349778|DRUG|Carmustine|Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
40852468|NCT00349778|DRUG|Filgrastim|Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
40852469|NCT03227666|BEHAVIORAL|Exercise|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
41165386|NCT01228305|OTHER|Acetaminophen|Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children \>=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
41382085|NCT00000705|DRUG|Zidovudine|
41382086|NCT06567067|DEVICE|Pulsenmore ES home ultrasound|Fetal Ultrasound scanning using Pulsenmore ES device followed with an interview by a human factoring researched
41382087|NCT06545019|BEHAVIORAL|Informative Video on Perioperative Anxiety and Maternal Satisfaction|An informative video designed to address potential sources of perioperative anxiety and dissatisfaction during elective lower segment caesarean section under spinal anaesthesia. The video provides details about the procedure, expected sensations, and management of discomfort to enhance patient understanding and reduce anxiety. It is administered to the intervention group of patients scheduled for elective caesarean section, allowing them to view it on their personal devices before the surgery.
41382088|NCT01906931|DEVICE|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
41382089|NCT01906931|DEVICE|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
41382090|NCT04572737|BEHAVIORAL|Activity plan to break up sitting time|This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.
41382091|NCT03367949|OTHER|Surgical guide designed from Impression inversion with markers|Rather than using optical scan of the cast , We will use impression inversion technique with VPS impression and adding CBCT Markers on the tray
41382092|NCT06505213|OTHER|no intervention|no intervention
41382093|NCT02651974|BEHAVIORAL|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
41382094|NCT02651974|BEHAVIORAL|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
41035835|NCT04686903|PROCEDURE|Caudal epidural block|"Technique Caudal epidural block~Three procedures during clinical trial observation :~* First procedure after enrolment into the study drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 4 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)~* Third procedure after 8 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)"
41035836|NCT03690505|BEHAVIORAL|Interviews|informant-based questionnaire semi-structured individual interviews focus group interviews
41035837|NCT02937246|DEVICE|SEMS(self-expandable metallic stent)|Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
41035838|NCT02937246|DEVICE|Stenting by ERCP (endoscopic retrograde cholangiopancreatography)|
41382095|NCT02651974|BEHAVIORAL|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
41382096|NCT04070534|OTHER|PALS|patient activated learning system
41382097|NCT01764594|BIOLOGICAL|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
41508258|NCT04060095|PROCEDURE|standardized noxious stimulus under general anesthesia.|"50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient."
41508259|NCT04770675|DIAGNOSTIC_TEST|Bronchoscopy|All subjects who are scheduled for a bronchoscopy may be eligible.
41035839|NCT01579123|PROCEDURE|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
41165387|NCT05917548|DEVICE|Teledentistry oral health promotion|Educational videos specially designed and validated for elderly (duration 4 to 6 minutes each one)
41382098|NCT01764594|OTHER|Placebo|Placebo comparator
40852470|NCT04131075|PROCEDURE|Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)|Coronary Angiography according to clinical indication and Multimodal Coronary Physiology Study (FFR, CFR, HMR) for functional assessment of intermediate coronary lesions
41382099|NCT02844088|OTHER|Meningococcus C conjugate vaccine|
40852471|NCT02239952|DRUG|Sunitinib|50 mg once daily, oral use for 14 days
40852472|NCT02239952|DRUG|vandetanib|300 mg, once daily, oral use for 14 days
40852473|NCT02239952|DRUG|Erlotinib|150 mg, once daily, oral use for 14 days
40852474|NCT01716780|OTHER|Intervention|"Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care"
41035840|NCT01579123|PROCEDURE|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
41165388|NCT05917548|BEHAVIORAL|Face-to-Face oral health promotion|Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
41165389|NCT01209741|DRUG|telcagepant potassium|\[INTERVENTION NAME: MK-0974 12MoRT\] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
41382100|NCT04769830|OTHER|Bowel sound|The characteristic data of bowel sounds, such as 24-hour average intestinal rate, duration of gastrointestinal sounds, amplitude, maximum frequency and average frequency, were collected to observe the differences of intestinal sounds among different AGI grades.
41382101|NCT04434235|OTHER|axial load|With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine
41382102|NCT02316743|DRUG|Levothyroxine supplementation|T4 supplementation for heart failure patients with subclinical hypothyroidism.
41382103|NCT02187939|OTHER|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
41382104|NCT02591173|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
41165390|NCT01209741|DRUG|MK-0974 5Mo5C|Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
41165391|NCT01209741|DRUG|MK-0974 12Mo5C|Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
41165392|NCT05579665|BIOLOGICAL|Platelet-rich Plasma|Research participants own blood will be used to prepare the platelet rich plasma injectate.
41382105|NCT02591173|DRUG|Saline|Normal saline will be used as the placebo comparator.
41165393|NCT05579665|BIOLOGICAL|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome|Conditioned Medium UC-MSCs Secretome which will be injected into the affected knee using ultrasound guidance.
41165394|NCT05579665|DRUG|Low Molecular Weight Hyaluronic Acid|low molecular weight hyaluronic acid which will be injected into the affected knee using ultrasound guidance.
41382106|NCT04163991|DRUG|VIB4920|liquid for IV infusion following dilution in normal saline
41382107|NCT04163991|DRUG|Placebo|0.9% saline for IV infusion
41165395|NCT03000647|PROCEDURE|Pelvic floor exercises guided by a physiotherapist|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)
40852475|NCT03954262|BEHAVIORAL|observation of propofol ANS response|received an induction bolus or TCI infusion of propofol
40852476|NCT02296255|BIOLOGICAL|Cervarix®, GlaxoSmithKline|3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
40852477|NCT00453804|DRUG|injectable naltrexone|
41382108|NCT02141373|DEVICE|Glubran 2|
41382109|NCT05473546|OTHER|ARTIFICIAL NUTRITION|ARTIFICIAL NUTRITION
41382110|NCT06536569|DEVICE|Internal limiting membrane (ILM) Peeling with Sharkskin Forceps|25g Grieshaber Sharkskin ILM Forceps with Reflex Handle
41382111|NCT06536569|DEVICE|Internal limiting membrane (ILM) Peeling with Standard Forceps|25g Grieshaber Standard ILM Forceps
41382112|NCT03965507|OTHER|Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation|
40852478|NCT00453804|DRUG|oral naltrexone|
40852479|NCT04316676|DIAGNOSTIC_TEST|PET-MPI Protocol|Patients with suspected CAD who are referred to a clinical PET-MPI will undergo the standard clinical protocol applied in the Emory Nuclear Medicine department.
41165396|NCT03000647|PROCEDURE|Non guided pelvic floor exercises|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
41165397|NCT00333281|DRUG|tadalafil|
41165398|NCT01522677|DRUG|PDT with 5-ALA radiosensitization|Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
41165399|NCT00056329|DRUG|Vitamin E|1,000 international units twice daily for three years
40852480|NCT04316676|DIAGNOSTIC_TEST|CT-MPI|"For the CT-MPI, dynamic volume CT myocardial perfusion applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium. The dynamic shuttle mode consists of an image acquisition during rapid, yet smooth back-and-forth movement of the CT scanner table, so that contrast media bolus passage can be evaluated within the entire left ventricle in a time-resolved fashion. This scan acquisition will be performed during pharmacologically induced stress and during rest conditions. CT-MPI studies will be contrast medium enhanced by 50-70 ml of iodinated contrast agent, administered at a flow rate of 5 mL/s."
40852481|NCT04316676|DIAGNOSTIC_TEST|CT-FFR|Coronary CT angiography (CCTA) will be performed for delineation of the coronary arteries, detection of potential coronary stenosis and FFR calculation. CCTA will be performed at rest following administration of intravenous contrast agent (50-70 mL of iodinated contrast material at a flow rate of 4-5 mL/s). A total radiation dose of approximately 8 millisievert (mSv) has expected to be administered with the stress/rest protocol to the patient. The total amount of contrast agent will not exceed 140 ml.
40852482|NCT04316676|DRUG|Regadenoson|Pharmacological stress testing for the CT-MPI scan will be performed with a single injection of 0.4 mg of regadenoson (Lexiscan).
40852483|NCT06578117|DEVICE|Vision Training and Learning Task|"Participants will be seated at a computer, and will be shown a random-noise visual stimulus drifting in one of eight directions. Participants will be instructed to indicate the direction of motion they perceive using a Sony Access Controller or a computer keyboard. Sound cues during stimulus presentation will also be used to ensure participants are aware of stimulus onset during the training task.~After several repetitions of this visual training, a second set of visual cues will be presented to evaluate participant's learning of the program. Responses will be provided in the same manner by input from the controller or the keyboard."
41035841|NCT06100497|DRUG|Pembrolizumab|Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment
41035842|NCT06100497|DRUG|Cisplatin|Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy
41035843|NCT06100497|DRUG|Paclitaxel-albumin|Mainly used for neoadjuvant treatment
41035844|NCT05168774|DRUG|Elamipretide|Elamipretide is a tetra peptide with limited blood brain barrier penetration being developed for use in a variety of mitochondrial disorders, including FRDA, mitochondrial myopathy and Barth Syndrome.
41035845|NCT03961165|DRUG|Butylscopolamine Bromide 20 MG/ML|1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
41165400|NCT00056329|DRUG|multivitamin|once daily for three years
41382113|NCT03039686|DRUG|RO7239361|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
41382114|NCT03039686|DRUG|Placebo for RO7239361|Take placebo subcutaneously on specified days over a 48 week blinded period
41382115|NCT02030509|OTHER|Quick diagnosis program|
41382116|NCT03361332|OTHER|Behavioral and fMRI|Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.
41035846|NCT03961165|DRUG|Sodium Chloride 9mg/mL|1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
41382117|NCT03059940|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
41382118|NCT03059940|PROCEDURE|Low Dose Computed Tomography Scan|Participants have a CT scan of chest to look for signs of lung cancer.
41382119|NCT03059940|OTHER|Shared Decision Making + Video|Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
41508260|NCT03043404|DEVICE|Transcatheter aortic valve replacement|TAVR with Lotus Valve Flex System
41508261|NCT03633097|OTHER|Acupuncture and Usual care|patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy
41508262|NCT03633097|DRUG|Usual care|patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
41508263|NCT02018991|PROCEDURE|Everolimus-Eluting Stent (EES)|Patients treated with EES
41508264|NCT02018991|PROCEDURE|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
41508265|NCT02018991|PROCEDURE|Biolimus-Eluting-Stent (BES)|Patients treated with BES
41508266|NCT04420273|BEHAVIORAL|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
41508267|NCT04420273|BEHAVIORAL|Active control:Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
41508268|NCT03035929|DRUG|Dexamethasone|A single dose of dexamethasone IV 4 mg will be administered.
41508269|NCT02813941|OTHER|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
41508270|NCT02813941|OTHER|Alternative GRADE SoF table|The alternative GRADE SoF table format will be developed from a user-testing survey.
40852484|NCT05545839|BEHAVIORAL|Transition coaching|Transition coaching sessions (8 sessions), covering paediatric to adult care, self-advocacy, medication management, general health, lifestyle and behaviours, future planning, screening for mood disorders and coping skills.
40852485|NCT06584019|OTHER|Range Of Motion applied group|Range Of Motion was applied once a day for approximately 20 minutes for 5 days.
40852486|NCT06399237|DEVICE|Foot Orthoses|Three types of foot orthoses (FO), Prefabricated FO, Custom FO, Custom with a 5° varus FO
40852487|NCT02819687|DRUG|RDX5791|
40852488|NCT02819687|DRUG|Placebo|
40852489|NCT04924998|DRUG|current treatment of AL-CM|current treatment of AL-CM
40852490|NCT00214058|DRUG|Carboplatin|
40852491|NCT00214058|DRUG|Docetaxel|
41508271|NCT02813941|OTHER|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published
41508272|NCT06365528|PROCEDURE|Subcutaneous tunnelling|The Subcutaneous tunnelling group will undergo PICC placement under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe and place with additional subcutaneous tunnelling. After vein puncture with the access needle, a Nitinol guidewire will be placed as usual. We will make a tunnel distal to the initial venepuncture site using an additional 14-gauge needle. After resolution of the loop over the venepuncture site, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction plus the subcutaneous tunnel before being inserted in the usual manner.
41508273|NCT06365528|PROCEDURE|Non-tunnelling|The Non-tunnelling group will have PICC placement with the traditional method under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe. After vein puncture with the access needle, a Nitinol guidewire will be placed. After, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction.
41508274|NCT01651793|OTHER|Caffeinated cocoa|70 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
41508275|NCT01651793|OTHER|Cocoa|21 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
41508276|NCT01651793|OTHER|Caffeine|473 ml brewed water containing 66 mg caffeine, caramel coloring and one packet Truvia sweetener
41508277|NCT01651793|OTHER|Placebo|473 ml of brewed water, caramel coloring and one packet Truvia sweetener
40852492|NCT02679170|DRUG|Crizotinib|Treatment with crizotinib following routine clinical practice
40852493|NCT02567565|OTHER|LipiView|tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
40852494|NCT03858374|DEVICE|transferred by air-suspending mattress|Put mattress in advance on the bed. When patients need to be transferred from bed to bed, fill the mattress with gas and keep it inflated, then pull the mattress .
40852495|NCT03858374|DEVICE|transferred by slide board|When patients need to be transferred from bed to bed, insert slide board under patient, then pull the slide board.
40852496|NCT03858374|DEVICE|transferred by bedsheet|When patients need to be transferred from bed to bed, just lift the bedsheet.
40852497|NCT05020210|DRUG|Sivelestat sodium|Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
40852498|NCT01387464|DRUG|ISV-303|0.075% bromfenac in DuraSite dosed QD
40852499|NCT01387464|DRUG|Bromday™|0.09% bromfenac dosed QD
41165401|NCT00056329|DRUG|Placebo|Placebo twice daily for three years
41165402|NCT02412111|DRUG|Ivacaftor|
41382120|NCT03059940|BEHAVIORAL|Cessation Counseling|Brief cessation counseling given by LDCT provider.
40852500|NCT03226470|BIOLOGICAL|T512|T512 suppository contain 500 µg of T512 and suppocire.
41165403|NCT02412111|DRUG|Tezacaftor/Ivacaftor|
41165404|NCT01130714|BEHAVIORAL|Exercise|Resistance training with resistance bands.
41165405|NCT02154347|DRUG|KAD-1229|
41382121|NCT03059940|BEHAVIORAL|Quitline|Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
40852501|NCT06333366|DEVICE|Intra-gastrointestinal monitoring device (PDT)|The PressureDOT(PDT) is an active intra-gastrointestinal device, that is intended to be introduced in the gastrointestinal tract, approximately along whole. The device is battery powered. The signal is wirelessly transmitted through outside the body and received by waist receiver, using an antenna array applied to the skin with a protection guard at the level of the abdomen.
40852502|NCT02748395|DRUG|Triamcinolone|
41382122|NCT03059940|BEHAVIORAL|Pharmacotherapy Discussion|Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
41035847|NCT03823118|DRUG|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
41382123|NCT03059940|DRUG|Nicotine Patch|Nicotine patch dispensed. Dosing at physician's discretion.
41382124|NCT03059940|DRUG|Anti-Smoking Drug|Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
41382125|NCT03059940|BEHAVIORAL|Tobacco Treatment Program|Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
41382126|NCT03059940|OTHER|Carbon Monoxide (CO) Level Test|Participant asked to blow air through a CO-measuring device.
41382127|NCT06019533|COMBINATION_PRODUCT|LVDS|Levonorgestrel Vaginal Delivery System
41382128|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
41382129|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
41382130|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
41382131|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
41382132|NCT05816304|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)|Digital CBTi is a computer-based cognitive behavioral therapy that provides strategies to improve sleep and daytime function (concentration, productivity) and decreases symptoms of sleep-related attributions, night-time thought content in individuals with insomnia. It is easily accessible with any internet-connected device, eg, computer, tabs, and smartphones.
41382133|NCT05303727|DRUG|Anti Thymocyte Globulin|2.5 mg/kg/day；2 doses on day -3 and day -2 for matched sibling donor transplantation；3 doses on day -4，-3 and day -2 for unrelated donor transplantation；4 doses on day -5，-4，-3 and day -2 for haploidentical donor transplantation
40852503|NCT02748395|OTHER|Placebo|
40852504|NCT02748395|DRUG|Lidocaine|
40852505|NCT00793169|PROCEDURE|Blood Draw|Serum levels were measured
40852506|NCT01022099|PROCEDURE|Implantation of a Total Knee Arthroplasty|"In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides."
40852507|NCT06191172|BEHAVIORAL|Reminiscence Therapy|Old objects and pictures of old objects that facilitate remembering about weekly topics will be taken to the institution by the researcher, and individuals within the scope of the research will be asked for their own photographs, if any.
40852508|NCT06191172|BEHAVIORAL|Montessori application|Drill toy Matching puzzle Chickpeas, rice sorting Lock, zipper Counting beans Making a tie Taking and pouring food with a scoop
40852509|NCT06191172|BEHAVIORAL|Environmental Layout|Dining place Music Lighting Heat
40852510|NCT06191172|BEHAVIORAL|Application of contrast ergonomic special equipment|White tablecloth Beveled red blue and yellow blue plate Ergonomic yellow and red fork, spoon and cup
40852511|NCT02422849|OTHER|hospital specialist|
40852512|NCT02422849|OTHER|General Practitioner|
41035848|NCT02639702|DRUG|Clozapine|Switching from twice-daily to once-daily clozapine dosing regimen
41035849|NCT01953926|DRUG|Neratinib|240 mg administered orally, once daily with food, continuously in 28 day cycles
41035850|NCT01953926|DRUG|Fulvestrant|500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
41035851|NCT01953926|DRUG|Trastuzumab|Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter
41035852|NCT01953926|DRUG|Paclitaxel|80mg/m\^2 administered IV on Days 1, 8, and 15 of every 4 week cycle
41035853|NCT05016882|DRUG|NNC0194 0499 50 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
41165406|NCT02154347|DRUG|Placebo|
41165407|NCT02154347|DRUG|Insulin|
41382134|NCT05303727|DRUG|Fludarabine|30 mg/m2/day for 5 days
41382135|NCT05303727|DRUG|Cyclophosphamide injection|60 mg/kg/day for 2 days in cord blood stem cell transplantation
41382136|NCT05303727|DRUG|Topotecan|2mg/m2/day for 3 days in cord blood stem cell transplantation
41382137|NCT05303727|DRUG|Melphalan|70mg/m2/day，for peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation；2 doses on day -3 and day -2 when conditioning regimen containing thiotepa；3 doses on day -4，-3 and day -2 when conditioning regimen not containing thiotepa；
41382138|NCT05303727|DRUG|Thiotepa|5 mg/kg/day for 2 days in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation
41382139|NCT05303727|DRUG|Busulfan|0.8mg/kg/dose；8 doses in cord blood stem cell transplantation；12 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen containing thiotepa；16 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen not containing thiotepa；
41382140|NCT05303727|DRUG|Cyclosporine|2.5\~4 mg/kg/dose every 12 hours orally；1.5\~2 mg /kg/dose every 12 hours intravenously; trough concentration maintained at 150\~250ng/ml
41382141|NCT05303727|DRUG|Tacrolimus|0.02\~0.03 mg/kg/day as continuous infusion or 12 hour divided doses
41382142|NCT05303727|DRUG|Mycophenolate Mofetil|15 mg/kg/dose every 12 hours
41382143|NCT05303727|DRUG|Methotrexate|15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
41035854|NCT05016882|DRUG|Placebo (NNC0194-0499)|Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
41382144|NCT02511873|DRUG|Fycompa|Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
41382145|NCT02511873|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
41382146|NCT01013402|DRUG|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
41382147|NCT01013402|DRUG|Human Insulin|0.1U/kg IV pulse.
41382148|NCT01071083|DRUG|natalizumab|300 mg intravenous every 4 weeks
40852513|NCT04887753|OTHER|Synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations.
40852514|NCT05037617|DRUG|Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).|"At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be \>= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation."
40852515|NCT01620814|DRUG|Dinoprostone|
40852516|NCT01620814|DRUG|misoprostol|
40852517|NCT01620814|DRUG|control|
40852518|NCT01984996|DEVICE|Freedom ProFlor Inguinal Hernia Implant|
41035855|NCT05016882|DRUG|Semaglutide 3 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
41035856|NCT05016882|DRUG|Semaglutide placebo|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
41035857|NCT05016882|DRUG|NNC0174 0833 10 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
41165408|NCT05345847|OTHER|Active Surveillance|Close monitoring of liver enzymes with steroid rescue strategy (watch and wait approach)
41165409|NCT05345847|OTHER|Early initiation|Immediate start of high-dose steroids
41165410|NCT03144778|BIOLOGICAL|Durvalumab|Given IV
41382149|NCT01071083|DRUG|interferon beta 1-a|30 ug intramuscular once per week
41382150|NCT01071083|DRUG|methylprednisolone|1000 mg intravenous every 4 weeks
41382151|NCT01071083|OTHER|IV placebo|placebo intravenous every 4 weeks
41382152|NCT01071083|DRUG|glatiramer acetate|20 mg subcutaneous once daily
41382153|NCT05393791|OTHER|Patient-specific adaptive therapy|Patients will start taking abiraterone or enzalutamide (AA/ENZ) daily. PSA will be measured every month as well as radiological evaluation by CT-scan and bone scan. Treatment will be continued until PSA has dropped \>50%. The treatment will then be paused. Once the PSA has risen again above the pretreatment baseline, treatment will be re-initiated. AA/ENZ will be stopped again after the PSA declines \>50% from the baseline. This will be continued until criteria for treatment failure are met (death by any cause or at least 2 out of 3 of the following events while on treatment: radiographic progression on CT-scan and/or bone scan, PSA progression or clinical progression).
41035858|NCT05016882|DRUG|NNC0174 0833 placebo|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
41035859|NCT06635213|OTHER|Desensitisation|This technique is utilized to decrease, or normalize, the body's response to particular sensations.
41165411|NCT03144778|BIOLOGICAL|Tremelimumab|Given IV
41382154|NCT05393791|DRUG|Abiraterone acetate|Use of abiraterone or enzalutamide
41382155|NCT05393791|DRUG|Enzalutamide|Use of abiraterone or enzalutamide
41382156|NCT04504097|BEHAVIORAL|m-Health|Participants receive a weekly bidirectional text message (SMS) asking how they are doing. They are requested to reply fine, or not fine, in which case they will be contacted with support by a peer navigator. If they do not reply to the message within the specified timeframe a peer navigator will follow up with them.
41382157|NCT04504097|DIAGNOSTIC_TEST|HIV self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
41382158|NCT00836238|BEHAVIORAL|Interview|Physical Function and Symptom Assessment Interviews
41382159|NCT00836238|OTHER|Physical Function Tests|3 physical function tests.
40852519|NCT05374551|OTHER|Transcranial magnetic stimulation|Transcranial magnetic stimulation will be used to stimulate brain activity in a brain region of experimental interest (lateral parietal cortex) and in a control brain region (vertex). All participants will experience both forms of stimulation, in separate sessions. Stimulation will be applied as a probe to understand the basic phenomenon of how brain processes support episodic memory.
40852520|NCT02513472|DRUG|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m\^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
41035860|NCT06635213|OTHER|Pain neuroscience education|PNE is an educational intervention aiming to alter a patient's beliefs and cognitions regarding their pain experience.
41165412|NCT01085812|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
41165413|NCT01085812|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily.
41382160|NCT04338256|BEHAVIORAL|Wellness and Resilience for College and Beyond (Undergraduate College Course)|"The course, Wellness and Resilience for College and Beyond was originally developed by James Mazza, PhD and colleagues at the University of Washington as a 10-week course. The course developers adapted their course materials to fit the needs of a 16-week semester for the purpose of this study. The Wellness Course teaches students evidence-based skills for improving mental health from dialectical behavior therapy, acceptance and commitment therapy, and the field of positive psychology. Classes meet for 2.5 hours weekly with approximately half of class time spent on teaching new content (lecture) and the other half spent with students working in small groups on practice and discussion exercises."
41382161|NCT04117048|DEVICE|LabPad® point-of-care|All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
41382162|NCT01132170|DRUG|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
41382163|NCT01876082|DRUG|PAZOPANIB treatment|"Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum"
41382164|NCT01876082|DRUG|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
41382165|NCT03869905|DRUG|Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
41382166|NCT03869905|DRUG|Placebo first then Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening
41382167|NCT01591499|DEVICE|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
41382168|NCT01591499|DEVICE|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
41382169|NCT03192332|DEVICE|Stent-retriever thrombectomy with revascularization device of the Solitaire™ type|Mechanical thrombectomy with a stent-retriever revascularization device
41035861|NCT06365580|DRUG|Kylo-0603 capsule|Administrated orally.
41035862|NCT06365580|DRUG|Placebo|Administrated orally.
41035863|NCT05617716|RADIATION|Conventional external beam radiation therapy dose (EBRT)|Participants will undergo 8 Gray in 1 fraction of EBRT
41382170|NCT03192332|DRUG|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)|Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
41035864|NCT05617716|RADIATION|Spine radiosurgery/stereotactic body radiation therapy standard dose|Participants will undergo 24 Gray in 2 fractions of SBRT
41035865|NCT05617716|RADIATION|Spine radiosurgery/stereotactic body radiation therapy high dose|Participants will undergo 19 Gray in 1 fraction of SBRT
41165414|NCT04314570|PROCEDURE|Saphenous Nerve Block with Ropivacaine Treatment|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive ropivacaine through the catheter from the start of the nerve block.
41035866|NCT02052505|PROCEDURE|Medication review|The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
41035867|NCT03401970|BEHAVIORAL|Acellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
41165415|NCT04314570|PROCEDURE|Saphenous Nerve Block with Saline Control|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
41165416|NCT04653064|BEHAVIORAL|Placebo Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic.
41165417|NCT04653064|BEHAVIORAL|Control Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as one of no effect.
41165418|NCT06120114|PROCEDURE|Modified percutaneous internal ring suturing|Laparoscopically guided percutaneous high ligation of indirect inguinal hernia in adults
41165419|NCT06279299|PROCEDURE|lateral pelvic lymph node dissection|Following the total mesorectal excision principle, the rectum and mesentery are removed, with careful protection of the pelvic autonomic nerves. After completing laparoscopic rectal resection, lateral lymph node dissection is performed. The lateral dissection follows these steps: ① Open the peritoneum at the bifurcation of the iliac vessels, dissect along the retroperitoneum adjacent to the ureter-bladder fascia, expose the lateral pelvic area, and carefully protect the ureter and hypogastric nerves. Open the peritoneum along the edge of the external iliac vessels close to the inguinal ligament, clear the lymphatic fatty tissue alongside the external iliac vessels along the edge of the iliopsoas and internal oblique muscles; ② After identifying the hypogastric nerve, dissect along the bladder-bladder fascia, separate the bladder and the fat tissue around the lateral pelvic space, completely remove the lymphatic tissue around the internal iliac vessels and hypogastric nerves.
41165420|NCT01208870|BEHAVIORAL|Variety Group|The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.
41165421|NCT01208870|BEHAVIORAL|Nutrition Education Control|The intervention will consist of our traditional family based weight control intervention.
41165422|NCT03577925|DIAGNOSTIC_TEST|HPV genotype test|HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.
41165423|NCT00487552|DEVICE|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
41165424|NCT03383809|DIETARY_SUPPLEMENT|Strawberry juice with Inulin|Mixture of polyphenols and non digestible carbohydrates
41165425|NCT03383809|DIETARY_SUPPLEMENT|Strawberry Juice|Source of Polyphenols
41165426|NCT03383809|DIETARY_SUPPLEMENT|Inulin|Source of non digestible carbohydrate
41165427|NCT00159549|BEHAVIORAL|education and training program|
41165428|NCT03503487|OTHER|3D informed consent|Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)
41165429|NCT01612767|DEVICE|PRO-Kinetic Energy Stent|Coronary artery stent implant
41165430|NCT04767802|DRUG|PTG-300|Hepcidin mimetic
41382171|NCT01436942|BEHAVIORAL|Exercise|"The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.~A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.~Dose: 12 weeks. Three times a week, 60 minutes."
41382172|NCT02766959|OTHER|Observational study|
41382173|NCT04946474|DRUG|Xingnaojing injection + Shuxuetong oral liquid|Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
41382174|NCT05939713|DEVICE|Cera™ VSD occluder implantation|To collect data from patients who have implanted with the device before 2022.
41382175|NCT01506570|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10\^3 plaque-forming unit \[PFU\] of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
41382176|NCT01506570|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV005|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
41382177|NCT01506570|BIOLOGICAL|Placebo|One SC injection at Day 0 and Day 180 of placebo
41383581|NCT01501071|DEVICE|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
41165431|NCT00001234|GENETIC|human glucocerebrosidase cDNA|
41165432|NCT01171300|OTHER|18F- FDG PET scans|We aim to investigate the value of FGD-PET for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
41165433|NCT01171300|OTHER|DW-MRI scans|We aim to investigate the value of DW-MRI for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
41382178|NCT02705417|PROCEDURE|preoperative color Doppler ultrasonographic vascular mapping|Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
41382179|NCT02705417|PROCEDURE|physical examination|Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
41382180|NCT02705417|PROCEDURE|medical history|medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease
41382181|NCT02705417|PROCEDURE|native arteriovenous fistula construction|surgigal creation of native arterial and venous anastomoses
41382182|NCT02705417|PROCEDURE|arteriovenous graft placement|surgical placement of arteriovenous graft
41382183|NCT06128200|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
41035868|NCT03401970|BEHAVIORAL|Cellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
41035869|NCT03401970|BEHAVIORAL|Low-carbohydrate high-fat diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
41035870|NCT04084808|DIETARY_SUPPLEMENT|Solution ingestion|Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
41035871|NCT04084808|BEHAVIORAL|Cognitive flexibility|"Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise."
41035872|NCT04084808|PROCEDURE|Brain oxygenation|"Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~\[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). \] Measured with near-infrared spectroscopy (NIRS)."
41035873|NCT04084808|OTHER|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
41035874|NCT04084808|PROCEDURE|Blood glucose|Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
41035875|NCT04084808|BEHAVIORAL|Perceived exertion|Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, \& Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
41035876|NCT04084808|BEHAVIORAL|High Intensity Interval Training bouts|6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
41382184|NCT06128200|DEVICE|Sham NEUROMARK System|Sham ablation procedure using the NEUROMARK System
41382185|NCT06358859|OTHER|Food is Medicine|Regularly distributed fruit and vegetable produce boxes and nutrition education materials.
41382186|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in first three days
41382187|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in first three days
41382188|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in second three days
41382189|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in second three days
41382190|NCT02392975|PROCEDURE|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
41508278|NCT01096797|DRUG|Sevoflurane|"* Anaesthesia induction: sevoflurane 4 to 6% by mask and IV propofol 2-6 mg/kg.~* Anaesthesia maintenance: sevoflurane 2-3 %~* Intraoperative and postoperative analgesia: IV fentanyl 1,5-2,5 mcg/kg, IV paracetamol 15 mg/kg~* Prevention of postoperative nausea and vomiting: dexamethasone 0,1 mg/kg, ondansetron 0,1 mg/kg"
41508279|NCT05810688|OTHER|eating rehabilitation training|The experimental group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education.
41382191|NCT02392975|PROCEDURE|Computed Tomography|The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
41508280|NCT00171951|DRUG|Pasireotide|Pasireotide 600 μg or 900 μg was administered as an SC injection.
41508281|NCT05963815|OTHER|Spine surgery|Patients operated with laminectomy, microscopic discectomy, percutaneous transforaminal endoscopic discectomy, and spondylodesis.
41508282|NCT00036361|DRUG|Aripiprazole|
41508283|NCT00167284|BEHAVIORAL|physician and patient education; physician practice redesign|
40852521|NCT02513472|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
40852522|NCT05014685|DRUG|Rabeprazole|20mg bid
41382192|NCT04434209|DEVICE|Subject management guided by NephroCheck® test|NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
41508284|NCT00967850|DRUG|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
41382193|NCT04434209|OTHER|Standard of Care|Standard of Care patient management
41382194|NCT00127296|DEVICE|FlexPen®|
40852523|NCT05014685|DRUG|Bismuth potassium citrate|0.6g bid
40852524|NCT05014685|DRUG|Metronidazole|0.4g tid
41382195|NCT00127296|DEVICE|vial and syringe|
40852525|NCT05014685|DRUG|Amoxicillin|1g tid
41382196|NCT02512991|OTHER|Helicopter Emergency Medical Service|May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
41382197|NCT02051673|BIOLOGICAL|Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
41508285|NCT00967850|DRUG|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
41508286|NCT05601466|DRUG|QN-023a|NK cell therapy
41508287|NCT05601466|DRUG|Cyclophosphamid|Lympho-conditioning Agent
41508288|NCT05601466|DRUG|Fludarabine|Lympho-conditioning Agent
41508289|NCT05601466|DRUG|Cytarabine|Lympho-conditioning Agent
41508290|NCT03777163|BIOLOGICAL|Butantan Institute Trivalent Seasonal Influenza Vaccine|Butantan Institute and Pasteur-Mérieux (present, Sanofi Pasteur) established a technology transfer in 1999 for the production of a trivalent influenza vaccine of inactivated split-virion using embryonated eggs. The technology transfer followed a progressive approach from importing the finished product, to packaging and quality control test for release (1999), and, finally, to the first batch of influenza vaccine entirely produced by Butantan (2011). In 2013, the Butantan vaccine was registered by the Brazilian National Agency of Sanitary Surveillance (ANVISA).
41508291|NCT03777163|BIOLOGICAL|Sanofi Trivalent Seasonal Influenza Vaccine|VAXIGRIP® was launched in 1968 and since then has been licensed in more than 100 countries and prequalified by WHO in 2011. Several clinical studies by Sanofi Pasteur have examined the safety and immunogenicity of Vaxigrip® in older children (8-10 years), adults (18-59 years), elderly (\> 60 years),11,12 children (six months to three years) 13 and pregnant women.
41508292|NCT01625988|DRUG|LY2951742|
41508293|NCT01625988|DRUG|Placebo|
40852526|NCT00048347|DRUG|AVONEX|30µg IM every week for 12 weeks
40852527|NCT03240770|DEVICE|VPro5 device|Use of the VPro5 device for 5 minutes a day
40852528|NCT03240770|OTHER|Deviation from Standard Tray Wear Time (14 Days)|Patients reduced Tray Wear Time Interval (14 Days)
40852529|NCT05693792|OTHER|Observational|No treatment regimen will be deployed in this follow-up study.
40852530|NCT03458650|DRUG|LXI-15028 50mg|In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
40852531|NCT03458650|DRUG|LXI-15028 100mg|100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
41382198|NCT00606996|BEHAVIORAL|Group interpersonal psychotherapy (IPT-G)|
41382199|NCT00606996|BEHAVIORAL|Psychoeducation on co-occurring disorders (PSYCHOED)|
41382200|NCT03147040|DRUG|Carboplatin|Chemotherapy treatment with carboplatin and atezolizumab
41382201|NCT03147040|DRUG|Atezolizumab|Chemotherapy treatment with carboplatin and atezolizumab
41382202|NCT06015711|DRUG|Maxigesic administration|Preoperative Maxigesic IV administration
41382203|NCT00339066|DRUG|Sertraline|
41508294|NCT01930201|PROCEDURE|Caudal epidural block|
41508295|NCT01930201|OTHER|General anesthesia|
41508296|NCT04604340|PROCEDURE|transradial access for neuroangiography|The choice of right vs left radial artery approach would be determined by the vessels that require the highest quality of imaging (e.g. if the left vertebral artery is key to diagnosis, a left radial approach would be chosen, otherwise a right radial approach would be likely most appropriate) - this decision is at the discretion of the interventionist.
41382204|NCT04657978|PROCEDURE|Substrate guided left atrial ablation|Ablation therapy targeting areas of low voltage, which may include encirclement, homogenization or targeting of abnormal electrograms and anchored to a non-conducting structure if the region is in close proximity or likely to create an isthmus for arrhythmias.
41382205|NCT01003470|OTHER|acupuncture|Xing Nao Kai Qiao Acupuncture
41382206|NCT01003470|BEHAVIORAL|rehabilitation|Kinesitherapy
41382207|NCT01003470|OTHER|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
41382208|NCT06082609|PROCEDURE|Removable partial denture|All patients will receive Removable partial denture by two different impression techniques
41382209|NCT02186470|RADIATION|accelerated partial breast irradiation|Undergo image-guided intensity-modulated APBI
41382210|NCT02186470|RADIATION|intensity-modulated radiation therapy|Undergo image-guided intensity-modulated APBI
41382211|NCT02186470|RADIATION|image-guided radiation therapy|Undergo image-guided intensity-modulated APBI
41382212|NCT02186470|PROCEDURE|therapeutic conventional surgery|Lumpectomy
41382213|NCT06147609|DEVICE|lower lingual holding arch space maintainer|lower lingual holding arch space maintainer is an orthodontic device which connects two molars lower dental arch. it has an archwire, adapted to the lingual side of the lower anterior teeth, that soldered to the bands on first permanent molar
41382214|NCT06147609|DEVICE|Removable partial denture space maintainer|Removable Partial Denture consists of a pink or gum-colored plastic base to which the new, artificial, replacement teeth are attached to. a metal framework holds the denture in place inside the mouth
41382215|NCT06536868|DRUG|Tislelizumab|Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).
41382216|NCT06536868|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).
41382217|NCT06536868|DRUG|Carboplatin or Cisplatin|Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).
41382218|NCT06536868|RADIATION|Thoracic radiotherapy|IMRT 30-45Gy/10-15f
41382219|NCT03992456|BIOLOGICAL|Panitumumab|Given IV
41382220|NCT03992456|OTHER|Quality-of-Life Assessment|Ancillary studies
41382221|NCT03992456|OTHER|Questionnaire Administration|Ancillary studies
41382222|NCT03992456|DRUG|Regorafenib|Given PO
41382223|NCT03992456|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
40852532|NCT03458650|DRUG|LXI-15028 200mg|single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
41382224|NCT05425823|OTHER|Health Belief Model Based Intervention|In intervention group-1, Information Form and PAVS-HBM will be applied as a pre-test to pregnant women who have completed their 28th gestational week. Childhood Vaccination Training Based on the Health Belief Model will be given in the prenatal period by organizing 2 face-to-face and individual sessions for the researcher's pregnant women. Each session will take approximately 30-45 minutes, with each session being in a different week. In addition, at the end of each session, HBM-based short messages will be sent to the pregnant woman's husband and recorded with the Short Message Tracking Form. Intervention group-2 will receive the same training, but no text messages will be sent.
41382225|NCT01556464|DEVICE|Auto-adjusting CPAP|A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
41382226|NCT05167396|DEVICE|Retinaute (BioSerenity)|Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards
41382227|NCT05167396|DEVICE|EEG Headset 64 electrodes (BioSemi)|EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals
41382228|NCT05167396|DEVICE|MonPackOne (Metrovision)|"Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards~WARNING : Device used only in 3 healthy controls to address the secondary objective"
41508297|NCT04604340|PROCEDURE|transfemoral access for neuroangiography|By convention, femoral access will be obtained on the right side, unless there is overlying disease or vessel abnormality detected by ultrasound/Doppler, as is usual clinical practice.
41382229|NCT02290782|RADIATION|Intraoperative radiotherapy (IORT)|"The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.~To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm."
41382230|NCT00061958|DRUG|arsenic trioxide|Given IV
41382231|NCT02515981|BEHAVIORAL|NH Medicaid Incentives Program|
40852533|NCT03458650|DRUG|Placebo|matching placebo tablets
41382232|NCT03392415|PROCEDURE|CTO PCI|attempted percutaneous coronary intervention of the chronic total coronary occlusion
41382233|NCT01411475|OTHER|Bifurcation restenosis classification|Classification of restenosis involving coronary bifurcation according to their pattern
41382234|NCT06146543|OTHER|Stress ball|Before the procedure begins, the patient's free hand will be given an elastic ball that is large enough to hold in the palm of the hand and squeeze easily. He/she will be asked to squeeze this ball slowly throughout the process. At the end of the procedure, the ball will be removed from his hand and the patient will be relieved.
41035877|NCT06331429|BEHAVIORAL|EmoTiCare|"The EMOTICARE technological platform intervenes in users through a serious game, i.e. a video game whose main purpose is to teach or provide the player with certain skills that serve to achieve a higher purpose than the game itself.~The game works in 6 areas, each of which refers to one of the variables that are analysed or considered important in the adaptation to the disease: Area 1. Psychoeducation of DM1; 2. Emotional awareness and expression; 3. Emotional regulation; 4. Problem solving; 5. Self-esteem and identity;6. Social skills and communication"
41382235|NCT04757675|DRUG|S-ketamine 0.3|0.3 μg/kg intravenous injection s-ketamin
41382236|NCT04757675|DRUG|S-ketamine 0.5|0.5 μg/kg intravenous injection s-ketamin
41382237|NCT04757675|DRUG|S-ketamine 2|2 μg/kg intranasal s-ketamin
41508298|NCT03924687|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) bibliotherapy for chronic pain|"The intervention consisted of the book Libérez-vous de la douleur par la méditation et l'ACT (Dionne, 2014) and a participant workbook, along with two phone calls of approximately 15 minutes each and weekly e-mails presenting the week's content. Participants also had access to audio meditation exercises on the book's website (http://liberezvousdeladouleur.com/meditations/)."
41508299|NCT01737073|BEHAVIORAL|IVR self-management|A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.
41508300|NCT01737073|BEHAVIORAL|Opioid monitoring|Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.
40852534|NCT02744651|DEVICE|EUS-FNA|"Please note the text in section Arm description"
41035878|NCT06624969|OTHER|virtual reality|Virtual reality program to reduce pain in orthopedic fractures
41035879|NCT04593888|BEHAVIORAL|Gluten reduced diet|Dietary advice focusing on reducing gluten intake in children
41035880|NCT02612402|DEVICE|messages generated by learning algorithm|THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
41035881|NCT02612402|DEVICE|constant weekly message reminding patient to exercise|THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
41035882|NCT02202473|DRUG|Lamivudine|
41035883|NCT02202473|DRUG|Lamivudine+Oxymatrine Capsules|
41508301|NCT01737073|OTHER|Enhanced usual care|Weekly automated wellness tip and usual clinical care
40852535|NCT02744651|DEVICE|EUS-Endodrill biopsy|"Please note the text in section Arm description"
40852536|NCT05642780|DRUG|SKB264|be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;
40852537|NCT05642780|DRUG|Pembrolizumab|be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;
41035884|NCT06519968|DRUG|AZD4604|AZD4604 will be administered as Dry Powder Inhalation (DPI).
41035885|NCT06519968|DRUG|Placebo|Placebo will be administered as DPI.
41035886|NCT06568705|RADIATION|Moderate hypofractionated Radiation Treatment|The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 43.5Gy in 15 fractions in patients who underwent breast conserving surgery or mastectomy.
41035887|NCT06568705|RADIATION|Ultrafractionated Radiation Treatment|The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 26Gy in 5 fractions in patients who underwent breast conserving surgery or mastectomy.
41035888|NCT05528081|OTHER|Phone interview|Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.
41035889|NCT05641168|OTHER|Adhesive material|Newly developed adhesive material
41035890|NCT05641168|OTHER|Standard adhesive material|Standard adhesive material
41035891|NCT00586105|DRUG|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
41382238|NCT04757675|DRUG|S-ketamine 1+Dexmedetomidine 1|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
41382239|NCT04757675|DRUG|S-ketamine 0.5 +Dexmedetomidine 2|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
41382240|NCT03425331|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
41382241|NCT03425331|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
41508302|NCT06582043|OTHER|SCARCr tester 1|Twice daily
41508303|NCT06582043|OTHER|Placebo|Twice daily
40852538|NCT05846815|DEVICE|ARVO 2.0 WEB|"Medical device software where the subject navigates in a virtual apartment, with the goal of performing the tasks given by a cartoon dragon character. The child is asked to perform the subtasks in the given order, except for the subtasks to be completed at a certain time or after a certain sound cue, but the completion order does not influence the scoring. One task scenario lasts until all subtasks are correctly performed or until the time limit of 60 s is reached.~The classification whether the subject belong to typically developed population is based on quantitative neurological performance indicators produced during the game. However, even if the activity performed is differential diagnostics, ARVO does not create any medical diagnosis. It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed."
41035892|NCT05551949|DRUG|Vaginal estradiol tablets|Vaginal estradiol tablets (10mcg).
41035893|NCT06448871|DIAGNOSTIC_TEST|Ultrasound assessment of the right lower extremity muscles|Rectus femoris cross sectional area (RFCSA), RF muscle thickness, vastus lateralis (VL) muscle thickness, Gastrocnemius medialis (GM) muscle thickness, VL pennation angle (PA), and GM PA.
41382242|NCT04950413|OTHER|Conventional physical therapy program|Infrared, Exercises, Stretching exercise of Suboccepital muscle
41382243|NCT04950413|OTHER|IASTM by M2t blade|A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2t blade will be cleaned with an alcohol pad. First, the M2T blade will used to ﬁnd the exact areas of restriction in affected muscles. Then the M2T blade will use at an angle of 45 to apply slow strokes along the muscle. Changes in soft tissue consistency will detected by the clinician through vibrations of the instrument when it slides on areas of irregular fibrosis of the underneath connective tissue. Once an adhesion is discovered, strokes are repeated for 5 min.
41382244|NCT04950413|DEVICE|Phonophoresis|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2 and. A 5 cm2 crystal head with an effective radiating area of 4.0 cm2 ±1.0 wills utilized for 5 Min for each trigger point of neck. lidocine gelwill applied instead of coupling US gel used for transmission.
41382245|NCT05519527|DRUG|Part 1 (STI-6129)|Given by vein (IV)
41382246|NCT05519527|DRUG|Part 2 (STI-6129)|Given by vein (IV)
41382247|NCT04794725|PROCEDURE|Blood sampling|blood samples from venepuncture (10mL)
41382248|NCT02317523|BEHAVIORAL|Behavioral Activation|Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy
41035894|NCT06448871|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DXA) scan|skeletal muscle mass (SM), appendicular skeletal muscle mass index (ASMI), total lean body mass (LBM), total fat mass (BF), percentage fat mass, and fat mass index (FMI).
41382249|NCT02317523|BEHAVIORAL|Information and Support|Six face-to-face sessions (60 minutes each) of Supportive Therapy
41035895|NCT01682460|DRUG|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
41382250|NCT02937285|DRUG|Interferon beta 1a|Subcutaneous injection of 44µg 3 times a week
41382251|NCT02937285|DRUG|Mitoxantrone|10 mg / m² monthly infusion for 6 months
41382252|NCT04206072|DRUG|D-0316 Capsule|"The initial dose of D-0316 is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD until disease progression or meet the discontinuation criteria. A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were confirmed T790M mutation positive may have the option to continuously receive D-0316."
41382253|NCT04206072|DRUG|Icotinib Hydrochloride Tablets|"Icotinib (125 mg three times daily, orally), treatment should continue until disease progression or meet the withdrawal criteria. A cycle of treatment is defined as 21 days of three times daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Icotinib arm and confirmed T790M mutation positive have the option to receive D-0316 (crossover to active D-0316)."
41035896|NCT02123693|OTHER|Osteopathic manipulative treatment|
41382254|NCT00761761|DRUG|Sensoril|
41382255|NCT00761761|OTHER|Placebo|
41382256|NCT00216073|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
41035897|NCT02123693|OTHER|Sham Therapy|
41035898|NCT02123693|OTHER|No Intervention|
41035899|NCT02571504|BEHAVIORAL|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
41035900|NCT06065072|DEVICE|Optical measurement|Optical measurements by optical biometers and an OCT
41035901|NCT01659723|DRUG|Hyperbaric Oxygen|100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
41035902|NCT02345031|DRUG|AUT00063|600 mg, orally, once a day, for 4 weeks
41035903|NCT02345031|DRUG|Placebo|orally, once a day, for 4 weeks
41035904|NCT03362554|BEHAVIORAL|Controlled diet and exercise.|"The intervention will involve 3 weeks of a diet and exercise program designed to cause a net energy decrease of 7000 kcal/week compared to habitual behaviour. This will be achieved through:~* Five exercise sessions per week at 70% VO2 max, using 400 kcal per session.~* Reduction of their standard diet by 5000 kcal per week~Before and after this intervention period participants will take part in a trial day which includes measurement of body composition (using DEXA) and blood sugar control (oral glucose tolerance test). Samples of blood, adipose, skeletal muscle and faeces will also be taken."
41035905|NCT01603576|DEVICE|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
41035906|NCT02277106|DRUG|SAGE-547|
41035907|NCT02277106|DRUG|Placebo|
41035908|NCT05916508|DRUG|0.454% stannous fluoride|Brush two times daily
41035909|NCT05916508|DRUG|0.76% sodium monofluorophosphate|Brush two times daily
41035910|NCT05916508|DRUG|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
41035911|NCT00364429|DRUG|[123]I-CNS 1261|Study Drug
41035912|NCT00364429|DRUG|Lorazepam|Study Drug
41035913|NCT00364429|DRUG|Risperidone|Study Drug
41035914|NCT05314413|PROCEDURE|Single Leg Immobilization|7-days of single leg immobilization to induce muscle atrophy
41035915|NCT01483001|DRUG|Cancer Stem Cells Sensitivity Assay|To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
41382257|NCT00216073|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
41382258|NCT00216073|DRUG|Trastuzumab|Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
41382259|NCT00305331|DRUG|Domperidone (drug)|
41382260|NCT01438346|BEHAVIORAL|Substance Abuse Education|10 weeks of usual care for substance abuse.
41382261|NCT01438346|BEHAVIORAL|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
41382262|NCT01414062|BEHAVIORAL|Cocinar Para Su Salud Program|A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
41382263|NCT01414062|BEHAVIORAL|Written dietary recommendations|Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the New York City (NYC)-based not-for-profit, God's Love We Deliver
41382264|NCT01777191|DRUG|Ixekizumab Auto-Injector|Administered SC by auto-injector
41382265|NCT01777191|DRUG|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
41382266|NCT02427425|DEVICE|TENS|
41382267|NCT01854125|BIOLOGICAL|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
41382268|NCT01854125|BIOLOGICAL|autologous bone marrow msenchymal stem cells transplantation|
41382269|NCT03960268|DRUG|Brodalumab|interleukin 17 receptor A antagonist
41382270|NCT02756169|OTHER|Intervention|Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
41382271|NCT00641810|BEHAVIORAL|Caffeine reduction|Reduction in daily caffeine consumption from usual amounts to none.
41382272|NCT06537973|OTHER|İndividualized care education|A single session of training will be given to the mothers in the experimental group. In addition, the mother will be provided with counseling by the researcher at any time she wishes. The aim is to increase the mother-infant bonding levels and self-efficacy of the mothers, who will be supported by the care plans that will be created based on Swanson\&#39;s Theory of Care, and to adapt more easily to the role of motherhood, by evaluating them with the help of check-lists after the observations.
41382273|NCT01187615|DRUG|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
41382274|NCT01187615|DRUG|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
41382275|NCT05193578|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide, 1.34 mg/mL
41508304|NCT03926520|DEVICE|Electroconvulsive Therapy (ECT)|Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.
41508305|NCT01756079|DRUG|boceprevir|
41508306|NCT01756079|BIOLOGICAL|PegIFN-2b|
41382276|NCT05193578|OTHER|Placebo|Semaglutide-Placebo
41508307|NCT01756079|DRUG|RBV|
41508308|NCT02411916|BIOLOGICAL|misoprostol|rectal insertion
41508309|NCT01699815|DRUG|Acetaminophen|
41508310|NCT05801588|OTHER|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.
41508311|NCT05801588|OTHER|Usual care|The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.
40852539|NCT05846815|OTHER|Conners Continuous Performance Test 3rd Edition™ (CPT 3)|"Subjects are required to respond by pressing the spacebar or the appropriate key on the mouse when any letter other than the letter X appears on the monitor. The Conners CPT 3 presents 14-minute, 360 scored stimuli trials (i.e., individual letters) on the screen, with 1, 2, or 4 sec. between the presentation of letters (i.e., the interstimulus interval; ISI). The 360 trials are divided into 6 blocks, with 3 sub-blocks each consisting of 20 trials. Each block lasts approximately 2 min and 20 sec. Scores and Score Dimensions of Attention Measured: Inattentiveness, Impulsivity, Sustained Attention and Vigilance. The Conners CPT 3 produces computer-generated reports that describe the respondent's performance.~It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed"
40852540|NCT06141876|DRUG|APEX-002-A02|Active
40852541|NCT06141876|OTHER|Placebo|placebo
40852542|NCT02868047|PROCEDURE|Endoscopic Ultrasound|Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
40852543|NCT05535829|OTHER|Laboratory analysis of samples|Laboratory analysis of samples
41382277|NCT01912391|DRUG|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
41382278|NCT01912391|DRUG|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
41382279|NCT04881448|DIAGNOSTIC_TEST|collection of serum/capillary creatinine values|collection of serum/capillary creatinine values
41382280|NCT03715335|OTHER|Targeted STI Screening|GC/CT screening will be offered to those who screen at risk or at high risk for STIs.
41508312|NCT01689779|DRUG|100,000 IU cholecalciferol|active drug
41508313|NCT01689779|DRUG|Placebo|comparator drug
41508314|NCT03151304|DRUG|Pracinostat|45 mg capsule
41508315|NCT03151304|DRUG|Azacitidine|SC or IV injection
41508316|NCT03281876|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
41508317|NCT03281876|BIOLOGICAL|Placebo|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
41508318|NCT02358902|DEVICE|tDCS|tDCS - DC stimulator, Neurocom, Germany
41508319|NCT02358902|PROCEDURE|active intervention of aerobic exercise|different types of aerobic exercise
41508320|NCT02358902|DEVICE|placebo tDCS|only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
41508321|NCT02358902|PROCEDURE|placebo AE|the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
41508322|NCT02128321|DRUG|Isavuconazole|oral
41508323|NCT02128321|DRUG|Repaglinide|oral
41508324|NCT02128321|DRUG|Caffeine|oral
41382281|NCT03715335|OTHER|Universally Offered STI Screening|GC/CT screening will be offered to all patients who meet the age eligibility criteria.
41382282|NCT04950803|DIETARY_SUPPLEMENT|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 20 billion CFU daily)
41382283|NCT04950803|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains active vitamin
41382284|NCT06359561|DEVICE|cervical lead placement|implant of cervical lead neurostimulation, using saluda medical devices
40852544|NCT04984577|DRUG|Compound Edaravone Injection-Low dose|Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days
41382285|NCT01518296|DEVICE|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
41382286|NCT04682639|DRUG|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
41382287|NCT04682639|DRUG|Placebo|Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
40852545|NCT04984577|DRUG|Compound Edaravone Injection-High dose|Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days
40852546|NCT04984577|DRUG|Edaravone Injection|Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days
40852547|NCT04984577|DRUG|Placebo injection|Placebo injection, one dose every 12 hours, continue for 14 days
40852548|NCT01683825|DRUG|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
41035916|NCT06162520|OTHER|Contrast-enhanced computed tomography (CECT) and 3D morphological analysis|Diagnosis models are established using quantitative morphological characteristics extracted from the 3D reconstructed bile duct from contrast-enhanced computed tomography (CECT) images.
41035917|NCT02616094|DEVICE|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
41382288|NCT04682639|DRUG|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
41382289|NCT01905007|DEVICE|Defibrillation testing|Defibrillation testing at initial ICD implantation
41382290|NCT05062161|BEHAVIORAL|Sleep hygiene/extension intervention|The 60-minute sleep hygiene/extension educational session include the following: This session will consist of questionnaires, handouts, videos, and a discussion. Topic examples include information on establishing a comfortable sleep environment, including strategies on how to extend sleep duration by a maximum of 1 hour over the duration of the 8-week trial for an average of 7.5 minutes per week, not to exceed 15 minutes per week. Participants will also receive educational brochures and a sleep diary.
40852549|NCT05414552|DRUG|ECP|Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks
41382291|NCT05062161|BEHAVIORAL|Control care|The 60-minute educational session will address sleep physiology but not sleep hygiene. This session will consist of questionnaires, handouts, videos, and a discussion. Participants will receive an educational brochure.
41382292|NCT02362646|BIOLOGICAL|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
41508325|NCT02928445|DRUG|RVT-101 35 mg|once daily, oral, 35-mg tablets
41382293|NCT02362646|DRUG|Control Solution|
41382294|NCT05632055|OTHER|blood draw|Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
41382295|NCT02066688|DRUG|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
41382296|NCT02066688|DRUG|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
41508326|NCT02928445|DRUG|RVT-101 70 mg|once daily, oral, 35-mg tablets
41035918|NCT02616094|DEVICE|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
41382297|NCT02066688|DRUG|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
41382298|NCT03969160|BEHAVIORAL|Imaginal exposure|Imaginal exposure to mental imagery of phobic and neutral stimuli
41382299|NCT06567275|PROCEDURE|block|ultrasound guided nerve block
41382300|NCT06429891|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
41382301|NCT06538428|GENETIC|DNA methylation profiling|measurement of methylation levels of MGMT, NUPR1,NDRG2,and GLI1 gene
41382302|NCT05936788|OTHER|Active cycle of breathing technique|Group A will receive ACBTs with 1 session a day for total 2 days in a week.
41382303|NCT05936788|OTHER|diaphragmatic breathing|Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
41382304|NCT03880955|DEVICE|ReUnion RSA System|The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
41382305|NCT05474794|DIAGNOSTIC_TEST|DFI-EUS|"All patients enrolled having a confirmed histologic diagnosis of GIST or leiomyoma will undergo endoscopic ultrasound evaluation.~First, the expert endoscopist will perform EUS-DFI examination for the detection of slow flow vascularization in SELS. Microvascularization EUS-Doppler evaluation will last between three and five minutes."
41382306|NCT05474794|DIAGNOSTIC_TEST|CE-EUS|"Immediately, after the first approach, CE-EUS (using Sulphur hexafluoride ultrasound contrast agent) will be performed for diagnosis confirmation. Sonovue will be administered intravenously in one (2.4 mL) or two administrations (4.8 ml), according to physician´s criteria, followed by an injected flush of 5 mL of sodium chloride solution (9 mg/mL).~CE-EUS it will take around 5 minutes, with a total diagnostic approach around one hour."
41382307|NCT03224234|DEVICE|Insulclock with feedback|Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.
41382308|NCT03224234|DEVICE|Insulclock without feedback|Not feedback on insulin administration.
41382309|NCT05061459|GENETIC|circANKRD36 as a new biomarker|expression levels of circANKRD36 in the development and progression of DN
41382310|NCT03972709|DRUG|Galegenimab|Intravitreal (ITV) injections of galegenimab
41382311|NCT03972709|DRUG|Sham Control|Sham control
41382312|NCT00268775|BEHAVIORAL|training and follow-up of pharmacists|
41508327|NCT00000978|DRUG|Zidovudine|
41508328|NCT00000978|DRUG|Zalcitabine|
41508329|NCT05082740|OTHER|Notification of a revised breast cancer risk estimate|These women will be given the opportunity to learn of their revised breast cancer risk estimate which has been re-calculated with the inclusion of new strong independent risk factors. These women will be offered a clinical consultation to discuss their risk and will a subset will be asked to take part in a qualitative interview about their experiences.
41508330|NCT06551285|DIETARY_SUPPLEMENT|Ovapro (Lifepro)|Dietary supplement that contains inositol, vitamin D, zinc, and curcumin.
41508331|NCT06176651|DRUG|Miebo|Subjects will be instructed to use the Miebo eye drop four times per day in both eyes during their participation in clinical trial. The subjects will be required to remove their contact lenses prior to instillation of the Miebo eye drop and must wait 30 minutes before reinserting their contact lenses.
41382313|NCT00268775|BEHAVIORAL|patient-directed discontinuation letter|
41382314|NCT00331929|DEVICE|Minato A 500 AS spirometer|Spirometry at rest
41508332|NCT02914210|DEVICE|Virtual physical therapy rehabilitation program|Virtual Exercise Rehabilitation Assistant (VERA), a virtual physical therapy delivery system installed in patient's home
41382315|NCT04612712|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I) : three doses of Donafenib tosylate tablets \[50 mg twice a day; 100 mg twice a day; 200 mg twice a day \] will be explored. In the dose expansion phase (phase II), patients with advanced hepatocellular carcinoma will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
41382316|NCT04612712|BIOLOGICAL|KN046 Injection|5mg/kg Q3W
41382317|NCT00345969|DRUG|Transdermal Testosterone gel (1%)|Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
41508333|NCT02914210|OTHER|No intervention|Traditional physical therapy delivered in clinic or via home-health visits
41035919|NCT02978365|OTHER|Questionnaires|Patients will fill self-reported functional shoulder scales (1. Western Ontario Shoulder Instability index - WOSI, and 2. Disabilities of Arm, Shoulder and Hand questionnaire - DASH), as well as a Fear Avoidance Belief Questionnaire (FABQ).
41035920|NCT02978365|DEVICE|Isokinetic Strength Measurement|Isokinetic strength will be measured using a Biodex Isokinetic System 4.0 (Shirley, NY)
41035921|NCT03669848|OTHER|Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO)
41035922|NCT02630667|OTHER|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
41165434|NCT01520077|DRUG|vytorin|Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
41165435|NCT06094335|DEVICE|Virtual reality rehabilitation|Children in this group received Virtual Reality Rehabilitation plus traditional physical therapy
41165436|NCT06094335|OTHER|Traditional physical therapy|Flexibility exercises, strengthening exercises, endurance exercises, and postural stability exercises
41165437|NCT02108652|DRUG|Atezolizumab|Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
41165438|NCT06215625|OTHER|Robot-assisted therapy|The TIGER system provides assistance for activities of daily living. Continuous passive mode of TIGER system provides passive range of motion as warm-up. Functional mode TIGER system provides functional training.
41165439|NCT06215625|OTHER|Task-oriented training|The TOT group will practice sensorimotor techniques for warming up, and then they will practice various functional tasks based on task-oriented approach.
41165440|NCT01748123|DRUG|Chlorthalidone|Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
40852550|NCT06584526|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the experimental groups).
41035923|NCT02630667|OTHER|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
41035924|NCT02630667|OTHER|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
41035925|NCT01335243|PROCEDURE|The Transforaminal Lumbar Interbody Fusion (TLIF) surgery|The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
41035926|NCT06486753|PROCEDURE|Chevron osteotomy bunion surgery with lateral soft tissue release|Lateral soft tissue release is often performed in hallux valgus correction, and there is preliminary evidence to suggest it may be useful in improving post-surgical outcomes for the Chevron osteotomy bunion surgery.
41035927|NCT00108095|DRUG|intravenous ondansetron|
41035928|NCT02574975|DRUG|methacholine|Methacholine,inhaled cumulative dosage 2.5mg
41035929|NCT02574975|DRUG|adenosine monophosphate|Adenosine monophosphate ,inhaled cumulative dosage 40mg
41165441|NCT01748123|DRUG|Hydrochlorothiazide|Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
41165442|NCT02624869|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
41165443|NCT02127489|DRUG|1 mL/kg bupivacaine 0.25%.|40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
41165444|NCT05865925|DRUG|LY010616|IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter
41165445|NCT06198413|GENETIC|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
41508334|NCT04414345|DRUG|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
41508335|NCT04414345|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily"
40852551|NCT06584526|OTHER|Physical Therapy and Aerobic Exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a cycle ergometer.
41165446|NCT00092365|DRUG|MK0966, rofecoxib|
41165447|NCT00092365|DRUG|Comparator: celecoxib, placebo|
41508336|NCT04274257|DRUG|Double-Blind Placebo|"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of placebo will be administered. In the active drug period, one additional cycle (rituximab) will be administered."
40852552|NCT06584526|OTHER|Physical Therapy and Strength Exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes strength exercise programme.
41035930|NCT02574975|DRUG|leukotriene D4|Leukotriene D4,inhaled cumulative dosage 2.4 μg
41035931|NCT02574975|DEVICE|Astograph Jupiter-21 airway reaction testing apparatus|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
41035932|NCT02574975|DRUG|budesonide /formoterol|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
41035933|NCT04124250|OTHER|Observational|Mass Drug Administration with a single co-administered dose of Ivermectin, DEC and Albendazole performed by Provincial and National Health Departments annually for two years
41035934|NCT06158750|DEVICE|p64/p48 MW HPC Flow Modulation Device|Endovascular intervention with p64/p48 MW HPC Flow Modulation Device was performed in patients diagnosed with intracranial aneurysms
41035935|NCT03839251|DRUG|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
41035936|NCT05883852|DRUG|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
41382318|NCT00345969|BEHAVIORAL|Supervised exercise training|Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.
41508337|NCT04274257|DRUG|Double-Blind Rituximab|"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of rituximab will be administered. In the active drug period, one additional cycle (rituximab) will be administered."
41508338|NCT00416611|BEHAVIORAL|Implementation of guidelines|
40852553|NCT02413047|DRUG|Azathioprine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
40852554|NCT02413047|DRUG|6 mercaptopurine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
40852555|NCT02413047|DRUG|Methotrexate|Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
40852556|NCT04371965|DRUG|Povidone-Iodine|Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days.
40852557|NCT03007602|OTHER|Upper Extremity Aerobic Exercise|"Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
41035937|NCT05883852|DRUG|carboplatin|Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
41035938|NCT05883852|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,
41035939|NCT05883852|DRUG|Pertuzumab|Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).
41165448|NCT04036773|DIETARY_SUPPLEMENT|Fruit and vegetable deliveries|Weekly home deliveries of approximately 15 pounds of fresh fruits \& vegetables
41165449|NCT06480331|PROCEDURE|Ultrasound-guided fistuloplasty|Radiation free fistuloplasty
41165450|NCT06480331|PROCEDURE|Fluoroscopy-guided fistuloplasty|Conventional fistuloplasty
41165451|NCT00115284|BEHAVIORAL|ABIM asthma practice improvement module|
41165452|NCT00787813|DRUG|N-Acetyl Cysteine|oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
41165453|NCT00787813|DRUG|Placebo|
41508339|NCT04637802|BEHAVIORAL|CBT (SurgeryPal)|The SurgeryPal intervention is a cognitive-behavioral program for youth undergoing major surgery. SurgeryPal is delivered in two 4-week phases: the pre-operative phase, and the post-operative phase. Each phase consists of 3 separate treatment modules for youth and parents, which teach cognitive and behavioral coping skills to target known psychosocial and behavioral risk factors (i.e. anxiety/distress and sleep disturbance) for poorer postsurgical outcomes, and provide training in pain self-management skills. Pre-operative modules include: 1) Preparing for surgery, 2) Coping with stress before surgery, and 3) Getting ready for the hospital. Postoperative modules include: 1) Coping at home after surgery, 2) Return to activities and school, and 3) Long-term recovery. Modules are self-guided and interactive, and focus on phases of preparation and recovery from surgery. The goal of the program is to reduce pain and enhance quality of life following surgery in youth.
41165454|NCT02511340|DRUG|Flumatinib mesylate tablet 600 mg qd|Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
41165455|NCT06193928|DRUG|Maralixibat|The recommended dosage is 380 mcg/kg once daily.
41165456|NCT03166397|DRUG|Fludarabine|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
41165457|NCT03166397|DRUG|Cyclophosphamide|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
40852558|NCT05248139|DRUG|Intraoperative delivery of medication, Kenalog (Triamcinolone)|Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
40852559|NCT05248139|DRUG|Topical post-operative eyedrops, Prednisolone acetate|Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
40852560|NCT00416455|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT
40852561|NCT00416455|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
40852562|NCT00416455|PROCEDURE|computed tomography|Undergo FDG PET/CT
40852563|NCT00416455|DRUG|ferumoxtran-10|Undergo femoxtran-10 MRI
40852564|NCT00416455|PROCEDURE|magnetic resonance imaging|Undergo femoxtran-10 MRI
40852565|NCT00416455|PROCEDURE|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
41035940|NCT05883852|DRUG|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
41165458|NCT03166397|BIOLOGICAL|TIL|TIL administration
41382319|NCT05857501|DEVICE|abdominopelvic computerized tomography (CT) without contrast|scan combines a series of X-ray images taken from different angles around your body and uses computer processing to create cross-sectional images (slices) of the bones, blood vessels and soft tissues inside your body. CT scan images provide more-detailed information than plain X-rays do.
41382320|NCT01440608|DRUG|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
40852566|NCT00416455|PROCEDURE|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
40852567|NCT00964652|OTHER|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
41508340|NCT04637802|BEHAVIORAL|Education|The patient education website will serve as the active comparator. The purpose is to control for time, attention, and online usage. Youth and parents will be provided access to an education website containing information about pediatric surgery at the same time interval as the active intervention; however, there will be no exposure to cognitive and behavioral coping skills. Similar to the CBT condition, the presurgery period of Education will be administered for one month prior to surgery and the postsurgery period will be administered for one month after the post-discharge assessment.
41382321|NCT01440608|DRUG|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
41382322|NCT01440608|DIETARY_SUPPLEMENT|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
41382323|NCT03184376|DIETARY_SUPPLEMENT|Prebiotic oligofructose|Powder format
41382324|NCT03184376|DIETARY_SUPPLEMENT|Placebo maltodextrin|Powder format
41382325|NCT03626246|OTHER|Kidney disease|"Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~* Bone density (DXA)~* Thoracic and lumbar spine plain films.~* HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~* Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~* Measure levels of Advanced Glycation End products (AGEs) in the skin."
41382326|NCT04477473|OTHER|Questionnaire-based observational study|"Questionnaire focusing on practical health care issues regarding respiratory support, health status and perception of the COVID-19 issue:~* Symptom score (related to noninvasive ventilation: NIV)~* Thymic disturbances (score of anxiety and depression)~* Compliance to treatment (assessed via tele-monitoring: routine procedure)"
41508341|NCT02390128|OTHER|observational only|
41508342|NCT00324987|BIOLOGICAL|Bevacizumab|Given IV
41382327|NCT00147472|OTHER|PET scan in addition to conventional CT imaging|PET scans, Pre and post radiation treatment
41508343|NCT00324987|DRUG|Imatinib Mesylate|Given PO
41382328|NCT00003652|DRUG|cisplatin|
41382329|NCT00003652|DRUG|fluorouracil|
41382330|NCT00003652|PROCEDURE|neoadjuvant therapy|
41382331|NCT00003652|RADIATION|radiation therapy|
41382332|NCT06181136|DRUG|DNL126|intravenous repeating dose
41508344|NCT00324987|OTHER|Laboratory Biomarker Analysis|Correlative studies
41508345|NCT00324987|OTHER|Pharmacological Study|Correlative studies
41508346|NCT00555841|DRUG|ALC and Placebo|ALC and Placebo
41508347|NCT02015065|DRUG|Vandetanib|Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
41508348|NCT02729909|DRUG|Lubiprostone|Lubiprostone capsules
41508349|NCT02729909|DRUG|Placebo|Lubiprostone placebo-matching capsules
41508350|NCT02792699|DRUG|ABP 798|Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
41508351|NCT02792699|DRUG|Rituximab (US)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
41508352|NCT02792699|DRUG|Rituximab (EU)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
41508353|NCT01992185|DRUG|Photocil for Vitiligo|Photocil for Vitiligo
41382333|NCT01655173|BEHAVIORAL|Cognitive behaviour therapy|"The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session."
41382334|NCT01655173|BEHAVIORAL|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
41382335|NCT06375577|DIETARY_SUPPLEMENT|45 grams Voom Pocket Rocket Electro Energy|Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
41382336|NCT06375577|DIETARY_SUPPLEMENT|45 grams SIS Go Isotonic Energy Gel|Participants will be required to consume 45 grams (in carbohydrates) SIS Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
41382337|NCT06375577|DIETARY_SUPPLEMENT|45 grams Maurten Gel 160|Participants will be required to consume 45 grams (in carbohydrates) Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
41382338|NCT00119080|BIOLOGICAL|meningococcal conjugate vaccine (Menactra)|
41382339|NCT02018601|PROCEDURE|BRILMA|
41508354|NCT01992185|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
41508355|NCT05349552|RADIATION|stereotactic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
41508356|NCT02128672|PROCEDURE|Spinal Cord Stimulator Lead Placement|
41508357|NCT00235677|PROCEDURE|Endoscopic gastroplication|
41508358|NCT00234962|DRUG|Lopinavir/Ritonavir|
41508359|NCT02428439|DRUG|bupropion or lamotrigine|Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
41508360|NCT02333656|OTHER|New OA model|"The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist."
40852568|NCT03043651|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
40852569|NCT03298178|PROCEDURE|TAVR|All patients who underwent transcatheter aortic valve replacement in Asan medical center, republic of Korea
40852570|NCT03298178|PROCEDURE|SAVR|All patients who underwent surgical aortic valve replacement in Asan medical center, republic of Korea
40852571|NCT02906267|OTHER|Diagnostic ultrasonography of gastric volume|Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
40852572|NCT00947115|PROCEDURE|Blood sampling|Blood samples were collected at Years 5, 6, 7, 8, 9 and 10.
41382340|NCT02018601|PROCEDURE|paravertebral block|
41382341|NCT02018601|DRUG|dexketoprofen|
41382342|NCT02018601|DRUG|paracetamol|
41382343|NCT04679649|OTHER|Manual spinal mobilisation physiotherapy|Manual spinal mobilisation is a physiotherapy technique to improve spinal mobility by gently applying pressure manually on the each segmental vertebrae by hands-on treatment of a physiotherapist.
41382344|NCT01856257|BIOLOGICAL|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
41382345|NCT01856257|BIOLOGICAL|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
41508361|NCT03624959|DRUG|Ozanimod|ozanimod
41508362|NCT03624959|DRUG|Gemfibrozil|Gemfibrozil
41508363|NCT03624959|DRUG|Itraconazole|Itraconazole
41508364|NCT03624959|DRUG|Rifampin|Rifampin
41508365|NCT02046603|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
41508366|NCT02046603|DRUG|DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
41508367|NCT02046603|DRUG|Oral Corticosteroids|Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
41508368|NCT02046603|DRUG|Methotrexate|Methotrexate per investigator's discretion.
41508369|NCT04015310|DEVICE|Quantitative Multi parametric MRI and enhanced MRCP|Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
41382346|NCT01856257|DRUG|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
41382347|NCT01856257|BIOLOGICAL|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
41382348|NCT01856257|DRUG|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
41382349|NCT01856257|DRUG|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
41508370|NCT03188744|OTHER|Assessment of the pelvic floor function|Vaginal palpation and perineometry.
41508371|NCT03188744|OTHER|Questionnaire application|Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.
41508372|NCT03825718|BIOLOGICAL|GC007F|GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.
41508373|NCT01992718|PROCEDURE|Evaluation of MRI, US for pelvic and uterine conditions|"Pelvic ultrasound with transabdominal and transvaginal imaging. The transvaginal ultrasound will include elastography (TVUS-E). Also, a pelvic MRI will be performed if not done in the last 6 months. The MRI is performed with IV gadolinium-based contrast (MultiHance ®).~A patient survey will be included."
41508374|NCT01992718|PROCEDURE|Patient preference between MRI and Ultrasound|"Subjects may take part in this arm because they have recently had a MRI performed and scheduled for, or have recently undergone a pelvic ultrasound.~Subjects will also be asked to complete a survey that will state their preference with regards to examination/imaging. This will be done over the phone and will take no longer than 30 minutes to complete."
41508375|NCT05993416|DRUG|Nedosiran|In adults and in adolescents (aged 12-17 years) weighing greater than or equal to (\>=) 50 kilograms (kg), Nedosiran will be administered via subcutaneous (SC) injection once monthly at a dose of 170 milligrams (mg). In adults and adolescents weighing \< 50 kg, nedosiran will be administered once monthly at a dose of 136 mg. The dose for participants aged 6 to 11 years will be 3.5 mg/kg monthly, not to exceed 170 mg.
41508376|NCT02965040|DRUG|Roxadustat|Oral
40852573|NCT00947115|PROCEDURE|Cervico-vaginal secretion (CVS) samples|CVS samples were collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteered for this procedure.
41035941|NCT05883852|DRUG|cyclophosphamide|An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
41035942|NCT05413876|OTHER|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
41035943|NCT05413876|OTHER|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
41382350|NCT01388101|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
41035944|NCT02353923|DIETARY_SUPPLEMENT|OcuStem Supplementation|2800 mg daily dosage of OcuStem, 2 capsules BID.
41035945|NCT00392561|DIETARY_SUPPLEMENT|Selenium|200 ug Selenium daily
41035946|NCT00392561|DIETARY_SUPPLEMENT|vitamin E|100 mg Vitamin E daily
41383582|NCT06049004|OTHER|Activities of Daily Living Protocol|The protocol is a performance-based objective measurement method based on repetition of daily activities. Participants are asked to perform the activities defined in the protocol at the same speed they do at home. The Londrina Protocol includes 5 stations: Station 1 Arranging Objects on the Table, Station 2 Walking with Bags, Station 3 Organizing Shelves, Station 4 Clothesline Task, Station 5 Walking. The completion time of the protocol is recorded.
41508377|NCT05868525|DRUG|Aspirin 325Mg Tab, Aspirin 81Mg Tab|Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
41508378|NCT04577209|DEVICE|Disposable oxygen face tent|Disposable oxygen face tent used to minimize aerosol particles (through suction) during aerosol generating anesthesia procedures.
41508379|NCT05204498|BEHAVIORAL|Education plan and adherence to exercise|"Through phone calls with a motivating sense at any time of the day, twice a week.~* It will be recorded in an Excel table each time the patient is called.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 8 weeks. At the end of week 8, patients will be referred to the pulmonary rehabilitation unit to evaluate the anthropometric parameters, assess dyspnea with the modified scale of the Medical Research Council, the hospital anxiety and depression scale, the Saint George respiratory questionnaire , the pulmonary information You need the questionnaire and the 6-minute walk test again."
41508380|NCT02859753|OTHER|Percutaneous Radiofrequency Ablation|
41508381|NCT02859753|OTHER|Percutaneous Microwave Ablation|
41035947|NCT04331366|DEVICE|GO2 PEEP MOUTHPIECE|The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.
41508382|NCT06551376|OTHER|Ovarian Stimulation Start|To compare ovarian response accordin to ovarian stimualtion start
41382351|NCT05468034|BEHAVIORAL|Exercise Intervention|Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
41382352|NCT00240786|DRUG|acetaminophen extended release|
41382353|NCT03378310|DRUG|BMS-986205 reference tablet|Single, 100 mg oral dose.
41382354|NCT03378310|DRUG|BMS-986205 tablet with free base|Single, 100 mg oral dose.
41382355|NCT04962659|BEHAVIORAL|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (\~1 hour each) delivered via telehealth. During sessions, the participant works with a therapist (e.g., board-certified music therapist) to learn and apply mindfulness practices via music-based meditations and mindful songwriting. Supported by the therapist, participants write two songs during the program.
41382356|NCT05344391|OTHER|BFR cycling|Cycling with BFR followed by shoulder exercises
41382357|NCT05344391|OTHER|Cycling without BFR|Cycling without BFR followed by shoulder exercises
41382358|NCT00923299|DRUG|cetuximab|Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.
41508383|NCT03885583|PROCEDURE|thoracic epidural block|thoracic epidural block with bupivacaine 0.25% will be given in the 8th thoracic space using ultrasound
40852574|NCT06583590|DRUG|Botulinum toxin A|Botulinum toxin (BoNT) is One of the most potent toxins known to humans produced by Clostridium botulinum that has been used to treat several striated and smooth muscle disorders. Because the pathophysiology and the reason for patients' lack of response to PDE5I is insufficient smooth muscle relaxation and veno-occlusive disorder (VOD) , BTX-A may prove to be a viable treatment for this patient population due to its availability to facilitate long-acting cavernosal smooth muscle relaxation by inhibition of the release of noradrenaline from the adrenergic neurons acting on the cavernosal smooth muscle. Thus, the dominant sympathetic basal tone of the cavernosal smooth muscle is essentially removed, facilitating the occurrence of an erection.
40852575|NCT06583590|DRUG|Tadalafil 5mg|Tadalafil is one of 5-phosphodiesterase inhibitors that used to treat male sexual function problems (impotence or erectile dysfunction-ED). In combination with sexual stimulation, tadalafil works by increasing blood flow to the penis to help a man get and keep an erection.Tadalafil is also used to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tadalafil is thought to work by relaxing the smooth muscle in the prostate and bladder.
41035948|NCT00765193|OTHER|Inspection of covered areas|Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
41035949|NCT04792346|RADIATION|breast/chest wall radiotherapy|34 Gy/10 fxs/2 wks to the whole breast/chest wall and locoregional lymph nodes; an optional single fraction 8 Gy boost was administered with electrons to the tumor bed in patients undergoing conservative surgery
41382359|NCT00923299|DRUG|trastuzumab|"Two dose levels of trastuzumab will be evaluated for Phase 1:~* Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;~* Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations."
41382360|NCT05879159|BEHAVIORAL|Questionnaires|Survey
41382361|NCT01431807|DRUG|SYR-472|oral, for up to 52 weeks.
41382362|NCT05981131|DRUG|N803 plus Bacillus Calmette-Guerin (BCG)|QUILT-2.005 phase 1b (NCT02138734) was an open-label, dose-escalation, multicenter study of intravesical Bacillus Calmette-Guerin (BCG) plus N-803 in BCG-naïve non muscle invasive bladder cancer (NMIBC). A modified 3 + 3 design was used. Three subjects were enrolled at each dose level starting at 100 μg/instillation of N-803 and subsequently increasing to 200 μg/instillation and 400 μg/instillation. A standard dose of BCG, 50 mg, was employed. The primary endpoints of the study were: determination of the maximum tolerated dose (MTD) and designation of the recommended dose (RD) of N-803 in combination with BCG in subjects who have BCG-naïve NMIBC; safety profile of N-803 plus BCG in treated subjects; and disease response rate in treated subjects. A total of 9 subjects with high-risk, high-grade, BCG-naïve, NMIBC were enrolled into 3 cohorts and treated by intravesical administration of N-803 plus BCG.
41382363|NCT05722275|DIAGNOSTIC_TEST|Peritoneal metastasis status ascertainment|Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.
41382364|NCT02753608|OTHER|Collection of exhaled breath condensate|An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
41382365|NCT00075465|DRUG|docetaxel|
41382366|NCT00075465|DRUG|epirubicin hydrochloride|
41508384|NCT03885583|PROCEDURE|paravertebral block|paravertebral block with 0.25 bupivacaine will be given at the level of the incision using ultrasound
41508385|NCT03165292|RADIATION|mIBG|Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
40852576|NCT04682535|OTHER|Social relationships|Exposure to social interactions with spouse, friends, and family. Perceived loneliness, emotional strain, and emotional support.
41035950|NCT03033303|BIOLOGICAL|Hu3F8|Day 1: hu3F8 infused iv over \~30 to 90 minutes. Day 3: hu3F8 infused iv over \~30 to 90 minutes. Day 5: hu3F8 infused iv over \~30 to 90 minutes.
41035951|NCT03033303|DRUG|GM-CSF|Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
41035952|NCT03033303|DRUG|Isotretinoin|Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
41165459|NCT03166397|DRUG|IL-2|Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
41165460|NCT03166397|DRUG|Nivolumab|Nivolumab 480 mg fixed dose
41165461|NCT03166397|DRUG|Ipilimumab|Ipilimumab 1 mg/kg up to 100 mg
41165462|NCT03166397|DRUG|FMT Protocol|"FMT given both directly into the colon via colonoscopy and orally using capsules (12 capsules each time).~FMT will be taken from melanoma patients treated with Anti PD-1 who achieved a durable response of more than 12 months."
41165463|NCT03524768|DIAGNOSTIC_TEST|skin laser speckle contrast imaging and video-capillaroscopy|Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment
41165464|NCT03762083|DEVICE|pHyph, Gedea pessary|pHyph is a vaginal tablet for the treatment of BV.
41165465|NCT02448498|BEHAVIORAL|Exercise Intervention|
41165466|NCT05375617|OTHER|Observational|No intervention
41165467|NCT00078234|DRUG|Oblimersen-rituximab-fludarabine|28-day cycles; Cycle 1: oblimersen by continuous IV infusion 1.5 mg/kg/d for 7 consecutive days, completing on Day 8; rituximab by IV infusion on Day 4 (125 mg/m2) and Day 6 (250 mg/m2); fludarabine 25 mg/m2 by IV infusion for 3 days, starting on Day 6. Subsequent cycles: oblimersen 3 mg/kg/d, completing on Day 8; rituximab 375 mg/m2 on Day 5; fludarabine 25 mg/m2 for 3 days starting the same day as rituximab
41165468|NCT00991029|DRUG|Clopidogrel|Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
41382367|NCT02246855|BIOLOGICAL|Gammaplex® (Human Normal Immunoglobulin)|
41382368|NCT00605839|DEVICE|GlucoPak|We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.
41382369|NCT00605839|DEVICE|Cell Phone|We will provide cell phones and access to the clinic to facilitate communications
41382370|NCT00605839|OTHER|Usual Care|This intervention was usual care, without either device.
41382371|NCT02792400|DRUG|LY2403021|Glucagon receptor antagonist
41508386|NCT03165292|DRUG|Topotecan|Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
41508387|NCT03165292|DRUG|Thiotepa|Day 1-3 Thiotepa
41508388|NCT03165292|PROCEDURE|Autologous stem cell transplant|ASCT as soon as radiation level allows it in ARM A
40852577|NCT01336153|DRUG|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
40852578|NCT01336153|DRUG|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
40852579|NCT00002913|DRUG|paclitaxel|Given IV
41035953|NCT06417099|DRUG|Dihydroartemisinin|dihydroartemisinin 40mg tid po for 90 consecutive days
41035954|NCT02987413|BIOLOGICAL|Autologous Mesenchymal stem cells (MSCs)|2 intrathecal autologous MSCs infusions (1x10\^8 cells) will be performed, escalated from 30 days apart
41165469|NCT00991029|DRUG|placebo|Loading dose of 8 tablets followed by one tablet daily for 89 days
41165470|NCT00082641|BIOLOGICAL|autologous dendritic cell-adenovirus p53 vaccine|Given subcutaneously on one of two schedules
41165471|NCT04658550|OTHER|Remote Behaviour Modification Program|The standard of care behaviour modification program for weight loss will be offered virtually due to the COVID-19 pandemic (prospective).
41382372|NCT02792400|DRUG|LY2403021 placebo|
41382373|NCT02792400|PROCEDURE|Standardised liquid meal|
41382374|NCT02792400|DRUG|Linagliptin|DPP-4-inhibitor
41382375|NCT02792400|DRUG|Linagliptin placebo|
41382376|NCT02792400|DRUG|Empagliflozin|SGLT2-inhibitor
41382377|NCT02792400|DRUG|Empagliflozin placebo|
41382378|NCT04875078|DEVICE|UVA-1 Phototherapy|UVA-1 Phototherapy treatments
40852580|NCT00002913|DRUG|cisplatin|Given IV
40852581|NCT00002913|DRUG|topotecan hydrochloride|Given IV
40852582|NCT00002913|BIOLOGICAL|filgrastim|Given SC
40852583|NCT02593318|DRUG|Oxaloacetate (OAA) 1g|Pills to be taken orally in 500mg dose two times per day
40852584|NCT02593318|DRUG|Oxaloacetate (OAA) 2g|Pills to be taken orally in 1000mg dose two times per day.
41165472|NCT04658550|OTHER|In Person Behaviour Modification Program|The standard of care behaviour modification program for weight loss was offered in person prior to the COVID-19 pandemic (retrospective).
41165473|NCT04080063|OTHER|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
41165474|NCT05599646|BEHAVIORAL|traditional pedometer based walking intervention|Participants were recommended to monitor their step count using traditional pedometer and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
41383583|NCT04835207|OTHER|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured: 1- LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"
41383584|NCT02108132|BIOLOGICAL|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
41508389|NCT02309138|DIAGNOSTIC_TEST|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
41508390|NCT02309138|DIAGNOSTIC_TEST|Gestational diabetes screening with fasting 2 hour 75g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
41508391|NCT00569855|DRUG|Phenoxybenzamine|0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
41035955|NCT04414982|BEHAVIORAL|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
41035956|NCT04414982|BEHAVIORAL|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
41035957|NCT06304233|DIAGNOSTIC_TEST|Echocardiography|ultrasound assessment of heart structure, volume and function
41035958|NCT06304233|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|MRI assessment of heart structure, volume, function and tissue characteristics
41035959|NCT06304233|DIAGNOSTIC_TEST|Electrocardiography|Assessment of cardiac rhythm and electrical activity
41035960|NCT06304233|OTHER|Blood sampling|To measure DISC1 mRNA expression and other potential biomarkers
41035961|NCT06291272|DIETARY_SUPPLEMENT|Psyllium|15 g psyllium + 15 g inulin
41035962|NCT06291272|DIETARY_SUPPLEMENT|Methylcellulose|15 g methylcellulose + 15 g inulin
41035963|NCT06291272|DIETARY_SUPPLEMENT|Inulin|15 inulin
41035964|NCT06291272|DIETARY_SUPPLEMENT|Maltodextrin|15 maltodextrin
41035965|NCT05853250|OTHER|Reiki/manual therapy|Reiki is delivered by gentle hand placement either on or slightly above the body by certified Reiki practitioners. In this study, Reiki will be delivered first, for 15 minutes and will involve light placement of hands on patients' head, chest, shoulders, hands, knees, and feet (\~ 3 minutes to each body part). Manual therapy techniques include light effleurage to head and feet (for 5 minutes; \~ 2.5 minutes to each body part) by the Reiki practitioner who delivered the Reiki therapy.
41035966|NCT01479920|DRUG|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
41035967|NCT01479920|PROCEDURE|DCEAS (Hwato®/ Dongbang®)|"Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.~Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable."
41035968|NCT01479920|PROCEDURE|n-CEA (Strietberger®)|Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
41035969|NCT04938895|BEHAVIORAL|Black Respondents Exposure to a Photo|Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
41035970|NCT02830594|RADIATION|External Beam Radiation Therapy|Undergo palliative external beam radiation therapy
41035971|NCT02830594|OTHER|Laboratory Biomarker Analysis|Correlative studies
41035972|NCT02830594|BIOLOGICAL|Pembrolizumab|Given IV
41035973|NCT01577706|DRUG|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
41035974|NCT01577706|DRUG|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
40852585|NCT02313974|PROCEDURE|Renal Biopsy|
40852586|NCT02706197|DEVICE|OxyChip|The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
41035975|NCT01577706|OTHER|Placebo|Placebo, gel-capsule, single-dose, 1-day
41035976|NCT04477980|OTHER|Disease outcome (mortality)|Mortality rate between the two groups
41035977|NCT02136277|DRUG|Hartmann's solution|Administered in 250ml boluses, until cardiac output has been optimised.
41035978|NCT03455426|DRUG|letrozole|Women will be randomizedfor ovarian stimulation with letrozole or to natural cycle IUI.
41035979|NCT04608474|DRUG|Evolocumab|Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.
41035980|NCT04608474|DRUG|Statins (Cardiovascular Agents)|Previously prescribed statin therapy.
41382379|NCT06567054|DEVICE|Measurements with the POROUS R3C ultrasound device at the midshaft tibia|The POROUS R3C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.
41382380|NCT06567054|DEVICE|DXA measurement of the hip and lumbar spine|"The following DXA measurements are to be performed:~* Spine L1-4~* Hip left~* Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R3C ultrasound scan."
41382381|NCT06567054|DEVICE|DXA-based Vertebral Fracture Assessment (VFA)|DXA-based Vertebral Fracture Assessment (VFA) of thoracic and lumbar spine from T4 to L5.
41382382|NCT06567054|DEVICE|Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)|Projectional radiography of thoracic spine T4-T12 and lumbar spine L1-L5.
41382383|NCT06170632|DEVICE|Biliary drainage|Biliary drainage with FC-SEMS Niti-S FLARE TYPE
41382384|NCT01527786|DRUG|Desvenlafaxine|50mg-100mg everyday for 12 weeks over 7 study visits
41382385|NCT02269800|DRUG|Benzalkonium chloride solution|Tid, 7 days
41035981|NCT03456193|PROCEDURE|LA transplant|"The proposed study treatment will include three central components:~* Harvest of the left atrium and pulmonary veins from a suitable donor~* Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis~* Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient."
41035982|NCT05225818|BEHAVIORAL|PLAN - Home|home-based intervention program for dementia evaluation, education, and care planning
41165475|NCT05599646|BEHAVIORAL|gamified pedometer based walking intervention|Participants were recommended to monitor their step count using gamified pedometer, earn money, compete friends and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
41165476|NCT05572385|BEHAVIORAL|CIAT + Conventional neurorehabilitative therapy|CIAT = Constrained induced aphasia therapy
41382386|NCT02269800|DRUG|Normal saline|Tid, 7 days
41382387|NCT03541356|COMBINATION_PRODUCT|Placebo|Delivered via the I231 POD (Precision Olfactory Delivery) device
41382388|NCT03541356|COMBINATION_PRODUCT|L-dopa 35 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril
41508392|NCT03316547|OTHER|SENSE Program|Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises \[passive range of motion (PROM), gentle stretching\]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
41035983|NCT03704818|DRUG|Dapagliflozin 5mg|Dapagliflozin treatment taken daily for 4-weeks.
41035984|NCT03704818|DRUG|Placebo Oral Tablet|Placebo treatment taken daily for 4-weeks.
41165477|NCT06085209|DEVICE|The truFreeze Spray Cryotherapy|A novel FDA cleared technique that allows for liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
41165478|NCT06085209|DEVICE|Ballon dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.
41165479|NCT06085209|DEVICE|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
41165480|NCT02625753|DRUG|Codeine|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
41382389|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
41382390|NCT03541356|COMBINATION_PRODUCT|L-dopa 140 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril
41382391|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg/carbidopa 7mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
41382392|NCT01144988|DRUG|Bevacizumab / Irinotecan|Bevacizumab (10mg/kg KG) Irinotecan (125 mg/ m2 or 340 mg/m2 depending on usage of EIAED)
41382393|NCT03918980|DRUG|LOU064|LOU064 will be administered as oral capsules in parts 1 to 6.
41165481|NCT02625753|DRUG|paracetamol|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
41165482|NCT02625753|DRUG|placebo|Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
41382394|NCT03918980|DRUG|Placebo|Matching placebo capsules will be administered in parts 1,2, 4 and 6.
41382395|NCT04382560|OTHER|Deep Breathing training|The intervention will comprise a psychoeducational part on the theorethical background underlying this technique and a pratical session in which partecipant will be instructed to inhale air with his/her nose and exhale with his/her mouth for a period of 3 seconds of inhalation and 7 seconds of exhalation (i.e., 6 cycles of breaths per minute;). During the session, the participant will be encouraged to put one hand over his/her chest and the other over the abdomen in order to see the difference between normal breathing and deep breathing. To help the subjects in the training, an online pacer will give the rhythm of respiration and will be used as visual feedback.
41383585|NCT02108132|BIOLOGICAL|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
41165483|NCT00816621|BEHAVIORAL|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
41035985|NCT04977362|OTHER|Enhanced Recovery After Surgery|Enhanced recovery after surgery is a multimodal, transdisciplinary care approach for patients undergoing surgical procedures. It is implemented in various surgical specialties, among others in cardiac surgery. The care approach aims at promotion of recovery of the patients throughout their perioperative process, reduction of complications, and early return to normal activities.
41382396|NCT04382560|OTHER|Compassion focused intervention|"The short compassion focused intervention will begin with a short psychoeducation on the evolved nature and difficulties of the human mind, such as tendencies for negativity bias, negative rumination, and self-criticism. Participants will then be offered insights into how humans can work with their 'tricky brains' using body-based and psychological-based practices aimed at increasing a grounding and soothing compassionate attitude towards ourselves and others. In particular, participants will be instructed to pratice a mindfulness technique designed to help them to become more aware of their present moment-to-moment and more compassionate towards their own emotions. They will then be guided to create an image conveying warmth and compassion to them. Lastly, participants will be guided to bring the image to mind and then write write a brief self-compassionate letter to themselves from that point of view."
41382397|NCT03829020|DRUG|Bortezomib|Given SC
41382398|NCT03829020|DRUG|Metformin Hydrochloride|Given PO
41382399|NCT03829020|DRUG|Nelfinavir Mesylate|Given PO
41382400|NCT00413465|DRUG|Escherichia Coli Endotoxin|
41382401|NCT06023758|DRUG|KN026|KN026：30 mg/kg Q3W
41508393|NCT02203331|DRUG|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
41382402|NCT06023758|DRUG|KN046|KN046：5 mg/kg Q3W
41382403|NCT06023758|DRUG|XELOX|Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W
41382404|NCT05838352|OTHER|telerehabilitation exercise|The telerehabilitation program is as follows; Respiratory exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities, using medium-hardness resistance exercise band. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. Exercises 1st-3rd weeks with 10 repetitions; 15 repetitions in weeks 4-6; In the 7th and 8th weeks, it will be done as 2 sets of 10 repetitions.Posture exercises: Basic posture exercises will be explained. Tabletop movements will be taught in clear, various positions that concern the spine, scapula and pelvis.Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking).
41382405|NCT05838352|OTHER|Control Group|The surveys in the outcome measures section will be applied once as a pre-test. Children in both groups will receive conventional institutional rehabilitation in the rehabilitation center. Children in the conventional rehabilitation group, which is the control group, will only be included in the supervised program. This group will not receive a telerehabilitation program.
41382406|NCT06022666|OTHER|Geriatric assessment|Geriatric assessment through PATH clinic which includes an evaluation of comorbidities, health trajectory and baseline frailty as well as conducting an in-depth discussion with the patient on how frailty stage impacts decision-making about surgery in order to co-develop a care plan.
41382407|NCT03980561|DRUG|Varenicline|Active medication
41382408|NCT03980561|DRUG|Placebo|Inactive medication
41382409|NCT06124846|BEHAVIORAL|CB-Abst|incentivized, biochemically verified abstinence via contingency management
41382410|NCT06124846|BEHAVIORAL|CB-Mon|monitoring with no required abstinence
41382411|NCT03710759|OTHER|Assistive autogenic Drainage|Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
41382412|NCT04071457|DRUG|Lenalidomide|Commercially available intervention
41382413|NCT04071457|DRUG|Daratumumab/rHuPH20|SWOG-Held IND
41508394|NCT02203331|DRUG|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
41508395|NCT02203331|DRUG|Anastrozole|Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
41508396|NCT02203331|DRUG|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
41035986|NCT04977362|OTHER|Treatment as Usual|treatment as usual according to standard care in heart valve surgery
41035987|NCT03285282|PROCEDURE|Thoracolumber interfascial plane block|Thoracolumber interfascial plane block versus placebo
41035988|NCT03166618|DEVICE|Juvéderm® VOLUMA XC|Juvéderm® VOLUMA XC hyaluronic acid injectable gel
41035989|NCT01248884|BIOLOGICAL|Infanrix hexa™|3 doses, intramuscular into left thigh
41382414|NCT06568757|OTHER|Wet Cupping|Wet cupping therapy will be applied once using disposable plastic vacuum cups to a total of 4 areas, which are recommended areas for headaches; cervical spine C7 (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupuncture point) and suboccipital region (FengFu DU-16 acupuncture point).
41508397|NCT00880789|BIOLOGICAL|CMV/AdV specific T cells|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
41508398|NCT05186792|OTHER|Test:mycoplasma|Retrospective analysis of records of recruits to a previous mycoplasma study.
41382415|NCT06568757|OTHER|No intervention|No treatment will be applied to individuals and the routine medical treatment program will continue.
41382416|NCT03985800|OTHER|TEAM|TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist.
41382417|NCT03985800|OTHER|TECH|TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools.
41382418|NCT03614949|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.
41382419|NCT03614949|DRUG|Atezolizumab|Atezolizumab 1200 mg intravenously (IV) every 3 weeks.
41382420|NCT02002949|PROCEDURE|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
41382421|NCT02002949|PROCEDURE|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
41382422|NCT03052374|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
41382423|NCT02998645|DRUG|eltrombopag|Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.
41382424|NCT02998645|DRUG|Cyclosporine|"Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows:~* 6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months~* 9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months~* 12-24 months: dose was maintained"
41382425|NCT05196802|COMBINATION_PRODUCT|mHeart.4u|The mHeart.4U is a multiple-components intervention entailing the adoption and use of technological devices and self-management recommendations tailored to behavioural modifications (e.g. physical exercise and dietary patterns)
41382426|NCT02729727|DEVICE|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
41382427|NCT05092802|DRUG|HLX208|450mg bid po
41382428|NCT00668369|PROCEDURE|Gradual immunosuppression drug withdrawal.|Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
41382429|NCT03902249|DRUG|Dexamethasone|
41035990|NCT01248884|BIOLOGICAL|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
41035991|NCT01248884|BIOLOGICAL|GSK217744|3 doses, intramuscular into left thigh
41382430|NCT02701049|OTHER|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
41382431|NCT02999646|OTHER|MVX-ONCO-1|Autologous cells: 1 vial containing 4x10\^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10\^5 MVX-1 cells
41382432|NCT03361709|DRUG|Dexamethasone|Dexamethasone will be injected intracamerally at the conclusion of Phacoemulsification
41382433|NCT03361709|DRUG|Saline Solutions, Intraocular|Only saline will be injected intracamerally at conclusion of Phacoemulsification
41508399|NCT06447194|DRUG|Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail|Please refer to description for interventional group.
41508400|NCT06447194|OTHER|Placebo|100mL paraspinal normal saline injection intraoperatively, once.
41508401|NCT01911286|PROCEDURE|Apnea test - Standard|
41508402|NCT01911286|PROCEDURE|Apnea test - CPAP|
41508403|NCT02213510|DEVICE|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
41035992|NCT04471818|DRUG|Ketamine|Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
41382434|NCT06335511|PROCEDURE|microsurgical decompression|decompression of neurological structures
41382435|NCT06335511|PROCEDURE|decompression and instrumented fusion|decompression of neurological structures and spine stabilization
41382436|NCT03444909|DEVICE|cardiotocograph|Monitoring of 20 min with the cardiotocograph
41382437|NCT03444909|DEVICE|Toconaute|Monitoring of 20 min withToconaute
41382438|NCT03444909|DEVICE|electrophysiological device (Micromed)|Monitoring of 20 min with the cardiotocograph
41382439|NCT00274807|BIOLOGICAL|filgrastim|
41382440|NCT00274807|DRUG|cytarabine|
41382441|NCT00274807|DRUG|etoposide|
40852587|NCT06449495|DEVICE|NIRVANA|"NIRVANA is a medical device using semi-immersive virtual reality for motor and cognitive neuro-rehabilitation.~NIRVANA creates a sensory room where the patient can have an immersive and stimulating experience by interacting directly with different realistic scenarios. The system creates different scenarios on the wall or floor, and the patient interacts with the stimuli provided. A motion-analysis device detects the patient's behavior and based on the projected environment provides highly stimulating and rehabilitative audiovisual feedback with full whole-body immersion. The system is preconfigured with a series of exercises, which can be customized based on different types of patients, intervening on the level of difficulty, speed of execution and sensitive area of the projection."
40852588|NCT01228526|DEVICE|PriMatrix|
40852589|NCT06426914|OTHER|Clinical Pilates|"Warmup: 5-10 minutes Pilates Clinical (Introductory program) The Hundred modified The Roll-up modified The roll-over modified Spine twist modified Single-leg circle modified Rolling like a ball Shoulder Bridge modified~For every Step emphasizing:~FOCUS: On muscle involved REPETITIONS: 3-5 VISUALIZATION: Imagination process (Different for each step) Cool down: 5 minutes Total Time: 30 minutes"
40852590|NCT06426914|OTHER|Cardiac Rehabilitation|"Chest Physical therapy (Chest percussions and active huffs as per need) Breathing strategies (Diaphragmatic and purse lip 1-3 sets \* 5 Reps/Day)~Functional mobility (walk /cycling as per patient tolerance)~Patient education and Wound care Sternal Precaution guidance"
40852591|NCT04486872|BIOLOGICAL|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells injection. Within 3 to 5 days after the pretreatment, the subjects received a single A-02 reinfusion, the infusion dose of each group of subjects 1.00 × 10\^6/kg, 3.00 × 10\^6/kg or 5.00 × 10\^6/kg (if applicable), it is recommended to complete the infusion within 30 min after cell recovery.
40852592|NCT05972837|DEVICE|Surface electrical stimulation (SES)|Participants will undergo 3 weeks (20 minutes/ time, three times/ week) of SES intervention.
40852593|NCT05972837|OTHER|Remote medical support|The remote medical support includes a session of video call with a rehabilitation doctor in the first week and weekly telehealth visits with a live physical therapist or physician. The contents of the video calls contain patient education, stretching exercises teaching and instructions of using SES for MPS.
40852594|NCT05127239|BEHAVIORAL|Smartphone Application with lifestyle modification Intervention|The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .
41382442|NCT00274807|DRUG|mitoxantrone hydrochloride|
40852595|NCT04776512|PROCEDURE|ESP Block With Bupivacain|bilateral lumbar ESP block using 0.375% Bupivacain
40852596|NCT04776512|PROCEDURE|Epidural Analgesia|Continuous Lumbar Epidural analgesia With 0,125% Bupivacain+0,25 mcg/ml Sufentanil
40852597|NCT05041972|DRUG|ARX788|ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).
40852598|NCT01022424|DRUG|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
41035993|NCT04471818|OTHER|Placebo|Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
41035994|NCT01592032|DRUG|Vancomycin antimicrobial-lock solution|Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
41035995|NCT01592032|DRUG|Teicoplanin antimicrobial-lock solution|Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
41382443|NCT05410769|BEHAVIORAL|Compassion Focused Therapy|This pilot study aims to propose for the first time a Compassion protocol (Compassion Program for Parkinson) to a group of patients with PD and a group of caregivers and to evaluate its feasibility and effectiveness. The investigators aim to assess whether the program is effective in improving the quality of life and psychiatric symptoms of the patients and caregivers. The Compassion program is a healthy form of self- acceptance, which involves being touched by one's own suffering, along with the desire to alleviate it and treat oneself with understanding and kindness. The duration of the protocol will be 6 weeks (1 meeting/ week of 2 hours). The investigators will recruit 40 patients and 20 caregivers who will be assessed pre and post intervention (Compassionate Mind Training) with interviews, self reports and measurement of the heart rate variability.
41382444|NCT01224769|DRUG|bendamustine +/- rituximab|
41382445|NCT06560255|DIETARY_SUPPLEMENT|n-3 fatty acid|Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
41382446|NCT06560255|OTHER|Rape seed oil|Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
41382447|NCT05508321|DIAGNOSTIC_TEST|Nasal brushing|Nasal brushing to harvest nasal cells and perform staining experiments
41382448|NCT05508321|DIAGNOSTIC_TEST|Sniffin' Sticks|Assessment of olfactory function
41382449|NCT06324968|DIAGNOSTIC_TEST|Positive serology for anti-SSA|Blood sample which detect serology for anti-SSA.
41382450|NCT01497860|DRUG|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
40852599|NCT03642730|DEVICE|TransThoracic Echocardiography imaging|ultrasound scanning
41035996|NCT01592032|DRUG|Linezolid antimicrobial-lock solution|Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
41035997|NCT01592032|DRUG|Daptomycin antimicrobial-lock solution|Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
41035998|NCT01592032|DRUG|Tigecycline antimicrobial-lock solution|Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
41165484|NCT00816621|BEHAVIORAL|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
41382451|NCT02259413|BEHAVIORAL|Exercise Rehabilitation|This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks
41382452|NCT06379139|OTHER|•Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube|Dynamic full-field optical coherence tomography analysis of endotracheal tube sections to better apprehend strucural characterization of endotracheal tube-deposited biofilm
41508404|NCT02213510|DEVICE|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
41165485|NCT00686088|DRUG|PRX302|Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
41165486|NCT03937232|BEHAVIORAL|Cross-Education|Home exercise program + usual care
41165487|NCT03937232|BEHAVIORAL|Mirror Visual Feedback|Home exercise program + usual care
41165488|NCT03937232|OTHER|Usual care|Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting
41382453|NCT05310604|PROCEDURE|Blood withdrawal|Single blood withdrawal for determination of immunoglobulin levels
40852600|NCT02659436|OTHER|Verbal-linguistic CBT|Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.
40852601|NCT02659436|OTHER|Imagery-based CBT|Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
41382454|NCT05654649|DRUG|0.9%sodium chloride|Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
41382455|NCT05654649|DRUG|Dexamethasone|Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
41382456|NCT04294498|DRUG|Durvalumab|Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma
41382457|NCT05140239|OTHER|No Intervention|Non Interventional
41382458|NCT04185259|OTHER|Acupuncture|The investigators will apply two Ashi points (the two most severe tender points in the most sensitive area over the anteromedial aspect of the heels), Chengshan (BL57), Taixi (KI3) and Kunlun (BL60) in this trial. With the patient in a prone position, the local skin will be routinely sterilized followed by a 10mm diameter and 5mm thick sterile adhesive pad pasting onto each selected acupoint. Ashi points will be perpendicularly inserted through the pad to the plantar fascia layer with a depth of approximately 15-20mm depending on the location. BL57, KI3 and BL60 will be punched perpendicularly 10-15mm deep into the skin through the pad. All needles except Ashi points will be manually stimulated by small, equal manipulations of lifting, thrusting, twirling and rotating to achieve De qi. Needles will be retained for 30 minutes per treatment. During each treatment, every needle will be manipulated three times every 10 minutes.
41508405|NCT05063851|DRUG|Memantine Hydrochloride Tablets|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
41035999|NCT01785238|OTHER|renal echography|renal echography to analyse the kidney
41036000|NCT01785238|OTHER|Blood sampling|Blood sampling to analyse different parameters of renal function
41036001|NCT01785238|OTHER|collection of an urine sample|Collection of an urine sample to perform analysis of renal function parameters
41165489|NCT05097898|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation
41382459|NCT04185259|OTHER|Sham acupuncture|Sham Ashi (0.5 cun away from Ashi, one 'cun' is equivalent to the greatest width of the individual patients' thumb, \~1.5 cm), sham BL57 (0.5 cun lateral to true BL57 horizontally), sham KI3 (midway between true KI3 and heel tendon) and sham BL60 (midway between true BL60 and heel tendon) will be used. Treatment protocol will be similar to that of the acupuncture group. The Hwato-brand disposable blunt-tipped needles (size 0.30 × 25 mm) will be inserted at sham points through adhesive pads to the skin without skin penetration. The needles will then be lifted, thrusted, twirled, and rotated evenly three times every ten minutes. No specific de qi response will be elicited.
41382460|NCT03144115|DRUG|Oxytocin|
41382461|NCT03144115|DRUG|Placebos|
41382462|NCT02092584|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
41382463|NCT02092584|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
41382464|NCT04043052|OTHER|Psychological evaluation|Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
41382465|NCT04043052|OTHER|Functional evaluation|Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
41382466|NCT04043052|BIOLOGICAL|Biological assessment|Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
41382467|NCT04043052|OTHER|Ecological Momentary Assessment|During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
41508406|NCT05063851|DRUG|Placebo|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
40852602|NCT05354271|OTHER|High-intensity interval training|Patients will cycle or walk/run four intervals of four-min at high intensity with the aim to reach 80-90% of peak oxygen consumption, 90-95% of peak heart rate, 15-17 Borg scale, shortness of breath). Each interval is separated by a three-min active recovery, at 50-60% of peak oxygen consumption or 70-75% of peak heart rate. Total exercise time will be 38 min including the warm-up and cool-down.
40852603|NCT05354271|OTHER|Moderate-intensity continuous training|Patients will cycle or walk/run continuously at moderate intensity (50-60% of peak oxygen consumption, 70-75% of peak heart rate) for 37 min. Total exercise time will be 47 min for the Moderate-intensity continuous training group including warm-up and cool-down (isoenergetic compared to high-intensity interval training).
40852604|NCT05809362|DEVICE|WHOOP 4.0 Strap|Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
40852605|NCT05809362|DEVICE|BioTel ePatch|Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
40852606|NCT05872347|DRUG|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral.
41165490|NCT05097898|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation
41382468|NCT01444469|DRUG|Zithromax|250mg \* 2 capsules once daily for three days
41382469|NCT01444469|DRUG|Placebo|Lactose powder
41382470|NCT01493609|BEHAVIORAL|Click-East app|Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
41508407|NCT05093829|BIOLOGICAL|NmCV-5|NmCV-5 is a pentavalent meningococcal (A, C, Y, W, X) polysaccharideconjugate vaccine composed of capsularpolysaccharides (PS) from Neisseria meningitidis serogroups A, C, Y, W, and X individually conjugated to a protein carrier, either mutant diphtheria toxoid (CRM197) or tetanus toxoid (TT).
41508408|NCT05093829|BIOLOGICAL|MenACWY-TT|MenACWY-TT (the comparator meningococcal vaccine) is a WHO-PQ quadrivalent meningococcal (A, C, Y, W) polysaccharide-conjugate vaccine manufactured by Pfizer.
41508409|NCT03245827|DRUG|Clomiphene|clomiphene capsule 25mg twice a week
40852607|NCT05905731|BIOLOGICAL|TCR-T|"Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10\^5 cells/kg to 5 x 10\^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment."
40852608|NCT00662909|DRUG|Mirabegron|Oral
40852609|NCT00662909|DRUG|Placebo|Oral
41036002|NCT01785238|OTHER|Blood pressure measurement|
41036003|NCT05544799|OTHER|No intervention|No intervension
41036004|NCT02995967|PROCEDURE|Hydrodistention|The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
40852610|NCT06396624|RADIATION|Intervention Group photobiomodulation|Seven spots on child's thorax and two spots on the face will be irradiated with 40s per point of photobiomodulation.
40852611|NCT06396624|OTHER|Control Group|The photobiomodulation device will positioned in seven spots on thorax and two in child's face, but it will not emit any time of radiation, since the device will be turned off.
41382471|NCT01734421|OTHER|Control group|6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
41382472|NCT01734421|DEVICE|Cell phone Aplication for Smarth Phone|
41382473|NCT06519799|OTHER|Menstrual hygiene products|The influence on the intimate health of each product will be evaluated. As you can't not use a menstrual product during menstruation, no control group is included
41382474|NCT03907709|BEHAVIORAL|In-Home Addiction Treatment Program|"* Treatment was delivered per treatment protocol~* Primary IHAT Care Team consisted of a licensed Care Coordinator (LPN, RN, MSW, LPC, or LMFT) and two Recovery Advisors~* Urine drug screens administered randomly~* Appointments were scheduled per protocol for 52 weeks~* Within first two weeks of care, all clients are provided an evaluation by a psychiatrist to ensure fitness for program"
41382475|NCT01064830|DRUG|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
41382476|NCT01064830|DRUG|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
41036005|NCT02995967|DRUG|Botulinum toxin-A|Intradetrusor injection of 100 units of botulinum toxin a
40852612|NCT03624595|DRUG|Dexmedetomidine|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
41382477|NCT06142448|DEVICE|Cueing app|"All participants that are included come to the movement lab for the baseline measurement. The baseline measurement consists out of extensive clinimetrics (for example MDS-UPDRS) to identify patient characteristics. With the use of an objective gait assessment, the effectiveness of both internal and external cueing is determined. This will divide the participants in three groups; responders, non-responders and in between. Participants who clearly respond to either internal or external cueing (determined as the responders) are asked to apply the working form of cueing in daily life during the six-month follow-up. During this period the participants will use a mobile application that can provide them with a rhythmic auditory stimulus and records the use of this application.~After 6 months, both the responders and non-responders are asked to return to the lab for the follow up measurement in which the baseline measurement is repeated to evaluate the effect of long-term cueing."
41382478|NCT03490539|DRUG|Mycophenolate Mofetil|oral tablets
41382479|NCT03490539|DRUG|Azathioprine|oral tablet
41382480|NCT00157040|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
41382481|NCT03981315|DIAGNOSTIC_TEST|Bile test|Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
41382482|NCT03981315|DIAGNOSTIC_TEST|Blood test|Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
41382483|NCT03981315|DIAGNOSTIC_TEST|Gall stone study|Study of the extracted gall stones, analyzing their composition, type, etc.
41382484|NCT03981315|DIAGNOSTIC_TEST|Microbiological bile test|Determination of the microbiological composition of the bile
41508410|NCT03245827|DRUG|Placebo|placebo capsule 25mg twice a week
41508411|NCT02963233|PROCEDURE|Closed reduction and percutaneous pinning and immobilization|
41508412|NCT02963233|PROCEDURE|Non-operative reduction and immobilization|
40852613|NCT03624595|DRUG|Placebo|Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
40852614|NCT02451124|DEVICE|non-endoscopic inflatable balloon for the esophagus|Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
40852615|NCT02451124|OTHER|Questionnaire Administration|Ancillary studies
40852616|NCT02451124|OTHER|Laboratory Biomarker Analysis|Correlative studies
40852617|NCT02451124|PROCEDURE|esophagogastroduodenoscopy|Standard of care, patients digestive tract scoped post balloon brushing
41508413|NCT00461201|PROCEDURE|Nurse practitioner care of patients|
41508414|NCT00587860|DRUG|St. John's wort|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
40852618|NCT02627989|DRUG|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
41508415|NCT00587860|DRUG|Placebo|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
41508416|NCT05298345|OTHER|Family Champions Project Primary Services|"Primary Services: participants receive 12 hours of TYRO Leadership curricula, 6 hours of Core Communication curricula.~Support Services (optional): participants choose from a menu of classes (1-3 hours) at the walk-in mini clinic to meet a variety of self-identified needs."
41508417|NCT02719275|BEHAVIORAL|Social Media Monitoring|Retrospective analyses of social media activity prior to crisis.
41508418|NCT05968417|OTHER|Observational study - sample collection only.|No intervention - blood and/or bone marrow sample collection only
41508419|NCT01670617|OTHER|Particulated Juvenile Articular Cartilage|Treatment of articular cartilage defects up to 7.5 cm2
41508420|NCT00359801|DRUG|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
40852619|NCT02627989|DRUG|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
41165491|NCT05097898|PROCEDURE|Blood and urine sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation
41508421|NCT00359801|DRUG|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
41508422|NCT06171828|DEVICE|Head-Mounted Display (HMD) to communicate with a supervisor remotely|Participants in the experimental group are oriented on using the education platform and communicating with the supervisor through an HMD for about 5 minutes. They then perform and save their ultrasound imaging. If they require assistance, they request help verbally through the HMD's communication system. The supervisor remotely observes and immediately assists upon request, utilizing the HMD and a 360-degree camera.
41508423|NCT06550856|PROCEDURE|SUTURE-CLOSURE OMENTOPEXY IN REPAIR OF PERFORATED PEPTIC ULCER|Patients presented with perforated peptic ulcer will be repaired using full thickness suture closure using 3/0 vicryl suture then omental patch laied over the sutures.
41508424|NCT06550856|PROCEDURE|OMENTOPEXY ALONE IN REPAIR OF PERFORATED PEPTIC ULCER|Patients presented with perforated peptic ulcer will be repaired by using omental patch without any attempt for primary closure of perforation.
40852620|NCT01112878|DRUG|Sugar pill|"Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
41382485|NCT06568523|DIAGNOSTIC_TEST|MAGENTIQ-COLO.|This is a diagnostic performance study; no randomization will be conducted. All subjects will undergo the same study procedures. The endoscopist performing the examinations cannot be blinded for the output of the investigational device in this study. Due to the nature of the intervention, it is not guaranteed that the patient is not awake during the procedure, therefore blinding for the patient is also not feasible.
41382486|NCT02159534|OTHER|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
41382487|NCT04918927|DRUG|Favipiravir|Oral Favipiravir 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7
41382488|NCT04918927|DRUG|Nitazoxanide|Nitazoxanide at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7
41382489|NCT04918927|OTHER|Nitazoxanide Placebo|Nitazoxanide matched placebo at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7.
41508425|NCT04168008|BEHAVIORAL|WISH Adherence|The educational sessions will consist of an adherence-centered curriculum.
41508426|NCT04168008|BEHAVIORAL|WISH Parenting|The educational sessions will focus on parenting and baby care.
41508427|NCT03112642|PROCEDURE|Local anesthetic block [0.35% marcaine]|In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block \[0.35% marcaine\] will be administered.
41508428|NCT03112642|DEVICE|Braun DIG-R-C Stimuplex Blockade Monitor System|The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
41508429|NCT00610246|DRUG|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
41508430|NCT04573114|PROCEDURE|Verticalization|Progressive levels of verticalization
40852621|NCT01112878|DRUG|Gabapentin|"Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
41508431|NCT06021418|DEVICE|DKB-119|Experimental and Acitve Comparator are applied 4 times to each of crow's feet on both sides of the subject.
41508432|NCT03209557|OTHER|SmartWatch SmokeBeat Application|The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
41508433|NCT02976948|OTHER|No intervention|
41508434|NCT00453050|DRUG|imiquimod|
41508435|NCT00453050|DRUG|indocyanine green solution|
41508436|NCT00453050|OTHER|flow cytometry|
41508437|NCT00453050|OTHER|immunologic technique|
41508438|NCT00453050|OTHER|laboratory biomarker analysis|
41508439|NCT03252730|OTHER|WO 4260 Cosmetic Product for Topical Use|Application on the hair scalp at least once a day over four weeks
41508440|NCT03099057|OTHER|follow-up of patients after interventional rhythm operation|The follow-up will take place at 3 months postoperatively, then at 1 year and then annually for 5 years.
41508441|NCT00658047|DRUG|CH-1504|Comparison of different doses of CH-1504
41508442|NCT00658047|DRUG|Methotrexate (MTX)|10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
41508443|NCT04496518|DEVICE|Intrinsic Antitachycardia Pacing (iATP) Therapy|iATP is a fully automated ATP therapy for monomorphic ventricular tachycardia (MVT).
41508444|NCT03576664|DRUG|Carvedilol 25mg|Cross-over, randomized, placebo-controlled study.
41508445|NCT03576664|DRUG|Placebo oral capsule|Cross-over, randomized, placebo-controlled study.
41508446|NCT01966250|DEVICE|electroacupuncture and usual care|"Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.~Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated."
41508447|NCT01966250|DEVICE|Usual care|Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
41508448|NCT05011318|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
41508449|NCT05011318|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
41508450|NCT02458209|BIOLOGICAL|bococizumab PFS:Pfizer|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover
41508451|NCT02458209|BIOLOGICAL|bococizumab PFS: BIP|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.
41508452|NCT02458209|BIOLOGICAL|bococizumab PFP|150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
41508453|NCT02764346|BEHAVIORAL|iCanCope app|"In addition to standard medical care, adolescents in the experimental group will receive access to the iCanCope smartphone app for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component."
40852622|NCT01112878|DRUG|Clonidine|"Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
40852623|NCT02744196|BIOLOGICAL|Acellbia|Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
40852624|NCT02744196|DRUG|Placebo|Placebo solution will look identical to the Acellbia solution.
40852625|NCT02744196|DRUG|Methotrexate|
41165492|NCT05097898|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24
41508454|NCT02764346|BEHAVIORAL|iCanCope attention control app|"The control group is designed to control for the potential effects on outcomes of time, attention, and smartphone use during the intervention. In addition to standard medical care, adolescents in the attention control group will receive access to the iCanCope control app, with limited functionality."
41508455|NCT01804972|OTHER|Verbal and written information|Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
41508456|NCT01804972|OTHER|Verbal and electronic information|Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
41508457|NCT01818115|DEVICE|Hydrus Implant|
41508458|NCT01818115|PROCEDURE|IOL placement|
41508459|NCT03437070|DRUG|Trabectedin|Administered intravenously per protocol on Day 1 for 21-day cycles.
41508460|NCT03437070|DRUG|Doxorubicin|Administered intravenously per protocol on Day 1 for 21-day cycles.
41508461|NCT03437070|DRUG|Olaratumab|Administered intravenously per protocol
41508462|NCT04814771|DRUG|[14C] TS-142|Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq \[14C\]TS-142 as an oral solution
41382490|NCT06027788|DEVICE|CardioGard Embolic Protection Cannula|The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.
41382491|NCT06027788|DEVICE|Standard Aortic Cannula|An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.
41382492|NCT03597620|DRUG|Metaderm|Metaderm cream and spray will be apply to subjects scalp and body.
41382493|NCT01757873|DRUG|Z160|
41382494|NCT01757873|DRUG|Placebo|
41382495|NCT02159573|BIOLOGICAL|natalizumab|Administered as per routine clinical practice
41382496|NCT02159573|DRUG|dimethyl fumarate|Administered as per routine clinical practice
41382497|NCT06566807|DRUG|Orelabrutinib, obinutuzumab|orelabrutinib，150mg，D1-D28 obinutuzumab，1000mg，D1、D8、D15/cycle1 D1/cycle2-6 . The patients will be treated with 6 cycles of O2 regimen. Patients with CR/PR after 6 cycles of O2 treatment will be treated with 1 year of single-agent orelabrutinib regimen.
41382498|NCT04196699|BEHAVIORAL|self-management program|"Our intervention will be based on the following framework and will consist of 3 phases :~Phase I: At the end of a medical consultation, the doctor will offer the patient the opportunity to benefit from a nursing consultation and remote monitoring to better manage his COPD. A nursing consultation will be scheduled during which the nurse will explain the procedure, obtain the written consent of the patient, and develop an educational diagnosis with the participation of the patient.~Phase II: During the next six weeks education sessions will be provide to the participants and a telephone number will be available in case of emergency and for any additional information.~Phase III: A final consultation will be scheduled at the nurse office to evaluate the patient's achievements and modify his/her educational assessment. A telephone follow-up will be conducted after one month to assess the maintenance of learning."
41382499|NCT06540807|DEVICE|Colovac Colorectal Anastomosis Protection Device|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
41382500|NCT06540807|PROCEDURE|Stoma creation|Diverting loop ileostomy
41382501|NCT05649787|BEHAVIORAL|Supervised aerobic training|Supervised moderate to high-intensity interval aerobic training
41382502|NCT05649787|BEHAVIORAL|Supervised aerobic plus low to moderate-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
41382503|NCT05649787|BEHAVIORAL|Supervised aerobic plus moderate to high-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
41508463|NCT03623347|OTHER|TMZ and BEV induction before chemoradiotherapy|New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.
41508464|NCT05083897|OTHER|hip adduction isometric contraction|addition of isometric hip adduction contraction to the knee extension for measuring knee extension peak torque by the isokinetic dynamometer
41508465|NCT01476566|BEHAVIORAL|Educational intervention|Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
41508466|NCT05430217|DRUG|Buspirone|1 tablet (15 mg) once per day for 28 days
41508467|NCT05430217|DRUG|Placebo|1 placebo tablet once per day for 28 days
41382504|NCT04341727|DRUG|Hydroxychloroquine Sulfate|anti-rheumatic drug (DMARD)
41382505|NCT04341727|DRUG|Azithromycin|Antibiotic
41382506|NCT04341727|DRUG|Chloroquine Sulfate|Antimalarial
41382507|NCT06562075|DEVICE|Decoria Intense Strong|"Decoria® Intense Strong is a HA-based, BDDE-crosslinked dermal filler. Decoria® Intense Strong dermal fillers are injected into dermal tissue to improve and define contouring of jawline profile, supporting overlying tissue to shape facial contours to desired level of correction.~Appropriate injection volume for the jawline will be determined by the Treating investigator according to IFU"
41382508|NCT06425601|DEVICE|SIL drain|Silicone chest tube used for pleural space drainage after VATS lobectomy
41508468|NCT05954221|PROCEDURE|Red cell lysis buffer (RCLB) application|The tissue is lysed with 50% concentration of RCLB for 15 min on a shaking device. If the lysis is judged to be insufficient, it can be repeated one more time. Finally, the treated tissue will be fixed with 10% formalin.
41508469|NCT05954221|PROCEDURE|Conventional processing|The tissue is fixed with 10% formalin.
41382509|NCT06425601|DEVICE|PVC drain|Polyvinyl chloride chest tube used for pleural space drainage after VATS lobectomy
41382510|NCT01465074|DRUG|Nicotine polacrilex|4 mg
41382511|NCT01465074|DRUG|Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum|30 min chewing, one dose
41382512|NCT00871806|DRUG|Commercial tablet with water|40 mg tablet, given once to each subject
41382513|NCT00871806|DRUG|ODT #1 without water|40 mg tablet given once to each subject
41382514|NCT00871806|DRUG|ODT #2 without water|40 mg tablet given once to each subject
41382515|NCT00871806|DRUG|ODT #1 with water|40 mg tablet given once to each subject
41382516|NCT00871806|DRUG|ODT #2 with water|40 mg tablet given once to each subject
41165493|NCT05097898|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
41382517|NCT02763007|DRUG|alogliptin+pioglitazone|alogliptin and pioglitazone add on metformin
41382518|NCT02763007|DRUG|alogliptin|nesina add on metformin
41382519|NCT02763007|DRUG|pioglitazone|actos add on metformin
41382520|NCT02214004|DRUG|Trastuzumab|"- Eight times IV administration of trastuzumab per 3 weeks~* Trastuzumab 8mg/kg on Day 1 of Cycle 1~* Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"
41382521|NCT02214004|DRUG|Letrozole|- Daily letrozole 2.5 mg/day for 24 weeks
41382522|NCT06031922|DEVICE|Microprocessor controlled knee|Microprocessor controlled knee
41382523|NCT02900976|BIOLOGICAL|Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes|Given IV
41382524|NCT02900976|BIOLOGICAL|Rituximab|Given IV
41382525|NCT01067339|DRUG|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
41382526|NCT01067339|DRUG|placebo|placebo, by mouth, once daily for six months
41382527|NCT00170898|DRUG|Lumiracoxib|
41382528|NCT02204839|DRUG|Basal insulin dose|
41382529|NCT04391686|DIAGNOSTIC_TEST|indirect calorimetry|to determine and compare the resting energy expenditure of each group
41508470|NCT03545204|OTHER|Kangaroo Mother Care Package|"The KMC package will include creation of KMC Champions from within the community, social mobilization to create awareness and its acceptance with families using powerful IEC tools such as docudrama, flip charts, pictorials in local languages; engagement of community and community leaders, capacity building of health care providers on Kangaroo mother care, essential newborn care ENC, policy dialogues with stake holders in the public and private sectors and delivery of a KMC kit  to the pregnant female by the Implementation team"
40852626|NCT00525005|DRUG|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
40852627|NCT02019875|DRUG|Rifampin|P450 inducer
40852628|NCT02019875|DRUG|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
41382530|NCT03724591|PROCEDURE|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
41382531|NCT03724591|PROCEDURE|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
41382532|NCT04205292|PROCEDURE|hysteroscopic|Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
41382533|NCT03408327|DEVICE|Wearable technology|Fitness wristband \& APP
40852629|NCT02019875|OTHER|Grapefruit Juice|CYP3A4 inhibitor in intestine
41165494|NCT05338112|DIAGNOSTIC_TEST|Tzanck smear|The Tzanck smear is gently taken with a sterile scalpel from the ground of erosion or bullous lesions of pemphigus vulgaris. The sample taken is examined by staining the slide.
41165495|NCT01648036|DRUG|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
41382534|NCT03408327|BEHAVIORAL|LINE group|Promote social interaction
41508471|NCT03545204|OTHER|Routine Standard Care|Routine Standard Care ( essential Newborn care )ENC
41508472|NCT05131828|DRUG|Metformin and clemastine in combination|"Metformin hydrochloride 500 mg prolonged release (SR) tablet for oral administration.~Clemastine hydrogen fumarate 1.34 mg tablet for oral administration."
41508473|NCT05131828|DRUG|Placebo|Placebo tablets to match both metformin and clemastine tablets.
40852630|NCT02019875|OTHER|Placebo|
41165496|NCT01648036|DRUG|Dalteparin|Dose 5000 IU, subcutaneous, daily
41165497|NCT02725398|DRUG|Buscopan|Buscopan is administered by endoscopic nurse in the Buscopan group,and then recording the outcome measures.
41382535|NCT03408327|BEHAVIORAL|Group activities|Which was developed by applying social cognitive theory
41382536|NCT03408327|DEVICE|Health promotion manual|Which was about general physical activity promotion content
41382537|NCT01433029|OTHER|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
41382538|NCT01433029|OTHER|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
41382539|NCT05572944|OTHER|LDCT lung cancer screen, immediately|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test and chest X ray~5. Arrenge chest CT right away, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~6. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
41036006|NCT02630264|DRUG|Endostatins|"Specification: 1mL/division, 1×1012 VP/1.0mL~E10A preparation:~1. Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.~2. Swirl gently. Do NOT shake.~Method of administration~1. E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.~2. After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.~3. Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding."
41382540|NCT05572944|OTHER|LDCT lung cancer screen, later|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test.~5. Arrange AI-asisted chest X-ray right away.~6. Arrange chest CT three years later, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~7. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
41382541|NCT03125564|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
41382542|NCT03125564|PROCEDURE|Sham|Infusion of sham
41382543|NCT03125564|PROCEDURE|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
41382544|NCT05985200|DRUG|BI 3032950|BI 3032950
41382545|NCT05985200|DRUG|Placebo matching BI 3032950|Placebo matching BI 3032950
41382546|NCT02187406|PROCEDURE|Modified ankle athletic taping|
41382547|NCT02187406|PROCEDURE|Traditional ankle athletic taping|
41382548|NCT04167839|OTHER|Sensory diet|Sensory diets are one of the interventions occupational therapists use in school-based settings to manage manifestations of sensory processing disorder. Sensory diets are composed of exercises and multisensory activities that are tailored for children and provide them sensorimotor experiences to facilitate their participation in daily activities.
41382549|NCT00293605|PROCEDURE|Total Hip Replacement|Implantation of one of 3 stem designs
41382550|NCT05545449|BEHAVIORAL|PrEP Peer Mentor Program|Five PrEP peer mentors will provide outreach, education, and referral for HIV pre-exposure prophylaxis. Peer mentors have received training on HIV, PrEP, family planning, adolescent development, peer support, and action planning. Interactions will include 1:1 informal interactions as well as planned group outreach interactions.
41382551|NCT05381025|DIETARY_SUPPLEMENT|Kava (Piper methysticum) extract|Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
41382552|NCT02157181|DRUG|2CdA +/- Rituximab|Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
41382553|NCT06565754|OTHER|BFR|"Blood flow restriction training is an accessory to a variety of different exercise modes (e.g., resistance exercise, walking, cycling) has recently become a popular research topic. It involves the application of pressurized cuffs to the proximal portion of each lower extremity or upper extremity. It enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet or cuff.~The 3rd Generation SmartCuffs® pump (SmartCuffs® 3.0 PRO) is Personalized Pressure feature which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it is calculate arterial occlusion pressure and set the optimal pressure for patient's body. There is no need for an external doppler probe or hand pump. This unit will do everything for patient. Smart Cuffs 3rd generation is FDA Approved Listed Class 1 device.~The automatized tourniquet (Smart Tools) contains a ring-shaped single- chamber"
41382554|NCT06565754|OTHER|strengthening exercise|Quadriceps strengthening exercises are part of the treatment of PFPS, but the heavy resistance exercises may aggravate knee pain. Blood flow restriction training (BFRT) provides a low-load quadriceps strengthening method to treat PFPS (Giles et al., 2017).
41382555|NCT06566313|BEHAVIORAL|transcranial Direct Current Stimulation|On the basis of conventional anti-PD drugs, the left M1 region (based on the C3 coordinates of EEG 10-20 system and the surrounding FC1, FC5, CP1, CP5 coordinates) was treated with cathodic tDCS. The electrical stimulation intensity was 2.0mA, the treatment time was 20min, and the treatment lasted for 10 days.
41382556|NCT06039956|PROCEDURE|Sentinel lymph Node Biopsy|The SLNB will be performed with 5 ml of undiluted methylene blue injected in equal aliquots, peri-tumoral, followed by a 5-minute massage prior to skin incision. Sentinel nodes will be defined as those that have uptake / visible blue staining or suspicious palpable nodes at the discretion of the operating surgeon. Sentinel nodes will be placed in formalin and sent separately. This will be followed by an immediate completion ALND, which will be similarly placed in formalin and sent separately from the SLNB specimen. Specimen radiographs will be performed on all specimens to confirm location of clip within SLNB vs. ALND specimens.
41036007|NCT02630264|DRUG|Paclitaxel injection|"Specification:~30mg/5mL,~Usage:~160mg/m2 on day 3, according to instruction."
41036008|NCT02630264|DRUG|Cisplatin injection|"Specification:~20mg~Usage:~Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction."
41036009|NCT02571569|DRUG|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
41036010|NCT02571569|DRUG|BAY1093884|Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
41036011|NCT03663751|DRUG|Decitabine|low-dose decitabine: 5mg/m2 daily for 5 days
41036012|NCT04323852|DRUG|Vitamin D|Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery
41036013|NCT04323852|DRUG|Placebo|Placebo
41036014|NCT03052179|DIETARY_SUPPLEMENT|Poly-biotic|Before-after treatment
41036015|NCT00868439|DRUG|patiromer|Active investigational drug
41036016|NCT00868439|DRUG|placebo|placebo
41036017|NCT03634774|OTHER|CHOICE+ Training Program|CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.
41382557|NCT02815189|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).
41382558|NCT02815189|DRUG|Acetaminophen 325 mg for Flare up|Each patient will be evaluated a week after completion the clinical procedures.
41382559|NCT05469854|DRUG|Linaprazan glurate|"Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses).~Linaprazan glurate hydrochloride (HCl), 25 mg and 100 mg (as base) oral tablets (200 mg and final dose level of maximum 400 mg)."
41382560|NCT05469854|DRUG|Placebo|Single dose, oral tablets
41382561|NCT00882804|DRUG|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in \~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
41382562|NCT00882804|DRUG|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
41382563|NCT05430009|RADIATION|Liver SBRT|24-45 Gy delivered in 3-5 fractions to 1-4 lesions.
41382564|NCT05430009|DRUG|Pembrolizumab|200 mg every 3 weeks or 400 mg every 6 weeks
41508474|NCT01098474|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
41508475|NCT01098474|BIOLOGICAL|Tritanrix™ HB+Hib|Intramuscular, 3 doses
41508476|NCT01098474|BIOLOGICAL|Prevnar™|Intramuscular, 3 doses
41508477|NCT01098474|BIOLOGICAL|Polio Sabin™|Oral, 3 doses
41508478|NCT01098474|BIOLOGICAL|Menjugate™|Intramuscular, 3 doses
41508479|NCT04187547|DRUG|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)"
41508480|NCT04187547|DRUG|Placebo|Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
41508481|NCT03778684|DIAGNOSTIC_TEST|Visceral fat thickness|An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.
41508482|NCT03778684|DIAGNOSTIC_TEST|Body mass index|Weight and height will be measured with subjects in a standing position wearing light clothes and no shoes.
41382565|NCT00885937|DRUG|Dexpanthenol (Sinecort, BAY81-2996)|1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)
41382566|NCT00885937|DRUG|Positive control, Na-laurylsulfat-solution|50 mikro liter of 0.5 % Sodium-laurylsulfate-solution
41382567|NCT00885937|DEVICE|Untreated skin under application chamber|Application of treatment chamber as in arm 1 and arm 2 on untreated skin
41382568|NCT04206436|DRUG|Cftr Modulators|CFTR modulators are drugs used to treat cystic fibrosis
41508483|NCT03488082|BEHAVIORAL|fMRI|saccadic adaptation (target presentations, with or without target jump) during fMRI exam
41508484|NCT01149408|DRUG|Decitabine (Dacogen)|Decitabine; 20 mg/m2; 1 hour intravenous infusion; 1 -3 days (will be given on a 28-day cycle for up to 18 months)
41508485|NCT04988919|DIETARY_SUPPLEMENT|4D|multi-ingredient supplement mixed with 24 ounces of water
41508486|NCT04988919|DIETARY_SUPPLEMENT|placebo|taste-matched placebo mixed with 24 ounces of water
41508487|NCT03204682|DEVICE|Repetitive transcranial magnetic stimulation|Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
41508488|NCT00294580|DRUG|Maloprim|
41508489|NCT01918202|DRUG|20 mg PF-02545920|Subject will receive a single dose of 20 mg PF-02545920.
41508490|NCT01918202|DRUG|PF-02545920|"The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.~This cohort is optional."
41508491|NCT01918202|DRUG|PF-02545920|The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
41508492|NCT01867983|BEHAVIORAL|Weight gain prevention and smoking cessation|"The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls."
41508493|NCT01867983|BEHAVIORAL|Smoking cessation|The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
41508494|NCT02890784|DRUG|dasatinib (SPRYCEL®)|Treatment optimization for patients with chronic myeloid leukemia (CML)
41508495|NCT00426439|DRUG|Chloroquine|Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
41508496|NCT00426439|DRUG|Artemether-lumefantrine (Coartem)|Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.
40852631|NCT01103063|DRUG|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
41036018|NCT06349369|DEVICE|transcranial direct current stimulation|tDCS is a non-invasive neuromodulation technique that has gained attention for its potential to influence neural activity and address cognitive and functional deficits in individuals with schizophrenia. It involves applying a weak direct electrical current to the scalp, which can increase or decrease the excitability of underlying brain regions.
41036019|NCT03110289|OTHER|superdonor FMT|"Fecal microbiota transplantation (FMT) is the transfer of feces from a healthy superdonor to the patient."
41036020|NCT03110289|OTHER|autologous FMT|Fecal microbiota transplantation (FMT) with feces from the patient him/herself
41036021|NCT01763944|BEHAVIORAL|Low carbohydrate diet|The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
41036022|NCT03181360|DRUG|Tenecteplase|Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
41036023|NCT03181360|OTHER|Control|Best standard treatment
41036024|NCT03721991|DIETARY_SUPPLEMENT|Gama amino butyric acid (GABA)|food supplement Gama amino butyric acid (GABA) as capsules
41036025|NCT03721991|DIETARY_SUPPLEMENT|placebo|matching placebo
41036026|NCT02014857|PROCEDURE|Gingival Crevicular Fluid Sampling|
41036027|NCT03845608|COMBINATION_PRODUCT|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity.recieve100 mg hydrocortisone in 250 ml normal saline at end of surgery and carbon dioxide will be removed by applying gentle abdominal pressure and removing carbon dioxide by passive exsufflation
41036028|NCT02451800|OTHER|in-class yoga|In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
41036029|NCT02451800|OTHER|yoga by DVD|Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
41036030|NCT02451800|OTHER|stretching by DVD|Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
41036031|NCT05783596|DRUG|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.
41036032|NCT05783596|DRUG|Glofitamab|T-cell bispecific humanized monoclonal antibody, via IV infusion.
41036033|NCT06019468|OTHER|Envolizumab combined with radiotherapy|Application of Envolizumab combined with radiotherapy for neoadjuvant treatment of locally advanced thymic cancer. Firstly, 20-40Gy radiation therapy was administered 10-20 times. Within one week after the start of radiation therapy, Envolizumab (300 mg, D1, Q3W, subcutaneous injection) was administered. Immunotherapy was maintained for 2-4 cycles, and surgery was performed after evaluation by the attending physician.
41036034|NCT06532175|DEVICE|Su-Jok|Su-jok seed therapy
41508497|NCT04569734|PROCEDURE|WATCHMAN device implant procedure utilizing ICE probe|The study will be a prospective, non-randomized multicenter registry of 100 patients undergoing LAA closure with the WATCHMAN device (possibly with WATCHMAN FLX when approved) utilizing an intra-procedural ICE probe under moderate sedation.
41508498|NCT06067503|DRUG|18F-fluorofuranylnorprogesterone|The dose of the investigational imaging agent, FFNP, is approximately 7 millicurie (mCi) (259 megabecquerels (MBq)), IV slow infusion over approximately two minutes followed by saline flush.
40852632|NCT01103063|DRUG|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
41036035|NCT00781625|DIETARY_SUPPLEMENT|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
41036036|NCT00781625|DIETARY_SUPPLEMENT|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
41036037|NCT00781625|DIETARY_SUPPLEMENT|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
41036038|NCT04627766|DEVICE|Monitoring with VT-Patch (Connected device manufactured by VitalTracer)|Patients will be monitored for 8 consecutive hours and vital signs will be recorded with VT-Patch and with the standard of care
41036039|NCT04593446|DRUG|Oral Sulfate Tablet(ORA·FANGⓇ)|"Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery~Subjects who are randomized into comparator will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery"
41036040|NCT04593446|DRUG|Sodium Picosulfate Solution(PicosolutionⓇ)|Sodium Picosulfate Solution(PicosolutionⓇ)
41382569|NCT04954625|PROCEDURE|Autologous Blood Patch|All patients will be assessed on the morning of postoperative Day 3 and 4 for the presence of an air leak. If an air leak is present, 60-100 ml of autologous blood will be drawn from a peripheral vein and immediately instilled into the chest tube. The individual who draws blood is that the discretion of the site principal investigator. The tubing will be elevated over an IV pole while the patient remains in bed, moving position every 15 minutes for 1 hour to distribute the blood throughout the pleural cavity. The tubing support will then be removed, allowing the chest tube to drain. After ABP intervention, the chest tube will remain to water seal, as long as the patient tolerates it.
41382570|NCT04954625|PROCEDURE|Standard of Care (per Physician)|Patients randomized to Standard of Care will be treated as their surgeon would as routine. This may mean postoperative observation, of another type of intervention.
41382571|NCT04874701|DRUG|Capsimax|Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
41382572|NCT04874701|OTHER|Energy restriction|Personalised diet plan targeting a 500 kcal/day energy restriction
41382573|NCT01819389|DRUG|Imatinib and Nilotinib|
41382574|NCT06319573|OTHER|Counseling Supported by Univfy® Report|The intervention consists of patients being counseled with the Univfy® PreIVF report during their second consultation. They will also be asked to fill in the same anonymous online questionnaire.
41382575|NCT06319573|OTHER|Standard Counseling|Patients in this group will be counseled as per standard care during their second consultation. They will be asked to complete an anonymous online validated questionnaire (see below) to assess their responses to the anonymous online questionnaire after consultation.
41382576|NCT03361527|OTHER|binaural beamformer|Each study participant will use an Advacned Bionics Naida CI Q90 loaner processor during the course of the study, an Advanced Bionics MyPilot remote control and- if applicable- a SmartPhone. the processors will be programmed with SoundWave and BEPSnet.
41382577|NCT06563440|OTHER|Digital app and information system|A custom digital app and information system that consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures point of care test image, interprets, and transmits results to the central ministry of health data center; (3) Education module - stores and plays back short educational videos for pre- and post-screening counseling; (4) SCD e-Passport module - entry and display of child's salient clinical information.
41382578|NCT02253199|DRUG|intranasal dexmedetomidine|"Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg."
41382579|NCT06566443|DRUG|Honokiol|Honokiol will be given orally at a starting dose of 1 capsule (250 mg/ capsule) per day for 2 weeks. Dose levels will escalate based on dose-limiting toxicity occurrence. We will start at one capsule (250 mg) once daily, dose 0 would be one capsule (250 mg) twice daily, dose +1 would be 500mg in the AM and 250mg in the evening, and +2 would be 500 mg twice daily.
41508499|NCT06067503|DEVICE|Liquid Biopsy|20ml of whole blood will be collected into two Ethylenediaminetetraacetic acid (EDTA) tubes at each timepoint, CTCs are isolated using the microfluidic Versatile Exclusion-based Rare Sample Analysis (VERSA) platform that integrates CTC capture with RNA extraction on a single chip using Exclusion-Based Sample Preparation (ESP) technology
41508500|NCT06067503|DEVICE|Positron Emission Tomography/Computed Tomography|FFNP drug in combination with PET/CT scans to image participant
41508501|NCT02302989|DRUG|Ranibizumab 0.5mg|
40852633|NCT00218699|BEHAVIORAL|Cognitive-Behavioral Intervention|
40852634|NCT00820417|DRUG|Cetuximab/Gefitinib combination and/or monotherapy|
40852635|NCT04957121|OTHER|on-hours|"If the begin time of anesthesia was between 8:00 to 17:59, it was defined as on-hours."
41382580|NCT05186727|OTHER|Family History education|The education, developed in partnership with community partners, intends to assist women to collect family history of breast cancer and share it with their providers.
41382581|NCT05186727|OTHER|Patient Ambassador|The support of a Patient Ambassador in addition to the education is also tested.
41382582|NCT01338701|PROCEDURE|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
41382583|NCT01338701|PROCEDURE|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
41382584|NCT01338701|OTHER|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
41382585|NCT00706927|DRUG|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
41382586|NCT00706927|DRUG|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
41508502|NCT04778904|BIOLOGICAL|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine
41508503|NCT04778904|BIOLOGICAL|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine
41508504|NCT04778904|BIOLOGICAL|Nivolumab|Human immunoglobulin G4 monoclonal antibody
40852636|NCT04957121|OTHER|off-hours|"If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as off-hours."
41036041|NCT03497325|DRUG|autologus platelet rich plasma|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
40852637|NCT05842018|DRUG|Toripalimab, Anlotinib and Chemotherapy|"Combination therapy:~Toripalimab 240mg will be intravenously administered on Day 1, Q3W; anlotinib: 12 mg qd d1-d14, d15-d21 discontinued, Q3W; investigator selected chemotherapy regimen (paclitaxel, pemetrexed or gemcitabine and other chemotherapeutic drugs which were not administered in the first-line therapy) for a total of 4 cycles.~Maintenance therapy:~After combination therapy, Patients who achieved complete response（CR）, partial response (PR), or stable disease (SD) were administered with toripalimab plus anlotinib as maintenance therapy. until disease progression or intolerable toxicity, treatment for 2 years, investigator decision, withdrawal of consent, or death."
40852638|NCT05386693|PROCEDURE|Ilioinguinal nerve block|Local anesthetic injection of the ilioinguinal nerve. This is performed in the outpatient clinic.
40852639|NCT06299839|DRUG|PAS-004|A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1 mg, 4mg, and 10 mg strength capsules, intended for oral administration once daily.
40852640|NCT05254327|DRUG|BMX-001|Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
40852641|NCT01122849|DEVICE|Prototype Nasal Dilator|Prototype nasal dilator AB2R11
40852642|NCT01122849|DEVICE|Marketed Nasal Strip|Breathe Right Nasal Strip- Clear small/medium
40852643|NCT01122849|DEVICE|Placebo Nasal Strip|Placebo strip
40852644|NCT05792917|DRUG|tafolecimab (a modified manufacturing process)|450mg，SC，single dose
40852645|NCT05792917|DRUG|tafolecimab (a original manufacturing process)|450mg，SC，single dose
40852646|NCT05370833|DEVICE|transcranial direct current stimulation|Anodal, 2mA, tDCS session applied on M1 for 20 minutes.
41382587|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath block with ropivacaine|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.3% ropivacaine 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
41508505|NCT00611624|RADIATION|Mammosite brachytherapy radiation|Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
41508506|NCT01285297|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Injection of up to 18 mL BMAC
41508507|NCT00351455|BEHAVIORAL|smoking cessation|
41508508|NCT00351455|BEHAVIORAL|tighter diabetic control|
41508509|NCT00351455|BEHAVIORAL|diet and exercise program|
40852647|NCT01749150|DRUG|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
40852648|NCT01749150|DRUG|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
40852649|NCT01749150|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 12 weeks
40852650|NCT01749150|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
40852651|NCT01749150|DRUG|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 12 weeks
40852652|NCT01749150|DRUG|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 24 weeks
40852653|NCT06275022|PROCEDURE|Inflow occlusion with perforation of septation and sclerotherapy|Inflow occlusion assisted by indocyanine green-fluorescence imaging combined with perforation of septation and sclerotherapy
40852654|NCT06275022|PROCEDURE|Perforation of septation and sclerotherapy|Perforation of septation and sclerotherapy
40852655|NCT06275022|PROCEDURE|Indocyanine green-guided partial resection and sclerotherapy|Indocyanine green-fluorescence imaging-guided partial resection and sclerotherapy
40852656|NCT06275022|PROCEDURE|Partial resection and sclerotherapy|Partial resection and sclerotherapy
40852657|NCT05226299|BIOLOGICAL|Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through a dosimeter-controlled nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. Individual doses will never exceed 1000 micromolar. Cumulative doses per session will never exceed 2000 micromolar. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
40852658|NCT05226299|BIOLOGICAL|Saline|Participants will be repeatedly exposed to a saline through a dosimeter-controlled nebulizer during treatment sessions. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session.
40852659|NCT06469528|DRUG|Colchicine 0.5 MG|Low dose daily colchicine
40852660|NCT04701736|DEVICE|Picture Medication Calendar|
40852661|NCT02371408|DRUG|ravidasvir hydrochloride|200 mg
40852662|NCT02371408|DRUG|sofosbuvir|400 mg
41508510|NCT01349777|DRUG|Pregrel®|Pregrel® 75mg daily for 12 months
41508511|NCT01349777|DRUG|Plavix®|Plavix® 75mg daily for 12 months
40852663|NCT02371408|DRUG|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
40852664|NCT05155774|DEVICE|Twin block|Twin Block orthodontic appliance for treating patients with Angle class II molar relationship and a large horizontal overjet, often in combination with an incomplete lip closure
41036042|NCT03497325|DRUG|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
41036043|NCT05685615|DRUG|BV100 plus Polymyxin B|Rifabutin for Infusion plus Polymyxin B for Injection
41508512|NCT00386347|DRUG|GSK364735 oral solution and oral tablets|
41508513|NCT03316274|DRUG|Nivolumab|Given via intralesional injection
41508514|NCT03042091|DRUG|Polyethylene Glycol|Given orally
41382588|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath puncture with saline|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.9% saline 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
41382589|NCT04203888|OTHER|Swedish Massage|60-minute Swedish Massage delivered in-home by a licensed massage therapist, 2 times per week with at least 48-hours between massage interventions.
41382590|NCT04203888|OTHER|Yoga|"60-minute yoga session delivered in-home by a certified yoga instructor, 2 times per week with at least 48-hours between yoga interventions.Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005)."
41382591|NCT01637064|DRUG|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
41382592|NCT04045834|DEVICE|68Ga-DOTA-TATE PET/MR and PET/CT imaging|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-TATE dose is about 2 MBq/kg body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi), 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
41382593|NCT00171899|DRUG|imatinib mesylate|
41382594|NCT06538571|DIAGNOSTIC_TEST|Near infrared spectroscopy|Noninvasive monitor for venous saturation
41382595|NCT01932515|BEHAVIORAL|A revised screening instrument for use in Deaf children|
41382596|NCT05037409|DRUG|PF-06823859|low dose or high dose intravenous infusion
41382597|NCT05037409|DRUG|Placebo|Intravenous infusion
41382598|NCT02558075|BEHAVIORAL|MoodLifters Sessions|This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
41382599|NCT05164562|OTHER|Data collection|Description: musculoskeletal disorders of upper limb evaluation
41382600|NCT04797637|DEVICE|ABBy® Adjustable Panniculus Retractor for Wound Care|The ABBy (G-Squared Medical, Brentwood, TN) is an extended-wear panniculus retractor/tissue stabilizer that is intended for use postoperatively after abdominal procedure. It is placed directly onto patient skin, superior to a transverse incision, and is then used to elevate redundant tissues away from an incision or wound (https://www.gsquaredmedical.com/How-it-Works.html). The ABBy can be removed and replaced by patients and can be used for up to 10 days. This study aims to assess the effect of ABBy use on postoperative pain, pain medication requirement, and patient satisfaction, when used as a patient-positioning device in women following cesarean delivery.
41382601|NCT03570307|OTHER|medical VS surgical evacuation of the uterus|mentioned above
41508515|NCT03042091|DRUG|Neomycin|Given orally
41508516|NCT03042091|DRUG|Metronidazole Hydrochloride|Given orally
41508517|NCT03042091|PROCEDURE|Therapeutic Conventional Surgery|Undergo colorectal resection
41508518|NCT05925998|OTHER|Observational study: no interventions|Not applicable as observational study with no intervention
41382602|NCT03099616|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
41508519|NCT02969421|OTHER|Cough method for placement of tenaculum|The intervention in this arm is the placement of tenaculum via cough method
40852665|NCT05075590|DIAGNOSTIC_TEST|Coronary Angiography|Following TAVR, the operators will attempt to selectively engage both the right and left coronary arteries. Catheter choice and engagement technique will be at the discretion of the operator.
40852666|NCT03468647|OTHER|soles|Volunteer must walk this this connected seamless to measure different walking parameters
40852667|NCT03468647|OTHER|weighting machine|This weighting machine measure weight evolution and equilibrate of volunteers
41508520|NCT02969421|OTHER|Slow Tenaculum Placement of tenaculum|The intervention in this arm is the placement of tenaculum via slow method
41508521|NCT03833778|OTHER|intervention group|The CED patients play the tablet-CED-quiz, while they wait for their doctor's appointment, so that gaps in the CED knowledge can be clarified during the doctor's consultation.
41508522|NCT02455895|DEVICE|iLid Cleanser|Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
41508523|NCT00965887|DRUG|MK0974 Ethanolate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
41508524|NCT00965887|DRUG|Comparator: MK0974 Hydrate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
41508525|NCT05336032|OTHER|Food (rice)|Cooked rice with 75 gm carbohydrate
41508526|NCT02595801|OTHER|Surgery in early childhood|Surgical interventions in early childhood (prior to completion of Early Development Instrument)
40852668|NCT03468647|OTHER|gripping force|this machine measure the gripping force of volunteer
41036044|NCT05685615|DRUG|BAT|The best avaialble antibiotic therapy to treat CRAB
41036045|NCT06534502|DRUG|Zonisamide Oral Product|Zonisamide oral suspension
41036046|NCT00518115|DRUG|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
41036047|NCT02599792|DRUG|CTP-656|
41036048|NCT02599792|DRUG|Placebo for CTP-656|
41508527|NCT04226521|PROCEDURE|Extracoropreal photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
41508528|NCT00258960|DRUG|Liposomal Doxorubicin|
41382603|NCT03099616|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
41382604|NCT02334839|OTHER|Observational only|Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
41382605|NCT05718505|DEVICE|Atmo Motility Gas Capsule System|"The Atmo System measures whole gut and regional gut transit times. Measurements of GI tract transit times are used for evaluating motility disorders.~Gastric emptying time (GET) is indicated for the evaluation of patients with suspected gastroparesis. Delayed GET is implicated in such disorders as idiopathic and diabetic gastroparesis and functional non-ulcer dyspepsia.~Colonic transit time (CTT) is indicated for the evaluation of colonic transit in patients with chronic constipation, to aid in differentiating slow and normal transit constipation. In the case where ileocecal junction transit cannot be determined the system will report combined Small and Large Bowel Transit Time (SLBTT).~Transit times are derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of fermentation activity, capsule tumble, and antenna reflectance. Not for use in pediatric patients."
41508529|NCT00258960|DRUG|Cyclophosphamide|
41508530|NCT00258960|DRUG|Trastuzumab|
41508531|NCT00205387|PROCEDURE|cardiac elastography and echocardiography|standard echocardiogram
41036049|NCT02599792|DRUG|Kalydeco|
41508532|NCT01246310|DIETARY_SUPPLEMENT|Inositol|
41508533|NCT01246310|DIETARY_SUPPLEMENT|Placebo|
41508534|NCT05228028|PROCEDURE|fascia iliaca compartement block|Ultrasound-guided suprainguinal FICB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
41508535|NCT05228028|PROCEDURE|quadratus lumborum block|Ultrasound-guided anterior QLB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
41508536|NCT03888963|PROCEDURE|PRF|patients will receive pulsed radiofrequency, 4 cycles (each cycle, 2 minutes) on the thoracic paravertebral nerves number 2,3, and 4 under fluroscopic guidance
41508537|NCT03888963|PROCEDURE|SHAM|patients will be subjected to the same procedure like PRF group without giving PRF
41508538|NCT01632280|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes-anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.~In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks."
41508539|NCT03119779|DRUG|MTA-Anglus|MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
41165498|NCT02725398|DRUG|Scopolamine|Scopolamine is administered by endoscopic nurse in the Scopolamine group,and then recording the outcome measures.
41508540|NCT03119779|DRUG|TheraCal|TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
41508541|NCT04587999|OTHER|bladder stimulation|"The bladder stimulation technique requires the presence of 2 people:~* The child must be held by an adult (caregiver or parent) under the armpits, legs dangling.~* the first person (the investigator), performs the stimulation technique consisting of: rapid tapping (frequency of about 100 / min), over the pubic area, at the level of the bladder, alternated with external rotational movements of the pits lumbar, in the kidneys. Alternate these 2 maneuvers every 30 seconds.~* The second person starts the stopwatch at the start of the stimulation, and is about to collect the urine, 2nd jet in a sterile pot~* The maneuver ends as soon as urine is obtained, and will be stopped after 5 minutes in case of failure."
41508542|NCT04587999|OTHER|Quick wee|"The Quick wee technique requires the presence of only one person:~Stimulation of the suprapubic area by circular movements, with a cold and wet compress held by sterile forceps.~Collection of urine in a sterile container."
41508543|NCT04406077|DEVICE|Ligasure|Using ligasure to treat hydrocele
41508544|NCT04582084|DRUG|Etanercept|Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
41508545|NCT03092973|DIAGNOSTIC_TEST|Ultrasound|
41382606|NCT05718505|DEVICE|SmartPill Monitoring System|"The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA."
41382607|NCT00052507|DRUG|bortezomib|
41382608|NCT06539208|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1
41382609|NCT04607265|DIAGNOSTIC_TEST|Cardiac MRI|Comparison of scar characteristics on cardiac MRI between the two groups.
41382610|NCT01870752|PROCEDURE|Transplantation of previously cryopreserved ovarian tissu|
41382611|NCT04285983|DRUG|Trelagliptin|Trelagliptin tablets
41382612|NCT01371006|DRUG|low dose|efavirenz single dosing once daily
41382613|NCT01371006|DRUG|normal dose|efavirenz once daily
41382614|NCT01371006|DRUG|low dose|Efavirenz single dosing once daily
41382615|NCT00869700|DRUG|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria"
41382616|NCT01284231|DRUG|MEDI-565|MEDI-565 will be administered by IV infusion
41508546|NCT01820234|OTHER|In-person dermatology evaluation|Every patient will be evaluated by an in person dermatologist present at the screening.
41508547|NCT01820234|OTHER|Store-and-forward teledermatology evaluation|Every patient will be evaluated online via a store and forward teledermatology modality.
41508548|NCT04107272|DEVICE|Real repetitive transcranial magnetic stimulation|"The real rTMS will be delivered over M1 (hand representation) of dual hemispheres with 10 trains of 10 Hz pulses for 10 seconds, with a total of 1,000 pulses per hemisphere. The real rTMS intensity will be set as 80% resting motor threshold and the interval between each train of pulses will be set as 50 seconds. The real rTMS will be delivered as daily session for five consecutive days, followed by two fortnightly maintenance sessions during the follow-up period after the completion of five daily sessions. The real rTMS will be delivered by designated physical therapists using figure-of-8 shaped coil."
41382617|NCT01284231|DRUG|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
41508549|NCT04107272|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham rTMS of this study will be delivered with the same active coil angled 90-degree way from the scalp. The intensity of sham rTMS will be set at lowest stimulator output that can generate similar noise to the real rTMS. The sham rTMS will be delivered in the same manner and duration with real rTMS.
41382618|NCT01284231|DRUG|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
41382619|NCT01284231|DRUG|MEDI-565|20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
41508550|NCT00693095|BIOLOGICAL|CMV-ALT + CMV-DCs|CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
41508551|NCT00693095|BIOLOGICAL|CMV-ALT + Saline|CMV-ALT (3 X 10e7) with Saline
41508552|NCT06550739|OTHER|Randomization|Randomly divide the data into a training set and a validation set in a 7:3 ratio
41508553|NCT04052620|DRUG|Diclofenac diethylamine 2.32% gel|Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
41508554|NCT04052620|DRUG|Diclofenac diethylamine 1.16% gel|Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 four times daily for 7 days.
41508555|NCT04052620|OTHER|Placebo|Participants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
41508556|NCT01893515|DRUG|PRC-4016|
41382620|NCT00755573|DRUG|Pregabalin|Pregabalin 300 mg - 600 mg BID
41382621|NCT00755573|DRUG|placebo|Regime as described for pregabalin
41382622|NCT05992207|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi#reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
41382623|NCT05992207|OTHER|physical therapy training|facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
41382624|NCT05883527|OTHER|Not applicable as not an intervention - PLwD and family/carers|Exploring the safeguarding process through interviews.
41382625|NCT05883527|OTHER|Not applicable as not an intervention - HCP's|Exploring the safeguarding process through interviews and a focus group.
41382626|NCT05266807|DRUG|oral capsulized Fecal Microbiota Transplantation|FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
41382627|NCT05266807|DRUG|Vancomycin or Fidaxomicin|Vancomycin or Fidaxomicin per os as initially prescribed per SoC
41382628|NCT02191969|BEHAVIORAL|Walk With Ease|A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.
41382629|NCT06125886|DIAGNOSTIC_TEST|transvaginal ultrasound and microscale endometrial sampling biopsy|Transvaginal ultrasound and endometrial micro tissue pathology examination are used concurrently for endometrial cancer screening in high-risk populations. The specificity, sensitivity, and optimal combination of the two screening methods are clarified, and a cost-effectiveness analysis is conducted on different screening strategy.
41382630|NCT05111561|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
41508557|NCT01893515|DRUG|Placebo|
41382631|NCT05111561|DRUG|Binimetinib|Given PO
41382632|NCT05111561|PROCEDURE|Biopsy|Undergo biopsy
41382633|NCT05111561|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41382634|NCT05111561|PROCEDURE|Computed Tomography|Undergo CT
41508558|NCT01004809|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
41508559|NCT01380548|DIETARY_SUPPLEMENT|Placebo|Placebo; once/day; for 12 weeks
41508560|NCT01380548|DIETARY_SUPPLEMENT|Iron alone|Iron (3 mg); once/day; for 12 weeks
41508561|NCT01380548|DIETARY_SUPPLEMENT|Low-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks
41508562|NCT01380548|DIETARY_SUPPLEMENT|Medium-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks
41508563|NCT01380548|DIETARY_SUPPLEMENT|High-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
40852669|NCT06259539|BEHAVIORAL|YouTube nutrition education|For those in the intervention group, the YouTube training modules had step-by-step recipe demonstrations, strategies on how to get your child to eat more new foods, social stories, First-Then visual chart, and other nutrition education materials. All the videos were less than 5 minutes long, and parents were assigned 2 videos per week for 8 consecutive weeks. Parents answered 2 open-ended questions each week related to the educational materials they reviewed.
40852670|NCT03515096|DRUG|Eltrombopag|Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
40852671|NCT03515096|DRUG|rhTPO|rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
41165499|NCT02725398|DRUG|physiological saline|Physiological saline is administered by endoscopic nurse in the physiological saline group,and then recording the outcome measures.
41165500|NCT03772613|DRUG|Unfractionated heparin|Administration of unfractionated heparin will be assessed using the activated clotting time
40852672|NCT05741112|DEVICE|Wearable device|The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.
40852673|NCT00590343|DRUG|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
41165501|NCT02951169|OTHER|No intervention|No intervention. Treatment are accordance with clinical practice.
41508564|NCT02542956|DRUG|Exparel|receive Exparel by injection
40852674|NCT02429830|DEVICE|LINX device|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
40852675|NCT05895240|DRUG|Ulinastatin|Nine MiU Ulinastatin in three divided doses 8 hourly for 3-5 days
41165502|NCT05124002|DRUG|Recombinant Human Adenovirus Type 5|H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10\^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10\^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10\^12 vp) if the maximum diameters of lesion is \> 10 cm.
41165503|NCT05124002|DRUG|HAIC of FOLFOX|Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium. The infusion will be continued for 2-3 days according to patients' tolerance and tumor conditions. The standard treatment for HAIC consists of 4-6 cycles, with the second cycle being 3 weeks after the end of the first HAIC cycle and the subsequent cycles being 4 weeks after the end of the previous HAIC.
41382635|NCT05111561|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41382636|NCT01823250|BEHAVIORAL|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
41382637|NCT01823250|BEHAVIORAL|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
41382638|NCT01823250|BEHAVIORAL|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
41382639|NCT01823250|BEHAVIORAL|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
41382640|NCT01913769|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
41382641|NCT00004232|BIOLOGICAL|filgrastim|
41382642|NCT00004232|DRUG|cyclosporine|
41382643|NCT00004232|DRUG|methylprednisolone|
41382644|NCT00004232|DRUG|prednisone|
41382645|NCT00004232|PROCEDURE|allogeneic bone marrow transplantation|
41508565|NCT02542956|DRUG|Marcaine|receive Marcaine in a pain pump
41508566|NCT02542956|DRUG|Marcaine|receive Marcaine by injection
41508567|NCT05119179|DRUG|Semaglutide|Glucagon-like Peptide 1 Receptor Agonist
41508568|NCT03568097|DRUG|Avelumab|10 mg/kg will be given as intravenous infusion (IV) every two weeks (q 2 weeks) until disease progression.
41508569|NCT01704274|OTHER|Low Dose GTN 0.0285 mg/hr|Low Dose GTN
40852676|NCT05636761|DIAGNOSTIC_TEST|Heart rate variability|Collection and Analysis of Heart Rate Variability
40852677|NCT05411289|PROCEDURE|acupressure|"Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6).~pressure was applied gradually for 30 seconds on the above mentioned points. Then this pressure was slowly intensified to the extent that the patient felt tingling, numbness, heaviness, and strain in the surrounding area."
41382646|NCT00004232|PROCEDURE|peripheral blood stem cell transplantation|
41382647|NCT01982539|DRUG|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
41382648|NCT00713765|DRUG|AZD3480|18 total doses of 40 mg, on days 1-18
41382649|NCT00713765|DRUG|Donepezil|One single dose of mg on day 5
41382650|NCT03976076|DRUG|JBPOS0101|JBPOS0101 (investigational product)
41382651|NCT02049580|DRUG|Thiotepa|Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
41382652|NCT02049580|DRUG|Fludarabine|"Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows:~CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day"
41382653|NCT02049580|DRUG|Cyclophosphamide|"Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.~Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)~Cyclophosphamide \[50 mg/kg/day IBW\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
41382654|NCT03003793|DIAGNOSTIC_TEST|Hyperinsulinemic euglycemic clamp|Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
41382655|NCT03958877|DRUG|BIIB017 (peginterferon beta-1a)|Administered as specified in the treatment arm
41382656|NCT03958877|DRUG|Interferon beta type 1a|Administered as specified in the treatment arm
41382657|NCT06537609|OTHER|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital.~De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol)."
41382658|NCT06537609|OTHER|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.~Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole."
41382659|NCT06537609|OTHER|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed."
41382660|NCT06537609|OTHER|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (Meropenem or Ertapenem) at standard doses"
41382661|NCT06537609|OTHER|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
41382662|NCT02866695|DRUG|ingenol mebutate gel 0.015%|ingenol mebutate gel 0.015% to be applied on treatment area
41382663|NCT03584035|BEHAVIORAL|sensory motor integration exercises|Sensorimotor integration exercises will be given in study group. The exercises will be performed in standing, sitting and walking. Exercises will be progressively increased from eye open to closed , floor to mat and head turns to right \& left under the supervision of physiotherapist. Sensorimotor integration exercises will take 45 minutes in each session.
41508570|NCT01704274|OTHER|High Dose GTN 0.057 mg/hr|High Dose GTN
40852678|NCT05411289|PROCEDURE|sham acupressure|Pressures were applied on sham points consecutively
40852679|NCT00605345|DRUG|Darbepoetin alfa|As prescribed
40852680|NCT00605345|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
41508571|NCT01704274|OTHER|Placebo|Placebo
41508572|NCT01770717|OTHER|Spatial Frequency Domain Imaging|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
41508573|NCT00030706|DRUG|ixabepilone|
41508574|NCT00898287|DRUG|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
41508575|NCT00898287|DRUG|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
40852681|NCT02409771|DEVICE|PRECIZON Presbyopic|Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
40852682|NCT05838092|DRUG|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
40852683|NCT05838092|DRUG|Placebo|Placebo
40852684|NCT00863291|DRUG|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
40852685|NCT00863291|DRUG|placebo|Placebo in a manner similar to the active comparator
40852686|NCT01712204|DRUG|Placebo|Placebo Capsule BID for 16 Weeks
40852687|NCT01712204|DRUG|AC-201|AC-201 50mg Capsule BID for 16 Weeks
40852688|NCT01712204|DRUG|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
40852689|NCT01487850|BIOLOGICAL|blood sample|blood sample in each musician to search for specific antibodies against molds isolated from instruments
41382664|NCT03584035|BEHAVIORAL|conventional physiotherapy|Conventional physiotherapy will take 30 minutes in each session, taking three sessions per weeks for six weeks. The exercises include simple lower extremity exercise and ambulatory training such as sit to stand, stepping, lateral and backward walking, and tandom walking etc.
41382665|NCT00684437|BEHAVIORAL|Focus Group|Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.
41382666|NCT00684437|BEHAVIORAL|Questionnaire|Questionnaires taking 15-30 minutes to complete.
41382667|NCT00713830|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
41382668|NCT00713830|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
41382669|NCT00713830|DEVICE|Pen auto-injector|
41382670|NCT00713830|DRUG|Sulfonylurea|Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
41382671|NCT00713830|DRUG|Metformin|Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.
41382672|NCT04875637|DIAGNOSTIC_TEST|WAI-MEMR|Using wideband acoustic reflectance for middle-ear muscle reflex.
41382673|NCT01398449|RADIATION|Elective nodal irradiation (ENI)|
41382674|NCT01398449|OTHER|Adjuvant chemotherapy only|
41382675|NCT02629627|DIETARY_SUPPLEMENT|Conjugated linoleic acid/Leucine|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
41382676|NCT02629627|DRUG|Metformin|Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
41382677|NCT02629627|DIETARY_SUPPLEMENT|Placebo of ACL/Leucine|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
41382678|NCT02629627|OTHER|Placebo of Metformin|homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
41382679|NCT04040738|PROCEDURE|Upper extremity surgery under general anaesthesia|Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance
41382680|NCT04040738|PROCEDURE|Upper extremity surgery under regional anaesthesia|Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14
41508576|NCT05753878|DRUG|HH-120 nasal spray, PartA cohort 1|A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.
41508577|NCT05753878|DRUG|HH-120 nasal spray, Part A cohort 2-7|A single dose of HH-120 nasal spray.
41508578|NCT05753878|DRUG|HH-120 nasal spray, Part A cohort 8-9|Two doses of HH-120 nasal spray.
41508579|NCT05753878|DRUG|HH-120 nasal spray, Part B|HH-120 nasal spray, 10 times daily for 7 consecutive days.
41508580|NCT05753878|OTHER|Placebo nasal spray, Part B|Placebo nasal spray, 10 times daily for 7 consecutive days.
41508581|NCT02064517|DEVICE|MTA|Creation of a barrier apicale in the MTA
41036050|NCT06413524|DEVICE|Whole-body Vibration Therapy|Each session consists of 10 minutes of warm-up exercises for the upper limbs, lower limbs, and spine, six sets of vibration training, and 10 minutes of stretching exercises at the end. Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. For the starting position, the patient stands relaxed on the platform, holding the WBV platform handles. After vibration starts, the patient squat and stand at a steady pace until the two minutes are over.
41382681|NCT05209139|DIETARY_SUPPLEMENT|Beetroot juice|One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
41382682|NCT05209139|DIETARY_SUPPLEMENT|Beetroot juice placebo|One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
41382683|NCT00402207|DRUG|extrafine HFA-beclomethasone|
41382684|NCT00402207|DRUG|HFA-fluticasone|
41382685|NCT03699956|COMBINATION_PRODUCT|RRx-001 + eLOOP Device|RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
41382686|NCT03699956|DRUG|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
41382687|NCT04160416|DRUG|Capecitabine-Oxaliplatin-Irinotecan Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
41382688|NCT00662974|OTHER|perineal massage with Wheat Germ Oil during the second stage of labor|30 ml of oil applied during labor
41382689|NCT00662974|OTHER|perineal massage with almond oil during the second stage of labor|30 ml of oil applied during labor
41382690|NCT05855473|OTHER|Auricular acupuncture|The NADA protocol used in this study uses five specific points on the ear: Shen men, sympathetic autonomic, lung, liver, and kidney. Using this protocol, semi-permanent needles and seeds were placed unilaterally at five specific points in the ear by a specialist physician certified in acupuncture.
41382691|NCT03790020|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
41382692|NCT02069145|DRUG|OMP-54F28 with Sorafenib|
41382693|NCT06538935|DRUG|adbelimumab|adbelimumab：1200mg iv d1 q3w
41508582|NCT02064517|DEVICE|Hydroxide of calcium|Revascularisation pulpaire with some hydroxide of calcium
41508583|NCT01679990|BIOLOGICAL|PLX-PAD Low dose|
41508584|NCT01679990|BIOLOGICAL|PLX-PAD high doses|
41508585|NCT01679990|BIOLOGICAL|Double Placebo|
41508586|NCT01679990|BIOLOGICAL|high dose +Placebo|
41382694|NCT06538935|PROCEDURE|SBRT|SBRT: SBRT: 8-30Gy/1-6F（dose is determined according to the tumor diameter）; tumor thrombus dose 30Gy /5-6F;
41382695|NCT06538935|DRUG|apatinib|apatinib：250mg po, qd
41382696|NCT05100628|DRUG|NOX66|"NOX66 800 mg (400 mg suppository twice daily \[BID\]).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
41382697|NCT05100628|DRUG|NOX66|"NOX66 1200 mg daily (600 mg suppository BID).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
41382698|NCT05100628|DRUG|NOX66|"NOX66 1800 mg daily (600 mg suppository thrice daily).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
41382699|NCT05100628|DRUG|NOX66|MTD of the combination of NOX66 and doxorubicin will be determined in the dose-escalation cohort of the study. The selected dose will be administered in combination with Doxorubicin.
41382700|NCT05100628|DRUG|Doxorubicin|Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
41382701|NCT04257773|BEHAVIORAL|REACH Forgiveness Workbook Intervention|Participants will be asked to complete the REACH Forgiveness Workbook
41382702|NCT03930901|OTHER|Health education learning package|Health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), \& nail clipper).
41382703|NCT04060979|DRUG|Nitric Oxide|Nitric Oxide given intermittently via inhalation
41382704|NCT04060979|OTHER|Standard Supportive treatment|Standard Supportive treatment (including oxygen)
41382705|NCT01243307|DRUG|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
41382706|NCT04631055|DEVICE|drug coated balloon|paclitaxel coated balloon catheter for intracranial PTA treatment
41382707|NCT04631055|DEVICE|stent system|The Intracranial Stent System comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.The product, APOLLO™ stent system, has the indication of endovascular treatment for intracranial stenosis approved by NMPA.
41382708|NCT01145872|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
41382709|NCT01145872|BEHAVIORAL|Health Enhancement Program|
41382710|NCT03813160|DRUG|Lenabasum 20 mg|oral capsule
41382711|NCT03813160|DRUG|Lenabasum 5 mg|oral capsule
41508587|NCT02494167|BIOLOGICAL|MultiTAA-specific T cells|"The 5 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2; Dose Level Four: 5 x 107 cells/m2; Dose Level Five: 1 x 108 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.~If patients with residual disease (Group B) have a partial response, complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions (or below the patient's original dose can be administered) at least 4 weeks apart."
41508588|NCT04780178|BEHAVIORAL|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias|A telephone-based acceptance and commitment therapy for caregivers
41036051|NCT06413524|DEVICE|Local Vibration Therapy|Each session consists of 10 minutes of warm-up exercises for the upper limbs, lower limbs, and spine, six sets of vibration training, and a final 10-minute stretching exercise. Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. After the warm-up exercise, the researcher helps the patient wear the localized vibration instrument. After the vibration begins, the patient squat and stand at a steady pace until the two minutes are over.
41165504|NCT06199206|OTHER|Theraputic Play|Before the procedures, therapeutic games will be played with the children and people of the intervention groups with eLPi dolls and other play materials prepared in accordance with anatomy. The parent will be with the child during this game, which will be played in his/her own room.
41165505|NCT02072798|DRUG|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
41382712|NCT03813160|DRUG|Placebo|oral capsule
41382713|NCT00660855|DRUG|parecoxib/valdecoxib|parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
41382714|NCT02788955|BEHAVIORAL|Dietary counselling|
41382715|NCT02788955|OTHER|Dietary Protein|
41508589|NCT05681039|DRUG|Tiragolumab|Given by IV (vein)
41165506|NCT00761397|BEHAVIORAL|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
41382716|NCT04426552|DRUG|dexmedetomidine|will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
41382717|NCT04426552|DRUG|sevoflurane|preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
41382718|NCT03853980|DEVICE|Focal Contouring System|Single treatment of skin resection (removal of loose skin)
41382719|NCT01721200|OTHER|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
41382720|NCT01721200|OTHER|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
41508590|NCT05681039|DRUG|Atezolizumab|Given by IV (vein)
40852690|NCT02210260|PROCEDURE|Spinal and infusion of local anaesthetic|"Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.~PLUS~Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine."
41382721|NCT01257737|DRUG|HPN-100|Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine \[PAGN\] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
41382722|NCT06119737|OTHER|Exercise|Effects of exercises on TSH levels
41382723|NCT01425515|BEHAVIORAL|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
41382724|NCT05672394|PROCEDURE|Continuous Serratus anterior plane block|in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .
41382725|NCT05672394|PROCEDURE|Thoracic Epidural|A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.
41382726|NCT05672394|DRUG|Bupivacaine|bupivacaine
41382727|NCT05672394|DRUG|lidocaine with epinephrine|3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
41382728|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
41508591|NCT05681039|BEHAVIORAL|Standard of Care|after care from surgery
41508592|NCT05681039|BEHAVIORAL|Questionnaires|Quality of life
41508593|NCT05681039|RADIATION|Cisplatin|Given by IV (vein)
41508594|NCT05681039|RADIATION|Carboplatin|Given by IV (vein)
41508595|NCT01611857|DRUG|Tivantinib|Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.
41508596|NCT01611857|DRUG|FOLFOX|The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.
41508597|NCT02909244|BIOLOGICAL|Biological sampling|Biological sampling
41508598|NCT01420965|DRUG|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
40852691|NCT02210260|PROCEDURE|Continuous infusion of local anaesthetic|A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
40852692|NCT02210260|DRUG|Bupivacaine|
41508599|NCT01420965|OTHER|Sipuleucel-T (Provenge)|Vaccine
41508600|NCT01420965|DRUG|Cyclophosphamide|Low dose- Immune Enhancer
40852693|NCT02210260|DRUG|Diamorphine|500mcg
40852694|NCT02210260|DEVICE|A Painbuster® catheter|
40852695|NCT02210260|DEVICE|25G Whitacre needle|
40852696|NCT02373774|DEVICE|Ultrasound|Patients will receive an ultrasound prior to lumbar puncture procedure to help visualize and select spinal interspace.
40852697|NCT01279681|BIOLOGICAL|bevacizumab|Given IV
40852698|NCT01279681|DRUG|capecitabine|Given PO
41508601|NCT06231095|DEVICE|continuous theta burst stimulation - cTBS|Continuous theta burst stimulation (cTBS) is a quicker and potentially more effective technique to reduce cortical hyperactivity than repetitive transcranial magnetic stimulation (rTMS). The study involves a cycle of 35 cTBS stimulations in the supplementary motor area (SMA) over 5 working days, with 7 stimulation sessions each day lasting 40 seconds. A 1-hour break between sessions will be observed, and each session will comprise 600 pulses at 90% of the motor threshold intensity.
40852699|NCT01279681|DRUG|fluorouracil|Given IV
40852700|NCT01279681|DRUG|leucovorin calcium|Given IV
40852701|NCT01279681|DRUG|oxaliplatin|Given IV
41165507|NCT00761397|BEHAVIORAL|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
41165508|NCT00761397|OTHER|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
41508602|NCT01739699|DRUG|Acetaminophen|
41508603|NCT01739699|DRUG|Placebo|
41382729|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
40852702|NCT05026216|DRUG|Qwo|Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenases AUX-I and AUX-II, in an approximate 1:1 mass ratio, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria. Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids. Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids.
41382730|NCT00390572|BEHAVIORAL|Sleep Specialty Consultation|The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.
41382731|NCT05335759|OTHER|Coaching programme for improvement and development of teaching skills in preceptorship|Training program An intervention based on coaching. The strategies of this program consisted of three 6-hour sessions using case studies and role-playing for motivation towards the development of the teaching role in the preceptorship of undergraduate nursing students and debriefing and a 4-hour booster session seven months later.
41382732|NCT01143610|PROCEDURE|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
41382733|NCT01143610|OTHER|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
41382734|NCT02704130|DEVICE|Transarterial embolization|In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.
41382735|NCT02704130|PROCEDURE|Microwave Ablation|Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
41382736|NCT05846503|BEHAVIORAL|1. Quality and info management system|"1. The intervention package prioritizes information and quality management with a focus on HTN screening, diagnosis, and treatment. From the point-of-care, flow charts placed in the patient file will ensure that vitals are performed in accordance with national guidelines.~2. The care coordinator will present data to clinic staff in multi-disciplinary meetings, providing an opportunity for programmatic feedback and discussion.~3. Patients will be encouraged to complete the vital signs measurements at each clinic visit. They will be provided with their BP readings and given info about what their reading means. They will be issued with pocket sized color coded booklets providing info on the measurement and what to do to control their BP.~4. Task shifting: A care coordinator will be the champion of the intervention package for the clinic.~5. All staff will receive apt training on how to use the patient flow chart, info management system and how to respond to abnormal BP values."
40852703|NCT02956798|RADIATION|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
40852704|NCT03372174|DEVICE|Maintaining mechanical ventilation during surgery|dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure
40852705|NCT03372174|DEVICE|Absence of mechanical ventilation during surgery|absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator
41036052|NCT06413524|DEVICE|Sham Comparator|Patients are instructed to perform squatting and standing exercises at home without vibration equipment. Health education is provided at the time of enrollment, and patients are instructed to perform the exercises twice a week at home, with follow-up via telephone to check compliance. Each session consists of 10 minutes of warm-up exercises for the upper limbs, lower limbs, and spine, six sets of squatting and standing exercises, and a final 10-minute stretching exercise. Each session includes six series, each lasting 2 minutes, with a 60-second rest interval between series. After the warm-up exercises, participants should hold onto large household furniture or walls and squat and stand at a steady pace until the two minutes are up.
41036053|NCT02516618|DRUG|Fasinumab|
41036054|NCT02516618|DRUG|Placebo|
41036055|NCT03341910|DRUG|DFD-03 Lotion, 0.1%|DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
40852706|NCT00533624|DRUG|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
41036056|NCT03341910|DRUG|Tazorac Cream, 0.1%|Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
40852707|NCT00533624|DRUG|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
40852708|NCT01337544|OTHER|HAPLOIDENTICAL IL-15 STIMULATED NK CELLS|ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
40852709|NCT00890682|DRUG|SKY0402|Local infiltration of 8cc SKY0402
40852710|NCT00890682|DRUG|Placebo|Local infiltration of 8cc Placebo
41036057|NCT03341910|DRUG|DFD-03 Vehicle Lotion 0%|Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
41036058|NCT03341910|DRUG|Tazorac Vehicle Cream 0%|Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
41036059|NCT03652753|DRUG|N-acetylcysteine|4 mL of a 20% solution of NAC will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
41036060|NCT03652753|DRUG|Saline|4 mL of a 20% solution of saline will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
41036061|NCT03057548|PROCEDURE|Cryo or RF Ablation only of Pulmonary Veins|"Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins~OR~FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.~Ablation of the Pulmonary Veins alone"
41382737|NCT03679234|OTHER|Routine infant formula|Routine infant formula with probiotic
40852711|NCT00423449|DRUG|vorinostat|Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
41036062|NCT03057548|PROCEDURE|Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW|"Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW~OR~RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW~Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)"
41036063|NCT04747977|DRUG|OTX-DED|0.2mg dexamethasone ophthalmic insert
41036064|NCT04747977|DRUG|OTX-DED|0.3mg dexamethasone ophthalmic insert
41036065|NCT04747977|DRUG|OTX-DED|Hydrogel vehicle ophthalmic insert
41036066|NCT04469179|BIOLOGICAL|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
41036067|NCT04469179|OTHER|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
41036068|NCT02089672|DEVICE|Catheter ablation|This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
41036069|NCT04020770|OTHER|Vibrating ball|Parameters: 5 30-sec bouts of 68Hz vibration followed by a 1-minute rest.
41036070|NCT01334801|PROCEDURE|Blood Draw|"Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:~1. BNP (Brain Natriuretic Peptide)~2. (PFA) Platelet Function Analyzer 100~3. von Willebrand Factor (vWF) antigen~4. (vWF) multimers~5. (vWF) \*activity by latex aggregation~6. Plasma stored for development of new testing approaches"
41382738|NCT04496765|PROCEDURE|Total mesorectal excision|Radical resection of rectal cancer and draining lymph nodes
41382739|NCT01764776|DRUG|LDE225|LDE225
41382740|NCT01293682|DRUG|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
40852712|NCT00423449|DRUG|Gemcitabine|Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
40852713|NCT00423449|DRUG|Platinum-based agent|Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
40852714|NCT05735249|DRUG|ARN-75039 oral capsules|SAD: Up to 5 single escalating doses MAD: Up to 3 escalating doses Food-effect: Selected single dose
40852715|NCT05735249|DRUG|Placebo|Given at frequency and amounts matching ARN- 75039 dosing regimen
40852716|NCT01902121|DRUG|Technosphere® Insulin 10U + 20U|Inhaled Insulin
40852717|NCT01902121|DRUG|Technosphere® Insulin 30U|Inhaled Insulin
41036071|NCT01739829|DEVICE|DIABECELL (R)|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
41036072|NCT01739829|DEVICE|DIABECELL (R)|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
41036073|NCT03699943|PROCEDURE|CaverStem|
41036074|NCT03117738|DRUG|AstroStem|Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
41036075|NCT03117738|OTHER|Placebo-Control|Saline with 30% auto-serum
41036076|NCT01796574|DIETARY_SUPPLEMENT|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
41036077|NCT06636214|BEHAVIORAL|CHATO-I|Online communication education program
41036078|NCT00936390|DRUG|bicalutamide|Administered orally at a dose of one 50 mg tablet per day, beginning within (before, same day as, or after) 10 days of the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
41165509|NCT00761397|OTHER|Questionnaire|Day 1 of study, 10 weeks after starting study, \& 12 months after starting study
41165510|NCT00594178|DEVICE|Motorized bicycle exercise training|Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
41165511|NCT03371537|PROCEDURE|Liver debit measure|Mesure of liver debit during hepatectomy
41165512|NCT01319227|PROCEDURE|Hip replacement|Hip arthroplasty with uncemented components
41382741|NCT05645263|OTHER|dieting Coca-cola|The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.
41383586|NCT04678700|OTHER|Chest physiotherapy post-covid19|"The sessions are divided into the following modules;~* Directed abdominal-diaphragmatic ventilation (10 times).~* Costal expansion exercises with the help of flexion and abduction of the upper limbs. (10 times)(1).~* Self-passive stretching of the ribcage and neck muscles, accessory to inspiration. The purpose of the stretching will be to increase the flexibility of the muscles to improve the vital capacity as has already been evidenced in other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (25)(26).~Relaxation time;Jacobson's progressive relaxation; we scan the body's condition.~Post-session evaluation by taking the respiratory frequency/ min and the Borg's dyspnea index, and level oxigen after the exercises."
41382742|NCT06565533|BEHAVIORAL|Retrogressive imagery (RETI)|"Week 1-2: Participants were asked to imagine a complete version of the FT imagery script included: a) Visualizing the court lines, the basket, and themselves standing at the free-throw line, focusing on their shooting technique. b) Imagining teammates and opponents positioned around the key, noting the main colors in the scene c) Imagining the coach standing on the sideline encouraging them, and paying attention to the sounds of the audience and the cheers from a close friend in the stands. d) Visualizing a high-pressure situation, experiencing the emotions felt during a real game with one second left on the clock, trailing by one point, with the game's outcome depending on their FT shot. Week 3-4: The exception of content dfrom the full script. Week 5-6: The exception of content cdfrom the full script. Week 7-8: The exception of content bcdfrom the full script."
41382743|NCT06565533|BEHAVIORAL|Virtual Reality (VR)|Standing on a lifelike full-sized basketball court, they observe smooth flooring and clear markings. Teammates and opponents don variously colored uniforms, while referees stand ready at the sidelines. Referees position teammates and opponents around the basket as participants feel the texture and weight of the basketball in their hands, as if gripping it for real. The sounds of cheering spectators and encouraging shouts from teammates and coaches further enhance their focus. Participants adjust their stance, noticing beads of sweat trickling down their arms as they prepare for the FT. With bent knees, they ready themselves for the shot, exerting every ounce of their strength as the ball leaves their hands and soars towards the basket. As the ball accurately swishes through the net, the crowd erupts into thunderous applause, and the scoreboard's change in score brings an overwhelming sense of joyous victory.
41165513|NCT00605566|DRUG|Sorafenib|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
41165514|NCT00605566|DRUG|Cyclophosphamide|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
41165515|NCT01700322|PROCEDURE|Coronary stenting|All patients will receive a drug eluting stent as clinically indicated.
41165516|NCT01700322|DRUG|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
41382744|NCT03252756|OTHER|Placebo|Saline taken by mouth (PO)
41382745|NCT03252756|DRUG|Phytocannabinoid cannabidiol (CBD)|CBD taken by mouth (PO)
41382746|NCT05162326|BIOLOGICAL|BC-101|Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.
41382747|NCT02086968|DRUG|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
41382748|NCT02086968|DRUG|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
41382749|NCT03755960|PROCEDURE|acupuncture|semistandardized selection of acupuncture points according to the clinical presentation of diabetic peripheral neuropathy (DPN) symptoms; 12 treatments over 8 weeks
41382750|NCT03755960|DRUG|routine care|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
41382751|NCT03359473|DRUG|GSK2881078|GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
41382752|NCT03359473|DRUG|Matching Placebo|Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
41382753|NCT04415177|DEVICE|EaseVRx headset with active intervention|VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.
41382754|NCT04415177|DEVICE|EaseVRx headset without active intervention|VR software developed by AppliedVR with neutral non-interactive content.
41382755|NCT06369909|PROCEDURE|EUS-FNA|For patients with pancreatic masses, EUS-FNA is performed to confirm pathological diagnosis, and pancreatic biopsy samples and duodenal mucosal biopsy samples are collected.
41508604|NCT01971047|DRUG|Regular Insulin|"Group 1 Treatment Arm,Follow dosing for BG \>180 per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose"
41036079|NCT00936390|DRUG|flutamide|Administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg, beginning within (before, same day as, or after) 10 days of with the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
41165517|NCT01700322|DRUG|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
41036080|NCT00936390|DRUG|LHRH agonist (antagonist) therapy|LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.
40852723|NCT05539313|DEVICE|High-density mapping|Patients will undergo magnetic resonance imaging of both atria, and interventional high-density mapping of both atria.
40852724|NCT06106191|BEHAVIORAL|Mindfulness meditation|Ordinary activities like breathing, eating, and walking are turned into a meditation by creating greater awareness of the moment-to-moment sensations, emotions, thoughts and behaviors that arise during these activities.
40852725|NCT06106191|OTHER|Perspectives on pain|Understanding pain from a mind-body perspective and viewing pain as a stressor on physical sensations, thoughts, emotions, and behavior.
40852726|NCT06106191|OTHER|Discussion|Discussion on patients' use of mindfulness to work with pain and pain-themed meditations.
40852727|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational innovator formulation
40852728|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation a
40852729|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation b
40852730|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation c
40852731|NCT04219904|OTHER|Fludeoxyglucose F-18|Given IV
40852732|NCT04219904|DRUG|Gadobutrol|Given IV
41382756|NCT00857922|OTHER|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
40852733|NCT04219904|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
41036081|NCT00936390|RADIATION|Dose-Escalated Radiation Therapy|External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.
41165518|NCT01700322|DRUG|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
41165519|NCT04210804|DIETARY_SUPPLEMENT|Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)|200mls Smoothie
41165520|NCT06186726|RADIATION|carbon ion radiotherapy|The patients received 72GyE/18 doses of carbon ion radiotherapy.
41165521|NCT00392535|RADIATION|conventional radiotherapy 74 Gy delivered in 37 fractions|
41382757|NCT04645927|DIETARY_SUPPLEMENT|flaxseed beverage|"Pizzey Ingredients Inc. introduced a flax beverage product that is a plant-based beverage product that is designed as an alternative to non-diary milks (almond milk \& soy milk). Each 330 ml serving of flax beverage contains 15 g flaxseed, which amounts to 3.75 gm of omega-3 fatty acid. Preventing MCI or even AD may be within reach, if appropriate measures are taken early enough using strategies such as dietary supplementation."
41165522|NCT00392535|RADIATION|hypofractionated radiation therapy 60 Gy in 20 fractions|
41165523|NCT00392535|RADIATION|hypofractionated radiation therapy 57 Gy in 19 fractions|
41165524|NCT02725008|DRUG|Dexamethasone|
41165525|NCT02725008|DRUG|placebo|to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
41165526|NCT04225039|DRUG|INCMGA00012|500mg IV neoadjuvant treatment; 500 mg adjuvant treatment
41165527|NCT04225039|DRUG|INCAGN01876|300mg IV neoadjuvant treatment; 300 mg adjuvant treatment
41165528|NCT04225039|DRUG|SRS|administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).
41165529|NCT04225039|PROCEDURE|Brain surgery|maximal safe surgical resection of the tumor.
41382758|NCT04645927|DIETARY_SUPPLEMENT|control beverage|Oat fibre control. For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
40852734|NCT04219904|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
40852735|NCT02754258|DRUG|MPH|60 days on oral methylphenidate administered 2 times daily before lunch and supper.
40852736|NCT02754258|DRUG|Placebo|60 days on oral placebo administered 2 times daily before lunch and supper
40852737|NCT04564677|DEVICE|Ifabond (Péters surgical)|Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.
40852738|NCT03876899|DIETARY_SUPPLEMENT|Evening Primrose Oil|botanical oil derivative from the seeds of Evening Primrose (Oenothera biennis),1,300 milligrams t.i.d.
40852739|NCT03876899|DIETARY_SUPPLEMENT|Placebo|Pill
40852740|NCT03342118|DRUG|Phloroglucin(Flospan®)|The experimental group was taken with Phloroglucin(Flospan®) before endoscopy.
41382759|NCT01396499|DRUG|BKM120|Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
41382760|NCT01876628|DRUG|Flucloxacillin|Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.
41382761|NCT01876628|DRUG|Clindamycin|Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
41382762|NCT01876628|DRUG|Placebo oral capsule|Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
40852741|NCT03342118|DRUG|Normal saline|The control group was treated with normal saline before endoscopy
40852742|NCT00832429|PROCEDURE|Lymph Node Mapping|Undergo lymph node mapping
40852743|NCT00832429|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
40852744|NCT00832429|DRUG|Technetium Tc-99m Sulfur Colloid|Given ID
40852745|NCT01629953|OTHER|Group vocational intervention|Group based manualized vocational rehabilitation
40852746|NCT01629953|OTHER|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
40852747|NCT00682955|DRUG|Zinc Sulphate|20 mg per day, Zinc Sulphate tablet has been given to subjects.
40852748|NCT00682955|DRUG|Zinc Sulphate|20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
40852749|NCT03192761|PROCEDURE|ACL reconstruction hamstrings|"HG reconstruction is performed according to the standard procedure of the department:~A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw"
40852750|NCT03192761|PROCEDURE|ACL reconstruction patella tendon|"PTBG reconstruction is performed according to the standard procedure of the department:~A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws."
40852751|NCT03192761|PROCEDURE|ACL reconstruction iliotibial tract|"TIFLG reconstruction is performed as follows:~The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in."
40852752|NCT05766657|DIETARY_SUPPLEMENT|Microbiome-targeted diet|The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.
40852753|NCT05766657|DIETARY_SUPPLEMENT|Usual care diet|Subjects on the control group will receive general dietetic advice for Obesity or T1D
41036082|NCT00781300|DRUG|Loteprednol Etabonate 0.5%|Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
41165530|NCT03230409|BEHAVIORAL|Leaflet written in the patient's/family mother tongue|At baseline visit, the parents or carers of the children and/or the young patients themselves (in the case of adolescents \>12 years of age), were given a leaflet including questions and answers about the most common doubts that people have about anti-TB treatment (what to do if you forget a dose, if you vomit, if you have stomach ache, etc.). The study nurse read and reviewed the leaflet with the family. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
41382763|NCT06516133|RADIATION|Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online adaptive radiotherapy|"Radiation: Complete the full course of radiotherapy using the original treatment plan.~Planning target volume (PTV) margin: 3mm;"
40852754|NCT05777395|PROCEDURE|Maitland Oscillatory Mobilization|Maitland Posteroanterior unilateral vertebral pressure and Maitland cervical rotation technique will be used.3 sets of 15 repetitions. Each set is of 30 seconds and each repetition is given for 2 seconds.
41036083|NCT00781300|DRUG|Dexamethasone 0.1%|The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
41036084|NCT01629004|OTHER|FOBT kit|Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
41036085|NCT01629004|OTHER|Mailed invitation|Mailed CRC screening invitation alone on behalf of family physician.
41036086|NCT03358225|PROCEDURE|anterior cervical discectomy and fusion|The patients undergoing anterior cervical discectomy and fusion sugery
41165531|NCT03230409|BEHAVIORAL|A follow-up telephone call|A follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits. The parents and/or patient were informed about this. This call was made to reinforce the information, answer any questions that may have arisen and insist on the importance of proper follow-up.
41382764|NCT06516133|DRUG|Chemotherapy|Chemotherapy: If given, platinum-based.
41382765|NCT06516133|RADIATION|Intensity modulated radiation therapy (IMRT) with smaller planning target volume (PTV) margin and online adaptive radiotherapy|"Radiation: During the course of radiotherapy, the treatment plan is adjusted online based on the anatomical and dosimetric changes in the target volumes and organs at risk of patients.~planning target volume (PTV) margin: smaller."
41382766|NCT06516133|DRUG|Chemotherapy|Chemotherapy: If given, platinum-based
41382767|NCT06128278|DRUG|S-equol|Oral supplementation of S-equol
41383587|NCT05562713|BEHAVIORAL|Present Bias without Loss Aversion|Small prize for each step completed; large prize for independent CIC
41508605|NCT01971047|DRUG|Humalog|"Group 2 treatment arm. Follow dosing for Blood glucose \> 180, per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose"
40852755|NCT05777395|PROCEDURE|Kaltenborn Sustained Stretch Mobilization|"Kaltenborn sustained stretch mobilizations. 3 sets of 15 repetitions for 3 seconds.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total.~* Mobilizations will be performed in Grade 1 and then progressed to 2 and 3.~* Kaltenborn technique used will be atlas-axis rotation"
40852756|NCT05777395|PROCEDURE|Conventional therapy|Moist heat, TENS, Neck Muscle Stretching, Neck muscle isometrics
41036087|NCT03358225|PROCEDURE|cervical artificial disc replacement|The patients undergoing cervical artificial disc replacement surgery
41036088|NCT03358225|PROCEDURE|hybrid surgery|The patients undergoing 1-level C-ADR plus 1-level ACDF surgery
41036089|NCT04564183|OTHER|Sample collection|Blood, Urine, Nail, Hair, Saliva, optional Stool
40852757|NCT00303225|DRUG|Vaccine: SIGA-246|
41036090|NCT04564183|OTHER|Questionnaires|SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire
41036091|NCT04564183|RADIATION|High resolution CT scan of the chest|Upon enrollment, all participants will undergo single prone volumetric thoracic chest CT scan. This will be performed at full inspiration using a 64-slice CT scanner.
40852758|NCT04554771|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 of standard of care neoadjuvant chemoradiation
40852759|NCT04554771|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously on days 1, 8, 15, 22 and 29
40852760|NCT04554771|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29
40852761|NCT04554771|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy
40852762|NCT01085877|DRUG|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
40852763|NCT01085877|DRUG|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
40852764|NCT02327988|OTHER|Cryotherapy|
40852765|NCT02327988|DEVICE|Laser therapy|
40852766|NCT00615030|DRUG|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
40852767|NCT00615030|DRUG|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
41036092|NCT04564183|DIAGNOSTIC_TEST|Pulmonary Function Test|All recruited participants will undergo a pre-bronchodilator spirometry test and a lung diffusion capacity test, both in accordance with ATS guidelines. Exercise capacity (maximum physical exertion) will be assessed by performing a 6-minute walk test, also according to ATS guidelines.
41036093|NCT01994330|DRUG|desmopressin|0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision
41036094|NCT03105362|DIETARY_SUPPLEMENT|Enterade® oral rehydration solution|Commercially available amino acid based oral rehydration solution
41036095|NCT05758064|DRUG|Duphaston|10 mg tablet will be given twice
41165865|NCT04099485|OTHER|Electronic Health Record Best Practice Advisory|The AFDST is a decision support tool that is embedded in our electronic health record system. Currently, this is a passive tool that requires the clinician to launch the tool if an analysis is desired. The experimental arm of this study will add a best practice advisory (BPA) that will trigger when a clinician is in the medical record of an AF patient who might gain substantial benefit (survival and quality of life) if treatment were changed from the current anticoagulation plan, which might be no anticoagulant therapy.
41165866|NCT00904722|DRUG|CT-011|Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
40852768|NCT00615030|DRUG|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
40852769|NCT00615030|DRUG|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
41382768|NCT05905874|OTHER|Machine learning-based prediction model|The machine learning-based prediction model will be used to forecast whether the presence of DVT and/or PTE or not in AECOPD patients after standardized treatment.
41382769|NCT00390507|PROCEDURE|Post-tetanic count frequency|
41382770|NCT01965015|DEVICE|Implantation of the V-Wave inter-atrial shunt|Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
40852770|NCT03186417|BIOLOGICAL|2 million hMSC/kg|2 million hMSCs/kg infusion
41036096|NCT05758064|DRUG|prolutex|subcutaneous injection daily
41036097|NCT02412930|PROCEDURE|Ultrasound-guided Paravertebral Block|"paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.~After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion."
41382771|NCT05598619|DIETARY_SUPPLEMENT|Vitamin C|Colon delivered vitamin C (ascorbic acid) for 12 weeks
41382772|NCT05598619|OTHER|placebo|Colon delivered placebo once a day for 12 weeks
40852771|NCT03186417|BIOLOGICAL|4 million hMSC/kg|4 million hMSC/kg infusion
40852772|NCT03186417|BIOLOGICAL|6 million hMSC/kg|6 million hMSC/kg infusion
40852773|NCT03186417|BIOLOGICAL|placebo|placebo infusion
40852774|NCT04305561|PROCEDURE|Contrast-enhanced ultrasound|"Ultrasound contrast agent: Stabilized sulfur hexafluoride microbubbles (SonoVue®, Bracco).~An 18 G needle will be placed in an antecubital vein and directly attached to a three-way stopcock with an extension tube.~The SonoVue® will be prepared and shaken shortly before injection in accordance with the instructions provided in the product information leaflet.~The patient will be injected with 1.2 ml SonoVue® at a pace of 1-2 ml/s using the 180 degree straight-flow channel of the three-way stopcock, directly followed by a 10 ml bolus of sodium chloride 9 mg/mL (0.9%) injected into the 90 degree channel of the three-way stopcock at a pace of approximately 2 ml/s.~A full examination will typically require one to two injections of 1.2 ml of SonoVue® (one injection per suspected parathyroid adenoma)."
41382773|NCT04955210|OTHER|Not applicable（Cohort study）|This is a prospective observational study and does not include interventions.
41382774|NCT00350818|DRUG|Azacitidine|8 mg/m\^2 Subcutaneously Once Daily for 5 Days
41382775|NCT01125358|DRUG|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
41382776|NCT01125358|DRUG|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
41382777|NCT00232778|DEVICE|GAMMA-Iridium-192 catheter|
40852775|NCT03672539|DRUG|Gemtuzumab Ozogamicin|Given IV
40852776|NCT03672539|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
40852777|NCT03672539|OTHER|Quality-of-Life Assessment|Ancillary studies
40852778|NCT04716101|OTHER|Massage therapy technique|The massage therapy technique consists of manual deep and slow compression and shearing forces applied on the lumbar spine muscles and thoracolumbar fascia in a distal to proximal direction.
40852779|NCT04716101|OTHER|Sham massage technique|For the sham massage technique the massage therapist will put the right palm at the participant's right lower back along erector spinae and likewise left palm at left lower back without applying force, holding the palm during 2 minutes and half.
40852780|NCT04009395|OTHER|Pregnant Women qualitative interviewing|one-on-one in depth interviewing of pregnant African migrant women living in the UK on the barriers and facilitators to healthy eating in pregnancy.
40852781|NCT04009395|OTHER|Midwives qualitative interviewing|one-on-one interviewing/focus group discussions with midwives on their perspectives regarding the provision of healthy eating advice to pregnant African migrant women living in the UK.
40852782|NCT02692001|OTHER|Intervention MealTrain menu|"Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled Eat like a superhero was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls."
40852783|NCT01709656|BIOLOGICAL|MSC|"human mesenchymal stem cells,1\*10\^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.~a total of 24 weeks for follow up."
40852784|NCT01709656|DRUG|"celecoxib, Celebrex®"|"non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up"
40852785|NCT02990676|BEHAVIORAL|Computerised cognitive training|Computerised cognitive training regime
40852786|NCT04686383|DRUG|CAL056 mesylate|Dosage form: 20 mg CAL056 mesylate/tablet
40852787|NCT00958165|DEVICE|CardioFocus EAS-AC|PVI for PAF
40852788|NCT01135095|RADIATION|low-dose imaging|"The study is designed to assess the validity of a low dose (\~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators.~D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient"
40852789|NCT06026878|DRUG|gemcitabine,nimotuzumab, toripalimab|same as before
40852790|NCT06026878|DRUG|gemcitabine, cisplatin|same as before
40852791|NCT03873935|OTHER|Evaluation of periodontal status|Clinical examination
40852792|NCT04734301|DEVICE|Intravaginal Electrical Stimulation (2 times/week)|IVES sessions were performed two times in a week, for 10 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback.
40852793|NCT04734301|DEVICE|Intravaginal Electrical Stimulation (5 times/week)|IVES performed in the same way as Group 1, except for frequency of treatment. IVES sessions were performed five times in a week, for 4 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. Stimulation parameters were the same as Group 1.
40852794|NCT05512416|DRUG|dalpiciclib plus letrozole|Six 4-week cycles of dalpiciclib orally, 150mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28
40852795|NCT02462018|DEVICE|WalkAide|"Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.~For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.~During the assessments each child will go through:~A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.~C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.~E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES."
40852796|NCT03207594|OTHER|Survey|Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.
40852797|NCT03207594|OTHER|Saliva sample|Subjects will have saliva collected by a member of the study team using a cotton swab.
40852798|NCT03207594|OTHER|Smoking Status questions|Subjects will be asked to complete an assessment asking questions about his/her current smoking status
41382778|NCT01904188|DEVICE|Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z regularly)|The Gene Z device or other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
40852799|NCT03458689|PROCEDURE|Left hemicolectomy, laparoscopic technique|Left hemicolectomy, Laparoscopic technique
40852800|NCT01235234|DRUG|CF101|orally q12h
40852801|NCT02663622|DRUG|Efprezimod alfa|Acute GVHD prophylaxis
40852802|NCT02663622|DRUG|Methotrexate|Acute GVHD prophylaxis
40852803|NCT02663622|DRUG|Tacrolimus|Acute GVHD prophylaxis
40852804|NCT02663622|DRUG|Placebo|100 ml saline IV infusion.
40852805|NCT03658824|OTHER|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
40852806|NCT05325021|DIAGNOSTIC_TEST|Axial length measurement in millimeter (mm) by optical biometry device|Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.
40852807|NCT05325021|DIAGNOSTIC_TEST|Autorefractometer to measure the refractive error in both eyes.|Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).
40852808|NCT02534246|DEVICE|Ultrasound biopsy needle Echo Tip ProCore|Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic \[Beacon\] 25 gauge) from single lesion.
40852809|NCT02534246|DEVICE|Ultrasound biopsy needle SharkCore|
40852810|NCT03797456|DRUG|ICP-022|ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
40852811|NCT01003652|PROCEDURE|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
40852812|NCT03698123|OTHER|Dietary Modification|Participants will be provided with meals, snacks and drinks with specific macronutrient compositions and encouraged to only eat and drink study meals, snacks and drinks and to avoid eating after 10:00 hours.
40852813|NCT03394352|OTHER|Activity on Board|During the collection phase, the study team will collect information on glucose values, activity measures and insulin settings. This information will be used to determine the meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the data collection phase and study admission.
40852814|NCT03394352|OTHER|Usual Diabetes Care|Subjects will perform their usual diabetes care including basal rate, meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the study admission.
40852815|NCT04360837|PROCEDURE|alveolar recruitment|incremental and decremental positive end-expiratory pressure alveolar recruitment
40852816|NCT05310331|COMBINATION_PRODUCT|Donafenib combined with paclitaxel and platinum ± PD-1 antibody|Patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate \> 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min \< creatinine clearance rate \< 60ml/min) ± PD-1 antibody every 3 weeks.
40852817|NCT05813704|DEVICE|Coronary Crossing System of Shanghai MicroPort Rhythm|The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
41382779|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of full-fat milk from corn-fed cows (fat >3.8%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
41382780|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of full-fat milk from grass-fed cows (fat >3.8%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
40852818|NCT02195141|RADIATION|conventional fraction|capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f
40852819|NCT02195141|RADIATION|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
40852820|NCT06216210|DRUG|opioid-FREE anesthesia.|"They received opioid-free anesthesia. These patients were provided a multimodal combination infusion. The administration of this infusion commenced at a dosage of 0.2 micrograms per kilogram per hour of dexmedetomidine. The Modified Mulimix cocktail, consisting of dexmedetomidine at a concentration of 10 ug/ml, Ketamine at a concentration of 2.5 mg/ml, and Lignocaine at a concentration of 20 mg/ml, was administered to a patient weighing 100 kg and if the weight is 110 Kg the rate will be increased by 10 percent, etc.,"
41382781|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of low-fat milk (fat <1.5%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
41382782|NCT06069427|BEHAVIORAL|Sprint interval training (SIT)|The SIT protocol consists of 4 repeated 30-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 4-minute warm-up consisting of unloaded pedalling. Each sprint will be followed by 4 minutes of unloaded pedalling.
40852821|NCT06216210|DRUG|opioid-CONTAINING anesthesia.|The process of inducing anesthesia included the injection of fentanyl at a dosage of 2 micrograms per kilogram during the induction phase. Additionally, morphine was administered at a dose of 0.03 milligrams per kilogram at the time of port insertion.
40852822|NCT01580202|DRUG|Entecavir|Entecavir 0.5mg daily per os
40852823|NCT01580202|DRUG|Lamivudine|lamivudine 100mg daily per os
41382783|NCT06069427|BEHAVIORAL|Reduced-exertion high-intensity interval training (REHIT|The REHIT protocol consists of 2 repeated 20-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 2-minute warm-up consisting of unloaded pedalling. The first sprint will be followed by 3 minutes of unloaded pedalling, and the second sprint will be followed by 4 minutes of unloaded pedalling.
41508606|NCT02391987|DEVICE|Tele-monitoring and health coaching|"Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.~Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management."
41508607|NCT05643872|DRUG|PTX-022|QTORIN rapamycin 3.9% anhydrous gel
41382784|NCT06069427|BEHAVIORAL|No-exercise control (CON)|The control condition will involve seated rest for a period equivalent to the other interventions.
41382785|NCT02603536|OTHER|WelTel|An evidence-based, text messaging solution for improving patient adherence.
41382786|NCT06271226|OTHER|acupressure|With acupressure, massage or pressure is applied to certain points on the body with fingers, hands or palms. The pressed points are the points on the skin that are sensitive to bioelectrical impulses and can easily transmit them.
41382787|NCT06271226|OTHER|placebo acupressure|n the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch
41382788|NCT06271226|OTHER|control group|During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).
41382789|NCT06542003|BEHAVIORAL|Movin' and Groovin' for Wellness|Movin' and Groovin' for Wellness (MGW) is a 10-week program consisting of facilitated drumming and dancing sessions. The sessions include guided activities involving drumming, dancing, and group improvisation. Each session lasts approximately 1.5 hours, with activities designed to improve mental well-being, enhance social connections, and foster creative expression. The sessions are guided by professional facilitators.
41382790|NCT05878600|OTHER|kendall's exercise|comparative effect of targeted cervical spine strengthening versus kendalls exercise will be analyzed
41508608|NCT06161779|OTHER|Surgical reconstruction|submental artery island flap (SMAIF) for the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer
41508609|NCT04873973|OTHER|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
41508610|NCT00478517|DRUG|Erythropoetin (rHuEPO, EPREX®)|
41508611|NCT02139137|OTHER|Computerized Cognitive Training - active|Cognitive training using working memory span task
41508612|NCT02139137|OTHER|Computerized cognitive training - sham|Sham training condition
41508613|NCT02753920|OTHER|voiding trial|1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
41508614|NCT02753920|DEVICE|Foley catheter|If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
40852824|NCT06167707|DRUG|SCP-111|Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose
40852825|NCT06167707|DRUG|Furosemide USP|Furosemide injection, USP 10 mg/mL, 40 mg IV over 2 minutes followed by 40 mg 2 hours later
40852826|NCT00687674|DRUG|dexamethasone|20 mg orally Days 1, 8, 15, 22 of 28 day cycle
41382791|NCT05878600|OTHER|cervical spine strengthening|sole effect of cervical spine strengthening will be analyzed
41382792|NCT02670980|DEVICE|Intelligent Retinal Implant System|
41382793|NCT04362761|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
41382794|NCT04362761|DRUG|IVA|Tablet for oral administration.
41383588|NCT05562713|BEHAVIORAL|Present Bias with Loss Aversion|Prizes only if fully independent CIC demonstrated
40852827|NCT00687674|DRUG|sorafenib tosylate|Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM \& 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
40852828|NCT00687674|DRUG|Lenalidomide|Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
40852829|NCT02503423|DRUG|ASTX660|described above
40852830|NCT02081599|DRUG|Teneli (Teneligliptin)|
40852831|NCT02081599|DRUG|Placebo|
40852832|NCT02081599|DRUG|Insulin|
40852833|NCT02408263|PROCEDURE|Total Hip Replacement (THR) and Total Knee Replacement (TKR)|Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.
40852834|NCT01916343|PROCEDURE|Study Laparoscopic Curriculum|
40852835|NCT06583759|PROCEDURE|Full coverage Crowns|The crown will be prepared accordingly. Try in of the best fitted crown will be done and cementation.
40852836|NCT02101489|OTHER|Foley Catheter|20 with intraoperative Foley catheter measurement of the urethral length and 20 without
40852837|NCT03296943|COMBINATION_PRODUCT|Essential oil|To inhale the essential oil in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
40852838|NCT03296943|COMBINATION_PRODUCT|Perfume|To inhale the perfume in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
40852839|NCT03296943|BEHAVIORAL|Cue-induced inhalants craving|Exposing individuals with a set of 12 pictures for one-minute (e.g., 5 second display per picture) every five minutes for three sets in total followed by another three sets of neutral/relaxing pictures of nature.
40852840|NCT02381275|DRUG|Tenofovir Disoproxil Fumarate|Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics
40852841|NCT06572852|OTHER|No intervention|No intervention
40852842|NCT03163901|OTHER|Osteopathic Manipulative Treatment|OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.
41382795|NCT00143546|DRUG|Defibrotide|Defibrotide to be administered approximately every 6 hours at an initial dose of 6.25 mg/kg/dose. Subsequent doses will be escalated with a plateau of 15 mg/kg/dose (or 60 mg/kg/day total). For patients with persistent VOD, the dose may be escalated by 10 mg/kg/day as needed to a maximum of 110 mg/kg/day total.
41382796|NCT00604734|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
40852843|NCT00049712|BIOLOGICAL|etaracizumab|
40852844|NCT01829022|PROCEDURE|E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
40852845|NCT00293436|DRUG|celecoxib|
40852846|NCT00293436|DRUG|erlotinib hydrochloride|
41382797|NCT04547478|DIAGNOSTIC_TEST|low dose chest CT(LDCT)|cross sectioned muscle area of the 1st vertebrae level obtained by LDCT
41382798|NCT00848666|DRUG|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
40852847|NCT00293436|PROCEDURE|adjuvant therapy|
40852848|NCT01320592|DRUG|PD0332991|
41036098|NCT02412930|DRUG|Group Tramadol|Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
41036099|NCT02412930|DRUG|Bupivacaine|
41036100|NCT02412930|DEVICE|Ultrasound|
41036101|NCT05505656|DIAGNOSTIC_TEST|hysteroscopic guided endomyometrial biopsy|we will obtain hysteroscopic guided endomyometrial biopsy in cases of adenomyosis
41382799|NCT03996694|DRUG|Belbuca 300 µg|Belbuca 300 µg buccal film
41382800|NCT03996694|DRUG|Belbuca 600 µg|Belbuca 600 µg buccal film
41382801|NCT03996694|DRUG|Belbuca 900 µg|Belbuca 900 µg buccal film
41382802|NCT03996694|DRUG|Oxycodone 30 mg|Oxycodone 30 mg capsule
41382803|NCT03996694|DRUG|Oxycodone 60 mg|Oxycodone 60 mg capsule
41382804|NCT03996694|DRUG|Placebo|placebo buccal film and oral placebo
41382805|NCT04471766|OTHER|Certified cloth face mask plus preventive information|Provision of two face masks sewed locally following a certified model tested for FORCE in the laboratory per residents \> 10 years old
40852849|NCT01320592|DRUG|Paclitaxel|
40852850|NCT01359189|DEVICE|ProxiScan (scintigraphic rectal probe)|"ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
40852851|NCT00783081|DRUG|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
40852852|NCT00783081|DRUG|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
40852853|NCT00783081|DRUG|Placebo|Placebo BID for 26 weeks.
40852854|NCT01301833|DRUG|teneligliptin|
40852855|NCT01301833|DRUG|glinide|
40852856|NCT01301833|DRUG|biguanide|
40852857|NCT01301833|DRUG|alpha-glucosidase inhibitor|
40852858|NCT03841435|RADIATION|Hypofractionated Radiotherapy|Radiotherapy Treatment, totaling 15 Gy, will be given in 3 fractions over 2 weeks.
40852859|NCT06259175|DRUG|Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
41382806|NCT04471766|BEHAVIORAL|Preventive information|Advice on how to prevent COVID-19 according to the government´ policy
41382807|NCT05968924|DEVICE|Podimetrics SmartMat|Participants receive training for stepping on SmartMat each day for 6 months. Monthly phone calls will be conducted to assess foot health and mat.
41383589|NCT01035229|DRUG|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
40852860|NCT06259175|DRUG|Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
40852861|NCT06259175|DRUG|Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
40852862|NCT01301170|PROCEDURE|dry needling|The needling will take place bilaterally at both the suboccipital region and the paravertebral muscles between C4 and T4. The needling will take place with the patient in the prone position. Following all needle placement, they will rotated clockwise till the point that tension on the needle is felt by the therapist. This will create more tension between the needle and tissue fibers, after which the needles were removed.
40852863|NCT01943591|DEVICE|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
41508615|NCT00808314|DRUG|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
41508616|NCT00808314|DRUG|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
41508617|NCT01691235|DEVICE|SIMpill device|The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
41508618|NCT04003493|OTHER|Nutrition and oral health intervention|The interventions included individualised nutrition and oral health care.
40852864|NCT02566590|DEVICE|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
40852865|NCT02566590|DIETARY_SUPPLEMENT|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
41382808|NCT06259760|DRUG|Nitroglycerin|during surgery, the patient received nitroglycerin infusion or nitroglycerin with labetalol to decrease blood pressure and to decrease blood loss. During the procedures and management, patients were executed of continuously monitoring of arterial blood pressure, hemodynamic changes such as cardiac output, stroke volume variation, peripheral oxygen saturation, and cerebral oximeter.
41382809|NCT02229487|OTHER|Oral glucose tolerance|
41382810|NCT05589701|RADIATION|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
41382811|NCT06395441|DIETARY_SUPPLEMENT|American Ginseng|Given PO
41382812|NCT06395441|DRUG|Placebo Administration|Given PO
41508619|NCT03672045|DRUG|Carbetocin|carbetocin administered IV, over 1 minute following delivery of the fetal head
41508620|NCT01905436|DRUG|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
40852866|NCT02566590|DIETARY_SUPPLEMENT|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
41036102|NCT03319277|OTHER|Decreased opiate prescription|The experimental group will receive 5 tablets of oxycodone 5mg at time of discharge with a paper backup prescription for an additional 10 tablets.
41036103|NCT03319277|OTHER|Routine opiate prescription|The comparator group will receive 28 tablets of oxycodone 5mg at time of discharge.
41382813|NCT06395441|OTHER|Questionnaire Administration|Ancillary studies
41382814|NCT05196230|DEVICE|Control Condition (Social Story)|The control condition is a social story, which is treatment as usual for preparing clients for their initial visit at Holland Bloorview's dental clinic. The control condition will be delivered through the study tablet. The investigators will ask parents to read it to their child once a day for the week leading up to their appointment. If the child is reading on their own, the investigators will request that parents be in the room with participants while they are. The social story takes approximately five minutes to read.
41508621|NCT03348618|BIOLOGICAL|IVIG|Intravenous immunoglobulin
41508622|NCT04141774|DEVICE|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
41508623|NCT04141774|BEHAVIORAL|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
41508624|NCT04141774|OTHER|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
41508625|NCT04141774|OTHER|EEG|EEG electrodes will be attached to the subject's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
41508626|NCT01689727|DRUG|Technetium Tc 99m EC20|
41508627|NCT03094637|DRUG|Azacitidine|Given IV
41036104|NCT02048943|DRUG|dovitinib lactate|Given PO
41382815|NCT05196230|DEVICE|Experimental Condition (360° Video)|The 360° video is from the point of view of a seated dental client and the participant will be able to explore the scene around them (navigating through the tablet's touch screen). The simulation will include scenes/features that may be anxiety-provoking for some participants. These will include loud noises commonly encountered in the dentist's office (e.g. tooth brushing, dental drills), as well as social stimuli (e.g. the dental clinician), and new environments (e.g., the dental visit room). The investigators will ensure that participants understand that they can stop at any time (e.g., if they are feeling anxious or overwhelmed), and the investigators will ask parents to explore the 360° video with their child for the week leading up to their appointment.
41382816|NCT04542902|BIOLOGICAL|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
41508628|NCT03094637|BIOLOGICAL|Pembrolizumab|Given IV
40852867|NCT03611673|OTHER|Smell Test|Oils are used for each of the different scents. Each scent will be put on an aromatherapy inhaling stick.
40852868|NCT03817112|DRUG|Dexmedetomidine Hydrochloride 0.1 MG/ML|Dexmedetomidine Hydrochloride 0.1 MG/ML infusion at 0.2-0.7 mcg/kg/min
40852869|NCT03817112|DRUG|Propofol 10 MG/ML|Propofol 10 MG/ML infusion at 0.3 -4 mg/kg/h
40852870|NCT04807257|COMBINATION_PRODUCT|Auger Molecular Therapy (AMT)|The AMT consists of intratumorally delivered IUdR and local irradiation via AUTRON Therapy System.
41508629|NCT05119257|BIOLOGICAL|Bispecific antibodies (bsAB)|BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity.
41508630|NCT06536959|DRUG|PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine|"For AML patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~For MDS patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 14 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~The venetoclax starting dose is 100 mg on the first day, ramping up to 200 mg on the second day and finally 400 mg once daily. The steady daily dose (after ramp-up phase) should be reduced to 100 mg (coadministered with moderate CYP3A inhibitors or P-gp inhibitors) and 70 mg (coadministered with strong CYP3A4 inhibitors)."
41508631|NCT04271917|DRUG|cannabidiol|Use of cannabidiol as an alternative to standard of care treatment of acute pain.
41508632|NCT04271917|DRUG|placebo|Inactive placebo oil to imitate CBD oil
41508633|NCT04271917|DRUG|acetaminophen 500mg and ibuprofen 200mg combo|standard of care
41508634|NCT00796757|DRUG|bevacizumab [Avastin]|10mg/kg iv infusion every 2 weeks
40852871|NCT04674657|DRUG|blood drug concentration|blood drug concentration
41036105|NCT02048943|DRUG|gemcitabine hydrochloride|Given IV
41036106|NCT02048943|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
41036107|NCT02048943|OTHER|pharmacological study|Correlative studies
41036108|NCT02048943|OTHER|laboratory biomarker analysis|Correlative studies
41036109|NCT02950493|OTHER|perflutren lipid microsphere|Definity and Lumason are tools for diagnosis used in echocardiography. Compare activated Definity or Lumason with compressed Definity or Lumason.
41036110|NCT02355808|BEHAVIORAL|Tailored Leaflet|
41036111|NCT02355808|BEHAVIORAL|GP visit|
41036112|NCT05566301|DRUG|Clopidogrel|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
41036113|NCT05566301|DRUG|Ticagrelor|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
41036114|NCT06634589|DRUG|BGB-16673|Administered orally
41382817|NCT04542902|PROCEDURE|Blood sampling|An amount of a person's blood taken from their body for use in medical.
41382818|NCT04542902|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
41382819|NCT01359072|OTHER|Self administered coping intervention|The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
41382820|NCT01923961|PROCEDURE|HDF NaCl|
41382821|NCT01923961|PROCEDURE|Hemodialysis|
41382822|NCT01923961|PROCEDURE|Standard Predilution Hemodiafiltration|
41382823|NCT03390452|BEHAVIORAL|Mobile Phone Messaging|"Parents of primary school children will receive Mobile Phone Messages regarding their children's oral hygiene maintenance and their positive dietary habits."
41382824|NCT00629668|GENETIC|TNF-alpha and HBV genotype|
41382825|NCT00629668|OTHER|TNF-alpha and HBV genotypes|
41382826|NCT05961371|OTHER|Resistance Training|Twice weekly resistance training progressing to 5 sets of 5 repetitions of 80-90% of one repetition maximum.
41382827|NCT06132685|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41382828|NCT06132685|PROCEDURE|Computed Tomography|Undergo CT scan
41382829|NCT06132685|DRUG|Dexamethasone|Given dexamethasone or IV
41382830|NCT06132685|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41382831|NCT06132685|OTHER|Questionnaire Administration|Ancillary studies
41382832|NCT04518475|DRUG|eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
41382833|NCT04518475|DRUG|eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
41382834|NCT06562582|DRUG|Bisoprolol Oral Tablet|Timing of drug intervention after PCI
41036115|NCT06634589|DRUG|sonrotoclax|Administered orally
41036116|NCT06634589|DRUG|Zanubrutinib|Administered orally
41036117|NCT03339076|DEVICE|"M3 MINI CATHETER"|"Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 Mini Catheter."
41036118|NCT03994627|DRUG|Olaratumab|Administered intravenously (IV)
41036119|NCT04769076|COMBINATION_PRODUCT|Paclitaxel（Albumin-bound）|Three courses of albumin-bound paclitaxel combined with cisplatin and PD-1 monoclonal antibody neoadjuvant treatment followed by cisplatin combined with IMRT (intensity modulated conformal radiotherapy) concurrent radiotherapy and chemotherapy
41382835|NCT06562582|DRUG|Ramipril Oral Product|Timing of drug intervention after PCI
41382836|NCT06562582|DRUG|Dapagliflozin Oral Product|Timing of drug intervention after PCI
41382837|NCT02161939|DRUG|Daclatasvir (BMS-790052)|
41382838|NCT02161939|DRUG|Sofosbuvir|
41382839|NCT03803514|DRUG|Recombinant EPO|Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
41382840|NCT03427788|DRUG|BAY2328065|Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets
41382841|NCT03427788|DRUG|Placebo|Matching placebo, once daily in an escalating manner as LSF or tablets
41382842|NCT03176953|DRUG|topiramate|active medication
41382843|NCT03176953|BEHAVIORAL|prolonged exposure|psychotherapy
41382844|NCT03176953|DRUG|placebo|non-active medication
41382845|NCT04298008|DRUG|AZD6738|AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
41382846|NCT04298008|DRUG|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
41382847|NCT05620706|BIOLOGICAL|GPC3 CAR-T cells|patients treated with GPC3 CAR-T cells
41382848|NCT02795949|DRUG|Antipseudomonal beta-lactam antibiotic|Pharmaceutical form: solution for infusion
41382849|NCT02795949|DRUG|De-escalation(short-spectrum antibiotic)|Pharmaceutical form: solution for infusion
41382850|NCT05327803|DRUG|Epetraborole|500 mg taken orally QD
41036120|NCT02428868|DRUG|tranexamic acid (Exacyl®)|1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
41036121|NCT02428868|DRUG|intravenous iron (Ferroven®)|2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
41382851|NCT05327803|DRUG|Placebo|Placebo taken orally QD
41382852|NCT06568276|PROCEDURE|Additional deep deltoid ligament suture|The deep deltoid ligament will be sutured through a curved incision lifting the tibialis posterior tendon out to be sutured back after tying the ligament to an anchor in the talus.
41382853|NCT03192631|OTHER|Financial incentive|Incentive of $15 Canadian
41382854|NCT04406272|DRUG|VB11|Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.
41508635|NCT00796757|DRUG|interferon alfa-2a|3 MIU sc t.i.w.
41382855|NCT04406272|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
41036122|NCT02428868|OTHER|Saline|20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
41036123|NCT05247151|OTHER|Oxytocin|Oxytocin nasal spray in a positive social setting.
41036124|NCT05247151|OTHER|Placebo|Placebo nasal spray in a positive social setting.
41036125|NCT04659655|PROCEDURE|automated annular suturing|RAM® Automated Suturing Technology. The RAM® DEVICE and SEW-EASY® DEVICE are automated suturing devices indicated for use in the approximation of soft tissue and prosthetic materials when used in conjunction with RAM® COR-SUTURE® QUICK LOAD® surgical suture. Devices will be used for the approximation of respective replacement valves during surgical aortic or mitral valve replacement as described in the study protocol. Cases may include use of the RAM® RING/RAM® RACK devices for suture management and the Aortic Root Retractor (ARR) with delivery device.
41036126|NCT06374602|DRUG|Pembrolizumab + Lenvatinib|Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody. Lenvatinib is Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
41382856|NCT04406272|OTHER|Placebo|Intravenous solution that has no therapeutic effect, used as a control in testing investigational drug.
41382857|NCT04406272|DRUG|Bevacizumab|A type of antibody, Bevacizumab is intravenously administered and works by binding to and disrupting the vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulates the formation of blood vessels. By disrupting VEGF, Bevacizumab helps to prevent the growth and maintenance of tumor blood vessels.
41382858|NCT05472363|DIAGNOSTIC_TEST|Electroencephalogram|A routine test that involves attaching small wires to the head to read the electrical activity of the brain
41382859|NCT05472363|PROCEDURE|Transcranial Magnetic Stimulation|Noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. An electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers repetitive magnetic pulses to simulate nerve cells in the brain.
41382860|NCT05472363|PROCEDURE|Transcranial Direct Current Stimulation|Noninvasive procedure that uses direct electrical currents to stimulate the brain. A constant, low intensity current is passed through two electrodes that are place on the head.
41382861|NCT01306968|DRUG|hyperbaric oxygen|"The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute)."
41382862|NCT01306968|OTHER|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
41382863|NCT06541002|BEHAVIORAL|SHIFT Intervention Group|Participants assigned to SHIFT will meet with their HCT clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or genital graft-versus-host disease; and start using SHIFT at their desired pace over 8 weeks to complete five modules.
41382864|NCT06541002|BEHAVIORAL|Enhanced Usual Care Group|Participants assigned to the enhanced usual care group will meet with their HCT clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or genital graft-versus-host disease; and maybe referred to a psychologist, urologist, or gynecologist at the participants' request or at the discretion of the HCT clinician.
41382865|NCT01977560|BEHAVIORAL|Intensive Lifestyle Intervention|Participants will be instructed to consume \~500 kcal/day less than their calculated estimated total daily energy requirements. The supervised exercise program will include both endurance and resistance exercise training sessions. The doses of diabetes medications will be adjusted by study physicians every 1-2 weeks, as needed to avoid hypoglycemia.
40852872|NCT03422666|DRUG|Teduglutide|Teduglutide
40852873|NCT03422666|DRUG|Placebo|Placebo
40852874|NCT06101277|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
41036127|NCT05261152|DRUG|drug product: capsules are containing S. boulardii, administered twice daily (250 mg)|Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
41036128|NCT03725683|DEVICE|Increased caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI(ankle-brachial pressure index);Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
41036129|NCT03725683|DEVICE|matched caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI index;Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
41165867|NCT00904722|DRUG|Rituximab|Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
40852875|NCT00033891|DRUG|Infliximab|
40852876|NCT02045693|DRUG|Methadone|
40852877|NCT02045693|DRUG|DCV 3DAA FDC|
40852878|NCT02045693|DRUG|BMS-791325|
40852879|NCT02045693|DRUG|Buprenorphine|
40852880|NCT02045693|DRUG|Naloxone|
41036130|NCT03491761|BIOLOGICAL|PRP Treatment|PRP will be prepared using an Arthrex ACP® kit (a low-leukocyte Autologous Conditioned Plasma system). This is a single-spin system that concentrates platelets and separates red blood cells (RBCs) as well as white blood cells (WBCs) from the treatment product.
41036131|NCT03491761|BIOLOGICAL|HA Treatment|Euflexxa will be used for treatment. It will be prepared according to the package insert.
41036132|NCT01404572|DRUG|Atazanavir (current formulation)|Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
41036133|NCT01404572|DRUG|Atazanavir, powder for oral use 1 (POU1)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
41036134|NCT01404572|DRUG|Atazanavir (POU2)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
41036135|NCT03689322|OTHER|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
41036136|NCT03689322|OTHER|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
41382866|NCT01977560|BEHAVIORAL|Standard Care|After receiving dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines participants will meet approximately every month for about 7 months with a study team member to record body weight, review diet and physical activity behaviors, and document medication use. Participants will continue their routine medical management, including regular clinic visits with their personal physician and/or diabetes educator during their participation in this study. Any changes medications will made by the participants' personal physician(s).
41382867|NCT05242107|DIETARY_SUPPLEMENT|Omega-3 supplement group|35 Neonates were given Omega 3 in a dose of 40mg/kg/day (8), after establishment of full-feeding and for 2 weeks duration. Omega-300 (Montana pharmaceutical industry) capsule was used which contains 1000mg Omega 3 fatty acids.
41508636|NCT01378247|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
41508637|NCT03512873|DRUG|Tranilast|Subjects will be treated with tranilast
41508638|NCT00442962|DRUG|Efavirenz|600-mg tablet taken orally daily
41508639|NCT00442962|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
41508640|NCT00102947|DRUG|daptomycin (up to 14 days)|
41508641|NCT04401215|BEHAVIORAL|Technology Augmented Treatment for Screening, Brief Intervention, Referral, and Treatment (SBIRT)|This group will answer to questions on the iPad at baseline visit and will receive up to 4 text messages per day asking about their Health and treatment during 30 days.
41036137|NCT03689322|OTHER|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
41036138|NCT06129773|PROCEDURE|antibiotic coated vicryl used for fascial closure|in this group fascial closure was done with antibiotic coated vicryl to compare with non coated vicryl after lapaprotomy in contaminated wounds
41036139|NCT03878810|BEHAVIORAL|Exergaming|A video game-based physical activity training applied using a commercial game console.
41036140|NCT03826667|DEVICE|Polyetheretherketone (PEEK) Shoulder Suture Anchors|"PEEK Suture Anchors, which include:~* HEALICOIL™ PK Preloaded Suture Anchors~* BIORAPTOR™ 2.3 PK Suture Anchors/BIORAPTOR™ Curved 2.3 PK Suture Anchors~* BIORAPTOR™ Knotless Suture Anchors~* MULTIFIX™ S Ultra Knotless Fixation System~* FOOTPRINT™ Ultra PK Suture Anchors~* TWINFIX™ Ultra PK Suture Anchors/TWINFIX™ Ultra Preloaded and with Needles~* SPEEDSCREW™ Knotless Fixation System~* SpeedLock Knotless Fixation Device"
41036141|NCT00922454|PROCEDURE|Endovascular Repair of the abdominal aorta|"Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment."
41382868|NCT05242107|OTHER|Full feeding without receiving any supplementation group|35 full term Growth Restriction( IUGR) neonates who were followed up to full feeding without receiving any supplementation.
41382869|NCT06380101|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
41382870|NCT02610842|OTHER|Handbook|"The handbook named Hands on - a hand care guide in Systemic Sclerosis contains instructions about the Systemic Sclerosis and hand exercises."
41382871|NCT06345768|OTHER|Stress Ball|It is a ball 5-6 cm in size and not too hard. It will be given to both hands of the patients and they will be asked to count from 1 to 5. This application will be repeated for 15 minutes.
41508642|NCT01561261|OTHER|Continuous tissue perfusion monitoring by near-infrared spectroscopy (NIRS) and intramuscular pressure (IMP)|Continuous monitoring of tissue perfusion using NIRS in all 4 leg muscle compartments and IMP via indwelling catheters in anterior and deep posterior compartments. These measures will not provided in real time to treating physicians. All clinical care, including the diagnosis of ACS, will be according to the current standard-of-care practiced at each institution, Clinicians may use the indwelling IMP monitor to obtain up to 2 discrete measures of IMP if they encounter a clinical situation in which they would normally measure IMP as an adjunct in their normal standard-of-care for the monitoring and diagnosis of compartment syndrome. Patients who undergo fasciotomy will also have NIRS and IMP values recorded from all 4 leg compartments immediately before and after fasciotomy.
41508643|NCT02931981|PROCEDURE|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
41036142|NCT00922454|DEVICE|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
41036143|NCT00922454|DEVICE|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
41036144|NCT06635486|BEHAVIORAL|Adapted cognitive-behavioral (CBT) intervention|The intervention is 6-12 sessions, depending on the symptom presentation of the participant. The weekly sessions last 60 minutes and will be delivered remotely and individually via Meet or a similar platform by trained lay providers. Intervention methods include cognitive re-structuring, behavioral activation, exposure to memories and situations, problem solving, and emotional regulation.
41165868|NCT00751634|DEVICE|Gaymar Rapr-Round (external cooling blanket)|Application of the device per its approved labeling
40852881|NCT04703491|BEHAVIORAL|Interactive and full-featured intervention|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements. They will play games based on Cognitive Bias Modification (CBM) paradigms, practice mindfulness, and chat with an automated empathic chatbot.
40852882|NCT04703491|BEHAVIORAL|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features
40852883|NCT04703491|OTHER|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
40852884|NCT03236987|DRUG|Clarithromycin 1000 MG|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
40852885|NCT03236987|DRUG|Azithromycin 250 mg|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
40852886|NCT03236987|DRUG|Rifampicin|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
40852887|NCT03236987|DRUG|Ethambutol|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
40852888|NCT06210230|DIETARY_SUPPLEMENT|MLCT supplementation|MLCT 25g/d for 6 months
41382872|NCT05681104|DIAGNOSTIC_TEST|Waist-height ratio|Waist-height ratio as early predictors of metabolic syndrome in primary school obese children
40852889|NCT06210230|DIETARY_SUPPLEMENT|Olive oil|Matching placebo (olive oil) 25g/d for 6 months
40852890|NCT01281033|PROCEDURE|Manual Thrombectomy|In patients in the thrombus-aspiration group, this step is followed by the advancing of the 6-French Export Aspiration Catheter (Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous aspiration.
40852891|NCT01281033|PROCEDURE|AngioJet Rheolytic Thrombectomy (RT) System|The AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter. Thrombectomy is accomplished by the introduction of a pressurized high velocity saline stream through directed orifices in the catheter distal tip so that thrombus is entrained (Bernoulli effect), dissociated into small particles, and evacuated from the body through the catheter and associated tubing. The pump set consists of a high pressure pulsatile pump which is used to generate the flow necessary for the dissociation and evacuation of thrombus, an effluent bag for the collection and storage of thrombus debris, and associated tubing.
41382873|NCT05681104|DIAGNOSTIC_TEST|body mass index|Body mass index as early predictors of metabolic syndrome in primary school obese children
41382874|NCT05681104|DIAGNOSTIC_TEST|Bio-electrical impedance analysis|Bio-electrical impedance analysis as early predictors of metabolic syndrome in primary school obese children
41382875|NCT00210925|DRUG|topiramate|
41382876|NCT00271037|PROCEDURE|Colpocleisis prolapse repair surgery|
41382877|NCT00271037|PROCEDURE|sling or other to treat or prevent stress incontinence|
40852892|NCT00372697|DRUG|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
41036145|NCT03923413|OTHER|Blood samples|Blood samples for MP evaluation
41036146|NCT04287374|BEHAVIORAL|Multi-component Well-being Intervention|The intervention asks participants to complete exercises based on three different skills. These skills include cognitive restructuring, gratitude and behavioral activation. After completing the program, participants will pick their favorite exercise to complete on a weekly basis for homework. In order to increase compliance with the homework, participants will complete a short plan in which they will identify when, where and with who they will complete the homework. The whole intervention takes approximately 20-30 minutes to complete.
41036147|NCT04287374|BEHAVIORAL|Study Skills|Participants are taught three different study skills/strategies. They are asked to make a plan to continue using these strategies after completing the intervention. The whole intervention takes approximately 20-30 minutes to complete.
41036148|NCT06458582|DEVICE|High-Flow Nasal Cannula|The intervention involves administering High-Flow Nasal Cannula therapy to very preterm infants immediately after birth.
41165869|NCT02048683|DRUG|Short term sedation with sevoflurane in ICU|
41165870|NCT01722864|DRUG|COV155|COV155 tablets
41165871|NCT02109861|DRUG|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
41165872|NCT02109861|DRUG|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
41165873|NCT02109861|DRUG|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
41382878|NCT03455530|OTHER|Industrial Hygiene-Enhance Community Health Worker Intervention|The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
41382879|NCT02773641|DRUG|Botulinum Toxin Type A|
40852893|NCT04802187|OTHER|RADx CHCs testing intervention strategy|The study team will support partner CHCs to implement workflows with some combination of dedicated testing staff, off-site testing, outreach/communications to priority populations, and linkage with local contact tracing systems. Implementation support will take the form of practice facilitation, rapid cycle testing (by supporting CHCs to review their internal data to assess the impact of workflow changes), and expert consultation from the research team on testing technology and testing location design.
41036149|NCT05234164|DEVICE|EXIST 6F NiTi Stent System FLEX|Subjects requiring treatment of the P1 segment of the proximal popliteal artery will be treated with the Exist 6F NiTi Stent FLEX type. Subjects requiring treatment of the SFA will undergo an additional calcification review based on the Fanelli classification. Subjects graded with Fanelli 1 or 2 will be treated with the Exist 6F NiTi Stent FLEX type.
41165532|NCT03230409|BIOLOGICAL|Eidus-Hamilton Test|E-H test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test. This test is a rapid, simple point-of-care method to detect urinary acetyl-isoniazid, the main metabolite of isoniazid, up to 12-24 hours following isoniazid administration and is used as a surrogate marker of treatment adherence. The test consists of placing 4 drops of a 10%potassium cyanide solution and 9 drops of a 10%chloramine solution in a test tube containing 4 drops of patient urine. The result is considered positive if a deep red color develops after 1 minute. If a pink color slowly appears,this indicates that there are only traces of the metabolite. If there is no change in color, the result is considered negative and suggests no recent isoniazid intake. The sensitivity and specificity of this test have been reported to be over 99%
40852894|NCT04802187|OTHER|Usual care control|CHCs implement testing strategies in accordance with their usual supports.
41036150|NCT05234164|DEVICE|EXIST 6F NiTi Stent System PULL|Subjects requiring treatment of the SFA will undergo a calcification review based on the Fanelli classification. Subjects graded with Fanelli grade 3 and 4 will be treated with the Exist 6F NiTi Stent PULL type.
41036151|NCT00981591|DRUG|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
41036152|NCT00981591|DRUG|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
41036153|NCT04320069|DEVICE|Omnipod Horizon™ Automated Glucose Control System|Omnipod Horizon™ Automated Glucose Control System use in Manual Mode
41036154|NCT04637204|DRUG|Cabozantinib|oral therapy
41036155|NCT04637204|DRUG|Axitinib|oral therapy
41036156|NCT00000154|PROCEDURE|Vitrectomy|
41036157|NCT00282620|DRUG|Magnesium L-lactate|
41036158|NCT01053208|DRUG|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
41036159|NCT00071669|PROCEDURE|Acupuncture|
41382880|NCT02773641|DRUG|Sterile Saline Solution|
41382881|NCT06080191|DRUG|CD19-CAR_Lenti_ALLO|"Biological/Vaccine: CD19-CAR_Lenti_ALLO~A single infusion of CD19-CAR_Lenti_ALLO on Day 0"
41382882|NCT02712359|OTHER|Blood sample collection|A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).
41382883|NCT04466436|OTHER|tryptophan|measurement of tryptophan in serum
41382884|NCT02658500|DIETARY_SUPPLEMENT|Infant Formula|
41036160|NCT06187753|DIAGNOSTIC_TEST|Sensory Profile|The Sensory Profile has 125 items that represent 14 functions of sensory processing and allows parents to report on their child's behavior.
41382885|NCT02658500|DIETARY_SUPPLEMENT|breast milk|
41382886|NCT06159699|OTHER|Online Survey|The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.
41382887|NCT06159699|DIAGNOSTIC_TEST|Genetic Testing|Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.
41382888|NCT00030849|BIOLOGICAL|recombinant interferon alfa|
41382889|NCT00030849|DRUG|bexarotene|
41382890|NCT03372395|OTHER|Lactobacillus rhamnosus BMX 54|Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).
41382891|NCT06381401|DRUG|bupivacaine 0.25%|superficial cervical plexus block using 10 ml of bupivacaine 0.25%
41382892|NCT06381401|DRUG|bupivacaine 0.125%|superficial cervical plexus block using 10 ml of bupivacaine 0.125%
41382893|NCT03278483|DRUG|Isoniazid 300 mg Oral Tablet|Isoniazid tablets 300mg daily plus pyridoxine 50mg daily
40852895|NCT05574088|PROCEDURE|Apical patency with file|After an informed consent , One group will receive apical patency intervention with k file number 10 while the other will be control group
40852896|NCT02211612|DIETARY_SUPPLEMENT|PUFA-group|
40852897|NCT02211612|DIETARY_SUPPLEMENT|SFA-group|
40852898|NCT04260347|DRUG|Alteplase|Intravenous injection
40852899|NCT00738751|DRUG|Panobinostat (LBH589)|Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
41036161|NCT04717804|OTHER|AIP CT|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
41036162|NCT04717804|OTHER|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
41382894|NCT03278483|DRUG|Rifampin 600 mg Oral Tablet|Rifampin capsules 600mg daily
41036163|NCT03140436|DRUG|sodium bicarbonate powders with grain size 65 µm|sodium bicarbonate powders with grain size 65 µm
41382895|NCT01982045|DEVICE|AttraX® Putty|Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
41382896|NCT01982045|OTHER|Autologous bone graft|Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
41382897|NCT05996549|DRUG|Quadrivalent Influenza Vaccine|All high-risk groups have been getting one dose of seasonal influenza vaccination (Inactivated Influenza Vaccine ), except children aged six months to 8 years, who will receive two doses four weeks apart. All vaccines are in the southern hemisphere, as Bangladesh's influenza season matches the southern hemisphere areas.
40852900|NCT00738751|DRUG|erlotinib|Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
40852901|NCT04767503|DRUG|Propofol|Maintence of anestheisa with propofol guided by the bispectral index in the range 40-60.
40852902|NCT04767503|DRUG|Desflurane|Maintence of anestheisa with desflurane guided by the bispectral index in the range 40-60.
41036164|NCT03140436|DRUG|sodium bicarbonate powders with grain size 40 µm|sodium bicarbonate powders with grain size 40 µm
41036165|NCT06269926|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Treatment for chronic pain that addresses the relationship between thoughts, feelings and behaviors.
41036166|NCT06269926|OTHER|Pain education|A booklet on chronic pain (in this study, an educational pamphlet from the Oregon state health department) that provides pain education in addition to usual medical care.
41036167|NCT05086133|DEVICE|transcranial magnetic stimulation|transcranial magnetic stimulation with continuous theta burst pattern, 90% RMT, 50Hz within train and 5Hz train for 200 train and 40 second in total.
41036168|NCT05086133|DEVICE|sham stimulation|TMS coil vertical to the brain surface, with same protocol as cTBS
41165533|NCT03230409|BEHAVIORAL|A written questionnaire|The parents or carers of the children and/or the young patients themselves were asked to complete a written questionnaire about adherence to anti-TB treatment on all the follow-up visits, which was partially adapted from two validated questionnaires on adherence to chronic therapies (SMAQ compliance test, Svarstad et al., 1999; and Hermes test, Rodríguez-Chamorro et al., 2008).
41165534|NCT00024570|DRUG|IL13-PE38QQR|
41165535|NCT00024570|PROCEDURE|targeted fusion protein therapy|
41165536|NCT00024570|PROCEDURE|surgery|
40852903|NCT05691114|BIOLOGICAL|hAESCs|human Amniotic Epithelial Stem Cells
40852904|NCT00924339|DIETARY_SUPPLEMENT|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
41165537|NCT04708483|DEVICE|Extra DCE-CT scan|DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria.
41165874|NCT01050387|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D (either 400 IU vs 1000 IU) given orally each day
41165875|NCT02014883|DRUG|GLUT1 DS|
41165876|NCT06443424|DEVICE|ultrasound device|usage of ultrasound device in pediatric airway asessment
41382898|NCT06075927|BIOLOGICAL|Virus specific T cells|"Subjects will receive partial HLA-matched viral-specific T cells (VSTs) against both CMV and EBV on one of the following dose levels:~Level One: 1 x 10\^7 cells/m2 Level Two: 2 x 10\^7cells/m2 Level Three: 5x 10\^7 cellss/m2"
41382899|NCT06454695|BEHAVIORAL|Future-oriented imagery rescripting|In this pilot study, in the screening phase, negative or catastrophic future-oriented images will be explored for all patients, including ratings of distress. The future-oriented imagery rescripting consists of 3-5 sessions; each image will be treated in one session, starting with the image that causes highest distress. The protocol is largely based on Hackmann (1998), with minor adaptations from other protocols.
41508644|NCT02758639|BEHAVIORAL|Wonders & Worries Psychosocial Intervention|Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
41508645|NCT03390803|OTHER|effect of hemifacial spasm on intraocular pressure|To evaluate the effect of Hemifacial spasm on Intraocular pressure measurement.
41382900|NCT06454695|OTHER|Treatment as Usual|Psychotherapy and/or medication
41382901|NCT01301378|PROCEDURE|Molteno 3 glaucoma drainage shunt|Patients needing glaucoma drainage surgery
41508646|NCT00894829|BIOLOGICAL|heparin sodium - Eurofarma|Heparin sodium 5.000 UI - Eurofarma
41508647|NCT00894829|BIOLOGICAL|heparin sodium - APP|Heparin sodium APP 5.000 USP
41508648|NCT05650840|PROCEDURE|Charcoal based whitening toothpaste (signal charcoal white& Detox toothpaste Unilever Mashreq - Egypt|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded.~Intervention drug : whitening toothpaste charcoal based whitening toothpaste compared to calcium carbonate and perlite whitening toothpaste~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush (Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination"
40852905|NCT00924339|DIETARY_SUPPLEMENT|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
40852906|NCT02452450|DRUG|Ibuprofen Acid|
40852907|NCT02452450|DRUG|Ibuprofen Lysine|
40852908|NCT02452450|DRUG|Ibuprofen Sodium|
40852909|NCT02452450|DRUG|Ibuprofen Liquid Capsules|
40852910|NCT02452450|DRUG|Paracetamol|
40852911|NCT01743742|DRUG|Vitamin E, Vitamin C|
41382902|NCT00096317|DRUG|ixabepilone|
41382903|NCT00096317|DRUG|ketoconazole|
41382904|NCT04420000|BEHAVIORAL|Mindfulness|Mindfulness based programme
41382905|NCT04420000|OTHER|Control|Treatment as usual
41382906|NCT00463385|DRUG|Pomalidomide|
41382907|NCT00463385|DRUG|Prednisone|Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
41382908|NCT00463385|DRUG|Placebo to pomalidomide|Matching pomalidomide placebo tablets
41382909|NCT00463385|DRUG|Placebo to prednisone|Matching prednisone placebo tablets
41508649|NCT05650840|PROCEDURE|Calcium carbonate /perlite containing whitening toothpaste (signal whitening moonlight toothpaste Unilever Mashreq - Egypt).|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using calcium carbonate /perlite containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded. The main operator will perform the tooth brushing procedures for all the patients himself twice daily.~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush(Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination Device used is atomic force microscopy to determine enamel abrasion after brushing"
41508650|NCT01948531|DRUG|Gynomunal® gel|A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
41382910|NCT02783508|DRUG|IV Meperidine|"Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered."
41382911|NCT02783508|DRUG|Nitrous Oxide|"Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered."
41382912|NCT04074109|COMBINATION_PRODUCT|Teleyoga|the yoga protocol will be delivered via a tablet computer to groups of participants
41382913|NCT04074109|BEHAVIORAL|In-person yoga|the yoga protocol will be delivered by a yoga instructor in the room to group of participants
41382914|NCT03105076|OTHER|Decision aids|Shared decision making with decision aids
41382915|NCT00530621|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
41382916|NCT00530621|DRUG|placebo|oral, daily
41382917|NCT00530621|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
41382918|NCT03833531|BEHAVIORAL|ImRS|ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.
41382919|NCT03833531|BEHAVIORAL|SFT|SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
41382920|NCT01655784|PROCEDURE|Coil Embolization with larger Diameter Coils|Eighteen Coils placed in cerebral aneurysm
41382921|NCT01655784|PROCEDURE|Coil Embolization with Standard Diameter Coils|Cerebral aneurysms will be embolized with standard diameter coils.
41382922|NCT01570127|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
41382923|NCT01570127|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
41382924|NCT01570127|PROCEDURE|Sham Acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
41382925|NCT01570127|OTHER|Waiting|No interventions were applied to the patients in this group.
41508651|NCT02465138|DRUG|Ketorolac|Intravenous ketorolac
41508652|NCT02465138|DRUG|Placebo|Intravenous saline
41508653|NCT06462755|OTHER|No intervention|no intervention
40852912|NCT01884896|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
40852913|NCT01884896|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
41382926|NCT05406310|DEVICE|Ablation Index-guided ablation|Radiofrequency catheter ablation guided by Ablation Index software.
41508654|NCT04525573|DEVICE|LLLT Combination Red/Gold/IR Therapy|Three LLLT combination treatments per week over the course of two consecutive weeks, and a final follow up on day-15 (total of 7 treatments).
40852914|NCT00158288|BEHAVIORAL|LAAM|
40852915|NCT00917839|DRUG|lamotrigine|100 mg, once daily, 12 months
40852916|NCT02251938|DRUG|DE-109 440 μg|Medium Dose
41382927|NCT05406310|DEVICE|High-power, short-duration ablation using QDOT Micro catheter|Radiofrequency catheter ablation guided by high-power, short-duration ablation using QDOT Micro catheter
41508655|NCT05257681|PROCEDURE|Interlobar fissure completion and pleural adhesiolysis|A video-assisted thoracic surgery or robotic approach will be used to perform pleural adhesiolysis and the lobar fissure adjacent to the previously targeted lobe during bronchoscopic lung volume reduction will be completed using a surgical stapler.
40852917|NCT00534976|DRUG|Comparator: montelukast sodium|"Patients 4-5 years: 4 mg Montelukast chewable tablet daily~Patients 6-14 years: 5 mg chewable tablet daily"
40852918|NCT00534976|DRUG|Comparator: Comparator: placebo (unspecified)|"Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily"
41382928|NCT01827085|DEVICE|Conventional Macintosh laryngoscope|
41382929|NCT01827085|DEVICE|Stortz videolaryngoscope|
41165538|NCT02238964|DEVICE|Strattice™ Reconstructive Tissue Matrix|The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.
41165539|NCT02238964|PROCEDURE|Standard Closure|The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
41165540|NCT05313906|DRUG|RC48+AK105+cisplatin|RC48 plus AK105 and cisplatin
41165541|NCT04996537|OTHER|Micro-video digiral learning|On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
41165542|NCT00001649|DRUG|Valaciclovir|
41165543|NCT06077877|DRUG|GSK4524101|GSK452101 will be administered.
41165544|NCT06077877|DRUG|Niraparib|Niraparib will be administered.
41382930|NCT03112707|DRUG|Aspirin|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
40852919|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
40852920|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
40852921|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
40852922|NCT04577430|DRUG|Normal saline|Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
40852923|NCT03787797|DIAGNOSTIC_TEST|Echocardiography|Assessment of epicardial adipose tissue thickness
41165545|NCT05515913|OTHER|Nutritional status|Nutritional status of children as analyzed by anthropometric indices was under study
41165546|NCT05515913|BEHAVIORAL|Eating behavior|The eating behavior of ASD children as analyzed by frequency of refusal of new food, sensitivity to food, food allergy and gastrointestinal systems was under study
41165547|NCT05515913|OTHER|Urine iodine concentration|the 24 urine iodine concentration of all subjects was under study
41165548|NCT05515913|OTHER|Nutrient intake|The nutrient intake as analyzed by three days food diary and major meal proximate analysis of subjects was under study
41165549|NCT05515913|OTHER|Dietary assessment|The food frequency and dietary diversity of all subjects as analyzed by food frequency questioner, dietary diversity score and food variety score was under study
41165550|NCT05515913|OTHER|Childhood autism rating scale|The autistic severity of ASD diagnosed children was under study as analyzed by childhood autism rating scale diagnosis
41165551|NCT00953862|DRUG|Atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
41165552|NCT00962806|BEHAVIORAL|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
41165553|NCT00962806|BEHAVIORAL|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
41165554|NCT03379779|DIAGNOSTIC_TEST|16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool|We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
41165555|NCT05696223|OTHER|Ultrasound|Doppler mesure
41165556|NCT05363605|DRUG|[225Ac]-FPI-1966|\[225Ac\]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.
41165557|NCT05363605|DRUG|[111In]-FPI-1967|\[111In\]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide. Participants will receive \[111In\]-FPI-1967 Injection of 185 MBq for imaging.
41165558|NCT05363605|BIOLOGICAL|vofatamab|Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope. In Phase 1, the dose depends on cohort assignment. In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.
41165559|NCT00936962|BIOLOGICAL|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
41165560|NCT04970381|DRUG|Rivaroxaban|Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.
41165561|NCT05021822|PROCEDURE|Erector spinae plane block|Bilateral erector spinae plane block will be performed preoperatively under ultrasound guidance using 15 ml bupivacaine on each side
41165562|NCT06276517|OTHER|questionnaire|self-questionnaire with 16 questions, rated from 0 to 4, giving a total of 0 to 52 points.
41165563|NCT06276517|OTHER|SS-QoL|49-question self-administered questionnaire covering 12 domains (including work/productivity, mood, social roles, family roles, personality, etc.).
40852924|NCT04880369|DIETARY_SUPPLEMENT|Soy isoflavones|Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein).
41382931|NCT03112707|DRUG|P2Y12 inhibitor|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
41382932|NCT01816334|DRUG|methylprednisolone|
41382933|NCT01816334|DRUG|Ketoprofen|
41508656|NCT04825912|BEHAVIORAL|Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience|The SST-LC is a brief structured intervention deliverable by video conference. The SST-LC Resilience protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors. The focus will be to test measures of resilience during the intervention period.
41508657|NCT06416956|DRUG|Caffeine|We will record infant\&#39;s brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped. The decision to change dose/stop treatment will be made by the clinical team as part of routine care. No changes in caffeine treatment will be carried out solely for research purposes.
41508658|NCT01403220|PROCEDURE|Hemodiafiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
41036169|NCT04207099|DEVICE|MolecuLight i:X Imaging Device|The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
41508659|NCT01403220|PROCEDURE|Hemofiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
41508660|NCT03149796|OTHER|laboratory blood tests|Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups
41508661|NCT04475172|COMBINATION_PRODUCT|Self-Adhesive Flowable Composite|"Fusio Self-Adhesive Flowable Composite combines the benefits of adhesive and restorative technology into one product . Immediately upon application Fusio conditions, bonds, and seals without the need for an etchant or an adhesive.~It is based on the bonding technology that uses glycerophosphate dimethacrylate(GPDM)to etch enamel and dentin, and hydroxyethyl methacrylate (HEMA) to enhance wetting and penetration by resin into dentin."
40852925|NCT04880369|DIETARY_SUPPLEMENT|Lignans|Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol)
40852926|NCT04880369|DIETARY_SUPPLEMENT|Placebo|The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc.
41165564|NCT06276517|OTHER|SF-36|multidimensional, generic scale, i.e. one that assesses health status independently of causal pathology, sex, age and treatment
41382934|NCT01816334|DRUG|Sodium Chloride|
41382935|NCT01211613|PROCEDURE|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
41382936|NCT01211613|DEVICE|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
41382937|NCT01211613|OTHER|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
41382938|NCT01198990|BEHAVIORAL|Group 1|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
41382939|NCT01198990|BEHAVIORAL|Group 2|Subjects will be randomized to the small change eating strategy and a physical activity goal.
41382940|NCT03144219|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) ultrasound monitoring|TCD monitoring comatose patients in ICU looking for signs of impaired cerebral compliance
41382941|NCT03144219|DIAGNOSTIC_TEST|Non invasive intracranial compliance monitoring|A sensor of cardiac beat by beat cranial dilation will be used for monitoring intracranial compliance, in non-invasive fashion.
41508662|NCT00233402|DRUG|Hexvix|Single Instillation, Transurethral Resection of the Bladder
41508663|NCT00233402|PROCEDURE|Standard white light cystoscopy|
41508664|NCT05017597|OTHER|Rehabilitation|Exercises completed, and rate of perceived exertion (RPE) will be reviewed during \& after each exercise session. Exercises will be modified by either increasing or decreasing the intensity. Decisions will be made based RPE, physical symptoms \& any identified barriers or supports. Weeks 1, 3, 5, \& 7, Cancer-related fatigue (CRF) education will be assigned. During weeks 2, 4, 6, \& 8, CRF education will be reviewed and a plan for how to apply the information will be developed. Participant will be guided through 6 steps of problem solving to address one occupational performance problem identified by participant within Canadian Occupational Performance Measure. Goal \& action plan for the week will be shared with the participant electronically. At the beginning of each session, participant will describe progress on previous week action plan. Based on participant's response, either a new goal will be developed or the current one modified..
41508665|NCT02593643|DRUG|Ketamine|
41508666|NCT02593643|DRUG|Midazolam|
41508667|NCT02593643|OTHER|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
41508668|NCT03323398|BIOLOGICAL|mRNA-2416|mRNA encoding human OX40L
41508669|NCT03323398|BIOLOGICAL|Durvalumab|PD-L1 inhibitor
41508670|NCT02666729|PROCEDURE|AF Ablation with contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
41508671|NCT02666729|PROCEDURE|AF Ablation without contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
41508672|NCT05880329|DIAGNOSTIC_TEST|Candidate POCTs for detecting UTI|POCT performance will be evaluated in participants who experience possible UTI.
41508673|NCT00108706|DRUG|Candesartan|
41508674|NCT02732262|DRUG|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.
41508675|NCT02732262|DRUG|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.
41036170|NCT04790318|PROCEDURE|Trans-incisional Quadratus lumborum block|patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume was limited to 20 ml
41036171|NCT04790318|PROCEDURE|Caudal block|patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
41036172|NCT04118530|OTHER|HSCT Patients|Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
41036173|NCT02242747|DRUG|ingenol mebutate|an application a day for three consecutive days in a pre-determined area
41036174|NCT02242747|DRUG|5% 5-FU|two applications a day for four weeks in a pre-determined area
41036175|NCT01850680|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
41036176|NCT01850680|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
41036177|NCT01850680|DRUG|methotrexate|Pharmaceutical form:capsule Route of administration: oral
41165565|NCT06276517|OTHER|CIQ-R|16-question questionnaire with answers rated from 0 to 2 to assess Social reintegration
41508676|NCT02732262|DRUG|Oxycodone, 0.02 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
41508677|NCT01034956|DEVICE|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
41508678|NCT03447743|DRUG|XR-NTX community location|XR-NTX will be administered at the local health care clinic
41036178|NCT01850680|DRUG|folic acid|Pharmaceutical form:tablet Route of administration: oral
41036179|NCT05663294|RADIATION|external beams radiotherapy|"External beam radiation therapy uses high doses of radiation to destroy cancer cells and shrink tumors. A large machine aims radiation at the cancer. The allowed schedules for external beams radiotherapy are:~* 40 Gy in 15 fractions;~* 30 Gy in 5 fractions;~* 40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours)."
41165566|NCT06276517|DIAGNOSTIC_TEST|BREFF|rapid frontal efficiency battery, 6 tests from 0 to 3 on each side
41508679|NCT01473407|BIOLOGICAL|Epoetin Hospira|Variable dose
41508680|NCT01473407|BIOLOGICAL|Epogen (Amgen)|Variable dose
41508681|NCT03533309|PROCEDURE|Computer guided surgical cutting guide|comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent
41508682|NCT03533309|PROCEDURE|Conventional alveolar ridge splitting|comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique.
41508683|NCT02442180|DRUG|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
41508684|NCT02442180|DRUG|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
41508685|NCT02442180|DRUG|placebo|equivalent to G-CSF doses
41508686|NCT02715011|DRUG|JNJ-63709178|Participants will receive JNJ-63709178 in Part 1 and Part 2.
41382942|NCT04545866|DRUG|budesonide (Pulmicort nebulizing suspension).|The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.
41382943|NCT04545866|DRUG|surfactant (poractant alfa;Curosurf)|The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.
41382944|NCT00771654|DRUG|Phentermine|Subjects will receive Phentermine 37.5mg everyday for one year
41382945|NCT00771654|OTHER|Placebo|daily for one year
41382946|NCT03945929|BEHAVIORAL|Distraction|"Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed."
41382947|NCT01023815|DRUG|everolimus|Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
41508687|NCT01776632|BEHAVIORAL|Physical activity|Promotoras led 6 free physical activity (PA) classes per week (2 walking groups, 2 cardio dance, and 2 strength training) at participating churches randomized to the intervention condition. Classes included prayer, warm-up, moderate-to-vigorous PA, cool-down, followed by discussion of a monthly health handout. Participants received copies of the handouts each month by mail, which promoted healthy PA habits. Promotoras conducted up to 5 motivational interviewing calls with each participant over the 2-year intervention using a guide to evaluate participants' PA engagement, barriers to being active, and solutions to those barriers. Promotoras advocated for changes to the social and built environments of the churches and surrounding neighborhoods in order to promote PA and healthy behaviors.
41508688|NCT01776632|BEHAVIORAL|Cancer screening|Promotoras provided a 6-session group-based workshop series on cancer screening and prevention (breast, cervical, colorectal, and skin cancers) at participating churches randomized to the attention-control condition. Participants received informational handouts developed by American Cancer Society and the National Cancer Institute to reinforce learning in addition to lists of local cancer screening resources. Promotoras conducted up to 4 motivational interviewing calls with each participant over the 2-year intervention to encourage screening, help overcome barriers to screening, and provide support for goals.
41508689|NCT01425658|DRUG|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
41508690|NCT01425658|DRUG|Clonidine|The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
41508691|NCT01425658|DRUG|Fentanyl|The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
41508692|NCT00333151|DRUG|liraglutide|
41508693|NCT00333151|DRUG|rosiglitazone|
41508694|NCT00333151|DRUG|metformin|
41508695|NCT01447277|PROCEDURE|Sciatic Block|Performing a sciatic block in addition to a femoral block preoperatively
41508696|NCT01447277|PROCEDURE|Femoral Block only|Performing a preoperative sciatic nerve block only
41508697|NCT01669187|OTHER|Education brochure|
41382948|NCT01023815|DRUG|cyclosporine|Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
41508698|NCT01669187|OTHER|Live education and exercise instruction|Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
41508699|NCT00302445|DRUG|Efalizumab|
41508700|NCT00302445|DEVICE|Narrow Band Phototherapy|
41382949|NCT01023815|DRUG|Prednison (continuous steroids)|continuous steroids
41382950|NCT00672308|OTHER|Benefiber|
41382951|NCT00672308|OTHER|Benefiber with ORS|Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
41382952|NCT00672308|OTHER|Benefiber with ORS|
41382953|NCT00672308|OTHER|Benefiber with ORS|
41165567|NCT06276517|DIAGNOSTIC_TEST|MoCA|MoCA is a screening test for neurocognitive impairment. It comprises 11 categories scored from 0 to 6 for a total of 0 to 30 points.
41382954|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
41508701|NCT03011593|OTHER|Nutrition Support Product|Nutrition support product contains macronutrients, micronutrients, glutamine, and prebiotics. Product is in powder form (41 grams per serving) and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
41508702|NCT04351555|DRUG|Osimertinib|Oral
41508703|NCT04351555|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
41508704|NCT04351555|DRUG|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
41508705|NCT04351555|DRUG|Placebo|Oral
41508706|NCT04351555|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
41382955|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
41382956|NCT05280613|BEHAVIORAL|Family Check-Up|See arm/group description
41382957|NCT05280613|BEHAVIORAL|Treatment as Usual|See arm/group description
41382958|NCT00024557|DRUG|IL13-PE38QQR|
41382959|NCT00024557|PROCEDURE|targeted fusion protein therapy|
41382960|NCT00024557|PROCEDURE|surgery|
41382961|NCT01790139|DRUG|Oral simethicone|10 mL of simethicone is administered as an agent to prevent colonic bubbles
41382962|NCT03315325|BIOLOGICAL|Human kisspeptin-10 (metastin 45-54)|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
41382963|NCT01910597|DRUG|SBG|
41382964|NCT04730973|DRUG|Evolocumab|Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy
41382965|NCT04730973|OTHER|lipid-lowering therapy (LLT)|lipid-lowering therapy (LLT)
41382966|NCT00518531|DRUG|alendronate|Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
40852927|NCT03893162|DIETARY_SUPPLEMENT|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains:~Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.~Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram."
40852928|NCT03893162|OTHER|Placebo|Visually identical capsules in identical packaging containing no active bacteria.
40852929|NCT04230824|DIETARY_SUPPLEMENT|Pre-workout plus and Protein recovery plus|products consumed prior and after exercise
40852930|NCT04230824|OTHER|Placebo|placebo product consumed prior and after exercise
40852931|NCT04230824|OTHER|6-week resistance training program|participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week)
40852932|NCT02227394|DRUG|Z7200|"Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)"
40852933|NCT02227394|DRUG|Symbicort® Turbohaler®|Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
40852934|NCT00837343|DRUG|quetiapine fumarate tablet (Seroquel)|Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
40852935|NCT02180841|DIETARY_SUPPLEMENT|Soy Protein Powder (25g/d)|Participants will consume 25g soy protein powder daily for a 6 week treatment period.
40852936|NCT02180841|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
41382967|NCT00518531|DRUG|denosumab|Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
41382968|NCT06155825|BEHAVIORAL|no intervention|Group 4 will receive no intervention
41508707|NCT01191944|DRUG|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
40852937|NCT02180841|DIETARY_SUPPLEMENT|Soy Protein Powder (50g/d)|Participants will consume 50g soy protein powder daily for a 6 week treatment period.
40852938|NCT01142622|DRUG|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
40852939|NCT01142622|DRUG|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
41165568|NCT06276517|OTHER|IADL|8 questions rated from 0 to 1 to assess functional outcome
41165569|NCT06276517|OTHER|mMRS|mMRS score from 0 to 4 to assess functional outcome
41165570|NCT06276517|OTHER|PCL-5|To assess the prevalence of post-traumatic stress using the PCL-5 self-questionnaire. PCL-5 is a 20-item self-administered questionnaire.
41165571|NCT06276517|OTHER|Brief-Cope|28-question self-questionnaires to study patients' coping strategies
41165877|NCT02016664|DRUG|Ketamine|The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
40852940|NCT03281083|DRUG|Levothyroxine Sodium|
40852941|NCT01007838|OTHER|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
40852942|NCT01007838|OTHER|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
40852943|NCT01007838|OTHER|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
41382969|NCT06155825|DRUG|nonnutritive suckling|Group 1 will receive nonnutritive suckling
41508708|NCT01191944|DRUG|pramipexole extended release tablet|0.375mg-4.5mg, once a day
41508709|NCT00799058|DRUG|dapivirine 4789|dapivirine gel 4789, 0.05%, 2.5g applied once daily
41508710|NCT00799058|DRUG|dapivirine gel 4759|dapivirine gel 4759, 0.05%, 2.5g applied once daily
41508711|NCT00799058|DRUG|Drug placebo|HEC-based universal placebo gel, 2.5g applied once daily
40852944|NCT01007838|OTHER|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
41382970|NCT06155825|DRUG|oral glucose 25%|Group 2 will receive oral glucose 25%
41382971|NCT06155825|BEHAVIORAL|facilitated tuckling|Group 3 will undergo facilitated tuckling
41382972|NCT06569004|DEVICE|randomised study, two group (experimental and control)|Use of IR beam before peripheral intravenous catheter application
41382973|NCT04338646|OTHER|Clinical tests|Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void
41382974|NCT05244109|OTHER|Blood sample|Blood samples (2 times; 21mL per visit)
41508712|NCT04472676|DRUG|LY3473329|Administered orally.
40852945|NCT01072994|DIETARY_SUPPLEMENT|Fish Oil|Differential proportional doses of DHA versus DHA and EPA
40852946|NCT02781168|DEVICE|use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
41036180|NCT05663294|RADIATION|brachytherapy|"Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment.~The schedule for brachytherapy are:~* 32 Gy in 8 twice-daily fractions for HDR;~* 30.3 Gy in 7 twice-daily fractions for HDR;~* 50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR."
41036181|NCT01325168|DRUG|syntocinon nasal spray|nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
41165572|NCT05028036|OTHER|Personalized lifestyle treatment program|"The personalized treatment program is based on the participants symptom profile and test results and is designed in collaboration with the participant. The treatment plan that may include several of the following components:~* Dietary changes~* Supplements~* Measures to improve sleep / circadian rhythm~* Stress management~* Physical exercise~The treatment plan is evaluated continuously by the participant and the therapist and adjusted accordingly. A total of 9 visits to the Nordic Clinic over one year is included in the treatment program."
41165573|NCT02107729|PROCEDURE|Large needle gauge lidocaine injection|21 G
40852947|NCT01748825|DRUG|MK-1775 (AZD1775)|MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
40852948|NCT03125772|DEVICE|TAXUS Element™ Paclitaxel-Eluting Stent System|Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.
40852949|NCT03125772|DEVICE|Xience PRIME Everolimus-Eluting Stent System|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
41165574|NCT02107729|PROCEDURE|Normal needle gauge lidocaine injection|23 G
41382975|NCT05244109|DRUG|anti-TNF antibody administration|Anti-TNF antibody administration, according to current recommendations and randomization results
41382976|NCT05244109|DRUG|anti-IL-17 antibody administration|Anti-IL-17 antibody administration, according to current recommendations and randomization results
41382977|NCT01626794|BIOLOGICAL|VARIVAX™ VEP|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
41382978|NCT01626794|BIOLOGICAL|VARIVAX™ 2007 Process|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
41382979|NCT01626794|BIOLOGICAL|M-M-R™ II|Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
41382980|NCT02815540|PROCEDURE|12-Lead ECG|Subjects will be monitored while on cannabidiol with a 12-Lead ECG and/or Holter monitoring
41382981|NCT02815540|DRUG|Cannabidiol|Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.
41382982|NCT06180174|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion
41382983|NCT00811031|DRUG|Taxotere|75 mg/m\^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
41382984|NCT00811031|DRUG|Prednisone|5 mg twice a day by mouth.
41382985|NCT06437353|DRUG|Paclitaxel|"First-line chemotherapy regimen:~* Paclitaxel: 175 mg/m², intravenous infusion, on day 1.~* Carboplatin: AUC 5, intravenous infusion, on day 1.~* Surufatinib：250 mg once daily, taken continuously.~Maintenance Therapy Regimen:~* Surufatinib: 250 mg once daily, taken continuously.~* Olaparib: 300 mg twice daily."
41382986|NCT04837196|DRUG|ASP7517|Intravenous (IV)
40852950|NCT00516867|RADIATION|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
40852951|NCT00516867|RADIATION|UV radiation|UVB 1.4 % and UVA 98.6
40852952|NCT03799939|DEVICE|Intervention group|Polyvinylidene fluoride mesh (Dynamesh IPST) is used on intraperitoneal onlay position to prevent parastomal hernia.
41036182|NCT01325168|DRUG|placebo nasal spray|nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
41036183|NCT02573519|RADIATION|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) \[11C\]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
41165575|NCT02107729|PROCEDURE|Small needle gauge lidocaine injection|27 G
41165576|NCT02596399|DRUG|DSTA4637S|Participants will receive DSTA4637S intravenously on Day 1.
41165577|NCT02596399|DRUG|Placebo|Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
41165578|NCT01845311|DEVICE|ReZolve2 Scaffold|
41165579|NCT05397210|DEVICE|Infinity-Lock Button System|Infinity-Lock Button System
41382987|NCT04837196|DRUG|Pembrolizumab|Intravenous (IV)
41382988|NCT03389776|PROCEDURE|Anesthesia|Occurrence and severity of postoperative sore throat could be determined by various factors other than the pressure of the cuff alone. In particular, cuff pressure measurement, duration of anaesthesia, airway manipulations e.g. multiple insertion attempts, could all be factors determining the occurrence of postoperative sore throat.
41382989|NCT05917938|DRUG|NNC0194-0499|NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
41382990|NCT02725840|RADIATION|Proton beam radiation therapy.|Proton bean radiation therapy interact differently with tissue with the result that protons are absorbed completely within the tissue instead of primarily passing through the entire body. The maximal depth of penetration is dependent upon the incoming velocity (energy) of the protons. Proton therapy utilizes this property to deliver radiation with very little dose beyond the targeted lesion. The dose-rate will be managed as part of the standard of care.
41508713|NCT04472676|DRUG|Placebo|Administered orally.
41036184|NCT02573519|DEVICE|3D-Transit|"3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:~1. A wireless electromagnetic capsule to be swallowed by the subject~2. A portable detector plate comprising four sensors worn in a belt around the waist~3. Specific software for visualizing and analyzing data"
41036185|NCT02573519|DRUG|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
41036186|NCT02573519|DEVICE|3D-Transit after Malone appendicostomy|3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
41036187|NCT02414893|PROCEDURE|Sleeve gastrectomy|Laparoscopic vertical gastrectomy as a bariatric procedure.
41036188|NCT00102895|DRUG|CP-724,714|
41036189|NCT02247427|DEVICE|Cardiac Resynchronization Therapy Device|Cardiac Resynchronization Therapy Device pacing activity, on or off
41036190|NCT06087601|DRUG|0.9% Sodium chloride|us-guided bilateral genicular nerves sham block with 0,5ml 0,9% normal saline
41036191|NCT06087601|DRUG|95% ethanol|us-guided bilateral genicular nerves neurolysis with 0,5ml 95% ethanol
41036192|NCT05884398|DRUG|Apalutamide|Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of Cycle 7 up to at least 18 months.
41036193|NCT05884398|DRUG|Androgen-deprivation Therapy (ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
41036194|NCT05373394|OTHER|Test battery|motor and neuropsychological test battery
41036195|NCT02497573|OTHER|Diffuse Weighted MRI|The DW MRI scans will be used to measure ADC and to calculate change in ADC between the 2 scans. Each scan will take approximately 30 minutes. Images will be acquired and analysed as per the separate scanning protocol.
41382991|NCT02725840|RADIATION|X-ray based radiation therapy|The three-dimensional (3D) mapping of radiation dose distributions permits detailed assessment of local vascular damage as a function of treatment factors of dose, dose-rate. The dose-rate will be managed as part of the standard of care.
41036196|NCT05238935|OTHER|prescribed physiotherapy course|provide full assessment and treatment program as postoperative rehabilitation management
41036197|NCT05175755|OTHER|Patients|The procedure involves taking a total of 12 ml of blood.
41036198|NCT00048516|DRUG|paricalcitol capsule|
41036199|NCT04189562|OTHER|SMS Intervention|Delivery of text messages will use the text messaging program Simple Online Family Intervention for ADHD (SOFIA).
41036200|NCT03996473|DRUG|Radium-223 dichloride (Xofigo, BAY 88-8223)|55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations
41382992|NCT02725840|PROCEDURE|Computed Tomography (CT) Scan|Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months
41036201|NCT03996473|DRUG|Pembrolizumab|200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations
41036202|NCT02367911|DRUG|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
41382993|NCT02725840|PROCEDURE|Pulmonary Function Test (PFT)|Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
41382994|NCT05098444|BEHAVIORAL|Cognitive behavioral psychotherapy|Internet-based Cognitive Behavioural Therapy aims to reduce the impairment due to endometriosis by using cognitive behavioural intervention techniques. Furthermore, therapy should enable the patients in coping with symptoms in the future.
41382995|NCT05098444|OTHER|Waiting list|Participants of the waiting list receive no treatment for 5 months. Afterwards they receive the same treatment as the experimental group.
41382996|NCT01689649|DRUG|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
41036203|NCT02367911|DRUG|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
41036204|NCT05294068|OTHER|standard of care for patients with cognitive impairments|clinical examination, radiological, biological and physiological examinations.
41036205|NCT05294068|OTHER|standard of care for patients with neuromotor impairments|clinical examination, radiological, biological and physiological examinations.
41036206|NCT05294068|OTHER|standard of care for patients with sensory impairments|clinical examination, radiological, biological and physiological examinations.
41036207|NCT02187991|DRUG|Paclitaxel|either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
41036208|NCT02187991|DRUG|Alisertib|40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
41036209|NCT00168025|DRUG|Immunoglobulins Intravenous (Human)|
41036210|NCT03919422|PROCEDURE|T2 paravertebral block|Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
41165580|NCT04334447|OTHER|Improved primary care HF diagnostics|Reimbursement of natriuretic peptide testing for participating general practitioners (GPs) Audit and feedback in GPs EHR
41165581|NCT04334447|OTHER|Heart Failure education|Reimbursement of heart failure education for patients at risk. Web-based training for participating general practitioners
41382997|NCT00769132|DRUG|Comparator: niacin + laropiprant|ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
41382998|NCT00769132|DRUG|Comparator: niacin|ER niacin 2 g tablet once daily for 7 days
41382999|NCT00769132|DRUG|Comparator: laropiprant|laropiprant 40 mg once daily for 7 days
41383000|NCT00769132|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
41383001|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
41383002|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
41383005|NCT01438827|DRUG|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
41383006|NCT01438827|DRUG|Placebo|Suspension for Injection, Every 6 weeks for one year
41383007|NCT06558526|DIETARY_SUPPLEMENT|Apple pectin (DE 57%)|Dietary intervention with apple pectin. Participants will orally take the supplement once a day, after dissolving it in 100 ml of water, for 6 months.
41383008|NCT06558526|DIETARY_SUPPLEMENT|Placebo|Dietary intervention with maltodextrin. Participants will orally take the placebo (maltodextrin) once a day, after dissolving it in 100ml of water, for 6 months.
41383009|NCT06212375|BEHAVIORAL|Vegetable variety|Either children are offered a variety of three vegetables or a single vegetable.
41383010|NCT06212375|BEHAVIORAL|Vegetable offering strategy|Either children can decide when to eat their vegetables or parents initiate a moment.
41383011|NCT04645732|BEHAVIORAL|Personalized exercise therapy and self-management support program|See description under Arms
41383012|NCT04645732|OTHER|Usual care|See description under Arms
41383013|NCT02426294|DRUG|Pioglitazone|
41383014|NCT02426294|DRUG|Glimepiride|
41383015|NCT05597514|OTHER|3D printed educational model|Slide-based presention plus 3D printed airway suction model
41383016|NCT05597514|OTHER|Tranditional model education|Slide-based presention plus tranditional model
41383017|NCT03586778|OTHER|dry needling|Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
41383018|NCT03586778|OTHER|manual therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
41383019|NCT03586778|OTHER|therapeutic exercise|Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
41383020|NCT02628418|OTHER|General Rehabilitation|All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.
41383021|NCT02628418|DEVICE|Specific hand rehabilitation by Gloreha device|"Each training session consisted of six parts:~1. A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);~2. 7 min of a number sequence (counting from one to five);~3. A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)~4. A sequence of wave-like finger movements (7 min)~5. A sequence of fist opening/closing (7 min)~6. A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min)."
41383022|NCT02628418|OTHER|Specific hand rehabilitation performed by physiotherapist|"The activities were:~1. Flexion-extension of the fingers (10 min);~2. Thumb opposition with the other fingers keeping the forearm in supine position (10 min);~3. Adduction and abduction of the fingers (10 min);~4. Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min)."
41383023|NCT00029107|DRUG|Rituximab|anti-CD20 monoclonal antibody
41036211|NCT03919422|PROCEDURE|interscalene brachial plexus block and superficial cervical plexus block|An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
41036212|NCT06589648|OTHER|mandala painting|Mandala coloring creates a relaxing effect on individuals because it starts with a pattern that develops like a flower around a point; it allows the individual to stay in the moment, to get away from stress, anxiety and worries, and it relaxes the mind.
41036213|NCT05178082|BEHAVIORAL|Educational Video-based Pain Program|Educational videos with 10 modules with information about pain.
41036214|NCT05178082|BEHAVIORAL|Empowered Relief Program|Educational online session for skills acquisition to manage pain. Empowered Relief TM by Beth Darnall ©2013-2022 Stanford University
41036215|NCT01697293|DRUG|Cyclophosphamide|Given IV
41036216|NCT01697293|DRUG|Doxorubicin Hydrochloride|Given IV
41036217|NCT01697293|OTHER|Laboratory Biomarker Analysis|Correlative studies
41036218|NCT01697293|DRUG|Paclitaxel|Given IV
41383024|NCT02263118|OTHER|Uni-directional SMS|Exposure to breastfeeding promoting SMSs
41383025|NCT02263118|DEVICE|Feature phone|Participants were given a feature phone.
41383026|NCT02263118|OTHER|Virtual communities|Exposure to virtual community communication via SMS
41383027|NCT02263118|OTHER|Hybrid setup|Exposure to virtual community and access to communications with health professional via SMS
41383028|NCT04656782|OTHER|Imaging survey|Participation as expert panelist in the imaging survey.
41383029|NCT04656782|OTHER|Facilitation|Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.
41383030|NCT03088280|DRUG|Thymoglobulin|reduced dose (3mg/Kg)
41383031|NCT02871336|OTHER|Data collection|
41508714|NCT00661895|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg tablets
41165582|NCT04334447|OTHER|Structured transitional protocol planning post-discharge care|Checklist-supported discharge protocol for HF patients including telephone contact with patients' general practitioners and a contact with the HF educator
41165583|NCT01292577|BEHAVIORAL|CET/PT|CET/PT is an 18-month comprehensive small group approach for the remediation of cognitive deficit in schizophrenia consisting of individual sessions and 45 group training sessions in social cognition that are integrated with an affect regulation approach and 60 hours of computer assisted training in attention, memory, and problem solving skills.
41165584|NCT01292577|BEHAVIORAL|Treatment as Usual|The usual care individuals with schizophrenia that misuse substances receive in the community for their conditions.
41165585|NCT01795859|DRUG|SD-809|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
41165586|NCT01795859|DRUG|Placebo|Placebo tablets are identical in appearance to SD-809 tablets.
41165587|NCT05742659|OTHER|A mobile-based interactive simulation scheme (MISS)|A mobile-based interactive simulation scheme (MISS) was proposed and developed to investigate its effects on facilitating hands-on learning of NG insertion in undergraduate medical students.
41165588|NCT04157023|DEVICE|Simulator-based Training of Direct Ophthalmoscopy|A digital simulator is used to teach the skills of direct ophthalmoscopy
41383032|NCT06072755|DEVICE|Finger pulse oximetry probe|This finger probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
41383033|NCT06072755|DEVICE|Transreflectance oximetry probe|This neck probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
41383034|NCT03141346|BEHAVIORAL|Sugar reduction health education program|A health education program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
41383035|NCT03141346|BEHAVIORAL|Control health education program|Control health education program provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
41383036|NCT03141346|OTHER|Home water delivery|Home delivery of bottled water administered over 24 months
41383037|NCT03829527|BEHAVIORAL|Psychotherapy|Psychological intervention combining a standardized treatment manual with a smartphone application
41383038|NCT00000847|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
41383039|NCT00000847|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
41383040|NCT00000847|BIOLOGICAL|rgp120/HIV-1 SF-2|
41383041|NCT05517707|DEVICE|Nasogastric Tube|Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
41383042|NCT00171080|DRUG|valsartan|
41383043|NCT00171080|DRUG|irbesartan|
41383044|NCT02095210|OTHER|Radiolabeled [68Ga]ABY-025|Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.
41508715|NCT00661895|DRUG|Lisinopril|Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
41165589|NCT00244907|DIETARY_SUPPLEMENT|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
41165590|NCT05235841|OTHER|acupressure|Acupressure is a complementary and supportive approach used in symptom management.
41383045|NCT03833934|DIAGNOSTIC_TEST|Plasma Next Generation Sequencing (NGS)|Liquid biospys
41383046|NCT05373017|OTHER|DANE Recovery Program|Virtual visits with care coordinator to carry out an individualized recovery plan
41383047|NCT05373017|OTHER|Questionnaires|Physical, cognitive, and psychological assessments
41383048|NCT06566001|PROCEDURE|control group|socket shield technique and allogenic bone graft
41383049|NCT03855462|DEVICE|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with MCT oil :~* Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~* MCT ablation after 4 to 6 weeks (after effective retinopexy)~* after MCT ablation, total follow-up duration by patient is 6 months."
41383050|NCT06250972|DRUG|Gemcitabine, Nab-paclitaxel, Irinotecan|continuing chemotherapy using the previous regimen until disease progression
41383051|NCT06250972|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy.
41383052|NCT02952300|PROCEDURE|neolix|single rotation file
41383053|NCT02952300|PROCEDURE|wave one|single reciprocation file
41383054|NCT04204135|PROCEDURE|LLIF or ALIF procedures|LLIF or ALIF procedures
41508716|NCT00661895|DRUG|Lisinopril and Hydrochlorothiazide|L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
41508717|NCT00661895|DRUG|Nifedipine XL|30 mg extended release tablets, 60 mg extended release tablets
41508718|NCT00661895|DRUG|Metoprolol tartrate|50 mg tablets \& 100 mg tablets
41508719|NCT00661895|DRUG|Atenolol|50 mg tablet
41508720|NCT00661895|DRUG|Valsartan|80 mg tablets \& 160 mg tablet
41508721|NCT00661895|DRUG|Doxazosin|4 mg tablets
41508722|NCT00661895|DRUG|Clonidine|0.2 mg tablets
41508723|NCT00661895|DRUG|Hydralazine|50 mg tablets
41383055|NCT03029559|OTHER|Intermittent Hypoxia|"A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia)."
41383056|NCT03029559|OTHER|Inspiratory Threshold Loading|Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.
41383057|NCT03029559|OTHER|Sham Intermittent Hypoxia|Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.
41383058|NCT06537661|OTHER|Virtual reality|Virtual reality (VR): is the artificial construction of a 3D environment viaThe VR glasses which were the source of visual and auditory feedback, were connected by Bluetooth to a mobile phone and all the videos of selected tasks.
41383059|NCT06537661|OTHER|Traditional exercises|"Active mobility exercises (jaw opening 6 times of 30 s; lateralization 10 times of 5 s; protrusion 10 times Of 5 s). Self-massage masticatory Muscles, After each session.~* Isometric contraction exercises Were included (3 times of 10 s)"
41383060|NCT04853888|BEHAVIORAL|ATTACH™ Parenting Program|"ATTACH™ parenting program offers an innovative, novel approach to early intervention, focusing on improving parent-child relationship quality by targeting parents' underlying reflective function (RF)-the ability to better understand one's own and one's child's thoughts and feelings. RF is essential for high quality parent-child relationships and secure parent-child attachment, both tied to child development and health, especially cognition, communication and inflammation.~."
41383061|NCT05572814|BEHAVIORAL|Decision Support|Prompts will be provided to clinicians signaling gaps in guideline-directed care
41383062|NCT05572814|BEHAVIORAL|Referral|Patients will be referred to an interdisciplinary, expert guideline-directed medical therapy team
41508724|NCT00661895|DRUG|Metoprolol succinate|50 mg tablet \& 100 mg tablet
41508725|NCT00661895|DRUG|Amlodipine|5 mg tablets \& 10 mg tablets
41508726|NCT00306995|BIOLOGICAL|SB218352_15|Non-adjuvanted pandemic influenza A formulation 1 vaccine
41508727|NCT00306995|BIOLOGICAL|SB218352_8|Non-adjuvanted pandemic influenza A formulation 2 vaccine
41508728|NCT00306995|BIOLOGICAL|SB218352_4|Non-adjuvanted pandemic influenza A formulation 3 vaccine
41036219|NCT01697293|PROCEDURE|Therapeutic Conventional Surgery|Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
41036220|NCT01697293|DRUG|Triciribine Phosphate|Given IV
41036221|NCT05472428|COMBINATION_PRODUCT|Autologous bone marrow mononuclear cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
41508729|NCT00306995|BIOLOGICAL|SB218352_2|Non-adjuvanted pandemic influenza A formulation 4 vaccine
41508730|NCT00306995|BIOLOGICAL|SB218352_8AL|Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine
41508731|NCT00306995|BIOLOGICAL|SB218352_4AL|Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine
41508732|NCT00306995|BIOLOGICAL|SB218352_2AL|Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
41036222|NCT01168492|DRUG|ketamine|0.5mg/kg ketamine iv
41508733|NCT05858918|DRUG|Clopidogrel|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily
41036223|NCT06186648|DRUG|Glofitamab + Obinutuzumab|Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
41036224|NCT00380068|DRUG|Ambrisentan|Oral tablets taken once daily.
41383063|NCT06416930|DRUG|Cadonilimab Combined with chemotherapy|Cadonilimab (15mg/kg, intravenous drip, D1) + gemcitabine (1250mg/m2, intravenous drip, D1/D8) or vinorelbine (30mg, oral, tiw, D1/D3/D5) or pemetrexed (500mg/m2, intravenous drip, D1), every 3 weeks.
41383064|NCT06060496|DEVICE|Active cTBS|Two cTBS sessions (each session delivering 3600 pulses) separated by 50 minutes
41383065|NCT06060496|DEVICE|Sham cTBS|Two sham cTBS sessions (sham mimics the experimental session but does not deliver any electricity to the brain) separated by 50 minutes
41383066|NCT05104268|DEVICE|Bocaliner|Bocaliner is an orally inserted device that is held within the mouth following the administration of mouthwashes, gels, and rinses that are used to treat pain associated with oral mucositis, and to reduce inflammation and to accelerate healing of oral mucositis.
41383067|NCT02162381|DRUG|methylphenidate|a single dose of methylphenidate 10 mg to be taken orally in the morning
41383068|NCT02162381|OTHER|guidance|subjects will be given an explanation and advice about how to perform well in visual field testing
41383069|NCT01591902|DRUG|Tesamorelin|Daily 2 mg subcutaneous injections of tesamorelin
41508734|NCT05858918|DRUG|Ticagrelor|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily
41508735|NCT03537131|DRUG|Dapagliflozin 10 MG Oral Tablet|taken once a day
41036225|NCT06226844|DEVICE|Music therapy walking program|In the experimental group (PEMA BeatMove), patients will benefit from an outpatient walking training program with app-based performance monitoring, combined with music therapy (BeatMove device). The program comprises 36 walking training sessions, with 30
41036226|NCT00955084|DRUG|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
41036227|NCT02811029|BEHAVIORAL|measurement of phonology|measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
41383070|NCT01591902|DRUG|Placebo-Control|3.0 mL vials
41508736|NCT02192398|DRUG|Guanfacine|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
41508737|NCT02192398|DRUG|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
41165591|NCT00546247|DRUG|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
41165592|NCT02860299|DRUG|citrate 4%|
41165593|NCT02860299|DRUG|unfractionated heparin|
41165594|NCT02860299|BIOLOGICAL|blood sample|
41165595|NCT00510198|DEVICE|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
41165596|NCT00510198|DEVICE|Standard of Care alone (clinical assessment)|Clinical assessment utilizing standard of care, alone.
41165597|NCT05286437|DRUG|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole|Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.
41165598|NCT03993561|OTHER|Treatment summary and survivorship care plan|Individually tailored counselling session will be implemented within 1 month of treatment completion.
41165599|NCT01042145|DRUG|Prednisone|2 mgs/kg for 3 days
41165600|NCT01042145|DRUG|Dexamethasone|0.6 mgs for one day, then placebo for 2 days
41165601|NCT06076824|DRUG|Methylprednisolone|The intervention group will recieve 7 mg/kg/day (or a maximum of 500 mg/day) of intravenous Methylprednisolone an hour before TAVR followed by 15 mg / 12h of Prednisone during 5 days after the intervention (starting 24h after the administration of Methylprednisolone).
41165602|NCT06076824|OTHER|Placebo|Saline solution
41165603|NCT00317850|DRUG|Gabapentin (Neurontin)|
41165604|NCT02153190|DEVICE|HYBRID|During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
41165605|NCT02153190|DEVICE|OPEN|During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
41165606|NCT02013895|DEVICE|99mTc-GSA|
41165607|NCT03693040|DEVICE|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their PrEP medication. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their PrEP medication.
41165608|NCT02038868|DRUG|ASP4901|oral
41165609|NCT02038868|DRUG|Tamsulosin|oral
41036228|NCT06559774|BEHAVIORAL|Hastiin Bidziil|Common Elements Treatment Approach (CETA) modified for cultural and gendered specific delivery for maximum community impact
41036229|NCT06559774|OTHER|Control condition - vehicle maintenance|Control condition was selected by the Community Research Council and includes five sessions on basic vehicle maintenance such as changing tire, checking fluid levels, and winterizing vehicles.
41036230|NCT00022256|DRUG|motexafin gadolinium|
41036231|NCT00022256|RADIATION|radiation therapy|
41036232|NCT03257826|DEVICE|kirschner wire|retrograde percutaneous kirschner wire was applied to stabilize the tibia.
41036233|NCT05777174|DRUG|MB-102|130 mg administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30-60 seconds.
41036234|NCT05777174|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements will be collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements will continue until the sensor no longer detects MB-102 in the body.
41036235|NCT02282501|OTHER|enteral feeding by nasogastric tube.|method of administration enteral feeding by nasogastric tube.
41036236|NCT01026974|BIOLOGICAL|rMenB|
41036237|NCT01026974|BIOLOGICAL|rMenB+OMV NZ|
41036238|NCT02682264|DRUG|CB-03-01 cream, 1%|Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
41036239|NCT01560520|BEHAVIORAL|Physical activity|Observation only
41036240|NCT03435133|DRUG|Prasugrel|60 mg oral bolus plus oral 10 mg once daily
41036241|NCT03435133|DRUG|Ticagrelor|180 mg oral bolus plus oral 90 mg every 12 hours daily
41036242|NCT01872169|OTHER|Disordered eating screening questionnaire|
41165610|NCT02038868|DRUG|Placebo|oral
41165611|NCT04731675|BIOLOGICAL|AMB-05X|AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R
41165612|NCT05598528|OTHER|Genomic profiles detection|The Paraffin-embedded tumor tissue at diagnosis is collected and assessed by Next- generation gene sequencing
41165613|NCT05598528|OTHER|circulating tumor DNA detection|The Plasma at diagnosis and at 1-month treatment are collected and assessed by Next-generation gene sequencing
41165614|NCT00611299|DIETARY_SUPPLEMENT|BB-12 and CRL 431|
41165615|NCT04560062|OTHER|Spontaneous changes in diabetes-related health care|The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
41165616|NCT03713073|DEVICE|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
41165617|NCT03713073|DEVICE|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
41165618|NCT02741258|DEVICE|Mepitel Film|Placement of Mepitel Film to prevent skin toxicity
41383071|NCT00432367|DRUG|Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine|"Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use."
41383072|NCT05031286|OTHER|Cutaneous thermal stimuli|Application of thermal stimuli of different intensities to the skin
41383073|NCT00633295|DRUG|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
41036243|NCT03861962|OTHER|"DNA sequencing called new generation (or NGS)"|"Redo HLA-typings with a method exploring all the genes (add DQA1, DRB3 / 4/5, DPB1 and DPA1), i.e. DNA sequencing called new generation, when this has not been done after the graft as part of the standard care"
41165619|NCT02741258|DRUG|skin cream|cream to treat skin erythema due to radiotherapy
41165620|NCT02101268|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
41165621|NCT02101268|DRUG|Best Available Therapy (BAT)|Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
41165622|NCT00873561|DRUG|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
41165623|NCT00668330|DRUG|Ibandronate+alfacalcidol+calcium|Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
41383074|NCT04575987|OTHER|Questionnaire|"Questionnaires will be sent by email or by post, in which questions about PFD, obstetrical history or dietetic follow-up will be asked.~Some obstetrical issues will be get from women medical files."
41383075|NCT06341270|DEVICE|transcutaneous electrical acupoint stimulation|transcutaneous electrical acupoint stimulation Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30min before anesthesia until be discharged from the postanaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery.The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
41383076|NCT06341270|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
41383077|NCT02475161|DRUG|JNJ-42847922|JNJ-42847922 will be administered as 20 mg tablet orally.
41165624|NCT00668330|DRUG|placebo ibandronate+alfacalcidol+calcium|placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
41165625|NCT03845075|DRUG|Tesofensine/Metoprolol|During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)
41383078|NCT02475161|DRUG|Rabeprazole|Rabeprazole will be administered as 20 mg tablet orally.
41383079|NCT03780452|DEVICE|novel dynamic compression intramedullary nail|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
41383080|NCT04402944|DRUG|Pulmozyme|Pulmozyme 2.5 mg BID
41383081|NCT04402944|DRUG|Placebo|Saline 2.5 mL BID
41383082|NCT01418534|DRUG|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
41383083|NCT05440175|OTHER|EMS, Mirror therapy & exercises|EMS will be applied with frequency between 20-100 Hz and pulse width between 20 to 450us and Mirror therapy for 30 minutes and four days per week for a total duration of 12 weeks. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
41036244|NCT01865370|DIETARY_SUPPLEMENT|Kochujang Pills|Kochujang Pills (34.5g/day)
41036245|NCT01865370|DIETARY_SUPPLEMENT|Placebo|Placebo (34.5g/day)
41165626|NCT03845075|DRUG|Placebo|During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol
41165627|NCT02877264|DRUG|vapendavir 132 mg capsule|
41383084|NCT05440175|OTHER|CIMT & exercises|Constraint induced movement therapy will be applied for 30 minutes and four days per week for a total duration of 12 weeks, it is a form of rehabilitation therapy that improves upper limb movement, it claims to improve the arm motor ability and the functional use of a paretic arm- hand. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
41383085|NCT05440175|OTHER|Mirror therapy & exercises|Mirror therapy will be given for 30 minutes and four days per week for a total duration of 12 weeks. The exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
41036246|NCT02734342|OTHER|exercise|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo \& Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
41036247|NCT02590354|OTHER|ART interruption|
41036248|NCT01636882|BIOLOGICAL|CVA21|
41036249|NCT00124904|BEHAVIORAL|Biofeedback|
41036250|NCT00124904|BEHAVIORAL|Kegel exercises|
41036251|NCT04237662|PROCEDURE|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
41036252|NCT04237662|DEVICE|Enamel Matrix Derivative application|Enamel Matrix Derivative will be applied in the sites with at least 6 mm of pocket depths
41036253|NCT02252211|DRUG|DS-8895a 1 mg/kg|Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
41036254|NCT02252211|DRUG|DS-8895a 3 mg/kg|Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
41036255|NCT02252211|DRUG|DS-8895a 10 mg/kg|Patients were to receive infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
41036256|NCT05834504|OTHER|Short distributed training (1-2 days)|"The intervention group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 1-2 days of break in between training sessions until proficiency level is achieved."
41036257|NCT06433180|DRUG|Administration of fecal microbiota transplantation ( FMT capsules)|Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.
41036258|NCT06433180|DRUG|Administration of the sham (PLACEBO)|Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.
41036259|NCT00982358|DRUG|Valsartan|
41036260|NCT00982358|OTHER|Placebo|
41036261|NCT05477134|OTHER|Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus|On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
41383086|NCT05204849|DEVICE|IRRAflow|Ventriculostomy using IRRAflow with active irrigation and aspiration
41383087|NCT05204849|PROCEDURE|Standard ventriculostomy|Standard passive external ventricular drainage
41036262|NCT05453474|GENETIC|Whole genome amplification|DNA is amplified by whole genome amplification
41036263|NCT05298176|DRUG|Afatinib, Osimertinib, Carboplatin and Pemetrexed|This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
41036264|NCT03131076|DIAGNOSTIC_TEST|IPMN follow up|Follow up with MRI and laboratory blood tests
41036265|NCT00058838|DRUG|sumanirole|
41165628|NCT02877264|DRUG|vapendavir 264 mg tablet|
41165629|NCT02877264|DRUG|vapendavir 24 mg/mL oral suspension|
41165630|NCT00848068|OTHER|FID 114657|artificial tears
41165631|NCT00848068|OTHER|OPTIVE Lubricant Eye Drops|artificial tears
41165632|NCT04225000|OTHER|Exercise Group|Control group included 6 different exercises to treat participants having PFPS. These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. These all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This exercise protocol was for 4 weeks and 3 sessions per week.
41165878|NCT02496143|DRUG|EC-18|EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.
41508738|NCT03473015|DEVICE|PICSO|The PICSO Impulse catheter is a 8F double lumen catheter with a 15.5x20mm long balloon at the distal end. The balloon inflates and deflates cyclically once deployed in the coronary sinus, leading to intermitted coronary sinus pressure increase. The catheter is connected to the console through two pneumatic tubes in which helium is shuttled to and from the balloon. In addition, the coronary sinus pressure is monitored through the center lumen of the catheter.
41508739|NCT02871492|DRUG|Pritelivir 5% w/w ointment|
41508740|NCT02871492|DRUG|Pritelivir ointment matching placebo|
41036266|NCT04371900|BEHAVIORAL|Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES randomized vouchers for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred from March 4, 2019, forward.
41383088|NCT06565559|DEVICE|Wearable Wireless Sensor|Stage III is a shadow mode evaluation of the device with participants wearing sensors pre-, intra-, and post-operatively. Sensor and clinical data will be collected contemporaneously in the clinical environment. No sensor data is made available to clinical teams for decision making, with no change in patient care.
41383089|NCT06072586|DRUG|BDTX-1535|BDTX-1535 is an inhibitor of EGFR mutations
41383090|NCT01233349|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
41383091|NCT01233349|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
41508741|NCT02871492|DRUG|Zovirax® cream|
41508742|NCT01516918|DRUG|VX-222|tablet, 400-mg twice daily
41508743|NCT01516918|DRUG|telaprevir|tablet, 1125-mg twice daily
41508744|NCT01516918|DRUG|ribavirin|tablet, 1000-mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
41508745|NCT01516918|BIOLOGICAL|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
41036267|NCT04371900|BEHAVIORAL|Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES randomized vouchers for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after November 4, 2019.
41036268|NCT02096900|DRUG|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
41036269|NCT02096900|DRUG|Midazolam|
41036270|NCT01504594|PROCEDURE|Intracoronary autologous stem cell infusion|Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
41036271|NCT05980936|OTHER|Screening for obstructive sleep apnea|Patient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep
41165633|NCT04225000|OTHER|Mobilization Group|"Experimental group included Anterior-Posterior (AP) tibiofemoral joint mobilization and all 6 exercises suggested controlled group for treating participants having PFPS; 3 sessions of mobilizations per week and total 4 weeks.~These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. Theses all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week."
41383092|NCT04813653|DRUG|cyclosporine in combination with carfilzomib and dexamethasone|patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.
41383093|NCT06567405|PROCEDURE|mechanical periodontal treatment|Patients will undergo subgingival scaling employing a Piezoelectric ultrasonic scaler to eliminate local factors.
41383094|NCT06567405|DEVICE|Derma pen with topical ascorbic Acid|local anesthesia of 2% lignocaine will be administered by infiltration technique in the anterior maxillary region. Microneedling of the mucosa will be performed using dermapen needles, employing an intermittent back-and-forth motion in the anterior maxillary and mandibular region for 30-40 seconds, reaching a depth of 1.5 mm. This will involve the creation of microholes in the gingival tissue using derma pen to enhance the concentration and penetration of the ascorbic Acid through the gingival tissues.
41383095|NCT01609127|DRUG|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
41383096|NCT01609127|DRUG|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
41383097|NCT01609127|DRUG|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
41508746|NCT05823857|OTHER|Aquatic Therapy|Participants in this experimental intervention group will perform trunk stabilization, which will be based on a variety of aquatic exercises in different positions, intended to activate the multifidus and transverse abdominis in a co-contraction. Additionally, hip exercises will be completed to promote the strengthening of the gluteus maximus, gluteus medius, and gluteus minimus muscles. The aim of these exercises is to enhance the strength and dynamic stability of the spine and its surrounding musculature in a functional and yet non-weight-bearing way. Each exercise will be performed 10 times while sustaining the muscles co-contraction for 5-10 seconds and will be progressed gradually. Each training session (60 minutes) will be supervised by a Certified Athletic Therapist and take place in the PERFORM AT Clinic/Swim Ex pool.
41508747|NCT05823857|OTHER|Standard Care|Participants in this experimental intervention group will receive the standard LBP treatment in the PERFORM Athletic Therapy clinic.Two Certified Athletic Therapists (AT) will be conducting the sessions. The ATs will complete a thorough assessment of the eligible participants with chronic LBP and administer a range of interventions including stretching, strengthening and stabilization exercise, aerobic conditioning, and manual mobilization techniques. Other modalities could include application of ice and heat, ultrasound, and transcutaneous electrical nerve stimulation (TENS).
41383098|NCT03633773|BIOLOGICAL|MUC-1 CART cell immunotherapy|After fludarabine and cyclophosphamide pre-chemotherapy，MUC-1 CART immunotherapy is given. A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
41383099|NCT01224418|DRUG|Tacrolimus|oral
41383100|NCT00514709|BIOLOGICAL|DTaP-HB PRP~T Combined Vaccine|0.5 mL, Intramuscular (IM)
41383101|NCT00514709|BIOLOGICAL|DTaP-HB-PRP~T vaccine|0.5 mL, IM
41383102|NCT00514709|BIOLOGICAL|Oral Polio Vaccine|Oral co-administered with study vaccine.
41383103|NCT00068770|RADIATION|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
41383104|NCT00068770|DRUG|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
41383105|NCT04349501|OTHER|Restriction Spectrum Imaging Magnetic Resonance Imaging|RSI is a multicompartment model of diffusion MRI that uses data acquired at multiple b-values to distinguish varied diffusion speeds (restricted intracellular, hindered extracellular, and approximately free diffusion).
41383106|NCT06004700|OTHER|Mobile Application|The current app contains a disease activity questionnaire, a mood scale, a sleep scale, a pain scale, and a functional status scale. The app triggers a brief set of questions each day and allows patients to answer them within 24 hours.
41383107|NCT04776135|DRUG|MT-1186|Suspension
41383108|NCT03751124|DRUG|Relugolix|Relugolix 40 mg tablet administered orally once daily
41383109|NCT03751124|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
41383110|NCT03751124|DRUG|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
41383111|NCT03751124|DRUG|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
41383112|NCT04935931|DRUG|Naltrexone|naltrexone 50 mg PO x 1
41383113|NCT02707718|BIOLOGICAL|blood sampling|during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement
41036272|NCT03185975|BEHAVIORAL|at-home test kit|Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.
41036273|NCT03185975|BEHAVIORAL|Motivational Interviewing and Certified Testing and Referral|Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
41036274|NCT03341390|DRUG|Aspirin|1 x 325 mg tablet of aspirin administered once daily
41036275|NCT03341390|DRUG|BMS-986177|200 mg of BMS-986177 administered twice daily
41036276|NCT03341390|DRUG|Placebo|200 mg of Placebo administered twice daily
41036277|NCT06113627|OTHER|Resistance Therapeutic Exercise|"Strength exercises will be aimed at large muscle groups, such as the shoulder, chest, back and also muscle groups of the lower extremities. In the initial 2 weeks, intervention will start with low intensities of around 55-65% of 1RM, which allows to perform around 15-20 repetitions. The first week there will be performed 2 series, while in the second week it will be 3 series.~Moderate intensity in the 2nd week, corresponding to 65-75% of 1RM and allowing for around 8-12 repetitions. 3 series will be maintained throughout this period of time.In addition to the progressive change in intensity, throughout the intervention the load will be increased by 5-10% when the patient performs the exercise too easily or when they can perform more repetitions than estimated. Rest between sets will be 2-3 minutes."
41036278|NCT06636136|DEVICE|OPRA|Surgery
41036279|NCT05360979|DRUG|envafolimab|Envafolimab: 300 mg, D1, Q3W, subcutaneously administered
41036280|NCT04172792|DIETARY_SUPPLEMENT|high-caloric fatty diet|see arm/group description
41036281|NCT04172792|DIETARY_SUPPLEMENT|ultra-high-caloric fatty diet|see arm/group description
41383114|NCT05559242|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor
41036282|NCT04172792|DIETARY_SUPPLEMENT|ultra-high-caloric carbohydrate-rich diet|see arm/group description
41036283|NCT06478147|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Commercially available Oral Nutritional Supplement alone consumed 90 minutes prior to an ad libitum breakfast
41036284|NCT06478147|DIETARY_SUPPLEMENT|Oral Nutritional Supplement + Whey Protein Hydrolysate|Whey Protein Hydrolysate dissolved in an Oral Nutritional Supplement consumed 90 minutes prior to an ad libitum breakfast
41383115|NCT05535582|DIAGNOSTIC_TEST|Investigation of clinical, laboratory and imaging profile|Complete and comprehensive medical interview will be conducted in each eligible patient after revascularization. In addition, patient's laboratory data will be recorded on admission and during hospitalization. Furthermore, each patient will undergo a full echocardiographic examination with a specific protocol.
41383116|NCT00299546|DRUG|Placebo|SC injections
41383117|NCT00299546|BIOLOGICAL|Golimumab 50 mg|SC injections
41383118|NCT00299546|BIOLOGICAL|Golimumab 100 mg|SC injections
41383119|NCT03313401|DRUG|Aflibercept|Intravitreal aflibercept injection
41036285|NCT06478147|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate + still water|Whey Protein Hydrolysate dissolved in still water consumed 90 minutes prior to an ad libitum breakfast
41383120|NCT03313401|DEVICE|Specular microscopy|Specular microscopy measurement after intravitreal aflibercept injection
41036286|NCT01029223|DRUG|ivabradine|
41036287|NCT01029223|DRUG|metoprolol|
41036288|NCT01029223|DRUG|placebo|
41036289|NCT01775904|DRUG|LY2886721 in a Capsule|Administered orally.
41036290|NCT01775904|DRUG|LY2886721 in an orally disintegrating tablet (ODT)|Administered orally.
41036291|NCT05574062|DEVICE|Study Phase: MiniMed 780G Auto Mode with G4S sensor|Subjects will start using the MiniMed™ 780G system in Auto Mode with G4S sensor.
41036292|NCT05574062|DEVICE|Study Phase: MiniMed 780G Manual Mode with G4S sensor|Subjects will start using the MiniMed™ 780G system in Manual Mode.
41036293|NCT05574062|DEVICE|Continuation phase: MiniMed 780G BLE 2.0 with DS5 sensor|Subjects will start using the MiniMed 780G BLE 2.0 with DS5 sensor
41036294|NCT05574062|DEVICE|Continuation Phase MiniMed 780G Auto Mode with G4S sensor|Subjects will start using the MiniMed™ 780G system in Auto Mode with G4S sensor.
41036295|NCT02932618|BIOLOGICAL|von Willebrand factor (Recombinant)|Lyophilized powder and solvent to prepare solution for injection.
41036296|NCT02932618|BIOLOGICAL|Antihemophilic Factor (Recombinant)|Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
41036297|NCT02653482|DRUG|Dapagliflozin|
41036298|NCT02653482|DRUG|Dapagliflozin matching placebo|
41036299|NCT03910153|DIETARY_SUPPLEMENT|MSPrebiotic|MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
41036300|NCT03910153|OTHER|Placebo|Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
41036301|NCT02580097|OTHER|MRI|MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.
41036302|NCT03205995|BIOLOGICAL|OMS721|Intravenous loading dose followed by daily subcutaneous injections
41036303|NCT00890955|DRUG|Amrubicin|"* Dose Level -1: 20mg/m2~* Dose Level 1: 25mg/m2~* Dose Level 2: 30mg/m2~* Dose Level 3: 35mg/m2~* Dose Level 4: 40mg/m2~Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle."
41036304|NCT00890955|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
41036305|NCT02356380|OTHER|Mobilization Type|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
41036306|NCT01876173|BEHAVIORAL|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
41165634|NCT05155722|DRUG|BAT1308|A 21 day treatment cycle was administered every 3 weeks (Q3W) on day 1 of each cycle. Six consecutive dosing cycles are recommended for the dose escalation phase. In the extended study phase, after the end of the 6th treatment cycle, after the risk and benefit are evaluated by the investigator in combination with the clinical practice, if the subjects are still in a state of clinical benefit (including CR, PR and SD), the investigator can decide to appropriately extend the treatment of BAT1308. Until disease progression, unacceptable toxicity, withdrawal of informed consent, loss of follow-up, death, acceptance of new antitumor therapy, termination of treatment by investigator evaluation, or 12 months after initial administration, whichever is the earliest.
41165635|NCT03029819|BEHAVIORAL|Mindfulness-based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).
41165636|NCT03029819|BEHAVIORAL|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
41383121|NCT02694393|DRUG|sodium nitrite|inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
41036307|NCT05758402|DIAGNOSTIC_TEST|Routine practice group|Routine practice group
41383122|NCT00263393|DRUG|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
41383123|NCT00263393|BEHAVIORAL|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
41383124|NCT06566079|DRUG|ISM6331|"Dosage form: Capsule for oral administration.~Frequency of administration: Once daily overall of treatment."
41383125|NCT03001427|BEHAVIORAL|Structured center-based lifestyle intervention|
41383126|NCT03001427|BEHAVIORAL|Standard education and physician advice|
41508748|NCT05676814|DRUG|Pecto-intercostal Fascial Block (PIFB)|PIFB done with bupivacaine and epinephrine
41036308|NCT05758402|DIAGNOSTIC_TEST|EARP group|EARP group
41036309|NCT00446316|DRUG|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
41508749|NCT05676814|DRUG|PIFB with adjuvants|PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone
41508750|NCT05756036|OTHER|None Observational study|Non interventional study
41508751|NCT01952314|DRUG|Naftopidil 75mg|naftopidil 75mg 1T qd hs
41508752|NCT01952314|DRUG|Placebo for Naftopidil|Placebo 1T qd hs
41383127|NCT03491800|BEHAVIORAL|Question/Topic Prompt List|A written document containing suggested questions that the family member and/or patient may want to ask the health care provider during the visit. A section is included for the patient to check which behaviors they would like for their family member to engage in during the visit and space is provided for the family member to check which behaviors they are willing to perform during the visit.
41383128|NCT03763708|DEVICE|Spinal Cord Stimulation|Programming
41383129|NCT00689273|DRUG|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
41383130|NCT00689273|DRUG|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
41383131|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe New Formula|Oral intake of Feihe New Formula
41383132|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe Stage 1 Formula|Oral intake of Feihe Stage 1 Formula
41508753|NCT01952314|DRUG|Standard treatment|Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
41383133|NCT02406937|DIETARY_SUPPLEMENT|Breast Feeding|Oral intake of breast milk
41383134|NCT05423769|DRUG|Fingolimod|0.5 mg hard gelatine capsules
41508754|NCT02897518|DEVICE|Imago V-Balde|the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual
41508755|NCT02897518|DEVICE|Glidescope|the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
41383135|NCT00233376|PROCEDURE|Access to an antibiotic decision support system|
41383136|NCT00233376|BEHAVIORAL|Distribution of local antibiotic guidelines|
41383137|NCT06542224|PROCEDURE|Deep Brain stimulation|All subjects will receive bilateral surgical implantation of DBS system.
41383138|NCT06315530|DRUG|Telitacicept|160mg once a week for 48 weeks
41383139|NCT06315530|DRUG|SOC|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
41508756|NCT02505087|DRUG|N-Acetylcysteine followed by Placebo|"Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout."
41383140|NCT06540898|BEHAVIORAL|Mindfulness-Based Eating and Movement Program|"This intervention integrates mindful eating practices and mindful movement into physical education classes for a duration of 8 weeks.~Each session begins with a 10-minute mindful eating practice designed to enhance participants; awareness of hunger and fullness cues, the sensory experience of eating, and their emotional responses to food. The program is to address food literacy, physical literacy, and social-emotional learning. It applied the principles of various established mindfulness and cognitive behavioral therapies and the book The Joy of Half a Cookie: Using Mindfulness to Lose Weight and End the Struggle with Food . It is grounded in the components of Mindfulness-Based Eating Awareness Training. The movement practices include basic poses in pairs and groups, and breath awareness techniques to facilitate a mindful connection with physical sensations and mental states."
41383141|NCT05831787|OTHER|Patient Reported Outcomes|Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.
41383142|NCT02501655|DEVICE|phase 1 - jet nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen
41508757|NCT02505087|DRUG|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
41508758|NCT00943748|DRUG|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
41508759|NCT00943748|DRUG|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
41383143|NCT02501655|DEVICE|Phase 2- mesh nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
41383590|NCT01035229|DRUG|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
41508760|NCT05309811|DEVICE|RLRL therapy|Each RLRL treatment lasts three minutes. RLRL treatments will be performed twice a day, with at least four hours between each RLRL treatment.
41508761|NCT05309811|DRUG|Routine IOP-lowering medications|Medications prescribed for IOP control by glaucoma specialists in the outpatient.
41508762|NCT02285088|DRUG|GBT440|GBT440 will be administered as oral capsules
41508763|NCT02285088|DRUG|Placebo|Matching placebo will be administered as oral capsules
41508764|NCT03539263|DIETARY_SUPPLEMENT|Bifihappy|"During the six weeks of treatment, the experimental group will take daily doses of 2,5 g with a concentration of 4x109 CFU/sachet of a mixture of lyophilised probiotic strains of the following species:~* Lactobacillus fermentum~* Lactobacillus rhamnosus~* Lactobacillus plantarum~* Bifidobacterium longum"
41508765|NCT03539263|OTHER|Placebo|During the six weeks of treatment, the experimental group will take daily doses of 2,5 g of maltodextrin
41508766|NCT02875223|DRUG|CC-90011|Specified dose on specified days
41508767|NCT02875223|DRUG|Rifampicin|Specified dose on specified days
41508768|NCT02875223|DRUG|Itraconazole|Specified dose on specified days
41508769|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3
41508770|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3
41508771|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3
41508772|NCT03436056|DRUG|Pembrolizumab|Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
41383144|NCT02463058|OTHER|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
41383145|NCT03105089|PROCEDURE|ischemic preconditioning|) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
41383146|NCT06282523|BEHAVIORAL|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
41383147|NCT06282523|BEHAVIORAL|HMRP web app|The HMRP web app is a meditation-based web-based app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMRP provides core content, with instruction administered through a curriculum of guided practices. HMRP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
41383148|NCT05003739|PROCEDURE|Hip arthroplasty with Logica Mirror femoral stem|Total or partial hip arthroplasty with implant of Logica Mirror femoral stem
41508773|NCT03513094|OTHER|Transversus Abdominis Contraction|Participants were educated on how to contract their transversus abdominis (TA) muscle after having a surface EMG biofeedback device placed on their abdomen to provide audible biofeedback. Participants were asked to ambulate while maintaining TA contraction while ambulating at 50% of maximal volitional isometric contraction.
41508774|NCT04641598|PROCEDURE|Endometrial Scratch|"An endometrial biopsy pipelle will be used to create endometrial injury in the form of a scratch."
41165637|NCT03029819|BEHAVIORAL|Self-Help guide|Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al. Clinical practice guideline for treating tobacco use and dependence, 2008).
41508775|NCT04641598|PROCEDURE|Sham procedure|Motions of performing an endometrial scratch will be performed including speculum placement and cervix cleansing, however, placement of the tenaculum and the endometrial scratch will not be performed.
41036310|NCT00446316|DRUG|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
41036311|NCT00626522|DRUG|Aclidinium bromide and formoterol|once daily
41036312|NCT00626522|DRUG|Aclidinium bromide and formoterol placebo|once daily
41036313|NCT02635477|BEHAVIORAL|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
41165638|NCT03029819|DRUG|Nicotine Patch|Patch therapy (beginning the week before quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
41508776|NCT02463357|DIETARY_SUPPLEMENT|Quercetin|
41508777|NCT02463357|DRUG|Nifedipine extended release|
41508778|NCT02463357|DRUG|Methazolamide|
41508779|NCT02463357|DRUG|Metformin|
41508780|NCT02463357|DRUG|Placebo|
41508781|NCT02463357|DRUG|Nitrite|
41036314|NCT02635477|BEHAVIORAL|Control|Behavioral: actigraphy device, step count measurement only
41165639|NCT03464383|DRUG|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
41165879|NCT02496143|DRUG|Placebo|Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
41165880|NCT05764590|DRUG|AP-306|A blood phosphorus lowering drug with a novel mechanism
41508782|NCT01861912|DEVICE|Arsenic trioxide TACE|Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities
41508783|NCT01861912|DRUG|Arsenic trioxide intravenous infusion|Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7\~14 days after TACE.
41508784|NCT01861912|DRUG|lipiodol|Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
41383149|NCT03442894|PROCEDURE|Standard Physical Therapy Treatment|All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
41383150|NCT03442894|PROCEDURE|Dry Needling|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits (they will occur at the same time). In 6 of the scheduled 10 visits, dry-needling intervention will be performed. They will have one DN session per week, which is consistent with typical clinical practice. After they complete their standard PT treatment, and while still in the clinic, the rotator cuff and periscapular muscles will be evaluated for the presence of MTrPs. Once located, the MTrPs will be treated with DN technique, as this is consistent with routine clinical practice. Potential muscles to receive TPDN treatment include the following: suprapsinatus, teres minor, infraspinatus, deltoid, upper trapezius, middle trapezius, levator scapula, pec major and pec minor.
41383151|NCT03442894|PROCEDURE|Sham Dry Needling|In addition to the standard PT treatment, patients in the sham DN group will receive what appears to be a DN treatment, but it will not be done with the acupuncture needles and the skin will not be punctured. The Sham DN procedure will be performed over the site of identified MTrPs using a guide tube and a toothpick. A guide tube is positioned firmly over the area to be treated and a toothpick is inserted in the guide tube. The clinician taps the toothpick to mimic the skin prick from a needle and the guide tube is removed. The clinician maintains pressure on the end of the toothpick and moves the end furthest from the skin in different directions to mimic the pistoning and changes in needle angle that occur in actual dry needling. Care will be taken to treat from 1-3 muscle groups for 5-10 seconds per MrTP identified.
41383152|NCT04668326|DEVICE|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
41383153|NCT04668326|DEVICE|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
41383154|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
41383155|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
41383156|NCT05375968|DRUG|Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
41383157|NCT05375968|DRUG|Compare change is SVC and SMA flow due to saline|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
41383158|NCT04718272|PROCEDURE|thoracic drainage management|After uniportal VATS pulmonary lobectomy, the traditional silicone tube which placed through the surgical incision was removed in the operating room in the experimental group.
41508785|NCT01861912|DRUG|NaCl solution|250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
41508786|NCT02543944|DRUG|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detoxification and transition to depot naltrexone.
41508787|NCT02543944|DRUG|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
41508788|NCT02543944|DRUG|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
41508789|NCT02543944|DRUG|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
41508790|NCT02543944|DRUG|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
41508791|NCT02543944|DRUG|Placebo|Microcrystalline cellulose
41036315|NCT04862793|DEVICE|Colonoscopy Progression Score (CoPS)|The Colonoscopy Progression Score consists of five different aspects: Travel length, Tip progression, chase efficiency, shaft movement without tip progression and looping.
41036316|NCT04862793|DEVICE|Colonoscopy Retraction Score (CoRS)|The Colonoscopy Retraction Score consists of three different aspects: Tip Retraction, Retraction Efficiency, and Retraction Distance.
41036317|NCT04609254|DRUG|Paracetamol|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
41165881|NCT05764590|DRUG|Sevelamer Carbonate|A phosphate binder
41383159|NCT00903409|DRUG|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) \[formerly known as Omacor\]
41383160|NCT00683891|DRUG|FazaClo (clozapine, USP) ODT|
41383161|NCT04220073|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005
41383162|NCT04220073|DRUG|placebo|placebo
41383163|NCT02454413|OTHER|denture brushing with water and soap|denture brushing with water and soap
41383164|NCT02454413|OTHER|ultrasonic denture cleaning|ultrasonic denture cleaning
41383165|NCT02454413|OTHER|cleansing tablet|addition of a cleansing tablet to the water in which the dentures are stored overnight
41383166|NCT02553005|PROCEDURE|Acupuncture|
41383167|NCT06111131|DEVICE|Enteroscopy|A procedure that uses a specially equipped endoscope to examine the small intestine lining. An enteroscopy uses an endoscope, a tube with a light and camera on the end and the endoscope, in the case of this study, is equipped with a single balloon overtube to advance the scope deeper into the small intestine, to reach the middle third of the small bowel.
41383168|NCT01473589|DRUG|Teriparatide|Administered by SC injection
41383169|NCT01473589|DRUG|Placebo|Administered by SC injection
41383170|NCT01473589|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
41383171|NCT01473589|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
41383172|NCT01940731|DRUG|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
41383173|NCT04395040|OTHER|Semi-structured interview|Semi-structured interview
41383174|NCT05005000|BIOLOGICAL|Micro-Fragmented Adipose Tissue (MFAT)|1ml of autologous micro-fragmented adipose tissue will be used.
41036318|NCT04609254|DRUG|Dexketoprofen|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
41036319|NCT04609254|DRUG|Ibuprofen|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
41036320|NCT02223234|BEHAVIORAL|Emails and 4 Home Visits|Weekly emails and 4 home visits with health educator
41383175|NCT05005000|DRUG|Triamcinolone Acetonide 10mg/mL|The control group will receive a 1ml intraarticular injection of triamcinolone acetonide 10mg/ml.
41383176|NCT00983255|DRUG|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
41383177|NCT00983255|DRUG|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
41383178|NCT04719208|OTHER|Water (E) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
41383179|NCT04719208|OTHER|Chlorhexidine gluconate (A) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
41383180|NCT04719208|OTHER|Hydrogen peroxide (B) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
41383181|NCT04719208|OTHER|Betadine (C) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
41383182|NCT04719208|OTHER|Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
41383183|NCT02670356|DIETARY_SUPPLEMENT|Fish oil|two 750 mg/capsules/day
41383184|NCT02670356|DIETARY_SUPPLEMENT|Krill oil|one 300 mg capsule/day
41383185|NCT03022799|DRUG|KM-819|
41383186|NCT03022799|DRUG|Placebo|
41383187|NCT04102514|BEHAVIORAL|Real-time Group Video|Dyads in the RGV arm will be asked to complete three 45 min sessions that include aerobic, resistance, and balance/coordination exercises delivered by a trained health coach via Zoom® software on an iPad during mos. 0-6, and 1 session/wk. during mos. 7-12 to groups of 5-8 dyads in their home along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
41508792|NCT02289456|DRUG|nab-Paclitaxel|
41383188|NCT04102514|BEHAVIORAL|Enhanced Usual Care|Dyads in the EUC arm, will be given a recommended exercise plan to follow on their own along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
41383189|NCT06566664|DEVICE|B Braun HNS 12 nerve stimulator|Nerve stimulator that is traditionally used for nerve localization during block placements.
41383190|NCT06566664|DEVICE|B Braun HNS 12 nerve stimulator sham control|Stimulator will be placed but will not be turned on.
41508793|NCT02289456|DRUG|Carboplatin|
41508794|NCT05378594|DIAGNOSTIC_TEST|Nasal allergen challenge|graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow
41508795|NCT02724514|OTHER|non-invasive image & bioimpedance based techniques|Ultrasound scans, bioimpedance measurements, clinical photographs and questionnaires will be performed before and after the massage.
41036321|NCT02223234|BEHAVIORAL|Control|Monthly emails on child health
41036322|NCT02223234|BEHAVIORAL|Emails and 2 home visits|Weekly emails and 2 home visits with health educator
41036323|NCT02457572|PROCEDURE|Valsalva maneuver|Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.
41036324|NCT02457572|OTHER|Fluid loading|We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
41036325|NCT05553808|DRUG|Docetaxel|Docetaxel was administered as IV infusion.
41036326|NCT05553808|DRUG|Feladilimab|Feladilimab was administered as IV infusion.
41036327|NCT01913600|DEVICE|Resolute Integrity Stent|Drug eluting stent (DES)
41036328|NCT00070590|DRUG|Bosentan|
41036329|NCT04423068|BEHAVIORAL|SexHealth II|SexHealth II is an intervention that will focus exclusively on provision of hormonal contraception counseling and provision for hospitalized female adolescents
41036330|NCT04423068|DRUG|Contraceptive|"The investigators will offer initiation of the following contraceptives:~Ethinyl Estradiol and Etonogestrel 0.015mg-0.12mg vaginal ring (Nuva Ring) Etonogestrel 68mg subcutaneous implant (Nexplanon) Medroxyprogesterone 150mg/ml 150 mg IM injection Ethinyl Estradiol and Norgestimate (Sprintec) 35mcg-0.25mg tablet Norelgestromin/Ethinyl estradiol transdermal patch (Ortho Evra) Norethindrone 0.35mg tablet~Emergency Contraception:~Ulipristal 30 mg tablet Levonorgestrel 1.5mg tablet"
41036331|NCT02285816|BIOLOGICAL|MG1MA3|MG1MA3: Boosting component of Oncolytic Vaccine
41036332|NCT02285816|BIOLOGICAL|AdMA3|AdMA3: Priming component of Oncolytic Vaccine
41036333|NCT01713413|DEVICE|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
41036334|NCT01713413|DEVICE|conventional nasal cannula|Using first the conventional nasal cannula and 24h later the Oxymizer
41036335|NCT03660683|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg PO QD
41036336|NCT03660683|DRUG|Saxagliptin 5mg|Saxagliptin 5 mg PO QD
41383191|NCT06567665|DIETARY_SUPPLEMENT|Leucine|Leucine is a dietary supplement that can be easily purchased over the counter at health food stores. It is an essential amino acid and is involved in stimulate muscle protein synthesis.
41508796|NCT04085055|DIAGNOSTIC_TEST|Solid pancreatic mass lesion biopsy|The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
41508797|NCT05139888|DEVICE|Single wavelength light (red) only|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy red light (640-660 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months.
41036337|NCT03660683|DRUG|Placebo Oral Tablet|Matching Placebo Tablets
41036338|NCT01664078|DEVICE|Endovascular AAA repair with InCraft®|
41036339|NCT01083251|DRUG|Peginterferon + Vitamin D|180 mcg/week + 400 IUX2/day
41036340|NCT01083251|DRUG|Peginterferon|180 mcg/week
41036341|NCT01083251|DRUG|Sebivo|Telbivudine 600 mg daily
41036342|NCT01083251|DRUG|entecavir+ vitamin d|entecavir 1 mg daily+ vitamin d
41036343|NCT00288158|DRUG|Allopurinol|
41036344|NCT00288158|DRUG|Probenecid|
41036345|NCT00288158|DRUG|Placebo|
41036346|NCT00653640|PROCEDURE|body weight supported treadmill training|BWSTT for 12 weeks, 3 times per week
41036347|NCT00653640|PROCEDURE|traditional physical therapy|traditional PT for 12 weeks, 3 times per week
41036348|NCT01154166|DRUG|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
41036349|NCT01154166|DRUG|Placebo|Placebo
41036350|NCT03591341|DIAGNOSTIC_TEST|melatonin level in pumped breast milk|diagnostic test of melatonin level in pumped breast milk
41036351|NCT02157038|DEVICE|Pedometer|
41383192|NCT02424799|DRUG|GSK2646264 0.5% topical cream|GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
41383193|NCT02424799|DRUG|GSK2646264 1% topical cream|GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
41383194|NCT02424799|DRUG|Placebo|Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
41383195|NCT01906801|DRUG|Glucosamine sulfate|
41383196|NCT01906801|DRUG|Diacerein|
41383197|NCT01906801|DRUG|Placebo (for Diacerein)|Sugar pill manufactured to mimic Diacerein 50 mg tablet
41383198|NCT01054469|PROCEDURE|TAP block placement with placebo|20 ml of normal saline (placebo)
41383199|NCT01054469|PROCEDURE|Placement of block with ropivacaine|20 ml of 0.5% ropivacaine hydrochloride
41383200|NCT03542253|PROCEDURE|Surgery|After surgical treatment, pathological specimens were extracted to obtain pathological results
41383201|NCT03509688|DRUG|entecavir+resveratrol|entecavir+resveratrol
41383202|NCT03509688|DRUG|Entecavir|Entecavir
41383203|NCT03509688|DRUG|entecavir+thymosin α1|entecavir+thymosin α1
41383204|NCT00745459|DRUG|NPO-11|20 mL NPO-11
41383205|NCT05872451|DRUG|Rocuronium Bromide|After measuring the initial current intensity, quantitative neuromuscular blockade monitoring is applied, and rocuronium (0.6 mg/kg) is administered.
41383206|NCT05872451|DIAGNOSTIC_TEST|Nerve stimulator|Measuring the minimum current intensity for the stimulation of the obturator nerve to show the contraction of the adductor longus muscle.
41383207|NCT02546180|OTHER|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
41508798|NCT05139888|DEVICE|Dual wavelength light (red/blue)|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy dual wavelength light (640-660 nm and 405-450 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months..
41383208|NCT02546180|OTHER|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
41383209|NCT05634629|PROCEDURE|Anterior Lamellar Recession|ALR is a common surgical treatment that splits the skin and orbicularis oculi muscle from the tarsus and conjunctiva to recede the anterior lamella and expose the tarsus. Interlamellar separation can be accomplished via a grey line technique, an eyelid crease approach, or a combination of the two
41383210|NCT05634629|PROCEDURE|Bilamellar Tarsal Rotation|the full-thickness transverse blepharotomy combined with everting sutures to rotate the inferior portion of the upper lid outwards and this procedure has a low recurrence risk
41383211|NCT06512389|DRUG|Oral solution|300 mg taken morning and evening
41383212|NCT06225401|OTHER|Simcapture PRE|Practice with the SimCapture for Skills interface before the traditional teaching with the teacher in the classroom
41508799|NCT01130493|DRUG|IPX066|experimental product
41508800|NCT01130493|DRUG|CLE|active comparator
41036352|NCT02157038|DEVICE|MRI|
41036353|NCT04282135|DIAGNOSTIC_TEST|MCC IMS|Diagnosis by MCC IMS
41036354|NCT04020991|DIAGNOSTIC_TEST|Sleep Study|Participants who noted to have Oxygen Desaturation Index more than 10 (moderate to severe OSA) will be referred to do formal sleep study and referral to Sleep Medicine Clinic
41036355|NCT00385931|DRUG|Valsartan and simvastatin|
41036356|NCT02898974|BEHAVIORAL|Medical Marijuana|To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
41383213|NCT06225401|OTHER|Simcapture POST|Practice with the SimCapture for Skills interface after the traditional teaching with the teacher in the classroom
41383214|NCT04437407|DEVICE|PB2-1 prototype|PB2-1 prototype is a belt-like wearable device similar to the original PrenaBelt designed for pregnant women that permits supine positioning of the pelvis but, when in this position, provides subtle pressure points to the user's body and thereby activates the body's natural mechanism to reposition itself to relieve discomfort. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
41383215|NCT04437407|DEVICE|PB2-2 prototype|PB2-2 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
41383216|NCT04437407|DEVICE|PB2-3 prototype|PB2-3 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
41383217|NCT04437407|DEVICE|PB2-4 prototype|PB2-4 prototype is a belt-like wearable device designed for pregnant women that prevents the user from achieving a supine position as the device allows right and left lateral pelvic tilt but prevents the user's pelvis from settling supine due to virtue of its design. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
41508801|NCT02588495|OTHER|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
41036357|NCT05949762|PROCEDURE|Venetoclax in Combination With Azacitidine and HA Regimen|"Patients diagnosed with primary AML based on morphology, immunophenotyping, and history and meeting the inclusion exclusion criteria were induced with Venetoclax in combination with Azacitidine and HA regimen.~Details for:~Venetoclax 200mg d1-10 Azacitidine 100mg/d (or 50-75mg/m2/d), d2-7 Hautriacontin 2mg/m2/d, d3-7 Cytarabine 100mg/m2/d, d3-8 (infusion 24h)"
41036358|NCT03760237|OTHER|observation only|No intervention, observational study only
41036359|NCT00791024|DRUG|CRC-Pharma 001|50 mg
41383218|NCT04437407|DEVICE|PB2-5 prototype|PB2-5 prototype is a belt-like wearable device designed for pregnant women that does not provide positional therapy. It can be worn anytime as a maternity support belt.
41383219|NCT04437407|DEVICE|Ajuvia-Active|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the active mode, it alerts the woman when her pelvis is in the supine position through a gentle vibratory alarm.
41383220|NCT04437407|DEVICE|Ajuvia-Passive|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the passive mode, it measures and records the position of the pelvis but does not alert the woman.
41508802|NCT03144310|OTHER|lung ultrasound|lung ultrasound and blood gas
41383221|NCT05652283|DRUG|Pamiparib|Pamiparib capsule 40 mg/time, twice a day, oral, 3 weeks as a cycle, 3 cycles
41383222|NCT05652283|DRUG|Surufatinib|Surufatinib 250 mg/time, once a day, oral, 3 weeks as a cycle, 2 cycles
41383223|NCT05924451|BEHAVIORAL|Immediate Loading|Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.
41508803|NCT04621344|DIAGNOSTIC_TEST|Guided bronchoscopy and/or endosonography|Endoscopic procedures aimed at sampling of intrathoracic lymph nodes or pulmonary lesions
41508804|NCT01548105|OTHER|Blood draw for the study participants|"These will include:~* Procollagen 1-N propeptide levels (PINP)~* Matrix metalloproteinase (MMP9)~* Plasma Vitamin C levels"
41508805|NCT05497791|DEVICE|transcranial laser stimulation associated with NMES|"The cluster was applied on the skin covering the head. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.~The NMES was started, after 5 minutes the transcranial laser stimulation (active or placebo-treatment) was started. Then, the therapies were combined. After finishing the transcranial laser stimulation (active or placebo-treatment), the NMES was continued until completing 30 minutes."
41036360|NCT00791024|DRUG|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
41036361|NCT03681158|DRUG|sodium valproate|Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral
41036362|NCT02205944|OTHER|Progressive Handgrip Exercise|"Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg \& Borg, 2001).~Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet."
41036363|NCT01098006|OTHER|Blood withdrawal|A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
41036364|NCT03370653|DRUG|Odiparcil|Investigational product: odiparcil 250 mg tablets
41036365|NCT03370653|OTHER|Placebo|Comparator: placebo tablets similar to odiparcil 250 mg tablets
41165640|NCT03464383|OTHER|Referral to Psychiatry|Participants randomized to control will have a psychiatry referral order placed by the treating epileptologist under typical care circumstances. This will be an internal or external referral order based on patient preference. If external, the order will be printed along with instructions for the patient to follow to find a provider covered by insurance.
41165641|NCT03464383|OTHER|Survey only|One time survey will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are ineligible for the treatment component of the study, or who decline the treatment study.
41165642|NCT02388113|BEHAVIORAL|accumulated exercise|
41165643|NCT02388113|BEHAVIORAL|traditional exercise|
41383224|NCT05717166|RADIATION|Palliative Radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
41383225|NCT05717166|DRUG|Chemotherapy|Pre-specified based on the standard of care approach for that patient.
41508806|NCT05497791|OTHER|Placebo|The transcranial laser was applied identically for all groups, but the null dose was used in the placebo group. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.
41508807|NCT03650530|OTHER|The Family Talk Intervention|The family meets two interventionists at six time points.
41508808|NCT04194645|DRUG|BI 474121 tablet|BI 474121 tablet
41508809|NCT04194645|DRUG|Placebo tablet|Placebo tablet
41508810|NCT04194645|DRUG|BI 474121 oral solution|BI 474121 oral solution
41508811|NCT04194645|DRUG|Placebo solution|Placebo solution
41036366|NCT04575467|DRUG|CBL-514|CBL-514 will be administered via injection into the subcutaneous adipose layer.
41036367|NCT05323734|DRUG|Ganaxalone|GNX will be administered
41508812|NCT00052598|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
41508813|NCT00052598|BIOLOGICAL|aldesleukin|Given SC
41508814|NCT00052598|OTHER|laboratory biomarker analysis|Correlative studies
41508815|NCT00052598|OTHER|flow cytometry|Correlative studies
41383226|NCT05717166|DRUG|Hormone therapy|Pre-specified based on the standard of care approach for that patient.
41383227|NCT05717166|DRUG|Immunotherapy|Pre-specified based on the standard of care approach for that patient.
41383228|NCT05717166|DRUG|Targeted Systemic Therapy|Pre-specified based on the standard of care approach for that patient.
41383229|NCT05717166|OTHER|Observation|Pre-specified based on the standard of care approach for that patient.
41383230|NCT05717166|RADIATION|Stereotactic Ablative Radiotherapy|"The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board.~Preferred doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every second day), and 35 Gy in 5 fractions (daily)."
41383231|NCT05717166|PROCEDURE|Surgery|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board. Because of the convenience in using SABR for all lesions, non-SABR modalities should only be used if they are likely to provide a benefit over SABR."
41383232|NCT05717166|OTHER|Radiofrequency Therapy (RFA)|Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.
41383233|NCT05717166|RADIATION|Fractionated Radiation|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~Tumors in the esophagus, stomach, small intestine or colon should be treated with either fractionated radiation or a lower SABR dose (e.g. 25 Gy in 5 fractions) to minimize the risk of perforation."
41508816|NCT05978752|PROCEDURE|Endoscopic gel embolization of gastric fundus varices and ligation of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with ligation.
41508817|NCT05978752|PROCEDURE|Endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with sclerotherapy.
41165882|NCT02805985|DEVICE|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
41383234|NCT03671135|OTHER|TCA Intrastromal Inlay|Anterior surface of Bowmans Layer Corneal Optical Correction Inlay
41383235|NCT05088382|DEVICE|LH Urine Test|Test for the qualitative measurement of LH in urine
41383236|NCT02449967|PROCEDURE|interventional therapy|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
41383237|NCT06367998|DRUG|Pregabalin|Pregabalin oral intake from the day before surgery to six weeks postoperatively
41508818|NCT05978752|PROCEDURE|Endoscopic gelatinous embolization of gastric varices (esophageal varices not treated)|For patients with GOV1 esophagogastric varices, only gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will not be treated.
41508819|NCT00219817|DRUG|RC-1291 HCl|
41508820|NCT00738257|DRUG|Pamidronate|
41508821|NCT01119573|GENETIC|RNA analysis|
41508822|NCT01119573|GENETIC|microarray analysis|
41508823|NCT01119573|GENETIC|reverse transcriptase-polymerase chain reaction|
41508824|NCT01119573|OTHER|laboratory biomarker analysis|
41508825|NCT05531110|DEVICE|Cataract surgery with insertion of Eyhance ICB00|Cataract surgery with insertion of Eyhance ICB00
41508826|NCT05531110|DEVICE|Cataract surgery with insertion of Alcon SN60WF|Cataract surgery with insertion of Alcon SN60WF
41508827|NCT03259412|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil Capsule
41508828|NCT03259412|DIETARY_SUPPLEMENT|Placebo|Olive Oil capsule manufactured to mimic fish oil capsule
41508829|NCT02658942|PROCEDURE|Ureteroscopy|In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
41508830|NCT02658942|PROCEDURE|Shockwave lithotripsy|In Group B patients, a Siemens Lithostar Lithotriptor
41508831|NCT05024357|DRUG|Dasatinib|Take Dasatinib orally for 1 year or 6 months post-HSCT.
41508832|NCT01221610|DEVICE|Passeo-18 Lux DRB|
41508833|NCT01221610|DEVICE|Standard PTA (POBA)|
41508834|NCT03503695|DEVICE|Sterile acupuncture semi-permanent (ASP) gold needles|
41508835|NCT06321679|PROCEDURE|Imaging evaluation|each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint
41508836|NCT01331629|OTHER|ART-THERAPIE|8 sessions of art therapy during radiotherapy
41508837|NCT04498117|BIOLOGICAL|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
41508838|NCT04498117|DRUG|Paclitaxel|175 mg/m\^2, every 3 weeks
41383238|NCT06126770|BEHAVIORAL|The social norm intervention|"The intervention will target Married adolescent girls, their spouses, and elderly/influential community members. Thirty-six 2-hour weekly sessions will be conducted with MAGs. The session topics will be categorized into two broad headings: i) Health and life skills sessions covering, for example topics such as sex and gender, rights, marriages, SRHR, and ii) Business and entrepreneurship sessions.~Spouses of the MAGs will receive 20 2-hour bi-weekly sessions. A total of three 2-hour couples sessions will be held. Elderly women and influential community members will have three 2-hour bi-monthly sessions. In addition, MAGs with leadership qualities will be identified and trained to conduct campaigns and activism. They will also receive training on income generating."
41383239|NCT05581797|OTHER|Psilocybin-assisted psychotherapy|8 sessions of interpersonal therapy and 2 doses of psilocybin
41383240|NCT06539585|PROCEDURE|Meiotic spindle status observation in polarized light|In patients older than 35 years and younger than 40 years, we will use a microscope with a polarizing filter to evaluate the position of meiotic spindles and polar bodies in oocytes collected from patients who were indicated for IVF and ICSI. Using an optical microscope with a Nikon CEE GmbH polarizing filter, the angle between PB and MS together with MS visibility will be determined.
41036368|NCT05323734|DRUG|Placebo|Placebo will be administered
41036369|NCT03297268|OTHER|Intervention with Home-Based Caregivers|We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.
41383241|NCT06539585|PROCEDURE|ICSI|ICSI will be performed according to standard protocol using ICSI/holding micropipettes (#002-5-30/#001-120-30, Microtech IVF, Czech Republic), polyvinylpyrrolidone (ICSI™, Vitrolife, Sweden), and Eppendorf (Hamburg, Germany) micromanipulation system equipped with thermoplate (Tokaohit, Japan). The oocytes will be cultivated individually, and their order preserved, so that the other outcomes (data from timelapse, clinical results) can be associated with individual oocytes. Oocytes will be denuded (HYASE-10X™, Vitrolife, Sweden) after OPU, and the maturation stage will be examined.
41383242|NCT00103155|PROCEDURE|conventional surgery|
41383243|NCT00103155|PROCEDURE|radiofrequency ablation|
41383244|NCT00418756|DRUG|Nilotinib|Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
41383245|NCT04501809|PROCEDURE|compare misoprostol with combined oxytocin and cervical foly catheter|we will compare using misoprostol alone in one group with oxytocin and cervical catheter in the other group
41508839|NCT04498117|DRUG|Carboplatin|AUC 6 IV Day 1 x 6 cycles (every 21 days)
41508840|NCT04498117|BIOLOGICAL|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
41508841|NCT04498117|DRUG|Carboplatin|AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
41508842|NCT01461538|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
41508843|NCT01461538|DRUG|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
41036370|NCT06085248|DEVICE|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
41036371|NCT06085248|BEHAVIORAL|Active walking|walking without RAS cue
41036372|NCT00839072|DRUG|Trazodone HCl|100 mg immediate-release tablet, dosing q8h
41036373|NCT00839072|DRUG|Trazodone HCl|300 mg extended-release caplet, single dose
41036374|NCT02020954|PROCEDURE|ECG, echocardiography, cardiac MRI, sera biomarkers|
41508844|NCT01461538|DRUG|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
41508845|NCT00072787|DRUG|S-1|
41508846|NCT00072787|DRUG|cisplatin|
41508847|NCT00953966|OTHER|Genetically modified potatoes|Starch from genetically modified potatoes
41508848|NCT00403585|DRUG|adefovir dipivoxil 10mg|
41508849|NCT04992208|BIOLOGICAL|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
41508850|NCT00582010|DRUG|inhaled nitric oxide|inhaled 80ppm for duration of surgery.
41508851|NCT00582010|DRUG|nitrogen gas|inhaled
41036375|NCT06177340|DEVICE|visualization of the sacrospinous ligament|visualization of the sacrospinous ligament by the Nanoscope system during sacrospinofixation
41036376|NCT03675022|DRUG|Dupilumab|The investigational drug is dupilumab, 300mg in 2ml solution for subcutaneous application. All Patients will receive dupilumab, 300mg, every two weeks (8 subcutaneous injections total).
41036377|NCT05695183|DEVICE|IV SafeLock|Designed to prevent patient access to intravenous lines in the hospital setting. The device locks with an institution specific key and protects the hub as well as all tubing access points.
41036378|NCT01944501|PROCEDURE|Transcranial Magnetic Stimulation|TMS over the left temporoparietal cortex
41036379|NCT01944501|PROCEDURE|Transcranial Direct Current Stimulation|TDCS over the left temporoparietal cortex
41036380|NCT01662882|DRUG|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
41036381|NCT02904304|DRUG|Desloratadine+Phenylephrine+Ibuprofen|01 tablet, orally, every 12 hours.
41036382|NCT02904304|DRUG|Placebo|01 tablet, orally, every 12 hours.
41036383|NCT04759820|DRUG|injecting Carbon Nanoparticles Suspension|injecting Carbon Nanoparticles Suspension for lymph node detection
41036384|NCT04759820|DRUG|Injecting indocyanine green|Injecting indocyanine green for lymph node detection
41508852|NCT05567276|BEHAVIORAL|Non-Violent Resistance parental training|Non-Violent Resistance parental training
41508853|NCT06328465|DIAGNOSTIC_TEST|Diffusion whole body MRI|Diffusion whole body MRI protocol, consisting of sagittal T1-weighted and T2-weighted sequences on the whole spine, axial T1 weighted, T2-weighted and diffusion-weighted images from head to mid-thigh, performed on a 1.5 T scanner.
41508854|NCT01851330|DRUG|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
41508855|NCT01851330|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
41508856|NCT05041920|DRUG|famitinib、omeprazole|famitinib malate, 25 mg on study day 1; omeprazole, 40 mg, qd on study day 10-14, 16-22; famotine malate together with omeprazole, on study day 15.
41508857|NCT04000282|DRUG|SAR442085|Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
41508858|NCT00004126|DRUG|oxaliplatin|
41508859|NCT00004126|DRUG|paclitaxel|
41165644|NCT02761863|OTHER|CD 74, VEGF detection|"All MPM samples will be subjected to immunohistochemistry with CD74 and VEGF antibodies.~The VEGF will be scored using a 0-3 scoring system to represent the percentage of cytoplasmic positively stained cells in the tumor portion, as follows: 0-10%, 11-30%, 31-60% and 61-100% positive staining correspond to score 0, 1, 2 and 3 respectively. Both CD74 and VEGF immunohistochemical markers will be furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression(3).~The CD74 expression will be recorded in the tumor and the stroma semiquantitatively using the histoscore method using four representative fields with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade."
41165645|NCT04213820|DEVICE|Transcranial magnetic stimulation|TMS (theta burst) will be administered consisting of bursts containing 3 pulses at 50 Hz and an intensity of 80% motor threshold repeated at 200 ms intervals (i.e., at 5 Hz) and a 10 s between burst triplet interval for a total for 190 s (600 pulses). The intervention will be given daily 5 times/week during 4 weeks.
41165646|NCT04213820|BEHAVIORAL|Body Image Intervention|Body image interventions delivered directly after TMS will include body exercises that target disturbed body image and psychoeducation about the body. Together with a therapist the participants with anorexia nervosa will explore and estimate their body size through feedback.
41165647|NCT04213820|BEHAVIORAL|Treatment as usual|Treatment as usual at the eating disorder unit, Child and adolescent psychiatric clinic and Psychiatric clinic is delivered during 4 weeks
41165648|NCT05531890|DRUG|GTX-102 medium dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
41165649|NCT05531890|DRUG|GTX-102 medium dose slow Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
41165650|NCT05531890|DRUG|GTX-102 high dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
41383246|NCT04690660|OTHER|Data collection for parameters of organ damage (cardiac and renal blood markers)|Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
41383247|NCT04690660|OTHER|Data collection for blood pressure (BP)|Clinic blood pressure and 24hour BP Measurements
41036385|NCT02068573|DEVICE|Ventilation|The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
41036386|NCT02068573|DEVICE|Placebo Ventilation|The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
41036387|NCT03371420|DRUG|PU-AD|
41036388|NCT03371420|DEVICE|PET Scan|
41036389|NCT03371420|OTHER|Blood Draws|
41165651|NCT05531890|DRUG|GTX-102 low dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
41165652|NCT05531890|DRUG|Betamethasone solution as intramuscular injection Period 1 and Period 2|reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
41383248|NCT04690660|OTHER|Home-based blood pressure management (substudy)|Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
41383249|NCT04690660|OTHER|Biomarker Profiles (substudy)|Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
41383250|NCT04690660|OTHER|Data collection on patient reported outcomes|Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )
41383251|NCT05341583|DRUG|Ensartinib|Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
41383252|NCT05341583|DRUG|Placebo|Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
41383253|NCT03666299|DRUG|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
41383254|NCT03666299|DRUG|Control|Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
41383255|NCT06224387|DRUG|CTS2190 capsules|4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
41036390|NCT03569280|COMBINATION_PRODUCT|Enzalutamide or Abiraterone or Apalutamid|Antitumor treatment
41036391|NCT04525391|DRUG|Durvalumab+AZD2811 to SCLC patients|AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.
41036392|NCT05729763|OTHER|3D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 3D images
41036393|NCT05729763|OTHER|2D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 2D images
41036394|NCT02363556|PROCEDURE|Misoprostol administered vaginally|
41036395|NCT02363556|PROCEDURE|Misoprostol administered buccally|
41036396|NCT02363556|PROCEDURE|Misoprostol administered vaginally with Dilapan|
41036397|NCT02363556|PROCEDURE|Misoprostol administered buccally with Dilapan|
41036398|NCT03108924|DRUG|Gefapixant|After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
41036399|NCT03750201|DEVICE|Direct Selective Trabeculoplasty|Laser surgery by automated direct automated SLT device to lower intraocular pressure
41036400|NCT03750201|DEVICE|Selective Trabeculoplasty|Laser surgery by standard SLT device to lower intraocular pressure
41165653|NCT05531890|DRUG|Betamethasone Oral Solution Period 1 and Period 2|Comparator product 0.1 mg/kg betamethasone oral drops solution
41165654|NCT02803593|BEHAVIORAL|Technology-based information and coaching/support program|The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
41165655|NCT02803593|BEHAVIORAL|American Cancer Society information on breast cancer|The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
41165656|NCT04363710|OTHER|Low Calorie Diet|800-1000 Kcal/day
41165657|NCT01281215|BEHAVIORAL|Education interventional|The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
41165658|NCT01134471|DEVICE|Ostene|applied to sternal surface
41165659|NCT01134471|DEVICE|Bonewax|applied to sternal surface
41165660|NCT01219777|DRUG|carboplatin|Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
41165661|NCT01219777|DRUG|Bevacizumab|Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
41165662|NCT01219777|DRUG|Paclitaxel|60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
41165663|NCT05985902|OTHER|Core Stabilization Exercises|"Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus ma"
41165664|NCT05985902|OTHER|Schroth Exercises|In the Schroth exercise training, there are 3-dimensional exercises that include the principles of axial reach, deflection, derotation, rotational breathing and stabilization.
41165665|NCT04758546|DIAGNOSTIC_TEST|Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial|Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
41165666|NCT04067908|OTHER|2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling|The samples taken during this study are taken at the same time as those taken in routine during the diagnosis of threat of premature labor. There are added 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling.
41165667|NCT04361968|OTHER|Animal-assisted placebo condition|Participants receive the same verbal information as in the Placebo condition. Additionally, participants will receive the same verbal information as in the Dog only condition.
41165668|NCT04361968|OTHER|Placebo condition|"Participants receive verbal information that they are receiving an analgesic cream (i.e. Antidolor, containing Lidocain), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
41383256|NCT01009073|DRUG|ABT-263|"ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed."
41383257|NCT01009073|DRUG|erlotinib|150 mg of erlotinib is taken orally once daily.
41036401|NCT05475418|PROCEDURE|Adipose tissue derived exosomes|200-300ml of the subject adipose tissue before centrifugation was collected, and the extracellular vesicles were retained after tissue homogenate and filter screening. The extracellular vesicles were mixed with sterile hydrogel and applied directly to the wound surface, and the wound was covered with an inert protective dressing.
41383258|NCT01009073|DRUG|irinotecan (3-week schedule)|"180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
41383259|NCT01009073|DRUG|irinotecan (weekly schedule)|"75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
41383260|NCT04761588|DIETARY_SUPPLEMENT|Tyr sphere|"Tyr sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP) and docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
41383261|NCT00131326|DEVICE|Synvisc (hylan G-F 20)|
41036402|NCT04933812|BEHAVIORAL|Facebook discussions and Virtual group meetings|Participants must join a study-specific private Facebook group and engage in discussion. Once the discussion is complete, participants have the opportunity to join virtual group sessions via Zoom
41036403|NCT01914926|DRUG|Metoprolol|
41036404|NCT01914926|DRUG|Diltiazem|
41036405|NCT04691869|DEVICE|Achilles EXPII|Portable ultrasound machine that measures a patient's bone density at the calcaneus.
41036406|NCT03977220|DRUG|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
41036407|NCT01495429|PROCEDURE|Central venous catheter|Placement of a peripherally inserted central venous catheter
41036408|NCT01495429|PROCEDURE|Central venous catheter|Placement of a centrally inserted central venous catheter
41508860|NCT03613727|DRUG|Intravenous (IV) and oral Vitamin C|"Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180"
41508861|NCT02131350|PROCEDURE|Photocoagulation|Photocoagulation include focal/grid laser and/or panretinal photocoagulation
41508862|NCT02131350|DRUG|Ranibizumab|
41383262|NCT03862807|DRUG|Patisiran|Patisiran was administered via IV infusion.
41383263|NCT03199898|DIAGNOSTIC_TEST|Silverman-Andersen Retraction Score|The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
41383264|NCT05362669|BEHAVIORAL|SMS invitation|Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.
41383265|NCT05362669|BEHAVIORAL|Phone call invitation|Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.
41383266|NCT03165630|BEHAVIORAL|Transportation incentives|Free transportation only for the first 3 months post-discharge.
41383267|NCT03165630|BEHAVIORAL|Transportation and rehabilitation services incentives|Free transportation and rehabilitation services 3 months post-discharge.
41383268|NCT05804201|PROCEDURE|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giob|(2) The EUS procedure will be performed with a therapeutic echoendoscope with a large working channel under guidance of ultrasound, endoscopy, and fluoroscopy. The echoendoscope will be positioned in the stomach or duodenum. Liver segment III, or sometimes segment II, will be punctured with an 19G needle. After puncture, a guidewire will be introduced in the dilated bile duct, and a Hot Giobor will be placed. All procedures will be performed with the patient and in the supine or prone position under monitored anesthesia.
41383269|NCT02102217|PROCEDURE|PRECious|Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
41383270|NCT02780115|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
41383271|NCT02780115|DRUG|AGN-190584 ophthalmic solution|1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
41383272|NCT02780115|DRUG|AGN-199201 Vehicle|Vehicle to AGN-199201
41383273|NCT02780115|DRUG|AGN-190584 Vehicle|Vehicle to AGN-190584
41383274|NCT00209430|DRUG|Iodixanol 320 mgI/mL|
41383275|NCT04384731|DRUG|poractant alfa|Patient receiving surfactant (3 mL/kg of a poractant alpha solution diluted to 16 mg/mL, resulting in a total dose of 48mg/kg) administred by bronchial fibroscopy. The total volume will be divided in each of the five lobar bronchi.
41383276|NCT00757198|DRUG|remifentanil|remifentanil infusion
41383277|NCT00757198|DRUG|remifentanil|remifentanil infusion
41383278|NCT01845194|DRUG|Codeine|"Treatment period 2:~5 mg Codeine once"
41383279|NCT01845194|DRUG|Midazolam|"Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once"
41383280|NCT01845194|DRUG|Pravastatin|"Treatment period 2:~5 mg Pravastatin once"
41383281|NCT01845194|DRUG|Torsemide|"Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once"
41383282|NCT01845194|DRUG|Talinolol|"Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once"
41383283|NCT01845194|DRUG|Caffeine|"Treatment period 1:~50 mg Caffeine 3x"
41383284|NCT01845194|DRUG|Metoprolol|"Treatment period 1:~5 mg Metoprolol 3x"
41383285|NCT04092491|OTHER|blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~* 2 PAXgene RNA tubes of 2 ml each~* 1 dry tube for creatinine and IgA assay~* 1 tube of NFs (5ml)"
41508863|NCT00261950|DRUG|Sensipar (Cinacalcet HCl)|All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
41036409|NCT00574080|DRUG|Interim/Maintenance Dexamethasone|20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
41383286|NCT05246150|BEHAVIORAL|nursing care practices|To determine the effect of nursing care practices on Near Infrared Spectroscopy (NIRS) levels in premature babies
41508864|NCT06178341|DEVICE|Kata Inhalations-App|"The Kata Inhalations-App is a digital product that bears a CE mark. The application provides algorithms to run an inhalation trainer. The inhalation trainer shows patients how to improve their inhalation maneuver in a simple and understandable way. For this purpose, the signals from the camera and microphone of the patient's smartphone are used to evaluate the individual steps of the inhalation maneuver in real-time to provide automatic, personalized feedback. Additional functions of the Kata Inhalations-App include the possibility to document health parameters and to receive inhalation reminders.~After set-up, subjects will use the application on their own as an add-on to their usual therapy for asthma. The total duration of application use will be 13 weeks, 1 week use of the Messinstrument (Measurement)-App for all subjects (Baseline period), followed by 12 weeks use of the Kata Inhalations-App (intervention) or the Messinstrument-App (control)."
41508865|NCT00862615|OTHER|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.|"Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.~Isotopes are :~(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)"
41508866|NCT02996773|DRUG|Bendamustine|After transplant, given intravenously on day +4 as part of Phase Ib.
41508867|NCT02996773|DRUG|Cyclophosphamide|After transplant, given intravenously on day +3 as part of Phase 1b.
41508868|NCT05871554|BEHAVIORAL|Mind-OP+|"Mind-OP is an online program designed to cultivate mindfulness and self-compassion developed by Beshai and his team. Mind-OP is self-guided, with four modules administered at a pace of one module per week (four weeks total). The version used for this study, Mind-OP+, is five weeks total, containing an extra module focused on connectedness.~The modules contain psychoeducational videos, guided audio meditations, goal-setting and motivational interviewing inspired exercises. Participants also have opportunities to engage with meditations and other exercises embedded within each module.~The first module (Week 1) introduces the concept of mindfulness. The second module (Week 2) focuses on attention to bodily sensations and thoughts. The third module (Week 3) introduces the concept of self-compassion. The fourth module (Week 4) focuses on the self-kindness component of self-compassion. The fifth module (Week 5) focuses on the concept of connectedness."
41508869|NCT02940496|DRUG|Elbasvir/Grazoprevir|Given PO
41508870|NCT02940496|OTHER|Laboratory Biomarker Analysis|Correlative studies
41508871|NCT02940496|BIOLOGICAL|Pembrolizumab|Given IV
41508872|NCT02940496|DRUG|Ribavirin|Given PO
41383287|NCT01232075|DRUG|Extended letrozole regimen|"Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
41383288|NCT01232075|DRUG|Clomiphene citrate regimen|"Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
41383289|NCT03099161|DRUG|preladenant|Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
41383290|NCT03099161|BIOLOGICAL|pembrolizumab|Administered as IV infusion on Day 1 of each 21-day cycle
41036410|NCT00574080|DRUG|Induction/Consolidation Dexamethasone|40 mg Days 1-4
41383291|NCT05343247|DIAGNOSTIC_TEST|Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
41383292|NCT05343247|DIAGNOSTIC_TEST|London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
41036411|NCT00574080|DRUG|Induction/Consolidation Cisplatin|10 mg/m2 by continuous infusion Days 1-4
41036412|NCT00574080|DRUG|Induction/Consolidation Adriamycin|10 mg/m2 by continuous infusion Days 1-4
41036413|NCT00574080|DRUG|InductionConsolidation Cyclophosphamide|400 mg/m2 by continuous infusion Days 1-4
41508873|NCT06156332|DRUG|surufatinib、serplulimab|"surufatinib:~250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab:~300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy.~Imaging was used every 6 weeks (±7 days) to evaluate tumor status until disease progression (RECIST 1.1) or death (during patient treatment), and tumor treatment and survival status after disease progression were recorded. The changes of neuroendocrine tumor markers were detected after treatment."
41508874|NCT04497012|DRUG|2mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
41508875|NCT04497012|DRUG|6 mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
41508876|NCT04665986|DRUG|Navelbine|Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
41508877|NCT04665986|DRUG|Docetaxel|Docetaxel 90mg/m2 on day 1, every 3 weeks
41508878|NCT00994578|BEHAVIORAL|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
41508879|NCT00994578|BEHAVIORAL|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
41383293|NCT06146517|OTHER|Clevr Sleeptime|Participants will trial Clevr Blends Sleeptime during weeks 1-4.
41383294|NCT06146517|OTHER|Clevr Matcha|Participants will trial Clevr Matcha during weeks 5-8.
41383295|NCT06146517|OTHER|Clevr Chai|Participants will trial Clevr Chai during weeks 9-12.
41383296|NCT05590182|DEVICE|Angiography|"Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.~A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention."
41383297|NCT03867500|DRUG|Niacin|Intravenous infusion, a titrated dose starting from 0.6 mg/min to a maximum of 2.8 mg/min (likely needed dose = 1.4 mg/min)
41383298|NCT03867500|DRUG|Saline|Intravenous infusion of 0.9% Sodium chloride (NaCl)
41383299|NCT03545360|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-703 device
41383300|NCT06566651|OTHER|Emotion Discrimination Task (EDT)|It estimates the subjective bias and sensitivity in discriminating between happy and angry facial expressions of different intensities of emotional expression
41383301|NCT04625634|OTHER|2 days of work heat stress|2 consecutive days of identical simulated structural firefighting tasks.
41383302|NCT06454955|DRUG|[68Ga] B7H3 Affibody-BCH|An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.
41383303|NCT01692470|DRUG|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
41383304|NCT04731909|DRUG|Toripalimab|Toripalimab 240mg,ivgtt,d1,q3w.
41383305|NCT04731909|DRUG|Anlotinib|Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.
41383306|NCT04731909|DRUG|Cisplatin|75mg/m2,d1,q3w,4-6 cycles in total.
41383307|NCT04731909|DRUG|Carboplatin|AUC=5,d1,q3w,4-6 cycles in total.
41383308|NCT05923320|BEHAVIORAL|training|The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
41383309|NCT05144958|DEVICE|Totally thoracoscopic LAAO - ATRICLIP|The device for surgical totally thoracoscopic left atrial appendage occlusion AtriClip® Gillinov-Cosgrove™ (AtriClip, AtriCure, Dayton, OH, USA) consists of an automatically closing clip placed in a deployment loop on a disposable holder with the head articulation of 60 degrees side-to-side and up/down. The several novel features of the system in comparison to previous ones, such as its length, maneuverability and releasing system, enable it to be used in a totally thoracoscopic fashion. The AtriClip® PRO has parallel titanium crossbars that equalize the force over the tissue trabeculations of the LAA during deployment, ensuring a sealed line at the base of the LAA orifice, as confirmed in preclinical and clinical studies. The clip can be opened and closed repeatedly before final deployment when only the correct placement is confirmed in TEE.
40852953|NCT06337708|BEHAVIORAL|Smart Walk|Smart Walk is a culturally tailored, Social Cognitive Theory-based multi-component smartphone delivered physical activity (PA) promotion intervention that delivered through the Smart Walk application, virtual physical activity coaching, and text messages. The Smart Walk smartphone application includes four key features: 1) personal profile pages, 2) culturally relevant multi-media physical activity promotion modules, 3) discussion boards, and 4) physical activity self-monitoring/tracking feature that integrates with Fitbit activity monitors for participants to track their daily, weekly, and monthly activity. Virtual physical activity coaches will actively engage and facilitate group-based dialogue among participants on the app discussion boards and provide individualized, one-on-one PA coaching via telephone or commercially available app-based video teleconferencing software (i.e., FaceTime, Zoom, Google hangouts).
40852954|NCT06337708|BEHAVIORAL|Fitbit|This intervention group will receive a Fitbit activity monitor and be encouraged to use the commercially available device to increase physical activity.
40852955|NCT03887221|DRUG|Safinamide 50 mg|Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
40852956|NCT03887221|DRUG|Safinamide 100mg|Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
41036414|NCT00574080|DRUG|Induction/Consolidation Etoposide|40 mg/m2 by continuous infusion Days 1-4
41036415|NCT00574080|DRUG|Induction Pegfilgrastim|6 mg Days 6 and 13
41036416|NCT00574080|DRUG|Transplant 1 Dexamethasone|20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
41036417|NCT00574080|DRUG|Transplant 1 Cisplatin|20 mg/m2 by continuous infusion Days -3 and -2
41036418|NCT00574080|DRUG|Transplant 1 Adriamycin|20 mg/m2 by continuous infusion Days -3 and -2
41165669|NCT04361968|OTHER|Dog only condition|"Participants will get a therapeutic rationale for the presence of the dog. The rationale is supported in the literature and therefore not invented for the purpose of this study. Participants will be told that: Studies have shown the presence of an animal can affect pain perception because the presence and the interaction with an animal can increase our Oxytocin level. Therefore, the investigators want to examine if the presence of a dog has an impact on your pain perception. While participants have to wait for the action time of the cream they are allowed to pet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Participants will still be able to see the dog."
41165670|NCT04361968|OTHER|Control Condition|Participants in this condition will receive no intervention. All instructions will be conveyed in a standardized manner to ensure that the participant-experimenter relationship is comparable in terms of friendliness and attention across all four conditions.
41165671|NCT05512078|PROCEDURE|bone positioning surgical guide|patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.
41383310|NCT05144958|DEVICE|Percutaneous LAAO - WATCHMAN|Using a modified Seldinger technique a vessel dilator and a guidewire are inserted into the femoral vein. Under trans-esophageal echocardiography and fluoroscopy guidance, an interatrial septum is punctured using typical trans-septal access. The pigtail catheter is placed in the distal portion of the left atrial appendage and then the access sheath is inserted. After choosing the appropriate Watchman size the device is deployed and seals the left atrial appendage.
41383591|NCT01035229|OTHER|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
41036419|NCT00574080|DRUG|Transplant 1 Cyclophosphamide|800 mg/m2 by continuous infusion Days -3 and -2
41036420|NCT00574080|DRUG|Transplant 1 Etoposide|80 mg/m2 by continuous infusion Days -3 and -2
41036421|NCT00574080|DRUG|Transplant 1 Melphalan|50 mg/m2 Days -2 and -1
41036422|NCT00574080|DRUG|Transplant 1 and 2 Pegfilgrastim|6 mg Day +6
41036423|NCT00574080|PROCEDURE|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Day 0
41036424|NCT00574080|DRUG|Transplant 2 Carmustine|300 mg/m2 Day -5
41036425|NCT00574080|DRUG|Transplant 2 Etoposide|200 mg/m2 Days -5, -4, -3, -2
41036426|NCT00574080|DRUG|Transplant 2 Cytarabine|400 mg/m2 Days -5, -4, -3, -2
41036427|NCT00574080|DRUG|Transplant 2 Melphalan|140 mg/m2 Day -1
41036428|NCT00574080|DRUG|Transplant 2 Dexamethasone|20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
41036429|NCT00574080|DRUG|Transplant 1 and 2 Bortezomib|1 mg/m2 Days -4, -1, +3, +7
41036430|NCT00574080|DRUG|Transplant 1 and 2 Thalidomide|200 mg Days -4 to +5
41036431|NCT02232893|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
41036432|NCT02232893|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
41036433|NCT00924885|DEVICE|Swemed Follicle Aspiration Set Reduced Single Lumen|Thin tip to penetrate the tissue
41036434|NCT00924885|DEVICE|Swemed Follicle Aspiration Set Single Lumen (1.4 mm)|Standard (1.4 mm) needle to penetrate the tissue
41036435|NCT03332862|PROCEDURE|catheter ablation|catheter ablation for atrial fibrillation treatment
41165672|NCT02703753|BEHAVIORAL|Lifestyle intervention|The investigational treatment consists of a lifestyle intervention targeting on a healthy diet, physical activity and, if applicable, smoking cessation.
40852957|NCT04238507|DEVICE|Guedel airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
41036436|NCT04230473|BIOLOGICAL|single dose of CNCT19|"Dose A: 0.25 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
41036437|NCT04844164|DRUG|Cholecalciferol 15000 UNT/ML Oral Solution|A single dose (150,000 IU) of cholecalciferol aqueous solution per os
41036438|NCT02362698|OTHER|electro-acupuncture|"13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.~HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour."
41036439|NCT02362698|OTHER|psychological intervention|Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
41036440|NCT00248729|DRUG|Etomidate (20mg) or Midazolam (7mg)|
41036441|NCT05042219|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter
41036442|NCT06585969|DRUG|Trastuzumab deruxtecan (T-DXd)|Trastuzumab deruxtexan every three weeks
41165673|NCT03845023|DRUG|AD036 Dose 1|AD036 Dose 1 oral capsule administered before sleep
41165674|NCT03845023|DRUG|AD036 Dose 2|AD036 Dose 2 oral capsule administered before sleep
41165675|NCT03845023|DRUG|AD036 Dose 3|AD036 Dose 3 oral capsule administered before sleep
41165676|NCT03845023|DRUG|Placebo|Placebo oral capsule administered before sleep
41165677|NCT00004090|DRUG|cisplatin|
41165678|NCT00004090|DRUG|gemcitabine hydrochloride|
41165679|NCT02618902|BIOLOGICAL|tolerogenic dendritic cells (tolDC)|dose-escalation
41165680|NCT04816708|BEHAVIORAL|LIFT Mindfulness|Mindfulness is a type of mind-body therapy that promotes a practice of non-judgmental awareness that can alleviate distress by uncoupling emotional reactions and habitual behavior from unpleasant symptoms, thoughts, and emotions. LIFT is a mobile mindfulness app which can assess levels of emotional distress via survey, and subsequently offer mindfulness content that has previously been used in ICU patients, where it was shown to reduce symptoms of depression, anxiety, and PTSD.
40852958|NCT04238507|DEVICE|USASK airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
41165681|NCT05934656|OTHER|Latent class analysis|"The investigators will conduct a longitudinal study comprising nested groups A to C of the study population, with progressively more detailed mechanistic investigations. No control group.~Group A will complete a CF-specific measure of gut symptoms (CFAbd-Score), a generic constipation score (PAC-SYM) and 24 hour dietary recall (Intake24).~Group B will have stool and blood for microbiome, inflammatory mediators and faecal fat.~Group C will have gut MRI and exploratory studies of inflammation."
41165682|NCT02622464|OTHER|micro injection of SVF in vocal cords|
40852959|NCT02785068|DRUG|MM-151|Oligoclonal antibody
40852960|NCT02785068|DRUG|nal-IRI|Nanoliposomal irinotecan
40852961|NCT02785068|DRUG|Leucovorin|folinic acid
40852962|NCT02785068|DRUG|5-FU|Chemotherapy
40852963|NCT04842383|DRUG|Hemp Oil|Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
40852964|NCT05307042|DIAGNOSTIC_TEST|Deamino Arginine Vasopressin (dDAVP)|After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
40852965|NCT02322970|DEVICE|transcranial Doppler|Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
40852966|NCT02720692|DRUG|N1539|
40852967|NCT02720692|DRUG|Intravenous Placebo|
41036443|NCT06585969|DRUG|Ribociclib with ET|Ribociclib with endocrine therapy
41036444|NCT06585969|DRUG|Abemaciclib with ET|Abemaciclib with endocrine therapy
41036445|NCT05557942|DRUG|AV-101|AV-101 (imatinib) administered via dry powder inhalation
41165683|NCT00574483|DRUG|quinacrine|100 mg day
41165684|NCT02592707|DRUG|Satoreotide tetraxetan|Satoreotide tetraxetan administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
41165685|NCT02592707|OTHER|Amino acid solution|"Given as an auxiliary product the day of the IMP infusion for safety reasons to protect the renal function.~Centres can use their established amino acid infusion or Ipsen amino acid solution (auxiliary medical product OPS301)"
41165686|NCT02592707|OTHER|Antiemetic|To counteract the known side effects of the amino acid infusion, such as nausea, dexamethasone (antiemetic) and as-required ondansetron will be administered 15 to 30 minutes before the start of the amino acid infusion (unless there are contraindications for these drugs).
41165687|NCT02176564|DRUG|inhaled bronchodilator|
41383592|NCT05392712|DEVICE|Magnetometer|inspection equipment for magnetocardiography
40852968|NCT05704660|BEHAVIORAL|Adjusted Cognitive-biased modification task|The intervention of the proposed project is based on a go/no-go task in which older adults need to quickly decide whether or not they should react to the stimulus. A rectangle containing an image, or a word will be presented on a screen. In the intervention group, older adults will be instructed to restrain their actions when the rectangle is tilted to the right and to react by pressing a key on the keyboard when the rectangle is tilted to the left, irrespective of the content of the rectangle (because the training is meant to be implicit). In order to train inhibitory processes counteracting the automatic attraction to sedentary behavior, 90% of the rectangles tilted to the right (counterbalanced across participants) will contain a picture or a word related to sedentary behavior. To foster the automatic attraction toward physical activity, 90% of the rectangles tilted to the left will contain a picture or a word related to physical activity.
41036446|NCT03317977|BEHAVIORAL|Reach for Control|In Phase 1 (weeks 1-4), the CHW conducts an initial intake and then completes a comprehensive functional analysis (FA) of behavior to determine the causes of poor asthma management for each youth regarding asthma management. In Phase 2 (weeks 5-20) is a treatment phase and consists of a combination of mandatory cognitive-behavioral skills training (CBST) modules (received by all families) and flexible CBST modules chosen and individualized based on the results of the Phase 1 FA. This includes but not limited to In-vivo Asthma Skills Training, Improving Family Communication and Behavioral Contracting. Phase 3 (weeks 21-24) involves termination planning and relapse prevention
41036447|NCT03317977|BEHAVIORAL|MATCH|Managing Asthma Through Case Management in Home (MATCH) is the current intervention provided by WCHAP to youth with poorly controlled asthma and their families.
41036448|NCT00439907|PROCEDURE|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
41036449|NCT00439907|PROCEDURE|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
41036450|NCT06507267|OTHER|Pain and Clinical Reflections in Pelvic Congestion Syndrome|Pain and Clinical Reflections in Pelvic Congestion Syndrome
41036451|NCT03137134|DRUG|Crizotinib|Crizotinib in a coated microsphere formulation
41036452|NCT03137134|DRUG|Esomeprazole|Proton pump inhibitor, esomeprazole
41036453|NCT00566267|DRUG|simvastatin 20 mg/ezetimibe|see protocol
41165688|NCT05689281|BEHAVIORAL|Peer PrEP Navigation|Ecological momentary assessments to identify and address stressors related to social determinants of health (e.g., housing, substance use, mental health), and motivational interviewing to support participants' health care empowerment and progression along the PrEP continuum.
41165689|NCT04218552|DRUG|AD209|PO, Once daily(QD), 8weeks
41165690|NCT04218552|DRUG|Amlodipine low|PO, Once daily(QD), 8weeks
41383311|NCT05144958|DEVICE|Hybrid- minimally invasive LAAO - LARIAT|LARIAT system consists of: A) endocardial magnet-tipped guidewire. It is placed inside the left atrial appendage through the introduction of a catheter into the femoral vein; B) epicardial magnet-tipped guidewire. It is placed on the outside of the left atrium through the atrial appendage puncture of the pericardium. Each wire has a magnet of opposite polarity enabling end-to-end alignment; C) A compliant occlusion balloon catheter to identify the LAA and allow for a very precise and effective seal of the left atrial appendage; D) The LARIAT suture delivery device. It is introduced by an earlier puncture of the pericardium in the vicinity of the left atrial appendage and guided over magnet wire onto the base of the LAAO. With the LARIAT suture delivery device, the lumen of the left atrial appendage is closed from outside the heart, resulting in the elimination of the thrombus source.
41383312|NCT04861415|RADIATION|Sterotactic Body Radiotherapy|Hypofractionated stereotactic radiation treatment.
41383313|NCT04861415|RADIATION|Conventionally Fractionated Radiation|External beam radiation therapy treatment
41383314|NCT06271798|OTHER|Life style modification advice|The lifestyle modification advice involves several key elements: reducing daily standing periods, avoiding excessive flexion of the knee joint during sitting, weight reduction, addressing cardio-respiratory conditions, incorporating venotonic agents, and utilizing below-knee elastic compression devices. These measures collectively aim to mitigate the development and progression of varicose veins, potentially preventing complications such as deep venous thrombosis and improving overall circulatory health.
41383315|NCT06271798|OTHER|Resistive exercise|Participants in group A will perform resistive exercise. The patients will be instructed to do seated toe raises exercise or standing toe raise exercise. The exercise will be performed for 30 minutes, three times per week for six weeks.
41383316|NCT06271798|OTHER|Aerobic exercises|Participants in group B will perform aerobic exercise. Each session will begin with 10 min of low-intensity treadmill walking for a warm-up. The subsequent aerobic component will involve incline treadmill walking for 20 min at a perceived exertion of 6-7 (i.e., somewhat hard) on Borg's 3-10 scale followed by 10 min of low-intensity treadmill walking for cool down. The exercise will be performed for 30 minutes, three times per week for six weeks.
41036454|NCT01059760|BEHAVIORAL|Fasting First|28±4 hours of water-only fasting followed by 28±4 hours fed
41165691|NCT04218552|DRUG|Amlodipine high|PO, Once daily(QD), 8weeks
41165692|NCT04218552|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
41165693|NCT06467214|BEHAVIORAL|CONNECTED|CONNECTED is a manualized, peer-led, group-based social isolation intervention for diverse veteran populations in VA primary care settings. It is delivered via videoconference through individual and group sessions over 8 weeks.
41165694|NCT06467214|BEHAVIORAL|VET BEFRIENDING|VET BEFRIENDING (attention control arm) consists of weekly social interactions with a research assistant (RA) over videoconference or phone.
41165695|NCT04239950|DRUG|Placebo|Placebo
41036455|NCT01059760|BEHAVIORAL|Fed First|28± 4 hours fed followed by 28± 4 hours of fasting
41036456|NCT01546896|DRUG|buspirone+alprazolam|day 1\~7: buspirone 10mg/d + alprazolam 0.5mg / day 8\~28: buspirone 20mg/d + alprazolam 0.5mg / day 29\~56: buspirone 20\~30mg/d + alprazolam 0.5mg
41036457|NCT01546896|DRUG|alprazolam|0.5mg/d
41165696|NCT04239950|DRUG|Ethyl Icosapentate|Ethyl Icosapentate
41165697|NCT06413277|DEVICE|Saluda Evoke Smart SCS System|Surgical implantation of the Saluda Evoke Smart SCS System targeting the conus medullaris for stimulation
40852969|NCT05704660|BEHAVIORAL|Cognitive-biased modification task|In the comparison group, instructions will be identical, but the percentage of physical activity and sedentary stimuli will be equal in each tilt condition (i.e., 50% sedentary stimuli and 50% physical activity stimuli in both right- and left-tilted rectangles)
40852970|NCT05620264|DIAGNOSTIC_TEST|Tear Sample Probe|Samples will be collected by conjunctival lavage of the affected eye without topical anesthesia. Sterile normal saline will be infused at room temperature into the lower conjunctival sac by gently pulling down the lower eyelid and with a needle-free insulin syringe. After few seconds, the lavage fluid will be aspirated back into the same syringe without the syringe touching the conjunctiva.
41165698|NCT05233098|DEVICE|Technetium-99m macroaggregated albumin (Tc-99m MAA)|Patients who are being evaluated for TheraSphere administration.
41383317|NCT01450150|DEVICE|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
41383318|NCT01450150|DEVICE|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
41383319|NCT03770481|BEHAVIORAL|nurse-led communication strategy|Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.
41383320|NCT03121560|DEVICE|Hysteroscopy|Hysteroscopy allows a direct visualization of the interior of the uterine cavity in order to invalidate or confirm the presence of uterine pathologies.In the pre-menopausal period, it is preferable to perform a hysteroscopy at the beginning of the follicular phase (just after the menstruations, when the endometrium is atrophic). Use of a rigid hysteroscope comprising a 2.9 mm optics and a 4.3 mm sheath with a 5 - bit operator channel allowing the realization of a biopsy.
41383321|NCT03121560|DEVICE|Hysterosonography|Hysterosonography (SIS) is an endovaginal ultrasound performed along with an injection of saline in order to observe the uterine cavity and detect any endometrial pathology. A 3D image can be associated with it to define the topography of a lesion. It is ideally performed in the first part of the cycle. Use of the GE Voluson E8 Ultrasound System.
41508880|NCT00994578|BEHAVIORAL|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
41036458|NCT01257867|DIETARY_SUPPLEMENT|Lithia water|Oral intake of approximately 2 litres (2L) daily for 4 weeks
41036459|NCT01257867|DIETARY_SUPPLEMENT|Natural spring water with negligible lithium levels|Oral intake of approximately 2 litres (2L) daily for 4 weeks
41036460|NCT05260801|OTHER|Bright Lighting|The bright lighting condition will administer the light intensity as determined from the finding of Study 1. Bright lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day.
41036461|NCT05260801|OTHER|Placebo Lighting|The placebo condition will expose participants to 150 lux, a light level that is equivalent to average room lighting. Placebo lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The placebo lighting condition will be applied to minimize the bias and false improvements that might occur due to experiencing new lighting conditions and devices.
41165699|NCT04270747|DRUG|ABP 938|Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
41165700|NCT04270747|DRUG|Aflibercept|Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
41165701|NCT00960505|OTHER|Alternate day fasting|
41165702|NCT00960505|OTHER|Calorie restriction|
41165703|NCT00960505|OTHER|Control diet|
41383322|NCT04375735|DRUG|Bovine Lipid Extract Surfactant|BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
41383323|NCT06538961|OTHER|Collection of blood samples|the collection of blood samples by finger stick, heel stick, ear stick, or venipuncture from individuals where the amount of blood does not exceed allowable amounts (see help).
41383324|NCT06538961|OTHER|Data Collection|Donor and Recipient's clinical information including clinical history, demographic characteristics labs, and imaging.
41383325|NCT06538961|OTHER|Urine Sample|Post-transplant monthly urine sample collection for 6 months
41383326|NCT04921189|DRUG|The combined supplement of Ascorbic acid, Thiamine, and Cortisol|"The combined administration of 3 drugs will be mixed in a 50 mL 0.9% saline bag respectively and administered through intravenous infusion over 60 min every 12 h for 3 days.~1. Ascorbic acid (Ascorbic acid Inj \[500mg\]®): 50 mg/kg, maximum single dose 3 g, daily dose 6 g~2. Thiamine (Thiamine hcl inj \[50mg\]®): 200 mg~3. Cortisol (Cortisolu inj \[100mg\]®): 100mg (The main exposure was corticosteroid therapy, defined as the use of systemic corticosteroids. But if unavailable, it could be converted to hydrocortisone-equivalent doses (methylprednisolone 1:5, dexamethasone 1:25, prednisolone 1:4).)"
41383327|NCT04921189|DRUG|Placebo|An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
41383328|NCT01341158|DRUG|human interferon-α|Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks
41383329|NCT00661960|DRUG|raltegravir|400mg tablet twice daily by mouth for nine months
41383330|NCT00661960|DRUG|efavirenz|600mg capsule once daily by mouth without regard to food
41383331|NCT06055894|DIETARY_SUPPLEMENT|Omega-3|For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily
41383332|NCT06055894|DIETARY_SUPPLEMENT|Curcumin|For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily
41383333|NCT06055894|DIETARY_SUPPLEMENT|Probiotic|For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily
41383334|NCT06055894|OTHER|Whole food, plant-based diet (WFPBD)|Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2).
41383335|NCT04483570|PROCEDURE|Redo-tethering operation|
41383336|NCT01408836|PROCEDURE|Plasma exchange|Plasma exchange
41383337|NCT01408836|DRUG|Intravenous methyl prednisolone|Intravenous methyl prednisolone
41383338|NCT01408836|DRUG|Methyl prednisolone|methyl prednisolone
41383339|NCT00391118|DRUG|enzastaurin|
41383340|NCT00391118|DRUG|carboplatin|
41383341|NCT00391118|DRUG|paclitaxel|
41383342|NCT00391118|DRUG|placebo|
41383343|NCT06567873|OTHER|Gastric Ultrasound Exam|A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
41508881|NCT04280640|OTHER|Blood Draw|A blood sample will be collected once, prior to treatment.
41165704|NCT00269997|DRUG|epoetin alfa|
41383344|NCT06384534|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
41383345|NCT06384534|OTHER|6-minute walk distance test with supplemental oxygen|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
41383346|NCT02015286|DEVICE|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
41508882|NCT01442688|DRUG|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
41383347|NCT04537052|PROCEDURE|Ven Restoration Therapy|This is a novel and promising method, applied percutaneously, in the treatment of deep venous insufficiency . In this method, developed based on the effects of compression garments, a polymer consisting of cyanoacrylate and hyaluronic acid is injected, with ultrasound-guidance, percutaneously around the femoral vein. In this way, the diameter of the vein is reduced, and function is restored to the inadequately functioning valve. The procedure is also called percutaneous valvuloplasty. The underlying idea in the development of this product was that hyaluronic acid might cause an increase in connective tissue, while cyanoacrylate could serve as an exoskeleton by forming heavy tissue.
41383348|NCT05276869|OTHER|WeeFIM instrument|In a formative setting, the WeeFIM tool examines functional independence in kids aged 6 months to 7 years old. It can also be used with children over the age of 7 who show functional ability. The instrument may be controlled by observational data or a meeting, and it takes 15 to 20 minutes to create \[10\].
41383349|NCT04501159|OTHER|blood sample pre, during and post HD|Assessment of ABG pre, during and post HD
41508883|NCT01442688|DRUG|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
41383350|NCT04501159|DEVICE|Non invasive cardiac output assessment|Four ECG style electrodes are placed on the thorax which indirectly measures cardiac output.
41508884|NCT02554162|OTHER|Rye products with varying structures|The satiating effect of rye products with various structures will be studied
41508885|NCT04698226|PROCEDURE|25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade|Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining and sulfur hexafluoride (SF6) tamponade
41508886|NCT04698226|PROCEDURE|25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade|"Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole."
41508887|NCT05188677|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
41508888|NCT05188677|BIOLOGICAL|Comirnaty Vaccine|intramuscular injection
41508889|NCT05188677|BIOLOGICAL|Vaxzevria Vaccine|intramuscular injection
41508890|NCT05188677|BIOLOGICAL|CoronaVac Vaccine|intramuscular injection
41508891|NCT04778475|OTHER|Intensive therapy|PT services twice a day for 3-5 days and then daily for the remainder of hospital stay
41508892|NCT04778475|OTHER|Standard of care therapy|PT services 3-5 times a week for 15 to 30 minutes
41508893|NCT03000478|BEHAVIORAL|Prolonged Exposure|
41508894|NCT03000478|BEHAVIORAL|Virtual Reality Exposure Therapy|
41383351|NCT06568588|DRUG|S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745|250 mg three times a day for 4 months
41383352|NCT06179290|OTHER|Ploom HTP Menthol HTS; MX3 (681)|Menthol heated tobacco product
41383353|NCT06179290|OTHER|Ploom HTP Tobacco HTS; R8 (120)|Non-menthol heated tobacco product
41383354|NCT06179290|OTHER|Smoking Abstinence (menthol)|No smoking or other tobacco product use for duration of the study, menthol group comparator
41383355|NCT06179290|OTHER|Smoking Abstinence (non-menthol)|No smoking or other tobacco product use for duration of the study, non-menthol group comparator
41508895|NCT01105871|DRUG|naloxone|4 mg naloxone in 10 ml saline given iv bolus
41508896|NCT01105871|DRUG|Placebo|10 ml of normal saline iv bolus
41508897|NCT03353012|DRUG|Etonogestrel Drug Implant|Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.
41508898|NCT03353012|DRUG|Levonorgestrel Drug Implant|Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
40852971|NCT02709603|DRUG|hyoscine butyl bromide|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
40852972|NCT02709603|DRUG|placebo|oral placebo; 2 tablets 30 minutes before the procedure
41383356|NCT04475536|DEVICE|TANSEI stent|stenting with the TANSEI sirolimus-eluting stent
41383357|NCT05859126|DIETARY_SUPPLEMENT|Maternal Choline Supplementation 930 mg/d|Mothers were supplemented with choline (930mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
41508899|NCT05167097|OTHER|ASSIST-linked Brief Intervention|WHO's ASSIST-linked Brief Intervention (with and without Steps 6-9, the decisional balance element)
41508900|NCT05167097|OTHER|Mindset Intervention|Standard mindset manipulation as used in research by Peter M. Gollwitzer and colleagues
41508901|NCT02022878|PROCEDURE|PCI of CTO|
41508902|NCT01412086|DRUG|No Intervention|No Intervention.
40852973|NCT00793130|DIETARY_SUPPLEMENT|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
40852974|NCT00996255|DRUG|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
40852975|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
40852976|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
40852977|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
41383358|NCT05859126|DIETARY_SUPPLEMENT|Maternal Choline Supplementation 480 mg/d|Mothers were supplemented with choline (480 mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
41383359|NCT02689986|DRUG|Bendamustine, Rituximab|Bendamustine, Rituximab
41508903|NCT03302676|DIETARY_SUPPLEMENT|Chewing gum|
41508904|NCT05011604|DEVICE|Full-Digital Workflow in Single-Tooth Implant Rehabilitation|"For all patients included in the study, a digital impression was taken using an intraoral scanner. A CBCT exam was performed on the mandibular or maxillary jaw with the missing tooth. The stl. and the dicom. files were then superimposed to allow the surgical planning.~Then it was elevated and reflected to increase the volume on the buccal side and exposed the bone surface. After this point, the implant was inserted, and another digital impression was taken.~Sutures 6.0 were positioned after healing abutment positioning to stabilize the soft tissues.~The final abutment and the provisional were designed and manufactured using cad-cam technology. One week thereafter, definitive abutment was positioned. Provisional restoration was then cemented using provisional cement removing all the possible occlusal contacts both in protrusive and in lateral positions. Three months thereafter, once osteointegration was obtained, definitive zirconia restoration was positioned and cemented."
41508905|NCT04359797|OTHER|Prone|Provider-recommended guidance on prone positioning of patients
41508906|NCT04359797|OTHER|Usual Care|No provider-recommendation, patients will remain in their natural choice of position
41508907|NCT02048332|BIOLOGICAL|Viral specific VST Infusion|"VSTs will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the below:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \>1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~* Evidence of PML or other CNS infection due to JC virus."
41508908|NCT01749423|BIOLOGICAL|OnabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
41508909|NCT02885766|DRUG|PF-114|
41508910|NCT00115453|RADIATION|irradiation|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
41036462|NCT05653466|BEHAVIORAL|Adaptive Spacing Condition|"Each of the 200 target words for practice are presented on a schedule determined by an algorithm that relies on the pattern of correct vs. incorrect responses for each item. Items in the active learning state need to be answered correctly a certain number of times before being categorized as learned. Each item must be answered correctly 3 times in a row (immediately, then at one-minute and five-minute intervals) before it is categorized as learned. Then, it will be scheduled at ever-increasing intervals, until answered incorrectly, at which point the item would be returned to the active learning state, requiring three correct responses in a row to return again to the learned expanding interval state."
41383360|NCT05519267|BEHAVIORAL|MBSWSC|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory (Maddock et al. 2019a). This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
41383361|NCT05519267|BEHAVIORAL|MBSC|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
41383362|NCT05656430|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
41383363|NCT00916617|DRUG|bapineuzumab|5 mg/week subcutaneous bapineuzumab
41383364|NCT05759988|DEVICE|Outpatient Foley catheter|Outpatient Foley catheter placement for induction of labor
41383365|NCT05722938|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
41383366|NCT05722938|DRUG|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
41383367|NCT04622540|PROCEDURE|External biliary drainage|Application of external biliary drainage through duct-to-duct anastomosis
41383368|NCT06458023|DEVICE|TetraGraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
41383369|NCT05302700|BEHAVIORAL|Early Parental Sensitivity Intervention|Parental sensitivity intervention include (1)Establish an emotional connection：Using the VR tour to introduce the environment, instruments and equipment of the neonatal intensive care unit, appearance of premature infants and pipeline wires on their bodies .(2)maintain physical proximity:proactively provide mothers with the opportunity to touch the body of preterm infants.(3) parents must understand their infant's cues:Using the Premature Infant Behavioral Clues Teaching Materials to play video and we will discuss and respond to the mother's questions.(4)engage in his/her care and communicate appropriately with him/her:We will discuss the behavioral clues of the preterm infant with the mother next to the incubator, encourage the mother to ask questions and participate in care activities such as changing diapers and stamping the baby's footprints on the card, asking the mother to write down the number of days of birth, corrected age, weight and what she wants to say for her baby.
40852978|NCT00973323|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
40852979|NCT04484701|DRUG|68Ga-PSMA-11|PET/CT scan with radiotracer 68Ga-PSMA-11
40852980|NCT01588600|OTHER|Dietary Fiber|Fiber added to breakfast
41036463|NCT05653466|BEHAVIORAL|High-Item Non-Adaptive Spacing Condition|Each of the 200 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
41383370|NCT06224764|OTHER|Mother and Father questionnaires|Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
41508911|NCT04198857|BEHAVIORAL|Develop a mobile app that supports self- management and treatment for Nepalese GDM patients|We will use a user-centered design approach to develop a mobile app for GDM (GDM-DH) that matches the needs and technological sophistication of the target users. The goal of the app would be to assist patients in self management of GDM by improving their adherence to the recommended diet and physical activity regimens. The app will be used to collect information such as the carbohydrate consumption, the daily activity status and blood glucose and blood pressure measurements taken at home by the patients. The app will be set up in the phone of the participants and their data will be collected. The participants will be able to assess the usability and feasibility of the app. The app will also help clinicians by generating easily digestible visual displays of patient data and behaviors, which can aid in their clinical decision-making and counseling.
41383371|NCT05864287|BEHAVIORAL|Bodies in motion intervention program|Intervention groups will be offered separately to male- and female-identifying athletes; each group will consist of six to eight athletes and multiple groups may be run each academic term. Facilitators will use the gender-specific programs in their delivery. Intervention athletes will receive a participant workbook as well as be invited to join a BIM-specific, private social media platform that will allow them to share, connect, and support each other through out their involvement in the program. As part of our mixed-methods design, we will also conduct qualitative interviews to explore the student athletes' experiences of the BIM program. Following intervention, we will invite 12-16 male and 12-16 female identifying athletes who completed the BIM program to participate in the structured interviews. Interviews will be semi-structured and are expected to last 60-90 minutes
41383372|NCT02803138|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
41383373|NCT02803138|DRUG|Dasabuvir|Tablet
41383374|NCT02803138|DRUG|Ribavirin|Tablet
41383375|NCT02803138|BEHAVIORAL|Patient support program|Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
41383376|NCT05477940|DEVICE|Absorbable zinc alloy drug eluting coronary stent system|"Absorbable zinc alloy drug eluting coronary stent system (hereinafter referred to as stent system) consists of delivery system and drug stent (hereinafter referred to as stent) pressed on the balloon end of the delivery system"
41383377|NCT06566924|OTHER|Control|Students in the control group were taken to the laboratory practice within one week after the training presentation. Students were expected to act in accordance with the skills of isolation precautions in line with the 'Sample Scenario'.
41383378|NCT06566924|OTHER|Training Group for Standardised Patient Simulation|One week after the training presentation, the experimental group was invited to the simulation training. Simulation training was carried out in a hospital environment. Materials to be used in standardised patient and isolated patient care were made availa
41383379|NCT04222478|OTHER|Specific auriculotherapy|"3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals."
41383380|NCT04222478|OTHER|Non-specific auriculotherapy|3 sessions of auriculotherapy with semi-permanent needles on non-specific points.
41383381|NCT04382599|BEHAVIORAL|Text warning with square background|The warning message is in white text on a black square background
41383382|NCT04382599|BEHAVIORAL|Text warning with octagon background|The warning message is in white text on a black octagon background
41508912|NCT06471855|DEVICE|Multidisciplinary Conventional and Technology-based Rehabilitation|Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. According to their individualized rehabilitation project, patients will undergo non-immersive VR-based rehabilitation. VR-based rehabilitation will consist of one daily session (3 weeks) and will be conducted by the implementation of a single non-immersive VR device among the D-WallTM (TechnoBody SRL, Italy), the Walker ViewTM (TechnoBody SRL, Italy). Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants.
41508913|NCT06471855|OTHER|Multidisciplinary Conventional Rehabilitation|Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to the patient's medical diagnosis, disability severity, and to consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
41383383|NCT04382599|BEHAVIORAL|Icon warning|The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
41383384|NCT04382599|BEHAVIORAL|Graphic warning|The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
41383385|NCT04182386|PROCEDURE|Portal vein embolization|Selective preoperative portal vein embolization
41383386|NCT04911075|DRUG|85% TCA Solution|"* TCA is an acetic acid analogue solution (CCl3COOH) which is formed from the reaction of acetic acid (CH3COOH) with chlorine (3Cl2).~* High concentrations (85 percent) of this solution can penetrate deeply into the epidermis-dermis layer and cause cells necrosis.~* This solution (1-2 milliliter) will be applied to participants cervical tissue (ectocervix and endocervix) using cotton swab for 1-3 minutes."
41383387|NCT02263222|DRUG|MDT-10013|
41383388|NCT04464200|DRUG|19(T2)28z1xx CAR T cells|2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.
41383389|NCT03666819|DEVICE|Carbon Dioxide Fractional Laser|Undergo CO2RE laser therapy
41383390|NCT03666819|OTHER|Questionnaire Administration|Ancillary studies
41383391|NCT06277466|DRUG|Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs|Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.
41383392|NCT06277466|DRUG|Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs|"The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.~In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing."
41383393|NCT00038467|DRUG|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
41508914|NCT04642365|DRUG|RO7296682|RO7296682 will be administered as per the schedules specified in the respective arms.
41508915|NCT04642365|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
41508916|NCT05101668|DEVICE|Intracranial Thrombosis Aspiration Catheter|Direct Aspiration
41508917|NCT02754765|DRUG|Bedaquiline|
41508918|NCT02754765|DRUG|Delamanid|
41383394|NCT00038467|DRUG|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
41383395|NCT05589649|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block
41383396|NCT05589649|PROCEDURE|Paravertebral block|Ultrasound-guided paravertebral block
41383397|NCT04736316|BEHAVIORAL|Early CCLAD|Community-based client led antiretroviral therapy delivery groups.
41383398|NCT05907044|BIOLOGICAL|RQ3013|0.15mL/dose containing mRNA 30μg
41383399|NCT05907044|BIOLOGICAL|RQ3025|0.15mL/dose containing mRNA 30μg
41383400|NCT05907044|BIOLOGICAL|RQ3027|0.15mL/dose containing mRNA 30μg
41383401|NCT06565377|BEHAVIORAL|Multimodal biopsychosocial teleprehabilitation|"Multimodal biopsychosocial teleprehabilitation containing (pain science and lifestyle) education, stress management and physical activity promotion, guided by shared decision making, motivational interviewing and solution focused therapy principles.~Format: 4 preoperative and 1 postoperative one-on-one (tele-)conferencing sessions with a physical therapist, supplemented by an informational booklet."
41383402|NCT06565377|OTHER|Best-evidence prehabilitation advice|Best-evidence prehabilitation advice in accordance with the NICE guideline on Joint Replacement (Primary): hip, knee and shoulder (2020), by means of an informational booklet.
41383403|NCT01017731|BIOLOGICAL|IMC-1121B|IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
41508919|NCT02754765|DRUG|Clofazimine|
41508920|NCT02754765|DRUG|Levofloxacin|
41508921|NCT02754765|DRUG|Moxifloxacin|
41508922|NCT02754765|DRUG|Linezolid|
41508923|NCT02754765|DRUG|Pyrazinamide|
41508924|NCT02754765|DRUG|Control arm MDR-TB regimen, consistent with WHO guidelines|Control arm MDR-TB regimen, consistent WHO guidelines
41508925|NCT00562783|DRUG|Vitaliver|
41508926|NCT00562783|DRUG|Placebo|
41508927|NCT04464070|DIETARY_SUPPLEMENT|niacin|induce biosynthesis of PGD2
41508928|NCT04464070|DRUG|aspirin|inhibition of cyclooxygenase
41508929|NCT04464070|OTHER|PGD2|labeled precursor
41383404|NCT01017731|DRUG|Moxifloxacin|Administered orally
41383405|NCT01017731|DRUG|Diphenhydramine|Administered IV
41508930|NCT01561846|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
40852981|NCT01428739|DEVICE|MRS|Procedure
40852982|NCT00310817|BIOLOGICAL|MenACWY-CRM conjugate vaccine, adjuvanted|
40852983|NCT00310817|BIOLOGICAL|MenACWY polysaccharide vaccine|
40852984|NCT00310817|BIOLOGICAL|MenACWY-CRM conjugate vaccine, unadjuvanted|
41383406|NCT03896373|OTHER|Blood samples|Blood samples
41508931|NCT01561846|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
41508932|NCT03619265|DIETARY_SUPPLEMENT|Prickly pear juice|3 ounces daily for 8 weeks.
41508933|NCT03619265|DIETARY_SUPPLEMENT|Pear-flavored juice|3 ounces daily for 8 weeks.
41508934|NCT06251089|DRUG|CPC mouthwash|0.07% CPC mouthwash
41508935|NCT06251089|DRUG|Placebo|placebo of the CPC mouthwash
41383407|NCT01177735|DRUG|Pomalidomide|Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
41383408|NCT06282029|BEHAVIORAL|Group Therapy|Acceptance and Commitment Therapy based group therapy
41383409|NCT01456598|PROCEDURE|Laparoscopic gastrectomy|"* After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~* As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
41383410|NCT01456598|PROCEDURE|Open gastrectomy|"* After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
41508936|NCT02982837|DRUG|PEG-IFN & Nucleos(t)tide analogues|Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
41508937|NCT02982837|DRUG|Nucleos(t)tide analogues|Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
40852985|NCT03308253|DEVICE|Stimulan Rapid Cure|Calcium sulfate dissolvable beads
40852986|NCT03308253|DRUG|Vancomycin|0.5 g Vancomycin per patient
40852987|NCT03308253|DRUG|Tobramycin|120 mg tobramycin per patient
40852988|NCT03308253|OTHER|Standard of Care|Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.
40852989|NCT06407297|DRUG|UCMSCs|Peripheral intravenous infusion of umbilical cord mesenchymal stem cells
40852990|NCT06407297|DRUG|Placebo|Peripheral intravenous infusion of Placebo
40852991|NCT00781833|DEVICE|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
40852992|NCT03540199|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
41383411|NCT05563142|PROCEDURE|deploying vascular closure device versus manual compression|patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
40852993|NCT03540199|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
41383412|NCT00696059|DRUG|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
41383413|NCT00530088|DRUG|porfimer sodium|IV
41383414|NCT00530088|DRUG|Photdynamic Therapy (PDT)|
41383415|NCT05937230|DEVICE|Drug-coated balloon|Paclitaxel is a pharmacologically active substance for anti-neointima.
41383416|NCT05937230|DEVICE|Drug-eluting stents|Drug-eluting stent is composed of a metal stent, primer, and drug coating.
41508938|NCT01954862|OTHER|Air Insufflation method.|Air Insufflation method.
41508939|NCT01954862|OTHER|CO2 insufflation|CO2 insufflation.
41508940|NCT01954862|OTHER|Water Immersion/CO2|Water Immersion during insertion, CO2 insufflation during withdrawal.
41508941|NCT01954862|OTHER|Water Exchange/CO2|Water Exchange during insertion, CO2 insufflation during withdrawal.
41508942|NCT01954862|OTHER|Water Immersion/AI|Water Immersion during insertion, AI insufflation during withdrawal.
41036464|NCT05653466|BEHAVIORAL|Low-Item Non-Adaptive Spacing Condition|Each of the 40 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
41383417|NCT05603819|DEVICE|EDIT-B|To perform EDIT-B test, questionnaires and 2x0.5 mL whole blood are collected from each patient.
41383418|NCT05664841|BEHAVIORAL|magic trick training|A typical session will begin with the magician demonstrating a magic trick then revealing the secret move of the trick.The participants will learn and practice each trick. With assistance from the magician, participants will develop an oralstory presentation for the trick. After participants master one trick, the magician will demonstrate and teach the next.
41383419|NCT04592731|DRUG|Gel containing Acetylated Natural Nucleotides|The study drug is a gel containing acetylated natural nucleotides.
41383420|NCT04592731|DRUG|Vehicle Gel|The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
41383421|NCT06565689|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
41383422|NCT03777800|BEHAVIORAL|Body therapy|"Body therapy involving direct physical treatments, conversations, breathing exercises and relaxation in the sessions. Moreover, the participants are taught how to practice vipassana or awareness meditation every day at home.~The body therapist works directly with the muscle armour and the treatment sessions have focus on creating a safe environment and enabling cognitive realisation and awareness of symptoms.~Each participant is assigned a practitioner who acts as contact person and 'lifeline'. Furthermore, a coordinator is assigned in ManuVision who will also act as contact person when needed for the veterans. This provides peace of mind, trust, and ensures retention. The coordinator or the practitioner follows up on the veteran's progress prior to each session."
41383423|NCT03777800|BEHAVIORAL|Treatment as usual|Standard treatment
41036465|NCT06635330|BIOLOGICAL|anti-CD19 CAR T cell therapy|Anti-CD19 CAR-T cell therapy for R/R B-ALL pediatric patients. For patients 50 kg and less: 0.2 to 5 in ten to the power of six live CAR+ T cells per kilogram of body weight/ For patients over 50 kg: 0.1 to 2.5 in ten to the power of eight live CAR+ T cells (without considering weight).
41383424|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
41383425|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
41383426|NCT01152931|DRUG|Lumefantrine + Artemether|Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
41383427|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A|Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
41383428|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin E|Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
41383429|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Zinc|Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
41383430|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + selenium|Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
41383431|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + vitamin A|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
41036466|NCT05734508|BIOLOGICAL|MVA-BN vaccine|A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus
41036467|NCT00077025|DRUG|Gefitinib|ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
41036468|NCT00077025|DRUG|Anastrozole|1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
41036469|NCT01556438|BIOLOGICAL|Tabalumab|Administered IV
41036470|NCT01556438|DRUG|Bortezomib IV|Administered IV
41036471|NCT01556438|DRUG|Bortezomib SC|Administered SC
41036472|NCT01556438|DRUG|Dexamethasone|Administered orally
41036473|NCT04985591|PROCEDURE|Liposuction|A small, inconspicuous incision was made in the liposuction group to dislodge fat out of the body.
41036474|NCT04985591|PROCEDURE|Other plastic surgery|Other plastic surgery like blepharoplasty or keloid excision.
41036475|NCT01823718|BIOLOGICAL|Injection of allogenic CTL EBV specific|
41036476|NCT01491854|OTHER|Bloodsampling|Bloodsampling
41036477|NCT03131557|DEVICE|Line extension of the Phonak Audéo B product family|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
41036478|NCT03131557|DEVICE|Phonak Audéo B|Phonak Audéo B will be fitted to the participants individual hearing loss.
41036479|NCT02977624|BEHAVIORAL|The Cognitive Orientation to daily Occupational Performance|
41036480|NCT00454558|DRUG|Riociguat (Adempas, BAY63-2521)|Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
41036481|NCT04722913|DIAGNOSTIC_TEST|Photogrametry , flexion rotation (FRT) test, Diagnosis of CGH according diagnostic criteria of the Cervicogenic Headache International Study Group (CHISG)|"Photogrammetry is the science and technology of obtaining reliable information about physical objects and the environment through the process of recording, measuring and interpreting photographic images and patterns of electromagnetic radiant imagery and other phenomena.~Flexion rotation (FRT) test:~FRT is a manual examination technique with high sensitivity and specificity. It is performed with the patient in supine by passively taking the cervical spine into full flexion. End-range cervical flexion imparts ligamentous tension that impedes movement at vertebral segments below C2.7 Maintaining the flexion position, the patient's head is then rotated to each side until the patient reports pain or the operator determines that end of motion has been achieved. It is then determined if a restriction in ROM is present."
41036482|NCT02828111|DRUG|Patidegib|
41036483|NCT02828111|DRUG|Vehicle gel|
41036484|NCT06286800|DEVICE|Transcranial direct current stimulation (tDCS) with OT|Weak direct current (0.5-2 mA) will be delivered for up to 20 minutes through surface electrodes which will be positioned using the ptDCS montage. The current will be increased and decreased ramp-like at the beginning and end of the 20-minute stimulation to lessen the itchy/numb skin sensation and decrease the likelihood of an innocuous phosphene-like visual phenomenon. The stimulation will be delivered during the first 20 minutes of occupational therapy targeted to the more affected upper extremity.
41036485|NCT06286800|DEVICE|Sham tDCS with OT|Same procedure and montage as with the active stimulation but the current will be increased then decreased ramp-like and switched off after 20 seconds instead of the 20 minutes to elicit the same cutaneous sensation as the other stimulation conditions. \[69\] This short length of stimulation is documented to elicit sensations comparable to those of real stimulation. With this procedure, subjects were unable to differentiate between tDCS and sham stimulation in our and other previous studies.
41165705|NCT06153498|DRUG|Remimazolam besylate|After a loading dose of 0.05mg/kg, a maintaining dose of 0.2mg/kg/h is given; It is recommended to adjust the infusion rate of Remazolam besylate for injection at a amplitude of 0.05mg/kg/h, mainly based on the RASS score of the subjects (the adjustment range is 0-1.0 mg/kg/h, and the maximum infusion rate is not more than 1.0mg/kg/h) until the subjects reach the optimal sedation level (-3≤RASS≤0).
41383432|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Vitamin E|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
41508943|NCT01954862|OTHER|Water Exchange/AI|Water Exchange during insertion, AI insufflation during withdrawal.
41036486|NCT03929146|DRUG|Exparel|Patients will receive a local injection of liposomal bupivacaine near the end of their shoulder arthroplasty operation.
41383433|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Zinc|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
41508944|NCT05397678|BIOLOGICAL|BCG-Denmark|AJ vaccines, Copenhagen 1331 strain
41508945|NCT05397678|BIOLOGICAL|BCG-Bulgaria|BB-NCIPD Ltd., BCG-SL 222 Sofia strain
41508946|NCT03478722|OTHER|Protein Meal|Ingestion of mixed meal containing 20 g of dietary protein
41508947|NCT03478722|OTHER|Stable Isotope Amino Acid Infusion|Continuous infusion of L-\[1-13C\]leucine (0.13 μmol⋅kg⋅min) and L-\[ring- 2H5\]phenylalanine (0.05 μmol⋅kg⋅min)
41508948|NCT03070587|BEHAVIORAL|Positive Affect Training for SAD|The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
41508949|NCT00237978|DRUG|Adapalen|
41508950|NCT00237978|RADIATION|VIS and wIRA|
41508951|NCT05089669|OTHER|Interactive e-book|The nasogastric tube feeding interactive e-book has a lot of elements such as text content, videos, pictures, links, and other interactive content with which the students can interact. The participants can use the interactive e-book to learn nasogastric tube feeding.
41508952|NCT05089669|OTHER|paper textbook|The paper textbook has text content and pictures. The participants can use the paper textbook to learn nasogastric tube feeding.
41036487|NCT03929146|PROCEDURE|Interscalene Nerve Block|Patients will undergo a pre-operative interscalene nerve block performed by the anesthesiology team.
41036488|NCT00007189|DRUG|Naproxen Sodium (Aleve)|
41036489|NCT00007189|DRUG|Celecoxib (Celebrex)|
41383434|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Selenium|Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if \> 1year. 50ug daily for 4 days if \< 1 year.
41383435|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A + vitamin E|Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if \< 1 year. 10,000 IU orally daily for 4 days if \> 1 year.
41383436|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if \< 1 year. 10,000IU daily for 4 days if \> 1 year. All administered orally.
41383437|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Selenium|Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if \< 1 year. 10,000IU orally daily for 4 days if \> 1 year.
41383438|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if \> 1 year. 50 ug orally daily for 4 days if \< 1 year.
41383439|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Zinc|Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if \< 1 year. 25 mg orally daily for 4 days if \> 1 year.
41383440|NCT00288782|DRUG|Mirtazapine|
41383441|NCT06068088|BEHAVIORAL|Self-administered survey at hospital|Self-administered survey on the food practices of the patient Completion before the beginning of chemoradiotherapy
41383442|NCT06068088|BIOLOGICAL|Blood sample for nutritional assessment|15 ml of blood sampled during nutritional examination before the beginning and during the month following the end of chemoradiotherapy
41383443|NCT06068088|OTHER|Consultation with nutritionist doctor and dietician|Before the beginning and during the month following the end of chemoradiotherapy Consultation of approximatively one hour
41383444|NCT04962815|DEVICE|Electroencephalogram (EEG) Test|EEG test and delirium assessments will be performed on subjects experiencing delirium in the ICU.
41383593|NCT06314009|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a functional Magnetic Resonance Imaging (fMRI) using arterial spin labeling (ASL) and other Magnetic Resonance (MR) sequences
41508953|NCT01499446|DRUG|GW685698X (fluticasone furoate) 100mcg Morning|GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
41508954|NCT01499446|DRUG|GW685698X (fluticasone furoate) 100mcg Evening|GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
41508955|NCT01499446|DRUG|GW685698X (fluticasone furoate) 250mcg Evening|GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
41508956|NCT01499446|DRUG|Placebo|Placebo inhaled twice daily (morning and evening) for 28 days
41508957|NCT01045668|PROCEDURE|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT
41508958|NCT01045668|PROCEDURE|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT as well as VT substrates
41508959|NCT03655314|OTHER|NEWT|The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
40852994|NCT06384755|BEHAVIORAL|Honest Open Proud program|The HOP program involves peer facilitated sessions, in which different stigma and disclosure related topics are introduced to the group, relevant tasks are completed individually, followed by group or two-and-two discussions related to the following topics: week 1 = pros and cons with disclosure, week 2 = different ways of disclosing, week 3 = formulating individual decisions of disclosure, week 6 = evaluating disclosure or non-disclosure in practice.
41036490|NCT03288116|DIAGNOSTIC_TEST|Scheimplug imaging and contrast and sensitivity test|examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
41036491|NCT06307626|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
41036492|NCT06307626|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
41036493|NCT03146520|DEVICE|EarlyTect Colon Cancer|SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit
41383445|NCT06563128|OTHER|Clearfil Majesty Posterior|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
41383446|NCT06563128|OTHER|Omnichroma Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
41383447|NCT06563128|OTHER|Zen Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
41383448|NCT06563128|OTHER|Vittra Aps Unique Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
41383449|NCT06563128|OTHER|Charisma Diamond Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
41383450|NCT03320031|DRUG|Linagliptin|Take linagliptin 5mg a day.
41383451|NCT03320031|DRUG|Humalog Mix 75/25|Administer subcutaneous premixed insulin twice a day.
41383452|NCT03906565|DRUG|utidelone injection|utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
41383453|NCT02207465|RADIATION|Radiotherapy|
41383454|NCT02207465|DRUG|Abraxane|Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane
41383455|NCT04061655|DRUG|Iron Isomaltoside 1000|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
41508960|NCT03655314|OTHER|Usual care|The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
41508961|NCT05880602|DIETARY_SUPPLEMENT|Nettle and Cranberry complex capsules|A specific capsule product, containing nettle and cranberry complex will be given to participants for oral intake for 8 weeks.
40852995|NCT01179152|DRUG|Budesonide turbuhaler, Budesonide+Formoterol turbuhaler|Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
40852996|NCT00869518|DRUG|rifabutin plus trimethoprim sulfamethoxazole|rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
41383456|NCT04061655|OTHER|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
41383457|NCT01031225|DRUG|STA 9090|STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
41383458|NCT02502565|OTHER|Uric acid level|
41383459|NCT00289939|BEHAVIORAL|Motivational interviewing to reduce risk for HIV and DV|
40852997|NCT00869518|DRUG|placebo plus trimethoprim-sulfamethoxazole|placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
41383460|NCT06110767|DEVICE|non-immersive virtual reality|Non-Immersive Virtual Reality Based Physical Activity Application: Application will be carried out 3 days a week, 30 minutes a day, for 4 weeks. Kinect Adventures and Kinect Sports game packages will be used using the Microsoft Kinect Xbox 360 game console. It is planned that the participants will engage in physical activity with these game packages.
41383594|NCT00057330|BIOLOGICAL|HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
41508962|NCT05880602|DIETARY_SUPPLEMENT|Placebo(starch)|A specific capsule product, containing starch will be given to participants for oral intake for 8 weeks.
40852998|NCT04137458|BIOLOGICAL|Biological analysis|Blood and salivary samples will be taken at inclusion and a psychiatric assessment will be carried out
40852999|NCT02644577|DRUG|Metformin|
40853000|NCT02644577|OTHER|Starch|
40853001|NCT00934128|DEVICE|Vapotherm|Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
41383461|NCT06110767|BEHAVIORAL|Healty Diet Programme|Healthy nutrition program: It will be implemented for 4 weeks.Healthy Nutrition Program: Türkiye Ministry of Health nutrition program will be prepared based on the recommendations of the Turkey Nutrition Guide published by the Ministry of Health in 2016 (TÜBER-2016). A personalized healthy nutrition program will be created in line with this guide, taking into account the age, gender and physical activity status of healthy individuals.
41383462|NCT06568874|COMBINATION_PRODUCT|Virtual Reality (VR) Therapy|"Intervention: Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
41383463|NCT06568874|DIAGNOSTIC_TEST|Conservative Treatment|"Intervention: Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
41383464|NCT01213004|PROCEDURE|respiration correlated CT scan|Thoracic malignancies (study group 1): Patients to be treated for gastro-esophageal junction (GEJ) malignancy undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation, which are used to correct patient position at treatment. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. In cases of GEJ malignancy, oral contrast is administered prior to the standard CT scan; this is done at the treating physician's discretion. The standard CT is used to design the radiation treatment plan, where as the RCCT is used to define a volume that encompasses the motion extent of the tumor with breathing and is transferred to the standard CT.
41383465|NCT01213004|PROCEDURE|respiration correlated CT scan|Abdominal malignancies (study group 2): Patients undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. Intravenous contrast is administered prior to the standard CT; this is done at the treating physician's discretion.
41383466|NCT04995510|OTHER|Observational|To evaluate your chronic obstructive pulmonary disease with Chronic Obstructive Pulmonary Disease assessment test, respiratory muscle strength with intraoral pressure measurement device, respiratory muscle endurance with increasing threshold load respiratory muscle endurance test, diaphragm thickness with ultrasound device, cardiorespiratory fitness with 6 Minute Walk Test, flexibility trunk lateral flexion test , back scratch test and sit and lie down test, muscle strength and endurance will be evaluated with push-up test, sit-up test, sit and stand test and hand grip strength, body composition will be evaluated by bioelectrical impedance analysis, physical activity will be questioned with the International Physical Activity Assessment Questionnaire, shortness of breath with the Mmrc Dyspnea Scale, and perception of fatigue and shortness of breath with the Modified Borg Scale.
41383467|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo HF-WBI
41383468|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo CF-WBI
41383469|NCT01266642|RADIATION|Hypofractionated Radiation Therapy|Undergo HF-WBI
41383470|NCT01266642|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
41383471|NCT01266642|OTHER|Quality-of-Life Assessment|Ancillary studies
41383472|NCT01266642|OTHER|Questionnaire Administration|Ancillary studies
41383473|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo HF-WBI
41383474|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo CF-WBI
40853002|NCT00934128|DEVICE|BIPAP|Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
40853003|NCT02596789|DEVICE|"TMS Magpro®, Magventure Inc device"|
40853004|NCT04680975|DRUG|Belumosudil|10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks
40853005|NCT00656864|DRUG|Pioglitazone|Starting dose at 15 mg for two weeks, then titrated up to 45 mg in the subsequent 2 weeks.
40853006|NCT00656864|DRUG|Placebo|placebo
41383475|NCT00380458|DEVICE|Coblation (radiofrequency-based device)|
41383476|NCT05026879|BIOLOGICAL|Inactivated COVID-19 vaccine (CoronaVac)|The adverse events due to an inactivated COVID-19 vaccine.
41383477|NCT02428491|BIOLOGICAL|Hexaxim®|DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
41383478|NCT03531684|DIETARY_SUPPLEMENT|MMFS-205-SR|Twice daily, oral, 500 mg tablets
41383479|NCT03531684|DIETARY_SUPPLEMENT|Placebo|Twice daily, oral
40853007|NCT02474407|DRUG|diazepam nasal spray|
40853008|NCT02474407|DRUG|diazepam rectal gel|
41036494|NCT01694303|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
41165706|NCT04107077|DRUG|Cisplatin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 200mg of Cisplatin
41036495|NCT04156308|OTHER|Osteopathic Manipulative Treatment (OMT) - Temp1|A total of 3 techniques selected from a list of 7 available techniques common to all centers will be applied in each session. The choice of techniques will be based on the results of the examination performed, the particularities of the patient and the clinical experience of the osteopath. In each session the techniques can change under the criteria of the osteopath. However, they will always be 3 and always within the list of available techniques.
41383480|NCT05465122|PROCEDURE|Carotid Endarterectomy|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
41383481|NCT05465122|PROCEDURE|FDA-approved carotid stents|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
41383482|NCT05465122|OTHER|Intensive Medical Management|INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
41383483|NCT01098058|OTHER|CBT plus treatment as usual|16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
41383484|NCT01098058|OTHER|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
41383485|NCT06347549|DIAGNOSTIC_TEST|Various intensities of inspiratory muscle training|"Each participant will be instructed to use a pressure threshold inspiratory loading device to perform, in random order, 10 breaths at an inspiratory intensity of 30%, 40%, 50%, 60%, 70%, and 80% of their maximum inspiratory pressure (MIP). A rest period of 15 minutes will be allowed between each inspiratory pressure set of 10 breaths. Simultaneous surface electromyographic (sEMG) recording of the right sternocleidomastoid muscle and ultrasound of right diaphragmatic thickness will be conducted during each breath.~The entire recording procedure will be repeated on a separate day. During the repeat measurements, participants will be provided with specific breathing instruction to focus on the use of the diaphragm and to inhale air to the lower part of the chest."
41383486|NCT02204449|BEHAVIORAL|Cardiac Rehabilitation Peer Mentorship|
41508963|NCT05689502|DEVICE|Treatment|Subjects will participate in 6 hours of therapy a day, 5 days a week, for 3 consecutive weeks. These sessions will include 2 hours of occupational therapy, 2 hours of physical therapy, and 2 hours of guided individual work. Some of these sessions will be in a group setting. The therapy sessions will be individualized to the subject's personal goals and will focus on improving the function of the arm most affected by the stroke. Sessions may include electrical stimulation of the muscles, if it is determined to be safe. At the end of each week, the therapists will recommend exercises for the subjects to continue to work on at home on the weekend.
41508964|NCT06113835|PROCEDURE|CTO PCI|percutaneous coronary intervention
41036496|NCT04156308|OTHER|Combined Exercises|A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
41036497|NCT03708198|DRUG|Liposomal Bupivacaine|intercostal block
40853009|NCT05205174|DEVICE|depth electrodes|The study will be conducted at a single center, in TBI patients requiring neurosurgical intervention in the form of EVD placement. During neurosurgical intervention at the bedside in the Intensive Care Unit (ICU), a single depth electrode will be placed in the brain adjacent to the EVD catheter in the same burr hole. After EVD and depth electrode placement, continuous recording of ECoG activity as well as relevant physiological parameters will be performed for the duration of clinically indicated invasive neuromonitoring in accordance with the standard of care for TBI patients. A single recording station is currently available for data collection, therefore, with an anticipated average recording period of 14 days, the study will take greater than 210 days to complete for a total of 15 patients.
40853010|NCT00098683|DRUG|amifostine trihydrate|
40853011|NCT05456620|OTHER|Exercise therapy|"The intervention treatment consists of a progressive 4-stage, criteria-based exercise protocol, in which the amount of tendon compression is limited. This includes:~1. Education: Specific information on the importance of limiting tendon compression during rehabilitation, as well as general information on load management, the importance of active exercise therapy and setting expectations.~2. Orthotic treatment: heel inserts to reduce ankle dorsiflexion during daily activities and sports~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) restricting the amount of tendon compression by limiting dorsiflexion of the ankle and prohibiting stretching"
40853012|NCT05456620|OTHER|Exercise therapy (usual care)|"The control treatment consists of a progressive 4-phase, criteria-based exercise protocol, in which the amount of tendon compression is not limited. This includes:~1. Education: general information on load management, the importance of active exercise therapy and setting expectations.~2. No orthotic treatment.~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) without any restriction around tendon compression and encouraging stretching"
40853013|NCT01996124|DRUG|Indacaterol Fumarate|150 mcg inhalation powder, hard capsules, once daily
40853014|NCT01996124|DRUG|Placebo|Fructose, dry inhalation powder, hard capsules via breezhaler
40853015|NCT06147414|BIOLOGICAL|Blood sample|"A blood sample (50 ml) will be taken in care of prenatal diagnosis and 40 ml will be used for study.~The 40 mL of blood needed for the research will be collected on BCT tubes (4 tubes).~During the study, in centers, the plasma samples will be stored at room temperature and will be sent to the laboratory within 24 hours (no centrifugation in centers).~The plasma samples will be then temporarily stored at -80°C in each co-investigating laboratory under the supervision of lab supervisor until the analysis. cfDNA will be extracted from the whole plasma sample before each sequencing run and stored à +4°C until the cfDNA sequencing."
41165707|NCT04107077|DRUG|Mitomycin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 30mg of Mitomycin C.
41165708|NCT00096109|DRUG|tanespimycin|Given IV
41383487|NCT06485596|DEVICE|XVIVO Heart Assist Transport System|Direct procurement of donor hearts from DCD donation
41383488|NCT00056537|DRUG|ABR-217620|Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
41383489|NCT01827072|DRUG|NPB-01|
41383490|NCT02417207|DRUG|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 \~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
41383491|NCT02417207|DRUG|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
41383492|NCT00718978|PROCEDURE|CSS grafting|grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
41383493|NCT01555242|DRUG|Aneustat (OMN54)|100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
41383494|NCT05251779|DRUG|Volatile Oil of Cang-Ai|The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
41383495|NCT05251779|DRUG|Bergamot essential oils|The control group will be given Bergamot essential oils for inhalation.
41508965|NCT03437031|DEVICE|Virtual Reality device|For those patients randomized to VR, the study staff member will explain the use of the Samsung VR goggle set, and thereafter will allow the patient to use the device freely for up to 30 minutes. Intervals of 2-5 minutes is suggested for first-time use, and patients will be to allowed to discontinue it at any time as long as they are not experiencing any discomfort or side effects (dizziness, motion sickness, etc.). The study staff member will be present at all times, and will work with hospital staff as necessary to ensure the patient is receiving appropriate clinical care throughout the duration of the intervention.
41383496|NCT00297882|DRUG|1. Artemether-Lumefantrine (AL)|Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
41508966|NCT03564938|DRUG|Regorafenib (Stivarga, BAY73-4506)|The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).
41508967|NCT03004339|DRUG|SOR007 Ointment 2.0%|
41383497|NCT00297882|DRUG|2. Amodiaquine-Artesunate (AQ-AS)|Amodiaquine-Artesunate (0H),D1(24H),D2(48H)= Artesunate 4mg/kg and Amodiaquine at 10mg/kg
41383498|NCT00946556|DRUG|Valacyclovir|1g po od for 2 months
41508968|NCT03004339|DRUG|SOR007 Ointment 1.0%|
41508969|NCT03004339|DRUG|SOR007 Ointment 0.3%|
41508970|NCT03004339|DRUG|SOR007 Ointment 0.15%|
41508971|NCT03004339|DRUG|SOR007 Ointment Placebo|
41508972|NCT03004339|DRUG|Taclonex® Ointment|
41383499|NCT00946556|DRUG|Placebo|Placebo po od for 2 months
41383500|NCT05518565|OTHER|No intervention|No intervention
41508973|NCT06476405|OTHER|Study Product A: Ploom® Non-Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product A: Ploom Non-menthol) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
41165709|NCT00096109|OTHER|laboratory biomarker analysis|Correlative studies
41165710|NCT03384771|BEHAVIORAL|MBSR|There is no study intervention per se, but participants will be teaching or enrolled in public 8-week MBSR classes.
41165711|NCT04863638|BIOLOGICAL|3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 42
41165712|NCT04863638|BIOLOGICAL|3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 111
41165713|NCT04863638|BIOLOGICAL|3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 171
41383501|NCT06450925|DRUG|Vitamin A|Enrolled subjects will receive one observed oral vitamin A dose, prior to their HSCT, in the outpatient clinic or inpatient Bone Marrow Transplant (BMT) floor.
41383502|NCT06450925|OTHER|Placebo|Placebo pills containing vegetable oil with lactose powder as a filler will be dispensed in patients who are randomized to the placebo arm.
41383503|NCT05417009|DEVICE|trans-cutaneous auricular sensory stimulation|Transcutaneous auricular sensory stimulation
41508974|NCT06476405|OTHER|Study Product B: Usual Brand Combustible Cigarette (UBCC) Non-Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product B: Non-menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
41508975|NCT06476405|OTHER|Study Product C: Ploom® Menthol Heated Tobacco Product (HTP)|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product C: Ploom® Menthol HTP) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
41508976|NCT06476405|OTHER|Study Product D: Usual Brand Combustible Cigarette (UBCC) Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product D: Menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
41508977|NCT03005665|DRUG|Acetazolamide|
41165714|NCT04863638|BIOLOGICAL|2 doses of vaccine|the schedule of Day 0, 21
41165715|NCT06238297|DIAGNOSTIC_TEST|MRSA nasal swab based de-escalation|Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
41165716|NCT03630965|OTHER|CPR Video|"A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale."
41165717|NCT01216059|PROCEDURE|Text message to cell phone|Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
41165718|NCT05393622|DEVICE|INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION|Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.
41165719|NCT00664261|BEHAVIORAL|smoking cessation intervention|
41165720|NCT00664261|OTHER|cancer prevention|
41383504|NCT06303687|OTHER|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
41383505|NCT05939401|OTHER|Biopsies|Biopsies and blood samples will be taken at time of diagnosis or recurrence
41165721|NCT00664261|OTHER|counseling intervention|
41165722|NCT00664261|OTHER|educational intervention|
41165723|NCT00664261|OTHER|laboratory biomarker analysis|
41165724|NCT00664261|OTHER|questionnaire administration|
41165725|NCT00664261|OTHER|survey administration|
41165726|NCT00664261|PROCEDURE|study of high risk factors|
41165727|NCT03041701|DRUG|Dasatinib|Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
41165728|NCT03041701|DRUG|Dasatinib|Twice daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
41165729|NCT03041701|DRUG|Ganitumab|Once every 2 weeks beginning on day 0.
41165730|NCT05077241|DEVICE|Inspiratory muscle training|Individuals will be instructed to perform a rapid contraction of the inspiratory muscles against a load and sustain it for 2 seconds in each maneuver.
41165731|NCT05756049|OTHER|compare antibiotic duration of therapy|To compare antibiotic duration of therapy before and after the implementation of the PCT protocol in the ICU.
41165732|NCT03695198|DRUG|LY3361237 - SC|LY3361237 administered SC
41165733|NCT03695198|DRUG|LY3361237 - IV|LY3361237 administered IV
41165734|NCT03695198|DRUG|Placebo - SC|Placebo administered SC
41165735|NCT03695198|DRUG|Placebo - IV|Placebo administered IV
41383506|NCT00301873|DRUG|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
41383507|NCT06529250|DRUG|HAD|"Induction therapy:Homoharringtonine: 2mg/㎡/d, days 1-7 Cytarabine: (Ara-c 100mg/㎡/d, day 1-4; 1g/㎡ /q12h, day 5-7), Daunorubicin: (DNR 40mg/㎡/d, day 1-3).~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5) . Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment."
40853016|NCT02317848|OTHER|polygraphy and ECG|polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
41383508|NCT06529250|DRUG|Daunorubicin+Cytarabine|"Cytarabine: (Ara-c 100mg/㎡/d, day 1-7), Daunorubicin: (DNR 60mg/㎡/d, day 1-3) or idarubicin (IDA 12mg/㎡/d, day 1-3).~Treatment did not achieve CR, and reinduction of IAC regimen was given.~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ ,d1-3, Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5). Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment."
41383509|NCT04671329|DEVICE|Affirm Contrast Biopsy procedure|Contrast Enhanced Digital Mammography (CEDM) is an extension of the existing indication for diagnostic mammography with the Selenia Dimensions system and 3Dimensions system. Biopsy targeting can be done on captured contrast enhanced images (scout and stereo pair). The CEDM application shall enable contrast enhanced breast imaging using a dual energy technique. This imaging technique can be used as an adjunct following mammography and/or ultrasound exams to localize a known or suspected lesion. Affirm Contrast Biopsy is intended for patients recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities.
41383510|NCT06541938|DIETARY_SUPPLEMENT|low FODMAP diet|You consume low FODMAP diet for 24 hours before taking the FODMAP challenge
41383511|NCT06541938|DIETARY_SUPPLEMENT|Lactose Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you will consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~25g sachet having lactose roughly equal to amount of lactose present in 1 large glass of milk"
41383512|NCT06541938|DIETARY_SUPPLEMENT|Fructose Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~25g sachet having fructose roughly equal to the amount of fructose present in 2 large apples"
41165736|NCT05082233|DRUG|SHR7280 tablets|Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；
41383595|NCT00057330|BIOLOGICAL|Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
41508978|NCT03005665|DRUG|Normal Saline|
41508979|NCT03451357|DIAGNOSTIC_TEST|Dependence degree already certificated by Dependence Law.|The European Council defines dependence as the state in which people, due to causes linked to the lack or loss of physical, psychological, or intellectual autonomy, are in need of assistance and/or significant help to carry out common activities of daily life. In primary care, the nurses in charge are trained of data collection. This situation needs of formal care provided by health or/and social workers, private or public.
41508980|NCT04350450|DRUG|Hydroxychloroquine|400 mg tablet
40853017|NCT06256263|PROCEDURE|total laryngectomy|pharyngeal repair after total laryngectomy
41165737|NCT03738098|BEHAVIORAL|Standard of Care|Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
41165738|NCT03738098|BEHAVIORAL|GUÍA|GUÍA for the ROR1 visit.
41165739|NCT01807936|PROCEDURE|Lymphadenectomy|
40853018|NCT01462396|DEVICE|CD34+ cells selected with the Miltenyi Clinimacs machine|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
40853019|NCT06003153|DRUG|oral semaglutide|Semaglutide is the only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for treatment of type 2 diabetes. Participants will receive 7 mg of oral semaglutide once daily for 14 days in between Visit 1 and Visit 2.
41165740|NCT05851456|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
41165741|NCT02710097|DRUG|Active inhaled cannabis|"\~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
41165742|NCT02710097|DRUG|Placebo|Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
40853084|NCT06366087|DRUG|Atropine Sulfate Ophthalmic Solution USP, 1%|Atropine Sulfate Ophthalmic Solution, USP 1% manufactured by Bausch \& Lomb Americas Inc., is a sterile topical anti-muscarinic indicated for mydriasis, cycloplegia, and penalization of the healthy eye to treat amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains the active ingredient atropine sulfate 10 mg, equivalent to 8.3 mg of atropine. Inactive ingredients are boric acid, hydroxypropyl methylcellulose, and water for injection, USP; hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0). Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in 0.4 mL single-dose vials and will be administered as a single dose to a single participant. 100 μL of Atropine Sulfate Ophthalmic Solution, USP 1% will be given sublingually by pipette to deliver 1.0 mg of atropine sulfate. Before administration, participants will be told to swallow. Once given, participants will be told to try not to swallow for 30 seconds and then swallow normally.
40853085|NCT06366087|DRUG|Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)|Atropine sulfate injection, USP is a muscarinic antagonist used for temporary blockade of severe/life-threatening muscarinic effects and to treat symptomatic bradycardia. Atropine Sulfate Injection, USP, 8 mg/20 mL (0.4 mg/mL) manufactured by Fresenius Kabi is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; and sodium chloride 9 mg; it may also contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8). Atropine Sulfate Injection, USP will be supplied in 8 mg/20 mL multidose vials (0.4 mg/mL). Each vial will be used to administer multiple doses to multiple participants. 2.5 mL will be injected into the mid-anterolateral thigh to deliver 1.0 mg of atropine sulfate. Vials will be dated/timed and will not be given after 24 hours of first entry.
40853086|NCT00799591|OTHER|Observational study so no intervention in the patient.|Observational study so no intervention in the patient.
41383620|NCT06173674|OTHER|Music intervention|"The music intervention will consist of three components including:~1. Playlist composition Six music genres playlists will be offered to patients, including Classical Music, Country Music, Folk Music, Hymns and Reglious Music, Jazz and Swing Music, Popular/Easy Listening/RNB and Soundtrack Music. Patients can also add their favourite music to the list as well.~2. Music Intervention Delivery The general criteria for intervention delivery are:1) Each session lasts at least 20 minutes; 2) The music will be delivered by a comfortable, wireless, on/off switch noise-cancelling headphone; 3) The volume will be adjusted according to the patient's preference and controlled at 65dB or lower; 4) The order of music in the playlists will be decided by the patient; 5) Music will be delivered in inpatient room and/or waiting area before surgery/procedure.~3. Cleaning and infection of the equipment We will comply with guidelines on disinfection of materials in the hospital."
40853087|NCT02187068|DRUG|Dexmedetomidine|Dexmedetomidine administered intravenously
40853088|NCT06066398|PROCEDURE|medical thoracoscope|Medical thoracoscopy will be performed during which pleural brush will be used first followed by forceps biopsy to obtain pleural specimens from suspect areas under visual control and pleural lavage will be performed by injecting 300 mL of normal saline
40853089|NCT06066398|DIAGNOSTIC_TEST|Forceps biopsy and pleural brush histopathology|Forceps biopsy and pleural brush will be obtained for histopathological examination for diagnosis
41509274|NCT01947998|DRUG|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
41509275|NCT01947998|DRUG|Warfarin|For VTE prevention, DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, warfarin.
41383621|NCT00902486|DRUG|INCB028050|4 mg capsules QD
41383622|NCT00902486|DRUG|INCB028050|7 mg capsules QD
41509276|NCT01947998|DRUG|Antiplatelet drugs|For the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor
41509277|NCT00194779|DRUG|doxorubicin hydrochloride|Given IV
40853090|NCT06066398|DIAGNOSTIC_TEST|pleural lavage cytology|pleural lavage will be obtained for cytological examination for diagnosis
41180001|NCT04650399|BIOLOGICAL|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
41383623|NCT00902486|DRUG|INCB028050|10 mg capsule QD
41383624|NCT00902486|DRUG|Placebo|Placebo matching INCB028050 QD
41383625|NCT02263677|DRUG|Sitagliptin|60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
41383626|NCT00447265|DRUG|Etanercept|1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
41383627|NCT00447265|DRUG|Lupus Treatment- Standard of Care|Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
41383628|NCT00447265|DRUG|Placebo|
41509278|NCT00194779|DRUG|cyclophosphamide|Given PO
41509279|NCT00194779|DRUG|paclitaxel|Given IV
41509280|NCT00194779|BIOLOGICAL|filgrastim|Given SC
41509281|NCT00194779|DRUG|capecitabine|Given PO
41509282|NCT00194779|DRUG|methotrexate|Given IV
41509283|NCT00194779|DRUG|vinorelbine tartrate|Given IV
40676479|NCT05705492|DRUG|Olanzapine|Given PO
41180002|NCT02169557|DRUG|Fexinidazole|
41180003|NCT02760147|DEVICE|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
40853091|NCT01517464|GENETIC|SGT-94|SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
40853092|NCT00652951|BIOLOGICAL|GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)|Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
40853093|NCT00652951|BIOLOGICAL|Infanrix™ hexa.|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
40853094|NCT00652951|BIOLOGICAL|Pediacel™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
40853095|NCT00652951|BIOLOGICAL|Prevenar™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
40853096|NCT05687162|BEHAVIORAL|Overcoming Loneliness three-week intervention|A self-guided online loneliness intervention with three 10-20 minute sessions. The intervention content draws heavily from Internet Cognitive Behavioral Therapy for Loneliness and follows the form of single-session mental health interventions.
40853097|NCT05687162|BEHAVIORAL|Overcoming Loneliness single-session intervention|The Overcoming Loneliness Three-Week Intervention condensed into a single-session intervention lasting 20-30 minutes.
40853098|NCT05687162|BEHAVIORAL|"Single-session Sharing Feelings program"|"A self-guided online supportive therapy intervention with a single 20-30 minute session intended to encourage users to share feelings with close others. Slightly modified from the Sharing Feelings intervention"
40853099|NCT05687162|BEHAVIORAL|The Blu Surfer program: a popular online content-based intervention for psychological distress|The Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to mental health. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
40853100|NCT05687162|BEHAVIORAL|The Action Brings Change (ABC) Program (TEAM Lab version)|The ABC project is a 20-30-minute SSI for teens based on behavioral activation. It was found to be efficacious for reducing depression, anxiety, hopelessness, and self-hate and increasing perceived control and agency in youth (link to SSI: https://osf.io/ch2tg/, license: http://creativecommons.org/licenses/by-nc-sa/4.0/). The researchers modified the phrasing in the intervention to make it more relevant to both teens and adults, as the original was designed for only teens.
40853101|NCT05687162|BEHAVIORAL|Online help-seeking as usual|"This intervention, created by the present research team, aims to emulate how one might find support on their own using the internet. In this condition, participants are asked to browse the internet for 25 minutes to find popular online content relevant to their personal struggles and create an annotated list of links to the content they find useful. The intervention is similar to a self-study condition, which found self-study and a video intervention equally increased mental health knowledge. The survey platform provides text entry boxes to help each participant create their guide and then provides a text version of their guide for them to keep."
40853102|NCT05687162|BEHAVIORAL|The Lonely Blu Surfer program: a popular online content-based intervention for loneliness|The Lonely Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to loneliness. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
40853103|NCT05687162|BEHAVIORAL|Overcoming loneliness SSI 8-minute version|A shortened version of an online self-guided intervention based on principles of CBT for loneliness. The research team created this intervention by cutting lengthy didactic material and exercises from the 23-minute version, while maintaining its core concepts.
41383629|NCT00123110|DRUG|metformin|Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
40853104|NCT02858947|PROCEDURE|Aelite Flo|Microhybrid flowable composite
40853105|NCT02858947|PROCEDURE|x-tra base|Bulk-fill flowable composite
40853106|NCT05295108|OTHER|Caring Connections|peer-based letter writing social connectedness intervention to improve social health outcomes
40853107|NCT05295108|OTHER|Attention control|informational materials provided to educate on life domains that are important to social health
41180004|NCT02760147|DEVICE|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
41383630|NCT00123110|DRUG|leuprolide injection|3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
41383631|NCT00123110|DRUG|placebo pill|matching pill twice a day for 12 weeks
41509284|NCT00194779|PROCEDURE|needle biopsy|Correlative studies
40853108|NCT06272500|OTHER|oral administration of receives only oral administration of placebo|receives only oral administration of placebo , with one capsule taken three times a day.
41180005|NCT02760147|DEVICE|PEEP Over Level|PEEP Level upward by 50%, 2 hours
41180006|NCT02760147|DEVICE|PEEP Under Level|PEEP Level downward by 50%, 2 hours
41180007|NCT06420050|BEHAVIORAL|Instagram Intervention|The intervention consists of a study Instagram page, which will post intervention content every day for 42 days.
41383632|NCT00123110|DRUG|placebo injection|matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
41383633|NCT00003861|OTHER|laboratory biomarker analysis|
41383634|NCT06033963|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
41383635|NCT06033963|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
41509285|NCT00194779|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
41509286|NCT00194779|OTHER|immunohistochemistry staining method|Correlative studies
40853109|NCT06272500|OTHER|oral administration of compound digestive enzyme capsule|receives only oral administration of compound digestive enzyme capsule, with one capsule taken three times a day.
40853110|NCT06272500|OTHER|oral administration of Betaine hydrochloride|receives oral administration of Betaine hydrochloride(BHCL),with one capsule before each meal.
40853111|NCT06496880|DIETARY_SUPPLEMENT|Oxyjun TM|One capsule daily to be taken after breakfast for 56 days
40853112|NCT06496880|DIETARY_SUPPLEMENT|Placebo|One capsule daily to be taken after breakfast for 56 days
40853113|NCT06130592|DIAGNOSTIC_TEST|ultrasound muscle imaging technique|ultrasound muscle imaging technique in antenatal ultrasound screening of congenital multiple arthrogryposis
40853114|NCT04067414|BIOLOGICAL|BZ019|"Subjects will be enrolled in three dose-groups:~Dose 1: 1×10\^6/kg CAR+ cells; Dose 2: 3×10\^6/kg CAR+ cells; Dose 3: 6×10\^6/kg CAR+ cells."
40853115|NCT04920097|OTHER|In-person training for seed placement and APA|In-person seed placement and a training for the participant or their caregiver to place the seeds on the ear points.
40853116|NCT04920097|OTHER|Virtual training for seed placement and APA|Self-administer APA by placing the seeds according to the video instruction found in the self-guided smartphone application for understanding and administering APA. Participant and/or a caregiver will follow the video instruction on seed placement.
41383636|NCT06170528|DEVICE|AURA_ALZ|AURA_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.
40853117|NCT04920097|OTHER|Usual Care|Participants will continue with usual care from oncologist.
40853118|NCT04920097|OTHER|Post-training zoom session for seed placement and APA coaching|Zoom session for seed placement and APA coaching, to occur after initial APA and seed placement training (initial training is either in person or guided by the smartphone app videos).
40853119|NCT03089541|BEHAVIORAL|Survey Arm|Contingency Management for completion of surveys and evidence of tobacco use status
41036666|NCT05916651|BEHAVIORAL|Learning to Offset Stress (LOS) (in Dutch: Leren Omgaan met Stress) training|The investigational treatment is the LOS training, which is an adaptation of two previously validated mindfulness-based programs: Mindfulness-Based Cognitive Therapy (MBCT) developed by Segal, Williams, and Teasdale (2002) and the Mindful2Work (M2W) program developed by de Bruin, Formsma, and Bögels (2018). The M2W program combines mindful physical activity, yoga, and mindfulness meditation to target stress symptoms and burn-out in adults. The LOS training was adapted from these programs to meet the needs of youth with internalizing problems. The training consists of 8 weekly 2-hour sessions that each comprise three elements: mindful physical activity (15-20 minutes), yoga (15-20 minutes), and mindfulness meditation exercises (80-90 minutes). In addition to attending group sessions, participants are invited to practice at home on a daily basis. Home practice consists of daily mindfulness practices comprising mindfulness exercises, yoga and mindful physical activity.
41036667|NCT05916651|BEHAVIORAL|Care as usual|"Youth who seek help for internalizing problems from a primary mental health practitioner, including student psychologists or mental health nurse practioners, but do not (yet) meet criteria for (major) mental illness are typically offered supportive counselling, aimed primarily at helping people feel understood and supported. Supportive counselling may also include instructions on behavioral activation, particularly when individuals report reduced activity and behavioral avoidance including social withdrawal. In addition, mental health practitioners commonly employ a watchful waiting policy for people with symptoms in the milder range, where they check-in with clients on a regular basis and refer for more intensive treatment if and when symptoms worsen."
40853120|NCT00000706|DRUG|Quinine sulfate|
41180008|NCT04259359|DRUG|Insect Venom|Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.
40853121|NCT00000706|DRUG|Probenecid|
41180009|NCT04540445|OTHER|Pupillary Assessment|Pupillary assessment with handheld pupillometer
41383637|NCT00138658|DRUG|custirsen sodium|Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
41383638|NCT05661071|OTHER|Modified Mini Mental Test:|To assess the cognitive function of children
40676480|NCT05705492|DRUG|Placebo Administration|Given PO
40853122|NCT00000706|DRUG|Zidovudine|
40853123|NCT05346406|DEVICE|Long Peripheral Catheter|Bard Powerglide 8 cm midline catheter
40853124|NCT05346406|DEVICE|Peripherally Inserted Central Catheter|Bard 3fr, 4fr or 6fr; Cook 4fr; or Medcomp 1.9fr and 2.6fr
40853125|NCT01444846|DRUG|SPI-1005 Low dose|Oral capsules, 200 mg ebselen, twice daily, 4 days
40853126|NCT01444846|DRUG|SPI-1005 Middle dose|Oral capsules, 400 mg ebselen, twice daily, 4 days
40853127|NCT01444846|DRUG|SPI-1005 High dose|Oral capsules, 600 mg ebselen, twice daily, 4 days
40853128|NCT01444846|DRUG|Placebo|Oral capsules, 0 mg ebselen, twice daily, 4 days
40853129|NCT01700153|OTHER|Robotic-assisted therapy|This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
40853130|NCT01700153|OTHER|Classical therapy|conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
40853131|NCT04518540|DRUG|lipoic acid group|"The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.~At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day."
40853132|NCT04518540|DRUG|control group|The patients will take domestic riluzole tablets 50mg orally, twice a day.
41383639|NCT05661071|OTHER|The Controlled Oral Word Association Test|To assess the cognitive function of children
41383640|NCT05661071|OTHER|The Central Nervous System Vital Signs|To assess the cognitive function of children
41383641|NCT05661071|OTHER|Conners' Parent Rating Scale-48 (Parent Report)|To assess attention-deficit/hyperactivity disorder
41383642|NCT05661071|OTHER|Child Behavior Checklist 6-18 ages (Parent Report)|To assesses both child adaptive behaviors and problem behaviors.
41383643|NCT05661071|OTHER|Strengths and Difficulties Questionnaire (Self-Reported)|It is a brief emotional and behavioural screening questionnaire for children and young people.
40853133|NCT06142292|BEHAVIORAL|Individual counseling|Individual counseling sessions with a licensed mental health counselor
41383644|NCT05661071|OTHER|Brooke Lower Extremity Functional Classification|To determine the functional status of the lower extremity
41383645|NCT05661071|OTHER|Motor Function Measurement-32 Items|To assessment of motor function and progression of weakness in neuromuscular disorders
41180010|NCT01289210|DRUG|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
41383646|NCT05661071|OTHER|Four Square Step Test|A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.
41383647|NCT05661071|OTHER|Six Minutes Walk Test|It evaluates the walking function and physical capacity of children at the submaximal level.
41383648|NCT05661071|OTHER|Timed Performance Test|10 meters Walk\& Run Test, Gower's(from a supine to a standing position), Right\& Left Leg Standing, Ascent/Descent of 4 Steps
41383649|NCT05782140|DEVICE|Mayo Clinic Watch Device|Mayo Clinic remote monitoring platform (Omni) that utilizes a wearable device with integrated physiological monitoring capabilities.
41383650|NCT00337155|DRUG|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
41383651|NCT06500026|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
41383652|NCT06500026|DRUG|Topotecan|Administration by intravenous infusion for a cycle of 3 weeks.
41383653|NCT03037918|DIETARY_SUPPLEMENT|Yakult light|A fermented milk drink containing the probiotic Lactobacillus casei Shirota
41383654|NCT05529173|DRUG|Povidone-Iodine 10%|Nasal swab stick application of Povidone-Iodine 10% prior to surgery
41383655|NCT05529173|DRUG|0.9% NaCl Solution|Nasal swab stick application of 0.9% NaCl Solution prior to surgery
41383656|NCT04980599|DIETARY_SUPPLEMENT|probiotic drink with Lactobacillus paracasei K56|Probiotic drink (K56 10\^11CFU) 350ml/d for 60days
41383657|NCT04980599|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin ,for 60days
41383658|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E3|Probiotic powder 3.0g/d (K56 10\^10cfu) 60days;
41383659|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E5|probiotic powder 8g/day for 60days
41383660|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E7|probiotic k56 capsule, 2capsules/d (10\^7cfu) for 60days
41383661|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E9|probiotic k56 capsule, 2capsules/d (10\^9cfu) for 60days
41383662|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E10|probiotic k56 capsule, 2capsules/d (10\^10cfu) for 60days
41383663|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E11|probiotic k56 capsule, 4capsules/d (10\^11cfu) for 60days
40676481|NCT05705492|OTHER|Questionnaire Administration|Ancillary studies
40676482|NCT06463665|BIOLOGICAL|Olvimulogene nanivacirepvec|Olvi-Vec is an engineered oncolytic vaccinia virus
40676483|NCT06463665|DRUG|Platinum chemotherapy: carboplatin or cisplatin|Administered according to local practice.
40853134|NCT06142292|BEHAVIORAL|Group counseling|Group counseling sessions with a licensed mental health counselor
41180011|NCT05675462|DRUG|Oncorine|a modified human recombinant type 5 adenovirus with genetic modifications
41180012|NCT05675462|DRUG|Tislelizumab|PD-1inhibitor
41180013|NCT05675462|DRUG|Lenvatinib|TKI
41180014|NCT00645580|DRUG|Fluvoxamine|Fluvoxamine 100mg/day PO for 6 weeks.
41180015|NCT05228015|DRUG|IK-930|tablets for oral administration
41383664|NCT05420636|DRUG|Iadademstat|Patients will be treated with iadademstat given at a dose of 150 microgram PO administered on a 5 day on-2 day off schedule every week (days 1 through 21)
41383665|NCT05420636|DRUG|Paclitaxel|Patients will be treated with Paclitaxel given at a dose of 80 mg/m2 intravenous administration weekly day 1, 8 and 15 (days 1 through 21).
41383666|NCT04229758|DRUG|Anticoagulants|DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
41383667|NCT02218515|PROCEDURE|Open Flap Debridement|Open Flap Debridement (Control Group)
41383668|NCT02218515|BIOLOGICAL|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
41383669|NCT02218515|BIOLOGICAL|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
41383670|NCT06566040|DEVICE|Wheelchair|Wheelchairs provided to hospital inpatients
41383671|NCT00503035|DRUG|Celecoxib|400 mg by mouth twice daily x 6 months
41383672|NCT00503035|PROCEDURE|Colonoscopy Biopsy|Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
41383673|NCT05397119|BIOLOGICAL|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
41383674|NCT05397119|BIOLOGICAL|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
41383675|NCT05397119|BIOLOGICAL|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
41383676|NCT05397119|BIOLOGICAL|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
41383677|NCT05397119|BIOLOGICAL|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
41383678|NCT05397119|BIOLOGICAL|H5N1 IIV - IM|90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization
41417768|NCT02301247|BEHAVIORAL|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
40853135|NCT02106403|OTHER|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
40853136|NCT02106403|OTHER|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
40853137|NCT02106403|OTHER|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
40853138|NCT04787354|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m2/day
40853139|NCT04787354|DRUG|Capecitabine|Capecitabine: 2,000 mg/m2/day
40853140|NCT05739461|OTHER|Dental implant|Dental implants with triangular cross-section neck design
40853141|NCT06407531|OTHER|VR-G|Patients watched videos with virtual glasses before undergoing colonoscopy
40853142|NCT06161610|DEVICE|LITT|The patients in the intervention group will receive LITT, other treatments, including systematic therapy and radiology therapy, would be not restricted except the craniotomy of resection before tumor progression or emergency. The patient is supposed to receive LITT post-randomization within 7 days.
40853143|NCT06161610|OTHER|Control|The patients in the control group will receive the best medical management under guidelines except LITT before tumor progression. Craniotomy will not be restricted,
40853144|NCT02755896|RADIATION|Arm 1 600 cGY x 5 fractions|Patients who are randomized to Arm 1 will receive either 600 cGY x 5 fractions over 5 consecutive days
40853145|NCT02755896|RADIATION|Arm 2 800 cGY x 3 fractions|Patients who are randomized to Arm 2 will receive 800 cGY x 3 fractions given every other day
41383679|NCT02362243|OTHER|Experimental Intervention|Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
41383680|NCT02362243|OTHER|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
40853146|NCT03155438|DIAGNOSTIC_TEST|Oxidative stress-related gene expression (RNA expression)|Oxidative stress-related gene expression (RNA expression),Superoxide dismutase 1 (SOD1) , SOD2 , Glutathione peroxidase (GPX) and Inducible nitric oxide synthase (iNOS) , measured by Real time PCR technique.
41509287|NCT00194779|BIOLOGICAL|trastuzumab|Given IV
40853147|NCT03155438|DIAGNOSTIC_TEST|oocyte competence biomarkers|Oocyte competence biomarkers ,GDF9, BMP15, Amphiregulin and CoQ10 measured by ELISA
40853148|NCT01786395|DRUG|UF-021|
40853149|NCT01786395|DRUG|Placebo|
40853150|NCT01986608|DRUG|Lacosamide infusion|"Strength: 10 mg/mL for infusion~Form: solution for infusion~Dosage: 200 mg, single dose~Duration: 30-minute infusion or 60-minute infusion"
40853151|NCT01986608|DRUG|Lacosamide oral|"Strength: 200 mg~Form: film-coated tablet~Dosage: 200 mg, single dose~Duration: single oral intake"
40853152|NCT00258817|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0 and Day 28)
40853153|NCT00258817|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0)
40853154|NCT03051308|COMBINATION_PRODUCT|NPT and UW Solution|Tissue preservation solutions for transplantation
40853155|NCT03765892|OTHER|Questionnaire (Adult)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the distribution of socio-professional categories.~Answering the questionnaires will take 45 minutes."
41036668|NCT02234531|DEVICE|EVER TEACHER|"The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called virtual teacher will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment."
41509288|NCT00194779|DRUG|tamoxifen citrate|Given PO
41509289|NCT00194779|DRUG|letrozole|Given PO
40853156|NCT03765892|OTHER|Questionnaire (Children)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the proportion of subjects having repeated grades.~Answering the questionnaires will take 45 minutes."
40853157|NCT03767751|BIOLOGICAL|Dual Specificity CD38 and bcma CAR-T Cells|1) Biological: Dual Specificity CD38 and BCMA CAR-T Cells,2)1-5X10E6/Kg
40853158|NCT03749811|DEVICE|Pupillometry|After induction of anesthesia and determination of the loss of consciousness of the participant, baseline diameter of pupil is measured by electronic pupillometry device. During anesthesia, participant's pupil diameter is repeatedly measured with 5-minute interval. Pupil dilation of 30% or more compared to baseline is indicative of insufficient analgesia.
40853159|NCT03727932|DEVICE|VioOne HIV Profile Supplemental Assay|The VioOne™ HIV Profile™ Supplemental Assay is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of Human Immunodeficiency Virus Type 1 (HIV-1 Group M \& Group O) and Type 2 (HIV-2) in human serum or plasma. The HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.
40853160|NCT05665907|OTHER|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
41180016|NCT05228015|DRUG|Osimertinib|tablets for oral administration
40853161|NCT03617146|BEHAVIORAL|Health coaching|The intervention will seek to help participants express their diabetes emotional needs and to work with them to figure out what can be done to meet those needs. Depending on the unique needs of each participant, the coaching approach for this study will include: improving motivation and self-efficacy for diabetes management using motivational interviewing and appreciative inquiry; building trust and rapport through mindful listening, open-ended inquiry, and perceptive reflections; and expressing empathy through nonviolent communication. Each participant will receive eight individual coaching sessions over a five month period. All coaching sessions will be delivered over the phone (i.e. telecoaching). The coaching intervention will be done by a certified health and wellness coach.
40853162|NCT03617146|OTHER|Diabetes Distress-specific Education|A diabetes distress-specific education that explains what diabetes distress is, why it matters, and its four domains. In addition, the participant is given feedback on his or her distress score and advised on ways to deal with the areas of greatest distress. Participant is linked with resources to overcome any expressed needs. The education is provided by a trained medical assistant.
40853163|NCT02056327|DEVICE|A novel monitoring suite of sensors will be inserted into the standard oral device.|
40853164|NCT05678634|BEHAVIORAL|Declarative learning with immediate feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 500 ms following a response (button press)
40853165|NCT05678634|BEHAVIORAL|Declarative learning with delayed feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 5000 ms following a response (button press)
40853166|NCT05678634|BEHAVIORAL|Probabilistic learning with immediate feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 500 ms following a response (button press)
40853167|NCT05678634|BEHAVIORAL|Probabilistic learning with delayed feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 5000 ms following a response (button press)
40853168|NCT05678634|BEHAVIORAL|Word learning task with active feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names through trial and error guided by feedback. Each response will be followed by feedback either indicating that the response is correct or prompting the child to try again (i.e., to correct an error)
40853169|NCT05678634|BEHAVIORAL|Word learning task with passive feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names. Regardless of response accuracy on each trial, each response will be followed by a visual presentation of the correct response.
40853170|NCT02748070|DRUG|Prednisone|
40853171|NCT02748070|DRUG|Flonase|
40853172|NCT00216216|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV q 3 weeks
41036669|NCT02234531|DEVICE|NEVER TEACHER|The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
41036670|NCT05827367|DEVICE|Ultrasound|"The high-power pain threshold ultrasound (HPPTUS) In this technique, which be applied in continuous mode with intensity from t0.5 to 2 watt/cm to elicit pain threshold the US probe was kept motionless, and the intensity progressively increased until the maximum level of pain patient can endure was selected, it was maintained on this level for 3 to 4 seconds and then decreased to half intensity for 15 seconds the treatment process was repeated three times."
41036671|NCT05827367|OTHER|Myofascial release technique|Plantar fascia myofascial release Soluse muscle myofascial release Gastrocnmias muscle myofascial release
41036672|NCT05827367|OTHER|Strength and stretching|Plantar fascia stretching Interstice foot muscles strengthing
41036673|NCT00360529|DRUG|flibanserin|flibanserin placebo versus 50 mg qhs versus 100 mg qhs
41036674|NCT01040104|OTHER|Skin sample|Taken from regularly discarded tissue during routine operation
41036675|NCT01040104|OTHER|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
41036676|NCT01040104|OTHER|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
41036677|NCT01040104|OTHER|Blood taking|Blood taking on day 0
41036678|NCT01040104|OTHER|Blood taking|Blood taking on day 90
41383681|NCT06189508|DRUG|NXT007|In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.
41036679|NCT06209710|PROCEDURE|Balloon Pulmonary Angioplasty combined with Pulmonary Artery Denervation|Participants in the intervention arm will undergo a combination of Balloon Pulmonary Angioplasty (BPA) and Pulmonary Artery Denervation (PADN), as part of this phase 2/3 clinical trial. The trial aims to determine the optimal number of radiofrequency (RF) ablation points required for effective PADN based on pulmonary artery size or diameter. The BPA procedure addresses segmental and subsegmental thrombi masses through pulmonary artery dilation, while the PADN procedure involves the placement of a denervation catheter near the bifurcation of the main pulmonary artery. RF energy is selectively applied, and ablation points are determined based on individual patient characteristics and expected therapeutic effects. This unique approach seeks to customize the intervention to the patient's specific pulmonary anatomy, contributing to the overall effectiveness of the treatment strategy.
41383682|NCT00002066|DRUG|Thymopentin|
40853173|NCT01309776|DRUG|Tianeptine|week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
41036680|NCT06209710|PROCEDURE|Balloon Pulmonary Angioplasty with Sham Pulmonary Artery Denervation|Participants receive Balloon Pulmonary Angioplasty (BPA) combined with a sham Pulmonary Artery Denervation (PADN) procedure. The sham PADN involves catheter placement mimicking the actual procedure without the application of radiofrequency energy
41417769|NCT01662466|DRUG|Testosterone cream (0.5mg per gram)|Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
41417770|NCT01662466|DIETARY_SUPPLEMENT|DHEA|DHEA 25mg tid
40853174|NCT01309776|DRUG|Escitalopram|week1 : 5mg/day q.d., week2: 10mg/day q.d.
41509290|NCT00194779|OTHER|laboratory biomarker analysis|Correlative studies
40853175|NCT00307788|PROCEDURE|acupuncture|acupuncture
41383683|NCT03506776|DEVICE|Education and Thermometer Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity. One-on-one teaching with the thermometer will be provided. Participants will be given a handout for reference on using the thermometer. The foot model will be marked with a zigzag pattern on the plantar surface to illustrate the path that should be used when measuring temperature. The support person will be included in the teaching if he/she will be assisting the participant to obtain temperature readings.
40853176|NCT03607955|DRUG|AVB-S6-500|AVB-S6-500 is supplied by Aravive Biologics
40853177|NCT03607955|DRUG|Paclitaxel|Commercially available
40853178|NCT03607955|DRUG|Carboplatin|Commercially available
40853179|NCT03607955|PROCEDURE|Tissue from Diagnostic Laparoscopy|-For patients scheduled to undergo a diagnostic laparoscopy for tissue diagnosis prior to neoadjuvant chemotherapy, a tissue biopsy section from the ovary or an intra-abdominal implant will be performed
40853180|NCT03607955|PROCEDURE|Tissue from Core biopsy|-Standard of care procedure but research specimens will be collected
40853181|NCT03607955|PROCEDURE|Interval Debulking|"* Standard of Care~* Research tissue samples will be collected"
40853182|NCT03607955|PROCEDURE|Peripheral blood|-Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively.
40853183|NCT03607955|PROCEDURE|Ascites collection|-A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available.
40853184|NCT03748719|DEVICE|Stereotactic Body Radiation Therapy (SBRT)|SBRT treatment
40853185|NCT04751877|DRUG|Isatuximab|Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
40853186|NCT04751877|DRUG|Lenalidomide|Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
41036681|NCT00875836|DRUG|Buspirone|Flexible dose, up to 60 mg daily
41036682|NCT00875836|DRUG|Placebo|Flexible dose, up to 60 mg daily
40853187|NCT04751877|DRUG|Bortezomib|Bortezomib sub-cutaneous, per 28 days cycle - Cycles 1 to 12: 1.3 mg/m2 on days 1, 8, 15. Cycles 13-18: 1.3 mg/m2 on days 1, 15.
40853188|NCT04751877|DRUG|Dexamethasone|Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
40853189|NCT01043991|DRUG|Darbepoetin alfa|
40853190|NCT01043991|DRUG|Placebo|
40853191|NCT05025878|DIETARY_SUPPLEMENT|[U-13C]Glucose|Patients are intravenously infused with 28g of \[U-13C\]glucose over a 5 hour period. Briefly, \[U-13C\]glucose will be provided by intravenous line containing 8g of \[U-13C\]glucose in 60 mL over 10 min. After 10 minutes, 4g of \[U-13C\]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.
41036683|NCT03337529|OTHER|Vitamin C|200 mg Vitamin C will be given on daily basis for 8 weeks
41036684|NCT03337529|OTHER|Placebo|200 mg placebo will be given on daily basis for 8 weeks
41036685|NCT03025906|DRUG|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
41036686|NCT03025906|DRUG|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
41036687|NCT04372966|DEVICE|Total hip arthroplasty|Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.
41036688|NCT02347761|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
41036689|NCT02347761|DRUG|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
41036690|NCT02347761|DRUG|Placebo BID eFlow Closed System (CS) nebulizer|Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
41509291|NCT06311019|DEVICE|Continuous glucose monitoring and use of connected insulinpen for bolus insulin|Continuous glucose monitoring (Abbott Freestyle Libre 2) and use of connected insulinpen (Novopen 6) for bolus insulin
41528285|NCT02760537|BEHAVIORAL|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
41528286|NCT05574218|PROCEDURE|Glycine air powder|Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with glycine powder air-polishing.
40853192|NCT02186145|DRUG|Association of metronidazole; nystatin and dexamethasone|
40853193|NCT02186145|DRUG|Flagyl|Vaginal cream of metronidazole and nystatin
40853194|NCT05189028|DRUG|gemcitabine and cisplatin|Neoadjuvant chemotherapy:gemcitabine and cisplatin
40853195|NCT03288922|PROCEDURE|Limited BF OL-HDF with SHF|"The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
40853196|NCT03288922|PROCEDURE|High-efficiency OL-HDF|"The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
40853197|NCT00650845|DRUG|Dotarem®-enhanced MRI|Single IV administration before MRI exam
41383684|NCT03506776|OTHER|Education Only Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity.
40853198|NCT00650845|OTHER|non-enhanced MRI|non injected MRI
40853199|NCT02831517|DRUG|BIIB074|Administered as specified in the treatment arm
40853200|NCT02831517|DRUG|Placebo|Matched Placebo
40853201|NCT00085891|DRUG|Quetiapine Fumarate|
40853202|NCT02036866|OTHER|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.
40853203|NCT02036866|OTHER|Physical Therapy Exercises|Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.
40853204|NCT02036866|OTHER|No Intervention|Patients will be instructed to maintain their usual activity level.
40853205|NCT02275442|OTHER|EPICES scale|
40853206|NCT02945514|OTHER|DayTwo machine learning algorithm|Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition
40853207|NCT05006950|DEVICE|Stryker1688 Fluorescence imaging system|The purpose of this study is to use SPY fluorescence imaging systems and indocyanine green (ICG) as a tool to determine the percentage of successful critical anatomy recognition and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.
40853208|NCT02260947|DRUG|PF-06273340|PF-06273340 50 mg
40853209|NCT02260947|DRUG|PF-06273340|PF-06273340 400 mg
40853210|NCT02260947|DRUG|Pregabalin|Pregabalin 300 mg
40853211|NCT02260947|DRUG|Ibuprofen|Ibuprofen 600 mg
40853212|NCT02260947|DRUG|Placebo|Matching Placebo
40853213|NCT02732782|OTHER|Isometric exercise|
40853214|NCT02732782|OTHER|Eccentric exercise|
40853215|NCT02384018|BIOLOGICAL|autologous mesenchymal stromal cell|Islet transplantation patients will receive autologous MSCs following islets infusion
40853216|NCT03969927|DEVICE|Low-Fidelity PDS|"The principal investigator recently developed a low cost ($10,000) low fidelity portable driving simulator (PDS) in the University of Kansas Laboratory for Advanced Rehabilitation Research in Simulation (LARRS) that measures 25.5 Wide, 32.5 High, and 25 Deep and requires only approximately 4 square feet of space.~This intervention uses the PDS to retrain study participants and improve their driving related skills."
40853217|NCT03969927|DEVICE|High Fidelity Fixed-Base Simulator|This intervention uses the large high-fidelity fixed-base driving simulator to retrain study participants and improve their driving related skills.
40853218|NCT03269058|DRUG|Dapagliflozin|Dapagliflozin 10 mg daily per os
40853219|NCT03269058|DRUG|Placebos|Placebo of Dapagliflozin per day per os
40853220|NCT01528722|DRUG|Bupivacaine|0.25% 20ml administered intraperitoneal
40853221|NCT01528722|OTHER|Normal saline|sodium chloride 0.9% solution
40853222|NCT02718716|DRUG|UCB7665|"* Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion"
41036691|NCT04622696|DIAGNOSTIC_TEST|Ultrasound imaging|Subjects in the performance cohort will undergo ultrasound imaging to assess the visibility of the HydroMARK Breast Biopsy Marker at 6-12 weeks post-implant. There is no intervention in the safety cohort (retrospective chart review).
41036692|NCT01314651|BEHAVIORAL|Stimulus Control and Sleep Restriction|5 instructions in stimulus control and individually-tailored sleep restriction
41383685|NCT00039572|DRUG|boronophenylalanine-fructose complex|
41383686|NCT06061328|BEHAVIORAL|OASIS DA training|The OASIS decision aid is a novel implementation strategy selection tool developed by a multidisciplinary team of experts using machine learning algorithms and user-centered design approaches.
41383687|NCT06061328|BEHAVIORAL|Current DA Tool training|The CFIR-ERIC Matching Tool is a currently available decision aid tool for selecting implementation strategies that is based on expert opinion.
41383688|NCT06262581|DRUG|Tisleizumab(BGB-A317)|200mg i.v. q3w
41383689|NCT00244881|DRUG|cediranib maleate|Given orally
40853223|NCT04078984|OTHER|Experimental|"* Daily measures of End Inspiratory Pressure with respiratory synchronisation optimised by use of EAdi~* Daily spontaneous breathing trial using low levels of pressure support~* Pplat, Respiratory System Compliance, Driving Pressure, PEEP, Tidal Volume will be monitored daily as well as clinical and other routine ventilatory data. Data concerning initial severity of ARDS, and duration of ARDS, controlled mechanical ventilation, sedation and neuromuscular blockade and date of first spontaneous breathing trial will be collected. A weaning test will be conducted daily."
40853224|NCT00448747|DRUG|AEZS-130 (formerly ARD-07)|A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
41383690|NCT00244881|OTHER|laboratory biomarker analysis|Correlative studies
40853225|NCT00448747|DRUG|L-ARG+GHRH|A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
40853226|NCT01347996|DRUG|histamine dihydrochloride and IL-2|Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg \[16,400 IU/kg\] body weight twice daily for 10, 21 day cycles
40853227|NCT02698254|BIOLOGICAL|Bevacizumab|
40853228|NCT02698254|OTHER|Quality-of-Life Assessment|Ancillary studies
40853229|NCT02698254|RADIATION|Radiation Therapy|Undergo radiation therapy with conventional fractionation
40853230|NCT05830071|DRUG|CHF5993|BDP/FF/GB 100/6/12.5 μg pMDI
40853231|NCT05830071|DRUG|CHF5259|GB 12.5 μg pMDI
40853232|NCT05830071|DRUG|Moxifloxacin 400mg|400 mg Oral Tablets
40853233|NCT05830071|DRUG|CHF5993 Placebo|placebo pMDI
40853234|NCT02396355|DEVICE|Investigational BD FACSPresto System|Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.
40853235|NCT02396355|DEVICE|BD FACSCalibur flow cytometer|Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.
40853236|NCT02396355|DEVICE|Sysmex hematology analyzer KX-21|Blood samples will be tested for hemoglobic concentration on the predicate, currently marketed Sysmex hematology analyzer KX-21
40853237|NCT05271760|PROCEDURE|Single-shot spinal analgesia|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml
41036693|NCT01314651|BEHAVIORAL|Lifestyle Modification|5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
41036694|NCT04916470|DRUG|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.
41036695|NCT04916470|DRUG|Placebo (Semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
41036696|NCT03436394|DRUG|Evobrutinib|Subjects will be administered a single oral dose of evobrutinib under fasting conditions.
41036697|NCT00491049|DRUG|0.5% levofloxacin eye drops|
41036698|NCT05403008|OTHER|Zirconomer improved|Zirconomer improved, is a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
41383691|NCT04509440|DRUG|isotonic dextrose 5% in water (D5W) solution|Neurol prolotherapy (NP) is the subcutaneous perineural injection of isotonic dextrose 5% in water (D5W) solution.
41383692|NCT04509440|DRUG|corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
41383693|NCT00079963|DIETARY_SUPPLEMENT|Vitamin C|1000 mg/day
41383694|NCT00079963|DIETARY_SUPPLEMENT|Vitamin E|800 IU/day
41383695|NCT00079963|DIETARY_SUPPLEMENT|Placebo|
41383696|NCT00345826|DRUG|dasatinib|
41383697|NCT06130839|OTHER|Rocker board training|Then intervention will be applied to the perturbation group as mention below at Rocker board (50 x 45 cm).the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after8th week (pre, mid and post intervention). Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between.
41417771|NCT01662466|DRUG|Placebo|Carrier cream without added testosterone in the identical type of pump
40676484|NCT06463665|DRUG|Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC|Administered according to local practice.
40676485|NCT06463665|DRUG|Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab|Administered according to local practice.
40676486|NCT06463665|DRUG|Docetaxel|Administered according to local practice.
40676487|NCT05449535|DRUG|JYB1904|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
40676488|NCT05449535|DRUG|Omalizumab|Dosage form: injection, powder, lyophilized, for solution； Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.
40676489|NCT05449535|DRUG|JYB1904 Placebo|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
40676490|NCT05169515|DRUG|SC Mosunetuzumab|Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days for Cycle 1 and 28 days for Cycles 2-12)
40676491|NCT05169515|DRUG|IV Glofitamab|Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
40676492|NCT05169515|DRUG|CC-220|Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
40676493|NCT05169515|DRUG|CC-99282|Arm 1: Participants will receive oral CC-99282 from Day 1-14 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12) Arm 2: Participants will receive oral CC-99282 from Day 1-10 of Cycle 3-12 (cycle length = 21 days)
40676494|NCT05169515|DRUG|Obinutuzumab|Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
40676495|NCT05169515|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
41383698|NCT06130839|OTHER|Stable surface training|the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after 8th week (pre, mid and post intervention).
41383699|NCT00758225|DRUG|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients \> 45 kg: 900 mg/day (2 tablets 3 times a day)
40853238|NCT05271760|PROCEDURE|Continuous epidural analgesia|Epidural analgesia is performed using a 16-gauge Tuohy epidural needle using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid a test dose of 3 ml lidocaine 1.5% with epinephrine 1:200000 will be given via inserted catheter, 10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse in a rate of 6 -14 ml/h.
40853239|NCT05271760|PROCEDURE|Combined spinal-epidural analgesia|"Epidural analgesia is performed using a combined spinal-epidural set. using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance, once epidural space will be detected, 27 G Whitacre spinal needle inserted through Touhy epidural needle, intrathecal injection of 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml. Then an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid.~10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse at a rate of 6 -14 ml/h if needed."
40853240|NCT05670613|OTHER|CDSS Canceling|The use of Clinical Decision Support System in Parenteral Nutrition
40853241|NCT00193921|DRUG|Vinorelbine|IV, 25mg/m2, days 1, 8, 22
40853242|NCT00193921|RADIATION|High dose Radiotherapy|External beam radiation, 40 Gy/20#/5 per week
40853243|NCT00193921|DRUG|Gemcitabine|200mg (flat dose) IV days 1, 8, 15
40853244|NCT00193921|DRUG|Cisplatin|20mg/m2, IV, weekly
40853245|NCT00193921|RADIATION|High Dose Radiotherapy|External beam radiation, 30 Gy/15#/5 per week
40853246|NCT01295957|BEHAVIORAL|reminiscence therapy|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
40853247|NCT01295957|BEHAVIORAL|comparison group|The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
41383700|NCT00006385|BIOLOGICAL|MART-1 antigen|
40853248|NCT01295957|OTHER|control|advise and informal counseling
41036699|NCT04013815|PROCEDURE|erector spinae plane block with ropivacaine|The block is performed immediately before surgery. by an ultrasound guide, with the probe positioned longitudinally, the spinous process of T5 is identified. A peripheral block needle is inserted in the cephalo-caudal direction (caliber 21G and length 10 cm) and 3 ml of physiological solution are injected to confirm the injection site: fascial plane between the erector spinae muscle and the large rhomboid, near the tip of the transverse process of T5. Once the correct position of the needle tip has been confirmed, ropivacaine 0.75% 20 ml is injected.
41036700|NCT04013815|PROCEDURE|Intercostal nerve block with ropivacaine|The intercostal nerve block will be performed by the surgeon at the time of thoracotomy from the 4th to the 8th intercostal space, by injecting 20 ml of 0.75% ropivacaine (4 ml for each space). The injection is performed at about 2-3 cm from the spine.
41383701|NCT00006385|BIOLOGICAL|gp100 antigen|
41383702|NCT00006385|BIOLOGICAL|incomplete Freund's adjuvant|
41036701|NCT06119698|BEHAVIORAL|GetActive+|This is a 10-week group mind body program focused on improving self- report, performance based and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increased in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
41036702|NCT02334800|DRUG|Palbociclib 75 mg Capsule|Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
41383703|NCT00006385|BIOLOGICAL|recombinant interferon alfa|
41036703|NCT04616157|BEHAVIORAL|ICBT-I|Cognitive-behavioral therapy for insomnia
41036704|NCT02574546|PROCEDURE|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
41383704|NCT00006385|BIOLOGICAL|sargramostim|
41383705|NCT00006385|BIOLOGICAL|tyrosinase peptide|
41383706|NCT01383759|DRUG|Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone|"The treatment has three phases:~1) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks. Long Term Follow Up will cease when all patients on study have fulfilled the requirements for at least five follow up appointments."
41383707|NCT03311386|DRUG|Actilyse|thrombolytic therapy
41383708|NCT03847532|GENETIC|Sanger sequencing method|Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.
41383709|NCT06565845|PROCEDURE|Surgery|patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.
40853249|NCT03220386|OTHER|Decolonization by nasal Octinidin treatment and skin washings|Patients receive nasal Octinidin treatment and skin washings for five consecutive days
40853250|NCT02806453|DIETARY_SUPPLEMENT|thickened formula|
40853251|NCT02806453|DIETARY_SUPPLEMENT|Mg alginate|
40853252|NCT02806453|BEHAVIORAL|reassurance with lifestyle changes|
40853253|NCT03063905|DRUG|Buprenorphine|Patients taking buprenorphine to wean off an opiate addiction
40853254|NCT05332652|DEVICE|trancranial magnetic stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
40853255|NCT00003883|DRUG|fluconazole|
40853256|NCT00003883|DRUG|itraconazole|
40853257|NCT05813691|DIAGNOSTIC_TEST|Meridan Bioscience Point of Care test against HCV antibodies|Point of care evaluation of antibodies against HCV obtaining a drop of capillary blood via puncture of the fingertip. If antibodies were detected, HCV RNA assay will be performed.
41036705|NCT06355986|BEHAVIORAL|Alert-based computerized decision support|An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the provider that his or her patient is at risk for stroke due to AF, and that there is no order for anticoagulation. Clinicians who receive the computer alert will have three options: 1) access an order template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence-based clinical practice guidelines to learn more about stroke prevention in AF, or 3) continue with order entry after providing an explanation for why anticoagulation was not prescribed.
41036706|NCT06066060|DRUG|JMKX000623|JMKX000623, administered orally ;
41036707|NCT06066060|DRUG|Metformin|Metformin,administered orally
41036708|NCT03987308|DRUG|Beinaglutide|Five-week Beinaglutide pump treatment group
41036709|NCT03987308|DRUG|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
41036710|NCT06426641|DEVICE|Polyethylene|There is no intervention
41036711|NCT00170118|BEHAVIORAL|motivational interviewing|
41036712|NCT05111236|OTHER|Routine physical therapy|Rehabilitation strategies in management of children with spastic CP
41383710|NCT06565845|DRUG|triple anti-tuberculosis drug|Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).
41383711|NCT01314859|DRUG|Nifedipine|"* Oral Treatment with Nifedipine capsules (10mg)~  * Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~ * Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~* Maximum Duration of the treatment: 48 hours."
40853258|NCT04913662|PROCEDURE|Pressurized Intraperitoneal Aerosol Chemotherapy|Aerosolization of chemotherapic agent for intraperitoneal chemotherapy
40853259|NCT03944408|PROCEDURE|stent implantation|stent implantation
40853260|NCT03388047|DEVICE|Endoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source|During surveillance endoscopy procedure, the endoscopist will insert the multispectral endoscopy probe through the working channel and use this to inspect the Barrett's oesophagus segment and any visible lesions
40853261|NCT02147288|DEVICE|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
40853262|NCT00550381|DRUG|HKI-357|Single-dose capsule
41036713|NCT05111236|OTHER|Traditional massage|Rehabilitation strategies in management of children with spastic CP
41036714|NCT06636227|DRUG|Diclofenac 100mg|Diclofenac 100mg
41036715|NCT06636227|DRUG|Diclofenac 75mg|Diclofenac 75mg
41036716|NCT06636227|DRUG|Diclofenac 50mg|Diclofenac 50mg
41383712|NCT01314859|DRUG|Atosiban|"* Intravenously Treatment with Atosiban (7.5mg/ml)~  * Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~ * Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~* Maximum Duration of the treatment: 48 hours."
41417772|NCT04258241|PROCEDURE|Local infiltration analgesia with local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
40853263|NCT02397044|PROCEDURE|Implant surgery|Compare surgical protocols
41036717|NCT06636227|DRUG|Placebo control|Placebo control
40853264|NCT00235144|DEVICE|sirolimus-coated Bx Velocity stent|drug-eluting stent
40853265|NCT00235144|DEVICE|uncoated Bx Velocity stent|bare-metal stent
40853266|NCT00583037|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
40853267|NCT03177928|DEVICE|Transthorathic echocardiogram|In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
40853268|NCT03867643|BIOLOGICAL|hepatitis B vaccine(HepB)|Children with anti-HBs at a low level (\<10mIU/mL and \[10,100) mIU/mL) were received a dose of hepatitis B vaccine booster after informed consent.
40853269|NCT06263816|DRUG|Experimental group: Patients will be treated with carvedilol.|Patients will receive the number of pills of carvedilol corresponding to the dose determined during the titration period (either one pill of 6.25 mg in the morning or 1 pill of 6.25 mg twice a day, 1 in the morning and 1 in the evening.
41036718|NCT01786967|DRUG|Fesoterodine Fumarate|FDA approved anticholinergic medication used for treatment of urge urinary incontinence
41036719|NCT02722746|DRUG|Ropivacaine|Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
41036720|NCT02722746|DRUG|Epinephrine|Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
41036721|NCT04901858|DIAGNOSTIC_TEST|Aspiration of haemarthrosis and high definition MRI|Aspiration of haemarthrosis and high definition MRI
41036722|NCT03453398|OTHER|Shifts working hours with different schedules|"Workers in Group 1, 2, and 3 will undergo three different shift work modalities presenting different schedules.~Importantly, as an inclusion criteria, workers have to be involved in the same shift modality for at least one year at the time at the beginning of the study."
41036723|NCT00120172|DRUG|oxaliplatin, capecitabine, bevacizumab|
41383713|NCT06568315|DIETARY_SUPPLEMENT|Concurrent multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement providing 30 mg elemental iron and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate together every morning from enrollment through the end of pregnancy
41383714|NCT06568315|DIETARY_SUPPLEMENT|Separate multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement (MMS) providing 30 mg elemental iron every morning and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate every evening from enrollment through the end of pregnancy
41383715|NCT06566573|OTHER|Pain|The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.
41383716|NCT06566573|OTHER|Normal Range of Motion|CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
41383717|NCT06566573|OTHER|Proprioceptive Sense|CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
41383718|NCT02300272|DEVICE|Polysomnograph|Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
41509292|NCT01381315|PROCEDURE|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur \<3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
41509293|NCT01381315|PROCEDURE|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative-that the lymphedema rate is \<0.13 for subjects undergoing ALND-if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
41509294|NCT06023459|DRUG|Injectable extended-release buprenorphine|Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
40853270|NCT06263816|OTHER|Control group: Patients will receive a placebo.|Patients will receive the number of pills of placebo corresponding to the dose determined during the titration period (either one pill in the morning or 1 pill twice a day: 1 in the morning and 1 in the evening).
41383719|NCT02300272|DEVICE|Actiwatch|This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
41383720|NCT03519386|COMBINATION_PRODUCT|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions.
41383721|NCT03519386|DRUG|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
41383722|NCT00455923|DRUG|Seretide|Seretide
41509295|NCT06023459|DRUG|Sublingual buprenorphine-naloxone|Participants randomized to the SL-BUP condition will receive SL-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
41509296|NCT01654172|DIETARY_SUPPLEMENT|High Flavanol Cocoa|Total daily flavanol intake provided by the high flavanol drink is \~900mg
41509297|NCT01654172|DIETARY_SUPPLEMENT|Low Flavanol Cocoa|
41509298|NCT02827734|DEVICE|multiple breath washout tests|
40853271|NCT05525650|DRUG|House Dust Mite Extract, Dermatophagoides Farinae|"\[Group 1\] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~\[Group 2\] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~\[Group 3\] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E."
40853272|NCT03893682|DRUG|CG-806|CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
41509299|NCT02827734|DEVICE|impulse oscillometry|
41509300|NCT02827734|DEVICE|body plethysmography|
41509301|NCT02876757|DRUG|5ARI|Exposure to finasteride/dutasteride
41509302|NCT04913012|COMBINATION_PRODUCT|Systematic aerobic training|Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
41509303|NCT04913012|COMBINATION_PRODUCT|Systematic resistance training|Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
40676497|NCT01144676|DRUG|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days."
41036724|NCT04833647|DIAGNOSTIC_TEST|Cardio-Pulmonary-Exercise-Testing (CPET)|Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study
41383723|NCT00455923|DRUG|Flixotide|Flixotide
41383724|NCT02264509|PROCEDURE|Ankle-Brachial index|The only procedure to be performed is the measurement of ABI for the diagnosis of arterial insufficiency.
40853273|NCT06508515|BEHAVIORAL|Unadapted Research Units in Behavioral Intervention (RUBI) implementation strategy|"The unadapted RUBI IS involves weekly, one hour educational meetings where sessions involve discussion of homework from the week prior (5 minutes), didactic instruction on targeted behavioral strategies (40 minutes), coaching and consultation around the newly learned strategy (10 minutes), and fidelity review, where RUBI implementation is observed (5 minutes). Finally, Attend\| Behavior® is a HIPAA-compliant mobile application support that is designed to support RUBI delivery and implementation."
40853274|NCT06508515|BEHAVIORAL|RUBI in Educational Settings (RUBIES)-Team|RUBIES is an 8-module intervention that provides educators a range of skills to support the building of a behavioral management toolbox to be used, as needed, with autistic children and disruptive behavior. The program emphasizes: 1) tailoring the intervention to the specific child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice; 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to modify behaviors. All educators will receive RUBIES training across 24 weeks via Zoom.
40853275|NCT06229262|DIETARY_SUPPLEMENT|Mango group|Participants will consume 1.5 cups of mangos per day for 12 weeks.
40853276|NCT06435312|DRUG|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants
40853277|NCT04481360|DEVICE|CT of the chest|Degree of affection on the lung infected by COVID19
40853278|NCT03666689|PROCEDURE|surgical technique|surgical reconstruction
40853279|NCT03910101|PROCEDURE|Hand surgery and intensive rehabilitation|Spasticity-correcting upper-limb surgery comprised lengthening of tendons, release of muscles, and occasionally correction of deformities. Rehabilitation starts the first post-operative day and comprised physiotherapy and occupational therapy. Patients are also taught a home-training program. Up to 1 week of intensive in-hospital rehabilitation followed 3 weeks after surgery and a new home-training program are designed.
40853280|NCT05894785|PROCEDURE|External cephalic version|An ECV attempt is made on the study group
40853281|NCT05299008|DRUG|Bethanechol|Infants whom will be treated with bethanechol for tracheobronchomalacia in level IV center Neonatal Intensive Care Unit.
40853282|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
40853283|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
40853284|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)|injection of Total Volume of each intravitreal injection is 100 µL
40853285|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)|injection of Total Volume of each intravitreal injection is 100 µL
40853286|NCT00249678|BEHAVIORAL|Behavior Therapy|
40853287|NCT01433172|BIOLOGICAL|Phase I - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design."
40853288|NCT01433172|BIOLOGICAL|Phase II - GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10\^6 irradiated H1944 tumor cells, 7.5 X 10\^6 irradiated H2122 cells, and containing 15 X 10\^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
40853289|NCT01433172|BIOLOGICAL|Phase II - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period."
40853290|NCT01578122|DEVICE|25mmHg ECS|"Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.~Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg)."
41383725|NCT04438980|DRUG|Methylprednisolone|-A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión
41383726|NCT04438980|OTHER|Placebo|-An infusion bag of 100 mL of 0.9% saline
41383727|NCT06569212|DRUG|Metoprolol|"Metoprolol Dosing:~Metoprolol Injection (instructions: 5mg, once) Metoprolol Tab (25mg PO, q12 hours, timed to start 1hr after Metoprolol Injection, 6 doses) If unable to take PO medication, Metoprolol Injection (instructions, 5mg q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"
41383728|NCT06569212|DRUG|Placebo|"Placebo Dosing:~Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"
41509304|NCT04913012|COMBINATION_PRODUCT|Aerobic training booster sessions|Supervised aerobic training booster sessions delivered in the follow up period (two sessions every fifth week).
41509305|NCT04913012|COMBINATION_PRODUCT|Resistance training booster sessions|Supervised resistance training booster sessions in the follow up period (two sessions every fifth week).
41509306|NCT00450801|DRUG|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
41509307|NCT00450801|DRUG|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
41509308|NCT00450801|DRUG|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
41509309|NCT00450801|DRUG|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
41509310|NCT00450801|DRUG|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
41165883|NCT03582150|DEVICE|Remote Monitoring with Ambulatory Detox|"* Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~* Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~* Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~* Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~* If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~* The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday."
41383729|NCT01262729|PROCEDURE|therapeutical hypothermia|Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
40853291|NCT01578122|DEVICE|35 mmHg ECS|Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
40853292|NCT01583842|DRUG|124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)|"124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration \& PET/CT scan 6 weeks later."
41383730|NCT01262729|DRUG|Xenon Inhalation|Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
41383731|NCT04539158|DEVICE|Direct Current Cardioversion|The patient is sedated and shocked using an external defibrillator to terminate the arrhythmia and restore a normal intrinsic rhythm (i.e., normal sinus rhythm).
40853293|NCT01583842|DRUG|124I-MIBG (carrier added)|"124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration \& PET/CT scan 6 weeks later."
40853294|NCT01583842|PROCEDURE|Positron Emission Tomography (PET) /Computerized tomography (CT)|A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.
40853295|NCT00350844|DRUG|Hydroxyurea|20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
40853296|NCT01770236|DRUG|IV acetaminophen|Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
40853297|NCT02337192|DRUG|Curcumin|
40853298|NCT02337192|DEVICE|LED|
40853299|NCT02337192|DRUG|Surfactant|
40853300|NCT02337192|DRUG|DMSO + water|
40853301|NCT02337192|DRUG|Chlorhexidine gluconate|
41383732|NCT05688800|DEVICE|conventional therapy|Participants in control group will receive conventional physical therapy treatment including Conventional TENS high frequency (90-130hz) low intensity according to the patient sensation for 30-45 min(Gozani, 2019) , continuous ultrasound with frequency 1 MHz and intensity 0.8 W/cm 2 will be applied by slow circular perpendicular movements with slightly deep pressure. Application time was 5 minutes at each side of the level of C7_T4 along the medial borders of the scapulae width, infra-red radiation will be four 15 minutes and directed perpendicular to the inter-scapular area, centered at the level of C7_T4 long and between the 2 medial borders of the scapulae width . Also combined stretching and strengthening exercise will be added due to its greater pain-relieving effect
41417773|NCT04258241|PROCEDURE|Local infiltration analgesia without local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 0.3 mg of epinephrine and 120 ml of normal saline.
41417774|NCT04258241|DEVICE|Needle|18-gauge 40 mm Sterican needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform local infiltration analgesia.
41417775|NCT04258241|DRUG|Solution with local anesthetic|Solution of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline will be used to perform local infiltration analgesia.
41509311|NCT00450801|DRUG|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
40853302|NCT04753749|DRUG|Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)|Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months
40853303|NCT04753749|DRUG|Standard DAPT|Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure
40853304|NCT02774369|BEHAVIORAL|Physical exercise|Individualized aerobic intervention program
40853305|NCT02774369|BEHAVIORAL|Cognitive-behavioral therapy|Psychological intervention combining behavioral, cognitive, and educational strategies
40853306|NCT03637569|OTHER|Measurement of triceps skinfold thickness|By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.
40853307|NCT01488201|DRUG|Placebo|
40853308|NCT01488201|DRUG|KHK4827|
40853309|NCT02902393|BIOLOGICAL|Thromboelastography|
40853310|NCT04861376|DRUG|Pueraria lobata|The dose of Pueraria lobata granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
40853311|NCT04861376|DRUG|Pueraria thomsoni|The dose of Pueraria thomsoni granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
40853312|NCT04861376|OTHER|Placebo|The placebo group will take the same dose as the other two groups.
40853313|NCT05768035|BIOLOGICAL|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors 6 days after haplo HSCT and 2 days after the last administration of cyclophosphamide
40853314|NCT00609570|DIETARY_SUPPLEMENT|NanoGreens|fruits and vegetables
40853315|NCT00609570|DIETARY_SUPPLEMENT|Whey protein|Whey
40853316|NCT00609570|DIETARY_SUPPLEMENT|Calcium pills|CA
41165884|NCT05583708|DRUG|Pembrolizumab|Pembrolizumab 400mg IV
41165885|NCT05583708|DRUG|Lutetium Lu 177 dotatate|7.4GBq (200 mCi) IV
40853317|NCT02404428|DIETARY_SUPPLEMENT|Standard broccoli soup|300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
40853318|NCT02404428|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
40853319|NCT05999500|BEHAVIORAL|Temple stay experience|Temple stay experience includes diet and behavior changes, such as vegetarian meals (ex. Balwoo Gongyang), mindful eating, no overeating, meditation, participation in daily monastic tasks.
40853320|NCT05357508|BEHAVIORAL|Intervention brochure|Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.
40853321|NCT05357508|BEHAVIORAL|Control brochure|Provide participants with general information about options for colorectal cancer screening.
40853322|NCT04057430|DEVICE|GumChucks|GumChucks® is an innovative flossing system resembling mini nunchucks. The two-handle design eliminates the need to wrap the floss around fingers, and a proper flossing technique is facilitated by the nature of its curved shaped.
41383733|NCT05688800|OTHER|Experimental group 1 : pressure release technique|Participants who are assigned to this group will receive conventionalphysical therapy treatment in addition to pressure release technique. the participant will be positioned either sitting or prone position according to his preferred position, the researcher will apply the pressure release procedure by a pressure below the PPT dependent onsoft tissue release. When the researcher detected a reduction in soft tissue resistance, the amount of compression will be increased. The pressure should -33- be nonpainful, applied at slow rate, and will maintained until release of tissue barrier. Further pressure was increased to reach a new barrier. The pressure will last 60 seconds. With the thumb or the second and third fingers, the non-painful manual therapy approach was applied to the active MTrPs of therhomboid muscle
41383734|NCT05688800|OTHER|Experimental group 2: thoracic spine manipulation|Thoracic spine manipulation will be performed as screw thrust manipulation technique; the vertebral transverse processes will beforced from posterior to anterior direction. The direction of the manipulation should be identified by applying springing test to the adjacent spinous process to determine the painful and stiff segment. Patient will be prone and researcher hand placement will be positioned as the following one pisiform on the right facet of the above, and the other pisiform on the left facet of the below vertebrae.A slack will be taken up. The thrust applied directly toward the patient once
41383735|NCT02341872|OTHER|Clinpro White Varnish (fluoride + calcium varnish)|Clinpro White Varnish will be applied to the teeth with brush.
40853323|NCT04057430|DEVICE|String floss|Traditional string floss used in this study was Oral-B Glide® Pro-Health Original Floss
40853324|NCT06185075|PROCEDURE|Implant crown delivery|Dental implant crown will be designed, fabricated by a dental lab, and delivered.
40853325|NCT04992845|DEVICE|Anterior Vertebral Body Tethering|The SCOLI-TETHER (MIScoli) System is intended for anterolateral vertebral body fixation and internal fastening of the convex side of the thoracic curvatures thereby reducing the deformity and preventing the progression of idiopathic scoliosis in growing children/adolescents at high risk for curve progression while preserving motion.
40853326|NCT03453580|RADIATION|multislice computed tomography portography|imaging modality
40853327|NCT06176638|BEHAVIORAL|RRF4H Combination Intervention|"MFG: is a family strengthening model where children and their parents sit together in groups of 8 to 10 families to discuss important issues. MFG approach provides a social support mechanism and strengthens family relationships by allowing families to share common experiences as well as effective strategies for addressing difficult issues; and focuses on reducing stigma and normalizing common experiences.~TAHC: This is a peer-led program that allows younger students to talk with peers about important issues that they face, gain role models, and identify positive social norms from older peers. It provides age-appropriate lessons and is delivered in a structured fashion. The curriculum consists of sixteen 50-minute lessons spread out over two academic years. Topics delivered in the curriculum include substance use, positive outlook on life, forming a positive self-concept, decision making and problem solving, coping with depression, bullying and social media."
40853328|NCT00337090|DRUG|YM178|
40853329|NCT04601805|DEVICE|Observation|We will record the vascular changes that follow the inflammatory bowel diseases
41036725|NCT02738177|DRUG|Misoprostol|2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)
41036726|NCT02738177|DRUG|Isosorbide-5-mononitrate|2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)
41036727|NCT02738177|DRUG|misoprostol and Isosorbide-5-mononitrate|1tablets of misoprostol (i.e.200 ug) \& 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
41036728|NCT02239783|DEVICE|total hip arthroplasty implant|
41383736|NCT02341872|OTHER|Curodont Repair|Curodont Repair solution be applied to the teeth in the form of drops
41383737|NCT04980391|BIOLOGICAL|RSV MAT|Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
41383738|NCT04980391|DRUG|Placebo|Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
41509312|NCT00450801|DRUG|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
40853330|NCT01059994|DRUG|Placebo sildenafil|Oral, daily, 1 week.
40853331|NCT01059994|DRUG|Sildenafil|oral, 25mg, daily for 1 week
41036729|NCT02980159|OTHER|Triage liaison physician|A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room
41165886|NCT01891890|DRUG|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
41383739|NCT04686968|PROCEDURE|Greenhouse Technique|First, the high-strength sutures were passed through the teared tendon, and then Crimson duvet procedure was performed on the footprint from the articular margin of the humeral head to the apex of the greater tubercle, followed by a lateral row anchor.
41383740|NCT04686968|PROCEDURE|Microfracture Combined With Suture Bridge Technique|A three-line anchor suture method is used as in the greenhouse technique, except that the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
41509313|NCT00450801|DRUG|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
40853332|NCT03831035|OTHER|Genetic analyse by whole exome sequencing|Exome sequencing requires analytic, bio informatic and interpretation steps.
40853333|NCT00273429|DRUG|timolol maleate 0.5%|
40853334|NCT00273429|DRUG|dorzolamide/timolol maleate fixed combination|
40853335|NCT00273429|DRUG|latanoprost 0.005%|
40853336|NCT00273429|DRUG|placebo|
40853337|NCT00038558|DRUG|Filgrastim SD/01|
40853338|NCT00038558|DRUG|Adriamycin|
40853339|NCT00038558|DRUG|Bleomycin|
40853340|NCT00038558|DRUG|Vinblastine|
40853341|NCT00038558|DRUG|DTIC|
40853342|NCT02395523|RADIATION|Proton Beam Therapy|"Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~* Clinical target volume (CTV) = GTV + internal target volume~* Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~* Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
41036730|NCT03800823|BEHAVIORAL|Parent group|In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.
41509314|NCT00450801|DRUG|Thalidomide|Maintenance therapy.
40853343|NCT06232785|DRUG|Ibuprofen|0.8g intravenous injection 30min before the end of the operation
40853344|NCT06232785|DRUG|sufentanil|0.2ug/kg intravenous injection 30min before the end of the operation
40853345|NCT06583278|DEVICE|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
40853346|NCT04280731|DIETARY_SUPPLEMENT|fermented quinoa|Quinoa drink fermented with lactic acid bacteria isolated from food
40853347|NCT01863329|PROCEDURE|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
40853348|NCT02601833|DEVICE|Silver Diamine Fluoride|No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.
40853349|NCT02601833|PROCEDURE|Conventional Caries Management|These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
40853350|NCT05403671|OTHER|Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer|Intervention includes exercising and relaxation in a group
40853351|NCT03441386|BEHAVIORAL|Physical Exercise Session|
40853352|NCT00642161|DRUG|budesonide|
40853353|NCT03517228|DEVICE|BAUM device|The robotic manipulator will be placed at the start of each case. The manipulator will be cleaned and sanitized using the same process as other reusable OR devices. Feasibility will be determined by the rate of successful robotic manipulator docking and if the manipulation of the uterus was successful for the duration of the procedure. The V-Care is an FDA approved uterine manipulator which will attach to the investigational BAUM. Placement of a BAUM will be noted on the operative note.
40853354|NCT04860141|DRUG|Gabapentin 600mg|The patient will take gabapentin 600mg 2 hours prior to the procedure
40853355|NCT04860141|DRUG|Placebo|the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
40853356|NCT05246709|DEVICE|Cyanoacrylate glue|"Adhesive to be applied on the PICC line site prior to usual standard film dressing over the site, such as SecurePortIV® Catheter Securement Adhesive by Adhezion Biomedical® Cyanoacrylate adhesive that is FDA-approved for securement of vascular access devices.~Securement method that provides microbial protection by sealing the insertion site."
40853357|NCT05246709|DEVICE|Standard transparent film dressing|A standard transparent polyurethane film dressing, such as 3M TEGADERM Film, for dressing the PICC line area.
40853358|NCT02386826|DRUG|INC280|"Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase"
40853359|NCT02386826|BIOLOGICAL|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
40853360|NCT06256744|OTHER|exercise|Resistance exercise
40853361|NCT02518633|DEVICE|Continuous positive airway pressure devices|overnight use of CPAP device
40853362|NCT04623814|OTHER|Food|HEC113995 20mg will be taken orally fasted or with food
41036731|NCT03800823|BEHAVIORAL|mHealth component|After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.
41417776|NCT04258241|DRUG|Solution without local anesthetic|Solution of 0.3 mg of epinephrine and 120 ml of normal saline will be used to perform local infiltration analgesia.
41417777|NCT01893138|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
40853363|NCT04623814|DRUG|HEC113995|HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
40853364|NCT04623814|DRUG|placebo|The placebo will be administered fasted or with food for 10 days.
41383741|NCT05043961|PROCEDURE|Palisade sacroiliac joint radiofrequency ablation using 3-tined needles|"Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.~The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.~Lesioning the L5 dorsal ramus:~o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion."
41509315|NCT00450801|DRUG|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
41383742|NCT06540547|BEHAVIORAL|MomMA Intervention|Parents will receive sessions of CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings. The number and specific content of sessions will be determined based on community partner feedback.
41509316|NCT00450801|DRUG|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
40853365|NCT04975100|DRUG|Sarcosine and SSRI|Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
40853366|NCT04975100|DRUG|Placebo and SSRI|Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
41036732|NCT03800823|BEHAVIORAL|Standard care|Standard care for overweight and obesity.
41383743|NCT04215120|DRUG|Desidustat Oral Tablet|Desidustat tablet
41509317|NCT00450801|DRUG|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
41509318|NCT00450801|DRUG|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
41383744|NCT04215120|DRUG|Epoetin Alfa|Epoetin Injection
41383745|NCT02010307|OTHER|blood extraction|6 ml blood extraction from each patients in all 3 arms of the study
41509319|NCT00450801|DRUG|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
41509320|NCT01707017|OTHER|Strength training|
41036733|NCT04039672|PROCEDURE|Skin biopsy|5mm skin metastasis or primary melanoma biopsy
41036734|NCT02576067|DRUG|Low dose methotrexate|Study participants will additionally receive 1 mg daily oral folate.
41383746|NCT03258515|DRUG|AZD6094 200 mg|A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.
40676498|NCT01144676|DRUG|placebo|The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
41383747|NCT03258515|OTHER|Placebo|AZD6094 matching placebo without any pharmacological activity.
41383748|NCT03258515|DRUG|Moxifloxacin|A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
41383749|NCT03372772|DRUG|Levocarnitine|Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
41509321|NCT03840187|DIAGNOSTIC_TEST|Digital cervicography|Colposcopist findings and digital cervicography employing Gynescope system
41509322|NCT00492778|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
41509323|NCT00492778|DRUG|Cisplatin|Given IV
41509324|NCT00492778|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41509325|NCT00492778|RADIATION|Internal Radiation Therapy|Given intracavitarily or interstitially
41509326|NCT04236934|OTHER|Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis|Questionnaire is about symptoms measured by Edmonton Symptom Assessment Score (ESAS) and dyspnea also by modified Borg Scale (MBS)
40676499|NCT01144676|DRUG|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours."
40676500|NCT01144676|DRUG|placebo|The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
40676501|NCT05887167|BIOLOGICAL|autologous hematopoietic stem cells added to planned CAR T|Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.
40676505|NCT05115422|BEHAVIORAL|'Coping with Brain Fog' program|The proposed intervention is an 8-week 'Coping with Brain Fog' program for cancer survivors, adapted for AYAs with cancer, with one 90-minute group session per week. The intended group size for the program is 8-12 participants. The program was developed to be delivered in person, however for the purposes of this study it will be conducted in a virtual setting. The overall goals of the program are to educate participants about cancer-related brain fog and enhance their cognitive function and wellbeing. To accomplish this, the program is segmented into three main components: memory skills, task management, and psychological wellbeing. For each component, participants are systematically introduced to evidence-based strategies to cumulatively build a repertoire of cognitive tools designed to reduce the impact of cancer-related brain fog. The program uses a manual and participant materials that are copyrighted by Maximum Capacity Inc.
40676507|NCT02262689|DRUG|GSK2256294|GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
40676508|NCT02262689|DRUG|Placebo|Matched Placebo will be supplied as gelatin capsule to be administered orally
40676509|NCT00000161|DRUG|Aspirin|
40676510|NCT00000161|DRUG|Beta-Carotene|
40853367|NCT02353195|OTHER|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
40853368|NCT04375514|DRUG|ARO-ENaC|single or multiple doses of ARO-ENaC by inhalation of nebulized solution
40853369|NCT04375514|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
41383750|NCT02107768|OTHER|Aerobic exercise|"Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .~Two fitness goals was to be achieved during the training session~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate."
41383751|NCT03891979|DRUG|Pembrolizumab|"Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.~Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29."
41383752|NCT03891979|DRUG|Ciprofloxacin 500mg PO BID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
41383753|NCT03891979|DRUG|Metronidazole 500mg PO TID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
41383754|NCT04655339|DRUG|Bilateral abdominal Lap-TAP|A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
41383755|NCT02566967|DRUG|tofacitinib|oral tofacitinib will be taken 2 times daily
41383756|NCT06520735|DEVICE|Transcutaneous electrical nerve stimulation|The pregnant women with emesis gravidarum will be treated by transcutaneous electrical nerve stimulation (TENS) on p6 acupuncture point for 30 minutes daily for 5 consecutive days.
41383757|NCT06520735|OTHER|Capsicum plaster|The pregnant women with emesis gravidarum will be treated with capsicum plaster on p6 acupuncture point for 12 hours per day for 5 consecutive days.
41383758|NCT01101269|DRUG|ACEI or ARB|Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.
41383759|NCT01101269|DRUG|Lisinopril|Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
41383760|NCT04469322|DIAGNOSTIC_TEST|Mental Health DNA Insight Test (Pathway Genomics)|Pharmacogenetic report based on the patients DNA profile at \~45 SNP markers covering 16 genes
41383761|NCT04469322|DIAGNOSTIC_TEST|Sham Test|"Names of 53 medications listed with use as directed"
41383762|NCT00424632|DRUG|PF-03814735|1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
41509327|NCT02569918|DEVICE|Surface electrical stimulation|"Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand Azzurra (Prensilia, Italy) and the robotic hand Multi-sensory Prosthetic Hand (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject."
41509328|NCT05665595|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
41509329|NCT05665595|BIOLOGICAL|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
40853370|NCT03874884|DRUG|Olaparib|"During dose escalation doses of olaparib that can be administered are 50mg BD D2-15, 100mg BD D2-15, 150mg BD D2-15, 200mg BD D2-15,250mg BD D2-15, 300mg BD D2-15, 200mg BD D4-14, 300mg BD D-4-14 or 400mg D-4-18 of a 42 day cycle for up to 6 cycles.~The recommended phase 2 dose of olaparib will be used in 2 consecutive dose expansion cohorts. The first cohort will received the recommended phase 2 dose of Olaparib on D4-14 of a 42 day cycle. Patients enrolled in the second dose expansion cohort will receive Olaparib continuously from cycle 1 day -4 to cycle 6 day 42."
40853371|NCT03874884|COMBINATION_PRODUCT|177Lu-PSMA|A fixed 7.4Gbq administered activity of 177Lu-PSMA will be given 6 weekly for up to 6 cycles.
41036735|NCT02576067|DRUG|Placebo|
41036736|NCT00124527|DRUG|Irofulven + capecitabine|
40676511|NCT00000161|DRUG|Vitamin C|
40676512|NCT00000161|DRUG|Vitamin E|
41036737|NCT02265900|OTHER|Exercise|One type of exercise
41036738|NCT02265900|OTHER|Exercise|A different type of exercise
40676513|NCT04737798|OTHER|oil pulling with coconut oil|using oil pulling therapy with coconut oil
40676514|NCT04737798|OTHER|oil pulling with sesame oil|using oil pulling therapy with sesame oil
40676515|NCT00459706|DEVICE|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
41036739|NCT02129738|DEVICE|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
41036740|NCT05859204|BEHAVIORAL|OT-led Exercise Group|Participants will complete pre-intervention self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin 10-minute educational session that describes the purpose of the exercise intervention and methods to remain safe during the intervention such as self-monitoring techniques. Following completion of the educational session, participants will complete a 30-minute exercise intervention under the guidance of the OT, which includes warm-up, high intensity interval training cardio, strength, kick boxing, cool-down, and yoga. Following completion of the exercise regimen, participants will participate in a 10-minute discussion and reflection with the OT and complete post-intervention self-report surveys. Participants in the intervention arm will also receive routine daily occupational therapy educational sessions received by the treatment as usual arm.
41165887|NCT01891890|DRUG|Levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
41383763|NCT06541925|DEVICE|Injection with the needle-free (NF) system|Before the injection procedure, the children were demonstrated the popping sound produced by device to prevent reflex reactions, and they informed that they would feel as if their gum were punched. The NF injection device was prepared according to the manufacturer's instructions, placed in full contact with the buccal mucosa and a pre-withdrawn dose of 0.1 ml was applied to the buccal region for topical purposes by the pushing the top of the device. After 10-15 seconds, the same procedure was repeated with withdrawn dose of 0.3 ml. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
41383764|NCT06541925|DEVICE|Injection with the traditional method (TM)|The depth of penetration was only a few millimeters and 0.3ml of anesthetic solution was deposited. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
41509330|NCT05000528|OTHER|therapeutic education|In groups of 5-6, patients will have a one-day therapeutic training session comprising 4 workshops: how to create a sleep agenda; normal sleep; sleep hygiene; medical treatments.
41509331|NCT05000528|OTHER|Actimetry|once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention
41509332|NCT06115083|OTHER|Pelvic floor re-education using bio-feedback and home training|Pelvic floor re-education using bio-feedback and home training
41509333|NCT03973307|DIAGNOSTIC_TEST|UroX bladder cancer biomarker test|Urine test using novel UroX biomarker test for bladder malignancy
41509334|NCT00822692|DRUG|Trim/ Sulfa DS|bactrim DS (800/160) two tablets PO BID x 7 days
41509335|NCT00822692|DRUG|placebo|matched placebo 2 pills PO BID x 7 days
41509336|NCT00486525|PROCEDURE|Yoga Therapy|Patients will undergo yoga therapy
41165888|NCT01891890|DRUG|Lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
41165889|NCT00304668|DRUG|dapivirine (TMC120) vaginal gel|
41383765|NCT02296671|DRUG|Pemetrexed|
41383766|NCT02296671|DRUG|Oxaliplatin|
41383767|NCT02296671|DRUG|Leucovorin|
41383768|NCT02296671|DRUG|Fluorouracil|
41383769|NCT02296671|GENETIC|Germline genotyping analyses for TSER|
41383770|NCT04764669|DRUG|E2027|Oral hypromellose capsules.
41509337|NCT02671929|BEHAVIORAL|self-help program|Access to the internet-based self-help program
41383771|NCT00830271|DEVICE|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
41383772|NCT00830271|DEVICE|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
41383773|NCT01525407|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
41383774|NCT01525407|DRUG|Atorvastatin Calcium|Given PO
41383775|NCT01525407|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
41383776|NCT01072318|DRUG|Letrozole|Letrozole 2.5mg
40676516|NCT00459706|DEVICE|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
41383777|NCT05165173|DIETARY_SUPPLEMENT|NanoD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of nanoparticles of D3 and instructed to consume it in the morning with a meal.
41509338|NCT02671929|BEHAVIORAL|therapeutic feedback|Therapeutic feedback on the written information sent to the online therapist
41509339|NCT05741372|DRUG|Rosuvastatin|Rosuvastatin
41509340|NCT05741372|DRUG|Digoxin|Digoxin
41509341|NCT05741372|DRUG|Metformin hydrochlorid|Metformin hydrochloride
41509342|NCT05741372|DRUG|Furosemide|Furosemide
41509343|NCT03893643|OTHER|no intervention|no intervention in an observational study
41509344|NCT00425373|DRUG|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
41509345|NCT00425373|DRUG|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
41509346|NCT00425373|DRUG|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
41509347|NCT00425373|DRUG|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
41509348|NCT00425373|DRUG|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
41509349|NCT00425373|DRUG|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
41509350|NCT00425373|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
41509351|NCT00425373|DRUG|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
41383778|NCT05165173|DIETARY_SUPPLEMENT|MicroD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of microparticles of D3 and instructed to consume it in the morning with a meal.
41383779|NCT06402890|DIETARY_SUPPLEMENT|Resistance training with collagen supplementation|"Participants performed 24 lower limb resistance training sessions over under supervision from the principal investigator. Participants were pair-matched, then allocated to hydrolysed collagen (COL) or a calorie-matched beverage comprising maltodextrin and non-caloric sweetener (PLA). Both COL and PLA consumed their respective supplements in conjunction with each resistance training session.~Baseline assessments of strength were used to set initial training loads. An example of weekly training is included below for indicative purposes:~Week 1 protocol:~Day 1:~* Barbell squat, 4 sets @ 90% 10-RM~* Romanian deadlift, 4 sets @ 90% 10-RM~Day 2:~* Hex bar deadlift, 4 sets @ 90% 10-RM~* Dumbbell goblet squat, 4 sets @ 90% 10-RM~Linear progression adjusted weekly loads. If participants completed the prescribed sets and reps, loads increased by 2.5-5 % the following week."
41036741|NCT05859204|BEHAVIORAL|Treatment as Usual - OT Groups|Participants will complete pre-session self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin daily educational session about the topic of choice for that day. Treatment groups are largely discussion-based and include the following topics: coping skills, self-esteem, sleep management, leisure, time management, life skills, decision making, and goal setting. Following completion of the educational session, participants will complete post-intervention self-report surveys.
41036742|NCT03070613|DRUG|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda (a lectin).
41383780|NCT01598740|DRUG|CLP|Oral administration
41383781|NCT01598740|DRUG|Spironolactone|oral administration
41036743|NCT01817413|PROCEDURE|Mineral trioxide aggregate|An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
41383782|NCT03259763|DEVICE|Lumen-apposing metal stent|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
41383783|NCT03259763|DEVICE|Self-expandable metal stent|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
41036744|NCT01817413|PROCEDURE|Revascularisation|Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
41036745|NCT02540200|DEVICE|BST-CarGel|BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
41383784|NCT05649423|OTHER|POSTURAL DRAINAGE WITH PERCUSSION|"Each position should be held for a minimum of five minutes. In each position, your chest should be lower than your hips to allow mucus to drain. On your back: Patient's chest should be lower than his hips, which you can achieve by lying on a slanted surface up about 18 to 20 inches. On your sides: With pillows under your hips, lie on one side. To clear congestion from the right and left lobes. On your stomach: Drape patient's body over a stack of pillows, this is best in clearance of mucus from the lower back area of the lungs.~Percussion The equipment required here is cupped hands of caregiver to deliver the force required to drain the thick secretions. Patient should be in a comfortable position to enhance the effect. This loosens the thick, sticky secretions from the walls of the lung allowing them to into the larger airways, The sound heard must be hollow. The force applied must be equal."
41417778|NCT01893138|BIOLOGICAL|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10\^6 cells.
41509352|NCT00425373|DRUG|Placebo|4 tablet and 2 capsule placebos taken once daily
41509353|NCT02862730|DEVICE|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
41417779|NCT03082781|DIETARY_SUPPLEMENT|NCDsport|Negative Calorie Diet supplemented with exercise
41417780|NCT03082781|DIETARY_SUPPLEMENT|LCDsport|Low-Calorie diet with exercise
41509354|NCT02862730|DEVICE|Subject's insulin pump|Subject will continue on their subcutaneous delivery of insulin on his/her own insulin pump using their own basal rates and carb ratios for meal boluses, managing their blood sugar as they normally would.
41528287|NCT05574218|PROCEDURE|Rubber cup polishing|Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with rubber cup and a polishing paste.
41036746|NCT02540200|PROCEDURE|Microfracture|It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
41036747|NCT04300738|DEVICE|CCS wit CT Scann measurement|Measurement with 2 devices
41036748|NCT05903001|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Ultrasound of the Diaphragm at the end of inspiration and expiration
41036749|NCT05903001|DIAGNOSTIC_TEST|Intercostal Muscle Ultrasound|Ultrasound of the Intercostal Muscles at the end of inspiration and expiration
41036750|NCT05903001|DIAGNOSTIC_TEST|Borg scale|Questionnaire for Perceived Exertion (Borg Rating of Perceived Exertion Scale)
41036751|NCT05903001|DIAGNOSTIC_TEST|MRC Breathlessness Scale|The MRC Dyspnoea Scale allows the patients to indicate the extent to which their breathlessness affects their mobility.
41036752|NCT05903001|DIAGNOSTIC_TEST|Respiratory Questionaire|Specialized respiratory questionnaire with different domains (Emotional Domain, Dyspnea Domain, Mastery Domain, Fatigue Domain)
41383785|NCT05649423|OTHER|Postural drainage|"* Each position should be held for a minimum of five minutes.~* In each position, your chest should be lower than your hips to allow mucus to drain On your back: Patient's chest should be lower than your hips, which you can achieve by lying on a slanted surface or propping patient's hips up about 18 to 20 inches~* This position is best for draining the bottom front parts of your lungs. On your sides: With pillows under your hips, lie on one side so that your chest is lower than your hips. To clear congestion from the bottom part of the right lung, lie on your left side. To clear congestion from the bottom part of your left lung, lie on your right side.~On your stomach: Drape patient's body over a stack of pillows or other object, and rest his arms by his head, with his chest lower than his hips. This position is best for clearing mucus in the lower back area of the lungs."
41383786|NCT00896038|DRUG|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
41509355|NCT02862730|DEVICE|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
40853372|NCT05318872|DEVICE|ENDOSWIR|Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.
40853373|NCT03442218|DRUG|Clorhexidine|Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
41383787|NCT00896038|DRUG|Placebo|Non-active placebo
40853374|NCT03442218|DRUG|Saline solution|Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
41036753|NCT05903001|DIAGNOSTIC_TEST|GINA classification of Asthma|Patients are classified according to the GINA classification of Asthma.
41036754|NCT05903001|DIAGNOSTIC_TEST|Measurement of respiratory mouth pressure|Inspiratory and expiratory Measurement of respiratory mouth pressure
41036755|NCT05903001|DIAGNOSTIC_TEST|SNIP|Measurement of Sniff Nasal Inspiratory Pressure
41036756|NCT05903001|DIAGNOSTIC_TEST|6-minute walking distance|The maximum walking distance achieved in 6 minutes
41036757|NCT05903001|DIAGNOSTIC_TEST|60 seconds sit-to-stand test|number of repetitions achieved in sitting down and standing up in 60 seconds
41036758|NCT05903001|DIAGNOSTIC_TEST|Electromyography|electromyography of the muscles of respiration via superficial electrodes
41036759|NCT05903001|DIAGNOSTIC_TEST|Lung Function|Measurement of lung function via body plethysmography
41036760|NCT05903001|DIAGNOSTIC_TEST|CAT-Questionnaire|COPD Assessment Test (CAT)
41036761|NCT05903001|DIAGNOSTIC_TEST|European Society of Cardiology (ESC)/ European Respiratory Society (ERS) risk group|Patients with pulmonary hypertension are classified according to the ESC/ERS risk group.
41036762|NCT05618353|DRUG|Colchicine|0.6 mg tablets
41036763|NCT05618353|DRUG|Placebo|Matching placebo
41036764|NCT04224155|DEVICE|enVista MX60EFH trifocal intraocular lenses (IOLs)|enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally
41036765|NCT04224155|DEVICE|enVista MX60E monofocal intraocular lenses (IOLs)|enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally
41036766|NCT05638867|DRUG|Aspirin + Clopidogrel + Rivaroxaban|Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily
41036767|NCT05638867|DRUG|Aspirin + Clopidogrel|Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily
41036768|NCT01054820|DRUG|FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%|One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
41036769|NCT05734118|DEVICE|Perfusion assessment by means of the SPY-PHI camera|Minutes after injection of ICG, the intestinal perfusion can and will be assessed using the SPY-PHI camera by Stryker Endoscopy. The operative plan will not be changed based on the results of the perfusion assessment. Images will be recorded and evaluated postoperatively.
41383788|NCT06466057|BEHAVIORAL|Metacognitive Therapy|A one-on-one face-to-face dialogue format will be used to conduct psychotherapy with each participant, and the treatment protocol will be based on the treatment manual for metacognitive therapy.
40676517|NCT03902717|PROCEDURE|Minimally invasive cardiac surgery|Patients will undergo minimally invasive cardiac surgery
41036770|NCT04424381|DRUG|Rivaroxaban 20 MG Oral Tablet [Xarelto]|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet \[Xarelto\].
41036771|NCT04424381|DRUG|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet.
41036772|NCT03405870|DRUG|Smoflipid|Administration of lipid injectable emulsion
41036773|NCT02395120|BEHAVIORAL|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
41036774|NCT02395120|BEHAVIORAL|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
41036775|NCT02395120|BEHAVIORAL|Reduced intervention letter|"Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control)."
41165890|NCT03962764|BEHAVIORAL|Responsible Fatherhood Program|24 hours of fatherhood curriculum, 6 hours of financial literacy, workforce development, and case management.
40853375|NCT01418742|DRUG|Panitumumab, Doxycycline/Placebo|comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
40853376|NCT01418742|DRUG|Panitumumab|mCRC patients receiving panitumumab as EGFR inhibitor.
40853377|NCT05367544|BEHAVIORAL|Health Education|All participants will receive education regardless of randomization status. On the day of enrollment, participants will be invited to attend education modules focused on HTN risk, diet, physical activity, stress management, and goal setting. Participants will also have access to culturally relevant, weekly online sessions, alternating between cooking shows and exercise
41383789|NCT06466057|OTHER|General mental health promotion|A general mental health mission will be conducted, not covering any metacognitive therapy related content, set for 8-15 weeks, 1 time per week
40853378|NCT05367544|BEHAVIORAL|Individual-Level Peer Support|Participants will receive bi-weekly peer support calls for 6 months, followed by monthly calls for another 6 months.
40853379|NCT05367544|BEHAVIORAL|Community-Level Peer Support|Church Leadership in churches randomized to intervention will identify 2-3 Peer Health Advocates from the church who will receive training on ways to promote a culture of health, encouraging church members to attend on-line cooking shows and exercise sessions. After training, these individuals will also work with Church Leadership to form a committee that will develop a project (e.g., community food pantry, farmer's market, Zumba instruction, small church gym) aimed at overcoming structural barriers to healthy behaviors. Each church will receive a small stipend for their project. Churches randomized to education alone will receive the community-level intervention after 12 months of participation in the study (delayed intervention)
40853380|NCT02098278|DRUG|CAT-2003|
40853381|NCT02098278|DRUG|Placebo|
40853382|NCT05874622|DRUG|VC005 tablets|VC005 groups repeat administration for 4 weeks
40853383|NCT05874622|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 4 weeks
40853384|NCT03302247|BIOLOGICAL|Nivolumab|Monoclonal antibody against non small cell lung cancer
40853385|NCT03302247|DRUG|Nivolumab+Gemcitabine|Gemcitabine is added to the Nivolumab treatment
40853386|NCT00240669|DEVICE|Resorbable device PLLA/PGA|
40853387|NCT00240669|DEVICE|Titanium device|
40853388|NCT00986362|DRUG|Ocriplasmin|175µg ocriplasmin intravitreal injection
41383790|NCT03335839|DRUG|tissue plasminogen activator|Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
41383791|NCT03335839|OTHER|Saline|Placebo
41383792|NCT03334942|BEHAVIORAL|Child and Family Traumatic Stress Intervention|The Child and Family Traumatic Stress Intervention (CFTSI) is a 5-8 session intervention, initiated within 60 days of trauma exposure for youth reporting acute PTSS. CFTSI is designed for children age 7 and older, and requires the involvement of a caregiver who knows the child well enough to report changes in the child's behavior and symptoms. CFTSI targets modifiable risk and protective factors during the early post-trauma period to promote recovery and reduce PTSS via caregiver-child communication and cognitive and emotional processing. CFTSI uses skill modules (e.g., sleep disturbance, intrusive thoughts, anxiety) to teach effective strategies to decrease a child's PTSS. Coping and communication skills are taught and practiced in caregiver-child sessions and in the home.
40853389|NCT00986362|DRUG|Placebo|Placebo intravitreal injection
40853390|NCT03226925|DIAGNOSTIC_TEST|Non-invasive mechanically-assisted ventilation|Mechanically ventilation will be done through facial masks connected to a respirator. Volunteers/patients are fully conscious during the ventilation.
41165891|NCT00583115|DRUG|Gleevec|260 mg/M2/day, given once daily by mouth
41383793|NCT01881217|DRUG|BAY1179470|BAY1179470 will be administered as a 1-hour intravenous infusion.
41383794|NCT00929552|DIETARY_SUPPLEMENT|Dietary oils (fish, vegetable oil)|6g pr day.
41383795|NCT04041063|DEVICE|Upper limb robotic training|"Subjects will remain seated in their own wheelchair in front of the InMotion Hand™ Robot (Interactive Motion Technologies, Massachusetts, MA, Figure 6) facing a video screen.~The arm of the participants will be abducted, forearm supported, and hand grasping a cone shaped handle. Velcro straps will lightly hold the forearm and fingers secure. The InMotion Hand™ robot attaches to the InMotion Arm™ robots to provide 'assisted-as-needed'™ gross grasp and release motion and support for functional reach. In each session, patients perform a total of 1024 movement repetitions (Cortes et al., 2013). Patients will receive a total of 18 sessions (3x/week, 6 weeks) comprising one hour of interactive hand robotic training. The interactive robotic features involve visuomotor task, moving the robotic manipulandum according to targets on a computer screen mounted at eye level."
40853391|NCT03226925|DIAGNOSTIC_TEST|Dynamic MRI acquisition|Dynamic MRI acquisition are specific dynamic sequences intended to visualise the motion of internal structures (anatomical structures or tumour) under non-invasive mechanically-assisted ventilation
41165892|NCT03602248|OTHER|Speed endurance training protocol A|1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)
40853392|NCT03226925|DIAGNOSTIC_TEST|Planning 4D-CT|In order to perform in-silico planning, 4D-CT will be acquired on patients under non-invasive mechanically-assisted ventilation
40853393|NCT02384512|DRUG|Azilect®|AZILECT® 1mg Tablets
40853394|NCT04532775|DRUG|magnesium|Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
40853395|NCT04532775|DRUG|Methylprednisolone|Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol).
40853396|NCT04532775|DRUG|Bupivacaine Hydrochloride|local anesthetic drug
40853397|NCT04532775|DRUG|saline 0.9%|solution for intravenous and epidural injection
40853398|NCT03840707|BEHAVIORAL|LIFEwithIBD|"LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease"
41165893|NCT03602248|OTHER|Speed endurance training protocol B|1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
41165894|NCT05353621|BEHAVIORAL|VAS reported Stress|VAS reported Stress measurement during simulation
40853399|NCT02399657|DRUG|Intravitreal dexamethasone 0.7mg implant|Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
40853400|NCT03512392|OTHER|Conservative fluid and deresuscitation strategy|Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
40853401|NCT03512392|OTHER|Usual care strategy|Usual care at the discretion of the clinical team
40853402|NCT06226584|DIETARY_SUPPLEMENT|multiple-strain probiotics|Juice HA capsule which contains more than one strain of probiotics
40853403|NCT06236334|BEHAVIORAL|ELFI lifestyle intervention|A (digital) lifestyle support intervention. Based on anthropometrics, food intake and lifestyle preferences, subjects will receive behavioral lifestyle support, especially with the focus on healthy food intake.
40853404|NCT02795845|DIETARY_SUPPLEMENT|Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Probiotic
41165895|NCT00791739|DRUG|trazodone, pregabalin|"* phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability~* phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability"
40853405|NCT02795845|OTHER|Placebo|capsule without active ingredient
41165896|NCT03134547|DRUG|low dose sevoflurane group|low volume volatile anesthetics (1.0%)
41165897|NCT03134547|DRUG|high dose sevoflurane group|high volume volatile anesthetics (2.5%)
41165898|NCT00979745|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 9 months.
41165899|NCT00979745|DRUG|Placebo|One 16mg subcutaneous implant every 2 months for 9 months.
41165900|NCT06102798|DEVICE|Acunpuncture|"For the bilateral BL25, sterile disposable steel needles (Hwato, China; 0.3 mm×75 mm) will be inserted through adhesive pads to a depth of 50-70mm until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Hwato, China; 0.3 mm×40 mm) will be inserted through adhesive pads to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi."
41165901|NCT06102798|DEVICE|Sham acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
41165902|NCT02666170|DRUG|Alpha-lipoic acid|
41165903|NCT05606198|OTHER|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
41165904|NCT03676478|OTHER|delayed start enteral support @ POD5|"instead of caloric suppletion, participants will receive mls of water over the jejunostomy feeding tube daily equivalent to the rate of increase of infusion of the control group as to preserve the same amount of fluid administration through the GI route as the control group.~This is continued until POD5 12.00h when enteral feeding is started according to the incremental regimen as defined for the SOC group. During the intervention, water is used as to maximize stimulation of the enteral route, however without giving nutritional support and need to prolong iv-infusion for maintaining the fluid balance in the participants. Also subjects in this interventional arm will end up with a caloric suppletion of 1.000kCal/24h by the end of postoperative day 7."
41036776|NCT02395120|BEHAVIORAL|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
41383796|NCT04041063|PROCEDURE|Nerve transfer surgery|C5 injury; Teres minor branch of axillary nerve transferred to long head of triceps branch of radial nerve (RN); Brachialis branch of musculocutaneous nerve to anterior interosseous nerve (AIN); Supinator branch of RN to posterior interosseous nerve (PIN). C6 injury; Teres minor branch of axillary nerve to long head of triceps branch of RN; Extensor carpi radialis brevis (ECRB) branch of RN to AIN; Supinator branch of RN to PIN. C7 injury with preserved triceps, loss of grasp/release; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN; Supinator branch of RN transferred to PIN. C7 injury with preserved triceps/finger extension, loss of grasp; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN.
41383797|NCT02487407|DRUG|ODM-109|ODM-109 1 mg capsule for oral administration.
41383798|NCT02487407|DRUG|Placebo for ODM-109|Placebo capsule for oral administration.
41509356|NCT02862730|DEVICE|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
41509357|NCT02074280|DRUG|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
41036777|NCT02395120|BEHAVIORAL|Reduced DIG|"Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide."
41036778|NCT03743038|DRUG|FMX101 vehicle|FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
40853406|NCT03438136|BEHAVIORAL|Adult Broad Learning Experiment (ABLE)|"This intervention implements six factors from early childhood experiences: individualized scaffolding (having a responsive teacher), forgiving environment (allowing the learner to make and learn from mistakes), growth mindset (believing that abilities can develop with effort), open-minded learning (exploring new experiences), serious commitment to learning (adopting a learning lifestyle), and learning multiple skills simultaneously."
41036779|NCT03743038|OTHER|Hydro-alcohol solution|Hydro-alcohol solution based vehicle (Test Article B)
41036780|NCT00536133|DRUG|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
41036781|NCT00536133|OTHER|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
41036782|NCT02672111|DRUG|CAM2038 q1w or q4w exposure to SL BPN/NX|
41036783|NCT02672111|DRUG|CAM2038 q1w or q4w new to BPN treatment|
41036784|NCT05388253|BEHAVIORAL|Static Stretching|Using Static Stretching exercises
41383799|NCT04556877|PROCEDURE|Intraabdominal pressure and optic nerve diameters|Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
41383800|NCT00989807|DRUG|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
41383801|NCT00131573|DEVICE|bion|battery powered bion microstimulator
41383802|NCT01845090|DRUG|Lanthanum carbonate|the effect on serum FGF23
41383803|NCT01845090|DRUG|Calcium Carbonate|Calcium carbonate 500mg\~1000 mg tid for 6 months
40853407|NCT03205176|DRUG|AZD5153|AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
40853408|NCT03205176|DRUG|Olaparib|Olaparib, 300 mg, will be taken BID as oral capsules.
40853409|NCT00779025|DEVICE|PD-F-5254|Female Personal Lubricant (MINE)
40853410|NCT00779025|DEVICE|10855-096|Male Personal Lubricant (YOURS)
40853411|NCT05591391|OTHER|Mallya cap|After Mallya cap is correctly attached to the insulin pen, it will automatically record treatment information (dose, time and date of injection) and send in real time to the Health2Sync's platform by Bluetooth transmission. Suggestions regarding dose titration and glycemic control will be communicated on the Health2Sync's platform.
40853412|NCT05591391|OTHER|Standard care|Suggestions regarding dose titration and glycemic control will be communicated by weekly telephone calls.
40853413|NCT00771771|OTHER|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
40853414|NCT00771771|OTHER|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
41036785|NCT05388253|BEHAVIORAL|Deep Kneading Massage|Using Deep Kneading Massage technique
41036786|NCT01359982|DRUG|RRx-001|Dose level 1 (10 mg/m2)
41036787|NCT01359982|DRUG|RRx-001|Dose Level 2 (16.7 mg/m2)
41383804|NCT00795379|BEHAVIORAL|Interoceptive Exposure|Exposure to internal stimuli.
41383805|NCT04907994|OTHER|Cohort|Nothing. Only implementation of a cohort with data collection via the SNDS.
41383806|NCT05149807|DRUG|SHR-1701 injection|SHR-1701 injection Tegafur Gimeracil Oteracil Potassium Oxaliplatin
41509358|NCT06281197|PROCEDURE|Conventional|Le Fort I osteotomy performed with conventional Le Fort
41509359|NCT06281197|PROCEDURE|Subspinal|Osteotomy was performed in the subspinal Le Fort I group that is described by Mommaerts
41509360|NCT04563715|DIAGNOSTIC_TEST|HIV counseling and testing|Receive HIV testing risk assessment and advice about risk reduction and future testing.
41036788|NCT01359982|DRUG|RRx-001|Dose Level 3 (24.6 mg/m2)
41036789|NCT01359982|DRUG|RRx-001|Dose Level 4 (33 mg/m2)
41036790|NCT01359982|DRUG|RRx-001|Dose Level 5 (55.0 mg/m2)
41036791|NCT01359982|DRUG|RRx-001|Dose Level 6 (83 mg/m2)
41036792|NCT00675740|DRUG|rosiglitazone|tablets 4 mg daily
41509361|NCT04563715|BEHAVIORAL|Network intervention|Key individuals are trained to provide advice about regular testing and risk reduction.
41509362|NCT04774016|OTHER|Test formula A without added pre- and pro-biotic|An identical formula as test formulas fortified with 2.20 mg iron as FeSO4-58 and 0.05 mg native iron per serving (235 ml), but without added pre- or probiotic.
41383807|NCT05149807|DRUG|Placebo|Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin
41036793|NCT00675740|BEHAVIORAL|physical exercise|stationary bike 5-6 times a week
41509363|NCT04774016|OTHER|Test formula B with synbiotic|Test formula fortified with 2.20 mg iron as FeSO4-57 and 0.05 mg native iron per serving (235 ml) and added synbiotic.
41509364|NCT04774016|OTHER|Test formula C with HMOs|Test formula fortified with 2.20 mg iron as FeSO4-54 and 0.05 mg native iron per serving (235 ml) and added HMOs.
41509365|NCT06095973|DRUG|GB-6002|Depending on the cohort, volume will be varied to administer.
41509366|NCT06095973|DRUG|Placebo|Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.
41509367|NCT06095973|DRUG|Naropin injection|Single dose of Naropin s.c. injection.
41509368|NCT04138043|DRUG|Placebo|Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
41509369|NCT04138043|DRUG|GSK2330811|GSK2330811 will be available as SC injection 150 mg/mL.
41509370|NCT04657211|OTHER|prospective observational cohort study|prospective observational cohort study
41383808|NCT06568614|DRUG|SYH2039|SYH2039 dosed orally
41383809|NCT06565507|DRUG|Oxfendazole single dose|Subjects will receive active oxfendazole, 20 mg/kg/day, orally, as a single dose. Oxfendazole placebo will be used at days 4 and 7 to maintain blinding between the two intervention arms.
41383810|NCT06565507|DRUG|Oxfendazole three doses|Subjects will receive active oxfendazole, 20 mg/kg/day, orally, in three days (1, 4 and 7)
41383811|NCT06565507|DRUG|albendazole plus praziquantel regime|Subjects will receive a combination of albendazole plus praziquantel, as a standard treatment for brain cysticercosis (neurocysticercosis), orally, for ten days. Albendazole will be given at 15/kg/d and praziquantel at 50/kg/d.
41383812|NCT06167798|OTHER|biopsy|two 2 mm gingival biopsies were obtained.
41383813|NCT01612780|DEVICE|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
41383814|NCT01658982|OTHER|cardiopulmonary exercise testing|3 minute step test compared to 6 minute bicycle test
41383815|NCT06537479|OTHER|Buteyko breathing technique|Participants will be advised to sit in a comfortable and relaxed position and take a shallow breath through nose, partially filling the lungs. Hold breath for 2-3 seconds and exhale slowly through the nose and emptying the lungs.
41509371|NCT02229474|BEHAVIORAL|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
41509372|NCT05635487|DRUG|SHR-A1811|SHR-A1811
41509373|NCT05635487|DRUG|Pyrotinib|Pyrotinib
41509374|NCT03395457|DRUG|Care as usual|Application of usual pharmacological care for chronic migraine
41509375|NCT03395457|OTHER|Manual Therapy|5 sessions of manual therapy over 12 weeks
40853415|NCT02612922|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
41036794|NCT00675740|OTHER|control|control without intervention
41036795|NCT05077787|OTHER|Massage therapy|Massage therapy includes stroking, kneading, rolling, tapping, vibration and effleurage over the face, chest ,abdomen and back. Massage therapy will be given for 5 minutes and will be repeated twice.
41036796|NCT05077787|OTHER|Kinaesthetic stimulation|Kinaesthetic stimulation includes passive flexion and extension movements of shoulder joint, elbow joint, hip joint, knee joint and both lower limbs together. It will be given for 5 minutes in each intervention
41509376|NCT02567279|DRUG|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
41383816|NCT06537479|OTHER|Chest Wall Mobilization|It started with positioning, sitting or standing with good posture, and relaxing shoulders and arms. Hands were placed on the chest with fingers wide and thumbs on side of ribcage. Inhale deep breaths with expansion of chest and hands move outward. Exhale slowly allowed the chest to drop and the hands to move inward.
41509377|NCT02567279|DRUG|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
41509378|NCT00489255|DRUG|Tigan®|Oral capsule, 300mg three times daily
41509379|NCT00489255|DRUG|Placebo|Oral capsule, three times daily
41509380|NCT00550459|DRUG|Tolvaptan|15-60 mg oral tablet given once a day for 21 days.
40853416|NCT02612922|DRUG|Placebo|Placebo administered orally twice daily for five days
41383817|NCT01861717|DRUG|lanreotide|Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
41383818|NCT01976663|DEVICE|JUVEDERM VOLIFT® XC|Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
41383819|NCT01976663|DEVICE|Control|Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
41509381|NCT00550459|DRUG|Placebo|Placebo tablet given once daily for 21 days
41528288|NCT03961737|PROCEDURE|prostate biopsies|"Before radiotherapy treatment, prostate biopsies will be performed in each patient. From these biopsies, explants will be performed. Half of these explants will be irradiated ex vivo and the other half will not receive any prior treatment.~Then the patient will receive radiotherapy. It will be reviewed 2 years after the end of radiotherapy. New prostate biopsies will be performed to evaluate the tumor response to radiotherapy and to characterize the immunohistochemical and transcriptomic profiles of non-responder patients."
41528289|NCT00191581|DRUG|Humalog Mix 50|
41528290|NCT00191581|DRUG|Human Insulin Mix 50:50|
41383820|NCT04868877|DRUG|MCLA-129|full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET
40853417|NCT01807299|DIETARY_SUPPLEMENT|Omega 3|Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.
41036797|NCT03727750|DRUG|Gemtuzumab Ozogamicin|Three doses of GO 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
41036798|NCT00402753|BEHAVIORAL|Ambulatory Physical Exercise Program|supervised exercise, 2 x / week
41036799|NCT03787394|OTHER|adding taste enhancer|Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain
41036800|NCT04941755|DRUG|BMS-986256|Specified dose on specified days
41036801|NCT04941755|DRUG|Famotidine|Specified dose on specified days
41036802|NCT02313142|BEHAVIORAL|Leg exercises|
41036803|NCT01752504|BEHAVIORAL|Community Mobilization|The proposed study seeks to continue C2P, a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth in targeted communities at five ATN sites. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action; developing coalitions that have a shared vision and mission; developing a strategic plan focused on structural changes to reduce risks associated with HIV; documenting processes; providing feedback as technical assistance to the coalitions; hosting regular working group meetings; and on-going capacity building.
41036804|NCT05281380|DIETARY_SUPPLEMENT|GIKAVI|Two tailormade supplements for patients; one for that underwent esophagectomy and one for (sub-)total gastrectomy.
41036805|NCT00672074|DRUG|Ipamorelin|IV
41036806|NCT00672074|DRUG|placebo|IV
41036807|NCT04748744|COMBINATION_PRODUCT|Butyrylcholinesterase|Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases
41165905|NCT04832581|BEHAVIORAL|The Self-Care Behavior Development Program|This program, which is based on the Orem Self Care Model, includes anatomical, physiological and hormonal changes, urinary system infections and preventive measures during pregnancy. The program is different from other researches in that it is based on a methodological theory and is created with up-to-date information.
41165906|NCT06037239|DRUG|Linperlisib in combined with Chidamide|"Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly.~Phase 2：dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle"
41165907|NCT02788526|PROCEDURE|Adjuvant TACE|1\~2 cycles TACE were performed as adjuvant therapy after radical hepatectomy
41165908|NCT02788526|PROCEDURE|Follow-up|Patients received just follow-up to monitor the recurrence of HCC
41165909|NCT06112522|DRUG|Tirbanibulin|Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
41383821|NCT04868877|DRUG|Osimertinib|Approved, 3rd-generation EGFR-TKI
41036808|NCT02667158|OTHER|Survey to Eval Relation between Shopping and Misuse, Abuse|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
41036809|NCT01273727|DRUG|Dexamethasone|intravitreal implant 0.7 mg 6 month duration
41036810|NCT01273727|DRUG|dexamethasone|intravitreal implant 0.7 mg duration 6 months
41036811|NCT04595708|BEHAVIORAL|Phone Call|Calls were made by volunteers trained to engage with participants. Call structure was unscripted and call length was recommended to be between 5-10 min.
40853418|NCT01807299|OTHER|Physical Training|
40853419|NCT02647424|DRUG|Letrozole|Letrozole 2.5 mg daily from Day 2 to 6
40853420|NCT02647424|DRUG|Clomiphene|After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
40853421|NCT00083135|BIOLOGICAL|filgrastim|
40853422|NCT00083135|PROCEDURE|autologous bone marrow transplantation|
41036812|NCT04390438|PROCEDURE|Percutaneous Electrolysis|Needle emplacement with a galvanic electrical current
41036813|NCT04390438|PROCEDURE|Dry needling|Needle emplacement without electrical current nor substance
41383822|NCT04868877|DRUG|Chemotherapy|administrated by IV infusion
41383823|NCT00555399|DRUG|Vorinostat|"Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days."
41383824|NCT00555399|DRUG|Isotretinoin|"Phase I/Arm 1: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m\^2/day PO x 21 days; Level -I = 100 mg/m\^2/day PO x 21 days; Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days."
41383825|NCT00555399|PROCEDURE|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
41383826|NCT00555399|DRUG|Temozolomide|"Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days."
40853423|NCT00083135|PROCEDURE|peripheral blood stem cell transplantation|
40853424|NCT00083135|RADIATION|iobenguane I 131|
41036814|NCT03044067|OTHER|Pain neuroscience education + Exercise|A session of Pain neuroscience education + Exercise covers the activity, strength and endurance of lower and upper muscles of the extremities. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
41383827|NCT04461431|PROCEDURE|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee for patients with injury of the posterolateral structure of the knee
41383828|NCT02140801|DRUG|Ticagrelor|Plain, round, yellow, filmcoated tablet, 90 mg
41383829|NCT02140801|DRUG|Clopidogrel|Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
41383830|NCT02623530|OTHER|Educational intervention|"Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC."
41383831|NCT00544349|BIOLOGICAL|cetuximab|
41383832|NCT00544349|DRUG|fluorouracil|
40853425|NCT01963156|BEHAVIORAL|Prescription synchronization|"Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the index medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.~Randomization will occur within strata of whether patients are enrolled in the ReadyFill@Mail program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point."
40853426|NCT05363111|BIOLOGICAL|Actinium Ac 225-DOTA-Daratumumab|Given IV
41383833|NCT00544349|DRUG|leucovorin calcium|
41383834|NCT00544349|DRUG|oxaliplatin|
41509382|NCT05706584|OTHER|control grup (skills lab.) and experimental group (mateverse skill lab.)|The universe of the study consists of students (N: 190) who took a pediatric nursing course in the 3rd year of the Teaching Department at Istanbul Medipol University. The sample of the study will consist of the students who took the 3rd year child health and diseases nursing course in the nursing department, accepted the study, and met the study criteria. It will try to reach the universe where the sample selection of the research will not be made. With the simple randomization method, students will be assigned to the experimental and control groups. Even the last digit of the student number will be randomized to the experimental group and odd ones will be randomized to the control group
41509383|NCT00002704|BIOLOGICAL|filgrastim|
41509384|NCT00002704|DRUG|asparaginase|
40853427|NCT05363111|BIOLOGICAL|Daratumumab|Given IV
40853428|NCT05363111|BIOLOGICAL|Indium In 111-DOTA-Daratumumab|Given IV
40853429|NCT04527146|OTHER|IMAGINE-PD|The Interactive, Multimedia Approach to Genetic Counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) is a novel, interactive, web-based, audiovisual, self-guided, genetic counseling tool in the development phase. Essential genetic counseling themes, outlined by a senior certified clinical genetics counselor in accordance with national guidelines, are presented in a web-based format, utilizing videos, text, pictures, and audio. Participants can interact with IMAGINE-PD at their own pace, with the ability to move backward and forward, repeat sections, and have the ability to submit questions to the genetic counselor via e-mail.
40853430|NCT04527146|OTHER|Virtual genetic counseling|The virtual visits will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors. The counseling visit will be conducted in real-time on an established and secure audiovisual conferencing telemedicine platform (BlueJeans) within the PennChart/EPIC electronic medical record dashboard.
41036815|NCT03044067|OTHER|Exercise|A session of exercise covers the activity, strength and endurance of lower and upper muscles of the extremities.
41383835|NCT03823859|DIAGNOSTIC_TEST|Indirect calorimetry|Resting energy expenditure
41036816|NCT04654416|DRUG|Corticosteroid with or without colchicine|We describe the clinical outcome of patients treated with corticosteroid and colchicine
41165910|NCT00219869|DRUG|Galantamine|
41165911|NCT00120185|DRUG|Interleukin-2|
41165912|NCT00356564|BIOLOGICAL|hepatitis B vaccine|
41165913|NCT06257641|OTHER|High-intensity Mediterranean diet intervention|Dietary education for the adoption of the Mediterranean diet, with monthly monitoring - mostly online - by nutritionists with experience in the field. Patients will be given 500 ml of extra virgin olive oil per week and informative material about the Mediterranean diet, as well as recipes and weekly menus.
41383836|NCT03823859|DIAGNOSTIC_TEST|Dual energy X-ray Absorptiometry (DXA)|Body composition
41383837|NCT03823859|DIAGNOSTIC_TEST|Blood sampling|fT4, fT3, TSH, HDL, LDL, triglycerides, cholesterol, HbA1c, Glucose Thyroid panel
41383838|NCT03978897|DEVICE|Blood flow restriction tourniquet|A blood flow restriction tourniquet, which impedes arterial flow to extremity at 50% of usual flow.
41383839|NCT03978897|OTHER|Evidence based physical/occupational therapy|Up to date physical/occupational therapy for lateral epicondylitis
41383840|NCT06096181|DRUG|Remifentanil TIVA|Remifentanil is more commonly used in the TIVA combination for pediatric patients having this surgery.
41383841|NCT06096181|DRUG|Dexmedetomidine TIVA|Dexmedetomidine is less commonly used in the TIVA combination for pediatric patients having this surgery.
41383842|NCT06096181|DRUG|Propofol TIVA|Propofol is an anesthetic drug that causes sleep during surgery.
41383843|NCT06562556|DEVICE|the breather device|investigate the effect of the breather device on ventilatory effort and in patients with myogenic temporomandibular joint disorders
41509385|NCT00002704|DRUG|cyclophosphamide|
41509386|NCT00002704|DRUG|daunorubicin hydrochloride|
41509387|NCT00002704|DRUG|dexamethasone|
41509388|NCT00002704|DRUG|etoposide|
41509389|NCT00002704|DRUG|leucovorin calcium|
41509390|NCT00002704|DRUG|liposomal cytarabine|
41509391|NCT00002704|DRUG|mercaptopurine|
41509392|NCT00002704|DRUG|mesna|
41509393|NCT00002704|DRUG|methotrexate|
41509394|NCT00002704|DRUG|therapeutic hydrocortisone|
41509395|NCT00002704|DRUG|thiotepa|
41509396|NCT00002704|DRUG|vincristine sulfate|
41509397|NCT00002704|RADIATION|low-LET electron therapy|
41509398|NCT00002704|RADIATION|low-LET photon therapy|
41509399|NCT01371539|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
41509400|NCT01371539|DEVICE|Comfilcon A contact lens|Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
40853431|NCT04527146|OTHER|Telephone genetic counseling|The telephone counseling will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors.
41383844|NCT06562556|OTHER|conventional exercise program|"-Therapeutic Ultrasound (US): Ultrasound therapy will be applied at the site of pain over the TMJ area with Frequency: 1 MHz, Mode: continuous, Duration: 6 min. each session 2-Myofascial release for masticatory muscles 3-The self-exercise Self exercise: include simplified myo-functional therapy. 10 repetitions, three: five times per day 4-Techniques to correct deglutition: swallowing a small amount of water and speaking while holding a semi-hard small object between the dental arches 5-Relaxation exercise of Masticator Muscle:10 repetitions, three.~6-Strain-counterstain (SCS): applied on the tender or trigger points of neck muscles on improving pain and pressure pain sensitivity in neck muscles"
41383845|NCT06267118|DRUG|Hypertonic Saline Solution, 1 Ml|Dilute 0.3 ml hypertonic saline with 3 ml normal saline for nebulization
41509401|NCT00958893|DRUG|25 mg Proellex|one 25 mg capsules
40853432|NCT03128047|DEVICE|Optune NovoTTF-200A System|Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab.
40853433|NCT04471506|OTHER|interval training|Ixercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program).
40853434|NCT04471506|OTHER|diet recommendations|the control group will follow diet recommendations for 12 weeks
40853435|NCT04471506|OTHER|mindfulness breathing|Mindful breathing is a exercise that involves using breathing as an object of attention. 15-minute mindful breathing intervention will be adapted. It consists of the following three steps: (a) adopt a physical posture, (b) establish a mindfulness anchor, and (c) maintain mindfulness
40853436|NCT00278616|BIOLOGICAL|Stem Cell Transplantation|Autologous Stem Cell Transplantation
40853437|NCT03559933|DEVICE|PEPNS System|PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
40853438|NCT02008227|DRUG|Atezolizumab|1200 mg IV infusion on Day 1 of each 21-day cycle
40853439|NCT02008227|DRUG|Docetaxel|75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle
40853440|NCT00278746|DRUG|Zinc and ORS|Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
40853441|NCT00278746|DRUG|ORS only|Promoted routine management of diarrhea in underfive with ORS
40853442|NCT06402006|PROCEDURE|PENG block|pericapsular nerve group block
40853443|NCT06402006|PROCEDURE|LFCN block|Lateral femoral cutaneous nerve block
40853444|NCT06402006|PROCEDURE|ESP block|Erector spinae plane block
40853445|NCT02226887|PROCEDURE|MESH|"1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * We add the mesh between the edges of the defect during fascia closure.~  * The skin is sutured purse string style.~3. Post-Op~   * Hospital discharge after verification of normal digestive transit."
40853446|NCT02226887|PROCEDURE|NO MESH|"1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * The skin is sutured purse string style.~Post-Op~- Hospital discharge after verification of normal digestive transit"
40853447|NCT02226887|RADIATION|Post-operative Imaging|Abdominal Tomography 1 year after ileostomy closure
40853448|NCT02226887|RADIATION|Pre-operative Imaging|Contrast study is used to ensure the integrity of the distal anastomosis
41383846|NCT06267118|DRUG|Adrenaline|dilute 0.3 ml adrenaline with 3 ml normal saline for nebulization
41383847|NCT01261650|DEVICE|transcranial direct current stimulation|
41383848|NCT01261650|DEVICE|sham treatment|
41383849|NCT03858920|DEVICE|Fibroscan of Liver|A non-invasive diagnostic device used to measure liver scarring
41383850|NCT03858920|PROCEDURE|Low-dose non-contrast CT|CT scan as part of routine research care
41528291|NCT01253629|DRUG|AFQ056|AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
40853449|NCT02226887|OTHER|Blood Test and C-reactive protein at 4th day|All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
40853450|NCT05643560|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice.
40853451|NCT03145948|DRUG|ABBV-553|It is administered orally.
40853452|NCT03145948|DRUG|Placebo|It is administered orally.
41528292|NCT01253629|DRUG|Placebo|Placebo medication identical in appearance to active medication was provided
41383851|NCT05661903|OTHER|Spinal Cord Stimulator Set to Minimal/No Stimulation Setting|Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.
40853453|NCT00891384|DRUG|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
40853454|NCT00891384|DRUG|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
40853455|NCT03475485|DEVICE|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
40853456|NCT03475485|DEVICE|Wearable Sensor|Subjects will wear an ID-Reader
40853457|NCT03475485|DEVICE|Placebo|A standard gelatin or HPMC capsule without an embedded ingestible wireless sensor.
40853458|NCT02278861|DRUG|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
40853459|NCT02278861|DRUG|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
40853460|NCT02278861|DRUG|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
40853461|NCT06085014|OTHER|Standard of care|All patients will undergo, as clinically indicated, AF ablation by pulmonary vein isolation achievable by radiofrequency, cryoenergy, or electroporation. All patients will preliminarily undergo electroanatomic mapping of the atrium by CARTO/Navx/Rhythmia system indifferently. Patients will be given follow-up visits at 3-6-12 months, during which any arrhythmic recurrences will be assessed
40853462|NCT06085014|OTHER|Data collection|There's no patient involvement. Data of patients who underwent ablative procedures two years before the start of the study will be retrospectively analyzed
40853463|NCT03325842|DIAGNOSTIC_TEST|ASKp|30 items questionnaire
40853464|NCT02146391|DRUG|Androxal 25 mg Capsules|
40853465|NCT00555217|DRUG|losartan|50 or 100mg/day
40853466|NCT00555217|DRUG|lisinopril|10, 20 or 40 mg/day
40853467|NCT01456065|BIOLOGICAL|Procure|The IMP (Investigational Medical Product) consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
40853468|NCT01456065|BIOLOGICAL|Procure|The IMP consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
40853469|NCT04879173|DEVICE|RS85 Ultrasound device|RS85 Ultrasound device manufactured by Samsung Medison
40853470|NCT02144025|DRUG|Cyclosporine|Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
40853471|NCT03327194|DEVICE|ADHEAR Audio Processor|"ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.~The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.~ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.~The ADHEAR Audio Processor has the CE mark."
40853472|NCT02774148|DRUG|IV Acetaminophen|The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
41036817|NCT03540927|BEHAVIORAL|PM+ for entrepreneurs|The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
41036818|NCT03540927|OTHER|Cash transfer to the Entrepreneurs|The entrepreneurs in the control arm will receive cash transfer only for their businesses.
41036819|NCT03222518|DRUG|Paracetamol|21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
41036820|NCT03222518|DRUG|NSAID|14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
41165914|NCT06009445|DIAGNOSTIC_TEST|Renal resistive index|"The calculation formula for Renal resistive index (RRI) as follows :~(systolic peak flow velocity _ diastolic minimum flow velocity )/systolic peak flow velocity .~will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care. After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or interlobar artery will be localized and three successive doppler measurements at different positions in the kidney (high, middle and low) will be performed, 3 times in each kidney. So a total number of 9 RRI values will be obtained in each kidney.~The median value of each section will be used and the 3 median values of each kidney will be averaged."
41165915|NCT04347785|PROCEDURE|carotid endarterectomy|shunt
41165916|NCT04358068|DRUG|Hydroxychloroquine (HCQ)|Administered orally
41165917|NCT04358068|DRUG|Azithromycin (Azithro)|Administered orally
40853473|NCT02774148|DRUG|PO Acetaminophen|The patient will receive 1,000mg po Acetaminophen every 8 hours.
40853474|NCT00049608|DIETARY_SUPPLEMENT|mistletoe extract|
40853475|NCT00049608|DRUG|gemcitabine hydrochloride|
40853476|NCT05898594|PROCEDURE|Low-dose Computed Tomography|Per standard care
40853477|NCT00044473|DRUG|levofloxacin|
40853478|NCT02599233|OTHER|Telephone conctact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires.
40853479|NCT02599233|OTHER|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
41165918|NCT04358068|DRUG|Placebo for Hydroxychloroquine|Administered orally
41036821|NCT03222518|DRUG|paracetamol-NSAID|21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
41383852|NCT05661903|OTHER|Usual Care|Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.
41509402|NCT04217954|DRUG|OXA, 5-FU and bevacizumab plus Toripalimab|"1. concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~   B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~   The concomitant treatment repeat every three week, up to 6 cycles.~2. Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks."
41509403|NCT04179318|DIAGNOSTIC_TEST|Geneswell BCT|Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.
41509404|NCT02083627|DRUG|rosuvastatin|Oral
41509405|NCT02083627|DRUG|fidaxomicin|Oral
41509406|NCT04175288|OTHER|Ultrasound, manual therapy and exercise|The experimental group will receive ultrasound (US) for 3 sessions a week for 4 weeks, with continuous US (1.8 w/cm2, 1 Mega Hz 8 minutes). Manual therapy will include posterior glides to talocrural joint, subtalar lateral glide, a 1st tarsometatarsal joint dorsal glide and extension mobilization to the 1st metatarsophalangeal joint. All participants in each group will be given specific exercises by the investgators targeting intrinsic and extrinsic muscles of the foot and ankle. Specific stretches for the plantar fascia and Achilles tendon, will be performed. Home exercises will be recorded using a log.
41509407|NCT02158715|DEVICE|Site of smartphone on chest compressor' arm|
41509408|NCT05681715|DRUG|Rozanolixizumab|Rozanolixizumab self-administration via Syringe Driver or Manual Push.
41509409|NCT05516979|DRUG|100 mg AP1189|AP1189 tablets for oral use
41509410|NCT05516979|DRUG|Placebo|Matching placebo for oral use
41528293|NCT02583451|DRUG|Placebo tablet matching lemborexant|Tablet form taken orally at bedtime.
41383853|NCT02309541|DEVICE|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
41383854|NCT02312752|DEVICE|Intra-epidermal stimulation electrode|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
41383855|NCT06568406|PROCEDURE|Physiotherapy|Examination by a physiotherapist: the first check-up with an examination and a therapeutic intervention with the patient is performed within 24-72 hours after delivery. This is followed by two regular outpatient check-ups by a physiotherapist for the purpose of therapy and education. The second check takes place after 6-8 weeks. And the third check occurs after 10-14 weeks after childbirth. In these three checks, data collection is carried out simultaneously (in order to complete the secondary objective). The patients are examined and monitored by the same physiotherapist.
41383856|NCT06568406|DIAGNOSTIC_TEST|Urogynaecology|Examination by a urogynaecologist this is carried out in the period of 14-18 weeks after childbirth in order to complete the primary objective. Data collection in order to complete the primary objective is done in the period of 14-18 weeks and 12-14 months after delivery (the online method without the need for a physical visit is preferred).
41383857|NCT06567418|DRUG|alirocumab 75mg/2week|patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference
41383858|NCT06567418|DRUG|statin ± ezetimibe|patients will be censored at initiation of alirocumab during the follow up visit
41383859|NCT03254407|OTHER|Screening medical record|Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
41383860|NCT02017782|DEVICE|Dust|Dust (250-300µg/m3),
41383861|NCT02017782|DEVICE|Ozone|(0,1ppm ozone),
41383862|NCT02017782|DEVICE|Dust and Ozone|Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
41383863|NCT02017782|DEVICE|Placebo (Filtered air)|Placebo treatment (Filtered air \<20 ug/m3)
41383864|NCT01900925|PROCEDURE|Prescriptive Hip Exercises and Manual Therapy techniques|1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
41383865|NCT01900925|PROCEDURE|Pragmatic low back pain treatment|"1. advise to stay active,~2. discourage bed rest,~3. appropriate medication use,~4. reassurance.~5. Short term use of manipulation/medication,~6. supervised exercise,~7. cognitive behavioral therapy,~8. multidisciplinary treatment,~9. termination of use of modalities."
41528294|NCT02583451|DRUG|Placebo tablet matching zopiclone|Tablet form taken orally at bedtime.
40676518|NCT01990196|DRUG|degarelix|"Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
40853480|NCT02599233|OTHER|In hospital questionnaires|Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
41036822|NCT04675788|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
41036823|NCT04675788|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval
41036824|NCT04675788|DRUG|Testosterone|Subjects will apply transdermal testosterone gel once daily every morning for 3 days
41036825|NCT04675788|DRUG|Placebo|Lactose capsules
41036826|NCT00863096|BIOLOGICAL|Gardasil|HPV vaccine
41036827|NCT01621217|DRUG|Cetuximab|Will be given weekly intravenously during study treatment.
41165919|NCT04358068|DRUG|Placebo for Azithromycin|Administered orally
40853481|NCT05224453|OTHER|Physical training and high protein diet|In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d)
40853482|NCT05224453|OTHER|Physical training and low protein diet|In addition to the integrated physical training exercises, group B received low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (\<1 g/kg aBW/d)
40853483|NCT03870204|DIAGNOSTIC_TEST|POC-CCA rapid urine test|Fresh urine samples will be tested by POC-CCA
40853484|NCT01598922|BEHAVIORAL|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
40853485|NCT01291407|DRUG|S-1|S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
40853486|NCT01291407|DRUG|S-1|S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
41383866|NCT06561334|PROCEDURE|Botulinum toxin injections|Botulinum toxin injection to ease spasms of vocal cord
41528295|NCT02583451|DRUG|Zopiclone 7.5 mg|7.5 mg tablet taken orally at bedtime.
40853487|NCT01291407|DRUG|S-1|S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
40853488|NCT01291407|DRUG|S-1|S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
40853489|NCT01291407|DRUG|S-1|S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
40853490|NCT01291407|DRUG|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
40853491|NCT04611087|BEHAVIORAL|Discussion|Attend focus groups
40853492|NCT04611087|OTHER|Interview|Attend interviews
40853493|NCT04611087|OTHER|Survey Administration|Ancillary studies
41528296|NCT02583451|DRUG|Lemborexant 2.5 mg|2.5 tablet taken orally at bedtime.
41383867|NCT03522155|BEHAVIORAL|Patient-centered communication of life expectancy|The intervention arm will test if patient-specific LE estimates via a targeted, patient-centered communication approach paired with LE-specific conjoint analysis data improves decisional conflict, quality of LE discussion, and reduces rates of overtreatment of Genitourinary malignancies.
41383868|NCT02206100|DRUG|PER977|reversal of edoxaban-induced anticoagulation
40853494|NCT01700543|PROCEDURE|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
40853495|NCT04701567|DIAGNOSTIC_TEST|Magnetic resonance imaging|Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
40853496|NCT00305630|DRUG|Periocular injection of triamcinolone acetonide 40mg|
40853497|NCT03843983|DEVICE|Lipiflow® application|"Lipiflow® will be applicated in both lids of each eye during 12 minutes once. Firstly, a drop of anesthetic will be instilled in each eye. Then, while the participant stays with his eyes closed, a one-used applicator will be placed covering the subject's lid. The instrument applies heat and pressure in the lid during 12 minutes. Time frame: between 2 and 7 days after visit 1.~Then, there will be 3 follow-up visits in 3, 6 and 12 months after treatment."
40853498|NCT05345275|OTHER|The facial expressions analyzed|The facial expressions associated with pain were analyzed by the researchers in the OpenFace program. The patient's pain scores were estimated in the Python program by combining the numerical outputs of facial expression analyses with machine learning algorithms.
40853499|NCT05600426|DRUG|cyclosporine|cyclosporine
40853500|NCT05600426|PROCEDURE|Matched Unrelated Donor Hematopoetic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
40853501|NCT05600426|DRUG|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
40853502|NCT05600426|DRUG|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
40853503|NCT05600426|DRUG|Methotrexate|methotrexate
40853504|NCT05600426|DRUG|Fludarabine|fludarabine
41383869|NCT02206100|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
41383870|NCT02206100|DRUG|enoxaparin|
40853505|NCT05600426|DRUG|Cyclophosphamide|cyclophosphamide
40853506|NCT05600426|RADIATION|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
41165920|NCT05321771|OTHER|Family caregiver application of HELP principles|The family caregiver will apply the principles of the HELP program in a structured manner following training by a nurse clinical specialist in geriatrics. These principles include engaging patients in conversation, particularly emphasizing orientation to time and place, encouraging eating and drinking, and assisting with early mobility.
41165921|NCT00092521|BIOLOGICAL|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
41383871|NCT03875235|DRUG|Durvalumab|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
41528297|NCT02583451|DRUG|Lemborexant 5 mg|5 mg tablet taken orally at bedtime.
40676519|NCT01990196|DRUG|enzalutamide|"Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
40676520|NCT01990196|DRUG|trametinib|"Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
40676521|NCT01990196|DRUG|dasatinib|"Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
40676522|NCT06579183|DIETARY_SUPPLEMENT|Extra Strength VitaJoy (ES/VJ)|Extra Strength VitaJoy Capsule, 2 capsules in the morning
40676523|NCT06579183|DIETARY_SUPPLEMENT|Extra Strength Vita Calm (ES/VC)|Extra Strength Vita Calm Capsule, 2 capsules in the evening
40676524|NCT06579183|DIETARY_SUPPLEMENT|Placebo|Placebo Capsule, 4 capsules in the morning and evening respectively
40676525|NCT01798407|DEVICE|Activa Tremor Control Sys (DBS Implant)|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
40676526|NCT01798407|OTHER|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
40853507|NCT05600426|PROCEDURE|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
40853508|NCT02794519|DRUG|Sirukumab|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
40853509|NCT02794519|DRUG|Placebo|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
41509411|NCT03636178|PROCEDURE|Classic alar base suture technique|An index finger will be used to apply extraoral pressure on the alar base region, and a dentate forceps will grasp this tissue through the intraoral incision. A suture bite will be taken at this point through the tissue previously held by the forceps. The same procedure will be applied on the opposite side. After passing the suture on both sides, it will be tightened with attention to the alar base response. If the alar base suture will be judged to be adequate, the vestibular incision will then be closed in a routine fashion, with or without performing a V-Y lip closure
40676527|NCT03155997|DRUG|Abemaciclib|Administered orally.
40676528|NCT03155997|DRUG|Standard Adjuvant Endocrine Therapy|Administered according to label instructions.
40676529|NCT04865549|PROCEDURE|SNB + TAD + Lymphadenectomy|Sentinel Node Biopsy + Targetted Axillary Dissection (Previously to surgery marked cN1 node) + Lymphadenectomy
40853510|NCT02794519|DRUG|Rescue medication|Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
40853511|NCT04481217|OTHER|Self-questionnaires battery|"* Childhood trauma questionnaire (Bernstein, Ahluvalia, Pogge, \& Handelsman, 1997; Bernstein et al., 2003)~* The Young schema questionnaire short form (SQ-SF ; Cottraux \& Black, 2006; Young, 1998).~* Dissociative experiences scale (Laroi et al., 2013).~* Launay-Slade hallucination scale (Bentall \& Slade, 1985; Launay \& Slade, 1981)~* Cardiff Anomalous Perceptions Scale (Bell et al., 2006)"
41036828|NCT01621217|DRUG|Mitomycin C|Will be given intravenously twice together with 5-Fluoruracil during study treatment.
41036829|NCT01621217|DRUG|5-Fluoruracil|Will be given intravenously twice together with Mitomycin C during study treatment
40676530|NCT02523066|DEVICE|Magna Ease|This study is non-intervention
40676531|NCT00834639|DRUG|divalproex sodium|delayed-release 500 mg tablet
40676532|NCT00834639|DRUG|Depakote®|delayed-release 500 mg tablet
40676533|NCT04181983|OTHER|Personalized exercise program|Home-based personalized exercise program using a smart phone app
40676534|NCT04181983|OTHER|WHO exercise guidelines|Standard exercise counselling according to WHO guidelines
40853512|NCT04481217|OTHER|Socio-demographic screening|age; gender; education; highest diploma; job; marital status; living place
40853513|NCT02218593|DEVICE|WREX orthosis|Upper extremity exoskleton used to assist movement
41036830|NCT01621217|RADIATION|Radiotherapy|Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
41036831|NCT06635538|DRUG|Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1|On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, a single injection of 150 mcg of CFA (Stimulation Day 1) will be administered.
41036832|NCT06635538|DRUG|Clomiphene Citrate (CC) 100 mg/day from D1|On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100/day continuing up to and including the day of ovulation triggering
41165922|NCT00092521|BIOLOGICAL|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
41528298|NCT02583451|DRUG|Lemborexant 10 mg|10 mg tablet taken orally at bedtime.
41528299|NCT01930162|DRUG|HSC835|HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
41528300|NCT00686608|DIETARY_SUPPLEMENT|glucose|0.3mg/kg of glucose
41036833|NCT06635538|DIAGNOSTIC_TEST|Monitoring cycle|Scan controls and blood exams will be performed on stimulation days 1, 6, 8, 10 and, according to clinical needs, until trigger day.
41036834|NCT06481917|OTHER|Advance care plan|Scheduling of 2 home visits by an expert nurse in the month following the return home and proposal to carry out an advance care plan.
41036835|NCT06481917|OTHER|Ergonomic analysis|Ergonomic analysis throughout the intervention
41036836|NCT06481917|OTHER|Evaluation of intervention acceptability|Evaluation of intervention acceptability after each home visit with patients and caregivers using a questionnaire
41036837|NCT02676479|DEVICE|Uterine Lavage Group|"The PI places the Lavage Catheter per instructions for use~* Use of a tenaculum or cervical stitch is required~* Use of saline to wash the cervix is required~* Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix."
41165923|NCT00092521|BIOLOGICAL|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
41383872|NCT03875235|DRUG|Placebo|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
41383873|NCT02787785|DEVICE|Subcutaneous Implantable Cardioverter Defibrillator|The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.
40853514|NCT01196351|OTHER|Dietary Supplement: water with noncalorie sweetener|
40853515|NCT01196351|OTHER|Activity: With noncalorie sweetener or glucose|
40853516|NCT05109923|DIETARY_SUPPLEMENT|Multi-Ingredient Herbal Supplement|Weeks 0-2 all participants consumed a placebo lead-in period and weeks 2-6 were intervention weeks. Throughout the 8 weeks (2 weeks placebo lead-in and 6 weeks intervention) participants were asked to consume 2 capsules (multi-ingredient supplement) upon waking in the morning and 2 capsules (multi-ingredient supplement) before bed.
40853517|NCT05109923|DIETARY_SUPPLEMENT|Placebo Supplement|Weeks 0-8 all participants consumed a placebo. Throughout the 8 weeks participants were asked to consume 2 capsules (placebo) upon waking in the morning and 2 capsules (placebo) before bed.
40853518|NCT01478308|DRUG|Metformin hydrochloride|Metformin is administered orally, with food. Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride. Tablets contain inactive ingredients including pofidone and magnesium stearate. The coating for 500mg and 850mg tablets contains hypromellose. Metformin is an antihyperglycemic agent which decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.In this study, Metformin will be given 850 mg orally, with food, once daily for 1 week starting the week before first docetaxel infusion, and thereafter 850 mg twice daily.
40853519|NCT01478308|DRUG|Docetaxel|Docetaxel will be administered 75 mg/m2 as one hour infusion on day 1 every 21 days.
40853520|NCT01478308|DRUG|Prednisone|Prednisone will be given 5mg orally twice daily which is the standard regimen with docetaxel
40853521|NCT04241471|PROCEDURE|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
40853522|NCT04241471|DEVICE|traditional incision and drainage (I&D)|traditional incision and drainage (I\&D)
40853523|NCT00697372|DEVICE|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
40853524|NCT00697372|DEVICE|Everolimus eluting stent|Implantation of Everolimus eluting stent
40853525|NCT03863808|BEHAVIORAL|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
40853526|NCT03863808|OTHER|Strengthening exercises|Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
40853527|NCT05267951|DEVICE|Open-loop Stimulation|Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.
40853528|NCT05267951|DEVICE|Close-loop Stimulation|Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.
40853529|NCT05267951|OTHER|Functional Task Practice|Exercise therapy consists of repeated functional hand and arm movements
40853530|NCT04150094|OTHER|Pelvic floor muscle training (PFMT)|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.
40853531|NCT04150094|OTHER|Pelvic floor muscle training + intravaginal vibratory stimulus|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.
40853532|NCT03878680|OTHER|Study questionnaires|"Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~1. Core questionnaire on wheezing.~2. Core questionnaire on rhinitis.~3. Core questionnaire on atopic dermatitis."
41528301|NCT00686608|DIETARY_SUPPLEMENT|fructose|fructose IV bolus
41528302|NCT00686608|DIETARY_SUPPLEMENT|saline|IV saline
41509412|NCT03636178|PROCEDURE|Modified alar base suture technique|The alar base will be marked with 3 landmarks: left alar base (point LAB), columella (point C), and right alar base (point RAB). A needle will be inserted through the skin at the nasofacial skin fold and exited through the fibroareolar tissue. A nonabsorbable suture without a needle will be inserted through the needle from the oral cavity to the outside. The needle will be retracted through point RAB without leaving the skin point, then returned to the oral cavity in a medial position. Finally the needle will be retracted from point RAB, leaving the suture through the soft tissue. The same procedure will be repeated on the other side. The 2 free ends of the sutures will be then tied together after passing through a hole made in the nasal spine.
41509413|NCT05013008|DRUG|Finerenone (Kerendia, BAY94-8862)|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
41509414|NCT05013008|DRUG|Placebo|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
41509415|NCT01790074|OTHER|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
41509416|NCT01790074|OTHER|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
41509417|NCT01443897|DIETARY_SUPPLEMENT|1,000 IU vitamin D2|capsule containing 1,000 IU vitamin D2
41509418|NCT01443897|DIETARY_SUPPLEMENT|placebo capsule|0 IU vitamin D2
41509419|NCT01443897|OTHER|mushrooms|untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
41509420|NCT01443897|OTHER|UVB-treated mushrooms, 400 IU vitamin D2|UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
41509421|NCT01443897|OTHER|UVB-treated mushrooms, 1,000 IU vitamin D2|UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
41509422|NCT02685683|DRUG|GED-0301|During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers subjects the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating no IP for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period. At Week 52, subjects who have achieved an endoscopic improvement of \>50% from baseline based on the SES-CD, as assessed by the central reader, and clinical improvement (HBI \<7), will have the option to continue receiving treatment for an additional year, up through Year 2 (ie, the Week 100 Visit).
41509423|NCT04340076|DRUG|Secukinumab|Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.
41509424|NCT04340076|DRUG|Ixekizumab|Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
41509425|NCT04340076|DRUG|Brodalumab|Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
41509426|NCT04340076|DRUG|Guselkumab|Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
41509427|NCT04340076|DRUG|Risankizumab|Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
41509428|NCT04340076|DRUG|Tildrakizumab|Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
41509429|NCT04340076|DRUG|Bimekizumab|Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.
41509430|NCT04050215|PROCEDURE|Computed Tomography|Undergo PET/CT
41509431|NCT04050215|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
41509432|NCT04050215|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41509433|NCT04050215|OTHER|Questionnaire Administration|Ancillary studies
41509434|NCT02199886|DRUG|BIBH 1|labeled with eight to ten millicurie of 131I
41509435|NCT03237338|PROCEDURE|ture acupuncture|"ture acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
40853533|NCT00321815|DRUG|PF-3512676 + Erlotinib|"PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.~Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity"
40853534|NCT00321815|DRUG|Erlotinib|Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
41036838|NCT05495854|DIAGNOSTIC_TEST|PCR test in the stool|"Patients randomized to the new strategy arm will receive a prescription for an Hp serology and a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment."
41036839|NCT05827068|BIOLOGICAL|mRNA-1011.1|Sterile liquid for injection
41036840|NCT05827068|BIOLOGICAL|mRNA-1011.2|Sterile liquid for injection
41036841|NCT05827068|BIOLOGICAL|mRNA-1012.1|Sterile liquid for injection
41509436|NCT03237338|PROCEDURE|sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
41509437|NCT06458647|OTHER|Video Streaming with Virtual Reality|In the study, patients in the intervention group will be watched videos of natural landscapes such as mountains, beaches and waterfalls with virtual reality goggles before the angiography procedure.
41509438|NCT03479801|PROCEDURE|Thyroid Surgical Methods|Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.
41509439|NCT05955183|DRUG|AZD5055|AZD5055 will be given orally to randomized participants as per the arm they are assigned.
41509440|NCT05955183|DRUG|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
41528303|NCT05321043|OTHER|Vitamin B2 labeling|Using medical non-toxic fluorescent agents, VB2 solution, to mark the patient's hands before endoscopy examination.
41383874|NCT04024280|OTHER|Physical exercise program|Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.
40853535|NCT05695274|BEHAVIORAL|Progressive muscle relaxation exercise|Experimental group Fibromyalgia patients will be provided with progressive relaxation exercises twice a week. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation.
40853536|NCT05675501|DRUG|Encapsulated Benzoyl Peroxide Cream|"Subjects will use a pea-size amount for each area of the face"
40853537|NCT03408184|DRUG|Lumbar paravertebral group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
40853538|NCT03408184|DRUG|The field block group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
40853539|NCT05900791|PROCEDURE|Primary knee arthroplasty|All patients surveyed have undergone primary knee arthroplasty approximately 1 year prior to survey distribution
40853540|NCT04557501|DIAGNOSTIC_TEST|PSMA PET/CT guided intensification of therapy|PSMA PET/CT prior to treatment.
40853541|NCT04557501|OTHER|Control Arm|Control - Treatment without PSMA PET/CT
40853542|NCT02486393|PROCEDURE|Parotid surgery|Surgery of the parotid gland tumours
40853543|NCT00707954|DRUG|TA-7284|Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
40853544|NCT00707954|DRUG|Placebo of TA-7284|Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
40853545|NCT01609504|PROCEDURE|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
40853546|NCT01609504|PROCEDURE|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
40853547|NCT05248880|DRUG|AGN-151586|Intramuscular Injection
40853548|NCT05248880|DRUG|Placebo|Intramuscular Injection
41036842|NCT05827068|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
41383875|NCT06000839|DEVICE|(D0) Intradermal injection - micropapula technique|First injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
41383876|NCT06000839|DEVICE|(D14) Intradermal injection - micropapula technique|Second injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
41528304|NCT01700972|PROCEDURE|Myocardial perfusion imaging|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
41036843|NCT05827068|BIOLOGICAL|mRNA-1010.2|Sterile liquid for injection
41036844|NCT05827068|BIOLOGICAL|mRNA-1010.3|Sterile liquid for injection
41383877|NCT06000839|DEVICE|(D28) Intradermal injection - micropapula technique|Third injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
41383878|NCT04045665|DRUG|Antiplatelet-only strategy|Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
41528305|NCT05472025|OTHER||
41528306|NCT02695966|PROCEDURE|Whipples Surgery|Whipples Surgery
41383879|NCT04045665|DRUG|Oral Anticoagulant plus background antiplatelet therapy|OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
41528307|NCT01966120|DRUG|BF-200 ALA gel|BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.
40853549|NCT02087969|PROCEDURE|Dry Needling|
40853550|NCT02087969|PROCEDURE|Stretching|
40853551|NCT01970267|PROCEDURE|Laser Ablation of Floaters|
40853552|NCT01970267|PROCEDURE|Sham Laser Treatment|Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.
40853553|NCT00850538|RADIATION|MRI|1.5T MRI exam of signal knee with knee coil (estimated time: 35 minutes)
40853554|NCT00850538|PROCEDURE|Primary Total Knee Replacement|Fluid, bone, and meniscus specimens obtained from total joint replacement will be collected.
41036845|NCT03449602|DEVICE|Mini-thoracoscopy|Thoracoscopic pleural biopsy with the mini-thoracoscope
41036846|NCT03449602|DEVICE|Conventional rigid thoraoscopy|Thoracoscopic pleural biopsy with the conventional rigid thoraoscope
41036847|NCT02828722|OTHER|Controlled light and noise|"Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs."
41036848|NCT02828722|OTHER|Controlled nutrition|"In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.~Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached."
41036849|NCT05169359|BEHAVIORAL|Speak Up! Video|Once a clinic begins active implementation (is ready to show the video) patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or a portable DVD player, computer or TV as appropriate to the site based on PDSA activities during implementation planning). The clinic staff will set patients up with comfortable headphones.
41383880|NCT04469868|BEHAVIORAL|No opioids at discharge|"Patients who are being scheduled for any major urologic cancer surgery (open or laparoscopic) will be counselled regarding post-operative pain and measures taken during surgery and during hospital stay.~They will be provided written information on these pain mitigation efforts and the adverse effects associated with opioids use and outpatient prescriptions.~Patients will be discharged from the hospital without any opioids prescriptions and instructions to use non-opioids analgesics.~Patients will complete a visual analog pain scale daily for 7 days after discharge from the hospital.~Patients will be able to call the clinic at anytime for any post-operative pain issues."
41036850|NCT04706468|DRUG|TG-1000|Capsules taken orally
41036851|NCT01328574|DRUG|TRC105|15 mg/kg intravenously
41509441|NCT04687683|OTHER|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions. This stretching exercise will be applied in 5 repetitions for one session.
41509442|NCT04687683|OTHER|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions for one session.
41036852|NCT02561858|OTHER|acid load test|
41036853|NCT05737810|OTHER|No treatment given|No treatment given
41036854|NCT01046305|BEHAVIORAL|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
41036855|NCT01046305|BEHAVIORAL|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
41036856|NCT01046305|BEHAVIORAL|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
41036857|NCT02311712|DEVICE|Capsule sponge|Capsule sponge cytology examination coupled with H\&E staining analysed for the presence of atypia and p53 immunohistochemistry
41036858|NCT06503211|BIOLOGICAL|UTAA09 injection|The subjects, who sign the informed consent forms and been screeneinclusion/exclusion criteria, will be assigned into 3 x 108\~1 x 1010 CD19-CAR - γδT cells.
41036859|NCT04830449|DRUG|HCP1904-2|Take it once daily for 8 weeks orally.
41036860|NCT04830449|DRUG|RLD2001-2|Take it once daily for 8 weeks orally.
41036861|NCT03588533|DRUG|Trastuzumab|"* Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~* Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks"
41036862|NCT03588533|DRUG|Capecitabine|- Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
41036863|NCT03588533|DRUG|Cisplatin|- Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks
41036864|NCT00062127|DRUG|irinotecan hydrochloride|Given IV
41036865|NCT00062127|DRUG|thalidomide|Given orally
41036866|NCT00062127|OTHER|pharmacological study|Correlative studies
41165924|NCT05194228|BEHAVIORAL|Ecologial Momentary Assessment settings|Various settings for ecological momentary assessments
41383881|NCT02983773|DRUG|THC 7.2%|1 smoked marijuana cigarette with 7.2% THC
41383882|NCT02983773|DRUG|THC 3.0%|1 smoked marijuana cigarette with 3.0% THC
41036867|NCT05921968|DRUG|Intravenous iron sucrose|"200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose)~o The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg"
41036868|NCT05921968|DRUG|Lactoferrin|100 mg twice daily orally before breakfast and dinner
41036869|NCT05003531|DRUG|IBI112 dose 2|Participants will receive placebo or dose 2 IBI112 SC
41036870|NCT05003531|DRUG|IBI112 dose 4|Participants will receive placebo or dose 4 IBI112 SC
41036871|NCT05003531|DRUG|IBI112 dose 1|Participants will receive placebo or dose 1 IBI112 SC
41036872|NCT05003531|DRUG|IBI112 dose 3|Participants will receive placebo or dose 3 IBI112 SC
41036873|NCT05003531|DRUG|placebo|Participants will receive placebo SC
41036874|NCT02624973|DRUG|Neoadjuvant tamoxifen + goserelin (premenopausal women)|
41383883|NCT02983773|DRUG|Placebo|1 smoked placebo marijuana cigarette
41383884|NCT00238108|DRUG|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
40853555|NCT05615207|OTHER|Motor Imagery as compared to physical practice for balance tasks|We will investigate if using motor imagery (mentally imagining and practicing a task) as a means of balance training is as effective as physical practice
40853556|NCT06524089|OTHER|Pilate training|Pilates based training exercises group will perform Pilates divided into two levels (beginner and intermediate). Each level will last for six sessions.
40853557|NCT06524089|OTHER|eccentric training|eccentric trunk training exercises group:The course of the intervention period is 12 sessions total, exercises performed for two to three sets with 10 to 15 repetitions each set and 2 min rest between each set
40853558|NCT05309148|BEHAVIORAL|Training on eye tracker based device|The intervention is based on the principle of visual biofeedback. The patient sees where his gaze is and can objectively assess and correct his visual error.
40853559|NCT05309148|BEHAVIORAL|Training with a neuropsychologist|The intervention is based on classical neuropsychological techniques aimed at correcting oculomotor disorders and improving visual attention (blank, psychometric, etc.)
40853560|NCT05309148|BEHAVIORAL|Training on eye tracker based device and with a neuropsychologist|This is combination of the first and second interventions
40853561|NCT05232331|DIETARY_SUPPLEMENT|Intake of nitrate rich vegetables|Nutritional intervention for 10 weeks to increase the consumption of vegetables rich in nitrate. At the beginning of the NSPT on visit 1 (week 2), the first of 5 nutritional interventions will begin with the objective of consuming \~ 350 mg of nitrate daily from vegetables
40853562|NCT01706588|DRUG|Diclofenac sodium|One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
40853563|NCT06370013|DRUG|Tinengotinib|Subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the TransThera parent study. Dose may be decreased by one dose level from the previously-received dose upon study entry, based on physician discretion.
40853564|NCT02641301|DRUG|Sustained release morphine sulfate, 30 mg|A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
41383885|NCT00238108|DRUG|Placebo|Placebo
41383886|NCT05714150|BEHAVIORAL|Complex Balance Tasks|The intervention will consist of a single session of practicing complex (cognitively engaging) balance tasks using an exergaming balance platform.
41383887|NCT00717158|BEHAVIORAL|Usual medical care|
41383888|NCT00717158|BEHAVIORAL|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
41383889|NCT00159367|DEVICE|Repetitive magnetic stimulation to the quadriceps|
41383890|NCT02804191|DRUG|LO2A|eye drop solution.
41383891|NCT02804191|DRUG|Saline|Placebo
41383892|NCT04132102|DRUG|Afatinib|Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
41383893|NCT03094949|PROCEDURE|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
40853565|NCT00894946|PROCEDURE|Lipiodol + IVF|IVF preceded by lipiodol
40853566|NCT00894946|PROCEDURE|IVF|IVF alone
40853567|NCT03680300|OTHER|Post Facilitation Stretch|"The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition."
41036875|NCT02624973|DRUG|Neoadjuvant letrozole (postmenopausal women)|
40853568|NCT03680300|OTHER|Post Isometric Relaxation|"The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times."
40853569|NCT03680300|OTHER|Friction Massage|Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
40853570|NCT03749278|BEHAVIORAL|Latina Friends Motivating the Soul (ALMA)|In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed
40853571|NCT03124082|DRUG|Remifentanil|continuous infusion intraop
41180017|NCT06296004|DEVICE|Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness by U.S|"Complete blood count (CBC) Erythrocyte sedimentation rate (ESR) measured by standard westergren method (mm/h).~Serum C-reactive protein (CRP) Liver function tests: aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~Renal function tests: serum creatinine and blood urea. Complete urine analysis.~Optical coherence tomography angiography (OCTA): . Bilateral common femoral vein (CFV) Doppler US"
41383894|NCT03094949|PROCEDURE|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
40853572|NCT03124082|DRUG|Ketamine|bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
40853573|NCT03124082|DRUG|Lidocaine|lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
41180018|NCT06258213|DRUG|ABP-745|0.5, 5 or 25 mg tablet
41180019|NCT06258213|DRUG|Placebo|Placebo tablet
41383895|NCT00740532|GENETIC|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
41383896|NCT04203758|OTHER|Cereal products based on rye|Participants will receive a fixed amount of rye based cereals products, corresponding to approx 650 kcal/day.
41383897|NCT04203758|OTHER|Cereal products based on wheat|Participants will receive a fixed amount of wheat based cereals products, corresponding to approx 650 kcal/day.
41383898|NCT03558607|DRUG|Ruxolitinib|"Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~* If Age \< 55 years and ECOG PS \< 2 : 7+3 regimen~* If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months."
41383899|NCT06537323|DRUG|Femoral nerve block with0.25% bupivacaine guided by ultrasound.|Femoral nerve block with0.25% bupivacaine guided by ultrasound.
41528308|NCT01966120|DRUG|Placebo to BF-200 ALA gel|The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
40853574|NCT03124082|DRUG|Clonidine|clonidine 4 mcg/kg
40853575|NCT01679873|OTHER|Assess one type of abstract in the randomized arm|Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made
41036876|NCT02624973|DRUG|Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|
41036877|NCT02624973|DRUG|Neoadjuvant docetaxel + cyclophosphamide|
40853576|NCT03361982|OTHER|Slow Freezing and Thawing|half of the surgically obtained testicular sperm will be frozen for 30 minutes and subsequently thawed prior to performing ICSI
40853577|NCT04039737|DRUG|Qingpeng Ointment|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
41036878|NCT02624973|DRUG|Neoadjuvant docetaxel|
40853578|NCT04647097|BEHAVIORAL|Standard intervention only|Standard intervention (SI) will be a part of standard care in all participating centers, and will be provided for all acute pancreatitis patients, who are hospitalized and their condition is alcohol induced. A specially trained study nurse will deliver the intervention, since they were found to be the most effective regarding the decrease in alcohol consumption and smoking. The cost- effectiveness of the intervention and the feasibility were also taken into account. The Assist-linked brief intervention according to the World Health Organization (WHO) will serve as the base for the intervention, with an avarage of 30 minutes, based on a review containing 69 randomized controlled trials, which concluded that longer intervention do not have additional benefit. The patients will be also educated about the disease course of acute pancreatitis during the standard intervention.
40853579|NCT04647097|BEHAVIORAL|Standard intervention plus repeated intervention|Standard intervention (SI) will be performed as described above. The repeated intervention will be delivered by the former mentioned same nurse and will be structured similarly to the standard intervention. Every visit and intervention will be individually altered according to the motivation of the patient, but they will follow the same structure. The sessions can be divided into three main parts: first, highlighting the harmful effects of smoking and alcohol on the pancreatic functions. Secondly, a discussion about the motivation of the patient will happen. The last portion of the session will focus on the responsibility of the individual to reach the desired goal will be highlighted. To enhance the efficacy of our intervention we wish to provide feed-back for the patient based on laboratory testing: the mean corpuscular volume (MCV) and gamma glutamyl-transferase (GGT) values will be measured right before the interview. The study nurse will not take part in patient care.
41165925|NCT04876768|PROCEDURE|Use of different concentrations of oxygen during ERCP|The endoscopic intervention will be conducted in the endoscopy suite located at UK Albert B. Chandler Hospital in Lexington, Kentucky. ERCP/EUS uses an endoscope which is a long flexible narrow tube with a camera at the end is passed through the mouth, esophagus, stomach and the first part of the duodenum. The goal is to access a small elevation in the duodenum called the papilla of Vater. This papilla drains the biliary and pancreatic ducts which brings digestive juices from the liver, gallbladder and the pancreas. The endoscopist will inject contrast dye through the papilla into the ducts and takes X-rays to show lesions such as stones, strictures or blockages. If appropriate these can be treated by passing instruments through a port in the endoscope. Immediately following the endoscopic intervention; complications (bleeding, aspiration, perforation) will be recorded by study personnel as either yes or no, which will be used to assess the overall success of the procedure.
41036879|NCT02624973|DRUG|Neoadjuvant docetaxel + trastuzumab + pertuzumab|
41036880|NCT02624973|DRUG|Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|
41036881|NCT02624973|DRUG|Neoadjuvant olaparib|
41036882|NCT02624973|DRUG|Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)|
41036883|NCT02624973|PROCEDURE|Breast conserving surgery or mastectomy + SNB/axillary dissection|After response to neoadjuvant treatment
41036884|NCT02624973|RADIATION|Postoperative radiotherapy breast/chest wall + regional lymph nodes|
41036885|NCT02624973|DRUG|Adjuvant trastuzumab|
41036886|NCT02624973|DRUG|Adjuvant letrozole (postmenopausal women)|
41165926|NCT01620307|DRUG|Sirolimus (Rapamune 2mg/day, Pfizer)|Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
41165927|NCT04342598|OTHER|Serum Vitamin D|Primary exposure assessed will be serum vitamin D (25(OH)D). Diet will also be assessed via Food Frequency Questionnaire.
41165928|NCT01410084|DIETARY_SUPPLEMENT|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
41165929|NCT01410084|DIETARY_SUPPLEMENT|Vitamin E|400 IU vitamin E once monthly for 5 months
41165930|NCT03679468|OTHER|Cognitive Rehabilitation|"RehaCom software~Information processing speed and attention modules"
41036887|NCT02624973|DRUG|Adjuvant tamoxifen + goserelin (premenopausal women)|
41165931|NCT03679468|OTHER|Sham Exercise|Sets of balance and stretching exercises
41165932|NCT03679468|OTHER|Sham Cognitive Rehabilitation|"Kompozer software~24 session module consisting of basic internet searches"
41165933|NCT03679468|OTHER|Aerobic Exercise|"Recumbent NuStep Bike~Aerobic cycling"
41383900|NCT06537323|DRUG|PENG block with0.25% bupivacaine guided by ultrasound.|PENG block with0.25% bupivacaine guided by ultrasound.
41383901|NCT06537323|DRUG|Preoperative IV fentanyl 100microgram|Preoperative IV fentanyl 100microgram
41383902|NCT05665530|DRUG|PRT2527|PRT2527 will be administered by intravenous infusion once weekly.
41383903|NCT05665530|DRUG|Zanubrutinib|Zanubrutinib will be provided in capsules for oral administration once or twice daily.
41383904|NCT05665530|DRUG|Venetoclax|Venetoclax will be provided in tablet for oral administration once daily
41383905|NCT06281522|OTHER|Operated patients with hydatid cyst of the lung|File screening and blood test results will be evaluated
41383906|NCT06564272|DRUG|KC1036|For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.
41383907|NCT00185107|DRUG|Colesevelam Hydrochloride|
41383908|NCT00185107|DRUG|Ezetimibe|
41383909|NCT00185107|DRUG|Simvastatin|
41383910|NCT04365829|DEVICE|"virtual reality headset Occulus GO"|"Use of a virtual reality headset for one week at a frequency of 3 days per week (D1, D3 and D5). During each session (1 hour), the subject will visualize a scene of natural virtual environment (a garden, animals in the wild, a grand Canyon) lasting 7 min using an virtual reality headset Occulus GO."
41509443|NCT04687683|OTHER|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions for one session.
41036888|NCT02624973|DRUG|Adjuvant palbociclib (if palbociclib given neoadjuvant)|
41383911|NCT03003858|DEVICE|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
41509444|NCT02934867|OTHER|Protocol phone advice|Protocol phone advice
41509445|NCT02934867|OTHER|Usual phone advice|Usual phone advice
41509446|NCT02027532|DRUG|Cefazolin|
41509447|NCT02027532|DRUG|Vancomycin|
41509448|NCT04460287|DIETARY_SUPPLEMENT|DHA Wet Mixing method|Children will drink milk contain 100 mg DHA wet mixing daily for 30 days
41509449|NCT04460287|DIETARY_SUPPLEMENT|DHA Dry Blending Method|Children will drink milk contain 100 mg DHA dry blending daily for 30 days
41509450|NCT04460287|DIETARY_SUPPLEMENT|Fish Oil|Children will have this intervention every day for 30 days
41509451|NCT01881984|DRUG|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
41509452|NCT04087915|DRUG|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
41509453|NCT03064724|BEHAVIORAL|"Interactive Mobile Doctor (iMD)"|"iMD delivers tailored interactive video education via a mobile tablet to smoking patients right before their clinic visit with a provider. iMD delivers the 5 A's (ask, advise, assess, assist, and arrange) and generates a bilingual tailored printout, which aims to increase patient-provider discussion on tobacco use and to promote smoking cessation. This version of iMD delivers the intervention in Korean or Vietnamese languages as preferred by the patient."
40853580|NCT03322917|BIOLOGICAL|PRP autologous|Autologous platelet rich plasma: 1 drop / 6 times a day during 6 weeks
41036889|NCT02624973|DRUG|Adjuvant Epirubicin+ Cyclophosphamide|
41036890|NCT06027320|BEHAVIORAL|Brain Health Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.
41036891|NCT06027320|BEHAVIORAL|Alzheimer Disease Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
41036892|NCT03627481|PROCEDURE|Endoscopic sinus surgery|Endoscopic sinus surgery for nasal polyposis
41036893|NCT02399579|OTHER|Provocation test|The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
41036894|NCT02268552|DRUG|branaplam|
41036895|NCT02190331|OTHER|Interventional program postural correction training|The postural correction training program was applied in the last 15-20 minutes of each PE class, twice a week, with the supervision and help of the PE teacher.
41383912|NCT05254015|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) includes cognitive rehabilitation of executive functioning and exposure therapy for discarding/not acquiring.
41383913|NCT05254015|BEHAVIORAL|Case Management|Case management includes linking to resources, monitoring health, and safety hazards.
41383914|NCT00081978|DRUG|TMC125|
41383915|NCT02230228|DRUG|ALK-001 (No generic name)|Daily, oral administration of ALK-001 capsules.
41383916|NCT01169831|OTHER|Exercise Training|2 weeks of daily aerobic exercise training
41509454|NCT00773474|DRUG|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
41509455|NCT04065360|BEHAVIORAL|Group Cognitive behavioural family intervention (CBFI)|four-week, four-session CBT-based family intervention programme
41383917|NCT01169831|OTHER|Exercise Cessation|Stopping all exercise for 2 weeks
41383918|NCT03363724|OTHER|HaGuide version 1.0 software module|
41509456|NCT04065360|BEHAVIORAL|Usual group psychoeducation|Treatment as usual in the institution studied
41509457|NCT04638101|BEHAVIORAL|Mindfulness-based intervention|Mindfulness-based intervention: The proposed MBI was designed based on well-known MBI programs including Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy and adapted to adolescents' needs and language. The program consisted of 8 weekly sessions in groups of up to 8 participants, lasting 1h30. Two MBI groups were offered per week (Wednesdays and Fridays) and participants had the possibility to choose the most convenient day for them. Two instructors were present for each group throughout the intervention.For each session one theme was addressed, such as attention and the stabilisation of the focus of attention, bodily sensations, breath, emotions, thoughts, compassion, stress, stress reactivity and coping strategies.
40853581|NCT04260607|DRUG|Ketamine Hydrochloride|"Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The experimental and placebo arms will receive a single dose of IV ketamine, 0.5 mg/kg in 100 cc NS or 100 cc of NS infused over 40 minutes.~3. Post ketamine re-evaluation of outcome measures at four and twenty-four hours will determine clinical effectiveness of ketamine intervention~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post ketamine re-evaluation of outcome measure at one-week post infusion will elucidate ketamine's durability of effect."
40853582|NCT04260607|DRUG|Normal saline|"Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~3. Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post Normal Saline re-evaluation of outcome measure at one-week post infusion."
40853583|NCT05789563|OTHER|Hypoxia and Smartwatch model|Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.
40853584|NCT00138775|DRUG|D-serine|
40853585|NCT05367297|DIAGNOSTIC_TEST|Coronary CT Angiogram|A computerized tomography (CT) coronary angiogram is non-invasive imaging test that looks at the arteries that supply blood to your heart.
40853586|NCT05613829|OTHER|Burn surgery|Patients underwent burn surgery
40853587|NCT04289792|DRUG|nab-Paclitaxel+Gemcitabine|Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.
40853588|NCT04289792|RADIATION|split-course SBRT|Radiation: During the first 1 and 2 cycles of chemotherapy, SBRT was given as a single irradiation of 10 Gy ⅹ 4 times (Days 2 and 16 of each 28-day cycle).
40853589|NCT03511157|OTHER|Ischemic Preconditioning|See Ischemic Preconditioning Experimental group description
40853590|NCT03511157|OTHER|Control Group|See Control group description
40853591|NCT04886778|DIETARY_SUPPLEMENT|Low-carbohydrate diet|Participants will be instructed to maintain a daily dietary energy intake of less than 1600 kcal.Based on the low-carbohydrate diet model, the proportion of daily intake of carbohydrate was about 30%, and this ratio was up to 30%, 40% of protein and fat respectively.Participants should choose unprocessed whole grains, potatoes, vegetables, meat, fish, eggs, soy products, sugar-free dairy products, designated varieties of low-GI fruits and nuts, etc. as breakfast, and avoid processed meats and high-fat red meat and poultry skins. Standard nutritious meal instead of daily lunch and dinner meals, that is to say, participants should take one nutritional bar for lunch and dinner (310 kcal totally, provided by Guangzhou Nanda Fett Nutrition and Health Consulting Co., Ltd.), and avoid starchy foods. Other food varieties are required to be the same as breakfast. Plant oil is the main cooking oil, and participants will be instructed to drink 2L water every day.
40853592|NCT04886778|DIETARY_SUPPLEMENT|Probiotic compound preparations|The probiotic compound preparation，named Junyi Yili® Probiotics，is made of Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus acidophilus and Bifidobacterium lactis, and resistant dextrin contained water-soluble dietary fiber. The subjects will take this probiotic compound preparations with purified water after three meals every day, 1 sachet each time.
40853593|NCT04886778|DIETARY_SUPPLEMENT|Placebo|Placebo is made of resistant dextrin which contained water-soluble dietary fiber. The subjects were taken this placebo with purified water after three meals every day, 1 sachet each time.
40853594|NCT05466357|PROCEDURE|Excision of pituitary tumor outside pseudocapsule|Dedicated high-resolution magnetic resonance imaging (MRI) protocols have been proposed to detect pituitary adenoma and accurately guide surgical removal. To accomplish complete PA removal and minimize the impact on pituitary functions, intraoperative navigation was used to identify the tumor pseudocapsule. Depending on different tumor sizes and pseudocapsule development, investigators adopted different resection strategies. The suspicious tissue was sent to the pathology department for histopathology intraoperatively. Long-term postoperative follow-up imaging and endocrine data were used to evaluate tumor prognosis before and after operation. Standardized management and established biobank is critical for pituitary adenomas.
40853595|NCT03301298|DRUG|SXC-2023|Oral capsule
40853596|NCT03301298|DRUG|Placebo oral capsule|Placebo given as oral capsule.
40853597|NCT00125320|DRUG|RSD1235|
40853598|NCT01106508|DRUG|LEQ506|
40853599|NCT03067623|DRUG|PRP|PRP intrauterine infusion
40853600|NCT03067623|DEVICE|Tomcat catheter|PRP intrauterine infusion by means Tomcat catheter
40853601|NCT06584370|PROCEDURE|Pericardial insufflation with carbon dioxide through a transatrial microcatheter|Separate the walls of the pericardium by insufflating the pericardial space with carbon dioide.
41036896|NCT02190331|OTHER|Control Group physical education classes|Only performed the physical education classes
41383919|NCT05682352|DRUG|LEO 158968|IV infusion or SC injection
41383920|NCT05682352|DRUG|Placebo|IV infusion or SC injection
41383921|NCT05682352|DRUG|LEO 158968|SC injection
41036897|NCT00749151|BEHAVIORAL|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
41165934|NCT02765386|DEVICE|Hybrid fittings for cochlear implant recipients|
41165935|NCT02483845|DRUG|Natalizumab|
41383922|NCT05682352|DRUG|Placebo|SC injection
41383923|NCT03006822|OTHER|Pressure release 90|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
41383924|NCT03006822|OTHER|Pressure release 60|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
41383925|NCT03006822|OTHER|Pressure release 30|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
41383926|NCT05219513|DRUG|RO7443904|RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
40853602|NCT04031989|DEVICE|CorVista Capture|The CorVista System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms developed by CorVista Health. Data collected with the CorVista System during this study will not be used to guide treatment.
41036898|NCT00321919|DRUG|epoetin beta [NeoRecormon]|Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
41036899|NCT00321919|DRUG|epoetin beta [NeoRecormon]|Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to \<10.5 g/dL had occurred.
41036900|NCT04628689|OTHER|quadratus lumborum block by paraspinous sagittal shift approach|quadratus lumborum block by paraspinous sagittal shift approach
41036901|NCT02662842|DEVICE|FlowSmart Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
41036902|NCT02662842|DEVICE|Current Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
41509458|NCT06548425|OTHER|Smart Phone Based Cardiac Telerehabilitation|"Smart Phone Based Cardiac Telerehabilitation~Frequency:3 sessions per week for 8 weeks Intensity: 40-60 % THR and modified borg scale 9 (very light- 13 (somewhat hard) Time: Approx. 30 Min Type: Aerobic \& strength Exercises"
41509459|NCT06548425|OTHER|Center based cardiac Rehabilitation|"Center based cardiac Rehabilitation~Frequency:3 sessions per week for 8 weeks Intensity: 40-60% THR and modified borg scale 9 (very light- 13 (somewhat hard)~Time: Approx. 30 Min Type: Aerobic \& strength Exercises"
41036903|NCT05194774|PROCEDURE|Greater Trochanter epiphysiodesis|epiphysiodesis by cortical screw and washer
41036904|NCT01785329|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
41036905|NCT06447857|OTHER|Cardiac MRI|This retrospective study included patients diagnosed with STEMI at the Affiliated Hospital of Xuzhou Medical University. All patients underwent CMR.
41036906|NCT01840423|DRUG|ODM-104|ODM-104
41036907|NCT01840423|DRUG|Placebo|Placebo
41036908|NCT01840423|DRUG|Entacapone|entacapone + levodopa/carbidopa
41036909|NCT01840423|DRUG|levodopa/carbidopa|entacapone + levodopa/carbidopa
41383927|NCT05219513|DRUG|Glofitamab|Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
41383928|NCT05219513|DRUG|Obinutuzumab|Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
41383929|NCT05219513|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
41383930|NCT02049931|DEVICE|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
40853603|NCT05621993|DRUG|Azvudine|Azvudine is a small molecular antiviral drug. On August 9, 2022, Azvudine was included in the Diagnostic and therapeutic protocol for COVID-9 in China.
40853604|NCT03157284|DIETARY_SUPPLEMENT|Rice Flour|For 12 weeks, a group of children will receive 7gr fermented rice flour according to a randomised, double-blind design.
40853605|NCT03157284|DIETARY_SUPPLEMENT|Placebo|For 12 weeks a group of children will receive a 7gr of a placebo (maltodextrin), according to a randomised, double-blind design.
41036910|NCT05477745|PROCEDURE|total knee arthroplasty|The surgeries were performed under general anesthesia. The medial parepatellar incision was introduced during the TKA. The femoral component size was selected according to the intro-operative measurement. The osteotomy was done according to the intramedullary guide and the cutting guide. After the proximal tibial osteotomy was finished, the cruciate-retaining Total Knee System was used. The lateral rotation of the femoral component was determined by the gap-balancing technique.
41036911|NCT02907346|BEHAVIORAL|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
41036912|NCT06544733|DRUG|GS-1720|Tablets administered orally without regard to food
41036913|NCT06544733|DRUG|GS-4182|Tablets administered orally without regard to food
41036914|NCT06544733|DRUG|Placebo to Match BVY|Tablets administered orally without regard to food
41036915|NCT06544733|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Tablets administered orally without regard to food
41036916|NCT06544733|DRUG|GS-1720/GS-4182 FDC|Tablets administered orally without regard to food
41036917|NCT06544733|DRUG|Placebo to Match GS1720/GS-4182 FDC|Tablets administered orally without regard to food
41036918|NCT01988246|DRUG|Aflibercept|Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
41036919|NCT01988246|DRUG|Sham|Sham injection. No actual injection. No medication is used.
41036920|NCT04586101|DEVICE|Trainings application|Participants have to train with the developed trainings application over six weeks. For this, individual training plans are implemented in the application based on orthopedic joint status and training recommendations of a sports scientist.
41036921|NCT04353869|BIOLOGICAL|Bio collection|venous blood sampling and collection of urine
41036922|NCT02818881|OTHER|High-speed yoga|
41036923|NCT02818881|OTHER|Low-speed yoga|
41383931|NCT02049931|DEVICE|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
41509460|NCT00742963|DRUG|TH-302|"TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2"
41509461|NCT03793127|OTHER|Maximal oxygen consumption (V02 max)|Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.
40853606|NCT02903498|DRUG|UFT|UFT 360mg/m2 qd po d1-14, q3w
41036924|NCT02936557|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-054)"
41036925|NCT00749138|DRUG|tamoxifen|giving drug tamoxifen
41165936|NCT01717170|DRUG|Tocilizumab|Tocilizumab (4 mg/kg or 8 mg/kg)
41383932|NCT02049931|DEVICE|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
41383933|NCT01184781|DEVICE|Comparison of capsule endoscopy Pillcam II™ versus colonoscopy|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
41383934|NCT00029042|DRUG|Infliximab|
40853607|NCT04331002|DRUG|Zilretta|ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide. It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter.
40853608|NCT04331002|OTHER|Placebo|5 mL normal saline
40853609|NCT06169982|DRUG|LY3209590|Administered SC
40853610|NCT00774800|DRUG|Humalog|
40853611|NCT00774800|DRUG|Humulin-R|
40853612|NCT00774800|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
40853613|NCT00774800|OTHER|Liquid meal|
40853614|NCT03194113|BEHAVIORAL|Trauma-focused treatment|Weekly sessions
40853615|NCT03194113|BEHAVIORAL|Emotion regulation training|Managing and tolerating negative emotions, e.g. anger, sadness. Weekly sessions; preparatory to Prolonged exposure treatment
40853616|NCT03194113|BEHAVIORAL|Intensive Trauma-focused treatment|Intensive version (3 sessions per week) of Trauma-focused treatment
41383935|NCT00685711|BIOLOGICAL|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
41383936|NCT03356834|DRUG|Tenofovir alafenamide(TAF)|25 mg tablet administered orally once daily
41383937|NCT03356834|DRUG|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily
41383938|NCT00993525|DRUG|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
40853617|NCT01364389|DRUG|AIN457|3 mg/kg
40853618|NCT01364389|DRUG|ACZ885|3 mg/kg
40853619|NCT01364389|DRUG|Prednisone|20 mg
40853620|NCT01364389|DRUG|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
40853621|NCT04563962|BEHAVIORAL|Contingency Management-ART|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated adherence to tenofovir-based ART or PrEP.
40853622|NCT04563962|BEHAVIORAL|Contingency Management-Methamphetamine|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
40853623|NCT03111329|OTHER|No aspiration of gastric residuals|No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
41383939|NCT00822601|DEVICE|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
41383940|NCT00822601|DEVICE|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
40853624|NCT05486611|DEVICE|W-GenZD Mobile Application|"W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
40853625|NCT05486611|DEVICE|Digital Education Application (W-EdZD)|"Digital Education will be available to the participant via the 'Quest GenZ' smartphone application but will be devoid of active elements included in WB002. We will source this material from kidshealth.org, which is supported by Nemours Children's Health. We have received permission to use their content.~The materials are written at an 8th grade reading level and will include general health (e.g., food plate guide, caffeine, online safety, study skills) articles. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date."
40853626|NCT04886713|DIAGNOSTIC_TEST|Adipose and myocardial tissue sampling|After median sternotomy tissue samples will be collected from the epicardial space, the abdominal wall and the myocardium.
41036926|NCT00851214|DEVICE|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
41036927|NCT04554875|DIAGNOSTIC_TEST|A scoring system|The scoring system was used to rate score patients.
41036928|NCT02026700|DEVICE|bariederm cream|patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
41036929|NCT03397264|BIOLOGICAL|Aflibercept|Intravitreal injection
41036930|NCT03397264|BIOLOGICAL|OPT-302|Intravitreal Injection
41036931|NCT03397264|OTHER|Sham intravitreal injection|Sham (mock) intravitreal injection
41036932|NCT06446349|OTHER|Brief motivational intervention|identification followed by a brief motivational intervention in pharmacies (BMI) based on the mobilisation of patients' psychosocial skills and the integration of tools to help reduce consumption of BZD/Z prescribed over the long term (≥ 6 months).
41036933|NCT00911872|DEVICE|collagen (EVOLENCE)|injectable collagen
41036934|NCT00583726|BEHAVIORAL|motivational interviewing|telephone counseling
41036935|NCT00583726|BEHAVIORAL|written materials only|dietary guidance materials and pedometers
41036936|NCT02291614|DRUG|AMG 211|continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days
41509462|NCT03793127|OTHER|Brown adipose tissue (BAT) imaging|Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2\* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.
40853627|NCT04886713|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|"Magnetic resonance imaging will be performed at 1.5 Tesla ('Intera', Philips Medical Systems, Best, The Netherlands). All subjects will be examined in the supine position with initial anatomy scans to cover the thorax to the first sacral vertebrae. The magnetic resonance imaging protocol is summarized in Figure 4.~The following imaging parameters will be acquired:~* Biventricular end-diastolic and end-systolic volume, ejection fraction, stroke volume~* Biventricular mass, wall thickness~* T1 mapping; native and \> 10 minutes post contrast injection as an estimate of left ventricular diffuse fibrosis and extracellular volume~* Late enhancement for detection of regional fibrosis and scar~* Myocardial feature tracking for analysis of deformation/motion~* Epicardial fat volume"
40853628|NCT04886713|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|After completion of a regular cardiac rehabilitation program patients are scheduled to undergo their discharge examination at 3 to 4 weeks after the operation in order to be functionally characterized. Cardiopulmonary exercise testing will be performed, if possible by patients condition, on a mechanically braked bicycle ergometer and respiratory gas exchange analysis via a mouthpiece or facemask.
41036937|NCT02300753|DRUG|EPI-743|EPI-743 is a quinone oxidation product of alpha-tocotrienol
41036938|NCT05510843|DRUG|THB001|100 mg capsules for oral administration
41383941|NCT00806416|DRUG|alendronate sodium (+) cholecalciferol|A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
41383942|NCT00806416|DRUG|Comparator: alendronate|A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
41383943|NCT00806416|DIETARY_SUPPLEMENT|Comparator: cholecalciferol (Vitamin D)|A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
41509463|NCT03793127|OTHER|Muscle function testing|This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.
41509464|NCT05820126|BIOLOGICAL|Cold-stored platelet concentrate|Patients will be transfused a unit of pooled, pathogen reduced platelets that have been stored for \>24 hours at 1-6˚C
41036939|NCT04250649|PROCEDURE|subcutaneous tissue disinfection|"Skin and subcutaneous incision (up to the muscular fascia) with superficial blade scalpel, disinfection of the subcutaneous tissue with 3cc of Betadine solution, placement of the retractors, dissection and development of the delto-pectoral interval with deep blade scalpel.~When the joint is opened, bacteriological smears are taken from 5 sites in the two groups. 1) exposed subcutaneous tissue, 2) surgeon's gloves (distal end of fingers), 3) superficial blade, 4) deep blade, 5) retractors.~The rest of the shoulder surgery procedure does not differ from what is commonly performed.~The samples are sent to bacteriology for bacterial culture. Anaerobic research is done specifically for P. acnes. The results are considered negative after 10 days."
41509465|NCT01757275|DRUG|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
41036940|NCT02479412|DRUG|800 μg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
41036941|NCT02479412|DRUG|250 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
41036942|NCT02479412|DRUG|58 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
41036943|NCT02479412|DRUG|Placebo once daily|Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
41383944|NCT03712046|DIAGNOSTIC_TEST|18F-FDG PET-CT|Patient will receive one injection of 18F-FDG and then undergo PET-CT imaging
41383945|NCT02703454|PROCEDURE|FIRM-guided RF ablation|
41383946|NCT02703454|PROCEDURE|Conventional RF ablation|
41383947|NCT04751786|DRUG|PRECIOUS-01|Subjects will be enrolled in one of three dosing cohorts (three subjects per cohort for the planned dose escalation with a planned extension to a total of six subjects for the two highest dosing cohorts for the evaluation of the pharmacodynamic effects of PRECIOUS-01 for determination of the RP2D, if MTD is not reached).
41383948|NCT04332835|DRUG|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
41036944|NCT02479412|DRUG|Salbutamol|Inhalation as needed
41509466|NCT01757275|DRUG|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
41509467|NCT01757275|DRUG|Esomeprazole Mg|40 mg tablet once daily for 27 days
41509468|NCT05912270|BEHAVIORAL|Orchestra in Class|See arm/group descriptions
41509469|NCT01823497|DRUG|Morphine|Morphine will be used to control pain post-surgery.
41036945|NCT06486168|PROCEDURE|NIVATS|Non-Intubated Video-Assisted Thoracic Surgery (NIVATS) is the least invasive approach available. It is part of an optimal Enhanced Recovery After Surgery (ERAS) pathway and allows for expanding surgical indications in patients with poor cardio-pulmonary function.
41036946|NCT05462665|BEHAVIORAL|theory training|theory training
41383949|NCT04332835|DRUG|Standard Therapy|Standard therapy defined by institutional protocol.
41383950|NCT00552682|DRUG|Duloxetine 60 mg, QD|Duloxetine 60 mg, 1 table/day, 1 year
41383951|NCT00003769|DRUG|perillyl alcohol|
41383952|NCT00003769|PROCEDURE|surgical procedure|
40853629|NCT04926948|OTHER|Immunotherapy|Immunotherapy
41036947|NCT05462665|BEHAVIORAL|theory and simulation training|theory and simulation training
41036948|NCT02363946|DRUG|ARC-AAT Injection|RNA interference-based, liver-targeted therapeutic
41036949|NCT02363946|OTHER|Placebo|0.9 % normal saline
41036950|NCT02363946|DRUG|Diphenhydramine|Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
41036951|NCT00694317|DRUG|Zaleplon|Short term treatment of insomnia
41036952|NCT02365467|DEVICE|Valiant Mona LSA Thoracic Stent Graft System|
41036953|NCT02169687|DEVICE|HIFU|High Intensity focalized Ultrasounds
41036954|NCT04700293|DIETARY_SUPPLEMENT|AYMES AMSTERDAM|AYMES AMSTERDAM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
41036955|NCT02324933|DRUG|Fentanyl|Fentanyl Patient Controlled Analgesia for post-operative pain management
41383953|NCT05219032|BEHAVIORAL|Professional Medical Interpreter|A professional medical interpreter accompanies patient to each appointment.
41383954|NCT02940392|DEVICE|Rezum System|"The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.~The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
41383955|NCT02629380|BIOLOGICAL|hyaluronic acid|A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
41383956|NCT02629380|PROCEDURE|meniscectomy alone|The patients randomized in this group will receive arthroscopic meniscectomy alone
40853630|NCT04926948|OTHER|Quality-of-Life Assessment|Ancillary studies
41036956|NCT02138591|PROCEDURE|Blood draw pre-operatively|Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
41417781|NCT04022499|BEHAVIORAL|Presessions|"The Pre-NDPP arm includes a pre-session with three components: 1) education about diabetes risks, 2) motivational interviewing (MI) to encourage participation in the NDPP and, 3) problem-solving of barriers to engagement."
40853631|NCT04926948|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
40853632|NCT00307203|DRUG|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
41036957|NCT02138591|PROCEDURE|Blood draw post-operative Day 1|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
41036958|NCT02138591|PROCEDURE|Blood draw post-operative Day 2|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
41036959|NCT00373594|DRUG|Rituximab|
41036960|NCT00373594|DRUG|Fludarabine|
41036961|NCT01692535|PROCEDURE|Intubation|Intubation with one of the six videolaryngoscopes
41036962|NCT04226430|DEVICE|Cytokine aphaeresis|The Cytosorb cartridge was either used alone in hemoperfusion mode or, if renal replacement therapy was clinically indicated, inserted proximally into a conventional continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. Before the start of the Cytosorb therapy, adequate anti-coagulation was confirmed when target partial thromboplastin time (PTT) of 60±80 seconds, or an activated clotting time (ACT) of 180±210 seconds was achieved with systemic heparin. Antibiotics were administered after each Cytosorb therapy whenever possible.
41036963|NCT02390284|DRUG|Latanoprost|Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
41036964|NCT02390284|DRUG|Bimatoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
41036965|NCT02390284|DRUG|Travoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
41036966|NCT02390284|DRUG|Timolol|Lower intraocular pressure by decreasing production of fluid
41036967|NCT02390284|DRUG|Dorzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
41036968|NCT02390284|DRUG|Brinzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
41383957|NCT04509596|DRUG|DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C|"Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg. If tolerated, dose will be escalated in subsequent cohorts until MTD.~Part B is twice daily oral dosing of DZD1516 in combination with capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle or with trastuzumab 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each 21-day cycle.~Part C is twice daily oral dosing of DZD1516 in combination with T-DM1 3.6 mg/kg intravenously (IV) once every 21 days"
41383958|NCT04846075|BEHAVIORAL|Ramadan fasting, praying, and welfare for poor|Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
41383959|NCT05462756|DRUG|Insulin Efsitora Alfa|Administered SC
41383960|NCT05462756|DRUG|Insulin Lispro (U100)|Administered SC
41383961|NCT05462756|DRUG|Insulin Glargine (U100)|Administered SC
41383962|NCT02794571|DRUG|Atezolizumab|Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.
41383963|NCT02794571|DRUG|Tiragolumab|Several dose levels will be evaluated for tiragolumab administered as a single agent and in combination with atezolizumab and/or other anti-cancer therapies. Tiragolumab will be given via IV infusion on Day 1 of each cycle (21-day or 28-day depending on study cohort and phase) until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent tiragolumab may receive combination treatment with tiragolumab and atezolizumab and/or other anti-cancer therapies. Combination treatment may continue until disease progression or loss of clinical benefit.
41383964|NCT02794571|DRUG|Carboplatin|Carboplatin, AUC of 6 milligram per milliliter per minute (mg/ml/min) for Cohorts A and B and AUC of 5 mg/ml/min for Cohort C, IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab IV infusion.
41383965|NCT02794571|DRUG|Cisplatin|Cisplatin 75 milligram per square meter (mg/m\^2) IV infusion will be administered on day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
40853633|NCT00307203|BEHAVIORAL|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
40853634|NCT00307203|DRUG|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
40853635|NCT05892328|OTHER|Watermelon Flesh Dose 1|1 cup watermelon flesh, \~152g, 7 days/week over a 4-week period
40853636|NCT05892328|OTHER|Watermelon Flesh Dose 2|2 cups watermelon flesh, \~304 g, 7 days/week over a 4-week period
40853637|NCT05892328|OTHER|Control|304g italian ice, 0 g watermelon, 7 days/week over a 4-week period
40853638|NCT03322150|DRUG|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
40853639|NCT03322150|DRUG|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
40853640|NCT00289926|DRUG|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
41383966|NCT02794571|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after carboplatin or cisplatin IV infusion with combination treatment of atezolizumab and tiragolumab.
41383967|NCT02794571|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment with atezolizumab and tiragolumab.
41383968|NCT02794571|DRUG|Etoposide|Etoposide 100 mg/m\^2 IV infusion will be administered on Days 1, 2, and 3 of each 21-day cycle with combination treatment of atezolizumab and tiragolumab.
41383969|NCT02794571|DRUG|Capecitabine|Capecitabine 1250 mg/m\^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.
41509470|NCT06040801|BEHAVIORAL|Frailty intervention measures|"Providing management and recommendations based on the specific impairment domain.~Assessment domain:~* Functional status~* Nutrition~* Comorbidity~* Mobility/Falls~* Mood~* Cognition~* Polypharmacy~* Social support."
40853641|NCT00289926|DRUG|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
40853642|NCT00757822|DRUG|Dronabinol|Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
40853643|NCT00757822|DRUG|Ondansetron|Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
40853644|NCT03325036|DIAGNOSTIC_TEST|Serum levels of immunologic profiles|Serum levels of immunologic profiles before and after chemoradiotherapy
40853645|NCT04778826|PROCEDURE|Lymphadenectomy|radical bloc dissection of all mediastinal lymph node stations
40853646|NCT01587430|DRUG|high dose ARA-C|high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
40853647|NCT01587430|DRUG|standard dose ARA-C|
40853648|NCT05905367|DRUG|Fentanyl|Symptom-inhibited IV fentanyl induction
40853649|NCT05905367|DRUG|Methadone|Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction
40853650|NCT05905367|DRUG|Slow-release oral morphine|Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction
40853651|NCT05897892|DIETARY_SUPPLEMENT|Clinical study on the mangrove sword bean food bar effect for older people|The treatment group consumed 50 g mangrove sword bean food bar each day during 15 days.
40853652|NCT04205734|DIAGNOSTIC_TEST|MTX Assessment|Measurement of Methotrexate Polyglutamate levels.
41036969|NCT02390284|DRUG|Acetazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
41036970|NCT02390284|DRUG|Methazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
41036971|NCT05839769|DIAGNOSTIC_TEST|Evaluation of median nerve with ultrasound|ultrasound examination wrist
41383970|NCT02794571|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
41383971|NCT02794571|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion will be administered on Day 1 of each 21-day cycle after treatment with tiragolumab.
41383972|NCT02831686|DRUG|Selinexor|
41383973|NCT02831686|DRUG|Ixazomib|
41509471|NCT02375165|PROCEDURE|phlebotomy|phlebotomy for collection of plasma and serum, \~30 cc
41509472|NCT00002960|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
41509473|NCT02051712|BEHAVIORAL|exercise training|individualized exercise training
41509474|NCT02051712|BEHAVIORAL|Adherence measures|Measures to increase adherence to exercise training
40853653|NCT03470402|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
40853654|NCT03470402|OTHER|BNAV|BNAV is a web-based decision support tool for healthcare providers with educational modules on genetic testing, chemoprevention, patient-centered care, and screening. BNAV also provides providers with a table outlining their enrolled patients' breast cancer risk, eligibility for genetic testing, and stated preferences.
40853655|NCT03470402|OTHER|iNYP|Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).
40853656|NCT03470402|OTHER|Standard Educational Material|Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic
40853657|NCT03470402|OTHER|High-Risk Message|Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
40853658|NCT01691040|DRUG|NOX-H94|intravenous injection
40853659|NCT01691040|DRUG|Placebo solution|intravenous injection
40853660|NCT06525584|DRUG|Ketamine Hcl 50Mg/Ml Inj|ketamine infusion at a dose of 0.1 mg/kg/hour for 16 hours
41509475|NCT00714116|DRUG|SBI-087|Single IV or SC dose of SBI-087
41509476|NCT02597127|DRUG|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
41509477|NCT02597127|DRUG|Normal Saline|Saline (sterile, normal, 0.9%) solution given as SC injections
41509478|NCT03333135|PROCEDURE|Pulsed Electromagnetic Field therapy (PEMF)|PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
41509479|NCT03333135|PROCEDURE|Pulsed Electromagnetic Field Sham therapy|PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
41509480|NCT03566615|DEVICE|CAP-straight|This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
41509481|NCT03566615|DEVICE|CAP-daisy|This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
40853661|NCT06525584|DRUG|Ketamine Hcl 50Mg/Ml Inj|ketamine infusion at a dose of 0.3 mg/kg/hour for 16 hours
40853662|NCT06525584|OTHER|Control|Without ketamine
40853663|NCT01708135|BEHAVIORAL|Use of smartphone app|
40853664|NCT01750723|DRUG|Acetazolamide|1 g diluted in 10 ml saline, i.v. bolus injection.
40853665|NCT03940391|DRUG|Chlorpheniramine and midazolam|Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.
40853666|NCT03940391|DRUG|Midazolam|Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.
40853667|NCT01166204|RADIATION|Radiotherapy|Radiotherapy
40853668|NCT03698019|PROCEDURE|Biospecimen Collection|Undergo collection of blood
40853669|NCT03698019|PROCEDURE|Computed Tomography|Undergo CT
40853670|NCT03698019|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40853671|NCT03698019|BIOLOGICAL|Pembrolizumab|Given IV
41509482|NCT03566615|OTHER|water|using water instead of traditional air insufflation to help insertion
41509483|NCT05870059|DRUG|Propolis mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use 5ml of propolis mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
40853672|NCT03698019|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41383974|NCT02831686|DRUG|Dexamethasone|
41383975|NCT04376073|DRUG|Niraparib|Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh \<77 kg) po QD day1\~21, Anlotinib 12mg po QD day1\~14
41383976|NCT04376073|DRUG|Anlotinib|Anlotinib 12mg po QD day1\~14. Starting dose of anlotinib changed to 10mg from 2020-11-13.
41417782|NCT04022499|BEHAVIORAL|National Diabetes Prevention Program|The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
41417783|NCT03095222|DRUG|Ketamine|To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.
40853673|NCT05769205|DEVICE|MRI|MRI with contrast
40853674|NCT06294340|OTHER|Exposure to loud pre-recorded road traffic noise|Participants of both arms will be exposed to the same loud pre-recorded road traffic noise in a laboratory setting.
41509484|NCT05870059|DRUG|Chlorhexidine mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use chlorhexidine mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
41509485|NCT02863926|BIOLOGICAL|Injection of cBMA aspirate into the index leg|Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
41509486|NCT02411825|DRUG|SAR425899|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
41509487|NCT02411825|DRUG|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
41509488|NCT02411825|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
41509489|NCT00790725|OTHER|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
41509490|NCT00790725|OTHER|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
41509491|NCT06274294|DRUG|CT-P13|Induction treatment.
41509492|NCT01587157|PROCEDURE|capnography|
41509493|NCT00805675|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
41509494|NCT00805675|DRUG|Tenofovir|Tenofovir disoproxil fumarate was supplied in 300 mg tablets
41509495|NCT00805675|DRUG|Telbivudine plus tenofovir|Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
41509496|NCT02237391|OTHER|CIPAP Program|The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.
41509497|NCT02237391|OTHER|Treatment as Usual (TAU)|Control group
41509498|NCT05361863|DEVICE|Orthodontic brackets|Interventions involving orthodontic brackets of different slot sizes
41509499|NCT03672227|BEHAVIORAL|Mealtime Matters Training|This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.
41509500|NCT03374007|BIOLOGICAL|Geptanolimab Injection 1mg/kg|single-dose:1mg/kg
41509501|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg|single-dose: 3mg/kg
41509502|NCT03374007|BIOLOGICAL|Geptanolimab Injection 10mg/kg|single-dose:10mg/kg
41509503|NCT03374007|BIOLOGICAL|Geptanolimab Injection 1mg/kg, q2w*6|multiple dosing: 1mg/kg, q2w\*6
41509504|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg, q2w*6|multiple dosing: 3mg/kg, q2w\*6
40853675|NCT02909374|OTHER|Balance training|The balance-training program was developed based on well-established principles of exercise and on the knowledge that balance control relies on the interaction of several physiological systems, as well as interaction with environmental factors and the performed task. It includes exercise with dual- and multi task performance. It is progressive as the exercises can be performed at different levels (basic, moderate, and advanced), making it progressively challenging for each individual throughout the whole program. The training is conducted as an individually tailored group program.
40853676|NCT04119596|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
40853677|NCT04119596|GENETIC|DNA-microarray genotyping|Taking a saliva sample for genotyping
41509505|NCT03374007|BIOLOGICAL|Geptanolimab Injection 10mg/kg, , q2w*6|multiple dosing: 10mg/kg, , q2w\*6
41509506|NCT03374007|BIOLOGICAL|Geptanolimab Injection 280mg, q3w|multiple dosing: 280mg, q3w
41509507|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg, q2w|multiple dosing: 3mg/kg, q2w
40853678|NCT04520399|OTHER|none intervention|there is no intervention in this study
40853679|NCT03219411|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks
41036972|NCT01346657|DRUG|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
41509508|NCT06171399|BEHAVIORAL|"All Natural descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
41509509|NCT06171399|BEHAVIORAL|"Gluten-free descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
41509510|NCT06171399|BEHAVIORAL|"Vegan descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
41509511|NCT06171399|BEHAVIORAL|"100% Organic descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
41509512|NCT06171399|BEHAVIORAL|"Handcrafted descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
40853680|NCT03219411|OTHER|placebo|Placebo administered orally as capsules three times a day over 12 weeks
40853681|NCT05933057|DRUG|Givinostat|Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
41165937|NCT00225277|DRUG|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
41165938|NCT00225277|DRUG|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
41165939|NCT04191148|DRUG|LBP-EC01|crPhage cocktail: at approximately 1.5 x 10\^10 to 3.0 x 10\^10 PFU/vial dosed BID by intraurethral administration
40853682|NCT05933057|DRUG|Placebo|Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
40853683|NCT05152771|OTHER|KETOGENIC DIET|"This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.~These patients are usually already admitted in the hospital for initial diagnosis and management. Therefore the initiation of the diet will be in the hospital during their admission if the parents/ caregivers agrees. A minimum of 2-3 days would be required to train the parents/caregivers."
41165940|NCT04191148|DRUG|Placebo|Lactated Ringers Solution for Injection dosed BID by intraurethral administration
41165941|NCT04335747|OTHER|COVID-19 infection|Hospitalisation due to a confirmed COVID-19 infection
40853684|NCT04958174|DEVICE|web-application|web application for monitoring children's development
41165942|NCT01728688|OTHER|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
41165943|NCT01728688|OTHER|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
41165944|NCT05203224|DRUG|Dornase Alfa|Intravenous Dornase alfa
41165945|NCT05923398|BEHAVIORAL|Digital Intervention Group|"Participants will use a Digital Intervention Suite composed of a virtual reality (VR) scenario, a web-based platform, and a wearable device to assess their stress response in near-real time and in a hypothetical stressful scenario.~During the VR scenario, physiological signals such as Galvanic Skin Response (GSR), Electrocardiogram (ECG), Respiratory Independence (RI), and Photoplethysmography will be measured. Additionally, an educational intervention video on how to deal with stress and distress will be shown to participants. We will then request participants to practice the skills taught during the intervention video in the VR scenario.~The wearable device (Oura Ring) will measure sleep, activity, readiness information, heart rate, heart rate variability, body temperature (delta), and respiratory rate. Additionally, the web-based platform will, through questionnaires, assess stress-related symptoms such as loneliness, anxiety, depression, and moral injury."
41383977|NCT06568484|DRUG|Bedaquiline|"CCs (Close Contacts) of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV negative, regardless of latent tuberculosis infection (LTBI) result by TST (tuberculin skin test) or IGRA (interferon-gamma release assay)~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Bedaquiline based on weight and/or age at Enrollment daily for four weeks (28 doses)"
41383978|NCT06568484|COMBINATION_PRODUCT|Isoniazid, rifapentine|"CCs of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV status negative, regardless of latent tuberculosis infection (LTBI) result (tuberculin skin test \[TST\] or interferon-gamma release assay \[IGRA\])~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~3HP: 3 months of weekly isoniazid (H) and rifapentine (P) (12 doses)~1HP: 1 month of daily isoniazid (H) and rifapentine (P) (28 doses)"
41383979|NCT06568484|DRUG|Levofloxacin|"CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Levofloxacin (LFX) based on weight at Enrollment daily for 6 months (182 doses)"
41417784|NCT03095222|DRUG|Opioids|Standard of care for pain management.
40853685|NCT04768543|DEVICE|Upper airway stimulation (Inspire Medical Systems, Inc.)|phasic hypoglossal nerve stimulation device
40853686|NCT03413306|DRUG|Eltrombopag|Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.
40853687|NCT03413306|DRUG|IST (ATG + CsA)|
41036973|NCT04232423|DRUG|Olanzapine 10 Mg ORAL TABLET|"* Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
41383980|NCT03387267|DEVICE|Dysphagia Detection System|The Nestle Health Sciences (NHSc) Dysphagia Detection System (DDS) is a portable, non-invasive device designed for use at the bedside. The investigational DDS has 3 basic components: Sensor Unit (suspended on a necklace), Sensor Fixation and a personal computer (PC) for collecting data. The Sensor Unit consists of a dual-axis accelerometer in a plastic housing that is attached to the front of a patient's neck just below the thyroid cartilage by the single-use, disposable fixation unit. The Sensor Unit is connected via a cable to an A/D converter which then connects via cable to the PC. The PC collects the examination data, which is then sent to dedicated application software (installed at the CRO), which interprets the acceleration data and displays the examination result.
41036974|NCT04232423|DRUG|Olanzapine 5 Mg ORAL TABLET|"* Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
41036975|NCT04232423|DRUG|Placebo ORAL TABLET|"* Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
41036976|NCT01815242|DRUG|nab-Paclitaxel|
41036977|NCT01815242|DRUG|Gemcitabine|
41036978|NCT01815242|DRUG|Carboplatin|
41165946|NCT04531813|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.
41383981|NCT06318091|BIOLOGICAL|platelet poor plasma gel|injection of platelet poor plasma gel in the dark circles around the eye to rejuvenate and improve pigmentation
41383982|NCT06318091|BIOLOGICAL|nanofat|injection of nanofat in the dark circles around the eye to rejuvenate and improve pigmentation
41383983|NCT03920527|DRUG|Itraconazole 400 mg|Duration of itraconazole
41383984|NCT03009591|OTHER|Experimental group|"Longitudinal surface sliding maneuver over the superficial fascia in the anterior region of the arm and the forearm. Applied in 3 strokes.~* Transverse sliding of the flexor muscles of the wrist and fingers.~* Transverse sliding for the biceps brachii muscle.~* Longitudinal surface sliding over the superficial fascia in the posterior arm region.~* Transverse sliding over the brachial triceps tendon.~* Transverse sliding for the pectoralis major muscle.~* Transverse sliding for the posterior axillary region pectoralis major muscle.~* Induction of the posterior axillary fold.~* Induction (crossed hands over the brachial region and forearm).~* Maneuver of transverse planes for the cervicothoracic region.~* Upper limb telescopic maneuver."
41383985|NCT01556646|DRUG|Tolvaptan|15 to 30mg qd titrated to sodium concentration
41383986|NCT00000394|PROCEDURE|Acupuncture therapy|
41383987|NCT01614158|DEVICE|perimetry|perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) \[Schiefer 2008\] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
41383988|NCT01614158|OTHER|D-BCVA|D-BCVA using EDTRS chart
41383989|NCT01614158|OTHER|RAPD|RAPD using swinging flashlight test
41383990|NCT01614158|DEVICE|IOP|IOP using applanation tonometer
41383991|NCT01614158|DEVICE|Spectralis OCT|RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
41509513|NCT06171399|BEHAVIORAL|"Made with live resin descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
41509514|NCT06171399|BEHAVIORAL|"Fast-acting descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
41165947|NCT04531813|DRUG|Positive Control-Sodium lauryl sulfate (SLS)|Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.
41383992|NCT01614158|OTHER|Fundus photography|Optic disk morphology will be documented by fundus photography
41383993|NCT05658731|RADIATION|substructure informed planning|Radiation Therapy with substructure informed planning determined by the PI.
41509515|NCT06171399|BEHAVIORAL|"Relax descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
41509516|NCT06171399|BEHAVIORAL|"Energy Boost descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
41383994|NCT05658731|OTHER|Neurocognitive Testing|California Verbal Learning Test (CVLT) and other cognition assessments.
41383995|NCT05658731|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) using whole brain diffusion tensor imaging (DTI) and resting state functional MRI (rsfMRI).
41383996|NCT05520060|OTHER|Physical support|Pharmacological and non-pharmacological methods in pain management, Mobilization, Position preferred by the woman, Fluid and nutritional support, Massage applications, Sacral pressure, Listening to music, Breathing and relaxation exercises
41165948|NCT04531813|OTHER|Negative Control|A blank patch was applied to the Negative Control test site.
41383997|NCT05520060|OTHER|Psychospiritual support|Effective communication, Encouragement to speak up and express fears, Support for faith-oriented practices
41417785|NCT01492062|DEVICE|Multiple Model Predictive Controller|Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
41383998|NCT05520060|OTHER|Environmental and sociocultural support|egulating the temperature, light and sound of the room, Environment that promotes respect for privacy, Reducing environmental noise, Information, Social support, Talking about cultural practices, Social support
41383999|NCT05520060|OTHER|Routine care|Admission to the delivery room, preparation for birth, delivery, postpartum care, etc.
41384000|NCT03815227|OTHER|Outpatient birth|Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
41384001|NCT03466788|OTHER|Self questionnaires of quality of life and living conditions|Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
41384002|NCT00602927|DRUG|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
41384003|NCT00602927|DRUG|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
41384004|NCT02238639|PROCEDURE|Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).|"If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.~If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation."
41384005|NCT00447291|DRUG|Supplement: Omega-3 Fish Oil|
41384006|NCT00447291|BEHAVIORAL|Multi-Disciplinary Nutrition & Exercise program|
41384007|NCT06136676|BEHAVIORAL|Arm 1 - Heart-Centred Spiritual Meditation: Christian contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks focused on Christian contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Christian tradition and prayer recitation with breathing to focus their attention on and connection to God.
40853688|NCT01090440|DRUG|GSK1144814|This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
40853689|NCT01402739|OTHER|Point of Care Coagulation Monitoring Guided Transfusion Algorithm|(thromboelastometry, aggregometry, blood gas analysis)
40853690|NCT01402739|OTHER|standard coagulation monitoring guided transfusion algorithm|aPTT, ACT, platelet count, hemoglobin, fibrinogen
40853691|NCT05211817|BEHAVIORAL|Complex lifestyle intervention|Volunteers will undergo a 3-month comprehensive lifestyle modification, consisting of a combined aerobic-strength training intervention, nutritional and psychological counseling. Regular examinations (body weight, waist circumference, body composition by bioimpedance) will be performed every week. Probands in the intervention and control groups will have the opportunity to participate in a long-term program of physical activity at BMC SAS after the end of the study.
41509517|NCT06171399|BEHAVIORAL|No descriptor (control)|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
40853692|NCT05211817|DIETARY_SUPPLEMENT|Carnosine|3 months carnosine supplementation (2 g per day) will be given in parallel with a complex lifestyle modification. Carnosine is a dipeptide of beta-alanyl l-histidine, which is found in skeletal muscle and in certain areas of the brain. It is a well-tolerated and approved food supplement in Slovakia. Scientists have extensive experience with the administration of carnosine (deCourten, Ukropcová et al, Obesity 2015 https://doi.org/10.1002/oby.21434; Schon, Ukropcova et al, 2019 DOI: 10.3390 / nu11061196 and others). Carnosine has the potential to positively affect glucose metabolism, and improve the adaptive response to exercise training interventions.
40853693|NCT05505864|BEHAVIORAL|Health Action Process Approach (HAPA)|Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change
40853694|NCT03878784|DRUG|Imigran|All patients will undergo this intervention on one of two study days
41165949|NCT00035802|DRUG|Topiramate|"Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
41165950|NCT00035802|DRUG|Placebo|Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
41165951|NCT00383747|DRUG|transdermal nicotine patch|14mg transdermal nicotine application
41165952|NCT00383747|DRUG|Transdermal Nicotine Patch|14mg transdermal nicotine application
41384008|NCT06136676|BEHAVIORAL|Arm 1 - Heart-Centred Spiritual Meditation: Islamic contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks, focused on Islamic contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Islamic tradition and prayer recitation with breathing to focus attention on and connection to God.
41384009|NCT06136676|BEHAVIORAL|Arm 2 - Action Control: Mindfulness Meditation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 week, focused on mindfulness meditation delivered through a mobile app. The intervention will consist of the mindfulness-based stress reduction program which emphasizes focused attention on breathing and sensations as well as the practice of non-judgemental acceptance of the present experience.
41509518|NCT03666273|DRUG|Bapotulimab (BAY1905254)|Intravenous administration of escalating doses of Bapotulimab
41509519|NCT03666273|DRUG|Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)|Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab
41509520|NCT05468424|OTHER|tablet (iPad or android) based role-playing game|The intervention is a tablet (iPad or android) based role-playing game called FarmVille. In FarmVille the player assumes the role of a farmer tasked with tending to crops and farm animals and using what is produced to craft goods which can be sold to expand the farm. The participant is required to play FarmVille for 5 or more hours a week for 8 weeks.
41165953|NCT04788966|DEVICE|the translation tool BabelDr|Doctors use a speech-enabled fixed-phrase translation tool to help communicate with an allophone patient.
41165954|NCT05591170|DRUG|Cholecalciferol 120 000 IU|single, oral administration of high dose of vitamin D
41384010|NCT06274385|DIETARY_SUPPLEMENT|Betalain-rich concentrate (AltRed)|"A single dose of 100 mg (2 x 50 mg) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
41384011|NCT06274385|OTHER|Placebo|"A single dose (2 x empty capsules) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
41384012|NCT04221204|DRUG|Highly selective FGFR1-3 inhibitor|All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily \[QD\], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first. The dose limiting toxicity (DLT) evaluation period includes the single-dose PK study period and the first treatment cycle (within 35 days after the first dose). The enrolled subjects will be sequentially assigned to the planned dose cohorts according to the protocol and receive 3D185 treatment to observe the occurrence of DLT.
41509521|NCT05468424|OTHER|tablet (iPad or android) based word puzzles and image puzzles|"This intervention is a selection of tablet (iPad or android) word puzzles and image puzzles. One word puzzle involves word making (i.e., making words from a set of random letters), and the other word searching (i.e., finding words on a grid of letters). One image puzzle is Flow Free, a game that requires the player to connect pairs of same coloured dots positioned on a grid ranging from 5x5 to 9x9. The other image puzzle is a jigsaw. The participant is required to play these games for 5 or more hours a week for 8 weeks."
41509522|NCT01890434|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
41509523|NCT05465655|OTHER|ECG monitoring for Conduction Disturbances|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
41509524|NCT06372210|DRUG|Placebo IEM tablet|Oral placebo-embedded IEM tablet.
41165955|NCT05717517|DEVICE|anterior segment oct|ant segment oct before and after corneal collagen cross-linking
41165956|NCT02987322|DIETARY_SUPPLEMENT|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
41165957|NCT01053897|BIOLOGICAL|GBT009|Intradermal Injection following surgery
41165958|NCT01053897|BIOLOGICAL|Placebo|Intradermal Injection following surgery
41165959|NCT02763163|BEHAVIORAL|Sun exposure routine|
41509525|NCT06372210|DRUG|Abilify MyCite®|Oral aripiprazole-embedded IEM tablet.
40853695|NCT03878784|OTHER|Isotonic Saline|All patients will undergo this intervention on one of two study days
41165960|NCT02934542|DEVICE|AutoLap system|
41165961|NCT00382798|DRUG|RO5024048|
40853696|NCT05942547|DRUG|Diosmin|diosmin 600mg twice daily
40853697|NCT05942547|DRUG|Placebo|twice daily
40853698|NCT00241904|BEHAVIORAL|Lifestyle Changes|Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
41165962|NCT04106713|BEHAVIORAL|Individual Psychotherapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
41180020|NCT04626804|OTHER|Remember Stuff: A Dyadic-focused Technology to Support Persons with Alzheimer's Disease in the Community|testing the usability, perceptions, and acceptability of R/S among dyads of older adults with early Alzheimer's disease and other related dementias
41180021|NCT05223868|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
41180022|NCT05223868|DRUG|Placebo|Placebo tablet will be administered orally.
41180023|NCT05203341|DRUG|Placebo|Matching placebo tablets
41180024|NCT05203341|DRUG|NBI-1065845|NBI-1065845 tablets
41180025|NCT02454504|DRUG|sugammadex|
41384013|NCT06123975|OTHER|Venous blood collection|Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation.
41384014|NCT05336318|BEHAVIORAL|Peer support|patients were supported by a mentor
41384015|NCT05963854|OTHER|Survey Curbside|Observational. Waste will be collected on specific days for 2 consecutive weeks and surveys will be completed to coincide with the waste collections.
41384016|NCT03299959|DEVICE|Agili-C implant|Agili-C implant
41384017|NCT03299959|PROCEDURE|SSOC|microfracture and/or debridement
41384018|NCT03415412|DEVICE|Clearfil Univesal Bond|Adhesive systems
41384019|NCT03415412|DEVICE|IBond Universal|Adhesive systems
41384020|NCT03415412|DEVICE|G-Premio Bond|Adhesive systems
41384021|NCT02396238|DEVICE|Celution Device|ADRCs prepared using the investigational Celution Device
40853699|NCT00241904|DRUG|Antiplatelet Agents|Aspirin 81 mg q day
41384022|NCT02396238|OTHER|Placebo|Placebo
41384023|NCT02789241|BIOLOGICAL|Endotoxin|Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
41384024|NCT02789241|OTHER|Placebo|Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
41509526|NCT06372210|DEVICE|D-Tect Patch|The D-Tect patch is a wearable sensor (WS) capable of detecting the ingestion of the IEM and measuring physiologic parameters. The WS automatically logs and stores the time when the IEM reaches the stomach and transmits the data to a smartphone.
40853700|NCT00241904|DRUG|Beta Blocker|Oral medication
40853701|NCT00241904|DRUG|ACE Inhibitors|Oral medications, received 1-2 times per day
40853702|NCT01138488|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).
40853703|NCT04677504|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
40853704|NCT04677504|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.
40853705|NCT04677504|OTHER|Placebo|Placebo matching bevacizumab will be administered intravenously on Day 1 of each 21-day cycle after atezolizumab.
40853706|NCT04677504|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
40853707|NCT04677504|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
40853708|NCT05336149|PROCEDURE|Alveolar ridge preservation using whole-tooth dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with whole-tooth dentin graft
40853709|NCT05336149|PROCEDURE|Alveolar ridge preservation using particulate dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with particulate dentin graft
41036979|NCT01544868|OTHER|Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover|Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
41036980|NCT03755505|DIAGNOSTIC_TEST|obtain samples from sputum, feces and urine|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
41036981|NCT04323618|DEVICE|Breathe Well|
41036982|NCT06490484|DRUG|HSK16149 20mg BID|Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.
41036983|NCT06490484|DRUG|Pregabalin 150mg BID|Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.
41036984|NCT02041195|DRUG|Setmelanotide|
40853710|NCT01609998|BIOLOGICAL|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
40853711|NCT01609998|BIOLOGICAL|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
40853712|NCT02134470|DRUG|Testosterone supplementation|Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
40853713|NCT00829114|DRUG|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
40853714|NCT00829114|DRUG|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
41036985|NCT02041195|DRUG|Placebo|
41036986|NCT01983293|DEVICE|QLV based implant strategy|
41036987|NCT01983293|DEVICE|Standard of care implant strategy|
41036988|NCT01606449|PROCEDURE|Surgical Therapy|"Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen."
41036989|NCT02724553|DEVICE|Acrylic lens implantation|
41180026|NCT02454504|DRUG|Neostigmine|
41036990|NCT03626948|DRUG|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
41036991|NCT05461625|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction
41384025|NCT06491719|OTHER|NCR300（Allogenic Ipsc-derived Natural Killer cells ）|"Patients will receive iNK cells i.V. infusion at 1.0x10\^8/kg on days +14d, +21d, +28d, and +35d post-transplant.~Continuation of the infusion after +35d post-transplant is at the discretion of the physician based on the patient's benefit."
41384026|NCT01041807|DRUG|amlodipine/losartan|amlodipine/losartan (COZAAR XQ) prescribed according to the current local label
41384027|NCT05916963|DRUG|Furosemide 40 mg|Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.
41384028|NCT04427618|DRUG|Tranexamic acid|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision
41384029|NCT04427618|DRUG|Normal saline|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision
41036992|NCT05461625|OTHER|ALL anatomic|anatomic anterolateral ligament reconstruction
41036993|NCT05461625|OTHER|ALL tenodesis|anterolateral ligament teondesis
41036994|NCT00954369|DRUG|[F-18]W372|"The individual doses of \[F-18\]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
41036995|NCT05634538|DEVICE|Robotic-assisted PCI with Corpath GRX® System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary interventions (PCI).
41036996|NCT05634538|PROCEDURE|Standard PCI|Percutaneous coronary intervention (PCI) is a procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart. This arm will be completed without robotic assistance.
41036997|NCT05411965|DRUG|BR3003(T)|"Test drug (T):BR3003 Boryung Pharmaceutical Co., Ltd."
41384030|NCT00143416|DRUG|Pegvisomant|
41384031|NCT06566027|OTHER|Skeletal, dental, soft tissue index changes in Activator group|After being interviewed and provided by a doctor with two kinds of appliances (Activator and EF class II standard) for treating class II malocclusion, the patients choose their appliance. The patients were separated into two groups (30 in each). Group 1 was treated with an Activator appliance (Activator group), whereas Group 2 was treated with an EF class II standard appliance (EF line group)
41384032|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin|
41384033|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin + Boceprevir|
41509527|NCT03740373|DRUG|BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.
41036998|NCT05411965|DRUG|BR3003B(R1)|"Reference drug 1 (R1): BR3003B of Celltrion Pharm, Inc."
41509528|NCT03740373|DRUG|BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.
40853715|NCT03642496|BIOLOGICAL|Low dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 0.75×10\*6/kg.
41036999|NCT05411965|DRUG|BR3003C(R2)|"Reference drug 2 (R2): BR3003C of AstraZeneca Korea"
41037000|NCT03421925|PROCEDURE|Laparoscopic totally extraperitoneal procedure for inguinal hernia|Laparoscopic totally extraperitoneal procedure for inguinal hernia is a technique that is done by not entering the peritoneal cavity
41037001|NCT03845348|OTHER|TD03|Shampoo TD 3 days
41037002|NCT03845348|OTHER|TD07|Shampoo TD 7 days
41037003|NCT03845348|DRUG|Ketoconazole 2% Shampoo|Ketoconazole 2% Shampoo
41037004|NCT03477448|DRUG|Bleomycin|"an antibiotic derived from Streptomyces verticillus, has an antitumor, antibacterial, and antiviral activity that may be related to its ability to bind with DNA, causing bleomycin strand scission and elimination of pyrimidine and purine bases. The bleomycin hydrolase enzyme, which is known to inactivate bleomycin, is normally found in all body tissues but is present in very small amounts in skin .~* Intra-lesional bleomycin injection (IBI) has been used for the treatment of warts."
41037005|NCT03477448|DRUG|Purified Protein Derivative|"is an extract of Mycobacterium tuberculosis and is used for testing exposure to tuberculin protein, either from a previous vaccination or from the environment. It contains live, attenuated Mycobacterium bovis.~* Using this protein derivative for immunotherapy of warts is important for two major aspects. First, because the obligatory immunization program in many developing countries - with high prevalence of wart in many of them - includes BCG vaccination. PPD has a high prevalence of immunity in the general population. Second, although immunotherapy is generally an inexpensive method of treatment in wart patients, PPD, among conventionally used antigens, is the cheapest"
41037006|NCT03932643|DRUG|ONC-201|"ONC-201 Capsules, 125 mg~Oral ONC-201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle."
41037007|NCT02393794|DRUG|Romidepsin|Histone deacetylase inhibitor
41037008|NCT02393794|DRUG|Cisplatin|Platinum compound
41384034|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin +Telaprevir|
41384035|NCT02758509|DRUG|Ledipasvir/Sofosbuvir|
41384036|NCT02758509|DRUG|Ombitasvir/paritaprevir/ritonavir+Dasabuvir|
41384037|NCT02758509|DRUG|Daclatasvir+Sofosbuvir|
41384038|NCT02758509|DRUG|Simeprevir+Sofosbuvir|
41037009|NCT02393794|DRUG|Nivolumab|Monoclonal antibody, checkpoint inhibitor
41037010|NCT00606372|PROCEDURE|OPCAB - the off-pump coronary artery bypass|surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
41180027|NCT00415701|DRUG|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
41180028|NCT00415701|DRUG|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
41180029|NCT00415701|DRUG|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
41509529|NCT04935684|DRUG|Fecal Microbiota Transplantation|"Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes."
41509530|NCT05560607|DRUG|AZD7503 Intervention|"Part A: Participants will be screened for histologic evidence of NAFLD or NASH and all eligibility criteria in part A prior to enrollment in part B.~Part B: Participants consented to part B will be administered the study drug over the course of 31 days. At the end of the study a liver biopsy will be collected to measure for endpoints."
41384039|NCT05552235|DEVICE|Elbow SOFT 300|15 patients will be included in this group and will used the medical device ElbowSOFT 300 during sport practice (at least 2 sport sessions per week), for 6 weeks.
41384040|NCT05552235|OTHER|Control group|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device), for at least 2 sport sessions per week during 6 weeks.
41384041|NCT05137639|PROCEDURE|Platelet-rich fibrin (PRF)|PRF was only applied in the experimental arm to improve wound bed conditions
41384042|NCT01711034|DRUG|OPB-111077|"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."
41384043|NCT02286726|OTHER|Laboratory Biomarker Analysis|Correlative studies
41509531|NCT05567770|DRUG|Actinium-J591|Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
41509532|NCT05567770|RADIATION|Stereotactic Body Radiation Therapy|Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
41509533|NCT05567770|DRUG|Androgen Deprivation Therapy|Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
41509534|NCT01090518|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
41509535|NCT01090518|DRUG|Hydrocortisone|30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
41509536|NCT01090518|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
41509537|NCT01307345|BEHAVIORAL|contingency management for abstinence|For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
41509538|NCT05863169|DEVICE|fNIRS-Neurofeedback|Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2\*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
41509539|NCT04335539|DRUG|Cefiderocol|Administered intravenously over 3 hours
41509540|NCT04335539|DRUG|Standard of Care|Standard of care antibiotics will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
41037011|NCT06061172|OTHER|gp-multitool.de|"The intervention is based on a digital tool, which implements recommendations of the S3 guideline multimorbidity of the German College of General Practitioners and Family Physicians. The tool includes nine questionnaires addressing four dimensions of care:~1. preferences (including a. treatment goals, and b. involvement of other persons in decision making);~2. activities (including a. activities and participation, and b. social support);~3. treatment (including a. problems with medication, and b. treatment burden);~4. complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~The GPs can send the questionnaires by email to the patients and the patients can fill out the questionnaires at their home or in the waiting room of the GP's practice using their own smartphones, tablets or computers. The digital tool also includes instructions for conducting a medication review. Results from talks between GPs and patients can be documented in the tool."
41509541|NCT01098487|DRUG|Eltrombopag olamine|Thrombopoietin receptor agonist
41528309|NCT01966120|PROCEDURE|Photodynamic therapy with BF-RhodoLED|After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
40853716|NCT03642496|BIOLOGICAL|Middle dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 1.5×10\*6/kg.
41037012|NCT00615966|DRUG|Diannexin|single dose, 200 µg/kg IV
41384044|NCT02286726|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
41384045|NCT01974869|DRUG|Anti-tumor necrosis factor alpha agents|Treatment with biologics
41384046|NCT04925622|DIAGNOSTIC_TEST|Complex eye movement exam|"Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice."
41384047|NCT00055159|PROCEDURE|Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)|
41384048|NCT03287102|PROCEDURE|Macular hole surgery|Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
41384049|NCT06308107|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
41384050|NCT06451679|OTHER|Observational|Observational prospective study
41384051|NCT01447628|DRUG|Saline|intravenous, no active drug
41509542|NCT03153033|BEHAVIORAL|Fatigue protocol|The figure 8 protocol (fatigue intervention) requires the participants to propel three times as many laps as possible for four minutes each with their wheelchair. The protocol has been developed and used previously. Every bout of four minutes is separated by 90 seconds of rest. Each lap consists of a right and left turn and two complete stops after half a lap. Measurements during the protocol include the Rate of Perceived Exertion (RPE) scale, heart rate, and propulsion kinetics.
41509543|NCT03792022|BEHAVIORAL|Adherence to timely vaccine uptake|Adherence to timely vaccine uptake
41509544|NCT02842073|DRUG|Naltrexone|Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
41384052|NCT01447628|DRUG|Ferinject or CosmoFer|Intravenous, 1000 mg iron
41384053|NCT00058045|BIOLOGICAL|aldesleukin|
41384054|NCT00058045|BIOLOGICAL|recombinant human stem cell factor|
41384055|NCT06501131|OTHER|full-spectrum light exposure|Subjects will stay in a room with full spectrum light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
41384056|NCT06501131|OTHER|specific spectrum absence light exposure|Subjects will stay in a room with ordinary LED light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
41384057|NCT04640701|OTHER||
41384058|NCT06264141|DRUG|Nitric Oxide Releasing Solution|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
41384059|NCT06264141|DEVICE|Nasal spray with isotonic saline|The Sponsor designed a dual-chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
41037013|NCT00615966|DRUG|Placebo|Single dose, IV
41509545|NCT02842073|DRUG|Bupropion|Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
41509546|NCT02181855|PROCEDURE|Full-thickness gastroplication (GERD-X)|Endoscopic full-thickness gastroplication wit the GERD-X device
41509547|NCT02781038|BEHAVIORAL|Teaching intervention|Subjects will receive a pamphlet which describes the relationship between smoking and negative outcomes in fracture healing.
41509548|NCT02781038|BEHAVIORAL|Control|Subjects in this group will not receive the pamphlet
41509549|NCT05798455|DRUG|Sodium Pentaborate|Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
41509550|NCT00910676|DRUG|Diprosone|"* Start of treatment: as soon as the EGF-R inhibitors treatment begins~* Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening~* Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.~* Period of treatment: 8 weeks"
41509551|NCT03832205|DEVICE|Capaciflector monitoring|Non-invasive capaciflector monitoring of respiratory rate and heart rate.
41509552|NCT02441725|OTHER|1-minute sit-to-stand test|Validation of the 1-minute sit-to-stand test in a COPD patient population
40853717|NCT03642496|BIOLOGICAL|High dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 3.0×10\*6/kg.
41037014|NCT00615966|DRUG|Diannexin|Single dose, 400 µg/kg IV
41037015|NCT03045666|OTHER|Exercise program|patients who are stable on Macitentan therapy (received in both groups before enrollment) and will exercise at a pulmonary rehabilitation program twice a week for 12 weeks
41037016|NCT06019312|DIETARY_SUPPLEMENT|Sanprobi IBS®|Patients will be treated with probiotics in combination with inulin, which is able to stimulate the growing of probiotic bacteria in gastrointestinal tract.
41180030|NCT00415701|DRUG|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
41384060|NCT04831502|DRUG|TAK-906|TAK-906 Tablets.
41384061|NCT04831502|DRUG|TAK-906|TAK-906 Capsules.
41384062|NCT00397904|BIOLOGICAL|cetuximab|
41384063|NCT00397904|DRUG|cisplatin|
41509553|NCT05328219|OTHER|Chewing gums with PEG solution|"Patients undergoing colonoscopy under experimental group was advised to take 2L of PEG solution and packets of sugarless sweet mint flavored chewing gums.~The patients are advised to Chew one stick of sugarless gum for at least 10 min after taking each glass of PEG solution and discard the chewing gum before taking next glass."
40853718|NCT04584957|DEVICE|VAC therapy|Prophylactic ciNPWT therapy (Prevena® KCI) entails placement of the device over a closed incision immediately post-operatively. Prevena® KCI may be left in place with no additional intervention for up to 7 days.
40853719|NCT01126944|DEVICE|heart mate II|left ventricular assist device
41384064|NCT00397904|DRUG|irinotecan hydrochloride|
41384065|NCT00397904|OTHER|immunohistochemistry staining method|
41384066|NCT00397904|OTHER|laboratory biomarker analysis|
41384067|NCT00397904|PROCEDURE|biopsy|
41384068|NCT06318975|BEHAVIORAL|Brief Alcohol Intervention|All Airmen will receive a standard BAI during the 4th week of Technical Training, the last week of enforced abstinence. The BAI is a group-based, one-hour session which includes the following components: Interactive discussion of the positives and negatives of drinking during training and heavy vs. moderate drinking; Discussion of USAF rules on alcohol use and penalties for violations; Discussion of impact of alcohol on military readiness; effects of alcohol and hangover on performance; Review of standard drinks, blood alcohol levels and tolerance; and normative feedback on the Airmen's drinking level compared to others. We will engage in a conversation about whether they have observed concerning patterns of alcohol misuse among other USAF personnel, and how to handle this, along with harm reduction and alcohol refusal strategies.
41509554|NCT05328219|OTHER|Standard of care|Standard of care
40853720|NCT05545683|BIOLOGICAL|VLA 2001|VLA2001 is a highly purified whole virus, inactivated, adjuvanted vaccine, using the manufacturing platform of Valneva's encephalitis (JE) vaccine
40853721|NCT01351116|RADIATION|EBR plus HDRIB|EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
41384069|NCT06318975|BEHAVIORAL|Automated and Targeted Text Messages|All messages are pre-written, and their timing is pre-planned - All Airmen will start receiving 3-5 text messages per week starting the Monday after they received the Brief Alcohol Intervention and lasting for six weeks. The intervention is also targeted to age, with some messaging differing for Airmen less than 21 years and those already 21 years old or who will turn 21 during the intervention period. All Airmen randomized to the text message arm will be enroll into the supplemental program, and may opt out at any time. Messages reinforce content of the BAI and provide additional, actionable advice on reducing or avoiding alcohol in more detail and specificity than time typically allows for during the BAI. Messages are sent on days and at times that were indicated as being preferred during formative development of the intervention. Messages are designed to maintain or enhance skill building. No drinking behavior is collected as part of the text messaging intervention
41528310|NCT05068180|DRUG|low-dose neuroleptanalgesia|Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
41528311|NCT05068180|DRUG|Placebo|The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
40853722|NCT01351116|RADIATION|EBR|EBR of 20 Gy in 5 daily fractions over one week
40853723|NCT03791775|DRUG|Polidocanol foam (Atossisclerol® 3%)|The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding
40853724|NCT05541445|DRUG|Pembrolizumab|The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
41037017|NCT02127164|DEVICE|"Veraflo device, Dakin's solution"|Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
41037018|NCT00618475|BEHAVIORAL|Cognitive behavioral therapy|"10 sessions~1 hour per week"
41037019|NCT03640260|BEHAVIORAL|breathing regulation with physical activity|The subjects will have education leaflets with breathing and oximetry level evaluation training.
41037020|NCT00116805|DRUG|TDF|300 mg tablet administered orally once daily
41037021|NCT00116805|DRUG|ADV|10 mg tablet administered orally once daily
41037022|NCT00116805|DRUG|TDF placebo|Tablet administered orally once daily
41037023|NCT00116805|DRUG|ADV placebo|Tablet administered orally once daily
41037024|NCT00116805|DRUG|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
41037025|NCT03583216|DIAGNOSTIC_TEST|Diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
41180031|NCT00415701|OTHER|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
41384070|NCT00219752|DRUG|Imatinib mesylate 400 mg|
41384071|NCT00030602|BIOLOGICAL|PSA prostate cancer vaccine|
41384072|NCT00030602|BIOLOGICAL|incomplete Freund's adjuvant|
41384073|NCT05655494|BEHAVIORAL|Stand-alone Research Portal|The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.
41384074|NCT05655494|BEHAVIORAL|Portal with Virtual Community Health Educator (vCHE)|The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
41384075|NCT06408298|DRUG|Hydroxychloroquine Sulfate 400Mg Tab|hydroxychloroquine sulfate tablet
41384076|NCT06408298|DRUG|Placebo|Inactive tablet
41384077|NCT00795483|DRUG|Zoledronic acid|Zoledronic Acid 5mg/year
41384078|NCT00795483|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications
41384079|NCT00795483|DRUG|Zoledronic acid|Zoledronic acid (5mg/2years)
41384080|NCT06280066|OTHER|Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers|The content of the Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers will include the Psychological Resiliency Program for Children and Adolescents developed by Akar (2018), laughter yoga, meditation, breathing exercises and therapeutic story sessions.
41384081|NCT01506986|DRUG|Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg|All three medications will be taken orally, twice daily, for seven days.
41384082|NCT01506986|DRUG|Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg|Medication to be taken orally, twice a day, for seven days.
41384083|NCT04874311|DRUG|Bintrafusp alfa|Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.
41384084|NCT04874311|DRUG|Doxorubicin|Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
41384085|NCT06070701|PROCEDURE|Superficial Parasternal Block (SIPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the superficial parasternal intercostal plane using real-time ultrasound guidance.
41528312|NCT03238664|PROCEDURE|Biopsy|Undergo biopsy of bladder tumor
41037026|NCT03583216|DIAGNOSTIC_TEST|Non-diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
41037027|NCT04675138|OTHER|No intervention will be provided to the subject|No intervention will be provided to the subject
41037028|NCT01990469|DRUG|Gemigliptin|DPP-4 inhibitor
41165963|NCT04106713|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven \[behaviours\] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing \[behavioural\] and emotional awareness, and situational and interoceptive exposure to emotion cues."
41165964|NCT04106713|BEHAVIORAL|Group Cognitive Behavioural Therapy (group CBT)|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
41037029|NCT01990469|DRUG|Gemigliptin placebo|Placebo of Gemigliptin
41037030|NCT06367621|DEVICE|iStatis Syphilis Antibody Test|1500 stored samples (plasma/serum) will be tested in a routine testing environment using the iStatis Syphilis Antibody Test diagnostic device. Results of tests will not be used for patient management decisions (observaltional).
41037031|NCT02011438|BEHAVIORAL|UTalk|Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
41165965|NCT02925234|DRUG|Panitumumab|Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.
41165966|NCT02925234|DRUG|Olaparib|Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.
41165967|NCT02925234|DRUG|Dabrafenib|Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.
41165968|NCT02925234|DRUG|Nilotinib|Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.
41180032|NCT05146115|OTHER|Realization of the Athletic Shoulder Test and the Modified Athletic Shoulder Test|The participants will have to perform both tests two times, with a 7-10 days rest period between the two sessions
41509555|NCT04323943|DEVICE|Ankle Foot orthosis (AFO)|"The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~* 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~* 6MWT where energy cost will be measured~* 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed"
41509556|NCT04151043|BEHAVIORAL|Suggestions|Verbal suggestions or no suggestions about treatment outcome
41509557|NCT04151043|DEVICE|Deep brain stimulation|Regulation of deep brain stimulation intensity
41509558|NCT00109226|DRUG|Avastin (Bevacizumab)|
41509559|NCT04290455|DEVICE|Microblepharoexfoliative procedure with BlephEx™|The device will be used to clean both upper and lower eyelid in the office visit.
41509560|NCT04290455|PROCEDURE|Eyelid cleansing with eyelid wipes (Optase)|Eyelid cleansing will be done with eyelid wipes (Optase) by one clinician
41509561|NCT04290455|PROCEDURE|Daily eyelid cleansing with eyelid wipes (Optase)|Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days
41509562|NCT00527410|DRUG|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
41509563|NCT05801224|DEVICE|Nitric Oxide|20ppm for 15 minutes delivered by INO max(Nitric Oxide) Company : INO therapeutics, Inc.
41037032|NCT03435393|PROCEDURE|Catheter ablation|Mapping of the epicardium and ablating areas of long fractionated potentials
41037033|NCT00061295|PROCEDURE|Body weight support treadmill training|
41037034|NCT03019211|OTHER|Exercise|
41037035|NCT05560854|BEHAVIORAL|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
41037036|NCT02389972|DRUG|Dasatinib|
41037037|NCT06388577|OTHER|Education|Participants in the intervention group (n = 36) will be administered the Epilepsy Education Programme based on Pender's Health Promotion Model by the researcher and will be given the education booklet developed by the researcher in line with the literature. The training topics of the intervention programme are: General information about epilepsy, seizure moment management, management of antiepileptic drug treatments, controlling the factors that may trigger seizures, and recommendations to parents about health promoting and protective behaviours. In the training, learning and teaching techniques such as presentation, video demonstration, question and answer sections, lecture and discussion will be applied. The training will last approximately one hour.
41037038|NCT02034578|DRUG|Apixaban|
41165969|NCT02925234|DRUG|Trametinib|Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.
41165970|NCT02925234|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.
41384086|NCT06070701|PROCEDURE|Erector Spinae Plane Block (ESPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the plane deep to the erector spinae muscle, typically at the level of the 5th thoracic vertebra, under real-time ultrasound guidance.
41384087|NCT06070701|DRUG|General anesthetic|During general anesthesia, fentanyl is administered according to NOL monitoring.
41384088|NCT06070701|DRUG|Morphine|Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.
41509564|NCT01960335|DIETARY_SUPPLEMENT|Whey Protein|Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
41509565|NCT01960335|DIETARY_SUPPLEMENT|Whey Protein and Resistance Exericse|Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.
41509566|NCT01960335|OTHER|Whey Protein and RISE exercise routine|Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
41509567|NCT04263025|BIOLOGICAL|Cryopreserved Umbilical Cord Allograft|"CLARIX® CORD 1K (Amniox Medical, Miami, FL) is an umbilical cord allograft processed using the patented CRYOTEK™ process by TissueTech Inc. to devitalize all living cells but retain the natural structural and biological characteristics relevant to this tissue \[43\]. CLARIX® CORD 1K (6x3 cm in size) will be cut into two longitudinal pieces (1.5 cm in width) and placed circumferentially around each NVB as a nerve wrap during RARP. CLARIX® CORD 1K has been in market since 2013 in the United States as a 361 human cell and tissue-based product (HCT/P) and is aseptically processed in compliance with current Good Tissue Practices (cGTP) as outlined in 21 CFR Part 1271."
41509568|NCT04263025|PROCEDURE|Robot-Assisted Radical Prostatectomy|Robot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy
41509569|NCT03723356|DIAGNOSTIC_TEST|Siemens Biograph mMR (molecular MR)|5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,
41037039|NCT00003135|DRUG|fluorouracil|
41037040|NCT00003135|DRUG|pegylated liposomal doxorubicin hydrochloride|
41037041|NCT00003135|PROCEDURE|hyperthermia treatment|
41037042|NCT01302119|DRUG|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
41037043|NCT01302119|DRUG|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
41037044|NCT00547391|PROCEDURE|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
41037045|NCT00547391|OTHER|no intervention|No intervention (controls). Follow up started from the day of randomization.
41037046|NCT01899846|DRUG|Hydroxyprogesterone caproate 250 mg/ml|
41037047|NCT03404128|OTHER|Questionnaires|Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
41037048|NCT06095726|BEHAVIORAL|Peppermint Inhalation|The researcher applied two drops (0,2ml) of 2% essential oil of peppermint on a piece of cotton. Then, each child was instructed to take three breaths of the essence that had been put on a piece of cotton before starting chemotherapy session with three minutes. In addition, the piece of cotton with peppermint essence was kept at bed side table to use by child as needed throughout the chemotherapy session. Inhalation of peppermint essence was applied for three consecutive chemotherapy sessions.
41037049|NCT06095726|BEHAVIORAL|Swedish Massage|Children were received Swedish massage therapy for twenty minutes prior to chemotherapy session in a private and special room with effleurage, petrissage, friction, and tapotement and vibration movements for three consecutive chemotherapy sessions. The researcher applied facilitating olive oil in hands and pre warmed before applying massage. The massage technique was applied in prone position with mild to moderate pressure with guidance by the child's feedback and tolerance by using non-scented olive oil. Children's privacy was considered.
41037050|NCT06316843|DRUG|Valacyclovir celecoxib dose 1|1500 mg valacyclovir 200 mg celecoxib taken two times a day
41180033|NCT04515407|OTHER|PAS at Rest|Paired Associative Stimulation will be delivered while the participant is seated and resting.
41384089|NCT05125822|OTHER|Meal replacement and lifestyle modification|Meal replacement and lifestyle modification
41384090|NCT03130777|DEVICE|Edwards Alterra Adaptive Prestent with SAPIEN 3 THV|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.
41384091|NCT01053169|BIOLOGICAL|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
41509570|NCT03723356|DIAGNOSTIC_TEST|fMRI|High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.
41509571|NCT03723356|DIAGNOSTIC_TEST|Diffusion Spectrum Imaging (DSI)|DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers
41509572|NCT06488339|DIETARY_SUPPLEMENT|Protein and oil supplement|Take 1 sachet/day replaced dinner
41509573|NCT00706862|DRUG|Talactoferrin|Oral, 1.5 grams twice per day
41509574|NCT00706862|DRUG|Placebo|Oral, twice per day
41509575|NCT05986227|DRUG|toripalimab FOLFOX|Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)
41509576|NCT00311597|PROCEDURE|Radiosurgery|single fractionated radiation therapy
41037051|NCT06316843|DRUG|Valacyclovir celecoxib dose 2|750 mg valacyclovir 200 celecoxib mg taken two times a day
41037052|NCT06316843|DRUG|Placebo|Placebo capsules colored matched to investigational product taken two times a day
41037053|NCT04084314|BIOLOGICAL|Erenumab|Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.
41037054|NCT05981768|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
41037055|NCT03815851|DEVICE|prophylactic drainage|place prophylactic drainage after surgery
41509577|NCT04196140|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
41037056|NCT03815851|DEVICE|no prophylactic drainage|Not place prophylactic drainage after surgery
41165971|NCT02925234|DRUG|Trastuzumab and Pertuzumab (combination treatment)|Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.
40853725|NCT05809492|OTHER|step test|"The step speed of 18 steps/min was chosen for the first level because it is suitable for all subjects and prevents them from being too fast at the end of the test.~the slow standardized initial tempo at Level 1 of 72 beats/min allowed familiarity with the coordinated cascading technology of the tests (step up and down in time with the metronome beat). Regular replacement of the leading leg was encouraged to prevent unilateral leg fatigue and November muscle pain.~pwCF selected 1-minute stage times for each level in accordance with the maximum exercise test (CPET) recommendations in 18; at each new level, the test speed was increased by two steps / minute to ensure a progressive change in exercise parameters; a suitable end test time of 16 minutes was achieved along with an initial speed of 18 steps/min. The fast pace of 194 beats/min (48 steps/min at Level 16), which was eventually reached, it was physically possible to perform safely."
40853726|NCT03064971|BEHAVIORAL|Standard Care|Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials
40853727|NCT03064971|BEHAVIORAL|smoking cessation DVD|"The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies"
40853728|NCT03064971|BEHAVIORAL|PTF DVD|Culturally specific smoking cessation DVD. This DVD contains 60 minutes of material.
41165972|NCT02925234|DRUG|Vemurafenib and Cobimetinib (combination treatment)|Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.
41165973|NCT02925234|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
41165974|NCT02925234|DRUG|Regorafenib|Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
40853729|NCT00527904|DRUG|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
41037057|NCT03521635|DRUG|Pramipexole SR|Tablets
41037058|NCT03521635|DRUG|Pramipexole IR|Tablets
41165975|NCT02925234|DRUG|Nivolumab|Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.
41509578|NCT05044195|BIOLOGICAL|aQIV|Participants receive a 0.5-mL intramuscular dose of aQIV on Day 1
41509579|NCT05044195|BIOLOGICAL|Comparator QIV|Participants receive a 0.5-mL intramuscular dose of Comparator QIV on Day 1
41037059|NCT06635369|DIAGNOSTIC_TEST|Periodontal Indices|Saliva, serum and periodontal indexes were obtained from patients
41037060|NCT02167074|DEVICE|25G FNA needle|
41037061|NCT02167074|DEVICE|20G ProCore FNB needle|
41037062|NCT00153764|DRUG|Cooper Complete One-A-Day Vitamin Supplement|
41037063|NCT03228511|DEVICE|endoscope|It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions
41165976|NCT02925234|DRUG|Afatinib|Afatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Afatinib might be expected based on their molecular tumor profile.
41509580|NCT02704169|OTHER|Spatially registered endoscopy|
41509581|NCT03678571|OTHER|Latrunculin A supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Latrunculin A
41509582|NCT04366323|DRUG|ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS|Two doses of 80 million adipose-tissue derived mesenchymal stem cells
41509583|NCT04941079|OTHER|no intervention|no intervention
41037064|NCT06191913|DEVICE|Near-infrared spectroscop|Before the induction of anesthesia, INVOS pediatric SomaSensor probe (Coviden, Dublin, Ireland) was placed on the patient's forearm and then connected to a monitor, which was used to continuously measure and assess the dynamic changes in the StO2
41384092|NCT01053169|BIOLOGICAL|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
41384093|NCT01053169|OTHER|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
41384094|NCT01097759|PROCEDURE|Surgery|Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
41384095|NCT00673712|DEVICE|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
41384096|NCT00673712|DRUG|Opioid based analgesia|"Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN"
41384097|NCT01833897|DRUG|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
41384098|NCT01833897|DRUG|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
41384099|NCT01833897|DRUG|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
41509584|NCT04969731|DRUG|Immuncell-LC|IV
41037065|NCT03261518|PROCEDURE|inferior vena cava ultrasound|Place the patient in the supine position. The degree of elevation of the head of the bed has not been shown to make a significant difference in measurements. The diameter of the IVC for calculation of the caval index should be measured 2 cm from where it enters the right atrium .An alternative way to visualize respiratory variation is to use M-mode, with the beam overlying the IVC 2 cm from the right atrium.The inspiratory and expiratory diameter can then be measured on the M-mode image, at the smallest and largest locations, respectively.
41037066|NCT06286293|OTHER|Neuropsychological assessment, driving simulator task|Neuropsychological assessment consisting of test measuring general cognitive abilities and social cognition. Driving simulator task measuring risk-taking.
41509585|NCT04969731|DRUG|Gemcitabine|IV
41165977|NCT02925234|DRUG|Dabrafenib and trametinib|Dabrafenib + trametinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Dabrafenib + Trametinib might be expected based on their molecular tumor profile.
41165978|NCT02925234|DRUG|Ribociclib|Ribociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Ribociclib might be expected based on their molecular tumor profile.
41384100|NCT05550025|DRUG|camrelizumab& apatinib|"TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.~The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
41384101|NCT00440193|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
41384102|NCT00440193|DRUG|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
41384103|NCT00359073|DRUG|montelukast|10 mg everyday
41509586|NCT02401997|BEHAVIORAL|sexual abstinence|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
41509587|NCT05622240|DRUG|99mTc-MIRC213|99mTc-MIRC213 were intravenous injected into the patients before the wholebody and SPECT/CT scans
41509588|NCT05806892|OTHER|Thera Pearl|"You can apply Thera°Pearl warm breast therapy before breastfeeding or during milking. You should do this application 4 times a day, in the morning, at noon, in the evening and at night before going to bed. Each application should be done on both breasts and should last at least 20 minutes.~Thera°Pearl Warm Breast Therapy has been developed to open milk ducts and accelerate milk flow.~Thermogel packs for Thera°Pearl hot therapy can be heated inside the fabric covers in the microwave for a maximum of 15 seconds or in hot water by removing the fabric covers. Packages that have been removed from the cover should be kept in boiling water for 1-2 minutes and then applied by putting them into the sheath."
41509589|NCT06581796|OTHER|pepsinogen-1|association between pepsinogen 1 serum level with hyperemesis gravidarum
41509590|NCT05054257|DRUG|Autologous CAR19 T lymphocytes|First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL
41037067|NCT03885531|DEVICE|Total knee arthroplasty with Journey II CR Total Knee System|TKA with Journey II CR Total Knee System
41037068|NCT00249236|DRUG|Risperidone, oral tablets|
41037069|NCT05853848|BEHAVIORAL|Postcard|Postcard with phone number to call for help scheduling a mammogram.
41037070|NCT05853848|BEHAVIORAL|Letter|Letter with phone number to call for help scheduling a mammogram.
41384104|NCT00359073|DRUG|placebo|like placebo
41384105|NCT06541509|DRUG|Semaglutide|"10 overweight patients with heart failure will be enrolled, including 5 patients with heart failure with preserved ejection fraction (HFpEF) and 5 patients with heart failure with reduced ejection fraction (HFrEF). The diagnosis of HFpEF and HFrEF will be based on the most recent European Society of Cardiology guidelines for the diagnosis and treatment of heart failure.~After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks. At the end of the 3-month and 4-month period, blood sample collections will be repeated. All blood samples will be sent to Stanford Cardiovascular Institute for further analyses. At baseline, and again at 4 months transthoracic echocardiography, 6-minute walk test, and body composition assessment will be performed."
41384106|NCT01964391|DRUG|Trastuzumab|Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
41384107|NCT01964391|DRUG|Doxorubicin|Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
41509591|NCT00741338|BIOLOGICAL|Laronidase|0.058 mg/kg - 0.58 mg/kg IV infusion weekly.
41509592|NCT00741338|DRUG|Cyclosporine A (CsA)|Orally three times daily.
40853730|NCT00527904|DRUG|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
40853731|NCT01447953|OTHER|Activity targeted pain rehabilitation|An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.
40853732|NCT01447953|OTHER|Treatment as usual|Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
40853733|NCT00571805|DRUG|varencline|2.0 mg/day varencline (1.0 mg BID)
40853734|NCT00571805|DRUG|placebo|matching placebo
40853735|NCT05904795|OTHER|PNF strengthening exercises|PNF strengthening exercises 10 repetitions, 1set , 4 days/week along with range of motion exercises total of 4 sessions were given consisting 40 minutes
40853736|NCT05904795|OTHER|de-lorme and watkins exercises|"The group was given de-lorme and watkins progressive resistance exercises along with range of motion exercises .10 repetitions, 1set, 4 days /week along with range of motion exercises.~total of 4 sessions per week each consisting of 40 minutes."
40853737|NCT03720288|DRUG|Acetazolamide|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
40853738|NCT03720288|DRUG|Placebo|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
40853739|NCT05296564|DRUG|CYCLOPHOSPHAMIDE and FLUDARABIN|1. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
41509593|NCT00741338|DRUG|Azathioprine (Aza)|Orally either every day for Cohort 1 or every other day for Cohort 2.
41509594|NCT04172597|DRUG|Poziotinib Hydrochloride|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
41509595|NCT04172597|DRUG|Loperamide|Loperamide as prescribed by the physician.
41509596|NCT03591510|DRUG|Midostaurin|midostaurin 30mg/m2 bid
41509597|NCT03591510|DRUG|Fludarabine|30mg/m2/day on D1-D5 of Block 2 FLADx
40853740|NCT05296564|DRUG|Cyclophosphamide|CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
40853741|NCT05296564|BIOLOGICAL|HBI 0201-ESO TCRT|HBI 0201-ESO TCRT will be infused on Day 0, after lymphodepletion. Three dose levels will be evaluated: 1x10E9, 5x10E9 and 1x10E10.
40853742|NCT05296564|DRUG|Aldesleukin|Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
40853743|NCT01584362|DRUG|oxfendazole|administration of a single oral 1.0 mg/kg dose of oxfendazole
40853744|NCT01584362|DRUG|placebo|single oral dose of placebo
40853745|NCT01584362|DRUG|oxfendazole|administration of a single oral 3.0 mg/kg dose of oxfendazole
40853746|NCT01584362|DRUG|oxfendazole|administration of a single oral 0.3 mg/kg dose of oxfendazole
41509598|NCT03591510|DRUG|Cytarabine|"Part 1:~2000mg/m2/day D1 to D5 of Block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 HAM 3000mg/m2 every 12 hours D1 to D3 Block 4 HA3E 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC~Part 2:~1000mg/m2 every 12 hours D1 to D3 Block 2 HAM 3000mg/m2 every 12 hours D1 to D3 Block 3 HA3E 1000mg/m2 every 12 hours D1 to D3 Block 4 HAM 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC"
41509599|NCT03591510|DRUG|Daunorubicin or idarubicin|daunorubicin 60 mg/m2/day OR idarubicin 12mg/m2/day On D2, D4, D6 of Block 2 FLADx
41509600|NCT03591510|DRUG|Mitoxantrone|10mg/m2/day D3 and D4
40853747|NCT01584362|DRUG|oxfendazole|administration of a single oral 10 mg/kg dose of oxfendazole
40853748|NCT01584362|DRUG|oxfendazole|administration of a single oral 20 mg/kg dose of oxfendazole
40853749|NCT01584362|DRUG|oxfendazole|administration of a single oral 30 mg/kg dose of oxfendazole
40853750|NCT03762018|DRUG|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
40853751|NCT03762018|DRUG|Pemetrexed|Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
41037071|NCT05853848|BEHAVIORAL|Auto-dialer|Auto-dialer with option to press button for help scheduling a mammogram.
41037072|NCT05853848|BEHAVIORAL|Live call|Live call offering help scheduling a mammogram.
41037073|NCT03524040|DEVICE|SEB-250|Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
41037074|NCT04149405|PROCEDURE|Phase 1 periodontal therapy|Scaling and root planning with ultrasonic and hand instruments under local anesthesia.
41037075|NCT04149405|DRUG|Bisphosphonate therapy|Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year
41165979|NCT02925234|DRUG|Lenvatinib|Lenvatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Lenvatinib might be expected based on their molecular tumor profile.
41165980|NCT02925234|DRUG|Pembrolizumab|Pembrolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Pembrolizumab might be expected based on their molecular tumor profile.
41165981|NCT02925234|DRUG|Durvalumab|Durvalumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Durvalumab might be expected based on their molecular tumor profile.
41384108|NCT01964391|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
41384109|NCT01964391|DRUG|Paclitaxel|Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
41384110|NCT01964391|DRUG|Docetaxel|Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
41384111|NCT01964391|DRUG|Carboplatin|Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
41384112|NCT01964391|DRUG|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy will be administered according to local guidelines in combination with trastuzumab in the neo-adjuvant setting. The study protocol does not mention any specific neo-adjuvant chemotherapy drug names.
41384113|NCT01508286|DRUG|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
41384114|NCT01508286|DRUG|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
41384115|NCT01508286|DRUG|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
41509601|NCT03591510|DRUG|Etoposide|100mg/m2/day D1 to D5
41509602|NCT05468801|OTHER|Individualized Homeopathic Remedy|An individualized homeopathic remedy selected for each subject according clinical homeopathic parameters will be administered daily in the form of oral globules as an add on to conventional treatment.
41509603|NCT05468801|OTHER|Placebo|Placebo plus Standard Pharmacologic Treatment
41509604|NCT03191591|BEHAVIORAL|First 1,000 Days Program Site|Program components will include 1) Enhancements to and improved use of electronic health records to improve the quality of preventive services and screening for social determinants of health; 2) Staff and provider training; 3) Consistent behavior change messaging; 4) Patient education via print materials, text messaging and short videos; and 5) Strengthening the integration of clinical and public health services to support behavior change and address social determinants of health.
41528313|NCT03238664|DEVICE|High-Intensity Focused Ultrasound Ablation|Undergo laparoscopic HIFU
40853752|NCT03762018|DRUG|Bevacizumab|Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
41165982|NCT02925234|DRUG|Rucaparib|Rucaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Rucaparib might be expected based on their molecular tumor profile.
41165983|NCT02925234|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
41165984|NCT02925234|DRUG|Palbociclib|Palbociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Palbociclib might be expected based on their molecular tumor profile.
41165985|NCT02925234|DRUG|Crizotinib|Crizotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Crizotinib might be expected based on their molecular tumor profile.
41384116|NCT05516498|DRUG|Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
41384117|NCT05516498|DRUG|Part A: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
41384118|NCT05516498|DRUG|Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
41384119|NCT05516498|DRUG|Part B: placebo (matching zibotentan capsule) + dapagliflozin|"placebo capsule (matching zibotentan capsule)~dapagliflozin tablet"
41384120|NCT05516498|DRUG|Part B: zibotentan (dose A) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
41384121|NCT05516498|DRUG|Part B: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
41384122|NCT05516498|DRUG|Part B: zibotentan (dose C) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
41384123|NCT00157573|DRUG|GM-CSF, sargramostim|GM-CSF subcutaneous injection
41384124|NCT02555254|PROCEDURE|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
41384125|NCT02555254|PROCEDURE|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
41384126|NCT02534467|DRUG|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
41528314|NCT03238664|OTHER|Laboratory Biomarker Analysis|Correlative studies
41528315|NCT03238664|PROCEDURE|Radical Cystectomy|Undergo RARC
41528316|NCT03238664|DEVICE|Ultrasonography|Undergo CEUS
41528317|NCT06575478|DRUG|Fuling Yunhua Granules|Fuling Yunhua Granules
41384127|NCT06316960|DRUG|Avapritinib|50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd, d1-28.
41384128|NCT06316960|DRUG|Azacitidine Injection|75mg/m2/d for weighing \>10kg, 2.5mg/kg/d for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
41384129|NCT06316960|DRUG|Decitabine Injection|20mg/m2/d for weighing \>10kg, 0.67mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
41384130|NCT06316960|DRUG|Idarubicin Hydrochloride|5mg/m2/day for weighing \>10kg, 0.17mg/kg/day for weighing ≤ 10kg, d 6, 8, 10 (d 8, 10, 12 for azacitidine) ivgtt, qod, more than 1 hour at 10 am.
41384131|NCT06316960|DRUG|Cytarabine|10mg/m2/day for weighing \>10kg, 0.33mg/kg/day for weighing ≤ 10kg, d6-15 （d8-17 for azacitidine ）, s.c., q12h.
41384132|NCT06316960|DRUG|Granulocyte Colony-Stimulating Factor|300ug/day for weighing \>10kg, 10ug/kg/day for weighing ≤10kg, d0-5, s.c., qd.
41384133|NCT05051657|DIETARY_SUPPLEMENT|PKU express plus|PKU express plus is a powdered protein substitute for the dietary management of PKU. It is formulated in a variety of flavours to provide a convenient, low volume, lower calorie, pre-measured protein substitute, containing a full micronutrient profile.
41384134|NCT01212926|DEVICE|Echographic analysis of myocardial deformation in 2D strain|
41384135|NCT05430308|PROCEDURE|Chlorhexidine scrub|Surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes
41509605|NCT03892603|OTHER|Strengthening exercises program|Participants from this group will be given a progressive shoulder strengthening exercises program based on 1 RM that will involve isometric, concentric and eccentric contractions. The exercises will target shoulder internal/external rotators and abductors and the scapular muscles. They will have to exercise every other day for 12 weeks. At each session with the therapist (6 over a 12 week period), strength will be reassessed and the program will be progressed accordingly. Any questions or concerns will also be addressed and participants will be requested to complete a paper based or digital record of their exercise participation.
41509606|NCT03892603|OTHER|Motor control exercises program|Each session will start with a series of clinical tests that will look at the influence of different corrections to alleviate symptoms during upper limb movements.The tests will be performed in a sequential format through four key areas: thoracic repositioning, scapula facilitation, humeral head procedures and neuromodulatory techniques. If a correction reduces pain, that technique will then be performed as exercises and incorporated into the participant's functional movement. In addition, motor control exercises during arm elevation, progressed through a standardized 6-phase retraining sequence, will be executed. Retraining phases will be graded according to: 1) resistance applied on the shoulder; and 2) use or non-use of feedback. Once participants reach pain free execution, the program will be progressed into re-education exercises according to the participants' work, sport and activities of daily living and will incorporate activities involving the upper and lower limbs.
41384136|NCT05430308|PROCEDURE|Povidone-iodine|The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution
41384137|NCT04217694|BEHAVIORAL|Cogstate Assessment Battery|Complete CogState testing
41384138|NCT04217694|DRUG|Memantine|Given PO
41384139|NCT04217694|DRUG|Memantine Hydrochloride|Given PO
41384140|NCT00137462|DRUG|torcetrapib/atorvastatin|
41384141|NCT00137462|DRUG|atorvastatin|
41384142|NCT00181974|DRUG|Tisseel Fibrin Sealant|
41037076|NCT02967302|DRUG|Morphine Sulfate|active intervention
41384143|NCT05924464|OTHER|Group Preconception Care|Groups of 6-10 patients to initiate biweekly virtual group care sessions on a rolling basis, with completion of enrollment and the virtual curriculum within a year.
41384144|NCT02525146|OTHER|Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention|
41384145|NCT02352207|OTHER|identification of a pulmonary malformation in the fetus|
41384146|NCT04317547|BEHAVIORAL|Steering Teens Safe (STS)|The goal of STS is to provide intervention parents with guidance and communication skills, which will enable parents to effectively communicate with their teens about specific driving safety topics (e.g., speeding, seatbelt use, distracted driving). Our proposed parent training has two components: an individualized virtual communication training (provided to parents via Skype by a trained research team member) and a parent-teen safe driving communication guide (available online).
41384147|NCT04317547|BEHAVIORAL|Driving Feedback Technology.|The driving feedback technology will include the Azūga™ in-vehicle device and smartphone app.
41384148|NCT04889378|OTHER|prehabilitation|very low calories diet (800-1000kcal/day) with moderate intensive aerobic exercise (1 hour per section; 3 sections per day)
41384149|NCT03868176|OTHER|short message service|short message service
41384150|NCT05631756|OTHER|Lung Ultrasound|Evaluation of the Lung Ultrasound Score in patients presenting an interstitial syndrom on the lung ultrasound and to compare it with PaO2/FiO2
41384151|NCT03700515|DRUG|Erythropoietin|Subjects receive weekly infusions of EPO
41384152|NCT03700515|DRUG|Placebo|Subjects receive weekly infusions of saline
41384153|NCT02255773|BEHAVIORAL|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
41037077|NCT02967302|DRUG|Triamcinolone|active control
41037078|NCT02967302|DRUG|placebo|placebo control
41037079|NCT02352558|DRUG|BBI608|Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
41037080|NCT02352558|DRUG|Dexamethasone|Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
41384154|NCT02255773|BEHAVIORAL|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
41384155|NCT00558831|DRUG|Benzoyl Peroxide|Benzoyl Peroxide 2.5%
41384156|NCT00558831|DRUG|Moisturizing Lotion|
41384157|NCT06470841|DRUG|CHG Combined With Venetoclax and Azacytidine|"Patients were treated by CHG Combined With Venetoclax and Azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14."
41384158|NCT03635060|PROCEDURE|Dorsal Bridge Plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
41384159|NCT03635060|PROCEDURE|Volar locking plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
41384160|NCT03275103|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
41384161|NCT03275103|DRUG|Tocilizumab|Tocilizumab will be administered as premedication during Cycle 1.
41509607|NCT03892603|OTHER|Education and advice|Each participant will be given written information about the shoulder (anatomy and function), basic pain science and will be directed to the Internet to watch a series of carefully selected educational videos. Comprehensive written advice will include: Information about the shoulder and the condition; Pain neuroscience; Activity modification (when to increase and decrease); Pain management (night and day); A series of educational videos to watch with 2 questions to answer per video: a) what was the most important message? and b) was there anything you didn't understand in the video?
41165986|NCT02925234|DRUG|Sunitinib|Sunitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Sunitinib might be expected based on their molecular tumor profile.
41509608|NCT05282563|PROCEDURE|double and a half layered esophagojejunal anastomosis|After the end of esophagojejunostomy, 3/0 barbed suture or absorbable suture was used. First, the anastomotic site was sutured continuously for one circle, with the suture spacing of 3-4 mm and the width of 4-5 mm. Then, the continuous horizontal mattress type seromuscular layer varus suture was used to embed the anastomotic stoma for one circle, and the suture width was 5\~8 mm above and below the anastomotic stoma. After the completion of esophagojejunostomy, the full-thickness reinforcement of the anastomosis and the embedding of the seromuscular layer can ensure the complete anastomosis of the mucosal layer of the anastomosis. The embedding of the seromuscular layer can also improve the anti-pressure and anti-tension of the anastomosis, and provide a guarantee for the primary healing of the anastomosis.
40853753|NCT03762018|DRUG|Atezolizumab|Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
40853754|NCT06407245|OTHER|Exercise Snacks|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application."
41509609|NCT02295917|DEVICE|Transvaginal sonography|Transvaginal sonography
41165987|NCT02925234|DRUG|Cabozantinib|Cabozantinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Cabozantinib might be expected based on their molecular tumor profile.
41384162|NCT05775289|DRUG|Tobemstomig|Participants will receive intravenous (IV) tobemstomig for four 21-day cycles
41384163|NCT05775289|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab four 21-day cycles
41509610|NCT02941835|RADIATION|pre-operative irradiation|pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
41528318|NCT06575478|DRUG|Fuling Yunhua Granules matched placebo|Fuling Yunhua Granules placebo
40853755|NCT06407245|OTHER|Placebo Exercise|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application."
41165988|NCT02925234|DRUG|Abemaciclib|Abemaciclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Abemaciclib might be expected based on their molecular tumor profile.
41180034|NCT04515407|OTHER|PAS - Active|Paired Associative Stimulation will be delivered while the participant is seated and producing submaximal background activity in the plantarflexor muscles.
41384164|NCT05775289|DRUG|Paclitaxel|Participants will receive IV paclitaxel Q3W for four 21-day cycles
41384165|NCT05775289|DRUG|Pemetrexed|Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity
41384166|NCT05775289|DRUG|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles
41384167|NCT01069458|OTHER|The high protein diet group and the low fat diet group|The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
40853756|NCT00595478|BEHAVIORAL|Motivational Enhancement Therapy (MET)/CBT+CM|Behavioral Treatment
40853757|NCT00595478|BEHAVIORAL|Motivational Enhancement Therapy (MET)/CBT|Behavioral Treatment
40853758|NCT04202133|BEHAVIORAL|WW (formerly Weight Watchers)|The WW intervention will consist of weekly group workshops for 16 weeks with WW Coaches and Guides.
41384168|NCT04839133|DEVICE|MyoSuitFeasibility|Participants will absolve feasibility tests with and without wearing a MyoSuit.
41384169|NCT01743664|BEHAVIORAL|EMDR|Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events
41384170|NCT01743664|BEHAVIORAL|Relaxation|The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
41384171|NCT06567119|BIOLOGICAL|SPOT-mRNA01|SPOT-mRNA01 (COL1A1 mRNA-loaded by EVs) ,single-dose subcutaneous injection
41384172|NCT06567119|OTHER|Placebo|Sterile isotonic solution, subcutaneous injection
41384173|NCT06540339|OTHER|Snapshot-audit studies do not necessitate any intervention in the defined cohorts.|Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
41384174|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FDOPA|Positron Emission Tomography (PET) with \[18F\]-FDOPA
41384175|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FEOBV|Positron Emission Tomography (PET) with \[18F\]-FEOBV
41384176|NCT03998852|DEVICE|Magnetic Resonnance Imaging (MRI)|MRI protocol will be performed on the same day that the \[18F\]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
41384177|NCT03998852|OTHER|Neuropsychological evaluation|Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
41384178|NCT01230502|DRUG|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|"Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy~Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.~Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples."
41384179|NCT01230502|OTHER|data and sample collection|"Group 2 : Donor specific regulation (DSR) + standard of care:~These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples"
41384180|NCT01230502|OTHER|data and sample collection|"Group 3 : Donor specific regulation (DSR) - standard of care:~These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months."
41384181|NCT02473107|OTHER|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
41384182|NCT02473107|OTHER|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
41384183|NCT00939965|DRUG|isotretinoin|
41384184|NCT00939965|GENETIC|DNA analysis|
41384185|NCT00939965|GENETIC|polymerase chain reaction|
41384186|NCT00939965|OTHER|laboratory biomarker analysis|
41384187|NCT00939965|OTHER|pharmacological study|
41384188|NCT06500052|DRUG|BL-M17D1|Administration by intravenous infusion for a cycle of 3 weeks.
41384189|NCT06260683|DRUG|Nicotine Replacement|Given nicotine patches and nicotine lozenges
41384190|NCT06260683|OTHER|Questionnaire Administration|Ancillary studies
41384191|NCT06260683|DEVICE|Vaping|Given Preferred Flavor e-liquid
41384192|NCT06260683|DEVICE|Vaping|Given Tobacco flavored e-liquid
41384193|NCT06137339|OTHER|Avocado Group|Participants will consume provided avocados daily and track consumption for the duration of the study. Participants will be adding avocados to their diet and will receive education on maintaining usual diet.
41384194|NCT05874518|OTHER|warm needling combined with electroacupuncture|Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation.
41384195|NCT05874518|DRUG|The treatment with letrozole tablets was started on the fifth day of the menstrual cycle|Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
40853759|NCT04202133|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered the WW intervention
40853760|NCT02983864|BEHAVIORAL|BASICS|A one session intervention focused on reducing drinking with motivational interviewing
40853761|NCT02983864|BEHAVIORAL|Integrated BASICS|A one session intervention focused on reducing drinking and sexual behavior while drinking
40853762|NCT02983864|BEHAVIORAL|Relaxation|A one session intervention focused on increasing relaxation skills
41509611|NCT00513136|BEHAVIORAL|Group based mind body medicine intervention|Small groups of women (5-15) will participate in 10 weekly sessions that will include learning relaxation and yoga techniques, principles of exercise and nutrition, cognitive behavioral therapy and exploration of common issues and concerns
41384196|NCT01977482|DRUG|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
41384197|NCT01977482|DRUG|Placebo|Matching placebo tablet for GSK1278863
41384198|NCT01977482|DRUG|rhEPO|rhEPO will be procured from local market
41384199|NCT06216080|OTHER|D-FF-OCT analysis of CVC|Dynamic full-field optical coherence tomography analysis of central venous catheter sections to better apprehend strucural characterization of central venous catheter-deposited biofilm
41384200|NCT06567171|PROCEDURE|This descriptive correlational study was conducted among 102 parents with children aged between 2 and 12 undergoing elective surgical procedures.|This descriptive correlational study was conducted among 102 parents with children aged between 2 and 12 undergoing elective surgical procedures. Parental use of pain relief strategies (PURPS) and parental postoperative pain management (PPPM) tools were used to collect data on the adequacy of knowledge of the use of different pain relief strategies and the skill of parental pain assessment, respectively. We used Spearman's rank correlation coefficient was used to determine the relationships between pain score given by parents and nurses. The statistical tests were performed at a 95% confidence interval and a 5% significance level.
41509612|NCT00513136|BEHAVIORAL|Group-based mind body medicine intervention + family focus|In addition to the 10 weekly group-based sessions, women and their key family members will meet twice with a cognitive therapist and family members will participate in selected aspects of the 10 week program.
41509613|NCT02371382|DEVICE|Arthroplasty hip|Hip replacement
41509614|NCT05462197|BEHAVIORAL|Qigong Wuqinxi|Wuqinxi is an exercise method developed by the ancient Chinese physician Hua Tuo by combining the ancient guide, breathing, and imitating the shapes of five animals, such as tiger, deer, bear, ape, and bird, combined with the zang-fu and meridian theory of traditional Chinese medicine. There have been studies in the past proven that this exercise can achieve health-promoting effects
41509615|NCT01333397|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 (single treatment cycle)
41509616|NCT01333397|BIOLOGICAL|Botulinum toxin type A|I.M. on day 1 (single treatment cycle)
41509617|NCT01333397|DRUG|Placebo|I.M. on day 1 (single treatment cycle)
40853763|NCT02983864|BEHAVIORAL|Integrated Bystander|A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
40853764|NCT01969435|DRUG|Carmustine|
40853765|NCT01969435|DRUG|Etoposide phosphate|
40853766|NCT01969435|DRUG|Cytarabine|
40853767|NCT01969435|DRUG|Melphalan HCl (propylene glycol-free)|
40853768|NCT00576225|DRUG|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
41037081|NCT02352558|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
41037082|NCT02352558|DRUG|Imatinib|Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
41509618|NCT04579848|DRUG|Methotrexate Tablets|Methotrexate 2.5mg oral tablet.
41509619|NCT04579848|DRUG|Placebo|Placebo capsule
41509620|NCT04579848|DRUG|Folic Acid 1 MG|Folic acid
41509621|NCT00253721|DRUG|Melphalan|"All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days"
41509622|NCT06550752|COMBINATION_PRODUCT|UC-MSCs and PRP|UC-MSCs are progenitor cells that can differentiate into various types of cells in the body and have the ability to regenerate and repair damaged tissue. During repair and regeneration, these cells secrete expedient and powerful bioactive paracrine factors including cytokines, chemokines, collagen, fibronectin, and growth factors promoting tissue repair, angiogenesis, and the regeneration of nerve cells as well as regulating cellular pathways including immunomodulation and inflammatory responses. Additionally, PRP contains numerous growth factors and cytokines, including vascular endothelial growth factor (VEGF), transforming growth factor beta-1 and beta-2 (TGF-β1/2), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), interleukin 8 and matrix metalloproteinases 2,9. The combined effect of these factors provided by PRP injections is proposed to have anti- inflammatory, reparative, neuroprotective and neurotrophic effects that contribute to the treatment of ED.
41509623|NCT01497769|BIOLOGICAL|Aerosol inhaled MVA85A|Aerosol inhaled MVA85A 1 x 10\^7 pfu and intradermal saline placebo
41509624|NCT01497769|BIOLOGICAL|Intradermal MVA85A|Intradermal MVA85A 1 x 10\^7 pfu and inhaled aerosol saline placebo
41509625|NCT05524337|BEHAVIORAL|white noise|"Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db."
40853769|NCT00576225|DRUG|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
40853770|NCT05533424|OTHER|quadratus lumborum|the patient will be positioned supine with lateral tilt , and the transducer was placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles were clearly identified. The external oblique muscle was followed posterolaterally until its posterior border was visualized . The probe was tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip was placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle was proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine was applied
41509626|NCT05524337|BEHAVIORAL|therapeutic touch|In the group where therapeutic touch will be applied, the heel blood collection procedure and the study will be explained to the family, and after the consent is obtained, the therapeutic touch will be applied to the baby 5 minutes before, during and after the procedure.
41384201|NCT01348659|DRUG|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
41384202|NCT01348659|DRUG|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
41384203|NCT02395601|DRUG|CPI-1205|Small molecule inhibitor of the enzyme EZH2
41384204|NCT04479943|OTHER|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
41384205|NCT06264271|BEHAVIORAL|structured nutrition intervention|Structured nutrition education on carbohydrate counting and flexible insulin dosing by qualified nutritionist.
41384206|NCT04520594|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
41384207|NCT04520594|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
41509627|NCT05524337|BEHAVIORAL|white noise and therapeutic touch|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time.
41509628|NCT02984371|PROCEDURE|Coronary artery bypass grafting|
41509629|NCT02984371|PROCEDURE|Epicardial ganglionated plexi ablation|
41509630|NCT02984371|PROCEDURE|implantable loop recorder|
41509631|NCT01560416|DRUG|Fulvestrant|
41509632|NCT01560416|DRUG|Ganetespib|
41384208|NCT06541561|DEVICE|transcutaneous electrical acupoint stimulation|"Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS) or the sham groups. In the TEAS group, the acupoints are bilateral neiguan (PC6) and Zusanli(ST 36) acupoints.~Patients will receive 30min TEAS before anesthesia until be discharged from the post anaesthesia care unit (PACU). The same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient."
41384209|NCT06541561|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
41384210|NCT05060913|DRUG|EMLA Cream|Effect of 5% Emla cream on pricking pain measured on VAS scale.
41384211|NCT05060913|DRUG|Benzocaine Gel|Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
41037083|NCT02352558|DRUG|Ibrutinib|Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
41037084|NCT00059813|BIOLOGICAL|recombinant interferon alfa|Given SC
41037085|NCT00059813|BIOLOGICAL|oblimersen sodium|Given IV
41037086|NCT00059813|OTHER|pharmacological study|Correlative studies
41384212|NCT03409159|DEVICE|LAAC|Left atrial appendage closure
41384213|NCT05527301|DRUG|Lactobacillus Fermentum|Lactobacillus Fermentum
41384214|NCT05527301|DRUG|Placebo|Placebo
41384215|NCT02712736|OTHER|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
41384216|NCT06190301|DRUG|Rituximab|Intralesional Rituximab Injection
41509633|NCT00345631|OTHER|Manual Compression|Manual compression
41509634|NCT00345631|DEVICE|Vascular Closure Device|Investigational vascular closure device
41509635|NCT00536692|DRUG|mecamylamine|topical ocular drops
41509636|NCT04557033|OTHER|Mindfulness intervention|My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media
41509637|NCT05473143|OTHER|Protocol-based fluid management|"Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components. Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components.~The first component of this prescription will be to define the 24h-fluid balance target either aiming for a negative fluid balance of 2 to 3% body weight (1.4-2.1 liters in a 70 Kg participant) (Option 1) or by aiming to avoid fluid accumulation by targeting a neutral fluid balance within 0.5% of body weight variation (-350 to +350 mL in a 70 Kg participant) (Option 2).~The second component is to pre-specify a prescription for fluid removal using KRT.~The third component is to prompt a daily re-evaluation of fluid intake by the attending care team."
41509638|NCT05473143|OTHER|Usual care|The net fluid removal and the rate of net fluid removal will not be protocolized and will be prescribed and adjusted according to the attending care team without any specific guidance. The use of the documents provided for the intervention group will not be permitted in the control arm.
41528319|NCT06575478|DRUG|Dihuang Baoyuan Granules|Dihuang Baoyuan Granules
41528320|NCT06575478|DRUG|Dihuang Baoyuan Granules matched placebo|Dihuang Baoyuan Granules placebo
41528321|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo single dose
41384217|NCT06190301|RADIATION|Involved Site Radiation Therapy|Involved Site Radiation Therapy
41384218|NCT04639635|OTHER|No intervention, this is a natural history progression study|The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.
41384219|NCT00683046|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
41384220|NCT00683046|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
41384221|NCT00683046|DRUG|Stem cells|Stem cell infusion on day 0.
41384222|NCT00683046|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
41384223|NCT02265640|DRUG|BIIL 284 BS boli|
41384224|NCT02265640|DRUG|BIIL 284 BS tablet C|
41384225|NCT02265640|OTHER|standard breakfast|
41528322|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo single dose with food effect
41528323|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo multiple dose
41384226|NCT04011904|OTHER|Cross-over study|Traditional Inuit Diet vs Westernized Diet
41384227|NCT03004430|BEHAVIORAL|Mantra Meditation|Silent mantra meditation with spiritual mantra
41509639|NCT03763474|COMBINATION_PRODUCT|Euglyca application|'Euglyca' is a mobile application developed by two of the authors (CC and DF). The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
41509640|NCT01458353|PROCEDURE|Stapled anastomosis|Stapled anastomosis after ileocolonic resection
41509641|NCT01458353|PROCEDURE|Handsewn anastomosis|Handsewn anastomosis after ileocolonic resection
41509642|NCT00030225|BIOLOGICAL|ELAD|
41509643|NCT00030225|OTHER|Standard of care (Control)|
41509644|NCT01656057|DRUG|Acetaminophen|Acetaminophen dissolved in 50 ml of water
41509645|NCT01656057|DRUG|Metformin|Metformin + acetaminophen dissolved in 50 ml of water
41509646|NCT01656057|DRUG|Colesevelam|Colesevelam + acetaminophen dissolved in 50 ml of water
41509647|NCT01656057|OTHER|Cholecystokinin-8|iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
41509648|NCT01656057|OTHER|Saline|iv. saline infusion 40 ml/hour for the first 60 minutes
41509649|NCT02681211|OTHER|Auricular Acupuncture|ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
41509650|NCT02681211|DRUG|Ketorolac 0.5mg/kg, max 30mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
41509651|NCT02681211|DRUG|Metoclopramide 0.1 mg/kg, max 10mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
41509652|NCT02681211|DRUG|Diphenhydramine 1mg/kg, max 50mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
41037087|NCT03752229|DEVICE|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41384228|NCT03004430|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation
41509653|NCT02681211|DRUG|Normal saline fluid bolus 20mL/kg, max 1000mL|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
41509654|NCT06233448|DEVICE|Indirect cardiometry|Measurements of thorathic fluid content
41509655|NCT06362863|DIETARY_SUPPLEMENT|enteral nutrition biscuits|Addition of enteral nutritional biscuits to existing pharmacological treatment.
40853771|NCT05533424|OTHER|transversus abdominis plane|the probe will located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall were identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique was used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine was injected. The same technique will be performed on the other side
41037088|NCT03752229|DEVICE|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41180035|NCT04515407|OTHER|PAS - Walking|Paired Associative Stimulation will be delivered while the participant is walking, during the late stance phase of the gait cycle.
41384229|NCT01830257|OTHER|sending message|Sending the suggestive short message
41384230|NCT00812305|DRUG|SKY0402 300mg in healthy patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
41180036|NCT02493946|BIOLOGICAL|Botulinum toxin type A|
41384231|NCT00812305|DRUG|SKY0402 300mg in hepatically impaired patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
41384232|NCT04278872|DRUG|SJX-653|administered orally once daily
41384233|NCT04278872|DRUG|Placebo|administered orally once daily
41384234|NCT03162120|DRUG|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
41384235|NCT03162120|DRUG|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
41384236|NCT06087029|PROCEDURE|TEVAR|Thoracic endovascular aortic repair
41509656|NCT02586155|DRUG|Apabetalone|100 mg capsule
41509657|NCT02586155|DRUG|Placebo|Capsule manufactured to mimic RVX000222 100 mg capsule
41509658|NCT02586155|DRUG|Atorvastatin|High-Intensity Statin
41509659|NCT02586155|DRUG|Rosuvastatin|High-Intensity Statin
41509660|NCT05549180|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo|The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo
41509661|NCT05549180|DRUG|Dovato 50Mg-300Mg Tablet + Biktarvy placebo|The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo
41509662|NCT02908971|BEHAVIORAL|soy based formula at infancy|The intervention is only past history of soy consumption
41509663|NCT01236443|DRUG|HPPH|3 mg/m2 IV
41509664|NCT05146843|DRUG|Mitoquinone|Mitoquinone pill, 20 mg/day
40853772|NCT06153368|DRUG|Cadonilimab+mFOLFIRINOX|"Cadonilimab 6 mg/kg，IVD，D1，Q2W~+mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle."
40853773|NCT04715971|DIAGNOSTIC_TEST|portable ultrasound bladder scan|A post-void residual volume was measured using a Verathon BladdersScan BVI 3000.
40853774|NCT01931163|DRUG|Everolimus|
40853775|NCT05643534|DRUG|Tenapanor 50 MG|Participants will receive tenapanor 50 mg BID (total of 100 mg daily)
40853776|NCT05643534|DRUG|Tenapanor 25 mg bid|Participants will receive tenapanor 25 mg BID (total of 50 mg daily)
41037089|NCT03752229|DEVICE|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037090|NCT03752229|DEVICE|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
40853777|NCT05643534|DRUG|Placebo|Participants will be randomized to receive matching placebo
40853778|NCT01886703|BEHAVIORAL|Pedometer Walking Program|All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
41037091|NCT03752229|DEVICE|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037092|NCT03752229|DEVICE|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41165989|NCT02925234|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
41384237|NCT06087029|OTHER|Guideline directed medical therapy and surveillance of dissection|Routine clinical care with suggested antihypertensive therapy and cardiovascular risk factor reduction as per appropriate cardiovascular guidelines.
41384238|NCT00878735|BEHAVIORAL|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
40853779|NCT00280085|PROCEDURE|MR imaging|
40853780|NCT00280085|PROCEDURE|Glucose clamp|
40853781|NCT00280085|DRUG|Arginine|
40853782|NCT06584058|DRUG|HPP737|\[14C\]HPP737 oral preparation, 20mg（150μCi）, once
40853783|NCT05496296|DEVICE|Altrazeal® Transforming Powder Dressing|Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm
41384239|NCT05349760|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
41384240|NCT05349760|DRUG|Placebo|Saline/D5W
41384241|NCT06321042|DEVICE|Knee arthroplasty|Knee arthroplasty surgery with perseus orthokey alignment device
41384242|NCT01827553|DRUG|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m\^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m\^2 2 h infusion, folinic acid 400 mg/ m\^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m\^2 for 90 minutes, bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2)
40853784|NCT06231979|DRUG|Dexmedetomidine|1 μg/kg Dexmedetomidine per side in erector spinae block
41384243|NCT01827553|RADIATION|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
41384244|NCT01827553|DRUG|Chemotherapy, gemcitabine|5 cycles of 300 mg/m\^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m\^2/d
41384245|NCT01827553|DRUG|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m\^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
41384246|NCT00580931|DRUG|Nicotinamide|1500 mg twice a day for 6 months
41384247|NCT00580931|DRUG|Enduramide placebo|1 tab twice a day
41384248|NCT04443231|DEVICE|Optical Coherence Tomography Angiography|AngioVue (Optovue, Fremont, CA, USA) was used to capture the OCTA images before ICL surgery and at 3 months follow-up.
40853785|NCT06231979|DRUG|Bupivacain|18 mL of bupivacaine 0.25 % per side in erector spinae block
40853786|NCT06231979|DRUG|Normal saline|2 ml normal saline 0.9% per side in erector spinae block
41037093|NCT03752229|DEVICE|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41165990|NCT02925234|DRUG|Atezolizumab and Bevacizumab|Atezolizumab + Bevacizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab + Bevacizumab might be expected based on their molecular tumor profile.
41180037|NCT02493946|DRUG|Placebo|
41180038|NCT04198571|DRUG|Zinforo (ceftaroline fosamil)|IV Solution
40853787|NCT05692102|OTHER|Evaluate quality of life after gynaecological malignancies diagnosis and treatment|diagnosis and treatment
40853788|NCT03915470|DRUG|XF-73|XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
40853789|NCT03915470|DRUG|Placebo|Placebo to match XF-73 nasal gel for colour and viscosity.
40853790|NCT00704288|DRUG|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
40853791|NCT02879825|DEVICE|Cardiac MRI|"Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)"
40853792|NCT02711007|DRUG|apatinib|Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
40853793|NCT00014833|OTHER|No intervention|No intervention
40853794|NCT01500486|DEVICE|NordiFlex PenMate™|Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
40853795|NCT05759182|DEVICE|pediatric/adolescent exoskeleton walking system|A pediatric/adolescent exoskeleton will be differentially applied according to each patient's gait level, 30 minutes a day, 3 times a week, 24 times in total for 8 weeks. When applying the intervention, the use of an appropriate stabilizing device (crutches, cane, harness, etc.) will be used according to the gait level of the study subject.
40853796|NCT00451516|DRUG|Herbal medicine (St. John's wort and Kava)|
40853797|NCT02476695|DEVICE|FibroTouch Examination|Liver stiffness measurements are performed using FibroTouch and the procedure is non-invasive and painless.
40853798|NCT02476695|DEVICE|FibroScan Examination|Liver stiffness measurements are performed using another transient elastography, FibroScan, and the procedure is non-invasive and painless.
40853799|NCT02476695|DEVICE|Ultrasonic B Examination|The ultrasonic B examination is made at an empty stomach for ≥8h. The inner diameter of liver, spleen, gallbladder, portal vein and splenoportal vein is measured through the ordinary two-dimensional ultrasonic examination. The echo data of liver surface/edge/parenchyma and gallbladder wall is scored to evaluate the severity of fibrosis.
40853800|NCT04374240|GENETIC|AdNRGM|"AdNRGM is an E1-E3 deleted, replication deficient type 5 adenovirus which contains the E. coli NTR gene regulated by the CMV promoter, an internal ribosomal entry site (IRES) and the human GMCSF gene.~CB1954 \[5-(aziridin-1-yl)-2,4-dinitrobenzamide\]"
40853801|NCT03507010|RADIATION|Radiotherapy|Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).
40853802|NCT03507010|OTHER|Sham Radiotherapy|Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.
41037094|NCT03752229|DEVICE|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037095|NCT03752229|DEVICE|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037096|NCT03752229|DEVICE|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037097|NCT03752229|DEVICE|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037098|NCT03752229|DEVICE|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037099|NCT03752229|DEVICE|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41165991|NCT02925234|DRUG|Ipilimumab and nivolumab|Ipilimumab+nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of ipilimimab + nivolumab might be expected based on their molecular tumor profile.
41165992|NCT02925234|DRUG|Entrectinib|Entrectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of entrectinib might be expected based on their molecular tumor profile.
41509665|NCT05146843|OTHER|Placebo|Placebo pill, 20 mg/day
41509666|NCT04439617|BIOLOGICAL|blood examination|use of the remaining 1-2 ml of blood in samples taken as part of routine care to study mitochondrial function
40853803|NCT00662545|DRUG|Entecavir with continued standard of care antiretroviral therapy|1 mg by mouth daily
40853804|NCT00662545|DRUG|continued standard of care with tenofovir in addition to emtricitabine or lamivudine|continued standard of care with tenofovir in addition to emtricitabine or lamivudine
40853805|NCT05413720|OTHER|two additional blood samples specific to research|proportion of activated monocyte cells (CD14+CD16+ phenotype) within monocytes in the acute phase
40853806|NCT05154318|PROCEDURE|Pericapsular Nerve Group Block|Nerve block targeting major hip joint sensory nerves.
40853807|NCT05154318|PROCEDURE|Fascia iliaca compartment block|Routine nerve block for hip fracture surgery.
40853808|NCT03225703|BEHAVIORAL|Hopping|A unilateral, hopping based exercise programme lasting six months.
40853809|NCT02154256|BEHAVIORAL|Increasing incentives|Offer incentives that increase over time.
41384249|NCT01016925|PROCEDURE|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
40853810|NCT02154256|BEHAVIORAL|Decreasing incentives|offer incentives that decrease over time
40853811|NCT02154256|BEHAVIORAL|stable incentives|offer incentives that are stable over time, but higher than usual care
40853812|NCT01635855|DEVICE|Belotero®|Hyaluronic acid dermal filler
40853813|NCT06508671|DRUG|DL-3-n-butylphthalide|Take butylphthalide soft capsules orally
40853814|NCT06508671|DRUG|Empty Medication Capsules|Take empty medication capsules orally
40853815|NCT00851929|DRUG|Ambrisentan|ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
41037100|NCT03752229|DEVICE|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037101|NCT03752229|DEVICE|Haemolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037102|NCT03752229|DEVICE|Haemolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41384250|NCT00567086|DRUG|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
41384251|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Drug: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
41384252|NCT06156761|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
41384253|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.
41037103|NCT03752229|DEVICE|Haemolnace Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037104|NCT03752229|DEVICE|Haemolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41384254|NCT06156761|DRUG|Capecitabine|Capecitabine (825 mg/m\^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.
41384255|NCT00433771|DEVICE|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
41384256|NCT00480363|PROCEDURE|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
41384257|NCT06100172|DEVICE|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS). Use of tAN for pain relief is an attractive alternative to pharmacologic and opioid-based approaches because it is safe and effective and presents no addiction liability.
41384258|NCT06100172|DEVICE|Sham Control Device|This device looks like the active device, but no stimulation will be delivered.
41509667|NCT06223802|BEHAVIORAL|biodex training|women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
41509668|NCT00000246|DRUG|Flumazenil|
40853816|NCT05810350|DRUG|Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed|Patients receive Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
40853817|NCT02106520|DRUG|Bevacizumab|
40853818|NCT02106520|DRUG|placebo|
40853819|NCT03071822|DRUG|cisplatin|PIGLETs
40853820|NCT03071822|DRUG|ifosfamide|PIGLETs
40853821|NCT03071822|DRUG|gemcitabine|PIGLETs
40853822|NCT03071822|DRUG|L-asparaginase|PIGLETs
40853823|NCT03071822|DRUG|etoposide|PIGLETs
40853824|NCT03071822|DRUG|dexamethasone|PIGLETs
40853825|NCT05122091|DRUG|Fruquintinib + SOX|Fruquintinib：5mg qd for 2 weeks on and 1 week off, q3w； SOX: Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area），d1-14，q3w； Oxaliplatin：130mg/m2，intravenous (IV) ，d1，q3w.
40853826|NCT00385749|DEVICE|RV apical vs RV septal defibrillation threshold testing|
40853827|NCT00105690|BEHAVIORAL|Telemedicine intervention|
40853828|NCT02017925|BEHAVIORAL|exercise intervention|Undergo pulmonary rehabilitation
40853829|NCT02017925|PROCEDURE|pulmonary complications management/prevention|Undergo pulmonary rehabilitation
40853830|NCT02017925|PROCEDURE|quality-of-life assessment|Ancillary studies
40853831|NCT02017925|OTHER|questionnaire administration|Ancillary studies
40853832|NCT06450392|DRUG|Tranexamic acid injection|100 mg/mL (manufactured concentration) local TXA injection in the orbit
40853833|NCT06450392|DRUG|Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML)|1g IV TXA
40853834|NCT06450392|DRUG|normal saline - injection|0.9% Normal Saline injection in the orbit
40853835|NCT06450392|DRUG|normal saline - intravenous|0.9% IV Normal Saline
40853836|NCT04894890|DRUG|secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription that have started before inclusion of the patient into the study will be enrolled.
41509669|NCT01553669|BEHAVIORAL|reminiscence therapy|The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
41509670|NCT05083065|BIOLOGICAL|Covid-19 vaccine|"* First dose or complete cycle of Comirnaty (Pfizer/BioNTech) vaccine~* First dose or complete cycle of Spikevax (Moderna) vaccine~* First dose or complete cycle of AstraZeneca/Vaxzevria vaccine~* Complete cycle of vaccination using one type of vaccine for the first dose and a different type for the second dose~* Janssen (Johnson \& Johnson) vaccine (single dose)"
41509671|NCT03231488|OTHER|Mindfulness intervention|A 10 minute mindfulness of breath exercise
40853837|NCT00511238|DRUG|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
40676535|NCT06618950|BEHAVIORAL|physical activity|The key factor that distinguishes this study from others is its comprehensive examination of the effects of regular physical activity on late adolescents, not only in terms of physical health but also regarding healthy lifestyle behaviors, self-esteem, and psychological well-being. While other studies typically focus on the benefits of physical activity for physical health, this research considers the broader psychological and social development of adolescents, offering a wider perspective. Additionally, its emphasis on the sustainability of a planned and structured physical activity regimen, along with its approach to transforming physical activity into a lifestyle, represents a significant difference.
40676536|NCT06295991|DEVICE|Lycra garment|Investigation of the effect on balance and respiratory functions by using specially produced lycra garments for 6 hours a day for 16 weeks
40853838|NCT00511238|DRUG|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
40853839|NCT02656953|OTHER|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
40853840|NCT02656953|OTHER|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
40853841|NCT04909658|BEHAVIORAL|ACT Matrix|"The ACT protocol group performs exercises to improve the psychological well-being of parents. The matrix is an ACT protocol that is usually presented visually to patients and consists of two intersecting lines that make up four quadrants, which provide a point of view on one's psychological actions and experiences. The vertical line is the line of experience, the upper part corresponds to the experience of life linked to the five senses - sight, hearing, taste, smell and touch - (experience of the five senses), the lower part refers to the experiences internal as thoughts and feelings (internal/mental experience). The horizontal line is the behavior line, the left side concerns the actions that perform the function of moving us away from experiences, emotions, unwanted thoughts (experiential avoid-ance), the right side indicates the actions we take to get closer and go towards our values (committed action)."
40853842|NCT04909658|BEHAVIORAL|PT Protocol|The PT protocol group received behavioral tasks related to child management. Parent training interventions carried out in groups can be a good solution to modify parent behavior by providing social support and new coping strategies. The intervention includes 24 weekly meetings lasting 90 minutes each. The total intervention is six months.
40853843|NCT05351866|DEVICE|CBT-based mobile intervention for depression|SparkRx is a 5-week program divided into levels intended to be completed weekly. SparkRx is a behavioral activation program. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and participant symptom check (PSC) in the mobile app. Tasks in the mobile app progress in a linear fashion (i.e., each task must be completed to progress to the next task).
40853844|NCT05351866|DEVICE|Mobile control with education about depression|The control mobile application will consist of 5 weeks of educational content about depression. Participants will be instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and PSC in the mobile app.
40853845|NCT01418079|DEVICE|O2 MedTech cerebral oximeter (Oxygen desaturation)|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
40853846|NCT00960479|DRUG|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
40853847|NCT00960479|DRUG|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
40853848|NCT00101985|DRUG|talnetant|
40853849|NCT04247295|DEVICE|Traditional Cast|Application of a traditional cast
40853850|NCT04247295|DEVICE|Woodcast|Application of a woodcast
40853851|NCT06574516|DRUG|Ibuprofen 200 mg|Ibuprofen every 8 hours for three days post operatively
40853852|NCT06574516|DRUG|paracetamol|Paracetamol PRN for three days
40853853|NCT06208774|PROCEDURE|Ultrasound-guided PENG or ISBP block|The diaphragmatic excursion will be measured in the supine position before the block and after surgery. A curvilinear US probe (5-7 MHz) will be placed at the subcostal area in the anterior axillary line, below the costal margin of the eighth and ninth ribs. The probe will be directed medially, cephalad, and dorsally to make the US beam reach the posterior third of the diaphragm perpendicularly. The probe will then be scanned along the long axis of the intercostal spaces, using the liver as the acoustic window on the right side and the spleen as on the left side. M-mode sampling line will be positioned perpendicularly to the diaphragm, and the diaphragmatic excursions could be measured during quiet and deep breathing.The measurement will be repeated three times, and the average value will be taken. After measurement of diaphragmatic excursion, patients will receive either a PENG block or an LV-ISBP block before induction of general anesthesia.
40676537|NCT06423430|DEVICE|Sham-stimulation|Sham-stimulation
40676538|NCT06423430|DEVICE|Active-stimulation|Active DBS
40676539|NCT00427206|DRUG|acetaminophen (4g/day)|
40676540|NCT00427206|DRUG|placebo|
40853854|NCT01478724|DIETARY_SUPPLEMENT|Milk proteins fraction|capsules, one per day, 24 months
40853855|NCT03722394|BEHAVIORAL|Pain Neuroscience Education|15 minute verbal one-on-one education session
40853856|NCT02024724|DRUG|Bupivacaine|4 mL of 0.25% bupivacaine
41037105|NCT03752229|DEVICE|Haemolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
40853857|NCT02024724|DRUG|Triamcinolone|40 mg of Triamcinolone
40853858|NCT02024724|DRUG|Dexamethasone|4 mg of Dexamethasone
40853859|NCT06555484|DEVICE|Cross Over Assignment Supplemental Oxygen and Supplemental Air|"Subjects repeatedly complete memory tests, either first while breathing supplemental oxygen or first while breathing supplemental air (in an order randomly assigned)."
41037106|NCT03752229|DEVICE|Haemolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
40853860|NCT01629758|BIOLOGICAL|Denenicokin|
41384259|NCT03574623|DEVICE|Electrical Stimulator|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).
40853861|NCT01629758|BIOLOGICAL|Nivolumab|
41165993|NCT02925234|DRUG|Talazoparib|Talazoparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of talazoparib might be expected based on their molecular tumor profile.
41384260|NCT03574623|BEHAVIORAL|Occupational Therapy|Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.
40676542|NCT00899171|GENETIC|DNA analysis|
40676543|NCT00899171|GENETIC|DNA methylation analysis|
40676544|NCT00899171|GENETIC|RNA analysis|
40676545|NCT00899171|GENETIC|gene expression analysis|
40676546|NCT00899171|GENETIC|reverse transcriptase-polymerase chain reaction|
40676547|NCT00899171|OTHER|laboratory biomarker analysis|
40676548|NCT04058535|BIOLOGICAL|Eylea|Aflibercept
40676549|NCT04058535|BIOLOGICAL|ALT-L9|Aflibercept biosimilar
40676550|NCT06620406|DIETARY_SUPPLEMENT|Synbiotic IVS-1|A mixture of the prebiotic potato resistant starch (RS, Bobs Red Mill) and the probiotic IVS-1 (Bifidobacterium adolescentis).
40676551|NCT06620406|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin, a carbohydrate packaged similarly to the study intervention
40676554|NCT01953874|DEVICE|MV ASV|Minute ventilation-targeted servo-ventilation therapy.
40676555|NCT01953874|DRUG|Optimized Medical Treatment|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
40676556|NCT00900549|DEVICE|CRT on|12 months
40676557|NCT00900549|DEVICE|CRT off|12-month
40676558|NCT06483815|DIAGNOSTIC_TEST|Culture, İsolation|Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.
40676559|NCT03018496|DIETARY_SUPPLEMENT|Beta-Hydroxy-Beta-Methylbutyrate|
40676560|NCT03018496|OTHER|Placebo|
40676561|NCT05093985|OTHER|Neuromuscular electrical stimulation with blood flow restriction|Neuromuscular electrical stimulation with blood flow restriction
40676562|NCT01565668|DRUG|AC220|oral
40676563|NCT02630329|PROCEDURE|vNOTES adnexectomy|Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
40676564|NCT02630329|PROCEDURE|Laparoscopic adnexectomy|Surgical removal of one or both adnexa by transabdominal laparoscopy
40676565|NCT06621914|DEVICE|BFR 80|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
40676566|NCT06621914|DEVICE|BFR40|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 40% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
40676567|NCT06463587|OTHER|Placebo|Participants will receive placebo matched to cladribine in two courses separated by 4 weeks.
40676568|NCT06463587|DRUG|Cladribine Low Dose|Participants will receive cladribine low dose in two courses separated by 4 weeks.
40676569|NCT06463587|DRUG|Cladribine High Dose|Participants will receive a total of cladribine high dose in two courses separated by 4 weeks.
40676570|NCT05701917|DEVICE|ClotTriever System|Mechanical thrombectomy
40676571|NCT05701917|DRUG|Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.|Anticoagulants are a group of medications that decrease your blood's ability to clot.
40676572|NCT04634240|PROCEDURE|Percutaneous Coronary Intervention (PCI)|PCI of all qualifying lesions.
40676573|NCT00308594|DRUG|Dexamethasone|
40676574|NCT05252390|DRUG|NUV-868|NUV-868 is an investigational drug for oral dosing.
40676575|NCT05252390|DRUG|Olaparib|Olaparib
40676576|NCT05252390|DRUG|Enzalutamide|Enzalutamide
40676577|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment A)|phase 3 tablets
40676578|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment B)|registration tablets
40676579|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment C)|registration tablets
40853862|NCT00924508|DEVICE|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
40853863|NCT00924508|DRUG|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
40853864|NCT01162915|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells.|Intrathecal infusion of a single dose of ex vivo expanded MSC.
40853865|NCT00434109|DRUG|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
40853866|NCT00434109|PROCEDURE|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
40853867|NCT05813002|OTHER|standard neural mobilization|is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
40853868|NCT05813002|OTHER|Distal to proximal neural mobilization|is a distal to proximal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
40853869|NCT05813002|OTHER|proximal to distal neural mobilization|is a proximal to distal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
40853870|NCT03217994|DRUG|gel HP|gel of hygrogen peroxide for teeth bleaching
40853871|NCT01209429|DRUG|GH hormone infusion|Norditropin 30 ng/kg/min
40853872|NCT01209429|BEHAVIORAL|42 hour fast|The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
40853873|NCT01209429|BEHAVIORAL|12 hour fast|12 hour fast will be used as a control scenario to 42 hour fast
40853874|NCT05107622|OTHER|FMUD+Probiotic|Full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation (Lactobacillus paracasei 28.4) twice a day for 30 days.
40853875|NCT05107622|OTHER|FMUD+Placebo|Full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation twice a day for 30 days.
40853876|NCT06578338|OTHER|Physical height measurement|Physical height will be measured and images will be collected for AI to estimate the height
40853877|NCT02736435|DEVICE|Magnetic Resonance Guided High Intensity Focused Ultrasound|Direct treatment of uterine fibroids with MR-HIFU
40853878|NCT02736435|DRUG|leuprolide acetate for depot suspension|Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU
40853879|NCT03009799|DRUG|Iota-Carrageenan|One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
40853880|NCT03009799|DRUG|Carmellose|1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
40853881|NCT05651672|DRUG|Pemigatinib|13.5mg, po, 2 weeks on/1 week off, Q3W
41037107|NCT03752229|DEVICE|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
40853882|NCT06325865|OTHER|Interview|Interview with ALS patient in which the experiences of unpleasant sensations or pain during study procedures are assessed in a qualitative manner.
41384261|NCT06567522|DRUG|Lumbar Erector Spinae Plane Block. L bupivacaína 0.25%|Ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%
41384262|NCT03252015|DRUG|Probe Drug Cocktail|Administered orally
41384263|NCT03252015|DRUG|Lasmiditan|Administered orally
40853883|NCT00970229|DRUG|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not \> 10% of 8 mCi limit)of \[123I\]MNI-420, followed by SPECT imaging.
40853884|NCT02628353|DIETARY_SUPPLEMENT|placebo|1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
40853885|NCT02628353|DIETARY_SUPPLEMENT|phenolic compound|1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
40853886|NCT00277784|PROCEDURE|Ultrasound examination|one ultrasound examination
40853887|NCT04233541|DIAGNOSTIC_TEST|Fall assessment|Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.
40853888|NCT00669383|DRUG|betamethasone|12 mg IM q 24 hours x 2 doses
40853889|NCT00669383|DRUG|placebo|Placebo IM q 24 hours x 2 doses
40853890|NCT00544336|OTHER|questionnaire administration|no intervention
40853891|NCT00544336|OTHER|survey administration|no intervention
40853892|NCT00544336|PROCEDURE|quality-of-life assessment|no intervention
40853893|NCT06400953|OTHER|Kinetic Brain Exercises and Core Stabilization Exercises|Kinetic Brain Exercise Program Kinetic brain exercises were applied to Group 1 in groups of 8-10 people, 2 days a week for 40 minutes for 8 weeks.These exercises include warm-up, main and cool-down phases. Warm-up; These are coordination-oriented movements that include 'brain buttons', 'cross crawl' and 'the thinking cap' exercises. Main phase; These are exercises that include coordination, selective attention, audio-visual focus and balance, consisting of perceptual, independent and dependent movements. Cooling phase; It aims to ensure hand-eye coordination by consisting of double doodle, throwing balls to each other and lazy 8s exercises.Exercises were selected from the kinetic brain exercise pool, modified and applied for 2-8 weeks.The exercises were done while sitting and standing, with increasing difficulty levels. The factor that made the levels difficult was the time and complexity of the incoming command. A game ball with a diameter of 7 cm was used for the exercises.
41037108|NCT03752229|DEVICE|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41384264|NCT03252015|DRUG|Placebo|Administered orally
40853894|NCT06400953|OTHER|Core Stabilization Exercises|Core Stabilization Exercise Program in groups of 8-10 people, for 40 minutes, 2 days a week, for 8 weeks.These exercises included a 5-minute active warm-up, a 30-minute Core Stabilization exercise that included upper and lower extremity movements, and immediately followed by a 5-minute cool-down exercise.The exercises are pilates-based and in the first stage of the program. Movements were performed in standing and sitting positions.Movements were started with 6-8 repetitions, increased by 1-2 repetitions each week, and in the last week, 12-15 repetitions were performed, with contraction times increasing from 5 seconds to 10 seconds. As the exercises progressed from easy to difficult, from simple movements to complex movements, the movements were continued by adding an elastic band and 0.5 kg weight.While advancing the exercise program, the exercises were personalized by taking into account the individual's strain levels.
40853895|NCT00976833|OTHER|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
40853896|NCT00976833|OTHER|Usual Care|Usual Physical Therapy care
40853897|NCT03197922|BEHAVIORAL|MIE Treatment|"Appointments consist of a series of sitting routines (i.e., sits). Each sit consists of 10 min on the toilet, followed by 1 min of standing, then repeating the 10 min on the toilet 1 min off, for up to 32 cumulative minutes of sitting. The first sit occurs prior to the administration of any medication providing an opportunity for an independent continent bowel movement."
40853898|NCT03197922|DRUG|Glycerin Suppository|If no continent bowel movement occurs with the first sit, trained staff administer a dose of a liquid glycerin suppository, immediately followed by another sit to ensure any resulting bowel movement is continent. Glycerin suppositories are replaced by bisacodyl if 2 days pass without a continent bowel movement using the liquid glycerin suppository. Behavioral intervention consists of potent positive reinforcers when a continent bowel movement occurs. As independent continent bowel movements begin to occur, the need for the medical regimen diminishes, and is gradually faded out entirely.
40853899|NCT03197922|COMBINATION_PRODUCT|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
40853900|NCT03731091|DRUG|Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%|Once daily for 4 weeks (28 days)
40853901|NCT03731091|DRUG|Enstilar® foam (LEO Pharma Inc.)|Once daily for 4 weeks (28 days)
41384265|NCT04662086|DRUG|Acebilustat|100 mg capsule administered orally once daily
40853902|NCT03731091|OTHER|Placebo of Calcipotriene/ betamethasone dipropionate topical foam|Once daily for 4 weeks (28 days)
40853903|NCT02799745|DRUG|Enzalutamide|Oral
40853904|NCT02799745|OTHER|Active Surveillance|
40853905|NCT04146935|DRUG|Burosumab Injection [Crysvita]|Burosumab/Crysvita SC injection monthly
40853906|NCT00083005|DRUG|docetaxel|
40853907|NCT00083005|DRUG|estramustine phosphate sodium|
40853908|NCT00083005|DRUG|thalidomide|
40853909|NCT02715986|DEVICE|3T MRI|Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
40853910|NCT04787978|OTHER|Physical Activity and Education Intervention|"The intervention involves peer teams, health coaches and community health workers \[CHW\]. Each participant will be assigned to a CHW and grouped into a team of 10-20 participants based on participant proximity to a Columbus Recreation and Parks Center. Each team will be assigned 4 health coaches, 2 medical students, 1 undergraduate student and 1 nursing student from OSU Health Sciences Colleges.~The lifestyle intervention is 24 weeks consisting of 1 hour and 15 minutes of in person training time per week. The training time consists of 45 minutes of physical activity and 30 minutes of educational content was informed by evidence-based strategies and stakeholder feedback.~Health coaches will implement the curriculum based on the Diabetes Prevention Program and the American Heart Association Check, Change, Control Program and develop team-based SMART (specific, measurable, achievable, relevant, and time-bound) wellness goals."
40853911|NCT00364091|DRUG|R89674 0.025% ophthalmic solution|
40853912|NCT04631848|DEVICE|ULTRASCORE™ Focused Force PTA Balloon|The device will be used for percutaneous transluminal angioplasty (PTA) to dilatate calcified stenoses in below the knee vessels
40853913|NCT00005949|BIOLOGICAL|aldesleukin|Given SC
40853914|NCT00005949|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|Given SC
40853915|NCT00005949|OTHER|laboratory biomarker analysis|Correlative studies
41384266|NCT04662086|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
41384267|NCT02676518|OTHER|serum|Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
41384268|NCT01347983|DRUG|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
41509672|NCT03231488|OTHER|Control intervention (unfocused attention)|A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
40853916|NCT00580385|OTHER|Tissue Procurement|MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
40853917|NCT06524908|BEHAVIORAL|Exercise and dietary calorie restriction|The intervention group received an exercise intervention three times a week (resistance exercise from 4:30-5:00 p.m. and aerobic exercise from 5:00-5:30 p.m.), and a caloric restriction intervention (guided semi-libre diet with caloric intake restricted to 75% of overall consumption, with parents keeping track of calories and food groups and receiving regular check-ups)
40853918|NCT00163020|DRUG|17-alpha-hydroxyprogesterone caproate injectable|250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
40853919|NCT00163020|DRUG|Placebo|Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
40853920|NCT04358224|BIOLOGICAL|Dupilumab Prefilled Syringe|open-label
40853921|NCT05843929|DIAGNOSTIC_TEST|LSCI|"1. A technician delivers a service at the home of the patient, who may be subject to different risk of ulcer, with the aim to analyse his/her foot through an integrated set of measurement technologies, based on:a-the piezoelectric insole that replaces missing pain sensation;b- Laser speckle contrast imaging technique (LSCI) that measures the blood flow;c- the multi points temperature device.~2. Data collected by the technician are sent via internet~3. On the basis of the clinical evaluation and doctor's report on points of foot sensitivity, a 3D model of the foot is created and used by the chiropodist;~4. Using the 3D model of the foot, the chiropodist uses a 3D Editor to design the 3D Model of the insole to enable the production of a tailored insole for the patient shoes~5. The final manufactured insole is then delivered to the patient;~6. A check survey is periodically carried out by the technician to scan the diabetic foot status progress"
40853922|NCT01189981|BEHAVIORAL|Lifestyle counseling|One health conversation at baseline
40853923|NCT01189981|BEHAVIORAL|eHealth intervention|SMS based encouragements to intensive exercise
40853924|NCT02034838|DRUG|atazanavir 300mg boosted with ritonavir 50 mg|"atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.~atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)"
40853925|NCT02377648|DEVICE|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS \<70%) associated with concomitant signs or symptoms of myocardial ischemia.
40853926|NCT04844853|DEVICE|electroencephalography|128-channel electroencephalography
40853927|NCT04844853|DEVICE|Tactile stimulation|Vibrotactile sequence on the forearm
40853928|NCT04844853|BEHAVIORAL|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
40853929|NCT04844853|BEHAVIORAL|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
40853930|NCT04844853|BEHAVIORAL|Laby 5-12|Test of motor planning using labyrinths
40853931|NCT04844853|BEHAVIORAL|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
40853932|NCT04844853|BEHAVIORAL|Stroop animals|Stroop test for preK children using animals instead of words
40853933|NCT05681494|PROCEDURE|Root canal treatment|after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.
40853934|NCT05681494|PROCEDURE|Vital pulp therapy|exposed pulp will be capped with 3 mm calcium silicate material
40853935|NCT00523081|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
40853936|NCT00523081|BEHAVIORAL|Active control|Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
40853937|NCT00952393|DRUG|Pharmacokinetic|Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
41037109|NCT03752229|DEVICE|ergoLance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
40853938|NCT00513435|DRUG|saracatinib|Given PO
40853939|NCT00513435|OTHER|laboratory biomarker analysis|Correlative studies
40853940|NCT00572013|DRUG|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
40853941|NCT00572013|DRUG|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
40853942|NCT00572013|PROCEDURE|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
41037110|NCT03752229|DEVICE|ergoLance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41165994|NCT02925234|DRUG|Dacomitinib|Dacomitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dacomitinib might be expected based on their molecular tumor profile.
41165995|NCT02925234|DRUG|Lorlatinib|Lorlatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of lorlatinib might be expected based on their molecular tumor profile.
41037111|NCT03752229|DEVICE|ergoLance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
40853943|NCT05833997|PROCEDURE|Monopolar Transurethral resection of bladder tumor|"Patients randomized to Monopolar TURBT will be operated using a 26F continuous-flow resectoscope sheaths and a single-pole working element to exclusive use of the resection. The power will be set to cut in 80w and 60w. The technique that will be performed will be the classic endoscopic resection from the top of the tumor until reaching the base, taking a sample from the base of the lesion (muscle layer). Fragments will be removed through an Ellik evacuator, and the solution used will be 3% glycine. After the procedure, the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation.~After 30-60 days of the first procedure, all patients diagnosed with a lamina propria invasion in the uro-pathology analysis (T1) will be submitted to a new monopolar TURBT."
40853944|NCT05833997|PROCEDURE|Holmium Laser resection of bladder tumor (HoLEBT)|"It will be used a 24-26F continuous-flow resectoscope sheath with a specific working element to use with a 600µm fiber to Laser Holmium.~Patients will be operated with the Megapulse 70w (Richard Wolf) and laser will be set to deliver the energy of 0,5J and 30-40Hz frequency, 15-20W of final energy. The solution used will be 0,9% saline solution. The resection will start from the base of the lesion, reaching the muscle layer to obtain a sample and resection of the whole tumor, without fragmentation. After this, the morcellation will be performed in the apex of tumor sparing the base with a long nephroscope, and the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation. The morcellated product will be sent to the pathology lab for detailed analysis."
41384269|NCT05015803|COMBINATION_PRODUCT|CBTi with Application|Participants randomized to this study arm will experience an attempted enhancement of standard video conferencing CBTi, that is facilitated with electronic device-based data and resources to the clinician. Noninvasive ambulatory worn and nearable devices deliver feedback of data to the clinician on an application interface. This information will be used to inform the therapeutic approach and to facilitate a living-space environment that is conducive to effective therapy.
41384270|NCT05015803|BEHAVIORAL|CBTi|Participants randomized to this study arm will experience standard CBTi that is delivered via video conferencing by a clinician, with some application interface use.
41384271|NCT05015803|BEHAVIORAL|Sleep Hygiene Education|Participants randomized to this study arm will experience sleep hygiene education and training, with some application interface use.
41384272|NCT04794049|DRUG|Lactulose|In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
41384273|NCT04794049|DRUG|Polyethylene Glycol (PEG)|In control cohort, patients use the standard split-dose bowel preparation regimen,
41384274|NCT06566222|PROCEDURE|chemoradiotherapy after surgery|chemoradiotherapy after surgery vs preoperative chemoradiotherapy
41384275|NCT06566222|OTHER|High-risk Factors|High-risk Factors vs low-risk Factors
41384276|NCT03657576|BIOLOGICAL|C134|C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.
41384277|NCT03533335|OTHER|Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)|Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
41384278|NCT05393830|BEHAVIORAL|Sleep Restriction|Three nights of sleep restricted to 4 hours per night.
41384279|NCT05935618|BEHAVIORAL|ACT-ING program ( Activity-based skill- and strength training to improve ingestion)|The intervention is based on a client-centered Occupational therapy task-oriented approach, in which real objects are employed in a realistic context. The intervention uses the effortful swallowing in combination with advancing steps of liquid and food items as resistive forces to challenge the swallow in a safe environment during eating and drinking activities. Progression is realized based on pre-determined progression rules to ensure the right challenges in combination with safety (Hansen et al, 2023).
41384280|NCT06564155|DEVICE|carotid duplex|measure Carotid intima media thickness
41384281|NCT02024386|DRUG|Riociguat|After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
41384282|NCT01583400|OTHER|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
41384283|NCT01583400|OTHER|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
40676580|NCT05024240|DIAGNOSTIC_TEST|Stabilometry|Probands will stand on stabilometric platform (double leg stance) and we will measure CoP parameters area and length. We also make this task harder by using foam and exclusion of visual control. Length of one test is 30s.
40676581|NCT05024240|DIAGNOSTIC_TEST|Stroop test|There are various names of colours written in non-matching font colour in this test. During this test probands are required to name the colour which is written in text not the colour of the font. We will measure reaction time and number of mistakes.
40676582|NCT05024240|DIAGNOSTIC_TEST|Backward counting test|In this counting test probands are given number from interval \<180-200\> and they are asked to subtract 7 during 30s interval of the testing. We will measure reaction time and number of mistakes.
40676583|NCT06590402|DRUG|Bupivacaine, Dexamethasone in Adductor Canal Block|0.25% 15-20ml bupivacaine (local anesthestic) delivered as part of the adductor canal block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the adductor canal block
41384284|NCT04824573|DEVICE|Inspiratory Muscle Training|Inspiratory Muscle Training (IMT) was performed with Powerbreathe Classic-Light Resistance device. To determine the intensity of the training, MIP values were measured with the help of the respiratory pressure meter-RP Check (MD Diagnostics Ltd. RP Check MIP \& MEP) device before each training. The pressure corresponding to 50 percent of the MIP value in the Powerbreathe device was determined as training workload. It was applied two days a week for four weeks, with five-set and five repetitions, for 20 minutes with 30 seconds rest in between. This inspiratory muscle training program has previously been used by several studies to improve respiratory muscle strength.
40676584|NCT06590402|DRUG|Bupivacaine, Dexamethasone in Anterior Femoral Cutaneous Nerve Block|10 ml of 0.25% bupivacaine (local anesthetic) delivered as part of the anterior femoral cutaneous nerve block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the anterior femoral cutaneous nerve block
40853945|NCT04550169|OTHER|Intensive Care Coordination|"Intensive care coordination will include:~* Discharge instructions and contacts for following up on care and treatment~* Referral information~* Appointment scheduling~* Medication instructions~* Intensive care coordination by a social worker, case manager, nurse, or care coordinator to connect Medical Assistance (MA) recipient to a primary care provider or to a managed care organization~* Information about other health and social resources, such as transportation and housing~* Sharing of information (discharge instructions, medication information, and care plan information) with managed care organization in which patients are enrolled, if applicable"
41384285|NCT04824573|OTHER|Manual Therapy|"In the manual diaphragm release technique; While the participant was breathing in, the physiotherapist raised his hand slowly to accompany the rising movement of the ribs and deepened the contact during exhalation. The maneuver was performed in two sets of 10 deep breaths.~In thoracic mobilization application; The physiotherapist, standing behind the participant, wrapped the crossed arms from his right upper arm with his left hand and performed stretching, extension, lateral flexion, and thoracic rotation with his right hand.~In HVLA thoracic manipulation; the physiotherapist, with the support hand on the participant's elbows, applied HVLA thrust in the posterior-anterior and inferior-superior directions with the help of his body while the manipulating hand was on the transverse processes.~For cervical joint mobilization; the physiotherapist was applied using the right hand in flexion, extension, right-left rotation, and lateral flexion directions."
41384286|NCT05669924|DRUG|Methylphenidate|0.35 mg/kg methylphenidate will be administered after baseline testing and 45 min-1 hr before post-intervention testing.
41384287|NCT05669924|DRUG|Placebo|Placebo for methylphenidate
41384288|NCT03026868|PROCEDURE|quadrilateral surface plate|Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
41384289|NCT06563050|PROCEDURE|Nebulized lidocaine|Subjects in group A underwent nebulization with 5 mL of 2% lidocaine for 15 minutes by using a jet nebulizer.
41384290|NCT06563050|PROCEDURE|Lidocaine spray|Subjects in group B will underwent 10% lidocaine spray solution will be sprayed 10 times at the oropharynx at 5 s interval.
41384291|NCT06563050|PROCEDURE|Combination of nebulized lidocaine and lidocaine spray|Group C: both nebulization and spray will be performed in the same manner except the number of spray will be 2 instead 10.
41384292|NCT03323359|DEVICE|Hemopatch|Hemopatch is applied upon the verification made by the surgeon of the presence of an appropriate target bleeding site in the hepatic parenchyma. At the time point of application a stopwatch starts simultaneously. Time to hemostasis is defined as the time required to obtain successful haemostasis in a single bleeding site. At 3 minutes the inspection will be made and, if haemostasis is not achieved, the treatment is considered failed and the Principal Investigator and/or his delegates is allowed to use additional haemostatic measures.The time to haemostasis will be recorded in the patient's medical record and in the electronic Case Report Form. The bleeding site will be observed for 1 additional minute at the end of the haemostatic procedure and, of the surgery to confirm the haemostasis.
41384293|NCT03323359|PROCEDURE|Common Surgical Techniques|Patients undergoing liver resection for any underlying disease and with resectable mass. The list of the underlying diseases is the following (but might not be limited to): Hepatocellular carcinoma, Hilar cholangiocarcinoma, Adrenal cancer metastasis, Breast cancer metastasis, Colorectal cancer metastasis, Ovarian cancer metastasis, Biliary carcinoma, Hemangioma, Hepatic adenoma, Focal nodular hyperplasia, Unilocular hydatid cyst, Multilocular, hydatid cyst.
41384294|NCT04635631|DRUG|talazoparib|Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
41384295|NCT00518011|DRUG|Erlotinib|150 mg po daily
41384296|NCT00518011|DRUG|Gemcitabine|As prescribed
41384297|NCT01912547|PROCEDURE|Blood draw for TEG analysis|Blood drawn for TEG analysis
41384298|NCT06555952|DRUG|MegaNatural-BP SR 150Mg Tablet|GSE MegaNatural BP
40676585|NCT02414178|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
40676586|NCT01054300|DRUG|Ertugliflozin 2 mg single dose|Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose
40676587|NCT01054300|DRUG|Ertugliflozin 2 mg split into twice daily|Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day
40676588|NCT01054300|DRUG|Ertugliflozin 4 mg single dose|Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose
40676589|NCT01054300|DRUG|Ertugliflozin 4 mg split into twice daily|Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day
40676590|NCT01054300|DRUG|Placebo|Placebo to ertugliflozin administered as a single dose
40676591|NCT06137638|DRUG|ENA-001|ENA-001 will be prepared in Ringer's lactate solution. A loading dose will be administered for 20 minutes followed by continuous infusion until the patient meets the criteria for PACU discharge (≥ 9 Aldrete score) or ABG reveals PaCO2 \< 30 mmHg with pH in the normal range. ENA-001 is for IV injection ready for use per subject by the investigational pharmacy, according to the randomization schedule.
40676592|NCT06608186|DRUG|Cetrorelix drug|a drug injection daily sc. from day 5 of stimulation till hCG trigger day
40853946|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
40853947|NCT04611802|OTHER|Placebo (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
40853948|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21
40853949|NCT04611802|OTHER|Placebo (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21
40853950|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
40853951|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)|In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
40853952|NCT01966224|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose."
40853953|NCT02623621|DRUG|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
40853954|NCT01445197|BIOLOGICAL|Biostate|200 IU/kg administered daily
40853955|NCT04560387|BEHAVIORAL|Physician-lead complex program of weight-reducing interventions|A structured motivational and goal directed program will be used for weight reduction involving physicians, nutritionists, educators and physiotherapists. Initially, based on the input data provided by the patient an individual nutritional plan will be designed with the aim of reducing caloric intake by 10%. Low-intensity aerobic exercise for 30 min will be prescribed 3-times a week with the aim of increasing the frequency to 5-times a week and participants will be offered the possibility to participate in regular physiotherapist-lead group exercises. Patients will be required to maintain a diet and physical activity diary. Regular reviews will be scheduled every 3-6 months according to the actual weight loss.
40853956|NCT04560387|PROCEDURE|Bariatric surgery - sleeve gastrectomy|Bariatric surgery will be performed based on actual medical indication and independently of patient's participation in the study. Sleeve gastrectomy was selected as the currently most frequent restrictive type of bariatric surgery with a proven efficacy on weight reduction, metabolic status and low-grade inflammation
40853957|NCT05487417|DRUG|Minocycline|Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
40853958|NCT04240158|DRUG|IW-6463|IW-6463 Tablet
40853959|NCT04240158|DRUG|Matching Placebo|Matching Placebo Tablet
40853960|NCT06297382|BEHAVIORAL|ChatGPT Based Nursing Process Training|"ChatGPT Based Nursing Process Training topics:~Lesson 1: Use of artificial intelligence and ChatGPT in healthcare Lesson 2: Using ChatGPT in determining nursing diagnoses and goals Lesson 3: Using ChatGPT to determine nursing interventions Lesson 4: Things to consider and ethical principles when using ChatGPT when creating a nursing process."
40853961|NCT02051322|DEVICE|Jet Nebulizer|
40853962|NCT02051322|DEVICE|Trunk Mask Nebulizer|
41165996|NCT02925234|DRUG|Erdafitinib|Erdafitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erdafitinib might be expected based on their molecular tumor profile.
41165997|NCT02925234|DRUG|Alpelisib|Alpelisib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of alpelisib might be expected based on their molecular tumor profile.
41165998|NCT02925234|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of niraparib might be expected based on their molecular tumor profile.
41165999|NCT02925234|DRUG|Pemigatinib|Pemigatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of pemigatinib might be expected based on their molecular tumor profile.
40853963|NCT02051322|DEVICE|Aerobika Nebulizer|
40853964|NCT01925547|DIETARY_SUPPLEMENT|Micellar curcumin|80 mg micellar curcumin (oral) three times a day for six weeks
40853965|NCT01925547|DIETARY_SUPPLEMENT|Placebo|Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
40853966|NCT00003336|BIOLOGICAL|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
40853967|NCT00003336|DRUG|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
40853968|NCT00003336|DRUG|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
40853969|NCT00003336|DRUG|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
40853970|NCT00003336|DRUG|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
40853971|NCT00003336|PROCEDURE|bone marrow ablation with stem cell support|
40853972|NCT00003336|PROCEDURE|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
40853973|NCT00003336|RADIATION|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
40853974|NCT04459871|BIOLOGICAL|recombinant human Thrombin(CHO cell)|2 rhThrombin, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
40853975|NCT04459871|BIOLOGICAL|placebo|placebo, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
40853976|NCT03219346|OTHER|oral care program|Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
40853977|NCT04153682|DIAGNOSTIC_TEST|Rapid Diagnostic Testing|Automated microbiological diagnostic device based on multiplex PCR analysis, allowing detection of multiple pathogens and resistance markers in one hour from invasive and non-invasive respiratory samples
40853978|NCT04153682|DIAGNOSTIC_TEST|Antimicrobial stewardship|After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).
40853979|NCT02564978|DRUG|Minocycline|Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
40853980|NCT03105336|BIOLOGICAL|axicabtagene ciloleucel|A single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered intravenously.
40853981|NCT03105336|DRUG|Cyclophosphamide|Administered intravenously
40853982|NCT03105336|DRUG|Fludarabine|Administered intravenously
40853983|NCT04043468|OTHER|Audit and feedback|Audit and feedback (A\&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.
40853984|NCT05017467|DRUG|undefinedCentella Asiatica Extract|"All patients were asked about scar hypertrophy, scar tenderness, and pillar pain.~The scar assessment was performed using the Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery.~Patients were asked to complete pre- and postoperative functional evaluations. The VAS score and QuickDASH test was used"
41037112|NCT03752229|DEVICE|Medlance (light blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037113|NCT03752229|DEVICE|Medlance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41166000|NCT02925234|DRUG|Selpercatinib|Selpercatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of selpercatinib might be expected based on their molecular tumor profile.
41166001|NCT02925234|DRUG|Tepotinib|Tepotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of tepotinib might be expected based on their molecular tumor profile.
41166002|NCT02230306|DRUG|Cobimetinib|60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
41166003|NCT02230306|DRUG|Vemurafenib|960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
41384299|NCT06555952|OTHER|Placebo Capsule|given in place of GSE MegaNatural BP
40853985|NCT00892775|BIOLOGICAL|Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
40853986|NCT00892775|BIOLOGICAL|GSK Biologicals' 208136, new formulation|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
40853987|NCT00782483|DEVICE|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
40853988|NCT00782483|DEVICE|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
40853989|NCT00782483|DEVICE|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
41384300|NCT02215434|DRUG|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
41384301|NCT02215434|DRUG|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
40853990|NCT03274063|OTHER|Supported self-management|Participants will be supplied with urate self-testing kits. Participants will have a mobile phone application installed which will prompt the participant to perform urate self-testing, enable the clinical research team to advise on escalation of urate lowering therapy, and collect quality of life data .
40853991|NCT03274063|OTHER|Usual care|Participants will have a mobile phone application installed which will allow the research team to collect quality of life data.
41384302|NCT06569030|BIOLOGICAL|spinal orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
41384303|NCT03759301|DRUG|Growth Hormones Somatropin Recombinant|Growth Hormones Somatropin Recombinant 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup
40853992|NCT01688115|PROCEDURE|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
41384304|NCT03759301|DRUG|Placebo saline solution|same volume as growth hormone ampule used
41384305|NCT02469675|DEVICE|Transcranial magnetic stimulation|One TMS pulse every 10 seconds for 20 minutes
41384306|NCT02469675|DEVICE|Median nerve stimulation|One median nerve pulse every 10 seconds for 20 minutes
41509673|NCT05991869|BEHAVIORAL|Point-of-care decision support intervention|"PCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as high priority one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly."
40853993|NCT01688115|OTHER|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
40853994|NCT05065853|DIAGNOSTIC_TEST|urine self-sampling group|collection of urine and vaginal samples
41037114|NCT03752229|DEVICE|Medlance (dark blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037115|NCT03752229|DEVICE|Medlance (yellow)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41384307|NCT02469675|DEVICE|Cervical transcutaneous stimulation|One cervical pulse every 10 seconds for 20 minutes
41384308|NCT06135129|DEVICE|Sonoelastography|Sonoelastography (SE) is a new ultrasound-based method measure the stiffness or elasticity of tissues, has no hazards on poatients.
41509674|NCT04779879|BIOLOGICAL|Sotrovimab (Gen1)|Participants will be randomized to receive an IV infusion of Sotrovimab Gen 1 material
41509675|NCT04779879|BIOLOGICAL|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion or by IM injection
41509676|NCT04779879|BIOLOGICAL|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion
41509677|NCT05065710|DRUG|ZL-1211|Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort
41509678|NCT00377832|DRUG|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
41509679|NCT03669185|DRUG|Pentalong|Pentalong, 2 x daily 1 tablet, intake max. 133 days
41509680|NCT03669185|DRUG|Placebos|Placebos, 2 x daily 1 tablet, intake max. 133 days
40853995|NCT05065853|DIAGNOSTIC_TEST|clinician-collected cervical sample group|A clinician takes a smear from cervix according to standard routine
41509681|NCT05949697|DIETARY_SUPPLEMENT|Dry Eye Drink|Dry Eye Drink is a dietary supplement containing electrolytes, vitamins and natural anti-inflammatories.
41509682|NCT05546008|DEVICE|Multislice CT|all patient will be subjected to echocardigraphy and multislice ct and compare thier results
40853996|NCT02632357|OTHER|Spinal Manipulation|
40853997|NCT01754493|DRUG|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
40853998|NCT03364309|DRUG|Ixekizumab|Administered SC
40853999|NCT03364309|DRUG|Placebo|Administered SC
40854000|NCT06340893|BEHAVIORAL|Exercise|Participants will participate in cardiovascular, agility, balance, strength and coordination training.
40854001|NCT06340893|BEHAVIORAL|Restful Play|This group will engage in restful play activities such as coloring and playing with legos.
40854002|NCT05590507|BEHAVIORAL|Mindfulness Audio Recordings|A 5-minute audio file aimed to increase likelihood of experiencing positive affect associated with physical activity. Participants will listen to a mindfulness audio file at the beginning of each physical activity session they choose to engage in during weeks 2-4
41037116|NCT03752229|DEVICE|Medlance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037117|NCT03752229|DEVICE|Medlance (red)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037118|NCT03752229|DEVICE|Unistik 3 Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41384309|NCT05943158|DRUG|myoinositol and folic acid|The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
41384310|NCT05943158|DRUG|folic acid|The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
41384311|NCT04957316|DEVICE|Triple-effect blood purification filter|Blood purification using the oXiris filter to remove endotoxin, cytokines, and uremic toxins.
41384312|NCT00782275|DRUG|bevacizumab|
41384313|NCT00782275|DRUG|temsirolimus|
41384314|NCT05987527|DIAGNOSTIC_TEST|Urine sample|Routine procedures
40854003|NCT00932867|DRUG|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
41384315|NCT05987527|DIAGNOSTIC_TEST|Blood sample|Routine procedures
41384316|NCT05987527|OTHER|Lifestyle questionnaire|Lifestyle questionnaire
40854004|NCT00765804|DRUG|EGP-437 with EyeGate® II System|Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
40854005|NCT00765804|DRUG|Sodium citrate buffer solution with EyeGate® II System|Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
41384317|NCT02351206|RADIATION|x-ray, MRI|
41384318|NCT00446771|DRUG|Mannitol|
41384319|NCT05972954|DRUG|OMT-28|once daily
41384320|NCT06520371|DEVICE|Percutaneous radiofrequency|For the percutaneous radiofrequency treatment, a medium electrode size will be placed on either side of the knee: one skin electrode on the inside and one on the outside of the knee for 15 minutes.
41384321|NCT06520371|DEVICE|Conventional radiofrequency|For the conventional radiofrequency treatment, a 50 Hz sensory stimulation will be performed with a 10 cm, 22 gauge, 10 mm active tip radiofrequency cannula. After receiving the appropriate sensory and motor stimuli, a radiofrequency of 90°C will be applied for 90 s.
41384322|NCT02414165|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
41384323|NCT02414165|DRUG|Toca FC|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
41384324|NCT02414165|DRUG|Lomustine|
41384325|NCT02414165|DRUG|Temozolomide|
41384326|NCT02414165|BIOLOGICAL|Bevacizumab|
41384327|NCT06039007|DIETARY_SUPPLEMENT|7-day Fasting-Mimicking Diet (7-DAY FMD)|This medically-designed dietary kit supplies food for 7 days, with Day 1 providing 1100 kcal, while days 2 to 5 provide 800 kcal per day.
41384328|NCT02046239|PROCEDURE|Suture Group|
41384329|NCT02046239|BIOLOGICAL|Staple Group (control)|
41384330|NCT03495700|PROCEDURE|L-PRF block|The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed
41384331|NCT03495700|PROCEDURE|DBBM|The use of bovine xenograft will be analysed
41384332|NCT04843501|BEHAVIORAL|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|CMB has 4 developmentally appropriate e-cigarette lessons, 20-30 minutes in each of 6th-8th grades. Strategies include small and large group discussions, parent interviews, role-plays, media literacy, and goal setting. E-cigarette focused science and humanities activities (2 per school year) are also provided. An informational tool kit will be provided to parents. Finally, 8 activity-based E-cig PE lessons are intended for either 7th or 8th grades, depending on school calendar. CMB provides study materials to teachers through an online access portal. A site-based management team will oversee program implementation. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar, offered at multiple times to accommodate teaching schedules. Project staff will meet routinely with participating schools to answer study questions.
41509683|NCT03088761|DEVICE|cuffed tracheal tube|the changes in cuff pressure will be determined using a cuff manometer
40854006|NCT00657579|DRUG|DE-104 ophthalmic solution, low concentration|
40854007|NCT00657579|DRUG|DE-104 ophthalmic solution, medium concentration|
40854008|NCT00657579|DRUG|DE-104 ophthalmic solution, high concentration|
41384333|NCT04843501|BEHAVIORAL|Texas Education Agency (TEA) required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes TEA developed online lessons and support materials and also includes elements of the CDC Know the Risks e-cigarette prevention program. This can be considered 'usual care'
41509684|NCT00295425|DRUG|Cyclosporine A versus mycophenolate mofetil for psoriasis|
41509685|NCT02065076|DRUG|Sodium polystyrene sulfonate|
41509686|NCT02065076|DRUG|Lactose with carob gum|
41384334|NCT06124534|DEVICE|Neurostimulation of the Occipital Nerve Field|BliStim Neurostimulation system
40854009|NCT00657579|DRUG|DE-104 vehicle|
40854010|NCT02776059|DRUG|Standard of care + pegfiltrastim|prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
40854011|NCT02776059|DRUG|Standard of care|Oral prednisolone or pentoxifyline for 28 days only
40854012|NCT00304655|DRUG|Aripiprazole|
40854013|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
41384335|NCT00924573|DRUG|Metformin|oral administration
41509687|NCT02618525|OTHER|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
40854014|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
41509688|NCT02618525|OTHER|Jaw thrust maneuver|Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
40854015|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
40854016|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
40854017|NCT00348309|DRUG|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
40854018|NCT00348309|DRUG|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
40854019|NCT00348309|OTHER|Placebo|Placebo
41509689|NCT06581029|OTHER|The multidimensional peer victimization scale (PVS)|The multidimensional peer victimization scale (PVS), a self-report scale for children and adolescents, was used to assess the victimization
41509690|NCT03284723|DRUG|PF-06804103|Dose Escalation Part - 1A Dose Expansion Part - 2A
41509691|NCT03284723|DRUG|PF-06804103 + Palbociclib +Letrozole|Dose Escalation - Part 1B Dose Expansion - Part 2B
41509692|NCT02905032|BEHAVIORAL|Decision Aid|Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
41509693|NCT03875924|OTHER|VWD treatments|Modalities and types of treatments in VWD patients for severe hemorrhagic events: INN, quantities, duration of treatment
41509694|NCT00002376|DRUG|Indinavir sulfate|
41509695|NCT00002376|DRUG|Lamivudine|
41509696|NCT00002376|DRUG|Stavudine|
41166004|NCT02406274|OTHER|Contrast Enhanced Spectral Mammography (CESM)|Women presenting to MSKCC with a palpable abnormality within the breast either self palpated \& or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) \& record their findings. They will then interpret the CESM \& record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding \& will either be called negative \& followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
41166005|NCT02950688|BIOLOGICAL|Seasonal LAIV|10\^7.0 fluorescent focus units (FFU); administered by intranasal spray
41166006|NCT02950688|BIOLOGICAL|Placebo|Administered by intranasal spray
41166007|NCT02950688|BIOLOGICAL|Wild-type A/California/2009-like Influenza Virus|Approximately 3.5 x 10\^6 TCID50; administered intranasally
41166008|NCT06126510|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)|VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle
41384336|NCT00924573|DRUG|placebo|oral administration
41509697|NCT00002376|DRUG|Zidovudine|
41509698|NCT00002376|DRUG|Didanosine|
41509699|NCT03774355|DRUG|CG1801|Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.
41509700|NCT03774355|DRUG|CGL1802|Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
40854020|NCT00348309|OTHER|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
40854021|NCT04166097|OTHER|Heart Smart Interventional Program|6-week program consisting of weekly didactic sessions that follow the steps outlined in the book.
41037119|NCT03752229|DEVICE|Unistik 3 Comfort|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41384337|NCT00924573|DRUG|Glimepiride (HOE490)|oral administration
41384338|NCT06269965|DEVICE|Regeneten® adding|Arthroscopic shoulder repair, in double row, with complete coverage of the foot print and addition of Regeneten®
41509701|NCT03643861|RADIATION|5 Fraction Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas
41384339|NCT00391092|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
41384340|NCT00391092|DRUG|Docetaxel|100mg/m2 iv every 3 weeks
41509702|NCT04561271|OTHER|foot reflexology|Patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. A neutral oil will be used. The technique associates specific movements of foot reflexology. The session is accompanied by relaxing music.
41509703|NCT04561271|OTHER|toucher massage|one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
41037120|NCT03752229|DEVICE|Unistik Touch|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41384341|NCT00391092|DRUG|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
41384342|NCT01353794|DRUG|Sorafenib (Nexavar, BAY43-9006)|The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
41384343|NCT01102972|DRUG|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
41384344|NCT01102972|DRUG|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
41509704|NCT01662219|OTHER|Superficial cervical plexus block for experimental group|15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
41509705|NCT05645549|BEHAVIORAL|Centering Pregnancy with Care Navigation|Centering Pregnancy is a group based prenatal care intervention. Centering Pregnancy is an evidenced based intervention that has 10 group sessions for pregnant women. Each session has dedicated educational material relative to pregnancy, birth, and infant feeding. In addition, all participants will be provided a bilingual Marshallese care navigator to aid in enrolling them in social support services.
41509706|NCT00139893|DRUG|Reglan ODT|
40854022|NCT02717039|PROCEDURE|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
40854023|NCT04448769|BIOLOGICAL|Anti-SARS-CoV-2 IgT seropositivity|"Each inhabitant who agrees to participate will have to :~* sign the consent form after receiving complete information~* complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms.~* take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM)."
40854024|NCT03821610|DRUG|Fludarabine|IV
40854025|NCT03821610|DRUG|Melphalan|IV
40854026|NCT03821610|DRUG|Alemtuzumab|IV
40854027|NCT03821610|DRUG|Cyclophosphamide|IV
40854028|NCT03821610|DRUG|Mesna|IV
40854029|NCT03821610|RADIATION|Total Body Irradiation (8Gy)|TBI (8Gy)
40854030|NCT06451562|DRUG|Lidocaine|a local anesthetic drug of the amino amide type
40854031|NCT05107765|DRUG|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by end of week 1, which is within standard titration parameters as per the investigator's brochure.
40854032|NCT05107765|DRUG|Placebo|Pill capsules will look same as that of active drug.
40854033|NCT05476172|DRUG|Dienogest Pill|The effect of dienogest on endometriosis pain symptoms.
40854034|NCT05476172|DRUG|Norethindrone Acetate|The effect of Norethindrone Acetateon endometriosis pain symptoms.
40854035|NCT01775605|DRUG|Synera|Synera Pain Patch
40854036|NCT02502825|OTHER|methacholine|methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
40854037|NCT02502825|DEVICE|Wright Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
40854038|NCT02502825|DEVICE|Devilbiss646 Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
40854039|NCT05992350|OTHER|Garmin physical activity tracker|The Garmin physical activity tracker is worn like a watch on the user. The tracker assesses several physical states, indicates when the body is at optimal time for activity or when the body needs to rest. The tracker also monitors stress levels and prompts relaxation when appropriate. The tracker sets goals with participants based on previously completed activity. The tracker alerts participants after a period of inactivity, encourages regular movement throughout the day, and decreases the amount of time spent sedentary.
41037121|NCT03752229|DEVICE|ReadyLance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037122|NCT03752229|DEVICE|ReadyLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037123|NCT03752229|DEVICE|AssureLance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41180039|NCT00746629|BEHAVIORAL|FOCUS|"Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit."
40854040|NCT04310566|DEVICE|JJVC Investigational Multifocal Contact Lens (senofilcon A c3)|TEST
40854041|NCT04310566|DEVICE|Dailies Total 1® Multifocal Contact Lens|CONTROL
40854042|NCT01267942|DRUG|Enhancin|"Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm."
40854043|NCT03742453|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
40854044|NCT03742453|DIAGNOSTIC_TEST|EOB-MRI|EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
40854045|NCT06205082|DRUG|LIT-00814|LIT-00814 is an oral tablet.
40854046|NCT01835002|DEVICE|Transcorneal electrostimulation|Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
40854047|NCT01622465|BEHAVIORAL|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
40854048|NCT01622465|BEHAVIORAL|Conventional exercises|Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
40854049|NCT06215313|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|In the EMDR condition, the Dutch version of the treatment protocol based on Shapiro's original work (2001) is followed. In the first session, the rationale of EMDR is explained. The patient describes the memory, and identifies the most aversive still image, the associated negative cognition, desired positive cognition, feelings, somatic sensations, and perceived tension, as measured by Subjective Unit of Distress (SUDs). Desensitization then begins by asking patients to focus on the still image while following the movement of a light bar or the therapist's fingers with their eyes (i.e., eye tracking task). Then, in the installation phase, the patient focuses on the positive cognition during the eye tracking task. When the validity of the positive cognition is 6 to 7 on a 7-point Likert scale, a body scan is performed to ensure that no unresolved traumatic material remains. Each session ends with a reflection and debriefing.
40854050|NCT06215313|BEHAVIORAL|Imagery Rescripting|The IR condition, following Arntz and Weertman's (1999) protocol, addresses traumatic or aversive memories by creating alternative scenarios. In the first session, the method is explained. The patient describes their memory in the present tense, from the first-person perspective, and describes associated feelings, thoughts, and emotional needs. The therapist then seeks permission to 'enter' the scene, guiding the patient to visualise an alternative, emotionally satisfying course of events. This may involve the therapist or patient intervening in the situation, ensuring the patient's emotional needs are met. The patient then relives the memory from the point of view of their younger self, with the adult-self intervening in the scene. The process continues until all emotional needs are fulfilled. Generally, one trauma memory is rescripted per session. The initial IR session involves therapist-led rescripting, with subsequent sessions encouraging patient-led rescripting whenever possible.
40854051|NCT02202369|OTHER|Multimodal Analgesia Treatment|Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
40854052|NCT02202369|OTHER|Standard of Care Pain Management Protocol|Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
40854053|NCT06525480|PROCEDURE|Percutaneous pulmonary thrombectomy|Pulmonary thrombus extraction
40854054|NCT02020317|BEHAVIORAL|decision support in potassium-inc. drug-drug-interactions|display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
40854055|NCT05889637|DIAGNOSTIC_TEST|Gastric ultrasound|Patient will be scanned first in the supine position and then in the right lateral decubitus position. The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region. Qualitative and quantitative assessments will be done.
40854056|NCT00559221|DRUG|FLAG+IDA|Fludarabine, cytarabine, G-CSF
40854057|NCT06583681|OTHER|The measuring of the sagittal curvatures of the spine|Research tool was Baseline Bubble inclinometer.
40854058|NCT04569981|OTHER|Climbing|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
40854059|NCT04569981|OTHER|Unsupervised activity group|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
40854060|NCT04383327|BEHAVIORAL|ParentCorps-Professional Development (PD)|Multi-component school-based intervention that promotes early childhood mental health and development. Teachers and PTAs (pre-primary to 4th grade) will participate in a 3-day ParentCorps-PD training before the 1st school term. They will also receive 8 sessions (12 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
40854061|NCT04383327|BEHAVIORAL|T-Wellness|A brief teacher stress management psychoeducation package, adapted from EBIs including a half-day workshop for common stress management and a half-day for burnout management, and three follow-up group support sessions (3 additional monthly 1-hr wellness sessions for teachers as a group in each school, a total 15 hours of coaching).
40854062|NCT01255995|DEVICE|Capsular Tension Ring|Capsular Tension Ring
40854063|NCT02908750|DRUG|Fexofenadine tablet dosing|Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
41037124|NCT03752229|DEVICE|AssureLance MicroFlow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037125|NCT03752229|DEVICE|Surgilance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037126|NCT03752229|DEVICE|Surgilance Lite (grey)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037127|NCT03752229|DEVICE|Surgilance Lite (purple)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41509707|NCT00700362|PROCEDURE|Insulin infusion (aspart)|The insulin infusion, a fast acting insulin analog (aspart) in 1 Unit/ml of NaCl, starts when the patients full fill the eligibility criteria and has signed the informed consent. The intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
40854064|NCT02908750|DRUG|Osimertininb tablet dosing|Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
40854065|NCT01678625|DEVICE|Train-of-four ratio calculation (T4-EMG)|TOF ratios will be compared between the EMG and AMG groups
40854066|NCT02450513|DRUG|Adalimumab|160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
40854067|NCT00658463|DRUG|Rosuvastatin|rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
40854068|NCT00658463|DRUG|Placebo|Placebo
41037128|NCT03752229|DEVICE|SteriLance Lite2|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037129|NCT03752229|DEVICE|SensiLance (pink)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41180040|NCT06109597|OTHER|75 g glucose tolerance test|Pregnant patient who visited obstetric clinic , who did 75 g glucose tolerance test
40854069|NCT01920308|DEVICE|5 mm Bard LifeStent Vascular Stent|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
40854070|NCT06307093|DRUG|RPH-075|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
40854071|NCT06307093|DRUG|Keytruda®|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
40854072|NCT04138680|BEHAVIORAL|Active Biofeedback|"The active biofeedback session will be done within the 7T MRI. It will include a pre-training run, 3 training runs, and a post-training run. Each run will be comprised of MOTIVATE and REST trials. During each MOTIVATE trial, subjects will be instructed to generate a heightened state of motivation. Participants will be encouraged to identify strategies that are personally relevant or useful and to monitor the efficacy of the strategies. Subjects will simultaneously view a progress bar on the screen during MOTIVATE trials that represents their VTA activity and they will be trained to try to increase the level of the bar by motivating themselves. For the active VTA biofeedback group, the progress bar will be updated every second to accurately convey level of VTA signal activation. During REST trials, all subjects will be instructed to count backwards. During the post-training 'test' run, subjects will be instructed to use the strategies they found to be most effective."
40854073|NCT04138680|BEHAVIORAL|Sham Biofeedback|The sham biofeedback session resembles the active condition, however, the thermometer seen during the MOTIVATE trials will represent yoked sham values.
40854074|NCT01549925|OTHER|Standard Surgical resection|standard surgical resection using clamps and surgical ligatures
40854075|NCT01549925|DEVICE|LIGASURE|resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
40854076|NCT03322410|BIOLOGICAL|modified Peritoneal Equilibration test|"Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky~*  High : D/P creatinine\>0,8; D/D0 glucose\<0,25~*  High average : 0,65\< D/P creatinine \<0,8; 0,25\< D/D0 glucose \<0,38~*  Low average : 0,5\< D/P creatinine \<0,65; 0,39\< D/D0 glucose \< 0,48~*  Low  : D/P creatinine\<0,5 ; D/D0 glucose\>0,49."
40854077|NCT05693506|OTHER|Cooking workshops|Cooking workshop in classic form, i.e. with recipes imposed by the dietician on the participants, or cooking workshops in the form of culinary challenges, i.e. without imposed recipes but according to the creativity of the participants
40854078|NCT04508153|DEVICE|Leva Pelvic Digital Health System|Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.
40854079|NCT04508153|OTHER|Kegel exercises|"Pelvic floor muscle training (PFMT), commonly referred to as Kegel exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI)."
40854080|NCT06141265|DRUG|Niraparib|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
40854081|NCT02401984|OTHER|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
40854082|NCT06572124|PROCEDURE|universal adhesive without Acid resistant silane coupling agent|After cavity preparations, enamel margins will be etched for 30 seconds then rinsed and dried, then the Universal adhesive without acid resistant silane coupling agent will be actively applied for 20 seconds then air thinned for 5 seconds then cured for 20 seconds.Then the composite restoration will be placed.
40854083|NCT06572124|PROCEDURE|universal adhesive with Acid resistant silane coupling agent|After cavity preparations, enamel margins will be etched for 30 seconds then rinsed and dried, then the Universal adhesive which contains acid resistant silane coupling agent will be actively applied for 20 seconds then air thinned for 5 seconds then cured for 20 seconds.Then the composite restoration will be placed.
41037130|NCT03752229|DEVICE|SteriLance Press|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037131|NCT03752229|DEVICE|SensiLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037132|NCT03752229|DEVICE|mylife|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41509708|NCT00700362|PROCEDURE|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
41509709|NCT03872973|OTHER|Neuromuscular Training|"The experimental group will perform neuromuscular exercise for 6 weeks.~The other experimental group will perform neuromuscular exercises with strobe glasses."
40854084|NCT01957813|BEHAVIORAL|Lifestyle Counseling|"Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.~Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation"
40854085|NCT01957813|OTHER|Standard Health Services|Peer education and health services
40854086|NCT03225378|OTHER|Fluid loading of 500 mL of crystalloid solution|Infusion of 500 mL of crystalloid solution in less than 15 minutes
40854087|NCT03225378|OTHER|Passive Leg Raising test|This intervention is done before the fluid loading in order to predict fluid responsiveness.
41384345|NCT02935946|OTHER|Cold Liquid Barium|Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.
41509710|NCT03872973|OTHER|Strobe Glasses|Stroboscopic glasses, which is characterized by intermittent vision obstruction, is a clinical tool that allows clinicians to examine sensory feedback in a progressive manner without fully seeing visual information.
40854088|NCT03483493|BEHAVIORAL|Exposure Response Prevention for tics|The intervention consists of evidence-based interventions adapted from previously published treatment manuals on Exposure and Response Prevention (ERP) and established behavioural intervention for tics protocols. Each of the 10 modules includes age-appropriate texts, animations and exercises. Prticipants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their parent/carer, the participant is instructed to provoke premonitory urges (the urge to tic often felt before the tic is expressed) and try to supress the need to express/demonstrate the tic, this known as 'exposure'.
40854089|NCT03483493|OTHER|Psychoeducation for tics|The comparator intervention reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors and strategies for describing tics to other people etc. Problem-solving and development of expertise in tic disorders is emphasised. The intervention includes strategies for promoting positive behaviours which will be rewarded by a parent as a parallel element to the tic control practice in the behavioural therapy arm. There is no information on tic control within the management package.
40854090|NCT00211887|DRUG|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
40854091|NCT00211887|DRUG|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
40854092|NCT00211887|OTHER|placebo|an inactive substance
40854093|NCT04522141|BEHAVIORAL|Self-control intervention|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Across the 8 weeks, participants receive daily reminders to wear their Fitbit. After the baseline week, participants will also receive interventional components that target self-control via the smartphone application MindHike. This intervention should help them achieve their activity goals. The self-control intervention teaches strategies how to potentiate desirable impulses and how to avoid undesirable impulses in daily life.
40854094|NCT04522141|BEHAVIORAL|Control condition|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Participants in this condition receive daily reminders to wear their Fitbit through the MindHike smartphone application. Participants in the control group will be matched with the self-control intervention group for how much contact they have with the app and the researchers.
40854095|NCT04667741|OTHER|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
40854096|NCT01657292|DRUG|Oleogel-S10 ointment|Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
40854097|NCT01657292|DEVICE|Octenilin® wound gel|Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
40854098|NCT05228483|DEVICE|CO2 fractional laser|CO2 fraction laser
40854099|NCT05228483|COMBINATION_PRODUCT|5-aminolevulinic acid (5-ALA) with red light illumination|5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).
41037133|NCT03752229|DEVICE|VeriFine|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037134|NCT03752229|DEVICE|Microdot|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
41037135|NCT04959370|DEVICE|internal fixation implantation of dynamic hip screw|Dynamic hip screws (DHS) are a femoral head-sparing orthopedic device used to treat femoral neck fractures.
41384346|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
41384347|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
41509711|NCT00052637|DRUG|hexaminolevulinate|
41509712|NCT00052637|PROCEDURE|biopsy|
41509713|NCT00052637|PROCEDURE|cystoscopy|
41509714|NCT03305627|OTHER|Short PAP|Perioperative antibiotic prophylaxis for 24h
41509715|NCT03305627|OTHER|Extended PAP|Perioperative antibiotic prophylaxis for \>48h
41509716|NCT03377374|DIETARY_SUPPLEMENT|Probiotic|L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.
41509717|NCT03377374|OTHER|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
41509718|NCT01047527|DRUG|Transdermal nicotine patch|Transdermal nicotine, 21mg/day
41528324|NCT03283657|BEHAVIORAL|DiRECT|DiRECT participants will meet with a medical assistant (MA) before a routinely scheduled office and formulate a preliminary treatment plan for T2D prevention. Participants will attend their scheduled physician visit, during which they may make a definitive treatment plan to initiate metformin and/or ILI.
41528325|NCT03283657|BEHAVIORAL|Usual care (UC)|Standard care with routine medical care.
41528326|NCT02678793|DRUG|CNTX-4975|
41384348|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
40854100|NCT05228483|DRUG|Mometasone furoate (MMF) 0.1% ointment|0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
41180041|NCT01035268|PROCEDURE|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
41384349|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
41384350|NCT05611372|DRUG|Rasagiline|1 mg rasagiline
41509719|NCT00839397|DRUG|Paroxetine|"Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI"
40854101|NCT02775916|DRUG|CDZ173|
40854102|NCT02775916|DRUG|Placebo|
40854103|NCT03404297|OTHER|Locally sourced compression therapy|The dressing is made up of a zinc oxide impregnated compression wrapping
40854104|NCT04233450|OTHER|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
40854105|NCT01128946|DRUG|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
40854106|NCT01128946|DRUG|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
40854107|NCT01128946|DRUG|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
40854108|NCT01193114|BEHAVIORAL|Ecologically Based Treatment (EBT)|Substance abuse treatment (the Community Reinforcement Approach), case management and housing.
40854109|NCT01193114|BEHAVIORAL|Treatment as Usual (TAU)|Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
40854110|NCT01149915|DRUG|TH-302|TH-302 will be administered as a 30-minute intravenous infusion daily for 5 days every 21 days. Patients who successfully complete a 3-week treatment cycle without evidence of significant treatment-related toxicity or clinically significant progressive disease will continue to receive treatment for up to six cycles.
40854111|NCT02133092|OTHER|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
40854112|NCT03369977|DEVICE|BioGlue Surgical Adhesive|BioGlue (produced by CryoLife in Kennesaw, GA) is a surgical adhesive with two components respectively purified bovine serum albumin (BSA) and Glutaraldehyde (their proportions are 4:1). Crosslinked bonds (covalent bonds) of Glutaraldehyde cross-link the protein on the surface of the tissue and the amino residue of the bovine serum albumin. BioGlue also adheres to the synthetic matrix material by a mechanical interlocking mechanism in the space of graft matrix.
40854113|NCT03369977|OTHER|Traditional Surgical Repair|Traditional surgical repair as determined by the surgeon
40854114|NCT05669053|BEHAVIORAL|Super U Story intervention|Participants in this condition will be asked to play a Roblox adventure video game called 'Super U Story'. They will play the game once and have between 6 - 30 minutes to complete the game.
40854115|NCT05669053|BEHAVIORAL|Alternative Roblox game|Participants in this condition will be asked to play an alternative Roblox adventure video game called Rainbow Friends Story (colour story). They will play the game once and have between 6 - 30 minutes to complete the game.
40854116|NCT05669053|BEHAVIORAL|Online word search|Participants in this condition will have 20 minutes to complete a series of word searches online.
40854117|NCT04178720|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
40854118|NCT04178720|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
40854119|NCT04178720|DEVICE|CLEAR CARE|Hydrogen peroxide-based system for cleaning and disinfecting silicone hydrogel contact lenses
40854120|NCT04266925|BEHAVIORAL|3 referees present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
40854121|NCT04266925|OTHER|1 referee present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
40854122|NCT03162237|OTHER|Porcine islets|"Porcine islets: 10000IEQ/Kg;~Tacrolimus: 0.087mg/kg, Bid;~mycophemo-latemofetil (MMF): 1g x 2/d;~NULOJIX(belatacept): Day 1 (prior to transplantation), Day 5, Week 2, Week 4, Week 8, Week 12 10mg/kg"
40854123|NCT03162237|OTHER|Autologous Treg|Autologous Treg: 2x10\^6/Kg
40854124|NCT05852236|OTHER|Assigned Interventions|Pressure ulcer care package application.
41180042|NCT02847429|DRUG|Crenolanib|
41180043|NCT02847429|DRUG|Placebo|
41180044|NCT03345745|DIAGNOSTIC_TEST|salivary samples|Salivary Hs-CRP, Fetuin-A and S100A12 levels and salivary flow rates were evaluated at baseline and a month after the treatments
41180045|NCT04174209|BEHAVIORAL|Cylinder|Patients who receive the Jackson Cross Cylinder Method
41180046|NCT04174209|BEHAVIORAL|Dial|Patients who receive the Astigmatic Dial Technique Method.
41384351|NCT06569082|DEVICE|CD34+ Selected Donor Cell Boost|The CliniMACS CD34 Reagent System is used to separate CD34 cells from the remaining stem cell product, using a peripheral blood stem cell sample provided by the original donor. These CD34 cells are then infused into the recipient following selection with the intent to restore function of the blood forming cells.
41384352|NCT06569082|PROCEDURE|Blood Stem Cell Infusion|The selected CD34 cells separated by the CliniMACS CD34 Reagent System are infused into the recipient.
41384353|NCT03603925|DIAGNOSTIC_TEST|Positron Emission Test / Magnetic Resonance (PET/MR)|The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.
40854125|NCT00748423|DRUG|Nitric Oxide|NO in inhalation for 3 days
41037136|NCT04959370|DEVICE|internal fixation implantation of cannulated compression screw|Cannulated Screw is designed to provide a minimally invasive method of anatomical fixation.
41509720|NCT04051346|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
41509721|NCT04051346|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
41509722|NCT04703595|GENETIC|To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.|"To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.~For the molecular study of the DNA sample of the patients, two techniques will be used: standard Polymerase chain reaction amplification with primers flanking the intron 2 fragment of the RFC1 gene and amplification using Repeated Primed Polymerase chain reaction in 3 independent reactions."
41037137|NCT02302729|DIETARY_SUPPLEMENT|Micronutrients|Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
41037138|NCT02302729|BEHAVIORAL|Responsive feeding|"Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil"
41384354|NCT03603925|DIAGNOSTIC_TEST|Positron Emission Test / Computed Tomography (PET/CT)|Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.
41384355|NCT05229562|DRUG|BIIB122|Administered as specified in the treatment arm.
41384356|NCT03348319|OTHER|radiation|Scanning cadaver organs
41384357|NCT02719782|BIOLOGICAL|Biological: TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
41509723|NCT01609205|BIOLOGICAL|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
41509724|NCT03519087|OTHER|Interdisciplinary Evaluation for Nonarthritic Hip Disease|The hip arthroscopist will conduct his or her standard-care evaluation including subjective interview, patient history, imaging, and physical examination. The physical therapist will conduct an assessment of posture and movement during sitting, standing, squatting, and walking. After providers discuss their findings, they will discuss the plan of care with the participant.
41509725|NCT03519087|OTHER|Posture and Movement Training|Physical therapists will lead participants through an intervention protocol to normalize seated and standing posture and function movement. Verbal, visual, and tactile cues, along with strengthening exercises will be provided to train posture and movement.
41509726|NCT03519087|OTHER|Treatment-of-choice|Participants may proceed with any treatment-of-choice, which may or may not have been recommended by their health care provider(s). Treatments will be recorded, but not controlled.
40854126|NCT00748423|DRUG|Placebo|Placebo in inhalation for 3 days
40854127|NCT01773187|DRUG|Pacritinib|
40854128|NCT01773187|DRUG|Best Available Therapy|
41384358|NCT04024852|OTHER|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
41509727|NCT00984724|BEHAVIORAL|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
40854129|NCT03062293|DEVICE|Functional Re-adaptive Exercise Device|Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
40854130|NCT05499533|PROCEDURE|implant site preparation|a hole were created in the edentulous ridge area before implant placement
41037139|NCT02302729|DIETARY_SUPPLEMENT|Placebo|Riboflavin Vitamin B2
41037140|NCT01197079|OTHER|Survey|Self administered anonymous survey
41037141|NCT02697253|DRUG|Exendin 9-39 and Sitagliptin|"Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
41037142|NCT02697253|DRUG|Placebo|"Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours."
41037143|NCT04810598|DRUG|Venetoclax|Oral Tablet
41384359|NCT06567158|OTHER|Moderate carbohydrate diet|During the moderate carbohydrate diet, participants will be asked to limit his/her carbohydrate intake to no more than 30% of their total energy intake.
40854131|NCT02128880|BEHAVIORAL|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
40854132|NCT02128880|BEHAVIORAL|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
41384360|NCT06567158|OTHER|Traditional diet|During the traditional diet, participants do not follow any diet, however their carbohydrate intake must be at least 50% of their total energy intake.
40854133|NCT03454607|DEVICE|FREE robot|FREE robot to hold endoscope
40854134|NCT01318148|DRUG|caspofungin|Intermittent intravenous application of caspofungin
40854135|NCT06291831|DRUG|nirmatrelvir, ritonavir|Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)
40854136|NCT06291831|OTHER|Controls|Patients who do not receive Nirmatrevir/ritonavir (Paxlovid)
40854137|NCT05650281|OTHER|NO INTERVENTION|NO INTERVENTION
40854138|NCT06146829|OTHER|no intervention|no intervention
40854139|NCT02014168|BIOLOGICAL|Viroflu® and MVA-NP+M1|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu."
40854140|NCT02014168|BIOLOGICAL|Viroflu® and saline placebo|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~0.9% saline placebo."
40854141|NCT05637788|DIAGNOSTIC_TEST|CT Scan Radiomics Features Extraction|Extraction of CT radiomics data through AI
40854142|NCT01477489|DRUG|Veliparib|Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
40854143|NCT01477489|RADIATION|Standard radiation treatment|Limited to 60 Gy.
41166009|NCT05889390|DEVICE|Oncotherm EHY-2030|Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
41166010|NCT05889390|DRUG|Paclitaxel|weekly paclitaxel for 12 weeks
41384361|NCT02284373|OTHER|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
41384362|NCT02284373|OTHER|Routine wound care for venous ulcers and lymphedema|wound care /dressings
41384363|NCT02284373|DEVICE|Flexitouch pneumonic compression|pneumonic compression only
41384364|NCT03121664|DRUG|PF06649751, Itraconazole|PF-06649751 0.25 mg on Days 1,2,3 PF-06649751 0.5 mg on Days 4,5,6 PF-06649751 1 mg on Days 7 to Day 25 Itracoanzole 200 mg on Days 12 to Day 25
41384365|NCT00000423|BEHAVIORAL|Social support group|
41384366|NCT00000423|BEHAVIORAL|Social support and education group|
41384367|NCT06417723|PROCEDURE|Maxillary nerve block|It is aimed to reach the maxillary nerve trace with a peripheral nerve block needle using the suprazigomatic approach and to create a temporary block in the maxillary nerve with local anaesthetic injection.
41384368|NCT05800327|DRUG|Levilimab|Subcutaneous or intravenous injection of levilimab with placebo.
41384369|NCT06163209|DIAGNOSTIC_TEST|Nasal Ultrasonography|"Ultrasonography of the external nose will be performed with the use of a high-resolution transducer (Clarius L20HD3 8-20 MHz) and a 3mm-thick disposable gel pad, according to the following protocol:~1. Sagittal plane, along the most prominent part of nasal dorsum.~2. Transverse plane, level of nasion.~3. Transverse plane, level of intercanthal line.~4. Transverse plane, level of rhinion.~5. Along inferior border of the right nasal bone.~6. Along inferior border of the left nasal bone.~7. Along medial part of the right orbital rim below frontomaxillary suture.~8. Along medial part of the right orbital rim below frontomaxillary suture.~9. Along the line connecting right frontomaxillary suture and the tip of the nose.~10. Along the line connecting left frontomaxillary suture and the tip of the nose.~At each location the transducer position will be adjusted until it is held perpendicular to the bone surface and a single image will be saved for further assessment."
41384370|NCT06163209|DIAGNOSTIC_TEST|Computed Tomography Scan of the Face|"A standard computed tomography scan of the face will be performed and the following areas will be assessed by an experienced radiologist:~1. Bony part of the nasal septum~2. Left nasal bone - part proximal to the intercanthal line~3. Right nasal bone - part proximal to the intercanthal line~4. Left nasal bone - part distal to the intercanthal line~5. Right nasal bone - part distal to the intercanthal line~6. Frontal process of the left maxilla~7. Frontal process of the right maxilla"
41384371|NCT04519294|DEVICE|SURE|The SURE stone evacuation procedure is a technique intended to more easily and completely remove a kidney stone during a kidney stone treatment. The urologist first uses a laser to break the kidney stone into small pieces. Then with the SURE procedure, the pieces are gently vacuumed out of the kidney instead of retrieving the pieces one-by-one with a basket or leaving them to pass naturally in the urine. Basketing is allowed and might be used with the SURE procedure, if needed to remove some small stones.
41384372|NCT04519294|DEVICE|Standard Ureteroscopy (Basketing)|This is a treatment in which the urologist uses a laser to break a kidney stone into small pieces and then uses a tool called a basket to retrieve the pieces one at a time.
41384373|NCT02797626|PROCEDURE|Primary retroperitoneal lymph-node dissection (pRPLND)|Open or laparoscopic robotic-assisted nerve-sparing retroperitoneal lymph node dissection (modified template RPLND, if possible ipsilateral nerve-sparing)
41384374|NCT00922337|DEVICE|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
41384375|NCT00630994|DRUG|Dacogen|
40854144|NCT02286232|BEHAVIORAL|Stretching exercise|This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.
40854145|NCT02286232|BEHAVIORAL|Self-care book|The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
40854146|NCT05393245|DRUG|Tiotropium+Olodaterol|Tiotropium+Olodaterol
40854147|NCT05393245|DEVICE|Spiolto Respimat|Spiolto Respimat Inhaler device
40854148|NCT05393245|DRUG|Long-acting muscarinic antagonists (LAMAs)|Long-acting muscarinic antagonists (LAMAs)
40854149|NCT05393245|DRUG|Long-acting β2-agonists (LABAs)|Long-acting β2-agonists (LABAs)
41037144|NCT03378167|BIOLOGICAL|MICROBIOTA|Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks. The fecal microbiota enema (RBX2660) prepared by Rebiotix has received Health Canada Clinical Trials Application (CTA), and U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection, and pediatric inflammatory bowel disease. The human-derived fecal oral microbiota capsule (RBX7455) has received U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection.
40854150|NCT00696839|BEHAVIORAL|Cognitive-behavioral therapy|3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
41166011|NCT05889390|DRUG|Carboplatin|added to weekly paclitaxel if patient has triple-negative breast cancer
41166012|NCT05889390|DRUG|Cyclophosphamide/Doxorubicin|according to the AC protocol
41166013|NCT05889390|PROCEDURE|Breast cancer removal surgery|Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
41384376|NCT01095029|DEVICE|Medtronic InterStim II - 3058|Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
41384377|NCT04231994|DEVICE|TPE|singular Therapeutic Plasma Exchange using fresh frozen Plasma as replacement fluid
41384378|NCT03901222|DEVICE|tDCS|20 minutes of anodal tDCS (C3 \& C4/FPZ) 2mA or sham
41166014|NCT03389451|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
40854151|NCT06262464|BEHAVIORAL|Prevention|A cognitive-behavioural prevention programme.
40854152|NCT04201613|DEVICE|Robotic exoskeleton|The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.
40854153|NCT04201613|BEHAVIORAL|Usual Care|This group will receive standard care with no additional therapy.
40854154|NCT06262724|PROCEDURE|Breast auto-augmentation|Single group assignment. All patients included were subjected to utilizing chest wall perforator flaps for breast reshaping.
40854155|NCT03955627|BEHAVIORAL|Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)|Self-management program which includes supervised exercise sessions in groups and group discussions for 8 weeks conducted by Zoom video, followed by an 8-week home-based version of the same program participants do on their own with bi-weekly coaching calls.
41180047|NCT04174209|BEHAVIORAL|Slit|Patients who receive the Stenopeic slit Method.
41384379|NCT06288490|DIETARY_SUPPLEMENT|amorphous calcium carbonate|
41384380|NCT00928785|BIOLOGICAL|REPEVAX|1 dose of 0.5 mL at Day 0
41384381|NCT00928785|BIOLOGICAL|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
41384382|NCT05317455|DRUG|Dichloroacetate|Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.
41384383|NCT00414986|BEHAVIORAL|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
41037145|NCT03378167|BIOLOGICAL|PLACEBO|"Placebo enema (Normal Saline) infused via colonoscope x 1 + oral placebo capsules (dextrose-containing capsules) x 6 weeks.~NOTE: Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist."
41384384|NCT00414986|BEHAVIORAL|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
40854156|NCT03057652|DEVICE|ReWalk|"ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
41384385|NCT00414986|BEHAVIORAL|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
41384386|NCT05147792|DEVICE|CLAAS|CLAAS
41384387|NCT05147792|DEVICE|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
41384388|NCT03680131|DRUG|EB01 Cream Placebo|Vehicle Cream containing 0% EB w/w applied BID
41037146|NCT00695903|DRUG|daptomycin|daptomycin 10 mg/kg IV every 24 hours
41166015|NCT05571306|OTHER|four core components care|"The intervention progresses throughout the first three months for the recently diagnosed T2DM patients and is divided into four core components: 1) Improve of cross-sectoral communication and information sharing, 2) ensure systematism in care, 3) guarantee participation at a one-stop-shop and a start-up conversation at the municipality, and 4) improve patients coping skills."
41166016|NCT02879799|OTHER|Implement Family Integrated Care|Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
41166017|NCT00649142|PROCEDURE|Open sutured mesh repair|Open sutured mesh repair
41166018|NCT00649142|PROCEDURE|Laparoscopic mesh glue fixation|Laparoscopic mesh glue fixation
41166019|NCT02353455|PROCEDURE|Blood sampling|In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
41166020|NCT04409522|DRUG|Melatonin|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
41166021|NCT04409522|DRUG|The usual treatment|Participants in this group will receive the usual treatment of COVID-19
41166022|NCT02895334|BEHAVIORAL|MyHeartBaby Program|Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
41166023|NCT06348745|DEVICE|ultrasound|5. Transthoracic ultrasound for both right and left diaphragm during inspiration and expiration.
41166024|NCT02840916|PROCEDURE|laser acupuncture|Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
41166025|NCT02840916|PROCEDURE|sham laser acupuncture|Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
41166026|NCT03690921|DRUG|Cisplatin|Given IV
41166027|NCT03690921|DRUG|Fluorouracil|Given IV
41166028|NCT03690921|RADIATION|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Undergo LET-IMPT
40854157|NCT03057652|DEVICE|EKSO|"EKSO is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~EKSO training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. EKSO phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
40854158|NCT03057652|DEVICE|REX|"REX is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~REX training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. REX phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
41166029|NCT03690921|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
40854159|NCT05496569|DRUG|TQB3616 capsule|TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
40854160|NCT05496569|DRUG|TQB3616 placebo|Placebo
40854161|NCT04813887|OTHER|questionnaire|Self-questionnaire on skin diseases reported during pregnancy
40854162|NCT02085109|DIETARY_SUPPLEMENT|Fat milkshake|
40854163|NCT02085109|DIETARY_SUPPLEMENT|Theobromine|
40854164|NCT04764318|BEHAVIORAL|Remote patient monitoring for hypertension|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician.
40854165|NCT04764318|BEHAVIORAL|Remote patient monitoring with care management|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician and providing care management services to support the enrollment and active use of this service.
40854166|NCT01647776|OTHER|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
40854167|NCT01647776|PROCEDURE|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors \[levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression\] as markers of risk of developing adenoma.
41037147|NCT00695903|DRUG|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
41037148|NCT05496582|DIAGNOSTIC_TEST|No intervention|No intervention
41037149|NCT02494791|BEHAVIORAL|Questionnaire, Educational Material|Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.
41037150|NCT05309265|OTHER|Multidisciplinary vocational rehabilitation intervention|"* Information aims to provide tailored information concerning the work law protection (this support is already provided for all patients, regardless the type of disease, and also for citizens);~* Occupational therapy aims to facilitate the reintegration in the previous workplace through the development of a rehabilitation intervention to overcome work difficulties in agreement with employee, employer and occupational physician,~* Social support aims to find new job opportunities (for those who have lost the employment due to the disease) through the giving of support in job search, curriculum preparation, skill analysis, professional retraining and education."
41037151|NCT05938634|BEHAVIORAL|Stage-matched interventions|Precontemplation-based intervention Contemplation-based intervention Preparation-based intervention Action-based intervention Maintenance-based intervention
41384389|NCT03680131|DRUG|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
41384390|NCT03680131|DRUG|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
41384391|NCT03680131|DRUG|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
41509728|NCT00984724|BEHAVIORAL|Telephone Counseling|"MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period"
41509729|NCT00984724|BEHAVIORAL|Quitline|Letter referring participants to a Quitline providing quit smoking services.
41509730|NCT00984724|BEHAVIORAL|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
41384392|NCT00798707|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|25 mg tablet, once daily dosing for 8 weeks
40854168|NCT01647776|OTHER|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
40854169|NCT03684382|OTHER|NeW-I group|A 5-week intervention offered to parents of children with chronic life-threatening illness using an internet-based narrative approach with life review elements. After completion of the first four weeks of the intervention, participants will receive a 'legacy' document which is a compiled and edited document of their narrative expression during the first four weeks. This legacy document is structured in a manner that enables participants to find a sense of spiritual well-being and hope in their experience of caring for their child through examination of past experiences and achievements as well as future aspirations.
40854170|NCT01669083|DRUG|GSK557296 10 mg|10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
41384393|NCT00798707|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
40854171|NCT01669083|DRUG|GSK557296 150 mg|150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
40854172|NCT01669083|DRUG|GSK557296 dose 3|Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
41037152|NCT03364205|BEHAVIORAL|solution-focused interview technique|This approach helps an individual make decisions about behavioral change, focusing particularly on his or her past achievements and looking forward to a time when the problems cease to exist.
41166030|NCT03690921|OTHER|Questionnaire Administration|Ancillary studies
41037153|NCT04015180|DRUG|Eylea (Aflibercept, BAY86-5321)|Treatment administered in 20090. Solution in a sterile glass vial, Dose A, IVT injection.
41384394|NCT00798707|DRUG|placebo|Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
41509731|NCT05636267|DRUG|AK119|AK119 IV every 3 weeks.
41509732|NCT05636267|DRUG|AK112|AK112 IV every 3 weeks.
41509733|NCT05636267|DRUG|Pemetrexed|Pemetrexed IV every 3 weeks.
41509734|NCT05636267|DRUG|Carboplatin|Carboplatin IV every 3 weeks.
41509735|NCT06469203|DRUG|Oxytocin|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."
41509736|NCT06469203|DRUG|Sodium Chloride 0.9% Inj|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."
41509737|NCT02943590|DRUG|Placebo|A pill taken once a day
41509738|NCT02943590|DRUG|Atorvastatin|A pill taken once a day
41509739|NCT02962518|DEVICE|Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and they are additionally treated with a non-customized Pressure Device. The standardized clips (K. Egner, Dental Technique, Neu-Ulm, Germany) used in our study is available in two different sizes for smaller or larger defects. According to the guidelines of the German Society of Dermatology, patients are advised to wear the clip at least 16 hours per day. Medically approved transparent acrylate is used so that change in skin color and therefore amount of pressure can be observed at all times. Allergic or toxic skin involvement can be visualized through the transparent surface. Adjusting of the clip is done with one or two screws."
41037154|NCT04015180|PROCEDURE|Laser photocoagulation|Treatment administered in 20090. Transpupillary conventional laser ablative therapy
41037155|NCT03332524|DRUG|SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg|2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
41384395|NCT00686231|DRUG|Nitroglycerin 15mg|15mg Nitroglycerin applied topically to one wrist
41384396|NCT00686231|DRUG|Nitroglycerin 30mg|30mg Nitroglycerin applied topically to one wrist
41384397|NCT00686231|DRUG|Lidocaine 20mg|20mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
41384398|NCT00686231|DRUG|Lidocaine 40mg|40mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
41384399|NCT00686231|DRUG|Placebo|Topical skin moisturizing cream with same appearance as active agent
41384400|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
41037156|NCT03332524|DRUG|2 capsules Ibuprofen and 1 placebo|Ibuprofen and placebo
41384401|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
41384402|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
41166031|NCT00575367|DRUG|AzaSite (azithromycin ophthalmic solution)|One drop ophthalmic solution at Visit 2
41384403|NCT00883740|DRUG|Pregabalin|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
41384404|NCT00883740|DRUG|Placebo|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
41384405|NCT06566625|DIAGNOSTIC_TEST|Cardiac MRI (CMR) examination|"An MRI examination of the heart (CMR) is presently performed as a follow-up examination in patients where an invasive coronary angiography (ICA) shows no obstructive findings. The intervention in this study is characterized by having the CMR performed before, rather than after, the ICA.~In addition, this study will implement some novel CMR sequences which have not been previously tested in this patient cohort:~* CMR Angiography (imaging the coronary arteries using MRI)~* CMR Fingerprinting (sequences which perform T1 and T2 mapping simultaneously)"
41384406|NCT06232135|OTHER|CBCT scan|analysis of the CBCT scan to assign a calcification stage to the subject's lower left third molar and accordingly calculate the estimated age of each subject
41509740|NCT02962518|PROCEDURE|Fillet Technique|"Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed."
40854173|NCT01669083|DRUG|GSK557296 dose 4|Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
41384407|NCT05511805|OTHER|Visual Analogue Scale (VAS),|The pain levels of the individuals participating in the study will be evaluated with the Visual Analog Scale. According to VAS, in the severity of pain; '0' means no pain, '10' means worst pain imaginable. During the study, the participants will be asked to rate their pain experienced in daily life and pain during evaluation between 0-10 points. Individuals with pain intensity of 3 and above according to VAS will be included in the study.
41384408|NCT05511805|OTHER|Oswestry Low Back Pain and Disability Questionnaire|The Oswestry scale will be used to determine the level of functional disability due to low back pain. In this questionnaire, 10 questions are asked about pain intensity, social life, weight lifting, walking, personal care, sitting, sleeping, sexual life, standing and travel. Each question has 6 options and the patient is asked to choose the statement that best describes his or her condition.
40854174|NCT00149903|DRUG|Mycophenolate sodium (enteric coated)|
40854175|NCT06524765|OTHER|Living conditions|There are many patients with multi-resistant bacterial infections in intensive care units (ICU), making it possible for a great deal of these pathogens to exist in the ICU environment. The exposure factors in this study were ICU environment or daily living environment.
41384409|NCT05511805|OTHER|Functional Low Back Pain Scale|The Functional Low Back Pain Scale will be used to evaluate how much the low back pain experienced by the people who will be included in the study affects their daily living activities. Evaluated functions; work and school activities, home activities, wearing shoes or socks, leaning forward, lifting an object from the ground, habits, sleeping, walking, sitting, climbing stairs, standing and driving. The questionnaire consists of 12 questions, and each item scores in the range of 0-5 points.
41509741|NCT02962518|DRUG|Triamcinolone|All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
41509742|NCT05544279|BEHAVIORAL|Education|Education is given about the focused disease and its nursing care management
40854176|NCT01196026|BIOLOGICAL|Fluarix™|One or two intramuscular injections
40854177|NCT01196026|BIOLOGICAL|Havrix™ Junior|Two intramuscular injections
40854178|NCT02376023|OTHER|mHealth|Text and voice messages sent to study participants reminding them to schedule a PAP smear.
40854179|NCT03158532|DRUG|Nitroglycerin I|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
40854180|NCT03158532|DRUG|Placebo I|Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
41509743|NCT00348829|PROCEDURE|mitral valve repair|surgical mitral valve repair
41509744|NCT05347329|DIETARY_SUPPLEMENT|Tongkat Ali Maca Plus|Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
40854181|NCT03158532|DRUG|Nitroglycerin II|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
40854182|NCT03158532|DRUG|Placebo II|Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
40854183|NCT04501796|DRUG|Double-Blind NT-I7|Administered by intramuscular (IM) injection
40854184|NCT04501796|DRUG|Double-Blind Placebo|Placebo
41037157|NCT03332524|DRUG|capsule Chlorpheniramine 4mg and 1 Placebo|Chlorpheniramine 4mg and one capsule Placebo 3/72days
41037158|NCT01416792|PROCEDURE|Centrifugation|
41037159|NCT01416792|PROCEDURE|Multiple-pass hemofiltration|The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
41037160|NCT02106026|OTHER|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
40854185|NCT03971448|DEVICE|LPWB|The LPWB will be placed by clinical staff who will have been trained on the proper application of this device at the initial ED visit. At ED discharge, both populations will receive identical documentation on recommendations for weight bearing, type and frequency of analgesics, reasons to return for medical attention. The only difference will be care instructions related to the specific immobilization device. Specifically, the experimental group will be permitted to remove the LPWB as early as one week post ED visit as tolerated by the patient's symptoms.
41037161|NCT06634550|OTHER|Mulligan technique|The participants will receive Mulligan technique (modified SNAGs) (10 rep. / 3 sets with 5 min rest in between) for 30 minutes, 3 sessions / week in addition to lifestyle modification advice for 4 weeks.
41384410|NCT05511805|DEVICE|Prokin TecnoBody isokinetic balance 2 device|For the one-leg balance test, the subject is positioned on one leg at the origin of the platform. The participant is asked to look at any stationary point or object in front of him. Participants are allowed to experiment on the platform of the meter for approximately 2-3 minutes. The stem sensor apparatus is then attached to coincide with the xiphoid projection. After the torso sensor is attached, the patient is placed in the dominant side position on one foot and the static balance test measurement is started. 30 seconds from the patient in this position. asked to stop.
41384411|NCT05511805|DEVICE|EMG|In our study, electromyography (EMG) device will be used to evaluate muscle strength. Electromyography is a method by which electrical activity analysis of muscles can be performed. In the study, the erector spina and multifidus muscles will be measured. Measurements are made with electrodes placed on the skin surface.
41384412|NCT05511805|DEVICE|Algometer|The pressure perception and pain threshold of pain sensitivity are determined and recorded with an algometer. The details of the application will be explained to the participant and it will be emphasized that the feeling of pressure he feels causes pain and that he should give a 'stop' command. The pressure force is increased until the patient receives the 'stop' command in the area to be applied. It is stopped by the command from the patient and the response on the algometer screen is recorded. These measurements are repeated 3 times. The average of these three recorded measurements is determined.
41384413|NCT05511805|DEVICE|Goniometer|Using the universal goniometer's measure of knee joint range of motion, sense of proprioception will be evaluated. For measurement, subjects are asked to lie on a stretcher in the prone position. The pivot point of the goniometer is placed in the center of the lateral knee joint condyle. The fixed arm of the goniometer is fixed in parallel at the level of the thoracantary major, and the movable arm is positioned at the level of the head of the fibula and the lateral malleolus. First of all, starting from the 0° extension position to the knee joint, the angle desired by the physiotherapist is made and the value in the goniometer is recorded. Then, the patient is asked to bring the knee joint, which is still in 0° extension, to the angle brought by the physiotherapist. Then the angle brought by the patient to the knee joint is recorded.
41384414|NCT00572169|DRUG|Velcade|Will be given in central venous catheter
41384415|NCT00572169|DRUG|Thalidomide|Capsule taken by mouth
41384416|NCT00572169|DRUG|Dexamethasone|A pill taken by mouth
41384417|NCT00572169|DRUG|Adriamycin|Given into the vein (IV) by a continuous infusion through a central catheter
41509745|NCT05440760|DEVICE|The Oculus Quest 2 Virtual Reality Headset|"The hardware includes the wireless headset with integrated headphones which will block the sight and sounds of the clinical setting as well as the hand controllers for the interactive VR experience, which will be delivered through any of three VR software options (subject may choose one or more from the following options):~* Titans of Space® PLUS developed by Drash VR, LLC (Murrieta, CA, USA)~* TRIPP® developed by TRIPP, Inc. (Los Angeles, CA, USA)~* Nature Treks VR published by Greener Games (Ironbridge, England, UK)"
41509746|NCT06329609|DEVICE|Airvo 3 with respiratory rate algorithm|Airvo 3 with respiratory rate algorithm is an active humidification system used to deliver high flow respiratory gases (air and/or oxygen) and monitor respiratory rate
41509747|NCT02905747|BEHAVIORAL|Medical Exercise Therapy|physiotherapy intervention with Medical exercise therapy (MET) during 3 months
41509748|NCT05411341|DEVICE|Argos (Alcon Laboratories, Inc.)|An ocular biometry examination will be performed on the affected eyes using the Argos device.
41509749|NCT05411341|DEVICE|IOLMaster 500 (Carl Zeiss Meditec AG)|An ocular biometry examination will be performed on the affected eyes using the IOL Master 500 device.
41509750|NCT03127111|GENETIC|Gene mutations analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for KRAS mutations, BRAF mutations, PIK3A mutations, and EGFR mutations, etc., by sequencing and for MSI analysis by PCR and capillary electrophoresis.
41509751|NCT03127111|GENETIC|Gene methylation analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for specific gene methylation or CIMP status analysis by MethyLight or bisulfite sequencing. Whole-genome bisulfite sequencing will be used to identify novel candidate set of predictive markers.
41509752|NCT03127111|GENETIC|Gene expression analysis|RNA extracted from paired fresh-frozen tumor and normal tissues or serum is used for specific gene expression analysis by real-time reverse-transcription PCR (RT-qPCR). RNA-seq will be used to identify novel candidate set of predictive markers.
40854186|NCT03971448|DEVICE|AKWC|If the patient is randomised to AKWC, it will be apply by a cast technician. Children with AKWC immobilization will be provided with up to two appointments in the orthopedic clinic. In case the AKWC could not been placed at initial visit, the first will be within 72 hours of the ED visit to have the fiberglass AKWC placed. The second appointment will be for cast removal.
40854187|NCT05280353|OTHER|Glubran 2|Application of Glubran 2 sealant (liquid) in axillary hollow
40854188|NCT04503720|DEVICE|CLoWI|Patients will receive a continuous wound infusion with ropivacaine and normal saline in the PCA pump.
40854189|NCT04503720|DEVICE|PCA|Patients will receive a continuous wound infusion with normal saline and morphine in the PCA pump.
40854190|NCT05361044|BIOLOGICAL|Blood samples Donnor|Additional samples will be preleved in the Normothermic Regional Reperfusion at 30 min, and blood sample will be collected at the end of the Normothermic Regional Reperfusion (4 samples of 5ml).
41037162|NCT06634550|OTHER|Core stability exercise|The participants will perform core stability exercises (spinus multifiduse ex, diaphragmatic strengthening ex, frontal plank, pelvic floor ex,) 3 sessions / week for 30 min each session in addition to lifestyle modification advice for 4 weeks
41037163|NCT06634550|OTHER|Lifestyle modification advice|The participants will receive lifestyle modification advice only for 4 weeks
41037164|NCT03877718|DRUG|Arm 1: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)
41037165|NCT03877718|DRUG|Arm 2: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)
41037166|NCT03877718|DRUG|Arm 3: Sumatriptan Succinate 100 mg capsule|One capsule of sumatriptan succinate 100 mg
40854191|NCT02736565|BIOLOGICAL|pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex|"Lipoplex is given intravenously as a single administration twice a week for 4 weeks for a total of 8 infusions per cycle followed by 2 weeks of rest. Treatment may continue as long as there is clinical benefit, no evidence of disease progression, and no other withdrawal criteria are met.~First dose started on Cycle 1 Week 1 Day 1 followed by observation and safety assessment for 13 days. If no toxicity was observed, then another single administration of study agent was given at Cycle 1 Week 3 Day 1 followed by observation and safety for 6 days. If no toxicity was observed, then study agent was given twice a week on Days 1 and 4 over 3 weeks, for a total of 8 infusions per cycle, followed by a 2-week washout before starting each subsequent cycle. Cycle 1 = 8 weeks. Each subsequent cycles = 6 weeks."
41384418|NCT00572169|DRUG|Cisplatin|Given into the vein (IV) by a continuous infusion through a central catheter
41384419|NCT00572169|DRUG|Cyclophosphamide|Given into the vein (IV) by a continuous infusion through a central catheter
41384420|NCT00572169|DRUG|Etoposide|Given into the vein (IV) by a continuous infusion through a central catheter
41384421|NCT03313154|OTHER|Neuropsychiatric screening|"Psychiatric diagnosis through:~1. clinical interview~2. the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~3. HAM-D (Hamilton Scale for Depression);~4. PHQ-9 (Patient's Health Questionnaire-9 items);~5. MDQ (Mood Disorders Questionnaire);~6. YMRS (Young Mania Rating Scale);~7. ASRM (Altman Self Rating Mania scale);~8. BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~   Assessment of Quality of Life:~9. SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R)."
41384422|NCT01410565|DRUG|Apaziquone|Apaziquone 4 mg in 40 mL diluent
41384423|NCT01410565|DRUG|Placebo|Placebo for Double Blind Phase
41384424|NCT05227807|BEHAVIORAL|mouth opening exercise|The intervention group receives an oral exercise intervention, including a 30-minute individual training, a multimedia oral exercise education video along with a print education booklet, and three follow-up phone calls.
41384425|NCT05227807|BEHAVIORAL|Usual care|routine care including written mouth exercise instructions
41384426|NCT04923607|DRUG|TQC2731|TQC2731 injection
41384427|NCT04923607|DRUG|Placebo|Matching placebo with no active ingredients
41384428|NCT06566495|DEVICE|collection of microbiological material from reusable tourniquets|"Microbiological analysis~The material was collected in each group in the same way."
41509753|NCT03127111|GENETIC|SNP analysis|Genomic DNA extracted from serum is used for specific SNP analysis by using sequencing. GWAS with SNPs array will be used to identify novel candidate set of predictive markers.
40854192|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
41384429|NCT00005886|DRUG|arzoxifene hydrochloride|
41509754|NCT03127111|GENETIC|Protein expression analysis|Tissue microarray made from formalin-fixed paraffin-embedded (FFPE) paired tumor and normal tissues is used for specific protein expression analysis by immunohistochemistry staining.
41509755|NCT05147012|OTHER|Data collected|"The variable of the characteristic of the patients (i.e.: age, sex, hypertension, diabetes, atrial fibrillation, coronary arteries diseases, body mass index (BMI), surgery, medications) were retrieved from the anesthesia consultation file (Easily, Hospices Civiles de Lyon, France).~We retrieved the mean arterial pressure from our local anesthesia software for each patient ( Diane®, Bow medical, Amiens France). We also performed an automatic extraction of data from our anesthesia software (Diane, Bow Medical, France) with a rate of 1 value / minute for some continuous arterial pressure.~All data was extracted from our institutional database and collected by a physician who was not involved in the care of the study patients."
40854193|NCT03170960|DRUG|atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
40854194|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
40854195|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
40854196|NCT01628055|BIOLOGICAL|Privigen|10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (\~3-4 hours depending on weight).
41509756|NCT05534061|BEHAVIORAL|Connect2Test|Brief motivational enhancement intervention to improve the likelihood of testing and vaccination among syringe exchange clients
41509757|NCT01849237|GENETIC|Mesenchymal stromal cells|MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10\^9/l).
41166032|NCT00575367|DRUG|Vigamox (moxifloxacin hydrochloride ophthalmic solution)|One drop ophthalmic solution at Visit 2
40854197|NCT01628055|OTHER|Normal Saline|"Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).~It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.~The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours."
41384430|NCT00005886|DRUG|tamoxifen citrate|
41384431|NCT05282810|OTHER|tympanoplasty|use of cartilage versus tempotalis fascia in tympanoplasty for recuurent perforation
41384432|NCT03030638|DRUG|Olodaterol|Drug
41384433|NCT03030638|DRUG|Indacaterol|Drug
41384434|NCT00003273|BIOLOGICAL|filgrastim|
41384435|NCT00003273|DRUG|carboplatin|
41384436|NCT00003273|DRUG|cisplatin|
41384437|NCT00003273|DRUG|cyclophosphamide|
41384438|NCT00003273|DRUG|etoposide|
41384439|NCT00003273|DRUG|leucovorin calcium|
41384440|NCT00003273|DRUG|methotrexate|
41384441|NCT00003273|DRUG|temozolomide|
41384442|NCT00003273|DRUG|thiotepa|
41384443|NCT00003273|DRUG|vincristine sulfate|
41384444|NCT00003273|PROCEDURE|autologous bone marrow transplantation|
41384445|NCT00003273|PROCEDURE|peripheral blood stem cell transplantation|
41384446|NCT00003273|RADIATION|radiation therapy|
41384447|NCT04212741|DIETARY_SUPPLEMENT|A+ HA(tm)|oral solution of hyaluronic acid mixture
41384448|NCT04212741|DIETARY_SUPPLEMENT|Placebo|oral solution with no-active ingredients
41384449|NCT03101215|DIETARY_SUPPLEMENT|phosphorus|adding of phosphorus to high carbohydrate meal
41384450|NCT03087773|DRUG|Empagliflozin 10 mg|The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.
41509758|NCT01849237|DRUG|Standard therapy of septic shock|Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
41509759|NCT03596086|DRUG|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
41509760|NCT00739063|DRUG|Tarceva|Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
41509761|NCT05812066|PROCEDURE|all ceramic single-retainer resin bonded fixed partial denture|The intervention will be all ceramic single-retainer RBFPD using the upper canine as abutment with minimum preparation on the lingual surface within the enamel providing maximum area for the retainer bonding, to replace the upper lateral incisor and will be compared with the control/comparator group which is the all ceramic single-retainer RBFPD using the upper central incisor.
41166033|NCT03561025|DIAGNOSTIC_TEST|18F-FDG-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-FDG
41166034|NCT03561025|DIAGNOSTIC_TEST|18F-GE180-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-GE180
41384451|NCT03087773|DRUG|Placebo Oral Tablet|The subject will receive Placebo orally once daily for 26 weeks.
41384452|NCT00216424|DRUG|Capecitabine (Xeloda)|
41384453|NCT05359640|OTHER|quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
41384454|NCT02061709|BIOLOGICAL|Ragweed-SPIRE|
41384455|NCT02061709|BIOLOGICAL|Placebo|
41384456|NCT03332212|DRUG|Empagliflozin|12 weeks
41384457|NCT03332212|DRUG|Placebo|12 Weeks
41384458|NCT00122148|BEHAVIORAL|Feedback on provision of care|
41384459|NCT06515665|BEHAVIORAL|therapeutic foot orthosis|They will be asked to behaviorally wear this shoe and perform the exercises daily for 6 weeks.
41509762|NCT05681598|DRUG|Hydroxyurea|The treatment started with a dose of 15mg/kg/day of HU. This initial dose was increased in steps of 5mg/kg/day every three months up to 35mg/kg/day or a maximal tolerated dose.
40854198|NCT06453681|OTHER|bilateral PECS|ectoralis nerve (Pecs) block, which is novel, less invasive regional analgesic technique.
41037167|NCT03877718|DRUG|Arm 4: Promethazine HCl 18.75 mg|One capsule of promethazine HCl 18.75 mg
41037168|NCT03877718|DRUG|Arm 5: Promethazine HCl 37.5 mg|One capsule of promethazine HCl 37.5 mg
41037169|NCT03877718|OTHER|Placebo|One capsule of placebo
41166035|NCT05768269|OTHER|No Intervention|As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
41384460|NCT04294290|BIOLOGICAL|hCT-MSC infusion|This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).
41384461|NCT03030482|PROCEDURE|touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
41384462|NCT05844826|DEVICE|SIMBA Capsule|Participants will swallow capsule
41384463|NCT05556031|OTHER|Standard care|Standard clinical care
41384464|NCT03463824|BEHAVIORAL|Experimental Group 1|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
41384465|NCT03463824|BEHAVIORAL|Experimental Group 2|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
41384466|NCT02656875|DRUG|TRV130|
41384467|NCT04372810|PROCEDURE|High Velocity Low Amplitude manipulation (HVLA)|The thrust manipulation technique was used, which consists of high speed and small amplitude manipulation. The therapeutic intervention was performed through decompressive maneuvers for the tibiotarsal joints. The choice of the place of application of the manipulation technique was delimited by the identification of the area or areas with compressive compartmental impairment and joint restriction. The use of the method depended directly on the identification of one or more regions of joint restraint.
41384468|NCT04372810|PROCEDURE|Care assessment and guidance|Evaluation and care guidelines on glycemic control and diabetic foot care.
41384469|NCT06495125|DRUG|Avutometinib|Given PO
41384470|NCT06495125|PROCEDURE|Biopsy|Undergo biopsy
41384471|NCT06495125|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41384472|NCT06495125|PROCEDURE|Computed Tomography|Undergo CT
41384473|NCT06495125|DRUG|Defactinib|Given PO
41384474|NCT06495125|BIOLOGICAL|Nivolumab|Given IV
41384475|NCT06495125|PROCEDURE|Positron Emission Tomography|Undergo PET
41384476|NCT06079801|DEVICE|Transcranial direct current stimulation (tDCS)|TDCS was delivered by a DC-Stimulator (Newronika, Italy) over both DLPC. The electrodes (35 cm2) were soaked in 0.9% NaCl. The anode was positioned on the left dorsolateral prefrontal cortex and the cathode on the right dorsolateral prefrontal cortex.
41384477|NCT06079801|DRUG|anti-CGRP-mAbs|CGRP-mAbs have been the first target-driven treatment to be approved for migraine prevention. Their efficacy and safety have been demonstrated in randomized controlled trials (RCT) as well as, in real-world evidence (RWE) studies
41384478|NCT03054935|OTHER|Indirect Calorimetry|Measurement of resting energy expenditure
41384479|NCT05601193|OTHER|autologous platelet-rich plasma|autologous PRP preparation was done by segregation of PRP following the centrifugation
41384480|NCT04359186|OTHER|Treatment Interruption Arm|Individuals with HIV on suppressive ART will interrupt their ART.
41384481|NCT06106282|OTHER|Non-Interventional Study|Non-Interventional Study
41166036|NCT02073253|OTHER|Noninvasive ventilation|In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
41166037|NCT04834063|DIAGNOSTIC_TEST|Serum Zinc a level|Diagnostic test
41384482|NCT03378999|DIETARY_SUPPLEMENT|Rhodospirillum rubrum|Capsules containing oven-dried Rhodospirillum rubrum
41384483|NCT03378999|DIETARY_SUPPLEMENT|Control|Capsules containing microcrystalline cellulose
41384484|NCT05887102|BEHAVIORAL|PACHA Program|Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
41384485|NCT02001038|OTHER|Survey|
41384486|NCT04662424|OTHER|music in labor|Women in the intervention group will be offered music in labor, defined listening to music from the randomization until the delivery of the baby. Women had the possibility to select the songs at their discretion
41384487|NCT03525327|OTHER|Line Dance Class|"Line or party dances to be taught will include:~Electric Slide (Mainland USA)Hukilau (Hawaii)Cupid Shuffle (Mainland USA)Poco Poco (Philippines)Cha Cha Slide (Mainland USA)Tush Push (Mainland USA)Trojan Crawl (Mainland USA)Wobble (Mainland USA)Goyang Maumere (Indonesia)"
41384488|NCT02561728|DEVICE|Hangar Helmet|Child will be fitted with the Hangar Helmet
41384489|NCT02561728|DEVICE|P-Pod Helmet|Child will be fitted with the P-Pod Helmet
41384490|NCT06567730|OTHER|Ni-ti Closed-coil Spring|Ni-Ti closed-coil spring is a passive compressed spring made up of super elastic Nickel-titanium. Two eyelets are attached to each side of the coil to facilitate its application. The eyelets will be engaged in the hooks of the second premolar and canine brackets and will apply a force of 150 gm.
41384491|NCT06567730|OTHER|Elastomeric Power chain|Elastomeric power chains are resilient and latex-free orthodontic materials. They are made up of elastic material and consist of many connected rings. Each ring is engaged in a bracket to apply a force of 175-300 gm.
41384492|NCT02145000|BIOLOGICAL|Rotavirus vaccine (BRV-PV)|Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
41384493|NCT02145000|BIOLOGICAL|Placebo|
40676593|NCT06608186|DRUG|Drospirenone drug|A drug drospirenone in the form of 1 tablet / d from day 5 of stimulation till hCG trigger day
40676594|NCT05856539|PROCEDURE|Erector spinae plane (ESP) block|ESP block is an opioid-sparing regional anesthetic involving bupivacaine and dexamethasone for lumbar spinal surgery with touted benefits including opioid use reduction and improved pain control.
41166038|NCT04834063|DIAGNOSTIC_TEST|serum selenium level|Diagnostic test
41384494|NCT04793815|PROCEDURE|Cryo-activation|The cryo-activation procedure involves the insertion of a cryoprobe in the tumor bed with subsequent application of very low temperatures leading to cell necrosis and tumor antigens release.
40854199|NCT06453681|DRUG|Dexmedetomidine|Dexmedetomidine is a potent α2 agonist. In our practice, dexmedetomidine is administered as an additive to regional anesthesia to improve the duration and quality of analgesia
40854200|NCT05269108|PROCEDURE|Fluoroscopy-free RIRS|RIRS for renal stone under direct visualization, without fluoroscopy
40854201|NCT05269108|PROCEDURE|Standard RIRS|RIRS for renal stone under fluoroscopy-guidance
41384495|NCT04793815|DRUG|Pembrolizumab|Following the cryo-activation procedure, patients will sequentially be treated with pembrolizumab (anti-PD-1) monotherapy.
41384496|NCT02987114|DRUG|PLT101|PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
41384497|NCT00107809|DRUG|Modafinil|
41384498|NCT01408407|OTHER|Aveeno cream|Apply cream on irradiated area twice a day
40854202|NCT01755871|DRUG|Fingolimod|0,5mg Fingolimod once a day
41384499|NCT01408407|OTHER|Alkagin paste|Apply Alkagin paste three times a day.
40854203|NCT00028327|DRUG|Lamivudine/Zidovudine|
40854204|NCT00028327|DRUG|Nelfinavir mesylate|
40854205|NCT00028327|DRUG|Efavirenz|
40854206|NCT00028327|DRUG|Lamivudine|
40854207|NCT00028327|DRUG|Zidovudine|
40854208|NCT05141149|DRUG|PBP1510 (400mg/16mL)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion
40854209|NCT05141149|DRUG|Gemcitabine (1000 mg/m^2)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.
40854210|NCT02161991|DRUG|Aprepitant|aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
41166039|NCT04834063|DIAGNOSTIC_TEST|Fibroscan measurement|Diagnostic test
41384500|NCT05524207|PROCEDURE|carotid artery stenting|Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis
41384501|NCT01019109|DEVICE|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
41384502|NCT01126359|DRUG|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
41384503|NCT01126359|DRUG|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
41384504|NCT00631709|OTHER|CareLink Remote Monitoring|Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits
41384505|NCT01643928|BIOLOGICAL|Rituximab-Pfizer (PF-05280586) x 3 courses|1000 mg intravenous infusion \[IV\] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
41384506|NCT01643928|BIOLOGICAL|Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
41384507|NCT01643928|BIOLOGICAL|Rituximab-US + Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
40854211|NCT02161991|DRUG|placebo|placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
40854212|NCT06166368|OTHER|Diurnal variation|Venous blood samples were obtained under standardized circumstances from 24 healthy young men every third hour through 24 hours, nine time points in total.
40854213|NCT00242099|PROCEDURE|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
40854214|NCT00586885|DRUG|L-alanine|6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
40854215|NCT05927363|OTHER|Therapeutic educational consolidation program in Phase 3 of cardiac rehabilitation associating a patient & caregiver partnership|"In the experimental group, patients benefit from the usual management as part of the phase 2 post-CR follow-up, with the provision of an information booklet on the benefits of physical activity, and a telephone contact in the event of any questions. In addition, they benefit from the Consolidation therapeutic education program in phase 3 of CR associating a patient \& caregiver partnership, which consists of two teleconsultation sessions at 2 and 4 months, followed by a remote group education workshop co-facilitated by the patient and caregiver partnership at 5 months.~Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions."
40854216|NCT05927363|OTHER|Teleconsultation at 2 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
40854217|NCT05927363|OTHER|Teleconsultation at 4 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
40854218|NCT05927363|OTHER|Remote group education workshop|This remote workshop will be co-facilitated by the patient and caregiver partnership at 5 months
41166040|NCT06158828|DRUG|Rabbit Anti thymocyte globulin|rATG is administered intravenously over 6-18 hours for a total of 2 to 3 doses. The daily dose is based on body weight and lymphocyte count.
41384508|NCT06366204|OTHER|Dietary Lysine Intakes|Participants consume 8 hourly meals that contain the assigned test lysine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.7 x Resting Energy Expenditure (REE) and adequate protein at 1.5 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and nitrogenous free cookies.
40854219|NCT05927363|OTHER|Administration of self-questionnaires: IPAQ, EMAPS, the Exercise Confidence Survey, EQ-5D-5L and the Mediterranean diet adherence score.|Patients are then randomly assigned to either the control group (usual management) or the experimental group (management with Patient and Caregiver partnership).
40854220|NCT05927363|DIAGNOSTIC_TEST|6-minute walk test and administers the modified Borg scale at its conclusion.|What is a modified Borg scale? The Modified Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered following a six-minute walking test, one of the most common and frequently used measures to assess disease severity in patients with pulmonary arterial hypertension. Upon conclusion of the 6-minute walking test, the modified Borg scale will be recorded.
40854221|NCT05927363|DIAGNOSTIC_TEST|Biological check-up|This check-up includes total cholesterol, LDL, HDL, triglycerides, HbA1c.
40854222|NCT05927363|DEVICE|Accelerometer|"An accelerometer is given to the patient, with instructions to wear it for 7 days following the visit (it will then be returned by post).Pre-stamped bubble envelopes are given to the patient to return their accelerometer to the measurement points specified in the follow-up."
40854223|NCT05927363|OTHER|Administration of a logbook|The patient is given a logbook for daily monitoring of non-measurable physical activities, treatments and medical procedures carried out, as well as any intercurrent events.
41037170|NCT04725721|BEHAVIORAL|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
41037171|NCT04725721|BEHAVIORAL|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
41166041|NCT06158828|DRUG|Busulfan|Busulfan is administered intravenously either Q6H or Q24H, with a recommended target Busulfan AUC of 70-90 mg\*h/L.
41166042|NCT06158828|DRUG|Fludarabine|Fludarabine is administered intravenously at a dose of 40 mg/m\^2/dose once daily for 4 days.
41384509|NCT05894382|DEVICE|Double Helix Design Defocus Lens Spectacle (RACE)|Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.
40854224|NCT00240500|BIOLOGICAL|Engerix™-B|In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
40854225|NCT01831674|DRUG|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
40854226|NCT01831674|DRUG|GLUCOPHAGE®XR tablet 750 mg|GLUCOPHAGE®XR 750 mg once a day
40854227|NCT02589106|DEVICE|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
41166043|NCT06158828|DRUG|Thiotepa|Thiotepa is administered intravenously at a dose of 5 mg/kg/dose Q12H for 2 doses.
41166044|NCT06158828|DRUG|Melphalan|Melphalan is administered intravenously at a dose of 70 mg/m\^2/dose once daily for 2 days.
41384510|NCT05894382|DEVICE|single-vision spetacle lens|single-vision spetacle lens wearing more than 10h/day.
40854228|NCT00079573|BEHAVIORAL|Atkins diet (extremely low carbohydrate)|
40854229|NCT00079573|BEHAVIORAL|Zone diet (low carbohydrate, high protein)|
40854230|NCT00079573|BEHAVIORAL|Ornish diet (very low fat)|
40854231|NCT00795301|DRUG|Capecitabine, Cetuximab, Oxaliplatin|
41384511|NCT00203892|BIOLOGICAL|modified CEA peptide (10mcg)|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
41384512|NCT00203892|BIOLOGICAL|modified CEA peptide (100mcg)|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
41384513|NCT00203892|BIOLOGICAL|modified CEA peptide (1000mcg)|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
41509763|NCT05928312|DRUG|Fruquintinib Combined With Chemotherapy|"1.Security introduction period:~\[1\] Safety introduction period (N=6), fruquintinib combined with three-week regimen:~1. Fruquintinib: Three-week regimen of combined chemotherapy: 4mg/d, orally, once a day, taking the drug for 2 weeks and stopping the drug for 1 week, 3 weeks as a treatment cycle.~\[2\] Safety introduction period (N=6), fruquintinib combined 2-week regimen:~1. Fruquintinib: two-week combination chemotherapy regimen: 4mg/d, orally, once a day, taking the drug for 3 weeks and stopping the drug for 1 week, 4 weeks as a treatment cycle.~2. Dose expansion phase design(N=60) Cohort 1 (30 patients) : Fruquintinib combined with oxaliplatin. Cohort 2 (30 patients) : Fruquintinib combined with irinotecan ."
40854232|NCT01114828|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
41037172|NCT06627920|DEVICE|Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor.|Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor to estimate blood pressure, heart rate and oxygen saturation.
41037173|NCT06055296|OTHER|COMPRENDO Peer Navigation Intervention|"Parents randomized to the intervention, COMPRENDO, will receive culture, language, and health literacy-concordant pre-accrual, accrual, and post-accrual activities in person led by a peer navigator for up to 4 weeks. Visit 1 (V1) will provide anticipatory guidance and education on a) general concepts of pediatric cancer research (standard of care, clinical trials, randomization); b) informed consent/assent, research affiliations (e.g., Children's Oncology Group); c) clinical trial types (therapeutic, non-therapeutic); d) voluntariness; and e) frequently asked questions, resources. Navigators will follow a script supported by culture, language and health-literacy concordant handouts and graphic materials, decision aids, and short video-clips. Navigators also provide support with decision-making and answer parents' questions. Three follow-up peer navigator visits (V2, V3, V4) over 4 weeks are tailored to the parents' needs."
41037174|NCT05404542|DRUG|Tavapadon|Oral tablets
41037175|NCT00492284|DRUG|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
41037176|NCT00492284|DRUG|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
41037177|NCT00492284|DRUG|ranibizumab|0.5 mg intravitreal injection
41037178|NCT00492284|DRUG|dexamethasone|0.5 mg intravitreal injection
41180048|NCT02420249|BEHAVIORAL|Qigong training|Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong \[in Chinese\]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
41384514|NCT06393907|DEVICE|Hemostatic Forceps|The experimental device will be used for control bleeding in high risk gastroduodenal ulcers.
41384515|NCT06393907|DEVICE|Bipolar Electrocautery Probes|The active comparator devices will be used for control bleeding in high risk gastroduodenal ulcers.
41384516|NCT00086931|DRUG|capecitabine|oral dose escalating, twice daily.
41384517|NCT00086931|DRUG|oxaliplatin|IV over 2 hours on days 1, 8, 15, 22, and 29.
41384518|NCT00086931|PROCEDURE|conventional surgery|curative-intent surgery 6-8 weeks after the completion of chemoradiotherapy
41509764|NCT06056141|DRUG|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
40854233|NCT01114828|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
40854234|NCT02736344|DEVICE|BioNIR Ridaforolimus Eluting Coronary Stent|
40854235|NCT01324362|DRUG|Placebo|Twice daily dosing
40854236|NCT01324362|DRUG|Placebo|Twice daily dosing
40854237|NCT01324362|DRUG|FP 100mcg|Twice daily dosing
40854238|NCT01324362|DRUG|FP 250mcg|Twice daily dosing
40854239|NCT01324362|DRUG|FP 500mcg|Twice daily dosing
40854240|NCT01324362|DRUG|FSC 100/50mcg|Twice daily dosing
40854241|NCT01324362|DRUG|FSC 250/50mcg|Twice daily dosing
40854242|NCT01324362|DRUG|FSC500/50mcg|Twice daily dosing
40854243|NCT03314311|BEHAVIORAL|Rehabilitation programme|The RESTORE trial is a 12 week multi-disciplinary intervention involving exercise, nutrition advice and education sessions
41384519|NCT00086931|PROCEDURE|neoadjuvant therapy|chemotherapy and radiation prior to surgery
41384520|NCT00086931|RADIATION|radiation therapy|once daily 5 days a week for 5.5 weeks
41384521|NCT05286931|DRUG|Ciprofloxacin 500 mg|Ciprofloxacin 500 MG, taken once orally.
41509765|NCT06056141|DEVICE|Foley Catheter|Transcervical Foley catheter (silicone, size 20F with 30ml balloon)
41509766|NCT03863548|OTHER|complication|collection of post-operative bleeding complications
40854244|NCT05426941|BEHAVIORAL|Music Imagery|Up to 30 participants will be randomized to receive 8 weekly Music Imagery sessions over 8-12 weeks.
40854245|NCT05426941|BEHAVIORAL|Music Listening|Up to 15 participants will be randomized to independent music listening.
40854246|NCT04292223|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
40854247|NCT05727657|DRUG|Satralizumab|120mg subcutaneous Day 0 and Day 14
40854248|NCT02606331|PROCEDURE|Piezosurgery|Corticotomy cuts will be performed by this technique.
40854249|NCT02606331|RADIATION|ER:YAG laser|Corticotomy cuts will be performed by this technique.
40854250|NCT02780544|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact with parent during eye examination.
40854251|NCT02780544|DEVICE|incubator|staying in incubator during eye examination.
40854252|NCT02780544|DRUG|Sucrose|oral sucrose before eye examination
41384522|NCT03949283|DIAGNOSTIC_TEST|ChemoID Assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
41509767|NCT01932333|DRUG|JNJ-40411813 50 mg|Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
41509768|NCT01932333|DRUG|JNJ-40411813 100 mg|Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
41509769|NCT01932333|DRUG|Placebo|Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
41509770|NCT06303843|OTHER|Transfer with an electric ride-on car|The children in the experimental group will be transported to the operating theatre by a electric ride-on car.
41509771|NCT05549505|DRUG|ARV-471|tablets
41509772|NCT05549505|DRUG|Anastrozole|1mg tablet
40854253|NCT06279507|DRUG|Sodium Hyaluronate|Sodium hyaluronate 2% (40 mg/2 mL), with molecular weight of 1-2 million dalton Other active ingredient : Mannitol 0.5% Preparation : Pre-filled syringe
40854254|NCT06279507|DRUG|Normal Saline|0.9% sodium chloride 2 mL prepared in plastic syringe
41509773|NCT05549505|PROCEDURE|Surgical resection of breast tumor|Participants will have surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)
41509774|NCT01331850|DRUG|Copegus|1000 mg or 1200 mg daily oral doses for 24 weeks
41509775|NCT01331850|DRUG|Copegus|1000 mg or 1200 mg daily oral doses for 48 weeks
41509776|NCT01331850|DRUG|Pegasys|180 microgram subcutaneously once weekly for 24 weeks
41509777|NCT01331850|DRUG|Pegasys|180 microgram subcutaneously once weekly for 48 weeks
41509778|NCT01331850|DRUG|RO5024048|1000 mg oral doses twice a day for 24 weeks
41509779|NCT01331850|DRUG|danoprevir|100 mg oral doses twice a day for 24 weeks
41509780|NCT01331850|DRUG|ritonavir|100 mg oral doses twice a day for 24 weeks
40854255|NCT06279507|DRUG|Triamcinolone Acetonide 10mg/mL|10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention
40854256|NCT04483336|OTHER|Virtual Reality Distraction|Virtual reality goggles are commercially available wearable devices that are used to view view videos and play video games three dimensionally.
41509781|NCT05344131|OTHER|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Biopsychosocial approach
41509782|NCT06291714|DEVICE|GDT-based hemodynamic management based on Clearsight device|Intraoperative use of a HPI-guided hemodynamic goal-directed protocol based on the non-invasive measurement of HPI (Clearsight system)
40854257|NCT04483336|OTHER|TV Screen Distraction|A cartoon video was played on a regular TV screen.
41180049|NCT06251999|DRUG|fospropofol sedation|Fospropofol sedation for same-day bidirectional endoscopy in elderly patients
41180050|NCT06251999|DRUG|Propofol|propofol
41509783|NCT01173120|DEVICE|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
41509784|NCT00146276|DRUG|gemcitabine|
41509785|NCT02927470|DEVICE|Sham TMS condition|A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of sham TBS, the subject will perform the working memory task for 45 minutes.
41509786|NCT02927470|DEVICE|OffLine TMS Condition|A total of 200 trains will be delivered successively in 40 s, totaling 600 pulses. The pulses will be delivered at 80% of motor thresholds. A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of TBS, or sham TBS, the subject will perform the working memory task for 45 minutes.
41509787|NCT02927470|DEVICE|Online TMS condition|A single train of pulses (3 pulses at 50Hz, duration 40ms) will be delivered once during a particular time epoch on each trial, followed by a minimum of 6 seconds of no stimulation. No more than 600 pulses will be applied in a single session. Similar to the offline TMS condition, a sham TMS coil will be used to measure baseline performance on the working memory task. In each session (frontal, sham) subjects will perform the working memory task for 45 minutes.
41509788|NCT01772875|PROCEDURE|bladder lavage|the bladder is rinced through the urinary catheter with the lavage solution
41509789|NCT02368483|OTHER|Neuromuscular training|Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
40892961|NCT02529072|BIOLOGICAL|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
41180051|NCT01349452|DRUG|Ganciclovir|Ganciclovir 0.15% Ophthalmic gel
41166045|NCT06158828|BIOLOGICAL|TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft|The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0. There is no maximum limit for CD34+ dose. A maximum dose of 1 x 10\^5/kg recipient weight of TCRαβ cells should not be exceeded in the final HPC product.
41166046|NCT06158828|BIOLOGICAL|memory-like natural killer cells|The ML NK cells (dose: max capped at 20 x 10\^6/kg recipient weight, minimum dose allowed is 0.5 x 10\^6/kg recipient weight) will be infused on Day +7.
41166047|NCT06158828|BIOLOGICAL|IL-2|IL-2 is administered subcutaneously at a dose of 1 million units/m\^2 on Days +7, +9, +11, +13, +15, +17, and +19 (7 doses total).
41384523|NCT03949283|DRUG|Standard Chemotherapy|"Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
41384524|NCT02426827|DEVICE|Spinal Cord Stimulation|
41384525|NCT01652872|BIOLOGICAL|Darbepoetin alfa|Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.
41384526|NCT01652872|OTHER|Placebo|Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.
41384527|NCT06193044|DRUG|Amlodipine/Valsartan|Amlodipine 10 mg \&valsartan 160 mg
41384528|NCT06193044|DRUG|Amlodipine 10 mg &valsartan 160 mg (Exforge)|Amlodipine 10 mg \&valsartan 160 mg
41384529|NCT02801838|DRUG|Morphine|If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
41384530|NCT04720573|DRUG|Neostigmine|50 mcg/kg neostigmine was used under the guidance of TOF monitoring after cessation of anesthesia.
41384531|NCT04720573|DRUG|Sugammadex|2 mg/kg sugammadex was used under the guidance of TOF monitoring after cessation of anesthesia.
41384532|NCT05166369|BEHAVIORAL|Communication skills training|"This intervention consists of a course on communication skills for healthcare professionals.~It will be done remotely via the internet and will include: communication skills training and optimal management of acute non-complicated RTI and delayed antibiotic prescription. Training modules will be delivered via a specific website password protected. Healthcare professionals will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
41384533|NCT05166369|BEHAVIORAL|Mobile phone application on RTI|"This intervention involves the use of a mobile phone application by parents and caregivers.~The mobile app will provide information, education and interactive tools about acute noncomplicated respiratory tract infections.~PC centres allocated to this group will display posters and flyers to inform parents and caregivers about the mobile app. Healthcare staff will also promote the use of this app by parents and caregivers.~The app information will be useful before the consultation, and will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making.~Importantly, the app will allow tailoring the guidance provided according to the type of infection or the number of days with symptoms.~Healthcare professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
41384534|NCT00460421|DRUG|Palifermin|Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
41384535|NCT00460421|RADIATION|Total Body irradiation|
41384536|NCT00460421|DRUG|Chemotherapy|High dose etoposide, Cyclophosphamide
41384537|NCT03907540|DRUG|Belumosudil 200 mg tablet|Belumosudil 200 mg tablet, development candidate
41509790|NCT05843747|OTHER|Sampling|During thier bariatric surgery, samples of adipose tissue will be done
41509791|NCT05019599|OTHER|low protein diet|Low protein diet (\<0.8g/kg/BW/day)
40854258|NCT04573608|DRUG|Papacarie|Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
41166048|NCT06158828|DRUG|Plerixafor|If suboptimal collection of stem cells is predicted, plerixafor may be administered at a dose of 0.24 mg/kg subcutaneous injection once (maximum 40mg/dose). For patients with renal impairment, plerixafor will be administered at a dose of 0.16 mg/kg subcutaneous injection (maximum 27 mg/day).
41166049|NCT06158828|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|G-CSF will be administered at a dose of 10 mcg/kg/day for 5 days, or 6 days if two days of collection are needed.
41384538|NCT03907540|DRUG|[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose|test investigational medicinal product
41384539|NCT03907540|DRUG|[14C]-KD025 200 mg capsule|test investigational medicinal product
41509792|NCT02532309|DRUG|Rosuvastatin (5mg，10mg，20mg)|Rosuvastatin dose adjusted by LDL-c level( If LDL-C\>1.1mmol/L and \<1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
41509793|NCT02532309|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
41509794|NCT02598921|RADIATION|three dimensional ultrasound|
41509795|NCT02598921|DEVICE|Office hysteroscopy|
41384540|NCT03473145|BEHAVIORAL|Health Coaching|Health Coaching sessions will be aimed at goal setting, implementing strategies, overcoming barriers, \& relapse prevention.
41384541|NCT03473145|DEVICE|activPAL inclinometer|Participants in the intervention study arms (B \& C) will wear the ActivPAL device for the first 4 weeks of the program and then again in weeks 8 and 9. The device will monitor their sitting and standing time and will allow Health Coaches to provide feedback and will assist the participant in developing an action plan.
41384542|NCT03473145|OTHER|Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.|Participants in the intervention study arms (B \& C) will receive tools to prompt standing or sit-to-stand transitions such as wearable wrist devices, standing desks or tables (Group B only), mechanical and/or electronic timers, or access to mobile apps or computer programs.
41384543|NCT04720885|PROCEDURE|kind of surgery|hysteroscopy, curettage, other
41384544|NCT05674864|DRUG|Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus|Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
41384545|NCT01004575|DEVICE|implantation of Kaname Cobalt-Chromium coronary stent|implantation of Kaname Cobalt-Chromium coronary stent
41384546|NCT05917314|OTHER|Slimbiotic Probiotic|"SlimBiotics Probiotic formula contains three probiotic strains of L. fermentum:~* Limosilactobacillus fermentum K7-Lb1~* Limosilactobacillus fermentum K8-Lb1~* Limosilactobacillus fermentum K11-Lb3 The product also contains Microcrystalline cellulose."
41384547|NCT05917314|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose.
41384548|NCT01766141|OTHER|Spinal manipulation|Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
41384549|NCT02246231|DEVICE|MR imaging|
41384550|NCT04482101|OTHER|Root canal obturation|Root canal filling
41384551|NCT06567990|DIAGNOSTIC_TEST|Non-invasive test for the screening of MASLD-related advanced fibrosis in patients with T2D.|"* Non-invasive blood biological tests = NAFLD Fibrosis Score, FIB-4 score, FNI score, Agile3+ score, FASTscore, ELF, Fibrotest, Fibrometer if performed in clinical care~* Non-invasive imaging = Transient elastography (FibroScan), Questionnaire assessing alcohol consumption"
40854259|NCT04573608|DRUG|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
40854260|NCT03514875|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation
40854261|NCT03514875|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in a double blinded, randomized, cross-over design
40854262|NCT04534322|DRUG|Melphalan Flufenamide|Melphalan flufenamide (melflufen) is an investigational peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
40854263|NCT04534322|DRUG|Dexamethasone|Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.
41180052|NCT01349452|DRUG|Artificial tear|Artificial tear 5 times per day
41384552|NCT06373978|DRUG|Diclofenac|50mg every 8hours as needed for pain
41384553|NCT06373978|DRUG|Tramadol|50mg every 8hours as needed for pain
41509796|NCT03616717|DRUG|Modafinil|"Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil"
41384554|NCT06373978|OTHER|Acetaminophen|1000mg every 8hours as needed for pain
41384555|NCT01793285|DRUG|ETANERCEPT|"During the LoadET study (0881A3-102090), subjects were treated with etanercept 100 mg versus 50 mg weekly. After completing this study, the subjects were allowed to continue the treatment with etanercept 50 mg weekly, etanercept 100 mg weekly, another drug, or abandoned medication at the discretion of their physician.~This is a non-interventional study in which historic data will be collected retrospectively from the patient's clinical history. During the historical period covered in the Study, patients would have received the treatment and the medical care that their treating physicians considered appropriate under the conditions of standard clinical practice."
41384556|NCT05086627|DRUG|Tislelizumab|Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).
41384557|NCT05086627|RADIATION|Short-course radiotherapy|Patients were treated with short-course neoadjuvant radiotherapy
41384558|NCT05086627|DRUG|Capecitabine+Oxaliplatin|Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
41384559|NCT04027777|DEVICE|Aktiia.product-P0|The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.
41384560|NCT06095362|DRUG|Bevacizumab-IRDye800CW|All patients will receive a dose of Bevacizumab-IRDye800CW, in a dose of 4.5, 10, or 25mg
41384561|NCT03458039|BEHAVIORAL|In-person CETA|The Common Elements Treatment Approach (CETA) is a transdiagnostic, multi-problem intervention designed to address adult and youth trauma, depression, anxiety, safety, and substance use. It is comprised of a small set of common elements found to be efficacious and prevalent across a range of EBTs to treat common mental health problems. CETA was designed to be flexible in the elements utilized, their order, and their dose (number of sessions) to allow counselors to address heterogeneity, comorbidity, and symptom fluctuations in and across clients. Treatment typically consists of 6 to 12 weekly, approximately 60-minute sessions delivered by lay workers.
41384562|NCT03458039|BEHAVIORAL|Telephone CETA|"For adaptation of the CETA manual for telephone delivery, the Applied Mental Health Research (AMHR) Group at Johns Hopkins University (JHU) reviewed evidence-based telehealth strategies and recommendations, telehealth ethical and legal guidelines, and clinical recommendations from telehealth providers. In addition, local TTTs in multiple contexts reviewed telehealth modifications and provided input that was incorporated into the final T-CETA manual used in this study. No changes were made to the structure, duration, and dose of CETA sessions, treatment components, or measurement-based clinical decision-making processes. Telehealth modifications, additions, and strategies were incorporated throughout the manual in delineated telehealth boxes. This way, the original manual was maintained outside of the telehealth boxes, allowing for clear identification and training of telehealth modifications for both new and existing CETA counselors."
41509797|NCT03616717|DRUG|placebo|Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
41509798|NCT05727098|DRUG|Bupivacaine Hydrochloride|injection of Bupivacaine 0.25% in ESPB
41509799|NCT05727098|DRUG|Bupivacaine Hydrochloride and dexmedetomedine|injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
41509800|NCT05727098|DRUG|Bupivacaine Hydrochloride and ketamine|injection of Bupivacaine 0.25% and ketamine in ESPB
41509801|NCT02847988|DEVICE|Neuromuscular electrical Stimulation (NMES)|Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
41509802|NCT02847988|DEVICE|Sham Stimulation|Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
41509803|NCT03845296|DRUG|Rucaparib|Given PO
41509804|NCT01026311|DRUG|Coenzyme q 10|200 mg of Coenzyme q 10
41509805|NCT01026311|DRUG|placebo|1 placebo q d during treatment period
40854264|NCT05095350|BIOLOGICAL|Probiotic powder|Probiotic powder containing 10 strains from Lactobacillus and Bifidobacterium genus.
41509806|NCT04080466|RADIATION|Low-dose CT Scan|"Low dose computed tomography, also known as qCT, is sensitive to the mineral content within bone tissue, and can assess bone mineral density, a strong predictor of bone strength and stiffness, which can influence the health of the cartilage. Participants will undergo a low dose CT scan of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
40854265|NCT05095350|BIOLOGICAL|Placebo powder|Placebo powder containing maltodextrin and no probiotics.
40854266|NCT01568294|DRUG|pomalidomide|2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
40854267|NCT04933487|DEVICE|IOL implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris. (Manufactured by PhysIOL sa/nv, Liège, Belgium).
40854268|NCT00959738|PROCEDURE|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
40854269|NCT00959738|PROCEDURE|diverting loop ileostomy without rod|diverting loop ileostomy without rod
41509807|NCT04080466|OTHER|Blood/Urine Collection|"Collection of blood and urine allows the researchers to look for a biomarker in the blood and urine that might help to predict the evolution of disease/hip osteoarthritis. Identifying a marker in the blood and urine that could be used for early detection of individuals with cam deformity that are at-risk of hip degeneration could greatly improve patient care.~Participants in the Cam Group will undergo the blood and urine collection twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo a blood and urine collection once as part of the study."
40854270|NCT00411372|DRUG|fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg|
41384563|NCT03458039|BEHAVIORAL|Treatment as Usual (TAU)|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care treatments for mental and behavioral health problems among AYA. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some AYA receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control participants if it has been found to be safe and effective
41384564|NCT05981118|DRUG|Betamethasone dipropionate 0.05%|0.05% cream group will be treated once daily on both legs until clear or up to 12 weeks
41384565|NCT05981118|DRUG|Tapinarof|1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks
41384566|NCT01544374|OTHER|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
41384567|NCT03899545|OTHER|Serratus Plane Block|0.5 ml /kg Bupivacaine/lidocaine mixture will be injected onto the serratus muscle
41384568|NCT03899545|OTHER|Serratus Plane Block plus Pectoral I Block|0.5 ml / kg %0.25 Bupivacaine/ %1 lidocaine mixture will be injected onto the serratus muscle and injected between the pectoralis minor/pectoralis major muscles.2/3 of the total drug will be applied for the serratus plane block and 1/3 of the total drug for the pectoral I block. If the total amount of the drug is less than 30 ml, it will be completed with isotonic saline to 30 ml.
41384569|NCT00722007|DEVICE|Cormet Hip Resurfacing|Cormet Hip Resurfacing implant
41384570|NCT02076139|DIETARY_SUPPLEMENT|Nyaditum resae® 10e4|
41384571|NCT02076139|DIETARY_SUPPLEMENT|Nyaditum resae® 10e5|
41384572|NCT02076139|OTHER|Distilled water|
41384573|NCT00870714|DRUG|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
41384574|NCT00870714|DRUG|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
41384575|NCT04578548|DRUG|GLPG2737|Capsules administered orally
41384576|NCT04578548|DRUG|Placebo|Matching placebo capsules administered orally
41384577|NCT04950322|DRUG|SHR-1701、CAPOX|SHR-1701 with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
41509808|NCT04080466|OTHER|Patient Reported Questionnaires|"The purpose of the questionnaires is to assess how much trouble the participant is having with their hip and how it affects their quality of life.~Participants in the Cam Group will complete the questionnaires twice; once before surgery and once 2-years post-operative. Participants in the Control Group will complete the questionnaires once as part of the study."
40854271|NCT06405477|DIETARY_SUPPLEMENT|L-arginine|Capsules of 3 grams of L-arginine per Dose
40854272|NCT06405477|DIETARY_SUPPLEMENT|Placebo|Capsules of 3 grams of maize Starch per Dose
41384578|NCT04950322|DRUG|Placebo、CAPOX|Placebo with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
41384579|NCT04365842|BEHAVIORAL|Digital exercise group|"Hand Rehabilitation Program: Developed hand exercise smartphone app which include: Self-assessment, (b) self-monitoring (c) exercises types/frequency/ diary, (d) patient education, (e) behavioral change and encouragement (f) exercise adherence Sample exercises~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle"
41384580|NCT04365842|OTHER|General Home Hand Therapy|"Hand rehabilitation home program will be given to the through the telephone messages with brochures.~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle"
41384581|NCT05366725|DRUG|Avelumab|As provided in real world practice
41384582|NCT03724422|RADIATION|Radiation|A dose of 500cGy will be delivered in 1 fraction to the isocenter. Radiation will be administered no later than 72 hours postoperatively
41384583|NCT00355680|DEVICE|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
41384584|NCT00355680|DEVICE|Green Laser (Iridex)|Already available green laser
41384585|NCT03791255|DRUG|Calcium silicate liner|new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
41384586|NCT03791255|DRUG|Calcium hydroxide liner|Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
41384587|NCT01735864|DRUG|Indirubin 200μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment containing 200 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
41384588|NCT01735864|DRUG|Indirubin 100 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 100 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
40676595|NCT04353167|OTHER|observational evaluation|Patients will be evaluated only observationally without intervention
40854273|NCT05654454|DRUG|Bevacizumab|Bevacizumab 15 mg/kg
40854274|NCT05654454|DRUG|Paclitaxel|Paclitaxel 175 mg/m2
40854275|NCT05654454|DRUG|Carboplatin|Carboplatin AUC 6
41384589|NCT01735864|DRUG|Indirubin 50 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 50 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
41384590|NCT01735864|DRUG|Indirubin 10 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 10 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
41384591|NCT06045832|DEVICE|MAXPOWER Biological Antibacterial Liquid|MAXPOWER Biological Antibacterial Liquid is a mouthwash product self-developed in China, which contains betaine, antibacterial peptide and other antimicrobial substances, which have been proved by experiments to have a good biological safety and at the same time have a killing effect on bacteria. Mouthwash belongs to the category of medical devices, not drugs.
41384592|NCT06045832|DEVICE|Water|Water
41384593|NCT00007735|DRUG|Doxycycline (200mg/day) or Placebo|
41384594|NCT04749121|DEVICE|UVC Irradiation|We used the Porcine epidemic diarrhea virus (PEDV) as the indicator virus .An N99 mask was contaminated by spraying or applying with the virus on the exterior and interior surface of each silicone mask. Also, 100 μl of the viral suspension was spotted onto the filter part of N99 masks. Following 20-30 minutes of drying, the silicone masks underwent each of the decontamination procedures which are ultraviolet-C (UV-C) irradiation and 70% alcohol treatment. For UV irradiation, N99 masks were placed in an UV-C incubator ) and were exposed for different times at 1, 10 and 20 minutes, respectively.Untreated control and treated N99 masks were analyzed for viral infectivity in VERO cell cultures. At 48 hours post-infection, cells were examined for evaluation the viral infectivity via observation of cytopathic effect. Results for each treatment express mean ± standard deviations of 3 biological replicates.
41384595|NCT04749121|DRUG|UVC Irradiation|Bacterial and fungal sampling were obtained from the inside and outside surface areas likely to the frequently touched and close contact with the face of hospital personnel. The cultures were then isolated onto the blood agars and Mac Conkey agars, respectively. After incubation, the total number of bacterial and fungal colonies were counted, recorded, and selected different colonies.
41384596|NCT04749121|DEVICE|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol),
41384597|NCT04749121|DEVICE|Tensile strength|We measured the tensile strength of the strap of the Silicone mask before and after the UVC irradiation to study the strength and reliliency of the strap
41384598|NCT06565793|DEVICE|Non Complex PCI|The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).
41384599|NCT06565793|DEVICE|Complex PCI|The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved complex percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).This designation is applied to angioplasty procedures that meet at least one criterion for complexity. The complex angioplasty involved patients with unprotected left coronary common trunk (UT-PCI), the use of rotablator rotary atherectomy (ARota-PCI), the angioplasty of chronic coronary occlusion (CCO-PCI), or the angioplasty of a bifurcation lesion (CBL-PCI).The highly intricate angioplasty procedure was conducted on patients who met at least two criteria indicative of complexity.
41384600|NCT04135456|DRUG|Mannitol|When the neurosurgeon starts the skin incision, 20% mannitol administered through the venous catheter with fulldrip in 5-10 minutes. Neurosurgeons evaluate the degree of brain relaxation after dura opening in 4 point scale (1=bulging brain, 2=firm brain, 3=satisfactorily relaxed, 4=perfectly relaxed).
41384601|NCT04473339|PROCEDURE|CRS+HIPEC|"Patients will undergo only CRS, HIPEC and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
41384602|NCT04473339|PROCEDURE|CRS alone|Patients will undergo only CRS and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.
41384603|NCT03945760|DRUG|Baricitinib|Baricitinib 2 mg
41384604|NCT03945760|DRUG|Placebo|Placebo
40854276|NCT00206440|DRUG|esomeprazole|nexium
40854277|NCT00206440|OTHER|Placebo|Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
40854278|NCT02397057|DRUG|Injectafer|
41509809|NCT04080466|RADIATION|EOS Scan|"The EOS® uses a new imaging technique that allows precise measurement of the hip and pelvis geometry and structure. This innovative x-ray technique exposes participants to 2-10 times less radiation than a routine x-ray and can capture multiple images at once.~Participants in the Cam Group will undergo the EOS scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
41037179|NCT02801045|BEHAVIORAL|art therapy|"Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:~* humanistic phenomenological focus~* transpersonal therapeutic bound~* transdisciplinarity in the artistic approach~* integrative-relational specialized counseling of the grief, loss and trauma aspects."
41037180|NCT01810588|DEVICE|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
41037181|NCT01810588|DRUG|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
41037182|NCT01810588|DRUG|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
40854279|NCT02397057|OTHER|Placebo|
40854280|NCT02105675|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa is the experimental therapy added on to Docetaxel
40854281|NCT02105675|DRUG|Docetaxel|Docetaxel is Standard of Care First Line Chemotherapy
40854282|NCT01178203|DRUG|Placebo|Placebo
40854283|NCT01178203|DRUG|Tramadol|Tab, 100mg in 6, 12 and 24 hours after root canal treatment
41384605|NCT03667586|BEHAVIORAL|Group cognitive behavioral therapy|Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients
41166050|NCT06158828|DEVICE|CliniMACS|After stem cells are collected by leukapheresis, in order to create the HPC product, the stem cells will be washed to remove platelets and the cell concentration will be adjusted per laboratory and CliniMACS technology recommendations. The cells are then labeled using the CliniMACS TCRαβ Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product.
41384606|NCT06354439|DRUG|Letrozole tablets|10 mg of letrozole PO for 7 days
41384607|NCT06354439|DRUG|Methotrexate Sodium|100 mg of methotrexate IM, single dose
41384608|NCT05136859|PROCEDURE|preserve|preserve the perivascular fat of the target cephalic vein
40854284|NCT01178203|DRUG|Novafen|325 mg in 6, 12 and 24 hours after root canal treatment
40854285|NCT01178203|DRUG|Naproxen|Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
40854286|NCT01459744|BEHAVIORAL|Communication training for cardiologists.|"Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.~Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.~Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills."
41384609|NCT05418517|PROCEDURE|Tracheostomy|temporary tracheostomy insertion
41384610|NCT05418517|PROCEDURE|Overnight intubation|Patient who had overnight intubation
41384611|NCT04729634|OTHER|Mobilization|Mobilization and breathing exercises according to clinical care
41384612|NCT05355194|OTHER|Kinesiotape|"Patients will be instructed to inhale while taping the application. The tape will be applied in a vertical direction from just below the navel to the pubic region, another tape will be applied over the initial tape in the horizontal direction with minimal stretch. Another tape will be applied over the lumbosacral region making a V shape. The arms of V shall lie over the lumbar region while the base shall rest over the caudal region. Taping will be maintained for at least 48 hours.~The interventions shall be applied for two consecutive menstrual cycles."
41384613|NCT05355194|OTHER|Pelvic Tilts|Patients will be asked to lie in a supine position with legs bent and toes facing forward. Afterward, they will be instructed to pull their belly inwards while pushing pelvis towards the ceiling and keep hip muscles tightened. This position will be maintained for 5 seconds with 3 sets of 20 repetitions. Pelvic tilts must be performed throughout the menstrual cycle.
41384614|NCT05145647|RADIATION|Add-on Brachytherapy|Brachytherapy protocol starts within 2 weeks after consolidative EBRT, subjects who are enrolled will receive brachytherapy with specified balloon applicator. High-dose-rate (HDR) brachytherapy system will be used in the treatment, 5-Gy per fraction is delivered to the pre-treatment esophageal length of primary tumor(s), second treatment if applicable will be finished within 2 weeks after the first one, a total of 5-10Gy in 1-2 fractions will be delivered.
41384615|NCT05145647|DEVICE|"BRAXX Esophageal Brachytherapy Applicator"|The device is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.
41384616|NCT05134727|DRUG|AZD5055|Healthy participants will receive AZD5055
41384617|NCT05134727|DRUG|Placebo|Healthy participants will receive placebo
40854287|NCT01459744|OTHER|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
40854288|NCT06356389|DRUG|JX11502MA|Oral capsule
40854289|NCT06356389|DRUG|Placebo|Oral capsule
40854290|NCT05492864|PROCEDURE|extrusion of the anterior teeth|sectional leveling and alignment of the teeth, then using of the extrusion arch as an overlay wire to treat the open bite
40854291|NCT03702036|DRUG|molibresib|molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
40854292|NCT04384029|OTHER|Covid-19 + patients|all the patients hospitalized in Geneva and SARS-Cov2 positive
40854293|NCT00880191|DRUG|dexamethasone|Given orally
40854294|NCT00880191|DRUG|gabapentin|Given orally
40854295|NCT00880191|OTHER|placebo|Given orally
40854296|NCT03650140|DIETARY_SUPPLEMENT|Tart cherry extract 60 mL|Subjects will receive a single 60 mL oral dose of tart cherry extract.
41384618|NCT00648583|DRUG|Ondansetron Tablets 24 mg|24mg, single dose fed
41384619|NCT00648583|DRUG|Zofran® Tablets 24 mg|24mg, single dose fed
41384620|NCT01666067|DRUG|placebo|
41384621|NCT01666067|DRUG|vytorin|
41384622|NCT01666067|DRUG|simvastatin|
41384623|NCT06439316|BEHAVIORAL|Sedentary behavior|Total sedentary time was assessed by self-reported daily hours of sitting
41384624|NCT06439316|BEHAVIORAL|Depressive symptoms|depressive symptoms were assessed by Patient Health Questionnaire 9 scale
41384625|NCT04051840|DRUG|ClinOleic (Baxter Healthcare, Deerfield, IL, USA)|ClinOleic group: Patients using ClinOleic or Structolipid-based lipid parenteral nutrition regimen. From day 0 to day 5, the goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid.
41166051|NCT05527743|OTHER|Invasive Physiotherapy|They will receive an invasive physiotherapy protocol of 3 sessions of percutaneous electrolysis and percutaneous neuromodulation guided by ultrasound, with a time margin of one week between the first and the second session and two weeks between the second and the third. Each session will last approximately 30 minutes. Each treatment session will consist of the application of 3 impacts of 3 seconds of 1.5mA intensity (1.5:3:3) (34), in a needle placed in an echoguided manner in the carpal tunnel in relation to the median nerve over the area of fibrosis or entrapment. Subsequently, a second needle will be placed ultrasound-guided at the level of the elbow crease in relation to the median nerve. A symmetric biphasic current with a frequency of 2Hz and a pulse width of 250µs (22,35) will be applied for 17 minutes (36), increasing the intensity of the current until a slight tolerable discomfort is produced in relation to the patient's symptomatology.
41166052|NCT05527743|OTHER|Sham|"The participants of the study corresponding to the sham group will receive the application of the transcutaneous electrical stimulation sham technique (37), placing the patches in the same points where the needles are located in the percutaneous electrolysis and percutaneous neuromodulation technique, remaining in the supine position for the necessary time after the technique is performed, until 30 minutes are completed, thus ensuring that the evaluator does not know to which group each patient has been assigned (37). This technique has been studied as a sham technique for electrolysis and neuromodulation interventions (37).~Once the study is completed and if the results are better in the IF group, the subjects in the sham group will be offered to receive this treatment. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of research."
41166053|NCT02242799|DRUG|Dolutegravir 50mg od|Dolutegravir 50mg once daily will be given either alone or in combination, as specified
41166054|NCT02242799|DRUG|Artemether-lumefantrine combination|Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
41166055|NCT02242799|DRUG|Artesunate-amodiaquine|Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
41166056|NCT04033770|OTHER|Urodynamic investigation|Urodynamic investigation using an air-charged measurement system
41166057|NCT04033770|OTHER|Urodynamic investigation|Urodynamic investigation using a water-perfused measurement system
41166058|NCT05226247|PROCEDURE|Spontaneous breathing trial|To perform cardiac and lung echography before and during a spontaneous breathing trial
41166059|NCT00020969|DRUG|arsenic trioxide|
41166060|NCT06059209|DIETARY_SUPPLEMENT|Enfamil NeuroPro|FDA Infant formula
41166061|NCT06059209|DIETARY_SUPPLEMENT|Enfamil Infant|FDA Infant formula
41166062|NCT02767102|OTHER|Red wine with melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
41166063|NCT02767102|OTHER|Red wine without melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
41384626|NCT03256526|DRUG|Placebo|0 mg
41384627|NCT03256526|DRUG|PF-06835919 Low Dose|75 mg once daily
41384628|NCT03256526|DRUG|PF-06835919 High Dose|300 mg once daily
40854297|NCT03650140|DIETARY_SUPPLEMENT|Tart cherry extract 120 mL|Subjects will receive a single 120 mL oral dose of tart cherry extract.
40854298|NCT01468350|DRUG|dalfampridine-ER 10mg|
41384629|NCT01523301|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~* For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~* For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
41384630|NCT01523301|DRUG|Placebo|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
41384631|NCT04514809|OTHER|human milk analized|After birth (24-72 hours) 15 ml, and end of the first month of birth 30 ml of milk from the mother will be milked in the appropriate way and put into the sterile milk collection container. The milk taken into the milk transport container will be delivered to the Nutrition Lab for analysis (moisture, protein, fat, lactose) by the researcher who arrives at the TUBITAK Mam Research Center as fresh within 3 hours
41384632|NCT00488007|DEVICE|Hearing aids used : PHONAK Savia and Valeo|5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
41384633|NCT06566183|PROCEDURE|Guideline-directed medical therapy (GDMT)|Participants receive guideline-directed medical therapy (GDMT).
41384634|NCT06566183|PROCEDURE|Coronary artery bypass grafting (CABG)|Participants receive coronary artery bypass grafting (CABG).
41384635|NCT06566183|PROCEDURE|Percutaneous coronary intervention (PCI).|Participants receive percutaneous coronary intervention (PCI).
41384636|NCT02257411|DEVICE|Ear-sized based|the sizes of the PLMA determined with the ear-based formula were compared with the sizes according to the manufacturer's weight-based formula
41384637|NCT06471738|DRUG|Zanubrutinib|BTK inhibitor
41384638|NCT06471738|BIOLOGICAL|Rituximab|Monoclonal antibody to CD20
41384639|NCT06471738|DRUG|Venetoclax|BCL-2 inhibitor
41384640|NCT03026842|DRUG|Decitabine|20 mg/m2/day for 5 days
41384641|NCT03026842|DRUG|Daunorubicin, Cytarabine|Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
41384642|NCT03026842|DRUG|Mitoxantrone, Cytarabine|Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
40854299|NCT01468350|OTHER|Placebo|
40854300|NCT04177212|DEVICE|MRZF111|MRZF111 kit consisting of one syringe of RADIESSE® Volume injectable implant, injection needles and additional components. Physiological saline solution (0.9% NaCl) is used to dilute Radiesse Volume by 1:2. Radiesse consists of calcium hydroxylapatite particles suspended in an aqueous-based gel carrier.
40854301|NCT06432504|OTHER|Caffeine content|Participants will drink the same volume of coffee with different amounts of caffeine.
40854302|NCT02865902|DEVICE|Low-Level Laser Therapy by Ezlase; Biolase®|comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
40854303|NCT03929640|DRUG|Acetaminophen|Acetaminophen 650 mg tablet every 6 hours
40854304|NCT03929640|DRUG|Placebo|Placebo oral tablet every 6 hours
41384643|NCT03026842|DRUG|Aclacinomycin, Cytarabine|Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
40854305|NCT03929640|DRUG|Ibuprofen|Ibuprofen 600 mg tablet every 6 hours
40854306|NCT03359252|PROCEDURE|non-stent assisted coiling|non-stent assisted coiling of unruptured intracranial aneurysm
40854307|NCT03359252|PROCEDURE|stent assisted coiling|stent assisted coiling of unruptured intracranial aneurysm
40854308|NCT02324816|DEVICE|The Zeltiq CoolSculpting System|The CoolSculpting System delivers non-invasive cooling for the reduction of subcutaneous fat.
40854309|NCT04607746|DEVICE|Capsule Endoscope|Capsule endoscope used to view colonic mucosa
40854310|NCT05407038|OTHER|Exercise Counseling|Receive call from health coach
40854311|NCT05407038|OTHER|Exercise Intervention|Undergo routine exercise
41037183|NCT01810588|DRUG|anti-thymocyte globulin (rabbit)|Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
41384644|NCT03474952|PROCEDURE|remote ischemic preconditioning (RIPC)|remote ischemic preconditioning consists of 4 cycles of 5-min ischemia and subsequent 5-min reperfusion using pneumatic cuff applied to upper arm
41384645|NCT03474952|PROCEDURE|sham-RIPC|ischemia pressure less than 10 mmHg (sham-RIPC)
41037184|NCT01810588|DRUG|Rituximab|Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
41384646|NCT02374008|DRUG|Ropivacaine|
41384647|NCT01850901|PROCEDURE|Renal sympathetic denervation|
41384648|NCT06244095|OTHER|Perturbation Therapy|The applicants were instructed to perform various exercises, including rotating their trunks, tossing a ball, and maintaining pelvis neutrality. They were also asked to reach the toy sideways with one hand. The 6-week intervention was conducted four days a week for 60 minutes each day, focusing on trunk rotation, standing, tossing, and catching the ball in various directions. The training sessions lasted for 20 minutes each.
40854312|NCT05407038|OTHER|Internet-Based Intervention|Receive Android tablet
40854313|NCT05407038|OTHER|Interview|Complete a qualitative interview
40854314|NCT05407038|OTHER|Medical Device Usage and Evaluation|Wear Garmin Vivofit and Nonin 3150 WristOx2 pulse oximeter
40854315|NCT05407038|OTHER|Questionnaire Administration|Ancillary studies
40854316|NCT06525896|DEVICE|NSSD|A robotically-controlled distractive force is applied to the lower back to produce decompression of the spinal column.
40854317|NCT06525896|DEVICE|Sham NSSD|A robotically-controlled distractive force (lower than the intervention) is applied to tension the belt and create a sense of decompression without producing decompression of the spinal column.
40854318|NCT01756404|DRUG|Canagliflozin (JNJ-28431754)|A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
40854319|NCT01756404|DRUG|Placebo|Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
40892962|NCT02628990|OTHER|1.6 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
40892963|NCT02628990|OTHER|2 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
40854320|NCT00166439|DRUG|Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)|"rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles"
40854321|NCT00369499|DEVICE|PFO Closure|
41384649|NCT06244095|OTHER|Trunk Control Therapy|For the duration of each session, the manual pushes and pulls were administered around once per minute and lasted for 20 minutes. A platform that can be moved in four directions.Choosing to step and stroll when there is an outside disturbance. When routine motions such as sit-to-stand transitions, disruptions are applied when standing, walking, or other activities. Training with continuous disruptions simulates scenarios such as uneven terrain. Both rope and cable excursions are above ground and last for 20 minutes. Briefly explain the platform to the participants. Asked the participants to push the torso and waist against the wall during the session. Emerging barriers during training sessions like small obstacles (e.g. pair of bricks) then Lean the participants with the support of the therapist and let them go. Asked them to Step on a mushy or slick surface in session for 20 minutes. Each intervention session took place for 60 minutes per day four days of week for 6 weeks.
41509810|NCT04080466|RADIATION|PET-MRI|"Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that allows physicians to examine bone and cartilage at the molecular level.~Participants in the Cam Group will undergo the scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
40854322|NCT03383380|DRUG|Rapamycin|Gain-of-function (GOF) PIK3CD mutations lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mTOR hyperphosphorylated. The mammalian/mechanistic target of rapamycin inhibitor rapamycin may be effective to control the progress of this disease.
40854323|NCT00284362|PROCEDURE|Arthroscopic or open surgery for hallux rigidus|
40854324|NCT03848936|OTHER|Survey|Survey includes age, gender, cerebral palsy type, education, mental status, working status, living conditions, comorbidities, pain, spasticity, contractures, deformities, mobility status and gross motor function classification system level
40854325|NCT02768519|DRUG|OTS167IV|diluted to final concentration with cherry syrup
40854326|NCT02768519|OTHER|Cherry syrup|
40854327|NCT04465292|DRUG|Tildrakizumab Prefilled Syringe|Patients will receive Tildrakizumab 100 mg subcutaneously at Weeks 0, 4, and 16. The study staff will administer each dose.
41166064|NCT04780971|DIAGNOSTIC_TEST|post-PCI Pd/Pa|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) of the CTO vessel will be performed directly. A staged procedure including several measurements is planned at 4 ± 2 weeks after the index procedure. These measurements consists of the same intra-coronary physiologic assessments at index procedure and OCT imaging of the stented segment in the CTO target vessel.
41509811|NCT04080466|OTHER|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Participants in the Cam Group will undergo the Motion Analysis session twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the Motion Analysis session once as part of the study."
41509812|NCT04080466|RADIATION|3T MRI|"Participants will undergo a 3-Tesla (3T) Magnetic Resonance Imaging (MRI) of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
41509813|NCT01399658|PROCEDURE|Image-guided brachytherapy|MRI-guided application of brachytherapy
41509814|NCT01399658|DRUG|3'-Deoxy-3'-18f-Fluorothymidine|Assessing tumor proliferation in Gynecologic cancer
41509815|NCT03362372|BEHAVIORAL|Mediterranean diet counseling|"The participants of the intervention CAP will enter into an educational program to increase adherence to the DiMet that will integrate three operational components:~1. Explain the particularities of DiMet and the benefits of its monitoring. It will be an individual visit of 25-30 minutes (V1) where the study variables will be collected and the medical tests will be performed and repeated annually for two years (V3 and V5).~2. Clarify the doubts of the DiMet monitoring and the advice received. It will be a telephone visit to reinforce the intervention, with annual frequency, for two years (V2 and V4).~3. Report on DiMet's own foods, cooking habits, adapted recipes and other related topics. It will be for access to an ad hoc designed nutrition blog."
41509816|NCT00257621|DRUG|GW640385|
41509817|NCT00257621|DRUG|Ritonavir|
41509818|NCT00368758|DRUG|Probiotic bacteria (Trevis R)|
40854328|NCT01105273|BIOLOGICAL|anti-thymocyte globulin|On days -3 to -1
40854329|NCT01105273|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
40854330|NCT01105273|DRUG|Fludarabine|30mg/M2 once daily IV on days -6 to -2
40854331|NCT01105273|DRUG|Cyclophosphamide|60 mg/kg IV on day-3 and -2
40854332|NCT01105273|PROCEDURE|CD3±CD19 depleted hematopoietic stem cell transplantation|Immunogenetic depletion on CliniMACS
40854333|NCT00008528|DRUG|Enfuvirtide|
41509819|NCT05269095|PROCEDURE|Spinal anesthesia only|Patients will receive spinal anesthesia with 2-3 ml 0.5% (10-15 mg) hyperbaric bupivacaine plus 25 ug fentanyl at the L3/4 interspaces.
41509820|NCT05269095|BIOLOGICAL|Spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive16 ml bupivacaine 0025% will be administered, and4 ml of this solution will be placed at each of the 4 target nerves.
41509821|NCT05269095|BIOLOGICAL|Ultrasound-guided Adductor Canal block (ACB) technique with infiltration of the interspace between popliteal artery and the capsule of posterior knee block ('PACK)|Adductor Canal block (ACB) technique will be performed using 16 ml bupivacaine 0025% As regarding the Popliteal artery and the capsule of posterior knee block ('PACK), it will be performed Using 16 ml bupivacaine 0.25%
40854334|NCT03419988|BEHAVIORAL|Exercise Intervention|24 sessions of aerobic exercise
40854335|NCT06017505|DIAGNOSTIC_TEST|electronic self administered gerocognitive examination (eSAGE)|A self-administered digital assessment that evaluates multiple cognitive domains: orientation, language, memory, executive function, calculations, abstraction, and visuospatial abilities, through multiple questions. Additionally, it includes the collection of six clinical variables: education, gender, race, family history of dementia, stroke, and emotion.
40854336|NCT06584045|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
40854337|NCT02975674|DEVICE|MT-12 dental implant|Placement of the MT-12 dental implant with Morse taper implant-abutment connection
40854338|NCT02975674|DEVICE|CON.INT dental implant|Placement of the CON.INT dental implant with internal hexagon implant-abutment connection
40854339|NCT06525129|OTHER|Cerebellar stimulation group (CbSG)|Anodal transcranial direct current stimulation was given using a portable battery-driven brain stimulator (The Brain Stimulator v3.0 Deluxe tDCS Kit, using Professional 3x3 inches Amrex Sponge Electrodes). Skin was prepared before application of electrodes by cleaning the skin surface using alcohol swabs. In cerebellar stimulation group (CbSG) a stimulation intensity of 2mA for duration of 20 minutes. In order to avoid sudden initiation and termination of the stimulation the first and last 10 seconds of anodal tDCS application, current will gradually fade in/fade out to avoid any sudden starting or stopping of the stimulation. For the CbSG active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right buccinator muscle.
40892964|NCT02628990|OTHER|1.6 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
40892965|NCT02628990|OTHER|2 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
40892966|NCT02628990|OTHER|Placebo|Lipid-lowering effect of Placebo Yoghurt Drink
41037185|NCT01810588|RADIATION|Total Body Irradiation|Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
41384650|NCT01218386|DRUG|Estradiol valerate|"Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation."
41384651|NCT03415139|DRUG|Oral Glucose Tolerance Test (OGTT)|A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.
41384652|NCT03415139|DRUG|2 OGTTs with and without GLP-1 analogue|A standard OGTT will be performed and a second OGTT procedure will be repeated on a different day with GLP-1 analogue.
41384653|NCT03415139|DRUG|Hyperglycemic clamp procedure|During the hyperglycemic clamp procedure, D20 will given, followed by phlebotomy.
41384654|NCT06519825|OTHER|Exercise|Inspiratory muscle strength training program will be applied to the FHP-C group for 7 days/6 weeks.
41384655|NCT00499252|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
41384656|NCT04527549|DRUG|Dabrafenib mesylate|Given PO
41384657|NCT04527549|DRUG|Hydroxychloroquine|Given PO
41384658|NCT04527549|DRUG|Placebo Administration|Given PO
41384659|NCT04527549|DRUG|Trametinib dimethyl sulfoxide|Given PO
41384660|NCT05535842|OTHER|GLOW|GLOW is an app for type 2 diabetes support and education that uses a conversational agent to help users develop self-management skills and learn about diabetes and healthy behaviours. This is achieved through a range of interactive strategies.
41384661|NCT01062022|BEHAVIORAL|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
41384662|NCT01062022|BEHAVIORAL|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
41384663|NCT03534635|DRUG|Pembrolizumab|Pembrolizumab monotherapy at 200 mg every 3 weeks for 2 years maximum.
41384664|NCT03534635|DRUG|Pembrolizumab - additional treatment|Patients may be retreated for one year of additional pembrolizubmab therapy (200 mg every 3 weeks).
41384665|NCT05029167|OTHER|Restrictive PaO2|Patients are randomized to a PaO2 target of 9-10 kPa (open-label).
41384666|NCT05029167|OTHER|Low normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
41384667|NCT05029167|OTHER|Liberal PaO2|Patients are randomized to a PaO2 target of 13-14 kPa (open-label).
41384668|NCT05029167|OTHER|High normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
41509822|NCT01948115|DRUG|equimolar mixture of oxygen and nitrous oxide or medical air|"We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention."
41509823|NCT02257775|GENETIC|n/a - observational|
41384669|NCT04995302|PROCEDURE|Microoneedling and Amnion Bilayer|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with amnion bilayer for 72 hours.
41384670|NCT04995302|PROCEDURE|Microoneedling|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with an antibacterial gauze dressing.
41384671|NCT00996008|DRUG|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
41384672|NCT00996008|DRUG|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
41384673|NCT04997369|DEVICE|Rezum|The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).
41384674|NCT00232245|DRUG|Fish oil|
41384675|NCT02132936|DRUG|LEO 90100 aerosol foam|
41384676|NCT02132936|DRUG|Aerosol foam vehicle|
41384677|NCT02132936|DRUG|Calcipotriol BDP gel|
41384678|NCT02132936|DRUG|Gel vehicle|
41384679|NCT01247753|BEHAVIORAL|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
41384680|NCT03347929|DRUG|Naproxen 500 Mg|10 days treatment with Naproxen 500 mg twice daily
41509824|NCT02679638|OTHER|Factors and perceptions questionnaire|A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
41509825|NCT02679638|OTHER|Qualitative interview|Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
41509826|NCT06277765|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
41509827|NCT06277765|OTHER|placebo|Placebo
41509828|NCT03120325|DEVICE|Vagal Nerve Stimulation|Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.
41509829|NCT03183596|DRUG|Bupivacaine|20-60cc of 0.25% Bupivacaine
41509830|NCT03183596|DRUG|Dexamethasone|2-4mg of Dexamethasone
41509831|NCT05709210|OTHER|Recording of smartphone usage data|Recording of smartphone usage data
41384681|NCT03347929|DRUG|Placebo|10 days treatment with Placebo1 tablet twice daily
41384682|NCT03821688|PROCEDURE|SAS-JB|single anastomosis sleeve jejunal bypass
41384683|NCT03821688|PROCEDURE|OAGB|one anastomosis gastric bypass
41384684|NCT03821688|PROCEDURE|LSG|laproscopic sleeve gastrectomy
41384685|NCT01016184|DIETARY_SUPPLEMENT|Vitamin D|Oral vitamin D 100,000 IU
41384686|NCT01016184|DIETARY_SUPPLEMENT|Placebo|Placebo
41509832|NCT01439256|BEHAVIORAL|Computer Controlled Telephone Counseling|The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program
41509833|NCT01439256|OTHER|Physician information and management recommendations|Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
41509834|NCT01226394|PROCEDURE|laparotomy plus HIPEC|Laparotomy + HIPEC
41509835|NCT05173857|DEVICE|Advance PTX|PTA in Dysfunctional Haemodialysis Access
41509836|NCT05173857|DEVICE|Advance LP (Low Profile)|Plain Old Balloon Angioplasty (POBA)
41509837|NCT05173857|DRUG|Paclitaxel (PTX)|Paclitaxel (PTX)
41509838|NCT06128486|DEVICE|Soft Contact Lens|Vision Correction
40892967|NCT03770546|BIOLOGICAL|Amnion Injection|Per the manufacturer, this is considered an injection of tissue/organic matter.
41166065|NCT02831998|DRUG|ZuraPrep|Apply topically.
41166066|NCT02831998|DRUG|ChloraPrep|Apply topically.
41384687|NCT00003786|DRUG|irofulven|
41384688|NCT04754607|OTHER|Low-Level Laser Therapy|Eight target points (superior, mediolateral, inferior border of the right and left thyroid lobes, right and left sides of the isthmus) will be marked with a surgical pen by determining the thyroid borders on the skin by thyroid ultrasonography by the specialist physician. Low-level laser (28.57 J / cm2) fixed applications will be made on the thyroid gland, approximately 1 cm from each other. In practice, the patient's neck will be maintained in the extension position. Each application will last 20 seconds and the radiant energy will be 2 J, the tip of the laser will be kept in contact with the skin and upright. Duration of treatment is 6 sessions 2 days a week. The cumulative dose will be 96 J.
41417786|NCT04175054|OTHER|Body-weight supported treadmill training in a room cooled to 16°C|Exercise will be performed on a treadmill using an overhead harness for safety in a temperature controlled-room at 16°C with 1:1 supervision. The high intensity group will maintain vigorous intensity with a target workload \>60% of heart rate reserve for 30 min (plus 5min warm up and 5min cool down) while the low-intensity group will walk at mild intensity (\<40% heart rate reserve) for the same duration. Heart rate, blood pressure, and rating of perceived exertion will be recorded throughout to monitor for potential adverse events and to ensure that target training zone heart rates are maintained. The intervention is 3 times per week for 12 weeks, with a 3-month run-in observational period to confirm disease stability, and 3-month follow-up to determine the sustainability of effects.
41037186|NCT01810588|DRUG|Mycophenolate Mofetil|Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (\<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
41037187|NCT01810588|DRUG|Tacrolimus|Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
41037188|NCT02393079|DEVICE|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
41037189|NCT02393079|DEVICE|Sham|A SHAM identical helmet will be used in the control group.
41037190|NCT01703455|DRUG|Sorafenib|400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
41037191|NCT06040866|OTHER|Exercise training|Exercise training will be applied in the non-menstrual period during 2 menstrual cycles as stretching and relaxation exercises. Stretching exercises will include general stretching and specific stretching exercises and will take approximately 20 minutes in total. After the stretching exercises, relaxation exercise will be performed with diaphragmatic breathing for 10 minutes. The exercises will be performed with music accompanied by a physiotherapist once a week, and it will be recommended to do the exercises as a home program for 2 sessions a week.
41166067|NCT02831998|DRUG|ZP Vehicle|Apply topically.
41166068|NCT01271153|DRUG|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
41166069|NCT01271153|DRUG|Placebo|A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
41166070|NCT00471172|BEHAVIORAL|Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week)|
41166071|NCT00471172|BEHAVIORAL|Face-to-face counseling by a dietitian (monthly)|
41166072|NCT00471172|BEHAVIORAL|Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)|
41384689|NCT05657054|OTHER|Exercise Intervention Targeting Hip Strengthening|An initial 16-week exercise intervention of 45 minutes of training 3 times a week in the patient's own home or at a rehabilitation center. Patients will be instructed by a physiotherapist during the first 3 sessions, in order to be able to perform the exercises at home. Subsequently, there are physiotherapist-supervised sessions once every second week. The delivery of the supervised sessions is based on the patient's preferences, either by physical attendance or remotely in the patient's home. The intervention will consist of 4 exercises adapted from the NEMEX program targeting lower extremity muscle strength, stability, postural function, and postural orientation. Progression is made when an exercise is performed with good sensorimotor control and good performance quality and with minimal exertion and adequate movement control. Progression is primarily provided by 3 levels of difficulty and secondly by varying the number of repetitions or where possible, by increasing the weight load.
41417787|NCT06325579|DEVICE|Immersive Virtual Reality for Dysphagia Treatment|Patients wore a VR headset while undergoing their rehabilitation session
41417788|NCT01383525|DEVICE|Direct Selective Trabeculoplasty device|Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
41417789|NCT06242756|PROCEDURE|Bladder catheterization|Patients placed in the catheterized group will have an indwelling catheter placed after anesthetic has been administered. It would be removed at 12 hours post cesarean section.
41037192|NCT06040866|OTHER|Pain neuroscience education|Participants in the first research arm will be given pain neuroscience education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
41166073|NCT00471172|BEHAVIORAL|Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week)|
41166074|NCT00471172|BEHAVIORAL|Self help|
41166075|NCT05896137|DRUG|CS0159 2mg|Oral QD
41166076|NCT05896137|DRUG|Placebo|Oral QD
41166077|NCT03036150|DRUG|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
41166078|NCT03036150|DRUG|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg
41166079|NCT02330562|DRUG|MRZ|"MRZ dosing in Phase 1 to range from 0.55 to 0.8 mg/m2. Dose Escalation: MRZ dose-escalation will occur using a standard 3+3 study design.~The RP2D of MRZ (0.8.mg/m2) will be used in a two stage design, with fifteen response-evaluable patients entered in the first stage. If 1 or more responses are observed at the MRZ RP2D, then the second stage will be implemented with an additional 15 response-evaluable patients treated."
41166080|NCT02330562|DRUG|BEV|BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
41166081|NCT03975296|PROCEDURE|preoperative single-shot TMQLB|"The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
41384690|NCT05657054|OTHER|Usual Care|The intervention will consist of a rehabilitation intervention corresponding to standard care in the participating municipalities (i.e. content and duration of intervention). The intervention will be delivered individually or as group training, based on a clinical assessment of the individual patients' needs. The intervention can be supported by home-based exercises following instruction from a physiotherapist, supplemented by the provision of written information or access to a virtual training program. The intervention occurs in either the rehabilitation center's gym or the patient's home. The training sessions may consist of some of the following parameters: Strength training, stretching, functional training e.g. walking and stair climbing, stability training, balance training, endurance training, and gait correction.
41384691|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added unripe banana flour|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
41384692|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added maltodextrin|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
41384693|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added inulin|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
41384694|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added nisin|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
41384695|NCT06525337|BEHAVIORAL|STANDARDCARE (STAND) group|Will receive a device and health coaching
41384696|NCT06525337|OTHER|CONTROL (CON) group|Will not use any devices or receive health coaching
41384697|NCT03046966|PROCEDURE|Intervention: Receives Training|"• Complete a Hands-on Intubation in the Simulation Lab with PI instructing:~* Using state of the art technology, a Storz C-MAC video laryngoscope~* Identifying anatomical landmarks~* Practice on the manikin until intubation occurs within 15 seconds"
41384698|NCT03046966|OTHER|Intervention: Control No Training|• Does not receive simulation training with PI. Only standard training.
41384699|NCT06277778|OTHER|Taekwondo training with music therapy|Taekwondo training with music therapy
41384700|NCT06277778|OTHER|Taekwondo training alone|Taekwondo training without music therapy
41384701|NCT01215955|DRUG|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
41384702|NCT01215955|DRUG|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
41384703|NCT03458910|BEHAVIORAL|HRV training|Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
41384704|NCT01585896|OTHER|Self-Help Group|The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, \& Steketee, 2007).
41384705|NCT04651582|BEHAVIORAL|Cognitive Training|20 hours of computerized activities designed to improve processing speed and divided attention
41384706|NCT04651582|BEHAVIORAL|Cognitive Stimulating Activities|20 hours of traditional computer games
41384707|NCT03394794|DEVICE|Pelvic floor rehabilitation|The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
41509839|NCT03458611|BEHAVIORAL|Active Intervention|An audiovisual expanding (looming) stimulus is presented repeatedly to patients during the intervention (Dent \& Humphreys, 2011). During the game a disk is presented to the player. This disk expands and contracts in size. The presentation of the disk coincides with the presentation of a sound that matches in frequency. The disk predicts the location where the next target will be presented. The player must discriminate between two types of target stimuli that are presented at the center of the disk. To discriminate between the two targets, the player receives a limited time window. The location of the disk and target stimuli are adjusted in real-time as a function of the player's performance. The primary goal of this algorithm is to present the multisensory looming stimuli more frequently in the contralesional field than in the ipsilesional field.
41509840|NCT03458611|BEHAVIORAL|Placebo Intervention|The active and placebo intervention are identical in all aspects except for the fact that stimulus presentation will be located in the center of the visual field.
41384708|NCT03939728|RADIATION|Chest radiography and lung ultrasound|We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
41384709|NCT02067585|DIETARY_SUPPLEMENT|Standardized Lipid meals|Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
41384710|NCT05949658|DRUG|Sirolimus|5mg, 10mg, or 15mg once weekly sirolimus
41384711|NCT05949658|DRUG|Everolimus|5mg, 10mg, or 15mg once weekly everolimus
41384712|NCT02406365|DEVICE|Diagnostic imaging aid for one-visit management of cervical lesions|
41384713|NCT05932407|DRUG|Vortioxetine Tablet|Vortioxetine Tablet
41384714|NCT05932407|DRUG|SSRI|SSRI: Selective Serotonin Reuptake Inhibitor
41384715|NCT03125707|OTHER|Registry study|
41384716|NCT00826176|DRUG|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
41384717|NCT04141839|BEHAVIORAL|Safer Bars|Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.
41384718|NCT05475535|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy
41384719|NCT05475535|BEHAVIORAL|Self-Compassion|Self-Compassion focused exercises
41384720|NCT05475535|BEHAVIORAL|Active Control|Engagement in a mobile application (Cooperation skills)
41384721|NCT04049448|DRUG|ABX464|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
41384722|NCT04141137|DEVICE|TricValve® System|The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.
41509841|NCT02457923|OTHER|Mobile phone counselling|i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules
41384723|NCT06565065|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|A full standardized lymphatic protocol will be performed, including thoracic inlet left and right, thoracoabdominal release, pelvic diaphragm release, pedal pump, splenic pump, and abdominal lymphatic pump. This treatment will be done by systematically working down and back up. The protocol will last a total of 12 minutes for each participant
41384724|NCT06565065|OTHER|Sham Light Touch|A full standardized 12-minute session in which treaters will mimic various osteopathic manipulative techniques at specific anatomical locations without applying pressure or manipulation.
41384725|NCT06565065|OTHER|Exercise Protocol|A full standardized moderate-intensity physical activity as defined by the Centers for Disease Control (CDC). Target heart rate for moderate-intensity exercise should be between 64 and 76% of maximum heart rate. To estimate age-related heart rate, subjects' age will be subtracted from 220. Then, that number will be multiplied by 75%, which will be standardized across all subjects in the study. Heart rate will be monitored with the use of an attached pulse-ox monitor. Treadmill speed will be adjusted accordingly so that each subject maintains a heart rate of 75% of their maximum heart rate. A brisk walk will be done on a flat treadmill and no incline will be utilized. Subjects will be allowed a minute of warm-up to get to the appropriate pace/target heart rate.
41384726|NCT05745441|BEHAVIORAL|Early Dinner|Dinner before DLMO
41384727|NCT05745441|BEHAVIORAL|Late Dinner|Dinner after DLMO
41384728|NCT05745441|DRUG|Early Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner before DLMO
41384729|NCT05745441|DRUG|Late Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner after DLMO
41384730|NCT04639310|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
41384731|NCT04639310|DRUG|Placebo|Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
41384732|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy ONCE|"rESWT application ONCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
41384733|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy TWİCE|"rESWT application TWİCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~A total of 2 sessions of rESWT will be applied on the same day after BTX-A injection and on the 7th day after BTX-A.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
41417790|NCT04868448|BIOLOGICAL|Covid-19 vaccines|Observation of individuals who received one or more doses of covid-19 vaccines.
41417791|NCT00999609|BIOLOGICAL|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
41509842|NCT04043455|DRUG|Olorinab|Olorinab Dose 1 capsule or tablet by mouth, 3 times per day up to 12 weeks
41509843|NCT04043455|DRUG|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 12 weeks
41509844|NCT04043455|DRUG|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 12 weeks
41509845|NCT04043455|DRUG|Placebo|Olorinab matching placebo capsule or tablet by mouth, 3 times per day up to 12 weeks
41509846|NCT04043455|DRUG|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 52 weeks
41509847|NCT04043455|DRUG|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 52 weeks
40676596|NCT06622902|OTHER|change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours|change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours
41509848|NCT00378495|DRUG|Miltefosine: initially 2.5 mg/kg/day for 28 days|
41509849|NCT03965897|BEHAVIORAL|Acceptance and Committment Therapy (ACT)|Overall, the goal of the ACT intervention is to cultivate psychological flexibility: to help Veterans respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. It increases patients' awareness of behaviors that exacerbate the pain (such as struggling with it) and recognition of avoidance strategies that interfere with life engagement.
40676597|NCT06622902|OTHER|change flow from 2 to 6 LPM. Follow TcCO2 for 3h|change flow from 2 to 6 LPM. Follow TcCO2 for 3h
40676598|NCT06622603|DRUG|Febuxostat|The minimal approved dose of febuxostat is 40 mg/day. We will use 0.5 tablet of febuxostat 40 mg or its placebo.
41166082|NCT03975296|PROCEDURE|preoperative single-shot TPVB|The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.
41384734|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy SHAM|"Radial Extracorporeal Shock Wave Therapy- SHAM The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Sham ESWT will be administered with the r-ESWT probe. The device will be switched on, the frequency, pressure and duration values will be set and then the device will be switched off and the probe will be kept in equal time with the active treatment, by playing a sound previously recorded during the real application."
41384735|NCT02636166|OTHER|Clearblue Investigational Pregnancy test|Clearblue Investigational Pregnancy test
41384736|NCT02636166|OTHER|Professional pregnancy test|Alere Professional use pregnancy test
41384737|NCT02636166|OTHER|Clearblue Marketed Pregnancy test|Clearblue Marketed Pregnancy test
41384738|NCT00334477|DRUG|tadalafil|
41384739|NCT03606109|DRUG|Tranexamic Acid (TXA)|One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects
41384740|NCT05109416|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution|Local anesthetic
41384741|NCT05109416|DRUG|Saline 0.9%|Isotonic crystaloid
40676599|NCT05157542|DRUG|Durvalumab|Day 1 and 22, 1500mg
40676600|NCT05157542|DRUG|nanoparticle albumin bound paclitaxel|Day1 and 22 nanoparticle albumin-bound paclitaxel 260 mg/m2 and carboplatin AUC 5
40676601|NCT05157542|RADIATION|low dose radiation therapy|10 Gy in 5 fractions, 20 Gy in 10 fractions, 30 Gy in 15 fractions respectively in our three groups from Day1
40854340|NCT06525129|OTHER|Cerebral (M1) Stimulation group (MSG)|In the M1 Stimulation Group (MSG) a similar intensity of current with 2mA was applied for a period of 20 minutes. Skin was cleaned with alcohol swab ahead of placing the electrodes. The anode was positioned over the lesioned M1 motor cortex area (C3, International 10-20 system) while the cathode was placed over the contra-lateral supraorbital area. Due to the large size of electrodes, the active electrode covered the area of M1 for the hand, arm, trunk, and the LL. Ten sessions of anodal tDCS were applied over a duration of 2 weeks. The stimulation was applied during active participation of patients in Biodex balance training.
41166083|NCT03975296|DRUG|patient controlled intravenous analgesia(PCIA)|at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
41166084|NCT02072421|PROCEDURE|PCI|
41384742|NCT04526379|BEHAVIORAL|Questionnaires|Evaluation of behavioral disorders of children with PWS by questionnaires
41384743|NCT04526379|DEVICE|t-VNS|Evaluation of the influence of 6 month-stimulation by t-VNS on emotional, cognitive, and behavioral/clinical characteristics of 12 children with PWS on 30 PWS patients included.
41384744|NCT05775237|DIETARY_SUPPLEMENT|Curcumin Gummies|Chew gummies thoroughly and completely before swallowing.
41384745|NCT05775237|DIETARY_SUPPLEMENT|Vitamin C Gummies|Chew gummies thoroughly and completely before swallowing.
41384746|NCT05775237|DIETARY_SUPPLEMENT|Multivitamin Gummies|Chew gummies thoroughly and completely before swallowing.
41384747|NCT05063318|DRUG|Lurbinectedin alone|The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.
40676602|NCT04070690|PROCEDURE|Concentration of dialysate bicarbonate|Adjust the dialysate bicarbonate concentration
40676603|NCT02484404|DRUG|Olaparib|Olaparib tablets will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (3mg/kg or 10mg/kg IV) and Olaparib tablets (200 mg or 300 mg BID) Ph II - MEDI4736 + Olaparib at RP2D
40676604|NCT02484404|DRUG|Cediranib|Cediranib will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (10mg/kg IV) and Cediranib (15 mg or 20 mg or 30 mg daily) Ph II - MEDI4736 + Cediranib at RP2D
40676605|NCT02484404|DRUG|Durvalumab|Ph I - Durvalumab will be administered once every 2 weeks for 12 months.
40676606|NCT02580669|OTHER|Neuropsychological assessment|A neuropsychological assessment is done
40676607|NCT02580669|OTHER|Neurologic consultation|A neurologic consultation is done
40676608|NCT02580669|OTHER|MRIs (with vasoreactivity testing)|MRIs (with vasoreactivity testing) is done
40676609|NCT03768440|PROCEDURE|continuous erector spinae block (ESB)|Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
40676610|NCT03768440|PROCEDURE|continuous paravertebral block (PVB)|The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
40676611|NCT03768440|DRUG|Ropivacaine|Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
40676612|NCT05388643|DIAGNOSTIC_TEST|Enhanced First Trimester GDM Screening|Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
41384748|NCT05063318|DRUG|Lurbinectedin+Itraconazole co-administration|The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.
41384749|NCT05862714|DRUG|Fluconazole|400 mg stat. Follow up at 4 weeks
41384750|NCT05862714|DRUG|Itraconazole|1000 mg stat. Follow up at 4 weeks
41384751|NCT03840031|OTHER|High Fe OFSP meal labelled with Fe-58|400 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
41384752|NCT03840031|OTHER|Control OFSP meal labelled with Fe-57|400 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
40892968|NCT03770546|DRUG|Betamethasone injection|Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.
41384753|NCT06562972|OTHER|Occlusal equilibration of complete denture using articulating paper|Occlusal equilibration of complete dentures is vital for ensuring proper function, comfort, and longevity. The process aims to evenly distribute occlusal forces, eliminate premature contacts, improve stability, reduce wear, and minimize tissue trauma. It involves methods like the articulating paper technique, pressure indicator paste, T-Scan digital analysis, and clinical observation. The process includes evaluating centric and eccentric contacts, making fine adjustments, and achieving balanced articulation. Regular follow-ups are essential to monitor occlusion and make necessary adjustments, contributing to patient satisfaction and denture lifespan.
41509850|NCT03965897|OTHER|Attention Control (AC)|Information on any other coping practices will be omitted. The group facilitators will present one topic at a time, using the Pain Manual, and the participants will discuss and reflect about issues and experiences related to each topic. If necessary, the group facilitators will raise specific discussion questions to facilitate group dialogue and participant involvement.
41509851|NCT06147427|PROCEDURE|ACL reconstruction with hamstrings combined with ALL plasty|ACL reconstruction with hamstrings combined anterolateral plasty using the ALL reconstruction technique (Gracilis throught the femur tunnel of the ACL graft and fixed to the tibia by an anchor on its point of isometry on the tibia).
40892969|NCT03123731|BEHAVIORAL|Control Arm|Wearing Physical Activity Monitor
40892970|NCT03123731|BEHAVIORAL|iSTEP|Physical Activity Intervention
40892971|NCT03123731|BEHAVIORAL|iSTEP|Physical Activity and Diet Intervention
40892972|NCT00631514|DRUG|acetaminophen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
40892973|NCT00631514|DRUG|ibuprofen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
40892974|NCT00631514|DRUG|piroxicam|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
40892975|NCT05391126|DRUG|Irinotecan|Usual dosing per package insert.
41037193|NCT06040866|OTHER|Biomedical pain education|Participants in the second research arm will be given biomedical pain education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
41166085|NCT01818427|BIOLOGICAL|infusion of 2 units of plasma|infusion of 2 units of plasma
41384754|NCT06562972|OTHER|Occlusal equilibration of complete denture using occulosense|Occulosense denture equilibration is a digital occlusal analysis technique used to optimize denture fit and function. It employs a thin sensor placed between the dentures to measure bite force and timing. The system provides real-time data on occlusal contacts, allowing dentists to identify and adjust pressure points precisely. This process ensures even distribution of bite forces, enhancing denture stability, comfort, and longevity. T-Scan equilibration can significantly improve patient satisfaction by reducing pain, increasing chewing efficiency, and minimizing denture-related issues like sore spots and uneven wear.
41384755|NCT00410839|PROCEDURE|ALA rich diet|
41384756|NCT00301925|BIOLOGICAL|pegfilgrastim|
41384757|NCT00301925|DRUG|capecitabine|
41384758|NCT00301925|DRUG|cyclophosphamide|
41384759|NCT00301925|DRUG|epirubicin hydrochloride|
41384760|NCT00301925|DRUG|fluorouracil|
41384761|NCT00301925|DRUG|methotrexate|
41384762|NCT00301925|PROCEDURE|adjuvant therapy|
41384763|NCT05083559|DEVICE|MPC AP algorithm|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
41384764|NCT05083559|DEVICE|Robust R-AP algorithm|The R-AP is a modified MPC algorithm. A new feature in the algorithm includes a model for missed meal insulin detection. The model includes estimations for carbohydrate consumption based glucose patterns to determine if that person has consumed a meal without announcing it to the system.
41384765|NCT05752344|OTHER|Counseling|Professional Counseling is an activity that aims to improve the client's quality of life. Supporting his strengths and his ability to self-determination, Counseling offers a space for listening and reflection in which to explore difficulties, related to evolutionary processes, transition phase, states of crisis and reinforcement of the ability to choose or change.
41384766|NCT04038307|DRUG|paracetamol|1gm
41384767|NCT04038307|DRUG|Saline Solution|100ml
41384768|NCT01059552|DRUG|vorinostat|vorinostat once daily for 12 weeks of therapy
41384769|NCT03246321|COMBINATION_PRODUCT|repetitive ePIPAC-OX|Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area \[BSA\]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.
41037194|NCT00922493|OTHER|inspiratory muscle training|"Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming hard due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.~An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º."
40854341|NCT06525129|OTHER|Sham Stimulation group (SSG)|In Sham Stimulation group (SSG) Ten sessions of anodal tDCS were applied over a duration of 2 weeks having same intensity i.e., 2 mA stimulation was used for a period of 30 seconds and then gradually ramped-down and turned off for the rest of the treatment time of 20 minutes. The same procedure for skin preparation was used as in the other two groups. Electrode placement for SSG was same as in MSG for half of the patients i.e. 8 participants; anode will be placed over the left (dominant) lesioned M1 whereas the cathode will be positioned over the right (contralateral) supraorbital area. For the other 8 participants the stimulation montages were similar to cerebellar stimulation group. The active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right Buccinator Muscle.
41384770|NCT01205373|DRUG|BI 671800|High dose oral drinking solution
41417792|NCT04300647|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
41509852|NCT06147427|PROCEDURE|ACL reconstruction with hamstrings combined with modified Lemaire's LET|ACL reconstruction with hamstrings combined with modified Lemaire's lateral extra-articular tenodesis technique (Fascia lata strip pedicled to the Gerdy and fixed to the femur throught the tunnel of the ACL graft).
41509853|NCT02352870|BEHAVIORAL|Computerised Cognitive Behavioural Therapy|Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis
41509854|NCT02352870|BEHAVIORAL|Telephone support|Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
41509855|NCT03855267|DRUG|Propofol 20 MG/ML|Pump propofol to keep bispectral index within 40 # 60
41509856|NCT03855267|DRUG|Propofol 20 mg/ml , etomidate 2 mg/ml|Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.
41509857|NCT03544944|DRUG|TJP-008-1|Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
41509858|NCT03544944|DRUG|TJP-008-2|Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
40854342|NCT00338923|DRUG|HO/03/03|
40854343|NCT01243827|DRUG|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP \<140/90 mmHg.
40854344|NCT01243827|DRUG|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP \<140/90 mmHg.
40854345|NCT04844528|DRUG|Nicotinamide|oral nicotinamide 500 mg twice daily (BID)
40854346|NCT04844528|DRUG|Placebo|oral placebo twice daily for first year. Cross over to oral nicotinamide 500 mg twice daily (BID) for year two.
40854347|NCT00296920|DEVICE|Deep Brain Stimulation|
41037195|NCT03104634|DRUG|Aclidinium bromide/formoterol fumarate dihydrate|Cross-over design with washout interval. Randomized order of active and placebo arm
41037196|NCT03104634|DRUG|Placebo|Placebo and delivery device matched to active intervention
40854348|NCT01711645|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
41417793|NCT04300647|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
41417794|NCT06545149|DIETARY_SUPPLEMENT|BioNutri AR-1,|intervention with fermented and nutritionally balanced food twice a day
41037197|NCT05942313|DRUG|Buprenorphine/ Methadone exposure|Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.
41509859|NCT03544944|DRUG|Coolprep powder|Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
41509860|NCT03399045|PROCEDURE|9-minute withdrawal|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw
41509861|NCT03399045|PROCEDURE|6-minute withdrawal|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw
41384771|NCT05144477|BEHAVIORAL|FAID Fear Intervention|Participants will receive a hard-cover diary, written instructions on diary completion, and a pen. A trained research assistant will meet with the participant face to face or via telephone and explain how to use the diary. Instructions will include recommended frequency for writing (at least twice a week) and tips on how to express themselves. Potential topics will also be addressed, including what to write about in the beginning, during the ICU, and after ICU discharge. The hard copy of the diary will remain with the family member participant, and they will be asked to continue writing in the diary at least until patient discharge from the hospital. Research assistants will check in with participants via weekly telephone calls to provide prompts to remind them to use the diary and support, as needed, if the participant reports difficulty in writing diary entries. These calls will last approximately 1-5 minutes and will continue until patient discharge from the hospital.
41384772|NCT01402193|DRUG|Pre-radiotherapy commencement of Arimidex|Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
41384773|NCT01402193|DRUG|Post radiotherapy commencement of Arimidex|Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
40854349|NCT05781464|PROCEDURE|Traditional chest physiotherapy|"Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator)."
40854350|NCT05781464|PROCEDURE|Prolonged slow expiration technique|The therapist places one hand on the thorax below the suprasternal notch and the other hand over the upper abdomen while the neonate is supine. Both hands will have hypothenar contact with the thorax and abdomen. At the end of the expiratory phase, the therapist places a compression force with both hands. Compression at the end of expiration with hypothenar eminence is kept for 2 or 3 breathing cycles. This technique is repeated several times, with a rest time between applications of about 5 or 10 spontaneous breaths.
41166086|NCT00250640|DRUG|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
41166087|NCT04583462|DRUG|Metformin|Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
41384774|NCT01402193|RADIATION|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
41384775|NCT01402193|RADIATION|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
41384776|NCT00087763|DRUG|Macugen ™ (pegaptanib sodium injection)|
41384777|NCT02292732|DRUG|Trametinib 0.5 mg|Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter \[mm\]) to be taken orally and once daily
41384778|NCT02292732|DRUG|Trametinib 2 mg|Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
41384779|NCT02292732|DRUG|ORTHO-NOVUM® tablet 1/35|Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
41509862|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single administration by anterior juxtascleral depot
41384780|NCT02292732|DRUG|Placebo|Each green tablet will contain only inert ingredients: D\&C yellow No. 10 Aluminum Lake, FD\&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
41384781|NCT05384119|DRUG|TTI-101|Oral tablet
41384782|NCT05384119|DRUG|Palbociclib|Oral capsule
41509863|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single administration by anterior juxtascleral depot
41509864|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 75 mg/mL|Single administration by anterior juxtascleral depot
41166088|NCT04583462|DRUG|Placebo|Control group : Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm) started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
41384783|NCT05384119|DRUG|Aromatase inhibitor (AI)|Oral tablet
41384784|NCT05384119|DRUG|fulvestrant|Oral tablet
41166089|NCT03243500|DRUG|Atracurium|5mg in 1 ml normal saline
41509865|NCT00691717|OTHER|Anecortave Acetate Vehicle|Single administration by anterior juxtascleral depot
41509866|NCT01807312|DEVICE|Endoscopic CO2 regulation unit and accessories|Olympus UCR Endoscopic CO2 Regulation Unit
41509867|NCT01807312|DEVICE|Placebo|
41166090|NCT03243500|DRUG|Lidocaine 2%|
41166091|NCT03243500|DRUG|Bupivacaine 0.5%|
41166092|NCT03243500|DRUG|hyaluronidase powder|1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
41166093|NCT03243500|PROCEDURE|per-caruncular peribulbar injection|The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
41166094|NCT00635570|DRUG|Ortho Tri-cyclen Lo|Low dose oral contraceptive
41384785|NCT05384119|DRUG|ribociclib|Oral tablet
41384786|NCT03632798|DIAGNOSTIC_TEST|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
41166095|NCT00635570|DEVICE|NuvaRing|Contraceptive vaginal ring
41384787|NCT03632798|DRUG|Chemotherapy|"Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel."
41384788|NCT04095546|OTHER|routine psychotherapy for Borderline Personality Disorder (BPD)|Routine psychotherapy as treatment for patients with Borderline Personality Disorder
41384789|NCT06567223|PROCEDURE|Vibration Therapy|will receive the whole body vibration therapy. Patient will be ask to stand on the vibration plate in semi flexed knee position will 3 minute time of rest and therapy. It will be given for four weeks three days per week. Acceleration will be 18.0 meter per second square and frequency will be from 30 to 40 Hz. Intensity of the therapy will increase throughout all the sessions
41384790|NCT06567223|COMBINATION_PRODUCT|Rhythmic auditory stimulation therapy.|will receive rhythmic auditory stimulation therapy. Rhythmic auditory stimulation will be given for 90 minutes along with 30 minutes of conventional physiotherapy. It will consist of 15 minutes of general body warming metronome rhythm which proceed towards RAS music based exercise of 60 minutes. This period also ends up with 15 minutes of relaxation exercise. Relaxing Music was provided through headphones having voice cancellation property for 15 min. The total session will be given three days per week for four weeks. Exercises such as lateral walking military march, anterior walking, one toe and one heel walking along with posterior walking through progression with the speed of the rhythm is done
41509868|NCT01301729|DRUG|Docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
41509869|NCT01301729|DRUG|Paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
41509870|NCT01301729|DRUG|Trastuzumab|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
41509871|NCT03639818|OTHER|individual sessions of cognitive remediation|The cognitive remediation will be led by a psychologist specialized in neuropsychology, trained and experienced in this method. Cognitive remediation will be performed at a rate of 1 to 2 sessions per week for the duration of the study. This treatment will be carried out individually for half in face-to-face session in the clinical immuno-hematology department, face-to-face with the neuropsychologist, half at home with computer-based home exercises using PRESCO software ® from HAPPYNEURON®
41509872|NCT01277211|DRUG|ENG 120 µg + EE 15 µg intravaginal ring|13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
41509873|NCT01277211|DRUG|DRSP 3 mg + EE 30 µg|13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
41166096|NCT03912974|DRUG|Escitalopram|see 'arm description'
41166097|NCT03912974|DRUG|Placebo oral capsule|see 'arm description'
41166098|NCT03978078|OTHER|Biological collection|- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
41509874|NCT03867747|RADIATION|Cardiac Radiosurgery|Image-guided stereotactic body radiation therapy
41509875|NCT03354715|DEVICE|Rapid prototyping Denture base|The introduction of rapid prototyping (RP)Stereo lithography (SLA) technology, which mainly depends on addition of layers of materials which would be polymerized using a light curing unit. It consists of a bath of photo polymerized liquid and ultraviolet unit for curing these layers, that would bond to each other till forming the full object. SLA has many advantage as high accuracy, high mechanical strength, smooth surface finish with close tolerance and fine details printing, but it has some limitation as it is only limited Material, in addition to the high material and equipment cost.
41509876|NCT03354715|DEVICE|Heat Cured Conventional Complete Denture|it is the main treatment for most of completely edentoulous Cases
41509877|NCT03404739|DRUG|Saline Solution|These patients will be given only one dose of ceftazidime at the start of POEM plus 2 doses of saline solution every 12 hours after the procedure.
41509878|NCT03404739|DRUG|Ceftazidime|These patients will be given ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure.
40854351|NCT04607811|BEHAVIORAL|Gamification with social incentives|Participants will select a step goal that is 33%, 40%, or 50% above their baseline step value. Participants in this group will participate in a game with points and levels to help motivate participants to meet their daily step goal. Additionally, all participants will identify a support partner to receive weekly updates on their performance and offer positive encouragement to help the participant meet their step goal.
40854352|NCT03872856|DEVICE|BP-ICAN|"One of two home blood pressure monitor devices will be used.~1. Omron 7 Series Wrist cuff~2. Omron 10 Series Upper Arm cuff"
40854353|NCT01516463|DRUG|Collagenase Santyl|Applied topically (2 mm thickness once daily)
41384791|NCT05268341|BEHAVIORAL|My Sentence Builder|computer-assisted treatment program for expressive grammar
41384792|NCT04356196|DRUG|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
41384793|NCT04356196|DRUG|Bisoprolol|Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.
41384794|NCT04356196|DRUG|Placebo oral tablet|Placebo oral tablet
41384795|NCT02217657|DEVICE|Thermocool Smart Touch Catheter|Physician informed to contact force
41384796|NCT06499935|OTHER|Rigid Taping|It is usually light brown or beige and is designed to hold firm, making it ideal for providing support or stability to a joint.
41384797|NCT06499935|OTHER|Kinesio-Taping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions.
41384798|NCT06499935|OTHER|Sham Taping|Sham taping is the use of any type of tape in a random and ineffective fashion for the purposes of comparison with other taping techniques and types.
41384799|NCT02058368|DRUG|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
41384800|NCT02058368|DRUG|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
41384801|NCT02058368|DRUG|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
41384802|NCT02058368|DRUG|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
41384803|NCT05853237|DEVICE|laser therapy for wound management|comparison between laser effect on post median sternotomy incision compared to traditional wound care
41384804|NCT00197561|DIETARY_SUPPLEMENT|Placebo|Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
41384805|NCT00197561|DIETARY_SUPPLEMENT|Selenium|200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
41384806|NCT03773393|BIOLOGICAL|CK0801|CK0801 (a Cord blood-derived T-regulatory cell product)
41384807|NCT03725722|DRUG|Delgocitinib cream|Cream for topical application
41384808|NCT03725722|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
41384809|NCT03230695|DEVICE|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
41384810|NCT03230695|DEVICE|Active stimulation|Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
41509879|NCT02891668|DRUG|Levothyroxine treatment|Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
41509880|NCT00681031|BIOLOGICAL|ZOSTAVAX®|One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
41509881|NCT05721287|DRUG|SBS-1000|SBS-1000 administered as a single continuous IV infusion over 60 minutes
41509882|NCT05721287|DRUG|Placebo|Normal saline (0.9% sodium chloride \[NaCl\]) administered as a single dose IV infusion over 60 minutes
41509883|NCT01799837|DRUG|[C-11]MENET|PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
41509884|NCT06309576|BEHAVIORAL|Fasting-refeeding cycle|Participants will be maintained in metabolic chambers and exposed to 1 day of energy balance with a standard diet, 2 days of fasting (only water), and 2 days of ad-libitum refeeding using a liquid diet provided in hydration bladders to avoid portion control.
40854354|NCT01516463|BIOLOGICAL|Bacitracin|Applied topically (2 mm thickness) once daily
41166099|NCT00502164|DRUG|AZD2171|
41509885|NCT03129555|DRUG|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
41384811|NCT03230695|DEVICE|Sham stimulation|In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
41384812|NCT06568666|OTHER|Lumbar spinal manipulation|Lumbar spinal manipulation was performed in the lateral recumbent position and HVLA thrust was applied to the segment where dysfunction was detected. The spinal process was determined as the contact point and the direction of HVLA thrust was from posterior to anterior.
41384813|NCT06568666|OTHER|Sacroiliac joint manipulation|The participant lies on his/her side on the healthy side; the lower knee is in extension while the upper knee is flexed and placed in the popliteal fossa of the lower knee. The participant's hands are left free on the ribs at the lower level. The practitioner crosses the movement barrier with the stabilizing hand, allowing the tissues to relax. The practitioner performs HVLA thrust of the iliac bone into posterior or anterior rotation (in the opposite direction of dysfunction) with the stabilizing hand
41384814|NCT00262184|DRUG|Soy Isoflavone|
41384815|NCT04828629|DIAGNOSTIC_TEST|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis.
41384816|NCT00396318|DRUG|tenecteplase|"2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.~Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg)."
41384817|NCT05923333|DIETARY_SUPPLEMENT|B. infantis Rosell®-33|B. infantis Rosell®-33 + maltodextrin
41384818|NCT05923333|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
41509886|NCT03129555|DRUG|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
41509887|NCT03129555|DRUG|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
41509888|NCT03129555|DRUG|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
41509889|NCT03794050|OTHER|Resistance training exercise|randomized complete crossover for acute resistance training exercise session
41509890|NCT03794050|OTHER|Aerobic training exercise|randomized complete crossover for acute aerobic exercise training exercise session
41509891|NCT06550544|PROCEDURE|Office hysteroscopy|"A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. Vaginoscopic approach will be used. A 5 F grasper will be used to grasp and extract the IUD.~Pain intensity will be assessed by visual analogue scale immediately after the procedure."
41509892|NCT06550544|PROCEDURE|Ultrasound guided|"An alligator forceps will be introduced into the uterine cavity under ultrasound sound guidance. The IUD will be grasped and extracted outside the uterus.~Pain intensity will be assessed by visual analogue scale immediately after the procedure."
41509893|NCT01721304|OTHER|Adaptive Conjoint Analysis|Computerized survey to elicit patient preferences
41509894|NCT04748107|DIAGNOSTIC_TEST|Impendence Cardiography|ICG is a noninvasive method of determining the amount of blood flow using the Non-Invasive Cardiac System - Cardiac Surveyor (NICaS) system, which provides an assessment of the cardiovascular system, respiratory system, and fluid retention.
41509895|NCT05623683|OTHER|Intermittent Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will walk on the treadmill for 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
41509896|NCT05623683|OTHER|Continuous Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will rest for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
41509897|NCT03288818|DRUG|Mechlorethamine Hydrochloride Gel|Given topically
40854355|NCT05507151|PROCEDURE|Endoscopic Sleeve Gastroplasty|endoscopic suturing of the stomach
41384819|NCT06105008|DRUG|Disitamab Vedotin|2.0 mg/kg intravenous (lV) infusion every 2 weeks
41384820|NCT06105008|DRUG|Toripalimab|3.0 mg/kg intravenous (lV) infusion every 2 weeks
41384821|NCT00002126|DRUG|Filgrastim|
41384822|NCT05494723|DRUG|YB-1113|Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
41384823|NCT03356769|DRUG|Aspirin|low-dose of aspirin, 5mg/Kg/d, once every day, 25mg per tablets
40854356|NCT03999060|DEVICE|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head
40854357|NCT01335269|DRUG|BI 853520|BI 853520 once daily in a dose escalation schedule
40854358|NCT03520075|DRUG|ASTX029|Described above
40854359|NCT01653990|DRUG|moxifloxacin|oral dose of 400mg moxifloxacin
40854360|NCT01653990|DRUG|moxifloxacin-placebo|Oral dose of a pill of moxifloxacin-placebo
40854361|NCT01273324|DEVICE|ADM Cup|ADM Cup
41166100|NCT02795715|DEVICE|tDCS|
41384824|NCT03356769|DRUG|AED|maintain the dosages and the drugs throughout the 3-month observation time
41384825|NCT03356769|DRUG|Placebo|placebo, 5mg/Kg/d, once every day, 25mg per tablets
41509898|NCT03288818|PROCEDURE|Total Skin Electron Beam Radiation Therapy|Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
41509899|NCT03956940|DEVICE|Intplex test|Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
40854362|NCT02170870|DRUG|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
40854363|NCT02170870|DRUG|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
40854364|NCT02170870|DRUG|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
40854365|NCT02819791|OTHER|Optimized conventional therapy alone|Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year
40854366|NCT02819791|BEHAVIORAL|Optimized conventional therapy with therapeutic education|"The objectives of this therapeutic education program involve:~* learning objectives and acquisition of knowledge and self-care skills making the patient more autonomous and facilitating its adherence.~* the objectives of acquiring coping skills ( self-confidence , stress management , setting projects ) to improve their quality of life .~* the development objectives respects the relevant criteria of quality , realism and principle of educational progress."
40854367|NCT02450162|PROCEDURE|lateral rectus recession (bilateral)|Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
40854368|NCT04282707|PROCEDURE|Endoscopic closure of ESD defect|Closure of ESD defect would be performed with clip loop purse string technique
40854369|NCT04282707|OTHER|Gastric ESD without closure of ESD defect|Historical control with patients undergoing ESD without closure of ESD defect
40854370|NCT00269633|DEVICE|Blue Light Box 467 nm|467 nm Blue LED Light
40854371|NCT00269633|DEVICE|Red Light Box 657 nm|657 nm Red LED Light
40854372|NCT02846649|BEHAVIORAL|PIER|Daily text message queries with tailored support
40854373|NCT01853605|DEVICE|Anatomically shaped silicone gel-filled breast implants|Surgical implant
40854374|NCT02186678|OTHER|PET-CT|
40854375|NCT05515991|OTHER|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|"SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team.~Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals."
40854376|NCT05515991|OTHER|SUPPORT-DIALYSIS Only|SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.
40854377|NCT05098171|BIOLOGICAL|Signal Switch Receptor Modified TIL|Adoptive transfer of 2x10\^8-1x10\^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.
40854378|NCT04289961|DIAGNOSTIC_TEST|Portal vein sampling|During Endoscopic UltraSound guided-Fine Needle Aspitation (EUS-FNA) a curvilinear echoendoscope is advanced to the distal stomach or duodenal bulb to provide a window of access to a branch of the PV. After verifying venous flow by Doppler signal, a 19-gauge EUS-FNA needle is advanced transhepatically into the portal vein branch. With the needle in the portal vein, the stylet is removed and negative-pressure suction is applied to aspirate blood. A transhepatic approach for portal vein branch access is an absolute requirement of this technique in order to minimize the risk of bleeding. The puncture site is monitored under EUS for complications.
40854379|NCT01719133|DRUG|placebo|saline solution
40854380|NCT01719133|DRUG|Histamine|positive control
40854381|NCT01719133|DRUG|AllerT1|synthetic peptide T1
41384826|NCT02856282|DRUG|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
41509900|NCT05537636|OTHER|Rehabiltiation using exercise and manual therapy|"A licensed Physical Therapist will provide manual therapy to help restore spinal and scapular mobility. In association with this patients will be prescribed home exercises using a phased approach.~Phase 1 to gain mobility of the spine and scapular motor control Phase 2 to gain shoulder mobility to strengthen scapular and spine musculature Phase 3 shoulder strengthening with long lever arms."
40854382|NCT01719133|DRUG|AllerT2|synthetic peptide T2
40854383|NCT01719133|DRUG|AllerT3|synthetic peptide T3
40854384|NCT01719133|DRUG|AllerT4|synthetic peptide T4
40854385|NCT01719133|DRUG|AllerT5|synthetic peptide T5
40854386|NCT01719133|DRUG|mix of AllerT1-T2-T3|mix of peptides T1, T2 and T3
40854387|NCT01719133|DRUG|mix of AllerT4-T5|mix T4-T5
40854388|NCT04776863|DEVICE|optical biometry measurement|The measurements of the individuals using smokeless tobacco and those who do not were taken by optical biometry.
41166101|NCT02795715|BEHAVIORAL|training|
41384827|NCT06565871|DRUG|HRS9531 Injection|Titration administration, SC
41384828|NCT06565871|DRUG|HRS9531 Injection|Titration administration, SC
41384829|NCT06565871|DRUG|Placebo Injection|SC
41417795|NCT00389636|DEVICE|TheraGauze|TheraGauze
41417796|NCT00389636|DRUG|Regranex|Regranex + TheraGauze
41509901|NCT03817827|OTHER|Acupuncture|this group will receive Acupuncture for 30 minutes three times per week
41509902|NCT03817827|DIETARY_SUPPLEMENT|Diet supplementary|Diet supplementary with soy product
41509903|NCT06297915|DRUG|Ketamine|Ketamine infusion was administered at 1 mg/kg (in 1 hour)
41509904|NCT06297915|DRUG|Lidocain|Lidocaine infusion was administered at 3 mg/kg (in 1 hour)
41509905|NCT03500380|DRUG|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
41509906|NCT03500380|DRUG|Lapatinib|Lapatinib 1250 mg orally once daily during each 21-day cycle.
41509907|NCT03500380|DRUG|Capecitabine|Capecitabine 2000 mg/m\^2 orally daily on Days 1-14 of each 21-day treatment cycle.
41509908|NCT01828801|DEVICE|Pinnacle Metal-on Metal|All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
41509909|NCT00071279|DRUG|SR34006 (idraparinux sodium) Injection|
41509910|NCT01915745|OTHER|Use of SMS|Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
41509911|NCT06577207|OTHER|Initial investigations for all cases|Initial investigations for all cases: 1. Pulse oximetry. 2. Complete blood count. 3. Electrolytes. 4. Kidney function test. 5. Random blood glucose 6. Other investigations ordered for certain cases according to clinical manifestation \& previous findings \> Lines of treatment will be recorded
41509912|NCT04060186|PROCEDURE|Balloninflation|Patient will inflate into a ballon made by a handglove 2-3times/h from 8:00-20:00 after evacuation of chronic subdural hematoma.
41384830|NCT03112096|DRUG|[18F]THK-5351|Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
41384831|NCT05269316|DRUG|IMP9064|IMP9064 Monotherapy administered for 21 days
41384832|NCT04166526|DEVICE|FDNIRS-DCS|FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.
41384833|NCT04166526|DEVICE|MRI|Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
41384834|NCT00128518|DRUG|Indapamide (T2)|1.5 mg/day during 4 weeks
41384835|NCT00128518|DRUG|Perindopril (T1)|4 mg/day during 1 week then 8 mg/day during 3 weeks
41384836|NCT00128518|DRUG|Placebo of Perindopril (P1)|1 pill/day during 1 week then 2 pills/day during 3 weeks
41384837|NCT00128518|DRUG|Placebo of Indapamide (P2)|1 pill/day during 4 weeks
41384838|NCT00170456|BIOLOGICAL|rPA vaccine containing alhydrogel|
41384839|NCT05179434|PROCEDURE|Retrograde renal graft reperfusion|Retrograde venous reperfusion of the renal graft during the kidney transplant procedure with consequent arterial reperfusion
41384840|NCT05179434|PROCEDURE|Conventional antegrade renal graft reperfusion (without retrograde reperfusion)|Conventional arterial antegrade renal graft reperfusion during the kidney transplant procedure
41384841|NCT00479739|DRUG|Salmeterol/fluticasone propionate or formoterol/budesonide|
41384842|NCT06540157|OTHER|Binaural Beat Music (BBM) Combined with Rhythmic Photic Stimulation (RPS)|Participants rested on a chair for 10 minutes before the intervention. Participants wore over-ear stereo headphones and RPS glasses, receiving 20 minutes of 10Hz BBM (embedded with classic old songs as mask music) and RPS. The BBM and RPS glasses were purchased from George Szeless's mindLightz.
41384843|NCT06540157|OTHER|Sham group|Participants rested on a chair for 10 minutes before the intervention. Participants wore the same headphones and RPS glasses as the BBM and RPS group but listened to classic Taiwanese old songs without the 10Hz light stimulation from the RPS glasses.
41384844|NCT06538922|BEHAVIORAL|Single Session Family Intervention|A health coach will deliver a 2-hour single-session consultation to support parent-teen dyadis in applying evidence-based family skills in daily life. Participants will then practice daily on their own for the next 7 days.
41384845|NCT05245227|DRUG|Sublingual Misoprostol|Misoprostol 400 mcg sublingual
41384846|NCT05245227|DRUG|IV Oxytocin|40 units IV Oxytocin in 1000 mL normal saline
41384847|NCT06417203|PROCEDURE|spinal anesthesia with hyberbaric bupivacaine|After standard ASA monitoring in the operation room, spinal anaesthesia was induced by injection of 12.5 mg hyperbaric bupivacaine into the subarachnoid space with the help of a spinal needle through the L4-5 intervertebral space.
41384848|NCT06417203|PROCEDURE|spinal anesthesia with hypobaric bupivacaine|After standard ASA monitoring in the operation room, spinal anaesthesia was induced by injection of 12.5 mg hyperbaric bupivacaine into the subarachnoid space with the help of a spinal needle through the L4-5 intervertebral space.
41384849|NCT03911960|BEHAVIORAL|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of acceptance and commitment therapy for tobacco cessation plus up to 8 weeks of nicotine patch
41384850|NCT03911960|BEHAVIORAL|Enhanced Usual Care|2 in person sessions of tobacco cessation counseling, up to 8 weeks of nicotine patch, referral to state quitline.
41384851|NCT05691218|DEVICE|Standard Nebulization|Beta-2 adrenergic agonist administred by standrad nebulization
41417797|NCT02192346|DRUG|2.4 mg/kg α-TEA|Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
41509913|NCT00351403|DRUG|Ribavirin|Rebetol 200 mg: applied as hard capsule
41509914|NCT00351403|DRUG|Peginterferon alfa 2b|PegIntron (50/80/100/120/150 microgram): applied by injection
41509915|NCT00041132|BIOLOGICAL|filgrastim|5 ug/kg
41509916|NCT00041132|BIOLOGICAL|rituximab|375 mg/m\^2 on day 1 of cycles 1-6
41509917|NCT00041132|DRUG|cyclophosphamide|300 mg/m\^2 on days 2-4 of cycles 1,3,5,7
41509918|NCT00041132|DRUG|cytarabine|12 g/m\^2 over days 3-4 of cycles 2,4,6,8
41509919|NCT00041132|DRUG|dexamethasone|40 mg on days 2-5 and 12-15 of cycles 1,3,5,7
40854389|NCT02904018|OTHER|teleconsultation|Patients performing oral care required as a result of their diagnosis by teleconsultation in vulnerable populations (elderly, disabled adults).
41166102|NCT00815022|DRUG|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
41166103|NCT02790112|OTHER|GnRHas|"Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty."
41509920|NCT00041132|DRUG|doxorubicin|16.6 mg/m\^2/day for days 5-7 of cycles 1,3,5,7
40854390|NCT03229733|DEVICE|Kinect|Receive Kinect games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks
41166104|NCT00796627|GENETIC|Healthy volunteers|Comparison of healthy volunteers to burn wounded volunteers
41384852|NCT05691218|DEVICE|A - Vibrating mesh nebulization|Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
41384853|NCT05691218|DEVICE|B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen|"High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device.~HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device"
41384854|NCT01777607|DEVICE|IMPELLA® RP|
41384855|NCT02076113|PROCEDURE|Ventral (Front) decompression with Fusion|Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
41384856|NCT02076113|PROCEDURE|Dorsal (Back) Decompression with Fusion|Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
41509921|NCT00041132|DRUG|leucovorin|170 mg over days 3-5 of cycles 2,4,6,8
41509922|NCT00041132|DRUG|methotrexate|1000 mg/m\^2 over days 2-3 of cycles 2,4,6,8
41166105|NCT00796627|OTHER|Burn volunteers|Comparison of burn wounded volunteers to healthy volunteers
41166106|NCT00314418|PROCEDURE|Colonoscopy in the prone position|
41166107|NCT01040923|DEVICE|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
41509923|NCT00041132|DRUG|vincristine|1.4 mg/m\^2 on days 5 and 12 of cycles 1,3,5,7
41166108|NCT03255915|DRUG|Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)|TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
41166109|NCT03255915|OTHER|Placebo|A placebo pod-IVR containing microcrystalline cellulose pods.
41509924|NCT06341205|DRUG|RiTUXimab Injection|Dose administered will depend on randomisation and for experimental Arm on the risk of having undetectable rituximab level after 3 months
41509925|NCT05594901|OTHER|Application of a prognostic score|The CRECOOLT score, for the prospective cohort, will be systematically calculated once week, or at the occurrence of complications, until 60 days after OLT. The therapeutic management of all patients, during both retrospective and prospective periods, will be established by the attending physicians according with routine practice and not dictated by study protocol.
41509926|NCT02856555|DRUG|Firsocostat|Capsules orally once daily.
41509927|NCT02856555|DRUG|Placebo|Placebo matched to firsocostat orally once daily.
40854391|NCT03229733|BEHAVIORAL|Traditional occupational therapy|Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.
40854392|NCT00087659|DRUG|zoledronic acid|
40854393|NCT00748371|DRUG|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
41166110|NCT04609410|PROCEDURE|Neuromuscular blockade|Neuromuscular blockade will be achieved via rocuronium intravenous administration and level will be monitored with train of four/post tetanic count monitoring
41166111|NCT01013064|DRUG|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
41166112|NCT01319747|PROCEDURE|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
41166113|NCT01319747|PROCEDURE|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
41509928|NCT05583825|OTHER|Rebozo App|It is a non-invasive, non-drug practical application made with Rebozo, a long and colorful fabric, two meters long and 70 cm wide, worn by Mexican women on their head and shoulders.
40854394|NCT00748371|DRUG|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
40854395|NCT00748371|DRUG|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
40854396|NCT03795220|DRUG|Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
40854397|NCT03795220|DRUG|Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
40854398|NCT03795220|DRUG|No Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
40854399|NCT03795220|DRUG|No Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
40854400|NCT04572451|DRUG|nivolumab|"Nivolumab (BMS-936558-01), 480 mg intravenous (every 4 weeks)~Treatment must be within 7 days of the last dose of radiation."
40854401|NCT04572451|DRUG|BMS-986253|"BMS-986253 (Anti-IL-8), 2,400 mg intravenous (every 2 weeks)~Treatment must be within 7 days of the last dose of radiation."
40854402|NCT04572451|RADIATION|Stereotactic Body Radiotherapy (SBRT)|"Stereotactic Body Radiotherapy (SBRT) (varying doses)~SBRT: Initial Dose fractionation of 3 or 5 fractions of radiation as determined by the location of the metastases to be irradiated, to at least 1 but no more than 4 metastatic lesions. There will be a minimum of 40 hours between treatments for an individual metastasis.~SBRT must be completed within a 14-day window, separate from the screening phase. Treatment with nivolumab and BMS-986253 must be within 7 days of the last dose of radiation."
40854403|NCT05050656|DRUG|Duloxetine 60mg|Duloxetine is a selective SNRI prescribed in depression, anxiety, and chronic pain like diabetic neuropathy and fibromyalgia, it acts through central and peripheral pain modulation
41384857|NCT02076113|PROCEDURE|Dorsal (back) Laminoplasty|Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
41384858|NCT05121688|OTHER|Physiotherapy|A Tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.
40854404|NCT05050656|DRUG|Placebo|placebo tablets identical to duloxetine tablets
40854405|NCT00438165|BEHAVIORAL|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
40854406|NCT01966913|DRUG|Bevacizumab|
40854407|NCT01966913|DRUG|ICE chemotherapy regimen|Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
40854408|NCT03721497|DRUG|Testosterone Undecanoate|The patients will be randomly assigned to either testosterone or placebo.
40854409|NCT05523050|PROCEDURE|active surgical intervention|two kinds: one is colostomy, and the other one is colonic exclusion
40854410|NCT03071289|RADIATION|Radiation Method B|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.
40854411|NCT03071289|DRUG|Cisplatin|The regimen of chemotherapy is cisplatin 30mg/m2 every week.
40854412|NCT03071289|RADIATION|Radiation Method A|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.
41384859|NCT03875300|BEHAVIORAL|Foodwise in Pregnancy|A 7 week programme of nutrition and lifestyle advice, delivered in community venues by trained Healthy Lifestyle Support Workers (HLSWs). Participants must meet study inclusion criteria.
41384860|NCT06565832|PROCEDURE|One-Minute Sit-to-Stand Test|This test involves sitting down and standing up from a normal height chair (can be a dining room or kitchen chair at home) for one minute. Participants can rest or stop at any time if fatigued. Participants will be asked to record your heart rate and oxygen levels before and after the test and will be given a monitor to do this with if they do not already have one. This test should take a maximum of 5 minutes.
41509929|NCT02210845|BEHAVIORAL|Supervised exercise|Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
41509930|NCT02210845|BEHAVIORAL|Financially incentivized weight Loss|Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
41509931|NCT02210845|OTHER|Standard Care at BCDiabetes|usual care dictated by GCP at BCDiabetes.ca
40854413|NCT05062486|DRUG|Resveratrol, Quercetin, Curcumin (RQC)|100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
40854414|NCT05062486|DRUG|Curcumin|1000 mg curcumin BID
40854415|NCT05485337|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
41384861|NCT06565832|PROCEDURE|Chester Step Test|This test involves the participant stepping up and down off of a step (this can be a bottom stair or doorstep at home) keeping up with the beat of a recording. The speed of the beat increases every 2 minutes, and the test continues until the participant cannot keep up with the pace, wish to stop or the test ends which takes 10 minutes. Participants will be asked to record heart rate and oxygen levels before and after the test. This test should take a maximum of 15 minutes.
41384862|NCT05095896|OTHER|ITP patients|ITP patients were enrolled in this study based on Chinese consensus of ITP.12 Patients were excluded as (1) receiving platelet transfusion within 7 days or ITP-related medication within 3 months (2) treated with lipid-lowing agents, including statins, fibrates, niacin, bile sequestrant resins, ezetimibe and so on.
41384863|NCT02790372|OTHER|Case conferencing|Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
41509932|NCT02498028|PROCEDURE|Cervical Fusion|Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)
41509933|NCT02498028|PROCEDURE|Cervical disc Prostheses|The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
41509934|NCT06286657|DIETARY_SUPPLEMENT|Xanthohumol|Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
41037198|NCT05661331|DEVICE|Transjugular intrahepatic portosystemic shunt|The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.
41037199|NCT01875926|BIOLOGICAL|ALX-0171|single dose of 200 mg ALX-0171 via oral inhalation
41166114|NCT04947826|PROCEDURE|HAIC (Hepatic arterial infusion chemotherapy)|For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
41166115|NCT04947826|DRUG|HLX10 (PD-1 antibody)|PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma
41166116|NCT04947826|DRUG|HLX04 (VEGF antibody)|Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.
41166117|NCT04947826|DRUG|Placebo|Placebo
41166118|NCT01397188|DEVICE|PiCCO|transpulmonary thermodilution technique
41166119|NCT01397188|OTHER|sham, no intervention|no intervention
41166120|NCT03876002|DRUG|[18F]PBR06|Subjects will undergo PET imaging using 1 single intravenous (IV) injection of \[18F\]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).
41166121|NCT05089981|DRUG|N acetyl cysteine|Intravenous use of N acetyl cysteine in prescribed doses
41166122|NCT05089981|DRUG|Placebo of N acetyl cysteine|Intravenous Placebo of N Acetyl cysteine in look alike form (Normal saline)
41166123|NCT04584879|BEHAVIORAL|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
41166124|NCT04584879|BEHAVIORAL|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
41166125|NCT04584879|BEHAVIORAL|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
40854416|NCT02888288|BEHAVIORAL|Mental Health Intervention|Includes a standard format of greetings, review of last session content, homework discussion, new topic, assigning homework and ends with a fun activity, relaxation or game. First session is a joint session with youth and caregivers. Topics include common stresses and worries experienced by HIV+ youth; relaxation and coping techniques; cognitive behavioral triangle; story of finding out HIV status and if willing, to discuss this in an individual session, peer group session, and with caregiver; identify circles of support; discuss stigma and how to disclose HIV status to others; consider values, hopes and dreams for the future, and how to use this information to live positively with HIV. ART adherence is woven into case examples and discussions.
41037200|NCT01875926|BIOLOGICAL|ALX-0171|repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
41037201|NCT01875926|BIOLOGICAL|ALX-0171|Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
41037202|NCT06283979|COMBINATION_PRODUCT|STIMULAN VG|Insertion of STIMULAN VG into the ulcer cavity prior to flap closure.
41037203|NCT06283979|PROCEDURE|Standard of Care|Standard of Care. Ulcer bursectomy, debridement and flap closure. Peri-operative antibiotics.
41166126|NCT05566028|DRUG|D745 formulation I|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
41166127|NCT05566028|DRUG|D745 formulation II|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
41166128|NCT05566028|DRUG|D745 Placebo|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
41166129|NCT02332083|DEVICE|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
41037204|NCT02097472|BIOLOGICAL|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
41037205|NCT02097472|BIOLOGICAL|Synflorix|"1 dose (0.5 mL) contains:~1 μg of each of the following pneumococcal polysaccharide serotypes:~1, 5, 6B, 7F, 9V, 14, and 23 F~And 3 μg of the following pneumococcal polysaccharide serotypes:~4, 18C and 19F.~The serotypes are conjugated to either:~protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein"
41166130|NCT02332083|DEVICE|Exergame|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
41166131|NCT02332083|OTHER|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1
41166132|NCT02332083|DEVICE|Aktiv Tramp|Participants will undergo a training program set from the 5 to 8 week, three times a week over 4 minutes.
41166133|NCT04724005|OTHER|No drug|No drug used
41166134|NCT05557149|DEVICE|Virtual Reality Exposure to Neutral Cues|Virtual reality exposure to neutral stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
41166135|NCT05557149|BEHAVIORAL|Respiratory Relaxation|Respiratory relaxation practise. No interaction with the investigator during the relaxation practise.
41384864|NCT05910320|DEVICE|Wearable Vital Signs Monitoring Device|The prototype will be used to non-invasively measure vital signs. This prototype (preliminary version) is composed of a sensor module, a rechargeable battery, and electrodes. The device is housed in a waterproof, silicone casing.
41509935|NCT06286657|DIETARY_SUPPLEMENT|Placebo|Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
41384865|NCT06345183|COMBINATION_PRODUCT|Nivolumab + Ipilimumab combination therapy|As per product label
41384866|NCT06345183|COMBINATION_PRODUCT|Pembrolizumab + Lenvatinib combination therapy|As per product label
41384867|NCT01319305|DEVICE|FinESS Sinus Treatment|balloon sinuplasty
41384868|NCT00093067|DRUG|daptomycin|
41384869|NCT03981614|DRUG|Binimetinib|Given PO
40854417|NCT02888288|BEHAVIORAL|Standard of Care|Standard of Care includes enhanced ART adherence based on clinic protocols and monthly HIV teaching sessions prior to adolescent clinic.
40854418|NCT01891474|DEVICE|U-health care|voice inception technique based U-healthcare service
41384870|NCT03981614|DRUG|Palbociclib|Given PO
41384871|NCT03981614|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
40854419|NCT03857542|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
40854420|NCT03857542|OTHER|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
40854421|NCT05464368|DRUG|[18F]RO-948|"Johns Hopkins University has conducted the first in human study in collaboration with Roche for 18F-RO948and found that 18F-RO948isa promising radioligand for imaging tau pathology in AD, showing excellent brain uptake and displaying little off-target binding(22, 17, 34).The injected activity for18F-RO948will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose of 370MBq(10mCi)has been selected based on the radiation dose estimates for18F-RO948gathered in human subjects provided by Michael Stabin, Ph.D., and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
41037206|NCT02097472|BIOLOGICAL|Pentavac|"Each PFS contains 0.5 ml (single dose):~Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection."
41384872|NCT02374931|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo 18F-FES PET/CT
41384873|NCT02374931|PROCEDURE|Positron Emission Tomography|Undergo 18F-FES PET/CT
41384874|NCT02374931|PROCEDURE|Computed Tomography|Undergo 18F-FES PET/CT
41384875|NCT02374931|OTHER|Laboratory Biomarker Analysis|Correlative studies
41384876|NCT06141954|DEVICE|Ultrasound waves therapy|Therapeutic ultrasound is proposed to deliver energy to deep tissue sites through ultrasonic waves, to produce increases in tissue temperature or non- thermal physiologic changes. Low level laser therapy penetrates particularly light waves that increase cellular metabolism.
41384877|NCT06141954|DEVICE|Low level laser therapy|Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
41384878|NCT05700942|DEVICE|High Dose Intervention-tsDCS|Subjects will receive a high dose tsDCS (2.5mA, 30 mins) LT (4x/week, 5 weeks)
41384879|NCT05700942|DEVICE|Low Dose Intervention-tsDCS|Subjects will receive a low dose tsDCS (2.5mA, 30 mins) LT (4xweek/ 5 weeks)
41037207|NCT02097472|OTHER|Saline|0.9% Sodium Chloride Injection, USP
41037208|NCT00243373|DEVICE|Barcode technology/eMAR|
41384880|NCT05130086|DRUG|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
41384881|NCT06568367|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
41384882|NCT06568367|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
41509936|NCT00091611|DRUG|IL-2 (interleukin-2)|
41509937|NCT00091611|DRUG|OKT3|
41037209|NCT01892072|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
41384883|NCT06568367|DRUG|Placebo|Placebo tablets, taken once daily
41384884|NCT04224142|DIETARY_SUPPLEMENT|PKU sphere|"PKU sphere is a Food for Special Medical Purposes (FSMP). This product is for use in the dietary management of phenylketonuria (PKU).~It is a powdered, low phenylalanine medical food containing a balanced mix of GMP, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and DHA.~It is available in 27g sachets providing 15g PE and contains 28mg Phe and 35g sachets providing 20g PE and contains 36mg Phe."
41384885|NCT06568627|DRUG|EscharEx (EX-03)|a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
41384886|NCT06568627|DRUG|Placebo (Gel vehicle)|A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
41384887|NCT06336174|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
41384888|NCT06336174|PROCEDURE|Endovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients underwent endovascular therapy and received standard medical management after surgery, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
41384889|NCT01124526|DRUG|Rituximab Fludarabine Cyclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)"
41384890|NCT04500054|OTHER|Music Listening|The music type was chosen by the patients and researchers did not have any influence on their choices.
41384891|NCT02595541|DRUG|milrinone|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.
41417798|NCT02192346|DRUG|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
41509938|NCT00091611|DRUG|Cyclophosphamide|
41509939|NCT00091611|DRUG|Fludarabine|
41509940|NCT00091611|DRUG|Mesna|
41384892|NCT02595541|DRUG|Sildenafil|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
41509941|NCT05186649|OTHER|WARFARIN|5 mg of daily dosage
41509942|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
41509943|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
41509944|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
41509945|NCT04957030|DIAGNOSTIC_TEST|ULDCT group|underwent ultralow-dose chest CT
41509946|NCT01258309|DRUG|olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
41509947|NCT01258309|DRUG|olopatadine hydrochloride 0.1% ophthalmic solution|One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.
41509948|NCT04728009|DIETARY_SUPPLEMENT|Longan and lingzhi mushroom syrup|Fresh fruit pulps of longan were stewed in hot water until they softened. No sugar and additives were added. The pulps were removed by filtration in order to obtain concentrated longan juice. After that, spray-dried powder of lingzhi mushroom extract was dissolved in water in the ratio of 1:2. To make the finished product, 99 g of longan juice was mixed with 1 g of the lingzhi extract in water. The sugar content of the syrup was 77 degrees Brix.
41509949|NCT03576079|DEVICE|Laser therapy|epic model biolase with an output of 4W, 1800 J wavelength with a continuous Laser mode.
41509950|NCT03576079|DEVICE|anterior re-positioning splint|hard acrylic anterior re-positioning splint
41509951|NCT03576079|DEVICE|inactive Laser therapy|sham Laser, with inactive beam
41509952|NCT05208489|OTHER|there is no intervention involved in this study|there is no intervention involved in this study.
41509953|NCT03812172|DRUG|99mTc-PYP or 99m Tc-HDP|10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) will be administered intravenously and imaging will be performed after 3 hours.
41509954|NCT04975204|DRUG|TQB3909 Tablets|TQB3909 is an inhibitor targeting BCL-2 protein
41509955|NCT04738695|DIAGNOSTIC_TEST|Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)|Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
41509956|NCT02975947|DEVICE|Humidified, warmed CO2 insufflation of open peritoneum using Fisher & Paykel's HUMIGARD (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand)|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide into the open peritoneal cavity using the Fisher \& Paykel's HUMIGARD system (Fisher \& Paykel Healthcare Ltd, Auckland, New Zealand). This will create a local atmosphere of 100% carbon dioxide (warmed, humidified) in the open peritoneal cavity.
41509957|NCT02975947|DEVICE|Standard heating|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head
41509958|NCT03475108|OTHER|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with type 1 diabetes over 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
40854422|NCT05464368|DRUG|18F-MK6240|"18F-MK6240 is an investigational PET radiotracer discovered by Merck Research Laboratories and is being developed by Cerveau Technologies, Inc.,for imaging neurofibrillary tangles (NFTs)in the brains of people withAlzheimerdisease.18F-MK6240 has been reported to exhibit good kinetics with high binding levels to brain regions associated with deposition of neurofibrillary tangles in people with AD(35,36).The tracer has been used to monitor the progression of AD.The injected activity for18F-MK6240 will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose will be 185MBq(5mCi) has been selected based on the radiation dose estimates gathered in human subjects(37)and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
40854423|NCT05464368|DRUG|18F-GTP1|"18F-GTP1is anInvestigational tau PET radiotracer being developed by Genentech for imaging intraneuronal neurofibrillary tangles in patients with AlzheimerDisease. 18F-GTP1 has been reported to exhibit high affinity and selectively for tau pathology, favorable dosimetry and brain kinetics. Degree of 18F-GTP1-specific binding increased withAD severity, could differentiate diagnostic cohorts, and monitor longitudinal change in tau burden.~18F-GTP1 will be provided from LMI sourced through Illinois or New Jersey certified location."
40854424|NCT02173171|OTHER|Information collection|Q3M Information collection
40854425|NCT04050813|BEHAVIORAL|Exercises program for hamstring architecture and function|To assess the effectiveness of the inertial flywheel resistance program in the architecture and function of the hamstrings post structural hamstring injury
41509959|NCT02291575|OTHER|Training|(please see Arm Description)
41509960|NCT02291575|OTHER|Control|This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
41509961|NCT06266611|DRUG|fsCBD Cannabidiol|Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
41037210|NCT03707977|DRUG|ART|ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.
41037211|NCT03707977|BIOLOGICAL|VRC01LS|Administered by intravenous (IV) infusion
41384893|NCT04093973|DIAGNOSTIC_TEST|bicycle stress echocardiography|Study subjects will perform supine bicycle exercise with echocardiography performed before, during, and after exercise. Definity (perflutren microbubble contrast agent) will be used as needed to enhance echo images.
41384894|NCT04311359|DRUG|Drugs, Generic|All drugs having 19 or more Brain Oedema cases reported to the FAERS database
41509962|NCT06266611|DRUG|Placebo|Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
41509963|NCT06266611|DRUG|bsCBD Cannabidiol|Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
41509964|NCT04439201|DRUG|Palbociclib|Given PO
41384895|NCT02377687|OTHER|observational study|
41509965|NCT00852007|BIOLOGICAL|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1|1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
41509966|NCT03739047|BEHAVIORAL|Desensitization with flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by desensitization. Desensitization will be conducted for 3, 45-minute treatment meals. Puree will be presented on a flipped EZ spoon after the desensitization sessions are completed. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
41509967|NCT03739047|BEHAVIORAL|flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by puree being presented from a flipped EZ spoon. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
41509968|NCT01566227|OTHER|Questionnaire|3 surveys with 10 questions each: one before, during and after treatment
41509969|NCT00743717|DEVICE|zirconia femoral component|total knee arthroplasty performed using implant with zirconia femoral component
40854426|NCT01238302|PROCEDURE|Conventional arthroscopic rotator cuff repair|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
41384896|NCT04740801|DEVICE|Ablation procedure|Catheter ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav StablePoint ablation catheter
41384897|NCT02642991|DEVICE|Phenacite|contact lens
40854427|NCT01238302|PROCEDURE|Arthroscopic rotator cuff repair with PRP|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
41384898|NCT02642991|DEVICE|comfilcon A|contact lens
41384899|NCT04533165|BEHAVIORAL|Exercise|12 week exercise prescription targeting 3 days of at least 30 min of aerobic exercise and 2 days of resistance exercise per week. Adapted to individual abilities, goals, and needs. Exercise intensity targets a 6-7 out of 10 on a 0-10 rate of perceived exertion scale.
41384900|NCT06567847|OTHER|Neurocognitive Enriched Exercise|An intervention planned, progressed, and conducted under the supervision of a physiotherapist, which enriches strengthening, balance, range of motion, stretching, and mobilization exercises with neurocognitive elements.
41384901|NCT06567847|OTHER|Standart Exercise|Supervised and progressively advanced interventions that include strengthening, balance, range of motion, stretching, and mobilization exercises.
41384902|NCT01365741|OTHER|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
41384903|NCT05779046|OTHER|HIT 1:1|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute).
41509970|NCT00743717|DEVICE|cobalt chrome femoral component|total knee arthroplasty performed using implant with cobalt chrome femoral component
41509971|NCT00396812|DRUG|Rituximab|"Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.~Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid."
41509972|NCT03791463|DRUG|salvianolic acid A|Following an overnight fast of at least 10 hours, a single dose of 90 mg salvianolic acid A will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
41509973|NCT01669603|DIETARY_SUPPLEMENT|Bifidobacterium lactis Bl-04|The study product will be a 2\*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.
41509974|NCT01669603|DIETARY_SUPPLEMENT|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
40854428|NCT04904874|DEVICE|intense pulsed light|treatment with 3 sessions of intense pulsed light, the second one after 2 weeks, the third one after 6 weeks
40854429|NCT06413238|DRUG|curcumin, saffron, Combination of saffron and curcumin and placebo|This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.
40854430|NCT02095080|DIETARY_SUPPLEMENT|Leucine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
40854431|NCT06043908|DRUG|artificial tear eyedrops|The intervention group and control group were treated with artificial tear eyedrops four times a day.
41417799|NCT02192346|DRUG|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
41384904|NCT05779046|OTHER|HIT 1:2|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
41384905|NCT05292339|DRUG|Triamcinolone injection to the shoulder, elbow, wrist, or hand|Triamcinolone is a corticosteroid that decreases the inflammatory process by inhibiting the release of arachidonic acid from phospholipids.
41384906|NCT05292339|DRUG|Ketorolac injection to the shoulder, elbow, wrist, or hand|Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.
41384907|NCT01462188|PROCEDURE|Immediate stenting|Primary coronary stenting
41384908|NCT01462188|PROCEDURE|Delayed stenting|Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
41384909|NCT01526707|DRUG|inhaled steroid|inhaled budesonide for 7 days
41384910|NCT05947149|OTHER|questionnaires administration|"Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\&N43, HADS, Brief COPE, BRCS.~Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS.~Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\&N43."
41384911|NCT00351078|DRUG|PTC124|4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
40854432|NCT06043908|DRUG|0.05% cyclosporine eyedrops|The intervention group was treated twice a day.
40854433|NCT06082856|DRUG|Dexmedetomidine|Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes
41384914|NCT04030884|DIETARY_SUPPLEMENT|Honey and water mixture|"60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day."
41417800|NCT02192346|DRUG|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
41417801|NCT02192346|DRUG|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
41509975|NCT01669603|BIOLOGICAL|Rhinovirus|rhinovirus for experimental challenge
41509976|NCT03685344|DRUG|Loncastuximab Tesirine and Durvalumab|intravenous infusion
40854434|NCT06082856|DRUG|Sufentanil|Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
40854435|NCT06371521|DIETARY_SUPPLEMENT|Sportlegs|Sportlegs contains lactate (from calcium lactate pentahydrate and magnesium lactate dihydrate), magnesium (from magnesium lactate dihydrate), calcium (from calcium lactate pentahydrate), and vitamin D (as cholecalciferol).
40854436|NCT06371521|DIETARY_SUPPLEMENT|Placebo|Empty Capsules to serve as a placebo control
40854437|NCT05313087|BIOLOGICAL|COVID-19 vaccine|assess response to vaccine
40854438|NCT05758350|BEHAVIORAL|home based IOPI swallow training|Use IOPI for tongue and labial muscle resistance training. Conventional training was the same as controlled group.
40854439|NCT02964442|OTHER|Capsinoids|12 mg of Gel capsules
40854440|NCT02964442|OTHER|Cold Stimulus|Cooling vest maintain at 14 degree Celsius
41037212|NCT03707977|BIOLOGICAL|10-1074|Administered by intravenous (IV) infusion
41037213|NCT00111657|BIOLOGICAL|Pegloticase|8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5
41037214|NCT03969069|DEVICE|MAPLe|Additional assessment with MAPLe
41037215|NCT03578874|DRUG|Sorafenib|PO
41037216|NCT03578874|DRUG|Capecitabine|PO
41037217|NCT03578874|DRUG|Oxaliplatin|IV
41037218|NCT03716713|DEVICE|CeraShield Endotracheal Tube|Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT
41037219|NCT05764850|GENETIC|Genome sequencing|"100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed.~For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis."
41037220|NCT02098200|DEVICE|TriCinch System|Percutaneous treatment of Tricuspid Regurgitation
41037221|NCT02483169|DRUG|cilostazol|Cilostazol 100mg bid
41037222|NCT02483169|DRUG|Probucol|Probucol 250mg bid
41037223|NCT02483169|DRUG|Aspirin|Aspirin 100mg qd
41037224|NCT02483169|DRUG|placebo of cilostazol|same shape and size of active cilostazol
41037225|NCT02483169|DRUG|Placebo of aspirin|same size and shape of active aspirin 100mg
41037226|NCT02483169|DEVICE|Intima-medial thickness|ultrasound measured IMT of both common carotid arteries
40854441|NCT06067204|DEVICE|Automatic ventilation|"The FDA-approved device used is Meditech MICROVENT RESUSCITATOR, which is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. It is powered by the airflow from the oxygen tank and provides ventilation in fixed interval. It has a pressure valve which will release the pressure once the airway pressure exceeds its threshold. In the current study, the threshold is set at 60 mmH2O. The tidal volume is set at 600 ml."
40854442|NCT06067204|DEVICE|Manual ventilation|The adult size bag-valve mask is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. The interval, pressure and volume of the ventilation is controlled by the emergency medical technicians.
41384915|NCT03622086|OTHER|Foundations of Fitness Program|The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight \& Wellness Center research core.
41509977|NCT04743687|DRUG|Zanubrutinib|Oral Zanuburutinib, 160mg twice a day
40854443|NCT00258791|DRUG|Ibuprofen|
40854444|NCT02235896|BEHAVIORAL|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
40854445|NCT03679624|DRUG|Ibrutinib|Ibrutinib, 420mg orally, once daily
40854446|NCT03679624|DRUG|Daratumumab|Daratumumab, 16 mg/kg intravenously, weekly for 8 weeks, bi weekly for 16 weeks, then monthly for up to 19 months.
40854447|NCT03522220|BEHAVIORAL|3D navigation video game intervention|Participants intensively train with a video game (Super Mario DS)
40854448|NCT03522220|BEHAVIORAL|video game intervention without 3D navigation|Participants train with a video game (Super Mario Bros)
40854449|NCT03522220|BEHAVIORAL|No 3D navigation|Participants read on a kindle device (control group)
40854450|NCT05552352|OTHER|Virtual Reality assisted information|Patients in the intervention group receive a VR instructional application in the patient's room the day before TAVI implantation and in the operational suite during TAVI implantation the next day. In this application, the patient is guided through different VR parts that repeat the indication, the procedure, the localities and the post-interventional phase of the implantation with the corresponding safety instructions.
40854451|NCT06027450|OTHER|NHIg prescription|Analysis of NHIg prescription
40854452|NCT03700489|OTHER|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
40854453|NCT01063153|DRUG|Osmotic Release Methylphenidate|During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
40854454|NCT03066414|PROCEDURE|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
40854455|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub A)|The algorithms act upon the digital audio signal received by the microphones and other sensors to enhance speech and attenuate noise prior to encoding the signal for delivery to a cochlear implant via the specified system.
41166136|NCT05557149|DEVICE|Virtual Reality Exposure to Cocaine-Related Cues|Virtual reality exposure to cocaine-related stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
41166137|NCT04061070|OTHER|Supplementation with mix of threalose plus polyphenols|The patients will be treated with a mix of trehalose plus polyphenols for 60 days
40854456|NCT06100393|DEVICE|Cochlear Limited standard-of-care pre-processing algorithms|Automatic Gain Control, SNR-NR, Forward Focus
40854457|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub B)|Spatial Automation profile
41166138|NCT04061070|OTHER|No Supplementation with mix of threalose plus polyphenols|The patients will not be treated with a mix trehalose plus polyphenols for 60 days
40854458|NCT00136552|DRUG|rituximab|
40854459|NCT00309270|DRUG|Campath-1H|
40854460|NCT00416325|DIETARY_SUPPLEMENT|lycopene|
40854461|NCT00416325|OTHER|laboratory biomarker analysis|
41166139|NCT02044614|OTHER|Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis|
41384916|NCT05782478|DIAGNOSTIC_TEST|Point of care Ultrasound according to study protocol|An emergency medicine specialist or resident will according to a structured protocol perform a structured ultrasound examination of the heart, the inferior vena cava and the lungs.
41417802|NCT02192346|DRUG|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
40854462|NCT03143764|BEHAVIORAL|Commuting with electrically assisted bicycles|25 participants were provided with electrically assisted bicycles fitted with GPS bike computers to record usage
40854463|NCT05177367|OTHER|Sequential Variety|3 courses each consisting of a different food
40854464|NCT05177367|OTHER|Simultaneous Variety|3 courses each consisting of 3 foods
40854465|NCT05177367|OTHER|Single Food|3 courses each consisting of the same food
41417803|NCT02192346|DRUG|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
41166140|NCT00849745|PROCEDURE|Nonmyeloablative allogeneic stem cell transplant|Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
41166141|NCT00853229|DRUG|pregabalin|pregabalin 150mg twice daily for 4 weeks
41166142|NCT04150341|DRUG|TD-8236|The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
41166143|NCT04150341|DRUG|Placebo|The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
41509978|NCT06377618|DIAGNOSTIC_TEST|Resistance Training and Core Strengthening Exercises Group|The regimen includes resistance training (using bands, weights, and bodyweight for major muscle groups) and core strengthening (targeting abdominal, lower back, hip, and gluteal muscles) exercises.
41509979|NCT06377618|DIAGNOSTIC_TEST|Resistance Training and Core Strengthening Exercises Group Plus Vitamin D Supplementation|Group 1 Intervention plus Vitamin D Supplementation: Daily vitamin D supplementation, with the dosage adjusted based on initial serum 25(OH)D levels to achieve and maintain optimal vitamin D
41037227|NCT06535451|OTHER|Screening|Annual LDCT, lung function test (spirometry), anxiety/depression assessments, and serum biomarkers tests over 3 years. Follow-up will continue for 5 and 10 years or until event completion (cancer diagnosis, end of follow-up, or death).
41037228|NCT00344123|DRUG|Tipranavir/Ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
41037229|NCT00344123|DRUG|Rosuvastatin|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."
41037230|NCT01930370|DRUG|Bicarbonate hemodialysis solution (low concentration)|One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
41037231|NCT01930370|DRUG|Bicarbonate hemodialysis solution (high concentration)|One-week experimental session with high dialysate bicarbonate (38 mmol/L)
41037232|NCT03719872|DIAGNOSTIC_TEST|Pre-Operative Transabdominal Ultrasound|Pre-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
41037233|NCT03719872|DIAGNOSTIC_TEST|Post-Operative Transabdominal Ultrasound|Post-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
41037234|NCT04969250|BIOLOGICAL|Moderna mRNA-1273 COVID-19 vaccine|100 µg intramuscular injection
41037235|NCT04969250|BIOLOGICAL|Pfizer BNT162b2 COVID-19 vaccine|30 µg intramuscular injection
41037236|NCT06138977|DEVICE|Powered prosthesis|A powered prosthesis will be used to restore normative leg biomechanics to above-knee amputee participants during different activities of daily life.
41037237|NCT03400891|BEHAVIORAL|Program based on the theory of planned behaviour|14 sessions of one hour to work TPB constructs: attitude, subjective norms, perceived behavioural control and intention.
41037238|NCT05734794|DRUG|Rituximab|Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.
41417804|NCT02192346|DRUG|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
41417805|NCT02192346|DRUG|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
41417806|NCT00347503|DRUG|ketorolac 0.4%, bromfenac 0.09%|
41417807|NCT04289636|BEHAVIORAL|Behavioral weight loss program|Using a combination of individual (\~1x/month) and group-based (\~3x/month) meetings, participants will be taught behavioral approaches for changing diet and exercise behaviors. This intervention will be 15 weeks in duration and will be delivered remotely using a video-conferencing platform.
41417808|NCT04289636|BEHAVIORAL|Self-compassion|This 8-week, group-based program will help train individuals on how to handle difficult emotions with greater ease, how to transform difficult relationships, and how to motivate and encourage oneself, rather than being self-critical.
41417809|NCT04289636|BEHAVIORAL|Nutrition and cooking education|This 8-week, group-based program will help individuals to improve the quality of their diet through nutrition education and basic cooking skills for preparing healthy meals.
41417810|NCT02343120|DRUG|Zanubrutinib|Oral administration by capsule
41037239|NCT05734794|DRUG|Steroid|Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
41037240|NCT04274608|DRUG|Botulinum toxin type A|Intragastric injection of Botulinum toxin type A
41037241|NCT04274608|BEHAVIORAL|Weight Management Program|12 week weight management program
41037242|NCT06530914|DRUG|MRG003 combined with Pucotenlimab|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
41417811|NCT03294538|DRUG|Generic Estradiol Vaginal Cream USP, 0.01%|Vaginal cream, generic formulation of the brand product.
40854466|NCT05177367|OTHER|Small portion|Small meal portion size
41037243|NCT06530914|DRUG|MRG003 combined with Pucotenlimab+Cisplatin|All interventions all drugs intravenous infusion, once every 3 weeks, a total of 3 cycles.
41037244|NCT03680599|BEHAVIORAL|Connection to Health for Smokers|Connection to Health for Smokers includes 5 core components supported by online tools: (1) comprehensive electronic patient survey, (2) automated summary report to flag areas of difficulty (3) interactive priority setting, (4) interactive action planning, and (5) electronic text reminders and followup.
41384917|NCT03654092|BEHAVIORAL|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
41384918|NCT06567951|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|This is the first time that prengnt women with maternal supraphysiological hypercholesterolemia will be suplemented with EVOO during pregnancy. The intervention will be daily EVOO suplementation (36mL) form gestational week 28 until delivery
41384919|NCT04926740|OTHER|Ringer's lactate|Ringer's lactate is the most commonly used balanced crystalloid. Compared to normal saline, balanced crystalloids have chloride concentrations similar to human plasma; therefore, treatment with balanced crystalloids may lead to faster DKA resolution.
41384920|NCT06565611|DRUG|Bremelanotide|Bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume
41384921|NCT06565611|DRUG|Tirzepatide|Tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.
41384922|NCT03751852|BEHAVIORAL|Exercise Coaching|28 classes in 16 weeks
41384923|NCT03751852|BEHAVIORAL|Psychoeducation|28 classes in 16 weeks
41384924|NCT02441959|PROCEDURE|Lumbar discectomy Open|Open Discectomy
41384925|NCT02441959|PROCEDURE|Lumbar discectomy Endoscopic|Endoscopic Discectomy
41384926|NCT06309472|DRUG|Mirtazapine|30mg mirtazapine at night, escalated to 45mg after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
41384927|NCT06309472|DRUG|Placebo|1 placebo capsule at night, escalated to 2 capsules after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
41509980|NCT01431365|BEHAVIORAL|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
41509981|NCT01431365|BEHAVIORAL|Passive Sitting Group|Participants will be required to sit passively for 10 minutes on a chair.
41509982|NCT02245087|DRUG|Atorvastatin|20 mg of atorvastatin daily
41509983|NCT05645133|DEVICE|Diagnostic Test|Diagnostic device to monitor coagulation properties of a whole blood sample at the point of care
41509984|NCT00173511|DEVICE|24 hr Holter monitor|
41509985|NCT03511027|DEVICE|SME + Karie Device|For the duration of the study, participants will use the Karie device to promote medication adherence. The Karie device prompts users to take their medication in the right amount at the right time.
41509986|NCT03511027|OTHER|SME only|At discharge, participants will be provided with self-medication education.
40854467|NCT05177367|OTHER|Large Portion|Large meal portion size
40854468|NCT00002230|DRUG|Hydroxyurea|
41037245|NCT03680599|BEHAVIORAL|Enhanced Standard of Care|Participants will complete a survey and receive standard one-on-one smoking cessation according to a usual care protocol delivered by health educators
41037246|NCT02871648|DRUG|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
41037247|NCT02871648|DRUG|Fludrocortisone|Fludrocortisone 0.1 mg
41384928|NCT04064333|DEVICE|Slow-Stream Expiratory Muscle Strength Training|All participants will receive an initial visit for training on the therapy protocol, use of a weekly therapy log to track breaths, and use and maintenance of the EMST device. This will constitute the first EMST session and will be included in the therapy log as Week 1, Day 1. Each participant will have a minimum of seven weekly check-in visits from the research assistant and/or a member of the research team, where the EMST150 resistance will be recorded and adjusted to maintain training at 75% of their maximum load, as measured using the EMST150 device instruction manual. During these check-in visits, participants will provide their completed weekly therapy log and receive a new log.
41509987|NCT06551480|DEVICE|Biometry|Only one eye from each patient will be included in the study. All subjects and patients included in the study will undergo biometric measurements with both devices (IOL master 500 and VCSEL based swept source optical biometry).
41509988|NCT01256502|DEVICE|SERI® Surgical Scaffold|Breast reconstruction surgery
41509989|NCT05808478|BEHAVIORAL|AAC + Eye Tracking|The AAC treatment will be supported by the use of an innovative high-tech tool, such as Eye Tracking. The duration of treatment will be 6 months, with sessions of 45 minutes twice a week.
41509990|NCT05808478|BEHAVIORAL|AAC|Treatment involves the use of conventional AAC, with low-tech tools, such as PECS or sign language. The duration of treatment will be six months, twice a week, with sessions of 45 minutes.
41509991|NCT03296527|DRUG|Follitropin alfa|GONAL-F dose was fixed for the first 5 stimulation days.
41509992|NCT03296527|DRUG|Follitropin delta|REKOVELLE (FE 999049) was fixed throughout the stimulation period.
40854469|NCT00002230|DRUG|Efavirenz|
40854470|NCT00002230|DRUG|Stavudine|
40854471|NCT00002230|DRUG|Didanosine|
40854472|NCT02942485|DRUG|Metronidazole|P/r suppositories
40854473|NCT02942485|DRUG|Tinidazole|P/o tablets
40854474|NCT03125551|DIETARY_SUPPLEMENT|Ginger|Ginger dosage at daily recommended allowance
41037248|NCT02871648|DRUG|Eplerenone|Epleronone 100 mg
41037249|NCT05860699|DRUG|Placebo|Placebo made by the same manufacturer to look like the active pills
41384929|NCT04762771|DRUG|Colchicine|"Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase \> 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral"
41384930|NCT03417674|COMBINATION_PRODUCT|Lifestyle intervention|Meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
41384931|NCT00358670|BIOLOGICAL|infliximab|"Infliximab maintenance therapy~intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2)."
41384932|NCT00358670|BIOLOGICAL|infliximab|"Infliximab intermittent therapy:~Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 \[NCT00251641\] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a \>=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse."
41384933|NCT02787746|DRUG|Donepezil|Eligible patients were treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d，the dose could be reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who could not endure the 10mg/d titration the 2nd time and were put back to 5mg/d or discontinuance of Aricept® should be considered as withdrawal from the study. There were a visit (visit 1) at week 0, the end of week 4 (visit 2) and the end of week 20 (visit 3), respectively.
41384934|NCT04141670|DRUG|S48168|A novel oral small molecule which is designed to repair leaky RYR1 channels
41384935|NCT06567561|BEHAVIORAL|Whole Foods Plant-Based Diet|Whole foods, predominantly plant-based diet, with the addition of fish, eggs, and fermented dairy.
41384936|NCT06567561|BEHAVIORAL|Usual Firehouse Diet|Usual firehouse meals.
41384937|NCT05916950|DEVICE|Thor laser atherectomy|Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system
41384938|NCT05778227|DRUG|Ethylene Diamine Tetra Acetic acid|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
41384939|NCT05778227|DRUG|smearOFF|Final irrigation of root canal treatment procedure will be done with 5ml of smearOFF for 1min.
41384940|NCT05778227|DRUG|Etidronic acid /sodium hypochlorite|During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
41384941|NCT05778227|DRUG|Maleic acid|Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
41417812|NCT03294538|DRUG|Estrace® Vaginal Cream USP, 0.01%|Vaginal cream, brand product.
40854475|NCT03125551|DIETARY_SUPPLEMENT|Garlic|Garlic dosage at daily recommended allowance
40854476|NCT03125551|DIETARY_SUPPLEMENT|Ginkgo Biloba|Ginkgo Biloba dosage at daily recommended allowance
40854477|NCT03125551|DIETARY_SUPPLEMENT|Ginseng|Ginseng dosage at daily recommended allowance
40854478|NCT03125551|OTHER|Placebo|Daily dosage strategy
40854479|NCT01578577|BEHAVIORAL|EHMI|The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
41166144|NCT03892928|DRUG|Dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
41166145|NCT04161885|DRUG|Venetoclax|Tablet; Oral
41166146|NCT04161885|DRUG|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
40854480|NCT01578577|BEHAVIORAL|Nurse Educator + EHMI|This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
40854481|NCT06265506|BEHAVIORAL|Contingency Management|Contingency Management (CM) is an intervention that uses positive reinforcement (e.g. gift cards) to reinforce a desired behavior (e.g. negative alcohol biomarker tests) on a frequent (e.g. weekly), escalating (e.g. $5/week) schedule (e.g. 26 weeks) in order to increase the occurrence of that behavior (e.g. long term alcohol abstinence or reduction in drinking).
40854482|NCT06265506|BEHAVIORAL|Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT)|CBT4CBT is an evidence-based online intervention that teaches CBT principles and skills to help people with alcohol use disorder reduce their drinking. CBT4CBT teaches CBT principles through video, graphics, audio instruction, and interactive exercises. Modules include video-based examples to emphasize learning of behavioral, cognitive, and affective strategies, with an emphasis on learning from examples of individuals using skills in a range of situations. Skills taught include functional analysis, coping with craving and emotions, problem solving, decision making, challenging thoughts, and assertive alcohol refusal. Interactive exercises and homework are used to encourage skills learning and practice.
41509993|NCT06281444|DEVICE|ESWT|"All patients in both groups will be applied with a home-based exercise program around for 30-minutes per day for four weeks. The exercises that mentioned in the research content are knee range of motion and strengthening exercises for the knee. It will be checked by phone on a weekly basis. Also, each patient in group 1 will receive shockwaves of continuous frequency and intensity (1000 shocks, 2.0 to 3.0 bar,10 Hz and 0.08-0.25mJ/mm2 energy range), while the second group of patients will receive sham-ESWT.~ESWT application will be applied to the medial part of the knee area on the side where the pain is described, or at the patellofemoral and tibiofemoral borders of the affected knee, and will be given in four sessions in total once a week."
41037250|NCT05860699|DRUG|Half dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
41037251|NCT05860699|DRUG|Full dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
41037252|NCT05516797|DEVICE|Continuous Glucose Monitoring (CGM)|Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring
41037253|NCT01848873|DRUG|Amlodipine|amlodipine 5mg daily
41037254|NCT01848873|DRUG|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid, daily.
41037255|NCT01848873|DRUG|amlodipine-FA tablet ,high dose group|amlodipine 5mg and folic acid 0.8mg daily
41037256|NCT01071850|DRUG|ipragliflozin|oral tablet
41037257|NCT01071850|DRUG|Metformin|oral tablet
41037258|NCT01071850|DRUG|Placebo|oral tablet
41037259|NCT03682094|DRUG|VSL#3|Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.
41037260|NCT03697850|DRUG|Atezolizumab|Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy
41037261|NCT03434119|DRUG|Insulin glargine/Lixisenatide|Insulin glargine (100 units per milliliter \[U/mL\]) and lixisenatide (33 micrograms per milliliter \[mcg/mL\]) self administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
41037262|NCT03434119|DRUG|Insulin glargine (HOE901)|Insulin glargine 100 U/mL self-administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting SMPG of 80 to 100 mg/dL (4.4 to 5.6 mmol/L) while avoiding hypoglycemia.
41509994|NCT06281444|DEVICE|Sham-ESWT|Sham ESWT application will be set to 1000 pulses, 2-3 bar pressure, 10 Hz frequency and 0 mJ/mm2 energy to be sham.
41509995|NCT05944926|BEHAVIORAL|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
41509996|NCT05944926|DRUG|Antidepressant medication (fluoxetine)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
41037263|NCT03434119|DRUG|Background therapy|Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
41037264|NCT01289912|DRUG|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
41037265|NCT01289912|DRUG|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
41037266|NCT00241254|DRUG|Cyclophosphamide (drug)|IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
41037267|NCT00241254|DRUG|Methylprednisolone (drug)|Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
41037268|NCT03555396|BEHAVIORAL|SMART Couples 2|The intervention will consist of 4 sessions with activities designed to strengthen communication and support within the couple to improve adherence to antiretroviral therapy and increase linkage to drug treatment services. The activities are based on cognitive-behavioral therapy. Participants' adherence will be monitored continuously through electronic monitoring devices and surveys completed at baseline and follow-up periods.
41037269|NCT03555396|BEHAVIORAL|Standard of Care|Standard of Care consists of an appointment with an AIDS Center nurse at baseline and two months later. Under current Standard of Care in Almaty, no behavioral intervention is provided. Participants obtain prescription refills and give blood for viral load and CD4 tests once every 6 months.
41037270|NCT02477618|DRUG|SAGE-547|
41384942|NCT03065517|DEVICE|VillageWhere App|VillageWhere is a mobile phone app for use on both Android and iOS platforms by youth with conduct disorders and their parents.
40854483|NCT00902460|DRUG|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
41384943|NCT03065517|DEVICE|Attention-Control Placebo App|Mobile phone app for use on both Android and iOS platforms.
41384944|NCT04268394|DRUG|CC-99677|CC-99677
41384945|NCT04268394|DRUG|Methotrexate|Methotrexate
41384946|NCT04268394|DRUG|Sulfasalazine|Sulfasalazine
41384947|NCT04268394|DRUG|Itraconazole|Itraconazole
41384948|NCT04268394|DRUG|Rifampin|Rifampin
41384949|NCT04268394|DRUG|Midazolam|Midazolam
41384950|NCT04268394|DRUG|Digoxin|Digoxin
41384951|NCT04268394|DRUG|Metformin|Metformin
41384952|NCT04268394|DRUG|Rosuvastatin|Rosuvastatin
41384953|NCT03384407|DEVICE|Red cell survival in INTERCEPT treated red cells|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
41384954|NCT03881605|DIAGNOSTIC_TEST|MRI screening|A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.
41384955|NCT02662556|DRUG|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
41384956|NCT03625648|DRUG|Pentoxifylline|The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
41384957|NCT03625648|DRUG|Placebo|placebo
41384958|NCT06111794|OTHER|REACH TBI|Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
41384959|NCT01904084|DEVICE|Volar locked plating|Operative treatment of distal radius fracture with volar locking plate
41037271|NCT02477618|DRUG|Placebo|Placebo
41037272|NCT01561248|DRUG|polyethylene glycol solution for daily bowel lavage.|At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
41384960|NCT01904084|DEVICE|Hoffman external fixator|Patients with distal radius fracture operated with Hoffman external fixator
41384961|NCT00665704|BEHAVIORAL|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
41384962|NCT02437539|DRUG|Injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE 105
41384963|NCT02437539|DEVICE|Positron Emission Tomography scans|Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
41384964|NCT04520711|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
41384965|NCT04520711|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
41384966|NCT04520711|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
40854484|NCT00902460|DRUG|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
40854485|NCT02074839|DRUG|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
40854486|NCT05985967|DEVICE|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
40854487|NCT05985967|DEVICE|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
41037273|NCT06534151|DEVICE|CRT implantation|A CRT is a device (that looks like a pacemaker) that will be used to help the ventricles contract synchronously.
41384967|NCT02032446|BIOLOGICAL|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)|"pentostatin, dose 1 mg/m2~§ MSC doses:~1. 3 patients → 3 infusions of 1x106 cells /kg~2. 3 patients → 3 infusions of 2x106 cells /kg~3. 3 patients → 3 infusions of 3x106 cells /kg"
41384968|NCT04925531|DRUG|Antibiotics|to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
41384969|NCT05912608|PROCEDURE|Conservative TAAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
41384970|NCT05912608|PROCEDURE|Extensive TAAAD-R|Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total hemiarch) or reimplantation of the innominate trunk only (partial hemiarch).
41384971|NCT05149989|DEVICE|Proning Pillow System|Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
41384972|NCT03273010|PROCEDURE|Free gingival graft|Free gingival graft was harvested from palatal donor site
41384973|NCT03273010|PROCEDURE|Cyanoacrylate application|Periacyrl was applied on palatal wounds
41037274|NCT03601832|PROCEDURE|4-D navigated stereotactic radiosurgical ablation|4-D Navigated Non-invasive radiosurgical ablation of ventricular tachycardia in patients with sustained monomorphic ventricular tachycardia/tachycardias after myocardial infarction.
41037275|NCT04243876|DIAGNOSTIC_TEST|paraoxanase enzyme level|presence of paraoxonase enzyme deficiency and associated troponin elevation
41037276|NCT01900990|DEVICE|Noninvasive ventilation weaning|We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
41037277|NCT05520580|PROCEDURE|Mother's push during CS|after uterotomy, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary
41037278|NCT01280487|DRUG|ZSTK474|Daily oral dosing for 21 days each cycle
41384974|NCT03801213|DEVICE|urinary catheterization|Urinary catheterization with pain controlled
41384975|NCT03801213|PROCEDURE|manual bladder stimulation technique|manual gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
41384976|NCT05438199|DEVICE|Toilet seat that measures waste output|Participants will use a toilet that includes a apparatus designed to measure waste output.
41384977|NCT04120701|DRUG|mFOLFOX6|Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
41384978|NCT01503502|DRUG|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
41384979|NCT01503502|DRUG|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
41384980|NCT05812131|BEHAVIORAL|COPEWeb online training|COPE training delivered via online COPEWEb to providers
41384981|NCT05812131|BEHAVIORAL|COPE In Person|COPE training provided in person to providers
41037279|NCT00413504|DRUG|Fondaparinux|
41037280|NCT02049073|DRUG|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
41037281|NCT02049073|DRUG|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
41037282|NCT05707637|OTHER|Ablation|Unipolar and bipolar ablation
41037283|NCT06197893|PROCEDURE|gingival unit graft+modified sling suture technique|The GUG was obtained from the maxillary premolar area. A sulcular incision including the marginal gingival tissue, and two vertical incisions, including the distal and mesial papillae, was made in the palatial parts of the premolars. Then, the incision lines were combined and a 1-1.5 mm thick graft of the desired dimensions was dissected. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique. First, the needle was passed through the graft slightly apical to the mesial papilla on the buccal side and removed from the lingual aspect including lingual papilla. Subsequently, on the distal side, the needle was passed from the lingual side to the buccal side, and it was passed through the graft slightly apical to the distal papilla and removed from the lingual gingiva again. Then it was knotted on the buccal graft by returning to the buccal starting point on the mesial side.
41384982|NCT03797339|OTHER|risk factors of adverse cardiovascular events|During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected
41384983|NCT03797339|OTHER|multi-omics target discovery|Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly. Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
41384984|NCT03797339|OTHER|validation|The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip. The methylation level of the functional region was detected by the target region enrichment methylation sequencing method. Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.
41166147|NCT04161885|OTHER|Best Supportive Care (BSC)|BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.
41166148|NCT04255173|DIAGNOSTIC_TEST|Body mass index|Body mass index is calculated as a ratio of height and weight, expressed as kg/m2
41166149|NCT04255173|DIAGNOSTIC_TEST|waist circumference|waist circumference is measured as cm
41417813|NCT03294538|DRUG|Vehicle Vaginal Cream|Vaginal cream, placebo. Has no active ingredient
41509997|NCT01050465|OTHER|health information prescription|Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
41509998|NCT03629184|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1.~Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days."
41509999|NCT03629184|DRUG|Oseltamivir|Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
41510000|NCT04110379|BEHAVIORAL|Virtual Reality (VR)|All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.
41510001|NCT04110379|BEHAVIORAL|Conventional Behavior Management Techniques|Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
41510002|NCT02879903|PROCEDURE|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets."
41510003|NCT02879903|PROCEDURE|Microbiological collect|Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
41510004|NCT02879903|PROCEDURE|Questionnaire|Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
41384985|NCT03797339|OTHER|Predictive mathematical models|Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
41510005|NCT01645787|DRUG|4-aminopyridine|10 mg/twice daily
41510006|NCT01645787|DRUG|Placebo|Crossover study involving one trial with sugar pill (placebo)
41510007|NCT01050439|PROCEDURE|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
41510008|NCT01050439|OTHER|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
41510009|NCT06239480|DRUG|QTORIN 3.9% Rapamycin Anhydrous Gel|QTORIN 3.9% Rapamycin Anhydrous Gel
41384986|NCT06514586|DRUG|Oxytocin|Oxytocin gel 600 IU . 1mg/g
41510010|NCT05081050|OTHER|Only Follow-up|No intervention is planned.
41510011|NCT03867097|DRUG|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
41510012|NCT03867097|DRUG|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
41384987|NCT06514586|OTHER|Hydroxypropyl methylcellulose|Placebo
41384988|NCT06023511|DEVICE|Electrical muscle stimulation|While study subjects are connected to standard ICU monitors, electrical muscle stimulation will be applied at the level of the quadriceps muscle to induce palpable or visible muscle contraction. (No control group or sham procedure in this study).
41510013|NCT01017627|OTHER|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
41510014|NCT01017627|OTHER|No change from normal routine|Normal unit policy for labs and anemia treatment
41384989|NCT03029000|DRUG|Tbo-filgrastim|solution for subcutaneous injection
41510015|NCT03383523|DRUG|Emodepside (BAY 44-4400)|2 tablets compared to the liquid formulation
41510016|NCT01687972|COMBINATION_PRODUCT|Insorb absorbable staples|Placement of Insorb absorbable staples at cesarean section
41510017|NCT01687972|COMBINATION_PRODUCT|Absorbable sutures|placement of absorbable sutures at cesarean section
41510018|NCT03147430|OTHER|Biomarkers|Experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.
41510019|NCT03010683|DRUG|Liraglutide|Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
41510020|NCT03010683|DRUG|Metformin|Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
41384990|NCT05591547|RADIATION|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|The lumpectomy bed will receive a total of 26 Gy in 5 fractions, with 1 fraction delivered per day. Ideally, the course of radiation therapy would be completed over 5 consecutive treatment days. Treatment must begin within 12 weeks of lumpectomy or re-excision of surgical margins and must be completed within 10 calendar days.
41384991|NCT01590537|DRUG|Levonorgestrel (Mirena, BAY86-5028)|intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
41384992|NCT01590537|DEVICE|Copper IUD|Copper device, inserted intrauterine
41510021|NCT02354625|BIOLOGICAL|Autologous human Schwann cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
41510022|NCT06353763|OTHER|Immersive virtual reality learning program|The immersive virtual reality learning programme was developed by the research team and two nurse experts in chronic wounds, who designed the learning content and script and created six pressure ulcer (PU) cases. Based on the standards of the European Pressure Ulcer Advisory Panel (EPUAP), the National Pressure Ulcer Advisory Panel (NPUAP) and the National Group for the Study and Advice on Pressure Ulcers and Chronic Wounds (GNEAUPP), prevention of healthy skin (case one), management of grade I, II, III and IV PUs (cases two to five) and an infected PU (debridement intervention) were developed. For each case, there was a formative version with immediate feedback and an evaluative one. Before starting the training, the students learned how to use the virtual reality glasses, buttons and joystick by playing a game that trained different dexterity movements. The computer assembly IVR application was developed using Unity 3D and the virtual objects were designed in 3Ds Max.
41510023|NCT06498843|OTHER|administration of an isotonic seawater solution (9g/L) in the nose|"1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis, and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days"
41510024|NCT06498843|OTHER|administration of a hypertonic seawater solution (21g/L) in the nose|"1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days"
41510025|NCT05407311|DRUG|64Cu-SAR-BBN|64Cu-SAR-BBN
40854488|NCT05985967|DEVICE|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
41384993|NCT01910701|BEHAVIORAL|Family Spirit|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
41384994|NCT02766686|RADIATION|Radiotherapy with protons|
41384995|NCT02766686|RADIATION|Radiotherapy with photons|
41384996|NCT05028881|OTHER|blood sampling|blood sampling for determining antibody responses
41384997|NCT04028570|RADIATION|Varying Doses of Background and Boost RT|3+3 radiation dose escalation model to see the maximum tolerated dose for background and boost radiation therapy.
41384998|NCT02192307|DEVICE|Potassium oxalate|
41384999|NCT01281631|DRUG|NP001|Low dose of NP001
41385000|NCT01281631|DRUG|NP001|High dose of NP001
41385001|NCT01281631|DRUG|Placebo|normal saline
41510026|NCT00270855|PROCEDURE|Arm Crank Ergometry|Use of an upper body cycle to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
41166150|NCT04255173|DIAGNOSTIC_TEST|hip circumference|hip circumference is measured as cm
41166151|NCT04255173|DIAGNOSTIC_TEST|height|height is measured as cm
41510027|NCT00270855|PROCEDURE|FES Cycle Ergometer|Use of an FES cycle ergometer to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
40854489|NCT05985967|OTHER|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
40854490|NCT02511886|DRUG|Arbaclofen Placarbil|Arbaclofen Placarbil
40854491|NCT02511886|DRUG|Placebo|Placebo matched tablets
40854492|NCT03118089|DIETARY_SUPPLEMENT|Biscuit style oral nutritional supplement|
40854493|NCT05742724|DRUG|Tetrahydrocannabinol-Cannabidiol Combination|Oral THC 0.1mg/kg and CBD 2.5mg/kg
40854494|NCT01696890|DEVICE|integrated follow-up|close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
41166152|NCT04255173|DIAGNOSTIC_TEST|Fat percentage|Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).
41385002|NCT02237885|DEVICE|NeuroSky MindWave Mobile|
41385003|NCT06279273|DEVICE|Transcranial direct current stimulation|Participants were treated for a total of 20 sessions with active or sham stimulation at 2 mA. Each session lasted 20 min at a fixed daytime interval.
41385004|NCT04908956|DRUG|Osimertinib|"Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home."
41385005|NCT04908956|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered using risk-adapted SBRT with a maximum of 5 SBRT fractions.
41385006|NCT05269615|DRUG|Valsartan 80 mg|The well-established angiotensin II receptor blocker (ARB) valsartan will be used in the present study to selectively block AT1 receptors. Valsartan is a generic medication widely used in hypertensive patients since 1996 as well as safely applied in physiological studies comprising healthy individuals.1-3 A minimal valsartan dose of 80 mg known to acutely reduce circulating EPO levels in healthy individuals will be provided 4 hours before starting Study 1 to optimize AT1 blockade according to valsartan's half-life.1-3 The same dose of valsartan (80 mg) will be provided 4 hours before each ET session in Study 2. The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste, smell, appearance and dosage. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
40854495|NCT01696890|DEVICE|standard care|no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
41385007|NCT05269615|DRUG|Placebo|The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste and smell. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
40854496|NCT05079919|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
40854497|NCT05079919|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
40854498|NCT03422965|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography images capture.
40854499|NCT03422965|DIAGNOSTIC_TEST|Blood test|Blood test, systemic markers
40854500|NCT03422965|DIAGNOSTIC_TEST|Urine test|Urine test, systemic markers
40854501|NCT03992846|DRUG|75 mg linzagolix tablet|For oral administration once daily
40854502|NCT03992846|DRUG|200 mg linzagolix tablet|For oral administration once daily
40854503|NCT03992846|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
40854504|NCT03992846|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
40854505|NCT03992846|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
40854506|NCT03992846|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
40854507|NCT00256802|DEVICE|MR-angiography, GTN|
40854508|NCT05253885|DEVICE|Smartphone use|"* Smartphone addiction scale (short version) higher than 33~* Smartphone users of 4-5 inches screen size smartphones, weighing 140-160 grams and dimensions less than 159\*79\*9 mm."
41037284|NCT06197893|PROCEDURE|Gingival unit graft and conventional suture technique|The GUG was obtained from the maxillary premolar area. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique. Conventional suture technique includes a horizontal matrix suture and 2 simple sutures. First the coronal part of the dissected graft was fixed to the recipient bed with a horizontal matrix suture, then with 2 simple sutures along the vertical incision line from mesial and distal sides with 5/0 polypropylene suture.
41166153|NCT04255173|DIAGNOSTIC_TEST|Skeletal muscle index|Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height \[m2\].
40854509|NCT03996031|DEVICE|Plan to Thrive smartphone application|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests.
40854510|NCT00651638|DRUG|Treatment with ARQ 197|Treatment with ARQ 197
40854511|NCT00302211|DRUG|Inhaled Iloprost (5 μg)|iloprost inhalation solution (Ventavis) (5 μg)
40854512|NCT00302211|DRUG|Inhaled Placebo|inhaled placebo
41166154|NCT04255173|DIAGNOSTIC_TEST|A body shape index (ABSI)|ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)
41385008|NCT06496711|OTHER|Cancer Patients; Institutions and their employees in the treatment and/or counseling of cancer patients|The study population will be surveyed at 3 yearly measurement time points by means of questionnaires and interviews on attitudes, barrier and support factors for participation in exercise therapy.
41385009|NCT01995058|DRUG|cabozantinib|Tablets taken orally
41385010|NCT01995058|DRUG|abiraterone|Tablets taken orally daily
41385011|NCT01995058|DRUG|prednisone|Tablets taken orally twice daily
41385012|NCT04342390|OTHER|High-Intensity Interval Training (HIIT)|The exercise we are studying is called high-intensity interval training, or HIIT. Participants in the exercise group will participate in the exercise program. Each exercise session will last up to 1 hour. All exercise sessions will be directed and monitored by an experienced exercise trainer or exercise physiologist.
41385013|NCT03955718|BEHAVIORAL|Motherly App|The Motherly app is a behavioral intervention aimed at preventing maternal depression and promoting child development.
41385014|NCT03955718|BEHAVIORAL|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
41385015|NCT03586986|DIAGNOSTIC_TEST|Brain MRI|Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
41385016|NCT03843307|DEVICE|Avazzia Tennant Biomodulator® PRO|High-voltage pulsed current (HVPC) electrical stimulation with Reactions and BEST™ (Bio-Electric Stimulation Technology) microcurrent that measure and change with tissue electrical characteristics.
41385017|NCT06344858|DRUG|Ketamine|One bolus of ketammine
41385018|NCT03992261|DRUG|Halobetasol Topical Foam|Foam
41385019|NCT00327652|DRUG|CRS-100|Live-attenuated Listeria monocytogenes
41385020|NCT03951701|OTHER|Evaluation of the supportive care|Evaluation of interest of a systematic screening for oncological supportive care needs
41385021|NCT04381468|DRUG|Pepinemab|Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
41385022|NCT04381468|DRUG|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
41385023|NCT02395094|BEHAVIORAL|Child Life|"Child Life preparation in surgical daycare can include:~* role-play using dolls and medical equipment (either toy doctor kits or true medical materials)~* the use of books/storyboards that show pictures of operating room and daycare routines~* teaching \& rehearsing coping and relaxation skills such as deep breathing and guided imagery~* age-appropriate explanation of what to expect throughout the day in SDCU"
41385024|NCT03099265|DRUG|neoadjuvant mFOLFIRINOX|Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
41385025|NCT03099265|DRUG|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
40676613|NCT05388643|DIAGNOSTIC_TEST|Routine Gestational Diabetes Screening|Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
40854513|NCT00302211|DRUG|Sildenafil|oral sildenafil (dosage between 60 and 300 mg/day)
40854514|NCT00302211|DRUG|Bosentan|oral bosentan (dosage between 62.5 and 125 mg BID)
40854515|NCT06060054|DIAGNOSTIC_TEST|Device measurements|Overnight device measurements
40854516|NCT04560075|BEHAVIORAL|Text2Connect|The T2C intervention aims to increase mental health self-efficacy though psychoeducation, self-monitoring of symptoms and stressors, and cues to action for college-bound youth.
40854517|NCT04560075|BEHAVIORAL|Psychoeducational Videos (PE) Only|Participants in this group will receive psychoeducation through the PE video library.
40854518|NCT00407017|DRUG|Gatifloxacin|
40854519|NCT00407017|DRUG|Ketorolac LS|
40854520|NCT00407017|DRUG|Pred Forte|
40854521|NCT00407017|DRUG|Moxifloxacin|
40854522|NCT00407017|DRUG|Nepafenac|
41037285|NCT06197893|PROCEDURE|Conventional graft and modified sling suture technique|Conventional graft dimensions were determined with aluminum foil and the foil was placed in the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The exterier edges of the foil were drawn with a scalpel and the 1-1.5 mm thick graft was dissected from the donor site. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique.
41385026|NCT06460298|DRUG|ProAgio Dose Levels (DL) 1,2,3,4|ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
40854523|NCT00407017|DRUG|EconoPred Plus|
40854524|NCT05795985|DIAGNOSTIC_TEST|calprotectin levels|dosage of calprotectin levels in patients with abdominal pain
40854525|NCT01429181|DRUG|Non-racemic mixture of methadone HCl|Non-racemic mixture of methadone HCl capsules, 5 mg
40854526|NCT00509626|BEHAVIORAL|exercise intervention|
40854527|NCT00509626|OTHER|questionnaire administration|
40854528|NCT00509626|PROCEDURE|CAM exercise therapy|
40854529|NCT00509626|PROCEDURE|management of therapy complications|
40854530|NCT00509626|PROCEDURE|psychosocial assessment and care|
41385027|NCT06460298|DRUG|ProAgio Dose Expansion|ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
40676614|NCT03403296|GENETIC|nProfiler I Stomach Cancer Assay Kit|qPCR by nProfiler I Stomach Cancer Assay Kit
40854531|NCT00509626|PROCEDURE|quality-of-life assessment|
40854532|NCT03179397|DEVICE|Model SC9|Experimental
40854533|NCT03179397|DEVICE|Model LI61SE|Active Comparator
40854534|NCT00524472|OTHER|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
41037286|NCT06197893|PROCEDURE|Conventional graft and conventional suture technique|Conventional graft obtained from the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique.
41037287|NCT04312594|DRUG|Jaktinib Hydrochloride Tablets|Patients were administered Jaktinib taken orally as tablets twice daily
41385028|NCT02996461|BIOLOGICAL|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
41385029|NCT04476459|DRUG|Camrelizumab|Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.
41417814|NCT00314171|DRUG|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
40854535|NCT00524472|OTHER|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
40854536|NCT00437411|BEHAVIORAL|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
40854537|NCT04429698|DIAGNOSTIC_TEST|Point of care ultrasonography|Point-of-care Ultrasonography is an imaging method performed with ultrasound aid to facilitate rapid diagnosis and interventions during emergency intervention.
40854538|NCT06244680|DEVICE|MRI of the prostate|Patients with suspicion for prostate cancer underwent mpMRI on a new 3-Tesla-MRI scanner with a maximum gradient strength of 200 mT/m, a slew rate of 200 T/m/s and DL reconstruction for image postprocessing.
40854539|NCT02340416|DEVICE|Transcranial Doppler Ultrasound, DWL Doppler BoxX|
40854540|NCT06154356|OTHER|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
41510028|NCT01117571|DEVICE|iUni® Unicompartmental Knee Resurfacing Device|The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
41510029|NCT02211443|BIOLOGICAL|Recombinant full human Anti-EGFR Monoclonal Antibody|
41510030|NCT00004492|DRUG|clotrimazole|
41510031|NCT00004492|DRUG|hydroxyurea|
41510032|NCT01652547|DRUG|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
41510033|NCT01652547|DRUG|Pasireotide lon acting release formulation|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
40854541|NCT06154356|OTHER|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
40854542|NCT01207752|DRUG|Systane Balance|Artificial tear emulsion drop
40854543|NCT01207752|DRUG|Optive Lubricant Eye Drops|Artificial tear eye drop
40676615|NCT03579186|DEVICE|OKS|Optokinetic stimulation
40854544|NCT02821013|DRUG|Intermittent PD-1 inhibitor therapy|
40854545|NCT02821013|DRUG|Continuous PD-1 inhibitor therapy|
40854546|NCT00709618|DRUG|Lapatinib, Vinorelbine|Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
40854547|NCT00089466|DRUG|AMD11070|AMD11070 taken daily. Dosage dependent on arm.
40854548|NCT01365858|OTHER|Rehabilitation|"The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy)."
41037288|NCT04312594|DRUG|Jaktinib Hydrochloride Tablets|Patients were administered Jaktinib taken orally as tablets twice daily
40676616|NCT03188068|DRUG|Sirolimus|Oral administration
40854549|NCT05954000|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
40854550|NCT04472455|DIAGNOSTIC_TEST|HRME|
40676617|NCT03188068|DRUG|Prednisolone|Oral administered with sirolimus
40854551|NCT04346836|BEHAVIORAL|Low-intensity, general-fitness exercises|"24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination."
41037289|NCT04312594|DRUG|Placebo|Patients were administered Placebo taken orally as tablets twice daily
41037290|NCT04440735|BIOLOGICAL|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
41510034|NCT03369197|DEVICE|Nasal Mask|Nasal anesthesia mask which covers the nose and attaches to the anesthesia circuit, allowing for variable positive pressure by setting the pop-off valve
41037291|NCT04440735|BIOLOGICAL|Atezolizumab|Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
41037292|NCT01220557|BEHAVIORAL|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
41037293|NCT01220557|BEHAVIORAL|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
41037294|NCT03568318|DRUG|Placebo|Tablets taken orally once a day
40854552|NCT04346836|BEHAVIORAL|Psychoeducation|A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.
40854553|NCT06210100|DEVICE|Active iTBS|Mag-TD stimulator
40854554|NCT06210100|DEVICE|Sham iTBS|Mag-TD stimulator
40854555|NCT03161080|DEVICE|Neovis Total Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
40854556|NCT03161080|DEVICE|Vismed Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
40854557|NCT03161080|DEVICE|Hydrabak® Eye Drops|Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
40854558|NCT06444802|DRUG|Linezolid|Linezolid dosing will be adapted according to a model informed precision dosing (TDMx)
40854559|NCT03920943|OTHER|Measurement of temperature using non-invasive means|The study intervention will involve paramedics using the TAT device to measure temperature non-invasively,the first measurements made at least 5 minutes after insertion of the temperature probe (control measurement #1), and also prior to departure from the sending facility (control measurement #2). Once the patient is in the transport vehicle and the vehicle in motion for at least 10 minutes, the paramedics will measure the patient's temperature non-invasively using the TAT. If the transport time exceeds 1 hour, additional measurements taken at 1 hour intervals for the duration of transport (up to a total of 8 hours).
40854560|NCT02563938|DRUG|AK001|Given parenterally.
40854561|NCT02563938|DRUG|Placebo|
40854562|NCT03034330|OTHER|Two-Tier Stroke Family Empowerment|The family-based care management intervention will be implemented in two tiers. The first tier is the Family Care Management that a care manager is responsible for empowering family caregivers to support their stroke survivors through reorganizing family roles, enhancing family functioning, and maximizing their family and community resources. The second tier is led by trained volunteers who are responsible for increasing the capacity of caregivers for the mastery of stroke care by providing psychoeducation, skill-training, and social support. Each caregiver participant will be assigned a care manager and a volunteer. All care managers who are social workers from the participating centres have undergone 4-day training to improve their knowledge of stroke and skills required for the intervention. Similarly, volunteers have undergone 6.5-day training to equip them with the knowledge and skills to conduct the intervention.
41037295|NCT03568318|DRUG|Upadacitinib|Tablets taken orally once a day
41037296|NCT03568318|DRUG|Topical corticosteroids (TCS)|"Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.~Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid."
41166155|NCT04255173|DIAGNOSTIC_TEST|Dual energy x ray absorptiometry (DXA)|Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
41385030|NCT04476459|DRUG|Apatinib|"Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase."
41385031|NCT04014413|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
41385032|NCT06568770|DRUG|USG GUIDED SUPRA-INGUINAL FASCIA ILIACA BLOCK|"With the patient in the proper position, the skin will be disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer will be moved laterally until the sartorius muscle is identified. As the needle will eventually pierce the fascia, maybe a pop will be felt. After negative aspiration, 1-2 mL of local anesthetic will be injected to confirm the proper injection plane between the fascia and the ilio-psoas muscle. A proper injection will result in the separation of the fascia iliaca by the local anesthetic in the medial-lateral direction from the point of injection as described. After the spread of the drug will be seen, the rest of the drug volume will be injected"
41417815|NCT00314171|DRUG|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
41510035|NCT03369197|DEVICE|Control: Nasal Cannula|Nasal cannula as per usual care
41510036|NCT05492643|BIOLOGICAL|one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)|all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
41037297|NCT00319215|DRUG|Ramelteon 8 mg|
41037298|NCT00319215|DRUG|Zopiclone 7.5 mg|
41037299|NCT04541238|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging
41166156|NCT04255173|DIAGNOSTIC_TEST|The Rapid Assessment of Physical Activity (RAPA) aerobic assessment|Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).
41166157|NCT05162196|RADIATION|SBRT|24Gy/3F
41417816|NCT03560609|DEVICE|Ophthalmodynamometer|The ODM (Baillart ophthlmodynamometer) is a disc attached to a piston that induces a controlled force on a fixed area. The device will be used to apply a pressure within the range of 10 mmHg - 50 mmHg 4 times to each eye. Each increase of pressure will last approximately 30 seconds. The device is FDA approved and will be used as routinely used in clinical practice
41037300|NCT01820728|DRUG|DA-3801 Injection|
41037301|NCT01820728|DRUG|Gonal-F®|
41037302|NCT04885829|DRUG|Tocilizumab Prefilled Syringe|0.9ml Subcutaneous pre-filled syringes containing 162mg of Tocilizumab.
41385033|NCT06568770|DRUG|PERICAPSULAR NERVE BLOCK|"an ultrasound probe will be placed over the line joining anterior superior iliac spine (ASIS) and pubic tubercle (PT) keeping lateral margin at ASIS and adjusted the probe to get a sonoanatomic view for PENG block. The needle entry point will be selected on the skin in such a manner that perpendicular needle entry will guide needle near target point iliopectineal eminence (IPE). The needle entry point will be anaesthetized with 2 ml 1% lidocaine and 22G 80mm stimuplex needle will be inserted out-of- plane to reach the bony rim near IPE avoiding injury to femoral nerve (visible just lateral to femoral artery). On bony contact, 20 ml 0.5% bupivacaine will be injected slowly with repeated aspiration to avoid intravascular injection. The correct needle position will be confirmed by drug spread under ilio-psoas muscle and then the rest of the drug volume will be injected."
41037303|NCT01300130|DIETARY_SUPPLEMENT|low docosahexaenoic acid formula|
41037304|NCT01300130|DIETARY_SUPPLEMENT|medium docosahexaenoic acid formula|
41037305|NCT01300130|DIETARY_SUPPLEMENT|high docosahexaenoic acid formula|
41166158|NCT05162196|DRUG|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
41037306|NCT01300130|DIETARY_SUPPLEMENT|breast milk|a non randomized group of breast milk fed infants was included
41166159|NCT05162196|DRUG|Niraparib|200mg qd
41166160|NCT03579433|DEVICE|ORA with VerifEye+|Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.
41166161|NCT03579433|OTHER|Alcon Barrett Toric Calculator|Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.
41166162|NCT03579433|DEVICE|Acrysof® IQ Toric IOL|Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
41166163|NCT04966936|OTHER|questionnaires for clinical assessments|Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)
41385034|NCT01972607|OTHER|Exercise Training|12 weeks of aerobic exercise training performed 3x/week at moderate intensity with sessions of 40 min.
41385035|NCT03715660|DIAGNOSTIC_TEST|Xpert bladder cancer monitor|Xpert Bladder Cancer Monitor, is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.The test utilizes a voided urine specimen and measures the levels of five targetmRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR). The Xpert Bladder Cancer Monitor is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer and should be used in conjunction with other clinical measures to assess disease recurrence.
41385036|NCT01277107|DRUG|Zaleplon AP formulation|Gastric retentive dual release Zaleplon
41385037|NCT01277107|DRUG|Placebo capsule|Identical placebo capsule
41385038|NCT04256135|OTHER|Mulligan mobilization|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
40854563|NCT03034330|OTHER|Volunteer Support Psychoeducation|The active control group will receive a standard, non-family-based psychoeducation intervention provided by the trained volunteers under the supervision of care managers. It will provide 4 in-home visits and 2 telephone follow-up interviews about psychoeducation for caregivers of stroke survivors.
40854564|NCT01821703|DRUG|LY3045697|Administered as oral solution
41037307|NCT05493553|DIETARY_SUPPLEMENT|Dietary supplement regimen|"The powdered, soluble fiber-based supplement contains soluble fibers, phytosterols, plant-derived polysaccharides, flavor, maltodextrin, orange juice powder, citric acid, vitamin and mineral blend, and sweetener. This is prepared in water and consumed twice per day, prior to a meal.~The yerba mate-based supplement (containing green yerba mate leaf extract, sweeteners, and flavor) is a powdered supplement prepared in water and consumed in the morning."
41037308|NCT05493553|OTHER|Dietary supplement and intermittent fasting regimen|The dietary supplement regimen is the same as in Phase 1. The intermittent fasting protocol consists of a 16-hour fasting period and an 8-hour eating window.
41037309|NCT06291168|OTHER|Chiropractic Manipulation (HVLA - High Velocity Low Amplitude)|"Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.~After determining that the movement disorder of the sacroiliac joints of the participant is caused by the impaired movement of the ilium in the posterior and inferior direction or the impaired movement of the ilium in the anterior and superior direction, the participant will be asked to take a side lying position.HVLA spinal manipulation was performed for less than one second from posterior to anterior, inferior to superior and medial to lateral directions."
41385039|NCT04256135|OTHER|AP Maitland mobilization|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
40854565|NCT01821703|DRUG|Placebo|Administered as oral solution
40854566|NCT01821703|DRUG|Spironolactone|Administered as capsule
41166164|NCT04966936|OTHER|2 minute walking test|the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).
41385040|NCT02704988|PROCEDURE|Carnoy Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution
40854567|NCT01821703|DRUG|Placebo|Administered as capsule
40854568|NCT05748457|BEHAVIORAL|Non-manualised family therapy.|Family therapy provided by qualified therapists without reference to a specific therapy manual.
41037310|NCT06291168|OTHER|Yoga-Based Exercise Program|"Yoga treatment includes exercise, respiration, balance and coordination, and stretching and will be performed by a physiotherapist with yoga certification. Patients will be evaluated before treatment, two weeks later, after treatment (at the end of the 8th week) and at the end of the 12th week after treatment (control).~Yoga exercises will be practiced with the classical yoga program, divided into groups of 3-4 people, for 8 weeks, 2 days a week, 60 minutes a day.~It will be applied as a yoga session program including breathing and warm-up exercises, suyanamaskar, various relaxation techniques and asanas."
41385041|NCT02704988|PROCEDURE|GEWF Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
41385042|NCT03753893|OTHER|No intervention used|no intervention used
41510037|NCT05492643|OTHER|Cellular Immunity|the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
40676618|NCT06620913|OTHER|Description of clinical, immunological and tumor features of patients harboring CV2 Abs|This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.
40854569|NCT05748457|BEHAVIORAL|Family Based Treatment|"Family therapy implemented according to the published Treatment manual for anorexia nervosa: A family-based approach by Lock \& Le Grange (2nd edition, 2015)."
40854570|NCT05175248|BEHAVIORAL|Plant-based Intervention Group|Participants in the intervention group will be instructed in ways to adopt a plant-based diet, use appropriate methods of food preparation, and make meals enjoyable and appetizing. The plant-based diet primarily emphasizes whole grains, vegetables, beans and legumes, and fruits. Animal products and added oils will be proscribed and the use of ultra-processed foods, sugar, and sugar-sweetened beverages will be discouraged. Fat intake will be limited to 20-30 g/day.
40854571|NCT04313270|DRUG|Evolocumab|12 weeks of treatment with Evolocumab
41037311|NCT06291168|OTHER|Conventional Exercises|Spinal stabilization exercises for the lumbar region will be given in 3 phases following the protocol given to the chiropractic manipulation group. The exercises will be performed two days a week with a physiotherapist. In order to facilitate the memorization and follow-up of the exercises, short videos will be made to facilitate compliance with the exercises by showing the exercises and methods of prevention of low back pain. Individuals will be called to the hospital two days a week for 8 weeks.
41037312|NCT06518577|BIOLOGICAL|Flucelvax (ccIIV4)|Participants will receive Flucelvax (ccIIV4)
41037313|NCT06518577|BIOLOGICAL|Flublok (RIV) or Fluzone (IIV)|Participants will receive Flublok (RIV) or Fluzone (IIV)
41037314|NCT04861987|DRUG|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
41037315|NCT04272268|DEVICE|Nasal High flow Oxygen|If the patient is successfully extubated within 4 hours following surgery and meets the post surgery inclusion/exclusion criteria, Nasal high flow oxygen will be administered continuously using a humidifier machine for 5 days. Breathing circuits and nasal cannulae will be connected to the machine to deliver oxygen at 20L/min to the patient.
41037316|NCT04728295|DEVICE|Exablate 4000|Exablate Pallidothalamic Tractotomy
41037317|NCT03215446|DRUG|maintenance of anaesthesia with propofol|
41037318|NCT03215446|DRUG|maintenance of anaesthesia with sevoflurane|
41037319|NCT03898206|OTHER|Breaking up sitting with walking breaks|See Breaking up sitting with walking breaks arm description
41037320|NCT03898206|OTHER|Prolonged sitting|See Prolonged sitting arm description
41037321|NCT01260844|DRUG|briakinumab|single dose briakinumab and 2 doses of CYP substrates
41037322|NCT01611701|PROCEDURE|cryoballoon ablation|In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
41385043|NCT00124579|DRUG|bortezomib|induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days
41385044|NCT00124579|DRUG|dexamethasone|induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression
41385045|NCT00124579|DRUG|thalidomide|100 mg/d PO days 1-21 every 21 days
41510038|NCT05492643|OTHER|Humoral Immunity|the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
41510039|NCT05492643|OTHER|Safety|all the 500 participants enrolled will undergo safety observation
40676619|NCT04450407|DRUG|LY3209590|Administered SC
40676620|NCT04450407|DRUG|Insulin Degludec|Administered SC
40854572|NCT00264537|DRUG|Placebo injections|SC injections
40854573|NCT00264537|DRUG|Placebo capsules|Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
40854574|NCT00264537|DRUG|Methotrexate capsules|Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
40854575|NCT00264537|BIOLOGICAL|Golimumab 50 mg injections|SC injections
40854576|NCT00264537|BIOLOGICAL|Golimumab 100 mg injections|SC injections
41510040|NCT01783795|OTHER|Genetic Analysis|
41528327|NCT05531812|OTHER|G2R with individual coaching|"1. Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~2. A one-time asset transfer of US$300 delivered \~7 months into the program;~3. Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~4. Individual coaching at home from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; Water, Sanitation and Hygiene (WASH) practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
40854577|NCT06131138|OTHER|Aquatic exercises|This include aquatic exercises thrice as week for 6 weeks.
41037323|NCT01611701|PROCEDURE|Radiofrequency ablation|n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s.
41037324|NCT05621460|OTHER|500mL carbonated water|Drink 500mL carbonated water immediately prior to head-up tilt test
41385046|NCT03192917|PROCEDURE|Low intensity extracorporeal shock wave treatment (LI-ESWT)|Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
41385047|NCT03192917|PROCEDURE|Low intensity extracorporeal shock wave treatment (LI-ESWT) sham|A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
41385048|NCT05659264|DRUG|mRNA-0184|mRNA-0184 dispersion for intravenous (IV) infusion
41385049|NCT05659264|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
41385050|NCT05059717|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
41385051|NCT05059717|PROCEDURE|Magnetic Resonance Imaging|Undergo MR DENSE imaging
41385052|NCT02173132|DRUG|Acetyl-L-carnitine|
41385053|NCT02173132|OTHER|Placebo|
41385054|NCT04918095|DEVICE|CareCOPD Platform|The subjects will be provided with CareCOPD devices for home monitoring of airway impedance, medication use, and symptoms data.
41385055|NCT02831478|DRUG|BAY987517|Applied liberally to the skin (Formulation: RB# Z16-071)
41528328|NCT05531812|OTHER|G2R with group coaching|"1. Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~2. A one-time asset transfer of US$300 delivered \~7 months into the program;~3. Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~4. Group coaching in a community setting from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; WASH practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
41385056|NCT02831478|DRUG|Sunscreen Lotion (RB# T78-190B)|Applied liberally to the skin
41385057|NCT00637598|RADIATION|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
41385058|NCT06247579|OTHER|Dietary polystyrene microplastics from disposable plastic tableware|Microplastic release from the daily use of disposable plastic materials (e.g., plastic boxes) when holding hot food or drink.
41385059|NCT05682560|BIOLOGICAL|RegeneCyte|HPC, Cord Blood
41385060|NCT05682560|OTHER|Placebo|Normal Saline
41385061|NCT00367601|DRUG|Erlotinib|Erlotinib 150 mg qd days 1-21
41037325|NCT05621460|OTHER|500mL still water|Drink 500mL still water immediately prior to head-up tilt test
41037326|NCT05621460|OTHER|50mL still water|Drink 50mL still water immediately prior to head-up tilt test
41037327|NCT01208454|DRUG|Isotretinoin|Given PO
41037328|NCT01208454|OTHER|Laboratory Biomarker Analysis|Correlative studies
41037329|NCT01208454|OTHER|Pharmacological Study|Correlative studies
41037330|NCT01208454|DRUG|Vorinostat|Given PO
41037331|NCT04050293|DRUG|SPN-538|Patients will receive SPN-538
41037332|NCT04050293|DRUG|Placebo|Patients will receive Placebo
41037333|NCT05771753|OTHER|Stretching Exercises|6 stretching exercises 2 repetitions x1 set, 3 days/week and targeted muscles stretching (Lower Back, Lower limb)
41037334|NCT05771753|OTHER|Dynamic core stabilizing exercises|This group received core stabilizing exercises 2 repetitions x1 set, 3 days/week and the targeted muscles were abdominals, lower back, and lower limb.
41037335|NCT04479618|DEVICE|Usual Practice|A saline soaked piece of gauze, conformed to the size of the open ulcer area, will be placed over the ulcer and held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
41385062|NCT00367601|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV, day 1
41385063|NCT06567704|BEHAVIORAL|Interviews|Interviews
41385064|NCT03253601|BEHAVIORAL|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
41385065|NCT02989259|DRUG|Apatinib|apatinib 500mg p.o. qd
41385066|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.
41385067|NCT04854707|DRUG|Follicle Stimulating Hormone/Luteinizing Hormone|Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.
41385068|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.
41510041|NCT01513278|DRUG|APN201|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
40854578|NCT06131138|OTHER|Core strengthening|This include core strengthening exercises thrice a week for 6 weeks
40854579|NCT04417231|DEVICE|CRP apheresis|"Selective CRP apheresis by use of the PentraSorb-CRP"
40854580|NCT03764683|DRUG|Suvorexant (Belsomra)|Suvorexant (Belsomra) is approved by the U.S. Food and Drug Administration (FDA) to treat insomnia. It has not yet been studied in people with bipolar disorder who have problems sleeping.
40854581|NCT03764683|DRUG|Placebo|Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
40854582|NCT05501470|DRUG|Probiotic|Probiotic
40854583|NCT05501470|DRUG|Placebo|Placebo
40854584|NCT05501470|DEVICE|CapScan®|"The only non-standard sample collection instrument is the CapScan® device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
40854585|NCT00766714|DEVICE|Cook K-SOFT-5100 catheter|A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
41166165|NCT04966936|OTHER|The gait analysis at the motion analysis laboratory.|Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared
41166166|NCT05466032|OTHER|Osteopathic Manual Manipulation (OMM) Curriculum|Osteopathic medical students are enrolled in the OMM curriculum while masters students are not enrolled.
41166167|NCT02073721|OTHER|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
41385069|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using agonists of GnRH only for suppression.
41385070|NCT04854707|DRUG|Follicle Stimulating Hormone/Luteinizing Hormone|Overall ovarian stimulation protocols with follitropin alpha biosimilar for at least 5 days+other recombinant and menotropins and short (antagonists of GnRH) or long protocol (agonist of GnRH).
41385071|NCT06143683|PROCEDURE|Early Mobilization|On post-operative day (POD) 1, active range of motion exercises of the elbow joint will be initiated under the observation and guidance of the physical therapy team. On POD 3, the patient will be transitioned to active as well as active-assisted range of motion exercises. The physical therapy team will provide an exercise sheet handout to patients (Appendix 5) and encourage patients to do the exercise for 10 repetitions, 2 times a day, holding each stretch for 30 seconds. On POD3, patients with non-meshed sheet hand grafts will undergo active range of motion exercises of the hands under the observation and guidance of the physical therapy team. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions.
41385072|NCT06143683|PROCEDURE|Late Mobilization|Following surgery, the patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint. From POD 1 to 4, the patient's affected extremity will be kept elevated and immobilized with a flexion blocking splint. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions. The physical therapy team will guide the patient on POD5 through range of motion exercises, starting with active, then active assisted, then passive as tolerated.
41385073|NCT02703779|DRUG|Bortezomib|Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
41385074|NCT02703779|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
41528329|NCT03252977|OTHER|Tailored regimen of IV PCA according to pain sensitivity|In tailored group, fentanyl dosage in IV PCA will be determined according to preoperative pain sensitivity. In control, group, fentanyl dosage in IV PCA will be determined without consideration of patient's pain sensitivity.
41385075|NCT02703779|DRUG|Mozobil|Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
40854586|NCT00766714|DEVICE|Frydman classical catheter|A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
40854587|NCT06257173|BEHAVIORAL|Education|The experimental group will receive 2 hours of patient safety training with a peer educator.
40854588|NCT05688969|OTHER|early versus late biopsy|early (3-6 weeks) versus late (6-8 months) biopsy
40854589|NCT04228601|DRUG|Fluzoparib|PARP
40854590|NCT04228601|DRUG|Fluzoparib placebo|Placebo
40854591|NCT04228601|DRUG|mFOLFIRINOX|mFOLFIRINOX
40854592|NCT00420069|DEVICE|MRTX device|device for ventilation
41385076|NCT00863239|DRUG|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.
41385077|NCT00863239|DRUG|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
41385078|NCT00863239|DRUG|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
41385079|NCT03963960|DEVICE|Hemodialysis with low dialysate flow|Hemodialysis with low dialysate flow
41385080|NCT03963960|DEVICE|Conventional triweekly high-flow hemodialysis|Conventional triweekly high-flow hemodialysis
41385081|NCT00006014|DRUG|semaxanib|
41385082|NCT03739684|DRUG|18F-DCFPyL|A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
41385083|NCT03739684|DIAGNOSTIC_TEST|PET/CT Imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
41385084|NCT00096473|DRUG|Donepezil hydrochloride|
41385085|NCT00897507|OTHER|Laboratory Biomarker Analysis|Correlative studies
41385086|NCT02208934|DRUG|PBF-999|5, 10, 20 and 40 mg of PBF-999
41385087|NCT02208934|DRUG|Placebo|Placebo for all dosis of PBF-999
41528330|NCT03252977|OTHER|Regimen of IV PCA without considering pain sensitivity|In control group, regimen of IV PCA will be determined without consideration about patient's pain sensitivity.
40854593|NCT02953574|PROCEDURE|daily sleep enhancement nursing protocol|
40854594|NCT05994027|BEHAVIORAL|ATTACH™ Online Platform Parenting Program|ATTACH Online Platform: Preserving and promoting optimal RF in parents who are experiencing adversities, enables parents to appropriately attribute affective states to their children and respond accurately to meet their children's needs, thus promoting sensitive/ responsive parent-child relationships.
40854595|NCT05276921|OTHER|ultrasound|Quadriceps and abdominal muscle ultrasonography
40854596|NCT03421106|BEHAVIORAL|Intervention Food Pantries|Food pantries will receive consulting services to transform their food offerings and environment in order to influence client health behaviors.
40854597|NCT03421106|OTHER|Control Food Pantries|Normal food pantry use
41037336|NCT04479618|DEVICE|Improvised dressing|A piece of a new food-grade plastic bag, cut slightly larger than the ulcer, will be placed over the ulcer, sealed at the edges with an emollient to create an occlusive dressing. The dressing will be gently conformed to the ulcer contours to eliminate dead space, and a slit will be cut in the center to allow excess fluid to escape into a clean absorbent material placed over the slit. The device will be held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
41385088|NCT03020966|DRUG|Acetaminophen|Oral acetaminophen, intravenous placebo
41385089|NCT03020966|DRUG|Acetaminophen|Intravenous acetaminophen, oral placebo
41385090|NCT04221217|DRUG|Icosapent|Icosapent (MND-2119) capsules.
41385091|NCT02890966|DRUG|SHR4640|Day1\~Day7:oral administration
41385092|NCT02890966|DRUG|placebo|Day1\~Day7:oral administration
41385093|NCT03438552|RADIATION|Stereotactic Body Radiotherapy|This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.
41385094|NCT03914469|BEHAVIORAL|Behavioral Intervention Group|The active intervention will include eight tele-delivered health coach sessions, three tele-based outcome assessments, and up to two semi-structured interviews at 6 months post-intervention. Each tele-based outcome assessment is roughly 45-60 minutes and will be conducted by a member of the research team. Each intervention session will be delivered by a trained health coach over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
41385095|NCT00213629|OTHER|transcriptome analysis|transcriptome analysis from muscle biopsy
41385096|NCT00213629|OTHER|T cell repertoire analysis|blood T cell repertoire analysis
41385097|NCT01188759|DRUG|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
41385098|NCT01188759|DRUG|Anidulafungin|"Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).~Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole."
41385099|NCT01188759|DRUG|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
41385100|NCT05227690|DRUG|CVL-231 10 mg|CVL-231 10 mg, oral (tablet), once per day for 6 weeks
41385101|NCT05227690|DRUG|Required CVL-231 30 mg|CVL-231 30 mg, oral (tablet), once per day for 6 weeks
41385102|NCT05227690|DRUG|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
41385103|NCT03449420|DIAGNOSTIC_TEST|thromboelastography|TEG5000® : Kaolin and Functional Fibrinogen tests on native blood sample
41385104|NCT03328286|BEHAVIORAL|Weekly group meeting w/psychotherapist|Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
41385105|NCT01016158|DRUG|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
41385106|NCT06292728|DEVICE|ENDOPLY System|One endoscopic procedure where the ENDOPLY System is used for endoscopic gastric plication.
41528331|NCT01001273|OTHER|Hyperinsulinemic Normoglycemic Clamp|The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
41037337|NCT04479618|DEVICE|Advanced dressing|A piece of polymeric membrane dressing, cut to extend at least 0.5cm beyond the open ulcer edges, will be placed over the ulcer and held in place with a wrap of stretch gauze. The approximate wound edges will be marked on the back of the dressing. Dressing changes will consist only of removing the dressing when the saturation level, visible through the wound backing, reaches the mark indicating the dressing edges and applying a new cut dressing. Changes will be conducted by the patient after they master the procedure.
41037338|NCT01401751|DEVICE|Hypoglycemia-Hyperglycemia Minimizer System|Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
41385107|NCT03998774|BEHAVIORAL|Evaluate the anxiolytic effect during dental care with MEOPA in children|"Primary Purpose: The main objective of this study is to evaluate the anxiolytic effect of EMONO in children during dental care.~Enrollment: 30"
41385108|NCT06566859|OTHER|NRS 0. hour|Numerical rating scala
41385109|NCT06566859|OTHER|NRS 6. Hour|Numerical rating scala
41385110|NCT06566859|OTHER|NRS 12. Hour|Numerical rating scala
41385111|NCT06566859|OTHER|NRS 24. Hour|Numerical rating scala
41385112|NCT06159686|DRUG|Hemp|The application of the hemp-containing cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
41385113|NCT06159686|DRUG|Placebo|The application of the placebo cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
41385114|NCT06113783|DEVICE|HYALUBRIX 60|1.5% solution of non-modified HA (60mg/4ml) obtained from bacterial fermentation with high molecular weight.
41385115|NCT04826952|PROCEDURE|Orchiectomy|Childhood testicular tumors deserve special diagnostic attention from the therapeutic point of view. A testicular tumor should be considered malignant until proven otherwise. In cases with suspicion of testicular tumors, the inguinal approach is preferred to the scrotal approach for scrotal violation.
41385116|NCT02557568|OTHER|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
41385117|NCT01550354|DRUG|administration of propofol|intravenous administration of propofol 2 mg/kg before intubation
41385118|NCT01550354|DRUG|administration of alfentanil|intravenous administration of alfentanil 14 μg/kg before intubation
41385119|NCT01550354|DRUG|administration of rocuronium|Intravenous administration of rocuronium 0.3 mg/kg before intubation
41385120|NCT01802762|DEVICE|NeMo Patch and NeMo Probe|A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
41385121|NCT02023723|DIETARY_SUPPLEMENT|Energy Drink|16oz energy drinks - 2 consumed within 60 minutes
41385122|NCT02023723|DIETARY_SUPPLEMENT|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
41385123|NCT01644461|OTHER|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
41037339|NCT03413436|DRUG|Lobaplatin|at least one cycle adjuvant chemotherapy after esophagectomy
41385124|NCT02776215|DRUG|tasimelteon|Melatonin receptor agonist
41037340|NCT03413436|DRUG|Cisplatin|at least one cycle adjuvant chemotherapy after esophagectomy
41037341|NCT00578994|DEVICE|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
41166168|NCT02073721|OTHER|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
41385125|NCT02310815|DEVICE|ReSure Sealant|
41385126|NCT01506817|PROCEDURE|Dynamic contrast-enhanced MRI of the hands|The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
41385127|NCT03296059|OTHER|conventional treatment with RBC transfusion|Besides conventional treatment, neonates is given RBC transfusion.
41385128|NCT03296059|OTHER|conventional treatment|neonates is treated with conventional treatment.
41385129|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
41385130|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
41385131|NCT05257018|DRUG|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~* Rituximab 375 mg / m\^2，D1~* Cyclophosphamide 750 mg / m\^2，D2~* Doxorubicin Hydrochloride Liposome Injection 35mg / m\^2，D2~* Vincristine 1.4mg/m\^2 (dose capped at 2 mg)，D2~* Prednisone 50 mg， bid D2-6~* Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24 h after chemotherapy）"
41385132|NCT05148455|OTHER|standard-of-care clinical skin examination|inspection of melanocytic nevi by dermatologist
41528332|NCT01706341|DRUG|administer acetate Ringer's solution|During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.
41528333|NCT01706341|DRUG|acetate Ringer's solution containing no glucose|
41528334|NCT01706341|DRUG|acetate Ringer's solution containing 1% glucose|
41417817|NCT03560609|DEVICE|Goldmann applanation tonometer|The Goldmann applanation tonometer (Haag-Streit, Basel, Switzerland) measures the IOP after the eye is numbed with a drop of anesthetic (proparacaine), which is approved by the FDA. Proparacaine is part of routine patient care using a tonometer regardless of participation in this study. The instrument's tip lightly touches the surface of the cornea and the IOP is measured. The device is FDA approved is routinely used in clinical practice.
41037342|NCT05234827|OTHER|Virtual Reality|Total time duration for session is 40 minutes which includes 5 min of warm exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 minutes of VR session and 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
41037343|NCT05234827|OTHER|Control|Control group receive endurance exercise testing in which stationary cycle is used for 30 min per session. It includes lower extremity strengthening i.e., increases hamstring and quadricep strength. Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
40854598|NCT03162419|DRUG|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
40854599|NCT03162419|BIOLOGICAL|Plasma Exchange|High volume plasma exchange sessions till a maximum of ten sessions.
40854600|NCT03162419|BIOLOGICAL|GCSF|The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
40854601|NCT02472704|DIETARY_SUPPLEMENT|Gluten challenge|gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
40854602|NCT02472704|DIETARY_SUPPLEMENT|Placebo challenge|placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
40854603|NCT00932412|DRUG|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
40854604|NCT00932412|DRUG|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
40854605|NCT04698993|DIAGNOSTIC_TEST|Dräger Antigen Test SARS-CoV-2|Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test
40854606|NCT01339897|DRUG|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
41037344|NCT01898819|DRUG|Dexmedetomidine|
41037345|NCT01898819|DRUG|saline|
41037346|NCT04601155|DEVICE|AlloSure|AlloSure is an analytically validated targeted next-generation sequencing (NGS) assay that uses single-nucleotide polymorphisms (SNPs) to measure the fraction of dd-cfDNA in transplant patients without the need for genotyping either the donor or the recipient.8
41037347|NCT05191576|OTHER|Children's sleep habits questionnaire (CSHQ)|"1. Children's Sleep Habits Questionnaire is a validated tool to screen sleep behavior in young children's assessment of pediatric sleep problems.~2. DSM-V Level II Sleep Disturbance- Child Report. is retrospective, 8-item self-report used to assess the pure domain of sleep disturbances in children and adolescents age of 11-17 years in the past seven days.Higher scores indicate more severe sleep disorders. High scores on a particular domain might indicate significant and problematic areas for the child that may warrant further assessment.~3. DSM -V Sleep Disturbance -Adult Report. is used to assess the pure domain of sleep disturbances in adults for the past seven days.~   SDQ).is used to screen emotional and behavioral problems in children.~4. SDQ is used to screen emotional and behavioral problems in children."
41037348|NCT05607693|DRUG|SHR3680 tablets|Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.
41037349|NCT00455195|BIOLOGICAL|alglucosidase alfa|IV infusion of 20 mg/kg; every other week (qow)
40854607|NCT01339897|DRUG|Placebo|Same administration procedures as active
41037350|NCT03068338|DEVICE|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
41037351|NCT03068338|DEVICE|Intermittent pneumatic compression|Conventional device used by hospitals
41037352|NCT03881735|DRUG|Enasidenib|Given PO
41166169|NCT05698862|DIETARY_SUPPLEMENT|Probiotic|Participants will be required to take a probiotic supplement of Lactobacillus brevis daily (1 capsule 5B CFU/day)
41166170|NCT05698862|DIETARY_SUPPLEMENT|Placebo|Participants will be required to take the placebo maltodextrin daily (1 capsule/day)
41166171|NCT04766047|DRUG|Dexmedetomidine|Administration of dexmedetomidine intraoperatively
41166172|NCT03245463|OTHER|Educational handout|The educational handout will include information on self-management strategies.
41166173|NCT03245463|OTHER|Verbal script|The verbal script will include details on self-management strategies that will be reviewed with the patient.
40854608|NCT01339897|DRUG|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
40854609|NCT01339897|DRUG|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
40854610|NCT01304004|OTHER|Satiety|"Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~1. Experimental drinkable yogurt enriched in proteins and fibres~2. Placebo drinkable yogurt (isocaloric and isovolumetric)"
40854611|NCT01098305|DRUG|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
40854612|NCT01098305|BEHAVIORAL|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
41385133|NCT05148455|DIAGNOSTIC_TEST|skin assessment with the 2D FotoFinder ATBM master system|The FotoFinder® ATBM master device provides the combination of total body mapping with deep learning-driven body scan algorithm which identifies all pigmented skin lesions of the body surface by pattern recognition software and supplies a risk assessment score (0.0-1.0; 0 indicating no suspicion for melanoma, 1 indicating a high suspicion for melanoma).The integrated software analyzer scores regarding malignancy probability of the moles (FotoFinder® score: 0.0-1.0) will be collected.
41385134|NCT05148455|OTHER|data collection by participant questionnaire|At baseline, the participants will complete a questionnaire concerning their previous exposure to sun, their current sun-related protective behaviours, their history of skin check frequency and skin cancer at baseline. Additionally, in each consultation newly-created study-specific questions concerning the participants' examination experience, the sun-related protective behaviours and worries about skin cancer throughout the study will be investigated.
41385135|NCT03107416|PROCEDURE|Hepatic artery embolization (HAE)|The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.
40854613|NCT03424356|DRUG|Rocuronium Bromide|0.15 mg/kg rocuronium bromide
40854614|NCT03424356|DRUG|Saline Solution|1-2 ml saline solution
41385136|NCT03107416|DRUG|Bumetanide|Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
41385137|NCT06098131|OTHER|Neurodynamic|Neurodynamic Slider and Tensioner Technique
40854615|NCT03424356|DRUG|Fentanyl|1mcg/kg for induction
40854616|NCT03424356|DRUG|Propofol|2-3mg/kg for anaesthetic induction
40854617|NCT03424356|PROCEDURE|cystoscopy|patients will treated with this surgical procedure
40854618|NCT04382222|PROCEDURE|prenatal ultrasound|prenatal cardiac ultrasound
40854619|NCT05389033|DIETARY_SUPPLEMENT|Probiotic bacteria|28 days daily supplementation with active probiotic
41037353|NCT03881735|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
41037354|NCT03846700|DEVICE|aquablation|"minimally invasive, robot-assisted and ultrasound-guided ablation of the prostate in targeted way and in heat-free way working by high pression water jet"
41166174|NCT03245463|DRUG|Hyaluronic Acid|All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.
41166175|NCT05417464|OTHER|Use of flowchart|Use of flowchart for screening, monitoring and management of conductive disorders after TAVR
41385138|NCT05572658|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
41385139|NCT05572658|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
40854620|NCT05389033|OTHER|Placebo Capsule|28 days daily supplementation with placebo
40854621|NCT01183949|DRUG|AT7519M|"Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m\^2/dose and will be increased to 27mg/m\^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose."
40854622|NCT01183949|DRUG|Bortezomib|Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design. The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
40854623|NCT03019718|OTHER|GSA-Online plus|A 12-week online writing intervention based on the Core Conflictual Relationship Theme Method (CCRT) with feedback provided by online therapists.
40854624|NCT02427776|BIOLOGICAL|Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope|1 administration comprising 5 - 50 millions of cells
40854625|NCT06446791|PROCEDURE|Mehri Turki Surgical Technique of the Webbed Neck|The incision was made at the junction of the hairless skin and the hairy skin from the mastoid up to the acromion. A subcutaneous undermining allows direct visual control to excise the fibrotic band. Then the hairy skin with a triangular shape was excised. The closure of the defect was done after undermining an anterior cervical flap which was translated in a posterosuperior direction. Z plasty was performed in front of the acromion to prevent scar contracture. Surgical scars are concealed in the hairline which was well placed. The same procedure is done at the same surgical field on the other side to achieve perfect symmetry.
40854626|NCT01139177|DEVICE|Stenting of atherosclerotic lesion(s)|Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
41037355|NCT03846700|DEVICE|holep|holmium laser enucleation of prostate
41037356|NCT03846700|DEVICE|pvp|photoselectivevaporization of prostate
41037357|NCT02393495|DEVICE|intrauterine device TCu 380A|
41037358|NCT06163755|DRUG|Methylprednisolone 40 MG Injection|Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
41166176|NCT00223210|DRUG|Quetiapine|Active Quetiapine
41166177|NCT00223210|DRUG|PLacebo|Placebo
41166178|NCT02625129|OTHER|Pharmacist-provided travel care|Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections
41385140|NCT06567548|OTHER|control group|An absorbable gelatin sponge is a sterile hemostatic agent primarily composed of purified porcine-derived gelatin. It is widely utilized in surgical procedures to control bleeding
41385141|NCT06567548|OTHER|Platelet-rich fibrin (PRF)|Platelet-rich fibrin (PRF) is a biomaterial derived from the patient's own blood, utilized primarily in regenerative medicine and surgery due to its rich content of growth factors and its ability to promote healing.
41166179|NCT03200236|BEHAVIORAL|Intensive Telephone Counseling (8 sessions) with nicotine replacement|Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
41385142|NCT06567548|OTHER|Albumin Platelet Rich- Fibrin|is an innovative biomaterial that combines the regenerative properties of platelet-rich fibrin (PRF) with the structural and functional benefits of albumin. This mixture is designed to enhance tissue healing and regeneration by utilizing autologous blood components.
41385143|NCT06468930|DEVICE|Low-level light therapy (LLLT)|LLLT therapy will be delivered using the Light Modulation® special facial mask (Espansione Marketing S.p.A., Bologna, Italy) which will be placed on the participant's face for 15 minutes. The mask has the shape of a half-face and will emit a red light in an LED system. The device has an emission power of 100 The mask has the shape of a half-face and will emit a red light in a light-emitting diode (LED) system. The device has an emission power of 100 milliwatts per square centimeter.
41385144|NCT06468930|DEVICE|Intense pulsed light (IPL)|The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim
41385145|NCT03190707|BEHAVIORAL|Intervention|"1. Detection of ill-being: An extended consultation with the midwife. The midwife will screen the women for symptoms of anxiety, depression and personality disorders.~2. Knowledge sharing: An additional midwife consultation accompanied by the health visitor. The aim of is sharing knowledge and transmission of information between the two sectors responsible for making a shared plan for the course of the process for the pregnant woman.~3. Strengthen parenting skills through:~   * Two visits by the health visitor before birth and eight after. The visits are based on the parent training program The Circle of Security, aiming at promoting a secure attachment between child and carer.~  * Teaching the woman/couple on the importance of breast-feeding and how to succeed."
41417818|NCT03560609|DEVICE|Pentacam|This device maps the cornea and provides pachymetry, topography and corneal aberration maps. The device is FDA approved and routinely used in clinical practice.
41037359|NCT04566250|COMBINATION_PRODUCT|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:~1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~2. A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
41166180|NCT03200236|BEHAVIORAL|Usual Care: Telephone counseling (3 sessions) with nicotine replacement|Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
41166181|NCT04915079|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|"PRISM is a novel resilience resource intervention consisting of five, one-on-one sessions lasting 30-50 minutes targeting specific teachable resilience skills: stress management, problem solving, goal setting, benefit finding, and meaning making. Sessions will occur at a time convenient to the patient with the first session to occur within 1 week of enrollment either while inpatient or if the patient is discharged, in the outpatient setting in-person or by HIPPA-compliant Zoom. After completion, participants will receive weekly booster contacts (invitations to practice reviewing certain skills) until the occurrence of a planned patient-clinician conversation, facilitated and arranged by study staff during the 5th session. All participants will receive paper worksheets to practice skills between sessions, plus access to a free, digital PRISM app (available only for patients enrolled in PRISM)."
41166182|NCT05993520|OTHER|Assessment|Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul Faculty of Medicine, and met the inclusion criteria, were included in the project. Participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated.
41166183|NCT01101997|DEVICE|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
41166184|NCT04488978|DRUG|Irbesartan/Amlodipine|QID
41528335|NCT01686464|DRUG|prednisone and valacyclovir treatments|patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
41528336|NCT01686464|DEVICE|Magnetic and Oxygen Treatment|MOMC treatment was given as daily 20 min section for 10 days with 2\~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2\~3.0 L / min for the same duration during all acupuncture sections.
40676625|NCT04342767|DEVICE|EZ Debride®|EZ Debride ® is intended for the mechanical debridement of topical wounds including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post Mohs' surgery, post-laser surgery, podiatric, wound dehiscence) trauma wounds (abrasions, lacerations, second-degree burns and skin tears), draining wounds and tunnelled /undermined wounds.
40676626|NCT00533689|PROCEDURE|Electroretinography (ERG), Visual Evoked Potentials (VEP)|
41037360|NCT01572727|DRUG|Paclitaxel|intravenous paclitaxel 80 mg/m2 per week given until progression
41037361|NCT01572727|DRUG|BKM120 matching placebo|"Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area."
41037362|NCT01572727|DRUG|BKM120|Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
41166185|NCT05377645|OTHER|Cyriax mobilization + traditional physiotherapy|TENS, US, exercise
41166186|NCT03159078|DRUG|Polymyxin B|Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
41385146|NCT04280939|PROCEDURE|spinal anesthesia|prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
41385147|NCT06542887|DRUG|Atomoxetine|Participants will continue receiving their treatment with atomoxetine at a dose of 0.5-1.4 mg/kg/day
41385148|NCT06542887|DRUG|Black Seed Oil Cap/Tab|Participants will receive black seed oil in the form of soft gelatin capsule 450 mg at a dose of 40-80 mg/kg/day given in one to two divided doses after meals for 12 weeks.
41385149|NCT06047249|BEHAVIORAL|KAP Popular Science Research|By conducting a survey questionnaire, investigate the knowledge, attitude, and practice tendencies of patients and their caregivers towards a certain disease, and conduct relevant science popularization；Pre discharge satisfaction survey questionnaire
41385150|NCT06047249|BEHAVIORAL|No KAP Popular Science Research|Pre discharge satisfaction survey questionnaire
41385151|NCT00685048|BEHAVIORAL|10 minutes of psycho-education|Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
41385152|NCT00685048|BEHAVIORAL|10 minutes of brief advice|Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
41385153|NCT00685048|BEHAVIORAL|four 50-minute individual therapy sessions of MET & CBT|MET \& CBT
41385154|NCT03365869|DRUG|Sirolimus|Sirolimus or placebo were added to patients every day
41385155|NCT01131208|GENETIC|gene expression analysis|
41510042|NCT01513278|DRUG|Placebo|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
40854627|NCT03043391|BIOLOGICAL|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
40854628|NCT02207491|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
40854629|NCT02207491|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
40676627|NCT02558621|DEVICE|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
40854630|NCT02207491|OTHER|Placebo|1 drop QD, AM, OU
41385156|NCT01131208|OTHER|laboratory biomarker analysis|
41385157|NCT06568835|BEHAVIORAL|exercise|such as walking, jogging, swimming, Tai Chi, etc. It needs to be at a certain frequency and intensity
41385158|NCT04457154|DEVICE|Inspire Upper Airway Stimulation System|Implant of the Inspire Upper Airway Stimulation System
41385159|NCT05801107|DRUG|WX-0593|WX-0593 Tablets 60 mg QD，once daily for 7 days, followed by 180 mg of WX-0593 tablets,once daily in a 21-days cycle.
41385160|NCT00213486|DRUG|irinotecan|
41385161|NCT05891496|DRUG|Semaglutide|Semagllutide will be administered once weekly subcutaneously.
41385162|NCT05891496|DRUG|Placebo|Placebo matched to semaglutide will be administered once weekly subcutaneously.
41385163|NCT05138614|OTHER|Medication for Opioid Use Disorder|medication management
41385164|NCT05138614|BEHAVIORAL|MISSION Critical Time Intervention|offering intensive community-based services that decrease in intensity over time
41385165|NCT05138614|BEHAVIORAL|MISSION Peer Support|including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders
41385166|NCT05138614|BEHAVIORAL|MISSION Dual Recovery Therapy|comprised of 13 structured co-occurring disorders treatment sessions
41385167|NCT02426125|DRUG|Ramucirumab|Administered IV
41385168|NCT02426125|DRUG|Docetaxel|Administered IV
41385169|NCT02426125|DRUG|Placebo|Administered IV
41510043|NCT00803439|DRUG|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
41510044|NCT00803439|DRUG|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
41528337|NCT00554515|DRUG|HD IL2|
41385170|NCT02395536|OTHER|office setting|An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers
41385171|NCT02395536|OTHER|hosptial setting|A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
41385172|NCT06519136|OTHER|Distance Reiki|"According to Usui, the second level Reiki application will be applied for 20 minutes a day between 19.00 and 21.00 in the evening for four consecutive days by the researcher who has completed his second level training, in accordance with the Second Level Reiki Application Protocol."
40854631|NCT04415411|OTHER|Nursing care based on the Theory of Human Caring|Planned nursing care based on 10 caritas processes of Theory of Human Caring.
40676628|NCT02499146|DRUG|Palbociclib|125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle
40854632|NCT06298786|DIAGNOSTIC_TEST|Functional 6-minute mastication test|All participants will be evaluated in 3 different phases. First, they will respond to the online TMD screener questionnaire. Then, they will be presentally evaluated using the DC/TMD and finally they will undergo the functional 6-minute mastication test.
40854633|NCT06533904|DEVICE|Percutaneous Cryoablation of Intercostal Nerves|Percutaneous Cryoablation of Intercostal Nerves
40854634|NCT06533904|OTHER|Multi-modal pain regimen|Standard rib fracture protocol including cyclooxygenase inhibitors, anti-neuropathic, muscle relaxers, short term anesthesia interventions (percutaneous block, epidural)
40854635|NCT05138627|OTHER|oral cryotherapy|Ice application protocol developed by the researcher by scanning the literature was prepared by taking the opinions of 5 faculty members who are experts in their fields. Also, the chamber of physics engineers and the chamber of chemical engineers' opinion was taken for the necessary corrections or improvements regarding the chemical/physical structure of the ice and the method applied. In the content of the protocol, materials, preparation before intraoral ice application (written and visual), steps of intraoral ice application (written and visual), termination of intraoral ice application, recording of intraoral ice application, and situations to be considered are explained in detail respectively.
40854636|NCT04453189|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.
40854637|NCT04453189|DRUG|Lansoprazole|Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.
40854638|NCT04453189|DRUG|Famotidine|Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.
40854639|NCT04165499|COMBINATION_PRODUCT|Combination of Plant Extracts (BSL_EP026)|Each participant will consume 2 capsules daily, in the morning and in the evening.
40854640|NCT04165499|COMBINATION_PRODUCT|Control|Each participant will consume 2 capsules daily, in the morning and in the evening.
40854641|NCT00328458|DRUG|EPO906 (epothilone B)|
40854642|NCT04787055|DEVICE|Receiver-in-canal hearing instrument|Receiver-in-canal hearing instrument
40854643|NCT06507696|OTHER|Ice Application|Drinking water was placed in a syringe and filled in the refrigerator
41037363|NCT04589923|DEVICE|Lifelight® Data Collect Blood Pressure Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
40854644|NCT06507696|OTHER|Wetted Gauze Application|Sterile gauze soaked with drinking water
41166187|NCT03418181|PROCEDURE|Standard Haemodialysis|Thrice weekly dialysis.
41166188|NCT03418181|PROCEDURE|Incremental dialysis|Individualised dialysis dose according to native kidney function.
41385173|NCT06519136|OTHER|Sham Reiki|It will be stated that remote energy application will be applied to the Sham Reiki group and no application will be made.
41385174|NCT05063149|DRUG|Broncho-Vaxom|Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
41385175|NCT05063149|OTHER|Placebo|Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
41385176|NCT03514173|DEVICE|Remote Patient Monitoring|Use of remote patient monitoring
41385177|NCT05945849|BIOLOGICAL|CD33KO-HSPC; CART33|"CD33KO-HSPC: Stem cell transplant (also known as bone marrow transplant) is a common treatment used for patients with blood cancers, but for this transplant we will first modify the cells, in order to make the CAR T-cell treatment safer for when the patient receives them later. The modification is a type of gene editing - this means changing the DNA of the cells, so that a protein that the bone marrow stem cells usually show on their surface is not shown any more. This makes the bone marrow cells invisible to the CAR T-cells, and makes this therapy safer for the patient. The protein is called CD33.~CART33: Chimeric Antigen Receptor T-cells (CART) are immune cells which are modified by adding a CAR molecule, which makes them much more efficient at finding and killing cancer cells. In this case, the CAR T-cells are programmed to target a protein called CD33, which is found on the surface of leukemia cells, and on healthy bone marrow cells."
41417819|NCT03560609|DEVICE|ORA|ORA is an air puff tonometer that applies controlled force to flattens the cornea and provides the corneal hysteresis and corneal resistance factor. The device is FDA approved and routinely used in clinical practice.
40676629|NCT02499146|DRUG|Letrozole|2.5 mg , orally once daily (continuously)
40676630|NCT02289781|DEVICE|posterior crowns|teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
40676631|NCT00209963|DRUG|Gaboxadol|
40854645|NCT04179253|DIAGNOSTIC_TEST|office micro hysteroscopy|One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
40854646|NCT03589027|DRUG|Levonorgestrel two rod sub-dermal implant|Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally
40854647|NCT03589027|DRUG|Rilpivirine|Oral ripilvirine 25mg once daily
40854648|NCT03589027|DRUG|Darunavir+Ritonavir|Oral DRV/r 600/100mg twice daily
40854649|NCT00119470|PROCEDURE|EUS-FNA|
40854650|NCT00119470|PROCEDURE|Conventional Surgical Technique|
40854651|NCT05015569|DEVICE|COVR Medical Garment|"COVR undergarments are available in a Half Short design for unilateral lower extremity procedures and a Bilateral (brief) style garment designed for bilateral lower extremity procedures. Either style may be worn for upper extremity, trunk, spine procedures, etc. where an undergarment would be preferred along with a standard hospital gown. The garments are available in a variety of sizes. The COVR garments can be released at the hip(s)/waistline for improved access to the lateral hip and include retractable panels for procedural access to the groin and genitals if needed by the care team."
40854652|NCT05015569|OTHER|Standard Patient Gown|The standard patient gown is provided to all patients in a hospital setting.
40854653|NCT02088021|DEVICE|Portico Transcatheter Aortic Valve|Placement of the SJM Portico aortic valve with a ALC delivery system
40854654|NCT03090204|PROCEDURE|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle at 4 time points during a session of intermittent hemodialysis : before the intermittent hemodialysis connection, just after starting hemodialysis, after 1 hour of hemodialysis and 5 minutes before restitution
40854655|NCT04599465|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
40854656|NCT04599465|DRUG|IVA|Tablets for oral administration.
40854657|NCT06462313|DRUG|Dobutamine|Patients with septic shock in Dobutamine group will be initiated on Dobutamine at 5 mcg/kg/min when electrocardiogram, invasive blood pressure, and oxygen saturation were monitored.
41037364|NCT04589923|DEVICE|Lifelight® Data Collect Oxygen Saturation Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
41385178|NCT06567353|DEVICE|Multi-mode tumor treatment system|All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. The treatment procedure includes: rapid freezing of the tumor tissue to form an ice ball extending 5mm beyond the lesion, maintaining this state for 5 minutes, followed by thawing and rewarming; subsequently, RFA is performed to ensure complete ablation, with the ablation zone including a safety margin of 5-10mm around the tumor.
40854658|NCT06462313|DRUG|Norepinephrine|Norepinephrine was titrated to maintain a mean arterial pressure at 65mmHg or more in both groups.
40854659|NCT01973413|DEVICE|Diabetes Assistant (DiAs)|The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
40854660|NCT01973413|DEVICE|Tandem t:slim Insulin Pump|FDA, market-approved insulin pump.
40854661|NCT01973413|DEVICE|Dexcom G4 Platinum sensor|FDA, market-approved continuous glucose monitor (CGM)
40854662|NCT06104332|DEVICE|ProRhinel Naturel spray nasal/ Allergic rhinitis|ProRhinel Naturel spray nasal: 21 days; 1 spray per nostril; 3 to 6 times per day
40854663|NCT06104332|DEVICE|ProRhinel EXTRA Eucalyptus spray nasal|ProRhinel EXTRA Eucalyptus spray nasal: until resolution of symptoms (period of 14 days maximum) ; 2 to 3 sprays per nostril; 6 times per day maximum
40854664|NCT06104332|DEVICE|RESPIMER Enfant|RESPIMER Enfant: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 4 times per day maximum
41037365|NCT00526123|DEVICE|Symmetric Tip Catheter|Dialysis catheter
41037366|NCT00526123|DEVICE|Conventional Split-tip Catheter|Dialysis Catheter
41037367|NCT00456638|DRUG|Depodur|Depodur vs. traditional management
41385179|NCT06567353|DEVICE|Radiofrequency ablation therapeutic apparatus|All subjects are treated using the radiofrequency ablation therapeutic apparatus (MedSphere International (Shanghai) Co., Ltd.), with the treatment procedure conducted according to the preset power and time parameters to ensure a safety margin of 5-10mm.
41385180|NCT02962115|BEHAVIORAL|Decision Aid Invitation|electronic invitation to complete web-based decision aid
41385181|NCT02708940|OTHER|Participatory technology development|Creating mobile support tools by patients and their therapists
41385182|NCT02708940|OTHER|Usual Care|Usual care as part of the UCLA PHP and IOP programs
41385183|NCT02973178|DEVICE|Scanadu Urine Device|Device to allow lay user to perform urinalysis test at home.
41385184|NCT02449109|PROCEDURE|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
41385185|NCT04426188|PROCEDURE|Heading series|10 headers from machine-projected soccer balls at standardized speeds
41385186|NCT04426188|DEVICE|Magnetic Resonance Imaging (MRI)|Brain MRI before and after a series
41385187|NCT04426188|OTHER|Cognitive computerized assessment|Cognitive evaluation carried out with two computerized tools
41385188|NCT04426188|PROCEDURE|Electrophysiological records|Electrophysiological recording of Motor Evoked Potentials consisting of the application of transcranial magnetic stimulations (TMS) and the collection of muscle activity by electromyogram (EMG)
41385189|NCT04426188|DEVICE|Dynamometer|Measure of the strength of the neck muscles using a dynamometer
41385190|NCT06566014|OTHER|Evaluation of XAI-assisted spina bifida diagnosis|AI feedback
41385191|NCT02531698|BIOLOGICAL|Bivalent rLP2086 Vaccine|1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
41385192|NCT02531698|BIOLOGICAL|Licensed pediatric hepatits A vaccine|1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
41385193|NCT02531698|OTHER|Normal Saline|Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
40854665|NCT06104332|DEVICE|Phytosun Aroms spray nasal MAX|Phytosun Aroms spray nasal MAX: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
40854666|NCT06104332|DEVICE|PHYSIOMER RHUME TRIPLE ACTION|PHYSIOMER RHUME TRIPLE ACTION: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
40854667|NCT06104332|DEVICE|Phytosun Aroms spray nasal decongestionnant|Phytosun Aroms spray nasal decongestionnant : until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 6 times per day maximum
41385194|NCT06283069|BEHAVIORAL|compilation of a questionnaire about LifeStyle|compilation of a questionnaire about LifeStyle
41385195|NCT04559776|OTHER|gait analysis|gait analysis with 3D optoelectronic system and surface EMG
41385196|NCT06496360|DIAGNOSTIC_TEST|Artificial Intelligence|The model employs machine learning algorithms to analyze CT imaging data of patients with non-small cell lung cancer. It focuses on the identification and assessment of features of the mediastinal fourth group lymph nodes, including size, shape, margins, and density. By extracting features related to lymph node metastasis, the model assists doctors in making more accurate diagnoses.
41385197|NCT06446973|OTHER|35 patients with meniscus tear|Have meniscus pathologies in one or both knees confirmed by MRI.
41510045|NCT02743429|DRUG|dinutuximab beta|"Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days."
41510046|NCT04077554|GENETIC|gene expression|determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
41510047|NCT00334373|PROCEDURE|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
41510048|NCT05238714|DRUG|venglustat|Powder for Oral solution
41510049|NCT02186444|OTHER|Personalized Health Information Navigator (PHIN)|"The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs."
41510050|NCT02186444|OTHER|NCI Information Booklets (IB)|"Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks."
40854668|NCT06104332|DEVICE|ProRhinel Naturel spray nasal/ URTI|ProRhinel Naturel spray nasal: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 3 to 6 times per day
41510051|NCT01842997|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
41385201|NCT06057233|DIAGNOSTIC_TEST|mqMRI and GABA-MRS|multiparametric quantitative MRI (mqMRI) and of GABA-edited magnetic resonance spectroscopy (GABA-MRS)
41385202|NCT01141569|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
41385203|NCT01141569|OTHER|Laboratory Biomarker Analysis|Correlative studies
41385204|NCT04708626|OTHER|Description and analysis|Collection of clinical, laboratory and radiological data from medical records.
41510052|NCT02417987|OTHER|Placebo|The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
41510053|NCT02417987|DRUG|High Volume injection|Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
41510054|NCT02417987|BIOLOGICAL|Autologous conditioned plasma (ACP)|Injection with 4 mls of ACP around the tendon
41385205|NCT04708626|OTHER|Description and analysis|Collection of laboratory data.
41385206|NCT01708694|DIETARY_SUPPLEMENT|Amylose|One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
41385207|NCT01708694|DIETARY_SUPPLEMENT|Amylopectin|"The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months."
41385208|NCT04369885|DEVICE|Go Home tablet with linked GoSpiro and 3230 Pulse Oximeter|All participants will receive the intervention consisting of a home telemedicine tablet platform (GoHome) that will collect multiple spirometry tests each week (including both forced and slow spirometry measurements), pulse oximetry, and QoL Questionnaire responses. The platform will remind patients to take their medications remind patients to perform measurements, send patients helpful information, and execute a UNC clinic established COPD Action Plan.The backend of the platform is a remote server (Monitored Therapeutics CarePortal) that collects the data, send out alerts to the Principal Investigator and can track and trend the data for them.
41510055|NCT04768426|DRUG|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.
41510056|NCT02565511|BIOLOGICAL|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
41510057|NCT02565511|OTHER|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
40854669|NCT03875664|DRUG|Liposomal bupivacaine|Extended-release local anesthetic
40854670|NCT03875664|DRUG|Placebo - injection|Injectable normal saline solution
40854671|NCT06040853|DRUG|Tranexamic acid intravenous administration|Participants will be given 15mg/kg tranexamic acid before the incision in ten minutes, 100 mg/h will continue until the end of the surgery.
40854672|NCT06040853|DRUG|Saline|Participant was given intravenous 100 ml saline
41385209|NCT05801094|DRUG|QL1604|QL1604 3 mg/kg Q3W
41385210|NCT01264328|DRUG|Panitumumab + paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
41385211|NCT02556528|BEHAVIORAL|Health Coaching|
41037368|NCT05879887|BEHAVIORAL|UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering)|UPHOLDS is a multicomponent, lay palliative care coach-led supportive care intervention designed to improve quality of life in individuals with advanced heart failure. In a series of weekly, one-on-one, 15-20 minute sessions, participants receive psychoeducation on palliative care principles (problem solving, self-care, symptom management, and advanced care planning), financial coaching (orientation to normalizing financial distress, introducing healthcare-related financial terms, exploring financial needs and steps to discussing finances in care decisions, and identifying financial resources in the health system and community), a one-time specialty palliative care outpatient clinic visit, as well as monthly follow-up.
41037369|NCT02114242|OTHER|CSF, blood and urine sampling|PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
41385212|NCT03993288|DRUG|Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
41385213|NCT03993288|DRUG|MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
41385214|NCT05643625|OTHER|Pilates exercise and myofascial release|Pilates exercise and myofascial relaxation technique will be applied to the experimental group and pilates exercise will be applied to the control group.
41385215|NCT04973748|BEHAVIORAL|Conditioned open-label placebo (COLP)|"Placebo oxycodone will be formulated to have the same physical appearance as liquid oxycodone and will be dispensed by the inpatient pharmacy and administered by the nursing staff. At all times that oxycodone or placebo medication is administered on post-operative day (POD) 1-5, the patient will undergo conditioning via exposure to a clove oil scent:~1. Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on POD 1-5.~2. Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5."
41385216|NCT04973748|BEHAVIORAL|Surveys about pain, opioid use and depression symptoms|"Surveys before surgery: Within 1 week prior to surgery, patients complete surveys about pain levels, opioid consumption, understanding of placebo effect and symptoms of depression.~Surveys after surgery: Through 6-months after surgery, patients complete surveys about pain levels, opioid consumption, side effects of opioids and symptoms of depression."
41385217|NCT06498817|BEHAVIORAL|Standard Recommendation|Standard recommendation given by government of Bangladesh on the use of oral rehydration solution (ORS) and a flyer on water treatment and handwashing with soap given at the health facility during the time of diarrhea patient treatment.
41385218|NCT06498817|BEHAVIORAL|CHoBI7 Scale-Up Program|Health promoter delivery of handwashing with soap, water treatment, and safe water storage module in the health facility to diarrhea patients and the patient's household members during the time of treatment. This module includes video testimonials from diarrhea patient households on how the patient benefits from adhering to the promoted behaviors, and a demonstration on how to construct homemade handwashing washing stations. This in-person module is reinforced by weekly voice, interactive voice response, and text messages for three months sent to the mobile phones of diarrhea patient household members from a doctor at diarrhea ward at local hospital.
41385219|NCT02813785|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
41385220|NCT02813785|DRUG|Docetaxel|Docetaxel will be administered as 75 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 21-day cycle.
41385221|NCT04934969|DIETARY_SUPPLEMENT|Adjunctive use of lavender and peppermint essential oils|passive inhalation aromatherapy following joint surgery
41385222|NCT05484830|PROCEDURE|Individualized HDR-approach|"Heparin concentration necessary to achieve target ACT \> 480 sec. calculated based on individual HDR-curve.~If HDR slope ˂80 s/IU/mL (reduced sensitivity to heparin), 1000 IU of AT concentrate (Antitrombin III Baxalta®, Takeda Pharma, Vallensbæk Strand, DK). Whole blood concentration of circulating heparin assessed by heparin assays. Additional heparin given as required. After weaning, protamine necessary to reverse circulating heparin calculated according to heparin-protamine titration measurement. After protamine, heparin reversal evaluated with low-range heparin-protamine titration cartridge and additional protamine given as required."
41510058|NCT02565511|DRUG|CNP520|CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
41385223|NCT05484830|PROCEDURE|Conventional ACT-approach|"Initial Heparin 400 IU/kg (500 IU/kg if treated with heparin prior to surgery). ACT Assessment with Hemochron® Signature Elite (ITC, International Technidyne Corp., Edison, NJ, USA).~Additional heparin until ACT \> 480 sec. If ACT \< 480 sec. after despite repeated heparin supplement with 1000 IU of AT III concentrate. Target ACT \> 480 sec. during normothermic CPB, and target ACT \> 700 seconds during hypothermia After weaning, protamine 10mg/mL (0.7 mg of protamine/ 100 IU total heparin administered). Heparin reversal is evaluated with an activated partial thromboplastin (APTT). If APTT \> 40 seconds, additional protamine (25-50 mg i.v.)."
41385224|NCT02444741|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
41385225|NCT02444741|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41385226|NCT02444741|OTHER|Laboratory Biomarker Analysis|Correlative studies
41385227|NCT02444741|BIOLOGICAL|Pembrolizumab|Given IV
41385228|NCT02444741|RADIATION|Proton Beam Radiation Therapy|Undergo PBRT
41385229|NCT02444741|RADIATION|Radiation Therapy|Undergo low dose radiation therapy
41385230|NCT02444741|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41385231|NCT04649892|DRUG|Naltrexone|Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient
40854673|NCT00950248|DRUG|Idebenone|idebenone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium povidone, magnesium stearate, silicon dioxide, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
40854674|NCT00950248|OTHER|placebo|lactose monohydrate, microcrystalline cellulose, magnesium stearate, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
40854675|NCT04867746|OTHER|data collection by health questionnaires|Health questionnaires to assess scores concerning pain and function of the treated leg and overall health
41510059|NCT02565511|OTHER|Placebo to CNP520|Placebo to CNP520 p.o. for the duration of the Treatment Epoch
40854676|NCT04867746|OTHER|assessment of muscle strength|Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (5 repetitions) and 240°/s (15 repetitions). Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight.
40854677|NCT04867746|OTHER|assessment of gait|Instrumented gait analysis on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany; 7168 sensors; area, 1.5 \* 0.5 m; range, 1-120 N/cm2; precision, 1-120 N/cm2 ± 5%; sampling rate, 120 Hz) and on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz). Simultaneously with the plantar pressure or force data, kinematic and electromyographic (EMG) data will be collected. Participants will then walk for 1 minute at their preferred walking speed (0% slope and at 15% slope) and at 1.2 m/s (0% slope). For all conditions, kinematic, EMG and pressure data will be recorded for 1 minute. Subsequently, the treadmill speed will be increased to preferred running speed and 2.3 m/s (0% slope), and data for 1 minute running will be recorded. Subjects will then complete overground walking and running trials on the walkway with embedded force plates.
41385232|NCT04649892|DRUG|Placebo|Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
41385233|NCT04649892|BEHAVIORAL|Psychoeducational|Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8
41385234|NCT04649892|DEVICE|Eye-tracking|"The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~* Before taking the first dose of naltrexone or placebo.~* One hour after taking the first dose of naltrexone or placebo.~* One week after continuous and daily use of naltrexone or placebo.~* At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo."
41385235|NCT00281827|DRUG|carboplatin|Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)
41385236|NCT00281827|DRUG|gemcitabine hydrochloride|Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.
41385237|NCT00281827|DRUG|thalidomide|Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.
41385238|NCT00281827|PROCEDURE|conventional surgery|Resection - between 2 and 6 weeks following last dose of chemotherapy.
41510060|NCT02565511|OTHER|Alum|Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
41510061|NCT04711811|BIOLOGICAL|HB-adMSC|Hope Biosciences adipose derived autologous mesenchymal stem cell product
41510062|NCT03709212|OTHER|interviews|20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.
41510063|NCT05326555|DIAGNOSTIC_TEST|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
40854678|NCT04867746|OTHER|assessment of squatting and single leg hops|Participants perform three jumps on a force plate. Maximum jump length, Maximum flexion and extension angles and joint moments will be identified. Subsequently, participants perform three squats onto two force plates (one per foot). On- and off times will be computed for each muscle and condition.
40854679|NCT04867746|OTHER|assessment of postural stability|The length of the centre of pressure path will be measured during two 30-second unipedal stance trials using a force plate.
40854680|NCT04565951|BEHAVIORAL|VA S.A.V.E.|The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
40854681|NCT04565951|BEHAVIORAL|Sham intervention|"A sham training consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
41385239|NCT06410859|DRUG|"Botulinum Toxin Type A for Injection,also known as HengLi®"|This study plans to enroll 240 subjects, and the efficacy measures \[VAS score, DSIS score, daily pain duration (if applicable), and number of daily pain episodes\] will be collected from subjects using the electronic Patient-Reported Outcomes (ePRO) throughout the study. The study period mainly consists of a screening period (14 days before the first dose), a double-blind treatment period (from the first dose to Week 12), and an extension period (from Week 13 to Week 52), including a maximum of 4 treatment cycles (each cycle lasts 12 week)
41385240|NCT03658356|OTHER|Video instructions|Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
41385241|NCT00595127|DRUG|Cyclophosphamide|Cyclophosphamide (10mg/kg/day x 4days)
41385242|NCT00595127|DRUG|Fludarabine|Fludarabine (30mg/m\^2/day x 5 days)
41385243|NCT00595127|RADIATION|Total body irradiation (TBI)|TBI (450 cGY in a single fraction)
41385244|NCT04651673|OTHER|This is a non interventional registry|All patients, at listed investigational sites, that get prescription for a knee orthosis indicated for Knee OA symptomatic treatment, get an invite to partake in the evaluation registry.
41510064|NCT01534169|DRUG|Dexamethasone|The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
41385245|NCT01502800|DRUG|ARQ 761|ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
41385246|NCT01502800|DRUG|ARQ 761 Weekly Administration|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
41385247|NCT01502800|DRUG|Bi-Weekly Administration of ARQ 761|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
41385248|NCT01502800|DRUG|Two Consecutive Weeks Administration of ARQ 761 with one week of rest|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
41385249|NCT05770778|OTHER|Inclined Backwalk|They will receive inclined backward treadmill gait training exercise for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child, three times weekly, over three months.
41385250|NCT05770778|OTHER|Knee Walk|They will receive kneel walk exercise programme for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child , three times weekly, over three months.
41385251|NCT06249035|DIAGNOSTIC_TEST|Transoesophageal echocardiography (TEE)|TEE is a diagnostic modality in which an ultrasound probe is inserted via the oesophagus in order to visualize the heart.
41510065|NCT00497913|DRUG|NaCl 0.9%|
41510066|NCT00497913|DRUG|Botulinum Toxin A|
41510067|NCT00535405|DRUG|Atorvastatin 10 mg|Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
41510068|NCT00535405|DRUG|Ezetimibe 10 mg/simvastatin 20 mg|Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
41510069|NCT00535405|DRUG|Atorvastatin 20 mg|Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
41510070|NCT00535405|DRUG|Ezetimibe 10 mg/simvastatin 40 mg|Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
41510071|NCT00535405|DRUG|Atorvastatin 40 mg|Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
41510072|NCT05714878|BEHAVIORAL|aerobic exercise; resistance exercise; nutritional support; psychological support|Patient with gastric cancer received two weeks of prehabilitation intervention. An individualized exercise program was established according to the FITT (Frequency, Intensity, Time and Type) principle. Aerobic exercise: 3-5 times/week, 30-60 min jogging or brisk walking per time, intensity based on heart rate and modified Borg-scale. Resistance exercise: 2-3 times/week, 10-12 RM per sets, 2-3 sets with 2 min interval rest, seated knee up, knee extension, etc. Nutritional support: 30kcal/kg/d, 1.5mg/kg/d protein, oral nutritional supplement with suggested recipes. Psychological support: provided with guidance on gastric cancer, regular online chat through Wechat, alcohol quitting, smoking cessation and light music.
40854682|NCT03406338|PROCEDURE|Fasciectomy|Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.
40854683|NCT03406338|DRUG|Collagenase Clostridium Histolyticum|Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
40854684|NCT03801226|DRUG|Two-hour dwell with 10% dextrose in sterile water|Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
40854685|NCT03801226|DRUG|Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose|Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
41037370|NCT02114242|OTHER|clinical measures of disease severity and progression|Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
41037371|NCT00907673|DEVICE|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
41037372|NCT02931734|DRUG|Resin modified glass ionomer|Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
41037373|NCT02931734|DRUG|Potassium Nitrate 2%|Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
41510073|NCT02459938|DRUG|Glucagon (ZP-Glucagon)|chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
41510074|NCT02459938|DRUG|Glucagon (GlucaGen)|recombinant glucagon administered via subcutaneous injection
41510075|NCT04482387|DEVICE|DigiVis visual acuity app|Self-testing of visual acuity app on two occasions
41510076|NCT04278456|BEHAVIORAL|postpartum depression|melatonin levels in c-sections with different anesthesia modalities.
41510077|NCT01198132|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.
40854686|NCT06167876|RADIATION|Stereotactic Body Radiotherapy (SBRT) Treatment|The intervention in this study utilizes Stereotactic Body Radiotherapy (SBRT) for treating Hypertrophic Obstructive Cardiomyopathy (HOCM). The process begins with precise localization and planning, employing CT scans, Cardiac MRI (CMR), and echocardiography to accurately identify the target area in the interventricular septum, while avoiding critical structures like the aortic valve, His bundle, and left ventricular papillary muscles. Pre-treatment preparation involves using customized fixation devices to limit patient movement and breathing, coupled with cone-beam CT scans for accurate alignment with the Treatment Planning System (TPS). The treatment itself is delivered using image-guided linear accelerators, administering a single, focused dose of 25 Gy to the targeted area. This approach ensures precise radiation delivery, maximizing treatment efficacy while minimizing risks to surrounding cardiac tissues.
40854687|NCT06167876|OTHER|Sham Procedure|The sham procedure in this study is designed to closely mimic the actual Stereotactic Body Radiotherapy (SBRT) process without delivering any radiation. Participants in this arm are subjected to the same initial steps as those in the SBRT group, including precise alignment with the linear accelerator using CT scans and the application of customized fixation devices to limit movement and breathing. However, in this sham intervention, the linear accelerator is activated but does not emit any radiation. The procedure replicates the environmental aspects of the actual treatment, such as the equipment's sounds and lighting, to maintain the study's single-blind nature. This method ensures that participants in the sham group experience a procedure identical in appearance and feel to the SBRT treatment, without receiving any therapeutic dose, thereby serving as an effective control for evaluating the true impact of SBRT in treating HOCM.
40854688|NCT03773523|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
40854689|NCT05397249|BEHAVIORAL|Mindfulness Training|The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.
40854690|NCT00206336|DRUG|Topiramate (drug)|Topiramate 25 mg to 200 mg
40854691|NCT04500886|DRUG|PEG-rhG-CSF|PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
40854692|NCT04500886|DRUG|rhG-CSF|rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
40854693|NCT03892239|BEHAVIORAL|RunIn3 Prevention Program|"The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.~Through a website we will make available informative texts, videos and infographics in order to increase the participant's knowledge regarding topics such as: musculoskeletal symptoms; foot strike patterns; training workload; running shoes; warming-up/cooling-down, stretching; and concomitant strength training."
40854694|NCT03892239|BEHAVIORAL|Feedback Based Surveillance|The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.
41037374|NCT02931734|PROCEDURE|Low level laser therapy|Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
41037375|NCT06223620|OTHER|review performance of water soluble contrast|review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
41037376|NCT01305967|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, Intravenous route, 16times for 2.5 months
41037377|NCT06392386|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injections
41037378|NCT00421252|DRUG|clopidogrel 600 mg|Clopidogrel load \> 2hrs pre-angiography
41037379|NCT00421252|DEVICE|arterial access sheath|randomize to 5Fr vs 6Fr
41037380|NCT00433784|DRUG|Clopidogrel|
41037381|NCT00433784|PROCEDURE|Blood sampling - platelet aggregation|
41037382|NCT00433784|PROCEDURE|Blood sampling - genotyping|
41385252|NCT04718727|DRUG|Placebo|oral Placebo tablets one-hour preoperatively
41510078|NCT01198132|DIETARY_SUPPLEMENT|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
41510079|NCT01198132|DRUG|Rebif|Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
40676632|NCT00878566|OTHER|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
40854695|NCT04057846|DEVICE|EUS guided transgastric drainage|Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
40854696|NCT02396563|PROCEDURE|epidural analgesia|
40854697|NCT02396563|DRUG|Ropivacaine|
40854698|NCT03156374|DEVICE|Test use|Use of home ovulation test to predict ovulation
40854699|NCT03009617|BEHAVIORAL|the educational program and counseling|to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
40854700|NCT04396158|RADIATION|radioactive iodine|80-200 mCi of radioactive iodine will be given to thyroid cancer patients
40854701|NCT04253002|BEHAVIORAL|Robinson's Culturally Adapted Coping with Stress Course (A-CWS)|Participants randomized to the experimental condition will take part in the Adapted Coping with Stress Course (A-CWS). The A-CWS is a 15-session, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills to adaptively cope with stress, using standard cognitive-behavioral strategies such as relaxation training and cognitive restructuring. Emphasis is given to the identification of individual and contextual factors associated with suicide risk and the unique day-to-day experiences of the youth, providing options for adaptive coping (e.g., positive thinking) that are culturally consistent. The A-CWS is structured and manualized to allow its transportability to service providers working in similar environments with similar youth.
40854702|NCT04253002|BEHAVIORAL|Standard Care Control Condition|Students meeting criteria for study inclusion and randomized into the standard care condition will be referred to the school-based health center (SBHC) mental health provider for case management. Standard care may range from (1) brief intervention by the SBHC mental health provider to (2) outside referral to local community service providers; these determinations will be made by the SBHC mental health team.
41510080|NCT05410964|DEVICE|VIO System|To investigate the potential for the VIO System to display microscopic skin structure in people of different age, sex, race, and skin health
40854703|NCT05097495|PROCEDURE|Only NNS|"Before the procedure, the Premature Infant Comfort Scale shall be filled out.~Procedure steps for the control group:~* Materials shall be prepared (napkins, non-sterile gloves, pacifier)~* Hands shall be washed; gloves shall be worn.~* The infant shall be given a NNS just before the procedure and continue until the 5th minute after the procedure.~* The diapers shall be changed.~* Hands shall be washed after the procedure.~* The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
41385253|NCT04718727|DRUG|5 mg Olanzapine Tablets|oral 5 mg Olanzapine tablets one-hour preoperatively
41385254|NCT04718727|DRUG|10 mg Olanzapine Tablets|oral 10 mg Olanzapine tablets one-hour preoperatively
40676633|NCT00878566|OTHER|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
40676634|NCT05731037|OTHER|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
41037383|NCT00966940|DRUG|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
41037384|NCT00966940|DRUG|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
41037385|NCT00605293|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv/month (starting dose)
41037386|NCT00605293|DRUG|Epoetin alfa|As prescribed
41037387|NCT02777151|DRUG|REGN3470-3471-3479|
41037388|NCT02777151|DRUG|Placebo|
41037389|NCT05320822|OTHER|Active Rehab (Group 2)|"The Active Rehab protocol builds off of initial chief complaints and duty profile and addresses symptom control followed by a progressive and prescribed integration of activities to full return to duty that should be integrated with the current PRA TBICoE protocols. The specific activity areas in the intervention include low-intensity aerobic exercise that does not exacerbate symptoms, cognition, balance, visual/vestibular, and comfort/ general well-being.~Participants can be progressed daily according to symptom limitations. At least 3-4 sessions each week are recommended based on a trial of sport-related mTBI and other interventions of this type concerning mTBI/concussion. During each phase, low level aerobic exercise that does not significantly exacerbate symptoms, such as nature walks, will be recommended. The additional activity types that may be chosen include cognitive, balance, visual/vestibular, and comfort/general well-being."
41385255|NCT04418115|OTHER|Acupuncture; based on Tradidtional Chinese Medicine|Acupuncture is a form of treatment that involves inserting very thin needles through a person's skin at specific points on the body, to various depths. Research suggests that it can help relieve pain, and it is used for a wide range of other complaints.
41385256|NCT03530007|DRUG|Normal saline|normal saline used for prevention of spinal shivering
41385257|NCT03530007|DRUG|Ondansetron 4 MG|ondansetron 4 MG used for prevention of spinal shivering
41385258|NCT03530007|DRUG|Ondansetron 8mg|ondansetron 8 MG used for prevention of spinal shivering
41385259|NCT06426186|PROCEDURE|Right-stellate ganglion block|The experimental group was given right stellate ganglion block 30 minutes before anesthesia
41385260|NCT01260194|DRUG|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
40854704|NCT05097495|PROCEDURE|NNS Combined with Breast Milk|"* Before the procedure, the Premature Infant Comfort Scale shall be filled out.~* Materials shall be prepared (napkins, non-sterile gloves, pacifier, breast milk, cup)~* Hands shall be washed; gloves shall be worn.~* The cylindrical part of a pacifier shall be in touch with breast milk for 5 seconds. The infant shall be given the pacifier, combined with breast milk, just before the procedure and continue until the 5th minute after the procedure.~* The diapers shall be changed.~* Hands shall be washed after the procedure.~* The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
40854705|NCT06342973|DEVICE|Xenograft and allograft|For the guided bone augmentation procedure, a crestal incision with one or two vertical incision will be made and a full thickness mucoperiosteal flap will be elevated. Decortication will be performed and the patient will receive grafting with DFDBA with a buccal overlay of xenograft. A bi-layered native collagen membrane will be used and fixed with tacks or sutures. Periosteal incisions will be made to get tension free primary closure. The flap will be closed with sutures. Patients will be prescribed antibiotics, analgesics and mouth rinses as appropriate.
40854706|NCT01549119|BIOLOGICAL|VAC-3S|Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
40854707|NCT01549119|BIOLOGICAL|Placebo|Comparison with experimental vaccine
40854708|NCT03830346|OTHER|Instrument-assisted|instrument-assisted soft tissue mobilization techniques (applied with the subject in prone position. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment) and post-isometric horizontal adduction stretches (carried out with the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times).
40854709|NCT01440816|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
40854710|NCT01440816|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
40854711|NCT05008926|DRUG|Naloxegol|Administration of Naloxegol 25 mg per day by nasogastric tube (SNG) or orogastric tube (SOG). The administration should be started within the first 24 hours after the patient is admitted to intensive care and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.
40854712|NCT05008926|DRUG|Placebo|Administration of the placebo according to the same procedures as the experimental arm.
40854713|NCT00517361|DRUG|carboplatin|AUC 6 in 250mL saline IV over 30 minutes
40854714|NCT00517361|DRUG|bevacizumab|15mg/kg in 100mL saline IV over 60 - 90 minutes
40854715|NCT01145339|DRUG|Lactase|1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
40854716|NCT01785823|OTHER|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
41166189|NCT04554953|DRUG|Combination drug containing fimasartan and statins|"Patients who correspond to one of the following:~1. Patients who are planning to be treated with a combination drug containing fimasartan and statins after being newly diagnosed with essential hypertension and primary hypercholesterolemia~2. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension or primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB or dyslipidemia treatment that is containing a statin~3. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension and primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB and dyslipidemia treatment that is containing a statin"
41166190|NCT01086332|DRUG|Nelfinavir|1250 mg twice daily
41166191|NCT01086332|DRUG|Gemcitabine|Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
41166192|NCT05871918|DRUG|TCbHP VS ddEC-THP|The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.
41166193|NCT00721214|DRUG|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
41166194|NCT02950181|DEVICE|NIRS|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
40676639|NCT04076423|DRUG|Dual Therapy|DTG + 3TC
40676640|NCT04076423|DRUG|Triple therapy|BIC / FTC / TAF
40676641|NCT03948035|DRUG|Elotuzumab|i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.
40676642|NCT03948035|DRUG|Carfilzomib|i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
40676643|NCT03948035|DRUG|Lenalidomide|hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
40676644|NCT03948035|DRUG|Dexamethasone|orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
41385261|NCT01246297|OTHER|Pulmonary Rehabilitation|Twice weekly exercise classes with an education component. For 8 weeks.
41037390|NCT05320822|OTHER|Progressive Return to Activity (Group 1)|Participant will be asked to use symptoms to guide activity from the time of the injury until participant is asymptomatic. Once asymptomatic, participant will begin the PRA TBICoE clinical recommendation. During this time clinicians will document activities in each stage in addition to initial symptom checklist, stage of PRA CoE progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
41037391|NCT02368353|OTHER|Cognitive behavioral therapy|
41037392|NCT02368353|OTHER|Supportive therapy|
41037393|NCT03362333|OTHER|Exercise|Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.
41037394|NCT03362333|OTHER|Pain neuroscience education|Pain neuroscience education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
41037395|NCT03975283|DRUG|Exparel 266 MG Per 20 ML Injection|266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
41037396|NCT03975283|DRUG|Bupivacaine Hcl 0.25% Inj|0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
41166195|NCT04502043|OTHER|Exercise therapy|"* Education~* Hip-specific strengthening exercises~* Functional lower limb strengthening exercises~* Core stability exercises~* Postural balance exercises"
41385262|NCT01246297|OTHER|Usual post operative care|Usual post operative care for post lung lobectomy patients for 8 weeks post discharge.
41385263|NCT00537056|PROCEDURE|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
40854717|NCT01785823|OTHER|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
41385264|NCT00537056|PROCEDURE|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
41385265|NCT00537056|DRUG|F-18 Fluoro-deoxi-glucose|15 mCi iv
41385266|NCT00537056|DRUG|Gadolinium-DTPA|0.1 mmol/kg iv
41385267|NCT00537056|DRUG|Sunitinib|50 mg/day po
41385268|NCT01710007|DRUG|1PC002|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
41385269|NCT01710007|DRUG|Lipitor|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
41385270|NCT04348292|DRUG|Durvalumab|Given IV
41385271|NCT04348292|DRUG|Sirolimus|Given PO
41385272|NCT04027907|OTHER|Flowcytometry|detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).
41385273|NCT05761522|OTHER|transthoracic echocardiography|"* Concerning the main judgment criterion and the secondary judgment criteria:~  * Left ventricular ejection fraction (LVEF) by the Simpson Biplane method,~ * Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)).~ * Tricuspid Annular Systolic Excursion (TAPSE) (mm)~ * S wave at the tricuspid ring (cm/s)~* Other parameters collected systematically:~  * Surface of the left ventricle (end-systolic and end-diastolic),~ * Global strain of the left ventricle~ * Mitral Annular Plane Systolic Excursion (MAPSE) (mm)~ * Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e');~ * Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)"
41385274|NCT06568445|DRUG|Maintenance at initial treatment sequential as-needed therapy with inhaled budesonide-formoterol(Symbicort 160/4.5) ®）|one inhalation twice daily for 4 weeks maintenance, sequential as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
41385275|NCT06568445|DRUG|as-needed therapy with inhaled budesonide-formoterol (Symbicort 160/4.5) ®）|as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
41385276|NCT05346939|DEVICE|dynamic taping|The athletic trainer will intervene with spiral dynamic technique by using a dynamic tape for the first test and a sham dynamic tape for the second test, or reverse the order.
41385277|NCT06017973|DIAGNOSTIC_TEST|MRI scan including arterial spin labelling of the brain|Arterial Spin Labelling sequence, T2-weighted FLAIR images and T1-weighted images and diffusion weighted imaging sequence will be recorded
40676645|NCT03948035|OTHER|autologous stem cell transplant|autologous stem cell transplant
40676647|NCT03079011|DRUG|Palbociclib 125mg|Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle
40676648|NCT03079011|DRUG|Aromatase Inhibitors|Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)
40676649|NCT03079011|DRUG|Fulvestrant Injectable Product|500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)
40676650|NCT01444729|DRUG|Xiapex|Xiapex administration will follow SMPC
40676651|NCT01444729|PROCEDURE|surgery|Non-pharmacological treatment
40676652|NCT03476174|DRUG|Pembrolizumab|Subjects will receive 200 mg pembrolizumab every 3 weeks for two cycles. Cycle length is 21 days (i.e., 3 weeks). On the last day of Cycle 2 (+/- 3 days), disease status will be assessed via imaging.
41385278|NCT06017973|DIAGNOSTIC_TEST|CT perfusion scan of the brain|Siemens Naeotom Alpha with quantum technology (photon-counting)
41385279|NCT06017973|DIAGNOSTIC_TEST|FDG-PET scan of the brain|An FDG-PET scan will be acquired on a GE Signa 3T PET-MR scanner. FDG-PET images will be assessed for focal hypermetabolism, including semiquantitative analysis of the maximal standard uptake value (SUVmax) relative to the SUVmax of the pons (SUVr pons)
41385280|NCT06516653|DEVICE|VasQ|External support implant for the arteriovenous fistula
41385281|NCT06516653|PROCEDURE|Arteriovenous fistula creation for dialysis vascular access|End to side fistula creation in the arm for dialysis vascular access
41385282|NCT02549885|OTHER|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
41385283|NCT02549885|OTHER|Static stretching|Static stretching of neck muscles.
41385284|NCT05954611|BIOLOGICAL|GR2002 injection|one single dose of GR2002 injection
41385285|NCT05954611|BIOLOGICAL|Placebo|one single dose of placebo
41385286|NCT05287711|BEHAVIORAL|Motivational Enhancement Therapy|In Session 1, the therapist provides personalized feedback on a range of assessment variables, including alcohol consumption levels, negative consequences from alcohol use, and family risk of alcoholism. Sessions 2-4 are follow-through sessions in which the therapist attempts to help the Veteran participant establish or reaffirm a commitment to an action plan for addressing alcohol concerns.
41385287|NCT05287711|BEHAVIORAL|Alcohol Education Control|Will consist of 4 weekly individual sessions, approximately 60 minutes each. AE therapists will explain that their job is to provide the Veteran participants with information and education about the effects of alcohol, and that it is up to the Veteran participant to use this information as he sees fit. In each session, the Veteran participant will watch an educational videotape in a comfortable consulting room and will be given an opportunity to discuss the videotape with the project therapist for approximately 10 minutes. Written educational materials will supplement the information provided in the videos, and the therapist will ask several structured questions to determine whether the Veteran participant understood the material presented in the video.
41385288|NCT05287711|BEHAVIORAL|Treatment as Usual|Supportive telephone monitoring sessions that ensure equal spacing between assessments across conditions and equal number of therapist contacts.
41385289|NCT05287711|BEHAVIORAL|Strength at Home|IPV intervention which consists of 12 weekly, 2-hour cognitive-behavioral sessions offered in a closed group format and co-led by doctoral level male and female therapists. Strength at Home is based on a social information processing model of trauma and IPV and provides material covering psychoeducation regarding trauma and IPV, conflict and anger management skills, assertiveness training, and skills in stress management and communication.
41385290|NCT00544713|DRUG|Carboxymethylcellulose and Glycerin based artificial tear|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
41385291|NCT00544713|DRUG|Carboxymethylcellulose|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
41385292|NCT06566287|OTHER|Immediate implant|Immediate Implant with Socket Shield Group
41385293|NCT06566287|OTHER|Delayed implant|Delayed Implant with Socket preserved with socket Shield and dentin graft Group
41385294|NCT06109402|DRUG|TQB2450|Specified dose on specified days
41385295|NCT06109402|DRUG|Carboplatin|Specified dose on specified days
41385296|NCT06109402|DRUG|Pemetrexed|Specified dose on specified days
41385297|NCT06109402|DRUG|Nab-paclitaxel|Specified dose on specified days
41385298|NCT06109402|PROCEDURE|Surgery|Surgery for II-IIIB (N2) non-small cell lung cancer
41385299|NCT06540677|OTHER|Musical training|Musical training with Meludia software, an online self-paced music training application
41385300|NCT04993339|DRUG|OOC|The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
41385301|NCT04419701|PROCEDURE|periarticular infiltration|"The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement."
41385302|NCT04419701|PROCEDURE|genicular nerve block|The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
41385303|NCT03022318|DRUG|carbidopa-levodopa 25-100 mg tablets|See arm/group descriptions
41385304|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
41385305|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
41385306|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
41385307|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
41385308|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
41385309|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
41385310|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10\^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 8.
41385311|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 8.
41385312|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10\^10vp at week 8.
41385313|NCT00650637|DRUG|Calcium Carbonate|Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12
41385314|NCT00650637|DRUG|nelfinavir|1250 mg twice a day
41385315|NCT00650637|DRUG|lamivudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
41385316|NCT00650637|DRUG|loperamide|If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;
41385317|NCT00650637|OTHER|Calcium carbonate not administered|Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
41385318|NCT00650637|DRUG|nelfinavir|nelfinavir 1250 mg twice a day
41385319|NCT00650637|DRUG|lamivudine + zidovudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
41385320|NCT06149624|BEHAVIORAL|upfront advice to walk|Control participants will be given upfront advice to walk and also given the wearable activity monitor (Fitbit) and asked to record the total steps achieved each day in a provided log book.
41385321|NCT06149624|BEHAVIORAL|Supervised exercise|The onsite physiotherapist will also be trained in appropriate supervision and monitoring of exercise therapy in participants with HIV. This training will include titration of the exercise prescription to ensure safe progress is achieved. Participants will be scheduled to come to Mildmay 2 times per week for eight weeks to perform treadmill walking exercise. Intensity will be regulated using 40-60% of heart rate reserve. Additionally, ratings of perceived exertion via the Adult OMNI Walk/Run Scale will be used to guide the intensity of exercise subjectively at a moderate level. The exercise dose participants complete are standard prescriptions for participants with HIV, according to the American College of Sports Medicine.19 The physiotherapist will document the total steps achieved, including the supervised treadmill sessions and activity completed outside the supervised exercise setting (provided by participants via a log book).
41385322|NCT02306018|DEVICE|EV1000™/volumeView™|
41385323|NCT05784363|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).
41385324|NCT05784363|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
41385325|NCT06196970|OTHER|Pilate exercises|After 10 minutes of warmup excercises, participatants perform pilates exercises, Pelvic curl : 45 seconds hold The Hundred : 45 seconds hold Bird Dog : 45 seconds hold Side plank : 45 seconds hold Frequency 3 days a week intensity 45 minutes hold a pose. Time will be 10 to 15 minutes.
41385326|NCT06196970|OTHER|Burpees exercises|"After 10 minutes of warmup excercises, participatants perform burppes excercises.~1. Stand straight with your feet shoulder-width apart.~2. Squat and place your hands in front of your feet.~3. Jump back until your legs are fully extended and your body is in plank position.~4. Do a push up, jump forward, and then push through the heels to return to the starting position.~5. Repeat until the set is complete. Frequency 3 days a week .Time 10 to 15 minutes with 10 reputation , 3 sets. Rest internal will be 10 seconds after each set."
41385327|NCT01467401|DRUG|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
40854718|NCT01785823|OTHER|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
41385328|NCT01467401|DRUG|biphasic human insulin|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
41385329|NCT03501407|DIAGNOSTIC_TEST|Blood samples|1 or 2 blood samples will be collected from the patient.
41385330|NCT03501407|DIAGNOSTIC_TEST|skin biopsy|A skin biopsy will be performed on the periphery of the erythema migrans
41385331|NCT03650179|OTHER|Observational study : No intervention|Observational study : No intervention. Only exporting data
41385332|NCT00457431|PROCEDURE|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
41510081|NCT05273450|BEHAVIORAL|Quitline Information with Reinforcement|The intervention arm involves direct referral to the Ohio Tobacco Quitline, with up to two brief follow-up telephone calls from the research team to elicit motivation to quit, emphasize benefits of calling the quitline, encourage use and address concerns. Participants are surveyed at baseline and at 3-month follow-up to assess awareness and use of the quitline.
41510082|NCT03438994|DIAGNOSTIC_TEST|Play.Care|iPad based game to assess movement as the player interacts with the screen
40854719|NCT00225498|DRUG|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
41510083|NCT04775615|DRUG|DDO-3055 tablets；Placebo|Low dose：DDO-3055 tablets for 7 days or Placebo for 7 days
40854720|NCT06366360|OTHER|Immersive Virtual Reality Intervention|"The immersive virtual reality rehabilitation protocol is an experimental protocol based on musical practice. This protocol will be based on the Piano Vision application, which allows several modes of music production: free or guided musical practice."
41385333|NCT05446116|PROCEDURE|partial splenic artery embolization|embolization of the splenic artery for the treatment of hypersplenism
41385334|NCT04624256|PROCEDURE|Discussion|Patients and physicians engage in discussion
41385335|NCT04624256|RADIATION|Hypofractionated Radiation Therapy|Undergo conventional hypofractionated radiation therapy
41385336|NCT04624256|RADIATION|Hypofractionated Radiation Therapy|Undergo moderate hypofractionated radiation therapy
41385337|NCT04624256|OTHER|Laboratory Biomarker Analysis|Correlative studies
41385338|NCT04624256|OTHER|Quality-of-Life Assessment|Ancillary studies
41385339|NCT04624256|OTHER|Questionnaire Administration|Ancillary studies
41385340|NCT04624256|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
41385341|NCT00097084|DRUG|insulin detemir|
41385342|NCT00097084|DRUG|insulin glargine|
40854721|NCT06366360|OTHER|Conventional rehabilitation|The conventional rehabilitation corresponds to the classically performed in the cognitive treatment of unilateral spatial neglect. It involves training visual scanning using barrage exercises, sequence identification, scene description, and pointing.
40854722|NCT00851461|DRUG|Goserelin|Goserelin 10.8 mg SC every 3 months
40854723|NCT00851461|PROCEDURE|Electrophysiologic study|Nerve conduction study Electromyogram
40854724|NCT00851461|PROCEDURE|tissue biopsy|skin and muscle biopsy before and after treatment every year
41385343|NCT00097084|DRUG|insulin aspart|
41385344|NCT06159335|RADIATION|F-Fluciclovine radiotracer|Participants will receive PET radiotracer and MRI
41385345|NCT04642131|DIETARY_SUPPLEMENT|Caffeine supplementation|Participants will wear standard insoles and ingest caffeine in liquid form (3mg/kg) with carbohydrates.
41385346|NCT04642131|DEVICE|Personalized insoles|Participants will wear personalized insoles and ingest a drink of carbohydrates without caffeine
40854725|NCT01665391|DRUG|fresolimumab|1 mg/kg total body weight administered intravenous (IV)
40854726|NCT01665391|DRUG|fresolimumab|4 mg/kg total body weight administered intravenous (IV)
40854727|NCT01665391|DRUG|Placebo|Placebo administered to match active treatment group
41385347|NCT04642131|OTHER|Control condition|Participants will wear standard insoles and ingest a drink of carbohydrates without caffeine
41385348|NCT01742390|DRUG|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
41385349|NCT01742390|DRUG|risperidone or paliperidone|
41385350|NCT04177173|DRUG|Simvastatin 20 mg|improvement of disease activity
41385351|NCT04177173|DRUG|Methotrexate 10 mg|improvement of disease activity
41385352|NCT06056323|DRUG|HB0045 Drug Product|Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.
40854728|NCT01629277|DEVICE|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
40854729|NCT01629277|DEVICE|standard insulin pump|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
40854730|NCT03250208|DIETARY_SUPPLEMENT|Probiotic|Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.
40854731|NCT03250208|OTHER|Placebo|Participants randomized to the control group will receive a placebo containing no active ingredients
40854732|NCT03771950|BEHAVIORAL|Early team based neuro-rehabilitation|A structured interview will be made by OT about activity level, and an examination of the patients bodily and neurological symptoms will be made by PT. Based on this result a rehabilitation plan is established consisting of the patient's goals, and the purpose that the patient shall be as active as possible without triggering symptoms. An individual exercise program is prescribed. Between each appointment the patient will have personal tasks to accomplish with the purpose of being active based on symptoms and the adaptation to the current level of energy. The perceived symptoms will be logged. A week-schedule will be created in the purpose of helping the patient to a balanced activity level in relation to their current capacity. The PT assesses physical activity level and reactions to physical strain. Adaptations are made to the exercise program and advice is given on physical activity and exercises. When appropriate OT advices about returning to work and adaptations concerning work.
41385353|NCT06511232|DRUG|Intraosseous Morphine|More recently, intraosseous infusion of analgesics and antibiotics has gained traction in the total joint arthroplasty literature. In knee arthroplasty patients, the combination of a spine and adductor canal block with an intraosseous infusion of morphine into the tibial tubercle prior to incision yielded lower pain in the immediate postoperative period and at 2 weeks, less pain medication use, and significantly better patient-reported outcomes while also reducing systemic opioid exposure in the early postoperative period compared to the spine and adductor block alone.3 No study to date in the available literature has evaluated the efficacy of intraosseous morphine infusion in managing acute postoperative pain in patients undergoing ACL reconstruction with bone-patellar tendon-bone autograft, so that is the intended evaluation point with this project.
40854733|NCT04423081|OTHER|EXIT scale|completion of EXIT scale translated in french
40854734|NCT01907763|DRUG|SOTB07 200mg|
40854735|NCT01907763|DRUG|SOTB07 400mg|
40854736|NCT01907763|DRUG|SOTB 200mg placebo|Placebo of SOTB07 200mg
40854737|NCT01907763|DRUG|SOTB 400mg placebo|Placebo of SOTB07 400mg
41385354|NCT06568718|DRUG|bovhyaluronidase azoximer|Longidaze 3000 IU intramuscularly once every 5 days with a course of 5 injections; Longidaze 3000 IU rectal suppositories once every 3 days with a course of 10 applications; Longidaze 3000 IU rectal suppositories once every 7 days with a course of 10 applications.
41385355|NCT06568718|DRUG|tamsulosin|Tamsulosin 0.4mg per os every day
41385356|NCT00024271|BIOLOGICAL|recombinant interferon gamma|
41385357|NCT00024271|DRUG|cisplatin|
41385358|NCT00024271|DRUG|doxorubicin hydrochloride|
41385359|NCT00024271|DRUG|gemcitabine hydrochloride|
41385360|NCT00024271|DRUG|mitomycin C|
41385361|NCT00024271|PROCEDURE|conventional surgery|
41385362|NCT00024271|PROCEDURE|hyperthermia treatment|
41385363|NCT00024271|RADIATION|radiation therapy|
41385364|NCT03338907|DRUG|Oxycarbon (5% CO2+ 95% O2)|Oxycarbon will be administered by mechanical ventilation
41385365|NCT01856296|PROCEDURE|Biopsy|
41385366|NCT04484987|OTHER|9 hours daily eating window|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
41385367|NCT04484987|OTHER|15 hours daily eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 15-hour window for 12 weeks.
41385368|NCT03544606|DRUG|isosorbide mononitrate|40 mg tablet of intra-vaginal IMN (Effox; MINAPHARMA, Cairo, Egypt) will be placed into the posterior fornix of the vagina, through a digital vaginal examination, every 4 h for a maximum of four doses.
41385369|NCT03544606|DRUG|Placebos|In placebo group (group 2) 40 mg intra-vaginal pyridoxine placebos every 4 h for a maximum of four doses will be given
41510084|NCT04775615|DRUG|DDO-3055 tablets；Placebo|Medium dose：DDO-3055 tablets for 7 days or Placebo for 7 days
41385370|NCT05489068|BEHAVIORAL|Motivational Interviewing at Intake (MII)|The MII will involve a goal-oriented and collaborative conversation about why the client wants treatment now, and how treatment might fit with his/her most important values. The provider will use open questions, reflective listening and autonomy support in a flexible, non-authoritative manner. Rather than asking specific questions in different life domains, the provider will explore with the client their desires, abilities, reasons, and needs for treatment, how treatment fits with their values, and what successful treatment looks like to them. The client's language about change will be strategically reinforced to increase its frequency and strength across the session.
41510085|NCT04775615|DRUG|DDO-3055 tablets；Placebo|High dose：DDO-3055 tablets for 7 days or Placebo for 7 days
41385371|NCT05489068|BEHAVIORAL|Intake as Usual (IAU)|In line with the American Society of Addiction Medicine (ASAM) guidelines, the IAU condition involves a semi-structured interview of the client's psychosocial history and clients answer a series of questions in the following domains: support system, living situation, educational, occupational, family, and medical history.
41385372|NCT02536625|OTHER|prospective study|
41385373|NCT01254994|DRUG|entecavir|Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
41166196|NCT02163798|BEHAVIORAL|12-week instructor-led Tai Chi training program|A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
41385374|NCT01254994|DRUG|Traditional comprehensive medical treatment|bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
41385375|NCT04645342|DEVICE|Baylis Versacross RF wire|Baylis Versacross radiofrequency wire is used for transseptal puncture during cardiac ablation procedure.
41385376|NCT04645342|DEVICE|Baylis RF needle|Baylis radiofrequency needle is used for transseptal puncture during cardiac ablation procedure.
41385377|NCT04611152|DRUG|KSI-301|Intravitreal Injection
41385378|NCT04611152|DRUG|Aflibercept|Intravitreal Injection
41385379|NCT04611152|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
41510086|NCT00996489|DEVICE|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
41510087|NCT03257865|DRUG|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
41510088|NCT03257865|DRUG|Placebo|Administered orally daily for 3 weeks.
41510089|NCT04944524|DRUG|Tofacitinib|"1. Tofacitinib 5mg twice a day for 12months;~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
41166197|NCT02163798|BEHAVIORAL|12-week instructor-led brisk walking training program|A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
41510090|NCT04944524|DRUG|Methotrexate|"1. Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week)~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
40854738|NCT05052567|DRUG|CEND-1|The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine
40854739|NCT02457676|BEHAVIORAL|Alert Program for Self-Regulation|"Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations."
40854740|NCT01698723|DRUG|Ribavirin|
40854741|NCT01698723|DRUG|Placebo|
41166198|NCT02883179|DRUG|lidocaine injection|anhydrous solution
41385380|NCT00852072|PROCEDURE|Single-operator cholangioscopy-guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
41385381|NCT00852072|PROCEDURE|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
41385382|NCT06248671|DRUG|Atorvastatin 40mg|Each tablet will be taken once daily for 84 days.
41385383|NCT06248671|DRUG|Placebo|Each tablet will be taken once daily for 84 days
41385384|NCT06248671|DRUG|Atorvastatin 20mg|Each tablet will be taken once daily for 84 days.
41385385|NCT06566950|PROCEDURE|Low load-BFRt|The participants' two legs will be subjected to 70% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as stairs, single leg squat, and single leg deadlift.
41510091|NCT05311904|OTHER|Survey|1 initial questionnaire and 1 monthly follow-up questionnaire for 11 months
41385386|NCT06566950|PROCEDURE|Sham Low load-BFRt|The participants' two legs will be subjected to 10% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as stairs, single leg squat, and single leg deadlift.
41385387|NCT06566950|PROCEDURE|High load-Eccentric training|The physical therapist will instruct the participants to complete eccentric exercises at a maximum of 70% repetitions, such as stairs, single leg squat, and single leg deadlift.
41385388|NCT04782687|DRUG|Selinexor|oral drug that comes in 20 mg tablets
40854742|NCT06060587|DRUG|Docetaxel|75 mg/m2 via IV
40854743|NCT06060587|DRUG|ADT|Prior to randomization as part of standard of care.
40854744|NCT06060587|DRUG|Abiraterone|1000 mg by mouth
40854745|NCT06085781|OTHER|fMRI|Functional Magnetic Resonance Imaging
40854746|NCT06085781|OTHER|Oral Pimonidazole|200 mg and 300 mg tablets
41037397|NCT06390241|DRUG|Avidin-biotin-Dota-90Y|Within 7-8 days after the VABB procedure, 6-10 mg avidin in 1 ml saline will be administered at the site of the occult carcinoma. Subsequently, 90Y DOTA-biotin in the range of 28-57-126 MBq (3 activity levels investigated) will be injected locally immediately after avidin injection.
41385389|NCT04782687|DRUG|Dexamethasone Oral|Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those \>75 years old may be administered a weekly dose of 20 mg dexamethasone.
41385390|NCT04782687|DRUG|Daratumumab|"Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter."
41385391|NCT04782687|DRUG|Lenalidomide|Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle
41385392|NCT05828745|DRUG|CB06-036|CB06-036 capsule
41385393|NCT05828745|DRUG|Placebo|Placebo capsule
41385394|NCT06565572|DRUG|nL-FLVC-001|nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous
41385395|NCT02032823|DRUG|Olaparib|Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
40854747|NCT03775512|DEVICE|RF Ablation with QDOT Micro|Subjects will be ablated using QDOT Micro catheter
40854748|NCT02905669|DEVICE|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
40854749|NCT03795727|DEVICE|MD ring and precontoured sectional matrix by TOR VM|MD ring (separation ring) and precontoured sectional matrix (thickness 0.035mm hard) and a wedge was used to secure matrix in place
40854750|NCT03795727|DEVICE|Circumferential matrix and tofflemire retainer by Kerr|Circumferential matrix (thickness 0.038mm) applied by tofflemire retainer and secured in place with wedge
41037398|NCT02015676|DRUG|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
40854751|NCT00763841|DEVICE|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
41385396|NCT02032823|DRUG|Placebo|Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
41385397|NCT01284725|DRUG|mycophenolate mofetil or azathioprine|
41385398|NCT01284725|OTHER|immunosuppressive treatment discontinuation|
41385399|NCT06441955|DRUG|Ritonavir-Boosted Nirmatrelvir (Paxlovid)|"Participant Selection and Baseline Data Collection: 6 months~* Longitudinal Observation and Intervention Implementation: 24 months~* Data Analysis and Findings Dissemination: 6 months Evaluate methodological advantages and limitations of an international pharmacosurveillance system based on electronic health records (EHRs). Adverse outcome; Electronic health record; Health informatics; Medication adherence; Pharmacoepidemiology; Pharmacosurveillance; Risk assessment."
40854752|NCT00763841|DEVICE|Sham|
40854753|NCT01949610|DRUG|14C-JNJ26489112|Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
40854754|NCT02780284|BEHAVIORAL|Physical activity intervention|150 minutes per week of moderate intensity cardiovascular exercise. The exercise sessions will include a minimum of 30 minutes of exercise each day, 3 to 5 times per week for a total of 150 minutes of exercise per week.
40854755|NCT02481739|OTHER|retrospective study|
40854756|NCT00543777|DIAGNOSTIC_TEST|Magnetic Resonance Elastogram|Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.
40854757|NCT00543777|DIAGNOSTIC_TEST|2-Point Dixon Magnetic Resonance Imaging|Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
40854758|NCT05014997|OTHER|no intervention|this study was designed as retrospective observational study
40854759|NCT05736601|DEVICE|focus motion knee brace|knee brace that captures knee motion
40854760|NCT02436538|OTHER|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
40854761|NCT00093652|DRUG|gefitinib|
40854762|NCT00093652|DRUG|oxaliplatin|
41037399|NCT02015676|DRUG|paclitaxel|60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression
41037400|NCT02015676|DRUG|Myocet|40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
41037401|NCT03349450|BIOLOGICAL|DPX-Survivac|DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
41037402|NCT03349450|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
40854763|NCT00093652|PROCEDURE|conventional surgery|
40854764|NCT00093652|PROCEDURE|neoadjuvant therapy|
40854765|NCT00093652|RADIATION|radiation therapy|
40854766|NCT01894932|BEHAVIORAL|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams \& Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
40854767|NCT01894932|BEHAVIORAL|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
40854768|NCT00066963|DEVICE|Fluoride Varnish|0.1 mL (1 drop) applied on each of 2 arches
40854769|NCT02037906|RADIATION|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
40854770|NCT02037906|RADIATION|Constant Energy SWL|Constant dose at 20 kv
40854771|NCT02037906|RADIATION|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
40854772|NCT04224961|DEVICE|Respiratory Muscle Training|Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.
40854773|NCT06426836|OTHER|Amoxicillin-clavulanate|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
40854774|NCT06426836|OTHER|Piperacillin-tazobactam|blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
40854775|NCT06426836|OTHER|Meropenem|blood sampling in patients receiving meropenem as part of routine clinical care.
40854776|NCT06426836|OTHER|Cefazolin|blood sampling in patients receiving cefazolin as part of routine clinical care.
40854777|NCT06426836|OTHER|Vancomycin|blood sampling in patients receiving vancomycin as part of routine clinical care.
40854778|NCT06426836|OTHER|Teicoplanin|blood sampling in patients receiving teicoplanin as part of routine clinical care.
40854779|NCT06426836|OTHER|Ciprofloxacin|blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
40854780|NCT06426836|OTHER|Amikacin|blood sampling in patients receiving amikacin as part of routine clinical care.
40854781|NCT02167516|DRUG|glucosamine sulfate|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
40854782|NCT02167516|DRUG|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
40854783|NCT05293184|OTHER|Observational study only|
40854784|NCT04316637|DRUG|Arimoclomol|Participants receive prescribed arimoclomol by oral administration
40854785|NCT05727982|DIAGNOSTIC_TEST|Venous blood samples, Biological samples analysis, Cardiology visit.|These interventions are important to study all patients recruited
40854786|NCT01456312|DRUG|Peginterferon alfa-2a|Duration and combination
40854787|NCT01456312|DRUG|Entecavir|combination
40854788|NCT01769196|DRUG|Simtuzumab|125 mg/mL single-dose vials administered subcutaneously once a week
40854789|NCT01769196|DRUG|Simtuzumab placebo|Simtuzumab placebo single-dose vials administered subcutaneously once a week
40854790|NCT02523781|OTHER|information pamphlet|The intervention group receives the information pamphlet
40854791|NCT06038734|DIAGNOSTIC_TEST|gastric ultrasound|Utilize POC gastric ultrasound to identify the presence of retained gastric contents.
40854792|NCT04983355|DIETARY_SUPPLEMENT|Fish Hydrolysate|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
40854793|NCT04983355|DIETARY_SUPPLEMENT|Placebo|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
40854794|NCT00286429|DRUG|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
40854795|NCT00286429|DRUG|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
40854796|NCT00286429|DRUG|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
40854797|NCT06317168|DIAGNOSTIC_TEST|Mean awake ambulatory BP measurements|Results from all four arms will be compared to the mean awake ambulatory BP measured on the same arm and started immediately following completion of the testing protocol.
40854798|NCT05287893|DRUG|Pyronaridine|Single dose
40854799|NCT05287893|BIOLOGICAL|P. falciparum IBSM infection|Induced Blood Stage Malaria
40854800|NCT05494359|DIAGNOSTIC_TEST|The nitrogen isotope|The nitrogen isotope of various mass in oral gas were detected.
40854801|NCT04109326|OTHER|APAD|"8 PA sessions supervised at the hospital centers and 44 unsupervised home sessions, to be performed twice a week.~6 consultations for nutrition education to teach the principles of well balanced diet, to foster weigh control during treatment, and to induce appropriate feeding behaviors after treatment."
40854802|NCT06367283|DRUG|Metformin|Metformin will be initiated at 500 mg once daily with breakfast meal. The dose will be increased with 500 mg every week until 2 g/day is reached, distributed as 1000 mg every morning and evening, together with a meal. If the subject cannot tolerate the maximum dose (2 g/day), the maximal tolerated dose will be given. The treatment period including titration is 16 weeks.
40854803|NCT06367283|DRUG|Placebo|Participants in the placebo group will receive a placebo tablet identical to the metformin tablet
40854804|NCT02762331|DRUG|Ascorbic Acid|Comparing safety and efficacy of IV Vitamin C in CABG patients
40854805|NCT02762331|DRUG|Placebo|Placebo intervention
40854806|NCT01445080|OTHER|Laboratory Biomarker Analysis|Correlative studies
40854807|NCT01445080|OTHER|Pharmacological Study|Correlative studies
40854808|NCT01445080|DRUG|Sorafenib Tosylate|Given orally
40854809|NCT03384875|DEVICE|CytoSorb|To evaluate the safety and performance of the CytoSorb® device to decrease the incidence or severity of acute kidney injury (AKI)
40854810|NCT03628976|OTHER|tVNS|Intervention
40854811|NCT03628976|OTHER|Motor training|Same finger training for both arms
40854812|NCT00908804|PROCEDURE|open appendectomy|
40854813|NCT00908804|PROCEDURE|laparoscopic appendectomy|
40854814|NCT01755728|DRUG|Paracetamol|Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
40854815|NCT01755728|DRUG|Ibuprofen|Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
40854816|NCT01755728|PROCEDURE|Closure of PDA|Open surgery for closure of PDA
40854817|NCT04274335|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|1 gram of tranexamic acid to be administered intravenously
40854818|NCT04274335|DRUG|Tranexamic Acid Oral Solution|4 grams of tranexamic acid given as an oral solution
40854819|NCT04274335|DRUG|Tranexamic Acid Injectable Product|1 gram of tranexamic acid given as 2 separate intramuscular injection
40854820|NCT04655092|BIOLOGICAL|P1101 (Ropeginterferon alfa-2b)|The subjects who have completed the 52-week treatment duration in Study A19-201 will be treated with P1101, starting at the dose at Week 50. The dose during this study may be increased or decreased up to 500 μg depending on the condition. This study will be continued as a post-marketing clinical study after acquisition of the marketing approval of P1101.
40854821|NCT00928694|DRUG|fenofibrate (U.S. formulation)|Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.
41385400|NCT06441955|DIAGNOSTIC_TEST|Physiological Evaluation|Common Medical laboratory work-up, Cancer screening test, Biomarkers, tissue biopsy, blood specimen, diagnostic imagining, Sensitivity and Specificity, HIV PCR, Viral load ( antigen), CD4- T cell count, while implementation of social mediators of prevention, promotion studies and conceptual models and quality of care.
41385401|NCT06441955|BIOLOGICAL|Moderna COVID-19 Vaccine|Single dose, 0.25 mL If previously vaccinated, ≥2 months after receipt of the last previous dose of COVID-19 vaccine
40854822|NCT00928694|DRUG|fenofibrate (UK formulation)|Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.
40854823|NCT04702022|DIAGNOSTIC_TEST|18FDG PET / CT|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.
40854824|NCT02650063|DRUG|DE-117|
40854825|NCT04922138|DRUG|Aumolertinib|All subjects who meet the enrollment conditions will be included in the Aumolertinib monotherapy group: Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day until recurrence or completion of treatment or reaching the standard of discontinuation.
40854826|NCT04440813|BEHAVIORAL|Education and Training by Clinicians|Training in the use of PPE and education about the risks of blood exposure.
40854827|NCT04440813|BEHAVIORAL|Training and Education from Traditional Healers and Clinicians|Training in the use of PPE and education about the risks of blood exposure.
40854828|NCT04284475|DIAGNOSTIC_TEST|Quadriceps strength|Using a handheld dynamometer, in supine position in a standardized position of the dominant leg Measurement of the maximal isometric voluntary quadriceps contraction Measure expressed as Newton and Newton/kg
40854829|NCT04284475|DIAGNOSTIC_TEST|Grip strength|Testing of dominant hand using a handgrip Measurement of the maximal isometric voluntary grip contraction Measure is expressed as kg
40854830|NCT04284475|DIAGNOSTIC_TEST|ICU mobility scale|Scoring the physical capacity of the patient on a 10-points validated scale: the ICU mobility scale
40854831|NCT00731146|OTHER|Ultrasound Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
40854832|NCT00731146|OTHER|Nerve Stimulator Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
40854833|NCT04736628|DRUG|Avenciguat|Avenciguat
40854834|NCT04736628|DRUG|Placebo|Placebo
40854835|NCT06443684|DIAGNOSTIC_TEST|MRD|MRD（LC-10）include 10 lung cancer-related driver gene mutation site
40854836|NCT01918280|PROCEDURE|Seminal analyses and testicular biopsy|Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
40854837|NCT06477185|DRUG|Doxycycline|Doxycycline is a bacteriostatic tetracycline antibiotic with ability to immunomodulate matrix metalloproteinases, enzymes well known to cause lung damage via breakdown lung extracellular matrix.
40854838|NCT06477185|DRUG|Placebo|This will be a chemically inert substance, designed to match oral doxycycline capsules but with no chemically active ingredients.
40854839|NCT04666896|OTHER|Tailored home-based exercise therapy|exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.
41166199|NCT02883179|DRUG|lidocaine-prilocaine cream|topical cream
41385402|NCT06441955|BEHAVIORAL|Biopsychological|Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
41385403|NCT06441955|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
41385404|NCT06441955|GENETIC|Genetic (including gene transfer, stem cell and recombinant DNA)|Full genome sequencing, complete genome sequencing, or entire genome sequencing, is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time to address the intersection of genomics and health disparities, recognizing that genetic variations can contribute to health disparities in several ways. Understanding these genetic contributions to health disparities is crucial for developing targeted interventions and personalized healthcare strategies that can help address these disparities. genetics, epidemiology, public health, and social sciences, the study aims to shed light on the complex interplay between genomics and health equity. To evaluate cellular errors and the effects of myocardial DNA, you may need to consider tests such as DNA sequence.
41385405|NCT06441955|COMBINATION_PRODUCT|Multidisciplinary approach|The aim of utilizes psychology-applied science and science in nursing frameworks to address health disparities and promote health and wellness across the health span to improve patient population outcomes, evaluate cost-effectiveness, and patient health literacy competencies. The experimental framework of a compilation of the bio-psychosocial model, Eric Erickson developmental stages, AI/AML, and cognitive learning theories address system decision making factors, for sound decision making and behavioral change cognitive behavioral therapies protocol segmentation demographic and urban areas affected by social-economic access to healthcare and related ethical stance of United States healthcare policy developmental outlines. Biology plays a role in the content of development stages, and the great debate of nurture vs. nature sets the foundation for addressing the psychosocial approach to healthcare integration as an applied science model for strengthening primary services and improving
41385406|NCT06565637|BEHAVIORAL|Promoting Resilience to Improve Disordered Eating|"See description under Arms"
41385407|NCT00431574|PROCEDURE|dosing|
41385408|NCT04265209|DRUG|SPECT|\[123I\]-FP-CIT SPECT imaging procedure
41385409|NCT04265209|DRUG|PET|\[18F\] LBT-999 PET imaging procedure
41510092|NCT03031418|DIAGNOSTIC_TEST|ExoDx Prostate Intelliscore|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
41510093|NCT05018377|PROCEDURE|Racz adhesolysis|adhesiolysis in failed back surgery
41385410|NCT01136044|OTHER|septocutaneous perforator flap|Perforator flaps can be based on septocutaneous or musculocutaneous perforators. If septocutaneous perforators are present, the harvest of these flaps is more straight forward and the dissection of the pedicle is easy.
41385411|NCT05235737|DRUG|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
41385412|NCT05235737|DRUG|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
41385413|NCT03212443|PROCEDURE|Suprascapular nerve- axillary nerve block combination|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
41510094|NCT05018377|DEVICE|NAVI adhesolysis|adhesiolysis in failed back surgery
41528338|NCT04287257|DEVICE|Fracture Healing Patch (FHP)|The Fracture Healing Patch (FHP) is an external silicone patch that contains inside micro-electronic modulus, which generates a pulsed electromagnetic field (PEMF) to enhance and improve fracture healing. The FHP is placed under the cast at the fracture site. Throughout the treatment period the FHP produces a pulsed electromagnetic field. The FHP houses a battery, a microelectronic module and a coil that produce the PEMF.
40854840|NCT04666896|OTHER|Standard home-based exercise therapy|The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
40854841|NCT06011369|PROCEDURE|Fluorescence in thyroid surgery|Fluorescence in thyroid surgery
40854842|NCT05219058|PROCEDURE|Biological mesh reconstruction|Patients receiving biological mesh of any kind or position as part of their reconstruction during surgery.
41166200|NCT04891471|RADIATION|Stereotactic RadioTherapy|To treat only brain metastasis identified through Magnetic Resonance imaging by means of stereotactic radiotherapy (experimental intervention) to determine if sparing of clinically uninvolved brain implies a better neurocognitive performance, quality of life and level of autonomy in activities of daily living respect to Whole Brain Irradiation (active comparator).
41166201|NCT04891471|RADIATION|Whole Brain Irradiation|To irradiate the entire brain, site of at least 5 parenchymal metastasis.
40854843|NCT05219058|PROCEDURE|Myocutaneous flap reconstruction|Patients receiving a myocutaneous flap of any kind as part of their reconstruction during surgery.
40854844|NCT05219058|PROCEDURE|Primary closure reconstruction|Patients receiving primary closure only using any suture material or technique as part of their reconstruction during surgery.
41385414|NCT03212443|PROCEDURE|Subacromial infiltration|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
41385415|NCT04553692|DRUG|Aplitabart (IGM-8444)|DR5 Agonist Investigational Drug
41385416|NCT04553692|DRUG|FOLFIRI|Chemotherapy Regimen
41385417|NCT04553692|DRUG|Bevacizumab (and approved biosimilars)|Targeted Therapy
41385418|NCT04553692|DRUG|Birinapant|SMAC-mimetic Investigational Drug
41385419|NCT04553692|DRUG|Venetoclax|Targeted Therapy
41385420|NCT04553692|DRUG|Gemcitabine|Chemotherapy
41385421|NCT04553692|DRUG|Docetaxel|Chemotherapy
41385422|NCT04553692|DRUG|Azacitidine|Chemotherapy
41385423|NCT03406611|DRUG|Pegtibatinase|Pegtibatinase sterile solution for subcutaneous injection
41385424|NCT03406611|DRUG|Placebo|Normal saline for subcutaneous injection
41510095|NCT00695058|DEVICE|Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.~In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.~In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw."
41385425|NCT03480165|DRUG|Parecoxib 20 MG/ML|1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)
41385426|NCT03480165|DRUG|Ropivacaine|19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
41385427|NCT06257966|DRUG|Exendin-4 Fc fusion protein injection(1.2mg）|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
41385428|NCT06257966|DRUG|Exendin-4 Fc fusion protein injection（2.4mg）|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
41510096|NCT05185765|OTHER|Bread|Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.
41510097|NCT06553352|DRUG|Zanubrutinib combined with Obinutuzumab|Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.
41385429|NCT06257966|DRUG|Dulaglutide|1.5 mg dulaglutide injection subcutaneously once a week for 54 weeks.
41510098|NCT00904657|DRUG|sunitinib (Sutent)|50 mg capsule Sutent, one application a day for five days
41510099|NCT01525914|DRUG|Dutasteride|dutasteride 0.5mg daily
40854845|NCT02449590|DIETARY_SUPPLEMENT|Onion powder|Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.
41385430|NCT06257966|DRUG|Metformin|Metformin hydrochloride tablets, oral administration, 54 weeks of treatment
41385431|NCT05619627|DRUG|Dexmedetomidine|Patients will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI
41385432|NCT05619627|DRUG|General anesthetic|Patients will receive inhalational anesthetic to provide general anesthesia for undergoing MRI
41385433|NCT05358795|BEHAVIORAL|Family Connections|Family Connections is based on the WHO endorsed Positive Connections manual.
41528339|NCT06211686|OTHER|Protein powder and Resistance exercise|"1. Protein powder supplementation 25-30 g/day~2. Resistance exercise 2 time/week"
40854846|NCT02449590|DIETARY_SUPPLEMENT|Placebo|Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
40854847|NCT02829580|PROCEDURE|Echocardiography|Measures by Doppler and study of endothelial function
40854848|NCT03636646|DEVICE|X.ray|Surgical treatement of posterior acetabular wall fractures
40854849|NCT05934903|DEVICE|Transcranial Direct Current Stimulation|Cathodal direct current stimulation at 0 or 2mA will be applied to subjects
40854850|NCT01505439|DRUG|solifenacin|oral
41037403|NCT03349450|DRUG|Cyclophosphamide 50mg|Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
41385434|NCT01759056|DRUG|AVX 470|active comparator
41385435|NCT01759056|DRUG|Placebo|
41385436|NCT00638118|DRUG|Fexofenadine|
41385437|NCT01772394|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
41385438|NCT01772394|BEHAVIORAL|Sham Therapy|The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
41385439|NCT01879709|BEHAVIORAL|Yoga Training|Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
41385440|NCT01879709|BEHAVIORAL|Physical Exercise|This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
40854851|NCT01119092|OTHER|"Sham (laying of hands) intervention"|The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
40854852|NCT01119092|OTHER|Grade IV AP joint mobilizations|3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
40854853|NCT06030167|BEHAVIORAL|Insecure attachment and psychosocial functioning in autistic adults|Questionaires about attachment, psychosocial functioning, depressive symptoms, paranoid ideation, and emotion regulation were administered to 83 autistic adults (50 males, 33 females).
40854854|NCT03124836|DEVICE|Pulse Oximeter Sensor|
41385441|NCT01879709|OTHER|Treatment as Usual|"Placebo Comparator: Treatment as Usual Group~Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided"
40854855|NCT01020552|OTHER|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
40854856|NCT04492111|PROCEDURE|post-extraction dental implant|Insertion of a dental implant immediately after tooth extraction.
40854857|NCT04840329|BEHAVIORAL|Education|One-time educational session about menstrual health and endometriosis
41385442|NCT06173765|OTHER|freeze-dried whole strawberry powder 36 g powder|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 3 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (36 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
41385443|NCT06173765|OTHER|freeze-dried whole strawberry powder 12 g|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 1 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (12 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
41385444|NCT06173765|OTHER|freeze-dried control powder 0 g strawberry|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 0 cup FW equivalent of strawberries. The freeze-dried powder is used as a control.~All drinks will be standardized to 41 g powder to match USDA Control arm."
41385445|NCT05650658|DEVICE|His/LBBP|Pacing at the level His-Bundle or left bundle branch is used to correct the underlying conduction abnormality, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular defibrillator endocardial lead for LVEF≤35% and by a right atrial endocardial lead for LVEF 36-50%.
41385446|NCT05650658|DEVICE|BiVP|"Biventricular pacing has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.~For LVEF≤35% a biventricular pacemaker-defibrillator will be implanted while for LVEF 36-50% a biventricular pacemaker will be implanted."
41385447|NCT06537531|OTHER|Compare VCI scale|Compare VCI scale
41510100|NCT01988129|OTHER|Sleep disorders education and screening|Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
40854858|NCT00544037|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
40854859|NCT05740943|DRUG|Lorlatinib|Patients were assigned to receive oral lorlatinib at a dose of 100 mg daily in a course of treatment that was measured in cycles of 28 days. 3 cycles of induction treatment will be required for the study.
40854860|NCT00352430|DRUG|Nitric Oxide/INP Pulse Delivery|
40854861|NCT00352430|DRUG|Nitric Oxide/INO Pulse Delivery|
40854862|NCT06075407|DEVICE|Assessment of fluid responsiveness by electrical cardiometry|"Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotropic, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3).~Transthoracic echocardiography (TTE) measurements will be performed equipped with echo probe. SV of the left ventricle will be calculated using LVOT diameter (D) just below the aortic valve from parasternal long-axis view and VTI measured in LVOT from apical 5 chamber view (by pulsed wave Doppler)."
40854863|NCT06267534|DEVICE|mindfulness-based mobile applications program|Every two days is the same practice sound file, which must be practiced in order, so each sound file will be locked, for example: 9/9, 9/10 listen to the first sound file practice, 9/11, 9/12 listen to the second Practice with two sound files... and so on. After two days, the sound files will be automatically unlocked, and the subjects can continue to practice. The first ten days need to be practiced in order. From the eleventh day, each sound file will be unlocked. You can choose an audio file to practice, and the page will record the time and items of the practice, and you can also use text to record your experience after the practice
40854864|NCT01900652|DRUG|Emibetuzumab|Administered IV
40854865|NCT01900652|DRUG|Erlotinib|Administered Orally
40854866|NCT03488277|OTHER|leg elevation|intra operative position that consists in leg elevation with a 30 cm height pillow under the patient's heels
40854867|NCT02956941|BEHAVIORAL|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
40854868|NCT04797351|BEHAVIORAL|Dialectical Behavior Therapy - Skills|Pre-treatment session + 12 sessions DBT Skills Group (only) intervention
41385448|NCT02277548|DRUG|Lyrica 300 mg|Lyrica 300 mg per day
41385449|NCT02277548|DRUG|Placebo|
41385450|NCT05394831|DRUG|JIN-A02|PO, QD
41385451|NCT01610284|DRUG|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
40854869|NCT01711125|DRUG|Baclofen 30mg/day|30mg/day 10 mg t.i.d
41385452|NCT01610284|DRUG|BKM120|BKM120 100 mg once daily
41385453|NCT01610284|DRUG|BKM120 matching placebo|BKM120 matching placebo, once daily
41510101|NCT05228431|DRUG|XELOX|Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.
40854870|NCT01711125|DRUG|Baclofen 75mg/day|75mg/day 25 mg t.i.d
40854871|NCT01711125|DRUG|Placebo|Placebo 3 matched tabs/day
40854872|NCT03105349|DRUG|elbasvir/grazoprevir|16 weeks treatment
40854873|NCT03105349|DRUG|Sofosbuvir|16 weeks treatment
40854874|NCT03105349|DRUG|Ribavirin|16 weeks treatment
40854875|NCT01855360|DRUG|Tauroursodeoxycholic Acid and Doxycycline|
40854876|NCT05729243|DRUG|Cytisine|Cytisine is a nicotinic acetylcholine receptor partial agonist and is a natural health product approved by Health Canada. Cytisine has been used for a long time in Europe for smoking cessation.
40854877|NCT05729243|OTHER|Placebo|A placebo identical in appearance to cytisine will be used
40854878|NCT02696213|OTHER|Systematic, Comprehensive, One to One Training (SCOOT)|An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
40854879|NCT02696213|OTHER|Six Week Delay|Participants will begin the SCOOT intervention after a six week delay.
41385454|NCT06260007|DRUG|Tribulus terrestris|Tribulus terrestris
41385455|NCT06260007|OTHER|Placebo|Placebo
41385456|NCT00571909|PROCEDURE|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
40854880|NCT00284219|DEVICE|Transcranial Magnetic Stimulation 10Hz|3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
40854881|NCT00284219|DEVICE|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
40854882|NCT00034827|DRUG|CI-1040|
40854883|NCT01413139|DEVICE|4F portfolio products from Biotronik|4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
40854884|NCT04254601|DEVICE|Narrow band ultraviolet B.|NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)
40854885|NCT04254601|DRUG|topical erythromycin cream 2% (Akne-Mycin- Egypt)|"two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves"
41385457|NCT05517005|DIETARY_SUPPLEMENT|Hype Bites Supplement|"The ingredients of the vitamin supplement are:~Chocolate liquor Sugar Cocoa butter Vanilla extract Vitamin B12 (as methylcobalamin) Tapioca Gum arabic Coloring (radish, apple, black currant) Carnauba Wax"
41385458|NCT03341715|DRUG|Mavoglurant (AFQ056)|2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
41385459|NCT03341715|OTHER|Placebo|Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
41385460|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
41385461|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
41385462|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
40854886|NCT03363620|DEVICE|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
40854887|NCT03363620|DEVICE|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
40854888|NCT05334628|PROCEDURE|Preoperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position.
41385463|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
41385464|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
41385465|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
41385466|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
41385467|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
41385468|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
41385469|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
41385470|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
41385471|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
41385472|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
41385473|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
41385474|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
41385475|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
41385476|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
40854889|NCT05334628|PROCEDURE|Postperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the lateral decubitus position.
40854890|NCT05220358|DRUG|Fostemsavir 600 MG [Rukobia]|FTR 600 mg PO BID added to daily suppressive HIV regimen
40854891|NCT05630677|DRUG|AZD5055 solution for infusion|Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.
40854892|NCT05630677|DRUG|AZD5055 oral suspension|Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.
40854893|NCT05630677|DRUG|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.
40854894|NCT05630677|DRUG|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)
40854895|NCT05630677|DRUG|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions \[Study Day 10 to 18\].
40854896|NCT05630677|DRUG|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
40854897|NCT01847989|DRUG|catridecacog|Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
40854898|NCT01847989|DRUG|placebo|Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
40854899|NCT02067936|DRUG|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
40854900|NCT02067936|DRUG|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
40854901|NCT02067936|DRUG|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
40854902|NCT02067936|DRUG|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
41166202|NCT06400797|OTHER|estimation of patient outcome by health care providers|On day 1 after study inclusion as well as day 4-7, the responsible health-care providers (at least one nurse, one resident and one consultant with the board certification intensive care medicine) will estimate the patient's expected functional outcome at 6 and 12 months after the start of ECMO therapy. Health-care providers responsible for the patient at that time will be surveyed (multiple questionnaires to detect specific differences within one person are not planned). For the purpose of functional outcome estimation, the modified Rankin scale (mRS) is used.
41166203|NCT01344499|PROCEDURE|Carbon dioxide|standard pneumoperitoneum with 100% CO2
41510102|NCT05228431|DRUG|Capecitabine monotherapy|During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.
40854903|NCT05465291|PROCEDURE|Exercise group|This group will receive passive/active range of motion (ROM) exercises. ROM exercises will include major muscle groups (i.e. biceps, triceps, and lower limbs) and will be applied from second day till seventh day of admission .
40854904|NCT05465291|PROCEDURE|Neuromuscular Electrical Muscle Stimulation group|"* Patients in NEMS group will receive neuromuscular electrical stimulation from second day till seventh day of admission.~* Neuromuscular electrical stimulation will be implemented simultaneously on the rectus femoris, vastus lateralis, and vastus medialis muscles of both lower limbs, with two stimulators, in two 30-min sessions per day starting from the second day till seventh day of admission ."
40854905|NCT05465291|PROCEDURE|Neuromuscular Electrical Muscle Stimulation and Exercise group|Patients in this group will be subjected to Neuromuscular Electrical Muscle Stimulation and Exercise.
40854906|NCT03144375|OTHER|Medical optimization and education|Medical treatment and education about the sinusitis disease process prior to surgery as compared to baseline surgical and treatment counseling
41166204|NCT01344499|PROCEDURE|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
41166205|NCT01344499|DRUG|Adept|instillation of 1 liter of fluid at the end of laparoscopy
41510103|NCT05228431|RADIATION|Radiation|The TV is expanded by 6-7mm to form PTV1, and the CTV is expanded by 6-7mm to form PTV2. The dose of PTV1 was 50Gy/25 times/35 days, and the dose of PTV2 was 45Gy/25 times/35 days, 5 times/week for a total of 5 weeks.
40854907|NCT03144375|PROCEDURE|Standard of Care sinus surgery|
40854908|NCT00117299|DRUG|PTK787/ZK222584|PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
41166206|NCT01344499|DRUG|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
41166207|NCT05510622|OTHER|Vaginal swab and endometrial biopsy|A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
41166208|NCT05089604|DRUG|Tacrolimus, Immediate Release, Oral|Twice Daily Tacrolimus
41166209|NCT05089604|DRUG|Tacrolimus Extended Release Oral Tablet|Once Daily Tacrolimus
41166210|NCT02169921|DEVICE|Atherectomy Catheter|"Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.~TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are participated in this arm."
40854914|NCT00500955|DRUG|Rosiglitazone|
40854915|NCT01874444|DEVICE|1|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS
41166211|NCT05530382|OTHER|self-guided learning|video-based self-directed learning for medical device training
41166212|NCT02554383|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
41166213|NCT02554383|DRUG|Placebo|placebo made to match the study antibiotic given twice a day orally for 10 days
40854916|NCT01874444|DEVICE|2|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
40854917|NCT01874444|DEVICE|3|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
40854918|NCT01874444|DEVICE|4|"Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
41385477|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
40854919|NCT00851279|DEVICE|Magnetic irrigated ablation catheter|Magnetic irrigated catheter to be used with the magnetic navigation system
40854920|NCT01771250|BIOLOGICAL|Insulin Peglispro|Daily doses administered SC.
40854921|NCT01771250|BIOLOGICAL|Insulin Glargine|Daily doses administered SC.
40854922|NCT01794260|DRUG|Cream from Zingiber cassumunar Roxb. extract|
40854923|NCT01794260|DRUG|Placebo cream|
40854924|NCT02956317|DRUG|STP705|The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
40854925|NCT02956317|DRUG|Placebo|Normal Saline
40854926|NCT02069392|BEHAVIORAL|Cognitive remediation training|
40854927|NCT02069392|DRUG|Nicotine polacrilex lozenge|Of interest are the effects of nicotine on cognitive remediation training benefits.
40854928|NCT06544512|OTHER|progressive relaxation exercise|looking at pain and anxiety by practicing progressive relaxation exercises
41166214|NCT03739671|DIETARY_SUPPLEMENT|Vitamin D|Group will receive 5000 units of vitamin D daily
41166215|NCT03739671|DIETARY_SUPPLEMENT|No Vitamin D|No vitamin D supplementation
41385478|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
41510104|NCT05308433|DEVICE|Functional MRI|The volunteer will have to imagine the smells evoked by different visual aids. This task will be carried out during 2 acquisition runs of about 10 minutes each. The volunteer should note (on a scale from 1 to 4) the pleasantness of the smell evoked.
40854929|NCT05858372|DIETARY_SUPPLEMENT|Chios Mastiha essential oil|1 soft gel capsule containing 200 mg of CMO and 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol
40854930|NCT05858372|OTHER|Placebo|Placebo
40854931|NCT04068116|PROCEDURE|Primary per-cutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty \& coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion \& reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
40854932|NCT04057521|OTHER|Care Coordination|Comprehensive care coordination.
40854933|NCT04231604|BEHAVIORAL|A Lust for Life|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in adolescents. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the adolescents' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
40854934|NCT04231604|BEHAVIORAL|Waiting list control|Control group placed on a twelve-week waiting list.
40854935|NCT04294602|OTHER|Exercise|Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.
40854936|NCT04294602|OTHER|Low Level Laser Therapy|LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points.
41166216|NCT02216149|DRUG|S-1|S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
41166217|NCT02216149|DRUG|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
41166218|NCT02216149|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1 every 3 weeks
41385479|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
41385480|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
41385481|NCT01289990|DRUG|Sitagliptin 100mg|Sitagliptin once daily
41385482|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
41510105|NCT05308433|OTHER|Virtual Reality: control|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. In the center of the maritime scene, it will be visible the black outlines of a frame. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
41385483|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
41385484|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
41385485|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
41385486|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
41385487|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
41385488|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
41385489|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
41385490|NCT06537947|PROCEDURE|Endovascular intervention using the SENTANTE endovascular robotic system|"1. Diagnostic procedure - placement of diagnostic catheter to intended vessel and performing angiography.~2. Percutaneous transluminal angioplasty (PTA)/stenting procedure - placement of balloon catheter or balloon expandable stent to intended vessel and effectively expanding it up to nominal pressure.~3. Coiling procedure - implantation of pushable coils or liquid embolization materials (such as microspheres) to an intended vessel."
41385491|NCT02163694|DRUG|Veliparib Placebo|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
41385492|NCT02163694|DRUG|Veliparib|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
40854937|NCT04294602|OTHER|Manuel Pressure Release|MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, manuel pressure applied trigger point in neck and mactication muscles
41510106|NCT05308433|OTHER|Virtual Reality: experimental|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. The visual support inserted in the center of the virtual scene will be the one defined as being the most facilitator of the olfactory imagination during the fMRI examination. The volunteer will be asked to concentrate on the smell evoked by this support. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
40854938|NCT04294602|OTHER|Patient Education|Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.
40854939|NCT02001935|DRUG|theophylline|After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
40854940|NCT06294392|BEHAVIORAL|KEEP-CK|The KEEP-CK model focuses on optimizing the role of kinship parents as the agents of positive change for children and youth. KEEP-CK groups for kinship parents are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-12 kinship parents attends each week. Each KEEP-CK group follows a manualized curriculum that emphasizes tailoring the content to the unique needs and cultures of the parent in the group and the youth in their care. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting. The key services connection elements of the model include: (a) parent discussions of services they are using or have used and (b) KEEP-CK group leaders share examples from a list of statewide and national services.
40854941|NCT04578067|BEHAVIORAL|Lifestyle intervention|on physical activity and healthier eating
40854942|NCT02347306|OTHER|Telephone interview|
40854943|NCT00366691|DRUG|Acular LS|
40854944|NCT00366691|DRUG|Lotemax|
40854945|NCT04481061|GENETIC|Electronic Decision Tool|Adolescents and a parent, if applicable, will use an electronic decision tool to make categorical choices of types of diseases (treatable, preventable, adult-onset, and carrier status) they want to learn about the adolescent. Granular choices can be made within each category.
40854946|NCT01371552|DEVICE|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
41385493|NCT02163694|DRUG|Carboplatin|Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.
41385494|NCT02163694|DRUG|Paclitaxel|Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.
41385495|NCT03191435|DEVICE|Inspiratory muscle training.|Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
41385496|NCT03191435|DEVICE|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
41385497|NCT03839784|COMBINATION_PRODUCT|Neurocognition Interventions|EEG, Neurocognitive Battery Testing, and Immune Profiles
41385498|NCT04192786|OTHER|Standard physiotherapy program+50 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (50 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
41510107|NCT06036186|DEVICE|BaroPacing treatment|BaroPacing for the first 3 weeks (day 8 to day 28) and then crossover to standard treatment for another 3 weeks (day 29 to day 49).
41510108|NCT06036186|DEVICE|Standard treatment|Individual Standard treatment as prescribed by the Physician to each subject for the first 3 weeks (day 8 to day 28) and then crossover to BaroPacing for another 3 weeks (day 29 to day 49).
40854947|NCT01371552|DEVICE|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
40854948|NCT01371552|DEVICE|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
40854949|NCT00415922|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
40854950|NCT02329899|OTHER|Second step of investigations|"Second step according to results of the first step:~* exploration of coagulation factors;~* factor XIII and fibrinolysis investigations;~* investigation of platelet function;~* investigation of thrombocytopenia."
41510109|NCT01500473|DRUG|Desogestrel|Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
41510110|NCT05919069|DRUG|AZD2693|Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
41510111|NCT02090166|OTHER|Blood test|a blood test will be taken from each patient
40854951|NCT03933761|DRUG|Pamiparib|60 mg of pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.
40854952|NCT05760768|BEHAVIORAL|Individualized exercise guidance|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
40854953|NCT02091843|PROCEDURE|DBS of the Basolateral Nucleus of the Amygdala|
41385499|NCT04192786|OTHER|Standard physiotherapy program+100 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (100 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
40854954|NCT02091843|DEVICE|Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala|
40854955|NCT02930915|DEVICE|Hand-held laser scanner|The laser scanning is non-intrusive and the scan can be completed in approximately 15 minutes. The scanning process involves the patient sitting in a chair while a researcher performs the scan. As a precautionary measure we require the patient to wear an eye mask as although the scanner is CE marked and completely safe . The process can be completed in stages (e.g. 3 x 5 minutes) with a break of 2-3 minutes between each session. The laser scanner will then be moved around the patient to obtain a set of 3D points forming the surface of the patient's head. We believe the laser scanning to be the most accurate way to acquire the surface of the patient's face / head and we wish to compare the models we obtain with surfaces rendered from the patient's CT data set.
40854956|NCT05541575|OTHER|VR films|A new virtual reality course for home care workers to experience the view of dementia people with BPSD and the relative feelings.
40854957|NCT02302872|DEVICE|ARTO System|
40854958|NCT06422013|DIETARY_SUPPLEMENT|GTB1|oral administration of GTB1 powder packet once daily
40854959|NCT06422013|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo powder packet once daily
40854960|NCT02435927|DRUG|ASLAN001+ CAPOX (Oxaliplatin, capecitabine)|ASLAN001 in combination with oxaliplatin and capecitabine
40854961|NCT02435927|DRUG|ASLAN001 + mFolfox6 (5-FU, leucovorin)|ASLAN001 in combination with 5-FU and leucovorin
40854962|NCT01978041|OTHER|Meal prepared with non fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).
40854963|NCT01978041|OTHER|Meal prepared with fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
40854964|NCT01978041|OTHER|Non fluoridated water|Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.
40854965|NCT01978041|OTHER|Fluoridated water|Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
40854966|NCT01978041|OTHER|Meal prepared to provide a fluoride dose of 60 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
41166219|NCT04699123|DRUG|NC318 800 mg|NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.
40854967|NCT01978041|OTHER|Meal prepared to provide a fluoride dose of 120 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
40854968|NCT03709784|DRUG|Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care|This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
40854969|NCT03709784|OTHER|One time survey|One time survey
40854970|NCT02725541|DRUG|Trastuzumab emtansine|HER2-targeted antibody drug conjugate of trastuzumab and DM1
41166220|NCT04699123|DRUG|NC318 400 mg|NC318 will be given intravenously (IV) every 2 weeks.
40854971|NCT05921175|DEVICE|RGT+ tSCS + conventional physiotherap|Subject will undergo 16 sessions of robotic gait training (RGT) + tSCS+ conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment. During tSCS, cathodes will be placed on the T11 and L1 spinous process. Reference/Ground electrodes placed over the ASIS It will be on biphasic mode with an overlap frequency of 10kHz, Burst Frequency of 30Hz, Pulse width of 1ms. Stimulation intensity ranges from 5-100 mA and will be adjusted according to the patient's response. The tSCS stimulation duration for each session will be 45 minutes in conjunction with the RGT training.
41166221|NCT04699123|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be given IV every 3 weeks
41166222|NCT04717947|PROCEDURE|Interval between NAT and surgery|Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.
41166223|NCT01470729|OTHER|metabolic and imaging biomarkers in SCA1,2,3 and 7 patients|MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
41166224|NCT01859221|RADIATION|Stereotactic radiation|Stereotactic radiation
41166225|NCT04178447|DRUG|Glepaglutide|Single dose of Glepaglutide 10 mg
41166226|NCT03023202|OTHER|PMMTB (Precision Medicine Molecular Tumor Board)|PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
41166227|NCT00843115|OTHER|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
41385500|NCT04192786|OTHER|Standard physiotherapy program|Standard physiotherapy program (strength, balance, gait exercises) for 60 minutes will be performed 3 days a week for 8 weeks.
41385501|NCT06514118|RADIATION|residual tumor irradiation|lung residual tumor will be given external beam irradiation for 50GY in 25 fractions in total
41385502|NCT00414011|DRUG|Moxifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
41385503|NCT00414011|DRUG|Gatifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
41385504|NCT04913311|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, stool, and bronchoalveolar lavage samples
41385505|NCT04913311|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with BAL
41510112|NCT05697614|DRUG|Valproic acid|valproic acid is used for general epilepsy type, used in experimental group
41510113|NCT05697614|DRUG|Carbamazepin|carbamazepine is used for focal type epilepsy, used in experimental group
41510114|NCT05697614|DRUG|Phenytoin|phenytoin is used for both general or focal epilepsy in case valproic acid or carbamazepine is contraindicated, used in experimental group
40854972|NCT05921175|DEVICE|RGT+ conventional physiotherapy|Subject will undergo 16 sessions of robotic gait training (RGT) + conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment.
40854973|NCT00903435|OTHER|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
40854974|NCT03977103|BIOLOGICAL|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
40854975|NCT00122174|BEHAVIORAL|Stress Busting Program for family caregivers|
40854976|NCT02695693|BEHAVIORAL|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
41385506|NCT04913311|OTHER|Chemoradiotherapy|Undergo concurrent chemoradiation per standard of care
40854977|NCT02695693|BEHAVIORAL|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
40854978|NCT02695693|BEHAVIORAL|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
40854979|NCT02695693|BEHAVIORAL|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
40854980|NCT03580681|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
40854981|NCT03580681|DIETARY_SUPPLEMENT|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
40854982|NCT02591485|BEHAVIORAL|Attention Control Training|In the ACT, participants perform six computerized attention training sessions, 10 minutes per training session over six weeks. In each session the dot-probe task is administered. This task is consisted of 160 trials. Each trial began with a centrally-presented fixation cross that then replaced by a pair of words presented. Following that, a target probe appeared in the location previously occupied by one of the words, and participants are requested to discriminate the probe type via button press. Targets appear with equal probability at the location of threat and neutral stimuli, in order to modify the fluctuations in attention allocation.
41385507|NCT04913311|PROCEDURE|Computed Tomography|Undergo computed tomography scan
41385508|NCT04913311|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
40854983|NCT03315572|OTHER|Interviewer administered version of ease of use items|The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
40854984|NCT03315572|OTHER|Self-administered version of ease of use items|The interview will be self-administered by subjects aged 8 to 11 years.
40854985|NCT03315572|OTHER|Caregiver version of ease of use items|Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
40854986|NCT02137096|DRUG|Etoposide phosphate|Etoposide is one of three drugs used in the high-dose conditioning phase
40854987|NCT02137096|DRUG|Carboplatin|Carboplatin is one of the drugs used in the high-dose conditioning phase.
40854988|NCT02137096|DRUG|Ifosfamide|Ifosfamide is one of the drugs used in the high-dose conditioning phase
40854989|NCT02137096|PROCEDURE|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
41385509|NCT04913311|DRUG|Immune Checkpoint Inhibitor|Receive CPI per standard of care
41385510|NCT04913311|PROCEDURE|Nasal Wash and Collection|Undergo nasal wash
41385511|NCT04913311|OTHER|Quality-of-Life Assessment|Ancillary studies
41385512|NCT04913311|OTHER|Questionnaire Administration|Ancillary studies
41385513|NCT04913311|PROCEDURE|Spirometry|Under lung spirometry tests
41385514|NCT03747094|DRUG|Fentanyl|0.5 mic/kg fentanyl will be given immediately before the procedure
41385515|NCT03747094|DRUG|Ketamine|0.25 mg ketamine will be administered immediately before the procedure
41510115|NCT05697614|DRUG|Lamotrigine|lamotrigine is used for general epilepsy type, used in control group
41510116|NCT05697614|DRUG|Clobazam|clobazam is used for both general or focal epilepsy in case if lamotrigine or oxcarbazepine is not possible to be administered and is used particularly in myoclonic jerk , used in control group
41510117|NCT05697614|DRUG|Oxcarbazepine|oxcarbazepine is used for focal type epilepsy, used in control group
41510118|NCT03142191|DRUG|CC-90001|CC-90001 is a potent, selective inhibitor of JNK.
41510119|NCT03142191|OTHER|Placebo|Placebo
41385516|NCT01333475|DRUG|MK-2206 + AZD6244|MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
41385517|NCT04770194|DRUG|SP-8008 Prototype Capsule A|Oral
41385518|NCT04770194|DRUG|SP-8008 Prototype Capsule B|Oral
41385519|NCT04770194|DRUG|Placebo|Oral
41385520|NCT03612713|DRUG|Oxycodone Medication First|Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
40854990|NCT01824550|OTHER|home-based exercise training condition|Home based endurance exercise training
40854991|NCT00663754|BEHAVIORAL|Dissonance-based eating disorder prevention program|Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
40854992|NCT00663754|BEHAVIORAL|Educational brochure|Participants will receive a mailed educational brochure about a healthy body image only.
40854993|NCT00495625|DRUG|Sunitinib Malate|Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
40854994|NCT06213155|DEVICE|Cryoneurolysis|Cryoneurolysis
40854995|NCT06213155|DEVICE|Stimulation|Stimulation
41037404|NCT03780764|OTHER|"A Pre-adjusted edgewise brackets: 3M Gemini Unitek, 0.022 Roth prescription brackets"|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and tied with elastomers (figure of 8)."
41037405|NCT03780764|OTHER|"Self- ligating brackets: Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets"|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and held in place by bracket's gate in the self-ligating brackets side."
41037406|NCT04753840|OTHER|Antihypertensive drugs|One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic
41037407|NCT04753840|OTHER|remote ischemic preconditioning（RIPC）|40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle)， a total of 4 cycles.
41037408|NCT04753840|BEHAVIORAL|lifestyle intervention|Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
41385521|NCT03612713|DRUG|Placebo First|Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
41385522|NCT03970252|DRUG|Fluorouracil|Given IV
41037409|NCT05880992|BEHAVIORAL|Exercise|Aerobic and Strength exercises (equipment free, simple, modifiable)
41037410|NCT05880992|DIETARY_SUPPLEMENT|Nutrition|Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)
41037411|NCT05880992|BEHAVIORAL|Mindfulness|Deep (box) breathing completing in the morning, evening and as needed.
41037412|NCT04302350|PROCEDURE|nitrous oxide|During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.
41385523|NCT03970252|DRUG|Irinotecan|Given IV
41385524|NCT03970252|DRUG|Irinotecan Hydrochloride|Given IV
41385525|NCT03970252|DRUG|Leucovorin|Given IV
41385526|NCT03970252|DRUG|Leucovorin Calcium|Given IV
41385527|NCT03970252|BIOLOGICAL|Nivolumab|Given IV
41385528|NCT03970252|DRUG|Oxaliplatin|Given IV
40854996|NCT04314674|DRUG|%3 HS bolus|After head fixation %3 HS bolus 3 ml/kg will be administered
40854997|NCT04314674|DRUG|%3 HS infusion 20 ml/h|After head fixation %3 HS 20 ml/h infusion will be administered
40854998|NCT04314674|DRUG|20% mannitol|After head fixation %20 mannitol 0.6 ml/kg will be administered
41385529|NCT03970252|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
41385530|NCT06568991|DIETARY_SUPPLEMENT|Low Protein Rice MATSUBUMAI|"Investigators will recruit 100 subjects participating in thePRE-ESRD education plan at KMUH. Subjects will receive dietary education of low protein diet (providing energy 25 to 35 Kcal/Kg/day, protein 0.6 to 0.8 g/Kg/day) by dietitians. Subjects will be randomly assigned to a observational group or rue low protein rice group."
40854999|NCT03053843|DIETARY_SUPPLEMENT|Mediterranean diet plus extra virgin olive oil|The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
40855000|NCT01438606|BIOLOGICAL|VSV-Indiana HIV gag vaccine|Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
41385531|NCT05475171|DRUG|Lorigerlimab|Given by vein (IV)
40855001|NCT01438606|BIOLOGICAL|Placebo injection (normal saline)|Administered IM in both deltoids at baseline and Week 8.
40855002|NCT03260296|OTHER|self-administered structured questionnaire|"Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.~The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences"
40855003|NCT06524193|BEHAVIORAL|Telepractice group voice therapy|"* Voice therapy delivered in group basis via telepractice.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia."
40855004|NCT06524193|BEHAVIORAL|Face-to-face group voice therapy|"* Voice therapy that will be delivered in group basis in-person with patients.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia."
40855005|NCT00781859|DRUG|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
40855006|NCT00781859|DRUG|Placebo|Placebo intravitreal injection
40855007|NCT06385054|DIETARY_SUPPLEMENT|Probiotic|Participants will be taking 1 sachet a day, at a similar time every day, dissolved in 10 ml of lukewarm water.
40855008|NCT06385054|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day, at a similar time every day, dissolved in 10 ml of lukewarm water.
40855009|NCT05209373|BEHAVIORAL|Intervention Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
40855010|NCT05209373|BEHAVIORAL|Positive Control Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
40855011|NCT03909308|BEHAVIORAL|Beach Tennis session|The Beach Tennis training session will be composed by a warm up of 5 min of BT in which technical exercises (i.e., serve, volley, forehand and backhand) will be performed After that, 3 BT small games of 12 min with a 2 minute interval between games using the conventional rules of sport will be performed. Before the session and after each small game, data regarding heart rate, blood pressure and rate perceived exertion will be recorded.
40855012|NCT05258916|PROCEDURE|Nurse consultation|nurse consultation carried out within two weeks after maternity discharged
40855013|NCT02183233|DRUG|Eschscholtzia Californica|
40855014|NCT02183233|DRUG|Eschscholtzia Californica Placebo|
40855015|NCT00890110|BIOLOGICAL|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
40855016|NCT05412368|OTHER|Focus Groups|Focus Groups
40855017|NCT05360082|OTHER|[11C]UCB-J|11C-labeled SV2A binding PET radioligand
40855018|NCT05360082|OTHER|[18F]SynVest-1|18F-labeled SV2A binding PET radioligand
40855019|NCT02741141|OTHER|New partograph based on the studies of Neal and Lowe|"The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.~Eventually, the only difference between the two arms is the moment when the active management of labour is started.~The oxytocin is administrated according to the department protocol."
40855020|NCT02741141|OTHER|Classical partograph|Classical partograph used as standard care
40855021|NCT04036812|PROCEDURE|Superficial cervical plexus block|superficial cervical plexus nerve block will be performed under the guidance of ultrasound
40855022|NCT04036812|OTHER|Control group|ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
41385532|NCT03123120|DRUG|Spesolimab|12 weeks treatment
40855023|NCT02799498|DEVICE|Auto-injector device|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
40855024|NCT02799498|OTHER|Etanercept (ENBREL®) via Manual injection|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
40855025|NCT02799498|DRUG|Etanercept (ENBREL®)|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
40855026|NCT00139919|DRUG|Bifeprunox|
40855027|NCT03849222|PROCEDURE|Apexification|
40855028|NCT03849222|DRUG|MTA|
40855029|NCT03849222|DRUG|Ca(OH)2|
40855030|NCT03849222|DRUG|Apical matrix|collagen membrane (Biocollagen; Bioteck:Turin, Italy)
40855031|NCT04044742|DRUG|Resiniferatoxin|Receiving Resiniferatoxin injection
40855032|NCT04044742|DRUG|Placebo|Receiving Placebo injection
40855033|NCT04483609|OTHER|Questionnaire administration pre test|After the translation and cultural adaptation of the SF-Qualiveen scale is completed, face-to-face pre-test will be performed on 10 patients with multiple sclerosis.
41037413|NCT03775850|BIOLOGICAL|EDP1503|4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU)
41385533|NCT03123120|DRUG|Placebo|12 weeks treatment
41385534|NCT02472431|OTHER|Intracavernosal administration of autologous ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.
41385535|NCT02472431|PROCEDURE|Liposuction|
41385536|NCT02472431|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
41385537|NCT05814510|BEHAVIORAL|Asthma CHAMPS full program|Full program includes (1) education for staff, students, and caregivers (2) environmental education and intervention (3) asthma care coordination (4) resources
41385538|NCT05814510|BEHAVIORAL|Asthma CHAMPS Wait List Control|Stepped wedge design
41385539|NCT05790850|BEHAVIORAL|Pre-operative physical exercise|Virtual instructor-guided twice weekly cycling-based high-intensity aerobic exercise program for a total of 30 days. Participants will use a study provided recumbent exercise bike and wristband fitness tracker to exercise and log the number of days they exercise with an instructor and self-directed cycling.
41510120|NCT05637203|BEHAVIORAL|THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement)|"THRIVE is an interpersonally focused recovery and care transition program. THRIVE (previously called RELATE in our SAMHSA grants) involves engaging a person during and following acute suicidal crisis in a sequence of interpersonally focused therapeutic tasks. The purpose of THRIVE is to help CSC guests re-build connections and contribute to the world in ways they find personally meaningful, while also transitioning safely to outpatient, community-based care. THRIVE involves a Belonging and Giving Reflections Group while at the CSC, followed by a 4-week, phone-based, recovery and care transition series of coaching calls."
41510121|NCT05637203|BEHAVIORAL|Discharge / Safety Planning|"* A written safety plan completed with the person~* Mental health appointment scheduled within seven days~* One phone follow-up call within 30 days"
41510122|NCT01911273|DRUG|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
41510123|NCT01911273|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
40855034|NCT04483609|OTHER|Questionnaire administration validation and reliability|After the pre-test is completed, if necessary, arrangements will be made, and then the validity and reliability of SF-Qualiveen will be made in 80 individuals with Multiple Sclerosis.First of all, participants will be asked to complete two questionnaires (SF-Qualiveen and Urinary Distress Inventory). Two weeks after this assessment, they will be asked to respond to SF-Qualiveen again.
40855035|NCT05020275|DIAGNOSTIC_TEST|Blood Samples|"* Samples for ctDNA blood concentration and osimertinib plasma concentration~* Sample for genetic polymorphisms"
41510124|NCT01911273|OTHER|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
41510125|NCT01911273|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
40855036|NCT02078128|DIETARY_SUPPLEMENT|oral beta-glucans|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
40855037|NCT02078128|DRUG|oral sugar powder|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
40855038|NCT04563195|DRUG|tibulizumab (LY3090106)|subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
40855039|NCT05145868|BEHAVIORAL|Alcohol Skills and Emotion Regulation Intervention|The text-based intervention will provide alcohol reduction strategies and emotion regulation skills.
41037414|NCT03775850|BIOLOGICAL|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
41385540|NCT05790850|BEHAVIORAL|Pre-operative mindfulness meditation practice|Daily self-directed mindfulness practice involving a guided imagery meditation for a total of 30 days. Participants will use a study provided guided-imagery meditation audio file loaded to a study provided wristband fitness tracker. Participants will log the number of days they listen to the audio file or participate in self-directed solitary psychological support.
41385541|NCT03542500|BEHAVIORAL|Youth Readiness Intervention (YRI)|The Youth Readiness Intervention integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
41510126|NCT05654311|OTHER|Nasal surgery|Nasal surgery under general anesthesia using inhalational agent (sevoflurane)
41510127|NCT01295320|PROCEDURE|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
41037415|NCT02186119|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
41037416|NCT02186119|DRUG|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
41037417|NCT02186119|OTHER|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
41037418|NCT02741960|DRUG|metformin|500 mg metformin three times daily
41385542|NCT03542500|BEHAVIORAL|Entrepreneurship Training|The youth capacity development component of GIZ's Entrepreneurship Training includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use.
41510128|NCT01223391|OTHER|Abdominal binder|External abdominal compression sequentially applied at 20 mmHg for 3 minutes, maximal tolerable level for 1.5 minutes and comfortable level for 2 minutes.
41510129|NCT01223391|OTHER|No abdominal binder|Standing without abdominal binder for 3 minutes
41037419|NCT02741960|DRUG|placebo|500 mg placebo three times daily
41166228|NCT02986750|DEVICE|Thealoz Duo Eye Drops|Manufacturer: Laboratoires Thea, France
41510130|NCT06427850|DRUG|Tranexamic acid|receive an injection of Tranexamic acid into the surgical site
41510131|NCT06427850|DRUG|Normal saline|receive an injection of Normal saline into the surgical site
41166229|NCT02986750|DEVICE|Optive Eye Drops|Manufacturer: Allergan Pharmaceuticals, Ireland
41166230|NCT02986750|DEVICE|Systane Ultra Eye Drops|Manufacturer: Alcon Pharma GmbH
41166231|NCT01263990|DEVICE|NexFin|noninvasive finger cuff system
40855040|NCT05145868|OTHER|Attention Control|Text-messages will be sent that include no intervention content to serve as an attention control
40855041|NCT06442488|DEVICE|Respiratory Monitoring System|Comparing the SNR and accuracy of measurement (RR, TV, MV, apnea duration) in a noisy external environment when the RMS has adaptive filtering and active noise cancellation turned on versus turned off.
40855042|NCT05512780|DRUG|Dalpiciclib|"An exploratory study of a single-arm, open design~All subjects enrolled will receive the following treatment:~Dalpiciclib combined with Letrozole, 28 days as one cycle."
41510132|NCT03708302|PROCEDURE|Unilateral serratus plane block|Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane in 5 mls aliquot after aspiration. Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sternum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane slowly in 5 ml aliquots after aspiration.
41510133|NCT03708302|PROCEDURE|Unilateral parasternal infrapectoral block|"Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane in 5 mls aliquot after aspiration.~Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sterum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane slowly in 5 ml aliquots after aspiration."
41510134|NCT05537350|DIETARY_SUPPLEMENT|Lumenato|Supplementation of 12 weeks
41510135|NCT02054052|DRUG|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
40855043|NCT04954924|OTHER|standardized physiotherapy program and Kinesio tape|
41510136|NCT05579314|DRUG|XW014|Oral tablets
41510137|NCT05579314|DRUG|Placebo|Matched oral placebo tablets
41166232|NCT02975297|DRUG|Exenatide|Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
41510138|NCT05579314|DRUG|XW014|Oral capsules
41510139|NCT05579314|DRUG|Placebo|Matched oral placebo capsules
41510140|NCT03971474|DRUG|Docetaxel|Given IV
40855044|NCT04386642|DRUG|Tranexamic acid|Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.
40855045|NCT04386642|DRUG|Placebo|normal saline solution in a clear 50-ml syringe
41510141|NCT03971474|DRUG|Gemcitabine|Given IV
41510142|NCT03971474|DRUG|Gemcitabine Hydrochloride|Given IV
41510143|NCT03971474|BIOLOGICAL|Pembrolizumab|Given IV
41510144|NCT03971474|DRUG|Pemetrexed|Given IV
41510145|NCT03971474|DRUG|Pemetrexed Disodium|Given IV
41510146|NCT03971474|BIOLOGICAL|Ramucirumab|Given IV
41510147|NCT03352739|DEVICE|DBS of the fornix, power on|"DBS of bilateral columns of the fornix is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
40855046|NCT04649463|DIAGNOSTIC_TEST|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
40855047|NCT01524146|PROCEDURE|Photodynamic Therapy|"PDT is a therapeutic approach that specifically targets neoplastic cells.~• PDT involves three components:~1. Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.~2. Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis~3. Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.~Technique:~Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.~Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months."
41510148|NCT03352739|DEVICE|DBS of the NbM, power on|"DBS of bilateral NbMs is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
41510149|NCT03352739|DEVICE|DBS of the fornix, power off|"DBS of bilateral columns of the fornix is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
40855048|NCT06239103|DEVICE|Pulsed electromagnetic field therapy|Pulsed electromagnetic field therapy for 10 minutes, using a PEMF device, at 1 mT, 15 Hz.
40855049|NCT06239103|DEVICE|Sham treatment|Sham treatment, using the same PEMF device
41166233|NCT02975297|DRUG|NRT|Nicotine Patch (21mg) / 24 hours.
41166234|NCT02975297|BEHAVIORAL|Counseling|Brief individual behavioral smoking cessation counseling.
41166235|NCT02975297|DRUG|Placebo|Normal saline.
41166236|NCT02945371|BEHAVIORAL|Person-centered inhibitory control training|A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.
41166237|NCT02945371|BEHAVIORAL|Active behavioral response training|A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
40855050|NCT04700540|DEVICE|Smartwatch Reminder (SR) system|The Smartwatch Reminder (SR) system will automatically transmit pictures and relevant information, such as name or relationship, to a smartwatch worn by the PWMC when family or friends visit.
41385543|NCT03039517|DEVICE|ACTitouch|The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
40855051|NCT04338763|DRUG|RP72|RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.
40855052|NCT04338763|DRUG|Gemcitabine|Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.
40855053|NCT01802190|GENETIC|Deafness patients|SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
40855054|NCT04918511|DRUG|OPD5|OPD5 solution for i.v. infusion
40855055|NCT05137769|BEHAVIORAL|Body Scan|The body scan is a core element of mindfulness-based stress reduction. Participants will listen to a 20-minute audio guide instructing them to focus on sensations in the body, place attention on one area of the body at a time, and progressively move attention throughout areas of the body.
41385544|NCT03039517|DEVICE|Compression garments (stockings)|"Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided."
41510150|NCT03352739|DEVICE|DBS of the NbM, power off|"DBS of bilateral NbMs is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
41510151|NCT00059592|DRUG|Valacyclovir|
40855056|NCT00901199|DRUG|Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.
40855057|NCT06314607|GENETIC|Prospective Biological Collection|"All samples that can be collected at each visit :~* Saliva sampling (added by the research)~* Collection of 2 to 4 additional tubes of blood (maximum 56mL) (added by the research if blood sampling in routine care)~* Urine and stool samples (added by the research)~* CSF sample residues (added by the research if lumbar punction in routine care)~* Lesion sample residues and surgical waste fragments (added by the research if surgery in routine care)"
40855058|NCT06314607|GENETIC|Retrospective Biological Collection|Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)
40855059|NCT02164266|DRUG|Placebo|Matching placebo daily oral administration
40855060|NCT02164266|DRUG|RO6799477|Daily oral administration of RO6799477
40855061|NCT05223049|OTHER|painDETECT questionnaire|The painDETECT questionnaire was specifically developed to detect neuropathic pain components in adult patients with low back pain. It is also used in detecting the neuropathic pain in rheumatic diseases. A score between ≤12 represents a nonneuropathic pain, ≥13 and ≤18 represents a possible neuropathic pain, while a score of ≥19 represents a neuropathic pain.
40855062|NCT05223049|OTHER|Douleur Neuropathique 4 questionnaire (DN4)|DN4 is a clinician-administered questionnaire consisting of 10 items. Seven items related to pain quality (i.e. sensory and pain descriptors) are based on an interview with the patient and 3 items based on the clinical examination. A score of ≥4 represents a neuropathic pain.
41166238|NCT01921114|DEVICE|BioFlo™ Peripherally Inserted Central Catheter (PICC)|
41166239|NCT01921114|DEVICE|Bard® Dual-Lumen PowerPICC SOLO2®|
41166240|NCT04605198|BEHAVIORAL|Modified Mindfulness-based Stress Reduction|Participants will be trained in mindfulness meditation and the applicability of mindfulness practices to daily life. During MBSR programming, teachers will lecture about key topics in mindfulness and lead class discussions. Participants are given homework assignments, such as listening to guided meditations. Participants are given opportunities to ask the instructor questions and to share their experiences with each other. Each session focuses on a different key topic. Topics are: Session 1: Introduction; Session 2: Understanding Perceptions; Session 3: Hatha Yoga, Sitting Meditation, Walking Meditation; Session 4: Concentration \& Awareness; Session 5: Unhealthy Patterns \&Getting Unstuck; Session 6: Transformational Coping Strategies; Session 7: Mini-retreat; Session 8: Maintaining Discipline \& Flexibility; Session 9: Course Review.
41166241|NCT04605198|BEHAVIORAL|Health Promotion Wellness Classes|Sessions will cover the following general wellness topics: Session 1; Introduction; Session 2: Envisioning Health Through Art; Session 3: Chronic Disease 1 (Heart Health); Session 4: Chronic Disease II (Diabetes); Session 5: Nutrition and Hydration; Session 6: Infectious Disease Prevention; Session 7: Skin Care; Session 8: Oral Health; Session 9: Promoting Social Integration \& Course Graduation.
41385545|NCT02618772|DRUG|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
41385546|NCT02618772|DRUG|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
41510152|NCT03759938|DRUG|Direct oral anticoagulant (DOAC)|Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
41510153|NCT01504997|DEVICE|Robot assisted distal gastrectomy (DaVinci)|patients who received robot assisted distal gastrectomy
41510154|NCT01000948|DRUG|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
41166242|NCT02044341|DRUG|AR01|drops administered an needed for pain
41166243|NCT02044341|DRUG|Glycerin ear drops|placebo drops administered for ear pain
41166244|NCT02606383|DRUG|Dapaconazole|
40855063|NCT05223049|OTHER|Short form-36|The 36-Item Short Form Survey (SF-36) is a self-reported measure of health. It comprises 36 questions which cover eight domains of health. 1) Limitations in physical activities because of health problems. 2) Limitations in social activities because of physical or emotional problems 3) Limitations in usual role activities because of physical health problems 4) Bodily pain 5) General mental health (psychological distress and well-being) 6) Limitations in usual role activities because of emotional problems 7) Vitality (energy and fatigue) 8) General health perceptions. Each domain is scored between 0 and 100 and a higher score represents a better outcome.
40855064|NCT05223049|OTHER|Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC)|SPARCC was created as a measure for enthesitis in spondyloarthritis in general. It assesses 16 enthesial sites. Total number of the enthesitis is the total score of the evaluation. Total score is between 0 and 16, and higher scores represent a worse outcome.
41385547|NCT00242567|DRUG|Zoledronic Acid|"Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes."
41385548|NCT00242567|DRUG|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
40855065|NCT05223049|OTHER|Numeric Rating Scale|Self reported pain scored between 0 (minimum)-10 (maximum). Higher scores represent a worse outcome.
41166245|NCT02606383|DRUG|Ketoconazole|
41166246|NCT01800578|DEVICE|monitor for depth of hypnosis|"evaluation of depth of hypnosis~--------------------------------------------------------------------------------"
41166247|NCT00600301|DRUG|Triamcinolone Acetonide and Bevacizumab|
41385549|NCT05455593|BEHAVIORAL|Water aerobics|1-hour session of water aerobics per week, for 3 months. A specialized trainer will carry out water aerobics sessions and will focus on motor coordination, strength and cardiovascular workout.
41385550|NCT05455593|BEHAVIORAL|Metacognitive Training (MCT)|1-hour session of MCT per week, for 3 months. A trained psychologist will carry out the MCT sessions. MCT addresses the most common cognitive biases in psychosis. Each session will focus on one topic, such as attributional style, jumping to conclusions, theory of mind, emotion recognition, memory or empathy.
41385551|NCT05455593|BEHAVIORAL|Combined intervention|Patients in this arm will participate in both in water aerobics and MCT sessions, once a week for each intervention.
41385552|NCT05558605|DIAGNOSTIC_TEST|AI-guided echo|AI-guided echocardiography
41385553|NCT05558605|DIAGNOSTIC_TEST|Standard echo|Standard echocardiography
41385554|NCT00168740|DRUG|rituximab|
41385555|NCT04591327|PROCEDURE|The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections|Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is\> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.
41385556|NCT04390100|DRUG|hyaluronic acid (Gengiegel 0.2% oral gel )|coverage of the free gingival graft area in the palate
41385557|NCT04390100|OTHER|Platelet rich fibrin|coverage of the free gingival graft area in the palate
41385558|NCT04390100|OTHER|Gel foam|coverage of the free gingival graft area in the palate
41385559|NCT02672488|DRUG|Sorafenib|Standard treatment for advanced HCC
41385560|NCT02672488|DRUG|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
41510155|NCT05861297|DRUG|Dexamethasone|Patients were initiated with High Dose-Dexamethasone with a dose of 40 mg/m2 daily for four days per week immediately after the diagnosis of ITP for 6 months
41166248|NCT00664456|DRUG|Adjuvant therapy|AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
41385561|NCT03348501|OTHER|survey for long-term follow-up of the disease|patients will be regularly asked about their state of health (occurrence of a major health event that required hospitalization, for example ...), and about their living conditions (alcohol and tobacco consumption, socio-economic environment). Questionnaires of quality of life and satisfaction related to care will also be offered at regular intervals to better know the impact of their disease on their daily lives and their perception of their care.
41385562|NCT01548573|DRUG|Dexamethasone|Given PO
41385563|NCT01548573|PROCEDURE|Tandem autologous stem cell transplant|
41385564|NCT01548573|DRUG|Cisplatin|Given IV
41510156|NCT05861297|DRUG|Prednisolone and Azathioprine|the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.
41510157|NCT05861297|DRUG|Rituximab|The third group received 500 mg/m2 intravenously of Rituximab once weekly for one month
41166249|NCT00664456|DRUG|Neoadjuvant therapy|3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
41510158|NCT05861297|DRUG|Eltrombopag|The fourth group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months
41510159|NCT05861297|DRUG|Romiplostim|The fifth group received 3μg/kg subcutaneous injection of Romiplostim once a week for 6 months
41510160|NCT00727012|DEVICE|mitral valve repair (SJM® Rigid Saddle Ring)|mitral valve repair due to mitral degenerative or functional disease
41510161|NCT03510390|DRUG|Metformin|850 mg, oral, twice daily, 9-14 days
41510162|NCT01016470|DIETARY_SUPPLEMENT|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
40855066|NCT05223049|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
40855067|NCT03405649|BEHAVIORAL|Group A|Muscle conditioning exercise for postpartum women and infants less than 20 weeks of age.
41166250|NCT00664456|RADIATION|Brachytherapy（iodine I 125）|Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
41385565|NCT01548573|DRUG|Doxorubicin|Given IV
40855068|NCT03405649|BEHAVIORAL|Group B|Muscle conditioning exercise for postpartum women and infants more than 20 weeks of age.
40855069|NCT06353906|DRUG|Carboplatin/Paclitaxel|Induction: three cycles of intravenous carboplatin AUC5 (max 750 mg) and paclitaxel 175 mg/m2, during cycle 1, 2 and 3 (day 1, 22, 43)
41166251|NCT03820869|OTHER|Family Training|Family Training
41166252|NCT03820869|OTHER|Occupational Therapy|Occupational Therapy
41385566|NCT01548573|DRUG|Cyclophosphamide|Given IV or PO
41385567|NCT01548573|DRUG|Etoposide|Given IV
41510163|NCT01016470|DIETARY_SUPPLEMENT|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
41510164|NCT01907230|DRUG|Entecavir|In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
41510165|NCT04071405|OTHER|Non-intervention|Non-intervention observational study
41510166|NCT04810715|OTHER|Patients with Ankylosing Spondylitis|Observational study, not applicable
40855070|NCT06353906|DRUG|Pembrolizumab|"Induction: two cycles of intravenous pembrolizumab 400 mg during cycle 1 and 3 (day 1 and 43)~Adjuvant: up to seven cycles of fixed-dose intravenous pembrolizumab 400 mg, on day 1 every 6 weeks within 3-9 weeks after surgery"
40855071|NCT06353906|PROCEDURE|Partial or total penectomy with inguinal and/or pelvic lymph node dissection|Resection of part or all of the penis with complete removal of suspect lymphnodes in the inguinal and/or pelvic area
40855072|NCT04314583|BEHAVIORAL|Attention Control|Participants in this group will be asked to recall 3 to 5 events from the prior day of the intervention and write, or if unable to write, speak about these events.
40855073|NCT04314583|BEHAVIORAL|Gratitude Journaling|The gratitude journaling intervention involves participants writing or speaking 3-5 things for which they are grateful and focusing on these attributes. Participants will do this weekly for 12 weeks.
40855074|NCT06356051|DEVICE|Echocardiography|cardiovascular evaluation
41166253|NCT03044002|DEVICE|Biotronik 4 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
41166254|NCT03044002|DEVICE|6 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
41385568|NCT01548573|DRUG|Bortezomib|Given IV
41385569|NCT01548573|DRUG|Thalidomide|Given PO
41385570|NCT01548573|DRUG|Melphalan|Given IV
41385571|NCT01649245|DRUG|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
41385572|NCT00445458|DRUG|HKI-272|
41385573|NCT00445458|DRUG|Paclitaxel|
41510167|NCT00616512|PROCEDURE|GF Strong Water Protocol|The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
41510168|NCT06235489|OTHER|Palfique Bulk Flow|removal of caries in primary molars and placement of restorative materials
41385574|NCT06388265|OTHER|Trifold information|Additional detailed and written information about the procedure will be given to the participants
41385575|NCT06250660|DIETARY_SUPPLEMENT|Strawberry Intervention|"This is an intervention based on the intake of strawberry, specifically the Fortuna variety. This intervention is based on the intake of 250 g of fresh strawberries per day for a month. The amount and duration of strawberry intake has been consulted in other studies carried out with strawberries."
41385576|NCT02594384|DRUG|LAM-002A|25 mg capsules or 50 mg capsules
41385577|NCT02594384|DRUG|Rituximab|375 mg/m2 by vein
41385578|NCT02594384|DRUG|Atezolizumab|1200 mg by vein
41385579|NCT03368872|OTHER|Astaxanthin formulation|Astaxanthin formulation containing AstaReal® astaxanthin (Haematococcus pluvialis algae extract), tocotrienol, and zinc will be orally administered starting on Day 1 until Day 120
41385580|NCT03368872|OTHER|Placebo|Placebo will be orally administered starting on Day 1 until Day 120.
41385581|NCT03368872|OTHER|Exercise training|The subjects will undergo interval treadmill incline protocol (target 85% HR max, 3 times a week for 40 to 60 minutes) starting on Day 31 until Day 120.
41385582|NCT04485624|OTHER|No intervention|Observational study
41385583|NCT03934242|OTHER|Questionnaire on new born's bedding|Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)
41385584|NCT02534207|DRUG|Basmisanil|Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
41385585|NCT03642886|BEHAVIORAL|Prescribed Detraining|Detraining is the deliberate act of reducing volume of exercise to observe subsequent changes in cardiac indices over time or the partial or complete loss of training of induced anatomical, physiological and performance adaptions. Detraining is primarily employed as a diagnostic tool to help differentiate Athletes' heart from cardiac pathology.
41385586|NCT01807780|BIOLOGICAL|biological monitoring|
41385587|NCT00915473|DRUG|bupivicaine|2.5 mL 0.5% bupivicaine
41385588|NCT00915473|DRUG|normal saline|2.75 mL normal saline
41385589|NCT00915473|DRUG|methylprednisolone|0.5 mL 20 mg methylprednisolone
41385590|NCT00915473|DRUG|lidocaine|0.25 mL 1% lidocaine
41385591|NCT05943327|DRUG|Lu AG06474|Oral Solution
41385592|NCT05943327|DRUG|Placebo|Oral Solution
41385593|NCT05943327|DRUG|Lu AG06474|Capsule
41385594|NCT01317069|DRUG|Fluorouracil implant|Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
41385595|NCT04681807|BEHAVIORAL|Emotion Recognition Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of an emotion recognition training exercise on iPad, lasting for a period of \~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
41385596|NCT04681807|BEHAVIORAL|Active Control Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of a control training exercise on iPad, lasting for a period of \~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
40855075|NCT04256681|OTHER|SNAP questionnaire|The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
41037420|NCT02967627|DEVICE|Incisional Negative Pressure Wound Therapy (iNPWT)|Incisional Negative Pressure Wound Therapy devices are lightweight, self contained, portable battery powered (or line powered), suction pumps for medical procedures where secretions and other body fluids and infectious materials must be removed through the application of continuous or intermittent negative pressure. The pumps are operated through computer software, having help and alarm features. The device is indicted for management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. The pumps may be used at patient's bedside. These are suitable for use in either hospitals or long term care facilities and nursing homes. These devices will be applied to closed laparotomy incisions with the aim to provide three days of continuous negative pressure of - 100mmHg.
41385597|NCT05995717|DIETARY_SUPPLEMENT|PKU UP|"PKU UP is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in children aged from one (1) to ten (10) years.~PKU UP is a neutral-flavoured, ready-to-drink, low-phenylalanine protein substitute containing a blend of glycomacropeptide (GMP) isolate, essential and non-essential amino acids, fat, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA)."
41385598|NCT06526494|DRUG|Metformin|Oral ingestion for 12 weeks
41510169|NCT00154518|PROCEDURE|Orthodontic treatment|
41510170|NCT01990586|DRUG|Rabeprazole sodium 20 mg Delayed Release tablet|
41510171|NCT00002817|BIOLOGICAL|sargramostim|
40855076|NCT01552356|OTHER|Laboratory Biomarker Analysis|Correlative studies
40855077|NCT01552356|DRUG|Pazopanib Hydrochloride|Given PO
40855078|NCT01552356|OTHER|Pharmacological Study|Correlative studies
41037421|NCT02967627|DEVICE|Sterile Gauze Dressing|In most cases, self-adhesive, absorbent dressings will be used for standard wound therapy. However, surgical teams may decide on alternative forms of sterile gauze dressings, as long as the wound site is kept clean and dry. Dressings should be taken down on the second post-operative day.
41385599|NCT06526494|OTHER|Placebo|Oral placebo for 12 weeks
41385600|NCT00880867|DRUG|Poly-ICLC|An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
41385601|NCT01947257|OTHER|the measure TRVMAX|by transthoracic echocardiography
41385602|NCT01947257|OTHER|the measure of the pulmonary artery|by transesophageal ultrasound
41385603|NCT01947257|OTHER|the direct measure of the pulmonary pressures|by right catheterization
41385604|NCT05184075|PROCEDURE|Standard hybrid coronary revascularization|Patients will undergo endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the diagnostic coronarography. Furthermore, they will receive a percutaneous coronary intervention (PCI) within four weeks after the endo-CABG.
41510172|NCT00002817|BIOLOGICAL|vaccinia-GM-CSF vaccine|
41510173|NCT04080739|DRUG|ropivicaine 0.2%|2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
41037422|NCT05198960|DRUG|Direct Oral Anticoagulants|Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.
41037423|NCT05198960|DRUG|Low-dose aspirin|Patients allocated to receive LDA: Aspirin 100 mg OD once daily.
41037424|NCT02156674|DRUG|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
41037425|NCT03689010|DRUG|Azelaic acid foam 15%|Azelaic acid foam 15%
41037426|NCT03689010|DRUG|Finacea® (Azelaic acid Foam) 15%|Azelaic acid foam 15%
41510174|NCT04353895|DEVICE|Guidance for pedicle screw insertion (Mazor Stealth)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
41037427|NCT03689010|DRUG|Vehicle of the test product|Vehicle of the test product
41037428|NCT03112382|DRUG|zinc supplement plus vitamin A and E|
41037429|NCT03112382|DRUG|vitamin A and E|
41037430|NCT05427669|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
41037431|NCT05427669|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
41037432|NCT02414191|BEHAVIORAL|Benchmarked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.
41037433|NCT02414191|BEHAVIORAL|Ranked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
41037434|NCT03177291|DRUG|Pirfenidone|"Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation."
41037435|NCT03177291|DRUG|Carboplatin|Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.
41037436|NCT03177291|DRUG|Paclitaxel|200 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
41037437|NCT03177291|DRUG|Pemetrexed|500 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
41037438|NCT01187758|BEHAVIORAL|Workshops and focus group meetings|Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
41037439|NCT05106231|BEHAVIORAL|PICC Program|Participants will attend the PICC program which consists of 4 sessions that involve Visualization in Participatory Programmes (VIPP) and quizzes to evaluate retention in diabetes knowledge.
41037440|NCT05106231|BEHAVIORAL|Control|The control arm received four sessions one-on-one education program by a pharmacist. It is a Malaysian national education pharmacy-led program to instil knowledge and inculcate medication adherence.
41037441|NCT05328531|DRUG|Genakumab for Injection|150 mg/1ml/bottle
41037442|NCT05328531|DRUG|Placebo for Genakumab for Injection|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection
41037443|NCT00179023|DRUG|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour
41510175|NCT04353895|DEVICE|Guidance for pedicle screw insertion (O-arm Navigation)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
41037444|NCT00179023|DRUG|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 30 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1-2 hours
41037445|NCT00179023|DRUG|Pseudoephedrine|30mg tablet,VO. Single dose.
41037446|NCT03570294|DRUG|Atosiban|The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
41037447|NCT04805723|PROCEDURE|VATS|"Video-assisted thoracoscopic surgery is a minimal invasive technique in which used to diagnose or treat for lung diseases. During this surgery, one or two small incisions are opened via camera and surgical instruments in patient's chest wall. Thus, less muscle and nerve tissue are damaged.~Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung."
41037448|NCT04805723|PROCEDURE|Thoracotomy|Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.
41037449|NCT03151434|DRUG|US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)|Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.
41037450|NCT03151434|DRUG|US Guided Paravertebral Catheter (0.2% ropivicaine bolus)|Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.
41037451|NCT03151434|DRUG|Thoracic Epidural (0.125% bupivicaine/hydromorphone)|Epidural catheter will be placed in the thoracic region prior to surgery.
41037452|NCT01412723|OTHER|Ferrous sulfate as dietary supplementation|Ferrous sulfate as dietary supplementation
41037453|NCT01412723|OTHER|Iron amino acid chelated as dietary supplementation|Iron amino acid chelated as dietary supplementation
41385605|NCT05184075|PROCEDURE|Reverse hybrid coronary revascularization|Patients will receive a percutaneous coronary intervention (PCI) within four weeks after the diagnostic coronarography. Furthermore, they will undergo the endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the PCI.
41528340|NCT03786328|BEHAVIORAL|Standard Psychiatric Treatment|Standard psychiatric treatment is offered individuals identified with a clinical mental disorder. Treatment will follow golden standard treatment in the psychiatric clinic, meaning a combination of therapy and psychopharmacological treatment.
40855079|NCT01680744|OTHER|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure \> 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
40855080|NCT00375518|DRUG|Atorvastatin|Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
41510176|NCT04634279|BEHAVIORAL|Collaborative care Plus|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In this model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care. In the Collaborative Care Plus condition, the care coordinator involves family in care, teaches family about naloxone use, and provides Caring Contacts, a suicide prevention method, to patients.
40855081|NCT00375518|DRUG|Placebo|Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
40855082|NCT06245382|DIETARY_SUPPLEMENT|Goode Health Beverage|This is a commercially available beverage powder that is high is healthy ingredients that are believed to be beneficial for physiological health.
40855083|NCT06245382|DIETARY_SUPPLEMENT|Vanilla Base Beverage Blend|This is a commercially available beverage powder.
41037454|NCT03725917|OTHER|Physiotherapy protocol|The intervention will consist of a physiotherapy protocol twice a week for twelve weeks. The protocol will be done in three phases, constituting each month, a phase of the protocol. The first two phases will include therapeutic exercise of progressive difficulty and manual therapy, while the last phase will include only one week of manual therapy and therapeutic exercise, the last three weeks being composed only of therapeutic exercise
41510177|NCT03296111|OTHER|Questionnaires on pain and quality of life|"Patients will be asked to complete several questionnaires about their pain and the impact on their quality of life.~They will complete the questionnaires in the ophthalmology consultation room or at home and return it by mail (or present it at the next consultation).~Patients will be asked to complete several questionnaires :~* Questionnaire about the characteristics of ocular neuropathic pain (7 items)~* DEQ-5 (Dry Eye Questionnaire)~* ODI (Ocular Surface Disease Index)~* BPI (Brief Pain Inventory)~* HADS (Hospital Anxiety and Depression Scale)"
41510178|NCT04410614|PROCEDURE|Free epithelial (gingival) graft|1mm thickness epithelial layer harvested from the palate (1st molar area) is grafted and stabilised at the dental or implant area deficient of keratinized mucosa
41037455|NCT04997174|DRUG|Celecoxib|Patients in ERAS group received celecoxib
41166255|NCT04071093|OTHER|Home Telemonitoring System (HTS)|The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
41385606|NCT02995928|PROCEDURE|Decompressive craniectomy|Decompressive craniectomy: All patients in the treatment group will receive decompressive craniectomy of at least 12 cm according to institutional guidelines and a published surgical protocol during the clipping surgery within 48 hours form the onset.
41385607|NCT02995928|PROCEDURE|Best medical treatment|Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
40855084|NCT06583629|BEHAVIORAL|Emotional Freedom Technique|EFT is a self-help technique that incorporates conscious awareness of thoughts and feelings with a gentle touch involving tapping with fingertips on acupuncture/acupressure points on the face, hands, and body. EFT also helps relieve primary physical and emotional symptoms. Gary Craig created EFT, which involved lightly tapping on the body on 12 acupressure sites (also known as acupoints). This acupoints are situated along the body's meridians, or virtual energy channels
40855085|NCT04955327|DRUG|A. Paniculata|Extract from A. Paniculata
41037456|NCT01734681|DRUG|G-202|
41037457|NCT02834780|DRUG|H3B-6527|H3B-6527 by mouth once or twice daily at specified doses.
41385608|NCT04921384|DRUG|Placebo|0.9% normal saline, intravenously
41510179|NCT06233773|PROCEDURE|Kinesio Taping|Kinesio Taping
40855086|NCT04955327|DRUG|A. Chilensis|Extract from A. Chilensis
41037458|NCT04980833|DRUG|Alpelisib|Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.
41037459|NCT01427075|PROCEDURE|LATERAL PHARYNGOPLASTY|tonsilectomy and lateral pharyngoplasty
41037460|NCT00278434|DRUG|Zoledronate|
41037461|NCT00278434|OTHER|Placebo (Saline)|
41037462|NCT04295564|OTHER|Additional 2 weeks of CPAP|Subjects will be randomized to an additional 2 weeks of CPAP vs. discontinuing CPAP per usual care.
41037463|NCT05189730|DRUG|Tirelizumab|Two cycles of Tirelizumab (200mg administered as an intravenous infusion over 30 minutes per 3 weeks), D1.
41166256|NCT03385798|PROCEDURE|Endowrist|Anastomosis made by Endowrist
41385609|NCT04921384|DRUG|Eptinezumab|Solution for infusion, intravenously
41385610|NCT01578018|OTHER|Measure DCAM levels in blood|Measure DCAM levels in blood
41385611|NCT01578018|OTHER|DCAM levels in blood|DCAM levels in blood
40855087|NCT04955327|DRUG|A. Paniculata and A. Chilensis|Combination of A. Paniculata and A. Chilensis
41385612|NCT04829422|DRUG|Lazertinib 240 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
41385613|NCT03910010|DRUG|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
40855088|NCT04955327|DRUG|Microcrystalline cellulose|Placebo comparator
41510180|NCT06233773|PROCEDURE|Manual Lymph Drainage|Manual Lymph Drainage Group
40855089|NCT04326582|OTHER|Observation|Determine of percentage of each type of arthritis in children, it's prognosis and outcome of treatment in comparison with international guidelines
40855090|NCT02452424|DRUG|PLX3397|PLX3397 capsules, 200 mg
40855091|NCT02452424|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 200 mg, IV
40855092|NCT01858740|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
40855093|NCT01858740|DRUG|Fludarabine Phosphate|Given IV
40855094|NCT01858740|OTHER|Laboratory Biomarker Analysis|Correlative studies
40855095|NCT01858740|DRUG|Methotrexate|Given IV
41166257|NCT03385798|PROCEDURE|Endo-GIA|Anastomosis made by Endo-GIA
41385614|NCT05782309|DRUG|Flavanol|Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment
41385615|NCT05782309|DRUG|Placebo|Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
41385616|NCT04837274|DIETARY_SUPPLEMENT|Placebo|Dextrose (480 mg)
41385617|NCT04837274|DIETARY_SUPPLEMENT|Active|Tary Cherry (480 mg)
41385618|NCT04682977|OTHER|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning)|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning) is an intervention designed to be delivered in primary care settings by an on-site occupational therapist. Based on the premise of preventing the physical and cognitive decline that is associated with aging and chronic disease, the 12-week intervention includes a comprehensive assessment of ADL functioning and ten intervention sessions addressing disease management, physical activity and executive functioning.
41385619|NCT04682977|OTHER|Usual primary care services|Usual primary care services might include monitoring of vitals and other relevant laboratory testing, prescription of medications for chronic disease management, as well as counseling for lifestyle changes.
41385620|NCT06562439|BEHAVIORAL|Sickle Cell Collaboration for Child Development|The Sickle Cell Collaboration for Child Development (SCCCD) combines the Parents as Teachers curriculum with experienced occupational therapy to help families and children meet their learning and developmental goals.
40855096|NCT01858740|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
40855097|NCT01858740|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
41166258|NCT02446379|DRUG|The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose|The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
41166259|NCT02446379|DEVICE|EnLightTM|The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
41166260|NCT02446379|DEVICE|LightPathTM Imaging System|The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
41166261|NCT05598138|BIOLOGICAL|Biological Collection|A blood sample (10 ml) will be taken for each patient included in the study.
41166262|NCT05685953|BIOLOGICAL|DNA vaccine OC-007|Plasmid DNA vaccine
41166263|NCT05685953|OTHER|Placebo|0.9% NaCl solution
41385621|NCT02817269|OTHER|Manual palpation|The manual palpation level will kept constant by applying enough digital pressure to cause the finger nail bed to blanch. When the nail will be turn pale, the amount of pressure will be measured at approximately 3 4kg/cm2 and will be maintained for 5-10 seconds to evoke referred pain. A manual palpation referred pain will be present if the pain radiated far enough for the patient to feel more than just a local pain.
41385622|NCT02817269|OTHER|Deep dry needling|Intramuscular needling will be carried out via deep dry needling into myofascial trigger point (MTrP) area without the introduction any substances. The aim is to elicit a local twitch response upon inserting the needle into the MTrP area and perform a neurological stimulation (by rotating the needle 360 degrees) to more easily evoke referred pain, holding for 10 seconds and then extracting the needle gently. The procedure will be followed by one minute of haemostatic compression.
41510181|NCT06233773|OTHER|Control Group|Control Group
41510182|NCT00762112|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
41510183|NCT02422524|DRUG|PA-824|Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
40855098|NCT01858740|DRUG|Tacrolimus|Given IV or PO
40855099|NCT01858740|DRUG|Thiotepa|Given IV
40855100|NCT01858740|RADIATION|Total-Body Irradiation|Undergo TBI
40855101|NCT04921904|DRUG|Abemaciclib|150mg dose administered orally twice daily every day
40855102|NCT04921904|DRUG|Ramucirumab|8mg/kg iv every 2 weeks until evidence of disease
40855103|NCT06341556|DRUG|Zanubrutinib|Patients diagnosed with mantle cell lymphoma who have achieved remission (CR or PR) by first-line immunochemotherapy, will be treated with Zanubrutinib monotherapy for 2 years (or until PD, intolerable toxicity, death, withdrawal, or study termination).
40855104|NCT04920383|DRUG|ALPN-202|Various doses
40855105|NCT04920383|DRUG|pembrolizumab KEYTRUDA®|Varies
40855106|NCT05464823|OTHER|Molecular Functional Portrait|Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test
40855107|NCT04386954|PROCEDURE|observational study|observation study
40855108|NCT02675010|OTHER|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
40855109|NCT00374933|DRUG|Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
40855110|NCT00374933|DRUG|"Prophylactic delayed ADLI"|"Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
40855111|NCT00374933|DRUG|"Prophylactic delayed activated donor lymphocyte infusion"|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
40855112|NCT01559051|PROCEDURE|Lipoaspiration with Local anesthesia|Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
41385623|NCT00753909|DRUG|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
41385624|NCT00753909|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
41385625|NCT00753909|DRUG|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
41385626|NCT06565910|DRUG|Liposomal bupivacaine plus bupivacaine|Liposomal bupivacaine is a prolonged-release formulation of the local anesthetic bupivacaine. This intervention involves the administration of liposomal bupivacaine plus bupivacaine as a local anesthetic for the pericapsular nerve group (PENG) block under ultrasound guidance. Liposomal bupivacaine is being investigated for its analgesic effect in postoperative pain management following hip replacement surgery. This formulation is designed to provide extended pain relief as compared to conventional bupivacaine formulations.
41510184|NCT04796298|PROCEDURE|Ballistic Hamstring Stretching|Athletes were asked to reach the floor in the BS group by leaning over in the standing posture without knee flexion. When they feel the tension in hamstring muscle groups, athletes were requested to make small rebounding motion at degrees between 3°-5° for half a minute.
41510185|NCT04796298|PROCEDURE|Hamstring Extender Exercise|Athletes were asked to applied 12 repetitions and 3 sets of hamstring extender exercise. Firstly athlete lies on his/her back. Then, athlete is asked to do 90 degrees of knee and hip flexion at the same time. Finally, the person is expected to perform slow repetitive knee extension to the point of maximal possible extension.
41510186|NCT04796298|PROCEDURE|Kinesiotape|Kinesio tape is applied on the hamstring muscle with a Y shape and %25 tension force.
41510187|NCT05387343|DIAGNOSTIC_TEST|Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test|Boosters will be given after month 3 after transplant, and the 2nd booster will be given 3 months after the first.
41510188|NCT02096432|BEHAVIORAL|Behavior Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
41510189|NCT02096432|BEHAVIORAL|Usual Community Care|Community standard care as usual
41510190|NCT05501535|DEVICE|ND:YAG LASER|The standard therapy for PCO is now Nd: YAG laser posterior capsulotomy, which has a success rate of more than 95%. The neodymium: yttrium-aluminum-garnet (Nd:YAG) laser, with a wavelength of 1064 nm, is a solid-state laser that may destroy ocular tissues by achieving optical breakdown with a brief, high-power pulse .Ionization or plasma production occurs in the ocular tissue as a result of optical breakdown. This plasma production subsequently generates acoustic and shock waves, which destroy tissue. Because of its cost-effectiveness, speed, and lack of invasiveness, it is the chosen treatment option in PCO
41037464|NCT05189730|DRUG|Paclitaxel|Two cycles of paclitaxel (135mg/m2 administered as an intravenous infusion per 3 weeks), D1.
41037465|NCT05189730|DRUG|Carboplatin|Two cycles of carboplatin(AUC=5 administered as an intravenous infusion per 3 weeks) D1.
41166264|NCT04713813|OTHER|Therapeutic exercise program via hippotherapy mechanical stimulator|Patients were planned to complete hippotherapy exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
41166265|NCT04713813|OTHER|Therapeutic home exercise program|Patients were planned to complete home exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
41166266|NCT04441996|BIOLOGICAL|Therapeutic plasma exchange (TPE)|Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.
41385627|NCT06565910|DRUG|Ropivacaine|Ropivacaine is a commonly used local anesthetic in clinical practice, and it serves as the active comparator intervention in this study. Participants in the comparator arm will receive ropivacaine as a local anesthetic for the PENG block under ultrasound guidance.
41385628|NCT04951817|DRUG|Ga-68 PSMA ligand|For PET/CT PSMA scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later.PSMA PET-CT scan was performed on a GE Discovery MI PET/CT system.
41385629|NCT06523400|DRUG|Mexiletine granules for prolonged-release oral suspension|Mexiletine PR
41510191|NCT04983186|DEVICE|Wearable sensor and smartphone application|Empatica E4 wearable sensor and custom-made headache smartphone application
41385630|NCT06523400|DRUG|Placebo|Matching Placebo
40855113|NCT03746717|DEVICE|occlusive wound closure|skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue
40855114|NCT03746717|DEVICE|conventional wound closure|wound closure with surgical staples
40855115|NCT06351449|OTHER|The patch under study is photographed using the SkinCam®|Unlike standard care, the patch under study is photographed using the SkinCam® and not a standard camera. The shooting and photographic remain similar to that of standard care, with only the camera used being changed.
41037466|NCT05189730|RADIATION|Neoadiuvant radiotherapy|Simultaneous radiotherapy would be consecutively performed for 4 weeks with the total dose of 40Gy (40Gy/ 4W /20F), D1.
41037467|NCT02925455|DEVICE|Contralaterally-controlled functional electrical stimulation|Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.
41037468|NCT02925455|DEVICE|Hand therapy video games|Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
40855116|NCT03245398|DRUG|Treatment with one of the two regimens of mebendazole|Once in the morning and once in the evening for 3 consecutive days
40855117|NCT02519595|DRUG|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
40855118|NCT02519595|DRUG|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
40855119|NCT02519595|DRUG|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
40855120|NCT02272712|BEHAVIORAL|Cognitive Behavioural Therapy|psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
40855121|NCT06549426|DRUG|anti-seizure medication + sedative agent(s)|"Stepwise approach:~1. a single dose of a parenteral benzodiazepine (lorazepam, midazolam, or diazepam) and a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)~2. a second parenteral anti-seizure medication plus a first continuous parenteral sedative agent (midazolam or propofol)~3. a second continuous parenteral sedative agent (midazolam, propofol, or ketamine)"
40855122|NCT03106636|BEHAVIORAL|KEEP-P|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.
41037469|NCT04760093|DIETARY_SUPPLEMENT|Low polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming low polyphenol concentration EVOO daily.
41385631|NCT01407107|DRUG|Nitroglycerin 0.2 MG/HR|0.2mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr).
41510192|NCT01171261|BEHAVIORAL|Health Games Field Trial|There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
41385632|NCT01407107|DRUG|Nitroglycerin 0.4 MG/HR|0.4mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients.
41385633|NCT01407107|DRUG|Nitroglycerin 0.6 MG/HR|0.6mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients and if this is well tolerated an even higher dose patch (0.6mg/hr) will be used.
41385634|NCT02487979|DRUG|Glembatumumab Vedotin|Given IV
41385635|NCT02487979|OTHER|Laboratory Biomarker Analysis|Correlative studies
41385636|NCT02487979|OTHER|Pharmacological Study|Correlative studies
41385637|NCT04904978|OTHER|Blanx Black Toothpaste|Use of Blanx Black Toothpaste twice a day per at least 2 minutes.
41385638|NCT04904978|OTHER|Colgate Sensation White|Use of Colgate Sensation White Toothpaste twice a day per at least 2 minutes
41385639|NCT06298487|OTHER|Patient questionnaires|Patients questionnaires, on paper or online (Microsoft Form) and data collection on patients medical file
41385640|NCT03109613|DEVICE|Positive end-expiratory pressure (PEEP)|level changes as per arm description
41385641|NCT06059547|DRUG|Nivolumab|Biological, monoclonal antibody
41037470|NCT04760093|DIETARY_SUPPLEMENT|High polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming high polyphenol concentration EVOO daily.
41037471|NCT01911403|PROCEDURE|Manual compression|Closure procedure by Manual compression
41037472|NCT01911403|DEVICE|Angio-Seal|Closure procedure by angio-Seal
41385642|NCT06059547|DRUG|Visugromab (CTL-002)|Biological, monoclonal antibody
41385643|NCT06059547|DRUG|Placebo|Placebo for Visugromab (CTL-002)
41385644|NCT04074798|BEHAVIORAL|assessment of hyperventilation, postural control and psychological behavior|assessment of hyperventilation, postural control and psychological behavior
41385645|NCT04903717|BEHAVIORAL|Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.
41385646|NCT00228878|PROCEDURE|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
40855123|NCT03106636|BEHAVIORAL|KEEP-P+|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
41037473|NCT06081348|DRUG|Sertraline|Oral capsule (25mg, 50mg, 100mg, 200mg)
41037474|NCT06081348|OTHER|Placebo|Oral placebo capsule
41037475|NCT03792113|PROCEDURE|Periodontal Flap Surgery|Periodontal access flap surgery will be performed in both test site followed by control site in each subject
40855124|NCT02836405|DEVICE|Transcranial Magnetic Stimulation|Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
40855125|NCT05058924|DRUG|Prophylactic low molecular weight heparin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.
40855126|NCT05058924|DRUG|Low molecular weight heparin and low-dose aspirin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for three weeks followed by ASA 81 mg orally daily for three weeks.
40855127|NCT04805437|DEVICE|3D TLSO|Brace treatment with Boston 3D 20 hours a day until skeletal maturity.
40855128|NCT04805437|DEVICE|Standard TLSO|Brace treatment with standard Boston brace 20 hours a day until skeletal maturity.
40855129|NCT04362423|DEVICE|fNIRS|Near infrared spectroscopy (NIRS) is a non-invasive, portable, relatively inexpensive optical technology similar to pulse oximetry except that it measures total hemoglobin, oxy-hemoglobin, and deoxyhemoglobin in brain tissue (capillaries) rather than arteries.
40855130|NCT03145259|DRUG|Diclofenac Epolamine Patch|patch
40855131|NCT03145259|DRUG|diclofenac sodium solution|solution
40855132|NCT05814952|GENETIC|LX103 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.
40855133|NCT05830669|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 cycles of 5 min inflation of a blood-pressure cuff to 200 millimetres of mercury (mmHG) (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed.
40855134|NCT05830669|PROCEDURE|Sham RIPC|3 cycles of 5 min inflation of a blood-pressure cuff to 20 mmHG to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed
40855135|NCT03469791|PROCEDURE|Surgical treatment of Degenerative Spondylolisthesis|
41166267|NCT04441996|OTHER|Standard of care|Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
41166268|NCT00000959|DRUG|Isoniazid|
41166269|NCT00000959|DRUG|Pyridoxine hydrochloride|
41166270|NCT02276209|DRUG|Dasotraline|Dasotraline 4 mg once daily
41166271|NCT02276209|DRUG|Dasotraline|Dasotraline 6 mg once daily
41385647|NCT05629117|BEHAVIORAL|Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education|Patients who are assigned to the DB-TEXT+PSE group will receive personalized short text message services twice weekly at approximately noon on Monday and Thursday for three months (12 weeks). Furthermore, they will receive the peer support education weekly from the peer supporter by telephone during three months
41510193|NCT00588588|PROCEDURE|Bronchoscopy|Bronchoscopy procedure
41385648|NCT05629117|BEHAVIORAL|Personalized Diabetes Text Messaging (DB-TEXT)|Personalized Diabetes Text Messaging (DB-TEXT)
41385649|NCT03599843|BEHAVIORAL|Exercise|Participants will complete a 12 week exercise session that will be comprised of aerobic and/or resistance and/or flexibility training.
41385650|NCT02179385|BEHAVIORAL|Health Coaching|
40855136|NCT02240355|DRUG|RO6885247|oral solution
40855137|NCT02240355|DRUG|placebo|oral solution
40855138|NCT05411744|DRUG|1 month Rifapentine, Isoniazid and Vitamin B6|Participants will be treated with one month (4 weeks) of daily Isoniazid, Rifapentine and Vitamin B6.
40855139|NCT04306263|DIETARY_SUPPLEMENT|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics
41510194|NCT00588588|PROCEDURE|Clinical pulmonary infection score (CPIS)|Calculate CPIS
41510195|NCT00538369|OTHER|Ramsay Scale|While receiving sedation, subjects will be monitored with the Ramsay scale
41510196|NCT00538369|DEVICE|Bispectral index monitor|While receiving sedation, subjects will receive BIS monitoring
41166272|NCT02276209|OTHER|Placebo|Placebo once daily
41166273|NCT03168698|DRUG|Carbetocin|Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
40855140|NCT04306263|DIETARY_SUPPLEMENT|Standard formula|Infants receiving a standard infant formula.
40855141|NCT04306263|DIETARY_SUPPLEMENT|Breastfeeding arm|Infants exclusively or predominantly breastfed (\>75%).
40855142|NCT03430232|DRUG|Placebo|Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%
40855143|NCT03430232|DRUG|STR-324 Dose Level 1|Short infusion of a solution for intravenous administration
40855144|NCT03430232|DRUG|STR-324 Dose Level 2|Short infusion of a solution for intravenous administration
40855145|NCT03430232|DRUG|STR-324 Dose Level 3|Short infusion of a solution for intravenous administration
40855146|NCT03430232|DRUG|STR-324 Dose Level 4|Short infusion of a solution for intravenous administration
40855147|NCT03430232|DRUG|STR-324 Dose Level 5|Short infusion of a solution for intravenous administration
40855148|NCT03430232|DRUG|STR-324 Dose Level 6|Short infusion of a solution for intravenous administration
40855149|NCT03430232|DRUG|STR-324 Dose Level 7|Short infusion of a solution for intravenous administration
40855150|NCT03430232|DRUG|STR-324 Dose Level 8|Short infusion of a solution for intravenous administration
40855151|NCT03430232|DRUG|STR-324 Dose Level A|Long infusion of a solution for intravenous administration
40855152|NCT03430232|DRUG|STR-324 Dose Level B|Long infusion of a solution for intravenous administration
41166274|NCT03168698|DRUG|Oxytocin|Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
41166275|NCT00328380|DRUG|Rifaximin|
41166276|NCT00138918|BIOLOGICAL|OGX-011|See Detailed Description, Treatment Plan
41166277|NCT02230293|OTHER|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
41166278|NCT02230293|OTHER|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
41166279|NCT02955706|DRUG|Acetyl-L-Carnitine|TID
41166280|NCT02955706|DRUG|Placebo of Acetyl-L-Carnitine|TID
41385651|NCT06537505|DRUG|Adebrelimab|Q3W,IV
41510197|NCT01223378|DRUG|BOL-303259-X|ophthalmic solution, various concentrations, once daily (QD) 28 days
41510198|NCT01223378|DRUG|Latanoprost|0.005% ophthalmic solution, QD 28 days
41510199|NCT05160740|DRUG|Indocyanine green for injection|ICG will be injected to participants preoperatively for molecular fluorescence image
41510200|NCT03214783|OTHER|Facial characteristics|The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.
41510201|NCT05086263|DEVICE|Pico G2 4k|"On this virtual reality headset, it will be loaded with an educational virtual reality mock MRI training titled Ready Teddy. This training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Furthermore, using audio/visual cues, when the viewer moves their head too much in a MRI like setting they are reminded to stay still. Biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure."
41510202|NCT04246827|BEHAVIORAL|Enhanced Lifestyle Weight Management|The Enhanced Lifestyle Weight Management program was a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors were integrated into a lifestyle behavioral weight loss intervention.
41510203|NCT04430192|DRUG|177Lu-PSMA-617|Patients 1-10 will be given 5GBq of 177Lu-PSMA. Patients 11-20 will be given 2 cycles of 5GBq of 177Lu-PSMA, separated by 6 weeks.
41510204|NCT04922723|DRUG|Daratumumab|Daratumumab will be administered by IV infusion to subjects in combination with current therapeutic strategies of surgical resection followed by a course of Temozolomide and radiation therapy.
41510205|NCT00137761|DRUG|ZD 1839|Taken orally once daily
41510206|NCT00137761|DRUG|Docetaxel|Given intravenously once weekly for 2 out of 3 weeks
41510207|NCT05783232|DIETARY_SUPPLEMENT|Placebo Control Form 1 Capsules|Participants will use their Placebo Control Form 1 Capsules as directed for a period of 4 weeks.
41510208|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.1 Capsules|Participants will use their Radicle Health Active Study Product 1.1 Capsules as directed for a period of 4 weeks.
41510209|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.2 Capsules|Participants will use their Radicle Health Active Study Product 1.2 Capsules as directed for a period of 4 weeks.
41385652|NCT06537505|DRUG|Apatinib|QoD
41385653|NCT06537505|PROCEDURE|microwave ablation|microwave ablation
41385654|NCT05784714|BEHAVIORAL|NOLA GEM|This is a mobile application that has 6 psychoeducational sessions and related skills, local resources, and a way for participants to track their progress. Further information is in the arm descriptions.
41385655|NCT05503030|DRUG|Nintedanib|Nintedanib
41385656|NCT04064931|DIAGNOSTIC_TEST|Detection of niacin and other vitamins in plasma|Detection of niacin and other vitamins in plasma
41385657|NCT00557830|DRUG|Sorafenib Escalated Dose|Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
41385658|NCT00557830|DRUG|Sorafenib Standard Dose|Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
41385659|NCT01578603|DIETARY_SUPPLEMENT|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
41385660|NCT01578603|DIETARY_SUPPLEMENT|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
41385661|NCT03494673|DIAGNOSTIC_TEST|BOLD MRI|"1. Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~2. BOLD MR images will be obtained by using a T2\*-weighted two-dimensional gradient-echo sequence with echoplanar readout."
41510210|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.3 Capsules|Participants will use their Radicle Health Active Study Product 1.3 Capsules as directed for a period of 4 weeks.
41510211|NCT05336188|DEVICE|Smartphone|Adjunctive Smartphone app for improving MAT outcomes
41510212|NCT00142389|BIOLOGICAL|pneumococcal polysaccharide and protein conjugate vaccines|
41385662|NCT03286595|OTHER|Mobi mHealth app|"Mobile application (i.e. the app) that patients interact with via their smartphone to collect daily and weekly survey information. Data is visualized on a clinician-facing Dashboard, which can be used to inform treatment."
41510213|NCT02033538|DRUG|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
40855153|NCT03430232|DRUG|STR-324 Dose Level C|Long infusion of a solution for intravenous administration
41385663|NCT00568464|DRUG|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
41385664|NCT02545868|BIOLOGICAL|23-PPV|The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
41510214|NCT03075020|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass
41510215|NCT03075020|OTHER|AIR|Room air will be administered as placebo
41510216|NCT04912232|DEVICE|Detection of Occult Hemorrhage in Trauma Patients|Non-invasive monitoring of trauma patients
41510217|NCT04170556|DRUG|Regorafenib|Regorafenib 160 mg/day 3 weeks on and 1 week off
40855154|NCT03430232|DRUG|Placebo|Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%
41510218|NCT04170556|DRUG|Nivolumab|Nivolumab at the dose of 1.5 mg/kg, 3 mg/kg or 240 mg/infusion every 2 weeks. Dose will be adjusted depending on the incidence of adverse events
41510219|NCT01822717|BEHAVIORAL|Nonvisual foot inspection|Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
41510220|NCT01822717|BEHAVIORAL|Usual Care|Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
41385665|NCT02545868|BIOLOGICAL|13-PCV Booster|The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).
41385666|NCT02545868|BIOLOGICAL|Influenza Vaccine|The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
41510221|NCT01134302|PROCEDURE|Norwood management strategy|Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.
41510222|NCT01134302|PROCEDURE|Hybrid Strategy|"Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.~The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies."
41510223|NCT05972330|DIETARY_SUPPLEMENT|VRx MyBiotics Oral Lozenges|VRx MyBiotics Oral Lozenges are composed of prebiotics, probiotics, and postbiotics.
41510224|NCT01241110|DRUG|Ofloxacin group A, Azitromycin group B|Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
41510225|NCT01241110|DRUG|azitromycin|azitromicin vs ofluxacin
40855155|NCT03967522|DRUG|Cabozantinib|All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
41166281|NCT02713737|DEVICE|heated humidified high-flow nasal cannula|HFNC device (Airvo™, Fisher＆Paykel, Auckland, New Zealand) with a heated circuit (Fisher＆Paykel,900PT501) and nasal cannula(optiflow TM,Fisher＆Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) \> 92%.
41385667|NCT02545868|BIOLOGICAL|KLH|KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
41385668|NCT02545868|DRUG|OCR|OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
41385669|NCT02545868|BIOLOGICAL|TT Vaccine|The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
41385670|NCT04795973|BEHAVIORAL|time-restricted fasting for 4 weeks|eat ad libitum from 7am to 5pm and fast in other time
41385671|NCT04795973|BEHAVIORAL|5:2 regimen for 4 weeks|chose two non-consecutive days per week to eat very little and eat ad libitum the other 5 days of the week
41510226|NCT04233424|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
41510227|NCT04233424|OTHER|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
41510228|NCT05207891|DEVICE|Intervention mattress|The intervention mattress, Tidewave, will be compared to the regular care mattress, CuroCell 4AD. Primary outcome will be change in pressure injury occurence, assessed according to the NPIAP 2019 Clinical Guidance, and marked up on pressure injury body-map figures. Secondary outcomes will be experienced quality of life, assessed with the Spinal Cord Injury Quality of Life Basic Data Set. Further mattress comfort, assessed with the Mattress Comfort Scale, sleep-wellness, assessed with the Insomnia Severity Index, and pain, assessed with the Brief Pain Inventory. Satisfaction in the participants and in the nursing staff will be assessed with custom made Likert scales. Resource use and experienced stain in the nursing staff will be assessed with custom made forms asking for number of persons needed in position change, number of position changes needed during bed-rest, and experienced strain related to the position changes.
41510229|NCT03168334|DRUG|IDP-123 Lotion|Tazarotene 0.045% Lotion
41385672|NCT02972086|BEHAVIORAL|Behavioral Parent Training (BPT)|A specific intervention modality that has been shown to improve key functional outcomes in youth with ADHD.
41385673|NCT00182273|PROCEDURE|Canalith repositioning maneuver (CRM)|
41510230|NCT03168334|DRUG|IDP-123 Vehicle Lotion|Vehicle Lotion
41528341|NCT03786328|BEHAVIORAL|Preventive Psychological Treatment|Preventive Psychological Treatment is offered individuals identified with a sub-clinical mental condition. Treatment consists of 8 sessions of cognitive-behavioural therapy.
40855156|NCT00862693|DRUG|Calcitriol|0.5ug/Biw
40855157|NCT01658761|PROCEDURE|vitrectomy|Surgery
40855158|NCT02649894|DEVICE|Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter|
40855159|NCT02649894|DEVICE|Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|
40855160|NCT00534547|PROCEDURE|Duodenal Exclusion|duodenal-jejunal bypass
40855161|NCT03403439|DRUG|BI 1015550|Reference and Test Treatment
40855162|NCT03403439|DRUG|itraconazole|Test treatment
40855163|NCT04639024|DRUG|ADCT-301|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
40855164|NCT04221646|DEVICE|BTL-899|Treatment with study device.
40855165|NCT00972530|BEHAVIORAL|immobilisation in a triangular sling|"Intervention group: Immobilisation 48 hours in a triangular sling (mitella)~Control group: normal activity without restrictions"
40855166|NCT06085326|OTHER|Smart Checklist|The digitized Smart Checklist includes three new features that currently do not exist on a paper checklist: 1) decision support prompts based on patient-provider dyad characteristics, 2) real time display of patient pertinent airway information from the EHR, and 3) high-risk warning alerts based on predictive analytics with potential explanatory factors from the model.
41166282|NCT02713737|DEVICE|noninvasive ventilation|TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 \> 92%.
41166283|NCT03972397|DEVICE|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYO2 cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
41166284|NCT03972397|DRUG|Bupivacaine liposomal injectable suspension|Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).
41166285|NCT03972397|DRUG|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
41385674|NCT04464382|PROCEDURE|Outpatient (OA)|"Patients who are candidates for OA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the OA group (case group), he will be discharged on an outpatient basis from the post-surgical stay unit without requiring hospital admission."
41385675|NCT04464382|PROCEDURE|Hospitalization appendectomy (HA)|"Patients who are candidates for HA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the case group (HA), he will be admitted in hospital beds."
41385676|NCT00567996|DRUG|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
41385677|NCT00567996|DRUG|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
40855167|NCT04887519|OTHER|No Intervention|This is a non-interventional study.
40855168|NCT02932748|DIETARY_SUPPLEMENT|Portion Controlled Meals (PCM)|Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
40855169|NCT02932748|BEHAVIORAL|Group Phone (GP)|Weight management program delivered via group conference call.
40855170|NCT02932748|DIETARY_SUPPLEMENT|Conventional Diet|Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
41385678|NCT00567996|DRUG|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
41385679|NCT00567996|DRUG|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
40855171|NCT02932748|BEHAVIORAL|Individual Phone (IP)|Weight management program delivered via individual phone call.
40855172|NCT02932748|BEHAVIORAL|Enhanced Usual Care (EUC)|Weight management topics delivered face-to-face at clinic office every 6 months.
40855173|NCT00584259|OTHER|Coffee|3 cups of coffee over a 24 hour period
40855174|NCT05686564|DRUG|ALXN1840|bis-choline tetrathiomolybdate
40855175|NCT02484352|DRUG|saline|different dosage of IV oxycodone was given before intubation
40855176|NCT02484352|DRUG|0.05 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
40855177|NCT02484352|DRUG|0.1 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
40855178|NCT02484352|DRUG|0.15 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
40855179|NCT02484352|DRUG|0.2 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
40855180|NCT02549001|DRUG|P-3058 10%|
40855181|NCT02549001|DRUG|vehicle of P-3058 10%|
40855182|NCT02549001|DRUG|amorolfine 5%|
40855183|NCT05950698|DEVICE|Holter Faros 360° EKG (Bittium Corporation)|Patients will lie down on the examination table, a five-lead ECG will be attached to their chest, and they should rest for 5 minutes before starting the ECG recording. ECG data will be collected for a 15-minute period Heart Rate Variability (HRV) recording will be performed between 09:00 and 12:00 in a fixed examination room to minimize environmental factors and diurnal fluctuations in autonomic nervous system functioning.
41510231|NCT03776149|DIETARY_SUPPLEMENT|Beetroot juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
41510232|NCT03776149|DIETARY_SUPPLEMENT|Black currant juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
41385680|NCT06502366|DRUG|BDA MDI HFO 160/180 μg|Budesonide/albuterol pressurized inhalation suspension, HFO
40855184|NCT05950698|DIAGNOSTIC_TEST|Beck Depression Inventory (BDI)|The BDI assesses the depression severity. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
40855185|NCT05950698|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scales - HADS|The HADS assesses the anxiety and depression symptoms. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
40855186|NCT05950698|DIAGNOSTIC_TEST|Three Factor Eating Questionnaire-R21 - TFEQ-R21|The TFEQ-R21assesses the quality of eating behavior. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
40855187|NCT05950698|DIAGNOSTIC_TEST|hort-Form Health Survey-36 itens - SF-36|he TFEQ-R21assesses the quality of life Divided into different areas (functional capacity, general health status, pain, vitality, social aspects, emotional aspects, and mental health). It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
41510233|NCT02740192|PROCEDURE|Adductor Canal Block|Post-op adductor canal block using Bupivacaine
40855188|NCT03127176|OTHER|Genome sequencing of fecal samples|Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
40855189|NCT03583970|DEVICE|Left Ventricular Assist Device Implantation|Veno-arterial extracorporeal membrane oxygenation prior to left ventricular assist device implantation : initial patients characteristics and 6 Month Follow-up
40855190|NCT02100969|DRUG|HIZENTRA ®|Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
40855191|NCT00145574|DRUG|colesevelam HCl|Tablets
40855192|NCT00145574|DRUG|placebo|Matching Tablets
40855193|NCT00550966|BEHAVIORAL|Psychoeducative program in fibromyalgic patients|Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
41166286|NCT02711813|DRUG|TAB08|biologic
41166287|NCT02711813|OTHER|Placebo|
41166288|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation I
41385681|NCT06502366|DRUG|BDA MDI HFA 160/180 μg|Budesonide/albuterol pressurized inhalation suspension, HFA
41385682|NCT06502366|DRUG|Placebo MDI HFA|Placebo pressurized inhalation suspension, HFA
41385683|NCT01961635|DEVICE|dental implants|place implant according fabricant guidelines, 2mm sub-crestally
41385684|NCT01961635|DEVICE|Zirconia abutments|place zirconia abutment on the day of implant placement
41385685|NCT01961635|DEVICE|Titanium Abutments|place titanium abutment on the day of implant placement
41385686|NCT01961635|DEVICE|cad-cam acrylic abutments|place cad-cam acrylic abutment on the day of implant placement
41385687|NCT01961635|PROCEDURE|Subcrestal|place implant 2mm below crestal bone
41385688|NCT01961635|DEVICE|platform-switch|abutment platform is narrow than implant diameter
41385689|NCT01961635|PROCEDURE|one-time one-abutment|place the final abutment on the day of surgery and not remove it
41510234|NCT02740192|PROCEDURE|Periarticular Injection|Intra-op periarticular injection of Ropivacaine
41510235|NCT02740192|DRUG|Ropivacaine|Ropivacaine was used for the periarticular injection
41510236|NCT02740192|DRUG|Bupivacaine|Bupivacaine was used for the periarticular injection
41510237|NCT02797197|PROCEDURE|handgrip strength test|
41510238|NCT02797197|DRUG|chemotherapy|
41510239|NCT04714073|DRUG|BI 706321|BI 706321
41510240|NCT04714073|DRUG|Itraconazole|Itraconazole
41166289|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation II
41166290|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation III
41166291|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation IV
41166292|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation V
41166293|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation VI
41166294|NCT00937521|BIOLOGICAL|Control|Control
41166295|NCT00937521|BIOLOGICAL|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
41385690|NCT01961635|PROCEDURE|Torque 20 n/cm2|the amount of torque applied to the abutment
41385691|NCT01445236|OTHER|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
41385692|NCT00308100|DRUG|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
41385693|NCT00308100|DRUG|5% Albumin|5% albumin, administered intra- and perioperatively
41385694|NCT04775082|DRUG|Liraglutide|"The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.~The dose will increase each week over 4 or 5 weeks until the final dose is reached."
41385695|NCT04775082|DRUG|Placebo|The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
41385696|NCT02871466|DRUG|stem cells infusion|
41510241|NCT05935202|DRUG|Mitapivat sulfate|Subjects enrolled Maximum dose: will receive Mitapivat during 56 weeks Starting dose: 50 mg BD Maximum dose: 100 mg BD
40855194|NCT04891354|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
40855195|NCT04891354|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
40855196|NCT00964821|BIOLOGICAL|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
40855197|NCT00964821|OTHER|Immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
40855198|NCT00964821|OTHER|Laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
40855199|NCT01080846|DRUG|Misoprostol|600 mcg of sublingual misoprostol
40855200|NCT03058900|DRUG|Fecal microbiota transplantation (FMT)|One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.
40855201|NCT03058900|OTHER|Drug: Placebo (saline)|One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.
40855202|NCT03058900|DRUG|Methotrexate (MTX)|Weekly methotrexate in maximum tolerable dosis
40855203|NCT03235947|DRUG|Fosfomycin disodium|Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
40855204|NCT03235947|DRUG|Trimethoprim / Sulfamethoxazole|Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
40855205|NCT03235947|DRUG|Intravenous placebo|Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
40855206|NCT04826939|DEVICE|PFDx device and leva device|Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.
41385697|NCT05301101|RADIATION|Re-irradiation|Patients will undergo re-irradiation following treatment planning based on current standard practice as determined by treating physicians and multidisciplinary teams.
40855207|NCT00682526|DEVICE|SmartLink Wireless Monitoring System (K033642)|All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
40855208|NCT05688696|DRUG|Orelabrutinib (Low Dose)|Subjects will be administered with lower dose of Orelabrutinib orally once daily in combination with SOC therapy
40855209|NCT05688696|DRUG|Orelabrutinib (High Dose)|Subjects will be administered with higher dose of Orelabrutinib orally once daily in combination with SOC therapy
40855210|NCT05688696|DRUG|Orelabrutinib Placebo|Subjects will be administered with Orelabrutinib Placebo orally once daily in combination with SOC therapy
41385698|NCT01826032|DEVICE|CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
41385699|NCT01826032|OTHER|Standard care for OSA|sleep higiene and dietary counseling
41385700|NCT00759668|DEVICE|Acrysof Natural ReSTOR SN60D3|Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.
40855211|NCT04966949|PROCEDURE|lateral prostate capsule sparing or neurovascular bundles sparing|When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
41385701|NCT00759668|DEVICE|Acrysof Natural Monofocal SN60AT|Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
41385702|NCT06566430|BEHAVIORAL|PrEP My Way intervention|Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).
41385703|NCT06566430|BEHAVIORAL|PrEP My Way intervention without STI testing|Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. This kit will not contain STI testing. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).
41385704|NCT06566430|BEHAVIORAL|Enhanced standard of care|These participants will receive PrEP (choice of oral, ring, or injection formulation), STI testing, and family planning at the clinic, as requested.
41385705|NCT02729350|BEHAVIORAL|Guided Relaxation video clip|This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.
41385706|NCT02729350|BEHAVIORAL|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute sickle cell disease experience discussion.
40855212|NCT04731519|BEHAVIORAL|Continuous Identity Cognitive Therapy (CI-CT)|CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The recovery oriented CI-CT for post acute suicidal episode Veterans includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
41385707|NCT02380716|DEVICE|GORE® Ascending Stent Graft|
41385708|NCT04819932|DRUG|DWJ1451|DWC202008 DWC202009
41385709|NCT04959708|OTHER|Insula treatment|he intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
41385710|NCT06540222|PROCEDURE|Sustained cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
41385711|NCT06540222|PROCEDURE|Routine (< 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
41385712|NCT00306137|DRUG|Trasylol (Aprotinin, BAYA0128)|"Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~* Stratum 1: complete primary pneumonectomy~* Stratum II: decortication or completion pneumonectomy~* Stratum III: esophagectomy by transhiatal approach~* Stratum IV: esophagectomy by transthoracic approach"
41510242|NCT00372814|BEHAVIORAL|Intensive Home-Based Family Therapy|Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
41510243|NCT00372814|BEHAVIORAL|Supportive Telephone Calls|Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
41510244|NCT02633787|BIOLOGICAL|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be administered in this trial
41385713|NCT00306137|DRUG|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
41510245|NCT04469504|OTHER|Prehabilitation program|4-week trimodal prehabilitation program: Exercise, nutritional supplementation, and psychological support
41510246|NCT04469504|DIETARY_SUPPLEMENT|Oral Impact|perioperative immunonutrition by ORAL IMPACT
41385714|NCT04285736|DRUG|Ivabradine|Ivabradine (5mg twice daily)
41385715|NCT04285736|DRUG|Conventional Treatment|
41385716|NCT05968482|DRUG|Diclofenac Sodium Gel|Topical application on both knees
41385717|NCT04431622|DEVICE|Hearing aid amplification algorithms|The investigators will use stimulus waveforms that have been amplified and recorded for each individual's hearing loss. These waveforms will be created using Desired Sensation Level, Version 5-C hearing aid targets on a continuum of increased signal manipulation. The NIH-funded open hearing aid platform will be used to provide precise control over hearing aid parameters to create waveforms with linear and fast-acting compression amplification. A third set of waveforms will be created using a current clinical hearing aid that uses typical noise reduction and compression parameters. Investigating the effects of hearing aid algorithms in young normal-hearing and older normal-hearing listeners will aid in interpretation of these effects in the older hearing-impaired listeners.
41385718|NCT00243672|DRUG|Atorvastatin|
41510247|NCT05375253|BIOLOGICAL|Donor Enriched Activated Natural Killer Cell Infusion|αβ TCR/CD19 depleted (DEA-NK) cells on day +7 post T-cell replete Haplo-Tx with PTCY
41510248|NCT05338931|DRUG|AT101(Anti-CD19 Chimeric Antigen Receptor T cell)|Anti-CD19 Chimeric Antigen Receptor T cell
41385719|NCT00243672|DRUG|Gemfibrozil|
41385720|NCT01365676|DRUG|GAMALINE® + HIPERICIN®|GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)
41385721|NCT01365676|DRUG|GAMALINE®|GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
41510249|NCT01577550|DRUG|BI 655066 (very high i.v. dose)|Single very high i.v. dose BI 655066
41510250|NCT01577550|DRUG|Placebo, i.v.|Single i.v. administration of placebo
41510251|NCT01577550|DRUG|BI 655066 (high s.c. dose)|Single high s.c. dose BI 655066
41510252|NCT01577550|DRUG|BI 655066 (low i.v. dose)|Single low i.v. dose BI 655066
41510253|NCT01577550|DRUG|BI 655066 (high medium i.v. dose)|Single high medium i.v. dose BI 655066
41510254|NCT01577550|DRUG|BI 655066 (very low i.v. dose)|Single very low i.v. dose BI 655066
41510255|NCT01577550|DRUG|BI 655066 (low s.c. dose)|Single low s.c. dose BI 655066
41510256|NCT01577550|DRUG|BI 655066 (high i.v. dose)|Single high i.v. dose BI 655066
41510257|NCT01577550|DRUG|Placebo, s.c.|Single s.c. administration of placebo
41510258|NCT01577550|DRUG|BI 655066 (low medium i.v. dose)|Single low medium i.v. dose BI 655066
41510259|NCT03347201|DEVICE|HMS Plus|Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.
41510260|NCT03815461|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8, S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle for 4-6 cycles.
41510261|NCT02452437|DRUG|Oxycodone|Controlled release oxycodone 40 mg twice daily
41510262|NCT06459492|BEHAVIORAL|puzzle game strategies|"One innovative approach uses puzzle game strategies, including crosswords, Sudoku, and other brain-teasing activities. These strategies have been shown to help maintain attention, improve memory, and keep older adults' thoughts clear and sharp. Additionally, engaging in these activities can provide psychological benefits by offering a sense of achievement, reducing stress, and fostering social interactions.~Given puzzle games' potential to enhance cognitive and psychological health, exploring their effectiveness as a non-pharmacological intervention for community-dwelling older adults is essential. This research aims to fill the gap by empirically investigating the impact of puzzle game strategies on cognitive functioning and psychological well-being in this demographic."
41037476|NCT03792113|OTHER|Autologous fibrin glue|Autologous fibrin glue procured from the subject's own venous blood will be used to approximate periodontal flaps following access periodontal surgery
41166296|NCT03691142|OTHER|Questionnaire|Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
41385722|NCT02886494|DRUG|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
41385723|NCT02886494|DRUG|Matched vehicle|BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
41385724|NCT00960687|DRUG|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
41385725|NCT00960687|DRUG|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
41385726|NCT06433765|OTHER|No intervention|No intervention
41385727|NCT03319693|GENETIC|Somatic Genetic|NGS analysis
41385728|NCT03387735|OTHER|Treatment as usual (TAU) + Internet|Patients in this group will receive TAU+internet and links to helpful websites.
41385729|NCT03387735|BEHAVIORAL|TAU + ElderTree|"For the patient, ElderTree provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.~For the clinic, ElderTree has a Clinician Report (CR), a visual dashboard of health-tracking data that can be customized based on the needs of the clinic. The CR provides alerts to the clinician when a patient passes a certain threshold. The dashboard is intended to help clinicians prepare for patient office visits."
41385730|NCT02093468|DRUG|MST-188|
41385731|NCT02093468|DRUG|Saline|
41385732|NCT00764244|PROCEDURE|Vitrectomy|Vitrectomy
41385733|NCT00764244|DRUG|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
41385734|NCT00764244|PROCEDURE|Laser photocoagulation|Laser photocoagulation
41385735|NCT03023098|DEVICE|Conventional PTA|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon
41385736|NCT03023098|DEVICE|Drug-eluting balloon|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
41510263|NCT00339144|DRUG|Dasatinib|tablets, Oral, 100 mg, once daily for 4 weeks
41510264|NCT00339144|DRUG|Dasatinib|tablets, Oral, 150 mg, once daily, 4 weeks
41037477|NCT03792113|OTHER|4-0 silk suture|Conventional 4-0 black silk suture will be used to approximate periodontal flaps following access flap surgery
41037478|NCT03835377|OTHER|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
41037479|NCT03835377|OTHER|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
41510265|NCT00339144|DRUG|Dasatinib|tablets, Oral, 200 mg, once daily for 4 weeks
41510266|NCT00601575|DRUG|Lithium|
41510267|NCT00613652|DRUG|AZD4877|10 mg IV (3 weeks treatment 1 week rest)
41510268|NCT04102917|DIAGNOSTIC_TEST|QFR assessment|The quantitative flow ratio (QFR) is a novel angiography-based method for noninvasive functional assessment of intermediate coronary lesions.
41037480|NCT01002326|BEHAVIORAL|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
41037481|NCT00105638|BEHAVIORAL|educational program, by telephone|
41037482|NCT03019536|DRUG|LY3303560 - IV|Administered IV
41037483|NCT03019536|DRUG|Placebo - IV|Administered IV
41037484|NCT03019536|DRUG|Florbetapir F 18|Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
41166297|NCT06136507|DRUG|FRSW107|experimental：Q3D.≥50EDs， Expansion phase：Q3D.100EDs
41166298|NCT03745378|OTHER|JAK2V617F mutation|JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,
41166299|NCT00053768|BIOLOGICAL|filgrastim|
41166300|NCT00053768|DRUG|EPOCH regimen|
41385737|NCT03869684|DRUG|MT-0814|Randomly assigned dose
41385738|NCT03869684|DRUG|Placebo|Placebo manufactured to mimic MT-0814
41385739|NCT04977817|DIETARY_SUPPLEMENT|Similac Probiotic Tri-Blend|Probiotic dietary supplement, Similac Probiotic Tri-Blend
41385740|NCT06184659|DRUG|Meropenem|For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion
41385741|NCT06184659|DRUG|Piperacillin/Tazobactam|Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion
41385742|NCT03069365|DRUG|Glecaprevir/pibrentasvir|Film-coated tablet
41037485|NCT03019536|DRUG|Flortaucipir F18|Administered IV during the PET scan performed during the study.
41037486|NCT04694274|DEVICE|stabilization splint|The device made of a hard acrylic on stone cast of the upper jaw in the centric relation position. It has a thickness of 1.5 mm at the level of the first molar.
41037487|NCT04694274|PROCEDURE|physical therapy|Home-exercise program included exercises for passive and active stretching, joint mobilization, passive extension, and translational movements to the right, left, and forward.
41037488|NCT04694274|DEVICE|placebo splint|The placebo splint was made of thin heat-treatable foil (0.5 mm). The foil was heated and printed over a plaster model of the upper jaw resulting in a very thin film over the occlusal surfaces of all teeth.
41385743|NCT00976859|BEHAVIORAL|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
41385744|NCT00976859|BEHAVIORAL|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
41385745|NCT05113277|BEHAVIORAL|Tonic Immobility Psychoeducation (TIP)|TIP is a 45-minute computerized psychoeducation intervention aimed at addressing maladaptive cognitions and emotions associated with TI while using educational and behavioral techniques commonly used in the treatment of trauma-related disorders. Throughout the psychoeducation program vignettes will be presented to clarify concepts and promote participant engagement. In addition, practice exercises and rating scales will be integrated, where applicable, to increase the interactive nature of the program. The following modules will be addressed in the TI psychoeducation intervention: education, myth busting, and behavioral experiments.
41510269|NCT01547702|BEHAVIORAL|Teacher Help for ADHD|"Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:~* Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology~* Session 2: Help establish teacher's role; goal setting; introduce behaviour planning~* Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals~* Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship~* Session 5: Help to use instructional interventions for ADHD~* Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours"
41385746|NCT05113277|BEHAVIORAL|Health Education Training (HET)|The Healthy Education Training intervention was developed as a 45-minute online intervention that provides education about physical health habits that can impact mental health, such as diet, exercise, and sleep. This intervention has been used in prior clinical trials to control for effects of general education, general coping techniques, and use of technology. Participants in past clinical trials have reported that HET is engaging and beneficial. However, HET is not expected to have an effect on the main symptom outcomes of the current study (guilt, shame, PTSD symptoms).
41385747|NCT04141085|OTHER|Endometrial biopsy|All groups will undergo a mock frozen embryo transfer cycle with an endometrial biopsy being performed as opposed to an embryo transfer
41385748|NCT06537921|DRUG|Minocycline 200mg|Dosage: 2x100mg/daily for 8 weeks
41510270|NCT02129322|DRUG|Sorafenib|
41510271|NCT02129322|DRUG|S-1|
41510272|NCT02129322|DRUG|Oxaliplatin|
41510273|NCT05015283|PROCEDURE|The laparoscopic One-anastomosis gastric bypass will consist of:|gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
41510274|NCT05015283|PROCEDURE|The laparoscopic Roux-en-Y gastric bypass will consist of:|the laparoscopic Roux-en-Y gastric bypass gastric sac size \< 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
41510275|NCT01456806|OTHER|Education|Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
41510276|NCT00690066|DRUG|PROCHYMAL®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
41510277|NCT00690066|DRUG|Placebo|Intravenous infusion of excipients of PROCHYMAL®
41510278|NCT03798925|OTHER|None Intervention|It is observational study
41510279|NCT04801511|DRUG|Vitamin C|High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
41510280|NCT04238650|DRUG|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
41510281|NCT04238650|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
41037489|NCT04388020|DEVICE|Tabletop prototype of eSpecs: Active projection of defocused image in the peripheral visual field|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
41037490|NCT04388020|DEVICE|Tabletop prototype of eSpecs: No Active projection of defocused image in the peripheral visual field|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
41037491|NCT03930472|BEHAVIORAL|Market vouchers|Receiving $80 in vouchers good for fruits and vegetables or for SNAP-eligible foods at 4 out of 5 markets in late July and in August, 2019.
41037492|NCT06516588|DEVICE|Transcranial Dirrect Current Stimulation|tDCS will deliver direct current through rubber electrodes in saline-soaked sponges. Device sends a low-level current from the positive electrode, the anode, to the negative electrode, the cathode. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10mA. The anode will be placed over the LDLPFC and the cathode over the contralateral supra-orbital area.
41510282|NCT00000525|DRUG|hydrochlorothiazide|
41510283|NCT00000525|BEHAVIORAL|diet, potassium supplementation|
41510284|NCT00000525|BEHAVIORAL|diet, magnesium supplementation|
41510285|NCT00000525|DRUG|triamterene|
41510286|NCT00000525|DRUG|chlorthalidone|
41385749|NCT03259646|BEHAVIORAL|Universal Education|Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
41385750|NCT04269031|DRUG|AZD2373 subcutaneous injection|Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
40855213|NCT04731519|BEHAVIORAL|General Health Education|General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
41385751|NCT04269031|DRUG|Placebo|Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
41385752|NCT00803673|DRUG|100mcg|100mcg '719
41385753|NCT00803673|DRUG|500mcg|500mcg '719
41385754|NCT00803673|DRUG|1000mcg|1000mcg '719
41385755|NCT00803673|DRUG|Placebo|Placebo '719
41385756|NCT01186744|DRUG|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
41385757|NCT01186744|DRUG|CP-690,550|10 mg oral BID
41385758|NCT01186744|DRUG|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
41385759|NCT01186744|DRUG|CP-690,550|5 mg oral BID
41385760|NCT00061945|DRUG|allopurinol|Given PO
41385761|NCT00061945|DRUG|cyclophosphamide|Given IV
41385762|NCT00061945|DRUG|daunorubicin hydrochloride|Given IV
41510287|NCT02732873|DEVICE|FibroFix Meniscal Scaffold|FibroFix™ Meniscus scaffold is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
41510288|NCT04620408|DRUG|SHR4640|Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
41510289|NCT00959218|DRUG|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
40855214|NCT01616680|DRUG|brentuximab vedotin|Given IV
41510290|NCT00959218|DRUG|Placebo|oral solution
41510291|NCT00998309|DRUG|Azithromycin SR|Zithromax SR 2g, taking once for treatment.
41510292|NCT01108718|OTHER|Tempur-Pedic Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.
41510293|NCT01108718|OTHER|Control Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
40855215|NCT01616680|OTHER|laboratory biomarker analysis|Correlative studies
40855216|NCT01616680|OTHER|pharmacological study|Correlative studies
40855217|NCT03172572|PROCEDURE|Minimally invasive pancreatoduodenectomy|Laparoscopic, robot-assisted, or hybrid resection
40855218|NCT03172572|PROCEDURE|Open pancreatoduodenectomy|Open resection
41037493|NCT05748405|DRUG|Placebo|Matching Tablets
41037494|NCT05748405|DRUG|AEF0217|Tablets of 100 mcg AEF0217
41166301|NCT00053768|DRUG|cyclophosphamide|
41166302|NCT00053768|DRUG|doxorubicin hydrochloride|
41385763|NCT00061945|DRUG|vincristine sulfate|Given IV
41385764|NCT00061945|DRUG|dexamethasone|Given PO and as eye drops
41510294|NCT01951924|DRUG|Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
41510295|NCT01951924|DRUG|Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
41385765|NCT00061945|DRUG|asparaginase|Given SC
41385766|NCT00061945|BIOLOGICAL|filgrastim|Given SC
41385767|NCT00061945|DRUG|imatinib mesylate|Given PO
41385768|NCT00061945|DRUG|methotrexate|Given IT, IV, and PO
41385769|NCT00061945|DRUG|cytarabine|Given IV
41385770|NCT00061945|DRUG|trimethoprim-sulfamethoxazole|Given PO
41385771|NCT00061945|DRUG|mercaptopurine|Given PO
41385772|NCT00061945|DRUG|leucovorin calcium|Given IV and PO
41385773|NCT00061945|BIOLOGICAL|alemtuzumab|Given SC
41385774|NCT00061945|DRUG|acyclovir|Given PO
41385775|NCT00061945|OTHER|laboratory biomarker analysis|Correlative studies
41385776|NCT00061945|OTHER|pharmacological study|Correlative studies
41385777|NCT04037683|DRUG|Misoprostol Oral Tablet|Misoprostol 25mcg orally given 2-hourly
41385778|NCT04037683|DRUG|Oxytocin|Oxytocin infusion
41385779|NCT01776060|OTHER|generation of 'omic markers of disease progression|Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression.
41385780|NCT02845037|DRUG|BIA 5-453|BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
41385781|NCT02845037|DRUG|Placebo|Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
40855219|NCT03276897|OTHER|Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)|A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
41037495|NCT06442553|DEVICE|GRR laser|A total of 15 sessions were applied to each patient for three weeks, five times per week.
41385782|NCT06390111|DRUG|nadofaragene firadenovec|The investigational medicinal product dose, concentration, and assessments are aligned with nadofaragene firadenovec US prescribing information.
41385783|NCT06568848|COMBINATION_PRODUCT|EKKO therapy|In this group 6 particepents will be included .the interventions will be given for 10 seconds on each finger tips . the session will be 30 mins. 4 to 5 sessions per week
41510296|NCT05383755|BEHAVIORAL|Digital intervention for pregnant adolescents living with HIV|The newly developed digital intervention will include SMS for reminder purposes and Web-based components such as virtual simulations, gamified elements, and didactic content to educate and build relevant skills (e.g., disclosure self-efficacy) to facilitate social support from caregiving family members. The intervention will (1) raise awareness about the intersecting stigmas of HIV and pregnancy; (2) highlight the effects of these stigmas on disclosure and social support; and (3) increase self-efficacy and communication skills for disclosure and enlistment of family members as social support allies. The goal of the intervention is to improve PMTCT engagement among pregnant unmarried ALHIV. Our theory-informed Web-based intervention will be use 3C Institute's Dynamic e-Learning Platform (DeLP), a customizable software platform that implements the evidence-based cognitive theory of multimedia learning (CTML) to effectively engage users.
41510297|NCT02300155|DRUG|Pregvit®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
41385784|NCT06568848|DIAGNOSTIC_TEST|Conservative Treatment|In this group 6 participants will be included .: Conservative treatment, which includes ROM isometric exercises (20 repetitions per limb), stretching exercises (10 seconds per limb with 3 repetitions), balance training (standing without belts for 20 minutes), and gait training (walking with a frame). The session will be 30 mins
41385785|NCT02191930|DRUG|B-CAP|
41385786|NCT02191930|DRUG|Brentuximab Vedotin|
41385787|NCT04125160|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring over 16 days
41385788|NCT04125160|DIAGNOSTIC_TEST|Glycaemic markers|Measurement of HbA1c, glycated albumin and fructosamine.
40855220|NCT01038167|DRUG|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
40855221|NCT01038167|DRUG|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
41037496|NCT06442553|DEVICE|Nd:YAG laser|A total of 10 sessions, five sessions per week, were applied
41385789|NCT05145660|RADIATION|intensity-modulated radiotherapy (IMRT) with reduced-volume|PGTVnx: 69.9Gy/2.12Gy/33f GTVrpn: 69.9Gy/2.12Gy/33f GTVnd: 69.9Gy/2.12Gy/33f GTVnd-suspicious: 60.06Gy/1.82Gy/33f PTV1: 60.06Gy/1.82Gy/33f PTV2: 50.96Gy/1.82Gy/28f
41510298|NCT02300155|DRUG|Orifer F®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
41510299|NCT04068792|OTHER|RSV Mobile Application|Participants will not receive any intervention in observational phase of this study. Participant's respiratory symptoms will be captured by RSV mobile application installed in participant's caregiver/parent mobile phone.
41510300|NCT04068792|DRUG|Placebo|Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally twice daily for 7 days.
41037497|NCT05605119|DRUG|AUR105|Once daily
40855222|NCT01038167|DRUG|cyclosporine|Solution, Oral, 100mg, Day 1 of Period 1
40855223|NCT01038167|DRUG|cyclosporine|Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
40855224|NCT01038167|DRUG|tacrolimus|Capsule, Oral, 2mg, Day 1 of Period 1
40855225|NCT01038167|DRUG|tacrolimus|Capsule, Oral, 0.5mg, Day 8 of Period 2
41037498|NCT01064739|DIETARY_SUPPLEMENT|Fava beans|Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
41037499|NCT01064739|OTHER|Fixed Sodium Diet|Fixed sodium low monoamine diet
41037500|NCT04196400|DRUG|steroid betamethasone|The steroid is injected using insulin needle in the subcutaneous tissue after finishing the repair
41037501|NCT00659334|DRUG|Ferumoxtran-10 (Combidex)|2.6 mg/kg
41166303|NCT00053768|DRUG|etoposide|
41166304|NCT00053768|DRUG|prednisone|
41166305|NCT00053768|DRUG|vincristine sulfate|
41385790|NCT05145660|DRUG|Chemotherapy|Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.
41385791|NCT03187873|BEHAVIORAL|Chama cha MamaToto|Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
41385792|NCT03923907|BEHAVIORAL|EIM intervention group|As in arm description
41385793|NCT01638260|DRUG|Liraglutide|Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
41385794|NCT01638260|BEHAVIORAL|NEAT|Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
41385795|NCT04070469|DRUG|Amoxicillin|dosage of plasma concentration of amoxicillin
41385796|NCT01845181|DRUG|PBF-680|Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
41385797|NCT01845181|DRUG|Placebo|1 or 2 or 3 capsules of placebo.
41385798|NCT00915980|PROCEDURE|gastric bypass surgery and testing|The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
41510301|NCT04068792|DRUG|JNJ-53718678 2.5 mg/kg|JNJ-53718678 will be administered to Age Group 1 twice daily for 7 days.
41385799|NCT01778452|PROCEDURE|endometrial biopsy|endometrial biopsy
41385800|NCT01164137|BEHAVIORAL|Medication Reconciliation|A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
41385801|NCT01887366|DRUG|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
41385802|NCT01887366|DRUG|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
41385803|NCT01887366|DRUG|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
41385804|NCT00231530|DRUG|topiramate|
41385805|NCT05644899|PROCEDURE|Interlaminar ultrasound-assisted intrathecal administration of nusinersen|All procedures were performed with patients either seated or placed in a lateral decubitus. After skin disinfection with 2% chlorhexidine in 70% alcohol, using a convex array, the L3-4 or L4-5 intervertebral space was identified and a left paramedian sagittal oblique view was obtained; the probe was rotated 90° into a transverse orientation, centered on the neuraxial midline, and moved in either the cephalad or caudal direction to obtain a transverse interlaminar view; the intersection between the two markings of the spinal midline and interspinous space was identified as the spinal entry point of the needle. After local anesthesia (LA) with lidocaine 2%, a 25-gauge non-traumatic 90 mm Whitacre spinal needle or a traumatic 90 mm Quincke spinal needle was used to access the subarachnoid space. After confirmation of cerebrospinal fluid (CSF) flow, 5 mL of CSF were removed. Subsequently, nusinersen was administered intrathecally over 1-3 min.
41510302|NCT04068792|DRUG|JNJ-53718678 3 mg/kg|JNJ-53718678 will be administered to Age Group 2 twice daily for 7 days.
41510303|NCT04068792|DRUG|JNJ-53718678 4.5 mg/kg|JNJ-53718678 will be administered to Age Group 3 twice daily for 7 days.
41510304|NCT03536611|DRUG|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
41385806|NCT05644899|PROCEDURE|Landmark-based intrathecal administration of nusinersen|All procedures were performed with patients placed in their most comfortable position (either seated or placed in a lateral decubitus). After skin disinfection with 2% chlorhexidine in 70% alcohol, conventional palpation of the superior aspect of iliac crest was performed and the palpated intercristal line was assumed to cross the spine at L4 vertebral body or L4-L5 interspace. The skin was marked with horizontal and vertical lines at the L3-L4 or L2-L3 interspaces and was referred as entry point of the needle. The procedure was then completed in the same fashion as for US-assisted technique.
41166306|NCT00053768|RADIATION|radiation therapy|
41385807|NCT00890409|DEVICE|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
41385808|NCT03311217|BEHAVIORAL|Healthy retail strategies|
41385809|NCT05879692|PROCEDURE|focused ultrasound|"focused ultra sound cavitation using a device of Mabel6 DUO Ultra Cavitation Technology system produced by DAEYANG MEDICAL COMPANY, KOREA will be applied on the abdominal region which extending bilaterally from the line extending from mid axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crest below.~the session of Focused Ultra Sound will take 25- 30 minutes, twice/week and with about three day intervals for 12 weeks."
41385810|NCT05879692|BEHAVIORAL|Low Caloric Diet (LCD) and a low (FODMAPs) diet|"The Low caloric diet (LCD) diet will be an equilibrated diet that had a caloric value 10% below the total metabolic expenditure (total energy expenditure) of each individual.~The low FODMAPs diet (LFD) is a diet low in fermentable oligo-, di-, mono- saccharides and polyols (FODMAPs)."
41385811|NCT05879692|OTHER|aerobic exercise|aerobic exercise program under direct supervision at a frequency of 3 times/week for 12 weeks, in the form of walking on a treadmill for 30 minutes with moderate intensity (12-14) according to The Borg Rating of Perceived Exertion (RPE) scale.
41385812|NCT04796168|PROCEDURE|Splinting (plaster of paris)|Placing stockinette followed by cotton rolls and 10-12 layer of posterior ankle splint made of plaster of paris
41385813|NCT05020730|DRUG|PTM-001|PTM-001 (400 mg) every day for 12 weeks
41385814|NCT05020730|DRUG|Placebo|Matching placebo every day for 12 weeks
41385815|NCT01002118|DRUG|Omega-3 Acid Ethyl Esters|1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
41510305|NCT03536611|DRUG|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
41385816|NCT01002118|DRUG|Placebo|4 capsules each day for 16 weeks
41385817|NCT00693056|DRUG|Placebo|Placebo (w/o API)
41510306|NCT02929056|BIOLOGICAL|AmnioExCel dressing and compression therapy|Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
41510307|NCT02929056|PROCEDURE|SOC alginate dressing and compression therapy|Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
41510308|NCT03971786|BEHAVIORAL|Quality of life|Assessment of quality of life through measuring scales
41166307|NCT04811118|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous infusion
41166308|NCT04811118|DRUG|Taxotere|Taxotere
40855226|NCT03427723|DEVICE|Accuvein®400|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
40855227|NCT03427723|OTHER|Standard care|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
40855228|NCT04903795|DRUG|hEGFRvIII-CD3 (BRiTE)|Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells
40855229|NCT01212393|BEHAVIORAL|reminders|In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
41385818|NCT00693056|DRUG|RX-10100 5mg|5 mg/dose of RX-10100
41385819|NCT00693056|DRUG|RX-10100 10mg|10 mg/dose of RX-10100
41385820|NCT00693056|DRUG|RX-10100 15mg|15 mg/dose of RX-10100
41385821|NCT06144931|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer then slides medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks. Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a standard 22 gauge spinal needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 20 ml 0.25% bupivacaine diluted with preservative free normal saline then deposited in this plane, lifting the psoas tendon. Care should be taken to avoid puncturing the psoas tendon.
41385822|NCT04639739|BIOLOGICAL|anti-CD19 CAR NK|2×106 /kg、6×106 /kg、2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion，the actual regiment is determined by the statue of patients.
41385823|NCT06536985|BEHAVIORAL|Oral Health Intervention|The intervention program included physical activity, functional oral exercises, basic dietary instruction and provided detailed oral health knowledge directly related to oral health behaviors.
41385824|NCT06536985|BEHAVIORAL|SMS intervention|Participants will receive general lifestyle advice via text message once or twice a week
41385825|NCT02709759|BEHAVIORAL|Motivational intervention|Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
41385826|NCT02709759|BEHAVIORAL|Brief Advice|Involves 5-10 minutes of brief counseling to reduce drinking
41385827|NCT02709759|BEHAVIORAL|Interactive text messaging|Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
41385828|NCT06568536|OTHER|Repeated behavioral assessments, functional electroencephalography and brain imagery, TMS-EEG|The presence of consciousness will be classified considering the highest level of consciousness revealed by repeated behavioral examinations, functional electroencephalography (task-based EEG), and functional brain imagery (task-based fMRI). Based on the results of this composite standard reference, we will evaluate the diagnostic and prognostic accuracy of TMS-EEG measurements of brain complexity
41385829|NCT04856917|DRUG|Imsidolimab|Humanized Monoclonal Antibody
41385830|NCT04856917|BIOLOGICAL|Placebo|Placebo
41385831|NCT06537284|BEHAVIORAL|ImRs-DSR|Imagery Rescripting with Memory Reconsolidation Disruption
41385832|NCT06537284|BEHAVIORAL|ImRs|Imagery Rescripting regular
41385833|NCT06452797|BEHAVIORAL|ProVent-14 score|A score to estimate one-year mortality for patients requiring at least 14 days of mechanical ventilation
41385834|NCT05134545|DEVICE|Genoss® DCB|Peripheral Drug Coated Balloon
41385835|NCT05134545|DEVICE|IN.PACT Admiral® DCB|Peripheral Drug Coated Balloon
41385836|NCT01062100|DEVICE|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
41385837|NCT05880537|OTHER|Nexeon Arterial Venous Allograft|Nexeon AVX allograft for hemodialysis access in end stage renal disease
40855230|NCT00174369|DRUG|PD-0325901|15 mg BID
41385838|NCT04860752|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Subjects will undergo TAVI
41385839|NCT04197882|BIOLOGICAL|OrienX010 Combination with Toripalimab injection|OrienX010 Produced by Oriengene Biotechnology Co.,Ltd. Strength: 1.0 mL/vial. Toripalimab infusion Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
41166309|NCT00904683|DRUG|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
41166310|NCT00904683|DRUG|Placebo|intravenously (IV) every 4 weeks for 80 weeks
41385840|NCT03455114|DEVICE|AssiAnchor|"The novel device, the capsular Anchor, was designed to secure the capsular bag to the scleral wall. The device is a one-piece, one-plane intraocular implant . It works like a paper clip; holding the anterior capsule between a central rod, placed in front of the capsule, and the two lateral arms, inserted through the eye surgery and placed behind the capsule."
41385841|NCT03770182|DEVICE|NEUROLITH|transcranial pulse stimulation (TPS)
41385842|NCT00002560|BIOLOGICAL|monoclonal antibody 3F8|
41385843|NCT00002560|BIOLOGICAL|sargramostim|
41385844|NCT06523309|OTHER|Electroacupuncture treatment|Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated.
41510309|NCT02289703|DRUG|Rivaroxaban 15 mg|Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
41510310|NCT05847348|DRUG|68Ga-PSMA-11|A single dose of 111 - 259 MBq administered intravenously over 3 -5 minutes
40855231|NCT03218436|PROCEDURE|CAP treatment|Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.
40855232|NCT02430883|PROCEDURE|Retrograde Intrarenal Surgery|endoscopic treatment of kidney stones with flexible renoscopy
40855233|NCT01356459|DEVICE|Mepilex Border Dressing|Soft silicone self adherent dressing
40855234|NCT01318837|DRUG|solifenacin|oral
40855235|NCT01240200|DRUG|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
41385845|NCT05498038|BEHAVIORAL|Aerobic Exercise|Participants are asked to complete at least 20 minutes of aerobic exercise every day, excluding clinic visits.
41385846|NCT01074853|DRUG|propranolol|10mg twice daily escalated to 80mg once daily
40855236|NCT01240200|DEVICE|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
40855237|NCT01825967|OTHER|C-reactive protein|measured C-reactive protein in all patients with acute diverticulitis
40855238|NCT02806960|DRUG|Nasal Glucagon|Administered intranasally.
40855239|NCT04691986|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside is a form of vitamin B3 and is naturally occurring in humans.
40855240|NCT04691986|OTHER|Placebo|Placebo pills contain micro cellulose powder.
40855241|NCT02434562|OTHER|Serum (with or without urine) samples|
40855242|NCT00942825|DRUG|CBP501 + Cisplatin + Pemetrexed|"CBP501, pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. CBP501 25 mg/m² will be administered as an i.v. infusion of 1 hour.~2. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes, immediately after the CBP501 infusion.~3. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
40855243|NCT00942825|DRUG|Cisplatin + Pemetrexed|"Pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes.~2. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
40855244|NCT00006116|DRUG|cisplatin|
40855245|NCT00006116|DRUG|gemcitabine hydrochloride|
40855246|NCT04177979|BEHAVIORAL|Near-assisted learning through trained peers|Students randomly allocated to this group were overseen during sessions by trained peer instructors.
40855247|NCT03483415|DRUG|Morphine Sulfate|Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.
40855248|NCT03483415|DRUG|Bupivacaine|Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine
41385847|NCT01074853|DRUG|placebo|Matched placebo
41385848|NCT05217537|DRUG|Omadacycline Injection [Nuzyra]|Single dose of 100 mg omadacycline IV in 100 mL of normal saline
40855249|NCT05805046|DEVICE|Negative Pressure Wound Therapy System|The study device combines a sterile dressing comprising gelling fibre technology to absorb wound exudate with negative pressure applied to the wound via a vacuum pump.
40855250|NCT02718092|DEVICE|Plastic Stent|Subjects who are randomized to this arm will receive a plastic stent
40855251|NCT02718092|DEVICE|Axios Fully Covered Self Expanding Metal Stent|Subjects who are randomized to this arm will receive the Axios FCEMS
41037502|NCT00659334|PROCEDURE|Neurosurgery|neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
41037503|NCT03347968|BIOLOGICAL|MEDI0382|All participants will receive MEDI0382
41037504|NCT03347968|DRUG|Warfarin|All participants will receive Warfarin
40855252|NCT00988091|DEVICE|1.2% Sodium Hyaluronate|IA-BioHA is supplied in a disposable 7 ml nominal volume glass syringe containing 60 mg/5 ml of 1.2% sodium hyaluronate. Participants are given a single injection in the target knee on Day 1 of the double-blind period and optionally on the first day of the open-label period (approximately week 27).
40855253|NCT00988091|DEVICE|Buffered Saline|IA-SA is supplied in a disposable 7 ml nominal volume glass syringe containing 5 ml of phosphate buffered saline. Participants are given a single injection in the target knee on Day 1 of the double-blind period.
40855254|NCT03888729|DRUG|sofosbubir/velpatasvir|SOF/VEL (400 mg/100 mg) FDC once daily
40855255|NCT03888729|DRUG|sofosbubir/velpatasvir/voxilaprevir|SOF/VEL/VOX (400 mg/100 mg/100 mg) FDC once daily
40855256|NCT01110031|BIOLOGICAL|Ofatumumab|Anti-CD20 monoclonal antibody
41037505|NCT03347968|DRUG|Esmolol|All participants will receive Esmolol
41037506|NCT03997422|PROCEDURE|Vertical Sleeve Gastrectomy (VSG)|Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
41385849|NCT05217537|DRUG|Omadacycline Oral Tablet|Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
41385850|NCT01689922|OTHER|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
41385851|NCT02342574|DRUG|F901318|Administration of active compound
41385852|NCT02342574|DRUG|Placebo|Administration of placebo
41385853|NCT05790200|DRUG|Cadonilimab|Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle.
41385854|NCT01439776|DRUG|Vit D|800IU/day
41510311|NCT05847348|OTHER|PET/CT or PET/MRI|PET/CT or PET/MRI will be acquired no sooner than 50 minutes post injection and not later than 100 minutes post injection with 68Ga-PSMA-11
41510312|NCT02998086|BEHAVIORAL|Promoting Resilience in Stress Management|Skills-based intervention designed to promote resilience resources
41510313|NCT03369769|OTHER|Activity|10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).
40855257|NCT04368780|OTHER|Effect of Progressive Muscle Relaxation Combined With Music|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 30-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles.
40855258|NCT03009734|DRUG|ATx201 dermal formulations 2%|Topical application of ATx201 dermal formulations 2%
40855259|NCT00391950|DRUG|Zoledronic acid|
40855260|NCT02376179|DEVICE|Cuffed ETT|
40855261|NCT04255589|DRUG|CKD-495 75mg|CKD-495 75mg Tab.
40855262|NCT04255589|DRUG|Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
40855263|NCT04255589|DRUG|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
40855264|NCT04255589|DRUG|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
40855265|NCT03753555|DRUG|Atorvastatin Calcium|20mg Qd for 12 months
40855266|NCT03753555|DRUG|Atorvastatin Calcium|40-80mg Qd for 6 months
40855267|NCT03753555|DRUG|Probucol|0.5g Bid for 6 months
40855268|NCT03753555|DRUG|PCSK9 inhibitor|Evolocumab 140mg subcutaneously injected, twice each month
40855269|NCT00413790|DRUG|Darifenacin|Darifenacin tablets 15 mg once daily
40855270|NCT00413790|DRUG|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
40855271|NCT00413790|DRUG|Placebo|Placebo tablet once daily
40855272|NCT00209703|DRUG|Oxaliplatin|
40855273|NCT00209703|DRUG|l-Leucovorin|
41385855|NCT01040546|BEHAVIORAL|Individualized education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months."
41385856|NCT01040546|BEHAVIORAL|Grouped education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months."
41510314|NCT03204448|DEVICE|BioCLIA Ro60|BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
41510315|NCT01845480|BEHAVIORAL|Wellness coaching|Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
40855274|NCT00209703|DRUG|5-Fluorouracil|
40855275|NCT04377555|DRUG|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
40855276|NCT01354119|PROCEDURE|Aortic stent-graft|Early intervention with aortic stent-graft
40855277|NCT02547558|PROCEDURE|Arterial blood gases|Measured through radial arterial catheter
40855278|NCT02547558|PROCEDURE|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
40855279|NCT02547558|PROCEDURE|Vital signs|As measured in clinical practice
41166311|NCT01307917|DIETARY_SUPPLEMENT|flavonoids|for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
40855280|NCT02547558|PROCEDURE|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
40855281|NCT02547558|PROCEDURE|Spirometry|In a daily calibrated spirometer.
40855282|NCT02547558|DRUG|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
40855283|NCT00407472|DEVICE|ATS-1 needle free device|
40855284|NCT05185050|DIAGNOSTIC_TEST|physical examination and measurement of spinal alignment|physical examination for scoliosis and myofascial pain syndrome, measurement of spinal coronal and sagittal alignment in X-ray, and pain intensity (with Visual analog scale) if necessary (for MPS group)
40855285|NCT02120326|DEVICE|Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* 2 mA intensity~* Continuous stimulation for 20 min with rise times and fall times of 10 seconds each"
40855286|NCT02120326|DEVICE|simulation of Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* The intensity of the stimulation current is 2 mA~* The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation."
40855287|NCT06010342|DRUG|TL118 Capsule|Oral administration
40855288|NCT04413097|PROCEDURE|Delayed Cord Clamping with Low Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and low oxygen concentration (FiO2 0.30) will be provided.
40855289|NCT04413097|PROCEDURE|Delayed Cord Clamping with High Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and high oxygen concentration (FiO2 1.0) will be provided.
40855290|NCT03704259|OTHER|Ceramic coating|coating the laparoscope lens with commercial brand ceramic coating, bought from car service centers specialized in such applications
40855291|NCT00974623|DEVICE|Bone graft substitute, autograft or allograft|spine fusion surgery utilizing any commercially available bone graft substitute(s), autograft or allograft
41385857|NCT04881331|OTHER|Analysis of electrosurgical smoke.|Patients undergo standard of care surgical removal of the malignant breast tumor. Electrosurgical knife is used to cut tissues according to standard practice. Fraction of the surgical smoke is captured for analysis and video record of the point of view of the surgeon is captured with a head-mounted camera.
41385858|NCT01205542|BEHAVIORAL|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
41166312|NCT05706636|DRUG|oral mini pulse|5mg / week oral dexamethasone
41166313|NCT05706636|DRUG|Topical cream|topical fluticasone cream for body lesions and topical tacrolimus for face lesions
41166314|NCT05706636|DEVICE|targeted phototherapy|twice weekly targeted excimer light sessions
41166315|NCT01664897|DRUG|Erlotinib Hydrochloride|Given PO
41385859|NCT01205542|BEHAVIORAL|Reference|Health check and advice to continue ordinary physical activity
41385860|NCT00430638|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
41385861|NCT00430638|DRUG|Placebo|Oral tablets administered for once daily for 12 weeks
41385862|NCT04583384|DIAGNOSTIC_TEST|1H-Spectroscopy MRI|"PRESS asymetric monovoxel  PROBE , TE 144 ms, TR 2500 ms, 768 or 1024 averages"
41385863|NCT04849858|DRUG|Bupivacaine|Participants in this group will receive a TAP block using the drug Bupivacaine.
40855292|NCT05483075|BEHAVIORAL|HCP-Guided Exercise Training Program|"Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity).~Two days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity.~The remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR)."
40855293|NCT00001894|PROCEDURE|pacemaker implantation|
40855294|NCT00001894|PROCEDURE|percutaneous transluminal septal ablation (PTSA)|
41166316|NCT01664897|OTHER|Laboratory Biomarker Analysis|Correlative studies
41385864|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine.
41385865|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine followed by a re-dosing during their hospitalization
41385866|NCT00134472|PROCEDURE|Therapeutic mild hypothermia|Keeping 32 - 34 degree celsius of core temperature at least for 72 hours.
41166317|NCT01811498|DRUG|Bevacizumab|
41166318|NCT05092477|BEHAVIORAL|Integrated Intervention for Breast Cancer Survivors with Diabetes|"All pilot participants will be required to have a SMB target to be included in this study. A SMB target will be chosen by the participant after reviewing their 18mo follow-up responses with the Care Coach. Participants may endorse a maladaptive belief or emotional response; however, this is not required to participate in this intervention. At each follow-up session, the Care Coach will review the participant's SMB goal and progress, address participant's challenges and suggest alternatives, and correct further misinformation on the disease(s). Additionally, the Care Coach will reinforce or introduce techniques that could help overcome barriers to reaching SMB goal and recommend participants to continue improving on the same goal or begin action planning towards a new SMB goal.~1. Just SMB concern~2. SMB + maladaptive belief + emotional response~3. SMB + maladaptive belief~4. SMB + emotional response"
41166319|NCT05092477|BEHAVIORAL|Attention Control|Participants in the control arm will receive a brochure to discuss healthy lifestyle behaviors to improve DM management. To control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes, participants also receive 4 calls to discuss study progress, thoughts and feelings about study/illness/behaviors, remind them about returning their pill bottles, and about scheduling for their upcoming 24mo follow-up study interview.
41385867|NCT00129532|DRUG|1.0% C31G SAVVY vaginal gel|
41385868|NCT04262024|DRUG|cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education|Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)
41385869|NCT04262024|DRUG|cabergoline 1.5-2 mg/week).orally daily for 1 month without health education|Women with hyperprolactiemia scheduled for cabergoline 1.5-2 mg/week).for one month will not be offered health education (group B)
41385870|NCT05905809|DEVICE|UniRelieverTM offloading brace (THUASNE)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
41385871|NCT05905809|DEVICE|Unloader One® X brace (Össur)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
41385872|NCT03150134|DRUG|Cyclosporine|Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)
41385873|NCT03150134|DRUG|routine reduction of immunosuppressive drugs(cyclosporine)|patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
40855295|NCT00203424|DRUG|Erlotinib + Bevacizumab|Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
41166320|NCT04470570|OTHER|Cross-Education|1) Cross-Education: The effect that exercising the uninvolved upper extremity will have a positive effect on the involved upper extremity.
41385874|NCT05860049|OTHER|Conventional physiotherapy|All participants in both groups (A and B) received conventional physiotherapy program including infrared thermotherapy, transcutaneous electrical nerve stimulation, stretching exercises for for Upper Trapezius, Levator Scapulae, Sternocleidomastoid and Scalenes muscles, and active neck ROM exercises, 3 sessions per week, for 4 weeks.
41385875|NCT05860049|OTHER|Core stability|All participants in both groups (A and B) received core stability exercises in the form of bridging exercise, bridging exercise on a ball, plank, and side plank 3 sessions per week, for 4 weeks.
41510316|NCT00032786|DRUG|natalizumab|
41510317|NCT06508320|BIOLOGICAL|mRNA-1083|IM injection in a deltoid muscle.
41385876|NCT05860049|DEVICE|Instrument assisted soft tissue mobilization|Each participant in group (B) was seated in a comfortable position. The participant's forehead rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) was applied to the skin around the neck area prior to treatment, and the M2T blade (Figure 4) was cleaned with an alcohol pad. First, the M2T blade was used to find the exact areas of restriction in the RT upper trapezius. Then, the M2T blade was used at an angle of 45°, utilizing treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion for approximately 3 minutes. This procedure was repeated twice a week, for 4 weeks.
41510318|NCT06582498|BEHAVIORAL|Active intervention|This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivors at randomization (2nd visit). Furthermore, they will be offered 3 individual sessions with health professionals (oncological dietitian, sports therapist, and oncological psychologist) and 3 group sessions with the same professionals. The duration of the individual visits is expected to be 45-60 minutes approximately, and group sessions will be planned for 1.5h duration approximately.
41510319|NCT06582498|BEHAVIORAL|Low-intensity intervention|This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivor at randomization (2nd visit). These recommendations are all based on information from the World Cancer Research Fund, the American Institute for Cancer Research, and the American Cancer Society.
41510320|NCT04615351|DRUG|Metformin|Medication
41510321|NCT05961501|DRUG|An aqueous solution containing CBD and CBN|An aqueous solution containing CBD and CBN, to drink at home in the dose determined by the attending physician
41510322|NCT05961501|OTHER|The aqueous solution of placebo|An aqueous solution of placebo, to drink at home in the dose determined by the attending physician
41510323|NCT05608837|DRUG|OCS-01|One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
41510324|NCT05889312|DIAGNOSTIC_TEST|18F-FSPG PET/CT in NSCLC|Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.
41510325|NCT05889312|DIAGNOSTIC_TEST|18F-FSPG PET/CT in HNSCC|Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.
41510326|NCT04292444|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.
41510327|NCT04292444|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).
41510328|NCT05723939|DIETARY_SUPPLEMENT|Carnosine supplementation|Intake of carnosine supplement in form of capsules or functionally enriched chicken meet for three weeks
41510329|NCT05723939|DIETARY_SUPPLEMENT|Controls|Intake of placebo capsules or regular chicken meet for three weeks
41037507|NCT01022437|OTHER|Geranium Oil with component PN-34|Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
41037508|NCT04522401|DIAGNOSTIC_TEST|"consultation: Bien vieillir"|Patients will benefit from a multidisciplinary assessment including a geriatric assessment standardized by a geriatrician, an evaluation by a dietician, an evaluation by an occupational therapist. They will then be exposed to a personalized plan of care in the form of a recommendation.Then, patients will be followed at home to evaluate the implementation of their personalized care plan at 3 months of their assessment day, then at 6 and 9 months.
41037509|NCT05558033|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
41037510|NCT05558033|OTHER|Football Training|Routine football trainings
41037511|NCT00715429|DRUG|vitamin d|After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.
41037512|NCT00715429|DRUG|placebo|After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
41510330|NCT04084457|DIETARY_SUPPLEMENT|Wild Blueberry powder|Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
41510331|NCT04084457|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment matched for fibre and vitamin C
41510332|NCT02255799|DRUG|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
41510333|NCT02255799|DRUG|Placebo|Placebo capsule once daily for 70 days.
41510334|NCT00325247|DRUG|ZINC|
41037513|NCT04663048|PROCEDURE|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.
41510335|NCT01662778|DRUG|1.5 microns at 50mg|STAG generated monodisperse 1.5micron particles
41510336|NCT01662778|DRUG|6 microns at 50mg|STAG generated monodisperse 6 micron particles
41510337|NCT01662778|DRUG|Placebo Comparator|No drug just solvent
41510338|NCT01662778|DRUG|MDI FP|
41510339|NCT00288730|DRUG|nesiritide|
41510340|NCT03683771|DIAGNOSTIC_TEST|Transvaginal US with Doppler study|Transvaginal Ultrasound with doppler study on endometrium will be made
41510341|NCT03893019|BIOLOGICAL|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
41510342|NCT04252339|DRUG|RLY-1971|RLY-1971 is an oral inhibitor of SHP2.
41510343|NCT04357548|DEVICE|FEEDBACK|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
41510344|NCT02850692|OTHER|measure of endothelial function|Arterial tone index measured by EndoPAT®. Patient should neither eat nor drink at least 4 hours before exam and should neither smoke 3 hours before the exam.
41037514|NCT05317000|DRUG|Combination 5-azacytidine and nivolumab|The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
41385877|NCT05157529|DEVICE|AQUABEAM Robotic System|"The AQUABEAM Robotic System is developed and manufactured by PROCEPT BioRobotics, Corp. It is intended for use in patients suffering from lower urinary tract (LUTS) resulting from benign prostatic hyperplasia (BPH). The AQUABEAM Robotic System is designed for cutting of prostate tissue during minimally invasive surgical procedure and shall be inserted via transurethral approach and is advanced through the urethra and into the prostatic urethra.~The system is designed to utilize a high-velocity sterile saline stream as the cutting medium which is projected through a nozzle positioned within the prostatic urethra. The nozzle assembly motion is driven by a motor system, controlled by the user. The pressure is generated by a high-velocity pump system controlled by the AQUABEAM Console. The user is allowed to adjust the desired flow rates manually. All functions are displayed on a medical panel computer. Pre-condition parameters are set on the console before operation."
41037515|NCT05317000|DRUG|5-azacytidine|Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
41037516|NCT05317000|DRUG|Nivolumab|"Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells."
41166321|NCT04470570|OTHER|Blood-Flow Restriction Training|1) Blood Flow Restriction: A type of resistance training using a blood-pressure like cuff that partially occludes venous blood flow to induce various neurohormonal effects and allows strength gains to be achieved at very low loads of resistance.
41385878|NCT05157529|DEVICE|Apogee 2300 digital color doppler ultrasound imaging system|"The SIUI Apogee 2300 is a digital ultrasound imaging system capable of the following operating modes: B-Mode (B, 2B, 4B), M-Mode, CFM, CPA, PWD, CWD, Combined (B, M, CFM, CPA, PWD, CWD, XBeam, Panoscope), others (3D, 4D, Trapezoidal /Extended Sector Imaging, Elastography, Anatomical M-mode, TDI, MFI, ECG, VS Flow, Color M, DICOM).~The system is designed for use in linear, convex, phased array and 3D scanning modes and supports linear, convex, phased array, 3D and endocavity (trans-vaginal and trans-rectal) transducers. The system has cine review, image zoom, measurements and calculations, image storage and review, printing and recording capabilities."
41385879|NCT03926728|BIOLOGICAL|CTH522-CAF01 IM|On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
41510345|NCT02850692|BIOLOGICAL|Blood sample|21 ml of blood to measure : hepatic workup, complete blood count (CBC), platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), C-reactive protein (CRP), lipid test, ionograms, creatinine, tissue plasminogen activator factor (tPA), plasminogen activator inhibitor-1 (PAI-1), tissue factor pathway inhibitor (TFPI), Willebrand factor, soluble thrombomodulin, blood levels of endoglin and syndecan. And level beta human chorionic gonadotropin (beta-HCG) for woman only.
41166322|NCT00476918|DRUG|Intravitreal injection (triamcinolone acetonide)|
41510346|NCT02850692|OTHER|Hepatic elastography|Hepatic elastography by Fibrocan®. Patient should neither eat nor drink at least 2 hours before exam. 10 successive measurements are made.
41166323|NCT02534753|DRUG|Ascor L 500® (Ascorbic Acid Injection, USP)|A sterile, solution containing 500 mg ascorbic acid per mL
41037517|NCT01558622|DRUG|dexketoprofen trometamol|50mg intravenous infusion
41037518|NCT01558622|DRUG|tramadol hydrochloride|100mg intravenous infusion
41037519|NCT01558622|DRUG|pethidine hydrochloride|50mg intravenous infusion
41037520|NCT01558622|DRUG|dexketoprofen trometamol + tramadol hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
41037521|NCT01558622|DRUG|dexketoprofen trometamol + pethidine hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
41166324|NCT04890886|DIAGNOSTIC_TEST|Thermal imaging|Use of a thermal imaging cameral to measure brown and white adipose tissue function
41166325|NCT04890886|DIAGNOSTIC_TEST|Echocardiogram|Echocardiographic imaging of the fetal heart to assess ventricular function
41037522|NCT01558622|DRUG|vitamin c|500mg intravenous infusion
41037523|NCT01604330|DRUG|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
41166326|NCT04890886|DIAGNOSTIC_TEST|ECG|ECG of the fetus and the neonate to look at the cardiac electrical activity
41166327|NCT04890886|DIAGNOSTIC_TEST|MRI scan|MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function
41166328|NCT04890886|DIAGNOSTIC_TEST|Serum blood markers|Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker
41166329|NCT00003162|PROCEDURE|pain therapy|
41166330|NCT00003162|RADIATION|radiation therapy|
41166331|NCT04063345|PROCEDURE|IVUS-guided PCI|Performing intravascular ultrasound before or/and after percutaneous intervention
41166332|NCT04063345|PROCEDURE|Angiography-guided PCI|Performing percutaneous intervention without intravascular ultrasound guidance
41166333|NCT00264498|DRUG|Gefitinib|oral tablet
40855296|NCT05342272|DRUG|Betaine taurine PVP gel|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
41037524|NCT01604330|DRUG|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
41037525|NCT05440110|DEVICE|active and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
41166334|NCT00264498|DRUG|Gemcitabine|intravenous injection
41166335|NCT00264498|DRUG|Carboplatin|intravenous injection
41385880|NCT03926728|BIOLOGICAL|CTH522-CAF09b IM|On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
41037526|NCT05440110|DEVICE|sham and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min. Sham stimulation applies the same iTBS protocol with the sham coil.
41037527|NCT05078190|OTHER|Social Determinants of Health|The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
41037528|NCT04728243|OTHER|WHO QualityRights e-training|The WHO QualityRights online training aims to increase knowledge about the rights of people with psychosocial disabilities and change negative attitudes towards these persons and their role as rights holders. Furthermore, the training provides mental health professionals with the skills necessary to support people with psychosocial disabilities to advocate for their rights. The WHO QualityRights online training includes five core modules: 1) Human rights; 2) Mental health, disability, and human rights; 3) The right to health and recovery; 4) Legal capacity and the right to decide; 5) Free from coercion, violence, and abuse. Each module is composed of presentations, videos, interactive exercises, and forum discussions involving all participants. In the online training forum discussions, particular attention will be given to issues relevant to the Ghanaian context.
41037529|NCT04728243|OTHER|WHO COVID-19 online training|The WHO novel coronavirus 2019 online training series provides a general introduction to COVID-19 and similar respiratory infections and information on what facilities and professionals should be doing to prevent and respond to COVID-19 cases. The training is similar in length to the WHO QualityRights training (13 h 15 min vs. 19 hours) and is intended for health professionals and other stakeholders.
41037530|NCT01828242|BEHAVIORAL|Empowerment model to improve dietary intake|Empowerment model using specific guidelines to improve dietary intake
41037531|NCT01828242|OTHER|Control group following conventional approach|Control group following conventional approach
41037532|NCT02623673|DRUG|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.|
41037533|NCT02978274|DRUG|MMF|MMF withdrawal by engraftment post haplo-SCT
41037534|NCT02978274|DRUG|MMF|MMF withdrawal by 2 month post haplo-SCT
41037535|NCT02088268|OTHER|wound healing|wound healing
41037536|NCT04485962|BIOLOGICAL|Fibroblasts and keratinocytes|"Autologous cultured fibroblasts and keratinocytes~For PR: The name  fibroblasts and keratinocytes is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
41037537|NCT02053350|DRUG|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
41166336|NCT06074653|OTHER|Mulligan Bent Leg Raise technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given.Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
41166337|NCT06074653|OTHER|PNF Contract Relax technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given. Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
41166338|NCT01709955|DIETARY_SUPPLEMENT|Glucomannan|750 MG of Glucomannan in capsule form
41166339|NCT01709955|OTHER|Placebo|750 mg of Cellulose powder in a capsule form
41166340|NCT01349036|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
41385881|NCT03926728|BIOLOGICAL|CTH522 ID|24 mcg CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 mL syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
41385882|NCT03926728|BIOLOGICAL|CTH522 TO|24 mcg CTH522 (12 mcg in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
41037538|NCT01725646|DRUG|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
41510347|NCT02850692|DIAGNOSTIC_TEST|Injected abdominal CT|"Patient should neither eat nor drink at least 4 hours before exam.~The examination is not realized if an abdominal scan or an MRI was performed in the five years prior to the day of the visit."
41037539|NCT01725646|DRUG|Placebo|Subjects in placebo group will take this drug
41037540|NCT02466022|DRUG|Dexmedetomidine|Bolus dose prior to spinal anesthetic
41037541|NCT02466022|DRUG|Bupivicaine|Intrathecal hyperbaric bupivicaine 12.75mg
41037542|NCT02466022|DRUG|Normal Saline|Bolus 0.1cc/kg Normal Saline over 10 min
41037543|NCT02466022|DRUG|Fentanyl|Intrathecal Fentanyl 10ug
41037544|NCT02466022|DRUG|Midazolam|0-4mg of IV Midazolam prn for rescue sedation
41037545|NCT06264362|BEHAVIORAL|Tailored Physical Activity Program|Adaptation of physical activity as an intervention for pain management using the 3-Step Tailored Approach: assessing in Step 1 the Person Living with Dementia (PLWD), in Step 2 the Environment, and in Step 3 the Caregiver. With this approach, traditional exercises can be adapted to 1) functional activities (e.g., stair climbing) that are tailored to the interests (e.g., dancing, boxing) and preserved abilities of PLWD; 2) preferred and well-tolerated environments (e.g., home); and 3) account for extent and type of interventionist and caregiver involvement.
41037546|NCT00249951|DRUG|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
41037547|NCT04198129|DRUG|Antibiotic treatment (Unasyn or Cleocin)|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
41037548|NCT04198129|DRUG|Antibiotic treatment (Augmentin or Cleocin)|the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
41385883|NCT03926728|BIOLOGICAL|Placebo (Saline)|Placebo only given as IM, ID and TO.
41385884|NCT05065957|DRUG|D07001-softgel capsules + Xeloda (or TS-1)|"D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)"
41385885|NCT05065957|DRUG|mFOLFOX|intravenous infusion on Day 1 for 14-day cycle
40892976|NCT05128916|BIOLOGICAL|intralesional platelet rich plasma|Three to fifteen milliliters of blood will be drawn from each patient then evacuated after detachment of syringe needle into 15 ml conical tube containing 3.8% sodium citrate solution. Blood will be centrifuged at 300 G-force (\~ 1500 RPM) for 10 minutes. This will allow the blood to separate into 3 layers: Upper platelet-poor plasma, middle platelet-rich plasma, and lower RBCs layers. The supernatant (upper third) will be removed and the middle third (PRP) will be aspirated and used for intralesional injection of affected nails.
40892977|NCT05128916|DRUG|Oral terbinafine|Patients in (PRP + terbinafine) and (terbinafine) groups will receive oral 250 mg terbinafine tablets taken immediately after a fatty meal, daily for a total of 3 months
40892978|NCT02757235|PROCEDURE|Irrigation fluid of body temperature|Irrigation fluid of body temperature will be used during burr hole evacuation of chronic subdural hematoma
41385886|NCT05100849|PROCEDURE|Kinect-based cognitive training|The Kinect-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. The cognitive training content will be projected onto a wall and patients will interact with the content, i.e., the selection of the appropriate response, through movement (kinect).
41385887|NCT05100849|PROCEDURE|Tablet-based cognitive training|The Tablet-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. Patients will interact with the cognitive training content through a tablet.
41510348|NCT02220517|DEVICE|MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
40892979|NCT02757235|PROCEDURE|Irrigation fluid of room temperature|Irrigation fluid of room temperature will be used during burr hole evacuation of chronic subdural hematoma.
40892980|NCT04008472|OTHER|Telemedecine|Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
40892981|NCT03962491|BEHAVIORAL|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app, with the opportunity for monetary rewards for completing daily surveys.
40892982|NCT03962491|BEHAVIORAL|Daily Self-Monitoring Surveys|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app.
40892983|NCT03288532|DRUG|Durvalumab|controlled infusion via an infusion pump into a peripheral or central vein
40892984|NCT03288532|DRUG|Tremelimumab|controlled infusion via an infusion pump into a peripheral or central vein
40892985|NCT05493917|BIOLOGICAL|an inactivated SARS-CoV-2 vaccine named BBIBP-CorV|Completed 2 doses of an inactivated SARS-CoV-2 vaccine more than 6 months ago and received a third dose of the vaccine
40892986|NCT02490098|OTHER|6-day intervention with sensor-augmented pump therapy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
40855297|NCT05342272|DRUG|Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of Biotene® Oral Balance gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
41385888|NCT01637207|OTHER|Palpation|Group A: Palpation Group
41385889|NCT01637207|OTHER|Ultrasound|Group B: Ultrasound Group
41385890|NCT01658215|DRUG|V0116 transdermal patch (Test treatment )|
41385891|NCT01658215|DRUG|Nicotine transdermal patch (Reference treatment )|
41385892|NCT00685763|RADIATION|Proton radiation and chemotherapy|"Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses"
41385893|NCT06539312|OTHER|APP assessment and management of asthma|APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.
41385894|NCT03486327|DRUG|BR55|A novel targeted ultrasound contrast agent
41385895|NCT06176248|DRUG|Triamcinolone Acetonide|1 injection of local anaesthetic (5 ml levobupivacaine 2.5 mg/mL) opposite the subscapular nerve, under ultrasound control, in a lateral decubitus or sitting position. Subsequently, they underwent Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.
41385896|NCT06176248|DRUG|saline solution|intramuscular injection of 1 ml saline under ultrasound control under the same conditions as the experimental group. Subsequently, they will undergo Xray-controlled arthrodistension under the same conditions as the experimental group
41385897|NCT01844986|DRUG|Olaparib 300mg tablets|Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
41385898|NCT02659826|DEVICE|anodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a direct current (DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (anode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 milliampere (mA), fade in and fade out of 10 seconds, during 20 minutes.
41385899|NCT02659826|DEVICE|cathodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (cathode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during 20 minutes.
41385900|NCT02659826|DEVICE|sham tsDCS|sham transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The electrode anode will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during only 30 seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus, early sensations (eg. mild to moderate tingling or itch) on stimulation site will be experienced without inducing any modulatory effects.
41385901|NCT02659826|DEVICE|Gait training|It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
41385902|NCT02659826|DEVICE|High frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20 hertz (Hz), 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28 seconds, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
41385903|NCT02659826|DEVICE|Low frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed.
41385904|NCT02659826|DEVICE|sham rTMS|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left primary motor area. After each rTMS session, presence of adverse effects will be computed.
41037549|NCT04198129|OTHER|Control Group|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care
41385905|NCT04062643|DIAGNOSTIC_TEST|Obesity assessment|Body mass index (BMI (kg/m2) was calculated from measurements of weight to the nearest kg and height
41385906|NCT06124326|DIETARY_SUPPLEMENT|Premenstrual Syndrome Supplement|Ginger, Curcumin, Organic Turmeric, Black Pepper, Magnesium, Zinc, Vitamin B6, Vitamin D.
41385907|NCT04922736|DEVICE|UVA-1 Phototherapy|All patients will receive UVA-1 Phototherapy treatments
41385908|NCT02572427|OTHER|Education for intubation skills|Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.
41385909|NCT02572427|OTHER|No added education for intubation skills|Routine training in neonatal resuscitation but no added experience in simulation lab.
41385910|NCT01874730|OTHER|Combined epidural-general anesthesia (CEGA)|Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
41385911|NCT01874730|DRUG|Volulyte® (6% HES 130/0.4 in balanced solution)|"For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg."
41385912|NCT01874730|OTHER|Patient-Controlled Epidural Analgesia (PCEA)|For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
41385913|NCT02543229|DRUG|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
41385914|NCT02543229|DRUG|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
41385915|NCT06541691|DRUG|Enteric-coated aspirin|Enteric-coated aspirin tablet 81 mg, once daily
41385916|NCT06541691|DRUG|Plain aspirin|Plain aspirin tablet 81 mg, once daily
41385917|NCT06541691|OTHER|Hybrid strategy|"A hybrid strategy composed from:~* A one-page educational flashcard~* Alerting patients on highly polluted days via text message~* Encouraging patients to stay at home or minimizing outdoor activity on highly polluted days~* Encouraging patients via text message to wear KN-95 facemasks (provided by the investigators of this study) during outdoors time on highly polluted days~* Encouraging patients to consume citrus fruits during highly polluted days"
41385918|NCT02823587|OTHER|Pulmonary Rehabilitation|The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.
41385919|NCT02823587|OTHER|Control|No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits
41385920|NCT06565481|OTHER|Measurement Properties (Reliability and Validity) of a Set of Assessments evaluating Physical Function in adult Participants with Hemophilia|"This study evaluates the reliability (Test-Retest) of six health related instruments that assess physical function in people with hemophilia: Short Physical Performance Battery, Unipedal Stance Test, Four Square Step Test, Timed up and Go, 1 kg Arm Lift Test, 30 Second Chair Stand Test. This study is needed to determine the psychometric properties of these six assessments. Validity of these test will be determined with the Short Form 36, the Hemophilia Activities List and the Hemophilia Joint Health Score Methodology: Reliability (Test re-test study and validity (cross sectional study) of the six tests reported in patients with hemophilia.~This intervention contains physiotherapie assessments, however, no drugs nor medical devices."
41385921|NCT01327989|DEVICE|Solitaire™ FR device|Mechanical Thrombectomy
41385922|NCT05351437|DRUG|MTx-COVAB36|MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.
41385923|NCT05351437|DRUG|Placebo|0.9% saline
41385924|NCT04980417|PROCEDURE|concomitant cholecystectomy|delayed cholecystectomy
41385925|NCT05517746|DRUG|BAY2395840 tablet|tablets, oral administration
41037550|NCT01173848|DRUG|Ergocalciferol|1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months
41385926|NCT05517746|DRUG|BAY2395840 oral solution|solution, oral administration
41385927|NCT05517746|DRUG|Placebo oral solution|Placebo matching BAY2395840, oral administration
41385928|NCT05517746|DRUG|Placebo tablet|Placebo matching BAY2395840, oral administration
41385929|NCT00307138|DRUG|hetastarch|
41385930|NCT04981782|OTHER|No study specific intervention, regular care.|Chiropractic care (regular care)
41385931|NCT00632476|OTHER|Placebo|Placebo capsule once a day
41037551|NCT01173848|DRUG|Cholecalciferol|1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
41037552|NCT00864448|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
41037553|NCT00864448|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
41037554|NCT05556408|DRUG|Succinylcholine|1.5mg/kg was given intravenously
41037555|NCT00235794|DRUG|temsirolimus|
41385932|NCT00632476|DIETARY_SUPPLEMENT|Vitamin C|A 500-mg vitamin C capsule once a day
41385933|NCT06537453|OTHER|Virtual Care|Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.
41385934|NCT02843529|OTHER|Altoida: neuropsychological, MRI, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
41385935|NCT03625752|DEVICE|Active Comparator: Active tDCS + Active TUS|Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
41385936|NCT03625752|DEVICE|Sham|Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
41510349|NCT02220517|DEVICE|MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
41385937|NCT05112939|DRUG|RPV LA|RPV LA will be administered at different formulations.
41385938|NCT05112939|DRUG|CAB LA|CAB LA will be administered at formulation 3.
41385939|NCT05859893|BEHAVIORAL|Classical Turkish Music Sessions|The participants attended an interactive livestreamed music performance. In selecting the mode, tempo, and songs to be performed, recommendations were obtained from the Applied Music Therapies Association, and the pieces with copyrighted recordings presented by the Edirne State Turkish Music Ensemble, under the leadership of the General Directorate of Fine Arts of the Ministry of Culture and Tourism. As part of the project, examples of traditional Turkish songs were presented to the elderly. The recommended genres and songs consist of vocal and instrumental works belonging to major and minor scales from the Classical Period, which spans from the 14th to the 20th century. In this respect an assembly of eight-musican consisting of five artists playing kanun, tanbur, ney, classical kemençe, and bendir, as well as two vocal soloists performed.
41385940|NCT02960724|OTHER|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
41510350|NCT06004791|DRUG|Herombopag + CsA|Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
41510351|NCT06004791|DRUG|rhTPO combined with Herombopag + CsA|rhTPO (15000U, subcutaneous injection, once a day for 7 days, once a month for 3 months)，Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
41510352|NCT05734612|DRUG|Colchicine|Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
41510353|NCT05734612|DRUG|Placebo (lactose)|Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
41510354|NCT01867463|BIOLOGICAL|Pfs25-EPA/Alhydrogel|The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
40855298|NCT03893500|DEVICE|Home-based 6 minute walk test|Participants will receive a loaner Apple Watch with the Walk.Talk.Track. (WTT, produced by PHaware) app downloaded. Participants will perform a daily 6MWT at home using the Apple Watch and WTT app. They will undergo a history and physical, blood draw, echocardiogram and in-clinic 6MWT at the baseline and 12-week follow up visit.
41037556|NCT01694862|PROCEDURE|Integrated FP/PNC service delivery|The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
41385941|NCT06568471|DRUG|Lerodalcibep|PCSK9 inhibitor
41385942|NCT06568471|DRUG|matching placebo|placebo
41385943|NCT02297724|OTHER|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
41510355|NCT01867463|BIOLOGICAL|Euvax B|Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
40855299|NCT02684149|PROCEDURE|relational touch|
40855300|NCT06254287|DRUG|Avatrombopag|Avatrombopag was given 40 mg/ time, once a day, orally, for 3 months.
40855301|NCT06254287|DRUG|Avatrombopag +rhTPO|Avatrombopag: 40 mg/ time, once a day, orally; rhTPO: 15000U/ time, once a day, subcutaneous injection; Both were 3 months.
40855302|NCT00291486|DRUG|Capecitabine|Capecitabine was administered orally at doses between 1000 and 1500 mg/m2/day depending on assigned dose level for 14 days per 21-day cycle. Daily doses were rounded to the nearest 150 mg.
41037557|NCT06188364|OTHER|Standard of Care|The usual Transition Supports and Services (USS) that prepare care partners of persons with TBI for post-rehabilitation discharge, so the the delivery of traditional CHW outreach services such as finding health, community and social determinants referrals, problem-solving, and connecting care partners to long-term supports/services
41385944|NCT03100786|DRUG|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
41385945|NCT03100786|OTHER|Placebo|Treatment with matched placebo: Standard saline for intravenous injection and placebo oral tablets containing cellulose
41385946|NCT03411122|DRUG|napabucasin|Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.
41385947|NCT03411122|DRUG|cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate|CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.
41385948|NCT06542068|BEHAVIORAL|Line Bot Assistance|"The chatbot is expected to provide self-help solutions and multiple counseling resources for stress and distress, options for face-to-face or online call requests, and a survey on mental health and stress.~In terms of keywords, it will establish counseling response resources and methods for finding resources for special sensitive situations (e.g., feeling moody, suicidal, stressed, not wanting to intern, etc.)."
41385949|NCT04425642|DRUG|Glucose/Amino acids|If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose and amino acids solutions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
41385950|NCT04425642|DRUG|Glucose/Amino acids/Lipids|If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose, amino acids and lipid emulsions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
41385951|NCT05573646|OTHER|Dual-task training|Participants will receive a one-hour online group-based dual-task training session twice a week for 12 weeks, giving a total intervention time of 24 hours. A co-design approach will be adopted to develop the training components in the dual-tasks. For the cognitive training component, arithmetic operation, verbal fluency, and upper limb/ finger movements are included. For the physical training component, we select chair-based exercises are included. A group-based training mode led by a facilitator will be adopted. During the session, participants will be asked to turn on their camera so that they can see and interact with each other. They will also have their audio on as they will have to participate in the cognitive tasks by voicing out their answers.
41385952|NCT05573646|OTHER|Attention Control|Participants will receive eight one-hour online group-based interactive education on health topics other than exercise and cognitive health.
41385953|NCT01354015|DEVICE|DRMS|USE OF TEXT MESSAGING SYSTEM
41385954|NCT03159000|DRUG|Saline|1ml of 1/3 saline
41385955|NCT03159000|COMBINATION_PRODUCT|lidocaine/bupivacaine|1ml of a 50% 2% lidocaine and 50% 0.5% bupivacaine
40855303|NCT00291486|DRUG|131I-huA33 (131-Iodine on humanised monoclonal antibody A33)|All patients received a dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 comprised a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I-huA33 therapy dose was determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
41037558|NCT06188364|OTHER|Experimental|"Novel aspects of the CHW experimental intervention for TBI care partners include:~1. CHW services begin prior to inpatient rehabilitation discharge;~2. care partners get timely, useful health management materials;~3. encounters focus on unlimited, brief, situation-focused calls to help care partners assess and resolve pressing concerns; and~4. long-term support capacity for care partners is built by establishing a reliable referral network of medical, community, and social services that become foundational resources beyond study completion."
41166341|NCT01580111|BIOLOGICAL|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
41166342|NCT04735913|DRUG|Abiraterone acetate tablets|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
41166343|NCT00706914|DRUG|Once-daily aclidinium/formoterol|Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning
41166344|NCT00706914|DRUG|Twice-daily formoterol fumarate|Inhaled formoterol fumarate 12 µg twice-daily (BID)
41385956|NCT00392717|DRUG|Atorvastatin|
41385957|NCT00392717|DRUG|Fish oils|
41385958|NCT06400095|DIAGNOSTIC_TEST|Poccl, Time constant, driving pressure|Ventilatory parameters
41385959|NCT00730067|DRUG|sildenafil|Sildenafil 50 mg three times daily
41385960|NCT00730067|DRUG|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
41385961|NCT05377866|OTHER|Remote proctoring using HoloLens|Assess Microsoft HoloLens as an interactive communication device in remote proctoring, and enhancement of teamwork in complex CTO procedures.
40676653|NCT03476174|DRUG|Interleukin-2|Following the pembrolizumab treatment, HD IL-2 treatment will commence. After completing the 2 cycles of pembrolizumab, High Dose Interleukin-2 (HD IL-2) will be administered. This will require a hospital stay of at least 5 days for each treatment cycle. Established guidelines will be followed for safely administering HD-IL-2 and managing toxicities from this treatment. Two treatment cycles will be administered, Cycle 2 being separated from Cycle 1 by approximately 9 days after completion (assuming subject has recovered from Cycle 1 adequately to proceed with Cycle 2). Four weeks after completion of the 2 cycles (called a course of HD IL-2 therapy), disease status will be monitored via CT of the chest and abdomen/pelvis using revised RECIST guidelines
41166345|NCT00706914|DRUG|Placebo to formoterol fumarate|Inhaled placebo to formoterol fumarate once-daily in the evening
41037559|NCT06244784|BEHAVIORAL|effectiveness of a training course on a healthy work environment for nurses and nursing assistants in a hospital|"Once the participants have been included in the study, they will be assigned to each group; control group and intervention group by convenience sampling. Baseline data will be collected in both groups. At this time, questionnaires will be collected in both populations and focus groups will be conducted in the professionals assigned to both groups. Once the data have been obtained, the intervention group will conduct the training course.~After the training, data will be collected again at three different times: 1) Right after the training: questionnaires and focus group will be collected from intervention group professionals; 2) 6 months after the training: questionnaires will be collected from control group and intervention group; 3) 12 months after the training: questionnaires will be collected and focus groups will be conducted in both groups."
41037560|NCT03966976|DEVICE|ECG monitoring & record|This is a mobile ECG recorder that not only records short portions of ECG on one or three leads, but also stores, processes and transmits their data to facilitate the diagnosis and to confirm the occurrence of AF arrhythmia episodes by the physician.
41037561|NCT03966976|OTHER|Conventional follow-up|Conventional follow-up
41037562|NCT06350903|OTHER|Fast + High-fat low-carbohydrate diet|Participants will be instructed to follow a strict HFLC diet starting on the morning of the day before the visit and to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications.
41037563|NCT06350903|COMBINATION_PRODUCT|Fast + Empagliflozin|Participants will be instructed to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications. Participants will also be instructed to take an oral dose of 50 mg of empagliflozin at 7am the morning before the experimental visit and on the day of the experimental visit.
41037564|NCT01053858|PROCEDURE|intravitreal injection|intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
41037565|NCT01823848|DRUG|Sodium phosphate enema|Rectally administered medication to treat constipation
41037566|NCT01823848|DRUG|Normal saline enema|Rectally administered medication to treat constipation
41037567|NCT01823848|DRUG|Mineral oil enema|Mineral oil enema administered to treat constipation. 66ml per rectum
41037568|NCT05319431|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
41037569|NCT05319431|DRUG|Lenvatinib|Subjects will receive lenvatinib until disease progression or for a maximum of 24 months
41037570|NCT05319431|PROCEDURE|TACE|On demand TACE
41037571|NCT02374827|PROCEDURE|Standard postpartum tubal ligation|Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)
41037572|NCT02374827|PROCEDURE|Complete Salpingectomy|Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
41037573|NCT03495050|DEVICE|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid aortic stenosis with the Evolut Pro/XL platform
41037574|NCT04348604|BEHAVIORAL|Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA)|"Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA): CAE-AYA participants will have 4 core in-person sessions (45-60 minutes each) spaced about 1 week apart over a period of approximately 4 weeks and one booster in-person session approximately 4 weeks after completion of the 4 core sessions (total of up to 5 in-person sessions spaced out over 8 weeks). There will be one follow-up phone call with a study interventionist, approximately 6 weeks post-baseline (timed half-way between completion of the core sessions and the booster session). All AYAs assigned to the CAE-AYA arm will receive all 4 modules (Psychoeducation on BD Medications; Communication with Providers \& Caregivers; Medication Routines; and Targeting Risky Behavior via Modified Motivational Enhancement Therapy (MET)), with the content within each module being customized to developmental stage and behavioral experience."
41166346|NCT00706914|DRUG|Once-daily formoterol fumarate|Inhaled formoterol fumarate 12 μg once-daily in the evening
41166347|NCT04112641|DRUG|Nicotinamide riboside|Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
41166348|NCT04112641|DRUG|Placebo capsules|Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
41166349|NCT03493568|DRUG|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.
41166350|NCT03493568|DRUG|Dolutegravir 50 mg plus one RTI|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
41166351|NCT02906696|DRUG|Bosutinib|Given PO
41166352|NCT02906696|OTHER|Laboratory Biomarker Analysis|Correlative studies
41385962|NCT01741259|DRUG|Meperidine|
41385963|NCT03877848|DEVICE|Percutaneous Coronary Intervention (PCI)|Patients enrolled to the study will undergo angiography followed by PCI according to current guidelines.
41385964|NCT05150197|DEVICE|VisuALL|Virtual Reality Visual Field Device
41385965|NCT05150197|DEVICE|Humphrey Visual Field|Standard of care Visual Field test
41385966|NCT03056716|PROCEDURE|Silastic vs conventional drain in thoracic surgery|Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
41385967|NCT04172727|DRUG|Bupivacaine Hcl 0.25% Inj|ultrasound-guided bilateral TFP block with 20 mL of 0.25% bupivacaine
41385968|NCT04172727|DRUG|saline 0.9%|ultrasound-guided bilateral TFP block with 20 mL of saline 0.9%
41385969|NCT05538286|DEVICE|ClearFit implant|The ClearFit implant is an FDA cleared implant in regular use in the United States. The ClearFit implant and other PMMA cranioplasty implants manufactured by Longeviti have been reported to be safe and effective as cranial implants that permit transcranial ultrasound to be performed. The PMMA cranioplasty implant (Longeviti Neuro Solutions, Hunt Valley, MD) is clear, sonolucent, and was recently shown to be safe and effective in transcranial ultrasonography for bypass patency assessment. The ClearFit cranioplasty being used in this study is industry standard of care.
41385970|NCT05538286|PROCEDURE|transcranial ultrasonography through sonolucent cranioplasty|The implantation of the ClearFit PMMA sonolucent implant permits TUSC to be performed at the bedside for patients in both the in-patient and outpatient settings. While the patient is an inpatient, the clinical or research teams will attempt to perform TUSC within 1 hour of neuroimaging if that neuroimaging is performed at a time when a trained ultrasound operator is present.
41037575|NCT04348604|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|Enhanced Treatment as Usual (ETAU): ETAU will consist of usual clinical care with prescribing clinicians and therapists, augmented by written materials specific to BD for AYAs and 6 follow-up telephone calls to briefly review the materials and be available for questions by social workers with mental health experience and at least some experience in working with AYA with BD. In order to ensure that there is not treatment contamination, different trained interventionists will be used for CAE and eTAU. Therapists will briefly review the materials and be available for questions during the phone calls. Materials will cover general self-management in BD. The calls will be relatively brief (maximum of 20-30 minutes).
41037576|NCT02205710|OTHER|Computerized cognitive training|
41037577|NCT02205710|OTHER|Computerized games|
41037578|NCT01309620|DIETARY_SUPPLEMENT|Zinc gluconate|Zinc gluconate (GNC, USA), 100 mg twice daily
41037579|NCT01309620|DIETARY_SUPPLEMENT|Placebo|Placebo, Twice Daily
41037580|NCT05802810|DRUG|[14C]JT001|Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.
41037581|NCT02078323|DRUG|Linaclotide|
41037582|NCT02078323|DRUG|Placebo|
41037583|NCT06436053|DEVICE|LBBAP with SyncAV|Acute changes in surface ECG QRS duration resulting from left bundle branch area pacing using various pacing configurations will be evaluated.
41037584|NCT02040480|DRUG|GSK2110183 Gelatin Capsule|White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
41037585|NCT02040480|DRUG|GSK2110183 IR Tablet|White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
41037586|NCT04658251|GENETIC|Blood and/or skin biopsy|Blood and/or skin biopsy will be withdrawn, for RNA extraction in order to test the effect of the variant on splicing.
41037587|NCT01873365|OTHER|Data collection|Case report forms (CRFs), logbooks and booklets.
41037588|NCT03203369|BIOLOGICAL|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
41385971|NCT03716804|DRUG|Tablet Nitrofurantoin|Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days
41385972|NCT03716804|DRUG|Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime|Tablet Ciprofloxacin (500 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefixime (200 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefuroxime (250 mg), two times daily in 12 hours interval for 7 days
41385973|NCT01311505|DRUG|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
41385974|NCT01311505|DRUG|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
41385975|NCT00228332|DRUG|Administration of zinkgluconaat or placebo|
41037589|NCT06129669|DRUG|Indocyanine green|Administration of ICG during surgery and recording of the fluorescence video to perform data analyses
41037590|NCT00454051|DRUG|Omalizumab|Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
41037591|NCT00454051|DRUG|placebo|Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
41037592|NCT01210391|OTHER|Extensively hydrolyzed whey infant formula|New hydrolyzed infant formula.
41037593|NCT01210391|OTHER|Extensively hydrolyzed casein infant formula|Commercially available infant formula.
41037594|NCT05585424|OTHER|AOT intervention|"The treatment will last 4 weeks, with an intensity of 3 sessions per week. During the sessions the MCI patient will observe his MCI partner and perform a programme of upper limb motor activities. At the same time the mild patient imitates the movement performed by the physiotherapist, all based on the AOT.~The activities will be based on items of the FUGL-MEYER scale. The sessions will last between 15 and 20 minutes and will be held three days a week. The intervention will last 5 weeks, with an initial assessment, 11 intervention sessions and a final assessment."
41037595|NCT03321643|DRUG|Atezolizumab|Given IV
41037596|NCT03321643|PROCEDURE|Biopsy|Undergo biopsy
41037597|NCT03321643|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41037598|NCT03321643|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41037599|NCT03321643|PROCEDURE|Computed Tomography|Undergo CT or PET-CT
41037600|NCT03321643|DRUG|Gemcitabine|Given IV
41037601|NCT03321643|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41037602|NCT03321643|DRUG|Oxaliplatin|Given IV
41037603|NCT03321643|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
41037604|NCT03321643|BIOLOGICAL|Rituximab|Given IV
41037605|NCT05051566|DRUG|LY3502970|Administered orally.
41037606|NCT05051566|DRUG|Esomeprazole|Administered orally.
41037607|NCT01022762|DRUG|repaglinide|Individually adjusted dose for 16 weeks
41037608|NCT01022762|DRUG|gliclazide|Individually adjusted dose for 16 weeks
41037609|NCT01130766|PROCEDURE|stereotactic radiosurgery (SRS)|Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
41037610|NCT03581305|DRUG|18F-FDOPA|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the dopaminergic (18F-FDOPA) system.
41037611|NCT03581305|DRUG|11C-DASB|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the serotonergic (11C-DASB) system.
41037612|NCT02348073|DRUG|Vayarin®, supplementation of n-3 PUFA|"Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.~At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product."
41037613|NCT02348073|DRUG|PLACEBO|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
41037614|NCT03775239|BEHAVIORAL|Mindfulness in Sex Therapy and Intimate Relationships (MSIR)|"Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing \& Exploring Week 3: Avoidance \& Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning"
41037615|NCT03775239|BEHAVIORAL|Treatment-as-usual|"The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy."
41037616|NCT03183427|DIAGNOSTIC_TEST|MR of the brain|MR of the brain without gadolinium, incl. T2-weighted image
41037617|NCT00345904|BIOLOGICAL|Fluarix|
41037618|NCT04152733|DEVICE|High flow nasal cannula|Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
41385976|NCT04419428|DEVICE|BiPAP A40 Expiratory Flow Limitation (EFL)|All participants in the observational registry will be using the BiPAP A40 EFL noninvasive ventilator as part of standard of care and will be participating in the same follows up and data collection. The BiPAP A-40 EFL ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Respiratory Insufficiency with the primary cause being COPD. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments.
41037619|NCT00821418|DEVICE|PulseHaler treatment|treatment is for two weeks, 3 times per day
41037620|NCT00821418|DEVICE|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
41037621|NCT05487508|DRUG|Dexamethasone|Administration of intraoperative 1 mg/kg body weight dexamethasone
41037622|NCT05487508|DRUG|Normal saline|Placebo (NaCl 0.9%)
41037623|NCT04980053|OTHER|massage|Intervention group Control group
41037624|NCT01437449|DRUG|Docetaxel|30 mg/m² by intravenous (IV) administration
41037625|NCT01437449|DRUG|Cisplatin|30 mg/m² by intravenous (IV) administration
41037626|NCT01437449|DRUG|Cetuximab|400 mg/m² by intravenous (IV) administration, thereafter 250 IV
41385977|NCT01612052|DRUG|Antibiotic Prophylaxis|Comparing the antibiotic treatment related to surgery
41385978|NCT02131753|DRUG|Cladribine s.c. injection, HCL treatment|Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
41385979|NCT02296788|BEHAVIORAL|Aerobic Exercise|The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
41385980|NCT02822807|BIOLOGICAL|Blood sampling|
41385981|NCT05832242|OTHER|Ultrasound|Point-of-care ultrasound in the emergency department
41037627|NCT01437449|DRUG|Carboplatin|Area under the free carboplatin plasma concentration versus time curve (AUC)=2 by intravenous (IV) administration
41037628|NCT06530953|BEHAVIORAL|Patient Navigator Model|The patient navigator model is an evidence-based intervention to improve access to healthcare services.
41037629|NCT02263404|DEVICE|Deep Brain Stimulation|DBS Implant Stimulation
41037630|NCT04584112|DRUG|Tiragolumab|Tiragolumab 840 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of every 28-day cycle.
41037631|NCT04584112|DRUG|Atezolizumab|Atezolizumab 1680 mg administered by IV infusion on Day 1 of every 28-day cycle.
41037632|NCT04584112|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 milligrams per square meter (mg/m\^2) administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
41037633|NCT04584112|DRUG|Tiragolumab|Tiragolumab 420 mg administered by IV infusion Q2W.
41037634|NCT04584112|DRUG|Atezolizumab|Atezolizumab 840 mg administered by IV infusion Q2W.
41037635|NCT04584112|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 administered by IV infusion QW.
41037636|NCT04584112|DRUG|Carboplatin|Carboplatin (area under the concentration-time curve \[AUC\]: 5 milligrams per milliliter per minute \[mg/mL/min\]) administered by IV infusion Q3W.
41037637|NCT04584112|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 Q2W administered by IV infusion.
41037638|NCT04584112|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m\^2 Q2W administered by IV infusion.
41037639|NCT04584112|DRUG|Granulocyte colony-stimulating factor (G-CSF)|G-CSF support for four doses.
41037640|NCT04584112|DRUG|Granulocyte-macrophage colony-stimulating factor (GM-CSF)|GM-CSF support for four doses.
41037641|NCT03116594|BIOLOGICAL|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
40855304|NCT05225857|DRUG|AGA2118|"Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC."
40855305|NCT05225857|DRUG|Placebo|"Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC."
40855306|NCT03357562|DEVICE|lung MRI|lung MRI without contrast injection
40855307|NCT06530732|PROCEDURE|Deep Cervical lymphatlc-Venous Anastomosis Surgery|Cervical deep lymphatic-venous anastomosis (dcLVA) can promote the flow of cerebrospinal fluid within the glymphatic system. The procedure involves connecting deep cervical lymphatic vessels to veins, reducing pressure on lymph nodes and allowing lymphatic fluid from high-pressure vessels to flow into the lower-pressure venous system. This surgical intervention enhances the clearance of waste in the glymphatic system, particularly amyloid-beta (Aβ) and tau proteins. By facilitating the removal of these AD-associated proteins from the brain, dcLVA can reduce local tissue fibrosis and cervical nerve compression, potentially reversing degenerative changes, slowing disease progression, and improving the quality of life for AD patients.
40855308|NCT06530732|DRUG|Lecanemab|The newly approved anti-beta-amyloid (Aβ) monoclonal antibody Lecanemab can delay AD progression but is only suitable for patients in the early stages. For those with moderate to severe AD, Lecanemab is not effective.
40855309|NCT02681289|OTHER|Early goal directed neuromotor therapy|Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.
40855310|NCT02243735|DRUG|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
40855311|NCT02243735|DRUG|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
40855312|NCT03875742|DEVICE|Ultraplex 360(Braun)|"This group will use as first needle the ultraplex 360 (Braun)"
40855313|NCT03875742|DEVICE|STIMUPLEX D SH, 30°(Braun)|"This group will use as first needle the  STIMUPLEX D SH, 30° (Braun)"
40855314|NCT06464263|DRUG|Dexmedetomidine|to investigate the postoperative analgesic-sedative effect of dexmedetomidine versus fentanyl-midazolam to achieve fast-track extubation after adult valvular cardiac surgeries.
41037642|NCT03116594|BIOLOGICAL|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
41037643|NCT01990950|DEVICE|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
41037644|NCT03744273|PROCEDURE|breast capsule biopsy|
41037645|NCT03720704|DEVICE|GORE VIABAHN VBX Balloon Expandable Endoprosthesis|GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.
41037646|NCT00197977|BEHAVIORAL|Educational program to address patients' expectations|
41037647|NCT01101737|OTHER|Nurse-led blood pressure clinic|Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.
41037648|NCT00563784|DRUG|Erlotinib|150 mg by mouth daily for 7 Weeks
41037649|NCT00563784|DRUG|Carboplatin|2 AUC by vein weekly for 7 Weeks
41037650|NCT00563784|DRUG|Paclitaxel|45 mg/m\^2 by vein weekly for 7 Weeks
40855315|NCT03002883|BEHAVIORAL|Usual Care|"Participant provided Quit Kit water bottle with small cessation aids (eg. sunflower seeds) and educated about student health as a cessation resource"
40855316|NCT03002883|BEHAVIORAL|Brief Motivational Interviewing|Peer educator conducts brief motivational interviewing about smoking cessation and participant goals
41037651|NCT00563784|RADIATION|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
41037652|NCT06189417|BEHAVIORAL|Health Extension Led club based Intervention|The Health Extension Workers-led club-based intervention primarily focuses on equipping individuals with the necessary knowledge and skills to enhance their self-management behavior. The intervention encompasses education on adopting healthy eating habits, promoting regular exercise, effectively managing weight, and supporting smoking cessation. It emphasizes the importance of regular blood sugar level monitoring, limiting alcohol intake, and reducing sedentary behavior. The intervention also includes counseling to provide guidance and support in adopting and maintaining healthy behaviors. Additionally, it highlights the significance of adhering to medication regimens for optimal health outcomes. If additional medical attention is required, the intervention provides referral services to nearby health facilities.
41037653|NCT00250887|DRUG|Gefitnib|
41037654|NCT03986853|PROCEDURE|Blood sampling|Blood sampling under general anesthesia
41037655|NCT00003269|BIOLOGICAL|sargramostim|
41037656|NCT00003269|DRUG|amifostine trihydrate|
41037657|NCT00003269|DRUG|cisplatin|
41037658|NCT00003269|DRUG|cyclophosphamide|
41037659|NCT00003269|DRUG|etoposide|
41037660|NCT00936858|DRUG|RAD001|
41037661|NCT02378168|OTHER|no intervention; retrospective study|
41037662|NCT05103761|OTHER|Study diet|A low carbohydrate diet (\<20g/day) is administered to achieve diet-induced ketosis.
41037663|NCT05103761|OTHER|Low glycemic index treatment diet|A diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis.
41037664|NCT03191318|OTHER|ERAS pathway|ERAS pathway after laparoscopic sleeve gastrectomy
41037665|NCT03191318|OTHER|Standard pathway|Standard pathway after laparoscopic sleeve gastrectomy
41037666|NCT00407446|DRUG|sildenafil|
41385982|NCT02919033|OTHER|Usual care|The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
41385983|NCT02919033|DEVICE|Self-management|"* Usual care~* Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~* All patients receive proficiency training in using the BP tele-monitor, and mobile App."
41385984|NCT02919033|OTHER|PCTM intervention|"* Usual care~* Self-management~* PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~* PCPs and cardiologists receive training of the CareLinker website."
41385985|NCT04461626|DEVICE|Persona fixed bearing knee system (All patients will receive Persona fixed bearing knee system)|
41385986|NCT04561934|DRUG|Silver diamine fluoride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
41385987|NCT04561934|OTHER|resin modified glassionomer cement|resin modified glassionomer cement
41510356|NCT01867463|BIOLOGICAL|Menactra|Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
41510357|NCT01739127|DRUG|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
41510358|NCT01739127|DRUG|Risperidone/Quetiapine|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
41510359|NCT05963724|DEVICE|Real-Time Computer Aided Detection|This intervention involves using computer-aided detection using a real-time system (GI-Genius, Medtronic)
41510360|NCT05963724|PROCEDURE|Stanford Colonoscopy|This involves white-light colonoscopy
41385988|NCT03092115|DEVICE|HIV medication adherence app|A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
41385989|NCT06113562|PROCEDURE|PFO closure|The participants will receive a onetime closure of a small hole in heart. The procedure usually takes up to an hour. The procedure is done with local anesthesia and conscious sedation. A catheter is inserted into a vein in upper thigh and threaded to heart to deploy the closure device. Either Gore septal occluder or Amplatzer PFO occluder
41385990|NCT05054621|BIOLOGICAL|Heterologous prime-boost schedule with AZD1222 and MVC-COV1901|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
41510361|NCT00795262|DRUG|Quinapril (Accupril) plus Alpha Lipoic Acid|Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
41510362|NCT00795262|DRUG|accupril, placebo|accupril 40 mg
41510363|NCT00795262|DRUG|accupril, alpha lipoic acid|accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
41510364|NCT06042582|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
41510365|NCT01010113|OTHER|Standard infant formula with prebiotics|From 0-6 months of age. As per standard requirement
41510366|NCT01010113|OTHER|Infant formula with synbiotics|From 0-6 months of age as per standard requirement
41510367|NCT00645632|DRUG|cisplatin|
41037667|NCT02084966|PROCEDURE|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
41510368|NCT00645632|DRUG|doxorubicin hydrochloride|
41510369|NCT00645632|DRUG|ifosfamide|
41510370|NCT00645632|DRUG|methotrexate|
41510371|NCT00645632|PROCEDURE|adjuvant therapy|
41510372|NCT00645632|PROCEDURE|neoadjuvant therapy|
41510373|NCT00645632|PROCEDURE|therapeutic conventional surgery|
41510374|NCT03859544|OTHER|Retrospective study|Retrospective study to search mutations associated with Central nervous system lymphoma and study of the prognostic impact (overall survival and progression-free survival) of these mutations.
41510375|NCT01734161|DRUG|Dexamethasone|8mg IV dexamethesone given
41510376|NCT01734161|DRUG|Placebo|Subjects randomized to placebo receive 50cc normal saline
40676654|NCT06621381|BEHAVIORAL|Concentrated exposure and response prevention|The intervention consists of: Psychoducation for the patients (1 session, 2-3h in group format), psychoeducation for the legal guardians (1 session, 3h in group format), exposure and response prevention (3-4 sessions, 9-12h over the course of one week, individual format), group reunions for sharing experiences, motivational work and relapse prevention ( 2 sessions, 3h)
40676655|NCT06624215|PROCEDURE|Appendectomy|Robotic-assisted or laparoscopic appendectomy for acute appendicitis.
41166353|NCT03684356|PROCEDURE|socket shield technique|immediate implant placement with buccal part of the root is retained
41385991|NCT05054621|BIOLOGICAL|Homologous prime-boost schedule with two doses of AZD1222|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
41385992|NCT03654807|BEHAVIORAL|High Intensity Walking|70-80% HRmax
41385993|NCT03654807|BEHAVIORAL|Casual Speed Walking|Self selected pace
41385994|NCT02784002|DRUG|Ridinilazole|
41385995|NCT02784002|DRUG|Fidaxomicin|
41385996|NCT06096259|DRUG|Metformin|Metformin is an oral anti-hyperglycemic agent widely used as first-line treatment for type II diabetes to improve glycemic control. It is the fourth most commonly prescribed drug in the United States. Participants will receive commercially available extended-release metformin 500mg tablets manufactured by Granules India Limited, Hyderabad, India and then sourced, packaged, and labeled for the study by Sharp Labs. The study will follow standard dosing procedures for extended-release metformin. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments weekly as tolerated, up to a maximum dose of 1500 mg daily.
41385997|NCT06096259|DRUG|Placebo|The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments weekly as tolerated, up to a maximum dose of 1500 mg daily.
41385998|NCT02618252|DEVICE|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
41385999|NCT02618252|DEVICE|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
41386000|NCT05780515|BIOLOGICAL|ANX009|ANX009 will be administered per schedule specified in the arm description.
41386001|NCT02392559|DRUG|Evolocumab|Dose of subcutaneous evolocumab every 4 weeks
41037668|NCT00108225|OTHER|LoBag Diet - test phase|A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.
41386002|NCT02392559|DRUG|Placebo|Dose of subcutaneous placebo treatment every 4 weeks
41386003|NCT02866123|OTHER|ultrasonography|
41386004|NCT02866123|RADIATION|pulmonary radiography|
41386005|NCT04554927|OTHER|WEB-Application|The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).
41386006|NCT04554927|OTHER|Standard accompaniment|Personalized schedule of medical follow-up given to the patient
41510377|NCT05149391|BIOLOGICAL|CD19/CD20-directed Chimeric Antigen Receptor T Cells|Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells, single infusion intravenously
41037669|NCT00108225|OTHER|LoBAG Diet - control phase|A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
41037670|NCT04349787|OTHER|Computer-aided diagnosis (CADx)|Optical diagnosis of colorectal polyps made with computer-aided diagnosis (CADx) using state-of-the-art machine learning methods and deep learning architectures.
41037671|NCT04349787|OTHER|BLI Adenoma Serrated International Classification (BASIC)|Optical diagnosis of colorectal polyps made with BLI Adenoma Serrated International Classification (BASIC), both by exert endoscopists and novices.
41037672|NCT03125265|OTHER|dietary intake of omega-3 and omega-6 polyunsaturated fatty acids|
41037673|NCT00925158|PROCEDURE|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
41037674|NCT02629510|DRUG|Tachosil|
41037675|NCT02777593|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
41037676|NCT01781572|DRUG|LEE011|LEE011 will be administered orally once daily
41037677|NCT01781572|DRUG|MEK162|MEK162 will be administered orally twice daily
41037678|NCT01349075|RADIATION|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
41166354|NCT03684356|PROCEDURE|xenograft|immediate implant placement with filling the buccal gap with xenograft
41386007|NCT01135316|DRUG|Ablavar|One dose of Ablavar will be administered for use during a contrast MRI examination
41386008|NCT06513988|DEVICE|MI-BCI combined with tDCS treatment|The treatment intervention was carried out in an independent and quite room and included following steps: During the MI-BCI based training, MI of leg flexion and extension training was first performed 10 times to accurate the training threshold, and then later in the formal BCI training, if the attention was reached the threshold, functional electrical stimulator was trigger to stimulate the corresponding muscle to execute the actual action. Additionally, the patient was given a brief training about how to operate tDCS device until he felt comfortable using it, and then asked to show and give feedback to the researcher. For motor function and pain improvement, tDCS is typically delivered with the anode electrode placed over the primary motor cortex (M1), and the cathode over the supraorbital area (SO) to trigger neuroplastic changes\[5\]. The MI-BCI combined with tDCS treatment was performed five days per week (in the late afternoon), and MI-BCI training for 30min.
41386009|NCT03356366|OTHER|MRI 3T|Magnetic Resonance Imaging 3 Tesla
41386010|NCT03356366|OTHER|MRI 1,5T|Magnetic Resonance Imaging 1,5 Tesla
41166355|NCT01027663|DIETARY_SUPPLEMENT|Iron Supplement|Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
41166356|NCT00344253|DRUG|Interferon beta|
41166357|NCT00344253|DRUG|Methotrexate|
41166358|NCT06245161|DEVICE|Quicksleeper5|intraosseous anesthesia for dental treatment
41166359|NCT06245161|DEVICE|conventional anesthesia|inferior alveolar nerve block for treating mandibular molars infiltration anesthesia for treating maxillary molars
41166360|NCT01801462|OTHER|Simulation-based training|
41386011|NCT03356366|OTHER|MRI 7T|Magnetic Resonance Imaging 7 Tesla
41386012|NCT06541821|OTHER|survey evaluation|assessment of physical activity, fear of movement, and ostomy compliance
41386013|NCT00004199|DRUG|cisplatin|
41386014|NCT00004199|DRUG|gemcitabine hydrochloride|
40855317|NCT03002883|BEHAVIORAL|Direct referral to quitline|Peer educator educates about state quitline services and gets verbal consent to use quitline's direct referral web portal for quitline to contact participant in 1-2 business days about free counseling services to make a quit plan
40855318|NCT02967510|DRUG|Estriol|
40855319|NCT02967510|DRUG|Placebo|
40855320|NCT05542654|OTHER|Foot Massage|Pregnant women in the intervention group were given a foot massage for 15 minutes each, for a total of 30 minutes for three days, while the control group did not receive foot massage.
41037679|NCT02491008|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
41037680|NCT02491008|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
41037681|NCT04939129|DIAGNOSTIC_TEST|The research is terminated by calculating the percentage of PVI changes with SAB formed by LRM after fluid challenge.|Measurements will begin after a hemodynamically stable period in the supine position.Heart rate, central venous pressure, systolic, diastolic and mean arterial pressure, peripheral oxygen saturation, PVI and BIS baseline values (baseline 1) will be recorded.LRM will be automatically adjusted in the mechanical ventilator(30 cm H2O/30 seconds) and all hemodynamic parameters where the maximum change at the end of 30 seconds, will be recorded(after LRM), and the differences initial baseline values will be calculated and recorded as percentages.After the recording of the second values, the crystalloid infusion at 10ml/kg will be made to the patient through the peripheral venous line within 15minutes, new baseline values will be taken before the test(baseline 2).After fluid replacement, LRM will be repeated in the same way. The values after LRM(Fluid Challenge-FC) will be recorded and differences between basal 2 values will be calculated and recorded as percentages.
41037682|NCT05997238|DRUG|without triamcinolone|The preparation contains only the basic formula. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
41037683|NCT05997238|DRUG|20mg triamcinolone|20mg triamcinolone was added to the preparation. Mix 20mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
41037684|NCT05997238|DRUG|40mg triamcinolone|40mg triamcinolone was added to the preparation. Mix 40mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
41037685|NCT05997238|DRUG|80mg triamcinolone|80mg triamcinolone was added to the preparation. Mix 80mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
41037686|NCT05829902|OTHER|Herbal extract drink|30 ml drink containing 600 mg of lemon balm extract, tea leaves, brown sugar and flavoring agent, two weeks daily
41386015|NCT00004199|DRUG|prinomastat|
40855321|NCT03918915|DRUG|SYD-101 Dose 1|Sterile topical ophthalmic solution
40855322|NCT03918915|DRUG|SYD-101 Dose 2|Sterile topical ophthalmic solution
41037687|NCT05829902|OTHER|Placebo|30 ml placebo drink containing maltodextrin, tea leaves, brown sugar and flavoring agent, two weeks daily
41166361|NCT05264142|DRUG|Voriconazole 200mg|Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.
41166362|NCT05264142|DRUG|FluvoxaMINE 50 Mg Oral Tablet|Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.
41386016|NCT05176301|RADIATION|computed tomography, Magnetic resonance image|Investigators measured the cervical cord and canal diameter by using CT and MRI that were previously taken.
41386017|NCT04876859|PROCEDURE|CRF of anterior sensitive branches to the hip|Steroid and anesthetic extra articular injection followed by denervation using CRF at 90 celsius degree during a period 90 minutes at the sensitive branches of obturator and femoral nerve, separately.
41386018|NCT04876859|PROCEDURE|Anesthetic block with steroid injection of anterior sensitive branches to the hip|Corticosteroid and anesthetic extra articular injection at the sensitive branches of obturator and femoral nerve, only
41386019|NCT01491737|DRUG|Pertuzumab|Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.
41386020|NCT01491737|DRUG|Trastuzumab|Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
41386021|NCT01491737|DRUG|Aromatase Inhibitor|Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
41386022|NCT01491737|DRUG|Induction Chemotherapy|Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
41386023|NCT00729703|DEVICE|Ovatio DR 6550|Dual-chamber ICD therapy with minimized ventricular pacing
41386024|NCT00729703|DEVICE|OVATIO DR 6550|Single-chamber device therapy with settings which are common in clinical practice.
41386025|NCT01162993|PROCEDURE|Spinal Cord Stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (≥50% relief of pain intensity on a weighted numeric rating scale (NRS) or a score of ≥6 on a seven-point Likert scale (1=very much worse; 7=very much improved) of the PGIC scale for pain and sleep) a definite spinal cord system will be implanted.
41510378|NCT06398301|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals."
41510379|NCT00006038|DRUG|cisplatin|
40855323|NCT03918915|DRUG|Vehicle|Sterile topical ophthalmic solution without active ingredient
41510380|NCT00006038|DRUG|docetaxel|
40855324|NCT00379912|DRUG|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
40855325|NCT00379912|DRUG|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
40855326|NCT00379912|DRUG|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
40855327|NCT04384055|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.
40855328|NCT01216137|OTHER|Exercise: Vestibular Rehabilitation|Balance and eye movement training
41510381|NCT00006038|DRUG|floxuridine|
41510382|NCT00006038|DRUG|fluorouracil|
41510383|NCT00006038|DRUG|leucovorin calcium|
40855329|NCT01216137|OTHER|Exercise|Bicycle ergometry and stretching
40855330|NCT02499705|DIETARY_SUPPLEMENT|Sucralose|2 packets
40855331|NCT02499705|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
40855332|NCT02499705|DIETARY_SUPPLEMENT|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
41037688|NCT04916223|OTHER|Therapeutic massage|"The massage therapists were scheduled on a rotating schedule with two alternates scheduled for each day to ensure adherence to assigned study arm and to avoid therapist effect as much as possible. For each enrolled subject, the therapist assessed the subject and created a treatment plan depending on his/her individual needs and preferences. For example, if a subject reported bothersome lower extremity pain, the therapist might focus the massage on that lower extremity or might avoid massaging that lower extremity, depending solely on the preference of the subject. Massage duration was determined by the assigned study arm."
41037689|NCT05403580|DRUG|Olanzapine|Given PO
41037690|NCT05403580|DRUG|Placebo Administration|Given PO
41166363|NCT05264142|DRUG|Omeprazole 10 MG Oral Tablet|Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.
41510384|NCT00006038|PROCEDURE|conventional surgery|
40855333|NCT00172341|DRUG|Staloral TM|
40855334|NCT01286077|DRUG|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
41510385|NCT05295719|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA)
41510386|NCT05295719|BEHAVIORAL|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
41510387|NCT05295719|DIETARY_SUPPLEMENT|Safflower oil|4 grams safflower oil (AlaskOmega®) per day
41510388|NCT05295719|BEHAVIORAL|Flexibility training|30 min of stretching 3 days/week for 6 weeks
40855335|NCT05976763|DRUG|Zanubrutinib|Given PO
40855336|NCT05976763|BIOLOGICAL|Rituximab|Given IV
40855337|NCT05976763|OTHER|Patient Observation|Undergo observation
40855338|NCT05976763|PROCEDURE|Bone Marrow Biopsy|undergo bone marrow biopsy
40855339|NCT05976763|OTHER|Fludeoxyglucose F-18|Given IV
40855340|NCT05976763|PROCEDURE|Positron Emission Tomography|Undergo PET
40855341|NCT05976763|PROCEDURE|Computed Tomography|Undergo CT
40855342|NCT05976763|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
40855343|NCT05976763|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
40855344|NCT05976763|PROCEDURE|Colonoscopy|Undergo colonoscopy
40855345|NCT05976763|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40855346|NCT05976763|OTHER|Questionnaire Administration|Ancillary studies
40855347|NCT00897455|GENETIC|DNA analysis|
40855348|NCT00897455|GENETIC|mutation analysis|
40855349|NCT00897455|GENETIC|polymorphism analysis|
40855350|NCT00897455|OTHER|laboratory biomarker analysis|
40855351|NCT00897455|PROCEDURE|evaluation of cancer risk factors|
41037691|NCT05403580|OTHER|Questionnaire Administration|Ancillary studies
41037692|NCT05123508|DEVICE|2940nm and BBL treatment|2940nm and BBL treatment
41037693|NCT05123508|OTHER|Non-treatment side (Control)|No treatment
41166364|NCT00485550|DRUG|Atomoxetine Hydrochloride|
41510389|NCT04284072|DEVICE|Sensor Dot|Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).
41510390|NCT06021691|BEHAVIORAL|Acquired nurturing environment|Superimposed effects of intrauterine high-sugar environment exposure and postnatal nurturing environment exposure
41510391|NCT03248427|DRUG|Ribociclib|Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
41510392|NCT03248427|DRUG|Letrozole 2.5mg|Daily continuous
41510393|NCT03248427|DRUG|Doxorubicin|60 mg/m2 as a continuous IV perfusion
41510394|NCT03248427|DRUG|Cyclophosphamide|600 MG/M2 in a 30 minutes IV infusion
41510395|NCT03248427|DRUG|Paclitaxel|80 mg/m2, in one hour IV infusion
41510396|NCT04740450|DEVICE|Kinesio taping|skin colored Kinesio-Tex Gold tape, 50 mm _ 5 m (Kinesio Holding Corp, Albuquerque, NM) tapped in technique described by Gozluklu et al in 2020
41510397|NCT04740450|DEVICE|Wound Tape|skin colored wound tape tapped in technique described by Gozluklu et al in 2020
41386026|NCT04840628|OTHER|Resistance of the respiratory system|increase the resistance of the respiratory system of the chronic obstructive pulmonary disease patients
41037694|NCT04090424|DEVICE|NovoSorb BTM|NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
41037695|NCT04090424|PROCEDURE|Standard of Care|Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.
41386027|NCT06488807|OTHER|Olfactory Enrichment|Each participant will be equipped with an electrical odor dispenser which allowed to distribute 8 odors (grapefruit, lavender, lemon, peppermint, menthol, tangerine, green tea, and bergamot). The choice of odors was guided by (1) pleasantness of the odors, (2) presence of slight trigeminal activation in some of the odors, e.g., peppermint, (3) evaporation characteristics, so that the odors would last for the duration of the experiment, (4) technical issues mostly in terms of compatibility with the odor cartridge, (5) availability, and (6) inspiration from the previous studies.
41386028|NCT06488807|OTHER|Sham|Water will be used in the dispenser.
41386029|NCT04821830|DRUG|carbidopa/levodopa, as prescribed by treating physician|"There will be 4 measurement states:~at baseline prior to chronic treatment initiation (OFF-No LDR); at baseline after a standard, acute oral dose (25/250 carbidopa/L-dopa), referenced in the protocol, but prescribed and provided by their prescribing physician as standard of care initial dosage (ON-No LDR); 2 months after initiation of chronic, stable L-dopa treatment (amounts and sequences as prescribed by treating physicians) but with no L-dopa for 10-12 hours prior to evaluation (Practical OFF- LDR); and after resuming subjects' usual physician-prescribed L-dopa dose (ON-LDR)."
41386030|NCT01048411|DRUG|Naja-comp.|homeopathic remedy
41037696|NCT03179839|BEHAVIORAL|Mindfulness-based Cognitive Therapy|"The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.~MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna."
41037697|NCT03179839|BEHAVIORAL|Psycho-education Program|As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.
41037698|NCT03179839|DRUG|sertraline, fluvoxamine|The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
41166365|NCT00485550|DRUG|Methylphenidate Hydrochloride|
41166366|NCT00485550|DRUG|Placebo|
41386031|NCT01048411|DRUG|Placebo|s.c. injection of NaCl-solution three times a week
41386032|NCT05723042|OTHER|EMS with CIMT|The interventions are consisted of 3weeks of casting the unaffected limb followed by 5 weeks of transference activities.The assisting hand assessment AHA was used to measure bimanual activity performance at baseline,8 weeks, 16 weeks. 20-minute application of currents and resistance exercises for the respective muscles of the area. The intervention group with 11 patients underwent a program of CIMT for one hour daily for 14 consecutive days or two hours per day, six days per week and a total of 12 weeks. A follow-up will be performed 12 weeks after the intervention. The healthy upper limb will be immobilized by orthosis or cast for six hours a day . Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
41510398|NCT00676832|DRUG|Placebo|Placebo solid capsule dosage form administered orally once daily.
41510399|NCT00676832|DRUG|COLAL-PRED|The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
41166367|NCT00816647|PROCEDURE|Patellofemoral stabilizing surgery|Comparison of surgical techniques
41166368|NCT02331810|DRUG|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
41166369|NCT02331810|DRUG|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
41166370|NCT01919346|DRUG|Eculizumab|
41166371|NCT01919346|DRUG|Normal Saline|
41166372|NCT05955677|DRUG|[68Ga]Ga-PSMA-D5|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-D5, and undergo PET/CT imaging within the specificed time.
41166373|NCT05955677|DRUG|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
41166374|NCT04410315|OTHER|Serum-lactate < 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
41166375|NCT04410315|OTHER|Serum-lactate >/= 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
41166376|NCT04715503|RADIATION|PET imaging, 18F-FDG|PET-MRI with 18F-FDG
41166377|NCT04715503|RADIATION|PET imaging, 68Ga-DOTANOC|PET-CT with 68Ga-DOTANOC
41166378|NCT03497780|PROCEDURE|Anterior cruciate ligament reconstruction|Primary surgical reconstruction of the rupture anterior cruciate ligament
41166379|NCT06545110|DRUG|Baricitinib Oral Tablet|Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.
41037699|NCT01693120|DEVICE|Medtronic Phased RF Ablation System|Phased RF ablation
41166380|NCT00097669|DRUG|Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo|multivitamin
41386033|NCT05723042|OTHER|EMS|this group will only receive baseline exercises (ROM and flexibility exercises) than apply electrical stimulations at specific motor points. Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
41386034|NCT03980860|OTHER|Exercise Type|The implementation of 2 types of exercise programs to reduce body fat
41386035|NCT04924114|DRUG|MK-6194|Subcutaneous injection
41386036|NCT04924114|DRUG|MK-6194-matching placebo|Subcutaneous injection
41386037|NCT04534387|OTHER|Spanish-Language Hearing Loss Toolkit for Self-Management|The materials include printed information and images designed to increase hearing loss knowledge and focus on self-management topics such as the fundamentals of the ear and hearing, communication strategies, speech understanding in noise, and hearing technology.
41386038|NCT04534387|OTHER|American Speech-Language-Hearing Association (ASHA) Audiology Series Spanish Language Handouts|Standard of care patient education handouts developed by ASHA in the Spanish language.
41510400|NCT04564092|DRUG|DaTSCAN™ Ioflupane (123I) Injection|Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.
41166381|NCT00097669|OTHER|Placebo|
41510401|NCT06164366|DEVICE|0 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 0 degrees
41510402|NCT06164366|DEVICE|45 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 45 degrees
41510403|NCT04458285|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous ACEI, ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
41037700|NCT00519181|DRUG|Valproic Acid|Valproic acid by oral route (20mg/Kg/day) during one year.
41037701|NCT00010491|PROCEDURE|Acupuncture|
41037702|NCT00010491|PROCEDURE|Moxibustion|
41037703|NCT04163302|BIOLOGICAL|CD19-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
41037704|NCT05981443|DEVICE|Dermabond|Use of Dermabond to close surgical incisions instead of non-absorbable sutures
41037705|NCT05981443|OTHER|Non-Absorbable Sutures|Use of conventional non-absorbable sutures to close surgical incisions
41386039|NCT03360721|DRUG|Abiraterone Acetate|Given PO
41386040|NCT03360721|DRUG|Apalutamide|Given PO
41510404|NCT04458285|DRUG|Valsartan 80mg Tablet|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
41037706|NCT02007850|DRUG|ropivacaine|Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
41037707|NCT02235948|DRUG|folic acid supplementation|0.8mg folic acid/day
41166382|NCT06543550|DRUG|Implantable gestrinone|1.6mg/kg of weight of gestrinone in pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region.
41166383|NCT06543550|DRUG|Oral Dienogest|Administered orally at 2 mg daily
41166384|NCT00730847|BIOLOGICAL|Cervarix|Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
41166385|NCT01865500|DRUG|Budesonide 4 mg|It will be evaluated at baseline, 24 h, 48 h and before discharge
41166386|NCT01865500|DRUG|Budesonide 8 mg|Baseline FEV1 and before discharge FEV1 were evaluated
41166387|NCT01865500|DRUG|Metil prednisolone|
41166388|NCT02068378|DEVICE|CMPE Optical Sensor Device|Christie Medical Physics \& Enginieering visual feedback with optical sensing device.
41166389|NCT05371145|BIOLOGICAL|Carnosine|Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.
41166390|NCT04001998|DRUG|BLD-2660|Randomized to active product
41386041|NCT03360721|DRUG|Prednisone|Given PO
41386042|NCT03987737|PROCEDURE|small urinary catheter placement in the rectum|The MRI technician will place a small urinary catheter in the rectum prior to MRI of the prostate to evacuate excessive gasses. This catheter will stay in the rectum during the whole MRI examination.
41386043|NCT01926301|PROCEDURE|continuous veno-venous hemodialysis|
41386044|NCT02591316|OTHER|no intervention|
41386045|NCT03297801|DIETARY_SUPPLEMENT|Fish oil supplements|Women who chose to supplement with fish oil during gestation or lactation.
41510405|NCT02737904|OTHER|APT|APT for 30 minutes per day on 5 days per week for 4 weeks: 2 minute warm up consisting of passive cycling, where the legs of the participant are moved passively by the APT at 10 revolutions per min (rpm). Next, the participant will cycle for up to 26 minutes, at 60rpm. In this phase, the participant is required to actively cycle and to maintain a symmetrical pattern of movement using the feedback on the display. If the participant is unable to actively cycle at any point during the 26 minute exercise period, or if they have a spasm, the MOTOmed APT will revert to the passive mode. The final phase is a cool down where participants again will have 2 minutes of passive cycling at 10rpm.
41510406|NCT02737904|OTHER|Usual care|Personalised in-patient rehabilitation programme
41510407|NCT05453097|DIAGNOSTIC_TEST|Selvester QRS Score with Preoperative ECG|Selvester QRS score will be calculated with the preoperative ECG of the patients.
41510408|NCT04871672|OTHER|Pilates Exercises|basic five pilates intermediate workout based on the principles of Pilates
41510409|NCT04871672|OTHER|Home Exercise program|home exercise
41510410|NCT02319278|DRUG|Ferumoxytol|Infusion following between paired MRI scans
41037708|NCT03386968|BEHAVIORAL|Active video gaming|"Children will visit Blythedale for 8 sessions, one 45-session visit per week, in place of one of the child's typical physical therapy sessions. During each session, children will play a video game on the X-Box Kinect system, using the games Kinect Adventures and Kinect Sports. The child will first play a Kinect Adventures game, which requires ambulating, ducking, and dodging one's way through an obstacle course."
41037709|NCT03386968|BEHAVIORAL|Usual care physical therapy|Children will attend their usual care physical therapy appointments at Blythedale.
41037710|NCT02911948|DRUG|Insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily
41037711|NCT02911948|DRUG|Insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily
41037712|NCT03874364|DEVICE|Lidocaine gel|10 ml 2% lidocaine gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
41037713|NCT03874364|OTHER|Counselling|Patients receive a brochure in the waiting room explaining the procedure in details.
41037714|NCT03874364|OTHER|Monitor|Patients are allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
41037715|NCT03874364|DEVICE|Lubricating gel|10 ml plain lubrificant gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
41037716|NCT03874364|OTHER|No counselling|Patients won't receive a brochure in the waiting room explaining the procedure in details.
41037717|NCT03874364|OTHER|No monitor|Patients are not allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
41037718|NCT05916768|OTHER|Pelargonium sidoides extract EPs® 7630|Kaloba® solution, a standardized alcoholic extract obtained from the roots of Pelargonium sidoides (EPs® 7630).
41386046|NCT05399186|OTHER|Early preoperative assessment and optimization|The interventional group received early preoperative assessment and optimization (6-12 months) prior to total joint arthroplastic surgery in cooperation between hospital and primary care
41386047|NCT04580173|DIAGNOSTIC_TEST|metabolomics analysis|Targeted and untargeted metabolomics-based analysis will be performed using Gas Chromatography tandem Mass Spectometry and Liquid Chromatography tandem Mass Spectrometry, in order to quantify serum biomarkers.
41386048|NCT05894668|OTHER|ECIRS|Endoscopic Combined Intrarenal Surgery
41386049|NCT02552394|DRUG|huJ591|HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
41386050|NCT01394120|DRUG|Targeted Therapy Tailored Treatment|"Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~* Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~* TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~* TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~* TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~* TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~* TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib"
41386051|NCT01394120|DRUG|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
41386052|NCT05259696|BIOLOGICAL|E-602|Subjects will receive E-602 (administered weekly, via IV infusion).
41386053|NCT05259696|BIOLOGICAL|Cemiplimab|Subjects will receive cemiplimab (administered once every 3 weeks, via IV infusion).
41386054|NCT05619484|DEVICE|Smart AFO|Diagnostic ankle-foot orthosis with AFO stiffness and range of motion settings adjusted using a mobile application
41386055|NCT06346756|OTHER|Treatment of dental caries.|The researchers used G-aenial Universal Injectable (GCI), G-aenial A'CHORD (GCA), Tetric Prime (TP), and Filtek Ultimate (FU) composites for premolar Class II restorations.
41386056|NCT04650516|DEVICE|Virtual reality|20 minutes treatment in virtual reality
41386057|NCT04650516|DEVICE|Digital control|20 minutes digital control movie on tablet without virtual reality
41386058|NCT06219135|OTHER|no intervention - Contamination group|there is no intervention for this group of patients
41386059|NCT06219135|BIOLOGICAL|blood sample - Bacteraemia group|for adult patients, in optional, blood sample will be taken. 27,5 ml of blood at H24-48 after inclusion and 5 ml of blood at day 30
41386060|NCT06404281|BIOLOGICAL|γδ T-PD-1 Ab cells|Cells will be extracted from a healthy donor, followed by ex-vivo expansion, activation and genetic engineering. The ex-vivo expanded γδ T-PD-1 Ab cells will be adoptively transfused to tumor patients.
41386061|NCT03883789|DIAGNOSTIC_TEST|FibroScan|FibroScan will be used to assess liver stiffness
40676659|NCT03917472|DRUG|Brolucizumab|Intravitreal injection
41037719|NCT05916768|OTHER|usual care|symptomatic treatments
41037720|NCT01751022|DEVICE|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead, separate analysis for each lead model
41037721|NCT05921877|DIAGNOSTIC_TEST|venous sampling|venous sampling
41037722|NCT06034262|BIOLOGICAL|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the PIPJ
41037723|NCT01055366|DRUG|Elazop (Azarga)|Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
41037724|NCT04372771|OTHER|Curves Circuit|The Curves Circuit consists performing 13 hydraulic resistance exercise machines that utilize bidirectional resistance that work all major muscle groups. These are interspersed with floor-based calisthenic exercises designed to maintain an elevated heart rate.
41037725|NCT04372771|OTHER|Weight Watchers|The Weight Watchers program encourages one to increase physical activity.
41037726|NCT06216457|DEVICE|AI software for Stroke|AI Software for Non-Contrast Head CT (Computed Tomography) and CT Angiography, utilized for Code Stroke screening, notification and triage.
41386062|NCT01150409|DRUG|hydrocortisone|1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
41386063|NCT01150409|DRUG|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
41037727|NCT05219240|OTHER|20Lighter Program|Visceral Adiposity-Focused Anti-Obesity Telehealth Program
41166391|NCT03722693|DEVICE|Functional electrical stimulation based treatment|Two types of multi-pad electrodes will be used during this study. Both were designed for covering the extrinsic muscles of the hand. Electrodes are comprised of 8 pads that act as anodes and 32 pads that acted as cathodes. The shape and distribution of the conductive pads within the electrodes were designed considering the motor points for achieving different movement primitives (wrist extension, wrist flexion, fingers extension, fingers flexion, index extension, index flexion, thumb extension, and thumb flexion). Each participant will receive 5 assessment sessions:1. before starting the interventions, 2. after the 7 days of standard care, 3. after 7 days of first FES based protocol, 4.after another 7 days of standard care and 5. after seven days of the other FES based intervention
41166392|NCT03087994|BEHAVIORAL|Nutritional guidance intervention|participants in this group will attend 12 meeting of nutritional guidance
41386064|NCT06568029|OTHER|Questionnaire|In the study, the validity and responsiveness of EQ-5D-3L will be assessed. The EQ-5D-3L measures HRQoL and consists of two parts. The first part contains five questions about mobility, daily activities, self-care, pain/discomfort, and anxiety/depression (EuroQoL 1990, Brooks 1996). Each question can be answered with no problem (1), some/moderate problem (2) unable to perform certain activities/having extreme problems (3). The answers can be summarized in an index value based on an existing preference-based value set. In this study, the EQ-5D-3L value set by Dolan (Dolan 1997) will be used for the main analyses and a Swedish experience-based value set in a sensitivity analysis (Burström, Sun et al. 2014). For the EQ-5D-3L index, 1 represents full health and 0 represents a value equal to being dead. EQ VAS measures the persons health today on a visual analogue scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health) (EuroQoL 1990, Brooks 1996).
41386065|NCT06543251|OTHER|High-intensity interval training group (HIIT)|The participants performed HIIT programs for 12 weeks involving walking/running on a treadmill preceded by a 10-min warm-up at low intensity and exercise with high intensity for 1 min at 85%-90% of the maximum heart rate alternating with low intensity at 50%-55% of the maximum heart rate for 2 min, for 24 minutes, and 10-min cool down.
41386066|NCT06543251|OTHER|Moderate continuous training group (MCT)|Subject participating in 30-min sessions for 12 weeks and Each session consisted of a 10-min warm up, walking/running on a treadmill 30 minutes at 65-70% Maximum Heart rate and 10-min cool down.
41386067|NCT06543251|OTHER|Sedentary control group (CON)|The control group had normal daily life.
41386068|NCT02591017|DRUG|Morphine|
40855352|NCT05356585|GENETIC|SignateraTM assay|A customized tumor-informed ctDNA test that, after receiving the tumor tissue, examines whole exome sequencing of a biopsied tumor to find the somatic tumor-derived mutations. From those mutations, the 16 most clonal mutations are used to create a personal assay
41037728|NCT04223180|DEVICE|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
41166393|NCT03087994|BEHAVIORAL|Nutritional guidance intervention|Participants in this group will only receive nutrition guidance once during the study
41166394|NCT00233389|DRUG|Rebamipide|
41166395|NCT05002530|DRUG|Aerosolized 13 cis retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
41386069|NCT02591017|DRUG|Ketamine|
41386070|NCT02591017|DRUG|Placebo|
41386071|NCT02591017|DRUG|Chitosan|
41037729|NCT01300546|DRUG|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
41037730|NCT01300546|DRUG|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
41037731|NCT03150056|DRUG|GSK525762|GSK525762 will be administered.
41166396|NCT05002530|DRUG|Aerosolized All trans retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
41166397|NCT05002530|OTHER|Standard therapy|Standard therapy
41166398|NCT01949883|DRUG|CPI-0610|
41386072|NCT02344914|DEVICE|receive Laboraide|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
41386073|NCT01956123|DRUG|Follitropin Delta (FE 999049)|
41386074|NCT01956123|DRUG|Follitropin Alfa (GONAL-F)|
40676660|NCT03917472|DRUG|Aflibercept|Intravitreal injection
40676661|NCT05062772|DIAGNOSTIC_TEST|Ultrasound|Intraoperative ultrasound imaging
41037732|NCT03150056|DRUG|Abiraterone|Abiraterone will be administered.
41166399|NCT00646711|DRUG|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
41166400|NCT00646711|DRUG|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
41386075|NCT05451407|DRUG|TQB2618 injection|Humanized IgG4 mab targeting TIM-3
41037733|NCT03150056|DRUG|Enzalutamide|Enzalutamide will be administered.
41037734|NCT03150056|DRUG|Prednisone|Prednisone will be administered as a concomitant medication in combination with abiraterone
41037735|NCT03969654|DEVICE|PERSONA Total Knee|Primary Total Knee Arthroplasty
41166401|NCT04402203|DRUG|Favipiravir|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
41386076|NCT05451407|DRUG|Toripalimab injection|Monoclonal antibody against Programmed death factor receptor 1
41386077|NCT02554825|BEHAVIORAL|Healthy Futures|Healthy Futures is an age-appropriate program that targets change at different social ecological levels-individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.
41386078|NCT02554825|BEHAVIORAL|Control|The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
41386079|NCT05787483|BEHAVIORAL|MindUP group|MindUP is a Collaborative for Academic, Social, and Emotional Learning SELect (CASEL) program, meaning the program is evidence-based and meets the adequate criteria for developing students' social and emotional competence at the highest level. MindUP addresses all five components of the CASEL SEL Framework: self-awareness, social awareness, self-management, responsible decision-making, and relationship skills (CASEL, 2020). Students are taught how the workings of the brain are related to emotions, behaviors, decision making, and learning. MindUP is the first program to provide clear instruction in both SEL and mindfulness.
41037736|NCT03969654|DEVICE|Vanguard Total Knee|Primary Total Knee Arthroplasty
41386080|NCT05787483|BEHAVIORAL|active control group|business as usual; regular wellness or SEL classes
41510411|NCT03839966|BEHAVIORAL|Interpretation Bias Modification for Loneliness|Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard \& Amir, 2008 and Beard, Weisberg, \& Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.
41510412|NCT03839966|BEHAVIORAL|Healthy Habits Psychoeducation and Relaxation|Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.
41037737|NCT03969654|DEVICE|NexGen Total Knee|Primary Total Knee Arthroplasty
41037738|NCT03910257|BEHAVIORAL|nutrition education module|12 activities of nutrition education module will deliver by the teacher. The activities consists of coloring my meal plate, playing pictures, story telling: Zizi and Ziko, pictures station, fruits and vegetables card, cooking class, planting bean sprouts, field visit to fruits and vegetables garden, making collages, dot to dot, watching video, making healthy snacks
41037739|NCT00470951|PROCEDURE|open rectal resection|open rectal resection
41037740|NCT00470951|PROCEDURE|laparoscopic rectal resection|laparoscopic assisted rectal resection
41037741|NCT05809037|DEVICE|transcutaneous auricular vagus nerve stimulation|In addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 Hz, pulse width is 300 µs, and biphasic.
41037742|NCT05809037|DEVICE|Sham stimulation|In addition to the conventional rehabilitation program, sham vagus nerve stimulation (0 mA) will be applied to the participants in the control group. Non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, and noninvasive auricular stimulation will be applied.
41037743|NCT03037710|DEVICE|HealthPatch|A multi-sensor device to collect continuous vital signs
41037744|NCT03199625|BEHAVIORAL|Cognitive therapy|
41037745|NCT03199625|BEHAVIORAL|Behavior therapy|
41166402|NCT04402203|DRUG|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
41166403|NCT04514796|DRUG|Adalimumab|SB5 (adalimumab), 40 mg, single-dose
41037746|NCT03199625|DRUG|SSRI antidepressants|
41037747|NCT03984669|DIAGNOSTIC_TEST|The Juvenile Disease Activity Score (JADAS)|The JADAS includes the following four measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) where 0 = no activity and 10 = maximum activity; parent global assessment of well-being, measured on a 0-10 VAS where 0 = very well and 10 = very poor; the erythrocyte sedimentation rate (ESR), normalized to a 0 to 10 scale; and a count of joints with active disease.
41166404|NCT05860400|BEHAVIORAL|Healthy life style|Healthy diet, regular exercise, and quitting smoking
41386081|NCT06565936|RADIATION|PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG|Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.
41037748|NCT03984669|BIOLOGICAL|(1-3)-ß-D-Glucan (BDG) assay (Fungitell)|Evaluation of the (1,3)-Beta-D-Glucans level in patients with JIA and correlation of the higher serum BDG levels with JIA activity of disease, comparatively with usual markers
41386082|NCT05285943|DRUG|Olive oil cream|Olive oil prepared in a base cream to be applied to irradiated areas.
41386083|NCT05285943|DRUG|Betamethasone Valerate Cream|Betamethasone valerate prepared in a base cream to be applied to irradiated areas.
41386084|NCT05285943|OTHER|Base Cream|The base cream used for preparation of both the betamethasone valerate cream and olive cream will be used as a placebo control to be applied to irradiated areas.
41386085|NCT04604496|DRUG|PF-06882961 20MG|PF-06882961 in 20 mg oral tablet will be administered on Day 1
41386086|NCT02360124|DRUG|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
41386087|NCT02360124|OTHER|Water as placebo|topical application of water as a placebo in the control arm
41386088|NCT02360124|OTHER|saturated potassium iodide solution|topical application of SDF solution followed by KI solution onto tooth root surfaces
41386089|NCT02260752|PROCEDURE|hysterectomy|surgical removal of the uterus
41386090|NCT02260752|PROCEDURE|Uterine arterial embolization|In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
41166405|NCT05860400|DRUG|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
41386091|NCT02260752|PROCEDURE|myomectomy|surgical procedure to remove uterine fibroids, but does not remove uterus
41386092|NCT02260752|DRUG|Medical Therapy|treatment of uterine fibroids with only medications, no procedure or surgery is used
41386093|NCT02260752|PROCEDURE|endometrial ablation|surgical procedure that destroys uterine lining via a telescope placed inside the uterus
41386094|NCT02260752|PROCEDURE|magnetic resonance guided focused ultrasound|procedure that destroys fibroids while inside an MRI machine
41386095|NCT02260752|PROCEDURE|radiofrequency ablation|procedure that uses heat to destroy uterine fibroids
41386096|NCT02314949|PROCEDURE|intestinal transplantation|
41386097|NCT06190873|BEHAVIORAL|post-discharge rehabilitation training|Telephone training will be provided for post-discharge rehabilitation
41386098|NCT04227769|DRUG|Anakinra Prefilled Syringe|Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo
41386099|NCT01262274|DRUG|Anastrozole|ANA is given 1mg daily for 24 weeks.
41386100|NCT01262274|DRUG|Anastrozole plus tegafur-uracil|ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
41386101|NCT01856686|DRUG|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
41166406|NCT05860400|DRUG|Immunosuppressive therapy|Glucocorticoids and/or immunosuppressive agents
41166407|NCT05860400|PROCEDURE|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
41166408|NCT05860400|DRUG|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
41166409|NCT01252056|DRUG|Probucol|250mg,Bid
41386102|NCT01856686|DIETARY_SUPPLEMENT|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
41386103|NCT05921331|DEVICE|The RJBC-APP|The RJBC-APP consists of the following features: 1. Login, logout, setting, and modification of personal information. 2. Full-course management included registering for information on the surgical treatment, viewing the results of the multidisciplinary team (MDT) discussion, generating the treatment process according to the MDT discussion, receiving the reminder of the treatment, confirming the completion of the treatment, filling in the follow-up information, and consulting a specialist nurse. 3. Questionnaire and feedback.
41386104|NCT05921331|OTHER|Routine post-surgical follow-up|The routine post-surgical follow-up is conducted in the outpatient clinic.
41386105|NCT02397083|DRUG|Everolimus|Given PO
41386106|NCT02397083|OTHER|Laboratory Biomarker Analysis|Correlative studies
41386107|NCT02397083|DEVICE|Levonorgestrel-Releasing Intrauterine System|Placed in the uterus
41386108|NCT06395584|DEVICE|White Light LED|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
41037749|NCT03745664|DRUG|Methylprednisolone Sodium Succinate|During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).
41037750|NCT03745664|DRUG|Saline Solution for Injection|During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
41037751|NCT00657618|DRUG|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
41166410|NCT01252056|DRUG|Probucol and Cilostazol|50-100mg,Bid
41386109|NCT06395584|DEVICE|Green Light LED|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
41386110|NCT00872573|DEVICE|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
41510413|NCT01108627|DRUG|open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®|• Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
41510414|NCT01108627|DRUG|foradil placebo|open-labeled inhaled corticosteroids (ICS); foradil placebo
41510415|NCT01108627|DRUG|foradil|open-labeled inhaled corticosteroids (ICS); foradil
41510416|NCT01375179|DRUG|KRP203|
41037752|NCT00440050|DRUG|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
41037753|NCT00440050|DRUG|Placebo|2 placebo capsules twice a day for 18 months
41386111|NCT06541977|BEHAVIORAL|Behavioral to reduce sedentary behvaior|This intervention will also utilize a geographical time app to raise awareness about participants' sedentary lifestyles, helping them identify opportunities to incorporate more movement into their daily routines. Furthermore, the program will implement the Wheel of Change behavior technique, which serves as a structured approach to facilitate lasting changes in health behaviors, empowering participants to take control of their physical activity levels and overall well-being.
41386112|NCT06541977|BEHAVIORAL|Physical activity|This intervention will be conducted with two weekly days of supervised and structured physical activity sessions, held at the university's facilities, providing participants with expert guidance and a supportive environment to enhance their physical fitness and overall health.
41510417|NCT01375179|DRUG|Placebo matching KRP203|
41037754|NCT01585103|DEVICE|Cytosponge|An ingestible gelatin capsule containing a compressed mesh attached to a string. The capsule is swallowed and once in the stomach, the gelatin dissolves and a spherical mesh of 3 cm diameter is released. The mesh is withdrawn through the mouth by the attached string and a cytologic specimen is collected.
41037755|NCT00058123|DRUG|poly ICLC|
41166411|NCT04299113|DRUG|Vinorelbine|Given IV
41386113|NCT06541977|PROCEDURE|Bariatric Surgery|In this intervention, bariatric surgery will be performed, accompanied by the usual hospital care, which includes comprehensive nutritional and physical activity advice. This standard care ensures that participants receive essential guidance and support for their dietary and exercise routines, complementing the surgical intervention.
41510418|NCT00002346|DRUG|Adefovir dipivoxil|
41510419|NCT00490841|DEVICE|Herculink Elite Renal Stent System|This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
41166412|NCT04299113|DRUG|Mocetinostat|Given PO
41166413|NCT00210964|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
41166414|NCT00210964|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
41166415|NCT05066919|PROCEDURE|Open plantar fasciotomy|In the surgical treated group, the plantar fascia is defined percutaneously (medial and lateral margin). An incision is then made just distal to the heel pad medially over the plantar fascia. A resection is performed 1 cm in length with a width corresponding to 50% of the medial band. The skin is sutured with nylon/nonresorbable suture. Postoperatively, the operated foot is elevated for the first 24 hours. Then free mobilization in postoperative shoe (ProCare shoe) is allowed. The dressing is left untouched for 3-5 days, after which it can be changed to a patch. After 14 days the sutures are removed and the patient allowed using regular shoes.
41386114|NCT03935451|DRUG|Apixaban 2.5 milligram|2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
41386115|NCT03935451|DRUG|Placebo Oral Tablet|placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
41386116|NCT06346054|DIAGNOSTIC_TEST|Breath analysis|Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath
41386117|NCT06346054|DIAGNOSTIC_TEST|Blood analysis|Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood
41510420|NCT02756611|DRUG|Venetoclax|Tablets for oral administration
41510421|NCT04351633|OTHER|questionnaire assesment|questionnaire assesment
41510422|NCT06093230|DRUG|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
41510423|NCT04552860|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
41510424|NCT06583122|PROCEDURE|Ultrasound Guided Approach|All enrolled patients will receive the new ultrasound-guided approach to occipital nerve radiofrequency ablation
41510425|NCT04666389|DRUG|Atorvastatin|To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
41510426|NCT05882903|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
41510427|NCT05882903|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
41510428|NCT01480245|DRUG|GSK2402968|6mg/kg/week
41510429|NCT00039338|PROCEDURE|conventional surgery|Radial hysterectomy
41510430|NCT00039338|PROCEDURE|neoadjuvant chemotherapy|Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.
41037756|NCT06352710|OTHER|OP-Tracker App|"There will be no study-specific therapeutic intervention. The OP-Tracker App will be downloaded and installed on the patient's smartphone. Preoperative assessment: baseline factors such as age, gender, medical conditions, type of disease and of surgery, EQ-5D-5L. Before and after surgery surgery, SWI (Quality of life) will be assessed daily using pop-ups; the patient will input the value (0-10) using a slide-bar. After completion of the surgery, the app will automatically modify the number of SWI assessments over time according to the occurrence of AEs. At any point in time, the patient will be able to register an AE in the smartphone app. The patient can select the AE via a drop-down menu in the app, and can additionally input free text in case of an AE of type other. Using a further drop-down menu, the patient will classify the AE according to the CDG and TDN grade. QoL assessments (EQ-5D-5L questionnaire) will pop up before, and at 3 and 12 months after surgery."
41037757|NCT06013800|OTHER|Measurement of sodium levels|Patients will get measurements of sodium levels daily in the first 48 hours, then daily or every other day until normal sodium levels (\>135mEq/L).
41386118|NCT01831518|DEVICE|CRT Implant|
41386119|NCT01831518|DEVICE|Body Surface ECG Mapping|
41037758|NCT01710072|DRUG|aspirin|
41386120|NCT00817778|DRUG|AZD1656|Subjects will be treated with tolerable dose twice daily for another 24 days.
41037759|NCT03695172|DRUG|Ropivacaine|Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine
41037760|NCT03695172|PROCEDURE|TAP block|Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
41386121|NCT00817778|DRUG|Placebo|Subjects will be treated with tolerable dose twice daily for another 24 days.
41386122|NCT02384837|DEVICE|EXCEL biodegradable polymer-coated sirolimus-eluting stent|
41386123|NCT00788723|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
41386124|NCT06346899|OTHER|No intervention|This is a non-interventional study.
41386125|NCT04393831|PROCEDURE|Retzius sparing|Retzius nerve sparing is a specific approach that avoids disrupting the structures involved in urinary and sexual function.
41386126|NCT04791709|BEHAVIORAL|Happy Older Latinos are Active (HOLA)|HOLA is a multicomponent health promotion intervention. First component is a one-on-one social and physical activation with the participant and the community health worker (CHW). Each session will last approximately 30 minutes at day 1 and week 8. The second component is a group walk led by a CHW for 45 minutes, 3 times a week, for 16 weeks. The third component consists of scheduling pleasant events at the end of each group walk session.
41386127|NCT05112263|DRUG|Tofacitinib|For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study
41386128|NCT05112263|DRUG|Cyclosporine|: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight
41386129|NCT00626574|DRUG|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
41386130|NCT00626574|DRUG|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
41386131|NCT03375996|DRUG|cyclopentolate 0.5% eye drops|cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)
41386132|NCT04803006|BIOLOGICAL|TCD601|Investigational Product
41386133|NCT03287141|DIAGNOSTIC_TEST|Shuttle walk test|A shuttle walk test was performed without any previous intervention.
41386134|NCT03287141|DEVICE|Noninvasive ventilation (Bi-pap)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
41037761|NCT03695172|BIOLOGICAL|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
41037762|NCT03695172|PROCEDURE|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.
41386135|NCT03287141|DEVICE|Noninvasive ventilation (CPAP)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
41386136|NCT00711165|DRUG|Placebo|2 puffs, qd
41386137|NCT00711165|DRUG|Mometasone Furoate|400 mcg, qd for 8 weeks
41386138|NCT00447694|DRUG|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
41386139|NCT06488417|DIETARY_SUPPLEMENT|Frankincense essential oil + boswellic acid supplement|This supplement contains frankincense essential oil and boswellic acid as its active ingredients.
41386140|NCT06488417|DIETARY_SUPPLEMENT|Frankincense essential oil supplement|This supplement contains frankincense essential oil as its active ingredient.
41386141|NCT05552430|DEVICE|RelieveVRx|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
41386142|NCT01984619|DEVICE|Cryotherapy for the utilization of wrinkle reduction (iovera)|
41386143|NCT02525627|DEVICE|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
41386144|NCT02525627|DEVICE|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
41386145|NCT02525627|DEVICE|Symax stem|Orthopaedic implant
41386146|NCT02525627|DEVICE|Accolade TMZF stem|Orthopaedic implant
41510431|NCT00039338|RADIATION|brachytherapy|Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.
41386147|NCT05550259|PROCEDURE|protocolized postextubation support|The intervention corresponds to a protocolized use of HFNO or NIV after extubation in accordance with the risk of extubation failure: a) 24H HFNO in patient at low risk of extubation failure b) 48H NIV+/-HFNO in patients at high risk of extubation failure
41386148|NCT05154994|DRUG|Belinostat|Given IV
41166416|NCT05066919|OTHER|Conservative treatment|In the conservative treatment group, patients are instructed in performing stretching exercises with plantar fascia specific stretching exercises 10 x 10 seconds, 3 times daily and high load strength training are every other day for 3 months. Each high load strength exercise consists of 3 seconds of concentric phase (lifting up with the heel) and 3 seconds of eccentric phase (lowering the heel) with 2 seconds of isometric pause (pause at maximum lifted heel). 12 repetitions max (RM) are performed, defined as the maximum (over) weight the patient can lift 12 times with full range of motion while performing the exercise correctly. 3 x 12 exercises are performed per workout. After 2 weeks, the load is while the number of repetitions is reduced to 10 RM with an increase to 4 repetitions per workout. After 4 weeks the intensity is increased to 8RM with 5 set. Patients are instructed to increase the load throughout the training period.
41386149|NCT05154994|BIOLOGICAL|Durvalumab|Given IV
41386150|NCT04499391|OTHER|Project ECHO|Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation. This differentiates ECHO from traditional learning and facilitates rapid dissemination of medical knowledge and increased capacity to deliver best-practice care.studying innovative approaches.
41037763|NCT01009268|PROCEDURE|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
41037764|NCT00321854|DRUG|pramipexole|
41037765|NCT05224050|BEHAVIORAL|Cognitive-Behavioral Smoking Cessation|Participants will be provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
41510432|NCT00039338|RADIATION|radiation therapy|Between 45-50 Gy, in fractions of 1.8 to 2 Gy.
41510433|NCT00039338|DRUG|cisplatin|Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
41386151|NCT01517568|DRUG|liraglutide [3H]|A single dose of 0.75 mg will be given as a subcutaneous injection
41386152|NCT04913259|OTHER|Remote monitoring|Online remote monitoring tool during the care of patients over the age of 65 who are receiving medical treatment for cancer
41386153|NCT01467570|DIETARY_SUPPLEMENT|oral rehydration solution Hipp ORS Apple 200|"Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)"
41386154|NCT01467570|DIETARY_SUPPLEMENT|ESPGHAN ORS|"Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)"
41386155|NCT03914937|OTHER|Virtual reality|A virtual reality device will be worn over the eyes that allows the patient to feel that they are at a quiet seaside beach.
41386156|NCT03914937|OTHER|Music|Music of the patient's choice will be played
41510434|NCT02513030|PROCEDURE|Defibrillation testing during ICD replacement|
40855353|NCT06413979|BEHAVIORAL|Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID)|(1) Family Engagement of caregivers and primary supports in treatment planning and services; (2) Relational Reframing of family constraints, resiliencies, and social capital connected to the youth's ID symptoms; (3) Functional Analysis of the youth's ID symptoms and related behaviors; (4) Cognitive-behavioral therapy (CBT) core techniques to address the youth's ID symptoms and functional needs, featuring three transdiagnostic interventions (emotion acceptance, emotional exposure, behavioral activation) to address negative affect and emotional dysregulation underlying both depression and anxiety; and (5) Family Psychoeducation and Safety Planning focused on education about comorbid SUD/ID and prevention of youth self-harm. All interventions featured in each module have strong empirical support.
41386157|NCT04976387|DRUG|Hydrocodone/Acetaminophen 5 Mg-325 Mg ORAL TABLET|Patients are instructed to take Hydrocodone/acetaminophen 5 mg-325 mg oral tablets every 6 hours as needed for treatment of severe pain
41510435|NCT06112847|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41510436|NCT06112847|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
41510437|NCT06112847|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
40855354|NCT00959205|DEVICE|CARTO 3D|CARTO (3D Electroanatomic imaging)
41037766|NCT05224050|BIOLOGICAL|Heart Rate Variability Biofeedback|Participants will be provided with seven individualized trainings in resonance breathing using biofeedback to help improve self-regulation.
41037767|NCT05224050|DRUG|Nicotine patch|All participants will be offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
41037768|NCT05917405|DRUG|Fludarabine|30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)
41037769|NCT05917405|DRUG|Busulfan|130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
41037770|NCT05917405|DRUG|ATG|Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
41386158|NCT04976387|DRUG|Ibuprofen 600 mg|Patients will take ibuprofen 600 mg every 6 hours as needed
41386159|NCT04976387|DRUG|Acetaminophen 650 MG|Patients will take Tylenol 650mg every 6 hours as needed
41386160|NCT01805258|DRUG|Nevirapine|The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
41386161|NCT01805258|DRUG|Efavirenz|The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
41386162|NCT06564610|PROCEDURE|Transversus abdominis block|The block will be performed by the surgeon by injecting local anesthetic at the beginning of surgery under the guidance of the laparoscope.
41510438|NCT06112847|OTHER|Electronic Health Record Review|Ancillary studies
41510439|NCT06112847|BIOLOGICAL|Epcoritamab|Given SC
41510440|NCT06112847|DRUG|Lenalidomide|Given PO
41510441|NCT06112847|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41386163|NCT06564610|PROCEDURE|Erector spinae block|The block will be performed by the anesthetist by injecting local anesthetic after induction of anesthesia under the guidance of the ultrasound.
41386164|NCT06564610|PROCEDURE|Bariatric surgery|Laparoscopic bariatric procedure will be performed
41386165|NCT06564610|DEVICE|Endotracheal intubation|An endotracheal tube will be inserted as a part of general anesthesia to all patients
41386166|NCT06564610|DRUG|Propofol|The patients will receive propofol for induction of anesthesia
41386167|NCT03235973|DRUG|Fludarabine-Cladribine-Busulfan conditioning regimen|"Conditioning regimen will be performed from day -6 to day -2 and contains:~* Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).~* Cladribine during 5 days (day-6 to day-2) at one the following define dose level:~  * Dose 1: 10 mg/m²/d~ * Dose 2: 15 mg/m²/d~ * Dose 3: 20 mg/m²/d~ * Dose 4: 25 mg/m²/d~* IV busulfan will be given on day-6 using fixed dose as following:~  * If age ≤ 60 years: starting dose of 130 mg/m²~ * If age \> 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses"
41386168|NCT00002774|DRUG|Tirapazamine|"Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.~Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.~Tirapazamine dose was as follows:~Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)~Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)~Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)"
41510442|NCT06112847|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41510443|NCT03149276|OTHER|Interpreter services|
41510444|NCT03018184|OTHER|MRI and Muscle Dynamometer|
40855355|NCT00959205|DEVICE|Angiography|Conventional fluoroscopically guided activation mapping
41386169|NCT00002774|DRUG|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
41386170|NCT00002774|DRUG|5-fluorouracil|"100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT."
41510445|NCT01224197|DRUG|TMC435|100 or 200 mg capsule, one single dose
41510446|NCT01224197|DRUG|TMC435|100 or 200 mg capsule, once daily for 5 days
41510447|NCT00271401|OTHER|Angioplasty|
41510448|NCT00271401|OTHER|Intracoronary Stent|
41510449|NCT00271401|DRUG|Abxicimab|
41510450|NCT00271401|DRUG|Heparin|
40855356|NCT06476353|OTHER|Analysis of Force and Pressure Requirements across Syringe Sizes for Pain Management Procedures|The investigators are analyzing the compression force required to plunge different syringe sizes to determine the operator's burden.
40855357|NCT04988750|DEVICE|NaviFUS System|Using the neuronavigator to precisely guide the ultrasound energy to brain tissues in real-time and intraoperatively.
41510451|NCT00271401|DRUG|Placebo|
41510452|NCT03104712|OTHER|Glucose #1|50g available carbohydrate
41510453|NCT03104712|OTHER|Glucose #2|50g available carbohydrate
40855358|NCT00543387|DRUG|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
41510454|NCT03104712|OTHER|Glucose #3|50g available carbohydrate
41510455|NCT03104712|OTHER|Spaghetti|50g available carbohydrate
41510456|NCT03104712|OTHER|Rice|50g available carbohydrate
41510457|NCT03104712|OTHER|Spaghetti + Tomato Sauce|50g available carbohydrate
41510458|NCT03104712|OTHER|Rice + Tomato Sauce|50g available carbohydrate
41510459|NCT03104712|OTHER|Spaghetti + Pesto|50g available carbohydrate
41510460|NCT03104712|OTHER|Rice + Pesto|50g available carbohydrate
40855359|NCT00543387|DRUG|docetaxel|Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.
40855360|NCT02121249|DEVICE|Renaissance, Mazor Robotics Ltd, Caesare, Israel|Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
40855361|NCT02121249|PROCEDURE|free hand technique|"No specific device is necessary in the free hand technique"
41037771|NCT05917405|DRUG|Clofarabine|30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
41037772|NCT03069222|OTHER|Standard Rehabilitative Treatment|The patients will participate in standard but comprehensive SCI specific rehabilitation therapy provided by the SCI program at KIR. The therapy consists of 3 hours per day, 5 days a week. Motor function therapy includes standardized procedures for range of motion, passive and active muscle activities, and therapies to improve mobility. The treatment program for the enrolled patients will be standardized by Dr. Kirshblum, Director of the SCI program at KIR and a Co-Investigator of the study. Patients usually receive 4 weeks of rehabilitation treatment; however, if any of them are discharged earlier from KIR, their out-patient treatment activities will be monitored and the patients will be tested based on the planned schedule.
41510461|NCT05904548|DEVICE|RF Ablation|RF ablation for type I atrial flutter under iCMR guidance
41510462|NCT04980989|DEVICE|Mobile software for follow-up of early breast cancer|The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
41510463|NCT05005897|BIOLOGICAL|Cyanocobalamin|Intramuscular injection of 400 µg cobalamin to children with elevated thcy at enrollment
41510464|NCT04117802|OTHER|Maple syrup|Substitution of refined sugar by an equivalent quantity of maple syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with maple syrup.
41510465|NCT04117802|OTHER|Placebo|Substitution of refined sugar by an equivalent quantity of maple-flavored sucrose syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with the placebo (sucrose syrup).
41510466|NCT01833650|DIETARY_SUPPLEMENT|thymus honey mouthwash|
41037773|NCT01045746|DEVICE|Stochastic resonance whole-body vibration A|over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
41037774|NCT01045746|DEVICE|Stochastic resonance whole-body vibration b|over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
41037775|NCT05094323|DRUG|Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine|Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.
41037776|NCT05094323|DRUG|Local wound infiltration with isobaric bupivacaine|Patients will receive local wound infiltration with isobaric bupivacaine.
41037777|NCT05094323|DRUG|Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine|Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
40855362|NCT00672906|BEHAVIORAL|Group Parent Training|Skills group for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
40855363|NCT00672906|BEHAVIORAL|Maudsley Family Therapy|Family therapy specifically adapted for the treatment of adolescent anorexia nervosa.
41037778|NCT03301051|BIOLOGICAL|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
41037779|NCT03301051|BIOLOGICAL|Placebo|Single dose of a Placebo
41037780|NCT04334668|DIETARY_SUPPLEMENT|Oral Sodium Chloride|Subjects will be randomized to receive 2 grams oral Sodium Chloride three times daily with meals for approximately 4 days
41037781|NCT04334668|OTHER|Placebo|Subjects will be randomized to receive a placebo three times daily with meals for approximately 4 days.
41037782|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
41037783|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (90 mg) by single SC injection every other week
41037784|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every other week
41037785|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every other week
41037786|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
41037787|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
41037788|NCT05751473|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|"Treatment will be given by telehealth or in person, depending on the participant preference.~Content is drawn from the Full Prolonged Exposure model and condensed so as to deliver the most efficacious components in a brief format. There will be 4-6 weekly 30-minute sessions. Treatment follows the standardized PE-PC manual and workbook. At the end of the final session, the counselor and participant will review treatment progress and either conclude treatment or refer the participant to outside mental healthcare for more intensive treatment.~Participants will complete surveys and complete homework during and following the study."
41037789|NCT05751473|BEHAVIORAL|EAP Treatment as Usual (TAU)|"Treatment will be given by telehealth or in person, depending on the participant preference and current EAP practices (4-6 weeks). This will be the standard of care practice at each EAP site. Usually, this includes up to six sessions of solution focused therapy, and referrals to an established network of community providers who specialize in PTSD treatment. All PTSD care received during the study will be collected and monitored as TAU. The type of TAU used will reflect the current practice in EAPs and will not be constrained in the study design. EAP staff will monitor and record all EAP care received, including tracking no shows and cancellations. Study team members will document care received outside of the EAP (including psychiatric medications) by self-report.~Participants will complete surveys and complete homework during and following the study."
41510467|NCT06336265|DIAGNOSTIC_TEST|Diaphragm ultrasound|Respiratory parameters, diaphragmatic activity, and variation rate of diaphragmatic thickness were recorded at the beginning of high-flow nasal cannula oxygen therapy, 1 hour after treatment, 3 hours after treatment, 6 hours after treatment, 9 hours after treatment, and 12 hours after treatment.
40855364|NCT02155920|DRUG|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
41037790|NCT01737580|DRUG|resiquimod|
41037791|NCT01737580|DRUG|placebo gel|
40855365|NCT00002201|DRUG|Ritonavir|
40855366|NCT00002201|DRUG|Nelfinavir mesylate|
40855367|NCT06245668|DEVICE|SaCoVLM™ video laryngeal mask|The SaCoVLM™ video laryngeal mask will be placed directly into the hypopharyngeal space until resistance is felt, following the recommended instructions for use.
41037792|NCT03339050|BEHAVIORAL|Health for Hearts United|The intervention was framed around three conceptual components (awareness building, clinical learning, and efficacy development), and four types of programming (church-initiated, joint programming, standard programming (culturally tailored post cards and newsletters), and data collection health promotion (generic materials, clinical sessions with an Registered Dietitian). Key messages were identified for the intervention including eating better, moving around more, reducing stress, and taking charge of your health.
41037793|NCT01278329|OTHER|"Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)"|Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
40855368|NCT06245668|DEVICE|LMA Supreme|The LMA Supreme will be inserted directly by hand and placed into the hypopharyngeal space until resistance is felt, as per the recommended instructions for use.
40855369|NCT05160896|DRUG|Raltitrexed|Raltitrexed 2 mg/m² iv, 15min. day 1
40855370|NCT05160896|DRUG|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min. day 1
40855371|NCT05160896|DRUG|Bevacizumab|Bevacizumab 5 mg/kg, iv, day 1
40855372|NCT05160896|DRUG|Cetuximab|cetuximab 500 mg/ m² , iv, day 1
40855373|NCT01107847|PROCEDURE|low flow pressure volume manoeuvre|In all patients a standard low flow pressure volume manoeuvre is applied by a respirator with a constant gas flow of 4 l/min starting at a zero end-expiratory pressure up to a tidal volume of 2 l or until a maximum airway pressure of 35 cm H2O was reached.
41037794|NCT04945174|BEHAVIORAL|Cardiorespiratory exercise combined with patient education and individual follow-up sessions|6 weeks of cardiorespiratory exercise combined with patient education at the hospital, followed by 6 weeks of cardiorespiratory exercise in the local municipality. Subsequently individual follow-up sessions with the aim to facilitate the patients to stay physically active in their everyday life
40855374|NCT04016844|DEVICE|transcranial direct current stimulation or SHAM|"A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.~In the sham condition, the participants will receive the initial 30 seconds of stimulation, after which the current will be set to 0. The same tDCS device (Soterix) will be used."
40855375|NCT01318408|DRUG|Levetiracetam|Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
40855376|NCT00874848|BIOLOGICAL|Imprime PGG Injection|4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
40855377|NCT00874848|BIOLOGICAL|Cetuximab|initial loading dose of 400 mg/m\^2 over 120 min and subsequent doses at 250 mg/m\^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
40855378|NCT00874848|DRUG|Paclitaxel|200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
40855379|NCT00874848|DRUG|Carboplatin|dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
41386171|NCT00002774|RADIATION|Radiotherapy (RT)|"During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery."
41386172|NCT01579292|BEHAVIORAL|Mobile phone based physical activity with intervention|This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
41386173|NCT01579292|BEHAVIORAL|Pedometer Only|This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
40855380|NCT01224743|DIETARY_SUPPLEMENT|Blend 1|Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
40855381|NCT01224743|DIETARY_SUPPLEMENT|Blend 2|Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
40855382|NCT01224743|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
40855383|NCT00003364|DRUG|cisplatin|
41166417|NCT05656963|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.
41386174|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the conventional whitening dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the conventional whitening dentifrice.
41386175|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the whitening dentifrice containing blue covarine|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the whitening dentifrice containing blue covarine.
41510468|NCT04967573|DRUG|Rivaroxaban|Rivaroxaban 20 mg or 10 mg for 3 months
40855384|NCT00003364|DRUG|cyclophosphamide|
40855385|NCT00003364|DRUG|doxorubicin hydrochloride|
40855386|NCT00003364|DRUG|etoposide|
40855387|NCT00003364|DRUG|vincristine sulfate|
40855388|NCT00003364|RADIATION|radiation therapy|
40855389|NCT01922791|DIETARY_SUPPLEMENT|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
40855390|NCT00099658|BIOLOGICAL|Pneumococcal polysaccharide-protein conjugate vaccine|Injection administered three times before the age of 24 weeks
40855391|NCT00680459|DRUG|70% ethanol|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
41037795|NCT02269670|DRUG|everolimus|Given PO
41037796|NCT02269670|DRUG|anastrozole|Given PO
41037797|NCT02269670|DRUG|letrozole|Given PO
41037798|NCT02269670|DRUG|tamoxifen citrate|Given PO
41037799|NCT02269670|DRUG|fulvestrant|Given IM or PO
41037800|NCT02269670|DRUG|megestrol acetate|Given PO
41037801|NCT05795582|DEVICE|POPMETRE® (Axelife , France)|Measurement with 2 devices
41037802|NCT00847262|DRUG|Temisartan|Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
41037803|NCT00847262|DRUG|Amlodipine|Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
41037804|NCT04957966|BEHAVIORAL|self-selected relaxing music|20 minutes music listening
41386176|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the regular dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the regular dentifrice.
41037805|NCT04454866|DRUG|Single injection of penehyclidine|A dose of penehyclidine hydrochloride (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
41386177|NCT02357173|OTHER|electronic cigarette|
41386178|NCT02357173|OTHER|cigarette group|
41386179|NCT03669640|DRUG|RO6889450|Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
41386180|NCT03669640|DRUG|Placebo|Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
41386181|NCT06566508|DRUG|Calcium Hydroxide Intracanal medication|Calcium Hydroxide Intracanal medication
41386182|NCT06566508|DRUG|Leddermix Intracanal medication|Leddermix Intracanal medication
41386183|NCT06566508|DRUG|Asiaticoside Intracanal medication|Asiaticoside Intracanal medication
41386184|NCT05005130|OTHER|TASKPEN|"TASKPEN is the name of the package of implementation strategies proposed by the investigators that are intended to deliver the WHO PEN intervention in routine HIV clinical practice settings in Zambia. TASKPEN has five components which will be the subject of stakeholder consultation and adaptation in this formative research protocol. The package of integrated HIV/NCD services includes:~1. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~2. Access to cardio-metabolic condition screening \& laboratory monitoring~3. Non communicable disease-focused electronic medical record module~4. Integrated non-communicable/HIV care (one stop shop for services)~5. Strengthened non-communicable disease (NCD) medication supply chain, including multi-month dispensing (MMD)"
41386185|NCT05533112|OTHER|Binaural Beat Stimulation|During binaural beats stimulation both ears receive a tone which varies slightly in its frequency. If the left ear is stimulated with a sinusoidal wave of 98 Hz and the right ear with a sinusoidal wave of 108 Hz, the brain will perceive this stimulation as a single tone at the mean frequency of 103 Hz. The amplitude of the perceived tone will fluctuate with a frequency that is equal to the difference of the two initial tones, i.e., 10 Hz
41386186|NCT03172390|DEVICE|4D Cardiac Magnetic Resonance|4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
41386187|NCT03512067|DEVICE|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
41386188|NCT03434626|BEHAVIORAL|ACP Education|Decision aid and Goals of Care Designation form information administered by Navigator
41386189|NCT03434626|OTHER|Usual care|Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician
41386190|NCT03027973|DRUG|UPA|Experimental drug
41037806|NCT04454866|DRUG|Continuous infusion of penehyclidine|A dose of penehyclidine hydrochloride (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine hydrochloride (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
41386191|NCT03027973|DRUG|TEA|Active comparator
41386192|NCT03027973|DRUG|Placebo (for UPA)|Sugar pill manufactured to mimic UPA 5 mg
41386193|NCT03027973|DRUG|Placebo (for TEA)|Sugar pill manufactured to mimic TEA 500mg
40855392|NCT00680459|DRUG|heparin flush solution|heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
40855393|NCT05502354|DEVICE|removal of transanal drainage tube|removal of transanal drainage tube after laparoscopic anterior resection for rectal carcinoma according to postoperative CRP trajectory
41386194|NCT00817258|DRUG|cisplatin|Cisplatin 40mg/m2,weekly
41037807|NCT04454866|DRUG|Placebo|A dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
41386195|NCT00817258|RADIATION|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|3D-CRT or IMRT
41037808|NCT01570101|DEVICE|CE Marked Sapheon Closure System|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
41166418|NCT04784637|DEVICE|Web Simulation Tool (WST)|WST will allow users of the Control-IQ system replay treatment scenarios in computer simulation, thereby allowing user training with carbohydrate and insulin action.
41386196|NCT04715737|DRUG|Vasopressin|Administration of vasopressin (20IU) intranasally
41386197|NCT04715737|DRUG|Oxytocin|Administration of oxytocin (24IU) intranasally
41386198|NCT04715737|DRUG|Placebo|Administration of placebo intranasally
41510469|NCT04413110|DEVICE|Polysomnography|PSG was carried out for 41 patients with subjective cognitive impairment and 41 age and sex-matched controls. PSG with standard EEG montage that includes bilateral EOG and four EEG leads were used. A single attended overnight PSG study was performed at the Clinical Neurophysiology Unit of Mansoura University Hospitals. Patients were studied in a quiet, darkened room with no medications were used to induce sleep. All participants underwent one night of laboratory-based PSG.
41037809|NCT06187467|OTHER|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires to quantify cortical and motor activities using portable EEG and lower limb sensors during dynamic balance and gait activities.
41037810|NCT05029765|DIETARY_SUPPLEMENT|Mediterranean diet|"Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates"
41037811|NCT05029765|DIETARY_SUPPLEMENT|Healthy diet (WHO recommendations)|Recommendations according to WHO
41166419|NCT04784637|DEVICE|Behavioral Adaptation Module (BAM)|BAM provides on-demand information to the participant primarily on glycemic risks.
41166420|NCT04784637|DEVICE|Auto Titration Module (ATM)|ATM provides recommendations to the participant to periodically update insulin parameters.
41037812|NCT05029765|DIETARY_SUPPLEMENT|Placebo|Placebo
41037813|NCT05029765|DIETARY_SUPPLEMENT|Biopolis-MIX42|Biopolis-MIX42: a capsule containing 10\^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum.
41037814|NCT06530823|DRUG|Pemigatinib and Durvalumab|Pemigatinib combined with Durvalumab Pemigatinib: 13.5mg, oral administration, once daily, swallow the entire tablet with or without food. Take for 2 weeks and then discontinue for 1 week. Durvalumab: 1500mg, intravenous infusion, once every three weeks. Each infusion should take over 60 minutes.
41166421|NCT04784637|DEVICE|Automated Insulin Delivery (AID) System|The t:slim X2 insulin pump with Control-IQ technology, Tandem Diabetes Care will be the AID in this study.
41166422|NCT01997749|DIETARY_SUPPLEMENT|Ketocal 4:1 (Nutricia)|
41166423|NCT01997749|DIETARY_SUPPLEMENT|Control diet: Regular diet offered at the hospitals|
41166424|NCT01997749|DIETARY_SUPPLEMENT|Ketogenic meals|
41166425|NCT00524810|DRUG|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
41166426|NCT00524810|DRUG|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
41166427|NCT00564252|DRUG|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
41166428|NCT04532762|DEVICE|nasal spray|Application of a nasal spray
41166429|NCT05992636|PROCEDURE|pneumoperitoneum insufflation (flow) rate|"Patiens who initiate with low insufflation flow (10 lt/min)~Patiens who initiate with high insufflation flow (40 lt/min)"
41166430|NCT01960348|DRUG|patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
41510470|NCT00512577|OTHER|Red blood cell transfusion|Pre-operative red blood cell transfusion
41510471|NCT06018038|DIAGNOSTIC_TEST|Maximal Exercise Capacity, Maximal Oxygen Consumption (VO2max)|Cardiopulmonary Exercise Testing (CPET)
41037815|NCT03588026|DRUG|rVA576|6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
41037816|NCT03588026|OTHER|Standard of care (SOC)|6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.
41037817|NCT05713617|BEHAVIORAL|PODER Familiar|Educational intervention designed to improve healthy behaviors of families of children with intellectual and developmental disabilities.
41037818|NCT05800132|DEVICE|MammoScreen|Diagnostic reading aid for breast cancer screening
41037819|NCT00605280|DRUG|Standard of Care|Clinicians decision to use optional laser therapy.
41037820|NCT00605280|DRUG|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
41037821|NCT04117035|PROCEDURE|Gamma Knife Radiosurgery (GKRS) personalised procedure|Personalised GKRS treatment
41037822|NCT04117035|PROCEDURE|GKRS standard care|Standard GKRS treatment
41037823|NCT01736813|DRUG|Maraviroc|Twelve patients with 300 mg/bid
41037824|NCT01903473|DRUG|Rapamycin|"Rapamycin will be started within 2 weeks after inclusion. Rapamycin will be given at 2-6 mg loading dose for one day, followed by approximately 1 mg daily to achieve a target trough level of 5 to 10 ng/mL. The frequency of trough level measurements will be done according to the investigator choice; Rapamycin may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.~Calcineurin inhibitor discontinuation within 2 weeks after rapamycin initiation. No other modification of immunosuppressive drugs and in particular no decrease in the dose of steroids (unless necessary for side effects)."
41166431|NCT01960348|DRUG|Sterile Normal Saline (0.9% NaCl)|administered by intravenous (IV) infusion
41166432|NCT01821729|DRUG|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
41166433|NCT01821729|DRUG|Losartan|Taken orally every day during Phase I for all 8 cycles
41166434|NCT01821729|RADIATION|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
41166435|NCT03536702|OTHER|Creative Writing Workshop|This group will participate in a writing workshop in group sessions.
41166436|NCT03536702|OTHER|Independent Writing - Control Group|This group will receive a book for a self writing session.
41166437|NCT02762292|DEVICE|Measurement of work of breathing using indirect calorimeter|"1. Preparation:~   1. Patient baseline characteristics will be collected.~  2. Connection of the Indirect Calorimeter to the respiratory circuit.~  3. Nasogastric tube installation: a specific modified Neurally Adjusted Ventilatory Assist (NAVA) catheter equipped with both microelectrodes for Electrical Activity of the diaphragme (EAdi) monitoring and an esophageal balloon (for esophageal pressure (PES) monitoring) will be installed.~2. Simultaneous recordings of: Oxygen Consumption (VO2) and Energy Expenditure (EE); Esophageal Pressure (PES), Airway Pressure (PAW), respiratory volume and flow; EAdi during (i) Conventional mechanical ventilation (ii) Spontaneous Breathing Trial in Continuous Positive Airway Pressure and (iii) Second period of Conventional mechanical ventilation with the same ventilator parameters set in STEP 1.~3. End of the physiological recordings. Collection of Pediatric Intensive Care Unit (PICU) outcome of patients."
41166438|NCT02795819|DRUG|AR-42|AR-42 tablets were taken orally once per day on 3 non-consecutive days during the first 3 weeks of each 4-week cycle. If treatment was interrupted during the cycle, the cycle was to be extended
41166439|NCT02795819|DRUG|Pazopanib|Pazopanib tablets were taken orally once daily continuously during each 4-week treatment cycle. There were no scheduled breaks in pazopanib therapy
41166440|NCT00280683|DRUG|L-arginine|subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
41510472|NCT01562860|PROCEDURE|Pronator Teres Release|Surgical release of median nerve compression
41510473|NCT01562860|PROCEDURE|dual compression release|Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
41510474|NCT01562860|PROCEDURE|dual compression release|both procedures will be done on the same day
41510475|NCT01562860|PROCEDURE|median nerve release only|only the carpal tunnel compression is released
41510476|NCT03624192|DEVICE|RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings
41510477|NCT03624192|OTHER|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
41037825|NCT01903473|OTHER|T regulatory cells|"One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 60-90 days after first day of rapamycin administration and after calcineurin inhibitor discontinuation. The infusion procedure will take one hour.~Low-dose Il-2 (1x106 IU/day) will be started the day of DTI and will be continued for a period of 2months in order to expand infused donor Tregs."
41037826|NCT02045238|DRUG|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
41386199|NCT06195358|DEVICE|Mobile Health (Smartphone) Application|The intervention arm will receive the smartphone application, which has been designed to engage primary caregivers directly in the active monitoring of their infants' development, and to provide tailored feedback and support for the provision of nurturing care. Study staff will make an initial home visit (less than an hour) to install the application on the caregiver phone and demonstrate use and collect baseline data. Subsequently, in the intervention arm, staff will make monthly visits (approximately 15 minutes duration) to assess functionality of the smartphone and answer questions/reinforce use.
41386200|NCT06195358|OTHER|Printed Caregiving Materials|The control arm will receive printed caregiving materials. In the control arm, staff will make monthly visits (approximately 15 minutes duration) to ask if there are questions about the printed caregiving materials.
41386201|NCT04253379|DIAGNOSTIC_TEST|Neuropsychological evaluation , Evaluation of theory of mind, Evaluation of executive functions, Evaluation of verbal skills|Several tests will be used: Raven's Advanced Progressive Matrices, auditory attention subtest of the NEPSY II, Peabody Picture Vocabulary test, specific comprehension test The cognitive TOM will be evaluated with questions about 4 stories of false beliefs. The affective TOM will be evaluated with a specific emotion inference task 4 adapted subtests from several validated scales will be used to investigate inhibition, cognitive flexibility and working memory The semantic and pragmatic competences will be evaluated with 4 comprehension tasks.
41386202|NCT05855525|BEHAVIORAL|Experience sampling|Participants will repeatedly and intermittently report the content of their ongoing, self-generated experiences based on an experience-sampling protocol in which self-report ratings will be triggered based on real-time analysis of the participant's current brain state. The protocol will be conducted while participants are undergoing MRI scanning.
41386203|NCT05801991|DEVICE|Neurolens|neurolens® is a type of spectacle lens that uses contoured prism to alleviate vergence demands and fatigue at near and, therefore, encourages comfortable vision.8 This spectacle design uses the neurolens® Measurement Device (nMD) to measure eye alignment and determine the spectacle lenses that are uniquely designed for each wearer.
41386204|NCT05801991|DEVICE|Placebo spectacle lens|Plano (no power) spectacle lenses will be assigned to the placebo group
41386205|NCT04497571|PROCEDURE|Piezoelectric osteotomy.|Implants placed using the ultrasonic technique.
41386206|NCT04497571|PROCEDURE|Conventional drilling|Implants placed using drilling technique
41386207|NCT03967106|OTHER|Ischaemic Preconditioning|IPC to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg above the systolic blood pressure (BP) followed by 5 minute cuff deflation.
41386208|NCT03967106|OTHER|Sham|Sham intervention to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg below the diastolic blood pressure (BP) followed by 5 minute cuff deflation.
41386209|NCT06433986|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT)Technique|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using MCAT.
41510478|NCT06582186|DRUG|Individualization of first voriconazole maintenance doses|Individualization of first voriconazole maintenance doses
41510479|NCT02633748|BEHAVIORAL|Mindfulness-Based Cancer Survivorship|Mindfulness-Based Cancer Survivorship (MBCS) is a four-week standardized mindfulness program, adapted for cancer survivors from Mindfulness-Based Stress Reduction (MBSR). MBCS teaches formal mindfulness practice (meditation) and informal mindfulness during daily activities. Mindfulness has been shown to help stress, fatigue, sleep complaints, and other symptoms but has not been extensively studied in cancer survivors.
41510480|NCT04205565|DRUG|Test group: L-oxiracetam Injection|L-oxiracetam injection, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
41510481|NCT04205565|DRUG|Control group: Oxiracetam Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.
41037827|NCT02045238|RADIATION|Chest X-Ray|
41510482|NCT04205565|DRUG|Placebo group: Placebo Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
41510483|NCT04508738|OTHER|ERP|"The ERP intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~ERP: 1) neck cooling with an iced gel pad, 2) drinking a ∼ 6% CHO solution, 3) mouth-rinsing with a ∼10% CHO, ∼6 mg ･ kg -1 caffeine solution, 4) performing submaximal squats and 5) hyperventilating a hyperoxic mixture"
41510484|NCT04508738|OTHER|Placebo|"The control intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~1) neck cooling with room temperature gel pack, 2) drinking an artificially sweetened solution, 3) mouth-rinsing with artificially sweetened solution (containing no caffeine), 4) performing unloaded squat manoeuvres, 5) deep breaths with room air"
41037828|NCT02045238|OTHER|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
41037829|NCT00649194|DRUG|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fed
41037830|NCT00649194|DRUG|Aciphex® Tablets 20 mg|20mg, single dose fed
41166441|NCT00280683|DRUG|Placebo|Placebo tablets that match the L-arginine intervention tablets will be given for three months
41510485|NCT00455156|DRUG|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
41510486|NCT05936515|OTHER|Training of nurses and nursing assistants|Training of nurses and nursing assistants, based on the model of hygiene correspondents, in order to disseminate good geriatric practices
41510487|NCT00118534|BEHAVIORAL|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
41510488|NCT00118534|BEHAVIORAL|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
41510489|NCT04556786|BEHAVIORAL|Transitions of care|The intervention was a pharmacist-led transitions of care program that include medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist at 60- and 90-day post-discharge in addition to the usual care.
41510490|NCT05247255|DRUG|Active Comparator|QL block with 0.25% ropivacaine
41386210|NCT06433986|PROCEDURE|Vestibular Incision Subperiosteal Tunnel Access (VISTA)Technique|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using VISTA.
41386211|NCT05576597|DRUG|Sodium Butyrate|2 capsules butyrate supplement once a day for 12 weeks
41386212|NCT00871104|DRUG|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
41386213|NCT00871104|DRUG|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
41386214|NCT05137301|DEVICE|X-ray bone age instrument|Bone age films were taken by X-ray bone age instrument
41386215|NCT05460377|BIOLOGICAL|Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intramuscularly by needle and syringe.
41386216|NCT05460377|BIOLOGICAL|Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intradermally by needle and syringe.
41386217|NCT05460377|BIOLOGICAL|Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intramuscularly by needle and syringe
41386218|NCT05460377|BIOLOGICAL|Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intradermally by needle and syringe
41386219|NCT04673266|DRUG|Romiplostim|All patients will begin weekly (+/- 2 days) romiplostim at 3 mcg/kg subcutaneously. The romiplostim dose will be titrated, based on weekly CBC/platelet counts.
41386220|NCT03003728|DRUG|Elotuzumab|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
41386221|NCT03003728|DRUG|Melphalan|Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
41386222|NCT03003728|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|ASCT on day -2
41386223|NCT03003728|BIOLOGICAL|Expanded Natural Killer (ENK) Cells|ENK cell infusion on day 0
41386224|NCT03003728|DRUG|ALT-803|ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
41386225|NCT05988593|DIETARY_SUPPLEMENT|placebo|consume one bottle (30 mL) per day
41386226|NCT05988593|DIETARY_SUPPLEMENT|MelaGene+|consume one bottle (30 mL) per day
41386227|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 native powder|
41386228|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 micelles|
41386229|NCT06542796|PROCEDURE|Immunotherapy combined with targeted therapy|Immunotherapy combined with targeted therapy
41386230|NCT06542796|OTHER|Standard treatment plan|Standard treatment plan
41510491|NCT05247255|DRUG|Placebo Comparator|QL block with saline
41510492|NCT02779166|DRUG|Celecoxib|Received 400mg celecoxib prior to surgery
41386231|NCT00377715|DRUG|Dimebon|
41386232|NCT00377715|DRUG|Placebo|
41386233|NCT01935557|DRUG|Continuous heparin infusion|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
41386234|NCT01935557|DRUG|Intermittent heparin infusion|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
41386235|NCT06453707|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
41386236|NCT05927207|OTHER|TRIP|TRIP is a mobile app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD), comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
41510493|NCT02779166|DRUG|placebo|
41510494|NCT04514432|OTHER|Music|If patients experienced agitation, they were able to request to listen to music for 30 minutes. They listened to genre playlists generated by the music application Spotify.
41510495|NCT02481869|BIOLOGICAL|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
41510496|NCT02481869|DRUG|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
41510497|NCT02405130|OTHER|intracoronary epinephrine|after failure of standard therapy patients will treated with epinephrine
41510498|NCT02405130|OTHER|no intracoronary epinephrine|patients will receive standard therapy only
41386237|NCT06565520|DEVICE|transcranial direct current stimulator|"The total amount of participation time per qualified subject will be approximately 150 minutes over two sessions. The participant screening session will take approximately 30 minutes, which is an appropriate amount of time to complete all screening tasks. The tDCS and sham sessions will take approximately a total of 120 minutes over two sessions.~The first session will include a screening (30 minutes) to ensure they qualify for the study, followed by a treatment session (60 minutes): including non-invasive brain stimulation combined with hip strengthening exercises and functional movement testing at UNLV Maryland Campus. Subjects will return for a second treatment session (60 minutes) 2 weeks after the first."
41510499|NCT05107271|DIAGNOSTIC_TEST|COVID-19 serosurvey|COVID-19 related antibody testing to assess immunogenicity of COVID-19 vaccines or post natural infection acquired immunity
41510500|NCT02489097|DRUG|Nitrous Oxide|Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture
41510501|NCT02489097|OTHER|Placebo|Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
41386238|NCT03533608|BEHAVIORAL|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
41510502|NCT02791451|DEVICE|telemonitoring|To predict exacerbation of COPD with wireless telemonitoring
41386239|NCT03966196|OTHER|Measurements of oxygen saturation and finger pressure during deep inspiration|Measurements during deep inspiration of oxygen saturation with pulse oximeter and finger pressure with pressure cuff
41510503|NCT05602324|DIETARY_SUPPLEMENT|Lauric Acid and Berberine|intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
41510504|NCT05179330|DEVICE|OMEGO®|Lower limb rehabilitation with and without visual feedback
41510505|NCT01782014|PROCEDURE|colonoscopy|colonoscopy using different methods of insufflation
41510506|NCT01382537|DEVICE|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
41510507|NCT01382537|DEVICE|InterX 5000|Placebo treatment
41510508|NCT03448887|DEVICE|Theranova|Extended HD with theranova
41510509|NCT03448887|DEVICE|Online hemodiafiltration|Online hemodiafiltration
41510510|NCT04936399|BIOLOGICAL|Nivolumab|Participants will receive Nivolumab after prior chemotherapy as part of an early access to medicines scheme (EAMS) program in the United Kingdom (UK)
41510511|NCT04960293|PROCEDURE|uterine artery embolization using spherical gelfoam|Uterine artery embolization is performed using spherical gelfoam. All other processes are same.
41510512|NCT04960293|PROCEDURE|uterine artery embolization using tri-acryl gelatin microsphere|Uterine artery embolization is performed using tris-acryl gelatin microsphere. All other processes are same.
41510513|NCT06583018|BEHAVIORAL|In-Person Mindfulness-based Group Session|A 3-hour group-based session in week 1 focused on experiential mindfulness practices. Participants will enhance their self-awareness of positive, neutral, and negative body sensations, feelings, and thoughts while engaging in healthy behaviors, particularly physical activity
41510514|NCT06583018|BEHAVIORAL|Ecological Momentary Interventions (EMI)|Participants will receive personalized instant messages with chat-based support throughout the 8-week intervention period. The message content is guided by existing international lifestyle modification guidelines and the Integrated Body-Mind-Spirit Model. The pre-set frequency of regular message delivery is five times per week. The schedule of message delivery will be personalized according to the participants' on-going needs/preferences over the intervention period. Chat-based support will be provided by trained research assistants, who will utilize motivational interviewing techniques to enhance participant compliance and effectiveness.
41510515|NCT06583018|BEHAVIORAL|In-person Group Session|A 3-hour group-based session in week 1 focused on general education on lifestyle modification based on the HEARTS technical package as recommended by the WHO, and will only receive reminder messages for the two assessment follow-ups. No chat-based support will be provided.
41510516|NCT06583018|DEVICE|Activity Monitoring|All participants will wear an accelerometer-based wristband activity tracker to monitor their physical activity in daily life.
41510517|NCT04594564|PROCEDURE|Total hip arthroplasty with Delta TT cup|Total hip arthroplasty using Delta TT cup and ceramic bearings
40855394|NCT05973253|DRUG|prepared drop of medroxy progestrone acetat 1%|In 37 patients who are candidates for photorefractive keratectomy, at the end of the procedure, in one eye randomly, in addition to the antibiotic drop that is routinely placed at the end of the procedure, a drop of prepared medroxyprogesterone is also placed. Then, a bandage contact lens is placed on the eyes, and the patient receives the routine post-procedure drops that include betamethasone and ciprofloxacin drops for both eyes.
40855395|NCT03221842|DRUG|C1-esterase inhibitor|C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
41510518|NCT05738278|BEHAVIORAL|HR-informed change in routine|"The intervention is given for a situation occuring at least ten times and accompanied by an increase in HR at least 80% of the time, during the two-week registration period. Change in care (intervention) is introduced from week 3.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure."
40855396|NCT03221842|DRUG|Placebo|Excipients of C1-INH plus albumin
41037831|NCT02440958|DRUG|modified FOLFIRINOX regimen|Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
41037832|NCT04184063|DRUG|NBMI|NBMI active treatment
41037833|NCT04184063|OTHER|Placebo|Placebo for comparison
41037834|NCT06451172|DRUG|ASO|Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.
41386240|NCT05626231|BEHAVIORAL|Gender-Affirming Psychotherapy (GAP) Training|"The GAP training is a modular online asynchronous training intervention designed to increase mental health providers' use of gender-affirming practices with GMY (ages 12-25). It was developed using community-engaged and human-centered design methods with key stakeholders (GMY, their caregivers, mental health providers). In this open trial, GAP training will be offered to mental health providers at a multisite mental health clinic in the U.S. (referred to as pilot site herein)."
41386241|NCT05141045|DIETARY_SUPPLEMENT|omega-3 PUFA supplement|participants were instructed to take 3.0 grams per day of omega-3 PUFA supplement
40855397|NCT05612334|BEHAVIORAL|exercise (5 minutes warm-up-30 minutes walking-5 minutes cooling down)|the breathing exercise group, which constituted the placebo control group, were first informed by the researcher about the correct breathing techniques and was given an informative training brochure prepared by the researcher containing the correct breathing exercise information.
40855398|NCT00746434|DRUG|Roflumilast cream|Roflumilast cream 0.5%
40855399|NCT00746434|DRUG|Placebo cream|Placebo cream
40855400|NCT03735992|BEHAVIORAL|Mind-body medicine group program|The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
40855401|NCT06393166|DRUG|Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection|Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle Gemcitabine hydrochloride: 1g/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle 5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle Oxaliplatin: 85 mg/m2 ,ivgtt, D29, every 6 weeks for a treatment cycle LV: 400 mg/m2 ,ivgtt over 2h, D29, every 6 weeks for a treatment cycle Serplulimab Injection: 3mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle. Bevacizumab Injection: 5mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle.
40855402|NCT03004352|OTHER|retrograde flow|Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.
40855403|NCT03004352|OTHER|oxygen|Supplemental 100% oxygen administered through a nasal cannula.
41037835|NCT01782066|BIOLOGICAL|MEN-ACYW135 reduced-dose intradermal administration|Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
41037836|NCT06027268|DRUG|Trilaciclib|IV infusion Day 1 and Day 8 every 21 days, at dose of 240 mg/m2
41386242|NCT05141045|DIETARY_SUPPLEMENT|placebo|placebo
41386243|NCT04272255|DRUG|scopolamine HBr|Nasal Gel
41037837|NCT06027268|DRUG|Pembrolizumab|IV infusion Day 1 every 21 days, at dose of 200 mg
41037838|NCT06027268|DRUG|Gemcitabine|IV infusion Day 1 and Day 8 every 21 days, at dose 1000 mg/m2
41037839|NCT06027268|DRUG|Carboplatin|IV infusion Day 1 and Day 8 every 21 days, at dose area under curve (AUC) 2 (maximum of 300 mg)
41037840|NCT06193876|OTHER|Petitgrain and ylang-ylang essential oil|Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.
41037841|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine , 5555 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
41386244|NCT04272255|DRUG|Transdermal Scopolamine|Patch
41386245|NCT01307488|DRUG|Ritonavir boosted Atazanavir + Lamivudine|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
41386246|NCT01307488|DRUG|Ritonavir boosted Atazanavir + 2 NRTIs|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
41386247|NCT04108884|DEVICE|App measurement|App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations
41386248|NCT04108884|DEVICE|14 day Holter ECG|14 day moblie patch Holter ECG for AF confirmation
40855404|NCT02881762|DRUG|Maraviroc|Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
40855405|NCT01674205|BIOLOGICAL|A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)|
40855406|NCT01674205|BIOLOGICAL|A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)|
41037842|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine , 5553 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
41037843|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine, 4444 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
41037844|NCT02806180|PROCEDURE|Dual Operator Ultrasound Guided IV placement|Second operator holds ultrasound probe.
41037845|NCT02806180|PROCEDURE|Single Operator Ultrasound Guided IV placement|Single operator holds ultrasound probe and places IV.
41037846|NCT05808387|DIETARY_SUPPLEMENT|Resveratrol|Trans-resveratrol, 1000 mg daily for 90 days
41037847|NCT05808387|DIETARY_SUPPLEMENT|Placebo|Starch, 1000 mg daily for 90 days
41386249|NCT02905318|DRUG|Palbociclib|125 mg orally on days 1-21 each 28 day cycle
41386250|NCT05675072|DRUG|FB2001|FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
41386251|NCT05675072|DRUG|FB2001 placebo|FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
41386252|NCT02179931|DRUG|Flupentixol/melitracen film-coated tablet|
40855407|NCT01674205|BIOLOGICAL|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)|
40855408|NCT01674205|BIOLOGICAL|Vaccine placebo (Leibovitz-15 [L-15])|
40855409|NCT01674205|BIOLOGICAL|Vaccine placebo (FluMist®)|
40855414|NCT05873972|DRUG|Cetuximab|"AEM A：The specialist's decision to add cetuximab to chemotherapy will be based on their own judgment~ARM B：The patient's CT imaging,genetic mutation information were input into the signature, and the FOLFOX+cetuximab regimen was selected when the output label was 1. FOLFOX+bevacizumab chemotherapy regimen was selected when the output label was 0"
40855415|NCT04119232|BEHAVIORAL|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
40855416|NCT01928901|DRUG|administration of Sinupret|
40855417|NCT01928901|DRUG|administration of Bronchipret|
40855418|NCT01928901|DRUG|administration of Sinupret Placebo|
40855419|NCT01928901|DRUG|administration of Bronchipret Placebo|
41037848|NCT00707031|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
40855420|NCT02522325|DRUG|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
40855421|NCT02522325|DRUG|Cocaine|Intranasal cocaine will be administered during experimental sessions.
41037849|NCT00707031|DEVICE|Pen auto-injector|
41037850|NCT00707031|DRUG|Exenatide|Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
40855422|NCT02522325|DRUG|Placebo|Placebo capsules will contain only cornstarch.
40855423|NCT01067144|DRUG|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
40855424|NCT01067144|DRUG|Lorazepam (active control)|0.5 mg Lorazepam (active control) given pre-operatively in a single dose.
40855425|NCT01067144|DRUG|Placebo (inactive)|2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
41037851|NCT00707031|DEVICE|Prefilled pen injector|
41037852|NCT00707031|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
41037853|NCT00229125|DRUG|Gabapentin|
41037854|NCT00229125|DRUG|Lorazepam|
41037855|NCT00006123|BIOLOGICAL|trastuzumab|
41037856|NCT00006123|DRUG|carboplatin|
41386253|NCT02179931|DRUG|Flupentixol/melitracen coated tablet (Deanxit®)|
41386254|NCT01166997|DEVICE|EkoSonic Endovascular System|The EkoSonic Endovascular System will be used to deliver \< 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
41386255|NCT01166997|DRUG|Unfractionated heparin|Intravenous unfractionated heparin used for anticoagulation treatment
41386256|NCT04442178|DRUG|CYT107|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
41386257|NCT04442178|DRUG|Placebo|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
40855426|NCT03543137|DRUG|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
41386258|NCT05384197|DRUG|Enhanced regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
41037857|NCT00006123|DRUG|carmustine|
41386259|NCT05384197|DRUG|Extended regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)"
41386260|NCT03596879|BEHAVIORAL|dCBTI|Online access to the digital CBTI program Sleepio based off of traditional face-to-face Cognitive Behavioral Therapy, six weekly sessions done online.
41386261|NCT03596879|BEHAVIORAL|Sleep Education|Six weekly email messages with sleep hygiene recommendations. Subjects are encouraged to read through the information and apply it to their sleep.
40855427|NCT03543137|DRUG|Nicorette Mini Lozenge|A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
40855428|NCT04414566|DRUG|gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil|Patients receive GP gemcitabine (1000 mg/m\^2 d1,8) and cisplatin (80mg/m\^2 d1) or TPF docetaxel (60mg/m\^2 on day 1), cisplatin (60mg/m\^2 on day 1) and fluorouracil (600mg/m\^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
40855429|NCT04414566|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
41037858|NCT00006123|DRUG|cisplatin|
41037859|NCT00006123|DRUG|cyclophosphamide|
41386262|NCT03447470|DRUG|RXC004|RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.
41037860|NCT00006123|DRUG|thiotepa|
41386263|NCT03447470|DRUG|Nivolumab|"RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1"
41386264|NCT05569421|DRUG|Treatment A: BGF MDI HFO|Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.
41386265|NCT05569421|DRUG|Treatment B: BGF MDI HFA|Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.
41386266|NCT03890835|PROCEDURE|MTA Pulpotomy.|Pulpotomy using MTA.
41386267|NCT03890835|PROCEDURE|Biodentine Pulpotomy|Pulpotomy using Biodentine
41386268|NCT05366153|DIAGNOSTIC_TEST|Coronary CT|Screening/Management Plan
40855430|NCT04414566|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m\^2 every 3 weeks for 3 cycles.
41037861|NCT00006123|PROCEDURE|peripheral blood stem cell transplantation|
41037862|NCT04939480|DRUG|Atezolizumab|Atezolizumab 1200 mg intravenous solution
41037863|NCT05884060|OTHER|No intervention|No interventions
41037864|NCT01839929|DRUG|Prograf|oral
41037865|NCT01839929|DRUG|Advagraf|oral
41037866|NCT02859792|DRUG|Riluzole|Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).
41037867|NCT02859792|DRUG|Placebo|placebo capsules 25 or 50 mg
41037868|NCT02859792|BIOLOGICAL|Blood Samples|v1;v2;v3;v4
41037869|NCT03664076|DIAGNOSTIC_TEST|COMISS score|cow's milk protein symptoms score awareness tool to select cow's milk protein allergy in infants
41037870|NCT05278910|OTHER|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour
41037871|NCT05278910|DIETARY_SUPPLEMENT|Fish oil + Roasted wheat flour|Assign fish oil and roasted wheat flour
41037872|NCT05278910|DIETARY_SUPPLEMENT|Soybean oil + Vegetable and fruit extracts|Assign soybean oil and vegetable and fruit extracts
41037873|NCT05278910|DIETARY_SUPPLEMENT|Fish oil + Vegetable and fruit extracts|Assign fish oil and vegetable and fruit extracts
41037874|NCT05245669|BIOLOGICAL|ENZ215|healthy volunteers receive ENZ215 (60mg) once
41166442|NCT05253079|OTHER|subcostal transversus plane block|Patient in TAP block group will receive oblique subcostal TAP while in supine position using a linear 6-13 MHz ultrasound transducer. The operator will place the ultrasound probe obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The landmarks, which included the rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin and xyphoid. The probe will be then moved laterally until the aponeurosis of the external, internal oblique, and transversus abdominis are seen, and then the probe will be moved further laterally until the transversus abdominis muscle is identified. The operator will direct the needle toward the transversus abdominis, and the local anesthetic solution will be injected after negative aspiration between the rectus abdominis and transversus abdominis muscles along the subcostal line (in-plane superomedial to inferolateral)
41386269|NCT06257186|OTHER|Art Therapy|Participants assigned to the Intervention (Art Therapy) arm will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The Art Therapy is given in addition to routine antenatal care.
41386270|NCT04425369|PROCEDURE|two-sided approaches for iliac crest bone graft|Only one side of the ilium was exposed when surgery.
41386271|NCT04095819|PROCEDURE|Middle Meningeal Artery procedure|Seal off the blood supply to the middle meningeal artery to prevent growth of the Subdural Hematoma
41386272|NCT04095819|PROCEDURE|Traditional Surgery|Drainage of Subdural Hematoma using Craniotomy or Burr Hole
41386273|NCT05961319|DEVICE|Smart-Home Monitoring|"During the study, various sensors will be employed to capture participant interactions with appliances and furniture. These sensors may include:~Interaction Sensors: These sensors are designed to recognize users' interactions with appliances and furniture within the smart environment.~Smart Biomechanics Devices: Devices such as a Fitbit device an internet of Things grip Dynamometer will be utilized to assess physical balance and strength.~Positioning System using Ultra-Wide Band (UWB) Technology: This positioning system leverages UWB technology, enabling furniture-level accuracies in interpreting self-care activities.~As participants engage with different elements of the smart environment, these sensors will collect data. Additionally, participants will be recorded via video to further enhance the observational data captured during the study."
41386274|NCT01755780|OTHER|Left interscalene block|
41386275|NCT01755780|OTHER|Right interscalene block|
41386276|NCT04650984|DRUG|Onfekafusp alfa|Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
40855431|NCT06271395|DRUG|Injectable Type A Botulinum Toxin|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
40855432|NCT02781610|DRUG|Standard of care IV antibiotic(s)|IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
40855433|NCT00630435|DRUG|Premarin®/MPA formulation A|
40855434|NCT00630435|DRUG|Premarin®/MPA formulation B|
41386277|NCT04650984|DRUG|Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
41386278|NCT06565624|PROCEDURE|Cotton Swab Nasal Stimulation|Nostril probing for the purpose of producing reflex tearing
41386279|NCT06465706|DEVICE|LAmbre investigational device|Randomized 1:1 to either experimental group or control group.
41386280|NCT04542330|BIOLOGICAL|BCG-Denmark|Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) administered by intradermal injection in the left deltoid region.
41386281|NCT04542330|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
40855435|NCT00630435|DRUG|Premarin®/MPA formulation C|
41386282|NCT00996918|DRUG|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
40855436|NCT00630435|DRUG|Premarin®/MPA currently marketed product|
40855437|NCT04840212|OTHER|Lavender-Sandalwood scented aromatherapy sticker|The Lavender-Sandalwood scented aromatherapy sticker will be placed on the patient gown.
40855438|NCT04140045|OTHER|Water intake|Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
40855439|NCT03630757|OTHER|Treatment|In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
40855440|NCT05018650|DEVICE|Route 92 Medical Reperfusion System|Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.
40855441|NCT03411421|DRUG|AL-794|AL-794 will be administered as tablets orally on Day 1 to Day 5.
41386283|NCT00996918|DRUG|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
41386284|NCT05309707|DEVICE|Endovascular exclusion|Endovascular exclusion by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
41386285|NCT06568068|BEHAVIORAL|training|"The intervention group that will receive training determined after randomization; In Stage 1 An introductory meeting will be held, ERGEP will be announced and educational materials will be distributed. Pretest applications will be done. In Stage 2 A week consisting of four weeks and eight sessions on the following topics determined within the scope of ERGEP Trainings planned to be held in two sessions will be given once.~1. Developmental periods (oral, anal, phallic, latent, genital)~2. Physical, psychological and social changes experienced in girls and boys during adolescence~3. Being an adolescent parent and healthy communication~4. Risky behaviors in life and sexual matters during adolescence In Stage 3 At the end of the training, measurement tools will be applied again. In Stage 4 Measuring tools will be repeated after 21 days"
41166443|NCT05253079|OTHER|erector spinae plane block|Patients in ESPB group will be turned to the lateral position and receive ESPB at the level of the 7th thoracic (T7) transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T7) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution will be injected below the muscle. the procedure will be repeated on the other side
41166444|NCT05028946|DRUG|Foralumab|Foralumab will be administered per dose and schedule specified in the arm description.
41166445|NCT00256347|DRUG|intramuscular injections of morphine|
41386286|NCT00547209|DRUG|air|60% air combined with 40% oxygen for ventilation
41386287|NCT00547209|DRUG|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
41386288|NCT01278446|OTHER|Extensively hydrolyzed, whey protein infant formula|New hydrolyzed formula
40855442|NCT03411421|DRUG|Placebo|Matching placebo tablets will be administered.
40855443|NCT03576911|DIETARY_SUPPLEMENT|Coenzyme Q10|
41037875|NCT05245669|BIOLOGICAL|EU Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
41166446|NCT02514226|PROCEDURE|supragingival treatment|In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.
41386289|NCT01278446|OTHER|Extensively hydrolyzed, casein protein infant formula|Commercially available hydrolyzed infant formula
41386290|NCT04671303|DRUG|Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
41037876|NCT05245669|BIOLOGICAL|US Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
41386291|NCT05907902|DRUG|Aspirin Enteric-coated Tablets|low-dose aspirin 100 mg once daily (one 100mg tablet).
41386292|NCT03202186|DRUG|Progesterone oral capsule|Oral capsule treatment
41386293|NCT03202186|DRUG|Placebo oral capsule|Oral capsule treatment
40855444|NCT03576911|OTHER|Placebo|
40855445|NCT00243711|DRUG|Carboxymethylcellulose sodium and Glycerin|
40855446|NCT05564039|DRUG|Tirzepatide|Administered SC
41037877|NCT02725632|DEVICE|CPAP|The patients on CPAP treatment will be followed-up for 1 month.
41037878|NCT04935502|OTHER|Home based exercises with postural and ergonomic training|Group A will be treated with stretching and strenghtening exercises for 40 minutes along with postural and ergonomic training for 15 minutes session 3 days/week for 4 week.
41037879|NCT04935502|OTHER|Home based exercises|Group B will be given stretching and strengthening exercises for 40 minutes, every alternate day (3 days per week) for 4 weeks.
41037880|NCT05216094|OTHER|smart phone App|stroke subjects completed tasks-oriented program demoed in the smart phone app with affected upper limb or bilateral arm movement for 12 weeks
41037881|NCT05216094|OTHER|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program with smart phone app ,without task-oriented program demoed function, for 12 weeks
41037882|NCT05956119|DEVICE|dry needling + physiotherapy (standard/usual care)|same that arm descrption
41166447|NCT02514226|PROCEDURE|periodontal treatment|All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.
41386294|NCT00270179|DRUG|epoetin alfa|
40855447|NCT05564039|DRUG|Dulaglutide|Administered SC
40855448|NCT00727792|PROCEDURE|MRI -Clinical|MRI done is standard of care
40855449|NCT00727792|PROCEDURE|MRI-Research|MRI includes extra sequences
40855450|NCT00285402|DRUG|AST-726 Low dose|
40855451|NCT00285402|DRUG|AST-726 High dose|
40855452|NCT00285402|DRUG|AST-726 Placebo|
40855453|NCT01450098|DRUG|LY2484595 Reference Formulation (RF)|Administered orally
40855454|NCT01450098|DRUG|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
40855455|NCT00930930|DRUG|cisplatin|Given IV
40855456|NCT00930930|DRUG|everolimus|Given orally
41037883|NCT05956119|OTHER|sham dry needling + physiotherapy (standard/usual care)|same that arm description
40855457|NCT00930930|DRUG|paclitaxel|Given IV
40855458|NCT00930930|OTHER|placebo|Given orally
40855459|NCT00930930|PROCEDURE|Venous blood draw|Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
40855460|NCT04248023|BEHAVIORAL|Practice Facilitation|A practice facilitator will be assigned the each participating practice to assist with the development of a workflow, screening process, counseling resources, and referral resources for unhealthy alcohol use. Practices in control group will receive delayed intervention at 3 months after their matched cohort of practices.
40855461|NCT02536924|BEHAVIORAL|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
41386295|NCT03705403|DRUG|Darleukin|The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
40855462|NCT02536924|BEHAVIORAL|Treatment as usual.|The patient will receive treatment as usual.
40855463|NCT00001954|DRUG|Etanercept|
40855464|NCT00244101|DRUG|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
40855465|NCT00244101|DEVICE|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
40855466|NCT00244101|DRUG|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
40855467|NCT00003199|DRUG|tamoxifen citrate|Given orally
40855468|NCT00003199|DRUG|busulfan|Given orally
40855469|NCT00003199|DRUG|thiotepa|Given IV
40855470|NCT00003199|DRUG|melphalan|Given IV
40855471|NCT00003199|BIOLOGICAL|aldesleukin|Given SC
40855472|NCT00003199|BIOLOGICAL|sargramostim|Given SC
40855473|NCT00003199|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell infusion
40855474|NCT00003199|RADIATION|radiation therapy|May undergo radiotherapy after completion of IL-2/GM-CSF
40855475|NCT00825903|BEHAVIORAL|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
40855476|NCT02604563|OTHER|Cognitive Assessment|-Baseline and no more frequently than every 6 months until death
40855477|NCT02604563|OTHER|Activities of Daily Living Questionnaire|"* 10 items about daily functional status~* Baseline and no more frequently than every 6 months until death"
40855478|NCT02604563|OTHER|Instrumental Activities of Daily Living, subscale of the OARS|"* 7 items about daily functional status~* Baseline and no more frequently than every 6 months until death"
40855479|NCT02604563|OTHER|Karnofsky Self-reported Performance Rating Scale|"* 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death"
40855480|NCT02604563|OTHER|Number of Falls|"* 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death"
40855481|NCT02604563|OTHER|Physical Health Section, subscale of the OARS|"* 13 items about comorbidity~* Baseline and no more frequently than every 6 months until death"
41037884|NCT02821273|OTHER|Modified INSURE technique|modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
41037885|NCT02821273|OTHER|INSURE technique|INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
41037886|NCT03193164|DEVICE|Neuromuscular Electrical Stimulation|The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.
41037887|NCT03193164|OTHER|Decubitus Position with the limbs raised to 20º|The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
41037888|NCT05308251|PROCEDURE|Lichtenstein Mesh Hernioplasty|The inguinal canal was opened and the hernia sac was dissected from the spermatic cord The deep inguinal ring was tightened with one or two polypropylene 2/0 sutures. The posterior wall of the inguinal canal was supported using the standard polypropylene mesh and fixed with 2/0 polyproline. The ilioinguinal nerve, iliohypogastric nerve, and genital branch of the genitofemoral nerve were preserved and care was taken to prevent entrapment.
41037889|NCT05522803|DEVICE|TMS followed by sham TMS|Transcranial Magnetic Stimulation followed by sham TMS
41037890|NCT05522803|DEVICE|Sham TMS followed by TMS|Sham Transcranial Magnetic Stimulation followed by TMS
41386296|NCT03705403|RADIATION|Radiation|Radiotherapy
41386297|NCT05117866|DRUG|prasugrel Monotherapy|Prasugrel Monotherapy according to the local dosage (Loading : 20mg, maintenance: 3.75mg/day)
41386298|NCT04793828|BEHAVIORAL|Velibra|Velibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content.
41166448|NCT02514226|PROCEDURE|periodontal treatment and photodynamic therapy|In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets \> 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.
41386299|NCT01068795|DRUG|enoxaparin|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
41386300|NCT02735226|OTHER|stroke network and policy intervention|Shanghai stroke service and network contributes to update the ability of stroke care of comprehensive and primary stroke center,to improve radiation ability of comprehensive stroke centers and try to form a close relationship between comprehensive stroke centers and its primary stroke centers.
41386301|NCT01125007|DEVICE|Two kind toothbrushes|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
41386302|NCT06361316|DRUG|Irinotecan liposome injection|Postoperative adjuvant therapy
41166449|NCT02514226|OTHER|dental hygiene orientation|Plaque Control through the use of toothbrush and floss
41166450|NCT03936764|OTHER|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~* Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~* Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~* Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~* Education to bronchial drainage techniques as well as directed coughing."
41386303|NCT05174078|OTHER|Medically-tailored meals|Medically tailored meals delivered to patients' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
41386304|NCT05174078|OTHER|Produce box and recipes|Weekly produce box and access to recipes via internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
41166451|NCT06492720|DEVICE|Focused ultrasound (FUS) treatment|The mechanism of action of FUS neuromodulation involves the activation of voltage-gated ion channels to induce temporary neuromodulation.
41386305|NCT02287142|PROCEDURE|Brachial plexus nerve block|All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
41386306|NCT05692596|OTHER|Data collection|Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.
41386307|NCT02613416|DRUG|Denosumab|monthly subcutaneous injections
41386308|NCT04067856|DRUG|Bevacizumab Injection|Intravitreal injection
41166452|NCT05036525|DEVICE|HANBIO BarriGel|an anti-adhesive product
41386309|NCT00877214|DRUG|Rituximab|Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
41386310|NCT00877214|DRUG|Rituximab / observation|Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
41510519|NCT05738278|BEHAVIORAL|Delayed HR-informed specific change in routine|"The intervention is given for a situation occuring at least twenty times and accompanied by an increase in HR at least 80% of the time, during the four-week registration period. Change in care (intervention) is introduced from week 5.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure."
41386311|NCT02308865|OTHER|multi disciplinary palliative care monthly consultations|multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
41386312|NCT05681780|BIOLOGICAL|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
41386313|NCT05681780|DRUG|Nivolumab|Nivolumab (Opdivo®), 360 mg, IV infusion every 3 weeks prior to TIL infusion, and then after TIL infusion 480 mg ever 4 weeks for up to 12 months.
41386314|NCT05681780|DRUG|Cyclophosphamide|Cyclophosphamide will be administered on days -7 and -6.
41386315|NCT05681780|DRUG|Fludarabine|Fludarabine will then be infused per institutional standard on Days -7 to -3.
41386316|NCT05681780|OTHER|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive a dose infusion TIL cells.
41386317|NCT05681780|DRUG|Interleukin-2 (IL2)|Participants will receive IL-2 for up to 6 doses, based on participants tolerance and investigator judgement. This will be given after the infusion of the T-cells.
41386318|NCT05405478|DRUG|Omalizumab|subcutaneous injection every 2 or 4 weeks, depending on the pretreatment serum total IgE level and body weight
41386319|NCT05405478|DIAGNOSTIC_TEST|SNOT22 score|score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24 (point range, 0-110)
41386320|NCT05052879|DRUG|Toronto association|Toronto association coated tablet, 20 mg + 30 mg or 20 mg + 60 mg, oral, 2 hours before the sexual intercourse.
41510520|NCT03335137|DIAGNOSTIC_TEST|Drug Level Monitoring|Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission
41510521|NCT05149560|DRUG|Ticagrelor 90mg|All patients will be prescribed ticagrelor as monotherapy
40855482|NCT02604563|OTHER|MOS Social Activity Survey|"* 4 items about social activity~* Baseline and no more frequently than every 6 months until death"
41510522|NCT01553955|PROCEDURE|Venipuncture|Blood draw for purposes of training in platelet rich plasma concentration. Trainees will be in pairs and each will draw blood from the other for use in the concentration process.
41510523|NCT03742505|DRUG|Cholecalciferol|Single enteral cholecalciferol load at a dose of 10,000 IU/kg (maximum 400,000 IU)
41510524|NCT03742505|OTHER|Placebo|Single enteral placebo dose equivalent in volume to the appropriate weight-based dose of cholecalciferol
41510525|NCT00386984|DRUG|Somatostatin (octreotide)|
41510526|NCT02688738|DRUG|Doxycycline|
41510527|NCT05760248|DRUG|10XB-101 Solution for Injection, 6.0%|The active drug (adipolytic) given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
40855483|NCT02604563|OTHER|Unintentional Weight Loss|"* 2 items about nutrition~* Baseline and no more frequently than every 6 months until death"
40855484|NCT02604563|GENETIC|Peripheral Blood Draw|-Baseline and no more frequently than every 6 months until death
41386321|NCT05052879|DRUG|Tadalafil|Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.
41386322|NCT05052879|OTHER|Tadalafil placebo|Tadalafil placebo coated tablet, oral, 2 hours before the sexual intercourse.
41386323|NCT05052879|OTHER|Toronto association placebo|Toronto association placebo coated tablet, oral, 2 hours before the sexual intercourse.
41386324|NCT02428959|DRUG|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
41386325|NCT06566248|DRUG|TQA3810 tablets+NUC|TQA3810 is a novel, effective and highly selective small-molecule oral Toll-like receptors-8 agonist.
41386326|NCT06566248|DRUG|Placebo+NUC|"NUC:~Entecavir Dispersible Tablets, Inhibit viral replication; Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors; Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication."
41386327|NCT06540924|OTHER|single nucleotide polymorphisms|The LBX1 (Ladybird Homeobox 1), TIMP2 (Tissue Inhibitor of Metalloprotease 2), GPR126 (G Protein-Coupled Receptor 126) and CHD7 (Chromodomain Helicase DNA Binding Protein 7) gene polymorphisms in adolescent idiopathic scoliosis patients and the control group were analyzed using real-time PCR with TaqMan probe SNP (single nucleotide polymorphism) primers (rs625039, rs11598564, rs6570507, rs121434341, rs11190870, rs8179090).
41386328|NCT00005009|BIOLOGICAL|Varivax®|Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
41386329|NCT01807910|DRUG|methyl-D9-choline|Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
40855485|NCT02604563|GENETIC|Buccal Swab|"* Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~* Baseline and no more frequently than every 6 months until death"
40855486|NCT02604563|OTHER|Heart Health and Smoking History from BRFSS questionnaire|"* 7 items about heart health and smoking history~* Baseline and no more frequently than every 6 months until death"
41510528|NCT05760248|DRUG|Placebo Solution for Injection (no active ingredient)|Placebo given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
41510529|NCT03810040|DEVICE|140 microns denuding pipette|the degranulated needle size was 140 microns
40855487|NCT02604563|OTHER|Gait Speed|"* Research coordinator will test gait speed~* Baseline and no more frequently than every 6 months until death"
41510530|NCT03810040|DEVICE|150 microns denuding pipette|the degranulated needle size was 150 microns
40855488|NCT02604563|OTHER|Grip Strength|"* Research coordinator will test grip strength~* Baseline and no more frequently than every 6 months until death"
40855489|NCT02604563|OTHER|Height and Weight measurements|-Baseline and no more frequently than every 6 months until death
40855490|NCT02604563|OTHER|Blood pressure measurement|-Baseline and no more frequently than every 6 months until death
40855491|NCT02604563|PROCEDURE|Optional bone marrow biopsy|-1 optional bone marrow biopsy
40855492|NCT02604563|PROCEDURE|Blood draw for trauma measurements|-For Arm E only
40855493|NCT04908358|OTHER|Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Stimulation of vagus nerve in the outer ear
40855494|NCT04908358|OTHER|Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Sham stimulation of vagus nerve in the outer ear
41166453|NCT00746356|DEVICE|Testing of the autocapture features of the device|Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.
41510531|NCT01689883|DEVICE|Current stimulator|This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
41510532|NCT03435510|BEHAVIORAL|Live Donor Champion Program|Even with adequate education of live donation, many KT candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide substantial instrumental support. An LDC is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed a 6-month program that provides education and advocacy training to waitlist candidates and their LDCs. The instrumental support provided by the LDC bridges a critical link between education and action.Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
41510533|NCT00580450|DRUG|Thymosin alpha 1|1.6 mg sc once a day for 16 weeks
41510534|NCT03249532|DEVICE|standard hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
41510535|NCT03249532|DEVICE|cool hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
41510536|NCT03249532|DEVICE|low volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
41386330|NCT06359756|PROCEDURE|Ischemic postconditioning in carotid surgery|After the initial declamping of the carotid artery the procedure is performed with 6 cycles of reperfusion of 30 seconds each (clamping of the internal carotid artery) which are successively followed by 6 cycles of ischemia lasting 30 seconds (clamping of the internal carotid artery). Clamping is done on the unaltered ICA, at the clamping site prior to performing CEA above the plaque termination point.
41386331|NCT06359756|PROCEDURE|Eversion Carotid Endarterectomy|Standard Eversion Carotid Endarterectomy
41510537|NCT03249532|DEVICE|high volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
41510538|NCT05717660|COMBINATION_PRODUCT|SBRT on all sites of metastatic disease+Apalutamide|oral Apalutamide 240 mg daily+ stereotactic body radiotherapy on all metastatic sites of disease, administered in 1-8 fractions for a total EQD2 of 50 Gy with an alpha/beta of 10.
40855495|NCT06246513|BIOLOGICAL|SRP-9003|Solution for single IV infusion
40855496|NCT06246513|DRUG|Glucocorticoid|Oral tablet (prophylactic)
40855497|NCT06321770|DIETARY_SUPPLEMENT|Bioactive collagen peptides|2,5 g collagen peptides
40855498|NCT06321770|DIETARY_SUPPLEMENT|Placebo|Placebo sachet daily
40855499|NCT01055314|BIOLOGICAL|Cixutumumab|Given IV
40855500|NCT01055314|DRUG|Cyclophosphamide|Given IV
40855501|NCT01055314|BIOLOGICAL|Dactinomycin|Given IV
40855502|NCT01055314|DRUG|Doxorubicin Hydrochloride|Given IV
40855503|NCT01055314|DRUG|Etoposide|Given IV
40855504|NCT01055314|DRUG|Ifosfamide|Given IV
40855505|NCT01055314|DRUG|Irinotecan Hydrochloride|Given IV
40855506|NCT01055314|OTHER|Laboratory Biomarker Analysis|Correlative studies
40855507|NCT01055314|DRUG|Temozolomide|Given PO
40855508|NCT01055314|DRUG|Vincristine Sulfate Liposome|Given IV
40855509|NCT02608463|BEHAVIORAL|painDETECT Questionnaire|This self-report questionnaire consists of 7 questions that address the quality of neuropathic pain syndromes. The first 5 questions ask about the gradation of pain, question 6 asks about the pain course pattern and question 7 asks about radiating pain. There are 4 additional questions (not counted in the total score) which asks the subject to rate their pain now and over the last 4 weeks and to mark on a body chart if there is pain radiating into other parts of the body.
41166454|NCT00746356|DEVICE|Testing of the autocapture features of the device|Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
41386332|NCT06567314|DRUG|Ivonescimab|Given by PO
40855510|NCT02608463|BEHAVIORAL|Pain Catastrophizing Scale|The PCS is a 13-item self-report scale. It asks subjects to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification, and helplessness.
41386333|NCT06060314|PROCEDURE|Conservative Approach|Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred
40855511|NCT02608463|BEHAVIORAL|Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale|"The 3-item, self-report Pain Intensity assesses how much a person hurts. The first 2 items assess pain intensity over the past 7 days; the last item asks subject to rate pain intensity right now. The 4-item, self-report Pain Interference measures the consequences of pain on relevant aspects of subject's life. It includes impairment in subject's social, cognitive, emotional, physical, \& recreational activities. It also incorporates items about sleep and enjoyment of life. It assesses pain interference over the past 7 days.~The 7-item, self-report Pain Behavior measures behaviors that typically indicate to others that an individual is experiencing pain. Measures include observations (sighing, crying), behaviors (resting, guarding, facial expressions, asking for help), \& verbal reports of pain. It assesses pain interference over the past 7 days.~All three scales, derived from the Patient Reported Outcomes Measurement Information System (PROMIS), are not disease specific."
40855512|NCT02608463|BEHAVIORAL|Beck Depression Inventory|The BDI is a widely used instrument that has been used in both clinical and non-clinical setting measuring depressive symptoms. It is a 21 item questionnaire with 4-5 responses for each question. Responses are coded 0-3 for the 4 point scales. The 5 point scales include an additional 2a and 2b response code. The symptom categories reflect overt behavioral manifestations of depression. The instrument has both a high degree of reliability and validity (Beck, Ward, Mendelson, Mock \& Erbaugh, 1961).
40855513|NCT02608463|BEHAVIORAL|Visual Analogue Scale|100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
40855514|NCT02608463|BEHAVIORAL|Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale|"The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD."
40855515|NCT02608463|DEVICE|Transcranial Magnetic Stimulation|Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
40855516|NCT05916469|DRUG|Levonorgestrel Intrauterine System|52 mg levonorgestrel intrauterine system
41386334|NCT06060314|PROCEDURE|Surgical Approach|Patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR)
41386335|NCT05066347|DEVICE|Cardiophone Plus|Cardiophone Plus (Bittium Faros 360 Mobile event recorder, Bittium Biosignals Ltd., Finland., an external loop recorder with 3 leads for 2 channels. Cardiophone Plus evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station without the need for any patient intervention (device-triggered transmission). This transmission occurs through the cell phone that comes with the device. The central monitoring station is in Windsor, Ontario (Canadian Cardiac Care) and is staffed round the clock by certified electrocardiographic technicians and a cardiologist on-call.
41386336|NCT06414265|DEVICE|Transcatheter mitral valve replacement|The SATURN TS TMVR System will be implanted through a transcatheter approach in patients with symptomatic mitral regurgitation.
41386337|NCT04352907|DEVICE|Continuous Glucose Sensor|Continuous glucose sensor results will be compared with arterial glucose samples
41510539|NCT03774407|DRUG|vaginal estriol|Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.
41510540|NCT00079950|DRUG|Pegamotecan|
41510541|NCT01019434|DRUG|temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
41510542|NCT01019434|DRUG|temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
41510543|NCT02376400|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29 or 57.
40855517|NCT05916469|DRUG|Norethindrone Acetate|norethindrone acetate 5 mg daily
40855518|NCT03703089|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
40855519|NCT03703089|DRUG|nab-paclitaxel|Administered by intravenous infusion over 30-40 minutes.
40855520|NCT03818451|DIETARY_SUPPLEMENT|Co-ultraPEALut (Glialia)|Co-ultraPEALut is administered to moderate traumatic brain injured patients for 180 days
40855521|NCT01294969|DRUG|AL-4943A|Once daily topical ocular allergy medication used for 7 days
40855522|NCT03944512|DRUG|Pravastatin|20 mg Pravastatin taken daily
40855523|NCT03944512|OTHER|Placebo|Identical appearing placebo pill
40855524|NCT04043039|PROCEDURE|Palatal wound bandage with PRF|palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
41510544|NCT02376400|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29 or 57.
41510545|NCT02376400|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
41510546|NCT05718934|DRUG|Neostigmine and glycopyrrolate|See arm descriptions
41386338|NCT05323409|BEHAVIORAL|OPTIMISE|OPTIMISE is a multilevel intervention that seeks to improve patient activation for comorbidity self-management during cancer treatment and coordination of care between oncologists and primary care physicians from point of diagnosis through the first year of post-treatment survivorship.
41510547|NCT05718934|DRUG|Sugammadex|See arm descriptions
41386339|NCT00792818|DRUG|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
41386340|NCT00792818|DRUG|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
41386341|NCT05764200|DIETARY_SUPPLEMENT|Two day supplementation of a complex fiber mixture|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
41510548|NCT03438019|DEVICE|PrO2|The PrO2 device is linked to a tablet via Bluetooth and provides the user with a graphic representation of their inspiratory effort throughout all of inspiration and real-time biofeedback. This device incorporates a standard 2mm leak to avoid glottal closure during maximal inspiration. The PrO2 provides measures of MIP (cmH2O), SMIP (PTU) and ID (seconds).
40855525|NCT04043039|PROCEDURE|Palatal wound bandage with Gelatine Sponge|palatal wound will be protected by gelatine sponge
40855526|NCT00932581|OTHER|Bradykinesia UPDRS Motor Full Examination|The first group will receive the full motor examination section in its original order.
40855527|NCT00932581|OTHER|Bradykinesia subscale of UPDRS Motor Examination|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
41386342|NCT05764200|DIETARY_SUPPLEMENT|Placebo supplementation|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
40855528|NCT04983420|OTHER|non-alcoholic Pilsner|intake of 1 L non-alcoholic Pilsner per day for 2 weeks
40855529|NCT04983420|OTHER|non-alcoholic wheat beer|intake of 1 L non-alcoholic wheat beer per day for 2 weeks
40855530|NCT04983420|OTHER|apple spritzer|intake of 1 L apple spritzer per day for 2 weeks
40855531|NCT04983420|OTHER|lemonade|intake of 1 L lemonade per day for 2 weeks
41386343|NCT02922439|BEHAVIORAL|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
41386344|NCT02922439|BEHAVIORAL|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
41386345|NCT01929837|DEVICE|E-fied navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
41386346|NCT01929837|DEVICE|non-navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
41386347|NCT01929837|DEVICE|sham E-field navigated rTMS|
41386348|NCT01929837|DEVICE|Navigated rTMS|1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
41386349|NCT02122744|DEVICE|Super Rapid Magstim Stimulator|"The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.~The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil."
41386350|NCT02122744|DEVICE|Super Rapid Magstim Stimulator (sham)|coil perpendicular to the scalp
41386351|NCT00002373|DRUG|Maribavir|
41386352|NCT03025659|OTHER|Pyruvate levels|An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
41386353|NCT05645055|OTHER|treat these patients with biologics|treat these patients with biologics
41510549|NCT03438019|DEVICE|Threshold Inspiratory Muscle Trainer|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
41510550|NCT05005052|DRUG|Vessel|Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.
41510551|NCT05005052|DRUG|Placebo|Placebo and no compression or venopharmaceutical regimen
41510552|NCT05242718|DIETARY_SUPPLEMENT|N-Acetyl-L-cysteine (NAC)|Health Canada Natural Product Number (NPN) 80056946
41510553|NCT05242718|DIETARY_SUPPLEMENT|Echinacea purpurea|Health Canada Natural Product Number (NPN) 80093896
41510554|NCT05242718|DIETARY_SUPPLEMENT|Curcumin|Health Canada Natural Product Number (NPN) 80043455
41386354|NCT00203957|DRUG|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
41386355|NCT00203957|DRUG|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
40855532|NCT00549445|DRUG|Azithromycin|250 mg daily
40855533|NCT00549445|DRUG|Placebo|Daily
41386356|NCT02578043|DRUG|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
40855534|NCT05856019|OTHER|J Stroke Myofascial Release|Group A will receive J stroke myofascial release on planter fascia (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
40855535|NCT05856019|OTHER|Ischemic Release on Gastrocnemius through Dry Cupping|Group B will ischemic release on gastrocnemius (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
40855536|NCT05793242|DEVICE|Hypervolt|HyperVolt Percussive Massage Device: this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a vibrating device to the back of the thigh with moderate pressure while continuously moving the device for 5 minutes.
40855537|NCT05793242|DEVICE|Body Tempering|Body Tempering:this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a moderately heavy metal device to the back of the thigh while continuously moving the device for 5 minutes.
40855538|NCT05793242|DEVICE|Dry cupping|Dry Cupping: This will be performed by a physical therapist while the participant is prone. The physical therapist will apply several negative pressure devices to the back of your thigh for 5 minutes.
40855539|NCT05793242|OTHER|Static stretching|Participants will perform a static stretch on their lower extremity. This stretch will be performed by having the participant loop a strap around their heel and grasping it with both hands followed by pulling the strap to raise the fully extended leg into hip flexion. The participant will be instructed to lift the leg until they reach their maximal tolerable point and then to hold the position for 30 seconds. They will then lower the extremity to the table and rest for 15 seconds This self-stretch sequence will be performed for 7 cycles so that the total intervention was equal to the intervention time of the other group (5 minutes).7
40855540|NCT00305149|PROCEDURE|interim therapy scintigraphy study gallium scan or PET/CT|
41037891|NCT03046212|DEVICE|Transcutaneous electrical nerve stimulation|TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
41386357|NCT02578043|DRUG|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
41386358|NCT02578043|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
41386359|NCT02060227|PROCEDURE|Open Latarjet procedure|
41510555|NCT05242718|DIETARY_SUPPLEMENT|Palmitoylethanolamide|Health Canada Natural Product Number (NPN) 80097472
41510556|NCT02587078|DRUG|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
40855541|NCT00305149|PROCEDURE|"interim gallium or PET/CT"|
40855542|NCT03626285|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
40855543|NCT03626285|DEVICE|CliniMACS CD34 Reagent System|CD34 selection ex vivo
40855544|NCT03626285|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Receive CD34-selected peripheral blood stem cells from related or unrelated donors
40855545|NCT03374033|DIETARY_SUPPLEMENT|NUTR +|one extra g/kg/d of protein and lipids starting before 48 hours after birth until 36 weeks postmenstrual age
40855546|NCT03374033|BEHAVIORAL|STIMUL +|Physical activity stimulation consists in flexion/extension of the 4 limbs and other motion exercises of the shoulder girdle and of the hips. This stimulation will take place before the feed for a mean of 30 times a week (minimum 24- maximum 36 times a week, 10 minutes each time) and will start within the 10th day of life until 36 weeks postmenstrual age
41037892|NCT03046212|OTHER|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
41037893|NCT04070924|OTHER|Bandaid|Bandaid dressing
41037894|NCT04070924|OTHER|Conventional bulky soft tissue dressing|Conventional bulky soft tissue dressing
41386360|NCT02060227|PROCEDURE|Arthroscopic Bankart repair|
41386361|NCT00960310|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
41386362|NCT00960310|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
41386363|NCT04373057|DIETARY_SUPPLEMENT|Galacto-oligosaccharide|GOS will be administered at determined dose levels per protocol once daily from about 30 days before transplant to about 4 weeks after transplant.
41386364|NCT04373057|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be administered at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
41386365|NCT05384327|OTHER|Interview|Interviews consist of semi-structured interviews focused on the theoretical knowledge a physician should possess before placing chest tube insertions.
41386366|NCT05384327|OTHER|Multiple Choice Question (MCQ) Test|"The test contains multiple choice questions based on these interviews. Participants will complete this test.~Validity evidence will be collected based on the results of this test."
41386367|NCT00185731|DRUG|Atorvastatin|80 mg orally once daily
41510557|NCT02587078|DRUG|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
41386368|NCT01937546|PROCEDURE|Primary delivery of anterior shoulder|
41386369|NCT01937546|PROCEDURE|Primary delivery posterior shoulder|
41386370|NCT03546699|DIAGNOSTIC_TEST|Estimation of hospital-wide incidence of ARDS|"Estimation of hospital-wide incidence of ARDS defined according to both the Berlin definition and the Kigali modification.~* To describe clinical characteristics and outcomes for these patients.~* To analyze the prognosis and time course of patients who initially meet criteria for Kigali-defined ARDS and subsequently progress to Berlin-defined ARDS.~For the subset of patients who have chest CT, to determine the sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans."
41510558|NCT00085384|BIOLOGICAL|PEG-interferon alfa-2b|Starting dose 1.0 mg/kg/week given subcutaneously
41510559|NCT00085384|DRUG|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.25 mg/kg/week given subcutaneously"
41510560|NCT00085384|BIOLOGICAL|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.5 mg/kg/week given subcutaneously~EG-Intron"
40855547|NCT04277065|PROCEDURE|BULLDOG ,A Useful Vascular Occlusion Tourniquet In Laparoscopic Liver Resection|Bulldog is an effectively performed approach for vascular occlusion during laparoscopic hepatectomy than traditional Pringle manuever.
40855548|NCT04277065|PROCEDURE|cotton tourniquet|cotton tourniquet
40855549|NCT04521244|OTHER|Thrust joint lumbar manipulation|Moist Hot pack of 14/15' over lumbar region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Bilateral Thrust Manipulation of Lumbar Spine from L1-L5 Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometer for lumbar flexion, extension and goniometer for lumbar side bending.These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
40855550|NCT04521244|OTHER|Lumbar mobilization|Moist Hot pack of 14/15' from L1 where ribcage ends up to the region of gluteal folds for 15 mins. Non Thrust Manipulation for 30 seconds Using Kaltenborn grade 3 (Stretch rotation mobilization).Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometerfor lumbar flexion, extension and goniometer for lumbar side bending. These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
40855551|NCT00189605|DEVICE|Perc-DLR/Perc-DLG|Device technique will be used per IFU
41510561|NCT05298826|DRUG|recombinant factor VIIa|using recombinant factor VIIa
41510562|NCT02367976|DRUG|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
41510563|NCT00315289|PROCEDURE|Nasolacrimal balloon catheter duct dilation|
41510564|NCT00315289|PROCEDURE|Nasolacrimal intubation|
41510565|NCT00315289|PROCEDURE|Simple Nasolacrimal duct probing|
41510566|NCT01689051|OTHER|human glucagon-like peptide 1 (7-36)amide|
41510567|NCT01689051|OTHER|human glucagon-like peptide 1 (9-36)amide|
41510568|NCT00629018|BIOLOGICAL|CD34+ autologous stem cell transplantation|Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
40855552|NCT00189605|DRUG|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)|Injection of steroid solution into the lumbar level
40855553|NCT03023293|OTHER|n-3 PUFAs consumption and irisin|The investigators plan to collect n-3 PUFAs and irisin information at 24-28 weeks' gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum
40855554|NCT05824169|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
40855555|NCT03707470|DEVICE|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and \>20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
40855556|NCT03707470|DEVICE|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 10 mmHg at both the ankle and thigh)
41386371|NCT04292756|PROCEDURE|Subtenon injection of 40 mg triamcinolone acetonide|Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.
41386372|NCT04292756|PROCEDURE|Intravitreal injection of 4 mg triamcinolone acetonide|Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.
41386373|NCT04292756|DIAGNOSTIC_TEST|Visometry|Ophthalmic examination
41386374|NCT04292756|DIAGNOSTIC_TEST|Fluorescent angiography|Ophthalmic examination
41386375|NCT04292756|DIAGNOSTIC_TEST|Refractometry|Ophthalmic examination
41386376|NCT04292756|DIAGNOSTIC_TEST|Slit lamp examination|Ophthalmic examination
41386377|NCT04292756|DIAGNOSTIC_TEST|Ophthalmoscopy|Ophthalmic examination
41386378|NCT04292756|DIAGNOSTIC_TEST|OKT|Ophthalmic examination
41386379|NCT04292756|DIAGNOSTIC_TEST|IOP|Ophthalmic examination
41386380|NCT00534521|DEVICE|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
41386381|NCT00534521|DEVICE|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
41386382|NCT06440486|DIETARY_SUPPLEMENT|Probiotics|Serum and fecal samples were collected at the beginning and end of the study to evaluate the effects of probiotic consumption on immune markers, metabolites, and gut microbiota before and after administration.
41386383|NCT01141049|DRUG|Gabapentin|During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
41386384|NCT01141049|OTHER|Placebo|Placebo, TID
41386385|NCT04926467|DRUG|Anakinra|"Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4.~Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8."
41386386|NCT06317870|PROCEDURE|Intrathecal morphine|"Spinal anesthesia will be performed as follows: patient will be placed in the lateral decubitus position on the non-operative side. Using sterile gloves red chlorhexidine 2% alcohol solution will be used for skin disinfection. The site will be secured with a sterile drape, and the L4-L5 lumbar space identified. After subcutaneous local infiltration with 1% lidocaine, a 25G Whitacre pencil point spinal needle will be used to access the intrathecal space with free flow of cerebrospinal fluid as confirmation. A mixture of 12.5 mg of isobaric bupivacaine and 100 mcg of morphine will be administered intrathecally.~After the spinal anesthesia, the intrathecal morphine (ITM) group will receive a sham PENG block with the block needle inserted subcutaneously, the anesthesiologist using the same verbal block confirmation commands aspirate, inject but the needle withdrawn without injection. This will create the appearance of an identical cutaneous injection site to ensure patient blinding."
41386387|NCT06317870|PROCEDURE|Pericapsular nerve group block (PENG)|"Spinal anesthesia with intrathecal injection of 12.5 mg of isobaric bupivacaine will be performed, followed by a PENG block.~After skin disinfection, a low frequency curvilinear ultrasound probe (2-5 MHz 8870, BK ultrasound, Peabody Massachussets, US) with a sterile covering will be used to identify the anterior inferior iliac spine, the pubic eminence and the psoas tendon with its fascial plane. A 22 gauge 10cm block needle (Sonoplex® Pajunk, Geisingen, DE), will be used to enter the fascial plane and 20ml of 0.75% Ropivacain (Fresenius Kabi, Krienz CH) will be injected."
41510569|NCT00629018|DRUG|Bone Marrow Stimulation|Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
41510570|NCT00629018|BIOLOGICAL|SC therapy|In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
41510571|NCT01150812|DRUG|AZD8165|Oral suspension, 2 mg/mL and 20 mg/mL, single doses
41510572|NCT02557763|DEVICE|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
41510573|NCT02234102|DEVICE|Endoscopically guided laser ablation HeartLight system|
41510574|NCT02620579|DRUG|Propranolol LA (60 mg)|Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
41510575|NCT02620579|DRUG|Placebo|Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
40855557|NCT03707470|PROCEDURE|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
40855558|NCT03318016|DRUG|Cyclophosphamide 500 MG|ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 500 mg/m2 on day 4 as a single IV dose along with hydration for a maximum of 6 doses
40855559|NCT03318016|DRUG|Cyclophosphamide 1000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 1000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
41386388|NCT04978194|OTHER|University-based intervention to promote better management of emotions and learning|It included 9 video capsules (that take place over 9 weeks), with the following themes: stress information, learning information, emotion and stress regulation strategies, cognitive and metacognitive learning strategies, motivation for learning, physical activity, diet, sleep, and managing worry and uncertainty. It is based on previous online student mental health intervention studies. It presents two innovative aspects: elements and examples specific to the COVID-19 pandemic and the addition of modules focused on learning strategies. The different modules were designed by 5 associate professors, 2 Master students in clinical psychology and 2 undergraduate students in psychology. For the control group, the videos will be posted every week on a You Tube channel and broadcast on a private discord group. For the hybrid group, student will have to attend 10 lessons of 2 hours. These courses include the viewing of videos and a time for discussion between students and the teacher.
41386389|NCT06307678|DRUG|Calcium Hydroxide|"The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium hydroxide based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length.~At the second appointment, medicamentswere removed, and second samplingwas performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated."
41386390|NCT06307678|DRUG|Calcium Silicate|"The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium silicate based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length. At the second appointment, medicaments were removed, and second sampling was performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated."
41386391|NCT04779242|DRUG|Omadacycline|IV for injection, oral tablets
41386392|NCT04779242|DRUG|Moxifloxacin|IV solution, oral tablets
41386393|NCT06567080|BIOLOGICAL|JWCAR201|JWCAR201 is a autologous CAR-T targeting CD19/CD20
41386394|NCT06568419|BEHAVIORAL|Transdiagnostic, work-focused Cognitive Behavioural Therapy|Transdiagnostic, work-focused Cognitive Behavioural Therapy focuses on core mechanisms that creates and maintain illness in depression and anxiety. Namely reducing avoidance and/or suppression of unwanted thoughts, avoidance of meaningful activity and increase cognitive flexibility while under psychological stress.
41386395|NCT05393882|RADIATION|Computed tomography coronary angiogram|"Preparation~* Rate control with oral beta-blockers or calcium channel blockers to achieve the target heart rate of 60 to 70 beats per minute~* Sublingual Nitroglycerin to be given on table if not contraindicated, 5 minutes prior to scanning~* 18G angiocath at a large antecubital vein for intravenous contrast injection~Scanning procedure Contrast CT angiogram (Retrospective gating)~* Contrast medium and injection protocol: 75ml Omnipaque 350 with 50ml saline chaser~* Automatic triggering started at the aorta of the level of left main coronary artery when the relative reached 100~* Scanning coverage: From the thoracic inlet to diaphragm"
41386396|NCT05255354|DEVICE|ClonoSEQ|Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.
41386397|NCT00589693|DRUG|Doripenem|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
41386398|NCT00589693|DRUG|Imipenem-Cilastatin|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
41386399|NCT00589693|DRUG|Placebo|Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
41386400|NCT01508923|DRUG|liraglutide|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
41386401|NCT01508923|DRUG|placebo|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
41528342|NCT05697497|BEHAVIORAL|Daily exercise intervention|Participants will complete four exercises each day, The first two weeks they will be instructed to complete as many repetitions as possible, each day, for 15 seconds and progressing to 30 seconds per exercise after the first two weeks. Participants are asked to increase their goal repetitions by 1 or 2 from their previous best each week. For all exercises with modifications, we will encourage participants to move to the next most difficult modification once they can do 15 repetitions of that exercise.
41037895|NCT05230238|DEVICE|Pituitary gland stimulation|Pituitary gland stimulation via an surface electrode connected to an external neurostimulator
41037896|NCT04085328|DEVICE|LID015385 soft contact lenses|Investigational silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
40855560|NCT03318016|DRUG|Cyclophosphamide 2000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 2000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
40855561|NCT03318016|DRUG|Cyclophosphamide 3000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 3000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
40855562|NCT03318016|DRUG|Cyclophosphamide 4000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 4000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
40855563|NCT03956966|DRUG|TQL block with saline|"drug: saline 21 ml 0.9% normal saline administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac analgesia In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block, ultrasound-guided"
40855564|NCT03956966|DRUG|TQL block with Bupivacaine|"Drug: saline~1mL 0.9% normal saline administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol 15 mg.kg will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
40855565|NCT03956966|DRUG|TQL block with Bupivacaine and dexamethasone|"Drug: dexamethasone~1 mL dexamethasone 4mg administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in MBP or HR of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
40855566|NCT05087875|BEHAVIORAL|TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. Participants set goals for reducing their drinking and learn strategies to help them achieve those goals. It requires four 30-minute sessions with a counselor using mobile phones.
40855567|NCT05087875|OTHER|No intervention|The comparison group will be evaluated based on daily self-monitoring data.
40855568|NCT01451385|DRUG|COV795|COV795 is a multilayer extended-release tablet for oral administration of oxycodone hydrochloride (15 mg) and acetaminophen (650 mg)
41037897|NCT04085328|DEVICE|Comfilcon A soft contact lenses|Silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
41037898|NCT04822220|OTHER|Fatigue Self-management Programme|Fatigue Self-management Programme
41386402|NCT04982718|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|"Self-testing will be performed using the OraQuick® HCV Self-Test manufactured by OraSure Technologies Inc., USA. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the OraQuick® HCV Rapid Antibody Test is prequalified by WHO and CE marked for professional use (sensitivity 98.1%, specificity 99.6%).~As it is not approved for self-test use in Malaysia, the OraQuick® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
41386403|NCT04982718|DIAGNOSTIC_TEST|First Response® HCV Self-Test|"Self-testing will be performed using the First Response® HCV Card Test (Self Test) manufactured by Premier Medical Corporation, India. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the First Response® HCV Card Test is CE-marked and currently under WHO review for professional use (sensitivity 100%, specificity 100%).~As it is not approved for self-test use in Malaysia, the First Response® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
41386404|NCT05614765|DRUG|Statin+Ezetimibe compound|Crezet Tablet, Litorvazet Tablet
41386405|NCT03528967|DRUG|Enoxaparin 40 mg / 0.4 mL Prefilled Syringe|
41386406|NCT03528967|DRUG|Aspirin 100 mg Oral Tablet, Enteric Coated|
41166455|NCT03480295|DEVICE|Hyaluronic acid 0.4% and Taurine 0.5%|4 drops /day in addition to the ongoing glaucoma treatment
41166456|NCT03480295|DEVICE|Hyaluronic acid 0.2%|4 drops /day in addition to the ongoing glaucoma treatment
41386407|NCT06567470|DRUG|CIT-013 low dose|Subcutaneous injection
41386408|NCT06567470|DRUG|CIT-013 high dose|Subcutaneous injection
41386409|NCT06567470|DRUG|Placebo|Subcutaneous injection
41386410|NCT06463756|OTHER|AI|"Radiomics extracts quantitative information from medical images to generate high-dimensional feature vectors for analysis. It aims to provide insights into disease processes and improve diagnosis.~Deep learning utilizes neural networks with multiple layers to learn complex patterns from data. In medical imaging, it enables accurate and efficient analysis for disease detection and diagnosis."
41386411|NCT03127943|DRUG|Lidocaine|Efficacy for mandibular molar and canine anesthesia
41528343|NCT02965573|BIOLOGICAL|ARGX-113|
41528344|NCT02965573|DRUG|Placebo|
41528345|NCT03743415|BEHAVIORAL|Handbook|see arm/group descriptions
41528346|NCT03743415|BEHAVIORAL|TIP-C plus Handbook|see arm/group descriptions
41386412|NCT06558630|PROCEDURE|Endotracheal intubation|Over the course of several years as many as possible ED centres in the Netherlands will be included in the collection of all data involving airway management. Airway management is defined as the process of planning, preparation and execution of endotracheal intubation.
41386413|NCT06536725|OTHER|Building Organoid-on-chips models|This project obtains surgical or biopsy samples from prostate cancer patients with visceral metastasis for the construction of organoids.
41386414|NCT05388201|OTHER|N95|3M N95 Respirator
41386415|NCT05388201|OTHER|KN95|KN95 Mask (with and without clip)
41386416|NCT05388201|OTHER|KF94|KF94 Mask (with and without clip)
41386417|NCT05388201|OTHER|Surgical|Surgical Mask (with and without clip)
41386418|NCT01426828|BIOLOGICAL|CD3/CD28|CD3/CD28 activated autologous lymphocytes intravenously
41386419|NCT03032237|OTHER|Nutritional intervention - protein-rich|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Intervention group will receive protein-rich meals and protein-rich foods and drinks."
41386420|NCT03032237|OTHER|Nutritional intervention - standard|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Control group will receive standard (not protein-rich) meals and standard foods and drinks."
41386421|NCT00293475|DRUG|Carboplatin|Given IA
41386422|NCT00293475|DRUG|Mannitol|Given IA
41386423|NCT00293475|DRUG|Methotrexate|Given IA
41386424|NCT00293475|OTHER|Quality-of-Life Assessment|Ancillary studies
41386425|NCT00293475|BIOLOGICAL|Rituximab|Given IV
41386426|NCT00293475|DRUG|Sodium Thiosulfate|Given IV
41386427|NCT06359418|DEVICE|Acupuncture|The acupuncture needle (size 0.30x40mm) will be inserted into DU20, EX-HN3 and GB8 acupoints at the depth of 15-30mm; The acupuncture needle (size 0.30x50mm or size 0.30x75mm) will be inserted into other acupoints at the depth of 40-70mm; Manipulation will be done after insertion (6 times of small amplitude and uniform twist).
41386428|NCT06359418|DEVICE|Sham acupuncture|The acupuncture needle (size 0.20x25mm) will be inserted into all acupoints at the depth of 2mm without any manipulation.
41386429|NCT03434808|OTHER|Whole Blood Donation|Study subjects will provide 250ml whole blood donation for the manufacture and banking of iPS cells.
41510576|NCT02620579|BEHAVIORAL|Shoulder Anatomy Education|Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
41510577|NCT02620579|BEHAVIORAL|Pain Processing Education|Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
41510578|NCT01591343|BIOLOGICAL|Depigoid® (500 DPP/ml)|"Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).~Dose:~Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection"
41510579|NCT00591773|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
41528347|NCT00271063|DRUG|Liposomal Annamycin|3-day IV infusion
40855569|NCT04558372|OTHER|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
40855570|NCT04558372|OTHER|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
41386430|NCT02291172|BEHAVIORAL|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
41386431|NCT05584839|OTHER|Statistically Analysis|The study was planned as a quantitative research. Socio-demographic information form, anthropometric measurements of hand grip strength, palm length, hand width length, wrist circumference length, Visual Analog Scale scale, EMG findings will be evaluated by hand dynamometer.
41386432|NCT05308576|BIOLOGICAL|SCTV01E|D0; intramuscular injection
41386433|NCT05308576|BIOLOGICAL|Placebo|D0; intramuscular injection
41386434|NCT06554665|OTHER|High-intensity interval training group|HIIT sessions will include a 3-minute warm-up, a 20-minute main exercise on a recumbent stepper, and a 2-minute cool-down. The HIIT main exercise will include ten 1-minute high-intensity exercises interspersed with ten 1-minute low-intensity exercises. The high-intensity level will start at 75% of the Heart Rate Reserve (HRR) and will be increased by 5% every 4 weeks to reach 90% at 12 weeks as tolerated.
41510580|NCT00591773|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
41510581|NCT00591773|DRUG|Chlorthalidone|Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
41510582|NCT01680003|DRUG|Hepar-P|
41386435|NCT06554665|OTHER|Moderate-intensity continuous training group|MICT sessions will include a 3-minute warm-up, a 20-minute main exercise on a recumbent stepper, and a 2-minute cool-down. The intensity of the MICT will start at 45% of the Heart Rate Reserve (HRR) and will be increased by 5% every 4 weeks to reach 60% at 12 weeks as tolerated.
41510583|NCT01680003|DRUG|Placebo for Hepar-P|
41510584|NCT05713565|DEVICE|A digital care solution for patients with Coronary Artery Disease|A digital care solution that provides remote patient monitoring and a patient support program specifically developed for CAD patients. The digital care solution empowers self-assessment of CAD symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
41510585|NCT05713565|OTHER|Standard of care for patients with Coronary Artery Disease|Follow-up and continuous care as usual in outpatient care (i.e., Standard of Care). The participants in the Standard of Care - control group will also receive an information leaflet about relevant lifestyle modifications for CAD.
41510586|NCT03669224|OTHER|Nano Care Gold|Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
41510587|NCT03669224|OTHER|No intervention|No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
40855571|NCT04558372|OTHER|exhaled breath sampling|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
40855572|NCT00930878|DEVICE|Cardiac Stenting|Drug Eluting stent
41386436|NCT06554665|OTHER|Stretching group|Participants in the stretching group will receive 25 minutes of full-body stretching. The intensity of stretching will reach the point of feeling tightness or slight discomfort. Static stretching at each site will hold for 10-30 s and repeat 2-4 times.
41386437|NCT05648097|DEVICE|Baldachin|"Environmental intervention: Equipment of a patient space of a patient with confirmed COVID-19 in open-space multiple bed Intermediate Care Unit areas with a mobile, optimally placed high efficiency particulate air (HEPA)-equivalent air filtration unit (Baldachin) in addition to existing room ventilation and hospital policy infection prevention and control measures."
41386438|NCT04631406|BIOLOGICAL|Neural Stem Cells|NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke
41386439|NCT02100241|PROCEDURE|Active stretching|The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
41386440|NCT05803382|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
41510588|NCT03669224|OTHER|Chlorhexidine|2 % chlorhexidine gluconate. This group will be compared with no intervention group.
41510589|NCT00474266|BIOLOGICAL|Meningococcal vaccine GSK134612 (Nimenrix)|Single dose intramuscular injection
41510590|NCT00474266|BIOLOGICAL|Priorix-Tetra|2-dose subcutaneous injection
41510591|NCT00474266|BIOLOGICAL|Meningitec|Single dose intramuscular injection
41510592|NCT06013098|DRUG|30%Oxygen|60%FiO2 in one lung ventilation and 30% FIO2 in both lungs ventilation
41166457|NCT04768868|DRUG|IMP7068|To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
41386441|NCT05803382|PROCEDURE|Biopsy|Undergo biopsy
41386442|NCT05803382|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41386443|NCT05803382|DRUG|Capecitabine|Given PO
41510593|NCT06013098|DRUG|60%Oxygen|100%FiO2 in one lung ventilation and 60% FIO2 in both lungs ventilation
41510594|NCT06581913|OTHER|Behavioral assessment|Eating Awareness, Acceptance of Food Cravings, Healthy Life Awareness Health Perception
41510595|NCT01013662|PROCEDURE|glycemic control|exogenous insulin
41386444|NCT05803382|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
41386445|NCT05803382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
41386446|NCT05803382|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41386447|NCT04208165|OTHER|ultrasound-guided nerve block PVB|Thoracic paravertebral block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
41386448|NCT04208165|OTHER|ultrasound-guided nerve block TAB|Transverse abdominis plane block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
41386449|NCT06565546|OTHER|Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin|CYP2D6 genotype testing for assessment of medication metabolism to guide prescription of postoperative pain medication
41386450|NCT06565546|OTHER|Acetaminophen and Gabapentin: standard postoperative pain medications|Participants will receive standard postoperative pain medications
41386451|NCT05478486|DRUG|MSP008-22|"It is single group assignment interventional model in this clinical trial, consisting of 5 cohorts of 3 patients in each, to be enrolled such that there exists an overall gender balance for the entire trial and to also ensure including minimum five (5) patients of TNBC and minimum five (5) male patients.~The trial will be initiated with dosing of a cohort of 03 patient with the Safe starting dose for MSP008-22. Dosing of the patients for the next higher dose cohort will initiate only after: (i) All 03 patients have been recruited in the lower dose Cohort and if a repeat Cohort at this dose level is recommended, another 03 patients have been recruited at same dose level (ii) all dosed patients have completed the allocated study cohort duration, (iii) safety and pharmacokinetic results have been reviewed by the Independent Dose Escalation Committee (DEC) and approved for dose escalation to next cohort."
41386452|NCT03889925|DRUG|Hyaluronan|Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.
41386453|NCT03889925|BIOLOGICAL|Autologous conditioned plasma|Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.
41386454|NCT01615900|OTHER|Teleconsultation / Standard consultation|"Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~* Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~* Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~* Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~* Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)"
41386455|NCT00294931|DRUG|irinotecan|
41386456|NCT00294931|DRUG|carboplatin|
41386457|NCT00294931|DRUG|bevacizumab|
41386458|NCT02653469|OTHER|Augmented ventilation|When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
41386459|NCT02653469|OTHER|Fluid loading|We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
41386460|NCT02502084|DEVICE|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
41386461|NCT06543186|OTHER|Oral health education lecture|Conventional oral health education will be given by trained and calibrated dentists.
40855573|NCT05270798|DRUG|triiodothyronine|Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.
40855574|NCT05643651|DRUG|Rivaroxaban Oral Tablet [Xarelto]|Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model- and clinical evidence-informed precision dosing
41386462|NCT06543186|OTHER|Oral health education via mHealth on WhatsaApp|For the oral health education intervention via mHealth, WhatsApp medium will be used to disseminate oral health educational material
41386463|NCT06543186|OTHER|Oral health education via Metaverse platform on Meta-OHE|For oral health education intervention via Meta-OHE, it will be done via computer.
41386464|NCT05090722|DEVICE|PureWick System|The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
41386465|NCT06472375|DIAGNOSTIC_TEST|holter|ambulant heart rate monitor (holter) for 24 hour.
41386466|NCT01916759|DRUG|Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)|Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
40855575|NCT05643651|DRUG|Aspirin or Clopidogrel|Aspirin \[3 \~5mg/(kg·d) once daily\] or Clopidogrel \[0.2\~1.0 mg/kg(\<2 years old),1 mg/kg(≥2 years old); once daily\]
40855576|NCT05643651|DRUG|Warfarin|Warfarin 0.05\~0.12 mg/(kg·d) once daily. INR should maintain within 1.5 to 2.5
40855577|NCT02987270|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine is an antimalarial in the artemisinin-based combination therapy class of drugs. It is the Kenya Ministry of Health second-line treatment for malaria in Kenya.
41166458|NCT02546505|OTHER|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
41386467|NCT02741609|DEVICE|Borrelia Diagnostic Test|The ALSI BDT is a high-yield in vitro cultivation method for Borrelia burgdorferi from venous whole blood samples.
41386468|NCT01059942|OTHER|mock handoff exposure|Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
41386469|NCT01059942|OTHER|Introduction of CEX tool in Actual Hand-offs|We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
41510596|NCT04843696|DEVICE|cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy)|the hospital-based NPV once per week in the maintenance program at least three times per month. The ventilator is set to the control model with a frequency of 12\~15 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot), and delivery of negative pressures ranging from -20 to -35 cm H2O.
40855578|NCT03963843|BEHAVIORAL|Guided ICBT|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
41386470|NCT00902278|BIOLOGICAL|Flulaval|one 0.5-mL dose via intramuscular injection
41510597|NCT04843696|BEHAVIORAL|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise)|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)
41528348|NCT06128330|DRUG|Tranexamic acid bolus 20 mg/kg|Bolus of tranexamic acid in the standard dose group
41386471|NCT00902278|BIOLOGICAL|Fluvirin|one 0.5-mL dose via intramuscular injection
41386472|NCT00902278|BIOLOGICAL|Fluzone|one 0.5-mL dose via intramuscular injection
41386473|NCT00902278|BIOLOGICAL|Fluarix|one 0.5-mL dose via intramuscular injection
41386474|NCT00902278|BIOLOGICAL|Afluria|one 0.5-mL dose via intramuscular injection
41386475|NCT05058027|DEVICE|GUARDIX-SG®|GUARDIX-SG® 6g prefilled syringe
41386476|NCT05058027|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
41386477|NCT00001972|DRUG|15 O Water|
41386478|NCT03125915|BEHAVIORAL|Communication skills training video|This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
41386479|NCT03125915|BEHAVIORAL|substance use module|This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
41386480|NCT03125915|BEHAVIORAL|Couples HIV Testing and Counseling|CHTC delivered as per the CDC protocol.
41386481|NCT04185831|DRUG|Atezolizumab|PD-L1 inhibitor
41386482|NCT04185831|DRUG|Everolimus|MTOR inhibitor
41386483|NCT04185831|DRUG|Cobimetinib|MEK inhibitor
41386484|NCT04185831|DRUG|Niraparib|PARP inhibitor
41386485|NCT00559975|BIOLOGICAL|Subunit influenza vaccine|0.5 mL single dose vaccine
40855579|NCT03963843|OTHER|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
40855580|NCT03481699|BEHAVIORAL|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
40855581|NCT03481699|OTHER|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
41166459|NCT02546505|OTHER|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
41166460|NCT04934605|PROCEDURE|Cochlear implantation|Cochlear implantation
41166461|NCT00441922|DRUG|Docetaxel|Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
41166462|NCT00441922|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
41166463|NCT04339140|DRUG|Zafirlukast|Oral tablets, 2x daily for 28 day cycle up to 1 year
41386486|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine|0.5 mL single dose vaccine
41166464|NCT05187000|DEVICE|individualized repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 10 consecutive sessions (one session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
41166465|NCT05187000|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.
41386487|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combined with CpG7909|0.5 ml influenza vaccine combined with 10 mcg of CpG7909
41386488|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 30 mcg of CpG7909
41386489|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 100 mcg of CpG7909
41386490|NCT03858998|OTHER|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
41386491|NCT03858998|OTHER|Control|Current routine HIV care in Tanzania.
41386492|NCT04483427|COMBINATION_PRODUCT|Nalbuphine, ketorolac, accufuser|multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser)
41386493|NCT05504369|OTHER|Magnetic tape|Tape with magnetic nanoparticles applied to the skin
41386494|NCT05504369|OTHER|Placebo tape|Tape without nano particles applied to the skin
41386495|NCT06548529|RADIATION|HER2 expression of PET imaging|Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with ADC
41386496|NCT02574507|BEHAVIORAL|Couples-Based Behavioral Weight and Symptom Management|Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
41386497|NCT00002879|DRUG|cladribine|
41386498|NCT04035694|OTHER|Media Aware Sexual Health - High School|Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
41386499|NCT06542497|DRUG|0.75% phentolamine ophthalmic solution|Once daily dosing
41386500|NCT06542497|DRUG|Placebo|Once daily dosing
41386501|NCT06217835|OTHER|To evaluate the response of an orthopedic insole|To evaluate the response of an orthopedic insole of different heights on gait.
41386502|NCT06217835|OTHER|evaluate activation of musculature|To evaluate the response caused by an orthopedic insole of different heights on the indicated musculature.
40855582|NCT04760405|OTHER|Tai Chi Easy|Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
40855583|NCT00176462|DRUG|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
40855584|NCT00176462|DRUG|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
40855585|NCT00176462|DRUG|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
40855586|NCT00176462|DRUG|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
40855587|NCT00176462|DRUG|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
40855588|NCT00176462|DRUG|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
40855589|NCT00176462|DRUG|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
40855590|NCT00176462|DRUG|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
40855591|NCT00176462|DRUG|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
40855592|NCT00176462|DRUG|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
40855593|NCT00176462|DRUG|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
40855594|NCT00176462|DRUG|Leucovorin|
40855595|NCT00168454|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
40855596|NCT00168454|DRUG|Placebo|Placebo (normal saline) injected into detrusor on Day 1
40855597|NCT04130672|PROCEDURE|Hot nasal packing with hot saline irrigation for hemostasis after adenoidectomy|After hot packing nasopharyngeal irrigation with 50 C saline
40855598|NCT04130672|PROCEDURE|Cold nasal packing with cold saline irrigation for hemostasis after adenoidectomy|After cold packing nasopharyngeal irrigation with 22 C saline
40855599|NCT05594628|OTHER|Neuromuscular training|"Neuromuscular training is designed as 8 weeks and 2 times a week, and approximately 20 minutes per session for Neuromuscular training+usual basketball training group. Other group is only going to keep attending usual basketball training.~Neuromuscular training consisted 3 exercises:~First exercise is passing the ball to side to side on bosu with standing on one leg. 60-90 seconds on time, 30-60 seconds off time. 2 sets for both passing sides and bilaterally.~Second exercise is standing on bosu unilaterally and while standing stabilized, switching basketball hand to hand as dribbling on the floor. Exercise will be on for 60-90 seconds and off for 30-60 seconds, 2 sets for each side Third exercise is jumping with one stance/leg, and landing with double stance while a therabant is attached to the belly and pulling with a minimum/medium force from one side. Changing legs after one jump, 6 times for both side is equal to 1 set of the exercise. It will be done 2 sets for both sides."
40855600|NCT05481489|DRUG|Atropine Sulfate|Atropine Sulfate 0.05% Ophthalmic Solution
40855601|NCT02548338|PROCEDURE|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
41166466|NCT01359722|DRUG|N-acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
41166467|NCT01359722|DRUG|Control|The control group will receive only the infusion of saline in the same doses and infusion rate.
41166468|NCT04254419|BIOLOGICAL|NK cells|"Natural killer cells will be taken from the patients peripheral blood cell collection. The administration of the cells will be done via an Ommaya intra-cavitary/intra-tumoral device.~Once the infusion is ready for administration patients will be admitted to the infusion unit for monitoring. NK cells will be administered through the Ommaya in approximately 2 milliliters over approximately 2 minutes; followed by 1 milliliter preservative-free normal saline flush over approximately 1 minute."
41166469|NCT02783053|DRUG|Metformin|Metformin vs no metformin
41166470|NCT00828529|DRUG|TMC207|
41528349|NCT06128330|DRUG|Tranexamic acid bolus 10 mg/kg|Bolus of tranexamic acid in the low dose group
41386503|NCT04138602|DEVICE|BTL Emsella|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
41386504|NCT04138602|DEVICE|Sham BTL Emsella|Sham subjects will be seated on the device in the same manner as the active treatment group. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level ( \< 10 % power).
40855602|NCT04382742|BEHAVIORAL|Dynamic Resistance Exercises|Modified Wingate protocol that incorprates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of Maximal Heart Rate (MHR) followed by one minute of cycling with no resistance. The protocol will be performed for 10 times for a duration of 20 minute of workout.
40855603|NCT01086371|OTHER|Rhythmic auditory stimulation|Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
40855604|NCT01086371|OTHER|Walking exercise|Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
40855605|NCT04680481|DEVICE|Transcranial alternating current stimulation|Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.
40855606|NCT01982461|DRUG|Rosuvastatin|10mg,once daily
40855607|NCT01982461|DRUG|Crestor®|10mg,once daily
40855608|NCT03981627|DRUG|ADO09 formulation|Subcutaneous injection of ADO09 formulation
40855609|NCT03981627|DRUG|NovoRapid®|Subcutaneous injection of insulin aspart
40855610|NCT04278976|OTHER|Implementation of CoBaTrICE|"The implemention of CoBaTrICE will include the three following essential elements:~1. Training the trainers. In order to provide high quality feedback to guide development of competence, tutors will receive a course in formative assessment, debriefing techniques, and effective feedback.~2. Workplace-based assessment (WbA) to promote learning and to guarantee that the predefined competences and skills are effectively acquired. Current Wb observation methods such as mini-clinical examination exercise, direct observation of procedural skills and multisource-feedback 360º will be used.~3. The use of an electronic portfolio specifically created as a personal collection of training documents that includes the record of formative assessments, activities, and the levels of competence achieved. The portfolio will help monitor progress of trainee's skills development and learning experiences contributing to an effective assessment, self-reflection and control of the learning process."
40855611|NCT04190732|BEHAVIORAL|Physician phone call|Often, patients will not have contact with a physician during the waiting period between embryo transfer and the pregnancy test. Participants in the intervention group will receive a phone call from one physician 3 to 4 days after fresh or frozen embryo transfer to check in. The physician will introduce themselves and state they are a part of the research team.
40855612|NCT05498467|DRUG|Anakinra|100 mg Anakinra injections s.c.
40855613|NCT05498467|DRUG|Sodium Chloride 9mg/ml Injection|9 mg Sodium Chloride injections s.c.
40855614|NCT04346992|OTHER|no intervention|no intervention
40855615|NCT03494582|PROCEDURE|Sacral Hysteropexy|Abdominal approach for uterine suspension
40855616|NCT03494582|PROCEDURE|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
40855617|NCT00773747|DRUG|Vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
40855618|NCT00773747|DRUG|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
40855619|NCT00773747|DRUG|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
41166471|NCT04419649|DRUG|KER-050|KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
41386505|NCT03827460|BEHAVIORAL|Abstinence from alcohol|Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol
40855620|NCT04038450|OTHER|No intervention|No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
40855621|NCT06472037|DRUG|Cadonilimab|10mg/kg，IV，D1，Q3W
40855622|NCT06472037|DRUG|Gemcitabine|1000mg/m2，IV，D1、D8、D15，Q4W
40855623|NCT06472037|DRUG|Nab paclitaxel|125mg/m2，IV，D1、D8、D15，Q4W
40855624|NCT05466331|OTHER|Mobile Tele-HCV Care|Study participants receive HCV care via telemedicine. Telemedicine appointments are performed on a mobile van.
40855625|NCT05466331|OTHER|Enhanced Usual Care|Study participants are referred to a clinician in their area for HCV care.
40855626|NCT05517655|DRUG|129Xe|Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
41386506|NCT03827460|BEHAVIORAL|Usual drinking|Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior
41386507|NCT03827460|DRUG|Intravenous Alcohol|During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.
40855627|NCT03803384|OTHER|Oxygen therapy|Oxygen supply during ESWT, once with the prescribed constant oxygen flow and once using an auto-regulated oxygen flow system setting the SpO2 target at 92%.
40855628|NCT04412707|DRUG|Melphalan|Peripheral versus central administration
40855629|NCT04412707|DRUG|Dexamethasone|Oral tablets
40855630|NCT00463619|DRUG|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
40855631|NCT04967027|DEVICE|ASCLU-300 TTF|BM treated by continuous TTFields treatment (ASCLU-300, approved by Chinese FDA)
41166472|NCT00857740|BEHAVIORAL|Education|Education about the neurophysiology of pain
41386508|NCT03347474|PROCEDURE|Bilateral surgical implantation of DBS system to NAc|The Medtronic, PINS and SceneRay DBS device will be utilized in the present study.
41528350|NCT06128330|DRUG|Tranexamic acid bolus 1 mg/kg|Bolus of tranexamic acid in the low dose group (to add into the CPB prime)
40855632|NCT02914574|OTHER|PowersTM strap|The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
41386509|NCT03906773|OTHER|Patient Centered Medical Home Based Electronic Framework for Advance Care Planning|The intervention tested a pre-visit ACP workflow centered around a framework sent via secure Electronic Health Record (EHR)-linked patient portal in a real world clinical setting. The primary objectives were to determine its impact on frequency and quality of ACP documentation.
41386510|NCT05350358|DEVICE|LeMaitre Cardial Dialine II|Surgical treatment for the replacement or bypass with LeMaitre Cardial Dialine II
41386511|NCT02484131|BEHAVIORAL|Educational materials/mail|Participants in this group will receive any educational materials by mail during hte follow-up period.
40855633|NCT00365040|PROCEDURE|Prk with mitomycin vs Lasik|
41037899|NCT06213766|DIAGNOSTIC_TEST|Cognitive assessment|"Group 1: Cognitively healthy subject:~After signing the consent form, during the only visit of the study, the investigator will administer to cognitively healthy subjects two cognitive screening tests to ensure that they meet the criteria for group 1. If performance on the cognitive scales prove to be borderline or below current standards (Montreal Cognitive Assessment ≥ 26/30 and MacNair Cognitive Difficulties Self-Rating Scale ≥15) for at least one of the 2 tests, the participant will prematurely end the study and may be offered an in-depth cognitive assessment as part of routine care.~Group 2: Patients suffering from Alzheimer's disease:~After signing the consent form, during the only visit of the study, the investigator will administer to patients the Montreal Cognitive Assessment to assess cognitive status."
41166473|NCT06310083|PROCEDURE|Submucosal Resection Turbinoplasty Versus Partial Inferior Turbinectomy|The study's Participants Were Randomly classified in two groups Interventional Group, applied for Submucosal Resection Turbinoplasty and the controlled group who were applied for Partial Inferior Turbinectomy
41166474|NCT03019198|DRUG|Tranexamic Acid Injectable Solution|Intravenous 15 mg per kilogram tranexamic acid
41386512|NCT02484131|BEHAVIORAL|Educational materials/participant choice|Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
41386513|NCT01922973|OTHER|Fasting|normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
41386514|NCT06157502|DRUG|Shuxuening Injection|Receiving 20 ml Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days
41386515|NCT06157502|OTHER|Placebo|Receiving 20 ml placebo Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days.
41386516|NCT01441401|DRUG|gabapentin|According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
41386517|NCT01356186|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
41528351|NCT06128330|DRUG|Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group|Tranexamic acid continuous infusion during the procedure
40855634|NCT05492097|BEHAVIORAL|Exercise Therapy|Traditional exercise therapy and NMES
40855635|NCT05492097|BEHAVIORAL|Exercise Therapy and Robotic Walking Training|Traditional exercise therapy and Robotic Walking Training
40855636|NCT00583063|DRUG|sunitinib|25 mg daily (oral dosing)
41166475|NCT03019198|DRUG|Placebo - Concentrate|
41166476|NCT01561456|DRUG|AXL1717|AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
41166477|NCT01561456|DRUG|Docetaxel|Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
41166478|NCT06479525|OTHER|Big Toe Flexor Strengthening Exercises|16 participants will be in experimental group A giving them Big Toe Flexor strengthening exercise protocol along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
41166479|NCT06479525|OTHER|Calf Strengthening Exercises|16 participants will be in experimental group B giving them calf strengthening exercises including towel curls and thera band exercises along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
41166480|NCT03080662|DEVICE|ORYGEN DUAL Sham Valve|Training of the inspiratory muscles during 5 weeks
40855637|NCT00583063|DRUG|rapamycin|4 mg daily (oral dosing)
41166481|NCT03080662|DEVICE|ORYGEN DUAL Valve|Training of the inspiratory muscles during 5 weeks
41166482|NCT00238719|DRUG|Venlafaxine ER|
41166483|NCT04185922|DEVICE|Hemopatch|As stated in Hemopatch arm description
40855638|NCT04298437|BEHAVIORAL|Addressing Depression and Positive Parenting Techniques (ADAPT) Program|The intervention is a targeted parenting intervention that has modules that help parents build emotion regulation skills, distress tolerance skills and alternative and more helpful ways of thinking about the causes of their child's EBD. The program also includes behavioral parent training skills building modules.
40855639|NCT06366425|DIAGNOSTIC_TEST|Blood sample then fibroscan|"The patient takes a blood test if none less than 6 months old is available, including a complete blood count (CBC) and a hepatic check. The FIB-4 score will be calculated from this blood test.~If the result of the FIB-4 test is greater than 2.67 the person will be contacted by the SELHV (Service Expert de Lutte contre les Hépatites Virales) of the University Hospital of Montpellier in order to schedule, if she wishes, a second non-invasive screening examination of liver fibrosis by Fibroscan."
40855640|NCT02424175|BIOLOGICAL|Fecal Microbiota Transplantation|
40855641|NCT00192816|BEHAVIORAL|reaction to pain|
40855642|NCT03003403|BEHAVIORAL|Intervention Program|Balance is testing a pragmatic approach to promote weight maintenance among overweight patients and patients with obesity within local community health centers who experience barriers to losing weight. The intervention utilizes the interactive obesity treatment approach, which creates an energy deficit by having participants achieve simple, straightforward, and concrete behavior change goals (e.g., no fast food, no sugary drinks, walk 10,000 steps per day). The Balance intervention involves tailored behavior change goals; self-monitoring using connected scales and mobile technologies; responsive coaching, and tailored feedback and skills training.
40855643|NCT01835223|DRUG|Tivozanib (1mg)|Given PO
40855644|NCT01835223|DRUG|Tivozanib (1.5mg)|Given PO
40855645|NCT04511858|OTHER|maximum effort test on a cycloergometer|5 h test on cycloergometer
40855646|NCT04511858|OTHER|maximum effort test on a treadmill|5 h test on treadmill
40855647|NCT00003512|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
40855648|NCT03570541|DRUG|Ropivacaine|30 mL ropivacaine 0,375% administered on each side as bilateral TQL blocks
41037900|NCT06213766|OTHER|Questionnaires|"For every participants (group 1 and 2):~During the only visit of the study and after the intervention 1, the participants will answer questionnaires about:~* Demographic data such as age, gender, weight, height, education level;~* Lifestyle habits such as usual mode of transport, sense of direction, use of GPS device, and video game practice;~* Quality of sleep over the previous month and the previous night;~* Cognitive reserve questionnaire from Rami et al., 2011;~* Concomitant treatment and comorbidities."
41037901|NCT06213766|DEVICE|Spatial navigation task with eye-tracking.|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1 and 2, the participants will complete the spatial navigation task with eye-tracking.~The participants will play the Sea Hero Quest video game and take on the role of the captain of a small boat that has to find its way through an aquatic environment. At the start of each level, the player is shown a map of the environment, with the boat's initial position and the buoys it must reach as quickly as possible in a set order. Once the map has been memorised, it disappears and the navigation begins.~Participants will play 6 levels of Sea Hero Quest (two training levels and four different navigation levels). This intervention will be proposed by a trained team member and participants will play on a digital tablet connected to an eye-tracker. The total duration of the task is 30 min (training phase + assessment sequences)."
41166484|NCT06342245|RADIATION|Radiofrequency coblation micro-tenotomy|Radiofrequency micro-tenotomy with low-temperature controlled ablation will be performed with the TOPAZ (Smith and Nephew) wand, which has a 1mm tip, and full thickness 1mm RF tendon debridement at 5mm intervals will be performed.
41386519|NCT05925049|DRUG|Natalizumab|Administered as specified in the treatment arm.
41386520|NCT06566755|DRUG|Cadonilimab (AK104) combined with chemotherapy and bevacizumab|"Participants receive Cadonilimab PLUS chemotherapy and bevacizumab of each 21-day cycle.~Treatment period (4-8 cycles)：~* Cadonilimab: 10mg/kg, intravenous infusion, D1, Q3W;~* CapeOx chemotherapy regimen Q3W+ bevacizumab, Q3W:~oxaliplatin: 130 mg/m2 intravenous infusion, D1, Q3W; capecitabine: 850 mg/m2 orally, D1-14, Q3W, twice daily; bevacizumab injection: 7.5mg/kg, IV, D1, Q3W. Maintenance treatment period：~* Cadonilimab: 10mg/kg, administered D1, Q3W;~* capecitabine: 1000 mg/m2 orally, D1-14, Q3W, twice daily;~* bevacizumab injection: 7.5mg/kg, IV, D1, Q3W."
41386521|NCT00282425|BIOLOGICAL|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
40855649|NCT03570541|DRUG|Acetaminophen|Every six hours postoperative, all patients are administered 1 g of acetaminophen.
40855650|NCT03570541|DEVICE|Patient controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
40855651|NCT03570541|DRUG|Morphine|intravenously administered morphine via PCA-pump
40855652|NCT03570541|DRUG|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
40855653|NCT03570541|DIAGNOSTIC_TEST|Blood samples|On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis
41386522|NCT06203288|BEHAVIORAL|Mindfulness-based social and emotional learning (MBSEL) program for educators|MBSEL for educators is a program designed to improve teachers' ability to deal with stress and enhance their well-being and teaching. Lessons include: (1) Introduction to the Science, (2) Brain, Attention, \& Well-being, (3) Positive Neuroscience, (4) Mindful Teaching, (5) Embracing Self-Compassion, (6) Finding Your Compass: Intentions for Mindful Living. This 2-hour program is self-paced and delivered online.
41386523|NCT06203288|BEHAVIORAL|Mindfulness-based social and emotional learning (MBSEL) program for students|MBSEL program for students consists of 17 lessons taught about once a week (40-50 minutes per lesson). The core mindfulness program practices (done every day for 3 minutes three times a day) consist of focusing on one's breathing and attentive listening to a single resonant sound. The lessons focus on promoting prosocial behavior (e.g., kindness, altruism), resiliency, well-being, and reducing stress in students. It also incorporates an eco-behavioral systems orientation.
41386524|NCT05351073|DRUG|NBO|Oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa)
41386525|NCT04222218|DEVICE|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
41386526|NCT03054168|DRUG|Sustanon 250|The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
41386527|NCT03054168|DRUG|Zoladex|The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).
41386528|NCT03054168|OTHER|Placebo|
41386529|NCT00317967|DRUG|Atorvastatin|80 mg pills daily
41386530|NCT00317967|DRUG|Placebo|80 mg pills daily
41386531|NCT04534088|BEHAVIORAL|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|Standard Behavioral Weight Loss Program
41386532|NCT04534088|BEHAVIORAL|Standard Behavioral Weight Loss plus Weight-Related VR app|Standard Behavioral Weight Loss plus Weight-Related VR app
41386533|NCT04801030|BEHAVIORAL|YourCoViDVaxFacts|The intervention will be delivered via multiple strategies- social media (YouTube, Facebook), radio, newspaper, tv ads, community partner networks. Participants receive culturally-tailored message on COVID-19 and the vaccine. The strategies will have a link that will open to a website that is optimized for viewing on a computer or mobile phone which has the look and feel of an app, but without requiring the user to download anything to the phone. On the website, participants will be prompted to select their top concerns from a list. Based on the responses, the top barriers or need will each be mapped to a corresponding educational message, which will be displayed to the user with appropriate images or graphics.
41386534|NCT00557700|DRUG|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
41386535|NCT00557700|DRUG|Administration of placebo|Administration of placebo
41166485|NCT02183350|DRUG|BI 1356 BS - single rising dose|
41386536|NCT06540365|BEHAVIORAL|Pathways and Resources for Engagement and Participation (PREP)|Each participant will work individually with an occupational therapist (OT) to pursue one leisure-oriented, community-based activity chosen by the young person. The participant will choose the community program using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will then search for the appropriate program, identify and remove potential environmental barriers to participation in that activity (e.g., accessibility, equipment), and educate program instructors regarding the person's specific needs. This process will include an expected 8 sessions lasting 12 to 18 weeks (depending on the assigned baseline length).
41386537|NCT04883411|DEVICE|CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
41510598|NCT01433055|DRUG|Minocycline|"Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
41166486|NCT02183350|DRUG|Placebo|
41166487|NCT04252170|DEVICE|Rehabilitation Therapy, Experimental on the BrightArm Compact device|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). An Occupational Therapist will assist as needed.
41386538|NCT05188807|DIAGNOSTIC_TEST|Airway ultrasonography|we will measure hyomental distance, skin-epiglottis distance, skin-hyoid distance, epiglottis-vocalcords distance
41386539|NCT02946619|BEHAVIORAL|Self-Regulation Condition|
41386540|NCT02946619|BEHAVIORAL|Enhanced self-Regulation Condition|
41386541|NCT06541483|PROCEDURE|Ultra-Fast-Track Cardiac Anesthesia(UFTCA)|(UFTCA)The researcher removed the endotracheal tube either immediately or within 1 hour of the end of the procedure.
41386542|NCT06541483|PROCEDURE|conventional general anesthesia (CGA)|(CGA)The researcher not extubated at the end of the operation and were admitted to the ICU under anesthesia with an endotracheal tube.
41386543|NCT04199104|DRUG|Lenvatinib|Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
41386544|NCT04199104|BIOLOGICAL|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
41386545|NCT04199104|DRUG|Placebo|Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
41386546|NCT06567535|PROCEDURE|Navigation and endoscopy|The model was reconstructed using patient CT data, and intraoperative surgery was performed using endoscopy and navigation.
41386547|NCT06567366|BIOLOGICAL|CAR T-cell therapy|Participants will receive CAR T-cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR T-cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
41386548|NCT06567366|DRUG|Glofitamab|"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15.~Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-6 (as relevant)."
41386549|NCT06567366|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
41386550|NCT05193435|OTHER|Pelvic floor exercises|Pelvic floor exercises for types I and II muscle fibers will be performed
41386551|NCT05193435|OTHER|Stabilization exercises|Lumbar spinal stabilization exercises will be performed
41386552|NCT02949219|OTHER|Laboratory Biomarker Analysis|Correlative studies
41386553|NCT02949219|BIOLOGICAL|Pembrolizumab|Given IV
41386554|NCT06558838|DRUG|acyclovir-penciclovir cream|Patients will treat their cold sore with active study drug based upon their randomization
41386555|NCT06558838|DRUG|Abreva|Patients will treat their cold sore with Abreva based upon their randomization
41386556|NCT03286426|DIAGNOSTIC_TEST|Pictor|The back of each eye will be imaged with Pictor. Visual acuity and color vision will be checked if patient able to cooperate with exam.
41386557|NCT01206946|DRUG|Betamethasone|A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
41386558|NCT01206946|OTHER|Normal Saline|Two doses of 2ml of normal saline given at 24 hourly intervals
41386559|NCT04032522|OTHER|point-of care (PoC) neonatal HIV early infant diagnosis (EID)|clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)
41386560|NCT02912884|DRUG|No cytoreductive vs cytoreductive drugs|No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
41386561|NCT01954784|DRUG|fludarabine phosphate|
41386562|NCT01954784|RADIATION|total-body irradiation|Undergo TBI
41386563|NCT01954784|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic hematopoietic SCT
41386564|NCT01954784|DRUG|cyclosporine|Given PO
41386565|NCT01954784|DRUG|mycophenolate mofetil|Given PO
41386566|NCT01954784|DRUG|bortezomib|Given SC
41386567|NCT01954784|DRUG|lenalidomide|Given PO
41386568|NCT01954784|OTHER|laboratory biomarker analysis|Correlative studies
41386569|NCT03716999|OTHER|Starlight Therapy|Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
41386570|NCT06567795|DEVICE|Hemotag|Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days
41386571|NCT03954899|DIETARY_SUPPLEMENT|melatonin|5mg of melatonin-otc 30 minutes before sleep
41386572|NCT03954899|OTHER|placebo|placebo 30 minutes before sleep
41386573|NCT01387672|DRUG|Nitrates (NABT Main trial)|nitroglycerin; isosorbide mononitrate
41386574|NCT01387672|OTHER|Placebo|Placebo ointment
40855654|NCT03570541|BEHAVIORAL|Quality of recovery-15 questionaire|On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a short questionaire.
41386575|NCT02878239|OTHER|Steps 1|Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
41386576|NCT02878239|OTHER|Steps 2|Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
41386577|NCT00045396|DRUG|tipifarnib|Given orally
41386578|NCT03582059|PROCEDURE|High Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of high frequency stimulation.
41386579|NCT03582059|PROCEDURE|Burst Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of burst frequency stimulation.
41386580|NCT02751255|DRUG|all-trans retinoic acid (ATRA)|Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is reached, at the dose of 45 mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled daratumumab infusion. The last administration of ATRA will be given in the evening of the day that daratumumab was administered (days -2, -1, and 0; day 0 is the day of daratumumab infusion).
41386581|NCT06251154|DEVICE|Lens 1|Daily disposable silicone hydrogel contact lens (diameter=14.0mm) for 15 minutes
41386582|NCT06251154|DEVICE|Lens 2|Daily disposable silicone hydrogel contact lens (diameter=14.1mm) for 15 minutes
41386583|NCT00950001|RADIATION|Stereotactic Radiosurgery|Undergo SRS
41386584|NCT04241068|DRUG|Aducanumab|Administered as specified in the treatment arm.
41386585|NCT02587000|DRUG|Ulipristal acetate|
41386586|NCT02587000|DRUG|Placebo|
40855655|NCT03570541|DIAGNOSTIC_TEST|Orthostatic hypotension|Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension.
40855656|NCT05099835|DRUG|Botox|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
40855657|NCT05099835|DRUG|triamcinolonacetonide|triamcinolonacetonide stellate ganglion injection
40855658|NCT00897468|OTHER|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
40855659|NCT00897468|OTHER|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
40855660|NCT04635514|PROCEDURE|Lateral colporrhaphy|
41386587|NCT00535301|DEVICE|grafted anterior prolapse repair|anterior vaginal prolapse repair with graft
41386588|NCT00535301|PROCEDURE|sutured anterior vaginal prolapse repair|anterior vaginal prolapse repair with suture
41386589|NCT05243966|DEVICE|Myriad Matrix™ and Myriad Morcells™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
41386590|NCT06568380|OTHER|Oyster consumption|Volunteers consume one of the four panel of oysters (Noro+Phage+, Noro+Phage-, Noro-Phage+ and Noro-Phage-).
41386591|NCT00438295|PROCEDURE|temperature control|
41386592|NCT03080402|DEVICE|Mechanical Perturbation Training|The training program will consist of three stages and subjects will progress through each neuromuscular training stage.The training will consist of double- to single-limb movements with progression of jumping, hopping, and pivoting maneuvers on the perturbation device with an emphasis on proper technique and landing. The initial four sessions will focus on primarily on jumping and hopping maneuvers on double- and single-limb in the sagittal plane. The intermediate four sessions will incorporate additional medial and lateral maneuvers with the plyometric tasks. The final four sessions will incorporate rotational and pivoting activities with the maneuvers. The resultant protocol has been derived and optimized from previous published research studies and prevention techniques.
41386593|NCT05540535|OTHER|Gait assessment|The average speed of gait and spatiotemporal gait parameters would be calculated by the APDM, inertial motion units. Participants will walk in their normal speed for 1 minute along a corridor, back and forth, with or without performing a cognitive task (single or DT). The DT condition will include serial subtraction (counting backwards out loud) in jumps of 3 from a random three-digit number. Randomization of numbers will be done using the excel function generating random numbers (Excel RAND function). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. Each condition will be performed once, and all conditions will be randomized.
41386594|NCT05540535|OTHER|Cognitive assessment|Participants will complete a computerized cognitive battery (CNS vital sign; CNSVS)that will include verbal memory, visual memory, Stroop test, shifting attention and 4-part continuous performance (sustained attention and working memory). Moreover, performance on the single cognitive task (serial subtraction in jumps of 3; measuring working memory and executive function) will also be evaluated while sitting (cognitive single task). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. These tests do not require the ability to hear in order to pass successfully. Also, there is a need for investigation of cognitive domains such as attention, memory, executive function, and cognitive flexibility in people with HL.
40855661|NCT05761002|BIOLOGICAL|the Quadrivalent Vaccine (Gardasil)|• Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions.
40855662|NCT01258023|BIOLOGICAL|Fluad 1x|"15 µg antigen/strain:~* A/California/07/2009 (H1N1) - like strain~* A/Perth/16/2009 (H3N2) - like strain~* B/Brisbane/60/2008- like strain MF59 adjuvant 9.75µg ai 0.5ml"
40855663|NCT02969356|BIOLOGICAL|Botulinum toxin type A|Dysport® administered in both upper and lower limbs (total dose of 1500 U per injection split between the 2 limbs).
40855664|NCT02969356|OTHER|GSC|The GSC is a motivational tool. The physiotherapist will teach each subject the stretching postures and exercises to perform on a daily basis throughout the study. These will be tailored to the individual subject's needs and will form the GSC therapy.
40855665|NCT05478135|DEVICE|NAVIFY Oncology Hub|NAVIFY Oncology Hub is a platform that aggregates and organizes disparate data into an intuitive, longitudinal view of the patient's cancer care journey. The platform is designed to optimize and support oncology workflows and decision-making by providing quick access to the most relevant data in one place, so that providers can make decisions more efficiently and collaborate more seamlessly.
40855666|NCT02606799|DEVICE|CytoSorb cytokine elimination|Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
40855667|NCT00258167|BEHAVIORAL|"filling the Experience of Caregiving Inventory"|8 weeks of group therapy for family members
41386595|NCT05069168|DIAGNOSTIC_TEST|Echocardiography before and after TAVR|"Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR.~cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume.~Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)"
41386596|NCT01129518|BIOLOGICAL|Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine|"In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two."
41386597|NCT01129518|BIOLOGICAL|Routine schedule immunisations except monovalent MenC vaccine|Routine schedule immunisations will be given according to NHS guidelines.
41386598|NCT03079869|DRUG|Ferric Citrate|One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
41386599|NCT06112093|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will be used to regulate the motor cortex to reduce headaches and post-concussion symptoms.
41386600|NCT06112093|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered by a sham coil as a comparator to the (active) rTMS. Sham rTMS will not change the brain function of the control group.
41386601|NCT03818867|PROCEDURE|Insertion of cervical cerclage|insertion of a stitch around the neck of the womb in order to provide extra support.
41386602|NCT01155258|DRUG|temsirolimus|Given IV
41386603|NCT01155258|DRUG|vinorelbine ditartrate|Given IV
41166488|NCT04473053|DRUG|Nafamostat Mesilate|Nafamostat has been shown to have potential antiviral effects against MERS CoV and is thought to possibly inhibit SARS CoV2 infection via inhibition of viral entry due to inhibition of TMPRSS2. In addition, nafamostat has potent anticoagulant properties which may provide benefit in patients with DIC, a common finding in serious cases of COVID-19. Nafamostat has been broadly well tolerated in clinical trials in patients with DIC and acute pancreatitis.
41386604|NCT06567626|OTHER|Decision Support Tool (DECIDE-CAD)|DECIDE-CAD is a decision support tool - designed using mixed methods through this study - which aims to enable shared decision making with people who are considering revascularisation options for coronary artery disease.
41386605|NCT06566066|OTHER|no intervention|register study without intervention
41386606|NCT06522906|BEHAVIORAL|Muscle Strengthening|Patients will be offered five video consultations (30-45 minutes each) with a physical therapist over 3 months. The physical therapist will prescribe an exercise program individualized to the OA patient that will include strengthening exercises (2 quadriceps, 1 hip/gluteal, 1 hamstrings/gluteal, 1 calf, and 1 other) to be performed at home 3x/week.
41386607|NCT06522906|BEHAVIORAL|General Physical Activity|The general program will consist of four 60-minute live video consultations conducted by a promotora. The first three sessions will be conducted every 2 weeks, with a booster session occurring one month later. The promotora will help dyads set achievable personalized physical activity goals.
41386608|NCT06522906|BEHAVIORAL|Education|Administered by a promotora, treatment will include 4 live video educational sessions about OA
41386609|NCT02147262|DRUG|doxycycline orally, 100 mg, bid, 14 days|
41386610|NCT02147262|DRUG|doxycycline orally, 100 mg, bid, 28 days|
41386611|NCT01502917|DRUG|Radioactive iodine-labeled monoclonal antibody omburtamab|Prior to treatment children will be pre-medicated with super-saturated potassium iodide \& liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations \& PET/CT or PET/MRI scans of the brain \& other organs. Clinical observations, intensive care unit monitoring, routine blood \& interval imaging studies (MRI \& PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
41386612|NCT01502917|RADIATION|External Beam Radiotherapy|Standard radiation therapy is given 4-6 weeks prior to study entry.
41386613|NCT03952663|PROCEDURE|inferior alveolar nerve lateralization and dental implant placement.|inferior alveolar nerve lateralization for placement of sufficiently long dental implants.
41386614|NCT03952663|PROCEDURE|platelet rich fibrin membrane around the nerve|platelet rich fibrin membrane is prepared from the patient's blood and placed around the nerve.
41386615|NCT02231307|DRUG|SUBLIVAC FIX Birch|
41386616|NCT02379650|DRUG|Hydroxychloroquine (HCQ)|
41386617|NCT02379650|DRUG|Placebo|
40855668|NCT02585921|BEHAVIORAL|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
40855669|NCT02585921|BEHAVIORAL|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
41386618|NCT06232759|DRUG|Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab|Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
41386619|NCT04437082|DEVICE|optical coherence tomography|imaging structural and vascular features of the eye
41386620|NCT06564467|DRUG|JMT202|subcutaneous injection
41386621|NCT06564467|DRUG|Placrbo|subcutaneous injection
41386622|NCT00364273|DRUG|GSK159802|GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
41386623|NCT00364273|DRUG|Placebo|Subjects will receive placebo administered using DISKUS inhaler.
41386624|NCT00364273|DRUG|Salmeterol|Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
41386625|NCT04962711|OTHER|Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
41386626|NCT04962711|OTHER|Usual care|provided by participants' usual healthcare professional(s)
41386627|NCT01396473|BEHAVIORAL|Policy and Environmental Change|Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
41386628|NCT00742859|DRUG|betrixaban|orally, once daily for at least 3 months
41386629|NCT00742859|DRUG|Warfarin|Warfarin will be prescribed by the investigator according to the standard of care.
40855670|NCT02406170|DRUG|Regorafenib|The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle
40855671|NCT02406170|DRUG|Paclitaxel|Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.
41166489|NCT04473053|DRUG|TD139|TD139 is a specific inhibitor of galectin-3 which has been investigated in healthy volunteers and patients with IPF. No serious drug related serious adverse events have been reported to date. TD139 had no impact on cardiac, haematological or biochemical measures of safety during trials in humans to date. Beneficial effects on biomarker measures of lung inflammation were observed in patients with IPF. It is the purpose of this investigation to examine the potential for delivery of this inhibitor in pre-ventilator patients hospitalised with COVID-19 to examine whether this may lead to detectable changes in blood biomarkers, reduce viral load and also reduce disease severity such as time to ventilation.
41166490|NCT04473053|OTHER|Standard care|Patients will receive standard care.
41386630|NCT04339361|DRUG|lidocaine spray|four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
41386631|NCT04339361|DRUG|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
41386632|NCT04339361|DRUG|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
41386633|NCT04164394|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
41386634|NCT04164394|DIETARY_SUPPLEMENT|I31 Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
41386635|NCT00893230|DIETARY_SUPPLEMENT|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
41386636|NCT00893230|DIETARY_SUPPLEMENT|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
41386637|NCT03674827|BIOLOGICAL|PF-06936308|PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.
41510599|NCT01433055|DRUG|Placebo|"Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
41510600|NCT02091024|DIETARY_SUPPLEMENT|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
41510601|NCT02091024|DIETARY_SUPPLEMENT|Placebo|Placebo 200mg, twice a day
41510602|NCT01392235|DRUG|Famitinib|25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
41510603|NCT05021432|OTHER|Virtual reality training group|This group will receive video based games
40855672|NCT04073485|PROCEDURE|Microwave ablation|Ultrasonogram is performed to identify the fibroid or adenomyoma. A trocar needle is placed into the lesion under local anesthesia. The MWA procedure is performed using appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
41386638|NCT05681026|BEHAVIORAL|Yoga Sessions|Participants will have up to 12 sessions, 3 sessions per week starting two weeks before the transplant and throughout the first 30 days of your hospitalization.
41386639|NCT05681026|BEHAVIORAL|Questionnaries|Participants will complete 4 questionnaires about any symptoms you may be having, any anxiety and/or depression you may be having, your quality of life, and your expectations about your treatment.
41386640|NCT05681026|BEHAVIORAL|Interviews|Participants will have an exit interview last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom, FaceTime, or other approved video call methods.). The interview will be audio and video recorded and transcribed (typed).
41386641|NCT00609063|DRUG|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
41386642|NCT00609063|DRUG|Placebo|Placebo capsules taken daily for 6 months
41386643|NCT01861600|OTHER|S-26 Gold|(13.4 g/L protein) with 100% Fat Blend A
41386644|NCT01861600|OTHER|S-26 Gold EF1|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
41386645|NCT01861600|OTHER|S-26 Gold EF2|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
41386646|NCT01861600|OTHER|S-26 Gold EF3|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
41386647|NCT01861600|OTHER|Human Milk|Human Milk
41386648|NCT06099041|DEVICE|Nd-YAG Laser for iris depigmentation|Nd-YAG Laser for iris depigmentation
41386649|NCT06116994|OTHER|The buccal infiltration anesthesia with a camouflaged dental syringe (Angelus ™)|In the test group, subjects will receive buccal infiltration anesthesia with the a camouflaged dental syringe. The used camouflaged dental syringe (Angelus ™) will consist of an alligator-shaped syringe sleeve that covers the dental syringe and makes it more friendly without affecting its function. The alligator-shaped syringe sleeve has three main components, which are the mouth, trunk, and rear feet. The mouth of the alligator sleeve covers the local anesthesia needle, the trunk covers the syringe barrel of the traditional dental syringe, and the rear feet hold the finger grip.
40855673|NCT02338089|DRUG|Oxytocin|Oxytocin, 100 micromolar solution
40855674|NCT00336297|PROCEDURE|Woman Abuse Screening Tool|
41386650|NCT06116994|OTHER|The buccal infiltration anesthesia with a conventional dental syringe|In the control group, subjects will receive buccal infiltration anesthesia with the conventional dental syringe.
41386651|NCT02496442|DEVICE|Aqueduct|Using Aqueduct in procedures to continuously supply the irrigation solutions
41386652|NCT04886232|DEVICE|VP1 Lido US|Hyaluronic acid dermal filler containing lidocaine
41386653|NCT04886232|DEVICE|Restylane Lyft Lidocaine|Hyaluronic acid dermal filler containing lidocaine
40855675|NCT00336297|PROCEDURE|Partner Violence Screen|
40855676|NCT00336297|PROCEDURE|Computerized screening|
40855677|NCT00336297|PROCEDURE|Face to face screening|
40855678|NCT00336297|PROCEDURE|Written screening on forms|
40855679|NCT00330122|PROCEDURE|fore locked plate|
40855680|NCT00330122|PROCEDURE|external radiocarpal fixer|
40855681|NCT00544791|DRUG|melatonin|5 mg, oral, daily dose for 6 months
41166491|NCT04473053|BIOLOGICAL|Allogeneic SARS-CoV-2 VSTs|The allogeneic SARS-CoV-2 VSTs are manufactured in a single stage process directly from the starting material procured from suitable post COVID-19 recovered individuals. This is an early dose escalation safety trial phase Ib/IIa interventional clinical trial with SARS-CoV-2 VSTs.
41386654|NCT06317337|OTHER|focused ultrasound cavitation augmented with aerobic exercises|Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity
41510604|NCT05021432|OTHER|Circuit Training group|They will receive Task-oriented Circuit training exercise program
41510605|NCT04625491|OTHER|Observational|Observational
40855682|NCT00544791|DRUG|placebo like melatonin tablets|
40855683|NCT02110095|DEVICE|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
40855684|NCT06464445|DEVICE|Monophasic iTBS|"iTBS protocol with monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of resting motor threshold (rMT)~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
40855685|NCT06464445|DEVICE|Biphasic iTBS|"iTBS protocol with biphasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
40855686|NCT06464445|DEVICE|Monophasic-Long iTBS|"iTBS protocol with long monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
40855687|NCT04203004|PROCEDURE|HOPE with cytokine filtration by CytoSorb|Cytokine filtration during HOPE
40855688|NCT00305487|DRUG|Ciclesonide nasal spray|
40855689|NCT04489472|DIETARY_SUPPLEMENT|Beet-it Juice|Patients will ingest 1 bottle (70ml) of beet-it juice (98% concentrated beet juice, 2% lemon juice containing 400 mg/6.5 mmol nitrate).
41386655|NCT06567782|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
41386656|NCT06567782|DRUG|CAPEOX|CAPEOX chemotherapy consisting of capecitabine and oxaliplatin will be administered.
41386657|NCT05736809|OTHER|Low-dye taping|Low-dye taing using 4 tapes around calcaneam
41386658|NCT05736809|OTHER|Plantar fascia stretching|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
41386659|NCT05736809|OTHER|sham taping|out of 21 participants 7 will be included in the study design as an plecebo group using sham taping in acute stage
41386660|NCT02539979|DRUG|Paracetamol|
41386661|NCT02539979|DRUG|Placebo - Normal Saline|Normal Saline 100cc
41386662|NCT03205163|BIOLOGICAL|Advate (Low Dose)|Participants received a single IV low dose of Advate 25 IU/kg.
41386663|NCT03205163|BIOLOGICAL|Advate (High Dose)|Participants received a single IV high dose of Advate 65 IU/kg.
41386664|NCT03205163|BIOLOGICAL|BIVV001 (Low Dose)|Participants received single IV low dose of BIVV001 25 IU/kg.
40855690|NCT06438055|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
41386665|NCT03205163|BIOLOGICAL|BIVV001 (High Dose)|Participants received single IV high dose of BIVV001 65 IU/kg.
41386666|NCT02379338|DRUG|[18F]Fluortriopride|All subjects will receive a \[18F\]Fluortriopride PET/CT scan
41386667|NCT06562335|OTHER|Booster|See description of arm. The Booster intervention has evolved from the PROfeel intervention. PROfeel is described in: https://doi.org/10.1186/s13063-022-06620-2
41386668|NCT06309121|DIETARY_SUPPLEMENT|Postbiotic ABB C3|A daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for the first 3 months of the study.
41386669|NCT06309121|DIETARY_SUPPLEMENT|Placebo|A daily dose of 550 mg of the placebo in individual sachets for the first 3 months of the study.
41386670|NCT06309121|DIETARY_SUPPLEMENT|Follow-up Postbiotic ABB C3 (Optional)|Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.
41386671|NCT01988337|DEVICE|Resin infiltration|The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
41386672|NCT01988337|OTHER|Mock treatment|"For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material."
41386673|NCT06393608|DRUG|Epsom salt|Epsom salt solution in water, 25% concentration
41386674|NCT06393608|OTHER|Water|Water
41386675|NCT06565819|DIAGNOSTIC_TEST|The second near-infrared region (NIR-II) imaging for lower extremity peripheral artery disease (PAD)|DUS was used as reference criteria to screen out patients newly diagnosed with PAD during follow-up. In this study, NIR-II imaging results of patients at follow-up and initial examination were collected to obtain a threshold for early diagnosis.
41386676|NCT04975113|OTHER|progressive neuromuscular exercise program|The exercises to be performed in the following week at the beginning of each week were explained by the researcher physiotherapist on the brochure and given as a home program and continued for a total of 12 weeks. The researcher physiotherapist saw the patients every week and carried out exercise compliance and control.
41386677|NCT04975113|OTHER|Exercise and Taping|"I taping for accurate positioning of the tissue was applied to the patients to neutralize the patellofemoral joint. During the knee flexion in the supine position, the tape was adhered to the skin with a moderate-to-extreme stretch (50%-75%) . Clinical therapeutic applications of the Kinesio taping methods (Tokyo, Japan: Ken Ikai Co Ltd.). In addition to the patellar taping, correction taping to neutralize the subtalar joint by elevating the midtarsal joint and medial arch was applied. The patients were positioned in prone lying and knee flexion position, the taping was started at the 5th metatarsal level on the dorsal side of the finger and finished extending towards the medial of the tibia . Tapings were renewed at the beginning of each week for 6 weeks."
41386678|NCT03307902|BIOLOGICAL|Imiquimod + ID HBVv|Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
41386679|NCT03307902|BIOLOGICAL|Aqueous + ID HBVv|Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
41386680|NCT03307902|BIOLOGICAL|Imiquimod + IM HBVv|Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
41386681|NCT03853213|BEHAVIORAL|Cognitive Bias Modification Training|"In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The letter appears in the neutral location on 90.6% of trials, thereby reinforcing participants' attending away from threat. In task 2, participants view a word or phrase corresponding to a threatening (e.g., dying) or benign (e.g., sleep) interpretation of a sentence (e.g., You have been waking up tired recently). They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback (Correct) is given for rejected threat interpretations and for benign interpretations. Otherwise, negative feedback (Incorrect) is given."
41510606|NCT05283564|OTHER|Percussive Ventilation Breathhold SABR (PVB-SABR)|Number of lung cancer patients with successful administration of PVB technique in PVB-SABR treatment
41510607|NCT03258203|OTHER|Preventing Overweight Using Novel Dietary Strategies|The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.
41166492|NCT04679740|DEVICE|Magmaris|MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
41166493|NCT05024409|DEVICE|Upper Extremity Orthotic|3D printed orthotic which uses elbow motion to facilitate finger extension
41166494|NCT05024409|OTHER|Occupational Therapy|6 weekly sessions of occupational therapy, without use of an assistive orthotic device
41386682|NCT03853213|BEHAVIORAL|Attention Control Training|In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The target letter is equally likely to appear in the threat location as the neutral location. Thus, participants' patterns of attention are not trained toward or away from threat. In task 2, participants view a word or short phrase corresponding to either a threatening or benign interpretation of a sentence that follows it. They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback and negative feedback are equally likely to be given regardless of whether participants endorse the threatening or benign interpretations.
40855691|NCT04910035|OTHER|Exercises Training|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
41386683|NCT02060240|BEHAVIORAL|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
41037902|NCT06213766|BIOLOGICAL|Blood sampling|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1, 2 and 3, a state-qualified nurse will take venous samples from 3 tubes of 4ml each.~These blood samples will be frozen and stored until the end of the study when they will be analysed:~* Sample 1: plasmatic Quanterix p-tau217 assay;~* Sample 2: apolipoprotein E genotyping;~* Sample 3: measurement of plasmatic creatinine levels. Neither the cognitively healthy subjects, nor the patients, nor the clinicians in charge of the patients included will be informed of the results of these biological assays (absence of clinical interest established at the present time of the APOE genotype and the p-tau217 protein level, absence of modification of the care pathway, in adequacy to the bioethics law of August 02, 2021. Creatinine level is used in this study as an adjustment variable to interpret the p-tau217 protein level and will not be used for clinical interpretation."
41037903|NCT03818139|OTHER|radiography thorax|The ultrasound of the thorax will be performed while waiting for the X-ray thorax
41037904|NCT04501315|DIAGNOSTIC_TEST|Blood, cerebrospinal fluid and urine samples|In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.
40855692|NCT05701696|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
40855693|NCT05701696|DIAGNOSTIC_TEST|Widespread pain index|Total the number of painful body areas
40855694|NCT05701696|DIAGNOSTIC_TEST|Symptom severity scale|The sum of the fatigue, waking unrefreshed and cognitive symptoms and the extent of somatic symptoms
40855695|NCT05701696|OTHER|Fibromyalgia impact questionnaire|A tool to assess health status in fibromyalgia
40855696|NCT05701696|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|An instrument for detecting depression and anxiety
40855697|NCT05701696|DIAGNOSTIC_TEST|Self-Leeds Assessment of Neuropathic Symptoms and Signs|An instrument used to identify pain of neuropathic origin
41037905|NCT03818672|DRUG|Rifaximin|Rifaximin 550 MG BID
41037906|NCT01625429|DRUG|nab-paclitaxel|nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
41037907|NCT03306212|DRUG|Botulinum toxin A|
41037908|NCT03306212|OTHER|Occupational Therapy|
41386684|NCT00981409|DRUG|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (\<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
41386685|NCT00981409|DRUG|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
40855698|NCT02756117|DRUG|L-Lysine|
41037909|NCT03306212|OTHER|Intermittent serial casting|
41386686|NCT06539494|DRUG|Omeprazole 40 MG|Proton pump inhibitor twice a day for 4 weeks
41386687|NCT05706116|BIOLOGICAL|Trichuris trichiura Egg Inoculum|Trichuris trichiura Egg Inoculum that will be used in this study is manufactured by obtaining T. trichiura eggs from the feces of a chronically infected human volunteer, who is negative for HIV, HBV, and HCV. Fecal material is processed following a qualified standard procedure, and after isolating eggs, they are stored at 2-8oC until use. Controls for the manufacturing process are tests for viability (microscopy of larval hatching), species identification (PCR), and microbial bioburden of the eggs.
41386688|NCT05055778|BEHAVIORAL|SmokefreeTXT|"The program is identical to the publicly available program available through the National Cancer Institute Smokefree.gov Initiative but has been set up to be delivered through a research account. The program will send 3-5 messages a day over 7 weeks, with one week to prepare for a quit attempt and 6 weeks of cessation support messages. Participants can get real time support for cravings, mood, and slips by texting keywords to the program. They keywords are CRAVE, MOOD, and SLIP. Participants can also re-set their quit date by texting NEW. The program asks questions each week to ask about smoking status and about mood and cravings."
41386689|NCT05049460|DEVICE|Theta Burst Stimulation|Four sessions of theta burst stimulation (TBS) at 120 % RMT and comprising 7200 pulses, given with functional targeting.
40855699|NCT02756117|DRUG|Normal (0.9%) Saline|
40855700|NCT05113381|DEVICE|CerebroFlo™ EVD Catheter|The CerebroFlo™ EVD Catheter is indicated for temporary insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid (CSF) in those patients with elevated intracranial pressure (ICP), intraventricular hemorrhage, or hydrocephalic shunt infections.
40855701|NCT02321345|OTHER|Palliative Care Support|Palliative care meetings Quality of Life Assessments
41037910|NCT03667950|PROCEDURE|Hyperspectral Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
40855702|NCT06267222|DEVICE|TRANSCRANIAL DIRECT CURRENT STIMULATION + exercises|Participants with SCA will receive trans-spinal tDCS and exercises. There will be no control group or sham stimulation. All participants will receive real tDCS stimulation
40855703|NCT02048085|DRUG|Ticagrelor|For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
41386690|NCT05049460|DEVICE|Sham TMS|Four sessions of sham TMS, done using the A/P MagVenture coil, with subject's head separated from the coil by foam padding.
41386691|NCT02516917|BEHAVIORAL|Attention Training Technique|
40855704|NCT02048085|DRUG|Clopidogrel|For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
40855705|NCT04742894|BEHAVIORAL|Visual Feedback Training|Participants will be trained to work with a computer setup to control the position of a visual cursor on the screen using their speech while their auditory feedback is altered. The goal of the training is to help improve speech production and motor control ability.
40855706|NCT04323072|PROCEDURE|Wide antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 2 cm.
40855707|NCT04323072|PROCEDURE|Smal antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 6 cm.
40855708|NCT01561521|DRUG|AKF-1|1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
40855709|NCT01561521|DRUG|AKF-1|1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
40855710|NCT01561521|DRUG|AKF-1|1 drop 0% in each eye at 2 separate times during a 14 day period
40855711|NCT05632302|DEVICE|nICP|The nICP probe contains infrared light sources that illuminate the deep brain tissue of the frontal lobe. Photodetectors in the probe detect the backscattered light, which is modulated by pulsation of the cerebral arteries.
41386692|NCT05645016|BEHAVIORAL|COEST|Adapted version of our COEST training, targeting Black church members.
41386693|NCT00637052|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
41386694|NCT04196439|PROCEDURE|continuous epidural analgesia|injection of local anaesthetic into epidural space
41386695|NCT04196439|PROCEDURE|supra-inguinal fascia iliaca compartment block|ultrasound guided injection of local anaesthetic into fascia iliaca compartment
41386696|NCT05419635|DRUG|Asundexian (BAY2433334)|Study intervention BAY2433334 will be administered as tablet taken orally.
41386697|NCT03983512|DEVICE|PULSTA TPV System|PULSTA transcatheter pulmonary valve replacement.
41386698|NCT03216681|DRUG|Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
41386699|NCT03216681|DRUG|Tanakan 40mg|Administered orally three times a day, 1 tablet each time, for 45 days.
41386700|NCT00016406|BIOLOGICAL|filgrastim|
41386701|NCT00016406|DRUG|cyclophosphamide|
40855712|NCT01361178|DRUG|SQ IVIG|Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week
40855713|NCT02580461|BEHAVIORAL|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
40855714|NCT00196144|DEVICE|Individualized Programming of PVAB|Performance of a test to detect far-field R-wave sensing
40855715|NCT00196144|DEVICE|Nominal PVAB|nominal pacemaker settings
40855716|NCT05929625|DEVICE|BTL-585-2 RF+US|The subjects of RF+US group will receive four simultaneous RF+US treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
40855717|NCT05929625|DEVICE|BTL-585-2 RF|The subjects of RF only study group will receive four RF treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
40855718|NCT00000228|DRUG|Buprenorphine|
40855719|NCT03042143|BIOLOGICAL|Human umbilical cord derived CD362 enriched MSCs|Infusion of Human umbilical cord derived CD362 enriched MSCs
40855720|NCT03042143|BIOLOGICAL|Placebo (Plasma-Lyte 148)|Infusion of placebo
40855721|NCT00661817|BEHAVIORAL|Lifestyle Modification Program|"Participants will receive a behavior change prescription and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support."
41037911|NCT02959437|DRUG|Azacitidine|Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.
41037912|NCT02959437|DRUG|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
41037913|NCT02959437|DRUG|Epacadostat|Epacadostat tablets will be administered orally twice daily.
41037914|NCT02959437|DRUG|INCB057643|INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
41037915|NCT02959437|DRUG|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.
41386702|NCT00016406|DRUG|doxorubicin|
41386703|NCT00016406|DRUG|paclitaxel|
41386704|NCT00016406|PROCEDURE|surgery|
40855722|NCT00661817|BEHAVIORAL|Usual Care and Reading Materials|"Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's Aim for a Healthy Weight brochure at the baseline study visit and again at the beginning of Year 2."
40855723|NCT00685113|DRUG|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
40855724|NCT00685113|DRUG|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
40855725|NCT00685113|DRUG|Placebo|Placebo vaginal ring inserted vaginally and replaced every 4 weeks
40855726|NCT01491997|BEHAVIORAL|Mind/Body Medicine Course 1|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
40855727|NCT01491997|BEHAVIORAL|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
40855728|NCT01890408|DRUG|wound infusion ropivacaine|"Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours."
40855729|NCT06006117|DRUG|Mosunetuzumab + Lenalidomide|"* Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~  * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~ * C2 to C12: 45 mg D1 28-days cycles~* Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)"
40855730|NCT06006117|DRUG|- Rituximab + Lenalidomide (28-days cycles|"* Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12"
40855731|NCT06006117|DRUG|- Rituximab + Bendamustine (28-days cycles)|"* Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~* Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6."
40855732|NCT06006117|DRUG|- Rituximab + CHOP (21-days cycles)|"* CHOP, IV standard dose from cycle 1 to 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)"
40855733|NCT05766176|DIAGNOSTIC_TEST|COVID-19 Antibody|This descriptive study examines the levels of neutralizing antibodies against COVID-19 in health workers before and after the Quantitative Anti-SARS-CoV-2 Test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV Spike (S) protein. -2, which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale after the 2nd booster COVID-19 vaccine in Surakarta, Indonesia.
40855734|NCT05238545|OTHER|gluten-free diet|Diet excluding foods containing gluten.
41037916|NCT02959437|DRUG|Epacadostat|Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.
41386705|NCT06482749|DEVICE|Repetitive transcranial magnetic stimulation|"Repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 4-6 pm\]). Parameters of rTMS: 8 shaped coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
41386706|NCT06482749|DEVICE|Sham stimulation|"Sham repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 4-6 pm\]). Parameters of rTMS: 8 shaped sham coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
40855735|NCT02813161|BIOLOGICAL|cellular and tissue based therapy|
40855736|NCT02813161|DEVICE|negative pressure wound therapy|
40855737|NCT02813161|PROCEDURE|debridement|
40855738|NCT02813161|PROCEDURE|advanced wound therapy|
40855739|NCT02813161|DIETARY_SUPPLEMENT|Nutritional screening|
40855740|NCT02813161|DEVICE|off-loading|
40855741|NCT02813161|DEVICE|Hyperbaric oxygen Therapy|
40855742|NCT03421912|OTHER|Cicaplast Balm B5|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
40855743|NCT03421912|OTHER|Dexeryl|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
40855744|NCT00720343|DRUG|Choline|Oral Choline 20 grams before surgery
40855745|NCT00720343|DRUG|Placebo|Gelatin Capsule
41037917|NCT02959437|DRUG|INCB059872|INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
40855746|NCT04766775|DEVICE|Silver Diamine Fluoride|Silver Diamine Fluoride (Riva Star) which contains silver, fluoride, ammonia and water.
40855747|NCT04375345|DEVICE|hip arthroplasty|complex primary total hip arthroplasty or revision total hip arthroplasty performed through anterolateral or posterolateral approach
40855748|NCT04217044|DIAGNOSTIC_TEST|Histopathology images based prediction of molecular pathology|Histopathology images based prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
40855749|NCT04632589|DRUG|Losartan Potassium|subjects ingest 50mg losartan potassium tablet daily for 6 weeks
41510608|NCT00880178|DRUG|Simvastatin and Extended-Release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
40855750|NCT04632589|DRUG|Placebo|subjects ingest placebo tablet daily for 6 weeks
40855751|NCT05571722|DRUG|Vancomycin Injection|Patients receive a dose of 30 mg/kg of vancomycin (2 hours infusion) starting 2.5 hours before the scheduled time of surgical incision as defined in the French guidelines.
41386707|NCT04083066|DRUG|rituximab in combination with methotrexate, cytarabine and dexamethasone|"Rituximab 375mg/m2D0 is soluble in 0.9% NS concentration 1mg/ml, micro pump is pumped in 4h HD-methotrexate 3.5g/m2 D1 dissolved in 0.9% NS intravenous drip HD-cytarabine 1g/m2 Q12H D2-3 Dissolved in 250ml 5% GS intravenously~Dexamethasone 40mg D1-5 is dissolved in 100ml 5% GS intravenous drip (21 days is a cycle)"
41386708|NCT03681769|DEVICE|iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the Universal Serial Bus (USB) key).
41386709|NCT03681769|DEVICE|Sham iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
41386710|NCT03681769|DEVICE|cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
41510609|NCT00880178|DRUG|Simvastatin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
41386711|NCT03681769|DEVICE|Sham cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
41386712|NCT01480882|PROCEDURE|Conventional Chest Physiotherapy (CCPT)|Conventional chest percussion will be applied for a duration of 15 minutes.
41386713|NCT01480882|DEVICE|Mechanical percussion (LEGA)|Mechanical chest percussion will be delivered by a device for 15 minutes.
41510610|NCT05129631|BEHAVIORAL|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD.
41510611|NCT01157988|DRUG|ibritumomab tiuxetan (Zevalin)|During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count \> 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
41510612|NCT01457937|DRUG|Pegylated Interferon, Ribavirin, Boceprevir|"PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)"
41510613|NCT02387411|OTHER|High-intensity interval exercise training|High-intensity interval exercise training \[4 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\]
41510614|NCT02387411|OTHER|Combined exercise training|High intensity \[2 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
41510615|NCT04947917|PROCEDURE|SpotTM Tattoo Ink|Ink injection
40855752|NCT05571722|DRUG|Linezolid Injection|Patients receive a dose of 1200 mg of linezolid (30 minutes infusion) 30 minutes before the scheduled time of surgical incision.
40855753|NCT05340036|PROCEDURE|Bimaxillary orthognathic surgery using conventional plates|"le fort I osteotomy will carried out in the classic way guided by the classic landmarks (maxillary roots apices) as described by Wassmund.~Complete separation of the maxillary segment using chisels and mallets in regular fashion.~Reposition maxilla using the interocclusal wafer while mandible is gently positioned to centric relation position.~Mandible is maintained in place until fixation of the maxilla with plates and screws takes place.~Complete separation of the mandibular segment using chisels and mallets in regular fashion.~Repositioning of mandible using the final interocclusal wafer while condylar segment is gently positioned to centric relation position.~Fixation of mandibular segments with plates and/or screws in regular fashion.~Incision was closed with 4-0 resorbable sutures in a continuous running fashion."
40855754|NCT05340036|PROCEDURE|Bimaxillary orthognathic surgery using patient specific plates|"The cutting guide of the maxilla will be placed onto the exposed bony surface and manipulated to the best fit.~Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.~Then, a reciprocating saw will be used to perform the planned Le Fort I osteotomy. After adequate maxillary mobilization and removal of bony interferences, the maxilla will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.~Then, the mandibular cutting guide will be fixed in the same manner and bilateral sagittal split osteotomy will be carried out.~After adequate mobilization, the mandible will be repositioned by the patient-specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws."
40855755|NCT06268964|DRUG|Trimebutine|Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.
41037918|NCT03755453|DEVICE|Hearing aid: Phonak Audéo B90-Direct|Hearing aids will be fitted to the participants individual hearing loss.
41037919|NCT02726451|OTHER|Basic Skin Care|Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
41037920|NCT02726451|OTHER|Active Skin Care|Sensi Peel®, Rejuvenating Serum, and C\&E Strength Max skin care products (PCA SKIN®) in addition to the Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
41037921|NCT01711203|OTHER|Motor Control|Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.
41386714|NCT04846049|OTHER|Comprehensive Care|"1. Comprehensive Geriatric Assessment (3 visits with a geriatrician alternating with 3 primary provider visits over 6 months)~2. Care Planning with Interdisciplinary Team~3. Care coordination~4. Co-management with Primary care~5. Social work needs assessment~6. Patient-centered telehealth using phone, home telehealth, patient portal, Video~7. Transportation provided for all visits~8. Referral to Geriatric primary care clinic and mental health per Veteran need~9. Goals of Care and Veteran preferences conversation~10. Educate primary care providers about HNHR population, home and community based services, collaboration"
41386715|NCT04846049|OTHER|Standard Care|No intervention or treatment will be provided.
41386716|NCT01976637|OTHER|no compression|no compression stockings worn during the study
41386717|NCT01976637|DEVICE|compression|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
41386718|NCT03778190|PROCEDURE|Corneal Foreign Body Removal|An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
41386719|NCT00291356|DRUG|GSK189075 oral tablets|
41386720|NCT00291356|DRUG|GW869682 oral tablets|
41386721|NCT06101719|DIAGNOSTIC_TEST|Enteral contrast challenge|Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.
41386722|NCT06091527|BEHAVIORAL|Yoga practice|90-minute group yoga classes twice weekly for 12 weeks.
41386723|NCT06091527|BEHAVIORAL|Education|90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.
41386724|NCT02202902|OTHER|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
41386725|NCT02202902|OTHER|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
41386726|NCT06416007|RADIATION|Lattice therapy (LRT)|5 Fractions LRT
41386727|NCT03080272|OTHER|no intervention will take place|Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
41386728|NCT03047031|DRUG|Nintedanib|Nintedanib
41386729|NCT03047031|DRUG|Pirfenidone|Pirfenidone
41510616|NCT05523583|OTHER|questionnaire|A trained interviewer (Clinical Research Associate : CRA) will administer a questionnaire soon after the diagnosis on the phone (within 15 calendar days after diagnosis). The participants are followed up during the first year following the diagnosis through 3 follow-up assessments (at 3, 6, and 12 months after the baseline assessment) and hospital record reviews. At each follow-up, a brief questionnaire will be administered by an interviewer (CRA) via telephone.
41510617|NCT00029029|PROCEDURE|pain therapy|
40855756|NCT06268964|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|Prescription of Lactobacillus rhamnosus 5 billion CFUs in chewable tablets, a single dose (night) for 8 weeks.
40855757|NCT06268964|OTHER|Placebo|Prescription of a placebo, 250 mg microcrystalline cellulose tablets, a single dose (night) for 8 weeks.
41037922|NCT01711203|OTHER|General Strengthening|General abdominal and lower quarter musculature strengthening
41037923|NCT06476717|PROCEDURE|Biopsy|Kidney allograft biopsy
41037924|NCT06476717|DIAGNOSTIC_TEST|Blood Biomarkers - cfDNA|dd-cfDNA
40855758|NCT06256341|OTHER|Cell cultivation, Antigen testing|"day 10, peripheral blood mononuclear cells were re-stimulated with the virus antigen U54 for 6 hours and, thereafter, stained for surface markers (CD3, CD4, CD8, CD56) and intracytoplasmatic activation markers (IL-2, IFN-γ, TNF-α) for flow cytometric detection of virus-specific T-cells. T-cells with intracytoplasmic expression of activation markers after stimulation with the virus antigen are HHV-6-specific T-cells. This indicated HHV-6 specific cellular immunity.~No more interventions in human except blood sampling, only basic research."
40855759|NCT01885624|BIOLOGICAL|TAB08|monoclonal antibody
41037925|NCT06476717|DRUG|Antirejection therapy|Patients will receive standard antirejection therapy according to center protocol.
41037926|NCT00905918|DIETARY_SUPPLEMENT|vitamin E|Given orally
41037927|NCT00905918|OTHER|laboratory biomarker analysis|All patients undergo biomarker analyses
41037928|NCT05972720|DRUG|Fludarabine (Conditional therapy)|Lymphodepletion chemotherapy
41037929|NCT05972720|DRUG|Cyclophosphamide Monohydrate (Conditional therapy)|Lymphodepletion chemotherapy
41037930|NCT05972720|DRUG|firi-cel (Experimental drug)|Investigational agent
40855760|NCT05882149|DIETARY_SUPPLEMENT|Single strain probiotic|"Sugar-free chewing gum with single strain probiotic and zinc.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
40855761|NCT05882149|DIETARY_SUPPLEMENT|Placebo|"Sugar-free chewing gum.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
40855762|NCT05767359|DRUG|Ciltacabtagene Autoleucel|Genetically modified autologous T-cell immunotherapy, via intravenous infusion per protocol.
41386730|NCT06352840|BEHAVIORAL|My Pelvic Plan Website|This is a self-directed program which integrates patient education about conditions that frequently contribute to pelvic pain, as well as instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Participants will have open access to the program over the 6-month intervention period. The intervention will be comprised of an active (12-week) phase and a maintenance (3-month) phase. Participants will receive a weekly text or email prompt directing patients to a specific module. All participants will receive prompts to the same modules for the first four weeks of the study, then during the next 8 weeks, participants will receive prompts to modules that corresponded to the most impactful symptoms on participant's baseline questionnaires. Following 12-week active phase, all participants will enter the maintenance phase.
40855763|NCT05767359|DRUG|Cyclophosphamide|Lymphodepleting conditioning regimen, nitrogen mustard-derivative, via intravenous infusion per standard care.
41037931|NCT03375944|OTHER|Rehabilitation|"The purpose of this work package is to evaluate short- and long-term clinical effects of optimal, continuous and regularly controlled tele-rehabilitation, which is based on exercise training, intensive dietary and educational program focused on lifestyle and risk factors modification. The main expectations of OCR is to normalize annual mortality to the level of the low risk healthy population."
41037932|NCT00265369|DRUG|Spores of Bacillus Clausii Probiotic Strain|
41510618|NCT00029029|PROCEDURE|radiofrequency ablation|
41510619|NCT02522715|DRUG|Cabazitaxel|Given IV
41510620|NCT02522715|DRUG|Enzalutamide|Given PO
41510621|NCT02522715|OTHER|Laboratory Biomarker Analysis|Correlative studies
41037933|NCT05711654|BEHAVIORAL|Health coaching|Coaching interview will be held with patients at regular intervals.
41037934|NCT01775228|BEHAVIORAL|Peer Support|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
41037935|NCT05186623|DRUG|Vedolizumab, Ustekinumab, or Tofacitinib|Drug administration and prospective follow-up for evaluating response
41037936|NCT02478619|OTHER|IMT group|"Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.~They will also receive the routine physical therapy in the post operative period."
41037937|NCT02478619|OTHER|Control group|Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
41166495|NCT05296252|BEHAVIORAL|mind-wandering intervention|"Participants in this condition receive a brief introduction to the potential impact of mind-wandering (before learning, proactive), and are redirected to lesson if probe-caught mind-wandering are endorsed (during learning, reactive)"
41510622|NCT02522715|OTHER|Pharmacological Study|Correlative studies
40855764|NCT05767359|DRUG|Fludarabine Phosphate|Lymphodepleting conditioning regimen, synthetic purine nucleoside, via intravenous infusion per standard care.
40855765|NCT06546046|DEVICE|ECG monitoring by telemetry device and patch-type ECG monitor at the same time|The patient undergoes electrocardiogram monitoring simultaneously through a telemetry device and a patch-type electrocardiograph.
40855766|NCT01103570|PROCEDURE|cholecystocholangiography|a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe
40855767|NCT01103570|PROCEDURE|cystic duct cholangiography|Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
41037938|NCT00411905|DRUG|Bortezomib|
41037939|NCT03819153|DRUG|Semaglutide|Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
41166496|NCT05296252|BEHAVIORAL|mind-wandering comparison|Participants in this condition receive no introduction, and only redirection, and the redirection is random, not in reaction to mind-wandering
41166497|NCT05654298|DRUG|Sumatriptan|Sumatriptan 100 mg
41166498|NCT05654298|DRUG|Ubrogepant|Ubrogepant 100 mg
41166499|NCT02384278|BEHAVIORAL|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
41510623|NCT02522715|DRUG|Prednisone|Given PO
41510624|NCT04573894|DIAGNOSTIC_TEST|Procalcitonin dosage|Plasma PCT levels measured by automated enzyme immunoassay (Kryptor).
41510625|NCT03299946|DRUG|Cabozantinib|Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
41510626|NCT03299946|DRUG|Nivolumab|Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
41386731|NCT06352840|BEHAVIORAL|Control Group website|Patients in the control group will undergo an active control intervention in which participants receive open access to a separate website that contains only the Monitoring Progress symptom tracker subpage over the 6-month study period. Control group participation will also be divided into an active (12-week) phase and a maintenance (3-month) phase. Similar to the intervention group, the control group will receive a weekly text (first 12 weeks) or email prompt directing them to a specific module or portion of the respective website. During the maintenance phase of the study, participants will receive monthly prompts to the Monitoring Progress subpage (without prompting to a specific symptom or activity).
41037940|NCT03819153|DRUG|Placebo (semaglutide)|Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
41037941|NCT01909310|PROCEDURE|head extension|the lungs are ventilated with the patient´s head extended
41386732|NCT05189145|DRUG|estradiol valerate|8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound
41386733|NCT05189145|OTHER|Hormonal monitoring progesterone, estradiol, luteinizing hormone|Serum Progesterone, estrogen \& LH measured on day 13 after priming endometrium with 8mg estradiol valerate on a daily basis beginning as early as the first day of menstrual cycle.
41166500|NCT00195884|BEHAVIORAL|Aerobic and Resistance Exercise|"Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program."
41166501|NCT04356638|DRUG|Midazolam|Oral Midazolam and intranasal placebo
41386734|NCT05189145|DIAGNOSTIC_TEST|transvaginal ultrasound examination|Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation
41386735|NCT05189145|DRUG|Progesterone 400 Mg Vaginal Suppository|Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each
41510627|NCT05635032|OTHER|Comprehensive clinical assessment and biological samples collection|To establish the first Portuguese registry and biobank of PF-ILDs, comprising both extensive patient-level data, and systematic biological sampling (DNA, RNA, plasma, serum, bronchoalveolar lavage, lung tissue) at baseline and repeated biological sampling of blood and pharyngeal swabs performed at 6, 12 and 18 months, or whenever progression criteria are met or an acute exacerbation occurs. Participants will have regular visits at maximum intervals of 6 months, when their clinical condition and lung function tests are reassessed. A high resolution computed tomography (HRCT) scan of the lung will be performed every 12 months. Progressive fibrosis will be diagnosed based on meeting at least two of the following three criteria, occurring within the last year: (i) worsening of symptoms; (ii) absolute decline in FVC ≥5% predicted or absolute decline in DLCO (corrected for Hb) ≥10% predicted; (iii) increased extent of fibrotic changes on HRCT.
41510628|NCT03414216|PROCEDURE|Group 1 early offloading surgery|As above.
41510629|NCT03414216|PROCEDURE|Group 2 - off-loading in fiberglass cast|As above.
41510630|NCT05179109|PROCEDURE|Minimally invasive surgery|Minimally invasive surgery for severe deep endometriosis
41510631|NCT02871323|BIOLOGICAL|Durvalumab|Given IV
41510632|NCT02871323|OTHER|Laboratory Biomarker Analysis|Correlative studies
41510633|NCT00005603|DRUG|asparaginase|
41510634|NCT00005603|DRUG|cyclophosphamide|
41166502|NCT04356638|DRUG|Dexmedetomidine|Intranasal Dexmedetomidine and oral placebo
41510635|NCT00005603|DRUG|cytarabine|
41166503|NCT04356638|OTHER|Placebo|Placebo orally and intranasally
41166504|NCT02940210|DEVICE|Mediclore® (adhesion barrier)|
41166505|NCT00001941|BIOLOGICAL|daclizumab|
41166506|NCT05193747|OTHER|Anesthesia depth monitoring|BIS monitor will be placed on the forehead according to the manufacturer recommendation and the anaesthesia team will be blinded to BIS monitor during the whole case. The initial BIS tracing will be recorded starting the surgery initiation (defined as the depth of anesthesia by the anaesthesiologist to initiate surgical intervention) and ending with end of surgical intervention.
41166507|NCT01051102|DRUG|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
41510636|NCT00005603|DRUG|daunorubicin hydrochloride|
41510637|NCT00005603|DRUG|dexamethasone|
41510638|NCT00005603|DRUG|doxorubicin hydrochloride|
41166508|NCT01051102|DRUG|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
41166509|NCT00619983|DRUG|donepezil|Group 1: Will receive donepezil 5mg once a day
41166510|NCT00619983|DRUG|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
41166511|NCT00619983|DRUG|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
41510639|NCT00005603|DRUG|mercaptopurine|
41510640|NCT00005603|DRUG|methotrexate|
41510641|NCT00005603|DRUG|prednisone|
41510642|NCT00005603|DRUG|thioguanine|
41510643|NCT00005603|DRUG|vincristine sulfate|
41510644|NCT05560386|BEHAVIORAL|Text messaging|text messaging content to support diabetes prevention.
41510645|NCT05560386|BEHAVIORAL|Virtual workshop|virtual workshop content to support diabetes prevention.
41510646|NCT00703872|DRUG|Oral HDV-Interferon + ribavarin|Naive pateints
41510647|NCT00703872|DRUG|Injectable HDV-Interferon + ribavarin|Nonresponders
41166512|NCT00619983|DRUG|placebo|Group 4: Will receive placebo pills
40855768|NCT01610336|DRUG|INC280|During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
40855769|NCT01610336|DRUG|Gefitinib|Gefitinib 250 mg taken once daily
41386736|NCT05189145|OTHER|Hormonal monitoring progesterone and estradiol|Measuring the serum Progesterone \& Estradiol in the early morning on the day of embryo transfer an progesterone supplementation adjusted as follows: Group II A: If P4 levels \< 5ng/dl, one 100 mg intramuscular injection daily added, Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added. Group II C: If P4 levels \>10ng, continued on 400 mg prontogest suppositories twice daily
40855770|NCT04033510|OTHER|Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm|Direct current cardioversion, PVAI-atrial fibrillation ablation, Minimally Invasive Surgical Maze procedure, Medications
40855771|NCT01281540|DRUG|Cisapride|one 10 mg tablet 4 times a day for 8 weeks
40855772|NCT01281540|DRUG|Placebo|one placebo tablet 4 times a day for 8 weeks
40855773|NCT03079596|PROCEDURE|ERAS perioperative cares|Patient's preoperative counseling \& education before surgery No Bowel preparation Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Fluid restriction \& Management by pulse contour analysis or transesophageal doppler Early mobilization Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD)) Epidural patient controlled analgesics (no opioids analgesics) Postoperative Nausea Active Control Thromboembolism prophylaxis by low molecular weighted heparin (LMWH) Perioperative High content Oxygen therapy No drain insertion No Levin tube Patients will be discharged at POD#4 if there's no problem.
40855774|NCT03079596|PROCEDURE|Conventional perioperative cares|No Patient's preoperative counseling \& education before surgery Bowel preparation No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Conventional Fluid Management by clinical signs (Urine output, heart rate etc.) Conventional Mobilization Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD) IV PCA Postoperative Nausea Control if needed No Thromboembolism prophylaxis No or Low Content Oxygen therapy Routine drain insertion Levin tube insertion if needed
40855775|NCT03565146|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of pigmented lesions
40855776|NCT05844020|BEHAVIORAL|Educational materials|Trauma-informed intimate partner violence screening, brief interventions, and referrals to treatment by providers
40855777|NCT01361893|OTHER|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
40855778|NCT02679287|DEVICE|CLC|The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
40855779|NCT00939458|DRUG|Lamotrigine|
40855780|NCT03218176|DEVICE|Proximal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
40855781|NCT03218176|DEVICE|Proximal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
41037942|NCT01909310|PROCEDURE|neutral position|the lungs are ventilated with the patient´s head in neutral position
41037943|NCT01909310|PROCEDURE|anaesthesiologist´s position|the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
41386737|NCT05189145|DRUG|Progesterone|group II A: 100 mg intramuscular injection daily Group II B: If P4 levels 5-10ng/dl dydrogesterone added
41386738|NCT06301477|OTHER|Resistant Starch|7.5g/m2 or 5.0g/m2 (body surface area) resistant starch oral consumption
41510648|NCT00039702|DRUG|[123] 5-I-A-85380|
40855782|NCT03218176|DEVICE|Distal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
40855783|NCT03218176|DEVICE|Distal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
41037944|NCT06089811|DIETARY_SUPPLEMENT|Prebiotic|Group 1 (prebiotic and placebo L-tryptophan): prebiotic (oligofructose, Orafti®P95, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day)
41037945|NCT06089811|DIETARY_SUPPLEMENT|L-Tryptophan|Group 2 (placebo prebiotic and L-tryptophan): L-tryptophan (3g/day) and placebo prebiotic (microcrystalline cellulose, 20g/day)
41037946|NCT06089811|DIETARY_SUPPLEMENT|Placebo|Group 3 (placebo prebiotic and placebo L-tryptophan): placebo prebiotic (microcrystalline cellulose, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day).
41037947|NCT03884751|BIOLOGICAL|CAR-GPC3 T Cells|CAR-GPC3 T Cells injection
41037948|NCT02943603|DRUG|mFLOFOX6 + pembrolizumab|the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
41166513|NCT00619983|DRUG|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
40855784|NCT03218176|DEVICE|Proximal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
40855785|NCT03218176|DEVICE|Proximal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
40855786|NCT03218176|DEVICE|Distal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
40855787|NCT03218176|DEVICE|Distal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
40855788|NCT00612196|DRUG|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
40855789|NCT00612196|DRUG|Placebo|
41037949|NCT00509847|DRUG|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
41037950|NCT02430194|DRUG|lonafarnib|antiviral farnesyl transferase inhibitor
41037951|NCT02430194|DRUG|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
41037952|NCT02430194|DRUG|Pegylated interferon-alfa-2a|immunomodulator
41037953|NCT02750254|DRUG|Fludarabine|
41037954|NCT02750254|RADIATION|Fractionated total body irradiation|
41386739|NCT06301477|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
41386740|NCT04185207|OTHER|no intervention|There is no intervention.
41386741|NCT06552572|DRUG|Glofitamab|Glofitamab is administered to patients who have residual disease after CD19 CAR T-cell therapy for their relapsed or refractory diffuse large B-cell lymphoma
41386742|NCT06254859|PROCEDURE|Traditional thyroid surgery.|The patient undergoes traditional thyroid surgery with concurrent intraoperative nerve monitoring technology.
41386743|NCT02365818|BIOLOGICAL|CG0070|
41510649|NCT02737774|DRUG|Icotinib|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
41510650|NCT02737774|DRUG|Pemetrexed/Carboplatin|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
40855790|NCT04527367|PROCEDURE|Innovative medical technologies in invasive cardiology and cardiac surgery|A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.
40855791|NCT04829916|DRUG|RMC-035|Multiple dosing during 48 hours following cardiac surgery
40855792|NCT04829916|DRUG|Placebo|Multiple dosing during 48 hours following cardiac surgery
41037955|NCT02750254|DRUG|Busulfan|
41037956|NCT02750254|DRUG|Cyclophosphamide|
41037957|NCT02750254|RADIATION|Single dose total body irradiation|
41037958|NCT02750254|DRUG|Melphalan|
41037959|NCT02750254|DRUG|Granulocyte-colony stimulating factor|
41037960|NCT02750254|PROCEDURE|Stem cell transplant|
41166514|NCT06069934|DRUG|Pridopidine|Pridopidine 45 mg once daily p.o. (or via feeding tube) over a 2-week up-titration period; followed by pridopidine 45 mg twice daily p.o. (or via feeding tube) for the remainder of the treatment period (through Week 104)
41386744|NCT06537245|OTHER|Massage|Massage was applied in the both quads during 5 or 10 minutes, with differents pressures.
41386745|NCT03725267|DRUG|Melatonin Pill|Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
41386746|NCT03725267|DRUG|Placebo oral capsule|Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
41386747|NCT05354336|DRUG|SHR6390(100mg)|SHR6390 at a single oral dose of 100 mg.
41386748|NCT05354336|DRUG|SHR6390(125mg)|SHR6390 at a single oral dose of 125 mg.
41386749|NCT05354336|DRUG|SHR6390(150mg)|SHR6390 at a single oral dose of 150 mg.
41386750|NCT04007744|BIOLOGICAL|Pembrolizumab|Given IV
41386751|NCT04007744|DRUG|Sonidegib|Given PO
41510651|NCT01965054|DIETARY_SUPPLEMENT|Fish Oil Supplement Group|1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
41386752|NCT06421623|OTHER|Program Including Various Workshops aiming to preserve elderly's autonomy through foot health|Combination of minimalist footwear, foot massages, and workshops to re-learn walking and posture
41386753|NCT01878500|DEVICE|Intraoperative stereotactic imaging with VectorVision|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
41386754|NCT03089931|PROCEDURE|Cervical spinal surgery|Cervical laminoplasty or anterior discectomy and fusion
41386755|NCT03033069|DRUG|Brexpiprazole|Brexpiprazole oral tablets.
41510652|NCT00365703|PROCEDURE|Feeding tube insertion|"1. Orogastric feeding tube~2. Nasogastric feeding tube"
41510653|NCT05491486|BEHAVIORAL|Mindfulness-based Group Therapy|see above
41166515|NCT00258362|DRUG|carboplatin|Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
41166516|NCT00258362|DRUG|docetaxel|75 mg/m\^2 on Day 1 of each course
41386756|NCT03033069|DRUG|Sertraline|Sertraline oral capsules.
41386757|NCT03033069|DRUG|Brexpiprazole Matching Placebo|Brexpiprazole matching placebo oral tablets.
41386758|NCT03033069|DRUG|Sertraline Matching Placebo|Sertraline matching placebo oral capsules.
41510654|NCT01688557|DEVICE|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
41510655|NCT01688557|DEVICE|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
40855793|NCT03202134|OTHER|opioid free anesthesia|general anesthesia blocking reflexes without using an opioid
40855794|NCT06256393|OTHER|Collection of biological samples|Collection of blood samples and intestinal biopsies during a surgery or colonoscopy for disease relapse
40855795|NCT01229722|DEVICE|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
41037961|NCT02750254|DRUG|Azacitidine|
41037962|NCT03188848|DRUG|BPI-3016|Single-dose subcutaneous injection of BPI-3016
41037963|NCT03188848|DRUG|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
41037964|NCT03461068|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.
41037965|NCT03461068|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.
41037966|NCT06430450|DIAGNOSTIC_TEST|Clinical measurements and saliva samples collection|Clinical measurements will be taken from all patients and saliva samples will be collected for biochemical analysis.
41037967|NCT01037920|BEHAVIORAL|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
40855796|NCT01229722|DEVICE|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
40855797|NCT02638168|DRUG|Immediate Release Methylphenidate|The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
40855798|NCT02638168|DRUG|Placebo|inert placebo ingredient
40855799|NCT04618744|DRUG|ORMD-0801 (Insulin) capsule 8 mg BD|8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
40855800|NCT04618744|OTHER|Placebo|Matching Placebo
40855801|NCT06027099|DRUG|Tizanidine|Tizanidine 2mg three times a day for 5 weeks after surgery
40855802|NCT06027099|BEHAVIORAL|MI-Opioid Taper|Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.
40855803|NCT06027099|DRUG|Placebo|1 tablet three times a day for 5 weeks after surgery
40855804|NCT06027099|BEHAVIORAL|Enhanced Usual Care|Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide \& Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.
40855805|NCT05751369|BEHAVIORAL|Education plus Support|Brief behavioral support for using TECW Tracker
40855806|NCT04994548|PROCEDURE|Endosocpic resection of early esophageal tumor|under general anesthesia, by mucosectomy or endoscopic submucosal dissection
40855807|NCT00206843|DEVICE|Triage BNP Test|
40855808|NCT06311422|OTHER|resin nanoceramic block|Resin-based CAD/CAM materials
41037968|NCT01037920|BEHAVIORAL|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
41037969|NCT02345148|DRUG|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
41037970|NCT04981665|DRUG|Tislelizumab|Tislelizumab 200mg IV Q3W
41037971|NCT04981665|DRUG|TACE|TACE will be performed after curative resection (4±1w)
41510656|NCT05798910|OTHER|ALS VR (VR based serious gaming module for advanced life support training)|Using VR based serious gaming module for advanced life support training instead of taking part in a classical lecture about advanced life support.
40855809|NCT06311422|OTHER|zirconia-reinforced lithium silicate|zirconia reinforced lithium silicate ceramic
40855810|NCT04188704|PROCEDURE|Interference screw|Anterior cruciate ligament reconstruction (anterior screw fixation or posterior screw fixation)
40855811|NCT03257683|DRUG|Ranolazine|Study group will receive additional therapeutic dosing of drug.
40855812|NCT04115137|DEVICE|pelvic varicose veins plug embolization|pelvic varicose veins plug embolization
40855813|NCT02412046|PROCEDURE|Muscle biopsy|
40855814|NCT06464016|DEVICE|Ventricular Assist Device with Berlin Heart EXCOR|"The Berlin Heart® EXCOR is a type of artificial heart pump that pulls blood from the ventricle and then sends that blood to the aorta or pulmonary trunc, thereby taking away extra work from the native heart. The device, which comes in several sizes, is not totally implanted inside the body."
40855815|NCT06507930|OTHER|Telehealth Hospice Visits|Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call.
41037972|NCT00971048|DEVICE|HP828-101|Topical test article applied once daily
41037973|NCT00971048|DEVICE|Hydrogel/Hydrocolloid|Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
41037974|NCT04238806|DRUG|Desflurane Inhalational agent|Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.
41037975|NCT01767740|DEVICE|ULTRABRAID PLUS SUTURE|Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
41037976|NCT01767740|DEVICE|ULTRABRAID SUTURE|Rotator Cuff Repair with ULTRABRAID SUTURE
41037977|NCT03385876|GENETIC|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
41166517|NCT00258362|RADIATION|radiation therapy|Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
40855816|NCT00496639|PROCEDURE|angioplasty|Balloonplasty of the stenotic lesion at the venous anastomosis of the thrombosed AV graft.
40855817|NCT00496639|PROCEDURE|stent placement|Balloonplasty plus stent deployment at the stenotic lesion at the venous anastomosis of the thrombosed AV graft
40855818|NCT03400163|DRUG|BMS-986036|BMS-986036 20 mg QD
41510657|NCT05798910|OTHER|Lecture based training for advanced life support|Taking part in a classical lecture about advanced life support.
40855819|NCT03400163|DRUG|Placebo|Placebo QD
41386759|NCT04832178|DIETARY_SUPPLEMENT|SUMOR|"SUMOR is a food supplement distributed in Italy by ArcaPharma. regularly entered in the register of Food Supplements of the Ministry of Health (number 62590). Formulated in prolonged-release tablets, each tablet contains the following substances:~* S-Adenosyl-L-Methionine sulfate p-toluenesulfonate 250 mg~* Betaine hydrochloride 250 mg~* Vitamin C 80 mg~* Vitamin B1 1.1 mg~* Vitamin B2 1.4 mg~* Vitamin B6 1.4 mg~* Vitamin B12 2,5 µg~* Folic Acid 200 µg~* Selenium 37 µg"
41386760|NCT04832178|OTHER|Placebo|Placebo tablet will be identical in appearance to the experimental product (SUMOR).
41386761|NCT04250896|OTHER|Control group|Standard child care in health unit plus exposure to EsIAN
40855820|NCT04146662|DIAGNOSTIC_TEST|Faecal immunochemical test|Faecal immunochemical test (FIT) and urine volatile organic compounds (VOC) analysis.
40855821|NCT00870987|BIOLOGICAL|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
40855822|NCT00870987|BIOLOGICAL|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
40855823|NCT06197711|BEHAVIORAL|PRISMA|"PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants; PRISMA has four sessions."
40855824|NCT01743443|OTHER|Cochet-Bonnet esthesiometer central corneal sensitivity|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
41386762|NCT04250896|BEHAVIORAL|SMS´s sending by cell phone for behavior change|SMS messages sent through a cell pone through the RapidPro platform on practices related to the prevention of infant malnutrition to primary caregivers and the strengthening of counseling for the prevention of infant malnutrition with health providers.
41386763|NCT03686137|OTHER|Data collection|Colelction of pre-operative, surgical and post-surgical data
41510658|NCT05481619|DRUG|Vedolizumab|"Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter.~Discontinue vedolizumab at week 14 in patients who do not show treatment benefit."
41510659|NCT01191034|DRUG|Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.|"The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.~This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod."
41510660|NCT02693860|DRUG|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute.
40855825|NCT01746225|DRUG|nab-Paclitaxel|Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
40855826|NCT02444052|DEVICE|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
40855827|NCT02444052|DEVICE|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
40855828|NCT05696496|DEVICE|night recording|"The patients/controls will arrive in the evening at the Sleep Laboratory (Functional Exploration Department of the Nervous System of the Clermont-Ferrand University Hospital) to carry out complete vPSG and test the new ESM intelligent duvetdevice. A qualified technician will place the electrodes according to the procedures usually followed at the Sleep Center for vPSG recording. The ESM duvet will be placed on the patient's body as a blanket, instead of the blankets normally provided by the hospital. Patients/controls will be monitored overnight by an infrared video camera."
40855829|NCT00056004|DRUG|zileuton|
40855830|NCT04949022|DEVICE|Medronic 780G insulin pump|Commercial hybrid closed loop system Medronic 780G
41037978|NCT04794803|DRUG|Reparixin|Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first.
41037979|NCT04794803|DRUG|Standard of care|Standard of care
41510661|NCT02693860|DRUG|89Zr-J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
41510662|NCT03790657|BEHAVIORAL|practice of a complex walking task|walking over obstacles
41510663|NCT03790657|DEVICE|Dosage A: transcranial direct current stimulation (tDCS)|mild electrical stimulation delivered to the frontal region of the brain
41510664|NCT03790657|DEVICE|Dosage B: transcranial direct current stimulation (tDCS)|mild electrical stimulation delivered to the frontal region of the brain
41037980|NCT02172508|DRUG|Tiotropium Inhalation Capsule|
41037981|NCT02172508|DRUG|Placebo Lactose Capsule|
41037982|NCT02385344|DEVICE|Medistim device|This registry is intended to document surgical findings, procedural changes, and adverse events occurring prior to discharge
41037983|NCT02315157|DRUG|Bendamustine|Given IV
41386764|NCT04210700|PROCEDURE|Fascia iliaca compartment block|"A linear ultrasound transducer is placed in a sagittal plane to identify the anterior superior iliac spine. By sliding the transducer medially, the fascia iliaca and abdominal internal oblique, sartorius, and iliopsoas muscles are identified. After identifying the bow-tie sign, a 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from caudal to cephalad until the needle tip penetrate the fascia iliaca. After negative aspiration, 0.35% ropivacaine 30mL with 1:400,000 epinephrine will be injected to separate the fascia iliaca and the iliacus muscle."
41510665|NCT06077474|OTHER|Testing the the DSM-5 UCLA Posttraumatic Stress Disorder Reaction Index Self-Report Scale for Children and Adolescents (PTSD-RI-5)|Administer the DSM-5 PTSD-RI-5 scale in 155 patients with exposed to traumatic events.
41510666|NCT06301191|DRUG|Semaglutide, 1.0 mg/mL|Semaglutide, 1.0 mg/mL
41510667|NCT06301191|DRUG|Dipeptidyl Peptidase 4 inhibitor|Dipeptidyl Peptidase 4 inhibitor
41510668|NCT05886712|OTHER|Naloxone|Naloxone
41510669|NCT05886712|OTHER|Usual intervention|usual administered drug for overdose
41510670|NCT02914860|DEVICE|Cardiac CT|"* Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map."
41510671|NCT02914860|PROCEDURE|Ablation Procedure|"1. CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~2. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~3. RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~4. Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~5. Control HFS~6. At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~7. Exit and entrance block confirmation~8. Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia."
41510672|NCT02914860|DEVICE|D-SPECT|
41510673|NCT05115487|DIAGNOSTIC_TEST|digital dynamometer|Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.
40855831|NCT01558453|DRUG|Oxaliplatin|"Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.~NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30)."
40855832|NCT01740401|DRUG|Cyclophosphamide|This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
40855833|NCT03451123|DRUG|FET PET/MRI|FET PET/MRI scan before and after surgery
40855834|NCT03999840|DRUG|cemdisiran|Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
40855835|NCT03999840|DRUG|Placebos|The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
41510674|NCT02609438|BEHAVIORAL|Short breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
41510675|NCT02609438|BEHAVIORAL|Long breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
41510676|NCT06461624|BIOLOGICAL|anti-GPC3 CAR-T|All subjects were intravenous administrated with CBG166.
41510677|NCT05019300|BIOLOGICAL|Exposure: COVID-19 severity|COVID-19 severity between 4 to 7 points according the seven-category scale of clinical status reported by Huang et al. (2021) and severe to critical symptomatic levels on spectrum of disease reported by Wu and McGoogan (2020).
41510678|NCT04320043|PROCEDURE|Anterior cervical decompression|Any of the following anterior surgical techniques used to decompress the cervical nerve roots or spinal cord; corpectomy, Anterior Cervical Discectomy (ACD), Anterior Cervical Decompression and Fusion (ACDF) or ACDF with Plating
41510679|NCT05233462|OTHER|standardized dose|intrathecal anesthesia with 10 mg of bupivacaine
41510680|NCT05233462|OTHER|adjusted dose|intrathecal anesthesia with 0.05 mg of bupivacaine par cm of patient's height
40855836|NCT04151134|DIAGNOSTIC_TEST|Step serial sectioning histological processing|Step serial sectioning histological processing
40855837|NCT02360228|DEVICE|tACS (alpha)|
40855838|NCT02360228|DEVICE|tDCS|
40855839|NCT01379196|DRUG|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
41037984|NCT01832116|DRUG|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
41037985|NCT00070473|DRUG|pemetrexed disodium|
41037986|NCT03818412|PROCEDURE|Archival tumor tissue collection and blood draws|Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.
41510681|NCT03397225|BEHAVIORAL|Lifestyle intervention|The educational sessions and individual sessions including dietary management and physical activity advices.
41386765|NCT04210700|PROCEDURE|Pericapsular nerve group block|A curvilinear ultrasound transducer is initially place on the anterior inferior iliac spine and then aligned to the iliopubic eminence by rotating around 45 degree. In this view, the iliopubic eminence, iliapsoas muscle and tendon, pectineus muscle, femoral artery and vein will be identified. A 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from lateral to medial until the needle tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After negative aspiration, 0.35% ropivacaine 20mL with 1:400,000 epinephrine will be injected.
41386766|NCT02367781|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression."
41386767|NCT02367781|DRUG|Carboplatin|Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
41386768|NCT02367781|DRUG|Nab-Paclitaxel|Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.
41386769|NCT02367781|DRUG|Pemetrexed|Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
41386770|NCT05775146|RADIATION|stereotactic body radiation treatment (SBRT)|SBRT uses 3D imaging to target high doses of radiation to the affected area. There is very little damage to the surrounding healthy tissue. SBRT works by damaging the DNA of the targeted cells. Then, the affected cells can't reproduce, which causes tumors to shrink.
41386771|NCT05013827|BEHAVIORAL|Filling in an online survey|Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
41386772|NCT05572424|OTHER|Adaptated Physical Activity (APA) + pedometer watch|"Adapted physical activities program : 12 weeks, 2 40-minutes sessions per week ( one broadcast live via online video conferencing and other one in autonomy according to a sequence of different personalized exercises defined by the APA's professional). Children are divided into 6 groups. Each session will be broken down into three parts: the warm-up (10mins), the session's corps alternating between five to eight of muscle strengthening, proprioception, and endurance exercises (20mins) and a cool-down with stretching (10mins). The physical activity performed during the sessions will be quantified with a heart rate monitor and the range of 60-70% of the maximum theoretical heart rate for each child will be respected.~A pedometer watch will wear during 1 year and will provide the number of steps."
41386773|NCT02437929|PROCEDURE|Mobilization|
41386774|NCT02437929|PROCEDURE|Positioning|
41386775|NCT02437929|PROCEDURE|Personal Hygiene Care|
41386776|NCT02437929|PROCEDURE|Bladder catheterization|
41386777|NCT02437929|PROCEDURE|Wound care|
41386778|NCT02437929|PROCEDURE|Subcutaneous drugs administration|
41386779|NCT03992612|OTHER|control group: usual medical care|The patients received usual medical care.
41386780|NCT03992612|BEHAVIORAL|MBPM- Mindfulness-Based Pain Management|8 group session of maindfulness-based treatment to management pain
41386781|NCT05145816|DRUG|Belantamab mafodotin 2.5 mg/kg (8 weeks)|2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
41386782|NCT05145816|DRUG|Belantamab mafodotin 1.9 mg/kg (8 weeks)|1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1
41510682|NCT00649779|DRUG|albuterol sulfate extended-release 8 mg tablets|8mg, single dose fasting
41510683|NCT00649779|DRUG|VoSpire™ ER 8 mg tablets|8mg, single dose fasting
41037987|NCT01440153|OTHER|Exercise Intervention|Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
41386783|NCT05145816|DRUG|Belantamab mafodotin 1.4 mg/kg (12 weeks)|1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
41386784|NCT05145816|DRUG|Belantamab mafodotin 1.9 mg/kg (12 weeks)|1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
41386785|NCT05145816|DRUG|Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages|Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks or 12 weeks as determined by Part 1 recommended dosages.
41386786|NCT05145816|DRUG|Belantamab mafodotin 1.0 mg/kg (12 weeks)|1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
41386787|NCT04574037|OTHER|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential)|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential) will determine the predictive functional outcome of the upper limb deficit according to the PREP2 algorithm.
41386788|NCT00334269|BEHAVIORAL|Health messaging at weekly home visits by health counsellor|
41386789|NCT00334269|BEHAVIORAL|Weekly home delivery of bottled spring water|
41386790|NCT00334269|BEHAVIORAL|Weekly afterschool physical activity program for 5-18y.o.|
41386791|NCT00334269|BEHAVIORAL|Cooking classes and grocery store tours with dietician|
41386792|NCT00334269|BEHAVIORAL|Pedometers to track/increase weekly physical activity|
41386793|NCT01855100|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
41386794|NCT03500887|DEVICE|intragastric bag|
41386795|NCT02394379|DEVICE|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
41386796|NCT00424931|DRUG|JNJ-17216498|50mg one time
41386797|NCT00424931|DRUG|JNJ-17216498|10mg one time
41386798|NCT00424931|DRUG|Modafinil|200 mg X 2
41386799|NCT03785652|DRUG|LY03005 extended-release tablets 40 mg|LY03005 extended-release tablets 40 mg group :40mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfas
40855840|NCT06128577|COMBINATION_PRODUCT|3-month intensive intervention|"Intensive nutritional interventions were as follows: i）Estimation of ideal body weight according to height, calculation of calories by giving 30-40kcal/kg/day according to BMI stratification, and calculation of daily protein requirement at 1.5g/kg/day, which was finally converted into daily dietary recommendations according to the results of the calculations. ii）Distribution of additional protein supplementation by whey protein, each sachet containing 15g of whey protein.~The resistance training program included 5 min of warm-up, 20 min of muscle strength training, and 5 min of slow walking and was performed three times a week. Resistance training involved a dumbbell and sandbags as weights for the major muscles of the upper and lower limbs. In the study, aerobic training is brisk walking or jogging for 30 minutes/day, five times a week."
40855841|NCT00632619|BEHAVIORAL|Group-based behavior therapy|Group-based behavior therapy with a parenting class will include 12 weeks of sessions that focus on reducing oppositional and aggressive behaviors. Children will participate in 12 weeks of social skills training integrated with a cognitive behavioral therapy (CBT) component to target mood symptoms. Parents will learn ways to identify and address their child's mood problems, communicate better with their child, and work with school staff to address academic and behavioral problems.
41037988|NCT01440153|OTHER|Passive Intervention|Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
41037989|NCT05071157|BEHAVIORAL|echocardiography|"* speckle tracking echocardiography~* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)~* bioimpedance~* blood test for biological assays (metabolomic analysis)"
41037990|NCT02278094|DEVICE|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
41037991|NCT02278094|DEVICE|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
41037992|NCT02278094|PROCEDURE|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
41037993|NCT02278094|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
41037994|NCT02420002|DRUG|Use of MEOPA during suturing|Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
41037995|NCT02420002|OTHER|Use of Hypnosis during suturing|Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).
41037996|NCT02420002|PROCEDURE|Stitch removal|6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
41386800|NCT03785652|DRUG|LY03005 extended-release tablets 80 mg group|"LY03005 extended-release tablets 80 mg group :~80mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
41386801|NCT03785652|DRUG|LY03005 extended-release tablets 120 mg group|"LY03005 extended-release tablets 120 mg group :~120mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
40855842|NCT00632619|DRUG|Stimulant medication therapy|All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
40855843|NCT00632619|BEHAVIORAL|Community-based psychosocial treatment|Participants will receive referrals to community-based psychosocial treatments that will focus on ADHD symptoms and management of aggression.
41037997|NCT01265069|DRUG|high dose dual therapy|rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
41386802|NCT03785652|DRUG|LY03005 extended-release tablets 160 mg group|"LY03005 extended-release tablets 160 mg group :~160mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
40855844|NCT02061514|PROCEDURE|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
41037998|NCT01265069|DRUG|concomitant therapy|rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
41037999|NCT03356925|DIAGNOSTIC_TEST|Xpert Ultra Point of Care testing|The intervention is the point of care Xpert Ultra TB diagnostic compared to the standard of care centralised TB testing at a centralised facility
41038000|NCT02775526|PROCEDURE|TOT|70 patients
41038001|NCT02775526|PROCEDURE|TVT|70 patients
41038002|NCT02775526|PROCEDURE|Burch Colposuspension|70 patients
40855845|NCT02061514|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
41038003|NCT02105116|DRUG|fludarabine phosphate|Given IV
41038004|NCT02105116|DRUG|cytarabine|Given IV
41038005|NCT02105116|BIOLOGICAL|donor lymphocytes|Undergo infusion of donor lymphocytes
41038006|NCT02105116|OTHER|laboratory biomarker analysis|Correlative studies
41038007|NCT02105116|DRUG|G-CSF|Given IV
41386803|NCT03785652|DRUG|Placebo group|"Placebo group :~Placebo ，orally once a day, at a regular morning time on an empty stomach or after breakfast"
41038008|NCT05974969|DRUG|BCD-264|a single intravenous infusion of BCD-264
41528352|NCT06149975|OTHER|motor-cognitive training|"The motor-cognitive training in this study will be conducted in form of a step-based dual-task training. A mat (approximately 90 x 90 cm) made from extra non-slip yoga mats is required. The mat is divided into 9 equal squares with a 3 x 3 pattern. Participants will be presented with stepping patterns which they must memorize and then execute on the mat in the pace given by a metronome. All participants will start at the same level. The progression will be adjusted individually according to the fixed criteria of the StepIt concept within the sessions. All sessions will be supervised by at least one physical therapist."
40855846|NCT06393647|OTHER|Frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36)|In our study, we aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery.
40855847|NCT04839549|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
41510684|NCT00588458|PROCEDURE|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
41510685|NCT03740581|DRUG|Insulin|Basal Bolus regimen (Participant to receive, Insulin \>= 3 times per day)
41510686|NCT03245411|BEHAVIORAL|Intervention|All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.
41510687|NCT00452556|DRUG|Docetaxel|Weekly
40855848|NCT04839549|DRUG|Fluoromethalone .01%|Fluoromethalone .01%
40855849|NCT05370443|BEHAVIORAL|Life Skills education program|"The World Health Organization (WHO), describes life skills as abilities for adaptive and positive behaviour that enables individuals to deal effectively with the demands and challenges of everyday life. Life Skills Education includes activities that support critical and creative thinking, coping with emotions and stress, self-awareness and empathy, decision-making and problem-solving, communication skills, and interpersonal relations."
40855850|NCT02380911|OTHER|Educational Intervention|"Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.~In addition, 2 intervention support tools are used at the intervention clinics:~1. A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.~2. On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions."
40855851|NCT05168228|PROCEDURE|Oil- versus waterbased contrast in hysterosalpingography (HSG)|The Neuro-H2Oil study looks at the offspring of the H2Oil study, a randomized controlled trial (RCT) comparing hysterosalpingography (HSG) with oil- versus water-based contrast during fertility work-up. For more information please see NTR 3270 (original H2Oil study), www.trialregister.nl. The control group is the Database for Controls in Neuroscience Studies (D-CNS), registered as NL9574 (https://www.trialregister.nl/trial/9574).
40855852|NCT05844358|DEVICE|MySpine MC|Spinal stabilization throught the support of patient specific guide, MySpine MC according to cortical bone trajectory technique
40855853|NCT01678612|OTHER|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
40855854|NCT05374330|OTHER|Electroacupuncture|Acupuncture needles are inserted into the body at standardized acupuncture points. An electrical current is then applied to 4 needles through 2 channels of electrical current. The sham group receives the same protocol with sham needles and sham electrical current.
40855855|NCT02787915|BIOLOGICAL|DC1-CTL|Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
40855856|NCT00839644|DEVICE|High frequency chest wall oscillation|Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
40855857|NCT00839644|DEVICE|Oscillatory Positive Expiratory Pressure|Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
41038009|NCT05974969|DRUG|Darzalex|a single intravenous infusion of Darzalex
41038010|NCT01221987|PROCEDURE|Cervical sampling|Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types
41038011|NCT01221987|OTHER|Data collection|Questionnaire completion
41038012|NCT06264050|DIAGNOSTIC_TEST|evalutaion scales|four scales will be administered to whom attend a psychological support group: BDI II (depression); Stai Y2 (trait anxiety); Cope NVI 25 (coping strategies) and Core OM (psychological state)
41038013|NCT01107184|PROCEDURE|Remote ischemic conditioning|Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.
41510688|NCT00452556|DRUG|Leuprolide Acetate (Eligard®)|2.5 years
41510689|NCT00452556|RADIATION|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
41510690|NCT00452556|RADIATION|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
41510691|NCT05114876|OTHER|Multicomponent delirium-risk prevention bundle|"This multidisciplinary intervention will introduce new practices including:~1. Direct-to-Patient Education Program~2. Directly informing anesthesia and surgery teams about high-risk patients by flagging their chart, and providing suggestions for POD mitigation~3. Flag charts as high risk for POD so that nursing staff in both the PACU and the wards are aware, facilitating implementation of CHASM interventions (i.e. evidence-based delirium prevention protocols).~4. Reinforce CHASM best practices with regular educational sessions for nurses."
41386804|NCT06537258|BEHAVIORAL|Biofeedback Enhanced Treatment|"At all 4 assessment points (T1-T4), HRV will be measured using the ECG module of the mobile MindWare system at a sampling rate of 500 Hz, and a Skin Conductance Response (SCR) will be collected at a sampling rate of 10 Hz using eSense for iPad. Electrodes to assess SCR and HRV will be attached to patients during an \~10-minute period.~A 5-minute initial baseline assessment will occur first followed by three 5-minute stress trials.~Stress tasks will be audio recorded to measure study fidelity, and participants will be asked to rate their subjective level of stress with each trial. At all assessment points (T1-T4), participants will be provided with stool collection kits to collect a stool sample within 3 days of the laboratory psychophysiological assessment.~At all assessment points (T1-T4), a blood draw of approximately 3 ml of blood will be collected."
41386805|NCT06438354|BIOLOGICAL|subgingival instrumentation plus Perisolv / hyaDent BG|Group A: Perisolv is applied prior to subgingival instrumentation for disinfecting purpose, hyaDent BG seals the site for accelerated blood clot stabilisation and support of cell proliferation.
41386806|NCT06438354|PROCEDURE|subgingival instrumentation|Group B: sites requiring re-treatment are subjected to subgingival scaling
41386807|NCT06320093|OTHER|SOUND Intervention|The intervention involved active (vocal and rhythmic production) and passive (listening to musical pieces) musical activities accompanied by motor coordination exercises. It consisted of 12 meetings (2 per week for 6 weeks) of 45 minutes each.
41386808|NCT03267316|BIOLOGICAL|CAN04|A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
41386809|NCT03267316|DRUG|Cisplatin|Standard of care treatment
41386810|NCT03267316|DRUG|Gemcitabine|Standard of care treatment
41386811|NCT03267316|DRUG|Nab-paclitaxel|Standard of care treatment
41386812|NCT03267316|DRUG|Carboplatin|Standard of care treatment
41386813|NCT03267316|DRUG|Pemetrexed|Standard of care treatment
41386814|NCT00713622|DRUG|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
41386815|NCT00713622|DRUG|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
41386816|NCT06537583|DEVICE|Parasym Neuromodulation Device (Treatment Group)|Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device
41386817|NCT06537583|DEVICE|Parasym Neuromodulation Device (Sham Group)|Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes
41386818|NCT01788163|GENETIC|EGFR mutation test|EGFR mutation being tested in tissue and blood
41386819|NCT02446496|DRUG|Cefadroxil tablets manufactured by GSK|Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
41386820|NCT02446496|DRUG|Cefadroxil tablets manufactured by NP|Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
41386821|NCT00018174|DRUG|Fluoxetine|
41166518|NCT05091554|PROCEDURE|intraoral ice pack application|Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.
41386822|NCT00018174|BEHAVIORAL|Behavioral group smoking cessation treatment|
41386823|NCT00018174|DRUG|Placebo|
41386824|NCT02687763|BIOLOGICAL|ProQuad|"2) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:~1. to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.~2. to participate in the three (3) antibody titer blood draws."
41386825|NCT04265456|DRUG|Pregabalin 100mg|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
41386826|NCT04265456|DRUG|Acetaminophen 1300mg|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
41386827|NCT02251431|DRUG|BYDUREON|Exenatide-extended release, Cohorts A and B
41386828|NCT02251431|DRUG|Placebo|Cohort A only
41386829|NCT06326112|DRUG|Furosemide Injection|o.5 mg/kg bid or tid IV
41386830|NCT06326112|DRUG|Metolazone Tablets|Diuretic as needed
41386831|NCT05421715|OTHER|TELEDUC-DIAB|"* Systematic monthly remote monitoring between traditional face-to-face consultations by a medical researcher using Kidia and My Diabby digital devices:~  * With downloading by the adolescent of all data on My Diabby platform (clinical data from diabetes monitoring)~ * Evaluation of adverse events related to the treatment of diabetes (hospitalizations and concomitant treatment)~ * Analysis of data collected via My Diabby and Kidia: glycemic balance, captured data, connection frequency, alerts and alarms, diabetes knowledge)~ * The proposal of a therapeutic education session according to the needs of the adolescent via the Kidia application~ * Treatment adaptation~* A follow-up in case there is an alert identified by the teenager, the relative or My Diabby/caregiver~  * The medical orientation of the patient according to the needs identified~ * A proposal for a therapeutic education session according to the needs of the adolescent via the Kidia application"
41386832|NCT02480855|OTHER|Questionnaire and feedback|
41386833|NCT01870921|DRUG|Ticagrelor|90mg/tablet, 1 tablet bid
41386834|NCT06542419|DEVICE|Brain Cooling|Brain cooling consists of a 30-minute seated period, in a dimly lit, quiet room, while listening to calming natural sounds, during which they will wear an Arctic Cooling Cap V1.30, set at a temperature of 33.0 degrees Fahrenheit. Participants will be asked to remain awake, refrain from observing a screen, and relax to the best of their ability. This brain cooling treatment will occur on 7 consecutive days.
41386835|NCT02328404|DRUG|50,000 IU vitamin D3|Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU
41386836|NCT02328404|DRUG|Placebo|Placebo film-coated tablet of Biodal 50,000 IU
41386837|NCT01793831|PROCEDURE|FMT|Standard FMT
41510692|NCT06248125|BEHAVIORAL|Singing intervention|The goal of this intervention is to improve the frequency and quality of active parent-infant interaction via infant-directed singing.
41510693|NCT06248125|BEHAVIORAL|Music listening intervention|This intervention follows the same structure as the singing intervention but focuses on the use of passive music listening rather than live singing.
40855858|NCT00839644|OTHER|PD&P: Postural drainage and percussion|Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
40855859|NCT03836911|OTHER|serious game|Effect of serious game on elderly in comparison of the physical activity adapted meeting
40855860|NCT03836911|OTHER|classic program|Effect of serious game on elderly in comparison of the physical activity adapted meeting
40855861|NCT06361017|PROCEDURE|endovascular thrombectomy|All individuals were anesthetized, with local or general anesthesia dependent on the cooperation level of the patient. During the procedure, it was mandatory to administer intravenous heparin to maintain the activated clotting time between 250 and 300 s, except for subjects who received intravenous alteplase. The procedures were performed through the femoral artery. The selection of stent retriever type and size, along with any required devices, such as guide wires and catheters, as well as the intervention strategy, was at the interventionists' discretion.
40855862|NCT02075151|PROCEDURE|Bronchial Thermoplasty|Bronchial thermoplasty
40855863|NCT01111344|DIETARY_SUPPLEMENT|Glizigen + Viusid|"Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 ______________3 daily applications~* 4 to 6.9 cm2 ______________4 daily applications~* 7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
40855864|NCT01111344|DIETARY_SUPPLEMENT|Placebo|"Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 ______________3 daily applications~* 4 to 6.9 cm2 ______________4 daily applications~* 7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
40855865|NCT05344586|OTHER|Hamstring stretching program with neural load|Participants will perform a hamstring stretch with neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, different tension parameters will be added in the following order (the next parameter shall not be introduced until the previous one has been exhausted): ankle dorsiflexion, cervical and craniocervical flexion, and hip flexion.
40855866|NCT05344586|OTHER|Hamstring stretching program without neural load|Participants will perform a hamstring stretch without neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, tension will be added by flexing their hip, keeping their ankle relaxed and their spine neutral.
40855867|NCT05231460|DRUG|Active Comparator: narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain"
40855868|NCT05231460|DRUG|Active Comparator: narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain"
40855869|NCT05231460|DRUG|non-narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day"
40855870|NCT05231460|DRUG|non-narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day"
40855871|NCT05708456|OTHER|Mobile application with symptom management|In this study, patients will be given evidence-based advice via a mobile application to manage their symptoms.
40855872|NCT03024125|OTHER|High protein|To observe the effect of a high protein (HP) diet over muscle mass, fat mass, and strength changes, focusing in differences between the NP and HP groups.
40855873|NCT03024125|OTHER|Normal protein|To observe the effect of a normal protein (NP) diet over muscle mass, fat mass, and strength changes
40855874|NCT03024125|OTHER|Training|The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.
40855875|NCT01600989|OTHER|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
40855876|NCT01600989|OTHER|blood sampling|Blood samples will be taken twice at a 7 day interval
40855877|NCT02141360|DEVICE|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
41038014|NCT01107184|PROCEDURE|Sham|Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
41038015|NCT05458011|DRUG|Fremanezumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
41038016|NCT05458011|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
41038017|NCT00457262|PROCEDURE|soy consumption|
41038018|NCT00504270|DRUG|Placebo|po daily
41038019|NCT00504270|DRUG|RG3421 120mg|120mg po daily
41510694|NCT06248125|BEHAVIORAL|Book reading intervention|This intervention follows the same structure as the singing intervention, but without the musical elements, while emphasizing enriched parent- infant interaction in non-musical (or less-musical) contexts.
41386838|NCT04387487|BEHAVIORAL|Multimedia video information|"During pre anesthesia visit after regular pre anesthesia check up patient will be asked to fill the Hamilton scoring questionnaire about anxiety.~After this a multimedia video information about spinal anesthesia of around 6 minutes will be shown to the intervention group during pre anesthesia visit. This video will contain explanation about how spinal anesthesia procedure is conducted. Patient will be allowed to ask questions.~On the day of surgery in the pre surgical area again Hamilton scoring questionnaire will be asked with the patients to check the level of anxiety."
41166519|NCT01860807|DRUG|Ibudilast|
41386839|NCT02203188|PROCEDURE|Lid debridgement scaling|
41386840|NCT00178763|DEVICE|Heckel Infrared Radiant Heat Device|thermotherapy, maintain a core temperature of 40 degrees centigrade for 6 hours duration
41386841|NCT00178763|OTHER|cisplatin, gemcitabine, interferon-alpha|cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.
41386842|NCT00178763|OTHER|thermochemotherapy|fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
41386843|NCT06036173|OTHER|diagnosis of lymphedema|being diagnosed with secondary lymphedema in the upper extremity according to the International Lymphedema Association
41386844|NCT06036173|OTHER|breast cancer surgery|be diagnosed and undergo surgery
41386845|NCT00696631|DRUG|Dronedarone (SR33589)|oral administration
41386846|NCT00696631|DRUG|Placebo|oral administration
41386847|NCT03906786|BEHAVIORAL|motivational interviewing|The intervention will consist of 4 structured medical consultations in the form of a motivational interviewing compared to usual care, covering a 12-month intervention period. In both groups, the frequency of visits (c / 3 months) and the variables collected will be the same.
41386848|NCT05822024|BEHAVIORAL|Promoting Pupils' Physical Literacy Intervention|The physical literacy intervention 3PL is based on activities, games, and modifications of the physical education classes to target and enhance pupils' physical literacy.
41386849|NCT00267579|BEHAVIORAL|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
41386850|NCT02491086|DRUG|Nicotine replacement therapy (NRT) sampling|1-week free NRT
41386851|NCT02491086|BEHAVIORAL|Smoking cessation counseling|Smoking cessation counseling
41166520|NCT01860807|DRUG|Placebo|
41386852|NCT01419405|DRUG|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
41386853|NCT01419405|DRUG|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
41386854|NCT01419405|DRUG|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
41386855|NCT03509012|DRUG|Durvalumab|IV (intravenous)
41386856|NCT03509012|DRUG|Tremelimumab|IV
41386857|NCT03509012|DRUG|Cisplatin (dose level 4)|IV
41386858|NCT03509012|DRUG|Cisplatin (dose level 3)|IV
41386859|NCT03509012|DRUG|Carboplatin (dose level 1)|IV
41386860|NCT03509012|DRUG|Carboplatin (dose level 2)|IV
41386861|NCT03509012|DRUG|Etoposide (dose level 1)|IV
41386862|NCT03509012|DRUG|Etoposide (dose level 2)|IV
41386863|NCT03509012|DRUG|Paclitaxel|IV
41386864|NCT03509012|DRUG|Pemetrexed|IV
41166521|NCT03955354|DRUG|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
41166522|NCT03955354|DRUG|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
41386865|NCT03509012|RADIATION|External beam radiation (dose level 1)|radiation therapy
41386866|NCT03509012|RADIATION|External beam radiation (dose level 2)|radiation therapy
41386867|NCT03509012|RADIATION|External beam radiation (hyperfractionated)|radiation therapy
41386868|NCT03509012|DRUG|Cisplatin (dose level 1)|IV
41386869|NCT03509012|DRUG|Cisplatin (dose level 2)|IV
41386870|NCT03509012|RADIATION|External beam radiation (standard)|radiation therapy
41386871|NCT05811260|OTHER|Myofascial Release technique|on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
41386872|NCT05811260|OTHER|Post facilitation stretch .|static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
41386873|NCT00317031|DRUG|Acamprosate or Naltrexone|mg\&d 90 days
41386874|NCT06404931|PROCEDURE|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device
41386875|NCT06404931|PROCEDURE|Vaginal hysterectomy plus anterior colporrhaphy|Vaginal hysterectomy plus anterior colporrhaphy
41386876|NCT06404931|PROCEDURE|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device
40855878|NCT04870372|DRUG|Selegiline|Subjects will receive one Selegiline tablet (5 mg) per day administered at breakfast. The initial dose of Selegiline is 5 mg/day and be up-titrated in 2-week intervals in increments of 5 mg up to 10 mg (which can be taken at breakfast or divided doses of 5 mg each taken at breakfast and lunch) according to the investigator's judgment, based on individual clinical response and tolerability.
41386877|NCT03872622|OTHER|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire.
40855879|NCT02052401|OTHER|Domiciliary Intervention|Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
41386878|NCT05110625|BEHAVIORAL|preDIABE-TEXT|Participants will receive text messages (three per week) in their mobile phones during six months.
41386879|NCT05110625|OTHER|Online Education|Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
40855880|NCT01549977|DRUG|Febuxostat|Febuxostat tablets
40855881|NCT01549977|DRUG|Placebo|Febuxostat placebo-matching tablets
40855882|NCT02138968|OTHER|Multidisciplinary intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
40855883|NCT04845893|OTHER|Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
41386880|NCT05967767|DEVICE|Normobaric Hypoxia Exposure|Hypoxia group were exposed to normobaric hypoxia equal to 3420 m (FiO2: 13.5-13.6 %).
41386881|NCT05967767|DEVICE|Normobaric Normoxia Exposure|Placebo group were exposed to normobaric normoxia equal to 162 m (FiO2: 20.9 %) through wearing the altitude generator mask.
40855884|NCT00160836|DEVICE|"Tissue sampling (G.I.U.M. catheter)"|
40855885|NCT01221350|DIETARY_SUPPLEMENT|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
41386882|NCT03229239|PROCEDURE|corneal stroma implantation|During the operation,implant the corneal stroma to the diseased cornea of keratoconus.
41386883|NCT04309760|OTHER|MRI|Subjects will receive structural and functional (resting state) MRI
41386884|NCT06555562|DEVICE|Ultrasound Stimulation|Ultrasound therapy will be administered to the appropriate target.
41386885|NCT06555562|DEVICE|Non-active ultrasound stimulation|Non-active ultrasound therapy will be administered to the appropriate target
40855886|NCT01221350|DIETARY_SUPPLEMENT|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
40855887|NCT00334243|DRUG|Microflare protocol for IVF|
40855888|NCT00334243|DRUG|Antagonist protocol for IVF|
41386886|NCT05161546|DEVICE|EEG and ERG measurements (Retinaute®, BioSerenity)|"The Retinaute® is a portable medical device developed by BioSerenity, France, for performing flash and pattern ERG. It comes in the form of a virtual reality headset, which can be used in outpatient facilities. It is non-invasive and uses skin electrodes for the collection of parameters.~ERG signals will be supplemented with 4 EEG channels, via cup electrodes applied to the skull and allowing the concomitant performance of an EEG."
41386887|NCT05161546|DEVICE|Actigraphy (Motion Watch 8®, CamNtech)|"Actigraphy is an ecological and non-invasive method allowing a reliable characterization of the sleep/wake cycle. It is a portable system for continuously measuring the motor activity of an individual and appreciating the alternation of activity periods (wakefulness) and rest periods (sleep).~An actigraph (MotionWatch8®, CamNtech) looks like a wristwatch that will be worn continuously, by convention on the wrist of the non-dominant hand, over periods ranging from several days to several weeks (here 21 days). Actigraphy does not present a known risk."
41510695|NCT00612092|RADIATION|Spiral image acquisition|standard spiral scan protocol
41510696|NCT00612092|RADIATION|sequential image acquisition|sequential CT scan protocol
41510697|NCT04881786|DEVICE|Orthodontic forces|56g force and 224g force
40855889|NCT00334243|DRUG|Demi-halt protocol for IVF|
40855890|NCT05501717|DRUG|ALXN2030|ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
40855891|NCT05501717|DRUG|Placebo|Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
40855892|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria adolescentis BD1|packet containing 10\^9 cells of Bifidobacteria adolescentis BD1
40855893|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10\^9 cells of Bifidobacteria animalis subsp. lactis BB-12
40855894|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10\^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
40855895|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10\^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
40855896|NCT02355210|DIETARY_SUPPLEMENT|galactooligosaccharide|5 g galactooligosaccharide
40855897|NCT02355210|DIETARY_SUPPLEMENT|Placebo|lactose powder, 5 grams
40855898|NCT02457468|DEVICE|coflex|
40855899|NCT01363661|DRUG|Coruno|Molsidomine 16 mg tablet, per os, once a day
40855900|NCT01363661|DRUG|Placebo|Placebo (16 mg tablet, per os; once-daily)
40855901|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc of 5% dextrose.
40855902|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc normal saline.
40855903|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc 5% dextrose.
40855904|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc normal saline.
40855905|NCT03796026|DRUG|Seltorexant 40 mg|Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
41386888|NCT05161546|BEHAVIORAL|Neuropsychological assessments|The purpose of this assessment is to establish a cognitive profile for each participant. It uses a series of tests widely described in the literature and commonly used today.
41386889|NCT05161546|DEVICE|Optical Coherence Tomography (OCT)|The Spectral Domain Optical Coherence Tomography (SD-OCT) is a modern ocular imaging process using infrared radiation and allowing to obtain in a few seconds, and in a non-invasive way, images in section of the eye. The OCT-Angiography (OCT-A) module increments on the OCT. It can detect the movement of the blood elements from sequential SD-OCT slices taken at the same location of the retina and obtain a map of the retinal and choroidal vessels, without injection of fluorescent dye. The device used for both exams will be the OCT spectral RS 3000 Advance 2 + Angioscan (NIDEK, Gamagori, Japan). SD-OCT and OCT-A examinations are fast, painless, non-contact and last less than a minute. There is no particular risk.
41386890|NCT04442373|DIAGNOSTIC_TEST|Rotational thromboelastometry|1.8 ml blood sample
40855906|NCT03796026|DRUG|Placebo|Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
41386891|NCT00551473|DRUG|Lavoltidine|
40855907|NCT00349869|BEHAVIORAL|yoga|8-week yoga program.
40855908|NCT05835180|DRUG|TVB-2640 - 50 mg|TVB-2640 -50 mg administered orally once daily
40855909|NCT00858637|DRUG|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
41386892|NCT03875716|RADIATION|Radiation therapy|Radiation therapy
41386893|NCT04221542|DRUG|AMG 509|AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).
41386894|NCT04221542|DRUG|Abiraterone|Abiraterone administered as oral tablets.
41386895|NCT04221542|DRUG|Enzalutamide|Enzalutamide administered as oral tablets.
41510698|NCT01755091|DRUG|Dronabinol|
41510699|NCT01755091|DRUG|Placebo (for Dronabinol)|
40855910|NCT00858637|DRUG|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
40855911|NCT00858637|DRUG|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
40855912|NCT00858637|DRUG|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
41038020|NCT00504270|DRUG|RG3421 20mg|20mg po daily
41038021|NCT02820779|DEVICE|WILLIS|WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. It can effectively shunt the blood flow and keep it off of the aneurysm wall.
41038022|NCT04597320|DRUG|Fentanyl|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
41038023|NCT04597320|DRUG|Esketamine|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
40855913|NCT01081899|OTHER|The LCP-I Program|The LCP-I Program is a continuous quality Improvement Program of end-of-life care implemented by a Palliative Care Unit (PCU) in a hospital Medical Ward.
40855914|NCT02947737|OTHER|Amniotic membrane dressing|We will place an amniotic membrane dressing on the donor site
41386896|NCT05979688|BEHAVIORAL|yogic breathing exercise|A typical session will begin with the yoga instructor demonstrating a breathing exercise technique. The participants will learn and practice each technique.
40855915|NCT02947737|OTHER|Gentamicin and xeroform dressing|We will place xeroform, gentamicin and telfa on the donor site
40855916|NCT03485521|PROCEDURE|The tracheobronchial aspiration|"Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure"
40855917|NCT01336413|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
40855918|NCT01336413|DRUG|Placebo|Same as active comparator, except placebo dispensed.
40855919|NCT03781453|BEHAVIORAL|POWERPLAY|"Employees from participating worksites will be invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
41166523|NCT06546514|OTHER|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
41166524|NCT01792778|DEVICE|ViaValve Safety IV Catheter|Insertion of the peripheral intravenous catheters into both upper extremities of subjects
41166525|NCT01792778|DEVICE|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|
41166526|NCT06339567|DIAGNOSTIC_TEST|Thrombotic profile|several thrombotic biological marker will be dosed in blood. (C protein, S protein, CRP us, Factor VIII, TFPI , nAPCsr, SHBG, nTMsr)
41166527|NCT00564564|DRUG|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
41166528|NCT00564564|DRUG|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
41386897|NCT00484120|DRUG|3%-Diclofenac-Nano-Emulsion Cream|3%-Diclofenac-Nano-Emulsion Cream
41386898|NCT00484120|DRUG|Placebo cream|Placebo cream
41386899|NCT04760574|DIAGNOSTIC_TEST|Testosterone|Serum total testosterone and free testosterone level
41386900|NCT05663333|OTHER|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy in the dermatology department before conventional histopathological analysis
41386901|NCT01176578|OTHER|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
41510700|NCT03567980|DRUG|Crisaborole|Application of topical crisaborole 2% ointment on the face for 4 weeks to evaluate the anti-inflammatory action of this agent and its utility in the treatment of facial seborrheic dermatitis.
41510701|NCT00005052|BIOLOGICAL|GM2-KLH vaccine|
40855922|NCT02453503|DRUG|Licorice|licorice mucoadhesive films evey 6 hours for two weeks
41510702|NCT00005052|BIOLOGICAL|QS21|
41510703|NCT00005052|PROCEDURE|adjuvant therapy|
41510704|NCT02708771|DRUG|Polyunsaturated fatty acids omega-3|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
41510705|NCT02708771|DRUG|Placebo|4 daily capsules of similar appearance and flavor without active ingredient
40855923|NCT02453503|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
40855924|NCT04259008|OTHER|Manganese omission|Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.
40855925|NCT04259008|OTHER|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."
40855926|NCT00519051|OTHER|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
40855927|NCT04373928|PROCEDURE|Drug guided by Mini-PDX/PDX|Chemotherapeutic agents guided by Mini-PDX/PDX will be applied to PC patients and the efficiency will be studied.
40855928|NCT00020124|DRUG|doxorubicin hydrochloride|
40855929|NCT04042324|DRUG|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
40855930|NCT04042324|DRUG|Heparin|Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
40855931|NCT04070417|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and socialisation
41166529|NCT04082481|DRUG|TAK-988|TAK-988 tablets.
41166530|NCT04082481|DRUG|TAK-988 Placebo|TAK-988 placebo-matching tablets.
41166531|NCT04097691|DRUG|GLUCOSE 10%|subcutaneous glucose 0.5 ml per site around subcutaneous nerves
41166532|NCT03754764|BIOLOGICAL|Specificity CD38 CAR-T Cells|1) Biological: Specificity CD38 CAR-T Cells 2) Day 0: 1-5x10e6/kg total dose .3) Other: Laboratory Biomarker Analysis
41386902|NCT05937750|DRUG|Imlifidase administered in the 20-HMedIdeS-19 (PAES) study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
41386903|NCT05937750|OTHER|Best available treatment administered in the 20-HMedIdeS-19 (PAES) study|Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
41386904|NCT02590978|PROCEDURE|Early cholecystectomy|Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.
41386905|NCT02590978|PROCEDURE|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed once complete resolution of abdominal tenderness, oral feeding and trending down in pancreatic laboratory is achieved
41386906|NCT02234427|DRUG|Aspirin|2-week aspirin therapy (81mg/day)
41386907|NCT03541668|DRUG|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.
41386908|NCT03541668|DRUG|Alteplase|Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
41386909|NCT04777591|DRUG|Liposomal bupivacaine TAP block|Group will receive Liposomal bupivacaine TAP block (mixed with plain bupivacaine) intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
41038024|NCT04597320|DRUG|Midazolam|"Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
41038025|NCT00325468|DRUG|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
41038026|NCT02376218|DRUG|Hypertonic 50% dextrose pleurodesis|Intrapleural administration of 180ml of hypertonic dextrose solution.
41038027|NCT05608629|DEVICE|Transcutaneous Non-Invasive Vagus Nerve Stimulation|The parasym is a system for delivering a fixed signal to stimulate the auricular branch of the vagus nerve. The device used is available without prescription in UK and EU. Similar devices have been used to treat migraine and one is in testing to be used for atrial fibrillation.
41166533|NCT00658840|DRUG|Capecitabine (Xeloda®)|Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
41386910|NCT04777591|DRUG|Bupivacain|Group will receive plain bupivacaine TAP block intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
41386911|NCT02034500|BIOLOGICAL|S. sonnei 1790GAHB|
41386912|NCT02034500|BIOLOGICAL|Placebo|
41386913|NCT06401993|PROCEDURE|"The dao qi tong luo group"|"The dao qi tong luo group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. Among them, the dao qi tong luo group will make patients feel qi."
41386914|NCT06401993|PROCEDURE|The acupuncture group|The acupuncture group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. The acupuncture group will not feel qi.
41386915|NCT03296215|OTHER|Observational|To determine different patterns of admission and their Outcome
41386916|NCT02367807|DRUG|Emtricitabine and tenofovir disoproxil fumarate|This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.
41386917|NCT00826865|DRUG|Levetiracetam|750 mg tablet
41386918|NCT05068102|DRUG|BI 765063|BI 765063
41386919|NCT05068102|DRUG|Ezabenlimab|Ezabenlimab
41386920|NCT05068102|DRUG|[89Zr]Zr- BI 765063|\[89Zr\]Zr- BI 765063, specifically radiolabelled for immune-Positron Emission Tomography (PET)
41386921|NCT05068102|DRUG|BI 770371|BI 770371
41038028|NCT04380454|DEVICE|Functional electrical stimulation (FES)|Functional electrical stimulation (FES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. An electrical stimulator will be used to deliver stimulation during walking (Grass S8800 stimulator with SIU8TB stimulus isolation unit; UDel stimulator). A customized, real-time system will be used to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains 170 will be delivered during gait. The intervention comprises 3 training sessions per week for a total of 12 training sessions. FES intensity is determined at the start of every training session as motor-level stimulation that elicits appropriate functional movements.
41038029|NCT04380454|OTHER|Fast treadmill walking|Fast treadmill walking (Fast) is a non-targeted intervention where no specific instructions are provided to target practice to the paretic leg or specific ankle deficits. The intervention comprises 3 training sessions per week for a total of 12 training sessions. Each training session includes six 6-minute walking bouts with 5-minute breaks between bouts.
41386922|NCT05068102|DRUG|[89Zr]Zr- BI 770371|\[89Zr\]Zr- BI 770371, specifically radiolabelled for immune-PET
41386923|NCT04047459|OTHER|Tissue samples collection and cells isolation|During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
41386924|NCT06541704|DRUG|Pozelimab|Subcutaneous (SC) injection
41386925|NCT06541704|DRUG|Cemdisiran|SC injection
41386926|NCT06541704|DRUG|Placebo|SC injection
40855932|NCT03258775|OTHER|water intake|After an overnight fast participants' RMR will be measured by indirect calorimetry for 30 minutes after which either a low (250ml) or high (500ml) dose of water will be consumed followed by an additional 90 minutes of indirect calorimetry. The test day will be repeated after 7-10 days with the second dose of water. The order in which the dose of water will be consumed will be randomized
40855933|NCT00966550|OTHER|Tomato|Tomato with high carb/fat meal
40855934|NCT00966550|OTHER|Non-tomato|Non-tomato with high carb/fat meal
40855935|NCT06200792|DEVICE|eSense device|eSense device for monitoring electrodermal activity. Visual analogic scale (VAS) for pain and discomfort; TOL-R tests for investigating working performances.
40855936|NCT03865641|DEVICE|Virtual reality rehabilitation|Task-specific training has been shown to be more effective when tasks were ordered in a random practice sequence using repetition and positive feedback. VR is an interactive and enjoyable intervention. VR creates a virtual rehabilitation scene in which the intensity of practice can be systemically manipulated.
40855937|NCT01424033|DRUG|N-Acetylcysteine|600mg by mouth, three times daily for 12 months
40855938|NCT02202343|BEHAVIORAL|school based health and nutrition education|
40855939|NCT02152761|DRUG|bimagrumab|Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
40855940|NCT02152761|OTHER|placebo|Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
40855941|NCT00006773|DRUG|bortezomib|Given IV
40855942|NCT02378545|DRUG|Oxygen|"On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask."
40855943|NCT01800591|BEHAVIORAL|Financial incentive|
40855944|NCT04903054|BIOLOGICAL|Lulizumab|Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.
40855945|NCT04903054|DRUG|Tacrolimus|Standard of Care: Renal transplant rejection prophylaxis.
40855946|NCT04903054|BIOLOGICAL|Thymoglobulin®|Standard of Care: Renal transplant rejection prophylaxis.
40855947|NCT04903054|DRUG|Methylprednisolone|Standard of Care: Renal transplant rejection prophylaxis.
40855948|NCT04903054|DRUG|Mycophenolate Mofetil|Standard of Care: Renal transplant rejection prophylaxis.
40855949|NCT04903054|DRUG|Prednisone|Standard of Care: Renal transplant rejection prophylaxis.
40855950|NCT01805479|OTHER|aerobic exercise|the active arm will be asked to perform 60% of maximum heart rate
40855951|NCT01805479|OTHER|stretching and flexibility program|stretching and flexibility program for the Placebo Comparator Arm
40855952|NCT00004223|DRUG|docetaxel|
40855953|NCT00004223|DRUG|gemcitabine hydrochloride|
41038030|NCT05451654|DRUG|Placebo|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
40855954|NCT05113537|DRUG|Abemaciclib|Given Orally
40855955|NCT05113537|DRUG|Lutetium Lu 177-PSMA-617|Given IV
40855956|NCT03928717|BEHAVIORAL|Text-Based Adherence Game|A mobile health intervention facilitated by a cloud-hosted web application and designed to promote adherence to HIV care through text message-delivered gamification strategies including peer comparison, point reinforcement, feedback on adherence outcomes, facilitation of social support, and use of an engaging and culturally-relevant story-line.
40855957|NCT03928717|BEHAVIORAL|Standard of Care (SOC)|A 10- to 20-minute in-person intervention led by a trained HIV treatment adherence counselor focused on providing basic knowledge of HIV and HIV treatment, motivating participants to engage in HIV treatment, and problem-solving barriers to adherence.
40855958|NCT06457867|PROCEDURE|microfragmented adipose tissue loaded on bovine graft|microfragmented adipose tissue loaded on bovine graft on ridge preservation
41038031|NCT05451654|DRUG|Experimental drug|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
41038032|NCT01443481|DRUG|Dovitinib|Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
41386927|NCT06390488|OTHER|Transcutaneous medial plantar nerve stimulation (T-MPNS)|T-MPNS will be conducted unilaterally in the supine position using the electrotherapy device with surface electrodes. Two round self-adhesive electrodes will be positioned, with the negative electrode near the metatarsal-phalangeal joint of the great toe on the medial aspect of the foot and the positive electrode approximately 2 cm inferior-posterior to the medial malleolus (in front of the Medio-Malleolar-Calcaneal axis). Channel 1 will provide active stimulation, while channel 2 will remain inactive.
41386928|NCT06390488|OTHER|Sham Transcutaneous medial plantar nerve stimulation (T-MPNS)|Sham T-MPNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the T-MPNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
41386929|NCT05415618|OTHER|Manual lymphatic drainage|Manual lymphatic drainage will be applied 5 days a week for about 15 minutes every day for 4 weeks.
40855959|NCT02828436|DEVICE|Precision Spectra System|Spinal Cord Stimulation
40855960|NCT02828436|BEHAVIORAL|Exercise Intervention|Standard Exercise
40855961|NCT03558490|DEVICE|ZEMY software|"The ZEMY software medical device integrates specific algorithms based on international and validated guidelines. It provides individually customized information and defines for the patient an adapted action to follow for each of the following reported symptoms or anti-cancer treatment-related toxicities: diarrhea, fatigue, nausea, vomiting, cutaneous and mucosal toxicities, pain, fever/febrile neutropenia, high blood pressure, anxiety and depression.~During the 3-month study period, participants will be asked to enter their symptoms among the 10 symptoms listed in ZEMY on their smartphone dedicated to the study. Consequently, ZEMY software will provide to the participants adapted real-time information to advise them on the management of the experienced symptom and recommend hygienic-dietetic advice and symptomatic treatments."
41038033|NCT05476146|PROCEDURE|Rerouting of the track in high anal fitula|Treatment of high anal fistula by rerouting
40855962|NCT03558490|DRUG|Investigator's choice of anti-cancer treatment (except immunotherapy)|All anti-cancer treatments (except immunotherapy) will be left to the free choice of investigators. Participants shall be prescribed by the healthcare team both of the following symptomatic treatments: loperamide or any other anti-diarrheic treatment in case of diarrhea; and a prescription for any medication indicated in case of nausea/vomiting. A written prescription will be made by the investigator at screening for loperamide or any other anti-diarrheic treatment and symptomatic treatment for nausea/vomiting with documented dosage and duration.
40855963|NCT03570359|DRUG|Interferon Beta-1A|Interferon Beta-1A via inhalation
40855964|NCT03570359|OTHER|Placebo|Placebo via inhalation
40855965|NCT04387578|DEVICE|fixed orthodontic appliance and arch wires|leveling and aligning stages in orthodontics
40855966|NCT05716932|PROCEDURE|Dual focal laser and intravitreal Ranibizumab injection|Direct and perilesional focal laser followed by a single intravitreal 0.5 mg ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) injection
40855967|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
40855968|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
40855969|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
40855970|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
40855971|NCT00310596|DRUG|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
40855972|NCT00310596|DRUG|Placebo|0,9% saline at 0,6mL/kg at bolus rate
40855973|NCT02209896|DEVICE|The Reprieve system|BlueWind Medical neurostimulator for the treatment of neuropathic pain
40855974|NCT06114927|BEHAVIORAL|Validation of a questionnaire|The Conceptualization of Pain Questionnaire (COPAQ-S) Spanish version consist of 15 items and asks respondents to respond if they believe the items/statements to be true or false, although they are allowed to respond undecided. A score of 0 is given to incorrect responses and those marked as undecided; the sum of all the correct answers gives the total score. The higher the score, the better the participant understands the concept of pain.
40855975|NCT02410239|BIOLOGICAL|Mesenchymal Stem Cells|
40855976|NCT06043973|DRUG|almonertinib|The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
40855977|NCT05587192|DIAGNOSTIC_TEST|18F-PSMA-1007 PET/CT based on diagnostic model|All enrolled patients will receive 18F-PSMA-1007 PET/CT based USTC diagnostic model before gaining the final pathological diagnosis to be used as experimental arm.
40855978|NCT01565694|DRUG|Solifenacin succinate|Oral suspension administered once a day via syringe.
40855979|NCT01060852|BEHAVIORAL|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
40855980|NCT00294294|BIOLOGICAL|Prevenar|
40855981|NCT00294294|BIOLOGICAL|Infanrix hexa|
41038034|NCT01766557|OTHER|Semi-controlled nutritional intervention with fish protein diet|After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
41166534|NCT00658840|RADIATION|Localization, simulation and immobilization|"Radiation dose and planning~1. Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.~2. Dose prescription : 90% isodose volume of prescribed dose encompassed PTV~3. The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated."
40855982|NCT01242605|DRUG|selumetinib|The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
40855983|NCT01242605|DRUG|gemcitabine|gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m\*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
40855984|NCT01242605|DRUG|cisplatin|cisplatin: 25 mg/m\*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
40855985|NCT00169156|DRUG|Rituximab|375 mg/m2 D1
40855986|NCT00169156|DRUG|Prednisone|40 mg/m2 D1 to D5
40855987|NCT00169156|DRUG|Doxorubicine|50 mg/m2 D1
40855988|NCT00169156|DRUG|Cyclophosphamide|750 mg/m2 D1
40855989|NCT00169156|DRUG|Vincristine|1,4 mg/m2 D1
40855990|NCT02592460|OTHER|poor-polyamines diet|Patients in this will receive a poor-polyamines diet during a week before and a week after foot surgery
40855991|NCT02592460|OTHER|high polyamines diet|Patients in this will receive a high-polyamines diet during a week before and a week after foot surgery
40855992|NCT05154253|DEVICE|Biomotum Spark: Robotic ankle assistance|A lightweight assistive wearable ankle robotic device.
40855993|NCT05154253|DEVICE|Biomotum Spark: Robotic ankle resistance|A lightweight resistive wearable ankle robotic device.
40855994|NCT05154253|OTHER|Standard gait training|Standard gait training without a device.
40855995|NCT05154253|DEVICE|Ankle foot orthosis|Standard ankle foot orthosis
40855996|NCT05154253|OTHER|Standard physical therapy|Physical therapy without a device.
40855997|NCT05154253|OTHER|Standard walking|Walking without a device
40855998|NCT00912457|DRUG|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
40855999|NCT00912457|DRUG|placebo|placebo 1 p/day for 28 days
40856000|NCT03853863|BEHAVIORAL|in-school walking training with minimalist shoes|Participants in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks. Similar to previous minimalist footwear studies, the intervention duration will be gradually increased over the 12-week training. In brief, subjects will wear the minimalist shoes for 1 out of 5 school days at the first week; 2 days at the second week, and so on until fully use of the minimalist shoes at the fifth week.
40856001|NCT03853863|BEHAVIORAL|in-school walking training with protective shoes|Participants in the TSW group will be given a pair of given a pair of protective shoes with arch support for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks,while follow the same wearing pattern as the MSW group.
40856002|NCT06327828|DEVICE|Semi-automated computer-aided treatment (Digital Thyroid, DigiThy)|Semi-automated computer-aided treatment based on a mathematical model
40856003|NCT06327828|PROCEDURE|Usual care|Guiding methimazole therapy based on the treating physician's decision
40856004|NCT00048698|PROCEDURE|TMS|
40856005|NCT00048698|PROCEDURE|EEG|
40856006|NCT06090084|OTHER|Evaluation|Functional capacity, balance, core muscle strength, trunk muscle structure, lower extremity muscle strength, upper extremity functions, fatigue and respiratory muscle strength will be evaluated.
40856007|NCT00791752|DRUG|AZD4017|ascending single doses (start dose 2 mg), oral suspension
40856008|NCT00791752|DRUG|Placebo|Placebo
41166535|NCT05037721|OTHER|gargling with green tea|experimental group using 0.5% green tea gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
41166536|NCT05037721|OTHER|gargling with water|using water gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
41166537|NCT02401971|DRUG|Thalidomide|Given orally
41386930|NCT05415618|DEVICE|splint|In splint treatment, a volar-supported splint that keeps the wrist in a neutral position will be preferred and it will be recommended to both groups to be used only at night for 4 weeks.
41386931|NCT05415618|OTHER|Nerve gliding|Median nerve gliding exercises as a home exercise program will be performed by the patient 5 days a week for 4 weeks. It will be performed in 6 different consecutive positions of the hand and wrist.
41386932|NCT00725725|BEHAVIORAL|Cognitive-behavioral therapy|Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
41386933|NCT00725725|DRUG|Org 25935|4 mg Org 25935 is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
40856009|NCT00003346|DRUG|acetaminophen|
40856010|NCT00003346|DRUG|acetylcysteine|
41166538|NCT02401971|DRUG|CPT-11|Given Ivgtt
41386934|NCT00725725|DRUG|Org 25935|12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
41386935|NCT00725725|DRUG|Placebo|Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
40856011|NCT00003346|DRUG|carmustine|
40856012|NCT03601702|DEVICE|Mechanical thrombectomy with EmboTrap ® II Device|Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)
41166539|NCT03696641|OTHER|glazed lithium disilicate crowns|glazing of IPS e.max crowns
40856013|NCT05776953|DRUG|Ketorolac|IV Ketorolac for pain
40856014|NCT02716181|DEVICE|"Атопик Soothing Cream"|Topical application of a study cream to involved skin areas twice a day.
40856015|NCT02716181|DEVICE|Placebo|Topical application of a study placebo cream to involved skin areas twice a day.
40856016|NCT02416154|PROCEDURE|Reproductive tract and blood sampling|Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
40856017|NCT06152107|PROCEDURE|BTVA treatment plus optimal medical therapy (GOLD guidelines)|"Patients in experimental group will be treated with the InterVapor System in at least 2 subsegments of different segments. Patients in control group will be treated with the InterVapor System in at least 1 segment.~A sequential procedure allows for at least 6 weeks and no longer than 6 months after the first procedure. Patients in both groups will be treated in the ipsilateral lobe in a single procedure with the air+tissue volume of at least≥500 ml and≤1,700 ml in per procedure. All patients will continue to receive optimal medical therapy (GOLD guidelines) for the duration of the study.~Follow-up visits will be scheduled at 1, 3, 6 and 12 months following the second procedure with examination of pulmonary function tests, HRCT, 6-minute walk test, SGRQ-C, mMRC, CAT questionnaires. All adverse events during the study will be recorded."
40856018|NCT04951505|DRUG|cefepime-taniborbactam|IV infusion
40856019|NCT00753454|DRUG|Certolizumab pegol|Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 \& Week 4, followed by 200 mg every 2 weeks).
41166540|NCT03696641|OTHER|polished lithium disilicate crowns|polishing of IPS e.max crowns
41166541|NCT05063123|DRUG|Flotetuzumab|Flotetuzumab will be given after at least 2 intensive chemotherapy cycles and before the start of the conditioning regimen prior to allo-HCT.
41166542|NCT04888845|BEHAVIORAL|Safety Plan|The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
41166543|NCT04888845|BEHAVIORAL|Crisis Response Plan|Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
41386936|NCT04638725|OTHER|Blood sample for genetic analysis|Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
40856020|NCT03941717|OTHER|Mindfulness-Based Condition|Each script for the mindfulness-based intervention was slightly modified to fit the context of a venipuncture, and begins with instructions to take deep breaths. Both scripts aim to cultivate present moment awareness of experiences, curiosity, nonjudgement, and acceptance of experiences as they unfold. In particular, the scripts ask that the participant visualize their worries and feelings as a cloud in the sky, and probes for curious thoughts about these experiences. The temporary nature of sensations is described, and the participant is asked to keep this openness and curiosity during the venipuncture.
40856021|NCT03941717|OTHER|Unfocused attention Condition|Each script for the unfocused attention task instructs participants to allow their mind and thoughts to roam. The aim is to encourage the participant to continue thinking and mind wandering as they typically would.
40856022|NCT01521663|DRUG|IPX159|
40856023|NCT01521663|DRUG|Placebo|
41166544|NCT04888845|BEHAVIORAL|Structured interview|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach.
41166545|NCT04888845|BEHAVIORAL|Narrative Assessment|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis."
41166546|NCT05506215|DEVICE|SynPath Acellular Dermal Matrix plus Off-loading Device|Application of SynPath
40856024|NCT04575571|OTHER|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews..|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.
40856025|NCT01792037|DRUG|Etomidate|
40856026|NCT01792037|DRUG|Midazolam|
40856027|NCT01792037|DRUG|methylprednisolone|
40856028|NCT04489082|DEVICE|Near Infrared Laser Stimulation|10 minutes of transcranial near infrared laser stimulation
40856029|NCT05166421|BIOLOGICAL|AZD7442|AZD7442 will be administered via IM route.
40856030|NCT05166421|BIOLOGICAL|AZD8895 (clonal cell line material)|AZD8895 will be administered via IM route.
40856031|NCT05166421|BIOLOGICAL|AZD1061 (clonal cell line material)|AZD1061 will be administered via IM route.
41166547|NCT05506215|DEVICE|Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device|Application Wound Dressing composed of Collagen and Alginate
41166548|NCT06386198|BEHAVIORAL|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
41166549|NCT00229710|DRUG|Tesaglitazar|0.5 in combination with insulin (with or without other oral antidiabetic drugs)
41386937|NCT03613194|PROCEDURE|Sampling|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~* Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~* Peritoneal liquid~* none tumoral peritoneum~* Portal blood~* Peripheral blood~* Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
41166550|NCT03409562|BEHAVIORAL|motor control training|Exercises to strengthen the lumbar musculature and control the posture.
41166551|NCT03409562|BEHAVIORAL|pain neurophysiology education|Educational sessions to improve patient's neurophysiology of pain knowledge.
41166552|NCT05725044|DIETARY_SUPPLEMENT|Ginsengberry concentrate|Ginsengberry concentrate
41166553|NCT05725044|DIETARY_SUPPLEMENT|Placebo|Placebo
41166554|NCT03618212|DIAGNOSTIC_TEST|MRI|Skeletal MRI and pelvic and spinal MRI
41166555|NCT03399838|DRUG|Dexmedetomidine|IN Dex for pediatric procedural sedation at the emergency department
41166556|NCT03399838|DRUG|Midazolam|po/pr midazolam as active comparator to dexmedetomidine for pediatric procedural sedation at the pediatric emergency department
40856032|NCT05166421|BIOLOGICAL|AZD8895 (cell pool material)|AZD8895 will be administered via IM route.
40856033|NCT05166421|BIOLOGICAL|AZD1061 (cell pool material)|AZD1061 will be administered via IM route.
40856034|NCT02657447|DRUG|Betalutin with lilotomab dose 1|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
40856035|NCT02657447|DRUG|Betalutin with lilotomab dose 2|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
40856036|NCT03082092|DRUG|Methylprednisolone Sodium Succinate|single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
40856037|NCT03082092|DRUG|Placebos|0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
40856038|NCT05706441|OTHER|Point-of-Care Ultrasound|Ultrasonographic scans of the lung and right hemidiaphragm were acquired after 30 min from the beginning of the SBT, or immediately before reconnecting the patient to the ventilator in the case of SBT failure occurring before
40856039|NCT01873625|BIOLOGICAL|mesenchymal cell transplantation|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
40856040|NCT01873625|BIOLOGICAL|placebo|
40856041|NCT03094533|DRUG|TIVA|total intravenous anesthesia with propofol
40856042|NCT03094533|DRUG|VIMA|volatile induction and maintenance anesthesia with sevoflurane
40856043|NCT00931775|DRUG|Pindolol|Pill orally administered. 15 mg/day t.i.d.
40856044|NCT02446080|DIETARY_SUPPLEMENT|Milk drink with probiotic culture|The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture
40856045|NCT02446080|DIETARY_SUPPLEMENT|Milk drink|The control group was asked to drink 150 ml per day of dairy drinks.
40856046|NCT03487185|DEVICE|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
40856047|NCT03487185|OTHER|Sleep Advice Control|Initial sleep advice counseling alone
40856048|NCT04091880|BIOLOGICAL|EV71 vaccine and influenza vaccine|simultaneously administrated with EV71 vaccine and influenza vaccine
40856049|NCT04091880|BIOLOGICAL|EV71 vaccine|administrated with EV71 vaccine only
40856050|NCT04091880|BIOLOGICAL|influenza vaccine|administrated with influenza vaccine only
40856051|NCT04343456|PROCEDURE|Salvage surgery with massive debulking|For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.
40856052|NCT03427463|DRUG|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
40856053|NCT03427463|DRUG|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
40856054|NCT00067379|PROCEDURE|interceptive orthodontic treatments|orthodontic procedures
41166557|NCT00230945|BEHAVIORAL|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
41166558|NCT00175656|PROCEDURE|Elimination of titanium elastic nail prominence at the insertion site and leaving the nails in situ|See Detailed Description.
41166559|NCT02757313|DRUG|Low dose THC marijuana|
41166560|NCT02757313|DRUG|High dose THC marijuana|
40856055|NCT01378767|DIETARY_SUPPLEMENT|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
40856056|NCT04979117|DEVICE|Superb Microvascular Imaging (SMI) (Toshiba)|to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.
40856057|NCT03374540|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
41166561|NCT02757313|DRUG|Placebo marijuana|
41166562|NCT02275013|DRUG|Levosimendan|
41166563|NCT03233347|DRUG|Brentuximab Vedotin|Given IV
41166564|NCT03233347|DRUG|Dacarbazine|Given IV
41166565|NCT03233347|DRUG|Doxorubicin|Given IV
41166566|NCT03233347|OTHER|Laboratory Biomarker Analysis|Correlative studies
41166567|NCT03233347|BIOLOGICAL|Nivolumab|Given IV
41166568|NCT03233347|DRUG|Vinblastine|Given IV
40856058|NCT03374540|DRUG|Vitamin K antagonist (VKA)|Individually adjusted dose
40856059|NCT05077332|DRUG|Famotidine|80 mg tablet, QID for 14 days
40856060|NCT05077332|DRUG|Celecoxib|400 mg (initial dose) then 200 mg capsule, BID for 5 days
40856061|NCT05077332|OTHER|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
40856062|NCT04158583|DRUG|RO7296682|RO7296682 will be administered by the schedules specified in the respective arms.
40856063|NCT00315016|DRUG|eplerenone|active comparator
40856064|NCT00315016|DRUG|fosinopril|doubling of fosinopril dose
40856065|NCT00315016|DRUG|placebo|placebo (double dummy)
40856066|NCT03979885|BEHAVIORAL|Smoking cessation counseling (Quitline)|Quitline offers community-based counseling session with a cessation counselor.
40856067|NCT03979885|BEHAVIORAL|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
40856068|NCT03979885|BEHAVIORAL|Financial incentives for smoking cessation|Participants will receive financial incentives for bioconfirmed smoking cessation.
40856069|NCT03979885|BEHAVIORAL|Financial incentives for use of evidence-based smoking cessation therapies|Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
40856070|NCT02443168|DRUG|AG-221|Part 1: oral solution containing 100 mg \[14C\]-AG-221
40856071|NCT02443168|RADIATION|14C AG-221|5 mL of 100 micrograms \[14C\] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
40856072|NCT02908789|RADIATION|Antimicrobial photodynamic therapy (aPDT)|Selective caries removal + Antimicrobial photodynamic therapy (aPDT) is an effective low potency laser that involves the activation of a photosensitizer( 0.01% methylene blue ) by a visible light source that creates chemical reactions, producing cytotoxic reactive oxygen species and causing oxidative stress and inactivation of pathogenic microorganisms + tooth restauration
40856073|NCT02908789|OTHER|Without Antimicrobial phothodynamic therapy|Selective caries removal + tooth restauration
40856074|NCT00788788|DRUG|HELIOX|HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
40856075|NCT02268825|DRUG|MK-3475|"MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose"
40856076|NCT01100359|DRUG|carboplatin|
40856077|NCT01100359|DRUG|liposome-encapsulated doxorubicin citrate|
40856078|NCT01100359|OTHER|laboratory biomarker analysis|
40856079|NCT01100359|PROCEDURE|quality-of-life assessment|
40856080|NCT05663671|DIAGNOSTIC_TEST|Diagnostic Test|30% of IBD patients are misdiagnosed. This affects surgical care of patients. Investigators have unveiled a signature discriminator between UC\&CC that also predicts the outcome of IC patients into authentic UC/CC. This is a bioassay that is specific, sensitive, linear, affordable, minimal risk, non-invasive and constitutes an inexpensive, simple to use, point-of-care test format. Investigators published data which have shown robust presence of DEFA5 in the colon crypt mucosa with aberrant expression of apparent crypt-cell-like cells (CCLCs) in areas identified with ectopic colon ileal metaplasia consistent with CC. Investigators propose to validate that UC/CC, the two unsolved medical sub-types of pathology can accurately be distinguished among IC patients by examining CCLCs secreted DEFA5 levels in endoscopy biopsies instantly. Diagnostics relies on the expression/localization/activation of DEFA5 and the ectopic CCLCs in the mucosal crypt of CC patients.
40856081|NCT00625781|DRUG|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose \>5.0 mmol/l or post meal value \>6.5 mmol/l according to study protocol.
41386938|NCT05395702|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
40856082|NCT00385138|DRUG|Cangrelor|cangrelor bolus (30 mcg/kg) \& cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
40856083|NCT00385138|DRUG|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
40856084|NCT00385138|DRUG|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
40856085|NCT00385138|DRUG|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
40856086|NCT00385138|DRUG|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
40856087|NCT03276546|BEHAVIORAL|shared decision-making tool (SHARE-D)|questionnaire
40856088|NCT02630303|DEVICE|LED-RL Phototherapy|"The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
40856089|NCT02630303|DEVICE|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
40856090|NCT02665572|BEHAVIORAL|bladder recycling|Bladder recycling will be done by the patient after proper education. It will be started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 300 cc of sterile water for 2 hours.
41386939|NCT01111084|DRUG|Follitropin alpha (r-FSH)|The dosage and administration of follitropin alpha was according to each centre's protocol and within technical specification recommendations.
41386940|NCT00993629|DRUG|pregnenolone|"Administered adjunctively to treatment as usual"
41038035|NCT01766557|OTHER|Semi-controlled intervention with other animal proteins|Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
41038036|NCT02625103|PROCEDURE|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
41038037|NCT02625103|DRUG|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
41038038|NCT06364189|BEHAVIORAL|Music|Individualized play lists of music with the beats accentuated will be developed at a range of cadences. The music intervention is such that during strength training participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), the tempo of playlists will be adjusted to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
41038039|NCT06364189|BEHAVIORAL|Exercise|"The ST incorporates single-leg exercises for balance training and training with resistance bands and body weight.~For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week."
41386941|NCT00993629|DRUG|placebo|adjunctive placebo
41386942|NCT03750916|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
41386943|NCT02125617|DRUG|Abiraterone|1000 mg/day
41386944|NCT02125617|DRUG|Prednisolone|10 mg/day
41386945|NCT05658107|DRUG|BI 765423|BI 765423
41386946|NCT05658107|DRUG|Placebo|Placebo
41386947|NCT02388607|OTHER|measurements|performance measurements
41386948|NCT04723173|DEVICE|Feature for noise reduction (on)|The noise reduction feature shall support the hearing aid user in noisy situations and shall reduce the listening effort.
40856091|NCT01248741|RADIATION|HDR prostate brachytherapy|"HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a boost combined with external beam radiotherapy"
40856092|NCT01865643|DEVICE|GlideScope|The GlideScope is used to assist with difficult tracheal intubation.
40856093|NCT02255994|DEVICE|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
40856094|NCT02255994|PROCEDURE|No mesh.|Patients in this arm had subvesical plication without reinforcement.
40856095|NCT04815746|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)-based skills|The CBT skills target reducing anxiety, (e.g., relaxation), changing negative appraisals (e.g., cognitive restructuring), coping skills training (e.g., enhancing adaptive skills), behavioral activation, interpersonal skills (e.g., communication skills) and building or enhancing social networks. The intervention will be administered online, and each module will last about 1-hour.
40856096|NCT04815746|BEHAVIORAL|Standard Education|Patients randomized to standard clinical care will receive standard education based on various resources (e.g., National Cancer Institute) relevant to pancreatic cancer.
40856097|NCT05350852|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
40856098|NCT01037686|RADIATION|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
40856099|NCT01037686|BEHAVIORAL|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
41038040|NCT03353935|OTHER|Validated questionnaires|Patients were administered pre- and post-operatively the three validated questionnaires ((FSFI, ICIQ-UI short form Italian, NBD score) investigating sexual, urinary, and fecal function, respectively.
40856100|NCT01037686|DEVICE|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
40856101|NCT00491582|DRUG|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
40856102|NCT01206582|BIOLOGICAL|Hemin|10 iv infusions for 8 weeks
41038041|NCT03516331|DRUG|FDL176 & FDL169 coadministration|CFTR corrector and potentiator
41038042|NCT03302962|BEHAVIORAL|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
41038043|NCT03249922|DEVICE|Spinal Cord Stimulation|Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
41038044|NCT06042348|DIAGNOSTIC_TEST|Trans abdominal ultrasound|Ultra sound of the uterus and uterine blood vessels
41038045|NCT04594694|DRUG|Obeticholic acid|5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily
41166569|NCT01004029|DRUG|Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL|1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
41038046|NCT04594694|DRUG|Bezafibrate 200 MG|200 mg IR tablet of Bezafibrate once daily for the remainder of the study
41038047|NCT04594694|DRUG|OCA Placebo|One tablet daily for the remainder of the study
41038048|NCT04594694|DRUG|Bezafibrate 200 mg Placebo|One tablet daily for the remainder of the study
41038049|NCT04594694|DRUG|Bezafibrate 400 MG|400 mg SR tablet of Bezafibrate once daily for the remainder of the study
41038050|NCT04594694|DRUG|Bezafibrate 400 mg Placebo|One tablet daily for the remainder of the study
41386949|NCT04723173|DEVICE|Feature for noise reduction (off)|To show the advantage of the noise reduction feature there is a comparison without the feature necessary.
40856103|NCT01206582|BIOLOGICAL|Albumin|10 iv infusions for 8 weeks
40856104|NCT00544219|BIOLOGICAL|rituximab|375 mg/m2 i.v. per cycle
40856105|NCT00544219|DRUG|cyclophosphamide|750 mg/m2 i.v. per cycle
40856106|NCT00544219|DRUG|doxorubicin hydrochloride|50 mg/m2 i.v. per cycle
40856107|NCT00544219|DRUG|prednisone|100 mg/day p.o. per cycle
40856108|NCT00544219|DRUG|vincristine sulfate|1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
40856109|NCT00544219|PROCEDURE|positron emission tomography|PET Scan during treatment
40856110|NCT03523572|DRUG|Trastuzumab deruxtecan|The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
40856111|NCT03523572|DRUG|Nivolumab|Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
40856112|NCT03927144|DRUG|AMG334|Subcutaneous Injection
40856113|NCT03927144|DRUG|Oral Prophylactic|SOC Oral Tablet/Capsule
41038051|NCT04594694|DRUG|OCA|OCA one tablet will be administered.
41038052|NCT04594694|DRUG|Bezafibrate|Bezafibrate one tablet will be administered.
41038053|NCT00615043|PROCEDURE|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
41038054|NCT00541515|DEVICE|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
41038055|NCT04928950|DRUG|Activated charcoal|Activated Charcoal, Powder, USP is carbon that has been treated to create low-volume pores that increase the area available for chemical reactions and adsorption. The most common pharmaceutical uses of activated charcoal is as a purification agent and antitoxin. All Spectrum Chemical USP products are manufactured, packaged and stored under current Good Manufacturing Practices (cGMP) per 21CFR part 211 in FDA registered and inspected facilities.
41386950|NCT01700907|DRUG|Desflurane|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
40856114|NCT00006195|DRUG|risperidone|
40856115|NCT00006195|DRUG|olanzapine|
41510706|NCT06132412|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.
41510707|NCT06132412|OTHER|physical therapy|Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.
40856116|NCT01011140|BEHAVIORAL|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
40856117|NCT04262076|OTHER|Pulpine with Polyamidoamine Dendrimer|Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
40856118|NCT06332963|BEHAVIORAL|Floatation-REST|Participants lay supine in one of two circular fiberglass pools that were custom-designed for research purposes. The floatation pools are 8 feet in diameter and contain 11 inches of reverse osmosis water saturated with \~1,800 pounds of Epsom salt (magnesium sulfate). This creates a dense saltwater solution with a specific gravity of \~1.26, allowing participants to effortlessly float on their back while the water hovers just above the ears. The temperature of the water and air is calibrated to approximate skin temperature (\~95.0 °F), helping to minimize the need for thermoregulation while reducing the boundary between air, body, and water. Clothing is usually not worn while floating since anything touching the body can generate somatosensory stimulation, detracting from the float experience. However, participants have the option to choose if they would prefer to float with a bathing suit or nude. During floatation-REST, visual, auditory, olfactory stimuli are minimized.
40856119|NCT06332963|BEHAVIORAL|IFT|Two ACT principles, contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the IFT condition, awareness and acceptance of bodily signals, thoughts, and emotions and being present with one's self (i.e., mindfulness focus is inward) are emphasized. All participants will engage in an introduction session. Followed by three IFT sessions. The experimental sessions are formatted the same for both conditions. Each begins with a clinician reviewing previous constructs and introducing a new skill. Then participants engage in their assigned condition intervention, followed by a debrief with a clinician. Practices in both conditions are matched as closely as possible for content. The mindful focus of IFT is internal toward thoughts, emotions, and body sensations. In the experimental sessions, participants will engage in a floatation-REST session while practicing acceptance and mindfulness-based skills presented to them.
41510708|NCT02068612|BEHAVIORAL|Moderate Intensity Continuous Training+Interval Training|
41510709|NCT02068612|BEHAVIORAL|Low Intensity Continuous Training|
40856120|NCT06332963|BEHAVIORAL|EFT|Two acceptance and commitment therapy modules contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the EFT condition, awareness and acceptance of thoughts and emotions and mindfulness of current experience are emphasized. The mindful focus of EFT is external, toward attending to experience as well as thoughts and emotions. During experimental sessions, participants will engage in a self-guided and computer-based practice of acceptance and mindfulness-based skills. These videos were created to ensure content was congruent with the material presented in the introduction sessions and represent skills that build from session to session.
40856121|NCT01317901|DRUG|TRU-016|100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
40856122|NCT01317901|DRUG|Bendamustine|Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
40856123|NCT01317901|DRUG|Rituximab|Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.
40856124|NCT04348981|DEVICE|Wearable fitness tracking device|Patients having a wearable fitness tracking device will be monitored for their level of activity after surgery. Declines in activity level will prompt a phone call from the surgical provider.
40856125|NCT04678388|DRUG|Reference drug|1 Cap., single oral administration under fasting condition
40856126|NCT04678388|DRUG|Test drug 1|1 Tab., single oral administration under fasting condition
40856127|NCT04678388|DRUG|Test drug 2|1 Tab., single oral administration under fasting condition
40856128|NCT05562258|BEHAVIORAL|Parent Coaching and Patient Education|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to a coach and patients will have access to weekly educational material.
41510710|NCT06432855|OTHER|Blood collection|20 ml-blood sample
41510711|NCT06432855|OTHER|saliva collection|saliva sample
41510712|NCT05387187|DRUG|Pu Yang Wan Wu Tang plus Pentoxifylline|Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
41510713|NCT05387187|DRUG|Pentoxifylline|Pentoxifylline 100mg TID
41510714|NCT05300750|OTHER|Oral fluids|Starting amount of oral fluid after 2 hours post C/s should be 5cm and then increase gradually to be 45-50 cm of oral fluid at 4 hours post C/s and 100 cm each hours later.
41510715|NCT05300750|OTHER|Chewing gum|Chewed free sugar gum for 15 minutes
40856129|NCT05562258|BEHAVIORAL|Parent Education and Patient Coaching|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to weekly educational material and patients will have access to a coach.
40856130|NCT05495165|OTHER|Therapeutic education for patients in nutrition|Stakeholders give preventive therapeutic education recommandations in their specific expertize
41510716|NCT03892018|DRUG|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
41510717|NCT04228016|DEVICE|Device: nastent™|Patients with Nasal obstruction at night, will be used intrasal stent during 15 nights. These are flexible silicone tubes that are lubricated and easy to insert into the nasal cavities, which would restore the permeability of the nasal cavities.
40856131|NCT01992835|OTHER|Grass pollen allergen extract|Each subject will be challenged with a grass pollen allergen extract and with placebo.
41386951|NCT01700907|DRUG|Sevoflurane|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
40856132|NCT01992835|OTHER|placebo|
40856133|NCT01267305|DRUG|Fondaparinux|2.5mg IH qd(8AM) after operation
40856134|NCT01267305|DRUG|Nadroparin Calcium|4100AxaIU IH qd(8AM) after operation
40856135|NCT01267305|DRUG|Nadroparin Calcium|4100AxaIU IH q12h(8Am,8Pm) after operation
40856136|NCT05132218|DRUG|Ensatinib|Prospective, exploratory, single-arm, multi-center, real-world research
40856137|NCT03463785|OTHER|cone beam computed tomography|The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol. The OSA patients will be treated with mandibular advancement device.
40856138|NCT01467921|DRUG|oxaliplatin|oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
40856139|NCT03910088|DRUG|Pregabalin 100Mg Oral Cap|giving a drug to relieve post-dural puncture headache
40856140|NCT03910088|DRUG|Hydrocortisone|Giving drug to relieve post-dural puncture headache
40856141|NCT03910088|DRUG|Acetaminophen|giving a drug to relieve post-dural puncture headache
40856142|NCT03910088|OTHER|oral fluids|giving oral fluids to maintain good hydration
41386952|NCT03664024|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
41386953|NCT03664024|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2 infusion, standard of care, Q3W, IV
40856143|NCT03910088|DRUG|Caffeine|giving a drug to relieve post-dural puncture headache
40856144|NCT03910088|DRUG|Diclofenac|giving a drug to relieve post-dural puncture headache
40856145|NCT02771197|DRUG|Fludarabine|
41386954|NCT03664024|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
40856146|NCT02771197|DRUG|Melphalan|
40856147|NCT02771197|DRUG|Pembrolizumab|
40856148|NCT04345315|OTHER|serological test|serological test assessing IgM and IgG directed against SARS-CoV-2
40856149|NCT04345315|OTHER|Rapid molecular test|Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab
40856150|NCT04345315|GENETIC|Next generation Sequencing (NGS) analysis|analysis of genetic variability of virus and host
41038056|NCT01820676|DEVICE|iUni G2+|The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
41166570|NCT01004029|DRUG|Vehicle|Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
41386955|NCT03664024|DRUG|Cisplatin|Cisplatin, 75 mg/m\^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
41386956|NCT02263586|BEHAVIORAL|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
41386957|NCT06371911|OTHER|Cureety telemonitoring|The digital telemonitoring platform, Cureety, has been designed to facilitate the monitoring of signs and symptoms of treatment-specific AEs and disease progression. The platform integrates Cureety TechCare, a CE marked algorithm that is a class I medical device
41510718|NCT05915260|DIAGNOSTIC_TEST|All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion|This is a observational follow up study accordingly all subjects will undergo the same examinations
40856151|NCT04345315|OTHER|serum chemistry analysis|Analysis of serum chemistry factors and coagulation panel in blood samples
40856152|NCT04119193|DEVICE|Novel smartphone application for blood pressure measurement|Continuous blood pressure measurements will be compared between the new application and the reference method (invasive radial arterial line) during 5 minutes of recordings.
40856153|NCT06202040|PROCEDURE|Bilateral Oblique Subcostal Transversus Abdominis Plane Block (OSTAP) will be performed.|The OSTAP block will be conducted in-plane using a 100mm 22 G needle and a linear probe under ultrasound (USG) guidance. The 20cc block will contain 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral OSTAP will be administered with 20cc (10cc per side). To apply the block, position the linear probe parallel to the rib edge immediately below it on the anterior abdominal wall. Visible will be the external, internal, transversus abdominis, and rectus muscle junction. The needle tip will move toward the TAP space (between the internal oblique and transversus abdominis muscles). To ensure medication delivery, the needle tip will be visible in the TAP and the drug will be aspirated negatively. USG will also observe drug distribution at the rectus abdominis muscle-TAP space junction.
40856154|NCT06202040|PROCEDURE|Bilateral Rectus Sheath Block (RSB) will be performed.|When the patient is in the supine position, the ultrasound (USG) linear probe is held in the transverse plane at the level just above the umbilicus, where the posterior rectus sheath is best visualized. Using the in-plane technique with a 100mm 22 G needle under USG guidance, the drug prepared will be administered between the rectus muscle and the posterior rectus sheath. For this block, a volume of 20cc will be prepared, consisting of 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral Rectus Sheath Block (RSB) will be applied with a total volume of 20cc, 10cc to each side.
40856155|NCT02901418|BIOLOGICAL|200 IU HBIG|additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
40856156|NCT05389176|DRUG|Esmolol|a continuous esmolol infusion titrated to maintain heart rate between 70/min and 100/min
40856157|NCT03842241|DEVICE|Non-custom made foot orthoses|Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
40856158|NCT01408459|DIETARY_SUPPLEMENT|Tomato Product|Motivational Telephone Counseling weekly
40856159|NCT01408459|DIETARY_SUPPLEMENT|Control|No Motivational telephone Counseling
41386958|NCT06371911|OTHER|OPTIMA or equivalent programs|"The programs consist of three stages:~1. The medical team make structured telephone calls with patients 2 to 3 days before the planned administration of injectable treatment. Adverse events and other relevant data are collected.~2. Patients undergo biological tests within 48 hours of the appointment and the results are sent by the laboratory to the centre.~3. Then, the physician assesses the data and decides whether to anticipate and validate the prescription of injectable treatments."
41038057|NCT04699266|DEVICE|Assigned Intervention (POD F GF)|The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects
41038058|NCT05804565|PROCEDURE|Bone Saw|The surgeon will use an oscillating microsaw to transect the metatarsal shaft
41038059|NCT05804565|PROCEDURE|Bone Cutter|The surgeon will use a manual bone cutter to transect the metatarsal shaft
41386959|NCT05910580|BEHAVIORAL|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment. Procedures for SBIRT delivery will be adapted to the flow of telemedicine visits.
41386960|NCT05794386|PROCEDURE|LVA-guided LA substrate modification|The LVA-guided additional LA ablation is included linear ablation or LVA zone border modification/isolation/ homogenization. The additional ablation strategies are finally selected at the physicians' discretion, considering LVA location and distribution.
41386961|NCT01005407|BIOLOGICAL|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
41386962|NCT01005407|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
41386963|NCT01909752|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
41386964|NCT01909752|BIOLOGICAL|DRibble vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
40856160|NCT00724984|DRUG|PCI-24781|"Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I."
40856161|NCT05723107|DRUG|Chemotherapy|Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.
40856162|NCT05723107|DEVICE|Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)|"EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).~The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes."
41038060|NCT01579708|BEHAVIORAL|Program SI! educational intervention|School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
41386965|NCT01909752|DRUG|Imiquimod|Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
41386966|NCT01909752|DRUG|GM-CSF|GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
41386967|NCT01909752|BIOLOGICAL|HPV vaccine|Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
41386968|NCT00022126|DRUG|asparaginase|
41386969|NCT00022126|DRUG|cyclophosphamide|
41386970|NCT00022126|DRUG|cyclosporine|
41038061|NCT03006523|PROCEDURE|Intrauterine insemination|IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
41038062|NCT03135951|DRUG|SPI-2012|Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
41038063|NCT00379613|DRUG|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
41386971|NCT00022126|DRUG|cytarabine|
41386972|NCT00022126|DRUG|daunorubicin hydrochloride|
41386973|NCT00022126|DRUG|dexamethasone|
41386974|NCT00022126|DRUG|doxorubicin hydrochloride|
41386975|NCT00022126|DRUG|mercaptopurine|
41386976|NCT00022126|DRUG|methotrexate|
41386977|NCT00022126|DRUG|methylprednisolone|
41386978|NCT00022126|DRUG|pegaspargase|
41386979|NCT00022126|DRUG|thioguanine|
40856163|NCT02515734|DRUG|fluorouracil|
40856164|NCT02515734|DRUG|Leucovorin|
40856165|NCT02515734|DRUG|irinotecan|
40856166|NCT02515734|DRUG|oxaliplatin|
40856167|NCT02515734|BIOLOGICAL|bevacizumab|
41038064|NCT00379613|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
41386980|NCT00022126|DRUG|vincristine sulfate|
41038065|NCT01358968|DRUG|LY2603618|Administered intravenously as a 1-hour infusion.
41166571|NCT01181583|BEHAVIORAL|Tailored Internet-delivered CBT|"This intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
41386981|NCT00022126|PROCEDURE|allogeneic bone marrow transplantation|
41386982|NCT00022126|RADIATION|radiation therapy|
41386983|NCT02454322|DRUG|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
41386984|NCT06409325|DEVICE|MST|MST was delivered with NS 7000 (Wuhan Yiruide Medical Equipment New Technology Co., Ltd.) using a round coil (125-mm diameter) positioned on the vertex.
41386985|NCT06409325|DEVICE|ECT|The bitemporal ECT procedure utilized the Thymatron System IV device (Somatics, USA).
41386986|NCT05665712|PROCEDURE|enhanced recovery|bundle of factors that have been shown to help with recovery in other surgical services such as good pain control, early ambulation, early nutrition
41386987|NCT00424515|DRUG|Imatinib|Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
41386988|NCT05537246|PROCEDURE|PWV|All cases were evaluated in the service before surgery. Pulse wave velocity measurement was performed with the MOBİL-O-GRAPH device, which is one of the noninvasive methods. Before measuring from patients; It was confirmed that there was no coffee/cigarette consumption within 30 minutes. After resting for 5 minutes in a quiet room, the cuff of the appropriate size was tied to the arm in such a way that it came to the brachial artery. The data recorded by the tonometer was transferred to the computer program. Care was taken that the patient did not move or talk during the measurement.
41386989|NCT05940467|OTHER|Sleep Loss|Participants will undergo periods of sleep loss in a laboratory setting and be monitored hourly for changes in indicators of arterial stiffness (i.e., pulse wave velocity).
41386990|NCT06290258|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation has been applied to patients with autism spectrum disorder in recent years. Fecal microbiota of healthy donors can be transplanted to patients through colonoscopy. Before donation, donors were comprehensively screened to rule out gastrointestinal symptoms and infections. Patients will receive colon preparation before transplantation. After the intervention, patients will have to stay in bed and be monitored for 24 hours to assure safety.
41386991|NCT02755727|PROCEDURE|Platelet Rich Plasma Injection|See Arms
40856168|NCT02515734|BIOLOGICAL|cetuximab|
40856169|NCT01000259|OTHER|Laboratory Biomarker Analysis|Samples are analyzed in laboratory studies
40856170|NCT01303601|DRUG|olanzapine|"Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks"
41038066|NCT01358968|DRUG|Desipramine|Administered orally
41386992|NCT02755727|PROCEDURE|Open Surgical Release|See arms
41386993|NCT05787860|DRUG|Ruxolitinib 1.5% Cream|topical ruxolitinib 1.5% cream twice daily for 4 weeks
41386994|NCT00822679|DRUG|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
40856171|NCT01303601|DRUG|Starch|
40856172|NCT05936398|BEHAVIORAL|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
40856173|NCT05936398|BEHAVIORAL|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
40856174|NCT02240511|DIETARY_SUPPLEMENT|RE and BCAA Supplementation|RE: Resistance Exercise BCAA: Branched Chain Aminoacids
40856175|NCT02240511|OTHER|Resistance Exercise|
40856176|NCT05645523|DRUG|Indocyanine Green|Given in to the vein (IV)
40856177|NCT03054649|DEVICE|HARMONI® Modular Intraocular Lens System|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
40856178|NCT03054649|PROCEDURE|Intraoperative optic exchange|Removal of one optic and replacement with another during cataract surgery for the purpose of improving refractive outcomes
40856179|NCT01597713|DRUG|NNC 0148-0000-0362|Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
41038067|NCT01358968|DRUG|Pemetrexed|Administered intravenously as a 10-minute infusion.
41038068|NCT01358968|DRUG|Gemcitabine|Administered intravenously as a 30-minute infusion.
41038069|NCT00476476|DRUG|Erlotinib|Orally every day for about 4-6 weeks
41038070|NCT02935335|DRUG|Menotrophin|
41386995|NCT00822679|OTHER|Placebo|Subjects are given placebo for 3 consecutive nights
41386996|NCT05243134|OTHER|Collect the clinical data|We analyze the influence of the anatomic deformity on the clinical efficacy at the follow-up.
41386997|NCT02272972|OTHER|Application of knowledge|Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
41386998|NCT00736138|PROCEDURE|training and pellots|training and pellots
41386999|NCT00348218|DEVICE|NeuroVision|
41510719|NCT02051556|BEHAVIORAL|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
41510720|NCT02051556|BEHAVIORAL|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
41510721|NCT02051556|BEHAVIORAL|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
41510722|NCT03486665|OTHER|Blood Sampling|Blood samples will be taken from all patients and healthy volunteers.
41510723|NCT03486665|OTHER|CSF Sampling|CSF sample will be taken from hospitalized newly diagnosed patients only.
41510724|NCT00296972|DRUG|peg interferon plus ribavirin|
41510725|NCT06486857|DIAGNOSTIC_TEST|a novel gas detection method for dyslipidemia screening|Multidimensional Mass Spectrometry Technologies Based on Exhaled Metabolic Fingerprint Spectra for Dyslipidemia Detection
41510726|NCT03638388|PROCEDURE|Dry needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of my muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and the subject will sit in a chair without moving my arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
41510727|NCT03638388|PROCEDURE|Dry needling with intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of the muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject sits in a chair without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
41510728|NCT05209789|BEHAVIORAL|HUGS|Group therapy with the participation of two therapist positively encouraging mother-baby interactions in a non-judgmental manner
41510729|NCT05209789|BEHAVIORAL|Playtime|Very little intervention from the therapists
41387000|NCT06233058|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Umeda Company Limited, Thailand
41510730|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 1: 50 ug
41510731|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
41510732|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
41510733|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
41510734|NCT01415102|DRUG|Placebo|Inhaled
40856180|NCT01597713|DRUG|insulin glargine|As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
40856181|NCT01597713|DRUG|placebo|Subjects will receive a single dose of oral placebo within each dose group
41510735|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
41038071|NCT04775680|BIOLOGICAL|ADG106 injection|ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle
41387001|NCT06233058|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Bayer AG, Berlin, Germany
40856182|NCT01597713|DRUG|NNC 0148-0000-0362|Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
41387002|NCT01016431|OTHER|Rate-adaptive pacemaker programming|The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
41387003|NCT01016431|OTHER|VVI at 40 bpm|ICDs will be programmed in VVI mode at 40 bpm
41510736|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
41510737|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
41510738|NCT01415102|DRUG|Placebo|Inhaled
41510739|NCT02304393|DRUG|Atezolizumab|Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
41510740|NCT02304393|DRUG|Selicrelumab|Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
41510741|NCT00757211|GENETIC|polymorphism analysis|
41510742|NCT00757211|OTHER|laboratory biomarker analysis|
41510743|NCT00757211|OTHER|questionnaire administration|
41510744|NCT02078700|OTHER|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
41510745|NCT02914353|DRUG|EP=7041|Factor X!a Inhibitor
40856183|NCT01597713|DRUG|NNC 0148-0000-0362|Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
40856184|NCT01597713|DRUG|NNC 0148-0000-0362|Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
40856185|NCT03084003|DIETARY_SUPPLEMENT|Almonds|
40856186|NCT03084003|DIETARY_SUPPLEMENT|Graham crackers|
40856187|NCT01834079|BIOLOGICAL|STEM CELL THERAPY|Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
41510746|NCT02914353|DRUG|Placebo|Normal Saline
41510747|NCT00425204|DRUG|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
40856188|NCT05981469|DEVICE|Cervical Stiffness Assessmenr|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
40856189|NCT05981469|OTHER|Bishop's Score Assessment|Sterile digital vaginal examination to illicit the Bishop's score (0-12).
40856190|NCT00193180|DRUG|Imatinib|Imatinib
40856191|NCT00193180|DRUG|Docetaxel|Docetaxel
40856192|NCT02557737|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
40856193|NCT03255577|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
41387004|NCT05786794|BEHAVIORAL|Patient Navigation Program for Hearing Health Care|Patients presenting for routine office visits will be invited to participate in the study and informed consent procedures and study enrollment will be conducted by a research assistant. Participants will then undergo baseline assessment. Following baseline measures, participants who screen positive for hearing loss will be contacted by the Patient Navigator (PN) to begin the intervention. The navigator will contact participants every 2 weeks to focus on addressing key aspects of Hearing Health Care (HHC): education, screening, diagnosis, and treatment. PNs will assist the patient to undergo a formal audiogram with the 12 months following enrollment. Each PN session will likely last between 10-30 minutes. Post-intervention data collection also administered by a trained interviewer, will occur following a diagnostic audiogram with an audiologist or at 12 months following enrollment.
40856194|NCT00474214|BEHAVIORAL|Early hospital discharge facilitated by close nurse practitioner follow-up|
40856195|NCT00192413|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
40856196|NCT00192413|BIOLOGICAL|Trivalent Inactivated Vaccine (TIV)|Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
40856197|NCT06302309|OTHER|Psychological intervention|The intervention consists of four sessions of a 'managing the mental state' intervention, of which the first and second session will take place in the home-setting of the patient; the two remaining sessions will take place remotely. The sessions include psychoeducation on what anxiety is and how stress and anxiety can influence FOG, identifying how people are allocating attention and engage in specific thought-processes (e.g. worrisome thoughts) during walking, and educating patients about 'managing the mental state' compensation strategies that involve ways to reduce anxiety or stress and will be specifically tailored to the individual patient.
40856198|NCT04036526|BIOLOGICAL|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
40856199|NCT04036526|OTHER|Placebo|Placebo
40856200|NCT04625764|PROCEDURE|Blood sampling and analysis|Blood sampling for pharmacokinetics (Plasma ticagrelor concentrations and its metabolite) and MEA platform testing (ADPtest, TRAPtest)
40856201|NCT01465815|DRUG|erlotinib hydrochloride|Given PO
41387005|NCT01665573|DRUG|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
40856202|NCT01465815|DRUG|linsitinib|Given PO
40856203|NCT01465815|DRUG|placebo|Given PO
40856204|NCT01465815|RADIATION|radiation therapy|Undergo radiation therapy
40856205|NCT01465815|PROCEDURE|therapeutic conventional surgery|Undergo planned surgery
40856206|NCT01465815|OTHER|laboratory biomarker analysis|Correlative studies
40856207|NCT01184924|BEHAVIORAL|Evaluation of the Arthritis Foundation Tai Chi Program|The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
40856208|NCT05370053|DIAGNOSTIC_TEST|ELF Test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
41387006|NCT01665573|DRUG|Placebo|Acquisition of conditioning Administration of placebo Extinction of conditioning
41387007|NCT06538909|DEVICE|VR|Virtual reality that simulates obstacles on the road during walking
41387008|NCT04426019|BEHAVIORAL|CLS Intervention|Community health workers (or promotoras) will deliver the CLS program either in face-to-face and/or group sessions to all women within 2 months of the baseline interview. Each session will last approximately 1 to 2 hours, and will include CLS materials adapted for this study.At the conclusion of the CLS program, promotoras will provide information about local and affordable providers delivering low-cost or free breast and cervical cancer screening services. Should a woman require follow-up for abnormal results, referrals will be given to programs,which provides assistance accessing cancer diagnostic and treatment services. Two weeks after delivering the education component of the CLS program, promotoras will call women to provide any further assistance needed. During these follow-up calls promotoras will provide on-going navigation support to women in need of mammography and Pap test screening
41387009|NCT04426019|BEHAVIORAL|No CLS intervention|This control arm will receive only usual practice care (print education) and will not receive the CLS intervention. They may receive the intervention after the study has been completed
41510748|NCT03456505|BEHAVIORAL|Mindfulness Meditation Training|A researcher will guide participants through 5 mindfulness meditations, each lasting 11 minutes in length.
40856209|NCT00730808|DIETARY_SUPPLEMENT|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
41038072|NCT04775680|BIOLOGICAL|PD-1 antibody injection|PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle
41387010|NCT02611531|BEHAVIORAL|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
41387011|NCT02611531|BEHAVIORAL|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
41387012|NCT01833221|DRUG|injection of 1% lidocaine, 2mL for facial nerve block|injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
41038073|NCT00896168|DRUG|Infliximab|Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
41387013|NCT00535873|DRUG|Lenalidomide|Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
41387014|NCT03015909|DRUG|Somatropin|
41387015|NCT00973531|DEVICE|Autotitrating Positive Airway Pressure (APAP)|Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
41387016|NCT00973531|DEVICE|Traditional Split Titration Polysomnogram|Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
41387017|NCT01166074|BIOLOGICAL|Subcutaneous IgG (SCIG)|Administered according to normal clinical practice
41387018|NCT04093479|OTHER|blood samples|blood samples will be taken repeatedly
40856210|NCT03520907|DRUG|Transversalis Fascia Plane Block|block will be performed under real-time ultrasound guidance
40856211|NCT03520907|DRUG|Ilioinguinal/iliohypogastric Nerve Block|block will be performed under real-time ultrasound guidance
40856212|NCT00227812|DRUG|Bupropion|
41038074|NCT00896168|DRUG|Methotrexate|MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
41038075|NCT04019938|RADIATION|Dual-energy X-ray absorptiometry|Cystatin C is measured as a part of routine investigation at the time of admission.
41038076|NCT02496013|DRUG|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
41038077|NCT02244866|DRUG|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
41387019|NCT06428006|BEHAVIORAL|Cognitive behavioral therapy for insomnia|"The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention"
41510749|NCT03456505|BEHAVIORAL|Active Listening|A researcher will read participants 5 selections from The Natural History of Selborne, each lasting 11 minutes in length.
40856213|NCT05984485|PROCEDURE|neoadjuvant chemotherapy plus total mesorectal excision|Neoadjuvant chemotherapy regimen recommended FOLFOX6, XELON, FOLFOX, mFOLFOX for 4-6 courses, and TME surgical treatment after preoperative tumor restaging 1-2 weeks after neoadjuvant chemotherapy.
40856214|NCT05984485|PROCEDURE|total mesorectal excision|Standard total mesorectal excision
41038078|NCT02244866|DRUG|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
40856215|NCT03851198|PROCEDURE|Standard Care or Usual Clinical Practice|The guidelines for the management according to the mild cognitive impairment in primary care will be the treatment guidelines for the Standard Care.
40856216|NCT00185575|DRUG|duloxetine|
40856217|NCT03439930|OTHER|Balance training|6 weeks lasting balance training program
41038079|NCT02248792|DRUG|Methotrexate|
40856218|NCT01625546|DEVICE|Whole Body Hyperthermia system|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
40856219|NCT03034824|PROCEDURE|SRP+940±15 nm diode laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
40856220|NCT03034824|PROCEDURE|SRP+Er,Cr:YSGG laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
41038080|NCT03694639|OTHER|ganglion impar block|CT sections were done in the axial plane 4 mm slice thickness to detect the site of sacrococcygeal disk. After a suitable section was confirmed, two distances were measured, one from patient's spine to the proper site of entry and the other from the site of entry to the target point.22 gauge spinal needle 12 cm was introduced until reach anterior to sacrococcygeal disk. When the needle tip location was ideal, 2 ml lidocaine mixed with1ml of radiopaque dye was injected. CT sagittal section was done to verify the retroperitoneal distribution of the dye. After good contrast spread confirmation, 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone was injected
41038081|NCT01835886|OTHER|Patients will ascend and descend a flight of 10 steps|Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
41038082|NCT06270966|DEVICE|Virtual Reality Cognitive Remediation|"Participants will undergo a 3-months cognitive remediation program using fully immersive VR with two sessions per week. Each session will last a maximum of sixty minutes and will be supervised by expert health professionals. The experimental group participated in an immersive VR-based CR program using the CEREBRUM software designed by clinicians and experts specializing in cognitive rehabilitation.~CEREBRUM provides 52 exercises: Attention, Working Memory, Memory and Learning and Cognitive Estimates. The intervention included 24 sessions."
41038083|NCT04391023|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique in which a very weak electrical current (2 mA) is applied to the scalp at the beginning of the session and then remains at 0 mA for the duration of the session to control for placebo-like effects. The anode and cathode will both be placed over the cerebellum.
41387020|NCT06428006|BEHAVIORAL|Sleep and lifestyle education|"The general sessions outlines are as follows with each session:~Session 1: Basic sleep education, stretching exercises Session 2: Sleep hygiene education (environmental factors \& sleep positions), stretching exercises Session 3: Sleep hygiene education (lifestyle factors), stretching exercises Session 4: Diet recommendations, stretching exercises Session 5: Exercises recommendations, stretching exercises Session 6: Discus maintaining achievements \& preventing relapses, stretching exercises"
40856221|NCT03034824|PROCEDURE|Scaling and root planing (SRP)-Control|Only Non-surgical periodontal treatment
40856222|NCT06436703|BIOLOGICAL|Influenza ModRNA Vaccine|Intramuscular injection
40856223|NCT06436703|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|Intramuscular injection
40856224|NCT06013384|DEVICE|Low-Intensity Focused Ultrasound Pulsation|Low-intensity focused ultrasound pulsation will be directed towards the target region at FDA-approved intensity levels in treatment sessions one and two.
41510750|NCT02539966|DEVICE|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold|Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
40856225|NCT06013384|DEVICE|Sham Low-Intensity Focused Ultrasound Pulsation|Sham low-intensity focused ultrasound pulsation will be given.
40856226|NCT02110862|OTHER|Transittime. Defecography|
40856227|NCT05347706|DIETARY_SUPPLEMENT|formula|Enteral feeding is started with in the first 24 hours of life. Human milk is encouraged, and preterm formula is fed when human milk is not available due to mother's or family's condition. Patients with feeding intolerance are temporarily fed with AAF or EHF instead of human milk or preterm formula. Once the patients with feeding intolerance show clinical improvement, AAF or EHF feeding is discontinued, and the previous feeding, either human milk or preterm formula is resumed
40856228|NCT04775641|OTHER|questionnaire|questionnaire
41387021|NCT00013273|PROCEDURE|Physical Conditioning|
41387022|NCT00444873|DRUG|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
41387023|NCT05220904|DEVICE|spectacles|Spectacle is the the most common treatment for refractive errors.
41387024|NCT05220904|DEVICE|perceptual learning|Blurred vision from the eyes can be improved by enhancing the brain's visual processing.
41387025|NCT05922592|PROCEDURE|crestal sinus lift using ballon technique|The sinus membrane will be elevated by using balloon technique with simultaneous Implant placement.
41510751|NCT02234076|BEHAVIORAL|VRET|
41510752|NCT02234076|BEHAVIORAL|TAU|Treatment as usual offered by the participating mental health care organisations
40856229|NCT02130596|BEHAVIORAL|Acceptance-Based Behavioral Intervention|
40856230|NCT02130596|OTHER|Nutritional Counselling|
40856231|NCT03701672|OTHER|Opioid Analgesic Treatment|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
41510753|NCT04370834|BIOLOGICAL|Tocilizumab|Given IV
41510754|NCT03681249|DRUG|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml twice a day for 24 weeks 150ml twice a day for 24 weeks
40856232|NCT02219373|DRUG|Gabapentin|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
40856233|NCT02219373|DRUG|Oxcarbazepine|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
41038084|NCT04391023|BEHAVIORAL|Balance Training|The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.
41038085|NCT04391023|DEVICE|2 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (2 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
41038086|NCT04391023|DEVICE|4 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (4 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
41166572|NCT01181583|BEHAVIORAL|Non-tailored Internet-delivered CBT|Specific text-based self-help for depression, which has previously been tested in three previous randomized trials. Anxiety symptoms will not be covered, but insomnia is included as a module together with advice on health.
41387026|NCT05922592|PROCEDURE|crestal sinus lift using densah burs|The sinus membrane will be elevated by using Densah burs with simultaneous Implant placement
41387027|NCT00716027|BEHAVIORAL|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
41387028|NCT00716027|BEHAVIORAL|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
41510755|NCT03681249|DRUG|ShenqiDihuang Decoction placebo|traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
41510756|NCT01207180|OTHER|Phone call follow-up|A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
41387029|NCT05193331|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
41510757|NCT01207180|OTHER|Satisfaction survey|Patients will be given a satisfaction survey.
41038087|NCT06490562|DRUG|PDCy|Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD
41387030|NCT05991492|DEVICE|Web-based Cognitive Behavioral Therapy for Insomnia (wCBT-I|Digital insomnia treatment
41387031|NCT02077660|DIETARY_SUPPLEMENT|Four green tea bags per day for 12 weeks|Four green tea bags per day for 12 weeks
41387032|NCT02077660|OTHER|4 daily placebo tea bags for 12 weeks|4 daily placebo tea bags for 12 weeks
41510758|NCT01207180|OTHER|Control group --- no intervention|Control group
41510759|NCT02392585|PROCEDURE|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
41038088|NCT06490562|DRUG|Non Cy|Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI
41166573|NCT01181583|BEHAVIORAL|Online discussion group|Participants take part of an online discussion group which are monitored daily. New discussion topics on depression are introduced every week.
41166574|NCT01624597|BEHAVIORAL|In-vehicle video feedback|An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
41387033|NCT05810974|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Subjects will consume 70ml shot (Beet-it Sport nitrate 400 shot, James White Drinks) and this drink contains 0.4g inorganic nitrate
41510760|NCT02392585|PROCEDURE|Triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
41510761|NCT01232933|DEVICE|VPS System|Use of the navigational VPS system during catheter placement
41510762|NCT04677101|DIAGNOSTIC_TEST|Liver Biopsy|Fine-needle liver biopsy
41510763|NCT04455321|PROCEDURE|Suture materials effect on istmocel|Effect of suture materials with different absorption times on istmocel
41387034|NCT05810974|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice + potassium nitrate (KNO3)|Nitrate-depleted beetroot juice (70ml) and 0.4g KNO3- will be mixed. (Same appearance and taste with Beet-it sport shot)
41387035|NCT05810974|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Subjects will consume 70ml of (Beet-it Placebo shot, James White Drinks). This drink is the same as the Beet-it Sport nitrate shot but has the nitrate removed.
41387036|NCT05278949|OTHER|The surgical intervention|The participant's primary IOL is re-fixed without utilizing any new material.
41387037|NCT04598009|DRUG|Binimetinib|Taken orally (PO) twice a day (BID)
41387038|NCT04598009|DRUG|Imatinib|Taken orally (PO) once a day (QD)
40856234|NCT02219373|OTHER|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
41387039|NCT02285452|DRUG|Zingiberis Rhizoma plv.|
41387040|NCT02285452|DRUG|Sinapis nigrea semen|
41387041|NCT02285452|DRUG|Placebo|
41387042|NCT01238523|PROCEDURE|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
41510764|NCT01632397|BEHAVIORAL|CBT-based counseling|Cognitive Behavior Therapy for PrEP adherence
40856235|NCT03725813|OTHER|Person-centred inpatient care|"The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention."
40856236|NCT01824355|DEVICE|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
40856237|NCT02607943|DRUG|Insulin Glargine|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
40856238|NCT02607943|DRUG|Regular Insulin|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
41387043|NCT01238523|PROCEDURE|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
41038089|NCT05323526|DIAGNOSTIC_TEST|Catquest-9SF questionnaire|Patients complete the questionnaire preoperatively and postoperatively.
41038090|NCT05323526|DIAGNOSTIC_TEST|Demographics and clinical parameters|The following clinical parameters are evaluated: age, gender, ocular and systemic comorbidities, educational level, preoperative and postoperative monocular distance uncorrected visual acuity (UVA), distance best spectacle-corrected visual acuity (BSCVA) of the eye for cataract surgery, binocular distance UVA and BSCVA, refraction, spherical equivalent (SE), and intraocular pressure.
41387044|NCT00646607|DRUG|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
41387045|NCT00646607|DRUG|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|standard treatment
41387046|NCT05297149|BEHAVIORAL|Hippotherapy|The hippotherapy program consisted of 6 weekly sessions that varied in duration between 20 and 30 minutes depending on the weekly program and the participant's condition. Each session started with brief greetings and contact with the horse.
41387047|NCT05297149|BEHAVIORAL|Home exrecises|The home exercise program consisted of the following balance training exercises: one leg standing on foam with eyes open and closed, double leg standing on foam with eyes open and closed, walking in tandem with eyes open and closed, balance exercises on an inclined surface, balance exercises in squat, and jumping over an obstacle on the ground. All participants performed the exercises under parental supervision, 3 times per week for 6 weeks. The physiotherapist made video calls to the children and parents to ensure their adherence to the home exercise program.
41387048|NCT01684306|DRUG|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
41387049|NCT01684306|DRUG|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
41387050|NCT05287802|OTHER|Balance and proprioception exercises|Balance and proprioception exercises using two different methods (classical balance training and Biodex) in addition to strengthening exercises
41387051|NCT05287802|OTHER|Home exercises program|Isometric exercises for the quadriceps and hamstrings at home
41510765|NCT01632397|BEHAVIORAL|Health education and supportive counseling|Time matched general supportive therapy of the type commonly available from community therapists.
41510766|NCT00005811|DRUG|topotecan hydrochloride|Given IT
41510767|NCT00005811|OTHER|laboratory biomarker analysis|Correlative studies
41510768|NCT02925403|BIOLOGICAL|R21/Matrix-M1|
41510769|NCT02925403|OTHER|Saline|
41510770|NCT05667376|OTHER|Local drug delivery|Local application of curcumin gel into the periodontal pocket
41510771|NCT05667376|DRUG|curcumin gel|curcumin gel
41510772|NCT04680026|DRUG|HBI-3000|Small molecule, multi-ion channel blocker
41510773|NCT04680026|DRUG|Placebo|Normal saline
41510774|NCT00134901|DRUG|Memantine|Memantine
41510775|NCT00134901|DRUG|placebo|placebo
41387052|NCT05335096|BEHAVIORAL|An AI-chatbot-based mHealth intervention|The participants assigned to the intervention group will get access to an AI-chatbot and can interact with the AI-chatbot at any time. In each round of the interactive communication, the chatbot will provide automated personalized messages containing PrEP, mental health, or HIV testing-related information, motivation and skills based on the participants' answers and will continuously update over time.
41387053|NCT05335096|BEHAVIORAL|An attention-chatbot-based mHealth intervention|The participants assigned to the control group will get access to an attention-chatbot and can interact with the attention-chatbot at any time. In each round of the interaction, the chatbot will provide pre-scripted time-attention health education messages to the participants.
40856239|NCT05300776|DIAGNOSTIC_TEST|M-ROSE analysis|"The M-ROSE analysis process consists of 3 procudures.~1. Specimen quality assessment. The BALF undergoes the process of smear, diff-quik stain, gram stain and are analyzed by experts to report the cytoloy and pathogen patterns to determine whether the sample is qualified according to the cell proportions. The qualified BALF samples are: squamous epithelial cell proportion\<1%, columnar epithelial cell proportion \<5% .~2. Distinguish infection and colonization. According to the cytoloy pattern, the proportion of neutrophils \> 50% often strongly suggests pulmonary bacterial infection; Neutrophil phagocytosis proportion\> 5% indicates infection, and phagocytosis of bacteria is the pathogen. Besides, fungal and hyphae can be found under the microscope.~3. Preliminary identification of infectious pathogens. Identify the infected bacteria and fungi, and the results are gram-positive cocci, gram-positive bacilli, gram-negative cocci, gram-negative bacilli, yeasts and molds."
40856240|NCT05213520|OTHER|Alternate Day Intermittent Energy Restriction|It is a dietary intervention designed to alternate between full energy consumption on one day and 40% of daily energy requirement on the following day.
41387054|NCT05335096|BEHAVIORAL|Educational materials|the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180).
41387055|NCT03338673|DEVICE|tDCS|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function
41387056|NCT03338673|OTHER|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
41510776|NCT01967914|OTHER|PVI|Measurement of PVI (plethysmography variability index)
41510777|NCT00736437|DRUG|ME-609|Cream applied topically 6 times daily over the UVR exposed area
41510778|NCT00736437|DRUG|Vehicle|Treatment applied 6 times daily over the UVR exposed area
41510779|NCT03105518|DRUG|Fentanyl|0.5, 1 mcg/kg
41510780|NCT03105518|DRUG|Acetaminophen|Single + Oxycodone
41510781|NCT03105518|DRUG|Oxycodone|With Acetaminophen
41510782|NCT03254264|BEHAVIORAL|Early Start Denver Model|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
41510783|NCT03254264|BEHAVIORAL|'as-usual' intervention|a control group receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
41510784|NCT00425763|DRUG|AQAS|AQAS dosed by body weight, on days 0, 1, 2
41510785|NCT00245687|DEVICE|Tiger Tube|
41510786|NCT03514108|DRUG|Hydralazine Isosorbide Dinitrate|Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
41510787|NCT03514108|DRUG|Placebo Oral Tablet|2 tablets x 3 daily
41510788|NCT03514108|DRUG|Metformin Hydrochloride|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
41510789|NCT03514108|DRUG|Placebo Oral Tablet|2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
41510790|NCT00176618|DRUG|sulindac|Sulindac 150 mg po BID
41510791|NCT00176618|DRUG|curcumin|Curcumin 250 mg po BID
41510792|NCT00520897|DRUG|Raltegravir (MK0518)|400mg BID; 48 weeks
41510793|NCT00520897|DRUG|Placebo|400mg QD
40856241|NCT05213520|OTHER|Reduced Calorie Diet|It is a dietary intervention designed to reduce daily calorie intake by 500-1000 kcal below an individual's daily calorie needs.
40856242|NCT02328534|BEHAVIORAL|Blastocyst Formation Rate|"Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
40856243|NCT02328534|PROCEDURE|Blastocyst Rate|"Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.~Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam."
41510794|NCT00520897|PROCEDURE|Leukopheresis|pack of cells as per protocol
41510795|NCT00520897|PROCEDURE|Sigmoid Biopsy|gut samples as per protocol
41510796|NCT02562573|DRUG|PBI4050|
41387057|NCT03244722|DIETARY_SUPPLEMENT|Very-low energy Diet (VLED)|Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
41387058|NCT03244722|OTHER|Standard of care (SOC)|Standard consultation with registered dietitian to determine appropriate caloric deficit for a low calorie diet, education and advice to achieve weight loss in obese women. Standard of care for normal weight women
41387059|NCT03203746|DRUG|Lycopene + SRP|
41387060|NCT03203746|PROCEDURE|SRP only|
41510797|NCT02757755|BIOLOGICAL|AB-SA01 (10^8 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
41510798|NCT02757755|BIOLOGICAL|AB-SA01 (10^9 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
41510799|NCT02757755|BIOLOGICAL|Placebo (for Cohort 10^8)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
41510800|NCT02757755|BIOLOGICAL|Placebo (for Cohort 10^9)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
41510801|NCT00104572|DRUG|Androgel (Testosterone Gel)|1 mg tablet for 12 months
41387061|NCT04411199|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
41510802|NCT00104572|DRUG|Anastrozole (Aromatase Inhibitor)|
41510803|NCT00104572|DRUG|Placebo tablet|Daily for 12 months
41387062|NCT04411199|OTHER|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
41387063|NCT05319977|BEHAVIORAL|Mobile incentive-based intervention|a technology-based behavioral intervention to address maternal alcohol use with mobile breathalyzer technology or/and urinalysis for biochemical verification of alcohol use, contingent financial incentives on alcohol abstinence, and text-based health promotion.
41387064|NCT02550509|DEVICE|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
41387065|NCT02550509|DEVICE|elastography|elastography to patient with stoke
40856244|NCT02328534|PROCEDURE|Pregnancy Rate|"All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
41387066|NCT03715816|BEHAVIORAL|Work break schedule|Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).
41387067|NCT02991651|DRUG|IRX4204|RXR agonist
41387068|NCT02991651|DRUG|erlotinib|inhibitor of phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor
41387069|NCT04857879|OTHER|GLA:D program (Good Life with osteoArthritis in Denmark)|GLA:D includes disease-specific education combined with neuromuscular exercises. Control interventions include disease-specific education combined with exercises to optimize movement and strength of the affected knee.
41387070|NCT00265239|DRUG|edaravone|intravenous administration of 30mg Edaravone just before reperfusion therapy
41387071|NCT01603927|DEVICE|Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).|Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
41387072|NCT01102608|DRUG|Ifosfamide|3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
41387073|NCT04361552|OTHER|Best Practice|Receive standard of care
41387074|NCT04361552|BIOLOGICAL|Tocilizumab|Given IV
41387075|NCT05452616|OTHER|ART first- Therapeutic use trial|ART initiation on the day of enrolment independent of TB investigations in PLHIV with presumptive TB but no signs of CNS disease. The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
41510804|NCT00104572|DRUG|Placebo gel|Daily for 12 months
41510805|NCT00104572|DIETARY_SUPPLEMENT|Calcium Cardone 500mg with vitamin D 400 IU|1 tablet three times a day
40856245|NCT01760772|DRUG|Exendin-9|Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
41387076|NCT05452616|OTHER|TB results first- Therapeutic use trial|Deferral of ART initiation until active TB has been refuted or confirmed. PLHIV presenting with symptoms (cough, fever, night sweat, weight loss) are defined as presumptive TB, and should have microbiological TB investigations. Routine TB investigations in Malawi and Lesotho usually consist of two sputum bottles for analysis using nucleic acid amplification tests (Xpert MTB/RIF (Ultra)).The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
41387077|NCT00006092|DRUG|Arsenic Trioxide|
40856246|NCT01760772|DRUG|GLP-1|Constant infusion of GLP-1 at 0.3 pmol/kg/min
40856247|NCT01760772|OTHER|saline|Constant infusion
41387078|NCT06360679|DEVICE|Endoscopic gastric restriction and biliodigestive diversion|The BariTon™ is endoscopically implanted and retrieved once treatment is completed
41510806|NCT02590965|DRUG|Fruquintinib|After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
41510807|NCT02590965|DRUG|Placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
41510808|NCT01888510|PROCEDURE|computed tomography|Undergo conventional free breathing CT
41510809|NCT01888510|PROCEDURE|4-dimensional computed tomography|Undergo 4D CT
41510810|NCT01888510|PROCEDURE|computed tomography|Undergo ABC CT
41510811|NCT01888510|PROCEDURE|cone-beam computed tomography|Undergo ABC CBCT
41510812|NCT01888510|PROCEDURE|cone-beam computed tomography|Undergo free breathing CBCT
41510813|NCT04110730|DEVICE|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion.
41510814|NCT04110730|BEHAVIORAL|Home Intervention|An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.
41510815|NCT01205087|DRUG|OKT3|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
41510816|NCT05872022|OTHER|No Intervention|This is a non-interventional study, therefore no intervention is used.
41510817|NCT05095844|BIOLOGICAL|vaccinated|Pfizer-BioNTech COVID-19 Vaccine, Moderna or J\&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)
41510818|NCT03068728|DEVICE|Arista|
41510819|NCT03068728|DEVICE|Nexfoam|
41510820|NCT03068728|DEVICE|Nasopore|
40856248|NCT03112655|DIAGNOSTIC_TEST|RNA and neopterin detection|Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin and 5-hydroxytryptophan will be quantified in cerebrospinal fluid taken at the same time points.
40856249|NCT04402723|DRUG|Donafenib|In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.
40856250|NCT05226312|OTHER|Local Warm Compress|The warm application will be made by the researcher for 15 minutes three times a day according to the local warm application process steps.
41038091|NCT04006327|OTHER|No intervention will be provided as this study is a cross-sectional observational study.|This item is not applicable because this study is a cross-sectional observational study and no intervention will be provided to participants.
41387079|NCT03574818|DRUG|Necitumumab-Gemcitabine-Cisplatin|"* Gemcitabine 1250mg/m2 IV on D1, D8~* Cisplatin 75mg / m2 IV on D1~* Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles."
41387080|NCT03574818|DIAGNOSTIC_TEST|Evaluation to determine if patient is a candidate to proceeed with surgical resection or not|Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
41387081|NCT06542445|DRUG|Oral CBD oil enriched with terpenes|"Stage I dosing, increasing titration:~days 1-2: 2.5 mg/kg BW/day; days 3-4: 5 mg/kg BW/day; day 5-7: 7.5 mg/kg BW/day; days 8-35: 10 mg/kg BW/day.~Stage II dosing, increasing titration:~days 36-37: 2.5 mg/kg BW/day; days 38-39: 5 mg/kg BW/day; day 40-42: 7.5 mg/kg BW/day; days 43-70:10 mg/kg BW/day."
41387082|NCT06542445|DRUG|Oral Placebo|Oral placebo oil that is similar in appearance and taste to the CBD oil. Titration and dosing identical to those described for the CBD oil.
41387083|NCT04522310|OTHER|MR-Pro-ADM|Dosage of MR-pro-ADM
41510821|NCT00314951|DRUG|Fidaxomicin|200 mg oral capsules two times daily (q12h regimen)
41510822|NCT00314951|DRUG|Vancomycin|125 mg capsules q6hr (4 times a day)
41510823|NCT00314951|DRUG|Matching Placebo to Fidaxomicin|Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
41038092|NCT03581721|DEVICE|enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer|"The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group"
41038093|NCT04082065|OTHER|conventional physical therapy|hot pack for 15 minutes Myofacial release (10 minutes) and Stretching of hamstrings and Piriformis (5 reps each with 2 second hold)
41038094|NCT04082065|OTHER|cyriax lumber manipulation group|Hot Pack, Myofacial Release, stretching of hamstrings and Piriformis (five reps each with 2 seconds hold) and Cyriax Lumbar Manipulation Techniques
41387084|NCT06290622|DRUG|Retifanlimab, INCAGN02385, INCAGN02390|"Treatment:~Retifanlimab -infused over 60 minutes for C1D1 followed by a 60-minute observation period. If no infusion related reactions are observed infusion may be reduced to 30 minutes and no further observation period is needed for future cycles. If there is a reaction continue with 60 minute infusion and observation period for following cycle. Retifanlimab should always be administered first.~INCAGN02385 and INCAGN02390 -individually administered over 30 minutes one after another. For first infusions of retifanlimab, INCAGN02385 and INCAGN02390, a 4 hour observation period is necessary after completion of all infusion. If no infusion related reactions are observed, for subsequent infusions no further observation period is needed for future cycles."
41387085|NCT02292407|DEVICE|LigaSure Precise instrument|LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
41387086|NCT05301452|RADIATION|Intravascular Irradiation of Blood (ILIB)|The laser treatment will be performed by a speech therapist and will have the following parameters: wavelength of 808 nm. It will be done twice a week for 8 weeks, in 20-minute sessions.
41387087|NCT05301452|RADIATION|Placebo Intravascular Irradiation of Blood (ILIB)|The photobiomodulation procedure will be simulated, but with the laser turned off. It will be done twice a week for 8 weeks, in 20-minute sessions.
41387088|NCT05301452|PROCEDURE|Orofacial Myofunctional Therapy|"Myofunctional therapy will be performed by a speech therapist specialized in the area. It will consist of 1 weekly session, where the functions of breathing, chewing and swallowing will be evaluated and addressed.~The following exercises will be indicated: nasal hygiene, inflated cheeks with the tip of the tongue on the palate, lingual sweep, tongue thrust against the palate, tongue touch on the last molars, chewing of soft solids and bolus assembly (20 minute therapy session)."
41387089|NCT01179256|DIETARY_SUPPLEMENT|CURCUMIN|oral supplementation of curcumin 2000mg
41387090|NCT01179256|OTHER|no intervention other than stopping study|no intervention other than stopping study
41387091|NCT06150001|DRUG|rocuronium-normal-saline mixture|rocuronium will be pre-diluted with 2mL of normal saline. Researchers will inject the mixture into intravenous catheter.
41387092|NCT06150001|DRUG|rocuronium-lidocaine mixture|rocuronium will be pre-diluted with 2mL of 2%lidocaine. Researchers will inject the mixture into intravenous catheter.
41387093|NCT06150001|DRUG|rocuronium-blood mixture|Researchers will connect a syringe which contains 0.8mg/kg of rocuronium intravenous catheter, and then withdraw blood into the syringe. Finally inject the mixture into intravenous catheter.
41387094|NCT05752474|BEHAVIORAL|Exercise|Physical therapy targeting flexibility, strength, and endurance will be delivered at the participant's home, center-based, or virtually via a twice-weekly (on average) schedule to provide a total of about 6-8 sessions during the 3-4 week study period. Participants will be asked to participate in self-directed exercise for at least 30 minutes per day for 4 or more days per week.
41387095|NCT05752474|BEHAVIORAL|Nutrition|One-hour virtual group nutrition education classes will be held once per week by a dietitian, focusing on optimal protein intake (1.2 grams per kg of body weight) for lean body mass preservation (from food sources and oral nutritional supplements) and muscle gain. Participants will also receive oral nutritional supplements (20-30 grams of protein/day provided by our study team).
41510824|NCT01106079|DRUG|Intensive management or Tight control|Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
41510825|NCT01106079|DRUG|Standard management - Control group|The control group will be seen every 12 weeks in a general rheumatology clinic and will receive standard care, involving standard DMARDs and biologics as appropriate. Treatment will be prescribed as felt appropriate by the treating physicians with no set protocol and no restrictions.
40856251|NCT03259061|DEVICE|Flexible fiberoptic nasopharyngoscopy|"1. Flexible fiberoptic nasopharyngoscopy (FFN) allows direct transnasal observation of the anatomy and dynamic activity of the velopharyngeal sphincter. Such observations can be recorded for permanent documentation by coupling FFN to a video camera with simultaneous audio recording. Numerous published reports discuss the advantages of FFN as a clinical method for evaluating velopharyngeal function during speech (10).~2. Cephalometric analysis, is the clinical application of cephalometry. It is analysis of the dental and skeletal relationships of a human skull and is frequently used by dentists, orthodontists, and oral and maxillofacial surgeons as a treatment planning tool.~Cephalometric analysis can also be applied for assessing the velopharyngeal structure and function. More specifically, velopharyngeal function in terms of its shape and mobility was analyzed quantitatively on the basis of cephalometric principle"
41038095|NCT00222833|DRUG|Aripiprazole|
41387096|NCT05752474|BEHAVIORAL|Meditation|One-hour virtual group meditation sessions will be held once per week by an experienced meditation teacher. Classes will focus on breathing techniques, yoga, and mindful meditation practices. Participants will be asked to participate in self-directed meditation for at least 12 minutes daily.
41387097|NCT05752474|BEHAVIORAL|Cognitive Behavioral Intervention|A 30-min telephone-based session with individual patients will take place to deliver cognitive behavioral strategies once per week by a professionally trained clinician. These strategies include education about frailty and surgery, increasing positive beliefs of the benefits of exercise and nutrition, discussing barriers, setting individualized goals for surgery and recovery, developing a detailed exercise and nutrition plan (including logistics), self-monitoring of progress using weekly exercise, diet, and meditation logs, and enhancing self-efficacy through the celebration of small wins.
41038096|NCT01175603|BEHAVIORAL|Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)|6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
41038097|NCT00439868|DRUG|WellbutrinXL|WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
41038098|NCT00439868|DRUG|placebo|Matching placebo tablets to WELLBUTRIN XL.
41510826|NCT02750956|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
41510827|NCT05982002|DEVICE|shock wave|ESWT (Chattanooga, Intelect RPW, USA) continues mode, hand piece transmitter R SW D20 /20mm, with the following Parameter: Shock pressure of 3-4 bars, wave frequency of 12 Hz.
41510828|NCT05982002|OTHER|Moderate intensity aerobic exercise|Treadmail training exercise 60%-75% of Maximum heart rate MHR 2 times/ week
41387098|NCT00104117|DRUG|XL999|XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.
41387099|NCT04317664|COMBINATION_PRODUCT|In-vehicle device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data; and 3) A customized biweekly driving summary report.
41510829|NCT05982002|OTHER|Energy-restricted diet|energy intake was 500K calorie below daily requirements on average three meals at the same time of the day
41510830|NCT02255968|DRUG|EDP-788|EDP-788 Capsules. All interventions are given as multiple doses.
41510831|NCT02255968|DRUG|Placebo|Matching placebo capsules. All interventions are given as multiple doses
41510832|NCT03744624|PROCEDURE|Laparoscopic liver resection|Laparoscopic liver resection for oncological purposes
41510833|NCT03744624|DEVICE|3D printing model|Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
41038099|NCT01362140|DRUG|Darbepoetin alfa|Administered by subcutaneous injection every 3 weeks
41038100|NCT01362140|DRUG|Placebo|Administered by subcutaneous injection every 3 weeks
41038101|NCT02766530|OTHER|PETMR study|Use of PETMR study to evaluate the treatment response of breast cancer women
41510834|NCT01860625|DRUG|Donepezil patch|
41510835|NCT01860625|DRUG|placebo|
41510836|NCT06205329|DRUG|WPV01 Dose 1-4|WPV01 Dose 1-4 or Placebo on day 1
41510837|NCT06205329|DRUG|WPV01 Dose 5-8 and Ritonavir|WPV01 Dose 5-8 and Ritonavir or Placebo on day 1
41510838|NCT06205329|DRUG|WPV01 Dose 9-12|WPV01 Dose 9-12 or Placebo from day 1 to day 6
41510839|NCT06205329|DRUG|WPV01 Dose 13-15 and Ritonavir|WPV01 Dose 13-15 and Ritonavir or Placebo from day 1 to day 6
41510840|NCT06205329|DRUG|WPV01 Dose 16|Cohort 1:WPV01 Dose 16 or Placebo (with high fat meal) Cohort 2:WPV01 Dose 16 or Placebo (fasted)
41510841|NCT02368314|DRUG|Sodium Enoxaparine|30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
41510842|NCT01560741|DEVICE|Telemonitoring tools|Patients will go home with telemedicine tools to monitor efficacy and compliance of non-invasive home mechanical ventilation
41510843|NCT01560741|DEVICE|Usual Care|The assessment of efficacy and compliance will be monitor at the end of third month. This is the date of the scheduled hospital visit.
41510844|NCT00003602|DRUG|cytarabine|
41510845|NCT00003602|DRUG|etoposide|
41510846|NCT00003602|DRUG|idarubicin|
41510847|NCT00003602|DRUG|mitoxantrone hydrochloride|
41510848|NCT05248802|DRUG|Placebo caplet of DLBS2411|1 caplet of placebo DLBS2411, twice daily
41510849|NCT05248802|DRUG|DLBS2411|1 caplet of DLBS2411 250 mg, twice daily
41510850|NCT03278691|DRUG|Saline|1 ml saline IV Q6H
41510851|NCT03278691|DRUG|Ketorolac|15 mg (15 mg/ml) IV Q6H
41510852|NCT03450473|DEVICE|SurgiMend® MP|SurgiMend MP® is an acellular dermal tissue matrix derived from bovine dermis. The device is supplied sterile in a variety of sizes to be trimmed by the surgeon to meet the individual patient's needs. SurgiMend MP® will be used for abdominal wall reinforcement in patients with complex ventral hernia repair.
41510853|NCT00807716|OTHER|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
41510854|NCT00807716|OTHER|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
41510855|NCT00929461|DRUG|Lipovenoes® 10% and Omegaven®,|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
41510856|NCT00018538|DRUG|calcifidiol|
41510857|NCT01597778|BIOLOGICAL|Haploidentical Bone Marrow Transplant|"The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35"
41510858|NCT01597778|BIOLOGICAL|Double Umbilical Cord Blood Transplant|"The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35"
41510859|NCT01308502|DEVICE|Dx-pH probe|Dx-pH probe with 24 hour recording
41510860|NCT03420911|DRUG|dexketoprofen trometamol|
41510861|NCT03420911|DRUG|Midazolam|
41166575|NCT01624597|BEHAVIORAL|Parent communication|Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
41510862|NCT03484650|DRUG|Lidocaine Hydrochloride|Lidocaine bolus to be given 1 hour pre-operatively
41510863|NCT03484650|DRUG|Lidocaine Hydrochloride|Lidocaine infusion will be started after the bolus and be continued for 24 hours post-operatively
41510864|NCT03484650|OTHER|Placebo|Control patients will receive a placebo bolus and infusion of saline to match the experimental arm.
41510865|NCT04588389|DRUG|Ropivacaine injection Location 1|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1
41510866|NCT04588389|DRUG|Ropivacaine injection Location 2|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2
41510867|NCT04588389|DRUG|Multimodal Pharmacological Management|standard of care multimodal pharmacological management
41510868|NCT01912261|DRUG|Placebo|one capsule orally daily times 84 days
41510869|NCT01912261|DRUG|Polysaccharide iron complex|150 mg daily orally times 84 days
41510870|NCT02829476|BIOLOGICAL|Osteoblast sample|culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis
41510871|NCT02186002|DRUG|ACT-451840 10 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
41510872|NCT02186002|DRUG|ACT-451840 50 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
41510873|NCT02186002|DRUG|ACT-451840 200 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
41387100|NCT04317664|BEHAVIORAL|Parent Communication|An individualized virtual training in communication strategies about driving safety along with a booster session will be delivered by a traffic safety communication specialist to subjects in the Feedback and Parent Communication Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
41387101|NCT06568328|BIOLOGICAL|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (1\~10×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
41387102|NCT06562751|OTHER|Questionnaire|Online questionnaire designed by the investigatory team.
40856252|NCT04153916|DEVICE|Neurotrigger eye blinking stimulator|"Phase 1 - The first stage is composed of a one-time participation for about three hours and involves:~1. Verifying compliance of the patients with the research inclusion and exclusion criteria~2. Completion of the study clinical report form (CRF) for this stage~3. Placement of the single use mini-electrodes that will be adhered to the facial skin near the non-blinking eye and coupled to the Neurotrigger stimulator to elicit eyelid closure.~Participants may be enrolled to the second phase up to one year from the first phase visit In the second stage the duration of the participation is about three weeks (six days a week) and includes daily use of the device for up to 10 hours a day. During nights the patient will continue is standard pattern of either eye closure or leaving the eye open, as the patient used to do prior to the study.~This stage will involve a patient with a partner that is designated to support the patient closely during the placement and adjustment of the system"
41387103|NCT06562751|OTHER|Focus group|Online focus group
41387104|NCT06562751|OTHER|Interview|Online semi-structured interview
40856253|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
41510874|NCT02186002|DRUG|ACT-451840 500 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
41510875|NCT02186002|DRUG|ACT-451840 1000 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
41387105|NCT06562751|OTHER|Workshop|Online and face to face co-production workshops
41510876|NCT02186002|DRUG|ACT-451840 (Dose to be determined)|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
40856254|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
41038102|NCT01835626|DRUG|Vismodegib|Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
41038103|NCT01835626|RADIATION|Radiation therapy|Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
41510877|NCT02186002|DRUG|Placebo|
41038104|NCT06275204|DRUG|Bismuth-based quadruple therapy|"Participants who are positive with H. pylori will receive bismuth-based quadruple therapy:~Antibiotic 1 - Amoxicillin 4 x 500 mg or Clarithromycin 2 x 400 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
41387106|NCT04551027|BEHAVIORAL|compensatory cognitive treatment|a brief group compensatory cognitive intervention including 12 meetings of 1 hour in a group of five and focuses on these cognitive domains: prospective memory, vigilance and attention, memory and learning and executive functions
41510878|NCT06550934|PROCEDURE|Fracture stabilization|isolated posterior surgical fracture stabilization vs. combined anterior-posterior surgical fracture stabilization
41510879|NCT03413579|BIOLOGICAL|Nimotuzumab ( h-R3)|Humanized monoclonal antibody
41510880|NCT03413579|OTHER|Placebo|
41387107|NCT00695604|DRUG|Placebo|Placebo via MDI.
41387108|NCT00695604|DRUG|Fluticasone|Fluticasone MDI.
41387109|NCT05861427|DRUG|Atogepant|Oral Tablet
41387110|NCT05861427|DRUG|Placebo for Atogepant|Oral Tablet
41510881|NCT04798092|PROCEDURE|parathyroidectomy|surgical removal of parathyroid adenoma(s) with postoperative biological cure
41510882|NCT01595347|DRUG|Hyper-oxigenated fatty acid|Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
41510883|NCT01595347|OTHER|Olive oil's cream|Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
41510884|NCT00171665|DRUG|Diclofenac topical sodium gel 1%|
41510885|NCT04107792|BEHAVIORAL|parental sense of competence workshop|The intervention will be a two-hour parent education workshop that provides education and teaches parent-mediated strategies for managing children's behaviours associated with SPIs.
41510886|NCT02521649|DRUG|G17DT|
40856255|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
40856256|NCT01504412|DRUG|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
40856257|NCT01504412|DRUG|Pregabalin capsules|Pregabalin oral capsules 150 mg administered twice a day
40856258|NCT00248586|BEHAVIORAL|Standard CBT (S-CBT)|Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.
40856259|NCT00248586|BEHAVIORAL|Minimal contact CBT (MC-CBT)|Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
40856260|NCT04996485|DRUG|Secukinumab Injection|Pathogenetic therapy with biologic drugs
40856261|NCT04996485|DRUG|Ustekinumab Injection|Pathogenetic therapy with biologic drugs
40856262|NCT04996485|DRUG|Dupilumab Injection|Pathogenetic therapy with biologic drugs
41387111|NCT05676164|DEVICE|KANG XIAN|This product is a liquid composed of silica, stabilizer, xylitol, flavoring agent and water. The pH value of the product is 5.0 \~ 8.0, and the total heavy metal content (measured by Pb2+) is less than 10µg/ml.
41387112|NCT05676164|DEVICE|TIAN XIA|The products are dark yellow granules made from rice, soybean, lotus root powder, orange peel, coix seed and yam.
41510887|NCT01673230|PROCEDURE|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
40856263|NCT04996485|OTHER|Symptomatic therapy|Active external agents, Emollients, systemic retinoids if needed
40856264|NCT05502445|OTHER|educational intervention|"In this group, the steps below are added:on the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance. On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements."
40856265|NCT05618067|BEHAVIORAL|breathing exercise training|Participants will engage in weekly breathing exercises. They will be trained once a week for 4 weeks, and will use an app called Inner Balance and an device called Firstbeat Bodyguard 3 to track data about their hearts while practicing the exercises at home for 10 minutes a day, twice a day, once before bedtime.
40856266|NCT03150420|DRUG|Sodium Thiosulfate|Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks
40856267|NCT03150420|DRUG|Placebo-Normal Saline|Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks
40856268|NCT05658705|PROCEDURE|15-min supine time|The length of preoperative supine time before AVS was 15 minutes.
40856269|NCT05658705|PROCEDURE|2-hour supine time|The length of preoperative supine time before AVS was 2 hours.
40856270|NCT00759408|DRUG|BQ-123|6-120 µg/min
40856271|NCT00673777|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
41166576|NCT05912569|PROCEDURE|Delay sentinel node biopsy|In the case of a patient undergoing breast-conserving surgery for intraductal carcinoma, the sentinel lymph node is not excised during the primary surgery but only marked for identification. I
41166577|NCT04513275|DRUG|non-medicine intervention|rating by MCCB only one time
41166578|NCT03664453|DRUG|omaveloxolone|Omaveloxolone 50 mg capsules
41166579|NCT04777097|OTHER|Blood sample|Two blood sample will be drawn. On the day of operation and the first postoperative day.
41387113|NCT05588375|BEHAVIORAL|home-based physical activity telemonitoring program|The home telehealth physical activity training program is a telemedicine physical activity training that uses Google Meet software to communicate and supervise through webcams.
41166580|NCT01721083|PROCEDURE|Procedure: Z-track|Subject received immunization by z-track
41166581|NCT01721083|PROCEDURE|Procedure: Bunch|Subject receives immunization by bunch method.
41510888|NCT01921686|OTHER|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
41510889|NCT02630576|DEVICE|Neuromuscular stimulation|Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
41510890|NCT06552182|DRUG|HUC2-344|per oral
41510891|NCT06552182|DRUG|HUC2-344-R1, HUC2-344-R2|per oral
41510892|NCT05122169|DRUG|Povidone-Iodine|Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
41166582|NCT04199455|DRUG|Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules)|"Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of EPACH recipe granules, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of NQABC recipe granules, dissolved with 200ml of boiled water, twice a day."
41387114|NCT05631652|DEVICE|PillSense System|The device is composed of an orally ingested PillSense capsule and a wireless handheld PillSense receiver for real-time display of sensor data. The capsule contains an optical sensor for in-vivo detection of blood. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
41387115|NCT03160365|PROCEDURE|ACQUISITION OF IMAGES|In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
41387116|NCT02515552|BEHAVIORAL|The Fibromyalgia Wellness Project|Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
41387117|NCT03494816|DRUG|Axitinib Oral Tablet|"Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
41387118|NCT05385796|OTHER|Loop taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. Care is taken to avoid erasing skin markings for respective algometer and ultrasound assessment by these wipes. The therapist applies 1-inch-width Elastikon tape around the heel, encircling and bunching the fat pad to centralize it and enhance its fullness and resilience to compression. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied to ensure strong support during weight-bearing activities. Participants will be instructed to wear the loop taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
41387119|NCT05385796|OTHER|Control taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. The therapist applies 1-inch-width Elastikon tape around the heel, lightly encircling the heel fat pad without any force/pressure or attempt to bunch or centralize the fat pad. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied. Participants will be instructed to wear the control taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
41387120|NCT00205465|DRUG|VX-765|
41387121|NCT02306174|BEHAVIORAL|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|"The group sessions consists of 20 classes, each lasting approximately 90 minutes and may consist of some or all of the following:~* A group agreement and a confidentiality contract~* Homework assignments~* Viewing informational videos about hoarding~* Behavioral experiments including sorting and discarding exercises~* Non-acquisition exposures~This course is based on the Manual Cognitive Rehabilitation and Exposure/Sorting Therapy for Compulsive Hoarding (Ayers et al., 2014)."
41387122|NCT02232685|DEVICE|18F-Choline PET/CT|18F-Choline PET/CT
41387123|NCT00331604|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
41387124|NCT00331604|DRUG|insulin detemir|Injection s.c., 50% of daily dose.
41387125|NCT00331604|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
41387126|NCT00331604|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
41387127|NCT03986164|DEVICE|Guided surgery with bovine spongious bone substitute|"A minimally traumatic extraction will be performed aiming at the preservation of tissue integrity. After this step, milling will be performed using a sequence of guides and cutters recommended by the Raptor Implacil / Bioparts (Implacil De Bortoli) system manufacturer for implant installation (Cone Morse 3.5mm from 11-13mm Implacil De Bortoli) in computer-guided surgeries.~In the spaces between the implant and the buccal bone plate will be filled with xenogene biomaterial (Geistlich Bio-Oss 0.25-1mm). Immediately after implant installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm - Implacil De Bortoli) will be placed.~If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days."
41387128|NCT03986164|DEVICE|Conventional surgery with bovine spongious bone substitute|The sequence of cutters recommended by the manufacturer for this type of surgery and installation of the same type of implant (Cone Morse due cone 3.5mm) will be adopted. The perforations of the collar for future insertion of the implants will be performed aiming the installation of the implants with its platform installed with sub-crestal position. The implant should be installed along the palatine wall to obtain primary stability, at the center of the mesio-distal width predetermined by the final restoration, with a minimum distance of 2 mm from the adjacent tooth, and 3 mm from the free gingival margin, becoming slightly palatinate (Kan et al, 2018). Immediately after installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm) will be placed. If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days.
41387129|NCT02384200|DRUG|nitrofurantoin monohydrate/macrocrystalline capsules|1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily
40856272|NCT05330767|DEVICE|DermaClose Continuous External Tissue Expander Device|Constant tension and self-tensioning device. Supplied sterile and for single use only.
40856273|NCT05330767|DEVICE|DermaClose XL Continuous External Tissue Expander Device|Intended for large wounds that are greater than 8 cm in width. Constant tension and self-tensioning device. Supplied sterile and for single use only
40856274|NCT05330767|DEVICE|Conventional wound dressings|Wet-to-dry, gauze, and negative pressure wound therapy.
40856275|NCT03319134|DEVICE|active anodal HD-tDCS|1) active anodal HD-tDCS with memory task
40856276|NCT03319134|DEVICE|sham HD-tDCS|2) sham HD-tDCS with memory task
41387130|NCT02384200|DRUG|ampicillin|IV (2 g)
40856277|NCT03319134|DEVICE|active cathodal HD-tDCS|3) active cathodal HD-tDCS with memory task
40856278|NCT01629459|BEHAVIORAL|Resistance exercise and protein supplementation|Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
40856279|NCT01198639|DEVICE|manual administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|the anesthesiologists are instructed to maintain the BIS values between 40 and 60 throughout anesthesia using target controlled infusion method
41387131|NCT02384200|DRUG|gentamicin|IV (5 mg/kg)
41387132|NCT02384200|DRUG|vancomycin|IV (1 g)
41038105|NCT06275204|DRUG|Levofloxacin-based quadruple therapy|"In case there will be a treatment failure after Protocol I is completed, the remaining patients with a positive infection will be referred to a secondary treatment:~Antibiotic 1 - Levofloxacin 1 x 500 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
41038106|NCT06275204|DRUG|Standard triple therapy|"Participants who are positive for H. pylori will receive a standard triple therapy:~Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg."
41038107|NCT06275204|DRUG|Levofloxacin-based triple|"Participants with treatment failure will be recommended second line treatment - levofloxacin-based:~Antibiotic 1 - Levofloxacin 2 x 500 mg, Antibiotic 2 - Amoxicillin 2 x 1000 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg"
41387133|NCT02384200|DRUG|ceftriaxone|IV (2 g)
41387134|NCT01487018|PROCEDURE|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
41387135|NCT01487018|PROCEDURE|Traditional Surgery|To compare with the experamental group.
41387136|NCT00566969|DRUG|sugar pill|Subjects randomized to placebo, carvedilol 25mg or 50mg
41387137|NCT00566969|DRUG|Carvedilol 25 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
41387138|NCT00566969|DRUG|Carvedilol 50 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
41510893|NCT05122169|DRUG|Chlorhexidine|Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
41510894|NCT03239847|OTHER|EndoPhys Sheath and Radial Arterial Line|
41510895|NCT03239847|OTHER|EndoPhys Sheath|
41387139|NCT00363428|BEHAVIORAL|exercise intervention|life style
41387140|NCT00363428|BEHAVIORAL|smoking cessation intervention|Life style
41387141|NCT00363428|OTHER|counseling intervention|life style
41387142|NCT00363428|OTHER|educational intervention|life style
41387143|NCT00363428|PROCEDURE|conventional surgery|life style
41387144|NCT00363428|PROCEDURE|pulmonary complications management/prevention|life style
41387145|NCT00123058|BEHAVIORAL|Nurse administered|Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.
41387146|NCT00123058|DEVICE|BP Monitor|Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.
41387147|NCT04668118|DRUG|Diquafosol|As a P2Y2 receptor agonist, diquafosol can be used to stabilize the tear film by stimulating P2Y2 receptors on the corneal epithelial cells and conjunctival goblet cell, which increase the secretion of tear fluid and mucin on the ocular surface, thereby repairing the ocular surface and stabilizing the tear film.
41510896|NCT06243146|OTHER|Titration of Inspired Oxygen|Titration of Inspired Oxygen During One-Lung Ventilation
41510897|NCT03281759|DEVICE|Transcranial LED Therapy (Active coil helmet)|The patients will undergo 18 sessions of repetitive transcranial LED stimulation.
41510898|NCT03281759|DEVICE|Transcranial LED Therapy (Inactive coil helmet)|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
40856280|NCT01198639|DEVICE|closed-loop administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|an algorithm is used to maintain automatically the BIS values between 40 and 60
40856281|NCT03774030|PROCEDURE|several virtual 3-D complex audio environments|The focus is a comparison of 3 hearing aid algorithms in a virtual 3-D complex audio Environment.
40856282|NCT05476016|DEVICE|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs HbA1c
41038108|NCT03185533|BEHAVIORAL|Quality improvement (QI) interventions|"1. The ED admissions exhibited prolonged length of stay.~2. The Interventions for Reducing Medical Decision Time:~1. The ED director created QI education sessions and reported monthly QI outcomes.~2. The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.~3. The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.~3. The Interventions for Reducing Boarding Time~1. The ED patients could be admitted before 8 a.m. if the bed was vacant.~2. The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.~3. Monthly QI outcomes were reported in the hospital affairs meeting."
41387148|NCT00511329|DRUG|somatropin [rDNA origin] for injection|Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
41387149|NCT03904667|OTHER|Watson on oncology surgery decision evaluation|Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
41387150|NCT01731431|OTHER|Insulin|
41387151|NCT01731431|DRUG|Glyburide|
41387152|NCT02507271|OTHER|Brain Fitness Program|This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.
41387153|NCT02507271|OTHER|Weekly Telephone Contact|This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
41387154|NCT05808894|PROCEDURE|extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy|Transect the pancreatic neck at ≥5mm and ≤10mm beyond the left side of the portal vein.
41387155|NCT03284515|BIOLOGICAL|Vaccination with a pertussis containing vaccine|Vaccination with a pertussis containing vaccine
41387156|NCT05920707|DRUG|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.
41387157|NCT05920707|DRUG|Intranasal Arginine Vasopressin|Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.
41387158|NCT05920707|DRUG|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.
41387159|NCT03881722|DIETARY_SUPPLEMENT|Mg alginate|Mg alginate after feedings
41387160|NCT05694169|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
41387161|NCT04089137|BEHAVIORAL|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
41387162|NCT05500456|DEVICE|Clear aligners|Each aligner will be worn for about two weeks, and then replaced by the next in the series until the final position is achieved.
41387163|NCT05500456|DEVICE|Fixed appliances|Conventional wires and brackets will be used.
41387164|NCT06211803|DIAGNOSTIC_TEST|Positron-Emission Tomography Imaging|Examination of radiation distribution in the patient brain and body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
41387165|NCT01379079|DRUG|Acetylsalicylic acid|aspirin intake at bedtime
40856283|NCT01949090|BIOLOGICAL|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
40856284|NCT01949090|BIOLOGICAL|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
40856285|NCT01856582|BIOLOGICAL|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
41038109|NCT02889991|OTHER|High Intensity Dry Needling|"This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear."
41038110|NCT02889991|OTHER|Low intensity Dry Needling|Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
41166583|NCT04199455|DRUG|Placebo|"Patients randomly assigned to the intervention group will receive recipe simulators as placebo. EPACH and NQABC granules and recipe simulators are indistinguishable, identical in size, shape, color, appearance. Placebo is no decocting granules contain 5% original formula, 20% bitter gourd extract, 75% dextrin, and caramel color. Those who are assigned to the control group will be given placebo and guideline-based standard stroke treatment.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of recipe simulator, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of recipe simulator, dissolved with 200ml of boiled water, twice a day."
41387166|NCT01379079|DRUG|Acetylsalicylic acid lysinate|aspirin intake on awakening
41387167|NCT05171127|PROCEDURE|Diffuse Reflectance Spectroscopy|Measurements of DRS patterns in extirpated tumor and cerebral tissue
41387168|NCT00764816|OTHER|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
41387169|NCT00764816|OTHER|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
41387170|NCT03864367|DEVICE|Device - Prism Medical FGA-700 Bariatric Floor Lift|This group will be using a Mobile Weight-Support Therapy (MWeST) device (the Prism Medical FGA-700 Bariatric Floor Lift) to determine if it improves mobilization of older patients with traumas of their legs.
41387171|NCT03797573|DEVICE|tDCS|tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.
41387172|NCT03797573|DEVICE|sham tDCS|Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.
41510899|NCT04876105|OTHER|Assesment of treatment preference|Multiple-choice survey questions were created by the researchers based on the studies in the literature regarding the pain and treatment preferences of the participants
41510900|NCT06365411|DIAGNOSTIC_TEST|Biomarker discovery and validation - with focus on genomic biomarkers|Biomarker discovery and validation - with focus on genomic biomarkers
40856286|NCT02742545|BEHAVIORAL|MayoExpertAdvisor|Access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
40856287|NCT04046224|BIOLOGICAL|ST-920|Single dose of investigational product ST-920
40856288|NCT03261453|DEVICE|Active Elipse Device|Intervention Device
40856289|NCT03261453|DEVICE|Elipse Sham Device|Control Device
41387173|NCT05762120|OTHER|Weight Management Programme|"Weight Management Programme which consists of 4 phases:~1. Very low calorie diet~2. Low calorie diet~3. Maintenance phase~4. Continuance phase"
40856290|NCT04279522|DEVICE|Relivion®DP- Active|Relivion®DP- Active stimulation device
41387174|NCT06235125|DRUG|Cytalux|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
41387175|NCT03911882|DIETARY_SUPPLEMENT|Celergen Administration|The food supplement Celergen was administered on a daily basis for a total of 3 months (90 days) to participating fibromyalgia patients
41510901|NCT04876950|COMBINATION_PRODUCT|Virtual care with remote automated monitoring|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
41510902|NCT05076357|BEHAVIORAL|Caloric Restriction|-30% of participants total energy requirements
41510903|NCT05076357|OTHER|Cold intervention|Sessions of 90min each every 2nd day involving cold exposure
41510904|NCT00129545|DEVICE|WATCHMAN Left Atrial Appendage Closure Technology|Implant of WATCHMAN Left Atrial Appendage Closure Technology
41510905|NCT00129545|DRUG|Warfarin|Subjects receive warfarin
41510906|NCT06489210|PROCEDURE|popliteal block|using ultrasound to detect sciatic nerve and popliteal fossa through different approaches using 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally
41510907|NCT06254456|DIAGNOSTIC_TEST|End expiratory occlusion test|Fluid responsiveness test
41510908|NCT00971373|OTHER|Vestagen scrubs|antimicrobial impregnated textile
41510909|NCT03600987|BEHAVIORAL|Simultaneous music and reading lyrics|listening to music with singing of the lyrics simultaneously with reading the written lyrics.
41510910|NCT03600987|BEHAVIORAL|Priming with music|priming by listening to music and singing of the lyrics followed by reading the written lyrics.
41510911|NCT03600987|BEHAVIORAL|Control|control condition using reading materials without music.
41510912|NCT04405297|DEVICE|Adipose-derived regenerative cells|Adipose-derived regenerative cells will be obtained from a small-volume lipoaspirate procedure. The lipoaspirate will then be enzymatically digested to produce a stromal vascular fraction (SVF) that will be injected into the targeted joint.
41510913|NCT04365192|DEVICE|I-gel|"The i-gel airway is a supraglottic airway management device made of thermoplastic elastomer, which is soft, gel-like, and transparent.~The i-gel has evolved as a device that accurately positions itself over the laryngeal framework, providing a reliable perilaryngeal seal, and therefore no cuff inflation is necessary."
41510914|NCT04365192|DEVICE|Self-pressurized air-Q|The self-pressured air-Q is a supraglottic airway management device The intracuff pressure of air-Q dynamically equilibrates with the airway pressure and adjusts to the patient's pharyngeal and periglottic anatomy, potentially providing improved airway fit and seal.
41510915|NCT01160328|DRUG|Leuprolide|7.5 mg - 1 month depot, 2 doses over 7 weeks
41510916|NCT01160328|DRUG|Testosterone|7.5g - 1% testosterone gel, daily x 7 weeks
41510917|NCT05666076|PROCEDURE|Pericapsular nerve block|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
41510918|NCT05666076|PROCEDURE|Suprascapular nerve block|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
41510919|NCT05666076|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
41510920|NCT05666076|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
41510921|NCT00687024|PROCEDURE|Magnetoencephalography|MEG will be performed on a whole head Omega 151-channel gradiometer system. At least 15 2-minute periods of spontaneous data are recorded. The sampling rate for data acquisition is 625Hz, with a bandpass filter of 3 to 70 Hz and a notch filter of 60Hz.
41510922|NCT00687024|PROCEDURE|MR imaging|MR imaging will be performed on a GE 1.5T system using a variety of sequences, including sagittal T1, axial T2, axial FLAIR, coronal dual echo, coronal FLAIR, axial 3D T2 frFSE and axial SPGR.
41510923|NCT00687024|PROCEDURE|Diffusion Tensor Imaging|Diffusion tensor imaging will be performed on the same scanner, using single shot diffusion-weighted echo planar imaging. Twenty-five 'xial contiguous slices are obtained aligned to the anterior commissure line to cover the whole brain, giving a total imaging time of 4min 40sec.
41510924|NCT00507533|PROCEDURE|Continuous positive airway pressure|
41510925|NCT00192803|DRUG|candesartan|
41510926|NCT05446558|PROCEDURE|Intracorporeal anastomosis|"Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.~Device:~Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis."
41510927|NCT05446558|PROCEDURE|Extracorporeal anastomosis|"A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.~Device:~Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis."
41510928|NCT02290405|BEHAVIORAL|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
41510929|NCT05549531|DRUG|ACT-1004-1239 (10 mg)|ACT-1004-1239 will be administered as 1 capsule of 10 mg strength to be taken under fed conditions.
41510930|NCT05549531|DRUG|Itraconazole (200 mg, o.d.)|Itraconazole 200 mg will be administered as capsules (2 x 100 mg capsule) to be taken under fed conditions.
41510931|NCT00111241|DRUG|aromatase inhibitors (letrozole, anastrozole)|Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study
41510932|NCT05294666|DRUG|Cyclosporine|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
41510933|NCT05294666|DRUG|tacrolimus|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
41510934|NCT05758233|PROCEDURE|Patients undergoing transversalis fascia plane block|The investigators applied a transversalis fascia plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
40856291|NCT04279522|DEVICE|Relivion®DP- Sham|Relivion®DP- Sham stimulation device
40856292|NCT01736670|DRUG|Triamcinolone Acetonide spray|
40856293|NCT01736670|DRUG|Triamcinolone acetonide cream|
40856294|NCT01736670|DRUG|Alcohol spray|
40856295|NCT05794581|DRUG|CT-868|CT-868
40856296|NCT05794581|DRUG|Placebo|Placebo as SC Injection
40856297|NCT05794581|DRUG|Victoza|Victoza as active comparator as SC Injection
40856298|NCT00274963|DRUG|bendamustine hydrochloride|
40856299|NCT00274963|DRUG|mitoxantrone hydrochloride|
40856300|NCT01504841|DRUG|Etravirine (ETR)|ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.
41038111|NCT02889991|OTHER|Fascial Mechanotransduction Dry Needling|"The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session."
40856301|NCT04160663|DIAGNOSTIC_TEST|Carotid Ultrasound|Uses sound waves to examine the blood flow through the carotid arteries and to determine the elastic properties or stiffness of the artery.
40856302|NCT01511068|DRUG|Leukine|Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
40856303|NCT00607867|OTHER|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
40856304|NCT00607867|OTHER|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
40856305|NCT00798525|DRUG|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of \> 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
40856306|NCT00798525|DRUG|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine \< 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
40856307|NCT05938998|BEHAVIORAL|Yoga; Support Group|BEHAVIORAL: Group Exercise Sessions- Yoga. BEHAVIORAL: Social Support Sessions
41166584|NCT05319132|OTHER|Adult subjects with ROSAH syndrome|The main objective is to evaluate the ex vivo inhibitory potential of DF-003 on alpha-1 kinase activity.
41166585|NCT03010345|DEVICE|Osmed self inflating tissue expanders|Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage
41166586|NCT03010345|OTHER|Iliac bone graft|Bone grafting the cleft without the use of osmed self inflating tissue expander
40856308|NCT01761019|DRUG|Taclonex Topical Suspension|topical medication for psoriasis
40856309|NCT05670158|BIOLOGICAL|Blood sampling|Blood will be collected into 2 EDTA and 1 heparin tube. The 2 EDTA tubes (4ml of blood in each) will be transported on ice to the proteomics platform in the next three hours, centrifuged and stored on -80 degrees Celcius in low-binding tubes for further molecular analysis. 1 heparin tube (5mL) will be sent to the Bacteriology-Virology Department for the active PBMC counting.
40856310|NCT05670158|PROCEDURE|Perilymph sampling|The perilymph collection will be performed during the cochlear implantation surgery at the same time as the round window opening. 5 to 15 microliters will be aspirated using an atraumatic spinal needle mounted onto 1 ml insulin syringe.
40856311|NCT02087111|DRUG|Telaprevir|375 mg film coated tablets
40856312|NCT02087111|DRUG|40 Kd Pegylated interferon alfa 2a|180 µg in pre-filled syringe for sub-cutaneous injection
40856313|NCT02087111|DRUG|Ribavirin|200 mg tablets
40856314|NCT04921228|BEHAVIORAL|Heart rate variability biofeedback|"* 5 days of 3-min HRV readings to establish baseline HRV~* After meeting with study personnel to review HRV biofeedback (BF) practice with the app, participants will be asked to begin HRV BF training for 5 min a day~* Participants will increase the length of HRV BF training by 5 min every few days until they reach 20 min a day of HRV BF training~* Participants will aim for 20 min of daily HRV BF training for 6 consecutive wks out of the 8-wk total BF training protocol~* Study personnel will follow the participants' progress with training via the online portal provided through the Optimal HRV app and have brief (15-min) check-in appts. with participants to discuss how they are experiencing HRV BF, what they find helpful, and barriers to their practice if they are having difficulties~* After completing the 8-wks of BF training (including 2 wks of 5-min titrations to the full 20-min protocol), participants will be asked to take 3-min HRV readings for 5 days to assess post-intervention HRV"
40856315|NCT00978146|DRUG|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
41387176|NCT06234930|DEVICE|Audiovisual stimulation VR system|Delivery of synchronized auditory and visual stimuli at varying frequencies via a VR headset.
41387177|NCT02093650|DRUG|black cohosh extract|Black cohosh extract 80 mg
41387178|NCT02093650|DRUG|Placebo|Soy bean oil
41387179|NCT02343497|DIETARY_SUPPLEMENT|Astaxanthin|
41387180|NCT02343497|DIETARY_SUPPLEMENT|Placebo|
41387181|NCT04632563|OTHER|Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)|A questionnaire regarding musculoskeletal past medical history and current symptoms.
41387182|NCT02405351|BEHAVIORAL|Adaptive Working Memory Training|"The working memory training task will consist of an online adaptive working memory program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
41387183|NCT03538522|DRUG|N-831(Traneurocin) 10 mg QD|Oral administration of 10 mg capsule of NA-831 QD for 24 weeks
41387184|NCT03538522|DRUG|NA-831 (Traneurocin) 20 mg QD|Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
41387185|NCT03538522|DRUG|NA-831 (Traneurocin) 40 mg QD|Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks
41510935|NCT05758233|PROCEDURE|Patients undergoing transversus abdominis plane block|The investigators applied a transversus abdominis plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
41387186|NCT03538522|DRUG|Placebo oral capsule QD|Oral administration of oral placebo capsule QD or 24 weeks
41387187|NCT00969267|OTHER|ear-acupuncture A|with needle stimulation
41387188|NCT00969267|OTHER|stimulation B|with bread stimulation on ear acupuncture point
41387189|NCT00969267|OTHER|stimulation C|without needle stimulation
41387190|NCT03845855|OTHER|virtual reality|Virtual reality with a game
41387191|NCT03845855|OTHER|robotic gait|robotic gait therapy
41387192|NCT06125964|BEHAVIORAL|Intensity-Based Goals|On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Intensity-based goals ask participants to maintain a target heart rate range during physical activity based on age-adjusted heart rate (HR) max. Goals progressively increase from 55% to 60% HR max across two weeks. Research staff will show participants how to monitor their heart rate using their Fitbit Versa. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on heart rate (intensity-based goals only) and exercise duration.
41387193|NCT06125964|BEHAVIORAL|Affect-Based Goals|"On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Affect-based goals ask participants to engage in either a type or context of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity in a place, in a social situation, or while listening to something that makes them feel good. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on exercise duration while featuring a smiley face emoticon."
41510936|NCT06551948|DIETARY_SUPPLEMENT|psyllium|15 g psyllium
41510937|NCT06551948|DIETARY_SUPPLEMENT|methylcellulose|15 gm methylcellulose
41510938|NCT06551948|DIETARY_SUPPLEMENT|maltodextrin|15 g maltodextrin
41510939|NCT06551948|DIETARY_SUPPLEMENT|inulin|15g inulin
41510940|NCT04861584|DRUG|Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin|4 cycle neoadjuvant therapy and radical cystectomy
41387194|NCT06125964|BEHAVIORAL|TYPE/CONTEXT Enhancement|The TYPE/CONTEXT enhancement will augment affect-based treatment effects by additionally providing tailored recommendations for activity types and contexts that satisfy personally important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk were used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm recommends the corresponding activity type or context while accounting for reported constraints. Different psychological needs will be selected each day. Tailored recommendations are incorporated immediately following the morning goal module.
41387195|NCT06125964|BEHAVIORAL|SAVOR Enhancement|The SAVOR enhancement will augment affect-based treatment effects by additionally implementing a brief savoring exercise on the smartphone during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty.
41510941|NCT02028676|OTHER|Clinically Driven Monitoring (CDM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
41510942|NCT02028676|OTHER|Laboratory plus Clinical Monitoring (LCM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
41510943|NCT02028676|DRUG|Arm A: ABC+3TC+NNRTI|Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
41510944|NCT02028676|DRUG|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
41510945|NCT02028676|DRUG|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
41510946|NCT02028676|DRUG|Once-daily ABC+3TC|
41038112|NCT02889991|OTHER|Technique Placebo of Dry Needling|"Technique with a total duration of 3 minutes per session:~* To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~* Monitor longitudinally taut band, with index and middle fingers.~* Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~* Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~* Remove the bridles and perform hemostasis with cotton.~* We will give end to the technique placebo of dry needling."
41038113|NCT06300008|DRUG|cetylated fatty acid|use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
41038114|NCT06300008|DRUG|Placebo|use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
41038115|NCT00342862|DRUG|Amevive exposure|Observational
41166587|NCT01584271|DEVICE|Natural Ear Comfort(TM), a botanical ear drops product|"Ear Comfort(TM): active ingredients - Thyme essential oil \& Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin."
41387196|NCT04022759|BEHAVIORAL|Treatment as Usual with Security Prime|"In addition to their treatment as usual (low-intensity guided self-help behavioural activation for depression), participants will complete an initial attachment security priming task during the first session with their allocated clinician. Participants will be prompted in their intervention workbook with a caption regarding what a secure attachment relationship represents. They will be asked to think of a person/ people with whom they feel they have this relationship, and list them. Following this, they are asked to plot these individuals on a diagram of concentric circles in relation to how close they feel this person is to them. The closer to the middle of the diagram the individual places each person, the closer they feel their relationship to that person is.~Prior to each session with their clinician, they will be prompted to complete a repeated security priming task in order to increase feelings of security prior to therapy sessions."
41510947|NCT02028676|DRUG|Twice-daily ABC+3TC|
40856316|NCT03168178|DRUG|Standard Antibiotic Treatment|"Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes"
40856317|NCT03168178|OTHER|No Antibiotic Treatment|Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
41038116|NCT01357967|DRUG|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
41510948|NCT02028676|DRUG|Continued cotrimoxazole prophylaxis|
41510949|NCT02028676|OTHER|Stopped cotrimoxazole prophylaxis|
40856318|NCT01582399|DRUG|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
40856319|NCT03487497|PROCEDURE|Lateral column lengthening osteotomy|Lengthening osteotomy of the lateral column of the foot
40856320|NCT06291064|DRUG|Cyclophosphamide|Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
40856321|NCT06291064|DRUG|Epirubicin|Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.
41038117|NCT01357967|DRUG|Seroquel XR adjunctive|"Quetiapine group:~seroquel XR 50mg Day 1 --\> 50mg Day 2 --\> 150mg Day 3 --\> 150mg Day 4 --\> adjustment usually at hs but can be daytime"
41038118|NCT04858269|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle
41038119|NCT04858269|DRUG|Carboplatin|Carboplatin dosed for area under the curve (AUC) 1.5 IV on days 1, 8, 15 of each 3-week cycle
41038120|NCT04858269|DRUG|Paclitaxel|Paclitaxel 45 mg/m2 on days 1, 8, 15 of 3-week cycle.
41166588|NCT03653377|OTHER|Self administrated questionnaire|Questionnaires are distributed to patients with their parents during their visit to the CF center.
40856322|NCT06291064|DRUG|Docetaxel|Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.
40856323|NCT06291064|DRUG|Carboplatin|Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.
40856324|NCT06291064|PROCEDURE|Breast Surgery|Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.
40856325|NCT06291064|DRUG|Capecitabine|Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.
40856326|NCT03492606|PROCEDURE|Samples|lumbar puncture, blood and CSF samples, SNPs analysis
40856327|NCT03694431|OTHER|Tech-supported HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
40856328|NCT03694431|OTHER|Standard HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
41387197|NCT04022759|BEHAVIORAL|Treatment as Usual (Behavioural Activation)|Clients will engage in treatment as usual. This involves low-intensity guided self-help behavioural activation for depression.
41387198|NCT06568081|OTHER|SloMo|SloMo, is a blended digital therapeutic for people who fear harm from others. It is based on cognitive-behavioural therapy for psychosis. An online therapy platform supports the delivery of 11 face-to-face sessions, which are synchronised to a native mobile app for use in daily life. SloMo works by helping people to notice their worries and fast thinking habits, and encourages them to slow down for a moment to find ways of feeling safer.
41387199|NCT02258399|BEHAVIORAL|Exercise|Moderate intensity exercise
40856329|NCT04204044|DRUG|Metformin Hydrochloride|Metformin Hydrochloride is used in PCO
40856330|NCT04204044|DRUG|Myo-inositol|Myo inositol used in PCO
40856331|NCT04954768|OTHER||This is a observational study, and there is no interventions.
40856332|NCT06458985|BEHAVIORAL|Disclosing Recovery: A Decision Aid and Toolkit|The Disclosing Recovery intervention is designed to help people in treatment for opioid use disorder (1) make key decisions regarding disclosure, including whether, why, what, how, and when to disclose, and (2) build skills to disclose, including planning what to say, practicing disclosure, and preparing for negative responses.
40856333|NCT02293603|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CDCs)|Intracoronary delivery of CAP-1002 or placebo
41038121|NCT01923155|PROCEDURE|Colonoscopy|
41038122|NCT00152776|DRUG|ovaria comp 10 globuli 3 times per day 24 weeks|order of intervention and placebo varies between Groups I-III
41038123|NCT06100627|DRUG|AP301|Orally administered
41038124|NCT05975268|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005/placebo
41038125|NCT04301778|DRUG|Durvalumab|"1. Durvalumab - 1500 mg via IV infusion over 60 minutes (-5/+10 min) on day 1 of each 28-day cycle (every 4 weeks).~2. Drug - 1500mg IV"
41038126|NCT04301778|DRUG|SNDX-6352|"1. SNDX-6352 - 3mg/kg via IV infusion over 30 minutes (-5/+10 min) on days 1 and 15 of each 28-day cycle (every 2 weeks), starting with cycle 2 (not given during cycle 1).~2. Drug - 3mg/kg IV"
41387200|NCT02258399|DIETARY_SUPPLEMENT|Breakfast|Breakfast consumption
41387201|NCT06346197|DRUG|Balstilimab|Balstilimab: 240mg, IV, Q2W, until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
41387202|NCT06346197|DRUG|Botensilimab|Botensilimab: 75mg, IV for up to 4 doses, Q6W until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
41387203|NCT06346197|DRUG|Folfox Protocol|oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks.Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
41387204|NCT06346197|DRUG|XELOX|Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
41387205|NCT06346197|DRUG|Nivolumab|240mg, IV, Q2. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
40856334|NCT02135510|DRUG|metoclopramide|
40856335|NCT02135510|DRUG|dexamethason|
41166589|NCT05142072|DRUG|Vitamin D3|intranasal film
40856336|NCT02135510|DRUG|palonosetron|
40856337|NCT05438732|DEVICE|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
40856338|NCT01574235|BIOLOGICAL|Nivestim®|
41038127|NCT02111590|DRUG|Immunoglobulins|SCIG dosage is individualized for each patient according to previous IVIG dosage
41038128|NCT01512862|DRUG|Calcitriol|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
41038129|NCT01512862|DRUG|Placebo|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
41038130|NCT00963365|DRUG|AZD6765|Single oral dose and single IV infusion of AZD6765
41038131|NCT00963365|DRUG|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
41038132|NCT01912612|DRUG|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
41038133|NCT00346060|DEVICE|Retinal transplantation instrument|
41038134|NCT00346060|DEVICE|Fetal tissue.|
41038135|NCT03546244|BEHAVIORAL|musical treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with musical treadmill
41387206|NCT00876109|DRUG|GDC-0941|GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
41387207|NCT05471063|DRUG|Amphotericin B Colloidal Dispersion|Amphotericin B Colloidal Dispersion 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) . The course of induction therapy is at least four weeks.
40856339|NCT02709330|DRUG|Lunasin Regimen|LunaRich X Capsules, Reliv Now, ProVantage
40856340|NCT02709330|OTHER|Historical control|Matched historical controls will be identified from the PatientsLikeMe database.
41038136|NCT03546244|BEHAVIORAL|Traditional treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with traditional treadmill
41387208|NCT05471063|DRUG|flucytosine|Flucytosine 100 mg/kg/d for induction therapy and consolidation therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks, and consolidation therapy for at least 6 weeks.
41510950|NCT04428879|DRUG|Topotecan Episcleral Plaque|Sustained Release Episcleral Topotecan Plaques (Chemoplaques) are glued to bare, dry sclera of the eye under conjunctiva and Tenon's capsule. A rolling six dose interpatient escalation schema will be employed. Chemoplaques with 0.6 mg and 0.9 mg of topotecan HCl formulation are available. Patients will receive 1 or 2 Chemoplaques per eye, to deliver 5 escalating doses: 0.6, 0.9, 1.2 \[2x0.6\], 1.5 \[0.6+0.9\] or 1.8 \[2x0.9\] mg. The prescribed dose will escalate or de-escalate by 0.3 mg at each level, and no patient will receive more than 1.8 mg of topotecan hydrochloride due to the physical limitations if the devices available. The planned removal is 42 days ± 7, unless dose limiting toxicity is observed, in which case the plaque is removed as soon as possible. The observation period for the purposes of dose-escalation will be 63 days (i.e. 21 days following Chemoplaque removal on day 42).
40856341|NCT05505006|DRUG|Ferric Carboxymaltose Injection|Anemic patients with ID will receive i.v. iron. Dosage will be based on Hb level and patient body weight.
40856342|NCT05505006|DRUG|Folic acid|Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month
40856343|NCT05505006|DRUG|B12|Anemic patients with B12 deficiency will receive B vitamin complex 1 tablet per day for 1 month
40856344|NCT03989401|OTHER|Multimedia video health education|The experimental group conducted multimedia video education while admission.
40856345|NCT03458156|BIOLOGICAL|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
41038137|NCT04338100|PROCEDURE|Follow-up at 14 days|Point of care chest ultrasonography and 14-day follow-up to assess the evolution of the infection and care requirement (invasive ventilation or death)
41038138|NCT03122418|BEHAVIORAL|Personal Fitness Device|Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
41038139|NCT04798976|DRUG|neoadjuvant/adjuvant therapy|chemotherapy/endocrine therapy/surgery/radiotherapy
41387209|NCT05471063|DRUG|fluconazole|Fluconazole (400-600 mg/d) for consolidation therapy for at least 6 weeks.
41387210|NCT06390423|DIAGNOSTIC_TEST|Passive leg raise, SVI via bioreactance, Echo based VTI|No interventions other than fluid challenge
40856346|NCT03458156|BIOLOGICAL|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
40856347|NCT03458156|OTHER|the control group|The patients will be assigned to the control group.
40856348|NCT05326867|DEVICE|Infiltration of 2% Lidocaine with Needle|Infiltration of 2% Lidocaine with Needle
40856349|NCT05326867|DEVICE|Infiltration of 2% Lidocaine without Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
40856350|NCT05546229|PROCEDURE|Microneedle based interstitial fluid collection|Interstitial fluid will be collected from the skin using microneedles and suction.
40856351|NCT04406558|OTHER|Questionnaire|An online questionnaire on the experience of the period of confinement and deconfinement will be sent to the cohort of adolescents followed at the CHI Creteil for a chronic disease or not. Forty adolescents will be randomly selected for a remote interview on the experience and memorization of the period of confinement and deconfinement.
41038140|NCT03398005|DRUG|CaPre|4 x 1 g capsules administered orally once a day for 26 weeks
41038141|NCT03398005|DRUG|Placebo|4 x 1 g capsules administered orally once a day for 26 weeks
41038142|NCT04956302|DRUG|Bortezomib|Given SC
41038143|NCT04956302|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
41038144|NCT04956302|DRUG|Dexamethasone|Given PO or IV
41038145|NCT04956302|DRUG|Panobinostat Lactate|Given PO
40856352|NCT00856947|DIETARY_SUPPLEMENT|Cholecalciferol D3|2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
40856353|NCT00856947|OTHER|Placebo tablet|2 tablets containing no active substance
40856354|NCT02363959|DRUG|Hyperbaric Oxygen Therapy|2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
41510951|NCT04078997|OTHER|nasopharyngeal swab|A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.
40856355|NCT02363959|PROCEDURE|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
41038146|NCT05807451|PROCEDURE|High Tibial Osteotomy (Uniplanar and Biplanar )|High Tibial Osteotomy using monoplanar and biplanar osteotomy techniques
41510952|NCT00808951|DRUG|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
40856356|NCT03070899|DRUG|OBE2109|OBE2109 100mg tablets for oral administration once daily
40856357|NCT03070899|DRUG|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
40856358|NCT03070899|DRUG|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
40856359|NCT03070899|DRUG|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
41038147|NCT01201590|DIETARY_SUPPLEMENT|High Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
41038148|NCT01201590|DIETARY_SUPPLEMENT|Low Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
41038149|NCT05918926|BEHAVIORAL|Exercise|Individualised remote exercise intervention
41038150|NCT04536272|DRUG|Heparin|Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
41038151|NCT04536272|DRUG|LMWH|Administration of LMWH guided by weight and renal function during ECLS.
41038152|NCT00236548|DRUG|risperidone|
41038153|NCT03955653|PROCEDURE|Femoral artey access|We will study the access to the femoral artery for cardiac catheterization or percutaneous coronary intervention
40856360|NCT02527785|DRUG|Oxaliplatin, Irinotecan, S-1(OIS)|"Treatment will be delivered every 2 weeks~1. oxaliplatin 65 mg/m2 iv on day 1~2. irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day po on day 1-7"
41038154|NCT01343550|OTHER|creativity group|This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
41038155|NCT06188572|OTHER|Michigan Neuropathy Screening Instrument|A two-step test consisting of symptom questionnaire and physical examination was used. The symptom questionnaire includes 15 questions about the legs and feet. Physical examination includes assessment of the appearance of the feet, Achilles reflex, thumb vibration and monofilament tests.
41387211|NCT05218317|DIAGNOSTIC_TEST|in-vivo Corneal Confocal Microscopy|All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany). Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes. A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.- Pharm. Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM. For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera. All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
41387212|NCT06536530|BEHAVIORAL|Exergame-Based Training|40-50 min sessions, two sessions per week, for a total of eight weeks.
41387213|NCT06536530|BEHAVIORAL|Cognitive-Based Training|40-50 min sessions, two sessions per week, for a total of eight weeks.
41387214|NCT06536530|BEHAVIORAL|Wait-List|Participants will not train with any program and they will not assist to any specific session or intervention
41387215|NCT05072145|OTHER|Telemedicine|Receiving care in a tele-ED hospital
41387216|NCT03299218|DIETARY_SUPPLEMENT|SNF (Wawamum)|A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.
41387217|NCT03299218|BEHAVIORAL|Social and behaviour change communication (SBCC)|SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.
40856361|NCT04040829|BEHAVIORAL|Cognitive remediation therapy (CR)|Cognitive remediation therapy is a behavioral intervention that aims to improve cognition. This intervention has the goal to produce long-term improvements in cognition as well as to generalize these improvements in daily functioning.
40856362|NCT04040829|BEHAVIORAL|Supported education (SE)|Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
40856363|NCT04040829|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
40856364|NCT06236373|OTHER|Focus Groups or Interviews|Focus groups and qualitative interview will be conducted with patients, caregivers and stake-holders trying to identify unmet needs of cancer survivors after the acute treatment phase. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
40856365|NCT05639257|DRUG|Lamotrigine|Lamotrigine tablets increasing dosis to maximal 300 mg daily
40856366|NCT05639257|DRUG|Namuscla|Namuscla tablets increasing dosis to maximal 501 mg daily
40856367|NCT03688516|BEHAVIORAL|Manipulation of valence and modality|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
40856368|NCT03688516|BEHAVIORAL|Spatial and recognition memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
40856369|NCT03688516|BEHAVIORAL|Source and content memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
41038156|NCT06188572|OTHER|Numeric Pain Scale|"In this simple method, which is frequently used to measure pain intensity in the clinic and whose validity and reliability have been demonstrated, the participant is asked to mark a number on a 10 cm scale with numbers ranging from 0 (no pain) to 10 (unbearable pain) for the pain."
41038157|NCT06188572|OTHER|Mandibular Function Disorder Questionnaire|This valid and reliable scale evaluating mandibular dysfunction consists of two dimensions and 17 questions.A high total score obtained from the questionnaire indicates a high level of impairment in jaw function
41387218|NCT03299218|OTHER|Cash|Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
41387219|NCT01902524|DRUG|Fentanyl-TTS|All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
41387220|NCT00288106|OTHER|Follow-up|No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
40856370|NCT05716360|DIAGNOSTIC_TEST|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
40856371|NCT05716360|PROCEDURE|Aneurysm Treatment with Flow-Diversion Therapy|Aneurysm Treatment with Flow-Diversion Therapy
40856372|NCT05716360|PROCEDURE|Aneurysm Treatment with Metalic Bare Stent|Aneurysm Treatment with Metalic Bare Stent
40856373|NCT05240625|DEVICE|"aetherAI Computer-aided Polyp Detection (CADe) Systems for Colonoscopy"|"The investigational medical device is intended to automatically detect potential polyps via colonoscopy in real-time during colonoscopy examinations.~The subject device contains an artificial intelligence/machine learning (AI/ML) advanced algorithm to aid the endoscopists in detection of colonic mucosal lesions and the detected polyps will be highlighted to the endoscopists during the real-time colonoscopy procedures."
40856374|NCT05240625|PROCEDURE|Standard colonoscopy|Standard colonoscopy procedure.
41387221|NCT04460521|DRUG|N-Acetyl cysteine|In addition to splinting, both groups will receive an oral tablet to take daily for 8 weeks. Participants assigned to the experimental group will receive oral NAC (500 mg PO daily for eight weeks; based on recommended daily dose for use as an antioxidant and dosing in previous human clinical trials and animal studies), and those assigned to the control group will be given a similar looking placebo with identical instructions. Tablets will be provided in a blister pack to assist with compliance.
41387222|NCT04460521|DEVICE|Wrist Splint|Participants in both arms will be given a standard prescription for a prefabricated night splint which keeps the wrist in a neutral position and instructed on proper use and the importance of consistent use. To limit splint variability, we will ensure that splint prescriptions are written such that a MedSpec Wrist Lacer II splint is obtained from the patient's pharmacy. This is the most commonly available brand locally and meets the criteria for wrist, metacarpophalangeal, and interphalangeal joint positioning. They will be advised to wear the splint consistently during sleeping hours on their affected wrist for eight weeks, as is the standard of practice.
41387223|NCT01393626|DRUG|Placebo|oral tablets twice daily
40856375|NCT01777776|DRUG|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
40856376|NCT01777776|DRUG|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
40856377|NCT06507826|BEHAVIORAL|Self-Compassionate Writing for Caregivers of Older Adults|Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).
41038158|NCT06188572|OTHER|Fonseca Anamnestic Index|This scale, which is valid and reliable as a TMJ disorder assessment tool, includes 10 questions. The presence of TMD is accepted in those with a score of 25.
41038159|NCT06188572|OTHER|Ferrans&Powers Quality of Life Index Diabetes Version|This index consists of two parts and a total of 68 items. A high score indicates a good quality of life.
41038160|NCT06062680|DRUG|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
41038161|NCT05250596|DRUG|Colchicine|Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge.
41038162|NCT05250596|DRUG|Atorvastatin|Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
41038163|NCT06302166|OTHER|High Intensity Circuit training (HICT)|High Intensity circuit training consisting of circuits of high intensity exercises and progressed up to 8 weeks will be provided.
41038164|NCT06302166|OTHER|Intermittent Fasting (IF)|Time restricted feeding will be used in which the intervention will begin with a 12:12 window leading to a 16:8 IF protocol.
41387224|NCT01393626|DRUG|CP-690,550|oral tablets twice daily
41038165|NCT06302166|OTHER|Combination of HICT and IF|The participants will follow both HICT and IF for 8 weeks.
41038166|NCT02672631|OTHER|physical examination|Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)
41387225|NCT01393626|DRUG|CP-690,550|oral tablets twice daily
40856378|NCT01407666|PROCEDURE|paravertebral blocks|use bilateral thoracic paravertebral blocks for pain control
40856379|NCT06082817|DRUG|Oral Testosterone Undecanoate|50mg oral testosterone undecanoate daily
40856380|NCT05465343|DRUG|Furmonertinib|Furmonertinib 160mg orally QD
40856381|NCT03604796|DRUG|Rectal Solution|Rectal acetaminophen at 15 mg/kg x 4/day for three days
40856382|NCT03604796|DRUG|Intravenous Infusion|Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
40856383|NCT00179946|PROCEDURE|HLA typing|
41038167|NCT02672631|OTHER|DTI|Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion
41038168|NCT02672631|OTHER|ENMG|Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential
41038169|NCT03119857|DRUG|Antiandrogen|
41387226|NCT00364416|OTHER|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
41387227|NCT05455411|BEHAVIORAL|Group-based Parent-implemented Training|A group-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
41387228|NCT05455411|BEHAVIORAL|Individual-based Parent-implemented Training|An individual-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online in a one-on-one format (approximately 25 hours distributed over 6 months).
41387229|NCT06562673|DRUG|intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar)|After insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under local anesthesia, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
40856384|NCT02503150|BIOLOGICAL|APDC + Chemotherapy|Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
40856385|NCT02503150|DRUG|Chemotherapy|Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
40856386|NCT05368194|DIETARY_SUPPLEMENT|Isocaloric Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
40856387|NCT05368194|DIETARY_SUPPLEMENT|Isocaloric Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
40856388|NCT05368194|DIETARY_SUPPLEMENT|Excess Calorie Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
41038170|NCT03119857|DRUG|Antiandrogen+docetaxel|"Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first.~Antiemetic therapy may be used if necessary."
41387230|NCT05924555|OTHER|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
41387231|NCT05924555|OTHER|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
41387232|NCT05924555|OTHER|Echography of upper leg|Determine upper leg muscle size
41387233|NCT05924555|OTHER|Hand grip strength with hand dynamometer|Determine muscle strength
41387234|NCT05924555|OTHER|Fill in questionnaires regarding physical activity|SQUASH, mMRC, questionnaire designed to report myopathic symptoms in LcFAOD patients.
41387235|NCT04400175|DEVICE|Valved ergonomic teat|Administration of milk with a feeding system with a valved ergonomic teat in late preterm newborns.
41387236|NCT04400175|DEVICE|Standard silicon teat|Administration of milk with a feeding system with a standard silicon teat
41387237|NCT02795780|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
41387238|NCT02795780|PROCEDURE|PET Scan|positron emission tomography (PET) scan
41387239|NCT04471792|DRUG|Creatine monohydrate|Creatine monohydrate will be used in combination with muscle stretching.
41387240|NCT04471792|DIETARY_SUPPLEMENT|Cellulose|Cellulose will be used in combination with muscle stretching.
41387241|NCT01453101|DRUG|Fludarabine monophosphate, melphalan, Bortezomib|"* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.~* Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2~* Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan."
41387242|NCT01818219|PROCEDURE|Records of EADI derived parameters|
41510953|NCT00808951|DRUG|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
41166590|NCT06254300|BEHAVIORAL|Exercise Training|The exercise program will consist of three sessions per week, each lasting 60 minutes. The aerobic exercise will gradually increase the duration throughout the program to 40 minutes and exercise intensity from 30% to 59% of heart rate reserve. The resistance training will include bodyweight functional exercises and resistance exercises using elastic bands. The intensity of resistance exercise will progressively increase according to levels of progressive length and resistance of the elastic bands. The volume of resistance training will start with one set of 8 repetions. It will then gradually increase alongside the program to 2 sets of 12 repetitions. Participants will also be guided to assess their subjective effort using the Borg scale (RPE 12-15).
40856389|NCT05368194|DIETARY_SUPPLEMENT|Excess Calorie Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
41166591|NCT03121612|DEVICE|CPAP|CPAP therapy
41166592|NCT03179774|DEVICE|Endovascular revascularization|All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
41166593|NCT00392886|DRUG|carboplatin|Given IV
41166594|NCT00392886|DRUG|cisplatin|Given IV
41166595|NCT00392886|DRUG|cyclophosphamide|Given IV
41166596|NCT00392886|DRUG|etoposide|Given IV and orally
41387243|NCT01674959|RADIATION|concurrent chemoradiation|"postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
41387244|NCT06274853|DRUG|GS-441524|Oral GS-441524 capsules
41510954|NCT03688048|DEVICE|Bright light treatment lamp|Exposure to bright white light (1 hour, 10 000 lux)
40856390|NCT06169813|OTHER|Nicotine Replacement Therapy (NRT)|NRT (daily patches and lozenges). NRT strength will be according to the established dosing guidelines for tobacco treatment. NRT is the standard of care in tobacco treatment and helped reduce CPD in prior trials
40856391|NCT06169813|OTHER|E-Cigarette (EC)|EC with single-use pods. Nicotine - 48 mg/ ml (4.8% nicotine) concentration.
40856392|NCT06169813|BEHAVIORAL|Counseling|Each participant will receive up to 5-motivational counseling sessions. The first session will also include orientation of EMA/EMI texting.
41038171|NCT06496932|OTHER|Listen to music|Women in the intervention groups will listen to nature and bird sounds through over-the-ear headphones after spinal anesthesia for cesarean section until the suturing is completed.
41038172|NCT00226239|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV over 1 hour, day 1
41038173|NCT00226239|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.
41038174|NCT00226239|DRUG|Cetuximab|Cetuximab dose will be 250 mg/m\^2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).
41038175|NCT00226239|PROCEDURE|Radiation Therapy|Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies\>6 MV may be utilized when appropriate to boost target localized centrally.
41038176|NCT03154801|OTHER|Paramedical care|Paramedical early detection of sexual dysfunction and sexual health counseling
41166597|NCT00392886|DRUG|methotrexate|Given IV
41166598|NCT00392886|DRUG|temozolomide|Given orally
41166599|NCT00392886|DRUG|thiotepa|Given IV
41166600|NCT00392886|DRUG|vincristine sulfate|Given IV
41166601|NCT00392886|PROCEDURE|autologous bone marrow transplantation|Given on day 0
41166602|NCT00392886|PROCEDURE|autologous hematopoietic stem cell transplantation|Given on day 0
41166603|NCT00392886|PROCEDURE|peripheral blood stem cell transplantation|Given on day 0
41166604|NCT00392886|RADIATION|radiation therapy|Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
41166605|NCT04011397|OTHER|Exercise intervention|Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting. Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.
41510955|NCT03688048|DEVICE|Sham negative ion generator|Placebo treatment with deactivated negative ion generator (1 hour, audible hum, no ions emitted)
40856393|NCT00252408|DRUG|Hormone replacement therapy|
40856394|NCT06514313|DRUG|Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine|Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion , 4 cycles.
40856395|NCT06514313|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 4 cycles
40856396|NCT02595294|PROCEDURE|Cervical Lateral Glide neural mobilization|Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
40856397|NCT03238625|DRUG|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 3:1
40856398|NCT03238625|DRUG|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 9:1
40856399|NCT03238625|DRUG|Lidocaine|Lidocaine injection
41038177|NCT06534398|DEVICE|Dental implant prosthesis with cantilever extension|A retrospective study on the radiographic and clinical findings of implant-supported dental prostheses with cantilever extensions in place and function for at least 10 years
41387245|NCT06274853|DRUG|Placebo|Placebo capsules
41387246|NCT04078893|OTHER|telephone recruitment|using telephone to recruit inactive donors on two different methods
41038178|NCT03618238|DRUG|Anlotinib|12 mg daily for continus 14 days every 21 days
41387247|NCT05638607|BEHAVIORAL|Intensified occupational therapy|The intervention is an intensified occupational therapy effort, which does not take time away from other occupational therapy efforts.
41038179|NCT03018405|BIOLOGICAL|NKR-2 cells|"In cohorts 1-6, the schedule of administration will be 3 NKR-2 doses administered with a 2-week interval. In absence of progressive disease at the first tumor assessment following NKR-2 administration (on Visit D29 for hematological tumors or on Visit D57 for solid tumors), and according to product availability, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval, at a dose of 1x109 NKR-2 cells per injection, or at the same dose of cycle 1 if it was below 1x109 NKR-2 cells.~Patients in cohorts 8-9 (solid arm) and 10-11 (hematological arm) of first segment will receive 3 treatment doses at 1x109 NKR-2 (cohorts 8 and 10) or 3x109 NKR-2 (cohorts 9 and 11) per injection, with a 1-week interval between each dose. A second cycle of three NKR-2 injections at the same dose as in 1st cycle will be administered 2 weeks after the third NKR-2 injection, and with a 2-week interval between each dose."
41387248|NCT01284816|PROCEDURE|bariatric surgery|The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
41387249|NCT03148327|DRUG|Durvalumab (MEDI 4736)|Early studies has shown to possibly reduce the growth of certain types of lung cancer
41387250|NCT03148327|RADIATION|Radiotherapy|Stereotactic Body Radiation Therapy (SABR)
41387251|NCT02757261|DEVICE|Laser|Low-level laser therapy administrated to acupoints
41387252|NCT02757261|DEVICE|Occlusal splint|Occlusal splint with expander
41387253|NCT02757261|DEVICE|Placebo laser|Placebo laser (Low-level laser therapy administrated to acupoints)
41387254|NCT01275521|DRUG|BONT-A intra-prostatic injection|"• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.~Interruption of the medical therapy 1 month after the injection;"
41387255|NCT01275521|DRUG|Optimized medical BPH treatment|Optimization of the medical therapy according to recent guidelines
41387256|NCT05557487|DIAGNOSTIC_TEST|Low dose computed tomography|"1. Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~2. Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~3. Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and \< 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening.~4. Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, including CEA, alpha-fetal protein, etc.~5. Check pulmonary function test."
41387257|NCT02989610|DEVICE|Omnidirectional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead.
41387258|NCT02989610|DEVICE|Directional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead.
41387259|NCT06133907|GENETIC|Serum|Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).
40856400|NCT03238625|DRUG|Sodium cloride 0.9%|Placebo
41038180|NCT04178733|DRUG|LY3493269 - SC|Administered SC
41038181|NCT04178733|DRUG|Placebo - SC|Administered SC
41387260|NCT05900739|BEHAVIORAL|Increase of fruit and vegetable consumption|"Week 1 Presentation of the program. Healthy eating Week 2 Fruit and vegetable: nutritional value, types, seasonality, benefits for health Week 3 Shopping Fruit and vegetable: tips, places, conservation methods Week 4 Healthy menu planning with My Plate Week 5 How to cook Fruit and Vegetable avoiding food waste Week 6 Healthy snacks using Fruit and vegetable Week 7 Batch cooking"
41387261|NCT05476276|DRUG|ISA specific|ISA specific interventions will be listed in their protocols.
41387262|NCT03347786|DRUG|Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure
41387263|NCT05226468|DRUG|NEI-01|"Part1:~Single dose period: Intravenous single dose of NEI-01 with 4 ascending dose levels.~Multiple dose period: Intravenous weekly dose of NEI-01 for 9 weeks with 4 ascending dose levels.~Part2:~Intravenous weekly dose of NEI-01 at the recommended dose obtained from Part 1"
41387264|NCT04889794|OTHER|GPS clinical intervention|Nurses and doctors in exposed FMGs and home care teams (HCTs) will be asked to refer to the FMG pharmacist all seniors undergoing cognitive evaluation OR referred to a memory clinic OR recently diagnosed with a cognitive disorder, for a complete and critical review of their medication therapy. FMG pharmacists will be asked to conduct an interview with each referred senior and his or her caregiver, if applicable, in order to establish the best possible treatment regimen. They will compare the information collected with another reliable data source (e.g., pharmacy records) in order to perform medication reconciliation and will then evaluate the medication related problems. Pharmacist will establish a care plan and the follow-ups to be carried out with the patient in collaboration with the health care team. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
41510956|NCT00761657|DRUG|Roxadustat|Capsule
40856401|NCT05325346|DRUG|VLX-1005|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
40856402|NCT05325346|DRUG|Argatroban|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
40856403|NCT01882699|DEVICE|Cereve Sleep System|cerebral hypothermia
41387265|NCT04803773|DEVICE|"UFOGUIDE patient transducer"|The transducer is maintained by a flexible/rigid structure, consisting of a support base, and three to four feet forming an arch around the area to be treated. These feet exist in several lengths (10, 20, 30, 40 cm) depending on the area to be treated and can be easily mounted on the base by fast attachment. The structure is based on the principle of granular jamming: it is flexible in its normal state, and can be stiffened by the application of depression within the feet.
41510957|NCT00761657|DRUG|Placebo|Capsule
41510958|NCT02215967|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
41510959|NCT02215967|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
41510960|NCT02215967|BIOLOGICAL|Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 15.0x10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
41387266|NCT02190383|BEHAVIORAL|Habit Reversal Training|awareness training, competing response training
41387267|NCT02364414|DEVICE|3Shape TRIOS (R)|Direct intra-oral scan of teeth and dentition
41510961|NCT01022697|OTHER|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
41387268|NCT03575325|DRUG|CPX-351|The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be performed through a central venous catheter, using an infusion pump to ensure that the drug is infused over the specified time period.
41510962|NCT06259435|BEHAVIORAL|Low-energy dense diet|Subjects will follow time-restricted eating of a low energy dense diet
41510963|NCT06259435|BEHAVIORAL|Usual diet|Subjects will follow time-restricted eating of the usual diet
41510964|NCT04957238|OTHER|ARBORea decision-making tool|Online ARBORea decision-making tool will guide the use of physical restraints in ICU patients based on objective information on neurological status, level of equipment related to critical illness, and patient's family presence and involvement in patient's surveillance.
41510965|NCT03578393|DEVICE|Virtual Reality Educational Program|The study group, in addition to providing the usual information about the anaesthetic-surgical process, will visualize an educational video through virtual reality glasses, of a maximum duration of 5 minutes. The video's explanation will be adapted according to the age ranges. Once the video is finished, if there aren't doubts, the visit will be concluded.
41510966|NCT00919295|DRUG|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
41510967|NCT00919295|DRUG|placebo|placebo
41510968|NCT04852029|OTHER|Low dose hCG|Patients will either maintain the current dose of have an increased dose prescribed based on randomization
41510969|NCT00706485|DEVICE|Yttrium-90 Plaque Applicator|Placed on the dura during surgery for 10-17 1/2 minutes
40856404|NCT03240094|OTHER|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
40856405|NCT01590693|DRUG|Botulinum toxin A|The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
40856406|NCT04152408|DEVICE|FiberSense System|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
41387269|NCT00874757|DRUG|Rosuvastatin|Healthy subjects received rosuvastatin 20 mg orally for 3 weeks. Inflammatory markers measured pre- and post- rosuvastatin treatment.
41510970|NCT03630380|OTHER|Clinical History|We will collect clinical history for each patient (days of illness, history of fever, cough, difficulty breathing, vomiting, chest pain).
41510971|NCT03630380|OTHER|Physical Exam Findings|We will collect physical exam findings including vital signs, WHO criteria for diagnosing pneumonia, and lung auscultation findings.
41510972|NCT03630380|OTHER|Laboratory Findings|We will collect laboratory findings (white blood cell counts, differential, and c-reactive protein) if ordered by the clinician.
41510973|NCT03630380|OTHER|Lung Ultrasound|We will perform lung ultrasound on all patients.
41510974|NCT04622241|OTHER|Eave Tubes|The eave tubes are PVC tubes with a diameter of 15 cm installed in the outer wall of occupied rooms (e.g. bedrooms and living rooms but not storage rooms) at 1.5-2 m intervals, fitted with electrostatic mesh inserts coated with insecticides. No additional screening will be done. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
41510975|NCT04622241|OTHER|Eave Ribbons|"Eave ribbons are 15 cm-wide triple-layered hessian fabrics (burlap-line fabric woven from sisal fibres, procured locally), in lengths starting 1 m that can be attached to houses using nails, adhesives or Velcro, without completely closing eave-spaces. The eave ribbons will be treated by study staff with a commonly used spatial repellent, transfluthrin. Eave ribbons will be retreated by study staff after 6 months (only in Phase II, if selected for inclusion in the cluster-randomised trial).~All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
41510976|NCT04622241|OTHER|Full House Screening|"Full house screening includes screening eaves/ceilings, ventilation openings, and windows. Eaves/ceiling, air vents, and windows of eligible houses will be screened with wire mesh or other locally available screening materials. or ceilings, if eaves are closed and ventilation openings. We are also filling in any gaps in the walls. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
41510977|NCT04622241|OTHER|Partial House Screening|Partial screening will include either screening of the eaves or installing a screened ceiling, where no ceiling is present. In traditional houses, a netting (either insecticide-impregnated or untreated) may be either fixed in multiple places in the rafters or by hanging from a single central point and attached to the walls. No other screening or filling of the gaps will be done in partially screened houses.All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
41038182|NCT04178733|DRUG|LY3493269 - IV|Administered IV
41038183|NCT00002411|DRUG|Nelfinavir mesylate|
41038184|NCT00002411|DRUG|Lamivudine|
41387270|NCT05918952|DIAGNOSTIC_TEST|Covid-19 Antibody Test|"The investigators propose to use the iHealth® Rapid COVID-19 Antigen Rapid Test. Per the EUA guidance, study participants will complete one test at a study location and receive one test to take home with instructions to complete it within 48 hours.~Each testing site will have a private designated space for customers to self-collect and test themselves privately. The edutainment video will serve as a resource for information on accurate test performance. Test one will be done in a private setting and results entered into REDcap and will also be written on a testing card with contact information for the purpose of follow-up. For test number two the customer will self-collect within 48 hours (per the FDA EUA for this particular test) and results will be entered into RedCap."
41387271|NCT05918952|OTHER|Short Clip videos|Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.
40856407|NCT05377619|DRUG|Prucalopride|prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
41387272|NCT01508325|DRUG|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (\>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was \>=90 mmHg measured every 4 weeks.
41387273|NCT01508325|DRUG|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was \>=140 mmHg and/or DBP was \>=90 mmHg measured every 4 weeks.
41387274|NCT05230160|OTHER|Intermittent Fasting|"Intermittent Fasting (IF) is a dietary intervention that involves periodic intervals of no or very limited energy intake. Fasting and feeding intervals vary and the practice of IF commonly consists of either a daily fast for 16 hours, a 24-hour fast on alternate days, or a fast two days per week on non-consecutive days.~For the study, the IF group will be asked to fast for 16 consecutive hours, 6 days per week. This means they will have an 8-hour eating window (e.g., eat from 10 a.m. to 6 p.m.) each day. They will be asked to eat the same types of food and the same amounts as usual, but only during the 8-hour eating window."
41387275|NCT06568783|DRUG|[18F]-FAPI-74|\[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
41387276|NCT03403712|DRUG|fosnetupitant/ palonosetron|intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
41387277|NCT03403712|DRUG|netupitant/palonosetron|oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
41387278|NCT03403712|DRUG|dexamethasone|Oral dexamethasone (12 mg)
41387279|NCT03464786|DEVICE|Lando® absorbable collagen membrane|Subjects who are fit for the study will be randomized to either intervention arms.
41387280|NCT03464786|DEVICE|Geistlich Bio-Gide resorbable bilayer membrane|Subjects who are fit for the study will be randomized to either intervention arms.
41387281|NCT05878405|OTHER|Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Given PO
41387282|NCT05878405|OTHER|Methylene Blue Oral Rinse|Given PO
41387283|NCT02850783|PROCEDURE|89Zr-nanocoll and Indocyanine Green|
41510978|NCT02852577|DRUG|Clonazepam|Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
41510979|NCT02852577|DRUG|Paroxetine|Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
40856408|NCT05377619|DRUG|Buspirone|buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
40856409|NCT05377619|DRUG|Placebo|placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner
40856410|NCT04714034|DIAGNOSTIC_TEST|"to develop and validate a scale measuring online dating addiction (ODA) in sexual minorities - the ODA Scale"|"Qualitative part: scale development and validation with testing in 3 different participant samples, i.e. preliminary testing (n=10), pilot testing (n=30-60), validation (n=300).~Quantitative part: longitudinal part conducted in the validation sample of the qualitative study part (n=300) with the aim to evaluate the association of ODA Scale scores with sexual health and mental health outcomes."
41038185|NCT00002411|DRUG|Stavudine|
40856411|NCT00946543|RADIATION|hypofractionated radiation therapy|
40856412|NCT00946543|RADIATION|intensity-modulated radiation therapy|
40856413|NCT03203083|OTHER|performance of the single leg squat task|The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
40856414|NCT03456232|OTHER|High-flux hemodialysis|High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.
40856415|NCT03456232|OTHER|Hemodiafiltration|Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.
40856416|NCT02215135|DRUG|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW\> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
40856417|NCT00825812|DRUG|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
41038186|NCT00002411|DRUG|Zidovudine|
41038187|NCT00002411|DRUG|Didanosine|
41387284|NCT05073302|PROCEDURE|Implantation of Nylon catheter (Device-less sentinel unit)|"Implantation of the Device-Less sentinel units. Ultrasound monitoring will be performed after Device-Less implantation. Standard Islet cell Transplantation: Will occur simultaneously Portal islet transplantation and subcutaneous islet transplantation in the Device-Less sentinel spaces.~Islets are maintained for a minimum of 6 hours up to 72 hours in supplemented CMRL1066-based media until the time of transplant.~Concomitant to portal vein infusion, islet transplantation will occur in all four (4) DL sentinel spaces.~To explant a unit, the Surgeon will make an incision and then carefully dissect the tissue engrafted around the transplant. The entire transplant site and any adherent tissue capsule can then be removed entirely from the pocket."
41387285|NCT02493985|OTHER|0.5% CO2|The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design
41510980|NCT01248676|OTHER|Multi-language Online Patient Education Module in addition to standard Patient Teaching|"Patients are usually be given a 5-10 minute new patient teaching before their radiation therapy simulation and planning appointment and before their first radiation therapy treatment appointment. Patients will be asked to view an online patient education module before their radiation therapy simulation and planning appointment or before their first radiation therapy treatment appointment. Then patients will be asked to participate in an interview session and fill out a survey (attached). They will still receive new patient teaching from the therapists before their radiation therapy simulation and planning or radiation therapy treatment appointment."
41510981|NCT06414356|DRUG|Ketamine|Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr. Participants will receive intravenous infusions of ketamine for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (ketamine 0.5 mg/kg IBW/hr)
41510982|NCT06414356|DRUG|Magnesium sulfate|Magnesium sulfate 3 grams will be diluted into 250 mL normal saline and infused at a rate of 62.5 mL/hr (over 4 hours until the entire contents are infused and then flushed with 20 mL of normal saline). The Mg only group will be randomly assigned to one of the treatment groups (moderate dose ketamine, or moderate dose ketamine +Mg) after 2 weeks and complete the full 24-week infusion treatment regime of the randomly selected treatment group in an outpatient setting.
41510983|NCT06414356|DRUG|Ketamine + Magnesium sulfate|Participants will receive intravenous infusions of ketamine and magnesium sulfate in combination. Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr Participants will receive intravenous infusions of ketamine and magnesium sulfate for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (Ketamine 0.5 mg/kg IBW/hr + magnesium sulfate 3 grams diluted into 250 mL normal saline)
41510984|NCT06582342|PROCEDURE|Three dimensional imaging technology (3D-PANC MSP model)|The processing of the CT images obtained in each center for the creation of the 3D model will be performed centrally by the team of radiologists and computer scientists of the company Cella Medical Solutions. This team will be blinded to the reports of the CT scans.For each patient 4 NCCN check-lists will be filled in without knowing the result of the surgery or the AP study: 2 based on the conventional CT and two based on the 3D-MSP study.
41387286|NCT02493985|OTHER|ambient air|The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
40856418|NCT00825812|DRUG|neostigmine|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
40856419|NCT03629353|PROCEDURE|endotracheal intubation|After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.
40856420|NCT03629353|PROCEDURE|high flow nasal cannula|After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
41038188|NCT04386096|OTHER|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommend tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
40856421|NCT04099784|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
40856422|NCT04099784|OTHER|Physical development and General Health|Physical development and General health examination
40856423|NCT04099784|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
40856424|NCT03781141|PROCEDURE|Wound closure|Comparison of two wound closures
40856425|NCT02481778|OTHER|Blood sampling|
40856426|NCT03591315|DIAGNOSTIC_TEST|resting state fMRI|Define the visual resting state network.
40856427|NCT03591315|DIAGNOSTIC_TEST|visual tasking state fMRI|Using visual task stimulation to identify the activation characteristic of primary visual cortex.
40856428|NCT03591315|DIAGNOSTIC_TEST|diffusion tensor imaging|Define the integrity of white matter fibers in the visual pathway.
41510985|NCT06582342|PROCEDURE|Computerized tomography group (conventional CT)|A multiphase CT (venous phase and pancreatographic phase) with 1mm thick slices and series of images in coronal, axial and sagittal reconstructions will be performed. This CT model will be performed at disease diagnosis and after completion of neoadjuvant chemotherapy treatment. Both CT scans will be independently reported by a radiologist from the hospital of origin. The preoperative CT scan will also be evaluated a posteriori by a radiologist from the sponsoring center with expertise in PAC. Both reports (the one from the radiologist of the center and the one from the radiologist of the sponsoring center) will be used to fill out the imaging study variables sheet based on the latest version of the NCCN 2022 guidelines. The radiologists will not know the outcome of the surgery or the anatomic pathology study at the time of the completion of the report.
41510986|NCT01072617|DEVICE|Transcranial magnetic stimulation via MagPro x100 device|"Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity.~Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system."
41510987|NCT00002422|DRUG|HE2000|
41510988|NCT03815214|BEHAVIORAL|Partial meal replacement program|Four meals consist of meal replacements made by OPTAVIA, such as shakes, soups, bars, biscuits, hot drinks, and puddings. Meal replacements will be provided to subjects without charge. For two other daily meals, subjects or their caregivers will be taught how to prepare meals consisting of 5-7 ounces (cooked) of a low-fat protein, 3 servings of non-starchy vegetables, and up to 2 servings of healthy fats.
41510989|NCT03815214|BEHAVIORAL|Dietary Counseling|Participants will receive one 45-minute counseling session on a healthy diet
41510990|NCT05800067|DRUG|axi-cel|Axicabtagene ciloleucel (Axi-cel) is an autologous anti-CD-19 chimeric antigen receptor(CAR) T-cell therapy approved by FDA in 2017 for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Now, it is the standard treatment for these patients recommended by NCCN and other guidelines. Axi-cel was approved for R/R LBCL patients who had received 2 or more prior lines of therapy on 2021 June in China.
41510991|NCT01478373|DRUG|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
41510992|NCT00002780|BIOLOGICAL|aldesleukin|
41510993|NCT00002780|BIOLOGICAL|cytokine therapy|
41510994|NCT00002780|BIOLOGICAL|sargramostim|
40856429|NCT03591315|DIAGNOSTIC_TEST|automated visual field|Identify the existence and type of visual field defect.
41510995|NCT00002780|DRUG|carboplatin|
41166606|NCT04011397|BEHAVIORAL|Usual care|Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management. Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.
41166607|NCT04498988|OTHER|Observational study without interventions|
41510996|NCT00002780|DRUG|cyclophosphamide|
41510997|NCT00002780|DRUG|thiotepa|
41510998|NCT00002780|PROCEDURE|peripheral blood stem cell transplantation|
41510999|NCT05600673|DRUG|Bimatoprost 0.03% solution|Topical Bimatoprost 0.03% solution
41511000|NCT05600673|DEVICE|CO2 fractional laser|CO2 fractional laser treatment
41511001|NCT02340481|DRUG|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
41511002|NCT02340481|DRUG|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
41511003|NCT02340481|DRUG|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
41511004|NCT02340481|DRUG|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
40856430|NCT03591315|DIAGNOSTIC_TEST|visual acuity|Assess the visual acuity by using ETDRS scales.
40856431|NCT01504685|PROCEDURE|Banded Laparoscopic Roux-en-Y gastric bypass|"A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
40856432|NCT01504685|PROCEDURE|Unbanded Laparoscopic Roux- en-Y gastric bypass|"A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
40856433|NCT04311762|DRUG|cisplatin|Intratumoral delivery of cisplatin via bronchoscopy (endobronchial ultrasound)
40856434|NCT06442670|DEVICE|Electroencephalography|Phase synchrony during the completion of the semantic memory task
40856435|NCT06029569|PROCEDURE|Rapamycin drug balloon angioplasty|Rapamycin drug balloon treatment for stenosis or blockage of the dialysis pathway in autologous arteriovenous fistula.
40856436|NCT06029569|PROCEDURE|Paclitaxel drug balloon angioplasty|Paclitaxel drug balloon therapy for stenosis or blockage of the dialysis pathway of autologous arteriovenous fistula.
40856437|NCT02436616|DEVICE|microEEG|"microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).~If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation."
41166608|NCT02778906|DRUG|Abatacept|Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis
41166609|NCT02778906|DRUG|Placebo|Administration of the comparator s.c. weekly in comparable to verum
41166610|NCT02822209|BEHAVIORAL|EORTC QLQ-C30|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
41511005|NCT04913142|OTHER|Fecal and oral samples|oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay
41511006|NCT00354692|DRUG|Sodium Ferric Gluconate and Iron sucrose|
41511007|NCT02292095|PROCEDURE|TAPB group|transverse abdominis plane block will be conducted by ultrasound and a single-injection of 20ml 0.75% ropivacaine will be conducted for nerve block at the end of surgery.After surgery,participants in this group will also receive patient controlled intravenous analgesia.
41511008|NCT02292095|PROCEDURE|PCIA group|The formula of patient controlled intravenous analgesia included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
41511009|NCT06432803|OTHER|PET-Scan analysis|Investigate and determine the clinical value of different cortex/striatal metabolic ratio patterns in each antibody-specific subtype of autoimmune encephalitis
41511010|NCT05098847|DRUG|Sintilimab|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
41511011|NCT05098847|DRUG|Lenvatinib|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
41511012|NCT05098847|DRUG|Cryoablation|Cryoablation treatment starts at day 0. Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
41511013|NCT00422604|DRUG|salmeterol|
41511014|NCT00422604|DRUG|tiotropium|
41511015|NCT00422604|DRUG|GSK233705|
41166611|NCT02822209|BEHAVIORAL|Satisfaction questionnaire - patient|The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
41511016|NCT02006732|DRUG|olodaterol|fixed dose combination
41511017|NCT02006732|DRUG|tiotropium|fixed dose combination
41511018|NCT02006732|DRUG|placebo|
41511019|NCT00346918|DRUG|Sirolimus|Standard plus Sirolimus
41511020|NCT00346918|OTHER|Standard|Standard
41166612|NCT02822209|BEHAVIORAL|Satisfaction questionnaire - general practitioner or home nurse|The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
41511021|NCT01522612|DRUG|Cetuximab|500 mg/m2 on day 1, Every 14 days Intravenously
41511022|NCT01522612|DRUG|5-fluorouracil|Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
41511023|NCT01522612|DRUG|leucovorin|Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
41511024|NCT02051621|DRUG|Antiarrhythmic drug|medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
41511025|NCT02051621|PROCEDURE|Cavo-tricuspid-isthmus-ablation|irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA
41511026|NCT02051621|PROCEDURE|Pulmonary vein isolation|pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
41511027|NCT01023035|DRUG|Boceprevir|800 mg given three times a day (TID), orally (PO)
41511028|NCT01023035|DRUG|Peginterferon alfa-2b (PEG2b)|1.5 µg/kg/week given subcutaneously (SC)
41511029|NCT01023035|DRUG|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
41511030|NCT01023035|DRUG|Erythropoietin|Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
40856438|NCT06142617|DRUG|Pembrolizumab, pemetrexed, platinum|Four cycles of platinum and pemetrexed in combination with pembrolizumab will be administered as first line therapy and up to 31 cycles pemetrexed and pembrolizumab maintenance therapy every 3 weeks.
41511031|NCT00524966|PROCEDURE|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
41511032|NCT03180645|OTHER|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
41511033|NCT03180645|OTHER|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
41511034|NCT03180645|OTHER|No treatment|No treatment
41511035|NCT05184452|DRUG|PGDM1400LS (5mg/kg, IV)|5 mg/kg to be administered via IV infusion
41511036|NCT05184452|DRUG|PGDM1400LS (20mg/kg, IV)|20 mg/kg to be administered via IV infusion
41511037|NCT05184452|DRUG|PGDM1400LS (20mg/kg, SC)|20 mg/kg to be administered via SC infusion
41511038|NCT05184452|DRUG|PGDM1400LS (40mg/kg, IV)|40 mg/kg to be administered via IV infusion
41511039|NCT05184452|DRUG|PGDM1400LS (40mg/kg, SC)|40 mg/kg to be administered via SC infusion
41511040|NCT05184452|DRUG|PGDM1400LS (1.4g, IV)|1.4gram to be administered via IV infusion
41511041|NCT05184452|DRUG|PGDM1400LS (1.4g, SC)|1.4gram to be administered via SC infusion
41511042|NCT05184452|DRUG|VRC07-523LS (20mg/kg, IV)|VRC07-523LS 20mg/kg administered via IV infusion
41511043|NCT05184452|DRUG|VRC07-523LS (20mg/kg, SC)|VRC07-523LS 20mg/kg administered via SC infusion
41511044|NCT05184452|DRUG|VRC07-523LS (1.4g, IV)|VRC07-523LS 1.4g administered via IV infusion
41511045|NCT05184452|DRUG|VRC07-523LS (1.4g, SC)|VRC07-523LS 1.4g administered via SC infusion
41511046|NCT05184452|DRUG|VRC07-523LS (40mg/kg, IV)|VRC07-523LS 40mg/kg administered via IV infusion
40856439|NCT06142617|DRUG|Osimertinib|Osimertinib will be the sequential treatment strategy at progression until resistance develops.
40856440|NCT00535002|DRUG|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
41038189|NCT04386096|OTHER|Mehealth for ADHD software with no medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) an online pediatrician report card; and 6) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
41038190|NCT03602118|DRUG|Phenobarbital Sodium Injection|Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
41387287|NCT03775382|OTHER|Ascorbic Acid|"Ascorbic acid will be infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
41387288|NCT03775382|OTHER|Normal Saline|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
41387289|NCT04898829|DIETARY_SUPPLEMENT|PKU explore|"For 28 consecutive days, participants will take their usual restricted therapeutic diet, either:~- Replacing their usual second stage concentrated protein substitute with PKU explore~OR~- Commencing PKU explore and gradually reducing their Phe-free formula for infants."
41387290|NCT05718882|DRUG|Lenvatinib Oral Product Plus VIC1911|"Lenvatinib: 8mg/day (≤ 60Kg), oral. VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral. 50mg bid is defined as DL(-1), 250mg bid is defined as DL(+1). A Bayesian Optimal Interval design schema will be followed to establish the maximum tolerated dose (MTD) of lenvatinib plus VIC-1911 combination and RP2D of VIC-1911 in HCC patients. The study would follow the Bayesian Optimal Interval Design with level size of 2 patients. The R package BOIN is available from CRAN."
41387291|NCT03155061|DRUG|ONO-4578|ONO-4578 specified dose on specified days
41387292|NCT03155061|DRUG|ONO-4538|ONO-4538 specified dose on specified days
41387293|NCT04776291|RADIATION|4D PET-CT Scan|The recruited patients will have a 4d PET-CT scan that is additional to the usual care.
41387294|NCT02418559|DRUG|JNJ-63623872 (300 mg)|Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
41387295|NCT02418559|DRUG|JNJ-63623872 (600 mg)|Participants will receive JNJ-63623872 600 mg (2\*300 mg) tablet orally once on Day 1 under fasted conditions.
41387296|NCT02418559|DRUG|JNJ-63623872 (1200 mg)|Participants will receive JNJ-63623872 1200 mg (4\*300 mg) tablet orally once on Day 1 under fasted conditions.
41387297|NCT02418559|DRUG|Placebo|Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
40856441|NCT00535002|DRUG|Placebo|
40856442|NCT00502008|DRUG|Coccinia Cordifolia (herbal extract)|
41387298|NCT05844995|DRUG|Acetaminophen/Naproxen Sodium|Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
41511047|NCT05184452|DRUG|PGT121.414.LS (20mg/kg, IV)|PGT121.414.LS 20mg/kg administered via IV infusion
40856443|NCT01865448|DIETARY_SUPPLEMENT|Omega-3 DHA|Patients take daily 2 tablets of Docosahexaenoic Acid
41166613|NCT02822209|BEHAVIORAL|EORTC QLQ-LC13|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
41511048|NCT05184452|DRUG|PGT121.414.LS (20mg/kg, SC)|PGT121.414.LS 20mg/kg administered via SC infusion
41511049|NCT05184452|DRUG|PGT121.414.LS (1.4g, IV)|PGT121.414.LS 1.4g administered via IV infusion
41511050|NCT05184452|DRUG|PGT121.414.LS (1.4g, SC)|PGT121.414.LS 1.4g administered via SC infusion
41511051|NCT05184452|DRUG|PGT121.414.LS (40mg/kg, IV)|PGT121.414.LS 40mg/kg administered via IV infusion
41511052|NCT05412953|OTHER|Questionnaire Administration|Complete questionnaire
41511053|NCT05412953|BEHAVIORAL|Tonation Breathing Technique|Participate in tonation breathing techniques
41511054|NCT05113745|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
41511055|NCT05113745|DRUG|Placebo|Placebo tablets, taken twice daily
41511056|NCT06550960|DEVICE|Evaluation of two biopsy systems|Each subject will have prostate biopsy taken in 6 locations in one lobe of the prostate and then biopsy in 6 locations in the other lobe of the prostate
40856444|NCT01865448|OTHER|Placebo|Patients in control group take daily 2 placebo capsule
40856445|NCT03683017|DEVICE|OrthoPulse 2.0|Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
40856446|NCT03683017|DEVICE|OrthoPulse 2.1|Patients are given OrthoPulse 2.1, an extended OrthoPulse device with zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
40856447|NCT03683017|DEVICE|Invisalign 3.5 Day Wear|Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.
41166614|NCT05465759|OTHER|disease|Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.
41387299|NCT01980082|DRUG|Cefazolin|Antibiotic
41387300|NCT01980082|DRUG|Placebo|Placebo
41387301|NCT00092651|DRUG|MK0653A, ezetimibe (+) simvastatin|
41511057|NCT06422936|DRUG|BO-112|Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
41511058|NCT00457132|DEVICE|APOS biomechanical gait system|
41511059|NCT00000543|BEHAVIORAL|dietary supplements|
41511060|NCT00000543|DRUG|calcium|
40856448|NCT03683017|DEVICE|Fixed Orthodontic Appliances (Braces)|Patients are fitted with a set of brackets and wires, as per standard orthodontic treatment by a qualified Principal Investigator (PI).
41387302|NCT00092651|DRUG|Comparators: simvastatin and ezetimibe|
41387303|NCT05044637|DRUG|Primaquine|7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
41387304|NCT05044637|DRUG|Primaquine|7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
41387305|NCT05044637|DRUG|Primaquine|14 days of unsupervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
41387306|NCT01248130|DRUG|Omega-3 Fatty Acid|Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
41387307|NCT05647733|PROCEDURE|Low splanchnic blood volume restrictive fluid management strategy|Hemodynamic goal-directed restrictive fluid management strategy.
41387308|NCT05647733|PROCEDURE|Optimized cardiac output liberal fluid management strategy|Permissive intraoperative hemodynamic goal-directed fluid management strategy that optimizes cardiac output throughout surgery
41387309|NCT05647733|PROCEDURE|Phlebotomy|Retrieval of blood in a blood donation bag performed prior to dissection and transfused back after graft reperfusion
41387310|NCT04594200|BEHAVIORAL|Audit and Feedback (A&F)|"In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing"
41387311|NCT02866409|PROCEDURE|scalp block|"In this group following nerves were blocked-~1. Supra-orbital nerve~2. Supra-trochlear nerve~3. Zygomatico-temporal nerve~4. Auriculo-temporal nerve~5. Posterior auricular branches of the greater auricular Nerve~6. The greater, lesser, and third occipital nerves"
41387312|NCT02866409|PROCEDURE|infiltration|The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
41387313|NCT02866409|DRUG|Dexmedetomidine|Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
41387314|NCT02866409|DRUG|Bupivacaine|20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
41387315|NCT00996632|PROCEDURE|ultrasonic knife (Ultracision®, Ethicon Endo Surgery)|mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
41387316|NCT00996632|PROCEDURE|conventional diarthermy knife|mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
41387317|NCT03291847|DEVICE|fetal monitoring|Maternal fetal monitoring
40856449|NCT02960464|DEVICE|Transcranial direct current stimulation|
41166615|NCT01723007|OTHER|Supplement|The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
41387318|NCT03291847|DRUG|Buprenorphine Naloxone|Treatment for opioid use disorder
41387319|NCT01080209|DRUG|Brimo PS DDS®|Patients who received Brimo PS DDS® intravitreal implant in a previous study.
41387320|NCT01080209|OTHER|Sham|Patients who recieved sham in a previous study.
41038191|NCT04749420|OTHER|Survey study|Cervical Radiculopathy Impact Scale (CRIS) will be applied
41038192|NCT02509533|DEVICE|V.A.C.®|Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.
41387321|NCT00832286|DRUG|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
41387322|NCT00577031|DRUG|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
41387323|NCT00577031|DRUG|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
41387324|NCT00577031|DRUG|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
41387325|NCT04311411|DRUG|Tirzepatide|Administered SC.
41387326|NCT04311411|DRUG|Placebo|Administered SC.
41387327|NCT04311411|DRUG|Liraglutide|Administered SC.
41387328|NCT06540040|DEVICE|Aquacel Ag|Aquacel Ag is a Hydrofibre wound dressing composed of non-woven sodium carboxymethylcellulose fibers integrated with ionic silver. It is designed to provide a moist wound environment and has antimicrobial properties to help reduce the risk of infection. The dressing will be applied post-operatively and changed according to a standardized protocol.
40856450|NCT02960464|DEVICE|Sham Transcranial direct current stimulation|
40856451|NCT04770272|DRUG|Atezolizumab 840 MG in 14 ML Injection|840 mg Day 1 for two weeks
40856452|NCT04770272|DRUG|Atezolizumab 1200 MG in 20 ML Injection|1200 mg Day 1 every 3 weeks for 8 cycles
40856453|NCT04770272|DRUG|Carboplatin|Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles
41038193|NCT02509533|DEVICE|dressing|Patients received usual dressing method (compresses) after a transplants of leg ulcers
41038194|NCT02958969|DRUG|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
40856454|NCT04770272|DRUG|Paclitaxel|Paclitaxel 80 mg/m² IV weekly x 12 cycles
40856455|NCT04770272|DRUG|Epirubicin|90 mg/m2, day 1 for 4 cycles (12 weeks)
41038195|NCT05017922|PROCEDURE|transarterial chemoembolization combined with endoscopic therapy|TACE: The tip of the catheter was advanced into tumor-feeding artery based on the tumor location and size. 5-Fu was injected. Then the chemolipiodolization was performed, using oxaliplatin, epirubicin and lipiodol. If stagnant flow did not realized, then injected pure lipiodol. If the tumor-feeding artery still cannot be completely embolized, several absorbable gelatin sponge particles would be injected. Endoscopic therapy: After the site of esophageal varices was identified by the gastroscopy, spiral ligation using the EVL device (COOK, MBL-6-F) was performed and ensure the varices were fully inhaled, 1-3 rubber bands were used totally. After EVL, water was sprayed to the ligation sites to check for bleeding. If gastric varices were found, EIS was performed using the 'sandwich method' of hypertonic glucose-tissue adhesive-normal saline. Make sure the needle entered the varieose vein before inject drugs, and repeated the injection if necessary.
41038196|NCT04560257|DEVICE|High flow nasal cannula HFNC|High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
41038197|NCT06485817|DRUG|Oxycodone|"3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later."
40856456|NCT04770272|DRUG|Cyclophosphamide|600 mg/m2, day 1 for 4 cycles (12 weeks)
40856457|NCT04770272|PROCEDURE|Biopsy Arm A|1st Biopsy two weeks after Baseline visit. 2nd Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 3rd Biopsy with tumor size greater 10 mm in diameter.
41038198|NCT06485817|DRUG|Placebo|"Pure saline was administered as the placebo condition.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later."
41038199|NCT06485817|BEHAVIORAL|Stress State Induction|"ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST).~The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting."
41038200|NCT06485817|BEHAVIORAL|Control State Induction|Two different control tasks matched to the stress conditions on key parameters outlined in the protocol.
41038201|NCT00303524|DRUG|Goserelin acetate|Injection 3.6 mg monthly
41038202|NCT00303524|DRUG|Goserelin acetate|injection 10.8 mg every 3 months
41038203|NCT06086730|DEVICE|blow bottle positive expiratory pressure|Water was poured into a 1 L plastic container until it reached a 10 cm height. A 30 cm long tube was put into the water in the bottle, 8 cm deep. The participants were instructed to close their mouths around the tubing in the apparatus for three seconds to produce bubbles, do this for a total of 10 breaths, perform two huffs, then cough. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized,Because it is a homemade device and can be used with less equipment and with more ease at home . patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes.
41166616|NCT01572298|DEVICE|allograft alone|use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
41166617|NCT01572298|DEVICE|allograft with autograft|use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
41387329|NCT06540040|DEVICE|OPSITE|OPSITE is a transparent waterproof dressing with a high Moisture Vapour Transmission Rate. It is intended to provide a protective barrier while allowing moisture vapor to escape, maintaining an optimal wound healing environment. The dressing will be applied post-operatively and changed according to a standardized protocol.
41387330|NCT06540040|DEVICE|MEPILEX POST OP BORDER|MEPILEX POST OP BORDER is a 4-layer foam dressing designed with flex technology for superior absorption and conformability. It helps manage exudate and protects the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
41387331|NCT06540040|DEVICE|Traditional Dressing|Traditional dressing involves the use of gauze pieces, surgical pads, and porous paper adhesive strips. This type of dressing is commonly used in post-operative care to absorb exudate and protect the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
41387332|NCT00903942|RADIATION|radiation therapy|1) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
41387333|NCT00903942|DRUG|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
41387334|NCT05367934|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch for stress
40856458|NCT04770272|PROCEDURE|Biopsy Arm B|1st Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 2nd Biopsy with tumor size greater 10mm in diameter.
40856459|NCT04770272|PROCEDURE|Surgery|After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.
40856460|NCT02531724|DRUG|Levosimendan|
40856461|NCT02531724|DRUG|Placebo|Sodium chloride
40856462|NCT04239651|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
40856463|NCT04239651|OTHER|Internet-Delivered Cognitive Behavior Therapy (iCBT)|Cognitive behavioral therapy (CBT) is an evidence-based, structured, intensive, time-limited, symptom-focused form of psychotherapy recommended for the treatment of major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured CBT delivered via the internet.
41511061|NCT05002439|OTHER|Multicomponent physical exercise program and a nutritional intervention|The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
41511062|NCT04998656|DEVICE|Werewolf FLOW 50|Use of Werewolf FLOW 50 electrocautery device during surgical treatment for ACL injury. This device is often used as standard of care when our other standard of care approach (use of no electrocautery device) is not used.
41511063|NCT04998656|OTHER|Control|Use of no electrocautery device during surgical treatment for ACL injury. This approach is often used as standard of care when our other standard of care approach (use of Werewolf FLOW 50 electrocautery device) is not used.
41511064|NCT01340131|DRUG|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
41511065|NCT01340131|DRUG|Combination Therapy|"Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily"
41511066|NCT02759393|DRUG|Dexlansoprazole|receiving 8-week PPI
41511067|NCT02759393|DRUG|Lansoprazole|receiving 8-week PPI
40856464|NCT04182672|DRUG|FX006|Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
40856465|NCT06482541|COMBINATION_PRODUCT|5 billion exosomes and saline solution microneedling|Participants will receive 5 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.
41511068|NCT00559533|DRUG|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
41511069|NCT06171100|DRUG|Tolvaptan|"Oral ingestion of low dose Tolvaptan (7.5mg daily) for management of inpatient hyponatraemia for 1st dose Tolvaptan group.~Oral ingestion of low dose Tolvaptan (7.5mg daily) or standard dose Tolvaptan (15mg daily) for 2nd dose Tolvaptan group."
41511070|NCT04348201|OTHER|foot reflexology|foot reflexology session which takes about 20 minutes. The position of the patient during reflexology session was a relaxed comfortable supine lying position. The therapist was sitting position at the level of the feet. The Session of reflexology was done on three points at both feet.
41511071|NCT04348201|DIETARY_SUPPLEMENT|dietary modification|diet must be rich in vitamins as fish and beans, calcium as milk and chess, low fat food through decrease oil in meals, high fiber food through all types of vegetables and fruits and restrict caffeine
41511072|NCT03561649|DRUG|Adalimumab|This trial will be conducted by rheumatologists who can follow patients with SpA and conduct this trial in good conditions and in accordance with regulatory and legal recommendations.
41511073|NCT01043887|DRUG|ridaforolimus|single oral dose administration 10 mg ridaforolimus
41387335|NCT01267968|DRUG|GSK2251052|1500 mg (dosing detailed in Arm description)
41387336|NCT00656019|DRUG|Vitamin D|0, 2000, 4000, and 6000 IU per day orally
41387337|NCT04641273|DRUG|BAY1817080|Tablet, intake orally.
41511074|NCT02568605|DIETARY_SUPPLEMENT|Prebiotic fibre|Oligofructose-enriched inulin (Synergy1)
41511075|NCT02568605|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
41511076|NCT02568605|BEHAVIORAL|Weight Loss|All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
41511077|NCT04786847|BIOLOGICAL|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-TLX591)
41511078|NCT05013125|DIAGNOSTIC_TEST|ENDO-AID CADe assisted Colonoscopy|ENDO-AID is a dedicated endoscopy Computer-Aided Diagnosis (CADe) system where suspicious lesions are automatically detected and highlighted on the main monitor in real-time, alerting the endoscopist during the procedure.
41511079|NCT02699073|DRUG|regorafenib|"160mg once daily during 3 weeks followed by 1 week off therapy.~Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity."
41511080|NCT01121081|DRUG|Alga Dunaliella Bardawil|4 capsules per day, 2 in the morning 2 in the evening for 3 month
41511081|NCT01121081|DRUG|Placebo|"Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month"
41511082|NCT05257057|DIAGNOSTIC_TEST|Immunohistochemical staining|Immunohistochemistry will be performed on the endometrial tissue specimens
41387338|NCT04641273|DRUG|Placebo for BAY1817080|Tablet, intake orally.
41387339|NCT04641273|DRUG|Placebo for Pregabalin|Capsule, intake orally.
41387340|NCT04641273|DRUG|Pregabalin|Capsule, intake orally. Starting dose 75 mg BID first week, increase to 150 mg BID in second week.
41511083|NCT01509274|BIOLOGICAL|Plasma|3 ml plasma injected once into the plantar fascia
41387341|NCT05432245|DEVICE|Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)|The cataract surgery will be performed first and if successful, only then will the MINIject be placed into supraciliary space.
41511084|NCT01509274|BIOLOGICAL|Saline|3 ml of saline injected once into the plantar fascia
41511085|NCT01509274|OTHER|Physiotherapy + heel cap|Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
41511086|NCT05972174|BIOLOGICAL|mRNA-1018 for H5N8|Sterile liquid for injection
41511087|NCT05972174|BIOLOGICAL|mRNA-1018 for H7N9|Sterile liquid for injection
41511088|NCT05972174|BIOLOGICAL|mRNA-1018 for H5 Only|Sterile liquid for injection
41511089|NCT05972174|BIOLOGICAL|mRNA-1018 for H7 Only|Sterile liquid for injection
41387342|NCT06025786|COMBINATION_PRODUCT|Benazir Nashonuma Program (BNP)|"Benazir Nashonuma Program (BNP)~Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy.~Conditional Cash Transfer (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
41166618|NCT04650659|DIAGNOSTIC_TEST|6-minute walk test part one|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. In patients who will accept an arterial line will be placed and blood gas will be analyzed.
41387343|NCT06334601|DIAGNOSTIC_TEST|Tests of upper airway collapsibility and muscle responsiveness.|"Upper airway collapsibility, upper airway muscle responsiveness and loop gain will be assessed during single study visit.~Polysomnography"
41387344|NCT00975338|OTHER|LIFEspan|Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.
41387345|NCT00975338|OTHER|Non-LIFEspan|Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.
41387346|NCT03659617|DEVICE|xenograft (BioOss Collagen)|Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)
41387347|NCT03916692|DIETARY_SUPPLEMENT|Carbohydrate drink|Meal replacement drink containing 200 kcal
41387348|NCT03916692|DIETARY_SUPPLEMENT|Energy smart Carbohydrate blend|Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
41387349|NCT03916692|DIETARY_SUPPLEMENT|Liquid Dextrose|Liquid Dextrose drink of 200 kcal
41387350|NCT00560573|DRUG|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
41387351|NCT00560573|DRUG|Cisplatin|"Cisplatin 75\* mg/m2 or 80\* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~\* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine"
41387352|NCT00560573|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
41387353|NCT00560573|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
41387354|NCT05636501|OTHER|Treat-to-target Prednisolone Taper|Systematic prednisolone taper
41387355|NCT05636501|OTHER|Usual care|Prednisolone taper performed by discretion of the patient's general practitioner.
41387356|NCT05437718|OTHER|Ropivacaine|Thoracic paravertebral block(TPVB) is performed on the patients who undergo the thermal ablation therapy.
41387357|NCT06539988|BEHAVIORAL|Clinician Coaching Sessions|PCPs will receive interactive coaching sessions from a Clinician Coach 2 months into the intervention period and again at 4 months into the intervention period.
41387358|NCT06539988|OTHER|Personalized text messages to patients|Drawing upon a library of messages that have previously been developed and refined, Veterans will receive 6 months of optimized text messages. The frequency of text messages will be determined based on feedback from Veterans in earlier phases of the research.
41387359|NCT06568198|DEVICE|Real tACS|α-tACS at a frequency of alpha band at S1
41387360|NCT06568198|DEVICE|Sham tACS|Sham tACS with no stimulation applied
41387361|NCT03828344|BIOLOGICAL|hUC-MSC suspension|Patients will be treated at dose of 0.75×10\^6 cells/kg of body weight (Cohort 1) or 1.5×10\^6 cells/kg of body weight (Cohort 2) via a single IV infusion using a blood transfusion kit.
41511090|NCT05972174|BIOLOGICAL|mRNA-1018 for H5 Only-CG|Sterile liquid for injection
41166619|NCT04650659|DIAGNOSTIC_TEST|6-minute walk test part two|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. No arterial line will be placed.
41387362|NCT03828344|BIOLOGICAL|Placebo|Placebo contains the same cell suspension as BX-U001 but without cells.
41387363|NCT06150131|OTHER|Exercise|Aerobic and strength exercise.
41387364|NCT06150131|OTHER|Exercise|Aerobic and strength exercise.
41387365|NCT05188118|DRUG|Cabozantinib|60mg oral once daily for 12 weeks
41387366|NCT05188118|DRUG|Ipilimumab|1mg/kg intravenous once every 3 weeks over 12 weeks
41387367|NCT05188118|DRUG|Nivolumab|3mg/kg intravenous once every 3 weeks over 12 weeks, then 480mg once every 4 weeks after
41387368|NCT05188118|DRUG|Lenvatinib|18mg oral once daily for 12 weeks
41387369|NCT05188118|DRUG|Everolimus|5mg oral once daily for 12 weeks
41511091|NCT06583161|BEHAVIORAL|Moderate drinking|Drink up to 16 grams of alcohol daily or almost daily \[repeated assessment center visit\] or 8-16 grams of alcohol 4 or more times per week \[web-based mental health questionnaire\]
41511092|NCT06583161|BEHAVIORAL|Quitting|No alcohol consumption
41511093|NCT06583161|BEHAVIORAL|Social drinking|Drink up to 16 grams of alcohol 1-2 days per week or drink 1-3 times per month or only on special occasions \[repeated assessment center visit\], or drink 8-16 grams of alcohol 2-3 times per week or drink 4 times per month or less \[web-based mental health questionnaire\]
41166620|NCT04650659|DIAGNOSTIC_TEST|1-minute sit-to-stand test|Measurement of: Number of repetitions, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured on the three anatomical locations mentioned above.
41511094|NCT06583161|BEHAVIORAL|Heavy/binge drinking|Drink more than 16 grams of alcohol daily or almost daily or more than 40 grams of alcohol 1-2 days per week \[repeated assessment center visit\], or 24 grams of alcohol or more 4 or more times per week or 40 grams of alcohol or more 2-3 times per week \[web-based mental health questionnaire\]
41511095|NCT05176873|DRUG|DZD8586|Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
41511096|NCT05176873|DRUG|Placebo|A single oral dose of placebo will be given.
41511097|NCT00298727|BEHAVIORAL|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
41387370|NCT06567964|PROCEDURE|Erector Spinae Plane Block(ESPB)|"ESPB was administered preoperatively under ultrasound guidance via a high-frequency linear probe (Sonosite M-Turbo, Fujifilm Sonosite Inc., USA) (Figure 1). The procedure was as follows:~1. Patient Positioning: The patient was positioned in the lateral decubitus position, with the side to be blocked uppermost.~2. Ultrasound Setup: A high-frequency linear ultrasound probe was placed in a parasagittal orientation over the transverse process of the lumbar vertebra at the level of surgery.~3. Needle Insertion: After skin disinfection with chlorhexidine, a 22-gauge, 100-mm needle (Stimuplex A, B. Braun Melsungen AG, Germany) was inserted in-plane to the ultrasound probe. The needle was advanced until the tip contacted the transverse process.~4. Injection: Following negative aspiration to ensure no vascular puncture, 20 mL of 0.5% bupivacaine was injected incrementally, with real-time ultrasound visualization to confirm the correct spread of the anesthetic solution."
41387371|NCT06567964|PROCEDURE|Wound infiltration|"Wound infiltration was performed by the surgeon at the end of the surgery via the following procedure:~1. Preparation: After hemostasis was achieved and before skin closure, 20 mL of 0.5% bupivacaine was prepared in a sterile syringe.~2. For infiltration, the anesthetic mixture was infiltrated into multiple layers of the surgical wound. This included the subcutaneous tissue and muscle layers, ensuring the even distribution of the anesthetic solution to cover the entire surgical area."
41387372|NCT06102967|BEHAVIORAL|delirium|Evaluation of delirium using the ICU Patient Ambiguity Assessment Form (CAM-ICU) 1 day, 2 days, 3 days, and 7 days after surgery
41387373|NCT05071209|DRUG|Elimusertib|Given PO
41387374|NCT06530706|DRUG|Esketamine|Esketamine 0.2mg/kg was pumped slowly after intubation, followed by 0.1mg/kg pumped until the end of the operation. In the PCIA pump, esketamine 1mg/kg was added to the sufentanil.
41387375|NCT06530706|DRUG|normal saline|Same volume of normal saline was pumped slowly after intubation, followed by the same volume of NS until the end of the operation. In the PCIA pump, only sufentanil was used.
41387376|NCT00803530|DRUG|ATO + Ascorbic acid|"ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution."
41387377|NCT03800134|DRUG|Durvalumab|1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
41387378|NCT03800134|OTHER|Placebo|Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
41387379|NCT03800134|DRUG|Carboplatin|Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
41511098|NCT00298727|BEHAVIORAL|ePBL|Online Problem-Based Course
41511099|NCT04488315|DRUG|Dexamethasone lipid microsphere plus ropivacaine|Local scalp infiltration solution will consist of 30ml miscible liquids containing 8 mg dexamethasone lipid microsphere, 150mg ropivacaine and normal saline.
41511100|NCT04488315|DRUG|Ropivacaine alone|Local scalp infiltration solution will consist of 30ml miscible liquids containing 150mg ropivacaine and normal saline
41511101|NCT03198676|DRUG|PrEP-001 6.4 mg|6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
41511102|NCT03198676|DRUG|PrEP-001 6.4 mg|6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
41511103|NCT03198676|DRUG|PrEP-001 3.2 mg|3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
41511104|NCT03198676|DRUG|Placebo|2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
41511105|NCT03198338|DRUG|0.25% Bupivacaine, 0.5mL/kg|Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
41511106|NCT03198338|DRUG|Normal Saline|0.9% Normal Saline
41166621|NCT04650659|DIAGNOSTIC_TEST|4-meters gait speed test|Measurement of: Time to complete the 4 meters course and calculation of the 4-meters-gait-speed.
41166622|NCT04650659|DIAGNOSTIC_TEST|Nailfold videocapillaroscopy|"Capillary density measurement of: The finger with the probe and the average of all the fingers.~NVC with 200 x magnification will be performed on the 2nd to 5th finger on both hands."
41166623|NCT04650659|DIAGNOSTIC_TEST|HR-pQCT|Imaging: One arm is scanned in a 9 mm-long volume of the distal radius (110 slices), and the distal part of the 2nd to 5th finger on both hands are scanned in a 36,08 mm-long volume (440 slices) at baseline and after 1 year.
41511107|NCT03198338|DEVICE|Ultrasound|Ultrasound guided TAP block
41511108|NCT06581991|DIETARY_SUPPLEMENT|Valine oral solution (50mg/ml) and isoleucine oral solution (25mg/ml)|Subjects will take valine oral solution (50mg/ml) in place of usual powdered valine supplement for 28 days. Subjects will then take isoleucine oral solution (25mg/ml) in place of their usual powdered isoleucine supplement for 28 days.
41511109|NCT00694200|DRUG|Vinorelbine|Vinorelbine per os 50 mg 3 times a week
41511110|NCT00694200|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 14 days
41511111|NCT02381184|DRUG|clomiphene citrate|receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
41511112|NCT02381184|PROCEDURE|laparoscopic ovarian drilling (LOD)|Laparoscopy was performed under general anesthesia, using three-puncture technique
40856466|NCT06482541|COMBINATION_PRODUCT|50 billion exosomes and saline solution microneedling|Participants will receive 50 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.
40856467|NCT05454657|DEVICE|Heart rate variability biofeedback + treatment as usual|"Heart rate variability biofeedback is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the baroreflex and increases heart rate variability.~Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation."
41387380|NCT03800134|DRUG|Cisplatin|75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
41166624|NCT04650659|DIAGNOSTIC_TEST|Hand x-ray|Imaging: Hand x-ray was performed on patients scanned with HR-pQCT, unless images were already available (≤ 1 year).
41166625|NCT04650659|DIAGNOSTIC_TEST|DEXA|Imaging: A bone density (DEXA) scan was performed on patients scanned with HR-pQCT, unless it was already available (≤ 2 years).
41166626|NCT05900401|OTHER|Bone Marrow Transplant|Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
41387381|NCT03800134|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
41387382|NCT03800134|DRUG|Paclitaxel|200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
41387383|NCT03800134|DRUG|Gemcitabine|1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
41387384|NCT03800134|PROCEDURE|Surgery|Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
41387385|NCT02827188|OTHER|Mega Team-videogame|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 30-35 minutes a day, approximately 5 days a week for a minimum of 21 days and a maximum of 25 days.
41387386|NCT06521138|BEHAVIORAL|Motivational interviewing group|The intervention group will receive motivational interviewing based on the transtheoretical model in addition to routine care. Motivational interviews are structured in line with the stages of change and behavioral change processes, which are the basic structures of the transtheoretical model. Three sessions of motivational interviewing with a session duration of 30 min will be implemented. Two sessions of motivational interviewing in the prenatal period and one session of motivational interviewing in the postnatal period.
41387387|NCT06521138|OTHER|Control group|Participants in the control group will receive routine care at the center.
41387388|NCT00590785|DRUG|Doxorubicin|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
41387389|NCT00590785|DRUG|Cyclophosphamide|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
41387390|NCT00590785|DRUG|G-CSF|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
41387391|NCT00590785|DRUG|tamoxifen|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
41387392|NCT00590785|DRUG|ciprofloxacin|High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
41387393|NCT04061057|DRUG|Lidocaine|"Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
41387394|NCT04061057|DRUG|Normal saline|"Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
40856468|NCT05454657|BEHAVIORAL|Treatment as usual only|Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
40856469|NCT06233565|DRUG|0.9%sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
40856470|NCT06233565|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
40856471|NCT06233565|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the popliteal nerve block
41387395|NCT00149773|BEHAVIORAL|Cognitive Therapy|
41387396|NCT05327790|DRUG|Lyophilized fecal microbiota (LFMT)|vedolizumab or ustekinumab + FMT vs placebo
41387397|NCT05327790|OTHER|Placebo|Placebo
40856472|NCT00344500|BEHAVIORAL|Behavioral Weight Loss Program|"Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient~* Be given a 7% weight loss goal~* Be assisted in obtaining a 500 calorie reduction per day~* Exercise for at least 30 min/day, at least 5 days a week~* Maintain weekly food and exercise diaries~* Be quizzed on their knowledge of healthy eating habits and nutrition"
40856473|NCT03785964|DRUG|Nirogacestat oral tablet|Nirogacestat tablet
40856474|NCT03785964|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic nirogacestat 50 mg tablet
40856475|NCT01811134|DEVICE|PIPELINE flow diverter stent|endovascular procedure using the medical device PIPELINE
40856476|NCT01811134|DEVICE|Coils, with or without expendable stent|endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
41387398|NCT03327532|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
41387399|NCT03327532|PROCEDURE|Cardio-pulmonary and peritoneal ultrasound|Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
41387400|NCT03327532|BIOLOGICAL|Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
41387401|NCT03327532|OTHER|Telephone interview|Telephone interview will be performed 3, 12 and 24 months after discharge from hospital
41387402|NCT03327532|BIOLOGICAL|Urinary sample retrieved for biological assessment and biobanking|Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital
41387403|NCT03327532|PROCEDURE|jugular and renal ultrasound (optional)|optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
41387404|NCT00567346|DRUG|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
40856477|NCT04912817|OTHER|Off the Shelf VR|"Operates using Oculus quest VR HMD and uses auditory and visual stimuli during the pain rehabilitation treatment. The Off-the-shelf VR program for Oculus Quest VR features a suite of off-the shelf applications that can be tailored by the PT and used with participants including. PR-VR sessions will be 30 minutes in total with approximately 20 minutes in the virtual experience and 10 minutes for set-up, screening, instructions, and rest breaks. The Off-the-shelf VR intervention group will also receive 30 minutes of usual care, and Standard Virtual Physiotherapy Treatment (SVPT) during the same appointment, for a total 1-hour usual care session length."
40856478|NCT04912817|OTHER|Custom VR|Operates using Oculus Quest VR HMD with PR-VR software developed with two gaming options: Fruity Feet and Space Burgers 2. Game settings are manipulated by the physiotherapist in session to target specific limb movements and intensity and also motivates participants to cycle using a leg ergometer. Motion sensors on the ergometer track the participants revolutions per minute. For participants in this study arm, a leg ergometer (DeskCycle) will be provided to them during the study phase alongside the Actigraph and Oculus Quest HMD. During the 30min VR portion of the session, 20 minutes will be dedicated to gaming and exercise, and 10 minutes dedicated for set up, tear down, and rest breaks. During the 20 minutes gaming time, a minimum of 15 minutes will be dedicated to Custom VR, with 5 minutes for 'free play' where the participant can opt to try an off-the-shelf VR game.
40856479|NCT03723772|DRUG|Insulin icodec|Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks
40856480|NCT03723772|DRUG|IGlar U100|Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.
40856481|NCT05195658|DEVICE|Thrombectomy and Stenting under neuroprotection|"Endovascular management of the stroke culprit lesion using the Micronet-covered CGuard stent under neuroprotection.~Transient flow achieved using a balloon guide catheter (e.g. MoMa or FlowGate) with additional active aspiration/s at key procedural steps. If indicated, targeted (extra- and/or intracranial) thrombus retrieval using either a thrombus aspiration device and/or a stentriever.~Use of pharmaco-sedation versus general anesthesia is as indicated clinically and is according to the anesthesiologist and operator decision - according to routine practice in the center.~Patient pre-procedural (including imaging and other diagnostic work-up), procedural, and post-procedural (including blood pressure tight control) management, including pharmacotherapy, are according to the AHA/ASA stroke management guidelines and the devices IFUs. Overall study patient management and intervention is according to routine clinical practice in the study center."
41038204|NCT06086730|DEVICE|acapella|"Make sure the frequency adjustment dial has been rotated counterclockwise to the lowest frequency-resistance setting before using the Acapella for the first time.On a chair, adopt a straight stance. maintaining a straight back and relaxing your elbows on a table. Now gradually tilt your head upward to maintain the opening of your upper airways.Inhale more deeply than you frequently do. Make sure your lips are encircling the mouthpiece, then blow into the device with a strong expiration.You should ideally blow out roughly twice as quickly as usual.For around ten breaths, keep going like this.Make careful to expel to clear the secretions from the airways after the final try. You can even conduct 2 to 3 huffs to improve secretion elimination when necessary.It should be noted that while using the device, you must be capable of exhale for a minimum of three to four seconds. patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes"
41038205|NCT06015321|DRUG|Enzalutamide|enzalutamide 160 mg PO daily
41387405|NCT00567346|DRUG|grass pollen extract|Patients will receive matching placebo sublingually
41387406|NCT01479556|DRUG|Pregabalin|Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
41387407|NCT01479556|DRUG|Placebo|150mg BID p.o.
41387408|NCT02632227|PROCEDURE|TFU(transfontanel ultrasound)|The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
41387409|NCT03943199|DIAGNOSTIC_TEST|Visual Analogue Scale for pain|Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.
41387410|NCT04461080|BEHAVIORAL|Community Health Worker|Trained Community Health Worker
41387411|NCT06065371|DRUG|Capecitabine|Capecitabine is a fluoropyrimidine that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase. Capecitabine is available in white or off-white tablets with doses of 500mg and 150mg doses. 500mg dose tablets will be used on this trial. Capecitabine will be ordered as a standard of care and provided commercially.
41511113|NCT00993356|DRUG|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection \[starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH \> 5 mU/L on GH day curve (GHDC)\] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
41511114|NCT00993356|PROCEDURE|Transsphenoidal surgery|
41387412|NCT06065371|DRUG|Sacituzumab govetican|"Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2-expressing cells and is covalently attached to the topoisomerase I inhibitor SN-38. Sacituzumab govitecan will be provided by Gilead Sciences.~Sacituzumab govitecan for injection, 180 mg and 200 mg, is available as a powder that is to be reconstituted with 20 mL of 0.9% Sodium Chloride Injection prior to intravenous infusion.~Following reconstitution, each single-dose vial of Sacituzumab govitecan results in a concentration of 10mg/mL with pH of 6.5."
41511115|NCT06454097|DIAGNOSTIC_TEST|Assess the response glioma to radiochemotherapy using radiogenomics-based AI model|Predict the radiochemotherapy sensitivity of patients with glioma using an established radiogenomics-based artificial intellegent mode
41511116|NCT02647697|DRUG|Radiprodil oral|"* Active Substance: Radiprodil~* Pharmaceutical Form: dry granules for oral suspension~* Concentration: 30 mg~* Route of Administration: oral use"
41511117|NCT05994885|PROCEDURE|Root surface debridement|the included patients will undergo full-mouth supra- and subgingival debridement by using ultrasonic device and manual instrumentation at baseline. This is followed, after 1 week, by performing root surface debridement for all pockets with PPD = 4-6 mm for each patient. All patients will be instructed to brush their teeth twice daily and will be supplied with the same type of tooth paste and toothbrush, with suitable interdental aids.
41511118|NCT04411914|DRUG|Clavulanic Acid|Drug will be given in 250mg capsules.
41511119|NCT04411914|OTHER|Placebo|Placebo
41511120|NCT03906422|DEVICE|3M Unitek 0.016 orthodontic archwire|Placement of 3M Unitek 0.016 archwire for orthodontic treatment
41511121|NCT03906422|DEVICE|"Device: 0.016 Ormco 27oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 27oC NiTi orthodontic archwire"
40856482|NCT01760343|BIOLOGICAL|Berinert|Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
41038206|NCT04325750|PROCEDURE|TECAR Therapy|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
41511122|NCT03906422|DEVICE|"Device: 0.016 Ormco 35oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 35oC NiTi orthodontic archwire"
41511123|NCT04639011|DRUG|Duloxetine|Three doses of 60 mg of oral duloxetine will be given to participants (right before operation, postop day 1, postop day 2)
40856483|NCT01760343|BIOLOGICAL|CSL830|CSL830 is a formulation of Berinert.
40856484|NCT04793113|OTHER|FreshlyFit Meals|FreshlyFit meals are low carbohydrate, high protein meals
40856485|NCT03587441|DRUG|Neostigmine Methylsulfate|20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution
40856486|NCT03587441|DRUG|Dextrose 5% in water|intrathecal
41038207|NCT04325750|OTHER|Placebo|simulated TECAR Therapy (machine off)
41038208|NCT03580733|DRUG|caspofungin antifungal therapy|caspofungin
41038209|NCT03580733|OTHER|placebo|placebo
41038210|NCT05324280|PROCEDURE|Acupuncture|Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture.
41038211|NCT02552004|DEVICE|pCLE|Histological examination by pCLE technique preceding the frozen section
41038212|NCT02552004|DRUG|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
41038213|NCT01764945|DRUG|BI 201335 (Reference)|soft gelatine capsule, oral administration
41038214|NCT01764945|DRUG|BI 201335 (Test)|oral solution 3
41038215|NCT01764945|DRUG|BI 201335 (Test)|oral solution 3
41038216|NCT01764945|DRUG|BI 201335 (Test)|oral solution 2
41038217|NCT01764945|DRUG|BI 201335 (Reference)|soft gelatine capsule, oral administration
41038218|NCT01764945|DRUG|BI 201335 (Test)|oral solution 1
41038219|NCT01764945|DRUG|BI 201335 (Test)|oral solution 1
41038220|NCT01764945|DRUG|BI 201335 (Test)|oral solution 2
41038221|NCT01575366|BEHAVIORAL|Tracking training|The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
41038222|NCT02425839|DEVICE|Ultrasound exam by Supersonic Shear Imaging® technique|Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.
41038223|NCT02425839|DEVICE|EMG examination by electromyograph Keypoint system|Experimented neurologist performs EMG examination.
41038224|NCT02287935|PROCEDURE|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
41038225|NCT02287935|PROCEDURE|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
41038226|NCT03185611|DRUG|Rifaximin|Antibiotics
41038227|NCT03185611|DRUG|Azathioprine|immunomodulator
41038228|NCT06236022|DRUG|Sirolimus|at a dose of 2 mg once daily
41038229|NCT05437380|DIAGNOSTIC_TEST|peritumoral microbubbles and contrast-enhanced ultrasonography|Inject 1ml microbubbles around the tumors. Then detect lymph vessel and lymph nodes under contrast-enhanced ultrasonography.
41038230|NCT05734560|DRUG|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
41387413|NCT03567200|BEHAVIORAL|Single-Arm Feasibility|Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
41511124|NCT04639011|OTHER|Placebo|Three doses of placebo will be given to participants (right before operation, postop day 1, postop day 2).
41387414|NCT06146504|DIETARY_SUPPLEMENT|CanXida Remove (Formula RMV)|Supplement composed of a 12 ingredient anti-fungal, anti-bacterial \& anti-parasite formula.
41387415|NCT06146504|OTHER|Placebo|Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.
41387416|NCT02296047|DRUG|Placebo|physiological saline
41387417|NCT02296047|DRUG|ipratropium bromide|80 µg inhalation once
41387418|NCT02296047|DRUG|salbutamol|400 µg inhalation once
41387419|NCT01093365|DRUG|Varenicline|"* 0.0 mg orally twice per day for three days (placebo)~* 0.5 mg orally twice per day for three days~* 1.0 mg orally twice per day for three days"
41387420|NCT03255226|DRUG|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
41387421|NCT00958698|OTHER|Communication Intervention|Ancillary studies
41387422|NCT00958698|OTHER|Educational Intervention|Ancillary studies
41387423|NCT00958698|OTHER|Internet-Based Intervention|Ancillary studies
41387424|NCT00958698|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
41387425|NCT00958698|OTHER|Quality-of-Life Assessment|Ancillary studies
41387426|NCT00958698|OTHER|Questionnaire Administration|Ancillary studies
41387427|NCT01382901|DRUG|Ferric Carboxymaltose (FCM)|
41387428|NCT01382901|DRUG|Placebo|
41511125|NCT04639011|OTHER|Standard of care (SOC) for tibial plateau surgery|Postoperative IV administration of opioids via a patient controlled analgesia (PCA) system which utilizes a hydromorphone pump.
40856487|NCT02200276|BIOLOGICAL|Influenza|
41038231|NCT05734560|DRUG|2141-V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
41038232|NCT06285877|PROCEDURE|Conventional therapy sessions|Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise.
41038233|NCT06285877|PROCEDURE|Conventional therapy sessions plus Nintendo Switch|Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise plus one hour a week of Nintendo Switch.
41387429|NCT00486642|DRUG|Bicalutamide|Given PO
41387430|NCT00486642|OTHER|Laboratory Biomarker Analysis|Correlative studies
41387431|NCT00486642|DRUG|Pazopanib Hydrochloride|Given PO
41038234|NCT00522158|DRUG|simvastatin|
41038235|NCT00522158|DRUG|atorvastatin|
41038236|NCT04898101|DRUG|Acalabrutinib|Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.
41387432|NCT00486642|OTHER|Pharmacological Study|Correlative studies
41387433|NCT04156282|PROCEDURE|knot burial technique|surgical suturing intervention
41387434|NCT04156282|PROCEDURE|classical closure|surgical suturing intervention
41387435|NCT05286983|BEHAVIORAL|Family Centred Care (FCC) interventions as potentially better practices (PBPs)|"After the previous period, additional Family Centred Care (FCC) elements will be introduced gradually every 6 months, covering staff training, parent education, psychosocial support for families, and last but not least, the neonatal intensive care unit environment.~The focus group consisting of nurses and healthcare professionals will meet regularly and will decide on new FCC interventions as potentially better practices (PBPs). New additional PBPs will be disseminated into the greater team through workshops, hands-on teaching, displays, etc. Potential PBPs for our department enclose:~Parent participation on rounds Parent skill self-assessment Parent-to-parent support Regular staff education Improvement of psychosocial support Improvement of neonatal unit surroundings to promote parent-infant-closeness"
41511126|NCT02771288|DEVICE|Bioresorbable Vascular Scaffold|
41511127|NCT01395927|DRUG|Rifampin|Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
41511128|NCT01395927|DRUG|Canagliflozin|Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
41511129|NCT05662956|DRUG|Venetoclax in combination with azacitidine and CAG|"Induction:~VA regimen：~Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21);~Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.~CAG regimen：~Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7;~Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7;~Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×10\^9/L；~Consolidation:~Drug: Cytarabine 3g/m2 q12h on days 1-3."
41511130|NCT01476514|OTHER|No intervention|The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
41511131|NCT06277089|OTHER|Casts|According to level of scoliosis cast done and recast in a serial manner
41387436|NCT03849079|OTHER|Hyponut|Prick tests with hyponut
41038237|NCT04898101|DRUG|Microtracer [14C]ACP-196|Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.
41038238|NCT04104867|DRUG|Itopride|the patients are instructed to take one pill of Itopride at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
41038239|NCT04104867|DRUG|Domperidone|the patients are instructed to take one pill of Domperidone at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
41038240|NCT04104867|OTHER|Placebo|the patients are instructed to take one pill of placebo at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
41038241|NCT02930239|OTHER|Gait rehabilitating with reduced bodyweight|Patients will perform 8 sessions of gait rehabilitation with reduced bodyweight using the anti gravity treadmill during week 2-5 post-surgery.
41038242|NCT02930239|OTHER|Standardized rehabilitation following an anterior cruciate ligament reconstruction at Linkoping University Hospital|Exercises for increased movement and circulation performed on a daily basis.
41038243|NCT01562574|DRUG|activated recombinant human factor VII|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
41038244|NCT01562574|DRUG|placebo|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
41038245|NCT03414138|BEHAVIORAL|Mindfulness Training|A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] will be used to teach patients to independently practice mindfulness meditation.
41038246|NCT03414138|BEHAVIORAL|Book Listening Control|Study volunteers will listen to four 20 minute blocks of The Natural History and Antiquities of Selborne throughout their interventions.
41038247|NCT00611143|DRUG|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
41038248|NCT05794269|OTHER|TQoR-15 questionnaire|The TQoR-15 questionnaire (Turkish version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
41038249|NCT00838110|DRUG|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 26
41387437|NCT02981667|OTHER|Exercise intensity|Participants were randomized to 1 or 2 exercise intensities, moderate or high (interval training).
41387438|NCT05837130|OTHER|Blood sample collection and an optional cerebrospinal fluid (CSF) collection|No study drug will be administered to study participants.
41387439|NCT05837130|OTHER|Blood sample collection|No study drug will be administered to study participants.
41387440|NCT00705796|DRUG|MPP10, testosterone|Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
41387441|NCT00705796|DRUG|Testosterone|AndroGel® 50 mg, once daily in the morning after washing/showering.
41511132|NCT02680951|DRUG|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
41511133|NCT02680951|DRUG|Fludarabine|"30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
41387442|NCT01413685|OTHER|Pharmacokinetics/dynamics|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
41387443|NCT03933982|DRUG|Pyrotinib Plus Vinorelbine|Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
41387444|NCT06569108|DRUG|KN057|KN057 will be administered subcutaneously once a week.
41511134|NCT02680951|DRUG|Cytarabine|"2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
40856488|NCT02286635|DRUG|Deflazacort and rifampin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
40856489|NCT02286635|DRUG|Deflazacort and Clarithromycin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
40856490|NCT05230784|OTHER|AirOk Air Purifier|The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold.
40856491|NCT05230784|OTHER|Placebo Air Filter|Participants in the placebo arm will receive an air purifier with only the EGAPA filter.
40856492|NCT04327726|DRUG|Dexmedetomidine Nebulization|ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment
40856493|NCT04327726|OTHER|0.9% Saline Nebulization|nebulization of 4mL 0.9% saline
40856494|NCT01522300|OTHER|Evaluation of the Tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study.
40856495|NCT01522300|OTHER|Avaluation of a medical device: the tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study
40856496|NCT01574651|DRUG|QVA149|QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
40856497|NCT01574651|DRUG|Placebo to tiotropium|Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules
40856498|NCT01574651|DRUG|Placebo to formoterol|Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.
40856499|NCT01574651|DRUG|Tiotropium|Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.
40856500|NCT01574651|DRUG|Formoterol|Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.
40856501|NCT01574651|DRUG|Placebo to QVA149|Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
41387445|NCT03192566|DRUG|Tylenol|Dosing of Tylenol for post operative pain control
41038250|NCT00838110|DRUG|Placebo|10 mg TID for week 1 followed by 20 mg TID through Week 26
41038251|NCT00838110|DRUG|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 12
41387446|NCT04439097|OTHER|Multicomponent physical exercise program associated with a Mediterranean diet|"In this basic structure of each sessions, traditional exercises of mobility, strength, balance and coordination are included with the main objective of improving functional capacities. But, besides, games and some activities are also included with the aim, not only of improving the functional capacity, but also working the cognitive functions to reinforce the global effects.~The Mediterranean diet will based in these main foods: 1) vegetables; 2) fruits; 3) fish or seafood; 4) legumes; 5) nuts; 6) bread or cereals; 7) white meat; 8) eggs; and 9)olive oil."
41387447|NCT04439097|OTHER|Usual care|Usual care and participants continue with their life normally, without participating in a standardized exercise program, and they will be instructed to maintain their current physical activity level.
41511135|NCT02680951|DRUG|Idarubicin|"8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
40856503|NCT02479815|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP)|Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
41038252|NCT00838110|DRUG|Placebo|20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
41038253|NCT00530361|DRUG|Nesiritide|
41038254|NCT06326801|OTHER|Resistive Diaphragmatic breathing exercise|"1. Resistive Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
41038255|NCT06326801|OTHER|Diaphragmatic breathing exercise|"1. Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
41038256|NCT06326801|OTHER|Conventional stroke physiotherapy|Conventional stroke physiotherapy
41387448|NCT04877535|DEVICE|ML-based report card|PACU and ward providers caring for participants will be notified by Anesthesia Control Tower clinicians before arrival if the patient's report card. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.The ML risk profile generated for each patient will include risk of 30 day mortality, risk of respiratory failure, risk of acute kidney injury, and risk of postoperative delirium
41387449|NCT05080218|DRUG|Upadacitinib|Hold UPA x 2 weeks at time of COVID booster
41387450|NCT05080218|DRUG|Abatacept|Hold SQ ABA x 2 weeks at time of COVID booster
41387451|NCT05080218|DRUG|Secukinumab|Hold SEC x 2 weeks at time of COVID booster
41387452|NCT05080218|DRUG|Tofacitinib|Hold TOF x 2 weeks at time of COVID booster
41387453|NCT05080218|DRUG|TNF Inhibitor|Hold SQ TNFi x 2 weeks at time of COVID booster
41387454|NCT05080218|DRUG|Canakinumab Injection|Hold CAN TNFi x 2 weeks at time of COVID booster
41387455|NCT05080218|DRUG|Baricitinib|Hold BAR x 2 weeks at time of COVID booster
41387456|NCT05080218|DRUG|Ixekizumab|Hold IXE x 2 weeks at time of COVID booster
41511136|NCT02680951|DRUG|Intrathecal (IT) cytarabine|"Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~* 30 mg for patients age 1 - 1.99~* 50 mg for patients age 2 - 2.99~* 70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment."
40856504|NCT05501834|OTHER|Supracondylar Pin Removal Before Imaging|Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider. The order of these steps differs from our current standard of care, during which patients' pins are removed following cast removal and x-ray imaging.
40856505|NCT03842449|DIAGNOSTIC_TEST|BabyCO|An expired CO measurement will be performed by BabyCO and the result will be returned to the smoking pregnant woman by the consultant.
41166627|NCT05900401|PROCEDURE|Peripheral Blood Stem Cell Collection|PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.
41166628|NCT05900401|DRUG|Fludarabine|Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)
41166629|NCT05900401|DRUG|Cyclophosphamide|Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4
41387457|NCT03141931|DIETARY_SUPPLEMENT|Supplement|Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
41387458|NCT03141931|DIETARY_SUPPLEMENT|Placebo|polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
41387459|NCT02453282|BIOLOGICAL|MEDI4736 (Durvalumab)|
41387460|NCT02453282|BIOLOGICAL|MEDI4736 (Durvalumab)+Tremelimumab|
41387461|NCT02453282|DRUG|Paclitaxel + Carboplatin|Chemotherapy Agents
41387462|NCT02453282|DRUG|Gemcitabine + Cisplatin|Chemotherapy Agents
41387463|NCT02453282|DRUG|Gemcitabine + Carboplatin|Chemotherapy Agents
41387464|NCT02453282|DRUG|Pemetrexed + Cisplatin|Chemotherapy Agents
41387465|NCT02453282|DRUG|Pemetrexed + Carboplatin|Chemotherapy Agents
41387466|NCT02453282|BIOLOGICAL|Tremelimumab|
41387467|NCT06562712|PROCEDURE|Conventional management|Patients will be subjected to conventional management for placenta accreta spectrum.
41387468|NCT06562712|PROCEDURE|Bilateral internal iliac artery balloon occlusion|Patients will be subjected to bilateral internal iliac artery balloon occlusion for placenta accreta spectrum.
41387469|NCT01483612|BEHAVIORAL|Interdisciplinary lifestyle intervention|"Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.~The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity."
41387470|NCT04219956|OTHER|Polyamine Deficient Diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
41387471|NCT03733184|PROCEDURE|Cytoreduction and Heated Intraperitoneal Surgery|Cytoreductive Surgery is a procedure that aims for the complete removal of all visible tumours affecting the protective lining of the abdomen. After the surgical procedure is completed, the surgeon introduces a heated, sterile solution mixed with chemotherapy drugs into the abdominal cavity (the HIPEC).
41387472|NCT01965431|DRUG|BI 207127|Medium dose oral administration
41387473|NCT01965431|DRUG|BI 207127 placebo|
41387474|NCT01965431|DRUG|Faldaprevir placebo|
41387475|NCT01965431|DRUG|Faldaprevir|Medium dose oral administration
41387476|NCT01965431|DRUG|Moxifloxacin (Avalox®)|
41387477|NCT03501017|OTHER|physical activity program|"The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).~Application of WHO Smoking Cessation Algorithm: After fagerström test was applied, the modified smoking cessation algorithm of WHO was applied to the individuals and those who decided to quit smoking were referred to smoking cessation outpatient clinics."
41387478|NCT03501017|OTHER|Routine Practice|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
41387479|NCT06560996|OTHER|Very low calorie diet with low protein content (VLCD-LP group)|Very low calorie diet (850 kcals per day) with low protein content (10%)
41387480|NCT06560996|OTHER|Very low calorie diet with high protein content (VLCD-HP group)|Very low calorie diet (850 kcals per day) with high protein content (30%)
41511137|NCT04522726|DRUG|Weiyang Yuping Fang|Weiyang Yuping fang is a combination of the classic ancient Yuping dispersion used to prevent qi deficiency and susceptibility and Bushen Naqi granules optimized formated by Professor Shao Changrong's experience in treating chronic cough and asthma.
41511138|NCT03767582|RADIATION|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
41511139|NCT03767582|DRUG|Nivolumab|Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
40856506|NCT03842449|OTHER|Biological samples|"The nature of the samples taken during the delivery are:~* maternal blood,~* cord blood~* placenta fragment"
40856507|NCT04569227|DRUG|EC-18|2000 mg PO daily
40856508|NCT04569227|DRUG|Placebo|PO daily
40856509|NCT04927403|OTHER|multimodal integrative naturopathic therapy concept|Use of conventional medicine, naturopathic approaches and complementary medical therapy methods
40856510|NCT06359080|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 10 weeks.
40856511|NCT05388617|DEVICE|Brera|The applicators will be placed in contact with the skin. The entire defined treatment area will then be treated by delivering energy to the skin. Temperature may be continuously monitored and recorded during treatment. Parameters may be adjusted throughout the treatment to increase subject comfort.
40856512|NCT05791227|DIAGNOSTIC_TEST|Sonographer Evaluation|A sonographer will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
40856513|NCT05791227|DIAGNOSTIC_TEST|AI Evaluation|An AI model will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
40856514|NCT05260762|DIETARY_SUPPLEMENT|Arabinoxylan|Dietary fiber product
41387481|NCT00965263|BIOLOGICAL|Cocaine vaccine (TA-CD)|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
41387482|NCT01027026|OTHER|Early discharge|The patients are discharged the same day as coronary angiography.
40856515|NCT05260762|DIETARY_SUPPLEMENT|Control|Potato starch
40856516|NCT00006133|DRUG|estradiol|
40856517|NCT00006133|DRUG|ethinyl estradiol|
40856518|NCT00006133|DRUG|medroxyprogesterone|
40856519|NCT00006133|DRUG|norethindrone|
40856520|NCT04584437|OTHER|Infrared Energy and Dietary Supplement|Infrared Energy with a wavelength of 5 - 20 microns. Multivitamins and minerals including Vitamin C Supplements.
41166630|NCT05900401|DRUG|Rituximab|Rituximab on study day -6
41387483|NCT01027026|OTHER|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
41387484|NCT05736952|DRUG|Oral Topotecan Combined With Anlotinib|Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.；Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment.
41387485|NCT01738009|OTHER|Induction of flow limitation|
41387486|NCT03169660|DRUG|Vascular endothelial growth factor trap-eye|Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
41387487|NCT04440631|OTHER|no intervention, observational only|no intervention, observational only
41511140|NCT03767582|DRUG|CCR2/CCR5 dual antagonist|CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
41511141|NCT03767582|DRUG|GVAX|Vaccine (5x10\^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
40856521|NCT04373005|DIAGNOSTIC_TEST|Nasopharyngeal (NP) swab|A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.
40856522|NCT04650386|BEHAVIORAL|Psychosocial support determined by adaptive treatment algorithm|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
41038257|NCT06530277|BEHAVIORAL|REMINDer (A digital environmental enrichment intervention)|"REMINDer adapts the REMIND program (Nicotra et al., 2022) for telehealth, integrating cognitive, motor, sensory, emotional, and social stimulation through music, dance-based movement, and mindfulness. The program consists of 2 online sessions/week for 60 minutes each over 6 weeks, led by trained facilitators experienced in dance movement therapy and mindfulness exercises. Sessions are divided into welcome/warm-up (10 min), training (40 min), and relaxation/feedback (10 min) phases. Using a structured manual, participants perform exercises that address the program's multimodal stimulation. The REMINDer program is delivered in a group setting via an online videoconferencing system. The intervention, no intervention (AB) group undergoes the training program between t1 and t2 and then resumes their normal lifestyle from t2 to t3. The no intervention, intervention group (BA) maintains its normal lifestyle from t1 to t2 and then participates in the training program from t2 to t3."
41387488|NCT05719844|DIAGNOSTIC_TEST|Neuropsychological tests|"List of neuropsychological tests:~* Matrix reasoning~* D2-R~* Coding~* Symbol search~* Digit span~* Alertness (computerized TAP battery)~* Divided Attention (computerized TAP battery)~* Go / No go (computerized TAP battery)~* Incompatibility (computerized TAP battery)~* Working memory (computerized TAP battery)~* 16-item Free and Cued Recall or Stories subtest of the Children Memory Scale (CMS) for children only (\< 17 years old)~* complex figure of the memory efficiency battery 144 or Word pairs of the Children Memory Scale for children only (\< 17 years old)"
41387489|NCT04676607|DRUG|SHR7390|SHR7390
41511142|NCT04343131|BEHAVIORAL|Dietary intervention|Crossover dietary manipulation using three different types of diet for 7 days each
40856523|NCT00008229|BIOLOGICAL|filgrastim|
40856524|NCT00008229|DRUG|melphalan|
41038258|NCT06281548|BEHAVIORAL|RESTART|Project RESTART (Resisting STigma And Revaluating your Thoughts) is a theory-informed, 4-week automated text message intervention to address self-stigma in people who use drugs. The intervention delivers two daily messages to participants for four weeks (56 messages total). Messages address the four components of the personal level of Stigma Resistance Theory: Not believing stigma/catching and challenging stigmatizing thoughts; empowering oneself through learning about substance use and one's own recovery; maintaining one's recovery and proving stigma wrong; and developing a meaningful identity and purpose apart from one's substance use. Content is informed by evidence-based psychotherapeutic approaches (e.g., Acceptance and Commitment Therapy) and health communication theory (e.g., Elaboration Likelihood Model). Messages include psychoeducation about substance use and stigma, coping advice, and suggestions for how to set personal goals, identify values, and build self-esteem.
41038259|NCT00307827|DRUG|Visilizumab|Visilizumab administered intravenously once per day for two days
41387490|NCT04960254|BEHAVIORAL|internet gaming addiction|"The Strengths and Difficulties Questionnaire (SDQ) parent : to asses behavioural change Socioeconomic Scale:It contains four main variables:1-The educational level of the father and mother.2-The occupation of the father and mother. 3-Total family income. 4-life style of the family.~Emotional Avoidance Strategy Inventory for Adolescents (EASI):The EASIA is a 17-item (Kennedy \& Ehrenreich-May 2017) measure assessing the use of emotionally avoidant strategies in adolescents.~The internet gaming addiction scale : t is used to evaluate internet gaming addiction."
41038260|NCT00843167|DIETARY_SUPPLEMENT|broccoli sprout extract|Given orally
41038261|NCT00843167|OTHER|placebo|Given orally
41038262|NCT04509947|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels.
41038263|NCT04509947|BIOLOGICAL|Placebo|Placebo will be administered as IM injection.
41166631|NCT05900401|DRUG|Siplizumab|Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.
41166632|NCT04937036|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
41166633|NCT02852278|OTHER|Web-based Survey|This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.
41166634|NCT00702650|DRUG|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 120 days
41387491|NCT06568913|DIAGNOSTIC_TEST|CBC|Platelets counts in pediatric patient with perisistent or chronicITP unresponsive to steroids
41387492|NCT02344459|DEVICE|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
40856525|NCT00008229|PROCEDURE|peripheral blood stem cell transplantation|
40856526|NCT00008229|RADIATION|holmium Ho 166 DOTMP|
40856527|NCT04027894|DRUG|Rifamycin SV MMX|200 mg Rifamycin SV-MMX® (CB-01-11)
41166635|NCT04685109|DEVICE|Alocross 0.2% Unit Dose|Eye Drops
41166636|NCT04685109|DEVICE|Vismed|Eye drops
41166637|NCT02230709|OTHER|Dry Needling|Needling with acupuncture needle in a myofascial trigger point.
41166638|NCT02230709|OTHER|"TENS and dry needling"|Application of TENS current after dry needling technique
41166639|NCT03739255|DEVICE|Cacicol20|Cacicol20 is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate One drop is instilled at each application to impregnate cornea.
41511143|NCT02536846|DRUG|Olanzapine|All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
41511144|NCT03750292|DEVICE|HEPAirX air filter|It is a trademarked, patented (U.S. Patent # 7,802,443), U.S. FDA approved Class II medical re-circulating air cleaner, built by Air Innovations, Inc. (North Syracuse, NY) to provide improved indoor air quality in the bedrooms of asthmatic children. Units to be used in the proposed study have a 99.97% efficient filter for particles 0.3 µm in size. The device provides a clean air delivery rate (CADR) of 9 per hour with 1.8 of them being outdoor air.
40856528|NCT04027894|DRUG|Placebo to Rifamycin SV-MMX|Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
41387493|NCT06039878|BEHAVIORAL|Bonding-Evoked Oxytocin|Mother participates in bonding activity with infant at ages 1, 3, and 6 months
40856529|NCT02425514|DEVICE|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
40856530|NCT02425514|DEVICE|NovoMax™|The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
41038264|NCT05086367|OTHER|Diaphragmatic and pursed lip breathing|Breathing exercises were performed. Two breathing techniques were applied to the participants. Diaphragmatic and pursed lip breathing were intervened along with routine physical therapy.
41166640|NCT03739255|DEVICE|Placebo|Ocluac is artificial tear which contains Hydroxypropylmethyl Cellulose and Sodium Chloride, It is presented in a 0.4 mL vial. One drop is delivered at each application.
41387494|NCT06039878|BEHAVIORAL|Distress Relieving Effects of Sucrose|Researcher elicits distress in the infant (sequence of unswaddling, pacifier removal, and arm restraint), followed by delivery of oral sucrose in one condition and water in other condition
41387495|NCT06039878|BEHAVIORAL|Hedonic Response to Sucrose|Researcher gives infant opportunity to suck from two bottles, one containing sucrose and one plain water at infant ages 1, 3, and 6 months
41387496|NCT06039878|BEHAVIORAL|Typical versus Challenging Feeding-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) regular size nipple versus smaller aperture nipple ('challenging') and (2) providing social interaction while feeding versus not.
41387497|NCT06039878|BEHAVIORAL|Caloric Compensation-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) offering a bottle feeding ad lib for 3 hours versus offering a bottle feeding every hour for 3 hours; (2) providing social interaction while feeding versus not.
40856531|NCT06369116|DEVICE|INSTI HCV Self Test|"Each participant will be presented with a packaged self-test and asked to conduct self testing. The Trained Observer will only watch the participant process at a short distance and take notes on the process; at no point will the observer respond to questions or assist with the testing process - only to encourage the participant to try to figure out the process as best they can use the instruction sheet.~The participant will then be permitted to perform the self-test and read their self test result. The observer is also going to observe the test result interpreted by the lay user and also themselves. After this step is complete, the Trained Observer will then perform fingerstick sample collection from lay user and run the sample on INSTI® HCV Self Test. The Trained Observer will then draw a venous whole blood sample from the participant for laboratory testing and final diagnosis will be given to the participant once laboratory results have been received."
40856532|NCT03775746|DRUG|Clopidogrel 75Mg Tablet|Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
40856533|NCT03775746|DRUG|Rivaroxaban 2.5Mg Tablet|Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)
40856534|NCT03775746|DRUG|Ticagrelor 90Mg Tablet|Prevention of atherothrombotic events in patients with acute coronary syndrome \[in combination with aspirin\]
40856535|NCT06383260|BEHAVIORAL|Behavioral diagnostic|Diagnosing the behavioral pattern
40856536|NCT03161106|DIETARY_SUPPLEMENT|Nutrition|Nutrional group-30 kcal/kg with 1.5 grm protein with protein supplements
41038265|NCT05086367|OTHER|Routine Physical Therapy|Routine physical therapy exercises were performed in which neck isometrics and neck range of motion exercises were performed
41166641|NCT00338949|DRUG|Switch|Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
41166642|NCT00338949|DRUG|Control|Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
41038266|NCT04286373|DEVICE|active stimulation then placebo stimulation|"The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The two stimulation periods will be separated by a 4 weeks wash-out period."
41038267|NCT04286373|DEVICE|placebo stimulation then active stimulation|"VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~The two stimulation periods will be separated by a 4 weeks wash-out period."
41038268|NCT04625712|PROCEDURE|Cholecystectomy|Cholecystectomy within the first week after a mild acute biliary pancreatitis
41038269|NCT02126293|DRUG|Zinc Supplement|
41387498|NCT06039878|BEHAVIORAL|Ability to Delay Gratification for Food in Infants-Social Task (ATDG-FIT-Social)|When mother indicates infant is hungry, she presents the infant the bottle but withholds feeding for 5 minutes, feeds for one minute, withholds feeding for 30 seconds, and then resumes feeding. She does so under two conditions (providing social interaction during feeding versus not) on two counterbalanced days at infant ages 1, 3, and 6 months.
41387499|NCT04924946|OTHER|Inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs|"* Time to monitor blood pressure values in target targets~* Need for administration of another antihypertensive drug~* Disappearance of organ failure attributable to hypertension~* Weaning from an extra-renal purification~* Weaning from mechanical ventilation~* Improved kidney function~* Iatrogenic hypotension~* Need for suspension of treatment~* Other side effect"
41387500|NCT00002634|BIOLOGICAL|filgrastim|
41387501|NCT00002634|BIOLOGICAL|monoclonal antibody 3F8|
41387502|NCT00002634|DRUG|cisplatin|
41387503|NCT00002634|DRUG|cyclophosphamide|
41387504|NCT00002634|DRUG|doxorubicin hydrochloride|
41387505|NCT00002634|DRUG|etoposide|
41511145|NCT03750292|DEVICE|control air filter|A placebo mode was added to the HEPAirX to provide only recirculation (without filtration or ventilation using outdoor air) and temperature control of the room air. The placebo filter is made of metal.
41038270|NCT02126293|PROCEDURE|Repeat blood and urine tests|
41038271|NCT04440566|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
41038272|NCT02485210|PROCEDURE|Endodontic treatment|It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
41038273|NCT04914533|DEVICE|Luminance RED Low Level Laser Therapy Device|Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.
41038274|NCT00885404|DRUG|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
41038275|NCT05396248|BEHAVIORAL|Memory Retraining Exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
41166643|NCT01194271|DRUG|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
41387506|NCT00002634|DRUG|mesna|
41387507|NCT00002634|DRUG|perfosfamide|
41387508|NCT00002634|DRUG|vincristine sulfate|
41387509|NCT00002634|PROCEDURE|autologous bone marrow transplantation|
41387510|NCT00002634|PROCEDURE|in vitro-treated bone marrow transplantation|
41511146|NCT05771948|DEVICE|CCoat|CCoat is a new intra-articular (IA) injectable joint lubricant for patients suffering from joint pain developed by Liposphere LTD. CCoat is a liposomal boundary lubricant which coats the cartilage surface and protects it from further damage and degradation.
41511147|NCT02181790|DEVICE|Excimer laser|twice weekly treatments with the excimer laser for a total of 8 weeks.
40856537|NCT03161106|DRUG|Lactulose|Lactulose plus diet consumed by patient
40856538|NCT03161106|DIETARY_SUPPLEMENT|Diet|Protein Powder 15 to 20 gm/meal/day
40856539|NCT01279603|DRUG|GO-203-2c|GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
41387511|NCT00002634|RADIATION|low-LET cobalt-60 gamma ray therapy|
41387512|NCT00002634|RADIATION|low-LET photon therapy|
41387513|NCT00002634|RADIATION|radioisotope therapy|
41387514|NCT02682173|OTHER|MR Abdomen|
41511148|NCT02181790|DRUG|Acitretin|17.5mg/d
41511149|NCT01994785|DIAGNOSTIC_TEST|Capnographic Monitoring|Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
41511150|NCT01238107|DRUG|MT-102|BETA BLOCKER
41387515|NCT03402126|OTHER|TPD RAMWare|TPD RAMWare injected into enrolled subject's Implantable cardioverter-defibrillator (ICD) device for use
41387516|NCT03840473|BEHAVIORAL|MET|The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.
41387517|NCT03840473|BEHAVIORAL|ICT|The patient lying in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position.18,22 The physiotherapist applied gradually increasing pressure to the MTrPs until the subject perceived the first noticeable pain. At that moment, the pressure was maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure was increased until the discomfort appeared again. This process was maintained for 90 seconds.
41387518|NCT03840473|BEHAVIORAL|Conventional Intervention|Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
41387519|NCT01048268|DRUG|glucose-dependent insulinotropic polypeptide|"For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight"
40856540|NCT04957394|BEHAVIORAL|Family Partner|"The Family Partner intervention is based on well-known elements for preventing child abuse and neglect, such as 1) high intensity intervention with home visitations, 2) coordination of services, 3) an ecological perspective, 4) parental guidance, and 5) an emphasis on a therapeutic relationship with parents to create trust, change and agency.~Family Partners must have relevant professional background and education, such as social work, child welfare services and other health/welfare occupations. They must have a personal attitude for relation-based service delivery in a home-setting, a long work experience and in-depth knowledge of municipal welfare services.~Each practitioner will follow five families. The estimated duration of the intervention is 12 months, but might go over longer stretches of time if it is considered beneficial for the families. The minimum duration of the intervention is 3 months."
40856541|NCT02234804|DEVICE|Xience Prime Stent|
40856542|NCT02234804|DEVICE|Medtronic Resolute Integrity stent|
40856543|NCT02234804|PROCEDURE|Angiography|
40856544|NCT02234804|PROCEDURE|OCT|
40856545|NCT04016259|DEVICE|Cranial Electrical Stimulation (CES)|CES will be applied for 60 minutes per session daily for 2 weeks (Monday to Friday) via the Alpha-Stim M Electromedical Products International, Inc., Mineral Wells, TX).
41038276|NCT05396248|BEHAVIORAL|Placebo Control Memory Exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
41387520|NCT01048268|DRUG|Placebo|copy GIP infusion rates
41387521|NCT04648774|PROCEDURE|Serratus anterior plane (SAP) block|With the patient in supine position, an ultrasound transducer will be used to find the 4th rib in the mid-axillary line. A 17g touhy needle will be introduced in-plane in an inferior to superior direction until its tip rests between the serratus anterior muscle and the 4th rib or the 3rd external intercostal muscle. A bolus of study drug 10ml (either ropivacaine 0.2% or normal saline) will be delivered though the needle. A 18g multiholed catheter will be inserted and secured to the patients' skin with adhesive dressings. A further 10ml of study drug will be administered through the catheter. The same procedure will be followed on the contralateral side. The study drug will be administered by programmed intermittent bolus (PIB) 10ml every 2 hours to each side in a staggered, alternating fashion. The PIB study drug will to be continued for 72 hours post-insertion.
41387522|NCT04648774|PROCEDURE|Normal saline placebo|Patients in both groups will receive the standard of care analgesic medications in the cardiovascular intensive care unit and the ward.
41387523|NCT00221052|DRUG|Diclofenac|
41387524|NCT05359341|DRUG|Sitagliptin 50 mg|Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
41387525|NCT05359341|DRUG|Empagliflozin 12.5 MG|Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
41511151|NCT04881487|RADIATION|Additional stereotactic body radiation therapy|5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
40856546|NCT04016259|DEVICE|Sham-CES|For sham CES, the electrodes will be identical look and be placed in the same positions as for active stimulation, but the stimulator will not deliver electrical current.
40856547|NCT04844268|BIOLOGICAL|Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT (HDT-301)) at a dose of 1 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
41038277|NCT06443268|DIAGNOSTIC_TEST|questionnaire, hair samples, blood samples, clinical exam|The following parameters will be sequentially assessed in caregivers and patients (baseline, at 3 months and at 12 months): 1) quality of life / functioning will be determined through questionnaires (SF-36, EQ-5DL, ECOG (Eastern Cooperative Oncology Group) / Karnofsky, Barthel Index, ICIQ) 2) stress levels \& anxiety levels, caregiver burden will be assessed by the following questionnaires: Distress Thermometer, SBQ-G, GAD-7, PHQ-9, PSS-10, ZBI, PAC. Cortisol will be measured in hair to indicate stress within the past 3 months \[18\]. Fasting glucose, lipid profiles and HbA1c along with blood count, sodium, potassium, creatinine, TSH (thyroid-stimulating hormone) will be measured in routine blood samples from patients at the time of clinical checkups. Blood pressure, pulse and BMI will be determined during clinical visit in patients and additionally in caregivers.
41038278|NCT04637412|OTHER|Menu label|Participants will be shown a sample of items from a restaurant menu, displayed with labels
41511152|NCT03958292|DEVICE|IODIM|Eye drops containing polyvinylpyrrolidone-Iodine (PVP-Iodine), hyaluronic acid and triglycerides
41511153|NCT01845727|DRUG|Topical Amphotericin B at 3%|
41511154|NCT02841982|PROCEDURE|single-injection QLB(quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
41387526|NCT05359341|DRUG|Sitagliptin 50 mg + Empagliflozin 12.5 MG|Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
40856548|NCT04844268|BIOLOGICAL|Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 5 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
41387527|NCT05359341|DRUG|Empagliflozin 12.5 MG + Sitagliptin 50 mg|Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
41038279|NCT00572234|DRUG|bupropion SR|12 week course of bupropion SR 150 mg, BID
41166644|NCT01194271|DRUG|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
41387528|NCT03035981|OTHER|White rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
41387529|NCT03035981|OTHER|White rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
41387530|NCT03035981|OTHER|White rice, slow|White and brown rice were tested for differences in gastric emptying rate and appetitive response
41387531|NCT03035981|OTHER|White rice, resistant|White and brown rice were tested for differences in gastric emptying rate and appetitive response
41387532|NCT03035981|OTHER|Brown rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
41387533|NCT03035981|OTHER|Brown rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
41387534|NCT03035981|OTHER|Fructooligosaccharide (FOS)|White and brown rice were tested for differences in gastric emptying rate and appetitive response
40856549|NCT04844268|BIOLOGICAL|Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 25 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
40856550|NCT04844268|BIOLOGICAL|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.
41038280|NCT04461951|OTHER|Lifestyles (exposure)|no intervention
41038281|NCT00263666|BIOLOGICAL|Rotarix|Oral vaccination
41038282|NCT00263666|BIOLOGICAL|Placebo|Oral administration
41038283|NCT00263666|BIOLOGICAL|Tritanrix-HB+Hib|Concomitant routine vaccination, IM administration
41038284|NCT00263666|BIOLOGICAL|Polio Sabin|Oral administration, concomitant routine vaccination
41166645|NCT01194271|PROCEDURE|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
41387535|NCT05677984|PROCEDURE|Awaken prone positioning ventilation|patients were mandated to keep a prone position for at least 12 hours.
41387536|NCT05904769|DEVICE|LIFELEAF Smartwatch|Noninvasive wearable smartwatch/monitor that utilizes photoplethysmography (PPG) which is a set of measurements acquired from the light flashed from the back of the watch and measuring the intensity of the reflected light from the blood in the blood vessels just below the skin at the wrist. Provides a non-invasive method for measuring blood glucose as well as alternative method for measuring blood pressure, heart rate and rhythm, etc.
41387537|NCT04954833|DEVICE|EMO-200|TEST Lens
41511155|NCT02841982|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
41511156|NCT02841982|DEVICE|PAJUNK StimuLong|
41511157|NCT02841982|DRUG|single dose ropivacaine|"* 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~* given immediately after the correct position of the tip of the needle has been verified."
41511158|NCT02841982|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|bolus: 1.5\~2mg, lock time: 10min, 1h limitation: 6\~8mg
40856551|NCT03549377|BEHAVIORAL|Deception|Participants will be deceived during delayed gratification task.
40856552|NCT04637425|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
41166646|NCT01125566|DRUG|BIBW 2992|patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
41166647|NCT01125566|DRUG|trastuzumab|patients receive trastuzumab 2mg/kg intravenously every week
41166648|NCT01125566|DRUG|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
41387538|NCT04954833|DEVICE|EMO-118|CONTROL Lens
40856553|NCT04637425|DRUG|Placebo|Matched tablets without any active substance.
41038285|NCT03276351|DEVICE|Long-Stemmed with Hybrid Fixation|Long-stemmed revision implant with hybrid fixation for total knee arthroplasty
41038286|NCT03276351|DEVICE|Short-Stemmed with Augmented Fixation|Short-stemmed primary implant with augmented fixation for total knee arthroplasty
41038287|NCT03360253|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 in drops|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle
41038288|NCT03360253|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
41038289|NCT00463710|DRUG|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
41038290|NCT01815164|BEHAVIORAL|Hypnotherapy|Gut-directed hypnotherapy administered by an experienced hypnotherapist.
41166649|NCT01125566|DRUG|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
41166650|NCT04134598|RADIATION|Breast irradiation (RT)|Irradiation of volume's portion Index quadrant) or whole volume of the residual breast.
41387539|NCT05053113|DEVICE|Activity Monitor|Monitor physical activity with FitBit
41387540|NCT05053113|DEVICE|Activity Monitor|Wear accelerometer
41387541|NCT05053113|OTHER|Educational Intervention|Receive educational newsletter
41387542|NCT05053113|OTHER|Survey Administration|Ancillary studies
41387543|NCT05053113|BEHAVIORAL|Telephone-Based Intervention|Receive phone call from health coach
41387544|NCT06540755|GENETIC|genetic polymorphism analysis|Genotype for IL-6 rs1800795 and PAPP-A rs7020782 polymorphisms were determined using real-time polymerase chain reaction with allele-specific probes.
41387545|NCT01153022|OTHER|joint mobilization techniques|In the experimental group, ankle joint mobilization was applied for five minutes, using grade II joint traction rhythmic oscillation (Mailland Scale) with the knee in 15° of flexion, subtalar in neutral and ankle in resting position (10º plantarflexion). During the control study, participants were placed under the same conditions as those of the experimental group but only the hands of the evaluator were placed in the foot, in the position of joint traction simulation.
41387546|NCT05166473|OTHER|Telerehabilitation group (n=21)|"This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients."
41387547|NCT05166473|OTHER|Control Group (n=21)|"After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises."
41387548|NCT02582359|DRUG|MLN9708|Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
41387549|NCT02582359|DRUG|Cytarabine|Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
41387550|NCT02582359|DRUG|Daunorubicin|Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
41387551|NCT06565988|DEVICE|Decoria Voluma|"Decoria® Voluma medical device is a sterile, single use Hyaloronic acid based dermal filler intended for aesthetic use, provided in the form of a nonpyrogenic, viscoelastic gel. It is composed of highly purified sodium hyaluronate of high molecular weight, dissolved in a physiological buffer at pH 6.0-7.5. The sodium hyaluronate is derived from microbial fermentation and is stabilized by crosslinking with the chemical agent BDDE (1,4 Butanediol Diglycidyl Ether).~Decoria® Voluma dermal fillers are injected into dermal tissue for the correction of midface volume deficit by tissue augmentation in cheek region, supporting overlying tissue to shape facial contours to desired level of correction. This is possible due to the capacity of HA to attract and bind large amounts of water, forming a viscous gel.~Appropriate injection volume for the cheek region(s) will be determined by the Treating investigator according to IFU."
41387552|NCT00810615|OTHER|Hyperbaric oxygen @ 2.4 ATA|Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
41387553|NCT00810615|OTHER|Sham treatment|
41387554|NCT05587101|DIAGNOSTIC_TEST|Urodynamic Study (Filling cystometry and pressure-flow study)|Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped. While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded.
41387555|NCT05587101|DIAGNOSTIC_TEST|Questionnaires|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance.
41387556|NCT05587101|DIAGNOSTIC_TEST|Uroflowmetry|Uroflowmetry test consists measuring the maximum urine flow rate, the average urine flow rate, the micturiated volume and postmictional urine volume. The maximum flow rate below 12 ml/sec in males and 18 ml/sec in females will be recorded as emptying phase disorder. Postvoid residual urine volume above 150 ml is a sign of incomplete emptying of bladder.
41387557|NCT04406883|DRUG|Extraction + filled with Simvastatin solution impregnated gelatin sponge|All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
41038291|NCT01815164|BEHAVIORAL|Educational intervention|Educational intervention vith education regarding Irritabel bowel Syndrome.
41038292|NCT05006781|DRUG|DAOIB|The DAOIB dose in each group will be fixed during the 24 weeks duration
41038293|NCT04455672|DEVICE|splints|"* Scaning of the maxillary and mandibular cast in the centric relation.~* The CAD/ CAM splints will be designed using Exocad s.~* The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~* The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~* Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~* All patient will be asked to wear their spints during sleeping only.~* In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months ."
41038294|NCT05101239|DEVICE|MRI imaging exam|3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)
41038295|NCT02212028|DRUG|prasugrel|the effects of whole tablets versus crushed tablets will be compared
41038296|NCT00611013|DEVICE|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
41387558|NCT06183645|DEVICE|Actimyo|Participants will wear 2 Actimyos in everyday life. Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
41387559|NCT04719728|DIAGNOSTIC_TEST|Aided pure tone audiometry|aided response, speech, evoked potential
41387560|NCT02594137|PROCEDURE|Without watertight duraplasty|After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
41387561|NCT02715466|DRUG|Balanced gelatine solution|Gelaspan combined with Sterofundin ISO
40856554|NCT00704860|OTHER|Open label pharmacotherapy|"Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,"
41038297|NCT02264795|DRUG|Lidocaine|Lidocaine 2% with epinephrine 5mcg/ml
41387562|NCT02715466|DRUG|Balanced electrolyte solution|Sterofundin ISO
41387563|NCT04253756|DEVICE|20-gauge BD Nexiva Diffusics|The BD Nexiva Diffusics catheters are suitable for use with power injectors when a direct connection is made.
41511159|NCT00750685|DEVICE|Mentor Smooth Becker 50 Expander/Breast Implant|The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
40856555|NCT03910114|DRUG|Magnevist|GBCA enhancement
41038298|NCT02264795|DRUG|Placebo|0.9% Sodium Chloride Solution
41166651|NCT04134598|DRUG|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|Adjuvant endocrine therapy as per local policy (letrozole/anastrozole/exemestane/tamoxifene for 5-year or switch schedules aromatase inhibitors/tamoxifen for 5-year).
41511160|NCT00150280|DRUG|celecoxib and ibuprofen SR|
41038299|NCT03405987|DIAGNOSTIC_TEST|Strain analysis by CMR|Strain analysis by CMR will be performed
41038300|NCT03464227|DRUG|UCB0107|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
41038301|NCT03464227|OTHER|Placebo|"* Pharmaceutical form: intravenous infusion~* Route of administration: intravenous use"
41038302|NCT04002934|DRUG|Bazedoxifene Acetate|40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
41038303|NCT02090101|DRUG|ANAKINRA|
41038304|NCT00251745|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
41038305|NCT00251745|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
41166652|NCT02866071|DRUG|Ketamine Hydrochloride|50mg IN Ketamine Hydrochloride
40856556|NCT03910114|DRUG|Dotarem|GBCA enhancement
40856557|NCT03910114|DRUG|Gadovist|GBCA enhancement
40856558|NCT04791618|BEHAVIORAL|Health360x plus health coach|Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self management skills
40856559|NCT04791618|BEHAVIORAL|Health360x only (High tech)|All participants will have access to Helath360x with reminders generated for goal setting.
40856560|NCT00241345|DRUG|Valganciclovir|
40856561|NCT00241345|DRUG|Ganciclovir|
41038306|NCT00251745|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
41038307|NCT04542343|BEHAVIORAL|Change in knowledge, motivation, skills, resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges.
41166653|NCT02866071|DRUG|Placebo-Comparator|50mg IN Placebo
41166654|NCT00216957|PROCEDURE|Coronary bypass surgery without cardiopulmonary bypass|
41387564|NCT01249690|DRUG|Bortezomib,Pirarubicin,Dexamethasone|Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
41387565|NCT01249690|DRUG|Thalidomide,Pirarubicin,Dexamethasone|Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
41387566|NCT03962660|OTHER|HaRTS-TRENDS|"HaRTS-TRENDS comprises 4, individual sessions delivered in the context of the interventionist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented heart-set or style. It comprises the delivery of 4 manualized components, including a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially available ENDS."
41387567|NCT03962660|OTHER|Standard Care (SC)|The 4-session, individual standard care control condition entails the well-documented and evidence-based 5 As intervention (i.e., Ask about nicotine use, Assess use, Advise to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange follow-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which can supply additional counseling and nicotine replacement therapy.
41387568|NCT01890109|BIOLOGICAL|Erenumab|Administered via subcutaneous injection.
41387569|NCT01890109|DRUG|Placebo|Administered via subcutaneous injection
41387570|NCT03925116|OTHER|COntraceptive pathway|alternative way of aiding patients in deciding contraception method
41387571|NCT04454619|DRUG|Hand antisepsis with Clorhexidine and solution|Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
40856562|NCT04679194|BIOLOGICAL|Mana 312|"Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT)."
41387572|NCT04225416|OTHER|Questionnaire/Structured Interview|No intervention
41387573|NCT00357565|BIOLOGICAL|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
41387574|NCT00357565|DRUG|busulfan|Administered 1.1 mg/kg if \<12 kg intravenous (IV) every 6 hours (0.8 mg/kg if \>12 kg IV every 6 hours on Days -8 through -5.
41387575|NCT00357565|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \>200 ng/mL. For children \< 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
41387576|NCT00357565|DRUG|fludarabine phosphate|Administered 25 mg/m\^2 intravenous (IV) over 60 minutes on Days -4 through -2.
41387577|NCT00357565|DRUG|melphalan|Administered 60 mg/m\^2 intravenous (IV) over 30 minutes on Days -4 through -2.
41387578|NCT00357565|DRUG|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients \<45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
41387579|NCT00357565|PROCEDURE|umbilical cord blood transplantation|The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
41387580|NCT03496935|DEVICE|Tunneled versus non-tunneled dialysis catheter insertion|The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.
41511161|NCT04853095|PROCEDURE|Peritoneal fixation (PerFix)|PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.
41511162|NCT04853095|PROCEDURE|Standard of care|ePLND without peritoneal flap fixation
41511163|NCT00582660|DRUG|Celecoxib|400 mg twice a day for 7 days prior to surgery
41038308|NCT04021953|BEHAVIORAL|People Like Us Online Video Series Intervention|"People Like Us miniseries incorporates key sexual health messages to:~1. Increase viewers' knowledge and perceptions of HIV and other STI risk;~2. Address homophobia and sexual orientation disclosure;~3. Increase safer-sex negotiation self-efficacy;~4. Promote positive attitudes towards condom use and other safe sex behaviors;~5. Build skills and self-efficacy for practicing safer sex;~6. Provide information on HIV and other STI testing and its benefits;~7. Provide information on resources for HIV/STI testing and other mental health services;~8. Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men."
41387581|NCT00109278|BIOLOGICAL|V205C, measles, mumps, and rubella virus vaccine live|
41511164|NCT00582660|DRUG|Placebo|one tablet of placebo will be given for 7 days prior to surgery
41511165|NCT00784108|DEVICE|Modulated Imaging (MI)|Modulated Imaging measure effect of Photodynamic therapy treatment
41511166|NCT00784108|OTHER|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
41511167|NCT06250946|DRUG|HRS-7535;Placebo|HRS-7535;Placebo
41511168|NCT06250946|DRUG|Placebo|Placebo
41511169|NCT05296174|OTHER|cognitive-oriented intervention program|The experimental group was offered six 40-minute courses once a week.
41511170|NCT05296174|OTHER|health education activities program|The control group was offered health education activities once a week.
41511171|NCT00590512|DIETARY_SUPPLEMENT|High sodium|
41511172|NCT00590512|DIETARY_SUPPLEMENT|Low sodium|
41511173|NCT05177185|RADIATION|Hippocampal-sparing|Dose constraint placed on hippocampi to minimize dose to hippocampi, while maintaining target coverage (at least 98% of brain metastasis volume must receive 100% of prescription dose).
41511174|NCT05177185|RADIATION|Stereotactic radiosurgery|Stereotactic radiosurgery (SRS) with prescription dose determined based on size of brain metastasis; 21 or 24 Gy in a single fraction if less than or equal to 20 mm, 18Gy in a single fraction in 21 - 30 mm, 15 Gy in a single fraction or 30 Gy in 5 fractions if 31 - 40 mm (physician discretion).
40856563|NCT05613023|RADIATION|SBRT|Stereotactic Body Radiotherapy
41387582|NCT00109278|BIOLOGICAL|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
41387583|NCT05043779|PROCEDURE|Awake Airway Nasoendoscopy|Preoperative Awake Airway Nasoendoscopy of upper airway
41387584|NCT06563492|DEVICE|insole|evaluation of individuals using different insoles
41387585|NCT06537778|DRUG|Atosiban|Women in the atosiban group received i.v. atosiban (Manufacturer: Pfizer, Germany) 30 min before the surgery with a bolus dose of 6.75 mg, and the infusion was continued with an infusion rate of 18 mg/h for 3 h. The dose of atosiban was then reduced to 6 mg/h for another 21 h.
41387586|NCT06537778|DRUG|Normal saline|Participants in the placebo group received only normal saline infusion for the same duration as atosiban group.
41511175|NCT01562938|DRUG|Placebo|Placebo
41511176|NCT01562938|DRUG|MEDI-557|MEDI-557 low-dose
41511177|NCT01562938|DRUG|MEDI-557|MEDI-557 high-dose
41511178|NCT02663843|DEVICE|i-gel airway|Fibreoptic intubation via i-gel airway device
41511179|NCT02663843|DEVICE|air-Q airway|Fibreoptic intubation via air-Q airway device
41038309|NCT04021953|BEHAVIORAL|Sexual Health Pamphlet (Standard of Care)|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
41387587|NCT01929148|PROCEDURE|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
41387588|NCT01929148|PROCEDURE|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
41387589|NCT00868816|DRUG|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
41387590|NCT00868816|DRUG|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
41387591|NCT06312761|DRUG|Relugolix 120Mg Tab|Relugolix 120 mg single dose - All subjects
41387592|NCT06312761|DIETARY_SUPPLEMENT|Curcumin|Curcumin 630 mg single dose
41387593|NCT06312761|DRUG|Testosterone Undecanoate 237 MG Oral Capsule|Testosterone Undecanoate 237 MG Oral Capsule
41387594|NCT00712907|DIETARY_SUPPLEMENT|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
41387595|NCT00712907|DIETARY_SUPPLEMENT|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
41387596|NCT00712907|OTHER|100% O2 (AGA) two times for 12 min|"Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997"
41387597|NCT03849170|BEHAVIORAL|Stress Inoculation Technique|Teaches athletes to use cognitive-behavioral techniques to reduce their stress response during sporting events.
41387598|NCT03849170|OTHER|Health Intervention|Will provide basic dietary and lifestyle guidelines that athletes should follow in their daily lives to maintain their health
41387599|NCT05785416|OTHER|Proprioceptive Neuromuscular Stretching - Contract Relax stretching (PNF-CR)|PNF-CR utilized the concept of autogenic inhibition of the muscle for improving the flexibility of the muscle. It includes stretching a muscle after a brief period of activation.
41387600|NCT05785416|OTHER|Static Stretching (SS)|The SS technique utilized the concept of creep for improving the hamstring flexibility. The stretch was maintained for a prolonged period passively by the therapist.
41038310|NCT04181554|OTHER|Measurement of postural stability|The postural stability will assess by using Biodex balance system.
41387601|NCT03371680|DRUG|Injection of 1-13 Carbon Leucine and deuterated water|All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
41387602|NCT02737072|DRUG|LY2510924|Administered SQ
41387603|NCT02737072|DRUG|Durvalumab|Administered IV
41387604|NCT06462222|DRUG|Toripalimab, pemetrexed|Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy
41387605|NCT03653637|BEHAVIORAL|Project Life Force|A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal. The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others. The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.
41387606|NCT03653637|BEHAVIORAL|Treatment as Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
41387607|NCT02332655|DRUG|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
41511180|NCT01328522|DRUG|SAR153191 (REGN88)|"Pharmaceutical form:solution~Route of administration: subcutaneous"
41511181|NCT04060446|DEVICE|Medical Device|Smoke cigarettes with CReSSMicro topography measurement device and BioRadio device
41387608|NCT01953731|DRUG|Palbociclib|"In period 1, patients will receive a single 125mg oral dose of palbociclib alone. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.~In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose."
41387609|NCT01953731|DRUG|Rifampin|In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
41387610|NCT00591526|DRUG|Arac|Ommit ARAC in the chemotherapy
41387611|NCT05370781|BEHAVIORAL|Peer Led Diabetes Self-Management Support|While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
41387612|NCT05370781|BEHAVIORAL|Diabetes Self-Management Education|Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.
41387613|NCT03076528|OTHER|Sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action
41387614|NCT03076528|OTHER|Non-technology foot and ankle exercise program|Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
41387615|NCT04335994|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
41387616|NCT04335994|DEVICE|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
40856564|NCT05218525|OTHER|Algorithm|"Participants in the intervention group will receive the general offer of the telehealth intervention including the telehealth system with the implemented COPD prediction algorithm. The participants are asked to measure their vital signs and respond to COPD related questions as usual. As usual refers to fixed days in the week, either Monday or Thursday, where the participants must measure their vital signs. In addition, the participants must weekly measure two oxygen saturation measurements drawn from the fingertip pulse oximeter."
41038311|NCT03088267|DRUG|amphetamine extended-release oral suspension, 2.5 mg/mL|5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
41387617|NCT04539236|DRUG|Lenalidomide|Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
41387618|NCT04539236|DRUG|Luspatercept|Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
41387619|NCT00797316|DRUG|Aliskiren|Aliskiren 150 mg or 300 mg taken once daily in oral form
41387620|NCT00797316|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
41387621|NCT05174273|BIOLOGICAL|Fecal Microbiota Transplantation|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut.
41387622|NCT05557968|OTHER|Conventional Therapy|"conventional therapy will be given for stroke patients and three assessments i.e. pre, post and follow up surveys, a session of 30 minutes, 3 times weekly for a six week period.~Total 18 sessions would be performed on each patient for six weeks"
41387623|NCT05557968|OTHER|Action Observation Therapy (AO)|"The video consists of :~1. Ascending and descending the step box.~2. Ascending and descending the stairs in the treatment room.~3. Holding the handrails to climb and descend the stairs inside and outside the building.~4. Climbing and descending the stairs inside and outside the building without holding the handle.~5. Climbing and descending the sidewalk block"
41511182|NCT04060446|OTHER|Questionnaire Administration|Ancillary studies
41511183|NCT04060446|BEHAVIORAL|Tobacco Smoking|Smoke cigarettes
41038312|NCT03088267|DRUG|Placebo extended-release oral suspension|6, 7 or 8 mL PO
41038313|NCT02635841|DRUG|Deferiprone|Ferriprox (deferiprone) 100 mg/mL oral solution
41511184|NCT03196843|DRUG|Raltitrexed|Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
41511185|NCT03196843|RADIATION|Intensity Modulated Radiotherapy|Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
41038314|NCT03592212|DRUG|Salbutamol|Measurement of bronchodilator response (BDR)
41038315|NCT03776981|OTHER|Core Activation|Volitional activation of the transversus abdominis muscle during self-selected paced ambulation for both groups.
41038316|NCT03776981|OTHER|Core Stabilization|Six-week core stabilization program for the group of participants with knee osteoarthritis.
41511186|NCT04350411|DEVICE|Conventional diathermy|Abdominal free flap raise performed with conventional diathermy. Settings: cutting 40 Watt, coagulation 40 Watt.
41511187|NCT04350411|DEVICE|PEAK PlasmaBlade™|Abdominal free flap raise performed with PEAK PlasmaBlade™ Settings: cutting 7 (35 Watt), coagulation 7 (35 Watt)
41511188|NCT00365092|PROCEDURE|Insertion of tympanostomy tubes|
41511189|NCT00428233|PROCEDURE|Leukemia cell harvest|Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
40856565|NCT02792153|DRUG|Estradiol|AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
40856566|NCT02258646|BEHAVIORAL|Exercise training at home|
41511190|NCT00242632|DRUG|Namenda|Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
41511191|NCT02498392|DRUG|JNJ-42165279|JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
41511192|NCT02498392|OTHER|Placebo|Matching Placebo will be administered orally.
41511193|NCT00893269|DRUG|eszopiclone|Oral capsule at dose recommended for adults
41387624|NCT04083274|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
41511194|NCT00893269|DRUG|Placebo|Participants receive placebo prior to sleep
41511195|NCT00893269|DRUG|ramelteon|ramelteon
41511196|NCT00893269|DRUG|zolpidem|zolpidem
41511197|NCT04990713|PROCEDURE|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients will receive local anesthetic via serratus plane block as opposed to saline placebo
41511198|NCT04990713|PROCEDURE|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients will receive saline placebo via serratus plane block
41038317|NCT02774057|DRUG|Captafer®|"2 pills daily. Contains~* Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~* Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~* Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~* Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems"
41511199|NCT02763826|DEVICE|transcranial direct current stimulation|brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
40856567|NCT02258646|BEHAVIORAL|Telemonitoring and education/self-management|
41038318|NCT02774057|DRUG|Iron Sulfate|195 mg Iron supplement
41038319|NCT01972516|DRUG|Tivozanib|
41038320|NCT05149274|DRUG|DWP14012 Tablet A|DWP14012 10mg
41038321|NCT05149274|DRUG|DWP14012 Tablet B|DWP14012 40mg
41038322|NCT03446443|DRUG|Honghe Fujie lotion|Before application，wash the vaginal area with water and dry it. Take10ml Hong He Fujie into dilution bottles，added to 100ml with warm boiled water, using diluted lotion for the rinse of vulva and vagina, twice daily for 7days.
41038323|NCT03446443|DRUG|Metronidazole Suppositories|Before bedtime，wash the vaginal area and put 0.5g Metronidazole Suppositories into posterior vaginal fornix，once daily for 7days.
41511200|NCT04634006|DEVICE|Home-based transcranial direct current (tDCS) device|tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
41511201|NCT03955003|BEHAVIORAL|Group Drumming|Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.
41511202|NCT03955003|OTHER|Attention Control|This is intended to control for time, place, and group affect.
41511203|NCT01491191|DIETARY_SUPPLEMENT|Palmitoylethanolamide|Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
41511204|NCT01491191|DIETARY_SUPPLEMENT|Placebo|Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
41511205|NCT00553176|OTHER|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
41511206|NCT02836548|DRUG|Vorinostat|vorinostat 360 milligram once daily
40856568|NCT00104650|GENETIC|AMG 162 180 mg (SC) q 12 weeks|A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.
40856569|NCT00104650|DRUG|IV Bisphosphonate q 4 weeks|IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
41038324|NCT05252767|BEHAVIORAL|Patient Engagement Tools|Experimental participants will receive the patient engagement tools or the educational guide after randomization. The participants in the experimental cohort will utilize the tools between visits with their clinic providers. During visits, clinic providers will review the completed tools with participants.
41038325|NCT05252767|BEHAVIORAL|Educational Guide|Control participants will receive a brief educational guide about pain management.
41038326|NCT00389714|DEVICE|dental restoration|
41038327|NCT02715921|OTHER|Tele-exercise|
41038328|NCT03989466|BIOLOGICAL|Alemtuzumab|Given IV
41038329|NCT03989466|DRUG|Itacitinib|Given PO
41038330|NCT03214497|DEVICE|Protector|All patients which are assigned to the Protector are studied with this laryngeal mask
41387625|NCT04083274|OTHER|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded"
41387626|NCT00146133|BEHAVIORAL|diet, exercise|
41387627|NCT01855321|DRUG|Vitamin D|The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
41528353|NCT04904497|BEHAVIORAL|Early Occupational Therapy|"Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: trained family members and health staff about the intervention process"
40856570|NCT00104650|GENETIC|AMG 162- 180 mg q 4 weeks|A 180 mg AMG 162 (SC) administered every 4 weeks for 6 doses in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 4 weeks for 26 doses.
40856571|NCT04578184|DIAGNOSTIC_TEST|Corneal epithelial thickness measurements|Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.
41038331|NCT03214497|DEVICE|Supreme|All patients which are assigned to the Supreme are studied with this laryngeal mask
41038332|NCT02362490|DRUG|peginterferon alpha 2a|in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
41387628|NCT01855321|DRUG|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
40856572|NCT03268941|DRUG|TAK-906 Maleate|TAK-906 Maleate Capsules
40856573|NCT03268941|DRUG|Metaclopramide|Metaclopramide Tablets
41038333|NCT03385018|PROCEDURE|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach|"* Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach~* The number of trocars is 6 or less~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Combined organ resection only in cholecystectomy and splenectomy~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
41038334|NCT03385018|PROCEDURE|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach|"* Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
41387629|NCT02341976|OTHER|Vibratory platform exercises|Different positions on vibratory platform with different frequencies
41387630|NCT00241319|DRUG|R89674 (generic name not yet established)|
41387631|NCT06568497|OTHER|Food|Food
41387632|NCT03539939|PROCEDURE|Coronally Advanced Flap|The coronally advanced flap (CAF) is a procedure frequently used in periodontal plastic surgery. The main objective of this surgical technique is to mobilize the gingival margin and reposition it at a level more coronal (incisal direction) than its original location. CAF is mainly used for the treatment of gingival recessions.
41387633|NCT03278639|BEHAVIORAL|Rhythmic Auditory Stimulation|Training will be directed to ameliorate gait and balance
40856574|NCT03268941|DRUG|TAK-906 Maleate Placebo|TAK-906 placebo-matching Capsules
41387634|NCT03278639|BEHAVIORAL|Kinesiology|Training will be directed to ameliorate gait and balance
41387635|NCT04103411|OTHER|24h-Ambulatory Blood Pressure|Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
40856575|NCT00787189|DEVICE|The Hearing Laser|Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
40856576|NCT00787189|DEVICE|Placebo Laser|inactive low level laser light therapy with no therapeutic output
41387636|NCT03576131|BIOLOGICAL|GEN1029 (HexaBody®-DR5/DR5)|GEN1029 will be administered intravenously. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
40856577|NCT04043650|BEHAVIORAL|HeartSteps|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
40856578|NCT06583265|DRUG|Observational|To observe if endometrial compaction ≥ 5% in down regulated FET cycles increases clinical pregnancy rate.
40856579|NCT03051386|BIOLOGICAL|VEE Vaccine|0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
40856580|NCT00050947|DRUG|oxcarbazepine|
40856581|NCT01023360|DRUG|Clopidogrel and proton pump inhibitors|"baseline detection --\> clopidogrel 75 mg PO QD for 1 week --\> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week --\>~1 week washout --\> aspirin 100mg PO QD for 1 week"
40856582|NCT02992392|DRUG|Liposic|one eye of the participant recieved Lipoic
40856583|NCT02992392|DRUG|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
40856584|NCT00177255|DRUG|Docetaxel|"Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
40856585|NCT00177255|DRUG|Capecitabine|"Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
40856586|NCT02150915|OTHER|Acupuncture therapy (leopard spot needling technique)|Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
40856587|NCT00098579|DRUG|alvocidib|Given IV
40856588|NCT00098579|DRUG|doxorubicin hydrochloride|Given IV
40856589|NCT01699165|DEVICE|Nasal filter|Active nasal filter
40856590|NCT01699165|DEVICE|Placebo nasal filter|Placebo nasal filter
40856591|NCT02057159|BIOLOGICAL|NeuroVax|TCR peptides in IFA
40856592|NCT02057159|BIOLOGICAL|IFA Placebo|IFA Placebo
41166655|NCT05217290|BEHAVIORAL|transtheoretical model|The Transtheoretic Model is a conscious behavior change model and argues that behavior change is a process and that the attempts made in accordance with the change stage of the individual facilitate the change, otherwise resistance to behavior change is developed.
41387637|NCT02242331|DRUG|Micardis®|
40856593|NCT03062111|PROCEDURE|ProTouch Laser Enucleation of Prostate (LEP)|Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
40856594|NCT03062111|PROCEDURE|Transurethral Resection of Prostate (TURP)|TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
40856595|NCT05696756|BEHAVIORAL|Personalized Web-based training for EMMA app|Participants will complete six sessions of training to support uptake and habit formation of EMMA app use with a personalized web-based training platform.
40856596|NCT05696756|BEHAVIORAL|Motivational Interviewing: Clinician Support|Participants will receive weekly brief check-ins with clinicians to motivate and support the problem-solving and habit formation aspects of the web-based training.
41166656|NCT02164136|PROCEDURE|L-PANP-TME|
41166657|NCT02164136|PROCEDURE|O-PANP-TME|
40856597|NCT01499966|PROCEDURE|Plaster of Paris/ Tubigrip|"After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks"
40856598|NCT05603598|DRUG|LEAP-2 Protein, Human|Intravenous infusion, mixed meal test, ad libitum meal test
40856599|NCT01939639|DRUG|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
40856600|NCT01939639|DRUG|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
40856601|NCT05511571|DEVICE|Transcutaneous electrical neural stimulation (TENS)|The TENS group: TENS application was implemented by the researchers in the patient room. The conventional TENS application took 30 minutes per session. The application continued until frequency reached 100 Hz, the pulse width reached 100 μs, and the current impedance reached a point where the women felt needling or tingling according to their tolerance. Before the application, the women were asked to lie in a supine position, and the area/skin where TENS would be applied was cleaned and dried. Two electrodes of TENS were placed 2 cm above the cesarean incision, and the other two electrodes 2 cm below the incision. The women were allowed to rest during the application, and they were accompanied by the researcher. A total of five TENS sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held.
41387638|NCT02350439|DRUG|Adenosine infusion at 200μg/Kg/min|Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
41387639|NCT04640909|OTHER|Peripheral blood samples withdrawal|Peripheral blood samples evaluation
41387640|NCT00256217|DRUG|Anastrozole|1 mg. oral every day for 2 - 4 weeks
41528354|NCT00002303|DRUG|Epoetin alfa|
41528355|NCT02289248|DRUG|Ketamine|Subjects will undergo a twice weekly two week course of IV infusions of ketamine
41528356|NCT02289248|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Subjects will undergo twice weekly CBT for a total of 8 weeks
40856602|NCT05511571|OTHER|Progressive relaxation exercises (PRE)|The PRE group: The PRE application was implemented in the patient room. A quiet and calm environment was prepared in the room for the intervention. The PRE application was implemented by the women under the researchers' instructions. Each session lasted 30 minutes. A total of five sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held. The PRE application includes exercises based on stretching and then the relaxation of different muscle groups, accompanied by deep breathing. The exercises were carried out in the following way: First doing a deep breathing exercise and then stretching all the muscles from feet to face accompanied by breathing in, keeping the breath, and finally relaxing the muscles by breathing out at the same time.
40856603|NCT05511571|OTHER|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)|The TENS+PRE group: The PRE and TENS applications were carried out together in this group. The administration of the interventions was the same as in groups where only TENS and only PRE applications were carried out. In this group, first, a 30-minute PRE application was implemented, which was followed by a 30-minute-TENS application.
41166658|NCT05065697|OTHER|Brain MRI|Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
40856604|NCT04890288|PROCEDURE|Interventional randomized controled trial (RCT) comparing two oxygenation methods to reduce desaturation during intubation vs standard of care.|Demonstrate that airway management supported by oxygen supplementation (either HFNC or low flow oxygen) can prevent significant desaturation (SpO2 \> 85%) among patients in pediatric intensive care units (PICU) and neonatal intensive care units (NICU).
40856605|NCT03870399|DRUG|Tamoxifen|The treatment to be used will be tamoxifen 20mg orally once daily.
40856606|NCT04519346|OTHER|intradermal injection|Mesotherapy was performed by an experienced and trained physician using disposable 4 mm and 6 mm long 30 Gauge needles (Meso-relle, Biotekne SRL, Italy)to the pericarotid region, glabella, and the area between the eyes and ears, and to the area of the head where pain occurred (such as frontal, parietal, occipital region) for each patient
40856607|NCT02171442|DRUG|BIBR 953 ZW Intravenously|5 mg, 2.8 MBq (76 µCi)
40856608|NCT02171442|DRUG|BIBR 1048 Oral Solution|200 mg free base, 2.8 MBq (76 µCi)
41166659|NCT03463577|OTHER|Safety assessment following routine immunization with Boostrix|Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
41166660|NCT02151071|DEVICE|EnLight|The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device
41166661|NCT02151071|DEVICE|LightPath|The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
41166662|NCT02358083|BEHAVIORAL|Provider Communication about Vaccination|There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
41166663|NCT05549336|DRUG|PD-1 inhibitor|PD-1 inhibitor is defined as the exposure factor in our cohort study, for the tumor patients with the treatment of PD-1 inhibitor are allocated to the Exposure group whereas those tumor patients without the treatment of PD-1 inhibitor are allocated to the Non-exposure group.
41166664|NCT03588819|RADIATION|SABR|26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
41166665|NCT03180554|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS system consists of a non-invasive, handheld stimulator and ear electrode that participants wear like an earphone. Intensity, pulse duration, and frequency of the tVNS stimulation is optimized in order to induce signals in thick-myelinated Aβ fibres of the auricular branch of the vagus nerve (ABVN).
41166666|NCT03180554|OTHER|Motivational nondirective resonance breathing (MNRB)|Motivational nondirective resonance breathing (MNRB) is a type of diaphragmatic breathing technique that trains the body to breathe at resonance frequency with a mental state of open-awareness.
40856609|NCT02145117|BEHAVIORAL|MBSR|Behavioral
40856610|NCT04784832|DEVICE|Transcranial magnetic stimulation|Magnetic stimulation of the cortex
40856611|NCT04784832|DEVICE|Peripheral Nerve Stimulation|Electric stimulation of the nerves
40856612|NCT04784832|DEVICE|Transcranial direct current stimulation|Electric stimulation of the cortex
40856613|NCT04784832|DEVICE|Paired Associative Stimulation|Combined magnetic and electric stimulation of cortex and nerve, respectively
40856614|NCT04784832|DEVICE|Wrist|Short-term immobilization of the arm
41166667|NCT05404217|OTHER|LN-OS-22|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
41166668|NCT05404217|OTHER|Maltodextrin|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
41166669|NCT05380102|DEVICE|Telemetry monitoring|All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).
41166670|NCT05380102|DEVICE|Continuous monitoring through Earlysense|EarlySense (USFDA approved ballistocardiography device) will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
41166671|NCT05380102|DEVICE|Continuous monitoring through Dozee VS|Dozee VS will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
41387641|NCT05553028|PROCEDURE|Computerised tomography|Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.
41387642|NCT04344782|DRUG|Bevacizumab Injection|Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.
41528357|NCT00774163|BIOLOGICAL|Lactobacillus reuteri|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
40856615|NCT04784832|DEVICE|Robotic arm|External perturbation of force field induced by robotic arm
41166672|NCT04280562|DEVICE|Sana Pain Reliever|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's normal settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
41387643|NCT00951717|BEHAVIORAL|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
41387644|NCT02617446|DRUG|Placebo|IV of matching saline solution
41387645|NCT02617446|DRUG|Istaroxime|IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime
41387646|NCT05619809|DIETARY_SUPPLEMENT|Thermogenic dietary supplement|Daily ingestion of OxyShred thermogenic dietary supplement.
41387647|NCT05619809|DIETARY_SUPPLEMENT|Protein supplement|Daily ingestion of protein supplement.
41387648|NCT05619809|DIETARY_SUPPLEMENT|Placebo supplement|Daily ingestion of a placebo dietary supplement.
41387649|NCT02079389|DEVICE|Lap+Lus|"In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection. In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a laparoscopic ultrasound examination of the primary tumor, liver and retroperitoneum.~All patients are given an CT scan of the abdomen after 3 months."
41387650|NCT01889927|OTHER|Exercise Intervention|The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
41387651|NCT01051973|BEHAVIORAL|Cognitive behavior therapy|A 10-week treatment based on exposure to symptoms and related feelings.
41387652|NCT01051973|BEHAVIORAL|Stress management|A 10-week stress management treatment including applied relaxation and dietary advice.
41387653|NCT00200590|DRUG|acetaminophen and nalbuphine|
41387654|NCT00200590|DRUG|acetaminophen and morphine|
41387655|NCT00200590|DRUG|acetaminophen and reduced dosage of prostaglandin|
41387656|NCT06541171|OTHER|Magnetic resonance imaging as fpr clinical practice|An abbreviated MR protocol of the abdomen will be used inh association with CT scan; it does not need contrast injection and does not add any risk for patients.
41387657|NCT05614466|OTHER|The Simply B Study|"This study will be conducted in three parts:~Part A: A prospective open label pilot intervention study, comparing the proportion of people with hepatitis B who are managed by their GP in primary care clinics before, 12 months and 24 months after implementation of the Simply B electronic hepatitis B support package.~Part B: A nested qualitative health services feasibility study using semi -structured interviews and thematic analysis Part C: A mathematical modelling study using a Markov model to determine cost effectiveness of Simply B for increasing hepatitis B treatment uptake compared to status quo of hospital care."
41387658|NCT04238780|PROCEDURE|Erector Spinae Plane Block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine needle was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml local anesthetics is done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
41387659|NCT04238780|PROCEDURE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
41387660|NCT02624817|DRUG|Sulfonylurea|See Arm description.
41387661|NCT05728918|DIETARY_SUPPLEMENT|Antrodia cinnamomea mycelia|Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months
41387662|NCT05728918|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, two capsules/day (600 mg/day) for 3 months
41387663|NCT03770273|BIOLOGICAL|sarilumab|sarilumab is a fully human anti-IL-6R(number sign) monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling
41387664|NCT03770273|OTHER|Placebo|Placebo
41387665|NCT02118818|GENETIC|Next generation sequencing|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
41387666|NCT02104401|DEVICE|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
41387667|NCT03451227|DRUG|Dexmedetomidine group|The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.
41387668|NCT03451227|DRUG|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
41528358|NCT00774163|OTHER|Placebo|5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
41528359|NCT04083638|DIAGNOSTIC_TEST|IFAB|Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
41528360|NCT04181892|PROCEDURE|Coronally advanced flap + connective tissue graft|connective tissue graft covered by a coronally advanced flap with connective tissue graft apical of the cementoenamel junction level
40856616|NCT04784832|DEVICE|Cervicomedullar stimulation|Electric stimulation of the muscle
40856617|NCT04784832|OTHER|Physical training|Training to perform the task by actually doing the task
40856618|NCT04784832|OTHER|Mental training|Training to perform the task by imaging doing the task
40856619|NCT04872699|DIAGNOSTIC_TEST|Serology testing, RT PCR|Periodic testings and testings with characteristic symptoms occur
41387669|NCT05097066|PROCEDURE|Neurosurgical procedure|Any neurosurgical procedure in the National Neurosurgical Audit Programme (NNAP) Coding Framework of neurosurgical procedures.
41387670|NCT06121661|DEVICE|APPRAISE Trauma Clinical Decision Support System|Real-time bedside decision-support system for trauma patient management
41387671|NCT06540820|DIAGNOSTIC_TEST|Dexa or Biompedance analysis with clinical and biochemical evaluations|All patients will undergo body composition study with DXA or Bioimpedance analysis which are the gold standard to determine % of fat mass and fat free mass, basal biochemical examinations and oral glucose tolerance test (OGTT), and clinical evaluation with waist circumference measurement. Moreover, all patients will undergo REMS ultrasound, TBS and BSI evaluation at DXA scan and hand grip test. In addition, all patients will undergo to clinical evaluation with specific nutritional, physical activity and sleep quality questionnaire assessments and an additional volume of blood.
41387672|NCT00945971|OTHER|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
41387673|NCT05187507|OTHER|Evaluation of the effectiveness of low- fluoridated toothpaste.|"Children will be given low- fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
40856620|NCT00614146|DEVICE|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
41038335|NCT04091139|BEHAVIORAL|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
41038336|NCT04091139|BEHAVIORAL|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
41038337|NCT01895972|DRUG|Latanoprostene bunod|
41038338|NCT01968239|DRUG|Ranibizumab|comparison of different re-treatment criteria for intravitreal injection of ranibizumab
41038339|NCT03065894|OTHER|Matched Physical Therapy Intervention|"Patients who are medium-risk will receive up to 6-8 physical therapy (PT) visits over a 3 month period that is guided by published evidence based practice guidelines. The PT treatment will be tailored to the physical findings and specific patient needs, and appropriate exercises, spinal mobilization/manipulation, strengthening/stretching as well as a home program will be given to improve patient pain and function and reduce disability.~Patients who are high-risk will receive the evidence based PT treatment as deemed necessary. In addition, the PT treatment will incorporate principles of psychologically informed practice to address psychosocial barriers (e.g., fear avoidance, anxiety, etc) that may be impeding disability reduction. This may include instruction on chronic pain rehabilitation techniques such as the use of: pacing in order to maintain or increase activity; graded activity principles in order to increase function; and pain education and understanding responses to pain."
41038340|NCT03065894|OTHER|Current Care in Family Medicine|Patient education, medication management
41038341|NCT00295750|DRUG|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
41038342|NCT00295750|DRUG|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
41038343|NCT00295750|DRUG|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
41038344|NCT04943198|DRUG|Vemurafenib|20 mg/kg/day
41038345|NCT02982252|BEHAVIORAL|CoPILOT|Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
41038346|NCT02808455|DRUG|(Treatment A)|Four 100-mg capsules of pacritinib administered as a single oral dose
41166673|NCT04280562|DEVICE|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
41166674|NCT01182207|DRUG|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
41166675|NCT01182207|DRUG|YAZ®|3 mg/0.02 mg Tablets
41166676|NCT05498454|BEHAVIORAL|Breathworks Mindfulness (Health or Stress Arm)|As for previous descriptions
41528361|NCT05142969|OTHER|2% Chlorhexidine bathing|Eight chlorhexidine-impregnated cloths are used in sequential order to wipe the body surfaces from neck to toe to avoid exposure of chlorhexidine to the mucous membranes of the eyes, ears and mouth.
41528362|NCT01886209|DRUG|Prednisone|
41528363|NCT01886209|DRUG|VX-509|
41528364|NCT01886209|DRUG|Methylprednisolone|
41038347|NCT02808455|DRUG|(Treatment B)|A single 80-mg oral solution dose of pacritinib
41038348|NCT02384954|BIOLOGICAL|Rituximab|Intravenous infusion 375 mg/m\^2.
41511207|NCT05628649|BEHAVIORAL|Teaching Kitchen Collaborative Curriculum|"Participants in the intervention arm will first attend 16 weeks of intensive 2-hour classes covering hands-on cooking skills, dietary recommendations (as described within the Harvard Healthy Eating Plate), mindfulness and stress reduction skills, activity and movement techniques, and tools for behavior change. Next, they will attend monthly booster classes for 8 months, with a final assessment for the sustainability of outcomes at 18 months. Sessions will be taught by a combination of a chef educator, dietitian, health coach, or medical doctor.~The study will consist of 2 cohorts of individuals from 4 teaching kitchen program institutions. Each institution will run one-two cycles of the program with each cycle including both a treatment and control group. Each individual cohort will consist of a maximum of 80 individuals; with 40 block-randomized to the intervention and 40 in the control group receiving normal standard of care (followed by their PCP)."
40856621|NCT00614146|PROCEDURE|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
41511208|NCT04607837|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
41511209|NCT04607837|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
41511210|NCT00715624|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
41511211|NCT00715624|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
40856622|NCT00614146|PROCEDURE|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
40856623|NCT06434246|BEHAVIORAL|pulley system exercise regimen|The warm-up consists of gentle stretching and basic mobility exercises to prepare the muscles and joints for the activity. Following this, the main segment of the session involves specific exercises using the pulley system, designed to target and improve motor function, strength, and coordination of the upper limbs. The therapist will adjust the exercises according to each child's individual abilities and progression over time. The session concludes with a cool-down period involving light activities and relaxation techniques to ensure a gradual return to baseline physiological states.
40856624|NCT06434246|BIOLOGICAL|physical therapy program for CP|Participants in the control group will attend physical therapy sessions twice per week. These sessions aim to maintain or improve physical functioning and manage the symptoms of cerebral palsy. Each session lasts approximately 45 to 60 minutes, These sessions include a variety of therapeutic exercises tailored to each child's needs but do not include the use of the pulley system. Typical activities might involve stretching, strengthening exercises, and manual therapy techniques to enhance joint mobility and muscle function.
40856625|NCT00096980|DRUG|Raptiva (efalizumab)|
40856626|NCT03822767|BIOLOGICAL|sIPV-sIPV-bOPV vaccination schedule|Two intramuscular injections of the investigational vaccine (0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Biotech Co., Ltd . The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
40856627|NCT03822767|BIOLOGICAL|wIPV-wIPV-bOPV vaccination schedule|Two intramuscular injections of the control vaccine(0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
41166677|NCT02392663|OTHER|Hypertonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
41038349|NCT02384954|BIOLOGICAL|N-803|Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.
41038350|NCT05265468|OTHER|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
41166678|NCT02392663|OTHER|Hyaneb solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
41511212|NCT00715624|DRUG|Basal Insulin|Dose to be kept stable.
41511213|NCT00715624|DRUG|Metformin|Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.
41511214|NCT00715624|DEVICE|Pen auto-injector|
41528365|NCT01847586|PROCEDURE|Paired Associative Stimulation|PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.
41038351|NCT05265468|OTHER|Lewit Group|Isometric muscular exercise acompained with stretching technique
41038352|NCT05265468|OTHER|Chaitow Group|Isometric muscular exercise acompained with stretching technique and diaphragmatic breathing
41038353|NCT05265468|OTHER|Placebo Group|No pain positioning of participants
41038354|NCT01478568|DRUG|mirabegron|oral
41038355|NCT01478568|DRUG|desipramine|oral
41038356|NCT02322957|DRUG|FV-100|Subjects will be randomized to one of two treatment sequences: AB or BA.
41038357|NCT02130193|DRUG|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
41038358|NCT02130193|DRUG|Placebo|Subjects will receive danirixin matching placebo
41038359|NCT00035126|DRUG|epothilone b|
41038360|NCT00489970|PROCEDURE|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
41038361|NCT00489970|BIOLOGICAL|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
41511215|NCT03431545|BEHAVIORAL|PALS and|"Play and Learning Strategies (PALS) include web-based parent training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Parents will begin their 11 week (infant) or 14 week (toddler) parenting program in October and complete it by April. There will be monthly Parent Meetings related to the content they are learning online. Post-assessments will occur in late April and May. Each weekly online parent session will take approximately 30 minutes to complete with a 40 - 60 minute weekly remote coach call."
40856628|NCT04359160|DEVICE|Orthense, Orthense, Digikare Inc. Blagnac, France|Mobile-app follow-up care, with questions and score
40856629|NCT04359160|OTHER|Questionnaire|Paper questionnaire follow-up, with questions and score
41387674|NCT05187507|OTHER|Evaluation of the effectiveness of fluoridated toothpaste.|"Children will be given e fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
41387675|NCT05187507|OTHER|Evaluation of the effectiveness of theobromine toothpaste (2%) toothpaste.|"Children will be given theobromine toothpaste(2%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
41528366|NCT01847586|PROCEDURE|Paired Associative Stimulation-Control|PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
40856630|NCT00077324|GENETIC|proteomic profiling|
40856631|NCT00077324|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
40856632|NCT00077324|PROCEDURE|biopsy|
40856633|NCT00077324|PROCEDURE|surgery|
40856634|NCT02944786|BEHAVIORAL|HOPE-model|There are four sessions of person-centered health dialogues. The sessions also include pain/stress management and education about stress and pain (the HOPE model that is an adolescent-centered school health prevention program when adolescents have chronic pain).
40856635|NCT02794233|OTHER|Impedance measurements|Refer to study description
40856636|NCT00939562|DRUG|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
40856637|NCT00939562|DRUG|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
41038362|NCT00489970|BIOLOGICAL|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
41038363|NCT00260468|OTHER|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
41038364|NCT03392311|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
41038365|NCT03392311|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.
41038366|NCT01562756|OTHER|HVLA-SM|High velocity, low amplitude spinal manipulation
41038367|NCT00709969|DRUG|Artemether-lumefantrine|20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - \< 10kg (BWG 1) = 6 doses of 1 tablet / 10 - \< 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
41038368|NCT01024322|DRUG|Ciprofloxicine or Vigamox or other.|Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
41038369|NCT01024322|DRUG|Nonsteroidal (Acular, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
41038370|NCT01024322|DRUG|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
41038371|NCT01335204|DRUG|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
41038372|NCT03443960|DRUG|TNX-102 SL 5.6 mg|Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.
41038373|NCT03443960|DRUG|Amrix 30 mg|Subjects randomly assigned to this treatment will swallow 1 capsules with a cup of water, and not to crush or chew it.
41038374|NCT05355974|DRUG|Norepinephrine|Norepinephrine continuous infusion at 0.10 mcg/kg/min
41038375|NCT05355974|DRUG|Lactated Ringers, Intravenous|500mL infusion run at 999mL/hr
41038376|NCT05355974|DRUG|normal saline|500mL infusion run at 999mL/hr
41038377|NCT05355974|DRUG|Plasma-lyte|500mL infusion run at 999mL/hr
41038378|NCT00786929|PROCEDURE|Catheter drainage|
41038379|NCT00786929|DRUG|Conservative treatment|
41038380|NCT00818753|DRUG|dabigatran 110 mg|comparison of different dabigatran dosages with unfractionated heparin
41038381|NCT00818753|DRUG|dabigatran 150 mg|comparison of different dabigatran dosages with unfractionated heparin
41038382|NCT00818753|DRUG|unfractionated heparin|comparison of different dosages dabigatran with unfractionated heparin
41387676|NCT05187507|OTHER|Evaluation of the effectiveness of theobromine toothpaste(4%) toothpaste.|"Children will be given theobromine toothpaste(4%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
41038383|NCT01680328|OTHER|19 injections|Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
41038384|NCT01680328|DRUG|sodium chloride 0.9% solution|Solution for injection.
41038385|NCT03580876|DRUG|addition of azathioprine|impact of addition of azathioprine after a switch of a second anti-TNF agent
41511216|NCT03431545|BEHAVIORAL|BEECH|"Beginning Education: Early Childcare at Home (BEECH) includes web-based teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Teachers will complete the 20 online sessions weekly, except for planned center closings due to holidays or agency-related events. The three in-person trainings will occur before Session 1 and after Sessions 8 and 14. Each weekly online teacher session will take approximately one-hour for a teacher to complete with a 30 minute weekly remote coach call. Each in-person teacher training will be 6-hours in duration."
41038386|NCT03580876|DRUG|Switch to a second anti-TNF drug alone|Switch to a second anti-TNF drug alone without addition of azathioprine
41038387|NCT02806375|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Day 0: Infusion of unmanipulated graft
41038388|NCT02806375|DRUG|Busulfan|Days -5 through -3: Busulfan 1 mg/kg po qid №10
41038389|NCT02806375|DRUG|Fludarabine monophosphate|Days -7 through -2: 30 mg/m2/day iv qd x 6 days
41038390|NCT02806375|DRUG|Cyclophosphamide|Day +3 and +4: 50 mg/kg/day iv qd
41038391|NCT02806375|DRUG|Ruxolitinib|Days -8 through -2 15 mg tid
41038392|NCT02806375|DRUG|Ruxolitinib|Days +5 through +100: 7.5 mg bid
41038393|NCT02950246|PROCEDURE|perineural catheterization implementation|Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use
41038394|NCT02950246|DRUG|2% alcoholic chlorhexidine|
41038395|NCT02950246|DRUG|povidon iodine|
41038396|NCT05470868|DRUG|Naphazoline / Hypromellose Ophthalmic|Naphazoline 0.03% / Hypromellose 0.2%
41038397|NCT02836418|DRUG|ATYR1940|Concentrate for solution for infusion
41038398|NCT00785655|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
41038399|NCT02836808|BEHAVIORAL|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.
41038400|NCT01333124|RADIATION|chemoradiotherapy with Gemcitabine|All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
41387677|NCT03111407|PROCEDURE|total knee arthroplasty|surgical procedure in which damaged parts of the knee joint are replaced with an implant.
41387678|NCT05021315|DRUG|10% povidone iodine|50 women who received preoperative vaginal cleansing with 10% povidone iodine.
41511217|NCT03431545|BEHAVIORAL|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
41511218|NCT02982291|PROCEDURE|Williams flexion protocol|The Williams flexion protocol group will participate in 15 treatment sessions.
41511219|NCT02982291|PROCEDURE|Focused spinal stenosis rehabilitation|The focused spinal stenosis rehabilitation group will participate in 5 treatment sessions.
41038401|NCT01333124|RADIATION|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine
41038402|NCT04323813|DIAGNOSTIC_TEST|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
41038403|NCT05836766|DRUG|Y-6 sublingual tablets|Take Y-6 sublingual tablets for 28 days continuously.
41038404|NCT05836766|DRUG|Placebo tablets of Y-6 sublingual tablet|Take Placebo tablets of Y-6 sublingual tablet for 28 days continuously.
41038405|NCT01166633|DRUG|pitavastatin|pitavastatin 2mg per daily
41038406|NCT01166633|DRUG|atorvastatin|atorvastatin 10mg per daily
41038407|NCT00735046|BEHAVIORAL|Cognitive behavioral therapy for early Alzheimer's disease|12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.
41038408|NCT00735046|OTHER|Control|Patients and proxies who are assigned to treatment as usual
41038409|NCT04866212|BEHAVIORAL|Beery- Buktenica Developmental Test of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
41038410|NCT04866212|BEHAVIORAL|Jebsen Taylor Hand Function Test|Investigation of hand skills by Jebsen Taylor Hand Function Test
41038411|NCT04866212|DIAGNOSTIC_TEST|Participation and Environment Measure - Children and Youth|Investigation of participation by Participation and Environment Measure - Children and Youth
41038412|NCT01331473|PROCEDURE|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
41387679|NCT00698607|DEVICE|Everolimus-eluting stent (Xience or Promus)|Use everolimus-eluting stent in the treatment of coronary stenosis
41387680|NCT00698607|DEVICE|Sirolimus-eluting stent (Cypher)|Use sirolimus-eluting stent in the treatment of coronary stenosis
40892987|NCT02490098|OTHER|6-day intervention with single-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
41038413|NCT01331473|PROCEDURE|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
41038414|NCT01740674|OTHER|Electronic data collection|
41038415|NCT02263651|PROCEDURE|Quilting suture without drainage|"In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (\<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.~Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.~The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area."
41387681|NCT00698607|DRUG|6-month clopidogrel therapy|Use clopidogrel for 6 months
41387682|NCT00698607|DRUG|12-month clopidogrel therapy|Use clopidogrel for 12 months
41387683|NCT06422832|OTHER|HeartLogic or TriageHF Algorithms for implantable devices|Activation of the HeartLogic and TriageHF algorithms for implantable devices and correctly act according to its design
41387684|NCT05635760|BEHAVIORAL|Group-based Parent-implemented Social Communication Training|The intervention will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
41387685|NCT05635760|BEHAVIORAL|Self-learning-based Parent-implemented Social Communication Training|Self-learning families will learn the same materials without the guidance of a therapist.
41387686|NCT00003607|RADIATION|radiation therapy|
41387687|NCT00532779|DRUG|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
41387688|NCT00532779|DRUG|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
41387689|NCT00532779|DRUG|Placebo|
41387690|NCT00532779|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
41387691|NCT01508572|DRUG|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
41038416|NCT02263651|PROCEDURE|Conventional closure with drainage|"The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.~The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent."
41387692|NCT05428059|OTHER|mobile education|The training content prepared by the researchers will be presented to the expert opinion. After the necessary arrangements, it will be installed on the mobile application. The mobile application will be downloaded to the patients' phones for one month. It will be in live consultation.
41387693|NCT04739852|OTHER|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
41038417|NCT05282238|DIAGNOSTIC_TEST|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose). The measurement of DeltaPnose will be obtained considering the average of 3 values registered during 3 breath after at least 3 minutes of stable and constant respiratory pattern. Pnose values will be measured before extubation (T0) and 30 minutes (T1), 2 hours (T2), 4 hours (T3), 12 hours (T4) , 24 hours (T5) and 48 hours (T6) after extubation.
41038418|NCT03028974|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
41038419|NCT03028974|BIOLOGICAL|FluMist®|FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
41387694|NCT06566976|OTHER|Exercise Intervention|Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.
41387695|NCT06566976|OTHER|VAPAHCS Rehabilitation Core Components|The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.
41387697|NCT00700037|DRUG|high-dose atorvastatin|20mg/day
41387698|NCT00700037|DRUG|low-dose atorvastatin|5mg/day
41387699|NCT06392321|DRUG|Fentanyl|comparison between bupivacaine, bupivacaine and fentanyl.
41387700|NCT06392321|DRUG|Dexmedetomidine|comparison between bupivacaine, bupivacaine and dexmedetomidine..
41387701|NCT00710086|DRUG|Hydromorphone|Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
41166679|NCT02392663|OTHER|Isotonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
41166680|NCT04512898|DRUG|Triple therapy for H.pylori|Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.
41166681|NCT03944902|DRUG|Cohort 1: Dose Escalation|The first 3 participants will be enrolled on a fixed dose of Niraparib and CB-839, 600mg. Participants will be evaluated for DLT's, if there are none, they will be enrolled in the next cohort.
41387702|NCT00710086|DRUG|Remifentanil|Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
41166682|NCT03944902|DRUG|Cohort 2: Dose Escalation|If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
41166683|NCT04782700|OTHER|Steroid Taper (Prednisone)|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
41166684|NCT00468065|DEVICE|VeinViewer|Veinveiwer is used to view veins subQ
41166685|NCT00468065|DEVICE|Veinviewer|near infrared light reveals veins subcutaneously
41166686|NCT06048809|OTHER|Stannous Fluoride Toothpaste (Sensodyne Repair and Protect)|Sensodyne Repair and Protect toothpaste containing 1100 ppm fluoride as SnF2.
41387703|NCT00719758|DRUG|TRK-100STP (BERASUS LA)|oral
41387704|NCT00719758|DRUG|AST-120 (Kremezin®)|oral
41387705|NCT05412069|DEVICE|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry, balloon expulsion test, and anal ultrasonography will be used as reference.
41387706|NCT02758951|OTHER|Perioperative systemic therapy|Neoadjuvant systemic therapy should start within four weeks after randomisation. Adjuvant systemic therapy should start within twelve weeks after CRS-HIPEC. In case of unacceptable toxicity or contraindications to oxaliplatin or irinotecan in the neoadjuvant setting, CAPOX or FOLFOX may be switched to FOLFIRI and vice versa. In case of unacceptable toxicity or contraindications to oxaliplatin in the adjuvant setting, CAPOX of FOLFOX may be switched to fluoropyrimidine monotherapy. Dose reduction, prohibited concomitant care, permitted concomitant care, and strategies to improve adherence are not specified a priori, but left to the discretion of the treating medical oncologist. Perioperative systemic therapy can be prematurely discontinued due to radiological or clinical disease progression, unacceptable toxicity, physicians decision, or at patients request.
41387707|NCT02758951|COMBINATION_PRODUCT|Perioperative CAPOX-bevacizumab|Four three-weekly neoadjuvant and adjuvant cycles of CAPOX (130 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 1000 mg/m2 BSA of capecitabine, orally twice daily on days 1-14), with bevacizumab (7.5 mg/kg body weight, IV on day 1) added to the first three neoadjuvant cycles.
41166687|NCT06048809|OTHER|Regular Fluoride Toothpaste (Colgate Cavity Protection)|Colgate Cavity Protection containing 1100 ppm fluoride as SMFP.
41387708|NCT02758951|COMBINATION_PRODUCT|Perioperative FOLFOX-bevacizumab|Six two-weekly neoadjuvant and adjuvant cycles of FOLFOX (85 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2), with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
41387709|NCT02758951|COMBINATION_PRODUCT|Perioperative FOLFIRI-bevacizumab|Six two-weekly neoadjuvant cycles of FOLFIRI (180 mg/m2 body-surface area \[BSA\] of irinotecan, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) and either four three-weekly (capecitabine (1000 mg/m2 BSA, orally twice daily on days 1-14) or six two-weekly (400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) adjuvant cycles of fluoropyrimidine monotherapy, with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
41511220|NCT01918566|DIETARY_SUPPLEMENT|tap water|
40856638|NCT06085508|BEHAVIORAL|Digital patient education to reduce kinesiophobia after MI and/or AF|Group-meetings 7 times via Zoom® video with a tutor (nurse, physiotherapist) and learn about PA, kinesiophobia, AF and/or MI. Scenarios start the problem-based learning process involving recorded lectures, behavioral activation, and exposure to PA. Week1: Programme intro. Formulation of individual goals. Home assignment (HA): Lecture PA after MI/AF. Week 2. Discuss HA. Scenario 1: Why PA after MI/AF? (PBL) Formulate questions\*. HA: Answer the questions. Week 3. Follow-up HA. Scenario 2. What is MI/AF.\* Week 4. Discuss HA. Scenario 3. Living with MI/AF and kinesiophobia - How to make a change?\* HA: Map weekly activities, rate as frightening/non-frightening. List PA and choose one to implement. Use SMART GOALS. Lecture: Kinesiophobia. Week 5. Discuss HA. Scenario 4. How can I reduce my fear for PA.\* SMART, the activity. Week 6. Discuss HA. Week 7. Own individual work. HA: Evaluate, revise, and perform activities. Week 8. Follow-up of the activity plan. Summarize the program.
40856639|NCT00284700|DRUG|Iron|
41166688|NCT00002597|DRUG|flutamide|Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.
41166689|NCT00002597|DRUG|Zoladex|3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
41166690|NCT00002597|DRUG|Lupron|7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
41166691|NCT00002597|RADIATION|radiation therapy|46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
41166692|NCT04280679|DEVICE|Sonovein 2|Patient are treated with the HIFU device and the pysician is doing a compressive bandage
41511221|NCT01918566|DIETARY_SUPPLEMENT|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube|
41511222|NCT01918566|DIETARY_SUPPLEMENT|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole|
41511223|NCT01918566|DIETARY_SUPPLEMENT|25g Fructose in 300ml tap water|
41387710|NCT02758951|PROCEDURE|CRS-HIPEC, experimental arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. The choice of HIPEC medication (oxaliplatin or mitomycin C) is left to the discretion of the treating physician, since neither one has a favourable safety or efficacy. CRS-HIPEC should be performed within six weeks after completion of neoadjuvant systemic therapy, and at least six weeks after the last administration of bevacizumab in order to minimise the risk of bevacizumab-related postoperative complications.
40856640|NCT04463342|COMBINATION_PRODUCT|Non Coated Glass Ionomer|KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.
40856641|NCT04463342|COMBINATION_PRODUCT|Conventional Glass Ionomer with Coat|Conventional Glass Ionomer with Coat
40856642|NCT01002183|DRUG|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
40856643|NCT06584474|DRUG|Azithromycin neubilization|"nebulized azithromycin (Xithrone, Amoun, Egypt) that will be initiated from day 7 of birth in a dose of 20 mg/kg/day in two divided doses for 3 weeks till the time of primary outcome assessment (at 28 days of age). Azithromycin solution for nebulization will be prepared from intravenous vials containing 500 mg lyophilized powder. First, each lyophilized powder vial will be prepared with 5 ml normal saline according to the manufacturer's instruction. The reconstituted solution will be diluted with 28.5 ml normal saline to make a final concentration of 17.5 mg/ml according to clinical pharmacy recommendation. For nebulization of azithromycin, 0.6 ml of final drug prepared solution will be taken for every~1 kg body weight of patient, then made up to 3 ml of normal saline and will be administered by Aerogen Jet Nebulizer every 12 hours using 8 liter/min of medical air or by face mask if not mechanically ventilated. According to the manufacturer's declaration, prepared azithro"
40856644|NCT06584474|DEVICE|Lung ultrasound|Device A mobile device (PHILIPS ® HD11 XE) with a 10-MHz linear probe will be used for chest ultrasound. It will be done at day 14 of postnatal life.
40856645|NCT03862235|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|The patients underwent to CMR examination on a Philips Achieve 1.5 device. Images were acquired coupled to the electrocardiogram and during respiratory pause, in four chambers, short axis and long axis of the left ventricle, in the same exact location in different sequences. A gradient - echo sequence (steady-state free precession) was used to evaluate cardiac function (functional evaluation). We will also evaluate T1 weighted images (T1 -relaxation times) and T2, performed sequentially, through spin-echo pulse (black-blood), triple inversion recovery sequence, for the morphological evaluation
40856646|NCT03862235|DIAGNOSTIC_TEST|Transthoracic echocardiography|The images were collected by the Vivid E9. The patients were submitted to one-dimensional (M-mode), two-dimensional (B-mode), and three-dimensional (three-dimensional) echocardiographic studies. The images obtained were associated with pulsed, continuous and color Doppler.
40856647|NCT04789889|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy
40856648|NCT04789889|RADIATION|postoperative radiotherapy|postoperative radiotherapy
40856649|NCT03807414|DEVICE|oXiris|Every center will prescribe EBPT with oXiris in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
41038420|NCT04363801|DRUG|DKN-01 300mg|Administered by IV infusion
41038421|NCT04363801|DRUG|DKN-01 600mg|Administered by IV infusion
41038422|NCT04363801|DRUG|DKN-01 400mg|Administered by IV infusion
41038423|NCT04363801|DRUG|Tislelizumab 200mg|Administered by IV infusion
41038424|NCT04363801|DRUG|Tislelizumab 400mg|Administered by IV infusion
41387711|NCT02758951|PROCEDURE|CRS-HIPEC, control arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. The choice of HIPEC medication (oxaliplatin or mitomycin C) is left to the discretion of the treating physician, since neither one has a favourable safety or efficacy. CRS-HIPEC should be performed within six weeks after randomisation.
41387712|NCT01551329|DRUG|Ketalar (ketamine)|Intravenous Ketamine 0.5mg/kg
41387713|NCT03173807|BEHAVIORAL|diet and exercise guidance and modifications|Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer
41387714|NCT01494649|DRUG|Test Toothpaste|0.454% stannous fluoride toothpaste
41387715|NCT01494649|DRUG|Negative Control Toothpaste|0.76% sodium monofluorophosphate toothpaste
41387716|NCT05837117|BEHAVIORAL|Patient's Perspective|"Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic.~Participants/Researchers will learn about your attitudes, beliefs, and feelings about sexual well-being"
41387717|NCT01915485|RADIATION|Lu 177|Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
41387718|NCT00099320|DRUG|exenatide|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units \[5 μg\] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units \[10 μg\] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
41387719|NCT00099320|DRUG|Placebo|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
41387720|NCT05365347|BEHAVIORAL|Cognitive Enhancement Therapy (CET)|Cognitive enhancement therapy is an evidence based intervention for schizophrenia focused on improving the cognitive domains of memory, attention span and learning ability. It has shown efficacy in reducing substance use as an indirect outcome but this will be the focus of this intervention.
41038425|NCT04363801|DRUG|Oxaliplatin|Administered by IV infusion
41038426|NCT04363801|DRUG|Capecitabine 1000mg/ m2 BID|Administered orally
41038427|NCT04363801|DRUG|Leucovorin Calcium|Administered by IV infusion
41038428|NCT04363801|DRUG|Fluorouracil|Administered by IV infusion
41387721|NCT00478673|DEVICE|NexStent Carotid Stent System (Monorail Delivery System)|Self-expanding carotid stent for treating patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
41511224|NCT01918566|DIETARY_SUPPLEMENT|75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39|
40856650|NCT02402140|OTHER|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
40856651|NCT02699320|OTHER|Complications|Not involved
40856652|NCT02722954|DRUG|Demcizumab|Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
41387722|NCT00478673|DEVICE|FilterWire EZ™ Embolic Protection System|Used as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
40856653|NCT02722954|DRUG|Pembrolizumab|Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
40856654|NCT03906539|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg per day
41387723|NCT01093716|DEVICE|Magstim Rapid® (rTMS)|Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
41387724|NCT03187288|DRUG|CFI-400945 Fumarate|CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
41387725|NCT02476500|PROCEDURE|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
40856655|NCT03906539|DIETARY_SUPPLEMENT|Virgin Coconut Oil (VCO)|Capsule VCO (1000 mg/day)
40856656|NCT03906539|OTHER|Placebo|Placebo capsule - 1 capsule per day
40856657|NCT00502788|DRUG|Peginterferon Alfa-2a and Ribavirin|"Patients will be treated with alfa-2a and ribavirin as follows:~Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
41387726|NCT04118855|DRUG|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
41387727|NCT04118855|DRUG|Axitinib|5 mg by mouth twice each day for 12 weeks prior to nephrectomy
41387728|NCT04765852|OTHER|High dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
40856658|NCT00502788|DRUG|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight \> 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
40856659|NCT04647123|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
41511225|NCT01918566|DIETARY_SUPPLEMENT|300ml tap water with 450ppm lactisole|
40856660|NCT00765570|RADIATION|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
40856661|NCT00765570|RADIATION|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
40856662|NCT00765570|RADIATION|Standard radiation|15 Standard radiation treatments
41511226|NCT03753191|DEVICE|transcranial direct current stimulation|Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
40856663|NCT00765570|RADIATION|Standard radiation|standard radiation treatment
40856664|NCT03567746|PROCEDURE|Underwater EMR|Polypectomy is performed under full water emersion avoiding the use of submucosal injection.
40856665|NCT03567746|PROCEDURE|Conventional EMR|It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
40856666|NCT00317304|BEHAVIORAL|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
40856667|NCT04395690|PROCEDURE|Dental Implant Placement in the posterior mandible|Surgery done in the posterior mandible with missing teeth for placing dental implants.
40856668|NCT02519205|OTHER|Survey|
40856669|NCT00917761|DRUG|Entecavir and peginterferon (Pegasys) (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
40856670|NCT00917761|DRUG|Peginterferon (Pegasys) (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
40856671|NCT00917761|DRUG|Peginterferon (Pegasys) (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
40856672|NCT04679974|BEHAVIORAL|Melodic-based Communication Therapy|"General procedures involved in (M.B.C.T.) are as follows: 25 common first words are selected as the targets (e.g., apple, ball, car, dog, cat, eat, go, etc.). Pictures and objects will be used as stimulus items. The top 3-5 incentives as identified by parent survey will be given according to the therapies specific reinforcement schedule. All treatment and evaluation sessions will be videotaped for future/further analysis and verification purposes. For the purposes of the study design, the same 25 words will be used for all participants.~Participants will first listen to the target word set to a melodic tone and rhythm on a compact disc (CD). Clinicians will present the stimulus item (e.g., apple) prior to beginning the steps. Therapy will then progress from clapping and singing the melody to answering sung questions and finally to answering spoken questions with the target word"
41387729|NCT04765852|OTHER|Low dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
41166693|NCT04334278|BEHAVIORAL|GetHealthy-OA|The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
41387730|NCT04765852|OTHER|Placebo|One placebo stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
41387731|NCT00146003|DRUG|Efalizumab treatment|
41387732|NCT03290976|OTHER|Acupuncture|"Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5"
41387733|NCT03290976|OTHER|"Multi-modality (Acupuncture plus)"|"A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:~* Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure~* Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner."
41387734|NCT04106947|OTHER|Questionnaires|Questionnaires
41387735|NCT05260307|OTHER|hearing aid condition|The intervention will be a hearing aid or a modification to the sound stimulus that simulates a hearing aid configuration, style, or processing strategy.
41387736|NCT05318807|OTHER|Assessment of level of readiness and need for personalised prehabilitation|"Patients asked to complete five validated questionnaires to assess their level of need and readiness:~1. Cancer Behaviour Inventory brief form - to measure self-efficacy for coping with cancer~2. Patient Activation Measure - to measure patient activation~3. Modified Godin Leisure Time Exercise Questionnaire - to monitor activity~4. Patient Generated Subjective Global Assessment - to identify malnutrition risk~5. Emotions thermometer - to detect emotional disorders and identify risk"
41511227|NCT00712790|DRUG|Sorafenib|Tablet, 400mg orally, twice daily
41038429|NCT03762473|DRUG|Study Group|Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.
40856673|NCT04280796|BEHAVIORAL|psychophysical tasks|"All participants perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other.~In addition, in Substudy 1 an operant learning paradigm will be implement to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement or vice versa.~In Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients."
40856674|NCT04280796|BEHAVIORAL|cognitive task|In Substudy 3 participants will perform a psychophysical task to assess metacognition in pain perception as an indicator of the cognitive-evaluative pain component.
41166694|NCT04334278|BEHAVIORAL|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth.
41166695|NCT03903562|BIOLOGICAL|V503|0.5 mL 9vHPV VLP Vaccine
40856675|NCT01670721|DRUG|AFLIBERCEPT|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
41038430|NCT03762473|DRUG|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of \< 1 at month 1, and BK data available and month 2,3, 6,9,12.
41038431|NCT01538381|DRUG|Afatinib|Afatinib for 2 weeks at a dose of 40 mg/day
41038432|NCT01538381|OTHER|Observation|Observation
41166696|NCT03883698|DRUG|Sofosbuvir|Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens
41166697|NCT03883698|DRUG|Daclatasvir 60 mg|Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
41166698|NCT05463926|BEHAVIORAL|PDA mobile application|"Parentbot - a Digital healthcare Assistant (PDA):~A mobile application-based psychosocial parenting intervention with integrated chatbot features. It consists of multimedia educational materials (text files, audio files and videos), discussion forums, guided mindfulness-based meditation videos, guided reflection and gratitude journals and a chatbot."
41166699|NCT01293799|BEHAVIORAL|Follow-up of PD patients´ theoretical and practical skills|Testing of patients knowledge and retraining if needed
41166700|NCT01183013|DRUG|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
41166701|NCT01183013|DRUG|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
41511228|NCT00712790|RADIATION|SIR-Spheres|one time treatment and capped at 3.0 Gbq
41511229|NCT02005835|OTHER|Community based peer support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment"
41166702|NCT01183013|DRUG|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
41387737|NCT05318807|OTHER|Formation of a personalised prehabilitation plan|"Prior to starting treatment, at week three and at week six, each patient will be invited to see a specialist dietitian for a one hour face-to-face personalised prehabilitation appointment to:~* Review the initial questionnaires to inform the personalised plan and goal setting~* Complete a further four questionnaires related to quality of life, diet and exercise~* Measure handgrip strength~* Assess functional capacity by completing the six minute walk test~A personalised plan is then agreed using SMART goals, taking into account the patient's priorities as indicated in their Patient Generated Index."
41166703|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
41387738|NCT05318807|OTHER|Daily diary|Each patient will be asked to keep a daily diary to record their symptoms, appetite, mobility and mood throughout their treatment as well as their adherence to goals. This will provide an indication of the impact of symptoms.
41166704|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
41166705|NCT01183013|DRUG|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
41166706|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
41387739|NCT02752451|OTHER|Non-Anatomic Arthroscopy Simulation|Knee arthroscopy training using Cigar Box Arthroscopy Trainer
41387740|NCT02752451|OTHER|Anatomic Arthroscopy Simulation|Knee arthroscopy training using Anatomic Knee Arthroscopy Trainer
41387741|NCT02752451|OTHER|Pre-assesment education|Reading material and lecture with only still images about performing diagnostic knee arthroscopy
41387742|NCT06444529|DRUG|Apraclonidine Hydrochloride Ophthalmic Solution|Investigational ophthalmic solution applied topically to the eye with a dropper bottle
41387743|NCT06444529|DRUG|Vehicle|Vehicle (inactive ingredients) applied topically to the eye with a dropper bottle
41387744|NCT02604186|OTHER|Botulinum Toxin Injections|Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.
41387745|NCT02604186|OTHER|Placebo Injections|Each patient in the placebo group will receive sterile sodium chloride injections at adductors and triceps surae muscles bilaterally.
41387746|NCT01892020|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
41387747|NCT01892020|DRUG|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
41387748|NCT02572973|OTHER|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
41166707|NCT04882748|OTHER|ADAMO|Physical therapy provided with or without the help of a robot
41166708|NCT02304562|BIOLOGICAL|UCB Mesenchymal Stem Cells treatment|reduce skin injury
41166709|NCT02564718|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
41387749|NCT06019286|DIAGNOSTIC_TEST|SCINEXA score|- 18 signs of extrinsic aging of SCINEXA score: sunburn, freckles, actinic lentigo, hyperpigmentation and/or melasma, change in phototype, yellowness, pseudoscars, coarse wrinkles, solar elastosis, cutis rhomboidalis, elastosis, comedones and cysts of Favre-Racouchot, xerosis, teleangectasias, permanent erythema, actinic keratosis, basal cell carcinoma, squamous cell carcinoma and malignant melanoma (extrinsic SCINEXA score). Each item will be scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). For some items (uneven pigmentation, cutis rhomboidalis nuchae, elastosis, comedones and cysts of Favre Racouchot, and malignant skin tumors, a binary scale was used: (yes) or (no). Maximun possible score is 54
41166710|NCT02592681|PROCEDURE|verum acupuncture|"Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian)."
41166711|NCT02592681|PROCEDURE|acupressure|"The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min."
41387750|NCT03257774|OTHER|Adhesive strip A|Strip consisting of a newly developed adhesive
41387751|NCT03257774|OTHER|Adhesive strip B|Strip consisting of a newly developed adhesive
41387752|NCT03257774|OTHER|Adhesive strip C|Strip consisting of a newly developed adhesive
41387753|NCT03343054|DRUG|talazoparib|Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
41387754|NCT05292222|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
41387755|NCT03237481|DRUG|HTX-011|HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
40856676|NCT01670721|DRUG|Irinotecan|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
40856677|NCT01670721|DRUG|Fluorouracil|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
40856678|NCT01670721|DRUG|Leucovorin|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
40856679|NCT01930838|PROCEDURE|Gastric bypass operation|
40856680|NCT02275741|BIOLOGICAL|prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)|Publically recommended protective vaccines in MS patients, vaccination applied according to the manufacturers description
40856681|NCT03386487|DRUG|PF 04457845|Study medication will be administered at 4mg by mouth daily for eight weeks.
40856682|NCT03386487|DRUG|Placebo Oral Tablet|Placebo comparator will be administered by mouth daily for eight weeks.
40856683|NCT06300073|DEVICE|Experimental: U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
40856684|NCT06300073|DEVICE|Placebo Comparator: Soft Manual Toothbrush|Twice daily brushing for 2 minutes with fluoride toothpaste
40856685|NCT05350449|BEHAVIORAL|Loving-kindness Meditation|Loving-kindness meditation is a type of mindfulness practice where the focus is on love/compassion and kindness for self and others. The guided meditation will be provided via recording device. The intervention is 4 week long.
40856686|NCT06201286|OTHER|Mulligan Concept|"Mulligan Concept was applied by the physiotherapist who received A-B module trainings. Mulligan techniques were performed with 3 sets of 10 repetitions and 15-20 seconds rest between sets. Mobilisations were applied to the spinous process of each vertebra of the lumbar region with 3 sets of 10 repetitions of SNAG and 3 sets of 10 repetitions of NAGS techniques. In the standing position, the physiotherapist took a position next to the patient and stabilised the patient by grasping the abdomen with one arm.~Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds."
40856687|NCT06201286|OTHER|Stretching and strengthening exercises|Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds.
40856688|NCT02478164|DRUG|Ponatinib|
40856689|NCT00838240|DRUG|clofarabine|Given IV
40856690|NCT00838240|DRUG|cytarabine|Given IV
40856691|NCT00838240|DRUG|idarubicin|Given IV
40856692|NCT00373178|DRUG|rosiglitazone|
40856693|NCT00373178|DRUG|metformin|
40856694|NCT00373178|DRUG|Anti-diabetic medications|
40856695|NCT00000422|BEHAVIORAL|Cognitive-behavioral psychotherapy and physical exercise|
40856696|NCT02816528|BEHAVIORAL|Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
40856697|NCT01166425|DRUG|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing \< 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
40856698|NCT01166425|DRUG|Placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
40856699|NCT02975258|PROCEDURE|Blood draw|Blood will be drawn for plasma, serum, and peripheral blood mononuclear cells.
40856700|NCT02975258|OTHER|Questionnaires|The following questionnaires are administered to participants by study personnel: Gingo Asthma Questionnaire (GAQ) and the Asthma Quality of Life questionnaire (AQL).
40856701|NCT02975258|PROCEDURE|Spirometry|Spirometry is a simple breathing test that measures the amount of air in one's lungs and how well one can move that air by forcefully blowing 3 or more times into a mouthpiece. A series of these maneuvers will be performed under the instruction of a respiratory technician or respiratory therapist.
40856702|NCT02975258|PROCEDURE|Methacholine challenge test|A methacholine challenge is a common test often used to support a diagnosis of asthma. The test consists of inhaling increasing doses of methacholine through a nebulizer to assess how quickly the participant's airways narrow.
41038433|NCT03595904|BEHAVIORAL|E-Motivate group|Participants in the e-Motivate group will receive standard clinical care which includes patient navigation (e.g., scheduling and reminders). They will also complete a 20-minute, motivational interviewing informed tablet app in the clinic immediately after they receive a referral for a screening colonoscopy. The tablet app consists of educational videos, interactive exercises (e.g., decisional balance), and personalized feedback (e.g., print summary).
41387756|NCT03237481|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 75 mg by injection
41387757|NCT03237481|DRUG|Saline placebo|Saline placebo by instillation
41387758|NCT03237481|DEVICE|Luer-lock applicator|Applicator for instillation
41387759|NCT03237481|DEVICE|Vial access device|Device for withdrawal of drug product
41387760|NCT06348173|DRUG|Mepolizumab|Compare the response to mepolizumab and benralizumab before and after treatment
41387761|NCT05135286|DRUG|BRIMOCHOL™ PF|A single drop in each eye at a visit.
41387762|NCT05135286|DRUG|Carbachol PF|A single drop in each eye at a visit.
41387763|NCT05135286|DRUG|Vehicle|A single drop in each eye at a visit.
41387764|NCT00938418|RADIATION|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
41387765|NCT01596049|DEVICE|Self-fixating Mesh|Using Self-fixating Mesh for Inguinal Hernia Repair
41387766|NCT01806259|DRUG|Ketorolac 30 mg IV|Active drug
41387767|NCT01806259|DRUG|Placebos|Placebo looking like the Active drug
41387768|NCT03851107|BEHAVIORAL|Engagement in 6-week community-based activity program|Participants engage in a 6-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 6 weeks - the actual intervention phase.
41387769|NCT00295529|BEHAVIORAL|Multifaceted educational intervention|Educational materials available at end of study
41387770|NCT04289467|DRUG|Fenfluramine|Open-label
41387771|NCT01783860|DRUG|Azithromycin|
41511230|NCT02005835|OTHER|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment"
41511231|NCT06397495|OTHER|Education|Cervical region manual therapy training will be given with flipped learning models.
40856703|NCT02975258|RADIATION|Quantitative CT scans|There will be a standard chest CT and an abdominal CT. The CT scans capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and the abdomen and will be performed during a breath-hold at end-inspiration. The investigators will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized. If the participant has had a research chest CT scan done recently, only the abdomen CT will be done.
40856704|NCT02975258|PROCEDURE|Urine pregnancy test|All female participants with childbearing potential will be asked to provide a urine sample for pregnancy testing. The result of the pregnancy test must be negative in order for her to be in this research study.
40856705|NCT02975258|PROCEDURE|Adipose biopsy|The doctor will obtain a sample of fat cells from the participant's abdomen. Numbing medicine will be applied. A needle is placed through the skin \& into the fat pad under the skin. A blunt-tip hollow cannula is then used to aspirate fat tissue through the incision.
40856706|NCT02975258|PROCEDURE|Exhaled nitric oxide measurement|The investigators will measure concentrations of exhaled nitric oxide by asking the participant to inhale deeply, and then exhale very slowly into a mouthpiece for between 10-15 seconds.
40856707|NCT06011837|DEVICE|Altered Auditory Feedback|Mumble Melody is an application that leverages Altered Auditory Feedback (AAF). During AAF, a person's speech is altered in near-real time. Mumble Melody modulates the user's voice and plays it back to them while they are speaking. Included are Unaltered (raw voice), Whisper (voiceless sound), Reverb (cathedral sound), and Harmonized (robotic sound) voice transformations.
40856708|NCT05959278|OTHER|App for vestibular rehabilitation|This app is a platform for performing conventional vestibular rehabilitation remotely
41387772|NCT01783860|DRUG|Doxycycline|
41387773|NCT02913469|DRUG|Morphine|The patients in group A would be administrated intravenous morphine 5mg
41387774|NCT02913469|DRUG|metoclopramide|the patients in group C would be administrated intravenous metoclopramide 10mg
41511232|NCT00717288|DRUG|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
41511233|NCT00717288|DRUG|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
41511234|NCT00717288|DRUG|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
41511235|NCT02904941|BIOLOGICAL|Amniotic Membrane Dressing|Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
41387775|NCT02913469|DRUG|saline|the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
41387776|NCT06247085|DRUG|Pegtibatinase|Full Target Dose of pegtibatinase BIW
41387777|NCT06247085|OTHER|Placebo|volume-matched saline SC BIW
41387778|NCT00759174|DRUG|No intervention|No intervention occurs in this observational study.
41387779|NCT00127569|DRUG|Rituximab|
41387780|NCT05966259|OTHER|Intervention Group- Intensive Multilevel Intervention|intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health.
41387781|NCT05966259|OTHER|Control Group|The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.
41387782|NCT05218031|BEHAVIORAL|Acceptance and Commitment Therapy|A 90-120 minute 5-week group intervention for unaccompanied minors. Each week there will be a different focus. Week 1: Grounding, Week 2: Unhooking, Week 3: Values, Week 4: Self-compassion, Week 5: Making room for unwanted thoughts and feelings.
41511236|NCT02904941|DEVICE|Synthetic Dressing|Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
41038434|NCT03595904|BEHAVIORAL|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy. In particular, they will receive patient navigation which includes scheduling the colonoscopy appointment, making reminder calls, and providing print materials regarding the bowel prep instructions.
41038435|NCT06470854|DRUG|Nebulized Dexmedetomidine|Nebulized Dexmedetomidine was prepared to provide 1 µg/kg and the calculated dose of DXM was diluted by 4-ml of 0.9% saline and was provided in the nebulizer to be nebulized in twice daily; i.e. every 12 hours for 72 hours
41038436|NCT06470854|PROCEDURE|Bilateral greater occipital nerve block|The injection solution was prepared by mixing 2-ml of 2% lidocaine with 2-ml (8 mg) of dexamethasone. A line was drawn extending between the mastoid process and the external occipital protuberance, this line was divided as a medial third and lateral two-thirds to localize the occipital artery and the greater occipital nerve was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline and injection was performed bilaterally to achieve bilateral block.
41038437|NCT02541552|DRUG|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
41038438|NCT02367261|DEVICE|SPI implant|SPI implant - the original spiral implant
41038439|NCT06273423|OTHER|OULA, Mind-body Physical Activity|Group dance fitness program with focus on the mind-body connection
41038440|NCT01262066|BEHAVIORAL|Lifeskills Workshop Intervention|Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
41038441|NCT02271126|DEVICE|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
41038442|NCT02271126|DEVICE|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
41038443|NCT02271126|DRUG|Heparin|Anticoagulation provided to patients in ECMO
41038444|NCT01741753|DRUG|BKM120|Orally, every morning
41387785|NCT06045195|DRUG|Pembrolizumab|"As induction therapy, all participants will receive one dose of single-agent pembrolizumab (P) followed by two cycles of chemo-immunotherapy consisting of pembrolizumab and an eBEACOPP variant without bleomycin (P-EACOPP). Response to induction therapy will be measured after P-mono (PET-1; only for scientific purposes) and after completion of 1x P and 2x P-EACOPP (PET-3).~Further systemic treatment is PET-3-guided. Complete metabolic responses will be consolidated with two cycles of P-EACOPP while participants with a positive PET-3 will receive four cycles of P-EACOPP. PET-positive lesions after completion of chemo-immunotherapy will be recommended for consolidating radiotherapy according to standard of care."
41511237|NCT02904941|PROCEDURE|Standard Wound Care|Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
41511238|NCT01268527|DRUG|0.03% E6201|Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
41511239|NCT01268527|DRUG|0.1% E6201|Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
40856709|NCT00721188|DRUG|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
40856710|NCT05551104|DRUG|Oral Nifedipine|Administration of oral nifedipine to control postpartum hypertension.
40856711|NCT05551104|DRUG|Oral Labetalol|Administration of oral labetalol to control postpartum hypertension.
40856712|NCT06552650|BEHAVIORAL|Exercise|Four supervised exercise interventions after surgery: One exercise education session per week from postoperative day 5 through 1 month Subsequent home-based exercise: Home-based exercise recommendations from 1 month to 3 months post-surgery
40856713|NCT06552650|OTHER|Usual Care|The full spectrum of patient care practices in which clinicians have the opportunity (which is not necessarily seized) to individualize care
40856714|NCT00654082|DRUG|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
40856715|NCT00654082|DRUG|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
40856716|NCT05926024|BEHAVIORAL|Exercise Recall Patient Reported Outcomes|Questionnaire items inquire about (1) the number of days of the week participants engage in walking for pleasure or exercise and (2) the number of minutes per day that participants engage in walking for pleasure or exercise. The same two questions are repeated pertaining to exercise in general. Completion of these items takes 1 minute to complete.
41038445|NCT01741753|DRUG|Abiraterone|Orally, 1000 mg, every morning
41038446|NCT01741753|DRUG|Prednisone|Orally, 5 mg, every morning
41038447|NCT00233558|DRUG|adalimumab (up to 9 months exposure)|
41038448|NCT00233558|DRUG|methotrexate|
41038449|NCT02266069|OTHER|Care Pathway for Primary Palliative Care|Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
41038450|NCT01409538|OTHER|Placebo Instructions|There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
41387786|NCT00411762|DRUG|Capecitabine|
41387787|NCT00411762|DRUG|PHY906|
40856717|NCT05926024|BEHAVIORAL|Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes|Health Behavior Questionnaire (HBQ)30 -- Questionnaire items pertain to the history of smoking, engagement in vigorous physical activity, alcohol consumption, and mortality status of parents, and take less than 1 minute to complete.
41511240|NCT01268527|DRUG|0.2% E6201|Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
41511241|NCT01268527|DRUG|0.005% E6201|Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
40856718|NCT05926024|BEHAVIORAL|Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes|"Functional Assessment of Cancer Therapy-General (FACT-G) is a quality of life and function measure developed and validated over 20 years ago that has been used in hundreds of cancer studies worldwide. It consists of four well-being domains -- physical, social/family, emotional, and functional. The FACT-G (Version 4) is a 27-item instrument that is formatted for self-administration and uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. It takes 6-8 minutes for an average patient to complete."
40856719|NCT05926024|BEHAVIORAL|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes|"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) is a 13-item scale that uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. This measure takes about 1 minute to complete."
40856720|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a)|PROMIS Cognitive Function (Short Form 8a) includes 8 items on a 5-point Likert-type scale ranging from very often/several times a day = 1 to never = 5, with higher scores indicating greater perceived loss of cognitive function. This measure takes less than 1 minute to complete.
40856721|NCT05926024|BEHAVIORAL|Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12)|Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) is a questionnaire that includes 12 items inquiring about symptoms in the past 7 days (0=not at all to 4=very much) pertaining to numbness or tingling in hands/feet, discomfort in hands/feet, joint pain or muscle cramps, weakness all over, trouble hearing, ringing/buzzing in ears, buttoning buttons, trouble feeling the shape of small objects in hands, trouble walking, and pain in hands/feet in cold temperatures. This measure takes about t 1 minute to complete.
40856722|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PROMIS|PROMIS Measures Global Health (10 items), Anxiety (6 items), Depression (8 items), and Stress (10 items). All items are on a 5-point Likert-type scale form never to very often. Completion of all 34 items should take no more than 3 minutes to complete.
40856723|NCT05926024|BEHAVIORAL|Patient Reported Outcomes FACT-Endocrine Symptoms|FACT-Endocrine Symptom is a 19-item questionnaire inquiring about hot flashes, cold sweats, night sweats; vaginal discharge, itching/irritation, bleeding or spotting, dryness; pain or discomfort with intercourse, loss of interest in sex; weight gain; lightheadedness; vomiting; diarrhea; headaches; bloating; breast sensitivity/tenderness; mood swings; irritability; pain in joints. Responses are on a 5- point Likert-type scale from not at all to very much. This measure takes about two minutes to complete.
40856724|NCT05926024|BEHAVIORAL|Patient Reported Outcomes Penn Arthralgia Aging Survey|Penn Arthralgia Aging Survey is an 8-item scale inquiring about joint pain, with a 4-point response scale from not at all to complete. Items pertaining to slowing down, stopping, being hesitant, unable to do this, and feeling unusually aged. This measure takes less than a minute to complete.
40856725|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE)|"PRO-CTCAE (patient-reported CTCAE) is Patients will be asked about the side effects of chemotherapy treatment at baseline, every 3 weeks during chemotherapy, at the end of chemotherapy, and at 6 months post-chemotherapy. Patients are asked to rate in the past 7 days the average severity, frequency, and intensity and a scale from 1=none/never/not at all to 5=very severe/very much/almost all of the time. Symptom list: Abdominal pain, Constipation, Diarrhea. Mucositis oral, Nausea, Vomiting, Edema limbs, Fatigue, Pain, Arthralgia, Myalgia, Peripheral sensory neuropathy, Anxiety, Depression, Insomnia, Dyspnea, Rash maculopapular, Hot flashes. Completion of these measures takes 5 minutes for an average patient"
40856726|NCT05926024|DIAGNOSTIC_TEST|p16 tumor suppressor gene|Blood samples will be obtained to test the p16 tumor suppressor gene from the subjects It is voluntary..
40856727|NCT06018623|OTHER|It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients|"It is an observational study and no non-routine procedures will be performed on patients.~Routine anesthesia procedure will be applied to the patients"
40856728|NCT05326646|DIETARY_SUPPLEMENT|Low FODMAP diet|After the realisation of a wireless motility capsule, patients will underwent 6 weeks of low FODMAP diet after dietician education. Symptomatic scores (IBS-SSS, GIQLI, HAD) and stools samples (metabolomic and lipidomic) will be performed before and after the low FODMAP diet.
41038451|NCT01409538|OTHER|Control condition|"This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control."
41038452|NCT04195009|PROCEDURE|major surgery under opioid free anesthesia without regional anesthesia|measuring nociception in every patient but blinded for attending anesthesiologist
41038453|NCT00115700|DRUG|Cyclophosphamide|1000 mg/m2 I.V. on day 1
41038454|NCT00115700|RADIATION|Radiotherapy|The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
41038455|NCT00115700|DRUG|Vincristine|1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
41038456|NCT00115700|DRUG|Prednisolone|50 mg/m2 orally daily for days 1 - 5
41038457|NCT00115700|DRUG|Rituximab|375 mg/m2 IV Infusion day 1
41038458|NCT01027546|DRUG|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
41038459|NCT00989651|BIOLOGICAL|Bevacizumab|Given IV
41038460|NCT00989651|DRUG|Carboplatin|Given IV
41038461|NCT00989651|DRUG|Cisplatin|Given IP
41038462|NCT00989651|OTHER|Laboratory Biomarker Analysis|Correlative studies
41038463|NCT00989651|DRUG|Paclitaxel|Given IV or IP
41511242|NCT01268527|DRUG|0.01% E6201|Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
41511243|NCT01268527|DRUG|0.05% E6201|Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
41511244|NCT01268527|OTHER|Placebo - 0.03% gel vehicle|Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
41038464|NCT00989651|DRUG|Veliparib|Given PO
41038465|NCT01587664|DEVICE|NewBreez ILP|NewBreez ILP implantation
41038466|NCT00586911|DRUG|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
41038467|NCT00586911|DRUG|Identical Placebo|Placebo
41387788|NCT03667742|DIAGNOSTIC_TEST|analysis of sweat and serum samples for protein markers|collection of blood and sweat samples (with Macroduct Sweat Collecting System) in patients with suspected tuberculosis or proven acute tuberculosis or pulmonary diseases (pneumonia, bronchitis, COPD) and analyzing serum and sweat for protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) by mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
41166712|NCT02592681|PROCEDURE|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
41166713|NCT04520841|DEVICE|Prevena TM|A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.
41387789|NCT02069886|DRUG|deferasirox|125, 250, 500 mg dispersable tablets
41387790|NCT03430557|PROCEDURE|PRP|platelet rich plasma
41387791|NCT03430557|PROCEDURE|periapical surgery without PRP|retrograde MTA filling will be done after apicectomy and flap will be closed without filling anything in the bony lesion.
41387792|NCT04747678|DRUG|Ivermectin|retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt
41387793|NCT01986400|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
41387794|NCT03004417|DRUG|CHF 6001 Dose1|CHF 6001 plus placebo
41387795|NCT03004417|DRUG|CHF 6001 Dose2|CHF 6001 only (high dose)
40856729|NCT04345679|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~200 mL over 4 hours
40856730|NCT05487911|DEVICE|Repetitive Transcranial Magnetic Stimulation|4 weeks of active rTMS (total of up to 20 sessions)
41387796|NCT03004417|OTHER|Placebo|Placebo only
41387797|NCT06568120|DEVICE|dragon themed nebulizer masks|This study is an experimental investigation aiming to evaluate the effect of a dragon-themed nebulizer mask (Figure 1), identified during a literature review by the researchers, on the duration of inhaler treatment application, treatment adherence, and children's fear levels. The dragon-designed nebulizer mask, with its colorful and toy-like appearance, is intended to calm children using pediatric aerosol masks. The mask is made of very soft, latex-free plastic, ensuring comfortable use for pediatric patients. It is compatible with all nebulizers and suitable for use in hospital settings. Unlike standard nebulizer masks, its appearance is designed with a dragon character specifically for pediatric patients. The mask is manufactured in China.
41387798|NCT04759716|OTHER|Health Literacy-based Weight Control Intervention|intervention arm will be applied to receive health literacy-based mobile Health App, smart sports watch Fitbit versa during the 12 months weight control program
41511245|NCT01268527|OTHER|Placebo - 0.1% gel vehicle|Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
40856731|NCT04010877|BIOLOGICAL|CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells|Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
41166714|NCT04520841|DEVICE|Dry dressing|A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery
41387799|NCT05116163|BEHAVIORAL|Individuation Intervention plus implicit bias educational modules|"Providers in the intervention are will be instructed to watch a brief set of freely available educational lessons and then they will meet with study team members to discuss their individuation countermeasure intervention. Providers will be given a choice of several individuation-related questions to better understand the unique characteristics of each patient. Once the provider decides on his/her choice phrases, the research team will assist with the development of a smart phrase (also called dot phrase) to allow them to incorporate this into a note. Once a week, providers in the intervention arm will receive an email reminding them to incorporate this question and the documentation into their encounters."
41387800|NCT05116163|OTHER|Implicit bias educational modules|Providers in the comparator arm will be given the same implicit bias educational modules to complete.
41387801|NCT00743119|DRUG|Placebo capsules|Placebo capsules
41387802|NCT00743119|DRUG|Inactive marijuana (0% THC)|Inactive marijuana cigarettes (0% THC) provided by NIDA
41387803|NCT00743119|DRUG|Low dose Dronabinol|Dronabinol 10mg
41387804|NCT00743119|DRUG|High dose Dronabinol|Dronabinol 20mg
41511246|NCT01268527|OTHER|Placebo - 0.2% gel vehicle|Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
40856732|NCT06530966|DRUG|ICP-332 Tablets|Eligible patients will receive ICP-332 tablets orally as per the protocol
40856733|NCT06530966|DRUG|ICP-332 Placebo Tablets|Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
40856734|NCT01771159|DEVICE|TBC|"The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor \[bladder\] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.~After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder."
41166715|NCT04263805|OTHER|Vignette with emphasis on research climate|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
41387805|NCT00743119|DRUG|Low THC marijuana|marijuana cigarettes (1.98% THC) provided by NIDA
41387806|NCT00743119|DRUG|High THC marijuana|Marijuana cigarettes (3.56% THC) provided by NIDA
41511247|NCT01268527|OTHER|Placebo - 0.05% gel vehicle|Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
41511248|NCT01268527|OTHER|Placebo - 0.01% gel vehicle|Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
41511249|NCT01268527|OTHER|Placebo - 0.05% gel vehicle|Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
41511250|NCT01268527|DRUG|Calcipotriene|Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.
41511251|NCT03852732|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
41511252|NCT03838900|DEVICE|Loop|The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
41511253|NCT01968564|DRUG|Placebo pill|sugar and other inert substances
41511254|NCT01968564|DRUG|High-dose curcumin pill|2000mg curcumin pill/day
41511255|NCT01968564|DRUG|Low-dose curcumin pill|500mg curcumin pill/day
41511256|NCT00611260|BEHAVIORAL|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
41511257|NCT00611260|OTHER|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
41511258|NCT01117649|DRUG|HES 10%|HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
40856735|NCT06272123|OTHER|no intervention|no intervention
40856736|NCT02139865|BEHAVIORAL|30% 1RM|Participant exercises using a protocol tailored at 30% of their 1RM
40856737|NCT02139865|BEHAVIORAL|80% 1RM|Participant exercises using a protocol tailored at 80% of their 1RM
40856738|NCT05266677|OTHER|blend of glycerides at certain proportions|combination of glycerides in specific proportions in a liquid oral supplement
41387807|NCT05755724|OTHER|3-D Teaching|Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.
41387808|NCT05755724|OTHER|2-D Teaching|Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
41511259|NCT01117649|DRUG|HES 6%|HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
41511260|NCT01117649|DRUG|balanced electrolyte solution|plasma adapted Ringer's solution
41511261|NCT05520125|BIOLOGICAL|Mesenchymal stem cells enriched by extracellular vesicles|Mesenchymal stem cells enriched by extracellular vesicles
40856739|NCT05266677|OTHER|glycerides used in current formulas|glycerides used in current formulas in a liquid oral supplement
40856740|NCT02474602|DEVICE|Active or Placebo Phototherapy (MR4)|Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
40856741|NCT04651491|DRUG|Kagocel|"The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~1. for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~2. for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days."
40856742|NCT03547895|DRUG|Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)|sofosbuvir 400mg+ribavirin 400mg+daclatasvir 60 mg were adminstered for 3 months
41387809|NCT06073873|DRUG|Ozanimod|According to local product label
41387810|NCT03146507|RADIATION|Ultrasound|ultrasound assessment of gestational age, amniotic fluid index, and fetal weight
41387811|NCT03146507|RADIATION|Doppler ultrasound|Umbilical artery and Middle cerebral artery Doppler blood flow assesment
41511262|NCT05520125|OTHER|Standard treatment of bone defects|Standard surgical treatment of bone defects
41511263|NCT06550583|DIAGNOSTIC_TEST|Pap smear /Test|"Patients will be placed in the lithotomy position, and a sterile bivalve speculum will be inserted into the vagina.~• A sample will be taken from the ectocervix by rotating a wooden Ayre spatula 360°. The sample will be quickly smeared onto a labeled glass slide and fixed with 95% ethyl alcohol in a jar to be sent to the Department of Pathology for cytopathological examination"
41511264|NCT06206850|DRUG|Osimertinib|Oral Osimertinib 80 mg once daily (QD) for the duration of 9 weeks (3 cycles).
41511265|NCT02627690|OTHER|islet transplanted|islet transplantation
41511266|NCT02627690|OTHER|non islet transplanted|no islet transplantation (for a non nephrologic reason)
41511267|NCT06399575|OTHER|Apnea Following Isocapnic Hypoxia|Decreasing end-tidal partial pressure of oxygen to 50 mmHg for five minutes, targeting 80-85% peripheral oxygen saturation. The end-tidal partial pressure of carbon dioxide will remain +1 mmHg above baseline levels. After five minutes of hypoxia, participants will complete an apnea.
41387812|NCT03146507|RADIATION|Fetal echocardiography|The cardiac output (ratio between right side cardiac outputs to left side cardiac output) was calculated
41387813|NCT03176511|BEHAVIORAL|A Matter of Balance plus Dual-Task Balance Challenge Group|Participants will receive the standard MOB classes, along with a 15-min DTBC each class, i.e., right and left foot ankle-reaching to three differently colored markers. Three colored dots are placed on the ground in an arc, using different colored stick-on dots. A chair can be placed in front of the color pattern, as needed for safety.
41387814|NCT03176511|BEHAVIORAL|A Matter of Balance Group|Participants will receive the standard MOB class, taught by a certified MOB, using course materials developed by MaineHealth's Partnering for Healthy Aging (http://www.mainehealth.org/pfha).
41387815|NCT01173588|OTHER|yogurt added with bifidobacteria and soluble fiber (YBF)|Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
41387816|NCT00418509|DRUG|Mometasone furoate|
41166716|NCT02111720|BEHAVIORAL|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
41387817|NCT00418509|DRUG|Formoterol fumarate|
41387818|NCT01682512|DRUG|BI 695500|
41387819|NCT01682512|DRUG|BI 695500|
40856743|NCT03547895|DRUG|vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion|symptomatic therapy for liver support, control of ascites and bleeding tendency.
40856744|NCT04473248|DEVICE|Spartan COVID-19 System|PCR analysis of patient samples using the Spartan COVID-19 System
40856745|NCT06386991|OTHER|Using ethylenediaminetetraacetic acid (EDTA), citric acid ((MONO/ANH) and etidronic acid (HEBP) to clean root canals during regenerative endodontic treatments|Regenerative endodontic treatment using different irrigation solutions
41166717|NCT02111720|BEHAVIORAL|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
40856746|NCT02636023|DEVICE|SPhENo-Cardiograph|SPhENo-Cardiograph
40856747|NCT04523337|BEHAVIORAL|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services. Patients will receive 2 hours of MISSION-CJ services per week during and after their stay in the mental health residential rehabilitation program (total of 6-months). Services are delivered using a Critical Time Intervention stepdown approach.
41038468|NCT04236791|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
41166718|NCT02223013|DRUG|BIBV 308 SE solution|
41166719|NCT02223013|DRUG|BIBV 308 SE capsule L|
41166720|NCT02223013|DRUG|BIBV 308 SE capsule S|
41387820|NCT01682512|DRUG|Rituxan®|
41387821|NCT01682512|DRUG|Rituxan®|
41387822|NCT01682512|DRUG|MabThera®|
41387823|NCT03973086|DIETARY_SUPPLEMENT|Citrus flavonone-O-glycosides- LD|Low Dose of 200 mg
41387824|NCT03973086|DIETARY_SUPPLEMENT|Citrus flavonone-O-glycosides- HD|High Dose of 400 mg
41387825|NCT03973086|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline Cellulose) of 400 mg
41387826|NCT06563973|OTHER|Milk odor|One hour before feeding time, 2 cc of breast milk was dripped onto a sterile sponge and placed inside the baby's incubator, close to the baby's nose (3 cm).
41387827|NCT06563973|OTHER|Pacifier|To support oral feeding, a pacifier was given for 3 minutes one hour before feeding time and for 2 minutes 10 minutes before feeding time.
41387828|NCT02237768|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
41387829|NCT02237768|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
41387830|NCT06568900|OTHER|cigarette smoking|continue smoking usual brand of cigarette
41387831|NCT06568900|OTHER|tobacco flavored and unflavored pouch|provide tobacco flavored and unflavored options of nicotine pouch
41387832|NCT06568900|OTHER|unrestricted flavor options pouch|provide unrestricted flavor options of nicotine pouch
41387833|NCT06408454|DIAGNOSTIC_TEST|Gingival crevicular fluid collection|Samples were taken from two mandibular molar teeth. Before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. GCF was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. After 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °C) and posterior analysis.
41511268|NCT01335035|DRUG|deferasirox|
41511269|NCT03766607|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
41511270|NCT03766607|DRUG|Ramucirumab|Ramucirumab 8 mg/kg administered intravenously on days 1 and 15 every 28 days
40856748|NCT04523337|BEHAVIORAL|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking Peer Support|The MISSION Peer Support Curriculum is rolling entry, and includes 24, one-hour exercises focused on co-occurring substance use and mental health disorders, recovery, and community integration.
41038469|NCT04236791|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
41038470|NCT03973320|OTHER|Chart Review|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty patients.
41038471|NCT04364646|BEHAVIORAL|Personalized Integrated Chronotherapy|Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.
41038472|NCT00738777|DRUG|Anastrozole|1 mg,QD,PO
41038473|NCT00738777|DRUG|Anastrozole+Fulvestrant|Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
41038474|NCT00738777|DRUG|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
41038475|NCT00738777|DRUG|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
41038476|NCT04100005|OTHER|No intervention|There is no intervention for this study.
41038477|NCT04392765|DEVICE|eXciteOSA|eXciteOSA transoral neurostimulation device
41038478|NCT03194802|BEHAVIORAL|Sleeping Without Pills Program|Participants receive this program online and are asked to log in daily for 6 weeks.
40856749|NCT04423692|OTHER|labs|A group of questions to women regarding Corona with laboratory finding suggestive of covid 19 and coagulopathy
40856750|NCT00306059|PROCEDURE|Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury|Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
40856751|NCT00889525|DRUG|Cabergoline|Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
41038479|NCT03194802|BEHAVIORAL|Self-monitoring|Participants enter sleep diary data online daily for 6 weeks
41038480|NCT03488901|OTHER|chemoresistance signature|to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy
41038481|NCT01632605|DRUG|Sirolimus|Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
41511271|NCT03766607|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
40856752|NCT01732016|OTHER|Normobaric hypoxia chamber|
40856753|NCT01472068|DEVICE|Inko RS Device|30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
40856754|NCT04370106|OTHER|Social leg program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
40856755|NCT04332718|DEVICE|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
40856756|NCT01546662|DIETARY_SUPPLEMENT|E-RH-06|Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
40856757|NCT01546662|DIETARY_SUPPLEMENT|Placebo|1/ 2 capsules, twice daily for 12 weeks
40856758|NCT05536570|DRUG|IncobotulinumtoxinA 100 UNT|Scalene injection
40856759|NCT03700567|OTHER|low temperature contrast|UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
41038482|NCT04988308|DRUG|Bermekimab|Bermekimab will be administered subcutaneously.
41038483|NCT04988308|DRUG|Adalimumab|Adalimumab will be administered subcutaneously.
41038484|NCT04988308|DRUG|Placebo|Placebo will be administered subcutaneously.
41038485|NCT00722761|DRUG|drospirenone and ethinyl estradiol|Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
41038486|NCT00722761|DRUG|Placebo tablet|Placebo tablet (no active drug) given once daily for 24 weeks
41038487|NCT02486328|DRUG|Midazolam|Dosage adjustment
41038488|NCT02486328|DRUG|Meperidine|Dosage adjustment
40856760|NCT03914755|DRUG|Tucatinib|Administered via oral tablet
40856761|NCT02279095|DRUG|Palovarotene dose level 1|Palovarotene was taken orally once daily at approximately the same time each day.
41038489|NCT02486328|DRUG|Remifentanil|Dosage adjustment
41038490|NCT02486328|DRUG|Propofol|Dosage adjustment
41038491|NCT05291780|RADIATION|Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be of at least 35-40 Gy in 5 fractions. The dose of SABR will be increased, case by case, respecting the maximum tolerance dose of the healthy structures.~Participants will SABR once a day for 5 days, Monday through Friday (around 1 week)."
41038492|NCT02856464|OTHER|DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)|
41038493|NCT02856464|OTHER|DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice|
41511272|NCT00317694|DRUG|Fermagate|Film coated tablet 500mg
41511273|NCT00317694|DRUG|Placebo|Oral administration, film coated tablet, 0mg
41511274|NCT05516966|DRUG|HRS9531|Administrated SC
41038494|NCT01835951|OTHER|Grouped Debriefing|Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
41387834|NCT06408454|DIAGNOSTIC_TEST|periodontal test|A periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. Additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained.
41387835|NCT00519948|DRUG|new MPS, opti-free express no rub MPS|
41387836|NCT05309174|PROCEDURE|USG-guided iSLN block|Ultrasound-guided internal branch of the upper laryngeal nerve block (USG-guided iSLN block) bilaterally with 5 ml of 0.375% ropivacaine , before general anesthesia.
41387837|NCT02192541|DRUG|Ziv-Aflibercept|Ziv-aflibercept is a soluble fusion protein with high binding affinity for vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placenta growth factor (PIGF) and thus confers anti-angiogenic activity
41166721|NCT04933838|DEVICE|atelocollagen|"This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.~Patients with chronic low back pain are randomized after obtaining informed consent for the study.~Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.~After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.~Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).~Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL)."
41387838|NCT02192541|DRUG|Ganetespib|Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
41387839|NCT01856231|BEHAVIORAL|Lifestyle physical activity - self-efficacy|Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
41387840|NCT06185556|PROCEDURE|Irreversible electroporation|Percutaneous (CT-guided) irreversible electroporation of 1-3 perivascular and peribiliary colorectal liver metastasis.
41387841|NCT06185556|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy (CT- or MRI-guided) of 1-3 perivascular and peribiliary colorectal liver metastases.
41387842|NCT00174473|DRUG|Voriconazole|
41387843|NCT01119352|DRUG|AZD7687|Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
41387844|NCT01119352|DRUG|Placebo|Oral suspension, once daily. Totally 8 doses
41511275|NCT05516966|DRUG|Placebo|Administrated SC
41511276|NCT05516966|DRUG|Dulaglutide Injection|Administrated SC
41511277|NCT04679493|DRUG|XC7 100 mg single|The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)
41511278|NCT04679493|DRUG|XC7 200 mg single|The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
41511279|NCT04679493|DRUG|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 capsules once)
40856762|NCT02279095|DRUG|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
40856763|NCT02279095|DRUG|Palovarotene dose level 3|Palovarotene will be taken orally once daily at approximately the same time each day.
40856764|NCT02279095|DRUG|Palovarotene dose level 4|Palovarotene will be taken orally once daily at approximately the same time each day.
41038495|NCT01835951|OTHER|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
41038496|NCT00126971|DRUG|chlorproguanil-dapsone|
41038497|NCT00778648|DIETARY_SUPPLEMENT|Juice Plus|"Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily."
41166722|NCT04621422|BIOLOGICAL|Subject carrying an amplification of nucleotide repeats in one of the following 9 genes FMR1, DMPK, ZNF9, SCA2, JPH3, HD, FXN, C9ORF72, RFC1|Biological/Vaccine: DNA Samples collection as part of usual care
41166723|NCT03121040|DIETARY_SUPPLEMENT|Vespa amino acid mixture|17 kinds of amino acids mixture in specific proportion
41166724|NCT00212797|DRUG|Org 34517|low dose Org 34517
41166725|NCT00212797|DRUG|Org 34517|high dose Org 34517
41038498|NCT00778648|DIETARY_SUPPLEMENT|Placebo|Four capsules of placebo daily.
41387845|NCT03443973|DRUG|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
41387846|NCT03443973|DRUG|Placebo|Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
41387847|NCT00105352|PROCEDURE|Mixed Meal Tolerance Test|
41387848|NCT00105352|PROCEDURE|Glucagon Stimulation Test|
41387849|NCT00359840|DRUG|darbepoetin alfa|
41387850|NCT04390035|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|Participants assigned to the test group will undergo blood flow restriction training 2 days per week beginning at week 1-2 post-surgery and continuing through week 16 post-surgery using the FDA-approved Delfi Personalized Tourniquet System (PTS) with personalized pressure of 80% of the limb occlusion pressure (LOP). The LOP is the amount of pressure required to fully occlude arterial and venous blood flow to the limb. Otherwise, both the test group and control group will follow a standard 6-month post-surgery rehabilitation protocol which is standard of care for ACLR recovery.
41511280|NCT04679493|DRUG|XC7 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
41511281|NCT04679493|DRUG|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)
41511282|NCT04844060|OTHER|Lumbar punction|Lumbar punction
40856765|NCT05830266|BEHAVIORAL|"Mindful with your Baby group-based therapist-guided intervention"|"This 8-sessions long intervention is one of very few interventions that actively includes the baby in the therapy sessions. The intervention includes the following sessions: Becoming aware of the autopilot, Practice to really look at your baby, Getting back in touch with yourself, Responding sensitively to your baby, Taking care of yourself in the difficult moments, Distance and proximity: it's both part of it, Dealing with expectations of yourself and the environment and Mindful parenting: trial and error. The intervention is a group-based therapist-guided intervention via a video-conferencing tool (e.g., Zoom)."
40856766|NCT05830266|BEHAVIORAL|"Mindful with your baby self-guided online intervention"|"This 8-sessions long intervention includes the following sessions: Autopilot, Fresh view, At home in your body, Responsive versus reactive parenting, Kindness to yourself, Distance and proximity, Boundaries and taking care of yourself and Mindful parenting - day by day. The intervention is an individual self-guided online intervention."
40856767|NCT05030350|DRUG|PH94B|Nasal spray
41387851|NCT00710060|BEHAVIORAL|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
41387852|NCT00710060|BEHAVIORAL|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
41387853|NCT03001869|DRUG|68Ga-HBED-CC-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT Scan
41387854|NCT06102707|DRUG|Fluzopril Combined With Apatinib|Fluzopril Capsules 100mg po bid Apatinib Mesylate Tablets 250mg po qd
40856768|NCT03563196|RADIATION|Chest Radiograph|Chest radiogram will be obtained on day 1
41387855|NCT02235415|DRUG|Motens® (lacidipine)|
41387856|NCT02115373|DRUG|Tepotinib|Participants received a single oral dose of Tepotinib 300 milligram (mg) in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
41387857|NCT02115373|DRUG|Tepotinib|Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
41387858|NCT02228369|DRUG|AZD3759|Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
41387859|NCT02228369|DRUG|AZD9291|AZD9291 160mg once daily
41387860|NCT04331418|DRUG|Dexmedetomidine|1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr
40856769|NCT03563196|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound will be done on day 1
40856770|NCT02345213|DRUG|E2020|E2020 tablets will be orally administered once daily after breakfast
40856771|NCT02345213|DRUG|Placebo|Matching placebo tablets will be orally administered once daily after breakfast
40856772|NCT01510158|DRUG|Lesinurad|Tablets, 200 mg once daily (qd)
40856773|NCT01510158|DRUG|Lesinurad|Tablets, 400 mg qd
40856774|NCT01510158|DRUG|Placebo|Tablets, Placebo qd
41387861|NCT04331418|PROCEDURE|caudal block|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
41387862|NCT00378482|DRUG|CP-675,206 (Tremelimumab)|15 mg/kg IV every 3 months as long as required
41387863|NCT00984828|DRUG|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
41387864|NCT06457204|DRUG|Pramipexole (from manufacturing site 1)|Pramipexole (from manufacturing site 1) - test treatment
41387865|NCT06457204|DRUG|Pramipexole (from manufacturing site 2)|Pramipexole (from manufacturing site 2) - reference treatment
41387866|NCT02476760|DRUG|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
41387867|NCT02476760|DRUG|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
41387868|NCT02476760|DRUG|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
40856775|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
41166726|NCT00212797|DRUG|Placebo|placebo
41166727|NCT04018885|DRUG|ALA 2.5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
40856776|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
40856777|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
40856778|NCT05633888|DEVICE|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
40856779|NCT00475904|DRUG|EpiCept-NP-1 Cream|ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
40856780|NCT00475904|DRUG|Gabapentin Capsules|1800mg/day capsules for 4 weeks
40856781|NCT00475904|DRUG|placebo|placebo cream and caps
40856782|NCT02930304|OTHER|first physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
40856783|NCT02930304|OTHER|second physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
40856784|NCT02930304|OTHER|third physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
41038499|NCT03905889|DRUG|Abemaciclib|Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).
41387869|NCT02476760|DRUG|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
41387870|NCT02476760|DRUG|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
41387871|NCT02476760|DRUG|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
41387872|NCT02476760|DRUG|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
41387873|NCT02476760|DRUG|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
41387874|NCT01700335|DRUG|SyB L-1101|"SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.~The dose will be administered intravenously for 72 continuous hours (3 days), followed by 11-day observation period. The treatment period of 14 days (3 days of administration + 11 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied."
41387875|NCT02630004|DRUG|Melatonin oral gel 3%|
41387876|NCT02630004|DRUG|Placebo oral gel|
41387877|NCT06540482|DIAGNOSTIC_TEST|Reliability test|The test was administered two days apart to evaluate the reliability of the retest test.
41387878|NCT03487614|BEHAVIORAL|Behavior-based parental intervention|Behavioral intervention designed to promote healthy feeding behaviors in parents of 2-5 year olds, and to modify parenting practices in a way that encourages adequate physical activity, sufficient sleep, and healthy nutrition, while limiting sedentary behaviors.
41387879|NCT03356431|OTHER|Supervised group exercise|"* Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec."
41387880|NCT03356431|OTHER|Home-based exercise|"* Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec."
41387881|NCT01462474|DRUG|Famitinib|Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
41387882|NCT01462474|DRUG|Cisplatin|100 mg/m2, D1, D22, and D43(q3w)
41387883|NCT01462474|RADIATION|radiation（IMRT）|IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
41387884|NCT06442137|DRUG|Chazhu Xiaozhi decoction|Below is the composition of Chazhu Xiaozhi decoction: Camellia Sinensis Radix 15g, Atractylodis Rhizoma 15g, Herba Gynostemmatis Pentaphylli 15g, Ilicis Cornutae Folium 15g, Alismatis Rhizoma 9g, Nelumbinis Folium 6g, Crataegi Fructus 6g, Polygoni Orientalis Fructus 3g.
41038500|NCT03905889|DRUG|Sunitinib|Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
41038501|NCT05403801|BEHAVIORAL|STAMP+CBT application|Use the STAMP+CBT mobile app for 4 weeks (intervention period, 4 weeks for content introduction, extended 2 weeks for review of content if patient's request this
41038502|NCT05403866|DRUG|LT3001 Drug Product|Administered by intravenous infusion
41038503|NCT05403866|DRUG|Placebo|Administered by intravenous infusion
41038504|NCT02605980|BEHAVIORAL|Sedentary time|
41166728|NCT04018885|DRUG|ALA 5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
41166729|NCT04018885|DRUG|ALA 10%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
41387885|NCT06442137|DRUG|Control placebo|The control placebo is a ten-fold dilution of the Chazhu Xiaozhi decoction, supplemented with colorants and bittering agents to mimic the appearance and color of the treatment drug.
41387886|NCT00788684|DRUG|rituximab|IV infusion once weekly for four doses
40856785|NCT01257945|BEHAVIORAL|Aerobic Exercise|
40856786|NCT01257945|BEHAVIORAL|Flexibility and Function exercise program|
40856787|NCT01257945|BEHAVIORAL|Home exercise program|
40856788|NCT00079092|DRUG|procarbazine hydrochloride|
40856789|NCT00079092|DRUG|thalidomide|
41038505|NCT02409173|DEVICE|Noninvasive positive airway pressure flow generator device|Noninvasive positive airway pressure flow generator device.
41038506|NCT02409173|PROCEDURE|Bariatric Surgery|Standard Roux-en-Y gastric bypass
41166730|NCT06065709|BEHAVIORAL|Mindfulness breath awareness meditation|Mindfulness breath awareness meditation
41387887|NCT00788684|DRUG|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
41387888|NCT01940276|DRUG|Abiraterone acetate|
41387889|NCT01940276|DRUG|Prednisone|
40856790|NCT02156778|BEHAVIORAL|Active Comparator: Extended Standard Care (Stroke Card)|"Standard Care plus~extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.~3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.~6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.~12-Mo clinical visit and outcome assessment."
40856791|NCT02156778|BEHAVIORAL|Active Comparator: Standard Care|"In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).~Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.~Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).~Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.~AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).~12-Mo clinical visit and outcome assessment."
41038507|NCT01320046|OTHER|Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage|"Patients will undergo the following evaluation:~1. Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~2. Medical history.~3. Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~4. Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~5. Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours."
41038508|NCT05716698|DIETARY_SUPPLEMENT|Pleurotus citrinopileatus after bio-optics (10 ug group)|The participants took D2 10ug per day for a total of 4 weeks.
41038509|NCT05716698|DIETARY_SUPPLEMENT|Pleurotus citrinopileatus after bio-optics (100 ug group)|The participants took D2 100ug per day for a total of 4 weeks.
41038510|NCT00317772|DRUG|Topotecan|"Phase I Starting Dose: 2 mg/m\^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.~Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15."
41038511|NCT00317772|DRUG|Gefitinib|"Phase I: 250 mg by mouth daily for 28 Days.~Phase II: 250 mg by mouth daily for 28 Days."
41038512|NCT02323971|DRUG|Ticagrelor|
41038513|NCT00689650|DEVICE|1540 nm fractional laser|
41038514|NCT01339585|DEVICE|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
41038515|NCT05160051|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET Scan|68Ga-FAPI-46 is a radiotracer that binds with high affinity to Fibroblast Activating Protein (FAP). FAP is physiologically expressed in many tissues during embryonic development, but in adults it is expressed only in the context of wound healing, fibrotic processes, and the stroma of many malignancies. Therefore, the study seeks to validate if 68Ga-FAPI-46 PET could be established as a diagnositc tool to detect solid tumors.
41038516|NCT03784339|OTHER|Physiotherapy + education|Participants will take part in a 30 minute education session surrounding fear of movement and catastrophizing thoughts. They will then receive standard care, which will involve strength exercises and taping if needed.
41038517|NCT03784339|OTHER|Physiotherapy|Standard physiotherapy care
41038518|NCT01260220|PROCEDURE|Circumferential Antral Ablation|The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
41038519|NCT01260220|PROCEDURE|Segmental Antral ablation|If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
41038520|NCT03541759|DRUG|Hydromorphone Hcl 4Mg Tab|Hydal retard 4Mg Tab 2 times after surgery as basic medication. Hydal retard 2.6Mg maximum 2 per 24h when NRS \> 5.
41166731|NCT00424177|DRUG|eltrombopag|experimental
41387890|NCT04264988|PROCEDURE|Stopping of pelvic bleeding via several surgical methods|Those surgical methods were pelvic packing, electrocautery, energy devices, suturing, fastener, muscle welding, procoagulant chemicals, and combination of those
41387891|NCT00949052|GENETIC|DNA analysis|
41387892|NCT00949052|GENETIC|polymorphism analysis|
41387893|NCT00949052|OTHER|laboratory biomarker analysis|
41387894|NCT00949052|OTHER|medical chart review|
41387895|NCT00949052|OTHER|questionnaire administration|
41387896|NCT00949052|PROCEDURE|assessment of therapy complications|
41387897|NCT00949052|PROCEDURE|evaluation of cancer risk factors|
41387898|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
41387899|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
40856792|NCT05961657|DIAGNOSTIC_TEST|Hemodynamic measurements by USCOM|We will measure cardiac output, cardiac index, and systemic vascular resistance index on 3, 7, and 14 postnatal days using the UltraSonic Cardiac Output Monitor.
40856793|NCT01772732|DRUG|Simotinib Hydrochloride|
41038521|NCT03541759|DRUG|Piritramide 15mg s.c.|Dipidolor 15mg s.c. 2 times after surgery as basic medication. Dipidolor 7.5mg s.c. maximum 2 per 24h when NRS \> 5.
41038522|NCT01881620|DEVICE|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
41166732|NCT02845375|DRUG|Sugammadex|Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
41387900|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
41387901|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
41387902|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
41387903|NCT06459401|DEVICE|Propulsion Neuroprosthesis|A neuroprosthesis is a textile-based surface neurostimulation system worn on the waist and paretic lower limb that delivers neurostimulation assistance via electroconductive pads placed on the skin over the target muscles. The neuroprosthesis provides dorsiflexor stimulation during swing phase for foot clearance and plantarflexor stimulation during stance phase for propulsion, delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
41387904|NCT03461029|DEVICE|BIS monitor|The investigators placed on the forehead of all patients the sensor BIS quatroTM, that connects with the monitor, and they registered sedation and recorded the values obtained.
41511283|NCT01635348|BEHAVIORAL|motor skill gait exercise|The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
41038523|NCT03701568|DRUG|dC/dT|Collection of retrospective data from TK2 patients previously treated with dC/dT
41038524|NCT04484467|DIETARY_SUPPLEMENT|Food Supplement With Standardized Menthol, Limonene, and Ginger|Components of Standart Zdorovya GASTRO: Peppermint oil (40% menthol, 1.5% limonene) - 240 mg, Ginger oil (14% gingerol) - 50 mg, olive oil - 440 mg, 1 capsule, 730 mg, once a day for 30 days
41038525|NCT04484467|OTHER|Placebo|Components of placebo Olive oil - 730 mg, 1 capsule, 730 mg, once a day for 30 days
41038526|NCT02246517|DRUG|N2O|
41387905|NCT02802007|DEVICE|Elipse Intragastric Balloon|
41387906|NCT05881863|OTHER|No intervention|This is an observational study
41387907|NCT02237118|DEVICE|Mepitel One|
41511284|NCT01635348|BEHAVIORAL|aerobic gait intervention|The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
41511285|NCT02792920|DEVICE|CoCr-EES|
41511286|NCT02503787|DEVICE|Spinal Cord Stimulation (SCS)|SCS programming options
41038527|NCT02246517|DRUG|Oxygen|
41038528|NCT04301336|DRUG|Omega 3|Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
41038529|NCT04301336|DRUG|Vit D|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
41166733|NCT02845375|DRUG|Neostigmine|Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
41387908|NCT02237118|DEVICE|UrgoTul|
41511287|NCT02430480|DRUG|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
41511288|NCT02430480|DRUG|Enzalutamide|160mg orally, daily for 24 weeks
41511289|NCT02430480|DEVICE|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
41511290|NCT00424229|DRUG|LENALIDOMIDE|
40856794|NCT03492541|OTHER|Propylene glycol-based eye drops|Nano-emulsion ocular lubricant
40856795|NCT04136730|BEHAVIORAL|Home-based|Resistance exercise carried out unsupervised at home
40856796|NCT03019094|DEVICE|The RENOVA tibial nerve stimulation system|Study participants will be implanted with the RENOVA tibial nerve stimulation system
41038530|NCT04301336|DRUG|Zinc sulfate|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
41038531|NCT04301336|DRUG|Statins (Cardiovascular Agents)|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
41038532|NCT04301336|DRUG|Hydroxy Urea|50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
41038533|NCT04301336|DRUG|Folic Acid Supplementation|Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
41166734|NCT02845375|DRUG|Placebo|Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
41511291|NCT04045353|BEHAVIORAL|Low carbohydrate diet education|A 200 page informational document that connects with an online application will be provided to subjects.
41166735|NCT04117815|DEVICE|Paxman Scalp Cooling System|"All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:~* Minimum 30 minutes pre-infusion cooling~* Cooling for the duration of chemotherapy infusion~* Minimum 90 minutes post-infusion cooling Scalp cooling is performed within the study group at each CT session."
41166736|NCT04117815|OTHER|Alopecia Assessments|"Patients (study group and reference group) will be assessed at the following time Points:~* Baseline~* at the half-way Point of the cyles~* at the last CT cycle~* 3 months after completion of Treatment~* 6-9 months after treatment completion~The assesments include the following~* Photographs of the head, which are evaluated using the CTCAEv4.0~* Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire"
41166737|NCT05546424|BEHAVIORAL|EMRESERVA|training program will be carried out in groups (up to 6 patients) who will meet one hour once a week for 5 months.
41166738|NCT05829135|DEVICE|Acuvue Oasys with Transitions|soft contact lenses with darkening technology
41387909|NCT04427514|DEVICE|Telemedicine software for data transmission and analysis in CAPD.|Telemedicine software is related to peritoneal dialysis. With the help of a tablet device running an Android system on patients and the care team and the smart devices attached to it (scales, blood pressure monitor), patients perform measurements in their homes in connection with solution changes. The resulting data is transmitted through the telemedicine system to the care team, which can take immediate intervention if necessary and notify the patient of any change in therapy.
41387910|NCT05949931|DRUG|Concurrent penpulimab and AVD|Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
41387911|NCT05949931|DRUG|Sequential penpulimab and AVD|Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
41387912|NCT06061601|DEVICE|Exoskeleton stroke group|The exoskeleton stroke group will receive gait rehabilitation with the TWIN-Acta exoskeleton
41387913|NCT06154122|DEVICE|Virtual Reality Upper Limb Rehabilitation Games|"A VR upper limb rehabilitation programme prescribed by the therapist with games chosen depending on the exercise task required and the level of difficulty adapted to the ability of the individual. The participant will use the VR system's user interface to navigate through menus to set their gameplay preferences and select which games to play.~The games of the intervention will involve facilitating and replicating upper limb movements including gross movements of the shoulder, such as rotation, abduction and addiction, movements of the upper and lower arms, such as flexion and extension of the elbow, and hand, wrist and finger movements, including wrist pronation supination, and finger flexion and extension, as well as tenodesis movements, grasping, and pinching."
41387914|NCT06154122|OTHER|Upper Limb Rehabilitation|Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.
41387915|NCT04911127|DRUG|200mg Cannabidiol by capsules twice daily|200mg twice daily via 50mg capsules
41387916|NCT04911127|DRUG|400mg Cannabidiol by capsules twice daily|400mg twice daily via 50mg capsules
41387917|NCT04911127|DRUG|Placebo capsules|MCT oil capsules as placebo for CBD
41387918|NCT00028938|BIOLOGICAL|epoetin alfa|
41387919|NCT00028938|DRUG|carboplatin|
41511292|NCT04045353|BEHAVIORAL|Low carbohydrate diet education with behavioral component|A 12 week course taught be a certified instructor will teach subjects about a low carbohydrate document. Subjects will also be given a 200 page informational document that connects with an online application.
40856797|NCT05839249|OTHER|JJ urological stents|recording complications of JJ stents during COVID19 pandemics
40856798|NCT00038233|DRUG|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
40856799|NCT04658043|OTHER|Intervention on socioemotional functioning|"A culturally sensitive intervention based on the train the trainer (or coach the coach) model for enhancing the social adaptive functioning of young children (aged 3-6) with ASD in China, via providing training for parents"
40856800|NCT06474312|BEHAVIORAL|Nae Disha|"Nae Disha for Life is a brief, multi-component, psychosocial promotion and resilience tool developed by Emmanuel Hospital Association, New Delhi. The purpose of this research work is to evaluate the feasibility, acceptance, and effectiveness of Nae Disha for Life tool in reducing suicide ideation among youth in Bundelkhand region. This will be implemented among the targeted schools of Nowgong block, Chhatarpur district."
40856801|NCT00558298|DRUG|risperidone|
40856802|NCT03742583|OTHER|Square Knot|Standard square knot
41166739|NCT03017313|DRUG|LHRH analogues|3-or 6-month formulations
41166740|NCT00900406|GENETIC|gene expression analysis|blood collection
41166741|NCT00900406|GENETIC|microarray analysis|Blood collection
41166742|NCT00900406|GENETIC|polymorphism analysis|Blood collection
41166743|NCT00900406|GENETIC|proteomic profiling|Blood collection
41166744|NCT00900406|OTHER|flow cytometry|Blood collection
41166745|NCT00900406|OTHER|immunologic technique|Blood collection
41166746|NCT00900406|OTHER|laboratory biomarker analysis|Blood collection
41166747|NCT00900406|PROCEDURE|biopsy|Blood collection
41166748|NCT03272711|DRUG|Vortioxetine 10 mg|
41387920|NCT00028938|DRUG|paclitaxel|
41387921|NCT00028938|RADIATION|radiation therapy|
41387922|NCT03593239|OTHER|Tobacco flavored JUUL 1.7% ENDS|Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)
41511293|NCT02301195|OTHER|Therapeutic horseback riding|Inclusion of horses as part of the therapeutic experience
41511294|NCT02301195|OTHER|Barn Activity Intervention|Equine-focused educational activities in small group setting without horses
41511295|NCT05061589|PROCEDURE|permanent colostomy|An operation that creates an opening for the colon through the abdomen
41511296|NCT00524420|DEVICE|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
41387923|NCT03593239|OTHER|Tobacco flavored JUUL 5% ENDS|Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)
41511297|NCT00524420|DEVICE|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
40856803|NCT03742583|OTHER|RHAP Knot|Reversing half-hitch alternating post knot
40856804|NCT00123175|DEVICE|Intrauterine Device|Mirena and Provera
40856805|NCT06583525|OTHER|Intensive Transition Support|A multidisciplinary transition team (nurse practitioner and social worker) will coordinate the transition process for each patient across multiple settings, focused on the youth's highest priority needs while also supporting the caregivers. Participants will receive case management and care navigation using an intensive transition support model provided through the partnership of a transition team. The transition team will collaborate with the participants existing care team to help coordinate care, provide consultation, and support adult and primary care accepting these youth for 1 year following the transfer. This Intervention is modelled on best practices by Health Quality Ontario's Quality Standards for Transition from Youth to Adult Health Care Services to support youth at high risk of having poor transitional outcomes as they move from pediatric to adult care.
41387924|NCT03593239|OTHER|Mint flavored JUUL 1.7% ENDS|Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)
41387925|NCT03593239|OTHER|Mint flavored JUUL 5% ENDS|Treatment with Mint flavored JUUL 5% ENDS(10 puffs)
41387926|NCT03593239|OTHER|Fruit Medley flavored JUUL 1.7% ENDS|Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)
41387927|NCT03593239|OTHER|Fruit Medley flavored JUUL 5% ENDS|Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)
41387928|NCT03593239|OTHER|Crème brulee flavored JUUL 1.7% ENDS|Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)
41387929|NCT03593239|OTHER|Crème brulee flavored JUUL 5% ENDS|Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)
41387930|NCT03593239|OTHER|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs
41387931|NCT03593239|OTHER|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs
41511298|NCT02213653|DRUG|ARM A : IV iron + epoietin zeta|"* Epoietin zeta at a dose of 450 IU / kg per week subcutaneously~* Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~  * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1."
41511299|NCT02213653|DRUG|ARM B: IV iron + epoietin zeta sequence|"* Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~* carboxymaltose ferric (Ferinject ®) at week 1~  * Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~ * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1."
40856806|NCT03360799|OTHER|Questionnaire Administration|Complete questionnaires
40856807|NCT00535119|DRUG|Carboplatin|Given IV
40856808|NCT00535119|OTHER|Laboratory Biomarker Analysis|Correlative studies
40856809|NCT00535119|DRUG|Paclitaxel|Given IV
40856810|NCT00535119|OTHER|Pharmacological Study|Correlative studies
41038534|NCT04301336|DRUG|Morphine Sulfate|Morphine medication as a pain killer is administered, if Patient weight \<50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
41038535|NCT04301336|PROCEDURE|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
41511300|NCT02213653|DRUG|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
41511301|NCT01470092|DRUG|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
40856811|NCT00535119|DRUG|Veliparib|Given PO
40856812|NCT02434042|DIETARY_SUPPLEMENT|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
40856813|NCT02434042|OTHER|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
40856814|NCT04896281|DIETARY_SUPPLEMENT|Phenylalanine-free milk|Once a plasma PHE level of ≥ 95 μM is noted, phenylalanine-free diet (Phenex-2®, Abbott Nutrition, Ohio, USA; or Phenyl-Free 2®, Mead Johnson Nutrition, Minnesota, USA) is started as the only nutrition source for enteral feeding, as per the recommendation of dieticians, in the following 4 days. The phenylalanine-free diet is free of PHE but is enriched with protein, potassium, tyrosine, and antioxidant micronutrients. After the completion of the study, diet will be back to normal diet for all patients.
41387932|NCT02416167|DRUG|FYU-981|
41387933|NCT02416167|DRUG|Placebo|
41387934|NCT03722849|DRUG|Adenosine Triphosphate|Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
41387935|NCT03722849|DRUG|Capsaicin|Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
41387936|NCT03722849|OTHER|Functional Brain Imaging|Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
41387937|NCT05349188|DIETARY_SUPPLEMENT|Melatonin 3 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills.
41387938|NCT05349188|DIETARY_SUPPLEMENT|Melatonin 0.5 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills.
41387939|NCT05349188|OTHER|Cellulose placebo pill|Participants will be provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills.
41387940|NCT06567249|PROCEDURE|Intracoronary hypothermia|This trial stands apart from other studies of intracoronary hypothermia, mainly because it will establish the role of intracoronary hypothermia in reducing infarct size not only in the left anterior descending artery territory but in other vessels as well, including the right coronary artery and circumflex coronary artery.
41387941|NCT06567249|OTHER|Standard percutaneous coronary intervention|Percutaneous coronary intervention is performed in a standard manner.
41387942|NCT06354972|PROCEDURE|Minimally invasive surgical procedure|All the experimental sites underwent a minimally-invasive surgical technique (MIST) procedure under magnification (Cortellini and Tonetti 2007). The full-thickness flap was minimally raised both on the buccal and oral side, avoiding vertical releasing incisions. Granulation tissue was scraped from the bony surfaces of the defect, and the root was debrided using minicurettes/ultrasonic device and chemically treated by EDTA. Regenerative procedure was carried out using a combination of enamel matrix derivatives and bone xenograft. The flaps were then repositioned and sutured in order to obtain passive primary closure.
41387943|NCT03594175|DRUG|CUSA-081|Participants received 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen
41387944|NCT03594175|DRUG|Placebo|Participants received 1 or 2 doses of placebo (normal saline) directly into the catheter lumen
41387945|NCT03594175|DRUG|Alteplase|Participants received 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
41387946|NCT03282617|BIOLOGICAL|CD137L-DC-EBV-VAX|Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
41387947|NCT00393978|DRUG|Quetiapine and placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
41387948|NCT00393978|DRUG|Quetiapine and Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
41038536|NCT05876065|DRUG|XC|Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
41038537|NCT05876065|DRUG|TPC|Any physician's choice as maintenance therapy (except for XC regimen)
41038538|NCT02014714|DRUG|Morphine|Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
41038539|NCT02014714|DRUG|Fentanyl|Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
41038540|NCT04847869|DEVICE|Ellex Integre NIR laser|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
41038541|NCT01212367|BIOLOGICAL|SCH 721015|1.0 x 10e12 viral particles on Days 1 and 4
41038542|NCT01212367|BIOLOGICAL|SCH 721015|3.0 x 10e11 viral particles on Days 1 and 4
41038543|NCT02710799|OTHER|Teleconsultation|The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.
41038544|NCT02710799|OTHER|Protocol|The informations provided in the referral list will be evaluated through the state's referrals protocols.
41038545|NCT05542576|DRUG|AMDX2011P|AMDX2011P single bolus injection intravenous for diagnostic review
41511302|NCT02965937|OTHER|Story-centred care intervention program|"Participants in the intervention group received the Story-Centred Care Intervention Program once a week for four weeks."
41511303|NCT02965937|OTHER|Health consultation control condition|The control group received a health consultation from researchers once a week for four weeks.. The health consultation will be tailored to the participants' needs. Based on a previous study12, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
41038546|NCT03277222|BIOLOGICAL|IN insulin|IN insulin twice daily taken after breakfast and again after dinner using the nasal delivery device.
41038547|NCT03277222|BIOLOGICAL|Sterile Saline placebo|Sterile Saline placebo twice daily taken after breakfast and again after dinner using the nasal delivery device.
41038548|NCT06351566|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol), 1600 IU per day.
41038549|NCT06351566|DIETARY_SUPPLEMENT|Prebiotics|Prebiotics (inulin), 10g per day.
41038550|NCT06351566|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
41038551|NCT06351566|DIETARY_SUPPLEMENT|Prebiotics placebo|Prebiotics placebo, 10g per day.
41387949|NCT06556745|DRUG|BKR-017|BKR-017 is an oral tablet formulation designed to target delivery of sodium butyrate to the colon via colon-targeting technology.
41387950|NCT06191380|BEHAVIORAL|PACE-MS|A single bout of cycling.
41387951|NCT03121989|DRUG|Hyperpolarized Pyruvate (13C) Injection|The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
40856815|NCT02470325|DRUG|Avidekel oil|Avidekel cannabis oil 6:1 CBD:THC
40856816|NCT02470325|DRUG|Enriched Avidekel oil|Enriched Avidekel cannabis oil 20:1 CBD:THC
40856817|NCT05414630|DRUG|Envafolimab|Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. The duration of treatment with Envafolimab should not exceed 2 years.
41038552|NCT06373094|DRUG|Donepezil Dihydroxynaphthalate for Injection|HHT201 will be injected into the muscle of gluteus.
41038553|NCT02068807|DIETARY_SUPPLEMENT|Lutein drops|After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
41387952|NCT03121989|OTHER|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that will act as a test object. The test object provides a signal that will be used to ensure that the MRI system is functioning properly for participants in Group 2 . The plastic ball does not come in contact with you and there are no known risks associated with it.
41387953|NCT03121989|DRUG|NAC|Participants will be receiving NAC as part of their clinical treatment.
41387954|NCT03706274|DRUG|CX-188|CX-188
41387955|NCT05339542|OTHER|platelet rich plasma|derived from patient own blood
40856818|NCT05602701|OTHER|Preoperative assessment|Preoperative assessment of physical fitness
40856819|NCT03187444|PROCEDURE|Examinations|Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
40856820|NCT04354675|GENETIC|Automated program (ChatBot)|Pre-test counseling and information through a pre-test automated genetic counseling program (ChatBot)
40856821|NCT04354675|GENETIC|Genetics counselor|Traditional in-person genetic counseling
40856822|NCT04354675|OTHER|BCGCKQ Survey|Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)
40856823|NCT04354675|OTHER|Satisfaction Survey|Survey assessing satisfaction with Decision-Genetic Testing
40856824|NCT04354675|DEVICE|Genetic testing|Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.
40856825|NCT00612560|DRUG|Anastrozole|1 mg per day
40856826|NCT00612560|DIETARY_SUPPLEMENT|flaxseed|25 g per day ground
40856827|NCT00612560|DRUG|Placebo|Placebo pill 1 per day
40856828|NCT02451514|BIOLOGICAL|MenABCWY+OMV vaccine|Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.
40856829|NCT02313584|DRUG|dabigatran|
40856830|NCT02313584|DRUG|placebo|
41038554|NCT02068807|DIETARY_SUPPLEMENT|Glucose drops|After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
41166749|NCT03272711|BEHAVIORAL|Cognitive training program|Online training program, 30 minutes a day, 5 times a week
41166750|NCT05856578|DRUG|Mulberry Twig Alkaloid Tablet|Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid
40856831|NCT04617730|DEVICE|Mepitel® film|This study is a comparative study between the standard procedure, which is to prescribe a hydro-active colloidal gel called Flamigel® to be applied to the irradiated area, and the use of Mepitel® Film.
40856832|NCT04617730|OTHER|Flamigel®|The control arm will be treated according to the standard of care.
40856833|NCT02120391|OTHER|iPhone Application|All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
40856834|NCT01923662|DEVICE|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
40856835|NCT03239444|DEVICE|Intracardiac echocardiography imaging|Wide visualization of the the heart anatomy and additional devices used during atrial fibrillation ablation procedures.
41038555|NCT04295226|OTHER|Structured follow-up after stroke.|Stroke-nurse managed follow-up 3 and 12 months after stroke and multidisciplinary rounds resulting in individual treatment plans for stroke-related health problems.
41166751|NCT05856578|DRUG|Canagliflozin|Canagliflozin 100mg po qd
41166752|NCT00000850|DRUG|Indinavir sulfate|
41166753|NCT00000850|DRUG|Sargramostim|
41166754|NCT00509457|BIOLOGICAL|GV 1001 Telomerase peptide|
41387956|NCT05339542|DRUG|MethylPREDNISolone 40 MG|active comparative intervention
41387957|NCT00006397|DRUG|Indinavir sulfate|
41387958|NCT00006397|DRUG|Ritonavir|
41387959|NCT00006397|DRUG|Stavudine|
41387960|NCT00006397|DRUG|Didanosine|
41387961|NCT03593356|BEHAVIORAL|Monthly cash gift payments of $333|These subjects receive $333 each month for 76 months via debit card.
41387962|NCT03593356|BEHAVIORAL|Monthly cash gift payments of $20|These subjects receive $20 each month for 76 months via debit card.
41387963|NCT04376918|DEVICE|Begin with BVGA|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
41387964|NCT04376918|DEVICE|Begin with Face-mask|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
40856836|NCT06163222|BEHAVIORAL|Additional message with behavioural science-informed content and associated web pages|Behavioural science-informed messages sent 14-days prior to outpatient appointment which include links to re-designed web pages
40856837|NCT06163222|OTHER|Usual communication strategy|Usual communications sent from outpatient services to remind participants about their appointments
40856838|NCT05035732|RADIATION|18F-fluciclovine|IV
40856839|NCT03209856|DRUG|Vitamin D|Vitamin D supplement will be given. Then, it will be maintained if pregnancy occurred
40856840|NCT00412243|DRUG|Clofarabine|40 mg/m\^2 Daily for 3 Days
40856841|NCT00412243|DRUG|Cyclophosphamide|Beginning dose 200 mg/m\^2 every 12 hours for 3 days
40856842|NCT01048658|DRUG|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
40856843|NCT01048658|OTHER|No Sevoflurane|Subject only standard of care drug regimens for anesthesia with this procedure.
40856844|NCT05579808|PROCEDURE|Epidural Analgesia|Using an aseptic technique while the patient is in sitting position, an epidural catheter was placed at the L2-L3 or L3-L4 interspace. Analgesia was established with the epidural administration of a low dose of local anaesthetic, plus a lipid-soluble opioid (ropivacaine 0.1% and sufentanyl 0.5%, 20 mL). Analgesia was maintained with a top-up regimen, using intermittent manual epidural boluses of increasing concentrations of ropivacaine, with up to 0.15% at full dilation, according to specific needs of individual participants.
40856845|NCT01237613|DEVICE|Artelon|Artelon Tissue Reinforcement
40856846|NCT04887259|BIOLOGICAL|LAVA-051|In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion
40856847|NCT04887259|BIOLOGICAL|Interleukin 2|In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients
40856848|NCT03521141|DRUG|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
40856849|NCT03521141|DRUG|Varenicline|FDA-approved smoking cessation pharmacotherapy
40856850|NCT03521141|GENETIC|Nicotine metabolism|Information on nicotine metabolism will be used to inform selection of medication.
40856851|NCT03521141|GENETIC|Genetically-informed lung cancer risk score|This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.
40856852|NCT03521141|BEHAVIORAL|"NCI Clearing the Air"|A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
40856853|NCT02952833|DRUG|Saline|Sodium chloride solution.
40856854|NCT02952833|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
40856855|NCT06268938|PROCEDURE|Canal wall down tympanomastoidectomy|Mastoid cavity obliteration by in canal wall down tympanomastoidectomy tympanomastoidectomy in cholesteatoma surgery
40856856|NCT02926638|DRUG|Erlotinib Hydrochloride|Given PO
40856857|NCT02926638|OTHER|Laboratory Biomarker Analysis|Correlative studies
40856858|NCT02926638|BIOLOGICAL|Rilotumumab|Given IV
40856859|NCT02787538|BEHAVIORAL|US-ANSWER-2 decision aid|US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
40856860|NCT02787538|BEHAVIORAL|Control group (Online medication guide)|Standard online medication guide.
40856861|NCT01035281|DRUG|Nabilone, flexible dosing|nabilone at 0.5 - 4 mg/day
40856862|NCT02703324|DRUG|LY900014|Administered subcutaneously (SC)
41166755|NCT06252090|OTHER|Short term mentalization-based treatment for adolescents (MBT-A)|The general framework of intervention corresponds to the Mentalization-Based Treatment model for adolescents (MBT-A). In this study, the model was adapted to a brief, time-limited format (12 sessions) aimed at both the adolescent and their family. The model retains the main characteristics of Mentalization-Based Therapy, such as the therapist's basic attitude toward actively promoting patients' mentalization, uncertainty of mental states, focus on the here and now, and the use of affect as a mechanism for change.
41166756|NCT00876499|BEHAVIORAL|Questionnaire|A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
40856863|NCT02703324|DRUG|Insulin Lispro|Administered SC
40856864|NCT05958680|BEHAVIORAL|ASDactive|An integrated theory-based intervention to promote habitual physical activity behaviours in autistic youth
40856865|NCT03647644|DIAGNOSTIC_TEST|Coagulation Laboratory Testing|Standard coagulation testing (Platelet count, Fibrinogen, PT/INR, aPTT), and Thromboelastogram as is routine and per institutional protocol in this population.
40856866|NCT00308854|PROCEDURE|Photodynamic Therapy|
40856867|NCT03536832|PROCEDURE|Cesarean Section with Vicryl|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with Vicryl.
40856868|NCT03536832|PROCEDURE|Cesarean Section with Prolen|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with prolen.
40856869|NCT05289479|PROCEDURE|Pre-heating of resin composite before application|the effect of preheating of resin composite before application in class II cavities
40856870|NCT05289479|PROCEDURE|no pre-heating of resin composite before application|The control group
40856871|NCT00230841|DEVICE|nebulized humidity|
40856872|NCT04269356|DRUG|BMS-986256|Specified dose on specified days
40856873|NCT04269356|DRUG|Milk of magnesia|Specified dose on specified days
40856874|NCT01873040|BEHAVIORAL|Social Media plus information pages|Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
40856875|NCT01873040|BEHAVIORAL|Vaccine Information Pages|Participants will receive access to the study vaccine website information pages.
41387965|NCT00442338|DRUG|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
41387966|NCT00442338|DRUG|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
41387967|NCT00442338|DRUG|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
41387968|NCT06058585|DRUG|Finerenone|Finerenone 10mg or 20mg tablets, oral, once daily
41387969|NCT06058585|DRUG|Placebo Finerenone|Finerenone matched placebo tablets, oral, once daily
41387970|NCT06058585|DRUG|Endothelin Receptor Antagonist|Endothelin Receptor Antagonist tablets, oral, once daily
41387971|NCT06058585|DRUG|Placebo Endothelin Receptor Antagonist|Placebo Endothelin Receptor Antagonist tablets, oral, once daily
41387972|NCT04089163|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.
41387973|NCT04089163|DRUG|Toca FC (extended-release formulation of flucytosine)|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
41387974|NCT01779349|DEVICE|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
41166757|NCT03895697|DRUG|dasiglucagon|Glucagon analogue
41387975|NCT02270840|DEVICE|CRT-D|Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
41038556|NCT03664713|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|EMDR is an 8-phase psychological treatment composed of protocols and standardized procedures applicable to both adults and children. The eight phases (patient history, patient preparation, evaluation of the main aspects of the memory, desensitization of the traumatic memory, installation of the positive cognition, body scan, close and re-evaluation) and the protocol of the time line of past-present-future, allow a holistic evaluation of the image of the traumatic memory, and allow for the patient to be well-prepared before processing past events which underlie current pathology, current situations which cause perturbation, and challenges and possible future stimuli which might lead to the appearance of symptoms. (Shapiro, 2014)
41038557|NCT02147548|DRUG|etifoxine|
41038558|NCT02147548|DRUG|lorazepam|
41166758|NCT06345898|DRUG|JWK002|Subretinal administration of gene therapy vector JWK002 to one eye.
41387976|NCT02321215|OTHER|Introductory Disease Education|This intervention will consist of two one-on-one education sessions, each lasting 30 minutes.
41387977|NCT06537024|PROCEDURE|RTSA|
41387978|NCT04585906|BEHAVIORAL|Common Elements Treatment Approach|The intervention integrates psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping.
41387979|NCT01880541|OTHER|hypnosedation|hypnosedation
41387980|NCT01880541|OTHER|general anesthésia|general anesthesia
41387981|NCT05335473|DRUG|Eribulin and Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
41528367|NCT05258305|DEVICE|AuraGen 1-2-3 with AuraClens|Autologous fat transfer (AFT) is a minimally invasive medical procedure that includes aspirating adipose tissue from one part of the body, and washing, filtering and re-injecting the processed fat tissue into a different part of the body with the primary purpose of adding volume. The AuraGen 1-2-3 with AuraClens is a lipoaspirate wash system designed to be used in the operating room in conjunction with a user-provided liposuction cannular, a vacuum source, and waste canister.
41038559|NCT02147548|DRUG|Placebo|
41038560|NCT04388839|DRUG|Vincristine|IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg
41038561|NCT04388839|DRUG|Cyclophosphamide|IV over 60 minutes with dosing ranging from 220mg to 1200mg
40856876|NCT00713544|DRUG|AZD5672|20 mg oral, once daily
41038562|NCT04388839|DRUG|Vinorelbine|IV push over 6-10 minutes with dosing ranging from 4mg-25mg
41038563|NCT04388839|DRUG|Actinomycin D|Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg
41038564|NCT04388839|DRUG|Cyclophosphamide Pill|Based on Body Surface Area (BSA) round to nearest 25mg
41387982|NCT03649607|OTHER|Accelerated Resolution Therapy|ART was developed to treat both physiological and cognitive aspects of PTSD, which has been described as a consequence of failed memory processing. The use of Voluntary Image Replacement (VIR) parallels imaging re-scripting in which a preexisting negative mental image is transformed into a more benign image. This has been successfully used to treat survivors of traumatic industrial accidents suffering from PTSD. Participants will complete five sessions over a 21-day period.
41387983|NCT00485368|DRUG|Coversyl (perindopril)|
41387984|NCT00975884|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
41387985|NCT02026102|BEHAVIORAL|ICD Decision Aid Toolkit|Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
41387986|NCT03327142|DIAGNOSTIC_TEST|Endoscopic Ultrasound-Guided FNA|Endoscopic Ultrasound Guided Fine Needle Aspiration of Puncture of Adrenal Glands
41387987|NCT01545752|OTHER|teaching by non-interactive CD|teaching book with non-interactive CD
41387988|NCT01545752|OTHER|Interactive CD|Teaching book with interactive CD
41387989|NCT04434638|OTHER|Transitions of Care Coordinator|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
41387990|NCT04434638|OTHER|Usual Care|Patients received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
41387991|NCT00540007|DRUG|Lenalidomide|
41387992|NCT02556931|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
41387993|NCT02556931|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
41387994|NCT02556931|RADIATION|Total body irradiation|Day -1: 200 cGy in a single fraction
41038565|NCT01750138|DRUG|Glutamine|
41038566|NCT01750138|DRUG|Dextrose powder|
41038567|NCT00869232|DRUG|Velcade|1.0mg/m2 days 1, 5, 8, \& 11
41038568|NCT00869232|DRUG|Melphalan|10 mg/m2 day 3
41038569|NCT00869232|DRUG|Thalidomide|200 mg days 5-8
41038570|NCT00869232|DRUG|Dexamethasone|40 mg day 5-8
41038571|NCT00869232|DRUG|Cisplatin|10 mg/m2 day 5-8
41038572|NCT00869232|DRUG|Adriamycin|10 mg/m2 day 5-8
41038573|NCT00869232|DRUG|Cyclophosphamide|400 mg/m2 day 5-8
41166759|NCT04244422|OTHER|PIEZOSURGERY VERSUS CONVENTIONAL SURGERY|Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments
41166760|NCT06483685|DRUG|Radiopharmaceuticals drugs|radiopharmaceuticals drugs included in the Anatomical Therapeutic Chemical (ATC) classification system.
41387995|NCT02556931|DRUG|Tacrolimus|Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.
41387996|NCT02556931|DRUG|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
41387997|NCT06112184|OTHER|SK-M11/3A1 Digital health program|Digital Health program with participants using an autoinjector delivered via the Sidekick mobile application (app)
41511304|NCT04574440|DEVICE|multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap that will be positioned on the patient's head according to international operational guidelines and will be secured to the temporal region of the patient's forehead. The NIRS cap is entirely non-invasive and does not pose any additional risk to the patient. Monitoring will be commenced prior to the induction of anesthesia. Subsequent surgical and medical care will not be affected.
41511305|NCT05671536|BEHAVIORAL|motivational interview|Intervention arm will receive motivational interview by the researcher, once a month for 4 times at least 20 minutes. The researcher received education about motivational interview.
41511306|NCT00273988|DRUG|nevirapine|
41166761|NCT03459612|DRUG|Lasmiditan|Administered orally
41166762|NCT03459612|DRUG|Placebo|Administered orally
41166763|NCT03459612|DRUG|Diphenhydramine|Administered orally
41038574|NCT00869232|DRUG|Etoposide|40 mg/m2 day 5-8
41166764|NCT03892551|OTHER|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 35 symptoms
41038575|NCT06303050|OTHER|Mental Imagery with task Oriented training group|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The experimental group will receive 20 minutes of MI training followed by 25 minutes of TOT for a total of 45 minutes, 5 days per week for 6 weeks. During each 45 minutes of session, the participants will perform warm-up exercise for 5 minutes to prepare the body for functional task and to improve overall performance. Regular breaks will give to the participants to avoid overexertion and fatigue during 45 minutes of continues practice. The 2 minutes rest period will provide to the partici-pants during each practice session
41038576|NCT06303050|OTHER|Task Oriented training group|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The control group will receive the Task oriented training for 25-30 minutes, 05 days a week for 06 weeks consisting of Warm up Period, Task oriented training In standing, forward stepping and sideward stepping, reaching in standing, Transition from sit to stand, Walk then back to sit, Walk with even steps, Walk with carrying objects.
41038577|NCT02657278|PROCEDURE|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
41166765|NCT03892551|OTHER|Reason for patient presentation at ED|Exploratory interview assessing reason for patient presentation at ED
41166766|NCT03892551|OTHER|physicians rating of severity of illness|numeric scale ranging from 0 (perfect condition) to 10 (extremely ill)
41166767|NCT03892551|DIAGNOSTIC_TEST|Assessment of vital signs|Assessment of vital signs (heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
40856877|NCT00713544|DRUG|Etanercept|50 mg, subcutaneous injection, weekly
40856878|NCT00713544|DRUG|Placebo|placebo, oral, once daily
41038578|NCT02100982|OTHER|Customized Care|Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
41038579|NCT02100982|OTHER|Care As Usual|Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
41038580|NCT05668754|DRUG|Serdexmethylphenidate|Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.
41038581|NCT05668754|OTHER|Placebo|Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.
41038582|NCT00002933|DRUG|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
41038583|NCT05956964|BEHAVIORAL|Sleep Restriction|5 hours of sleep for 3 days
41038584|NCT05956964|BEHAVIORAL|Sleep Adequate|9 hours of sleep for 3 days
41038585|NCT03838042|DRUG|Nivolumab and Entinostat|Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.
41038586|NCT06486259|OTHER|Controlled mechanical ventilation|Patients were ventilated under similar tidal volume, respiratory rate, and plateau pressure. PEEP was the adjustment variable to reach a similar plateau pressure
41166768|NCT03892551|OTHER|Clinical Frailty Scale|Assessment of frailty by Clinical Frailty Scale (CFS): assess patients' frailty level from 1, very fit, to 9, terminally ill
41387998|NCT03370627|BIOLOGICAL|Monoclonal anti-cd303 antibody|Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.
41387999|NCT06539143|DRUG|Lidocaine|The Paracervical Block with lidocaine for manual vacuum aspiration
41388000|NCT02706041|PROCEDURE|Definitive Closure Laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
41388001|NCT02706041|PROCEDURE|Damage Control Laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
41388002|NCT04109768|BEHAVIORAL|nutrition and activity|16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
41388003|NCT03647280|DRUG|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
41388004|NCT03647280|DRUG|Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
41388005|NCT06272812|BIOLOGICAL|MTBVAC|Vaccine Dose: MTBVAC 5x10\^5 Formulation (approximately, per standard dose): 3 - 17x10\^5 CFU Sucrose Sodium glutamate Presentation: Lyophilized pellet in vials (10 doses) Volume: 0.1 mL/dose Intradermal
40856879|NCT00713544|DRUG|AZD5672|50 mg oral, once daily
40856880|NCT00713544|DRUG|AZD5672|100 mg oral, once daily
40856881|NCT00713544|DRUG|AZD5672|150 mg oral, once daily
40856882|NCT01332383|DRUG|Naratriptan|
40856883|NCT03416127|DRUG|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
40856884|NCT03416127|DRUG|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
41166769|NCT03892551|OTHER|Impaired mobility on presentation (IMOP)|Assessment of IMOP: defined as being unable to stand unaided or walk without help
41388006|NCT06272812|BIOLOGICAL|Placebo|0.9% saline Volume: 0.1 mL/dose Intradermal
41388007|NCT00776269|PROCEDURE|argon laser and radiofrequency|
41388008|NCT06410573|BEHAVIORAL|Breast Self-Examination and Practice|In the training, women will be divided into 5 groups and the training will be held in 5 separate sessions in one day. A training program will be completed with 9 women. All trainings will be conducted under the same conditions in the school's training room. Before the training, women will be informed about the training and their permission and consent will be obtained. The training prepared by the researcher will be presented to the women in the experimental group of the study. The presentation used in the training will include information about breast cancer, breast cancer screening programs and breast self-examination. In the presentation, the steps of breast self-examination will be shown step by step using visual materials.
41388009|NCT02390973|PROCEDURE|Sleeve Gastrectomy|
40856885|NCT03416127|DRUG|Placebo|Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
41388010|NCT02390973|PROCEDURE|Roux-en-Y Gastric Bypass|
41388011|NCT02390973|PROCEDURE|Biliopancreatic Diversion with Duodenal Switch|
41388012|NCT02390973|OTHER|Medical management|
41388013|NCT02170142|DEVICE|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
41511307|NCT00004186|DRUG|carboplatin|
40856886|NCT03903419|DIAGNOSTIC_TEST|Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.|"This study is a non-randomized, prospective, feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy for glioblastoma.~Patients with a MRI performed since the end of the radiotherapy until 12 months of follow up after the end of radiotherapy, will be referred for both 68Ga-PSMA and 18F-FDOPA PET-CT, whatever the conclusion of the MRI (post radiation modifications, relapse or doubtful MRI)."
40856887|NCT05055934|DRUG|SHR-1314 injection|SHR-1314 injection
40856888|NCT05055934|DRUG|placebo|placebo
41511308|NCT00004186|DRUG|etoposide|
41388014|NCT06568601|GENETIC|Pharmacogenetic and polygenic risk testing|The intervention involves: genetic testing; interpretation; and prior to and shortly following an upcoming appointment, communication to patients and providers about the patients' predicted statin efficacy and toxicity, genetic risk for CVD, and individualized recommended statin type/dose.
41388015|NCT06568601|OTHER|Active control|The control condition involves receipt of a report highlighting the risk of cardiovascular disease and benefits of statins (without genetic test
41388016|NCT00956709|DRUG|levobupivacaïne 0,5 %|20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
41388017|NCT00956709|DRUG|ropivacaïne 0,5 %|20mL de ropivacaïne 0,5 %
41511309|NCT00004186|DRUG|ifosfamide|
41166770|NCT03892551|OTHER|Assessment of suspected diagnosis and differential diagnoses|Assessment of treating physician's suspected diagnosis and differential diagnoses. Answers will be recorded in free text form.
40856890|NCT03840954|OTHER|Neuromuscular Electrical Stimulation|"The application of NMES will be performed with the patient positioned in the supine position in the bed. Self-adhesive electrodes will be positioned at the motor points of the quadriceps and anterior tibial muscles respectively. A symmetrical biphasic pulsed current with a frequency of 80 Hz, a pulse width of 500 μs and an intensity at the motor threshold will be applied up to the maximum tolerated by the patient. ON and OFF time and total session time will be used according to protocol with progressive increase of the total intervention time and reduction of OFF time of the NMES. The device used will be the Neurodyn II model, manufactured by IBRAMED.~Patients will receive NMES for as long as they remain hospitalized or for up to 3 weeks."
40856891|NCT05020080|OTHER|Operant conditioning of motor evoked potentials|MEPs elicited by TMS will be applied at the hot spot for the wrist extensor carpi radialis. During training trials, participants will be asked to increase the size of their MEP response. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
40856892|NCT05023993|OTHER|Exercise Intervention|Complete home exercise
40856893|NCT05023993|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Given PO
40856894|NCT04417608|PROCEDURE|Infraclavicular brachial plexus block|Ultrasound-guided infraclavicular brachial plexus block
40856895|NCT02312050|DRUG|GCS-100|1 mg, 3 mg, or 9 mg IV push injections
40856896|NCT02312050|DRUG|Placebo|
40856897|NCT03991455|DEVICE|Apyx device|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
41166771|NCT03587519|PROCEDURE|Early|Early ileostomy closure
41166772|NCT03587519|PROCEDURE|Late|Late ileostomy closure
41388018|NCT06270537|DEVICE|Stent-Graft Dominus® Endoprosthesis|Placement of the Dominus® Stent-Graft for endovascular repair of diseases of the Thoracic Aorta
41388019|NCT00334828|DRUG|eritoran tetrasodium|Intravenous infusion at a total dose of 105 mg.
41388020|NCT00334828|DRUG|Placebo|Matching placebo; intravenous infusion.
41388021|NCT06568809|OTHER|Time interval between recovery of body temperature and operation|The time between body temperature recovery and surgery was collected as categorical factor and was scheduled to be analyzed in the following categories: 0-2 weeks; 3-4 weeks; 5-6 weeks; 7-8 weeks; And ≥ 3 months (control group).
41388022|NCT05770596|DRUG|vitamin C group|patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
41388023|NCT05770596|OTHER|placebo group|patients in this group will receive placebo tablets with the same manner; orally 1 hour before surgery and for 50 days starting from the 2nd postoperative day.
41511310|NCT00004186|DRUG|topotecan hydrochloride|
41511311|NCT00004186|RADIATION|radiation therapy|
41511312|NCT00012922|BEHAVIORAL|Low Literacy Intervention for Colorectal Cancer Screening|
41511313|NCT00534456|DRUG|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
41511314|NCT00534456|DRUG|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
41511315|NCT02652949|DEVICE|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
40856898|NCT05121948|DRUG|HC-7366|HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration. Each capsule contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. Capsules are supplied in 3 strengths: 10, 25, and 100 mg HC-7366 free acid equivalent.
40856899|NCT00002357|DRUG|HBY 097|
40856900|NCT00002357|DRUG|Zidovudine|
40856901|NCT00532298|BIOLOGICAL|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
40856902|NCT00532298|BIOLOGICAL|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
40856903|NCT00532298|BIOLOGICAL|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
40856904|NCT00532298|BIOLOGICAL|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
40856905|NCT00756418|DRUG|montelukast|montelukast 5 mg QD 4-weeks.
40856906|NCT00756418|DRUG|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
40856907|NCT01612130|DRUG|100 mg of Valeriana officinalis L|A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
40856908|NCT01612130|DRUG|Placebo 100mg|A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
40856909|NCT04247737|OTHER|gluten free diet|Participants keep a gluten free diet for six weeks
41388024|NCT05807347|DRUG|Venetoclax|VA regimen Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7. CAG regimen Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7 Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7 Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×109/L
41388025|NCT03519360|OTHER|UFR-restricted dialysis|UFR's are limited to a maximum of 10 mL/kg/hr for the duration of the session. In order to prevent progressive volume overload and the need for additional hemodialysis sessions to manage volume gains in this scenario, subjects will crossover weekly between the restricted and unrestricted UFR interventions.
41388026|NCT03519360|OTHER|UFR-unrestricted dialysis|UFR's will be unlimited and prescribed according to the standard of care.
41388027|NCT04075045|BEHAVIORAL|Wellth Smartphone App|Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).
41388028|NCT04075045|BEHAVIORAL|Targeted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at pharmacies.
41388029|NCT04075045|BEHAVIORAL|Non-Restricted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at most stores, except for prohibited purchases such as alcohol, tobacco, or firearms, and is not redeemable for cash.
41388030|NCT01598415|DRUG|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
41388031|NCT01598415|DRUG|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
41388032|NCT06518720|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with supportive therapy.
41388033|NCT04229277|DIAGNOSTIC_TEST|optical coherence tomography|comparison of four imaging technologies in skin tumour diagnosis
41388034|NCT02559531|DEVICE|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
41388035|NCT03285412|DRUG|Ribociclib|Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.
41388036|NCT03285412|OTHER|Endocrine therapy|Hormone therapy
41388037|NCT01822964|DEVICE|targeted brain cooling (33°C) by RhinoChill device|targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
41388038|NCT01822964|DEVICE|Placebo - current clinical practice, no cooling|
40856910|NCT01983085|DEVICE|NOx dressing|The NOx dressing should be changed at least every 2 days.
40856911|NCT01983085|DEVICE|Standard of Care|Dressing changed as per normal clinical practice
40856912|NCT02068625|DRUG|Rasagiline|Rasagiline 1mg daily orally for 7 days
40856913|NCT02068625|DRUG|Placebo|Oral treatment with placebo for 7 days
40856914|NCT03620084|DEVICE|Expiratory Muscle Strength Training (EMST)|The target home practice frequency on the EMST-150 is: 5 repetitions of forceful expiration each time, 5 times daily, 5 days a week for 8 weeks, following the training protocol used by Hutcheson et al. (2017).
40856915|NCT02709811|DRUG|Electrochemotherapy|
40856916|NCT03295760|DRUG|Q10 Coenzyme|
40856917|NCT03306719|BIOLOGICAL|Blood sampling|Serial blood sampling
41388039|NCT05182008|OTHER|Decision aid|Online interactive decision aid on method of early abortion
41388040|NCT05182008|OTHER|Usual care|Patients will be directed to the abortion clinic website
40856918|NCT06087484|BEHAVIORAL|Mindfulness Intervention for Emotional Distress and Insomnia (MIED-I)|The MIED-I program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs).Also, a portion of the CBT-I will be added to the course to provide psychoeducation for insomnia. Variables that have been shown to be effective in interventions for insomnia in past studies, such as awareness, non-responsiveness, and self-compassion, will also be added to better alleviate insomnia symptoms
40856919|NCT05799131|DEVICE|QBX (5F/6F) Peripheral Balloon Expandable Stent System|"The QBX Stent System is a flexible, balloon expandable stent, made of a cobalt chromium alloy manufactured by QualiMed Innovative Medizinprodukte GmbH. The design is suitable for peripheral vessel diameters from 5 to 10 mm.~The QBX Stent System is available as 6F and 5F variations where the 6F system is mounted on an 0.035 over-the-wire delivery system, and the 5F is mounted on an 0.018 over-the-wire delivery system. Both are available in a full range of diameters and lengths."
40856920|NCT00211328|DRUG|anecortave acetate|
40856921|NCT01382238|DRUG|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
40856922|NCT01382238|DRUG|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
40856923|NCT06072417|OTHER|Assessment without intervention at High altitude|Assessments at High altitude corresponding to Baseline measures
40856924|NCT06072417|OTHER|Relocation to sea level for 2 days|Participants will be relocated to sea level and intervention and have assessements there.
40856925|NCT05156957|OTHER|physiotherapeutic intervention|The intervention consists of a brief physiotherapeutic assessment by a short physical performance battery, a brief information on the expected course of the condition and instructions on self-management regarding back friendly behaviour (eg. respecting the pain, staying active and back friendly movement strategies). Additionally, three exercises for daily self-guided therapy are included to the intervention: Turning in bed and coming to a sitting position, sit to stand and squats standing in front of a wall.
40856926|NCT00121186|DRUG|fludarabine phosphate|30 mg/m\^2 on days -6 to -2 (2-6 days before transplant).
40856927|NCT00121186|DRUG|melphalan|70 mg/m\^2 on days -3 and -2 (2-3 days before transplant).
40856928|NCT00121186|DRUG|methotrexate|5 mg/m\^2 on days 1, 3, and 7 post-transplant.
40856929|NCT00121186|DRUG|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
40856930|NCT00121186|PROCEDURE|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
40856931|NCT00121186|PROCEDURE|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
40856932|NCT06241053|OTHER|Multimodal therapy with McConnell taping|"Multimodal therapy includes core exercises, hip exercises and vastus medialis training.~Core exercises include curls ups, toa taps, side planks, supine straight leg raising, side lying straight leg raising, prone knee flexion, draw foot circles in supine and side lying, prone cobra, hip and knee extension, weight bearing, hip flexion sitting on ball, wight bearing forward and backward on the ball, stairs up on Swiss ball. Hip training includes Hip abduction, Hip external rotation in standing and sitting. VMO muscle strengthening will includes squats with a ball."
40856933|NCT06241053|OTHER|Multimodal therapy without McConnell taping|Multimodal therapy without McConnell taping
40856934|NCT02648568|BEHAVIORAL|Hypnosis plus relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
40856935|NCT02648568|BEHAVIORAL|Relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
40856936|NCT04926246|DRUG|R1: Reference Product X|under fasted conditions
40856937|NCT04926246|DRUG|T1: Test Product M|under fasted conditions
40856938|NCT04926246|DRUG|T2: Test Product N|under fasted conditions
40856939|NCT04926246|DRUG|T3: Test Product O|under fasted conditions
40856940|NCT04926246|DRUG|T4: Test Product O|under fed conditions
40856941|NCT04926246|DRUG|R2: Reference Product Y|under fasted conditions
40856942|NCT04926246|DRUG|T5: Test Product P|under fasted conditions
40856943|NCT04926246|DRUG|T6: Test Product P|under fed conditions
40856944|NCT04926246|DRUG|T7: Test Product Q|under fasted conditions
41388041|NCT01588678|DRUG|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
41388042|NCT05812924|BIOLOGICAL|Platelet-rich plasma (PRP)|0.1-0.2 mL injections of platelet-rich plasma (PRP) will be injected to the vulvovaginal area. The injections will be placed every 5mm and at an angle of 60° into the mucosa and lamina propria of the posterior wall of the vagina.
41388043|NCT04608656|OTHER|Provision of livestock feeds|Households will receive livestock feeds (ranch cubes) for the select lactating animals during the dry season
41388044|NCT04608656|OTHER|Nutrition counselling|Households will receive livestock feeds (ranch cubes) for the select lactating animals and will also be enrolled in to a nutrition counselling programme
41388045|NCT00458016|DRUG|MB07803|Daily oral administration
41388046|NCT00458016|DRUG|Placebo|Daily oral administration
41388047|NCT04583631|PROCEDURE|Adenoidectomy surgery|All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.
40856945|NCT04926246|DRUG|R3: Reference Product Z|under fasted conditions
40856946|NCT04926246|DRUG|T8: Test Product S|under fasted conditions
40856947|NCT04926246|DRUG|T9: Test Product S|under fed conditions
40856948|NCT04926246|DRUG|T10: Test Product U|under fasted conditions
41166773|NCT03698630|DRUG|Prednisolone Sodium Phosphate|Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
41388048|NCT00759759|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
41388049|NCT00759759|DRUG|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
41388050|NCT00090337|PROCEDURE|acupuncture therapy|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks
41388051|NCT00090337|PROCEDURE|standard follow-up care|Patients undergo standard care
41388052|NCT00174486|DRUG|UK0369,003|
41388053|NCT00174486|DRUG|Cialis (Tadalafil)|
41388054|NCT04907916|OTHER|SIRTUIN1|The NAD dependent deacetylase activity of Sirtuin1
40856949|NCT02181283|BEHAVIORAL|W+W|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps."
40856950|NCT02181283|BEHAVIORAL|W+P|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support."
41388055|NCT01683331|DRUG|Insulin treatment for hyperglycemia|
40856951|NCT02917395|DEVICE|echocardiography|Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
40856952|NCT01221493|PROCEDURE|Cryo biopsy|Cryoprobe, Erbe Company
40856953|NCT00117039|DRUG|Aranesp®|
41166774|NCT03698630|DRUG|Dexamethasone|"Dexamethasone 2 mg tablets (Organon Ireland Ltd). Round, 6 mm, flat, white tablet with the code XC/8 engraved on one surface and Organon\* on the other containing 2 mg dexamethasone."
41166775|NCT06382571|DRUG|Renin-Angiotensin System Inhibitor|
41166776|NCT05400252|BEHAVIORAL|Omnis Salutis|Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports
41388056|NCT05286580|BEHAVIORAL|Morbidity and mortality conference toolkit|"* Standardized slide deck~* Code of conduct~* Conference planning checklist~* Case documentation form"
41388057|NCT00802776|PROCEDURE|Femtosecond laser assisted keratoplasty|
41388058|NCT00802776|PROCEDURE|PKP|
41388059|NCT03414307|PROCEDURE|Intracerebral catheter placement|Image guided stereotactic placement of intra-hemorrhage catheters to evacuate intra-cerebral hemorrhage
41388060|NCT03414307|DEVICE|Robot-assisted intracerebral catheter|ROSA is a robotic device with trajectory planning software that can be used to aid in planning multiple trajectories to large, irregular clots, and aids in navigating into and out of the cerebral hematoma with minimum human error.
41388061|NCT05732818|DEVICE|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
41388062|NCT05348018|DEVICE|Playing Serious Games during a four-week test period in addition to conventional lectures|Playing SGs during a four-week test period in addition to conventional lectures in oral rehabilitation
41388063|NCT04620863|OTHER|t-DCS group|All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
41388064|NCT04620863|OTHER|Sham group|The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
41388065|NCT05105035|DRUG|Ceftazidime or meropenem|Patients will be prescribed ceftazidime or meropenem intravenously as per standard of care for at least 14 days while in the hospital
41388066|NCT05105035|DRUG|ARV-1801|Patients will be prescribed ARV-1801 at 1500mg 12 hours apart on Day 1 and 600mg every 12 hours for Days 2-14.
40856954|NCT04691674|PROCEDURE|Endoscopy|Endoscopic removal of the pancreatic stent
40856955|NCT02951494|OTHER|AlterG Anti-gravity treadmill|Participants in this group will complete a 12 week aerobic exercise training protocol with 40% lower body weight support on an AlterG Anti-gravity treadmill
40856956|NCT00103740|DRUG|zoledronic acid|5 mg zoledronic acid in 5 mL of sterile water for infusion
40856957|NCT00103740|DRUG|placebo to zoledronic acid|5 mL of sterile water for infusion
41388067|NCT05105035|DRUG|Placebo|Patients will be prescribed placebo every 12 hours for Days 1-14.
41388068|NCT05298215|BIOLOGICAL|UB-221|UB-221 is a recombinant humanized IgG1 monoclonal antibody with neutralizing capability against soluble human IgE and CD23-bound IgE for the treatment of allergic diseases. The activity of UB-221 is directly through the high-affinity binding with soluble and membrane bound IgE. The neutralization of soluble IgE will desensitize the activation of mast cells and basophils by inhibiting IgE cross-linking and down-regulation of FcεRI (high affinity IgE receptor) expression on those cells. The binding to CD23-bound IgE may inhibit IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes.
41388069|NCT05298215|OTHER|sterile saline solution|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
41388070|NCT06539689|DEVICE|Sperstent® peripheral spot stent system|Sperstent® peripheral spot stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
41388071|NCT06539689|DEVICE|Everflex® self-expanding peripheral stent system|Everflex® self-expanding peripheral stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
41388072|NCT02386722|DEVICE|Smartinhaler/POEMS with audio reminders and additional support calls|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
41511316|NCT06399744|PROCEDURE|sclerotherapy|injection of sclerosing agent (tetracycline or polidocanol) into ovarian cyst after aspiration of its contents
40856958|NCT00103740|DRUG|Risedronate|30mg oral tablets overencapsulated to match the placebo capsules
40856959|NCT00103740|DRUG|Placebo to risedronate|oral capsules
41511317|NCT05051514|DIAGNOSTIC_TEST|Evaluation|To examine the differences in postural stability, anxiety/depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
41511318|NCT00141778|DRUG|Placebo|Matching placebo taken once a day
41511319|NCT00141778|DRUG|Ramipril|Taken orally, once a day
40856960|NCT00103740|DRUG|Calcium and vitamin D supplements|Calcium and vitamin D supplements were supplied
41511320|NCT00141778|DRUG|Spironolactone|Taken orally, once a day
41511321|NCT06196489|BEHAVIORAL|adapted vaping cessation intervention|Behavioral intervention for vaping cessation
41511322|NCT04952350|DRUG|Atorvastatin 40 Mg Oral Tablet|Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
40856961|NCT06189131|DEVICE|Ventriject|Ventriject is a non-exercise method for estimating V02Max
40856962|NCT00270062|DRUG|epoetin alfa|
40856963|NCT03081871|OTHER|Pharmacist-led cardiovascular risk service (CVRS)|CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
40856964|NCT03081871|OTHER|Mobile access to study Personal Health Record|Only subjects assigned to the intervention arm will have access to the mobile app version of the study personal Health Record.
40856965|NCT03081871|OTHER|Web access to study Personal Health Record|Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
41038587|NCT01920230|BEHAVIORAL|Mindfulness-ACT-intervention|Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams \& Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.
41038588|NCT01920230|BEHAVIORAL|No intervention|Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
41038589|NCT03926091|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
41038590|NCT03926091|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
41511323|NCT04952350|OTHER|Placebo|A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).
41511324|NCT05638061|OTHER|Soy protein|Soy foods or isolated soy protein
40856966|NCT00566462|DRUG|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
40856967|NCT00566462|DRUG|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
41511325|NCT03474874|DEVICE|NeoMatriX Collagen Dressing|Collagen wound dressing
40856968|NCT05280600|OTHER|Not applicable - non-interventional study|Not applicable - non-interventional study
40856969|NCT04906304|DRUG|Everolimus Pill|standard dose versus low dose Sandimun
40856970|NCT04906304|DRUG|Sandimmun (Neoral) dose plus cellcept|Sandimmun (Neoral) dose plus cellcept
41038591|NCT03479372|DRUG|PAN-90806 Ophthalmic Suspension|PAN-90806 provided in single-use dropper bottles for topical ocular administration
41038592|NCT01893242|DRUG|Aleglitazar|Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
41166777|NCT05400252|BEHAVIORAL|Health and Wellness|Health \& Wellness is an educational wellness intervention
41166778|NCT03168399|DIETARY_SUPPLEMENT|PKU Explore|PKU Explore is an unflavoured, powdered, phenylalanine-free, protein substitute, containing essential and non-essential amino acids, carbohydrate, sugar, vitamins, minerals, trace elements and the long chain polyunsaturated fatty acids (LCPs); arachidonic acid (AA) and docosahexaenoic acid (DHA).
41388073|NCT02306434|BEHAVIORAL|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
41388074|NCT02306434|OTHER|Standard care-counselling|Standard care (Counselling by midwives)
41388075|NCT04619472|DEVICE|Pulmonary Radiofrequency Ablation System and the Disposable Pulmonary Radiofrequency Ablation Catheter|The conjunction of the pulmonary RFA system with the disposable pulmonary RFA catheter developed by Hangzhou Broncus Medical Co., Ltd. is aim to specifically target lung tumors. The ablation catheter is designed to reach the tumor through the bronchial pathway.
41388076|NCT06317363|OTHER|Base Line + ACEPELLA|Group A (baseline treatment + acapella) consisting of 15 participants will receive (baseline treatment aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition to using Acapella). The primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
41388077|NCT06317363|OTHER|Base Line + Manual Chest Physiotherapy|The group B consisting of 15 participants will receive base line treatment. aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition chest physiotherapy percussing for 20 minute. The s primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
41388078|NCT06542484|DRUG|Gefapixant Citrate|An additional treatment of gefapixiant will be performed for 12 weeks.
41388079|NCT06567093|OTHER|Baby Foot and Leg Massage|"Baby Foot Massage stages~* The baby is placed on his back, either on the bed or on the couch.~* One of the baby's feet is lifted into the air by grasping the back of the ankle.~* Start stroking with circular movements, starting from the heel and moving up to the toes. Stroking should be done with the thumb.~* Here, it might be good to get between the toes.~* The same procedure is applied to the other foot.~* Massage is continued until it is noticed that the baby calms down.~Baby Leg Massage stages~* Start by lifting the leg to be massaged.~* Here, the palms of both hands are used. The baby's leg is placed between both hands and the leg is stroked by moving the palms in opposite directions. This movement is continued from above the ankle to the hip.~* The same procedure is applied to the other leg.~* Massage is continued until the baby calms down."
41388080|NCT02711579|DRUG|Celecoxib|
41388081|NCT02711579|DRUG|Placebo|
41388082|NCT06557473|DRUG|Lidocaine IV|1.5mg/kg IV for induction of GA
41388083|NCT06557473|DRUG|Fentanyl|Fentanyl IV 2 µg/kg for GA induction
41388084|NCT00896701|OTHER|flow cytometry|
41388085|NCT00896701|OTHER|immunologic technique|
41388086|NCT00896701|OTHER|laboratory biomarker analysis|
41388087|NCT02627885|BEHAVIORAL|Internet-based CBT|Through the use of CBT material at an Internet-platform, we aim for behavioral changes in the subjects to improve everyday level of functioning and quality of life.
41388088|NCT02627885|OTHER|SMT|Standard Medical Treatment includes pharmacological management and other typical medical interventions for the patient group but no behavioural interventions
41511326|NCT04365803|PROCEDURE|vacuum-assisted breast biopsy|patient with radiological complete response after neoadjuvant chemotherapy undergo to vacuum assisted breast biopsy and the to definitive surgery
41038593|NCT01893242|DRUG|Placebo|Matching placebo to aleglitazar, once a day for approximately 3 years
41388089|NCT03138135|BEHAVIORAL|HOME Study intervention|Access to home HIV test kits, home STI self-collection kits, the HOME Study website, and the SexPro HIV risk assessment tool.
41388090|NCT03138135|BEHAVIORAL|Control|Counseling about the importance of quarterly HIV/STI testing and a PrEP information pamphlet.
41388091|NCT00837031|DRUG|Lenalidomide|The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
41388092|NCT00837031|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
41388093|NCT05123586|DRUG|LY3361237|Administered SC
41511327|NCT00193050|DRUG|Gemcitabine|Gemcitabine
41511328|NCT00193050|DRUG|Epirubicin|Epirubicin
41511329|NCT00193050|DRUG|Docetaxel|Docetaxel
41511330|NCT03400592|DRUG|Irinotecan|180 mg/m2 IV once every 2 weeks until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
41511331|NCT03400592|DRUG|nimotuzumab|400mg IV once weekly until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
41511332|NCT00533286|DRUG|benzodiacepine|diazepam (2 x 5 mg/ die)
41511333|NCT02436226|DRUG|Clomiphene citrate and Human chorionic gonadotropin (HCG)|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
41038594|NCT01194960|DRUG|Docetaxel|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
41038595|NCT01194960|DRUG|TroVax|Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37
41038596|NCT02322671|DRUG|Reference Montelukast|It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
41388094|NCT05123586|DRUG|Placebo|Administered SC
40856971|NCT06303596|OTHER|Hippotherapy|Hippotherapy: Hippotherapy in psychiatry is not concerned only about the patient sitting on a horse and the horseback movement influencing the physical condition of the patient and his functional and postural disorders. This therapy is concerned with positive effects on a patient's mental state and use mainly contact with the horse, work with the horse from the ground and riding on horseback. It aims for enjoyment, social communication, and the development of cognitive and executive functions.
41388095|NCT04939701|DRUG|ASP0739|Intravenous (IV)
41388096|NCT00287352|DRUG|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
41388097|NCT00287352|DRUG|Olanzapine and placebo|Olanzapine continuing as clinically indicated
41388098|NCT01971229|OTHER|Carbohydrate based drink|After consumption of the test drink to record the insulin response and gastric emptying.
41388099|NCT01971229|OTHER|Whey protein based drink|After consumption of the test drink to record the insulin response and gastric emptying.
41388100|NCT06565468|DEVICE|Cold water immersion pool.|Participants will complete a session of cold-water immersion within one hour of finishing the last training session of the day. Cold water immersion will consist of ten minutes of submersion to the neck in a cold-water tub with a target temperature of 55 degrees Fahrenheit (daily temperatures will be recorded at the time of each session). The acceptable range for the cold water immersion protocol will be from 53-57 degrees Fahrenheit. The immersion process will not be completed if the temperature of the water is outside of this range. Participants will complete five sessions per week, with a total of 10 sessions to be completed over the 14-day intervention.
41388101|NCT04934332|PROCEDURE|Ultrasound|Ultrasound examination at 1 week and 5 weeks after admission.
41388102|NCT04934332|PROCEDURE|CT scan|CT scan at 5 weeks after admission. CT scan reader will be blinded to clinical data.
41388103|NCT04934332|PROCEDURE|Clinical examination|Weekly clinical examination from week-2 to week-5.
41388104|NCT01241812|BEHAVIORAL|Lower limb muscle strengthening|Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
40856972|NCT06303596|OTHER|Standard psychiatric treatment|Standard psychiatric treatment: Standard psychiatric treatment includes medication and routine activities provided by the Community Mental Health Center.
40856973|NCT02154841|BEHAVIORAL|Questionnaire, taste test, visual food test|
40856974|NCT00300313|DRUG|Escitalopram|10 to 20 mg / day
40856975|NCT00300313|DRUG|Placebo|1-2 capsules
40856976|NCT00648362|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fasting
40856977|NCT00648362|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fasting
40856978|NCT01848119|DRUG|Gabapentin|
41038597|NCT02322671|DRUG|Test 1 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
41038598|NCT02322671|DRUG|Test 2 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
41038599|NCT01745432|DEVICE|ADBLOCK|Laparoscopic surgery
41038600|NCT01601574|BEHAVIORAL|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
41388105|NCT02803190|BEHAVIORAL|ICG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with focus on central muscle groups. ICG subjects received once weekly group exercise.
41388106|NCT02803190|BEHAVIORAL|MTG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program on central muscle groups. MTG subjects received twice weekly machine-based resistance training on major and central muscle groups.
41388107|NCT00833976|DRUG|Lovaza|4 grams per day
40856979|NCT01848119|DRUG|lactose|
41388108|NCT02305329|DRUG|BIA 9-1067|
41388109|NCT06552377|DEVICE|Ultrasound Attenuation imaging measurement|Participant to undergo conventional ultrasound scanning with attenuation measurement as well.
41388110|NCT05663216|OTHER|Blood sampling|6 ml blood sampling at Day 0, 1, 3, 7. Broncho-alveolar sampling, if performed in routine care.
41388111|NCT06562530|DEVICE|high tone power therapy|sessions are applied for 30 minutes, 3 times per week, for 3 months
41388112|NCT06562530|DEVICE|transcutaneous electrical nerve stimulation (TENS)|sessions are applied for 30 minutes, 3 times per week, for 3 months
41388113|NCT06562530|OTHER|selected physical therapy program|sessions are applied for 1 hour, 3 times per week, for 3 months in form o fstretching exercise , range of motion exercises , conventional gait training progressive resistance exercises
41417820|NCT03560609|DEVICE|Optical Coherence Tomography (OCT)|OCT is a non-contact,real-time, high resolution, and reproducible imaging modality that provides in-vivo optical cross-sectional scanning of the retina, the ONH and of the anterior segment structures including the cornea. Clinical staff will perform subject testing, not research coordinators. Information about these non-FDA approved OCTs and the multi-modal adaptive optics system can be found in appendices A, B, C, and D. With all devices, the participant sits in a slit lamp like frame. A low power laser light is projected toward the back of their eyes while the subject fixates on a target. None of the systems produce harmful radioactive radiation.
40856980|NCT01060696|DRUG|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
40856981|NCT00466921|DRUG|lenalidomide|10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
40856982|NCT01292096|OTHER|Provision of extra (care coordination and management) services|The pilot intervention begins at the patient's bedside in the hospital and continue after his/her discharge into the community, utilizing a flexible and intensive care management model with a multi-disciplinary team approach. Community Based Care Managers (CBCMs) overseen by a social worker, will connect patients to needed community services including housing for homeless patients, accompany patients to appointments and facilitate transportation to medical, benefits enrollment, and perform other services based in the hospital and community.
40856983|NCT04587310|DIAGNOSTIC_TEST|Laparoscopic Sleeve Gastrectomy|bariatric surgery
40856984|NCT01528189|OTHER|Hyperinsulinemic normoglycemic clamp|Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
40856985|NCT01528189|OTHER|Standard glucose management|Blood glucose levels will be treated by a standard insulin sliding scale.
40856986|NCT06148883|PROCEDURE|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation is the implantation of a biological aortic valve percutaneously
40856987|NCT02211248|OTHER|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
40856988|NCT02211248|OTHER|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
40856989|NCT03592485|PROCEDURE|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
41388114|NCT04417127|OTHER|Integrated Community-Based (ICB) Care|The intervention will include the following components: (1) integrated care visits by clinical team occurring monthly during months 1-6 of the trial, and then quarterly for the remaining months (7-18), which include vital signs screening, consultation with a clinical officer, medication distribution (ART and other chronic and acute medications), and point- of-care (POC) laboratory testing (creatinine, blood glucose and hemoglobin A1C, and viral load as it becomes available); (2) peer support for promoting ART adherence during every monthly MF meeting; (3) referrals to facilities for emergency or acute care needs that are not feasible to address in the community. Integrated care refers to delivery of primary, HIV and NCD-related care, incorporating a focus on both chronic and acute needs.
41511334|NCT02436226|DRUG|Clomiphene citrate|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
41166779|NCT05287685|BEHAVIORAL|Screen media adapted School Readiness Parenting Program|For the screen time adapted parenting intervention, screen time intervention components will be infused into the SRPP (described below) to address three primary areas shown in research to play an important role in healthy screen media use: (1) reducing and managing screen time use; (2) maximizing benefits of screen time content; and (3) promoting positive parent-child interactions during co-use of screen media. Psychoeducation and practice of these strategies will be incorporated into sessions of the SRPP in which relevant behavioral concepts are addressed.The screen time adapted parenting intervention will utilize the same format (large group, 8 weekly 1.5 hour sessions) as the SRPP.
41166780|NCT05287685|BEHAVIORAL|School Readiness Parenting Program|The SRPP is an 8-week parenting program for parents of preschool aged children with externalizing behavior problems. The SRPP targets child externalizing behavior problems specifically, as well as to help parents promote children's school readiness skills. The SRPP follows a group Parent-Child Interaction Therapy (PCIT) model and also uses motivational interviewing and modelling problem solving approaches. The SRPP utilizes a large group format (10-15 parents) with weekly sessions lasting 1.5 hours. The SRPP curriculum contains traditional aspects of behavioral management strategies (e.g., improving parenting skills and the parent-child relationship; discipline strategies such as time out). Specific sessions of the SRPP also directly target parental interactions during children's learning activities and setting up homework and household structure and routines. In its original form, SRPP does not address children's screen time.
40856990|NCT03592485|PROCEDURE|Pectoral Fascia block|Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
41166781|NCT04538222|OTHER|physical activity|aerobic exercise, muscle strength and stretching, nutrition education
41166782|NCT06271083|BEHAVIORAL|Exposure with response prevention|The central component of the intervention will be ERP. During the treatment, participants will receive information about tics and how to work with ERP. Continuously throughout the treatment patients will work with exposing themselves to situations that trigger their premonitory urges and practice suppressing their tics. They will learn different strategies to provoke their premonitory urges to make suppression of their tics more challenging and gradually increase the time they can suppress the tics. A central tool in the treatment will be the Ticstimer, a worksheet where patients will continuously record their ERP practice, and the time they manage to suppress tics. The patients will be encouraged to work with the Ticstimer daily.
40856991|NCT03592485|DRUG|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
40856992|NCT03592485|PROCEDURE|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
40856993|NCT03592485|DRUG|paracetamol|Paracetamol will be given i.v. every 6 hours.
40856994|NCT04876352|OTHER|Upper limb/handwriting exercises in an immersive virtual reality setting (VR-training)|"Progressively difficult multimodal physiotherapy under the augmented visual feedback induced by the VR. Participants will wear a head-mounted display and their upper limb movements during the training will be captured by a motion tracker. Patients will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) under the augmented visual feedback provided by the use of VR in increasingly wide range of movement; active upper limb multi-joints movements under the augmented visual feedback provided by the use of VR (following trajectories designed in the virtual space - movement involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage in VR context on a tablet and a smartphone.~30 minutes of exercises, 2 times a week, for 8 weeks."
41388115|NCT04417127|OTHER|Microfinance|"Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning."
41511335|NCT01061801|BEHAVIORAL|Emotional expression|Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
41038601|NCT01601574|OTHER|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
41038602|NCT06336148|DRUG|ACTM-838|Escalating doses of ACTM-838 in Part 1a and recommended dose in Part 1b
41038603|NCT00553267|DRUG|fixed dose combination of telmisartan+amlodipine|
41038604|NCT00553267|DRUG|amlodipine|
41038605|NCT03498248|DRUG|lenograstim|injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
41038606|NCT05833750|OTHER|Reflexology|In the intervention group, reflexology was applied to the feet twice a week for 8 weeks.
41038607|NCT05855330|DRUG|Arginine Hydrochloride|Arginine will be infused based on the manufacturer's instructions (R-Gene 10, Pfizer), over 30 minutes. However, rates may be slowed to over 60 minutes for patients experiencing symptoms of flushing, nausea, vomiting, or headache at the research team's discretion. Pediatric doses will be drawn up by the pharmacy.
41038608|NCT05440526|PROCEDURE|Herbst Group|"Herbst Group:~1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint."
41388116|NCT05362409|DRUG|5 Aminolevulinic Acid|5-aminolevulinic acid \[5-ALA\] administered orally 20 mg/kg every 4 weeks
41388117|NCT05362409|DEVICE|CV01-delivered ultrasound|CV01-delivered ultrasound every 4 weeks
41388118|NCT06565728|DRUG|Vitamin D3 2000 UNT Oral Tablet|To assess the role of vitamin D3, versus sildenafil citrate, versus control group in pregnancies complicated by fetal growth restriction
41388119|NCT06567717|DRUG|Zinc|Zinc has not previously been investigated in the treatment of IPF.
41166783|NCT06271083|BEHAVIORAL|Brief psychoeducation with general psychological support|Participants who are randomized to the control group will receive access to brief psychoeducational content in the platform in combination with general psychological support from a therapist. No active BT components (BT, Habit Reversal Training, applied relaxation) are provided to the participants in the control group. The therapists will welcome the patients to the treatment, encourage them to engage in the treatment content and reach out to the therapist if they have any questions. Thereafter, the therapists will only reply to the patients' messages without taking any contact initiative themselves (unless there is an indication of severe deterioration or severe depressive symptoms or suicidal ideation requiring medical attention)
41388120|NCT06567717|OTHER|Placebos for zinc and nicotinamide riboside|These will be identical in appearance to the active substances
41388121|NCT06567717|DRUG|Nicotinamide riboside|Nicotinamide riboside has not previously been investigated in the treatment of IPF.
41388122|NCT00155259|DRUG|Docetaxel , Cisplatin , Capecitabine|
41388123|NCT00755937|OTHER|Data collection post infusion|
41388124|NCT05674721|DRUG|Advil PM Liqui-Gels Minis|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule which is a size reduction of the currently marketed reference product.
41388125|NCT05674721|DRUG|Advil PM Liqui-Gels|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule.
41388126|NCT00457418|DRUG|PEG-Intron|
41166784|NCT01674517|DRUG|Montelukast sodium chewable tablets 4mg and 5mg|Montelukast sodium chewable tablets 4mg and 5mg
41166785|NCT04714788|DEVICE|RECAP_MyLife mobile app|"The intervention will be the use of a mobile application for collecting data from cohorts participants, envisioning to engage participants and collect continuous unbiased records. Participants in the intervention group will install the mobile application on their smartphones on the beginning of the trial and will be asked to self-report information on mood every day. Simultaneously, physical activity (number of steps) will be passively tracked through real-time information.~Participants will complete baseline and post-intervention measures of mood status based on the Circumplex Mood Model and IPAQ-Short form. Following these measures, participants will be asked to complete questionnaires on usability (SUS scale) and acceptability of the intervention."
41166786|NCT04714788|OTHER|Usual data collection methods|Participants in this group will provide data through usual types of data collection methods (face-to-face assessments, mailed questionnaires, online questionnaires).
41166787|NCT03240497|BEHAVIORAL|Cold Exposure|"The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol \[7\]."
41166788|NCT03240497|BEHAVIORAL|Strength Ventilation|The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
41388127|NCT04261322|RADIATION|x ray exposure|exposure of whole body to x ray
41388128|NCT02050373|RADIATION|Low-Level laser|Application of laser therapy in low power mucosa jugal right and left upper and lower labial mucosa, floor of the mouth, tongue side of the right and left and belly of the tongue.
41388129|NCT03628222|DEVICE|ENB-TBLB|"ENB Guidance: The iLungTM SuperNavigator system will be used, it comprises of iLungTM ENB system, location catheter and guide catheter. The guide catheter can supply a 1.9 mm working channel for biopsy tools.~The location catheter is inserted into the guide catheter beforehand, then both are introduced via the working channel of the bronchoscope. Under guidance of ENB system, the location catheter reaches the lesion, and actual distance is confirmed by the X-ray.~TBLB: Location catheter is retracted, then the biopsy forceps and brush was introduced, and pathologic specimens are obtained."
41388130|NCT03628222|DEVICE|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and pathologic specimens are obtained.
41388131|NCT02583607|DEVICE|Brava|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
41388132|NCT01514409|DIETARY_SUPPLEMENT|5-Hydroxytryptophan|"Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.~5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia."
41511336|NCT06550817|OTHER|Growth mindset intervention|Online intervention is implemented and it lasts about 20 minutes each time, while face-to-face intervention lasts about 30 minutes each time, and they are carried out for a total of six weeks, face-to-face or telephone intervention is implemented once every two weeks for about 15 minutes each time
41388133|NCT01514409|DIETARY_SUPPLEMENT|Pharmaceutical grade silica|Pharmaceutical grade silica was utilized as placebo
41388134|NCT01966107|DRUG|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
41388135|NCT01966107|DRUG|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
41166789|NCT02949232|DRUG|Prednisolone|prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
41166790|NCT02949232|DRUG|Placebo Oral Tablet|Dosing following the tapering scheme of the treatment of the treatment arm
41166791|NCT00543101|DRUG|Darunavir (DRV/r)|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
41166792|NCT00543101|DRUG|continue on current dual boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (\< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
41166793|NCT03108638|BEHAVIORAL|R3 Supervisor Implementation Strategy|Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
41166794|NCT00996359|BIOLOGICAL|Irradiated haploidentical allogeneic lymphocytes|Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
41166795|NCT00996359|RADIATION|total-body irradiation|100 cGy TBI
41166796|NCT03436043|DEVICE|Transmural Plastic stenting|After metal stent removal in patients of disconnected pancreatic duct syndrome, transmural plastic- double pig tail stent will be placed into the residual necrotic cavity with the standard duodenoscope.
41166797|NCT00605995|DRUG|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
41166798|NCT01816685|DEVICE|CPAP|
41166799|NCT04706858|DIETARY_SUPPLEMENT|Dietary fiber supplementation|Randomization to the order of first fiber: either inulin or arabinoxylan. Third cycle will include a mix of 5 fibers: inulin, arabinoxylan, resistant starch, glucomannan, and acacia gum.
41166800|NCT06478901|DEVICE|Echocardiography|Echocardiography assited by Artificial intelligence
41166801|NCT05560750|PROCEDURE|Frenotomy|Releasing the tongue-tie with scissors
41166802|NCT05560750|PROCEDURE|Oral physiotherapy|Gentle parental activation of the mouth area and the tongue for 1 month
41166803|NCT00700453|BEHAVIORAL|Control group with no video game play|Subjects will abstain from all video game play during study participation.
41166804|NCT00700453|BEHAVIORAL|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
41166805|NCT00700453|BEHAVIORAL|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
41166806|NCT00700453|BEHAVIORAL|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
41166807|NCT03503162|DEVICE|Pure-Vu System|The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
41166808|NCT03158935|DRUG|Cyclophosphamide|Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
41166809|NCT03158935|DRUG|Fludarabine|Cohort 1: i.v., 25mg/m2 per day for 5 days
41166810|NCT03158935|PROCEDURE|Pembrolizumab|Cohort 1 and 2: i.v., 200mg every 3 weeks
41166811|NCT03158935|BIOLOGICAL|Tumor-Infiltrating Lymphocytes (TILs)|Cohort 1 and 2: i.v., 1x10\^10 - 1.6x10\^11 cells
41166812|NCT03158935|BIOLOGICAL|Interleukin-2 (IL-2)|Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
41166813|NCT00865813|PROCEDURE|Punch Biopsy|"1. Instillation of anesthetic eye drops.~2. Asepsis~3. Placement of surgical cloths and drapes~4. Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.~5. Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions~6. Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade"
41388136|NCT01466959|OTHER|citrate dialysate (CD)|Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
41388137|NCT01466959|OTHER|acetic-acid based dialysate (AD)|Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
41388138|NCT05854316|DIAGNOSTIC_TEST|Comprehensive Biomechanical assessment|Magnetic resonance images, electromyography and dynamometry data will be used, together with data from the gait assessment and clinical questionnaires/measures, to characterize the biomechanics of the participants, and to develop and inform personalised musculoskeletal models
41388139|NCT00523887|DRUG|Fentanyl transdermal therapeutic system|
41388140|NCT03574194|DIETARY_SUPPLEMENT|Methionine-restricted diet|The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
41166814|NCT01087814|DRUG|Efavirenz|Subject will take efavirenz for 5 days.
41166815|NCT01087814|DRUG|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
41166816|NCT00151827|DRUG|Olmesartan medoxomil|Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
41166817|NCT00151827|DRUG|Losartan|Medications are taken once daily before breakfast with water.
41166818|NCT00151827|DRUG|Furosemide oral tablets|If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
41166819|NCT00237861|DRUG|risperidone|
41388141|NCT04220034|BIOLOGICAL|Blood sample|Blood sample will be collected to determine development or increase level frequencies of different types of autoantibodies in patients receiving ICI for the first time
41166820|NCT00237861|DRUG|olanzapine|
41166821|NCT00237861|DRUG|quetiapine|
41388142|NCT05267873|DRUG|Duloxetine, Vortioxetine|Medications for major depressive disorder
41388143|NCT01238172|OTHER|dietary education and counseling|
41388144|NCT01238172|OTHER|prostate cancer foundation booklet|
41388145|NCT06265285|OTHER|Home Health Encounter|Receive in-home visits by a home health nurse
41388146|NCT06265285|BIOLOGICAL|Nivolumab|Given SC
41388147|NCT06265285|PROCEDURE|Patient Monitoring|Undergo remote patient monitoring
41388148|NCT06265285|OTHER|Questionnaire Administration|Ancillary studies
41388149|NCT05576285|DIAGNOSTIC_TEST|ophthalmoscopy and fundus photography through dilated pupills|ophthalmoscopy and fundus photography through dilated pupills
41388150|NCT04070599|BIOLOGICAL|Collection of biological samples|A collection of biological samples will be carried out, with the remainders of the immunological samples taken on dry tube: the serum of the patients, taken at the initial diagnosis, will be kept frozen at -20 ° C.
41388151|NCT02741752|PROCEDURE|Decortication|cortical bone perforation
41388152|NCT03250065|DEVICE|Application of prototype sensor to a standard endotracheal tube|During anaesthesia the device under study, a prototype saturation sensor will be applied to a standard endotracheal tube that ventilates the patient as normal.
41388153|NCT04666012|BIOLOGICAL|AdCLD-CoV19|Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
41388154|NCT00265863|DRUG|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
41511337|NCT06550817|OTHER|E-health Program|face-to-face e-health teaching in the first 6 weeks, and telephone follow-up were conducted once a week, for about 10 minutes each time in the last 6 weeks
41511338|NCT01495078|PROCEDURE|Telemonitoring|"Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses."
41511339|NCT04022876|DRUG|ALRN-6924|ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
41511340|NCT04022876|DRUG|Carboplatin|Carboplatin administered IV on Day 1 of every 21-day cycle.
41511341|NCT04022876|DRUG|Pemetrexed|Pemetrexed administered IV on Day 1 of every 21-day cycle.
40856995|NCT04876352|OTHER|Upper limb/handwriting exercises in a real setting (RS-training)|"Participants will perform progressively difficult multimodal physiotherapy in a real setting. Participants will be encouraged to perform their upper limb movements during the training in order to perform faster and ampler movements. They will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) in increasingly wide range of movement under the feedback provided by therapist; active upper limb multi-joints movements under the feedback provided by the therapist (following trajectories designed on a table or on a blackboard - movements involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage under the supervision of the therapist.~30 minutes of exercises, 2 times a week, for 8 weeks."
40856996|NCT04876352|OTHER|No intervention|Only baseline evaluations, without longitudinal assessment
41166822|NCT01544504|DRUG|Norepinephrine|Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
41166823|NCT06068244|OTHER|3D printed crowns|3D printed crowns
41166824|NCT06068244|OTHER|Zirconia crowns|Nu smile zirconia crowns
41388155|NCT03745027|DIAGNOSTIC_TEST|in vitro fertilization|All patients underwent gonadotropin-releasing hormone agonist (GnRHa) treatment for in vitro fertilization and Follicular fluid sialic acid levels are measured.
41388156|NCT05072093|BEHAVIORAL|PrEP discontinuation intervention|Men taking daily oral PrEP (Truvada) will receive a monthly screener through the mobile app. If answers to screener questions indicate a participant is at risk for PrEP discontinuation, then a peer navigator will deliver a motivational interviewing intervention and a clinician will consult with the participant. These efforts are intended to avert PrEP discontinuation.
41388157|NCT05072093|DRUG|Offering of on-demand oral PrEP|For men who are not interested in daily oral PrEP or plan to discontinue daily oral PrEP, the investigators will offer on-demand oral PrEP (Truvada) which will allow them to take it immediately before/after a sexual encounter. It is hoped that this will serve as an alternative to daily oral PrEP use that is desirable for some people.
41388158|NCT05072093|DRUG|Offering of STI PEP|All men in the cohort will be offered STI PEP (doxycycline) to use after condomless sex with the goal of averting STI diagnoses. At a dosage of 200 mg to be taken in a single dose ideally within 24 hours of possible exposure (e.g. condomless anal sex) and no later than 72 hours after exposure. Participants will be dispensed enough pills to allow for up to 3 weekly doses of 200mg doxycycline (i.e. 6 pills/week) for 3 months (the interval between STI testing visits).
41511342|NCT04022876|DRUG|Placebo|Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
41511343|NCT04022876|DRUG|ALRN-6924|ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.
41511344|NCT04022876|DRUG|Topotecan|Topotecan administered IV on Days 1-5 of every 21-day cycle.
41511345|NCT03297060|OTHER|SSL Implementation Strategy|Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
41166825|NCT02610621|PROCEDURE|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
41511346|NCT05496244|DEVICE|Laparoscopy|Laparoscopic surgery
41511347|NCT05496244|DEVICE|Robotic-assisted surgery|Robotic-assisted surgery
41166826|NCT00560313|BIOLOGICAL|Men ACWY CRM|A single dose of a 0.5 mL injectable solution
41166827|NCT00560313|BIOLOGICAL|4CMenB|All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
41166828|NCT00159341|PROCEDURE|Nasal lavage|Nasal lavage was carried out at specified timepoints
41511348|NCT03763305|DRUG|Propofol continuous infusion|Propofol intravenous continuous infusion for anesthetic induction and maintenance
41511349|NCT03763305|DRUG|Remifentanil|Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
41511350|NCT03763305|DRUG|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol 1.5\~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).
41388159|NCT05072093|DRUG|Injectable PrEP|For men who are interested in injectable PrEP, they will be referred to local providers to access Apretude (Cabotegravir injection) every two months. In the study, their use of the medication will be monitored through monthly surveys during which they have the option to indicate interest in switching to oral PrEP.
41388160|NCT03130855|DRUG|inferior alveolar nerve block with 4% articaine|an anesthetic technique using 4% articaine anesthetic solution
41388161|NCT03130855|DRUG|buccal infiltration with 4% articaine|anesthetic technique using 4% articaine anesthetic solution
41388162|NCT06400329|OTHER|Pain Neuroscience Education|PNE focuses more on the neurophysiology of pain and approaches it from the perspective that knee OA pain is manageable, using neutral to positive language and emphasizes the importance of physical function and staying active
41388163|NCT06400329|OTHER|Standard Pain Education|In Standard Pain Education, the emphasis is on the structural pathology of knee OA and the outdated but common understanding of the disease process as a degenerative one, potentially conveying negative and threatening language
41388164|NCT04313686|BEHAVIORAL|Mindfulness-based therapy|Based on randomization, those who first receive the mindfulness training program are the intervention group. Participants would meet weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
41388165|NCT04313686|BEHAVIORAL|No-intervention|Participants who were randomized into this group would continue to receive their usual follow-up care at the usual neurology outpatient clinic.
41388166|NCT03857139|DRUG|Nicotine patch|Participants will receive the transdermal nicotine patch (TNP) to use during the first 2 weeks post-quit. We chose the TNP because of the extensive empirical literature supporting its effectiveness and safety, ease of use, and relatively benign side effect profile. Anxiety and depressive symptoms predict poor smoking cessation outcomes among individuals receiving NRT , suggesting that emotional disturbance influences relapse even in the context of NRT.
41511351|NCT03763305|DRUG|Desflurane|1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance
41511352|NCT03763305|DRUG|Propofol bolus injection|Propofol intravenous injection for anesthetic induction
41511353|NCT03763305|DRUG|Fentanyl|Fentanyl intravenous injection for anesthetic induction
41511354|NCT03315078|BIOLOGICAL|CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT|Administered by intravenous (IV) infusion
41511355|NCT03315078|DRUG|Palifermin|Administered by IV infusion at a dose of 60 mg/kg/day
41511356|NCT03315078|DRUG|Busulfan|Administered by IV infusion at a dose of approximately 3 mg/kg per day
41511357|NCT02770482|BIOLOGICAL|spinal fluid collection|
41511358|NCT02288312|DRUG|BIA 2-093|
41511359|NCT06187038|OTHER|Therapeutic exercises|The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
40856997|NCT02657304|BEHAVIORAL|Coaching group|patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.
41511360|NCT06187038|OTHER|Therapeutic exercises + pain neuroscience education program|"In addition to the therapeutic exercise protocol previously reported in the control group, research participants allocated to the experimental group will undergo an education program in the neurosciences of chronic pain carried out one day a week between the two therapeutic exercise sessions lasting ten weeks.~The chronic pain neuroscience education program will be based on three domains. Making sense of pain, Exposure with control, and Lifestyle changes also urge modifications aimed at improving sleep, stress, and anxiety."
41511361|NCT01964079|DRUG|Amlodipine|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
40856998|NCT02657304|OTHER|Control group|patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
40856999|NCT05527821|DRUG|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle
41166829|NCT00159341|PROCEDURE|Nasal filter paper|Nasal filter paper was placed at specified timepoints
41511362|NCT01964079|DRUG|Losartan|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
41511363|NCT01778634|DRUG|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
41511364|NCT01778634|DRUG|Placebo|D5W
41511365|NCT05856851|DRUG|Alteplase|See arm/group descriptions.
40857000|NCT05527821|DRUG|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
40857001|NCT05527821|RADIATION|Short course radiotherapy|5Gy\*5F short course radiotherapy will be delivered
40857002|NCT04724967|DRUG|CeraVe Hydrating Cleanser|topical cleanser applied twice a day for 28 days
40857003|NCT04724967|DRUG|CeraVe Moisturizing Cream|topical cream applied twice a day for 28 days
40857004|NCT05240365|DEVICE|SDF modified Hall technique|"* Preparation for Hall technique and selection of the crown.~* Clinical application of SDF.~* Cementation of the selected crown."
41511366|NCT03904264|DEVICE|Receiver in the canal (RIC) hearing aids|The RIC hearing aids fitted to subjects in arm 1 of the study will be manufactured by Widex.
40857005|NCT05240365|DEVICE|Conventional pulpotomy and stainless steel crown|"* Teeth will be anesthetized .~* Rubber dam will be used and high suction in pulpotomy procedure.~* Cavity outline will be performed by sterile #330 high speed bur using water spray.~* Caries will be removed by large spoon excavator.~* pulpal exposure will be occurred then the roof of pulp chamber will be removed by low speed round bur. Hemostasis will be obtained by applying pressure with moist cotton pellet with saline.~* Teeth will be treated by using sterile cotton pellet with formcresol for three to five min then, remove it.~* Pulp stumps of will be dressed with reinforced zinc oxide eugenol, IRM®\*~* Tooth Preparation will be done followed by placement of stainless-steel crown"
40857006|NCT00484978|PROCEDURE|Stereotactic Radiosurgery|
40857007|NCT04035239|DEVICE|BGS goggles|BGS goggles use for 3-6 weeks
40857008|NCT01453010|OTHER|Self-directed Upper Limb SaeboFlex Training|"Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.~Participants are closely monitored at least once a week by a saebo-trained therapist."
40857009|NCT00033488|OTHER|cytology specimen collection procedure|
40857010|NCT00033488|PROCEDURE|annual screening|
40857011|NCT00033488|PROCEDURE|comparison of screening methods|
40857012|NCT05945446|DIAGNOSTIC_TEST|Galectin 3|Women diagnosed with Placenta Accreta Spectrum (PAS) were invited to join the study, providing they had no known systemic diseases (e.g. chronic hypertension, diabetes, hypothyroidism, chronic renal-liver diseases, etc.), autoimmune disorders, multiple pregnancies, or the presence of fetal structural and chromosomal anomalies. They also did not have cholestasis of pregnancy, preterm delivery, or evidence of chronic and active infection.
40857013|NCT00847886|DRUG|LX3305|Daily oral intake of LX3305 for 14 days.
40857014|NCT00847886|DRUG|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
40857015|NCT00847886|DRUG|Methotrexate|Once weekly stable-dose methotrexate.
40857016|NCT05572164|PROCEDURE|TRADITIONAL EPIDURAL|epidural technique used for intraoperative analgesia (the EPL group; local anesthetics will be delivered via epidural catheter guided by SPI to provide intraoperative analgesia)
40857017|NCT05572164|PROCEDURE|DURAL PUNCTURE EPIDURAL|group on whom dural puncture epidural technique used for intraoperative analgesia ( the DPL group; local anesthetics will be delivered via an epidural catheter placed after a dural pucture performed with the SPI guidance to provide intraoperative analgesia)
40857018|NCT01229306|PROCEDURE|Ablation|Ablation of atrial fibrillation
40857019|NCT05582772|OTHER|GA+M Intervention|Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.
40857020|NCT05582772|OTHER|RSM intervention|Telephone-based, symptom management of patients with cancer
40857021|NCT05582772|OTHER|GA+RSM intervention|Combining a geriatric assessment and remote symptom control
40857022|NCT00719355|BEHAVIORAL|Walking with poles|Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
40857023|NCT00719355|BEHAVIORAL|Walking exercise|Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
40857024|NCT03301350|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
40857025|NCT03301350|DRUG|Paclitaxel|Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
40857026|NCT03301350|DRUG|Doxorubicin|Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
40857027|NCT03301350|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
40857028|NCT03301350|DRUG|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
40857029|NCT03301350|DRUG|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
40857030|NCT00851786|BIOLOGICAL|ZOSTAVAX|Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
41511367|NCT05532709|OTHER|Plyometric training|m level one (weeks one and two; 1-2 sets of 10 repetitions) to level two (weeks three and four; 1-2 sets of 8 repetitions) and finally level three (weeks five and six; 1-2 sets of 6 repetitions). Plyometric training programs included both leg jumps, single-leg jumps, hurdle jumps, drop jumps, box jumps or lunge jumps
41388167|NCT06514209|DRUG|cisatracurium|The initial bolus dose of cisatracurium injection is 0.05-0.1mg/kg, followed by a continuous infusion of 1ug/kg/min of cisatracurium, with data on vital signs, respiratory mechanics, TOF response, etc. recorded after a 15-minute wait. The maintenance infusion dose of cisatracurium is then gradually increased in a gradient of 0.5ug/kg/min, with data collection after a 15-minute wait after each increase. If the patient\&#39;s spontaneous breathing completely disappears, the infusion dose of cisatracurium will no longer be increased, and the titration will end.
41388168|NCT03456973|BEHAVIORAL|Nurse AMIE|Supportive care software platform
41388169|NCT03412461|OTHER|Thought Spot|Thought Spot is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area.
41388170|NCT03412461|OTHER|Resource Pamphlet|The resource pamphlet that participants will be given will include information on the mental health and wellness services available at their respective post-secondary institution.
41511368|NCT05532709|OTHER|Circuit training|"The circuit training consists of 6 exercises, divided in 2 blocks (1st block contains~½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes."
41511369|NCT01944163|OTHER|Applying a referral model|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
41388171|NCT06295731|DRUG|INBRX-106|INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)
41388172|NCT06295731|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)
41388173|NCT00897273|GENETIC|comparative genomic hybridization|
41388174|NCT00897273|GENETIC|gene expression analysis|
41388175|NCT00897273|OTHER|study of socioeconomic and demographic variables|
41388176|NCT00897273|PROCEDURE|evaluation of cancer risk factors|
41388177|NCT00897273|PROCEDURE|study of high risk factors|
41388178|NCT05743686|DEVICE|Application|The participants will have access to an app allowing them to report their adverse effects to oral chemotherapy. Basic advices will be given and the hospital pharmacists will be warned.
41388179|NCT01614808|OTHER|laboratory biomarker analysis|Correlative studies
41388180|NCT06099327|DEVICE|Image-based vital sign monitoring|Unobtrusive, vital signs measurements with remote photoplethysmography
41388181|NCT01875991|DRUG|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
41388182|NCT01875991|DRUG|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
41388183|NCT01987843|DRUG|MT-1303-Low|
41511370|NCT05355376|PROCEDURE|Bundle of measures to decreased SSI|
41511371|NCT06151769|OTHER|topical pomegranate seed oil|Intervention groups: In addition to the routine care of the patients, Pomegranate seed oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days. The patient follow-up form will be completed by the researcher every day at 12:00 noon. Again, on the 6th day of the application, evaluation surveys with the Braden risk assessment scale will be conducted by the researcher.
41511372|NCT06151769|OTHER|Sesame oil|Sesame oil
41511373|NCT02633592|OTHER|HRARM|Patients and healthy volunteers are investigated in the seated and lying position during HRAM
41511374|NCT02633592|OTHER|MRI Defecography|Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
41511375|NCT04708223|DEVICE|Direct restorative treatment with fast-curing composites (Tetric PowerFill/ Tetric PowerFlow)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric PowerFill/ Tetric PowerFlow (test group) was cured for 3 s.
40857031|NCT00851786|BIOLOGICAL|Placebo|Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
41388184|NCT01987843|DRUG|MT-1303-Middle|
41388185|NCT01987843|DRUG|MT-1303-High|
41388186|NCT01987843|DRUG|Placebo|
41388187|NCT02343822|OTHER|Platelet Rich Plasma Injection|"Plasma component of blood rich in growth factors~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
41388188|NCT02343822|OTHER|Saline Injection|"Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
41388189|NCT02522949|DEVICE|ColdZyme® mouth spray|
41388190|NCT02522949|DEVICE|Placebo|
41388191|NCT05069428|DRUG|Ramelteon 8mg|administered crushed, orally at 20:30
41388192|NCT04669756|PROCEDURE|ovariopexy|if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall
41388193|NCT04669756|PROCEDURE|placebo operation|in arm D sutures are transabdominal only
41388194|NCT00006225|BIOLOGICAL|filgrastim|
41388195|NCT00006225|BIOLOGICAL|recombinant flt3 ligand|
41388196|NCT00006225|BIOLOGICAL|recombinant human thrombopoietin|
41388197|NCT00006225|BIOLOGICAL|recombinant interleukin-3|
41388198|NCT00006225|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
41388199|NCT03841903|DIAGNOSTIC_TEST|spinal cord MRI|high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)
40857032|NCT05013203|DIAGNOSTIC_TEST|Tissue culture|Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic
40857033|NCT05013203|DIAGNOSTIC_TEST|Next Generation Sequencing|Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)
40857034|NCT04688255|BEHAVIORAL|MSTEP|Aerobic exercise that is advanced weekly
40857035|NCT04688255|BEHAVIORAL|Stretching|Stretching exercises that are advanced weekly
40857036|NCT00742183|DEVICE|Mepilex|Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
40857037|NCT00742183|DEVICE|Silvadene|Silvadene - dressing changes every day, more frequently if needed
40857038|NCT05144139|BIOLOGICAL|COVID-19 mRNA vaccine|Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval
40857039|NCT01897948|OTHER|Milk-based beverage without DHA|
40857040|NCT01897948|OTHER|Milk-based beverage with DHA at mid level|
40857041|NCT01897948|OTHER|Milk-based beverage with DHA at high level|
40857042|NCT01479361|DRUG|Atovaquone 750 mg twice daily|
40857043|NCT01479361|DRUG|Atovaquone 1500 mg twice daily|
40857044|NCT03671304|DEVICE|Fitbit Versa|"Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days."
40857045|NCT06098534|BEHAVIORAL|Hospi'Senior|The Hospi'Senior room is equipped with conventional furnishings (same bed and same armchair as a conventional room) to which have been added technological innovations and innovations in furnishings. Innovative technologies cover bed equipment, patient mobility (autonomous and assisted), lighting, communication and social space.
40857046|NCT06098534|BEHAVIORAL|Conventional room|"The conventional room is a classic hospital room not equipped with the innovative technologies found in the Hospi'Senior room.~The room is equipped with a bed, bedside table, adjustable bed table with castors and an armchair."
40857047|NCT04977401|PROCEDURE|Endoscopic submucosal dissection|Dissecting superficial gastric or rectal lesion/polyp after injection of the submucosa for lifting, using a electrosurgical knife through the endoscope
40857048|NCT04977401|DEVICE|use of Orise Gel as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (ORISE gel) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
40857049|NCT04977401|DEVICE|use of glycerol as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (glycerol) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
40857050|NCT03694834|DRUG|Pembrolizumab|"A single dose of Pembrolizumab (200 mg) will be administered IV over 30 min (-5 /+10 min) approximately 3 weeks prior to the scheduled hysterectomy.~Pembrolizumab (200 mg) will be administered IV over 30 min (-5/+10 min) every three weeks in combination with paclitaxel and carboplatin as adjuvant therapy over 6 cycles. Pembrolizumab should be given on D1 of each cycle after the infusion of cytotoxics."
40857051|NCT03694834|PROCEDURE|Hysterectomy|Hysterectomy/Surgical Staging per institutional standard of care.
41388200|NCT02543164|OTHER|REFERENCE: white bread|"Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
41388201|NCT02543164|OTHER|TEST: b-glucan enriched bread|"Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
40857052|NCT02602418|OTHER|Adaptive WM CogMed Training|"12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects."
40857053|NCT02602418|OTHER|Nonadaptive WM CogMed Training|"The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions)."
40857054|NCT00305539|DRUG|adalimumab|40 mg sc / for 3 months
41511376|NCT04708223|DEVICE|Direct restorative treatment with conventionally applied composites (Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill (control group) were conventionally cured for 10 s per increment.
41511377|NCT00999817|DRUG|reference [dextromethorphan]|single 30 mg oral dose
40857055|NCT00305539|DRUG|placebo|placebo
40857056|NCT06330337|DRUG|Temozolomide（TMZ） injection or oral administration|Oral administration of TMZ150-200mg/m2/ day, continuous use for 5 days, discontinued for 23 days, for a treatment cycle, a total of 6 cycles.
40857057|NCT06330337|DRUG|Albumin-Bound Paclitaxel(ABX) intravenous drip|ABX was administered intravenously at a dose of 110mg/m2 on days 1 and 8 of a 28-day treatment cycle
40857058|NCT06330337|DEVICE|Specific mode electroacupuncture stimulation(SMES) intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off).The 28-day treatment cycle was followed by simultaneous intervention with ABX on days 1 and 8."
41388202|NCT02517346|OTHER|Standard follow-up|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
41511378|NCT00999817|DRUG|test [PF-00299804 + dextromethorphan]|single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
41511379|NCT04110210|DRUG|Bilateral Ultrasound-Guided Erector Spinae Plane Block|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
40857059|NCT03387020|DRUG|Everolimus|Given PO
40857060|NCT03387020|OTHER|Laboratory Biomarker Analysis|Correlative studies
40857061|NCT03387020|OTHER|Pharmacological Study|Correlative studies
40857062|NCT03387020|DRUG|Ribociclib|Given PO
40857063|NCT00772265|BIOLOGICAL|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
41388203|NCT02517346|OTHER|Telemonitoring|Follow up by telemonitoring system during 3 months
41388204|NCT05780944|BEHAVIORAL|Paced Bottle-Feeding Education|Participants will be asked to review an educational handout that outlines how to implement PBF during bottle-feeding interactions. Participants will then be asked to watch a video that further describes PBF and illustrates how to implement it with a live infant. A trained research assistant will then answer questions, further explain PBF, and demonstrate PBF with a baby doll, using a standardized script
41388205|NCT04059900|DRUG|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
41388206|NCT04059900|DRUG|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
41388207|NCT06569160|DEVICE|UVGI (Ultra-Violet Germicidal Irradiation Device)|Retirement homes are equipped with numerous airborne pathogen inactivation devices using UVGI.
41388208|NCT00929201|DRUG|Sitagliptin phosphate/metformin hydrochloride FDC|Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
41388209|NCT00929201|DRUG|Sitagliptin phosphate|Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
41388210|NCT00929201|DRUG|Metformin hydrochloride|Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
41388211|NCT05606913|DRUG|dulaglutide|Dulaglutide administered subcutaneously (SC) once a week.
41511380|NCT04110210|DRUG|Morphine Consumption|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
41511381|NCT06582472|PROCEDURE|Ophthalmological examination including imaging assessments|Ophthalmological examination including imaging assessments (SD-OCT, Spectral Domain Optical Coherence Tomography, a procedure to study and quantify possible retinal neurodegeneration and OCT-A, Optical coherence tomography angiography, a procedure to study and quantify possible retinal vascular abnormalities)
41511382|NCT06582472|PROCEDURE|confocal analysis of cornea|Confocal analysis of cornea: a procedure to study and quantify possible corneal nerve degeneration as a marker of involvement of diabetic neuropathy
40857064|NCT00772265|BIOLOGICAL|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
40857065|NCT06173908|PROCEDURE|cell treatment|Autologous epidermal basal cells were used to repair nonhealing postoperative wound
40857066|NCT06173908|PROCEDURE|control treatment|anyother treatments except autologous epidermal basal cells were used to repair nonhealing postoperative wound
40857067|NCT06091150|PROCEDURE|Endovascular management of direct carotid-cavernous fistula|Coiling and embolization of direct carotid-cavernous fistula
40857068|NCT00991939|DRUG|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients \< 60 kg and 40 mg/day for patients \> 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
41166830|NCT00159341|PROCEDURE|Blood sampling|Blood sampling was performed as a routine safety check
41388212|NCT05606913|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
41388213|NCT03795064|PROCEDURE|Foam sclerotherapy|Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.
41388214|NCT03795064|PROCEDURE|Endothermal ablation|Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.
41388215|NCT05204628|DRUG|XZP-3621|XZP-3621 tablets will be administered orally at a dose of 500 mg QD until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
41388216|NCT05204628|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
41388217|NCT06003673|COMBINATION_PRODUCT|neoadjuvant therapy|The enrolled patients undergo 2 cycles of neoadjuvant therapy, with each cycle consisting of treatment every 3 weeks. On the first day of the first treatment cycle, conventional transarterial chemoembolization (TACE) is performed, and concomitant intravenous infusion of tislelizumab at a dose of 200mg is given, followed by oral administration of lenvatinib at a dose of 8/12mg once daily. On the first day of the second cycle, tislelizumab is again administered intravenously at a dose of 200mg, TACE is not repeated, and lenvatinib treatment is continued. Within 2-4 weeks after the completion of neoadjuvant therapy, the investigator evaluates the tumor's suitability for surgical resection based on a comprehensive assessment of imaging results. Subsequently, eligible patients undergo tumor resection surgery, followed by follow-up for survival and safety monitoring.
41511383|NCT06582472|PROCEDURE|Dynamic Vessel Analyzer (DVA)|Dynamic Vessel Analyzer (DVA), a device that measures the response of retinal arteries and veins to a standardized stimulus (flickering light) allowing direct quantification of the inflammatory status of the retinal vasculature
41511384|NCT06582472|PROCEDURE|tear sampling collection|Collect and analyze tear samples to identify biomarkers in tears and at the endothelium of the ocular surface through impression conjunctival cytology and the quantitative/qualitative analysis of pro-inflammatory cytokines
41038609|NCT05440526|DEVICE|TFBC Group|"TFBC Group:~1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months."
41038610|NCT04083248|BEHAVIORAL|Feasibility group|Same as arm description
41511385|NCT06582472|PROCEDURE|blood sampling collection|collection and analysis of blood samples to identify diabetic retinopathy biomarkers and early abnormalities of the vascular retinal system.
41388218|NCT02962869|DRUG|BAY987517|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
41388219|NCT02962869|OTHER|Untreated skin|One site is patched without treatment as control
41388220|NCT06567821|DEVICE|RELIEVA SPINPLUS® NAV Balloon Sinusplasty System|The non-navigated device being used is the RELIEVA SPINPLUS® Balloon Sinusplasty System and the navigated device being used is the RELIEVA SPINPLUS® NAV Balloon Sinusplasty System. Both devices being used are standard devices that are currently FDA approved and used in practice for sinus dilation at Cedars-Sinai Medical Center.
41388221|NCT02404272|OTHER|Educational oral feeding nurse program|"A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.~The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.~Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained"
41388222|NCT05315986|DIETARY_SUPPLEMENT|Saffr'Inside; 30mg|Ingestion of one gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
41388223|NCT05315986|BEHAVIORAL|Enhanced Sleep Education|Psycho-education based multi-component sleep intervention
41511386|NCT02964312|DEVICE|Nasal Implant|Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
41511387|NCT01377818|PROCEDURE|ventilation|"positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.~Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night)."
41511388|NCT01377818|PROCEDURE|excecise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~* 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~* Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
41511389|NCT01377818|PROCEDURE|Both|both types of intervention
41388224|NCT05315986|DIETARY_SUPPLEMENT|Placebo food supplement|Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
41417821|NCT05067764|PROCEDURE|Aponeurectomy with grafting|"The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system.~The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions."
41511390|NCT04931121|DRUG|Viscosupplements|Synovial fluid is collected as part of a conventional injection of viscosupplement
41511391|NCT04678050|DRUG|Ketamine/ propofol|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
41511392|NCT04678050|DRUG|Dexmedetomidine|Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
41511393|NCT01627678|DRUG|Vacc-C5/GM-CSF|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
41511394|NCT01627678|DRUG|Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
41511395|NCT03435471|OTHER|Prophylactic Swallowing Home Exercise Program|The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
41511396|NCT03435471|OTHER|Clinician-Directed Prophylactic Swallowing Exercises|Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises
41511397|NCT05446779|DIAGNOSTIC_TEST|Adrenal aldosterone synthase (CYP11B2) staining|Immunoshistochemical diagnosis of primary aldosteronism
41511398|NCT05446779|DIAGNOSTIC_TEST|Adrenal cortisol synthase (CYP11B1) staining|Immunoshistochemical diagnosis of adrenal hypercortisolism
40857069|NCT00991939|DRUG|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients \> 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients \< 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
40857070|NCT04853719|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|oral anticoagulants plus antiplatelet agent
41511399|NCT05446779|DIAGNOSTIC_TEST|Histopathological analysis|Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
41511400|NCT03171012|OTHER|Lower limbs CRT|cycle ergometer for lower limbs
40857071|NCT04003740|DEVICE|Home-based transcranial direct current stimulation|The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
40857072|NCT00348673|DRUG|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
40857073|NCT00348673|DRUG|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
40857074|NCT04322617|DRUG|Anlotinib plus the same Immune Checkpoint Inhibitors.|Anlotinib, 8mg po qd, D1-D14 every 21days.
41038611|NCT03529474|OTHER|Psychology and Physiotherapy group|"Psychological program: 4 sessions,2 hours each,4 months~* Psychoeducation.Influence of psychological factors on chronic pain: modulators of pain experience. Biopsychosocial model of pain.~* Training techniques of psychological management of pain:Diaphragmatic Breathing and Progressive Muscle Relaxation to control vicious circle pain-tension-pain.~* Kinesiophobia. Rational regulation of the activity level:Cognitive therapy (management of irrational believes about pain) and Organisation of time and reinforcement activities.~Physiotherapy program:3 sessions per week,1 hour per session,4 months:~* Aerobic exercise:walking, cycling~* Warm-up: active ROM exercises of inferior and superior extremities (ISE)~* Progressive resistance training with elastic bands of ISE~* Stretching of ISE"
41038612|NCT03529474|OTHER|Placebo comparator: control group|Control group Normal daily activities Usual daily activities
41511401|NCT03171012|OTHER|Upper limbs CRT|cycle ergometer for upper limbs
41038613|NCT01217073|DRUG|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
41038614|NCT01217073|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
41038615|NCT01217073|DRUG|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
41038616|NCT01217073|DRUG|Metformin|Metformin 500 mg oral tablet administered once or twice daily
41038617|NCT01217073|DRUG|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
41511402|NCT03171012|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.
41038618|NCT05774964|DRUG|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area
41511403|NCT03171012|OTHER|respiration|respiration
41511404|NCT06489236|BEHAVIORAL|Vaccine Confidence: Skills to Promote Vaccination in the Pediatric Consultations|Intervention mapping principles guided a multidisciplinary team through the development of the intervention. The intervention is a 12-hour training program focused on improving vaccination promotion and vaccine hesitancy management during pediatric consultations. The program comprises 10 hours of online education and 2 hours of in-person activities. Online training materials (short video lectures, video case studies, and readings) were structured in three learning modules covering vaccine and vaccine hesitancy technical information, vaccination promotion communication strategies, and practice organizational resources. In-person activities involved role-playings and group discussions. Intervention content is evidence-based. As a participation incentive, pediatric nurses and pediatricians who complete all program activities, including a multiple-choice final test, will receive 2,5 accredited continuing medical education credits.
41511405|NCT00150956|PROCEDURE|Daily home hemodialysis|
41511406|NCT06300190|PROCEDURE|Biceps tenodesis alone|Biceps tenodesis in superior labrum anteroposterior lesion type IV
41511407|NCT06300190|PROCEDURE|Biceps tenodesis and labrum repair|Biceps tenodesis and labrum repair by anchors in superior labrum anteroposterior lesion type IV
41511408|NCT01644240|DRUG|TD-8954|Intravenous infusion
41511409|NCT01644240|DRUG|Placebo - saline|Intravenous infusion
41511410|NCT00098423|DRUG|tanespimycin|Given IV
41511411|NCT00098423|DRUG|cytarabine|Given IV
40857075|NCT04322617|DRUG|Anlotinib plus the new Immune Checkpoint Inhibitors.|Anlotinib, 8mg po qd, D1-D14 every 21days.
40857076|NCT04322617|DRUG|Anlotinib|Anlotinib, 8mg po qd, D1-D14 every 21days.
40857077|NCT00992459|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
40857078|NCT00992459|DRUG|Buphenyl (NaPBA)|Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
40857079|NCT00370916|BEHAVIORAL|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
40857080|NCT00370916|BEHAVIORAL|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
40857081|NCT01428531|DRUG|Fondaparinux Sodium|
41038619|NCT05774964|DRUG|S1|Orally on d2-d15 at 20 mg three times daily
41038620|NCT05774964|DRUG|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
41038621|NCT05774964|DRUG|Metronidazole|Metronidazole 0.4g/time, qd
41038622|NCT05774964|DRUG|Vitamin A|Vitamin A 5,000 units/time, qd
41038623|NCT05774964|DRUG|Folic acid|Folic acid 5 mg/time, qd
41388225|NCT06566560|OTHER|redispensing oral anticancer drugs|"Participants will receive oral anticancer drugs according to their regular prescriptions, distributed in the original manufacturer's package. Following the guideline, some oral anticancer drug (i.e. requiring temperature storage up to 25C degrees) will be supplemented with a validated temperature indicator (Timestrip Neo, customer configuration), enclosed with a seal bag. Patients are requested to return unused oral anticancer drugs to the outpatient pharmacy that distributed them.~Pharmacy staff will assess the quality of returned oral anticancer drugs, applying the following criteria:~1. the seal bag is unopened~2. the drug package is unopend and undamaged~3. the expiry date is ≥ 3 months~4. the medication has not been stored outside the product label storage claim~Oral anticancer drugs that meet all criteria are restocked, and consecutively redispensed to participants visiting the same outpatient pharmacy."
41511412|NCT05939765|DRUG|Antipsychotic|Participants will undergo a systematic neuropsychiatric assessement at regular intervals. Any change in medication, together with aggressive or dysfunctional behaviour will be continually recorded. The time period prior to the change in medication will be classified as control, the time after as case; therefore each patient becomes his own control.
41511413|NCT04044872|DIAGNOSTIC_TEST|[1-13C]pyruvate along with MRI imaging|\[1-13C\]pyruvate: 0.1 mmol/kg dose will be injected at 5 mL/s followed by a 25 mL saline flush at 5 mL/s at the time of imaging performed at baseline (prior to radiation therapy), and 1 month after completion of radiation therapy.
41511414|NCT03200717|DRUG|Pazopanib|Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.
41511415|NCT01386255|DRUG|Baclofen|The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
41511416|NCT01386255|DRUG|placebo|placebo. No other names
40857082|NCT00913939|PROCEDURE|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).
41388226|NCT04466488|BEHAVIORAL|Choice Architecture|"1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach, including an ink stamp or pre-printed sticker for quick entry of the ART prescription along with TPT and cotrimoxazole.~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
41038624|NCT05188573|DEVICE|Early detection pancreatic cancer test|Blood collection and pancreatic cancer early detection testing with return of results
41388227|NCT06122571|OTHER|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
41388228|NCT00812227|BEHAVIORAL|Psychodynamic Psychotherapy|Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
41388229|NCT04905927|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
41388230|NCT04506346|DIAGNOSTIC_TEST|difficult tracheal intubation|Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view
41388231|NCT02639195|OTHER|Treatment|Retrospective chart review of patients treated with manual therapy.
41388232|NCT04766970|BEHAVIORAL|ADOS-2 Module 4|Assessment in person using standardized Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) Module 4.
41388233|NCT04766970|BEHAVIORAL|Adapted Telehealth ADOS-2 Module 4|Assessment via telehealth/teleconference platform using an adapted ADOS-2, Module 4 assessment protocol.
41388234|NCT06013423|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41388235|NCT06013423|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
41388236|NCT06013423|DRUG|Cyclophosphamide|Receive IV
41388237|NCT06013423|DRUG|Cyclosporine|Receive IV or PO
41388238|NCT06013423|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
41388239|NCT06013423|PROCEDURE|Echocardiography|Undergo ECHO
41388240|NCT06013423|DRUG|Fludarabine Phosphate|Receive IV
41388241|NCT06013423|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
41511417|NCT00469664|DRUG|Guanfacine/Tenex|
41511418|NCT06568224|DRUG|Mesalazine|oral mesalazine 1g qid
41511419|NCT02452476|DRUG|CHF5633|Rescue treatment (if needed)
41511420|NCT02452476|DRUG|Poractant alfa|Rescue treatment (if needed)
41511421|NCT00172029|DRUG|Zoledronic acid|
41511422|NCT01350245|RADIATION|Total Body Irradiation (TBI)|Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
41511423|NCT01350245|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
40857083|NCT00913939|PROCEDURE|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
40857084|NCT06094790|DRUG|CORT125134 150 mg|CORT125134 150 mg (3 X 50 mg current capsule formulation)
40857085|NCT06094790|DRUG|CORT125134 250 mg|CORT125134 250 mg (5 X 50 mg current capsule formulation)
41388242|NCT06013423|DRUG|Mycophenolate Mofetil|Receive IV
41388243|NCT06013423|OTHER|Survey Administration|Ancillary studies
41388244|NCT06013423|DRUG|Thiotepa|Receive IV
41388245|NCT06013423|RADIATION|Total-Body Irradiation|Undergo high-dose or middle-intensity TBI
41511424|NCT01350245|DRUG|Cyclophosphamide|Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
41511425|NCT01350245|DRUG|Mycophenolate Mofetil (MMF)|Started the day before the transplant to prevent graft versus host disease (GVHD)
41511426|NCT01350245|DRUG|Tacrolimus|Started the day before the transplant to prevent graft-versus-host disease (GVHD)
41511427|NCT01350245|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
40857086|NCT06094790|DRUG|CORT125134 dose to be determined|CORT125134 current capsule formulation, dose to be determined
40857087|NCT04800237|DRUG|VQW-765|oral capsule
40857088|NCT04800237|DRUG|Placebo|oral capsule
40857089|NCT03487211|DRUG|Duloxetine|Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
40857090|NCT03487211|DRUG|Escitalopram|Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
41388246|NCT06013423|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
41511428|NCT01660425|BEHAVIORAL|Enhancement with psychosocial intervention|
40857091|NCT02470481|OTHER|No Intervention|This is an obervational study
40857092|NCT01600079|BIOLOGICAL|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
40857093|NCT05140460|BEHAVIORAL|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR)|The intervention entails distribution of a children's book with a cultural pride theme and the cultural pride parent book-sharing guide. Intervention participants select and receive a developmentally appropriate (baby, toddler, or preschool) book that features African American, Latino, Asian or diverse cultural pride perspectives.
40857094|NCT05140460|BEHAVIORAL|Reach Out and Read (ROR)|The control condition involves distribution of a standard ROR book and book-sharing advice. Distributed books are developmentally appropriate (baby, toddler, or preschool).
40857095|NCT02397148|RADIATION|Computed Tomography|imagery with ionizing radiation
40857096|NCT02397148|RADIATION|Cone Beam Computed Tomography|imagery with ionizing radiation
40857097|NCT03631134|DRUG|SGLT2 inhibitor|Patients will be gave SGLT2 inhibitor 10mg per day
40857098|NCT05635838|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
40857099|NCT05635838|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
40857100|NCT02692755|DRUG|Palbociclib + Letrozole or Fulvestrant|Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
40857101|NCT03939975|DRUG|pembrolizumab or nivolumab or JS001|ICIs therapy of nivolumab (3 mg/kg, per 2 weeks) or pembrolizumab (2 mg/kg, per 3 weeks) or JS001 (240mg, per 3 weeks) was performed until the off-treatment criteria were met. For participants with stable disease or atypical progression to ICIs therapy, thermal ablation of radiofrequency ablation or microwave ablation was performed addtionally.
41038625|NCT05188573|DEVICE|Early detection pancreatic cancer test and MRI Imaging|Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging
41511429|NCT00979199|OTHER|Non invasive cardiac imaging|Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
41511430|NCT03420521|DRUG|Nivolumab|240mg IV over 60 minutes Q2W
41388247|NCT04509752|OTHER|Survey|An online survey will be sent to each clinic to answer the survey questions.
41511431|NCT03420521|DRUG|Ipilimumab|1mg/kg IV over 30 minutes Q6W
41511432|NCT00271232|DEVICE|Cardiac resynchronization therapy|
40857102|NCT04803227|DRUG|Emricasan|Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.
40857103|NCT04803227|OTHER|Placebo|Placebo BID \*days 1-14). Oral (capsule) administration.
40857104|NCT03030469|OTHER|Change in electronic health record default for new opioid analgesic prescriptions|
40857105|NCT01248949|DRUG|MEDI3617|Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
40857106|NCT01248949|DRUG|Bevacizumab|Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
40857107|NCT01248949|DRUG|Paclitaxel|Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.
40857108|NCT01248949|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.
40857109|NCT06395532|OTHER|Observetional|After admission to the ICU, patients will be continuously monitored with ICU standard monitoring in addition to IPI using (Capnostream™ Medtronic). IPI will be recorded after transfer to the ICU, as well as at 2, 6, 12, 18 and 24 hours.
40857110|NCT05076890|DIETARY_SUPPLEMENT|15 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
40857111|NCT05076890|DIETARY_SUPPLEMENT|50 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
41038626|NCT00931372|DRUG|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
41038627|NCT00931372|DRUG|Placebo|Subcutaneous injection
41388248|NCT05445037|DEVICE|hemodynamic continuous monitoring|Continuous monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to assess cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.
41388249|NCT05445037|DEVICE|Standard Monitoring|Standard monitoring will be done with non-invasive blood pressure, heart rate, NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, axillary temperature, BIS value. In addition, patients will use Clearsight, but the device will be blind to the anesthesiologist. Pressure monitoring will be every 5 min.
41388250|NCT02808663|BIOLOGICAL|fecal calprotectin concentration|
41511433|NCT06529471|OTHER|Massage group|The patient in the massage group will be visited by the practitioner 3 times at 10:00-14:00-20:00 on the first day after surgery and a back massage will be applied. The patient in the massage group will be placed in an orthopnea position during the application. The massage procedure lasts an average of 30 minutes and is applied to the cervical 3 and thoracic 12 vertebrae.
41511434|NCT05737355|DIETARY_SUPPLEMENT|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
41511435|NCT05737355|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
41511436|NCT03697824|DRUG|GSK3377794|GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
41511437|NCT03697824|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.
41511438|NCT03697824|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
41038628|NCT06167668|OTHER|the routine chronic disease management mode|indoor temperature and humidity adjustment, regular ventilation and hygiene of ward and clinic environment, promotion of patients' health awareness by distributing disease brochures, regular inspection of wards, and home nursing and health guidance based on disease knowledge when discharged
41388251|NCT02808663|BIOLOGICAL|blood collection|
41388252|NCT01842516|DRUG|LCB01-0371 800mg|LCB0-0371 800mg
41388253|NCT01842516|DRUG|LCB01-0371 1200mg|LCB01-0371 1200mg
41388254|NCT01842516|DRUG|Placebo|Placebo
41388255|NCT02606370|OTHER|Unstable shoe|Wearing Unstable shoes during 1 month
41388256|NCT04036786|BEHAVIORAL|study group|We prepared a preeclampsia education booklet in accordance with the literature,The content of the booklet was guided by the opinion of experts. It was written in easily understandable language and contained attractive and colorful illustrations. This booklet contents were definition and risk factors for the development of preeclampsia, maternal and fetal damages, recommendations for preventing its development (diet, rest, study, exercise, coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital, risk of developing in subsequent pregnancies, and its results. Pregnant women in the study group were given education and counseling at four times in addition to standard care, using the preeclampsia education booklet, in a special place. The participants' questions were answered, and each received a copy of the booklet.
41388257|NCT04036786|BEHAVIORAL|standard care|standard pregnancy follow up
41511439|NCT03697824|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
41511440|NCT01260701|DRUG|Akt Inhibitor MK2206|Given PO
41511441|NCT03464721|DEVICE|issued with SMART ANGEL device|patients will use the technology at home to record and transmit data for blood pressure and oxygen saturation
41038629|NCT06167668|OTHER|the family-centered family enabling health management mode|The specific measures were as follows :(1) intervention group construction. (2) Online knowledge promotion. (3) Disease assessment.(4) Medication guidance reminder.(5) Enabling psychological counseling.
41038630|NCT05153980|DEVICE|Warm-up + Blood Flow Restriction cuff (smart-cuff pro device, acting as pressurized tourniquet)|Blood Flow Restriction
40857112|NCT03990428|BEHAVIORAL|online surveys|Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
41038631|NCT05153980|OTHER|Warm-up|Warm-up without any special intervention (no Blood Flow Restriction)
41388258|NCT00953927|BIOLOGICAL|MVA85A/AERAS-485|Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10\^8 pfu.
41388259|NCT00953927|BIOLOGICAL|Candida Skin Test Antigen|1 test, administered once as a placebo control.
41511442|NCT05330260|DIAGNOSTIC_TEST|neurocognitive test battery|Assessment of the incidence of late postoperative cognitive decline (LPOCD)
41511443|NCT04975711|DRUG|HIP2105|Test drug
41511444|NCT04975711|DRUG|RLD2104|Reference drug
41511445|NCT05883124|DRUG|Rivastigmine twice-weekly 9,5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
40857113|NCT05728398|OTHER|Music|Music played within the fluoroscopy suite during an interventional radiology procedure.
40857114|NCT05728398|OTHER|No Music|No music played within the fluoroscopy suite during an interventional radiology procedure.
41038632|NCT04632875|BEHAVIORAL|Loving-Kindness Meditation|Approximately 15-minute sessions are administered 6 days per week
41038633|NCT04632875|BEHAVIORAL|Relaxation Meditation|Approximately 15-minute sessions are administered 6 days per week
41038634|NCT02773615|PROCEDURE|Cardiac computed tomography|Non-invasive CT scan of the heart
41038635|NCT02264028|DRUG|[14C]-DK-AH 269 CL, solution for infusion|
41038636|NCT02264028|DRUG|[14C]-DK-AH 269 CL, drinking solution|
41038637|NCT02724943|BEHAVIORAL|BMI screening|Physician screening of patients to identify patients who are overweight or obese.
41038638|NCT02724943|BEHAVIORAL|Next Steps brief clinical intervention|This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).
41388260|NCT05152004|DRUG|Pariet|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
41388261|NCT05152004|DRUG|Amolin|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
41388262|NCT05152004|DRUG|Klaricid|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
41388263|NCT05152004|DRUG|Flagyl|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
41388264|NCT05232565|PROCEDURE|Percutaneous Transluminal Coronary Angioplasty|Angioplasty intervention of coronary vessels or coronary bypass graft stenosis
41388265|NCT00150475|PROCEDURE|Powered Air purifying respirator|
41388266|NCT04310735|BEHAVIORAL|Verbal smoking expectancy manipulation|Instructions regarding whether or not participants will have an opportunity to smoke during the experimental session.
41388267|NCT05526274|DIAGNOSTIC_TEST|Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)|VCTE with associated CAP is an effective, non-invasive and safe diagnostic method to estimate the degree of fibrosis and steatosis in the liver.
41388268|NCT04196270|DRUG|Ropivacaine injection|In a dose finding study the total volume of ropivacaine changes according to the biased coin up-and-down sequential design
41388269|NCT01933412|BIOLOGICAL|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
41388270|NCT01933412|BIOLOGICAL|Engerix B Hepatitis B Vaccine|
41388271|NCT00486213|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
41511446|NCT05883124|DRUG|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
41511447|NCT04379427|DEVICE|Sanmina Biosensor|non-invasive blood glucose measurement using the Sanmina Biosensor referenced with the invasive reference blood glucose device YSI 2400 Plus.
41511448|NCT00706589|DRUG|aripiprazole|Initial dose : 2mg, Maximum dose : 20mg
41511449|NCT00706589|DRUG|placebo|Initial dose: 2mg, Maximum dose:20mg
41511450|NCT00098605|DRUG|lapatinib ditosylate|Given orally
40857115|NCT00386243|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.
40857116|NCT00386243|BEHAVIORAL|Pain self-management program|The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.
40857117|NCT00386243|DRUG|Co-Analgesic Therapy|"Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram"
40857118|NCT00386243|DRUG|Opioid Analgesics|Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
40857119|NCT01957371|BEHAVIORAL|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.
40857120|NCT03890744|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
40857121|NCT05767112|OTHER|Supplement administation|HMB was administred in 3 different forms: 1) HMB-FA in clear capsules; 2) HMB-Ca in gelatine capsules; 3) HMB-Ca dissolved in water. All treatments provided 1g of HMB. Blood samples were taken before and on multiple time points following ingestion.
40857122|NCT06127719|OTHER|questionnaires|before surgery, patients are asked to fill out the questionnaires as stated in the outcome measures paragraph
40857123|NCT02487004|DEVICE|hemodialysis|
40857124|NCT02805855|DRUG|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
41038639|NCT02724943|BEHAVIORAL|MEND/CATCH|MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.
41038640|NCT02724943|BEHAVIORAL|MEND/CATCH Transition Phase|The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.
41038641|NCT02724943|BEHAVIORAL|Next Steps Self-Paced Booklet|Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
41038642|NCT05717933|DIAGNOSTIC_TEST|thyroid hormones|Thyroid function among pediatric patients with type1 diabetes mellitus at the first presentation, from patients' characteristics to disease severity
41038643|NCT03947918|BEHAVIORAL|Short sleep|Child will be asked to sleep for less than 8 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent daily text messages or phone call reminders.
41038644|NCT03947918|BEHAVIORAL|Long sleep|Child will be asked to sleep for more than 10 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent text messages or phone call reminders.
41038645|NCT01639885|DRUG|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
41038646|NCT01639885|DRUG|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
41388272|NCT00486213|OTHER|Placebo|
40857125|NCT04903197|DRUG|VAY736|VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.
40857126|NCT04903197|DRUG|lenalidomide|Immune-modulatory agent that enhances activation of NK cells.
40857127|NCT05162313|DEVICE|confirmation of endotracheal tube positioning|After performing the tube insertion by direct laryngoscopy, videolaringoscopy or fiberoptic technique, the attending neonatologist will connect both the colorimetric capnometer and the proximal flow-sensor to the tracheal tube. If the flow sensor is not proximal but incorporated into the mechanical ventilator, the care provider will connect the capnometer only. During the procedure, the information given by the capnometer will be evaluated by the care provider performing the intubation, while the flow sensor information will be monitored only by a study investigator, who will not reveal any details to the care provider. In particular, the yellow color change by the capnometer and the presence of exhalation flow curves on the ventilator screen will be considered as confirmation of correct tracheal tube positioning, respectively.
40857128|NCT01405612|DRUG|Midazolam|Single oral administration on Day 1 or Day 5
40857129|NCT01405612|DRUG|Ulimorelin|Intravenous infusion of 480 micrograms/kg on Days 1 to 5
40857130|NCT02728089|DRUG|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
40857131|NCT05611021|BEHAVIORAL|Exercise|Three conditions will be tested: Walking, arm-cranking and control condition.
41388273|NCT01256398|BIOLOGICAL|Alemtuzumab|Given IV
41388274|NCT01256398|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood allogeneic HCT
41388275|NCT01256398|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood autologous HCT
41388276|NCT01256398|DRUG|Cyclophosphamide|Given IV
41388277|NCT01256398|DRUG|Cytarabine|Given IV
41388278|NCT01256398|DRUG|Dasatinib|Given PO
41388279|NCT01256398|DRUG|Daunorubicin Hydrochloride|Given IV
41388280|NCT01256398|DRUG|Dexamethasone|Given PO or IV
41388281|NCT01256398|DRUG|Etoposide Phosphate|Given IV
41388282|NCT01256398|BIOLOGICAL|Filgrastim|Given SC
41388283|NCT01256398|DRUG|Fludarabine Phosphate|Given IV
40857132|NCT06493240|RADIATION|radiation|45 Gy radiation dose in 25 fractions to the pelvis
40857133|NCT06493240|DRUG|PD-1 Monoclonal Antibody|200mg Sintilimab after radiation (3 times, 2-week interval)
40857134|NCT06493240|PROCEDURE|TME surgery|TME surgery for 6\~8 weeks after radiation
40857135|NCT01677858|DRUG|Carfilzomib|Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
40857136|NCT01677858|DRUG|Dexamethasone|Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
40857137|NCT02346253|RADIATION|Internal Radiation Therapy|Undergo high-dose-rate brachytherapy
40857138|NCT02346253|DRUG|Bicalutamide|Given PO
40857139|NCT02346253|DRUG|Leuprolide Acetate|Given IM or SC
40857140|NCT02346253|DRUG|Goserelin Acetate|Given SC
40857141|NCT02346253|DRUG|Triptorelin Pamoate|Given IM
40857142|NCT02346253|DRUG|Degarelix|Given SC
40857143|NCT02346253|OTHER|Laboratory Biomarker Analysis|Correlative studies
40857144|NCT02346253|OTHER|Quality-of-Life Assessment|Ancillary studies
40857145|NCT05361018|OTHER|Whole Body Vibration exercise - WBV|participants will be randomised to two different training interventions
40857146|NCT01695356|DRUG|290-400 nm sunscreen|A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
40857147|NCT01695356|DRUG|290-800 nm sunscreen|A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
40857148|NCT04515901|DRUG|2% lidocaine|Viscous lidocaine
40857149|NCT04515901|OTHER|Placebo|Methylcellulose and cherry flavouring
40857150|NCT05310812|DIAGNOSTIC_TEST|Biochemical evaluation.|Blood will be taken for biochemical evaluation-ELISA.
40857151|NCT01843062|DRUG|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
40857152|NCT01843062|DRUG|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
41038647|NCT01639885|BIOLOGICAL|p53 SLP|8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
41038648|NCT04556708|OTHER|salin irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
41038649|NCT04556708|OTHER|ozonated water irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozonated water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
40857153|NCT01843062|DRUG|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
41388284|NCT01256398|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood autologous or allogeneic HCT
41388285|NCT01256398|OTHER|Laboratory Biomarker Analysis|Correlative studies
40857154|NCT06075121|OTHER|Abdominal massage|Patients in the massage group will receive an abdominal massage twice a day for 5 days, between 10.00 in the morning and 22.00 in the evening. Enteral nutrition will be interrupted twice a day for 5 days, between 09.30-10.00 in the morning and 21.30-22.00 in the evening, and patients will receive an abdominal massage for 15 minutes.
40857155|NCT02913378|PROCEDURE|Osteosynthesis with locking plate|Open reduction and osteosynthesis with locking plate
40857156|NCT02913378|PROCEDURE|Sling|Conservative treatment with sling and rehabilitation
40857157|NCT03256201|BEHAVIORAL|Nutritional Counseling|Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake.
40857158|NCT03256201|BEHAVIORAL|Standard Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
40857159|NCT03256201|BEHAVIORAL|Enhanced Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
40857160|NCT01372176|OTHER|Early Goal-Directed Nutrition|"1. Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).~2. Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.~3. Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN)."
40857161|NCT01372176|OTHER|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
40857162|NCT05371912|DEVICE|Trans Cranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation technique that alters cortical excitability by repeated induction of electromagnetic activity. FDA approved for depression, rTMS is a promising tool in the field of neuropsychiatry with an excellent safety profile.
40857163|NCT02812719|DRUG|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
40857164|NCT02812719|DRUG|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
40857165|NCT00539305|DRUG|testosterone gel|50-100mg applied topically daily for six months
40857166|NCT00539305|DRUG|placebo gel|applied topically daily for six months
40857167|NCT05811169|GENETIC|Next generation sequencing|Next generation sequencing
40857168|NCT02779049|OTHER|Blood examination|blood sampling
40857169|NCT02225834|DRUG|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
40857170|NCT06496165|DRUG|Remimazolam|Intravenous pump injection. The loading dose will be 0.1mg/kg, the maintenance dose will be 0.1-0.5mg/kg/h, with the target RASS be -2-0
40857171|NCT06496165|DRUG|Propofol|Intravenous pump injection. The loading dose will be 0.5mg/kg, the maintenance dose will be 1-4mg/kg/h, with the target RASS be -2-0
40857172|NCT01358058|RADIATION|Proton radiation|Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
40857173|NCT06104111|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 bolus at days 0, 28 and 56. Blood samples taken at days 0, 1, 28, 29, 56, 57 ad 84
40857174|NCT00554047|OTHER|Multidisciplinary Memory Clinic|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)
40857175|NCT00554047|OTHER|General Practitioners|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
40857176|NCT01963845|DRUG|Sitagliptin|
40857177|NCT01963845|DRUG|Placebo|
40857178|NCT03521245|OTHER|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
40857179|NCT03521245|OTHER|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
40857180|NCT03521245|DRUG|Trastuzumab|Standard Trastuzumab treatment regimen recommended for breast cancer
40857181|NCT03521245|DRUG|Chemotherapy|Standard chemotherapy regimen recommended for breast cancer
40857182|NCT04056897|BIOLOGICAL|BCD-132, 125 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
41038650|NCT04556708|OTHER|chlorhexidine irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
41038651|NCT01519713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
41038652|NCT06482372|DEVICE|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation at both cerebral hemisphere
40857183|NCT04056897|DRUG|Teriflunomide|14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
40857184|NCT04056897|DRUG|Placebo|intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
40857185|NCT04056897|BIOLOGICAL|BCD-132, 500 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
40857186|NCT00414518|DRUG|Tenofovir disoproxil fumarate/Emtricitabine|300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
40857187|NCT00414518|DRUG|Lopinavir/Ritonavir|Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
40857188|NCT02035917|DEVICE|Locking plate|
40857189|NCT02035917|DEVICE|Non-Locking plate|
40857190|NCT05938803|BEHAVIORAL|PASEO|The intervention consists of community-based accompaniment intervention aimed at facilitating the transition to adult HIV care for adolescents living with HIV in Lima, Peru.The intervention includes the following activities: health systems navigation and accompaniment to clinic visits, monthly check-ins with an entry-level health worker, social support provided through peer support groups, education sessions, resolution of acute needs, and individualized adherence support.
40857191|NCT01444885|DRUG|Placebo|2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
40857192|NCT04468841|DIAGNOSTIC_TEST|cfDNA testing|peripheral blood samples collected before initiation of standard therapy, after 2 cycles of therapy, at the completion of 6-8 cycles of induction therapy, and then every 6 months for a total of 2 years from the initiation of therapy using a cfDNA assay. For retrospective patients, blood samples will be collected once.
40857193|NCT04468841|OTHER|sample of saliva or fingernail clipping|collected in clinic one time
41038653|NCT01592318|DRUG|danoprevir|Fixed dose combination tablet with ritonavir, single oral dose
41038654|NCT01592318|DRUG|danoprevir|Reference tablet, single oral dose
41038655|NCT01592318|DRUG|ritonavir|Fixed dose combination tablet with danoprevir, single oral dose
41038656|NCT01592318|DRUG|ritonavir|Reference tablet, single oral dose
40857194|NCT04468841|DIAGNOSTIC_TEST|pre-treatment test specimen|From bone marrow, blood, lymph node, or alternate site to identify tumor-specific mutations. For retrospective patients initial tumor tissue (if available).
40857195|NCT04468841|DIAGNOSTIC_TEST|PET/CT, CT, or MRI testing|PET/CT scans are required at baseline and at the patient's end-of-treatment visit. The other standard-of-care scan timepoints can be performed using PET/CT, dedicated CT, or MRI per the treating investigator's discretion.
41388286|NCT01256398|DRUG|Leucovorin Calcium|Given IV or PO
41388287|NCT01256398|DRUG|Melphalan|Given IV
41388288|NCT01256398|DRUG|Mercaptopurine|Given PO
41388289|NCT01256398|DRUG|Methotrexate|Given IT, IV, or PO
41388290|NCT01256398|BIOLOGICAL|Pegfilgrastim|Given SC
41388291|NCT01256398|OTHER|Pharmacological Study|Correlative studies
41388292|NCT01256398|DRUG|Tacrolimus|Given IV or PO
41388293|NCT01256398|DRUG|Vincristine Sulfate|Given IV
41388294|NCT02152930|DRUG|Omega-3 fatty acids|1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
41388295|NCT06262490|DEVICE|Traditional ultrasound therapy|Ultrasound therapy for 2 session per week for until completing 12 treatment sessions (six weeks) with frequencies up to 3 MHz are used clinically to promote healing
41388296|NCT06262490|OTHER|Pelvic floor rehabilitation|Pelvic floor rehabilitation for 3 sessions per week for (six weeks) until completing 18 sessions with sessions lasting between 30-45 minutes
40857196|NCT06423924|OTHER|no intervention|no intervention
41388297|NCT02606864|DRUG|Nifurtimox (BAYa2502)|Oral Intake of 4 x 30 mg nifurtimox tablets
40857197|NCT02381015|GENETIC|Genetic Risk Score: Number Format|Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.
40857198|NCT02381015|GENETIC|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
40857199|NCT02381015|BEHAVIORAL|Family History: Number Format|Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
40857200|NCT02381015|BEHAVIORAL|Family History: Number + Pictograph|Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
40857201|NCT05619367|DRUG|Odronextamab|
40857202|NCT04327791|DRUG|Baloxavir|administered PO once
40857203|NCT04327791|DRUG|Placebos|administered PO once
41388298|NCT06315413|PROCEDURE|Socket preservation using xenograft and composite plug|Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with injected flowable composite plug which will then be stabilized using 5.0 polypropylene suture material with a figure of eight suture.
41388299|NCT06315413|PROCEDURE|Socket preservation using xenograft and intentionally exposed d-PTFE|Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with d-PTFE membrane which will the be left exposed intentionally. This will be followed by securing the membrane using 5.0 polypropylene suture material with a figure of eight suture.
41388300|NCT04682561|BEHAVIORAL|Supportive Trauma Exposure Preparation Program|The Supportive Trauma Exposure Preparation Program is based on the theory that the ability to set compassionate boundaries will enhance acceptance of the reality of trauma in the workplace, and will also increase the cognitive/emotional/physical energy needed to engage in adaptive emotional strategies in response to trauma exposure. Therefore, the goal of therapy is to learn to set compassionate boundaries and engage with oneself and others from a perspective of self-empowerment and acceptance of life events. Concepts and skills will be addressed through the following modules: 1) understanding of trauma and its effects, 2) personal rights and boundaries, 3) emotional literacy, 4) distress tolerance and emotion regulation skills building, 5) communication skills building, 6) self-compassion and acceptance, and 7) enhancing self-care.
41388301|NCT05071235|DEVICE|LG1 (LLLT group 1)|Application of LLLT (low-level laser therapy) AsGa 904 nm 10 J/cm².
41388302|NCT05071235|DEVICE|LG2 (LLLT group 2)|Application of LLLT (low-level laser therapy) AsGa 904 nm 8 J/cm².
41388303|NCT05071235|DEVICE|LG3 (LLLT group 3)|Application of LLLT (low-level laser therapy) AsGa 904 nm 4 J/cm².
41388304|NCT05071235|DEVICE|CG (control group)|Application of placebo LLLT (low-level laser therapy), that is, with the device turned off.
41388305|NCT05071235|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
40857207|NCT00694668|BEHAVIORAL|Cognitive Behavioral treatment|Brief cognitive behavioral therapy (12 sessions)
40857208|NCT00694668|BEHAVIORAL|Mindfulness based cognitive therapy|9 sessions MBCT in a group-format (up to 8 persons)
40857209|NCT03139123|OTHER|Hemodynamic monitoring during passive leg raising|Measurement of hypotensive episodes related to preload dependance.
40857210|NCT00245037|BIOLOGICAL|therapeutic allogeneic lymphocytes|A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
41038657|NCT00594269|DRUG|Risperidone|Discontinuation
41038658|NCT00594269|DRUG|Escitalopram|Discontinuation
41038659|NCT00594269|DRUG|Citalopram|Discontinuation
41038660|NCT00594269|DRUG|Sertraline|Discontinuation
41038661|NCT00594269|DRUG|Paroxetine|Discontinuation
41038662|NCT05641558|DRUG|611 150mg|subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
41388306|NCT01457729|BEHAVIORAL|Motivation by Telephone Call|Telephone call not exceeding 10 minutes according to a protocol
41388307|NCT00858611|DRUG|VRC-FLUDNA047-00-VP|
41388308|NCT00858611|DRUG|Flulaval (Registered) Seasonal Influenza Vaccine|
41511451|NCT00098605|OTHER|laboratory biomarker analysis|Correlative studies
40857211|NCT00245037|DRUG|busulfan|"Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.~IV busulfan is available and diluted and administered per package insert guidelines."
41388309|NCT03948737|DRUG|Alpha-Tocopherol|all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
41388310|NCT03948737|DRUG|Placebo oral tablet|
41388311|NCT02599610|OTHER|Digital vaginal examination|Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
41388312|NCT02599610|DEVICE|Transperineal ultrasound examination|Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
41038663|NCT05641558|DRUG|611 300mg|subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)
41038664|NCT05641558|DRUG|611 600mg|subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
41038665|NCT05641558|OTHER|Placebo|During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.
41038666|NCT01640808|DRUG|NIK-333(peretinoin)|600mg (8 x 75mg capsules) orally, twice a day
41038667|NCT01640808|DRUG|Placebo|Placebo (8 x Placebo capsules) orally, twice a day
41038668|NCT01596582|BEHAVIORAL|Risk Assessment|Patients randomized to the experimental arm will be asked a complete the ACNI risk assessment tool after reviewing a web-based colorectal cancer decision aid. The ACNI uses a point based system to stratify patients into low (mean rate of ACN \~3%) versus intermediate/high (\~ 8%) risk groups based on responses to 6 items: age (50-59, 60-69, 70+), sex (male/female), race/ethnicity (non-Hispanic black, other), smoking history (never, \<20 years, 20+ years), daily alcohol intake (\< 2 vs. \>/=2 drinks) and use of non-steroidal anti-inflammatory drugs (ever, never). The index represents a prototype version of the Advanced Colorectal Neoplasia Index (Am J Gastroenterol 2015;110:1062-71).
41038669|NCT00001430|PROCEDURE|PBSC|
41388313|NCT03159611|DRUG|Tenoten for children|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
41388314|NCT03159611|DRUG|Placebo|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
41388315|NCT06430307|DRUG|Saussurea Involucrata Liquid Tonic|This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.
41388316|NCT01432782|DRUG|Placebo|Saline 4 ml
41388317|NCT01432782|DRUG|Botulinum Toxin Type A|per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
41388318|NCT02855788|DRUG|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly|metronomic chemotherapy
41038670|NCT00001430|DRUG|IL-2|
41038671|NCT00001430|DRUG|EPOCH II|
41038672|NCT06535971|OTHER|Manual therapy combined exercise|"1. Manual therapy included fascia release, progressive passive stretch, mobilization, etc.(depend on subject's current condition)~2. Exercise included muscle strengthening, trunk (spine) stabilization exercise. (depend on subject's current condition)"
41038673|NCT05293080|OTHER|Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)|Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g. amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.
41038674|NCT05293080|OTHER|Usual care for atrial fibrillation|Usual care for atrial fibrillation according to current guidelines. Usual care will mainly comprise rate control by approved drugs. We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.
41038675|NCT03528018|DEVICE|REACt system|The REACt system is a virtual reality-based paradigm for upper limb rehabilitation that allows for interaction of individuals with restricted movements from active responses triggered when they attempt to perform a movement. The experimental system also provides multisensory stimulation in the visual, auditory, and tactile channels, and transcranial direct current stimulation coherent to the observed movements
41038676|NCT03528018|OTHER|Physical therapy|Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
41388319|NCT05207176|DRUG|DWP16001|Subjects should fast except for drinking water after 10 p.m. in order to maintain a fasting state for at least 10 hours before administration. On dosing days (5d to 10d), except for 1d and 11d, breakfast can be consumed from about 1 hour after administration of the clinical trial drug. Subjects should swallow the investigational drug whole with 150 mL of water, and should not chew the drug before swallowing. Subjects should fast for 4 hours after dosing, and can drink water freely from 2 hours after dosing.
41388320|NCT02366065|DRUG|Acetaminophen|Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
41388321|NCT00549107|DRUG|Levosimendan|
41388322|NCT00549107|DRUG|Milrinone|
41388323|NCT05109273|PROCEDURE|Transcatheter ablation|Three-dimensional electroanatomic mapping and radiofrequency ablation with irrigated catheter
41388324|NCT04979078|DEVICE|Photobiomodulation therapy (PBMT)|Patients will receive PBM on the sole of their feet and palms of their hands
41388325|NCT01713478|OTHER|echocardiography|The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
41511452|NCT00098605|PROCEDURE|quality-of-life assessment|Ancillary studies
40857212|NCT00245037|DRUG|cyclosporine|"Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).~- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d."
40857213|NCT00245037|DRUG|fludarabine phosphate|"Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.~* Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.~* Monitoring: Fludarabine level is not monitored.~* Dose Adjustments: There are no provisions for fludarabine dose adjustments."
40857214|NCT00245037|DRUG|mycophenolate mofetil|"Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.~* Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).~* Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg)."
40857215|NCT00245037|PROCEDURE|peripheral blood stem cell transplantation|"Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:~* In autologous transplants, patients receive their own stem cells.~* In syngeneic transplants, patients receive stem cells from their identical twin.~* In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used."
40857216|NCT00245037|RADIATION|Total Body Irradiation (TBI)|"TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.~* Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.~* Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min."
40857217|NCT00245037|DRUG|Granulocyte colony-stimulating factor (G-CSF)|"Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).~It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.~* Toxicities: At the dosage used, the most common side effect will be medullary bone pain.~* Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all)."
40857218|NCT00245037|DRUG|Phenytoin|This drug is used to prevent seizures while on chemotherapy.
40857219|NCT00245037|DRUG|Methotrexate|Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
40857220|NCT05711472|OTHER|birth ball exercise|birth ball exercise used in childbirth
40857221|NCT04814147|PROCEDURE|Sleeve gastrectomy|Measure of NLRP3 inflammasome preoperative activation level by the expression of NLRP3, IL-1β, IL18 and caspase-1 mRNAs in subcutaneous and visceral adipose tissue. of the epiploon;
40857222|NCT03566706|BEHAVIORAL|Discussion Tool: Unhealthy Eating|Parents will randomly be assigned to one of three discussion tools that will provide parents with tools on how to communicate with their children about unhealthy eating, marijuana use, or sedentary behavior.
40857223|NCT03566706|BEHAVIORAL|Discussion Tool: Marijuana Use|Parent Discussion Tools
41388326|NCT05124990|DIAGNOSTIC_TEST|thermal imaging|no risk infrared thermal image would be used to capture pictures of the patients joints that are reported to be painful during a rheumatoid arthritis flare along iwth labs such as esr and crp. these will then be fed to a machine learning algorithm that will learn to predict the DAS 28 score for the RA patient and their flare.
41388327|NCT05260658|DRUG|CFTX-1554|CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).
41388328|NCT05260658|DRUG|Placebo|CFTX-1554 matching placebo
41388329|NCT04486807|DIAGNOSTIC_TEST|Elite badminton players|The population was all the elite badminton players followed in a University Hospital Centre and the National Institute of Sport, Expertise, and Performance. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed during the badminton season (Nineteen elite badminton players and followed over the badminton season (from september 2018 to may 2019 or from september 2019 to may 2020)
41388330|NCT01466673|DRUG|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
41388331|NCT01466673|DRUG|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
40857224|NCT03566706|BEHAVIORAL|Discussion Tool: Sedentary Behavior|Parent Discussion Tools
40857225|NCT04346446|DRUG|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion
40857226|NCT04346446|OTHER|Supportive Care|Supportive Care
40857227|NCT04346446|DRUG|Random Donor Plasma|Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement
40857228|NCT01122693|DEVICE|eZono - high-quality 2D ultrasound images|higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.
41038677|NCT05061264|PROCEDURE|Abdominal wall reconstruction|The repair of abdominal wall defects with polyvinylidene (PVDF) mesh
41511453|NCT00098605|OTHER|questionnaire administration|Ancillary studies
41388332|NCT04621097|DEVICE|pulsed electromagnetic field|it is a device for magnetotherapy and it is one of the most recent noninvasive physical therapy modality which is used in multiple physical therapy fields . it consist of an appliance, motorized bed and solenoid . the appliance must be connected to electrical supplying 230 =10% at a frequency of 50 or 60 HZ with earth connection . the intensity and spatial lay out of the generated magnetic field depend on the type of solenoid used
40857229|NCT01122693|DEVICE|standard 2D ultrasound images|current standard in two-dimensional (2D) ultrasound images
40857230|NCT05270239|BEHAVIORAL|N-back Cognitive Training|N-back task mainly trains working memory and information processing speed. This training lasts 10 days (1 hour per day).
40857231|NCT05270239|BEHAVIORAL|Virtual Reality Motor and Cognitive Training|"Virtual Reality Ball Task mainly trains inhibitory control, attention, working memory and motor functions. This training lasts 10 days (30 minutes per day)"
40857232|NCT04548856|PROCEDURE|Microsurgical clipping|Subjects randomized to surgical therapy will receive treatment from one neurosurgeon expert in surgery for ruptured aneurysms.
40857233|NCT04548856|PROCEDURE|Endovascular embolization|Subjects randomized to endovascular therapy will be treated by one endovascular expert in such treatment. Endovascular treatment will include all modern accepted surgical techniques.
40857234|NCT04787172|RADIATION|Multi Slice computed tomography|use of MSCT as a diagnostic tool in evaluation of patients with congenital cardiovascular anomalies
40857235|NCT01839149|DRUG|TI-001|TI-001 is intranasal oxytocin
40857236|NCT01839149|DRUG|Placebo|
40857237|NCT06399250|OTHER|meal service|We're not subjecting patients to an intervention, as we will evaluate the current in-hospital meal service. As the three channel food concept is standard of care, we're not subjecting patients to dietary or behavioral changes. We will compare the data to an historic control.
40857238|NCT04479696|OTHER|Educational Intervention|Receive standard of care verbal and written education materials
40857239|NCT04479696|OTHER|Questionnaire Administration|Ancillary studies
41388333|NCT04621097|OTHER|treadmill training|supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
41388334|NCT04621097|DRUG|Medication|regular medications
41388335|NCT02751372|DRUG|BAY 987517|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.
40857240|NCT04479696|OTHER|Survey Administration|Complete optional survey
40857241|NCT04479696|OTHER|Video|Watch NIRS video
40857242|NCT04302233|OTHER|New pharmaceutical support (NPS)|The only difference between these 2 groups is that patients in the NPS group benefit from additional visual and oral information on the characteristics of their implant and on medical device vigilance during their hospitalization.
40857243|NCT06457711|DIETARY_SUPPLEMENT|Free diet Group (FDG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the Mediterranean diet and follow the dietary recommendations outlined in Harvard's Healthy Eating Plate.
40857244|NCT06457711|DIETARY_SUPPLEMENT|Very low Calorie Ketogenic Diet Group (VLCKDG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the very low-calorie ketogenic diet (VLCKD) protocol
40857245|NCT06457711|DIETARY_SUPPLEMENT|Intermittent Fasting Group (IFG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the intermittent fasting schedule
40857246|NCT02133781|BIOLOGICAL|Fluzone® 2009-2010 Formula|This vaccine is given intramuscularly
40857247|NCT02133781|BIOLOGICAL|FluMist® 2009-2010 Formula|This vaccine is given intranasally
40857248|NCT00734968|DRUG|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
40857249|NCT00734968|OTHER|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
41038678|NCT01275573|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation will be applied on the contralateral primary cortical motor on the painful side for the Parkinson's disease patients and on the left primary cortical motor for the healthy volunteer. The stimulation frequency will be 20 Hz during 26 min with an intensity stimulation equal of 95% of the motor threshold.
41038679|NCT04226924|DRUG|Trehalose|90 mg/ml trehalose solution for IV infusion
41038680|NCT03061253|OTHER|Electronic Cigarette and behavioural change support.|The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
41038681|NCT03061253|OTHER|Nicotine-Free Electronic Cigarette and behavioural change support.|Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
41038682|NCT03061253|OTHER|Nicotine Replacement Therapy and behavioural change support.|Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
41038683|NCT04118153|DRUG|Abatacept|Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL) per dose.
41038684|NCT01846338|DIETARY_SUPPLEMENT|green tea extract EGCG|EGCG, 500mg, tid, 4 weeks
41038685|NCT04101643|DRUG|evolocumab|Eligible patients receive subcutaneous injections of evolocumab 420 mg
40857250|NCT01411956|OTHER|"24-minute video episode of patient education TV sitcom White Coats"|The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
40857251|NCT01411956|OTHER|Placebo video|The control group watched a 25-minute patient education video on depression.
40857252|NCT04870125|DRUG|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
40857253|NCT04870125|OTHER|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
40857254|NCT03579043|OTHER|Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
40857255|NCT03579043|OTHER|Non-Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
40857256|NCT03579043|OTHER|Carbonated Water|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
40857257|NCT06002516|OTHER|RELIEF-pathway|"The personalized web-based education tool contains information on:~* Information of cause and symptoms of functional dyspepsia, irritable bowel syndrome and uncomplicated symptomatic cholecystolithiasis;~* Symptom checker based on the ROME III and ROME IV criteria;~* Red flags symptoms defined as direct or indirect signs of upper GI hemorrhage.~* Lifestyle adjustments to improve abdominal symptoms and quality of life.~* Information on effect of upper gastrointestinal endoscopy, colonoscopy and laparoscopic cholecystectomy.~After the web-based education tool is completed we will offer an additional visit at the Prevention and Lifestyle clinic, this is optional and not obligatory."
40857258|NCT05795192|DRUG|SB17170|Taking SB17170 orally once a day
40857259|NCT05795192|DRUG|Placebo|Taking Placebo orally once a day
40857260|NCT03492034|DEVICE|IUD during CS|IUD insertion during CS
40857261|NCT03492034|DEVICE|IUD after puerperium|IUD after puerperium
40857262|NCT02602158|DIETARY_SUPPLEMENT|Octanoic acid (1-13C, 99%)|"13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
40857263|NCT02602158|DIETARY_SUPPLEMENT|TRIOCTANOIN (1,1,1-13C3, 99%)|"13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
40857264|NCT05320172|DRUG|Autologous platelet rich plasma eye drops|Fifty milliliters of patient's own whole blood will be placed in five 10-ml vacutainer tubes containing anticoagulant-citrate-dextrose solution (1.4 ml) and centrifuged at 200g for 11 min. The upper two layers of the centrifuged blood, the plasma and buffy coat layer will be separated in a sterile manner and diluted to 20 % (v/v) with a sterile saline solution. The final preparation is divided into 5-ml bottles wrapped in aluminum foil for protection from ultraviolet light. The patients are instructed to store these bottles at -20 °C until required. The bottles being used will be maintained under refrigerated conditions at 4 °C.
40857265|NCT05669872|DRUG|Ferric Carboxymaltose 50Mg/Ml Inj 20Ml|ferric carboxymaltose 1000mg, fixed dose for intervention group
40857266|NCT05669872|DRUG|RBC|pack RBC transfusion
41388336|NCT02751372|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
40857267|NCT02397538|DRUG|Fimasartan|
40857268|NCT02397538|DRUG|Amlodipine|
40857269|NCT02397538|DRUG|Rosuvastatin|
40857270|NCT02850380|OTHER|"FLIP SWITCHES DOWN IN WEIGHTLESSNESS"|"The circular instrument panel that subjects will see into the cylindrical mask consists of one switch surrounded by a luminous ring (left part of the figure below). The switch can be flipped into any direction within the full 360° range. The switch provides no visual cues about down, but the experimenter can add such cues by means of visually polarized labelling displayed on a circular black screen at the center of the panel (right part the figure below)."
41038686|NCT02837341|DEVICE|Philips®Vital Sign Device - Camera-based system (Prototype)|"Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate"
41038687|NCT03212105|BEHAVIORAL|60 Second Video|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
40857271|NCT04456192|BEHAVIORAL|Indoor Cycling Interval Exercise Training|"The 3-month intervention consisted of a physical exercise program involving three indoor cycling sessions per week, with a total of 36 training sessions. Subjects exercised on cycle ergometers Schwinn® Evolution® (Schwinn Bicycle Company, Boulder, Colorado, USA). Each session lasted approximately 55 minutes. Training sessions consisted of a 5-min low-intensity warm-up (cycling at 50-65% of maximum heart rate (HRmax)), 40 min of main training at an intensity of 65-95% of HRmax, 5 min of non-weight-bearing cycling, finishing with 5 min of low-intensity cool-down stretching and breathing exercises.~Main part of the training was interval. Each exercise session consisted of 3 to 4 high intensity intervals with intensity exceeding 80% of HRmax, often reaching anaerobic threshold. High intensity intervals lasted approximately 4-minutes and were interspersed by recovery periods at 65-80% of HRmax."
40857272|NCT00003864|DRUG|carboplatin|
40857273|NCT00003864|DRUG|docetaxel|
41388337|NCT02483260|DRUG|Ribavirin|"1. Loading dose, 33 mg/kg (maximum dose: 2.64 g)~2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses)."
40857274|NCT00335296|DEVICE|PFx catheter|
41388338|NCT00002973|DRUG|melphalan|
40857275|NCT00242996|BIOLOGICAL|filgrastim|
40857276|NCT00242996|BIOLOGICAL|rituximab|
40857277|NCT00242996|BIOLOGICAL|sargramostim|
40857278|NCT00242996|DRUG|carmustine|
41511454|NCT05484492|BIOLOGICAL|demineralized and mineralized combination putty bone allograft|Subjects in this group will receive an intrasocket demineralized and mineralized combination putty bone allograft following tooth extraction
41511455|NCT05484492|BIOLOGICAL|calcium phosphosilicate putty alloplast graft|Subjects in this group will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft following tooth extraction
40857279|NCT00242996|DRUG|cyclophosphamide|
40857280|NCT00242996|DRUG|etoposide|
40857281|NCT00242996|PROCEDURE|adjuvant therapy|
40857282|NCT00242996|PROCEDURE|bone marrow ablation with stem cell support|
40857283|NCT00242996|PROCEDURE|peripheral blood stem cell transplantation|
40857284|NCT04451499|OTHER|Smartphone app|The study specific smartphone app site will be based on current literature plus investigators experience and will include a wide knowledge on types of surgeries, dietary guidelines pre- and post-surgery, fluids type and amount, knowledge on supplementation use pre and post-surgery, general dietary knowledge, psychological information, physical activity, recommendation and tips for long-term surgery success, emphasis will be made on long-term follow-up meetings with the bariatric team and practical information on the preparation to the hospitalization process. The smartphone app site will contain video-based modules and encouraging messages. Patients will be encouraged to use the platform to ask questions and receive answers regarding any aspect of the surgery.
40857285|NCT06409143|DEVICE|HD-tES|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
40857286|NCT06409143|DEVICE|Sham HD-tES|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
40857287|NCT06409143|OTHER|UE rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.
40857288|NCT06409143|DEVICE|HD-tES (Bilateral)|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds.
41511456|NCT03093701|DRUG|TLC399 (ProDex)|2-vial system: TLC399-DSP and TLC399-Lipid
40857289|NCT02761382|OTHER|Mindfulness-based psychological treatment|
40857290|NCT02761382|OTHER|Non-specific psychological treatment|
40857291|NCT03778450|DRUG|Analgesics, Opioid|"Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients."
40857292|NCT03778450|DRUG|Non-Opioid Analgesic|Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
40857293|NCT04270539|BEHAVIORAL|Nap|Participants will be given 20-min nap opportunity in the classroom on a daily basis during school-days.
41388339|NCT00002973|PROCEDURE|hyperthermia treatment|
41388340|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone furoate/vilanterol
41388341|NCT03662711|DRUG|Bronchodilator Agents|Tiotropium
40857294|NCT05267119|PROCEDURE|Swab|The scalp was swabbed with five strokes which were performed each in a vertical, horizontal, left diagonal, and right diagonal direction. The swab was moved back and forth for 10 times
41388342|NCT03662711|DRUG|Bronchodilator Agents|Indacaterol
41511457|NCT03303235|DRUG|Methylergonovine|IV vs IM
41511458|NCT05590364|DEVICE|Profhilo® Body|Dosage form: Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride.
41511459|NCT03020771|BIOLOGICAL|KIRIM-KONGO-VAX|Crimean-Congo Hemorrhagic Fever Vaccine
41511460|NCT03020771|OTHER|Placebo|
41388343|NCT03662711|DRUG|Bronchodilator Agents|Umeclidinium/vilanterol
40857295|NCT02561442|DRUG|ceftriaxone|
40857296|NCT02502045|DEVICE|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
40857297|NCT02502045|DEVICE|Non-therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
40857298|NCT02907684|DIETARY_SUPPLEMENT|Almonds|Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
40857299|NCT02907684|DIETARY_SUPPLEMENT|Muffins/Crackers|"Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation."
40857300|NCT02205528|DRUG|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
40857301|NCT02205528|DRUG|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
41038688|NCT03212105|OTHER|Educational Brochure|The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
41038689|NCT01192906|DRUG|Placebo|Oral doses, once a day for 52 weeks
41388344|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone propionate/salmeterol
41388345|NCT03662711|DRUG|Bronchodilator Agents|Beclometasone dipropionate/formoterol
41038690|NCT01192906|DRUG|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
41038691|NCT01192906|DRUG|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
41038692|NCT06064227|OTHER|training intervention|"In this experimental study, the subject matter and sessions of the educational intervention, the effect of which was tested, were prepared based on evidence on preventable risk factors through health behavior change. The educational intervention consists of the following topics:~Nutrition and physical exercise, chronic disease management and polypharmacy, anti-smoking and stress management, preventive health services, access to health screenings and immunization."
41038693|NCT01641250|DRUG|RO5429083|Multiple escalating doses
41038694|NCT01641250|DRUG|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
41038695|NCT06449833|DRUG|Henagliflozein and Metformin|The experimental group will be treated with 10mg Henagliflozein and Metformin.
41388346|NCT03662711|DRUG|Bronchodilator Agents|Budesonide formoterol
41038696|NCT06449833|DRUG|Linagliptin and Metformin|The control group will be treated with 5mg Linagliptin and Metformin.
41038697|NCT05898867|OTHER|Saline|Open label intra-articular injection of isotonic saline.
41038698|NCT02439710|OTHER|Quality of life measure (survey)|The QoL tool is a questionnaire
41038699|NCT04522518|DEVICE|PmP-C App|"The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to."
41038700|NCT01754662|DIETARY_SUPPLEMENT|Soy protein|2 bars daily for 8 weeks.
41038701|NCT01754662|DIETARY_SUPPLEMENT|Isoflavones|2 bars daily for 8 weeks.
41038702|NCT01754662|DIETARY_SUPPLEMENT|Cocoa|2 bars daily for 8 weeks.
41038703|NCT01754662|DIETARY_SUPPLEMENT|Placebo|
41038704|NCT00687648|DRUG|anastrozole|Given as previously prescribed
41038705|NCT00687648|DRUG|cyclophosphamide|Given by mouth
41038706|NCT00687648|DRUG|exemestane|Given as previously prescribed
41388347|NCT03662711|DRUG|Bronchodilator Agents|Glycopyrronium
41388348|NCT03662711|DRUG|Bronchodilator Agents|Aclidinium
41388349|NCT03662711|DRUG|Bronchodilator Agents|Umeclidinium
41388350|NCT03662711|DRUG|Bronchodilator Agents|Formoterol
40857302|NCT02205528|DRUG|Placebo|Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
40857303|NCT02205528|DRUG|NNC0090-2746|NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
41388351|NCT03662711|DRUG|Bronchodilator Agents|Indacaterol glycopyrronium
41388352|NCT03662711|DRUG|Bronchodilator Agents|Salmeterol
41388353|NCT03662711|DRUG|Bronchodilator Agents|Tiotropium olodaterol
41388354|NCT03662711|DRUG|Bronchodilator Agents|Aclidinium/formoterol
41388355|NCT03662711|DRUG|Bronchodilator Agents|Olodaterol
41388356|NCT03662711|DRUG|Bronchodilator Agents|Formoterol/glycopyrronium bromide/beclometasone dipropionate
41388357|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone furoate/umeclidinium bromide/vilanterol
41388358|NCT00157729|DRUG|pyridoxal-5'-phosphate with and without ACE inhibitor|
41388359|NCT05408728|PROCEDURE|Endoscopic biopsy|Upper small intestinal biopsies from patients undergoing BS will be collected during routine standard of care screening EGD and again from the same patients at 1 year during routine standard of care surveillance EGD (esophageal reflux screening/surveillance). Biopsy-derived enteroid cultures and tissue samples from pre- and one-year post BS will be examined for expression level of sugar transporters and gluconeogenic enzymes; glucose and fructose absorption
41388360|NCT05362955|DRUG|Intravaginal 5-Fluorouracil (5-FU)|Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.
40857304|NCT04014985|OTHER|An extensive biological assessment|To study the morphology of red blood cells, the markers of oxidative stress and the signaling pathway of IFGF1.
40857305|NCT02315560|DEVICE|TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS|electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
40857306|NCT03432169|OTHER|Yoga (stretching plus mindfulness)|Stretching plus mindfulness
40857307|NCT03432169|OTHER|Stretching|Stretching alone
40857308|NCT03811314|DEVICE|Strength training|Using dumbbells, butterfly machine and vertical leg press machine for strength training, 12 repetition maximum weight for 12 repetition, three times a day, five days a week, for a total of four weeks
40857309|NCT03811314|DEVICE|Aerobic training|Using stationary bicycle to perform cardiopulmonary endurance training in 50-70 heart rate reserve for 20 minutes, five days per week, for a total of four weeks
40857310|NCT03811314|DEVICE|Isokinetic trinaing|Using Biodex isokinetic dynanometer and set it in isokinetic mode in 60 degree per second
40857311|NCT03811314|DEVICE|Isotonic training|Using Biodex isokinetic dynanometer and set it in isotonic mode at 60% of the maximal peak torque
40857312|NCT01009008|DEVICE|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
40857313|NCT03908359|PROCEDURE|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
40857314|NCT03908359|PROCEDURE|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
41388361|NCT00997672|DRUG|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
41388362|NCT00997672|DRUG|Placebo|
41388363|NCT05777369|DRUG|Rituximab|375 mg/m2, d0
41388364|NCT05777369|DRUG|Mitoxantrone hydrochloride liposome|18 mg/m2, d1
41388365|NCT05777369|DRUG|Cyclophosphamide|750 mg/m2, d1
41388366|NCT05777369|DRUG|Vincristine/Vindesine|Vincristine: 1.4 mg/m2, d1(The maximum dose was 2 mg) Vindesine: 3 mg/m2, d1
41511461|NCT04875351|DIAGNOSTIC_TEST|Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test|The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (\>5 year) endocrine therapy.
41511462|NCT05405504|DEVICE|Remote Dielectric Sensing (ReDS)|Non-invasive device designed for the measurement of lung fluid using extremely low power electromagnetic waves. The ReDS Pro System V2.7 system has CE approval (3900874CE01) and FDA clearance.
41511463|NCT00369486|PROCEDURE|Focal laser photocoagulation|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
40857315|NCT03047239|DEVICE|SENSIMED Triggerfish|Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours
40857316|NCT02919072|DRUG|Chloroprocaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
40857317|NCT02919072|DRUG|Ropivacaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
40857318|NCT00534963|PROCEDURE|cervical vs. uterine placement of balloon catheter|
40857319|NCT00531869|BEHAVIORAL|biases towards products|
40857320|NCT00119366|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
40857321|NCT00119366|DRUG|fludarabine phosphate|Given IV
40857322|NCT00119366|RADIATION|total-body irradiation|Undergo TBI
40857323|NCT00119366|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
41388367|NCT05777369|DRUG|Prednisone|60 mg/m2, d1\~d5
40857324|NCT00119366|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
40857325|NCT00119366|DRUG|cyclosporine|Given IV or PO
40857326|NCT00119366|DRUG|mycophenolate mofetil|Given PO
41388368|NCT02996448|DRUG|NDV-3A|A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
41388369|NCT02461407|DRUG|Anlotinib|Anlotinib p.o. qd
41511464|NCT00369486|DRUG|40mg triamcinolone|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
41511465|NCT00369486|DRUG|20mg triamcinolone|Anterior peribulbar injection of 20 mg triamcinolone
41511466|NCT00369486|DRUG|40mg triamcinolone + laser|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
41388370|NCT02461407|DRUG|Placebo|Placebo p.o. qd
41388371|NCT01057160|DRUG|Rizatriptan|use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
41388372|NCT04551859|OTHER|Dynamic Pelvic Floor MRI|6 months after surgery, a Dynamic Pelvic Floor MRI is performed
41388373|NCT04074122|DIAGNOSTIC_TEST|Adenosine and epinephrine, isoprenaline provocation|High-resolution electromechanical mapping at baseline and after provocative measures.
41388374|NCT01519895|BEHAVIORAL|Telephone intervention|counseling and education support
41511467|NCT00369486|DRUG|20mg triamcinolone + laser|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
41388375|NCT06567145|BEHAVIORAL|Narrative Enhancement Cognitive Therapy (NECT)|The Narrative Enhancement and Cognitive Therapy (NECT) consists of 20 group sessions divided into five parts: orientation (2 sessions), psychoeducation on stigma (3 sessions), cognitive restructuring (7 sessions), narrative enhancement (7 sessions), and a concluding reflection (1 session). The program helps participants challenge self-stigmatizing beliefs, develop coping skills, and create a new, positive narrative about themselves. Each session lasts about an hour, with a structured format of introduction, main discussion, and conclusion, encouraging active participation and reflection on personal experiences. The intervention ultimately fosters self-efficacy, control, and hope for the future.
41388376|NCT06173986|DRUG|PD-1inhibitor|PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year
41388377|NCT06173986|DRUG|nab-paclitaxel + cisplatin|Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles
40857327|NCT00119366|OTHER|laboratory biomarker analysis|Correlative studies
41388378|NCT06173986|RADIATION|Radiotherapy|Primary tumor and metastatic lymph nodes, DT:45-50Gy/25fx, starting within 4 weeks following the completion of the last induction immunochemotherapy cycle
41388379|NCT05553600|DEVICE|Tampon BR|Modified Regular Absorbency Tampons
41388380|NCT05553600|DEVICE|Tampon CR|Reference Regular Absorbency Tampons
41388381|NCT05553600|DEVICE|Tampon BS|Modified Super Absorbency Tampons
41388382|NCT05553600|DEVICE|Tampon CS|Reference Super Absorbency Tampons
41388383|NCT00654446|DRUG|Rosuvastatin|
41388384|NCT00654446|DRUG|Simvastatin|
40857328|NCT04885413|DRUG|Niraparib in Combination With Anti-PD1 Antibody|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
41388385|NCT02413879|DEVICE|CleanCision|Wound protection during colorectal surgery.
41511468|NCT03541317|BEHAVIORAL|Stage 1 Strategy: REP|Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation.
41511469|NCT03541317|BEHAVIORAL|Stage 1 Strategy: REP + Coaching|"Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; ongoing technical assistance in CBT implementation; and weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
40857329|NCT04998981|DRUG|K-877 0.1 mg tablet|K-877 0.1 mg tablet x 2 twice daily
40857330|NCT04998981|DRUG|Fenofibrate 200 mg capsule|Fenofibrate 200 mg capsule once daily
40857331|NCT04998981|DRUG|Placebo tablet|Placebo tablet x 2 twice daily
40857332|NCT04998981|DRUG|Placebo capsule|Placebo capsule once daily
40857333|NCT04998981|DRUG|K-877 0.1 mg tablet|K-877 0.1 mg tablet twice daily
40857334|NCT04998981|DRUG|Placebo tablet|Placebo tablet twice daily
41038707|NCT00687648|DRUG|letrozole|Given as previously prescribed
41038708|NCT00687648|DRUG|methotrexate|Given by mouth
41038709|NCT00687648|DRUG|prednisolone|Given by mouth
41038710|NCT04625543|DRUG|Sintilimab Injection plus Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; Sintilimab Injection 200mg on day 22; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
41038711|NCT04625543|DRUG|Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
41038712|NCT05245929|DEVICE|Distalization|Distalizing the posterior maxillary segment
41038713|NCT05812001|BEHAVIORAL|Exergames-acceptance and commitment therapy (e-ACT)|In the e-ACT training program, participants will perform a 30-minute per session Nintendo-program on TV for three days per week and a 50-minute ACT session per week for 8 weeks which will take place in the psychology labs of AMDI, USM. The ACT session will be held after 30 minutes break following the completion of the final exergame session of the week. Hence, the total duration of each weekly e-ACT training session will be approximately 2 hours. In addition, each weekly e-ACT training session will be held at the same time (± 2 hours) and at the same venue.
41038714|NCT05812001|BEHAVIORAL|Acceptance and commitment therapy (ACT)|As for the ACT intervention, each ACT session will run for 50 minutes, one session per week for 8 weeks. Each weekly ACT session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
41038715|NCT00146575|DEVICE|Sirolimus-eluting stent (Cypher)|patients have been implanted a Cypher stent
41038716|NCT00146575|DEVICE|Paclitaxel-eluting stent (Taxus)|patients have been implanted a Taxus stent
41038717|NCT06170008|DEVICE|Physical microstructure-modified transparent silicone film sheet|The main component of the physical microstructure-modified transparent silicone film sheet is transparent silicone rubber, which has a three-dimensional microstructure on its trauma contact surface through physical mechanics treatment, which can provide effective mechanical stimulation for trauma healing. And after testing, the silicone film sheet is breathable, light-permeable, non-toxic and non-allergenic. It is expected to significantly reduce the number of dressing changes, reduce the damage to the wound and the painful stimulation to the patient during dressing changes, and promote the healing of the wound to a certain extent, thus improving the quality of wound repair and saving medical costs.
41038718|NCT06170008|DEVICE|Decellularized pig skin|Decellularized pig skin is an allogeneic trauma covering from pigs and is a commonly used trauma covering for second-degree burn wounds. It adheres to clean superficial wounds, creates a temporary barrier to the wound, reduces wound exudation, limits loss of body components, improves microcirculatory stasis, provides a microenvironment suitable for wound healing, protects inter-ecological tissue, promotes repair and regeneration, and reduces pain. Its disadvantages are: soft structure, difficult to fix the trauma; opaque, unable to observe the trauma; pigskin needs to be stored under suitable temperature and humidity, and has a limited time. When used, decellularized pig skin is directly covered on conventionally treated second-degree burn wounds.
40857335|NCT05719675|BEHAVIORAL|Intervention|"The general outline of the intervention is divided into three phases:~1. Dispositional alteration, where the aim will be to obtain precise information on the barriers that patients encounter in carrying out their treatment and thus focus the issues to achieve an awareness of the disease by altering some of the factors that give rise to the realization of behaviors that interfere with treatment adherence.~2. Alteration of one's own behavior, focused on the development of healthy habits that are consistent with the indications of the health team for the proper management of the disease.~3. Alteration of the behavior of others, focused on the development of skills in the participants so that they are able to modify the behavior of other people close to them through health promotion strategies."
40857336|NCT04120272|PROCEDURE|Spine surgery|Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
40857337|NCT00214539|PROCEDURE|Bronchial Thermoplasty with the Alair System|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
40857338|NCT00214539|DRUG|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
41388386|NCT00934778|PROCEDURE|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
41388387|NCT06376773|PROCEDURE|combination chemotherapy with Apatinib or Camrelizumab|Apatinib, chemotherapy alone, Camrelizumab
41388388|NCT04282733|BEHAVIORAL|Mindfulness Rounds|"Throughout the 8-week study period, a different mindfulness practice will be introduced weekly in 3 separate 15-minute live sessions. Posters describing the particular practice of the week will be placed around the Unit as visual reminders to encourage actual practice."
41388389|NCT02936479|DRUG|C1-INH (Berinert)|
41388390|NCT01984931|DRUG|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
41388391|NCT01984931|DRUG|Metoclopramide hydrochloride monohydrate|
41388392|NCT01470352|DRUG|Doluxetine|30 mg/d
40857339|NCT04717817|DEVICE|Inspiratory muscle training (IMT) using an IMT Threshold device (Philips)|Inspiratory muscle training on a daily basis prior to surgery during 2-3 weeks
40857340|NCT04717817|OTHER|Standard physiotherapy|Standard instructions and physiotherapy prior to surgery during 2-3 weeks
40857341|NCT05820854|OTHER|Self-assess and reporting self-care self-efficacy levels|Patients will have to self-report the self-care self-efficacy levels they experienced in managing the OAC therapy.
40857342|NCT00520910|DRUG|Polypodium leucotomos|Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
40857343|NCT06153537|DRUG|Insulin degludec|Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
40857344|NCT00742716|DRUG|CTA018 Injection|Comparison of different dosages of drug
40857345|NCT03631758|OTHER|Evidence-based information|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
41388393|NCT01470352|DRUG|Placebo|suger pill 30mg/d
40857346|NCT03631758|BEHAVIORAL|Patient Decision Aid|Patient Decision Aid for breast cancer screening decision
40857347|NCT03631758|OTHER|Sham information|Educational information not specific to mammography or cancer screening
40857348|NCT04940546|DRUG|Sintilimab|Mode of administration: Intravenously
40857349|NCT04940546|DRUG|Oxaliplatin|Mode of administration: Intravenously
40857350|NCT04940546|DRUG|Capecitabine|Mode of administration: Orally
40857351|NCT04940546|DRUG|Bevacizumab|Mode of administration: Intravenously
40857352|NCT05169424|DEVICE|Trelegy Ellipta|Trelegy Ellipta
40857353|NCT05169424|DEVICE|Stiolto Respimat|Stiolto Respimat
40857354|NCT05169424|DRUG|Tiotropium + Olodaterol (5/5 mcg)|Tiotropium + Olodaterol (5/5 mcg)
40857355|NCT05169424|DRUG|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
41388394|NCT02339428|DRUG|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
41388395|NCT02339428|DRUG|Placebo|Inactive pill manufactured to mimic diclofenac tablet
41388396|NCT00530439|OTHER|Lifestyle intervention|Dietician counselling and physical training
41388397|NCT00530439|OTHER|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
41388398|NCT00530439|BEHAVIORAL|Physical activity, dietetic counselling|"The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week."
41388399|NCT06567938|PROCEDURE|Percutaneous coronary intervention|PCI with DES implantation
41388400|NCT03086980|OTHER|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
41388401|NCT03086980|OTHER|Treatment as Usual|Usual Care will be provided.
41388402|NCT06107127|PROCEDURE|STOP|Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
40857356|NCT01800630|DRUG|Gemcitabine HCl Oral Formulation|
41388403|NCT00919802|DRUG|Oxytocin|A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
41388404|NCT00919802|OTHER|Saline as a nasal spray|A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
41388405|NCT06017856|OTHER|Life style intervention program|Life style intervention program for the obese/overweight subjects conducted regardless of this study at the child sport and health center at Meir medical center
41388406|NCT00176852|DRUG|Busulfan, Fludarabine, ATG, TLI|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
41388407|NCT00176852|DRUG|Busulfan, Cyclophosphamide, ATG, GCSF|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC \>2500 x 2 days.
41388408|NCT00176852|DRUG|Campath, Fludarabine, Cyclophosphamide|Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
41388409|NCT00176852|RADIATION|Total Body Irradiation|300 cGY Day -1
41511470|NCT03541317|BEHAVIORAL|Stage 2 Strategy: Augment with Facilitation|In addition to first-line treatment (REP or REP + Coaching), schools will also receive support from a Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support SPs in strategic thinking and leadership skills to address organizational barriers.
40857357|NCT02863328|DRUG|semaglutide|Oral administration once-daily.
41038719|NCT06170008|DEVICE|Vaseline gauze|Vaseline gauze is the most commonly used conventional dressing for the implant area, which is mainly made of skimmed cotton gauze impregnated with petroleum jelly and paraffin oil, which has a lubricating effect and can promote the growth of granulation and wound healing. However, its moisturizing time is relatively short and requires frequent dressing changes; moreover, petroleum jelly gauze often adheres to the wound surface severely, which may cause bleeding and new epidermal damage during dressing changes and affect the wound healing; the wound surface is constantly oozing blood and fluid, and the dressing cannot be effectively isolated from the outside world after wetting, which increases the chance of infection. Vaseline gauze is applied directly to the post-operative skin grafting wound.
41038720|NCT03047668|DIETARY_SUPPLEMENT|diet with/without supplementation|diet with/without supplementation with PUFAs
41038721|NCT00965432|DRUG|STX107|Single dose of an oral suspension
41166831|NCT05103098|DRUG|misoprostol 400 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 400 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
41388410|NCT00176852|PROCEDURE|Stem cell infusion|Given Day 0
41388411|NCT02163629|BEHAVIORAL|Stress management|
41388412|NCT04341207|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg 3 times a day for 10 days
41388413|NCT04341207|DRUG|Azithromycin|Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days
41388414|NCT00572468|DRUG|Simvastatin|40 mg of simvastatin
41388415|NCT00572468|OTHER|Placebo|placebo
40857358|NCT02863328|DRUG|empagliflozin|Oral administration once-daily.
40857359|NCT01969630|DEVICE|PEB|Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation
40857360|NCT01969630|DEVICE|PES|Systematic Paclitaxel eluting stent angioplasty
41388416|NCT02674074|DEVICE|infrared thermography|measurement of corneal temperature by infrared thermography before and after cold provocation
40857361|NCT01819896|DRUG|Pacemaker and defibrillator|
40857362|NCT04120402|DRUG|EP-104IAR 25 mg|Single 5 mL intra-articular injection
40857363|NCT04120402|DRUG|Vehicle|Single 5 mL intra-articular injection
40857364|NCT02775448|DRUG|Carduus marianus 6cH|
40857365|NCT02775448|DRUG|Carduus marianus 12cH|
40857366|NCT02775448|DRUG|Carduus marianus 30cH|
40857367|NCT02775448|DRUG|Placebo|
41388417|NCT00728988|DRUG|Atorvastatin|80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
41388418|NCT00728988|DRUG|Atorvastatin|40mg daily after PCI for 30 days.
41388419|NCT06356038|PROCEDURE|intra-operative phrenic nerve infiltration|patients received the intra-operative infiltration of phrenic nerve by the surgeon who injected 10 ml of Ropivacaine 0.75% (the same procedure routinely adopted in our clinical practice for local analgesia at the level of the intercostal space) in the peri-neurotic pericardial fat, near the diaphragm. Infiltration is made with a deflated lung, after pulmonary resection and chest tube insertion.
41388420|NCT02560207|DRUG|Cefotaxime|To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.
41388421|NCT00335985|DRUG|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
41511471|NCT03541317|BEHAVIORAL|Stage 2 Strategy: No augmentation|Schools will continue to receive their first-line treatment (REP or REP + Coaching); no additional support will be offered.
41388422|NCT00335985|DRUG|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
41388423|NCT03791918|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
41388424|NCT03791918|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
41511472|NCT06581588|DEVICE|THRIVE|Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen
41511473|NCT06581588|DEVICE|THRIVE combine nasopharyngeal airway|Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen and nasopharyngeal airway
41511474|NCT06581094|DIETARY_SUPPLEMENT|UCII, glucosamine and curcumin|The dosage was 42 mg UCII, 460 mg glucosamine and 380 mg curcumin per day, and placebo (only 42 mg UCII).
40857368|NCT02775448|BEHAVIORAL|Exercise|aerobic exercise, 30 minutes, daily
40857369|NCT02775448|OTHER|Diet|1600 calories
40857370|NCT03764306|PROCEDURE|Carotid Artery Stenting|Carotid artery stenting was considered successful if there was no residual stenosis greater than 20%, and there was no dissection of target artery following the procedure.
40857371|NCT03764306|PROCEDURE|Endarterectomy carotid artery|Surgical endarterectomy was considered successful if there was no residual stenosis after procedure, without symptoms.
40857372|NCT02488005|DEVICE|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
40857373|NCT00555672|DRUG|5-fluorouracil|5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
40857374|NCT00555672|DRUG|cisplatin|Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
41038722|NCT03777098|DEVICE|Strepic® Device|The Strepic® device is a qualitative point-of-care diagnostic test for the detection of GAS pharyngitis. The test uses direct visualization of the pharynx with a light source of specified wavelengths, causing excitation of endogenous fluorophores that emit a characteristic colored light pattern. White light images may give additional diagnostic accuracy through use of an artificial intelligence analysis of a large set of images of GAS and non-GAS pharyngitis.
40857375|NCT00555672|DRUG|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
40857376|NCT02285387|PROCEDURE|Rhythm control|"1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~2. Cardioversion after 1 month~3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~4. If AF recur, RFCA"
40857377|NCT02285387|PROCEDURE|Rate control|"1. No AAD, just anticoagulation~2. HR control between 60\~110bpm (with beta blocker, calcium channel blocker, digoxin)~3. Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
40857378|NCT04027751|DRUG|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia induction
40857379|NCT04027751|DRUG|Placebos|Investigators administrated intravenously 0.9% saline solution as a placebo
40857380|NCT04971720|DRUG|Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.
41038723|NCT04233268|DIAGNOSTIC_TEST|Rapid Pathogen Detection|Rapid assays for pathogen detection on bronchoalveolar lavage fluid
40857381|NCT04971720|DRUG|Valsartan 80 mg Oral Tablet|The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.
40857382|NCT05630040|DEVICE|Non-invasive vagus nerve stimulation|Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.
41038724|NCT02526264|OTHER|Education program|Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
41388425|NCT03791918|PROCEDURE|TACE|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. TACE Drug Protocol were injected.
41388426|NCT03791918|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
41388427|NCT01416207|DRUG|Avonex|4 weekly injections of Avonex (IM)
40857383|NCT05630040|DEVICE|Sham Intervention|Participants will take a placebo device home for 6 weeks and use daily.
41038725|NCT03215797|DRUG|phenylephrine|phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
41038726|NCT03215797|DRUG|Norepinephrine|Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
41388428|NCT06290427|DEVICE|DaVinci RAPN|Robot-assisted Partial Nephrectomy with DaVinci® Surgical System
41388429|NCT06290427|DEVICE|Hugo RAS RAPN|Robot-assisted Partial Nephrectomy with Hugo™ RAS System
41388430|NCT06290427|DEVICE|Versius® RAPN|Robot-assisted Partial Nephrectomy with Versius® System
41511475|NCT01675648|DRUG|Lofexidine|
41038727|NCT03895424|DIETARY_SUPPLEMENT|IFAC|This intervention will contain the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope 58Fe
41511476|NCT01675648|DRUG|Diazepam|
41511477|NCT01675648|DRUG|Placebo for Lofexidine|
41511478|NCT01675648|DRUG|Placebo for Diazepam|
41511479|NCT01694225|OTHER|bubble packaging for monthly prescription|Monthly bubble packaging among women prescribed anti-estrogens
41511480|NCT01494116|OTHER|900 mL of 0.9% Normal Saline|"The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered."
41388431|NCT03884907|PROCEDURE|The patients will receive human bone graft screws surgically|All patients undergo Hallux valgus correction according to the Austin procedure using human bone graft screws.
41511481|NCT06581497|DRUG|ICIs|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.
41511482|NCT06581497|PROCEDURE|ICIs+MWA|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines. All patients, except for those enrolled in ICIs, should also undergo MWA treatment.
41511483|NCT04105673|OTHER|Clinical examination and survey|Children will be seen during an one consultation. A clinical examination and survey are realized.
41166832|NCT05103098|DRUG|misoprostol 800 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
41511484|NCT01045330|BEHAVIORAL|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
41511485|NCT03189992|DRUG|Bushen-Jianpi Dedoction|A traditional chinese medicine prescription
40857384|NCT01181869|DEVICE|oxygen|oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
40857385|NCT04909203|DEVICE|iKinnect2.0|iKinnect2.0 is a paired mobile phone app for use on both Android and iOS operating systems by youth with conduct disorders and their parents.
40857386|NCT04909203|DEVICE|Active Control App|Mobile phone app for use on both Android and iOS operating systems for GPS tracking of other persons.
40857387|NCT04480632|BIOLOGICAL|Convalescent plasma|ABO compatible convalescent plasma obtained from from recovered COVID-19 patients
41388432|NCT03333382|DEVICE|Plastic biliary stent|Plastic biliary stent which functions largely as a wick to siphon bile flow from the site of anastomotic leak.
41511486|NCT03189992|DRUG|cinobufotalin injection|an effective Chinese preparation to treat malignant tumor.
40857388|NCT05700994|BEHAVIORAL|Peer Contingency Management|Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals)
40857389|NCT05700994|BEHAVIORAL|Standard of Care Contingency Management|Participants allocated to standard of care contingency management will receive incentives for peer encounters.
40857390|NCT06064071|DEVICE|Nordlys SWT IPL|Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators
41511487|NCT02952586|DRUG|Avelumab|Avelumab + SOC Chemoradiation
41511488|NCT02952586|OTHER|Chemoradiation|Cisplatin + Radiation Therapy
41511489|NCT05669235|DIAGNOSTIC_TEST|Questionnaires|A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.
40857391|NCT06064071|PROCEDURE|Meibomian Gland Expression (MGX)|Meibomian glands are squeezed (by applying force on the inner and outer surfaces of the eyelid with a specially designed forceps, Q-tips, or fingers) in order to unclog obstructed glands and evacuate their content (the meibum), which in MGD is often viscous and thus causing obstruction
40857392|NCT06064071|DEVICE|Sham Nordlys SWT IPL|Sham treatment with Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators device turned off
41038728|NCT03895424|DIETARY_SUPPLEMENT|MIFAC|This intervention will contain the micellarized form of the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope with 57Fe
41388433|NCT03333382|DEVICE|FCSEMS|FCSEMS has a relatively larger expansile diameter and membrane coating to provide an actual seal at site of anastomotic leak.
41388434|NCT02885974|DRUG|Celecoxib|Celecoxib (100 mg daily)
41388435|NCT02885974|DRUG|Gemcitabine|1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.
41511490|NCT04511585|BEHAVIORAL|Great Live and Move Challenge|Physical activity program for children
41511491|NCT03709511|OTHER|Cardiac rehabilitation|perioperative rehabilitation consists of education, inspiratory muscle training, active cycle of breathing techniques, and early mobilization.
41038729|NCT03895424|DIETARY_SUPPLEMENT|Control Ferrous Sulfate|This intervention will contain ferrous sulfate in the form of a solution labelled with the iron isotope 54Fe. A capsule with the same amount of fat as in the other arms will be administered to the participants
41038730|NCT04862182|DIAGNOSTIC_TEST|Trans-perineal ultrasound|Intrapartum trans-perineal ultrasound in predicting the mode of delivery.
41388436|NCT02885974|DRUG|Cisplatin|70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.
41388437|NCT04315831|DRUG|Transdermal Buprenorphine|Intervention will be applied for patients with moderate to severe cancer pain
41388438|NCT06458595|DRUG|KH658|KH658 Ophthalmic Injection
41388439|NCT01243645|BEHAVIORAL|biofeedback training|
41388440|NCT05543863|DIAGNOSTIC_TEST|Platelet function testing|platelet function testing (Platelet function analyzer-100 (PFA-100) collagen epinephrine closure time, VerifyNowⓇ Assays (aspirin, P2Y12)) before surgery and 5 days, 3 months after surgery
41511492|NCT04666454|DRUG|Adenosine|Adenosine infusion 70 µg/kg/min for 3 hours.
41511493|NCT04666454|DRUG|Dipyridamole 200 mg|200 mg b.i.d
41511494|NCT04666454|DRUG|Apixaban 5 mg Oral Tablet|5mg b.i.d
41511495|NCT04666454|OTHER|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome|This treatment will vary depending on local routines and the degree of adherence to the recommendations.
41511496|NCT01320501|DRUG|Erlotinib|All patients will receive: TarcevaTM 150mg/day PO.
40857393|NCT03989362|DRUG|Vopratelimab|Specified dose on specified days
41388441|NCT05643131|DEVICE|Hyivy Intravaginal Device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
41388442|NCT00001001|DRUG|Zidovudine|
41388443|NCT00207974|DRUG|Marine active|
40857394|NCT03989362|DRUG|Ipilimumab|Specified dose on specified days
40857395|NCT03346200|DRUG|Tamoxifen Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
40857396|NCT03346200|DRUG|Placebo Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
40857397|NCT04357483|DRUG|flowable thrombin containing collagen hemostat matrix|A 5 ml flowable hemostat matrix (CollaStat®) was applied to the stump or anastomosis site after pancreatectomy.
40857398|NCT04357483|DRUG|thrombin coated L-dopa contained collagen patch|A 5x2.5cm sized thrombin coated L-dopa contained collagen patch (CollaSeal®) was applied to the stump or anastomosis site after pancreatectomy.
40857399|NCT01904045|OTHER|tacrolimus Advagraf|intake of Advagraf once daily for 3 months
40857400|NCT01904045|OTHER|tacrolimus Prograf|intake of Prograf twice daily for 3 months
40857401|NCT05499468|OTHER|Popular-Opinion Leader-led encouragement during training meetings and informal conversation|Investigators adapted evidence-based principles from the Popular Opinion Leader framework to increase utilizations of existing one-on-one emotional support resources for physicians-in-training at Stanford (an effective HIV prevention intervention developed by the CDC for changing social norms and reducing behavioral risk factors led by influential members of a community, trained to promote behavior change). All intervention activities designed to encourage utilization were delivered as part of health promotion during pre-existing clinical training meetings and no data was collected during these workshops. Identified POLs were recruited and trained to encourage their colleagues to use existing support resources and engage in two 30-60 minute workshops scheduled to occur during training meetings.
40857402|NCT06493734|RADIATION|Stereotactic body radiation therapy|SBRT will be delivered in 15 fractions of 4 to 4.5Gy (risk-adapted), one fraction each weekday for 3 weeks.
41038731|NCT01303666|PROCEDURE|Intra-articular CSI|After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
41388444|NCT06541106|OTHER|Multi-disciplinary assessment|"1. Comprehensive evaluation was performed by multi-disciplinary experts to assess the prognosis of unruptured VBDAs and develop appropriate treatment strategies.~2. Preoperative cranial MRI, CTA, DSA and other imaging tests were used to determine the aneurysm site, morphology, size, presence of compression symptoms, and whether it was accompanied by an intramural hematoma."
41038732|NCT01303666|PROCEDURE|TI of the knee|"This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.~After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles."
41388445|NCT02952794|PROCEDURE|endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer|
41388446|NCT01642693|RADIATION|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
41388447|NCT01642693|OTHER|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
41388448|NCT05521087|DRUG|JNJ-75276617|JNJ-75276617 will be administered orally.
41388449|NCT05521087|DRUG|Fludarabine|Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.
40857403|NCT00559247|DRUG|BMS-650032 or Placebo|Oral, Once daily, Single Dose
40857404|NCT03472586|BIOLOGICAL|Ipilimumab|Given IV
41388450|NCT05521087|DRUG|Cytarabine|Cytarabine chemotherapy will be administered as IV infusion for participants with AML.
41388451|NCT05521087|DRUG|Intrathecal Chemotherapy|Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.
40857405|NCT03472586|BIOLOGICAL|Nivolumab|Given IV
40857406|NCT03472586|DRUG|Embolization Therapy|Undergo immunoembolization
40857407|NCT00002399|DRUG|Posaconazole|
40857408|NCT00002399|DRUG|Fluconazole|
40857409|NCT02978833|BIOLOGICAL|PRP|
40857410|NCT02978833|BIOLOGICAL|Whole Blood|
40857411|NCT02978833|DEVICE|Ultrasound|
40857412|NCT03787355|COMBINATION_PRODUCT|Morse connection Implants|2 neighboring morse connection Implants of Zinedent - Strauman
40857413|NCT02717494|BIOLOGICAL|PPV-23|PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.
40857414|NCT02717494|BIOLOGICAL|PCV-10|PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
40857415|NCT02717494|OTHER|NaCl|NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.
41038733|NCT04897165|OTHER|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants received access to three online lectures at the start of the first, third, and forth training week (each lasting 60 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
41166833|NCT03398421|DRUG|Nemiralisib|Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTA® is a registered trademark of GlaxoSmithKline group of companies.
41166834|NCT03398421|DRUG|Itraconazole|Itraconazole will be given as 100 mg per capsule per day administered orally with water
40857416|NCT01035619|DRUG|moxidectin|Single Dose Moxidectin 4 mg
40857417|NCT02369419|OTHER|Frailty|CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as \<14/17 points using the ONCODAGE score
40857418|NCT01702246|DRUG|Simvastatin|40 mg, orally, once daily for 3 months
40857419|NCT00741013|DRUG|placebo pill and placebo IV|"Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
40857420|NCT00741013|DRUG|Lovastatin pill and placebo IV|"lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
40857421|NCT00741013|DRUG|placebo pill and recombinant human activated protein C IV|"placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
40857422|NCT00741013|BIOLOGICAL|Endotoxin|Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
40857423|NCT01218581|DRUG|received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)|
40857424|NCT03097536|OTHER|Luna Bar|Luna Bar (blueberry bliss or lemon zest flavor) product of Clif
40857425|NCT02386449|DRUG|sodium picosulfate, magnesium oxide and citric acid (Picoprep®)|
40857426|NCT02386449|DRUG|mannitol|
41038734|NCT04897165|OTHER|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants attended three live lectures at the start of the first, third, and forth training week (each lasting 90 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
41038735|NCT02492100|BEHAVIORAL|Multi-modality sexual dysfunction intervention|
41038736|NCT02160587|DRUG|Chloraprep|ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
41038737|NCT02160587|DRUG|0.9% Physiological Saline|0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
41038738|NCT02160587|OTHER|ZuraPrep without IPA|ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
41038739|NCT05426551|OTHER|Dual isotope method|The digestibility of amino acids will be determined within each arm by the collection of ileal digesta owing to naso-ileal intubation device and by plasma samples with the dual isotope method.
41038740|NCT06088264|DRUG|BMS-986322|Specified dose on specified days.
41388452|NCT05521087|DRUG|Dexamethasone|Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.
41388453|NCT05521087|DRUG|Vincristine|Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.
41388454|NCT05521087|DRUG|Pegaspargase|Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.
41388455|NCT00085826|DRUG|Exisulind|
41388456|NCT04379102|OTHER|with NT/TLA (NT or also referred to as therapy with local anesthetics (TLA) )|Patients who visited our family planning clinic and opted for IUD application for contraception purposes were also offered NT/TLA treatments simultaneously. 40 patients who matched the inclusion criteria and received IUDs and NT/TLA treatments were included in the study group and 41 patients who only received IUDs were included in the control group. All patients received copper IUDs and none of them were on additional hormonal treatment. Before the insertion of IUD, women in the therapy group received NT treatment with 6ml of 1% procaine injected transvaginal into the cervix at 5 and 7 o'clock localizations.
41038741|NCT04425564|DRUG|metronomic XELOX|
41038742|NCT04425564|DRUG|Classic XELOX|
41388457|NCT06542354|BEHAVIORAL|Physical exercise|Physical exercises personally scheduled consisting of daily aerobic exercise(30mins) of fast walking(≥5km) and resisitance training.
41388458|NCT06542354|DIETARY_SUPPLEMENT|Nutrition supplement|Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Oral nutrition supplement (ENSURE) is provided daily seperated in 2 doses
41388459|NCT06542354|BEHAVIORAL|Mental support|Relaxation exercise and psychological counselling delivered by weekly telephone follow-up
41388460|NCT00488839|DRUG|IPX056 20 mg|IPX056 Extended Release capsule containing 20 mg baclofen
40857427|NCT02386449|DRUG|Bisacodyl|
40857428|NCT05888753|PROCEDURE|Adrenalectomy|Scheduled adrenal surgery
40857429|NCT06225687|OTHER|Heat Application|The researcher will conduct daily measurements of gastric residual volume (GRV) and abdominal circumference, listen to bowel sounds, and assess distension from the first day of enteral nutrition initiation. Additionally, they will record the frequency of vomiting/defecation. Subsequently, a 15-minute hot application will be applied to the abdominal/lumbar region.
40857430|NCT03469687|DEVICE|Symax uncemented hip stem|
40857431|NCT02856204|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood
40857432|NCT02856204|OTHER|Laboratory Biomarker Analysis|Correlative studies
40857433|NCT00214981|DRUG|Modafinil|
41038743|NCT04425564|OTHER|Blood samples for pharmacological studies|
41038744|NCT00956865|OTHER|Voucher|Vouchers given to reimburse transportation
41166835|NCT00857233|DRUG|Memantine|20 mg oral tablets once daily
41166836|NCT03420261|BIOLOGICAL|0.9% saline|Fluid administration
41166837|NCT03420261|BIOLOGICAL|HES 130/0.4|Fluid administration
41038745|NCT00956865|OTHER|Telephone Call|Telephone reminder calls
41388461|NCT00488839|DRUG|IPX056 40 mg|IPX056 Extended Release capsule containing 40 mg baclofen
41388462|NCT00488839|DRUG|Encapsulated Baclofen 20 mg|Baclofen 20mg tablet was encapsulated for blinding.
41388463|NCT00488839|DRUG|Placebo Baclofen Tablet|Placebo capsule encapsulated placebo Baclofen tablet
41038746|NCT00956865|OTHER|Contact|Contact at senior center to encourage follow up
41388464|NCT00488839|DRUG|IPX056 10 mg|IPX056 Extended Release capsule containing 10 mg baclofen
41511497|NCT04601571|DEVICE|CORTRAK Stylet|The stylet is a component of the CORTRAK feeding tube system used to confirm the correct placement of the feeding tube
41511498|NCT05286866|PROCEDURE|Dental implant bed preparation|Drilling an osteotomy for placement of a dental implant
41511499|NCT03707210|BEHAVIORAL|VR training program|Use VR software to make a training education program.
41511500|NCT00743418|DEVICE|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
40857434|NCT00600210|DRUG|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
40857435|NCT00600210|DRUG|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
40857436|NCT00600210|RADIATION|Radiation Therapy|"Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions."
40857437|NCT06009055|DRUG|Remimazolam|0.3mg/kg，injection completed in 30 seconds
40857438|NCT06009055|DRUG|Propofol|2mg/kg，injection completed in 30 seconds
41038747|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
41038748|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
41038749|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
41038750|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
41038751|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
41038752|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
41038753|NCT03112018|BEHAVIORAL|data strengthening|Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
41038754|NCT03112018|BEHAVIORAL|modified Safe childbirth checklist - control|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
41038755|NCT03112018|BEHAVIORAL|modified Safe childbirth checklist - enhanced|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
41388465|NCT00488839|DRUG|IPX056 30 mg|IPX056 Extended Release capsule containing 30 mg baclofen
41038756|NCT03112018|BEHAVIORAL|PRONTO training|Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
41038757|NCT03112018|BEHAVIORAL|QI cycles|Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
41038758|NCT00450086|DRUG|Budesonide|9 mg per day
41388466|NCT00488839|DRUG|IPX056 35 mg|IPX056 Extended Release capsule containing 35 mg baclofen
41388467|NCT00488839|DRUG|Placebo IPX056 20 mg|Placebo capsule for IPX056 20 mg
41388468|NCT00488839|DRUG|Placebo IPX056 40 mg|Placebo capsule for IPX056 40 mg
41388469|NCT04040907|DRUG|XNW3009|XNW3009 is a small molecule hURAT1 inhibitor
41388470|NCT04040907|DRUG|Placebo|Placebo and active drug will have the same appearance
41388471|NCT04503031|DEVICE|TaperGuard endotracheal tube|TaperGuard endotracheal tube is intubated
41511501|NCT01134432|DRUG|prednisolone + mabthera|"Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks"
41511502|NCT01134432|DRUG|Prednisolone|Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
41511503|NCT03481049|BEHAVIORAL|Usual CM|Behavioral reinforcement for alcohol abstinence
41038759|NCT00450086|DRUG|Mesalazine|3 g per day
41038760|NCT00450086|DRUG|Placebo|0 g per day
41388472|NCT04503031|DEVICE|cylindrical endotracheal tube|endotracheal tube is intubated
41388473|NCT01154673|DRUG|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
41388474|NCT01154673|DRUG|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
41511504|NCT03481049|BEHAVIORAL|High-Magnitude CM|Behavioral reinforcement for alcohol abstinence
41511505|NCT03481049|BEHAVIORAL|Shaping CM|Behavioral reinforcement for alcohol abstinence
41511506|NCT02681510|DRUG|Varenicline|Standard FDA approved 12 weeks of treatment with Varenicline
41511507|NCT02681510|DRUG|Nicotine Transdermal Patch|Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
41511508|NCT02681510|DRUG|Nicotine Mini|Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
41511509|NCT03530839|PROCEDURE|Arthrodesis|see study group description
41388475|NCT01154673|DRUG|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
41388476|NCT01154673|DRUG|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
41388477|NCT01728363|DRUG|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
41511510|NCT03530839|PROCEDURE|Resection arthroplasty|see study group description
41511511|NCT01407237|DRUG|Angiotensin II Infusion|Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
41511512|NCT06077812|BEHAVIORAL|RELAXaHEAD Smartphone App|Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.
41511513|NCT06077812|BEHAVIORAL|In-Person Training|Participants will receive in-person training in migraine self-management techniques.
41511514|NCT06077812|BEHAVIORAL|Virtual Training|Participants will receive virtual training in migraine self-management techniques.
41511515|NCT01982955|DRUG|Tepotinib|Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.
41511516|NCT01982955|DRUG|Gefitinib|Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.
40857439|NCT05001204|DRUG|68Ga-NOTA-RM26|68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
41388478|NCT00828581|DRUG|lorcaserin|
41388479|NCT03974217|DRUG|Talazoparib|Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate \[ADP\]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.
41388480|NCT03974217|DRUG|Decitabine|Decitabine is a drug that is meant to inhibit DNA methylation to restore normal functions to genes and helps to support normal cell production in the bone marrow and the death of abnormal bone marrow cells.
41511517|NCT01982955|DRUG|Pemetrexed|Pemetrexed was administered at a dose of 500 milligram per square meter (mg/m\^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
41511518|NCT01982955|DRUG|Cisplatin|Cisplatin was administered at a dose of 75 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
41511519|NCT01982955|DRUG|Carboplatin|Carboplatin was administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
41511520|NCT03159247|BEHAVIORAL|eyeGuide|The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
41038761|NCT00145093|DRUG|Baker's yeast (Bio Chromium)|
41038762|NCT01187693|OTHER|shoe lift|shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
41166838|NCT02291809|BIOLOGICAL|REMUNE|Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
41511521|NCT05545189|DIAGNOSTIC_TEST|colonoscopy,polypectomy|polyp removal during colonoscopy
41511522|NCT05932043|DIAGNOSTIC_TEST|This is a non-interventional study|None (this is a non-interventional study)
41511523|NCT03635476|OTHER|Qualitative interview study|The group in question is part of a research program aimed at developing and evaluating the LIFANA Nutrition Solution, a meal planning recommended system, which suggests meals based on the user's personal profile. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists.
41511524|NCT02904863|BIOLOGICAL|Extra blood draw samples|
41528368|NCT02510664|BEHAVIORAL|Diabetes Strengths Study|"The intervention consists of: (A) assessing youth and family diabetes strengths and adherence prior to each visit, and (B) training diabetes care providers to tailor their clinical encounters around reinforcing each patient and family's unique diabetes strengths profile generated from the strengths and adherence assessments."
41038763|NCT00206791|DEVICE|MBCP-Gel (tm)|
41038764|NCT05317234|GENETIC|Whole-exome sequencing|The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
41511525|NCT06198244|DEVICE|Transcutaneous Electrical Nerve Stimulation(TENS)|Defecation frequency per week, abdominal pain or discomfort, type of stool, severity of the constipation, frequency and consistency of stool, were measured before the commencement of treatment by using Romes-IV criteria, Visual Analogue Scale (VAS),Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS).After taking the measurements apply TENS on abdomen i.e. on the lower gastrointestinal tract, placed two skin electrodes of TENS on the abdomen lateral to the umbilicus and other two electrodes on back side at T9-L2 level for a month (20 minutes per session and 3 times a week) along with baseline treatment in which general movements were performed. After the completion of treatment same tools were used to re-assess the defecation frequency per week, abdominal pain or discomfort, type of stool, and severity of the constipation, frequency and consistency of stool for the measurement of final reading(Pre and post-treatment).
41511526|NCT06198244|OTHER|Baseline Treatment|In control group, after the recruitment of participants according to the inclusion criteria. The baseline measurement were recorded by using Romes-IV criteria, Visual Analogue Scale (VAS), Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS). The baseline treatment is given in which general movements were performed i.e. Double knee-to-chest movement, sitting, standing, rolling as well as stretching of calf, hamstrings, adductors of both sides. Again assess the patient severity of constipation, frequency and consistency of stool, abdominal pain and functional status after the end of last session of the treatment(Pre and Post-treatment method).
41388481|NCT04804293|DEVICE|FDA approved ultrasound system with shear wave elastography capability|The investigators will acquire at least 4 acquisitions for each of 2 locations on the wrist. The objective is to correlate SWE measurements with patient-reported measures of symptom severity and functional status scores and severity of pre-operative electrodiagnostic tests (EDX). Evaluate the treatment response to surgical decompression or corticosteroid injection, using quantitative SWE and correlate the results to repeated patient reported outcomes with Boston CTQ, and objective clinical improvement with Semmes-Weinstein monofilament evaluation for recovery of sensibility, and grip and lateral pinch strength.
41388482|NCT05480488|DRUG|Midazolam|Subjects will receive a single oral dose of 2 mg midazolam (Treatment A, B, and C).
41511527|NCT00000967|DRUG|Interferon alfa-2a|
41511528|NCT00000967|DRUG|Zidovudine|
41511529|NCT00001021|BIOLOGICAL|rgp120/HIV-1IIIB|
41511530|NCT00001021|BIOLOGICAL|rgp120/HIV-1MN|
41511531|NCT05110820|DIAGNOSTIC_TEST|Automated quantitative pupillometer|Quantitative measurement of pupillary variables was performed at the time of arrival at the ED (0 h), and at the 6-, 12-, and 24-h time points on hospital day (HD) 1. The worst value among those recorded within 24 h and during the total measurement period was selected as the 24-h and total lowest values. If a patient was discharged before HD 3, measurements were taken only until discharge. The initial value was measured within 1 h after arrival at the ED because of the requisite time for obtaining informed consent before enrollment. At each time point, the lowest values for the NPi and qPLR of each eye were retained for analysis. The sPLR (standard PLR) was serially measured in the ED and after admission by emergency physicians using a manual penlight. We classified the reactivity of the sPLR as reactive, sluggish, or non-reactive. Non-reactive sPLR was defined when pupillary reactivity was not identified bilaterally.
41511532|NCT06560918|DEVICE|hearing aids|OTC devices for a week
41038765|NCT01859481|DRUG|Placebo|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
41388483|NCT05480488|DRUG|Warfarin|Subjects will receive a single oral dose of 25 mg warfarin (Treatment A and B).
41388484|NCT05480488|DRUG|Daridorexant|Subjects will receive an o.d. oral dose of 50 mg daridorexant from Day 1 to Day 7 of Treatment B and a single oral dose of 50 mg daridorexant on Day 1 of Treatment C.
41388485|NCT03273712|RADIATION|90Y-DOTA tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.
41388486|NCT03273712|DIAGNOSTIC_TEST|68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
41388487|NCT03273712|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
41388488|NCT04217031|OTHER|No intervention|No intervention
41388489|NCT01413152|BIOLOGICAL|blood and semen sampling, specific biological exams and biobank and self administered questionnaires|blood and semen sampling, specific biological exams and biobank and self administered questionnaires
41388490|NCT05074602|DRUG|SHR8008|Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral
41388491|NCT05074602|DRUG|Fluconazole|Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral
41388492|NCT00386100|DRUG|Avandamet 6 mg/1500 mg (ttd)|One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
41166839|NCT01744756|DRUG|Bevacizumab|One subconjunctival aplication of Bevacizumabe 0,5ml
41388493|NCT00386100|DRUG|Avandamet 4 mg/1000 mg (ttd)|One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
41511533|NCT06072573|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
41511534|NCT06072573|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
41388494|NCT00386100|DRUG|Avandamet 2 mg/500 mg (ttd)|one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
41388495|NCT00386100|DRUG|Avandamet 8 mg/ 2000 mg (ttd)|Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
41166840|NCT05786456|PROCEDURE|Discussion|Participate in group and web-based self-study sessions
41388496|NCT00386100|DRUG|Metformin 500 mg (ttd)|One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
41388497|NCT00386100|DRUG|Metformin 1000 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
41511535|NCT03086486|DRUG|Pretomanid|200mg tablets
41511536|NCT03086486|DRUG|Linezolid|Scored 600mg tablets
41511537|NCT03086486|DRUG|Bedaquiline|100mg tablets
41511538|NCT03086486|DRUG|Placebo Linezolid|Scored 600 mg tablets
41511539|NCT00789035|DRUG|BI 10773|
41511540|NCT00789035|DRUG|placebo|
41511541|NCT00789035|DRUG|metformin|
41388498|NCT00386100|DRUG|Metformin 1500 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
41388499|NCT00386100|DRUG|Metformin 2000 mg (ttd)|Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
41388500|NCT01754480|BIOLOGICAL|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
41388501|NCT01754480|DEVICE|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
41511542|NCT03560128|DEVICE|Endocuff Vision device|Subjects randomized to undergo a colonoscopy procedure with the Endocuff Vision device will have this device placed on the colonoscope used during their procedure.
41511543|NCT03560128|DEVICE|AmplifEYE device|Subjects randomized to undergo a colonoscopy procedure with the AmplifEYE device will have this device placed on the colonoscope used during their procedure.
41511544|NCT02189837|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
41511545|NCT02189837|DRUG|Atorvastatin|Administered by mouth
41511546|NCT02189837|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
41511547|NCT02189837|DRUG|Placebo to Atorvastatin|Administered by mouth
41511548|NCT05187728|OTHER|No Intervention|No more intervention will be given.
40857440|NCT03614325|OTHER|Virtual Reality Immersive Relaxation|The software developed by VRHealth allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
40857441|NCT02430857|OTHER|OMT|Manuel osteopathic treatment of the spine
41166841|NCT05786456|OTHER|Informational Intervention|Receive handouts
41166842|NCT05786456|OTHER|Media Intervention|View videos
41166843|NCT05786456|OTHER|Questionnaire Administration|Ancillary studies
41166844|NCT05786456|BEHAVIORAL|Telephone-Based Intervention|Participate in check-in calls
41388502|NCT00303134|DRUG|Islet Cell Transplantation|Islet Cell Transplantation for patients with type 1 diabetes mellitus
41388503|NCT01544816|OTHER|Snack Product|control food product
41388504|NCT01544816|OTHER|Snack Product|Experimental food product containing ingredient 1
41388505|NCT01544816|OTHER|Snack Product|Experimental food product containing ingredient 2
41388506|NCT06132100|DEVICE|digitalized incentive spirometry|digitalized incentive spirometry
41388507|NCT06132100|DEVICE|traditional incentive spirometry|traditional incentive spirometry
41388508|NCT05083468|DRUG|SR750 tablet|The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.
41388509|NCT05083468|DRUG|matching placebo|The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.
41388510|NCT00774202|DRUG|Rituxan, Cyclophosphamide, Vincristine, Prednisone|'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.
41388511|NCT00774202|DRUG|Higher Dose of Rituximab|rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
41511549|NCT03392350|BEHAVIORAL|Physician Body Scan Consultation with Behavioral Intervention|The RENEW™ program consisted of 7 bi-monthly face-to-face web sessions over 16-18 weeks followed by an average of 15 monthly check-in sessions (maintenance) over 80 weeks.This included modules on responding to stress, enhancing effects of relaxation, nourishing theimmune system, physical activity, and social support.
41511550|NCT06563895|DRUG|Acoramidis|TTR stabilizer administered orally twice daily (BID)
41511551|NCT06563895|DRUG|Placebo oral tablet|Non-active control administered orally twice daily (BID)
41511552|NCT05881434|OTHER|Emergency Department Visit Expectations Questionnaire|Patients presented with novel questionnaire designed to illicit patient's self-reported expectations across four domains (overall purpose of visit, medication intervention, imaging intervention and disposition) during check-in when arriving at the emergency department. Patients instructed to present the completed questionnaire to the treating provider.
41388512|NCT03663959|PROCEDURE|vaginal sacrospinous fixation procedure with dr.Aksakal's desta suture carrier|A right sacrospinous fixation using Dr. Aksakal's Desta suture carrier with two permanent sutures that combined the sacrospinous ligament and vaginal cuff fascia was done. The Desta suture carrier was developed for deep pelvic surgery, and the suture depth can be easily adjusted. After the vaginal hysterectomy, under the vaginal cuff mucosa, we created a tunnel through the spinous process with a straight tool. After passing the rectovaginal pillars, the perirectal space was entered and the ischial spine was palpated. With the help of an index finger placed on the spinous process, we placed two permanent sutures 1.5-2 cm medial to the spinous process on the sacrospinous ligament and iliococcygeus muscle complex using the Desta suture carrier. Next, permanent sutures were combined with the pubocervicovaginal and rectovaginal fascia under the vaginal cuff mucosa.
41388513|NCT03663959|PROCEDURE|Laparoscopic Pectocolpopexy procedure|First, the peritoneal layer above and lateral to the bladder was opened parallel to the round ligament toward the pelvic side wall on the right side. Then, with the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medial to the external iliac vein, the iliopectineal ligament was found . At this point, a segment of approximately 3-4 cm2 was formed, exposing the iliopectineal (Cooper's) ligament. In this area, behind the obliterated umbilical artery, the obturator nerve could be seen, and special care was given not to make contact with the nerve. The same area on the left side was prepared using the same steps. Then, anterior part of the vaginal cuff was prepared for mesh fixation. Bilaterally, the ends of a polypropylene monofilament mesh (1,5x15 cm) were fixed to the iliopectineal ligament with nonabsorbable polypropylene or polyester sutures . The vaginal cuff was elevated to POP-Q level 0-1.
41388514|NCT00005879|DRUG|arzoxifene|one tablet daily
41511553|NCT05967884|DRUG|Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab|Arm A: Cemiplimab: 350mg IV x 1 dose administered prior to surgery Arm B: Cemiplimab + Dupilumab: Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery
41511554|NCT04198272|BEHAVIORAL|CyberRwanda|The CyberRwanda intervention consists of three primary components: 1. STORIES: The CyberRwanda curriculum empowers youth to learn about family planning and reproductive health and employment skills and to set goals for their futures through age-appropriate, interactive, digital and printed stories and activities. 2. LEARN: Q\&As and videos related to family planning and reproductive health. 3. SHOP: Youth can directly purchase health products, including menstrual hygiene and contraceptive products (emergency contraception, condoms, and oral contraceptive pills) online. The online health facility finder tool links youth to health facilities for longer-acting methods. All participating pharmacies will be trained to give unbiased, nonjudgmental information and services.
41511555|NCT02605915|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
41511556|NCT02605915|DRUG|Carboplatin|Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter\*min (mg/mL\*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.
41511557|NCT02605915|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 administered via IV infusion on Day 1 every 21-days for 6 cycles.
41511558|NCT02605915|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.
41511559|NCT02605915|DRUG|Trastuzumab|Trastuzumab 8 milligram per kilogram (mg/kg) loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
41511560|NCT02605915|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle. Dose de-escalation may occur for trastuzumab emtansine, from the full trastuzumab emtansine dose at 3.6 mg/kg on Day 1 of every 21-day cycle, potentially to 3.0 mg/kg (Cohort 1C) or 2.4 mg/kg q3w (Cohort 1D).
41511561|NCT02605915|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.
41038766|NCT01859481|DRUG|Eletriptan HBr 40 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
41511562|NCT02605915|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.
41511563|NCT01570686|DRUG|Aliskiren|Aliskiren 300 mg once daily
41511564|NCT03617666|DRUG|Avelumab|Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab 10 mg/kg intravenously given every 2 weeks.
41038767|NCT01859481|DRUG|Eletriptan HBr 80 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
41511565|NCT00900419|OTHER|immunohistochemistry staining method|Laboratory test
41511566|NCT00900419|OTHER|laboratory biomarker analysis|Laboratory Test
41511567|NCT00900419|OTHER|sputum cytology|Laboratory Test
41511568|NCT00900419|PROCEDURE|biopsy|Laboratory Test
41511569|NCT06197178|BIOLOGICAL|LCAR-G08 cells|Prior to infusion of the LCAR-G08, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
41388515|NCT00005879|DRUG|Placebo|matched tablet dialy
41388516|NCT01106118|DRUG|Vardenafil (Levitra, BAY38-9456)|Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician
41511570|NCT02862015|OTHER|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
41511571|NCT02862015|DRUG|FOLFIRINOX or Gemcitabine based chemotherapy|As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
41511572|NCT06241625|DIAGNOSTIC_TEST|Virtual Reality (VR) Contrast Function Test|Patients perform a new Virtual Reality (VR) Contrast Function Test
41038768|NCT04099810|DIAGNOSTIC_TEST|three-dimensional echocardiography|"A focused echocardiographic exam will be performed. In details will be acquired:~* high frame rate imaging clips acquired in a static position with attention to endocardial border optimization, minimum of 3 beats recorded with 'Acquire 2', of: a. Left ventricle 2c/3c/4c; b. left ventricle SAB, SAX-M, SAX-A; c. right ventricular focused apical view.~* Full volumes: a. 3d left ventricular apical acquisition; b. right ventricular apical acquisition; c. subcostal right ventricular acquisition."
41038769|NCT03178266|DEVICE|Knee Arthroplasty|Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
41038770|NCT04999813|COMBINATION_PRODUCT|Comprehensive intensive intervention|"* Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy~  * Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.~    * Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.~      * Weight loss guidance."
41166845|NCT03453424|PROCEDURE|TEA+DEX|intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.
41166846|NCT03453424|PROCEDURE|TEA|"Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.~then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml."
41166847|NCT03030105|DRUG|BPN14770|investigational drug
41166848|NCT03030105|DRUG|BPN14770 placebo|placebo
41388517|NCT03865992|DIETARY_SUPPLEMENT|Curcumin|Given capsules for oral administration
41388518|NCT03865992|OTHER|Placebo|Given capsules for oral administration
41511573|NCT03687840|DIAGNOSTIC_TEST|gait analysis|Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
41511574|NCT03166098|DIAGNOSTIC_TEST|Cognitive Function Assessments|The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
41511575|NCT00626457|BEHAVIORAL|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
41511576|NCT04394039|OTHER|Public space exposure|landscapes with nature and/or classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to noncontemplative ones.
41388519|NCT03865992|OTHER|Nanoemulsion|Given nanoemulsion curcumin PO
41388520|NCT03865992|OTHER|Quality-of-Life Assessment|Ancillary studies
41388521|NCT03865992|BEHAVIORAL|Questionnaire|Ancillary studies
41388522|NCT03179956|DRUG|Ribociclib|Treatment with ribociclib \[600mg\] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
41388523|NCT01850108|DRUG|Thymoglobulin|"Day 9 before BMT: 0.5mg/kg IV; Days 8 \& 7 before BMT: 2mg/kg IV~Days 8 \& 7 - 2mg/kg IV before BMT"
41388524|NCT01850108|DRUG|Fludarabine|Days 6 and 2 before BMT: 30mg/m2/day IV
41388525|NCT01850108|DRUG|Cyclophosphamide (CTX)|Days 6 and 5 before BMT: 14.5mg/kg IV; Days 3 and 4 after BMT: 50mg/kg/day
41388526|NCT01850108|DRUG|Mesna|Days 3 \& 4 after BMT: 40 mg/kg IV
41388527|NCT01850108|DRUG|Sirolimus|Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
41388528|NCT01850108|DRUG|Mycophenolate mofetil (MMF)|15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
41388529|NCT01850108|PROCEDURE|Bone marrow transplantation|Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
41038771|NCT06473896|DRUG|Ketalar|a dissociative anesthetic used medically for induction and maintenance of anesthesia
41511577|NCT05778578|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
41511578|NCT05565430|OTHER|Acute Hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
41388530|NCT01850108|RADIATION|Total body irradiation|200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
41388531|NCT02011516|DRUG|Baclofen|
41511579|NCT05565430|OTHER|Chronic hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
41511580|NCT05565430|DRUG|Effects of anticholinergic medication|Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.
41511581|NCT00691730|OTHER|laboratory biomarker analysis|Only sample collection, no other intervention - Correlative studies
40857442|NCT00962325|BEHAVIORAL|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
40857443|NCT03781440|PROCEDURE|Bilateral ESP catheter with lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
40857444|NCT03781440|PROCEDURE|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
40857445|NCT00209859|DRUG|Methotrexate|
40857446|NCT00209859|DRUG|Intraarticular betamethasone|
40857447|NCT00209859|DRUG|Cyclosporine/placebo-cyclosporine|
40857448|NCT01645410|DRUG|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
40857449|NCT03255551|DRUG|Amosartan|amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
40857450|NCT01857297|BIOLOGICAL|Enzira® vaccine|
40857451|NCT06535620|OTHER|red wine with alcohol|200 ml of red wine - Demi sec Bordeaux wine 'La Dorni' (alcohol content at 20ºC of 10.1% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
40857452|NCT06535620|OTHER|red wine without alcohol|200 ml of red wine without alcohol - Demi sec Bordeaux wine 'Casa Navaronne' (alcohol content at 20ºC of 0.23% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
40857453|NCT02458781|DRUG|Metronidazole|Metronidazole 500mg given twice daily for 14 days
40857454|NCT02458781|DRUG|Ciprofloxacin|Ciprofloxacin 500mg given twice daily for 14 days
40857455|NCT02458781|DRUG|Placebo|Placebo given twice daily for 14 days
41038772|NCT06473896|DRUG|Dexmedetomidine|an agonist of α2-adrenergic receptors in certain parts of the brain used for sedation
41388532|NCT02011516|BEHAVIORAL|Psychosocial|
41388533|NCT02011516|DRUG|Placebo|
41038773|NCT05627128|OTHER|DAIN|Participants in the experimental arm will have access to the newly created DAIN curriculum including menus, recipes, and recorded 'how to' recipes. Participants in the experimental arm will also have once-per-week dietary counseling with DAIN-trained nutritionists and monthly cooking classes with a DAIN-trained chef.
41038774|NCT04433169|DRUG|All-trans Retinoic Acid|ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles
41038775|NCT04433169|DRUG|VEGFR inhibitor|VEGFR inhibitor
41038776|NCT04433169|DRUG|Chemotherapy|chemotherapy
41388534|NCT00666718|DRUG|Insulin Glargine|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
41388535|NCT00666718|DRUG|Insulin Lispro Protamine Suspension (ILPS)|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
41388536|NCT00666718|DRUG|Insulin Lispro|subcutaneous injections prior to meals, 24 weeks
41388537|NCT05303844|DRUG|H101|H101 intratumorally injection starts at day 0.
41511582|NCT05646459|DRUG|cannabidiol|This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
41511583|NCT05646459|DEVICE|floss|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
41511584|NCT05646459|DEVICE|proxabrush|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
41511585|NCT04513392|PROCEDURE|Laser treatment|A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.
41511586|NCT06551337|DRUG|Vitamin D3|The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU.
41511587|NCT06133361|BIOLOGICAL|PRP injection|The PRP will be prepared according to a well-established technique and then injected into the palatal mucosa of the upper anterior teeth before retraction.
41511588|NCT06133361|PROCEDURE|En-masse retraction of upper anterior teeth|The anterior teeth will be moved backward in an en-masse retraction way using a frictionless method. The anterior teeth will be manipulated as one block. Coil springs will be stretched between the power arms (in the anterior area) to the miniscrews placed in the posterior area bilaterally.
41528369|NCT06273514|OTHER|TECAR|"TECAR therapy performs using a WINBACK® 1s device (Daeyang Medical Co. Ltd, South Korea) with a maximum power of 100W. A 500 kHz frequency capacitive electrode is applied directly to the active MTrP in the UT. The closed electrode is placed distally on the arm. Lowpulse modulation use during treatment with half-second pauses. This enables the application of the current directly into the MTrP without enrolling the entire muscle. The single exposure last for 10 min. The current dose participant-dependent and ranged from 40 to 60% (100% = 100 Watts).~Each time, before and after treatment, and 30 days after the first therapy, the following features will be asses: pain intensity, muscle strength, and ROM."
40857456|NCT05137899|COMBINATION_PRODUCT|Neoadjuvant|Neoadjuvant atezolizumab/bevacizumab or neoadjuvant SBRT prior to hepatectomy
41388538|NCT05303844|DRUG|Tislelizumab|Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
41038777|NCT06356064|DEVICE|Extracorporeal shock wave therapy|Radİal ESWT and focus ESWT
41038778|NCT02119416|DRUG|Placebo Administration first|"All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg"
41038779|NCT02119416|DRUG|Low Caffeine Administration first (1mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg"
41038780|NCT02119416|DRUG|High Caffeine Administration first (2mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg"
41038781|NCT02474927|DRUG|Carfilzomib|Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)
41038782|NCT00829387|BEHAVIORAL|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
41038783|NCT00829387|BEHAVIORAL|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
41038784|NCT03886818|DEVICE|Standard dressings|Standard dressings will be used from surgery to wound healing
41038785|NCT03886818|DEVICE|PICO strategy|The PICO system with negatif pression will be used from surgery to day 7. After that, standard dressing will be used untill the wound Healing.
41038786|NCT01657422|BEHAVIORAL|PACE+|Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
41038787|NCT01126593|DRUG|0.5% bupivacaine|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.
41388539|NCT01251692|PROCEDURE|Surgery|The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
41388540|NCT02983227|DRUG|GDC-0853|GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
40857457|NCT05047952|DRUG|Vortioxetine|"Participants aged 18-64 years receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.~Per product monograph, participants aged 65+ years receiving vortioxetine will be provided 5 mg/day on days 1-14 of the treatment period, and will be titrated to 10 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 10 mg/day, unless adjudicated otherwise by a study clinician."
41038788|NCT01126593|DRUG|Normal Saline|The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
41511589|NCT05596656|DIAGNOSTIC_TEST|skin prick test|"Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet."
40857458|NCT05047952|DRUG|Placebo|A placebo pill will be taken once daily.
41038789|NCT01490632|DRUG|Placebo|Administered orally
41511590|NCT00633347|DRUG|Antagonist GnRH Cetrotide|Cetrotide 0.25 mg. daily/ 7 days
41511591|NCT00633347|DRUG|Agonist GnRH Acetate Triptoreline|Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
40857459|NCT03731247|DEVICE|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
40857460|NCT03731247|DEVICE|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
40857461|NCT02148055|OTHER|Comparaison between MR and autopsy in the macroscopic evaluation of intra uterine death.|
41038790|NCT01490632|DRUG|Baricitinib|Administered orally
41038791|NCT00373776|DRUG|miltefosine 2.5 mg/kg/day for 28 days|
41038792|NCT04592068|DEVICE|Retinal multi-diseases diagnosed by DL algorithm|DL algorithm automatically classify multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
41038793|NCT04592068|OTHER|Retinal multi-diseases diagnosed by expert panel|Expert panel classifies multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
41038794|NCT03762395|DRUG|CXA-10|6 weeks of treatment with 150 mg/day of orally administered CXA-10
41038795|NCT03762395|DRUG|Matching Placebo|6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
41038796|NCT04092218|OTHER|Questionnaire|"Data will be obtained through a written questionnaire to determine the type of parenting style of parents or caregivers.~The collected data will be saved and tabulated on computer and finally statistically analysed."
41038797|NCT02000245|BEHAVIORAL|verbal expression for compassion|The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)
41038798|NCT02000245|BEHAVIORAL|touch|The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
41038799|NCT00498719|BEHAVIORAL|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
41038800|NCT00498719|OTHER|Control Group|Standard educational support.
41038801|NCT00313404|BIOLOGICAL|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
41038802|NCT03667027|DEVICE|Respiratory support|Mechanical ventilation or extracorporeal life support
41038803|NCT04396834|DRUG|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
41038804|NCT04396834|DRUG|Placebo oral tablet|Placebo Oral Tablet (BID)
41511592|NCT03389516|OTHER|Polymem|wound care dressings
41511593|NCT03389516|OTHER|Lanolin|wound care oinment
41511594|NCT02240615|DEVICE|Sinopsys Lacrimal Stent|Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
41511595|NCT06359912|DRUG|EPCs|IV
41511596|NCT06359912|BEHAVIORAL|Clinical standard treatment (CST)|Clinical standard treatment
41038805|NCT02544243|DRUG|Vinorelbine|
41038806|NCT02544243|DRUG|Gemcitabine|
41038807|NCT02544243|DRUG|Cisplatin|
41511597|NCT04214197|DRUG|Crisaborole 2% Top Oint|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
41038808|NCT05121753|DIETARY_SUPPLEMENT|Survey investigating Infant formula feeding in newborns|A database will be created that allows individuals to register and enter information about the premature infant's feeding history and symptoms/ medical history.
41511598|NCT00032383|BEHAVIORAL|Tai Chi|
41511599|NCT04007198|DRUG|EQ001|Itolizumab \[Bmab 600\]
41511600|NCT04007198|DRUG|EQ001 Placebo|EQ001 Placebo
41511601|NCT02439216|DRUG|Edasalonexent|
41038809|NCT01037348|DRUG|ranibizumab 0.5mg|
41511602|NCT02439216|DRUG|Placebo|
41511603|NCT05052112|OTHER|E-PR-01|Active arm
41511604|NCT05052112|OTHER|E- PR-02|Placebo arm
41511605|NCT06456242|BEHAVIORAL|CounsCM+MedCM (Health Rewards)|Small financial incentives for completing quitline calls (CounsCM) plus small financial incentives for taking varenicline (MedCM).
41511606|NCT02717455|DRUG|LBH589|"STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria."
41511607|NCT03751007|BIOLOGICAL|AG019 - Low Dose|Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)
41038810|NCT04740515|OTHER|pharmacists involved PPMTM|This was an open labelled randomised study. Preterm Infants With iron supplementation were recruited and arbitrarily divided into the intervention group (usual care plus PPMTM) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
41038811|NCT03903133|DRUG|Vitamin E|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
41038812|NCT04499794|DRUG|ALK inhibitor|ALK inhibitor treatment on ALK fusion positive NSCLC patients
41038813|NCT05330962|OTHER|Framingham study cardiovascular disease 10-years risk assessment score|A personal interview questionnaire
41038814|NCT05844813|DRUG|Doxorubicin+Ifosfamide+Anlotinib(AI+A)|Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks \* 3 Circles
41038815|NCT05844813|PROCEDURE|Radical Surgery|Radical sarcoma resectional surgery
41038816|NCT06155968|PROCEDURE|QL block|"The curvilinear probe (2 5 MHz, SonoSite Turbo M) is placed in the transverse axial plane just cranial to the iliac crest. The shamrock sign was visualised (viz., the transverse process (TP) of vertebra L4 is the stem, whereas the erector spinae muscle (ESM) posteriorly, quadratus lumborum (QL) muscle laterally and the psoas major (PM) muscle anteriorly represent the three leaves). The needle is introduced using an in plane technique from the posterior end of the transducer through the QL muscle. The target for injection is the fascial plane between the QL and PM muscles.."
41038817|NCT06155968|DRUG|PCA|the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min
41038818|NCT04458350|BEHAVIORAL|Digital Promotions Group|Digital promotions on the Fresh EBT app and Facebook will run for 13 weeks, advertising a SNAP fruit and vegetable incentive at farmers' markets in New England. The intervention will be applied to zip codes randomized to the intervention arm.
41038819|NCT02723838|BIOLOGICAL|REOLYSIN®|3 cycles (each cycle = 21 days). Cohort 1: 3x10E10 TCID50 intratumoral via cystoscopy on Day 1 of each cycle. Cohort 2: 3x10E10 TCID50 intratumoral via cystoscopy on Day 2 of each cycle.
41166849|NCT03030105|DRUG|Donepezil|comparator
41166850|NCT03030105|DRUG|Donepezil placebo|placebo
41166851|NCT03030105|DRUG|Scopolamine 0.6 MG/ML|cognition impairment
41511608|NCT03751007|DRUG|Teplizumab|Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).
41511609|NCT03751007|DRUG|Placebo-AG019|Formulated identically to AG019 with the active ingredient removed.
41511610|NCT03751007|DRUG|Placebo-Teplizumab|Formulated identically to teplizumab with the active ingredient removed.
41511611|NCT03751007|BIOLOGICAL|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks
41511612|NCT03751007|BIOLOGICAL|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 8 weeks.
41511613|NCT01445704|DIETARY_SUPPLEMENT|Probiotics|"The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05."
40857462|NCT01005095|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
41388541|NCT06423937|DRUG|combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab|"Procedure/Surgery: HAIC After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.~TOMOX（Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2）/ TOMIRI（Raltitrexed 2 mg/m2 ，Irinotecan 120mg/m2） Drug: Fruquintinib 3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC Drug: Camrelizumab 200mg, ivgtt,, 21 days for a cycle"
41388542|NCT05214599|DRUG|Budesonide Gel|Twice daily regimen
41388543|NCT03210142|PROCEDURE|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation to open upper airway.
41388544|NCT04187469|DRUG|Moxifloxacin, Isoniazid, Rifampicin|"Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day \> 50 kg 600 mg/day, Isoniazid 300 mg/day.~All treatment is taken daily, for a duration of up to 6 months depending on treatment arm."
41388545|NCT04187469|DRUG|Rifampicin,Isoniazid,Pyrazinamide,Ethambutol|"Rifampicin ≤50 kg 450 mg/day, \>50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, \>50 kg 1000mg/day.~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
41388546|NCT01135901|BEHAVIORAL|Behavioural change programme|The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
41388547|NCT05860712|OTHER|Irrigation|Cinnamon to be prepared were mixed with 50% ethanol and this suspension was placed on the magnetic stirrer for 4 hours.Whitman's filter paper was used to obtain the filtrate which was then dried to obtain the extract. The extract was dried to evaporate the solvent to prevent the influence of extracting agent (ethanol) on the final extract. Cinnamon extract was obtained using cinnamon bark which was pulverized into medium coarse granules. The extracting agent and the procedure to obtain the final extract.These extracts were stored in dark coloured bottles at 4 degree Celsius until use.
40857463|NCT01005095|DIETARY_SUPPLEMENT|Vitamin D3|Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
40857464|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 6.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
40857465|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 12.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
40857466|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 18.75mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
40857467|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 25.0mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
40857468|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 31.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
40857469|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 37.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
40857470|NCT05924594|DRUG|Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
40857471|NCT04833114|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
40857472|NCT04833114|DRUG|Mabthera|Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
40857473|NCT04833114|DRUG|Ifosfamide|Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
40857474|NCT04833114|DRUG|Carboplatin|Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
40857475|NCT04833114|DRUG|Etoposide|Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
40857476|NCT03186027|DIETARY_SUPPLEMENT|Coenzyme Q10 plus NADH|"Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect"
40857477|NCT03186027|DIETARY_SUPPLEMENT|phosphoserine plus vitamin C|"Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo"
40857478|NCT01866358|PROCEDURE|Intraosseous infusion|Using intraosseous infusion for resustation in this group
40857479|NCT01866358|PROCEDURE|Umbilical vein infusion|Using umbilical vein infusion for resustation in this group
40857480|NCT00743782|DRUG|Synthetic Human Parathyroid Hormone 1-34|
41038820|NCT02723838|DRUG|Gemcitabine|3 cycles (each cycle = 21 days). Cohort 1: 1000mg/m2 intravenously on Day 2 and Day 9 of Cycle 2 and Cycle 3. Cohort 2: 1000mg/m2 intravenously on Day 1 and Day 8 of each cycle.
41038821|NCT02723838|DRUG|Cisplatin|3 cycles (each cycle = 21 days). Cohort 1: 70 mg/m2 intravenously on Day 2 of Cycle 2 and Cycle 3. Cohort 2: 70 mg/m2 intravenously on Day 1 of each cycle.
41038822|NCT05394246|DRUG|FluoAB|Drug Injection: FluoAB (fluorescent-labeled IgG)
41388548|NCT00296582|BEHAVIORAL|Gastric Motor Function Measurement|
41511614|NCT01445704|DIETARY_SUPPLEMENT|Placebo|The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
41038823|NCT03832127|DRUG|18F-Fludarabine|Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma
41388549|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"* Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
41388550|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"* Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
41388551|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
41511615|NCT03775486|DRUG|Durvalumab|Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
41511616|NCT03775486|DRUG|Placebo for Olaparib|Matching tablet
41511617|NCT03775486|DRUG|Olaparib|150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
41511618|NCT03775486|DRUG|Nab-paclitaxel+carboplatin|Standard of Care chemotherapy (squamous and non-squamous patients)
41511619|NCT03775486|DRUG|Gemcitabine+carboplatin|Standard of Care chemotherapy (squamous patients only)
41511620|NCT03775486|DRUG|Pemetrexed+carboplatin|Standard of Care chemotherapy (non-squamous patients only)
41511621|NCT03775486|DRUG|Gemcitabine+cisplatin|Standard of Care chemotherapy (squamous patients only)
41511622|NCT03775486|DRUG|Pemetrexed+cisplatin|Standard of Care chemotherapy (non-squamous patients only)
41511623|NCT05968300|BEHAVIORAL|INFORMED-Living Well|1) LHW outreach support providing responsive education and support; and 2) a 6-week automated SMS text messaging
41511624|NCT05968300|BEHAVIORAL|Text Messaging Only|A 6-week automated SMS text messaging
41511625|NCT04283422|DIAGNOSTIC_TEST|Biofire filmarray|"Identification of microorganisms including:~1. Isolation of microorganisms:~   The sample will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates,~2. Identification of the organism by Vitek2~3. Antibiotic sensitivity test of the organism by Vitek2~4. Identification of the organism by Biofire filmarray"
41511626|NCT04555434|DIETARY_SUPPLEMENT|Probiotics|"* Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10\^9 CFU / day)~* Control group Main ingredient: Crystalline cellulose"
41038824|NCT05314439|DRUG|ION904|ION904 will be administered by SC injection.
41038825|NCT05314439|DRUG|Placebo|Placebo will be administered by SC injection.
41038826|NCT00233077|BEHAVIORAL|Patient Assistance|Patients will be surveyed to assess their knowledge about cancer \& its treatment, experience with \& access to health care system, trust, depression, social support \& self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
41038827|NCT00233077|BEHAVIORAL|Information only|Control patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
41038828|NCT01973933|DRUG|Metformin and Pyrimethamine|
41038829|NCT01564550|DRUG|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
41038830|NCT01564550|DRUG|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
41038831|NCT01564550|OTHER|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
41038832|NCT01564550|OTHER|no diet|The subjects will ingest a non-restricted diet prior to the study day.
41038833|NCT00717860|DRUG|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
41038834|NCT00717860|DRUG|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
41166852|NCT03030105|DRUG|Scopolamine placebo|placebo
41388552|NCT04178018|DEVICE|Photoacoustic imaging|-Emerging technique in which a short-pulsed laser beam penetrates diffusively into a tissue sample
41528370|NCT06273514|OTHER|Dry needling|"Dry needling performs using SOMA needles (25 mm x 0.3 mm). During the therapy, the participant is in a prone position. The affected UT region is disinfect before needling. The taut band localizes between the thumb and index finger of the researcher. The needle within the plastic guide tube is place over the MTrP at the UT. The needle directly inserts into the MTrP. A local twitch response confirms the accuracy of the puncture. Needling performs using Hong's fast in, fast out technique. The needle will be withdrawn if no twitching will observe."
41528371|NCT00504712|DRUG|Testosterone|Sustanon- 200mg- Intramuscular testosterone every 2 weeks
41388553|NCT04178018|DEVICE|Ultrasound|-The ultrasound is being used in conjunction with the photoacoustic imaging
41511627|NCT04902014|BEHAVIORAL|Motivational Interviewing|The individuals will be scheduled for and participate in six biweekly in person SDT based MI sessions. These sessions will take place in the HPCRL at CSU. The MI sessions will be conducted by a PhD student who has been trained by a MI practitioner. Participants will be provided a log book and will be asked to log their PA, with the goal of completing at least 150 minutes of PA per week. They will set biweekly PA goals, which will be discussed in the MI sessions. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
41511628|NCT04902014|BEHAVIORAL|Education|These participants will receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting. These participants will not do any other study related activities. At the conclusion of the study, these participants will be offered the chance to participate in one MI session.
41528372|NCT00504712|DRUG|saline|Saline injection every two weeks
41528373|NCT01383707|DRUG|5-Fluorouracil (5-FU)|Participants will receive 5-FU 400 mg per meter-squared (mg/m\^2) IV dose on Day 1 of each 2 weeks' cycle followed by 2400 mg/m\^2, continuous infusion over 46 hours up to 12 cycles.
40857481|NCT05429398|DRUG|Linperlisib Tablet|"1. Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~2. Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib."
41528374|NCT01383707|DRUG|Bevacizumab|Participants will receive 5 mg/kg bevacizumab IV dose on Day 1 of each 2 weeks' cycle up to Cycle 5 and thereafter cycles 7 to 12; followed by maintenance therapy of 5 mg/kg IV every 2 weeks up to 52 weeks (26 cycles).
40857482|NCT02898402|PROCEDURE|blood sample and questionnaire|In addition to normal blood sample performed at entry before delivery, an extra 5 ml blood sample will be taken to establish Q fever serodiagnosis and a short questionnaire will be filled in for clinical and epidemiological data.
40857483|NCT03570814|DRUG|Administration of Albendazole on Day 1|Participants will receive Albendazole 400mg on study day 1.
40857484|NCT03570814|DRUG|Administration of Ivermectin on Day 1|Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
40857485|NCT03570814|DRUG|Administration of Azithromycin on Day 1|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
40857486|NCT03570814|DRUG|Administration of Azithromycin on Day 15|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
40857487|NCT03956524|BIOLOGICAL|EuTCV|Single 0.5 mL dose of TCV of EuBiologics co., Ltd.
40857488|NCT03956524|BIOLOGICAL|Typbar-TCV™|Single 0.5 mL dose of TCV of Bharat Biotech
40857489|NCT03956524|BIOLOGICAL|Typhim Vi®|Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur
40857490|NCT03330795|BIOLOGICAL|CD3/CD19 neg allogeneic BMT|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
40857491|NCT01822262|PROCEDURE|minimally invasive cholecystolithotomy with gallbladder reservation|
40857492|NCT01822262|PROCEDURE|laparoscopic cholecystectomy|
40857493|NCT05037019|PROCEDURE|Radiation therapy|Women diagnosed with early stage breast cancer are given a single dose of stereotactic body radiation therapy (SBRT) prior to any other treatment in the context of delayed lumpectomy due to the COVID-19 pandemic.
40857494|NCT00410007|BEHAVIORAL|High Sodium Diet|250-350 mmol
40857495|NCT00410007|BEHAVIORAL|Low Sodium Diet|25-35 mmol
40857496|NCT00410007|BEHAVIORAL|Hypertonic saline infusion|7 ml/ kg of 3% saline were given over 30 minutes.
40857497|NCT01593592|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
40857498|NCT01593592|DIETARY_SUPPLEMENT|Placebo|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
40857499|NCT01593592|DRUG|Omeprazole|All patients will receive omeprazole 20 mg b.i.d for 2 week
40857500|NCT01593592|DRUG|Amoxicillin|amoxicillin 1000 mg b.i.d for 2 weeks
40857501|NCT01593592|DRUG|Clarithromycin|clarithromycin 500mg b.i.d for 2 weeks
40857502|NCT03285269|DIAGNOSTIC_TEST|Ultrasound Protocol|Ultrasound of the inferior vena cava, heart and lungs.
40857503|NCT03285269|DEVICE|Bioreactance|Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
41388554|NCT02499406|BEHAVIORAL|Dialectical behavior therapy skills group|Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
41388555|NCT03107442|BEHAVIORAL|Aerobic exercise|12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous \[40-85% of the individual's heart rate reserve\] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
41388556|NCT01422720|DRUG|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
41388557|NCT05924568|OTHER|Educational session with Keep Your Move in the Tube and PrimusRS|
41388558|NCT03946111|DRUG|Naltrexone and Bupropion|Participants randomly assigned to this arm will receive 12 weeks of Naltrexone and Bupropion medication.
41388559|NCT03946111|OTHER|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
41388560|NCT02670512|DEVICE|Telehome Monitoring|
41528375|NCT01383707|DRUG|Levofolinic acid|Participants will receive levofolinic acid 200 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
41166853|NCT04158973|OTHER|Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge|At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
41388561|NCT06537102|OTHER|Unilateral laparoscopic ovarian drilling|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Unilateral: was done on the larger ovary."
41388562|NCT06537102|OTHER|Bilateral laparoscopic ovarian drilling|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Bilateral: Using dose adjusted according to ovarian volume."
41388563|NCT05284474|DIAGNOSTIC_TEST|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF)|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF) will be incorporated to the management of early-onset small fetuses (estimated fetal weight ≤10th percentile)
41388564|NCT03213769|DRUG|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
41166854|NCT04158973|OTHER|Routine VTE prophylaxis in hospital|Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
41388565|NCT03213769|DRUG|Carpabol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
41388566|NCT04616079|DRUG|REGN6490|Single dose of REGN6490
41388567|NCT04616079|DRUG|Placebo|Placebo matching single dose of REGN6490
41388568|NCT00872365|BEHAVIORAL|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
41528376|NCT01383707|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
41166855|NCT05447728|DIAGNOSTIC_TEST|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
41388569|NCT00872365|DIETARY_SUPPLEMENT|Micronutrients|Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
41388570|NCT00872365|OTHER|Activities of daily living + placebo|"Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.~Placebo Comparator: Equivalent to placebo (maltodextrin)."
41388571|NCT00081835|DRUG|NP-016 Vaccine Immune Globulin (IV-VIG)|
41166856|NCT05447728|DIAGNOSTIC_TEST|PRESTO|The PRESTO study is a group of 8 pre-hospital stroke scales used to detect large vessel occlusion strokes.
41528377|NCT01831076|DRUG|Exemestane|Given PO
41528378|NCT01831076|DRUG|Exemestane and tamoxifen|exemestane 25 mg po daily and tamoxifen 20 mg po daily given concurrently for 4 months prior to surgery
41528379|NCT01870011|DRUG|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
41166857|NCT03354234|OTHER|Head up tilt (HUT)|Model of -Gz: HUT up to 75 degrees (maximum)
41166858|NCT03354234|OTHER|Lower body negative pressure (LBNP)|Model of -Gz: LBNP down to -100 mmHg (maximum)
41166859|NCT03354234|OTHER|Head down tilt (HDT)|Model of +Gz: HDT down to -30 degrees (maximum)
41166860|NCT03354234|DEVICE|Tilt table|Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s
41388572|NCT03940027|PROCEDURE|EUS-guided celiac plexus neurolysis|EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.
41388573|NCT01364246|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
41388574|NCT00272623|PROCEDURE|Seldinger technique or venous cut-down for port placement|
41511629|NCT04902014|BEHAVIORAL|Wearable Fitness Trackers|Individuals assigned to this experimental condition will be given a wrist-worn WFT and will be instructed to wear it for the duration of the study. They will also download the corresponding mobile application on their smartphones. They will be trained by a member of our team on how to utilize the WFT and mobile application. The intended WFT tracks daily steps, miles traveled, kcals expended, and daily activity time. This device provides these data to the wearer via a small screen. Participants will be instructed to aim to complete at least 150 minutes of PA per week. Researchers will have the capability to track participant daily PA via the WFT and associated API. These individuals will be asked to set biweekly PA goals. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
41511630|NCT04902014|BEHAVIORAL|Wearable Fitness Tracker+|These individuals will be given the wrist-worn WFT, be instructed to wear it for the duration of the study AND be scheduled for six SDT based MI sessions. These participants will also be trained by a member of our team on how to utilize the WFT and associated application. They will be instructed to aim to complete 150 minutes of PA per week. These participants will be asked to set biweekly PA goals which will be discussed in MI sessions. Researchers will have the capability to track participant daily PA via the WFT and associated API. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
41511631|NCT06033937|DEVICE|PFO occlusion|Patients in PFO occlusion group received PFO closure using devices.
41511632|NCT01163864|BEHAVIORAL|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
41511633|NCT01163864|BEHAVIORAL|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
41511634|NCT02216500|DIETARY_SUPPLEMENT|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
41511635|NCT04575610|DRUG|PF-06650833|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric \[NG\] tube, orogastric \[OG\] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
41511636|NCT04575610|DRUG|Placebo|Matching placebo tablets will be administered.
40857504|NCT03285269|PROCEDURE|Passive Leg Raise|A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
40857505|NCT02837029|OTHER|Laboratory Biomarker Analysis|Correlative studies
40857506|NCT02837029|BIOLOGICAL|Nivolumab|Given IV
40857507|NCT02837029|RADIATION|Yttrium Y 90 Glass Microspheres|Given IA
40857508|NCT06324396|DRUG|Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg)|A single oral dose of sildenafil will be administered to all study subjects.
40857509|NCT06324396|DRUG|Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)|A single oral dose of pravastatin will be administered to all study subjects.
40857510|NCT03928795|PROCEDURE|elective caesarean section|elective caesarean section
40857511|NCT03593044|DRUG|0.01% concentration atropine drops|One drop of 0.01% concentration atropine in each eye at night for seven days.
40857512|NCT00648700|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
41166861|NCT03354234|DEVICE|LBNP chamber|Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s
41388575|NCT01518465|DRUG|dalteparin|Given SC
41388576|NCT01518465|DRUG|lenalidomide|Given PO
41388577|NCT01518465|DRUG|dexamethasone|Given PO
41388578|NCT01518465|OTHER|laboratory biomarker analysis|Correlative studies
41388579|NCT03408236|DRUG|Botulinum toxin type A|Experimental
41388580|NCT03408236|DRUG|Botulinum toxin type A|Active Comparator
41388581|NCT02181842|DRUG|Pioglitazone|Pioglitazone tablets
41038835|NCT05465889|DRUG|Oral sulfate solution (OSS)|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Take 177ml sodium, potassium and magnesium sulfates oral solution (diluted to 480ml) within 30 minutes 14-16 hours before colonoscopy, followed by two doses of 480ml warm water within 1 hour; Repeat the procedure 3-4 hours before colonoscopy.
41038836|NCT05465889|DRUG|Polyethylene Glycol Electrolyte|Take 1000 ml polyethylene glycol electrolyte solution within 1 hour at 8 p.m. the day before colonoscopy; take 2000 ml polyethylene glycol electrolyte solution within 2 hour 4-6 hours before colonoscopy.
41038837|NCT01889953|OTHER|EUS-guided biliary drainage|"Based on the patient's condition, the will receive:~* Rendezvous technique~* Direct transluminal access transesophageal technique~* Direct transluminal access transduodenal technique~* or direct transluminal access using transgastric approach"
41038838|NCT01505296|DRUG|Antiarrhythmic drug|propafenone, flecainide, sotalol, dofetilide
41038839|NCT01505296|PROCEDURE|Catheter ablation|Complete PVI
41038840|NCT01759589|DRUG|Propofol|1 mg/kg propofol IV (over 15 sec) during anesthesia induction
41038841|NCT01759589|DRUG|Remifentanil and propofol|1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
40857513|NCT00648700|DRUG|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
41038842|NCT01759589|DRUG|Sevoflurane|Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
41038843|NCT04838262|OTHER|Acute Stressors|Sympathetic nervous system activity and blood pressure will be measured before, during, and after several acute laboratory-based cognitive (Stroop Color Word Test), emotional (International Affective Picture System), and physiological (Cold Pressor Test) stressors.
41038844|NCT00060450|DRUG|nitric oxide for inhalation|Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
41038845|NCT00060450|DRUG|Placebo|Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
41038846|NCT04805125|BIOLOGICAL|Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)|intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28
41038847|NCT04805125|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)|intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21
41038848|NCT00052468|DRUG|TCG|
41038849|NCT00052468|DRUG|TC|
41038850|NCT01374542|PROCEDURE|Respiratory endoscopy|Bronchoscopy, thoracoscopy, endobronchial ultrasound
41038851|NCT04313881|DRUG|Magrolimab|Administered intravenously
41038852|NCT04313881|DRUG|Azacitidine|Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
41038853|NCT04313881|DRUG|Placebo|Placebo to match magrolimab administered intravenously
40857514|NCT02546492|DRUG|Acthar gel|Administration of the study drug in addition to the current maintenance immunosuppressive agents
41038854|NCT06109038|OTHER|Conventional PT + ITB release with graston technique|"An emollient will be applied to the leg from the lateral joint line along the tibial condyle to just below the iliac crest. The instrument GT-4 will be used for treatment. The tool was used to assess the soft tissue in three locations on the lateral leg: anterior to the ITB, over the ITB, and posterior to the ITB. Brushing and strumming strokes were performed to the tissue utilising the instrument's convex surface. Treatment time with the instrument is 8 -10 mins .~Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions)."
41038855|NCT06109038|OTHER|Conventional PT|Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions).
41038856|NCT03214913|OTHER|Early Goal Directed Therapy|EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.
41038857|NCT03214913|OTHER|Ruijin Strategy|"Ruijin Strategy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%\~35%."
41038858|NCT05164159|DRUG|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 \~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
41038859|NCT05164159|DRUG|remimazolam group|In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
41038860|NCT01233791|DRUG|Vaginal Diazepam Suppository|10mg compounded vaginal suppository
41038861|NCT01233791|DRUG|Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
41038862|NCT04669496|DRUG|Neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
40857515|NCT06098716|BEHAVIORAL|Self Regulation|How to plan for Family PA
40857516|NCT06098716|BEHAVIORAL|Identity & Family functioning|Increasing self-identity to increase parental support of child PA \& family functioning
41038863|NCT02515136|BEHAVIORAL|Stimulus-response|See summary
41038864|NCT05170373|PROCEDURE|ESP block|Before general anesthesia, ESP block was applied from the T12 vertebra level with 10 ml 0.5% bupivacaine HCL 5 ml 2% lidocaine HCL 5 ml 0.9% isotonic NaCl mixture
41388582|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Bilateral Stimulation|TMS protocol of 22 sessions of bilateral active 1800 pulses.
40857517|NCT05441267|DRUG|Semaglutide Oral Tablet|Oral semaglutide 14mg daily (option to reduce to 7mg daily)
40857518|NCT05441267|DRUG|Placebo oral tablet|Placebo oral semaglutide
40857519|NCT02994875|DIETARY_SUPPLEMENT|N-acetylcysteine|NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
41166862|NCT06479486|DIAGNOSTIC_TEST|Assigned Interventions|warm up: global range of motion exercises; breathing control. Aerobic training: walking, cycling, stepping Resistance training: free weights(major muscle groups of upper and lower limbs and trunk Cool down; Breathing control and stretching exercises.
41166863|NCT01311414|DRUG|cafedrine/theodrenaline, urapidil|Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
41388583|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Sham Stimulation|TMS protocol of 22 sessions of sham bilateral 1800 pulses.
41388584|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Unilateral Stimulation|TMS protocol of 22 sessions of left active 1800 pulses and right sham 1800 pulses.
41511637|NCT03530683|DRUG|Maplirpacept (PF-07901801)|maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.
41166864|NCT02983877|BEHAVIORAL|iTAB-CV|"Stage 1 of the intervention will be introduced. Researchers will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month, participants will receive alternating daily texts with educational and motivational content and a daily mood rating request to both monitor their mood and to determine adherence to the intervention.~In the second stage for the following month, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1."
41166865|NCT01964339|OTHER|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.|Venous blood gas, basic metabolic panel, PSG variable data collection.
41166866|NCT01964339|OTHER|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.|Arterial blood gas, basic metabolic panel, PSG variable data collection
41166867|NCT02470611|DRUG|Sodium alendronate|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% sodium alendronate gel
41166868|NCT02470611|OTHER|Placebo|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% placebo gel
41388585|NCT00001729|DRUG|Ribavirin|
41388586|NCT00568100|PROCEDURE|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
41388587|NCT04181697|DEVICE|PA measurement with Fitbit Charge 3|Measurement of PA with Fitbit for all participants and controls.
41511638|NCT03530683|DRUG|Azacitidine|intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks
41511639|NCT03530683|DRUG|Venetoclax|orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole
40857520|NCT02994875|OTHER|Placebo|Sugar pill
41166869|NCT02026245|DEVICE|Data gloves to perform movements|"Using the electronic data gloves to perform a set routine of movements:~* 5DT 'dataglove 14 Ultra' Electronic glove (commercially available)~* New 'Tyndall/UU' developmental dataglove"
41388588|NCT04181697|DEVICE|PA measurement with Fitbit and ActiGraph GT3X|Measurement of PA with ActiGraph for a subgroup of 20 participants.
41388589|NCT01838278|BEHAVIORAL|Vojta Physiotherapy Method|Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
41388590|NCT05887973|BEHAVIORAL|The T.R.I.G.G.E.R Project|"The T.R.I.G.G.E.R Project includes the following core components to address root causes of gun violence:~* Summer Employment~* Social and Emotional Learning~* Future Orientation~* Adult and Peer Support~* Critical Consciousness~* Civic Efficacy and Engagement"
41388591|NCT01770197|DRUG|IV rt-PA|IV rt-PA treatment
41388592|NCT03541798|PROCEDURE|positions of patients for combined spinal-epidural anesthesia|Patients in groups will be positioned according to the study groups for performing combined spinal epidural anesthesia.
41388593|NCT03541798|PROCEDURE|Combined spinal epidural anesthesia|After positioning, a combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia after identification of subarachnoidal space.
41388594|NCT00944008|DRUG|DepoCyte|
41511640|NCT03530683|DRUG|Carfilzomib|Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.
41511641|NCT03530683|DRUG|Dexamethasone|starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles
41511642|NCT03530683|DRUG|Anti-CD20 Targeting agent|Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.
41511643|NCT03530683|DRUG|Isatuximab|"F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1."
41528380|NCT01870011|DRUG|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
41528381|NCT02124200|DEVICE|EGO/CE4, 9mg nicotine|
41511644|NCT03305250|DEVICE|Implantable Loop Recorder|An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
41388595|NCT01227954|RADIATION|intensity-modulated radiation therapy|30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
41511645|NCT01711463|DRUG|Fluticasone Furoate/Vilanterol|50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
41511646|NCT01711463|DRUG|Placebo|Placebo inhaled once daily for 7 days in each treatment period.
41511647|NCT03423719|DIETARY_SUPPLEMENT|Fiit-ns®|Fiit-ns® is a blend of polyphenol-rich extracts from grapefruit, grape, green tea, guarana and black carrot. It also provides Vitamin B3. Daily dosage is 900 mg in two 450 mg-capsules for 16 weeks.
41511648|NCT03423719|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 900 mg in two 450 mg-capsules of identical appearance than the supplement capsule for 16 weeks.
41511649|NCT06552000|DEVICE|NovoTTF-200T System|Exposure/Frequency: 150 kHz Route: Transdermal through patented microarray system to the hemithorax affected with cancer, 2-4 week duration, target 18 hours/day (on average)
40857521|NCT01947764|BEHAVIORAL|HADITHI Intervention|"The HADITHI Intervention consists of a culturally adapted, multi-component clinic-based intervention designed to support families in pediatric HIV disclosure in Kenya.~In addition to the Usual Care components, the HADITHI Intervention clinics will have the following intervention components:~Culturally modified curricula materials, including videotaped narratives, to guide counseling and group sessions.~Dedicated disclosure counselors to initiate and conduct disclosure, with one-on-one counseling for caregivers and children, as well as family-based sessions.~Post-disclosure peer support groups, facilitated by the disclosure counselors, for children who have gone through disclosure."
41038865|NCT05184725|DEVICE|SaMD CARINAE|SaMD CARINAE delivers the following digital therapeutic intervention to the patients: 1) Personalised patient-centred health education program to improve patient's disease and recovery self-management skills. 2) AI-based behaviour change program to promote healthier lifestyle habits. 3) Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety. 4) A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.
41038866|NCT05321420|DRUG|Placebo|placebo
41038867|NCT05321420|DRUG|Pirfenidone|pirfenidone 801 mg TID
41511650|NCT03727880|DRUG|Pembrolizumab|Following standard of care neoadjuvant chemotherapy, subjects will receive two doses of pembrolizumab (200mg) IV 3 weeks apart prior to surgery. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 8 doses of pembrolizumab (200mg) IV 3 weeks apart.
41388596|NCT04274088|PROCEDURE|Cataract surgery|Phacoemulsification surgery
41388597|NCT04332874|PROCEDURE|Isolated Limb Infusion|ILI will be performed within 18 days of initiation of pembrolizumab. ILI (infusion of melphalan and dactinomycin into the affected limb via arterial catheter) will be performed in the interventional radiology suite under anesthesia. In pediatric patients, the pediatric pharmacist w ill be consulted prior to the procedure, and an appropriate prophylactic anti-emetic therapy and dose will be selected for the individual patient.
41388598|NCT04332874|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200 mg will be administered intravenously on Day 1 and every 3 weeks(+/= 3 days) thereafter. In adolescent patients, the dosing of pembrolizumab w ill be 2 mg/kg up to a maximum of 200 mg.
41388599|NCT04332874|DRUG|infusion of melphalan and dactinomycin|infusion of melphalan and dactinomycin
41038868|NCT05321420|DRUG|Deupirfenidone|Deupirfenidone
41038869|NCT06345027|BIOLOGICAL|Treatment Arm A|"Each patient will receive one T cell infusion.~CD70.CAR Dose Levels / Cell Dose (transduced cells):~Dose Level -1: 3 x 10\^5 cells/kg Dose Level 1 (starting dose level): 1 x 10\^6 cells/kg Dose Level 2: 3 x 10\^6 cells/kg Dose Level 3: 1 x 10\^7 cells/kg~\*First three patients treated on the study will be adults 18 years of age or older."
41038870|NCT05110859|OTHER|in-depth individual interviews|in-depth individual interviews to explore their perspectives on their first work experience during covid-19 pandemic
41038871|NCT01857115|DRUG|Carfilzomib|
41038872|NCT01857115|DRUG|Cyclophosphamide|
41038873|NCT01857115|DRUG|Dexamethasone|
41038874|NCT05136573|BEHAVIORAL|Combined Exercises|Combined Exercises
41038875|NCT01673139|BEHAVIORAL|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
41038876|NCT01673139|BEHAVIORAL|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
41038877|NCT01673139|BEHAVIORAL|Control|Given information on recommendations for physical activity.
41038878|NCT04672304|OTHER|Al-Husban University Naser|filling a questionnaire
41038879|NCT05261178|OTHER|Evaluation of satisfaction and the level of daily living activities using the prosthesis|Evaluation of satisfaction with using the prosthesis with TAPES (Trinity Amputation and Prosthesis Experience Scale) and the level of daily living activities using the prosthesis with SF-36 (Short Form-36)
41038880|NCT06467045|OTHER|Pediatric patients who received sedation for magnetic resonance imaging|Pediatric patients who underwent MRI under sedation will be prospectively observed. All non-intubated patients under the age of 16 will be included in the study. The demographic data, comorbidities, and medications of the patients, the procedures performed, the anesthetic drugs used, the expertise duration of the anesthesiologist, and the adverse effects encountered will be recorded.
41388600|NCT00828516|OTHER|Acupuncture and moxibustion|Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
41388601|NCT05981573|DEVICE|ISF extraction device 1|FDA approved microneedle attached to blotter paper tested for ability to extract 1ul of interstitial fluid
41388602|NCT05981573|DIAGNOSTIC_TEST|Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo|Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Electrochemical Assay
41388603|NCT05981573|DEVICE|Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo|Measurement of Methadone and its metabolites in ISF with LC-MS and DPV
41388604|NCT05981573|DRUG|Measurement of Methadone in ISF before and after taking prescribed dose|Measurement of methadone in ISF using DPV ex vivo versus in vivo . (Accuracy comparison - sensitivity, specificity, level of detection, and standard deviations )
41038881|NCT04110769|DIAGNOSTIC_TEST|next generation sequencing|the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.
41038882|NCT04110769|DIAGNOSTIC_TEST|following next generation sequencing|The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.
41038883|NCT05441072|DEVICE|BulbiCam|"The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs."
41166870|NCT00840671|DRUG|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
41388605|NCT05981573|DEVICE|ISF Extraction Device 2|Up to 15 minute periods of continuous ISF collection for analysis
41388606|NCT02634567|BEHAVIORAL|Cogmed Working Memory Training (CWMT)|The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
41388607|NCT01130805|DRUG|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
41388608|NCT04012008|OTHER|Comprehensive care|"* Regular follow-up by nephrologists every 1-3 month~* Multidisciplinary team consisting pharmacists, nurses, and dieticians"
41388609|NCT04012008|OTHER|Standard care|"* Regular follow-up by internists every 3 month~* May consult nephrologists case-by-case"
41388610|NCT02706522|DIETARY_SUPPLEMENT|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
41388611|NCT02706522|DIETARY_SUPPLEMENT|Allocated to Placebo group|Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
41388612|NCT04428060|OTHER|PERSEUS CPR|Resuscitation based on patient physiology
41388613|NCT04428060|OTHER|Standard CPR|Resuscitation based on current guidelines
41388614|NCT00053027|BIOLOGICAL|rituximab|
41388615|NCT00053027|DRUG|cladribine|
41388616|NCT00435240|BEHAVIORAL|Paleolithic diet|
41388617|NCT06540326|DRUG|irinotecan liposome (II)|irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab
41388618|NCT06540326|DRUG|fluorouracil|fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab
41388619|NCT06540326|DRUG|cetuximab|cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
41166871|NCT00840671|DRUG|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
41166872|NCT02176356|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
41388620|NCT06540326|DRUG|bevacizumab|bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
41166873|NCT02176356|DRUG|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
41166874|NCT02176356|DEVICE|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
41388621|NCT05641246|DRUG|(CARBAMIDE®)|Urea is used to treat dry/rough skin conditions (such as eczema, psoriasis, corns, callus) and some nail problems (such as ingrown nails). It may also be used to help remove dead tissue in some wounds to help wound healing. Urea is known as a keratolytic. It increases moisture in the skin by softening/dissolving the horny substance (keratin) holding the top layer of skin cells together. This effect helps the dead skin cells fall off and helps the skin keep more water in.
41388622|NCT05641246|DRUG|(VOLTAREN®) Emulgel 1%|(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has a cooling effect.
40857522|NCT00579072|BEHAVIORAL|Questionaires|We will use a 6-month longitudinal design to assess the short-term cognitive effects of androgen ablation therapy. We will collect 6-month longitudinal data on 170 men with prostate cancer. All 170 men will be hormone naïve at the start of this study (Hormone Naïve Group). These 170 men will consist of two subgroups. The first subgroup will comprise 70 men with prostate cancer age 65 and older scheduled to start androgen ablation therapy. Their cognitive functioning will be assessed prior to starting androgen ablation therapy or within 21 days after initiation, (i.e. baseline) and then 6 months later (Androgen Ablation Subgroup).The second subgroup will serve as a control group, and consist of 100 men with prostate cancer age 65 and older who are at least 1-year post definitive localized treatment with no evidence of disease and no plan to start androgen ablation therapy (No Androgen Ablation Subgroup).
41038884|NCT03562000|DEVICE|Cough Assistance and Systematic Non-Invasive Ventilation|"A standardised bundle of intervention will be tested using the combination of two medical devices previously used in daily clinical practice but without guideline and objective selection criteria, namely:~1. A mechanical cough assistance technic using the Cough Assist device (Model E70® by Philips Respironics, Carlsbad, CA, USA) before extubation then after extubation then 3 times a day (with possible additional treatment on demand) during 7 days maximum (with a possible cessation if the patient has strictly no bronchial overload during three consecutive physiotherapy sessions)~2. A systematic Non-Invasive ventilation during 24h minimum to indirectly improve the clearance of bronchial overload and to reduce the overall risk of re-intubation related a relative hypoventilation associated to the weak cough."
41166875|NCT02176356|DEVICE|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
41166876|NCT02176356|DEVICE|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
41388623|NCT00874042|DRUG|Treatment with ARQ 197 in combination with gemcitabine|"Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest."
41038885|NCT03562000|PROCEDURE|control group using the current gold standard of care after extubation, namely the manual drainage by a physiotherapist and the consensual use of Non-invasive ventilation|"1. After extubation, the physiotherapy will be managed according to standard care and cough assistance will be only manual. The use of a dedicated cough assistance device will be allowed if the bronchial overload clearance is repeatedly insufficient according to the physiotherapist in charge.~2. Non-invasive ventilation will not be systematic and only used in case of pre-defined condition, such as: age \> 65 years-old, BMI \> 30, Chronic cardiac failure, COPD, hypercapnia at the end of the weaning trial, post-operative admissions after abdominal and thoracic surgery."
41388624|NCT01749618|BEHAVIORAL|Education and Feedback|Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
41388625|NCT03895307|OTHER|kinesio tape|two 15 cm I type kinesio tape applied longitudinally
41166877|NCT05897528|OTHER|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups
41166878|NCT02209727|DRUG|131I-Sibrotuzumab|50 mg Sibrotuzumab conjugated with 131I
41166879|NCT00905359|PROCEDURE|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
41166880|NCT00905359|PROCEDURE|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
41388626|NCT03895307|OTHER|local anesthetic|local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection
41388627|NCT03895307|OTHER|local serum physiologic|serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
41388628|NCT01955473|DRUG|Sym004|Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
41388629|NCT05404568|PROCEDURE|Total knee arthroplasty|We included patients with knee osteoarthritis who planned to take total knee arthroplasty
41388630|NCT03843034|GENETIC|Measure endometrial markers|Endometrial biopsies will be taken from participants in both groups
41038886|NCT01128413|DEVICE|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
41388631|NCT06401642|DRUG|Zavegepant|10 mg intranasal
41388632|NCT02163278|DRUG|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
41388633|NCT02163278|DRUG|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
41388634|NCT04807634|DRUG|Intravenous Lipid Emulsion (Intralipid 20%)|Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
41388635|NCT06536946|BIOLOGICAL|Immunohistochemical staining|Staining of cutanous squamous cell carcinoma and its mimickers by monoclonal antibodies against human B-catenin by immunohistochemical procedures
40857523|NCT00579072|BEHAVIORAL|Questionaires|To supplement the pilot data collected in Aim 1, Aim 2 we will utilize a group comparison design to assess the long-term cognitive effects of androgen ablation therapy. We will collect data on the cognitive functioning of 110 men with prostate cancer age 65 and older who have been on continuous androgen ablation therapy for 1-3 years (2-Year Androgen Ablation Group). These men will complete the study battery once (i.e., the neuropsychological battery, psychosocial questionnaires, and a functional status battery). We will compare the cognitive functioning of these 110 men in the 2-Year Androgen Ablation Group to the 170 men with prostate cancer who are hormone naïve (Hormone Naïve Group).
41038887|NCT01128413|DEVICE|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
41038888|NCT01128413|DEVICE|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
41038889|NCT01128413|BEHAVIORAL|CURVES Questionnaire|The CURVES (CardiovascUlar Response \& Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
41038890|NCT01128413|BIOLOGICAL|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, \& 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
41038891|NCT01128413|BIOLOGICAL|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a \>/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
41166881|NCT01673100|BEHAVIORAL|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
41166882|NCT04310527|DRUG|Enasidenib|Enasidenib
41166883|NCT00979329|OTHER|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
41166884|NCT02478385|OTHER|Supportive care in a specially designed labour room|Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
41166885|NCT03807700|DRUG|Experimental Denture Adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
41388636|NCT04622618|DRUG|Gabapentin|Anticonvulsant, Antiemetic, Analgesic
41388637|NCT01624155|BEHAVIORAL|Education|EMR referral to teratogen and contraception counseling
41388638|NCT01818037|PROCEDURE|Cataract surgery|
41388639|NCT00765999|DRUG|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
41511651|NCT03727880|DRUG|Defactinib|Following 2 cycles of standard of care neoadjuvant chemotherapy, subjects will receive 400 mg defactinib twice a day up until 2 days preceding their surgery (approximately 6 weeks) during the immunotherapy cycles with pembrolizumab. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 400mg defactinib twice a day for 24 weeks.
41388640|NCT03768388|DRUG|levoketoconazole|food effect
41388641|NCT02494583|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
41511652|NCT05500950|OTHER|CDU and CT-DCG or CT examination|patients with space occupying lesions in the lacrimal sac area completed CDU and CT-DCG or CT examination before surgery
41511653|NCT01922505|DRUG|PPI triple therapy|
41511654|NCT01155973|BEHAVIORAL|EDUCORE intervention|Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients
41511655|NCT01155973|OTHER|Control group|SCORE oral information and counseling as standard practice care
40857524|NCT00579072|DEVICE|fMRI scan (optional)|Main study participants will be offered to complete an optional fMRI. Fifteen participants from the No Androgen Ablation Subgroup and 15 participants from the Comparison Androgen Ablation Subgroup or Longitudinal Androgen Ablation Subgroup will be recruited for this portion of the study. The fMRI will be scheduled either the same day as the neurocognitive assessment or within eight weeks of the neurocognitive testing. The fMRI will be performed only once at baseline for the Comparison Androgen Ablation Subgroup. The fMRI will be performed at the follow-up time point for the Longitudinal Androgen Ablation Subgroup. The fMRI will be performed at baseline for the No Androgen Ablation Subgroup; if the fMRI can not be completed at baseline (due to participant schedule conflict, lack of fMRI availability, staff schedule conflict, etc.), then the scan will be conducted at the follow-up time point if possible.
40857525|NCT01792115|DRUG|Vitamin E 200 IU/d|Supplement-low dose
40857526|NCT01792115|DRUG|Vitamin E 400 IU/d|Supplement-intermediate dose
41388642|NCT02494583|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
40857527|NCT01792115|DRUG|Vitamin E 800 IU/d|Supplement High Dose
40857528|NCT01792115|BEHAVIORAL|Diet and Exercise|Diet and Exercise for all Arms of the study at baseline
41038892|NCT01128413|BIOLOGICAL|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
41166886|NCT01058083|DRUG|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
41388643|NCT02494583|DRUG|5-FU|5-FU 800 mg/m\^2/day IV continuous from Day 1-5 of each 3-week cycle.
41511656|NCT00226980|DRUG|Thalidomide|
41511657|NCT00226980|DRUG|Capecitabine|
41511658|NCT04218734|DRUG|DBPR108|DBPR108: 100 mg, once daily for 24 weeks.
41511659|NCT04218734|DRUG|metformin hydrochloride|metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.
41511660|NCT04218734|DRUG|placepo|placebo:100 mg, once daily for 24 weeks.
41511661|NCT00003126|DRUG|Interleukin-2|High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
41511662|NCT03577301|BEHAVIORAL|Clinic-based Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based intervention sessions.
41511663|NCT03577301|BEHAVIORAL|Remote Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver intervention sessions to the participant in a location remote from the clinic setting.
40857529|NCT02444325|BEHAVIORAL|Group prenatal care|Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
40857530|NCT01511016|DRUG|"Human recombinant leptin (metreleptin)"|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
40857531|NCT01511016|DRUG|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
40857532|NCT04064762|DEVICE|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with Prolonged Exposure Therapy.
40857533|NCT00306527|BIOLOGICAL|Cell culture derived influenza vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
40857534|NCT00306527|BIOLOGICAL|egg-derived influenza subunit vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
40857535|NCT06212622|DRUG|Alfentanil|Subcutaneous injection
40857536|NCT06212622|DRUG|Oxycodone|Oral solution
41388644|NCT02494583|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
41388645|NCT02494583|DRUG|Placebo|Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
41388646|NCT01211496|BEHAVIORAL|High-speed power training|High speed resistance training, 3 sessions per week for 12 weeks
41388647|NCT01211496|BEHAVIORAL|Slow-speed strength training|Slow speed resistance training, 3 sessions per week for 12 weeks
41511664|NCT03577301|BEHAVIORAL|Multi-modal Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based or remote intervention sessions. First MI session is in person immediately after baseline. Sessions 2-4 can be delivered in person or remotely based on youth preference.
41511665|NCT01107691|OTHER|Amount of resistance offered in training|to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
41511666|NCT05707793|OTHER|Evaluating sexual function, quality of life and pelvic floor muscle strength, as well as thickness and force (strength) of voluntary contractions of the core muscles|Evaluation through Vaginal Laxity Questionnaire, Female Sexual Function Index, Short-Form 36 Health Survey, modified Oxford grading scale and ultrasound imaging
41511667|NCT02757326|DRUG|Opaganib|Opaganib, \[3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt\] is an orally available inhibitor of the enzyme SK2.
41528382|NCT02172664|PROCEDURE|Self etch enamel etching|The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.
41038893|NCT05399953|OTHER|Myofascial Release Technique|"Sternocleidomastoid, Upper trapezius, Suboccipital region, Scalenes, Pectoral release, Scapular and hyoid mobilization techniques.~Duration: 6 weeks, 1 supervised session per week, and the session lasted 30 minutes."
41166887|NCT01058083|DRUG|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
41388648|NCT03457727|DRUG|Danirixin|Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
41388649|NCT03457727|DRUG|Omeprazole|Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
41388650|NCT00209495|DRUG|Pregabalin; Dexamethasone|Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
41388651|NCT01339468|DRUG|Advagraf|oral
41388652|NCT01339468|DRUG|Prograf|oral
41388653|NCT01339468|DRUG|Prograf|intravenous
41388654|NCT06459076|DEVICE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE)|Immediately after ceasing assisted ventilation, before intubation the age-appropriate nasal prongs were applied and weight-specific high flow rates delivered using the Optiflow THRIVETM system. The flow rates applied were as follows: 0-15 kg, 2 litres kg-1 min-1；15-30 kg, 35 litres min-1; 30-50 kg, 40 litres min-1; and\>50 kg, 50 litres min-1.
41388655|NCT00739206|DRUG|SAR97276A|Dose based on body weight
41388656|NCT03022929|BEHAVIORAL|Enhanced Antimicrobial Stewardship Commitment and Feedback|Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
41388657|NCT03166709|BEHAVIORAL|Preventing Addiction Related Suicide (PARS)|PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal
41388658|NCT03166709|BEHAVIORAL|Intensive Outpatient Program standard session|Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study.
41388659|NCT01635127|DRUG|Canakinumab|150mg s.c.
41511668|NCT02091856|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
41511669|NCT04505566|DRUG|Ketorolac 0.45% ophthalmic solution|Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
41511670|NCT04505566|DRUG|Placebo - Preservative-free artificial tears|Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
41511671|NCT04505566|OTHER|Aqueous PGE2 and inflammatory cytokines measurements|After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
41166888|NCT01058083|DRUG|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
41166889|NCT01058083|DRUG|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
41166890|NCT01058083|DRUG|Placebo|Placebo, Oral, 0 mg, daily, 28 days
41166891|NCT03596463|OTHER|Breast cancer treatment|Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
41388660|NCT01635127|DRUG|Placebo|Constituent of canakinumab
40857537|NCT03579277|PROCEDURE|Radial Forearm Free Flap|Subjects in this arm will undergo a radial forearm free flap.
41166892|NCT02397226|PROCEDURE|Radiofrequency ablation|
41166893|NCT02397226|PROCEDURE|High ligation/stripping|
41166894|NCT02397226|DEVICE|Radiofrequency ablation catheter|
41166895|NCT02397226|PROCEDURE|Tumescent anesthesia|
41166896|NCT02397226|PROCEDURE|General anesthesia|
41166897|NCT02397226|DEVICE|Vein stripping catheter|
41166898|NCT00985283|BEHAVIORAL|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
41166899|NCT00985283|BEHAVIORAL|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
41166900|NCT05964959|OTHER|Mouth Educational Program|The Mouth Educational Program is a nurse-led patient education program for dry mouth in patients with a life-limiting condition or frailty.
41388661|NCT02632383|DEVICE|Young with Diabetes - app|"The mHealth app Young with Diabetes containes 8 main functions:~1. Contact your health care provider (ask questions, set the agenda for the next clinical visit)~2. My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)~3. Chatroom~4. Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)~5. Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)~6. Tips packages (Receive a tip about alcohol, drivers license etc.)~7. To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)~8. Reminder"
41388662|NCT01066039|DRUG|Bisoprolol|Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
41388663|NCT02845973|BIOLOGICAL|gut microbiota|
41388664|NCT03719261|DRUG|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
41388665|NCT03719261|DRUG|Sodium Hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
41388666|NCT03852407|DRUG|Thymoglobulin|ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)
41388667|NCT03852407|DRUG|Melphalan|100mg/m² on day -2
41388668|NCT03852407|DRUG|Fludarabine|30mg/m² on days -6, -5, -4, -3, and -2
41388669|NCT03852407|DRUG|Cyclophosphamid|50 mg/kg on days +3 and +4.
41388670|NCT00425282|DRUG|RWJ-333369|
41511672|NCT03791684|DEVICE|Cross linking|Cross linking strategy either standard or accelerated
41388671|NCT00006096|DRUG|cisplatin|
41388672|NCT00006096|RADIATION|radiation therapy|
41388673|NCT06542692|DEVICE|Whole Body Vibration|treatment duration, frequency
41388674|NCT06542692|DEVICE|physical therapy modalities|ultrasound, hot pack, tens
41511673|NCT01507311|DRUG|liraglutide|A single dose injected subcutaneously (under the skin)
41038894|NCT05399953|OTHER|Exercise|"Therapeutic exercise: passive and active range of motion, strengthening and postural exercise in order to improve shoulder and cervical mobility, muscle flexibility, strength and endurance, postural control and movement patterns; 2) stretching of pectoral muscles and serratus anterior; 3) scar tissue massage to reduce scar tissue's stiffness.~Duration of the intervention: 6 weeks (1 supervised session and 2 individual per week). Each exercise will be done 1-3 sets and 5-10 repetitions.The session lasted 30 minutes.~Exercise diary will be utilized in order to follow the exercise program."
41038895|NCT05399953|OTHER|Scar Tissue Massage|Circular, Up and Down, Side to Side technique
40857538|NCT03579277|PROCEDURE|Ulnar Forearm Free Flap|Subjects in this arm will undergo an ulnar forearm free flap.
41038896|NCT00798720|DRUG|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
41038897|NCT00798720|DRUG|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
41038898|NCT06395350|DEVICE|Spire Health Monitor|Use of Health Monitor is Assessed
41038899|NCT02636634|OTHER|imaging|
41038900|NCT03119454|DRUG|Diprospan|Intramuscular
41166901|NCT05964959|OTHER|Care as Usual|Care as usual is defined as the standard dry mouth care as provided by participants' own treating physicians.
41388675|NCT02689726|DRUG|GTL001+|
41388676|NCT02689726|DRUG|Aldara|5% imiquimod cream
41388677|NCT00928135|DRUG|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
41388678|NCT00928135|DRUG|Hypertonic saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
41388679|NCT06030271|DEVICE|Microcatheter|Support and facilitate the placement of the guidewire in the coronary artery with a CTO.
41388680|NCT05112679|DEVICE|PROPRIO FOOT® by Ossur|Active prostheses like the PROPRIO FOOT® offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and transepidermal water loss measurement to check skin health.
41388681|NCT05112679|DEVICE|Empower ankle by Ottobock|Active prostheses -such as the Empower ankle offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and trans epidermal water loss measurement to check skin health.
41388682|NCT06365151|OTHER|Osteopathic manual therapy|osteopathic manual treatment aimed at improving the function and pain of the temporomandibular joint.
41511674|NCT01507311|DRUG|placebo|A single dose injected subcutaneously (under the skin)
41511675|NCT03998397|BIOLOGICAL|blood alcohol concentration withdrawal|The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department
41511676|NCT01153373|BEHAVIORAL|Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only."
41511677|NCT01153373|BEHAVIORAL|Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
41388683|NCT06365151|OTHER|Sham osteopathic manual therapy|a sham osteopathic manual treatment without therapeutic effect
40857539|NCT00476827|DRUG|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
40857540|NCT00476827|DRUG|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
41511678|NCT03817541|DEVICE|Edmon (reg), BBraun|exhaled propofol will be compared With plasma propofol values
41388684|NCT02748616|DRUG|Ursodiol|Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
41388685|NCT02773446|BIOLOGICAL|ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer|ETEC Bacteria
41511679|NCT03360955|PROCEDURE|Anesthesia|Different anesthesia technique will be compared to find out which one offers better outcome to perform ultrafast track extubation
40857541|NCT00476827|DRUG|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
41388686|NCT05265624|BEHAVIORAL|Early disclosure of genetic testing results|Early disclosure group receives results of genetic testing at Month 1
41388687|NCT05265624|BEHAVIORAL|Late disclosure of genetic testing results|Late disclosure group receives results of genetic testing at Month 12
41388688|NCT06079437|PROCEDURE|Cheer|Maximum isometric contraction was performed with cheering.
41388689|NCT06079437|PROCEDURE|The cold pressure test|Maximum isometric contraction was performed with the cold pressure test.
41388690|NCT02777931|DRUG|NFC-1|NFC-1 is supplied as size 2 hard gelatin capsules.
41388691|NCT02777931|DRUG|Placebo|Matching placebo capsules
41388692|NCT04688814|PROCEDURE|Single puncture combined lumbar erector spinae plane block and quadrates lumborum block|"Patients will lay laterally with the fracture side independent, a curvilinear transducer will be placed in a parasagittal plane 3-4 cm lateral to the lumbar spinous process of L4.The probe is shifted slowly to the lateral side till the transverse processes disappear. After subcutaneous local infiltration with lidocaine 1% at the cephalic end of the probe, the block needle is advanced through the erector spinae and QL muscles, until it pierces the epimysium of the QL muscle. LA is injected anterior to the QL, between the QL and psoas muscles.~Then the caudal end of the probe is rotated slowly medially towards lumbar spine till the transverse process of L4 appears in the ultrasound image. The needle is withdrawn to subcutaneous tissue, then advanced in plane towards transverse process of L4. After contacting it, LA is deposited between transverse process and overlying ESM."
40857542|NCT00476827|DRUG|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
40857543|NCT00476827|DRUG|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
40857544|NCT00476827|DRUG|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
41038901|NCT04543123|DEVICE|tDCS treatment|Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).
40857545|NCT05355948|DEVICE|MEMO Patch PLUS for 1 day|Individuals randomized to one-day monitoring will wear MEMO Patch PLUS for 1 day. After that, confirm the monitoring result and carry out a fixed schedule.
41038902|NCT04543123|DRUG|Antidepressant Drug(escitalopram)|Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
41388693|NCT04688814|DRUG|Morphine Sulfate|Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine
41388694|NCT05375682|OTHER|Integrated care program|Core Component 1: Fostering Collaboration and Capacity Core Component 2: Streamlined communication process for referrals and care planning Core Component 3: Coordinated Care Conferences
41388695|NCT01560182|GENETIC|OTL-200 Gene Therapy|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA
41388696|NCT06544473|DRUG|17-beta estradiol|Treatment with orally administered estrogen for 14 days
41388697|NCT06544473|DRUG|17-beta estradiol|Treatment with transdermally administered estrogen for 14 days
41388698|NCT06119373|OTHER|Single daily icodextrin exchange|PD initiation with single daily exchange of 2-liter icodextrin-based dialysis solution.
41388699|NCT06119373|OTHER|Conventional PD group|PD is initiated with 2 to 3 exchanges of 2-liter glucose-based dialysis solution.
41511680|NCT00001725|DRUG|Dextromethorphan|
41511681|NCT03366207|DRUG|Ciprofloxacin|Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
41038903|NCT04195464|OTHER|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
41038904|NCT04195464|OTHER|Sham dry needling|Sham Dry needling use a non-penetrating acupuncture needle
41388700|NCT05070689|PROCEDURE|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
41388701|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
41388702|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
41511682|NCT00208273|DRUG|Letrozole - Concomitant|
41511683|NCT00208273|DRUG|Letrozole - Sequential|
41038905|NCT06131866|OTHER|Psychoeducation based on Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
41038906|NCT04528511|DEVICE|Continuous Electronic Monitor|All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden
41166902|NCT06035185|PROCEDURE|apical shaping size|24 patients will randomly be assigned to two groups according to the apical shaping size during root canal treatment: 25/.04 and 35/.04. Microbiological sampling of the teeth will be done with paper cones in three steps during the root canal treatment: 1. Sterility control samples (SR1) from the tooth surface after cavity preparation, 2. The first microbiological sample (S1) from the root canal after the initial file reaches the working length. 3. The second microbiological sample (S2) from the root canal after the shaping and irrigation of the root canal is finished. 4. The third microbiological sample (S3) from the root canal after the irrigation activation in the root canal is finished.The samples will be sent to the genetic analysis laboratory for further analysis in the cold chain using a Droplet Digital PCR.
41166903|NCT03671239|BEHAVIORAL|Placebo rectal insert|Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
41166904|NCT03671239|BEHAVIORAL|Placebo rectal suppository|Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
41388703|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
41388704|NCT06241794|PROCEDURE|Group M-TAPA|Aseptic conditions are ensured in the area where the block will be performed. Under ultrasound guidance, a linear probe at the sagittal plane and costochondral angle is used to identify the transversus abdominis, internal oblique, and external oblique muscles at the level of the 10th rib. To visualize the lower surface of the rib cartilage in the midline, a sagittal angle is applied with the probe in the direction of the costochondral angle at the edge of the 10th rib. Using a 22-G, 80-100 mm block needle with an in-plane technique, the needle is advanced cranially. The needle tip is directed towards the posterior surface of the 10th rib cartilage, underneath the condyle. Subsequently, 20 ml of 0.25% concentration bupivacaine is injected beneath the condyle. The same procedure will be applied to the opposite side using the same technique.
41388705|NCT06241794|PROCEDURE|Group Serratus Intercostal Plane Block and Rectus Sheath Block|"Serratus intercostal plane block:The serratus anterior muscle and intercostal muscles are identified at the level of 8th rib along the right mid-axillary line.Using block needle,20 ml of 0.25% Bupivacaine is injected into the interfascial plane between these muscles.The SIPB will be performed only on the right side.~Rectus sheath block:a linear probe is placed in a transverse position just above the umbilicus and slightly lateral to the midline.After visualizing the rectus abdominis muscle, posterior rectus sheath,and the hypoechoic space between them,block needle is advanced in-plane along the subcutaneous tissue.The needle is progressed until reaching the space between the epimysium of the muscle and the posterior rectus sheath, passing horizontally through the anterior rectus sheath of the rectus abdominis muscle.10 ml of 0.25% bupivacaine is injected.Adequate spread will lift the epimysium of rectus abdominis muscle while displacing the posterior fascia and peritoneum downward"
41388706|NCT00450177|DRUG|Ferrous Sulfate|Iron group
41388707|NCT00450177|DRUG|Placebo Oral Tablet|Placebo group
41388708|NCT01368757|DRUG|Revlimid|"Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen."
41388709|NCT04653701|COMBINATION_PRODUCT|Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter|We will perform chemoembolization technique in those patients (during 1 year) with indications for this treatment in relation with guidelines (early and intermediate hepatocellular carcinoma). Specific microcatheter and microparticles will be use (Mentioned above)
41388710|NCT02519582|DRUG|Niclosamide|2 g per day orally
41388711|NCT00088023|DRUG|PT-523 for Injection|
41511684|NCT01597973|DRUG|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
41511685|NCT01597973|DRUG|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
41511686|NCT00100880|DRUG|lenalidomide|Given PO
41511687|NCT00100880|PROCEDURE|perfusion-weighted magnetic resonance imaging|Correlative studies
41511688|NCT00100880|PROCEDURE|diffusion-weighted magnetic resonance imaging|Correlative studies
40857546|NCT05355948|DEVICE|MEMO Patch PLUS for More than 8-days|Individuals randomized to More than 8-days monitoring will wear MEMO Patch PLUS for 8 days \~ 14 days at their voluntarily. After that, confirm the monitoring result and carry out a fixed schedule.
40857547|NCT02289807|DRUG|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
41166905|NCT03671239|BEHAVIORAL|Placebo rectal douche|Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
41388712|NCT05292781|OTHER|CHOICES|An innovative web application to provide interactive information about reproductive health options for people with SCD or SCT. CHOICES is a multimedia intervention that provides targeted and tailored information for participants to become informed ns about their reproductive health options. Targeted to their sex and tailored to their SC reproductive health knowledge, reproductive health behavior during the previous 6 mo, and parenting plan (e.g., intention to have child with SCD or not), CHOICES presents information about options to help the participant achieve their parenting plan through reproductive partner selection based on sickle cell status, prenatal testing, ovum and sperm donation, advanced reproductive technologies, and options to avoid pregnancy or adopt. The website will be housed on secure University of Florida (UF) servers and accessible via computers or mobile devices (e.g., tablets, smart phones); device capture will inform plans for long-term dissemination.
41511689|NCT00100880|OTHER|laboratory biomarker analysis|Correlative studies
41166906|NCT05465928|DEVICE|Active rTMS|rTMS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each rTMS treatment, the magnetic field is generated by a coil which is placed on the head near the brain region of interest, and further, an electrical current is induced to modulate brain activity.
41166907|NCT05465928|DEVICE|Sham rTMS|The sham rTMS stimulation is performed based on a sham coil which will mimic scalp sensations and the acoustic artifact of the active stimulation, without delivering any magnetic pulse.
41511690|NCT04082338|BEHAVIORAL|VPN|"The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period."
41511691|NCT04082338|BEHAVIORAL|TM|Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
41511692|NCT04133012|OTHER|Samplings|"* blood samples~* rectal biopsies~* nodes biopsies~* cutaneous fat tissues biopsies~* semen sample"
41511693|NCT04234971|DRUG|Intervention group (DBM/BMP)|All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
41511694|NCT04234971|DRUG|Control group(autologous ICBG)|The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
41511695|NCT05667025|OTHER|Conservative rehabilitation|Joint range of motion, strengthening, balance-coordination and stretching exercises included in the conservative physiotherapy program 5 days a week for a total of 6 weeks
41511696|NCT05667025|OTHER|Cycling Functional Electrical Stimulation in addition to Conservative Rehabilitation|In addition to conservative treatment, cycling FES to the affected lower extremity for 20 minutes, 3 days a week for 4 weeks. During the treatment, the patient will be seated on a chair and her feet will be fixed to the pedal with velcro tape, and the comfort during the treatment will be provided with calf supports.
41511697|NCT01962818|OTHER|HFOV combined with sigh breaths|"It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
41511698|NCT03431714|DRUG|Artesunate amodiaquine|Drugs were administered under observation of the study nurse for three days
40857548|NCT02289807|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
41166908|NCT02880969|BEHAVIORAL|answering questionnaires|
41511699|NCT03610152|BEHAVIORAL|Hospital Policy change|Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
41388713|NCT05292781|OTHER|eBook|e-Book contains information typically shared in clinical SCD care, including stick figure representation of inheritance because the investigator considers it unethical to withhold this basic information. It does not include other information related to the SCKnowIQ knowledge items or any of the behaviors needed to implement a parenting plan. Although not as long as CHOICES, the e-Book is sufficiently long, attractive, and engaging to retain participants randomized to the usual care control group; key factors for an adequate control condition. Interestingly, during the study and in interviews after the study, many e-Book participants commented that they were pleased to be assigned to the intervention group (they had not), which indicates that the control condition is sufficient for its intent--2-yr longitudinal retention of the sample. Also, human contact is the same for both groups, and the time-on-task on the computer is unlikely to influence study knowledge and behavior endpoints.
41388714|NCT01148680|BIOLOGICAL|Islet Graft|Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
41388715|NCT03976349|DRUG|BIIB094|Administered as specified in the treatment arm.
41388716|NCT03976349|DRUG|Placebo|Administered as specified in the treatment arm.
41511700|NCT02412917|DRUG|FV-100|antiviral nucleoside analog
41511701|NCT02412917|DRUG|valacyclovir|antiviral nucleoside analog
41511702|NCT03989492|OTHER|systemic and local stressors|Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.
41511703|NCT05853419|DEVICE|Robotic-assisted PCI|Robotic-assisted PCI will be performed according to the routine hospital practices, current scientific guidelines and following Instructions for Use (IFU) provided by the manufacturer
41511704|NCT02085447|BEHAVIORAL|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
41511705|NCT02687347|DRUG|oral methadone|Oral methadone is the study drug
41511706|NCT02687347|DRUG|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
41511707|NCT05036512|DRUG|GBT021601|Administered orally with water as a single dose in the morning.
40857549|NCT01505374|PROCEDURE|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
41388717|NCT04526249|DEVICE|rapid pulse confirmation device|device used to detect pulsatile blood blood during and after cardiac arrest
41388718|NCT03183973|BIOLOGICAL|PRF|patients who will receive PRF suspension
41388719|NCT03183973|BIOLOGICAL|placebo group|patients who will receive Placebo
41511708|NCT06017050|BEHAVIORAL|BullyDown|BullyDown is an 8 week, text messaging-based prevention program aimed to prevent bullying behaviors among middle school-aged youth. Message content is based upon the social-emotional learning model.
41511709|NCT06017050|BEHAVIORAL|Attention-matched control|The attention-matched control will receive the messages for the same number of days as the intervention. Content will talk about 'healthy lifestyle' topics, such as fitness and healthy social media use.
41528383|NCT02172664|PROCEDURE|selective etch protocol|Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.
40857550|NCT01505374|PROCEDURE|Control Technique|The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
41388720|NCT03923816|DRUG|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).&Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).|comparison of two intraoperative fluid strategies upon hepatic outcome in hepatobiliary surgery
41388721|NCT05256940|BEHAVIORAL|Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, that is delivered in three sessions in person, virtually, or by telephone.
41388722|NCT05256940|OTHER|Enhanced usual care (EUC)|Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
41388723|NCT01015456|DRUG|mycophenolate sodium|per oral, twice daily, for 12 months
41528384|NCT02172664|DEVICE|Adhese Universal|the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions
40857551|NCT00200668|DRUG|FDG = fluorodeoxyglucose|
40857552|NCT01821859|DRUG|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
40857553|NCT01821859|DRUG|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
40857554|NCT03580980|DRUG|Paracetamol and ketamine|intravenous paracetamol and ketamine followed by ketorolac
40857555|NCT03580980|PROCEDURE|Caudal levobupivacaine|an epidural injection of morphine and levobupivacaine through the caudal space
40857556|NCT03580980|DRUG|Morphine|patient controlled analgesia by morphine
40857557|NCT01618695|DRUG|Perampanel|"Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day.~Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day."
41038907|NCT05450848|DEVICE|StrataXRT|StrataXRT is a flexible wound dressing for the prevention and treatment of radiation dermatitis. It is in the form of a gel which, when applied, creates a protective film that maintains skin integrity. The product is used to relieve low grade inflammatory radiation changes such as dry, itching, flaking, peeling and irritated skin. For more severe inflammatory changes with open wound components, StrataXRT reduces pain, redness and heat and helps soothe the exposed skin areas. StrataXRT can be applied where skin integrity has been compromised and may also be used in conjunction with other adjunctive treatments to improve overall results. StrataXRT contains Polydimethylsiloxanes, Siloxanes and Alkylmethyl Silicones and is transparent and odourless. It does not contain alcohols, parabens or fragrances. StrataXRT can be used with or without a secondary protective dressing. It is suitable for children and people with sensitive skin.
41038908|NCT05450848|OTHER|Sorbolene|Aqueous cream (moisturizer) that soothes itchiness and dryness of the skin, and aids skin hydration. It is non-greasy, fragrance free, colour free, GMO free, paraben free and pH balanced.
41038909|NCT01821469|BEHAVIORAL|psychoeducation|Bipolar disorders are educated to learn about their pathology
41038910|NCT01109992|DRUG|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
41166909|NCT05214937|BEHAVIORAL|Intervention|During the first two weeks (baseline), participants will be asked to maintain their regular movement routine to set a baseline daily average step count. Phases I-III will involve self-regulatory strategies (e.g., action planning), address reducing/interrupting sedentary time, and step counts. Participants will be encouraged to increase their steps by 1000 steps/day from the baseline phase during each subsequent phase (i.e., 3000 steps above baseline by Phase III). Phases IV-V will be a maintenance phase through which participants will be encouraged to maintain 3000 steps per day above baseline. The sessions will be grounded within the Multi-Process Action Control Framework and address perceived capability/opportunity and instrumental/affective attitudes. The 1-on-1 sessions will focus on regulation (action \& coping planning, social support, goal setting) and reflexive processing (self-regulation, habit). The final one on one session will be a booster session to revisit previous topics.
41388724|NCT01015456|DRUG|cyclophosphamide|intravenous, monthly, for 6 months
41388725|NCT00187174|DRUG|Everolimus|The drug is given orally in 28 day courses.
41388726|NCT05220865|PROCEDURE|Hall Technique|"* Only food scraps or debris will be removed from the caries cavity.~* The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~* If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~* The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~* The child will be asked to bite firmly until the crown is pushed down over the tooth.~* If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~* The child will continue to bite on a cotton roll until the cement hardens~* Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
41511710|NCT04852523|DRUG|18F-fluciclovine|18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates striking amounts of Axumin, where it is considered a normal finding. Pancreatic beta-cell function may be slow to recover following pancreatic transplantation and may vary as a function of perioperative steroid administration, acute rejection, inadequate islet cell transplantation, allograft pancreatitis or compromised blood supply. Viability of the allograft is a common clinical concern and is difficult to assess based on insulin, C-peptide, and blood sugar levels. Rapid identification of compromised allograft viability is critical in the management of these patients.
41511711|NCT03905577|BEHAVIORAL|Action Observation|Action Observation training
41038911|NCT01109992|DRUG|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
41038912|NCT03391323|DEVICE|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
41038913|NCT03391323|DEVICE|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
41038914|NCT00715546|PROCEDURE|autologous transplantation of liposuction material enriched with adipose-derived stem cells|Lipoinjection enriched with adipose-derived stem-cells.
41038915|NCT05354050|DRUG|DARE-BV1|2% Clindamycin 100 MG
41166910|NCT05214937|BEHAVIORAL|FitBit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living. They will receive a FitBit orientation session with a movement specialist prior to the 12-week control period.
41166911|NCT01729923|DRUG|Capecitabine|Given PO
41166912|NCT01729923|DRUG|Celecoxib|Given PO
41166913|NCT01729923|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41166914|NCT01729923|OTHER|Laboratory Biomarker Analysis|Correlative studies
41166915|NCT01729923|OTHER|Quality-of-Life Assessment|Ancillary studies
41166916|NCT01729923|RADIATION|Radiation Therapy|Undergo radiation therapy
41038916|NCT02179112|PROCEDURE|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
41166917|NCT01729923|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
41166918|NCT01729923|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
41038917|NCT03234426|OTHER|Perturbation|Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety
41038918|NCT03234426|OTHER|Conventional Physiotherapy Treatment|Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks
41511712|NCT03905577|BEHAVIORAL|Motor imagery|Motor imagery protocol
40857558|NCT01618695|DRUG|Placebo|"Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day."
40857559|NCT05050461|OTHER|Immunological analyses|Immunological analyses will be performed at inclusion in both arms
40857560|NCT01210898|BIOLOGICAL|Adjuvanted seasonal influenza vaccine|Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
40857561|NCT00691184|DRUG|Placebo|0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
40857562|NCT00691184|DRUG|Terbinafine Hydrochloride|10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
40857563|NCT00691184|DRUG|Terbinafine Hydrochloride|1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
40857564|NCT00691184|DRUG|Terbinafine|Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
40857565|NCT03288636|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
40857566|NCT03288636|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
41388727|NCT05220865|PROCEDURE|Modified Hall Technique|"* Food scraps or debris will be cleaned from the caries cavity and infected soft carious dentin tissue will be excavated with hand instruments.~* The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~* If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~* The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~* The child will be asked to bite firmly until the crown is pushed down over the tooth.~* If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~* The child will continue to bite on a cotton roll until the cement hardens~* Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
41388728|NCT06156046|DIAGNOSTIC_TEST|skin prick test|Skin prick test for bee venom
41388729|NCT06156046|DIAGNOSTIC_TEST|Blood tests|IgE/G and T cell tolerance studies
41388730|NCT06542783|BEHAVIORAL|referring to the results of AI model output|determining the ANA pattern type with or without referring to the results of AI model output.
41388731|NCT02275182|DRUG|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
41388732|NCT02275182|DRUG|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
41388733|NCT02957461|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor assessment. BrainScope Ahead 200iD device will be used to perform EEG.
41388734|NCT04406129|BIOLOGICAL|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool.
41511713|NCT03905577|BEHAVIORAL|Placebo Action observation|Placebo Action Observation
41511714|NCT06353698|DIETARY_SUPPLEMENT|fasting mimicking diet|Fasting mimicking diet is limited calorie diet to enhance the effectiveness of chemotherapy
41511715|NCT01970137|DRUG|KPS-0373, High dose|
41511716|NCT01970137|DRUG|KPS-0373, Low dose|
40857567|NCT03288636|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
40857568|NCT03288636|DRUG|Placebo|Placebo
40857569|NCT02451995|DEVICE|Ripple Mapping guided AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping
41388735|NCT04406129|OTHER|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug.
41388736|NCT01585064|OTHER|DAS28-IOMS|Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of \< 2.4.
41511717|NCT03063411|OTHER|Executive Function Intervention|In the executive function training group, children will complete computerised tasks requiring working memory and inhibitory control over four weekly sessions lasting 15-20 minutes. The aim is to improve their executive function skills. In the active control group, children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
40857570|NCT02451995|DEVICE|Local activation Time Mapping AT Ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of local activation time mapping
40857571|NCT03326206|OTHER|COPE Program|The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
41511718|NCT03063411|OTHER|Active Control Group|This is the active control condition. Children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
41511719|NCT00297076|DRUG|GW873140|
41511720|NCT05281510|DRUG|Vesatolimod|Administered orally
41511721|NCT05281510|BIOLOGICAL|VRC07523LS|Administered intravenously
40857572|NCT03634930|BEHAVIORAL|observation|Observation of growth, infant bodycomposition, 24h-drinkingvolume
40857573|NCT03971409|BIOLOGICAL|Anti-OX40 Antibody PF-04518600|Given IV
40857574|NCT03971409|DRUG|Avelumab|Given IV
40857575|NCT03971409|DRUG|Binimetinib|Given PO
40857576|NCT03971409|BIOLOGICAL|Utomilumab|Given IV
40857577|NCT03971409|DRUG|Liposomal Doxorubicin|Given IV
40857578|NCT03971409|DRUG|Sacituzumab Govitecan|Given IV
40857579|NCT01004926|DEVICE|Echelon foot|One Echelon foot for each subject, for a period of a month.
41511722|NCT05281510|BIOLOGICAL|CAP256V2LS|Administered intravenously
41511723|NCT00000542|DRUG|Inhibitors, ACE|
41511724|NCT00000542|DRUG|amlodipine|
41511725|NCT00000542|DRUG|lisinopril|
41511726|NCT00000542|DRUG|doxazosin|
41388737|NCT01585064|OTHER|0SJ-IOMS|Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.
41511727|NCT00000542|DRUG|chlorthalidone|
41511728|NCT00000542|DRUG|pravastatin|
41511729|NCT00000542|BEHAVIORAL|diet, fat-restricted|
40857580|NCT00729625|DEVICE|robotic device|"The device has a small air muscle that when activated will slowly lift their fingers and wrist from your resting wrist position. This device is classified as a non-significant risk device by the FDA (see attached letter dated 1-15-05). The patient should not experience any pain or discomfort during this stretching activity. If they do experience any pain or discomfort they can activate a stop switch located on the control box with their unimpaired hand."
41388738|NCT01585064|OTHER|Routine Care (RC)|Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
40857581|NCT01435629|DRUG|somatropin|Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
40857582|NCT01598467|PROCEDURE|Robotic assisted sacrocolpopexy (RASC)|Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
41388739|NCT03875131|OTHER|Biomarkers of Dementia and Cognitive Decline|"Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months.~The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline.~* Mini-Mental Status Evaluation~* Hachinski Ischemic Scale~* Cognitive Subscale of Alzheimer's Disease Assessment Scale~* Disability Assessment for dementia~* Quality of life improvement as assessed by:~  * Minnesota Living with Heart Failure Scale~ * Anti-Clot Treatment Scale (ACTS) Quality of Life Survey"
41388740|NCT06567288|PROCEDURE|spencer mscle energy technique|The effectiveness of MET found in chronic capsulitis is due to its effect on relieving pain, ensuring ROM incretions, and developing functional activities due to the muscle contraction in a precise direction and in a monitored position over resistance to assist in improving joint range by advancing joint flexibility. This procedure is suggested for all joints with limited ROM (Butt \& Tanveer, 2022).
41388741|NCT04896918|BEHAVIORAL|Tobacco use|
41388742|NCT04766593|OTHER|Oncological functional reeducation program|"It will consist of the following actions:~1. Prescription of multimodal physical exercise.~2. Retraining in activities of daily living."
41388743|NCT06015217|DRUG|"Cetaphil Healing Ointment"|"Subjects will use Cetaphil Healing Ointment on the diaper rash area with every diaper change"
41388744|NCT06541743|DEVICE|Regular Toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
41511730|NCT03209843|PROCEDURE|Percutaneous recanalization of chronic total occlusion|Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
41511731|NCT01319526|GENETIC|DNA analysis|
41511732|NCT01319526|GENETIC|RNA analysis|
41511733|NCT01319526|OTHER|laboratory biomarker analysis|
41511734|NCT05544929|DRUG|KFA115|Immunomodulatory agent
41511735|NCT05544929|DRUG|pembrolizumab|Anti-PD-1 antibody
41511736|NCT01495000|DRUG|denosumab|60mg subcutaneous injection, single dose
40857583|NCT05300789|OTHER|Follow-up|There is no intervention. Patients are just going to be registered and oncologic follow-up data are going to be recorded.
41511737|NCT01495000|DRUG|placebo|placebo subcutaneous injection, single dose
41511738|NCT01815476|RADIATION|Radiation Therapy Positioning Intervention|All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
41511739|NCT06581653|BEHAVIORAL|Phone-based PERT education intervention|Participants who allocate to the intervention group will receive regular phone-based PERT education intervention by professional team.
40857584|NCT01832155|BEHAVIORAL|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
41511740|NCT02371434|BIOLOGICAL|autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)|autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 10\^6, 1 x 10\^6, and 2.5-3 x 10\^6 cells/kg body weight in cohorts of three patients each.
41511741|NCT01225250|DEVICE|Polydioxanone (PDS) plates|0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
40857585|NCT01832155|BEHAVIORAL|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
41388745|NCT06541743|DEVICE|Musical toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
40857586|NCT01286025|BEHAVIORAL|video case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate
41166919|NCT04938739|OTHER|Cognitive Behavioral Therapy|"The first 6 sessions: the cognitive part was explained with the support of a PowerPoint presentation using diagrams, images, and texts. The therapist explained the lumbar engine behavior, the neurophysiologic basis of pain, the importance of the participant's involvement in the treatment (e.g., coping and motivation), and the maintenance of good ergonomics which was aimed at modifying the physiologic response to the pain system.~The second 12 sessions: concepts viewed in the first session were revised; as well, the operant and respondent parts were explained."
41166920|NCT04938739|OTHER|Home program exercises|Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
41166921|NCT02201771|DRUG|Aspirin|
41388746|NCT06541743|DEVICE|Electric toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
41388747|NCT02253407|BIOLOGICAL|MMR vaccine|
41388748|NCT02224300|BEHAVIORAL|Internet-based education of venous leg ulcer nursing care|Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
41388749|NCT01980316|DRUG|Argatroban|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
41388750|NCT01980316|DRUG|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
41388751|NCT00354731|DRUG|pentoxifylline|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
41388752|NCT00354731|DRUG|Corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
41528385|NCT04463251|BIOLOGICAL|RPH-104 80 mg|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
40857587|NCT01286025|BEHAVIORAL|Text case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate. The transcript of these video-recordings will form the basis of the text-based case presentation modality.
40857588|NCT04348032|DRUG|PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd|Patients receive PLD and apatinib at the same time. The dose of intravenous chemotherapy drug is calculated according to the body surface area, and the dose of oral drug apatinib is 250mg qd. Dose suspension and dose reduction are allowed only when patients have serious adverse reactions. The intravenous chemotherapy drug PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%), and the oral drug apatinib dose is only allowed to be reduced once (250mg gravity QD changed to 250mg gravity Qod). Otherwise the patients will drop out of the study.
40857589|NCT04348032|DRUG|PLD 40mg/m2 ivgtt q4w|The dose of intravenous chemotherapy drug is calculated according to the body surface area. When patients have serious adverse reactions, dose suspension and dose reduction are allowed. The PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%).
40857590|NCT04847765|DEVICE|VIPUN Gastric Monitoring System prototype|"The VIPUN Balloon Catheter prototype is a nasogastric feeding tube with integrated balloon that can be inflated with a preset volume of air. Intraballoon pressure changes are recorded outside the body. Gastric contractions can be detected in the pressure profile.~The recording lasts 30 minutes and is combined with simultaneous cine magnetic resonance imaging."
40857591|NCT05423964|DIAGNOSTIC_TEST|AI use in Endoscopy Room|The use of AI versus no AI in comparing the detection of adenomas during Endoscopy procedures.
40857592|NCT05423964|OTHER|Non-AI use Standard of Care endoscopy room|Non-AI use in comparing the detection of adenomas during Endoscopy procedures.
40857593|NCT04227132|DEVICE|Adaptive computer game training|Patients sit in front of a computer monitor and play the adaptive videogame with a joystick. The game requires to orient and move inside a maze, and it includes phases that engage multitasking abilities. The level and speed of the game is adapted online to patients' performance.
40857594|NCT04227132|DEVICE|Standard computerized training|Patients sit in front of the computer monitor and perform simple computerized exercises using a keyboard to respond. Exercises are organized into modules according to the trained cognitive functions. Patients will perform four different modules that are designed for neglect rehabilitation. The level of exercises adapts periodically based on patient's performance.
40857595|NCT00932321|DRUG|Norethindrone Acetate/Ethinyl Estradiol 24 Days|One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
40857596|NCT00932321|DRUG|Norethindrone Acetate /Ethinyl Estradiol 21 Days|One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
41166922|NCT02201771|DRUG|Ticagrelor|
41166923|NCT00237614|DRUG|intravenous and oral N-acetylcysteine|
41388753|NCT03262519|DIAGNOSTIC_TEST|Computer based neurocognitive testing|Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
41388754|NCT02816749|PROCEDURE|Maggot debridement therapy|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
41388755|NCT02816749|PROCEDURE|Conventional Dressing Therapy|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
41388756|NCT02810496|GENETIC|blood collection for mutation characterization|
41388757|NCT01291186|DRUG|BPV6NO|intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
41511742|NCT01225250|PROCEDURE|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
41038919|NCT04817553|OTHER|exposure to COVID19|Observational study of IgG4 patients with pancreatobiliary involvement who were diagnosed with COVID19
41038920|NCT00093054|DRUG|Cranberry juice|TID dosage for UTI treatment
41038921|NCT00093054|DIETARY_SUPPLEMENT|Placebo cranberry juice|TID placebo dosage to match active comparator
41038922|NCT02423187|OTHER|No Intervention|
41511743|NCT01225250|PROCEDURE|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
41038923|NCT01733004|DRUG|MM-141|
41038924|NCT03079752|BEHAVIORAL|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment of suspected problems at 12 and 24 months of age
41038925|NCT03079752|BEHAVIORAL|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
41038926|NCT03079752|BEHAVIORAL|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
41038927|NCT03079752|BEHAVIORAL|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
41038928|NCT01060982|DEVICE|Ultrasonic ablation device|One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
41038929|NCT04825587|PROCEDURE|Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.|By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
41038930|NCT04045392|BEHAVIORAL|Mediterranean diet|Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
41038931|NCT05999955|DRUG|Neomycin/ Dexameythasone/Xylometazoline|The active-control in the phase II study was a commercial form of nasal spray containing Dexamethasone/Neomycin/Xylometazoline. This formulation is approved by Vietnam's Ministry of Health as a treatment regime for rhinosinusitis. Dexamethasone sodium phosphate is fluoromethyl prednisolone, a synthetic glucocorticoid. Dexamethasone has the main effects of glucocorticoids as anti-inflammatory, antiallergic and immunosuppressant. Neomycin sulfate is an antibiotic belonging to the group of aminoglycosides that have a bactericidal mechanism due to inhibition of bacterial protein biosynthesis. In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatment
41038932|NCT05999955|COMBINATION_PRODUCT|Bacillus subtilis DSM32444|Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/ PCBALA In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatmen.
41388758|NCT01291186|DRUG|BPV7NO|intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
41388759|NCT01291186|DRUG|BPV8NO|intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
41388760|NCT01291186|DRUG|BPV9NO|intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
41388761|NCT01291186|DRUG|BPV10NO|intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
41388762|NCT01291186|DRUG|BPV11NO|intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
41388763|NCT01291186|DRUG|BPV6O|intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
41388764|NCT01291186|DRUG|BPV7O|intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
41388765|NCT01291186|DRUG|BPV8O|intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
41511744|NCT00150605|DRUG|Extended-release carbamazepine|
40857597|NCT00572208|DRUG|Gabapentin group|"Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~1. st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~2. nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~3. rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~4. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~5. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)"
40857598|NCT02755220|DEVICE|Cingularbio® Aortic valve replacement|the patients will be replaced by Cingularbio heart valve
40857599|NCT04124640|OTHER|Patients' data (baseline characteristics, clinical and outcomes) from routine care visits|Use of a standardized scale to collect clinical and patient-centered data, to assess the effectiveness of Libicare in real life in female 45-65 years old. Patients' data (baseline characteristics, clinical and outcomes) will be collected according to sites routine care.
41388766|NCT01291186|DRUG|BPV9O|intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
41388767|NCT01291186|DRUG|BPV10O|intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
40857600|NCT01716741|OTHER|Enzyme analysis|
40857601|NCT04099615|PROCEDURE|Somatosensory Evoked Potentials|We stimulate both median nerves at wrist by means of surface adhesive electrodes. We apply square wave electrical pulses of 0.2 ms duration at a frequency of 5.7Hz. SEPs are recorded in a referential fashion from the C3' and C4' positions and from a reference electrode at Fpz or Cz' electrodes(international 10-20 system) with needle electrodes. The target signal is the presence of N20 response ipsilateral to the stroke site and, if present, measure amplitude and latency comparing with the contralateral if present. SEPs are registered during the whole procedure.
40857602|NCT03688074|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
40857603|NCT03688074|OTHER|Placebo|Placebo subcutaneous injection
40857604|NCT00015795|DEVICE|airway interruption test|
40857605|NCT00614848|DEVICE|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
40857606|NCT03046576|DIAGNOSTIC_TEST|plasma DPP4 activity|DPP4a was determined by enzymatic assays.
40857607|NCT05451563|DEVICE|Double-S|Wearable device for intercourse
40857608|NCT00130611|OTHER|BNP measurement|
40857609|NCT00130611|OTHER|Clinical examination|
40857610|NCT00762047|DEVICE|Durasphere FI|Durasphere Injection
40857611|NCT00762047|DEVICE|Sham|Sham injection with anesthesia
40857612|NCT01063647|DRUG|Treosulfan|10 g/m² i.v. infusion, day -6, -5, -4
41388768|NCT01291186|DRUG|BPV11O|intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
41388769|NCT00891501|PROCEDURE|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
40857613|NCT01063647|DRUG|Treosulfan|12 g/m² i.v. infusion, day -6, -5, -4
40857614|NCT01063647|DRUG|Treosulfan|14 g/m² i.v. infusion, day -6, -5, -4
40857615|NCT00390663|PROCEDURE|Nasal Cautery|
41388770|NCT00891501|PROCEDURE|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
41388771|NCT05078632|OTHER|Montreal-Toulouse Test adapted in eye tracking|participant pass an eye tracking test to evaluate comprehension
40857616|NCT05036317|DRUG|Empagliflozin (Jardiance®;|Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
40857617|NCT05036317|OTHER|Placebo Control Intervention|Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.
40857618|NCT00474617|DRUG|Sugammadex|
40857619|NCT00474617|DRUG|Rocurium|intravenous (IV) single bolus dose of 0.6 mg.kg-1
40857620|NCT03075358|DRUG|Lidocaine spray|Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.
40857621|NCT03075358|OTHER|Normal saline spray|0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
40857622|NCT01462617|DRUG|GSK2269557|Study Drug
40857623|NCT01462617|DRUG|GSK2269557 matching placebo|Study Drug
40857624|NCT04951466|BEHAVIORAL|Mindfulness-based therapy for insomnia (MBTI)|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
40857625|NCT04951466|BEHAVIORAL|Healthy lifestyle intervention|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
41388772|NCT06354959|BEHAVIORAL|Prehabilitation|8-week community based prehab program
41528386|NCT04463251|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial
41528387|NCT05672095|PROCEDURE|Biopsy|Undergo needle or core biopsy
41528388|NCT05672095|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
40857626|NCT04342078|DIETARY_SUPPLEMENT|Vitamin D|To investigate the effect of one year vitamin D supplementation in preterm born adults (4000 IU = 100 micrograms a day if serum concentration is \< 30 nmol/l, 2000 IU = 50 micrograms a day if 30-50 nmol/l and 1000 IU = 25 micrograms a day if \> 50-80 nmol/l, and no additional supplement if \> 80 nmol/l) on health outcomes (bones, teeth, muscles, heart, lungs) . The target level of vitamin D concentration by every 4 months interval is 80 - 120 nmol/l .(Preterm Adult group)
40857628|NCT06058325|OTHER|Healthy school lunch|The healthy school lunch will be co-created together with school staff, parents, and children, and should be healthy according guidelines of the Dutch nutrition center.
40857629|NCT05393973|OTHER|Core stability exercises along with conventional physical therapy|"Core stability exercises included neck isometric exercises(flexion, extension, lateral flexion, rotation), chin tuck, chin tuck into towel, cervical extension + 10 minutes hot pack+ 10 minutes stretching (cervical flexors, extensors, rotators), session will be of 30-40 minutes, three times a week, for 4 weeks duration.~Chin Tuck: In standing subject pulls back the chin( as if trying to make a double chin) while keeping the eyes level. This will be done for 15 repetitions.~Cervical extension: In a standing position, the subject grasps the base of the neck, with both hands while extending the neck as far as possible. This will be done for 15 repetitions"
40857630|NCT05393973|OTHER|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercise will be executed in the following order, assume supine posture on the treatment bed by fully extending their legs and putting them back on the bed in the most comfortable posture with hands on the abdomen. Second, while in the supine posture, support the head with one hand and insert a small Swiss ball near the back of the head with the other hand. Third, after having contacted the ball to the area below the back of the head, slowly turn the head and neck in the shape of the number '8'. Fourth, after having set 3 repetitions of rotating the head and neck for 10 seconds and then taking 10 seconds of general resting as 1 set of exercise, a total of 3 sets of exercise were executed with 1 minute of general resting taken between each set of exercise. Then perform neck flexion, extension, side bending, and rotation, hold each movement for 10 seconds + Hot pack (10 minutes) + 10 minutes of cervical stretching. Perform the exercise three times a week for 4 weeks duration.
40857631|NCT06051903|OTHER|Mobilization wih movement|The purpose of this study is to determine the effect of talar mobilization with movement versus acupuncture on knee pain and function in the postmenopausal women
40857632|NCT06040164|OTHER|Observational study|No intervention will be performed
40857633|NCT05971927|BEHAVIORAL|Simulation education|Randomly assigned experimental group students performed eight different vaginal examination scenarios in the laboratory on the fetal monitoring and labor progress model set for cervical dilatation, cervical effacement, presenting fetal part, presence of amniotic membrane and fetal descent. The researchers repeated the vaginal examination scenario and informed the students about the evaluation results after each student had performed the vaginal examination scenario prepared by the researchers. This process continued until the experimental group students completed eight different vaginal examination scenarios.
40857634|NCT02736916|RADIATION|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
40857635|NCT02736916|RADIATION|Conventional PCI|LD-SCLC patients with conventional PCI
40857636|NCT04600414|OTHER|Collaborative Care for Mental Health Disorders|CoCM is based on six key principles: 1) evidence-based, 2) measurement-based, 3) team-based, 4) population-based, 5) patient-centered, and 6) accountable. CoCM supports the delivery of evidence-based pharmacological and psychosocial treatments. CoCM is measurement-based with screening and monitoring of patient-reported outcomes over time to assess treatment response and facilitate treatment adjustments. CoCM is team-based led by a primary care provider with support from a care manager in consultation with a psychiatrist who provides treatment recommendations for patients who are not responding. CoCM is population-based whereby a registry is used to monitor treatment engagement and facilitate the identification of patients falling through the cracks. CoCM is patient-centered with proactive outreach to engage and activate patients. Collaborative care is accountable with continuous quality improvement to meet clinic performance benchmarks.
40857637|NCT04600414|OTHER|Collaborative Care for Opioid Use Disorder|"Pharmacologic treatment of OUD will rely mainly on transmucosal buprenorphine/naloxone prescribed by primary care providers with DATA 2000 waivers. Measurement-based care and treat to target are fundamental principles of CoCM and will be incorporated into the intervention. Care managers will ask four yes/no questions about: 1) opioid withdrawal symptoms, 2) illicit opioid craving, 3) illicit opioid use, 4) medication side effects. If necessary, consulting psychiatrists will then recommend a change to the treatment plan to the primary care provider. In the case of buprenorphine/naloxone, options for changing the treatment plan include: 1) increasing the dosage (max dose 32mg), 2) augmenting with clonidine, 3) switching to injectable buprenorphine, and/or 4) intensifying psychosocial interventions. If the patient is experiencing medication side effects, but not opioid withdrawal symptoms or illicit opioid craving, consideration will be given to lowering the medication dosage."
40857638|NCT04659473|OTHER|Online survey|This study aims to apply a rapid online survey to determine the Spanish situation in this third wave of the pandemic.
40857639|NCT06299644|DEVICE|Endoscopic Sleeve Gastroplasty - Belt and Suspenders|Endoscopic sleeve gastroplasty using belt and suspender plications.
40857640|NCT06299644|DEVICE|Endoscopic Sleeve Gastroplasty - Belt|Endoscopic sleeve gastroplasty using belt only plications.
40857641|NCT02231684|DRUG|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
41388773|NCT00820183|OTHER|Quality Improvement plan for Hypertension Control|"Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:~Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation"
41388774|NCT02040207|DRUG|AM-101|AM-101 gel for intratympanic injection
41511745|NCT05752825|RADIATION|HR-pQCT|HR-pQCT is a 3-dimensional imaging modality that can be applied to bone and joints in vivo, in order to non-invasively assess the quantity and quality of trabecular and cortical bone compartments separately. HR-pQCT will be applied to peripheral skeletal sites, namely the distal radius and tibia, where image slices equivalent to 9 mm of bone will be acquired. From this, parameters such as volumetric bone mineral density (vBMD), cortical density, cortical porosity, trabecular density, trabecular thickness, trabecular spacing and others will be calculated using specialized software. In the same scanning session, images of the wrist and ankle joints will be produced and analyzed for features of arthrosis, such as erosions, osteophytosis and others.
41528389|NCT05672095|DRUG|Niraparib|Given PO
41528390|NCT05672095|OTHER|Questionnaire Administration|Ancillary studies
41528391|NCT05672095|DIETARY_SUPPLEMENT|Selenium|Given IV
41511746|NCT05752825|RADIATION|DXA scan|Through DXA scans, we will obtain information regarding body composition, hip and spine bone mineral density, as well as examine any previous vertebral fractures using vertebral fracture assessment (VFA). VFA is a function of DXA scanners which allows for visualization of thoracic and lumbar vertebrae (usually T4-L4) in order to detect vertebral fractures34. Vertebral fractures can then be classified as either mild, moderate or severe using the method described by Genant et al35.
41511747|NCT05752825|DIAGNOSTIC_TEST|Bone microindentation|Using the OsteoProbe®, we will by microindentation measure the bone material strength index (BMSi), an in vivo surrogate measure of the fracture resistance of the cortical bone in the tibia. The participant is placed in a supine position with the examined leg rotated slightly outward. After identifying the site of interest, located midway between the medial tibial plateau and the medial malleolus, disinfectant is applied to the skin of the tibia being examined. Finally, under local anesthesia and fully sterile conditions, a test probe is inserted through the skin and onto the midshaft of the tibia, and the fracture resistance of the bone tissue is measured.
41511748|NCT05752825|DIAGNOSTIC_TEST|Hand grip and leg extension strength|Hand grip strength will be assessed using a digital hand dynamometer as a measure of peripheral muscle strength. Leg extensor strength will be examined using the peak torque measured by an isometric dynamometer mounted on a fixed chair. 3 attempts will be given for each method, and the maximum value recorded.
41511749|NCT05752825|DIAGNOSTIC_TEST|Timed up-and-go test|The TUG test is a functional test frequently used to assess balance in older individuals and is performed by measuring the time it takes for an individual to go from sitting to standing position, walk 3 meters, turn around and return to sitting position. A TUG score of \>13,5 seconds is associated with an increased risk of falls.
41528392|NCT02768480|OTHER|Primary Care|Patients will be followed by primary care team according to the usual health system routine.
40857642|NCT02231684|DRUG|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
40857643|NCT04567394|BEHAVIORAL|Peer Network Counseling-txt|4-week text counseling program
40857644|NCT00078247|DRUG|Abacavir|300 mg tablet taken orally twice daily
40857645|NCT00078247|DRUG|Lamivudine|300 mg tablet taken orally daily
40857646|NCT00078247|DRUG|Zidovudine|300 mg tablet taken orally twice daily
40857647|NCT00078247|DRUG|Tuberculosis treatment|Tuberculosis treatment
40857648|NCT01189695|DRUG|Ritonavir-boosted lopinavir|Lopinavir/ritonavir 200/50 mg every 12 hours
40857649|NCT01189695|DRUG|optimized background regimens (OBRs)|Optimized background regimens such as NRTIs, etravirine or raltegravir
40857650|NCT02759250|DRUG|ARGX-110|
40857651|NCT05378737|DRUG|BAT8006 for Injection|Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
41388775|NCT05435872|DEVICE|The Artificial intelligence Cloud Platform|The Artificial intelligence Cloud Platform would be used as the auxiliary device for endoscopists during the whole endoscopic examination to help endoscopists complete the quality control, indicate potential lesions, and aid in diagnosis.
41388776|NCT02056574|DRUG|NA-1|
40857652|NCT01454986|DRUG|ALXN1007|Single dose, IV
40857653|NCT01454986|OTHER|Placebo|Single dose, IV
40857654|NCT01647893|DRUG|CTB-001|IV bolus or IV infusion
40857655|NCT00365924|DRUG|Forteo|Open label single arm study with Forteo as an intervention
40857656|NCT01331980|DEVICE|Peripheral quantitative computed tomography (pQCT)|A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit
40857657|NCT01331980|DEVICE|Dual X-ray absorptiometry (DXA)|A total body DXA scan will be conducted at a single study visit
40857658|NCT02623582|BIOLOGICAL|Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Given IV
40857659|NCT02623582|DRUG|Cyclophosphamide|Given IV
40857660|NCT05286502|DEVICE|fundus photography|color fundus photography
40857661|NCT05529836|DEVICE|electroacupunture|The participants in EA group will receive acupuncture with PSD at bilateral Hegu (LI4), bilateral Quchi (LU5), bilateral Xuehai (SP10) and bilateral San Yinjiao (SP6). After skin disinfection, followed at an angle of 90°, acupuncture needles were inserted approximately 50 to 60 mm into the skin. When achieving qi, connect the four pairs of electrodes, two each on bilateral Quchi (LI4) and Hegu (LI11), two each on bilateral Xuehai (SP10) and San Yinjiao (SP6), and they are all ipsilateral to one another. The duration of the electroacupuncture stimulation is 30 minutes, and the current intensity ranges from 1 to 5 mA with a continuous wave of 20 Hz. For two weeks straight, the participants will have three therapy sessions each week (preferably every other day), for a total of six sessions.
40857662|NCT05529836|DEVICE|sham electroacupuncture|Participants in the SEA group will receive sham electroacupuncture with PSD, but not energizing the electropuncture device. Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no electricity output only.
40857663|NCT05529836|DEVICE|sham acupuncture|Participants in the SAC group will receive sham acupuncture with PSD and PSN on sham acupoints (the non-meridian and non-acupuncture points). Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no skin penetration, electricity output, or needle manipulation for achieving qi.
41388777|NCT02056574|DRUG|Placebo|
40857664|NCT05695885|BEHAVIORAL|STEPS|behavioral counseling
40857665|NCT05695885|BEHAVIORAL|Services as usual (SAU)|behavioral counseling normally provided
40857666|NCT00391313|DRUG|Chloroquine|
40857667|NCT00187473|PROCEDURE|liver biopsy|Liver biopsy every 5 years
40857668|NCT02769221|DEVICE|Rigid video stylet|
41388778|NCT01854801|OTHER|Individual medical Care|Individual medical care in occupational and environmental diseases centers
41388779|NCT01854801|OTHER|Individual electromagnetic exposures|During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
41388780|NCT06538714|OTHER|MIIT|"12-week supervised exercise program consisting of moderate-intensity interval training (MIIT)~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~3 exercise sessions per week.~Additionally, participants receive no individualized nutritional counseling."
41166924|NCT05088538|OTHER|Patient Education|After completing the necessary forms, it is planned to give the QR-coded education booklet prepared by the researcher to the patients and to inform the patients and their relatives about the use of QR codes. At that time, it is planned that the teaching will be carried out using various training methods such as lecture, question-answer, demonstration and practice. It is thought that the teaching will be divided into 3 parts: pre-operative, post-operative and discharge. According to the physical conditions of the clinic, it is planned to provide patient education in an suitable area for teaching as much as possible. Patients will be reminded that they can access the information whenever they want and as many times as they want by scanning the QR code from their phone.
41166925|NCT06295042|OTHER|BREAST-Q Questionnaire|Patient-reported outcome measure
41166926|NCT05173233|DEVICE|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
41388781|NCT06538714|OTHER|MIIT + HIIT|"12-week supervised exercise program consisting of moderate-intensity interval training (MIIT) (6-week) and high-intensity interval training (HIIT) (6-week).~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~HIIT: 3 series of 5 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 7-9, as well as two series of 10 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 10-12.~3 exercise sessions per week. Additionally, participants receive no individualized nutritional counseling."
41388782|NCT06538714|OTHER|Control group|"Habitual physical activity No additional physical intervention~Additionally, participants receive no individualized nutritional counseling."
41388783|NCT02547779|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
41166927|NCT05899621|DRUG|Obinutuzumab|Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
41166928|NCT05899621|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
41166929|NCT05899621|DRUG|Bendamustine|Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.
41166930|NCT05899621|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
41166931|NCT05899621|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
41388784|NCT02547779|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
41388785|NCT00130663|DEVICE|PDA blood pressure screening program and chart reminder|
41388786|NCT00102388|DRUG|vildagliptin|
41388787|NCT00102388|DRUG|Gliclazide|
41388788|NCT02806635|BEHAVIORAL|OurRelationship|
41388789|NCT02806635|BEHAVIORAL|PREP Online|
41388790|NCT01461369|DRUG|Diclofenac|35 mg bid Capsules
40857669|NCT02769221|DEVICE|Video laryngoscope|
40857670|NCT00381693|DRUG|azacitidine|
40857671|NCT04435028|DRUG|Ketotifen 1 MG|Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months
40857672|NCT05822622|OTHER|echocardiography|to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
40857673|NCT05311267|OTHER|Action observation training|Subject is asked to observe videos with motor contents
40857674|NCT01090193|PROCEDURE|Whipple operation,Hepaticojejunostomy|Whipple operation, Hepaticojejunostomy
40857675|NCT01224717|DRUG|PTH134|
40857676|NCT01224717|DRUG|Placebo|
40857677|NCT01224717|DRUG|Forsteo|
41166932|NCT05899621|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
40857678|NCT03024190|OTHER|Kinesiotaping|The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
40857679|NCT03024190|OTHER|stretching exercise|15- min stretching exercise for upper extremity twice daily
40857680|NCT03024190|OTHER|OT rehabilitation program|regular rehabilitation program for 3 weeks
41166933|NCT05899621|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
41166934|NCT00249730|DRUG|Sildenafil|
41166935|NCT04620369|DRUG|Placebo Administration|Instill isotonic nasal saline intranasally
41166936|NCT04620369|OTHER|Questionnaire Administration|Ancillary studies
41166937|NCT04620369|DRUG|Rose Geranium in Sesame Oil Nasal Spray|Instill intranasally
41166938|NCT01653249|BIOLOGICAL|Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
41166939|NCT02315053|OTHER|Low dose FDG PET/CT 5 x.|Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
41166940|NCT02097849|DRUG|dimethyl fumarate|Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.
40857681|NCT06458452|OTHER|Using Virtual Reality based serious gaming module for Advanced Cardiac Life Support|Group VG will use Artificial Intelligence driven Voice Recognition as an interface for game control whereas Group CG will only use hand held Virtual Reality controllers as an interface for game control
40857682|NCT00654979|DEVICE|SafeFlo IVC Filter|SafeFlo IVC Filter
40857683|NCT03539601|DRUG|Crisaborole ointment, 2%|Applied twice a day (BID)
40857684|NCT03539601|DRUG|Hydrocortisone butyrate cream, 0.1%|Applied BID
40857685|NCT03539601|DRUG|Pimecrolimus cream, 1%|Applied BID
40857686|NCT03539601|DRUG|Crisaborole Vehicle|Applied BID
41388791|NCT01461369|DRUG|Diclofenac|35 mg tid Capsules
41388792|NCT01461369|DRUG|Placebo|Capsules
41388793|NCT04440163|BIOLOGICAL|MenABCWY|N meningitidis groups A, B, C, W, and Y vaccine
41388794|NCT04440163|BIOLOGICAL|Saline|Placebo
41388795|NCT04440163|BIOLOGICAL|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
40857687|NCT01147354|DIETARY_SUPPLEMENT|selenium yeast|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
40857688|NCT01147354|OTHER|placebo capsules|The patients in this arm took one placebo capsule daily for 12 weeks.
40857689|NCT03160898|DRUG|Reldesemtiv|Oral tablet
40857690|NCT03160898|DRUG|Placebo|Oral tablet
40857691|NCT03833466|DRUG|metformin and chemotherapy|"Drug: Metformin Metformin is orally administered as 500mg bid for 7 days and escaladed to 500mg tid if adverse events are tolerated.~Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.~Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle."
40857692|NCT03190434|DEVICE|AL-SENSE|The AL-SENSE reacts differently when in contact with amniotic fluid than it does with urine. The indicator changes color to blue-green and fades back to yellow in case of urine and changes to stable blue-green in case of amniotic fluid.
40857693|NCT00314964|DRUG|PD-0299685|
40857694|NCT00866073|DRUG|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
40857695|NCT03383510|OTHER|Climate friendly diet|Participants in the 'Climate friendly' group will be assigned a diet generating low emissions of greenhouse gases. The target is to reduce the participants' diet-related carbon dioxide equivalents (CO2e) to 2.5 kg per person and day, which is approximately a reduction by 50% compared the average CO2e, according to a previous study on diet-related CO2e in Sweden. The participants will be instructed to reduce their consumption of beef and dairy products and increase their consumption of plant-foods i.e. fruits, vegetables, legumes and whole-grain cereals.
40857696|NCT03383510|OTHER|Organic diet|Participants in the 'Organic group' will be assigned an organic diet with very low, or no, content of pesticides. The participants will be instructed to replace at least 50% of their food intake with organic foods.
40857697|NCT03383510|OTHER|Climate friendly and organic diet|The participants in the 'Climate friendly and organic diet group' will be assigned a combination of a climate friendly and organic diet generating low emissions of greenhouse gas and having very low levels of pesticides. The target is to reduce the participants' diet-related CO2e to 2.5 kg per person and day. The participants will be instructed to replace at least 50% of their food intake with organic products.
40857698|NCT03383510|OTHER|Control group (Control diet)|"A conventional diet according to the Nordic Nutrition Recommendations (NNR). The participants will get information about the present dietary guidelines and how they can adhere to the guidelines, for example, by implementing the plate model for meals and learning about recommended levels of intake of macronutrients, micronutrients, fiber and energy."
40857699|NCT03935243|BEHAVIORAL|equine assisted therapy|The equine assisted group therapy is carried out by a riding therapist (nurse psychiatry HF, certified riding therapist SG-TR). There is a detailed plan for the PT.
40857700|NCT03935243|BEHAVIORAL|activating control phase|The control phase includes a generally activating employment offer, such as board games, light physical activations, roundtables and artistic design.
40857701|NCT05690048|DRUG|Fecal microbiota transfer|FMT via capsule (50 g of fecal matter) on day 0 and day 21.
40857702|NCT05690048|DRUG|Vancomycin Oral Capsule|Vancomycin orally (125 mg 4xd, day -3 to 0).
40857703|NCT05690048|DRUG|Atezolizumab + Bevacizumab|Atezolizumab 1200mg i.v. \& Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).
40857704|NCT05690048|DRUG|Placebo Vancomycin Oral Capsule|Placebo Vancomycin orally (125 mg 4xd, day -3 to 0).
40857705|NCT05690048|DRUG|Placebo Fecal microbiota transfer|Placebo Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21.
40857706|NCT03215199|OTHER|NAPT|Web-based depression and distress monitoring application
40857707|NCT00880295|PROCEDURE|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
40857708|NCT00880295|PROCEDURE|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
40857709|NCT06443983|OTHER|AI-supported case|In the artificial intelligence-supported case lesson, students will listen to audio and visual content prepared by artificial intelligence.
40857710|NCT00785473|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
40857711|NCT00785473|DIETARY_SUPPLEMENT|calcium carbonate|calcium carbonate 500 mg daily for 2 years
40857712|NCT03326700|PROCEDURE|Inguinal Hernia Repair|Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
40857716|NCT06208995|OTHER|36-Item Short Form Survey Instrument (SF-36)|Answering 36 questions in a quality-of-life survey (RAND 36-Item Health Survey 1.0): https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/survey-instrument.html
40857717|NCT02699567|OTHER|No intervention|
41388796|NCT04440163|BIOLOGICAL|MenACWY-CRM|Meningococcal group A, C, W-135, and Y conjugate vaccine
41511750|NCT05752825|DIAGNOSTIC_TEST|Stabilometry|Postural control will be assessed by means of a force platform that registers Center of Pressure (CoP) as a measure of postural stability. Measurements are performed under a variety of conditions, including eyes open/closed and on different surfaces. From the CoP measurements, parameters such as CoP range and CoP velocity in both antero-posterior and medial-lateral directions will be calculated using specialized software.
40857718|NCT02861898|DRUG|Intra-arterial Cetuximab|
40857719|NCT02861898|DRUG|Intra-arterial Mannitol|
40857720|NCT05900232|DIAGNOSTIC_TEST|Anti _KU antibodies|aim of the work is to determine the relationship between Anti_Ku antibodies and SLE manifestations the study will include 60 SLE cases diagnosed by SLICC criteria and the activity of SLE will be calculated by SELDAI criteria, which is tool composed of 24 clinical and laboratory variables.
41166941|NCT02097849|BIOLOGICAL|tetanus diphtheria toxoids vaccine|Administered as described in the treatment arm
41166942|NCT02097849|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Administered as described in the treatment arm
40857721|NCT03360474|BEHAVIORAL|Delirium Screen|Patients who screen positive for delirium will be assessed for pain, electrolyte imbalances,infection, the use of deliriogenic medications and any issues will be resolved. Those with persistent delirium following all other intervention will be treated with antipsychotic medication.
40857722|NCT05159570|DIETARY_SUPPLEMENT|Ketone ester|Commercially available ketone supplement
40857723|NCT05159570|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
40857724|NCT06466382|OTHER|Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling|The intervention studied is a treatment recommendation by a specialized molecular tumorboard (mTB). This recommendation is based on an MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs/ experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.
40857725|NCT06466382|DRUG|Carboplatin / Paclitaxel Chemotherapy|2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg/m2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg/m2 weekly
40857726|NCT02843841|OTHER|Blood and fecal sample.|Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
40857727|NCT00565123|DRUG|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
40857728|NCT00565123|DRUG|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
40857729|NCT01996280|BEHAVIORAL|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hrs. The MI includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan; It is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
41038933|NCT05382780|OTHER|The breather respiratory muscle trainer|The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.
41038934|NCT05382780|OTHER|Diaphragmatic and localized breathing exercises|"A. Diaphragmatic breathing exercises:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~B. Localized Breathing:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~C. Mild Interval training exercise"
41038935|NCT05382780|OTHER|interval aerobic training and respiratory training|mild intensity interval aerobic training and respiratory training on treadmill
41038936|NCT02862106|BIOLOGICAL|εPA-44|subcutaneously injection of εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
41388797|NCT04631185|DRUG|Single pre-operative dose of intravenous antibiotics with intraoperative redosing|Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. In case of allergy to cefazolin, intravenous clindamycin will be prescribed. For allergy to both antibiotics, an appropriate antibiotic should be chosen by the surgeon and documented. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
41388798|NCT04631185|DRUG|One week of post-operative antibiotics|The patients will be prescribed one week of Cephalosporin Antibiotic (Keflex/Duricef/Other) of their surgeon's choice.
41388799|NCT01033175|PROCEDURE|maximal cardiopulmonary exercise testing|Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
41388800|NCT01033175|PROCEDURE|peripheral blood samples|Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
41388801|NCT04815408|DRUG|BGB-A317|PD-1 antibody，Tislelizumab (BGB-A317)
41388802|NCT04815408|DRUG|albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5|albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
41388803|NCT00576849|DRUG|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
41388804|NCT00576849|DRUG|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
41388805|NCT00576849|DRUG|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
41388806|NCT04269746|DIAGNOSTIC_TEST|CCAT1|Long Non coding RNA
41388807|NCT00122031|DEVICE|Deep Brain Stimulation with Medtronic Activa Neurostimulator|Deep brain stimulation (DBS) at 130 Hz
41166943|NCT02097849|BIOLOGICAL|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|Administered as described in the treatment arm
41166944|NCT02097849|DRUG|non-pegylated interferon|Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
41166945|NCT02947581|DRUG|Albendazole and praziquantel|Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
41166946|NCT02947581|DRUG|Albendazole and praziquantel placebo|PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
41166947|NCT02921139|RADIATION|Stereotactic ablative radiotherapy (SABR)|Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
41511751|NCT05752825|DIAGNOSTIC_TEST|Nerve conduction test|To fully examine all components of balance, nerve conduction will be tested using a handheld device called NC-stat DPN-Check in order to assess any peripheral neuropathy.
41038937|NCT06119633|PROCEDURE|Immediate tissue expander and lipofilling after mastectomy|Implant-based breast reconstruction and fat grafting after salvage or prophylactic mastectomy in patients previously exposed to radiation therapy on the breast as adjuvant treatment after breast conserving surgery (BCS) or on thoracic wall for Hodgkin Lymphoma (HL).
41038938|NCT02883114|DRUG|PF-06648671|Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
41038939|NCT02883114|DRUG|Itraconazole|Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
41038940|NCT04541134|DRUG|Pelubiprofen 45mg|Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)
41038941|NCT04541134|DRUG|Placebo|Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
41038942|NCT00755482|DRUG|Aquamin F|
41038943|NCT00755482|DRUG|Placebo (maltodextran)|
41038944|NCT04474626|DRUG|Isoquercetin|Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.
41038945|NCT02605954|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
41038946|NCT02605954|DRUG|ABC/3TC|600/300 mg tablets administered orally once daily
41038947|NCT02605954|DRUG|Third Antiretroviral Agent|"Third antiretroviral agents could include one of the following:~* ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~* DRV+COBI or DRV/COBI FDC~* darunavir (DRV; Prezista®) + RTV~* lopinavir/ritonavir (LPV/r; Kaletra®)~* atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~* efavirenz (EFV; Sustiva®)~* etravirine (ETR; Intelence®)~* nevirapine (NVP; Viramune®)~* rilpivirine (RPV; Edurant®)~* dolutegravir (DTG; Tivicay®)~* raltegravir (RAL; Isentress®)~* fosamprenavir (FPV; Lexiva®) + RTV~* saquinavir (SQV; Invirase®) + RTV~* ATV (no booster)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG"
41038948|NCT06486740|DEVICE|mesofiller aox|The investigated product M-AOX-2021 was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. The both sessions was conducted within 14 days interval.
41166948|NCT02921139|PROCEDURE|Re-Transcatheter arterial chemoembolization (re-TACE)|Patients with HCC after incomplete TACE are randomized to further re-TACE.
41166949|NCT04387903|PROCEDURE|Surgical re-interventionafter pancreaticoduodenectomy|Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.
41166950|NCT04438330|OTHER|Nickel sulfate hexahydrate|Patch test
41166951|NCT00131898|PROCEDURE|Surgical Resection|
41166952|NCT00131898|PROCEDURE|Intensity Modulated Radiation Therapy (IMRT)|
41166953|NCT06302413|DEVICE|Virtual Reality|They will receive a Virtual Reality Park experience, which is an empty park with no avatars. They will then have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
41388808|NCT04006691|DRUG|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
41388809|NCT02134769|DEVICE|Bionecteur|Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
41038949|NCT02478411|PROCEDURE|Cycle ergometer physiotherapy|15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy
41038950|NCT02478411|PROCEDURE|Conventional physiotherapy|30 minutes of conventional physiotherapy
41038951|NCT05020223|OTHER|Vital pulp therapy|Vital pulp therapy different modalities for management of deep carious lesion in primary teeth
41388810|NCT01481961|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
41388811|NCT03425773|BIOLOGICAL|BVAC-B|Autologous B cell and monocyte presenting HER2/neu antigen
41038952|NCT04786158|DRUG|Apomorphine|Reporting the effects of subcutaneous apomorphine on pain and on quality of life
41038953|NCT02053948|PROCEDURE|Pursestring Wound Closure|
41166954|NCT06302413|DEVICE|Virtual Reality|They will receive a Virtual Reality Park experience, which is an empty park with no avatars.
41388812|NCT06199973|DRUG|SHR-A1811|SHR-A1811(4.8 mg/kg) was administered intravenously on the first day of each cycle, once every 3 weeks (Q3W)
41388813|NCT06199973|DRUG|TAS-102, Regorafenib , Fruquintinib|physician choiced treatment,include: TAS-102(35 mg/m2, maximum 80 mg per dose), twice daily (BID) , once every 4 weeks (Q4W) , up to 3 years; or Regorafenib 160mg, once daily (QD) , once every 4 weeks (Q4W) , up to 3 years; or Fruquintinib 5mg once daily (QD) , once every 4 weeks (Q4W) , up to 3 years.
41166955|NCT01537406|RADIATION|BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY|LONG TERM OUTCOMES OF A MULTICENTRE CONTROLLED CLINICAL TRIAL OF BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
41388814|NCT05742061|DRUG|Corticosteroid|The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
41388815|NCT05742061|OTHER|Platelet Rich Plasma|PRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.
41511752|NCT05752825|DIAGNOSTIC_TEST|Visual acuity test|Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).
41511753|NCT00325871|PROCEDURE|concurrent chemoradiation|
41511754|NCT06228001|DEVICE|Actimyo|Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
41511755|NCT05966415|DIETARY_SUPPLEMENT|Endocalyx Pro|4 capsules once daily OR 2 capsules twice daily.
41511756|NCT05966415|OTHER|placebo|4 capsules once daily OR 2 capsules twice daily
41511757|NCT05761665|OTHER|Evaluation|Kinesiophobia=Tampa scale Balance=Berg Balance Scale Falling=The Fall Activity Scale( Tinetti) Walking speed=Timed Get Up and Walk Test ,Two-Minute Walking Test Fragility=Frail Fragility Questionnaire, Clinical Fragility Scale
41511758|NCT02351661|OTHER|There was no intervention|observational study, no intervention
40857730|NCT01996280|BEHAVIORAL|Culturally Tailored MI|CTMI is a single brief motivational intervention lasting 1.5hrs. The CTMI follows the same sequence of structured strategies as the MI arm, and while the components in CTMI and MI are parallel, the focus within them is different. CTMI components culturally relevant material, such as acculturation stress. The CTMI components, which are MI structured strategies, are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback element, such as ethnic normative feedback related to drinking.
41511759|NCT03632915|DRUG|Levetiracetam|Standard of care
41511760|NCT03632915|DRUG|Lacosamide|Standard of care
41038954|NCT02053948|PROCEDURE|Gunsight Skin Incision and Closure Technique|
41038955|NCT02804854|DRUG|Neutrophil Activation Probe (NAP)|Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
41038956|NCT02151279|OTHER|Chitosan as wine fining agent|The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
41166956|NCT06134583|PROCEDURE|Superior cervical sympathetic block group|5 ml bupivacaine 0.5% will be injected around the internal carotid artery at the level of carotid bifurcation
41166957|NCT06134583|PROCEDURE|Stellate ganglion block group|5 ml bupivacaine 0.5% will be injected between the common carotid artery and longus capitis muscle at the level of C7 vertebra
41166958|NCT00317447|DRUG|Oral Prednisone|
41166959|NCT04187430|BEHAVIORAL|Retrospective|Those patients with a positive sample for ICD will be randomly selected from the microbiology database.
41511761|NCT03632915|DRUG|Phenytoin|Standard of care
41511762|NCT03632915|DRUG|Phenobarbital|Standard of care
41511763|NCT03632915|DRUG|Ketamine|Standard of care
41511764|NCT03632915|DRUG|Valproic Acid|Standard of care
41511765|NCT00215423|DRUG|Formoterol Fumarate|
41511766|NCT03758716|DRUG|FB825, FB825-15D11, Anti-CemX|Pharmaceutical form: 20mg/ml solution Route of administration: IV
41511767|NCT00779831|DRUG|120 mg Pseudoephedrine hydrochloride extended release tablets|
40857731|NCT00357617|DRUG|celecoxib|
41511768|NCT06357585|OTHER|Web based education|Web-based training will be provided to the parents in the experimental group regarding care practices for children diagnosed with leukemia.
40857732|NCT00357617|GENETIC|microarray analysis|
40857733|NCT00357617|GENETIC|protein expression analysis|
40857734|NCT00357617|OTHER|immunoenzyme technique|
41511769|NCT06357585|OTHER|inactive group|Parents in the control group will continue to receive routine care and treatment.
41511770|NCT05088850|OTHER|no intervention|no intervention
41511771|NCT00125671|DRUG|Warfarin|
40857735|NCT00357617|OTHER|immunohistochemistry staining method|
40857736|NCT00357617|OTHER|laboratory biomarker analysis|
40857737|NCT00357617|PROCEDURE|biopsy|
40857738|NCT00357617|PROCEDURE|conventional surgery|
40857739|NCT00357617|PROCEDURE|neoadjuvant therapy|
41038957|NCT02151279|OTHER|Control|
41038958|NCT03959865|DRUG|Long-acting GLP-1RA|Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg
41038959|NCT03959865|DRUG|Short-acting GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or exenatide 10 mcg or 20 mcg bid or lixisenatide 10 mcg or 20 mcg / day.
41038960|NCT03959865|DRUG|Human-based GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or dulaglutide 0.75 or 1.5 mg / week
41388816|NCT02006355|DRUG|Ropivacaine|
41511772|NCT02016183|DRUG|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
41511773|NCT02749500|OTHER|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
41511774|NCT02749500|DEVICE|m2 BAT|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy.
41511775|NCT06582797|OTHER|discontinuation of ART|patient will discontinue their standard of care HIV treatment with ART while being closely monitored
41166960|NCT04187430|BEHAVIORAL|Prospective|After the routine identification of a case of DCI by the microbiology laboratory, those new cases will be included in the study.
41166961|NCT00691678|DRUG|Chondroitin|400mg chondroitin three times a day (TID) for twenty-four weeks
41166962|NCT00691678|DRUG|Glucosamine|500mg glucosamine TID for twenty-four weeks
41166963|NCT05183243|DRUG|GH21 Capsule|GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
41166964|NCT06478576|DEVICE|multibranched stent graft system|To evaluate the feasibility of multibranched stent graft system for Endovascular Treatment of Thoracoabdominal Aortic Aneurysm(TAAA)
41166965|NCT04932226|DEVICE|cloth mask|Buff bandana double layer worn over nose and mouth
41166966|NCT04932226|DEVICE|surgical mask|standard surgical mask
41166967|NCT04932226|DEVICE|FFP2 respirator|filtering facepiece 2 respirator
41388817|NCT01652482|DRUG|5-fluorouracil|Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter \[mg/m\^2\] administered as intravenous bolus and then 5-FU 2400 mg/m\^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
41388818|NCT01652482|DRUG|Cetuximab|Cetuximab 400 mg/m\^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m\^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
41388819|NCT01652482|DRUG|Irinotecan|Standard Irinotecan chemotherapy (180 milligram per square meter \[mg/m\^2\] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
41511776|NCT01662687|DRUG|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy."
41511777|NCT01662687|DRUG|Kytril inj.+Kytril tab.|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~* Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~* Kytril tab. 1mg: administered twice a day by orally at Day 2\~4."
41166968|NCT03951012|PROCEDURE|Blood draw|Participants will be approached during their regular clinic visits and asked if an extra tube of blood may be collected prior to the treatment. If consent is not obtained before this visit, a participant will be asked later in the same day. The amount of blood collected will be 2 teaspoons (10mL).
41511778|NCT05821335|OTHER|Leap motion assisted rehabilitation|Hand Therapy via leap motion sensor
41166969|NCT04578899|DEVICE|Transvertebral magnetic stimulation|Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
41166970|NCT00996814|BEHAVIORAL|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
41166971|NCT03987464|BEHAVIORAL|Planning for the Future|This intervention will include attending an advance directives meeting, a living arrangements workshop, and a psychosocial education training workshop.
41166972|NCT03987464|BEHAVIORAL|Enhanced Medical Engagement|This intervention includes creating a health portfolio, health record access training, and a medical engagement workshop
41166973|NCT03987464|BEHAVIORAL|Confidence Building and Social Engagement|This intervention includes mindfulness training, a pre-experience training techniques workshop and a memory strategies class.
41166974|NCT03987464|BEHAVIORAL|Physical Intervention|This intervention includes physical/occupational therapy (PT/OT), a home safety assessment, and an independent exercise program.
41511779|NCT05821335|OTHER|Traditional program|Hand Therapy by physiotherapist via traditional methods
41511780|NCT03757312|DIAGNOSTIC_TEST|Ultrasound|Ocular ultrasound to measure optic nerve sheath diameter (ONSD).
41166975|NCT03987464|BEHAVIORAL|Medical Adherence|This intervention includes using automated pillboxes to ensure medication compliance, optimizing appropriate medication use through review, and engaging with memory medications via class.
41166976|NCT03644615|OTHER|Mindfluness and usual care|Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.
41166977|NCT03644615|OTHER|Usual care|No intervention on the patients
41388820|NCT01652482|DRUG|Leucovorin|Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
41388821|NCT01652482|DRUG|MEHD7945A|MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
41511781|NCT05854524|PROCEDURE|Aerobic exercise|The intervention is exercise and there are no drugs or devices used in this trial. The exercise consists of two intensity levels of a 30-minute aerobic exercise intervention with both arms crossing over to both conditions: low intensity exercise (60-70% of estimated maximum heart rate (EMRH)) and moderate-vigorous intensity exercise (75-85% of EMHR).
41511782|NCT00902694|BEHAVIORAL|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
41511783|NCT00902694|OTHER|Control|group health classes quarterly with topics not related to weight
41388822|NCT02233881|DRUG|Atrovent® - inhalets|
41388823|NCT02588742|DIETARY_SUPPLEMENT|Melatonin|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
40857740|NCT01957202|DRUG|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
40857741|NCT01957202|DRUG|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
40857742|NCT01957202|DRUG|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
40857743|NCT01957202|DRUG|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
40857744|NCT03658447|DRUG|Pembrolizumab|200mg Pembrolizumab given 3 weekly for upto 35 cycles
40857745|NCT03658447|DRUG|177Lu-PSMA|6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
40857746|NCT01252706|BEHAVIORAL|brief intervention|limit time giving information, motivation, empathy, responsibility, self control
41388824|NCT02588742|DIETARY_SUPPLEMENT|Placebo|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
41388825|NCT03022019|DEVICE|ReNovaCell|
41388826|NCT03534830|DIAGNOSTIC_TEST|MRI|pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
41388827|NCT01888978|DRUG|Gem-OX|
41388828|NCT01888978|DRUG|Gem-5FU|
41388829|NCT01888978|DRUG|Gem-Tax|
41388830|NCT01888978|DRUG|Modified FOLFOX-6|
41388831|NCT01888978|DRUG|Ox-Tax|
41388832|NCT01888978|DRUG|FOLFIRI|
41388833|NCT01888978|DRUG|Tax-Iri|
41388834|NCT04045600|BEHAVIORAL|Trad FCT|This intervention emulates a traditional reinforcement schedule-thinning method during FCT in which clinicians program delays to reinforcement without discriminative stimuli (e.g., the child learns that some FCRs result in reinforcement and some do not). By programming reinforcement approximately every 15 s, the rate of reinforcement will be equivalent to mult FCT. During Period 1 of this project, trad FCT served as an appropriate control condition to which mult FCT could be compared.
41388835|NCT04045600|BEHAVIORAL|Mult FCT|This intervention involves correlating discriminative stimuli (e.g., purple and yellow index cards) with times in which reinforcement for the functional communication response (FCR) is and is not available. During Period 1 of this project, this procedure resulted in rapid reduction of destructive behavior and mitigated resurgence and renewal when the discriminative stimuli were used as programmed.
41388836|NCT04045600|BEHAVIORAL|Mult FCT + Stimulus Fading|This condition is similar to mult FCT except that the experimenters will gradually incorporate natural stimuli (e.g., rugs, tables, lamps) into sessions to approximate target settings that may occasion relapse typically without such gradual stimulus fading.
41388837|NCT03428217|DRUG|CB-839|Oral glutaminase inhibitor
41388838|NCT03428217|DRUG|Cabozantinib|Oral receptor tyrosine kinase inhibitor
41388839|NCT03428217|DRUG|Placebo|Placebo tablets
41388840|NCT02837263|RADIATION|Stereotactic body radiotherapy (SBRT)|"SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.~SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning."
41388841|NCT02837263|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
41388842|NCT05614999|OTHER|Endoscopy training curriculum|Eight sessions training in endoscopic tip control using Varix trainer model I.
41388843|NCT00597727|DRUG|Peanut SLIT|Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
41388844|NCT00597727|DRUG|Placebo SLIT|Liquid glycerin without peanut which are dosed under the tongue.
41388845|NCT02414490|DRUG|Intravenous Immunoglobulin|The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
41388846|NCT05242146|DRUG|GB5121|Capsule containing GB5121
41388847|NCT05515627|DRUG|Atezolizumab|Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
41388848|NCT01104935|DRUG|trastuzumab monotherapy|
41388849|NCT01104935|DRUG|trastuzumab and chemotherapy|
41388850|NCT00179218|DRUG|nutritional supplementation|oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
41388851|NCT00179218|BEHAVIORAL|exercise|leg press exercise; every other day, 3 days per week, for 6 months
41388852|NCT03367273|OTHER|skin biopsy|Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject
41388853|NCT02001285|DRUG|Remifentanil|During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
41388854|NCT02065882|BIOLOGICAL|BT524 (fibrinogen concentrate from human plasma)|single intravenous infusion
41511784|NCT03846193|BIOLOGICAL|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
41511785|NCT03846193|BIOLOGICAL|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
41511786|NCT03846193|BIOLOGICAL|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
41511787|NCT03846193|BIOLOGICAL|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
40857747|NCT05303818|DRUG|Rivaroxaban 10 MG|Patients in post-operative colonic cancer will receive rivaroxaban 10mg/daily for 28 days after surgery
41511788|NCT03846193|DEVICE|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
41511789|NCT03846193|DEVICE|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
41511790|NCT03846193|DEVICE|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
41511791|NCT03872687|DEVICE|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size that will fit the interdental spaces around the implant.
40857748|NCT03776201|OTHER|Balance Training|We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.
40857749|NCT05485623|DEVICE|PulseNmore FC|"Pulsenmore Ltd. has developed a small portable vaginal ultrasound device for personal use at home. The ultrasound device allows to scan and assess both the uterus and the ovaries. This ultrasound device connects to a smartphone and a user-friendly application simplifies its use. This ultrasound device is based on the company's 'Pulsenmore ES ultrasound system' which is a small abdominal ultrasound device for home and self-use by pregnant women. This (abdominal) ultrasound device allows scanning and detection of fetal pulse, count fetal movements, assess the amount of amniotic fluid and more. The device is an abdominal ultrasound probe that connects to a smartphone using a specially designed socket. The main difference between the devices is the different design of the ultrasound vaginal probe.~The device consists of 2 components: a cradle and an application (software). The cradle contains the electronic components and the ultrasound probe."
40857750|NCT04615039|DEVICE|PROFEMUR® Preserve Classic Femoral Stem|Single study group of subjects, either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with any type of polyethylene and ceramic acetabular shells, acetabular liners and femoral heads.
41511792|NCT03872687|DEVICE|interdental brushes|Subjects in this group will only receive interdental brushes
41511793|NCT02074007|DRUG|AR01|drops administered as needed for pain
41511794|NCT02074007|DRUG|Placebo Comparator|Glycerin ear drops (placebo) drops administered as needed for ear pain
41511795|NCT03349346|DRUG|Idelalisib|Tablet (s) or dispersible tablets for suspension administered orally twice daily
41511796|NCT03349346|DRUG|Rituximab|375 mg/m\^2 administered intravenously
41511797|NCT03349346|DRUG|Ifosfamide|3 mg/m\^2 administered intravenously
41511798|NCT03349346|DRUG|Carboplatin|635 mg/m\^2 administered intravenously
41511799|NCT03349346|DRUG|Etoposide|100 mg/m\^2 administered intravenously
41511800|NCT00307086|DRUG|Bortezomib|the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
41511801|NCT00307086|DRUG|Melphalan|Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
41511802|NCT00307086|PROCEDURE|PBSCT|PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
41511803|NCT05115695|OTHER|traditional physiotherapy approach|Traditional upper extremity strengthening and tonus regulation (weight shifting, weight bearing, active reaching in sitting exercises) exercises consisting of Neurodevelopmental Therapy (NDT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
40857751|NCT01843023|DRUG|Extended Release Naltrexone|naltrexone for extended release injectable suspension
40857752|NCT01843023|BEHAVIORAL|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
40857753|NCT01843023|DRUG|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
40857754|NCT00276809|BIOLOGICAL|alemtuzumab|
41511804|NCT05115695|OTHER|muscle strengthening exercise/Proprioceptive Neuromuscular Facilitation (PNF)|Muscle strengthening with scapular and upper extremity patterns of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
41511805|NCT02268877|OTHER|Emergency Medicine Physician Ultrasound|An ultrasound will be performed by an emergency medicine resident or attending physician
41511806|NCT02268877|DEVICE|Ultrasound|An ultrasound will be performed by a radiology department technician
40857755|NCT00276809|BIOLOGICAL|filgrastim|
40857756|NCT00276809|DRUG|carmustine|
40857757|NCT00276809|DRUG|cyclophosphamide|
41511807|NCT05450419|DIETARY_SUPPLEMENT|Vitamin D3|8pc (576,000 IU/40ml) vitamin D3 on week 1, then 1pc (72,000 IU/5ml) vitamin D3 on week 2, week 3 \& week 4.
41511808|NCT05450419|DIETARY_SUPPLEMENT|placebo|8pc placebo on week 1, then 1pc placebo on week 2, week 3 \& week 4.
41511809|NCT06460805|DIETARY_SUPPLEMENT|Partial enteral nutrition|70% caloric intake from enteral nutrition formula and 30% caloric intake from a limited range of solid foods
41511810|NCT05198180|DRUG|Topical 30%Potassium hydroxide solution|Patients will apply the solution every day under occlusion for 3 months
41511811|NCT05198180|DRUG|Topical 45% hydrogen peroxide solution|Patients will apply the solution every day under occlusion
41511812|NCT02135614|DRUG|Presatovir|Presatovir 200 mg (4 x 50 mg tablets) administered orally
41511813|NCT02135614|DRUG|Presatovir placebo|Presatovir placebo tablets administered orally
41511814|NCT06058104|DEVICE|Charades based mobile digital therapeutic|The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child 15 minutes 3-4 times per week for 8 weeks.
41388855|NCT03476837|BEHAVIORAL|Treatment|The CHWs will go to the homes of the WCGs who enroll in the study and will use a culturally-adapted motivational interviewing protocol, educational messages pilot tested during the formative research phase, and biofeedback based on the child's saliva sample and WCG's carbon monoxide. Saliva samples will be collect from one child in the home at baseline and final. Baseline saliva data and carbon monoxide monitoring will be used to develop feedback that aims to motivate WCGs to implement and sustain comprehensive smoke free policies. The intervention will last 6 months. We will measure changes in primary and secondary outcomes at multiple assessment points.
40857758|NCT00276809|DRUG|cytarabine|
40857759|NCT00276809|DRUG|dexamethasone|
40857760|NCT00276809|DRUG|etoposide|
40857761|NCT00276809|DRUG|fludarabine phosphate|
40857762|NCT00276809|DRUG|melphalan|
40857763|NCT00276809|PROCEDURE|autologous bone marrow transplantation|
40857764|NCT00276809|PROCEDURE|peripheral blood stem cell transplantation|
40857765|NCT00276809|RADIATION|radiation therapy|
40857766|NCT01542710|DRUG|Ganfort|Bimatoprost/Timolol fixed combination
40857767|NCT01542710|DRUG|Duotrav|Fixed combination of Travoprost and Timolol
41388856|NCT03476837|BEHAVIORAL|Control|Following baseline assessment, at 1, 3, and 6 months, WCGs in the control group will educational materials in the mail. Final follow-up assessments will occur at 12 months.
41388857|NCT06518993|DEVICE|Total hip arthroplasty with a Trinity cup and a Meije Duo cementless stem|Subjects clinically suitable for a primary THR surgery with Trinity cup and Meije Duo cementless femoral stem.
41388858|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control
41388859|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
41388860|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
41388861|NCT01304563|BIOLOGICAL|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental
41388862|NCT03526185|DRUG|Tumor Infiltrating Lymphocytes|The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
41388863|NCT03526185|DRUG|Nivolumab and Ipilimumab|• Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
41388864|NCT01834573|BEHAVIORAL|physical exercise|10 weeks physical exercise; three times a week
41511815|NCT03893084|OTHER|Pregnancy preparation training|Pregnancy preparation education; folic acid use, physical activity, nutrition, addictions counseling issues are included.
41511816|NCT02548390|DRUG|RXDX-107|Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
41388865|NCT02063386|DRUG|AZD1722|Single oral dose 15 mg of \[14C\]AZD1722
41388866|NCT04931134|DEVICE|Trigeminal nerve stimulation - active|Active trigeminal nerve stimulation
41388867|NCT04931134|DEVICE|Trigeminal nerve stimulation - sham|Sham trigeminal nerve stimulation
41388868|NCT02955784|DEVICE|Sinasprite Mobile App|Mobile App
40857768|NCT06068036|BEHAVIORAL|Telehealth intervention: HEARTS technical package + activity monitor (Smartwatch Mi Band 7®)|Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
40857769|NCT06068036|BEHAVIORAL|Telehealth intervention: HEARTS technical package|The same intervention as the experimental group, but without the additional use of the physical activity monitor (Smartwatch Mi Band 7®).
40857770|NCT05082246|OTHER|Conscious Breathing|During the Conscious Breathing session, participants will be asked to sit comfortably and with gently closed eyes. Participants will be guided through several different kinds of breathing techniques, where the will focus will be on the expansion of the chest or abdomen, releasing all tension from the body, and visualizing breathing light into the body.
40857771|NCT05082246|OTHER|Heartfulness Meditation|During the Heartfulness Meditation session, participants will be asked to sit comfortably and with gently closed eyes. Starting with the feet and working towards the head, participants will be asked to relax each part of the body. Then participants will focus on the heart and imagine it filled with light and love. Participants will sit in this relaxed state for a few minutes to allow all stress and cares to be released.
41038961|NCT03959865|DRUG|Exendin-based GLP-1RA|Exenatide 10 mcg or 20 mcg day or 2 mg / week or lixisenatide 10 mcg or 20 mcg / day.
41038962|NCT03959865|DRUG|Fixed ratio BI/GLP-1RA combination|Insulin degludec / liraglutide (0.036/U) or insulin glargine / lixisenatide (0.5 mcg/U)
41388869|NCT04155957|OTHER|Rapid Recovery Rehabilitation Programme|"Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises."
41388870|NCT04155957|DEVICE|ReHub|"Participants use a telerehabilitation platform, ReHub, as a guide to perform the TKA rehabilitation exercises of the Rapid Recovery Rehabilitation Programme intervention.~The exercise plan in ReHub is carried out by a site physiotherapist on the first day after discharge by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor that transmits data to the platform.~The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. At the end of each exercise, participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
41388871|NCT02233465|PROCEDURE|IPOM Mesh-repair parastomal hernia|Safety study for mesh-repair of parastomal hernia
41511817|NCT05017246|DRUG|Bupivacaine|-Epidural bupivacaine 0.1% 2-6ml/hr based on MAP within 10% of patient's baseline MAP
41511818|NCT05017246|DRUG|Morphine|-Preservative-free intrathecal morphine (duramorph) 150mcg injection (0.15ml or a 0.5mg/0.5ml prepared solution)
41511819|NCT05017246|DRUG|Lidocaine|-Lidocaine infusion 1 mg/kg ideal body weight (IBW)
41511820|NCT01464632|DEVICE|EPIK™ uni-compartmental knee|This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
41511821|NCT04555317|COMBINATION_PRODUCT|Musculoskeletal health package|3 month prehabilitation exercise program during radiotherapy with assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
41511822|NCT04530955|DEVICE|Prometra II Programmable Pump - Flowonix Medical|The valve gated Prometra II Programmable Pump will be replacing the prior peristaltic Synchromed II pump and a 20% dose decrease will be performed at the time of the replacement.
41388872|NCT03555500|OTHER|Non fasting|Non fasting group is allowed for clear fluids and food up to the time of the procedure.
41388873|NCT04976088|DRUG|Diclofenac Sodium 140 mg medicated plaster|Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day
41388874|NCT04976088|DRUG|Diclofenac epolamine (DIEP) 180mg medicated plaster, Flector|Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day
41388875|NCT04976088|DRUG|Placebo|Placebo: Placebo plaster, topical application once a day.
41511823|NCT01657435|DEVICE|Ceramax Acetabular System|28mm Ceramic-on-ceramic Acetabular Cup System
41511824|NCT05107648|BEHAVIORAL|Gardner GOALS|12 lesson curriculum focusing on healthy eating, increased physical activity and decreased screen time
40857772|NCT05082246|OTHER|Emotional Freedom Technique|"During the Emotional Freedom Technique session, participants will be asked to tap lightly on several acupressure points while saying a variety of statements regarding pain, anxiety, depression or stress. As participants tap on the acupressure points, participants will repeat phrases of affirmation and acceptance, and also talk through how pain, anxiety, depression or stress may cause distress but can learn to release these feelings. participants will be given a picture of where each of the acupressure points lie on the face, chest or head, and will also be given a script of what to say while tapping on each acupressure point. In addition, participants will be given a description of what each acupressure point means - its associated organ and what emotion that point helps to release."
40857773|NCT06016868|PROCEDURE|Tumor tissue|Each newly diagnosed patient with LACC who meets the inclusion criteria will undergo cervical cancer biopsy either during the outpatient clinical examination or during examination during anesthetic. Part of the biopsy will be sent for histopathological analysis, while the remaining tissue will be embedded in OCT compound and immediately frozen at -80°C prior to transfer to biobank for subsequent analysis.
41388876|NCT02993016|PROCEDURE|patient-specific instruments|
41388877|NCT02993016|DEVICE|The Signature™ Vanguard|
41511825|NCT04358055|DEVICE|WET® gel|In each application, a puff should be administered in each nostril every two seconds, with minimal inspirations, up to a sensation of lubrication in the external conduct is perceived. Then the patient should proceed with short inspirations and light touching of ala of the nose, to favour the distribution of the gel. A maximum of 4 erogations (2/nostril) is allowed in each application session.
41511826|NCT02688660|OTHER|MRI Scans|
41511827|NCT02396719|DEVICE|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
41511828|NCT05445492|DEVICE|CPM Device|The CPM device and reference device are used simultaneous to validate the CPM device.
41511829|NCT04031625|OTHER|Metastatic Colorectal Cancer Database|Metastatic Colorectal Cancer Database
41511830|NCT03906110|BEHAVIORAL|Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) Materials|Educational materials (photonovella +DVD) + Fecal Immunochemical Test (FIT) kit. Offers colorectal cancer screening information using a novella format. Materials describe colorectal cancer and screening tests that are available, and procedures for completing FIT kit.
41511831|NCT03906110|BEHAVIORAL|Contact Message|Card with a general message about colorectal cancer screening. This same message will be delivered at 3 time points.
41511832|NCT03906110|BEHAVIORAL|Personalized One on One Education|"* Trained study coordinators will meet with participant for a brief 15 minute educational session delivered in clinic that summarizes information from the materials and demonstrates FIT collection.~* Email or text reminders with brief messages in clear language will be sent that aim to remind and prompt patients to complete FIT.~* For participants that are not responsive to above, trained study staff will address specific FIT specific hinderances by telephone or in clinic.~* Participants will receive a one page summary of key points of salience of repeat screening GET FIT AGAIN. Another FIT kit is provided."
41511833|NCT03906110|DIAGNOSTIC_TEST|Fecal Immunochemical Test (FIT)|The Fecal Immunochemical Test (FIT), is a screening test that detects hemoglobin in stool samples, only requiring one stool sample.
41388878|NCT02993016|PROCEDURE|conventional instruments|
41388879|NCT02993016|DEVICE|Vanguard PS(posterior stabilized)|
41388880|NCT00533585|DRUG|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
41388881|NCT00533585|DRUG|Paclitaxel|200 mg/m\^2 By Vein Over 3 Hours on Day 1.
41388882|NCT00533585|DRUG|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
40857774|NCT06016868|PROCEDURE|Blood sample|Every patient will undergo a peripheral venous blood sample which will be processed to analyze the presence of the proteins codified by three RNA species (ANXA2-NDRG1-STAT1). This blood sample will be performed before starting the treatment with exclusive CTRT.
40857775|NCT06051344|DRUG|Zoledronic acid|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
40857776|NCT05179525|DRUG|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
40857777|NCT05179525|DRUG|Risperdal 4mg Tablet|4 mg oral risperidone once daily for 7 days
40857778|NCT03138161|DRUG|Trabectedin|Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
40857779|NCT03138161|DRUG|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
40857780|NCT03138161|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
41388883|NCT00533585|DRUG|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
40857781|NCT03071393|DEVICE|Hypoxia via Hypoxico Hyp-123|During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
40857782|NCT03071393|DEVICE|Sham via Hypoxico Hyp-123|During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
40857783|NCT06304623|BIOLOGICAL|Autologous adipose-derived SVF IV administration|Subjects received an intravenous injection of autologous adipose-derived SVF.
41388884|NCT04441801|OTHER|stretching exercise|Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position
41388885|NCT03644459|BIOLOGICAL|LYN00101|"Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.~Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg."
41388886|NCT04701658|DRUG|Bamlanivimab|Administered intravenously.
41388887|NCT05128331|DIETARY_SUPPLEMENT|spermidineLife|dietary supplement that is made of natural wheat germ extract with high spermidine content
41388888|NCT05128331|DIETARY_SUPPLEMENT|Placebo|dietary supplement that is made of cellulose.
41388889|NCT00140738|BIOLOGICAL|GSK Biologicals' 719125|Patients receive six vaccinations at two-week intervals
41511834|NCT01232452|DRUG|Pemetrexed|Administered intravenously (IV)
41511835|NCT01232452|DRUG|Cisplatin|Administered IV
40857784|NCT01916434|OTHER|High PUFA Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (\~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
40857785|NCT01916434|OTHER|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (\~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
41388890|NCT00315328|DRUG|Atropine|Atropine 1% each weekend day in the sound eye
41388891|NCT00315328|DEVICE|Patching|Patching 2 hours per day
41388892|NCT00315328|PROCEDURE|Near activities|near visual activities for at least one hour per day
41388893|NCT04501341|BIOLOGICAL|Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC|Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas according to the results of previous pancreatic CT-scan, performed by interventional radiologist. The target is to distribute the BM-MNCs equally in all part of the pancreas. Dosage: 1 x 10\^5 - 1 x 10\^6 CD34 cells/kgBW
41388894|NCT04501341|BIOLOGICAL|Intravenous Infusion of UC-MSC|Allogeneic umbilical cord tissue-derived mesenchymal stem cells will be given via intravenous infusion. Dosage: 2 x 10\^6 cells/kgBW, twice, with three months interval
41511836|NCT01232452|DRUG|Cixutumumab|Administered IV
41511837|NCT00074308|DRUG|imatinib mesylate|Given orally
41511838|NCT00074308|BIOLOGICAL|bevacizumab|Given IV
41511839|NCT00074308|OTHER|pharmacological study|Correlative studies
41511840|NCT00074308|OTHER|laboratory biomarker analysis|Correlative studies
41511841|NCT03551821|DRUG|ATI-50002|Topical Solution
41511842|NCT00528047|DRUG|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
41388895|NCT06127979|PROCEDURE|core needle biopsy|Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied
41388896|NCT06127979|OTHER|blood draw|blood draw
41388897|NCT00247130|DRUG|Omeprazole|
41388898|NCT00247130|DRUG|Ranitidine|
41388899|NCT05770219|DRUG|TAK-755|TAK-755 as IV injection at dose calculated based on the participant's body weight as measured at each dosing visit. For most participants, the final volume of infusion will be between 5 and 14 mL.
41388900|NCT02184169|DEVICE|General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments|Breath to breath VO2 measurements
41511843|NCT00792961|DEVICE|Endomicroscopy|Rigid drop-in endomicroscope imaging probe
41511844|NCT02771470|DRUG|Probiotics|Microbial composition using probiotic
40857786|NCT01916434|OTHER|No salmon|The placebo group will continue to consume their habitual diet.
40857787|NCT03041896|DEVICE|coflex® Interlaminar Technology|Interlaminer Technology
40857788|NCT05535413|DRUG|UTD1 combined with capecitabine|"UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle."
40857789|NCT01554449|PROCEDURE|serious game reeducation|It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
40857790|NCT01554449|PROCEDURE|functional MRI|the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
40857791|NCT00887926|BIOLOGICAL|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
40857792|NCT04596748|DIETARY_SUPPLEMENT|Probiotic|Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102
41388901|NCT02184169|DEVICE|Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr|Edwards continuous SVO2 measurement system
41388902|NCT05385276|PROCEDURE|Transverse supraumbilical incision|The skin incision will be performed as a straight transverse skin incision 3-5cm above umbilicus after maximum retraction the panniculus caudally using two towel clips, to facilitate the approach to the lower uterine segment The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm) .
41388903|NCT05385276|PROCEDURE|Pfannenstiel Incision|The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm).
41388904|NCT06385145|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
41388905|NCT06385145|DRUG|PEG-rhGH with present preparation (R)|A single subcutaneous injection of PEG-rhGH with present preparation
41388906|NCT05785221|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive general dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
41388907|NCT05785221|BEHAVIORAL|Personalized nutritional and lifestyle weight reduction intervention|Participants will receive personalized dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes, physical activities and sleep conditions and APP-connected scale will be used to monitor their weight changes during interventions.
41388908|NCT00046020|DRUG|Venlafaxine ER|
41511845|NCT02771470|DRUG|placebo|Microbiota modulation using placebo
41511846|NCT05446012|DIAGNOSTIC_TEST|thyroid function tests|blood sample for thyroid function tests (TSH,T3,T3,Anti peroxidase antibody, anti thyroglobulin antibody)
40857793|NCT04596748|DIETARY_SUPPLEMENT|Placebo|Placebo caps
40857794|NCT00729963|DRUG|Sibutramine|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (\< 1.8 kg) over the first month of treatment.
40857795|NCT00729963|DEVICE|CPAP|
41511847|NCT01210872|OTHER|questionnaire administration|
41511848|NCT01210872|PROCEDURE|quality-of-life assessment|
41511849|NCT01210872|PROCEDURE|standard follow-up care|
41511850|NCT04298632|BEHAVIORAL|Safety Education Program|this is a pesticide safety education program
41511851|NCT00138008|DRUG|endocrine therapy|Drug: endocrine therapy
41511852|NCT00138008|PROCEDURE|radiotherapy|Procedure/Surgery: radiotherapy
41511853|NCT02796053|DRUG|TAB08|The TAB08 will be administered intravenously, by infusion.
41511854|NCT02796053|OTHER|Placebo|The Placebo to TAB08 will be administered intravenously, by infusion.
41511855|NCT06471374|BEHAVIORAL|Circadian rhythm assessment|Participants will arrive approximately 8 hours before participant's scheduled bedtime to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 66 hours (2.75 days). Upon awakening in the morning, participants will start a routine of up to 39 hours of wakefulness, under bedrest conditions. Saliva will be sampled frequently and blood will be drawn 3 times. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will be provided scheduled bathroom breaks when participants will use a commode next to the bed. Outside these scheduled bathroom breaks, participants will be provided a bedpan to use to go to the bathroom. At the end of the research procedures for Visit 4 participants will be given a recovery sleep opportunity and be discharged from the lab in the morning near participant's typical waketime.
41511856|NCT06471374|BEHAVIORAL|Light sensitivity assessment|Participants will arrive in the afternoon to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 48 hours (2 days). Upon awakening in the morning, participants will be exposed to dim candlelight and then later in the day alternating intensities of dim and room light when we keep participants awake for up to 23 hours (We will ask participants to remain in bed seated for \~12.5 hours). Saliva will be sampled frequently. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will then have a second 9-hour sleep opportunity.
41511857|NCT02045901|DRUG|Diclegis|On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
40857796|NCT04505332|PROCEDURE|arthroplasty|back pain in orthopedists due to working actively and performing arthroplasty every day
41388909|NCT05931952|OTHER|Buteyko breathing technique|"Group A: Buteyko breathing technique and conventional (chest physiotherapy) treatment for 5 times a week for about 20 minutes in one session for a period of 4 weeks. There are three steps involved in buteyko breathing technique.~Step 1; control pause breathing test (patient is asked to sit in an upright position and take normal breath. After this, asked the patient to take small breath-in for 2s and out for 3s. Control pause phase should not exceed for \>30 seconds).~Step 2; maximum pause or shallow breathing (patient is asked to place fingers under the nose to monitor inflow of air. 2 or 3 flickers of air is taken in and exhale as slowly as possible).~Step 3; combine step 1 and 2. Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
41388910|NCT05931952|OTHER|Papworth method|"Papworth method and conventional chest physiotherapy (bronchial drainage) treatment. Intervention will be given for a period of 5 sessions per week for 1 month. Duration of each session will be 20 minutes. This technique is performed particularly during remission period that make it feasible for respiratory physiotherapist to integrate this method into activities of daily living. Papworth method has five components including Papworth method ameliorates asthmatic symptoms breathing, education, relaxation, combination of breathing and relaxation exercise and home exercises and also improves quality of life.~Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
41388911|NCT06036706|RADIATION|Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning|Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy...)
41388912|NCT06036706|RADIATION|Hypo-fractionated stereotactic brain irradiation|Patients receiving hypo-fractionated stereotactic brain irradiation
41388913|NCT06036706|RADIATION|Normo-fractionated proton therapy brain irradiation|Patients receiving normo-fractionated proton therapy brain irradiation
41388914|NCT06036706|OTHER|Cognitive assessment by a trained neuropsychologis|Participants without any meningioma, cancer history or neurological comorbidities will undergo cognitive assessment by a trained neuropsychologist, similarly as for patients
41511858|NCT02045901|DRUG|Placebo (Sugar Pill)|On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
41511859|NCT00758966|DRUG|Fluoxetine 60 mg|Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
41511860|NCT00758966|DRUG|Naltrexone 32 mg and fluoxetine 60 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
40857797|NCT01327677|DRUG|Fentanyl|25-50 mcg every 20 minutes
40857798|NCT01327677|DRUG|Fentanyl|20mcg/demand dose with an 8 minute lock out
40857799|NCT02497729|PROCEDURE|Written Checklist|Use of a written checklist pre and peri-intubation
40857800|NCT02497729|PROCEDURE|Head of Bed Up|Raising the patient's head of bed to 25 degrees
40857801|NCT02463682|DEVICE|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
40857802|NCT02463682|DEVICE|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
40857803|NCT03472326|DRUG|GS-9131|Tablet(s) administered orally once daily
40857804|NCT03472326|DRUG|BIC|Tablet(s) administered orally once daily
40857805|NCT03472326|DRUG|TAF|Tablet(s) administered orally once daily
40857806|NCT03472326|DRUG|ARV regimen|ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
40857807|NCT03472326|DRUG|DRV|Tablet(s) administered orally once daily
40857808|NCT03472326|DRUG|RTV|Tablet(s) administered orally once daily
40857809|NCT02290041|DRUG|Infusion of MSC|Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).
40857810|NCT02290041|DRUG|Infusion of placebo|Infusion of placebo (weeks 0-4-8-20)
40857811|NCT04603118|PROCEDURE|Optic ultrasonography|
40857812|NCT04603118|PROCEDURE|Lumbar puncture|
40857813|NCT00904488|DRUG|Addition of oral Metolazone|Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
40857814|NCT00904488|DRUG|Furosemide dose escalation|Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
40857815|NCT05844241|OTHER|Music and Theta Auditory Beat Stimulation|Listening to music and ABS for 30 minutes.
41388915|NCT05270109|PROCEDURE|BiZact|"In the hot group the peritonsillar space is dissected and sealed in one step by a bipolar instrument (BiZactTM). The instrument uses Valley Lab adjustable bipolar energy. Energy is automatically adjusted and delivered to the tissue in order minimize thermal tissue damage and seal blood vessels less than 3mm in diameter while dividing the soft tissue."
41388916|NCT05270109|PROCEDURE|Cold Steel|"In the cold steel group the peritonsillar space is dissected with metal instruments, and bleeding is typically controlled by ligation or electrocautery."
41388917|NCT02740673|DEVICE|Driving simulator|Patients are asked to use a driving simulator to test their driving skills
41388918|NCT05932927|BIOLOGICAL|Proteomic sequencing|Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups
41388919|NCT05093335|DRUG|[68Ga]-Pentixafor|An intravenous bolus of 4.1 mCi (150 MBq) ± 10% of \[68Ga\]-Pentixafor will be injected in all participants.
41388920|NCT00289731|BIOLOGICAL|TWINRIX™|Intramuscular injection, 3 doses
41388921|NCT00289731|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
41511861|NCT00758966|DRUG|Naltrexone SR 32 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
41511862|NCT05291611|BEHAVIORAL|Online-based Cognitive-behavioral Therapy for OCD|26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
41511863|NCT06303531|DIETARY_SUPPLEMENT|Ferrous Fumarate|Ferrous Fumarate - 300 mg
41511864|NCT06303531|DIETARY_SUPPLEMENT|Polysaccharide Iron|Polysaccharide Iron - 150 mg
41511865|NCT06303531|DIETARY_SUPPLEMENT|Ferrous Ascorbate|Ferrous Ascorbate - 100 mg
41511866|NCT06455813|DRUG|Bisacodyl|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
41511867|NCT06455813|DRUG|Macrogol 3350 and electrolytes|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
41511868|NCT06455813|DRUG|A combination of macrogol 3350 and electrolytes and bisacodyl|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
40857816|NCT05844241|OTHER|Audiobooks|Listening to audiobooks for 30 minutes
41038963|NCT03959865|DRUG|Flexible BI/GLP-1RA combination|GLP-1RA (Liraglutide or dulaglutide or exenatide or lixisenatide) and basal insulin (BI, glargine, degludec, detemir, NPH insulin)
41038964|NCT01356017|DRUG|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
41388922|NCT00289731|BIOLOGICAL|HAVRIX™|Intramuscular injection, 2 doses
41388923|NCT00289731|BIOLOGICAL|HB VAX PRO™|Intramuscular injection, 3 doses
41388924|NCT00289731|BIOLOGICAL|Vaqta™|Intramuscular injection, 2 doses
41388925|NCT05371418|PROCEDURE|surgical (guided tissue regeneration)|In group 1 (G1), ten teeth over erupted with angular bone loss were treated by guided tissue regeneration (GTR) followed by Orthodontic intrusion
41388926|NCT05371418|DEVICE|orthodontic intrusion followed by guided tissue regeneration GTR|. In group 2 (G2), ten teeth over erupted with angular bone loss were treated by Orthodontic intrusion (OI) followed by guided tissue regeneration (GTR)
41388927|NCT00318409|DRUG|Bupropion|
41388928|NCT00318409|DRUG|Placebo|
40857817|NCT02076282|OTHER|1 MRI scan|"For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast"
40857818|NCT04407741|DRUG|SHR2554+SHR1701|SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes
40857819|NCT04407741|DRUG|SHR1701|SHR1701: 30mg/kg, IV, over 30 minutes
40857820|NCT01121432|PROCEDURE|endobronchial ultrasound-guided transbronchial needle aspiration|One time for aspiration/biopsy. The duration about 1-2 hour.
41038965|NCT01356017|DRUG|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
41038966|NCT02201069|BEHAVIORAL|health coaching|
41038967|NCT00240318|DRUG|Rosuvastatin calcium|
41038968|NCT04341116|DRUG|TJ003234|patients receive a single infusion
41038969|NCT04341116|DRUG|Placebo|patients receive a single infusion
41388929|NCT05953883|PROCEDURE|Tumor and blood sample|Analyzing proteogenomic profiles in order to find individual platinum-induced modifications on tumor tissue of HGSOC according to chemotherapy response score (CRS). Whole genome sequencing (WGS), transcriptomic (RNAseq) and proteomics analyses on OC tissue samples before and after a standard platinum-based chemotherapy will be carried out and correlated to clinical variables.
41388930|NCT05912179|DIAGNOSTIC_TEST|Liver biopsy - percutaneous|liver biopsy obtained using percutaneous ultrasound guided technique
41388931|NCT05912179|DIAGNOSTIC_TEST|Liver biopsy - transjugular|liver biopsy obtained using an interventional transjugular approach
41388932|NCT05912179|DIAGNOSTIC_TEST|liver biopsy - EUS guided|liver biopsy obtained during endoscopic ultrasound
41388933|NCT06540144|DRUG|rozanolixizumab|rozanolixizumab solution for injection
41388934|NCT02135094|DEVICE|Active ultrasound therapy device|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
41388935|NCT02135094|DEVICE|Placebo ultrasound therapy device|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
41388936|NCT03300232|BEHAVIORAL|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
41388937|NCT04604561|DEVICE|EnVisio SmartClip|The Envisio SmartClip is an FDA-cleared (approved) device for localization of in-breast lesions. While using The EnVisio™ Navigation System, the system will detect the presence of the SmartClip™ Soft Tissue Marker(s) and provide real-time three-dimensional navigation during the surgery.
41388938|NCT04604561|DEVICE|EnVisio™ Navigation System|The EnVisio™ Navigation System acquires and analyzes electromagnetic signatures that display the relative distance, depth, and direction from the tip of the electrosurgical tool to the implanted SmartClipTM(s) within the surgeon's field of view during the procedure.
41388939|NCT06564649|DIAGNOSTIC_TEST|CXCL10 Monitoring at clinical frequency|The intervention is the implementation of real-time, serial urinary CXCL10 monitoring, with protocolized further clinical responses in the setting of elevated urinary CXCL10 levels.
41388940|NCT06018246|DIETARY_SUPPLEMENT|Malnutrition five-step treatment model + conventional nutritional intervention|"1. Before operation：Same as arm description.~2. After operation:Same as control group.~3. Out-of-hospital: Same as before operation.~4. Strengthening Health Education and psychological intervention:Dietitians need to strengthen health education and communicate with patients during the implementation of nutrition intervention.For patients who actively cooperate with treatment, dietitians can give encouragement.~5. Exercise Instruction:After the operation, according to the tolerance, the dietitian can instruct the patient to take a certain time walking every day, gradually increase the patient's muscle endurance and improve the body resistance."
41388941|NCT06018246|OTHER|Conventional nutritional intervention|Routine nutrition support in department.Nutritionists will give patients routine parenteral nutrition support via peripheral or central vein 0-48 hours after surgery and then start enteral nutrition support 48-72 hours after surgery.Patients were initially given half of their enteral nutrition and the rest was supplemented with parenteral nutrition.After adaptation, the patient stopped parenteral nutrition and all nutrition came from enteral nutrition.After the patient's gastrointestinal function gradually recovered, the enteral nutrition could gradually decrease.At this time, nutritionists can let the patient eat some light liquid food, but pay attention to eating a small amount of multiple times.After adaptation, patients can gradually transition from liquid diet to semi-liquid diet.We will educate patients and their families about diet and encourage them to eat more high-quality protein-rich foods.
41388942|NCT00732784|DRUG|Imatinib mesylate|Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
41388943|NCT00732784|DIETARY_SUPPLEMENT|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
41388944|NCT00062036|BIOLOGICAL|aldesleukin|
41038970|NCT04262518|DEVICE|Outcomes4Me Mobile App|A mobile app that provides patient navigation and treatment and clinical trial options to people with breast cancer
41388945|NCT00062036|BIOLOGICAL|filgrastim|
41388946|NCT00062036|BIOLOGICAL|incomplete Freund's adjuvant|
41388947|NCT00062036|BIOLOGICAL|interleukin-2 gene|
41388948|NCT00062036|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
41388949|NCT00062036|DRUG|cyclophosphamide|
41388950|NCT00062036|DRUG|fludarabine phosphate|
41388951|NCT05694156|OTHER|Music-based cognitive training|8-week music-based cognitive training
41038971|NCT06204627|DEVICE|TDCS|Technique of non-invasive brain stimulation by direct current (TDCS) which involves the modulation of excitability and brain activity, capable of promoting reorganization of the cortical representation of the body schema or motor planning, and consequently, pain relief.
41038972|NCT06204627|DEVICE|Recognize (hand) - Laterality|This technique stimulates the ability to recognize hand images as right/left quicklPatients with chronic pain present delayed recognition of hand laterality, which is related to the duration of symptoms and the pain evoked by the execution of the movement. Thus, this technique can have beneficial effects in breaking the pain.
41038973|NCT06204627|OTHER|Sham TDCS|TDCS sham: The device remains inactive for 20 minutes.
41038974|NCT06204627|OTHER|Landscape recognition|Image recognition training that does not refer to right/left discrimination.
41038975|NCT01427868|DRUG|LB80380 maleate salt|183 mg (150 mg as a free base)
41388952|NCT01255579|DRUG|Salmeterol Fluticasone|salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
41388953|NCT01255579|DRUG|formoterol - beclometasone|formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
41388954|NCT03454672|DEVICE|Tixel|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
41388955|NCT03454672|DEVICE|Laser|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
41038976|NCT01427868|DRUG|LB80380 free base|150 mg
41038977|NCT01716312|DRUG|Omalizumab|For each subject, treatment with omalizumab will start with a loading dose of 600 mg followed by a maintenance dose of 300 mg every 4 weeks. The study drug will be administered as a subcutaneous injection. On Week 0 and Week 16 the medication or placebo will be administered to subjects via 4 subcutaneous injections; the remaining weeks 2 injections will be administered.Subjects will be given written directions on dealing with adverse reactions. They will also receive an Epi-Pen before discharge and instructions on how to use it.
41388956|NCT05436301|OTHER|Pain Catastrophizing Scale|"Personal and disease-related inquiries of the participants will be recorded in the demographic registration form. To assess the validity of the Pain Catastrophizing Scale-Child (PCS-C) scale, the Pediatric Quality of Life Questionnaire (PEDSQL) 3.0 Arthritis Module, Childhood Health Assessment Questionnaire (CHAQ), and Juvenile Idiopathic Arthritis Disease Activity Score (JADAS) will be administered to the participants. In this way, the consistency of the developed scale with similar questionnaires that were previously reported to be valid will be examined. In order to determine the reliability of the Pain Catastrophizing Scale-Child (PCS-C) scale, test-retest will be performed at one week intervals for the participants whose treatment has not undergone any change. The consistency of the scale will be determined by the data of the participants who have the first and second scale scores. Interviews will be conducted by face-to-face method."
41388957|NCT05417126|BIOLOGICAL|Gene Therapy-vMCO-010|The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
41388958|NCT06233175|OTHER|combined kinetic chain exercises|combined kinetic chain exercises in form of wall slide ,terminal knee extension ,forward step up and down ,side step up and down ,straight leg raise ,seated knee extension ,stretching exercises , hot back and trans cutaneous electrical stimulation,
41388959|NCT06233175|OTHER|conventional|stretching exercises and hot back and trans cutaneous electrical stimulation,with out combined kinetic chain exercises
40857821|NCT01550757|BEHAVIORAL|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
40857822|NCT01224366|DRUG|Vildagliptin|
41038978|NCT00293267|DRUG|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
41038979|NCT00293267|DRUG|Comparator: Placebo|Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
41038980|NCT04417959|PROCEDURE|Phaco-DSAEK|The intervention will be performed as a DSAEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DSAEK.
41038981|NCT04417959|PROCEDURE|Phaco-DMEK|The intervention will be performed as a DMEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DMEK.
41038982|NCT02635880|DEVICE|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
41038983|NCT04666168|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
41388960|NCT00921765|DRUG|Saline|Saline single bolus dose followed by saline single bolus dose iv
41388961|NCT00921765|DRUG|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
41388962|NCT00921765|DRUG|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
41388963|NCT00921765|DRUG|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
41388964|NCT05171920|DRUG|Auxora|All patients will receive 2.0 mg/kg (1.25 mL/kg) of Auxora at 0 hour and 1.6 mg/kg (1 mL/kg) at both 24 hours and 48 hours from the Start of the First Infusion of Auxora (SFIA) at 0 hour over 4 hours. Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive extended treatment with Auxora 1.6 mg/kg (1 mL/kg) at 72, 96, and 120 hours from the SFIA
41388965|NCT05171920|DRUG|Placebo|Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive 1 mL/kg of Placebo at 72, 96, and 120 hours from the SFIA.
41388966|NCT04922788|BIOLOGICAL|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant
41388967|NCT04922788|BIOLOGICAL|Placebo|0,5 mg Aluminum adjuvant
40857823|NCT01224366|DRUG|Placebo|
40857824|NCT01363908|DRUG|SPD602|
41038984|NCT04666168|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
41038985|NCT04666168|PROCEDURE|Leukapheresis|Leukapheresis
41038986|NCT05312138|DEVICE|Repetitive Transcranial Magnetic Stimulation|The treatment will be internally cooled 70 mm double coil and 110 mm round coil, accompanied by a physiotherapist and neurologist. The coil will be placed on the precentral gyrus. Practices will be held, with each session lasting 20 minutes. Cortical excitability will be provided by high frequency (HF) stimulation (5-Hz).
41038987|NCT05312138|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation|The treatment parameters will be applied with a pulse current time of 200 μsec, a fixed frequency of 10 Hz, a treatment time of 20 minutes, and a current intensity that the patient can tolerate, which will not cause flexion in the big toe or fan movement in the other fingers. Self-adhesive surface electrodes will be used for stimulation. During the treatment, the patient will lie on his back. The negative electrode will be placed 2 cm posterior to the medial malleolus and the positive electrode will be placed 10 cm proximal.
41388968|NCT04704817|OTHER|obsevation|prospective data collection for colonic or rectal surgery
41388969|NCT05678218|PROCEDURE|Endoscopic Ultrasound registration|Registration of all findings during Endoscopic Ultrasound
41388970|NCT03286400|DEVICE|CTAG Device with ACTIVE CONTROL|Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.
41388971|NCT06529458|OTHER|Intervention 1 Group|The researcher will apply pressure to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy. He will also have the patient or a relative repeat the method and do it at home three times a day before meals for 5 days.
41388972|NCT06529458|OTHER|Intervention 2 Group|The researcher will apply drops of ginger oil to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy, using circular motions. At the same time, the researcher will have the patient or a relative repeat the method and apply it at home three times a day before meals for 5 days.
41388973|NCT06529458|OTHER|Control Group|No interference will be made
41388974|NCT03165331|OTHER|Ung Face IT|Ung Face IT is an online intervention tool (programme) that provides easy access to specialist advice and support via a home computer/tablet, using illustrations, information, videos, and interactive activities, and a discussion forum for participants only (supervised by the research team). Through these tools, it provides advice and teaches coping skills based on cognitive behavioural therapy and social interaction skills training.
41388975|NCT03303807|DEVICE|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)|A low-flow CO2 removal device (Prismalung®, Baxter) will be used with a conventional renal replacement therapy (RRT) platform (Prismaflex®, Baxter). In patients already treated with continuous RRT because of renal failure or metabolic acidosis, the HF 1400® (Baxter) set will be used to combine RRT and decarboxylation. Gas flow through the gas exchanger will be set up to 10 L/min, with an oxygen concentration from 0.21 to 1 and a blood flow of 200-400 mL/min. Patients will be ventilated with a target tidal volume of 6 ml/kg (predicted body weight) and a target plateau pressure below 30 cmH2O.
41388976|NCT03751527|DEVICE|ZENFLEX peripheral stent system|The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.
41388977|NCT01270607|PROCEDURE|Acupuncture|Treatment given twice per week for 4 weeks
41388978|NCT04615286|OTHER|Short course (2-3 weeks) of antibiotics|Shorter course of antibiotic than standard care of 4-6 weeks
41388979|NCT04615286|OTHER|Standard (long course) of antibiotics|4-6 weeks of antibiotics
41388980|NCT03250507|DRUG|Bupivacaine|0.25% bupivacaine for TAP block
41511869|NCT05771389|DIAGNOSTIC_TEST|serum raftlin-1 protein levels|Lipid raft linker 1 (Raftlin-1) is a protein which enables double-stranded RNA binding activity. It is involved in T cell receptor signaling pathway; membrane raft assembly; and positive regulation of growth rate. It acts upstream of or within dsRNA transport; response to exogenous dsRNA; and toll-like receptor signaling pathway. Located in endosome; membrane raft; and plasma membrane.
41511870|NCT00462917|BEHAVIORAL|Pleiotropic info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during an in-person disclosure session."
40857825|NCT02434419|DEVICE|PENS|The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.
41388981|NCT03250507|DRUG|Liposomal bupivacaine|Exparel for TAP block
41388982|NCT03250507|DRUG|Saline|Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
41388983|NCT03711669|BEHAVIORAL|Immunosuppression withdrawal|IS will be tapered gradually over a period of 6 months. Azathioprine will be stopped during the first 3 months, reducing the dose 50% every month. Prednisone will be tapered 2.5mg monthly until total withdrawal. During withdrawal and the first year after stopping treatment patients will undergo laboratory tests on a monthly basis, afterwards follow-up will be done every 3 months until the end of the project.
41388984|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, low-fat|A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
41388985|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, medium-fat|A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
41388986|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, high-fat|A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
41388987|NCT01257529|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
41388988|NCT05135143|COMBINATION_PRODUCT|Antioxidant formula|Administration of antioxidant formula 3 times a day and once daily.
41388989|NCT01921725|DEVICE|hydrophilic-based dressing (KoCarbonTM)|"BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes."
41388990|NCT04742816|DIAGNOSTIC_TEST|IHX-CL measurements|The distribution of measured IHX-CL values and other continuous variables will be assessed to ensure a parametric distribution.
41388991|NCT04742816|DRUG|Iohexol|Iohexol clearance measurement
41388992|NCT05418257|OTHER|(exposure) telemedicine|medical counseling or treatment only using phone
41388993|NCT04247646|DIETARY_SUPPLEMENT|Melatonin|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
41388994|NCT04247646|DIETARY_SUPPLEMENT|Placebo|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
41511871|NCT00462917|BEHAVIORAL|AD-only info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
41388995|NCT03654365|OTHER|Bulk ordering and bulk messaging|Patients in the intervention group had the hepatitis screening test ordered for them in bulk and then a bulk message sent to them through the personal health record describing hepatitis C and how they could be tested.
41388996|NCT03654365|OTHER|Routine alerting|Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
41388997|NCT04058600|BEHAVIORAL|Virtual Reality Software|Patients will be exposed to a virtual reality software that simulates the hospital environment, from admission to the operating room and the recovery room.
41388998|NCT05037942|OTHER|Blood flow restriction at 40% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 40% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
41388999|NCT05037942|OTHER|Blood flow restriction at 80% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 80% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
41389000|NCT06323473|DIETARY_SUPPLEMENT|Black Maitake Prothera|Mushroom extract; liquid
41389001|NCT06567106|OTHER|Ultrasound application|Apply ultrasound to the participant within a safe range.
41389002|NCT06567106|OTHER|No ultrasound application|No ultrasound application to the participant.
41389003|NCT01854515|DRUG|Budesonide|
41389004|NCT01854515|DRUG|Dexamethasone acetate|
41389005|NCT04390074|OTHER|COVID-19 and Intensive Care|No intervention, observational.
41389006|NCT00343642|DRUG|Active fructo-oligosaccharide|2 teaspoons of active fructo-oligosaccharides daily and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
41389007|NCT00343642|DRUG|Placebo fructo-oligosaccharide|2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily) and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
41389008|NCT00343642|DIETARY_SUPPLEMENT|Diet|A restrictive anti-inflammatory diet developed by the research team and 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily)
41389009|NCT03409497|OTHER|Concord Grape Juice|Concord Grape Juice
41389010|NCT03409497|OTHER|Low flavonoid low essence beverage|Low flavonoid low essence beverage
41389011|NCT03409497|OTHER|Low flavonoid beverage|Low flavonoid beverage
41389012|NCT03799874|DRUG|Inhaled Carbon Monoxide at 200 ppm|Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.
41389013|NCT03799874|OTHER|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
40857826|NCT02434419|OTHER|Specific training|Patients underwent specific training exercises to improve pectoral fitness.
40857827|NCT00064961|BEHAVIORAL|Individualized dietary-control and exercise program|
40857828|NCT00064961|BEHAVIORAL|Weight-management and smoking cessation maintenance|
41389014|NCT03233373|DEVICE|Seek CompactPro thermal imager|A device with image/video recording capability, it is non-invasive and only relies on infrared emissions from heat sources (the patient).
41389015|NCT02033577|PROCEDURE|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
41389016|NCT02033577|PROCEDURE|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
41389017|NCT06170541|DEVICE|Aquilion Precision|Ultra-High Resolution CT (UHR CT) capable of resolving anatomy as small as 150 microns, providing CT image quality with resolution typically seen only in cath labs. The UHR detector is newly designed to provide more than twice the resolution when compared with today's CT technology, with an all-new detector as well as tube, gantry and reconstruction technologies.
41389018|NCT06170541|DEVICE|Conventional Computed Tomography|Conventional reconstruction Computed Tomography (CT) represents a pivotal approach in medical imaging.
41389019|NCT04150588|DRUG|Efrin drops|The amount that the eyelid rise after Erin drops before surgery
40857829|NCT00064961|BEHAVIORAL|Smoking Cessation program|
40857830|NCT03262168|OTHER|Exercise Programme|Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
40857831|NCT05856981|DRUG|ADU-1805|anti-SIRPα monoclonal antibody
40857832|NCT05856981|DRUG|Pembrolizumab|Keytruda
40857833|NCT04995211|DEVICE|Assessment of resting energy expenditure|We will assess the resting metabolic rate and respiratory exchange ratio of twenty healthy adults, with every metabolic cart on two days in the morning. The assessment will last 30 minutes on each metabolic cart, with 15-minute breaks between measurements. The order of the metabolic carts will be randomly selected and replicated the second day.
40857834|NCT04311125|PROCEDURE|Mini posterior approach Total Hip Replacement|Total hip replacement in patients suffering from hip osteoarthritis using the mini posterior approach
40857835|NCT04311125|PROCEDURE|Anterior approach total hip replacement without a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis without the aid of a traction table
41389020|NCT04769908|DRUG|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
41389021|NCT04769908|DRUG|Lenvatinib|Lenvatinib, 8mg or 12mg, po, QD
41389022|NCT04769908|DRUG|Sintilimab|Sintilimab, IV, 200mg, q3w
41389023|NCT02757300|DEVICE|Hypopharyngeal packing|After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
41389024|NCT02757300|DEVICE|Without Hypopharyngeal packing|After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
41166978|NCT04362098|BEHAVIORAL|Home visiting Program for Young Pregnant Women|The visitation program was elaborated based in the following theoretical principles: a) Albert Bandura's self-efficacy theory; b) Urie Brofenbrenner's bioecological theory, which recognizes the importance of the insertion of individuals in families in varied contexts of life in society; c) John Bowlby and Mary Ainsworth's attachment theory. The basic premises of the intervention are health care, environmental health, life course development, development of parenting ability, relationship with friends and family, and social service support.
41166979|NCT03903523|DEVICE|Lumen apposing metal stent (LAMS)|Stent positioning
41389025|NCT02341209|DRUG|Doxycycline monohydrate|Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
41389026|NCT03673475|PROCEDURE|Assessment of fluid responsiveness|assessment of intravascular volume status using pleth variebility index and internal jugular vein distensibility in major abdominal surgery
41389027|NCT05831267|OTHER|Fibrin Glue|Blood samples were collected from the antecubital vein of the right or left arm of the patient and drawn into sterile Titanium tubes immediately. The tubes were then centrifuged for 12 minutes at 2800 rpm and room temperature
40857836|NCT04311125|PROCEDURE|Anterior approach total hip replacement with a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis with the aid of a traction table
40857837|NCT03940300|DIETARY_SUPPLEMENT|Fresh organic vegetables|"Individual participation in this program will take 12 weeks, from screening and enrollment through evaluation. Once enrolled, visits will occur on a weekly basis to ensure that participants receive each week's dose of fresh organic vegetables. At an optional Visit 13, offered 6 months after Visit 1, an additional health screening will be conducted."
40857838|NCT00705367|DRUG|Placebo|Infusion, Intravenous, single dose, Day 1
40857839|NCT00705367|DRUG|Abatacept|Infusion, Intravenous, 30mg/kg, single dose, Day 1
40857840|NCT00705367|DRUG|Abatacept|Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
40857841|NCT01391936|PROCEDURE|Tension Band Wiring|AO technique of TBW for fixation of fracture.
40857842|NCT01391936|PROCEDURE|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
41038988|NCT05574127|BEHAVIORAL|Behavioral Activation|"Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
41038989|NCT05574127|BEHAVIORAL|Supportive Psychotherapy|"Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
41389028|NCT05831267|OTHER|T-PRF|The contents of the two containers (human fibrinogen, human thrombin) will be mixed with distilled water and then aspirated by two syringes after that, the two solutions will be mixed together and injected into the empty compartment around the dental implant under the sinus mucosal lining using auto mixing applicator.
41389029|NCT05831267|OTHER|Negative control|this group will not receive any material.
41389030|NCT01040676|BEHAVIORAL|Automated Telephone Nutrition Support|See Intervention Group description.
41038990|NCT01260350|DRUG|SOF|Sofosbuvir (SOF) tablets administered orally once daily
41038991|NCT01260350|DRUG|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
41038992|NCT01260350|DRUG|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
41389031|NCT05180630|DEVICE|Audeo P90 hearing aid with custom earmolds using dynamic venting|Audeo P90 hearing aids coupled to custom earmolds that use dynamic venting.
41389032|NCT05180630|DEVICE|Audeo P90 hearing aid with Open domes|Audeo P90 hearing aid coupled with non-custom, manufacturer open domes
41389033|NCT05180630|DEVICE|Audeo P90 hearing aid with Vented domes|Audeo P90 hearing aid coupled with non-custom, manufacturer vented domes
41389034|NCT05199311|DRUG|Carfilzomib|20 mg/m2 C1D1; 56 mg/m2 thereafter
41389035|NCT05199311|DRUG|Iberdomide|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
40857843|NCT02301026|DRUG|5% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
40857844|NCT00465023|PROCEDURE|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
41038993|NCT01260350|DRUG|LDV|Ledipasvir (LDV) tablets administered orally once daily
40857845|NCT06034249|BEHAVIORAL|Mindfulness-Based VR|Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.
40857846|NCT06034249|BEHAVIORAL|Audio|The mindfulness-based audio files for six weeks.
40857847|NCT05606276|OTHER|Eccentric Exercise|Individuals will do a randomized crossover intervention involving maximal eccentric contractions (2 sets of 6 per leg; experimental condition)
40857848|NCT05606276|OTHER|Cycle ergometer|Individuals will do a randomized crossover intervention involving cycling (active control) exercise
40857849|NCT05083312|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
41038994|NCT01260350|DRUG|GS-9669|GS-9669 tablets administered orally once daily
41038995|NCT01260350|DRUG|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
40857850|NCT05083312|DRUG|Placebo oral tablet|Placebo orally disintegrating tablet
40857851|NCT02431078|PROCEDURE|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
40857852|NCT05096000|BEHAVIORAL|InterMob: a randomized controlled trial aimed at reducing car use in regular car users|Intermob is a theory- and evidence-based behavioral intervention that combines public transport/bicycle and motivational techniques (action planning, personalized transport advice, goal setting).
40857853|NCT05096000|OTHER|Active control: Air pollution information|The active control intervention is based on a discussion about air pollution, the effects of air pollution on health, the association between air pollution and transport.
40857854|NCT02276443|DRUG|Chemotherapy|Receive standard chemotherapy
41389036|NCT05199311|DRUG|Oral Dexamethasone|40 mg (\<=75 years old); 20 mg (\>75 years old)
41389037|NCT05799365|OTHER|GMFCS-FR Turkish Adaptation|GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.
41166980|NCT04903847|DRUG|Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Two-drug therapy
41166981|NCT04903847|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Three-drug therapy
41166982|NCT03494621|BEHAVIORAL|Protecting Babies While they Sleep Curriculum|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. .
41166983|NCT02732002|PROCEDURE|OCBRA ( Objective Criteria Based REhabilitation Algorithm|The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
41166984|NCT00487526|PROCEDURE|duodenal jejunal bypass|
41389038|NCT00669136|DRUG|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
41389039|NCT01280565|DRUG|Masitinib|Masitinib 7.5 mg/kg/day
41389040|NCT01280565|DRUG|Dacarbazine|IV bolus at 1,000 mg/m2 once every 3 weeks
41389041|NCT03665246|BEHAVIORAL|Integrated Mothers and Babies Course|The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
41389042|NCT02400827|OTHER|malignant cells|
40857855|NCT02276443|OTHER|Immunotherapy|Receive standard immunotherapy
40857856|NCT02276443|OTHER|Laboratory Biomarker Analysis|Correlative studies
40857857|NCT02276443|PROCEDURE|Lymph Node Biopsy|Undergo baseline lymph node evaluation
40857858|NCT02276443|PROCEDURE|Ultrasonography|Undergo standard ultrasound
40857859|NCT00126776|BEHAVIORAL|case management|case/self management for COPD vs usual care
40857860|NCT00126776|BEHAVIORAL|usual care|usual care for COPD
40857861|NCT00133601|BEHAVIORAL|Cognitive Behavioral Therapy|CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
40857862|NCT03349788|PROCEDURE|LCA-nP|The group underwent lapaoroscopic radical rectectomy without preserving left colic artery.
41389043|NCT04347161|DEVICE|Conversational Agent/Chatbot|Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
41389044|NCT04347161|OTHER|Usual Care|Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
41389045|NCT06420401|DIETARY_SUPPLEMENT|araboxylan|During the study period, subjects are instructed to take one pocket of arabosylan per day during the first week, followed by two pockets of araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
40857863|NCT03349788|PROCEDURE|LCA-P|The group underwent lapaoroscopic radical rectectomy with preserving left colic artery.
40857864|NCT05112003|DEVICE|Translingual neurostimulation|The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
41166985|NCT02985034|PROCEDURE|RFA|Radiofrequency ablation (RFA) is performed according to routine practice, and then safety margin is assessed by a) visual side-by-side comparison between pre-RFA MRI and post-RFA CT, and b) registration software for two modalities.
41166986|NCT02034747|DRUG|Advagraf|oral
40857865|NCT02287467|BIOLOGICAL|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
40857866|NCT02287467|BIOLOGICAL|Placebo for IVIG|Administered IV as 500 mL of normal saline
40857867|NCT03005548|DEVICE|Transcranial direct current stimulation|"Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins."
40857868|NCT03005548|DRUG|Morphine|"In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning."
40857869|NCT05196191|BIOLOGICAL|VIAGENEX Max|Collagenous membrane derived from umbilical cord
40857870|NCT05196191|PROCEDURE|Hibiclens wash|Antiseptic skin cleanser
40857871|NCT05967650|BIOLOGICAL|standard hepatitis B vaccine|IBD patients with negative HBV will be diveded in to two arms first arm vaccinated with standard HBV vaccine regemin( dose 0.2.6)
40857872|NCT05967650|BIOLOGICAL|accelerated HBV Vaccine|IBD patients with negative HBV will be diveded in to two arms second arm vaccinated with accelerated HBV vaccine regemin( dose 1.2.3)
40857873|NCT00806728|DRUG|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
40857874|NCT00806728|DRUG|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
40857875|NCT02114606|DEVICE|Cytosponge™ Cell Collection Device|The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
40857876|NCT03321422|OTHER|No intervention Observational study|follow up of the function of the hip after lateral shelf acetabuloplasty by harris hip score and WOMAC score
40857877|NCT01359202|BIOLOGICAL|rfVIIa|80ug/kg IV bolus
40857878|NCT01359202|OTHER|Standard saline solution|Saline
40857879|NCT04661046|DRUG|Traditional Chinese Medicine|Chinese medicine prescription
40857880|NCT01964625|OTHER|PET-CT Scan|PET-CT scan will be done at baseline (per standard of care), at onset and confirmation of chronic GvHD and after initiation of therapy to assess response.
41038996|NCT06005766|BEHAVIORAL|Metacognitive Skills Training (MCT)|The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
41038997|NCT06005766|OTHER|Treatment as usual|Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
41038998|NCT00126412|DRUG|123I-mIBG (meta-iodobenzylguanidine)|
41038999|NCT05205265|DEVICE|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
41039000|NCT01392560|DRUG|BI 10773|Oral once daily
41166987|NCT02034747|DRUG|Corticosteroid|oral
41389046|NCT06420401|DIETARY_SUPPLEMENT|inulin|During the study period, subjects are instructed to take one pocket of inulin per day during the first week, followed by two pockets of inulin per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
41389047|NCT06420401|DIETARY_SUPPLEMENT|inulin and araboxylan|During the study period, subjects are instructed to take one pocket of inulin and araboxylan per day during the first week, followed by two pockets of inulin and araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
41389048|NCT06420401|DIETARY_SUPPLEMENT|placebo control|During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
41511872|NCT00462917|BEHAVIORAL|Pleiotropic info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during a telephone disclosure session."
41511873|NCT00462917|BEHAVIORAL|AD-only info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
41511874|NCT01625091|DRUG|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
41511875|NCT01625091|DRUG|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
41511876|NCT06582537|PROCEDURE|Participants sample collection|A skeletal muscle biopsy and a venous blood sample will be collected. The skin biopsy will be obtained during the incision needed for the muscle biopsy.
41511877|NCT04512664|OTHER|cold application|cold application with gel pacs
40857881|NCT00828763|DRUG|[14c}-GSK1349572|HIV-Integrase inhibitor labelled with a carbon 14 marker
40857882|NCT04055909|DRUG|nangibotide low dose|nangibotide 0.3 mg/kg/h
40857883|NCT04055909|DRUG|nangibotide high dose|nangibotide 1.0 mg/kg/h
40857884|NCT04055909|DRUG|placebo|matching placebo
40857885|NCT03047421|DIAGNOSTIC_TEST|Comparison of accuracy of DES-OSA and P-SAP scores|Comparison of accuracy of DES-OSA and P-SAP scores with the result of the PSG (polysomnography)
41511878|NCT00420732|BIOLOGICAL|HyperAcute-Lung Cancer Vaccine|300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
41511879|NCT03156504|DRUG|Ketamine Hydrochloride|Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
41511880|NCT01226030|DRUG|M2ES 7.5mg|M2ES 7.5mg
41511881|NCT01226030|DRUG|M2ES 15mg|M2ES 15mg
40857886|NCT03098225|RADIATION|Orbital radiotherapy|A high-voltage linear accelerator will be used and a cumulative radiation dose of 20 Gy will be delivered to each eye in 10 fractionated doses over a period of 2 weeks. All patients will be treated in both eyes.
41511882|NCT01226030|DRUG|M2ES 30mg|M2ES 30mg
41511883|NCT01226030|DRUG|M2ES 60mg|M2ES 60mg
40857887|NCT03098225|DRUG|Methylprednisolone|Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
40857888|NCT03654885|DEVICE|XEN-45 Gel Stent|XEN-45 gel stent device implant
40857889|NCT03654885|PROCEDURE|Trabeculectomy|Trabeculectomy surgery
40857890|NCT02395614|DRUG|Chlorhexidine irrigation|- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
40857891|NCT02395614|DRUG|triple antibiotic irrigation|"-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket"
40857892|NCT03998969|DRUG|Pantoprazole|Pantoprazole 40mg tablet
40857893|NCT03998969|DRUG|DA-5204|DA-5204 tablet
40857894|NCT03998969|DRUG|Placebo|Film-coated tablet manufactured to mimic DA-5204
40857895|NCT04402879|PROCEDURE|Prone Positioning (PP)|"The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day until the occurrence of a primary outcome event or hospital discharge.~The target duration (dose) of PP is \> 8 hours per day for up to 60 days, or until oxygen requirements are \< 2 L per minute or \< 2 L per minute above baseline home oxygen requirements."
40857896|NCT02524158|BEHAVIORAL|Yoga Therapy for CLBP|Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
40857897|NCT02533492|DEVICE|vicryl|wound closure with vicryl suture
41389049|NCT00865306|BEHAVIORAL|"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents."|"This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments."
40857898|NCT02533492|DEVICE|Vicryl plus|wound closure with vicryl plus suture
40857899|NCT00587704|PROCEDURE|PVB using nerve stimulation|5ml of 1% ropivacaine injected incrementally
40857900|NCT00587704|PROCEDURE|PVB using anatomic landmarks|5ml of 1% ropivacaine injected incrementally
40857901|NCT00003712|DRUG|temsirolimus|"•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.~The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.~•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II."
40857902|NCT03970369|BEHAVIORAL|Usual care|Personalized goals and an activity prescription.
40857903|NCT03970369|BEHAVIORAL|Monitor|Participants wear a step counter to track activity goals.
40857904|NCT05249569|DRUG|Axitinib|Axitinib to be administered orally BID
41389050|NCT00002902|DRUG|irinotecan hydrochloride|
41389051|NCT00002902|DRUG|raltitrexed|
41389052|NCT03224741|BEHAVIORAL|Monetary Incentive|Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).
41389053|NCT03224741|BEHAVIORAL|Information|Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.
41389054|NCT03224741|BEHAVIORAL|Active Choice|"Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010)."
41511884|NCT05083026|DIAGNOSTIC_TEST|COVID-19 neutralizing antibody|"This study enrolled persons already who received COVID-19 vaccination under government policy.~1. We collect 5mL blood at 2, 4, 6, 9, 12 months after COVID-19 vaccination~2. isolate serum and store in -80 degree deep freezer~3. measure neutralizing Antibody"
40857905|NCT05249569|DRUG|Avelumab|Avelumab to be administered as a 1-hour IV infusion on Day 1 and Day 15 of each 28-day cycle.
40857906|NCT05249569|DRUG|Bavituximab|Bavituximab to be administered weekly on Days 1, 8, 15 and 22 of the 28-day cycle.
40857907|NCT03812315|COMBINATION_PRODUCT|Propolis chewing gum|Children who will use chewing gum will be instructed to chew a gum for 20 minutes once after breakfast and another before bed time for two weeks.
40857908|NCT03812315|COMBINATION_PRODUCT|Propolis mouthwash|Children who will use mouthwash will be instructed to rinse with 10 ml for 60 seconds twice daily once after breakfast and another before bedtime for two weeks.
40857909|NCT06160947|OTHER|Usual Medical Care|In both the intervention and control arms of the study, usual medical care will be defined as any and all medical care provided to patients with chronic non-cancer back or neck pain at an Ontario CHC, including: primary care provider consultation visits, prescription medication (e.g., muscle relaxants, anti-inflammatories, anti-depressants, opioid and non-opioid analgesics), referral for diagnostic testing (e.g., lab work, imaging) or specialist consultation, as well as other co-interventions (e.g., visits with nurses, dieticians, social workers, or physiotherapists) as determined by their PCP. PCPs will also engage study participants in a formal effort to reduce their opioid use within the framework of each CHC's current opioid-reduction practices.
41039001|NCT01214772|DRUG|heparin|5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
41039002|NCT04609891|DRUG|Avatrombopag|10×109/L\<PLT\<75×109/L, avatrombopag tablet 60 mg once a day for 5-10 days.
41039003|NCT03130400|PROCEDURE|Observational gait analysis procedure|All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
41389055|NCT05012735|DRUG|Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
41389056|NCT05012735|DEVICE|Prototype Ultrathin Hydrocolloid Bandage|Participants will cover their closed and popped pimples in the evening with one or two bandages from Days 0 through 6.
41511885|NCT05999214|DIAGNOSTIC_TEST|99mTc-H7ND SPECT/CT imaging performed|99mTc-H7ND SPECT/CT imaging positive (+) was defined as the presence of at least one measurable lesion and the uptake of the lesion was greater than that of normal liver in the experimental group, and patients were divided into SD+ and SD-. According to the guidelines and routine clinical practice, SD- patients were treated with the original regimen or maintenance treatment, and SD+ patients were divided into continuation of the original regimen or second-line treatment according to the MDT discussion results.
41511886|NCT03545542|DIAGNOSTIC_TEST|Initial fecal microbiome|Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.
41389057|NCT02360059|DRUG|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
41389058|NCT02360059|OTHER|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
41389059|NCT02360059|BEHAVIORAL|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
41389060|NCT02360059|OTHER|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
41389061|NCT03137758|DRUG|PCUR - 101|PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
41389062|NCT06008639|DEVICE|treatment group-Device: NirsCure - Active NirsCure - Active settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
41511887|NCT03545542|DIAGNOSTIC_TEST|Initial fecal volatile organic compounds|Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
41511888|NCT03545542|DIAGNOSTIC_TEST|Initial breath volatile organic compounds|Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
40857910|NCT06160947|OTHER|Usual Medical Care + Chiropractic Care|Treatment sessions may include high-velocity, low-amplitude spinal manipulative therapy, as well as any or all of the following: spinal mobilization, soft-tissue massage/trigger point therapy, education and reassurance (e.g., pain management, ergonomic and activities of daily living recommendations), and home advice (e.g., icing, spinal stretching, core muscle strengthening, and cardiovascular exercises). As part of the intervention, chiropractic clinicians will engage PCPs in a collaborative effort to support opioid tapering. Consistent with current clinical practice guidelines, participants will be provided up to a maximum of 18 chiropractic visits during the active care period, although participants may continue with treatment after the 12-week period (e.g., one visit, every 2-4 weeks) to manage episodes of exacerbation/flare-up.
40857911|NCT02885246|OTHER|Data collection|The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
40857912|NCT06491784|OTHER|Exercise Therapy|12 week personalised exercise, nutrition and wellbeing programme
40857913|NCT03960112|DEVICE|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
41389063|NCT06008639|DEVICE|placebo group-Device: NirsCure - Sham NirsCure - Sham settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
41389064|NCT04778176|COMBINATION_PRODUCT|continuous oral delivery of levodopa/carbidopa|The system consists of a reusable custom dental retainer, its case, and a pre-filled, single-use container which continuously releases levodopa/carbidopa into the back of the mouth.
41389065|NCT04913220|DRUG|THOR-707|Solution for infusion: intravenous infusion
41389066|NCT04913220|DRUG|Cemiplimab|Solution for infusion: intravenous infusion
41389067|NCT05876208|OTHER|BAND Connect's VirtuaCare™ platform|Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
41389068|NCT05876208|OTHER|Standard of Care Physical Therapy|Standard of care physical therapy without the use of the BAND CVCP
41389069|NCT02953418|DEVICE|Radiofrequency ablation|RFA
41389070|NCT04149054|BEHAVIORAL|"Mobile health app called Hola Bebe"|For the pilot, all participants received a mobile app that contained 6 interactive audio/written modules in Spanish and English on the following topics: healthy eating; physical activity; portion control; eating healthy while eating out; eating out in Chinese, Italian, Mexican restaurants; and eating out in fast food restaurants. As noted above, the mobile app was customizable to include personalized activity reminders/notifications, and tailored action plans, along with videos for easy at-home exercises and user-friendly, easy-to-follow recipes.
41389071|NCT00842088|DRUG|Placebo|Matching placebo capsule. Administered orally once a day on dosing days.
41389072|NCT00842088|DRUG|HQK-1001|HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
41389073|NCT02183701|DRUG|Telmisartan|
41389074|NCT02183701|DRUG|Losartan + Hydrochlorothiazide|
41389075|NCT02183701|DRUG|Placebo|
41389076|NCT04662684|DRUG|Rivaroxaban 10 MG|No intervention
41389077|NCT04040959|DRUG|Nicotinamide riboside|Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
41389078|NCT05175014|BIOLOGICAL|PCV10 full dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a full dose.
41389079|NCT05175014|BIOLOGICAL|PCV10 fractional dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a fractional dose.
41389080|NCT01314222|DRUG|BMS-954561|
41389081|NCT01314222|DRUG|Pregabalin|
41389082|NCT01314222|DRUG|Placebo matching BMS-954561|
41389083|NCT01314222|DRUG|Placebo matching Pregabalin|
41389084|NCT00403923|DIETARY_SUPPLEMENT|Lactose in water|
41511889|NCT03545542|DIAGNOSTIC_TEST|Microbiome under chemotherapy|Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to Société Internationale d´Onclogie Pediatrique Neuroblastoma Group (SIOPEN) guidelines
41039004|NCT05985187|DRUG|TQB2440 injection + Trastuzumab + Docetaxel|"TQB2440 injection is a biosimilar of Perjeta® (Pertuzumab injection) developed by Chia Tai Tianqing Pharmaceutical Group. Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
41389085|NCT00712660|DRUG|antipsychotic dose increase|20% increase in the dose of current antipsychotic medication
41389086|NCT00712660|OTHER|no intervention|Treatment as usual
41389087|NCT06249217|BEHAVIORAL|Good Nights Sleep Program|The Good Nights Sleep Program arm adapts established evidence-based motivational practices to change child and family sleep environments and sleep hygiene practices. At Week 0, participants will provide a comprehensive assessment of sleep environment and sleep hygiene practices and will be issued a Fitbit watch to wear for the duration of the study. At Week 2, participants will receive information about the benefits of good sleep, feedback about their sleep environment and sleep hygiene practices based on the Week 0 assessment data to implement at home, and sleep environment modification items based on participant-identified areas of need (e.g., a fan, sound machine, bedding). At Week 4, families in the Good Nights Sleep Program arm will provide post-intervention assessment data and feedback on the intervention and families in the Waitlist-Control arm can elect to receive the intervention if they choose to.
41389088|NCT04356092|DIAGNOSTIC_TEST|2D perfusion digital subtraction angiography of the foot.|2D perfusion digital subtraction angiography of the foot was performed after infrapopliteal angioplasty and Perfusion Blood Volume (PBV), Mean Transit Time (MTT), and Perfusion Blood Flow (PBF) maps were extracted by analyzing Time-Intensity Curves and signal intensity on the perfused vessel mask.
41389089|NCT00425516|DRUG|Taxotere|
41389090|NCT00425516|DRUG|5-Fluorouracil|
41389091|NCT00425516|DRUG|Epirubicin|
41389092|NCT00425516|DRUG|Cyclophosphamide|
41389093|NCT03568929|DRUG|Idelalisib|Tablets administered according to the product information and treatment guidelines in routine clinical practice
41389094|NCT02532023|DIETARY_SUPPLEMENT|omega 3 fatty acid|omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months
41389095|NCT02532023|DIETARY_SUPPLEMENT|curcumin|curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months
41389096|NCT02532023|DIETARY_SUPPLEMENT|omega 3 fatty acid placebo|omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months
41389097|NCT02532023|DIETARY_SUPPLEMENT|curcumin placebo|curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months
41389098|NCT00752401|DRUG|Cholecalciferol|6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels \>2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.
41389099|NCT00752401|DRUG|Placebo|An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
41389100|NCT00460252|PROCEDURE|insulin titration applying a computer algorithm|
41389101|NCT03746080|DRUG|Plerixafor|Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation
41389102|NCT03746080|DRUG|Temozolomide|Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.
41389103|NCT03746080|RADIATION|Whole-Brain Radiotherapy (WBRT)|Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations
41389104|NCT03746080|RADIATION|Radiation Therapy|Radiotherapy consists of 30 Gy in 15 fractions
41389105|NCT04048720|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will be offered eight group FNI sessions.
41389106|NCT02083770|BEHAVIORAL|Cancer Clinical Trials Education Program|Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
41389107|NCT03915041|DEVICE|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
41389108|NCT03915041|DEVICE|VR +sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
40857914|NCT00994526|OTHER|Ham|Ham : 180 g per day during 4 days
40857915|NCT00994526|OTHER|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
40857916|NCT00994526|OTHER|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
41389109|NCT06568861|DRUG|ALG-097558|Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)
41389110|NCT01999322|DRUG|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
41389111|NCT01999322|DRUG|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
41389112|NCT00527527|PROCEDURE|flexion distraction|Chiropractic treatment using the flexion distraction apparatus
40857917|NCT06115590|DIETARY_SUPPLEMENT|Nutritional supplement|Nutritional intervention hypothesized to have an acute anxiolytic effect
40857918|NCT01036321|DRUG|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
40857919|NCT01036321|DRUG|Methyl cellulose blend|Placebo - Take 2 capsules daily
41389113|NCT00527527|OTHER|placebo control|Placebo for comparison with flexion distraction treatment
41511890|NCT03545542|DIAGNOSTIC_TEST|Fecal volatile organic compounds under chemotherapy|"Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
40857920|NCT04788394|OTHER|data review|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~* Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~* Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\].~* Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
41166988|NCT06176898|DEVICE|Neurostimulating device|"A trained practitioner will apply the neurostimulator to the patient's ear. The patient will wear the neurostimulator for a period of three week with the position of the neurostimulator moving from one ear to the other on a weekly basis. After 3 weeks the neurostimulator will be removed and the patient will then undergo further clinical assessment at week 8.~At the 8 week clinical assessment, the patient will undergo the same assessments, namely:~* Six minute walking test (6MWT)~* Quality of life assessment using both generic (Short form 12) and disease specific (Vascuqol) questionnaires"
41166989|NCT02941848|DRUG|HGP0816|
41389114|NCT01400373|DEVICE|Prehospital intra-nasal cooling with RhinoChill|Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
41389115|NCT05442359|DRUG|Nano-bio fusion gingival gel|Thin coat applied to cover the palate after free gingival graft harvest. A stent will be placed to retain its effect. Patients will receive the gel to be used at home twice daily till 3rd week and once in the 4th week
41389116|NCT05442359|DEVICE|stent|Applied as a palatal stent for palatal wound
41389117|NCT00817869|OTHER|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
41389118|NCT02269501|OTHER|Exercise treatment|
41389119|NCT01547273|PROCEDURE|bone graft inside socket only|bone graft inside socket only
41389120|NCT01547273|PROCEDURE|bone graft inside and outside socket|bone graft inside and outside socket
41166990|NCT02941848|DRUG|HGP1404|
41166991|NCT02941848|DRUG|HCP1306|
41166992|NCT06002633|OTHER|Alcohol|Participants will consume beverages containing alcohol.
41166993|NCT06002633|OTHER|Placebo|Participants will consume beverages containing a very low dose of alcohol (placebo condition).
41389121|NCT01547273|PROCEDURE|no bone graft|no bone graft
41389122|NCT04423731|DRUG|Folfirinox|Neoadjuvant chemotherapy is given according to different regimens, preferably FOLFIRINOX according to the recommendations in the national Norwegian guidelines. The choice of chemotherapy regimen is decided by the treating oncologist.
41389123|NCT00000510|DRUG|aspirin|
41389124|NCT00000510|DRUG|dipyridamole|
41389125|NCT00000510|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
41389126|NCT00116129|DRUG|Ibutamoren Mesylate (MK-0677)|Ibutamoren Mesylate 25 mg/day
41389127|NCT01715259|DRUG|Abiraterone acetate: participants with end-stage renal disease|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
41389128|NCT01715259|DRUG|Abiraterone acetate: matched control participants with normal renal function|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
41389129|NCT06111560|OTHER|We do not have any interventions. This study is based on obseravation.|observational retrospective study without any interventions
41389130|NCT04698278|DEVICE|PanOptix Trifocal Intraocular Lens|This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.
41389131|NCT02312531|DRUG|Hepatitis B immunoglobulin|Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
41166994|NCT05216198|OTHER|Check of the different exams performed at the emergencies|Check of the different exams performed at the emergencies
41166995|NCT01586533|DRUG|Zoenasa-1:4|Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)
41166996|NCT01586533|DRUG|Mesalamine Enema|Mesalamine Rectal Suspension Enema (4.0g mesalamine \[5-ASA\], 60ml)
41166997|NCT00694733|DRUG|Placebo injection|Normal saline injection IM monthly for 4 months
41166998|NCT00694733|DRUG|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
41166999|NCT00694733|DRUG|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
41167000|NCT00694733|DRUG|placebo|Placebo Cream 1ml applied twice daily for four months
41167001|NCT00694733|DRUG|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
41167002|NCT01487902|DRUG|ADT|Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
41167003|NCT01487902|DRUG|No ADT|Docetaxel-prednisolone (TAX327 regimen) alone
41389132|NCT06222411|OTHER|evaluate the impact of organizational interventions for physician development on wellbeing|There is an increasing demand for healthcare organizations and hospitals to address factors contributing to stress and burnout as well as provide effective solutions at an organizational level
41511891|NCT03545542|DIAGNOSTIC_TEST|Breath volatile organic compounds under chemotherapy|"Breath sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
41511892|NCT03545542|DIAGNOSTIC_TEST|Final microbiome|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
41511893|NCT03545542|DIAGNOSTIC_TEST|Final fecal volatile organic compounds|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
40857921|NCT04788394|OTHER|data comparing|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory-confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~* Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~* Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\].~* Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
41167004|NCT04379817|DIAGNOSTIC_TEST|Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT|Assess somatostatin receptor expression
41167005|NCT03540615|DRUG|BAY1830839|Dose escalation in healthy male subjects
41389133|NCT05000918|DIETARY_SUPPLEMENT|Okara protein hydrolysate (OPH)|Okara protein hydrolysate (OPH) was a pack of dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight.
41389134|NCT03837340|OTHER|CMHT|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
41389135|NCT03837340|OTHER|CAU|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
41389136|NCT01398982|DRUG|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
41389137|NCT01398982|DRUG|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
41389138|NCT04452097|BIOLOGICAL|Human umbilical cord mesenchymal stem cells + best supportive care|hUC-MSC product will be administered intravenously in addition to the standard of care treatment.
41511894|NCT03545542|DIAGNOSTIC_TEST|Final breath volatile organic compounds|Breath sampling 3 weeks after completion of chemotherapy Neuroblastoma group
41511895|NCT00805467|DRUG|Fostamatinib Disodium (R935788)|50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
41511896|NCT04831814|DIAGNOSTIC_TEST|Near Focus NBI|Colonoscopy with near focus narrowing band imaging technology . Optical specifications include a 2 mm near field focal depth. Optical diagnosis of polyps were according to NICE and WASP, respectively.
41511897|NCT04831814|DIAGNOSTIC_TEST|Standard Focus NBI|Colonoscopy with narrow band imaging technology.Optical diagnosis of polyps were according to NICE and WASP, respectively.
41511898|NCT05528978|BEHAVIORAL|Shambhavi Kriya|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
41511899|NCT06048952|BEHAVIORAL|Music Therapy|Huseyni maqam, Pentatonic music
41511900|NCT00697151|DRUG|Warfarin|Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
41511901|NCT00697151|DRUG|Aspirin|Aspirin 325 mg once a day; placebo warfarin once a day
41511902|NCT00734058|DEVICE|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
41511903|NCT03814655|PROCEDURE|Full digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be full digital.
41511904|NCT03814655|PROCEDURE|Partially digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be partially digital.
41511905|NCT02214992|DRUG|Telmisartan/Ramipril|Fixed dose combination tablet
41511906|NCT02214992|DRUG|Telmisartan|
40857922|NCT00637416|DRUG|Lansoprazole|Lansoprazole 30 mg taken by mouth daily for 3 months
40857923|NCT00637416|OTHER|Placebo|placebo taken by mouth daily for 3 months
41389139|NCT04452097|OTHER|Placebo control + best supportive care|Placebo control will be administered intravenously in addition to the standard of care treatment.
41389140|NCT05589428|DIETARY_SUPPLEMENT|Low sodium bread|Bread low in sodium
41389141|NCT05589428|OTHER|Placebo|Normal bread from bakery
41389142|NCT05658289|PROCEDURE|Coracoid Transfer|For patients randomized to the active comparator group, the coracoid process and conjoined tendon will be cut and transferred to the anterior rim of the glenoid through an incision in the subscapularis muscle.
41389143|NCT05658289|PROCEDURE|Distal Tibia Allograft with Bankart repair|For the experimental group, a distal tibia allograft will be prepped, cut (20mm x 10mm x 15mm), and inserted into the anterior aspect of the shoulder through a far medial portal. The distal tibia allograft will be attached to the anterior glenoid using cannulated screws. A soft tissue repair, Bankart repair, is performed above the graft.
41389144|NCT01042002|BEHAVIORAL|High intensity exercise|High intensity exercise 3xweek for minimum 6 weeks
41389145|NCT02740660|DRUG|Caffeine 100mg / Albuterol 4mg|
41389146|NCT02740660|DRUG|Placebo|
41389147|NCT02740660|BEHAVIORAL|Family weight management counseling|
41389148|NCT04682210|DRUG|Sintilimab|Sintilimab 200mg IV Q3W
41511907|NCT02214992|DRUG|Ramipril capsule|
40857924|NCT02360891|OTHER|biomarkers (composite analysis)|biological, imaging, electrophysiological and anatomopathological examinations
40857925|NCT01529034|DRUG|USL261|
41389149|NCT04682210|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg IV Q3W
41389150|NCT02431715|DRUG|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)|"All patients will have their weight and baseline vital signs recorded.~The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.~The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.~Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.~Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians."
41389151|NCT01340703|PROCEDURE|vitrectomy without laser or gas tamponade|vitrectomy without laser or gas tamponade
41389152|NCT06280027|OTHER|survey|An online survey was generated to quantitatively evaluate the level of esthetic perception.
40857926|NCT03603483|PROCEDURE|procedure|"Patients of sever aortic stenosis 1: increase the diameter of aortic anulus by prosthetic patch or pericardial patch.~Patients of sever aortic stenosis 1:only conventional aortic valve prosthesis will be used"
40857927|NCT01018485|DRUG|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
40857928|NCT00975949|OTHER|Survey|Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
40857929|NCT01984502|RADIATION|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
40857930|NCT00458458|DRUG|Norethindrone Acetate (NA)|52 weeks of treatment with Norethindrone Acetate
40857931|NCT00458458|DRUG|GnRH Agonist (Lupron Depot)|24 weeks of treatment with Lupron Depot then 28 weeks of treatment with Norethindrone Acetate
41389153|NCT05354427|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with implantabale spacers.
41389154|NCT01826968|PROCEDURE|Alveolar Recruitment maneuver|In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
41389155|NCT04753918|DRUG|Porfimer sodium|Photofrin 2mg/kg was iv injected 48-50 hours before light illumination.
41389156|NCT04753918|DRUG|Ethiodized oil|In hybrid operation room setting, a navigational bronchoscope guide sheath was inserted to the proximal end of the tumor region. About 5 ml Lipiodol was infused to full cover whole the tumor.
41389157|NCT04753918|PROCEDURE|Novel light delivery methods of photodynamic therapy|Using high-refraction index contrast medium: lipiodol as a light diffusor to enhance the range of photodynamic therapy
41389158|NCT04753918|DEVICE|Fiber optic|A cylindrical laser fiber was then inserted through the guide sheath to the tumor region then illuminate light to complete the photodynamic therapy.
41511908|NCT02214992|DRUG|Ramipril tablet|
41511909|NCT01587287|DEVICE|Corneal power measurement|All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
41511910|NCT05236192|BEHAVIORAL|Take Root Home Visitation (TRHV)|TRHV is a home-visiting, standardized program that home visitors can use to structure their time spent with families during home visits.
41511911|NCT05236192|BEHAVIORAL|Services as Usual (SAU)|SAU includes an installation's current NPSP home visiting practice, which may vary across the installations participating in this study.
41511912|NCT06261424|PROCEDURE|IMPACT - rehabIlitation prograM for sPAstiC aTaxias|The rehabilitation program will last 12 weeks and consists of three training sessions of 60 minutes per week (2 sessions in a therapy room and 1 session in an adapted pool with multiple levels of water) for a total of 36 sessions. Participants will be divided into 7 subgroups of 6 participants and each sub-group will be supervised by one physiotherapist (PT) and one physiotherapy technologist for safety considerations. It will focus on these three domains: 1) postural control; balance, trunk-limbs and multi-joints control and coordination and 3) functional mobility. Each domain contains a standardized list of exercises with different difficulty levels and specific times allocation. All exercises will be executed by the participants at each session at the appropriate difficulty level. The initial level of difficulty for each exercise will be determined by the PT based on individual results of the pre-intervention assessment and on individual performance, fatigue level and safety.
41389159|NCT03190018|DEVICE|lCarry Life System Peritoneal Dialysis (CLS PD)|The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
41389160|NCT05959707|BIOLOGICAL|VRC01.23LS|VRC01.23LS will be administered IV over approximately 30 to 60 minutes.
41389161|NCT05959707|BIOLOGICAL|PGT121.414.LS|PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.
41389162|NCT05959707|BIOLOGICAL|PGDM1400LS|PGDM1400LS will be administered IV over approximately 30 to 60 minutes.
41389163|NCT01216319|DEVICE|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
41389164|NCT06232369|DEVICE|Active repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is accurately delivered to the intended target by an optic navigation and a deep pulse protocol at 90% of the tested threshold for 15-minute stimulation duration."
41389165|NCT06232369|DEVICE|Sham repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is placed on the scalp to mimic the sensation and sounds of the actual treatment but without letting the magnetic field reach the brain tissue for 15-minute duration."
41389166|NCT06204848|DEVICE|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
40857932|NCT00795236|DRUG|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
40857933|NCT00770601|DRUG|Canakinumab|
40857934|NCT01646242|PROCEDURE|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
40857935|NCT01646242|PROCEDURE|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
40857936|NCT02150447|DRUG|Proton pump inhibitor|Lansoprazole 30 mg, daily
40857937|NCT02150447|DRUG|Placebo|Placebo, daily
40857938|NCT00666406|DRUG|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
41389167|NCT05406596|DEVICE|LiquID GCE Use|Use of the LiquID GCE to aid in percutaneous coronary intervention (PCI)
41389168|NCT01468974|DEVICE|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
41389169|NCT06221683|DRUG|Homoharringtonine|3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours
41389170|NCT06221683|DRUG|Cytarabine|100mg/m2/q12h for weighing \>10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing \>10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;
41389171|NCT06221683|DRUG|Etoposide|100mg/m2/d for weighing \>10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours
40857939|NCT00666406|DRUG|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
41389172|NCT06221683|DRUG|Venetoclax|100mg/m2/d for weighing \>10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd
41389173|NCT06221683|DRUG|Mitoxantrone hydrochloride liposome|5mg/m2/d for weighing \>10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.
41389174|NCT06221683|DRUG|Recombinant Human Granulocyte Colony-Stimulating Factor|5ug/kg/d, d1-10, s.c., qd, at 1pm
41389175|NCT06221683|DRUG|Idarubicin Hydrochloride|3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.
41167006|NCT03540615|DRUG|Placebo|Matching placebo
41389176|NCT06221683|DRUG|Sorafenib|100mg/m2/day for weighing \>10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd
40857940|NCT03478033|DRUG|Rifampicin|Rifampicin capsules, 150mg
40857941|NCT03478033|DRUG|Rifabutin|Rifabutin capsules, 150mg
40857942|NCT00730080|DRUG|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
40857943|NCT00742417|BIOLOGICAL|Albutein 5%|"18 Plasma Exchanges using Albutein 5%:~* three weeks of intensive treatment with two plasma exchanges per week~* six weeks of maintenance treatment with one weekly plasma exchange~* three months of maintenance treatment with one plasma exchange every two weeks"
41039005|NCT05985187|DRUG|Perjeta + Trastuzumab + Docetaxel|"Perjeta® with the general name Pertuzumab injection, is a recombinant humanized monoclonal antibody targeting the extracellular second domain of human epidermal growth factor receptor 2 (HER2). Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
41039006|NCT03704376|DRUG|30 ml of 0.2% ropivacaine|
41389177|NCT06221683|DRUG|Gilteritinib|20mg/m2/day for weighing \>10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd
41389178|NCT06221683|DRUG|Avapritinib|50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd
41389179|NCT03309631|DIAGNOSTIC_TEST|In vitro Diagnostic|
41389180|NCT05478603|DRUG|PF-07081532|PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1
41511913|NCT02224989|BEHAVIORAL|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 10 weeks.
41511914|NCT03347825|PROCEDURE|Robotic-assisted lobectomy using da Vinci Surgical System|Robotic-assisted lobectomy
41511915|NCT03347825|PROCEDURE|VATS (video assisted thoracic surgery)|VATS (video assisted thoracic surgery)
40857944|NCT00742417|OTHER|Control|Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
40857945|NCT00582998|PROCEDURE|Standard Wound Dressing|Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
40857946|NCT00582998|DEVICE|Vacuum Assisted Closure Device|Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
40857947|NCT00079716|DRUG|SGN-40 (anti-huCD40 mAb)|0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
40857948|NCT04648683|BEHAVIORAL|Individual telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a one-on-one telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 75 minutes each (except the first session which lasts 90 minutes).
40857949|NCT04648683|BEHAVIORAL|Group telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a group-delivered telehealth (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 90 minutes each.
41039007|NCT03704376|DRUG|15 ml of 0.2% ropivacaine|
41039008|NCT03704376|DRUG|100 mcg clonidine|
41039009|NCT03704376|DEVICE|High-frequency linear ultrasound transducer|
41039010|NCT03955432|DEVICE|Reveal LINQ ICM System|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population.
41167007|NCT04363853|DRUG|Tocilizumab 20 MG/ML|We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
41389181|NCT01610167|DEVICE|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
41389182|NCT01610167|DEVICE|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
41389183|NCT01610167|DEVICE|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
41389184|NCT06014359|DRUG|Saline|Patients will be Nebulized with 3 mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
41389185|NCT06014359|DRUG|Dexmedetomidine|Patients will be Nebulized with Dexmedetomidine (1 mcg/kg) in 3mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
41389186|NCT01925742|OTHER|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
41389187|NCT01925742|OTHER|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
41389188|NCT01925742|OTHER|Semiconductor MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
41511916|NCT03347825|PROCEDURE|Open lobectomy|Open lobectomy
41511917|NCT00687830|DRUG|Polyethylene Glycol afternoon|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
41511918|NCT00687830|DRUG|Polyethylene Glycol morning|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
41039011|NCT06211400|OTHER|Whole body vibration exercise|6-week supervised whole body vibration exercise programme (training sessions three times per week lasting 10 min) alongside a lifestyle education programme
41039012|NCT00242112|PROCEDURE|MRI Prostate|
41167008|NCT05828563|DIAGNOSTIC_TEST|Blood sample test|Blood sample will be taken to determine immunological indices
41511919|NCT04197778|DRUG|DDO-3055 tablet|DDO-3055 tablet, 2 single doses separated by 6 days.
41511920|NCT02467140|DEVICE|Parietex ProGrib self-fixating mesh|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
41039013|NCT06104475|OTHER|CT scan|A CT scan will be requested for every patient in addition to the chest X-ray
41039014|NCT00380848|PROCEDURE|Hemodiafiltration|
41039015|NCT04822038|DIETARY_SUPPLEMENT|Vitamin D3|5000 UI Vitamin D3 daily by 4 weeks
41039016|NCT04822038|OTHER|Dietary recommendations|Dietary recommendations based on food rich in 25 (OH) vitamin D
41039017|NCT02158299|DRUG|Avitene|
41039018|NCT02158299|DRUG|Sapylin|
41039019|NCT02158299|BEHAVIORAL|axillary drainage|
41167009|NCT05867914|DEVICE|Inhaled Nitric Oxide (iNO)|eNOfit system delivering iNO
41167010|NCT04006236|OTHER|Experimental Infant Formula|Feed Ad Libitum
41167011|NCT04006236|OTHER|Control Infant Formula|Feed Ad Libitum
41511921|NCT02467140|DEVICE|Tack fixation|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
40857950|NCT05741398|DEVICE|VR system by Demaod|non-invasive light pulse generated by a non-contacting device for the treatment of the symptoms of dry eyes and MDG
41039020|NCT02158299|OTHER|reexamine|
41039021|NCT05615792|OTHER|No intervention|No intervention
41039022|NCT04288570|PROCEDURE|suture anchor socket creation with punch|suture anchor socket creation with punch
41039023|NCT04288570|PROCEDURE|suture anchor socket creation with drill|suture anchor socket creation with drill
41039024|NCT04169139|DEVICE|MIST (minimally invasive surgical therapy)|REPaiR Periodontal Therapy
41039025|NCT01426191|DRUG|xinzhijun|"durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)~1.5-3.0g,iv,bid or tid for 5-12 days;~Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days"
41039026|NCT02999555|PROCEDURE|Ovum pickup|Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
41039027|NCT01293448|DEVICE|Cryoballoon Ablation|"Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)"
41039028|NCT02732925|DEVICE|Arm 2 Balloon Kyphoplasty|"Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment~Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy"
41039029|NCT02732925|PROCEDURE|Conservative Management|"Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~* Concomitant treatment with bisphosphonates~* Pain relief as required~* Systemic chemotherapy for Myeloma disease~* Bed rest~* Radiotherapy~* Physiotherapy"
41167012|NCT05799261|PROCEDURE|Control (standard protocol)|The control group will be treated according to standard protocols of the Department of Periodontology of the university of Bern and receive conventional scaling and root planing. Supra- and subgingival hard and soft tissue deposits are being removed by means of hand instruments and ultra-sonic scalers followed by rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists.
41389189|NCT01925742|OTHER|Optical-based MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
41389190|NCT01925742|OTHER|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
41511922|NCT03104569|PROCEDURE|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
41511923|NCT00199394|DRUG|Istradefylline (KW-6002)|
40857951|NCT05869188|DRUG|Isotretinoin|"* Evaluate serum irisin level in acne vulgaris and compare it with healthy control .~* Evaluate the effect of systemic isotretinoin on serum irisin in acne vulgaris patients ."
40857952|NCT00118742|DRUG|mycophenolate mofetil [CellCept]|1-1.5 g orally or intravenously twice daily
40857953|NCT00118742|DRUG|Tacrolimus|As prescribed, for 12 months
40857954|NCT00118742|DRUG|Cyclosporine|As prescribed, for 12 months
40857955|NCT00118742|DRUG|Sirolimus|2-4 mg orally once daily for 9-11 months
40857956|NCT04347629|BEHAVIORAL|Advance Care Planning Video Decision Aid|The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
40857957|NCT00966251|DRUG|CT-011|CT-011
41511924|NCT00619060|DRUG|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
41511925|NCT00619060|DRUG|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
41389191|NCT01342367|DRUG|Bicalutamide|Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
41389192|NCT01342367|DRUG|Dutasteride|Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
41389193|NCT01342367|DRUG|Finasteride|Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
41389194|NCT01342367|RADIATION|Radiation|7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
41389195|NCT04074473|DRUG|propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
41389196|NCT04074473|PROCEDURE|Esophageal varice ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
41389197|NCT04074473|OTHER|DC propranolol|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
41389198|NCT05114265|DRUG|KUR-101|Single oral dose of KUR-101
41389199|NCT05114265|DRUG|OxyNorm|Single oral dose of OxyNorm
41389200|NCT05114265|DRUG|Placebo|Single oral dose of placebo
41389201|NCT04179773|OTHER|Current care study|"Observational study in two parts:~1. Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~2. Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject."
41389202|NCT01838863|BIOLOGICAL|Type AB plasma|The plasma is thawed and administered to subjects in the experimental (plasma) arm.
41389203|NCT01838863|DRUG|Crystalloid fluid (standard of care for resuscitation)|Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
41389204|NCT01881178|DIETARY_SUPPLEMENT|NOPALEA|
41389205|NCT00929864|DRUG|Abatacept|Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
41389206|NCT00929864|DRUG|Adalimumab|Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
40857958|NCT01152034|BEHAVIORAL|psychoeducation group therapy|This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
40857959|NCT01669772|DRUG|DA-9701 and placebo|Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
40857960|NCT01669772|DRUG|Placebo and DA-9701|Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
40857961|NCT03635996|DRUG|Etripamil NS 70 mg|All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.
41039030|NCT04721054|DRUG|Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)|patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
41039031|NCT04721054|DRUG|general anesthesia effect on heart rate in Laparoscopic Cholecystectomy|patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
41039032|NCT00558428|DRUG|fixed dose combination of telmisartan+amlodipine|
41039033|NCT00558428|DRUG|amlodipine|
41167013|NCT05799261|PROCEDURE|Test (Guided Biofilm management)|"The test group will be treated according to a novel treatment concept (Guided biofilm management, GBM):~1. Staining of all tooth surfaces to detect soft and hard deposits.~2. Removal of supra- and subgingival hard and soft bacterial deposits by means of an erythritol powder air-polishing.~3. If present, the supra- and subgingival hard deposits (e.g. calculus) will be removed by means of a slim ultrasonic tip (Piezon PS, EMS, Nyon Switzerland) without any additional use of hand instruments.~4. Another sub- and supragingival application of erythritol powder air-polishing without any rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists."
41389207|NCT05174559|OTHER|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU. PreKUnil® inactive LNAA is a customized placebo for this research.
41389208|NCT02231671|DRUG|ALS-008176|
41389209|NCT02231671|DRUG|ALS-008112|
41389210|NCT02543515|PROCEDURE|office hysteroscopy|diagnostic procedure
41389211|NCT01566474|DRUG|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
41389212|NCT01566474|DRUG|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
41389213|NCT01732666|DRUG|Nefopam|20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
41389214|NCT01732666|DRUG|low dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
41389215|NCT01732666|DRUG|high dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
41511926|NCT01971437|PROCEDURE|Cystodistension & Cystoscopy|Women with refractory OAB receiving Cystoscopy and cystodistension
41389216|NCT01179191|DRUG|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
41389217|NCT01171131|OTHER|Blood/saliva sampling|one-time blood sample (\~ 1 TBS) and saliva sample (\~ 1 tsp)
41389218|NCT01139801|DRUG|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
41389219|NCT01139801|DRUG|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
41389220|NCT00060489|DRUG|SEROQUEL (quetiapine fumarate) Tablets|
41389221|NCT06542731|DRUG|ONO-4578|Specified dose on specified days
41389222|NCT06542731|DRUG|ONO-4538|Specified dose on specified days
41389223|NCT06542731|DRUG|Docetaxel|Specified dose on specified days
41389224|NCT06542731|DRUG|Ramucirumab|Specified dose on specified days
41389225|NCT06114810|BIOLOGICAL|polio vaccines: nOPV2, bOPV, IPV|Co-administration of nOPV2 with bOPV along with IPV with different sequential or combination schedules.
41389226|NCT01041937|PROCEDURE|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
40857962|NCT03635996|DEVICE|Aptar Pharma Nasal Spray Bidose System|Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
40857963|NCT03223337|DRUG|Daprodustat (GSK1278863)|Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
40857964|NCT06098248|DIAGNOSTIC_TEST|cCeLL - Ex vivo|Neoplastic brain tissue biopsied from participant will be visualized, and images will be captured using cCeLL - Ex vivo.
40857965|NCT00999440|DRUG|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
40857966|NCT04334993|DRUG|Blinatumomab|Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.
40857967|NCT00258804|DRUG|Insulin glargine|
40857968|NCT06271889|DEVICE|Non-stress test|It will be performed with the HUNTLEIGH brand BD4000XS-2 model NST device located at the maternity clinic to listen to the fetal heart sound, approximately min 3 max 5 min will be listened to. According to the studies conducted in the literature, the half-life of adrenaline in plasma is 3 minutes when an invasive/noninvasive intervention is performed on an adult individual. Therefore, the fetal heart rate will be listened to for 3 minutes (Dalal \& Grujic; 2021; https://www.medicines.org.uk/emc/product/6284/smpc#gref https://www.ncbi.nlm.nih.gov/books/NBK482160 / )
40857969|NCT01325688|DRUG|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
40857970|NCT01325688|DEVICE|Aluminium disk|
40857971|NCT01325688|DEVICE|OpSite(TM) disk|
41167014|NCT04933981|DIAGNOSTIC_TEST|Nasopharyngeal swab for SARS-CoV-2|in the interventional group, regular, i.e. twice to three times weekly, SARS-CoV-2 testing was offered to health-care workers and visitors of nursing homes
40857972|NCT01107665|DRUG|Pazopanib and Paclitaxel|Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
40857973|NCT04610398|DRUG|Dexamethasone 4mg|s. arm/group description
41167015|NCT02160678|DRUG|Vehicle|Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle
40857974|NCT04610398|DRUG|NaCl 0.9%|s. arm/group description
40857975|NCT05413408|OTHER|Education and contact|"The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).~The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks."
41167016|NCT02160678|DRUG|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G \& W Laboratories, Inc.) - test product
41389227|NCT01041937|PROCEDURE|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
41389228|NCT03957317|OTHER|Eye mask and ear plugs|Subjects receive one pair of eye mask and ear plugs during their stay in the surgical ICU.
41389229|NCT04808960|DIAGNOSTIC_TEST|clinical Computed Tomography|Clinical CT was acquired (scanned at 1.25mm x 1.25mm on a standard algorithm and then reformatted into an axial, coronal and sagittal series at 3mm x 2mm) on all fully intact cadavers prior to the onset of this study by the Schulich School of Medicine \& Dentistry at the University of Western Ontario, in accordance with the Anatomy Act of Ontario and guidelines of Western's Committee for Cadaveric Use in Research.
41389230|NCT03961945|DEVICE|Sponge Capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
41389231|NCT03535506|DRUG|Palbociclib|Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
41511927|NCT04574687|OTHER|Neurodevelopmental Techniques|)Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
41511928|NCT04574687|OTHER|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
41389232|NCT03564535|DEVICE|Self fixating group|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11\*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
41389233|NCT03564535|DEVICE|Tacker fixation group|Patients will be undergoing polyester mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
41389234|NCT02765542|OTHER|Automated disease assessment & self-care support phone calls|Automated disease assessment \& self-care support phone calls for up to 12 weeks.
41389235|NCT03858660|OTHER|No intervention|No intervention
41389236|NCT01031134|BEHAVIORAL|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
41511929|NCT03536741|PROCEDURE|TAP block and RS block + General Intravenous Anesthestic|transversus abdominis plane block and rectus sheath block
41511930|NCT03536741|DRUG|General Intravenous Anesthetic|General Intravenous Anesthetic
41511931|NCT05803239|PROCEDURE|EBUS-TBNA|Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.
41511932|NCT05803239|PROCEDURE|EBUS-TBMC via a tunnel|Participants with lymphadenopathy would receive EBUS-TBMC via a tunnel attempts to conduct diagnoses.
41528393|NCT02768480|OTHER|Phone Calls Support and Primary Care|Patients in intervention group will receive periodic phone calls (every three months) and will have a toll-free number to resolve questions about the disease management. The phone-calls will be performed by trained nurses and will follow a structured format. Nurses will address some topics: patient's treatment adherence, technique of insulin administration, disease understanding, hypoglycaemia management, healthy diet, smoke cessation and foot care.
41528394|NCT04972552|DIETARY_SUPPLEMENT|coenzyme Q10|Participants will take 800-1200 mg of coenzyme Q10 capsule per day
40857976|NCT00248807|DRUG|1.25 mg enalaprilat IV|an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)
40857977|NCT00248807|OTHER|Head up tilt (HUT)|45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
41167017|NCT02160678|DRUG|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
40857978|NCT02240771|PROCEDURE|Transarterial chemotherapy|"Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes."
41167018|NCT04735198|PROCEDURE|Primary tumor surgery|Large bowel resection.
41167019|NCT04735198|PROCEDURE|Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy|Large bowel resection combined and cholecystectomy.
41167020|NCT01128114|DRUG|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
41167021|NCT04301115|OTHER|attachment|unilateral attachment from rehine 83
40857979|NCT02240771|DRUG|Oral chemotherapy|"Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.~Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD~Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count \& Platelet count would be monitored every 15 days"
40857980|NCT04321434|OTHER|Hyperoxia|
41389237|NCT01031134|OTHER|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
41389238|NCT04015479|DIETARY_SUPPLEMENT|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
41389239|NCT04015479|BEHAVIORAL|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
41389240|NCT03543046|DEVICE|Tortle Midliner|The Tortle Midliner will be applied in the treatment group within the first 3 hours of life and maintained until 72 hours of life.
41511933|NCT05382403|DEVICE|Jada® System|This is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted. The device is made of medical grade silicone. The distal end, which is placed in the uterus, is an elliptical loop. The circular cervical seal, just outside the external cervical os, is filled with 60 - 120 mL sterile water. Low-level vacuum (80 ± 10 mm Hg) is applied and pooled blood is evacuated from the uterus as it collapses. Once there is no bleeding, the device remains in the uterus for at least 1 hour. The suction is then disconnected, the seal emptied of water, the device left in place, and the patient monitored for an additional 30 minutes. If bleeding remains controlled, the device is removed. If bleeding is uncontrolled with the Jada® System patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
41511934|NCT05382403|OTHER|Standard care|Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
41511935|NCT04307888|DEVICE|Perclose Proglide (Abbott)|Common Femoral Artery percutaneous access closure by means of Perclose Proglide device
41511936|NCT05220644|PROCEDURE|Protocols for the management of end-of-life symptoms|Application of the care protocol and data collection
41511937|NCT00442871|DRUG|eltrombopag|eltrombopag 50 mg oral
41511938|NCT03637426|OTHER|Laser|GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours.
41528395|NCT04972552|OTHER|Watermelon diet|Participants will be asked to eat watermelon at a minimum of one meal per day 3-5 days a week
40857981|NCT04321434|OTHER|Normoxia|
40857982|NCT04321434|DEVICE|laser Doppler|laser Doppler
40857983|NCT05269966|BIOLOGICAL|Injection Brolucizumab|"Single-chain antibody fragment (scFv)~Brolucizumab 6 mg was administered by Intravitreal (IVT) injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients received loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) were performed based on Best Corrected Visual Acuity (BCVA) and Optical Coherence Tomography (OCT) to assess whether the patient required q8w or q12w dosing."
40857984|NCT02813239|OTHER|hCG|Oocyte maturation with hCG
41039034|NCT03047200|BIOLOGICAL|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
41039035|NCT01251003|BIOLOGICAL|Autologous cord blood|there is no minimum acceptable dose, and the maximum allowable dose will be 10x10(9)cells/kg given IV (in the vein), one time infusion
41039036|NCT05239039|DRUG|spesolimab|spesolimab
41039037|NCT05374980|DIETARY_SUPPLEMENT|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
41528396|NCT04972552|OTHER|Usual Diet|Participants will be asked to eat a usual diet but not eat any watermelon as part of their usual diet
40857985|NCT02813239|OTHER|hCG + GnRH agonist|Oocyte maturation with hCG + GnRH agonist
40857986|NCT05002179|DRUG|Echinaforce Chewable tablets|"Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution."
40857987|NCT04576026|BEHAVIORAL|mental fatiguing task|a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention
40857988|NCT04576026|BEHAVIORAL|45 - minute simulated soccer game|an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport
41039038|NCT05374980|DIETARY_SUPPLEMENT|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
41039039|NCT06446843|COMBINATION_PRODUCT|(Arthrocentesis following i-PRF +HA)|Intra-articular I-PRF with HA will be injected in the joint,1 ml of I-PRF will be injected inside the joint, Then from 25mg/ml of HA , 1ml will be injected into the superior joint space
41167022|NCT04301115|OTHER|bridge|tooth implant supported bridge
41167023|NCT04301115|OTHER|CONVENTIONAL|conventional metalic partial denture
41167024|NCT04751461|OTHER|Product A|P0213420, a 1.8% nicotine ENDS product
41167025|NCT04751461|OTHER|Product B|P0213520, a 1.8% nicotine ENDS product
41167026|NCT04751461|OTHER|Product C|P0211220, a 1.8% nicotine ENDS product
41389241|NCT00116259|DRUG|Aripiprazole|
41389242|NCT04537130|BIOLOGICAL|IN01 vaccine|"INO1 vaccine is a biological compound comprising generated and purified from recombinant bacteria culture that contains a protein consisting of EGF-4-EGF portion and the Cholera Toxin B-Subunit Domain G33D sequence (CTB-G33D) separated by 4 amino acids and 14 amino acids respectively glycine/serine-rich linkers.~IN01 is a recombinant growth factor fusion molecule which, once injected into the patient, stimulates the immune system to produce polyclonal anti-Epidermal Growth Factor (anti-EGF) neutralizing antibodies. This vaccine-led active immunisation is a new approach to target the growth factor pathways allowing for combinations with other small molecule inhibitors in order to obtain a sustained efficacy with an acceptable toxicity.~The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor growth or other pathophysiologies such as fibrosis."
41389243|NCT05736432|DIETARY_SUPPLEMENT|Blueberries|Experimental condition
40857989|NCT04576026|BEHAVIORAL|cognitive function|The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
40857990|NCT02306798|DRUG|TP05|One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
41389244|NCT05736432|DIETARY_SUPPLEMENT|Placebo|Placebo condition
41389245|NCT02275039|BIOLOGICAL|modified vaccinia virus ankara vaccine expressing p53|Given SC
41167027|NCT04751461|OTHER|Product D|P0211820, a 1.8% nicotine ENDS product
41167028|NCT04751461|OTHER|Product E|P0213417, a 2.4% nicotine ENDS product
41389246|NCT02275039|DRUG|gemcitabine hydrochloride|Given IV
41389247|NCT02275039|OTHER|laboratory biomarker analysis|Correlative studies
41389248|NCT02432521|OTHER|Conventional rehabilitation program from IMREA|The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.
41389249|NCT06566300|PROCEDURE|injection of autologous nanofat grafting|Injection of nanfat graft
41389250|NCT06566300|PROCEDURE|microneedling with autologus nanofat graft|delivery of nanofat graft with microneedling
41389251|NCT04676386|DIAGNOSTIC_TEST|Primary Immune Response (PIR) test by Biodesix, Inc.|Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
41389252|NCT06322355|DIAGNOSTIC_TEST|Coronary angiography, Fractional Flow Reserve measurement, Intravascular ultrasound|Invasive CAG was conducted following standard clinical procedures, encompassing multiple projections of both the left and right coronary arteries. The FFR was precisely measured using either an intracoronary pressure wire (Pressure Wire X; Abbott Vascular, Santa Clara, USA) or a rapid-exchange pressure microcatheter (Insight Lifetech, Shanghai, China) during peak hyperemia. This state of maximal hyperemia was achieved through the intravenous infusion of adenosine triphosphate (ATP) at a concentration of 150 μg/kg/min, administered via the forearm vein. Upon completion of the FFR assessment, the pressure wire or microcatheter was carefully retracted to the tip of the guiding catheter for a routine drift check. IVUS imaging was meticulously conducted using the iLab™ IVUS system, coupled with a 40-MHz OptiCross IVUS catheter (Boston Scientific, Fremont, USA), at a steady pullback speed of 0.5 mm/s.
41389253|NCT04296071|OTHER|Research study|Blood and tracheal aspirates will be collected
40857991|NCT03536559|DRUG|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
40857992|NCT03536559|DRUG|Placebo|Placebo is liquid with identical color and taste
40857993|NCT02104466|PROCEDURE|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
41389254|NCT01220128|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
41389255|NCT01220128|DRUG|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
41389256|NCT01220128|DRUG|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
41389257|NCT01220128|DRUG|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
41511939|NCT03637426|OTHER|nano-hydroxyapatite|The GnHAP volunteers were submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications
40857994|NCT03211975|OTHER|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses
40857995|NCT04343755|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
40857996|NCT03282513|DRUG|AG-120 (Ivosidenib)|Single 500 mg dose of AG-120 (Ivosidenib).
40857997|NCT05426278|DEVICE|Bair hugger and Forces air warmer|The EQUATOR™ (EQ-5000) air-warmer is a convective warmer, with the average and maximum Contact Surface Temperatures of 39℃ \& 44℃ Respectively. Temperature on this device can be set at 36℃ , 40℃ , 44℃. The 3M™ Bair Hugger ™ (SW-2003) upper body blanket is used to warm the body from head till the xiphisternum
40857998|NCT03749720|OTHER|Blood sample|Blood sample taken from cervical cancer patients at time of diagnosis (baseline) and follow-up visits.
40857999|NCT04248543|DEVICE|qMRI with Gadoteridol contrast agent|quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.
40858000|NCT03954080|DEVICE|Intraspinal-optimal stim therapy|During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
40858001|NCT03243357|PROCEDURE|TF Adaptive (First Apical Binding File)|"Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on protocol of First Apical Binding File The enlargement of the root canal will be performed with three files larger than the diameter of the previously established initial apical file."
41389258|NCT01220128|DRUG|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
41389259|NCT01220128|DRUG|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
41511940|NCT03637426|OTHER|Laser + nano-hydroxyapatite|GLASERnHAP first received laser application and subsequently the application of nanohydroxyapatite according to the manufacturer's recommendations.
41511941|NCT03637426|OTHER|PLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
41528397|NCT04972552|OTHER|Placebo|Participants will be asked to take 800-1200 mg of a placebo capsule per day
40858002|NCT03243357|PROCEDURE|TF Adaptive (Control)|"Procedure: TF Adaptive System NiTi (Nickel titanium)Endo File System The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on manufacturer's protocol The enlargement of the root canal will be performed according to the manufacturer's directions."
40858003|NCT01584739|DRUG|AZD8683|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
40858004|NCT01584739|DRUG|Placebo|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
40858005|NCT05578872|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
40858006|NCT05578872|DRUG|Pembrolizumab|Pembrolizumab administered by intravenous (IV) infusion
40858007|NCT05578872|DRUG|Ipilimumab|Ipilimumab administered by intravenous (IV) infusion
40858008|NCT04257526|BEHAVIORAL|Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy.|Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'.
40858009|NCT05183230|BEHAVIORAL|WellPATH-PREVENT|WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
41167029|NCT05624086|BEHAVIORAL|exercise|Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
41167030|NCT05212272|PROCEDURE|PET-MRI Brain Scan|Before starting radiation, participants will have a PET scan and MRI scan of the brain. After 2 to 3 weeks of radiation treatments, participants will have a repeat PET scan. Then 1 month after radiation participants will have another PET scan
41167031|NCT05212272|DIAGNOSTIC_TEST|Blood draw|Blood draws will be taken at baseline, one month after radiation treatment and 3 to 4 months after radiation treatment.
41389260|NCT01220128|DRUG|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
41389261|NCT01220128|DRUG|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
41389262|NCT01220128|DRUG|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
41511942|NCT03038386|OTHER|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
41511943|NCT01514461|DRUG|LCQ908|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
41511944|NCT01514461|DRUG|Placebo|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
41511945|NCT02044263|BEHAVIORAL|Internet CBT-i SHUTi|Computer program SHUTi is based on the same theoretical model of insomnia and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. Specifically, CBT-I usually consists of one or more of the following: psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
41511946|NCT02044263|BEHAVIORAL|face-to-face CBT-i|
41511947|NCT04464850|DRUG|Intravenous iron|"Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session. Iron sucrose will be given for 24 weeks during study period.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~The dosage of intravenous iron will be adjusted according to serum ferritin levels as follows.~Serum ferritin \<500 mg/dl: iron sucrose 100 mg every 2 weeks Serum ferritin 500-800 mg/dl: iron sucrose 100 mg every 4 weeks Serum ferritin \>800 mg/dl: discontinue iron sucrose"
41511948|NCT04464850|DRUG|Oral iron|"1 tablet, three times a day, of iron fumarate will be prescribed for 24 weeks of study period.~The dosage of iron fumarate will be adjusted according to serum ferritin levels as follows.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~Serum ferritin \<500 mg/dl: iron fumarate 200 mg three times daily Serum ferritin 500-800 mg/dl: iron fumarate 200 mg once daily Serum ferritin \>800 mg/dl: discontinue iron fumarate"
41511949|NCT02933437|DRUG|Ajmaline|Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
41511950|NCT03532828|OTHER|polysomnography|Patients will have a polygraphy, a postural evaluation including Vicon system, EOS imaging, ang a force platform
41511951|NCT05523466|OTHER|Acupuncture Active|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Active acupuncture using specific Traditional Chinese Acupuncture points: E36, BP6, F3, IG4, for 20 minutes.
41511952|NCT05523466|OTHER|Acupuncture Sham|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Sham acupuncture using sham points (points not recognized as Acupuncture points), with the duration of 20 minutes
41389263|NCT01220128|DRUG|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
41511953|NCT01842529|BIOLOGICAL|botulinum toxin injection|
41511954|NCT01842529|BIOLOGICAL|0.9% normal saline injection|
41511955|NCT01842529|DEVICE|Implantable loop recorder|
41511956|NCT00986050|DRUG|Abciximab|Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
41511957|NCT00986050|DEVICE|bare metal stent prokinetic, chrono, skylor or bluemedical|bare metal stent in culprit artery in acute myocardial infarction
41511958|NCT00986050|DEVICE|drug eluting stent (sirolimus eluting) - CYPHER stent|stent implantation in culprit artery in acute myocardial infarction
41511959|NCT06575465|BEHAVIORAL|Healthy lifestyle nutrition, culture and physical activity workshops|The intervention will include monthly sessions in the community setting of physical activity. In addition, monthly nutrition and culture sessions will be held.
41511960|NCT06575465|OTHER|Usual care|Usual care patients receive in their primary health care
41511961|NCT02354404|BIOLOGICAL|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
41511962|NCT02354404|BIOLOGICAL|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].
41511963|NCT02354404|BIOLOGICAL|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
41167032|NCT05212272|BEHAVIORAL|Memory testing|3 sessions with simple tests to evaluate how the brain is working. These tests primarily check things like memory, attention, and thought process. The whole set of tests will take 1 hour each time.
41511964|NCT02176265|DEVICE|Qvanteq bioactive coronary stent|PCI
41528398|NCT06071364|DIAGNOSTIC_TEST|Ultrasonography imaging and Hand-held dynamometer (HHD)|"Ultrasound imaging system will be used to evaluate the thickness, cross -sectional area and fat infiltration of lumbar extensors lumbar multifidus , erector spinae and quadratus lumborum muscles.~The hand-held dynamometer assessing isometric lumbar muscles strength"
41389264|NCT01220128|DRUG|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
41389265|NCT00550420|DRUG|Rosiglitazone XR|experimental drug
41389266|NCT00068653|DRUG|Celecoxib|Celecoxib 400mg orally two times a day, taken with meals.
41389267|NCT00068653|DRUG|ZD1839|ZD1839 250 mg po every day, taken with or without food.
41389268|NCT04930198|BEHAVIORAL|PeerNaija|All participants (N=50) will receive daily medication reminders and access to the virtual support group on the PEERNaija app. Participants will be randomized to receive a social incentive (n=25) or a social plus financial incentive (n=25), PEER+, and be followed for 24 weeks.
40858010|NCT05183230|BEHAVIORAL|Optimized WellPATH-PREVENT|The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.
41511965|NCT01199380|BEHAVIORAL|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
41511966|NCT01199380|BEHAVIORAL|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
41511967|NCT01199380|DRUG|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
40858011|NCT04164420|BEHAVIORAL|Oral neuromuscular training and orofacial sensory-vibration|Oral neuromuscular training is performed by using an oral device. The device is placed pre-dentally behind closed lips, and the participant is sitting in an up-right position. The participant is the instructed to hold the device against a gradually-increasing horizontal pulling force for 5-10 s, whilst trying to resist the force by tightening the lips and pressing the head backward against a head rest.
40858012|NCT04164420|BEHAVIORAL|Orofacial sensory-vibration stimulation|All participants in the control group is given orofacial sensory-vibration stimulation by using an electrical toothbrush. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
40858013|NCT02274792|DRUG|Etanercept|Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
41389269|NCT01874015|BIOLOGICAL|mesenchymal cell transplantation|Mesenchymal cell transplantation in patients with Crohn's disease.
40858014|NCT01623375|DRUG|insulin degludec|A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
41389270|NCT01874015|BIOLOGICAL|mesenchymal cell and fibroblast injection|Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
41511968|NCT01284361|DEVICE|30 cm Intermittent Catheter|Randomized cross-over
41511969|NCT01284361|DEVICE|40 cm Intermittent Catheter|randomized cross-over
41511970|NCT03146104|DRUG|Propofol|Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
41511971|NCT03146104|DRUG|Isoflurane|in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
41511972|NCT06582381|OTHER|Meal set A|morning meal: low carbohydrate, low protein, low fat afternoon meal: high carbohydrate, high protein, high fat
41511973|NCT06582381|OTHER|Meal set B|morning meal: low carbohydrate, high protien, low fat meal afternoon meal: high carbohydrate, low protein, high fat meal
41511974|NCT06582381|OTHER|Meal set C|morning meal: low carbohydrate, low protien, low fat meal afternoon meal: high carbohydrate, high protein, low fat meal
41511975|NCT06582381|OTHER|Meal set D|morning meal: high carbohydrate, low protien, low fat meal afternoon meal: low carbohydrate, high protein, high fat meal
41511976|NCT01296087|DRUG|TC-6987|TC-6987 50 mg capsule given once daily on Days 1 to 28
40858015|NCT01623375|DRUG|insulin degludec|A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
40858016|NCT02196935|OTHER|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
41167033|NCT05212272|PROCEDURE|Optional lumbar puncture for cerebrospinal fluid collection|Participants that consent for cerebrospinal fluid collection will have 6 and 20 ml of cerebrospinal collected at baseline.
41167034|NCT04745377|DIAGNOSTIC_TEST|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
41167035|NCT02981537|DEVICE|two-staged endobronchial blocker insertion|positioning endobronchial blockers in two-staged method
41167036|NCT02981537|DEVICE|single-staged endobronchial blocker insertion|positioning endobronchial blockers in traditional single-staged method
41389271|NCT02286284|DEVICE|Apheresis for extracorporal removal of sFlt-1|
41511977|NCT01296087|DRUG|Placebo|Matching placebo capsule given once daily on Days 1 to 28
41511978|NCT00251511|DRUG|Arsenic Trioxide|
41511979|NCT05293821|DIAGNOSTIC_TEST|TriQuik IVD|TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.
41511980|NCT04189601|DIAGNOSTIC_TEST|Complement measurements|Blood and urine tests to assess the complement activation state
41389272|NCT01955031|OTHER|telemonitoring|A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.
41389273|NCT01955031|OTHER|Usual care|Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
41389274|NCT06165510|DEVICE|Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.|2 stage procedure - minimally-invasive epicardial ablation with left atrial appendage exclusion using LARIAT procedure via a subxiphoid incision. This is then combined with endocardial radiofrequency catheter ablation in a separate staged procedure.
41389275|NCT06165510|PROCEDURE|Standard Endocardial Catheter Ablation|Standard percutaneous endocardial catheter ablation of atrial fibrillation
41389276|NCT00300573|DRUG|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
41389277|NCT01308073|DEVICE|Hemodialysis with EMIC 2 filters|Patients with indication for routine continuous hemodialysis due to acute renal insufficiency
41389278|NCT03311828|BIOLOGICAL|Daratumumab|Given IV
41389279|NCT03311828|DRUG|Imaging Agent|Given Copper 64Cu-DOTA-daratumumab IV
41389280|NCT03311828|PROCEDURE|Positron Emission Tomography|Undergo PET
41389281|NCT03311828|OTHER|Pharmacological Study|Correlative studies
41389282|NCT04425954|PROCEDURE|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
41389283|NCT00461396|DRUG|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
41389284|NCT00434148|DRUG|Pasireotide|
41389285|NCT04171089|BEHAVIORAL|Child- Safety Plan Intervention|The intervention includes recognizing and knowing the individual's warning signs for a suicidal crisis, their personal coping/distraction skills, people to contact, as well as a restriction of the means to hurt oneself.
41389286|NCT03573024|DRUG|Azacitidine|On day 1 of cycle 1, azacitidine 75 mg/m2 SC or IV will be given, and will continue for 7 days.
41389287|NCT03573024|DRUG|Venetoclax|Starting on day 1 of cycle 1, venetoclax will be initiated. It will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3 and 600 mg on day 4. The patient then continues to take the 600mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day. On days the subject is given azacitidine, venetoclax must be given first.
41389288|NCT04668131|DRUG|Sodium hyaluronate eye drops|eye drops, three times a day
41389289|NCT04668131|OTHER|acupuncture|three times a week
41389290|NCT00646256|BEHAVIORAL|COGPACK training, psychoeducation|Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
41389291|NCT03962218|PROCEDURE|aquatic physiotherapy|specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
41389292|NCT03199846|OTHER|Non-Interventional|Non-Interventional
40858017|NCT05792189|OTHER|Timed Up and Go Test on subjects with ORIF of distal femur fractures|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
41389293|NCT02368769|DEVICE|During Tele-expertise|
41389294|NCT00057018|PROCEDURE|Constraint-induced movement therapy|
41511981|NCT04196283|DRUG|ABBV-368|Intravenous (IV) infusion
41511982|NCT04196283|DRUG|Tilsotolimod|Intratumoral (IT) injection
41511983|NCT04196283|DRUG|Nab-paclitaxel|Intravenous (IV) infusion
41167037|NCT06457191|DRUG|Roflumilast|Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.
41167038|NCT06457191|DRUG|Placebo|Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.
41389295|NCT04327609|DEVICE|SELUTION SLR™ DEB|Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.
41511984|NCT04196283|DRUG|ABBV-181|Intravenous (IV) infusion
41511985|NCT03080870|OTHER|Art|Multicomponent art intervention
41511986|NCT04618731|DIAGNOSTIC_TEST|caries prevalence def ,DMF|the examination will carried out on dental chair using diagnostic set
41511987|NCT03685214|DRUG|0.9% saline|we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
41511988|NCT03685214|DRUG|lactated Ringer's solution|we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
41511989|NCT01595685|DRUG|Telbivudine|Telbivudine 600 mg Daily Oral
41511990|NCT01595685|DRUG|Entecavir|Entecavir 0.5 mg Daily Oral
41389296|NCT04327609|DEVICE|Control Arm|The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.
40858018|NCT05792189|OTHER|Koos Jr assesment on subjects with ORIF of distal femur fractures|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
40858019|NCT05792189|OTHER|Timed Up and Go Test on subjects with DFR of distal femur fracture|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
40858020|NCT05792189|OTHER|Koos Jr assesment on subjects with DFR of distal femur fracture|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
40858021|NCT03443804|DRUG|Test(DW1401)|DW1401+Placebo of Stillen tab.
40858022|NCT03443804|DRUG|Reference(Stillen tab.)|Stillen tab.+Placebo of DW1401
40858023|NCT00791089|DRUG|LOVAZA Omega 3-acid ethyl esters|Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
40858024|NCT00791089|DRUG|LOVAZA|(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
40858025|NCT00791089|OTHER|placebo|Control group will receive placebo before \& after ablation.
40858026|NCT00854815|PROCEDURE|Irrigation|Irrigation of the area with at least 500ml NS using the power suction/irrigator
40858027|NCT00854815|PROCEDURE|No Irrigation|Suction only using suction/irrigator
40858028|NCT01763606|DRUG|Enoxaparin|Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
40858029|NCT01763606|DRUG|Aspirin|Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
41389297|NCT06420427|DIAGNOSTIC_TEST|Assess the risk of recurrence and the efficacy of medication|Evaluation of recurrence risk and medication efficacy through liquid biopsy
41389298|NCT04443673|DIETARY_SUPPLEMENT|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
40858030|NCT01351961|BIOLOGICAL|blood sampling|take a sample of blood, 46 ml
40858031|NCT01351961|PROCEDURE|brain MRI and TEP cerebral|magnetic resonance imaging
40858032|NCT01351961|OTHER|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
40858033|NCT01351961|OTHER|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
40858034|NCT01351961|PROCEDURE|Vascular explorations|Pulse wave velocity, VWF, IMT
40858035|NCT01351961|BIOLOGICAL|Urine sample|
40858036|NCT04811495|OTHER|Physiotherapy treatment|A treatment plan is carried out which aims to improve pain, muscle balance and range of motion of the temporomandibular joint.
41167039|NCT06457191|DEVICE|Intermittent theta-burst stimulation transcranial magnetic stimulation|Intermittent theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 190 seconds.
40858037|NCT04370353|DIETARY_SUPPLEMENT|Cocoa flavanols|Flavonoid-rich cocoa powder, containing 100mg total flavanols per 316mg.
40858038|NCT04370353|DIETARY_SUPPLEMENT|Placebo supplement|Microcrystalline filler, containing 0mg total flavanols.
40858039|NCT05643339|DIAGNOSTIC_TEST|microvascular flow imaging|microvascular flow imaging
40858040|NCT04034004|BEHAVIORAL|Mindfulness|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
41167040|NCT06457191|DEVICE|Continuous theta-burst stimulation transcranial magnetic stimulation|Continuous theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 1800 pulses over 120 seconds.
41389299|NCT03257137|OTHER|Diet Quality|Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
41389300|NCT01283373|DRUG|DSTP3086S|DSTP3086S administered intravenously
41389301|NCT01283373|DRUG|DSTP3086S|Escalating intravenous dose
41389302|NCT06104592|RADIATION|Comprehensive Ablative Bridging Irradiation (CABI)|Participants will receive radiation therapy to all pretreatment lesions that are able to be feasibly and safely treated.
40858041|NCT04034004|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.
41389303|NCT06104592|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Yascarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
41389304|NCT05205824|OTHER|algorithm validation|stroke subjects are measured to validate algorithms previously developed after including healthy subjects
41389305|NCT03490331|OTHER|Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)|Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
41389306|NCT06521853|OTHER|PEEK With Autogenous Bone Graft|placement of PEEK With Autogenous Bone Graft
41389307|NCT06521853|OTHER|PEEK With Xenograft|placement of PEEK With xenograft
41389308|NCT03928613|BEHAVIORAL|tablet based Cognitive Training based on location information|Participants perform Tablet based Cognitive training using interactive voice services and tags three times (minimum 30 minutes per time) a week for 6 weeks
41389309|NCT05153590|DRUG|Saxenda®|"Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups."
41389310|NCT01990079|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
41389311|NCT01990079|DRUG|nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
41389312|NCT01990079|OTHER|Smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
41389313|NCT01990079|BEHAVIORAL|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
41389314|NCT01990079|OTHER|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
41389315|NCT05652101|OTHER|collection of medical data|"The data collected concerns:~* Sex~* Age~* Socio-professional category of patients or parents / level of education of the parents~* Family history~* Neonatal patient data (pregnancy, childbirth)~* Clinical data (age of onset of symptoms, evolution of these symptoms over the years, psychomotor development, schooling, learning difficulties, rehabilitation)~* Therapeutic data (treatments tried, their dosage and effectiveness, changes in dosage over the years)~* Paraclinical examinations (Magnetic Resonance Imaging (MRI), scanner, Electroencephalography (EEG))~* Genetic data if available"
41389316|NCT05652101|OTHER|Vineland Adaptive Behaviour Scales (VABS2) questionnaire|"This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults.~Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose."
41528399|NCT01510301|DEVICE|Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)|"To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;~* Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;~* Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence."
40858042|NCT04034004|OTHER|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion will cease till the end of the experiment.
40858043|NCT04034004|BEHAVIORAL|Meditation|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
40858044|NCT00281346|PROCEDURE|Doppler echocardiography|Echocardiography
40858045|NCT00257361|DRUG|D-Cycloserine|
41167041|NCT04560023|OTHER|Exposition to multimedia content|Video and images watched on a tablet. Patient could decide which information want to watch.
41167042|NCT01742650|PROCEDURE|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
41167043|NCT01742650|PROCEDURE|TightRope|TightRope transfixation of syndesmosis
40858046|NCT00571038|BEHAVIORAL|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
40858047|NCT00571038|BEHAVIORAL|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
40858048|NCT03152591|DRUG|LIK066|LIK066 tablets for oral administration
40858049|NCT03152591|DRUG|Placebo|Placebo tablets matching LIK066 tablets, for oral administration
40858050|NCT03616509|DRUG|Growth hormone|12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
40858051|NCT03616509|DRUG|Placebo|2 months on placebo, sodium chloride 0,9% injections
40858052|NCT04808739|BIOLOGICAL|Adalimumab|Analysis of survival of adalimumab biosimilar in clinical practice
40858053|NCT00254670|DRUG|Naltrexone|
40858054|NCT01900587|DRUG|Tapentadol ER Tamper-resistant Formulation (TRF)|Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
40858055|NCT01900587|DRUG|Tapentadol ER Prolonged-Release 2 (PR2)|Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
40858056|NCT05383456|DIAGNOSTIC_TEST|Diagnostic Test|Standard diagnostic tests.
40858057|NCT05383456|DRUG|HIV Anti-retroviral Background Therapy|"All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study."
40858058|NCT03680443|OTHER|assembly in THA revision|A single-center continuous series of 62 patients receiving such an assembly in THA revision was assessed retrospectively at a minimum 5 years' follow-up. Failure due to aseptic loosening or instability and implant survival at last follow-up were analyzed.
40858059|NCT06432335|OTHER|E-Socket Monitoring|Limb-socket motion data is collected during participant take-home use. Bimonthly telephone interviews are conducted to assess participant residual limb health status. Analysis is conducted to determine if limb motions and activity changes precede limb health changes.
40858060|NCT02688985|DRUG|Ocrelizumab|Ocrelizumab will be administered as IV infusion.
40858061|NCT02688985|PROCEDURE|Lumbar Puncture|Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
40858062|NCT02688985|DRUG|Methyloprednisolone|Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
41167044|NCT02872519|DRUG|(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|Given by IV
41167045|NCT02872519|PROCEDURE|Positron Emission Tomography|Undergo scan
41528400|NCT01981460|PROCEDURE|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
41528401|NCT03447925|DRUG|Medicinal Plant|Medicinal Plant Extract with vaseline cream
40858063|NCT02688985|DRUG|Antihistamine|Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
40858064|NCT05984602|DRUG|Canakinumab|250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle
40858065|NCT05984602|DRUG|Tislelizumab|300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle
40858066|NCT05984602|DRUG|Nab-Paclitaxel|125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
40858067|NCT05984602|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
40858068|NCT05830175|OTHER|manual therapy for cervikal region|Joint mobilization: In the stroke individuals included in the mobilization group, Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization was applied with the Maitland method starting from the upper cervical region towards the lower cervical region, in 3 sets, 2 minutes and 1 minute rest.
40858069|NCT05830175|OTHER|osteopathic suboccipital myofascial release technique|The patient lies comfortably in the supine position. The therapist's forearms are supported on the treatment table, with the metacarpophalangeal and proximal interphalangeal joints flexed to approximately 45 degrees. After the therapist places his hands on the area where the patient's suboccipital muscles connect the occiput, he asks the patient to relax and rest his head on his fingers. Therapist pays attention to positioning the fingertips in suboccipital area No traction is performed during this technique. The position is maintained until the patient is relaxed. This treatment takes approximately 3-4 minutes.
40858070|NCT00933868|DRUG|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
40858071|NCT00933868|DRUG|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
40858072|NCT03814408|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene, PGK-FANCA-WPRE
40858073|NCT05952388|OTHER|Behavioral Patient care|chart review
41039040|NCT05338788|OTHER|neck pain and dual task|"The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB)."
41167046|NCT02872519|OTHER|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
41528402|NCT03447925|DRUG|Salicylate|Salicylate 10% with vaseline cream
41389317|NCT05968755|DEVICE|A chatbot designed to promote PrEP awareness and uptake for Black MSM|Participants in the intervention group will have access to a theory-informed (Self-Determination Theory) chatbot and receive an automated personalized question message (root-node message) from the chatbot. The root-node messages are questions written into the chatbot algorithms to initiate interactive communication with participants. In each round of the interactive communication, the chatbot will provide automated personalized PrEP-related information, autonomous motivation, and psychological needs based on Self-Determination Theory constructs.
41389318|NCT05968755|OTHER|General educational messages|Participants in the control group will received general education messages from a research assistant including healthy diet, exercise, and COVID-19 prevention. The frequency of contact will be pre-specified by participants in interviews prior to the RCT.
41389319|NCT05036447|OTHER|Moderate-Heavy Resistance Exercise|"Leg press: 3 x 8 repetitions at 75% of 1 repetition maximum, 3 minutes rest between sets.~Knee extension: 3 x 6 repetitions at 85% of 1 repetition maximum, 3 minutes rest between sets."
41389320|NCT05660837|BEHAVIORAL|T1: Mixed mode social support group|"This group will receive programs in both online and off-line setting. There will be one face-to-face group session to get to know participant's peer group members. After the in-person group meeting, participants will meet in WhatsApp group. In WhatsApp group, facilitator will provide the following program~1. In person get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. In-person baking class x 1 session"
41389321|NCT05660837|BEHAVIORAL|T2: Online mode social support group|"This group will receive the same program as mixed mode social support group. The key differences would be delivery of all program components online.~1. Online get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. Online baking class x 1 session through WhatsApp"
41389322|NCT03013517|DRUG|Viaskin Peanut 250µg|DBV712 250 µg, once daily
41389323|NCT01234428|PROCEDURE|Laparoscopic surgery|Gastric banding
41389324|NCT01234428|PROCEDURE|gastric banding|laparoscopic gastric banding
41389325|NCT00158795|BIOLOGICAL|Haemophilus Influenza type b vaccine|
41389326|NCT05321121|DRUG|Dexmedetomidine|Dexmedotomidine for Acute Pain Control in Patients with Multiple Rib Fractures
40858074|NCT02402582|OTHER|Family-centered empowerment model|FCEM and Control groups had similar inpatient care. Patients in the intervention group received care employing the FCEM in four stages. Stage 1: Awareness and cognition. During 3-5 group sessions they were evaluated for their insight into their perceived illness severity and perceived sensitivity, or the degree to which they felt threatened by their illness. Stage 2: Expectations. 3-5 sessions. Stage 3: Acceptance. Assessed using an educational participation method in group discussion. Stage 4: Formative summative evaluations. The formative evaluation encourages patients to internalize their locus of control by seeing his/her self-empowerment (increasing self-responsibility about their health). Summative evaluations were performed to evaluate the influence of the intervention on HRQoL dimensions, perceived stress and anxiety -- assessed at baseline and at 3 months post-intervention. Empowerment was measured at baseline and at 10 days post-intervention by deploying FCEM questionnaires.
40858075|NCT02402582|OTHER|Control|FCEM and Control groups had similar inpatient care. Upon discharge the Control group underwent routine care and follow-up.
40858076|NCT03917095|DEVICE|The Colonic Transendoscopic enteral Tubing.|The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).
40858077|NCT03917095|DRUG|Glutamine|The medications were infused into the colon
40858078|NCT03917095|DRUG|Mesalazine|The medications were infused into the colon
41039041|NCT05233228|DRUG|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
41039042|NCT05233228|BEHAVIORAL|Self-help materials (to support smoking cessation)|"The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit."
41167047|NCT03503383|BEHAVIORAL|Patient Health Questionnaire-9|PHQ-9 for assessing and monitoring depression severity
41389327|NCT05321121|OTHER|Placebo|The control arm will receive an infusion of normal saline
41389328|NCT00791154|DRUG|AMG 479|AMG 479 is administered to subjects
41389329|NCT00791154|DRUG|Etoposide|Etoposide is administered to subjects
41389330|NCT00791154|DRUG|Placebo|Placebo is administered with Carboplatin and Etoposide
41389331|NCT00791154|DRUG|AMG 102|AMG 102 is administered to subjects
41389332|NCT00791154|DRUG|Carboplatin|Carboplatin is administered to some subjects in combination
41389333|NCT00791154|DRUG|Cisplatin|Cisplatin is administered to some subjects in combination
41389334|NCT02399488|DEVICE|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
41389335|NCT04745325|BEHAVIORAL|SMAART Canada smartphone app|a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion
41389336|NCT04767022|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB)|Drug Coated Balloon
41389337|NCT04767022|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)|Drug Coated Balloon
41389338|NCT02533505|DRUG|Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints
41039043|NCT05233228|BEHAVIORAL|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 26-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
41167048|NCT03503383|BEHAVIORAL|Generalized Anxiety Disorder Scale (GAD-7)|to diagnose generalized anxiety disorder, the GAD-7 also proved to have good sensitivity and specificity as a screener for panic, social anxiety, and post-traumatic stress disorder
41167049|NCT02314585|OTHER|Exercise|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
41389339|NCT02533505|DRUG|Matching Placebo pMDI 160/4.5 μg|Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
41389340|NCT01286207|DRUG|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
40858079|NCT05370872|DIAGNOSTIC_TEST|Remote functional testing protocol|Clients in the remote functional testing protocol group will be asked to describe their functional capacity limits using a clinician guided motivational interviewing approach and will also be asked to complete a mobility screening protocol to provide the clinician with the opportunity to observe the clients natural movements.
41039044|NCT02114593|BEHAVIORAL|Parent support program|Parent support program
41039045|NCT03315000|DRUG|Vilanterol and Fluticasone Furoate|Same as vilanterol arm description
41039046|NCT03315000|DRUG|Fluticasone Furoate|Same as fluticasone arm description
41039047|NCT03315000|DRUG|Placebos|Same as placebo arm description
41039048|NCT04166357|DIAGNOSTIC_TEST|neuromuscular ultrasound|Neuromuscular ultrasound refers to a field in medicine in which ultrasound is used to diagnosis and guide treatment for people with neuromuscular diseases. Neuromuscular ultrasound is often combined with electrodiagnosis, and particularly nerve conduction studies and EMG, to improve the accuracy of diagnosis and add anatomic information to the functional information obtained with electrodiagnosis. It has been demonstrated that neuromuscular ultrasound adds value to the diagnosis of nerve disease in over 80% of cases.
41167050|NCT02314585|OTHER|Education|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
41167051|NCT00516828|DRUG|cytarabine|subcutaneously twice daily from Day 1 to 10
41389341|NCT01286207|DRUG|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
41389342|NCT01286207|DRUG|Standard Care|Active standard care
41167052|NCT05705336|DRUG|Tranexamic Acid Oral Product|Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.
41167053|NCT05705336|DRUG|Placebo pills|Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
41389343|NCT01817764|DRUG|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
41389344|NCT01817764|DRUG|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
41528403|NCT03447925|DRUG|Vaseline|Vaseline cream
41528404|NCT02660567|PROCEDURE|Amr maneuver|sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
40858080|NCT06418672|BEHAVIORAL|Go Sun Smart Georgia (GSSG)|"Go Sun Smart Georgia (GSSG) is an educational, train-the-trainer, and technical assistance program for Georgia worksites that employ outdoor workers.~GSSG is delivered through personal contacts with senior worksite managers, employee training, and distribution of educational materials. In meetings with managers, trained coaches work to increase perceived need for workplace sun safety, cite advice from national authorities (e.g., CDC and NIOSH), plan for policy implementation, alter policies/education and/or workplace to improve fit, clarify changes to other managers/ employees, and bundle sun safety with worksite safety.~The intervention period will last 12-16 weeks in each of the groups."
41039049|NCT02696148|DRUG|liraglutide|For subcutaneous (s.c., under the skin) injection once daily.
41389345|NCT01817764|DRUG|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
41511991|NCT00200902|DRUG|Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
41389346|NCT00391040|BEHAVIORAL|SGS education|
41389347|NCT01788137|DRUG|chemotherapy (CHOP)|Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
41389348|NCT01788137|DRUG|chemotherapy(c-ATT)|Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
41389349|NCT00572156|DRUG|NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg once daily injection
41389350|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
40858081|NCT03287037|DEVICE|tDCS over DLPFC|We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients. Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients were maintained on their treatment throughout the study period.
40858082|NCT00630344|DRUG|RAD001|
40858083|NCT00630344|DRUG|Bicalutamide|
40858084|NCT02159976|DRUG|Pantoprazole|Pantoprazole 40mg bid
40858085|NCT02159976|DRUG|Amoxicillin|Amoxicillin 1000mg bid
40858086|NCT02159976|DRUG|Clarithromycin|Clarithromycin 500mg bid
40858087|NCT02159976|DRUG|Metronidazole|Metronidazole 500mg tid
40858088|NCT02159976|DRUG|Tetracycline|Tetracycline 1000mg bid
40858089|NCT02159976|DRUG|Bismuth|Bismuth 600mg bid
40858090|NCT00735722|DEVICE|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
40858091|NCT02544919|DRUG|SMOF lipid (SMOFLIPID) pre treatment|Experimental Arm
40858092|NCT04367246|OTHER|No Intervention|No intervention is assigned.
40858093|NCT04124705|DRUG|Armour® Thyroid|Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
40858094|NCT04124705|DRUG|Levothyroxine|Administered orally once a day; the daily dose could range from 25- 200 µg.
40858095|NCT04168671|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise test|Continuous laryngoscopy during exercise test
41039050|NCT02696148|DRUG|placebo|For subcutaneous (s.c., under the skin) injection once daily.
41389351|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
40858096|NCT04086199|PROCEDURE|Lumbar discectomy|Lumbar discectomy either by an anterior extraperitoneal approach or by a posterior midline approach.
40858097|NCT03710642|DRUG|Prazosin|Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules
40858098|NCT03710642|DRUG|Placebo oral capsule|Placebo capsule matched to appearance of active drug.
40858099|NCT00856726|DRUG|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
40858100|NCT00288236|DRUG|Rimonabant (SR141716)|
40858101|NCT00288236|DRUG|Placebo|
40858102|NCT00003154|DRUG|aminocamptothecin colloidal dispersion|120 hour continuous infusion of aminocamptothecin colloidal dispersion (AC/CD) once a week for 2 weeks, followed by 1 week of rest. Patients are assessed after every 2 courses of therapy. Treatment with aminocamptothecin continues indefinitely if there is tumor shrinkage or stable disease and no significant toxicity is experienced. Patients are followed every 3 months.
40858103|NCT04465890|DRUG|ASC22|200mg/1ml/1bottle
40858104|NCT04465890|DRUG|sodium chloride|90mg/10ml/1 bottle
41389352|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
41389353|NCT01031342|PROCEDURE|Early colonoscopy|Colonoscopy within 12 hours of presentation
41389354|NCT01031342|PROCEDURE|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
41389355|NCT05984329|OTHER|Retrospective analysis of patients' choice|Retrospective analysis of patients' choice of tonic or Burst DR(TM) waves for their analgesic effect.
41389356|NCT01531062|DRUG|Nigella sative|Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
41389357|NCT01531062|DIETARY_SUPPLEMENT|black sticky rice|300 mg capsule bid, 56 days
41389358|NCT06522607|DEVICE|rapid palatal expander|Clinical evaluation of the patients who will be treated with rapid palatal expander for about 6 month.
40858105|NCT06154707|DRUG|Denosumab Injection|Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
40858106|NCT06154707|OTHER|Normal saline injection (1.0ml/ branch)|Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements.
40858107|NCT06242301|OTHER|The collective person-centered dialogue intervention|"* Educate and train the interdisciplinary team and staff.~* Upon hospitalisation, the interdisciplinary team introduces an interactive dialogue tool to patients and their relatives. The tool is designed to facilitate a person-centered dialogue and assess the patients' needs, motivations, and challenges regarding eating and physical activity during hospitalization and in everyday settings.~* Following the needs assessment, the interdisciplinary team will introduce and initiate a personalised action plan based on a predefined template that includes suggestions for actions related to the needs assessment.~* Collaboratively, the interdisciplinary team, patients, and relatives evaluate and adjust the action plan, discussing relevant actions and potential community support for maintaining daily activities.~* Before discharge, discussions are guided by predefined questions. Patients receive a contact number for follow-up and information on oral nutritional supplementation prescriptions."
40858108|NCT02069119|DRUG|OPC-108459|
40858109|NCT02069119|DRUG|Placebo|
40858110|NCT03114332|PROCEDURE|Subcutaneous Drain|A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
40858111|NCT00651716|OTHER|flow cytometry|Lymphocyte Analysis: Lymphocyte subset studies will be performed on samples obtained from the patient, donor, or graft. Aliquots will be analyzed using standard flow cytometry.
40858112|NCT00651716|OTHER|laboratory biomarker analysis|Identification of gut-homing and skin-homing Treg subsets
40858113|NCT00651716|OTHER|Data Collection|Patient samples will receive an alphanumeric code assigned by the principal investigator so that patient and donor identity will be known only to study investigators and research staff. Clinical records on each patient will be reviewed by participating investigators or research staff on a routine basis so that relevant clinical information including survival, malignancy relapse, and GVHD can be included in the patient database. Flow cytometry results will also be included in this database.
40858114|NCT02249611|DEVICE|Mobile physical activity promotion tool|"1. Mobile activity sensor~2. Smartphone with APP~3. Interactional webpage of internet~4. Evidence based health information~5. Individualized reminding messages according to the data from activity recording system~6. Personal counseling from professional personnel"
40858115|NCT02249611|OTHER|Standard care|Counseling on lifestyles with health education material
40858116|NCT01991236|BEHAVIORAL|Video|Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
40858117|NCT01991236|BEHAVIORAL|Standard Script|Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
40858118|NCT05449691|PROCEDURE|One-stage immediate breast reconstruction|One-stage mesh assisted implant breast reconstruction
40858119|NCT01632436|DRUG|Pixantrone|Experimental Drug
40858120|NCT02411019|BIOLOGICAL|GX-188E|In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
40858121|NCT05888987|BIOLOGICAL|PCR multiplex by FilmArray|PCR multiplex by FilmArray system on corneal swabbing sample
41039051|NCT05261633|DEVICE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.
41039052|NCT01143948|DRUG|Glargine & Glulisine|Basal Glargine \& bolus Glulisine
41039053|NCT01143948|DRUG|Regular insulin|Sliding scale regular insulin
41039054|NCT01143948|DRUG|NPH & regular insulin|Basal NPH \& bolus regular insulin
41039055|NCT06025565|DIAGNOSTIC_TEST|Pain Experience Measures|Patient reported outcomes measures, quantitative sensory testing, and physical examination measures.
41039056|NCT00818857|BEHAVIORAL|Early Intervention|At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
41039057|NCT00818857|BEHAVIORAL|Delayed intervention|One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
41167054|NCT04100239|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|MBSR is designed to complement any existing medical treatments, and focuses on the development of mindfulness meditation practice to alleviate psychological distress. MBCL is designed as a follow-up intervention to MBSR and aims to help individuals to turn towards suffering and developing a kind attitude to the self.
41389359|NCT06567132|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a single session using an ultrasonic device and a manual scaler. Polishing was done using polishing paste and rubber cup. Clinical periodontal indices, saliva and gingival crevicular samples were repeated after six weeks follow-up period.
41389360|NCT02282007|BEHAVIORAL|Individual NPMP to the participants|The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
41389361|NCT05137418|BIOLOGICAL|COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
41389362|NCT05724316|DIETARY_SUPPLEMENT|Vitamin D supplement|N/A (says not to repeat information here)
41389363|NCT01988493|DRUG|Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
40858122|NCT04436172|PROCEDURE|spinal anesthesia|The spinal anesthesia was given by a trained anesthetist in an equipped room, after all aseptic measures. A 20 gauge intravenous cannula was inserted for maintaining a peripheral line and 0.9% normal saline was used for loading the patient. The pulse and blood pressure were monitored non-invasively. The median approach was utilized and intrathecal space was accessed via 25 gauge Quiincke bevel(Becton Dickinson/Pakistan ) through L4-L5. A block was performed by using 5 mg hyperbaric bupivacaine (Abocain 0.5%/Abbot) after ensuring swirling. Block height was monitored via pinprick test after every three minutes, for 20 minutes until there was no progression. The couple was left alone. The couples received prior training and were explained precautions.
40858123|NCT01847976|DRUG|Doxycycline|Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
40858124|NCT01835665|DRUG|Nimodipine|Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
40858125|NCT01599013|DRUG|Vinflunine, Gemcitabine|"* Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
40858126|NCT01599013|DRUG|Vinflunine, Carboplatin|"* Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
40858127|NCT04602442|DRUG|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
40858128|NCT04602442|DRUG|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
40858129|NCT04602442|DRUG|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
40858130|NCT06407050|BEHAVIORAL|4 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 8 hours from 7 am to 3 pm and another 2,000 steps between 3:40 pm to 4 pm. Participant will then stay inactive from 4 pm to 8 pm and do a cycling for one hour in the lab. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
40858131|NCT06407050|BEHAVIORAL|8 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 4 hours from 7 am to 11 am and then 2,000 steps between 11:40 am to 12 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Participant will then stay inactive from 12 pm to 8 pm and do a cycling for one hour in the lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
40858132|NCT06407050|BEHAVIORAL|12 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day, participant will take 2,000 steps between 7:40 am to 8 am and then stay inactive from 8 am to 8 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Right after the inactivity intervention, participant will do a 1-hr cycling in lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
41039058|NCT03099434|BEHAVIORAL|Facebook App|This web-based mobile application allows candidates to write a simple and effective story to share with their previously built network on Facebook to help share their story and identify a potential live donor.
41167055|NCT05054283|DIAGNOSTIC_TEST|Inflamatory biomarkers|laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.
41167056|NCT05001997|DIETARY_SUPPLEMENT|Lactose free probiotic yogurt|Probiotics are non-pathogenic, live microbes that when eaten or administered In adequate amount, it confer health benefits to host. Only lactose free probiotic yogurt containing cultures such as Lactobacillus acidophilus and Bifidobacterium lactis will be selected.
41389364|NCT01988493|DRUG|Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
40858133|NCT05876468|DEVICE|Continuous anterior chest compression|"Patients with severe to moderate ARDS who were placed in prone position by the attending physician :~* First CACC : the applied pressure is equal to the one observed in the prone position~* Second CACC : The applied pressure is set at 60 - 80 cmH20"
40858134|NCT05733052|OTHER|Polyester suture|A No2 polyester suture will be used for tying special anatomical structures fr telieving the symptom. of stress urinary incontinence
41039059|NCT03099434|BEHAVIORAL|Live Donor Champion + Facebook App|"A Live Donor Champion (LDC) is a friend, family member, or community member who serves as an advocate for the candidate in their pursuit of live donation. The investigators have developed a six-month program that provides education and advocacy training to waitlist candidates and their LDCs."
41039060|NCT03538015|DRUG|Carvedilol 3.125 mg|Participants will receive a 3.125 mg oral dose of carvedilol twice daily during the 4-week treatment period
41039061|NCT03538015|DRUG|Carvedilol 2.5 mg|Participants will receive a 2.5 mg oral dose of carvedilol twice daily during the 4-week treatment period
41039062|NCT03538015|DRUG|Placebo capsule|Participants will receive a matching oral dose of placebo capsule twice daily during the 4-week treatment period
40858135|NCT00826618|DRUG|ranibizumab|This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
40858136|NCT03499314|DEVICE|Active RS-tDCS +At-Home Manual Dexterity Training|Bilateral M1-SO electrode placement; Active= anodal 2.0 mA dose × 20 minutes
41389365|NCT01988493|DRUG|Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
40858137|NCT03499314|DEVICE|Sham RS-tDCS +At-Home Manual Dexterity Training|"Designed to ensure blinding, includes initial and ending ramp-up/down stimulation for 60 seconds"
40858138|NCT03499314|OTHER|Manual dexterity training|Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
41039063|NCT02298192|DRUG|insulin degludec/liraglutide|For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
41167057|NCT06162065|DRUG|Oxybutynin Pill|pharmacological antimuscarinic treatment
41167058|NCT06162065|DIETARY_SUPPLEMENT|Boldo supplement|treatment supplemented with boldo
41167059|NCT01114308|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
41167060|NCT01114308|DRUG|placebo implant|Implant contains ethylene vinyl acetate
41167061|NCT01114308|DRUG|Buprenorphine|sublingual buprenorphine/naloxone tablets
41389366|NCT01988493|DRUG|Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
41389367|NCT01988493|DRUG|Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
41389368|NCT02996617|DRUG|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF.If their WBC≤1×10\^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10\^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
41511992|NCT00200902|OTHER|Placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
41511993|NCT00200902|BEHAVIORAL|Interpersonal Clinical Interaction (ICI)|Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
41511994|NCT00070551|BIOLOGICAL|GTI-2040|Given IV
41511995|NCT00070551|DRUG|cytarabine|Given IV
41511996|NCT00070551|OTHER|pharmacological study|Optional correlative studies
41511997|NCT00070551|OTHER|laboratory biomarker analysis|Optional correlative studies
40858139|NCT00568126|DRUG|Maca Root|3g/day of Maca Root for 12 weeks.
40858140|NCT00568126|DRUG|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
40858141|NCT04239742|DIAGNOSTIC_TEST|F18-fluciclovine PET/CT|370 MBq ±10% 18F-Fluciclovin + low-dose CT scan, from skull base to pelvis.
40858142|NCT04239742|DIAGNOSTIC_TEST|F18-PSMA-1007 PET/CT|4 MBq/kg ±10% F18-PSMA + low-dose CT scan, from skull base to pelvis
40858143|NCT01409876|RADIATION|brachytherapy|interstitial image- guided PDR/HDR brachytherapy
40858144|NCT03781505|DRUG|Paracetamol +caudal ropivacaine|Paracetamol + Ropivacaine
40858145|NCT03781505|DRUG|Placebo|Caudal ropivacaine
40858146|NCT03833219|BEHAVIORAL|Weekly feedback|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week.
40858147|NCT03833219|BEHAVIORAL|End of intervention period incentive|Notify participant about potential incentive at the end of the intervention period, but do not provide weekly feedback about performance.
40858148|NCT03833219|BEHAVIORAL|Loss-framed weekly incentive|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week. Pay participant weekly according to where they fall on the distribution each week.
40858149|NCT04875091|BEHAVIORAL|Ready SET Health|"This behavioral weight loss intervention will span 16 weeks. The first session (Week 1) will be a virtual Weight Loss 101 group kick-off followed by 15 weeks of a technology-mediated program consisting of the following: weekly emailed content (videos and readings explaining key skills and strategies to produce weight loss) and weekly emailed tailored feedback (based on self-monitoring data from participants). A trained interventionist (coach) will lead the group session, provide weekly tailored feedback, and monitor participant progress."
40858150|NCT04431492|PROCEDURE|CABG|aminoacids and NO levels
40858151|NCT01807598|DRUG|Brentuximab vedotin|
40858152|NCT03515356|BEHAVIORAL|MI-Walk Intervention|Eight-week motivational enhancement therapy and home-based aerobic walking intervention
40858153|NCT03515356|BEHAVIORAL|Physical Activity Education Pamphlet|Physical activity education pamphlet only
40858154|NCT04305366|OTHER|Tissue collection|Blood draw, Fine Needle Aspiration, Saliva Swab, Tumor/tissue sample
40858155|NCT02272374|PROCEDURE|AVF creation|
40858156|NCT02272374|PROCEDURE|TCC placement|
40858157|NCT02272374|PROCEDURE|AVG creation|
41167062|NCT05503693|DRUG|AP303 50 μg|AP303 tablet
41389369|NCT02996617|DRUG|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
41389370|NCT03760523|DRUG|Minnelide|Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
41511998|NCT04117685|OTHER|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
40858158|NCT05547568|PROCEDURE|Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy|
40858159|NCT01938040|DRUG|ibuprofen|single preoperative dose prior to surgery
40858160|NCT01938040|OTHER|sugar water/placebo|single preoperative dose prior to surgery
40858161|NCT05042583|PROCEDURE|Stellate ganglion block|The probe direction was 30-45 degrees from the sagittal plane of the neck. The anterior nodules of the transverse process of the sixth cervical vertebra were displayed. The important anatomical structures were distinguished, and the internal carotid artery and longus cervical muscle were observed. A 25G, 6cm puncture needle was used with the tip beveled downward, and the needle path and tip were shown under ultrasound. The tip reached the high-echo sieve structure between the carotid artery and longus cervical muscle, and the drug solution was injected after withdrawal without blood and gas . The experimental group was injected with 6ml 0.5% ropivacaine.
40858162|NCT03373838|OTHER|Census|Survey and interview
40858163|NCT05604742|DRUG|Belimumab (Benlysta)|Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
40858164|NCT00432341|BIOLOGICAL|botulinum toxin type A|200 Units at Visit 1 (Day 1)
41039064|NCT03142048|OTHER|Schools of Health for the Elderly|"The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing"
41039065|NCT06164470|BEHAVIORAL|Support Group|monthly virtual patient support with multidisciplinary education for 12 sessions
41039066|NCT06350032|DRUG|preservative-free parenteral treprostinil|Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.
41039067|NCT00725296|BIOLOGICAL|Remicade (Infliximab)|Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
41039068|NCT02742168|RADIATION|99mTc-3PRGD2|"Diagnostic group：For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.~Efficacy evaluation group：patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment)，whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers."
41039069|NCT03583918|DEVICE|HighThroughput Micro Coring Device|Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device
41039070|NCT00428350|DRUG|Quetiapine Fumarate (Seroquel)|
41039071|NCT00430768|BIOLOGICAL|rAAV1-CB-hAAT|
41167063|NCT05503693|DRUG|AP303 150 μg|AP303 tablet
41389371|NCT04986566|OTHER|Best Practice|Use standard reporting procedures
41389372|NCT04986566|BEHAVIORAL|Health Education|Use Aetonixx app
41389373|NCT04986566|OTHER|Medical Device Usage and Evaluation|Wear Vivofit 4
41389374|NCT04986566|OTHER|Quality-of-Life Assessment|Complete questionnaires
41389375|NCT03756207|PROCEDURE|multidisciplinary bladder-preservation therapy|Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
40858165|NCT00432341|BIOLOGICAL|botulinum toxin type A|500 Units at Visit 1 (Day 1)
40858166|NCT04120363|DRUG|Testosterone Undecanoate|single intramuscular injection of 750 mg testosterone undecanoate
40858167|NCT04120363|DRUG|Sesame Oil|single intramuscular injection of 750 mg sesame oil solution
40858168|NCT02440685|DRUG|ASN002 Dose Escalation|Multiple ascending doses of ASN002 assigned by cohort
40858169|NCT02440685|DRUG|ASN002 RD|Recommended dose of ASN002 from Part A
40858170|NCT01191177|DRUG|Lovaza (omega-3-acid ethyl ester)|supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test
40858171|NCT01191177|DIETARY_SUPPLEMENT|Corn oil|1 gram per kilogram body weight per day, not exceeding 4 grams
40858172|NCT02193191|DRUG|Plerixafor|
40858173|NCT03305770|DEVICE|verofilcon A contact lenses|Daily disposable soft contact lenses
41389376|NCT01946087|PROCEDURE|Remote ischemic preconditioning at left upper arm|Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) \& 5 min reperfusion (deflation)
40858174|NCT03305770|DEVICE|delefilcon A contact lenses|Daily disposable soft contact lenses
40858175|NCT01958983|BEHAVIORAL|Music Therapy Group Session|
40858176|NCT03077230|BEHAVIORAL|Pre/Post Test of a Lung Cancer Screening Decision Aid|After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
40858177|NCT02391181|DRUG|Iron Sucrose Azad|Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
40858178|NCT02391181|DRUG|Venofer®|Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
40858179|NCT03745521|OTHER|no intervention|no intervention
40858180|NCT01667653|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsule once daily
40858181|NCT01667653|DIETARY_SUPPLEMENT|Placebo|Placebo capsule once daily
40858182|NCT05274269|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
41389377|NCT01946087|PROCEDURE|Control group|keeping the cuff deflated
41511999|NCT04805112|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits to distribute to their sexual partners for partner testing or couple testing. Phone interviews will be conducted with the participants to assess whether they provided a HIV self-test to their partner, if the test was used, how it was used (partner testing or couple testing), if the partner disclosed his results, the partner's reaction to the results, and if the partner went for confirmatory testing
41512000|NCT06007716|OTHER|reflexology massage|5 minutes of classic message on the left foot, 15 minutes of reflexology message, and 5 minutes of classic message on the right foot, 15 minutes of reflexology message, a total of 40 minutes of massage. 30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, reflexology massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
41512001|NCT06007716|OTHER|Placebo massage|Placebo reflexology massage was applied to each foot for 20 minutes, for a total of 40 minutes.30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, Placebo massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
40858183|NCT05274269|DRUG|IVA|Tablet for oral administration.
40858184|NCT05274269|OTHER|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
40858185|NCT05274269|OTHER|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
40858186|NCT03715244|PROCEDURE|Spinal anesthesia with short-acting local anesthetics|Spinal anesthesia in patients with duration of surgery \< 90 minutes
41512002|NCT04254341|OTHER|patients with OSA|Sleep study
40858187|NCT03715244|PROCEDURE|General anesthesia (current standard)|General anesthesia in patients with duration of surgery \< 90 minutes
40858188|NCT00195286|DRUG|piperacillin/tazobactam|
40858189|NCT04521985|PROCEDURE|thoracolumbar kyphosis surgery|patients receiving surgery or not
41167064|NCT05503693|DRUG|AP303 300 μg|AP303 tablet
41389378|NCT01376180|DRUG|Lamotrigine|Administered according to the prescribing information in the locally approved label by the authorities
41389379|NCT06568653|PROCEDURE|exosome|human placenta mesenchymal stem cell-derived exosome
41389380|NCT06568653|PROCEDURE|routine conventional fistulotomy|routine conventional fistulotomy
41389381|NCT01692418|DRUG|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
41389382|NCT01692418|DRUG|Normal saline|Normal saline will be administered as an i.v. infusion (100ml normal saline)
41389383|NCT05764837|OTHER|Foam Rolling|Foam rolling was performed for 4 minutes with the goal of affecting the entire myofascial posterior chain.
40858190|NCT01128192|DRUG|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
40858191|NCT05799417|OTHER|Acoustic stimuli|During different states of sedation/anaesthesia and sleep, acoustic stimuli will be presented and compared to a within-subject baseline.
40858192|NCT00728091|DRUG|Satavaptan|tablets
41389384|NCT04167280|DRUG|Ipratropium Metered Dose Inhaler|MDI to deliver 20mcg per puff ipratropium bromide
41389385|NCT04167280|DRUG|placebo metered dose inhaler|matched MDI to deliver inactive drug
40858193|NCT00728091|DRUG|placebo|tablets
40858194|NCT01939327|DRUG|Lenalidomide/Rituximab|
40858195|NCT06392334|OTHER|Biopsy|Biopsy of lung tissue
41167065|NCT05503693|DRUG|AP303 600 μg|AP303 tablet
41167066|NCT05503693|DRUG|Placebo 50 μg|Placebo tablet
41167067|NCT05503693|DRUG|Placebo 150 μg|Placebo tablet
41167068|NCT05503693|DRUG|Placebo 300 μg|Placebo tablet
41167069|NCT05503693|DRUG|Placebo 600 μg|Placebo tablet
41389386|NCT04177745|OTHER|Hot application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute.
41389387|NCT04177745|OTHER|Cold application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute.
41389388|NCT02432456|DRUG|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
41389389|NCT02432456|DRUG|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
41389390|NCT02432456|PROCEDURE|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
41389391|NCT02432456|DRUG|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
41389392|NCT02432456|DRUG|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate \> 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
41389393|NCT02432456|DRUG|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
41389394|NCT02432456|DRUG|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
41389395|NCT02432456|DRUG|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
41389396|NCT04608578|BEHAVIORAL|Silver|A serious game to improve mental health in youth
41389397|NCT00003119|BIOLOGICAL|filgrastim|
41389398|NCT00003119|BIOLOGICAL|sargramostim|
41512003|NCT05472246|DEVICE|Wearing a virtual reality headset|VR group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure
41512004|NCT00947921|PROCEDURE|Plasty|Restrictive Annuloplasty
40858196|NCT00230958|DRUG|Viramidine|
40858197|NCT00230958|DRUG|Ribavirin|
40858198|NCT00230958|DRUG|pegylated interferon alfa-2b|
41389399|NCT00003119|DRUG|carboplatin|
41512005|NCT00947921|PROCEDURE|Prosthesis|Valve replacement
40858199|NCT02473367|DRUG|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
40858200|NCT02473367|DRUG|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
40858201|NCT02473367|DRUG|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
40858202|NCT03871699|DRUG|Ferric carboxymaltose|Administration of Ferric Carboxymaltose intravenously, one dose only.
40858203|NCT00006249|BIOLOGICAL|pegylated interferon alfa|
40858204|NCT00006249|PROCEDURE|adjuvant therapy|
40858205|NCT01939184|DRUG|WC3055|12.5, 25, 50 or 75 mg dose
40858206|NCT01939184|OTHER|Placebo|Placebo
40858207|NCT03896945|DRUG|Placebo|oral capsules
40858208|NCT03896945|DRUG|AVP-786|oral capsules
40858209|NCT05331586|BEHAVIORAL|Remote Exercise|The pregnant women will perform a home-based structured exercise programme. The exercise will be remotely monitored since the first gestational trimester until delivery
41389400|NCT00003119|DRUG|cyclophosphamide|
41389401|NCT00003119|DRUG|doxorubicin hydrochloride|
41389402|NCT00003119|DRUG|etoposide|
41389403|NCT00003119|PROCEDURE|adjuvant therapy|
41389404|NCT00003119|PROCEDURE|conventional surgery|
41389405|NCT00003119|RADIATION|radiation therapy|
41389406|NCT00394992|DRUG|oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
41512006|NCT04353635|DEVICE|dolphin 3d|software
41512007|NCT02237586|BIOLOGICAL|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
40858210|NCT02117180|OTHER|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
40858211|NCT00623870|DRUG|RO5045337|Multiple ascending doses
40858212|NCT02421718|RADIATION|Radiotherapy|
40858213|NCT02189291|PROCEDURE|Immediate catheter removal|The indwelling catheter will be removed prior to exiting the operating room.
40858214|NCT02189291|PROCEDURE|Post op day 1 catheter removal|For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
41512008|NCT00717717|BEHAVIORAL|Intervention|One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
41512009|NCT01555216|DRUG|Single injection posterior tibial nerve block|5 ml of 0.5% ropivacaine
41512010|NCT01555216|DRUG|Posterior tibial nerve catheter|5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
41512011|NCT01868347|OTHER|treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
41512012|NCT01868347|OTHER|control|PEEP after pneumoperitoneum and trendelenburg
40858215|NCT00136045|DRUG|Rotigotine|
40858216|NCT02989753|DIETARY_SUPPLEMENT|VAL070-A|After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
40858217|NCT02989753|DIETARY_SUPPLEMENT|VAL070-B|After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
40858218|NCT02989753|DIETARY_SUPPLEMENT|Placebo|After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
40858219|NCT04382885|DRUG|Cariprazine|Oral Solution
41389407|NCT00394992|DRUG|Oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
41389408|NCT05833373|DEVICE|Vagal stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. Stimulation frequency is 20Hz, pulsewidth is 200µs and amplitude is determined individually.
40858220|NCT03977766|PROCEDURE|Chemotherapy prevalidation|"Outpatient Chemotherapy prevalidation will done~* with the help of a nurse, using the digital application, for cycle 2 and 3.~* by the patient alone, using the digital application, for cycle 4 and 5."
40858221|NCT01029847|DRUG|Adalimumab|Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
40858222|NCT01029847|DRUG|Placebo|"sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines."
40858223|NCT02489942|DRUG|Jardiance|Empagliflozin
40858224|NCT00269555|DRUG|Genistein Combined Polysaccharide (GCP)|
40858225|NCT02152176|DEVICE|Titration of morphine by Patient Controlled Analgesy|PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
40858226|NCT00481923|DRUG|rimonabant (SR141716)|
40858227|NCT02523378|BEHAVIORAL|Edmonton Symptom Assessment Scale|Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
41167070|NCT05449847|BIOLOGICAL|Blood Sampling|Blood sampling under a complete aseptic conditions
41389409|NCT05833373|DEVICE|Sham stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. In this case to perform a sham stimulation a non conducting ear electrode is used. The device is set to the same settings with a frequency of 20Hz, a pulsewidth of 200µs and an amplitude that is determined individually.
41389410|NCT03060148|DEVICE|Medtronic neurostimulation system|Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
41389411|NCT04442763|DEVICE|Densah Burs|osseodensification method
41389412|NCT04442763|DEVICE|Standard drills|conventional drilling
41389413|NCT00438932|DRUG|Lanthanum Carbonate|Lanthanum carbonate 1000mg 3x/day
41389414|NCT00438932|DIETARY_SUPPLEMENT|Low Phosphorus Diet|Low phosphorus diet will consist of 800 mg of phosphorus per day.
41512013|NCT04269993|DRUG|Cannabis: placebo and medium THC/medium CBD|Vaporized cannabis: placebo and medium THC/medium CBD
41512014|NCT01888939|OTHER|Walking on a Treadmill|
40858228|NCT02523378|BEHAVIORAL|Interview|After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
40858229|NCT01838915|DIETARY_SUPPLEMENT|Prebiotics+Glutamine|"Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.~Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function."
40858230|NCT01838915|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, 20 g.
40858231|NCT05130749|OTHER|Questionnaire|The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.
40858232|NCT03860805|PROCEDURE|Laparoscopic tubal ligation|Laparoscopic tubal ligation
40858233|NCT03860805|PROCEDURE|Laparoscopic bilateral salpingectomy|Laparoscopic bilateral salpingectomy
40858234|NCT00917618|OTHER|Exercise|Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.
40858235|NCT00917618|OTHER|Control|Patients randomized to the control arm were instructed not to change their baseline exercise programs
40858236|NCT04306588|OTHER|Exercise|Participants are undergoing a 12 weeks tele-rehabilitation program.
41389415|NCT00438932|DIETARY_SUPPLEMENT|Unrestricted Phosphorus Diet|Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
41389416|NCT00438932|DRUG|Placebo|Lanthanum Carbonate placebo given three times a day with meals.
41389417|NCT03506425|DRUG|Triheptanoin|Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.
41512015|NCT01888939|OTHER|Sedendary Activities Only|
41512016|NCT00132860|DRUG|azithromycin|
40858237|NCT01277874|DEVICE|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
40858238|NCT01277874|DEVICE|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
40858239|NCT05851326|DEVICE|Active Sonodyn|Sonodyn emits ultrasound, electrical and magnetic stimulation signals with a pre-defined, fixed set of parameters for each of the independently operated power sources.
40858240|NCT05851326|DEVICE|Sham|Non-functional Sonodyn device that cannot convey any energy signals to the device output, however, looks and behaves fully identical as the active Sonodyn device.
40858241|NCT06114186|DEVICE|FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data|using remote monitoring and real-time glucose data sharing with a Follower.
40858242|NCT06114186|OTHER|standard of care|self reported HbA1C or GMI
41389418|NCT06412991|BEHAVIORAL|Cycle Therapy|The patient will either ambulate a short distance to recumbent bike which will be stored on the postsurgical 1 unit or be assisted out of bed to use floor cycle bike.
40858243|NCT01619917|DEVICE|Fractional Vascular Laser|laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result
40858244|NCT02705196|GENETIC|delolimogene mupadenorepvec|oncolytic virus encoding TMZ-CD40L and 4-1BBL
40858245|NCT02705196|DRUG|gemcitabine|chemotherapy
40858246|NCT02705196|DRUG|nab-paclitaxel|chemotherapy
40858247|NCT02705196|BIOLOGICAL|atezolizumab|anti-PD-L1 antibody
40858248|NCT05275595|OTHER|Medical records review|"Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January."
40858249|NCT05275595|OTHER|Medical records review|Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.
40858250|NCT01550809|OTHER|iBolus|Insulin bolus calculated from data obtained through CGM
40858251|NCT01550809|OTHER|tBolus (traditional bolus)|Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
40858252|NCT04120961|DRUG|prolonged continuous use of bivalirudin|prolonged continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)
41512017|NCT05262023|DRUG|DNL593|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
41389419|NCT05231161|DIAGNOSTIC_TEST|Index of Microvascular Resistance|The invasive diagnostic procedure will be performed in at least one coronary artery. The left anterior descending coronary artery will be the preferred target vessel; however, if technical factors precluded guidewire-based assessment of this artery (e.g., tortuous anatomy), then the left circumflex or right coronary artery can be selected. In the case of multiple measurements per patient, the lowest FFR or highest IMR will be used for analysis. A coronary wire with a pressure and temperature sensor (PressureWire X, Abbott Vascular, Santa Clara, CA, USA) will be advanced to the mid to distal segment of the coronary artery. Bolus thermodilution technique with three 3-cc saline injections in rest and hyperemia will be used.
41512018|NCT05262023|DRUG|Placebo|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
40858253|NCT04120961|DRUG|bivalirudin use during ePCI|bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)
41512019|NCT02702570|BEHAVIORAL|CASA|Each participant serves as his/her own control. Measures administered before and after the behavioral intervention.
40858254|NCT00607087|DRUG|Insulin glulisine|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
40858255|NCT00607087|DRUG|Insulin lispro|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
40858256|NCT00607087|DRUG|Insulin aspart|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
41512020|NCT03786458|BEHAVIORAL|web-based decision aid|The decision aid is then developed further process of evidence synthesis and multidisciplinary external review.
40858257|NCT03596983|BEHAVIORAL|Sleep Intervention|"* Sleep Diaries (Daily)~* Fitbit 24/7~* Phone/ video conference calls (weekly with study team)~* Epworth Sleepiness Scale (weekly)~* PROMIS fatigue scale-evening (weekly)"
40858258|NCT03596983|BEHAVIORAL|Week 2 Intervention|"* Sleep Diaries (Daily)~* Phone Calls (weekly with study team)~* Wrist Accelerometry and fitbit 24/7 for 14 days~* SAFTEE Questionnaire~* ASA24~* Behavioral risk factor surveillance system (smoking and alcohol use questions)~* Psychological well-being (SF36)~* Index of Self Regulation~* PROMIS fatigue scale-morning (weekly)~* PROMIS fatigue scale-evening (weekly)~* Epworth Sleepiness Scale (weekly)"
40858259|NCT03987516|OTHER|Active exercising|Patients allocated to the experimental group were included in an active exercising program adapted to each patient
40858260|NCT01940835|PROCEDURE|Upper endoscopy with small bowel biopsies and brushings.|
40858261|NCT01940835|OTHER|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
40858262|NCT01940835|OTHER|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
40858263|NCT05154526|OTHER|Manual Therapy|Manual Therapy: High velocity-low amplitude technique
40858264|NCT05154526|OTHER|Exercise Program|Exercise program
40858265|NCT01687101|DRUG|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
40858266|NCT00005644|DRUG|gemcitabine hydrochloride|
40858267|NCT00005644|DRUG|paclitaxel|
40858268|NCT06196606|DRUG|Botulinum toxin type A for injection|Botulinum toxin was injected into the upper esophageal sphincter of each patient
41389420|NCT04000373|DEVICE|Ekso GT™ exoskeleton|The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
40858269|NCT00120965|DEVICE|AutoPulse|Standard device settings
40858270|NCT00120965|OTHER|Manual CPR|Manual CPR
40858271|NCT04975178|BIOLOGICAL|MTBVAC|MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. We hypothesize that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.
40858272|NCT04975178|BIOLOGICAL|BCG|BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.
40858273|NCT06584240|DRUG|Sequence 1|Single treatment, intramuscularly injected. The total injection 100-150U.
40858274|NCT06584240|DRUG|Sequence 2|Single treatment, intramuscularly injected. The total injection 200-250U.
40858275|NCT06584240|DRUG|Sequence 3|Single treatment, intramuscularly injected. The total injection 350-400U.
40858276|NCT06584240|DRUG|Sequence 4|Single treatment, intramuscularly injected. The total injection ≤400U.
40858277|NCT06584240|DRUG|Sequence 5|Single treatment, intramuscularly injected.
40858278|NCT00657163|DRUG|fluoxetine|fluoxetine per os 20 mg daily
40858279|NCT00657163|DRUG|placebo|placebo per os daily
40858280|NCT00973687|DRUG|Ora Sweet|A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
40858281|NCT00973687|DRUG|Dexamethasone|
40858282|NCT03181399|DRUG|Triheptanoin|. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
40858283|NCT04681963|OTHER|Clinical Assessment within 4 hours of admission|Demographics, Symptoms, Severity scores (Triage at admission, confusion, urea, respiration, blood pressure, age (CURB 65) and pneumonia severity score (PSI), clinical parameters, blood testing, chest x-rays, comorbidities, electro-cardiogram
41039072|NCT01540851|BEHAVIORAL|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
41039073|NCT01540851|OTHER|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
41389421|NCT01315054|BEHAVIORAL|MMT provider dosage training|Training on methadone dosing provided to health care providers working in methadone maintenance clinics
41389422|NCT01315054|BEHAVIORAL|targeted counseling|targeted counseling provided to methadone maintenance clinic attendees
41389423|NCT01315054|OTHER|national guidelines|Provided a hard copy of the existing national guidelines for methadone dosing
41389424|NCT02458365|BEHAVIORAL|Teen Choices: A Program for Healthy Nonviolent Relationships|A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
41389425|NCT02458365|BEHAVIORAL|Health In Motion|A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
40858284|NCT02369913|OTHER|Blood Drawn|Both groups will have 1 teaspoon of blood drawn for analysis.
40858285|NCT05836168|DIETARY_SUPPLEMENT|Omnibiotic Stress Repair|multispecies probiotic
40858286|NCT05836168|DIETARY_SUPPLEMENT|Placebo|Placebo
40858287|NCT02809339|OTHER|Questionnaires|
40858288|NCT02694900|OTHER|Manually chest compressions|Chest compressions performed manually without any device
40858289|NCT02694900|DEVICE|Cardiopump|Chest compressions performed with Cardiopump
40858290|NCT02694900|DEVICE|LifeLine ARM|Chest compressions performed using mechanical chest compressions system LifeLine ARM
41039074|NCT06269770|DRUG|Tapentadol|Add tapentadol, for effective pain management in a multimodal setting during TKR.
41039075|NCT06269770|DRUG|Tramadol|Add tramadol, for effective pain management in a multimodal setting during TKR.
41039076|NCT01738048|PROCEDURE|Reconstruction|Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
41039077|NCT04396613|PROCEDURE|Closure technique|Randomized assignment to one of three known, effective closure techniques
41039078|NCT04301271|DRUG|Simvastatin 40mg|12 weeks 40 mg Simvastatin add-on
41039079|NCT04301271|DRUG|Placebo oral tablet|12 weeks Placebo add-on
41039080|NCT02115958|BIOLOGICAL|cancer stem cell vaccine|
41389426|NCT04876807|DRUG|ACP-196|In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
41389427|NCT04876807|DRUG|Omeprazole|Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.
40858291|NCT04118049|OTHER|BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel.|BiopHreshTM is a vaginal probiotic supplement that is offered over the counter and contains four different lactobacilli strains (L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus). RestoreTM is a moisturizing personal lubricant that has been on the market for three years. Participants will use 1 probiotic capsule with RestoreTM gel nightly three times weekly.
40858292|NCT04118049|OTHER|Standard Care|Standard care arm is standard care for pessary use. Pessary maintenance will be performed standardly by their provider.
40858293|NCT05700383|BEHAVIORAL|GetActive-Fitbit|GetActive-Fitbit is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive-Fitbit sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
40858294|NCT05700383|BEHAVIORAL|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive-Fitbit program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
40858295|NCT03084835|BEHAVIORAL|Usual Care|Brief cessation counseling
40858296|NCT03084835|BEHAVIORAL|WEB+TXT|Access to Become an Ex website plus text messaging
40858297|NCT03084835|BEHAVIORAL|WEB+TXT+TTS|Access to Become an Ex website plus text messaging plus consult with a trained tobacco treatment specialist
40858298|NCT02191332|DRUG|Viramune|
40858299|NCT03060954|DEVICE|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
40858300|NCT03060954|DEVICE|FINE VISION®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
40858301|NCT03306992|BEHAVIORAL|Personalized Exercise Program|"The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (\~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention."
40858302|NCT02041338|DRUG|Paclitaxel and carboplatin|
40858303|NCT02041338|DRUG|Paclitaxel|
40858304|NCT02041338|DRUG|Epirubicin and Paclitaxel|
41039081|NCT06241664|DEVICE|AEYE-DS Software|An Artificial Intelligence (AI) software device to be used as a diagnostic tool to assist healthcare providers in screening for diabetic retinopathy (DR) using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with DR.
40858305|NCT00406172|DRUG|Bevacizumab|
40858306|NCT01822197|DEVICE|Phototherapy|light will be administered at a minimum distance of 12 inches away to provide 10,000 lux
40858307|NCT03036020|RADIATION|CereTom Neurologica Samsung|Diagnosis of acute stroke patients by cerebral CT diagnostics prehospital
40858308|NCT02678507|OTHER|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
40858309|NCT03374371|DIAGNOSTIC_TEST|high-throughput sequencing|technique of high-throughput sequencing of the markers present in the genome of the S. epidermidis strains responsible for infection in order to help to discriminate the true infections of the contaminations
41039082|NCT03776513|BEHAVIORAL|an MRI examination|The MRI examination implies the realization of an emotional associative memory task
41039083|NCT05991752|DIAGNOSTIC_TEST|ROMA score evaluation|Every 4 months, for 3 years, patients in the experimental group will done a biological examination based on assessment of the ROMA score (CA125+HE4 assay).
41039084|NCT03809481|DRUG|Danaparoid Sodium|inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
41039085|NCT03809481|DRUG|Argatroban|Synthetic direct thrombin inhibitor
40858310|NCT03653143|BEHAVIORAL|JASPER|JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
40858311|NCT05610527|OTHER|Proposed study design and randomization scenarios|Present hypothetical study scenarios and assess willingness to be randomized based on the adapted 7-item Attitudes to Randomized Trials Questionnaire
40858312|NCT05610527|OTHER|Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments|We will electronically administer Ulcerative Colitis (UC) and Crohn's Disease validated PRO instruments, including the daily symptom modules and weekly quality of life modules for 12 weeks to all 200 participants
41389428|NCT06543238|OTHER|Breastfeeding card game group|Breastfeeding card game group: Breastfeeding education will be given to 30 primiparous pregnant women in the intervention group using the card game method twice, two weeks apart.
40858313|NCT05610527|OTHER|Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing|In an Aim 3 sub study of 30% of participants, we will collect inflammatory markers commonly used to assess disease activity and risk of relapse in inflammatory bowel disease patients, including weekly blood samples of high sensitivity c-reactive protein (13 total) and monthly ferritin, albumin, and WBC, as well monthly stool specimens (4 total) for fecal calprotectin
40858314|NCT01514201|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
40858315|NCT01514201|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
41389429|NCT02399059|PROCEDURE|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
41389430|NCT02399059|PROCEDURE|Normal saline lavage|Peritoneal irrigation with normal saline
41389431|NCT00684216|DRUG|capecitabine|200 mg, BID, PO, QD until progression of disease
40858316|NCT01514201|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
40858317|NCT01514201|OTHER|Pharmacological Study|Correlative studies
40858318|NCT01514201|DRUG|Temozolomide|Given PO
40858319|NCT01514201|DRUG|Veliparib|Given PO
40858320|NCT02682732|PROCEDURE|FDG-PET/CT guided bone marrow sampling|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be used to obtain two different samples from avid and dim bone marrow areas.
40858321|NCT01673828|DRUG|Allopregnanolone injection|Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
40858322|NCT01673828|DRUG|Placebo injection|Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
40858323|NCT06465004|DIETARY_SUPPLEMENT|Consumption of protein - rich drink|The participants will drink on of three protein - rich drinks
40858324|NCT00082914|BIOLOGICAL|denileukin diftitox|
40858325|NCT03522792|OTHER|Neurotensin|Intravenous infusion of neurotensin
40858326|NCT03522792|OTHER|Saline|Intravenous infusion of saline
40858327|NCT03522792|OTHER|Ad libitum meal|Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
40858328|NCT03522792|OTHER|Liquid meal|A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
40858329|NCT05909384|OTHER|Survey|Multiple rounds of surveys collecting information on sepsis diagnosis and management in resource-limited settings.
40858330|NCT00282659|DRUG|magnesium L-lactate|
40858331|NCT03994666|BIOLOGICAL|allogeneic umbilical cord-derived mesenchymal stem cells|Injection of mesenchymal stem cells
40858332|NCT03994666|BIOLOGICAL|Placebo (NaCl)|Placebo injection
40858333|NCT06351345|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).
40858334|NCT05897034|DRUG|Doxycyclin|Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated
40858335|NCT05897034|DRUG|Pentoxifylline|Pentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity
40858336|NCT05897034|DRUG|Nitazoxanide 500Mg Oral Tablet|Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections
40858337|NCT00377858|DRUG|Insulin lispro mid mixture (MM)|Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
40858338|NCT00377858|DRUG|Insulin glargine|Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
40858339|NCT06439771|DRUG|YL202 should be intravenously infused|For each patient, YL202 should be intravenously infused over 60±10 min.
40858340|NCT00110500|GENETIC|hVEGF-A|
40858341|NCT01496469|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
40858342|NCT01496469|DRUG|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
40858343|NCT01961622|DEVICE|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
40858344|NCT01961622|DEVICE|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
40858345|NCT01502228|DRUG|150-Water|Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.
40858346|NCT01502228|DRUG|62Cu-ethylglyoxal bis|Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.
40858347|NCT01502228|PROCEDURE|Positron Emission Tomography|PET Scan
40858348|NCT01502228|DRUG|Sunitinib|
40858349|NCT04371939|DRUG|Romiplostim|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II."
40858350|NCT04371939|DRUG|Eltrombopag|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (\>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I."
40858351|NCT00640848|DRUG|almorexant|1 dose of 400 mg in two treatment sequences
40858352|NCT00640848|DRUG|almorexant|1 dose of 200 mg in two treatment sequences
40858353|NCT00640848|DRUG|almorexant|1 dose of 100 mg in two treatment sequences
40858354|NCT00640848|DRUG|almorexant|1 dose of 50 mg mg in two treatment sequences
40858355|NCT00640848|DRUG|almorexant|1 dose of 1000 mg in two treatment sequences
40858356|NCT02800525|DEVICE|Picosecond laser|Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.
40858357|NCT02800525|DEVICE|Q-switched Nd:YAG laser|Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
40858358|NCT03415945|DEVICE|Cardiac resynchronization therapy (CRT)|All study participants have a clinical indication for CRT and will receive CRT implantation as part of their routine medical care. Additionally, participants will receive temporary left and right ventricular septal pacing electrodes and a temporary PressureWire to investigate the acute hemodynamic effect of left ventricular septal pacing, using patients as their own controls.
40858359|NCT01456169|DRUG|Azilsartan medoxomil/placebo|Azilsartan medoxomil and placebo to chlorthalidone combination tablets
40858360|NCT01456169|DRUG|Azilsartan medoxomil - chlorthalidone|Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
40858361|NCT04104776|DRUG|CPI-0209|CPI-0209 alone
40858362|NCT04522167|DRUG|FYB203 (Proposed aflibercept biosimilar)|Patients will receive 1 IVT injection of FYB203 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
40858363|NCT04522167|DRUG|Eylea® (Aflibercept)|Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
40858364|NCT03854513|DEVICE|dialysis machine|A machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged
40858365|NCT05260827|OTHER|Heated tobacco product|Sham heated tobacco product
40858366|NCT02428569|BEHAVIORAL|PREPARED Decision Support|The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
40858367|NCT01142882|BEHAVIORAL|Traditional Prevention|Participants in the traditional prevention intervention condition will complete two sessions (of approx. one hour in duration) across the course of a week, conducted by a trained HIV (and infectious disease) prevention educator; these sessions will typically be conducted in small groups of 2-4 participants but may be offered individually.
40858368|NCT01142882|BEHAVIORAL|Web-based Prevention|Participants in the web-based intervention condition will complete an interactive, web-based HIV, hepatitis and STI prevention program. Youth will be asked to complete a customized plan of approximately 2-4 hours in length using the web-based tool; participants will complete two 60-minute sessions per week until they complete their customized plan. Participants can choose to access this intervention using dedicated computer stations set up at their substance abuse treatment setting or can complete these sessions at their own home via the web.
40858369|NCT00955396|DRUG|GSK1014802|Tablets
40858370|NCT00955396|DRUG|Placebo|Tablets
40858371|NCT02649556|OTHER|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.
40858372|NCT02649556|OTHER|CC|"Ad libitum use of CC in an ambulatory setting for 26 weeks.~The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product."
40858373|NCT03792256|DRUG|Palbociclib|Given PO (or via NG- tube)
40858374|NCT03792256|DRUG|Cytarabine|Given intrathecally (IT)
41389432|NCT00684216|DRUG|hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)|either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
40858375|NCT03792256|DRUG|Methotrexate|Given intrathecally (IT)
40858376|NCT03792256|DRUG|Hydrocortisone|Given IT
40858377|NCT03792256|DRUG|Doxorubicin|Given intravenously (IV)
40858378|NCT03792256|DRUG|Prednisolone|Either prednisone or prednisolone is given PO
40858379|NCT03792256|DRUG|Vincristine|Given IV
40858380|NCT03792256|DRUG|Pegaspargase|Given IV
40858381|NCT03792256|DRUG|Hydrocortisone|Given intrathecally (IT)
40858382|NCT03792256|DRUG|Prednisone|Either prednisone or prednisolone is given PO
40858383|NCT06289517|DRUG|68Ga-Her2-affibody|68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.
41389433|NCT03413969|BEHAVIORAL|CREATION|The physician-oriented intervention will consist of a two-day weekend retreat that focuses on the application of CREATION Health principles in order to reduce burnout and perceived stress and improve well-being and empathy. There will be one four-hour session about each of the following CREATION Health principles: Choice, Trust, Interpersonal Relationships, and Outlook.
40858384|NCT04863872|OTHER|Proactive Care Management|Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
40858385|NCT04863872|BEHAVIORAL|my hypo compass education program|Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
40858386|NCT03337971|DIETARY_SUPPLEMENT|PLACEBO|A food-grade proprietary product containing corn starch in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
40858387|NCT03337971|DIETARY_SUPPLEMENT|MBPM|A food-grade proprietary product containing per 100g; milk protein (46.4%), carbohydrate (40.6%), fat (0.7%), Vitamin D (2ug); calcium (1840mg) in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
40858388|NCT06520124|DEVICE|Essilor® Stellest® spectacle lens|Spectacle lens with highly aspherical lenslets.
40858389|NCT06520124|DEVICE|Single-vision spectacle lens|Standard single-vision distance spectacle lens.
40858390|NCT05380440|BEHAVIORAL|Families Actively Improving Relationships (FAIR)|FAIR is a behavioral intervention for the treatment of parental substance abuse and child neglect for families involved in the child welfare system. This project will adapt the existing FAIR intervention for prevention. FAIR involves four major treatment components, supported by ongoing purposeful engagement : (1) Substance use treatment including contingency management and positive reinforcement, frequent urinalysis, relationship building, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; and (4) Resource building and provision of ancillary supports including assistance with housing and employment.
40858391|NCT05380440|BEHAVIORAL|Standard Case Management and Referral|Parents will be referred for a substance abuse and mental health assessment with possible resulting treatment. Child Welfare treatment plans typically include a series of recommendations, including parenting classes, securing safe housing, psychosocial treatment (e.g., domestic violence), accessing self-sufficiency services (e.g., food stamps, WIC), securing employment or education, and meeting court dates and requirements.
40858392|NCT02500953|DRUG|ASP3325|
40858393|NCT02500953|DRUG|Placebo|
40858394|NCT00834262|DRUG|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40858395|NCT00834262|DRUG|biphasic insulin aspart 50|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40858396|NCT00834262|DRUG|biphasic insulin aspart 70|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
40858397|NCT00950898|OTHER|decaff|2 mugs of decaffeinated coffee
40858398|NCT00950898|OTHER|caffcoff|2 mugs of caffeinated coffee
41389434|NCT02913651|DEVICE|Polysomnography|The polysomnography, for both groups, was performed accordance with standard practice
40858399|NCT00950898|OTHER|caffeine|2 mugs of hot water containing caffeine
40858400|NCT00950898|OTHER|placebo|2 mugs of hot water
40858401|NCT02766634|BIOLOGICAL|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
40858402|NCT02766634|BIOLOGICAL|U.S.-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
40858403|NCT02545764|OTHER|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
40858404|NCT06040944|DRUG|antipsychotic drugs inducing hyperprolactinemia|not exposed
40858405|NCT06017180|OTHER|Myofascial Release Techniques|Volleyball players will perform these practices with a physiotherapist 3 days a week for 8 weeks (24 sessions), and their routine sports training will continue. Participants in the group will be shown how to use rolling materials. The application will be performed as 2 sets in a session using the body weight of the person, as 10 rolls in 1 minute. The application time will be 2 minutes in total for each session. There will be 30 seconds of rest between sets. The participation rate limit for the sessions was determined as 80%. The application rate will be controlled with a metronome. The pressure to be created using body weight will be controlled by a numerical pain scale. The technique will be applied to the biceps brachii, latissimuss dorsi, upper trapezius, pectoralis minor, pectoralis major, and thoracic extensor muscles. During the application, a foam roller and a rolling stick (Thera-Band, Hygienic Corporation, Akron, OH) will be used.
40858406|NCT06017180|OTHER|Sham myofascial release technique|It was planned to apply the sham myofascial release technique to the athletes in the control group. In this application; with the help of the palm of the hand, pressure will be applied to the surface of the relevant muscles, first without pressure for 1 minute, then after resting for 30 seconds. The given pressure will be 2 out of 10 (0: No pain/discomfort due to pressure, 10: Unbearable pain/discomfort due to pressure). This group will also be given the right to receive a myofascial relaxation program which the experimental group received, after the study period ended.
40858407|NCT02309801|DIETARY_SUPPLEMENT|Daidzin|Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).
40858408|NCT02309801|DIETARY_SUPPLEMENT|Alcohol|Alcohol single oral dose
40858409|NCT06206460|OTHER|Online Assessment|"Online Assessment which consists of:~* Sociodemographic data (life changes, medical and gynaecological history)~* German PMS symptom diary retrospectively for last menstrual cycle~* Quality of Life Inventory (SF-12)~* Expectancy of relief"
40858410|NCT00965575|DRUG|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
40858411|NCT00965575|DRUG|Placebos|Placebo. Taken 30 minutes prior to bedtime for four weeks.
40858412|NCT04142294|DIETARY_SUPPLEMENT|Histidine|ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks
41389435|NCT00990093|DEVICE|test intermittent catheter|CH 12 hydrophilic coated catheter
41389436|NCT00990093|DEVICE|Intermittent catheterization|CH 12 hydrophilic catheter
41389437|NCT03800186|OTHER|Proximal type A|Patients with fracture of proximal type A
41389438|NCT03800186|OTHER|Proximal type B|Patients with fracture of proximal type B
40858413|NCT00080301|DRUG|Ixabepilone + Capecitabine|"Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity"
41389439|NCT03800186|OTHER|Proximal type C|Patients with fracture of proximal type C
41389440|NCT03800186|OTHER|femoral shaft|Patients with fracture of femoral shaft
41389441|NCT03800186|OTHER|distal femur|Patients with fracture of distal femur
41389442|NCT03109860|BEHAVIORAL|Open-hidden|Administration of a treatment openly (in full view of the patient) vs hidden (without the patient's knowledge).
41389443|NCT06538844|DRUG|Intravenous infusion of human albumin|Administer 0.5g/kg of 25% human albumin intravenously as soon as possible within 60 minutes after randomization. And administer 0.5g/kg of 25% ALB intravenously every day on the second, third, and fourth days after randomization.
41389444|NCT06538844|DRUG|Saline|Equivalent volume of isotonic saline control
41389445|NCT05763277|DIAGNOSTIC_TEST|Early response evaluation|Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
41389446|NCT02044965|OTHER|Antibiotic|2 mg/kg per day via oral ingestion.
40858414|NCT00080301|DRUG|Capecitabine|Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
41389447|NCT02044965|DRUG|Probiotic|2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
40858415|NCT02721602|BEHAVIORAL|Families Preventing Diabetes Together|Families in the intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
40858416|NCT05962892|OTHER|No Intervention|No Intervention
40858417|NCT04499560|DIETARY_SUPPLEMENT|Supplement Drink|Superfoods based nutritional supplement
40858418|NCT03478800|PROCEDURE|Acupuncture|Each treatment would take approximately 15-20 minutes and would take place immediately after practice for a total of five treatments. The needles are standard (0.2mm diameter #36 gauge 1 inch stainless steel) and during each treatment, 3-6 needles would be placed in the lower extremity in any of the following muscle groups: quadriceps, hamstrings, anterior tibialis, gastrocnemius-soleus complex, medial head of the gastrocnemius, peroneal muscles, or iliotibial band. The athletes would complete brief pre- and post-treatment surveys.
41389448|NCT04499690|BEHAVIORAL|Managing Cancer and Living Meaningfully|A brief, individual, manualized psychosocial intervention for patients with advanced and metastatic cancer
41389449|NCT00266461|DRUG|Daikenchuto Extract Granules (TU-100)|
41389450|NCT03241407|OTHER|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a placebo toothpaste.
41389451|NCT03241407|OTHER|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
41389452|NCT03008252|OTHER|Lactose breath test|Lactose breath test in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
41389453|NCT03008252|OTHER|DBPC cow's milk protein challenge|DBPC cow's milk protein challenge in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
41389454|NCT03447054|BEHAVIORAL|Combined TDCS active and ICT active|Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
41389455|NCT03447054|BEHAVIORAL|Combined TDCS sham and ICT active|Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
41389456|NCT03447054|BEHAVIORAL|Combined TDCS active and ICT inactive|Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
41389457|NCT03447054|BEHAVIORAL|Combined Sham TDCS and inactive ICT|Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
41389458|NCT02812368|DRUG|Clonidine|
41389459|NCT02812368|DRUG|Placebo (for clonidine)|Placebo pill manufactured to mimic clonidine
40858419|NCT02362750|OTHER|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
40858420|NCT02362750|OTHER|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
41389460|NCT05100394|RADIATION|Laser Therapy|Therapeutic laser therapy was applied.
41389461|NCT05100394|OTHER|Ultrasound + Moist Heat pack + Exercises|Ultrasound therapy, a moist heat pack, and a home exercise program were given.
41389462|NCT01687400|DRUG|decitabine|
41389463|NCT03874585|BEHAVIORAL|Group counseling and nicotine replacement|Participants will receive a 30-minute group smoking cessation counseling session and a supply of nicotine replacement.
41389464|NCT03874585|BEHAVIORAL|Group counseling, nicotine replacement, and text messaging support|Participants will receive a 30-minute group smoking cessation counseling session, a supply of nicotine replacement, and the 6-week text messaging intervention to provide ongoing support for quitting
41389465|NCT04333199|BEHAVIORAL|Timely|Email
41389466|NCT04333199|BEHAVIORAL|Transparency|Email
41389467|NCT04333199|BEHAVIORAL|Foot-in-the-door|Email
41389468|NCT05835999|DRUG|Everolimus 0.5 MG once per day|Everolimus is considered an mTOR kinase inhibitor
41389469|NCT05835999|DRUG|Everolimus 5 MG once per week|Everolimus is considered an mTOR kinase inhibitor
41389470|NCT05835999|DRUG|Placebo once per day|No therapeutic effect
41389471|NCT05835999|DRUG|Placebo once per week|No therapeutic effect
41389472|NCT02094573|DRUG|Brigatinib|Brigatinib tablets
41389473|NCT01030276|OTHER|Bright light therapy|Bright light therapy
40858421|NCT02362750|OTHER|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
40858422|NCT02362750|OTHER|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
40858423|NCT02362750|OTHER|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
40858424|NCT02362750|OTHER|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
40858425|NCT02362750|OTHER|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
40858426|NCT02598206|DRUG|PF-04136309|"Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets."
40858427|NCT06473792|OTHER|Probiotic Toothpaste|"Composition: Main - Water, calcium carbonate, calcium glycerophosphate, glycerin, xylitol, sodium bicarbonate, sweet fennel oil (Foeniculum vulgare), carrageenan, maltodextrin, Dental-Lac (Lactobacillus paracasei), potassium sorbate, yucca (Y. filamentosa) powder, stevia leaf extract (Eupatorium rebaudiana bertoni), zinc chloride.~Usage: This is mint flavored toothpaste containing Lactobacillus paracasei which has demonstrated the ability to help address harmful strains of oral flora, and promotes the maintenance of a healthy teeth and gums. The participant will be instructed to brush with it twice daily."
40858428|NCT05958797|DRUG|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance
40858429|NCT05958797|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
40858430|NCT06407284|OTHER|Produce Prescription Group|Participants will receive 16 produce bags, each containing approximately 50 servings of F\&V. The produce bags will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V bags will be distributed to families every 2 weeks for 16 distributions (over approximately 32 weeks). Participants will also receive nutrition education, including MyPlate.gov's Start Simple App for adolescents, and a Virtual Culinary Medicine Program for parents; these nutrition education programs are theory-driven, tailored to diverse populations, and proven to support behavior change.
40858431|NCT06407284|OTHER|Control Group|Participants in this group will be selected from de-identified Electronic Health Record (EHR) provided by Legacy Community Health with a 1-to-1 match to the intervention group participant's demographic characteristics and Medicaid eligibility.
40858432|NCT02303249|OTHER|Review of discharges and cross-sectoral video conferencing immediately after discharge|The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
40858433|NCT04140630|OTHER|No intervention|No intervention; 1 week observational study
40858434|NCT03682692|DRUG|ACEI/CCB|benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
40858435|NCT03682692|DRUG|ACEI/DIU|benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
40858436|NCT00126360|DRUG|Timing of Anastrozole in respect to radiotherapy|
41039086|NCT04401384|DRUG|Diclectin|Diclectin (combination of 10 mg doxylamine and 10 mg pyridoxine hydrochloride in a delayed release tablet) During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of Diclectin or placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
41389474|NCT01030276|OTHER|"Inactive placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
41389475|NCT01938742|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, \& 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
41389476|NCT01938742|DRUG|MF59|MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 \& 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
41389477|NCT04450979|DIETARY_SUPPLEMENT|Bioactive hydrolysate|Participants given a bioactive vegetable hydrolysate to take one dose each morning and one dose each evening for the duration of the study.
40858437|NCT05900037|DEVICE|GATT-Patch|"GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
40858438|NCT05900037|DEVICE|SURGICEL® Original|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is indicated for use in surgical procedures to assist in the control of capillary, venous and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective.
40858439|NCT01576497|PROCEDURE|EUS-FNA|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
41512021|NCT04447560|PROCEDURE|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol and two researchers will measure the radius and area of those vessels separately. Researchers who are measuring the radius and area of vessels won't know whether those images belong to pre or post- ESP block. The results two researchers measure will be compared statistically and if there are no statistically significant differences, the mean value of their separate recordings will be taken into account for the statistical analysis.
41512022|NCT02211417|DRUG|Oral DS107|
40858440|NCT01576497|DEVICE|EUS-FNA with suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
40858441|NCT01576497|DEVICE|EUS-FNA without suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
40858442|NCT00622505|DRUG|zoledronic acid|Zoledronic acid concentrate (4 mg/5 milliliters \[ml\]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
40858443|NCT01420926|DRUG|Bortezomib|Given SC
40858444|NCT01420926|DRUG|Decitabine|Given IV
25887831|NCT03738982|DEVICE|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
41389478|NCT02908698|DRUG|Prednisone|"Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight"
41389479|NCT02908698|DRUG|Placebo Control|Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
41389480|NCT05809986|OTHER|Ofatumumab|There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
41389481|NCT01592227|DRUG|Marketed paracetamol|Marketed paracetamol
41389482|NCT01592227|DRUG|Experimental paracetamol formulation|Experimental paracetamol formulation
41389483|NCT03711942|PROCEDURE|Intra orifice barrier|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.3mm GP in the orifice was removed and intraorifice barrier and 2mm thick base was given of GIC.
41389484|NCT03711942|PROCEDURE|Base|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration
41389485|NCT03711942|PROCEDURE|Control|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin
41389486|NCT06299631|PROCEDURE|Ileocolic resection|Ileocolic resection by open or laparoscopic approach
41389487|NCT01832545|OTHER|Aquatic Exercise|
41389488|NCT01832545|BEHAVIORAL|Educational Program|Control Group
41512023|NCT02211417|DRUG|Placebo|
41512024|NCT00006207|DRUG|PRO 2000|
40858445|NCT01420926|OTHER|Laboratory Biomarker Analysis|Correlative studies
40858446|NCT01420926|OTHER|Pharmacological Study|Correlative studies
40858447|NCT01420926|OTHER|Quality-of-Life Assessment|Ancillary studies
41389489|NCT05816083|BEHAVIORAL|Virtual Reality Tool|Virtual Reality Tool for At-Risk Trauma-Exposed Young People
41512025|NCT06228586|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form:Liquid solution-Route of administration:Intramuscular injection
41512026|NCT05324124|DRUG|Selpercatinib|Administered orally.
41512027|NCT02245607|BEHAVIORAL|Compensatory Cognitive Training|
41512028|NCT02245607|BEHAVIORAL|Recreational Therapy|
41512029|NCT01439802|DEVICE|Copper IUD placement at time Cesarean Delivery (Copper T 380A)|Placement of Paragard IUD at time of Cesarean Delivery
41512030|NCT06292117|OTHER|CYP2C19 Genotype|qPCR-based genotyping assay interrogating all Association for Molecular Pathology (AMP) recommended Tier 1 and Tier 2 single nucleotide polymorphisms (SNPs) for CYP2C19 (\*2, \*3, \*4, \*5, \*6, \*7, \*8, \*9, \*10, \*17, \*35)
41512031|NCT03674398|BEHAVIORAL|Exercise+CT|The exercise+CT group is asked to participate in 30 minutes of aerobic exercise followed by a 20-minute cognitive training (CT) program that targets attention and memory. Training will take place following exercise due to elevated levels of brain-derived neurotrophic factor and increased arousal, which is theorized to benefit cognitive task performance. Computerized CT exercises will be delivered using participants' smartphone. Adherence to the computerized CT program is monitored using electronic data upload after each training session. Participants are asked to engage in three sessions per week with the first week taking place in a lab-setting. Participants are asked to continue the aerobic exercise and CT program at home for the subsequent three weeks.
41512032|NCT03674398|BEHAVIORAL|Exercise only|The exercise only group will receive the same exercise prescription as the exercise+CT group. Participants in this group are asked to watch 20 minutes of health-related educational videos post-exercise. Videos are administered via participants' smartphones. After each video session, participants answer multiple-choice questions that assess engagement. Following the first week of treatment in-lab, participants are asked to continue watching health-related videos, post-exercise, for three weeks at home.
40858448|NCT01420926|OTHER|Questionnaire Administration|Ancillary studies
40858449|NCT02353715|DRUG|Enzalutamide|
40858450|NCT02353715|DRUG|Abiraterone acetate|
40858451|NCT02353715|DRUG|Sipuleucel-T|
40858452|NCT04467281|DRUG|89Zr-DFO-daratumumab|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
40858453|NCT04467281|DIAGNOSTIC_TEST|PET/CT|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
40858454|NCT00032981|BEHAVIORAL|Behavior Therapy|
40858455|NCT03402724|OTHER|echographic|Patients are called for an echographic evaluation in the implanting center in case of the usual care
40858456|NCT01132313|DRUG|BI 207127|28 weeks, high dose, TID
41389490|NCT04219800|BEHAVIORAL|Patient-centered counselling and written material|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
41389491|NCT04219800|BEHAVIORAL|mHealth|"1. Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~2. SMS text messages; reminds of activity breaks.~3. Mobile video instruction for standing pause gymnastics."
41512033|NCT03281018|BEHAVIORAL|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session|The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
41512034|NCT05782673|DEVICE|wearable MAIJU for motor assessment|The novel multisensor wearable MAIJU will be used to measure infants' motor performance at home. The recordings are repeated at 2 months intervals betveen 6 and 18 months of age.
41512035|NCT04156581|DRUG|Bupivacaine|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures.
41512036|NCT04156581|DRUG|Dexamethasone|Dexamethasone is a corticosteroid that reduces inflammation.
41512037|NCT04156581|OTHER|Saline|Saline is a mixture of NaCl and water that can be used as a placebo.
41512038|NCT00082277|DRUG|Anastrozole|1mg/Day Oral
41389492|NCT04619069|RADIATION|SBRT|SBRT to all sites of metastatic disease as seen on PSMA PET scan
41389493|NCT04619069|DRUG|Hormone therapy|Intermittent Hormone Therapy per physician discretion (Min. 8 months)
41389494|NCT01822015|DRUG|Sirolimus|Given PO
41512039|NCT00082277|DRUG|Risedronate Sodium|35mg/week, oral
41512040|NCT06581276|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is an evidence-based behavioral pain treatment intervention for Chronic Pain, anxiety and depression, and substance use disorders, being studied as a group-based therapy delivered by substance use counselors in an opioid treatment program.
41512041|NCT02447601|DRUG|PEX168|200µg,injected subcutaneously,once a week.
41512042|NCT02447601|DRUG|Simvastatin|40mg,oral,two times
40858457|NCT01132313|DRUG|BI 201335|40 weeks, QD
40858458|NCT01132313|DRUG|BI 207127|4 weeks, low dose TID
40858459|NCT01132313|DRUG|BI 201335|24 weeks, QD
40858460|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
40858461|NCT01132313|DRUG|Ribavirin|28 weeks, according to label
40858462|NCT01132313|DRUG|Ribavirin|28 weeks, according to label
40858463|NCT01132313|DRUG|BI 207127|40 weeks, high dose, TID
40858464|NCT01132313|DRUG|BI 207127|24 weeks, very high dose, BID
40858465|NCT01132313|DRUG|BI 207127|16 weeks, standard dose, BID
40858466|NCT01132313|DRUG|BI 201335|24 weeks, QD
40858467|NCT01132313|DRUG|Ribavirin|48 weeks, according to label
40858468|NCT01132313|DRUG|Ribavirin|40 weeks, according to label
40858469|NCT01132313|DRUG|BI 207127|16 weeks, high dose, TID
40858470|NCT01132313|DRUG|BI 207127|28 weeks, high dose, TID
40858471|NCT01132313|DRUG|BI 201335|28 weeks, QD
40858472|NCT01132313|DRUG|BI 201335|16 weeks, QD
40858473|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
40858474|NCT01132313|DRUG|BI 201335|24 weeks, QD
40858475|NCT01132313|DRUG|BI 201335|28 weeks, QD
40858476|NCT01132313|DRUG|BI 207127|24 weeks, standard dose, BID
40858477|NCT01132313|DRUG|BI 201335|24 weeks, QD
40858478|NCT01132313|DRUG|BI 201335|16 weeks, QD
40858479|NCT01132313|DRUG|BI 207127|16 weeks, high dose, BID
41389495|NCT01822015|DRUG|Idarubicin|Given IV
41389496|NCT01822015|DRUG|Cytarabine|Given IV
41389497|NCT00547807|OTHER|Non-nutritive sucking|Non-nutritive sucking is applied by using a gloved finger
41389498|NCT00547807|OTHER|Swaddling|Swaddling is an age-old practice of wrapping infants snugly in swaddling cloths, blankets or similar cloth so that movement of the limbs is tightly restricted
40858480|NCT01132313|DRUG|BI 201335|24 weeks, QD
40858481|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
40858482|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
40858483|NCT01132313|DRUG|BI 207217|28 weeks, high dose BID
40858484|NCT01132313|DRUG|BI 201335|16 weeks, QD
40858485|NCT01132313|DRUG|BI 207127|24 weeks, high dose, TID
40858486|NCT01132313|DRUG|Ribavirin|48 weeks, according to label
40858487|NCT01132313|DRUG|BI 207127|4 weeks, high dose, TID
40858488|NCT01132313|DRUG|BI 201335|28 weeks, QD
40858489|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
40858490|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
40858491|NCT03029923|BEHAVIORAL|Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
40858492|NCT03029923|BEHAVIORAL|Smoking cessation plus Health and Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
40858493|NCT05342766|DIETARY_SUPPLEMENT|Nutrigenetic|"Each grup will receive two interventions (Nutrigenetic and Standard), in a cross-over design (3 months each), spaced by a wash-out period (3 months)."
41389499|NCT03843268|DEVICE|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
41389500|NCT03843268|DEVICE|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
41389501|NCT04955873|DEVICE|Treatment of the dental extraction socket using newly-released biomaterials|Treatment of the dental extraction socket with the combined use with the combined use of a newly-released xenogenic bone granules and a resorbable collagen membrane.
40858494|NCT05370131|OTHER|Avatar-Based Education Program in Hydrocephalus (ABEP-H)|The avatar-based education program in hydrocephalus (ABEP-H) aimed to help parents acquire the knowledge and develop the skills necessary for the care of hydrocephalus children with VP shunts and prevent shunt infection and dysfunction.
40858495|NCT00627250|DRUG|Amantadine|Amantadine 100 mg every morning and 12 noon
40858496|NCT01888224|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
40858497|NCT04364360|DIETARY_SUPPLEMENT|Sulforaphane extract|2x BroccoMax® capsules day, giving a total daily dose of 30 mg of Sulforaphane Glucosinolate Per day
40858498|NCT04499625|PROCEDURE|Sinus floor elevation|
40858499|NCT04499625|DEVICE|Sinus floor elevation using an ultrasonic device|
41167071|NCT06371430|DEVICE|Dental Implant insertion and tooth extraction|"The osteotomies were carried out at a speed of 800 rpm, using sequential burs of similar diameter for both the maxilar and the mandibular side. The drilling protocols followed the recommendations provided by the manufacturer, the Galaxy-Ziacom implant system, for standard drilling.~The insertion of the implants was initiated using a motor handpiece at a speed of 20-50 rpm, without irrigation. The installation process was completed using a manual surgical torque wrench indicator. The maximum torque value (Ncm) reached at the end of implant insertion was recorded as the insertion torque (IT). A total of 264 implants were inserted in 33 patients, 160 implants were post-extraction and 104 implants were inserted after at least one-month post-extraction. The sutures were typically removed 1 week after the surgery, during the postoperative follow-up appointment."
41167072|NCT05500898|DRUG|DWP16001|Tablets, Oral, multiple doses of DWP16001
41167073|NCT05500898|DRUG|DWC202204+DWC202205|Tablets, Oral, multiple doses of DWC202204 and DWC202205 in combination
41389502|NCT04955873|DEVICE|Treatment of the dental extraction socket using well-known biomaterials|Treatment of the dental extraction socket with the combined use of a well-known xenogenic bone granules and a resorbable collagen membrane
41389503|NCT01770639|PROCEDURE|MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
41389504|NCT04635904|BEHAVIORAL|Imaginal exposure one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios multiple times while honing in on the most negative aspects.
41512043|NCT03854630|DRUG|Engerix-B|The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.
40858500|NCT03733613|OTHER|no intervention|no intervention
40858501|NCT03355066|DRUG|SM08502|SM08502 tablets to be administered orally.
40858502|NCT01288001|DRUG|Ostenil plus|2% Sodium Hyaluronate plus Mannitol injection
41167074|NCT05500898|DRUG|DWP16001+DWC202204+DWC202205|Tablets, Oral, DWP16001 , multiple doses of DWC202204 and DWC202205 in combination
41167075|NCT00519064|BIOLOGICAL|Adjuvanted influenza vaccine|
41167076|NCT01990313|DEVICE|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
41167077|NCT00672672|BIOLOGICAL|autologous platelet gel|Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
41389505|NCT04635904|BEHAVIORAL|Imagery rescriptinf one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) o imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery.
40858503|NCT05081206|DRUG|Propofol infusion via manually controlled pump.|Patients will receive propofol bolus 2.5-3 mg/kg, for anesthesia induction and anesthesia maintenance was continued according to the Mc Farlan scheme, meaning continuous propofol infusion is used, with gradual reduction of the infusion speed in timely manner, depending on the duration of surgery: 15mg/kg/h...13mg/kg/h...11mg/kg/h...9mg/kg/h...6mg/kg/h.
40858504|NCT05081206|DRUG|Propofol infusion via target controlled pump.|Pedfusor model was used for delivering target controlled plasma concentration, with target concentration for anesthesia induction of 4 mcg/kg body weight and then 3 mcg/kg.
40858505|NCT05934019|DEVICE|EMPATIA 1|The internet-program EMPATIA is hosted on a secure website https://selfhelp.psy.unibe.ch run by the Faculty of Human Sciences and is accessible from any regular internet browser. The software is not CE-marked as it has been developed for research purposes only. EMPATIA consists of 8 sessions and 1 booster session 3 weeks after the last session. It targets transdiagnostic mechanisms that have been identified in several mental disorders in adolescents: behavioral avoidance, repetitive negative thinking including intolerance of uncertainty, emotion, self-critical perfectionism and rejection sensitivity. The contents of EMPATIA are evidence-based and well-established cognitive-behavioral interventions dedicated to the respective transdiagnostic mechanism. The self-help program consists of psychoeducation, cognitive restructuring, relaxation and acceptance-based interventions, exposure and behavioral experiments and behavioral activation as treatment components.
40858506|NCT00783614|DRUG|Aspirin 325mg|Patients randomized to Aspirin 325mg po daily versus placebo pill daily
40858507|NCT00783614|DRUG|Antiretroviral therapy (ART)|Patients randomized to start ART immediately or defer use for 1 month
40858508|NCT01771523|PROCEDURE|Thyroidectomy|total thyroidectomy or lobectomy
40858509|NCT01771523|DEVICE|use of drain|drain will be used
40858510|NCT00943332|PROCEDURE|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
40858511|NCT03938896|OTHER|platelet rich plasma|Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area. The patient was kept in the supine position for twentyminutes and then discharged
40858512|NCT03938896|OTHER|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle. After injection, participants were advised to stay sitting without foot movement for 15 minutes
40858513|NCT01110369|DIETARY_SUPPLEMENT|Protein drink|Protein drink twice a day during 6 months.
40858514|NCT01110369|OTHER|Resistance exercise training|Resistance exercise training twice per week during 6 months.
40858515|NCT01110369|DIETARY_SUPPLEMENT|Placebo drink|Placebo drink twice a day during 6 months.
41389506|NCT01485705|OTHER|Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not|"When child is admitted at Intensive Care Unit (ICU) for suspicion of bacterial infection that is not nosocomial, data on child's infection and cares received, is completed on an electronic Case Report Form (e-CRF) by Doctor of ICU. Characteristic optimal or not of initial medical care is then determined by the independent experts blinded from issue of the care."
41389507|NCT03496207|DRUG|Placebo|Placebo
41389508|NCT03496207|DRUG|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
41389509|NCT03496207|OTHER|SOC|SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
41389510|NCT05078801|PROCEDURE|Endoscopic drainage|ERCP and/or EUS-guided biliary drainage
41389511|NCT05078801|PROCEDURE|Percutaneous transhepatic biliary drainage|US or CT-guided percutaneous drainage
40858516|NCT03790059|DRUG|H101|Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.
40858517|NCT03790059|PROCEDURE|RFA|Treat the samll HCC with the RFA.
40858518|NCT02085018|DRUG|Omeprazole|Drug
40858519|NCT02085018|DRUG|Matched placebo|Matched placebo
41039087|NCT04401384|DRUG|Diclectin placebo|Diclectin placebo will be packed and tested by a commercial pharmacy supply company specifically for this study. It have the same appearance, size, batch, odor, and taste compared with Diclectin. During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
41389512|NCT03610646|DRUG|MYL-1701P|"Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
41389513|NCT03610646|DRUG|Eylea|"Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
41389514|NCT02540720|DRUG|Dexamethasone|
41389515|NCT02540720|DRUG|Gamma globulin|
41389516|NCT02540720|PROCEDURE|Hemoperfusion|
41389517|NCT02696018|DEVICE|Ultrasonography|Ultrasonographic assessment of the diaphragm function
40858520|NCT06267391|DEVICE|ReCET Treatment|Treatment arm will receive the ReCET therapy. The ReCET procedure utilizes the ReCET catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum. Participants will be followed for 12 months post procedure.
40858521|NCT06267391|DEVICE|Sham Procedure|The Control arm will receive a sham procedure. The sham procedure consists of placing the ReCET catheter as described above without therapy applied. Participants will be followed for 12 months post procedure and will be offered cross-over to receive the ReCET therapy after 12 months.
40858522|NCT04747587|OTHER|Reaching Session|"Two x 45 minutes sessions of reaching tasks. Patients in the stroke group will perform the task with the paretic arm using a weight reduction system, allowing movement in the horizontal plane.~Subjects in the control group will perform the task with the randomly selected arm weighted at 80% of their maximum voluntary shoulder torque"
40858523|NCT02764658|DEVICE|Pulmonary recovery on the AECOPD|The combination effect of negative pressure ventilation, limb muscle exercise training program and fibit monitor on acute exacerbation of AECOPD. To investigate the daily physical activity in routine care patients with after AECOPD and stable stage.
40858524|NCT02764658|OTHER|Routine care on the AECOPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.
40858525|NCT02764658|OTHER|Routine care on the stable COPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
40858526|NCT00548145|DRUG|Pitavastatin|2 mg by orally/day Duration: 12 months
40858527|NCT00548145|DRUG|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
40858528|NCT02135237|BEHAVIORAL|Prize Contingency Management for Alcohol Abstinence|The systematic reinforcement of desired behaviors and the withholding of reinforcement for undesired behaviors
40858529|NCT02135237|BEHAVIORAL|Standard Care|
40858530|NCT00665535|PROCEDURE|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3, or 4 hours
40858531|NCT00665535|PROCEDURE|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3 or 4 hours
40858532|NCT05912972|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
40858533|NCT02094651|DRUG|divalproex sodium|The drug is an FDA approved medication for seizures but has not been approved for the treatment of epileptiform EEG abnormalities in the absence of clinical seizures.
40858534|NCT02094651|OTHER|Placebo|The placebo is an inactive substance that looks like the active drug.
40858535|NCT02404818|PROCEDURE|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
41389518|NCT05288374|DRUG|Celecoxib 100 mg|Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
40858536|NCT02404818|PROCEDURE|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
40858537|NCT05549830|OTHER|Patient Positioning|"In the preoperative period, the patient/patient relative will be informed about the possible surgical position and the importance of placing the patient in a different position before and after surgery.~İn the postoperative period, the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals."
40858538|NCT04289311|BEHAVIORAL|Voice Crisis Alert V2|An mHealth intervention (app) with multiple components for self-management behavior development. Components include: electronic educational information, symptom monitoring and tracking, communication with a provider, health history entry and storage (including medication adherence).
40858539|NCT02189512|OTHER|blood sampling|cases - blood sampling controles - blood sampling
40858540|NCT03548467|BIOLOGICAL|VB10.NEO|VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).
40858541|NCT03548467|DRUG|Bempegaldesleukin|0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.
40858542|NCT00724672|DRUG|etanercept|etanercept 50 mg subcutaneously once weekly
40858543|NCT00724672|DRUG|infliximab|infliximab 3 mg/kg IV at Weeks 0, 2, and 6
40858544|NCT00724672|DRUG|adalimumab|adalimumab 40 mg subcutaneously biweekly
40858545|NCT03101501|DRUG|Mitomycin c|Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.
40858546|NCT03101501|DEVICE|Raindrop Near Vision Inlay|Implanted to improve near vision in Presbyopic or Pseudophakic subjects.
41389519|NCT05288374|DRUG|Placebo|Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
41389520|NCT00808015|DRUG|varenicline|Champix will be prescribed as per usual practice and at the sole discretion of the physician
41389521|NCT00892424|DRUG|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
40858547|NCT05936073|DIAGNOSTIC_TEST|Patients co-infected HBV/HDV|Step 1: collection of SNDS data from 2016 to 2020 Snapshot of the prescription of the Delta tests and the tests usually prescribed simultaneously (HBV but also HIV and HCV) in one year. The investigator will collect the number of tests performed once for a given patient: anti-HDV, HDV RNA, HBsAg, anti-HCV, anti-HIV, and for each test, the description of the profile and the geographical distribution of prescribers in the metropolitan area; the description of age and sex of the patients screened. Step 2: collection of anti-HDV and RNA tests performed in French private and Public laboratories over the year 2019 Anti-HDV and HDV RNA are subcontracted by most private laboratories to two specialized biology companies. Number of HDV tests prescribed, technique used, number of positive tests and name of the requesting laboratory will be collected. The investigator will then go back to the prescriber of the positive tests, identify the patient, his epidemiological profile and his medical care.
40858548|NCT03162471|DIAGNOSTIC_TEST|non-contact measurement of intraocular pressure|Non-contact measurement of corneal biomechanical properties and intraocular pressure with an Ocular Response Analyzer. Parameters measured: corneal hysteresis (CH), corneal resistance factor (CRF), Goldman-correlated IOP (IOPg), corneal compensated IOP (IOPcc) and waveform score (WS).
40858549|NCT04149561|OTHER|communication skill measurement with self report questionnaire|Demographic information form, Communication Function Classification System, Functional Communication Classification System, The Gross Motor Function Classification System and Manual Ability Classification System will be filled in for the patients.
40858550|NCT05761990|OTHER|POST ISOMTERIC RELAXATION TECHNIQUE|"POST ISOMETRIC RELAXATION TECHNIQUES~* Stretching the hypertonic muscle to the point when movement resistance is initially felt or just past the point of discomfort.~* For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side. To help with this, the individual should breathe in.~* The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~* Starting with this new barrier, the procedure is carried out two or three more times."
40858551|NCT05761990|OTHER|NOVEL STRETCHING|"NOVEL STRETCHING The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones. This position is thought to provide more flexibility of mobility while causing less discomfort. The subjects were instructed to hold this position while tightening or squeezing their gluteal muscles. They were also instructed to stretch by jerkily turning their shoulders inward as far as possible. Using the second hand, the stretch was pushed forward to the point of mild discomfort while contraction was maintained."
40858552|NCT03769038|DEVICE|chronic total occlusion|chronic total occlusion of coronary atery was opened and then stents were placed
40858553|NCT01375023|RADIATION|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
40858554|NCT01375023|BIOLOGICAL|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
40858555|NCT04878965|DEVICE|Smartwatch|Smartwatch apparatus to measure strong emotions (e.g., anxiety)
40858556|NCT02630914|DEVICE|The AtriCure Synergy Ablation System|The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
40858557|NCT00505557|PROCEDURE|Transaxillary dual plane technique|
40858558|NCT00852787|DRUG|Digoxin immune fab|Intravenously one time
40858559|NCT00852787|DRUG|Placebo|Intravenously one time
40858560|NCT05349357|OTHER|Sliding Neural mobilization|Sliding neural mobilization to femoral, sciatic and tibial nerve
40858561|NCT05349357|OTHER|Tensioner Neural mobilization|Tensioner neural mobilization to femoral, sciatic and tibial nerve
40858562|NCT05349357|OTHER|Stretching exercises|Stretching exercises
40858563|NCT05349357|DEVICE|TENS|TENS
40858564|NCT00756990|DRUG|Depot Naltrexone|228mg of injectable naltrexone
40858565|NCT05728268|DRUG|dose-dense nab-paclitaxel followed by EC|dose-dense nab-paclitaxel followed by EC
40858566|NCT00128895|DRUG|azathioprine|azathioprine 2 mg/kg oral once daily, duration according to arm
40858567|NCT05322720|BIOLOGICAL|EOC202|EOC202 will be SC injection
40858568|NCT05322720|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel will be Iv injection
40858569|NCT04383457|DEVICE|RIA-device (Remote Investigation and Assessment)|The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face.
40858570|NCT04102072|DIAGNOSTIC_TEST|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
40858571|NCT04102072|DIAGNOSTIC_TEST|dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. Echocardiography was performed after 5-10 minutes of continuous infusion, and hemodynamic data were recorded.
40858572|NCT01989247|BEHAVIORAL|Self-management programme|Seven weekly group-based sessions for people with anxiety and depressive symptoms
40858573|NCT05681065|DEVICE|TeNDER tool|"The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of healthcare professionals. Each participant will use the sensor that suits their needs:~Sleep quality detector; Position sensor; Smart band; Smart watch; Microphone and speaker; rgb (real sense) sensor; Binary door and window sensor; Environmental sensor."
40858574|NCT00004030|DRUG|VX-853|
41167078|NCT05844865|OTHER|Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)|Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.
40858575|NCT00004030|DRUG|pegylated liposomal doxorubicin hydrochloride|
40858576|NCT05639192|BIOLOGICAL|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
40858577|NCT05639192|OTHER|Placebo|Placebo will be administered once per week as an i.v. infusion
41512044|NCT02366169|DEVICE|Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure|The procedure is performed transorally under general anesthesia. The physicians staples the fundus of the stomach to the esophagus approximately 3cm superior to the Z-line in 2 or more locations. The procedural result is anatomically and functionally similar to standard anterior fundoplication (Dor-Thal operation). The staples are standard, 4.8mm titanium surgical staples. Each application of the device fires a quintuplet of staples (5) in three staggered rows. Anti-retching medications at the time of the procedure are essential.
41512045|NCT01458691|PROCEDURE|Steroid injection into the glenohumeral joint|"* Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance."
41512046|NCT01458691|PROCEDURE|Allogeneic PRP injection into the glenohumeral joint|"* Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance."
40858578|NCT03646474|DRUG|tranexamic Acid infusion|The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.
40858579|NCT03646474|DRUG|saline infusion|In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
40858580|NCT03155724|DEVICE|MultiPole Pacing|CRT non-responders are programmed with MultiPole pacing ON.
41167079|NCT04042818|DIAGNOSTIC_TEST|Rehabilitative Ultrasound|Ultrasound imagining
41389522|NCT04775368|OTHER|Administering diagnosis orientation questionnaires for the screening of possible sleep disorders|Several diagnosis orientation self-questionnaires will be conducted by the patient following his or her inclusion in order to detect, among other things, possible sleep disorders.
41389523|NCT03989180|DEVICE|C-Scan System|"* Subjects will receive detailed instructions (verbally and written) about the normal operation of the recorder and how to handle it during normal daily routine. They will be asked to document all their daily activity in a personal diary (attached)~* The recorder will be secured to their lower back to test its functionality"
41389524|NCT05877235|DIETARY_SUPPLEMENT|Quercetin|Trans-quercetin, 1000 mg daily for 60 days
41389525|NCT05877235|DIETARY_SUPPLEMENT|Placebo|Starch, 1000 mg daily for 60 days
41389526|NCT04602208|PROCEDURE|Retrospectively review of medical data in patients treated by focal HIFU for primary localized prostate cancer|This study concern the patients with localized prostate cancer treated by Focal HIFU for low or intermediate risk disease. Three surgeons experienced in HIFU performed the procedures. Patients were treated with the Ablatherm device \[EDAP TMS S.A., Vaulx-en-Velin, France\] until July 2013 and then with the Focal-One device \[EDAP TMS S.A.\]. The data of all the patients treated between November 2009 to December 2016, at Edouard Herriot Hospital (Lyon, France), were prospectively maintain within a central database and retrospectively reviewed. The study primary outcome was retreatment-free survival (RFS) defined as any additional further treatment: local (FT/PGA for in-field or out-of-field recurrences or radical prostatectomy or external beam radiotherapy or whole gland HIFU) or systemic salvage treatment, a positive biopsy revealing PCa with an ISUP grade≥ 2 in nontreated patients, PCa metastasis or PCa specific death. The adverse events and functional outcomes were also evaluated.
41389527|NCT01954082|DRUG|myo-Inositol 5% Injection|"Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose)."
41389528|NCT01954082|DRUG|Placebo|% glucose(dextrose)
41512047|NCT03352687|PROCEDURE|anterior SSAX|block of the suprascapular nerve block for shoulder surgery by anterior way
41512048|NCT03352687|PROCEDURE|posterior SSAX|block of the suprascapular nerve block for shoulder surgery by posterior way
41512049|NCT06241469|DRUG|Sintilimab,nab-paclitaxel and tegio|Immunotherapy combined with chemotherapy
41512050|NCT05084482|OTHER|Prediction models|The prediction scores are validated by the CAM-ICU scores up to 14 days after ICU admission.
40858581|NCT06167733|DEVICE|VERTICA Active device|VERTICA device with a therapeutic RF energy level
40858582|NCT06167733|DEVICE|VERTICA Sham device|VERTICA device with a low, non-therapeutic RF energy level
40858583|NCT03057015|DRUG|Clonidine|50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
41167080|NCT03866980|BIOLOGICAL|AK105|IV infusion
41512051|NCT03071276|DRUG|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
40858584|NCT03057015|DRUG|Placebo|Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
40858585|NCT03057015|DRUG|Ropivacaine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
40858586|NCT03057015|DRUG|Dexamethasone|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
40858587|NCT03057015|DRUG|Epinephrine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
40858588|NCT03933228|PROCEDURE|Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
41167081|NCT03866980|DRUG|carboplatin|IV infusion
41167082|NCT03866980|DRUG|pemetrexed|IV infusion
40858589|NCT03933228|PROCEDURE|Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
40858590|NCT00546000|DRUG|Fluticasone propionate 0.05% lotion|Daily applications
40858591|NCT03852667|BEHAVIORAL|Pain Neuroscience Education|The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
40858592|NCT03852667|OTHER|Exercise therapy|The exercise therapy varies form analytical exercises in the first sessions, to functional and sports related exercises near the following sessions. The first session focuses on the lumbar neuromuscular control of the patients: first a voluntary contraction of the Transversus Abdominis muscle, the Multifidus muscle and the pelvic floor muscles is learned. When the subject is able to maintain the combined contraction for 10 times, the exercises evolve to more complicated tasks. In the final stage, more functional and sport specific tasks will be exercised.
40858593|NCT01578655|DRUG|cabazitaxel|Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
40858594|NCT01578655|DRUG|prednisone|Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles
40858595|NCT01578655|DRUG|custirsen sodium|Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
40858596|NCT05972005|OTHER|The Intervention (Stronger at Home Intervention)|The home-based intervention includes 8 visits by a PT and/or PTA. The PT conducts 3 visits for initial assessment, program design, coaching, and discharge assessments. The program targets personal goals and provides pain self-management support. The second PT visit at 6 weeks allows for reassessment and adjustments. The intervention ensures adherence through multiple sessions, tailored exercises, barrier-solving support, and motivational strategies. The PTA conducts solo visits every other week, assisting with exercises and education under PT supervision. This inclusion reduces wait times and improves efficiency. The clinical team consists of at least 2 PTs and 2 PTAs trained for 3 days. The exercise program adheres to evidence-based principles, involving a 30-minute session with warm-up, exercise, and cool-down. Participants are encouraged to exercise 5 times a week, focusing on strengthening, balance, and functionality. Feasible compliance rates were observed in the pilot study.
40858597|NCT05972005|OTHER|Usual care (Control)|The control group will receive usual home care provided by the healthcare system, which could vary between cases. We'll document their received care during follow-ups as it is inconsistent and poorly recorded. Regular check-in calls by the study coordinator will remind them of assessments, reducing attrition.
40858598|NCT00311883|DRUG|hydroxychloroquine|
40858599|NCT00104624|DRUG|docetaxel|
40858600|NCT00104624|PROCEDURE|quality-of-life assessment|
40858601|NCT00002306|DRUG|Fluconazole|
41389529|NCT00757263|GENETIC|polymorphism analysis|
41389530|NCT00757263|OTHER|laboratory biomarker analysis|
41389531|NCT00757263|OTHER|questionnaire administration|
40858602|NCT04561908|DEVICE|Transseptal puncture with Brockenbrough-needle|Conventional transseptal puncture with Brockenbrough-needle
40858603|NCT04561908|DEVICE|Microguidewire-assisted transseptal puncture|Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)
40858604|NCT02581215|DRUG|mFOLFIRINOX|"mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia."
40858605|NCT02581215|DRUG|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
40858606|NCT02581215|OTHER|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
40858607|NCT05234047|PROCEDURE|MDCT (multidetector computed tomography)|MDCT will be performed at inclusion and after 2 years
40858608|NCT05234047|PROCEDURE|Dual-energy X-ray absorptiometry|DXA will be performed at inclusion, 1 and 2 years after inclusion
41039088|NCT04401384|DEVICE|Active acupuncture|Participants will receive active acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
41389532|NCT05754437|DEVICE|Low Level Light Therapy|light-emitting diodes (LED), λ = 633 ± 10 nm; power of 100 mW/cm2, 15 minutes
41389533|NCT00003166|DRUG|bryostatin 1|Given IV
41389534|NCT00003166|DRUG|vincristine sulfate|Given IV
41389535|NCT00003166|OTHER|laboratory biomarker analysis|Correlative studies
41389536|NCT02875431|PROCEDURE|Patients undergo ACDF or cervical vertebral body replacement|
41389537|NCT00000318|DRUG|Buprenorphine|"1. Experimental Maintenance treatment with daily medication~2. Experimental Maintenance treatment with thrice-weekly medication"
41389538|NCT02532140|DRUG|WCK 5107 250 mg to 2000 mg|
41389539|NCT02532140|DRUG|Cefepime 2000 mg|
41389540|NCT02532140|DRUG|WCK 5107 1000/2000 mg with Cefepime 2000 mg combination|
41389541|NCT02532140|DRUG|Placebo|
41389542|NCT05942131|OTHER|Group-based laughter yoga|"A total of 8 sessions of laughter yoga will be applied to the students in the intervention group, 2 sessions per week. Each session will last 45 minutes on average. Each session will consist of groups of 7 people. An information meeting about the sessions will be held with the midwifery students who volunteered to participate in the study and assigned to the intervention group before starting laughter yoga. Midwifery students will be administered Secondary Traumatic Stress Scale for Social Media Users and Beck Depression Inventory before and after 4-6 weeks."
41389543|NCT05705544|DEVICE|ILLUMISITE™ Platform (EMN bronchoscopy)|Providers will utilize the ILLUMISITE™ Platform (EMN) machine to perform a diagnostic bronchoscopy procedure.
41389544|NCT05705544|DEVICE|Ion™ Endoluminal System (SSCB bronchoscopy)|Providers will utilize the Ion™ Endoluminal System (SSCB) machine to perform a diagnostic bronchoscopy procedure.
41389545|NCT02453100|BEHAVIORAL|Mobility and pelvic floor exercise|Mobility and pelvic floor exercises
41512052|NCT03071276|DRUG|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
41512053|NCT03071276|DRUG|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
41512054|NCT03071276|DRUG|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
41039089|NCT04401384|DEVICE|Sham acupuncture|Blunt-tipped placebo needles will be used. Participants will receive sham acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6). Then, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
41039090|NCT01751828|DRUG|Sertraline|
41389546|NCT02453100|BEHAVIORAL|Education|Education on simple ways to manage incontinence
41389547|NCT00287235|DEVICE|MARS|
41389548|NCT00287235|DRUG|Standard Medical Therapy|
41389549|NCT01297569|DRUG|Ranibizumab|
41389550|NCT04127994|OTHER|Comparing 3 versus 6 meals in type 2 diabetes patients|We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability
41389551|NCT06408428|DEVICE|PANAXIUM MicroECoG|The PANAXIUM microelectrode ( 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.
41389552|NCT06541613|DRUG|local anesthetic injection (bupivacaine)|The in-plane technique with a 22G, 80 mm block needle is used to inject 30 ml of 0.25% bupivacaine into the external oblique intercostal plane on both sides.
41389553|NCT06541613|OTHER|normal saline injection|the control group will receive 30ml of normal saline bilaterally into the external oblique intercostal plane on both sides
41389554|NCT00927979|DRUG|10 mLRopivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
41512055|NCT04710615|DEVICE|Synapse platform|"The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.~The Synapse platform offers a panel of functions to help the doctor to prescribe medication."
41512056|NCT01082497|BEHAVIORAL|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
41039091|NCT04100772|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular other name:PCV13i
41039092|NCT04100772|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular other name:Prevnar
41167083|NCT03866980|DRUG|placebo|IV infusion
41167084|NCT03866980|DRUG|Anlotinib|PO
41389555|NCT00927979|DRUG|Water for injection|Intraperitoneal nebulization of 10 mL water for injection
41389556|NCT00927979|DRUG|10 mL Ropivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
41389557|NCT02618707|OTHER|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
41389558|NCT01420367|DRUG|metronidazole and cephalzolin|IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
41389559|NCT01000857|DRUG|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
41512057|NCT02163265|PROCEDURE|Surgery|Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
41512058|NCT05845983|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
41512059|NCT05845983|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin solid drink (food grade, MD20, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g, twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
41512060|NCT00003392|BIOLOGICAL|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
41512061|NCT00003392|DRUG|carboplatin|18 AUC IV, approximately days 21, 42
41512062|NCT00003392|DRUG|cyclophosphamide|4 gm/m2 IV, day 1
41512063|NCT00003392|DRUG|melphalan|140 mg/m2 IV , approximately day 63
41512064|NCT00003392|DRUG|paclitaxel|170 mg/m2 IV day 1
41512065|NCT00003392|PROCEDURE|bone marrow ablation with stem cell support|
41512066|NCT00003392|PROCEDURE|peripheral blood stem cell transplantation|
40858609|NCT03308006|BIOLOGICAL|Stem cells|Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
40858610|NCT04768621|OTHER|Questionary|Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
40858611|NCT02335307|GENETIC|CYP2D6 genotyping|CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
40858612|NCT02335307|OTHER|Pain assessment questionnaire|A pain assessment questionnaire will be administered at baseline and 3 months.
40858613|NCT02335307|OTHER|Physician assessment|20-item survey administered to physicians treating patients enrolled in the study
40858614|NCT05990361|DIAGNOSTIC_TEST|clinical diagnostic test|"The clinical diagnosis tests are Active Straight Leg Rise ASLR, Posterior Pelvic Pain Provocation, Long Dorsal Sacroiliac Ligament Palpation (LDSLP), Pelvic Compression, Pelvic Distraction, Patrick-Faber Test (PF), and Gaenslen Test (GT).~The subjects who had at least one positive result from ASLR and P4 Tests; and at least two positive results from the Pelvic Compression and Distraction, PF, GT and LDSLP tests are classified as with PGP group."
40858615|NCT05992363|DEVICE|ureteral stent\s insertion|ureteral stent\\s insertion in the operating room
40858616|NCT01776606|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
40858617|NCT01776606|DRUG|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
41039093|NCT05940532|DRUG|Sugemalimab and Chemotherapy|"Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years."
41039094|NCT00958269|DRUG|dutogliptin|100 mg QD
41039095|NCT00958269|DRUG|dutogliptin|200 mg QD
41039096|NCT00958269|DRUG|placebo|
41039097|NCT00958269|DRUG|sitagliptin|25 mg QD
41389560|NCT04252040|DEVICE|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
41389561|NCT06564337|DEVICE|Surveyed zirconia crown|Patient recruitment will be from the patient population that presents to the undergraduate dental clinic requiring removable dental prosthesis (RPD) to replace missing teeth. Selection of abutment teeth for zirconia surveyed crowns will be similar to that currently utilized when selecting RPD abutments to be restored with either porcelain fused to metal or full metal surveyed crowns for tissue and tooth supported RPD's.
41389562|NCT04313712|DRUG|ibogaine with magnesium treatment|Participants will receive magnesium sulfate intravenously and ibogaine orally.
41389563|NCT06341192|PROCEDURE|Single-bundle ACL combined anterolateral ligament reconstruction|"Single-Bundle ACL + ALL Reconstruction Group:~Patients in this group will undergo reconstruction of the anterior cruciate ligament (ACL) using a single-bundle graft technique.~In addition, they will have the anterolateral ligament (ALL) reconstructed using a portion of the same graft material.~The single ACL bundle is typically positioned to replicate the anatomic footprint of the native ACL.~For the ALL reconstruction, a commonly used technique is the Sonnery-Cottet ALL reconstruction using a gracilis tendon graft.~This combines an intra-articular ACL reconstruction with an extra-articular lateral tenodesis to improve rotational instability."
41512067|NCT01434914|DRUG|octenisept®|Cutaneous solution
41512068|NCT01434914|DRUG|Placebo|Cutaneous use
41512069|NCT06136000|OTHER|Sacral erectör spinae plane block|Group S will be placed on their side. Asepsis is fifth in the transverse plane under antisepsis standards. high-frequency linear USG probe into the spinous process . The USG probe will be shifted caudally to visualize the first and second median sacral crest. The USG probe is then placed on the second medial It will be placed 3-4 cm lateral to the sacral apex and the mid-sacral apex will be imaged. On the USG screen, from top to bottom, erector spinae muscle, multifidus muscle and sacral intermediate The crest will be displayed. 0.25% bupivacaine will be administered in a total volume of 0.5ml/kg (maximum 20 cc ) by applying negative aspiration with the in-plane technique with a 50 mm Stimuplex A needle.
40858618|NCT05395325|OTHER|Kinesiotaping|Kinesio tape would be applied (1)over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. (2) from above the scapula spine to the medial deltoid. (3) from medial border of scapula to anterior deltoid.This intervention would be executed for five days per week for three weeks.
40858619|NCT05395325|OTHER|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period
40858620|NCT05395325|OTHER|Steroid injection|all the steroid injection would be executed by physicians. The 23G needles would be used for the injections. The examiners would be clear and familiar with the protocol, and the injections would be executed for only one time during the study period in experimental group.
41039098|NCT00958269|DRUG|sitagliptin|50 mg QD
41039099|NCT04543110|DRUG|Durvalumab|Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
40858621|NCT02475278|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
40858622|NCT03376737|DRUG|Apatinib|Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)
40858623|NCT03770221|BEHAVIORAL|CATCH|Brief, intensive case management service.
41389564|NCT06341192|PROCEDURE|Double-bundle ACL combined anterolateral ligament reconstruction|"Double-Bundle ACL + ALL Reconstruction Group:~Patients in this group will undergo anatomic double-bundle ACL reconstruction using two graft bundles to more anatomically replicate the native ACL\&#39;s anteromedial and posterolateral bundles.~Like the single-bundle group, they will also have supplemental ALL reconstruction performed using a portion of the graft material.~The double-bundle ACL reconstruction aims to better restore the ACL\&#39;s complex anatomic footprint and bundles\&#39; tension patterns."
40858624|NCT03770221|OTHER|Financial Incentive|Financial incentive for maintaining contact with CATCH service providers.
40858625|NCT03377153|DIETARY_SUPPLEMENT|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
40858626|NCT03377153|OTHER|control|no supplementation
40858627|NCT01304602|DRUG|Irinotecan|IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level
40858628|NCT01304602|DRUG|BKM120|BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
40858629|NCT02270554|DEVICE|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
40858630|NCT05639296|OTHER|Discovery learning (DL)|"DL makes the trainee practice before giving them instruction, Do-Then-Tell, thereby promoting their ability to use and build upon their existing knowledge."
41389565|NCT04388527|BIOLOGICAL|COVID-19 Convalescent Plasma|Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.
40858631|NCT02458053|BEHAVIORAL|Attends with partner|The index partner will participate in intervention as a couple with their female counterpart.
41512070|NCT06136000|OTHER|Ring Block|The patient is under general anesthesia. Before the surgical procedure begins, the pediatric surgeon administers 0.5ml/kg (maximum 20cc) 0.25% bupivacaine to the base of the root of the penis with a 25-gauge needle at 3, 6, 9, and 12 o'clock.
41512071|NCT03016273|PROCEDURE|creation of bladder flap|Creation of the bladder flap, i.e., dissecting the urinary bladder from the lower segment of the uterus is a standard part of cesarean section (CS).
40858632|NCT02458053|BEHAVIORAL|Couples Skill Training|Participants and their partners will attend a pre session covering topics to assist them in working together to facilitate lifestyle changes.
40858633|NCT02458053|BEHAVIORAL|Face to face group sessions|Group sessions will consists of components in traditional weight management programs.
40858634|NCT02458053|BEHAVIORAL|Self Monitor|Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.
40858635|NCT02458053|OTHER|Notebook|The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.
40858636|NCT02458053|BEHAVIORAL|Feedback|Each participant will receive a tailored email providing feedback on their weekly progress.
40858637|NCT00334984|DRUG|glutamine|
40858638|NCT00334984|PROCEDURE|chemoprotection|
40858639|NCT00334984|PROCEDURE|management of therapy complications|
40858640|NCT00334984|PROCEDURE|therapeutic nutritional supplementation|
40858641|NCT06164834|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
40858642|NCT06164834|DRUG|Tegoprazan 25 mg|Tegoprazan 25 mg tablet
40858643|NCT06164834|DRUG|Esomeprazole 20mg|Esomeprazole 20 mg tablet
40858644|NCT01789437|DEVICE|Dexamethasone Intravitreal Implant (Ozuredex)|
40858645|NCT02039284|DEVICE|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
40858646|NCT02039284|DEVICE|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
40858647|NCT02039284|DEVICE|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
40858648|NCT02039284|DEVICE|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
41039100|NCT04543110|RADIATION|Immune Modulating Radiation|Neoadjuvant Immune-Modulating Radiation prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
41389566|NCT04824144|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).
41389567|NCT02908828|DIETARY_SUPPLEMENT|Calanus oil|
41389568|NCT02908828|DIETARY_SUPPLEMENT|placebo dietary oil|
41389569|NCT06536647|DIAGNOSTIC_TEST|Contactless measurement of patient vital signs using the VitalsTM system|Contactless measurement of the patient blood pressure, heart rate, respiratory rate, body temperature and SpO2 will be carried out using the VitalsTM platform based on facial video data.
41389570|NCT02885259|DRUG|rHuPH20|human immunoglobulin and one vial of recombinant human hyaluronidase
41167085|NCT02845310|PROCEDURE|Restricted fluid therapy group|Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV \< 10% - MAP \>65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP \> 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (\>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.
41167086|NCT02845310|PROCEDURE|Standard fluid management|Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
41167087|NCT05124821|DEVICE|Central venous catheter intended to be used for children during routine clinical practice|Device will applied according to instruction for use (IFU) and respective indication during routine clinical practice.
41389571|NCT03923114|RADIATION|Ga-68-NODAGA-exendin-4 PET/CT|PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
41512072|NCT06340997|DEVICE|Transesophageal echocardiography|"* D.Echocardiography(Transthoracic and transesophageal):~* 2D echocardiography (to detect LA function, severity of MS and Wilkins score).~The following conventional parameters were measured :~* left atrial volume index (LAVi), and left ventricular ejection fraction (LVEF) by modified biplane Simpson's rule , left atrial emptying fraction calculated as (LAVi max-LAVi min)/LAVi max × 100 ,\]degree of concomitant mitral regurgitation. The maximum and minimum LAA areas were measured by planimetry. LAA area change (%) was calculated using the following formula: LAA area change = \[(maximal LAA area-minimal LAA area)/maximal LAA area\] × 100.~* Transesophageal echocardiogram (TEE) (to detect LAA function) .~* LAA flow velocity patterns by pulsed-wave Doppler~* Early diastolic emptying velocity~* Late diastolic emptying velocity or LAA contraction flow~* LAA filling velocity~* Systolic reflection waves~* Two-Dimensional- LAA fractional area change (LAAAC%)"
41389572|NCT01019278|RADIATION|proton beam radiation therapy|Undergo external proton beam radiation
41512073|NCT02961088|OTHER|Pasta as part of a low GI/GL diet|
41512074|NCT06105723|BEHAVIORAL|Pathway to Healthy Aging care|The ICOPE-based personalized care planning comprises two home visits. In 1st visit, a comprehensive assessment proposed by the WHO-ICOPE model is conducted to identify eight possible health problems including malnutrition, reduced physical fitness, fall risk, cognitive decline, insomnia, pain, psychological distress and social loneliness. After health problem identification, each participant receives a personalized care prescription. 2nd visit adopts a goal-oriented empowerment 3-step cycle to personalize the care planning: 1) communicating assessment results to increase healthy self-awareness; 2) supporting setting person-directed goals to address health problems; 3) identifying health actions and personalizing goal setting to participants' contexts. The 12-week healthy aging empowerment comprises three core activities for healthy aging promotion, including interactive health education, health message broadcasts, and three case conferences for goal monitoring and health counseling.
41512075|NCT03168022|DRUG|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
41512076|NCT03168022|DRUG|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
40858649|NCT04482582|RADIATION|Cryoneurolysis|Patients will be offered a minimally invasive solution known as cryoneurolysis. By directly applying a cold cryoneurolysis probe to the nerves the axon is destroyed, resulting in Wallerian degeneration of the distal nerve without distorting epineurial or perineurial tissue. Application of cryoneurolysis will help reduce the amount of narcotics the patient would need to take and instead provide them longer term pain control with minimal risk.
40858650|NCT04482582|OTHER|Standard of Care|Patients will be provided regular standard of care at the Stanford Hospital with long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.
41389573|NCT01019278|RADIATION|radiation therapy treatment planning/simulation|
40858651|NCT05743361|DIAGNOSTIC_TEST|Blood sampling|Detection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
41167088|NCT01351883|DIETARY_SUPPLEMENT|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
41167089|NCT01764698|BEHAVIORAL|CALM-SUD|6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
41167090|NCT01764698|BEHAVIORAL|Treatment as usual|The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
41389574|NCT01019278|DRUG|cisplatin|Given IV
41389575|NCT04711512|BEHAVIORAL|Encouragement/Support|Messages that focus on improving self-efficacy and motivation for physical activity
41389576|NCT04711512|BEHAVIORAL|Social Comparison|Messages that provide exposure to another person's physical activity engagement data (for comparison)
41389577|NCT06568887|COMBINATION_PRODUCT|Dextrose Water|Individuals in this group will receive three injections of 5% dextrose water per week for six weeks period to treat their pain in sacroiliac joint and then their responce will b documented.
41389578|NCT06568887|COMBINATION_PRODUCT|Corticosteroid Injection|Individuals in this group will receive three corticosteroid injections per week for a period of six weeks to treat their pain in Sacroiliac joint and then their responce will also be documented.
41512077|NCT00185588|DRUG|Vatalanib|Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
41512078|NCT00185588|DRUG|Gemcitabine|850 mg/m2
41389579|NCT00003892|DRUG|ISIS 5132|4mg/kg/day IV for 21 days every 4 weeks.
40858652|NCT04526041|OTHER|Nasofibroscopy|Laryngeal exploration performed using a flexible fibrescope while singing.
40858653|NCT04526041|OTHER|Electroglottography|Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.
40858654|NCT04526041|OTHER|Air flow measurement + acoustic signal recording|Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)
40858655|NCT04526041|OTHER|Questionnaire|Questionnaire on subject singing habits, the way it use and perceive the use of his body when singing.
40858656|NCT03878589|DRUG|Oxytocin (OT)|During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
40858657|NCT03878589|DRUG|Placebo (P)|During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
40858658|NCT01104727|PROCEDURE|4-Ports Cholecystectomy (4PC)|a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
40858659|NCT01104727|PROCEDURE|Single-Port Cholecystectomy (SPC)|"a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
40858660|NCT04320355|OTHER|Soft tissue manual therapy|The intervention is a type of massage.
40858661|NCT03100604|DRUG|desflurane,|Patients were divided into two groups according to inhalation agent administered for the surgery; Sevofluran, Group S (n=25) and Desfluran, Group D (N=25).
40858662|NCT03100604|DRUG|Sevoflurane|For a drug, use generic name if established. Use the same name as in the associated Arm/Group Description(s).
40858663|NCT06206018|PROCEDURE|PROM_R knee rehabilitation program|"The rehabilitation program consists of 5 weekly sessions for 4 weeks, supervised by a specialized physiotherapist at every session.~All patients follow the same order of treatment and exercises, starting with massage and mobilization, followed by the corresponding exercise program, and ending with Neuromuscular Electrical Stimulation (NMES) and cryotherapy."
40858664|NCT04243993|OTHER|Calcium silicate cement|Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.
40858665|NCT05258149|DEVICE|JJVC Investigational Multifocal Contact Lenses|TEST
40858666|NCT05258149|DEVICE|Dailies Total 1® Multifocal Contact Lenses|CONTROL
40858667|NCT04544358|BEHAVIORAL|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
40858668|NCT00016328|DRUG|temsirolimus|Given IV
40858669|NCT00016328|OTHER|laboratory biomarker analysis|Correlative studies
40858670|NCT00016328|OTHER|pharmacological study|Correlative studies
41167091|NCT03849768|DRUG|HS-10296|Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
41389580|NCT06049173|OTHER|novel recruitment maneuver therapy|The use of abdominal compression cardiopulmonary resuscitation apparatus for new recruitment maneuver therapy: the use of autonomous ventilation mode (PSV or CPAP) during mechanical ventilation, followed by abdominal compression recruitment maneuver therapy, the number of times of each compression is 5-10, each time the duration of 30 to 40s, and then adjust to the previous breathing pattern.
41389581|NCT02322242|DRUG|Systemic Dexamethasone|Intravenous infusion of dexamethasone (4mg)
41389582|NCT02322242|DRUG|Perineural dexamethasone|Perinerual administration of dexamethasone (4mg)
41389583|NCT00883259|DRUG|Metformin|850 mg twice daily
41389584|NCT00883259|OTHER|Placebo|Microcristallyne cellulose 1 table twice daily
40858671|NCT03449719|RADIATION|SBRT - Ablative radiation Therapy|"The current phase II randomized trial,Ablative Radiation Therapy in patients with Oligometastatic castration resistant prostate cancer (ARTO trial) aims to evaluate the difference in PSA response rate between the experimental arm (AA+SBRT) and control arm (AA) in metastatic castration-resistant prostate cancer patients."
40858672|NCT03449719|DRUG|Abiraterone Acetate|systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
40858673|NCT05580939|OTHER|Intervention group|They use Web-based Simulation Application for 4 weeks
40858674|NCT04761133|DRUG|Povidone-Iodine pleural irrigation|Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load
41389585|NCT00326300|DRUG|methylphenidate hydrochloride extended-release tablets|
41389586|NCT06500039|OTHER|Positive Psychological Intervention Program|An intervention method consisting of three good things in life and gratitude activities was determined for the intervention group. It will take four weeks. Three good deeds will be held for two weeks, and gratitude activities will be held for the last two weeks. Participants will record the interventions on a prepared booklet.
41389587|NCT06500039|OTHER|Writing Daily Routines|An activity was planned for the control group participants to write their daily routines. They will write down their sleep, nutrition, hygiene and shopping routines, which will be different each week for four weeks. Control group participants will also be given a booklet to write on.
40858675|NCT01460758|DEVICE|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
40858676|NCT01460758|DEVICE|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
40858677|NCT01460758|DEVICE|Placebo Stimulation|Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
40858678|NCT00584415|DEVICE|GP ablation + PV isolation|All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
40858679|NCT00674414|BIOLOGICAL|trastuzumab|Trastuzumab (Herceptin®) IV once weekly
40858680|NCT00674414|DRUG|everolimus|Oral everolimus once daily
40858681|NCT00674414|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
40858682|NCT04354324|DRUG|Radioiodine|The test group: low dosage (30mci). The control group: high dosage (100mci).
41167092|NCT03849768|DRUG|Gefitinib|Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
41167093|NCT04756206|DRUG|Dutasteride 0.5 mg|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
41167094|NCT04756206|DRUG|Placebo|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
41167095|NCT02510222|DIETARY_SUPPLEMENT|Oral magnesium sulfate|Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
41167096|NCT02510222|OTHER|Placebo|
41167097|NCT00485706|PROCEDURE|high calcium dialysate|
41167098|NCT04885634|DRUG|Semaglutide Injectable Product|Subcutaneous injection of Semaglutide 2.4 mg once weekly
41167099|NCT04885634|DRUG|Placebo|Subcutaneous injection of volume-matched placebo once weekly
41389588|NCT00545441|DEVICE|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
41389589|NCT00545441|DEVICE|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
40858683|NCT04656457|DEVICE|Treadmill|Treadmill is not used to harness power, but as exercise machines for running or walking in one place. Rather than the user powering the mill, the machine provides a moving platform with a wide conveyor belt driven by an electric motor or a flywheel. The belt moves to the rear, requiring the user to walk or run at a speed matching that of the belt. The rate at which the belt moves is the rate of walking or running. Thus, the speed of running may be controlled and measured
41167100|NCT01084993|DRUG|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
41528405|NCT01569971|OTHER|Assessment|In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
41528406|NCT01775059|DEVICE|Integrated sensor and infusion set.|
41167101|NCT01084993|DRUG|Heparin|70 U/kg
41167102|NCT03181906|OTHER|Pre-Consultation Medication Reconciliation|Medication reconciliation service to be done for participants randomised to the intervention group
41167103|NCT02019238|OTHER|Pulmonary Vein Isolation procedure|comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
40858684|NCT04656457|OTHER|resisted exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting)
40858685|NCT00587678|DRUG|Simvastatin|40mg each night
40858686|NCT00587678|DRUG|Ezetimibe|10mg daily
40858687|NCT00587678|DRUG|Simvastatin/Ezetimibe|40mg/10mg each night
40858688|NCT05596604|OTHER|survey- no intervention|survey- no intervention
40858689|NCT03222297|DEVICE|early skull repair|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
40858690|NCT03222297|DEVICE|late-stage skull repair|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
41167104|NCT04959461|BEHAVIORAL|webCHAT|A self-guided, single session web intervention that utilizes a motivational interviewing style to prevent impaired driving
41167105|NCT04959461|BEHAVIORAL|Usual Care|6 hours of driver education
41389590|NCT03349437|DEVICE|Vitabreath Device|The VitaBreath device is designed for non-continuous use only and typical device use is expected to be for 2-3 minutes. The device should only be operated for less than 10 minutes at a time. After such time, the device should be turned off for at least 30 minutes
41389591|NCT03349437|OTHER|Pursed Lip Breathing|Pursed lip breathing (PLB) is the standard of care and will be used as the control condition comparator.
41389592|NCT00583128|DRUG|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
41389593|NCT00583128|DRUG|Celphere® CP-305|oral, placebo, sachet, 2 grams three times daily for 8 weeks
41389594|NCT06296459|OTHER|3D R100 scanner|A cone beam computed tomography used for planning of implant surgery
41389595|NCT06296459|OTHER|Conventional Radiograph|Imaging used as standard of care to plan for implant surgery
41389596|NCT04078659|DRUG|Propofol infusion|Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
41389597|NCT04078659|DRUG|Magnesium Sulfate infusion|Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
41389598|NCT04078659|DRUG|Lidocaine|Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
41389599|NCT04078659|DRUG|Fentanyl|Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
41389600|NCT04078659|DRUG|Propofol|Patients will receive propofol in a dose of 1-2 mg /kg
41389601|NCT04078659|DRUG|Atracurium|Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
41389602|NCT04078659|PROCEDURE|Mechanical Ventilation|Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
41389603|NCT04492007|BEHAVIORAL|Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)|Participants will receive personalized self-care information and guidance based on their symptoms and signs of complications (e.g., skin infection, fatigue) from the web-based telehealth PRISMS program. They will also have access through this website a peer support online forum that is moderated by a research nurse as well as professional support through videoconferencing/telephone from the research nurse and also their healthcare providers at the hospital(s) if they experience moderate to severe symptoms and/or abnormal sign (e.g., body temperature is greater than 98.6 C
41389604|NCT05257174|DIETARY_SUPPLEMENT|Jing Si Herbal Tea LIQUID PACKETS|intake Jing Si Herbal Tea LIQUID PACKETS twice daily for three months
41389605|NCT05257174|DIETARY_SUPPLEMENT|Placebo|intake Placebo twice daily for three months
41389606|NCT00561093|DRUG|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
41528407|NCT05884736|OTHER|Neuromonitoring|Multimodal neuromonitoring will include: Transcranial colour-coded Doppler (TCCD), Electroencephalography (EEG), and Somatosensory evoked potentials (SSEP) or brainstem auditory evoked potentials (BAEP)
41528408|NCT03324620|OTHER|Specific program functional and respiratory rehabilitation|It is a question of introducing a small program of physical activation pre-transplantation of hematopoietic progenitors, to continue developing it during the hospitalization and to use the functional measurements as a measure of its impact, as well as the different quality of life questionnaires.
40858691|NCT03305315|OTHER|Measurements of jaw movement|Jaw mobility will be measured during simple movements of the mouth (opening the mouth, side-to-side and backwards-and-forwards movement of the jaw). These movements will be measured using a specific apparatus, part of which will be placed on the head like a helmet with the other part placed in the mouth and stuck to the teeth using a dental adhesive. The part in the mouth is specifically designed for this purpose. Measurements using this apparatus will take around 30 minutes.
40858692|NCT03305315|OTHER|Measurement of natural electrical activity of facial muscles|Natural electrical activity of the facial muscles will be measured using electrodes placed on the skin.
40858693|NCT02825524|DEVICE|Habib™ EndoHBP|During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
40858694|NCT01966289|DRUG|CY|CY is administered intravenously at 200 mg/m2
41039101|NCT05411458|OTHER|Aerobic and Relaxation Exercises|"12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~Aerobic exercise (AE) program:The aerobic training program was applied as walking for 40 minutes in the open air. The Rating of Perceived Exertion (RPE) Borg Scale (6-20) was used to determine the walking pace, and they were asked to walk according to the light (11-12) level according to the Borg scale.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
41039102|NCT02815553|PROCEDURE|Direct Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy|
41039103|NCT02815553|PROCEDURE|Direct Transthoracic Cardiac Tumor Laser Ablation Therapy|
41389607|NCT00561093|DIETARY_SUPPLEMENT|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
40858695|NCT01966289|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells
40858696|NCT01966289|DRUG|SGI-110|SGI-110 is administered subcutaneously at 60 mg/m2
40858697|NCT05117190|PROCEDURE|Facial Allotransplantation|
40858698|NCT03079895|BEHAVIORAL|Thrive|Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
40858699|NCT06429449|DRUG|Venetoclax|Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.
40858700|NCT06429449|DRUG|Azacitidine|An analog of the pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
41039104|NCT03681626|PROCEDURE|no tracheal suction|No tracheal suctioning during extubation
41039105|NCT03681626|PROCEDURE|tracheal suction|tracheal suctioning during extubation
41389608|NCT00561093|DIETARY_SUPPLEMENT|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
41528409|NCT00550043|DRUG|INCB018424|
41528410|NCT00550043|DRUG|Placebo|
40858701|NCT06429449|DRUG|Mitoxantrone|Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use.
40858702|NCT05338034|DRUG|HPG1860|The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
40858703|NCT05338034|DRUG|Placebo|Capsule
40858704|NCT05799768|BEHAVIORAL|Ketogenic diet|Ketogenic diet counseling
40858705|NCT03685227|OTHER|Yoga Nidra|This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
40858706|NCT05726006|OTHER|No Intervention in This study|No Intervention in This study
41039106|NCT04827212|BEHAVIORAL|Companion|"Companion integrates wearable sensing with the smartphone to develop a behavior-aware, virtual system that uses a human-in-the-loop approach to enable meaningful two-way communication. Companion builds rich models of typical behavior using sensors and context sensitive ecological momentary assessment to deliver intervention components and behavior change strategies using socially engaging, contextually salient, and tailored text-message conversations in near-real-time."
41039107|NCT00827450|DIETARY_SUPPLEMENT|Ctl|Control, isocaloric diet; no coffee
41039108|NCT00827450|DIETARY_SUPPLEMENT|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
41039109|NCT00827450|DIETARY_SUPPLEMENT|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
41389609|NCT00561093|DRUG|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
41389610|NCT00561093|DIETARY_SUPPLEMENT|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
41389611|NCT00561093|DIETARY_SUPPLEMENT|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
41389612|NCT03276962|BIOLOGICAL|RTS,S/AS01E (Full dose)|Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
41389613|NCT03276962|BIOLOGICAL|RTS,S/AS01E (1/5th dose)|Participants will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).
41389614|NCT03276962|BIOLOGICAL|Rabies vaccine|Participants will receive intramuscular injection of rabies vaccine (0.1 ml).
41389615|NCT04477317|DRUG|4% Articaine Hydrochloride with 1:100,000 Adrenaline|new Egyptian articane anesthetic solution.
41389616|NCT04477317|DRUG|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin|Mepecaine-L is the brand name of the Egyptian 2% Mepivacaine. It is the most commonly used anesthetic solution in Egypt due to its availability and its lower cost.
41389617|NCT06539780|BEHAVIORAL|Imagery Rescripting|In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 60 minutes.
41528411|NCT03972189|DRUG|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
40858707|NCT02053636|DRUG|lucitanib|
40858708|NCT02750319|DRUG|Amiodarone|
40858709|NCT02750319|DRUG|N-Acetylcysteine|
40858710|NCT02750319|DRUG|Placebo|
40858711|NCT03286452|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly™ Antimicrobial Wound Matrix consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB) intended for the management of wounds.
40858712|NCT00971139|BEHAVIORAL|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
40858713|NCT01586949|BEHAVIORAL|Daily Challenge|Web-based behavioral intervention aiming to improve individuals' well-being.
40858714|NCT02698826|OTHER|Protocol for rapid FiO2 optimization|"We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas \[ABG\] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value \<100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction."
40858715|NCT00190723|DRUG|Enzastaurin|
40858716|NCT03117855|DRUG|Capecitabine|Given PO
40858717|NCT03117855|OTHER|Laboratory Biomarker Analysis|Correlative studies
40858718|NCT03117855|RADIATION|Radioembolization|Undergo yttrium Y-90 radioembolization
40858719|NCT05698602|DEVICE|NivolisMonitor|"NivolisMonitor comprises a sensing element and controller to measure respiratory values, such as pressure and flow optionnally temperature, relative humidity and oxygen concentration, of a patient being treated with a respiratory therapy devices NIV, CPAP or HDN.~NivolisMonitor is inserted between the respiratory assistance device and the mask or cannula inline with the standard patient circuit used routinely with the respiratory assistance device.~NivolisMonitor functions are:~* measure the respiratory values from the builtin sensor (Pressure, Flow, Temperature, Humidity, Oxygen fraction),~* store the measurements in the embedded memory~* extract from the measurement basic respiratory markers:~* detect if and when a patient is using the respiratory assist device,~* calculate leakage~* calculate respiratory frequency~* transmit the measured values via the NivolisBox component to NivolisPortal"
41039110|NCT00827450|DIETARY_SUPPLEMENT|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
41039111|NCT00827450|DIETARY_SUPPLEMENT|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
41039112|NCT02401191|DRUG|FEX60/PE10|Pharmaceutical form:tablet Route of administration: oral
41039113|NCT05969067|PROCEDURE|Tunneling Technique during RA SCP|As described in the intervention arm above
41039114|NCT05969067|PROCEDURE|Dissection Technique during RA SCP|As described in the intervention arm above
41039115|NCT05247996|PROCEDURE|Transcatheter arterial chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
41039116|NCT05247996|DRUG|Multi-target Drug Therapy|Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight \< 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
41039117|NCT05247996|DRUG|Immunocheckpoint Inhibitor Therapy|Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
41389618|NCT05829473|OTHER|Breathing Exercise Group|A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
41512079|NCT05547217|DEVICE|Hand Therapy using the MyHand System|The MyHandTM System is a smart-mechatronic device programmed with proprietary hand function training regiments (protocols) based on deep research in neuroplasticity. It provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy. Participants will undergo a 2-hour training session, 2-3 days per week, over 12 weeks, for a total of 30 sessions. Hand function therapy will be administered in a specific and gamified manner to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
40858720|NCT05698602|DEVICE|NivolisAnton|"NivolisAnton device enables wireless and remote communication from tcPCO2 monitors which measure transcuteanously CO2 and O2 partial pressures in the blood (tcPCO2 \& tcPO2) .~NivolisAnton device connects to the serial port of tcPCO2 monitor, detects if the monitor is actively measuring blood gas values, collects the measurements from the monitor by following manufacturer's communication protocol and stores the collected values in its internal memory. When applicable per the manufacturer recommendations, NivolisAnton collects the values to apply the drift correction as per the manufacturer recommendations.~NivolisAnton transmits the collected data to external receiving devices, such as Medical Devices (NivolisMonitor or another Medical Device that is granted approved data access by Vivardis) via Bluetooth or data servers (NivolisBox as an example) via WIFI. This data is thereafter transmitted by previously mentioned devices to the NivolisPortal server for archiving."
41039118|NCT05247996|PROCEDURE|Systemic Intravenous Chemotherapy|GEMOX regimen (gemcitabine 1000mg/m2, oxaliplatin 100mg/m2) is given for systemic intravenous chemotherapy after the exclusion of contraindications for chemotherapy, and the presence of active lesions is assessed by laboratory and imaging examinations after every two courses of treatment. If active lesions remain, repeated systemic intravenous chemotherapy may be performed. The frequency of chemotherapy is determined by the investigator and is given according to the needs of the patient, usually 6 times with an interval of 21-28 days.
41039119|NCT01962493|OTHER|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
41039120|NCT01962493|OTHER|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
41039121|NCT01962493|DRUG|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
41039122|NCT02680054|DRUG|Insulin, Asp(B28)-|This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
41039123|NCT00198562|DRUG|Amlodipine, Losartan|amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
41039124|NCT06316427|DRUG|Autologous CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.
41039125|NCT06316427|DRUG|Prior-HSCT donor-derived CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.
41512080|NCT01584817|OTHER|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
40858721|NCT05318404|DIETARY_SUPPLEMENT|Jejunostomy feeding|Maintain jejunostomy feeding till postoperative 1st visit after esophagectomy in delayed feeding group
40858722|NCT05332132|DEVICE|Heracure Device|Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
41039126|NCT06316427|DRUG|New donor-derived CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.
40858723|NCT02459444|DEVICE|Powerbreathe|Respiratory equipment for physiotherapy, offering to load muscles inspiratory
41039127|NCT05244473|DRUG|brentuximab vedotin|Given into the vein (IV; intravenously)
41039128|NCT05244473|DRUG|Placebo|Given by IV
40858724|NCT02459444|OTHER|Physiotherapy|This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
41039129|NCT05244473|DRUG|ART|Daily use of a combination of HIV medicines
41039130|NCT05020639|DRUG|TQB3820 tablets|TQB3820 is a novel cereblon-modulating agent.
41039131|NCT01390467|DRUG|Cantab®|Randomized study, double-blind, crossover, controlled versus placebo.
41389619|NCT05829473|OTHER|Guided Imagery Group|10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
41512081|NCT00202930|DRUG|anti-CD20 (Rituximab)|4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
41512082|NCT03024788|DEVICE|syringe, fundus camera etc|Physical examination, fundus examination, blood and urine samples collection
40858725|NCT00924248|DRUG|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
40858726|NCT02848807|DIETARY_SUPPLEMENT|NUTRIDRINK Compact Protein|high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
40858727|NCT02750488|DRUG|BAY987517|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
41512083|NCT03587038|DRUG|OKN 007|400 mg OKN-007/mL in a phosphate buffer
41512084|NCT03587038|DRUG|Temozolomide|75 mg/m2
40858728|NCT02750488|OTHER|Untreated skin|One site is patched without treatment as control
40858729|NCT06204536|OTHER|Tech-enabled ABA treatment planning|The tech-enabled ABA treatment planning will involve the use of a proprietary MLA integrated within a proprietary software application for use on a tablet, phone, or other smart device by BCBAs (one proprietary software application, one non-proprietary software application). The proprietary application provides functionality for treatment plan development, including templates and centralized resource availability. This tech will be used as adjunct or auxiliary tools to develop and manage ABA treatment plans. The proposed period of time for this intervention (the latter portion of the study subsequent to the non-interventional phases) will be 24 months.
41039132|NCT05134454|DIAGNOSTIC_TEST|Extended ECG investigation|At least two long-term ambulatory ECG recordings with a duration of 14 days each using Philips ePatch (https://www.myheartmonitor.com/device/epatch/). The two recordings should be 2-4 months apart.
41512085|NCT03587038|RADIATION|Photon/Proton IMRT|standard of care treatment to be given 1 to 2 hours after OKN-007
40858730|NCT01635881|DEVICE|Emerge™ 1.20 mm PTCA Dilatation Catheter|"The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.~The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures."
41039133|NCT01603069|DRUG|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
41039134|NCT01603069|DRUG|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
41039135|NCT01603069|DRUG|Placebo|Placebo to AZD3241 BID
41512086|NCT00751192|DEVICE|HIV-testing motivational videos|
41512087|NCT00751192|DEVICE|Standard public health text|
41512088|NCT04975854|BEHAVIORAL|Exposure Therapy (Virtual Reality)|Virtual reality scenarios consists of increasingly intense exposures to phobic stimuli (e.g., looking over railings from various floor levels) with the support of the therapist. The goal of VRET is sufficient reduction in anxiety to allow the patients to expose themselves to heights in everyday situations.
41512089|NCT04975854|OTHER|Information Session|This includes 20-minute information session about general principles of exposure therapy before the start of the study.
40858731|NCT01919801|DRUG|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
40858732|NCT01919801|DRUG|Placebo|
40858733|NCT01932502|DRUG|clobazam (Onfi)|"Subject's clonazepam will be converted to the following Onfi doses per day:~Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.~Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.~Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.~Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.~The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.~Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated"
41039136|NCT00794612|DRUG|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
41039137|NCT02698072|OTHER|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
41039138|NCT02698072|DEVICE|Dry needling|Dry needling needle AGUPUNT®
41039139|NCT02698072|DEVICE|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
41039140|NCT00137033|DRUG|Celecoxib|
41039141|NCT00137033|DRUG|Naproxen|
41039142|NCT00137033|DRUG|ASA|
41039143|NCT04385953|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
40858734|NCT01932502|DRUG|Initial conversion and titration|Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
40858735|NCT01932502|DRUG|Conversion schedule - Week 1|"The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg."
41389620|NCT04440007|DRUG|Abivertinib|Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.
41389621|NCT04440007|OTHER|Standard of Care|Standard of Care as determined by the Investigator
40858736|NCT01932502|DRUG|Conversion schedule - Week 2|Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
41512090|NCT03825224|PROCEDURE|Diagnostic Test: Myostrain|This test measures the contraction of the heart muscle in one to three heartbeats per plane. It's a pulse sequence that produces images that reveal the underlying contraction fo the muscle of a healthy heart and associated weaknesses in case of disease.
41512091|NCT05114733|BEHAVIORAL|InVEST|Individualized vocational and educational support and training -- participant works with BA level school/ work coach for four months
40858737|NCT01932502|DRUG|Conversion schedule - Week 3|Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
40858738|NCT05819697|OTHER|FIRE Trial/Track Your Happiness notifications|"All participants will receive notifications to their smart phones 3 times a day for 12 weeks. They will be asked questions related to burning mouth, to exercise as well as non-clinical Track Your Happiness questions, e.g., Are you interacting with anyone right now? How do you feel right now?"
40858739|NCT04298957|PROCEDURE|Cone biopsy|Cone biopsy if transformation Zone (TZ) 2 or TZ 3
40858740|NCT03450382|OTHER|Hans Kai Education|9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
40858741|NCT00000358|DRUG|Lofexidine|
40858742|NCT03812536|OTHER|No Void|Currently the protocol at The Ohio State University Hospital requires voiding spontaneously prior to discharge from the PACU. Our intervention group will be discharged home without having to void spontaneously as a discharge criteria.
40858743|NCT06078436|DEVICE|Pulmonary artery catheter|Pulmonary artery catheter monitoring or not
40858744|NCT05164627|DRUG|Dexmedetomidine|patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
40858745|NCT05164627|DRUG|Magnesium Sulphate|patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
41039144|NCT01780922|OTHER|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
41039145|NCT01780922|OTHER|Cranberry Extract Beverage|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
41389622|NCT02350322|OTHER|Schoolmeal with fatty fish|Schoolmeal with fatty fish three times a week for 12 weeks
41389623|NCT02350322|OTHER|Schoolmeal without fish|Schoolmeal with meat/cheese three times a week for 12 weeks
41389624|NCT02350322|DIETARY_SUPPLEMENT|Supplement|Omega-3 capsules three times a week for 12 weeks
41389625|NCT05709626|DRUG|No aspirin (Prasugurel monotherapy)|12-month prasugrel monotherapy
40858746|NCT05164627|DRUG|Normal saline|After patient arrival at the PACU, Paediatric Anaesthesia Emergence Delirium (PAED) scale ,Ramsay sedation scores (RSS), emergence agitation, HR, and mean arterial blood pressure (MAP) were recorded every 5 min during the first 30 min, then every 10 min for the remaining 30 min of the recovery room stay. Patients were then transferred to the ward. All postoperative observations and scores were performed by the same anesthesiologist who was blinded to the group assignment
40858747|NCT04699383|DRUG|Sodium Stibogluconate with allopurinol|Routine administration of SSG/allopurinol combination treatment, from 1-5 cycles
40858748|NCT03499093|OTHER|OES|"The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test."
41039146|NCT01780922|OTHER|Non-Cranberry Beverage|Beverage absent cranberry at a dose of 15.2 ounces consumed within 15 minutes
41389626|NCT05709626|DRUG|12-month DAPT|12-month dual antiplatelet therapy with prasugrel and aspirin
41389627|NCT01067989|DRUG|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|"1. Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~2. Capecitabine Tab. 500mg, 1+2/day, continuously.~3. Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~4. Celecoxib Tab. 200mg, 1x2/day, continuously.~5. Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)"
41389628|NCT00639587|DRUG|Ketotifen|Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
41389629|NCT00639587|DRUG|Cetirizine|Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
41389630|NCT01226654|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging EDSS
41512092|NCT03090646|OTHER|Financial Incentive|Up to three gift cards to a major online retailer.
41512093|NCT02673814|BIOLOGICAL|durvalumab|
41512094|NCT02673814|BIOLOGICAL|bavituximab|
41512095|NCT03427515|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|30 days of supplementation, 6x10\^9 CFU/day
41512096|NCT03427515|DIETARY_SUPPLEMENT|Saccharomyces boulardii (CNCM I-1079)|30 days of supplementation, 5x10\^9 CFU/day
41512097|NCT03427515|DIETARY_SUPPLEMENT|Placebo|30 days of supplementation
41512098|NCT01059461|DRUG|Cerebrolysin®|injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
41512099|NCT04603326|PROCEDURE|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
41528412|NCT03920839|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks.
40858749|NCT00260884|BEHAVIORAL|conventional gastrectomy or radical lymph node dissection|
40858750|NCT05230472|DRUG|Simvastatin|simvastatin 60 mg tab
40858751|NCT00649428|BIOLOGICAL|Autologous Human Fibroblast (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection treatments administered 5 ± 1 weeks apart on each side of the face."
40858752|NCT00649428|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection visits administered 5 ± 1 weeks apart on each side of the face."
40858753|NCT02352753|DRUG|Denosumab|Subcutaneous (SC) injection.
40858754|NCT05599971|DRUG|intralesional combined digoxin and furosemide|15 patients will receive intralesional combined digoxin and furosemide, with maximum 5 warts per session. 0.2 mL of lignocaine (20 mg/mL) will be used as a local analgesic and after few minutes, 0.1 mL of combined digoxin and furosemide solution will be slowly injected into the base of each wart. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
40858755|NCT05599971|DRUG|intralesional injection of 5- Fluorouracil|15 patients will receive intralesional injection of 5- Fluorouracil (50mg/ml) in full concentration into the wart using a 27- gauge insulin syringe till the entire lesion begins to puff up. The maximum dose injected per session will be 2ml of 5-FU. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
41389631|NCT03256708|DIETARY_SUPPLEMENT|Prolardii|Prolardii: 2 capsules per day for 12 to 15 days
41389632|NCT03256708|DIETARY_SUPPLEMENT|Placebo|Inactive ingredients
40858756|NCT05599971|OTHER|intralesional saline|15 patients will receive intralesional saline. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
41167106|NCT05236140|DEVICE|Perineal electrical stimulation|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
41389633|NCT05652816|PROCEDURE|Split-thickness skin graft|Transplantation of autologous skin to burn area
41389634|NCT05652816|BIOLOGICAL|Artificial skin graft|Decellularized amnion membrane formed into 3-D matrix
41389635|NCT05652816|BIOLOGICAL|Artificial skin graft co-culture|Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
41389636|NCT03582501|OTHER|Lower body negative pressure|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
41389637|NCT00142454|DRUG|Imiquimod|Patients applied imiquimod cream at bedtime every day for 5 consecutive days (for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4) at a dose of 250 mg as supplied in single-use packets to a 4 x 5 cm area of healthy skin, alternating among the extremities (upper inner arms and inner thighs) in each cycle. The cream was to be rubbed into the skin until it was no longer visible. Patients were encouraged to wash their hands before and after applying cream. The application site was not occluded. The next morning, 6 to 10 hours after initial application, the treated area was washed with mild soap and water to remove any residual cream.
41389638|NCT00142454|BIOLOGICAL|NY-ESO-1 protein|NY-ESO-1 protein was injected intradermally by a study physician or nurse at a dose of 100 μg into the imiquimod-pretreated area on Day 3 of each cycle for 4 consecutive 21-day cycles.
41039147|NCT00127101|DRUG|vorinostat|Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
41389639|NCT06539091|DRUG|Fluzoparib|The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
40858757|NCT03594136|DEVICE|Raumedic Neurovent-P-tel|Insertion of a Neurovent-P-tel in adults to study normal intracranial pressure
41039148|NCT00127101|DRUG|Comparator: bexarotene|Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
41039149|NCT05496127|OTHER|Sensorimotor Exercises and Yoga|Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.
41039150|NCT00698646|DRUG|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
41039151|NCT00698646|DRUG|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
41039152|NCT00698646|DRUG|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
41389640|NCT06539091|DRUG|Apatinib Mesylate|The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are also required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
40858758|NCT02454777|BEHAVIORAL|Exercise Intervention|Undergo HIT
40858759|NCT02454777|OTHER|Laboratory Biomarker Analysis|Correlative studies
40858760|NCT02454777|OTHER|Quality-of-Life Assessment|Ancillary studies
40858761|NCT02454777|OTHER|Questionnaire Administration|Ancillary studies
40858762|NCT05904067|BIOLOGICAL|COVID Convalescent Plasma|200 ml of COVID Convalescent Plasma at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cells transplantation.
40858763|NCT00452790|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
40858764|NCT00452790|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
41389641|NCT02465710|PROCEDURE|Pelvic organ prolapse surgery without mesh|retrospective study
41389642|NCT02465710|PROCEDURE|Pelvic organ prolapse surgery with mesh|
41389643|NCT03377387|DRUG|Capecitabine|Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.
41389644|NCT03377387|DRUG|Neratinib|Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Phase II The MD has been determined as 240mg of neratinib
41389645|NCT03377387|BEHAVIORAL|EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30|Questionnaires Every Cycle (+/- 3 days) (For phase II)
41389646|NCT02120859|DEVICE|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (\> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis \< 40% and FFR \> 0.8.
41389647|NCT02120859|DEVICE|Provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
41389648|NCT06169020|DEVICE|Resting and maximal oxygen consumtion|All subjects will undergo tests for resting and maximal oxygen consumption while simoultaneously wearing a number of wearables and a heart rate monitor. They will also be tested for health related physical fitness and resting blood pressure. Their body composition will also be measured.
41389649|NCT06169020|DEVICE|Free living energy expenditure|All subjects will ingest a dose of doubly labelled water after which they will be fitted with several wearables. They will live their ordinary lives except that they will collect daily urine samples.
41389650|NCT05920018|DIETARY_SUPPLEMENT|Vivomixx®|Daily application of four sachets, i.e. 1.800 bio bacteria/day for 48 weeks
41389651|NCT05920018|DIETARY_SUPPLEMENT|Conjugated linoleic acid (CLA/Tonalin® FFA 80)|Daily application of two capsules p.o., i.e. 2g/day for 48 weeks
41389652|NCT05920018|OTHER|Maltose placebo|Daily application of four sachets for 48 weeks
41389653|NCT05920018|OTHER|Sunflower oil placebo|Daily application of two capsules p.o for 48 weeks
41389654|NCT06568133|DRUG|UIC201603 and co-administration of UIC201603 and UIC201604|"* UIC201603 2 Caps/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 days"
41512100|NCT06278896|DRUG|Cessation of antibiotics|Stop antibiotic therapy after episode of fever if afebrile for 48 hours, no clinically documented source of bacterial infection, and no hemodynamic or respiratory decompensation.
41512101|NCT04996979|DRUG|Ropivacaine 0.5% Injectable Solution|Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
41167107|NCT04505345|BEHAVIORAL|Cognitive training using the Systemic Lisbon Battery|The Systemic Lisbon Battery comprises exercises for cognitive rehabilitation developed to describe diverse activities of daily living.
41167108|NCT04505345|BEHAVIORAL|Treatment-as-usual|Treatment as usual for alcohol use disorder from Casa de Saúde do Telhal is delivered according to the Minnesota Model.
41512102|NCT04996979|DRUG|Placebo|Standard care
41512103|NCT02333084|DIETARY_SUPPLEMENT|PRN Joint Health Formula|
41512104|NCT02333084|DIETARY_SUPPLEMENT|placebo|
41512105|NCT02333084|DIETARY_SUPPLEMENT|PRN Flex Omega Benefits® combination|
41512106|NCT01531088|BEHAVIORAL|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
41512107|NCT05390593|DEVICE|iTBS-1800|Participants in the 1800-pulse intermittent TBS (iTBS-1800) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
41512108|NCT05390593|DEVICE|iTBS-1200|Participants in the 1200-pulse intermittent TBS (iTBS-1200) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
41512109|NCT05578599|DEVICE|Swiftsure CCS device|The Swiftsure CSS device will be used twice per patient in addition to standard oral health care procedures among intubated adult patients undergoing mechanical ventilation in the ICU.
41167109|NCT05707715|DEVICE|XSensor|"A pressure mapping system (X3 SENSOR PX 100:64.160.02, X-Sensor®, Calgary, Canada) was used to record the pressure distribution in mmHg of the head and shoulder section \[18,19\]. Pressure distribution was recorded for 1 minute for each lying position. The purpose of these measurements was to describe the pressure distribution created by the participants in the pillow and the supported areas, as well as to find out the differences that may occur between the pillows. Lower pressure values measured by the device were defined as high comfort, while more contact of the head area with the pillow was accepted as high support."
41389655|NCT06568133|DRUG|UIC201604 and co-administration of UIC201603 and UIC201604|"* UIC201604 1 Tabs/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 daysadministration of UIC201603 and UIC201604"
41389656|NCT04349826|DRUG|Azithromycin|Azithromycin 20 mg/kg/day for 7 days
41389657|NCT04349826|DRUG|Cefixime|cefixime 20-30 mg/kg/day for 7 days
41528413|NCT03920839|DRUG|Gemcitabine|Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles.
40858765|NCT05179148|BEHAVIORAL|Motivational Interviewing|MI is a client-centered counselling style for strengthening a person's own motivation and commitment to change. MI helps evoke the person's own motivation for changes through reflective listening, engaging, evoking, and planning
40858766|NCT04786795|DRUG|Compound Azintamide Enteric-coated Tablets|the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
41389658|NCT04349826|DRUG|Placebo|cefixime-matched placebo for 7 days
41528414|NCT03920839|DRUG|Cisplatin|Cisplatin administered intravenously on Day 1 of 21-day cycles.
40858767|NCT04786795|DRUG|Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets|the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
40858768|NCT00590863|DRUG|SSRI + placebo|Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
40858769|NCT00590863|DRUG|Escitalopram + Bupropion SR|Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
40858770|NCT00590863|DRUG|Venlafaxine XR + Mirtazapine|Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
41039153|NCT03709368|OTHER|Hardware|Community sessions will be provided to each of the sub-villages (n=27) teaching participants how to build a tippy tap, how to build an improved latrine, and how to make liquid soap. In addition, an existing water gravity flow scheme will be rehabilitated and extended, 350 tippy taps and 350 pans for pour flush latrines will be distributed, and sanitation blocks will be built in four schools. Within these schools, SWASH school hygiene clubs will be organized.
41039154|NCT03709368|BEHAVIORAL|CLTS|CLTS sanitation and HW sessions will be given. A first session will focus on sanitation, covering 7 exercises: 1) sanitation or social map, 2) transect walk, 3) shit calculation, 4) medical expenses, 5) shit flow diagram, and 6) water/shit demo, 7) community declaration. A second session will focus on HW, involving 10 exercises: 1) anal cleansing materials, 2) shit and shake, 3) cassava/egg demonstration, 4) charcoal smearing, 5) smelly hands, 6) feces on baby nappies, 7) scratch \& smell, 8) wall contamination, 9) food sharing, 10) dirt under fingernails. These sessions will take approximately 3-5 hours each. Follow-up community meetings and household visits will take place to monitor improvement.
41039155|NCT03709368|BEHAVIORAL|PHAST|PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
41039156|NCT03709368|BEHAVIORAL|RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of these add-on visits is based on the RANAS manual: 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). First, baseline data is gathered through a questionnaire to better understand the context that is at play. Next, this data is analyzed in a do'er non-do'er analysis. Only those behavioral factors that are significantly different between do'ers and non-do'ers will be included in the intervention, as these are, at least theoretically, considered to be decisive for HW and latrine use behavior in the current setting.
41039157|NCT03709368|BEHAVIORAL|mini-RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of the mini-RANAS add-on intervention is based on the 'Norm Behavior Change Techniques' from the RANAS manual 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). During the mini-RANAS household visits, emphasis will be put on norms and volunteers will encourage participants to become a role model by improving HW and sanitation infrastructure and behavior.
41039158|NCT03709368|OTHER|Placebo poster|One household visit will be offered. During this visit, a placebo poster will be distributed focusing on first aid. The topics to be discussed are burns, cuts and grazes. The main goal of this household visit is to avoid jealousy among the control cohort.
41039159|NCT05627193|OTHER|Teleclinic|Instead of visiting surgeon after travelling from far flung areas for a post surgery follow up appointment, the follow up visit will be done using telephone.
41039160|NCT05627193|OTHER|Physical Clinic|Patients will have to travel to come physically to hospital to meet the operating surgeon.
41039161|NCT04514848|DEVICE|INSTI Multiplex HIV-1/2 Syphilis AB test|For the detection of antibodies to syphilis and HIV
41039162|NCT04514848|DEVICE|Multiplo Rapid TP/HIV test|For the detection of antibodies to syphilis and HIV
41039163|NCT01702727|DEVICE|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
41039164|NCT01702727|DEVICE|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
41039165|NCT01702727|DEVICE|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
41039166|NCT02125175|RADIATION|Hypofractionated IMRT boost Radiotherapy|
41039167|NCT01691066|BEHAVIORAL|Infant Toddler Years PRT|
41389659|NCT01018342|DRUG|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
41389660|NCT01018342|DRUG|Macrobid® Capsules 100 mg|
40858771|NCT05609435|OTHER|REASSURE|REASSURE is comprised of three components that are intended to be integrated into survivorship care at each follow-up visit: 1) An online patient-reported outcome (PRO) assessment to comprehensively evaluate survivors' symptoms and concerns; 2) A tailored follow-up recommendation based on pre-established thresholds for reported symptoms and concerns. Survivors who report symptoms or concerns have a follow-up visit to discuss findings whereas survivors without symptoms or concerns will avoid a follow-up visit; and 3) Online survivorship messaging sent after the visit, which includes reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps survivors can take to reduce cancer risk.
40858772|NCT00358436|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
40858773|NCT00358436|DRUG|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
40858774|NCT02262702|DRUG|Paracetamol 665 mg|Paracetamol 665 mg tablet
40858775|NCT02262702|DRUG|Paracetamol 500 mg|Paracetamol 500 mg tablet
40858776|NCT00002203|DRUG|Lamivudine/Zidovudine|
40858777|NCT00002203|DRUG|Lamivudine|
40858778|NCT00002203|DRUG|Zidovudine|
41389661|NCT05090397|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
40858779|NCT05624073|DEVICE|Air-QTM Blocker|The Air-QTM Blocker (Cookgas LLC, Mercury Medical, Clearwater, FL, USA) is a SAD that is intended for use as a primary airway seal and an aid for tracheal intubation in situations of anticipated or unanticipated difficult airways. Its design includes a large airway tube inner diameter, a short airway tube length, and a tethered, removable standard 15mm circuit adapter. These features enable direct insertion of larger tracheal tubes up to 7.5 and 8.5mm inner diameters for Air-Q sizes 3.5 and 4.5 respectively (according to body weight; size 3.5: 50-70Kg, size 4.5:70-100Kg). In addition to the soft blocker channel (guide tube) that acts as a conduit for placing medical devices such as NG (Nasogastric) or Blocker tubes. NG tubes are used to decompress and suction the stomach. Standard NG tubes up to 18 Fr. are suitable for all Air-Q Blocker sizes
40858780|NCT05624073|DEVICE|LarySealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in: sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr. Both devices accommodated standard conventional endotracheal tubes for intubation.
40858781|NCT01415401|DRUG|Brinzolamide 1% / timolol 0.5% maleate fixed combination|
40858782|NCT04340453|OTHER|Exercise with Blood Flow restriction training|3 times a week for 4 weeks to a total of 12 sessions. BFR cuff (Sports Rehab Tourniquet©) will be used, with a width of 10cm and a length of 116cm or 84cm depending on the diameter of the participants thigh. Therapy sessions will be supervised and in groups. Exercises focus on strengthening the hip extensors and abductors, as well as the quadriceps both in open and closed kinetic chain. Exercises will be carried out using will be set at a load of 30% of 1RM with a limb occlusion pressure (LOP) of 70%. The first set will consist of 30reps. followed by 3 sets of 15reps. at 2:2 (con/ecc) at 60bpm by Metronome app. with auditory cue. Rest between sets will be 30sec and between exercises 2min. Cuffs will be deflated during the resting period between exercises and re-inflated at the beginning of the next exercise. Exercise progression will be individualized based on assessments at the beginning of each week. The duration has been estimated to be approximately 60min. including LOP estimation.
40858783|NCT04340453|OTHER|Hip and Knee Exercise Program|A supervised hip and knee strengthening exercise protocol with a combination of stretching, 3 times a week for 4 weeks to a total of 12 sessions. Exercises focus on hip extensors, abductors, as well as the quadriceps and hamstrings strength. Open Kinetic Chain (OKC) exercises will be executed first followed by CKC exercises. Exercises using weights or mechanical resistance will be set at a load of 70% of 1RM and 3 sets of 10 rep. for each exercise. Elastic band exercises will be set at 10RM for 3 sets. Tempo will be set by the Metronome app installed on a Smartphone at 1:2 (con/ecc) at 60bpm with auditory cue. Rest between sets will be 30sec and between exercises 2min. Exercise progression will be individualized based on assessments at the beginning of each week. The duration of each session is estimated to be approximately 45min, with the exception of the first session of each week which is estimated to be 80min due to the addition of strength testing
40858784|NCT04340453|OTHER|stretching|Both groups will receive stretching of the hamstrings, plantar flexors, quadriceps and Iliotibial Band (ITB) in the same manor at the end of each session. Passive stretching will be executed by the physiotherapist with 3x30sec stretch for each muscle group
41039168|NCT03549910|PROCEDURE|APRVplus protocol|Physiology-driven APRVplus protocol
41039169|NCT03549910|PROCEDURE|Low tidal volume ventilation|Low tidal volume lung protective ventilation
41039170|NCT03298126|PROCEDURE|TR BAND removal protocol|To assess radial artery patency after specific protocol used as already described in previous section.
41039171|NCT00957502|DEVICE|ENTact™ Septal Stapler|1 year aged septal staples
41039172|NCT00957502|DEVICE|ENTact™ Septal Stapler|18 Month Aged Staples
41039173|NCT05864781|BEHAVIORAL|Jigsaw Technique|Jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
41039174|NCT02156713|BEHAVIORAL|CIMT Camp|
41039175|NCT05735873|OTHER|Low-energy diet|Twenty-one pre-made, low-energy meals delivered weekly to the subject for 12 weeks.
41389662|NCT05090397|DEVICE|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current Stimulation
41389663|NCT00034359|DRUG|ACH-126,443|
41389664|NCT00034359|DRUG|Lamivudine|
41389665|NCT00034359|DRUG|Placebo|
41039176|NCT03580265|DEVICE|laser phototherapy device with low level laser|The wavelength of low level laser is 808nm and the power output of low level laser is 300mW.
41528415|NCT03920839|DRUG|Pemetrexed|Pemetrexed administered intravenously on Day 1 of 21-day cycles.
41528416|NCT03920839|DRUG|Carboplatin|Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.
41528417|NCT03920839|DRUG|Paclitaxel|Paclitaxel administered intravenously on Day 1 of 21-day cycles.
41528418|NCT02992353|PROCEDURE|Three-port pulmonary resection surgery|Three-port pulmonary resection surgery
40858785|NCT01295645|DRUG|Cidofovir|0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
40858786|NCT01295645|OTHER|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
40858787|NCT02982421|BEHAVIORAL|Group art therapy|Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.
40858788|NCT02982421|BEHAVIORAL|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
40858789|NCT05555706|DRUG|B013+Nab-Paclitaxel|"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
41512110|NCT01931878|DRUG|incobotulinumtoxinA|The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
41512111|NCT01931878|DRUG|Placebo|The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
40858790|NCT01461707|BEHAVIORAL|Mobile phone-based physical activity|Participants will receive the mobile phone-based physical activity program using the trial app.
40858791|NCT01461707|BEHAVIORAL|Activity monitor|Participants will receive an activity monitor
40858792|NCT00081055|BIOLOGICAL|autologous expanded mesenchymal stem cells OTI-010|
40858793|NCT00081055|DRUG|busulfan|
41039177|NCT05774366|DRUG|Remimazolam|General anesthesia was induced with 12 mg/kg/hr of intravenous remimazolam. When loss of consciousness was achieved, the infusion rate of remimazolam was reduced to 1mg/kg/hr for maintenance. At the end of surgery, 0.2 mg of flumazenil is administered.
41039178|NCT05774366|DRUG|Desflurane|Desflurane (1 minimum alveolar concentration (MAC) of end-tidal desflurane concentration) is used for the maintenance of general anesthesia. Induction of general anesthesia is achieved with 1-2 mg/kg of intravenous propofol bolus.
41039179|NCT03071692|DRUG|K-877|0.2mg tablet
41389666|NCT05661656|PROCEDURE|Intra-arterial chemoinfusion of breast cancer|Patients will be cannulated via the femoral artery. Then, a 4F fixed-curve catheter (Cobra catheter, Cook Corporation, Bloomington) was advanced to the ipsilateral subclavian artery. Digital subtraction angiography (DSA) was performed to determine tumor arterial blood supply. Super selection of the internal mammary artery done by micro-catheter. Chemo-infusion was decided by the major feeding artery. The intra-arterial chemoinfusion regimen consisted of docetaxel 75 mg/m2 and epirubicin 50 mg/m2 in 200 mL of normal saline and 5% glucose; the drugs were slowly infused via the catheter over at least 15 minutes. Intraarterial infusion was performed once every 3 weeks on average.
41389667|NCT02824991|PROCEDURE|detection of local twitch response intensities during dry needling|
41512112|NCT03074786|DRUG|Dapivirine|Silicone elastomer vaginal matrix ring
41512113|NCT03074786|DRUG|Truvada|Tablets to be taken orally daily
40858794|NCT00081055|DRUG|cyclophosphamide|
40858795|NCT00081055|DRUG|cyclosporine|
40858796|NCT00081055|DRUG|methotrexate|
40858797|NCT00081055|PROCEDURE|peripheral blood stem cell transplantation|
40858798|NCT00081055|RADIATION|radiation therapy|
41039180|NCT03071692|DRUG|Placebo|K-877 matching placebo tablet
40858799|NCT04585841|DRUG|Cannabidiol|Patients will receive cannabidiol in the period of time they receive chemotherapy.
40858800|NCT03261791|DRUG|Apatinib|Apatinib mesylate tablets 500 mg po qd.
40858801|NCT05165758|OTHER|Self-assessment questionnaires|Subjects will pass the SF-36 score (mental health items) and the EPICES index
40858802|NCT03657290|DRUG|vadadustat|Vadadustat Tablets
40858803|NCT04639219|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
40858804|NCT04202237|OTHER|Speckle Doppler imaging|Speckle Doppler Laser imaging
40858805|NCT04202237|OTHER|Blood sample|Blood sampling
40858806|NCT05791968|PROCEDURE|Whole blood standard donation|Effects of a standard whole blood donation on iron stores and insulin sensitivity.
40858807|NCT01706523|DRUG|STX209 (arbaclofen)|Long-term, daily, orally-administered STX209
40858808|NCT02033746|DEVICE|Han's Acupoint Nerve Stimulator|frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).
40858809|NCT01902329|DRUG|HMA|azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
40858810|NCT01902329|DRUG|SGN-CD33A|Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
40858811|NCT05055817|OTHER|bloody stool group|bloody stool appear in the hospitalized neonate
40858812|NCT05055817|OTHER|non-bloody stool group|bloody stool do not appear in the hospitalized neonate
41039181|NCT05130151|BEHAVIORAL|Youth Health SMS|The intervention is comprised of an automated two-way text messaging and interactive voice recognition service that provides sexual reproductive health (SRH) and HIV prevention information. The proposed intervention will add PrEP information and mental health and alcohol use screeners to the platform with the goal of promoting linkage to HIV clinics and to phone-based mental health counseling for symptomatic participants.
41039182|NCT01227681|DRUG|G-CSF|G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
41039183|NCT01227681|DRUG|Placebo|Sodium Chloride (NaCl) 0.9 %
41039184|NCT04497168|DRUG|Citalopram 20mg|20mg daily
41039185|NCT04497168|DRUG|Placebo|matching placebo pills
41039186|NCT03510104|DRUG|MRX-2843|MRX-2843 capsules
41389668|NCT05406622|DEVICE|MOTIV Sirolimus-Eluting Bioresorbable Scaffold|Participants will receive the MOTIV device
41389669|NCT05406622|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
41389670|NCT05764902|BEHAVIORAL|Patient-tailored intervention|The intervention group will receive various tailored interventions designed to address multiple patient preferences, including sleeping, eating, and resting habits, hobbies, visitation preferences, religious and spiritual needs, preferences for independence and privacy, and any other specific requests or requirements.
41389671|NCT04793165|DEVICE|Non-hybrid closed-loop system with ARG algorithm|To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting
41389672|NCT05138900|RADIATION|SBRT|SBRT for central non small cell lung cancer
41389673|NCT04475068|PROCEDURE|Lateral Position (left and right lateral decubitus)|Prior to initiating the protocol, patients will be sedated deeply with sedatives and opioids and paralyzed. Patients will be evaluated in 5 positions sequentially: 1) Supine 2) Left lateral 3) Supine 4) Right lateral 5) Supine. The side with the least ventilation evaluated by EIT will define which side will start the sequence. Each step will last 30 minutes. Aeration measured by Electric Impedance Tomography (EIT) and lung ultrasound, distribution of the lung ventilation and perfusion measured by EIT, ventilator and hemodynamic parameters, esophageal pressure, and blood gas analysis will be recorded at the end of each step. Continuous monitoring of blood pressure, heart rate and saturation of arterial blood (SpO2) will be carried out during all steps of the protocol to assess the tolerance to the procedure.
41389674|NCT02139579|DRUG|Bevacizumab|7.5 mg/kg every 3 weeks
41389675|NCT06381375|OTHER|Anti Tuberculosis Drug|"1. Estimate the prevalence of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients.~2. Assess the outcome of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients (response to treatment and the prevalence of life-threatening events)."
41389676|NCT06566105|GENETIC|precision medicine approach|precision medicine approach to improvement of risk stratification of hepatic and cardiovascular complications in non-alcoholic fatty liver disease in a group of healthy subjects at increased risk of metabolic pathologies
41389677|NCT02858076|DRUG|2-mg Intravitreous Aflibercept Injection|Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
41389678|NCT02858076|PROCEDURE|Prompt Vitrectomy Plus Panretinal Photocoagulation|Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
40858813|NCT03045718|BEHAVIORAL|Horticultural Therapy|The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
41039187|NCT05804877|BEHAVIORAL|mindfulness-based cognitive therapy|Participants in the experimental group would be arranged to attend online mindfulness-based cognitive programs for eight weeks. Each week was divided into 3 parts, which were detailed mindfulness-based skills training with pictures or short videos, techniques application in different scenarios, and concepts consolidation through a web-based assignment.
41039188|NCT05804877|OTHER|Mental health education|The mental health education was delivered on the platform of LINE to the control group 3 times a week for 8 weeks
41039189|NCT05088928|DRUG|Apixaban|Direct Acting Oral Anti coagulant
41039190|NCT05088928|DRUG|Rivaroxaban|Direct Acting Oral Anti coagulant
41167110|NCT00634920|DRUG|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
41167111|NCT00634920|DRUG|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
41389679|NCT04476017|DRUG|SAGE-718|Oral tablets.
41389680|NCT01977625|DRUG|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
41389681|NCT01977625|OTHER|Placebo|To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
41389682|NCT04895228|PROCEDURE|injection|triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance
41389683|NCT02665026|PROCEDURE|stoma closure at different times|Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer
41389684|NCT06539325|DIAGNOSTIC_TEST|Diagnosis algorithm according to the delay between travel and consultation|Tests : RT-PCR for the most common arboviruses (Dengue, Zika, Chikungunya, and West Nile virus) and serology for dengue infection (NS1 antigen, and IgM and IgG), serologies for chronic viral infections (HIV, HBV and HCV) and schistosomiasis, Blood cultures and Innovativ Diagnostics : panel Dragonfly and two metagenomic analyses
41389685|NCT04506125|OTHER|Haemoglobin 9.5 g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 9,5 g/dL
41389686|NCT04506125|OTHER|Haemoglobine 7.5g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 7,5 g/dL
41528419|NCT02992353|PROCEDURE|Single-port or two-port surgery|Single-port or two-port pulmonary resection surgery
41528420|NCT04948346|OTHER|diagnosed with ALS|diagnosed with ALS
41039191|NCT01349569|DRUG|Lenalidomide|Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
41167112|NCT00634920|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
41167113|NCT00634920|DRUG|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
41512114|NCT03511092|DIETARY_SUPPLEMENT|HMB-FA|One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
41389687|NCT06568250|BEHAVIORAL|RAMP program|The RAMP program is a 12-week virtual program consisting of an individual session (50 minutes) with a Whole Health Coach followed by 11 weekly interactive group sessions (90 minutes each) with pre-recorded expert led education videos, mind-body skill training and practice, and facilitated discussions.
41512115|NCT03511092|DIETARY_SUPPLEMENT|HMB-Ca|One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
41512116|NCT03511092|DIETARY_SUPPLEMENT|alfa-HICA|Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.
41512117|NCT03511092|OTHER|Placebo comparator|One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
40858814|NCT02343406|DRUG|Depatuxizumab mafodotin|Adults: intravenous administration (1.25 mg/kg or 1.0 mg/kg body weight) over 30 to 40 minutes once every 2 weeks until one of the treatment withdrawal criteria was met. The dose was 1.25 mg/kg in the original protocol (Version 1) and Version 2, Amendment 1, and was lowered to 1.0 mg/kg in protocol Version 3, Amendment 2. Pediatric participants: Intravenous administration (1.0 mg/kg body weight for those who were 6 to 17 years old at the date of first dose, or 1.3 mg/kg for those who were 0 to 5 years old) over 30 to 40 minutes or as directed by the guidelines once every 2 weeks until one of the treatment withdrawal criteria was met, for a maximum of one year. If used in combination with temozolomide, depatuxizumab mafodotin was dosed on Day 1 and Day 15 of the TMZ cycle (assuming a standard regimen of 200 mg/m\^2/day for 5 days of each 28-day cycle; for other TMZ schedules, timing of the depatuxizumab mafodotin dosing schedule were to be discussed with the medical monitor).
40858815|NCT02343406|DRUG|Temozolomide|Capsules administered orally, 150 mg/m\^2 on Days 1-5 for the first 28-day cycle, with dose escalation to 200 mg/m\^2 in subsequent cycles in case of adequate tolerance until one of the treatment withdrawal criteria was met.
40858816|NCT02343406|DRUG|Lomustine|Capsules administered orally, 110 mg/m\^2 on Day 1 of every 42-day treatment period. Treatment continued until one of the treatment withdrawal criteria was met, for a maximum of one year.
40858817|NCT05668598|DIAGNOSTIC_TEST|ecological MAI test|"Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.~Study test is ecological MAI."
41167114|NCT00634920|DRUG|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
41389688|NCT00213031|DRUG|Carraguard (PC-515)|
41389689|NCT01397656|PROCEDURE|CPR using 30:2 ratio|Participants will begin performing CPR using a ratio of 30 compressions to 2 ventilations. Participants will then cross over to the other intervention and use continuous compressions.
41389690|NCT01397656|PROCEDURE|CPR using continuous compressions|Participants will begin performing CPR using continuous chest compressions. Participants will then cross-over to the other intervention arm and perform CPR using a ratio of 30 compressions to 2 ventilations.
41389691|NCT06424704|DIAGNOSTIC_TEST|Microbiological culture|Samples taken from chronic suppurative otitis media patients in the Medical Microbiology Laboratory of Selçuk University Faculty of Medicine will be planted in 5% sheep blood Columbia agar, eosin methylene blue agar and saboraud dextrose agar, and the media will be incubated at 37oC for 24-48 hours. Growing bacteria and fungi were examined using traditional methods \[Gram staining, catalase test, coagulase test, bacitracin disk, PYR test (L-pyrrolidonyl-β-naphthylamide), oxidase test, IMViC test, lactophenol cotton blue, etc.\] and VITEK 2 (bioMerieux, France).
41389692|NCT06566157|DIETARY_SUPPLEMENT|Probiotic|LPLDL®
41389693|NCT06566157|DIETARY_SUPPLEMENT|Prebiotic|WellBiome® prebiotic complex: Inulin 67%, XOS 27%, Magnesium Chloride (MgCl2) 9.8 %
41512118|NCT02912182|DRUG|Betamethasone|Betamethasone intravenous
41512119|NCT02912182|DRUG|Placebo|Placebo intravenous NaCl intravenous administration Placebo tablets
41512120|NCT02912182|DRUG|Prednisolone|Oral tablets
41512121|NCT01756430|DRUG|Carvedilol SR 32mg, QD|"* Carvedilol SR 32mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
41389694|NCT06566157|DIETARY_SUPPLEMENT|Maltodextrin (Corn)|Placebo
41512122|NCT01756430|DRUG|Carvedilol SR 64mg, QD|"* Carvedilol SR 64mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
41512123|NCT01756430|DRUG|Carvedilol IR 25mg, QD|"* Carvedilol IR 25mg QD for 4 weeks~* With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks."
41512124|NCT01756430|DRUG|Carvedilol IR 25mg, BID|"* Carvedilol IR 25mg BID for 4 weeks~* With the others investigation product placebo 2 capsules QD for 4 weeks."
41512125|NCT03659214|BEHAVIORAL|Questionnaires|Answering 4 questionnaires : anxiety, depression, quality of life and adherence
41512126|NCT06194617|DRUG|Direct oral anticoagulant|Patients take DOACs according to their condition, with the dosage determined by the clinical physician.
41528421|NCT06576973|DRUG|Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib|Adbelimumab 1200mg Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Apatinib 250mg Po Day 2-4. Preoperative neoadjuvant therapy for 4 cycles, one cycle every 21 days.
41512127|NCT05469334|BEHAVIORAL|DeStress for Health Program Participants|Behavioral: DeStress for Health Program The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals, with an additional class five as a check in that will be used for survey completion. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
41512128|NCT06582459|DEVICE|HFNC treatment|HFNC treatment HFNC therapy. The initial flow rate of 50-60 L/min was subsequently adjusted to maintain an oxygen saturation (SpO2) ≥92%. The FiO2 was titrated to maintain the PaO2 between 60 and 80 mmHg.
41039192|NCT01349569|BIOLOGICAL|Allogeneic Myeloma Vaccine|A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.
41167115|NCT00545571|DRUG|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
41512129|NCT06582459|DEVICE|NIV treatment|NIV treatment A Mindray SV300 ventilator (Mindray Medical International Limited, Shenzhen, China) was used to deliver NIV via an oronasal mask. The initial inspiratory positive airway pressure (IPAP) was 12-15 cmH2O and adjusted later to achieve a tidal volume of 6-8 mL/kg of predicted body weight and a respiratory rate of \&amp;lt;30 breaths/min. The expiratory positive airway pressure (EPAP) was established at 5-8 cmH2O. Additional-ly, FiO2 was titrated to maintain a PaO2 between 60 and 80 mmHg.
40858818|NCT06116006|OTHER|Upper limb pointing movements in 3 experimental conditions|Recording of cerebral hemodynamic with fNIRS during upper limb pointing movements with a robotic device in three conditions: movements with robot assistance, movements without robot assistance and movements with robot resistance. Each subject are recorded during 6 trials for each condition (18 trials). The order is counterbalanced among the subjects.
40858819|NCT04971356|DRUG|Aspirin 100mg for 1-month (immediately after PCI)|Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm
41039193|NCT01349569|BIOLOGICAL|Prevnar-13|Prevnar-13 will be administered at 0.5ml dose by intramuscular injection at the same time as GVAX vaccine.
41039194|NCT01197222|DEVICE|EndoClear Lens Cleaning Device|EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
41039195|NCT02216123|DRUG|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
41167116|NCT04969224|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablet for oral administration.
41167117|NCT04969224|DRUG|IVA|Tablet for oral administration.
41167118|NCT05845840|DRUG|BRII-297|Escalating doses of BRII-297 will be given in different cohorts i.e., Cohorts 1 through 6
41389695|NCT03469440|OTHER|Continuous central venous oxygenation monitoring|"Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.~* First, isotonic crystalloid, 10 up to 20 mL/kg, will be administered in boluses to achieve continuous central venous oxygen saturation higher than 65% in non-cyanogenic and 55% in cyanogenic.~* Second, if not achieved with fluid administration, will be targeted by initiating and titrating inotropics (dobutamine or milrinone). If the mean arterial pressure is lower than 50 mm Hg will be associated epinephrine.~* If the ScvO2 is lower than 65% in non-cyanogenic and 55% in cyanogenic and the hemoglobin was lower than 8g/dl, red blood cells (20mL/Kg) will be transfused to achieve a hemoglobin level of at least 8g/dL."
41389696|NCT03469440|OTHER|Standard protocol|The control group will keep the standard therapy to achieve mean arterial pressure higher than 50mmHg, central venous pressure 8 to 12 mmHg, urinay debit higher than 0,5ml/kg/h, hemoglobin higher or equal than 8g/dL, arterial oxygen saturation higher or equal than 92% in non-cyanogenic and 80% cyanogenic, central venous oxygen saturation higher or equal than 65% in non-cyanogenic and 55% in cyanogenic.
41512130|NCT03816475|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance.
40858820|NCT04971356|DRUG|Ticagrelor 90mg for 6-month (immediately after PCI)|Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm
40858821|NCT04971356|DRUG|Aspirin 100mg for 6-month (6-month post PCI)|Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm
40858822|NCT04971356|DRUG|Aspirin 100mg for 12-month (immediately after PCI)|Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
40858823|NCT04971356|DRUG|Ticagrelor 90mg for 12-month (immediately after PCI)|Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
40858824|NCT03165422|OTHER|Non-Interventional|Non-Interventional
40858825|NCT05440734|DRUG|Melatonin|2 Mg Oral Tablet, slow release
40858826|NCT05440734|DRUG|Placebo|placebo pill identical to the treatment pill
40858827|NCT00013741|BEHAVIORAL|Tailored Education Messages|
40858828|NCT04331470|DRUG|Levamisole Pill + Budesonide+Formoterol inhaler|Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours
40858829|NCT04331470|DRUG|Lopinavir/Ritonavir + hydoxychloroquine|Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
40858830|NCT02921490|DEVICE|FDG PET/MR examination.|All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
41512131|NCT00876330|OTHER|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
41512132|NCT00876330|OTHER|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
41512133|NCT00876330|OTHER|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
41512134|NCT00876330|OTHER|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
41512135|NCT05298865|BEHAVIORAL|Positive imagination stimulation|The intervention messages aim to generate participants' positive mental image toward their life and also to relieve parental stress by shifting their attention to positive life events. The positive affect cues will be developed based on qualitative interviews with 30 parents from our previous study during pandemic and also extended literatures on positive psychology. Our previous qualitative interview aimed to understand parental concerns on flu and COVID-19 vaccination, parental life stressors throughout the pandemic were also explored. The positive cues will be discussed and evaluated by the research team with an aim to cover major positive life events that are personal relevant to parents, including positive social support (friendship), positive family support (family gathering), qualified time spent with children (here we will also embed a gratitude practice to elicit strong positive feelings), and cultivate positive self by imagining achieving personal goals in the future.
41512136|NCT05298865|BEHAVIORAL|Neutral recall message|The control message aims to equate time and attention as in the intervention group. Therefore, a recall task will be assigned to participants. Brief texts will be provided to guide participants to memorize their life senarios but not to induce emotions. Messages include the following: recall the breakfast and lunch you had yesterday; recall the clothes and shoes you wore yesterday; recall the kitchen in your home; recall one of the chairs in your home; recall the routes to the nearest supermarket and subway of your house.
41512137|NCT02325076|DEVICE|Spirodoc|A device to detect the physical condition of the lungs
41389697|NCT03753373|OTHER|Acupuncture|Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).
41512138|NCT04970303|DRUG|Methylphenidate|Retina or Concerta
41389698|NCT03753373|OTHER|Home Exercise Program|Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
41512139|NCT03434522|DEVICE|vBloc Maestro Rechargeable System|vBloc therapy consists of a neuromodulation device that delivers intermittent, controllable electrical blocking algorithms, to the intra-abdominal vagus nerve for the treatment of obesity.
41512140|NCT00067743|DRUG|Lenalidomide|supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
41512141|NCT02089659|DRUG|Doravirine|Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
41512142|NCT04775303|DRUG|Cyclosporine 0.1% (Ikervis®) eye drop|One drop of Cyclosporine 0.1% (Ikervis®) eye drop once daily for 12 weeks
41512143|NCT00451204|DRUG|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
41039196|NCT02216123|DRUG|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
41167119|NCT05845840|DRUG|Placebo|Escalating doses of placebo will be given in different cohorts i.e., Cohorts 1 through 6
41167120|NCT03304613|BEHAVIORAL|Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management|Already noted.
41389699|NCT05969782|DEVICE|EVAR|Endovascular repair of aortoiliac aneurysm using Zenith or Endurant
41512144|NCT00451204|DRUG|Placebo|Placebo capsule, once a day, treatment duration is 2 years
41167121|NCT03304613|BEHAVIORAL|Promoting Resilience through Innovative Self-Management|Already noted.
41167122|NCT00053378|DRUG|paricalcitol injection (Zemplar)|
41167123|NCT00053378|BEHAVIORAL|Effects on calcium regulation|
41167124|NCT00053378|BEHAVIORAL|Administration of elemental Ca during hypocalcemic ICU pts.|
41039197|NCT02216123|DRUG|Chloroquine|"One of two formulations of commercially available generic chloroquine may be utilized in this study:~1. tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~2. tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base)."
41167125|NCT01667172|DEVICE|Point-of-Care C Reactive Protein measurement on capillary blood|capillary blood fingerstick method to determine C Reactive Protein level in the blood
41167126|NCT05288777|DRUG|T-DM1|Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.
41167127|NCT05288777|DRUG|Capecitabine|Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months
41167128|NCT05288777|RADIATION|External Beam Radiation Therapy 0|Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
41167129|NCT05288777|RADIATION|External Beam Radiation Therapy 1|Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
41167130|NCT05871190|OTHER|İnjectable platelet rich fibrin|I-PRF is a type of platelet-rich fibrin (PRF) product obtained from the patient's own blood. PRF is a kind of tissue regeneration product of blood, rich in platelets, growth factors and cellular components.
41167131|NCT05871190|PROCEDURE|Gingivectomy anad gingivoplasty|leveling and regulation of the gingiva
41167132|NCT06475027|OTHER|TBDESJS|Chinese herbal tea TBDESJS
41167133|NCT06475027|OTHER|Acupuncture|acupuncture GB20 or GB20 plus BL2
41389700|NCT00529802|DRUG|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
41512145|NCT00451204|DRUG|Copaxone|Injection, once a day, all subjects
41512146|NCT00616421|BIOLOGICAL|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
41512147|NCT00616421|BIOLOGICAL|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
40858831|NCT04312347|DRUG|Tamoxifen dose adjustment|Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
41039198|NCT02216123|DRUG|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
41039199|NCT02216123|DRUG|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
41167134|NCT04111900|BEHAVIORAL|Sleep/Circadian Friendly|This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
41039200|NCT02468427|OTHER|hands-on teaching|Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
41039201|NCT02468427|OTHER|Frontal teaching|Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.
41389701|NCT03271541|DRUG|Bitopertin|Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
41389702|NCT04959279|OTHER|ED-TREAT|Patients will be assessed and treated based on a clinical decision support system.
41039202|NCT06019832|PROCEDURE|Total Knee Arthroplasty (TKA)|Both study arms will undergo TKA
41039203|NCT06019832|DEVICE|Stemmed Tibial Implant|A stemmed tibial implant
41389703|NCT05274568|DRUG|[18F]UCB-2897|"Investigational Agent:~\[18F\]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product \[18F\]UCB2897is delivered in normal saline (0.9 % sodium chloride \[NaCl\]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. \[18F\]UCB2897 will be stored at ambient temperature in its original container."
41389704|NCT00683904|DRUG|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
41389705|NCT00683904|DRUG|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m\^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m\^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
41389706|NCT00619671|DRUG|Rituximab (Rituxan)|Four weekly IV infusions of Rituxan with dosage individually calculated per subject.
41389707|NCT06568926|DIAGNOSTIC_TEST|Serum Ferritin level|follow up to the ferritin level in beta thalaseemia patients on oral chelation therapy
41389708|NCT00500656|DRUG|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
41389709|NCT00500656|DRUG|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
41389710|NCT00500656|DRUG|Oral Placebo|hard capsule matched to tranexamic acid
41389711|NCT00500656|DRUG|S.C. Placebo|solution for injection, matched to icatibant for injection
41389712|NCT03584204|DIAGNOSTIC_TEST|imaging|computed tomography, magnetic resosnance imaging, ultrasound
41039204|NCT06019832|DEVICE|Non-stemmed tibial implant|non-stemmed tibial implants
41039205|NCT00690703|DEVICE|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
41039206|NCT05947877|PROCEDURE|Non-pharmacological pain management strategies|Non-pharmacological pain management strategies
41389713|NCT06037031|DRUG|Drug: PF-07923568|A single dose of PF-07923568 administered orally as 4 capsules
41389714|NCT00101894|DRUG|FOLFOX-4|"The FOLFOX-4 regimen will be administered every 2 weeks as follows:~Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed"
41512148|NCT00616421|BIOLOGICAL|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
41512149|NCT02649569|DEVICE|Monitoring Device|Wear activity monitor
41512150|NCT02649569|OTHER|Quality-of-Life Assessment|Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
41512151|NCT00665782|OTHER|laboratory biomarker analysis|
41512152|NCT00665782|OTHER|questionnaire administration|
41512153|NCT00665782|OTHER|study of socioeconomic and demographic variables|
41512154|NCT00665782|PROCEDURE|assessment of therapy complications|
41512155|NCT00665782|PROCEDURE|psychosocial assessment and care|
41512156|NCT00665782|PROCEDURE|therapeutic conventional surgery|
41389715|NCT00101894|DRUG|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDGF receptor, and Kit.
41389716|NCT00101894|BIOLOGICAL|Panitumumab (Part 1a only)|Panitumumab will be administered by IV infusion at a dose of 6 mg/kg on day 1 of each 2-week cycle.
41512157|NCT04983134|BEHAVIORAL|Enhanced CHW Intervention|community-based intervention
41512158|NCT03096158|OTHER|Ventilatory Muscle Training (TREMVEN)|"Early cardiac rehabilitation after coronary artery bypass graft:~The enrolled participants will perform IMT or P-IMT for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit."
41512159|NCT03096158|OTHER|Aerobic Training (AERO)|"Early cardiac rehabilitation after coronary artery bypass graft:~It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, SpO2 and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit."
41512160|NCT03096158|OTHER|Isometric Handgrip Training (ISO)|"Early cardiac rehabilitation after coronary artery bypass graft:~Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit."
41512161|NCT04122040|DRUG|Roxithromycin 300 MG|Roxithromycin 300 mg oral per day
41512162|NCT04122040|DRUG|Placebo|Placebo one table oral once dialy
41512163|NCT04400422|DIETARY_SUPPLEMENT|Lipano formula|Subjects will be asked to take an MCT infant formula to assess the tolerability, compliance and overall acceptability of the product for patient with LCHAD
41512164|NCT04498026|DEVICE|Adherus Dural Sealant System|Adherus Dural Sealant, In situ polymerizing sealant
41512165|NCT04498026|DEVICE|DuraSeal Exact Dural Sealant System|DuraSeal Exact (P080013b)
41512166|NCT03649997|DRUG|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
41512167|NCT03649997|DRUG|Placebo|Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
41512168|NCT03649997|DRUG|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
41512169|NCT04327323|DEVICE|CCM device implantation|CCM implantation involves the introduction of two active fixation stimulation leads, fixed on the interventricular septum, and connected to the CCM generator (Optimizer Smart IV, Impulse Dynamic, and any subsequent versions of the same device) inserted in the subcutaneous or submuscular pocket. The implantation is ususally performed using vascular access via right or left cephalic or subclavian vein. The CCM signal consists of 2-3 biphasic pulses lasting 10 msec (total duration of about 20 ms) with an amplitude between 4.0 and 7.5 V, delivered during the absolute refractory period of the ventricle, at a distance of 40 msec from ventricular sensing. The CCM device is compatible with other pacing and defibrillation devices already implanted in the patient; at the time of the implantation, the devices are checked in order to confirm the absence of interference between the devices. The patient is instructed to charge the device battery weekly.
41512170|NCT05632926|DRUG|40 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
41512171|NCT05632926|DRUG|60 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
41512172|NCT05632926|DRUG|80 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
41512173|NCT03883035|OTHER|automatic quality-control system|Automatic quality-control system could real-time measuring endoscopic inspection completeness, detecting gastric neoplasms and evaluating gastric mucosal visibility.
41512174|NCT04267432|DIETARY_SUPPLEMENT|Placebo|Blank
41512175|NCT04267432|DIETARY_SUPPLEMENT|TCI633|Probiotics
41512176|NCT04267432|DRUG|Type 2 collagen|Positive control group
41512177|NCT04028167|DRUG|Sequential FLOT followed by chemoradiation|Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
41512178|NCT05238610|PROCEDURE|PFO closure|PFO-closure will be performed after 3-6 month of observation and monitoring for paroxysmal atrial fibrillation
41039207|NCT00740948|DRUG|Rituximab (mabthera) Injection|2 \* 1g of Rituximab at the 1st day and at the 14th day.
41167135|NCT00224978|DRUG|Chloroquine|
41039208|NCT00740948|DRUG|Placebo: NaCl 0.9% or Glucose 5%|2\* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
41039209|NCT03643952|DRUG|Daptomycin for Injection|Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 mL saline over 30-60 minutes depending upon infection type and age level.
41039210|NCT02234674|OTHER|Current intensive CDP|"Standard Intensive CDP including~* manual lymph drainage,~* pressotherapy and~* bandaging"
40858832|NCT03761901|DRUG|1L treatment|chemotherapy, EGFR TKI, immunotherapy, other
41389717|NCT00101894|DRUG|FOLFIRI|Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
41389718|NCT00111774|DRUG|ABX-EGF|
41389719|NCT05527834|DRUG|VNRX-7145|Single oral dose
41389720|NCT05527834|DRUG|Ceftibuten|Single oral dose
41389721|NCT02088294|BEHAVIORAL|Lifestyle Education (LS)|See arm description
41389722|NCT02088294|BEHAVIORAL|LS + Stress Reduction Guided Imagery|See Arm Description
40858833|NCT03761901|DRUG|2L Treatment|Chemotherapy, EGFR TKI, immunotherapy, other
40858834|NCT03761901|DRUG|3L treatment|chemotherapy, EGFR TKI, immunotherapy, other
40858835|NCT02683434|DEVICE|Kinesio Taping application|Therapeutic taping application applied to skin affecting muscle, fascia, circulation, ligaments, tendons and joints.
40858836|NCT01895595|BEHAVIORAL|Guided Imagery|
40858837|NCT01895595|BEHAVIORAL|Digital Storytelling|
41167136|NCT03315234|GENETIC|SNPs associated with CAD|Genotyping will be carried out by Real-Time PCR
40858838|NCT01332253|DRUG|Intravenous ibuprofen|Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
40858839|NCT01332253|OTHER|Normal Saline|Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
40858840|NCT06279832|OTHER|trascriptomic profiling|The mutational and copy number analyses will be complemented by transcriptomic profiling. RNA will be extracted from FFPE samples using miRNAeasy FFPE kit (Qiagen) and checked for quality and quantify by 2100 Bioanalyzer instrument (Agilent) and Qubit Fluorometer (ThermoFisher), respectively. Transcriptome analyses will be performed by RNA-seq. We will apply total RNAseq using the Illumina® TruSeq Stranded Total RNA workflow that provides a solution allowing the detection of whole transcriptome, splicing variants, and transcript fusions of human RNA isolated from FFPE samples. Libraries will be run using the Illumina's Novaseq6000 system, with a least 50 millions of reads/sample, the minimum read depth for the correct evaluation of low expressed transcripts.
40858841|NCT05158517|DRUG|Subcutaneous vedolizumab|Patients will be switched from IV vedolizumab into subcutaneous vedolizumab
40858842|NCT02321553|OTHER|Brown rice|brown rice cake
40858843|NCT02321553|OTHER|White rice|white rice cake
40858844|NCT04737018|OTHER|Fugl-Meyer Assessment (FMA)|assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34
40858845|NCT04737018|OTHER|Medical Research Concil (MRC)|evaluation of muscular strength score from 0 to 5
40858846|NCT04737018|OTHER|2 Minute Walk Test (2MWT)|Assess functional walking and aerobic abilities
40858847|NCT04737018|OTHER|Timed Up & Go Test|measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down
40858848|NCT04737018|OTHER|Modified Ashworth Scale|score from 0 to 4 evaluation of spasticity
41389723|NCT02088294|BEHAVIORAL|LS + Activity/Eating Guided Imagery|See arm description
40858849|NCT04737018|OTHER|Postural Assessment Scale for Stroke|score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position
41389724|NCT04793932|DRUG|PAXG|Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days
41389725|NCT04793932|DRUG|mFOLFIRINOX|Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days
41389726|NCT04793932|DRUG|short-course chemotherapy|other two months of chemotherapy after surgery
41389727|NCT04793932|DRUG|long-course chemotherapy|other two months of chemotherapy before surgery
41389728|NCT06016101|OTHER|100 Patients|"For patients and professionals: retrieval of socio-demographic data~For patients :~* Pill counting~* Morisky questionnaire"
40858850|NCT04737018|DEVICE|posturographic recording|analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform
40858851|NCT04737018|OTHER|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
40858852|NCT04737018|OTHER|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
40858853|NCT05642520|PROCEDURE|Oval section abutment of 2.9 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
41039211|NCT02234674|OTHER|intensive CDP where Stendo pulsating suit replaces pressotherapy|The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.
41039212|NCT03475550|OTHER|Standard of Care|The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.
41039213|NCT05308173|PROCEDURE|Surgical Aortic Valve Replacement|Cardiac surgery under cardio-pulmonary bypass, via sternotomy or minimally invasive approach with the replacement of native valve with a biological or mechanic prosthesis.
41389729|NCT06016101|OTHER|Healthcare professionals (20 doctors, 20 pharmacists and 20 nurses)|"For patients and professionals: retrieval of socio-demographic data~For healthcare professionals :~* Evaluation of user experience~* Evaluation of the report produced by the application"
41389730|NCT01291069|DRUG|Tadalafil Citrate|If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
41389731|NCT01291069|DRUG|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
41389732|NCT05633095|DEVICE|Neuclare|It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
41512179|NCT00401661|DRUG|Alfuzosin|One tablet of 10mg once daily at the end of evening meal
41167137|NCT06310226|DEVICE|Epidural electrical spinal cord stimulator|Epidural electrical spinal cord stimulator turned on vs. turned off
41389733|NCT05410509|PROCEDURE|Trans-arterial embolization (TAE)|Trans-arterial embolization (TAE) is a minimally-invasive procedure in which the tumor-feeding arteries are catheterized under x-ray guidance and therapeutically occluded. TAE of the kidney is routinely performed in clinical practice for traumatic or iatrogenic injury or to de-vascularize tumors such as angiomyolipomas, oncocytomas, and RCC. The procedure has a long clinical history of success with a very low major complication rate. TAE of RCC with or without percutaneous cryoablation (PA) has been described in retrospective case series as a mechanism to destroy the tumor, reduce bleeding complications from PA, or improve symptoms of RCC such as pain or hematuria. However, these findings have yet to be confirmed in a rigorous, prospective fashion.
41389734|NCT02099331|DRUG|Melatonin|
41389735|NCT02099331|DRUG|Placebo (for Melatonin)|Sugar pill manufactured to mimic Melatonin 20 mg
41389736|NCT01020773|BEHAVIORAL|spontaneous breathing trial|
41039214|NCT05308173|PROCEDURE|Transcutenous Aortic Valve Implantation|Transfemoral implantation of aortic bioprosthesis with one of the devices available in Poland.
41039215|NCT02218567|BEHAVIORAL|questionnaire qualilty of life|
41389737|NCT04322968|DRUG|A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.|Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
41389738|NCT01329705|DEVICE|Ankle Dorsiflexion Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
41389739|NCT01329705|OTHER|Standard of care|"Patients will begin a 12 week course of physical therapy with once-weekly therapy appointment, focusing on:~* range of motion stretching of the Achilles tendon, hamstrings, hip flexors and any other tight musculature~* strengthening of tibialis anterior to allow dorsiflexion in swing phase of gait as well as strengthening of other weak musculature~* gait training to improve heel strike and toe off, stride length, and gait progression~* sensory, proprioceptive training in foot position and degree of plantarflexion or dorsiflexion~* no electric stimulation (e-stim) will be utilized"
41389740|NCT02726672|DEVICE|respiratory rehabilitation using Powerbreathe|10 minutes 2 times a day : 30 inspirations per session during 10 weeks
40858854|NCT05642520|PROCEDURE|Circular section abutment of 3.3 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
40858855|NCT06089837|DRUG|EC5026 oral tablet|"2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)"
40858856|NCT06089837|DRUG|Placebo oral tablet|2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
40858857|NCT04161937|BEHAVIORAL|Behavioural Intervention|Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
40858858|NCT04692519|BEHAVIORAL|Duet Language Intervention Modules|The Duet 2.0 intervention modules promote the following guiding principles that help build effective communication. Below are the 5 principles covered in the six Duet modules: 1) General Awareness: Awareness and knowledge of child development 2) Creating Opportunities: Opportunities for communication during everyday activities 3) Conversational Duets: Rhythmic and reciprocal early language interactions 4) Scaffolding: Providing just enough help to support child independence 5) Harmonizing: Using the strategies together. These modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. The modules were informed and narrated by community members and carefully designed to address specific needs of high-risk communities. The modules have also been translated into Spanish, making sure to encompass specific cultural and dialect needs. Translation accuracy was verified by a qualified Spanish translator.
40858859|NCT04308629|OTHER|Transcranial direct current stimulation|
40858860|NCT03825211|PROCEDURE|Continuous suture in the perineals lesions|A continuous suture of the vagina, muscle and skin is performed continuously, without knotting or cutting the suture thread.
40858861|NCT03825211|PROCEDURE|Discontinuous suture in the perineals lesions|Suture the muscle independently of the vagina and independently of the skin
40858862|NCT06236685|DEVICE|Electric impedance tomography|EIT is rarely used during general anesthesia for standard procedures. In the anesthesia arm, all patients will be monitored by EIT.
40858863|NCT05550935|DEVICE|High-flow Nasal Cannula|HFNC is a device that, in this study, will give the maximum flow (60 L/min), with minimum adjusted temperature (31°C) and FiO2 of 21% or room air.
40858864|NCT02701153|PROCEDURE|Conventional Surgery|Undergo surgery
41039216|NCT02218567|BEHAVIORAL|psychological interview|
41039217|NCT02218567|BEHAVIORAL|psychological tests|
41039218|NCT02218567|OTHER|Motor evaluation|
41389741|NCT00089310|RADIATION|technetium-99|0.25 mCi in 4 equal doses
41039219|NCT02218567|BEHAVIORAL|Behavioral evaluation|
41039220|NCT02218567|BEHAVIORAL|cognitive tests|
41039221|NCT03604081|OTHER|CIMT|Intervention group will receive one hour of intense massed practice of lower extremity either in the form of shaping or task practice.
41039222|NCT03604081|OTHER|Conventional Physical Therapy|1 hour as per current standard of care that follows stroke clinical practice guideline.
41167138|NCT04205955|OTHER|Best Practice|Receive healthy living education via phone call
41389742|NCT01897558|DEVICE|Pacemaker implantation|
41167139|NCT04205955|DIETARY_SUPPLEMENT|Dietary Intervention|Receive diet modification coaching via phone call
41167140|NCT04205955|OTHER|Message|Receive motivational messages via email and/or text message
41389743|NCT03859570|DRUG|Pentoxifylline|Pentoxifylline (PTX) is a methylxanthine derivative that is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). This enzyme, which has at least 5 subtypes, is responsible for inactivation of the important second messengers, Cyclic adenosine monophosphate (AMP) and cyclic guanosine monophosphate (GMP)
41389744|NCT03859570|DRUG|Placebos|Placebo
41389745|NCT04143997|DIAGNOSTIC_TEST|A clinical Transthoracic echocardiogram|A previously clinically completed transthoracic echocardiogram will be utilized to assess for diastolic dysfunction in the presence of normal systolic function for patients with previously diagnosed peripartum cardiomyopathy.
41389746|NCT02349009|DRUG|C-82 Topical Gel, 1%|active
41389747|NCT02349009|DRUG|C-82 Topical Gel, Placebo|placebo
41389748|NCT01791127|DEVICE|market-released BIOTRONIK pacemaker system including one or two Siello S leads.|
41389749|NCT01679418|DEVICE|Placement of a wound drain post surgery (Redon; Medicoplast)|The wound drain, type Redon Drainage 3.0 mm in diameter
41389750|NCT01679418|OTHER|No-drain after surgery|After surgery, no drain was put
41389751|NCT03178474|OTHER|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
41389752|NCT03178474|OTHER|TOFER Infant formula,TOFER®|TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
41389753|NCT03178474|OTHER|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
41389754|NCT06567041|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
41389755|NCT06567041|DRUG|Placebo|Placebo will be administered subcutaneously.
41389756|NCT01578343|DRUG|Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat|"1. Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~2. Consolidation treatment for responders Patients not eligible for transplantation~   * Vorinostat maintenance up to 6 cycles~  * 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~  * Delay of the start of the next cycle by up to 7 days will be acceptable.~  * If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~  * High-dose chemotherapy followed by autologous stem cell transplantation"
41389757|NCT03901027|BEHAVIORAL|Therapeutic Conversation Interventions|Parents (N=31) at the Children's Hospital at the National University Hospital of Iceland, got two sessions of the FAM-SOTC intervention focusing on emotional support, evidence based information and recommendations and on the strengths of family members. The parents meet with the Advanced Practice Nurse at the Children´s Hospital without the child in both sessions, but each session lasted for 45 to 90 minutes. The sessions were offered with 4-8 weeks interval.
41389758|NCT04861831|OTHER|Power Centering for Seniors intervention|Power Centering for Seniors is an innovative East-meets-West intervention (75-minute, twice weekly, supervised group classes over 12 weeks) that integrates Western best practice muscle strength and balance training components with Chinese Tai Chi/Qi Gong to improve mobility and quality of life in older, community-dwelling adults. Home practice is recommended (approximately 30 minutes three times per week on non-course days). The modularly designed course consists of four cycles with six themes repeated in each cycle. Course exercises increase in intensity throughout the twelve-week intervention period. Repetition of cycles and themes prepares participants for continuing their individualized version of the program after the group course intervention is complete. This should lead to long-term practice of the exercises learned in the intervention and to sustained positive effects of the training.
41389759|NCT04227652|DRUG|Ibuprofen administration|Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
41389760|NCT06568965|OTHER|De-stress & happy gut powder-U001|Take one sachet daily, 30 minutes before breakfast, for 60 days
41389761|NCT06568965|OTHER|De-Stress & Happy Gut powder-I001|Take one sachet daily, 30 minutes before breakfast, for 60 days
41167141|NCT04205955|OTHER|Quality-of-Life Assessment|Ancillary studies
41167142|NCT04205955|OTHER|Questionnaire Administration|Ancillary studies
41167143|NCT02428816|OTHER|MRI acquisition|MRI acquisitions
40858865|NCT02701153|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
41167144|NCT02428816|BEHAVIORAL|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
41167145|NCT03800485|DEVICE|IMT|A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
41167146|NCT04307641|BEHAVIORAL|2 Page Information Sheet|2 page information sheet about medication abortion
41512180|NCT06223776|PROCEDURE|Sleep restriction|Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
41167147|NCT06434233|DRUG|Acetaminophen|"All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter."
41389762|NCT06568965|OTHER|Placebo Powder 001|Take one sachet daily, 30 minutes before breakfast, for 60 days
41167148|NCT06434233|DRUG|Ibuprofen|"All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter."
41389763|NCT05513859|PROCEDURE|Craniotomy|Undergo craniotomy
41389764|NCT05513859|DEVICE|Quantitative Oblique Back-Illumination Microscopy|Undergo intraoperative microscopy utilizing qOBM
41389765|NCT06539806|DRUG|Losartan 50mg Tab|The efficacy of losartan on response rate in both metastatic and locally advanced pancreatic cancer patients
41389766|NCT02860273|DEVICE|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen at 21% in COPD patients involved in a Pulmonary Rehabilitation program.
40858866|NCT02701153|OTHER|Laboratory Biomarker Analysis|Correlative studies
40858867|NCT02701153|OTHER|Questionnaire Administration|Ancillary studies
40858868|NCT00818051|RADIATION|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
40858869|NCT00952081|DRUG|Clevidipine|Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
40858870|NCT05396144|DRUG|Nitrous oxide|Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
40858871|NCT00001146|DRUG|Ethyl Eicosapentaenoic Acid|
40858872|NCT00001146|DRUG|OmegaBrite|
40858873|NCT04208438|DIAGNOSTIC_TEST|BVI Device|Non-Invasive measurement of jugular blood volume using Mespere BVI device
40858874|NCT04208438|DIAGNOSTIC_TEST|Point-of-Care Ultrasound|Point-of-Care ultrasound of external and internal jugular veins
40858875|NCT03689816|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
40858876|NCT03689816|PROCEDURE|gastric bypass|gastric bypass
40858877|NCT03887234|PROCEDURE|Coracoclavicular ligament reconstruction|Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation
40858878|NCT00650767|DRUG|ARRY-438162, MEK inhibitor; oral|multiple dose, single schedule
40858879|NCT00650767|DRUG|Placebo; oral|matching placebo
40858880|NCT04406649|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
41389767|NCT02860273|DEVICE|Treadmill|Exercise capacity testing in COPD patients involved in a Pulmonary Rehabilitation Program.
41389768|NCT00306852|PROCEDURE|Baerveldt implant|Patients will be randomized to receive a 350 mm\^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)
41389769|NCT00306852|PROCEDURE|Trabeculectomy with mitomycin C|Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm\^2 Baerveldt glaucoma implant
40858881|NCT02777489|DRUG|Perindopril|Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
40858882|NCT03370224|BEHAVIORAL|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
40858883|NCT03370224|BEHAVIORAL|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
40858884|NCT05489367|BIOLOGICAL|sars cov 2 biontec vaccine|volunteers will be expected to receive 2 doses of vaccine
41167149|NCT06434233|DRUG|Oxycodone|"Patients randomized to Arm 1 will receive Oxycodone 5 mg orally every 4 hours as needed x 12 tablets at post-operative discharge~Patients randomized to Arm 2 will not receive an Oxycodone prescription at post-operative discharge.~However, participants will be informed that if they need additional pain medications, these will not be withheld. Participants in the second arm who require additional pain medications will receive the same amount of Oxycodone as in arm 1"
41167150|NCT04913623|PROCEDURE|Hip Replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
41512181|NCT05911061|BIOLOGICAL|High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with high dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
41512182|NCT05911061|BIOLOGICAL|Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
41512183|NCT05911061|BIOLOGICAL|control group|boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)
41512184|NCT05911061|BIOLOGICAL|Placebo group|saline
41512185|NCT06012851|BEHAVIORAL|Mobile behavioral parent training (mBPT) and prompts|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access. In-the-moment feedback will include parenting feedback and parenting strategies.
40858885|NCT06531070|DIETARY_SUPPLEMENT|Nitrate|"A four-day supplementation period, separated by one week including a 3-day washout period between conditions will be applied before conducting strength and endurance assessments~Days 1 to 3 the randomly assigned supplement (N, NC, or PLA) will be ingested 2 hr before a standard low-volume training session including 3 sets of 8 to 10 reps of squat and deadlift using a very light load (e.g., own body mass) and flexibility exercises following by 5 min of running at self-paced intensity rated as light (12) with the rating of perceived exertion Borg Scale.~Day 4: the assigned supplement will be ingested 2.5 h before the assessments~Assessment of strength and endurance will be conducted"
40858886|NCT04944849|DIAGNOSTIC_TEST|Reaction Time Tests|While doing our research, the reaction time test in the Human Benchmark application, where the reaction time to many different stimuli on the computer can be evaluated, the Aim Trainer test and the auditory reaction time tests at https://playback.fm/audio-reaction-time will be applied.
40858887|NCT02950480|DRUG|zafirlukast|Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.
40858888|NCT02950480|OTHER|Standard of Care (no intervention)|Standard of Care (no intervention)
40858889|NCT01186055|BEHAVIORAL|Smoking Cessation Counseling|Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
40858890|NCT03736941|OTHER|Patients with venous leg|The medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. It will be dispensed in town pharmacies. After inclusion, follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.
40858891|NCT00933998|OTHER|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
40858892|NCT05633472|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
40858893|NCT05633472|OTHER|Placebo|Placebo
40858894|NCT04916236|DRUG|RMC-4630|"* SHP2-inhibitor~* Powder in capsule~* Administered on day 1 and day 2 of every week"
40858895|NCT04916236|DRUG|LY3214996|"* ERK inhibitor~* Powder in capsule~* Administered every day"
40858896|NCT02156414|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy
40858897|NCT02156414|PROCEDURE|Extended Lymphadenectomy|Extended Lymphadenectomy
40858898|NCT04102527|OTHER|Questionnaires|"Patients have to complete the study questionnaires every 2 months :~* Digestive Functional Score of Neurological Patients~* Bowel Function Index~* Severity score for constipation~* Bristol Scale~* Constipation assessment scale~* Estimate scale of risk of constipation"
41039223|NCT03986112|BIOLOGICAL|carotid sonography and inferior vena cava sonography|Carotid and venous ultrasonography is performed in a comfortable state. Corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. After inferior vena cava sonography, the collapsibility Index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. Propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / mL using the Target Control System. Blood pressure and heart rate are measured at prior to induction, 1 minute after induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. Post-induction hypotension is considered as a decrease of 20% or more of baseline blood pressure or a mean arterial blood pressure of less than 60 mmHg. In the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.
41167151|NCT02861625|BEHAVIORAL|Letter of condolence and post-death medical consultation|Process of sending a letter of condolence with consultation proposition.
41167152|NCT02144168|DIETARY_SUPPLEMENT|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
40858899|NCT01478334|BEHAVIORAL|high intensity interval training|"First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.~Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period."
40858900|NCT01478334|BEHAVIORAL|Control|"First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.~Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion."
40858901|NCT05937789|DIETARY_SUPPLEMENT|Vitamin D3|Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
40858902|NCT05937789|DIETARY_SUPPLEMENT|Medium Chain Triglycerides (MCT)|Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
41039224|NCT05154682|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone will be given every 4 hours as needed for 2 weeks after surgery
41039225|NCT05154682|DRUG|Acetaminophen 500Mg Tab|Acetaminophen will be taken every 4 hours for 2 weeks after surgery
41167153|NCT02144168|DIETARY_SUPPLEMENT|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
41512186|NCT02766335|DRUG|Docetaxel|Given IV
41512187|NCT02766335|BIOLOGICAL|Durvalumab|Given IV
40858903|NCT04153045|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
40858904|NCT00292019|PROCEDURE|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
40858905|NCT01564147|OTHER|immediate therapeutic education|Access to the course of immediate therapeutic education
40858906|NCT01564147|OTHER|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
40858907|NCT01158781|BEHAVIORAL|Experimental: gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
41389770|NCT04992338|DEVICE|Mobile app|The CarpeDiem application is a mobile application, designed in collaboration with the Health and Nutrition Technology Unit (UTNS, Eurecat) and the translational research group on respiratory medicine of the Institut de Recerca Biomèdica de Lleida. The application is available for devices with Android as the operative system and its advanced interface allows the user to monitor their physical activity, sleep and diet and motivate them to meet personalized goals through gamification. To do this, the user must answer the questionnaires that they will find on the main page of the application with a predetermined frequency, as well as perform missions that will help them acquire healthier habits. In addition, the user will receive motivational messages and recommendations through notifications that will help and guide them to achieve their missions and achieve their goals, and as a result of changing habits.
40858908|NCT01836302|OTHER|Observation|
40858909|NCT05681702|DRUG|aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.
40858910|NCT05681702|DRUG|prasugrel or ticagrelor|After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.
40858911|NCT01431053|DRUG|aspirin|Aspirin 50mg po daily
40858912|NCT01431053|DRUG|Exemestane|Exemestane 25mg po daily
40858913|NCT00646425|DRUG|Basiliximab|40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
40858914|NCT00646425|DRUG|Placebo|Placebo to match basiliximab
40858915|NCT02197663|PROCEDURE|acupuncture(44mm in length and 32-gauge)|"The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.~The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen."
41389771|NCT05673018|DEVICE|Multi-Cancer Early Detection Test (Galleri®)|Blood collection and multi-cancer early detection testing with return of results.
41389772|NCT02329496|DEVICE|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
40858916|NCT05039957|OTHER|joint preparation|fixation of fracture with joint preparation
41512188|NCT02766335|OTHER|Laboratory Biomarker Analysis|Correlative studies
40858917|NCT05039957|OTHER|without joint preparation|fixation of fracture without joint preparation
40858918|NCT00988273|DEVICE|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.
40858919|NCT00988273|DEVICE|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
40858920|NCT03769766|DRUG|Curcumin|Take medication one 500 mg pill of BCM-95 taken twice daily
40858921|NCT03769766|DRUG|Placebo|Take medication one 500mg pill twice daily
40858922|NCT05126836|DRUG|Cilostazol 100Mg Tab|Cilostazol Twice a Day
40858923|NCT05126836|DRUG|Placebo|Placebo
41512189|NCT05259527|DRUG|Ergocalciferol Capsules|Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.
40858924|NCT01150097|DRUG|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
40858925|NCT01150097|DRUG|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
41039226|NCT05154682|DRUG|Naproxen 500 Mg|Naproxen will be taken every 12 hours for 2 weeks after surgery
41039227|NCT04690855|DRUG|Talazoparib|Talazoparib 1 mg Orally Day 1 to Day 28
41039228|NCT04690855|DRUG|Atezolizumab|Atezolizumab 840 mg IV over 60 minutes Day 15 of Cycle 1 then Day 1 and Day 15 of subsequent Cycles
41039229|NCT04690855|RADIATION|Radiation|Radiation 8 Gy will be given in 3 fractions QOD beginning Day 12, 13 or 14 of Cycle 1 but 24-72 hours prior to 1st dose of Atezolizumab
41039230|NCT03801239|DIAGNOSTIC_TEST|Urodynamic Study|during visit Week 0 patients had urodynamic study
41039231|NCT03801239|DIAGNOSTIC_TEST|OABSS questionnaire fulfilment|during visit Week 0 and Week 2 patients fulfilled OABSS
41039232|NCT03801239|DIAGNOSTIC_TEST|UDI-6 questionnaire fulfilment|during visit Week 2 patients fulfilled UDI-6 questionnaire
40858926|NCT01150097|DRUG|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
40858927|NCT01150097|DRUG|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
41039233|NCT03801239|DIAGNOSTIC_TEST|IIQ-7 questionnaire fulfilment|during visit Week 2 patients fulfilled IIQ-7 questionnaire
40858928|NCT01150097|DRUG|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
40858929|NCT01150097|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
40858930|NCT02760641|OTHER|Egg-based diet (EBD)|Participants will be asked to consume a carbohydrate-restricted diet including whole eggs for 8 weeks. Eggs will be provided.
40858931|NCT02760641|OTHER|Carbohydrate-based diet (CBD)|Participants will be asked to consume a low fat, carbohydrate-based diet for 8 weeks. Breakfast food items will be provided.
40858932|NCT02628561|DEVICE|Transcranial direct current stimulation|
40858933|NCT02628561|BEHAVIORAL|Constraint-Induced Movement Therapy|
40858934|NCT04871958|DEVICE|Continuous glucose monitoring (CGM, Dexcom G6)|"The Dexcom G6 sensor will be placed on the back of the upper arm at admission and changed after 10 days. In the participants randomized to Real-time CGM, glucose values will be transmitted through Bluetooth to a mobile phone at the bedside. From this phone data are transmitted to a tablet in the nursing station.~In the blinded CGM group, sensor readings will be blinded to patient and healthcare providers.~The MDI groups will be managed with basal/bolus insulin regimen, as clinically indicated.~V-Go will be placed on the abdomen each morning. Insulin-naïve patients randomized to the V-Go system will start at the lowest basal rate (20 UI/24h).~On daily basis, expert diabetologists will retrospectively review CGM data and provide indications for insulin therapy adjustments."
40858935|NCT00721240|DRUG|montelukast|5mg montelukast once daily for 12 weeks
40858936|NCT05884775|OTHER|Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool|Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.
40858937|NCT01905449|BEHAVIORAL|Ultrasound visual feedback|Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
40858938|NCT02663830|DRUG|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
40858939|NCT02663830|DRUG|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
41039234|NCT06294301|BIOLOGICAL|LP-005 Dose 1 (Single)|A single dose of LP-005 (Dose 1) was administered intravenously.
41039235|NCT06294301|BIOLOGICAL|LP-005 Dose 2 (Single)|A single dose of LP-005 (Dose 2) was administered intravenously.
41039236|NCT06294301|BIOLOGICAL|LP-005 Dose 3 (Single)|A single dose of LP-005 (Dose 3) was administered intravenously.
41389773|NCT00379925|BEHAVIORAL|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
41389774|NCT02963909|BIOLOGICAL|IXIARO|An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).
41039237|NCT06294301|BIOLOGICAL|LP-005 Dose 4 (Single)|A single dose of LP-005 (Dose 4) was administered intravenously.
41039238|NCT06294301|BIOLOGICAL|LP-005 Dose 5 (Single)|A single dose of LP-005 (Dose 5) was administered intravenously.
41389775|NCT02963909|OTHER|Placebo|0.9% Sodium Chloride 5 mcg
41389776|NCT02963909|BIOLOGICAL|YF Vax 17D Strain|A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.
41389777|NCT02963909|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
41512190|NCT05259527|DIETARY_SUPPLEMENT|Cholecalciferol Capsules|Vitamin D3 5,000IU by mouth daily
41512191|NCT04570787|PROCEDURE|Urinary bladder catheterisation|Installation of Foley catheter into the urinary bladder
41039239|NCT06294301|BIOLOGICAL|LP-005 Dose 6 (Single)|A single dose of LP-005 (Dose 6) was administered intravenously.
41039240|NCT06294301|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered intravenously.
41039241|NCT06294301|BIOLOGICAL|LP-005 Dose 7 (Multiple)|LP-005 (Dose 7) was administered multiple times intravenously.
41528422|NCT06576973|PROCEDURE|Esophagectomy|Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive IvorLewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy. The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon.
40858940|NCT02783092|DRUG|Cannabidiol|Oral solution of cannabidiol 200 mg / mL dissolved in corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
40858941|NCT02783092|DRUG|Placebo|The placebo will be an oral solution of corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
40858942|NCT00626171|PROCEDURE|Allergen Challenge|Allergen challenge
40858943|NCT02384733|RADIATION|Loco-regional RT|
40858944|NCT02265718|DRUG|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
40858945|NCT02265718|DRUG|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
40858946|NCT02265718|DRUG|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
40858947|NCT02265718|DRUG|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
40858948|NCT05522556|DRUG|Ritlecitinib|capsules
40858949|NCT04015206|OTHER|Group Interpersonal Psychotherapy|Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
40858950|NCT03770117|PROCEDURE|Prehabilitation|Participants who underwent Prehabilitation will have their CT scans analysed.
40858951|NCT03770117|PROCEDURE|Standard Procedure|Patients who underwent a panctratoduodenectomy and did not receive any Prehabilitation will have their CT scans analysed and compared.
40858952|NCT00487071|DEVICE|Anal fistula plug|
40858953|NCT05993910|OTHER|Hyperthermie Register|"* die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C),~* die Dauer der Anwendung und~* die simultane Therapie mit Chemo- und/oder Strahlentherapie"
40858954|NCT01860833|DRUG|Ibuprofen|time of treatment 14 days
40858955|NCT01860833|DRUG|Celecoxib|time of treatment 14 days
40858956|NCT01860833|DRUG|Diclofenac|time of treatment 14 days
40858957|NCT04770402|OTHER|Acupuncture|12 acupuncture sessions over 10 weeks
40858958|NCT04770402|OTHER|Standard of Care CIPN management|Investigator directed standard of care management of CIPN
40858959|NCT05508919|DEVICE|Biofeedback|EMG, RESP, and TEMP Biofeedback Training
40858960|NCT05508919|OTHER|Writing Sessions|The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week
40858961|NCT06281093|OTHER|questionary|Parental questionnaire on pregnancy history and environmental exposure
40858962|NCT06281093|OTHER|Daily continuous recording of radiofrequency exposure levels|Daily continuous recording of radiofrequency exposure levels (1 week) by positioning a dosimeter close to the incubator
40858963|NCT06281093|OTHER|Follow-up of daily infants clinical parameters|Follow-up of daily infants clinical parameters
40858964|NCT06281093|OTHER|recording of cerebral (EEG)|recording of cerebral (EEG)
40858965|NCT06281093|OTHER|autonomic nervous (ECG) activity|autonomic nervous (ECG) activity
40858966|NCT04683367|PROCEDURE|laparoscopic surgery|laparoscopic repair of hernia
40858967|NCT05712720|DRUG|Experimental: Group 1|RZ402 50 mg oral tablet, once daily for 3 months
40858968|NCT05712720|DRUG|Experimental: Group 2|RZ402 200mg oral tablet, once daily for 3 months
40858969|NCT05712720|DRUG|Experimental: Group 3|RZ402 400mg oral tablet, once daily for 3 months
40858970|NCT05712720|OTHER|Placebo: Group 4|Placebo, once daily for 3 months
40858971|NCT01887132|DRUG|Donepezil|
40858972|NCT01887132|DRUG|Placebo|
40858973|NCT05879497|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
40858974|NCT04205682|DRUG|Cannabidiol|CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5
40858975|NCT04205682|DRUG|Placebo|Placebo capsules administered BD for 5 days
41039242|NCT06294301|BIOLOGICAL|LP-005 Dose 8 (Multiple)|LP-005 (Dose 8) was administered multiple times intravenously.
41039243|NCT06294301|BIOLOGICAL|LP-005 Dose 9 (Multiple)|LP-005 (Dose 9) was administered multiple times intravenously.
41039244|NCT06294301|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times intravenously.
41039245|NCT04163705|DIAGNOSTIC_TEST|blood sample collection|Routine Laboratory Analysis
41039246|NCT05363566|DEVICE|airway divice|inserted airway device
41039247|NCT05188846|OTHER|SDF|"1. Group 1: cleaning the occlusal surface to be treated with toothbrush. Decayed tissue from the affected teeth will not be removed for the SDF group.~Clinical procedure for SDF application: it will apply according to the SDF manufacturer Instructions as follows:(1) the surrounding gingival tissues and lips will be protected with petroleum jelly to avoid staining and irritation,(2) the affected tooth will be isolated and keep dry with cotton rolls and saliva ejectors, (3) one drop of SDF (SDI RIVA STAR ), will be placed into a disposable dish, (4) SDF will be applied with a micro-sponge directly to the affected tooth surface(s), (5) allowed to soak in for 2 min, then air-dried. Then will be followed by the Potassium iodide (KI) liquid to decrease discoloration caused by SDF. The KI liquid will be reapplied until no more white perception observed to form."
41039248|NCT05188846|OTHER|SDF + ART (SMART technique )|2. Group 2: SDF+ART clinical procedure: (1)cleaning the occlusal surface to be treated with toothbrush.,(2) carious dentin will be removed using a small excavator (Spoon excavator ),(3) the cavity will be cleaned and dried, (4)cavity walls and floor will be conditioned for 10s, then washed and dried, (5) SDF will be applied as mentioned above followed by cavity restoration using resin-reinforced glass ionomer restorative material (SDI RIVA ).
40858976|NCT02583295|BEHAVIORAL|Music sound|The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
40858977|NCT02583295|BEHAVIORAL|Maternal sound|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
40858978|NCT00881647|OTHER|Cognitive Behavioral Treatment for Insomnia (CBT-I)|CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
41528423|NCT06576973|OTHER|Collecting samples from participant|Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use. 20 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery. Tumour sample will be collected before neoadjuvant therapy and after surgery.
40858979|NCT00779493|DIETARY_SUPPLEMENT|curcumin|curcumin 900mg twice daily by mouth
40858980|NCT00779493|DIETARY_SUPPLEMENT|placebo|placebo capsule to simulate 900mg curcumin capsule
40858981|NCT05225363|BIOLOGICAL|Chimeric Antigen Receptor T-cells|Receive TAG72-CAR T cells IP
40858982|NCT05225363|DRUG|Cyclophosphamide|Given IV
41039249|NCT04179487|DIAGNOSTIC_TEST|OPTICA CTPA Protocol|Low dose CT pulmonary angiogram protocol
40858983|NCT05225363|DRUG|Fludarabine|Given IV
40858984|NCT00751803|DRUG|BI 44370 TA Low Dose|
40858985|NCT00751803|DRUG|Eletriptan|
40858986|NCT00751803|DRUG|Placebo|
40858987|NCT00751803|DRUG|BI 44370 TA Medium Dose|
40858988|NCT06495138|DEVICE|StableEyes|"Gaze stabilization exercises using the StableEyes device for the incremental vestibular-ocular reflex adaptation approach.~The StableEyes device consists of a lightweight head unit with a 9-dimension inertial measurement unit and electrostatic micro-mirror that dynamically controls the 2-dimensional position of a 1-milliwatt red laser projected on a wall 1 meter in front of the subject. StableEyes is controlled via a lightweight control unit with a touchscreen interface tethered by cable to the head unit."
40858989|NCT05932472|DRUG|Aspirin|Aspirin at currently prescribed dose
41167154|NCT01531907|OTHER|Study visit procedures|"Anthropometric measurements to include:~* Weight, height, and BMI.~* Waist and hip circumference~* Triceps skinfold thickness~* Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours."
40858990|NCT03265340|DEVICE|dTMS|
40858991|NCT00714415|DRUG|BeneFIX|Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
40858992|NCT03863756|RADIATION|EOS|The new EOS-technology (EOS imaging, Paris, France) based on a low-dose X-ray system allows 3D modeling of the spine based on 2-dimensional
41039250|NCT02968420|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
41039251|NCT03774186|DEVICE|Hybrid closed-loop therapy|Hybrid closed-loop therapy with a proportional integral derivative (PID) algorithm
41167155|NCT00878293|DRUG|GRT6005|liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
41167156|NCT00878293|DRUG|MS Continus®|60 mg, capsule, once daily
40858993|NCT00303485|DRUG|Placebo|po monthly for 6 months
40858994|NCT00303485|DRUG|Vitamin D and calcium supplementation|As prescribed
40858995|NCT00303485|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
40858996|NCT03688464|DRUG|Melatonin|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
41167157|NCT00878293|DRUG|Placebo|liquid formulation and capsule, once daily
41167158|NCT03035318|DEVICE|DePuy Global® Anchor Peg Glenoid Instrumentation|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Glenoid Instrumentation.
40858997|NCT03688464|DRUG|Diphenhydramine|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
40858998|NCT03688464|DRUG|Placebos|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
41039252|NCT03774186|DEVICE|Sensor-augmented pump therapy|Insulin pump + non-communicating CGM
41039253|NCT02763527|BEHAVIORAL|Smoking reduction|A brief intervention on smoking reduction plus a smoking reduction leaflet
41039254|NCT02763527|BEHAVIORAL|Smoking Cessation|A brief advice on quitting plus a leaflet on smoking cessation
41039255|NCT05141669|DRUG|Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
41167159|NCT03035318|DEVICE|DePuy Global® Anchor Peg Instrumentation with SmartBone™|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Instrumentation with SmartBone™.
41167160|NCT03035318|DEVICE|IRI with SmartBone™|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBone™.
41528424|NCT06578611|COMBINATION_PRODUCT|Enhanced recovery after surgery|Recommended pre-, intra-, and post-operative care interventions in the enhanced recovery after surgery.
41039256|NCT06580574|DRUG|PD1/PDL1 antibody monotherapy, up to 24 weeks|non-specific, according to Drug Instructions
41039257|NCT06580574|COMBINATION_PRODUCT|Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks|Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd
41167161|NCT03035318|DEVICE|RTI with SmartBone™|Placement of glenoid component will be performed using Real Time Instrumentation (RTI) with SmartBone™.
41167162|NCT03035318|DEVICE|IRI with SmartBase|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBase.
41512192|NCT05593809|RADIATION|SPECT with pentavalent 99mTc DMSA|"A dose of 555-740 MBq 99mTc (V) DMSA is injected into a peripheral vein. Delayed brain SPECT/CT images will be obtained at 2-3 h after injection. Imaging will be performed on a hybrid dual head SPECT/CT machine (Symbia T, Siemens, Erlangen, Germany) fitted with a low energy high-resolution collimator, using 15% energy window set at 140 keV.~SPECT images are acquired in a noncircular 360° arc for a total of 64 frames, 25-s/frame, using a 128 × 128 matrix size. Following SPECT acquisition, low-dose CT is acquired for anatomical localization and attenuation correction. The used CT parameters are: tube voltage 130 kV, tube current 80 mA, and slice thickness 1 mm. Images will be reconstructed using manufacturer's iterative protocol (four iterations, four subsets, and Gaussian filter 8 mm). The reconstructed images will be reviewed on a viewing workstation running OsiriX MD version 6.5.2 (Pixmeo, Bernex, Switzerland)."
41512193|NCT03135002|OTHER|Other|
41512194|NCT02297399|DRUG|PEG-ascorbate 2L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
40858999|NCT04195217|BEHAVIORAL|Art therapy|"When the patient is placed in a treatment room, a nurse or the ARC proposes to complete the questionnaires corresponding to his visit in accordance with the diagram of the investigations, then retrieve the questionnaire and forward it to the art therapist Then, the art therapist intervenes ans propose different Artistic supports : paint, watercolor pencils, pastels, pencils, clay , origami, music in as an accompaniment to artistic creation.~The workshop runs from 30 minutes to 2:30. It can be cut by doctors and nurses interventions during medical care. The limit of care is set at 2:30 for reasons of concentration of the patient, organization of the service but the patient is an actor of his care, and chooses when the session ends.~At the end of intervention, the nurse or the ARC proposes at patient to complete the end questionnaire. Theses last are retrieve it and to forward it to the art therapist."
40859000|NCT02625844|OTHER|No intervention|No intervention administered in this study.
40859001|NCT01641601|DEVICE|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
40859002|NCT02689115|OTHER|Genetic relative expression|The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
41167163|NCT06416319|DEVICE|Daily Activity Goal and Feedback|The daily activity target is a fixed number of steps. The exact number of steps is determined beforehand as part of the case number planning in a pilot study with ten participants and adjusted if necessary. The activity target we suggest is 8000 steps. In addition, the participants receive feedback several times a day about the steps needed to reach the goal and whether they have ultimately reached the daily goal.
40859003|NCT04428957|OTHER|Telemonitoring|Daily telemonitoring of heart rate (HR), blood pressure (BP), pulse oximetry (SpO2), spirometry (FVC), activity (accelerometry) and severity of cough and dyspnea
40859004|NCT04967404|DIETARY_SUPPLEMENT|Phosphatidylserine|800 mg per day for 10 days
40859005|NCT00660179|DRUG|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
40859006|NCT00660179|DRUG|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
40859007|NCT00660179|DRUG|placebo|Matching placebo, once daily
41167164|NCT05661253|DRUG|25 ml of bupivacaine 0.25% via serratus anterior block|patients will receive conventional serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia,
41167165|NCT05661253|DRUG|25 ml of bupivacaine 0.25% via modified serratus anterior palne block|patients will receive modified serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia.
41167166|NCT04744805|OTHER|face mask or not|long term face mask wear
41167167|NCT02647788|DRUG|Acetaminophen/Ibuprofen|After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
41167168|NCT02647788|DRUG|Acetaminophen/Codeine|After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
41167169|NCT05832619|DRUG|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
41167170|NCT05832619|DEVICE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
41167171|NCT05832619|DEVICE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
41039258|NCT06580574|PROCEDURE|Radical surgery|Radical surgery will be recommended per local treatment standards.
41039259|NCT05646186|DIETARY_SUPPLEMENT|Personalized dietary intervention based on microbiome analysis|Personalized dietary intervention based on individual microbiome analysis
41039260|NCT05646186|DIETARY_SUPPLEMENT|Low-FODMAP diet|Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet
41512195|NCT02297399|DRUG|PEG 4L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
41512196|NCT01314937|DRUG|Mebendazole|Single-dose 500 mg mebendazole tablet
41512197|NCT01314937|OTHER|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
41512198|NCT00614640|BIOLOGICAL|DermaVir patch|DNA Vaccine
41512199|NCT00614640|BIOLOGICAL|Placebo patch|10% dextrose (D-glucose) solution
41512200|NCT00316927|DRUG|acetylsalicylic acid|
41512201|NCT00316927|DRUG|dexamethasone|
41512202|NCT00316927|DRUG|diethylstilbestrol|
41512203|NCT02468050|BEHAVIORAL|Moderate intensity exercise training|6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
41512204|NCT02468050|BEHAVIORAL|Self Management of exercise|In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
41512205|NCT00269425|BEHAVIORAL|American Heart Association Step 2 diet|Low fat diet with patient education and diet analysis
40859008|NCT04852939|OTHER|Bowen's technique|"Initially, cup move is performed which requires a vertically rolling Bowen move over the posterior border of the deltoid muscle above the axillary crease.~The subject's arm is held flexed at 90 degrees at mid-chest height. Then, the elbow is slowly and passively moved in the direction of the opposite shoulder.~After maximal adduction of the arm, the therapist firmly taps the lateral aspect of the shoulder with the heel of his/her hand.~The arm is then carried back to the original start position, where the therapist gently moves superiorly and slightly laterally over the anterior fibers of the deltoid. The arm is then carefully lowered.~The therapist strives to undertake a minimum of moves and procedures to trigger the body's own self-healing powers and assess how much pressure to use and where and when to perform a move to release the build-up of stress.~40-minute sessions thrice a week for 6 weeks."
40859009|NCT04852939|OTHER|Conventional physical therapy|"* Hot pack and transcutaneous electrical nerve stimulator (TENS) for 15 minutes.~* Pendulum stretch, 10 revolutions.~* Cross body stretch, 4 repetitions.~* Towel stretch/hand behind the back, 4 repetitions.~* Isometric internal and external rotation exercises. 40-minute sessions thrice a week for 6 weeks."
40859010|NCT00765063|DRUG|Fragmin|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
40859011|NCT05705557|DEVICE|ABSOLOK™ Clip System|Use of ABSOLOK™ Clip System during parenchymal transection for open liver resection
40859012|NCT00954499|BEHAVIORAL|Tactile stimulation added to Standard care|"* Parent rubs the infant's skin near the injection site just before, during and after the injection.~* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close."
40859013|NCT00954499|BEHAVIORAL|Standard care|"* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close."
40859014|NCT01177189|DIETARY_SUPPLEMENT|Vitamins C, E, and alpha lipoic acid|Oral antioxidant cocktail or placebo to be consumed daily
40859015|NCT00823667|OTHER|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
40859016|NCT00823667|OTHER|medical chart review|Occurs at 1 year post study enrollment
40859017|NCT00823667|OTHER|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
40859018|NCT00823667|PROCEDURE|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
41039261|NCT05572138|DIAGNOSTIC_TEST|Body Impedance Analysis|Body Impedance Analysis
41039262|NCT06257069|DEVICE|Tremor Retrainer Smartphone Application|The Tremor Retrainer smartphone application uses the smartphone's built-in accelerometer to calculate a patient's tremor frequency when the smartphone is strapped to the patient's wrist. The application will provide auditory cues to the patient with a treatment frequency at 2/3 the patient's baseline tremor frequency for half a session, then 1/3 the patient's baseline tremor frequency for the second half of the session. Meanwhile, oscillatory movements will be continuously analyzed with frequency calculated and displayed relative to goal frequency, so that the patient receives continuous feedback via a visual dial as to whether they are meeting treatment goals. Intervention will consist of a one-week Tremor Retrainment Protocol.
41039263|NCT05211765|DIAGNOSTIC_TEST|Superior vena cava transthoracic evaluation|The superior vena cava will be observed with a cardiac ultrasound machine, its diameter in different respiratory phases evaluated and compared with fluid response.
41039264|NCT04608370|BEHAVIORAL|Active tPBM session|In this project, taking the method of random, double blindness and control, participants in the active tPBM group will take active tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
41512206|NCT00269425|BEHAVIORAL|Mediterranean diet|Mediterranean style diet with patient education and diet analysis
41512207|NCT06438835|DIAGNOSTIC_TEST|PneuFlex AFO Assist|It features a pneumatic artificial muscle designed to enhance ankle foot orthosis functionally for patients with mobility issues.
41389778|NCT03956901|OTHER|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \\ kg crystalloid infusion to be started~If PVI \<13 MAP is \<65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI \<13 MAP\> 65 mmHg to continue fluid infusion If PVI\> 13 MAP \<65 mmHg, 250 ml bolus crystalloid \\ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI \<13.~PVI\> 13 MAP \<65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl \<13."
41389779|NCT00431236|DRUG|Oral Casopitant (GW679769)|
41389780|NCT00431236|DRUG|IV Casopitant (GW679769)|
41389781|NCT00431236|DRUG|IV ondansetron hydrochloride|
41389782|NCT00431236|DRUG|Oral dexamethasone|
41389783|NCT05699811|BIOLOGICAL|MSC-IFNα|MSC-IFNα form a dose of 2×10\^6 cells/kg, intravenous infusion every 4-6 weeks
41389784|NCT05699811|DRUG|Nab paclitaxel|125mg/m2, intravenous infusion every 4-6 weeks
41389785|NCT05699811|DRUG|Cyclophosphamide|200mg/m2, intravenous infusion every 4-6 weeks
41389786|NCT05699811|DRUG|Anti-PD-1 monoclonal antibody|200mg, intravenous infusion every 4-6 weeks
41389787|NCT02139085|DEVICE|GSV Electrocoagulation|The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.
41167172|NCT00610025|PROCEDURE|Transgastric access to the abdomen|Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
41389788|NCT02139085|DEVICE|GSV Radiofrequency|The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
41389789|NCT03649256|DIAGNOSTIC_TEST|Thickness of lower uterine segment scar|Ultrasound measurement of thickness of the uterine scar at 3 and 6 months
41389790|NCT01900392|BEHAVIORAL|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
41389791|NCT02252497|DRUG|Active comparator : Tranexamic Acid (Exacyl)|"* 1g Exacyl Intra Venous, just before surgery~* Then infusion of 1g of Exacyl over eight hours ."
41389792|NCT02252497|DRUG|Placebo comparator : physiologic serum|"* 1g Intra Venous just before surgery~* Then infusion of 1g of physiologic serum over eight hours"
41389793|NCT01456000|DEVICE|EAS-AC (HeartLight)|Pulmonary vien isolation
41389794|NCT01456000|PROCEDURE|Control Arm Ablation|Treatment with standard ablation.
41167173|NCT04578418|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Hydrolyzed collagen supplementation twice daily
41167174|NCT04578418|OTHER|Heavy slow resistance training|Heavy slow resistance training 3 times weekly
41389795|NCT03726086|DIAGNOSTIC_TEST|laryngoscopy|A flexible camera (fiberoptic endoscope) is placed in the patient's nose to view the nose, throat, and airway.
41389796|NCT03850262|RADIATION|MRI|"The study will be done on 1.5T MR unit (Siemens) and 1.5T MR unit (Philips) at Assuit University Hospital, or 1.5T MR unit (G.E.) at Eman General Hospital.~* The field of view varied between 14 cm and 16 cm, and slice thickness varied between 3 and 4 mm, with 0.5 mm intersection gap.~* Imaging sequences included sagittal PD proton density, T2 and STIR, axial PD, coronal STIR and coronal oblique."
41389797|NCT02378467|DRUG|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
41167175|NCT04578418|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation twice daily
41167176|NCT05084599|DRUG|Metaraminol 2.7μg/kg/min|After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
41167177|NCT05084599|DRUG|Metaraminol 2μg/kg/min|After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.
41167178|NCT03217461|PROCEDURE|CorneaL epithelial autograft|After removal of the recipient's diseased dermoid, a size-match donor epithelial tissue will be obtained from the healthy area of the same eye (corneal epithelial autograft) using femtosecond laser technology, with the goal of closure of bare stromal area by sutured corneal epithelial tissue to ensure the integrity of ocular surface. This closure may also create a microenvironment that stimulates stromal cells' regenerative capacity and regulates their epithelial-mesenchymal transition process.
41389798|NCT02378467|DRUG|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
41389799|NCT00291512|BEHAVIORAL|Theory-based counseling program|
41389800|NCT06461676|DRUG|Ventrix Bio Extracellular Matrix|VentriGel will be administered by injection into the right ventricle of the heart in the following defined doses per injection. There will be a total of 8 injections. The proposed dose of up to 0.6 mL is administered as up to 8 sequential injections of 4 injections of 0.1 mL each and 4 injections of 0.05 mL each.
41389801|NCT04214418|DRUG|Cobimetinib|(40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2
41389802|NCT04214418|DRUG|Hydroxychloroquine|(600mg) orally twice daily on days 1-28 of each 28-day cycle
41389803|NCT04214418|DRUG|Atezolizumab|840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)
41389804|NCT04114526|OTHER|Nicotine Replacement Therapy|"CHAs meet with all interested residents to discuss taking steps towards quitting. The CHAs follow a four step program with all participant 1) get to know the resident and their smoking, 2) Assess what the resident is ready to do to take steps towards quitting, 3) discuss using nicotine replacement therapy (NRT) in the form of patches, gum or lozenges, 4) set one goal for taking steps towards quitting. CHAs will attempt to follow up with participants after the initial encounter. There is no limit on the number of times the CHA may talk with the participants. Some follow interactions will be brief encounters in the neighborhood, while others will be at scheduled. All contacts with each participant will be tracked.~We will provide up to 6 weeks of NRT patches, gum and lozenges to participants who are interested in using NRT to help them quit."
41389805|NCT06566794|DRUG|Caffeine Tablet|0,5 x 100 mg tablet (50 mg caffeine).
41389806|NCT06566794|DRUG|Bupropion Hydrochloride Capsels|1 x 20 mg tablet.
41389807|NCT06566794|DRUG|Repaglinide Capsels|1 x 0,05 mg tablet.
41389808|NCT06566794|DRUG|Flurbiprofen Capsels|1 x 10 mg tablet.
41389809|NCT06566794|DRUG|Omeprazole 10 MG|1 x 10 mg tablet.
41389810|NCT06566794|DRUG|Dextromethorphan Oral Solution|5,0 ml of 2 mg/ml oral solution (10 mg dextromethorphan).
41389811|NCT06566794|DRUG|Midazolam oral solution|0,5 ml of 2 mg/ml oral solution (1,0 mg midazolam).
41389812|NCT06566794|DRUG|Simvastatin tablets|1 x 10 mg tablet.
41389813|NCT06566794|DRUG|Placebo|2 x placebo tablets in the Placebo Phase/Arm
41389814|NCT06566794|DRUG|Carvedilol|2 x 25 mg tablets
41389815|NCT06566794|DRUG|Diclofenac|1 x 50 mg tablet (three times daily for three days)
41389816|NCT00176501|BIOLOGICAL|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
41389817|NCT05590325|DRUG|Dolutegravir|"Single dose of the DTG-DT in two sequential cohorts and multiple-doses of the DTG-DT or DTG-ODF in a two cohorts.~Qualitative Acceptability will be collected from mothers and health workers in structured discussion guides."
41389818|NCT05627349|DEVICE|wrist splinting|standard wrist splinting at night for 2 weeks
41389819|NCT05627349|DEVICE|FSN|FSN is a single-use disposable needle(Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.). The needle body is solid, and covered with a plastic tube. The needle penetrates the skin with insertion device. Under the guidance of ultrasound, the needle enter the loose subcutaneous layer obliquely without penetrating into the muscle. This is the difference from traditional acupuncture. The insertion point is midpoint of the anterior forearm. The needle tip is toward the carpal tunnel. After the needle is inserted, SM and RA are performed. The frequency of SM is 200 times in two minutes. The method of SM is to make a horizontal fan swaying with the base of the needle as the fulcrum. RA is performed while SM-slowly make a fist for 10 seconds and then relax for 5 seconds. Eight times of RA in two minutes. After the FNS treatment, the needle was withdrawn.
41389820|NCT06538805|OTHER|Minimal invasive management of dental caries|Minimal invasive management of dental caries among dentists
41389821|NCT06107959|OTHER|Pre-surgical nutrition, hydration, RMR, and body composition assessments|Urine sample, InBody device platform, Metabolic cart with hood to collect RMR.
41389822|NCT06107959|OTHER|Post-surgical nutrition, hydration, RMR and body composition assessments|Same as pre-surgical tests at 1 week, 3 weeks, 6 weeks, and 12 weeks follow up time points.
41389823|NCT02756078|DEVICE|TEST Contact Lens|
41389824|NCT02756078|DEVICE|CONTROL Contact Lens|
41389825|NCT05764434|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)
40859019|NCT00823667|PROCEDURE|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
41389826|NCT05884138|OTHER|exercise and nutritional support|resistance exercise and protein supplementation including branched chain amino acids for 12 weeks
41389827|NCT02056431|BEHAVIORAL|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
41389828|NCT04493099|DRUG|Alvocidib Hydrochloride|Given IV
40859020|NCT00823667|PROCEDURE|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
40859021|NCT05950984|OTHER|Drug Infusion Pump Monitoring|Intravenous vancomycin administration accuracy will be determined by comparing data obtained from drug infusion pumps with manually input administration times from the electronic Prescribing and Medicines Administration (ePMA) system.
41389829|NCT04493099|DRUG|Decitabine|Given IV
41389830|NCT04493099|DRUG|Venetoclax|Given PO
41389831|NCT02780999|DEVICE|Whale orthosis|Participants will be teach how to use the Whale orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain
41389832|NCT02780999|DEVICE|Colditz orthosis|Participants will be teach how to use the Colditz orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain.
41389833|NCT01094509|BEHAVIORAL|Tai Chi|Tai Chi classes and exercises
41389834|NCT01094509|BEHAVIORAL|Guided autobiography|Autobiographical writing in class and at home
41389835|NCT01094509|BEHAVIORAL|Qigong|Qigong classes and exercises (exploratory)
41167179|NCT03217461|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
41389836|NCT01094509|BEHAVIORAL|Successful aging|Seminar series on the theme of successful aging
41389837|NCT01094509|BEHAVIORAL|Combination|Combination of Tai Chi exercises and autobiographical writing
41389838|NCT01094509|BEHAVIORAL|Comparison|No assigned behavioral activity (exploratory)
41389839|NCT04900415|DRUG|Vitamin A|Metabolic supplement for neurogenesis at the olfactory apparatus
41389840|NCT04900415|DEVICE|Electronic portable aromatic rehabilitation (EPAR) diffuser|Handheld essential oil ultrasonication diffuser technology
41389841|NCT05396443|BEHAVIORAL|Black Girls for Wellness Telehealth|Weekly for 12 weeks, adolescent-caregiver dyads will attend 1) a live stream group Wellness (mindfulness, nutrition lesson, dance class, program reflection) session (90 min/wk) and 2) a home cooking experience using ingredients sent to participants' homes (60 min/wk) with their caregiver. Others in the home (e.g., siblings) will be encouraged to participate in activities as well.
41389842|NCT02494947|BEHAVIORAL|high intensity interval-based aerobic exercise|Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.
41389843|NCT02494947|OTHER|Usual care|
41389844|NCT02038959|OTHER|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
40859022|NCT06127628|PROCEDURE|Ultrasound-guided scalp block with ropivacaine 0.375%|Scalp block will be performed under USG guidance, using the technique described by Tsan et al. The block needle used will be an echogenic block needle, with a length of 50 mm, and a diameter of 22 G. Trained personnel comprising of the investigators in this study will perform the scalp block. Using ultrasound to identify landmarks, ropivacaine 0.375% will be administered in volumes of 1.5 ml to 3 ml. The nerves targeted will be the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater auricular, lesser occipital, greater occipital and third occipital nerves.
40859023|NCT02918474|OTHER|Decision Aid|Use decision making tool
40859024|NCT02918474|OTHER|Questionnaire Administration|Ancillary studies
41039265|NCT04608370|BEHAVIORAL|Sham tPBM session|In this project, taking the method of random, double blindness and control, participants in the sham tPBM group will take sham tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
41039266|NCT06026410|DRUG|KO-2806|Oral administration
40859025|NCT06273397|DRUG|Acetazolamide 250 MG|Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
40859026|NCT06273397|DRUG|Metolazone 2.5 MG|Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
40859027|NCT06273397|DRUG|Furosemide Injection|Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
40859028|NCT02160652|PROCEDURE|Laparoscopic ureteral re-implantation.|Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
40859029|NCT01858766|DRUG|SOF|400 mg tablet administered orally once daily
41039267|NCT06026410|DRUG|Cabozantinib|Oral administration
40859030|NCT01858766|DRUG|VEL|Tablet administered orally once daily
40859031|NCT01858766|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
41039268|NCT06026410|DRUG|Adagrasib|Oral administration
41167180|NCT03217461|PROCEDURE|Limbal autograft|Simple dermoid excision will be performed, followed by closure of the bare sclera by sutured femtosecond laser-assisted limbal autograft.
41167181|NCT03217461|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
41167182|NCT01143883|OTHER|Silverlon|Silverlon dressings are gauze impregnated with silver ions
41167183|NCT01143883|OTHER|Standard of Care Dressing|Standard dry gauze dressing
41167184|NCT02719925|OTHER|Mg(+)|"* 1,5 L per day during 30 days~* No livestyle counseling"
41167185|NCT02719925|OTHER|Mg(-)|1,5 L water per day during 30 days No lifestyle counseling
41167186|NCT01050361|PROCEDURE|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
41167187|NCT05221437|OTHER|antibiotic prescription|
41167188|NCT01675310|DRUG|medical nutrition therapy + metformin|
41167189|NCT01675310|BEHAVIORAL|Medical nutrition therapy|medical nutrition therapy
41167190|NCT03289702|DRUG|CORETOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
41167191|NCT03289702|DRUG|BOTOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
41167192|NCT00345800|DRUG|Sodium Oxybate (Xyrem)|"* Active Substance: Sodium Oxybate~* Pharmaceutical form: Oral Solution~* Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~* Route of administration: Oral"
41167193|NCT06385041|OTHER|Intervention group 1|Additional exercise program with balance and strength trainings will include 3 times/week. Patients will get an individualized exercise program for frailty syndrome, which will include strength exercises (with elastic resistance bands and weights up to 2kg 30-50% 1RM) and balance training (with unstable surfaces). The program will be performed by 3 sets with 10 repetitions 3 times/week 30-45 minutes.
41167194|NCT06385041|OTHER|Intervention group 2|Additional exercise program with balance and strength trainings will include 3 times/week 30-45 minutes. Patients will get an individualized program for frailty syndrome, with interactive technologies: gait training with Biodex GaitTrainerTM3 with visual, audio feedback and incline up to 10-15 min, Zebris FDM-T, with virtual barriers, thus simulating real environment for the patient, while performing a cognitive task up to 10-15 min, for balance training we will use a computerized Biodex board. Exercises will be performed with the programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training. For strength training we will use equipment HUR based on pneumatic (air pressure) technology. For strength training intensity 30-50% 1-RM, 10 repetitions with 3 sets. Leg press, leg extension, leg abduction, leg adduction will be performed with pneumatic technology.
41167195|NCT02712307|DRUG|Phenoxymethylpenicillin|
41167196|NCT01579721|PROCEDURE|Single Incision Laparoscopic Surgery|Single incision laparoscopic surgery for rectal cancer
41389845|NCT00422773|DRUG|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
41167197|NCT04666376|OTHER|evaluation of the effectiveness of vitrification technique on ovarian tissue quality|there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.
41389846|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low and epinephrine (T1)|A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.
41389847|NCT03399435|COMBINATION_PRODUCT|Bupivacaine low combined with epinephrine (C1)|A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.
40859032|NCT06122974|DEVICE|Drug Eluting Temporary Spur Stent System|The Spur Stent consists of a sirolimus coated stent and balloon that is retrievable after delivery of the sirolimus formulation.
40859033|NCT06122974|DEVICE|Percutaneous Transluminal Balloon Angioplasty|A balloon catheter is inserted across a lesion and inflated to fracture and compress the plaque, creating a larger lumen and improved blood flow through the artery.
40859034|NCT01517555|DRUG|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
41167198|NCT05614323|OTHER|Interview and determining taste and smell with taste strips and Sniffin' Sticks|The Patient-Generated Subjective Global Assessment (PG-SGA) Short Form will be filled in by the participants. Next, a semi-structured in-depth interview will be performed in a quiet environment. The interview will take a maximum of one hour and will take place once. Topics that will be discussed are eating-related problems, the taste and smell of the offered hospital food, the choice in hospital food, the ambience during the eating moments, the use of protein-enriched snacks, the difference between eating at home and at the hospital, personal tips- and-tricks to maintain adequate nutritional intake, and how patients' think that food enjoyment can be improved in the hospital. The interview will be recorded. At last, taste and smell will be objectively determined with respectively taste strips and Sniffin' Sticks.
41167199|NCT02974309|BEHAVIORAL|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
41167200|NCT02974309|BEHAVIORAL|Routine|All youth in this condition are asked to follow the routines set by their clinical care team.
41167201|NCT05054465|DRUG|Navitoclax|P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD
40859035|NCT01517555|DRUG|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
40859036|NCT01517555|DRUG|paracetamol|One single dose of 1 g. Tablet
40859037|NCT02830321|OTHER|helicopacter pylori stool antigen test (CER TEST BIOTEC)|Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
40859038|NCT00313105|DRUG|Smokeless tobacco (Oliver Twist pellets)|individual visits with counseling
40859039|NCT00313105|BEHAVIORAL|smoking cessation counseling|individual visits
40859040|NCT02153580|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
40859041|NCT02153580|DRUG|Bendamustine Hydrochloride|Given IV
40859042|NCT02153580|DRUG|Cyclophosphamide|Given IV
40859043|NCT02153580|DRUG|Etoposide|Given IV
40859044|NCT02153580|DRUG|Fludarabine Phosphate|Given IV
40859045|NCT04706481|PROCEDURE|Specimen Collection|Specimens obtained from surgical, phlebotomy or other non-invasive procedure
40859046|NCT04573686|DRUG|Erythropoietin|Erythropoietin will be given subcutenous to all patients
40859047|NCT01377662|DRUG|OND-PR002 and MPh-IR|"Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR"
41167202|NCT05054465|DRUG|Venetoclax|P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD
41167203|NCT04317001|DRUG|Modafinil|Treatment will be with 100mg of modafinil for the two week primary phase of the study
41167204|NCT04317001|DRUG|Placebo|placebo
41389848|NCT03399435|COMBINATION_PRODUCT|Bupivacaine high combined with epinephrine (C2)|A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.
41389849|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low (T2)|A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.
41389850|NCT03399435|DRUG|Bupivacaine low (C3)|A single injection: Bupivacaine from 10 to 80 mg.
40859048|NCT01377662|OTHER|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
40859049|NCT01455896|DRUG|ITCA 650|ITCA 650
40859050|NCT01455896|OTHER|ITCA placebo|ITCA placebo
40859051|NCT06293313|PROCEDURE|Mindfulness training|Before starting the study, an appointment will be made to meet with the students participating in the mindfulness group with randomization on the specified day and time. The students and the researcher will meet in a quiet, calm room of the school. Students will be informed about the practice of mindfulness and their written and verbal consents will be obtained before participating in the study. Then, a pre-test will be applied to the students who agree to participate in the study.
40859052|NCT06293313|OTHER|Will not be given any application|Before starting the research, the students in the control group determined by the randomization method will be informed about the research. Written and verbal consent will be obtained from the students that the students agree to participate in the research. Afterwards, students will meet in a quiet and calm room of the school on the specified day and time. Before starting the research, students will be given a pre-test. A mid-term test will be performed 8 weeks after the pre-test.
41389851|NCT03399435|DRUG|Bupivacaine high (C4)|A single injection: Bupivacaine 100 mg.
40859053|NCT00769912|DRUG|50% N2O- 50%O2 mixture|50% N2O- 50%O2 mixture administration
40859054|NCT00769912|DRUG|Placebo (air)|Placebo administration during the intervention
40859055|NCT06245252|OTHER|passive stretching for group A|A description of stretch is performed 3 times per week for 12 weeks. The stretches included (in the order they were applied): Seated knee flexor (bilateral); Seated knee flexor-hip adductor (bilateral); Seated shoulder lateral flexor (bilateral); Supine hip flexor- knee extensor (unilateral). Seated hip external rotators, extensor (unilateral); Seated shoulder extensors, adductors, retractors (unilateral). Supine knee flexor-plantar flexor (unilateral); Prone hip flexor (unilateral); Seated shoulder flexors, depressors (bilateral); Seated shoulder and elbow flexors (unilateral).
40859056|NCT06245252|OTHER|electrical stimulation for group b|reated by 30 minutes electrical stimulation three times per week for 12 weeks
40859057|NCT02334293|DRUG|Omegaven|Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
40859058|NCT05542758|OTHER|Total Body HIIT Program|One repetition maximums (1RM) and body weight (BW) will be recorded at prior to and at 6 weeks to tailor the program. The circuit will be completed twice during each session and the exercises will include: squats, medicine ball forward chest throws, medicine ball overhead throw, farmers walk, seated shoulder press, seated row sitting on a fitness ball, aerobic riser step-ups, foot ladder drills, and twisting medicine ball passes. The anaerobic component will be completed once during a session and on a stationary bike. The progression of exercise:rest seconds will be 20:40 for Weeks 1-4, 30:30 for Weeks 5-8, and 40:20 for Weeks 9-12. Each session will start with a 5 minute warm up and end with a 5-minute cool down. Participants will be given real time feedback about heart rate (goal range: 85-95% HRmax) and exercise movement velocity. Participants will be encouraged to surpass the velocity of the previous repetition.
40859059|NCT02553395|DEVICE|Phenacite (Test) contact lens|
41389852|NCT03399435|DRUG|Neosaxitoxin (T3)|A single injection: Neosaxitoxin will be between 1.25 and 60 µg.
41389853|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with epinephrine (T4)|A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.
41389854|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low and epinephrine|A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.
40859060|NCT02553395|DEVICE|comfilcon A contact lens|
40859061|NCT06020703|BEHAVIORAL|Fermented Food Diet|Subjects will incorporate 1 serving of fermented food a day and increase to 6 more each day as tolerated for 4 weeks. After the initial 4 weeks, subjects will eat 6 or more servings of fermented foods each day for 8 weeks.
40859062|NCT05981482|DIAGNOSTIC_TEST|OxVPS|Comparing a new screening tool, the Oxford visual perception screening, to the gold standard, Rivermead Perceptual Battery Assessment.
40859063|NCT01404780|DEVICE|GlideScope (GVL)|The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
40859064|NCT01404780|DEVICE|Macintosh Direct Laryngoscope (MDL)|Current standard of care at UHN for 50 years
41389855|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low|A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).
40859065|NCT05432752|DEVICE|Concussion Pen|Device will measure the distance from the eye to the Concussion Pen for ocular motor functions.
40859066|NCT04295525|DIETARY_SUPPLEMENT|400 mg mucoadhesive oral tablet|AqualiefTM (Metis Healthcare s.r.l., Milano, Italy)
41039269|NCT01785966|BEHAVIORAL|Daily checklist and clinician prompting|"Interventions are:~Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.~Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items."
41167205|NCT05592236|OTHER|Dynamic compression garments|Dynamic compression garments for 2 hours a day in addition to standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
41167206|NCT05592236|OTHER|Standard therapy|Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
40859067|NCT04295525|DIETARY_SUPPLEMENT|placebo mucoadhesive oral tablet|placebo
40859068|NCT02581735|OTHER|Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
40859069|NCT03406013|BEHAVIORAL|Written Information|Receive written information on diet and exercise relevant to older men with prostate cancer
40859070|NCT03406013|BEHAVIORAL|Prescription|Participants receive tailored exercise prescription and tailored diet recommendations
41389856|NCT05847569|BIOLOGICAL|Belantamab Mafodotin|Given IV
40859071|NCT03406013|BEHAVIORAL|Technology|Participants receive motivational text messages and can electronically log and track their exercise and diet habits
40859072|NCT03406013|BEHAVIORAL|Coaching|Participants receive access to an exercise and diet coach to provide advice by phone and/or email
41389857|NCT05847569|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
41389858|NCT05847569|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
41389859|NCT05847569|PROCEDURE|Bone Marrow Biopsy|Undergo biopsy
41389860|NCT05847569|PROCEDURE|Computed Tomography|Undergo CT scan
41389861|NCT05847569|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
41389862|NCT05847569|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
41389863|NCT02022410|OTHER|CAS after primary and revision TKA|CAS and RAPT
40859073|NCT03293030|DRUG|Dupilumab|Dupilumab treatment
40859074|NCT00377208|BEHAVIORAL|Web-Based Intervention|"My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor."
40859075|NCT05802862|DRUG|Insulin Degludec and Insulin Aspart|administered subcutaneously, once a day
40859076|NCT01744548|BEHAVIORAL|tCBT treatment|The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
40859077|NCT05297591|OTHER|assessment of UL function and prognostic factors|clinical assessments and questionnaires
40859078|NCT06337812|DIETARY_SUPPLEMENT|Potato Starch|"Participants will consume 10 grams (1/2 a packet) of Bob's Red Mill Potato Starch twice a day for the first 7 days and then increase to 20 grams (full packet) of potato starch for approximately 3 weeks. Potato starch can be mixed into cold food or beverage for consumption.~In addition, participants will have evaluations and provide blood and stool samples during the study."
40859079|NCT01887184|DRUG|Dexmedetomidine|Dexmedetomidine 1.5mcg/kg was given intranasally
40859080|NCT01887184|DRUG|Placebo|Intranasal saline was given
40859081|NCT00904904|DRUG|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
40859082|NCT00904904|DRUG|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
40859083|NCT01284023|OTHER|Shaving|Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
40859084|NCT00467129|GENETIC|microarray analysis|
40859085|NCT00467129|GENETIC|mutation analysis|
40859086|NCT00467129|GENETIC|polymerase chain reaction|
40859087|NCT00467129|GENETIC|polymorphism analysis|
40859088|NCT00467129|OTHER|laboratory biomarker analysis|
40859089|NCT00467129|OTHER|questionnaire administration|
41039270|NCT04940429|DEVICE|Neurofit|This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.
41039271|NCT04940429|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score|During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.
41039272|NCT01060293|DRUG|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
41039273|NCT01060293|DRUG|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
41167207|NCT02602353|DRUG|Loxoprofen Pain Patch|One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days
41167208|NCT02602353|DRUG|Placebo Patch|One Placebo Patch applied daily for 3 days
41167209|NCT02602353|DRUG|No Treatment|No Treatment for 3 days
41389864|NCT00538707|BEHAVIORAL|2-minute Bondet test|2-minute Bondet test
41389865|NCT01696227|DRUG|Nissle 1917|Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
41167210|NCT02490605|PROCEDURE|occlusal plate group|occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
40859090|NCT05490576|RADIATION|[18F] PI-2620 Tau Ligand|Tau binding ligand
40859091|NCT02737345|OTHER|Rotem|
40859092|NCT03315039|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
40859093|NCT05377138|OTHER|Online PEP/PrEP delivery|Delivery of PEP or PrEP after online consultation and HIVST image upload.
40859094|NCT02575170|DRUG|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
40859095|NCT02575170|DRUG|Ringer's lactate solution|200 ml of Ringer's lactate solution
40859096|NCT00592904|DRUG|E2007|Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
40859097|NCT01009606|OTHER|Usual strategy|Usual strategy
40859098|NCT01009606|OTHER|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
40859099|NCT00217568|BIOLOGICAL|pegfilgrastim|
40859100|NCT00217568|DRUG|carboplatin|
40859101|NCT00217568|DRUG|docetaxel|
40859102|NCT05099796|PROCEDURE|Transforaminal epidural steroid injection|
40859103|NCT05099796|PROCEDURE|Caudal epidural steroid injection|
40859104|NCT03723369|DEVICE|accupuncture|accupuncture
41512208|NCT02831426|DEVICE|Two-stage with Acellular Dermal Matrix (CELLIS® Breast)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by an ADM (CELLIS® Breast, MECCELLIS BIOTECH, 40 rue Chef de Baie, 17000, La Rochelle FRANCE) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
41528425|NCT02560922|BEHAVIORAL|Pain Coping Skills Training (CST)|The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
40859105|NCT00896025|DRUG|N-acetylcysteine|"Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.~NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.~i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour~ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours~iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours~iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours~v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours"
41389866|NCT06047301|BEHAVIORAL|Pathways|Delivered by a nurse or other healthcare provider, includes 2 in-person sessions, and phone check-ins, and occurs primarily during infusion visits. Includes a Pathways Toolkit with handouts on values and goal setting, as well as resources on symptom management, lung cancer stigma, communication strategies, and other cancer center resources.
40859106|NCT02502942|BEHAVIORAL|Upper Airway Muscle Exercise|Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.
40859107|NCT02502942|BEHAVIORAL|Sham Exercise|Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
41389867|NCT06047301|BEHAVIORAL|Enhanced Usual Care|Pathways Toolkit handouts on symptom management, lung cancer stigma, communication strategies, and other cancer center resources provided to participants. The Toolkit will be reviewed with patients in person to orient them to its purpose and contents.
41528426|NCT03436654|DRUG|Apalutamide|240mg daily orally
40859108|NCT05458804|DEVICE|VR training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different paces and intensities of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
40859109|NCT04375059|OTHER|using interactive attention training system|using the interactive attention training system to children with Attention Deficit Hyperactivity Disorder
40859110|NCT04579159|DEVICE|Preventicus heartbeat app in combination with wearables|CE certified devices
41389868|NCT04624841|DRUG|Indocyanine Green|2.5-7.5 mg (0.05 mg/kg) injection
40859111|NCT01247168|DRUG|AZD2461|oral capsules, continuous dosing and intermittent dosing
40859112|NCT03975686|OTHER|neuromuscual realigning exercise|neuromuscular realigning exercise
41389869|NCT02267759|DEVICE|McGrath videolaryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, McGrath videolaryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
41389870|NCT02267759|DEVICE|Macintosh laryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, Macintosh laryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
41389871|NCT06058507|DIAGNOSTIC_TEST|CT angiography|No intervention was made
41389872|NCT04567173|DRUG|Anti-SARS-CoV-2 convalescent plasma|convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19
40859113|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (TG form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
41039274|NCT01060293|DRUG|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
41039275|NCT00177554|DRUG|Chemotherapy and Radioimmunotherapy|CHOP-R x 3 cycles followed by zevalin and extended rituximab
41389873|NCT00264082|DRUG|Zometa(drug)|
41389874|NCT01614925|DEVICE|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
41389875|NCT01614925|PROCEDURE|Periodontal surgery|Periodontal surgery alone
41389876|NCT05672160|DIAGNOSTIC_TEST|CT evaluated sarcopenia|At L3 level of CT scan we will measure the area and density of muscles and fat tissue. We devided the patients to sarcopenia and non-sarcopenia groups according to these values.
40859114|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (EE form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
40859115|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 [MaxSimil (MAG form of omega-3)]|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. At each blood draw time points, a questionnaire will be administered to the particpant to monitor if they experiencec side effects with the dietary supplement they ingested in the morning."
41039276|NCT01421563|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
41039277|NCT03139487|DRUG|Rivaroxaban|15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks
41039278|NCT03139487|DRUG|Dalteparin|200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks
41039279|NCT03139487|DRUG|apixaban|10 mg q12 hours for 7days followed by 5mg q12 hours for 21 weeks
41512209|NCT02831426|DEVICE|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by a Titanium Coated Polypropylene Mesh (TiLOOOP® Bra, pfm medical, ag Wankelstraße 60 ,50996 Köln GERMANY) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
41512210|NCT02287714|PROCEDURE|Instep without gastrocnemius recession|Patient will receive an instep plantar fascial release without gastrocnemius recession.
41512211|NCT02287714|PROCEDURE|Instep with gastrocnemius recession|Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
41528427|NCT03436654|DRUG|Abiraterone Acetate|1000mg daily orally
40859116|NCT01999400|DRUG|Pentasa 500 mg capsule x 2 with 240 mL water; single dose|
41039280|NCT06393348|DRUG|HRS-7535|HRS-7535
41039281|NCT06393348|DRUG|Placebo|Placebo
41039282|NCT01656551|DRUG|Gemcitabine|
41039283|NCT01656551|DRUG|Pemetrexed|500 mg/m2 day 1 every 3 weeks
41039284|NCT01656551|DRUG|Cisplatin|60 mg/m2 day 1 every 3 weeks
41039285|NCT04304144|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
41039286|NCT04304144|DRUG|SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)|According to institutional standard of care.
41039287|NCT04304144|DRUG|Daratumumab|Treatment for AL amyloidosis
41039288|NCT00712023|DEVICE|warming device (a reusable, custom-made forced- air warming mattress)|"2=forced-air warming mattress~1=circulating-water mattress"
41039289|NCT02159833|OTHER|Intranasal challenge with active substance (food protein)|
41039290|NCT02159833|OTHER|Intranasal challenge with placebo|
41167211|NCT02490605|PROCEDURE|therapeutic exercises|"The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions"
41167212|NCT02226497|DEVICE|Health Telemonitoring|Use home telemonitoring device
41167213|NCT02226497|OTHER|Quality-of-Life Assessment|Ancillary studies
41167214|NCT02226497|OTHER|Questionnaire Administration|Ancillary studies
41167215|NCT02226497|PROCEDURE|Supportive Care|Receive standard outpatient supportive care
41167216|NCT04657601|DEVICE|DiLumen C2 Endolumenal Interventional Platform|Dual balloon accessory to an endoscope and related instruments
41039291|NCT05066724|DRUG|Centanafadine|400 mg total daily dose Centanafadine Sustained Release, oral tablets
41039292|NCT06046053|DRUG|Placebo Vaginal Film with Square Corners|"2 x 2 placebo vaginal film with square corners"
41039293|NCT06046053|DRUG|Placebo Vaginal Film with Rounded Corners|"2 x 2 placebo vaginal film with rounded corners"
41039294|NCT02239679|DRUG|Aminolevulinic Acid|20% ALA applied to face for one hour prior to 10 J/cm2 blue light
41039295|NCT02239679|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light
41039296|NCT02239679|DEVICE|BLU-U|10 J/cm2 blue light delivered at 10 mW/cm2
41039297|NCT02239679|PROCEDURE|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
41039298|NCT02591654|DRUG|Pembrolizumab|Each patient will receive pembrolizumab 200mg administered as a 30 minute intravenous (IV) infusion every 3 weeks for an indefinite period.
41039299|NCT02591654|DRUG|FLT PET|FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.
41039300|NCT00639873|DRUG|Artesunate|2 or 4 mg/kg/day for 7 days
41039301|NCT00639873|DRUG|quinine-doxycycline|quinine-doxycycline for 7 days
41039302|NCT00717990|DRUG|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
40859117|NCT01999400|DRUG|Apriso 375 mg capsule x 3 with 240 mL water; single dose|
40859118|NCT01999400|DRUG|Lialda 1200 mg tablet x 1 with 240 mL water; single dose|
41389877|NCT00858559|DEVICE|Implantable cardioverter defibrillator with Home Monitoring function|Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
41389878|NCT00858559|DEVICE|Standard implantable cardioverter defibrillator|Implantable cardioverter defibrillators used as standard devices without Home Monitoring
41389879|NCT04529096|DRUG|LY3016859|Administered IV
41389880|NCT04529096|DRUG|Placebo|Administered IV
41389881|NCT03940586|DRUG|Letermovir oral granules|Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
41389882|NCT03940586|DRUG|Letermovir tablet|Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
41512212|NCT05835674|DIAGNOSTIC_TEST|Early intervention program|"At enrollment visit: History and examination, MRI, evaluation of comorbidities, medication and genomic testing. HINE, GMA (if below 5 mo), AIMS, SHAI, PSS and DASS-21 questionnaire.~At 6 mo visit: Examination and evaluation of comorbidities, medication and HINE and AIMS~At 12 mo visit: Examination and evaluation of comorbidities, medication and HINE, AIMS, HAI, PSS and DASS-21 questionnaire.~At 18 mo visit: Examination and evaluation of comorbidities, medication and HINE~At 24 mo visit: Examination and evaluation of comorbidities, medication and HINE, PDMS-2, GMFM-66, BSID-IV-cog, MPOC-20 ,PSS, and DASS-21 questionnaire. GMFCS and Mini MACS if CP."
41512213|NCT05082974|DRUG|OC-01 (varenicline 0.6mg/ml) nasal spray|OC-01 (varenicline 0.6mg/ml) nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of Drye Eye Disease. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
41512214|NCT05082974|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray \[control\]
40859119|NCT01999400|DRUG|Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose|
40859120|NCT00003811|BIOLOGICAL|bleomycin sulfate|
40859121|NCT00003811|DRUG|amifostine trihydrate|
40859122|NCT00003811|DRUG|cisplatin|
41512215|NCT00985244|DRUG|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
41512216|NCT00985244|DRUG|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
41528428|NCT03436654|DRUG|Prednisone|5mg BID orally
40859123|NCT00003811|DRUG|etoposide|
40859124|NCT00003811|PROCEDURE|conventional surgery|
40859125|NCT03060278|BEHAVIORAL|Self-help materials|Self-help smoking cessation materials.
40859126|NCT03060278|DRUG|nicotine patch|Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke \< 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
41389883|NCT03940586|DRUG|Letermovir intravenous|Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
41389884|NCT03283007|DRUG|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
40859127|NCT03060278|OTHER|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
40859128|NCT03060278|BEHAVIORAL|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
40859129|NCT01928927|DRUG|Telmisartan|Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
40859130|NCT03012711|OTHER|Neuromuscular exercise training|
40859131|NCT03690895|OTHER|Retrospective survival analysis|Kaplan-Meier model
40859132|NCT01247194|DRUG|PPI-461|capsule, oral, once daily for 3 days
40859133|NCT01247194|DRUG|Placebo|capsules, oral, once daily for 3 days
41389885|NCT03283007|DRUG|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
41389886|NCT02407756|DRUG|Dupilumab|
41389887|NCT05451134|OTHER|Catecholamines|Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
40859134|NCT00291018|DEVICE|Total Disc Replacement|Total Disc Replacement using ProDisc-C
40859135|NCT00291018|DEVICE|ACDF|Anterior Cervical Discectomy and Fusion
40859136|NCT01301313|DRUG|Levosimendan|Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
40859137|NCT01301313|DRUG|Conventional intensified inotropic treatment|Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
40859138|NCT02524002|DIETARY_SUPPLEMENT|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
40859139|NCT02524002|DIETARY_SUPPLEMENT|Usual clear diet|Usual clear liquids
40859140|NCT05015270|DIAGNOSTIC_TEST|Medications or percutaneous coronary intervention|In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed
40859141|NCT04759105|DRUG|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal/stem cells
40859142|NCT04759105|OTHER|Sham Procedure|anaesthesia, no disc injection, no placebo injection
40859143|NCT04406025|PROCEDURE|participation in Regional Anesthesia Seminar|this group of anesthesiologists attended the Regional Anesthesia Seminar
40859144|NCT04406025|PROCEDURE|no participation in Regional Anesthesia Seminar|this group of anesthesiologists did not attend the Regional Anesthesia Seminar
41389888|NCT01892605|BEHAVIORAL|music listening|The treatment group listened to Mozart K.448 for eight minutes once daily before bedtime for at least six months.
41389889|NCT02998515|DEVICE|Companion (Liquid oxygen device)|
41389890|NCT02998515|DEVICE|Activox (concentrator)|
41389891|NCT05766761|BEHAVIORAL|Intervention condition, the usual prenatal care plus the alcohol intervention|The intervention is theory-driven, based on Motivational Enhancement Theory (MET), and uses motivational strategies to promote alcohol reduction.
41512217|NCT05161910|OTHER|Biomarkers|Kidney biomarkers appear to be useful in differential diagnosis between acute tubular necrosis (ATN) and other types of acute kidney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI).
40859145|NCT06122038|DIETARY_SUPPLEMENT|Tart Cherry Extract Powder|Tart Cherry Extract Powder (NordicCherry, SpecNova, LLC). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
41389892|NCT00720304|DRUG|docetaxel|Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
41389893|NCT00720304|DRUG|erlotinib hydrochloride|oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
41389894|NCT00720304|GENETIC|fluorescence in situ hybridization|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
41389895|NCT00720304|GENETIC|polymerase chain reaction|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
41389896|NCT00720304|OTHER|immunoenzyme technique|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
41389897|NCT00720304|OTHER|immunohistochemistry staining method|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
41512218|NCT02294214|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
41512219|NCT02294214|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
41512220|NCT02294214|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
41512221|NCT00191191|DRUG|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
41512222|NCT00191191|DRUG|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
40859146|NCT06122038|DIETARY_SUPPLEMENT|Placebo|Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
40859147|NCT05049382|PROCEDURE|Extraction of impacted mandibular third molar|surgical extraction of impacted mandibular third molar tooth
40859148|NCT06371846|OTHER|Selected signals from Pacing System Analyzers|Comparative observational, prospective, multicenter study between the signals obtained by PSA vs MPS of consecutive patients who underwent a LBBAP strategy as first intention.
40859149|NCT03948841|OTHER|magnetic resonance imaging|
40859150|NCT00821496|DRUG|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
40859151|NCT00261027|DRUG|Exemestane|
40859152|NCT03932760|BEHAVIORAL|UPLIFT Program|UPLIFT is based on cognitive behavioral therapy and mindfulness-based practices. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
40859153|NCT03932760|BEHAVIORAL|Attention Control Group|Program is based on standard prenatal, childbirth, infant feeding, and parenting education curriculum. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
41512223|NCT00781807|OTHER|multi-module rehabilitation program|"The multi-module rehabilitation program includes:~1. Nutrition management~2. Home-based ergometer training program~3. Psychosocial support"
40859154|NCT06284083|DIAGNOSTIC_TEST|taking a blood sample|Blood samples collected from patienst, only 7 mL
40859155|NCT06104150|OTHER|Intervallic submaximal exercise test|Intervallic submáximal exercise test on a cycle ergometer: 5 min warm-up at 80% of First Lactate Threshold (LT1), and subsequent sets of 1.5 min at 20% above the Second Lactate Threshold (LT2) alternated with recoveries of 5 min at 80% of LT1, ending with a 20 min recovery at 80% of LT1.
41039303|NCT00717990|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
41039304|NCT00717990|DRUG|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
41039305|NCT06013644|DEVICE|Acupuncture needle|a weekly session for 4-6 weeks on needle for each acupoint for at least 20 minutes the included acupoints are ST6, ST7, SI 18, ST 19, GB 2
41389898|NCT00720304|OTHER|laboratory biomarker analysis|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
41512224|NCT05949021|DRUG|Combination of liposomal doxorubicin|Combination of liposomal doxorubicin 30 milligrams per square meter and carboplatin (area under the curve 5), administered every 4 weeks for 4 cycles.
41512225|NCT00290004|DRUG|motexafin gadolinium|
41512226|NCT04944173|DRUG|Durvalumab|Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
41528429|NCT03436654|PROCEDURE|Radical Prostatectomy|A laparoscopic, robotic-assisted, or open approach to RP is permitted at the discretion of the operating surgeon.
41389899|NCT00720304|OTHER|pharmacological study|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
40859156|NCT06335017|DIETARY_SUPPLEMENT|Induction of labor|In both groups the balloon catheter will be removed at nearly 12 hours after insertion. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
41389900|NCT00720304|PROCEDURE|therapeutic conventional surgery|At 6-8 weeks after completion of chemoradiotherapy, patients with N2 or greater cervical lymph node involvement at baseline or with residual disease may undergo surgery.Patients with persistent disease during study therapy undergo salvage surgery 6-12 weeks after completion of chemoradiotherapy.
40859157|NCT04543695|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy|"Radiotherapy:~50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
40859158|NCT04543695|DRUG|XELOX|"Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course"
40859159|NCT04543695|DRUG|mFOLFOX|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
40859160|NCT04543695|PROCEDURE|TME|Total mesorectal excision
41039306|NCT06013644|DEVICE|Dry needle|a weekly session for 4-6 weeks the trigger point is held by thumb and index fingers and the needle approaches the point perpendicular to the skin and rotated clockwise for 2-3 minutes
40859161|NCT04780412|DRUG|Misoprostol|Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.
40859162|NCT04780412|DRUG|Placebo|Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
41039307|NCT06013644|DRUG|Botox Injectable Product|each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
41167217|NCT01498783|DRUG|5-fluorouracil|5-fluorouracil, bolus dose of 500 mg/m\^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
41389901|NCT00720304|RADIATION|intensity-modulated radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
41389902|NCT00720304|RADIATION|radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
41389903|NCT00563524|DRUG|ILV-094|SC and IV administration on days 1, 14, 28, and 42
41389904|NCT06084273|OTHER|Bobath Exercises|"The Bobath approach aims to enhance postural and neuromotor control goal-directedly, leading to functional improvement. Our study selected the Bobath 30 exercises from the fundamental exercises to create a program specific to the goal and targeting functionality.~The ten Bobath exercises performed by all participants in the study are as follows: Bridging Exercise, Latissimus Stretch Exercise, Autoinhibition Exercise, Dorsiflexion Training, Sitting Balance Training, Upper Extremity Weight Shifting Exercise, Lower Extremity Weight Shifting Exercise, Oblique Abdominal Strengthening Exercise, Knee Control Training, and Walking Training."
41389905|NCT06084273|OTHER|Breathing Exercises,Breathing Exercises, Bobath Exercises|"The puckered lip breathing exercise aims to prevent the closure of the small airways by creating pressure during expiration. During the exercise, the individual is asked to follow these steps:~1. Breathe calmly and slowly through the nose.~2. Pucker the lips as if whistling or inflating a balloon.~3. Exhale the breath with puckered lips. Relaxation exercises Progressive Muscle Relaxation Technique: Progressive muscle relaxation is one of the easiest methods to learn and apply, developed by Jacobson. It involves voluntarily tensing and relaxing large muscle groups regularly and sequentially. The participant was encouraged to wear comfortable clothing, breathe deeply, and exhale. The technique can be performed in a sitting or lying position. Music can be played to contribute to the participant's relaxation."
41389906|NCT02800278|OTHER|observational|describe bone status and outcome of odontoid fracture
41389907|NCT02464085|OTHER|Longitudinal evaluation of recovery|Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
41389908|NCT03023007|PROCEDURE|Loco-regional anaesthesia|Loco-regional anaesthesia
41039308|NCT00983073|DRUG|Tapentadol|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
40859163|NCT00694018|OTHER|Education and standard care|Educational program for individuals with chronic back pain.
41039309|NCT01178086|DRUG|Rituximab|Rituximab IV
41167218|NCT02609802|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
41167219|NCT02609802|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
41167220|NCT06235385|OTHER|Intervention not provided|This study is purely observational
41167221|NCT01238393|DRUG|intravitreal ranibizumab|monthly injections x3 +/- 2nd series of 3
41167222|NCT02973802|BIOLOGICAL|ATX-GD-59|Disease specific immune modulating treatment for Graves Disease
40859164|NCT00694018|BEHAVIORAL|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
40859165|NCT00927212|DRUG|AS101 ointment|Twice daily topical application
40859166|NCT00369642|BEHAVIORAL|Cognitive-behavioral therapy|
40859167|NCT04979676|BEHAVIORAL|Cognitive Therapy|Experimental psychotherapy based on the cognitive model for social anxiety disorder, applied individually and remotely to participants fulfilling inclusion criteria.
40859168|NCT04979676|BEHAVIORAL|Compassion-focused Therapy|Experimental psychotherapy based on the principles of the compassion-focused model, applied individually and remotely to participants fulfilling inclusion criteria.
41389909|NCT04057573|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
40859169|NCT04979676|BEHAVIORAL|Acceptance and Commitment Therapy|Experimental psychotherapy based on the principles of the acceptance and commitment model, applied individually and remotely to participants fulfilling inclusion criteria.
40859170|NCT03560167|DEVICE|AccuCinch® Ventricular Restoration System|AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
40859171|NCT05310981|BEHAVIORAL|iCanChange|iCC is a psychological app based intervention that will be delivered in form of up to 24 brief (10-15 minutes) interactive modules developed based on the principles of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). During the intervention, participants will be offered MI and CBT-based activities (i.e., modules and strategies) aiming at facilitating change in cannabis use. At any point during the intervention, participants can reference modules that had been completed. Due to the frequency of behavioral stage changes in this population (e.g., regression in behavioral stage of change), stage of change will be monitored regularly throughout the intervention. During the follow-up period (i.e., Week 12-24), participants will have continuous access to the smart phone application and all built-in add-ons as described above. During this period, they will have access to 3 booster session.
40859172|NCT00542607|DRUG|levocetirizine dihydrochloride|
40859173|NCT04814121|DRUG|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
40859174|NCT04814121|DRUG|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
40859175|NCT03826238|DIAGNOSTIC_TEST|Validation Gate task|"The task is to observe several moving unfilled white circles on a dark background. The circles move in straight paths. Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a jump. The subjects' task is to press the space bar every time they detect a displacement (e.g. jump). A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions. During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting. Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls. Task-dependent EEG data will be recorded during the Validation Gate task."
41167223|NCT00287547|DRUG|CTLA4Ig / Abatacept|
41389910|NCT04057573|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
41389911|NCT06393673|DRUG|HS-10384 tablet Dose 1|Administered orally QD
41167224|NCT01159483|DRUG|PF-04958242|Administered as specified in the treatment arm
41389912|NCT06393673|DRUG|HS-10384 tablet Dose 2|Administered orally QD
41512227|NCT04944173|RADIATION|Stereotactic Body Radiotherapy|Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.
41512228|NCT04944173|DIAGNOSTIC_TEST|Circulating Tumor DNA assay|After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
41512229|NCT02478879|DRUG|ZP-PTH|Patch applied daily for 30 minutes, 14 days
41512230|NCT02478879|DRUG|FORTEO|Subcutaneous injection administration daily for 14 days
40859176|NCT02376868|DEVICE|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
40859177|NCT02376868|DEVICE|iVue|OCT machines used for diagnostic purposes
41167225|NCT01159483|DRUG|Placebo|Administered as specified in the treatment arm
41167226|NCT01041768|PROCEDURE|Bariatric surgery|Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
41167227|NCT02821078|OTHER|4D flow imaging sequence|4D flow imaging sequence
41389913|NCT06393673|DRUG|HS-10384-matched placebo tablets|Administered orally QD
41389914|NCT05449158|PROCEDURE|left atrial pressure regulation|For patients after atrioventricular node ablation combined with left atrial appendage closure, the regulation of left atrial pressure can be controlled by adjusting the frequency of pacemaker.
41389915|NCT03932838|OTHER|Clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
41389916|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
41389917|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
41389918|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
41389919|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
41389920|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
41389921|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
41389922|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
41389923|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
41389924|NCT00664417|BIOLOGICAL|Physiological saline|0.5 mL, IM, 2 injections
41512231|NCT02574065|DRUG|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
41512232|NCT02574065|OTHER|The placebo consists of an identical formulation without L. reuteri DSM 17938|
41512233|NCT03252561|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
41389925|NCT05789511|DEVICE|High Resolution Electrogastography|a new generation 64- channel high-resolution electrogastrography recording technology by Alimetry Limited that is able to record and analyze body surface gastric mapping/ HR-EGG
41389926|NCT01022177|PROCEDURE|acupuncture|acupuncture of the eye in traditional chinese schematics
41389927|NCT01242228|DRUG|ipragliflozin|oral
41389928|NCT01242228|DRUG|DPP-4 inhibitor|oral
41389929|NCT01052038|DRUG|Placebo administration|Placebo administration
40859178|NCT02808910|BEHAVIORAL|Nudged to eat less added salt and more other seasonings|
40859179|NCT02808910|BEHAVIORAL|Nudged to avoid foods high in salt content, and to choose foods low in salt content|
40859180|NCT02808910|BEHAVIORAL|Nudged to eat more vegetables|
40859181|NCT02808910|BEHAVIORAL|Nudged to eat smaller portions|
40859182|NCT02808910|BEHAVIORAL|Nudged to eat less calorie-dense food|
40859183|NCT02611843|BEHAVIORAL|Peer-Supported Web CBT|
40859184|NCT02611843|BEHAVIORAL|Self-Managed Web CBT|
40859185|NCT01732770|BIOLOGICAL|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
41389930|NCT01052038|DRUG|Dexamethasone 0.05mg/kr administration|Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
41389931|NCT01052038|DRUG|Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
41389933|NCT06120452|OTHER|Rael Miracle Clear Complete Acne Serum|"This acne serum contains the following ingredients:~1.5% Salicylic acid. 2% Niacinamide. 0.5% Zinc Pyrrolidone Carboxylic Acid (PCA). Hyaluronic Acid."
41389934|NCT02985567|OTHER|Intraocular pressure evaluation|Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
41389935|NCT02280915|OTHER|Savoury food product|
41389936|NCT02762968|DIETARY_SUPPLEMENT|Placebo|Placebo capsules similar to the experimental treatments.
41389937|NCT02762968|DIETARY_SUPPLEMENT|HMB|Capsules containing calcium HMB.
41389938|NCT02762968|DIETARY_SUPPLEMENT|BC30|Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
41512234|NCT03252561|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
40859186|NCT01732770|DRUG|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
40859187|NCT01732770|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
40859188|NCT01732770|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
40859189|NCT02797392|BEHAVIORAL|Lifestyle intervention|1) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
40859190|NCT05455528|DIAGNOSTIC_TEST|estimated GFR calculation|The estimated GFR is computed with Modification of Diet in Renal Disease (MDRD) formula
40859191|NCT03430934|COMBINATION_PRODUCT|NAVI mapping with Indocyanine green|Moh's tumor imaging with Indocyanine green
40859192|NCT06064383|DEVICE|suicide attacks|select the most common causes, risk factors, methods and circumstances surrounding suicidal attempts in children and adolescents at aaiut university children hospital
40859193|NCT00513942|OTHER|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
40859194|NCT04633928|BIOLOGICAL|N-TEC: Autologous nasal chondrocytes and ECM proteins|Cells expanded in vitro and cultured in a collagen type I//III scaffold
41389939|NCT06568640|PROCEDURE|Superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
41389940|NCT05768919|DRUG|Concurrent CRT Period|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over 3 hours Schedule: Weekly: Weeks 1,2, 3,4,5,6 Cycle length: 6 weeks~Agent: TMZ Premedications/Precautions No food 2 hr before and after dosing Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener PRN. Dose: 75 mg/m2 Route: Oral Schedule: Daily during term of RT Cycle Length: 6 weeks~Agent: Radiotherapy Premedications/Precautions: n/a Dose: 2 Gy Route: External beam therapy Schedule: Monday-Friday Cycle Length 6 weeks"
41389941|NCT05768919|DRUG|Post-CRT Period|Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over 3 hours Schedule: Weekly: Weeks 7,8,9,10 Cycle length: 4 weeks
41512235|NCT01140165|OTHER|cheese|the effect of cheese intake versus butter intake on blood lipids (primarily)
40859195|NCT05030168|DRUG|Ketosteril|ketoanalogues of essential amino acid
40859196|NCT05641415|OTHER|Imaging|MRI and x-ray of both shoulders
40859197|NCT03863431|OTHER|High-fat diet|"Participants will consume a high fat diet for 14 days with approximately 65% of energy from fat. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
40859198|NCT03863431|OTHER|High-carbohydrate diet|"Participants will consume a high fat diet for 14 days with approximately 70% of energy from carbohydrate. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
41389942|NCT05768919|DRUG|Adjuvant Period|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over 3 hours Schedule: Weekly: Adjuvant Cycles 1-6: Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks~Agent: TMZ Premedication/Precautions: No food 2 hr before and after dosing. Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener prn Dose: 150-200 mg/m2 (Cycles 1-6) Route: Oral Schedule: Daily Cycle Length: 4 weeks"
41389943|NCT00005609|BIOLOGICAL|rituximab|
41389944|NCT03996980|DEVICE|Custom-made foot orthoses Versus a flat insole|Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
40859199|NCT03219632|DRUG|Fimasartan|Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.
40859200|NCT03226834|DEVICE|MUSIC CARE|Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles
40859201|NCT03226834|OTHER|PERSONAL PLAY-LIST|Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
40859202|NCT02075788|OTHER|Commercial white bread|
41039310|NCT03577600|PROCEDURE|QMRT with the Cytotron®|Cytotron® utilizes a combination of instantaneous magnetic field and RF at the safe, lowerend of the EM spectrum. Radiofrequency waves are computed based on individualized PD measurements of the target lesion(s) for therapeutic purpose. Its working principle is based on the underlying theory of magnetic resonance.
41167228|NCT04219878|BEHAVIORAL|Know@Home|Participants randomly assigned to the Know@Home arm will access the features of Know@Home by downloading the app or accessing the website. The contents were developed to serve as a comprehensive mobile HIV prevention platform for MSM or TGW, with HIV prevention and care information and links to resources. This intervention arm provides an toolkit that allows users to access information about prevention services as their needs change. Participants will have access to Know@Home for the study period. The Know@Home arm will offer participants the opportunity to order free condoms and lubricant as well as an at-home sexually transmitted infection (STI) testing kit.
41167229|NCT04219878|OTHER|Self-test Kit|All participants will be shipped two at-home HIV self-tests. They will also receive a link to a previously-produced video that fully describes the specimen collection process, pointing out common errors and providing tips for successful collection. Participants will interact with study staff through phone, email, or text. Information to schedule a video HIV testing and counseling session with study staff will be made available to participants in all arms via a website, email, and/or text.
41167230|NCT02923609|BIOLOGICAL|Cell Therapy|Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStar® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.
41167231|NCT00913068|PROCEDURE|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
41167232|NCT00913068|PROCEDURE|standard post op pain control|opiates
41528430|NCT03436654|PROCEDURE|Extended Pelvic lymphadenectomy|To be performed concurrently with prostatectomy. Bilateral pelvic lymphadenectomy should include complete removal of all pelvic lymph nodes within the broad template described and includes the external iliac, hypogastric, obturator, and pre-sacral lymph nodes
41389945|NCT05602935|DRUG|Camrelizumab|200mg, intravenously, d1
41389946|NCT05602935|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
40859203|NCT02075788|OTHER|Corn based products (porridge etc.)|
40859204|NCT02075788|OTHER|Millet based products (porridge etc.)|
40859205|NCT04748614|OTHER|Cost|ICU cost
40859206|NCT03761238|DEVICE|Molecular Adsorbent Recirculating System|MARS therapy will start within 24-48 h after randomization and be given on 3 consecutive days in sessions of 8-12 h. The patients are observed for 2 days following the last session, with focus on bilirubin INR and signs of encephalopathy, and can thereafter receive 3 additional sessions in case of no or partial response to treatment.
40859207|NCT03761238|OTHER|Standard medical treatment (SMT)|Patient management and standard medical treatment (SMT) as specified in the study protocol.
40859208|NCT05865717|BEHAVIORAL|Quantitative sampling|A questionnaire asks about demographics, lifestyle (including cigarette smoking) \& desk job hours, eating habits, sleep patterns, mental health, and motivation. Data on the frequency and size of regular food consumption will be gathered by completing a survey. Physical activity will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University (Lifestyle Assessment Short Form, 2018).
40859209|NCT05865717|OTHER|Qualitative interviews|Thematic analysis will be done dividing into 4 different themes Personal life, professional life, Concept of Healthiness, Improving Lifestyle
41039311|NCT05642481|DIAGNOSTIC_TEST|Therapeutic drug monitoring in plasma of mother and child and in breastmilk|Measurement of drug concentration in plasma of mother and if possible of child and in breastmilk
41039312|NCT00700401|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms/week sc for 24 weeks
41039313|NCT00700401|DRUG|ribavirin [Copegus]|800mg po daily for 24 weeks
41039314|NCT04365660|DRUG|18-F FTC 146|Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration
40859210|NCT04543292|DEVICE|MATFILL (PTFE)|Filling of the prosthetic chimney with the compressed material
41039315|NCT01343407|DRUG|MK-1029 10 mg|Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
41167233|NCT01560871|BEHAVIORAL|High-intensity IMT plus walking|"The IMT intensity was set at 60% of PImax which was reassessed weekly. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.~For the walking program, it was the same as the one for the control group."
41389947|NCT05602935|PROCEDURE|Surgery|Surgery
41167234|NCT01560871|BEHAVIORAL|Low-intensity IMT plus walking|"The IMT training was 3 sets of 10 repetitions, or when the participant felt tired. Participants returned to our facility every week to reassess PImax.~For the walking program, each participant was given a pedometer and a heart rate monitor to track daily step counts and heart rate. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion scale. Participants began at least 10 to 15 minutes, once to twice a day, for 7 days a week, and eventually progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
41039316|NCT01343407|DRUG|MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
41039317|NCT01343407|DRUG|Placebo for MK-1029 10 mg|"Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design."
41039318|NCT01343407|DRUG|Placebo for MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
41039319|NCT03411655|DEVICE|Ambu Aura GainTM|Time and success rate
41039320|NCT03411655|DEVICE|Ambu® Aura-ITM|Time and success rate
41039321|NCT01373528|DRUG|Budesonide irrigation|A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
41039322|NCT01867151|DIETARY_SUPPLEMENT|Gluten Free Diet|
41039323|NCT01867151|DIETARY_SUPPLEMENT|Normal Diet|
41039324|NCT01206738|BEHAVIORAL|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
41039325|NCT01206738|BEHAVIORAL|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
41039326|NCT01206738|BEHAVIORAL|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
41039327|NCT05789433|BEHAVIORAL|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
41039328|NCT05789433|BEHAVIORAL|Progressive stretching|Statistic stretching of eight major muscle groups
41039329|NCT04994457|DEVICE|Virtual Reality Visual Field|A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses
41167235|NCT05980819|OTHER|Sustainability lecture and opportunity to create a project|Pure education
40859211|NCT01559675|DRUG|Hydrocortisone High Dose|Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
40859212|NCT01559675|DRUG|Hydrocortisone Low Dose|1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
41167236|NCT00181532|DRUG|Celecoxib|
41167237|NCT06063447|OTHER|Examination|Posture Evaluation, Scoliosis Examination, Pelvic Floor Assesments
41512236|NCT04809922|DEVICE|cardiac wearable devices|"five cardiac wearable devices~* Apple Watch, Apple Inc., Model Number: A1977 / A1978~* Kardia Mobile, AliveCor Inc., AC-009/Kardia Mobile 6L, AliveCor Inc., AC-019~* Fitbit Sense, Fitbit, Inc, Model Number: FB512~* Samsung Galaxy Watch 3 Samsung Inc., Model Number: SM-R855F~* Withings Scanwatch, Withings SA, Model Number: HWA09 Used for recording of one single-lead ECG. The results will be 274 compared to a simultaneous 12-lead ECG, which is considered the gold standard for detecting AF. There is no comparator in this trial."
40859213|NCT06224179|PROCEDURE|ultrasound guided subcostal TAP block|"patients will be randomly divided into two groups using a computer generated random number chart.~Group A received ultrasound guided subcostal TAP block,"
41039330|NCT04994457|DIAGNOSTIC_TEST|Standard Automated Perimetry|Standard of care perimeter
41039331|NCT01715987|DRUG|Tenofovir Disoproxil Fumarate|300mg, oral daily for two years
41039332|NCT01715987|DRUG|Entecavir|0.5mg oral daily for two years.
41039333|NCT00680212|DIETARY_SUPPLEMENT|dietary carotenoids|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule
41039334|NCT00680212|DIETARY_SUPPLEMENT|spinach, rice, and synthetic beta-carotene|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose
41167238|NCT04137718|OTHER|nonIntervention|nonIntervention
41167239|NCT03822195|PROCEDURE|Carotid endoarterectomy|Surgical removal of carotid bifurcation plaque and arterial repair (direct suture or patch)
40859214|NCT06224179|PROCEDURE|ultrasound guided combined posterior and subcostal TAP block|"patients will be randomly divided into two groups using a computer generated random number chart.~Group B received ultrasound guided combined posterior and subcostal TAP block,"
40859215|NCT00711971|DRUG|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
40859216|NCT00711971|DRUG|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
41167240|NCT04696133|OTHER|fine motor skills|stretching and strengthening exercises in addition to exercises to enhance fine motor skills
41167241|NCT04696133|OTHER|sensory integration|"* Tactile stimulation~* Proprioceptive stimulation"
41167242|NCT05219929|DRUG|Tetracycline 500 Mg|500 mg three times daily
41167243|NCT05219929|OTHER|Placebo|Placebo for Tetracycline given same way as Tetracycline.
40859217|NCT00711971|DRUG|placebo|control arm
41039335|NCT01464203|OTHER|CT coronary angiography|"CT coronary angiography:~This allows two distinct assessments of the coronary arteries to be made:~* coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.~* contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries."
41167244|NCT04673877|DRUG|Systemic IV Vancomycin|1 g of vancomycin will be delivered intravenously over a period of one hour prior to tourniquet inflation.
40859218|NCT03503760|DEVICE|LIMFA Therapy®|It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.
40859219|NCT00278733|BEHAVIORAL|Brief intervention (physician advice)|
41039336|NCT01464203|OTHER|Standard of Care|The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
41039337|NCT03196648|OTHER|Gingival health formulation in an accelerating device|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
41039338|NCT03196648|OTHER|Gingival health formulation on a toothbrush|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
41039339|NCT03196648|OTHER|OTC fluoride toothpaste|OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
41039340|NCT02768896|BEHAVIORAL|Baseline|Patients will walk naturally with EEG measuring brain waves
41039341|NCT02768896|BEHAVIORAL|visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
41039342|NCT02768896|BEHAVIORAL|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
41039343|NCT02768896|BEHAVIORAL|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
41039344|NCT00450411|RADIATION|125-Iodine|Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy
41039345|NCT00450411|RADIATION|103-palladium|Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
41039346|NCT05947474|DRUG|ORB-011|Drug: ORB-011 is dosed via IV infusion
41039347|NCT06233318|PROCEDURE|Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
41039348|NCT06233318|PROCEDURE|Pecto-intercostal Fascial Block with normal saline|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
41039349|NCT03106818|DRUG|bupivacain with magnesium sulphate|will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
41039350|NCT03106818|DRUG|Bupivacaine only|will receive bupivacain 0.125% infusion in the presternum , for 48 hours
41167245|NCT04673877|PROCEDURE|Bier Block|After exsanguination of the limb and elevation of the tourniquet in the prepped and draped patient, Vancomycin will be injected into a superficial vein in the hand, wrist or forearm.
41389948|NCT03904043|RADIATION|Radiation therapy|-Monday-Friday treatment is strongly recommended
41389949|NCT03904043|DRUG|FOLFOX regimen|-CAPOX can be given as alternative
41039351|NCT03106818|DRUG|conventional|only conventional post operative analgesics will be used
41039352|NCT04846608|OTHER|Observation|Observation
41389950|NCT03904043|OTHER|Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire|-Baseline, completion of chemotherapy (3-8 weeks after the end of chemotherapy), and 10 to 14 months after radiotherapy
41389951|NCT03904043|PROCEDURE|Rectal biopsy samples|-Multiple biopsy samples of the rectal tumor will be taken from the patient tumor prior to treatment initiation for genomic extraction. For patients at affiliate sites who do not have enough tissue from the diagnostic biopsy, a repeat pre-treatment biopsy is optional.
41389952|NCT03904043|PROCEDURE|Blood for ctDNA|-Prior to the start of treatment, Post radiation therapy labs (with standard of care (SOC) CBC/CMP prior to start of cycle 1 of chemotherapy), Day 1 of cycle 2 of chemotherapy (with SOC CBC/CMP), Completion of chemotherapy (3-8 weeks after the end of chemotherapy), 10-14 months after RT (if this visit aligns with a follow-up time point, one draw can be used to satisfy both time points), months 3, 6, 9, 12, 16, 20, 24 until salvage surgery or 2 years from completion of chemotherapy (whichever is first)
41417822|NCT05067764|PROCEDURE|Aponeurectomy alone|The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block. The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force. A tourniquet is placed on the arm to be treated and inflated to 250mmHg. Broken incisions are then made opposite the cords to be excised, which are located by palpation. Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible. Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years. Skin closure is most often possible by direct suture or by means of local fatty skin flaps. In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.
41512237|NCT03423940|BEHAVIORAL|Functional communication training|"During functional communication training (FCT), the social consequence (e.g., attention, toys, breaks from instructions) that heretofore reinforced destructive behavior (i.e., as determined through a functional analysis) is delivered contingent on an appropriate communication response, while destructive behavior is on extinction (i.e., reinforcers are no longer provided). For example, if a functional analysis shows that aggression is reinforced by escape from demands, FCT would typically involve (a) teaching the child to access breaks from demands via a functional communication response (FCR; e.g., saying, Break, please) and (b) placing destructive behavior on extinction (i.e., continuing with scheduled demands independent of destructive behavior)."
41389953|NCT03187080|PROCEDURE|Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
41417825|NCT02125266|DRUG|V404|Sustained Release
41512238|NCT05765500|DRUG|Relugolix|Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
40859220|NCT04602117|DRUG|Vic-trastuzumab duocarmazine (SYD985) + paclitaxel|"SYD985 (\[vic-\]trastuzumab duocarmazine) an antibody-drug conjugate or ADC being developed by Byondis B.V. (Nijmegen, The Netherlands), consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA, which has potent antineoplastic activity.~Eligible patients will receive infusions of SYD985 every three weeks and of paclitaxel weekly."
40859221|NCT02265250|OTHER|MRI|Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries
40859222|NCT02265250|OTHER|PET/MRI|Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries
40859223|NCT02265250|OTHER|Laboratory blood test|Cardiovascular biomarkers
40859224|NCT00866255|DEVICE|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
40859225|NCT03070535|OTHER|HIGH and LOW meal ingestion|The study will examine CSF biomarker responses to HIGH and LOW meals in 80 men and women with and without the E4 allele in a cross-over design. After an overnight fast, participants will ingest either a HIGH or LOW meal on separate days 3-5 weeks apart in random order. Three hours after meal ingestion, participants will undergo a cognitive battery, followed by spinal fluid collection. Blood samples will also be taken at 7 time points before and after meal ingestion.
40859226|NCT02388334|OTHER|to develop a standardized questionnaire|"to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).~The development of this standardized tool will also :~* identify the specific support needs of the caregivers~* study the links between the quality of care as perceived by the professionals, patients and caregivers~* identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results."
40859227|NCT06418659|DRUG|CD-801|CD-801 will be administered intravenously for the treatment of HCC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.
40859228|NCT05629130|DEVICE|embolization with spherical microparticles embosphere|embolization of affected joints with spherical microparticles embosphere
41389954|NCT03187080|OTHER|Enhanced recovery after breast surgery (ERABS) strategies|"For comparing ERABS strategies to current standard of care, the following perioperative strategies will be utilized:~* Standardized written information given preoperatively.~* Allow clear liquids for up to 2 hours prior to arrival at the surgery center.~* Use paravertebral block to augment postoperative pain control.~* Standardized multimodal analgesic regimen~* Antiemetics~* Easily accessible call-in or walk-in postop care/support~The proposed strategies differ from standard of care in the following ways:~* PVB is less commonly used in elective surgery.~* Patients do not eat or drink after midnight.~* There is no standardized preoperative information packet.~* Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers."
41389955|NCT03187080|PROCEDURE|Sham paravertebral block using saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
41389956|NCT03187080|DRUG|Paravertebral block using local anesthetic|Use of local anesthetic (0.25% bupivacaine) that is \*NOT\* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
41389957|NCT05498831|OTHER|Pain assessment at 15 minutes, 30 minutes, 60 minutes, 120 minutes after initial assessment by the triage nurse|Pain will be assessed using a numerical scale
41512239|NCT05765500|DRUG|Leuprolide|Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
41389958|NCT06479746|BEHAVIORAL|Emotional support|Emotional support helps the woman giving birth effectively, meets her emotional needs and expectations, ensures her comfort, improves birth outcomes, increases her self-esteem, ensures a positive birth experience and facilitates her transition into the role of motherhood.
41512240|NCT02281422|DRUG|BIA 2-093|
41512241|NCT01573299|OTHER|Mobilization of stroke patients|"In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset."
41389959|NCT00368914|DRUG|sirolimus|
41389960|NCT00368914|OTHER|laboratory biomarker analysis|
41389961|NCT00368914|OTHER|pharmacological study|
41512242|NCT04931979|DRUG|Pembrolizumab Injection [Keytruda]|Up to 17 cycles of pembrolizumab until disease progression, toxicity, death, or withdrawal of IC (whichever occurs first)
41512243|NCT04931979|RADIATION|Salvage Radiation Therapy (SRT)|SRT according to standard of care (SRT with at least 66 Gy)
41389962|NCT00368914|PROCEDURE|biopsy|
41389963|NCT06425146|PROCEDURE|Cytobrush sample|Healthy oral mucosa will be collected using a cytobrush, which is a minimally invasive method for patients
41389964|NCT06425146|PROCEDURE|Blood sampling|Blood sampling (6 mL), taken from a routine biological exam
41512244|NCT01729949|DIETARY_SUPPLEMENT|Active Treatment Beverage|Strawberry and Blackcurrent extract
41512245|NCT01729949|DIETARY_SUPPLEMENT|Placebo Treatment Beverage|without active components
41512246|NCT02680236|OTHER|Art Therapy Group|"Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use~At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post."
41512247|NCT05178069|DRUG|: Placebo for Probiotic|Capsule manufactured without active ingredients.
40859229|NCT02757144|DRUG|DWP14012|DWP14012 tablets
40859230|NCT02757144|DRUG|Placebo|DWP14012 placebo-matching tablets, Active control placebo-matching tablets
40859231|NCT02757144|DRUG|Esomeprazole|Nexium®
41389965|NCT06566768|DRUG|Deucravacitinib|Specified dose on specified days
41389966|NCT04350073|DEVICE|Q-NRG Metobolic Cart Device|COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
41512248|NCT05178069|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus G
41512249|NCT02819284|DRUG|KPI-121 0.25% Ophthalmic Suspension|
41512250|NCT02819284|DRUG|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
41512251|NCT01439412|PROCEDURE|Acupuncture and standard treatment|"This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.~In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.~The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji (Jiaji) bilaterally in the segments of the L2-L4 for 5 minutes."
41528431|NCT03436654|DRUG|GnRH agonist/antagonist|Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)
40859232|NCT00351910|DRUG|Quetiapine|
40859233|NCT00351910|DRUG|Amitriptyline|
40859234|NCT00351910|DRUG|Bupropion|
40859235|NCT00351910|DRUG|Citalopram|
41389967|NCT04350073|DEVICE|MuscleSound Ultrasound|COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
41389968|NCT04350073|DEVICE|Multifrequency Bioimpedance Spectroscopy|COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
41389969|NCT05494580|DRUG|Pamiparib|Oral
41389970|NCT05494580|DRUG|Surufatinib|Oral
41389971|NCT02228746|DIETARY_SUPPLEMENT|Alpha-galacto-oligosaccharides|6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
41389972|NCT00976313|PROCEDURE|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
41389973|NCT00976313|OTHER|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
41389974|NCT02353299|DRUG|Silenor 6 mg|Silenor 6 mg single nighttime dose.
41389975|NCT02353299|DRUG|zolpidem 10 mg|Zolpidem 10 mg single nighttime dose
41389976|NCT02353299|DRUG|Placebo|placebo single nighttime dose-1.5 hours
41389977|NCT02353299|DRUG|Placebo|placebo single nighttime dose-4 hours
41389978|NCT06339008|DRUG|LY3650150|Administered SC
41389979|NCT06339008|DRUG|Placebo|Administered SC
41389980|NCT06339008|DRUG|Standard therapy for INCS|Administered as intranasal spray
41389981|NCT01383954|DRUG|Diclofenac Gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
41389982|NCT06255730|PROCEDURE|Stellate Ganglion Block|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41389983|NCT06255730|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41389984|NCT02641171|OTHER|Specimen sampling|exhaled air samples blood samples fecal samples
41389985|NCT05466838|DRUG|PERT at discharge|Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day. Dose escalation 100,000 units lipase with meals and 50,000 units with snacks.
41389986|NCT05466838|OTHER|Standard of Care|Initiation of PERT if clinical symptoms of PEI develop or worsen. Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day.
41389987|NCT03963856|OTHER|parbolic flight|weightlessness during parabolic flight
41389988|NCT03455647|BEHAVIORAL|ASF promotion plus Girinka|Behavior change communication promoting the consumption of milk produced in the household and other optimal maternal and child nutrition practices. The intervention will be implemented by government of Rwanda Community Health Workers.
41389989|NCT04843800|PROCEDURE|Manual therapy|Acupuncture, Chiropractic are recognized complementary medicines and Therapeutic Massage is an alternative healing practice.
41512252|NCT01439412|OTHER|Standard treatment in general practice|This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
41389990|NCT02643810|OTHER|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
41389991|NCT04493554|DRUG|Vasopressin|Administration of vasopressin (20 IU) intranasally
41389992|NCT04493554|DRUG|Placebo|Administration of placebo intranasally
41389993|NCT00792948|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
41389994|NCT00792948|DRUG|Cyclophosphamide|Given IV
41389995|NCT00792948|DRUG|Cytarabine|Given IT
41389996|NCT00792948|DRUG|Dasatinib|Given PO
41389997|NCT00792948|DRUG|Dexamethasone|Given IV or PO
41389998|NCT00792948|DRUG|Doxorubicin Hydrochloride|Given IV
41389999|NCT00792948|DRUG|Etoposide|Given IV
41390000|NCT00792948|BIOLOGICAL|Filgrastim|Given SC
41390001|NCT00792948|OTHER|Laboratory Biomarker Analysis|Correlative studies
41512253|NCT04465981|DIAGNOSTIC_TEST|Sampling|Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.
41512254|NCT02552901|DRUG|0.1 mg/kg ICG Dose|least efficacious dose
41512255|NCT02552901|DRUG|0.5 mg/kg ICG dose|per package insert
41390002|NCT00792948|DRUG|Leucovorin Calcium|Given IV
41390003|NCT00792948|DRUG|Methotrexate|Given IV or IT
41512256|NCT06119594|DEVICE|Body Comp Pro connected scale (Withings manufacturer)|Patients in the intervention group will use the connected scale at a minimum frequency of once a week from receipt of the scale and throughout their participation in the research (6 months)
41512257|NCT01269541|DRUG|Mupirocin|Topical in the nose 3 times daily for 5 days
41512258|NCT01269541|DRUG|Rifampin+Clindamycine or Trimehoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
41167246|NCT04673877|DRUG|Vancomycin|500 mg diluted in 50 cc normal saline of injection into superficial vein in the hand, wrist or forearm
41512259|NCT03831204|DEVICE|biopac|"Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus."
41039353|NCT00563108|DRUG|Basiliximab|
41039354|NCT00563108|DRUG|Placebo|
41039355|NCT01840540|DRUG|Arterial infusion of autologous mesenchymal stem cells|
41039356|NCT03813940|BIOLOGICAL|HPV Vaccine,135μg/0.5ml|HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
41039357|NCT03813940|BIOLOGICAL|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
41039358|NCT04443738|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for recieved treatment will be conducted over the phone for patients.
41039359|NCT00854451|DRUG|omeprazole plus amoxicillin|
41039360|NCT00854451|DRUG|omeprazole plus amoxicillin|
41039361|NCT00854451|DRUG|omeprazole plus amoxicillin|
41039362|NCT00854451|DRUG|omeprazole plus amoxicillin|
41039363|NCT03584698|DRUG|Misoprostol 100Mcg Tab|women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
41167247|NCT04240236|PROCEDURE|Scalp block|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
41167248|NCT04240236|OTHER|Control Group|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
41167249|NCT00004178|BIOLOGICAL|therapeutic autologous lymphocytes|
41390004|NCT00792948|DRUG|Methylprednisolone|Given IV
40859236|NCT00351910|DRUG|Duloxetine|
40859237|NCT00351910|DRUG|Escitalopram|
40859238|NCT00351910|DRUG|Fluoxetine|
40859239|NCT00351910|DRUG|Paroxetine|
40859240|NCT00351910|DRUG|Sertraline|
41167250|NCT04637516|DEVICE|"Animation program BlinkBlink"|Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.
41167251|NCT03171116|OTHER|none intervention|it is not an interventional study; it is an observational study
41167252|NCT03738306|OTHER|Mezieres Method|"The Mézières treatment have 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain: the paravertebral muscles and latissimus dorsi."
41167253|NCT03738306|OTHER|Conventional Physiotherapy|therapeutic exercise; physical agents
40859241|NCT00351910|DRUG|Venlafaxine|
41039364|NCT03584698|DRUG|Evening Primrose Oil 1000 MG|women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
41039365|NCT01290432|DIETARY_SUPPLEMENT|Inofolic Plus|Inofolic Plus contains folic acid and myoinositol and melatonin
41390005|NCT00792948|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic stem cell transplant
41039366|NCT00000392|DRUG|Peptide T|
41039367|NCT00000392|DRUG|Placebo|
41039368|NCT00996996|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|"Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass."
41039369|NCT02647112|OTHER|Bladder EpiCheck|Urine test for the monitoring of bladder cancer recurrence
41039370|NCT01428648|BEHAVIORAL|Ballroom Dancing Classes|bi-weekly, 12-Week ballroom dance classes
41039371|NCT04584060|COMBINATION_PRODUCT|ERAS protocols|ERAS protocols including avoidance of prolonged pre-operative fasting and early removal of Ryle, surgical drains and urinary catheter
41039372|NCT04584060|COMBINATION_PRODUCT|Early oral feeding|Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward
41390006|NCT00792948|DRUG|Prednisone|Given PO
41390007|NCT00792948|DRUG|Sirolimus|Given PO
41390008|NCT00792948|DRUG|Tacrolimus|Given IV
41390009|NCT00792948|RADIATION|Total-Body Irradiation|Undergo TBI
41390010|NCT00792948|DRUG|Vincristine Sulfate|Given IV
41390011|NCT02264301|DRUG|Puerarin injection 400 mg|
41390012|NCT02264301|DRUG|Qingkailing injection 40 ml|
41390013|NCT05021588|PROCEDURE|steroid and anticoagulants according to different protocols.|As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.
41390014|NCT00063700|PROCEDURE|reducing exposure to marketing pressures|
41512260|NCT03831204|DIAGNOSTIC_TEST|prognostic scores|Effect and GWTGHF were calculated for every patient
40859242|NCT04872543|DRUG|ASTX727|ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.
41390015|NCT06270459|DEVICE|HMAN Robot|The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
41390016|NCT03772184|PROCEDURE|Cervical inversion|inverting the cervical lip after delivery
41390017|NCT01839565|DEVICE|Quadrilateral Surface Plate|Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
41390018|NCT04953208|DEVICE|active tDCS|Treatment will be applied daily 5 days/week for a period of 6 weeks, which equals a tDCS stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
41390019|NCT04953208|DEVICE|sham tDCS|sham stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
41390020|NCT04953208|BEHAVIORAL|cognitive and emotional control video game|a video game targeting cognitive and emotional control. total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
41390021|NCT04953208|BEHAVIORAL|sham video game|a video game which does not target cognitive control, played for total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
41390022|NCT05548543|DRUG|HCP2202|Take it once per period.
41390023|NCT05548543|DRUG|RLD2202|Take it once per period.
41390024|NCT05548543|DRUG|RLD2203|Take it once per period.
41390025|NCT05784727|DEVICE|Earswitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
41390026|NCT05426473|OTHER|QuickDASH form|Patients have to complete these two forms, Quick DASH and SF-36, before surgery then 6 weeks after
41390027|NCT00639158|DRUG|ABT-335|135 mg capsule, daily, 12 weeks
41390028|NCT00639158|DRUG|placebo|placebo capsule, daily, 12 weeks
41390029|NCT00639158|DRUG|atorvastatin|40 mg, tablet, daily, 12 weeks
41390030|NCT00639158|DRUG|ezetimibe|10 mg capsule, daily, 12 weeks
41390031|NCT00849524|BIOLOGICAL|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
41390032|NCT04709029|DRUG|Dexamethasone intravenous|Evaluation of intravenous dexamethazone in prevention of postdural puncture headache
41390033|NCT04709029|DRUG|Dexamethasone intrathecal|Evaluation of intrathecal dexamethazone in prevention of postdural puncture headache
41390034|NCT01253889|DRUG|Glucose 25% oral solution|0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
41039373|NCT04584060|COMBINATION_PRODUCT|Prophylaxis against DVT|Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
41390035|NCT01253889|OTHER|Oral water|0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
41390036|NCT00871065|DRUG|Sildenafil citrate|20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
41390037|NCT06438159|OTHER|Cardiac rehabilitation with Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is as follows:~* 8 weekly group sessions of 2h30 led by the mindfulness instructor,~* Sessions of around 45 minutes a day to be carried out by the patient, at home, for personal training,~* An intensive day between the 6th and 7th sessions to explore certain practices more intensively, in order to support participants in effectively integrating mindfulness meditation into various life situations."
41390038|NCT06438159|OTHER|Conventional cardiac rehabilitation|The usual cardiac rehabilitation program combines exercise training and therapeutic education workshops, with a daily session for four weeks.
41390039|NCT01380860|PROCEDURE|Colostomy with mesh implantation|Colostomy with mesh implantation
41390040|NCT01380860|PROCEDURE|Simple colostomy|Colostomy with no mesh implantation.
41390041|NCT02746029|OTHER|Clinical examination|
41390042|NCT04385264|DRUG|Hydroxychloroquine|Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
41390043|NCT04385264|DRUG|Mannitol|Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD
41390044|NCT00864409|DRUG|ropivacaine 0,2%|Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
41390045|NCT00864409|DRUG|saline.9%|Wound infiltration with 170 mL sterile saline
41390046|NCT03724292|DRUG|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
41512261|NCT04040556|OTHER|Simulation class|Pediatric anesthesia simulation class for anesthesia residences
41512262|NCT06147648|DRUG|Tacrolimus Sustained-release Capsules|Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
41528432|NCT03436654|RADIATION|Stereotactic Body Radiation Therapy|Subjects undergo SBRT in cycle 4, then salvage radiation therapy in cycles 7-8. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity
41390047|NCT03724292|DRUG|VTP-43742|VTP-43742 administered as oral capsule(s) once daily
41390048|NCT00898742|GENETIC|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
41528433|NCT00167011|PROCEDURE|CT|
41528434|NCT05348772|DRUG|AmnioPul-02|Mesenchymal stem / stromal cells, MSC
41512263|NCT00504751|DRUG|bortezomib, dexamethasone, ifosfamide|"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"
41512264|NCT00504751|DRUG|mesna, cisplatin, etoposide, rituximab|"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"
41390049|NCT00898742|GENETIC|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
41167254|NCT04959500|DRUG|Anlotinib Hydrochloride|Drug: Anlotinib Hydrochloride Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
41512265|NCT00741507|BEHAVIORAL|Alcohol drinking|Never drinking of alcohol
41512266|NCT00741507|BEHAVIORAL|Alcohol drinking|"Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
41512267|NCT00741507|BEHAVIORAL|Alcohol drinking|"Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
41167255|NCT04959500|DRUG|Placebo|Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
41512268|NCT00741507|BEHAVIORAL|Alcohol drinking|"Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
40859243|NCT04391114|PROCEDURE|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to TURP and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay \[4\]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low \[5\]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay \[6\].
41167256|NCT04959500|RADIATION|Radiation Therapy|Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0 Gy given 5 days a week for a total of 54-60 Gy.
40859244|NCT04391114|PROCEDURE|Top-Down HoLEP|The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique.
41167257|NCT04959500|DRUG|Temozolomide|Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
41512269|NCT00741507|BEHAVIORAL|Alcohol drinking|"Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)"
41167258|NCT02785731|PROCEDURE|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
41167259|NCT02785731|PROCEDURE|Blood draw|Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
41390050|NCT00898742|OTHER|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
41390051|NCT01678924|DRUG|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
41390052|NCT01678924|DRUG|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
41390053|NCT01385670|DEVICE|Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)|Transcatheter PFO closure
41390054|NCT01436669|DEVICE|Home Telemonitoring System (The Zodiac, Philips Health care)|Full blood count (FBC) home tele-monitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haematocrit, white cell count and neutrophil count).
41512270|NCT01984827|DRUG|Moxifloxacin|"1. a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~2. a single oral dose of 400mg Moxifloxacin plus C-peptide~3. a single oral dose of 400mg Moxifloxacin~4. placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m."
41512271|NCT01984827|OTHER|hyper-glycaemic clamp|a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
41512272|NCT03221244|DEVICE|VR Treatment|Distractors
41512273|NCT03221244|DEVICE|VR Active Control|No distractors
41512274|NCT06582628|DRUG|Enzalutamide capsule|Enzalutamide capsules 160 mg orally daily
41512275|NCT06582628|DRUG|Enzalutamide capsule and Talazoparib capsule|Enzalutamide capsules 160 mg plus talazoparib capsules 0.5 mg, both orally daily
41512276|NCT06280521|OTHER|fGQ-ASC|French version of the Girl Questionnaire for Autism Spectrum Conditions (fGQ-ASC)
40859245|NCT01946152|DRUG|Dexamethasone|Given PO
40859246|NCT01946152|BIOLOGICAL|Filgrastim-sndz|Given SC
40859247|NCT01946152|OTHER|Laboratory Biomarker Analysis|Correlative studies
40859248|NCT01946152|DRUG|Pomalidomide|Given PO
41167260|NCT02785731|PROCEDURE|laparotomy or laparoscopy|A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
41167261|NCT04115267|RADIATION|Radiotherapy|Combined modality
41390055|NCT00913861|BEHAVIORAL|hypnosis|Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
41390056|NCT00913861|DRUG|standard sedation|Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
41390057|NCT00913861|BEHAVIORAL|Structured attention|Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
41390058|NCT04694339|OTHER|Survey|Survey
41390059|NCT03922815|DRUG|rescue fentanyl|a rescue dose of fentanyl 0,5 mcg per kilogram of body
41390060|NCT03922815|DRUG|rescue propofol|propofol in a single dose of 0,5 mg/kg of body weight
41390061|NCT01818414|DRUG|Misoprostol|400 mcg of buccal misoprostol, 3 hours prior to planned D\&E
41390062|NCT01818414|DRUG|Folic Acid|4 mg of buccal folic acid, 3 hours prior to planned D\&E
41390063|NCT06008977|OTHER|Exercise Test|Supervised pedaling on an ergometer (stationary bike) at a moderate pace for a goal of 30 minutes. The exercise test will be scheduled at infusion visits 1, 6, and 12 or 1 and 3 over the treatment cycle, depending on the group assignment.
41390064|NCT03667170|BIOLOGICAL|KN035|subcutaneous injection
41390065|NCT01086735|BIOLOGICAL|donor lymphocyte infusion|Donor T-cell transduction
41390066|NCT01238211|DRUG|Cytarabine|Given IV
41390067|NCT01238211|DRUG|Dasatinib|Given PO
41390068|NCT01238211|DRUG|Daunorubicin Hydrochloride|Given IV
41390069|NCT01238211|OTHER|Laboratory Biomarker Analysis|Correlative studies
41390070|NCT06541834|DEVICE|Retinal imaging|Data of retinal imaging were acquired using Spectralis (Heidelberg, Germany) and California (Optos, UK).
41390071|NCT03417531|DIETARY_SUPPLEMENT|Protein Supplement|Predosed protein powder; can be added to various dishes and drinks
41390072|NCT03417531|DIETARY_SUPPLEMENT|Protein-free Supplement|Predosed protein-free powder; can be added to various dishes and drinks
41390073|NCT03417531|PROCEDURE|Active Exercise|Program includes five strength exercises that can be easily performed at home
41390074|NCT03417531|PROCEDURE|Control Exercise|Program includes five flexibility exercises that can be easily performed at home
41390075|NCT00047554|DRUG|Travoprost, 0.004% ophthalmic solution|
41390076|NCT01908998|OTHER|Sandal|Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
41512277|NCT02165735|BEHAVIORAL|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.
41512278|NCT02165735|OTHER|Usual care|Usual HIV care
41512279|NCT01231776|OTHER|electronic acupuncture|applying a stimula on neiguang and shenmen through electronic acupuncture
40859249|NCT01877213|BEHAVIORAL|Coaching with coordinate care|The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
40859250|NCT04079998|DEVICE|Procellera®|Application of Procellera® dressing.
40859251|NCT04079998|OTHER|Standard of Care|Application of standard of care dressings as prescribed.
40859252|NCT02602119|DRUG|OTL38|Infusion of OTL38 prior to surgery
40859253|NCT03369912|BIOLOGICAL|CSJ148|Active
40859254|NCT03369912|OTHER|Placebo|No Drug
40859255|NCT00816192|PROCEDURE|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
40859256|NCT05655949|DRUG|Gemcitabine|Intravenous infusion
40859257|NCT05655949|DRUG|Cisplatin|Intravenous infusion
40859258|NCT05655949|DRUG|Durvalumab|Intravenous infusion
40859259|NCT05655949|RADIATION|Yttrium-90|Injection of radiation microsphere beads
41390077|NCT03128073|DEVICE|Carry life system, ultrafiltration (CLS UF)|The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
41390078|NCT01053078|DRUG|Naltrexone|1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
41390079|NCT01053078|OTHER|Placebo|1 month treatment; placebo tablet once daily for 28 days
41390080|NCT02440074|OTHER|Autologous bone marrow mesenchymal stem cells|Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
41390081|NCT05635773|DEVICE|Use of Alexa Visual Cognitive aid|The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.
41390082|NCT02185235|DEVICE|Electrical Stimulation|"The Chartered Society of Physiotherapy recommends the following standard for electrical devices.~Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.~Treatment time: 5 minutes initially, gradually increasing to 20 minutes."
41390083|NCT02185235|DEVICE|Biofeedback|Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies
41390084|NCT02185235|OTHER|Pelvic Floor Training|"First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.~Repeat this exercise to 20 minutes each session."
41390085|NCT00629629|BEHAVIORAL|Dietary Advice|"Step 1 - Provide Exclusive breastfeeding up to 6 mo.~Step 2- After 6 mo, gradually introduce complementary foods and continue breastfeeding up to 2 y or more.~Step 3 - Complementary foods should be given 3 times a day (cereals, beans, fruits, and vegetables) if the child is breastfed, and 5 times a day if not.~Step 4- Mealtimes must be adjusted to the children's cues of hunger and satiety.~Step 5: Foods should gradually get thicker up to the time when the child is able to eat a family meal. Complementary foods should not be liquefied.~Step 6: A large variety of healthy foods should be given daily to guarantee the intake of different nutrients.~Step 7: Different fruits and vegetables should be offered daily. Step 8: Sugar, sweets, soft drinks, salty snacks, cookies, and processed and fried foods must be avoided.~Step 9: Good hygiene practices in food preparation and handling.~Step 10: Adequate feeding during child illness."
41390086|NCT06520995|OTHER|Educational video program|Diabetes education video contents are as follows; Type 2 diabetes definition, symptoms and the effect of diabetes on cognitive functions, Medical nutrition therapy and healthy nutrition recommendations in Type 2 diabetes, The importance of diabetes and exercise, Oral antidiabetic treatments, Insulin treatment, Hypoglycemia symptoms, findings and treatment, Macrovascular complications in diabetes, Microvascular complications in diabetes, Foot Protection and care recommendations, Diabetes self-care skills and problem-solving strategies, Diabetes and stress management.
41390087|NCT06520995|OTHER|A mobile application|This mobile application is a science-based application that patients can access via their smartphone or tablet. It consists of verbal, numerical, visual, logical, memory and attention categories and contains 24 different gamified mind exercises
41390088|NCT00296829|BIOLOGICAL|Inactivated, split-virion influenza vaccine|
41390089|NCT03634488|DRUG|hydroxyurea (20mg/kg/day)|Treatment of severe malnutrition in children with SCA in northern Nigeria
41512280|NCT04254848|OTHER|oral stereognostic test|Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
41512281|NCT06249061|DIETARY_SUPPLEMENT|oral sodium bicarbonate|Those in the oral sodium bicarbonate intervention group will be encouraged to sip a solution of 1 imperial teaspoon (\~5g) of sodium bicarbonate dissolved into 250ml of water throughout labour with other drinks. If the first solution is fully consumed, a second solution will be prepared and offered. Thus, each participant can receive a maximum dose of 2 imperial teaspoons (\~10g) of sodium bicarbonate.
41512282|NCT02234492|DRUG|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
41512283|NCT00293111|DRUG|SDX-101 (R-Etodolac)|
41512284|NCT04208100|DEVICE|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery. The 595nm and 660nm wavelengths of the Lutronic PicoPlus Laser system are used for the treatment of benign pigmented lesions.
41512285|NCT00980031|DRUG|Eplerenone|25mg PO daily (QD)for 6 months
41512286|NCT00980031|DRUG|Lactose Tablet|Lactose tablet
41512287|NCT04493671|DRUG|TBAJ-876 10mg|TBAJ-876 10mg tablets, oral suspension, orally administered
41512288|NCT04493671|DRUG|TBAJ-876 25mg|TBAJ-876 25mg tablets,oral suspension, orally administered
41512289|NCT04493671|DRUG|TBAJ-876 50mg|TBAJ-876 50mg tablets,oral suspension, orally administered
41512290|NCT04493671|DRUG|TBAJ-876 100mg|TBAJ-876 100mg tablets, oral suspension, orally administered
41512291|NCT04493671|DRUG|TBAJ-876 200mg|TBAJ-876 200mg tablets, oral suspension, orally administered
41512292|NCT04493671|DRUG|TBAJ-876 400mg|TBAJ-876 400mg tablets, oral suspension, orally administered
41512293|NCT04493671|DRUG|TBAJ-876 Dose XXXmg for Food cohort|Based on exposure levels from initial cohorts, a dose will be chosen for the food-effect cohort.
41512294|NCT04493671|DRUG|TBAJ-876 XXXmg for Part 2|Part 2, Multiple ascending dose (MAD) cohorts doses to be determined.
41512295|NCT04493671|DRUG|Matching Placebo for TBAJ-876 tablet|Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered
41512296|NCT05998629|DEVICE|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
41512297|NCT05998629|OTHER|Standard of Care laboratory procedure for measurement of sweat|a skin-interface sweat measurement using a smart-watch type device
41512298|NCT01659151|DRUG|High Dose Interleukin-2 (IL-2)|A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.
41512299|NCT01659151|PROCEDURE|ACT with TIL Infusion|Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).
41390090|NCT03634488|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food|Treatment of severe malnutrition in children with and without SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeutic food
41390091|NCT01038531|OTHER|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
41390092|NCT01038531|OTHER|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
41390093|NCT02146235|BEHAVIORAL|Psycho-Music Therapy|
41390094|NCT01538589|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
41390095|NCT02791711|OTHER|High Flow Nasal Cannula|Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
41390096|NCT00741117|PROCEDURE|Arterial Blood Gas|One blood gas sample will be obtained from an artery in the arm.
41390097|NCT00741117|PROCEDURE|Pulse Oximetry Machine|A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
41390098|NCT00741117|PROCEDURE|Direct and Indirect Serum Bilirubin Measurement|One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
41390099|NCT05349032|DIETARY_SUPPLEMENT|Curcumin|Oral supplement
41390100|NCT00963599|DRUG|Comparator: montelukast/loratadine|montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
41390101|NCT00963599|DRUG|Comparator: montelukast|montelukast 10 mg tablet taken once daily at bed time for 2 weeks
41390102|NCT00963599|DRUG|Comparator: loratadine|loratadine 10 mg tablet taken once daily at bed time for 2 weeks
41390103|NCT00963599|DRUG|Comparator: placebo|placebo tablet taken once daily at bed time for 2 weeks
41167262|NCT02675218|OTHER|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
41390104|NCT02035683|PROCEDURE|PET/CT|PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
41390105|NCT04196582|DEVICE|Comparison of LMA Gastro Airway® and Gastro-Laryngeal Tube in patients who will undergo biliopancreatic procedures.|comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
41390106|NCT04675073|PROCEDURE|Ventricular tachycardia substrate-based radiofrequency ablation|The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.
41512300|NCT01659151|DRUG|Vemurafenib|Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.
41512301|NCT01659151|DRUG|Lymphodepletion|"The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more space for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion."
41512302|NCT04500717|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
41390107|NCT06298500|DEVICE|hernia repair surgery|In recent years, atraumatic mesh fixation with tissue adhesive has increasingly become the method of choice. It is the recommended mesh fixation method by the International Hernia Society Guidelines. In this study patients with inguinal hernia are treated by placing a prosthetic mesh in one of the layers of the abdominal wall to cover the weakness, the mesh is fixed by Histoacryl LapFix,
41390108|NCT02934568|DRUG|LEE011|Single agent LEE011 or in combination with other treatments
41390109|NCT04730544|DRUG|Nivolumab 480mg + Ipilimumab|Nivolumab 480 mg q4w + Ipilimumab 1 mg/kg q6w
41390110|NCT04730544|DRUG|Nivolumab 240 mg + Ipilimumab|induction phase : Nivolumab 240 mg q3w + Ipilimumab 1 mg/kg q3w and then maintenance : Nivolumab 480 mg q4w
41390111|NCT02238886|DIETARY_SUPPLEMENT|Parenteral nutrition. SMOFKABIVEN infusion in central vene. Fresenius Kabi|
41390112|NCT05728216|OTHER|Dynamic full-field optical coherence tomography analysis of kidney biopsy|Dynamic full-field optical coherence tomography analysis of kidney biopsy in the nephrology department before conventional histopathological analysis
41390113|NCT02232139|DRUG|Midazolam|The participants receive the pharmacological premedication before the surgery anyway
41390114|NCT05005676|DIAGNOSTIC_TEST|acceleromyography|Simultaneous measurement of the time course of a neuromuscular block with 2 acceleromyographs
41390115|NCT00344526|DRUG|Melphalan|
41390116|NCT00344526|DRUG|Dexamethasone|
41390117|NCT00344526|PROCEDURE|Autologous stem cell transplantation|
41390118|NCT00254488|DRUG|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
41390119|NCT00254488|DRUG|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
41390120|NCT05199207|BEHAVIORAL|Physical activity programm|adapted physical activity during 3 month
40859260|NCT02357121|DEVICE|Focal Laser Ablation|Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
40859261|NCT01626092|DRUG|Campath-1H|A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
41167263|NCT00483028|DRUG|donezepil (Aricept)|
41167264|NCT05664399|OTHER|Surprise events|Subjects will be subjected to 4 surprise events, two using Virtual Reality simulations of falling out of a boat, and 2 involving falling into dunk tanks of cool and thermoneutral water.
41167265|NCT01754532|BIOLOGICAL|Hair Sample|Analysis of hair cortisol levels
41390121|NCT02083588|DEVICE|dTMS|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
41390122|NCT00566631|DRUG|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
41512303|NCT04500717|DRUG|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
41512304|NCT04912089|BEHAVIORAL|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
41390123|NCT00701558|DRUG|Erlotinib|150 mg po daily
41390124|NCT00701558|DRUG|Gemcitabine|1000 mg/m\^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
41390125|NCT02149862|OTHER|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
41512305|NCT00064987|PROCEDURE|Testicular biopsy|Outpatient surgical procedure.
41512306|NCT00064987|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
41512307|NCT00064987|DRUG|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
41512308|NCT03694756|DEVICE|TMEM-MRI|TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.
41512309|NCT03694756|PROCEDURE|FNA|FNA: The patients who are recruited prior to biopsy (Cohort A) will have had TMEM-MRI performed prior to biopsy. They will then present to radiology for ultrasound-guided core biopsy of the breast mass. FNA will be performed during this procedure. The FNA will be performed after local anesthetic is administered but prior to insertion of the core biopsy needle. FNA will be performed by the radiologist under direct sonographic visualization of the mass. Five passes will be obtained with a 25 gauge needle. The FNA material will be expelled into 1.5 ml Eppendorf tube containing phosphate buffered saline with EDTA.
41390126|NCT04098068|DRUG|MK-3475|MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
41390127|NCT00901420|PROCEDURE|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
40859262|NCT01626092|DRUG|Clofarabine|"A daily dose of 40 mg/m2 will be administered IV over 2 hours on days -9,~-8, -7, -6, and -5."
40859263|NCT01626092|DRUG|Melphalan|A single dose of 140 mg/m2 will be given IV on day -4 over 15 minutes.
40859264|NCT01626092|RADIATION|Total Body Irradiation with Marrow Boosting|"1. Dose to total body 200 cGy in single dose~2. Dose to bone marrow of the following bones 800 cGy in 5 divided daily fractions (160 cGy x 5 doses ). Treated with up to 3 abutting VMAT photon arcs from top of head to maximum inferior border."
40859265|NCT01626092|BIOLOGICAL|Hematopoietic stem cell transplantation|Patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.
40859266|NCT01626092|DRUG|Cyclosporine A|Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg, twice daily. An attempt will be made to maintain a trough cyclosporine level of 200 mg/L to 400 mg/L.
40859267|NCT01626092|DRUG|Mycophenolate mofetil|Patients will receive mycophenolate mofetil (MMF) therapy beginning on day -3. Dosing of MMF will be 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg/dose three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously.
40859268|NCT00439296|DRUG|ABT-751|"Treatment Course 1:~Oral capsule to be given daily for 21 days at assigned dose.~Treatment Course 2:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.~Treatment Course 3:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest."
40859269|NCT00439296|DRUG|Dexamethasone|"In Treatment Course 1 only:~* 10 mg/m2/day divided BID.~* Take dexamethasone by mouth days 1-14."
41390128|NCT00901420|BEHAVIORAL|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
41390129|NCT01803035|DRUG|LTX-109 1 %|
41390130|NCT01803035|DRUG|LTX-109 2 %|
41390131|NCT01803035|DRUG|Placebo gel|
41390132|NCT03424694|RADIATION|HDR brachytherapy as monotherapy|
41390133|NCT01716507|PROCEDURE|Retinal Detachment repair|Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
41390134|NCT05163431|DEVICE|Hallux Valgus orthosis|Custom designed orthosis and manufactured by 3D printing.
41390135|NCT05880420|DEVICE|Caregiver operations with medication accessories|After at least an initial outpatient medication (24/72 hours), home medication every 7 days (caregiver) for a total of 10 weeks.
41512310|NCT04446247|DIAGNOSTIC_TEST|Owlet Smart Sock Sensor 3rd Generation|Pulse Oximetry
41512311|NCT02903706|OTHER|Measure of Plasmodium prevalence (PCR)|
41512312|NCT02010645|DRUG|Eltrombopag|Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
41512313|NCT02010645|DRUG|Decitabine|Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
41512314|NCT01624025|OTHER|Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
41512315|NCT05217576|DEVICE|NBM-200|Finger Prick and Venipuncture
41528435|NCT06104020|OTHER|Intraoperative fluid management stratigies.|"Regimens of different intraoperative fluid management The restrictive fluid group (RG) aims to achieve a net zero fluid balance and involves a 2 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 4 mL/kg/hr.~The other group of patients, the liberal group (LG), will receive a 10 ml/kg bolus at anesthesia induction,followed by an intraoperative crystalloid infusion at a rate of 8 ml/kg/hr."
41167266|NCT01644188|DRUG|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
41390136|NCT05880420|DEVICE|Nurse operations with medication accessories|Outpatient medication every week (for a total of 10 weeks). Patients adhering to this arm will be followed at the IGAV nursing clinic of the IFOs.
41390137|NCT03614065|DRUG|endostar|endostatin
41390138|NCT03614065|DRUG|Placebos|saline solution
41390139|NCT03614065|RADIATION|radiotherapy|radiotherapy
41390140|NCT03990246|OTHER|Acid stable emulsion with solid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are crystalline. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.2% of the emulsifier sorbitan monooleate (Tween80)
41390141|NCT03990246|OTHER|Acid stable emulsion with liquid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.2% of the emulsifier sorbitan monooleate (Tween80)
41390142|NCT03990246|OTHER|Acid unstable emulsion with solid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are solid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.5% of the emulsifier sorbitan monostearate (Span60)
41390143|NCT03990246|OTHER|Acid unstable emulsion with liquid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.5% of the emulsifier sorbitan monostearate (Span60)
41417826|NCT05757011|PROCEDURE|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.
41417827|NCT01364870|DEVICE|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
40859270|NCT00439296|DRUG|PEG-asparaginase|"In Treatment Course 1:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on days 4, 11 and 18.~In Treatment Course 2:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on day 15."
40859271|NCT00439296|DRUG|Doxorubicin|"In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1."
40859272|NCT00439296|DRUG|Cytarabine|"* Given Intrathecally on day 1 of course 1 at the dose defined by age below.~  * 30 mg for patients age 1-1.99~ * 50 mg for patients age 2-2.99~ * 70 mg for patients \>3 years of age~* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.~In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12."
40859273|NCT00439296|DRUG|Methotrexate|"In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose"
40859274|NCT00439296|DRUG|Cyclophosphamide|Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
41167267|NCT01644188|DRUG|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
41167268|NCT01644188|DRUG|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
41167269|NCT01644188|DRUG|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
40859275|NCT00439296|DRUG|6-thioguanine|Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
40859276|NCT03213288|DIETARY_SUPPLEMENT|Delphinidin type anthocyanins|Bilberry extract containing Delphinidin type anthocyanins
40859277|NCT03213288|DIETARY_SUPPLEMENT|Cyanidin type anthocyanins|Black rice extract containing Cyanidin type anthocyanins
41167270|NCT01644188|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
41528436|NCT01962103|DRUG|nab-paclitaxel|nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
40859278|NCT03213288|DIETARY_SUPPLEMENT|Placebo|No anthocyanins
40859279|NCT05144711|PROCEDURE|Selective caries excavation|Selective caries excavation leaving stained but leathery dentine towards the pulp
40859280|NCT05144711|PROCEDURE|Non selective caries excavation|Complete excavation of caries regardless of the risk of pulp exposure
41167271|NCT04956614|DEVICE|immobilisation duration|immobilisation duration of 2,4,6 week after suture of Achilles tendon
41167272|NCT03401723|OTHER|3D-Colonoscopy Progression Score|3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
41390144|NCT06406231|DEVICE|comparing efficacy of TENS and PEMF in knee osteoarthritis|"Sessions will be conducted by a physiotherapist from the center, trained in the technique.Three sessions per week for three weeks. We used an Automatic Program (approximately 20 minutes).~For each group, the physical therapy was given as below:~G2: Patients treated with magnetotherapy:~-Device used: a prototype of a Health magnetic therapy (H.M.T) generator developed by a group of engineering researchers at the University of Tunis El Manar, employing low-frequency electromagnetic waves. The chosen program is Analgesia. An applicator containing magnets will be placed on the affected knees. The patient will sit on a chair bending knees.~G1 : Patients treated with TENS~-Device used: TENS from ECO2 from Schwa Medico, 2016, France. We chose the Gate control program (high frequency). The patient will sit with bent knees on a chair and adhesive patches will be placed on the affected knee. The intensity will be adapted to the patient's tolerance in both groups."
41512316|NCT06025240|DIAGNOSTIC_TEST|cf-DNA|In addition to the standard of care tests, participants will have an additional blood sample (dd-cf DNA). A cohort study patients who have undergone high immunological risk kidney transplant at our centre defined as a re-transplant, where the cRF is \>20% or where there is a level 4 HLA-mismatch. We will take a single plasma sample for dd-cfDNA testing at 6-12 months post-transplant and pair this with an assessment of renal function (creatinine, eGFR), MSU, BK and CMV PCR, single antigen bead (SAB) monitoring of HLA-specific antibodies and allograft USS.
41512317|NCT06025240|DIAGNOSTIC_TEST|Immunological Events following renal transplant in older age|Determine the overall frequency of immunological events and de novo HLA specific antibody formation in the \<60 and \>60 age population. Standard of care test taken at the different time intervals for routine storage. We will use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
41512318|NCT06025240|OTHER|Determining Predictive Models for Post-transplant HLA-specific Antibody Formation|A machine learning model will be developed in Python using a range of pre- and post-transplant variables to determine a predictive model for de novo HLA-specific antibody following renal transplant.
40859281|NCT02059304|DEVICE|Measurement of cervical length with embryo transfer catheter|
40859282|NCT02732548|OTHER|Negative Pressure Wound Therapy (NPWT)|
40859283|NCT02732548|OTHER|MIRODERM Application(s)|
40859284|NCT02732548|OTHER|Standard Care|wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
41390145|NCT05799378|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg capsules. Administered orally.
41390146|NCT05799378|DRUG|Placebo|Hydroxychloroquine-matching placebo capsule. Administered orally.
41390147|NCT06419855|DEVICE|Human collagen matrix graft|Is a porous cross-linked human collagen Matrix or Sponge, used as a scaffold in the repair and restoration of dura mater defects, following craniotomy, laminectomy or in general when there is intentional (surgical procedure) or accidental damage to the dura mater.
41390148|NCT06419855|DEVICE|Bovine collagen matrix graft|Is a porous type 1 collagen matrix derived from bovine Achilles tendon, this matrix is absorbed after 8 weeks and is used for the repair and restoration of dura mater defects.
41390149|NCT04157361|DIAGNOSTIC_TEST|Collection of breath condensate|Breath condensate will be collected from the patients involved in study.
41390150|NCT03251209|OTHER|Physical practice|Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).
41390151|NCT03251209|OTHER|Mental practice|Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.
41390152|NCT03251209|OTHER|Videotherapy|Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
41390153|NCT01154400|DIETARY_SUPPLEMENT|Casein protein hydrolysates|15 g casein protein hydrolysates + 15 g maltodextrin
41390154|NCT01154400|DIETARY_SUPPLEMENT|Whey protein hydrolysates|15 g whey protein isolate + 15 g maltodextrin
41390155|NCT01154400|DIETARY_SUPPLEMENT|Casein protein hydrolysates + LEU|15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
41390156|NCT01154400|DIETARY_SUPPLEMENT|Whey protein hydrolysates + LEU|15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
41390157|NCT02411110|COMBINATION_PRODUCT|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
41512319|NCT04146012|DEVICE|Artegraft® Collagen Vascular Graft™ (Artegraft)|The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
40859285|NCT00722956|DRUG|AZD5672|100 mg once daily, 10 days
40859286|NCT00722956|DRUG|atorvastatin|one single dose of 40 mg on day 10
40859287|NCT04701190|DRUG|Noradrenalin 10 microgram bolus|The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
40859288|NCT04701190|DRUG|Noradrenaline 5 microgram bolus|The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
40859289|NCT04701190|DRUG|Noradrenaline 0.1 microgram/kg/minute infusion|"Infusion dosage: 0.1 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
40859290|NCT04701190|DRUG|Noradrenaline 0.05 microgram/kg/minute infusion|"Infusion dosage: 0.05 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
40859291|NCT04701190|DRUG|Infusion dosage: 0.075 microgram/kg/minute infusion|"nfusion dosage: 0.075 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
40859292|NCT04701190|PROCEDURE|Spinal anesthesia|Spinal anesthesia using 0.5% 10 milligram heavy bupivacaine plus 12.5 microgram fentanyl
41390158|NCT02411110|COMBINATION_PRODUCT|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
41390159|NCT00139490|BEHAVIORAL|Health Education Program|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
41390160|NCT00139490|BEHAVIORAL|Basic Group|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
41390161|NCT00139490|BEHAVIORAL|Control Group|Usual Care
41390162|NCT01819701|DIETARY_SUPPLEMENT|LC-1000|L-carnitine 1000 mg /d
41390163|NCT01819701|DIETARY_SUPPLEMENT|LC-2000|L-carnitine: 2000 mg/d
41390164|NCT01819701|DIETARY_SUPPLEMENT|Q10-150|Coenzyme Q10: 150 mg/d
41390165|NCT01819701|DIETARY_SUPPLEMENT|Q10-300|Coenzyme Q10: 300 mg/d
41390166|NCT01819701|OTHER|Placebo|
40859293|NCT00668603|DRUG|17-b-estradiol|2mg oral daily for 6 months
41390167|NCT06310473|DRUG|Cadonilimab|10mg/kg intravenous (IV) every 3 weeks ;
41390168|NCT06310473|DRUG|Oxaliplatin|130mg/m², iv drip for 2h, d1, q3w;
41390169|NCT06310473|DRUG|Capecitabine|1000mg/m² po, Bid, d1-14, q3w ;
41390170|NCT01906580|DRUG|Peg-IFNα-2a|180ug peg-IFNα-2a, subcutaneous injection per week
41390171|NCT01906580|DRUG|Entecavir|0.5mg,oral administration every day
41390172|NCT03095482|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
41390173|NCT03095482|BEHAVIORAL|In vivo exposure therapy|Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
41390174|NCT02470962|OTHER|Observation|Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
41390175|NCT03537222|DIAGNOSTIC_TEST|Myeloma Patient Outcome Scale (MyPOS)|Patients complete the MyPOS questionnaire on quality of life
41512320|NCT03802071|DRUG|Durvalumab+doxorubicin cobination|Durvalumab 1500mg IV Doxorubicin 75mg/m2 IV D1 Q3weeks (up to 8cycles)
41512321|NCT05434689|DRUG|Iberdomide|Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.
41512322|NCT05434689|DRUG|Daratumumab|Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma
41512323|NCT05434689|DRUG|Dexamethasone|Corticosteroid active against multiple myeloma in combination with other agents
41512324|NCT05434689|DRUG|Carfilzomib|Second generation proteasome inhibitor with activity in multiple myeloma
40859294|NCT00668603|DRUG|17-b-estradiol + medroxyprogeterone acetate|2mg E2 + 5mg MPA daily for 6 months
40859295|NCT00668603|DRUG|17-b-estradiol hemihydrate|1 mg skin gel daily for 6 months
40859296|NCT00668603|DRUG|placebo pill + gel|placebo daily for 6 months
40859297|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 1 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
41512325|NCT01200069|DRUG|Placebo infusion|Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
41512326|NCT01200069|DRUG|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
40859298|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 2 for NG and CT|A combination test using target amplification to detect RNA from NG and CT.
40859299|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 3 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
40859300|NCT02338050|BIOLOGICAL|Moxetumomab Pasudotox|
41390176|NCT01205529|DRUG|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
41528437|NCT01962103|DRUG|nab-paclitaxel|IV infusion
40859301|NCT02674347|DRUG|3 g or 6 g Zidebactam|IV for over a duration of 60 minutes
40859302|NCT02674347|DRUG|Placebo|IV matching the Investigational drug
40859303|NCT01561742|DRUG|Minocycline|Minocycline will be given orally at 200 mg a day for 4 months
40859304|NCT01561742|DRUG|Placebo|EquivalentPlacebo will be given
40859305|NCT00328367|DRUG|aripiprazole|aripiprazole augmentation of clozapine
41390177|NCT05152407|OTHER|Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)|Serums will be topically applied twice a day (mornings and evenings).
41390178|NCT01528631|OTHER|D-Fagomine|30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
41390179|NCT01528631|OTHER|D-Fagomine|0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
41390180|NCT03786809|DRUG|Cimifuga Racemosa|Experimental group will use 160mg of Cimifuga Racemosa for 28 days
41390181|NCT03786809|DRUG|Placebo|patients of the placebo group will use placebo once a day for 28 days
41390182|NCT02959554|DRUG|Nivolumab|240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
41390183|NCT02959554|DRUG|Sunitinib|According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
41390184|NCT02959554|DRUG|Pazopanib|According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
41390185|NCT00571220|PROCEDURE|gastric bypass surgery|weight loss bariatric surgery
41512327|NCT01485822|PROCEDURE|Trabecular Meshwork Tissue Collection|A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
41512328|NCT01485822|DRUG|Travoprost 0.004% ophthalmic solution|
41039374|NCT04966468|DEVICE|Virtual Reality|The Lenovo Mirage Solo Headset will be kept at home by the patient for the duration of the study (4 days). The VR headset will be equipped with 10 non-interactive videos and a short interactive game. The videos and the game are characterized by relaxing scenarios. The game will require the active interaction of the patient. At the end of the observational period, the investigator will download the usage data to detect information about the patient's use. Before and after each use of the VR headset, the patient will be asked to fulfil the Edmonton Symptom Assessment Scale (ESAS). On T0, the patient will be asked to wear a wearable device, the Empatica E4 wristband measuring physiological parameters. On day T1, the patient will return the VR headset and the wristband to the investigator and will fulfil again the HADS and BPI questionnaires.
41167273|NCT03401723|OTHER|Endoscopy Training System|"The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~1. Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~2. Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~3. Loop Management - The management of a standard alfa-loop.~4. Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal."
41167274|NCT03401723|OTHER|3D-Colonoscopy Retraction Score|3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
41167275|NCT03598725|DRUG|Coagulation Factor VIII|Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
41167276|NCT03598725|DRUG|Prednisone|2mg/kg every day for 4 weeks then typering in 3 months
41167277|NCT03598725|DRUG|Rituximab|375mg/Square meter for consecutive 4 months
41167278|NCT02046798|DRUG|ASP3652|oral
41167279|NCT03510806|DIETARY_SUPPLEMENT|Supplement|dietary supplement contain protein from milk and fruit extract
41167280|NCT03510806|OTHER|Placebo|color, taste, and calorie-matched placebo
41390186|NCT00571220|OTHER|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
41167281|NCT05038709|DEVICE|The Pink Pad Hip Kit|The pad is placed between the patient and the traction table to reduce pressure to the pudendal nerve exerted by the perineal post.
41390187|NCT00665626|DRUG|Fostamatinib disodium (R935788)|R935788 100 mg tablet, orally, twice-a-day
41390188|NCT00665626|DRUG|Placebo|Placebo, orally, twice-a-day
41512329|NCT03742193|DRUG|Apatinib|Apatinib 250mg tablet by mouth, bid. 48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.
41512330|NCT03742193|DRUG|GD regimen|"One cycle: gemcitabine 900 mg/m\^2 over 90 min on Day 1, and gemcitabine 900 mg/m\^2 and docetaxel 75 mg/m\^2 on Day 8. Every 21 days were eligible.~1\~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken."
41512331|NCT01028482|DRUG|Sertraline|"group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months"
40859306|NCT00328367|DRUG|placebo|placebo
40859307|NCT02377999|DRUG|Picato|
40859308|NCT01385657|DRUG|Placebo|A total of 4 doses were administered.
41390189|NCT03402620|DRUG|Gonadotropins|Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
41390190|NCT06538233|DRUG|Buffered articaine|Injecting buffered articaine in maxillary anterior region and evaluate pain response.
41390191|NCT06538233|DRUG|Non buffered articaine|Injecting non buffered articaine in maxillary anterior region and evaluate pain response.
41390192|NCT03105882|DEVICE|Neuro-Spinal Scaffold|Experimental: Neuro-Spinal Scaffold
41512332|NCT01028482|DRUG|placebo|placebo
41512333|NCT01028482|OTHER|psychotherapy|psychotherapy
41512334|NCT05237492|DRUG|Tramadol|Blood samples will be drawn from 15 patients. Tramadol will be added to all this samples in-vitro and its influence on platelets´ function will be measured.
41512335|NCT06221826|DRUG|Mexidol|Neurocytoprotector
41512336|NCT01835041|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
41512337|NCT01835041|DRUG|oxaliplatin|Given IV
41512338|NCT01835041|DRUG|leucovorin calcium|Given IV
41512339|NCT01835041|DRUG|irinotecan hydrochloride|Given IV
40859309|NCT01385657|DRUG|Dupilumab|A total of 4 doses were administered.
40859310|NCT01385657|OTHER|Background treatment|Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.
41512340|NCT01835041|DRUG|fluorouracil|Given IV
41512341|NCT01835041|OTHER|laboratory biomarker analysis|Correlative studies
41512342|NCT00489827|DRUG|Intravenous infusion of saline|Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
41512343|NCT00489827|OTHER|Intravenous glutamate infusion|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
41512344|NCT01722630|DRUG|Dopamine|
41528438|NCT03270657|DEVICE|IPG; RC+S|We will measure the effects of varying stimulation parameters on the neural activity in subjects with Parkinson's disease (PD).
40859311|NCT02990039|BEHAVIORAL|Counseling letter|The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.
41512345|NCT05237778|BEHAVIORAL|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where we associate a sound with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, we want to accelerate the remission of nightmares.
41390193|NCT04297488|DIETARY_SUPPLEMENT|Bifidobacteria and Lactobacilli triple viable capsules|Bifidobacteria and Lactobacilli triple viable capsules (provided by Shenzhen Wan he Pharmaceutical Co., Ltd., China) are bilayer mini pellets and are resistant to gastric acid. So Bifidobacterium billion Lactobacillus can only be released in intestine. Participants will take 1.27g (contain 3 billion Bifidobacterium and 1 billion Lactobacillus) once daily.
41390194|NCT03585868|OTHER|Placebo|Beverage with no flavonoids
41390195|NCT03585868|OTHER|Flavonoids|Flavonoids-enriched cacao beverage
41390196|NCT03585868|DIETARY_SUPPLEMENT|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
41390197|NCT00297492|BEHAVIORAL|Reduction Phone Counseling|Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
41390198|NCT00297492|BEHAVIORAL|Abrupt Phone Counseling|Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
41390199|NCT00297492|BEHAVIORAL|Minimal Abrupt Phone Counseling|Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
41390200|NCT00297492|DRUG|Pre-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke."
40859312|NCT06532084|DRUG|Sorafenib|Sorafenib 200 mg bid for 168 days starting in the time fram between engraftment with neutrophils \> 1.0 x 10\^9/L, white blood cells\> 1.5 x 10\^9/L, platelets\> 1.5 x 10\^9/L and day+100 after allogeneic hematopoietic cell trnaplantation
40859313|NCT03204370|DRUG|Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM]|A subgroup of MPS4A patients will be treated by VIMIZIM drug, prescribed in usual care
41390201|NCT00297492|DRUG|Post-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke."
41390202|NCT00000160|PROCEDURE|Xenon Photocoagulation|
41390203|NCT00000160|PROCEDURE|Argon Photocoagulation|
41390204|NCT00000160|PROCEDURE|Photocoagulation|
41512346|NCT05237778|BEHAVIORAL|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without any association with a sound.
41390205|NCT02865642|DRUG|Serotonin Uptake Inhibitors|
41390206|NCT02865642|DRUG|Placebo|
41390207|NCT02872337|BEHAVIORAL|Preoperative Physical Therapy Session|This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
41512347|NCT01208805|BEHAVIORAL|Recording spinal cord evoked potentials|Recording spinal cord evoked potentials from patients suffering from intractable pain in whom epidural electrodes have already been implanted
41512348|NCT00055731|DRUG|bicalutamide|
40676662|NCT06124248|BEHAVIORAL|RISE intervention|"The RISE intervention: a 15-weeks blended behavioral intervention, where a primary care physiotherapist coaches participants on striking the balance in their 24h activity pattern, with a focus on reducing and interrupting their sedentary time. This will subsequently lead to an increase in physical activity. Next to that, insights into their personal sleep pattern, sleep hygiene rules and advices will be provided.~Primary care physiotherapists coach people with a first-ever stroke in their home setting by using behavior change techniques and the RISE eCoaching system. The RISE eCoaching system consists of 1) an activity monitor, 2) a smartphone application that provides real-time feedback and contains e-learning modules, 3) a monitoring dashboard for the physiotherapist. Participants receive participatory support from someone from their social network (e.g., partner or close friend) who joins them in the intervention."
40859314|NCT05651906|PROCEDURE|Kidney Transplantation|Kidney transplantation as the best option for patients with end-stage kidney disease.
40859315|NCT01494077|OTHER|Laboratory processing for results|There is no intervention. Extra fluid that is normally discarded will be processed.
41167282|NCT00468130|DRUG|Aripiprazole|Subjects under 40 kg will be started on 2.5mg per day of aripiprazole for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
41167283|NCT00468130|DRUG|Placebos|"Inactive tablet made to resemble active tablet~Subjects under 40 kg will be started on 2.5mg per day of placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects"
41167284|NCT01607528|DIETARY_SUPPLEMENT|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
41167285|NCT01607528|DIETARY_SUPPLEMENT|Placebo|A similar looking and tasting powder with no active substances
41167286|NCT00318981|DRUG|Concerta|
41390208|NCT02872337|BEHAVIORAL|Group Preoperative Education Session (per the standard of care)|
41390209|NCT01188005|DEVICE|n-CPAP|administration of continuous positive airway pressure through a nasal device
41390210|NCT01188005|DEVICE|Oxygen supplementation|Oxygen supplementation (3L) through nasal spectacles
41390211|NCT01188005|DRUG|Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine|Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
41512349|NCT00055731|DRUG|Goserelin Acetate|
41512350|NCT00055731|DRUG|docetaxel|
41512351|NCT00055731|DRUG|Estramustine phosphate sodium|
41167287|NCT03575195|DRUG|Rifaximin|Rifaximin 550mg orally
41167288|NCT03575195|OTHER|Placebo|Placebo control
41390212|NCT00187057|DRUG|vinblastine, vincristine, prednisone, daunorubicin|See Detailed Description section for details of treatment interventions.
41390213|NCT00187057|DRUG|doxorubicin, methotrexate, cyclophosphamide, L-asparaginase|See Detailed Description section for details of treatment interventions.
41390214|NCT00187057|DRUG|etoposide, cytarabine, mercaptopurine|See Detailed Description section for details of treatment interventions.
41390215|NCT00187057|DRUG|dexamethasone, procarbazine|See Detailed Description section for details of treatment interventions.
41390216|NCT00187057|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
41390217|NCT04677894|DEVICE|Laryngoscopy|During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
41512352|NCT00055731|DRUG|acetylsalicylic acid|
41512353|NCT00055731|PROCEDURE|conventional surgery|
41167289|NCT03705364|OTHER|Fall Management program|Comprehensive fall management program that develops strategies for non-ambulatory wheelchair users living with MS to develpo strategies to recover from a fall.
41167290|NCT01184534|BEHAVIORAL|Video|5 minute multimedia presentation (video)
41167291|NCT01184534|BEHAVIORAL|Questionnaires|2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
41167292|NCT01576913|OTHER|Music listening|Listening to tempo music while cycling in an exercise test
41512354|NCT00055731|RADIATION|radiation therapy|
41512355|NCT06582862|OTHER|Exercise|Subjects will do aerobic and anaerobic exercise
41512356|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
41512357|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
41512358|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
41512359|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
41528439|NCT03570619|DRUG|Nivolumab|"Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.~Patients in arm Metastatic CRPC will receive therapy with monotherapy nivolumab therapy at flat dose 480 mg IV every 4 weeks for up to 104 weeks of total therapy."
40676663|NCT00531713|DRUG|Triiodothyronine|50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
40859316|NCT00696046|PROCEDURE|Intrabone Marrow Injection|Cord blood CB units will be thawed in a 37° CB cells will be resuspended in 20ml salinesolution + dextran/albumin, and aliquoted in 4 syringes of 5ml Pts were prepared in a surgical \& steril room The anaesthesia consist in a short propofol sedation The injection will last 8-15 minutes. 1° sedation is established, a standard needle for bone marrow aspiration (14 gauge) was inserted few cms in the supero-posterior iliac crest then, an aspiration of about 0.5-1 ml will be performed to assess that the needle was securely introduced in the bone marrow cavity After, we will insert the syringe containing 4-5ml of CB cell suspension which will be gently infused This procedure will be then repeated for all the remaining aliquots at a distance of 2-3cm from the previous one following the iliac crest
40859317|NCT02726724|OTHER|5 observers|
40859318|NCT02726724|OTHER|1 observer|
40859319|NCT05798221|BEHAVIORAL|Complementary self-help strategies in addition to treatment as usual|The 10-week group program consists of self-help strategies from complementary medicine approaches of TEM (Traditional European Medicine), TCM (Traditional Chinese Medicine), and TIM (Traditional Indian Medicine) in addition to treatment as usual
41039375|NCT04966468|OTHER|Control|"The investigator will illustrate to the patient how to use the tablet for watching videos, suggesting using it especially in moments of psycho-physical discomfort. The tablet will be given to the patient for the duration of the study (four days). The tablet will be equipped with 10 non-interactive 2D videos characterized by relaxing settings with natural or artistic scenarios, giving a passive use to the patient. Before and after each use of the tablet, patient has to fullfil the ESAS digitally inserted into the tablet. Patient can answer by selecting the answer on the touchscreen. Without filling the scale, the patient will not be able to access the videos inserted in the tablet. On day T1, patient will return the tablet to the investigator and fill out the HADS and BPI questionnaires."
41039376|NCT04769167|OTHER|Stool and Blood Specimen Collection|Stool and Blood specimens will be collected at 3 designated time points
41167293|NCT03896074|DRUG|Atezolizumab|Atezolizumab administered intravenously at 1200 mg every 3 weeks
41390218|NCT01304017|OTHER|Virtual Reality|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing
41039377|NCT04769167|OTHER|Follow-up Medical Record Review|Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.
41167294|NCT03896074|DRUG|Bevacizumab|Bevacizumab intravenously at 15 mg/kg every 3 weeks
41167295|NCT01702870|PROCEDURE|Magnetic Resonance Imaging|
41167296|NCT05864885|DRUG|Minoxidil|Topical formulation applied once a day.
41167297|NCT00579449|BEHAVIORAL|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
41167298|NCT00579449|BEHAVIORAL|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
41167299|NCT04567810|DRUG|anti-SARS-CoV-2 IgY|anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
41167300|NCT04567810|DRUG|Placebo|Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
41167301|NCT03487263|BIOLOGICAL|IC14|chimeric monoclonal antibody against human IC14
41167302|NCT02145897|BIOLOGICAL|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
41167303|NCT02145897|BIOLOGICAL|Autologous Adipose Derieved MSCs|Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
41167304|NCT02145897|OTHER|Control|
41390219|NCT01304017|OTHER|Traditional Therapy|The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
41390220|NCT04651218|BEHAVIORAL|exericse|participants perform aerobic exercise until they expend 500 kcal
41390221|NCT00781131|DRUG|Pregabalin|pregabalin 75 or 150 mg
41528440|NCT03570619|DRUG|Ipilimumab|Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.
41528441|NCT05447650|DEVICE|i-Lumen(TM) AMD|Transpalpebral microcrurrent stimulation
41390222|NCT00781131|DRUG|Placebo|lactulose placebo
41528442|NCT05447650|DEVICE|i-Lumen(TM) AMD Sham|Transpalpebral sham stimulation
40676664|NCT06175234|DEVICE|Ablation Treatment|For subjects with paroxysmal AF, Pulmonary Vein Isolation will be performed with the FARAWAVE NAV catheter. For subjects with persistent AF, left atrial posterior wall isolation (PWI) may also be performed at the discretion of the investigator, with the FARAWAVE NAV PFA catheter.
40859320|NCT05798221|OTHER|Treatment as usual|The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
40859321|NCT00197899|DRUG|E. Coli endotoxin|
40859322|NCT05581069|BEHAVIORAL|STEPS|STEPS is a psychosocial intervention that targets self-determination, self-regulation, and self-knowledge to improve functional independence and quality of life in adults.
40859323|NCT01033916|OTHER|LIBERAL|The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
40859324|NCT01302353|DRUG|Emulsified Isoflurane|
41390223|NCT02041000|OTHER|Adipose Derived Stem Cells|
41390224|NCT01785472|DRUG|LCZ696|LCZ696 200 mg tablet
41390225|NCT01785472|DRUG|Olmesartan|Olmesartan 20 mg capsule
41390226|NCT01785472|DRUG|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
41390227|NCT01785472|DRUG|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
41512360|NCT06577922|OTHER|Establishment of a simulation lab and provision of simulation based trainings|In each hospital, the investigators will perform an initial need assessment to identify the existing skills labs' space, equipment and trained human resources. Then, maternal and neonatal health simulation labs will be established in each hospital. One simulation lab will have 5 rooms- one auditorium hall, one debrief room, two simulation rooms, and one high fidelity simulation room. Equipment and manikins required for practicing maternal and neonatal health related skills will be installed in the simulation lab, along with guidance/ checklists for skills practice. After completion of lab set-up, trainings will be provided to trainers/ MNH staff of each hospital on simulation based methodology, especially focusing on Essential Care for Labor and Birth (ECLB), Bleeding after Birth (BAB), and Helping Babies Breathe (HBB) modules. Similarly, the investigators will also provide training for simulation lab operation and maintenance.
41512361|NCT04757597|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 10-14 days after enrollment.
41512362|NCT01107197|DIETARY_SUPPLEMENT|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
40859325|NCT05133765|DEVICE|Insulin pump|Alterations in insulin pump therapy or carbohydrate consumption
40859326|NCT01970306|DEVICE|MatriStem PSM|All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
40859327|NCT03833804|OTHER|Processing of clinical notes in the EHR data collected during routine care|Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
40859328|NCT04427020|DIETARY_SUPPLEMENT|Milk protein + GBI-30|Both conditions matched flavor, color, and serving size
41039378|NCT03297788|RADIATION|SRS|"For SRS the dose prescription to the PTV will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)"
41167305|NCT02356796|OTHER|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
41167306|NCT02356796|OTHER|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
40859329|NCT04427020|DIETARY_SUPPLEMENT|Milk protein|Both conditions matched flavor, color, and serving size
41039379|NCT03297788|RADIATION|WBRT|WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.
41390228|NCT01146886|DRUG|Placebo to BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
41039380|NCT03512327|OTHER|Autoimmune protocol (AIP) diet|Autoimmune protocol diet, designed as a 6 week step wise elimination phase followed by 5 week maintenance phase.
41039381|NCT02739438|OTHER|Electronic cigarette use|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months.
41167307|NCT02798692|BIOLOGICAL|Low dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
41390229|NCT01146886|DRUG|BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
41390230|NCT02223598|DRUG|CB-5083|
41390231|NCT02223598|DRUG|Dexamethasone|
41039382|NCT02739438|OTHER|Cigarette use|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
41039383|NCT02739438|OTHER|Control group|Subjects with no history of prior conventional cigarette (\< 100 cigarettes lifetime) or electronic cigarette use.
41390232|NCT00212810|DRUG|Topiramate|
41390233|NCT04810507|DRUG|Anagliptin BID Treatment|Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
41390234|NCT04161118|DRUG|CTL019|IV Infusion
41390235|NCT02554344|DRUG|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
41390236|NCT02702271|DEVICE|WATCHMAN FLX|Left atrial appendage closure with WATCHMAN FLX
41390237|NCT03701516|DEVICE|etafilcon A with novel molding process|TEST Lens
40859330|NCT04852198|PROCEDURE|OAGB|Simplified gastric bypass procedure
41390238|NCT03701516|DEVICE|etafilcon A with current molding process|CONTROL Lens
41390239|NCT04142866|DEVICE|Anodal transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the active tDCS condition, stimulation continues for the first 20 minutes of the 60-minute treatment session, and then ramps back down to 0 milliamps (mA).
41390240|NCT04142866|DEVICE|Sham transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
41390241|NCT04142866|BEHAVIORAL|Speech-Language Therapy (SLT)|Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
41512363|NCT01107197|DIETARY_SUPPLEMENT|Control formula|Isonitrogenous isocaloric oral formula
41512364|NCT02996292|DEVICE|Traditional brackets|Treating of crowding using traditional brackets
41512365|NCT02996292|DEVICE|Active self-ligating brackets|Treating of crowding using active self-ligating brackets
41512366|NCT02996292|DEVICE|Passive self-ligating brackets|Treating of crowding using passive self-ligating brackets
41512367|NCT05212077|OTHER|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
40859331|NCT04852198|PROCEDURE|RYGB|Roux-en-Y gastric bypass. Standard procedure in the Netherlands
40859332|NCT02899091|BIOLOGICAL|CB-AC-02|"Stage1:~① Group1: CB-AC-02 administration on day 0~② Group2: CB-AC-02 administration on day 0 and on week 4 (repeated injection)~Stage2~① Arm1: K-MMSE 20\~26 CB-AC-02 administration on day 0 and on week 4 (repeated injection)~② Arm2: K-MMSE 10\~19 CB-AC-02 administration on day 0 and on week 4 (repeated injection)"
40859333|NCT02899091|BIOLOGICAL|Placebo|"Stage2:~Placebo administration on day 0 and on week 4 (repeated injection)"
40859334|NCT00897221|DRUG|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
40859335|NCT00897221|DRUG|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
41512368|NCT05212077|OTHER|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
41512369|NCT04632576|OTHER|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will given.
41512370|NCT04060056|OTHER|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
41512371|NCT04060056|OTHER|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
41512372|NCT04060056|OTHER|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
41512373|NCT03484702|DRUG|JCAR017|Specified dose on specified days
41512374|NCT02918812|DRUG|Intracervical lidocaine|Intracervical lidocaine injected at four different points
41512375|NCT02918812|DRUG|Intramuscular Diclofenac|Intramuscular Diclofenac 30 mins before HSG
41512376|NCT00637494|DRUG|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
40859336|NCT03658733|DRUG|esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
41039384|NCT06219746|DIAGNOSTIC_TEST|PSMA-imaging|Subjects undergo additional imaging i.e. PSMA/SPECT/CT and PSMA/PET/CT
41039385|NCT05545553|DEVICE|Piezosurgery|Piezosurgery used as an osteotomy device
41512377|NCT00637494|DRUG|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
41390242|NCT03628001|PROCEDURE|ERCP|Pts will be randomized with or without sphinterectomy.
40859337|NCT03658733|DRUG|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
40859338|NCT05750576|DEVICE|Chlorhexidine-impregnated dressings|Sterile adhesive transparent dressings impregnated with Chlorhexidine Gluconate gel applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
40859339|NCT05750576|DEVICE|Non impregnated dressings|Single transparent adhesive dressings not impregnated with Chlorhexidine Gluconate applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
40859340|NCT00531635|DRUG|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
41167308|NCT02798692|BIOLOGICAL|Medium dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
40859341|NCT01915173|DRUG|Supplement|Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
40859342|NCT01915173|DRUG|Placebo|Lactose tablets
40859343|NCT01915173|BEHAVIORAL|Expanded Interview|
41390243|NCT00365469|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
40859344|NCT01915173|BEHAVIORAL|Standard Interview|
41390244|NCT00365469|OTHER|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
40859345|NCT01237236|DRUG|LEE011|
41390245|NCT00779844|PROCEDURE|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
41390246|NCT00779844|PROCEDURE|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
41390247|NCT01333631|DRUG|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
40859346|NCT00397436|PROCEDURE|UV Irradiation|UV irradiation
40859347|NCT06413797|BEHAVIORAL|FDA warnings + Image|For six days (days 2-7) participants will be contacted and asked to complete a daily survey. As part of the survey, participants will view FDA-proposed LCC warnings with images at 30% size on a cigarillo package. Participants will be contacted each day to be invited to complete the survey for that day of the study protocol.
40859348|NCT06413797|BEHAVIORAL|FDA Warnings Text-Only|Participants will receive messages including images in 30% size.
40859349|NCT06413797|BEHAVIORAL|Surgeon General Text-Only Warnings|Participants will receive messages including Surgeon General Text-only Warnings.
40859350|NCT00566852|DRUG|Memantine|Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
41039386|NCT05545553|DEVICE|Conventional burs|Conventional burs used as an osteotomy device
41039387|NCT02511431|DRUG|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
41167309|NCT02798692|BIOLOGICAL|High dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
41167310|NCT02798692|BIOLOGICAL|Placebo|Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
41390248|NCT01273584|DRUG|Metformin|Maximum dosage 500 mg 2 tablets 3 times a day (with each meal) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
41390249|NCT01273584|DRUG|Placebo|Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
41039388|NCT02511431|DRUG|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.
41039389|NCT02511431|OTHER|Placebo|Placebo
41039390|NCT05744895|DEVICE|Device: Robotic MAKO total knee|Prospective TKA patient receiving total knee arthroplasty using the MAKO robotic machine
41039391|NCT05744895|DEVICE|FocusMotion knee brace|Focusmotion knee brace measures range of motion during exercises
41039392|NCT05744895|DEVICE|Fitbit tracking device|Fitbit will measure patients steps, HR, and sleep
41039393|NCT05744895|DEVICE|FocusMotion app|Will survey patients with PROMS
41039394|NCT02853968|PROCEDURE|Blood draw/buccal swab|The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.
41167311|NCT04156347|DRUG|Episcleral Topotecan|Transscleral Topotecan
41390250|NCT01770678|OTHER|Constraint Induced Movement Therapy|A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
41390251|NCT01931501|DRUG|Torrent's Montelukast Sodium Chewable Tablets 5mg|
41390252|NCT01931501|DRUG|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
41390253|NCT03087929|OTHER|Follow up|
41390254|NCT05176080|DRUG|Famitinib|Famitinib orally, daily or every other day
41390255|NCT05176080|DRUG|SHR6390|SHR6390 orally, daily for 3 weeks followed by 1 week off
41390256|NCT05176080|DRUG|Fulvestrant|Fulvestrant
41390257|NCT05697107|DRUG|Ripretinib Oral Tablet|Oral kinase inhibitor
41390258|NCT04398888|OTHER|Banxie Xiexin Decoction (BXD)|A modified Banxie Xiexin Decoction based on Chinese medicine syndrome differentiation.
41390259|NCT00530452|DRUG|CG100649|Dual-acting COX-2 inhibitor \& carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
41512378|NCT03495375|DIETARY_SUPPLEMENT|Treatment with a probiotic|All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.
40859351|NCT00566852|OTHER|Placebo|Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
41390260|NCT00530452|DRUG|Silicified microcrystalline cellulose + talc|Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
41390261|NCT06090500|PROCEDURE|Cryotherapy|preoperative submucosal infiltration injection of cold saline solution (2-5 degrees Celsius)
41390262|NCT06090500|PROCEDURE|Diclofenac sodium|preoperative submucosal infiltration injection of Diclofenac sodium (25mg/ml)
40859352|NCT00566852|RADIATION|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
40859353|NCT00345865|DRUG|carmustine|Day -6, 300 mg/m\^2 over 2 hour
40859354|NCT00345865|DRUG|cyclophosphamide|"NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m\^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing."
40859355|NCT00345865|DRUG|etoposide|"NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.~HL without radiation: 150 mg/m\^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4."
41390263|NCT06090500|PROCEDURE|Dexamethasone sodium phosphate|preoperative submucosal infiltration injection of dexamethasone sodium phosphate (4mg/ml)
41390264|NCT05741983|PROCEDURE|Microfracture (MFx)|The ankle arthroscopy will be a standard procedure. The lesion will be identified, measured and prepared with curettage and soft tissue shaver. Preparation includes debridement of the unstable cartilage and in case of a chondral defect associated with a bone defect, the subchondral cyst is debrided. After debridement, the defect is classified and the lesion size is measured again.The microfracture will be performed with a microfracture awl. In cases of a chondral defect associated with a bone defect (osteochondral defect) the bone lesion must be treated concomitantly. Portal closure will be with steri-strips. All patients will follow the standard postoperative rehabilitation protocol including post op non-weight bearing and range of motion exercises for 6 weeks.
41390265|NCT05741983|DEVICE|Chondro-Gide®|After the microfracture is performed and before the concomitant treatment of a bony lesion (if present), the defect size will be templated, and the membrane cut into its correct size. The joint is then drained and the membrane will be applied over the defect and stabilised with Fibrin glue. In cases of a osteochondral defect the bone lesion must be treated concomitantly. Once the bone defect has been treated, the Chondro-Gide® membrane is used to cover the site, and to support new cartilage tissue formation at the joint interface. Fluid will be reintroduced, and the stability of the membrane will be confirmed arthroscopically.
41390266|NCT04152252|OTHER|Real time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
41390267|NCT04152252|BEHAVIORAL|Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
41390268|NCT02586545|OTHER|Shared care|
41390269|NCT01246986|DRUG|LY2157299|Administered orally
40859356|NCT00345865|PROCEDURE|peripheral blood stem cell transplantation|Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
40859357|NCT00345865|RADIATION|irradiation therapy|"Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~* \> 1000 cGy to whole lung, kidney, or abdominal bath.~* \> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~* \> 3600 cGy to whole brain."
41039395|NCT02289131|PROCEDURE|Tooth Brushing Protocol|A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
41390270|NCT01246986|DRUG|Sorafenib|Administered orally
41390271|NCT01246986|DRUG|Ramucirumab|Administered IV
41512379|NCT03495375|OTHER|Treatment with placebo|All participants will take the placebo once daily for 10 weeks.
41512380|NCT00307021|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|3-dose intramuscular injection, 2 different formulations
41390272|NCT01558869|DRUG|Capecitabine|1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
41390273|NCT01558869|DRUG|Oxaliplatin|70 mg/m2 IV on day 1 of a 2-week cycle
41390274|NCT01558869|DRUG|Irinotecan|130 mg/m2 IV on day 1 of a 2-week cycle
41512381|NCT00362336|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
41512382|NCT00362336|BIOLOGICAL|CombAct-HIB®|0.5 mL, IM
41512383|NCT00362336|BIOLOGICAL|Engerix B® Pediatric|0.5 mL, IM
41512384|NCT02559180|DRUG|aflibercept|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
41512385|NCT05974852|OTHER|Ocrelizumab|Non-interventional
41512386|NCT04982302|PROCEDURE|Non-surgical periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets
41512387|NCT04622748|BEHAVIORAL|Trier Social Stress Test|8-min oral calculation and 5-min speech
41390275|NCT03874533|DEVICE|Self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests ; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
41390276|NCT03406039|BEHAVIORAL|Integrated Online CBT and MI|The treatment condition will have access to 12 treatment modules and have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, young adults will identify goals related to alcohol use and mood, learn strategies to cope with alcohol cravings, triggers, and social pressures, and learn how to prevent relapse. There will also be several modules to target anxiety and depression, focusing on strategies designed to help reduce negative thinking and worry, increase behavioural activation, and increase self-care (e.g., sleep hygiene).Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
41390277|NCT00145652|DRUG|Neo-Recormon and Venofer|
41390278|NCT04297254|DRUG|Lenvatinib|Lenvatinib capsules.
41390279|NCT00695981|PROCEDURE|Rotator cuff repair|Rotator cuff repair + physical therapy according to a standardized protocol
41390280|NCT00695981|PROCEDURE|Conservative treatment|Physiotherapy according to a standardized protocol
41390281|NCT06134973|DIAGNOSTIC_TEST|ultrasonic testing|ultrasonic testing
41390282|NCT04960774|OTHER|Observational study, no intervention|Observational study, no intervention
41390283|NCT00869141|DRUG|glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)|Subjects may receive glaucoma medications after Ahmed valve implantation
41390284|NCT06266975|DEVICE|Biobsy from kidney|using tyrosine kinase inhibitors particulary imatinib in ttt CML patients
41390285|NCT02404779|DRUG|cisatracurium besilate|
41390286|NCT02404779|OTHER|Placebo|
41390287|NCT06336226|PROCEDURE|Brachio basilic arterio venous fistula one stage versus two stage|Comparative study between one stage brachio basilic arterio venous fistula versus two stage
41390288|NCT05210998|OTHER|Gradual Aerobic exercise training AND Respiratory muscle training|Combined Exercise Group
41390289|NCT05210998|OTHER|Gradual Aerobic exercise training|Aerobic exercise Group
41390290|NCT05048745|PROCEDURE|interval appendectomy|interval appendectomy
41390291|NCT02369627|DEVICE|Rapid HIV Self-Test (OraQuick® In-home HIV Test)|The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
41390292|NCT02369627|DEVICE|Conventional Home-Based HIV Test (Home Access Express)|The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
41390293|NCT02369627|OTHER|Community/Medical-Based HIV Test|The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
41390294|NCT03771768|RADIATION|Diode laser 980nm&100 mWatt|Diode laser 980 nm \&100 milli Watt.
41390295|NCT03771768|DRUG|Triamcinolone Acetonide|0.1 \&5gm paste 4 times/day
41390296|NCT01701778|DRUG|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline"
40859358|NCT00345865|BIOLOGICAL|G-CSF|"Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF."
40859359|NCT00345865|DRUG|Cytarabine|100 mg/m\^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
40859360|NCT04556279|PROCEDURE|adrenalectomy|Surgical removal of an adrenal gland containing an aldosterone secreting adenoma.
41390297|NCT01701778|DRUG|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg"
41390298|NCT01701778|DRUG|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline"
40859361|NCT04556279|DRUG|Aldosterone Antagonist|Medical treatment of primary hyperaldosteronism.
41390299|NCT01701778|DRUG|sevoflurane|Induction and maintain anaesthesia
41390300|NCT05958459|OTHER|Eye Exercise|The individuals in the study group will perform home-based eye exercises for at least 1 session (\~30 min.) every day for a total of 12 weeks, after the patient's condition is stable, starting from the 7th day after the surgery. After the initial assessment, participants will be given illustrated brochures describing the exercises and will be taught how to perform the exercises. Whether individuals comply with the exercise program will be closely monitored (by keeping a diary, online meetings and periodically calling individuals). The control group, on the other hand, will not perform any exercise, but will only be evaluated. Eye exercises include eight steps. These; Covering the eyes with the palm of the hand, blinking, lateral gaze, anterior and lateral gaze, rotational gaze, up-down gaze, nasal tip gaze, and near and far gaze.
41390301|NCT05958459|OTHER|no intervention|no intervention
41039396|NCT01650259|DRUG|OAD|OAD except Trazenta tablets
41039397|NCT01650259|DRUG|Trazenta|Linagliptin
41039398|NCT00251953|DRUG|Tesaglitazar|
41039399|NCT00251953|DRUG|Metformin|
41039400|NCT02935062|BEHAVIORAL|Traditional Phonological Therapy|Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
41039401|NCT02935062|BEHAVIORAL|Software Phonological Therapy- SIFALA|The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
41039402|NCT02935062|BEHAVIORAL|Placebo Therapy|No intervention to improve speech.
41512388|NCT02765425|DEVICE|AMES|Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
41390302|NCT00435825|DRUG|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
41390303|NCT02414074|BEHAVIORAL|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
41390304|NCT02414074|BEHAVIORAL|Parent Education|Everyday Parenting is a parent training curriculum.
41390305|NCT03405701|PROCEDURE|IVM|Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
41390306|NCT03405701|PROCEDURE|IVF|Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
41390307|NCT05114018|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Daily oral dose
41390308|NCT05114018|DIETARY_SUPPLEMENT|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
41390309|NCT00108758|DRUG|activated recombinant human factor VII|
41390310|NCT00720473|DRUG|Lamotrigine|Lamotrigine with dosage range from 25 mg to 200 mg per day.
41390311|NCT00822263|DRUG|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
41390312|NCT00822263|DRUG|Placebo|Control for study
41390313|NCT01093040|DRUG|CAT-354|150 mg CAT-354 or placebo given SC on Day 1
41390314|NCT01093040|DRUG|CAT-354|300 mg CAT-354 or placebo given SC on Day 1
41390315|NCT01093040|DRUG|CAT 354|600 mg CAT-354 or placebo given SC on Day 1
40859362|NCT00279916|DRUG|Triamcinolone acetonide nasal spray|"Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms)."
41390316|NCT05730829|OTHER|pain informed movement|group classes twice weekly for 8 weeks of neuromuscular exercise in combination with mind-body techniques such as breath regulation, muscle tension regulation, relaxation, mindfulness, awareness of pain related thoughts and emotions.
41390317|NCT05730829|OTHER|standard neuromuscular exercise|group classes twice weekly for 8 weeks of neuromuscular exercise.
41390318|NCT05730829|OTHER|Pain Neuroscience Education (PNE)|The pain neuroscience education (PNE) will be delivered in videos addressing concepts such as the purpose of pain, neurophysiological changes of pain, movement guidelines when pain persists, and self-care techniques to impact neurophysiology and support moving with ease that include breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness.
41390319|NCT05730829|OTHER|Standard osteoarthritis (OA) education|The standard osteoarthritis (OA) education will address the following topics, OA prevalence, risk factors, symptoms, diagnosis, treatment, role of exercise, surgery, self-management
41390320|NCT04822558|OTHER|Plantar pressure measurement|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
41390321|NCT04822558|OTHER|Gait analysis|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
41390322|NCT04822558|PROCEDURE|Ankle and hindfoot reconstruction surgery|Ankle and hindfoot reconstruction surgery
41390323|NCT00998582|DRUG|Tenofovir disoproxil|Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
41390324|NCT02367729|DEVICE|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
41390325|NCT02367729|DEVICE|Sham|Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
41417828|NCT01364870|DEVICE|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
40859363|NCT00279916|DRUG|Placebo nasal spray|"Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily."
40859364|NCT00760318|DRUG|Keppra|There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
40859365|NCT04364295|DEVICE|Spinal Surgery with SeaSpine product|Implanted with SeaSpine spinal or orthobiologic product
41039403|NCT00712842|OTHER|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
41390326|NCT04389619|DEVICE|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency. Fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
41390327|NCT04389619|PROCEDURE|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. o Scars treated with intralesional steroids will be subgrouped into two groups, one group treated with only intralesional steroids and the other group treated with intralesional steroids and followed by microneedling. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
41390328|NCT02637609|OTHER|Likert Scale|Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
41390329|NCT02637609|OTHER|Best-Worst Scaling (Case 1)|Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
41390330|NCT06222398|DEVICE|Exoskeleton|The study will include one group of patients who are current exoskeleton users.
41390331|NCT01932801|DRUG|XR-NTX|
41390332|NCT01932801|OTHER|Placebo|
41390333|NCT01932801|BEHAVIORAL|HRC|
41390334|NCT01379365|DEVICE|Cryo-Touch III|Percutaneous treatment with the device
41390335|NCT01178112|DRUG|Trientine|Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
41390336|NCT01178112|DRUG|Carboplatin|Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
41512389|NCT01228799|PROCEDURE|trabeculectomy|trabeculectomy with mitomycin C 0.2mg/ml
41512390|NCT01228799|PROCEDURE|Canaloplasty|Canaloplasty with implant of suture
40859366|NCT05419934|BEHAVIORAL|EMDR therapy|"Children will receive an EMDR psychotherapy comprising 8 treatment phases. As the treatment progresses, the child will proceed to desensitize the events of adversity experienced.~Phase 1 and 2, before the desensitization phases:~1. History of the patient (collection of anamnesis)~2. Securing the patient, preparing for the desensitization phases~   Desensitization phases, to be repeated for each traumatic event to be desensitized:~3. Evaluation of the target to be treated~4. Desensitization~5. Installation of positive beliefs~6. Body scanner (verification of body non-response)~7. Closure, verification that the patient is in a stable emotional state allowing him to leave the session~   Reassessment phase, to be repeated for each traumatic event that has been desensitized:~8. Reassessment of the traumatic target, verification of complete desensitization."
41512391|NCT05797844|OTHER|Active implementational educational strategy|4 follow-up visits (active implemantation strategy) were carried out for ETT cuff pressure management using the one-on-one demonstration technique every 21 days. These follow-ups included adherence to evidence-based guidelines, nurses' application of endotracheal cuff pressure measurement and solving the problems encountered during its implementation. Uncertainties associated with evidence-based guidance on endotracheal tube cuff pressure control were clarified during these sessions.
41512392|NCT05797844|OTHER|Passive implementational educational strategy|Theoretical training on endotracheal tube cuff pressure management through a 4-hour presentation prepared with evidence-based guide and literature. A PowerPoint presentation including endotracheal tube cuff pressure normal values, complications related to endotracheal tube cuff pressure, management of endotracheal tube cuff pressure, endotracheal tube cuff pressure control methods, methods affecting endotracheal tube cuff pressure, how to measure endotracheal tube cuff pressure was made.
41039404|NCT06285682|DIETARY_SUPPLEMENT|OliPhenolia®)|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. Participants will consume three doses within the entire study, one dose per visit, separated by a ≥3 day wash out period.
41039405|NCT02170740|DRUG|BIBR 1048 MS - low dose|
41039406|NCT02170740|DRUG|BIBR 1048 MS - high dose|
41039407|NCT02170740|DRUG|BIBR 1048 MS + Pantoprazole|
41039408|NCT02228265|OTHER|Cytology Specimen Collection Procedure|Undergo blood and tissue collection
41390337|NCT01178112|DRUG|Trientine MTD|Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.
41390338|NCT01178112|DRUG|Carboplatin MTD|Maximum tolerated dose found in MTD Dose Escalation Group
41390339|NCT01178112|OTHER|PK Testing|Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
41390340|NCT05065242|BEHAVIORAL|Cognitive Behavioural Therapy|Sleep restriction, Stimulus control, sleep hygiene and cognitive techniques to handle sleep disturbing thoughts.
41390341|NCT05381883|OTHER|Questionnaire|"Participants will answer socio-demographic questions, questions about the lifetime experience of potentially traumatic events, the presence of a known psychological or medical disorder and the taking of medication, and a series of psychological assessment questionnaires.~The questionnaires, performed outside routine care, are as follows :~Posttraumatic stress disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 Beck Depression Inventory-Fast Screen General Anxiety Disorder-7 Coping Inventory for Stressful Situations Maslach Burnout Inventory Medical Outcomes Study Short-Form~The total time for completing the questionnaires is estimated at 20 minutes"
41390342|NCT05640375|DRUG|Methylprednisolone|Single dose, 1 mg/kg
41390343|NCT03355222|BEHAVIORAL|Promotion of chicken eggs|Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.
41390344|NCT00774722|DRUG|Metronidazole|10% ointment, three times daily for 14 days
41512393|NCT02106234|OTHER|No prophylactic iv hydration|Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
41512394|NCT01810510|PROCEDURE|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
41390345|NCT02256319|DRUG|Dexmedetomidine|Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
41390346|NCT02256319|DRUG|Propofol|The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
41390347|NCT03494205|DRUG|Urtica comp. gel|"Urtica comp. gel is a Swissmedic registered medication. The scope of application of Urtica comp. is an imbalanced, affected process of skin-regeneration, in particular when stemming from an overdose of heat or light.~It is applied in first and second-degree burn and scalding, sunburn, allergic and hyperergic (excessive) skin conditions (dermatoses), insect bites, abrasions and ulcers."
41390348|NCT03494205|DRUG|"institutional standard skin care Excipial-Hydrolotion"|"The institutional standard skin care Excipial-Hydrolotion is available to all patients"
41390349|NCT03660514|BEHAVIORAL|Jovenes Sanos|FP counselors in intervention clinics will a) provide counseling and education regarding risk of partner detection of FP methods, and women's and girls' strategies to use FP methods to minimize partner detection risk integrated into standard FP counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPC (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) distribute palm-sized educational materials on RC and IPV, as well as IPV services.
41390350|NCT00607906|DRUG|SB-756050 immediate release capsule|SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
41390351|NCT00607906|DRUG|SB-756050 modified release capsule|SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
41390352|NCT00607906|DRUG|Placebo|Subjects will also receive placebo capsules.
41390353|NCT00949572|BIOLOGICAL|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
41417829|NCT06356675|DRUG|Tislelizumab|200mg iv D1 Q3W
41512395|NCT01810510|PROCEDURE|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
41512396|NCT06581770|OTHER|Survey using a questionnaire.|It is a validity and reliability study that can evaluate digital health readiness.
41512397|NCT06581770|OTHER|Survey using a questionnaire.|This is a reliability and validity study.
41512398|NCT03631316|DRUG|Generic Valganciclovir|900 mg daily during 4 days
41512399|NCT03631316|DRUG|Innovative Valganciclovir|900 mg daily during 4 days
41512400|NCT00791544|DRUG|AVE1642|intravenous infusion
41512401|NCT00791544|DRUG|sorafenib|oral intake
41512402|NCT00791544|DRUG|erlotinib|oral intake
41417830|NCT06356675|DRUG|Anlotinib|Anlotinib 12mg D1-12 Q3W
41039409|NCT02228265|DRUG|Enzalutamide|Given PO
41039410|NCT02228265|OTHER|Laboratory Biomarker Analysis|Correlative studies
41039411|NCT06496997|DRUG|Methylprednisolone|Methylprednisolone at a dose of 1 mg/kg/day (an average dose of 70 mg/day based on 70 kg body weight)
41039412|NCT06496997|DRUG|Dexamethasone|Dexamethasone at an equivalent dose of 13 mg/day
41039413|NCT06496997|DRUG|Hydrocortisone|Hydrocortisone at an equivalent dose of 350 mg/day
41039414|NCT02660632|OTHER|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
41390354|NCT00949572|BIOLOGICAL|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
41390355|NCT00854386|DRUG|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
41390356|NCT00854386|DRUG|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
41167312|NCT04380883|DEVICE|InnoSEAL+TRB|InnoSEAL is a catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc.). Chitosan-Catechol in InnoSEAL instantly forms an adhesive barrier upon blood contact. It is intended for use under the care of a healthcare professional. The dressing is indicated for the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes. TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. We will apply InnoSEAL and TRB together.
41167313|NCT04380883|DEVICE|TRB alone|TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. It will be the comparing arm.
41512403|NCT06204029|BEHAVIORAL|Everyone can sing|"The choir lessons are taught by a trained choir leader in close collaboration with the teacher in each class. The choir leaders and music teachers at the school also facilitate choir in the morning for selected or all classes. A special AKS pedagogy is developed and based on the inclusive nature of joyful musicking with body and voice. The pedagogy is developed to ensure that everyone is taken care of, so all children regardless of social or cultural background develop social and professional competencies central to a positive school life. The most important elements in this pedagogy include: A co-teacher system; Each student has a choir partner; Discipline in the classroom lessons is maintained by clear, simple, and subtle means."
41390357|NCT03467828|GENETIC|polymorphism analyzing|Blood samples will be taken to EDTA containing tubes and then will be analyzed for genetic polymorphisms.
41512404|NCT01790087|DRUG|ANX-188 Therapeutic Dose|
41390358|NCT01781689|PROCEDURE|Functional Electric Stimulation|apply to the hemiplegia affected limbs, helping movement
41390359|NCT01781689|OTHER|Rehabilitation programs|include occupational therapy and physical therapy
41167314|NCT02485314|OTHER|Participation|The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
41167315|NCT04660578|PROCEDURE|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
41390360|NCT04772469|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
41390361|NCT04772469|OTHER|Small monetary incentives|Use of small incentive voucher (\~$5) to encourage linkage to confirmatory testing.
41390362|NCT04772469|BEHAVIORAL|Use of SMS/text reminders to motivate adherence to ART or PrEP|"Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support."
41390363|NCT01058876|DRUG|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
41390364|NCT06160882|OTHER|Powered Prosthesis Training and EMG data collection|"Participants are fit for a custom instrumented socket for collection of surface EMG signals and use with the powered lower limb prosthesis.~EMG control sites will be located using clinical best practices. Once socket fit is completed, the prosthetist will attach and align the powered prosthesis. The participant will be instructed to walk with the powered prosthesis for level ground walking, incline walking, stair climbing and non-weight bearing independence control activities. A non-weight bearing independent control system will be configured. These data are used to train a pattern recognition control system which can control the leg knee and ankle joints respectively, either in a virtual environment or with the physical prosthesis The participants will complete functional, biomechanical, metabolic, and patient reported outcome measures."
41390365|NCT06160882|PROCEDURE|Perform Osseointegration (OI) surgery and Targeted Muscle Reinnervation (TMR)|"Participants will undergo OI Surgery 1 +TMR and recovery. Following recovery, participants will receive OI surgery 2 where the abutment is connected to the fixture with in the femur. Participants will receive standard post-surgical care and participate in the OPRA rehab program through the Shirley Ryan AbilityLab. The participant uses their clinically prescribed prosthetic knee unit for training in the OPRA rehab program.~Post-Surgery Fitting and Powered Leg Prosthesis Training: EMG signals are measured using a custom fit electrode band on the residual limb that is tethered to the prosthesis. Participants are fit with the powered prosthesis using their OI interface and trained on its use. The participant will complete non-weight-bearing neural control tasks as done prior to surgery. The participants will complete functional, biomechanical, metabolic, and patient-reported outcome measures using the OI interface and the powered leg prosthesis."
41512405|NCT01790087|DRUG|ANX-188 Supratherapeutic dose|
41512406|NCT01790087|DRUG|Saline|
41512407|NCT01790087|DRUG|Moxifloxacin|
41512408|NCT01574690|DEVICE|Mespere Venus System|For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam
41512409|NCT01574690|PROCEDURE|Right heart catheterization (RHC)|Invasive procedure to assess CVP. Standard of care.
41512410|NCT01574690|PROCEDURE|Physical examination of jugular vein|Physicians assess CVP using the subject's jugular vein.
41512411|NCT05929859|BEHAVIORAL|Speech Motor Chaining|Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.
41512412|NCT03437473|DEVICE|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
41390366|NCT02540473|BEHAVIORAL|Manualized Therapy|Relational psychotherapy mothers
41390367|NCT02540473|BEHAVIORAL|Control Group|one hour of free time to do with as they wish
41390368|NCT01883531|DRUG|Inhaled Mannitol|Active treatment is inhaled mannitol with a particle size of 3-4 microns
41390369|NCT01883531|DRUG|Inhaled Placebo|The PLacebo is non respirable mannitol due to the big size particle
41390370|NCT03441958|BIOLOGICAL|ECT-001 (UM171) expanded cord blood|ECT-001 expanded cord-blood will be produced and infused on site
41390371|NCT01318200|PROCEDURE|Transarterial Chemoembolization|Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
41390372|NCT01318200|RADIATION|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
41390373|NCT05673915|DEVICE|ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS)|Stimulation setting 0.1 mA daily for a 2-month period. Each daily treatment will last for approximately 30 minutes.
41390374|NCT05673915|DEVICE|ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)|Stimulation setting 2.0 mA daily for a 2-month period. A Each daily treatment will last for approximately 30 minutes.
41390375|NCT01923207|DRUG|DX-2930|
41390376|NCT01923207|DRUG|Placebo|placebo, subcutaneous administration
41512413|NCT05778812|BEHAVIORAL|Full Sleep|"Daily lessons about sleep and skills that can help with sleep. Participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach, for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
40676665|NCT06619067|DIETARY_SUPPLEMENT|PROBAFLOR|PROBAFLOR is a food supplement made up of 11 bacterial strains and inulin. The bacterial strains present are: Bifidobacterium lactis BLC1, Lactococcus lactis LL82, Lactobacillus plantarum 14D, Lactobacillus acidophilus LA1, Streptococcus thermophilus Z57, Bifidobacterium longum SP54, Lactobacillus rhamnosus SP1, Lactobacillus bulgaricus LB2, Bifidobacterium bifidum SP9,Lactobacillus salivarius SP2, Lactobacillus casei BGP93.
40676666|NCT06619067|OTHER|Placebo|Placebo
40676667|NCT06620497|PROCEDURE|stress free implant bar|SFI bar was sectioned and adjusted on the model for more convenience and to save the time of the appointment. The bar (Cendres Metaux, Switzerland) abutments were screwed to the implant analogues.
41167316|NCT00944892|DRUG|REGN475|2 Administrations of REGN475 within 24 weeks.
41390377|NCT02548117|DRUG|Finasteride|Subjects will take 5 mg finasteride orally every day for about 2 years.
41390378|NCT02729545|OTHER|Tung's acupuncture|The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
41390379|NCT02729545|DRUG|Cyproterone acetate/ethinylestradiol (CPA/EE)|Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
41390380|NCT06070493|OTHER|classic physiotherapy program|For individuals of control group, a hot pack was applied to the shoulder area for 15 minutes, while the individuals were in the sitting position. The conventional mode of transcutaneous electrical nerve stimulation was used. Frequency was adjusted in the range of 50-100 Hz, and the amplitude intensity was adjusted between 10-30 milliampere with the intensity of mild tingling without causing any excessive discomfort or contractions. Electrodes were placed at the anterior, posterior, superior, and inferior of the shoulder region. In the exercise program of the patients, joint range of motion exercises, stretching, scapular stabilization, rotator cuff, and shoulder muscle strengthening exercises were given.
41390381|NCT06070493|OTHER|Myofascial release|myofascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the lateral neck and shoulder, pectoral region, scapulothoracic area, and arm regions for 5 minutes for optimum benefit.
41390382|NCT03954964|BEHAVIORAL|Education on disposal of opioids|Current class curriculum including education about pain management with additional education about the disposal of opioids.
41390383|NCT00438035|PROCEDURE|ECG spectral|
41390384|NCT06540183|PROCEDURE|Percutaneous intramyocardial septal radiofrequency ablation|Percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) is an innovative minimally invasive ablation treatment. Under the real-time transthoracic echocardiography guidance, a radiofrequency electrode needle is introduced into the hypertrophied interventricular septum via the percutaneous intramyocardial approach. Then the needle tip is pushed to the target region of the interventricular septal (IVS) basal segment 8 to 10 mm from the subaortic valve. The main objective of PIMSRA is to reduce ventricular septal hypertrophy and left ventricular outflow tract obstruction by means of thermal ablation.
41417831|NCT04894513|OTHER|Kabat motor control re-education therapy|Kabat motor control re-education therapy that includes specific movements with predefined patterns of facial muscles exercises, which is spiral and diagonal movements involve the facial muscles, which are brought to train in global patterns. The program of treatment for three times per week for six weeks.
41417832|NCT04894513|OTHER|conventional selected program|the conventional selected program in the form of electrical stimulation (Faradic current) of affected muscles, facial muscle exercise program in front of the mirror, and home advices.
41390385|NCT03863652|PROCEDURE|Percutaneous coronary intervention via snuffbox approach|After local anesthesia on left or right anatomical snuffbox with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by an insertion of the 5Fr. or 6Fr radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan). The selection of puncture device is at physician discretion.
41390386|NCT03151226|DEVICE|Capnography monitoring|capnography and pulse oximetry will be initiated in the recovery room and worn for 12-24 hours post delivery
41390387|NCT03300882|OTHER|Procedure|Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
41390388|NCT02379676|DRUG|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
41390389|NCT02379676|DRUG|Clopidogrel|Clopidogrel 75mg once daily for 30 days
40859367|NCT05419934|BEHAVIORAL|Routine Care|Children in the routine care group receive psychological monitoring administered by the Lenval Foundation (CHU de Nice - France) within the Pediatric Psychotrauma Assessment Center (Centre d'évaluation du psychotraumatisme pédiatrique - CE2P). The proposed treatment is a psychological follow-up associated with relational support psychotherapy
40859368|NCT02209701|DRUG|Porfiromycin|
41390390|NCT06136494|BEHAVIORAL|Internet-delivered cognitive behavioural therapy|Psychoeducation aims at teaching patients about chest pain and anxiety and their impact on daily life. Mindfulness is used to raise awareness of what is going on in the body and emotions and to learn how to relate to chest pain. Physical activity consists of psychoeducation and recommendations regarding physical activity with the goal to get patients to learn that their heart tolerates physical activity and to reduce cardiac anxiety and avoidance of physical activity. Avoidance/exposure is to teach patients how avoidance and safety behaviours can maintain/exacerbate chest pain and negatively impact daily life. Acceptance is about learning to accept having the chest pain without letting it take over one's life. The participants will have weekly assignments with weekly feedback and advice. Reminders and encouraging messages will be sent to motivate participants to complete the intervention. The treatment will be carried out through our own web platform.
41390391|NCT06136494|BEHAVIORAL|Attention control|General support via weekly email contact to check how participants are feeling and how they are dealing with their situation. iCBT will be offered after 3 months.
41390392|NCT06538454|BEHAVIORAL|Resistance training|"The exercises will be the same in both stages: squat, bench press, stiff, rowing, hip thrust and shoulder press. Futhermore, the rest interval (2 minutes) and the exercise order (alterning upper and lower limbs) also will be the same in the stages.~In the chronic experiment, the resistance training will be carried for 10 weeks with 2 weekly sessions in alternate days. The sets in both groups will be carried close to muscle failure.~The difference between groups is the intensity, who reflects the repetition zone. The 80%1RM group will be perform 8-10 repetitions per set, while the 60%1RM group will be perform 18-20 repetitions."
41390393|NCT06393816|DRUG|Durvalumab with etoposide and Carboplatin/Cisplatin|"Combination of durvalumab with etoposide and Carboplatin/Cisplatin as First Line Treatment in Patients With Large-cell Neuroendocrine Carcinomas of the Lung.~All patients (either with confirmed diagnosis or not) will be treated and followed-up:~* During the induction: every 3 weeks for 12 weeks (4 cycles)~* During the maintenance: every 4 weeks for 24 months"
41390394|NCT03512626|DEVICE|OptiVis, Aaren Scientific|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
41390395|NCT03512626|DEVICE|Monofocal IOL|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
41390396|NCT03749525|DRUG|shenfu injection|we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
40859369|NCT04389723|DIETARY_SUPPLEMENT|Qualia Mind|Multi-ingredient Dietary supplement
40859370|NCT04389723|DIETARY_SUPPLEMENT|Placebo|Multi-ingredient Placebo
41390397|NCT06017011|OTHER|Total contact cast|Total contact cast will be put on the patient at the diagnosis of Acute charcot neuroarthropathy and the patient will be followed till clinical remission and after that till 6months post clinical remission. F18 Fluoride PET scan and MRI of the foot with DWI and ADC sequence to be done at baseline, Clinical remission, 3months post clinical remission and 6months post clinical remission to quantitate the process of remission.
41390398|NCT02854722|DRUG|Deferasirox and calcium-vitamin D3|"deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy."
41390399|NCT02854722|DRUG|Calcium-vitamin D3|Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
41390400|NCT01336218|DRUG|fostamatinib|oral tablets, 150mg (3 X 50mg) single dose per period
41390401|NCT01336218|DRUG|rifampicin|oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
41417833|NCT03318692|PROCEDURE|spondylodesis|Dorsal instrumentation with transpedicular screws (spondylodesis)
40859371|NCT05118698|DRUG|Gynostemma|Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
40859372|NCT05118698|OTHER|Spinach|For the spinach powder group, each patient will take spinach powder with nearly no saponin content, 3 times a day for 3 months.
40859373|NCT02697318|DRUG|Timolol maleate 0.5% ophthalmic solution|
40859374|NCT01474720|DRUG|Zostavax vaccine|Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
40859375|NCT04141423|DRUG|Tregopil|Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.
41390402|NCT03994419|PROCEDURE|Anaesthesia for surgery|Observational study observing proportion of obese and overweight children attending for surgery. Observing adverse events following general anaesthesia for surgery in obese versus healthy weight children.
41390403|NCT00734617|DRUG|Nicotine Patch|"Groups 1 \& 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 \& 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day"
41390404|NCT06481709|DRUG|RLF-OD032|100 mg/mL oral suspension
41390405|NCT06481709|DRUG|Kuvan|100 mg powder for oral solution
41390406|NCT04904588|DRUG|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
41390407|NCT04904588|DRUG|Busulfan|Given IV pre-transplant as part of conditioning regimen
41390408|NCT04904588|DRUG|Fludarabine|Given IV pre-transplant as part of conditioning regimen
41390409|NCT04904588|RADIATION|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
41390410|NCT04904588|DRUG|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
41390411|NCT04904588|DRUG|Melphalan|Given IV pre-transplant as part of conditioning regimen
41390412|NCT04904588|PROCEDURE|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.
41390413|NCT04904588|PROCEDURE|Bone Marrow Hematopoietic Stem Cell Transplantation|Bone marrow graft is infused from a mismatched unrelated donor on Day 0.
41390414|NCT04904588|DRUG|Post-transplant Cyclophosphamide|Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.
41390415|NCT04904588|DRUG|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.
41390416|NCT04904588|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.
41390417|NCT04904588|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
41512414|NCT05778812|BEHAVIORAL|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
41390418|NCT04904588|OTHER|Patient-Reported Outcomes|Survey assessments will be administered to study participants pre- and post-transplant.
41390419|NCT04511884|DIAGNOSTIC_TEST|Next-generation sequencing|The patient who may be diagnosed with cryptogenic organizing pneumonia will be detected through next-generation sequencing.
41390420|NCT03820999|OTHER|Oral and written information on tick-bites and Lyme disease|See under study arm descriptions
41390421|NCT05275231|BEHAVIORAL|Intensive lifestyle interventions (ILIs)|Intensive lifestyle interventions (ILIs) is a group-based programs designed to promote weight loss through a combination of diet, activity, and behavior change, decrease Type 2 Diabetes (T2D) incidence in people with prediabetes and reduced complications among people with T2D.
41390422|NCT05250947|DEVICE|Angel® Concentrated Platelet Rich Plasma System|Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.
41390423|NCT05250947|DRUG|Platelet Rich Plasma|6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint
41390424|NCT06539039|PROCEDURE|non surgical periodontal therapy|participants received full mouth one stage debridement using hand instruments and use of universal curette for sub gingival debridement and ultrasonic scalers through use of supragingival and subgingival ultrasonic tips
41390425|NCT06073717|BEHAVIORAL|Exercise|Participants will complete a 5-month exercise program structured in 4 blocks of 5 weeks. Three supervised and combined aerobic/strength exercise sessions each week will be performed together with an aerobic weekly challenge. Aerobic exercise will be performed for 20-30 minutes using a treadmill, bicycle, or circuit training at light to moderate intensities (40-75% of heart rate reserve) during the first two blocks; gradually achieving high intensity (\>75% of HHR) in the last two blocks. Heart rate and the subjective perception of the exertion scale (6-20 Borg scale) will be monitored. Strength exercises will be started at light to moderate intensities (2 sets of 15-20 repetitions at 40-50% of repetition maximum), performed muscle actions at high intensities in the last two blocks (2 sets of 8-15 repetitions at 50-75% RM); using elastic bands, free weights, and weights gym exercises.
41390426|NCT06073717|BEHAVIORAL|Motor-cognitive Training|Participants will complete the same four-block exercise program in terms of type, frequency, intensity, and volume of physical/motor training. Simultaneous with the progression of physical/motor training, the complexity of cognitive stimulation will be increased according to the performance of the participants. General dual-task training will be performed, which describes the use of a physical/motor intervention with different cognitive stimulations (memory, language, intelligence, attention, processing speed, calculation, inhibitory control) that are not specific to the methods to be used for their assessment.
41512415|NCT06132061|OTHER|universal prevention|Health education related to depression to strengthen the participants' self-care skills to reduce sub-health risk factors.
41512416|NCT06132061|OTHER|selective prevention|Psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) aimed at risk factors to prevent more severe depressive symptoms.
40859376|NCT05766826|OTHER|Coupons for safe water program: Treatment|Randomly selected women in the treatment group will receive coupons for free chlorine solutions to be redeemed at the health facility each month.
41390427|NCT06073717|BEHAVIORAL|Health and Wellness|Participants randomly assigned to the health and wellness group will be advised and re-educated to support and improve health aspects. Participants in this group will aim to achieve the physical activity recommendations, and in addition, they will receive bi-weekly emails and phone call coaching with tools to empower patients with knowledge about physical exercise, nutrition, and brain health guidelines. Following completion of the 5-month exercise program, this group will receive an exercise program for 12 weeks.
41390428|NCT01747239|DRUG|Cabazitaxel|25 mg/m2 IV every three weeks
41390429|NCT06289335|DRUG|saline solution|20 mL of saline
41390430|NCT05469503|DIETARY_SUPPLEMENT|TOTUM-854|12 weeks of TOTUM-854 supplementation
41390431|NCT05469503|DIETARY_SUPPLEMENT|Placebo|12 weeks of placebo supplementation
41390432|NCT03460119|DEVICE|High Flow Nasal Cannula Oxygen|The high flow device that we used was an air oxygen blender (Whisper FlowⓇ), which allows FiO2 adjustment between 0.30 and 1.0 and can deliver a gas flow from 10 to 150 l/min. The gas mixture was routed from a heated humidifier (MR850 with MR 290 chamber) through a one line heated inspiratory circuit (RT241) to the subject at a temperature of 37°C via a nasal cannula (OptiflowⓇ).
41390433|NCT02487368|DEVICE|Needle stimulation pad|
41167317|NCT00944892|OTHER|Placebo|Placebo to match REGN475 doses
41167318|NCT00835510|DRUG|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
41167319|NCT00835510|DRUG|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
41167320|NCT00835510|DRUG|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
41512417|NCT06132061|OTHER|targeted prevention|Therapeutic psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) to reduce patients' depressive symptoms.
41512418|NCT06132061|OTHER|Waiting treatment.|Waiting treatment.
41390434|NCT03526796|PROCEDURE|Hyperbaric oxygen therapy|Patients were maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
41390435|NCT03970382|BIOLOGICAL|NeoTCR-P1 adoptive cell therapy|The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.
40676668|NCT06620497|PROCEDURE|milled bar|bar abutments were attached to the analogues and scan bodies were threaded into the bar abutments. The cast was scanned using a lab scanner (Ceramill, Amann Girrbach, Germany). The milled bar was selected from the software (Exocad DentalCAD) and designed digitally to connect the implants.
40676669|NCT06622408|OTHER|HypnoVR© virtual reality headset|Adherence to the use of the virtual reality headset will be reported by a percentage of use at each stage of care.
40859377|NCT05766826|OTHER|Coupons for safe water program: Control|Randomly selected women in the treatment group will not receive coupons for free chlorine solutions after enrollment.
40859378|NCT01806675|DRUG|18F-fludeoxyglucose (18F-FDG)|18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan
40859379|NCT01806675|DRUG|18F-FPPRGD2|18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.
41167321|NCT03842436|DEVICE|Digital pill|Digital pills over encapsulating Truvada
41167322|NCT03842436|DRUG|Truvada|Truvada prescribed with digital pills for PrEP
41167323|NCT05653973|DRUG|Acetylcholine|acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
41167324|NCT05653973|DRUG|Endothelin-1|endothelin-1, endothelin-1 + BQ-788 (endothelin receptor type B-inhibitor), and endothelin-1 + BQ-123 (endothelin receptor type A-inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelin-mediated constriction and the role of the receptor subtypes in this response.
41167325|NCT00781417|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU once a week for 12 weeks then every other week for 40 weeks
41167326|NCT00781417|OTHER|Placebo|Matching Placebo
41167327|NCT01213992|DRUG|Iron isomaltoside 1000|Single dose of 500 mg administered as a bolus undiluted over 2 min.
41167328|NCT01213992|DRUG|Iron isomaltoside 1000|Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
41167329|NCT03128528|DRUG|Empagliflozin 10mg|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
41167330|NCT03128528|DRUG|Placebo Oral Tablet|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
41390436|NCT03970382|BIOLOGICAL|nivolumab|Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody
41390437|NCT03970382|BIOLOGICAL|IL-2|IL-2 is a biologic response modifier. It is a type of protein called a cytokine.
41390438|NCT02941822|DRUG|Ambroxol|Details outlines in the intervention description.
41390439|NCT02726373|OTHER|type of walking|Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
41390440|NCT05685693|PROCEDURE|Robotic-assisted total knee arthroplasty (raTKA)|Robotic-assisted total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. The robot (ROSA Knee System, Zimmer Biomet, US) assists in planning and placement of the implants and resection sites.
41390441|NCT05685693|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. In conventional TKAs, no patient-specific instrumentation or robotic assistance is provided.
41512419|NCT01267487|DRUG|Heparin fixed doses|"Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT \> 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery."
41512420|NCT01267487|DRUG|PO continuous infusion of Protamine|25mg/hour in IV continuous infusion during first 6 PO hours
41512421|NCT01267487|DRUG|Heparin and protamine titration|"Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve."
41390442|NCT02148835|OTHER|Sausage: Triomeg|Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
41390443|NCT02148835|OTHER|Sausage: Control|Control sausage: as active, but no EPA+DHA ethyl-ester.
41390444|NCT01412710|DRUG|Cholecalciferol|4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.
40859380|NCT04712708|DEVICE|Rebound Therapy|Rebound therapy is the therapeutic use of full sized trampoline or mini sized trampoline. It provides opportunities for exercise recreation and therapy; and it is distinct from gymnastic trampolining. It is used for facilitating movements, improving balance, enhancing coordination and promoting motor performances in children with different disorders includes learning disabilities, communication disorders and motor dysfunction (Rebound Therapy South Africa, 2020; The Chartered society of Physiotherapists, 2016).
41512422|NCT06452134|DRUG|Coenzyme Q10 100 MG Oral Tablet|Coenzyme Q10 oral Tablet with dosage of 100mg daily given for a period of 30 days after surgery.
41039415|NCT02660632|OTHER|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
41039416|NCT05517317|COMBINATION_PRODUCT|Autologous BMMC transplantation|One administration of autologous bone marrow mononuclear cells via the hepatic artery
41390445|NCT06273917|OTHER|PRIDE|"Pharmacists present in the ED will perform medication reconciliation for eligible patients. This will be done to demonstrate the feasibility of the PRIDE intervention in the ED for patients with ADRD and MCI. Patients eligible for medication reconciliation will be enrolled in Aim 2 of the study.~Outpatient prescribers of these patients who are discharged from the ED will be contacted by the ED pharmacist on the date of ED discharge and will receive a medication report including fill data 90-100 days after the ED visit.~At the completion of the study, the outpatient clinicians will also receive a questionnaire about the acceptability of the PRIDE program including the Acceptability of Intervention Measure to complete electronically."
41039417|NCT05755191|DRUG|NEU-411|Oral Doses
41390446|NCT04120714|DEVICE|Active tDCS|active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions
41390447|NCT04120714|DEVICE|Placebo tDCS|inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions
41167331|NCT03408340|PROCEDURE|Paravertebral Nerve Block|Participants will be induced for anesthesia with propofol 3 milligram/kilogram (mg/kg) or ketamine 2mg/kg (if there is intravenous (IV) access) or sevoflurane with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established. A NIRS pad will be used for cerebral oximetry as well as another NIRS pad for spinal cord oximetry. The patient will be intubated, and then will be positioned laterally for the nerve block at approximately the left T3-4 level. A linear ultrasound probe with a sterile sheath will be used to provide imaging for the paravertebral nerve block. The injected solution will be 1 milliliter/kilogram (mL/kg) of 0.2% ropivacaine with 5 mcg/mL (1:200,000) epinephrine. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will not be infiltrated with additional local anesthetic at the conclusion of the case.
41390448|NCT04120714|OTHER|Questionnaires|"* visual analogue scale (VAS)~* impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)~* Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)~* Go-No go test~* HAM-D scale~* SF-12 quality of life scale"
41390449|NCT05309031|OTHER|Water Immersion|Participants will enter the pool, which has a thermoneutral temperature of 33°C (92°F), warm enough to be comfortable, but cool enough to avoid an increase in HR with similar ambient air temperature. A maximum depth of 4 to 4 feet 6 inches allows ample room participants to be immersed to the chest, float vertically and move in the pool. During 45 min of immersion, they will be instructed to stand, walk and move ad lib. Noodles will be available to hang or rest on in a vertical position. Taller participants will remain at the pool's deep end. The timeframe was chosen to approximate our previous immersion intervention length.
41390450|NCT03545529|OTHER|Innovativ supported|addition of connected tools and stronger accompaniment to prevent falls
41390451|NCT01138852|DRUG|Ampicillin-sulbactam|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
41390452|NCT01138852|DRUG|Cefuroxime|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
41512423|NCT06452134|DRUG|Placebo|Exactly same looking agent in the form of a tablet with same size and color to CoezymeQ10 with no active property given for a period of 30 days after surgery.
41512424|NCT04682522|DRUG|Metronidazole Oral|250 mg Three times a day
41039418|NCT05755191|DRUG|Placebo|Oral Doses
41039419|NCT04758312|BEHAVIORAL|MY-Skills Mobile|Yoga and Self-Management Education
41039420|NCT05118685|DRUG|Conjugated Estrogens vaginal cream 0,625mg|the particepant will receive vaginal estrogen cream one tube every night for 14 nights; then, one tube for 2 nights in 1 week (two tubes every week) for 10 weeks.
41167332|NCT03408340|DRUG|Standard of Care Anesthesia|Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established. The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
41512425|NCT02228850|DRUG|Alprostadil|
41512426|NCT02228850|OTHER|Placebo|
41390453|NCT00256100|DRUG|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
41390454|NCT04981405|BIOLOGICAL|COVID-19 Vaccines|"Gam-COVID-Vac EpiVacCorona COVIVAC"
41390455|NCT01652573|DRUG|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
41390456|NCT01652573|DRUG|Saline Nasal Spray Placebo|
41390457|NCT01637259|DRUG|arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors|NRTI + PI
41390458|NCT01637259|DRUG|Arm 2 boosted protease inhibitors and maraviroc|PI + maraviroc
41390459|NCT01637259|DRUG|Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc|NRTI + maraviroc
41390460|NCT02643394|DRUG|Oral Acetaminophen|1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
41390461|NCT02643394|DRUG|Intravenous acetaminophen|400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
41390462|NCT00732342|BEHAVIORAL|Contingency Management|Prizes given for targeted behavior of abstinence
41390463|NCT04236635|DRUG|Collagenase Clostridium Histolyticum Single Injection Technique|CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.
41039421|NCT05118685|COMBINATION_PRODUCT|platelet rich plasma|First, a topical anesthetic cream will be applied to the vaginal wall. Delaying the PRP injection for 20 minutes after anesthetics application achieved complete or near-complete analgesia for the procedure. Peripheral blood will be drawn from the arm and centrifuged to yield 5 cc of PRP. then PRP will be administered to the anterior vaginal wall using 27-G needles once every 3 weeks for 4 times and PRP is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
41039422|NCT00195910|DRUG|Morphine|0.1 mg/kg IV morphine
41390464|NCT04236635|DRUG|Collagenase Clostridium Histolyticum Multiple Injection Technique|CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.
41390465|NCT03354962|COMBINATION_PRODUCT|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab alone (standard dosage regimen)
41512427|NCT04124445|PROCEDURE|Pulsed Radiofrequency Ablation|"Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain."
41390466|NCT03354962|COMBINATION_PRODUCT|Combined treatment schema|SBRT (recommended optimal dose) with Nivolumab + Ipilimumab (standard dosage regimen)
41390467|NCT05663931|OTHER|DM Discharge Toolkit|"The DM Discharge Toolkit is a multi-modal intervention consisting of a 3-D printed DM survival kit that stores DM self-care supplies (e.g., glucose meter) and technical skills (e.g., injection) simulation materials (e.g. simulation skin), whose use is integrated with a website (https://mydiabeteskit.com) containing standardized DM Survival education content."
41512428|NCT05748587|DIAGNOSTIC_TEST|Serum Iron|Serum iron levels in study groups
41512429|NCT05748587|DIAGNOSTIC_TEST|RBCs Alpha-synuclein|α-syn levels in RBCs
41512430|NCT05748587|DIAGNOSTIC_TEST|Serum Soluble lymphocyte activation gene|sLAG-3 in the serum of study groups
41390468|NCT04581031|DEVICE|Continuous vital sign monitoring - Isansys Patient Status Engine|CE marked wearable continuous vital signs monitors
41390469|NCT04581031|OTHER|Machine Learning/AI Algorithm|Patient data will be subjected to machine learning/AI algorithms to determine whether algorithms may be beneficial as an early indication of patient's condition worsening.
41390470|NCT03986918|DEVICE|Routine Total Hip Arthroplasty|Patients undergoing routine total hip arthroplasty will receive surveys regarding survivorship and outcomes.
41390471|NCT01825616|DIETARY_SUPPLEMENT|Vitamin D2 mushroom powder|Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
41390472|NCT01825616|OTHER|Placebo|Mushroom powder without vitamin D2
41390473|NCT05531838|DEVICE|Fu Lishan instant sense hospital dynamic glucose monitoring system|Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.
41512431|NCT05748587|RADIATION|Brain computed tomography|Brain CT of patients after admission
41512432|NCT05748587|DIAGNOSTIC_TEST|Brain Iron|Iron in brain homogenate of rats
41512433|NCT05748587|DIAGNOSTIC_TEST|Brain Alpha-synuclein|α-syn expression in rat's brain
41512434|NCT05748587|DIAGNOSTIC_TEST|Brain lymphocyte activation gene|LAG-3 expression in rat's brain
41512435|NCT05748587|DRUG|Deferoxamine|intramuscular deferoxamine (200 mg/kg) injection to rats
41039423|NCT00195910|DRUG|Hydromorphone|0.015 mg/kg IV hydromorphone
41167333|NCT04249050|DIETARY_SUPPLEMENT|Oral Impact powder|Oral nutritional supplement containing fish oil, arginine and RNA
41390474|NCT03539848|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
41390475|NCT02484235|OTHER|HIIT|Group training with HIIT 3 times per week during 10 sessions
41390476|NCT02484235|OTHER|Strength|Group training with strength exercises 3 times per week during 10 sessions
41390477|NCT04449588|DRUG|BDB-001 Injection|BDB-001 Injection+Conventional treatment
41390478|NCT04449588|OTHER|Conventional treatment|Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.
41390479|NCT01938521|DIETARY_SUPPLEMENT|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
41390480|NCT01938521|DIETARY_SUPPLEMENT|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
41390481|NCT04501263|BEHAVIORAL|DEMCoN Educational Intervention|Educational programme on constipation for Health care professionals in this clinical specialist palliative care
41390482|NCT04237779|BIOLOGICAL|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in micro testicular sperm extraction (TESE) material.
41390483|NCT06422156|RADIATION|Stereotactic body radiation|Patients will receive SBRT with doses ranging from 35-40 Gy in five fractions.
41390484|NCT06422156|DRUG|Nimotuzumab|Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg on day 1 and 8 of a 21-day cycle until disease progression.
41390485|NCT06422156|DRUG|mono-chemotherapy|Patients will receive mono-chemotherapy (Gemcitabine, S-1 or capecitabine) until disease progression.
41167334|NCT01785147|DRUG|BP1.4979|BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
41390486|NCT00546832|DRUG|TDS-943 (topical diclofenac sodium 4% spray)|
41390487|NCT00546832|DRUG|celecoxib|
41390488|NCT00546832|OTHER|placebo|
41390489|NCT02517099|DRUG|Beclometasone|Beclometasone dipropionate 200mcg bd for 4 months
41167335|NCT01785147|DRUG|Placebo|
41167336|NCT03416569|DRUG|Placebo|placebo skin patch + placebo capsule
41167337|NCT03416569|DRUG|Nicotine|nicotine patch (7 mg/24 hrs) + placebo capsule
41167338|NCT03416569|DRUG|Prazosin|placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)
41167339|NCT03416569|DRUG|Nicotine + Prazosin|nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)
41167340|NCT05896111|PROCEDURE|Physical therapy exercises.|Exercises to treat hemiparetic cerebral palsy
41167341|NCT04150185|PROCEDURE|Donor hepatectomy|
41167342|NCT05370014|BEHAVIORAL|Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM)|The intervention consists of two planning sessions with the dyad (over 2 weeks) followed by eight topic-guided sessions delivered the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly) (Table 3). Key components of these televisits include COVID-19 risk mitigation, chronic disease management, medication adherence, family functioning/support, and community and health systems resource identification and referral with ongoing goal planning. The RN-CHW will meet weekly for progress review, follow up planning, and setting up anticipatory guidance for the next session with the dyads. The RN and CHW will also review IC or survivor dissatisfaction and other issues that require more immediate attention. RN-CHW planning will be assessed to make sure each televisit remain topic focused yet incorporates flexibility to suit the needs of each dyad.
41167343|NCT04758676|OTHER|Nutritional and physiotherapy protocol, BIA|Study subjects will be treated using the nutritional and physiotherapy protocol, based upon the results of measurements, using bioimpedance analysis.
41167344|NCT04758676|OTHER|Standard of care|Study subjects will receive the current standard of care.
41167345|NCT00992121|DRUG|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
41390490|NCT02517099|DRUG|Co-amoxiclav|Co-amoxiclav 0.3ml/kg bd for 4 weeks
41390491|NCT02517099|DRUG|Azithromycin|Azithromycin 10mg/kg od for 4 weeks
41390492|NCT04106856|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
41390493|NCT04106856|DRUG|Losartan|Given PO
41390494|NCT04106856|DRUG|Losartan Potassium|Given PO
41390495|NCT04106856|OTHER|Quality-of-Life Assessment|Ancillary studies
41390496|NCT04106856|OTHER|Questionnaire Administration|Ancillary studies
41390497|NCT01364259|DRUG|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
41390498|NCT01364259|PROCEDURE|CyberKnife stereotactic radiosurgery|CyberKnife stereotactic radiosurgery
41390499|NCT03457337|DRUG|S-1 plus Gefitinib|S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
41390500|NCT03457337|DRUG|Gefitinib|Gefitinib: 250mg, 1 day, orally
41390501|NCT06453720|PROCEDURE|Colonoscopy|A colonoscopy will be performed as part of routine clinical care for all participants, with the study not requiring any additional scheduling commitments outside of routine care.
41390502|NCT03091400|DRUG|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
41390503|NCT03091400|DRUG|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
41390504|NCT04618315|DEVICE|Hearing Aids|Receiver-in-the-ear hearing aids.
41390505|NCT01561586|DRUG|Weekly cisplatin with RT|"Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
41417834|NCT03318692|PROCEDURE|CT|CT of operated area is performed within 7 days of surgery
41417835|NCT02238223|DRUG|Alesion®|
41417836|NCT04786652|DEVICE|estimated stroke volume variation (esSVV, Nihon Kohden, Japan)|Assessment of the estimated stroke volume variation (esSVV, Nihon Kohden, Japan) in the early postoperative period after OPCAB
41167346|NCT00992121|DRUG|Pazopanib 2 week|"Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
41167347|NCT00992121|DRUG|Pazopanib 3 week|"Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
41167348|NCT03209245|BIOLOGICAL|Purethal Mites|perennial allergren specific immunotherapy during 24 months
41167349|NCT03209245|OTHER|placebo injection|perrenial injection wich were administered in same protocol as Purethal
41390506|NCT01561586|DRUG|Tri-weekly cisplatin with RT|"Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
41390507|NCT00149552|DIETARY_SUPPLEMENT|zinc|supplementation with zinc gluconate
41390508|NCT00115466|PROCEDURE|Non-surgical autologous implant of ASCs|
41390509|NCT06568978|OTHER|Assessments of respiratory parameters|respiratory muscle strength, respiratory function test
41390510|NCT05773352|DEVICE|Tornier Perform® Humeral System - Fracture|"A replacement of shoulder joints for anatomic and reverse shoulder arthroplasty.~A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains."
41390511|NCT00958685|DIETARY_SUPPLEMENT|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
41390512|NCT00958685|DIETARY_SUPPLEMENT|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
41390513|NCT05649852|OTHER|Socio-aesthetic care|Group A (Socio-aesthetic care): 3 sessions carried out by a socio-esthetician, during the first administration of chemotherapy.
41390514|NCT05649852|OTHER|Supportive care|Group B (control) will not benefit of socio-aesthetic care during chemotherapy but will benefit all existing support care in the center and accessible to patients: psychology consultation, sophrology, art therapy, physiotherapy, hypnosis. The patient will receive support care (maximum 2) during the intercure.
41390515|NCT03503227|DRUG|prednisolone|daily oral low dose prednisolone (10 mg/day) :a glucocorticoid
41390516|NCT03503227|DRUG|Acetyl Salicylic acid|daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent
41390517|NCT01547637|PROCEDURE|Obturator nerve block|Peripheral obturator nerve block using 10 ml of 2% lidocaine
41390518|NCT01547637|PROCEDURE|Obturator nerve block|Ultrasound guided peripheral obturator nerve block
41390519|NCT04252690|DEVICE|MOBIDERM® autofit : auto-adjustable compression stocking|"The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization).~Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics).~Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually.~Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey)."
41390520|NCT01552629|DRUG|QGE031|
41390521|NCT01552629|DRUG|Placebo|
41512436|NCT02945969|BEHAVIORAL|Low Sodium Diet|Once randomized to the Intervention program, study participants will be grouped into intervention cohorts of approximately 10 participants per group to facilitate group counseling sessions. Both the intensive intervention phase and the maintenance phase will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake. Success of the intervention will be assessed by comparing the urine sodium measurements from 24-hour urine collections performed at screening, 12 weeks and 24 weeks.
41390522|NCT01552629|DRUG|Cyclosporine A|
41167350|NCT03209245|DIAGNOSTIC_TEST|monitoring of allergen specific IgE|measurement the serum specific IgE at the start and at the end of trial
41167351|NCT03209245|DIAGNOSTIC_TEST|monitoring of allergen specific IgG4|measurement the serum specific IgG4 at the start and at the end of trial
41167352|NCT00236184|DRUG|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
41390523|NCT02622607|DRUG|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
41390524|NCT04693182|OTHER|Shift schedule without quick returns|The intervention entails implementing a shift schedule which abolishes or substantially reduces the number of quick returns (less than 11 hours of rest between two shifts) for a six-month intervention period.
41390525|NCT01103401|DRUG|Drug: Tobramycin 0.3% - Dexamethasone 0.1%|one drop four times per day
41390526|NCT01103401|DRUG|Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine|Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
41390527|NCT00190684|DRUG|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
41390528|NCT03529318|PROCEDURE|Biopsies from endoscopy|"1) Patients scheduled for endoscopy (EGD or colonoscopy) for IBD will be consented to allow physicians who are performing endoscopies to take additional biopsies and blood samples for research purposes."
41390529|NCT01079078|DRUG|Acetaminophen|
41390530|NCT02821117|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management."
41390531|NCT05224518|BEHAVIORAL|elastic band training|elastic band training include stretching exercises
41390532|NCT01372527|OTHER|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
41390533|NCT04380701|BIOLOGICAL|BNT162a1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
41390534|NCT04380701|BIOLOGICAL|BNT162b1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
41390535|NCT04380701|BIOLOGICAL|BNT162b2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
41390536|NCT04380701|BIOLOGICAL|BNT162c2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
41390537|NCT04819282|DIAGNOSTIC_TEST|Senior Fitness Test|Senior Fitness Test, simple and easy to use, was used to evaluate physical performance.
41390538|NCT03380182|OTHER|Acupressure Band|These bands use pressure to stimulate the P6 acupuncture point.
41390539|NCT03380182|OTHER|Sham Band|These sham bands are used to make it seem like the band is using pressure to stimulate the P6 acupuncture point.
41390540|NCT04870307|OTHER|Dissemination and Implementation Research|Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D\&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
41390541|NCT04556500|OTHER|investigating the psychometric properties of Turkish Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)|AHEMD-T will apply to parents who have 18-42 months child/children
41512437|NCT05316610|BEHAVIORAL|Body Confident Athletes|The Body Confident Athletes program is a five-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10 girls. The organizations will work with the community partner and researchers on how to schedule the intervention over a five-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sport organizations. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Skills (20 mins), Game Time (20 mins), and The Final Score (15 mins). A variety of activity modalities are utilized to convey learning outcomes, including group and individual activities, and discussion-, writing- and movement-based activities.
41039424|NCT01414387|PROCEDURE|Carotid filter|"Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.~The filter used for this trial is the RX accunet embolic protection system manufactured by abbott."
41512438|NCT00137176|DRUG|Rebif|Rebif 44mcg TIW
41512439|NCT00613171|DRUG|STI571|STI571 tablets taken orally once a day
41512440|NCT03771287|DEVICE|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
41512441|NCT03771287|DEVICE|Oticon omni-directional microphone algorithm|Omni-directional microphone setups come standard for all Oticon hearing aid models. The hearing microphones have equal sensitivity across all directions.
41039425|NCT01414387|PROCEDURE|Carotid reversal of flow|On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
41039426|NCT00345241|DRUG|Systane Ocular Drops (OTC)|
41039427|NCT00345241|DRUG|Placebo - Saline Drops|
41039428|NCT06009341|OTHER|Rehabilitation|The control group will not be trained. Only exercise brochure including muscle strengthening and stretching will be given. In addition, the intervention group will be taught the training program and applications.
41039429|NCT00796081|DRUG|ER OROS paliperidone, paliperidone ER|
41039430|NCT05571631|OTHER|exercise|Arm ergometer will aplied as an aerobic exercise. Combination of balance training and arm ergometer exerise program will applied.
41039431|NCT02955511|DEVICE|Blade MAC size 3|Patient will be intubated using the DL- Blade MAC size 3
41039432|NCT02955511|DEVICE|Blade MAC size 3.5|Patient will be intubated using the DL- Blade MAC size 3.5
41039433|NCT02955511|DEVICE|Inscope Blade size 3.5|Patient will be intubated using the Inscope Blade size 3.5
41039434|NCT02361320|PROCEDURE|Computed Tomography (CT)|Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
41039435|NCT02361320|BEHAVIORAL|Questionnaire|Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
41039436|NCT01039051|BEHAVIORAL|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
41390542|NCT05355987|OTHER|Early oncological supportive care|Several appointments (at diagnosis, 3 months, 6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
41390543|NCT05355987|OTHER|Delayed oncological supportive care|Two appointments (6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
41390544|NCT02234258|BEHAVIORAL|Cognitive behavioral social skills|
41167353|NCT00236184|OTHER|Placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
41167354|NCT00505414|DRUG|Tapentadol in the Titration Phase|
41390545|NCT02234258|BEHAVIORAL|Psychoeducation|
41390546|NCT01258452|DRUG|CHF 5074|Drug is administered to subject in a fasting state
41390547|NCT01258452|DRUG|CHF 5974|Drug is administered to subject after consumption of a high fat, high calorie meal
41390548|NCT01968837|OTHER|Cervical cancer screening|
41390549|NCT05886673|OTHER|experimental cream|experimental cream
41390550|NCT05886673|OTHER|standard of care|standard of care
41390551|NCT05940688|BEHAVIORAL|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
41390552|NCT05940688|BEHAVIORAL|Community Health Worker|Health care information delivered via CHW.
41390553|NCT05940688|BEHAVIORAL|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
41390554|NCT01399073|BEHAVIORAL|virtual reality setup|testing for neglect in a virtual reality setup
41390555|NCT01399073|BEHAVIORAL|paper and pencil tests|testing for neglect with the classical paper-and-pencil tests
41390556|NCT01399073|OTHER|c-mri|structural and functional (resting state) imaging
41167355|NCT00505414|DRUG|Morphine in the Maintenance Phase|"Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase."
41390557|NCT05303831|OTHER|Mechanical ventilator|patients on a mechanical ventilators in ICU will be followed for 28-days for clinical outcomes
41390558|NCT05715788|DRUG|Nitric oxide|Nitric oxide inhalation at 20 ppm
41390559|NCT05715788|BEHAVIORAL|prone positioning|vatilation in prone position
41390560|NCT04275388|DRUG|Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
41390561|NCT04275388|DRUG|Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
41390562|NCT03969784|OTHER|blood draw, tumoral biopsy tissus|Patient will have specific blood draw and part of their tumoral tissu biopsied
41390563|NCT03284424|BIOLOGICAL|Pembrolizumab|IV infusion
40676670|NCT06622187|DRUG|Desmopressin (DDAVP)|Patients in the intervention group will receive desmopressin 0.3ug/kg administered as an intravenous infusion 1h before the proposed procedure
41167356|NCT00505414|DRUG|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
41390564|NCT03593772|BEHAVIORAL|Mission Reconnect|This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
41390565|NCT02595528|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
41390566|NCT02595528|DRUG|AGN-190584 ophthalmic solution|1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
41390567|NCT02595528|DRUG|AGN-190584 vehicle|Vehicle to AGN-190584
41512442|NCT06028295|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
41512443|NCT06028295|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
41390568|NCT02595528|DRUG|AGN-199201 + AGN-190584 Combination|1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
41390569|NCT02595528|DRUG|AGN-199201 vehicle|Vehicle to AGN-199201
41512444|NCT06028295|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
41512445|NCT02892149|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
41390570|NCT04814888|OTHER|intubation with a cuffed ETT by a printed 3D airway model|Two anaesthesiologists unaware of patient's demographic data such as patient's height, weight, and age predicted and recorded ETT size by inserting various sized cuffed-ETTs (MallinckrodtTM Hi-Lo tracheal tube, Covidien, Ireland) to a printed 3D airway model. If the diameter of trachea undersized, air leak around ETT can occur. In that case, we can use that ETT after inflating the pilot balloon with small amount of air. Standard monitoring (non-invasive blood pressure measurement, electrocardiogram, and pulse oximetry) was applied to pediatric patients in the operating room and general anesthesia was induced with ketamine 1 mg/kg and rocuronium 0.6 mg/kg and maintained with sevoflurane. After intubation with a cuffed ETT by a printed 3D airway model was finished, an air leak test was performed by one of three anaesthesiologists dedicated to pediatric cardiac anesthesia.
41390571|NCT00349882|DEVICE|soft contact lens|
41390572|NCT00349882|DRUG|Marketed multipurpose disinfection regimen|
41390573|NCT03067506|OTHER|No intervention|No intervention
41390574|NCT02818179|RADIATION|THERMOGRAPHY IMAGING|
41390575|NCT05986565|BEHAVIORAL|Families Moving Forward (FMF) Teacher adapted training|The FMF Connect Teacher Companion website is designed to offer teachers evidence-based education about FASD and strategies to support students with FASD. It is adapted from the FMF Program and FMF Connect, evidence based interventions to support caregivers of children with FASD. The FMF Program and FMF Connect aim to improve caregivers' efficacy and satisfaction as a parent, efficacy, attributions for their child's behavior, and the parent-child relationship.
41390576|NCT02396069|DRUG|JPI-289|PARP-1 inhibitor
40859381|NCT04712708|OTHER|Physical Therapy Program|"The Mat Exercises:~Stretching exercises to all spastic muscle groups (Kalkman et al., 2018). Gentle exercises was applied for 40-60 seconds and repeated from 3-5 times/ movement as supported by (Fragala et al., 2003).~Strengthening Exercises:~Dynamic Rising Positioning~The Gym Exercises:"
41390577|NCT02396069|DRUG|Placebo|Placebo
41390578|NCT04726839|OTHER|Standard of care for stroke management and evaluation of functionnal outcome at 3 months|Additional tubes at inclusion (maximum 13 mL) Collection of the mRS data during a routine visit if planned at 3 months +/-15 days or, if not during a specific research phone call at 3 months
41390579|NCT01188642|BEHAVIORAL|obesity lifestyle intervention|physical activity 5 times per week + nutrition education
41390580|NCT00504127|DRUG|Naproxcinod 375 mg bid|Naproxcinod 375 mg bid
41390581|NCT00504127|DRUG|Naproxcinod 750 mg bid|Naproxcinod 750 mg bid
41390582|NCT00504127|DRUG|Naproxen 500 mg bid|Naproxen 500 mg bid
40859382|NCT03371784|DRUG|Hydrocortisone|I.V. administration
40859383|NCT03371784|DRUG|Placebo|I.V. administration
40859384|NCT00881114|DRUG|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
40859385|NCT00881114|DRUG|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
40859386|NCT03265236|DIAGNOSTIC_TEST|Anti - modified citrullinate vimentin|patients with early and late RA
41390583|NCT00504127|DRUG|placebo|placebo
41390584|NCT03959423|DEVICE|AHCL insulin pump system|670G 4.0 system with GS3; 780G system with G4S (continued access phase);
41390585|NCT04465916|DRUG|EYP001a|Oral tablets
41390586|NCT04465916|DRUG|Placebo|Oral tablets
41390587|NCT04465916|DRUG|Nucleotide analogue (Entecavir or Tenofovir Disoproxil)|Oral tablets
41390588|NCT01307631|DRUG|Akt Inhibitor MK2206|Given PO
41390589|NCT01307631|OTHER|Laboratory Biomarker Analysis|Correlative studies
41390590|NCT01552005|DRUG|Saxagliptin|No Intervention
41390591|NCT00814619|BIOLOGICAL|panitumumab|Given IV
41390592|NCT00814619|DRUG|capecitabine|Given orally
41390593|NCT00814619|PROCEDURE|therapeutic conventional surgery|Patients undergo surgical resection
41390594|NCT00814619|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
41390595|NCT05955235|OTHER|Not Applicable(Observation Study)|Not Applicable(Observation Study)
41390596|NCT06537895|OTHER|EDCRN questionnaires|Participants will complete questionnaires and have blood and other physical tests as specified in the EDCRN dataset.
41390597|NCT00858234|DRUG|Vorinostat|Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.
41390598|NCT00858234|DRUG|Bortezomib|Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.
41390599|NCT00479765|DRUG|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
41390600|NCT00916292|DRUG|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
41390601|NCT00916292|DRUG|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
41167357|NCT00505414|DRUG|Tapentadol in the Maintenance Phase|The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
41167358|NCT00505414|DRUG|Morphine in the Titration Phase|After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
41390602|NCT00164086|DRUG|atorvastatin|
40859387|NCT04131179|BEHAVIORAL|Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP)|"Y-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the self-harm attempt, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking,relapse prevention strategies and training on anger management and assertiveness."
40859388|NCT04357808|DRUG|Sarilumab|Single dose treatment with sarilumab 2 x 200 mg subcutaneously
40859389|NCT04357808|OTHER|Standar of care|Usual clinical care
40859390|NCT02613585|OTHER|Permethrin Impregnated Clothing|Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
41167359|NCT02085902|DRUG|Ropivacaine|
41167360|NCT05725733|OTHER|Physical Therapy|The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.
40859391|NCT01279616|DRUG|Fludarabine monophosphate|180 mg/m2 over 6 days.
40859392|NCT01279616|DRUG|Rituximab|375 mg/m2 on day -13 and day -3
40859393|NCT01279616|DRUG|Busulfan|AUC 1000-1200 microM.mt
41167361|NCT02224183|BEHAVIORAL|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
41390603|NCT01033201|OTHER|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
41390604|NCT00291330|DRUG|dabigatran etexilate 150 mg|twice daily
41390605|NCT00291330|DRUG|warfarin (INR 2-3)|prn to maintain INR (2-3)
40859394|NCT01279616|DRUG|ATG|2.5 mg/kg for 3 days
41390606|NCT05280873|DRUG|Pirfenidone, methylprednisolone|Methylprednisolone 2 mg / kg / d+ pirfenidone (starting from 200mg tid, increasing to 600mg tid within one week and maintaining) . Methylprednisolone was reduced according to the researcher's evaluation of the patient's condition and the specific course of treatment was determined.
41390607|NCT05280873|DRUG|Methylprednisolone|Methylprednisolone 2 mg / kg / d . Methylprednisolone was gradually reduced after the improvement of symptoms and imaging. The treatment course was 6-8 weeks
41390608|NCT00181831|DEVICE|Proton Magnetic Resonance Spectroscopy|
41390609|NCT03591107|OTHER|PTSD Care Management (PCM)|Collaborative care for PTSD facilitated by a trained CM who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist in addition to education and feedback
41390610|NCT03591107|OTHER|Minimally Enhanced Usual Care (MEU)|Education and feedback alone
41390611|NCT01556165|DRUG|rasagiline|1 mg/day, tablets, once daily, orally
41390612|NCT01556165|DRUG|placebo|tablets, once daily, orally
41390613|NCT03871569|OTHER|bucco-dental teleexpertise|A bucco-dental consultation remotely using telemedicine system
40859395|NCT01279616|DRUG|Cyclophosphamide|50 mg/kg on day +3
40859396|NCT01279616|DRUG|Mycophenolate mofetil|15 mg/kg q 8 hours
40859397|NCT01279616|DRUG|Tacrolimus|0.03 mg/kg /d
40859398|NCT02481531|OTHER|Previously marketed infant formula|
40859399|NCT02481531|OTHER|Previously marketed formula using a similar protein|
40859400|NCT04890470|DRUG|Oxytocin|intranasal administration of oxytocin (24 IU)
40859401|NCT04890470|DRUG|Vasopressin|intranasal administration of vasopressin (20 IU)
40859402|NCT04890470|DRUG|Placebo|intranasal administration of placebo
40859403|NCT03976206|BIOLOGICAL|Very small embryonic-like stem cell|We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
40859404|NCT01942174|BIOLOGICAL|Prevenar 13|Vaccination at the beginning of the study (day 0)
40859405|NCT01942174|BIOLOGICAL|Pneumo23 / Pneumovax|Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company
41390614|NCT03235531|DRUG|Valproate|Valproate is an anti-epileptic medication that can influence the chemical changes in the brain that result from alcohol withdrawal syndrome (AWS) via three mechanisms of action: (1) an increase in GABA activity, (2) inhibition of glutamate binding to NMDA, and (3) restoration of the balance between dopamine and acetylcholine activity. VPA may be effective in the prevention of AWS, and could serve as efficacious adjuvant to traditional benzodiazepine (BZD) therapy for AWS, both decreasing symptoms of AWS and decreasing the use of BZDs.
41390615|NCT03235531|DRUG|Lorazepam|Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
41390616|NCT01328054|DRUG|lapatinib|lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
41390617|NCT01328054|DRUG|placebo matching lapatinib|placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
41390618|NCT05357781|DIAGNOSTIC_TEST|Laboratory test|Frequency of fatigue (defined as Fatigue Scala for Motor and Cognitive Function (FSMC) total ≥ 43 points) in MS patients with IgG-deficiency
41390619|NCT01244516|DEVICE|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
41390620|NCT01244516|DEVICE|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
41390621|NCT01244516|DEVICE|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
41390622|NCT01341522|PROCEDURE|MRI exam|MRI exam
41390623|NCT01341522|PROCEDURE|control|waiting room
41390624|NCT00079144|BIOLOGICAL|NY-ESO-1 peptide vaccine|
41390625|NCT00079144|BIOLOGICAL|aldesleukin|
41167362|NCT02224183|BEHAVIORAL|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
41390626|NCT00079144|BIOLOGICAL|filgrastim|
41390627|NCT00079144|BIOLOGICAL|incomplete Freund's adjuvant|
40859406|NCT01942174|DRUG|Methotrexate - Immediate|concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
41390628|NCT00079144|BIOLOGICAL|therapeutic autologous lymphocytes|
41390629|NCT00079144|DRUG|cyclophosphamide|
41390630|NCT00079144|DRUG|fludarabine phosphate|
41390631|NCT01493063|OTHER|Physiopathology|Samples of breastmilk and infant serum and questionnaires.
41390632|NCT03740828|DEVICE|KIDScore D3|Embryos are scored using the KIDScore D3 algorithm based on annotated morphokinetic parameters.
41390633|NCT05974865|BEHAVIORAL|Healthy Babies and Healthy Moms|
41390634|NCT05974865|BEHAVIORAL|Baby Basics Prenatal Guide|
40859407|NCT01942174|DRUG|Methotrexate - Delay|"For period group, methotrexate is Initiated \& month after the antipneumococcal vaccination by prevenar 13"
40859408|NCT00596830|DRUG|CP-751,871 (Figitumumab)|CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
41390635|NCT05001763|DRUG|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
41390636|NCT05001763|DRUG|Placebo|Glucose, 2mg, tablet.
41390637|NCT01459679|DEVICE|KXL System (15 mW/cm2)|UVA irradiation for 8 minutes at 15 mW/cm2
41390638|NCT01459679|DEVICE|KXL System (30 mW/cm2)|UVA irradiation for 4 minutes at 30 mW/cm2
41390639|NCT01459679|DEVICE|KXL System (45 mW/cm2)|UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2
40859409|NCT00596830|DRUG|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
41390640|NCT01459679|DRUG|riboflavin ophthalmic solution|Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
41390641|NCT05761132|DRUG|Pembrolizumab|neoadjuvant immunotherapy
41390642|NCT04113538|DRUG|Aflibercept|Intraocular injection of 2 ml (40mg/ml)
41390643|NCT02428231|DRUG|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
41390644|NCT05066607|DRUG|Isatuximab|Patient will receive the association of Isatuximab, Pomalidomide and Dexamethasone during 9 or 12 cycles.
41390645|NCT05146284|DRUG|PXL770|Tablet
41390646|NCT01316588|OTHER|Plastic adesive drape|Plastic adhesive drape intraoperatively on patients skin around the surgical wound on the chest and bare skin on the leg
41390647|NCT01316588|OTHER|Microbial Sealant|Microbial sealant intraoperatively on patients skin around the surgical wound on the leg and bare skin on the chest
41390648|NCT06541990|BEHAVIORAL|HARMONY|A psychoeducational intervention for patients with HCC
41390649|NCT06541990|OTHER|Enhanced usual care|A supportive care resource guide
41390650|NCT06558201|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
41390651|NCT01051999|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine powder
41390652|NCT01051999|DIETARY_SUPPLEMENT|L-alanine|L-alanine oral powder
41390653|NCT04643782|DEVICE|ANNE Sleep|ANNE sleep system
41390654|NCT00003692|PROCEDURE|therapeutic thoracoscopy|
41390655|NCT00003692|PROCEDURE|video-assisted surgery|
41390656|NCT02405494|DIETARY_SUPPLEMENT|Beverage 1|
41390657|NCT02405494|DIETARY_SUPPLEMENT|Beverage 2|
41390658|NCT02405494|DIETARY_SUPPLEMENT|Beverage 3|
41390659|NCT02405494|DIETARY_SUPPLEMENT|Beverage 4|
41390660|NCT02405494|DIETARY_SUPPLEMENT|Beverage 5|
41390661|NCT02405494|DIETARY_SUPPLEMENT|Beverage 6|
41390662|NCT02405494|DIETARY_SUPPLEMENT|Beverage 7|
41390663|NCT02405494|DIETARY_SUPPLEMENT|Beverage 8|
41390664|NCT02405494|DIETARY_SUPPLEMENT|Beverage 9|
41390665|NCT05965622|BEHAVIORAL|Attachment Based Family Therapy (ABFT) + Treatment As Usual (TAU)|"Attachment Based Family Therapy (ABFT): ABFT is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Therefore, ABFT focuses on strengthening parent-child attachment bonds to create a protective and secure base for young adult development. Sessions are scheduled weekly, and the intervention lasts on average 16 weeks.~The participants in the ABFT condition will also receive treatment as usual (TAU)."
41390666|NCT05965622|BEHAVIORAL|Treatment As Usual (TAU)|The participants in the treatment as usual (TAU) condition will only receive regular existing care to treat suicidality in young adults.
41390667|NCT06412107|OTHER|True acupressure|Participants will receive a 7-week true self-acupressure practice and a 12-week follow-up.
41390668|NCT06412107|OTHER|Sham acupressure|Participants will receive a 7-week sham self-acupressure practice and a 12-week follow-up.
41390669|NCT06412107|OTHER|Usual care|Routine methods of treatment and care along with an updated education booklet.
41390670|NCT02691312|DEVICE|Digital Retinography System|The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
40859410|NCT00596830|DRUG|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
41390671|NCT04567160|DRUG|Propofol|"In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model.~After tracheal intubation, TCI of remifentanil is paused."
41390672|NCT04567160|DRUG|Sevoflurane|In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.
41390673|NCT00549120|DRUG|Propranolol|40 mg tablets
41390674|NCT00549120|DRUG|Salbutamol|Metered dose inhaler (600 μg)
41390675|NCT00549120|DRUG|Ipratropium|Metered dose inhaler (40 μg)
41390676|NCT00549120|DRUG|Placebo|Placebo for propranolol tablets
40859411|NCT00596830|DRUG|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
40859412|NCT00596830|DRUG|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
41390677|NCT03196739|DEVICE|Virtual rehabilitation|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for upper limb rehabilitation using immersive virtual reality under the assistance of an occupational therapist.
41390678|NCT03782688|DIAGNOSTIC_TEST|FFRCT planner|Non-invasive post-PCI fractional flow reserve prediction
41390679|NCT02525562|DEVICE|Triathlon Total Knee System with X3 insert|Total knee replacement
41390680|NCT02525562|DEVICE|Scorpio NRG Total Knee System with X3 insert|Total knee replacement
41512446|NCT02892149|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
41512447|NCT03658395|PROCEDURE|Laparoscopic Sacrocolopopexy|The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
40859413|NCT04131946|OTHER|Community-Based (Intervention Arm)|Community dispensed FIT
40859414|NCT03194126|PROCEDURE|Mifepristone + Misoprostol OR oxytocine + laminaria|Three laminaria placed 12 hours prior to administration of misoprostol
40859415|NCT03194126|PROCEDURE|Mifepristone + Misoprostol OR oxytocine|standart support
41390681|NCT02525562|DEVICE|Triathlon PKR System with X3 insert|Partial Knee Resurfacing
41390682|NCT02525562|PROCEDURE|Total Knee Replacement|Total Knee Replacement
41390683|NCT02525562|PROCEDURE|Partial Knee Resurfacing|Partial Knee Resurfacing
41390684|NCT03428009|OTHER|Magnetic Resonance Imaging|Study interventions are minimal risk.
41390685|NCT00127257|BEHAVIORAL|Biofeedback|
41390686|NCT00127257|DRUG|Diazepam|
41390687|NCT00127257|BEHAVIORAL|Pelvic floor retraining|
41390688|NCT06541912|PROCEDURE|conventional implant|"A full thickness mucoperiosteal flap was elevated under local anesthesia, osteotomy sites were prepared according to manufacturer's instructions and parallel pin was used to confirm position and angulation of osteotomy site. Conventional implant placement was done on one side.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and check the primary stability of the implant. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures."
41390689|NCT06541912|PROCEDURE|UV implant|"A full thickness mucoperiosteal flap was elevated under local anesthesia and osteotomy sites were prepared according to manufacturer's instructions. Parallel pin was used to confirm position and angulation of osteotomy site. UV implant was activated using UV Activator2 and placed in another site.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and primary stability of the implant was measured. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures."
41390690|NCT03213080|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) procedure.
41390691|NCT06542705|DEVICE|Arthrex Internal Brace|The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
41390692|NCT06542705|PROCEDURE|ACL Reconstruction|All patients will undergo ACL reconstruction (ACLR) with or without an internal brace. ACLR technique will be standardized to standard anteromedial (AM) portal femoral drilling to ensure consistency between surgeons.
41390693|NCT00581386|DEVICE|LTS-D|supra-glottic airway device
41390694|NCT00581386|DEVICE|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
41390695|NCT00581386|DEVICE|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
41390696|NCT04965402|DRUG|BMS-986166|Specified dose on specified days
41390697|NCT04965402|OTHER|Placebo|Specified dose on specified days
41390698|NCT04654286|PROCEDURE|Nerve transfer procedure|"1. Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle.~2. Donor nerve is checked for its viability with an electric stimulator during surgery~3. Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis."
41390699|NCT04654286|PROCEDURE|Nerve transfer with HAM-AdMSC composite wrapping|When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)
41039437|NCT02427126|DRUG|Apixaban|Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery
41039438|NCT02427126|DRUG|Aspirin|Acetylic Salicylic Acid 100mg o.d.; 12 Months
40859416|NCT05958849|DRUG|Sovalteinib Solutumab Tegeo|Soventinib in combination with solutumab and tegeo for advanced pancreatic cancer
40859417|NCT02292446|DRUG|Ruxolitinib|supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
41039439|NCT00047879|BIOLOGICAL|PEG-interferon alfa-2b|0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
41039440|NCT00047879|DRUG|Thalidomide|Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
41039441|NCT06536127|DIAGNOSTIC_TEST|Blood samples|Nk cells and ImmunoScore
41039442|NCT03936686|OTHER|Survey tool to assess CVD risk factor knowledge|The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.
41039443|NCT01461668|DRUG|Retapamulin|Two times a day for 5 days
41039444|NCT01461668|DRUG|Placebo|Two times a day for 5 days
41039445|NCT02854774|BEHAVIORAL|Muscle activation exercises|Activation of either muscles activating the knee or hip.
41390700|NCT02364219|OTHER|Prewarming|Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
41390701|NCT02364219|DEVICE|Microdialysis|71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
41390702|NCT01810393|DRUG|Trastuzumab|Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
40859418|NCT00868127|DRUG|Lapaquistat acetate|"Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
41039446|NCT03483987|DRUG|Sof+Ledi+R arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
41039447|NCT03483987|DRUG|Sof+Ledi+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
41039448|NCT03483987|DRUG|Sof+Dacla+R arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
41390703|NCT03665480|DRUG|G-SCF|In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
41512448|NCT03658395|PROCEDURE|Posterior repair|The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
41417837|NCT04786652|DIAGNOSTIC_TEST|Assessment of fluid responsiveness in mechanically ventilated patients after OPCAB|In mechanically ventilated patients after OPCAB within two hrs after intervention: passive leg raising (PLR), increased PEEP, and mini-fluid load (mFL) tests will be followed by standard fluid load (sFL). Monitoring: SVVPCA, PPVPCA, esSVV, HLI, PVI, pre-ejection fraction (PEP, echocardiography), CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase (PEP).
41512449|NCT02676765|DRUG|allergen extract tablet|1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
40859419|NCT00868127|DRUG|Lapaquistat acetate and additional lipid-lowering therapy|"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
41167363|NCT05590962|OTHER|EHR Nudge|Clinicians in Arm 1 (intervention) will receive a EHR notification with option to opt-out for palliative care referral for any eligible high-risk patient, defined by a risk score ≥1 for Stage IV cancer patients and ≥2 for Stage III cancer patients. If the risk score is above 8, they will be scheduled within 2 weeks, and all other patients will be scheduled within 4 weeks. Clinician will have the option to opt-out for any patient by responding to the notification which will be sent to the research coordinator. If the clinician does not respond, the research coordinator will approach patient via telephone, explain the rationale for referral based on a predetermined script, and offer and schedule an outpatient or telemedicine palliative care consultation per patient preference. Follow-up visits will occur at the discretion of the palliative care clinician, usually monthly.
40859420|NCT05783414|BEHAVIORAL|f2f CST|An evidence-based group CST protocol adapted for Hong Kong Chinese culture. It consists of 14 sessions of group activities (group size: 6) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
41039449|NCT03483987|DRUG|Sof+Dacla+R+Peg-IFN arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
41039450|NCT03483987|DRUG|Sof+Velpa+R arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
41039451|NCT03483987|DRUG|Sof+Velpa+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
41039452|NCT04197843|DEVICE|NaviCam (ANKON)|The NaviCam (ANKON) is a miniaturised wireless endoscope in a single use capsule. It can be remotely controlled with the patient in a magnetic console. The operator to the magnetic-driven NaviCam sits in a computer workstation and manipulates the capsule suspended in a waterfilled stomach. After careful examination of the stomach, the capsule is then allowed to passed through the pylorus into duodenum and small bowel. The patient wears harness with small bowel imaging capabilities.
41039453|NCT02172755|DRUG|BIA 2-093|During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
41039454|NCT04801550|DEVICE|Millimeter waves local exposure|several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure
41167364|NCT03723122|BEHAVIORAL|Dyadic Communication Reinforcement Intervention|Psycho-educative and behavioral intervention centered on cancer-related dyadic communication
41167365|NCT01019798|DRUG|sunitinib, docetaxel, cisplatin|"1. Sunitinib given 10 days within 14 days of each cycle。~2. Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.~3. Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.~4. Overall 12 cycles (24 weeks)"
41167366|NCT04815343|DEVICE|Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)|Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback
41167367|NCT05298293|DEVICE|ONCOLAXY Follow-up|"The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard."
41167368|NCT01951378|DEVICE|Hudson RCI® nebulizer|After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS \> 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
41167369|NCT01951378|DEVICE|NebuTech® HDN® nebulizer|All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
41390704|NCT01784419|DRUG|ivacaftor|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
41390705|NCT01784419|DRUG|Placebo|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
41390706|NCT02162511|DEVICE|CliniMACS CD34+ cell enrichment and T-cell depletion|
41390707|NCT01294605|BIOLOGICAL|Boostrix™ (dTpa)|Intramuscular, 3 doses
41390708|NCT01294605|BIOLOGICAL|GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)|Intramuscular, single dose
41390709|NCT01294605|BIOLOGICAL|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 2 doses
41390710|NCT01294605|BIOLOGICAL|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 3 doses
41390711|NCT04371419|BEHAVIORAL|Messaging|"o The video messages each participant in one of the treatment groups sees will be randomized on the following dimensions. The different versions are clearly demarcated in the US Doctors Scripts document.~* Racial or ethnic identity of the doctor delivering the messages: concordant vs. discordant identity to the subject.~* Whether the message includes an acknowledgment of elephant in the room issues for each target group: trust in the medical system or fear of deportation.~* Whether the social distancing component of the message is delivered by Dr. Birx of the CDC or recorded by the MGH physicians.~* Whether individuals are given information about how representative individuals perceive mask wearers of color. This information comes from results of our nationally representative pilot survey.~* Some individuals in a control group will see messages later."
41390712|NCT05672173|PROCEDURE|Biopsy|Undergo tumor biopsy
41039455|NCT01558154|DRUG|Chinese herbs|Chinese herbs special for depression
41039456|NCT01558154|PROCEDURE|acupuncture|six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
41039457|NCT01558154|OTHER|Psychotherapy|Thought Imprint Psychotherapy under lower Resistance State
41039458|NCT01558154|DEVICE|Transcranial magnetic stimulation|Give magnetic stimulation at head
41039459|NCT05446168|DRUG|tributyrin|Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
41039460|NCT03131388|DIAGNOSTIC_TEST|Access AMH Assay|
41039461|NCT02570126|BIOLOGICAL|Varilrix HSA-free|2 doses will be administered, one at Day 0 and the other at Day 42
41167370|NCT01951378|DRUG|Albuterol|Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
41390713|NCT05672173|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
41390714|NCT05672173|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
41390715|NCT05672173|PROCEDURE|Computed Tomography|Undergo PET/CT
41390716|NCT05672173|DRUG|Cyclophosphamide|Given IV
41390717|NCT05672173|DRUG|Fludarabine|Given IV
41390718|NCT05672173|DRUG|Ibrutinib|Given PO
41390719|NCT05672173|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
41390720|NCT05672173|BIOLOGICAL|Nivolumab|Given IV
41390721|NCT05672173|PROCEDURE|Pheresis|Undergo apheresis
41390722|NCT05672173|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
41390723|NCT05380882|DRUG|TQB2930 injection|TQB2930 is an anti-HER2 bispecific antibody.
41039462|NCT02570126|BIOLOGICAL|Varilrix™|2 doses will be administered, one at Day 0 and the other at Day 42
41039463|NCT01505023|DIETARY_SUPPLEMENT|Partial meal replacement|The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
41039464|NCT01505023|DIETARY_SUPPLEMENT|Partial meal replacement with inulin|The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
41039465|NCT01505023|DIETARY_SUPPLEMENT|Inulin|Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
41039466|NCT05854472|OTHER|smartphone based application use|A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
41167371|NCT01253447|DRUG|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
41167372|NCT01253447|OTHER|laboratory biomarker analysis|Correlative studies
40859421|NCT05783414|BEHAVIORAL|f2f carer support|Centre-based carer support programme for dementia carers provided in a community care service centre, which provide group education on caring skills, mutual support groups, and group-based self-care training over 6 months.
40859422|NCT05783414|BEHAVIORAL|vCST|A home-based version of f2f CST delivered via an information and communication technology platform (Zoom plus a web-based CST platform). It consists of 14 sessions of group activities (group size: 3) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
40859423|NCT05783414|BEHAVIORAL|online carer support|A home-based carer support service delivered via an information and communication technology platform (Zoom plus a web-based carer platform). It consists of 4 group sessions (group size: 6) and 3 individual sessions, and 3 optional self-learning sessions over 6 months, with an empowering care management approach to strengthen carer self-efficacy.
41167373|NCT04283123|BEHAVIORAL|Automated Bidet|During the first intervention visit, a licensed contractor will install the bidets in participants' homes. The OT will then educate and train the caregiver and care recipient to successfully use the bidet, and make any modifications to the remote as needed. Throughout the intervention, the OT will use motivational enhancement strategies. The OT will make minor modifications to the remote as needed. A second intervention visit will occur 1-2 weeks post-installation to address any new difficulties. Check-in phone calls will be offered to the caregiver and care recipient if needed.
41167374|NCT04283123|OTHER|No Intervention|Waitlist control
41167375|NCT04016805|DRUG|Ublituximab|"* recombinant chimeric anti-CD20 monoclonal antibody~* administered as an IV infusion"
41167376|NCT04016805|DRUG|Umbralisib|"* Phosphoinositide-3-kinase (PI3K) delta inhibitor~* Tablet form, to taken orally on a daily basis"
41167377|NCT04016805|DRUG|Ibrutinib|"* Bruton Tyrosine Kinase (BTK) inhibitor~* Tablet form, to taken orally on a daily basis"
41167378|NCT04016805|DRUG|Venetoclax|"* BCL-2 inhibitor~* Tablet form, to be taken orally"
41167379|NCT04016805|DRUG|Acalabrutinib Oral Capsule|Kinase inhibitor, capsule form, to be taken orally
41167380|NCT04298541|DRUG|Ga-68- DOTATATE|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
41167381|NCT04298541|DRUG|Ga-68-DOTATOC|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
41167382|NCT01196585|PROCEDURE|CT-Guided pleural needle biopsy with Abrams' needle|Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.
41167383|NCT01196585|PROCEDURE|Ultrasonography guided cutting pleural needle biopsy|Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
41167384|NCT04804059|DRUG|[14C]-APX001 Oral Solution|Total dose containing NMT 3.1 MBq (84.0 µCi) 14C
41167385|NCT04804059|DRUG|[14C]-APX001 Solution for Infusion|Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
41167386|NCT05364645|DRUG|Carboplatin|Given IV
41167387|NCT05364645|DRUG|Pemetrexed|Given IV
41167388|NCT05364645|DRUG|Selpercatinib|Given PO
41167389|NCT02179853|DRUG|Anakinra|First two doses IV followed by SQ dosing
41167390|NCT04680637|DRUG|Efavaleukin Alfa|Administered as a subcutaneous (SC) injection.
41167391|NCT04680637|DRUG|Placebo|Administered as a subcutaneous (SC) injection.
41167392|NCT04680637|OTHER|Standard of Care|Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.
41167393|NCT01214681|DIETARY_SUPPLEMENT|Maltodextrin and Amioca starch|12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
41167394|NCT01214681|DIETARY_SUPPLEMENT|Hi-maize 260|23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
41167395|NCT01214681|DIETARY_SUPPLEMENT|Polydextrose|12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
41167396|NCT01214681|DIETARY_SUPPLEMENT|Hi-maize 260 and polydextrose|12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
41167397|NCT00661713|BIOLOGICAL|rMenB+OMV NZ|
41390724|NCT01261429|DRUG|Tasigna|"The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.~The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes."
41512450|NCT02676765|DRUG|Placebo tablet|1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
41167398|NCT00661713|BIOLOGICAL|Placebo|
40859424|NCT03132701|DRUG|Magnesium|Mg is administered during anesthesia until 5 minutes before surgery ends
40859425|NCT03132701|DRUG|Saline|Same volume of saline is infused until 5 minutes before surgery ends
40859426|NCT02746640|PROCEDURE|Cardiopulmonary resuscitation (CPR)|If there is a cardiopulmonary arrest, investigators observe the working processes of cardiopulmonary resuscitation.
41039467|NCT03505632|DEVICE|Recruitment with low PEEP|Volume controlled ventilation with TV 6-8 ml/PBW . RR adjusted to keep the EtCO2 35-40 mmHg. I/E ratio1:2 and FiO2 0.40.Patients will receive PEEP of 5cmH2O. RM will be done by increasing the PEEP in stepwise manner. First PEEP increase to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths) and finally PEEP raise to 20 cmH2O (10 breaths).Then PEEP decrease by 5 cmH2O increments every (3 breaths) until back to PEEP 5 cmH2O. RM will take 2 minutes. RM will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40 cmH2O. Monitoring of the following parameters :Dynamic lung compliance ,Horowitz index ,dead space and driving pressure .
41167399|NCT03796598|DRUG|Fecal Microbial transplant Capsules|Oral capsules of FMT
41167400|NCT03796598|DRUG|Fecal Microbial Transplant Enema|FMT enema
41167401|NCT03796598|OTHER|Placebo|Placebo
41167402|NCT03626025|OTHER|Spaced learning|Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
41167403|NCT05548413|BEHAVIORAL|FamLit|The FamLit (Family-focused and Literacy-sensitive strategy) is an interactive, multi-component intervention supported by the FamLit intervention Guide, including both spoken and printed materials written at a 4th-grade reading level for HF patients and their primary CPs.Three constructs guide the intervention, based on the Theory of Planned Behavior (TPB): 1) develop patient and CP positive attitudes through HF instruction and teach-back; 2) form positive subjective norms through coaching to improve patient and CP communication, support, and teamwork; and 3) increase perceived behavioral control through coaching and role-playing to empower patients and CPs to overcome individual barriers to adherence. This intervention also includes use of the SimpleMed+ electronic pillbox.
41167404|NCT05548413|BEHAVIORAL|Attention Control|Participants in this group will talk with an interventionist to discuss general health. This intervention also includes use of the SimpleMed+ electronic pillbox.
40859427|NCT06207526|BEHAVIORAL|Blended face-to-face and smartphone intervention|The intervention comprises two phases: an initial stage involves baseline assessment, in-depth app training, psychoeducation, and EMA monitoring for functional analysis. The subsequent phase focuses on identifying and implementing individual coping strategies, forming the basis for daily personalized EMI reminders. Over six days, participants receive ten daily surveys to gauge fluctuations in paranoia and delusional ideation. EMA-derived feedback, considering antecedents and coping responses, shapes a personalized EMI. Four sessions with a psychologist involve discussing app feedback, emphasizing functional analysis, coding coping strategies into the app, assessing utility, and adapting as needed. Post-session two, five coping reminders and an eight-item evening survey are sent daily for two blocks of ten days to monitor delusional ideations and coping strategy effectiveness.
40859428|NCT01991522|BEHAVIORAL|Curriculum Group|
41167405|NCT02049515|DRUG|IPI-145|PI3K Inhibitor
41167406|NCT02049515|DRUG|Ofatumumab|Monoclonal antibody
41167407|NCT05338541|DRUG|Tucidinostat and etoposide|Tucidinostat: 3+3 design，14 mg/m2，17.5 mg/m2，23 mg/m2 etoposide: 50mg/m2,
41167408|NCT06003699|BEHAVIORAL|Search Inside Yourself (SIY) program|The present project involves the delivery of the Search Inside Yourself (SIY) program. The SIY Program is organized into 6 thematic modules. The first module introduces mindfulness and emotional intelligence and provides scientific evidence for the benefits of practicing mindfulness. The second module introduces Self-Awareness. The remaining four modules cover other domains based on Daniel Goleman's original framework of Emotional Intelligence: self-management, motivation, empathy, and leadership. Each module is associated with a set of practices, such as focused attention, body scan, journaling, empathic listening, and a Leadership Commitment exercise. The program will be delivered over 4 weeks, with one 3-hour session per week for a total of 12 hours that will take to complete all the modules.
41390725|NCT02881463|OTHER|therapeutical exercises|Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
41390726|NCT03345953|DRUG|BP 1.4979|Double blind versus placebo
41390727|NCT03345953|DRUG|Placebo|Double blind versus placebo
41390728|NCT00397072|DRUG|ZK 219477|
41390729|NCT06517849|BEHAVIORAL|Monetary Incentive for Take-Up of Cognitive Behavioral Therapy|Both treatment arms will be offered a monetary incentive (in form of a retail gift card) for undergoing a certain number of CBT sessions.
41390730|NCT05178043|DRUG|Nivolumab|Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).
41390731|NCT05178043|DRUG|GT90001|GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
41390732|NCT06537440|OTHER|electro-acupuncture|Electroacupuncture ST25 Tianshu (double), TE6 Zhigou (double), LI4 Hegu (double), ST36 Ashisanli (double), ST37 Shangjuhu (double)
41390733|NCT05117073|DIAGNOSTIC_TEST|ASCITIC FLUID CULTURE|Ten milliliters of ascitic fluid will be collected at the bedside and inoculated into aerobic and anaerobic blood culture bottles. Bacterial culture will be performed manually using MacConkey and blood agar plate
41390734|NCT04144231|BEHAVIORAL|iCBT-I|Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
41390735|NCT04144231|BEHAVIORAL|GCBT-I|Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
40859429|NCT01991522|BEHAVIORAL|Self-directed learning group|
41390736|NCT02406742|DRUG|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
41512451|NCT01068548|OTHER|reminder|computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
40859430|NCT03779048|BEHAVIORAL|Behavioral Treatment|Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).
40859431|NCT03779048|DRUG|Placebo|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
40859432|NCT03779048|DRUG|Phentermine 15 MG|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
40859433|NCT04532034|BEHAVIORAL|Peer-Delivered Decision Support Intervention|An intervention provided by a trained peer interventionist to facilitate treatment decision making among emerging adults with early psychosis. Specific components of this intervention may include facilitating access to information, clarifying values, helping a person obtain the needed support to make a decision, and screening for implementation barriers. Due to having lived experience of a mental health condition, the peer interventionist will also be able to provide unique types of information and support within the coaching process.
40859434|NCT05882461|BEHAVIORAL|90Second Caregiver health letter|Participant receives the weekly health letter via email
40859435|NCT00253123|DRUG|risperidone|
40859436|NCT02305212|BEHAVIORAL|Cogmed|
40859437|NCT00025558|BIOLOGICAL|filgrastim|
40859438|NCT00025558|DRUG|carboplatin|
40859439|NCT00025558|DRUG|temozolomide|
40859440|NCT00025558|DRUG|thiotepa|
41039468|NCT03505632|DEVICE|High PEEP without RM|Volume controlled ventilation will carried out with tidal volume 6-8 ml/kg for predicted body weight. The PBW calculated according to the formula : 50 + 0.91 × {height (cm)-152.4} for men and 45.5 + 0.91 × {height (cm) - 152.4} for women. The respiratory rate adjusted to keep the EtCO2= 35-40 mmHg. The inspiratory to expiratory ratio (I:E ratio) 1:2 and FiO2 0.40.Patients will receive high PEEP of 15cmH2O from the start and continue all through the procedure . Monitoring of dynamic lung compliance,Horowitz index,dead space and driving pressure will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O.
41039469|NCT03137303|DEVICE|Spirometry at initial visit|Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.
41039470|NCT03137303|DRUG|Albuterol|The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
41039471|NCT03137303|DEVICE|Spirometry at 12-month follow-up|At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group.
41390737|NCT02406742|DRUG|Ibrutinib|
41390738|NCT02406742|DRUG|Obinutuzumab|Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
41390739|NCT05416359|DRUG|TQB3915 tablets|TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
40859441|NCT00025558|PROCEDURE|autologous bone marrow transplantation|
40859442|NCT00025558|PROCEDURE|peripheral blood stem cell transplantation|
40859443|NCT05584280|DEVICE|Orsiro stent on shelf|Cluster randomization to Orsiro stent on shelf vs. control
40859444|NCT05584280|DEVICE|Promus stent on shelf|Cluster randomization to Promus stent on shelf vs. treatment
40859445|NCT01835158|DRUG|Cabozantinib S-malate|Given PO
40859446|NCT01835158|OTHER|Laboratory Biomarker Analysis|Correlative studies
40859447|NCT01835158|DRUG|Sunitinib Malate|Given PO
40859448|NCT03136289|BEHAVIORAL|Family Consumer Behaviors|The relationship between family consumer behaviours (healthy food availability and supermarket spending) and adolescent prediabetes and diabetes.
40859449|NCT03648957|BEHAVIORAL|Lifestyle counselling|First behavioral counselling session will be conducted before discharge and follow-up session will be offered with 3-4 weeks intervals either by telephone or in the outpatient clinic.
40859450|NCT03648957|BEHAVIORAL|Usual care|Usual stroke care discharge session; including written and verbal encouragement to a healthy lifestyle.
40859451|NCT03648957|DEVICE|Activity tracker|Participants are encouraged to wear a activity tracker to monitor their physical activity
41039472|NCT03516448|DRUG|Gan Fu Le Tablets|6 Tablets，tid,po
41039473|NCT03516448|DRUG|Tyroserleutide for injection|6mg/d, 5days,ivgtt
41039474|NCT03516448|DRUG|Placebo|0mg/d, 5days,ivgtt
41167409|NCT06158178|DIAGNOSTIC_TEST|Diagnostic accuracy|The PET CT study with choline, being part of the normal standard diagnostic work-up of the patients, was performed following the normal clinical protocol. By analyzing the data retrospectively, the time elapsed following the prostatectomy operation and the follow up time after the choline PETCT study will be evaluated.
41167410|NCT00428025|DRUG|diclofenac|100 mg diclofenac rectal suppository
41167411|NCT00428025|DRUG|placebo|similar shape and size suppository
41390740|NCT06543134|PROCEDURE|surgery|ENT surgery lasting more than half an hour
41390741|NCT06543134|PROCEDURE|sedation scale|Measurement of postoperative recovery with the Richmond agitation scale and the Riker sedation scale
41390742|NCT00136734|DRUG|Methylphenidate|
41390743|NCT00136734|OTHER|placebo|placebo
41390744|NCT00552227|DRUG|ruboxistaurin|oral 32 mg daily
41390745|NCT00552227|OTHER|placebo|placebo
41390746|NCT05617573|PROCEDURE|Total knee arthroplasty due to advanced osteoarthritis.|Postoperative usage of intravenous methylprednisolone
41390747|NCT00888030|OTHER|there are no interventions currently listed for this study|
41390748|NCT02441179|OTHER|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
41390749|NCT02441179|OTHER|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
41390750|NCT02441179|OTHER|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
41390751|NCT01811121|DRUG|5-aminolévulinique acid (5-ALA)|oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
41390752|NCT01811121|DRUG|Placebo|Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
41390753|NCT00221572|PROCEDURE|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
41390754|NCT00397839|DRUG|Ibandronate|Ibandronate orally (tablet) at a dose of 150 mg once per month
41390755|NCT00397839|DRUG|placebo|Placebo orally (tablet) at a dose of 150 mg once per month
41390756|NCT04058431|OTHER|Osteopathic Manipulative Treatment|Osteopathic manipulative treatment (OMT) is defined as the therapeutic application of manually guided forces by an osteopathic physician to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. Somatic (body framework) dysfunction or altered function of related components is observed in the skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Techniques can use a direct method where the restrictive barrier is engaged and a final activating force is applied to correct the somatic dysfunction, or an indirect method where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions
41390757|NCT04058431|OTHER|Control- No Intervention|This group will refrain from getting OMT while in the study.
41390758|NCT04947059|DRUG|Gemcitabine Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with gemcitabine combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
40676671|NCT06622187|DRUG|Sodium Chloride|Patients in the control group will receive sodium chloride 0.9% 100mL administered as an intravenous infusion 1h before the proposed procedure
41167412|NCT02988349|OTHER|Colgate® Sensitive Pro-Relief® toothpaste|Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
41167413|NCT00890539|DRUG|Methacholine challenge|Clinical and research test used in asthma
41167414|NCT03747614|DRUG|Fluorometholone|"Fluorometh010neEyeDrops:~Brand names: Allergan Pharmaceuticals Ireland, Serial number: J20130061, NDC 60758-880-05. Tacrolimus Brand names: Senju Pharmaceutical Co., Ltd. Fukusaki Plant Serial number: H20130452"
41167415|NCT03747614|DEVICE|Functional Slit-Lamp Biomicroscopy|A traditional slit lamp (HAAG-STREIT SWISS MADE 900.7.2.34925) was used, and a digital camera (Canon 60D. Canon Inc, Melville, NY) was attached via an inherent camera port. Custom software was used to measure the conjunctival microvascular BFV and vessel diameter using a protocol that has been previously described in detail. At baseline, video clips were recorded on six fields of the bulbar conjunctiva, which was approximately 1 mm from the limbus. During the follow-up visits, attention was given to relocating the vessel segments for these 6 fields.
41390759|NCT04947059|DRUG|Epirubicin Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with epirubicin combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
41390760|NCT03939403|DRUG|Time of administration of Corifollitropin Alfa|"The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use."
41390761|NCT02832739|DEVICE|SENACA - ICT based self-management support system|SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==\> www.senaca.ch
41390762|NCT02564952|DRUG|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
41390763|NCT02564952|DRUG|Clobazam|Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.
41390764|NCT04992169|BEHAVIORAL|Smartphone-App Parent Training in Pivotal Response Treatment|Parents are trained in Pivotal Response Treatment, Pivotal Response Treatment is a well-known, scientifically supported treatment that focuses on using child motivation, play-based lessons, and parent involvement to target the language skills and social engagement of children with autism. The core smartphone app will offer eight interactive lessons in PRT, consisting of video examples, slides, and brief quizzes.
41390765|NCT05267184|PROCEDURE|Endovascular treatment of the middle meningeal artery|The middle meningeal artery on the same side(s) as the chronic subdural hematoma is embolized with liquid embolic agents.
40676672|NCT06618391|DRUG|Envafolimab|Envolimab :150 mg/time, intratumoral injection, at least 5 sites; Recombinant human endostatin： Q3W for 4-6 cycles，Maintenance therapy 210 mg ,CIV 72 hours ,administered as continuous intravenous pump, administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
41390766|NCT05267184|PROCEDURE|Standard neurosurgical hematoma evacuation|Standard neurosurgical evacuation of chronic subdural hematoma through burr-hole or mini craniotomy and postoperative subdural or subgaleal drainage.
41390767|NCT04523831|DRUG|Ivermectin and Doxycycline|Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days
41390768|NCT04523831|DRUG|Standard of care|Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
41390769|NCT01440023|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.
41390770|NCT01440023|BEHAVIORAL|Computerized Response Inhibition Training|Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
41390771|NCT01440023|BEHAVIORAL|Computerized Placebo Cognitive Training|Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
41390772|NCT01447316|OTHER|Subject outcomes following bariatric surgery|Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
41390773|NCT05628766|OTHER|complete blood count|Thiol/disulphide levels in the blood will be checked by taking complete blood count
41390774|NCT06396221|DRUG|Estetrol 15 mg/Drospirenone 3 mg (24/4)|Completing a pack (28 pills) of Estetrol 15 mg/Drospirenone 3 mg (24/4), starting on day 7-9 of menstrual cycle
41390775|NCT06396221|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
41390776|NCT06290609|DEVICE|Vibrotactile Coordinated Reset|The experimental device, the Stanford CR Glove, is designed to deliver vibratory stimulation to the fingertips of each hand according to a specific pattern, known as vibrotactile Coordinated Reset, which theoretically disrupts abnormal neuronal synchrony and is expected to restore function.
41390777|NCT05420818|PROCEDURE|Transversalis Fascia Inversion|This study will be carried out at SBU Istanbul Training and Research Hospital, General Surgery Clinic. Patients diagnosed with M2 and M3 direct primary inguinal hernia according to EHS classification and who will undergo TEP repair surgery will be randomized into 2 groups. After direct hernia reduction in the patients in the first group, the transversalis fascia at the hernia site will be pulled inward and fixed to the Cooper ligament with 2 or 3 absorbable tackers. Standard surgery will then be continued. The patients in the second group will undergo standard surgery without any seroma prevention procedure. Demographic data of patients in both groups, postoperative pain (VAS values) at postoperative 1st, 7th day and 3rd month, clinical/radiological seroma rate, postoperative pain, QOL, recurrence and other complications will be recorded. When the desired number of patients and follow-up period are reached, the data in the 2 groups will be compared.
41390778|NCT05573373|DRUG|Parimparib|The dosage and protocol of the drug were carried out according to the description.
41390779|NCT05573373|DRUG|Chemotherapy drug|The dosage and protocol of the drug were carried out according to the description.
40859452|NCT01374633|DRUG|1: Sevoflurane|"Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
40859453|NCT02595619|DEVICE|RRT plus ECCO2R|Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
40859454|NCT00793507|OTHER|Oral Health Care Early Intervention Project|The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
41390780|NCT05573373|DRUG|Targeted Therapy Agent|The dosage and protocol of the drug were carried out according to the description.
41390781|NCT04498299|DIAGNOSTIC_TEST|echocardiogram 2D|The patient is accelerating against a workload that gradually increases at a constant rate during the exercise, images will be obtained by echocardiography. The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms.
41390782|NCT06340126|OTHER|Active release techniques|Active release techniques are soft tissue systems or movement-based techniques. It is used to treat muscles, nerves, fascia, ligaments, and tendons.
41390783|NCT06340126|OTHER|Relaxation exercises|Relaxation exercises include breathing exercises, pelvic floor exercises, and postural exercises. Exercises will be done in a sitting position
41390784|NCT04974645|DEVICE|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
40676673|NCT06618391|DRUG|Recombinant human endostatin|Recombinant human endostatin: 15mg/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
40859455|NCT02919254|DIETARY_SUPPLEMENT|Beet It Sport Shot|Commercially available concentrated beetroot juice supplement intended for athletes.
40859456|NCT02919254|OTHER|Placebo|Fruit juice cordial containing negligible nitrate
40676674|NCT06618391|DRUG|recombinant human adenovirus type 5|Recombinant Human Adenovirus Type 5: 1.0ml/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
40859457|NCT03226496|BEHAVIORAL|motivational interviewing|
41390785|NCT04974645|OTHER|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
41390786|NCT02129530|BEHAVIORAL|Community Social Mobilization program|
41390787|NCT00140101|DEVICE|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
41167416|NCT00392704|DRUG|Bevacizumab|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
41167417|NCT00392704|DRUG|Erlotinib|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
41390788|NCT00140101|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
41390789|NCT05091879|GENETIC|Multigene pharmacogenomics test|This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
41039475|NCT06105073|PROCEDURE|Pulmonary Rehabilitation Program|Consecutive patients who attend with a confirmed diagnosis of Systemic Sclerosis associated Interstitial Lung disease, at the Speciality Hospital from the Medical Center La Raza IMSS. The anxiety and depression questionnaire will be applied to them. Goldberg, as well as the SF-36 questionnaire to evaluate quality of life and the SySQ questionnaire to evaluate functionality, to include these data in the analysis, these questionnaires are validated in our population and have been widely used. All participants (T0) will undergo Forced Spirometry, Carbon Monoxide Diffusion Capacity and Cardiopulmonary Exercise Test. Then they will enter a supervised pulmonary rehabilitation program that consists of 36 sessions, which is equivalent to 12 weeks. At the end of this period (T1), again the respiratory function tests (spirometry, DLCO and Cardiopulmonary Exercise Test) as well as the Goldberg, SF-36 and SySq questionnaires.
41390790|NCT04586569|OTHER|Pediatric Interactive Relational Agent (PIRA)|The PIRA is an interactive, online tool used to educate children and families about their child's upcoming surgical and anesthesia experience.
41390791|NCT05769192|OTHER|Classical physiotherapy and classical massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. Classical massage, known as Swedish massage, will be applied on the lumbar region in prone position. All applications will be done 5 days a week for 3 weeks.
41390792|NCT05769192|OTHER|Classical physiotherapy and placebo massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. In addition, placebo massage, applied without using any technique, will be applied to the lumbar region in the prone position. All applications will be done 5 days a week for 3 weeks.
41390793|NCT02102022|DRUG|ADI-PEG 20 plus modified FOLFOX6|
41390794|NCT00068445|DRUG|lamotrigine|
40859458|NCT01648972|DRUG|Gastrografin|
41039476|NCT01627327|DRUG|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
41039477|NCT01627327|DRUG|tiotropium bromide 18mcg|inhalation powder
41039478|NCT01501708|DRUG|Caspofugin based combination therapy|"Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.~* All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.~* In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given."
41039479|NCT03077724|DRUG|Fish oil|Fish oil supplementation
41039480|NCT03077724|DRUG|Placebos|Olive Oil capsules
41039481|NCT05668728|OTHER|Group 1: Peppering|Before injection we will palpate the muscles of trapezius, m. rhomboideus, m. levator scapula for finding painful trigger points, and we will mark the point. the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. The needle will be inserted and removed until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
40859459|NCT01648972|DRUG|Placebo|
40859460|NCT04661982|OTHER|Long-term Follow-up|Undergo long term follow-up
41390795|NCT00068445|OTHER|Placebo|
41512452|NCT00704626|OTHER|Blood Draw|A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.
40859461|NCT04661982|OTHER|Questionnaire Administration|Ancillary studies
40859462|NCT04661982|OTHER|Quality-of-Life Assessment|Ancillary studies
40859463|NCT02465372|BEHAVIORAL|CSPAP|Comprehensive School Physical Activity Program.
40859464|NCT03772262|DIETARY_SUPPLEMENT|goldenseal|Oral 500 mg capsules
41390796|NCT03207360|BEHAVIORAL|Pain Coping Skills|Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly videoconference-delivered sessions that will last between 45 and 60 minutes.
41390797|NCT06536582|BIOLOGICAL|Platelet rich growth factor injection (autologous product)|All patients will undergo two PRGF injections, one at recruitment and one 14 days after the first injection. The injection site will be the shoulder with tendinopathy.
41390798|NCT02524665|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
41390799|NCT02524665|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
41390800|NCT02524665|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
41167418|NCT00392704|DRUG|Paclitaxel|"Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy"
41167419|NCT00392704|DRUG|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
41167420|NCT00392704|RADIATION|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
41390801|NCT02524665|OTHER|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
41512453|NCT00704626|OTHER|Cheek swab|A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.
40859465|NCT03772262|DRUG|Metformin|Oral solution
40859466|NCT03772262|DRUG|Furosemide|Oral solution
40859467|NCT03772262|DRUG|Midazolam oral solution|Oral syrup
40859468|NCT03772262|DRUG|Rosuvastatin Oral Tablet|Oral tablet
41390802|NCT02524665|OTHER|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
41390803|NCT02524665|OTHER|Skin Perfecting Lotion|Available over the counter.
41390804|NCT01010230|DEVICE|LMHF mechanical stimulation active device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
41390805|NCT01010230|DEVICE|LMHF mechanical stimulation placebo device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
41390806|NCT05800366|DRUG|Glofitamab|human IgG1-bispecific antibody, via IV infusion
41512454|NCT00652054|DRUG|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
41512455|NCT01056289|DRUG|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
41512456|NCT01056289|DRUG|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
41512457|NCT01056289|DRUG|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
41512458|NCT05593744|OTHER|no intervention|This is an observational study so not involved intervention
40859469|NCT06334848|PROCEDURE|transobturator tape|Women with stress urinary incontinence are treated by transobturator tape versus mini sling
40859470|NCT05363189|PROCEDURE|Venous augmentation|Increasing the venous drainage of a deep inferior epigastric artery perforator (DIEP) flap by anastomosing the superficial inferior epigastric vein to the cephalic vein
40859471|NCT05363189|PROCEDURE|Traditional ERAS (enhanced recovery after surgery) protocol|Pre-, peri-, and post-operative care as described in the ERAS protocol
40859472|NCT05363189|PROCEDURE|Sahlgrenska recovery protocol|Pre-, peri-, and post-operative care as described in the Sahlgrenska recovery protocol
41167421|NCT00570921|DRUG|Everolimus|Everolimus tablets, two-5 mg tablets a day
41167422|NCT00570921|DRUG|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
41167423|NCT02997683|DEVICE|Body Vibration platform GALILEO|3 month home based training on whole Body Vibration platform GALILEO
41167424|NCT02997683|OTHER|exercises at home on the floor|exercises at home on the floor
41390807|NCT05800366|DRUG|Polatuzumab|an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion
41390808|NCT05800366|DRUG|Rituximab|Per standard care, via IV infusion
41390809|NCT05800366|DRUG|Doxorubicin Hydrochloride|Per standard care, via IV infusion
41390810|NCT05800366|DRUG|Cyclophosphamide|Per standard care, via IV infusion
41390811|NCT05800366|DRUG|Prednisone|Per standard care, orally
40859473|NCT05363189|PROCEDURE|No venous augmentation|Traditional deep inferior epigastric artery perforator flap (DIEP)
40859474|NCT00351065|DRUG|SK3530|
40859475|NCT02113033|DEVICE|Equilia® Vagal Nerve Stimulation|Vagal Nerve Stimulation synchronized with cardiac activity
40859476|NCT00930085|OTHER|SELDI-TOF MS for plasmatic proteic profile|An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
41390812|NCT03308123|OTHER|Observational study, not interventional|Not an intervention study
41390813|NCT05485571|DEVICE|derma pen|"Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks"
41390814|NCT05140863|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
41390815|NCT05140863|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
41390816|NCT05140863|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 12-weeks fixed dose
41390817|NCT04917029|DRUG|Bupivacaine hydrochloride perineurally|Arm 1; Bupivacaine hydrochloride 40 ml 0.25% perineurally in FICB
40859477|NCT01286740|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
40859478|NCT01587040|DRUG|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
40859479|NCT01587040|DRUG|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
40859480|NCT03239080|DRUG|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
40859481|NCT03239080|OTHER|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
41390818|NCT04917029|DRUG|Dexmedetmidine infusion|Arm 1: infusion of Dexmedetmidine 0.5 µg/kg/h
41390819|NCT04917029|DRUG|Dexmedetomidine perineurally|Arm 2:Dexmedetomidine perineurally in FICB 80µg
40859482|NCT03234413|DRUG|Botulinum toxin type A|Botulinum toxin type A
40859483|NCT05733442|OTHER|Treatment as usual (TAU)|TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.
41390820|NCT03203005|DRUG|IMA970A plus CV8102 and Cyclophosphamide|"Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms \[µg\] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months."
41390821|NCT04218344|OTHER|60mls of blood donated for research analysis|All patients presenting with a possible Acute Coronary Syndrome will be invited to donate 60 mls of blood at the time of their angiogram.
41390822|NCT01653223|DRUG|simvastatin|"In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months."
41390823|NCT06390358|OTHER|Tefillin|Wrapping of arm
40859484|NCT05733442|OTHER|CHaRRM-CN|The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).
40859485|NCT02047214|DRUG|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
41167425|NCT02507687|DRUG|Bimatoprost SR|Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration. The Bimatoprost SR implant is injected into the anterior chamber via the corneal limbus using the prefilled applicator.
41390824|NCT00727896|BEHAVIORAL|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
41390825|NCT00727896|DRUG|Diabetes Treatment|Life style modification and drug therapy
41390826|NCT06246526|DEVICE|Evoke|The Saluda Medical Evoke® CL-SCS System (Evoke System). The Evoke System measures and records spinal cord (SC) activation resulting from stimulation via evoked compound action potentials (ECAPs). The Evoke System can be programmed to provide ECAP-controlled, closed-loop SCS or open-loop, fixed-output (traditional) SCS; ECAPs may be measured and recorded in either stimulation mode.
41512459|NCT01606774|OTHER|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
41390827|NCT06056531|OTHER|Near infrared light imaging|The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers.
41512460|NCT05741827|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention focusing on diet and physical activity
41512461|NCT02373449|OTHER|RS-fMRI|Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
40859486|NCT02047214|DRUG|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
40859487|NCT06238284|OTHER|no intervention|Since it is a retrospective study, no intervention is needed.
40859488|NCT04063592|PROCEDURE|Residual limb revision|Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
40859489|NCT02330692|OTHER|No intervention|
40859490|NCT01330329|BEHAVIORAL|Standard behavioral treatment|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.
40859491|NCT01330329|BEHAVIORAL|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
40859492|NCT04548804|DIAGNOSTIC_TEST|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan
41167426|NCT02507687|DRUG|Sham Bimatoprost SR|Sham bimatoprost SR performed using the same procedure as for Bimatoprost SR using an needleless applicator that touches the eye at the area of insertion but does not deliver an implant into the anterior chamber.
41167427|NCT02507687|PROCEDURE|Selective Laser Trabeculoplasty|"SLT is a laser procedure that targets the melanin, or pigment, in specific cells of the eye.~An ophthalmologist performed 360 degrees of SLT using a standardized method."
41167428|NCT02507687|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham SLT is performed on the contralateral eye using the same method as for SLT, with the exception that the laser is not switched to the active state.
41167429|NCT03371485|BIOLOGICAL|AST-VAC2|Allogeneic dendritic cell vaccine.
41390828|NCT06056531|OTHER|Isometric exercise with stress ball|Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball.
41390829|NCT04359420|OTHER|BC-Predict|BC-Predict is an automated system for offering an assessment of breast cancer risk to women when they receive their NHS Breast Screening Programme invitation, and generating letters to feedback this risk to women and relevant healthcare professionals. Women at higher risk are offered chemoprevention drugs and additional mammography
41167430|NCT03677245|OTHER|Strider Balance Bike|Learning to ride a Strider balance bike
41167431|NCT03022578|PROCEDURE|Laser Interstitial Thermal Therapy|Undergo LITT
41167432|NCT03022578|DRUG|Lomustine|Given PO
41167433|NCT04921878|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle) for a maximum of 6 cycles.
41167434|NCT04864717|DRUG|Doxycycline 100mg po once daily x 6 months|active intervention
41167435|NCT04864717|DRUG|Isotretinoin 40 mg po once daily x 6 months|active intervention
41390830|NCT04359420|OTHER|NHS Breast Screening Programme|usual care from NHS Breast Screening Programme, consisting of mammography every three years for most women.
41512462|NCT02373449|DRUG|Ketamine|Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
41512463|NCT03228797|PROCEDURE|an ultrasound guided rectus sheath block|
41512464|NCT03228797|PROCEDURE|multiholed catheter|gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision
41512465|NCT03228797|PROCEDURE|an ultrasound guided rectus sheath block &multiholed catheter|a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
41512466|NCT00136253|BEHAVIORAL|Help dietitians and patients address specific nutritional barriers|
41512467|NCT02000791|OTHER|Comparison of fibreoptic view|
41512468|NCT01469728|PROCEDURE|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
40859493|NCT01178099|DRUG|Prasugrel|Oral, daily for 12 days
40859494|NCT01406197|DRUG|Experimental: Vaginal progesterone|Vaginal progesterone formulation (150 mg micronized progesterone daily)
40859495|NCT01406197|DRUG|Experimental: Topical progesterone|Progesterone will be applied daily (150 mg micronized progesterone)by topical application
40859496|NCT01406197|DRUG|Experimental: Intramuscular progesterone|Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
41167436|NCT02419963|PROCEDURE|endoscopy for tissue biopsy|endoscopy to obtain tissue biopsy for analysis of biomarker status
41167437|NCT02419963|OTHER|Blood Sample|Blood draw to evaluate serotonin and Vit D level.
41167438|NCT02419963|OTHER|Stool Sample|Stool sample to evaluate microbiome fingerprint.
41039482|NCT05668728|OTHER|group 2: spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapula will be identified and marked by palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the dry needle is inserted at each point found, it will be spinned counterclockwise and left. Waiting time for each patient will be limited to 15 minutes. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
41039483|NCT05668728|OTHER|group 3: Peppering and spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapul will be identified and marked with palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the needle is inserted and removed, it will be spinned counterclockwise for 15 minutes in each patient until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program. With this method, dry needling will be applied to the patient 4 times a week, once a week.
41039484|NCT05121519|OTHER|Consume coffee|Drink coffee regularly (recommend at least 1 cup of coffee per day)
40859497|NCT01057186|DIETARY_SUPPLEMENT|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
41039485|NCT05121519|OTHER|Avoid coffee|Abstain from coffee and other caffeinated beverages
41039486|NCT02549898|DRUG|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
41039487|NCT02549898|DRUG|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
41039488|NCT02549898|OTHER|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
41039489|NCT02549898|OTHER|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
41039490|NCT03492281|DRUG|vibegron|single daily oral dose of vibegron 75 mg for 12 weeks
41039491|NCT03492281|DRUG|Vibegron placebo|placebo to match vibegron (experimental drug)
41039492|NCT03492281|DRUG|Tolterodine Tartrate ER|single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
41039493|NCT03492281|DRUG|Tolterodine placebo|placebo to match tolterodine (active comparator)
41039494|NCT01371851|DRUG|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
41039495|NCT01055769|DRUG|Linezolid|"1. Linezolid OS 600 MG~2. Linezolid Tablet 600 MG"
41417838|NCT04786652|DIAGNOSTIC_TEST|Assessment of fluid responsiveness in spontaneously breathing patients at 18 hrs of the postoperative period|2) In spontaneously breathing patients at 18 hrs of the postoperative period: PLR, and mFL tests followed by sFL. Monitoring: SVVPCA, PPVPCA, esSVV, PVI, PEP, CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase.
41512469|NCT01469728|PROCEDURE|Awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
41039496|NCT01055769|DRUG|Linezolid|"1. Linezolid Tablet 600 MG~2. Linezolid OS 600 MG"
41167439|NCT05426161|DRUG|Botulinum Toxin A|Botulinum Toxin A (10 units per cm2 wound areal) will be injected subcutaneously around the wound (1-2 cm from wound edge) maximum 200 units at each injection time.The total dose of BoNTA is maximum 400 units. Patient will receive one or two treatments in total.
41417839|NCT05669599|BIOLOGICAL|Maridebart Cafraglutide|Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.
41417840|NCT05669599|DRUG|Placebo|Participants will receive placebo by SC injection.
41417841|NCT00003898|DIETARY_SUPPLEMENT|glutamine|Oral
41512470|NCT02112851|OTHER|Orange flavored beverage|Intervention involves consumption of one beverage of 240ml following baseline measurements
41512471|NCT03346096|DRUG|Thiotepa|fixed dose 5mg/kg on days -7-6
40859498|NCT01057186|DRUG|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
41039497|NCT03424824|DRUG|BP1.3656 low dose|Tablet, once daily oral administration at the low dose
41039498|NCT03424824|DRUG|BP1.3656 intermediate dose|Tablet, once daily oral administration at the intermediate dose
41039499|NCT03424824|DRUG|Placebo|Tablet, once daily oral administration
41039500|NCT03424824|DRUG|BP1.3656 high dose|Tablet, once daily oral administration at the high dose
41167440|NCT02259062|OTHER|Music with brief mindfulness intervention|Music listening with mindfulness therapy
41167441|NCT02259062|OTHER|Music listening alone|
41167442|NCT02259062|OTHER|Audiobook listening|
41167443|NCT01817712|BEHAVIORAL|Individual Placement & Support|"IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation."
41417842|NCT00554151|DEVICE|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
41417843|NCT00648453|DRUG|Clopidogrel (Plavix)|
41417844|NCT01064128|PROCEDURE|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
41417845|NCT01064128|PROCEDURE|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
41417846|NCT04529109|DEVICE|etafilcon A investigational cosmetic lens 1|TEST
41417847|NCT04529109|DEVICE|etafilcon A investigational cosmetic lens 2|CONTROL
40859499|NCT04492501|PROCEDURE|Therapeutic Plasma exchange|1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
40859500|NCT04492501|BIOLOGICAL|Convalescent Plasma|"Convalescent plasma as part of replacement therapy (200-400ml) if reported within 14 days of illness. An IgG titer of \> 1.320 will be considered suitable for use. It will be Collected from person previously infected with Covid-19 and meet following criteria;~1. After 28 day of illness till 3 months~2. Symptom free 2 weeks prior to donation~3. Negative two consecutive PCRs any time between initial positivity and before donation~4. Anti SARS-CoV2 IgG positive, IgM negative~5. Fulfills healthy donor criteria as per WHO/AABB guidelines~6. Volume of plasma to be collected: 900-1200 ml through Apheresis OR plasma separated from phlebotomy donation"
40859501|NCT04492501|DRUG|Tocilizumab|A predefined number of patients having evidence of cytokine release storm with normal procalcitonin level for three consecutive days, a normal blood culture and IL-6 level \> 3 times ULN will be given 1-2 doses of Tocilizumab (80mg IV) . Following contraindications to Tocilizumab will be considered (Allergy to any monoclonal Ab, ANC \< 1000, Platelets \< 50, ALT or AST \> 5 times ULN, Pregnancy and breast feeding, Post TB lung). Some patients will receive it alone in addition to standard treatment whereas in few patients where indicated it will be given in combination with MSC or Remdesivir or both
40859502|NCT04492501|DRUG|Remdesivir|It will be given to selected patients who have evidence of hypoxemia and presented with in 14 days of illness. For adults requiring invasive mechanical ventilation the dosage of remdesivir is a single loading dose of 200 mg sta on Day 1 followed by once daily maintenance doses of 100 mg IV for 9 days (days 2 through 10). For adults not requiring invasive mechanical ventilation 5 standard doses will be used. However, patients with known hypersensitivity to Remdesivir, multi organ failure, ALT \> 5 times ULN and GFR \< 30ml/minute will not be given Remdesivir. In some patients, where indicated other novel treatments including MSC therapy, Tocilizumab and therapeutic plasma exchange will be given.
40859503|NCT04492501|BIOLOGICAL|Mesenchymal stem cell therapy|Single Dose of 2 x 106 cells/kg will be administered either alone or in combination with other novel therapies. At Armed Forces Bone Marrow Transplant Centre (AFBMTC), MSCs will be isolated from bone marrow harvested cells. About 50ml bone marrow will be collected from iliac crest using aseptic technique in syringes primed with anticoagulant. The collected sample will be diluted with Phosphate Buffer Saline (PBS) and MSCs will be separated using density gradient centrifugation. After resuspension the cells will be seeded at a fixed concentration of 100,000 cells/cm2 in specially designed flasks and incubated at 37Oc in 5% CO2. Medium will be changed after every third day till harvesting of MSCs from the flasks. Once confluent (approximately day 20) the cells will be harvested with sterile techniques using Trypsin- EDTA solution.
40859504|NCT00398099|DRUG|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
40859505|NCT04033055|PROCEDURE|Inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
40859506|NCT04033055|PROCEDURE|Inguinal hernia repair with CycloMesh™ soaked in saline solution NaCl 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
40859507|NCT02914665|DRUG|elamipretide|20 mg elamipretide administered intravenously once daily for 7 consecutive days
40859508|NCT02914665|DRUG|Placebo|Placebo administered intravenously once daily for 7 consecutive days
40859509|NCT05246800|OTHER|Structured 8-week mHealth mindfulness program|The mindfulness application was developed by Minddistrict The content of the app was developed by professionals in the field of mental healthcare and based on the principles of MBSR and MBCT The app consisted of a structured program, with chapters on psycho-education on mindfulness and the importance of practicing; acting on auto-pilot, conscious attention; non-judgmental attention, awareness; doing versus being-modus; attention for breath and body, conscious response; acceptance; a mindful attitude towards thoughts; applying mindfulness in daily life and staying mindful.
40859510|NCT00108316|DRUG|Fluoxetine (Liquid Prozac)|
40859511|NCT04311255|PROCEDURE|regional anesthesia for the upper limb|pecs-II block and intercostal nerve block
40859512|NCT05233592|DEVICE|CGM|Patients wear a CGM to measure the effects of the COVID-19 booster vaccine on blood sugar levels.
41039501|NCT03213158|DRUG|Ixazomib Oral Capsule|Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.
41039502|NCT00201006|BEHAVIORAL|Face-to-face counseling|Biweekly group behavioral counseling sessions conducted in a face-to-face format
41039503|NCT00201006|BEHAVIORAL|Telephone counseling|Biweekly telephone counseling sessions conducted in a one-on-one format
41039504|NCT00201006|OTHER|Mail contact|Biweekly written newsletters with weight management advice delivered via U.S. mail
41039505|NCT05366777|DRUG|acetaminophen/ibuprofen fixed-dose combination|Intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) fixed-dose combination (total 100 ml)
41039506|NCT05366777|DRUG|Saline|100 ml of normal saline
41039507|NCT05278000|OTHER|Presence of scarcity mindset|"This observational study will examine whether~1. Individuals exhibiting a scarcity mindset have lower adherence to asthma controller medication~2. Individuals with higher rates of future discounting have lower adherence to controller medication~3. Individuals with unmet social needs are more likely to experience scarcity and have higher rates of future discounting, and whether these relationships mediate adherence to asthma controller medication"
40859513|NCT03806686|BIOLOGICAL|Placebo|Sterile normal saline
40859514|NCT03806686|BIOLOGICAL|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
40859515|NCT01359943|BIOLOGICAL|secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
40859516|NCT01359943|DRUG|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
40859517|NCT03874572|BIOLOGICAL|Allogeneic adipose derived stem/stromal cells|Culture expanded allogeneic adipose derived stem/stromal cells
40859518|NCT03838081|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S),|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
41390831|NCT02969473|DRUG|Docetaxel|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
41390832|NCT02969473|DRUG|Fluorouracil|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
41390833|NCT01898624|DRUG|mirabegron|oral
41390834|NCT01998035|DRUG|RomiDEPsin 10 MG/M2|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10 mg/m2)"
41390835|NCT01998035|DRUG|Oral 5-Azacitidine 100 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100 mg)"
41390836|NCT01998035|DRUG|Romidepsin 14 MG/M2|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (14 mg/m2)"
41390837|NCT01998035|DRUG|Oral 5-Azacitidine 200 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (200 mg)"
41390838|NCT01998035|DRUG|Oral 5-Azacitidine 300 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (300 mg)"
40859519|NCT03838081|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
40859520|NCT03838081|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
41039508|NCT06041035|DRUG|QLS31905|Administered as an intravenous infusion.
41039509|NCT06041035|DRUG|Nab paclitaxel|125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
41417848|NCT06314503|DEVICE|WEAKID|"Six treatments over the course of two weeks with the WEAKID system:~* Week 1 (without the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment~* Week 2 (with the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment"
41417849|NCT03428594|BIOLOGICAL|CKD-11101|
41417850|NCT03428594|BIOLOGICAL|NESP|
41417851|NCT02423902|BIOLOGICAL|Ad-RTS-hIL-12|Approximately 1.0x10\^12 viral particles (vp) per injection
40859521|NCT03838081|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
40859522|NCT05204030|OTHER|HPV Twitter Education Program - Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine narrative messages (i.e., stories). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
41039510|NCT06041035|DRUG|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
41039511|NCT06041035|DRUG|Oxaliplatin|85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
41039512|NCT06041035|DRUG|Capecitabine|1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.
41039513|NCT06041035|DRUG|Cisplatin|25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
41039514|NCT04719780|BEHAVIORAL|Emotionally Focused Therapy for Individuals|Emotionally Focused Therapy for Individuals (EFIT) is formulated as a transdiagnostic treatment to treat depression and anxiety, adapted from the well-studied Emotionally Focused Therapy. EFIT has been formulated as an attachment-based alternative to current cognitive approaches (e.g., Cognitive Behavioural Therapy). The strong evidence for insecure attachment as an underlying factor in psychopathology, especially depression and anxiety, positions this theory well as a foundational principle to support psychotherapy for these conditions.
41417852|NCT02423902|DRUG|Veledimex|7 oral doses of veledimex
40859523|NCT05204030|OTHER|HPV Twitter Education Program - Non-Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine non-narrative messages (i.e., scientific information - numbers and facts). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
40859524|NCT03724929|PROCEDURE|Blood sample|Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.
40859525|NCT03724929|DEVICE|Rectosigmoidoscopy|Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52.
40859526|NCT01438450|DRUG|Oral|"Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week"
40859527|NCT01438450|OTHER|Supportive|No specific therapy will be given
40859528|NCT06461832|PROCEDURE|Group 1|In patients undergoing a hysterectomy, an epidural catheter is placed via the L3-4 or L4-5 spinal space, followed by the application of a standardized general anesthesia protocol.
40859529|NCT06461832|PROCEDURE|Group 2|In patients undergoing hysterectomy, 15-20 mg of heavy bupivacaine is injected into the intrathecal area via the L3-4 or L4-5 spinal space, using a spinal needle. Following the removal of the spinal needle, an epidural catheter is then placed through the same opening.
40859530|NCT02418052|PROCEDURE|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
40859531|NCT02843503|DEVICE|Arterialized-venous reference (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
40859532|NCT02843503|DEVICE|Venous reference measurement (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
40859533|NCT02843503|DEVICE|Capillary reference (SMBG)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
40859534|NCT03420274|BEHAVIORAL|NEST|This is a point-of-care shared decision-making instrument.
40859535|NCT03420274|BEHAVIORAL|Usual care|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
41167444|NCT01817712|BEHAVIORAL|VA Transitional Work Program|"The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role."
41167445|NCT03427008|OTHER|mHealth Intervention|The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
41167446|NCT02332200|OTHER|Physical Therapy|Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
41167447|NCT00000133|PROCEDURE|Trans-scleral Cryotherapy|
41167448|NCT00703105|BIOLOGICAL|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
41167449|NCT04566198|OTHER|Questionnaire|The participants will have to filled out a questionnaire about their working conditions and their lifestyle habits.
40859536|NCT02702180|DRUG|Molgramostim|300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
41167450|NCT01004185|DRUG|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM \& 2 Asacol 400mg PM; 33-\<54kg = 5 Asacol 400 mg AM \& 4 Asacol 400mg PM; 54-\<90kg = 6 Asacol 400mg AM \& PM
41167451|NCT01004185|DRUG|Asacol 400 mg|17-\<33kg = 2 Asacol 400mg \& 1 placebo AM, 1 Asacol 400mg \& 1 placebo PM; 33-\<54kg = 3 Asacol 400mg \& 2 placebo AM, 2 Asacol 400mg \& 2 placebo PM; 54-\<90kg = 3 Asacol 400mg \& 3 placebo AM \& PM
41167452|NCT06220071|OTHER|Case series review of clinical and radiographic data|Extraction of clinical and radiographic data related to patients' history from medical records
41167453|NCT01792843|BEHAVIORAL|data|"* comparisons of clinical characteristics~* comparisons of cognitive profiles~* comparisons of grey matter density patterns~* comparisons of EEG rhythms features"
41167454|NCT00661544|DRUG|Arsenic Trioxide|Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
41167455|NCT00661544|DRUG|Melphalan|Dose Levels 1, 2, \& 3: 100 mg/m2 IV Days -4, -3.
41167456|NCT00661544|DRUG|Ascorbic Acid|Dose Levels 1, 2, \& 3: 1000 mg IV Days -9 to -3.
41167457|NCT03371121|OTHER|AT-AMIC (arthroscopic talus autologous matrix induced chondrogenesis)|to fill arthroscopically osteochondral talar lesion
41167458|NCT05910697|OTHER|MyProstateScore 2.0 Results|Being shown the results of a diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy and how it changes clinical practice.
41167459|NCT05434585|BIOLOGICAL|ABO1009-DP|Vaccine
41167460|NCT05434585|BIOLOGICAL|ABO-CoV.617.2|Vaccine
41167461|NCT05434585|OTHER|Placebo|Placebo
41167462|NCT02143310|DEVICE|EVP|
41512472|NCT05815017|DEVICE|Yoomi Physical Therapy Software|Physical Therapy software via a computer/monitor will be set up for the patient. It will begin with a tutorial video for different exercises in the form of games and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
41390839|NCT01488799|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioural Therapy|Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
41390840|NCT02177864|DIETARY_SUPPLEMENT|Fiber|
41390841|NCT02177864|OTHER|Placebo (low fiber bar)|
41390842|NCT04056091|PROCEDURE|Back rub stimulation|Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (back rubs). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
41390843|NCT04056091|PROCEDURE|Foot flicks stimulation|Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (foot flicks). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
41390844|NCT04637282|DRUG|PLX-200|15 mg/mL oral solution of experimental drug
41390845|NCT04637282|DRUG|Placebo|Taste and color-matched drug-free solution
41390846|NCT05584774|PROCEDURE|PELDAN|percutaneous endoscopic lumbar dissectomy and annuloplasty and nucleoplasty
41390847|NCT01987258|BEHAVIORAL|Interval Walking|
41390848|NCT01987258|BEHAVIORAL|Continuous walking|
41390849|NCT03151967|DRUG|Lactobacillus crispatus CTV-05|vaginal applicator with medium containing drug
41390850|NCT03151967|DRUG|Placebo|vaginal applicator with medium containing no drug
40859537|NCT02702180|DRUG|Placebo|Placebo nebulizer solution for inhalation
41390851|NCT05503914|RADIATION|low-dose radiotherapy|On the first and second days of induction chemotherapy, local tumor were irradiated with 0.5Gy bid for 4 times.
41390852|NCT01925378|DRUG|Nelfinavir|"All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration."
41390853|NCT00350194|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
41390854|NCT03853356|DEVICE|Orthoss|Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
41390855|NCT00243282|BEHAVIORAL|Relaxation Response (instruction, pocket practice card prov)|
41390856|NCT00243282|BEHAVIORAL|Mindfulness training using model developed from UMass|
41390857|NCT03717974|OTHER|Telemedecine follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by telemedicine. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
41390858|NCT03717974|OTHER|Mobile team follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by mobile team. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
41390859|NCT05674266|DEVICE|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
40859538|NCT02702180|DEVICE|PARI eFlow nebulizer system|PARI eFlow nebulizer system
40859539|NCT01204021|BEHAVIORAL|Tai Chi Chih|12 weeks of weekly classes of Tai Chi Chih
41390860|NCT05674266|DEVICE|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
40859540|NCT01204021|BEHAVIORAL|Stress Education Control|Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
41390861|NCT03801759|DRUG|Vadadustat|Oral dose 600 mg
41390862|NCT03801759|DRUG|Furosemide|Oral Furosemide
41390863|NCT03801759|DRUG|Adefovir|Oral Adefovir
41390864|NCT03801759|DRUG|Digoxin|Oral Digoxin
41390865|NCT02792088|DRUG|Besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
41390866|NCT02792088|DRUG|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
41390867|NCT06394921|PROCEDURE|2 day cardiopulmonary exercise test|Consecutive day 2 day CPET and follow up for 7 days for subjective feelings/fatigue.
41390868|NCT02149199|DRUG|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
41512473|NCT05761899|COMBINATION_PRODUCT|Gene-Corrected Macrophages administered by bronchoscopic instillation|This study will evaluate administration of autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments on three occasions at 2-month intervals in patients with hPAP. The target (maximum) number of cells to be administered is 778 million gene-corrected macrophages per 70 kg patient, which is equal to 11.1 million cells/kg of ideal body weight.
41512474|NCT05203783|OTHER|McKenzie Exercises|"McKenzie exercises: The McKenzie set consists of 5 exercises.~1. Prone-lying~2. Prone-extension~3. Prone press ups~4. Progressive extension with pillows~5. Standing extension"
40859541|NCT05314907|DEVICE|Explanation on how to use self-sampling device and training in the screening visit.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is collected for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn Brush and after the woman collects an HPV sample by self-sampling in the same medical center as a trainning.~Finally, a new cervibrush (Evalyn brush) is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
40859542|NCT05314907|OTHER|Only explanation on how to use self-sampling device.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is taken for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn.~Finally, a Evalyn brush is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
40859543|NCT00755495|DRUG|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
40859544|NCT00755495|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
40859545|NCT00755495|DRUG|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
40859546|NCT00755495|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
40859547|NCT02389036|DRUG|SDD Oral Paste|A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
40859548|NCT02389036|DRUG|SDD Gastric Suspension|2. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 \^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
41039515|NCT04719780|BEHAVIORAL|Self-Help CBT Training|Individuals in the Waitlist Control Group will receive access to MoodGym, a self-help online program that helps teach CBT interventions. This access will last 15 weeks and is self-driven, meaning participants proceed through the program at their own pace.
40859549|NCT02389036|DRUG|Intravenous Antibiotic|A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
41039516|NCT01922115|DRUG|Trospium Chloride|Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
41039517|NCT01922115|DRUG|Placebo|
41390869|NCT02149199|DRUG|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
41390870|NCT02149199|DRUG|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
41417853|NCT05760664|OTHER|Group Experimental/Fascial Fitness|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
40859550|NCT01849406|DRUG|nasal spray Budesonide|one week therapy of nasal budesonide twice per day
40859551|NCT01849406|DRUG|Nasal spray Normal Saline|one week therapy of nasal normal saline twice per day
40859552|NCT00526591|DRUG|Everolimus|Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week
40859553|NCT00526591|PROCEDURE|conventional surgery|Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
40859554|NCT04270084|BEHAVIORAL|Alive-Family|All participants receive lifestyle modification through use of m-health app
40859555|NCT02742376|OTHER|Soft surface|A sponge rectangle used in physiotherapy will be placed on the floor,
40859556|NCT02742376|OTHER|Floor|A marked path on the floor where the subject is instructed to walk.
40859557|NCT02742376|OTHER|Kyboot shoes|Special shoes will be worn by the subject.
40859558|NCT03831217|PROCEDURE|mid urethral sling surgery|patients with clinically and/or urodynamically proven stress urinary incontinence underwent mid urethral sling surgery under general anesthesia.
40859559|NCT02411435|DRUG|CAB|CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
40859560|NCT02411435|DRUG|RIF|RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
40859561|NCT04383782|BEHAVIORAL|Expectancy Challenge|Expectancy challenge intervention (see description in study arms).
40859562|NCT04383782|BEHAVIORAL|Expectancy Challenge + Behavioral Activation|Expectancy challenge + behavioral activation interventions (see description in study arms)
40859563|NCT04383782|BEHAVIORAL|Control|Neutral reading condition (see description in study arms).
41039518|NCT06195917|DEVICE|Robotic-assisted Interventional Percutaneous transhepatic puncture|Robotic-assisted Interventional Percutaneous transhepatic puncture
41039519|NCT01114568|DRUG|Ertugliflozin 10 mg tablet|A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
41039520|NCT01114568|DRUG|Ertugliflozin OC Fast|Formulation B) Ertugliflozin 10 mg OC Fast
41039521|NCT01114568|DRUG|Ertugliflozin OC Slow|Formulation C) Ertugliflozin 10 mg OC Slow
41039522|NCT06303739|DRUG|psilocybin|25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.
41039523|NCT01763931|DRUG|Digoxin|Digoxin once daily for 2 weeks prior to definitive breast surgery.
41039524|NCT02077166|DRUG|Ibrutinib|
41039525|NCT02077166|DRUG|Lenalidomide|
41039526|NCT02077166|DRUG|Rituximab|
41167463|NCT04883021|DEVICE|Dual Target Theta Burst Stimulation|"TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.~Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold."
41167464|NCT02902653|DRUG|Oral misoprostol|hourly titrated misoprostol
41167465|NCT02902653|DRUG|Vaginal misoprostol|Administration of 25 microgs every 6 hours, maximum 150 microgr
41167466|NCT02902653|DRUG|Vaginal dinoprostone|Vaginal delivery system of 10mg of dinoprostone
41167467|NCT04134884|DRUG|Talazoparib|Talazoparib will be taken on days 4-21, 6-21 or 1-21 at a dose level of 0.25, 0.5, 0.75 or 1.0 mg depending on cohort assignment
41167468|NCT04134884|DRUG|ASTX727|ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
41167469|NCT01101061|DRUG|Romosozumab|Administered by subcutaneous injection
41167470|NCT01101061|DRUG|Placebo|Administered by subcutaneous injection
41167471|NCT04759950|BEHAVIORAL|Multicomponent Physical Activity Program|The proposed physical exercise intervention follows the American College of Sports Medicine (ACSM, 2017) and the American Stroke Association (Billinger et al., 2014) recommendations for stroke patients. The five weekly 45-minute sessions are divided into (1) three sessions guided and supervised telematically by a physical exercise specialist and a physiotherapist; (2) and two autonomous exercise sessions. The supervised sessions include exercises to work aerobic capacity, muscle strength and endurance, flexibility, agility, and balance. The intensity of these exercises is prescribed individually according to each participant's initial level and are gradually increased as the program progresses. Participants are encouraged to walk at a similar intensity on autonomous physical exercise days as performed in the guided sessions (moderate intensity), based on the Borg scale of perceived exertion (Borg, 1982).
41167472|NCT04759950|BEHAVIORAL|Mindfulness-Based Stress Reduction Program|This intervention follows an adaptation of the scheme and instructions of the official Mindfulness-Based Stress Reduction (MBSR) program designed by Jon Kabat-Zinn. It includes body scanning, sitting meditation, and gentle hatha yoga techniques. An accredited mindfulness instructor leads the 12-week online program, which comprises a presentation session, followed by eight intervention sessions (once a week, lasting 2.5 hours) and an intensive practice session interspersed between sessions six and seven. Apart from the supervised session, the therapist asks participants to carry out some independent practice daily.
41167473|NCT04759950|BEHAVIORAL|Computerized Cognitive Training|An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
41167474|NCT03751553|DRUG|obsteric gel(k-Y jelly)|A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson\&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that have purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child manually or using the sterile obstetric gel applicator without any manipulation or massage.
41039527|NCT03993769|OTHER|A19010-F|A snus product
41039528|NCT03993769|OTHER|B19010-F|A snus product
41167475|NCT04237714|BEHAVIORAL|Smiling is fun|"Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador."
41167476|NCT00142688|BEHAVIORAL|Physical activity|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
41167477|NCT00142688|BEHAVIORAL|Wellness|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
41167478|NCT00514475|DRUG|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
41167479|NCT04823364|OTHER|Neurotransmitters evaluation by MRS|Baseline MRS screening for volunteers and ADHD groups and repeated measurement for ADHD group after taking stimulant drug treatment
41167480|NCT00571896|DRUG|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
40859564|NCT02593942|DRUG|Remifentanil|0.1-0.5 mcg/kg/min infusion
40859565|NCT02593942|DRUG|Propofol|75-200 mcg/kg/min infusion
40859566|NCT05179239|DRUG|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
40859567|NCT05179239|DRUG|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
40859568|NCT05179239|DRUG|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|Placebo + paclitaxel + cisplatin/carboplatin ± BP102
40859569|NCT04090411|DRUG|Induction- PF-06480605 50 mg SC Q4W|PF-06480605
40859570|NCT04090411|DRUG|Induction- PF-06480605 150 mg SC Q4W|PF-06480605
40859571|NCT04090411|DRUG|Induction- PF-06480605 450 mg SC Q4W|PF-06480605
40859572|NCT04090411|OTHER|Induction- Placebo SC Q4W|0 mg Placebo
40859573|NCT04090411|DRUG|Chronic- PF-06480605 50 mg SC Q4W|PF-06480605
40859574|NCT04090411|DRUG|Chronic- PF-06480605 150 mg SC Q4W|PF-06480605
40859575|NCT04090411|DRUG|Chronic- PF-06480605 450 mg SC Q4W|PF-06480605
40859576|NCT00133042|DRUG|omalizumab|
40859577|NCT03083301|OTHER|Medical Files data extraction|Medical Files data extraction
41039529|NCT06137261|DIAGNOSTIC_TEST|Screening for heart failure|"• Anamnesis and Physical examination: Focus on signs of HF; will be performed by a trained employee.~• ECG: A standard 12-lead ECG will be recorded by a trained employee and will be interpreted by an experienced cardiologist.~• Echocardiography: A standard full echocardiogram will be acquired by a trained employee.~• Blood biomarkers: Venous blood samples will be taken and circulating levels of a broad range of markers related to obesity and/or heart failure will be determined. Also, an extra 10 mL blood sample will be drawn during the same venepuncture to be stored to determine additional biomarkers at a later stage.~• EQ-5D-5L questionnaire: EQ-5D-5L comprises five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which are divided into five degrees of severity, ranging from 'no problems' to 'extreme problems'."
41167481|NCT00571896|DRUG|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
41167482|NCT01957592|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
41167483|NCT03544437|PROCEDURE|extraperitoneal laparoscopic extended retroperitoneal lymph node dissection|"All patients underwent extraperitoneal laparoscopic RNU with bladder cuff excision with concomitant extended RPLND performed by one of two urology surgeons at Renji Hospital.~The anatomical boundaries of the lymph node dissection were deﬁned by the ipsilateral side of UUT-UC. In patients with right-sided UUT-UC, the template of dissection consisted of (i) right perihilar lymph nodes, (ii) paracaval lymph nodes, (iii) interaortocaval lymph nodes and (iv) right pelvic lymph nodes (common, external and obturator lymph nodes).~In patients with left-sided UUT-UC, the template of dissection included (i) left perihilar lymph nodes, (ii) para-aortic lymph nodes, and (iii) left pelvic lymph nodes (common, external and obturator lymph nodes ). Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
40859578|NCT00246701|DRUG|Simvastatin|Simvastatin
40859579|NCT00246701|DRUG|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
40859580|NCT02150278|BEHAVIORAL|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
40859581|NCT02989883|OTHER|peroral endoscopic myotomy|The procedure consists of four steps: 1) mucosal incision 10-15 cm above the esophagogastric junction to allow entry into the submucosa, 2) creation of a submucosal tunnel until the lower esophageal sphincter is reached, 3) myotomy of the circular muscle layer, and 4) closure of the mucosal entry with endoclips.
40859582|NCT05343377|DIAGNOSTIC_TEST|circulate free methylated EBV DNA|Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS
40859583|NCT00960492|DRUG|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
40859584|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
40859585|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
40859586|NCT00960492|RADIATION|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
40859587|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
40859588|NCT00452868|DRUG|Donepezil|Donepezil 5 milligrams a day for 6 weeks
40859589|NCT06069947|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
40859590|NCT03369249|BEHAVIORAL|Link2CARE|The Link2CARE intervention consists of 4 sessions. Session 1 consists of a one-on-one meeting with a Health Coach, during which participants will be offered an oral rapid HIV test and STI test. Sessions 2, 3, and 4 are group-based. During these sessions, participants will engage in discussions and activities regarding sexual and substance use risk behaviors.
40859591|NCT04327024|DRUG|Verinurad|"The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.~Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol."
40859592|NCT04327024|DRUG|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol
40859593|NCT04327024|DRUG|Placebo for verinurad|Matching Capsule
40859594|NCT04327024|DRUG|Placebo for allopurinol|Matching tablet
40859595|NCT00490958|DRUG|telmisartan|
40859596|NCT05357027|BIOLOGICAL|TC-E202 cells|T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
41167484|NCT00841230|DRUG|Deanxit|Deanxit 1x/day
40859597|NCT05357027|DRUG|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.
40859598|NCT05357027|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
40859599|NCT05357027|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
40859600|NCT03437577|DRUG|immediate-release tacrolimus|Standard of care for transplant patients
40859601|NCT03437577|DRUG|extended release tacrolimus|Experimental care
40859602|NCT01593553|OTHER|ECG screening for atrial fibrillation using intermittent ECG recorder|ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
40859603|NCT06121089|PROCEDURE|ileocecal resection with extended D3 lymphadenectomy.|Laparoscopy ileocecal resectionith extended D3 lymphadenectomy including 201, 202, 203 and 213 groups of lymph nodes. Manual double-row ileo-ascendo-anastomosis.
40859604|NCT06121089|PROCEDURE|Right hemicolectomy with D3 lymphadenectomy.|Laparoscopy right hemicolectomy with D3 lymphadenectomy including 201, 202, 203, 213, 211, 212, 221, 222-rt groups of lymph nodes. Manual double-row ileo-transverse-anastomosis.
40859605|NCT01483183|DRUG|OPC-108459|"Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1"
40859606|NCT01483183|DRUG|Placebo|Placebo dose, 10-minute constant rate IV infusion
40859607|NCT05490030|DRUG|TNO155|Single oral dose of TNO155 on Day 1
40859608|NCT00534859|DEVICE|High Risk PCI|High Risk Percutaneous Coronary Intervention
41039530|NCT04378348|BEHAVIORAL|Motivational Interview (MI)|The MI dialogue will begin with an introduction where the LDL is asked about the type of work he does and his concerns regarding dangers in his workplace. This will be followed by a decisional balance exercise where the interviewer will engage the LDL in thinking about the pros and cons of taking jobs with many dangers and jobs with less dangers. Using a figure of a traffic light, the interviewer will proceed to measure how important it is for the LDL to reduce the dangers in his work place and identify his reasons for its importance. Next, the interviewer will measure the LDL's level of confidence in his ability to reduce the dangers in his workplace.Together, they will develop a plan to reduce the dangers in the workplace. Finally, the interviewer will summarize the safety plan to the LDL and will explain that the team will return to the corner in one month to see how the implementation of his plan went and to conduct a post-test survey
41039531|NCT04378348|BEHAVIORAL|Participatory Group Activity|Participants will view a figure of a pyramid representing the steps they can take to reduce the dangers in their workplace and the things that are in their control to reduce the dangers followed by pictures of dangerous work environments. They will be engaged in hazard identification and situational awareness by identifying and sharing out loud the dangers they see in the picture. Participants will also engage in problem solving by coming up with strategies they could use to reduce the dangers they identified in the picture and will measure their level of confidence in their ability to implement the strategies they have come up with, should they find themselves in a similar work situation. The group facilitator will summarize what the group has said and what they have learned during the group activity and will ask participants to voluntarily make a personal promise to take concrete steps to reduce the dangers at their work.
41167485|NCT00841230|DRUG|Lactose placebo|Lactose used as placebo
40859609|NCT04756648|DRUG|CT0180 Cells|Five dose levels were tentatively determined.
40859610|NCT04467034|BEHAVIORAL|Stanford Tobacco Prevention Toolkit curriculum|Stanford Toolkit curriculum delivered as a 5-session course in a school classroom setting.
40859611|NCT05875298|OTHER|physical therapy protocol|the patients will receive physical therapy protocol in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus.
40859612|NCT05875298|OTHER|physical therapy protocol and medical drugs|the patients will receive physical therapy protocol and medical drugs in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus. The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
40859613|NCT05875298|OTHER|medical drugs|The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
40859614|NCT06135935|OTHER|No-added-sugar ice cream|The initial focus of this clinical trial will be the impact on postprandial glycaemia of 300g of ice cream, since, from a nutrition perspective, the flavored milks and ice creams are very similar in composition.
40859615|NCT06135935|OTHER|Conventional products|The overconsumption of sugar-added conventional products leads to an increased risk of poor control of glycaemic levels.
40859616|NCT04857580|DEVICE|CTS Device|Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.
41512475|NCT05203783|OTHER|Kinesio Tape Application|Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day
41512476|NCT06582836|BEHAVIORAL|The objective of the study was to investigate the effect of prior engagement of tooth with orthodontic appliance on post extraction pain among orthodontic patients|In this randomized clinical trial, 44 patients were recruited who needed bilateral extractions of first premolars in upper arches. Patients were divided into two groups based on the timing of extractions. Group A needed extractions before alignment while Group B needed extractions for retraction of anterior teeth. Group A was sent for extractions first while Group B went for orthodontic bonding and banding procedures for orthodontic treatment. After series of aligning wires (0.014, 0.016, 17x25, 19x25 Heat activated NiTi and 19x25 SS) patients from group B were sent for extractions. For pain assessment, an 11-point numerical rating scale (NRS) were given to record pain intensity at 2, 4, 8, 12 and then 24 hours after extraction for the next 7 days.
41512477|NCT03091179|DEVICE|THRIVE|active nasal oxygen delivery system
41512478|NCT03091179|DEVICE|Endotracheal tube|a plastic tube for mechanical ventilation
41512479|NCT06411964|DIETARY_SUPPLEMENT|Prebiotic|Commercially available supplement (Bimuno)
41512480|NCT06411964|DIETARY_SUPPLEMENT|Placebo control|maltodextrin control supplement
41512481|NCT00461942|DRUG|Green Tea Polyphenols (EGCG/ECG)|
41512482|NCT01477723|OTHER|Experimental Oral Nutritional Supplement|Experimental ONS orally Two 8 fl oz servings/day
40859617|NCT02172378|DRUG|Tiotropium inhalation capsules|
40859618|NCT02172378|DRUG|Placebo inhalation capsules|
40859619|NCT00219505|PROCEDURE|acupuncture|
40859620|NCT04208555|DRUG|Boric Acid Vaginal Suppository|Boric acid vaginal suppository (600 mg/day) for 14 days
41039532|NCT04378348|BEHAVIORAL|Control Condition|At control corner sites, we will recruit another 35 Latino day laborer participants.Participants in the control group will receive OSHA pamphlets with standard workplace safety and health information. During our needs assessment survey, we collected information regarding workrelated injuries. Results from this survey indicate the following 4 categories are the highest cause of injury among surveyed Latino day laborers: 1) moving heavy objects, 2) falls, 3) being struck by falling or lying objects, and 4) serious cuts. The OSHA materials that will be distributed to participants will include safety and health information regarding these four topics. Furthermore, given that the LDL are continuously exposed to the sun (e.g., at the corner while waiting for work, at work, and on their way to and from work), heat exposure will also be included in the OSHA materials.
41039533|NCT02635269|OTHER|Sugar|10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
41167486|NCT02496598|PROCEDURE|In Vitro Follicle Activation (IVA)|Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
41167487|NCT02496598|DRUG|Follicle Activation|Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
41167488|NCT01709396|RADIATION|ED-TBI|Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
41167489|NCT00004478|DRUG|droxidopa|
41167490|NCT03703349|DRUG|Magnesium Sulfate|Magnesium sulfate will be prescribed by the surgeon / Anesthesiologist and will be taken orally by the patient for the 3 days preceding the surgery
41167491|NCT03703349|DRUG|Placebo Oral Tablet|Placebo for Magnesium
41512483|NCT02068313|RADIATION|Toxicity and outcome measures of IMRT|
41512484|NCT04707794|DRUG|Sevoflurane|Sevoflurane delivery will will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
41512485|NCT04707794|DRUG|Desflurane|Desflurane delivery will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
41512486|NCT03187535|DEVICE|TEAS via ES-130|Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.
40859621|NCT04208555|DRUG|Terconazole Vaginal Suppository|Terconazole 80 mg vaginal suppository daily for 6 days
40859622|NCT00256724|DEVICE|Impedance Threshold Device|Active impedance threshold device
40859623|NCT00256724|DEVICE|sham ITD|sham impedance threshold device
41512487|NCT03187535|OTHER|No TEAS|No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.
40859624|NCT04916912|PROCEDURE|coronary artery bypass grafting|Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.
40859625|NCT06366841|OTHER|Psychological tests administration|Psychological tests administration to evaluate stigma, personality characteristics and quality of life of rectal and anal cancer patients.
40859626|NCT03907150|DIAGNOSTIC_TEST|Strain ultrasound|Post-interpretation of recorded ultrasound loops
40859627|NCT01427933|BIOLOGICAL|Ramucirumab (IMC-1121B)|Administered intravenously
40859628|NCT01427933|DRUG|Eribulin|Administered intravenously
40859629|NCT05275101|BEHAVIORAL|Crisis Response Planning|Individuals complete an experimental collaborative suicide intervention.
40859630|NCT05275101|BEHAVIORAL|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
40859631|NCT05034601|PROCEDURE|ESPB group|A 21-gauge 100-mm needle will be inserted into the fascial layer beneath the iliocostalis, longissimus, and spinalis muscles. A bolus of 0.25% ropivacaine 0.5 ml/kg will be injected into the fascial layer. Contralateral ESPB will be performed similarly.
40859632|NCT05034601|PROCEDURE|TPVB group|A 21-gauge 100-mm insulated needle will be inserted into the paravertebral space via an in-plane parasagittal approach. After perforating the costotransverse ligament, 0.25% ropivacaine 0.5 ml/kg will be injected. Anterior movement of the pleura indicated the appropriate spread of the local anesthetics in the paravertebral space. The process will be repeated on the contralateral side.
41039534|NCT02998281|DEVICE|Threshold (IMT)|Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
41512488|NCT03161977|OTHER|Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
41512489|NCT02771769|OTHER|blood draw|Participants will have a venous blood draw of \~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
41512490|NCT05708430|DRUG|SVF injection into wrist|Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
40859633|NCT02326597|OTHER|Decision Aid Tool|The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.
40859634|NCT02326597|OTHER|Standard Practice|Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
40859635|NCT01672424|OTHER|Ice Chips|11 ounces of ice chips given to the laboring parturient
40859636|NCT01672424|OTHER|Protein Drink|Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
40859637|NCT02734745|DEVICE|flash glucose monitoring|Patients will use Freestyle Libre for 14 days at home, during this period they will have to perform at least 7 measurements of capillary blood glucose per day . Patients also will go to our clinical center on two separate occasions , to run a test breakfast. In one of the two occasions it will be specifically induced a moderate initial hyperglycemia and subsequent hypoglycemia . During the test meal and in the subsequent hours for a total of 6 hours , will be carried out frequent blood sampling for measurement of blood glucose using the Yellow Springs glucose analyzer ( YSI system ) , simultaneous measurements with Freestyle Libre and with glucometer.
40859638|NCT03080948|BEHAVIORAL|survey|Research assessments as part of this protocol will be scheduled during routine clinic visits
40859639|NCT03080948|OTHER|Saliva samples|Germline DNA analysis
40859640|NCT05257291|DRUG|Melatonin|Supplementation with 1 mg/day of melatonin for 1 year
41512491|NCT03816943|BEHAVIORAL|Whatsapp|a WhatsApp message with encouraging words will be sent after bond up
41512492|NCT03816943|BEHAVIORAL|Call|a telephone call will be made after bond up to provide encoring words
41512493|NCT06421597|DRUG|Prednisolone|prednisoline 25 mg/day for seven days
40859641|NCT05385003|DIETARY_SUPPLEMENT|anserine|During the study period, subjects are instructed to take one capsule of anserine daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
40859642|NCT05385003|DIETARY_SUPPLEMENT|Sunflower peptide|During the study period, subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
41039535|NCT05019339|BEHAVIORAL|Healthy HomeStyles|Comparison of 2 educational interventions
41039536|NCT05019339|BEHAVIORAL|Eat Healthy Be Active|Comparison of 2 educational interventions
41039537|NCT03565887|DRUG|RVL-1201|RVL-1201 ophthalmic solution 0.1%
41039538|NCT03565887|OTHER|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
40859643|NCT05385003|DIETARY_SUPPLEMENT|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
40859644|NCT04848272|DRUG|Lanadelumab|Monoclonal antibody that targets active plasma kallikrein
40859645|NCT04848272|OTHER|Saline control|Saline control
40859646|NCT03877302|OTHER|reflexology|foot reflexology
40859647|NCT03956212|DRUG|Doxycycline 7 days|Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
41039539|NCT03896035|BEHAVIORAL|Behavioral Intervention Group|The behavioral intervention is designed for older Veterans with cLBP and depression and will include 8 individual telephone sessions delivered by health coaches over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
41039540|NCT05909631|OTHER|Beetroot juice|250 ml of concentrated beetroot juice, were given to participants in the BJ groups .This was carried out in the morning, 30 minutes before breakfast, and on an empty stomach.
40859648|NCT03956212|DRUG|Doxycycline 14 days|Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
41039541|NCT05909631|OTHER|placebo|250 ml of a placebo
41039542|NCT05909631|OTHER|Mediterranean diet alone (MeD)|Mediterranean diet alone (MeD)
41039543|NCT05909631|COMBINATION_PRODUCT|Mediterranean diet with beet juice (BJ+MeD)|Mediterranean diet with beet juice (BJ+MeD).
41512494|NCT06421597|DRUG|Placebo|Placebo treatment for seven days
41512495|NCT04341324|OTHER|It is an observational study.|
41512496|NCT06301906|DRUG|LipoCol Forte Capsule 600mg bid|LipoCol Forte Capsule 600mg bid for 12 months
41512497|NCT02054286|BIOLOGICAL|THV01-1|Intramuscular injection of THV01-1 (week 0)
41512498|NCT02054286|BIOLOGICAL|THV01-2|Intramuscular injection of THV01-2 (week 8)
40859649|NCT02105038|OTHER|Spinner knob|
40859650|NCT02105038|OTHER|No Knob|
41039544|NCT05188001|OTHER|Not an Interventional Study|Not an interventional Study
41512499|NCT02054286|BIOLOGICAL|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
41512500|NCT02371473|DRUG|Acetazolamide-placebo|The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
41512501|NCT02371473|DRUG|Placebo-acetazolamide|The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
40859651|NCT05746156|DIAGNOSTIC_TEST|lymphatic mapping|"1. Peritumoral injection of \[99mTc\]Tc-nanocolloid in 6-8 evenly distributed depots on both sides of the tumor, during investigation under anaesthesia. Number of depots depending on the size and localisation of the tumor.~2. Planair and SPECT/CT imaging van de abdomen/pelvis 3h and 12-24h after injection at the department of radiology and nucleair medicine."
40859652|NCT00644488|DRUG|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
41390871|NCT03478345|BEHAVIORAL|endocrine disruptor chemical reduction intervention|Participants will take part in a 4-week intervention consisting of a modified (shortened) version of the Diabetes Prevention Program diet and physical activity group education program, with instructions to reduce endocrine disruptor chemical exposure through changes in food handling and personal care products.
41512502|NCT05379842|OTHER|Education on a healthy lifestyle and health literacy|Traditional motivational face-to-face workshops with lifestyle (nutritional, physical activity, sleep) advice every 3 months
41512503|NCT05379842|OTHER|Education on a healthy lifestyle and health literacy|E-learning and digital (with videos -YouTube channel or WhatsApp/text message) educational workshops with lifestyle (nutritional, physical activity, sleep) advice every 15 days
41512504|NCT06247410|DRUG|Rotigotine 8Mg/24Hrs Patch|Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days
41512505|NCT00973063|BEHAVIORAL|Routine sterile gloving|routinely new sterile gloving just before sampling
41512506|NCT05096910|PROCEDURE|Uterine Closure with monofilament or polyfilament suture materials|Postoperative 6th-month isthmocele rates
41512507|NCT03851029|OTHER|Tai chi|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
41512508|NCT03851029|OTHER|Aerobic Training|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
41512509|NCT03092219|DEVICE|TEOSYAL RHA Redensity|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
41512510|NCT06581133|DEVICE|Alarm system|Generic alarm system programmed to sound during the night to try to induce arousals from sleep.
41167492|NCT05082181|BEHAVIORAL|UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is an 8-week program that combines cognitive behavioral therapy (CBT) and mindfulness techniques and is delivered to small groups of participants by phone. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home practice assignment. CBT-related skills include thought monitoring, identifying cognitive distortions, problem identification, goal setting, and identifying supports. Relaxation exercises are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to breath, sights and sounds and other meditations. Audio guides are provided for home practice of mindfulness exercises.
41512511|NCT02499848|DRUG|PRX302|Single prostate cancer lesion injected with PRX302.
41512512|NCT01461915|DRUG|Nab paclitaxel|Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
41512513|NCT01461915|DRUG|Gemcitabine|Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).
41512514|NCT01461915|DRUG|Dociparstat|Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.
41512515|NCT02122029|BEHAVIORAL|Lifestyle counselling|Behavioral techniques for weight management
41512516|NCT02122029|PROCEDURE|Bariatric Surgery|Vertical Banding Gastroplasty
40859653|NCT00226811|DRUG|Sunitinib|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
40859654|NCT05595473|DRUG|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV
40859655|NCT05595473|DRUG|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV
40859656|NCT05595473|DRUG|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV
40859657|NCT05595473|DRUG|RZ-001 Dose 4|RZ-001 Dose 4 and VGCV
41390872|NCT06568354|OTHER|Yoga|The yoga program was applied to all patients in this group, accompanied by a physiotherapist. Sessions included selected breathing, warm-up, and relaxation exercises.
41390873|NCT06568354|OTHER|Motor control exercises|Motor control exercises with three different progressive phases were applied to all patients in this group accompanied by a physiotherapist.
41512517|NCT00899522|OTHER|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
41512518|NCT00899522|PROCEDURE|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
41512519|NCT06106347|DEVICE|mfERG device (RETIscan; Roland Instruments, Wiesbaden, Germany)|physiological macular function
41512520|NCT01738347|DRUG|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
41512521|NCT03979755|OTHER|Application of questionnaires|Application of questionnaires described by telephone.
41390874|NCT03620760|DRUG|Ticagrelor 90 mg|Ticagrelor (AZD6140) 90 mg twice daily dose
41390875|NCT03620760|DRUG|Ticagrelor 45 mg|Ticagrelor (AZD6140) 45 mg twice daily dose
41390876|NCT03620760|DRUG|Aspirin|Aspirin 100 mg once daily dose
41512522|NCT03879785|OTHER|Screening|Screening and validation of assessment tool translated into Spanish
40859658|NCT03517761|BIOLOGICAL|Bone Marrow Concentrate treatment|While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate. Patients will be repositioned in the prone position to then receive upper cervical injections to C0-C3 ligaments and facets.Patients will receive 2 of these treatment procedures 3 months apart.
41390877|NCT00881595|DRUG|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
41390878|NCT00881595|RADIATION|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
41390879|NCT00881595|PROCEDURE|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
41390880|NCT02857296|OTHER|interview and observation|
41417854|NCT05760664|OTHER|Group Sham/Static stretching exercise|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
40676675|NCT05796284|BEHAVIORAL|Breast pressure relief intervention at the end of pregnancy|When teaching pregnant women, the researchers will use tablet computers and models to explain the operation of breast combing and acupressure one-on-one, and use the model to demonstrate. Emphasis on breast grooming during pregnancy, twice a day, once in the morning and evening, 5 minutes on one breast each time, 10 minutes on both sides; strengthen breast grooming and acupressure after delivery. The first breast combing, 5 minutes on one breast each time, and 10 minutes on both sides 4 to 6 times a day. After combing, according to expert advice, massage the 6 acupoints around the breast for 5-10 seconds, and then use hand expressing or breastfeeding to discharge the milk .
40859659|NCT03517761|OTHER|Sham Control|Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.Patients will also receive small skin punctures to the back of the neck to mimic ligament and facet injections. Patients will receive 2 of these procedure 3 months apart.
40859660|NCT03310814|OTHER|Personalized nutrition|Receives individualized nutrition information
40859661|NCT05944679|RADIATION|No Xray|Just one Xray 12 months after the intervention
41167493|NCT05082181|BEHAVIORAL|BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program delivered in 8 weekly group sessions. Each weekly session is 1 hour long and is comprised of a check-in period, introduction of the week's topic, and group discussion. Weekly BOOST session topics include: (1) personal experience of epilepsy; (2) personal experience of mood problems (depression, anxiety, stress); (3) seizure triggers; (4) concerns related to epilepsy treatment (e.g., medication adherence, side effects); (5) changes in seizures over time; (6) the impact of behavior (e.g., sleep, substance use) on seizures; (7) social relationships and epilepsy; and (8) review of the BOOST experience.
41167494|NCT03987659|PROCEDURE|Irrigation protocols that promote release of dECMs|Irrigation protocols that promote release of dECMs
41167495|NCT03987659|PROCEDURE|Conventional Irrigation protocols|Conventional Irrigation protocols
41167496|NCT01145820|DIETARY_SUPPLEMENT|Juice plus|Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
41167497|NCT01718431|OTHER|test meal|
41167498|NCT01718431|OTHER|reference meal|
41167499|NCT00334971|PROCEDURE|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
41167500|NCT02893488|DRUG|DTG/ABC/3TC FDC DISPERSIBLE TABLET|DTG/ABC/3TC FDC dispersible tablet
41167501|NCT02893488|DRUG|EPZICOM (ABC/3TC)|"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."
41167502|NCT02893488|DRUG|TIVICAY (DTG)|TIVICAY will be available as white, round, biconvex tablets
41167503|NCT03411798|DRUG|Yisaipu®|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR \& CRP reduce to normal and BASDAI\<4) maintenance.
41167504|NCT05849324|DEVICE|Straight needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, straight needle is going to be used.
41167505|NCT05849324|DEVICE|Bent needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, bent needle is going to be used.
41167506|NCT00469859|DRUG|cytarabine|given IV
41167507|NCT00469859|DRUG|idarubicin|Given IV
41167508|NCT00469859|DRUG|lestaurtinib|Given orally
41167509|NCT03481556|DRUG|Melphalan flufenamide (Melflufen)|Intravenous infusion
41167510|NCT03481556|DRUG|Dexamethasone|Oral tablets
41167511|NCT03481556|DRUG|Bortezomib|Subcutaneous administration
41167512|NCT03481556|DRUG|Daratumumab|Intravenous infusion
41167513|NCT06183671|DRUG|JX09 or placebo SAD|For Part 1 SAD: JX09/placebo in capsule will be administered as a single oral dose. The nominal dose escalation scheme for the cohorts is 1, 3, 10, 30, 100, and 300 mg.
41167514|NCT06183671|DRUG|JX09 or placebo MAD|For Part 2 MAD: JX09/placebo in capsule will be administered for 11 days (once daily) The nominal dose escalation scheme for the cohorts is 2, 5, 10 and 20 mg.
41167515|NCT06183671|DRUG|JX09|For Part 3 FE: JX09 in capsule will be administered as a two single oral doses separated by 15 days. The nominal dose is 10 mg.
41167516|NCT04266847|DEVICE|monofocal IOL,bifocal IOL,or trifocal IOL|phacoemulsification and implantation of IOL.IOL may be monofocal IOL,bifocal IOL,or trifocal IOL
41167517|NCT01940783|RADIATION|Cone Beam Computed Tomography (CBCT)|Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
40859662|NCT05944679|RADIATION|Xray|Xray at 1, 3, 6 and 12 months after intervention
40859663|NCT04276519|PROCEDURE|Physiotherapeutic, non-invasive position-induced opening of the intervertebral foramen|Opening of the mechanical interface of the nerve root, neurodynamics
40859664|NCT01921504|DEVICE|Acupuncture|"Acupuncture treatment~1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 \~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
40859665|NCT05808140|DRUG|Indocyanine Green|Preoperatively, a single dose of intravenous indocyanine green is administered
40859666|NCT05808140|DEVICE|Fluorescence imaging|Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively
40859667|NCT04985461|DEVICE|dental occlusion ties maxillo-mandibular fixation|"This research study is being done to determine if dental occlusion ties can adequately align and stabilize jaw fractures. The chief goal of jaw fracture repair is to ensure that the teeth align normally. Traditionally, alignment has been accomplished by using steel wires and bars (having the jaw wired). Dental occlusion ties are newer devices similar to cable ties or zip ties that are wrapped around and/or between some of the teeth and secured. This procedure is intended to hold the teeth in similar alignment as wires, yet with less application time and less damage to the gums."
40859668|NCT04085497|OTHER|Treatment|KT application: KT application includes 2 stages. The banding in the first step is directed to the patellar tendon in order to absorb the load of the knee. The second step is directed directly on the medial plica to benefit from its analgesic effect. For the first step, an I-band is measured from the top of the patella to the tuberositas tibia. I-band is 6 cm wide and 5 mm thick. This I-band is cut into Y-band. First, the part of the band above the patella is pasted with 10% tension. Then the patient's knee is flexed to maximum flexion and the tails of the band are pasted around the patella with 0% tension. The tails of the band are combined together on the tuberositas and completed. For the second step, 4 I-bands 8 cm long and 1.5 cm wide are prepared. The middle of the I-bands is attached to the medial plica with a 0% tension, giving a star shape.
40859669|NCT06010784|BEHAVIORAL|Family support|"* Family tip sheets sent via mobile text at the start of the program and then every 3 weeks, to a total of 6 mobile text messages~* Weeks 1-4 (4 weeks):~  i. Welcome package mailed in the first week of the program ii. Weekly: one 10-lbs box of produce iii. Recipes accompanying each box (sample recipe card attached to submission) iv. Bi-Weekly: Grocery store gift cards (2x USD 20, to a total of USD 40)~* Weeks 5-19 (total of 10 weeks over the 19-week study timeline):~  i. An optional online form (goal sheet) is sent to the parent/caregiver every other week (total 5) with questions about trying new FV items to be submitted in the next 7 days. As an incentive, a USD 10 gift card is sent to those who complete it (a potential total of USD 50).~ii. Week 11: an extra USD 20 gift card in the week after a school holiday to re-engage participants due to the school-year break."
40859670|NCT06010784|BEHAVIORAL|BGCAA's after-school program with CATCH curriculum|"1. The whole BGCAA's after-school program runs for 3h, Mon-Fri for the school year across all sites where the organization offers the program. All children enrolled are expected to attend a minimum of 2x/week.~2. In the BGCAA's after-school program, children participate in active recreational time (approx. 60 min, offered 1x/week at a minimum) which is a mixture of free play, structured physical activity games, and/or sports activities (including soccer, football, and basketball).~3. Uniquely to sites participating in the study, BGCAA's staff will deliver selected CATCH (Coordinated Approach to Child Health) curriculum components in blocks of 45-60 min, 2x/week, as part of the after-school program. The curriculum will focus on healthy eating education and physical activity designed for elementary school-aged children. More information on CATCH at https://catch.org/ (accessed 8/11/2023)"
40859671|NCT01112787|DRUG|Tazarotene Foam|Tazarotene Foam
41390881|NCT03797365|OTHER|Classical rehabilitation|"Participants will benefit from two-phases perineal rehabilitation:~First phase will include the PFM's awareness and voluntary contraction learning with manual, biofeedback technics and functional electro stimulation. These exercises will call out the manual rehabilitation technics, biofeedback and electro stimulation. Each classical rehabilitation session will take 30 minutes with 20 minutes of active working, twice per week. About the self-training, there will be no consensus for optimal homemade exercises.~For the second phase, a behavior analyze will be summarized in order to update the favoring and inappropriate situations. The strategy put in place will be organized in unlearning of deleterious perineal habits and learning new behavior program. The main goal will be the perineal locking set up, which must be systematic before and during efforts. During this phase, the physiotherapist will twice weekly perform evaluations (similar to those in the first phase)"
41512523|NCT05603325|OTHER|Person Centered Practice|"Staff will be asked to:~* Complete two surveys on two occasions, once before the intervention sessions and once following the last session. The first survey is views on patient feedback and the other is about the workplace culture and how person-centred it is.~* Attend 6 x 2 hour facilitated workshops which will involve getting ready to work with patient feedback, establishing values and visions for the intervention group, critically reviewing the ways patients are offered the opportunity to give feedback~* Engage in changes in practice (e.g. how staff offer patients the opportunity to provide feedback and the way staff make changes in response to this feedback);~* Attend a final focus group to evaluate the workshop programme."
40859672|NCT01112787|DRUG|Vehicle Foam|Vehicle Foam
40859673|NCT01112787|DRUG|Sodium Laural Sulfate|Sodium Laural Sulfate
41417855|NCT05760664|OTHER|Control Group/Placebo|The placebo intervention will be performed using ultrasound turned off in the thoracolumbar region for 15 minutes followed by rest for 15 minutes for 6 weeks, twice a week. Participants will be evaluated on the first day, fourth week and sixth week of intervention.
41417856|NCT05062850|OTHER|observation|Our study does not involve an intervention. Chronic diseases and geriatric syndromes of the participants will be studied.
41417857|NCT04782609|DRUG|Icapamespib|to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions.
41512524|NCT05603325|OTHER|Interview|Interviews will be used to gather views about how easy or difficult it is to give feedback and how it feels to consider and/or give feedback
41512525|NCT01894087|BEHAVIORAL|TBI - Cohort 1|
40859674|NCT01112787|DRUG|Distilled Water|Distilled Water
40859675|NCT06446986|OTHER|Single and Dual-Task Timed Up and Go Test|Timed Up and Go Test will be conducted. Then, for motor-motor dual-task evaluation, the test will be repeated while the subjects carry a tray containing 4 glasses of water without spilling the water. The time required to complete each test will be recorded in seconds.
40859676|NCT06446986|OTHER|Single and Dual-Task Tandem Walking Test|"The tandem walking test will be performed. Then, for cognitive-motor dual-task tandem walking test assessment, the test will be repeated while the subject completes one of 3 different cognitive tasks. These cognitive tasks used during dual-task trials will be switched between trials in an attempt to avoid a practice effect. The time required to complete each test will be recorded in seconds.~The cognitive tasks are as follows:~1. Counting down by six or seven from a randomly presented 2-digit number~2. Counting backward the months starting from a randomly selected month~3. Spelling a five-letter word backwards"
40859677|NCT06446986|OTHER|Simple Shoulder Test|Simple Shoulder Test contains 12 items and rates pain and function in patients with shoulder problems. Each item has two options and is scored either ''1 = yes'' or ''0 = no''. The total score ranges from 0 to 12. Higher scores indicate better physical functions.
40859678|NCT00213499|PROCEDURE|non invasive ventilation|
40859679|NCT03565016|OTHER|no interventional study|no interventional study
40859680|NCT01103427|DEVICE|Internet-based behavioral coaching|"Those in the active comparator arm will benefit from automated coaching by e-mails with advice, information and support for smoking cessation. These e-mails will be adapted to their personal profile."
41167518|NCT01940783|DEVICE|Magnetic Resonance Imaging (MRI)|One pre-operative (before cochlear implantation) MRI scan of the cochlea.
41167519|NCT00552513|PROCEDURE|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) as soon as possible (and within 24 hours of randomisation).
41167520|NCT00552513|PROCEDURE|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) any time after 36 hours after randomisation.
41167521|NCT05864118|DIAGNOSTIC_TEST|Respiratory pathogen panel PCR test|Respiratory pathogen panel PCR test and COVID-19 antibody test.
41390882|NCT03797365|BEHAVIORAL|Cognitive associated rehabilitation|The cognitive associated rehabilitation group randomized participants will have to execute twice a day the rehabilitation protocol. Each cognitive rehabilitation session will take three minutes. Participants will have to synergistically execute attentional tests (N-Back Test) and execute a perineal contraction during the contraction instructions. (10 randomized auditory stimuli in three minutes). The attentional tests' difficulty will be gradually increased each 15 days. N-Back Test modalities are the followings: the participant will visualize a series of random numbers. First difficulty step will be to click the dedicated button when the volunteer will see the indicated letter. The second difficulty step will be to click the dedicated button when she will see two consecutives times the same letter. The third difficulty step will be to click the dedicated button when she will see two times the same letter separated by one different letter, and so on...
41390883|NCT04474288|DIAGNOSTIC_TEST|SARS-CoV-2 antibody testing|venipuncture for SARS-CoV-2 IgG
41390884|NCT00399919|DRUG|Propionyl-L-Carnitine|2 grams per day for six months
41390885|NCT00399919|DRUG|PLC|2 grams/day for six months
41512526|NCT01894087|BEHAVIORAL|TBI - Cohort 2|
40859681|NCT01103427|DEVICE|SMS based coaching|Those in the experimental SMS based coaching arm will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
40859682|NCT01103427|DEVICE|SMS coaching - UNN recruited|Those in the experimental SMS based coaching arm- UNN recruited - will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
40859683|NCT01103427|DEVICE|SMS craving function - UNN recruited|Those in the experimental SMS based craving/panic function arm - will in addition to the automated coaching by SMS have a panic/craving SMS function. Thus by sending a SMS they will receive instant advise and support for smoking cessation by SMS.
40859684|NCT02181764|DRUG|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
40859685|NCT05836883|BIOLOGICAL|ExoFlo|Local injection of bone marrow mesenchymal stem cell derived extracellular vesicles
40859686|NCT05836883|OTHER|Local injection of normal saline|Placebo
40859687|NCT03031366|OTHER|3d roadmap guidance|TIPS was established using 3d roadmap
40859688|NCT03031366|OTHER|conventional TIPS procedure|conventional TIPS procedure using wedged hepatic venography
40859689|NCT05471089|DEVICE|Diathermy by emission of Radiofrequency|Applied only to experimental group
40859690|NCT05471089|OTHER|Therapeutic exercise|Applied to both arms/groups
40859691|NCT04747899|OTHER|Positional release technique|"Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.~Positional release technique position will maintained for almost 90 seconds. This technique will be repeated for three times each session, with 10 sec relaxation, 3 days/week.~Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions were given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
41167522|NCT05864118|DIAGNOSTIC_TEST|COVID-19 antibody test|COVID-19 antibody test
41167523|NCT02554422|DEVICE|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
41167524|NCT00251290|PROCEDURE|auto-titrating continuous positive airway pressure|Continuous positive Airway pressure (CPAP) use for 90 days post TIA
41390886|NCT06538168|BEHAVIORAL|Diabetes Self-Management Education (DSME)|The intervention, Diabetes Self-Management Education (DSME), involves a structured educational program including daily reminders regarding medication, and foot care, educational-led video weekly, and handouts for the management od diabetes and foot care to enhance knowledge and skills in managing diabetes and preventing complications like diabetic foot ulcers (DFUs).
41512527|NCT06093893|DRUG|Dexmedetomidine|1 mcg/kg will be administered intravenously over 10 minutes; followed by maintenance infusion of 0.2 to 1 mcg/kg/hour.
41512528|NCT06093893|DRUG|Nicardipine|1 mg will be administered intravenously and increase by 0.5-1 mg if the initial dose is ineffective, to a maximum of 15 mg / hour or
41390887|NCT00937053|OTHER|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
41390888|NCT00937053|OTHER|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
40859692|NCT04747899|OTHER|Traditional physical therapy|"Hot pack for 15-mins. Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions are given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
40859693|NCT01771237|BEHAVIORAL|MyPeeps Manualized Group Intervention|Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
40859694|NCT01771237|BEHAVIORAL|Standard Sexual Health Education|Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
41167525|NCT03886597|OTHER|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
41167526|NCT03886597|OTHER|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
41167527|NCT03886597|OTHER|Table Olives|All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.
41167528|NCT02055456|DRUG|Nandrolone Decanoate|
41167529|NCT04315116|DRUG|pyrotinib maleate|a single oral dose of pyrotinib maleate on day 1 \& day10 .
41167530|NCT04315116|DRUG|Loperamide|Loperamide 4 mg bid from day 7 to day 13
41512529|NCT06093893|DRUG|Labetalol|20 - 80 mg will be administered intravenously at 10-minute intervals to maximum of 300 mg;
41512530|NCT05840055|BEHAVIORAL|Acceptance and Commitment Therapy|"Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a third wave behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis."
41512531|NCT02614105|PROCEDURE|Pelvic floor muscle training|16 weeks of group-based exercise
41390889|NCT00937053|OTHER|Platelet transfusion|Patients whose platelets fall below 10 x 10\*9 will be transfused with platelets
41390890|NCT01063439|DRUG|Busulfan, Etoposide, Cytarabine, Melphalan|Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
41390891|NCT01222182|DRUG|atorvastatin|All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
41390892|NCT02670993|BEHAVIORAL|Singing sessions.|Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.
41390893|NCT02670993|BEHAVIORAL|Painting sessions.|Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
41390894|NCT06111417|OTHER|Questionnaires|"3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients :~* STAI-Y (State-Trait Anxiety Inventory)~* Patient's Questionnaire~* Practitioner's questionnaire"
41512532|NCT02614105|PROCEDURE|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
41512533|NCT02614105|OTHER|Control|Brief information only
40859695|NCT03232866|OTHER|Pilates exercise|Pilates methods exercises
40859696|NCT05921565|BEHAVIORAL|Interventional Behavioral Arm|All participants will receive a weight loss intervention that includes 8 coaching sessions guided by a workbook they will at their baseline visit. During these sessions, they will meet with a health coach individually for up to 10-15 minutes via telephone or video conference to learn and discuss weight loss strategies. Health coaches will provide feedback and instruction (by phone or email) based on progress and challenges encountered during the intervention. Participants will receive a weight management app custom-built for the research study. The app will display participants' dietary intake, physical activity, and weight data and goals on the smartphone, and participants will use the app to log dietary intake, physical activity, and weight daily.
40859697|NCT02056093|DEVICE|PSV mode|Application of PSV in all patients
41390895|NCT06111417|OTHER|Communication of the results of the BRCA1/2 ultra rapid test|Communication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test
40859698|NCT02056093|DEVICE|PAV mode|Application of PAV mode in all patients
40859699|NCT02056093|DEVICE|NAVA|
41512534|NCT03885115|BEHAVIORAL|Intervention|Involves 12-weeks of education related to healthy behaviors, nutrition, and exercise from certified fitness instructors.
40859700|NCT03056339|DRUG|Fludarabine|30 mg/m2 by vein on Days -5 to -3.
40859701|NCT03056339|DRUG|Cyclophosphamide|300 mg/m2 by vein on Days -5 to -3.
40859702|NCT03056339|DRUG|Mesna|300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.
41390896|NCT06542861|OTHER|High-frequency simulation-based team training|"The intervention is a standardized high-frequency training program as described in intervention arm. It is supported by four preliminary initiatives:~1. 15 extra pediatric simulation facilitators were educated, bringing the total number up to 40.~2. A two-day pre-intervention workshop for all pediatric simulation facilitators.~3. A scenario bank containing standardized scenarios on common pediatric and neonatal emergencies was created and made accessible for simulation facilitators to support consistency in the intervention.~4. Purchase of equipment. Eight Leardal manikins. Four SimPads. Four monitors. During the intervention year, these will rotate between the pediatric departments."
40859703|NCT03056339|BIOLOGICAL|iC9/CAR.19/IL15-Transduced CB-NK Cells|"Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.~Starting dose: 10E5"
40859704|NCT03056339|DRUG|AP1903|If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
40859705|NCT04047979|BIOLOGICAL|Shingrix®|A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.
40859706|NCT05484115|DEVICE|endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|treatment of AAA's with wide proximal neck diameters with Endurant II/IIs endograft system
40859707|NCT05484115|DEVICE|endosuture aneurysm repair (ESAR) using Heli-FX EndoAnchor system|treatment of AAA's with wide proximal neck diameters with the Endurant II/IIs in conjunction with the Heli-FX EndoAnchor system
40859708|NCT05810311|DRUG|Roxadustat|"The group will receive Roxadustat (Evrenzo) three times weekly at an initial dose of 70mg (for body weight \<100.0 kg) or 100 mg (for body weight weight ≥100.0 kg). The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."
40859709|NCT05810311|DRUG|Darbepoietin Alfa|"The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week. The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."
41390897|NCT06004076|OTHER|Release of upper track of deep front fascial line|I will work on upper track of deep front fascial line, I will make release to diaphragm,mediastinum,scalene muscles, scalene fascia,Fascia endothoracic, transversus thoracis,Infrahyoid muscles, fascia pretracheal and Suprahyoid muscles.
41390898|NCT06004076|OTHER|Corrective exercises for upper crossed syndrome|strength for scapular muscles and deep neck flexor
41390899|NCT04252326|OTHER|Survey|Doctors, Nurses and Dentists filled survey about adverse drug reractions
41390900|NCT06032767|OTHER|observational group|patients initially diagnosed with nasopharyngeal carcinoma treated with IMRT
41390901|NCT05318287|BEHAVIORAL|Walk with Me|Walk with Me is a perinatal grief mobile application to provide supportive care to bereaved parents. The application includes modules to guide bereaved parents through strategies to help support them through their grieving.
41390902|NCT05414019|OTHER|Mini-screw|7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
41390903|NCT05414019|OTHER|Utility arch|7 patients will receive an intrusive force delivered by intrusive utility arch.
40859710|NCT03458949|OTHER|awareness campaign|awareness campaign for colorectal cancer screening in the workplace
40859711|NCT02094092|OTHER|ProTectis drops (five drops per day) for 21 days|
41390904|NCT05414019|OTHER|Nitinol reverse curve wire|7 patients will receive an intrusive force delivered by Nitinol reverse curve wire
41390905|NCT06517823|DRUG|Etoricoxib + Cyanocobalamin fixed dose|One tablet of 90 mg / 0.50 mg a day
41390906|NCT06517823|DRUG|Etoricoxib fixed dose|One pill of 90 mg a day
41390907|NCT04818151|DRUG|Warfarin|Warfarin treatment for VTE
40859712|NCT02094092|OTHER|Placebo drops (five drops per day) for 21 days|
41390908|NCT04818151|DRUG|Apixaban|Apixaban treatment for VTE
41512535|NCT02377297|PROCEDURE|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
41512536|NCT02377297|PROCEDURE|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
40859713|NCT06108206|OTHER|Adaptive Radiotherapy|"Each patient will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of chemo-RT,~2. Week #1- on Fractions # 4 or 5~3. Week #2- between Fractions # 6-10 (at least 5 days after the Week 1 MRI)~4. Week #3- between Fractions # 11-15 (at least 5 days after the Week 2 MRI)~5. Week #4- between Fractions # 16-20 gadolinium contrast (at least 5 days after the Week 3 MRI)~6. Week #5- on Fractions # 24 or 25 (after the start of the Conedown)~7. Week #6- +/- 3 days of Fraction #30 (end of RT)~Patients receiving hypofractionated radiotherapy will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of your standard of care chemotherapy radiation treatment (chemo-RT),~2. Week #1 - on Fractions #4 or 5~3. Week #2 - between Fractions #6-10 (at least 5 days after the Week 1 MRI)~4. Week #3 - between Fractions #11-15 (at least 5 days after the Week 2 MRI)"
41390909|NCT00266552|DRUG|risperidone|
41512537|NCT02377297|PROCEDURE|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
40859714|NCT03469713|DRUG|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
41390910|NCT03684473|BEHAVIORAL|Online Mindfulness-Based CBT & Trauma-Informed Yoga Intervention|"8 Weekly Online modules consisting of one weekly video of yoga postures combined with breath awareness and daily guided meditation audios, and a breath technique manual form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series."
40859715|NCT02822898|DRUG|NaCl 0.9% in Glucose 5% with 40mEq Potassium|NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
40859716|NCT02822898|DRUG|Glucion 5%|Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
40859717|NCT05725980|DIAGNOSTIC_TEST|Cephalometric analysis|Cephalometric analysis will be performed evaluating upper airways landmarks.
40859718|NCT02490592|OTHER|Fluoride Foam|Fluoride foam - Flúor Care (NaF 1.23%) (G1)
40859719|NCT02490592|OTHER|Fluoride gel|Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
40859720|NCT02950909|PROCEDURE|Static exercise for emphasized neck extensors|Emphasized activation of the deep neck extensors was searched for applying a localized resistance with the thumb and index finger at the level of the vertebral arch of C4 while pushing into flexion in a ventral-cranial direction, approximately parallel to the surface of the zygapophyseal joint, asking the patient to resist maximally during 6 seconds in sitting position
40859721|NCT02950909|PROCEDURE|Dynamic exercise for emphasized neck extensors|The patient was asked to fix his gaze at an object lying between both elbows hoping to in order to emphasize extension in the lower cervical spine and consequently activation of the extensors in this region.
40859722|NCT02950909|PROCEDURE|Static exercise for general neck extensors|Emphasized activation of all neck extensors was searched for applying the resistance with the therapist's hand or a wall respectively a towel at the occiput in sitting position
40859723|NCT02950909|PROCEDURE|Dynamic exercise for general neck extensors|. The patient was asked to fix his gaze at an object lying between both hands. Extension consequently occurred in the entire cervical spine.
40859724|NCT01867502|DRUG|MET + Vildagliptin Group|"Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator."
40859725|NCT01867502|DRUG|MET + Glibenclamide Group|"The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator."
40859726|NCT04619732|DIAGNOSTIC_TEST|Monitoring biochemical concentrations during cold machine perfusion|Three microdialysis probes will be introduced into the kidney tissues, the vein and ureter in order to measure creatinine, glucose and lactate while the organ is undergoing cold perfusion prior to transplantation.
40859727|NCT00191230|DRUG|gemcitabine|
40859728|NCT00191230|DRUG|carboplatin|
40859729|NCT00191230|DRUG|cisplatin|
40859730|NCT01947751|PROCEDURE|CVC exchange|CVC exchange when related infection is suspected
41390911|NCT04822428|OTHER|Osteopathic manipulation|Osteopathic manipulative techniques including; suboccipital release technique,sacral release technique, diaphragmatic release, mesentery release, and Colonic manipulation
41390912|NCT06350331|OTHER|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, photo, and voice interactions.
41390913|NCT05476081|DRUG|Aspirin|Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment
41390914|NCT05476081|DRUG|Clopidogrel|Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment
41390915|NCT05476081|DRUG|Ticagrelor|Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment
41390916|NCT00554177|DRUG|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
40859731|NCT01947751|DRUG|CVC maintenance|CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
40859732|NCT02058563|BIOLOGICAL|Priorix®|1 dose administered as a subcutaneous (SC) injection.
41390917|NCT00554177|DRUG|Placebo|2 doses of 1200mg, administered 2-3 days apart
41390918|NCT06542185|OTHER|online education|online education
41390919|NCT00159081|DRUG|Haloperidol, Risperidone (drug)|targeted dose of 2-4 mg/day over 1 year
40859733|NCT02058563|BIOLOGICAL|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
40859734|NCT04764227|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
40859735|NCT04764227|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
40859736|NCT04764227|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 28Fx
41390920|NCT02241200|DRUG|DA3880|
41512538|NCT04671693|OTHER|PASCA intervention|"At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology."
40859737|NCT01255618|DEVICE|INVOS 5100|Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
40859738|NCT00921843|DRUG|Methadone 0.1mg/kg|Subjects will receive methadone as their intraoperative opioid.
40859739|NCT00921843|DRUG|Methadone 0.2mg/kg|Subjects will receive methadone as their intraoperative opioid.
40859740|NCT00921843|DRUG|Methadone 0.3mg/kg|Subjects will receive methadone as their intraoperative opioid.
40859741|NCT00921843|DRUG|Control|Subjects will not receive methadone as their intraoperative opioid.
40859742|NCT05150015|DEVICE|To assess the feasibility of giving intravenous antibiotics to adult inpatients using elastomeric infusion pumps (EMPs)|Single arm study
40859743|NCT06136013|BEHAVIORAL|HIIT|1 minute of exercise at 90% of their PPO, followed by a 1-minute rest at 40-60% of their peak power output using a cycle ergometer.
40859744|NCT05181124|DRUG|coadministration of JP-1366 and aceclofenac|An open-label, multiple-dosing, fixed sequence, 3-period design
40859745|NCT05181124|DRUG|coadministration of JP-1366 and meloxicam|An open-label, multiple-dosing, fixed sequence, 3-period design
40859746|NCT05181124|DRUG|coadministration of JP-1366 and naproxen|An open-label, multiple-dosing, fixed sequence, 3-period design
40859747|NCT05181124|DRUG|single-dosing of JP-1366 in Korean and Caucasian|An open-label, single-dosing, parallel design
40859748|NCT00983320|DRUG|quetiapine|flexible dosage (50 to 300 mg)
40859749|NCT00983320|DRUG|placebo|placebo
40859750|NCT00921778|DEVICE|Lapcone|Use of Lapcone during LSH
41390921|NCT02241200|DRUG|Aranesp|
41390922|NCT03676673|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
41390923|NCT00016835|PROCEDURE|Supra-gingival scaling and placebo|Included in arm/group description.
41390924|NCT00016835|PROCEDURE|Subgingival scaling and metronidazole|Included in arm/group description.
41390925|NCT00016835|PROCEDURE|Subgingival scaling and doxycycline|Included in arm/group description.
40859751|NCT00921778|PROCEDURE|laparoscopic supracervical hysterectomy|laparoscopic supracervical hysterectomy
40859752|NCT04270708|DRUG|Dexmedetomidine|Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG
40859753|NCT04270708|DRUG|Triclofos 100 MG/ML|Patients with Autism will be treated with oral Triclofos as a sedative for EEG
40859754|NCT04077853|DRUG|17 Hydroxyprogesterone Capronate|Intramuscular injection 250 mg
40859755|NCT02669212|BEHAVIORAL|Cardiopulmonary Exercise Test (CPET)|All participants will undergo an exercise stress test
40859756|NCT05899400|DIAGNOSTIC_TEST|Diascopic iON Image Analysis System|A scanning digital optical train that images sputum slides for automated analysis by a tuberculosis detecting algorithm
40859757|NCT03350815|DRUG|150 mg open-label secukinumab|All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.
40859758|NCT03350815|DRUG|150 mg double-blinded secukinumab|Treatment Period 2 Patients who achieved responder status entered Treatment Period 2 and continued to receive 150 mg s.c. (1 s.c. injection of secukinumab 150 mg)
40859759|NCT03350815|DRUG|300 mg double-blinded secukinumab|Treatment Period 2 300 mg (2 s.c. injections of the 150 mg dose)
40859760|NCT04046146|DRUG|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
41390926|NCT04508621|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
40859761|NCT04046146|DEVICE|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
40859762|NCT05842252|PROCEDURE|greater trochanter transfer, subtrochanteric valgus osteotomy|greater trochanter transfer, subtrochanteric valgus osteotomy fixation by wagner TB and locked plate
41390927|NCT04508621|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
41417858|NCT02096419|DRUG|Clopidogrel dose adjustment|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity \>18U and \<18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if \>46U; not changed if 19-46U; decreased by 75 mg if \<19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients \>70 years 150 mg)"
41417859|NCT03204526|DEVICE|deep brain stimulation|
41417860|NCT00593281|DRUG|Hylenex|Add Hylenex to SC injection of Morphine
40859763|NCT00627367|DRUG|Hydromorphone|Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
40859764|NCT00627367|DRUG|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clinician
40859765|NCT01389037|BEHAVIORAL|Health Literacy-focused Self-help|Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
40859766|NCT01389037|BEHAVIORAL|Delayed Intervention Control|Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
41390928|NCT02509520|DIETARY_SUPPLEMENT|MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|The MPR provides strength and cardiopulmonary endurance training, which consist of exercises to promote function movements. Intensity is based on patient's hemodynamic responses and subjective report using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a moderately intense physiologic response. The NMES protocol requires self-adhesive surface electrodes be placed on quadriceps muscles and lower leg bilaterally, twice daily. This protocol is based on prior NMES protocols used to stimulate muscle protein synthesis in older diabetic patients, preserve muscle mass in intensive care patients and increase strength in older adults after knee replacement. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver \~15g of essential amino acids per serving, with a goal of 1.6 g/kg/day.
40859767|NCT01162902|DRUG|Diltiazem treated group|Diltiazem 180mg for 9 months
40859768|NCT01162902|DRUG|Bisoprolol treated group|Bisoprolol 5mg for 9 months
40859769|NCT01162902|DRUG|Candesartan treated group|Candesartan 32mg for 9 months
40859770|NCT04475120|DRUG|liposomal lactoferrin|oral and intra-nasal formulation
40859771|NCT04475120|DRUG|SOC therapy|oral administration
40859772|NCT02449161|DRUG|MPA|
40859773|NCT02449161|DRUG|placebo|
40859774|NCT02790801|OTHER|observation|observation
40859775|NCT06436391|OTHER|Kinesio taping|Kinesio taping will be applied to the lateral part of the baby's heel to increase blood flow. Blood collection will always be performed by the same nurse
40859776|NCT06436391|OTHER|ShotBlocker|Shotblocker will be applied to the baby's heel average 10-15 seconds with minimal pressure.
40859777|NCT02013297|RADIATION|SBRT treatment|"For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.~For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.~For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.~For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.~For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy."
41390929|NCT00452998|PROCEDURE|Q-switched fd Nd:yag in Laser Iridotomy|
41390930|NCT00566618|DRUG|Dasatinib|"Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
40859778|NCT02489292|BIOLOGICAL|HepaStem|HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
40859779|NCT00255541|DRUG|Tesaglitazar|
40859780|NCT00255541|DRUG|Glibenclamide|
40859781|NCT05524584|DRUG|Fulvestrant|Given intramuscularly
40859782|NCT05524584|DRUG|Anastrozole|Given orally
40859783|NCT05524584|DRUG|Abemaciclib|Given orally
40859784|NCT05581459|OTHER|63 Hz Vibration|Vibrations of 63 Hz were applied with handheld vibration device.
40859785|NCT05581459|OTHER|42 Hz Vibration|Vibrations of 42 Hz were applied with handheld vibration device.
40859786|NCT05581459|OTHER|Sham vibration|Handheld device was applied to the participants without any vibrations.
40859787|NCT02737475|DRUG|BMS-986178|Specified dose on specified days
40859788|NCT02737475|DRUG|Nivolumab|Specified dose on specified days
40859789|NCT02737475|DRUG|Ipilimumab|Specified dose on specified days
40859790|NCT02737475|BIOLOGICAL|Tetanus vaccine|Specified dose on specified days
40859791|NCT02737475|BIOLOGICAL|DPV-001 vaccine|DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days
40859792|NCT02737475|DRUG|Cyclophosphamide|Specified dose on specified days
40859793|NCT04616222|DRUG|CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
40859794|NCT04616222|DRUG|Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
40859795|NCT05114538|BEHAVIORAL|Reciprocal Imitation Training|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and IJA during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal skills. It is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by parents and siblings.
40859796|NCT02865655|PROCEDURE|Hysteroscopic|
40859797|NCT05696886|DRUG|Pethidine|Group A received Pethidine alone in the period between January 2021 and December 2021
40859798|NCT05696886|DRUG|Tramadol with pethidine|Group B got Tramadol with pethidine in the period between January 2022 and December 2022
40859799|NCT00066404|BIOLOGICAL|recombinant adenovirus-hIFN-beta|
40859800|NCT06237400|DRUG|ZG19018|ZG19018 Given by PO (mouth)
40859801|NCT02445326|DRUG|Dexamethasone|
41390931|NCT00566618|DRUG|Zoledronic Acid|"Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
41390932|NCT05084209|BEHAVIORAL|Parkinson's medical decision making support|Participants will be asked to view and work through medical decision making support resources. The resources will include information on medical decisions that may occur in Parkinson's disease, and general medical decisions that anyone may need to make (i.e. choosing a medical decision maker). The resources will also include suggestions on how to discuss these decisions.
41390933|NCT03757741|DIAGNOSTIC_TEST|Cardiac imaging tests|2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will
41167531|NCT05418686|BIOLOGICAL|Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.|"* Adherence to colchicine therapy will be assessed by the Girerd questionnaire (6 questions ) completed by the patient at the inclusion visit.~* A blood sample (8ml) is taken, including a haemogram, CRP and creatinine and proteinuria.~* Standard on-site stool analysis for C. difficile toxin.~For research purposes, samples of:~* Stool. If the patient is unable to produce stools on the day of the visit, a collection kit with 2 tubes containing a preservative will be given to him/her as well as a stamped envelope to take the sample at home and send it by post within 10 days according to a validated procedure.~* A strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex.~* In patients with baldness or bleached hair only: pubic and/or axillary hair, a pencil-sized strand.~* Additional blood (5ml) and urine (2ml) samples for colchicine determination."
40859802|NCT02445326|OTHER|Placebo Vehicle|
40859803|NCT01073202|DRUG|ursodeoxycholic acid|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
41390934|NCT03757741|DIAGNOSTIC_TEST|Venous blood samle collection|Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.
41390935|NCT02528318|COMBINATION_PRODUCT|Lucinactant for inhalation|Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
41390936|NCT02528318|DEVICE|nCPAP alone|nCPAP therapy
41390937|NCT02065973|BIOLOGICAL|R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7|
41390938|NCT02838329|OTHER|warming of ropivacaine for BT|
41390939|NCT02838329|DRUG|Ropivicaine|
41390940|NCT03799094|DRUG|Vitamin C|Participants will receive intravenous vitamin C therapy at the indicated dose.
41390941|NCT03799094|DRUG|Tyrosine kinase inhibitor|Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
41390942|NCT06044259|PROCEDURE|AMDS; Artivion, Atlanta, Georgia, US|Ascyrus Medical Dissection Stent (AMDS; Artivion, Atlanta, Georgia, US) hybrid prosthesis which comprises a proximal sewing collar and a distal self-expanding nitinol un-covered stent.
41390943|NCT06044259|PROCEDURE|Conventional hemiarch replacement|Coventional open hemiarch replacement
41390944|NCT06116448|OTHER|high-fidelity simulation|The high-fidelity simulation involved a student and a computer-based mannikin. Prior to the start of the scenario, a pre-briefing session was provided. The scenario was executed with the help of the researcher from the control room. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
41390945|NCT06116448|OTHER|hybrid simulation|The hybrid simulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
41390946|NCT06116448|OTHER|telesimulation|The telesimulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Students and patients communicated via video conferencing. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
41390947|NCT02173301|DRUG|XP23829 400 mg QD|active dose 1
40676676|NCT05796284|OTHER|Routine care|Cases in the routine care group received routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery.
40859804|NCT01073202|DRUG|identical-appearing placebo|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
40859805|NCT01450761|BIOLOGICAL|Ipilimumab|
41390948|NCT02173301|DRUG|XP 23829 800 mg QD|active dose 2
41390949|NCT02173301|DRUG|XP23829 400 mg BID|active dose 3
40676677|NCT06620120|DEVICE|Insoles|"At the D0 visit, if the patient is assigned to the arm with insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm."
40859806|NCT01450761|BIOLOGICAL|Placebo matching Ipilimumab|
40859807|NCT01450761|DRUG|Etoposide|
40859808|NCT01450761|DRUG|Cisplatin|
40859809|NCT01450761|DRUG|Carboplatin|
40859810|NCT03562312|OTHER|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
40859811|NCT03562312|OTHER|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
40859812|NCT03831100|BEHAVIORAL|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
40859813|NCT03831100|BEHAVIORAL|Active Control|AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session (Table 5) is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
40859814|NCT04215900|BEHAVIORAL|High-speed yoga multi-directional yoga|The yoga training will be performed over a 4-month period where classes will be held two times per week. Each session will include a warm-up, speed and balance training section, and cooldown phase. The yoga program will include four separate progressions with the first four weeks serving as a familiarization phase, where the participants will be introduced to the poses and proper technique will be demonstrated. The second four-week phase will emphasize a speed component used to target improvements in aerobic capacity. The same poses previously learned will be used. The final two phases will increase in intensity maintaining the speed element and include skill-based training, where the participants will be asked to complete each pose moving as quickly as possible in response to visual and auditory cues.
40859815|NCT02097030|DEVICE|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
40859816|NCT02097030|DEVICE|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
40859817|NCT02097030|DEVICE|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
40859818|NCT02732964|OTHER|Pandora Music|Patients enrolled will be exposed to Pandora music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
40859819|NCT02732964|OTHER|Mozart Music|Patients enrolled will be exposed to Mozart music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
40859820|NCT06056583|DRUG|Cimetidine 200 MG|Cimetidine will serve as the probe drug
40859821|NCT03301610|OTHER|Mobile Education Delivery|Patients will be provided with an iPad on admission to the post-surgical unit and will remain with the patient until discharge. The patient, independently or with the nurse, may use the program at any point during the inpatient care experience. The RN will use the iPad to engage patients in their pain management.
40859822|NCT03301610|OTHER|Standard Verbal and Written Education|Patients will be provided with two pamphlets on pain management on admission to the post-surgical unit. Nurses will follow-up with verbal instruction based on patient need. This will continue through hospital stay. Additional printed education materials are available through the department of patient education and verbal instruction may be tailored based on nursing assessment and patient need.
40859823|NCT00799435|DRUG|Exenatide|5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
40859824|NCT01480310|DRUG|MCAF5352A|may receive up to 3 subcutaneous doses of MCAF5352A
40859825|NCT01480310|DRUG|Placebo|may receive up to 3 subcutaneous doses of placebo
40859826|NCT01712802|OTHER|Denture Adhesives: Cream|Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
40859827|NCT01712802|OTHER|Denture Adhesives: Powder|Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
40859828|NCT01712802|OTHER|Saline|work as control for Denture Adhesives: Cream and Powder
40859829|NCT06467461|DIAGNOSTIC_TEST|Skin biopsy|Skin biopsy to detect systemic alpha-synuclein pathology in 5-HT RBD
40676678|NCT06620120|OTHER|Without insoles|"At the D0 visit, if the patient is assigned to the arm without insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm."
40859830|NCT06467461|DIAGNOSTIC_TEST|Speech testing|Speech Testing to quantify evolving signs of 5-HT RBD
40859831|NCT06467461|DIAGNOSTIC_TEST|Ultra high field 7T MRI|7T MRI to examine 5-HT RBD for evidence of brainstem neurodegeneration
40859832|NCT00650403|DRUG|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fed
40676679|NCT06345157|DRUG|Ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate treatment with ofatumumab (Kesimpta®) will be based solely on clinical judgement and according to the SmPC and AIFA reimbursement criteria.
40859833|NCT00650403|DRUG|Paxil® 40 mg Tablet|40mg, single dose fed
40859834|NCT06409247|BEHAVIORAL|iExposure|There will be 4 treatment sessions, covering the iExposure intervention. The intervention and assessment process is entirely self-guided. Each session will last approximately 60 minutes. Participants will complete 10 mock-interaction trials for each session.
40859835|NCT06409247|BEHAVIORAL|iExposure plus attention guidance|The attention guidance condition consists of two unique components in addition to the standard iExposure intervention: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given a target audience member to focus their gaze on during each impromptu response. They will be told that they should look at and focus on the target audience member for the whole response. In each progressive session the number of trials where the participant is directed to focus on an uninterested audience member will increase.
40859836|NCT06409247|BEHAVIORAL|iExposure plus attention control|The attention control condition consists of two unique components in addition to the standard iExposure intervention (1) the intervention rationale will include information about the importance of developing attention control; (2) participants will be given a central region of the screen (non-audience member) to focus on. They will be told that they should look at and focus on the central region for the whole response.
40859837|NCT05168020|BEHAVIORAL|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress
40859838|NCT05168020|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress
40859839|NCT01594619|DRUG|Naloxegol|Oral 25mg tablet
40859840|NCT01594619|DRUG|Diltiazem XR|Oral 240mg tablet
40859841|NCT00031759|DRUG|imiquimod|
40859842|NCT00031759|PROCEDURE|Ablative or excisional therapy|
40859843|NCT01363089|DRUG|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
40859844|NCT01363089|DRUG|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
40859845|NCT04820413|OTHER|Faecal microbiota transplantation|FMT by daily enema with donor faeces
40859846|NCT05838157|BIOLOGICAL|prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)|at least one dose of prophylactic HPV vaccine including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV)
40859847|NCT04246658|OTHER|conventional physical therapy program|traditional physical therapy program
40859848|NCT04246658|OTHER|gait training on platform swing walkway|gait training on platform swing walkway for 30 minute.
40859849|NCT02586727|DRUG|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
40859850|NCT00187252|DEVICE|Atrial Overdrive Pacing|Pacemaker/ ICD implant
40859851|NCT02624453|DRUG|Fluconazole|Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
40859852|NCT02624453|DRUG|Antiretroviral therapy|First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
40859853|NCT02363621|DRUG|Ranibizumab 0.3 mg|Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg
40859854|NCT02363621|DRUG|Aflibercept 2.0 mg|Patient will receive intravitreal injection of Aflibercept 2.0 mg
40859855|NCT01661894|DEVICE|BrainPalTM|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
40859856|NCT04428229|OTHER|Optic nerve sheath diameter|Pre and post-trendelenburg optic nerve sheath diameter will be measured
40859857|NCT05185999|DRUG|Icodextrin/Dextrose|Single 8 hour dwell of a 500mL intraperitoneal sodium-free 30% Icodextrin / 10% Dextrose solution
40859858|NCT01436474|DRUG|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
40859859|NCT01436474|DRUG|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
40859860|NCT05987163|DEVICE|GP0116|GP0116 is an injectable, sterile, transparent product.
40859861|NCT05987163|DEVICE|Active Comparator: FDA approved dermal filler device|FDA approved dermal filler device
40859862|NCT06226038|OTHER|Magnet disc|Magnetic field promote proliferation and stimulate osteoblast differentiation
40859863|NCT06226038|OTHER|Stainless steel|For control
40859864|NCT02501499|OTHER|Breastfeeding Buddies|a 2 hour breastfeeding workshop and if mother chooses, she is matched with a buddy who will contact her and offer breastfeeding support
40859865|NCT06335316|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40859866|NCT06335316|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)
41390950|NCT02173301|DRUG|Placebo|control
41390951|NCT03751319|OTHER|CGA|Comprehensive Geriatric Assessment
41390952|NCT03095963|OTHER|a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)|Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
41390953|NCT03095963|DRUG|levothyroxin|replacement therapy for hypothyroidism
41390954|NCT06460246|DEVICE|Pulse Oximeter|The subjects will have a 22-gauge catheter inserted in the radial artery to measure the oxygen saturation of arterial blood and also wear pulse oximeters.
41390955|NCT02256059|PROCEDURE|Plate osteosynthesis|Plate osteosynthesis using LCP plate (Synthes)
41390956|NCT00153868|BIOLOGICAL|darbepoetin alfa|The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience \<1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations \>13.0 g/dL.
41390957|NCT05598463|DEVICE|OASIS Pro|This device can track the joint movement and provide real-time feedback on the exercise performance and accuracy using Kinect camera sensor, and Wearable sensor (IMU). This device is connected to the website, which available for medical staff prescribe the exercise protocol and monitor individual exercise adherence.
41390958|NCT04991896|DRUG|Flecainide Injectable Product|Flecainide is given as an IV infusion of 1.5 mg/kg (max 150 mg) in DW 5% over 10 min under continuous monitoring. Concomitant administration of a b-blocker is also applied in all patients. The dose and type of b-blocker are selected according to heart rate during the AF and patient's medical history.
41390959|NCT04206787|DRUG|Afatinib|drug
41390960|NCT00305071|DRUG|compound cranberry extract tablet|
41390961|NCT04949984|DEVICE|Bright light therapy|BLT consisted of 30-minute morning sessions with an intensity of 10,000 lux, five days a week (Monday to Friday), for 4 weeks.
41390962|NCT02103634|DEVICE|NaF PET/MRI|
41390963|NCT02103634|DEVICE|NaF PET/CT|NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.
41390964|NCT02103634|DEVICE|FDG PET/CT|
41390965|NCT00677677|BIOLOGICAL|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
41390966|NCT06567587|DRUG|Dexmedetomidine|Effect o dexmedetomine on agitated normal and psychotic patients on BIPAP who are suffer exaggerated COPD
41390967|NCT06567587|DEVICE|BIPAP|Put exaggerated COPD patients on non invasive ventillation
41390968|NCT06301737|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
41390969|NCT06301737|PROCEDURE|Injection|the patients were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41390970|NCT06301737|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41390971|NCT00407043|DRUG|Lotemax|
41390972|NCT00407043|DRUG|Restasis|
41390973|NCT02420665|DRUG|Proflavine|0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
41390974|NCT02420665|DEVICE|HRME Imaging|HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
41390975|NCT02420665|BEHAVIORAL|Phone Call|Study staff follow up with participant by phone one month after procedure.
41390976|NCT02420665|PROCEDURE|Colposcopy|Colposcopy performed after visual inspection of cervix.
41390977|NCT02420665|DRUG|Acetic Acid|3 - 5% added to cervix before visual inspection.
41390978|NCT05774769|PROCEDURE|Commissural edge to edge mitral valve repair|Edge to edge is the suture of mitral valve leaflets tissue in the regurgitant spot. If the regurgitant jet is near a mitral commissure, it is called a commissural edge to edge.
41390979|NCT02212886|DRUG|GA Depot 80 mg|Recruitment completed
41390980|NCT02212886|DRUG|GA Depot 40 mg|Recruitment completed
41390981|NCT00118222|DRUG|porfimer sodium|All patients receive porfimer sodium IV.
41390982|NCT00118222|PROCEDURE|adjuvant therapy|All patients receive porfimer sodium IV.
41390983|NCT00118222|PROCEDURE|conventional surgery|All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
41390984|NCT04049695|BEHAVIORAL|Exercise|This intervention is based on Control Theory and Social Cognitive Theory and includes: 1) weekly emails with tips and tools to set personalized exercise goals and to increase exercise; 2) Health coaching phone sessions; 3) wrist worn monitor such as a Fitbit to track activity
41390985|NCT04049695|BEHAVIORAL|Control|This intervention includes: 1) weekly emails with tips and tools to support health and wellness such as brain health, stress management, nutrition; 2) Health coaching phone sessions
41390987|NCT03876873|PROCEDURE|Head Rotation During Face Mask Ventilation|Participants will receive face mask ventilation in either a neutral head position (practice standard position) or a head rotation position (45 degree angle).
41390988|NCT03876873|DEVICE|Medline Top Valve Anesthesia Mask|Face mask used per standard of care to provide oxygen to subjects before surgical procedures.
41390989|NCT05525637|DRUG|YZJ-1139 20mg|YZJ-1139 20mg tablets, once daily in the evening
41390990|NCT05525637|DRUG|YZJ-1139 40mg|YZJ-1139 40mg tablets, once daily in the evening
41390991|NCT05525637|DRUG|Placebo|Match placebo tablets, once daily in the evening
41417861|NCT03103100|DRUG|1% Lidocaine|10 mL of 1% lidocaine
41390992|NCT05776160|DRUG|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
41390993|NCT05296369|DRUG|Folic acid|Folic acid was added during the period prior to concurrent chemoradiotherapy
40859867|NCT06335316|BEHAVIORAL|Comprehensive therapy|All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
40859868|NCT06335316|BEHAVIORAL|placebo|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Only normal saline was used
40859869|NCT05743088|BEHAVIORAL|questionnaire|The questionnaire consists of the following parts: socio-demographic data of participants, student perception and attitude towards the COVID-19 pandemic and its consequences, as well as practices of preventive measures in the community.
40859870|NCT01280695|DRUG|Placebo|Placebo Capsules
40859871|NCT01280695|DRUG|MSDC-0602 100 mg|MSDC-0602 100 mg Capsules
40859872|NCT01280695|DRUG|MSDC-0602 250 mg|MSDC-0602 250 mg Capsules
40859873|NCT01280695|DRUG|MSDC-0602 250 mg|MSDC-0602 500 mg Capsules
41390994|NCT02091388|DRUG|LY03004|
41390995|NCT02091388|DRUG|Risperdal® Consta®|
40859874|NCT01280695|DRUG|Pioglitazone|Pioglitazone 45 mg Capsules
41390996|NCT05277831|OTHER|Guided Imagery Intervention|Participants in the Guided Imagery Intervention receive 6 sessions of a Guided Imagery plus standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to create or revise guided imagery scripts. After the session, coaches record the script as a digital audio file and send to the participant. Participants listen to their audio file every day and practice behavioral skills between sessions.
41390997|NCT05277831|OTHER|Standard Behavioral Control|Participants in the Standard Behavioral Control condition receive 6 sessions of a standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to identify lifestyle changes to support tobacco cessation, and set a schedule for practicing new behavioral strategies. Participants complete exercises in a quit booklet every day and practice behavioral skills between sessions.
40859875|NCT00946790|DRUG|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
40859876|NCT00946790|DRUG|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
40859877|NCT05677659|DRUG|VGL101|Solution administered via Intravenous Infusion (IV)
40859878|NCT02652260|DRUG|Doravirine, Tenofovir, Lamivudine - Blinded|A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period
40859879|NCT02652260|DRUG|Doravirine, Tenofovir, Lamivudine - Open-Label|A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.
40859880|NCT02652260|DRUG|ATRIPLA^TM|A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
40859881|NCT02652260|DRUG|Placebo to ATRIPLA™|A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period
40859882|NCT02652260|DRUG|Placebo to Doravirine, Tenofovir, Lamivudine|A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
41390998|NCT02282826|DRUG|GZ402668|Pharmaceutical form:solution Route of administration: intravenous
40859883|NCT05254483|BEHAVIORAL|UNICEF kid power program immediately|"The intervention will be delivered via the UNICEF Kid Power website (https://www.unicefkidpower.org/) and any screened device such as a computer, smartphone, smart TV or an electronic tablet can be used to watch the videos and perform the assigned physical activity.~Participants will self-select activities 5 days a week. The participants will have the choice to undertake the physical activity in bouts and accumulate it over the course of the day.~To promote adherence to intervention, a weekly email with reminder to perform the physical activity will be sent to parents. In addition, research-based articles on the importance of physical activity and behavior change in children will also be emailed."
40859884|NCT05254483|BEHAVIORAL|UNICEF kid power program for waitlist control|The wait-list control group will perform physical activity as usual and will only receive a weekly email on the importance of healthy dietary habits in children. The intervention will last 12 weeks. At the end of the study, the wait-list control group will be offered the UNICEF Kid Power intervention for a duration of 12-weeks
40859885|NCT05254483|DEVICE|ActiGraph Accelerometer|The participants will be mailed accelerometers and instructed to wear for 7 consecutive days during their waking hours, prior to the start of intervention. The mail containing the accelerometer will accompany pictorial instructions, explaining in detail the correct way of wearing it.
40859886|NCT01078649|DRUG|Debio 1143 (AT-406)|Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
40859887|NCT02255461|DRUG|palbociclib isethionate|Given PO
40859888|NCT02255461|OTHER|pharmacological study|Correlative studies
40859889|NCT02255461|OTHER|laboratory biomarker analysis|Correlative studies
41167532|NCT04148118|BIOLOGICAL|BW-1010: 50 µg - sprayer - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
41039545|NCT06015204|PROCEDURE|Interscalene brachial plexus block targeting the C5-to-C6 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C6 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
41039546|NCT06015204|PROCEDURE|Interscalene brachial plexus block targeting the C5-to-C8 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C8 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
41039547|NCT03671837|OTHER|Oxygen|15 L/min O2
41039548|NCT03671837|OTHER|Air|15 L/min air
41039549|NCT05227001|BIOLOGICAL|PF-07852352 Influenza saRNA 1|Intramuscular injection
41039550|NCT05227001|BIOLOGICAL|PF-07836391 Influenza saRNA|Intramuscular injection
41039551|NCT05227001|BIOLOGICAL|PF-07836394 Influenza saRNA|Intramuscular injection
41390999|NCT02282826|DRUG|placebo|Pharmaceutical form:solution Route of administration: intravenous
41391000|NCT02282826|DRUG|GZ402668|Pharmaceutical form:solution Route of administration: subcutaneous
41391001|NCT02282826|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
41391002|NCT02282826|DRUG|acyclovir|Pharmaceutical form:tablet Route of administration: oral
41391003|NCT04833452|PROCEDURE|Endoscopic dacryocystorhinostomy|Endoscopic DCR
41391004|NCT05445830|PROCEDURE|High-Intensity-Interval-Exercise|Subjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
41039552|NCT05227001|BIOLOGICAL|PF-07836395 Influenza saRNA|Intramuscular injection
41039553|NCT05227001|BIOLOGICAL|PF-07836396 Influenza saRNA|Intramuscular injection
41039554|NCT05227001|BIOLOGICAL|PF-07867246 Influenza saRNA|Intramuscular injection
41039555|NCT05227001|BIOLOGICAL|Placebo|Intramuscular injection
41039556|NCT05227001|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|Intramuscular injection
41039557|NCT05227001|BIOLOGICAL|PF-07871987 Influenza saRNA|Intramuscular injection
41039558|NCT05227001|BIOLOGICAL|PF-07914705 Influenza saRNA|Intramuscular injection
41039559|NCT05227001|BIOLOGICAL|PF-07915048 Influenza saRNA|Intramuscular injection
41039560|NCT03458572|DEVICE|Seirin Pyonex press needle acupuncture|Acupuncture
41039561|NCT04091074|DRUG|Ticagrelor|Half of patients undergoing carotid stenting take ticagrelor+aspirin
41039562|NCT04091074|DRUG|Clopidogrel|Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin
41039563|NCT04091074|PROCEDURE|Carotid stenting|Patients with carotid stenosis will undergo carotid stenting
41039564|NCT02191982|BEHAVIORAL|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
41391005|NCT05445830|PROCEDURE|Moderate-Intensity-Continuous-Exercise|Subjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
41417862|NCT03103100|DRUG|0.25% Bupivacaine|10 mL of 0.25% bupivacaine
41417863|NCT03103100|DRUG|Bupivacaine plus Lidocaine|5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
40859890|NCT06474637|DEVICE|AEON Endoscopic Powered Stapler Handle and Reload|The AEON™ Endoscopic Stapler places two triple-staggered rows of titanium staples while simultaneously transecting between the two triple-staggered rows of staples. The size of the staples and staple line length are based on the selection of the Stapler Reload (2.0mm, 2.5mm, 3.25mm, 4.0mm, 5.0mm and 5.5mm).
40859891|NCT03306511|OTHER|Repeated-sprint test|6x30-meter sprint interspersed with 90-s rest
40859892|NCT04139356|PROCEDURE|Deep breaths|Patients will undergo a 6 minutes protocol. Baseline: 1 minute normal breaths. Intervention: 1 minute with 10 deep breaths, 1 each 6 secs. Pulse-oxymetry will be continuously recorded.
40859893|NCT04734067|OTHER|Immune checkpoint inhibitors(ICIs) therapy|Patients with malignant tumors who first received ICIs
40859894|NCT04417153|BEHAVIORAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.
40859895|NCT06346015|PROCEDURE|Gamma Entrainment Stimulation|"Audio-assisted therapy: receive audio therapy with a specific device for 30 minutes, once in the morning and evening for 3 months.~(Binaural beat treatment group: receive binaural beat treatment with a specific device for 30 minutes, once in the morning and evening, for 3 months.）"
40859896|NCT00108771|DRUG|ZR-02-01 Fentanyl Transdermal Matrix Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
40859897|NCT00108771|DRUG|Placebo Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
41039565|NCT06053567|BEHAVIORAL|Aerobic Exercise|Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training.
41039566|NCT06053567|BEHAVIORAL|Counseling|Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources.
41039567|NCT06053567|DRUG|Nicotine patch|On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).
40859898|NCT03642509|DEVICE|Left atrial appendage occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
40859899|NCT03642509|DRUG|NOAC|Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.
40859900|NCT03282097|BEHAVIORAL|DECAD decision aid|A mammography decision aid directed toward family caregivers of older women with Alzheimer's disease and other dementias to assist with decisions about breast cancer screening.
41039568|NCT02380547|OTHER|Sonographic diaphragmatic measurements|
41039569|NCT04452526|OTHER|Best Practice|Receive usual care
41391006|NCT05445830|PROCEDURE|Strength training|Subjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
41391007|NCT05445830|PROCEDURE|Baseline assessment|Subjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
41512539|NCT04952818|DIAGNOSTIC_TEST|RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)|Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).
41512540|NCT01959061|DRUG|Raltitrexed|4mg, every 4 weeks,transhepatic arterial infusion
40859901|NCT03282097|OTHER|Home safety guide|The home safety guide to provide tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards.
40859902|NCT02478099|DRUG|MPDL3280A|Anti-PD-L1 antibody
40859903|NCT03068754|DRUG|Acthar|Repository corticotropin for subcutaneous injection
40859904|NCT03068754|DRUG|Placebo|Matching placebo for subcutaneous injection
41039570|NCT04452526|OTHER|Educational Intervention|Receive educational materials
41039571|NCT04452526|OTHER|Questionnaire Administration|Ancillary studies
41039572|NCT04452526|OTHER|Reminder|Receive reminder letter
41167533|NCT04148118|BIOLOGICAL|BW-1010: 50 µg - pipette - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
41167534|NCT04148118|BIOLOGICAL|BW-1010: 100 µg - sprayer - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart"
40859905|NCT04209595|DRUG|PLX038|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. PLX038 (PEGylated SN38) will be administered as a 1 hour (-10 minutes / +30 minutes) intravenous (IV) infusion on Day 1 of each cycle (21 days).
41167535|NCT04148118|BIOLOGICAL|BW-1010: 100 µg - pipette - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
41391008|NCT05445830|PROCEDURE|1 year follow-up|Subjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
41391009|NCT01875419|DEVICE|Transcranial direct current stimulation (tDCS)|"Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.~Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between."
41391010|NCT01875419|BEHAVIORAL|Cognitive Behavioural Therapy|8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
40859906|NCT04209595|DRUG|Rucaparib|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. Rucaparib will be given orally at designated dose twice a day on days 5 to 19 of every 21-day cycle.
41391011|NCT05841706|BIOLOGICAL|Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)|Receive conservative transfusion strategy (Hgb \< 7 g/dL)
41391012|NCT05841706|BIOLOGICAL|Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)|Receive liberal transfusion strategy (Hgb \< 9 g/dL)
41391013|NCT05841706|PROCEDURE|Computed Tomography|Undergo CT scan
41391014|NCT05841706|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
41391015|NCT05841706|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41391016|NCT05841706|OTHER|Survey Administration|Ancillary studies
41391017|NCT05841706|PROCEDURE|Pancreatectomy|surgical removal of all or part of pancreas
41391018|NCT06453005|PROCEDURE|SMART Hall Technique or procedure|"The SMART Hall technique, a minimally invasive approach in pediatric dentistry for managing caries in primary teeth, involves gentle cavity preparation using hand instruments and minimal local anesthesia. A glass ionomer cement is used for restoration, followed by crown adaptation and cementation. Postoperative care and follow-up assessments at 3 and 6 months are included.~The Stainless Steel Crown (SSC) technique for restoring extensively decayed primary molars involves tooth preparation, crown selection, adaptation, and cementation. Postoperative care and follow-up assessments at 3 and 6 months are also part of the procedure."
41391019|NCT02836704|DRUG|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous injection"
40859907|NCT04209595|DRUG|Ondansetron|Participants will be recommended to have 8 mg of ondansetron taken with a small meal or snack to prevent nausea and vomiting approximately 30 minutes prior to each dose of rucaparib.
40859908|NCT01755455|DRUG|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
40859909|NCT01755455|DRUG|Placebo|Matching placebo capsule
40859910|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrolyte and quality of recovery of the patients
41167536|NCT04148118|BIOLOGICAL|Saline (Placebo) - sprayer - IN|"Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
40859911|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 1.0 μg/kg, maintenance dose with 0.25 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patient
40859912|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patients
40859913|NCT04771637|DRUG|Normal saline|Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients
40859914|NCT01922908|BIOLOGICAL|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
40859915|NCT01922908|BIOLOGICAL|Placebo Comparator|Normal saline
41391020|NCT02836704|DRUG|metformin|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
41391021|NCT02836704|DRUG|acarbose|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
41391022|NCT05666674|OTHER|TSA algorithms|Our study will be composed of an experimental and an active comparator (i.e., control) arm. Both arms will perform a postural tremor test (PTT) to elicit parkinsonian tremors. The PTT is where subjects stabilize their backs against a wall and position their hands in the air against gravity for two minutes. The experimental arm will receive VR plus activated Tremor Stabilization Algorithms (TSA-ON) while the active comparator arm will receive VR only (TSA-OFF). Thus, subjects in the experimental arm will not see their digital arms tremor while those in the active comparator arm will. Our primary outcome is the severity of PTT elicited tremors. Tremors will be recorded by VR motion-capture controllers.
41391023|NCT00140322|BEHAVIORAL|Exercise, fall risk reduction|
41391024|NCT00701935|DRUG|placebo|subcutaneous injection, twice a day
41391025|NCT00701935|DRUG|exenatide|subcutaneous injection, twice a day, 10mcg
41391026|NCT04700215|DEVICE|BiPAP|To give bilevel positive airway pressure to the lungs
41391027|NCT04700215|DEVICE|Incentive spirometry|IS for 15 minutes after every 4 hours
41391028|NCT02200614|DRUG|Darolutamide (Nubeqa, BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
41391029|NCT02200614|DRUG|Placebo|Matching placebo 2 tablets twice daily with food.
41391030|NCT05040035|DIAGNOSTIC_TEST|ACT measurement|Measurement of active clotting time (ACT)
41391031|NCT05331846|BEHAVIORAL|the smell of breast milk|Smell of breast milk during endotracheal aspiration will reduce pain and stress
41391032|NCT01906034|BEHAVIORAL|Exercise with supervision|
41391033|NCT01906034|BEHAVIORAL|Home-based without supervision|
41391034|NCT01266473|OTHER|Physiotherapy|Physiotherapy for Airway Clearance
41391035|NCT02125734|DRUG|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
41391036|NCT02125734|DRUG|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
41391037|NCT00943384|DEVICE|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
41391038|NCT04326569|OTHER|Blood sample|Blood sample to quantify copeptin
40859916|NCT01005498|DIETARY_SUPPLEMENT|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
40859917|NCT01005498|DIETARY_SUPPLEMENT|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
40859918|NCT05456971|DEVICE|Art Filler Volume|Midface correction with injectable hyaluronic acid based-filler
40859919|NCT05456971|DEVICE|Art Filler Lips|Lipscorrection with injectable hyaluronic acid based-filler
40859920|NCT00262899|BEHAVIORAL|counseling intervention|
40859921|NCT00262899|OTHER|educational intervention|
40859922|NCT00262899|PROCEDURE|psychosocial assessment and care|
40859923|NCT04370613|BEHAVIORAL|Prospective Imagery visualization task|Participant visualizes brief mental imagery of prospective situations of different valence (neutral, positive, negative).
40859924|NCT00584519|OTHER|non-interventional|non-interventional
40859925|NCT02032498|DRUG|Indocyanine Green|Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
40859926|NCT04030793|DEVICE|Individualized transcranial direct current stimulation|Based on tDCS stimulation, individualized stimulation during 30 minutes with sitting position.
41039573|NCT02808962|PROCEDURE|Cooled RFA of sacral lateral branches|A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
41039574|NCT00784810|DRUG|Oxycodone/Naloxone|5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
41039575|NCT00784810|DRUG|Codeine/Paracetamol|15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
41039576|NCT00907829|DRUG|lidocaine|comparison of the effect of the drug to help improve finger function
41391039|NCT05288842|BIOLOGICAL|Lumbar puncture|5 mL of CSF
41391040|NCT05288842|BIOLOGICAL|blood sample|6x5 mL of blood sample collected :1 dry tube, 2 EDTA tubes, 1 fluoride tube, and 2 polypropylene tubes
41391041|NCT03046147|PROCEDURE|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery for morbid obesity
41391042|NCT05409807|DEVICE|Ultrasound guided smart glasses assisted|Ultrasound guided smart glasses assisted interscalene nerve block
41391043|NCT05409807|DEVICE|Ultrasound guided|Ultrasound guided interscalene nerve block
41391044|NCT01339000|DRUG|Glycosylated Recombinant Human Interleukin-7|Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection
41391045|NCT01339000|BIOLOGICAL|Diphtheria/Tetanus Vaccine|Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.
41391046|NCT01339000|BIOLOGICAL|Polio Vaccine|Polio Vaccine will be administered according to the randomized schedule per protocol.
41391047|NCT01339000|BIOLOGICAL|Pneumococcal Vaccine|Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.
41391048|NCT01339000|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.
41391049|NCT01339000|BIOLOGICAL|Hepatitis B Vaccine|Hepatitis B vaccine will be administered according to the randomization schedule per protocol.
41391050|NCT00522327|OTHER|remote simultaneous medical interpreting|remote simultaneous medical interpretation
41391051|NCT00522327|OTHER|usual and customary|usual and customary interpreting
41391052|NCT00522327|OTHER|ENglish speaking|English speakers
40859927|NCT04030793|DEVICE|Conventional transcranial direct current stimulation|Conventional tDCS stimulation during 30 minutes with sitting position.
40859928|NCT02779413|DRUG|insulin degludec|Patients will be treated with commercially available Tresiba® FlexTouch® according to routine clinical practice at the discretion of the treating physician.
40859929|NCT06168669|DIAGNOSTIC_TEST|xBar system|xBar system is surgical drain with embedded sensors. Collected data will be evaluated for an ability to identify anastomotic leaks. The xBar system does not have therapeutic indication.
40859930|NCT02610946|BEHAVIORAL|Electronic application|Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
40859931|NCT02610946|BEHAVIORAL|Paper-based|Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
40859932|NCT03261219|DEVICE|Intrapulmonary Percussive ventilation|mode of airway clearance using mouthpiece and alternating air currents applied directly to the airway
40859933|NCT03261219|DEVICE|Chest Physiotherapy Vest (Incourage)|mode of airway clearance using external vibratory vest
41391053|NCT05402319|COMBINATION_PRODUCT|Antibiotic combination therapy|Anti-infective treatment with at least two different types of sensitive antibiotics.
41391054|NCT02446197|OTHER|Patient Directed Exercise Group|Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
41391055|NCT05011019|DRUG|AL2846 capsules|AL2846 is a multi-target receptor tyrosine kinase inhibitor.
41512541|NCT01959061|DRUG|Oxaliplatin|100\~150mg, every 4 weeks, transhepatic arterial infusion
40859934|NCT03637478|BEHAVIORAL|Enhanced Systems of Care Team|E-SOC team will be increasing connections between clinical care and community partners, such as schools, juvenile justice and child-serving state agencies, to reduce disparities in access to mental health/substance use evaluation and treatment. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning. Overall goals are: earlier identification of mental health needs including child trauma; increased treatment access and adherence; care delivered in least restrictive settings; care experience reflecting active youth and family engagement; program sustainability and replicability.
40859935|NCT03582891|DEVICE|Summit RC+S for Motor|Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
40859936|NCT03582891|DIAGNOSTIC_TEST|8-week pilot trial of Closed-loop vs. Open-loop Stimulation|These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
40859937|NCT03582891|DEVICE|Summit RC+S for Sleep|Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
40859938|NCT01663064|DEVICE|Endovascular treatment (Zenith® p-Branch™ endovascular graft)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
40859939|NCT00767806|DRUG|Duloxetine|60 mg orally once daily for 12 weeks
40859940|NCT00767806|DRUG|Placebo|Placebo once daily orally for 12 weeks
40859941|NCT05851976|DRUG|Naproxen|Naproxen 500mg twice daily for 16 days
41391056|NCT04147052|BEHAVIORAL|iSLEEPms|Participants randomized to iSLEEPms complete daily online sleep diary forms and weekly online educational modules. Modules focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are scored each week, and feedback is provided to participants to guide adjustments to their recommended bedtimes and wake times. Telephone support is available to provide clarification around module content.
40859942|NCT05851976|DRUG|Duloxetine|Duloxetine 60mg daily for 14 days
40859943|NCT06109064|BIOLOGICAL|Unrelated Umbilical Cord Blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
40859944|NCT06109064|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
40859945|NCT06109064|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
40859946|NCT06109064|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
40859947|NCT04680429|DRUG|RP7214|Participants will receive single and multiple ascending doses of RP7214
41039577|NCT00907829|DEVICE|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
41167537|NCT04148118|BIOLOGICAL|Saline (Placebo) - pipette - IN|"Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
40859948|NCT04680429|DRUG|Placebo|Participants will receive single and multiple ascending doses of matching placebo
40859949|NCT02356718|BEHAVIORAL|Cognitive training activities|Training activities consist of computer tasks designed to improve memory and cognition. The intervention consists of 45-minute training sessions delivered regularly during inpatient treatment.
40859950|NCT02356718|BEHAVIORAL|Inpatient psychosocial therapy|Group psychosocial therapy delivered in an inpatient setting.
41391057|NCT01462552|DRUG|Lapatanib|Prescription of lapatinib (Tykerb)
41391058|NCT00831038|PROCEDURE|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
41391059|NCT04307225|DEVICE|Zenicor|Handheld Thumb ECG monitoring device
41039578|NCT05315193|OTHER|Structured In-patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
41167538|NCT04148118|BIOLOGICAL|BioThrax (positive control) - SC|"BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart."
41167539|NCT03602222|BEHAVIORAL|Mobile web training LGBT mental health|Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).
41167540|NCT03602222|BEHAVIORAL|In-person training LGBT mental health|In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
41391060|NCT04169425|PROCEDURE|elective diverting ileostomy|
41391061|NCT05110144|DRUG|Duloxetine 30 MG|30mg orally for 4 weeks
41167541|NCT03864341|BEHAVIORAL|Referral to homelessness prevention services|Referral to Homebase homelessness prevention services offered by community-based organizations in NYC
41167542|NCT03864341|BEHAVIORAL|Substance use services|Referral to substance use services (SBIRT and peer counselor/social work contact) available at Bellevue Hospital
41512542|NCT01959061|DRUG|lipiodol|5-20ml, every 4 weeks, hepatic artery embolization
40859951|NCT00752479|BIOLOGICAL|Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|"Cell therapy~Mesenchymal cells infusion.~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
40859952|NCT00752479|DRUG|Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil|"Routine immunosuppressive therapy~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
41167543|NCT03864341|BEHAVIORAL|Follow-up|Follow-up to assist participants in receiving homelessness prevention services
41391062|NCT05110144|DRUG|Duloxetine 60 MG|60mg orally for 4 weeks
41391063|NCT05110144|DRUG|Amitriptyline 25 MG|25 mg orally for 4 weeks
41391064|NCT05110144|DRUG|Amitriptyline 50 MG|50 mg orally for 4 weeks
41391065|NCT05110144|DRUG|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
41167544|NCT03492710|BIOLOGICAL|Immunoglobulin|Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
41391066|NCT05110144|DRUG|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
41391067|NCT01097850|DRUG|henna paste|Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
40859953|NCT05881954|PROCEDURE|Groin infection|Femoral artery reconstruction with tubulized pericardium patch
40859954|NCT06408038|OTHER|For each patient included, the samples described below will be collected:|"* A single blood sample will be taken before initiation of the metastatic treatment line. The volume of total blood sampled is 34mL.~* A tumour sample (FFPE block already archived) from a metastasis (other than bone) if available or, failing this, from the primary breast tumour, will be sent to the sponsor in order to meet the objectives of the study.~Once the blood sample has been taken, patients will have completed their participation in the study."
40859955|NCT01180686|DEVICE|Activator IV single impulse instrument|This is a manually operated device that delivers a single thrust into the joint involved.
40859956|NCT01180686|DEVICE|Multiple thrust Impulse adjusting instrument|A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
40859957|NCT02134925|OTHER|Laboratory Biomarker Analysis|Correlative studies
41167545|NCT06236828|DEVICE|Mechanical Thrombectomy|The endovascular mechanical thrombectomy methods mainly include stent retriever thrombectomy, ADAPT thrombus aspiration technique, or their combination.
41391068|NCT00827359|DRUG|Everolimus|Tablet form taken orally once a day
41391069|NCT00350337|BIOLOGICAL|Pre-transfection F17|Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
41391070|NCT00350337|BIOLOGICAL|Post-transfection F17|Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
40859958|NCT02134925|BIOLOGICAL|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
41167546|NCT05096078|OTHER|Diet|Special diet program for gestational diabetes
41391071|NCT00350337|BIOLOGICAL|Post-transfection F19|Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
41391072|NCT00350337|OTHER|Placebo|Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
41391073|NCT06538103|PROCEDURE|Eye soft surgery|Early lower eyelid surgery will be performed in accordance with the protocol previously described by Di Stadio, with medial or lateral eyelid lifting surgery as indicated. The indication for eye surgery are in case of ectropion (exposure of the conjunctiva due to a reduction in tension of the anterior compartment of the eye muscle) and lagophthalmos (incomplete /abnormal closure of the eye with eyelid in closed position) a lateral lower eyelid lifting surgery is performed. otherwise, in presence of epiphora (the eversion of the lachrymal point) and lagophthalmos medial lower eyelid lifting surgery is done.
41391074|NCT06538103|OTHER|Physical Rehabilitation|Kabat therapy and neuromuscular reeducation (NMR) at home Kabat therapy involved thrice-weekly 35-minute sessions.
41391075|NCT05844644|DIETARY_SUPPLEMENT|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
40859959|NCT02134925|OTHER|Quality-of-Life Assessment|Ancillary studies
40859960|NCT02134925|OTHER|Saline|Given SC
41039579|NCT05315193|OTHER|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
41167547|NCT05096078|OTHER|Exercise|The circuit exercise program will consist of a medium-intensity circuit training for 50 minutes, 3 days a week, detailing the main muscle groups of the patients (chest, back, biceps, triceps, deltoid, quadriceps, thigh and calf muscles). Exercise intensity will be monitored using Borg's scale of perceived exertion, with a target intensity of 12 to 14. 8 exercises will be given in a continuous, circuit-type manner with short 1-minute rests.
41167548|NCT02325830|DEVICE|Carillon Mitral Contour System|Percutaneous mitral valve repair
40859961|NCT01797263|OTHER|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
41039580|NCT03265600|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program that can be delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours long for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action planning protocol during Week 7.
41039581|NCT03265600|BEHAVIORAL|60-minute Introduction to Mindfulness|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, discussion, and an orientation to an 8-week mindfulness group. They are also given a list of leading community, online, print, and smartphone mindfulness resources.
40859962|NCT01797263|OTHER|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
41039582|NCT02327026|PROCEDURE|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
40859963|NCT01934010|DRUG|AM-101|AM-101 gel for intratympanic injection
40859964|NCT00217217|DEVICE|Echo-Planar Magnetic Resonance Imaging (EP-MRSI)|variable-setting low-frequency MRI
40859965|NCT02333799|DRUG|Bedaquiline|100mg tablets
40859966|NCT02333799|DRUG|PA-824|200mg tablets
40859967|NCT02333799|DRUG|Linezolid|Scored 600mg tablets
41167549|NCT04912583|DEVICE|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
41167550|NCT04912583|DEVICE|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
41167551|NCT03689439|DIAGNOSTIC_TEST|bone scintigraphy|bone scintigraphy
41167552|NCT01120288|DRUG|EZN-2968|
41167553|NCT05946122|DRUG|Atorvastatin 40 Mg Oral Tablet|oral atorvastatin for renal protection
41167554|NCT05946122|DRUG|placebo drug|tablet resembles atorvastatin
41167555|NCT00510263|DRUG|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
41167556|NCT00510263|DRUG|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
41167557|NCT00510263|DRUG|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
40859968|NCT02586948|DEVICE|extracorporeal CO2 removal (Hemolung device)|ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
40859969|NCT00390650|DRUG|Saredutant|
40859970|NCT05271916|DRUG|Dacomitinib+Anlotinib|The dose of each drug in the combination Decomitinib and Anlotinib will be escalated or de-escalated until the recommended phase II dose (RP2D) is reached. Patients will then be treated with RP2D orally once a day.
40859971|NCT05271916|DRUG|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg once a day until progressive disease.
40859972|NCT01771796|BEHAVIORAL|Aerobic and muscle resistance training|After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
40859973|NCT06216821|DRUG|standard DAPT|standard DAPT with aspirin and a P2Y12 inhibitor for 12 months after DES implantation.
41167558|NCT00510263|DRUG|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
41391076|NCT03810742|DRUG|Nanoliposomal Irinotecan|Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
41391077|NCT05357209|DEVICE|Avidhrt Sense Heart Monitor|Use of Avidhrt Sense Heart Monitor review ECG signals.
41391078|NCT00689208|DRUG|Atropine|10 ug/kg bolus, 4 ug/kg/h infusion
41391079|NCT00689208|DRUG|Physostigmine|0,12ug/kg/min
41391080|NCT00689208|DRUG|Placebo Sodium|
40859974|NCT06216821|DRUG|OPT-CAD score guided DAPT de-escalation|De-escalation DAPT at 3 months for moderate to high risk patients and de-escalation DAPT at 1 month for low risk patients.
40859975|NCT03422497|OTHER|Male sex|Male sex-as listed in the discharge abstract database
40859976|NCT03422497|OTHER|Female sex|Male sex-as listed in the discharge abstract database
40859977|NCT04355793|DRUG|Ruxolitinib|Ruxolitinib starting dose level 5 mg orally, twice daily (BID).
40859978|NCT02951078|PROCEDURE|Thulium Laser en Bloc Resection of bladder tumor|
40859979|NCT02951078|PROCEDURE|Electrical transurethral resection of bladder tumor|
40859980|NCT05405335|OTHER|Prone Positioning Maneuver|intermittent prone positioning for eight hours per day for seven days. each cycle should not be less than 30 minutes or more than 3 hours.
40859981|NCT03954821|DEVICE|prefabricated insoles|
40859982|NCT00889824|DEVICE|balance prosthesis|vibrotactile stimulation
40859983|NCT06552637|DEVICE|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
40859984|NCT04045379|PROCEDURE|LASER|Use of the SmartXide Touch V²LR, Co2 Laser System to perform ambulatory intravaginal and vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
40859985|NCT04045379|PROCEDURE|Microablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured.
40859986|NCT04045379|DRUG|Estriol|The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
40859987|NCT01181817|OTHER|fMRI and MRS|fMRI and MRS
40859988|NCT05692544|PROCEDURE|Phototherapy treatment|only patients was proscribe to phototherapy treatment can participate in the study
40859989|NCT00582777|BEHAVIORAL|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
40859990|NCT00582777|BEHAVIORAL|HS DOSING|Take your usual BP meds at bed time
40859991|NCT00582777|DRUG|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
40859992|NCT00005773|DRUG|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had \<=20 mm Hg increase in PaO2 (less than full response).
40859993|NCT00005773|DRUG|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI \>=25).
40859994|NCT03251937|DEVICE|Spectra WaveWriter SCS System|Multiple modalities of stimulation therapy
40859995|NCT04119674|DRUG|Drug is Anlotinib.|Anlotinib 8 mg/day (Chia-tai Tianqing Pharmaceutical Co., Ltd.) was given orally on days 1 to 14 per 3-week cycle for 2 cycles during concomitant therapy and maximally 8 cycles during adjuvant chemotherapy. One week after discontinuation of adjuvant chemotherapy, anlotinib 8 mg/day was given for maintenance .
40859996|NCT04119674|DRUG|Drug is Temozolomide Capsule.|Temozolomide 75 mg/m2/day was taken for maximally 49 days during concurrent chemoradiotherapy. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients received adjuvant temozolomide for 5 days every 28 days, first cycle 150 mg/m2/day and subsequent cycles 200 mg/m2/day for maximally 6 cycles .
40859997|NCT04119674|RADIATION|Radiotherapy was initiated 4 to 6 weeks postoperatively.|Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.
40859998|NCT05285540|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
41391081|NCT06476743|OTHER|Sensory Integration Therapy|This group will receive sensory integration therapy for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week for 8 week.
41391082|NCT06476743|OTHER|Balance Board Training|This group will receive balance board training for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week.
41391083|NCT04737915|BEHAVIORAL|Exposure Therapy (In Vivo)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a virtual environment.
41391084|NCT04737915|BEHAVIORAL|Exposure Therapy (Virtual Reality)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a real environment.
41391085|NCT03102788|BEHAVIORAL|Rheumatologist-led care.|"Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid.~The rheumatologist may also refer participants to occupational therapy if needed."
41512543|NCT03456388|DRUG|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
40859999|NCT05285540|DRUG|DT-216 matching Placebo|Placebo will be administered by intravenous (IV) injection
40860000|NCT04637737|DEVICE|anterioposterior Weight Shifting Training with Visual Biofeedback|"The training group received an additional anterioposterior weight shifting training with visual Biofeedback 5 times per week for 4weeks. AP training is made to instantly know your training status during training by measuring and processing the foot pressure in real time using the F-Scan (Tekscan) hardware system and Software Development Kit (SDK).~Before training, all patients are instructed to place both feet at shoulder width, place the inverted foot approximately 30 cm in front of the unaffected side foot, move the body forward with the chest straight in an upright position, and be instructed to put the weight on the affected side.~On the screen shown, measure the maximum weight distribution during the first 10 times and set the value added by 5% as the target value.~It is designed to induce the maximum weight shift through the archery game."
40860001|NCT04637737|BEHAVIORAL|Conventional therapy|The control group received the usual gait training.
40860002|NCT01797055|DRUG|Human apotransferrin|intravenous infusion
40860003|NCT05549791|DRUG|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
41039583|NCT02327026|PROCEDURE|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
41391086|NCT03102788|BEHAVIORAL|Occupational therapist-led care.|Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
41391087|NCT01542684|DRUG|Azacytidine|Starting dose: 40 mg/m\^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
41391088|NCT01542684|DRUG|GM-CSF|250 mcg/m\^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
40860004|NCT05528393|DIAGNOSTIC_TEST|Blood sampling|blood sampling
41039584|NCT02959996|DRUG|Liposomal bupivacaine|liposomal bupivacaine injection in the Pfannenstiel incision
41039585|NCT02959996|DRUG|Placebo|placebo injection in the Pfannenstiel incision
41167559|NCT02160470|BEHAVIORAL|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
41167560|NCT02160470|BEHAVIORAL|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
41391089|NCT03218631|DRUG|Oxandrin|"The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints.~Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing."
40860005|NCT00346788|PROCEDURE|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
40860006|NCT01397461|DRUG|ozenoxacin placebo|cream
40860007|NCT01397461|DRUG|retapamulin 1% ointment|ointment
40860008|NCT01397461|DRUG|ozenoxacin 1% cream|1% cream
41039586|NCT03698851|DEVICE|Guidor® and Guidor easy-graft® CRYSTAL|A compound of biphasic calcium phosphate, 60 % hydroxyapatite and 40 % beta-tricalcium phosphate. The beta-tricalcium phosphate component completely resorbs via physiological dissolution in 5-15 months, while the interconnected hydroxyapatite remains embedded in the implantation site and forms an integrated long term osteoconductive scaffold with new bone.
41039587|NCT03698851|DEVICE|Guidor® and Guidor easy-graft® CLASSIC|Phase-pure beta-tricalcium phosphate that offers complete resorption via physiological dissolution in 5-15 months. This material has been used in oral surgery for more than 25 years and there are extensive research available on it.
41039588|NCT02530307|DRUG|HT-3951|
41039589|NCT02530307|DRUG|Placebo|
40860009|NCT04730856|DRUG|Tinzaparin|"day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home."
40860010|NCT05702138|OTHER|Physical therapy|The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).
40860011|NCT04034303|GENETIC|analysis of genetic and epigenetic risk factors|analysis of gene, methylation and expression, microbiome
41039590|NCT02403726|PROCEDURE|Operation|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.
41167561|NCT02160470|BEHAVIORAL|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
41391090|NCT05305378|DEVICE|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded intraoperatively in each patient before, during, and after ICGA in the same surgical field of view to guarantee comparability of the methods.
41391091|NCT06536699|RADIATION|Radiotherapy - hypofractionated|Hypofractionated Radiotherapy of 55 Gy in 20 fractions in definitive setting and 52.5 Gy in 20 fractions in adjuvant setting. Total duration - 4 Weeks
41391092|NCT06536699|RADIATION|Radiotherapy - Conventional|Conventional Radiotherapy of 66 Gy in 30 fractions in definitive setting and 60 Gy in 30 fractions in adjuvant setting. Total duration - 6 Weeks
41391093|NCT00500695|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing
41391094|NCT00500695|BEHAVIORAL|Psychoeducation|Psychoeducation
40860012|NCT02722200|DRUG|hydrocortisone|Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
40860013|NCT02722200|OTHER|saline|Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
40860014|NCT00806039|OTHER|Early Renal Involvement|Renal Consultation
41391095|NCT01883999|DEVICE|GORE® EXCLUDER® Iliac Branch Endoprosthesis|
41391096|NCT00736931|DRUG|Brivaracetam|Brivaracetam 10 mg tablets
41391097|NCT00736931|DRUG|levetiracetam|500mg tablets
41391098|NCT00736931|DRUG|lorazepam|lorazepam 2 mg over encapsulated tablets
41391099|NCT00736931|OTHER|placebo|placebo capsules
41391100|NCT00694031|PROCEDURE|Hemodialysis|3 times per week
40860015|NCT01076530|DRUG|vorinostat|
40860016|NCT01076530|DRUG|temozolomide|
40860017|NCT01076530|OTHER|diagnostic laboratory biomarker analysis|
40860018|NCT01076530|OTHER|pharmacological study|
40860019|NCT06451081|BEHAVIORAL|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
40860020|NCT06451081|BEHAVIORAL|Opt-out active referral|Participants will be automatically referred to a smoking cessation service upon joining the trial, unless they choose to opt out. Contacts of participants will be delivered to a service provider of their choice or based on their living district and preferred treatment modality
40860021|NCT06451081|BEHAVIORAL|Behavioral economic mobile messaging|Participants will receive behavioural economics-informed messages via mobile instant messaging for 3 months
40860022|NCT06451081|BEHAVIORAL|Opt-in active referral|Participants will be offered a referral to a smoking cessation service. Contacts of participants who opt-in will be delivered to a service provider of their choice
40860023|NCT03576859|OTHER|blood sample|Peripheral venous blood is collected before liver transplantation and after restoration of liver function
40860024|NCT03208634|DEVICE|Robotic intervention|One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
40860025|NCT00002984|DRUG|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
40860026|NCT00002984|DRUG|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
41039591|NCT02403726|PROCEDURE|Non-operative treatment|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
41167562|NCT02160470|BEHAVIORAL|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
41391101|NCT00694031|PROCEDURE|On-line hemodiafiltration|3 times per week
41391102|NCT00018746|DEVICE|repetitive transcranial magnetic stimulation|
41391103|NCT00029328|DRUG|etanercept|
41417864|NCT02992171|BEHAVIORAL|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
41417865|NCT03236181|OTHER|SFA|High saturated fatty acid/SFA oil source
41417866|NCT03236181|OTHER|MUFA|High monounsaturated fatty acid/MUFA oil source
40860027|NCT00002984|DRUG|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
40860028|NCT00002984|PROCEDURE|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
40860029|NCT00002984|RADIATION|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
40860030|NCT02935530|DRUG|s-LMWH|2125KU, subcutaneous injection of 5-10 days
40860031|NCT02935530|DRUG|LMWH|4250KU, subcutaneous injection of 5-10 days
41417867|NCT03236181|OTHER|PUFA|High polyunsaturated fatty acid (linoleic)/PUFA oil source
41417868|NCT03236181|OTHER|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
40860032|NCT02935530|DRUG|Argatroban|20mg, injection for 5-10 days
40860033|NCT01331109|DRUG|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
41391104|NCT04222556|BEHAVIORAL|Thiwáhe Gluwáš'akapi|Thiwáhe Gluwáš'akapi (TG, sacred home in which family is made strong) is a cultural adaptation of the Strengthening Families Program for Parents and Youth 10-14 (SFP 10-14). TG, like SFP 10-14, is a 7-week family-based prevention program with separate youth and adult sessions followed by family sessions. Videos teach content and spark discussion; games and activities foster interaction and provide opportunities to practice skills. Four key adaptations were made to create TG: (1) cultural kinship teachings and tribal language kinship words were embedded throughout; (2) a parent session on coping with stress was enhanced to teach recognizing and responding to trauma reactions in youth; (3) a session on listening was moved earlier in the curriculum, given cultural oral tradition; (4) session videos were remade with local actors and adapted scenarios. A multiphase optimization strategy design was used to test potential adaptations, resulting in the optimized TG program.
41391105|NCT04222556|BEHAVIORAL|Woyute Waśte|Woyute Waśte (WW) was adapted from the Colorado School of Public Health's Integrated Nutrition Education Program (INEP) for the culture and context of the reservation. Families will meet for 1 session to participate in hands-on activities - preparing healthy meals, family physical activity, and sugary drinks. They will discuss setting healthy goals and tracking progress, receive recipes and water bottles, and for 6 weeks after the session, will get text messages with additional program content.
41039592|NCT06430567|DEVICE|Blood flow restriction (50% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability|"Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 1) BFR Group with 50% AOP compression~Group 1 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 30-15-15-15 at 40% 1RM (repetition maximum)~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure."
41039593|NCT06430567|DEVICE|Blood flow restriction (10% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability|"Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 2) BFR Group with 10% AOP compression~Group 2 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 15-15-15-15 at 70% 1RM~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure."
41391106|NCT01227096|DEVICE|Electrical acupuncture stimulation|electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
41391107|NCT05243654|DRUG|Metformin|Metformin 1000mg XR OD + standard-of-care MDT
41391108|NCT05243654|DRUG|Placebo|Placebo + standard-of-care MDT
41391109|NCT03801018|OTHER|Questionnary and Interviews|"An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation."
41391110|NCT06358807|PROCEDURE|Arthroscopic microfracture with intraoperative local PRP gel injection|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion.~PRP preparation and local injection:~PRP is harvested using a PRP preparation kit via centrifugation. Fifty milliliters of autologous venous blood are drawn from the patient and processed. Platelet count is measured for quality control. On average 4 ml of (range 3-6) PRP is obtained and mixed with thrombin calcium agent in preparation for PRP gel. PRP gel is administered to the injured area using a blunt and long-tip injector, with direct visualization under arthroscope."
41391111|NCT06358807|PROCEDURE|Isolated microfracture|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion."
41391112|NCT00063596|DRUG|Vitamin A supplementation|
40860034|NCT04096287|BIOLOGICAL|PNT001|PNT001 diluted in 5% dextrose
40860035|NCT04096287|DRUG|Placebo|5% dextrose
40860036|NCT01101789|PROCEDURE|triclosan coated suture for surgical wound closure|triclosan coated suture for surgical wound closure
40860037|NCT01101789|PROCEDURE|regular sutures for surgical wound closure|
40860038|NCT00018967|DRUG|glucarpidase|
40860039|NCT02057172|DRUG|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
40860040|NCT02057172|DRUG|liraglutide|Liraglutide is a GLP-1 agonist.
40860041|NCT02057172|DRUG|Placebo|Placebo
41391113|NCT05105360|PROCEDURE|Closure method of Petersen's space|Surgeons closed Petersen's space between the mesentery of the jejunal Roux limb and the mesentery of the transverse colon at the posterior side of esophago-jejunostomy or gastro-jejunostomy from the mesentery root to the bowel side using a nonabsorbable barbed suture V-LocTM 3-0 (Medtronic VR, Minneapolis, MN, USA).
41391114|NCT05105360|PROCEDURE|Mesentery fixation method|Surgeons fixed the jejunal mesentery (jejunojejunostomy\[J-J\] distal 30 cm) to the transverse mesocolon using non-absorbable barbed suture VLocTM 3-0 sutures. The suture area was exposed by grasping the jejunum side mesentery (jejunal side, at site 30cm distal J-J) and the transverse mesocolon (colonic side). The jejunal side mesentery was fixed to the colonic side mesocolon between the jejunum and the transverse colon using nonabsorbable barbed V-LocTM 3-0 sutures.The suture started between jejunal mesentery just below of SMA vascular arcade and transverse mesocolon, and it finished when it reaches the root of the mesentery. To anchor the mesentery, continuous suturing with V-Loc two-point backward sutures were performed at the final step.
41391115|NCT00112515|DRUG|modafinil|
41512544|NCT03456388|DRUG|placebo enteric-coated tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
41512545|NCT06581965|OTHER|Short duration prophylaxis|"Only during hospitalization: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guideline Antitrombotisch beleid. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use (same type as used for control group)."
41512546|NCT06581965|OTHER|Higher intensity and longer duration prophylaxis|"The use of any thrombocyte aggregation inhibitors should be discontinued 5 days prior to surgery. Day 0-2: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.~Day 3: Apixaban 5mg b.i.d., continued until 6 weeks after surgery, conditional on the fact that no active bleeding of the surgical wound can be observed. In case of active bleeding, the prophylactic dose of thrombosis prophylaxis is continued. Thereafter, in case no active bleeding has been observed for 24 hours, the 5mg b.i.d. apixaban treatment will be started.~The 5mg b.i.d. apixaban dose will be adjusted to 2.5mg b.i.d. in case of an impaired kidney function (defined as eGFR 10-30ml/min)."
40860042|NCT02602522|DRUG|Shandong Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
40860043|NCT02602522|DRUG|Sichuan Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
41391116|NCT00112515|PROCEDURE|cognitive assessment|
41512547|NCT06581965|OTHER|Control|4 weeks: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.
41512548|NCT01320293|DRUG|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]|40mg subcutaneously, every other week for 6 months
41512549|NCT04905628|DEVICE|Dexcom CGM System|Dexcom CGM System
40860044|NCT01557088|OTHER|Blood sampling from the Coronary Sinus and Aorta|Blood samples will be obtained from the aorta and the coronary sinus during the clinically scheduled angiogram and endothelial function testing.
40860045|NCT01557088|PROCEDURE|Intravascular Ultrasound of the coronary artery.|Intravascular Ultrasound will be completed for those subjects testing positive for coronary endothelial dysfunction during a clinically scheduled angiogram and endothelial function testing.
41391117|NCT00112515|PROCEDURE|psychosocial assessment and care|
40860046|NCT05277558|OTHER|Observational|Investigators are observing brain health over time (21 months) in these groups
41391118|NCT00112515|PROCEDURE|quality-of-life assessment|
41391119|NCT01789008|OTHER|Determination of Advanced Fibrosis in Alcoholic Liver Disease|
41391120|NCT01305135|DRUG|azacitidine and idarubicin|azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
41391121|NCT04069104|BEHAVIORAL|ABCD Information|The intervention condition includes exposure to a message emphasizing the ABCD strategy to identify malignant melanoma.
41391122|NCT04069104|BEHAVIORAL|UDS information|The intervention condition includes exposure to a message emphasizing the UDS strategy to identify malignant melanoma.
41391123|NCT04069104|BEHAVIORAL|Standard (clinical) feedback|Feedback on mole identification task provided by a dermatologist.
40860047|NCT03319004|DEVICE|apply phase lag entropy sensor|apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
40860048|NCT00003967|DRUG|etoposide|
40860049|NCT00003967|DRUG|topotecan hydrochloride|
40860050|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with mild hepatic function
40860051|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with moderate hepatic function
41391124|NCT04069104|BEHAVIORAL|Motivational feedback|Feedback on mole identification task provided by a dermatologist plus exposure to a motivational fear appeal message designed to increase skin self exam intentions.
41391125|NCT02924337|DRUG|Placebo|
41391126|NCT02924337|DRUG|Imeglimin|
41391127|NCT02924337|DRUG|Moxifloxacin|
41417869|NCT04483583|DRUG|Ticagrelor 60mg|Patients will be administered a 180 mg loading dose followed by a 60 mg bid for the duration of the study.
41391128|NCT03271463|BEHAVIORAL|Selective Control Assessment of Lower Extremity (SCALE)|Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
41391129|NCT05212831|DEVICE|Inogen One® G4|Inogen One® G4 will be used for a minimum of 3h per day at Setting 3 during the intervention period.
41391130|NCT05188027|OTHER|Aerobic Exercise|Walking at 60% of maximal aerobic capacity on a treadmill
41391131|NCT05188027|OTHER|Resistance Exercise|Performing one set of 10 repetitions of 10 different weight-lifting exercises
41391132|NCT05188027|OTHER|No exercise|Participants will rest in a supine position for 30 minutes.
41391133|NCT04064437|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
41391134|NCT04064437|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.
41391135|NCT04064437|DIAGNOSTIC_TEST|Biochemical tests|The investigators perform blood and urine tests in every participant.
41391136|NCT04064437|DIAGNOSTIC_TEST|DXA scan|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.
41391137|NCT04064437|DIAGNOSTIC_TEST|AGE Reader|The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
41391138|NCT05402865|DRUG|Denosumab|Denosumab, subcutaneous injection, specific usage to see the medical records. Non-denosumab, specific usage to see the medical records.
41391139|NCT04831931|OTHER|Exercise Program Applied by Telerehabilitation|"Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups."
41391140|NCT02503566|DEVICE|Optical coherence tomography|Optical coherence tomography performed during regular coronary angiography
41391141|NCT00731510|DIETARY_SUPPLEMENT|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
41391142|NCT00731510|DIETARY_SUPPLEMENT|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
41391143|NCT00677586|PROCEDURE|simultaneous resection of liver metastasis and the rectal primary tumor|simultaneous resection of liver metastasis and the rectal primary tumor
41391144|NCT00677586|PROCEDURE|staged resection of liver metastasis and the rectal primary tumor|Patients received resection of the rectal tumor. 1 months later received resection of liver metastasis
41391145|NCT05270694|BEHAVIORAL|Public Health Intervention Package|"The intervention package consists of two components:~1. At the time of study enrollment, participants will attend an in-person training on how to properly take an at-home COVID-19 test. Study staff will verbally walk through the steps of the test with the participant while the participant administers the test on themselves, with the opportunity to ask questions and receive corrective feedback, as needed.~2. To make COVID-19 testing more accessible, participants will be provided five at-home COVID-19 testing kits at the training and then every other month throughout the course of the year-long study for a total of 35 kits."
41391146|NCT03649906|PROCEDURE|Optimized Localization Technique|The small pulmonary nodules of the subjects will be located using an optimized pre-loaded microcoil puncture locating method.
41391147|NCT01845701|DRUG|Artesunate-Amodiaquine|"Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.~Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.~The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®)."
41417870|NCT04483583|DRUG|Clopidogrel|Patients will be administered a 600 mg loading dose followed by a 75 mg daily for the duration of the study.
41417871|NCT02545946|DEVICE|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I\&D
41391148|NCT01845701|DRUG|Dihydroartemisinine-Piperaquine|It is a bisquinoline antimalarial drug (1,3-bis\[1-(7-chloro-4 quinolyl)-4- piperazinyl\]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
41512550|NCT01132833|OTHER|enzyme-linked immunosorbent assay|Measurement of markers of coagulation and endothelial activation
41039594|NCT06293157|PROCEDURE|Transpedicular spinal stabilization - carbon fibers-based implants|Transpedicular stabilization with carbon fiber and PEEK-based implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
41039595|NCT06293157|PROCEDURE|Transpedicular spinal stabilization - titanium implants|Transpedicular stabilization with titanium implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
41039596|NCT06293157|RADIATION|Stereotactic body radiotherapy|Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.
41391149|NCT01845701|DRUG|Artemether-lumefantrine combination|CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
41391150|NCT05181761|OTHER|Gel Polish|One hand of a subject with receive nail polish to compare bacterial growth between hands with gel nail polish to those without.
41391151|NCT04874116|BEHAVIORAL|Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging|Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
41391152|NCT04874116|BEHAVIORAL|Mobile text messaging|Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
41391153|NCT05895214|PROCEDURE|oncological relevance of the mesopancreas|Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
41391154|NCT00585039|DRUG|xopenex|will receive xopenex rather than albuterol to treat acute exacerbation
41417872|NCT02545946|OTHER|traditional I&D with or without packing|abscess will be drained with a traditional I\&D with or without packing (as deemed appropriate by ER doctor)
41512551|NCT01132833|OTHER|laboratory biomarker analysis|The PPP will be used for in vitro assays to measure TF activity, coagulation markers and markers of endothelial cell damage
41512552|NCT01132833|OTHER|medical chart review|The patient's clinical course with respect to development of venous thromboembolism and response to treatment will be monitored for a total of 3 months from enrollment.
41512553|NCT00490984|DEVICE|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
40860052|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with normal hepatic function
41512554|NCT00217555|DRUG|gemcitabine hydrochloride|
41512555|NCT00217555|DRUG|topotecan hydrochloride|
40860053|NCT05375721|PROCEDURE|ST36 acupoint injection|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
40860054|NCT02175979|DIETARY_SUPPLEMENT|enriched enteral nutrition|enriched enteral tube feeding perioperative
41512556|NCT05378555|DRUG|Ketamine Hydrochloride|All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis. Patients will receive 0.5 mg/kg ketamine Q8hrs for 48 hours.
40860055|NCT02175979|DIETARY_SUPPLEMENT|standard|standard of care
40860056|NCT04299035|PROCEDURE|Erector spinae plane block|Erector spinae plane block
40860057|NCT01389492|OTHER|frozen meat cutlets meal|250 g of meat cutlets
40860058|NCT01389492|OTHER|meat meals|250 g of meat meal for 4 days
41512557|NCT05475860|DEVICE|implantable cardiac electronic device recipients|implantable cardiac electronic device recipients for any clinical indication
41512558|NCT05002088|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of a failed surgical aortic valve bioprosthesis, Valve-in-Valve (ViV), in patients who were considered to be at increased risk for redo surgical aortic valve replacement
41512559|NCT04384094|DEVICE|Esthesiometer measurement|Measuring the corneal sensitivity using rebound technology.
41391155|NCT05610982|BEHAVIORAL|Yoga Program|The yoga program involves two weekly 60-minute group-based classes. Participants can attend in-person or online (via Zoom). In total, 24 classes will be offered across 12 weeks. The program structure has been developed and approved by certified yoga instructors (n=12) and adults diagnosed with gynecologic cancer (n=6). The classes will follow a flexible base class that the instructor can then adapt as they see fit to promote participants' comfort, safety, and engagement. The program will also include group discussions and journaling that participants may participate in, if they choose. Finally, participants will be encouraged to access an online database of pre-recorded short-duration yoga practices to support their at-home practice.
41391156|NCT04501549|PROCEDURE|percutaneous coronary intervention|PCI will be performed according to local practice.The bifurcation lesion will be imaged by OCT on at least two time-points for each patient. Plaque morphology will be characterized by OCT. Off-line quantitative coronary angiography (QCA) will be performed before and after PCI and the following QCA parameters will be computed: reference vessel diameter (RVD), lesion length and diameter stenosis (DS) of Main Vessel (MV) and side branch (SB). Blood samples will be taken prior to PCI and 8-12 hours later to determine peri-procedural myocardial injury and infarction following PCI by measuring serum Troponin.
41391157|NCT02458898|BEHAVIORAL|Educational Text Message Reminders|45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
41391158|NCT01416298|OTHER|Continuous Renal Replacement Therapy|The investigators will use the NGAL data daily to 1) drive initiation of CRRT in children with elevated NGAL and \> 10-20% fluid overload and 2) drive CRRT discontinuation in patients with decreasing NGAL concentrations. All members of the Critical Care Medicine and Nephrology divisions have agreed that initiation of CRRT within 24-48 hours of a patient reaching \>10% fluid overload is clinically acceptable, and that often the decision to start CRRT has been arbitrary in the past, based on physician bias or preference. All members agree that the current standard of 24-48 hours after \>10% is achieved is acceptable and now will be put into standard clinical practice.
41391159|NCT01345058|DRUG|lacosamide|"Lacosamide maximum of 200 mg/day, to be titrated as follows:~* Week 1: 50 mg twice a day~* Beginning Week 2: 100 mg twice a day."
41391160|NCT01345058|DRUG|levetiracetam|Low dose ≤1500 mg/day, High dose \>1500 mg/day
41039597|NCT05415813|OTHER|Ischemic Compression|It includes conventional Physical therapy, hot packs (75°C) for 20 minutes, and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold, and 10-second relaxation between two repetitions) as a baseline treatment. For the Ischemic compression, the patient will be in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position physiotherapist will apply gradually increasing pressure to the Trigger points until the subject perceived the first noticeable pain. At that moment, the pressure will be maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure will be increased until the discomfort appears again. This process will be maintained for 90 seconds.
41391161|NCT02624921|OTHER|There was no intervention.|Participants were transported one day to a urban setting, one day to a green space, one day to a beach. No intervention was done.
41391162|NCT04312399|PROCEDURE|blood take|Blood is taken to analyse degratdation products of the metabolism of amyloid
41391163|NCT03569566|OTHER|Age, Genes, Training, Tickbourne Disease and Endurance|Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
41391164|NCT01184378|DIETARY_SUPPLEMENT|dairy lipids and soluble milk proteins|one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
41391165|NCT05241626|DIAGNOSTIC_TEST|AS-OCT|Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness
41512560|NCT04333485|OTHER|Home-based Active Case Finding (HACF)|Existing healthcare workers at the participating NTEP TB units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer a standardized TB symptom screen questionnaire to treated TB cases and their household contacts (HHC). All those who screen positive will have a spot sputum taken at the home for microbiological testing at the TB unit.
41039598|NCT05415813|OTHER|Ischemic compression with Muscle Energy Technique|The Participants will receive all the treatments given to the active comparator group and they will also receive the Muscle Energy Technique treatment in supine position and the practitioner will stabilize the shoulder of the affected side with one hand, while the ear/mastoid area of the affected side will be held by the opposite hand. The head and neck were then bent towards the contralateral side, flexed, and ipsilaterally rotated. The subjects will then shrug the stabilized shoulder towards the ear at a sub-maximal pain-free effort (20% of the available strength). The isometric contraction will be held for 7-10s. This position will be maintained for 30 seconds and repeated three to five times per treatment session. Treatment sessions will be given on alternate days.
41039599|NCT01791218|PROCEDURE|CABG, AVR or CABG+AVR and PVI|
41039600|NCT01791218|PROCEDURE|CABG, AVR or CABG+AVR|
41039601|NCT01460329|DEVICE|Ultrasonic Cardiac Output Monitor (USCOM).|This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
40860059|NCT05175586|DIAGNOSTIC_TEST|First data analysis|A series of questions were asked to a number of patients with diagnoses related to primary idiopathic stiff shoulder and/or extrinsic stiff shoulder secondary to trauma or surgery. These patients are part of the physiotherapy clinic receiving the research. This questionnaire answers basic questions for the structure of the study such as age and sex, physical behaviour during the week, endurance, athletic disability, reason for attending the clinic, exploratory motor tests, etc. Subsequently, physiotherapeutic tests related to the pathology within the research were performed consisting of joint range, percentage of shoulder disability and pain scale.
41391166|NCT00310700|BIOLOGICAL|Meningococcal C conjugate vaccine|
41391167|NCT03899506|DRUG|Olanzapine|Patients receiving Olanzapine per the ED protocol
41391168|NCT03899506|DRUG|Midazolam|Patients receiving Midazolam per the ED protocol
40860060|NCT05175586|PROCEDURE|Second data analysis|Three treatment sessions of Percutaneous Neuromodulation (PNM) and Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 1) and three treatment sessions of Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 2) were performed at a rate of two sessions per month for three months. These therapies were compared with the clinical examination performed prior to each new session to verify changes in joint range, percentage of shoulder disability, strength and pain scale.
40860061|NCT05175586|OTHER|database|Age and sex were expressed as mean ± standard deviation (SD). The rest of the variables were expressed as mean, absolute and relative frequency. The chi-square test was used to analyse the differences between the examinations in terms of the time taken and the treatments used in the two groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
40860062|NCT04152915|DRUG|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 7 weeks
40860063|NCT00002359|BIOLOGICAL|HIV-1 Immunogen|
40860064|NCT00659932|BEHAVIORAL|Immediate Cognitive behavioural therapy (CBT)|The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
41039602|NCT05646953|OTHER|Facial Beauty Oil|"Mode of Usage Step 1- Wash face, pat dry Step 2 - Gently massage 2-3 drops of Vasu Facial Beauty Oil over the face and neck till it gets absorbed and keep it overnight.~Step 3 - Use it for 60 days Frequency - Daily before going to bed. Route of Administration - Topical"
41039603|NCT02388724|DRUG|Vonoprazan|Vonoprazan tablets
41039604|NCT02388724|DRUG|Lansoprazole|Lansoprazole capsules
41039605|NCT02388724|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
41167563|NCT02604706|DEVICE|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
41391169|NCT05229315|DRUG|Toripalimab|PD-1 Immune Checkpoint Inhibitor Combined With IMRT,used at 2 weeks before radiotherapy, once every 2 weeks, 10 cycles in total
40860065|NCT00659932|BEHAVIORAL|Delayed CBT|Commencement of the CBT Group Program is delayed 3 months
40860066|NCT02718209|DEVICE|Mid-Infrared Spectroscopy with ATR|
40860067|NCT05341726|BEHAVIORAL|BREATHE Intervention|BREATHE utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
40860068|NCT05341726|BEHAVIORAL|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
41391170|NCT05229315|PROCEDURE|Intensity modulated radiotherapy|Intensity modulated radiotherapy
41391171|NCT04559217|BIOLOGICAL|Radiopharmaceutical 68Ga-DOTATATE|Injection of 68Ga-DOTATATE followed by PET/CT acquisition
41391172|NCT03601806|OTHER|Laboratory Biomarker Analysis|Correlative studies
41039606|NCT02388724|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
41039607|NCT05709834|OTHER|Autogenic training|"Relaxation procedures will be performed in the following steps: First step - preparation: Each pre-eclamptic woman will be instructed about this method of treatment and its importance for reducing blood pressure to gain her confidence and cooperation during treatment. Second step - AT: The session began with a few minutes of mental relaxation as the patient will be asked to imagine herself in a lovely place that makes her relaxed. Each session include 18 exercises combining both relaxation and auto-suggestion (limb heaviness exercise, limb warmth exercise, cardiac exercise, respiration exercise, solar plexus warmth exercise, and forehead cooling exercise).~About 30 sec will be allowed for each exercise and a further 30-40 sec will allowed for continuing attention focusing by the patient. Third step - termination"
41391173|NCT03601806|DRUG|Pomalidomide|Given PO
41039608|NCT05709834|OTHER|Conventional treatment|Patients will receive conventional treatment
41039609|NCT03382496|OTHER|Non-Interventional|Non-Interventional
41039610|NCT06150027|OTHER|Systematic referral to a palliative care team|"Patients randomized in the experimental arm will be systematically referred to a palliative care team.~A follow-up in palliative care will be initiated for all within a maximum of 15 days after the date of randomization."
41391174|NCT05052320|DEVICE|Audiological assessment|TO assess audiological profile in recovered covid19 subjects
41391175|NCT00962182|DRUG|STAN1|3-4 capsules/day at meals
41391176|NCT00962182|DRUG|Placebo enzyme|3-4 capsules/day at meals
41391177|NCT00962182|DRUG|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
40860069|NCT02665182|BEHAVIORAL|Up-positioning of the testes|Patients in the experimental arm are asked to elevate their testes during the treatment.
40860070|NCT03924869|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT
40860071|NCT03924869|BIOLOGICAL|Pembrolizumab|IV infusion
40860072|NCT03924869|DRUG|Placebo|IV infusion
40860073|NCT04514822|DIAGNOSTIC_TEST|Dynamic PET|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.
40860074|NCT01354717|DRUG|Brand Carac|treatment of actinic keratosis
40860075|NCT01354717|DRUG|Generic 0.5% 5-fluorouracil cream|treatment of actinic keratosis
40860076|NCT01354717|OTHER|Placebo cream|treatment of actinic keratosis
40860077|NCT02152306|DRUG|Fimasartan and Amlodipine|
40860078|NCT02152306|DRUG|Fimasartan|
40860079|NCT02630472|DRUG|Quinine Sulfate|Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.
40860080|NCT02630472|DRUG|Placebo|In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
40860081|NCT03634163|BEHAVIORAL|Neighbourhood exchange|Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange
40860082|NCT03634163|BEHAVIORAL|Quality of Life Assessment|Completion of baseline measures
40860083|NCT05596227|DRUG|Propofol|Induction of anesthesia will be by IV propofol (2-2.5 mg/kg)
40860084|NCT05596227|DRUG|Fentanyl|Fentanyl will be injected during the induction of anesthesia (1-1.5 mg/kg)
40860085|NCT05596227|DRUG|Rocuronium|Rocuronium will be injected during induction of anesthesia (0.6 mg/ kg)
40860086|NCT05596227|DRUG|Sevoflurane|Sevoflurane inhalationa anesthesia will be used for maintainance of anesthesia
40860087|NCT05596227|OTHER|Erector spinae plane block|In the ESPB group, the probe will be placed in the parasagittal plane at the level of the L3 vertebrae. The spinous process will be visualized, and the probe will move 3 cm laterally from the midline. The erector spinae muscle will be visualized above the transverse process. The needle will be punctured in the craniocaudal direction using the in-plane technique. The needle will be directed superior to the transverse process . Then, 2 mL normal saline solution was injected into the deep fascia of the erector spinae muscle to confirm the proper injection site. After ensuring the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same ESPB procedure will be performed on the other side. In total, 40 mL of 0.25% bupivacaine was administered.
41167564|NCT02604706|DEVICE|LP acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. LP-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
41512561|NCT04333485|OTHER|Telephonic Active Case Finding (TACF)|Existing healthcare workers at the participating NTEP TB Units will administer a standardized TB symptom screen questionnaire to the index patient via telephone calls at 6 and 12 months post-treatment completion. The index patient will also be asked about any TB symptoms among household contacts (HHCs). If TB is suspected among any HH members, a home visit will be conducted and spot sputum specimens will be collected for microbiological testing at the TB unit.
40860088|NCT05596227|OTHER|Thoracolumbar interfascial plane block|In the mTLIP group, the probe will be placed vertically at the L3 vertebrae level. The spinous process and the interspinous muscles (i.e., multifidus, longissimus, and iliocostalis) will be visualized as the anatomic guide points. The probe will move laterally to identify the longissimus and iliocostalis muscles. The needle will be inserted between the longissimus and iliocostalis in the medial-to-lateral direction using the in-plane technique. After confirming the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same mTLIP procedure will be performed on the opposite side. In total, 40 mL of 0.25% bupivacaine will be administered.
40860089|NCT00895115|DIETARY_SUPPLEMENT|vitamin E|Given once daily
41167565|NCT02604706|BEHAVIORAL|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
40860090|NCT00895115|PROCEDURE|sham intervention|No supplementation
40860091|NCT04789876|OTHER|Phosphate mobile app|The phosphate mobile app has the features of i) matching phosphate binder with dietary phosphate intake, ii) educational videos of phosphate management, iii) food database with local food items, iv) record-keeping and goal setting.
40860092|NCT04789876|BEHAVIORAL|One-off dietary counselling with a phosphate booklet|One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study. Patients received a complimentary phosphate booklet after the counselling session. The phosphate booklet contains similar educational information as per the phosphate mobile app excluding the matching of phosphate binder with dietary phosphate information.
40860093|NCT03055520|OTHER|cognitive training|The Kumon method (www.kumon.com) of arithmetic calculation employs the errorless-learning (EL) strategy and consists of a structured, hierarchical series of exercises, beginning with simple ones (e.g. addition and subtraction) and then proceeding to more complex exercises (e.g. advanced algebra, calculus).
40860094|NCT03055520|OTHER|placebo|nonspecific recreation including befriending and free simple activities.
40860095|NCT03266406|DRUG|Hyaluronidase|4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine
40860096|NCT00719680|BIOLOGICAL|IgPro20|
40860097|NCT02473900|DRUG|HIP1403|Oseltamivir 75mg
40860098|NCT02473900|DRUG|HGP0919|Oseltamivir phosphate 75mg
40860099|NCT03871244|PROCEDURE|Less red blood cell transfusions|The instructions given to caregivers will be to consider prescribing a red blood cell transfusion only if the hemoglobin level is ≤ 70 g per L.
40860100|NCT03871244|PROCEDURE|More red blood cell transfusion (standard transfusion strategy in PICU)|The instructions given to caregivers will be to prescribe a red blood cell transfusion according to their usual standard practice
40860101|NCT02773485|RADIATION|High Dose Radiation|The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
40860102|NCT02773485|DRUG|Systemic chemotherapy|This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
40860103|NCT05135663|DRUG|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
40860104|NCT05135663|DRUG|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
40860105|NCT03549104|BEHAVIORAL|Fear Reduction Intervention|FREE
40860106|NCT03549104|BEHAVIORAL|Attention Control|DSMES
40860107|NCT04479332|PROCEDURE|Tracheal intubation and cardiopulmonary resuscitation|Critical patients at the emergency room who require tracheal intubation and/or cardiopulmonary resuscitation will be sequentially allocated to either the resuscitation area or negative pressure isolation room for treatment by the designated medical staff wearing personal protective equipment.
40860108|NCT02203994|DEVICE|"Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)"|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
40860109|NCT02779790|OTHER|Liquid Meal Replacements|An intervention that contains a mixture of protein, carbohydrate, and fat, along with added vitamins and minerals in liquid ready-to-drink or powder formulas that require mixing.
40860110|NCT02708810|DEVICE|Unframed Virtual Cone|A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
40860111|NCT02708810|RADIATION|80 Gy Radiation|
40860112|NCT03949608|OTHER|E-learning|"The intervention consists of the presentation and installation of an internet tool to educate the patient about his heart condition and about his medications in addition to usual care. The tool is an interactive web-hosting video called Mon Coeur, mon BASIC adaptable to smartphones and tablets. The total length of the video is around 15 minutes. The e-learning is interactive because of the possibility to click in the video to have more details about a particular point. The tool includes a part about the heart and particularly about the ACS (physiopathology, diagnosis, coronarography, angioplasty). A second part includes an education about the medications prescribed. The patient will select the medication being prescribed and receive information about it."
40860113|NCT03516422|PROCEDURE|ULTRASOUND DEBRIDEMENT|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
40860114|NCT03516422|OTHER|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
40860115|NCT01365364|BEHAVIORAL|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
40860116|NCT01365364|BEHAVIORAL|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
41391178|NCT05585268|OTHER|Medication reconciliation supplemented with MedSafer and deprescribing brochures|This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
41391179|NCT04085263|PROCEDURE|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
41391180|NCT04085263|PROCEDURE|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
41391181|NCT02268331|OTHER|Active Surveillance|
41391182|NCT02268331|OTHER|Passive Surveillance|
40860117|NCT05230758|DRUG|Metformin hydrochloride (HCl) 500mg tablet|"Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API) and are white, round, biconvex, film-coated tablets, with a score line on one face and debossed with HMR on the other. Each tablet contains the non-medicinal ingredients magnesium stearate and povidone. Tablet coating is comprised of hydroxypropyl methylcellulose, polyethylene glycol and titanium dioxide."
40860118|NCT05230758|DRUG|Placebo|Matching white round tablet containing excipients only. The placebo tablets will match the active drug as closely as possible in terms of appearance.
40860119|NCT06284655|BEHAVIORAL|group-based combined with innovative technology education|The intervention combines brief group-based psychoeducation, and digital video- and written information, to deliver an early self-management educational program. The intervention introduces a group-breaking approach, featuring a self-managed peer co-led educational group, in collaboration with user representatives from Vårres and the ADHD organisation. This patient-centred educational programme covers crucial topics such as self-help tools, treatment options and experiences, patients' rights, and self-management, in addition to treatment as usual.
40860120|NCT06284655|OTHER|Standard treatment|Treatment as usual.
40860121|NCT06049329|DRUG|NNC0487-0111|Participants will get one tablet to swallow at the same time of the day.
40860122|NCT06049329|DRUG|Placebo (NNC0487-0111)|Participants will get one tablet to swallow at the same time of the day.
40860123|NCT04655573|PROCEDURE|Breast Cancer Tumor Resection|Patients with ABC will be receiving a biopsy, and a PDMO from the patient's biopsies will be generated from it. It is a model correlating clinical response with PDMO sensitivity to the most common forms of chemotherapy used in advanced breast cancer care.
40860124|NCT02246426|OTHER|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
40860125|NCT02246426|OTHER|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
40860126|NCT02233972|DRUG|Midazolam|
40860127|NCT02233972|DRUG|Ginkgolides Meglumine Injection|
40860128|NCT02233972|DRUG|placebo|
40860129|NCT00394550|PROCEDURE|supraglottoplasty with laser|"Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children"
40860130|NCT00394550|PROCEDURE|supraglottoplasty with laser|laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
40860131|NCT01260597|BEHAVIORAL|IVR intervention|If individuals report having any smoking in the previous 30 days, the IVR will deliver questions to identify barriers to quit line re-enrollment and motivational messages to promote the re-enrollment
40860132|NCT01260597|BEHAVIORAL|IVR control|If individuals report any smoking in the last 30 days the IVR will thank them for their time and the call will end
40860133|NCT06147141|BEHAVIORAL|Online Peer Companion Intervention|Ordinary children would be paired with ASD children before the interventions. Dyads in the OPCI would have a total of 12 sessions within two months, each lasting 30-60 minutes. The longest interval between two sessions couldn't exceed two weeks. Researchers would recommend a series of companion themes for children to choose from (e.g., daily sharing and drawing). Ordinary children and ASD children need to discuss activities that are of mutual interest before each session. A researcher assistant would be online to ensure the normal development of the interventions and be responsible for video recording of the exchanges at the beginning of each session. Except for extreme circumstances, he or she would turn off the video and sound throughout the process and withdraw soon. During the interventions, parents would play a supporting role when children express needs without over-involvement.
40860134|NCT06147141|BEHAVIORAL|Wait-List|Dyads in the WLG would only participate in preliminary training and measurement during the implementation of the intervention. After completing the post-test, this study will implement the same online peer companionship intervention.
40860135|NCT01421953|DEVICE|CT-simulation and 4D PET-CT|Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
40860136|NCT04987502|OTHER|Virtual Reality|8 sessions of virtual reality with 3D audio and visual rendering
40860137|NCT04987502|BEHAVIORAL|Standard treatment|counselling, relaxation techniques, sound enrichment
40860138|NCT02458833|BEHAVIORAL|Home Plate|Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
40860139|NCT00870012|DRUG|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
40860140|NCT00870012|OTHER|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
41391183|NCT04971915|OTHER|minimalist footwear|The intervention consists of wearing the minimalist footwear in recommended progression during the interventional period (6months). The intial load starts at 2,500 steps a day and will be gradually increased up according to the participant´s tolerance rate to the footwear wearing to fully use over the final period. Participants are instructed to report all issues and difficulties possibly connected to the intervention. There will be the opportunity to consult any issue connected with footwear or their wearing through the duration of the research.
41391184|NCT02577900|DEVICE|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
41512562|NCT05952531|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image IIM lesions in skeletal muscle, heart, lung, skin and potential tumor by PET/CT.
41512563|NCT00468364|DRUG|insulin glargine|
41391185|NCT02577900|DEVICE|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
41391186|NCT02577900|DEVICE|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
41391187|NCT02793999|DEVICE|Near-Infrared Spectroscopy (NIRS)|
40860141|NCT01740024|BIOLOGICAL|1 (Dose Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
40860142|NCT00853151|DRUG|LY2428757|14 mg subcutaneous injection 1 time a week for 5 weeks
40860143|NCT00853151|DRUG|TT223|subcutaneous injection once a day for 4 weeks
40860144|NCT00853151|DRUG|Placebo for LY2428757|subcutaneous injection 1 time a week for 5 weeks
40860145|NCT00853151|DRUG|Placebo for TT223|subcutaneous injection once a day for 4 weeks
40860146|NCT02925624|PROCEDURE|Pulmonary vein isolation|
40860147|NCT03291717|BEHAVIORAL|Bridging Community Gaps Photovoice (BCGP)|Participants assigned to this group will be part of the 6-month long BCGP intervention, which involves a 12- week class that meets weekly, followed by three booster sessions - one per month in the three months following the class, and up to 24 sessions of individual support as needed throughout the 6 months provided on a weekly basis either in person or by phone. The BCGP classes follow a manualized curriculum with sessions that combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing community participation goals, all refined with input from individuals with a lived experience.
41512564|NCT00468364|DRUG|NPH insulin|
40860148|NCT01860313|BEHAVIORAL|Web-based interactive education|An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
40860149|NCT01860313|BEHAVIORAL|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
40860150|NCT04671264|DEVICE|Sallowing VC during six weeks|"follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0\~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl)."
40860151|NCT04229628|OTHER|No special intervention|No special intervention
40860152|NCT03833063|DRUG|botulinum toxin A|glabellar injections with botulinum toxin A
40860153|NCT03833063|DRUG|Placebos|glabellar injections with sodium chloride
41039611|NCT05777642|DIETARY_SUPPLEMENT|Oxygen Nanobubble|This contains oxygenated nanobubbles made from lecithin and natural flavourings (Liquorice, glycerol, and citric acid)
41039612|NCT05777642|DIETARY_SUPPLEMENT|Placebo|This does not contain nanobubbles and is made from natural flavourings (Liquorice, glycerol, and citric acid)
41039613|NCT01725828|DEVICE|Ultrasound|Using the Ultrasound to determine the location of the CTM.
40860154|NCT03401775|OTHER|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
40860155|NCT02906397|DRUG|Galunisertib 150mg by mouth twice a day|on days 1-14 of 28 day cycles
41039614|NCT01725828|OTHER|External Palpation|Using External Palpation to identify cricothyoid membrane
41039615|NCT04092374|PROCEDURE|Locking compression plates|Fixation of sternal fracture using locking compression mechanism
41039616|NCT03883633|BEHAVIORAL|ReCODE Protocol|Functional medicine approach to address symptoms of Alzheimer's and cognitive decline
41167566|NCT01395498|OTHER|laboratory testing of PCP and CMV genetic material|laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
41167567|NCT01081119|BEHAVIORAL|Project CHOICE|Voluntary after school program offered 1 day per week for 30 minutes
41167568|NCT01301703|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)|a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
41167569|NCT06034899|DRUG|BMS-986196|Specified dose on specified days
41512565|NCT02773602|DRUG|Dexamethasone|200 μgm/kg of dexamethasone in 1 ml saline
41512566|NCT02773602|DRUG|Clonidine|2 μg/kg of clonidine in 1 ml saline
41512567|NCT02773602|DRUG|Normal Saline|1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
41512568|NCT00860392|DRUG|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
41167570|NCT02828163|OTHER|Autologous Platelet rich plasma|Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.
41167571|NCT02828163|DRUG|Triamcinolone Acetonide|10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
41512569|NCT06306261|OTHER|questionnaire|UC patients will be subjected to a questionnaire each month about their habits.
41167572|NCT01860547|DIETARY_SUPPLEMENT|Bilberries|Frozen bilberries, 100 g/d
41391188|NCT06112405|OTHER|App-based CCAAP|App-based CCAAP, could remind patients take controller and reliever when asthma symptoms get worse through mobile.
40860156|NCT02906397|RADIATION|Stereotactic Body Radiotherapy (SBRT)|18GY delivered in one fraction between C1D15 and C1D28
40860157|NCT03550274|DEVICE|App-based exercise rehabilitation|"App-based exercise rehabilitation available on any mobile device and/or tablet using Android or iOS operating systems. The app Injurymap© is hosting the exercise program. The app requires user-registrations and a monthly paid subscription fee to access the exercise program. The participants in this study will not be charged for using the app.~The exercise program consists of three phases with increasing difficulty. Each phase consists of several categories of exercise types. The categories are 1) mobility, 2) stability/balance, 3) strength and 4) stretching. Within each phase, there can be more than one exercise for each category. This makes it possible to adjust the difficulty of the exercises depending on user-feedback."
40860158|NCT03798327|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
40860159|NCT06205238|OTHER|CGA|"CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up."
40860160|NCT00765180|DEVICE|TRE vs. NBI|TRE NBI
40860161|NCT03676244|DEVICE|immediate implant in defected anterior maxillary esthetic zone|"Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment."
40860162|NCT06312436|PROCEDURE|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Temporary aortic occlusion can limit haemorrhage, can help to maintain perfusion to the heart and brain, and may be associated with improved survival.
40860163|NCT04542954|OTHER|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East
40860164|NCT02147756|DEVICE|CO2RE|"Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation."
40860165|NCT02147756|DEVICE|Repair|
40860166|NCT04188093|OTHER|PACU discharge criteria and continuous monitoring on the ward|"* PACU discharge criteria (modified aldrete score).~* Continous monitoring of vital signs 96 postoperative hours"
40860167|NCT02859103|DRUG|Desvenlafaxine|Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
40860168|NCT03592368|DEVICE|IBT|Interpretation bias training
41167573|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn berry|Dried sea buckthorn berries, 20 g/d
41167574|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn phenolic extract|Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
40860169|NCT04175028|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
40860170|NCT05858892|OTHER|usual care|usual care(rehabilitation program)
40860171|NCT00913419|DRUG|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories|
40860172|NCT00913419|DRUG|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme|
41167575|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn oil|Sea buckthorn oil, 4 g (8 capsules)/d
41391189|NCT06112405|OTHER|Written CCAAP|Written CCAAP, conventional management for patients with asthma, remind them take controller and reliever when asthma symptoms get worse.
41391190|NCT00393835|DRUG|Azithromycin SR|
41391191|NCT04591600|DRUG|Ivermectin and Doxycyline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
41391192|NCT04591600|DRUG|Standard of care|"Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed"
41391193|NCT02956005|DRUG|ENVARSUS®|ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
40860173|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose|Intravitreally (IVT) injection.
40860174|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg|Intravitreally (IVT) injection.
41391194|NCT04473729|OTHER|Audiovisual speech training in noise for children|Children will participate in listening training in the form of an iPad app
41391195|NCT00893867|DRUG|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
41391196|NCT00893867|DRUG|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
41039617|NCT06470321|BEHAVIORAL|Flexiquit Computerized Smoking Cessation Program|Flexiquit is an avatar-led, self-directed computerized program delivering evidence-based techniques to assist with smoking cessation. It includes motivational interviewing, psychoeducation on nicotine addiction, cognitive-behavioral strategies for coping with cravings, relapse prevention, and stress/emotion regulation skills training. Participants receive the program over 6 months and their adherence is monitored. The program provides tailored feedback to support abstinence.
41167576|NCT06175221|BIOLOGICAL|Tumor lysate, particle only (TLPO) vaccine|A novel technology in which a patient's tumor lysate (TL) is loaded into microparticles for DC phagocytosis and antigen processing allows for vaccine efficacy, while minimizing tissue demands by only requiring approximately 250-500ug of tumor. Immature DCs avidly phagocytose small particles in the range of 1-5 microns. Tumor tissue collected from the patient undergoes a process of freeze-thaw cycling to create a TL suspension. The microparticles, yeast-cell wall particles (YCWP), are created from Saccharomyces cerevisiae by NaOH/HCl digestion of all non-cell wall components and washed, producing β-glycan shells. The TL is then loaded into these YCWP.
41039618|NCT03274843|OTHER|Activity of everyday life|Kitchen workshop
41039619|NCT01625897|DRUG|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
41039620|NCT01625897|DRUG|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
41039621|NCT02358603|DIAGNOSTIC_TEST|Chronotropic Incompetence Diagnostic Algorithm|
41167577|NCT06146413|DRUG|Double trigger|GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before ovum pick-up
41167578|NCT06146413|DRUG|HCG trigger|hCG ( 10000 IU) is administered 36 h before ovum pick-up
41167579|NCT02204319|DEVICE|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
40860175|NCT05850520|DRUG|Sham|Sham procedure will be given on visits when an active injection is not planned.
41039622|NCT04408573|OTHER|Cycling deep brain stimulation|Deep Brain Stimulation applied in cycling - periods of stimulation ON intercalated with periods of stimulation OFF
40860176|NCT05850520|DIAGNOSTIC_TEST|Fluorescein|Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
41039623|NCT04224077|DIAGNOSTIC_TEST|Optimisation of DTI sequences|Optimisation of DTI sequences in the study of lumbar roots by MRI
41167580|NCT02896101|DRUG|Pimecrolimus Cream, 1%|
41167581|NCT02896101|DRUG|Elidel® (pimecrolimus) Cream|
41167582|NCT02896101|DRUG|Placebo of Pimecrolimus Cream, 1%|
41167583|NCT01396200|DRUG|Hydroxychloroquine|Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
41167584|NCT01396200|DRUG|Rapamycin|Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
40860177|NCT03400475|DRUG|Simvastatin|One topical application in peri-implant gingival crevice
40860178|NCT03400475|OTHER|Placebo|One topical application in peri-implant gingival crevice
41391197|NCT06381596|DEVICE|OcuMet Beacon|OcuMet Beacon is a novel fundus camera the can detect, capture, and assess FPF.
40860179|NCT02110667|DEVICE|Transperineal Ultrasound|
40860180|NCT05184634|OTHER|PHYSICAL ACTIVITY LEVELS|Determination of physical activity levels of MetS individuals
40860181|NCT05184634|OTHER|DEPRESSION LEVELS|To determine the depression levels of MetS individuals
40860182|NCT05184634|OTHER|FATİGUE SEVERİTY|To determine the severity of fatigue of MetS individuals
41039624|NCT00673972|RADIATION|gastric scintigraphy|"All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window."
41039625|NCT01851148|OTHER|osteopathic manipulative treatment|It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
41039626|NCT01851148|OTHER|sham treatment|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence"
41167585|NCT01010997|DEVICE|Foresee Home|using the Foresee home device
41391198|NCT04741139|DRUG|Acetaminophen and Diphenhydramine Only Product|Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
41391199|NCT03759418|DEVICE|exclusion of the left atrial appendage|A trans esophageal echocardiogram will be performed to assess the Atriclip device in the closure of the left atrial appendage in patients that had surgery at least 12 months ago.
40860183|NCT05184634|OTHER|QUALITY OF LIFE|To determine the quality of life of MetS individuals
40860184|NCT02092792|DRUG|DLYE5953A|Escalating doses of DLYE5953A
40860185|NCT02092792|DRUG|DLYE5953A|Administration of DLYE5953A at the recommended phase II dose (RP2D)
40860186|NCT00921791|DEVICE|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
41167586|NCT02853305|BIOLOGICAL|Pembrolizumab|IV infusion
41167587|NCT02853305|DRUG|Cisplatin|IV infusion
41167588|NCT02853305|DRUG|Carboplatin|IV infusion
41167589|NCT02853305|DRUG|Gemcitabine|IV infusion
40860187|NCT00921791|DEVICE|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
40860188|NCT00921791|BEHAVIORAL|Pharmaceutical care|consultations with the pharmacists
40860189|NCT00921791|OTHER|Usual care|Consultation with the physician.
41039627|NCT01851148|DRUG|triptans|administration of triptans drug treatment according to international guidelines
41167590|NCT05621213|OTHER|Teleconsultation assisted by a physiotherapist or nurse|"A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions.~This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver."
41167591|NCT01530386|DRUG|Lacosamide|Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
41167592|NCT05090475|BEHAVIORAL|Academic detailing intervention|Academic detailing or educational outreach is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
40860190|NCT05218642|DRUG|KX- 826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
40860191|NCT05218642|DRUG|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
40860192|NCT05218642|DRUG|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
40860193|NCT05218642|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp twice daily or once daily for 24 weeks
40860194|NCT03078894|DIAGNOSTIC_TEST|Zika|Zika Diagnostic test
41167593|NCT03382288|DEVICE|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The experimental intervention is an optical, non-contact examination with the investigational device EYESTAR 900.
41167594|NCT06301971|DRUG|Emraclidine|Oral solution/suspension
41039628|NCT04361929|DEVICE|Ultrasound|The following ultrasound measurements will be assessed: DS-HB, HMDR, TT, TT-S, TW, EW, ET, DS-E, and DS-V.
41391200|NCT02123069|DEVICE|Brachial artery catheter|A catheter will be placed in the brachial artery by a physician on the study day.
41391201|NCT02123069|DRUG|Acetylcholine|Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
41039629|NCT05258825|DRUG|Monoferric|A single intravenous dose of 1000 mg of Monoferric will be administered to a patient 3-4 weeks before anticipated surgery.
41039630|NCT00778674|DRUG|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
41039631|NCT01556373|OTHER|NA : non interventional study|NA : non interventional study
41391202|NCT02123069|DRUG|Nitroprusside|Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
41391203|NCT02123069|DRUG|Norepinephrine|Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
41391204|NCT02123069|DRUG|Nitroprusside and phenylephrine|A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
41391205|NCT01990898|DRUG|Cyclosporine|Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
41391206|NCT00800722|DRUG|Rapamycin Treatment of Port Wine Stain|Treatment of Port Wine Stain
41391207|NCT04172779|DRUG|Erlotinib Hydrochloride|Oral administration of erlotinib 25mg tablet
41391208|NCT00646100|PROCEDURE|transcatheter arterial chemoembolization|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
41391209|NCT02650609|DRUG|Methylprednisolone|
41391210|NCT02650609|DRUG|Placebo|
41391211|NCT06537596|DRUG|89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)|Single administration of 89Zr-TLX300-CDx
40860195|NCT03078894|DIAGNOSTIC_TEST|Chikagunya|Chikagunya Diagnostic test
40860196|NCT03078894|DIAGNOSTIC_TEST|Dengue|Dengue Diagnostic test
40860197|NCT03487744|OTHER|Osmolite 1.5|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
40860198|NCT03487744|OTHER|Promote without fiber|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
40860199|NCT05490940|DRUG|Tisseel®|"The investigational medical product (IMP) in this study is Tisseel®, which is a tissue sealer consisting of two components:~1. Sealer protein: Human fibrinogen as glue component and synthetic Aprotinin, which delays fibrinolysis.~2. Human thrombin: Thrombin is an unique molecule that functions both as a procoagulant and anticoagulant. It activates platelets through its receptor on the platelets and regulates its own. generation by activating coagulation factors V, VIII and even XI resulting in a burst of thrombin formation.~Its indications are a better hemostasis, enforcement of vessel/gastrointestinal sutures and tissue sutures (mesh grafts, flaps etc)."
40860200|NCT03583853|DEVICE|real time PCR|real time PCR will be used for determination of expression of autophagy genes
40860201|NCT04519463|DRUG|Xylocaine Mucosal Product|Xylocaine 10% Nasal Spray
40860202|NCT04519463|DRUG|Placebo|Sodium Chloride 0.9%
40860203|NCT04099121|DEVICE|Ultrasound Imaging|3D ultrasound of the pelvic floor and vaginal cavity will be obtained by using a commercial ultrasound system.
41167595|NCT04028947|PROCEDURE|Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty|Prophylactic infrapatellar saphenous nerve neurectomy will be performed at the same time as the TKA.
41167596|NCT02752217|OTHER|Inspiratory Muscle Training|Inspiratory muscle training at 25%MIP with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
41039632|NCT03438162|BEHAVIORAL|Education|Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
41167597|NCT02752217|OTHER|Control|Inspiratory muscle training at 2 cmH2O with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
41039633|NCT02978027|BEHAVIORAL|Brief Advice|
41039634|NCT02978027|BEHAVIORAL|NIAAA Clinician's Guide|
41167598|NCT03384836|OTHER|Laboratory Biomarker Analysis|Correlative studies
41167599|NCT03384836|BIOLOGICAL|Pembrolizumab|Given IV
41391212|NCT05062031|DEVICE|Defocus Incorporated Multiple Segments® (DIMS®) lenses|Daily wear for 24 months. Lenses have a central monofocal optical zone correcting spherical or spherocylindrical ametropia, surrounded by a ring made up of 300 defocusing pellets. This lens geometry reduces the phenomenon of blurred image projected in the retinal periphery, encountered when myopic eyes are corrected with monofocal lenses.
40860204|NCT06502782|DIAGNOSTIC_TEST|digital assesment|Gingival recession sites were scanned with an intraoral optical surface scanner, and STL images were recorded. The images were imported into image analysis software. The depth, width and area of gingival recession were calculated using Autocat program.
41039635|NCT02978027|BEHAVIORAL|Motivational Interviewing (MI)|
41039636|NCT02638038|DRUG|INT131|INT- 131
41167600|NCT03384836|DRUG|Propranolol Hydrochloride|Given PO
41167601|NCT01262118|DRUG|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
41167602|NCT04830878|DRUG|Methotrexate|Systemic and intraoperative intravitreal injection of methotrexate
41167603|NCT00163007|PROCEDURE|Nutritional support|
41167604|NCT01585818|OTHER|Low Glycemic Index (LGI) intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
41167605|NCT01585818|OTHER|Standard Diet Intervention|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
41167606|NCT05432505|OTHER|ligamentum teres tenodesis|Identification of ligamentum teres ligamentum teres tenodesis
41391213|NCT05062031|DRUG|Atropine 0.05% eyedrops|One drop each evening in both eyes for 24 months.
41391214|NCT05062031|DEVICE|Monofocal lenses|Daily wear for 24 months
41391215|NCT05446480|DRUG|Desloratadine|Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.
41391216|NCT05446480|DRUG|Placebo|Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.
41391217|NCT05446480|OTHER|No Intervention|No pill ingestion during the trial - to discern the presence of a placebo effect from baseline inflammatory response
41391218|NCT02252484|OTHER|Weight Loss Program|Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
41391219|NCT02252484|OTHER|Standard of Care|Standard of Care for this patient population.
41039637|NCT04768400|DRUG|Arm I (MEP)|Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
41039638|NCT04139070|DRUG|Bleomycin|Electroporation in combination with systemically administered bleomycin
41391220|NCT05602974|RADIATION|stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy
40860205|NCT01154777|BEHAVIORAL|Neurofeedback training|60 sessions of Neurofeedback on 6-18 year olds with Autism
40860206|NCT01943812|DRUG|Estradiol and progeterone|Estradiol and progesterone
40860207|NCT01959841|DRUG|ASP2151|200 mg once daily or 400 mg once daily
40860208|NCT01959841|DRUG|valaciclovir|1000 mg three times daily
40860209|NCT03271502|PROCEDURE|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
41039639|NCT01734304|BIOLOGICAL|DC vaccination for postremission therapy in AML|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
41039640|NCT00398008|DRUG|Buprenorphine/Subutex|Opioid agonist medication to treat opiate dependence
41039641|NCT00398008|DRUG|Naltrexone|Opioid antagonist medication to treat opiate dependence
41039642|NCT00398008|BEHAVIORAL|Drug counseling|DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
41391221|NCT05602974|OTHER|regular follow-up|regular follow-up
41391222|NCT03159988|DRUG|Angiotensin-(1-7)|Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
41391223|NCT03159988|BEHAVIORAL|Memory Training|50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
41417873|NCT02388178|DRUG|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
40860210|NCT03271502|PROCEDURE|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
40860211|NCT04139850|DRUG|Discontinuation of antiviral treatment in chronic hepatitis B cohort patients|For the selective patients in the cohort with long-term antiviral therapy and with conditions such as HBeAg negative or loss more than one year, antiviral therapy is able to be discontinued with an intensive inspection who agreed to the process. If there are need of this intervention, another multicenter IRB approval will be taken.
40860212|NCT04366661|DIAGNOSTIC_TEST|low dose CT|Invited participants from institutes exposed to a high level of smoke pollution such as employees of Transport and Oil Ministries are inquired for their personal history of cigarette smoking then subjected to low dose CT
40860213|NCT02984917|PROCEDURE|Anterior transversalis fascia approach|Patients will undergo inguinal hernia repair via the anterior transversalis fascia approach.
40860214|NCT02984917|PROCEDURE|Preperitoneal space approach|Patients will undergo inguinal hernia repair via the preperitoneal space approach.
40860215|NCT05314335|OTHER|Reflexology socks+walking|Patients should wear reflexology socks; Wearing clothes and walking 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday)
40860216|NCT05314335|OTHER|Just walking|Patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks.
41417874|NCT02388178|DRUG|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
41417875|NCT02388178|DRUG|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
40860217|NCT04981652|DIETARY_SUPPLEMENT|Whole Milk|Participants will consume twice daily whole milk beverages in addition to a standardized diet.
40860218|NCT04981652|DIETARY_SUPPLEMENT|Skim Milk|Participants will consume twice daily skim milk beverages in addition to a standardized diet.
40860219|NCT04981652|DIETARY_SUPPLEMENT|Almond Beverage|Participants will consume twice daily almond beverages in addition to a standardized diet.
40860220|NCT00771966|PROCEDURE|Standard therapy|Standard therapy
40860221|NCT00771966|PROCEDURE|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
41039643|NCT00101855|PROCEDURE|An evidence based tailored web site|
41039644|NCT00064727|DRUG|Avandia (Rosiglitazone)|
40860222|NCT03292068|COMBINATION_PRODUCT|Acupuncture, acupressure|"Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care."
41039645|NCT00064727|DRUG|Avanclia (Rosiqlitazone)|
41039646|NCT02813850|DEVICE|oxygen therapy|Oxygen therapy early in the night (2L/min) during 4hours per days
41039647|NCT02730494|DEVICE|Lcr Regenerans® vaginal capsules|
41039648|NCT02730494|DEVICE|Lcr Regenerans® vaginal tablet|
41039649|NCT03044301|COMBINATION_PRODUCT|Intramuscular ZENEO® injection|Sodium Chloride (0.9 %)
41039650|NCT03044301|COMBINATION_PRODUCT|Subcutaneous high ZENEO® injection|Sodium Chloride (0.9 %)
41039651|NCT03044301|COMBINATION_PRODUCT|Subcutaneous low ZENEO® injection|Sodium Chloride (0.9 %)
41417876|NCT00913107|DRUG|Lamictal®|"The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days."
41417877|NCT00913107|DRUG|Tegretol®|"The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days."
41417878|NCT01368003|DRUG|STA9090|200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
41417879|NCT01368003|DRUG|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
41417880|NCT02576509|DRUG|Nivolumab|Specified Dose on Specified Days
41417881|NCT02576509|DRUG|Sorafenib|Specified Dose on Specified Days
41417882|NCT01106963|PROCEDURE|Tibial intramedullary nailing|Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
41417883|NCT03827109|BEHAVIORAL|Group educational activities|Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.
41417884|NCT03827109|BEHAVIORAL|IBD educational website|Website with age-appropriate educational information, including information from the group educational activities.
41417885|NCT03827109|BEHAVIORAL|Monthly check-in calls from program coordinator|Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). During the COVID-19 pandemic, virtual activities are encouraged. For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.
41391224|NCT04717232|OTHER|Blended learning approach to mentoring education for dental health care professionals|The participants in the intervention group are dentists´ and dental hygienists´. The mentoring education for dental health care professionals (3 ECTS credits) will be organized by the program leader in Dentistry at the place-blinded. The aim of the mentoring education is to build understanding of how to support a student's professional development (both basic education and specialization) and transfer skills that are relevant to working as an independent expert in oral health care.
40860223|NCT03292068|DIETARY_SUPPLEMENT|Timbal diet|Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
40860224|NCT03292068|OTHER|Extended telephone counseling|Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
40860225|NCT00970918|PROCEDURE|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
40860226|NCT00970918|BIOLOGICAL|Blood sample testing for hs-CRP|one time, blood sample taking
40860227|NCT02630511|DRUG|Mannitol|Mannitol consists of inhaling 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg mannitol, resulting in a maximum cumulative dose of 635 mg
40860228|NCT02630511|DRUG|Methacholine|Methacholine consists of inhaling 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL
40860229|NCT02630511|DRUG|Placebo|Placebo consists of inhaling humidified air
40860230|NCT02630511|OTHER|Rest|
40860231|NCT02630511|OTHER|Exercise|
40860232|NCT01354925|DRUG|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
40860233|NCT01354925|DRUG|Standard of care|Standard of care during Ramadan according to physicians decision
40860234|NCT02532465|DEVICE|Air-Q|
40860235|NCT02532465|DEVICE|i-gel|
40860236|NCT03020706|DRUG|Magnesium Sulfate, Injectable|magnesium sulphate intravenous administration during general anesthesia
41039652|NCT03948568|COMBINATION_PRODUCT|Endocrine Therapy and Radiotherapy|Endocrine therapy and radiotherapy administered either concurrently or sequentially
41039653|NCT03421054|DIETARY_SUPPLEMENT|patients assuming nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
41039654|NCT01816594|DRUG|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
41039655|NCT01816594|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
40860237|NCT02657889|DRUG|niraparib|
40860238|NCT02657889|BIOLOGICAL|pembrolizumab|
40860239|NCT05657873|RADIATION|L-SABR|L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.
40860240|NCT05657873|BIOLOGICAL|Anti-PD-(L)1 based immunotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
40860241|NCT05657873|DRUG|Platinum based chemotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
40860242|NCT06019078|DEVICE|SedLine|Continuous 4 channel processed neurological monitor
41391225|NCT04717232|OTHER|The interprofessional online mentoring education|The participants in the intervention group are dentists´ and dental hygienists´. The interprofessional online mentoring education (3 ECTS credits) will be organized in collaboration with the Finnish Dental Association in an online environment. The aim of the intervention is to in-crease mentors' competence in guidance processes and interactions, supporting students´ goal-oriented learning and professional evaluation, and providing constructive feedback.
41391226|NCT04259801|DRUG|NNC0480-0389|Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.
40860243|NCT05078372|DRUG|ropivacaine and midazolam intraarticular administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure, and intraarticular administration of those drugs.
40860244|NCT05078372|DRUG|ropivacaine and midazolam epidural administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure
40860245|NCT05980585|DEVICE|CPM Device|Daily use of the CPM wearable device
40860246|NCT01883544|DRUG|ALXN1007|
40860247|NCT01568840|OTHER|Global Postural Reeducation Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.
40860248|NCT01568840|OTHER|Segmental Exercises Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
40860249|NCT06298136|BEHAVIORAL|mindfulness-based intervention|Audio exercises as homework assignment will be included. Four instructor-led online real time sessions are provided
40860250|NCT06298136|BEHAVIORAL|child behavior management|worksheet will be provided to guide parents and children in behavior change. Four instructor-led online real time sessions are provided.
40860251|NCT03605446|DIETARY_SUPPLEMENT|Biscuit acceptance|Acceptance of high protein biscuits
40860252|NCT01756196|DRUG|Spinal Steroid Injection|Steroid Injection
41039656|NCT01816594|DRUG|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
41039657|NCT01816594|DRUG|BKM120 Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
41391227|NCT04259801|DRUG|Semaglutide|Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
41039658|NCT05787639|DRUG|Evorpacept|After stereotactic radiation to primary tumor and neck on week 1 of study, Evorpacept 45 mg/kg is administered by IV infusion every three weeks starting on Week 2, Day 1 of study for a total two 21-day cycles (6 weeks)
41039659|NCT03491644|DRUG|Titrated Oxygen|Restrictive treatment with oxygen.
41039660|NCT03491644|DRUG|Liberal Oxygen|Liberal treatment with oxygen.
41039661|NCT01183676|DRUG|DEPAKOTE® Tablets, 500 MG|1 x 500 mg Tablet, under fed conditions
41039662|NCT01183676|DRUG|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 x 500 mg Tablet, under fed conditions
41039663|NCT05420103|OTHER|Accelerated Stroke Ambulation Program|Stroke Rehabilitation Program
41039664|NCT04302857|OTHER|routine MRI|MRI with routine DTI sequence
41039665|NCT06382350|DEVICE|MiniMed 780 G|none, observational study
41039666|NCT00514735|PROCEDURE|Medtronic Cardiac Ablation System|Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.
41039667|NCT00514735|DRUG|Class I or III Antiarrhythmic Medications|Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
41039668|NCT04039399|PROCEDURE|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive one session of the intervention (45 minutes total).
41391228|NCT04259801|DRUG|Placebo (NNC0480-0389)|Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.
41391229|NCT04259801|DRUG|Placebo (semaglutide)|Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
41391230|NCT03976245|DRUG|Etanercept|injection
41391231|NCT03976245|DRUG|tofacitinib|tablet
40860253|NCT03967054|DRUG|Ivermectin|Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.
40860254|NCT03967054|DRUG|Placebo oral tablet|placebo in the same size, color and shape at the ivermectin tablet
40860255|NCT04207749|DEVICE|LID015385 contact lenses|Investigational soft contact lenses
40860256|NCT04207749|DEVICE|Comfilcon A contact lenses|Commercially available soft contact lenses
40860257|NCT04207749|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
40860258|NCT02682147|DRUG|Hypoxia administration study group|scan completed after 5 minutes of breathing in hypoxic air
40860259|NCT02682147|DRUG|Hyperoxia administration study group|scan completed after up to 15 minutes of breathing in hyperoxic air
40860260|NCT02682147|DRUG|Sildenafil|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
40860261|NCT01729299|DRUG|Exendin (9-39)|
40860262|NCT01729299|DRUG|acyl ghrelin|
40860263|NCT01729299|DRUG|saline|
40860264|NCT04197180|PROCEDURE|Hybrid Argon Plasma Coagulation|Argon Plasma Coagulation after water injection for local ablation
40860265|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
40860266|NCT01525615|DRUG|tiotropium+olodaterol (low dose)|2.5 µg tiotropium + 5 µg olodaterol
40860267|NCT01525615|DRUG|tiotropium + olodaterol (high dose)|5 µg tiotropium + 5 µg olodaterol
40860268|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
40860269|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
40860270|NCT01525615|DRUG|placebo to tiotropium+olodaterol|comparator
40860271|NCT04267835|PROCEDURE|MIDCAB|Surgery: MIDCAB
40860272|NCT04267835|PROCEDURE|thoracotomy OPCABG|Surgery: thoracotomy OPCABG
41039669|NCT04039399|PROCEDURE|Sham Ischemic Conditioning|There will also be an IC Sham group which is identical to the IC intervention, except the cuff is only inflated to 10 mmHg, which is a high enough pressure to perceive cuff tightness but not high enough to have any physiological effects.
41039670|NCT00674986|DEVICE|Accu-Chek 360° View Blood Glucose Analysis Tool|
41039671|NCT00674986|DEVICE|Accu-Chek Aviva Glucose Meter|
41039672|NCT03346876|PROCEDURE|Nuss surgery|surgical correction for pectus excacatum
41391232|NCT05048771|OTHER|Questionnaire|Patients will be surveyed through self-administered questionnaires and semidirected interviews with a psychologist
41391233|NCT00406107|DRUG|pegaptanib sodium (Macugen)|Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
41391234|NCT05052827|DIETARY_SUPPLEMENT|Milk Protein Concentrate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 363 Carbs (g): 5.60 Protein (g): 82.60 Fat (g): 1.12 Total BCAA (g): 15.67 Total EAA (g): 34.66 Total AA (g): 83.27"
41391235|NCT05052827|DIETARY_SUPPLEMENT|Rice Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 394 Carbs (g): 6.50 Protein (g): 86.70 Fat (g): 2.39 Total BCAA (g): 14.98 Total EAA (g): 30.62 Total AA (g): 86.11"
41391236|NCT05052827|DIETARY_SUPPLEMENT|Soy Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 377 Carbs (g): 2.12 Protein (g): 88.8 Fat (g): 0.60 Total BCAA (g): 13.88 Total EAA (g): 31.74 Total AA (g): 89.39"
40860273|NCT05113446|DIAGNOSTIC_TEST|Delirium assessment using S-CAM|Twice a day, the rounds of nurses in shifts, 8:00 am - 10:00 am, 4:00 pm - 6:00 pm Trained research assistants assessed delirium using S-CAM
40860274|NCT00988949|DRUG|PF-04455242|Single oral 18 mg dose of PF-04455242.
40860275|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
40860276|NCT00988949|OTHER|Placebo|Oral placebo.
41167607|NCT04700475|DEVICE|low level laser|"Laser will be performed with a GaAlAs diode laser at a wavelength of 808 nm, 100-mW output power, laser beam area of 0.03 cm2, and in continuous wave mode, three times a week, on alternate days. Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions.~The total energy per session (56 J) will be divided into 14 irradiation points, as marked on the overlying skin (Fig.2). Each irradiation point received a dose of 4 J over an irradiation time of 40 s.~With exclusion of tumor area or area of removed tumor laser will be applied as following:~• Extra oral application: The laser will be used extraorally at eight points in the parotid glands (bilaterally, four points in each gland), at four points in the submandibular glands (bilaterally, two points in each gland~• Intraoral application: The will be used intraorally at two points in the sublingual glands bilaterally, one point in each gland ."
40860277|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
40860278|NCT00988949|DRUG|PF-04455242|Single 30 mg oral dose of PF-04455242.
40860279|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
40860280|NCT06536608|OTHER|Massage|"The Oketani Method is based upon practical breastfeeding theory, but is original in its practice. Oketani breast massage improves breastmilk secretion, can prevent and treat problems such as mastitis. In addition, the massage is painless, allowing your body to relax and breathe, something very much appreciated by mothers.~The Oketani breast massage consists of massaging and milking the base of the breasts. These delicate glands are massaged as well as protected."
40860281|NCT03407755|PROCEDURE|Intraocular gas|Participants randomized to either air or SF6 gas in the anterior chamber.
41039673|NCT06372769|DIAGNOSTIC_TEST|electromyograph and kinesiograph|"The sEMG of the anterior temporalis (TA), masseter (MM), sternocleidomastoid (cervical group, CG), and digastric (DA) were recorded simultaneously with an sEMG device (K7/EMG, USA) using disposable silver/silver chloride bipolar surface electrodes.~First, sEMG was conducted on four pairs of muscles (TA, MM, CG, and DA) in the MPP, and subjects were guided to maintain the face and jaw as relaxed as possible. To determine the relative efficiency of muscle function, the second test was performed to measure the sEMG of TA and MM during the maximal biting force against natural dentition. In the third test, subjects were guided to clench three times to monitor early motor unit recruitment as they closed from rest through freeway space to initial tooth contact.~Kinesiographic recordings were performed using a kinesiograph (K7/Computerized Mandibular Scanning (CMS), USA) that measured the maximum mouth opening (MMO) and opening and closing velocities."
41167608|NCT04700475|DRUG|citric acid solution|citric acid solution applied as a mouth rinse
41167609|NCT00848393|DRUG|Fentanyl (High Dose)|Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
41391237|NCT04408300|PROCEDURE|Ophthalmological exam|Retinophotography, OCT-A (Optical Coherence Tomography- Angiography), OCT-B scan (Optical Coherence Tomography B Scan), Measurement of corrected visual acuity in ETDRS (Early Treatment Diabetic Retinopathy Study), Measurement of intraocular pressure, adaptive optics
40860282|NCT03523767|BIOLOGICAL|S.typhi Injection|0.5 ml of S.typhi injection
41528443|NCT04411810|DEVICE|Nevisense 3.0|Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in the US. Nevisense 3.0 will be used as a one-time exposure of \<8 seconds per lesion. Disposable electrodes that contact the participant are 5mm x 5mm in size. Nevisense 3.0 measures electrical impedance of skin lesions and provides an output called the electrical impedence spectroscopy (EIS) score. Electrical impedance is a measure of a material's overall resistance to the flow of alternating electric currents of various frequencies. The principle is that electrical impedance is different in normal versus abnormal tissue.
40860283|NCT03523767|BIOLOGICAL|Normal Saline Injection|0.5 ml of normal saline injection
40860284|NCT01979952|DRUG|Matching Placebo|twice daily dosing
40860285|NCT01979952|DRUG|Nintedanib|gelating capsule
41167610|NCT00848393|DRUG|Fentanyl (Low Dose)|Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
40860286|NCT02644343|DEVICE|Custom Sound|Custom Sound is the programming software used to program Nucleus cochlear implants.
40860287|NCT04295239|PROCEDURE|MRI|Pre and Post operative MRI
41391238|NCT06202807|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
41512570|NCT04648787|BEHAVIORAL|family-integrated care|One week after admission, the parents of premature infants were informed by telephone one day in advance to enter the ward for family participation nursing, and the guidance of daily life nursing for premature infants was given on the same day, including hand hygiene, breast feeding, pacification, changing diapers, bathing and establishment of parent-child relationship. Before discharge, theparents of premature infants should be informed by telephone one day in advance to enter the ward again for family participation nursing, and half a day's guidance was given, including observation and treatment of common symptoms and signs, guidance of home safety prevention and learning to write diary of premature infants.
41512571|NCT04648787|BEHAVIORAL|traditional nursing|In hospital education: the health education manual for premature infants will be issued at the time of discharge; the patient's condition will be answered by telephone from 14:00 to 16:00 every day.
41512572|NCT04708054|DRUG|Busulfan|Given IV
40860288|NCT03686293|OTHER|Standardized breakfast|One tablet of paracetamol (500 mg) and a glass of water (150 mL) is consumed followed by a breakfast consisting of white bread, butter, jam, and juice (300 mL) and
41512573|NCT04708054|DRUG|Cladribine|Given IV
40860289|NCT02468726|DEVICE|NER1008 enema|NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
40860290|NCT02468726|DRUG|Fleet|Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
40860291|NCT06319534|BEHAVIORAL|Comprehensive rehabilitation|All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
40860292|NCT06319534|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40860293|NCT06319534|DRUG|Lidocaine Hydrochloride|the patients are provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
40860294|NCT06319534|BEHAVIORAL|placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
41039674|NCT04305925|DEVICE|Focal Laser Ablation|Orion system to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy. MRI guidance will be achieved by MRI/ultrasound fusion, overlaying stored MRI images upon real-time ultrasound images. Interstitial laser treatments would be achieved by inserting the fiber into the cancerous regions guided by the Artemis image-fusion device. Applications of laser energy up to 15 watts of power will be used to treat the target region.
41167611|NCT00848393|DRUG|Fentanyl (Low Dose) + Dexmedetomidine|Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
41167612|NCT03084198|PROCEDURE|hiHep Bioartificial Liver Support System|Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
41167613|NCT03084198|PROCEDURE|Standard care for ALF|A standard of care for subjects with acute liver failure.
41167614|NCT05771025|PROCEDURE|Hepatectomy|Patients in the hepatectomy group receive liver resection.
41167615|NCT03523325|OTHER|Exercise treatment|Treatment protocol is an exercise program consisting of four different phases (Silbernagel protocol). The progression consists of increasing number of repetitions, resistance, speed and range of motion of the exercises. A pain-monitoring model is used to adjust the exercise loads and progression through the four phases.
41512574|NCT04708054|DRUG|Fludarabine Phosphate|Given IV
41512575|NCT04708054|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell transplantation
41512576|NCT04708054|DRUG|Thiotepa|Given IV
41512577|NCT04708054|DRUG|Venetoclax|Given PO
41167616|NCT04112277|DRUG|Cumulative morphine consumption|morphine equivalent \[mg\] 24 hours after the procedure
41391239|NCT06202807|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
41391240|NCT06202807|BEHAVIORAL|comprehensive rehabilitation therapy|"Including：~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
41391241|NCT02300818|DEVICE|Pulsed Electromagnetic Field Therapy|Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
41391242|NCT02300818|DRUG|Seawater eyedrops|Eye-drops daily 1 time a day for 12 weeks
41391243|NCT04193033|OTHER|FLOW intervention|The FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
41391244|NCT02368119|BIOLOGICAL|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)
41391245|NCT02368119|BIOLOGICAL|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)
41512578|NCT06272721|DIAGNOSTIC_TEST|Griffiths Scale|The Griffiths Mental Development Scales II are key tools for assessing children's psychomotor development from ages 0 to 6, praised for their strong psychometric properties. They evaluate various functional areas through six subscales, combining parental reports and direct observations of the child's behavior. The areas include locomotion, personal-social interaction, learning and language, eye-hand coordination, and performance, excluding the optional practical reasoning section for older children in this study. The Development Quotient (DQ), calculated by comparing mental and chronological ages, indicates developmental progress or delay, with an average score around 100 ± 15.
41512579|NCT02657005|DRUG|TK216|Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
41512580|NCT04535687|DRUG|Fluzoparib|Fluzoparib
40860295|NCT04031859|DRUG|acetylsalicylic acid|It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
40860296|NCT00043511|BIOLOGICAL|pGA2/JS2 Plasmid DNA Vaccine|
40860297|NCT02186665|DRUG|calcitriol ointment|
41039675|NCT03991611|OTHER|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
41391246|NCT02368119|BIOLOGICAL|MVA-EbolaZ|IM injection of MVA-EbolaZ vaccine
41391247|NCT02368119|OTHER|Placebo|IM injection injection of Phosphate Buffered Saline
41512581|NCT01515917|DRUG|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
41512582|NCT01515917|DRUG|Omega-3|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.
41512583|NCT01515917|OTHER|Rice bran oil|Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.
41512584|NCT01515917|OTHER|Microcrystalline Cellulose|Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
40860298|NCT02186665|DRUG|placebo comparator|
41512585|NCT05406921|BEHAVIORAL|MIND at Home|Maximizing Independence at Home-MIND at Home (MIND) is a comprehensive care coordination program born from geriatric psychiatry. This model takes an interdisciplinary, collaborative care approach to care by systematically assessing and addressing a wide range of dementia-care related needs of both PLWD and their care partners that place both at increased risk for poor outcomes.
41512586|NCT02064296|DEVICE|Needle acupuncture (Traditional Acupuncture)|This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device (AS Super 4 digital needle stimulator).
41512587|NCT02064296|DEVICE|Laser acupuncture (Non-traditional Acupuncture)|For non-traditional acupuncture, a laser acupuncture device (Vita Laser 650, Lhasa OMS) will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
41512588|NCT05729490|RADIATION|Coronary computed tomography angiography|"All patients will be subjected to:~Two CT scans (coronary calcium scoring and angiography) using 128 or 160-row scanners with a slice thickness of 0.5 mm (Revolution Evo 128, GE Health care, Chicago, Illinois, USA) or (Aquilion 160, Canon Medical Systems, Tochigi, Japan). Calcium scoring will be performed with the use of prospective electrocardiographic gating with 400-ms gantry rotation, 120-kV tube voltage, and 300-mA tube current. For CTA, retrospective electrocardiographic gating will be used, with heart rate adjusted gantry rotations of 350 ms to 500 ms to enable adaptive multisegmented reconstruction.~Iopromide (Ultravist 370, Bayer AG, Berlin, Germany) is the intravenous contrast medium that will be used for CTA. Beta-blockers will be given if the resting heart rate is 70 beats/min."
41391248|NCT03690986|BIOLOGICAL|VX15/2503|Given IV
41391249|NCT03690986|BIOLOGICAL|Ipilimumab|Given IV
41391250|NCT03690986|BIOLOGICAL|Nivolumab|Given IV
41391251|NCT02397174|OTHER|mediterranean diet, restricted calorie|50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months
41391252|NCT02397174|OTHER|hypocaloric diet, restricted calorie|50 pcos women will be assigned to standardized hypocaloric diet for 6 months
41391253|NCT01506063|DRUG|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
41391254|NCT03888092|DRUG|Z650|receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
41512589|NCT02565940|OTHER|biopsy|
41512590|NCT04420845|BEHAVIORAL|Diabetes Self-Management and Support (DSMES) and Sleep Hygiene Education and Support (SHES)|SHES outlines the importance of sleep for people with type 2 diabetes mellitus and provide practical information and guidance about sleep habits. Specifically, the focus will be on: avoiding consumption of caffeine, nicotine, alcohol; avoiding use of light emitting devices before bedtime; avoiding excessive intake of fluids or heavy meals before bedtime; promoting regulation of light, noise, and temperature in the bedroom; timing of and importance of exercise; maintaining consistent sleep and wake times; establishing a pre-bedtime routine; and managing stress.
41039676|NCT03991611|OTHER|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
41391255|NCT00666731|OTHER|medical chart review|Demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history.
41391256|NCT00666731|OTHER|questionnaire administration|Collection of personal information, medical history, diet and lifestyle habits, any past or current environmental exposures and to re-create a family tree for any cancers that have occurred in any family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, year of birth, age of death) will be recorded.
41512591|NCT01169792|DRUG|tamoxifen|
41039677|NCT03991611|OTHER|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
41391257|NCT00666731|OTHER|study of socioeconomic and demographic variables|Repository
41391258|NCT00666731|PROCEDURE|Excess human biological tissue|Tissue procurement.
41512592|NCT02824055|DRUG|Placebo|Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
41512593|NCT02824055|DRUG|RO5545965|Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
41512594|NCT03583476|DRUG|Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole|Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
41391259|NCT00666731|PROCEDURE|quality-of-life assessment|Cancer care.
41391260|NCT04363294|DIAGNOSTIC_TEST|PYP scan|99mTc-labeled pyrophosphate
41391261|NCT06271135|BEHAVIORAL|CAPILLARY REPAIR SERUM 30ml|Cosmetic procedures were performed on a group of patients after a cosmetic interview containing questions about contraindications to the procedure. The treatment was performed 3-times at 2-week intervals and consisted of cavitation peeling and sonophore-sis with an antioxidant preparation dedicated to vascular skin. The F-808 Skin Scrubber device was used for the treatment. After a month, the procedure was repeated. The stages of a cosmetologist's procedure during a cosmetic intervention were as follows: 1. make-up removal; 2. skin diagnostics, exclusion of contraindications, discussion of the procedure; 3. cavitation peeling - gentle skin cleansing using ultrasound; 4. applying an antioxidant cosmetic mixture (composition: rutin, horse chestnut and arnica extract, acerola, vitamin C, moisturizing complex of algae); 5. performing sonophoresis treatment; 6. applying the cream at the end; 7. discussion of indications for further care.
41391262|NCT00116207|DRUG|ORAL ANTIOXIDANT|Comparison of triple antioxidant combination therapy vs placebo.
41391263|NCT00842894|DRUG|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
41391264|NCT00842894|DRUG|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
41391265|NCT02543086|DRUG|KAE609|Study drug
41391266|NCT02543086|DRUG|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
41391267|NCT00166374|PROCEDURE|balloon kyphoplasty|
41391268|NCT05481554|BIOLOGICAL|Stool sample|Only 1 stool sample will be collected during the patient hospitalisation scheduled within standard care.
41391269|NCT03783845|COMBINATION_PRODUCT|amoxicillin 500mg and metronidazole 400mg|metronidazole 400mg and amoxicillin 500mg three times daily for two weeks
41391270|NCT03554642|DEVICE|Walkbot|Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.
41391271|NCT03554642|BEHAVIORAL|Physical Therapy|30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
41391272|NCT04691739|OTHER|occupational therapy|occupational therapy sessions include a set of standardized test exercises plus additional modalities that are optimized to each patient's needs according to the clinical judgement of the treating therapist
41391273|NCT06382220|DRUG|Bupivacain|drug injection
41391274|NCT06236074|OTHER|Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours|Observation Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours
41391275|NCT06236074|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
41391276|NCT03416153|DRUG|Carboplatin|AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.
41391277|NCT03416153|RADIATION|Radiation Therapy|Patients will initially receive a single prescription of 70 Gy to PTV1 in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). Dose will be reduced to 54Gy to high risk PTV and 43.2Gy to low risk PTV all in 27 fractions for patients who meet pPET-CT and iPET-CT parameters.
41512595|NCT03655730|OTHER|weekly psychotherapeutic individual sessions|weekly psychotherapeutic individual sessions following the IPT method during one year
41512596|NCT03655730|OTHER|Usual care|the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
40860299|NCT01587144|DRUG|Lucanthone|Lucanthone will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
41391278|NCT03416153|DRUG|Paclitaxel|30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.
41391279|NCT01909817|PROCEDURE|Routine coronary angiogram|
41391280|NCT01005680|DRUG|Pemetrexed|500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
41391281|NCT01005680|DRUG|Gemcitabine|1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
41391282|NCT01005680|DRUG|Cisplatin|75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
41391283|NCT01839227|OTHER|Neurologic and neuropsychologic tests|"Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.~Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.~Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.~There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery."
41391284|NCT06515717|DIETARY_SUPPLEMENT|ketone ester|oral supplement
41391285|NCT06515717|DIETARY_SUPPLEMENT|dextrose (placebo)|oral supplement calorie and taste matched to ketone supplement
41391286|NCT01155635|DRUG|Carvedilol|Use of Carvedilol with any dose
41039678|NCT03991611|OTHER|6 months follow-up to assess the prevalence of PTSD symptoms|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 items during the telephone follow-up, 6 months after ICU discharge .
41512597|NCT03748446|DRUG|Xenon|The investigators have chosen to use as a maximum concentration about half the general anesthetic partial pressure of xenon (35%=70%/2) to achieve a dose that is sub-anesthetic. This concentration of xenon is very close to that at which subjects emerging from xenon anesthesia first respond to verbal commands, commonly referred to as MAC awake.
41512598|NCT03748446|DRUG|Nitrogen gas|nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual
41167617|NCT00397020|DRUG|divalproex ER|Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
41167618|NCT00397020|DRUG|quetiapine|Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
41167619|NCT04853407|DRUG|LY03005 extended-release tablet|orally once a day
41167620|NCT04853407|DRUG|Placebo|orally once a day
41167621|NCT02972242|RADIATION|Field of View|Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography
41167622|NCT03384147|DIETARY_SUPPLEMENT|Drinking|Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks
41167623|NCT03384147|OTHER|Abstaining|Participants are abstaining from all alcoholic beverages for three weeks
41167624|NCT01281917|DRUG|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
41167625|NCT01281917|DRUG|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
41167626|NCT04376112|OTHER|Pharmacist and pillpack intervention|These participants will be randomized into one of the following two cohorts: standard of care (SOC) and pharmacy intervention group (blister packaging + MTM services). For pharmacy intervention (PI) group, the POCT will be used to measure HbA1c and blood pressure (BP) at baseline, 3, and 6 months during medication therapy management (MTM) service. Recommendation from MTM services will be documented in the patients' electronic medical records (EMRs) and shared with their primary care providers. For the SOC group, HbA1c and BP will be measured at the physician's office and researchers will have an access to participants' EMR.
41167627|NCT04376112|OTHER|Standard of care|None. Regular visits to primary care physician. Will measure HbA1c and blood pressure at baseline, 3, and 6 months
41167628|NCT05390996|OTHER|dental implant placement|dental implant placement by using a different drilling techniques
41167629|NCT02652390|DRUG|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
41167630|NCT02652390|DRUG|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
41167631|NCT02652390|OTHER|Saline|2 mL saline + 1 mL lidocaine
41167632|NCT05042362|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
41167633|NCT05042362|DRUG|Placebo|Matching placebo orally once daily
41167634|NCT04830761|BEHAVIORAL|Motivation|The key constructs targeted by the motivational module are attitudes towards the target behavior, risk perception, outcome expectancies and self-efficacy. The intervention includes the following techniques: information about health consequences, salience of consequences, goal setting (behavior), problem solving, verbal persuasion about capabilities, focus on past success (Michie et al., 2013)
40860300|NCT01587144|DRUG|Temozolomide (TMZ)|"TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the common terminology criteria (CTC) nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
40860301|NCT01587144|RADIATION|Radiation|60 Gy administered in 30 fractions for 42 days in the concomitant phase.
41039679|NCT03991611|OTHER|1 year follow-up to assess psychiatric morbidity|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 and CTQ items during the telephone follow-up, 1 year after ICU discharge .
41039680|NCT05568992|DEVICE|AI system of optical detection of advanced adenomas|AI system of optical detection of advanced adenomas
41167635|NCT04830761|BEHAVIORAL|Habit|The goal of the habit module is to guide participants to perform correct hand hygiene at self-selected key times repeatedly. The aim is that the behavior will be translated into a habit. The intervention includes the following techniques: Information about antecedents, self-monitoring of behavior, action planning, prompts/cues, habit formation, behavioral practice/ rehearsal, prompts/cues (physical cue) (Michie et al., 2013).
41167636|NCT04830761|BEHAVIORAL|Social|The key constructs targeted by the social module are perceived norms including descriptive norms and injunctive norm. The intervention includes the following techniques: Monitoring of behavior by others, social incentive, social comparison, social reward, restructuring the physical environment, information about others approval, credible source, information about health consequences, feedback on behavior (Michie et al., 2013).
41167637|NCT01249677|DRUG|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
41167638|NCT04472988|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|"The first session will be assigned to the assessment and the exploration of the personal history and for presenting the method to the client. Then, each case will be conceptualized according to the Model of Two Method Approach and the protocol for the treatment will be used. The procedure will be organized around targeting the most ten disturbing memories which happened before the illness debut, including stressful or traumatic memories from childhood. The rationale behind this approach is that adverse events leave traces in the neural network of an individual in such a way that these cause a variety of emotional or cognitive symptoms. If we consider the illness as being also a symptom of a traumatic past, then we expect that by accessing the dysfunctionally stored memory and stimulating the innate processing system, the symptoms of the illness diminish."
41167639|NCT04472988|OTHER|Placebo|The participants randomised in this group will receive a protocol focused only on present and future (present symptoms, daily problems, future projects). The psychologist will lead the discussion anywhere except for the past.
41167640|NCT04472988|DRUG|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
41167641|NCT04036253|BIOLOGICAL|Erythropoietin alfa|Prefilled syringes of erythropoietin
41167642|NCT01606891|BEHAVIORAL|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
41391287|NCT01155635|DRUG|No Carvedilol|No use of Carvedilol
41391288|NCT03880929|OTHER|no intervention|no intervention
40860302|NCT01587144|DRUG|Placebo|Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
40860303|NCT01041313|DRUG|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
40860304|NCT01041313|DRUG|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
40860305|NCT03068702|DEVICE|Optical Coherence Tomography Angiography|
40860306|NCT00935311|DRUG|ABT-712 Extended-release|ABT-712 extended-release tablet
40860307|NCT00935311|DRUG|Hydrocodone/Acetaminophen Immediate-release|Hydrocodone/acetaminophen immediate-release tablet
40860308|NCT00935311|DRUG|Placebo|Placebo tablet
40860309|NCT04102995|DRUG|Sepranolone injection low dose|Subcutaneous (SC) administration
40860310|NCT04102995|DRUG|Sepranolone injection high dose|Subcutaneous (SC) administration
41512599|NCT05575882|OTHER|Skin hydration|Skin hydration outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
40860311|NCT04102995|DRUG|Placebo injection|Subcutaneous (SC) administration
40860312|NCT00529425|DRUG|Ropivacaine|
40860313|NCT06025981|OTHER|Preliminary Phase|In the preliminary phase, the characterization of the functionality of the SWalker robotic system, as well as the functionality of the Virtual Reality system, will be carried out. All descriptive usability questionnaires completed by the participants and electro-biomechanical parameters will be collected using the robot's measurement systems to analyze the functionality.
40860314|NCT06025981|OTHER|Phase I - Early gait rehabilitation|In the first phase, the participants will carry out the rehabilitation program for hip fracture in acute phase that will last 6 weeks. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the usual rehabilitation guidelines that integrate exercises aimed at improving strength, gait, functional mobility and balance. In the case of the experimental group, a robotic walker will be used to practice walking.
40860315|NCT06025981|OTHER|Phase II - Maintenance gait function ( with VR)|In the second phase, participants will carry out a 6-week program to consolidate walking function. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the use of the robotic system for gait exercise. In the case of the experimental group, the use of virtual reality will also be integrated.
41039681|NCT03913585|BEHAVIORAL|Lifestyle intervention|Upon inclusion and consent all patients receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is systematically registered and collated with existing Electronic Patient Record (EPR) data and the patients risk of developing a lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All patients receive digital feedback including a personal health profile and targeted advice. Patients at high risk of lifestyle-related disease(s) are offered targeted prevention activities at the GP including a health examination and if needed a health dialog. Patients with health risk behavior are offered behavior counselling in the municipality and community health services, if necessary. Patients diagnosed with a lifestyle related disease and patients with a healthy lifestyle are not offered any further services.
40860316|NCT03484247|OTHER|Infraclavicular brachial plexus block|Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
40860317|NCT03484247|OTHER|axillary brachial plexus block|Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
40860318|NCT03282929|DEVICE|Part 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order
40860319|NCT03282929|DEVICE|Part 2 Group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
40860320|NCT03282929|DRUG|Part 2 group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
40860321|NCT03282929|DEVICE|Part 2 group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
40860322|NCT03282929|DEVICE|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
40860323|NCT06324292|PROCEDURE|complete denture, CG|fabrication of conventional complete denture followed by a digital denture
40860324|NCT06324292|PROCEDURE|complete denture, DG|fabrication of digital complete denture followed by a conventional one
40860325|NCT04220944|DRUG|Sintilimab|Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.
40860326|NCT04220944|PROCEDURE|Microwave Ablation|The ablation area should covered at least two thirds the size of the nodules.
40860327|NCT04220944|PROCEDURE|TACE|Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.
40860328|NCT00994006|DIETARY_SUPPLEMENT|Magnesium oxide|520 mg of elemental magnesium q.d.
41039682|NCT05564234|PROCEDURE|laparoscopy then primary cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score , if less than 8 primary cytoreductive surgery were done.
40860329|NCT00994006|DIETARY_SUPPLEMENT|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
40860330|NCT02583919|DRUG|ISIS-GCGRRx- Dose Level 1|once weekly dosing for 26 weeks
40860331|NCT02583919|DRUG|ISIS-GCGRRx- Dose Level 2|once weekly dosing for 26 weeks
40860332|NCT02583919|DRUG|Placebo|once weekly dosing for 26 weeks
40860333|NCT00764062|DRUG|Amoxicillin|Amoxicillin :drug
40860334|NCT01073449|PROCEDURE|In-hospital follow-up of cardiac device|Electrical measures taken during normal follow-up and clinical status of the patient
40860335|NCT03257124|DRUG|AZD9291|AZD9291 160mg per oral daily (1 cycle of 28 days)
40860336|NCT06310421|DIAGNOSTIC_TEST|Screening SMA test|Drops of blood from a puncture from the newborn's heel are collected, dried for 24 hours at room temperature and then sent to the laboratory for analysis. The screening test is a first-level molecular genetic test that allows the identification of patients affected by SMA who present the homozygous deletion of exon 7 of the SMN1 gene using the Real Time polymerase chain reaction (PCR) technique. This qualitative method is based on the use of specific fluorescent probes that discriminate the SMN1 gene from its survival motor neuron 2 (SMN2) homologue and also allow the quality assessment of genomic DNA through amplification of an internal control gene. When a positive testing patient is identified, the birth center is promptly notified to call the family and carry out a further blood sample aimed at confirming the possible diagnosis with a second level test.
40860337|NCT00301418|DRUG|Erlotinib|Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
40860338|NCT02002741|DRUG|Paracetamol|Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
40860339|NCT02002741|DRUG|Placebo|Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
40860340|NCT04117529|OTHER|Blood sample|Collection of 2 blood sample : The first one at the inclusion in the study, the second one between 6 months and 9 months after the inclusion. The sample consists of 2 tubes of EthyleneDiamineTetraAcetic (EDTA) of 7 mL.
40860341|NCT01578681|PROCEDURE|Low Expiration Open glottis inferolateral (ELTGOL)|Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
40860342|NCT01578681|PROCEDURE|Stretching|Patient will be instructed to do muscle stretching of the thorax
40860343|NCT00022802|DEVICE|Image-guided surgical system|
40860344|NCT02348996|OTHER|Bioimpedance|status of overhydration determine by BCM once a week to determine dry weight
40860345|NCT02348996|OTHER|Clinical evaluation|Doctors or nurses will evaluate patients on a daily basis and determine dry weight
40860346|NCT00721448|DRUG|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
40860347|NCT00721448|DRUG|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
40860348|NCT03003962|DRUG|Durvalumab (MEDI4736)|Anti-PD-L1 monoclonal Antibody monotherapy
40860349|NCT03003962|DRUG|Paclitaxel + carboplatin|Chemotherapy Agents
40860350|NCT03003962|DRUG|Gemcitabine + cisplatin|Chemotherapy Agents
40860351|NCT03003962|DRUG|Gemcitabine + carboplatin|Chemotherapy Agents
41039683|NCT05564234|PROCEDURE|laparoscopy then neoadjuvant chemotherapy followed by interval cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score and provides the histological diagnosis , if score more than 8 the patient were received neoadjuvant chemotherapy followed by interval cytoreductive surgery
41039684|NCT05775614|DEVICE|UroTainer®|Clinical effect of preventive treatment - catheter flushing with UroTainer®
41039685|NCT05775614|DEVICE|Saline|Clinical effect of preventive treatment - catheter flushing with saline solution
40860352|NCT03003962|DRUG|Pemetrexed + cisplatin|Chemotherapy Agent
40860353|NCT03003962|DRUG|Pemetrexed + carboplatin|Chemotherapy Agent
40860354|NCT01817439|DRUG|Amiodarone|patients will be randomly assigned to oral OR IV Amiodarone
40860355|NCT03418636|BEHAVIORAL|Staying Safe (Ssafe)|Staying Safe motivates and teaches young people who inject drugs (PWID) planning skills and drug use management strategies to enable long-term risk avoidance and the implementation of healthy protective behaviors. Content is presented through guided discussions and role playing exercises, and relies heavily on interactive participation by group members to foster peer-based learning and social reinforcement processes.
40860356|NCT03418636|BEHAVIORAL|Healthy Living|The content of the Healthy Living intervention is based on the DHHS' Eat Healthy, Be Active Community Workshop curriculum, supplemented with basic sleep hygiene education. Science-based dietary and light physical activity guidelines are demonstrated and promoted to help participants develop and maintain a healthy lifestyle.
40860357|NCT04951583|COMBINATION_PRODUCT|FMT + ICI|"This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules."
40860358|NCT06233006|OTHER|Assessment|upper extremity functions (hand skills, hand and finger grip strength, reaction time, position sense, upper extremity strength and endurance) and health-related quality of life
41039686|NCT01535716|BEHAVIORAL|hemodynamic optimization strategy driven by the ECOM|"goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) \& cardiac index (CI).~goals:~* SVV \< 11%~* IC \> 2,2 ml/min/m²~During the anesthesia"
41039687|NCT01535716|BEHAVIORAL|standard management strategy|"goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index~* Diuresis \> 0,5ml/kg/h~* Blood pressure , PAM \> 65 mmHg~* Pulse pressure variation~* CVP 8 to 12 cmH20~* Visual aspect of the heart~* Overload signs During the anesthesia"
41512600|NCT05575882|OTHER|Barrier function measurement|TEWL measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
40860359|NCT06393114|OTHER|Fermented oat-based product|Participants will incorporate a novel fermented product into their habitual diet for three weeks. In addition, the consumption of dairy and plant-based dairy alternatives is restricted. Cereal product consumption, specifically bread and porridge, is slightly restricted to prevent gastrointestinal symptoms caused by the increased intake of dietary fibre. Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
41039688|NCT04026776|DRUG|Allopurinol|Study Part 2- Preterm group only: After Visit 5 preterm born participants will start allopurinol 200 mg daily PO for 6 weeks. The 1 week high and low salt diets and assessments will be repeated while on allopurinol.
41039689|NCT04026776|OTHER|Dietary Intervention|High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.
41039690|NCT05411887|DRUG|Rosuvastatin, Olmesartan Medoxomil|Olostar Tablet
41039691|NCT06311695|DEVICE|Contrast Enhanced Mammography|Contrast Enhanced Mammography
41039692|NCT01327326|DRUG|Naltrexone|Oral, 50 mg, 1 Time Dose
41039693|NCT01327326|DRUG|Placebo|Oral, 1 Time Dose
41039694|NCT04618185|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI to study gut function and transit without the risk of exposure to ionising radiation.
41039695|NCT01271322|RADIATION|neoadjuvant radiochemotherapy in metabolic non responders|Metabolic non-responders, with a SUV decrease of less than 35%, discontinue induction chemotherapy and proceed to an intensified radiochemotherapy treatment
41039696|NCT05550142|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose|50μg/dose
41039697|NCT05550142|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose|100μg/dose
41039698|NCT05550142|DRUG|Placebo|Saline solution
41039699|NCT00762320|DRUG|Low dose Kaletra tablets|Lopinavir/Ritonavir tablets 100mg/25mg
41039700|NCT00957476|DIETARY_SUPPLEMENT|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
41039701|NCT03939052|DIETARY_SUPPLEMENT|Free amino acids intake|Oral consumption of eight hourly experimental meals- -4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil -4 isotopically labeled experimental meals. The same protocol will be repeated with glycomacropeptide (GMP).
41167643|NCT00709540|BIOLOGICAL|ACE-011 or placebo|multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)
41167644|NCT05906901|OTHER|Cranial listening technique|5 minutes
41167645|NCT05906901|OTHER|Suboccipital muscles inhibition technique|6 minutes
41167646|NCT00121446|DRUG|tenecteplase|
41167647|NCT00121446|DRUG|enoxaparin|
41167648|NCT00121446|DRUG|clopidogrel|
41039702|NCT01507870|PROCEDURE|onlay mesh placement|prophylactic onlay mesh in patients with median laparotomy
41039703|NCT04537962|OTHER|Colgate Periogard® mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Periogard® mouthwash
41039704|NCT04537962|OTHER|Colgate Peroxyl® mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Peroxyl® mouthwash
41039705|NCT04537962|OTHER|Colgate Total® Mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Total® Mouthwash
41039706|NCT04537962|OTHER|Toothpaste with sodium monofluorophosphate|Patients will be submitted to brushing with toothpaste with sodium monofluorophosphate
41039707|NCT04537962|OTHER|Toothpaste with sodium fluoride and zinc|Patients will be submitted to brushing with toothpaste with sodium fluoride and zinc
41039708|NCT04537962|OTHER|Toothpaste with tin fluoride|Patients will be submitted to brushing with toothpaste with tin fluoride
41167649|NCT00121446|PROCEDURE|percutaneous coronary intervention|
41167650|NCT00369603|DRUG|Razadyne ER|4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
41167651|NCT00369603|DRUG|Aricept|8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
41167652|NCT00054678|DRUG|MyoCell™|
41167653|NCT00054678|DEVICE|MyoCath™|
41167654|NCT00075283|DEVICE|Lokomat (Robotic Orthosis) combined with slat belt treadmill|
41512601|NCT05575882|OTHER|Potential of hydrogen measurement (pH)|pH measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
41512602|NCT05575882|OTHER|Clinical evaluation of atopic dermatitis|EASI score on each visit. Non invasive technique.
41512603|NCT05575882|OTHER|Quality of life assessment|Cardiff questionnaires to assess quality of life of subjects and their family members.
41512604|NCT05575882|OTHER|Assessment of the effect on itching and sleep disturbances|Visual analogue scale from 0 to 10
41512605|NCT05575882|OTHER|Assessment of the tolerance of the study product or placebo|By collection of Adverse Events (AEs) on daily log and electronic Case Report Form (eCRF).
40860360|NCT06393114|OTHER|Unfermented oat-based product|Participants will incorporate a novel unfermented product into their habitual diet for three weeks. Dietary adjustments and other guidance are consistent with those described during the fermented product intervention.
41512606|NCT05314803|BEHAVIORAL|Yoga|Participants receive the yoga program, which is delivered by a trained yoga instructor (completed at least a 200-hour yoga teacher training, Yoga Thrive Teacher Training Certification (or similar), and/or practical experience working with individuals affected by cancer). The first class of the week is comprised of 45 minutes of gentle, progressive, hatha-based yoga sequencing and postures with the last 15 minutes focused on guided behaviour change and mindfulness techniques that varies week-to-week, based on the participants in the class. The second class of the week is 60 minutes of gentle, yin-based yoga sequencing and postures with an element of opening and relaxing.
41039709|NCT04764396|COMBINATION_PRODUCT|Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)|The fine needle biopsy (FNB) needle will be flushed with 1 mL of heparin (100 USP/mL) and then flushed with air. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed with 1 mL of heparin (100 USP/mL) and flushed with air before next pass is made.
40860361|NCT00087334|DRUG|capecitabine|
40860362|NCT00087334|DRUG|gefitinib|
41039710|NCT04764396|DRUG|Saline|FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
41167655|NCT05965960|DEVICE|TUS Active|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 30 W/cm2 Isppa
41167656|NCT05965960|DEVICE|TUS Sham|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 0 W/cm2 Isppa
41167657|NCT00004097|DRUG|fluorouracil|
41167658|NCT00004097|DRUG|gemcitabine hydrochloride|
41167659|NCT00004097|DRUG|paclitaxel|
41167660|NCT00004097|RADIATION|radiation therapy|
41167661|NCT02869945|GENETIC|Identification of COMT HH, COMT HL or COMT LL genes|COMT HH, COMT HL or COMT LL genes identification
41167662|NCT02869945|OTHER|Brain MRI with resting state scan|MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.
41167663|NCT02869945|OTHER|Brain MPET|Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
41167664|NCT03299413|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected intravenously
41167665|NCT04531878|DRUG|4-Phenylbutyrate|4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB). In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
41167666|NCT04582513|OTHER|AnCHor-Checklist implementation|a standardized checklist using the SBAR concept according to the recommendations of the DGAI
41167667|NCT02633397|DRUG|Riociguat|Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
41167668|NCT02633397|DRUG|Placebo|Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
41167669|NCT00607256|DRUG|[S,S]-reboxetine|S_S reboxetine dosed daily.
41167670|NCT06284798|DRUG|NNC0650-0013 A|NNC0650-0013 will be administered subcutaneously or intravenously.
41167671|NCT06284798|DRUG|Placebo|Subcutaneous administration.
41167672|NCT00522509|DRUG|Floxuridine FUDR|
41167673|NCT03756025|PROCEDURE|Atraumatic Restorative Treatment (ART)|The atraumatic restorations were performed in the dental office by a single operator trained in the ART Technique \[20\], who received the restorative material already prepared by a trained auxiliary, ensuring blinding of the study. The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin spoons, with subsequent conditioning of the cavity with a polyacrylic acid solution at 11.5% (DFL) applied with a microbrush for 10 seconds. Immediately after, the cavity was washed and dried with cotton balls. In this step, according to the randomization, the respective GIC was inserted and subsequent digital compression was performed for 30 seconds. After occlusal adjustment, the ARTs were protected with finish gloss Alfa Bond® (DFL).
41167674|NCT05998226|OTHER|Virtual Antimicrobial stewardship Team (VAT)|The VAT consists of at least a clinical microbiologist and a clinician from the NH. Ideally, a pharmacist will also attend. They conduct a weekly (digital) meeting for nine months to evaluate the antibiotic prescriptions of the clinician attending the VAT meeting, based on a standardized protocol according to the current national infection treatment guidelines.
41167675|NCT04353817|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration qd in the morning.
41167676|NCT04353817|DRUG|IVA|Tablet for oral administration qd in the evening.
41512607|NCT03732963|DRUG|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
40860363|NCT00087334|DRUG|oxaliplatin|
41039711|NCT06241404|PROCEDURE|trigger point therapy|patients who have been treated for shoulder tendinopathy by trigger point therapy
41039712|NCT06241404|PROCEDURE|Exercise therapy|patients who have been treated for shoulder tendinopathy by exercise therapy
41039713|NCT05228600|DRUG|YL-13027|"YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo\[1,2-a\]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature."
41039714|NCT03712644|DEVICE|FFR-guided coronary revascularization|Stenoses in range of 50-90% diameter stenosis in major coronary arteries will be assessed by FFR, and revascularized if FFR equal to or lower than 0.80. Lesions above 90% diameter stenosis in will be revascularized without further assessment.
41167677|NCT04353817|OTHER|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration once daily (qd) in the morning.
41167678|NCT04353817|OTHER|Placebo (matched to IVA)|Placebo matched to IVA for oral administration qd in the evening.
41167679|NCT01137877|OTHER|Milk based infant formula powder|milk based infant formula ad lib
41391289|NCT01758315|OTHER|Training and in-office coaching|Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
41391290|NCT03072329|PROCEDURE|Pudendal nerve block|
41391291|NCT03072329|DRUG|Bupivacaine|
41391292|NCT04033627|PROCEDURE|In Vitro T cells depletion using CliniMCAS system|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
41391293|NCT01491282|OTHER|Enabling and disabling VNS|No intervention
41512608|NCT03732963|DRUG|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
41512609|NCT02358512|OTHER|Enteral feeding|Bolus feeds or continuous feeds during a 10-day ICU stay
41512610|NCT00361647|PROCEDURE|Diagnostic screening for occult malignancy|
41512611|NCT02390882|DRUG|Placebo|Placebo
40860364|NCT02737124|DRUG|Acetaminophen|Acetaminophen will be given 24 hours before scheduled surgery.
40860365|NCT02737124|OTHER|Placebo|Placebo will be given to subjects 24 hours before scheduled surgery.
41039715|NCT00075062|PROCEDURE|Flexible Sigmoidoscopy|
41039716|NCT00075062|PROCEDURE|Rectal Biopsy|
41039717|NCT03033823|DRUG|Magnesium|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
41039718|NCT03033823|DRUG|Placebo Oral Tablet|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
41039719|NCT02453581|DRUG|OZ439|OZ439 Powder for Oral Suspension
41039720|NCT06240442|OTHER|Fasted exercise|Bodyweight interval exercise performed 5 minutes before the start of a mixed-macronutrient breakfast meal
41167680|NCT01137877|OTHER|Investigational Infant Formula #1|Milk based infant formula ad lib
41167681|NCT01137877|OTHER|Investigational Infant Formula #2|Milk based infant formula powder ad lib
41167682|NCT01137877|OTHER|Human Milk|Human milk ad lib
41167683|NCT01222533|DRUG|Tiotropium medium|Tiotropium inhalation solution medium dose
41167684|NCT01222533|DRUG|Tiotropium low|Tiotropium inhalation solution low dose
40860366|NCT04487522|PROCEDURE|Open retromuscular ventral hernia repair|With the subject under general anesthesia, a single incision is made in the abdomen. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
41167685|NCT01222533|DRUG|Tiotropium high|Tiotropium inhalation solution high dose
41167686|NCT01222533|DRUG|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
41167687|NCT01222533|DRUG|Tiotropium placebo|Placebo inhalation solution
41391294|NCT00816517|BIOLOGICAL|injection of botulinum toxin type A.|35 to 100 units injected around a skin lesion (plaque) one time.
41391295|NCT00118573|PROCEDURE|EVAR (Endovascular repair of Abdominal Aortic aneurysm)|AAA repair with endografting
41512612|NCT02390882|DRUG|HGP0412 capsule|Tamsulon high dose
41512613|NCT02390882|DRUG|HIP1402 capsule|Tamsulon high dose
41512614|NCT00452244|DRUG|simvastatin|Simvastatin 40mg/QD po daily every 3 weeks
41512615|NCT00452244|DRUG|gefitinib only|gefitinib 250mg/QD po daily every 3 weeks
41512616|NCT03389347|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow aspirate and blood
41512617|NCT03389347|DEVICE|High Throughput Screening|Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay
41512618|NCT03389347|OTHER|Laboratory Biomarker Analysis|Correlative studies
41391296|NCT00118573|PROCEDURE|Surveillance|Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
41391297|NCT02028156|OTHER|Partially Hydrolyzed Infant Formula|Commercially available infant formula
41391298|NCT00387231|PROCEDURE|Percutaneous coronary angioplasty/intervention (PCI)|
41391299|NCT00387231|DRUG|Anti-ischemic drug therapy|
41391300|NCT00295308|DRUG|Clonidine|clonidine up to 0.3 mg/day oral
41039721|NCT06240442|OTHER|Fed exercise|Bodyweight interval exercise performed 10 minutes after the start of consuming a mixed-macronutrient breakfast meal
41039722|NCT01580072|OTHER|self-monitoring for patients with severe COPD|Intervention Group entering vital parameters via Web Portal or automatic call center.
41039723|NCT01580072|OTHER|nurse-monitoring for patients with severe COPD|Nurses are entering vital parameters of the patient with mobile devices.
41039724|NCT05560672|OTHER|Human Umbilical Cord blood mononuclear cells|Intravenous infusion of cord blood mononuclear cells
41039725|NCT05974527|DRUG|Sublingual film containing dexmedetomidine (BXCL501)|Enrolled participants will receive an initial dose of BXCL501 180mcg. Following the FDA dosing suggestions, participants with mild or moderate hepatic impairment (Child-Pugh Class A or B) will receive a reduced initial dose of 120mcg and participants with severe hepatic impairment (Child-Pugh Class C) will receive a reduced initial dose of 90mcg. Geriatric patients (≥ 65 years old) will receive a reduced initial dose of 120mcg.
41039726|NCT03907124|DRUG|Genetically-guided treatment with FDA-approved psychotropic drugs|Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
41039727|NCT03907124|DRUG|Treatment as usual (TAU)|All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
41039728|NCT06011590|OTHER|No intervention.|No intervention.
41039729|NCT02283060|DRUG|Stribild|To be administered orally, once daily with food.
41039730|NCT02283060|DRUG|Atripla|To be administered orally, once daily at bedtime on an empty stomach
41039731|NCT02232113|DRUG|CERA|changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
41039732|NCT03598413|DIETARY_SUPPLEMENT|Omega-3|200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
41039733|NCT03195257|OTHER|GIP|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
41039734|NCT03195257|OTHER|GLP-1|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
41167688|NCT03714542|OTHER|Pre- and postoperative MRI|
41391301|NCT00295308|DRUG|Placebo|oral capsules daily
41391302|NCT01896700|DRUG|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
41512619|NCT05114213|RADIATION|SBRT|online adaptive MR-guided hypofractionated stereotactic radiotherapy
41039735|NCT03195257|OTHER|Saline|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
41039736|NCT00726206|OTHER|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
41039737|NCT02862457|DRUG|Epacadostat 25 mg|Oral administration
41039738|NCT02862457|DRUG|Epacadostat 100 mg|Oral administration
41039739|NCT02862457|BIOLOGICAL|pembrolizumab 200 mg|Intravenous (IV) infusion
41039740|NCT02862457|DRUG|Cisplatin 75 mg/m^2|IV infusion
41039741|NCT02862457|DRUG|Carboplatin Area Under the Curve (AUC) 5|IV infusion
41039742|NCT02862457|DRUG|Pemetrexed 500 mg/m^2|IV infusion
41391303|NCT01896700|DRUG|Placebo|Escalating matched dose of placebo
41391304|NCT02574260|BIOLOGICAL|Talimogene Laherparepvec|Administered by intratumoral injection.
41391305|NCT02915588|OTHER|early isometric loading after rotator cuff surgery|
41391306|NCT02915588|OTHER|passive motion after rotator cuff surgery|
41391307|NCT05161559|PROCEDURE|Etching with phosphoric acid gel (3M ESPE, St. Paul, MN, USA)|Etching enamel surface using phosphoric acid gel (3M ESPE, St. Paul, MN, USA)
41391308|NCT05161559|PROCEDURE|Self-etch adhesive (Kuraray, Tokyo, Japan)|No Etching enamel surface using phosphoric acid (self-etch technique) (Kuraray, Tokyo, Japan)
41391309|NCT05161559|PROCEDURE|Chemical bond adhesive (GC, Corporation, Tokyo, Japan)|Chemical bond with hydroxyapatite crystals of Enamel (GC, Corporation, Tokyo, Japan)
41391310|NCT04503707|DRUG|Follitropin Delta|The Intervention (solution for injection) is delivered with a pre-filled injection pen. The REKOVELLE dose will be based on a recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the ELECSYS AMH Plus Immunoassay.
41391311|NCT02962739|DRUG|emtricitabine 200 mg/tenofovir alafenamide 25mg|1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
41512620|NCT05114213|DRUG|SOC chemotherapy|The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
41512621|NCT01602393|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
41039743|NCT02862457|DRUG|Paclitaxel 200 mg/m^2|IV infusion
41039744|NCT02862457|DRUG|Carboplatin AUC 6|IV infusion
41512622|NCT01602393|DRUG|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
41512623|NCT01602393|DRUG|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
41512624|NCT00477880|BIOLOGICAL|Cetuximab|
41167689|NCT03107884|DRUG|Metformin (Bed Rest)|A clinical oral dose of Metformin will be given to participant daily during bed rest
41039745|NCT05242991|DEVICE|Photobiomodulation therapy|Light therapy for the management of oral side effects related to radiotherapy, mainly in the decrease of oral mucositis (OM) rates and OM severity, healing of OM ulcers and pain relief.
41039746|NCT01798927|DEVICE|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
41039747|NCT05884346|OTHER|Ultrahigh-frequency ultrasound|Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease
41039748|NCT03796455|DIETARY_SUPPLEMENT|Capsule + Powder supplementation|For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).
41039749|NCT03796455|OTHER|stable tracer infusion|labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day
41039750|NCT06409026|DRUG|Sotatercept|As per FDA indications, sotatercept will be administered as 0.3 mg/kg injection for the first dose followed by 0.7 mg/kg injections for subsequent doses.
41039751|NCT00233922|DEVICE|Osteosheet(r)|
41039752|NCT00225654|DEVICE|coronary stent|
41039753|NCT05847426|OTHER|Provision of standard audiological + fNIRS test results|Infants with hearing loss will be tested using functional near-infrared spectroscopy (fNIRS) and a patented analysis algorithm to measure sound detection and discrimination. Their standard audiological test results will also be collected from their audiology service provider/s. Both sets of test results will be given to the participating audiologists in the experimental arm.
41039754|NCT05847426|OTHER|Provision of standard audiological test results only|The provision of test results to the audiologist will be the same as in the experimental arm, but without the fNIRS test results included.
41039755|NCT03664869|DRUG|BCG instillation therapy|Induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
41167690|NCT03107884|DRUG|Placebo (Bed Rest)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
41167691|NCT03107884|DRUG|Metformin (2 week run-in only)|A clinical oral dose of Metformin will be given to participant daily during a two week run-in period only.
41167692|NCT03107884|DRUG|Placebo (2 week run-in only)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin 2 week run-in treatment group.
41167693|NCT06160011|OTHER|Electrical dry needling + Conventional physiotherapy|Electrical dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
41167694|NCT06160011|OTHER|Dry needling + Conventional physiotherapy|Dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
41167695|NCT06160011|OTHER|Conventional physiotherapy|Conventional physiotherapy treatment (massage, pressure release): 2 sessions
41167696|NCT04160910|DRUG|5-Hydroxytryptophan|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
41167697|NCT04160910|DRUG|Placebo|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
41167698|NCT05088109|DIAGNOSTIC_TEST|early mortality prediction using septic shock indices|The Shock Index (SI) is the ratio of pulse rate to systolic blood pressure calculated by dividing pulse rate (beat/min) by systolic blood pressure (mm Hg). The adjusted shock index (ASI) is SI calculated after adjusting the heart rate according to body temperature that 10 beats will be added to the heart rate for every 1.0 °C rise in the body temperature above 37.0 °C. The modified shock index (MSI) is a ratio of heart rate to mean blood pressure (MAP). The DSI is a ratio of heart rate to diastolic blood pressure (DAP).
41391312|NCT03757793|DEVICE|FORE-SIGHT ELITE monitor|At end of surgery, one sensor of the FORE-SIGHT Elite monitor is placed on the DIEP flap or two sensors in case of bilateral DIEP flaps for monitoring perfusion and oxygen consumption in the free flap. A control sensor of the FORE-SIGHT Elite monitor placed on the abdomen where tissue is taken to perform the DIEP flap. This sensor reflects normal tissue oxygenation. Data obtained from the FORE-SIGHT Elite monitor will be compared to data obtained from physical examination, which is standard of care for flap monitoring.
40860367|NCT04487522|PROCEDURE|Laparoscopic retromuscular ventral hernia repair|With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
40860368|NCT04487522|DEVICE|Robotic-assisted retromuscular ventral hernia repair|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
40860369|NCT00491933|PROCEDURE|Quantiferon-TB Gold assay|
41391313|NCT02360579|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
40860370|NCT00491933|PROCEDURE|Tuberculin skin test|
40860371|NCT01199224|DRUG|veliparib|veliparib formulation A
40860372|NCT01199224|DRUG|veliparib|veliparib formulation B
40860373|NCT01199224|DRUG|veliparib|veliparib formulation C
40860374|NCT01199224|DRUG|veliparib|veliparib formulation C
40860375|NCT03643627|DRUG|SYNT001|single IV infusion
40860376|NCT03643627|DRUG|Placebo|single IV infusion
41167699|NCT01540578|OTHER|laboratory biomarker analysis|Correlative studies
41167700|NCT03552276|DRUG|SUNPG18_07 I|injection
41167701|NCT03552276|DRUG|SUNPG18_07 II|injection
41167702|NCT03552276|DRUG|SUNPG18_07 III|injection
41167703|NCT02726035|DRUG|Naltrexone|oral naltrexone 50 mg daily
41391314|NCT06248073|BEHAVIORAL|on-line self-management training|To encourage adherence to the home program among early-stage Parkinson's disease participants, the investigators have developed various self-management topics, including medication adherence and exercise benefits. The home program is categorized into two dimensions: daily function and exercise. The investigators will provides participants with detailed guidelines to ensure safe execution of the program independently.
41512625|NCT00699998|DRUG|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
41167704|NCT02726035|OTHER|Placebo|oral placebo (appearing identical to naltrexone) once daily
41167705|NCT00519285|DRUG|Aflibercept|"25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle"
41167706|NCT00519285|DRUG|Placebo (for aflibercept)|"Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle"
41167707|NCT00519285|DRUG|Docetaxel|"Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)"
41039756|NCT03664869|DRUG|Sequential BCG and EMDA mitomycin C|"Induction period includes nine weekly instillations of sequential BCG and EMDA-MMC instillations applied as three cycles of BCG, BCG and EMDA-MMC. Induction period is followed by maintenance period of nine monthly instillations of sequential EMDA-MMC and BCG applied with three cycles of EMDA-MMC, EMDA-MMC and BCG.~BCG instillation is performed as a standard instillation.~Mitomycin C is administered with electromotive drug administration (EMDA) device (Instillation: 40 mg mitomycin C with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water, EMDA settings: current rise rate 30-50 microamperes per second, max 25 milliamperes, treatment duration 30 min)"
41039757|NCT01605929|PROCEDURE|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
41039758|NCT04752423|OTHER|Pre operative assessment|"Anxiety assessment : Numeric rating scale (patient and caregiver), APAIS scale (patient), Covi Scale (Caregiver)~Verbalization : anesthesia-related concerns (expressed by patient and considered by caregiver)"
41039759|NCT03705091|DIAGNOSTIC_TEST|Magnetic resonance imaging|ASL and DWI MRI
41039760|NCT02742948|DRUG|ceftriaxone|IV ceftriaxone (2g) will be given to all participants
41039761|NCT02063828|DEVICE|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 12 weeks.
41167708|NCT00519285|DRUG|Prednisone or Prednisolone|"Marketed formulation~5 mg twice daily PO from day 1 continuously"
41167709|NCT01648478|OTHER|It is a hyperinsulinemic-euglycemic clamp.|"The hyperinsulinemic-euglycemic clamp includes three periods:~* A basal period (from T-30 to T0)~* The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~* The infusion of glucose at variable rate (so as to maintain euglycemia)"
41391315|NCT06248073|BEHAVIORAL|onsite task-related training|Participants will receive interventions at Chang Gung Memorial Hospital. A certified occupational therapist will conduct the interventions. These sessions will involve functional tasks tailored to each participant's skill level, with two to four varied tasks per session. Additionally, participants will be given booklets to guide them in self-managing similar exercises at home, mirroring the home program of the self-management group.
41512626|NCT00699998|DRUG|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
41167710|NCT04092049|OTHER|lollipop|chewing lollipop for 10 minutes
41512627|NCT00699998|DRUG|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
41167711|NCT02114983|OTHER|compression ultrasonography|CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
41167712|NCT05568355|BEHAVIORAL|GET2HOME Intervention|Intervention bundle designed to improve discharge effectiveness
41167713|NCT04634955|PROCEDURE|tranforaminal epidural injection|tranforaminal epidural injection which is performed by fluoroscopic guidance
41167714|NCT00129506|DRUG|methotrexate + misoprostol|
41391316|NCT01844869|DRUG|omacetaxine mepesuccinate|
41391317|NCT02050607|OTHER|fecal microbiota transplantation from healthy lean donors|fecal microbiota transplantation from healthy lean donors
41512628|NCT02185079|BEHAVIORAL|Training to proficiency|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be trained to proficience based on the metrics developed for labor epidural catheter placement in a epidural simulator.
41512629|NCT02185079|BEHAVIORAL|Conventional training|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
41512630|NCT04315506|BEHAVIORAL|#EnufSnuff.TXT Intervention|The SGR program will reduce smokeless tobacco until you reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
41512631|NCT04315506|BEHAVIORAL|Enough Snuff Intervention|Participants will be sent the Enough Snuff cessation manual. One weeks after it is sent, participants will then receive text messages from the study team twice a week for ten weeks.
41039762|NCT02063828|DEVICE|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 12 weeks.
41167715|NCT00129506|DRUG|misoprostol|
41167716|NCT03269695|DRUG|PF-06687234|SC QW
41167717|NCT03269695|DRUG|Placebo|SC QW
41512632|NCT02537691|DRUG|FP|ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.
41512633|NCT02537691|DRUG|LABA|LABA will be administered as per investigator discretion.
41512634|NCT02537691|DRUG|LTRA|LTRA will be administered as per investigator discretion.
41512635|NCT02537691|DRUG|LAMA|LAMA will be administered as per investigator discretion.
41512636|NCT02537691|DRUG|Theophylline|Theophylline will be administered as per investigator discretion.
41512637|NCT02537691|DRUG|Oral Corticosteroids|Oral corticosteroids will be administered as per investigator discretion.
41512638|NCT05356507|OTHER|Patient population|Questionnaires, standard of care
41512639|NCT03767660|DRUG|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
40860377|NCT02645292|DEVICE|1 mile walk using treadmill|Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.
40860378|NCT02645292|DEVICE|Stair Climbing|Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
41512640|NCT06364059|PROCEDURE|Decompressive craniectomy with evacuation of subdural hematoma|Adult patients who underwent decompressive craniectomy with evacuation of subdural hematoma.
41512641|NCT05810103|DRUG|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
40860379|NCT04184297|DRUG|Tiotropium and Olodaterol (Tio+Olo)|drug
40860380|NCT04184297|DRUG|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)|drug
40860381|NCT02564185|OTHER|Usual practice|
40860382|NCT02564185|OTHER|Education program|
40860383|NCT05856266|PROCEDURE|Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)|Ultrasound examination
40860384|NCT05856266|OTHER|Haemophilia Joint Health Score (HJHS)|Functional joint examination
40860385|NCT03787550|DRUG|The Sedatives, analgesics and antibiotics|The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
40860386|NCT01579890|DRUG|Diclofenac|diclofenac topical lotion
40860387|NCT06110013|DEVICE|Electrical cardiometry|"All included patients will be connected to Electrical cardiometry device. The electrodes will be placed over the bare skin of patients at the following sites:~A. on the left neck below the ear B. directly superior to the midpoint of the left clavicle C. along the left mid-axillary line at the level of the xiphoid process D. two inches below the third electrode. High frequency signals pass through 2 acting electrodes, the other 2 measuring electrodes detect changes in bioimpedance resistance to allow continuous hemodynamic monitoring, then data will be analysed to give comprehensive picture of the hemodynamic circulatory system, allowing differential diagnosis for a patient management"
41039763|NCT02063828|DEVICE|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 12 weeks.
41512642|NCT02271932|OTHER|Non-operative|Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
41512643|NCT01073085|BEHAVIORAL|"Web-based automated coaching by e-mails"|
41512644|NCT01073085|BEHAVIORAL|Self-help guide|
41512645|NCT02841501|GENETIC|Analysis of genetic polymorphisms|An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
41512646|NCT05784025|DEVICE|AlterG|Experimental device reducing weight perception by inducing a no-gravity environment which facilitates the execution of rehabilitation programs
40860388|NCT05031793|OTHER|TCM|TCM include oral chinese herb, laser acupuncture, tuina, nasal steam inhalation.
40860389|NCT05031793|OTHER|Western medicine|Western medicine include nasal spray steroid, oral antihistamine
40860390|NCT01015781|PROCEDURE|Progressive Tinnitus Management|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support"
41512647|NCT05884502|DRUG|combination of high-dose rosuvastatin and ezetimibe|combination of rosuvastatin 20mg and ezetimibe 10mg
41512648|NCT05884502|DRUG|high-dose rosuvastatin single administration|rosuvastatin 20mg monotherapy
40860391|NCT01015781|PROCEDURE|Wait List Control|VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
40860392|NCT00156416|BEHAVIORAL|Mindfulness Meditation|8 weeks of meditation training
41039764|NCT02652988|OTHER|Active-tDCS|Active home-based tDCS applied at home.
41039765|NCT02652988|OTHER|Sham-tDCS|Sham home-based tDCS applied at home.
41039766|NCT01688700|DRUG|Nimotuzumab combined with paclitaxel and cisplatin|"Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
41512649|NCT01845688|DRUG|Losartan Tablets & QingReMoShen Granule|
41512650|NCT01845688|DRUG|Losartan Tablets & Placebo Granule|
41039767|NCT02954523|DRUG|Dasatinib|oral every day
41039768|NCT02954523|DRUG|Osimertinib|oral every day
41512651|NCT05835908|OTHER|Phone questionnaire|Patients will be contacted by the investigator to collect information regarding follow-up from the initial call to the Emergency call center until the patient is taken care of in the health care facility to which he/she has been admitted.
41512652|NCT03493412|DRUG|Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)|5 mg/kg will be used as the dose of BH4
41512653|NCT03493412|DRUG|Placebo|Placebo
41512654|NCT00129571|DRUG|XL820|
41512655|NCT01570114|DEVICE|Fully covered metallic colonic stent|Endoscopically insertion of fully covered metallic colonic stent
41512656|NCT06566690|DEVICE|Addition of ORi monitoring to SpO2 monitoring|Integration of Oxygen Reserve Index (ORi) monitoring into standard SpO2 monitoring
41512657|NCT02446756|OTHER|acupuncture|
41512658|NCT02446756|OTHER|physiotherapy|
41512659|NCT02368418|PROCEDURE|PCP|PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
41512660|NCT02368418|PROCEDURE|SRS|SRS is short for a community-based Salt Reduction program delivered by community health educators.
41512661|NCT03545893|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
41512662|NCT03545893|DRUG|OxyCODONE 5 Mg Oral Tablet|Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
41512663|NCT00580892|DEVICE|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
41512664|NCT05719935|DEVICE|KinematX total wrist arthroplasty system|The KinematX total wrist implant is a joint metal/polymer semi-constrained cemented prosthesis that utilizes an articulation that mimics the midcarpal joint instead of the radiocarpal joint.
41512665|NCT04422600|OTHER|There is no other intervention, only clinical treatment.|The investigators will then correlate that exposure with neurodevelopmental outcomes.
41512666|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
41512667|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
41039769|NCT00403416|DRUG|AEB071|
41039770|NCT00403416|DRUG|Mycophenolic Acid|
41167718|NCT04622475|BIOLOGICAL|Fecal Microbiota Transplant (FMT) Capsule|When enrolled in the study, subjects will ingest 20 FMT capsules/day orally for 3 consecutive days. If the syndrome is not completely recovered or relapse 14 days after the first administration, the subject will receive a booster dose (20 capsules/day for 3 consecutive days).
41167719|NCT04106570|OTHER|fatiguability of the knee extensors|fatiguability of the knee extensors (in N.m) measured with a dynamometer.
41167720|NCT02246218|DRUG|RAVICTI|
41167721|NCT01880437|DRUG|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
41167722|NCT01880437|DRUG|vismodegib|Cohorts 1 and 2: 150 mg orally daily
41167723|NCT00591409|DRUG|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered."
41167724|NCT00591409|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered"
41391318|NCT06003491|DEVICE|Intra-articular Cages|Using reduction using posterior intra-articular distraction and fusion technique with cages.
41391319|NCT05090085|OTHER|3M Adper Single Bond2|Two-step etch and rinse dental adhesive system
41391320|NCT05090085|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
41391321|NCT05090085|OTHER|3m ESPE etch|32% phosphoric acid
41512668|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
41512669|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
41512670|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
41512671|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
41512672|NCT03333265|DRUG|100mg Berberine hydrochloride|patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months
41512673|NCT03333265|DRUG|300mg Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months
41512674|NCT03333265|DRUG|Placebo Oral Tablet|patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
41512675|NCT02386137|DEVICE|Contrast-enhancement ultrasound with Sonovue|
41512676|NCT01983241|BIOLOGICAL|Alpha-1 MP|
41512677|NCT01983241|OTHER|0.9% Sodium Chloride for Injection, USP|
41512678|NCT02575833|DRUG|Erenumab|A single dose of erenumab 140 mg infused over approximately 60 minutes.
41391322|NCT05090085|OTHER|OT Primer|Dimethyl Sulfoxide DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
41391323|NCT01540682|DRUG|MLN8237|Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
41391324|NCT01540682|DRUG|Cetuximab|\~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
41512679|NCT02575833|DRUG|Placebo|A single dose of a matching volume of placebo infused over approximately 60 minutes.
41512680|NCT02396511|BIOLOGICAL|TRC105|weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
41512681|NCT02396511|BIOLOGICAL|Bevacizumab|Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
41512682|NCT02223988|PROCEDURE|subglottic secretion removal|
41039771|NCT04439422|BEHAVIORAL|Short ADHD Intervention|Short, intensive psychological intervention based on CBT and DBT practices
41039772|NCT04439422|OTHER|Self-help material with limited therapist support|Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
41039773|NCT03620344|OTHER|ADH-Me Book and ADHD Informational Brochure|"Understanding ADHD information brochure published by American Academy of Pediatrics and a children's book about ADHD condition"
41167725|NCT04555005|OTHER|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
41167726|NCT01035047|OTHER|Clinical decision unit care, coupled with cardiac MRI|After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
41391325|NCT01540682|RADIATION|Radiotherapy|Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of \~70 Gy.
41391326|NCT00002227|DRUG|Efavirenz|
41391327|NCT00002227|DRUG|Lamivudine|
41391328|NCT00002227|DRUG|Stavudine|
41391329|NCT04685941|DRUG|Drug-mediated hyperemia|Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.
41391330|NCT04685941|OTHER|Flow-mediated hyperemia|Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.
41391331|NCT02149537|DRUG|hydroxyurea|
41167727|NCT04116281|OTHER|Rehabilitation after breast cancer surgery|All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
41167728|NCT03378934|DRUG|Berberine|Berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4 weeks (Stage 3).
41391332|NCT05224479|OTHER|Traditional workflow triage|Workflow triage is based on order location, STAT designation, and first-in-first-out status.
41391333|NCT05224479|OTHER|Machine learning workflow triage|Workflow triage is based on the machine learning model's confidence of abnormality.
41391334|NCT05224479|OTHER|Random workflow triage|Workflow triage is based on random order.
41039774|NCT03620344|OTHER|ADHD Informational Brochure Only|"Understanding ADHD information brochure published by American Academy of Pediatrics"
41391335|NCT06005337|BEHAVIORAL|Blogshots 1-3|"1. Don't routinely do a throat swab when children present with a sore throat if they have a cough, rhinitis, or hoarseness~2. Don't recommend the use of cough and cold remedies in children under six years of age~3. Don't use antibiotics for acute asthma exacerbations without clear signs of bacterial infection"
41391336|NCT06005337|BEHAVIORAL|Blogshots 4-6|"1. Don't routinely use antibiotics in children with uncomplicated sore throats~2. Don't prescribe antibiotics in adults with bronchitis/asthma and children with bronchiolitis~3. Don't use antibiotics in adults and children with uncomplicated acute otitis media"
41391337|NCT00064935|PROCEDURE|Endometrial biopsy|
41391338|NCT02766088|PROCEDURE|Blood sample collection|All participants will have an enrolment visit with collection of a blood sample and a termination contact/visit. Participants or their parents/guardians will be contacted weekly or every two weeks to monitor the occurrence of febrile episodes. Additional visits will be made if febrile episodes occur. In case of dengue suspicion, a blood sample will be collected.
41391339|NCT03547531|OTHER|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
41391340|NCT03547531|OTHER|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
41512683|NCT05677035|DRUG|LINO-1713 1 tablet|LINO-1713 1 tablet is administered once. Oral administration with 200mL of water
41391341|NCT02854189|DEVICE|Oxford unicompartmental knee arthroplasty|The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
41391342|NCT06476873|BEHAVIORAL|Online self-questionnaire.|"Descriptive, cross-sectional study This study is aimed at adult chemsex users over the last 12 months (having experimented with chemsex at least once over the last 12 months) and with a good understanding of French.~An online LimeSurvey-type self-questionnaire will be accessible via a URL link to collect and secure the data. A presentation of the study, information on chemsex and help and care services, as well as the information note will be available.~The questionnaire will be distributed via a QR code, giving direct access to the study's web page, or directly via the web link. Posters and flyers will be used in hospitals and/or private clinics, addictology centers, STI prevention and screening centers and associations, as well as via social networks, dating apps and sites, and the online and print press."
41391343|NCT05731388|DIAGNOSTIC_TEST|Push enteroscopy|A push enteroscopy using a pediatric colonoscope will be performed along with capsule endoscopy. These are part of the standard of care.
41391344|NCT06078995|DRUG|Tenecteplase|Thrombolysis wtih rhTNK-tPA
41391345|NCT06078995|DRUG|Alteplase|Thrombolysis wtih rt-PA
41391346|NCT02704299|BIOLOGICAL|Autologous T cells-Based Immunotherapy|TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
41039775|NCT05597969|BEHAVIORAL|FoodCoach|The FoodCoach app displays transparent analysis and recommendations regarding participant's food purchases recorded on their loyalty cards. It tries to help participants understand why and how they should/can shop more healthily, motivating them to change their unhealthy food purchase behavior.
41039776|NCT00743366|DRUG|Marijuana|0,6.2% THC
41039777|NCT00743366|DRUG|Quetiapine|200 mg/day
41039778|NCT00743366|DRUG|Placebo oral capsule|
41039779|NCT04460118|PROCEDURE|Bristow surgery fixed by the screw|Bristow surgery fixed by the screw
41039780|NCT04460118|PROCEDURE|Bristow surgery fixed by the suture button|Bristow surgery fixed by the suture button
41167729|NCT03378934|DRUG|Standard treatment|Standard treatment for 12±1 weeks.
41167730|NCT03378934|DRUG|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
41167731|NCT03378934|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
41391347|NCT00835068|OTHER|No intervention|As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
40860393|NCT00633529|DRUG|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
41167732|NCT00963443|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
41167733|NCT00963443|DRUG|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
41391348|NCT01836003|OTHER|Tokafatso programmatic intervention|"Tokafatso programmatic intervention:~* SMS-based platform for delivery of CD4 test results~* Participatory educational session for clinic staff~* Loan program for HIV and CD4 testing supplies~* Facilitation of tracing of HAART-eligible pregnant women"
41391349|NCT00309127|BEHAVIORAL|Multidisciplinary team care|
41391350|NCT04525859|BIOLOGICAL|Safety|See previous Safety group description
41391351|NCT04525859|BIOLOGICAL|Expansion Cohort|See previous Expansion Cohort
41391352|NCT04767542|DRUG|Intravenous Infusion|analgesic
41512684|NCT05677035|DRUG|LINO-1713 once a day for 24 days|Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.
41512685|NCT04190121|DIETARY_SUPPLEMENT|prosure|The study group will receive the dietary supplement preoperatively and for three months after the operation
41167734|NCT00963443|DRUG|Placebo|Matching Placebo
40860394|NCT01817504|PROCEDURE|Systematic transplantectomy|Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.
40860395|NCT01817504|PROCEDURE|Progressive reduction of immunosuppression|"Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.~In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group."
41167735|NCT05248698|BEHAVIORAL|lifestyle change|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
41512686|NCT04888832|OTHER|Work requirement exemption months|Cross-randomized intervention will test effect of additional exemption months before work requirements in SNAP become binding and extensions of the standard SNAP recertification period.
40860396|NCT01136408|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
40860397|NCT01136408|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
40860398|NCT01136408|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
41167736|NCT05248698|OTHER|exercise|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
41167737|NCT00349622|DRUG|ceftriaxone|"Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years."
41167738|NCT00349622|OTHER|placebo|an inactive substance
41167739|NCT06292559|DEVICE|Bilateral STN deep brain stimulation|patients with Meige syndrome underwent bilateral subthalamic stimulation
41167740|NCT06292559|DEVICE|Bilateral GPi deep brain stimulation|patients with Meige syndrome underwent bilateral pallidal stimulation
41167741|NCT04765553|DRUG|NI-0501|emapalumab single i.v infusion (1 mg/kg)
41167742|NCT04765553|DRUG|Saline|Saline single i.v infusion
41167743|NCT01438515|DRUG|Rifampin|600mg po once daily x 7 days
41391353|NCT04767542|PROCEDURE|Local anesthesia|Local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally to transverses abdominis muscle
41391354|NCT02214498|DRUG|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
41391355|NCT02214498|DRUG|Placebo|
41391356|NCT00333073|DEVICE|Bulkamid|initial injection with option for second (if required)
41391357|NCT04185701|OTHER|SiVIEW software|Eye examination by a technician with the SiVIEW software
41391358|NCT04185701|OTHER|Expert|Eye examination by an expert including optimal correction in distance and near vision
41391359|NCT05437484|BEHAVIORAL|Peer-led BASICS|"The peer-led BASICS session consisted in a face-to-face 50-minute motivational interview. In this meeting, the peer counsellor oriented the participant using a personalized graphic feedback sheet, with topics including participant's drinking pattern; level of intoxication; perceived and actual descriptive drinking norms, alcohol expectancies; drinking consequences; individual risk factors; financial costs; alcohol caloric consumption, and hours of exercise required to burn those calories, and protective behavioral strategies. Participants received a copy of the personalized feedback, a personalized BAC card, and a tips sheet.~BASICS facilitators were volunteer undergraduate nursing students from who attented a pre-training course and showed being competent to conduct BASICS-based motivational interview and knowledgeable about alcohol."
41512687|NCT04860180|PROCEDURE|adrenalectomy|
41167744|NCT01438515|DRUG|Doxycycline|100mg po twice daily x 7 days
41167745|NCT01438515|OTHER|2% mupirocin ointment|\~ 1cm applied to the anterior nares twice daily for 7 days
41167746|NCT01438515|OTHER|4% chlorhexidine gluconate|Daily full body wash (including hair) for 7 days
41391360|NCT05450042|DEVICE|SELUTION SLR DCB|Sirolimus DCB
41391361|NCT05450042|DEVICE|Paclitaxel DCB|Paclitaxel DCB
41391362|NCT03571854|DEVICE|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
41512688|NCT03419689|PROCEDURE|Tumour tissue collection|"Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression"
41391363|NCT03571854|DEVICE|Group VCV|Volume controlled ventilation
41512689|NCT03419689|PROCEDURE|Blood sample collection|"Blood samples will be taken:~* At the time of first diagnosis~* About 1 week after starting any treatment~* At each radiological response assessment~* At each subsequent relapse or disease progression"
41391364|NCT01060631|DEVICE|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
40860399|NCT03466853|DIAGNOSTIC_TEST|Clinical assessment of nutritional status (CANS) score|Systematized inspection and estimation of loss of SC tissues and muscles of nine superficial physical parameters including hair and buccal fat in the cheeks, chin and neck, arms, back, inter or subscapular skin, buttocks, legs, chest, and abdominal wall skin. These signs will be rated from 1 (worst, severe FM) to 4 (best, well nourished), and the highest and lowest total scores are 36 and 9, 3respectively. A total score of \<25 is considered as fetal malnutrition.
40860400|NCT03466853|DIAGNOSTIC_TEST|Anthropometric indices|weight, length and head circumference
40860401|NCT03466853|DIAGNOSTIC_TEST|Proportionality indices|MAC/HC ratio (Calculation for each infant and value will be plotted on and compared with a standard curve). Ponderal index . A PI \<2.2 is considered as malnutrition). Body mass index (BMI= weight (kg) / length2 (m). A BMI \<11.2 kg/m2 is considered as malnutrition)
40860402|NCT01199419|PROCEDURE|comparison of PCI vs. CABG in multivessel disease|invasive treatment of coronary artery disease
41391365|NCT01060631|DEVICE|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
41391366|NCT00003673|DRUG|chemotherapy|
41391367|NCT00003673|DRUG|gemtuzumab ozogamicin|
41391368|NCT04266119|BEHAVIORAL|Online HOPE intervention|Online HOPE intervention to increase mental health literacy
41391369|NCT00437710|PROCEDURE|cell therapy, bone marrow derived stem cell|
41391370|NCT02488473|DRUG|Dexmedetomidine|100 ug dexmedetomidine added to the ropivacaine nerveblock
41391371|NCT02488473|DRUG|Ropivacaine|20 ml Ropivacaine 5mg/ml
41391372|NCT02488473|DRUG|Isotonic Saline|Placebo
41391373|NCT02120482|DEVICE|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
41512690|NCT03419689|PROCEDURE|Ascites Collection|"Ascites will be collected if paracentesis is required during any of the following time points:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression"
41391374|NCT05991778|DEVICE|Bioelectrical impedance vector analysis (BIVA)|BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.
41391375|NCT05991778|DIAGNOSTIC_TEST|Blood and urine analysis|For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.
41391376|NCT05991778|DIAGNOSTIC_TEST|cumulative water balance|Cumulative balance is the sum of daily fluid balances during hospitalization.
41391377|NCT04334330|DRUG|Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant|ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
41391378|NCT01837485|DRUG|Lactol|The Symbiotic Lactol® (Bioplus Life Sciences Pvt.) was applied 3 times a day for 3 months. Lactol is composed of the followings; Lactobacillus Sporogenes (15 × 107 Spores), Fructo-Oligosaccharides, Microcrystalline Cellulose, Sodium starch Glycolate, Povidone, Hypermellose Stearate, Sillicon Dioxide, and Propylene Glycol.
41391379|NCT01837485|DRUG|Placebo|Placebo pill was applied 3 times a day for 3 months
41391380|NCT00332345|DRUG|brimonidine/timolol fixed combination|
41391381|NCT04254263|DRUG|pyrotinib|pyrotinib 400 mg, orally once daily for one year
41391382|NCT05613920|BEHAVIORAL|diet management program based on the nudge strategy|The intervention group received a 12-week dietary management intervention based on the nudge strategy. The MINDSPACE framework was used, which has nine intervention categories. Face-to-face intervention and telephone follow-up were used to provide targeted dietary management.
41512691|NCT03419689|PROCEDURE|Fluid Collection|Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
41512692|NCT04413201|DRUG|Afatinib|Afatinib followed by osimertinib or ICT
41512693|NCT04413201|DRUG|Osimertinib|Osimertinib followed by ICT
41512694|NCT05778461|DRUG|L-ornithine L-Aspartate|LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
41512695|NCT05778461|DRUG|Placebo|Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
41039781|NCT04617639|BEHAVIORAL|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion \[RPE\] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
41167747|NCT02735434|BEHAVIORAL|Internet-based ACT|The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
41391383|NCT00244660|PROCEDURE|Frequent blood pressure measurements|
41391384|NCT00244660|BEHAVIORAL|Education|
41391385|NCT01861730|BIOLOGICAL|AERAS-404|AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
41391386|NCT01861730|BIOLOGICAL|Placebo|Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
41391387|NCT06568107|BEHAVIORAL|Environmental And Sensory Experience (EASE) intervention|The participant will be exposed to 30 minutes of a still nature image and associated nature sounds (60-80 beats per minute). An brief interview will occur with the legally authorized representative to find out what nature scene would meet the preference of the person living with dementia and persistent vocalizations.
41391388|NCT03061773|OTHER|Exercise|Physical training: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of Flexibility training (unsupervised). As stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.
41512696|NCT02531048|DEVICE|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
41512697|NCT02531048|DEVICE|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
41512698|NCT02531048|DEVICE|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
41512699|NCT02531048|DEVICE|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
41512700|NCT01838850|DRUG|CS8635 20/5/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day."
41512701|NCT01838850|DRUG|Olmetec® Plus 20/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day."
41512702|NCT06325605|DRUG|Bifidobacterium|3 capsules, 3 times a day, for 8 consecutive weeks
40860403|NCT02183766|DIETARY_SUPPLEMENT|Galactooligosaccharide prebiotic|6 mL once a day
41391389|NCT03061773|BEHAVIORAL|Conventional hospital treatment|Conventional hospital treatment: The patients did not perform physical training
41391390|NCT02177773|PROCEDURE|Computed Tomography (CT)|Undergo Gallium Ga 68-DOTA-TOC PET/CT
41391391|NCT02177773|DRUG|Gallium Ga 68-Edotreotide|Given Intravenously (IV) before imaging
41391392|NCT02177773|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo gallium Ga 68-DOTA-TOC PET/MRI
41391393|NCT02177773|PROCEDURE|Positron Emission Tomography (PET)|Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
41391394|NCT06007573|DRUG|The control group received oral nimodipine tablets|The control group received oral nimodipine tablets
41391395|NCT04885816|DEVICE|Drug Eluting Balloon (DEB)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DEB, and the diameter and pressure used aims a balloon to artery ratio of 1. In case of significant recoil (more than 30% for main vessels and 50% for side vessels), coronary perforation or flow limiting dissection, provisional stent will be implanted with a stent to artery ratio of 1.1 with stent post-dilatation when indicated. Device will be used in accordance with the CE mark instructions.~DAPT will be given for a month with aspirin and a P2Y12 inhibitor (clopidogrel will be favored). Single anti-platelet therapy (SAPT) with aspirin will be continued thereafter."
41391396|NCT04885816|DEVICE|Drug Eluting Stents (DES)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Devices will be used in accordance with the CE mark instructions.~DAPT will be indicated according to actual international guidelines."
41512703|NCT06325605|DEVICE|High-frequency rTMS|"In the rTMS treatment, the transcranial magnetic stimulation device with an 8-shaped coil with a diameter of 70mm was placed on the dorsolateral area of the left prefrontal lobe of the patient. The motor threshold was set to 90%. A 10-Hz pulse sequence was applied for 4 secs followed by a 20 secs interval. 10 pulses per train were used, and the total stimulation time was 30mins per day, 4 times a week, for 8 consecutive weeks."
41512704|NCT06325605|DRUG|Escitalopram Oxalate|Oral escitalopram oxalate. The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks
41512705|NCT01207310|BEHAVIORAL|smoking cessation counseling|two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
41512706|NCT01207310|DRUG|Nicotine patch|8 weeks' worth of nicotine patches
41512707|NCT01207310|DEVICE|alphanumeric pager|therapeutic messages to be delivered for three months
41512708|NCT03556124|DEVICE|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
41512709|NCT03556124|DEVICE|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
41512710|NCT03556124|DEVICE|Active - Conventional tDCS|Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.
41512711|NCT03556124|DEVICE|Sham - Conventional tDCS|Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
41039782|NCT04617639|BEHAVIORAL|Standard care|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
41391397|NCT04765254|OTHER|no intervention as it is an observational study|both groups will be monitored for the disease progress or deterioration and mortality rate
41391398|NCT03638752|OTHER|Comprehensive education group|"The details of Comprehensive education are as follows:~1. introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~2. instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~3. provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~4. inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~5. inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~6. inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
41391399|NCT03430089|BIOLOGICAL|Shz QIV 0.25 mL, 2 doses|Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.
41391400|NCT03430089|BIOLOGICAL|Shz QIV 0.5 mL, 2 doses|Administered intramuscularly into the deltoid muscle, 28 days apart
41391401|NCT03430089|BIOLOGICAL|Shz QIV 0.5 mL, single dose|Administered intramuscularly into the deltoid muscle.
41391402|NCT00420290|DRUG|kineret|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
41391403|NCT00420290|DRUG|placebo|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
41391404|NCT06542510|BEHAVIORAL|working night shift|working night shift
40860404|NCT02183766|DRUG|Maltodextrin|6 mL once a day
41039783|NCT04617639|BEHAVIORAL|Observation group|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel
40860405|NCT04909866|COMBINATION_PRODUCT|TACE+Lenvatininb+Camrelizumab|Patients included in the trial were treated with TACE, lenvatinib combined with Camrelizumab.
41391405|NCT00731601|DRUG|pantoprazole|pantoprazole 40 mg/q6h IV infusion for three days
40860406|NCT01378325|DRUG|Phenylephrine|Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline
40860407|NCT01378325|DRUG|saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
40860408|NCT03191266|DEVICE|Active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
40860409|NCT03191266|DEVICE|Sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
40860410|NCT00005084|PROCEDURE|conventional surgery|
40860411|NCT00005084|PROCEDURE|magnetic resonance spectroscopic imaging|
40860412|NCT00005084|RADIATION|radiation therapy|
41391406|NCT00731601|DRUG|pantoprazole|pantoprazole 8 mg/h IV infusion for three days
40860413|NCT06172647|DIAGNOSTIC_TEST|Colonoscopy|Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)
40860414|NCT00432406|DRUG|Infliximab|Infliximab 5 mg/kg given at day 1, week 2, week 6
40860415|NCT00432406|DRUG|Etanercept|Etanercept 25 mg twice weekly
40860416|NCT04206488|DRUG|JNJ-70033093|Participants will receive JNJ-70033093 orally.
40860417|NCT04206488|DRUG|Digoxin|Participants will receive digoxin orally.
40860418|NCT05011513|DRUG|PF-07321332|PF-07321332 (tablet)
40860419|NCT05011513|DRUG|Ritonavir|Ritonavir (capsule)
40860420|NCT05011513|DRUG|Placebo|Placebo (tablet)
41391407|NCT04972760|DRUG|Baricitinib|Baricitinib, 4 mg/d, oral route for 24 weeks
41391408|NCT04972760|DRUG|Placebo|Placebo, 4 mg/d, oral route for 24 weeks
41391409|NCT02738489|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
41391410|NCT06320899|DEVICE|SpineShape System IV straight rod elastic|Implantation of SpineShape System IV straight rod elastic
41391411|NCT06320899|DEVICE|SpineShape System IV straight rod medium|Implantation of SpineShape System IV straight rod medium (mid-flex)
40860421|NCT05011513|DRUG|Placebo|Placebo (capsule)
40860422|NCT03796117|DEVICE|Pulsed current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, evaluation of the discomfort level, current intensity, analysis of neuromuscular efficiency and clinical efficiency, 2 configurations (PC1 and PC2) will be used.~PC1, will be set at a frequency of 100 Hz, phase duration of 1000 microseconds, ON-OFF time of 5s:10s.~PC2, will be set at a frequency of 100 Hz, phase duration of 200 microseconds ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the PC1 configuration will be used."
40860423|NCT03796117|DEVICE|Russian Current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, discomfort level, current intensity, neuromuscular efficiency and clinical efficiency, 2 configurations (RC1 and RC2) will be used.~RC1, will be set to a frequency of 100 Hz, burst duty cycle of 20%, ON-OFF time of 5s:10s.~RC2, will be set at a frequency of 100 Hz, burst duty cycle of 50%, ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the RC2 configuration will be used."
40860424|NCT06071650|BEHAVIORAL|Exercise to a Heart Rate (HR) Zone|Participants prescribed moderate intensity aerobic exercise using personalised heartrate zones with a goal of sustaining an intensity level by maintaining their heartrate above 50 percent of their heartrate reserve level for their prescribed duration
41391412|NCT06320899|DEVICE|SpineShape System IV straight rod stiff|Implantation of SpineShape System IV straight rod stiff (low-flex)
41391413|NCT01408056|DRUG|Timolol 0.5% Gel Forming Solution (GFS)|"Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day"
41391414|NCT01408056|DRUG|Mupirocin 2% Ointment|Topical application twice per day for 60 days
41391415|NCT01518621|RADIATION|Radiation|Whole brain radiation
41039784|NCT00209417|DRUG|Iodixanol 320-Arm 1|
41391416|NCT01518621|DRUG|Radiation plus erlotinib|Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
41391417|NCT04432818|BEHAVIORAL|Pack Health's digital life coaching (DLC)|Pack Health smartphone-based DLC platform will be provided for 16-week subscription which allows unlimited bidirectional communication between enrolled participants and their life coach
41039785|NCT00209417|DRUG|Iopamidol 300-Arm 2|
41039786|NCT04524468|DIAGNOSTIC_TEST|Transthoracic echocardiography|Conventional 2-D transthoracic echocardiography was performed to all patients
41039787|NCT05737082|DRUG|HCP2201|Take 2 tablets once per period
41039788|NCT05737082|DRUG|RLD2205|Take 2 tablets once per period
41039789|NCT05737082|DRUG|RLD2206|Take 1 tablet once per period
41391418|NCT00001144|DRUG|Modified bone marrow stem cell transplantation|
41391419|NCT01921036|PROCEDURE|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
41391420|NCT01921036|PROCEDURE|combined exercise|Moderate endurance and resistance exercise once a week over six months
41391421|NCT02703974|BEHAVIORAL|Early handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete."
41391422|NCT02703974|BEHAVIORAL|Late handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3."
41391423|NCT02703974|BEHAVIORAL|Nudge|"A nudge will be built in each randomly selected school and will consist of:~1. Connecting latrines to the handwashing station via paved pathways that are painted bright colors~2. Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations~The nudges will be constructed at the end of week 3 and 4, after Phase II data collection is complete within each randomly assigned nudge school."
41391424|NCT02703974|BEHAVIORAL|Education|"Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:~* Importance of handwashing~* Method of handwashing~* Critical times of handwashing~* Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.~The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school."
41391425|NCT00255476|DRUG|gefitinib|
41391426|NCT00255476|DRUG|cisplatin|
41391427|NCT00255476|DRUG|5-flourouracil|
41391428|NCT01382134|DRUG|Aspirin, desmopressin|Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only
41391429|NCT01382134|DRUG|Placebo, desmopressin|Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
41391430|NCT02677402|OTHER|immersion|
41391431|NCT05143086|OTHER|Mouthwash 100% Nano-F|Use 10 ml of mouthwash 100% Nanoencapsulated Fluoride after brushing for one week, twice a day.
41391432|NCT05143086|OTHER|Mouthwash 50% Nano-F|Use 10 ml of mouthwash 50% Nanoencapsulated Fluoride after brushing for one week, twice a day.
41391433|NCT05143086|OTHER|Mouthwash standard|Use 10 ml of mothwash after brushing for one week, twice a day. It's for the positive control of fluoride.
41039790|NCT02812810|DEVICE|active rTMS|
41391434|NCT05143086|OTHER|Placebo|Use 10 ml of mouthwash without fluoride
41039791|NCT02812810|DEVICE|sham rTMS|
41039792|NCT01917526|DEVICE|oxygen mask|
41391435|NCT03560115|DIAGNOSTIC_TEST|Single-heel rise test|Single heel-rise test is used to assess the strength of plantar-flexors clinically
41391436|NCT02833558|DEVICE|PuraStat®|PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
41391437|NCT02833558|PROCEDURE|Electrocautery|Electrocautery (coagulation current) to stop bleeding during ESD
41391438|NCT06522230|OTHER|Fascial Stretch Therapy|Fascial Stretch Protocol uses a combination of circumduction, traction, proprioceptive neuromuscular facilitation (PNF) and specific FST maneuvers. Stretch is applied in both active \& passive methods taking into consideration: (1) Oscillatory - slow passive joint oscillations (back and forth movement in a regular rhythm). Small controlled oscillations help with proprioceptors around the joints, acilitates blood flow, gently stretches the ligaments, tendons, nerves, \& muscles and slows the nervous system down; (2) Traction - allows for assessment of the joint capsule movement and to decompress the joint. (3) Movement - designed to enhance the reflexes and are intentionally gentle to maximize benefits; (4) PNF - helps improve flexibility by alternating muscle contractions and relaxations. This stimulates the neuromuscular system, allowing muscles to relax deeper and increase range of motion. (5) Breath - allows the body to increase oxygen consumption to facilitate recovery.
41391439|NCT01581073|DRUG|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
41391440|NCT00201734|DRUG|Capecitabine|Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
41391441|NCT00201734|DRUG|Carboplatin|Levels 1-5: AUC of 6 every 4 weeks.
41391442|NCT00201734|DRUG|Paclitaxel|Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
41391443|NCT01123980|DRUG|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
41039793|NCT01917526|DEVICE|oxygen cannula|
41039794|NCT06052241|DRUG|shampoos and scalp serums|shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
41391444|NCT01123980|DRUG|metformin|"China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day."
41391445|NCT01123980|DRUG|glimepiride|"China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day."
40860425|NCT01909089|DRUG|Spinal administration of chloroprocaine.|"In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~* effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~* Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally."
40860426|NCT02942758|DRUG|low-dose Azacitidine|Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
40860427|NCT02942758|DRUG|Pioglitazone|Pioglitazone 45 mg p.o. continuously from day 1
40860428|NCT02942758|DRUG|ATRA|ATRA \*45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; \*this regimen will be chosen for the first dose to be evaluated.
40860429|NCT02942758|DRUG|standard-dose AZA|Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
40860430|NCT04741919|PROCEDURE|Yag Laser peripheral Iridotomy|Laser peripheral iridotomy will be performed using neo-dynium:yttrium:aluminium-garnet laser after pretreatment with 2% pilocarpine and brimonidine 0.15%. Superior LPIs will be placed between the 11- and 1-o'clock positions such that they were covered completely by the upper eyelid; nasal/temporal LPIs will be placed between the 2- and 4-o'clock positions or the 8- and 10-o'clock positions such that they were completely clear of the lid margin. Preference will be given to iris crypts, avoiding iris vessels when possible. Laser peripheral iridotomies will be performed in both eyes during the same visit and will be confirmed to be patent after the procedure. Intraoperative data collected will include initial per-shot laser energy in milli joules, number of laser shots, and total laser energy in millijoules. All the patients will be treated with flurometholone 0.1% eye drops QID for 5 days after surgery.
40860431|NCT01427426|DIETARY_SUPPLEMENT|All Greens|All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
40860432|NCT01427426|OTHER|Control Formulation|The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
40860433|NCT00434642|DRUG|Carboplatin|Carboplatin was provided as commercially available drug.
40860434|NCT00434642|DRUG|Gemcitabine|Gemcitabine was provided as commercially available drug.
40860435|NCT00434642|DRUG|Bevacizumab|Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL \[25 mg/mL\]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
40860436|NCT00434642|DRUG|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
41391446|NCT01123980|DRUG|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
40860437|NCT03464019|DRUG|Etripamil|Etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
40860438|NCT03464019|DRUG|Placebo|Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
40860439|NCT03464019|DRUG|Etripamil Test Dose|During the Test Dose, etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
40860440|NCT01324661|BEHAVIORAL|Ostracism|Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
41391447|NCT02820935|DRUG|CC-220|
41391448|NCT02820935|DRUG|Rifampin|
40860441|NCT03529981|OTHER|Tuned Vibroacoustic Stimulation (TVS)|TVS is an exteroceptive cue that may reduce subjective and physiological indicators of stress and increase behavioral performance
40860442|NCT03529981|OTHER|no active intervention|No intervention will be administered
40860443|NCT00565851|BIOLOGICAL|Bevacizumab|Given IV
40860444|NCT00565851|DRUG|Carboplatin|Given IV
41039795|NCT03691467|DEVICE|immediate dental implant|immediate dental implant placement in freshly extracted socket.
41039796|NCT03691467|DRUG|Hyaluronic Acid|topical application of hyaluronic acid
41391449|NCT02820935|DRUG|Itraconazole|
40860445|NCT00565851|DRUG|Docetaxel|Given IV
40860446|NCT00565851|DRUG|Gemcitabine Hydrochloride|Given IV
40860447|NCT00565851|OTHER|Laboratory Biomarker Analysis|Correlative studies
40860448|NCT00565851|DRUG|Paclitaxel|Given IV
40860449|NCT00565851|OTHER|Quality-of-Life Assessment|Ancillary studies
41039797|NCT02948569|DRUG|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
41391450|NCT04975282|DEVICE|Bottle feeding|Bottle was used as an alternative oral feeding method for preterm infants.
41391451|NCT04975282|DEVICE|Cup feeding|Cup was used as an alternative oral feeding method for preterm infants.
41391452|NCT04591769|DEVICE|Different tracheal tube cuff design|Comparison of effect between 2 different designs of tracheal tube cuff
41417886|NCT03827109|BEHAVIORAL|Mentor|Mentees will be matched with a mentor for a year-long, 1:1 mentee-mentor relationship. Matching mentors and mentees is based on gender (same), age, geographical proximity, ethnicity, and interests. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month, one of which can be attending a group activity together. Due to the COVID-19 pandemic, a modification was approved so that all study activities can be conducted virtually, e.g., the in-person mentor-mentee monthly activity can be conducted via Skype, and group activities are live streamed
41391453|NCT04034199|DRUG|Denosumab|Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.
41391454|NCT04034199|DRUG|Zoledronic Acid|Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
41391455|NCT00788008|DRUG|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
41391456|NCT04783792|DIETARY_SUPPLEMENT|Ascorbic acid / phytochemical supplement|Ascorbic acid / phytochemical supplement
41391457|NCT04783792|DIETARY_SUPPLEMENT|Ascorbic acid|Ascorbic acid
41391458|NCT00975273|BEHAVIORAL|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
41391459|NCT00975273|BEHAVIORAL|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
41391460|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.
41391461|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
41391462|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
41391463|NCT05155020|BIOLOGICAL|Placebo|Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.
41391464|NCT00829439|DRUG|Levodopa/Carbidopa (4:1)|"Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
41391465|NCT00668109|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg one hour prior to sexual intercourse
41391466|NCT00668109|DRUG|Tadalafil|10 mg taken approximately 24 hours prior to sexual intercourse
41391467|NCT01535391|DRUG|Nilotinib|Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).
41391468|NCT04368182|BIOLOGICAL|Autologous C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
41391469|NCT00004009|DRUG|tipifarnib|
40860450|NCT01629173|PROCEDURE|Dynamic impression insole|We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
41167748|NCT02735434|OTHER|Internet-based discussion forum|The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
41391470|NCT04299737|OTHER|Treatment Bundle (as defined below)|Patient decolonization within one hour of incision, improved environmental cleaning (frequency and quality, including but not limited to targeted use of no touch disinfection with UV-C treatment), provider hand hygiene leveraging proximity, improved catheter disinfection, and surveillance optimization.
41391471|NCT04886869|DIETARY_SUPPLEMENT|caffeine|oral consumption
41391472|NCT00819858|DIETARY_SUPPLEMENT|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
41391473|NCT04099082|OTHER|samples|blood sample nasal swab
40860451|NCT01629173|PROCEDURE|Custom molded insole|The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
40860452|NCT01629173|PROCEDURE|9-mm uncompressed Plastazote|We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
41391474|NCT04676919|DEVICE|phonophoresis therapy with pulsed mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
41391475|NCT04676919|DEVICE|phonophoresis therapy with continuous mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
41391476|NCT04676919|DEVICE|sham ultrasound|sham ultrasound therapy, five days a week for three weeks
41391477|NCT05892965|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
40860453|NCT01629173|PROCEDURE|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
41391478|NCT01293409|OTHER|Transcranial Brain-Targeted Bright Light Treatment|Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
40860454|NCT00666224|DRUG|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
40860455|NCT00666224|DRUG|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
40860456|NCT00666224|DRUG|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
40860457|NCT01804881|BEHAVIORAL|Lifestyle counseling|Six week program to address problematic eating
40860458|NCT00830466|DRUG|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
40860459|NCT01115673|DRUG|Acetaminophen|Acetaminophen Caplet - single dose
40860460|NCT01115673|DRUG|Placebo Control|0 mg Caplet - single dose
40860461|NCT05809193|BEHAVIORAL|Family-Focused Therapy|"After the patient and family are informed, they are included in the therapy group on a voluntary basis. After evaluation by independent evaluators, therapy sessions are started by therapists.~Session 1: Goal Setting, Treatment Overview, Symptoms, Vulnerability Stress Model Session 2: Stress and Coping Skills, Regulation of sleep habits, Relaxation exercises Session 3: Optimizing Family Support; Prevention Plan, Medication adherence Session 4: Overview of Communication Skills; Expressing Positive Feelings, Active Listening Session 5: Making Positive Requests for Change, Communication Clarity Session 6: Expressing Negative Feelings Session 7: Introduction to Problem Solving Skills Session 8 and 9: Problem Solving Skills, Termination of Treatment The same psychometric assessment will be repeated before and after FFT. Intra-group comparisons will be made. Also study groups will be compared using time by group interactions to investigate the differences in therapy response."
40860462|NCT05566171|DIETARY_SUPPLEMENT|Activia Probiotic Yogurt|Activia probiotic Yogurt will be consumed by participants in this group
40860463|NCT06240949|DEVICE|Positional Release Technique|Positional Release Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
40860464|NCT06240949|DEVICE|Manual Pressure Technique|Manual Pressure Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
40860465|NCT01407757|GENETIC|DNA analysis|
41039798|NCT06060457|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
41039799|NCT06060457|BIOLOGICAL|mRNA-1345|Suspension for injection
41391479|NCT06303882|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
41391480|NCT06303882|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
40860466|NCT01407757|GENETIC|gene expression analysis|
40860467|NCT01407757|OTHER|laboratory biomarker analysis|
40860468|NCT01407757|OTHER|pharmacogenomic studies|
40860469|NCT00449124|DRUG|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
40860470|NCT00449124|BIOLOGICAL|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.
40860471|NCT03053570|DEVICE|Cryoballoon|use Cryoballoon to isolation the Pulmonary Vein
40860472|NCT03053570|DEVICE|Radiofrequency Energy(Contact Force)|use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein
40860473|NCT03081884|DRUG|FACBC PET-CT Imaging|"Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.~Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection."
41039800|NCT06060457|BIOLOGICAL|Fluzone HD|Suspension for injection
41039801|NCT02319811|PROCEDURE|Cryopreserved meniscus transplants|Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
41391481|NCT06303882|BEHAVIORAL|conventional cognitive training|including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
41391482|NCT04201418|DRUG|Patisiran|Patisiran-lipid complex injection, for intravenous use
41391483|NCT04791865|BEHAVIORAL|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
40860474|NCT05921838|OTHER||
41039802|NCT05488392|PROCEDURE|Hypothermia with intrajugular cooling|Hypothermia with intrajugular cooling will be applied after successful recanalization of the culprit internal carotid artery/middle cerebral artery. The perfusion rate will be set at 30 ml/min. Low temperature saline will be infused into the internal jugular vein for 10 min, 15 min, 20 min, 25 min, and 30 min successively.
41039803|NCT00000602|DRUG|hydroxyurea|
41039804|NCT00006136|DRUG|arginine butyrate|
41039805|NCT00006136|DRUG|epoetin alfa|
41391484|NCT04791865|BEHAVIORAL|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
41391485|NCT03171610|DRUG|Sufentanil group|PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
41391486|NCT03171610|DRUG|Fentanyl group|PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
41391487|NCT00973856|OTHER|PURELL VF481|One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
41391488|NCT00973856|OTHER|Placebo Solution|One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
41391489|NCT04268784|DRUG|DNL343|Single and repeating oral dose(s)
41391490|NCT04268784|DRUG|Placebo|Single and repeating oral dose(s)
41391491|NCT03695406|BEHAVIORAL|Mind-Body Program for Fear of Recurrence|An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.
41391492|NCT00533884|OTHER|Assessment of therapy complications|Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
41391493|NCT00533884|OTHER|Neurocognitive assessment|Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
41391494|NCT00533884|OTHER|Quality-of-life assessment|Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
41391495|NCT05151796|DRUG|Aspirin|Daily aspirin intake for cardiovascular prevention
41391496|NCT00028730|BIOLOGICAL|anti-thymocyte globulin|
41391497|NCT00028730|BIOLOGICAL|filgrastim|
41391498|NCT00028730|DRUG|cyclophosphamide|
41391499|NCT00028730|DRUG|fludarabine phosphate|
40860475|NCT02960607|DRUG|Icotinib|Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
41039806|NCT03877042|DEVICE|Cruciate-retaining (CR) prostheses|One leg is conducted TKA with Cruciate-retaining (CR) prostheses.
40860476|NCT05432492|DRUG|AK112|IV infusion, specified dose on specified days
40860477|NCT03793426|BIOLOGICAL|Fibryga|Human plasma-derived fibrinogen concentrate
40860478|NCT00003515|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
41039807|NCT03877042|DEVICE|Posterior-stabilized (PS) prostheses|One leg is conducted TKA with Posterior-stabilized (PS) prostheses.
41039808|NCT05969093|DIAGNOSTIC_TEST|Tinel's Sign performed at different wrist positions|Participants will undergo the Tinel's Sign at different wrist positions while EMG activity and NCV are recorded to investigate the effect of wrist position on median nerve activity.
41391500|NCT00028730|DRUG|thiotepa|
41391501|NCT00028730|PROCEDURE|allogeneic bone marrow transplantation|
41391502|NCT00028730|RADIATION|radiation therapy|
41391503|NCT00921804|DRUG|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
41391504|NCT00921804|DRUG|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
41039809|NCT00002803|DRUG|cyclophosphamide|
41391505|NCT00921804|DRUG|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
41391506|NCT00921804|DRUG|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
41391507|NCT00913471|OTHER|blood samples|"Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy."
40860479|NCT01080807|DRUG|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
41039810|NCT00002803|DRUG|doxorubicin hydrochloride|
41039811|NCT00002803|DRUG|vincristine sulfate|
41039812|NCT00002803|PROCEDURE|conventional surgery|
41039813|NCT02554968|OTHER|Questionnaires|
41391508|NCT00085852|BIOLOGICAL|BLVR|10 mL Hydrogel
41391509|NCT00640614|BIOLOGICAL|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
41391510|NCT03522090|DIAGNOSTIC_TEST|lower neck CT|Computerised tomography of the lower neck done as part of initial CT thorax and lower abdomen
41512712|NCT05280301|DEVICE|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer and the SVD every 2 minutes. At the end of the 30 minute treatment, the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
41512713|NCT06339697|DRUG|different types of laxatives (compounded polyethylene glycol electrolyte dispersions and compounded sodium pico-sulfate)|Bowel preparation with different types of laxatives (compounded polyethylene glycol electrolytes and compounded sodium picosulfate)
41391511|NCT04514146|OTHER|Water-only fasting|In-patient water-only fasting for at least 10 days followed by at least 5 days of refeeding
41391512|NCT04008082|DRUG|Lenvatinib|Lenvatinib capsule.
41391513|NCT01543607|DEVICE|Radiofrequency ablation catheter (Habib EndoHBP)|Catheter placement into bile duct
41512714|NCT04199052|BEHAVIORAL|LinkPositively|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
41512715|NCT05469295|DEVICE|CGM MB-1701 device treatment|This is a pre-approved motorized traction device.
41512716|NCT05469295|DEVICE|CGM MB-1701 Sham device treatment|It is manufactured in the same way as the test device and the operation pattern. However, the actual effect of the massage is minimized.
41512717|NCT04834609|PROCEDURE|Injection of autologous adipose tissue in anal fistula|
40860480|NCT01080807|DRUG|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
41391514|NCT01698762|OTHER|Multimedia Patient Decision Aids (MM-PtDAs)|Patient group will watch a DVD of information about their disease type.
41391515|NCT01698762|OTHER|Comparative Effectiveness Research Summary Guide (CERSG)|Patient group to read a booklet about their disease type.
40860481|NCT00473200|DIETARY_SUPPLEMENT|S-adenosylmethionine|1200 mg daily
40860482|NCT03154996|DRUG|Topotecan|"Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)"
40860483|NCT03154996|DRUG|Gadolinium|Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
40860484|NCT03154996|DEVICE|Synchromed II infusion pumps|Implanted subcutaneously to facilitate chronic infusion.
40860485|NCT05452733|BEHAVIORAL|differences of behavior between sleepwalking and non sleepwalking patient|movement registry done by camera when low intensity sound are send to patient during sleep.
41512718|NCT04841005|OTHER|The Square-Step Exercise Training|The Square-Step Exercise is instructed to walk according to the step pattern shown on a 100 \* 250 cm mat, divided into 40 squares of 25 cm each. It includes forward, backward, lateral and diagonal steps, and step patterns are progressively made more complex. Each pattern consists of two to 16 steps; Individuals are asked to repeat the step pattern until they reach the end of the mat. Each step pattern is repeated 4-10 times to ensure that individuals can complete the pattern. The individuals included in the study will exercise in easy-difficulty patterns for the first 2 weeks, medium-difficulty patterns in the 3rd and 4th weeks, medium and advanced patterns in the 5th and 6th weeks, and advanced patterns in the 7th and 8th weeks. The square-step exercise group will perform 15 minutes of warm-up exercise, 30 minutes of progressive square-step exercise, and 10 minutes of cool-down exercise accompanied by a physiotherapist, 3 days a week.
40860486|NCT03482037|DRUG|Rec 0/0438 1 mg or Rec 0/0438 2 mg|Each vial content will be administered via the catheter used for the self-catheterization
41391516|NCT01698762|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 3, and at 6 months.
41391517|NCT04778007|OTHER|Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire|The Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire consists of 8 questions related with globus pharyngeus symptoms.
41391518|NCT01625286|DRUG|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
40860487|NCT03482037|DRUG|placebo|Each vial content will be administered via the catheter used for the self-catheterization
41039814|NCT06097091|OTHER|Self-management education|A self-management of the FM handbook will be provided. SME will be delivered via weekly video calls over a 6-week period. The video call lasting for 15 minutes, will consist of reviewing the weekly self-management content (5 min), questioning and answering related to the content of the self-management handbook (5 min), and a debriefing session (5 min).
41391519|NCT01625286|DRUG|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
40860488|NCT02652156|DRUG|Bupivacaine|60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.
40860489|NCT02652156|DRUG|Exparel®|20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
40860490|NCT02652156|DRUG|Ropivacaine|40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
40860491|NCT00970437|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
40860492|NCT00970437|BEHAVIORAL|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
40860493|NCT02542826|OTHER|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
40860494|NCT03010033|OTHER|pulmonary rehabilitation|"pulmonary rehabilitation (preoperative part): lower extremity endurance training (using bike ergometer for 3 days, 2 times/day, 15-20min/time) or stair climbing training (3 days, 2 times/day, 30min/time), keep dyspnea index (Borg) score between 5 to 7 points. And inspiratory muscle training (using threshold inspiratory muscle trainer for 3 days, 5 times/day, 2 sessions/time, every session includes 10-20 cycle respirations).~pulmonary rehabilitation (postoperative part): inspiratory muscle training (using threshold inspiratory muscle trainer until hospital discharge, 3-5 times/day, 1 session/time, every session includes 10-20 cycle respirations)."
40860495|NCT06236386|OTHER|VR Experience|VR headset and video experience.
41167749|NCT05493098|OTHER|dry needling|"The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more Dry needling:~The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes."
41167750|NCT05493098|OTHER|sham (placebo) dry needling:|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
41167751|NCT01458847|DRUG|cis-UCA solution|Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
41167752|NCT01458847|DRUG|cis-UCA solution|Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
41167753|NCT01458847|DRUG|cis-UCA solution|Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
41167754|NCT00275145|BEHAVIORAL|Resistance Training|Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets
41167755|NCT00275145|BEHAVIORAL|Aerobic Exercise|Exercise at 75% of maximal capacity for approximately 2 hours per week
41167756|NCT00275145|BEHAVIORAL|Combo|Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group
41167757|NCT00275145|BEHAVIORAL|Continued Sedentary lifestyle|No changes
41167758|NCT02482935|DRUG|Abemaciclib|Administered orally
41167759|NCT04615910|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
41167760|NCT03779477|BEHAVIORAL|Coping with Stress Course|The Coping with Stress Program is a group program, which is developed by Clarke and Lewinson (1995) for the prevention of depression in high-risk adolescents. It is based on cognitive-behavioral therapy principles and contains psychoeducation and cognitive-behavioral therapy interventions. There are handbooks available for the group leader of the program and the participating adolescents. In the handbook developed for the group leader, there is detailed information about the objective of each session and the implemented interventions. The adolescents will find lists organized for the fulfillment of the tasks in the handbook prepared for them. The handbooks of the program were translated in Turkish and experts were consulted for their validity.
41417887|NCT03827109|BEHAVIORAL|Fun group activities|"Program participants vote on fun group activities to participate in for support and to learn self-management skills through experiential opportunities and modeling. These are live streamed during the COVID-19 pandemic."
40860496|NCT00740584|DRUG|3% SPL7013 Gel (VivaGel)|A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
40860497|NCT04472234|OTHER|BPA levels|BPA (Bisfenol A) in urine, blood and follicle fluid samples
40860498|NCT03496675|BEHAVIORAL|Group Music Therapy|The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.
40860499|NCT03496675|BEHAVIORAL|Recreational Choir Singing|RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.
40860500|NCT03496675|OTHER|Standard care|May include pharmacological and non-pharmacological interventions as locally available
40860501|NCT00668837|DRUG|Paliperidone|
40860502|NCT06147999|DEVICE|Biophotonizer - a Biophoton Generator|A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.
40860503|NCT04851054|PROCEDURE|Surgery for colon cancer with intention to cure|Surgery by open or laparoscopic approach
40860504|NCT06132503|DRUG|LP-284|LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.
40860505|NCT04086095|DEVICE|Neofact application aid|The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).
40860506|NCT00195533|DRUG|piperacillin-tazobactam|
40860507|NCT00195533|DRUG|glycopeptide|
40860508|NCT02756572|DRUG|Cladribine|Given IV
40860509|NCT02756572|DRUG|Cyclosporine|Given PO
40860510|NCT02756572|DRUG|Cytarabine|Given IV
40860511|NCT02756572|BIOLOGICAL|Filgrastim|Given SC
40860512|NCT02756572|DRUG|Fludarabine Phosphate|
40860513|NCT02756572|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
41167761|NCT05413863|BIOLOGICAL|Biocon's Human Insulin R U-500|Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).
41167762|NCT05413863|BIOLOGICAL|Humulin® R U-500 (US Reference Product)|Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)
40860514|NCT02756572|OTHER|Laboratory Biomarker Analysis|Correlative studies
40860515|NCT02756572|DRUG|Melphalan|Given IV
40860516|NCT02756572|DRUG|Mitoxantrone Hydrochloride|Given IV
40860517|NCT02756572|DRUG|Mycophenolate Mofetil|Given PO
41167763|NCT02049112|DEVICE|Salivary equivalent|14-day treatment with salivary equivalent sticks
41167764|NCT02049112|DEVICE|Aequasyal|14-day treatment with Aequasyal oral spray
41167765|NCT02049112|DEVICE|Biotene|14-day treatment with Biotene oral spray
41167766|NCT01023945|DRUG|ASP1941|oral
41167767|NCT01023945|DRUG|Placebo|oral
41167768|NCT02660112|DRUG|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
40860518|NCT02756572|OTHER|Questionnaire Administration|Ancillary studies
40860519|NCT02756572|DRUG|Sirolimus|Given PO
40860520|NCT02756572|RADIATION|Total-Body Irradiation|Undergo TBI
40860521|NCT02756572|DRUG|Melphalan Hydrochloride|Given IV
40860522|NCT03962075|PROCEDURE|laparoscopic paravaginal repair|Using a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique
40860523|NCT01485328|DRUG|AMARGOL®|per oral solution, 40 mL single dose
40860524|NCT04713956|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
40860525|NCT04713956|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
40860526|NCT04713956|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
40860527|NCT04713956|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
40860528|NCT04713956|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
40860529|NCT05984043|BEHAVIORAL|Biofeedback|Heart-rate Variability Biofeedback
40860530|NCT05984043|OTHER|Waitlist|Waitlist control group
40860531|NCT04702841|DRUG|Chimeric antigen receptor modified γδ T cells|Dosage: the total dosage of reinfusion is 0.2-5 × 10\^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
40860532|NCT00414141|BIOLOGICAL|Grass MATA MPL|4 subcutaneous injections
40860533|NCT00414141|BIOLOGICAL|Placebo|4 subcutaneous injections
40860534|NCT03158441|DIAGNOSTIC_TEST|Breast MRI|comparison of DTI to dynamic MRI
40860535|NCT00939536|DRUG|Zolpidem Tartrate Tablets 10 mg|
40860536|NCT00776971|OTHER|Sugar-sweetened soft drink|500mL as a preload drink
40860537|NCT00776971|OTHER|Aspartame-sweetened soft drink|500mL as a preload drink
40860538|NCT00776971|OTHER|Semi-skimmed milk|500mL as a preload drink
40860539|NCT00776971|OTHER|Water|500mL as a preload drink
40860540|NCT01518374|DRUG|Florbetapir F 18|370 MBq (10 mCi)
40860541|NCT05971069|PROCEDURE|Group1|Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
40860542|NCT05971069|PROCEDURE|Group2|Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
40860543|NCT05971069|PROCEDURE|Group3|No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
40860544|NCT05730413|DRUG|Bisoprolol|Bisoprolol dose was divided to be taken as 2.5 mg twice per day from hospital admission to discharge.
40860545|NCT05730413|DRUG|Bisoprolol|Bisoprolol was taken as 5 mg per day from hospital admission till discharge.
40860546|NCT00943930|DRUG|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
40860547|NCT05731479|OTHER|Diathermy + exercise group|The Diathermy + Exercise group will receive diathermy for 15 minutes, of which 5 minutes will be applied in the capacitive method and 10 minutes in the resistive method. You will then perform 20 minutes of the following exercises: 1) Bird-Dog, 2) Crunch, 3) Obliques, 4) Drawing, 5) Half plank and 6) Side-plank. You will perform 8-12 repetitions and 3 sets of each exercise. 3 sessions of 35 minutes per week for 8 weeks.
40860548|NCT05731479|OTHER|Diathermy placebo + exercise group|The Placebo + Exercise group will receive 15 minutes of application of the diathermy device without energy emission. It will then perform the same therapeutic exercise protocol described in the GDE. 3 sessions of 35 minutes per week for 8 weeks.
40860549|NCT01929382|DRUG|interferon gamma 1b|Standard therapy vs dose titration
40860550|NCT05433025|DEVICE|Cervigard Neck Collar|A device used to treat neck pain caused by forward head posture
40860551|NCT00731679|DRUG|Rifaximin|
40860552|NCT00731679|DRUG|Placebo|
40860553|NCT03116685|BIOLOGICAL|Oxabact OC5 - Oxalobacter formigenes HC-1|Active study drug
40860554|NCT03116685|OTHER|Placebo|Placebo
40860555|NCT02466984|DRUG|metoclopramide intravenous|Administration route
40860556|NCT03915314|DIAGNOSTIC_TEST|Neuropsychological tests|The investigators do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Quality of Recovery Score - 40 (QoR-40),CAGE Alcoholism Questionnaire,blood albumin、hemoglobin content、ALT、AST、BUN、Cr、1 day before the surgery（baseline);serum biomarkers of endothelial dysfunction，blood brain barrier disruption and neuronal injury to be measured at 2 time points,1 day before the surgery（baseline）and postoperative day 1； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery.
40860557|NCT05987696|DRUG|CD33/CLL1 dual CAR-NK cell|NK cell therapy
40860558|NCT05987696|DRUG|Cyclophosphamid|Lympho-conditioning Agent
40860559|NCT05987696|DRUG|Fludarabine|Lympho-conditioning Agent
40860560|NCT05987696|DRUG|Cytarabine|Lympho-conditioning Agent
40860561|NCT05987696|DRUG|CD33 CAR-NK cell|NK cell therapy
41167769|NCT05957809|OTHER|Structured exercise training|"This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks. • Warm-up program - 10 minutes~* Strength training on unstable surfaces - 25-30 minutes~* High repetition muscular endurance training - 25-30 minutes~* Cool-down program - 10 minutes"
41167770|NCT00616577|DRUG|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
41167771|NCT00616577|DRUG|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
41167772|NCT00616577|DRUG|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
41167773|NCT06338436|DEVICE|Proton Radiation Therapy System (ProBeam)|All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.
40860562|NCT05987696|DRUG|super NK cell|NK cell therapy
40860563|NCT01372969|DRUG|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
40860564|NCT02352844|DRUG|Everolimus|
40860565|NCT02024139|OTHER|Chewing Sugarless Gum|Chewing sugar free gum three times per day for 5-10 minutes
40860566|NCT02024139|OTHER|Using Mouthwash|Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day
40860567|NCT00032734|DRUG|satavaptan (SR121463B)|
40860568|NCT04859426|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
40860569|NCT00479856|DRUG|Lapatinib|Small molecule tyrosine kinase inhibitor
40860570|NCT00479856|DRUG|Capecitabine|Chemotherapy
40860571|NCT00479856|DRUG|Docetaxel|Chemotherapy
40860572|NCT00479856|DRUG|nab-Paclitaxel|Chemotherapy
40860573|NCT02586623|DRUG|Droxidopa capsules|100, 200 or 300 mg
40860574|NCT02586623|DRUG|Placebo capsules|
40860575|NCT03009422|DRUG|Local application pentostam|
40860576|NCT03009422|DRUG|intra-lisional pentostam|
40860577|NCT03009422|DEVICE|fractional CO2 laser|
40860578|NCT02672462|DEVICE|Radio frequency renal denervation system (Golden Leaf GL-06E15A)|
40860579|NCT03670563|OTHER|Short foot exercise protocol|Exercises that target intrinsic foot muscles
40860580|NCT03670563|OTHER|Short foot exercise plus NMES|Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
40860581|NCT02246907|OTHER|Exercise|All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery. The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded. Each exercise session will be divided into two parts. One part will be administered in the morning and the second one late in the afternoon. There will be a period of rest of at least 36 hours between each exercise session.
40860582|NCT00858208|DRUG|pegaptanib sodium|pegaptanib sodium intravitreal injection every 6 weeks for 2 years
40860583|NCT04583332|OTHER|Rhymes|"Participants will be provided with a choice of 3 Nursery rhymes (Wheels on the bus, Old McDonald and Twinkle Twinkle Little Star) Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
40860584|NCT04583332|OTHER|Individual Items in Rhymes|"Participants will be provided with a choice of 3 pictures within the initial choice making of the 2 Nursery rhymes (Wheels on the bus and Old McDonald ) Wheels on the Bus will include - mama/wipers/horn McDonalds - cow/dog/cat Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
40860585|NCT04583332|OTHER|Objects|Participants will be provided with 2,3 and 4 sensory objects. Participants will opt for an object by making a choice between these objects, if this is achieved then the child will be moved to picture level and symbol.
40860586|NCT06440941|OTHER|chatbot-based mindfulness-based stress reduction|During the intervention, participants will be involved in a developed chatbot and undergo a single-item assessment to verify the stability of their mental states for subsequent mindfulness-based stress reduction (MBSR) sessions, deemed stable if rated as excellent, very good, or good; They will then engage in conversations with the chatbot, responding to prompts like What is the most recent thing that made you happy? to foster interactive communication and relaxation. Subsequently, participants need to follow guided MBSR sessions and are encouraged to interact with the chatbot for at least one hour daily; all interactions will be monitored and recorded. After eight weeks, a post-intervention assessment will be conducted, followed by pre-post statistical analyses. A total of ten participants with the most and least significant changes in depression levels will be selected for an open-ended questionnaire.
40860587|NCT00352677|DRUG|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
40860588|NCT00934219|DRUG|Omega-3-Acid Ethyl Esters|LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
40860589|NCT02462720|DRUG|Varithena®|Varithena® treatment in accordance with full prescribing information and instructions for use
40860590|NCT02462720|DEVICE|Radiofrequency ablation|Radiofrequency ablation conducted per physicians' standard of care.
40860591|NCT04322188|OTHER||this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice
40860592|NCT02548208|DEVICE|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
41391520|NCT01625286|DRUG|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
40860593|NCT02548208|DEVICE|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
40860594|NCT05747703|COMBINATION_PRODUCT|Ria Treatment Platform|combined medication, coaching, education, and monitoring
40860595|NCT01913951|DRUG|vosaroxin|Given IV over 10 minutes on Day 1 and 4
41039815|NCT06097091|BEHAVIORAL|pain neuroscience education|"Participants in the experimental group will receive a 6-week PNE program. The PNE program that is designed to explain pain to the participants will be implemented via 6 individual face-to-face sessions, each lasting for 45 minutes over a 6-week period. Printed take-home materials will be provided to the participants to enhance learning. The goal of PNE is to increase participants' knowledge about pain to help them reconceptualize their beliefs about pain and decrease perceived threats of pain. The content will be composed according to the second edition of the book, Explain Pain by Butler and Mosley (2013) as well as etiologies of fibromyalgia. Accordingly, the PI has developed the preliminary PNE content."
41039816|NCT05041673|DRUG|Metformin|Antidiabetic drugs
41039817|NCT03717961|DRUG|BOTOX® solution|Botox solution + Saline serum + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
41167774|NCT01388478|DRUG|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with the physician prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
41167775|NCT03112408|BEHAVIORAL|Forward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
40860596|NCT01913951|DRUG|Azacitidine|Given SC or IV over 15 minutes on days 1-7
40860597|NCT01366482|DEVICE|Cotavance Drug-Eluting Balloon|Treatment with a paclitaxel-coated angioplasty balloon (without preceding plaque excision)
40860598|NCT01366482|DEVICE|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision with a SilverHawk or TurboHawk plaque excision device followed by treatment with a paclitaxel-coated angioplasty balloon
40860599|NCT01366482|DEVICE|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
40860600|NCT01645254|DRUG|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
40860601|NCT01668849|DIETARY_SUPPLEMENT|Grape extract|Grape extract self-administered by mouth daily for 35 days
40860602|NCT01668849|DRUG|Lortab, Fentanyl patch, mouthwash|Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
40860603|NCT03274544|OTHER|PROLUNG|"Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):~* Huang Qi (Radix Astragali Membranaceus): 2 g~* Dan Shen (Radix Salviae Miltiorrhizae): 1 g~* Jiang Huang (Rhizoma Curcumae Longae): 1 g~* Yin Xing (Semen Gingko Bilobae): 1 g~* Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g~* Bai He (Bulbus Lilii): 1g~* Jin Yin Hua (Flos Lonicerae Japonicae): 1 g~* Zi Su Ye (Folium Perillae Frutescentis): 1 g~* Yin Yang Huo (Herba Epimedii): 1g"
40860604|NCT05813457|OTHER|PRESTO Early Identification Program|"The program combines :~1. A population-based information component (information campaign aimed at the general population).~2. A training component for the LPAs (Front Line Actors: general practitioners, school and university medicine, pharmacists, teenagers school and university medicine, pharmacists, teenagers' homes, association networks, SAMU, firemen, etc.).~3. Facilitated access to care for FPE patients in the form of a pivot mobile team that can directly meet the patient at the request of the LPA, initiate care and ensure the relay within a the relay within 4 weeks to the existing specialized psychiatric structures on the site (CMP, CATTP (CMP, CATTP, day hospital, hospitalization unit, child and adolescent psychiatry services) adolescent psychiatry services)"
40860605|NCT05682742|DEVICE|Robotic-assisted Surgery|Subjects scheduled to undergo robotic-assisted surgery
40860606|NCT06364462|OTHER|lifestyle intervention|Dietary recommendations should consider energy restriction and exclusion of MAFLD-mediating components (processed food, food and beverages high in added fructose). A Mediterranean type diet is advisable. Both aerobic exercise and resistance training effectively reduce liver fat and should be tailored based on patient preferences to ensure long-term adherence.
40860607|NCT06170918|DRUG|Remimazolam|remimazolam is given intravenously
40860608|NCT02694302|DEVICE|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
41039818|NCT03717961|DRUG|Placebo group|Placebo + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
41039819|NCT01509729|PROCEDURE|Sham operation|A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
41039820|NCT01509729|PROCEDURE|Knee arthroscopic surgery|A randomized group of patients was given small patches with active 5% lidocaine.
41039821|NCT01164995|DRUG|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
41039822|NCT02901457|OTHER|"The Healthy Body Image intervention"|Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
41039823|NCT06497400|OTHER|Brazilian Jiu Jitsu|Instruction of two classes each week for ten weeks of Brazilian Jiu Jitsu
41391521|NCT01625286|DRUG|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
41391522|NCT01131702|DRUG|Ranitidine|Ranitidine Tablets, 300 mg
40860609|NCT02694302|DEVICE|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
40860610|NCT04050618|DEVICE|fanfilcon A test lens|Silicone hydrogel contact lens
41039824|NCT06497400|OTHER|Hatha Yoga|Instruction of two classes each week for ten weeks of Hatha Yoga
41039825|NCT06497400|OTHER|Waitlist|Participant will waitlist for 5 weeks and then be allowed to decide which intervention they want to do Group A/ Jiu Jitsu or Group B/Yoga for ten weeks..
41391523|NCT02693652|BIOLOGICAL|CVI-HBV-002|"* Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection"
40860611|NCT04050618|DEVICE|ocufilcon D control lens|hydrogel contact lens
40860612|NCT04050618|DEVICE|etafilcon A control lens|hydrogel contact lens
40860613|NCT04966260|OTHER|Standardized Virtual Reality|This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional standard VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
41039826|NCT05674695|DRUG|Ciclosporin|Any systemic drug used for atopic dermatitis in clinical practice
41039827|NCT00344461|DRUG|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
41039828|NCT06411457|DRUG|SHR-A1811+Adebrelimab|Assess the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer SHR-A1811 : 6.4mg/kg , q3w，d1, ivgtt Adebrelimab : 1200mg, q3w，d1, ivgtt
41039829|NCT06367166|DRUG|"Venarus® (diosmin and hesperidin)"|"Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months"
41039830|NCT06367166|PROCEDURE|Endovenous laser ablation (EVLA) with miniphlebectomy|Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.
41039831|NCT06367166|OTHER|Elastic compression|All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment
41167776|NCT03112408|BEHAVIORAL|Backward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
41391524|NCT03907475|PROCEDURE|Biopsy|Undergo tissue biopsy
41167777|NCT03112408|BEHAVIORAL|Execution of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
40860614|NCT04966260|OTHER|Control|This is a one session intervention, where participants will be asked to view a two-dimensional video on an iPad. The activity session will be approximately 15 minutes in length. Prior to starting the activity session, the therapeutic recreation staff will explain the activity.
40860615|NCT04966260|OTHER|Personalized Virtual Reality|This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional personalized VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
40860616|NCT01012258|BIOLOGICAL|Cetuximab + concomitant boost radiotherapy|"Cetuximab 400 milligram/square meter (mg/m\^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~* Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~* Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval"
40860617|NCT00629811|DRUG|Avotermin (Juvista)|"Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:~* Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)~* Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)~Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds."
40860618|NCT00629811|DRUG|Placebo|"Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug."
41167778|NCT03112408|BEHAVIORAL|Generation of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
41167779|NCT06009172|OTHER|Auricular point acupressure (APA)|Auricular point acupressure (APA) is a method derived from Traditional Chinese Medicine. PCOS women in the APA group began to apply pressure on the first day of enrollment. Patients were instructed to press each acupuncture point 3 times a day for 30 times. The PCOS woman is then trained to go to the outpatient clinic every 5-7 days to change the auricular acupressure sticker. The intervention period was 4 weeks.
41039832|NCT06367166|OTHER|Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores|The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment
41391525|NCT03907475|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41039833|NCT01542606|DEVICE|NORMA-SENSE|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
41391526|NCT03907475|DRUG|Capecitabine|Given PO
41039834|NCT01353313|DRUG|Hydrocortisone|"Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
41039835|NCT01353313|DRUG|Placebo|"Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
41039836|NCT00517712|DRUG|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
41039837|NCT01008033|DRUG|IDP-108|Topical application once a day for 48 weeks
41039838|NCT01008033|DRUG|Vehicle|Topical application once a day for 48 weeks
41039839|NCT06099626|OTHER|Different types of disease|Groups were observed according to disease type
41167780|NCT01294410|DRUG|Placebo|Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
41167781|NCT01294410|DRUG|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
41391527|NCT03907475|DRUG|Carboplatin|Given IV
41391528|NCT03907475|PROCEDURE|Computed Tomography|Undergo CT
41391529|NCT03907475|BIOLOGICAL|Durvalumab|Given IV
41391530|NCT03907475|PROCEDURE|Echocardiography|Undergo ECHO
41391531|NCT03907475|DRUG|Gemcitabine Hydrochloride|Given IV
41391532|NCT03907475|DRUG|Nab-paclitaxel|Given IV
41391533|NCT03907475|DRUG|Paclitaxel|Given IV
41391534|NCT03907475|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
41391535|NCT02106793|DRUG|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
41391536|NCT02106793|DRUG|Identical placebo solution|Identical placebo solution
41391537|NCT02258607|DRUG|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
40860621|NCT02529163|OTHER|Late-life Schizophrenia ICP|"The ICP medication algorithms first trial begins with:~* Risperidone titrated to a max dose~Failure to Risperidone will lead to a second trial with either:~* Quetiapine OR Aripiprazole~If subject refuses or if this trial does not work, then offer:~* Ziprasidone or Loxapine~Failure of 2 anti-psychotic trials results in:~* Clozapine trial~If subject refuses a Clozapine trial then:~* Olanzapine offered~titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E~If compliance is an issue then a depot preparation:~* Paliperidone~* Risperidone~* Flupentixol~* Aripiprazole~Physicians will be prompted for non-pharmacological interventions"
40860622|NCT02529163|OTHER|Treatment as Usual|"The TAU group will be offered non-pharmacological interventions such as (but not limited to):~* metabolic monitoring~* skin hygiene~* pain management~* nutritional counseling~* family counselling~* Financial/housing support~* Group CBT (Cognitive Behavioral Therapy)~Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.~Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:~* Risperidone~* Aripiprazole~* Quetiapine~* Olanzapine~* Paliperidone~* Clozapine~* Ziprasidone~Max dosing and the time to reach the target dose is done at the discretion of the treating physician."
40860623|NCT05722548|DRUG|Indomethacin suppository|100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia
40860624|NCT05722548|OTHER|Standard Medical Treatment|Standard Medical Treatment
40860625|NCT04756804|DRUG|70% v/v Isopropyl Alcohol Surgical Solution|Patient preoperative skin preparation
40860626|NCT04756804|DRUG|2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol|Patient preoperative skin preparation
40860627|NCT02690350|DRUG|U3-1784|Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
40860628|NCT00297323|DRUG|Topiramate|75 patients over the age of 2 years old with epilepsy.
40860629|NCT05583916|PROCEDURE|Same Day Discharge - Video-Assisted Thoracoscopic Surgery (VATS) Lung|All patients will be scheduled to surgery at the start of the day and will be discharged within the same day as the procedure.
40860630|NCT00123318|DRUG|epirubicin|50mg/m2 IV day 1
40860631|NCT00123318|DRUG|cisplatin|60mg/m2 IV day 1
40860632|NCT00123318|DRUG|5-fluorouracil|5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line
40860633|NCT00123318|RADIATION|Radiotherapy|45Gy 25 Fractions, 5 days/week for 5 weeks
40860634|NCT00567359|DRUG|Erlotinib|Oral drug taken daily around the same time. Starting dose is 150mg once daily.
40860635|NCT01108913|DRUG|Bimosiamose|
41167782|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
40860636|NCT01108913|DRUG|Placebo|
40860637|NCT03845647|PROCEDURE|contralateral central lymph node dissection|contralateral central lymph node dissection
40860638|NCT05981027|OTHER|Mulligan bent leg raise technique|In this study, while the participant was lying on his back on a high bed, the physiotherapist sat on the lateral side of the leg to be treated, placing the popliteal fossa of the participant's knee on his shoulder. The hip and knee of the leg to be stretched were placed in 90° flexion. Distraction was applied to the lower end of the femur, and the participant was asked to push the physiotherapist's shoulder with his leg and then relax. At this relaxation point, the physiotherapist pushed the flexed knee as far as possible in the direction of the ipsilateral shoulder in a painless range.
40860639|NCT05981027|OTHER|Static stretching exercise|The participant lay on a stretcher in the supine position with his back straight. The physiotherapist placed the participant's leg on his shoulder with the knee in full extension and supported by the ankle and flexed the hip as much as possible until a tension was felt in the posterior thigh. This position was maintained for 30 seconds.
41039840|NCT02603653|DEVICE|Virtual radial task in 3D|The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.
41039841|NCT00403832|DEVICE|intraocular lenses: Two foldable, acrylic, sharp edged IOLs: AcrySof™ (AcrySof SA60AT, Alcon), and Akreos adapt™ (Bausch & Lomb)|
41039842|NCT03412669|OTHER|Supporting Addiction Affected Families Effectively|Counselling
41039843|NCT03412669|OTHER|Enhanced Usual Care|Information sheet
41039844|NCT02802800|OTHER|Plyometric training|Plyometric exercises
41039845|NCT04591522|OTHER|Healthy fecal bacteria liquid|Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.
41039846|NCT02189551|BEHAVIORAL|Gait training with Lokomat Pro|
41167783|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
41167784|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
41167785|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
41167786|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
41167787|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
41039847|NCT02189551|BEHAVIORAL|Gait training with Lokomat Pro FreeD|
41039848|NCT04010994|PROCEDURE|Transorbital electrical stimulation|Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
41039849|NCT02353650|DIETARY_SUPPLEMENT|Q10|
41039850|NCT02353650|DIETARY_SUPPLEMENT|placebo|
41391538|NCT02258607|DRUG|Trametinib|Trametinib tablet administered orally once daily
41039851|NCT00290641|BIOLOGICAL|filgrastim|
41039852|NCT00290641|BIOLOGICAL|graft-versus-tumor induction therapy|
41039853|NCT00290641|DRUG|cyclophosphamide|
41039854|NCT00290641|DRUG|cyclosporine|
41039855|NCT00290641|DRUG|fludarabine phosphate|
41039856|NCT00290641|DRUG|mycophenolate mofetil|
40860640|NCT05765123|DIAGNOSTIC_TEST|Oral glucose tolerance test|A drink containing 75g of glucose together with 150mg carbon-13 sodium acetate in 300ml water
40860641|NCT04770038|BEHAVIORAL|Dialectical Behavior Therapy (DBT)|Evidence-based psychotherapy for the treatment of Borderline Personality Disorder
40860642|NCT05073926|OTHER|No intervention is part of the study protocol|No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
40860643|NCT02088489|DEVICE|Atrial flutter irrigated catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with conventional irrigated Thermocool® (Biosense Webster, Diamond Bar, CA) catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
40860644|NCT02088489|DEVICE|Atrial flutter porous tip catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with Porous tip Thermocool® SF(Biosense Webster, Diamond Bar, CA)irrigated catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
40860645|NCT00083525|DRUG|WX-UK1 in combination with Capecitabine|
40860646|NCT02738554|OTHER|Treatment cessation|Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
40860647|NCT01222780|DRUG|Marqibo|Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle
40860648|NCT01433562|DRUG|DLBS1425|DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
40860649|NCT01433562|DRUG|Placebo DLBS1425|Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
41039857|NCT00290641|PROCEDURE|umbilical cord blood transplantation|
41039858|NCT00290641|RADIATION|radiation therapy|
41039859|NCT03494387|DRUG|Oxygen|80% versus 30% inspiratory oxygen concentration
41512719|NCT04841005|OTHER|Strengthening Exercise Training|Thera-Band brand elastic bands will be used to apply resistance in strengthening training. To determine the intensity of the exercise, the perceived difficulty level after 15 repetitions with the elastic band will be evaluated with the Borg scale. If the perceived difficulty level is at the level of 12-14 (slightly difficult), it will be considered as the starting difficulty level.In the strengthening exercise group will perform, shoulder abduction, shoulder press after elbow flexion, horizontal abduction, punching with an elastic band, triceps strengthening, external rotation of the shoulder, hip abduction with external rotation and sit-to-stand exercises for 8 weeks, 3 days / week , 3 sets / sessions, 8-12 repetitions. For each exercise, it will be applied as 8 repetitions in the initial workload. In the next exercise sessions, the number of repetitions will be increased until the patient can comfortably perform 12 repetitions with the same load.
41512720|NCT05029219|DEVICE|Arm I (Virtual reality group)|"In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The test group receives about 60 minutes of training using a virtual reality program."
40860650|NCT03986203|DEVICE|Spry Belt|The Spry Belt delivers energy to the user that may help prevent bone loss. Participants will wear the device for 30 minutes a day, 5 days a week for one year. The active and sham devices are identical except for the specific energy that is delivered to the user.
40860651|NCT01636986|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses for daily wear, daily disposable use
40860652|NCT01636986|DEVICE|Etafilcon A contact lenses|Hydrogel contact lenses for daily wear, daily disposable use
40860653|NCT03505203|BEHAVIORAL|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
40860654|NCT03505203|BEHAVIORAL|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe.
40860655|NCT00392730|DIETARY_SUPPLEMENT|Remove Mn from PN if evidence of increased brain Mn on MRI|Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
40860656|NCT03035799|OTHER|Paleolithic diet|Paleolithic diet
40860657|NCT03035799|OTHER|General Healthful Diet|General Healthful Diet
40860658|NCT02457156|PROCEDURE|Blumgart Anastomosis|"1. Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied."
40860659|NCT02457156|PROCEDURE|Cattell-Warren Anastomosis|"1. Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied."
41039860|NCT03494387|DRUG|Antioxidants|Antioxidants versus placebo
41039861|NCT00245895|DRUG|Aranesp|Aranesp
41039862|NCT00733538|DRUG|zometa|patients receiving treatment during their follow-up
41167788|NCT04684966|DEVICE|Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined quadriceps and triceps surae ESNM using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (EG group).
40860660|NCT02457156|DRUG|Octreotide|Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
40860661|NCT05211427|PROCEDURE|Biopsy|Biopsy of an oropharynx tumor or of a healthy oropharynx mucosa
40860662|NCT04953637|OTHER|Physiotherapy|Participants in the physiotherapy group will receive gait and balance focused physiotherapy at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks.
40860663|NCT01766180|DRUG|Fruitflow-II|150 mg/day for 3 months, orally
40860664|NCT01766180|DRUG|resVida|150 mg/day for 3 months, orally
40860665|NCT04942613|BEHAVIORAL|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
40860666|NCT04942613|OTHER|Physical Therapy Interventions|strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise
40860667|NCT04942613|OTHER|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene
40860668|NCT04942613|OTHER|Qualitative Interview|Qualitative interview to explore patient perspectives of the multicomponent telerehabilitation program (physical therapy, biobehavioral interventions, technology, and social support interventions) and how they contribute to program engagement and participation as well as changes in physical activity.
40860669|NCT00270309|BEHAVIORAL|Self-management|
40860670|NCT02936817|DEVICE|Aerobika® Device|For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
40860671|NCT02936817|RADIATION|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
40860672|NCT04054076|DEVICE|Prefabricated insoles|The participants received prefabricated insoles
40860673|NCT04054076|DEVICE|Soft custom-made insoles|The participants received soft custom-made insoles
41039863|NCT05812651|OTHER|Inspiratory muscle fatigue|"Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80% MIP). Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure MIP, until MIP measurement decrease of more than 10% from baseline will be performed.~When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation."
41039864|NCT02118220|OTHER|Concussion Questionnaire|
41167789|NCT04684966|DEVICE|Sham Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined sham NMES of the quadriceps and triceps surae performed using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (CG group)
41167790|NCT03961997|DRUG|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
41391539|NCT06134765|DRUG|Bemalenograstim alfa|Bemalenograstim alfa,20mg, once every treatment
41039865|NCT01018394|DRUG|nicotine lozenges|4 mg nicotine lozenges for a maximum duration of 12 weeks used ad lib - up to 8 nicotine lozenges per day.
41391540|NCT04078087|DRUG|Non obese|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
40860674|NCT04054076|DEVICE|Hard custom-made insoles|The participants received hard custom-made insoles
40860675|NCT00891228|DRUG|Testosterone|Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
40860676|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
41391541|NCT04078087|DRUG|Obese.|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
41417888|NCT03827109|BEHAVIORAL|Parent support group|Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing during group events (virtually during the COVID-19 pandemic).
40860677|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
40860678|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
40860679|NCT04872595|OTHER|Personalized rATG (P-rATG)|P-rATG days (always starting on Day -12 to -10)
40860680|NCT04872595|RADIATION|Hyper fractionated total body irradiation|"(1375 - 1500cGy\*) Day -9 to -6~\*TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
41039866|NCT01018394|DRUG|tobacco-free snuff|Tobacco-free snuff used ad lib for a maximum of 12 weeks
41039867|NCT03581812|DIETARY_SUPPLEMENT|Intervention snack 1|To be eaten instead of regular snacks twice a day for 4 weeks.
41167791|NCT03961997|DRUG|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
40860681|NCT04872595|DRUG|Thiotepa|(5mg/kg/day x 2 day) Day -5 to -4
40860682|NCT04872595|DRUG|Cyclophosphamide|(60mg/kg/day x 2 days) Day -3 to -2
41391542|NCT05340517|PROCEDURE|video-assisted rib planting|Give the patient intercostal nerve block and laryngeal mask anesthesia, after that, put the patient in lateral position. Make a 4-6cm posterolateral incision along the lower edge of the scapula，sever latissimus dorsi and serratus anterior and reach the rib surface. Lift the scapula with the abdominal retractor (or xiphoid retractor), Free adhesion tissue inside the scapula and put in the thoracoscopic lens. Free the tissue of the upper and lower edges of the ribs carefully, reset ribs and insert rib plate, which is fixed by 90° electric drill and locking screw.
41391543|NCT02041182|BEHAVIORAL|Pre-Visit Questionnaire|
41391544|NCT04345887|DRUG|Spironolactone 100mg|2x100 mg spironolactone for 5 consecutive days
41391545|NCT04345887|DRUG|Placebo oral tablet|2 x1 placebo tablet
41391546|NCT00200473|DRUG|Nebivolol|
41039868|NCT03581812|DIETARY_SUPPLEMENT|Intervention snack 2|To be eaten instead of regular snacks twice a day for 4 weeks.
41039869|NCT03581812|DIETARY_SUPPLEMENT|Control snack|To be eaten instead of regular snacks twice a day for 4 weeks.
40860683|NCT04872595|DRUG|GCSF|Day +7
40860684|NCT04872595|DRUG|Busulfan|Day -9 to -7 doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg\*h/L
40860685|NCT04872595|DRUG|Melphalan|(70mg/m2/day x 2 days) Day -6 to -5
41039870|NCT01972958|OTHER|comprehensive care|comprehensice assessment,physical activity training, community resources referral, health education.
41039871|NCT00272168|BEHAVIORAL|Maryland Program for Vocational Effectiveness|psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
41039872|NCT00272168|OTHER|Supportive Treatment for SMI|Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
41039873|NCT02504073|OTHER|No intervention|No intervention
41039874|NCT05225493|BEHAVIORAL|Peer to peer feedback|HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing
41039875|NCT05225493|DIAGNOSTIC_TEST|HIV rapid test|Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV
41039876|NCT02559336|OTHER|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
41039877|NCT00529399|DRUG|GAD-Alum|Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
41039878|NCT00529399|DRUG|GAD-Alum and Aluminum hydroxide|Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
41039879|NCT00529399|DRUG|Aluminum hydroxide|Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
41039880|NCT05040451|DEVICE|Carillon Mitral Contour System|"The Carillon Mitral Contour System (XE2) consists of the following components:~* An implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~* A delivery system which consists of a custom 9F delivery catheter and a handle assembly."
41039881|NCT06167187|PROCEDURE|bilateral inferior alveolar nerve block|Placing the tip of the thumb or forefinger into the coronoid notch (retromolar fossa) to help visualize the vertical height at which the needle will enter, and retracting the cheek to expose the pterygomandibular triangle. Placing the barrel of the syringe over the contralateral lower 1st and 2nd premolars and resting the side of the needle tip against the lateral edge of the pterygomandibular raphe, aiming the tip of the needle into the pterygomandibular triangle, with the bevel facing the ramus. Advancing the needle tip slightly into the mucosa until it is stopped by the ramus (typically after about 2 to 2.5 cm of insertion) and withdrawing needle 1 mm away from bone. Aspirating to rule out intravascular placement. If aspiration reveals intravascular placement, withdrawal of the needle will be done 2 to 3 mm, then reaspirating prior to injection. Slowly injecting about 2 to 4 milliliters of bupivacaine 0.5% anesthetic in each side..
41039882|NCT06167187|DRUG|Ketorolac and fentanyl|in control group, Patients will not receive the block and pain will be controlled according to institutional protocol using 30 mg ketorolac IV and fentanyl increments as needed.
41391547|NCT00002628|BIOLOGICAL|filgrastim|
41391548|NCT00002628|DRUG|carboplatin|
40860686|NCT04872595|DRUG|Fludarabine|(25mg/m2/day x 5 days) Day -6 to -2
41391549|NCT00002628|DRUG|cyclophosphamide|
41391550|NCT00002628|DRUG|mesna|
41391551|NCT00002628|DRUG|paclitaxel|
41391552|NCT00002628|PROCEDURE|peripheral blood stem cell transplantation|
41391553|NCT06242600|DEVICE|Drainage of the bladder by indwelling Foley catheter|Drainage of the bladder by transurethral catheterization with an indwelling Foley catheter of patients undergoing a TUR-B procedure and in need of a Foley catheter for up to 24 hrs.
41391554|NCT06542471|DEVICE|Dual intramedullary nailing|- Elastic nailing for radius under image guidance through distal entry point and physeal sparing technique.
41391555|NCT06542471|DEVICE|Dual plating|- ORIF for radius done first through volar approach.
41391556|NCT04128696|DRUG|feladilimab|feladilimab is available as an intravenous infusion.
41391557|NCT04128696|DRUG|Pembrolizumab|Pembrolizumab is available as an intravenous infusion.
41391558|NCT04128696|DRUG|Placebo|Placebo is available as an intravenous infusion.
41417889|NCT04025879|BIOLOGICAL|Nivolumab|Specified dose on specified days
40860687|NCT03590314|DEVICE|Experimental group - robot assisted arm training (Armotion®)|"Passive mobilization and stretching exercises for affected upper limb (10 minutes) followed by robot-assisted exercises (35 minutes). Were selected four types of exercises contained within the Armotion® software:~* Collect the coins~* Drive the car~* Wash the dishes~* Burst the balloons~For increment the difficulty, we have varied the assisted and non-assisted modality, increasing the number of repetitions over the study period."
40860688|NCT03590314|OTHER|Control group - conventional treatment|Upper limb passive mobilization and stretching (10 minutes) followed by exercises (35 minutes) that incorporated single or multi-joints movements for the scapula, shoulder and elbow, performed in different positions (i.e. supine and standing position). The increase of difficulty and progression of intensity were obtained by increasing ROM, repetitions and performing movements against gravity or against slight resistance.
40860689|NCT01388907|OTHER|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
40860690|NCT01388907|DEVICE|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
40860691|NCT03072264|BEHAVIORAL|Body in Mind Training (BMT)|Session 1 - Stop; Session 2 - Intention; Session 3 - Attention; Session 4 - Scientist Myself; Session 5 - Self-Compassion; Sessions 6, 7, 8 - Practice.
40860692|NCT03072264|DRUG|Fluoxetine|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
40860693|NCT03072264|BEHAVIORAL|Quality of Life Group|Session 1 - Psychoeducation; Session 2 - Substance Use; Session 3 - Sleep; Session 4 - Physical Exercise; Session 5 - Healthy Eating; Sessions 6, 7,8 - discussions.
41039883|NCT01592643|DEVICE|Eye Shield|The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
40860694|NCT05211206|OTHER|IV fluids|Amount of intravenous fluids delivered
40860695|NCT03056742|BIOLOGICAL|Stempeucel(R)|Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells
41039884|NCT01354158|DRUG|Droxidopa|Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
41391559|NCT06138795|DRUG|AZD2389|Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.
40860696|NCT04807335|DRUG|CT001|nasal spray
41391560|NCT06138795|DRUG|Placebo|Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
41391561|NCT02773888|DEVICE|HS-1000|
41391562|NCT02440100|DRUG|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
41391563|NCT02440100|DRUG|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
41391564|NCT02440100|DRUG|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
40860697|NCT04807335|DRUG|Ketamine|iv single dose
40860698|NCT04807335|DRUG|sufentanil|iv single dose
41039885|NCT03910127|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
41391565|NCT00257088|BEHAVIORAL|whole day first grade program|
41391566|NCT00660049|DEVICE|SNaP Advanced Wound Care System|Application of negative pressure device daily per instructions
41391567|NCT00660049|OTHER|SNaP|Daily use
41391568|NCT00660049|OTHER|SNaP|Daily application per protocol
40860699|NCT04089761|DEVICE|Nerivio|Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
41039886|NCT03910127|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
41039887|NCT03910127|DRUG|Anlotinib|matching placebo
41039888|NCT01369862|BIOLOGICAL|GHB16L2|A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants
41039889|NCT01369862|BIOLOGICAL|Placebo|SPGNH buffer
41039890|NCT03925376|PROCEDURE|Redo cardiac surgery|Redo cardiac surgery is technically challenging due to scarring of tissues resulting in loss of tissue planes, adhesions, multiple comorbid factors and risk of injury during re-entry.Suggested techniques in coronary artery surgery with a left internal mammary artery include routing the graft through a slit in the pericardium to minimize the possibility of adherence to the sternal table.
41039891|NCT02895087|OTHER|Diurnal Variation Group|This intervention occurs over one 24-hour period. Eligible participants will be required to be admitted into a supervised environment for 24-hours arriving no later than 0730. Blood draws will then be taken every 4 hours (0800, 1200, 1600, 2000, 2400 and 0400). Care will be taken to ensure the total blood draws (including the screening visit) stay within Red Cross Guidelines (less than 500 ml every 8 weeks).
41039892|NCT02895087|OTHER|External Stress Group|"2 visits will be required, each lasting approximately 2.5 hours in the afternoon.~At both visits participants will rest quietly for 15 minutes, then have 3 blood draws and 4 saliva samples over approximately one hour. Participants will also be required to complete short questionnaires about their mood and experience.~At the second visit, participants will also complete some thinking and talking tasks. In addition the autonomic nervous system of the participant's will be monitored throughout the visit."
41167792|NCT03961997|DRUG|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
41167793|NCT01874665|DRUG|Ponatinib|Ponatinib 45 mg, tablets, orally, once-daily.
41391569|NCT02759627|OTHER|Robotic-Assisted Gait Training|"There were three intervention arms in this study,~1. Robotic-Assisted Gait Training,~2. Conventional Training,~3. Combined Training."
41167794|NCT00397137|PROCEDURE|Circular stapled anopexy|Patients receiving stapled anopexy to treat haemorrhoids
41167795|NCT00397137|PROCEDURE|Closed diathermy haemorrhoidectomy|Conventional haemorrhoidectomy as described by Ferguson method
41167796|NCT03889054|BEHAVIORAL|Education program|"The education sessions will be given in 3 opportunities (15-30, 45 and at 90 days from diagnosis of the exacerbation) and it will be individualized. The program will include measures of self-care and self-management recommended in patients with COPD:~1. Plan of action in an exacerbation.~2. Education related to COPD.~3. Information on pharmacological medication.~4. Management of the exacerbation.~5. Management of stress and / or anxiety.~6. Nutritional recommendations.~7. Physical exercise recommendations.~8. Healthy lifestyle recommendations. The first session will last 90 minutes and will be explain according to the contents of the manual Controlling COPD. A presentation designed for this purpose will be displayed and this manual will be provided to patients to carry out their reading at home. The second and third sessions will last 15 minutes and the purpose will be to resolve doubts."
41167797|NCT04228354|DRUG|Semaglutide|Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks
41391570|NCT00934622|DEVICE|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
41391571|NCT02079428|OTHER|No interventions|
41039893|NCT00912548|DRUG|goserelin|"1. Zoladex™ administration:~   Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~2. Sequence of administration Zoladex depot:~   The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~3. Dosage:~   Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~4. Storage instructions for Zoladex™ Zoladex™ is kept a room temperature."
41039894|NCT00912548|DRUG|tamoxifen|"1. Dose and period of Tamoxifen therapy:~   Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~2. Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light."
41039895|NCT03769467|BIOLOGICAL|tabelecleucel|Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
41039896|NCT03769467|BIOLOGICAL|pembrolizumab|pembrolizumab IV infusion
41039897|NCT01383733|DRUG|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
41167798|NCT02971228|DRUG|Insulin Lispro|Used to lower blood glucose. Commercially available by prescription and is indicated for patients with type 1 diabetes mellitus (T1DM), but not for use in a bionic pancreas. Individualized dose based on metabolic needs and frequent monitoring of blood glucose.
41167799|NCT02971228|DRUG|ZP4207 (dasiglucagon)|A glucagon analog not yet approved by the FDA. Subcutaneous administration in one BP arm.
41167800|NCT02971228|DRUG|Glucagon|A hormone normally made by the pancreas to raise blood glucose. Used to treat low blood sugar. Commercially available by prescription and is indicated for patients with T1DM in severe hypoglycemia, but not for use in a BP. Subcutaneous administration in one BP arm.
41167801|NCT02971228|DEVICE|iPhone-based bionic pancreas|An experimental device.
41167802|NCT02971228|DEVICE|iLet-based bionic pancreas|An experimental device.
41167803|NCT06007105|BEHAVIORAL|SUCCEED Community-Based Intervention|"The main components of the intervention are peer support, case management and livelihoods activities, delivered by a peer support worker and a community support worker. The peer support worker has lived experience of psychosis and draws on a variety of manualised tools and techniques adapted from previous studies. The community support worker mobilises families and communities to activate resources in support of participants (e.g., education and employment, social and recreational activities), drawing on established models of mental health case management and community-based inclusive development. The peer support worker and community support worker also run self-help groups for people with lived experience and their family members, respectively. Self-help group meetings are also used as an opportunity for group livelihoods activities taking an ABCD (asset-based community development approach."
41167804|NCT04493645|BEHAVIORAL|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to restore ankle joint range of motion, strength, postural control, and functional movement. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
41391572|NCT05813665|DRUG|Narlumosbart|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
41391573|NCT05813665|DRUG|Denosumab|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
41391574|NCT05558852|PROCEDURE|Laparoscopic Meshless Sacrocolpopexy Technique|Meshless sacrocolpopexy: laparoscopic approach to central and anterior compartment prolapse
41391575|NCT00004288|DRUG|olsalazine|
41391576|NCT05785026|OTHER|Menthol inhalation|300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
41391577|NCT05785026|OTHER|Strawberry scent|600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
41039898|NCT02267395|OTHER|(1) cranio-cervical flexion test;|Test to determine level of strength for Deep Neck Flexor muscles
41039899|NCT02267395|OTHER|(2) scapular dyskinesis test|Test to determine scapular control
41039900|NCT02267395|OTHER|(3) deep neck flexor endurance test.|Test do determine endurance for the deep neck flexor muscle group.
41039901|NCT02203474|DRUG|Tiotropium HFA BAI 5 mcg|
41039902|NCT02203474|DRUG|Tiotropium 18 mcg Capsule|
41039903|NCT02203474|DRUG|Placebo|Placebo
41039904|NCT05320731|PROCEDURE|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
41167805|NCT04493645|BEHAVIORAL|Foot Intensive Rehabilitation (FIRE)|6 weeks of FIRE will be given along with elements of SOC. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
41391578|NCT03881579|BEHAVIORAL|nurse-led supportive care assessment|Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm
41167806|NCT05949645|DEVICE|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
41391579|NCT06541093|BIOLOGICAL|UVAX-1107|Novel HIV-1 protein nanoparticles vaccine candidate (WT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants
41391580|NCT06541093|BIOLOGICAL|UVAX-1197|Novel HIV-1 protein nanoparticles vaccine candidate (GT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants
41391581|NCT06541093|OTHER|Placebo|Saline injection
41391582|NCT03640442|OTHER|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
41391583|NCT03640442|OTHER|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
41391584|NCT02442115|OTHER|Treatment of Functional Constipation by|The NASPGHAN protocol is used by pediatric gastroenterologist to treat functional constipation. Status is monitored at 4 visits and adjustments to treatment are made based on clinical standards and judgment.
41391585|NCT00324090|BEHAVIORAL|High and low glycemic index|
41512721|NCT05029219|DEVICE|Arm II (Self study group)|"In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The control group have provided with video materials and books provided during audiovisual education and have given time for self-study for 60 minutes. Subsequently, a second test is performed with a fluroscopy-guided lumbar transforaminal epidural block with a human-shaped phantom."
41512722|NCT05305066|DRUG|TNFi|TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.
41512723|NCT05305066|DRUG|Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight \<100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)
41167807|NCT05050435|PROCEDURE|Early extubation|Patients of the 2 groups are extubated at different moments: either immediately postoperatively, in the operating room, or after a few hours monitoring in ICU
41512724|NCT05305066|DRUG|JAKi|JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)
41391586|NCT02119182|BEHAVIORAL|In-Person Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.
41512725|NCT01723475|BIOLOGICAL|BAY2010112|Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
41512726|NCT01723475|BIOLOGICAL|BAY2010112|Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
41512727|NCT02776943|BIOLOGICAL|umbilical cord mesenchymal stem cells|
41512728|NCT02776943|DEVICE|Hyaluronic acid|
41512729|NCT03027024|DEVICE|Implantation of IOL: PhysIOL POD F GF|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
41391587|NCT02119182|BEHAVIORAL|Phone Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.
41391588|NCT02119182|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|3T Research MRI at 2 weeks and 6 months.
41391589|NCT02119182|PROCEDURE|Blood Draw for Plasma, DNA, Serum, RNA|Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only).
41391590|NCT00423228|DRUG|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
41391591|NCT00423228|DRUG|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
41391592|NCT06232707|DRUG|Alnuctamab|Specified dose on specified days
41512730|NCT04599478|DRUG|Naltrexone and Bupropion medication|NB medication will be taken daily in pill form.
41167808|NCT00002061|DRUG|Inosine pranobex|
41391593|NCT06232707|DRUG|Pomalidomide|Specified dose on specified days
41391594|NCT06232707|DRUG|Daratumumab|Specified dose on specified days
41391595|NCT06232707|DRUG|Elotuzumab|Specified dose on specified days
41391596|NCT06232707|DRUG|Carfilzomib|Specified dose on specified days
41391597|NCT06232707|DRUG|Dexamethasone|Specified dose on specified days
41391598|NCT02933827|DRUG|ELIXCYTE|Adipose-derived stem cells (ADSCs)
41391599|NCT00351156|PROCEDURE|Blood sample|
41512731|NCT04599478|BEHAVIORAL|Behavioral Weight Loss|Behavioral Weight Loss (BWL) counseling includes weekly sessions.
41512732|NCT04599478|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
41512733|NCT05886205|DRUG|iPSC-Exos|iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
41512734|NCT01406574|DRUG|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
41391600|NCT00419900|PROCEDURE|diagnosis of breast cancer by x-ray diffraction of hair|
41391601|NCT05571280|DIETARY_SUPPLEMENT|Nutritional Supplementation|"The Small-quantity lipid-based nutrient supplementation (SQ-LNS) consists of micronutrients delivered in a lipid-based vehicle. All pregnant women (as of 12 weeks self-referred) within households who were randomly included in the study in the nutritional supplementation arm and their children as of 6 months of age will receive the SQ-LNS.~● Pregnant women: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake.~Total = 12/13 months approximately.~● Children from 6 months of age: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake. Total = 18 months.~The distribution will be made by ADECOS on a fortnightly basis.~A family ration will be distributed: family supplementation is presented in a basket of locally produced basic foods that complement the usual diet. The caloric distribution of the basket will be 45% of cereals, 30% of pulses, and 25% in oil, and 1 kg of iodized salt."
41391602|NCT05571280|BEHAVIORAL|Money transfers|The distribution of the amounts will be made through the corresponding financial providers, together with the Municipal or Communal Administration authorities, the Assistants of Community Activities, the Investigator's personnel, and the ADECOS. The distribution frequency will be every 3 months until the end of the study.
41391603|NCT05571280|BEHAVIORAL|Standard intervention|"The activities included are the following:~1. Community interventions against malnutrition and promotion of adequate nutrition: raise awareness of malnutrition and training mothers to recognize signs of malnutrition.~2. Community interventions in promoting hygiene and proper sanitation: a) Promotion of Community-Led Total Sanitation approach (CLTS)strategy: community awareness of the entire population included in the cluster about the dangers of open defecation, and the direct link to malnutrition; b) Promotion of Baby-Wash strategy: to make the community aware of the problems and consequences of unsafe water consumption.~3. Biannual supplementation with vitamin A for children from 6 to 24 months of age.~4. Biannual deworming (albendazole/mebendazole) for children from 12 months to 24 months of age and pregnant women as of 2nd quarter.~5. Malaria prophylaxis with sulfadoxine-pyrimethamine (SP) in pregnant women as of 13 weeks of pregnancy."
41391604|NCT03347227|PROCEDURE|Catheter ablation|Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
41391605|NCT01979588|OTHER|What's Going Around tool|Provider has access to the What's Going Around tool
41391606|NCT01979588|OTHER|Control|Provider does not have access to the What's Going Around tool but received information regarding the tool prior to study initiation
41391607|NCT04084028|BEHAVIORAL|Active Cooking Classes|6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation.
41391608|NCT04084028|BEHAVIORAL|Meal Kits|Students receive 6 weeks of home delivered meal kits. Meal kits include ingredients and detailed instructions for 3 meals, which each serve two people. Students may select meals from a list of 18 options that include vegan, vegetarian, and gluten free options.
41417890|NCT04025879|DRUG|Carboplatin|Specified dose on specified days
41417891|NCT04025879|DRUG|Cisplatin|Specified dose on specified days
40860700|NCT05426070|BEHAVIORAL|Strength training-based exercise|Participants will take part in two group-based Zoom exercise sessions and two individual exercise sessions per week for three months. Exercise sessions will include a combination of various aerobic (e.g., jogging in place, high knees) and muscle strengthening exercises (e.g., burpees, push-ups, lunges, body weight squats) designed to keep heart rate in the 60-85% range of maximum heart rate. Participants will choose from a variety of options for their two individual sessions (e.g., online exercise video, jogging or walking outside, prescribed exercise session listed on the website, or any other exercise) and modifications for each exercise will be made depending on the participant's ability and current fitness and strength level. Participants will be instructed to stop exercising if problems occur and will receive training and handouts on how to recognize problems such as angina and myocardial infarction.
40860701|NCT04800146|PROCEDURE|Blood sample|Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination
40860702|NCT05771740|DEVICE|Stemoscope (bluetooth sound amplifier)|The bluetooth device will be placed in six locations on the front and six locations on the back of the chest and sound recordings stored for each location.
40860703|NCT00356967|DRUG|dianicline|
40860704|NCT00437814|DRUG|Ketamine, effect on intracranial pressure|
40860705|NCT00052585|DRUG|irinotecan hydrochloride|Given IV
40860706|NCT00052585|DRUG|gefitinib|Given orally
40860707|NCT00052585|DRUG|leucovorin calcium|Given IV
41039905|NCT05320731|PROCEDURE|Atomization with lidocaine|A simple atomization device as a modification of the McKenzie technique will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
41039906|NCT00968682|BIOLOGICAL|trastuzumab|
41039907|NCT00968682|OTHER|laboratory biomarker analysis|
41039908|NCT00968682|PROCEDURE|assessment of therapy complications|
40860708|NCT00052585|DRUG|fluorouracil|Given IV
40860709|NCT00128310|DRUG|Vinorelbine|
40860710|NCT00128310|DRUG|Gemcitabine|
40860711|NCT00589771|DRUG|Saccharomyces boulardii|"1. Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
40860712|NCT00589771|DRUG|Placebo|"1. Cap Placebo TDS for six weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
41391609|NCT04084028|BEHAVIORAL|Recipes|Students are emailed a set of recipes once a week for 6 weeks. Recipes include options for breakfast, lunch, dinner, and snacks. Recipe sets include vegan, vegetarian, and gluten-free options. This intervention was cancelled by COVID-related disruptions and did not take place.
41391610|NCT03932474|COMBINATION_PRODUCT|SAMEUp|One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
41391611|NCT03932474|OTHER|Placebo|One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet
41391612|NCT02475980|BEHAVIORAL|Comprehensive contraception counseling|The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
41391613|NCT06539455|DRUG|standard anti-TB treatment|standard anti-TB treatment in line with international guidelines (isoniazid , rifampin, ethambutol, and pyrazinamide)
41391614|NCT05273398|DRUG|nasal diazepam|Nasal administration of diazepam
41391615|NCT04514328|DEVICE|cerebral 18F-FDG PET-CT|cerebral 18F-FDG PET-CT exam after walking in the garden while 2 weeks (75 minutes/per day from Monday to Friday)
41391616|NCT05680311|BIOLOGICAL|measurement of serum autotaxin serum level|autotaxin expression
41391617|NCT05598645|DEVICE|Thulium Fibre Laser|Participants will undergo treatment using the TFL
41391618|NCT05598645|DEVICE|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
41391619|NCT05875116|BEHAVIORAL|Virtual reality|The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.
41391620|NCT05875116|BEHAVIORAL|Modified constraint-induced movement therapy|"Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb attached to the chest, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the free paretic arm and the fixed healthy arm, for 5 hours a day."
41512735|NCT01406574|DRUG|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
40860713|NCT00479713|DRUG|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
40860714|NCT00479713|DRUG|Comparator : rosuvastatin calcium|rosuvastatin 10mg. The treatment duration will be 6 weeks.
41391621|NCT05875116|BEHAVIORAL|Usual Physical and Occupational Therapy|The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.
41391622|NCT00732394|OTHER|MSDR|"The MSDR® questionnaire establishes an individual's musculoskeletal functional status using information gathered from 1) a questionnaire the patient fills out regarding medical history, chronic medical conditions, and health risk factors; 2) anatomic pain survey completed by the patient; and 3) evaluation by a trained researcher of various patient biometric parameters related to range of motion. Stratifying an individual into a risk category with this evidence-based assessment tool then permits an assessment of which patients respond long term to therapy.~MSDR® demonstrates the ability to benchmark specific musculoskeletal findings (both clinical and sub-clinical) to ICD-9 Diagnoses supported by diagnostic, radiographic and/or MRI findings where clinically indicated."
41512736|NCT04201730|PROCEDURE|Enhanced Recovery After Surgery （ERAS）|Preoperative education，Preoperative nutritional support，Preoperative bowel preparation，Preventative applying of antibiotics，Intraoperative warming，Goal-directed fluid therapy，Postoperative analgesia，Postoperative diet, drainage and activity management，Prevention of deep vein thrombosis.
40860715|NCT00479713|DRUG|Comparator: Placebo (unspecified)|rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
40860716|NCT00479713|DRUG|Comparator: Placebo (unspecified)|ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
40860717|NCT00998088|OTHER|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
41391623|NCT02955394|DRUG|Enzalutamide|160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.
41391624|NCT02955394|DRUG|Fulvestrant|500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
41417892|NCT04025879|DRUG|Paclitaxel|Specified dose on specified days
41417893|NCT04025879|DRUG|Pemetrexed|Specified dose on specified days
41417894|NCT04025879|DRUG|Placebo|Specified dose on specified days
41512737|NCT00518700|OTHER|new MPS|
41512738|NCT00518700|OTHER|RepleniSH|
41512739|NCT00273897|DEVICE|Phoresor II|
41512740|NCT00929279|DRUG|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
41512741|NCT00929279|DRUG|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
40860718|NCT00998088|DRUG|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
40860719|NCT00998088|DEVICE|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
40860720|NCT00998088|DEVICE|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
40860721|NCT00998088|OTHER|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
41417895|NCT04025879|DRUG|Docetaxel|Specified dose on specified days
41512742|NCT02567240|OTHER|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
41512743|NCT06416514|OTHER|Personalized intervention|Personalized intervention means implementing multi-component non-pharmacological interventions based on different health profiles，such as art therapy, exercise therapy, cognitive therapy and other monotherapies. Usual care means care as routine.
40860722|NCT00998088|OTHER|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
40860723|NCT00998088|DEVICE|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
40860724|NCT04457063|PROCEDURE|PKP|"1. The horizontal axis was marked with a pointed marker at the slit lamp immediately before surgery.~2. TICL loading into the STAAR injector cartridge~3. Temporal clear corneal 3 mm incision \& 2-side ports then viscoelastic injection into the AC~4. Implantation of the TICL using the injector, then rotation according to the implantation diagram guided with Mendez protractor, and lastly placement of the haptics under the iris.~5. Pupil constriction with A.Ch.~6. Washing the viscoelastic \&Wound hydration.~7. Topical antibiotic steroids (Vigamox and Tobradex) 4 times /day for 3weeks"
40860725|NCT05616481|PROCEDURE|Laparoscopic Burch colposuspension|The original Burch procedure will be performed
40860726|NCT05616481|PROCEDURE|Modefied Burch (TOT - like)|more lateral fixation to avoid post-operative voiding dysfunction
40860727|NCT05281198|DIETARY_SUPPLEMENT|tart cherry juice|2, 8oz bottles of Montmorency tart cherry juice daily; 8oz taken in AM, 8oz taken in PM
41391625|NCT04023318|BEHAVIORAL|Integrated Lifestyle Intervention|This program is grounded in data demonstrating the dysregulation across multiple domains and considerable life stressors experienced by this population. The central hypothesis is that by simultaneously ameliorating psychological dysregulation and directly targeting proinflammatory behaviors, ILI operates on multiple proposed mediators of poor treatment outcomes in this population, thereby enhancing treatment outcomes. As such, the overall framework emphasizes integration of self-regulation as it applies to both psychological functioning and weight control. Content will highlight the interconnectedness of mood, stress, eating and exercise behaviors, and risk for inflammation and disease. Each treatment session will present a combination of behavioral and psychological content, representing a truly integrated approach. Participants will meet for 75-minute group sessions weekly for months 1-2, followed by bi-weekly groups in months 3-4, for a total of 12 groups.
40860728|NCT05281198|DIETARY_SUPPLEMENT|Placebo|2, 8oz bottles of placebo juice daily; 8oz taken in AM, 8oz taken in PM
40860729|NCT06245733|OTHER|Compassion-Based Education Program Adapted for Adults|Training will be given once a week. This training will last 10 weeks in total.
41039909|NCT06418373|BEHAVIORAL|Get Ready with My Heart Program|"In the intervention group, adolescent CHD patients undergo a comprehensive assessment by cardiology and cardiothoracic experts to determine their suitability for transitional care management. Based on the Get Ready with My Heart Program, a personalized transition plan is developed, offering courses and resources that enhance self-management skills such as medication management, symptom monitoring, and health record maintenance. Throughout the transition period, regular support and follow-ups are provided to ensure that both patients and their families are adequately supported. The program includes regular assessments of transition readiness and quality of life changes to understand the intervention's impact and make necessary adjustments. Additionally, feedback is actively collected from patients and their families to continuously improve and refine the program."
41391626|NCT03174925|DEVICE|Siemens Acuson S3000 ultrasound system|Shear Wave Elastography
41391627|NCT05761015|DRUG|therapeutic program including intermittent drug intake and multimodal rehabilitation program|"The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~* gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~* cardiovascular risk (according to Agostino scale \& SCORE);~The molecule with therefore be:~* no risk: niflumic acid, 250 mg per intake;~* gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~* cardiovascular risk only: ketoprofen, 50-100 mg per intake;~* double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week."
41391628|NCT01083901|BEHAVIORAL|Resistance training|high intensity progressive resistance exercise training
40860730|NCT06166199|BEHAVIORAL|HIIT combined with resistance training|"Patients with SLE will undergo supervised HIIT on an ergometercycle, 4 x 4 minutes interval, (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week.~Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week."
40860731|NCT03529968|PROCEDURE|esophagectomy|Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy
40860732|NCT02872246|DRUG|BAY 987516|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
40860733|NCT02872246|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
40860734|NCT00307905|DRUG|Traumeel S|homeopathic remedy
40860735|NCT00307905|DRUG|Placebo remedy|identical size, shape and taste of treatment medication
40860736|NCT01637155|DRUG|Cholecalciferol|One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
40860737|NCT03625284|DIETARY_SUPPLEMENT|Placebo|Edible oil
41167809|NCT06105996|BEHAVIORAL|Interoceptive training|There will be 6 interoceptive training sessions carried out over two months. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy and the accuracy of their subjective confidence rating, relative to their objective accuracy.
40860738|NCT03625284|DIETARY_SUPPLEMENT|FucoVital|Microalgae oil extract
40860739|NCT02184858|DRUG|lisinopril, ACE-inhibitor|Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
41391629|NCT01200316|PROCEDURE|Standard of Care|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
40860740|NCT01758913|DRUG|Ibuprofen|To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
41391630|NCT01200316|PROCEDURE|Rocking Chair Motion|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
41512744|NCT04598386|OTHER|PR Lotion - AMP Human Performance|Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.
41512745|NCT04598386|OTHER|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
41167810|NCT04921748|PROCEDURE|Neurorehabilitation|All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks. The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.
41167811|NCT05159986|PROCEDURE|Group that received aplication of Diadynamic currents associated to Exercise during eight weeks with three sessions a week|Diadynamic currents was performed followed by exercises (divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week).
41391631|NCT01200316|BEHAVIORAL|Questionnaire|Beginning on day of surgery till discharge (3-5 days)
41391632|NCT05459168|OTHER|Calm Meditation Smartphone App Feedback|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
41391633|NCT05459168|OTHER|Cancer-Specific Meditation App Prototype Design|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
41391634|NCT05459168|DEVICE|Cancer-Specific Meditation App Prototype|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
41391635|NCT04309955|PROCEDURE|pigtail catheter|After inserting the chest tube, add a pigtail catheter into the posterior axillary lines of the 7th intercostal.
41391636|NCT00189696|DRUG|YM060|
41512746|NCT04205058|DIETARY_SUPPLEMENT|Standard coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
41512747|NCT04205058|DIETARY_SUPPLEMENT|Caffeine-free coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
40860741|NCT02521922|DEVICE|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
40860742|NCT02521922|DEVICE|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
40860743|NCT00133861|DRUG|Botulinum toxin|
40860744|NCT01688375|DRUG|Ursodeoxycholic Acid|UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
41167812|NCT05159986|OTHER|Group that received exercise during eight weeks with three sessions a week|The intervention was divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week. Each session lasted 45 minutes.
41167813|NCT02787811|DEVICE|Intrauterine insemenation|Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
41167814|NCT03233633|DRUG|Medical Marijuana|oral capsule, high ratio CBD:THC
41167815|NCT05258877|OTHER|Plasma samples|Up to 80ml of plasma may be collected from each participant over the 24 hour sampling period to be used for PK analysis.
41167816|NCT04390412|RADIATION|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA treatment plan
41167817|NCT04614571|DIETARY_SUPPLEMENT|Gluten Powder|Administered orally daily for 14 days
41391637|NCT05113862|BIOLOGICAL|LD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
41391638|NCT05113862|BIOLOGICAL|LD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
41391639|NCT05113862|BIOLOGICAL|HD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
41391640|NCT05113862|BIOLOGICAL|HD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
41391641|NCT04438629|DRUG|COVID-19 treatment|COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.
41391642|NCT00142324|DRUG|Donepezil|
41391643|NCT02299674|OTHER|Level overground ambulation|
41391644|NCT01804530|DRUG|PLX7486 TsOH|PLX7486 TsOH capsules, 50mg
41391645|NCT00004086|BIOLOGICAL|filgrastim|
41391646|NCT00004086|DRUG|cisplatin|
40860745|NCT03063281|OTHER|BIological analysis|Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
40860746|NCT06023706|DRUG|Capsaicin 179 Mg Cutaneous Patch|1 patch applied once for 1 hour
40860747|NCT06023706|DRUG|Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)|1 patch applied once for 1 hour
40860748|NCT02598284|OTHER|Point of Care|Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
40860749|NCT02598284|OTHER|Population Management|"Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).~Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program."
41391647|NCT00004086|DRUG|cytarabine|
40860750|NCT00321464|BIOLOGICAL|Denosumab|Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
40860751|NCT00321464|DRUG|Zoledronic Acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
40860752|NCT02883374|DRUG|Chidamide|
40860753|NCT06050694|DRUG|glofitamab|Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6
40860754|NCT01434849|DRUG|topical 0.5% Timolol maleate|topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
40860755|NCT01434849|DRUG|Control (placebo) group|Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
40860756|NCT01944124|BEHAVIORAL|Mobile Health|Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.
40860757|NCT01944124|BEHAVIORAL|Exercise Prescription|An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
41039910|NCT06418373|BEHAVIORAL|Conventional intervention|Adolescent CHD patients and their caregivers receive comprehensive health education and medical management. Upon admission, a detailed assessment of each patient's medical history and physical examination is conducted. A treatment and perioperative care plan is then tailored, including medication management with anticoagulants and antiarrhythmics, and surgery-related health guidance. Regular cardiac monitoring and follow-up assessments ensure treatment effectiveness and health status updates. Post-discharge, patients receive lifestyle management advice through remote consultations, focusing on diet and physical activity. Additionally, training on recognizing and managing emergencies is provided, equipping patients and caregivers to handle potential crises effectively. This holistic approach aims to improve both immediate and long-term health outcomes for adolescent CHD patients.
41039911|NCT00930293|BEHAVIORAL|Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|16 weekly IPT-PS sessions, each lasting approximately 45 minutes
41039912|NCT00930293|BEHAVIORAL|Brief Supportive Psychotherapy (BSP)|16 weekly BPS sessions, each lasting approximately 45 minutes
41391648|NCT00004086|DRUG|etoposide|
41391649|NCT00004086|DRUG|ifosfamide|
41391650|NCT00004086|PROCEDURE|autologous bone marrow transplantation|
41391651|NCT00004086|PROCEDURE|peripheral blood stem cell transplantation|
41039913|NCT00930293|DRUG|Citalopram hydrobromide|A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
41039914|NCT02212756|DRUG|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
41039915|NCT02212756|DRUG|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
41039916|NCT05591339|BIOLOGICAL|BCG vaccine (two doses, 4 weeks apart)|BCG vaccine provided intradermally at the upper arm.
41039917|NCT05591339|BIOLOGICAL|Saline placebo (Two doses, 4 weeks apart)|Participants randomized to the control group (placebo) will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
41391652|NCT00004086|RADIATION|indium In 111 LL2 IgG|
41391653|NCT00004086|RADIATION|yttrium Y 90 epratuzumab|
41391654|NCT02672774|PROCEDURE|Magnification endoscopy with narrow band imaging|Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.
41512748|NCT04205058|DIETARY_SUPPLEMENT|Drinking water|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
40860758|NCT02412098|DRUG|Eleclazine|Eleclazine tablets administered orally
41391655|NCT02672774|DEVICE|Probe based confocal laser endomicroscopy|Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.
41417896|NCT05328713|DIAGNOSTIC_TEST|Cardiac MRI|This study will use Cardiac MRI to identify subclinical cardiac dysfunction.
41512749|NCT06432816|DIETARY_SUPPLEMENT|NANO-PSO|NANO-PSO or Oil of pomegranate seed with nanotechnology, they are capsules with a net content of 640 mg with a dosage indicated by sponsor of 2 capsules in fast
41391656|NCT06112301|DIAGNOSTIC_TEST|IdentiClone Dx IGH (IC IGH Dx) Assay|The IdentiClone Dx IGH Assay is an in vitro diagnostic product intended for qualitative, capillary electrophoresis based-detection of clonality in immunoglobulin heavy chain gene rearrangements (IGH) in peripheral blood specimens as an adjunctive method for the diagnosis of B-cell lymphoproliferative disease
41391657|NCT03405909|DIAGNOSTIC_TEST|contrast enhanced ultrasound (CEUS)|CEUS with SonoVue following standardized protocol
41391658|NCT03405909|DIAGNOSTIC_TEST|MRI|CE-MRI following standardized protocol
41391659|NCT03405909|DIAGNOSTIC_TEST|Histology|diagnostic liver biopsy
41391660|NCT01257828|DRUG|riluzole|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
41391661|NCT01257828|DRUG|Placebo medication|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
41039918|NCT05656950|PROCEDURE|Assessment|Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.
41039919|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)|Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
41039920|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
41391662|NCT01298154|OTHER|Dietary intervention|Dietary treatments with beverages
41391663|NCT00875537|OTHER|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
41391664|NCT00875537|OTHER|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
41391665|NCT05303480|DRUG|Chlormethine|Chlormethine gel 0.016%
41391666|NCT04853394|BEHAVIORAL|MASLIHAT|peer educator intervention
41391667|NCT04853394|BEHAVIORAL|TANSIHAT|health education intervention
41391668|NCT00593931|OTHER|fMRI|Functional Magnetic Resonance Imaging without contrast
41391669|NCT01920373|DRUG|Group A (corticosteroid injection group)|
40860759|NCT02114138|PROCEDURE|pathogenesis of perioperative acute kidney injury|understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
41039921|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
41039922|NCT05283694|DRUG|risankizumab|Subcutaneous Injection via prepared syringe
41167818|NCT01989923|OTHER|Nicotine Replacement Therapy|Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
41391670|NCT01920373|BIOLOGICAL|Group B (platelet rich plasma injection group)|
41391671|NCT06279936|OTHER|Neuropsychological battery|COVID-19 patients with persistent complaints of cognitive disabilities (more than 4 weeks post-infection) in daily life are examined with an extensive neuropsychological test battery (see below) at the outpatient clinic of the University Psychiatric Centre in Duffel and at the University Hospital Antwerp. This battery covers a broad range of reliable and valid tests divided into six cognitive domains: attention, memory, visuospatial functions, language, executive functions and psychomotor speed/coordination. The neuropsychological examination lasts an average of 2 hours per participant. The tests are carried out by the same experienced neuropsychologist and also follow a standardized sequence. In addition to the neuropsychological assessment, two self-report scales are filled out by each patient. These scales are used to detect possible complaints of fatigue and possible cognitive problems which are experienced by the patient during daily life activities.
41391672|NCT06279936|OTHER|Surveys and symptom severity questionnaires|Both self-rated surveys and clinician administered questionnaires
41391673|NCT06279936|OTHER|Blood withdrawal|"Blood samples will be collected in a standardized manner by venipuncture. Two blood vials will be collected and processed to perform the following analyses:~* serum collection tube(s) allowing for HERV-W ENV and serological assays~* plasma collection tubes for the assessment of other immune-related biomarkers (including but not limited to CRP, IL-6, IL-1b, TNF-a, IFN-g, tryptophan, kynurenine, 3-OH-kynurenine, quinolinic acid, kynurenic acid, enzymes of the kynurenine pathway)."
41391674|NCT06279936|OTHER|Saliva swabs|Salivary cortisol measures will be used as functional measure of the HPA axis activity, as the unbound cortisol fraction in saliva is highly correlated to plasma cortisol. Baseline diurnal cortisol and CAR levels will be measured using saliva, collected at home with Salivette® (Sarstedt) synthetic swabs. The rationale behind the choice of home sampling, is to maximize normal circumstances and to minimize stress related to the measuring procedure.
41391675|NCT02068404|DRUG|Nifedipine|
41391676|NCT06540391|BIOLOGICAL|MB097|Live bacterial therapeutic for oral administration
41391677|NCT06540391|BIOLOGICAL|Pembrolizumab|IV infusion
41391678|NCT06540391|DRUG|Vancomycin|Antibiotic
41391679|NCT00002338|DRUG|Raluridine|
41512750|NCT06432816|OTHER|PLACEBO|"Placebo physically identical to NANO-PSO capsules:~Soft gelatin capsules 640 mg edible oil 35for PLACEBO Oil edible, oval shape, 640 mg."
40860760|NCT02114138|DIAGNOSTIC_TEST|urine collection|urine collection will be performed on both the control group and hospitalized participants
41039923|NCT05283694|DRUG|risankizumab|Subcutaneous Injection via syringe pump
41039924|NCT00517738|OTHER|Physical training|A program of exercising under strict surveillance, with endurance and coordination maneuvers
41039925|NCT00517738|OTHER|Diet intervention|Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
41512751|NCT04979936|PROCEDURE|laparoscopic cholecystectomy|
41512752|NCT04979936|PROCEDURE|percutaneous cholecystostomy|
40860761|NCT00959595|DRUG|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
40860762|NCT00959595|DRUG|EMLA cream|50g applied according to description of intervention
40860763|NCT02289794|BIOLOGICAL|E.coli bioconjugate vaccine|Single dose, intramuscular injection (0.5 mL)
41039926|NCT02647398|BEHAVIORAL|Vigorous aerobic training|Supervised vigorous aerobic training
41039927|NCT01508429|OTHER|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
41039928|NCT01508429|DRUG|Misoprostol|800mcg misoprostol (4 200mcg tablets administered sublingually)
41039929|NCT03821168|DRUG|injection of bevacizumab and erythropoietin|injection of bevacizumab and erythropoietin
41039930|NCT03821168|DRUG|injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
41391680|NCT01950338|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
41391681|NCT00071708|DRUG|Duloxetine Hydrochloride|
40860764|NCT02289794|BIOLOGICAL|Placebo|Single dose, intramuscular injection (0.5 mL)
40860765|NCT05220306|DEVICE|Monitoring of vital signs|The MouthLab is a hand-held device. The user holds the unit in their left hand with the Mouthpiece between the teeth and lips and breathes normally into the device for 30 seconds.
40860766|NCT05932225|OTHER|Propylene glycol solution/drops|commercially available eye drops
40860767|NCT01401517|DRUG|sodium nitrite|0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
40860768|NCT03589261|DEVICE|MRI (magnetic resonance imaging)|Fluid challenge will be performed with 500 ml of intra venous NaCl (0.9%). Hepatic blood flow measurement will be performed using MRI.
40860769|NCT00005024|DRUG|carboplatin|
41039931|NCT02303184|DRUG|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
41039932|NCT02303184|DRUG|Sham|suprachoroidal sham procedure
41167819|NCT01989923|DEVICE|Electronic Cigarettes|The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
41167820|NCT06486506|OTHER|Analysis|Analysis and review of imaging and clinical data
41391682|NCT00006044|DRUG|therapeutic testosterone|
40860770|NCT00005024|DRUG|cyclophosphamide|
40860771|NCT00005024|DRUG|doxorubicin hydrochloride|
40860772|NCT00005024|DRUG|granisetron hydrochloride|
40860773|NCT04336072|BEHAVIORAL|RFPP|
40860774|NCT04336072|BEHAVIORAL|TFCBT|
41391683|NCT00337129|DRUG|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
41391684|NCT02026037|BEHAVIORAL|Brief Treatment for Acutely Burned Patients (BTBP)|Brief Treatment for Acutely Burned Patients (BTBP) adapts CBT principles that have been validated with non-burn trauma survivors to the treatment of hospitalized burn patients. BTBP consists of three 1 to 1½ hour sessions per week for two weeks, as well as two sessions for family members or partners/spouses.
41391685|NCT02845635|OTHER|Personal history of multiple sclerosis|Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.
40860775|NCT03020927|BEHAVIORAL|Reciprocal Imitation Training (Therapist-Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills.
40860776|NCT03020927|BEHAVIORAL|Reciprocal Imitation Training (Therapist + Parent Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills, using a combination of therapist-delivered intervention and parent training to deliver intervention in the home setting.
40860777|NCT01336140|DRUG|Aminophylline|75 mg of intravenous aminophylline
40860778|NCT01336140|DRUG|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
40860779|NCT05379465|OTHER|No intervention|No intervention was done.
41039933|NCT02303184|DRUG|IVT aflibercept|2 mg intravitreal injection of aflibercept
41039934|NCT03333850|DEVICE|Visual feedback of physical activity|A monitor (tablet) will display the level of physical activity during hospitalisation. The monitor will be placed at the bedside (table).
41039935|NCT03333850|DEVICE|No feedback of physical activity|There will be no visual feedback of the physical activity (no monitor placed at the bedside (table)).
41039936|NCT03333850|DEVICE|Measurement of physical activity|A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
41039937|NCT01121042|DRUG|Ondansetron|8mg per day oral capsule
41039938|NCT01121042|DRUG|Placebo|daily oral capsule matched to active study medication. Made form 100% lactose powder
41039939|NCT06305338|OTHER|Optical Coherence Tomography|the study releated measurements will be performed: IOLMaster 700, Casia 2 and Pentacam HR.
41039940|NCT01508039|OTHER|Chitin Micro Particle|"The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).~A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)"
41039941|NCT01904448|DEVICE|Auditory Brainstem Implantation in Children|
41039942|NCT04850846|DRUG|Metformin XR|Orally by mouth
41039943|NCT04850846|OTHER|Placebo|Orally by mouth
40860780|NCT05044858|PROCEDURE|Midpoint transverse process block group|After marking the level of the incision by surgeon (commonly T5- T6) The patient will be situated in the lateral position, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally 3 cm lateral to the spinous process at the level of skin incision. 100-mm short bevel echogenic needle (Contiplex, B.Braun, Germany) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura titrated bolus of 20 ml of 0.25% bupivacaine and dexamethazone 8 mg will be injected at the target site. At end of the surgery general anaesthesia will be stopped with reversal of muscle relaxation and awakening of patient
40860781|NCT05044858|PROCEDURE|Sham group|"General anesthesia will be induced with the same protocol and MTP block will be done but with injection of placebo (2 ml normal saline) instead of local anesthetic .~On arrival to the PACU postoperative Numerical Rating scale at rest and coughing will be recorded, analgesia will be maintained with intravenous paracetamol 1 g every 8 h and required additional rescue analgesia (morphine) at any time will be calculated."
40860782|NCT03158194|BEHAVIORAL|CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
40860783|NCT01311609|OTHER|Systane|Systane Lubricant Eye Drops \[1-2 Drops in each eye four times daily (QID)\]
40860784|NCT00811681|DRUG|pioglitazone|administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
41391686|NCT01637675|DRUG|20 mg sildenafil citrate by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
41391687|NCT01637675|DRUG|sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
41391688|NCT04174196|DRUG|CC-486|Participants will be treated with CC-486 and lenalidomide for 6 cycles
41391689|NCT04174196|DRUG|Lenalidomide|Participants will be treated with CC-486 and lenalidomide for 6 cycles
41512753|NCT03289819|DRUG|Pembrolizumab|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w.
40860785|NCT00811681|DRUG|Placebo|a placebo administered orally once a day after the first visit and for a total of 2 years.
41512754|NCT03289819|DRUG|nab-paclitaxel|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
40860786|NCT00771888|DRUG|lanreotide|lanreotide
40860787|NCT03058055|BEHAVIORAL|Placebo|The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
40860788|NCT03058055|BEHAVIORAL|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
40860789|NCT03058055|BEHAVIORAL|Reading|Book club that includes weekly one hour meetings and daily reading assignments
40860790|NCT01458262|OTHER|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
40860791|NCT06360848|OTHER|surgery|SURGICAL TREATMENT OF PSEUDARTHROSIS OF THE HUMERUS
40860792|NCT01994044|PROCEDURE|Cervical fusion|
40860793|NCT04965324|OTHER|Anaesthesia Depth|
40860794|NCT01543074|DIETARY_SUPPLEMENT|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
40860795|NCT01543074|DIETARY_SUPPLEMENT|Garlic oil|1 pill = 30 mg garlic oil/day
40860796|NCT01543074|DRUG|BSE|2 pills = 200 micromoles of Sulforaphane/day
40860797|NCT01543074|DIETARY_SUPPLEMENT|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
41039944|NCT00793468|DRUG|GSK598809|GSK598809 once daily for 12 weeks
41391690|NCT04174196|RADIATION|Radiation Therapy|Radiation therapy will be initiated to the plasmacytoma after cycle 2
41391691|NCT00061646|DRUG|ABT-510/Thrombospondin-1 mimetic|
40860798|NCT04355208|OTHER|(3M™ Filtek™ Universal )|universal nanofillers resin composite (3M™ Filtek™ Universal )
40860799|NCT05538676|DIAGNOSTIC_TEST|BPA-PET imaging|PET imaging
40860800|NCT05292716|DEVICE|MitraClip|MitraClip
40860801|NCT02396212|BIOLOGICAL|Canakinumab|canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.
41039945|NCT00793468|DRUG|Nicotine Replacement Transdermal Patch|All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
41039946|NCT00793468|DRUG|Placebo|Placebo once daily for 12 weeks
41167821|NCT01732588|DRUG|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
41167822|NCT01732588|DRUG|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
41391692|NCT00061646|DRUG|Carboplatin/Taxol|
41391693|NCT05103514|OTHER|Online Survey|There are no interventions planned for this study. This is an observational study only.
40860802|NCT04867733|OTHER|Micropatch (microneedle patch)|Each micropatch contains an array of 50 microneedles.
40860803|NCT01462240|DEVICE|LPS Flex Porous Femoral Components|Porous femoral components in total knee arthroplasty
40860804|NCT01436786|OTHER|Guided Imagery|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
40860805|NCT06401863|OTHER|Shared Decision Making Tool|EHR-integrated SDM for Patients on Oral Anticoagulants and other medications that might increase the risk of hemorrhage
40860806|NCT06078852|DIAGNOSTIC_TEST|Diaphragmatic ultrasound|Each patient will undergo a diaphragmatic ultrasound using a MyLab TM 50 Gold Cardiovascular ultrasound machine (Esaote Spa, Rome, Italy), both in a semi-recumbent position (45° inclined bed) and in sitting position. If the patient is unable to maintain the supine position, the examination will be assessed only in the sitting position. Diaphragmatic thickness (DT) and diaphragmatic contractility will be assessed bilaterally with a 10 MHz linear probe. The amplitude of the diaphragm excursion will also be calculated with a 5 MHz convex probe in order to evaluate the cranio-caudal excursion of the diaphragm.
40860807|NCT04849169|DEVICE|Experimental|Prolonged balloon inflation for hemorrhage management due to coronary artery perforation.
40860808|NCT02072265|DEVICE|Infrared thermal images|
40860809|NCT00646360|DIETARY_SUPPLEMENT|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
41039947|NCT02635633|DEVICE|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7\*(DEF-DM1) \[DEF = distance over EF; DM1 = distance over M1\]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
41039948|NCT04464668|BEHAVIORAL|Provider Tools|Providers will be trained to use Electronic Medical Record (EMR) tools and prompts, and an organization wide cancer control champion will be trained to motivate providers and navigate patients.
41391694|NCT03570580|OTHER|OSA scoring|OSA scoring (four scores: STOP-Bang, P-SAP, OSA50, DES-OSA were performed by several scorers on each patients, after what agreement between scores will be evaluated).
41512755|NCT03289819|DRUG|Epirubicin|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
40860810|NCT00646360|DIETARY_SUPPLEMENT|Placebo|2 tablets daily during pregnancy
40860811|NCT03237715|OTHER|Assessment of unbound bilirubin levels|Collection of residual blood for measurement of unbound bilirubin
40860812|NCT06351150|DRUG|Angiotensin II Injection|1、Angiotensin II injection is a naturally occurring octapeptide hormone in the human renin angiotensin aldosterone system (RAAS). It is the main effector molecule of the RAAS system and one of the strongest known vasoconstrictors, involved in neurohumoral regulation.
40860813|NCT06351150|DRUG|0.9% sodium chloride injection|0.9% sodium chloride injection, not containing active ingredients.
40860814|NCT03413124|DRUG|MGL-3196 Tablet|MGL-3196 in Tablet form
40860815|NCT03413124|DRUG|MGL-3196 Capsule|MGL-3196 in Capsule form
40860816|NCT06139341|DRUG|BI 765845|BI 765845
41391695|NCT00542958|DRUG|NK012|9.0, 12.0, 16.0, 21.0, 28.0 mg/m\^2, and to be determined. Intravenous infusion
40860817|NCT06139341|DRUG|Placebo|Placebo
40860818|NCT05349786|OTHER|Physical activity program|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. After the data obtained in the pre-test, the pedometers, which were calibrated and checked by the researchers, were delivered to the patients. At the end of each day of walking with pedometer monitoring, they were asked to record data such as the number of steps, walking hour, walking time, distance and complaints encountered during walking on the walking monitoring chart given to the patient by the researchers. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
40860819|NCT05109624|PROCEDURE|prolonged prone position ventilation|patients mechanically ventilated with SARS COV 2 will be subjected to a longer than usual period of prone position ventilation
40860820|NCT04138641|DRUG|Cangrelor|Cangrelor intravenous
41391696|NCT04557982|PROCEDURE|A painful procedure (peripheral venepuncture)|The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.
41391697|NCT01825876|DRUG|Evacetrapib|Oral administration
41391698|NCT01825876|DRUG|Warfarin|Oral administration
40860821|NCT02938208|DEVICE|Jupiter Full Face Mask|Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
40860822|NCT01443702|DRUG|Lapis Judaicus|2 g capsule per day.
40860823|NCT01443702|DRUG|Placebo|2 g capsule per day.
40860824|NCT00981461|DEVICE|HairMax LaserComb|Device application 3 times week, for 26 weeks
40860825|NCT00981461|DEVICE|Control Device|Device application 3 times week, for 26 weeks
40860826|NCT04531241|DEVICE|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with a novel manufacturing technology
40860827|NCT04531241|DEVICE|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with the current manufacturing technology
40860828|NCT03825302|DIAGNOSTIC_TEST|Methacholine challenge|Methacholine inhalation challenge will be administered to both male and females with asthma
41391699|NCT00423488|DRUG|Ezetimibe 10 mg|1 x 10-mg tablet, provided as blinded study treatment
41391700|NCT00423488|DRUG|Simvastatin 20 mg|1 x 20-mg tablet, provided as open-label study treatment
41391701|NCT00423488|DRUG|Ezetimibe Placebo|1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment
41391702|NCT00423488|DRUG|Simvastatin 20 mg|1 x 20-mg tablet, provided as blinded study treatment
41391703|NCT00423488|DRUG|Simvastatin Placebo|1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
41391704|NCT04456985|DIETARY_SUPPLEMENT|Folic acid and vitamin B12|Take folic acid and VitB12 for 3 consecutive days before surgery
41391705|NCT04456985|DIETARY_SUPPLEMENT|brown sugar aqueous|take 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation
41391706|NCT01117714|PROCEDURE|Integrated Staging for Early Detection of Metastases in Lung Cancer|To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
41391707|NCT02522754|BIOLOGICAL|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
41391708|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
41391709|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
41391710|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
41512756|NCT03289819|DRUG|Cyclophosphamide|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
41512757|NCT03672591|OTHER|Renal clearance examination|Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
40860829|NCT03825302|DIAGNOSTIC_TEST|Mannitol challenge|Mannitol inhalation challenge will be administered to both male and females with asthma
40860830|NCT00832416|DRUG|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
40860831|NCT00832416|DRUG|Placebo|One Placebo tablet daily.
40860832|NCT05909839|OTHER|7T MRI network analysis for deep brain stimulation in essential tremor|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in ET patients.
40860833|NCT03979859|DRUG|WCK 4873|
41039949|NCT04464668|BEHAVIORAL|Provider surveys|Remote/electronic data collection surveys will be conducted with clinic institution leaders, cancer control champions, and providers from various clinic locations to solicit feedback about implementation processes at three time points (baseline, mid-point and end of study implementation)
41039950|NCT02065336|DRUG|ARC-520|
41039951|NCT02065336|DRUG|Placebo|
41039952|NCT02065336|DRUG|entecavir|
41039953|NCT02065336|DRUG|chlorpheniramine|In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.
41039954|NCT00891267|DRUG|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
41039955|NCT00891267|DRUG|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
41039956|NCT00891267|DRUG|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
41391711|NCT04974359|DRUG|Lu AG06466|Lu AG06466 - capsules
41391712|NCT04974359|DRUG|Placebo|Placebo - capsules
41391713|NCT02353429|DRUG|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
41391714|NCT00000135|DRUG|MSL-109|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
41391715|NCT00000135|OTHER|Placebo|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
41391716|NCT01516684|DRUG|placebo administration|Given topically
41391717|NCT01516684|DRUG|EMLA|Given topically
41391718|NCT01516684|DRUG|propofol|Given IV
41391719|NCT01516684|DRUG|fentanyl citrate|Given IV
41391720|NCT01843439|DIETARY_SUPPLEMENT|Magnesium|
41391721|NCT01843439|BEHAVIORAL|Education for asthma action plan|
41512758|NCT03106428|DRUG|MEDI7247|The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
41391722|NCT01843439|BEHAVIORAL|hot-lines for acute exacerbation of asthma|
41391723|NCT01843439|BEHAVIORAL|Inhaler technique training|
41391724|NCT01089985|DRUG|Autologous serum eyedrops|3 times a day for the duration of the study
41391725|NCT01835808|DEVICE|Fractional flow reserve (St. Jude Medical pressure-wire)|CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
41391726|NCT02190344|DEVICE|8-channel paddle coil|MRI Coil
41391727|NCT03631056|BIOLOGICAL|Human Acellular Vessel (HAV)|
41391728|NCT02049554|OTHER|Preconception Care Screener|
41391729|NCT03891875|COMBINATION_PRODUCT|Subcutaneous elamipretide through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
41417897|NCT02763722|OTHER|Emollient spray product|All patients will be instructed to use emollients spray on entire skin at least twice a day for four weeks.
41512759|NCT02439021|DEVICE|COBRA|
41512760|NCT02439021|DEVICE|LMA|
41512761|NCT01382888|DRUG|Heparin 2,400 IU /ml Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
40860834|NCT03979859|DRUG|Placebo Oral Tablet|
40860835|NCT03785158|OTHER|Liquid Melatonin|Melatonin is a natural supplement.
40860836|NCT03785158|OTHER|Placebo|Similar looking/tasting placebo syrup
40860837|NCT00994422|DRUG|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
40860838|NCT00994422|DRUG|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
40860839|NCT04405973|DEVICE|vv-ECMO|vv-ECMO required in severe COVID-19 ARDS
40860840|NCT04832191|DEVICE|CE-SM|contrast enhanced spectral mammography \&contrast enhanced magnetic resonance imaging
40860841|NCT01776034|BEHAVIORAL|SystemCHANGE Group Lifestyle counseling|
40860842|NCT01776034|BEHAVIORAL|Phone Lifestyle Counseling|
40860843|NCT04087577|OTHER|conventional physical therapy|includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning
41391730|NCT03891875|COMBINATION_PRODUCT|Subcutaneos placebo through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
41391731|NCT00918697|PROCEDURE|Mechanical debridement|For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.
41391732|NCT00918697|PROCEDURE|Alcohol-assisted debridement|For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
41391733|NCT05460325|DRUG|Lanadelumab|Lanadelumab subcutaneous injection.
41417898|NCT03500484|DRUG|Liraglutide|Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
40860844|NCT04087577|OTHER|mirror therapy|mirror therapy
40860845|NCT00982826|DRUG|ABT-072|See Arms information for a detailed description.
40860846|NCT00982826|DRUG|Placebo|See Arms information for a detailed description.
40860847|NCT03319823|DRUG|Thiazide Treatment Group|"Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure \<160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment"
40860848|NCT03319823|DRUG|Intensified Thiazide Treatment Group|At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure \>120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure \>120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is \<120.
40860849|NCT03319823|DRUG|Combination Medication Treatment Group|"Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~* Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~* After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~  * If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~ * If sleep systolic blood pressure is \> 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy."
40860850|NCT02675608|BIOLOGICAL|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
40860851|NCT00006591|DRUG|Ritonavir|
40860852|NCT00006591|DRUG|Amprenavir|
40860853|NCT01691157|OTHER|Evidence based exercise protocol|An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy
40860854|NCT01691157|OTHER|Usual physiotherapy without exercise|Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
40860855|NCT06295861|OTHER|no different intervention between the two cohort.|no different intervention between the two cohort.
40860856|NCT04555564|PROCEDURE|Technicium 99 MAA infusion|4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.
40860857|NCT04869969|PROCEDURE|percutaneous nephrolithotomy (supine position)|percutaneous nephrolithotomy to be done in the supine position
40860858|NCT04869969|PROCEDURE|percutaneous nephrolithotomy ( prone position)|percutaneous nephrolithotomy in the prone position
40860859|NCT01822418|DRUG|agomelatine|Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day
40860860|NCT00239889|DRUG|Salmon calcitonin|
40860861|NCT05748171|DRUG|Inotuzumab ozogamicin|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved in several countries for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle.
41039957|NCT04817280|OTHER|Ice Swimming|The intervention is not made in the course of a research study. Ice swimming has been introduced earlier by a given group. The group was made up of people who already swim in ice.
40860862|NCT05748171|DRUG|ALLR3|The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and asparaginase) has been adopted by pediatric oncology groups as treatment for pediatric relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
41039958|NCT01848080|BEHAVIORAL|Tai Chi based exercise program|A Tai Chi based exercise program that uses movement repetition favoring directional adjustments in space, supervised by a physiotherapist, has been shown to be effective in improving balance in individuals with physical impairments, including those presenting with sequelae following a stroke.
41039959|NCT05530135|OTHER|Exercise program|Exercise program
41039960|NCT05530135|OTHER|Cognitive behavioural therapy|Cognitive behavioural therapy
41039961|NCT05530135|OTHER|Standard clinical care|Standard clinical care
41039962|NCT01772433|DIETARY_SUPPLEMENT|Olive oil|Phonophoresis with Olive oil for 10 day, daily
41039963|NCT01772433|DRUG|Phonophoresis gel|Phonophoresis with base gel for 10 days, daily
41039964|NCT05080569|DRUG|Progesterone Vaginal Product|3dd200mg
41039965|NCT05080569|DRUG|Placebo|3dd1 vaginal capsule
41039966|NCT03774628|BIOLOGICAL|Chengdu Kanghua (one booster shot)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0
41039967|NCT03774628|BIOLOGICAL|Chengdu Kanghua (two booster shots)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3
41039968|NCT02073396|DIAGNOSTIC_TEST|Blood test|Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.
41039969|NCT00344786|DRUG|CNF2024 (BIIB021)|"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."
41039970|NCT01297933|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
41039971|NCT04213196|DRUG|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
41167823|NCT01732588|DRUG|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
41512762|NCT01382888|DRUG|Placebo Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
40860863|NCT04190901|BEHAVIORAL|Simulated Black Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
41039972|NCT04213196|DRUG|HSK21542|Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
41039973|NCT04213196|DRUG|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
41167824|NCT04833244|BEHAVIORAL|Triangular Forearm Support|The intervention, the Triangular Forearm Support requires drawing the shoulders away from the subject's head and neck. This requires at least a mild force that this action can oppose. The most-favored maneuver is to have patients stand 2 feet away from a wall, interlock their fingers, and place their forearms to form two sides of an equilateral triangle against the wall. They then place their heads within the triangle, the backs of their heads close to or in on contact with the heels of their hands. Then, pressing against the wall with their elbows and forearms, they draw their shoulders as far away from the wall as possible, retaining contact between the wall and the tops of their heads. Subjects remain in this position for 45 seconds, at which time they stand erect and repeat the abduction and flexion maneuver.
41167825|NCT04833244|BEHAVIORAL|Placebo|Patients will be asked to raise arms overhead for 45 seconds.
41039974|NCT04213196|DRUG|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
41039975|NCT04213196|DRUG|HSK21542|Intravenous injection 0.75 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
41039976|NCT04213196|DRUG|HSK21542|Intravenous injection 1.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
41039977|NCT04213196|DRUG|HSK21542|Intravenous injection 2.25 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
41039978|NCT04213196|DRUG|HSK21542|Intravenous injection 3.375 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
41039979|NCT04213196|DRUG|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
41039980|NCT00381940|DRUG|ifosfamide|Given IV
41039981|NCT00381940|DRUG|bortezomib|Given IV
41512763|NCT00754650|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
41039982|NCT00381940|DRUG|vinorelbine tartrate|Given IV
41039983|NCT00381940|BIOLOGICAL|filgrastim|Given IV or SC
41039984|NCT00314197|BEHAVIORAL|Telephone Linked Care - Behavior Change Counseling System|
41039985|NCT00314197|BEHAVIORAL|Telephone-linked behavioral counseling|
41167826|NCT02854397|OTHER|blood sample|
41167827|NCT03937037|PROCEDURE|Saline irrigation|100ml saline irrigation after CBD stone removal with routine ERCP procedure
41167828|NCT01750086|DRUG|Teriparatide 40-mcg subcutaneous injection|
41167829|NCT01750086|DRUG|Denosumab Injection|One-time Denosumab injection
41512764|NCT01937871|DRUG|5 mg Tadalafil|Administered orally
41512765|NCT01937871|DRUG|Placebo|Administered orally
41512766|NCT01937871|DRUG|0.2 mg Tamsulosin|Administered orally
41512767|NCT00026065|BEHAVIORAL|Biofeedback|
40860864|NCT04190901|BEHAVIORAL|Simulated Black Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
40860865|NCT04190901|BEHAVIORAL|Simulated White Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
40860866|NCT04190901|BEHAVIORAL|Simulated White Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
40860867|NCT04252573|DEVICE|Chimney Endovascular Aortic Sealing (ChEVAS) System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
40860868|NCT01726582|DRUG|Milestone 1: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
40860869|NCT01726582|RADIATION|Milestone 2: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or intensity-modulated radiation therapy (IMRT) techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
40860870|NCT01726582|DRUG|Milestone 3: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
41391734|NCT01681979|DRUG|Fluticasone propionate (with and without concurrent salmeterol)|"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
40860871|NCT01726582|RADIATION|Milestone 3: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
40860872|NCT01726582|DRUG|Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery|A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
40860873|NCT01726582|RADIATION|Milestone 4: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
40860874|NCT01726582|DRUG|Milestone 5: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
40860875|NCT01726582|RADIATION|Milestone 5: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
40860876|NCT01726582|DRUG|Milestone 6: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
40860877|NCT01726582|RADIATION|Milestone 6: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
41039986|NCT01453595|DRUG|BEZ235|"BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily"
41039987|NCT01388816|DRUG|DRL-17822 or placebo|DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
41039988|NCT06267053|DIAGNOSTIC_TEST|Direct digital radiography|All the participants had anterior posterior and lateral knee xray taken within 3 months of diagnosis
41039989|NCT06267053|DIAGNOSTIC_TEST|25-OH Vitamin D|All the participants had serum 25-OH Vitamin D levels measured from venous blood within 30 days of diagnosis
41039990|NCT06267053|DIAGNOSTIC_TEST|Vitamin B12|All the participants had serum Vitamin B12 levels measured from venous blood within 30 days of diagnosis
41039991|NCT06267053|DIAGNOSTIC_TEST|Folic acid|All the participants had serum folic acid levels measured from venous blood within 30 days of diagnosis
41167830|NCT01750086|DRUG|Alendronate Oral Tablet|weekly alendronate for 8 weeks
41167831|NCT05524285|DEVICE|Intracranial Support Catheter|Endovascular procedure using the intracranial support catheter which approved by NMPA
41167832|NCT05524285|DEVICE|Guide Catheter|Endovascular procedure using the guide catheter which approved by NMPA
41391735|NCT06540612|OTHER|Aerobic exercise|Aerobic exercise is a set of physical activities that work large muscle groups continuously and rhythmically.
41512768|NCT00102752|DRUG|Glufosfamide|
41391736|NCT06540612|BEHAVIORAL|Physical activity counseling|Physical activity counselling is a service that provides personalized guidance and support to help individuals adopt a healthy lifestyle.
41391737|NCT05709054|OTHER|Experimental: Diaphragmatic Manual Therapy Group A|"Experimental: Diaphragmatic Manual Therapy plus Breathing Retraining Exercises group:~Diaphragm manual therapy will be carried out and consists of a technique intended to stretch and mobilise the diaphragmatic muscle fibers indirectly. The maneuver will be performed in two sets of 10 repetitions, within a 1-minute interval for 10 minutes.~Breathing retraining exercises will be implemented for 30 minutes, consisting of:~i) recognition of the abnormal breathing pattern ii) diaphragmatic breathing ii) nose breathing iii) slow breathing and controlled breath holding after exhalation iv) adaptation of the new breathing pattern in everyday life activities and various positions (supine, semi-sitting, sitting) v) breathing control in speech."
41391738|NCT05709054|OTHER|Sham Breathing Retraining Exercises Group B|"Sham Breathing Retraining Exercises Group B:~Breathing retraining exercises will be implemented for 30 minutes, consisting of :~i) recognition of the abnormal breathing pattern ii) diaphragmatic breathing ii) nose breathing iii) slow breathing and controlled breath holding after exhalation iv) adaptation of the new breathing pattern in everyday life activities and various positions (supine, semi-sitting, sitting) v) breathing control in speech."
41391739|NCT05862116|OTHER|Survey form|Patients will be asked to fill a survey form that consists of socio-demographic information, Turkish Health Literacy Scale -32, Short Form-36 Health Survey and Oswestry Disability Index.
41391740|NCT00367679|DRUG|Pazopanib|Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
41391741|NCT00675701|DRUG|placebo|capsules
41512769|NCT00102752|DRUG|Gemcitabine|
41512770|NCT06128408|DRUG|risperidone, olanzapine, aripiprazole|Participants from the retrospective cohort were randomly assigned to one of the three drug groups of risperidone, olanzapine and aripiprazole for a period of 1 years of treatment.
41512771|NCT02574182|RADIATION|Brain MRI|"Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters"
41512772|NCT05475197|DEVICE|Kinesio taping|We planned to perform two different taping applications to evaluate the acute effect of kinesio taping application on the carpal tunnels of individuals with carpal tunnel syndrome.
41512773|NCT06551662|DEVICE|Paclitaxel drug-coated balloons|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
41512774|NCT06551662|DEVICE|Sirolimus drug-coated balloons|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
41512775|NCT06551662|DEVICE|New generation drug-eluting stent|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
41512776|NCT02107924|PROCEDURE|APPI of TKR-Stimulan|
41512777|NCT04407273|DRUG|observational|observational study
41512778|NCT03998267|DEVICE|Droobi|A new mobile application, specifically built for the diabetes patients in Qatar with the help of local expertise.
41512779|NCT03998267|OTHER|Standard of care|Standard of care including physicians, dietetics and diabetes educators support
41512780|NCT01428154|DRUG|Darbepoetin alfa|A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
40860878|NCT01726582|RADIATION|Milestone 7: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
40860879|NCT01726582|DRUG|Milestone 8: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
41512781|NCT04639284|DRUG|Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies|Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
41512782|NCT01042769|DRUG|Aleglitazar|aleglitazar 150 micrograms po daily
41512783|NCT01042769|DRUG|Placebo|placebo control po daily
41512784|NCT06178003|BIOLOGICAL|Tpdelansbsalbac|Tpdelansbsalbac,which is Knockdown of ansB, a gene that expresses L-mentholase secreted into the extracellular region, on the basis of the genetic background of bacterium VNP20009, and construction of an ansB gene-deficient mutant strain, ΔansB.
40860880|NCT01726582|DRUG|Milestone 9: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
40860881|NCT01726582|OTHER|Milestone 10: No additional therapy after surgery|The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
41512785|NCT01262872|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
40860882|NCT02124681|DRUG|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
40860883|NCT02124681|OTHER|Placebo|Placebo PO for 13±1 weeks
40860884|NCT04750304|BEHAVIORAL|Application ARTHe|Patient will use ARTHe Application for 3 months
41512786|NCT01262872|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
41512787|NCT01262872|BIOLOGICAL|Synflorix™|Intramuscular injection
41512788|NCT01262872|BIOLOGICAL|Prevnar13™|Intramuscular injection
41512789|NCT01262872|BIOLOGICAL|Tritanrix™-HepB/Hib|Intramuscular injection
41512790|NCT01262872|BIOLOGICAL|Polio Sabin™|Orally
41512791|NCT01262872|BIOLOGICAL|M-Vac™|Intramuscular injection
41512792|NCT01262872|BIOLOGICAL|Stamaril™|Intramuscular injection
41512793|NCT03829605|OTHER|Measurement of hydrogen sulfide|Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia
41512794|NCT00853099|BIOLOGICAL|adalimumab|
41512795|NCT00853099|DRUG|placebo|
41512796|NCT01749202|DIETARY_SUPPLEMENT|Sunflower Oil Softgels|3 x 500 mg softgel capsules/day
41512797|NCT01749202|DIETARY_SUPPLEMENT|EPA softgels|3 x 500 mg softgel capsules/day
40860885|NCT05026359|DEVICE|Bilateral ankle coordination training|Developed a novel bilateral ankle coordination training program with visual feedback and bilateral ankle control, based on the concept of bilateral movement therapy. The bilateral ankle coordination training includes 3 days a week, 30 minutes each time, lasting 4 weeks, and a total of 12 training sessions.
40860886|NCT04770493|DRUG|Lamotrigine|Participants will be randomized to lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks. A comparator group will receive placebo (sugar pills).
40860887|NCT04770493|DRUG|Placebo|Matching placebo (sugar pill)
40860888|NCT00604630|DRUG|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
40860889|NCT00604630|DRUG|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
40860890|NCT00171171|DRUG|deferasirox|
40860891|NCT06140966|DRUG|Daratumumab|Given by vein: days 1 and 8 of each Induction cycle; days 1 and 15 of each Consolidation cycle; and day 1of each Maintenance cycle.
40860892|NCT06140966|DRUG|Carfilzomib|Given by vein: days 1,2,8 and 9 of each Induction cycle; days 1, 2, 8, 9,15, and 16 of each Consolidation cycle; days 1, 2,15, and 16 of each Maintenance cycle.
40860893|NCT06140966|DRUG|Lenalidomide|Given by mouth: days 1-7 of each Induction cycle; days 1-14 of each Consolidation cycle.
40860894|NCT06140966|DRUG|Dexamethasone|Given by mouth or by vein: days 1, 8, 15, and 22 of each Induction cycle; days 1, 8, 15, and 22 of each Consolidation cycle; and days 1 and 15 of every cycle during Maintenance
40860895|NCT06140966|DRUG|Cisplatin|Given by vein: days 1-4 of each Induction cycle
40860896|NCT06140966|DRUG|epirubicin|Given by vein: days 1-4 of each Induction cycle
40860897|NCT06140966|DRUG|Cyclophosphamide|Given by vein: days 1-4 of each Induction cycle
40860898|NCT06140966|DRUG|Etoposide|Given by vein: days 1-4 of each Induction cycle
40860899|NCT06140966|DRUG|Melphalan|Given by vein: day -1 of Transplant
40860900|NCT06140966|PROCEDURE|ASCT|day 0 of Transplant
40860901|NCT06140966|DRUG|bortezomib|given by subcutaneous injection: days 1, 4, 8, and 11 of pretrial induction chemotherapy
40860902|NCT05699824|DRUG|Carvedilol Day2|Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
41512798|NCT01749202|OTHER|Sunflower Oil Food|3 servings/day
40860903|NCT05699824|OTHER|Standard Medical Treatment|All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol. Standard Medical Treatment
40860904|NCT05699824|DRUG|Carvedilol Day6|Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
40860905|NCT00308971|DRUG|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 4 months
40860906|NCT00308971|DRUG|alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 4 months
40860907|NCT00308971|DRUG|placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
41167833|NCT02108847|DRUG|.2% Ropivacaine|
41391742|NCT00675701|DRUG|lixivaptan|capsules
41391743|NCT00675701|DRUG|moxifloxacin|tablets
41391744|NCT02394431|OTHER|Cardiac echography|Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
41391745|NCT02394431|OTHER|Biological parameters|Hemoglobin levels, red cells, hematocrit, iron, ferritin
40860908|NCT00308971|DRUG|placebo|placebo for alpha lipoic acid; 2 pills daily for 4 months
40860909|NCT04529343|OTHER|Virtual reality mediated upper extremity rehabilitation|"Game-based exercise will be applied for different range of motion of the upper extremity. Gamified exercise program consisting of 4 different scenarios will be applied 3 days a week for 6 weeks to the patients in the virtual reality group. A session takes an average of 45 minutes.~Games to be applied;~1. Finger flexion-extension (10 minutes / session)~2. Wrist flexion, extension, ulnar and radial deviation (10 minutes / session)~3. Forearm pronation and supination (10 minutes / session)~4. Elbow flexion-extension-shoulder internal and external rotation (15 minutes / session) will have scenarios controlled with. All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes."
40860910|NCT04529343|OTHER|Classical exercise therapy for upper extremities|All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
40860911|NCT02393937|DRUG|Reference: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
40860912|NCT02393937|DRUG|Test: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
40860913|NCT02393937|DRUG|Placebo Gel|Participants are assigned to one of three groups in parallel for the duration of the study
40860914|NCT06395038|DRUG|Abatacept plus Aldesleukin|CTLA4IgG plus Low dose Interleukin-2 (Aldesleukin) administration to modify immune responses
40860915|NCT00402870|DEVICE|ProSeal LMA|ProSeal LMA vs Tracheal Tube
40860916|NCT00402870|DEVICE|ProSeal LMA, Tracheal Tube|ProSeal LMA vs Tracheal Tube
40860917|NCT01389869|BIOLOGICAL|Sniffing emotional tears|A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
40860918|NCT01389869|BIOLOGICAL|Sniffing trickled saline|A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
40860919|NCT01389869|BIOLOGICAL|Sniffing fasting plasma|A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
41167834|NCT02108847|DRUG|Saline|
41167835|NCT02108847|PROCEDURE|Fascia Iliaca Block|Ultrasound-guided regional anesthesia block to the groin area.
41167836|NCT00526097|DRUG|Bisacodyl 10 mg|2 x 5 mg bisacodyl once daily
41167837|NCT00526097|DRUG|Placebo|Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
41391746|NCT02394431|OTHER|Clinical parameters|Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
41512799|NCT01749202|OTHER|SDA soybean Oil Food|3 servings/day
40860920|NCT01389869|BIOLOGICAL|Sniffing postprandial plasma|A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
40860921|NCT04236752|RADIATION|Stereotactic Ablative Body Radiation (SBRT)|
40860922|NCT05831488|OTHER|Non-Interventional|Non Interventional
40860923|NCT03763019|PROCEDURE|Conventional rehabilitation|Static and dynamic control of position, balance skills, weight shift, and activities of daily living.
40860924|NCT03763019|PROCEDURE|Respiratory rehabilitation|Forced expiration, forced inspiration (thoracal expansion exercise), coughing exercise, incentive spirometric trainer, diaphragmatic respiration exercise, autogenic drainage, percussion.
40860925|NCT00003727|BIOLOGICAL|filgrastim|
40860926|NCT00003727|BIOLOGICAL|recombinant interferon alfa|
40860927|NCT00003727|BIOLOGICAL|sargramostim|
40860928|NCT00003727|BIOLOGICAL|therapeutic autologous lymphocytes|
40860929|NCT00003727|DRUG|carmustine|
40860930|NCT00003727|DRUG|cyclophosphamide|
40860931|NCT00003727|DRUG|etoposide|
40860932|NCT00003727|DRUG|gemcitabine hydrochloride|
40860933|NCT00003727|DRUG|melphalan|
40860934|NCT00003727|PROCEDURE|bone marrow ablation with stem cell support|
40860935|NCT00003727|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
40860936|NCT02277925|OTHER|Polytetrafluoroethylene|Suture used to attach mesh during sacral colpopexy surgery
40860937|NCT02277925|OTHER|Polydioxanone|Suture used to attach mesh during sacral colpopexy surgery
40860938|NCT01022138|BIOLOGICAL|HER2Bi-armed activated T cells|Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.
41039992|NCT03611348|DRUG|Latanoprost|"Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~* To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded."
41039993|NCT03611348|DEVICE|Microneedling|A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points
41039994|NCT02332590|DRUG|Sarilumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
41039995|NCT02332590|DRUG|Adalimumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
41039996|NCT02332590|DRUG|Placebo (for sarilumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
41039997|NCT02332590|DRUG|Placebo (for adalimumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
41039998|NCT01936025|DRUG|Dextromethorphan|
40860939|NCT01022138|DRUG|Cyclophosphamide|After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
40860940|NCT01022138|OTHER|Laboratory biomarker analysis|The association between the \[18F\]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored.
40860941|NCT04736381|DRUG|Belatacept Injection [Nulojix]|Drugs administrated are part of the usual care
40860942|NCT00494585|DRUG|CEP-701|80 mg orally twice a day for 30 days
40860943|NCT03332836|BIOLOGICAL|HM12460A|HM12460A is a long-acting insulin
40860944|NCT02949999|DRUG|Voclosporin|
40860945|NCT00554450|DRUG|Dapagliflozin|Tablets, Oral, once daily
40860946|NCT05747742|DEVICE|RLRL device|Crossover device (RLRL of 50% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
40860947|NCT01435213|DRUG|Atipamezole|Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
40860948|NCT01435213|DRUG|Atomoxetine|A single dose of 1.2 mg/kg of atomoxetine administered orally
40860949|NCT01435213|DRUG|Ketamine|A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
40860950|NCT01435213|OTHER|Cold pressor test|30-45 min cold pressor test of the foot
40860951|NCT01435213|DRUG|Insulin|Insulin administered as an intravenous infusion to induce hypoglycemia
40860952|NCT01435213|DRUG|Placebo|A single dose of placebo (capsules) administered orally
40860953|NCT03043885|DEVICE|FDBA|Graft material used to graft extraction socket
40860954|NCT03043885|DEVICE|PRF|Autologous blood product used to graft extraction socket
40860955|NCT03043885|PROCEDURE|Blood Clot|Surgical treatment of extraction socket without addition of graft material
40860956|NCT03477396|DRUG|Aromatase Inhibitor|Aromatase inhibitor per treating investigator's discretion
40860957|NCT03477396|OTHER|Laboratory Biomarker Analysis|Correlative studies
40860958|NCT03477396|OTHER|Pharmacokinetic Study|Correlative studies
40860959|NCT03477396|OTHER|Questionnaire Administration|Ancillary studies
40860960|NCT03477396|DRUG|Ribociclib|Given PO
40860961|NCT06089746|OTHER|NIPT|Coordinated suite of DME and training to support continuous maintenance of flexion posture during the 6 week trial.
40860962|NCT01391663|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
40860963|NCT01391663|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
40860964|NCT01391663|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
40860965|NCT05021770|DRUG|Orelabrutinib|150mg or 200mg orally daily
40860966|NCT05021770|DRUG|Orelabrutinib|RP2D
40860967|NCT05021770|DRUG|Thiotepa|30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
40860968|NCT00325117|DRUG|Vildagliptin|
41039999|NCT01936025|DRUG|Sitagliptin|
41040000|NCT01936025|DRUG|Placebo|
41040001|NCT02495025|BEHAVIORAL|Telephone-based developmental screening and care coordination|
40860969|NCT05509426|BEHAVIORAL|Cognitive Rehabilitation|This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.
40860970|NCT03077542|PROCEDURE|haploidentical stem cell transplant|haploidentical stem cell transplant
40860971|NCT03077542|DRUG|Sirolimus|conditioning regimen
40860972|NCT03077542|DRUG|Alemtuzumab|conditioning regimen
40860973|NCT03077542|DRUG|Pentostatin|conditioning regimen
40860974|NCT03077542|DRUG|Cyclophosphamide|conditioning regimen
40860975|NCT03077542|DRUG|Hydroxyurea|conditioning regimen
40860976|NCT03077542|DRUG|Filgrastim|A haploidentical relative donor will receive filgrastim (G-CSF) 10 to 16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of peripheral blood hematopoietic progenitor cells (PBPC) after the 5th day (and after the 6th day if required).
40860977|NCT02629822|DRUG|Doravirine/lamivudine/tenofovir disoproxil fumarate|FDC tablet containing MK-1439 (doravirine) 100 mg / lamivudine 300 mg / tenofovir disoproxil fumarate 300 mg taken by mouth.
40860978|NCT03461146|DRUG|MT-6548|Oral tablet
40860979|NCT02638649|PROCEDURE|Lung ultrasound|At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.
40860980|NCT02638649|DEVICE|ultrasound|
40860981|NCT04993443|DRUG|LQ036|"For Each part of the study, a staggered dosing schedule may be used for the first dose level, in each cohort including 2 sentinel subjects (1 active and 1 placebo) initiating dosing first and the remaining 6 subjects for Part A-C and 8 subjects for Part D initiating dosing no sooner than the next day. Each study part (A, B, C, and D) will be completed sequentially, but with partial overlapping. Part B and C may only be initiated after review of the safety, tolerability, and PK data following dosing of the SAD Cohort 3 or 4.~Part D may be initiated when safety tolerability and PK data are known and deemed acceptable by the SRC for multiple doses in Part B, at least at the same concentration to be administered in Part D."
41391747|NCT04472065|DIETARY_SUPPLEMENT|Lactobacillus reuteri|1 chewable tablet of probiotic dietary supplement (200 million CFU of L. reuteri DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
40860982|NCT04993443|OTHER|Matching Placebo|Matching Placebo for LQ036: Matching Placebo
40860983|NCT02083536|RADIATION|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
41040002|NCT05663424|OTHER|rTMS-PTi|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus immediate rehabilitation programs
41040003|NCT05663424|OTHER|rTMS-PTd|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus delayed rehabilitation programs (\>2hr)
41040004|NCT05663424|OTHER|rTMSs-PT|10 daily sessions of sham rTMS (to vertex) plus rehabilitation programs
40860984|NCT02083536|DRUG|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
40860985|NCT02199925|DRUG|Gammaplex 5%|
40860986|NCT00595491|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage|Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
40860987|NCT01818102|DEVICE|Width 1000 HU/Level -450 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.
41040005|NCT04146714|OTHER|Substance use questionnaire|Screening questionnaire about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
41391748|NCT04472065|OTHER|Placebo|1 chewable placebo tablet containing all the same ingredients except L. reuteri (DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
41391749|NCT06518837|DRUG|Tirzepatide|The intervention aims to assess the feasibility, safety, and efficacy of tirzepatide for weight loss in patients with early-stage hormone receptor-positive, HER2-negative breast cancer, potentially improving treatment outcomes and overall health.
41391750|NCT02846740|DEVICE|Alpha-Stim®.|cranial electrical stimulation
41040006|NCT04146714|OTHER|Physical activity questionnaire|Screening questionnaire about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
41391751|NCT02846740|BEHAVIORAL|Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale|A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
41391752|NCT01672814|DRUG|riboflavin ophthalmic solution|Administration of riboflavin every 2 minutes for 20 minutes
41391753|NCT01672814|DEVICE|Vedera KXS Microwave System|The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
41391754|NCT00417859|DEVICE|Total knee arthroplasty: mobile bearing|Total knee arthroplasty: mobile bearing
41391755|NCT01202994|DRUG|18F-Flutemetamol|"All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).~For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.~The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images."
41391756|NCT02609178|PROCEDURE|FGP|To execute FGP technique, the occlusal surface of the interim should be back cut to leave at least 1mm occlusal space. Then apply the recording resin. Ask the subjects to close the mouth to maximum intercuspal position then perform right lateral, left lateral and protrusive movements in succession ending in maximum intercuspation position. Excessive resin then should be trimmed off and Bausch articulating paper would be used to mark the intercuspal contacts. Zinc oxide is then applied to check eccentric occlusion, trimmed off resin if there're interferences. Then the interim would be used as a copy to design the occlusal surface of the crown. (CAD/CAM)
41391757|NCT02609178|PROCEDURE|AVR|the crowns in this group would be designed by setting virtual articulator to average mode (CAD/CAM)
41391758|NCT00275236|DRUG|Rotigotine|
41391759|NCT00141479|DRUG|Bifeprunox|
41391760|NCT03910582|PROCEDURE|personalized frozen-thawed embryo transfer|The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
41391761|NCT03910582|PROCEDURE|routine frozen-thawed embryo transfer|The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
41391762|NCT03527537|DRUG|Insulin|Insulin may be administered base on glucose log values. The dosing of the insulin will be determined by the provider using typical management of gestational diabetes.
41391763|NCT05676879|OTHER|Ice massage was applied to the SP6 points|Ice massage was applied to the SP6 points (SP6 point is located 3-4 fingers above the posterior malleolus bone, that is, 4 fingers above the ankle) of the pregnant women in first stage of childbirth at 4-5 cm, 6-7 cm, and 8-9 cm cervical dilatations during 3 contractions.
41391764|NCT03151993|DRUG|Recombinant staphylokinase|10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
41391765|NCT03151993|DRUG|Alteplase|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
41391766|NCT00366678|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
41391767|NCT00366678|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
41167838|NCT01746277|DRUG|combined group|chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
41391768|NCT00366678|DRUG|Pentavac|The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
41391769|NCT00203632|DRUG|rosiglitazone/placebo|
41391770|NCT03953911|BIOLOGICAL|Mobile Clinic|This intervention involves the availability of a free mobile clinic operated by Cedar-Sinai Medical Center providing free HPV vaccinations at school campuses.
41391771|NCT03953911|BEHAVIORAL|Educational Sessions for Parents|This intervention involves providing free weekly educational sessions for parents of students at the participant schools pertaining to the HPV Vaccination.
41512800|NCT06090201|OTHER|3-Tesla brain MRI and a comprehensive neuropsychological assessment|Patients with a moderate to severe form of congenital haemophilia A or B or a severe form of von Willebrand disease will be consecutively recruited in the study during a routine follow-up visit at the Haemostasis and Transfusion Department of the Lille University Hospital.
40860988|NCT01818102|DEVICE|Width 400 HU/Level 25 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
41391772|NCT00047294|DRUG|celecoxib|
41391773|NCT00047294|DRUG|temozolomide|
41391774|NCT00047294|DRUG|thalidomide|
40860989|NCT00005085|DRUG|becatecarin|
41040007|NCT01891916|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|Extensively hydrolyzed formula containing Lactobacillus GG
41040008|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h.
41040009|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
41040010|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
41040011|NCT01064037|DRUG|Placebo|Infusion during 48h
41167839|NCT01746277|DRUG|Sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
41391775|NCT00047294|PROCEDURE|adjuvant therapy|
41391776|NCT04989231|BIOLOGICAL|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months
41391777|NCT04989231|BIOLOGICAL|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively;Single intramuscular injection of the control vaccine (0.5ml) at 18 months
41391778|NCT01158976|DIETARY_SUPPLEMENT|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
41391779|NCT01158976|OTHER|Placebo|soybean oils with strawberry flavoring
41512801|NCT02451761|BIOLOGICAL|Blood sampling|
41512802|NCT04042844|BIOLOGICAL|BRTX-100|Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate.
41512803|NCT04042844|DRUG|Saline|Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution
40860990|NCT01624116|DRUG|Acarbose|Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
40860991|NCT01624116|OTHER|Diet and lifestyle|Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
40860992|NCT01624116|DRUG|Metformin|Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
40860993|NCT01624116|DRUG|Metformin/ Glimepride|Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
41167840|NCT03190629|DEVICE|High-flux hemodialysis|Hemodialysis treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Hemodialysis treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care).
41040012|NCT05907824|OTHER|Histopathological review, long-term prognosis and quality of life follow-up|Histopathological review, long-term prognosis and quality of life follow-up
41512804|NCT06115525|OTHER|mNUTRIC score|The mNUTRIC score is a useful means of gauging the nutritional risk of patients in intensive care. Originally designed for IC unit patients, the score is calculated even when patient cooperation is unfeasible, making it applicable for intubated patients. Information necessary for calculation can be obtained from the patient's kin. The mNUTRIC score (without IL-6) classifies patients according to predefined metrics. The following information is necessary: (1) the patient's age, (2) their APACHE II score, (3) their SOFA score, (4) their comorbidities, and (5) the number of days they were hospitalized before being admitted to ICU.
41512805|NCT06115525|OTHER|NRS-2002|The NRS-2002 score is a tool utilised to measure the nutritional risk of patients in intensive care units. This tool was specifically developed for the purpose of evaluating intensive care unit patients and can be calculated without requiring the patient's active involvement. Additionally, it can be applied to patients who have been intubated and the required information can be sourced from their family members or relatives. The Nutritional Risk Screening (NRS)-2002 assesses a patient's nutritional risk based on five variables: (1) recent unexplained weight loss, (2) appetite, (3) BMI, (4) disease-related stress factors (comorbidities), and (5) age over 70 years which is an additional risk factor.
41512806|NCT01259271|DEVICE|Selective Nerve Stimulation (SNS) stimulator device|Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.
41512807|NCT02861014|BIOLOGICAL|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
41512808|NCT00963066|DEVICE|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
41512809|NCT00963066|DEVICE|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
41512810|NCT00963066|DEVICE|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
41512811|NCT04393714|PROCEDURE|Alveolar ridge preservation after extraction|atraumatic extraction followed by graft material insertion
40860994|NCT01624116|DRUG|Metformin/Sitagliptin|Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
40860995|NCT05045300|PROCEDURE|Ultrasound guided Selective trunk block|High definition ultrasound images that were acquired during USG SeTB are routinely stored in the hard disk of ultrasound machine in DICOM (Digital Imaging and Communications in Medicine) format will be used for this review. The images of principal investigator's previous research studies with Clinical trial registration: NCT04752410 and NCT04773405 will also be retrieved. The ultrasound imaging was performed before (scout scan), during and immediately after the USG SeTB. As is the principal investigator's standard practice, all ultrasound scan was performed in a sequential manner (SUIT: Sequential Ultrasound Imaging Technique) with the orientation marker of the transducer directed laterally so as to obtain a transverse oblique view of the brachial plexus block at the supraclavicular fossa. Approximate 50 cases who had undergone USG SeTB for surgical anesthesia during upper extremity surgery since January 1 2020 to June 30, 2021 will be evaluated by two anesthesiologists.
41391780|NCT03446716|BEHAVIORAL|Sleep Extension|Child attempted to go to bed 90 mins in advance of their normal bedtime.
41391781|NCT00854607|OTHER|No Intervention|Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
41391782|NCT01528046|DRUG|Vincristine|Vincristine (VCR) = 1.5 mg/m\^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
41391783|NCT01528046|DRUG|Irinotecan|Irinotecan (IRN) = 50 mg/m\^2/day, days 1-5, IV over 60 minutes
41391784|NCT01528046|DRUG|Temozolomide|Temozolomide (TEM) = 50 mg/m\^2/day by mouth (PO) Days 1-5
41391785|NCT01528046|DRUG|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
41391786|NCT05219773|DEVICE|NuvoAir Air Next spirometer|"* The collection of medical history and demographic data~* Spirometry testing in both the clinic and home setting.~* The measurement of height and weight.~* The evaluation of the perception of home spirometry via a survey."
41391787|NCT06061718|DRUG|iDose TR|anchored intracameral implant containing travoprost
40860996|NCT01871519|DEVICE|Balloon kyphoplasty|The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
40860997|NCT01770171|DRUG|Bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
40860998|NCT01770171|DRUG|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
40860999|NCT02206035|DRUG|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
40861000|NCT02206035|DRUG|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m\^2 Days +3, +6 and +11.
40861001|NCT02206035|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
40861002|NCT01347242|GENETIC|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
41040013|NCT05858996|BEHAVIORAL|Pain-CPG-EIT|"Following randomization champions and stakeholder team members from the communities will be identified. The investigators will recommend the following individuals to be members of the stakeholder team: a nurse in a leadership position (e.g., director of nursing); the designated champion(s); nursing home administrator; physician/medical director, nurse practitioner and/or physician assistant; unit nurse; nursing assistant; activity staff; social worker; pharmacist; and rehabilitation therapists.~Following the first stakeholder team meeting, treatment communities will be provided with a research nurse facilitator to work 8 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to provide the four components of the PAIN-CPG-EIT."
41040014|NCT05858996|OTHER|Pain-CPG-Education Only|The Pain-CPG-Education only group will be provided with the same education as used in Component II of the Pain-CPG-EIT intervention. The education will be provided based on the preferences of the community (this may be face-to-face; online; or via handouts).
41391788|NCT02097368|PROCEDURE|tongue strength measurement|tongue strength measurement
41391789|NCT02097368|PROCEDURE|respiratory function measurement|respiratory function measurement
41040015|NCT01736228|DEVICE|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
41040016|NCT03206346|DRUG|Ingavirin|Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
41391790|NCT02097368|PROCEDURE|swallowing tests|swallowing tests
41391791|NCT02097368|OTHER|Magnetic resonance imaging|Magnetic resonance imaging
41391792|NCT02111382|OTHER|CV4 Cranial (4th ventricle technique) Osteopathic Manipulative|"The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.~When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.~The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths."
41391793|NCT02111382|OTHER|CV4 (4th ventricle technique) manual therapy sham technique|"The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.~The CV4 sham will be performed by a registered physiotherapist."
41391794|NCT05837065|OTHER|observing whether HCC patients having tumor micronecrosis|whether HCC patients having tumor micronecrosis or not
41391795|NCT03121469|DEVICE|Papillon +TM|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
41391796|NCT06123494|DRUG|SHR-A1811|SHR-A1811 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
41391797|NCT06123494|DRUG|Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan|Ramucirumab 8mg/kg，D 1,15 + Paclitaxel 80mg/m2，D1,8,15，Q4W; Paclitaxel 80mg/m2，D1,8,15，Q4W; Docetaxel 75mg/m2，D1，Q3W; Irinotecan 150mg/m2，D1，Q2W.
40861003|NCT02112617|RADIATION|Proton Beam Radiation Therapy|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
40861004|NCT02053090|BEHAVIORAL|Group Education and Stretching|
40861005|NCT02053090|PROCEDURE|Group Acupuncture|
40861006|NCT04328220|DIAGNOSTIC_TEST|chest ultrasound|"A point-of-care lung ultrasound exam will be performed within 24h of admission to PICU and serial follow up according to each case.~chest x-ray will be performed for comparison with ultrasound findings."
40861007|NCT01890837|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
40861008|NCT01890837|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
40861009|NCT01435486|DRUG|Caffeine citrate|Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
40861010|NCT01435486|DRUG|Normal saline|Placebo with an equivalent volume of normal saline.
41040017|NCT03206346|DRUG|Placebo oral capsule|Placebo, capsules daily for 5 days.
40861011|NCT05200676|DEVICE|ePatch|ePatch registers the heart rate continuously when attached to the chest of the participant.
40861012|NCT05200676|DEVICE|SmartPill|SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.
40861013|NCT00636285|DRUG|Placebo|Placebo
40861014|NCT00636285|DRUG|BSYX-A110|BSYX-A110, Dosed intravenously, 3 mg/kg
40861015|NCT00636285|DRUG|BSYX-A110|BSYX-A110, Dosed intravenously, 10 mg/kg
40861016|NCT02087449|DEVICE|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
40861017|NCT00223483|GENETIC|Isolation of genomic DNA|One time blood draw
40861018|NCT00139230|DRUG|Taxotere|
40861019|NCT00139230|DRUG|Cisplatin|
40861020|NCT00139230|DRUG|5-Fluorouracil|
40861021|NCT00139230|DRUG|Leucovorin|
40861022|NCT00139230|DRUG|G-CSF|
40861023|NCT00139230|DRUG|Ciprofloxacin|
40861024|NCT03236077|BEHAVIORAL|Fit and Fab|participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
40861025|NCT00028704|PROCEDURE|conventional surgery|
40861026|NCT00028704|RADIATION|radiation therapy|
40861027|NCT00056693|DRUG|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity
40861028|NCT02154919|PROCEDURE|Percutaneous coronary intervention|
40861029|NCT03600740|DEVICE|DBS Programming|DBS Programming may be temporarily altered based on imaging data to measure a change in clinical symptoms.
40861030|NCT04182243|OTHER|Evaluation of job satisfaction in emergency health care providers by questionnaire|
41167841|NCT03190629|DEVICE|On line-hemodiafiltration|Post-dilution on line-hemodiafiltration treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Post-dilution on line-hemodiafiltration treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care), with automatic adjustment of the substitution fluid flow rate for maximising substitution volume while simultaneously avoiding haemoconcentration and filter clotting.
41391798|NCT04250519|DRUG|Sodium Hypochlorite|Sodium hypochlorite is used as intracanal irrigant to minimize the post operative pain
41391799|NCT04098159|DEVICE|duplex ultrasound|regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion
41391800|NCT04948385|DRUG|Propofol|deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
41391801|NCT04948385|PROCEDURE|No sedation|No sedation
41391802|NCT01403428|OTHER|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
41391803|NCT03576469|BIOLOGICAL|C1-esterase inhibitor [recombinant] (C1-INH-R)|C1-INH-R is FDA approved and indicated for the treatment of acute attacks of angioedema in adolescent and adult patients with Hereditary Angioedema (HAE) as a replacement for low levels of C1-esterase inhibitor or low function of C1-esterase inhibitor
41417899|NCT04853459|PROCEDURE|Border modeling..Measurement|By using light cure to make border modeling in complete denture.
41417900|NCT03093909|DRUG|Gemcitabine|Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
40861031|NCT01040442|OTHER|vibration stimuli|A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.
40861032|NCT05030207|DIAGNOSTIC_TEST|Real-time Gated 4DCT|Real-time gated four-dimensional cone beam computed tomography (4DCT) will be conducted at the simulation session. The Real-Time Gated 4DCT will be conducted while the patient moves through the rotating X-ray imager. This method detects and then pauses the CT beam during irregular breathing events.
41167842|NCT02622711|BEHAVIORAL|DI|Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
40861033|NCT05030207|DIAGNOSTIC_TEST|Conventional 4DCT|Four-dimensional computed tomography (4DCT), the standard of care for modern high-precision stereotactic ablative body radiotherapy (SABR), will be conducted at the simulation session. It will run continuously while the patient moves through the rotating X-ray imager.
40861034|NCT01096693|DRUG|Urocortin 2, Urocortin 3|"After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3."
41391804|NCT00183469|DRUG|Lamotrigine|If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.
41391805|NCT00183469|DRUG|Divalproex (DIV) ER|If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.
41167843|NCT02622711|BEHAVIORAL|PAI|Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
41167844|NCT02622711|BEHAVIORAL|PADI|Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
41391806|NCT00183469|DRUG|Placebo|During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
41391807|NCT01891786|BEHAVIORAL|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
41391808|NCT01891786|BEHAVIORAL|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
41167845|NCT02622711|BEHAVIORAL|LII|Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
41391809|NCT02898064|DEVICE|thoracolumbosacral orthosis or cervicothoracolumbar orthosis|"An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used."
41391810|NCT02898064|OTHER|Standard care|Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
41391811|NCT05891873|DIAGNOSTIC_TEST|CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
41391812|NCT05891873|DIAGNOSTIC_TEST|ICDSC|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
41391813|NCT05891873|DIAGNOSTIC_TEST|4AT|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
41391814|NCT05891873|DIAGNOSTIC_TEST|p(s)CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
41391815|NCT05891873|DIAGNOSTIC_TEST|CAPD|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
41040018|NCT05624658|COMBINATION_PRODUCT|Combined Lipid-lowering Therapy|the effect of high-dose combined lipid-lowering therapy (statins+ezetimibe vs statins+PCSK9 inhibitors) on the vulnerability characteristics of atherosclerotic plaques assessed using multimodal imaging (coronary artery computed tomography and optical coherence tomography), as well as biomarkers in patients with acute coronary syndrome for 52 weeks.
41040019|NCT00587327|DRUG|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
41040020|NCT00587327|DRUG|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
41040021|NCT00587327|DRUG|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
41167846|NCT01977183|DIETARY_SUPPLEMENT|MSPrebiotic|Potato Resistant Starch
41167847|NCT01977183|DIETARY_SUPPLEMENT|Placebo|Placebo - Corn Starch
41167848|NCT01413022|DRUG|Oxaliplatin|
41391816|NCT05891873|DIAGNOSTIC_TEST|MASTcz (The Mississippi Aphasia Screening Test)|People with aphasia will be examined by a skilled speech therapist.
41391817|NCT05891873|DIAGNOSTIC_TEST|EEG|Patients with positive delirium will undergo EEG examination. 10-min native EEG.
41417901|NCT02185781|OTHER|Autologous NK cells infusions|"Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.~The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance."
41040022|NCT01786512|DRUG|Omecamtiv Mecarbil Matrix F1 Formulation|Modified release tablets for oral administration
41040023|NCT01786512|DRUG|Omecamtiv Mecarbil Matrix F2 Formulation|Modified release tablets for oral administration
41167849|NCT01413022|DRUG|Irinotecan|
41040024|NCT01786512|DRUG|Placebo|Modified release tablets matching to omecamtiv mecarbil
41167850|NCT01413022|DRUG|Leucovorin|
41167851|NCT01413022|DRUG|Fluorouracil|
41167852|NCT01413022|OTHER|laboratory biomarker analysis|Correlative studies
41167853|NCT01413022|OTHER|flow cytometry|Correlative studies
41167854|NCT01413022|OTHER|immunohistochemistry staining method|Correlative studies
41391818|NCT05268965|BEHAVIORAL|Experimental: group comparison|"* Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~* State-Trait-Anxiety Inventory (Spielberger, 1993)~* Beck Depression Inventory (BDI-II, 1998)~* Cognitive Emotional Regulation Questionnaire (Jermann \& al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~* Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~* Step 2: experience of the same scenarios in virtual reality"
41391819|NCT05795517|DRUG|HSK31679 low dose|HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
41391820|NCT05795517|DRUG|HSK31679 medium dose|HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
41391821|NCT05795517|DRUG|HSK31679 high dose|HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
41167855|NCT01413022|OTHER|pharmacological study|Correlative studies
41391822|NCT05795517|DRUG|Placebo|placebo ，QD，oral，Day1 to week 12
41391823|NCT05795517|DRUG|Ezetimibe 10mg|Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12
41391824|NCT04824300|PROCEDURE|erector spinae block|Erector spina plane block (ESP) is a technique used in many surgeries for anesthesia and analgesia. It is frequently preferred by anesthesiologists for postoperative analgesia recently because it is easy to apply and no complications are reported in the literature. Erector spina muscle, with arms of iliocostalis, longissimus and spinalis, is located parallel to the spine, from the back of the skull to the pelvis. The injected local anesthetic is distributed in many levels in the cranio-caudal direction and blocks the intercostal spinal nerves, causing sensory block. Providing the necessary perioperative analgesia due to the complex innervation of the breast tissue is a big controversy among anesthesiologists. Multimodal analgesia methods with various regional blocks are more preferred. Erector Spina Plane block is also preferred as another method since it provides both perioperative and postoperative analgesia
41391825|NCT04112615|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
41391826|NCT02394353|DEVICE|Transient hepatic elastography|
41391827|NCT06419673|DRUG|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
41391828|NCT06419673|DRUG|Cisplatin|IV infusion
41391829|NCT06419673|DRUG|Carboplatin|IV infusion
41391830|NCT06419673|RADIATION|Brachytherapy and External Beam Radiotherapy|Brachytherapy and External Beam Radiotherapy
40861035|NCT01096693|DRUG|Saline placebo|"After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
41391831|NCT00057785|DRUG|cisplatin|100 mg/m\^2 intravenously on days 1, 22, and 43 and 80 mg/m\^2 intravenously on days 71, 99, and 127
41391832|NCT00057785|DRUG|fluorouracil|1000 mg/m\^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
41391833|NCT00057785|RADIATION|Intensity modulated radiation therapy|The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume \[CTV\] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
41391834|NCT06485492|PROCEDURE|Implant an aneurysm embolization system|The product uses minimally invasive interventional method to treat intracranial aneurysms approved for application. The study physician selects the appropriate size and/or shape of the aneurysm based on the size and shape of the intracranial arterioma. The aneurysm embolization system device is inserted into the arterioma through a compatible neurovascular microcatheter.
41391835|NCT04808765|PROCEDURE|Immediate Breast reconstruction|immediate mastectomy with breast reconstruction with implants or expanders
41391836|NCT02199834|BEHAVIORAL|Peer support|15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
40861036|NCT00791908|PROCEDURE|Electrodessication|Treatment applied to a third of the torso at each study visit.
40861037|NCT00791908|PROCEDURE|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
41167856|NCT01413022|DRUG|PF-04136309|
41167857|NCT03104777|BEHAVIORAL|Behaviourally Informed Intervention Materials|"The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:~Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.~Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.~Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress."
41391837|NCT02199834|BEHAVIORAL|Personalized feedback report|Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
41391838|NCT04200781|DRUG|Granules of Shengdi Dahuang Decoction|Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
41391839|NCT04200781|DRUG|Placebo|Placebo granules has the same appearence, weight, shape and color as the experimental drug.
41391840|NCT00951899|DRUG|Colesevelam|Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
41040025|NCT01786512|DRUG|Omecamtiv Mecarbil Swellable Core Technology F2|Modified release tablets for oral administration
41040026|NCT04512521|DRUG|Mepolizumab|Mepolizumab therapy
41040027|NCT04051229|BEHAVIORAL|6-week exercise training program|Participants will walk at 50% Heart Rate Reserve (HRR) 3 to 5 days per week for 6 weeks at the Department of Health and Exercise Science Clinical Research Center under the supervision of study staff.
41391841|NCT00951899|OTHER|Placebo|Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
40861038|NCT00791908|PROCEDURE|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
40861039|NCT02226718|OTHER|Administration of questionnaire|
40861040|NCT03374579|DIAGNOSTIC_TEST|Fluid challenge|Fluid challenge and measure change in co2 gap
40861041|NCT03832751|OTHER|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
40861042|NCT00394706|DEVICE|Impedance Threshold Device (ITD)|Use of Impedance Threshold Device (ITD)
40861043|NCT00394706|DEVICE|Sham ITD|Sham ITD
40861044|NCT00394706|OTHER|Analyze early|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
40861045|NCT00394706|OTHER|Analyze later|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
40861046|NCT03712787|DRUG|Tilavonemab|solution for IV infusion
40861047|NCT06042634|BEHAVIORAL|Online psychoeducation|Online psychoeducation aimed to enhance the knowledge and skill of family caregivers of people with dementia, who could not physically attend in-person class. Knowledge covering dementia caregiving including disease nature, communication skill, stress and coping, daily care, management of behavioral and psychological symptoms of dementia, and future planning. The intervention provided opportunities to practice through simulation and weekly home assignment. There was a total of 6 sessions and provided weekly. Each session lasted for 2 hours. Participants had discussion with peers and coached by a facilitator. Online psychoeducation wad delivered via Zoom videoconferencing.
40861048|NCT06042634|BEHAVIORAL|Face-to-face psychoeducation|Face-to-face psychoeducation has the same content and flow of presentation as online psychoeducation.
41391842|NCT00951899|BEHAVIORAL|Diet|Subjects were instructed to follow a weight maintenance diet (\~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
41391843|NCT00951899|DRUG|Metformin|Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
41391844|NCT05620459|PROCEDURE|Ridge augmentation using chin bone ring with simultaneous implant placement|surgical guides are to be used to harvest chin bone ring, the rings are to be used for bone augmentation in extraction sockets (salama and salama classsification type II),simultaneously implant placement.
41040028|NCT04051229|BEHAVIORAL|Standardized isoenergetic high fat diet|Prior to the submaximal exercise testing visits, all participants will be provided with 3 days of a standardized isoenergetic high fat diet (20% of kcals from carbohydrate, 65% fat; 15% protein) to promote lipid oxidation. The meals will be prepared and provided by the Clinical Research Unit of Wake Forest Baptist Health. Participants will pick up 3 days' worth of food and snacks 4 days prior the testing visit. For the 3 days leading up to the visit, participants will eat the provided foods and complete a compliance assessment.
41040029|NCT04068753|DRUG|Niraparib|Niraparib: 200 mg, oral, once daily, days 1-21
41040030|NCT04068753|DRUG|dostarlimab|dostarlimab: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks for up to two years
41391845|NCT01638754|PROCEDURE|Image guided Cardiac Resynchronization Therapy (CRT) device lead placement.|Participants will have a cardiac MRI scan prior to insertion of CRT device and an image guided map will be created to guide placement of Cardiac Resynchronization Therapy (CRT) pacing leads to the most optimal target on the patients heart.
41391846|NCT01638754|PROCEDURE|optimizing myocardial lead placement for Cardiac Resynchronization Therapy (CRT) devices|optimal lead placement will be determined by 3D model of coronary vein anatomy, myocardial scar and mechanical dyssynchrony
41391847|NCT03909373|OTHER|PSFS|Patients will complete the patient specific functional scale. no intervention being administered
41391848|NCT01418352|DRUG|Aripiprazole|Aripiprazole tablets once weekly for 8 weeks.
41391849|NCT01418352|DRUG|Placebo|Aripiprazole matching-placebo once-weekly for 8 weeks.
41417902|NCT01742975|DEVICE|IFABOND (TM)|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
40861049|NCT05421013|DRUG|STP705|STP705 targets TGFB-1 and COX-2 mRNA respectively.
40861050|NCT03758534|OTHER|No intervention|This is a retrospective chart review study.
40861051|NCT01764555|DRUG|acetaminophen 2 g|
40861052|NCT00465088|DRUG|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
40861053|NCT00465088|DRUG|atorvastatin|40 mg at bedtime
40861054|NCT04385459|OTHER|Coronary artery disease|Exposure
40861055|NCT00972725|BIOLOGICAL|GSK Biologicals' HIV vaccine (732461)|1 dose intramuscular injection
40861056|NCT00972725|DRUG|Chloroquine|One dose of 300 mg
40861057|NCT02291419|DRUG|ticagrelor|ticagrelor 90 mg bid
40861058|NCT02291419|DRUG|aspirin|aspirin 81 mg daily
40861059|NCT03683342|PROCEDURE|Ankle Block|Ankle block will be performed prior to surgery under ultrasound guidance
40861060|NCT03683342|PROCEDURE|Sciatic nerve block|Sciatic nerve block will be performed prior to surgery under ultrasound guidance
40861061|NCT04307277|DRUG|Standard of care + chemotherapy|Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)
40861062|NCT04307277|OTHER|Standard of care|Surgical excision with external radiotherapy (if applicable)
40861063|NCT03654937|BIOLOGICAL|Influenza Vaccination|"Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH \& Co. KG, Munich, Germany, batch: AFLBA 152AB."
40861064|NCT05920135|DRUG|BBT-207|BBT-207 given orally alone
40861065|NCT01959139|DRUG|PEGPH20|3 ug/kg on Day 1, IV over 15 minutes
40861066|NCT01959139|DRUG|Oxaliplatin|85 mg/m\^2, on Day 2, IV over 2 hours
40861067|NCT01959139|DRUG|Leucovorin|400 mg/m\^2, on Day 2, IV over 2 hours
40861068|NCT01959139|DRUG|Irinotecan|180 mg/m\^2, on Day 2, IV over 1.5 hours
40861069|NCT01959139|DRUG|5-fluorouracil|2,400 mg/m\^2, Days 2-4, IV over 46 hours
41040031|NCT06225765|PROCEDURE|Transoral endoscopic thyroidectomy vestibular approach (TOETVA)|Remote access thyroid surgery
41391850|NCT04912635|OTHER|Neo App|Neo is a smartphone-based dashboard application that utilizes concepts from behavioral science and health psychology to support patients to improve their adherence to therapy. This is done through behavior change techniques and intervention functions (Michie, Atkins \& West, 2014). This app is designed to prompt participants' self-regulation of lifestyle and health behaviors, to support adherence to therapy. Such self-regulation of lifestyle behaviors is informed by presenting health metric data (through wearables, myAir (biofeedback) and self-report), in an easy to understand dashboard platform on the app. Participants will be asked to use their PAP device (as normal), use a Withings blood pressure cuff and activity monitor. This data is brought into the Neo app through an API Exchange gateway. This data will be presented to the participant and communicated in an easy to understand way.
41391851|NCT03120520|DRUG|Plecanatide|
41391852|NCT03120520|DRUG|Matching placebo|
41391853|NCT05762263|BEHAVIORAL|Dietary|Depending on the allocation arm, participants will be advised to follow a particular dietary plan (either flexitarian eating, time-restricted eating or both combined).
41391854|NCT01550068|DIAGNOSTIC_TEST|Echocardiography|
41391855|NCT05698420|DEVICE|Dialysis using the Theranova-400 device.|Patients receive hemodialysis treatment using the Theranova-400 dialyzer.
41391856|NCT05698420|DEVICE|Dialysis using the FX80 device.|Patients receive hemodialysis treatment using the FX80 dialyzer.
41391857|NCT01058044|OTHER|"Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System "|"Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy"
41391858|NCT06015880|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
41391859|NCT06015880|PROCEDURE|Computed Tomography|Undergo PET/CT
41391860|NCT06015880|DRUG|Lenalidomide|Given PO
41391861|NCT06015880|BIOLOGICAL|Mosunetuzumab|Given IV
41391862|NCT06015880|DRUG|Polatuzumab Vedotin|Given IV
41391863|NCT06015880|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
40861070|NCT03893032|DRUG|Modafinil 200mg|single 200 mg dose
40861071|NCT03893032|DRUG|mixed amphetamine salts|single 10 mg dose
40861072|NCT03893032|DRUG|Placebo|single oral-administration placebo tablet
40861073|NCT01657175|OTHER|Supportive care|"The patients will be randomized to control or supportive care groups.~The control group will be given care as usual wich include clinical follow-ups at the surgical department.~The supportive care group get in addition to the clinical follow-ups a supportive care programme including:~* Discharge information about surgery and life after surgery together with their relatives.~* Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.~* Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery"
40861074|NCT05258136|DRUG|low-dose CD20 monoclonal antibody injection|To comprehend the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
40861075|NCT04435275|OTHER|Virtual Assistant first, then Human Coach|Instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a VA (e-coach) in place of a safety officer (a human coach).
40861076|NCT04435275|OTHER|Human Coach first, then Virtual Assistant|instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a safety officer (a human coach).
40861077|NCT04054141|DEVICE|Mag Stim|rTMS
40861078|NCT02618161|RADIATION|HDR Brachytherapy|HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
40861079|NCT02618161|RADIATION|External beam Radiotherapy|External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
41040032|NCT06225765|PROCEDURE|Traditional Open Thyroidectomy|Open thyroidectomy via trans-cervical approach
41040033|NCT05652062|DEVICE|Prizvalve® system|Transcatheter valve-in-valve replacement
41040034|NCT05415735|BEHAVIORAL|Stress Management and Resiliency Training Program|This is a multimodal mind-body program designed to teach participants a variety of different strategies to reduce their physiologic stress response.
41391864|NCT01174368|BIOLOGICAL|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
41417903|NCT02684552|DEVICE|Non invasive ventilation|Training on treadmill with Non invasive ventilation
41040035|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
41040036|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
41040037|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
41417904|NCT02684552|DEVICE|Oxygen|Training on treadmill with oxygen
41512812|NCT02742883|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
41512813|NCT02474277|OTHER|30 sec chair stand test|diagnostic test for functional impairment
41512814|NCT04524195|DRUG|[18F]F-AraG Injection|Single dose of 5 mCi+/- \[18F\]F-AraG IV injection followed by the PET/CT scan. A baseline \[18F\]F-AraG PET/CT will be performed at about 0-7 days before patient receives the first dose of PD-1/PD-L1 immunotherapy. A second \[18F\]F-AraG PET-CT will be performed at less than 14 days after the first dose of PD-1/PD-L1 immunotherapy is administered and before the second dose of PD-1/PD-L1 immunotherapy is given.
41512815|NCT01526057|BIOLOGICAL|PF-05280586|1000 mg, IV on days 1 and 15
41040038|NCT05119920|DRUG|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
41040039|NCT05984953|DRUG|statin|40 mg of rosuvastatin daily for 8-12 weeks
41040040|NCT05984953|DRUG|evolocumab|140 mg evolocumab every 2 weeks (26 weeks)
41040041|NCT04477642|DRUG|Abatacept|10mg/kg intravenously administered on Day 1
41512816|NCT01526057|BIOLOGICAL|MabThera|1000 mg, IV on days 1 and 15
41512817|NCT01526057|BIOLOGICAL|Rituxan|1000 mg, IV on days 1 and 15
41512818|NCT01750190|DRUG|Roxadustat|Oral tablets
41512819|NCT01750190|DRUG|Placebo|Oral tablets
40861080|NCT01919229|DRUG|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
40861081|NCT01919229|DRUG|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
40861082|NCT04767906|DRUG|Cabozantinib|The medication is taken once a day for 336 days (max.). The start dose is 60mg and can be reduced according to the physicians decision. 40mg and 20mg are also available.
40861083|NCT03489889|DRUG|Ursodeoxycholic Acid 300mg tablet|Cross-over study: Ursodeoxycholic Acid 300mg tablet and after Ursodeoxycholic Acid 300mg capsule
40861084|NCT03489889|DRUG|Ursodeoxycholic Acid 300mg capsule|Cross-over study: Ursodeoxycholic Acid 300mg capsule and after Ursodeoxycholic Acid 300mg tablet
41391865|NCT04308109|BEHAVIORAL|Simulation|Simulation involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. The simulation will last approximately 2 hours and will end with reviewing the taped session as part of debriefing. Both active arms will occur in the simulation center or sleep lab and replicate the same clinical situations by the same simulation instructor.
41391866|NCT02881970|DRUG|autologous cord blood stem cell|Injection of 5.107 / kg autologous mononuclear cells from umbilical cord blood
41391867|NCT02173626|BEHAVIORAL|Mindfulness Training|Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
41391868|NCT01672307|DRUG|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
41391869|NCT01672307|DRUG|Placebo|Placebo is applied twice daily to the other eyebrow.
41391870|NCT04446819|DEVICE|Compression gloves|Patients wear small-size compression gloves (one or two size smaller than suitable size) for dominant hands and suitable-size compression gloves for non-dominant hands for 90 minutes during the administration of albumin-binding paclitaxel (start from 30 minutes before albumin-binding paclitaxel infusion).
41512820|NCT02983747|OTHER|PRP Treatment(P)|Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
41512821|NCT02983747|DRUG|Medication Treatment(Loxoprofen Sodium tablets,M)|Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
40861085|NCT02919046|BIOLOGICAL|GD2-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
40861086|NCT03261609|OTHER|preterm birth|The study compares young adult subjects born premature (\< 29 weeks) versus term (-\> 37 weeks)
40861087|NCT04718623|DIAGNOSTIC_TEST|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations by ELISA technique
40861088|NCT00500188|DRUG|Imatinib Mesylate (Gleevec)|300 mg orally twice daily
40861089|NCT01582711|BEHAVIORAL|Self Administered Therapy (SAT)|Self Administered Therapy (SAT)
41391871|NCT03598673|DRUG|The Efficacy and Tolerability of Nebivolol in Nigerians|To determine the effect of Nevibolol on office blood pressure of Blacks residing in Nigeria
41391872|NCT00727298|BIOLOGICAL|Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
41391873|NCT06148337|DIETARY_SUPPLEMENT|unhydrolyzed eggshell membrane|an unhydrolyzed, minimally processed chicken eggshell membrane powder.
41391874|NCT06148337|DIETARY_SUPPLEMENT|Placebo|psyllium husk fiber powder
41391875|NCT05233371|OTHER|Parenting Stress Index (PSI)|"collected by self-questionnaire during the follow-up carried out within the framework of the usual care (at 4, 9, 24 months of corrected age, +/- 18 months according to the neurodevelopmental evolution).~Parental stress will be measured at each visit with the same parent (father or mother)."
41391876|NCT05233371|OTHER|Collection of health care consumption|"Type and number of health professionals consulted between the different visits scheduled as part of the usual follow-up of the Dijon Bourgogne University Hospital,~* Frequency and duration of rehabilitation sessions by type of health professionals,~* Follow-up methods (institutional or private),~Consumption of care will be evaluated by means of self-questionnaires given to parents during follow-up consultations as part of the usual care."
41391877|NCT05233371|OTHER|Assessment of parent satisfaction|"their level of information, their child's follow-up, and the support provided by the professionals.~Satisfaction will be evaluated by means of a self-questionnaire (Likert scale) given to parents during follow-up consultations as part of their usual care."
41391878|NCT00716586|DRUG|2% dorzolamide|Carbonic anhydrase inhibitor, Trusopt (2% dorzolamide)
41512822|NCT03514290|RADIATION|Low-lever laser|Received Low-lever laser therapy using the infrared spectrum, with a wavelength of 808 nm in its active medium AsGaAl (arsenic-gallium-aluminum), at two points: on the central of cervical and medial regions of incisors, canines and premolars in the corresponding hemi-arch. At each point, 60 J/cm2 was applied during 16 seconds with an irradiance of 3.75 W/cm² using the therapeutic visible infrared device.
41512823|NCT03514290|OTHER|Tooth bleaching|Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.
41512824|NCT03514290|OTHER|Placebo|The laser tip was positioned similarly to experimental group but without light irradiation
40861090|NCT01582711|BEHAVIORAL|SMS reminders|Short Message Service (SMS) text reminders
40861091|NCT01582711|DRUG|isoniazid and rifapentine|rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
40861092|NCT04677010|OTHER|Cycle exercise|10 weeks of cycle exercise on a cycle ergometer with motor.
41391879|NCT03987022|DRUG|Ketorolac|Use of non-steroidal anti-inflammatory drug for pain control post operatively
40861093|NCT05060770|GENETIC|transcriptomic analysis|transcriptomic analysis on preserved tumor tissue
41391880|NCT03987022|DRUG|Opioids|Use of narcotic for pain control post operatively
41391881|NCT03987022|OTHER|Ice Packs|Placement of Ice packs on surgical sites post operatively
41391882|NCT03987022|DRUG|Tylenol|Use of pain medication post operatively
40861094|NCT04485949|COMBINATION_PRODUCT|IGV-001 Cell Immunotherapy|IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.
40861095|NCT04485949|COMBINATION_PRODUCT|Placebo|Placebo in implantable biodiffusion chambers containing a predetermined inactive solution.
40861096|NCT04485949|PROCEDURE|Standard of Care (SOC): Radiation Therapy|Radiation therapy administered per institutional standards.
40861097|NCT04485949|DRUG|SOC: Temozolomide|Temozolomide administered orally.
40861098|NCT00655616|DRUG|Montelukast Placebo|"Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
40861099|NCT00655616|DRUG|Salmeterol, Montelukast|"Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
40861100|NCT00563459|DRUG|carisbamate|400-1200 mg/day for 12 months
40861101|NCT00563459|DRUG|topiramate|200-400mg/day for 12 months
40861102|NCT00563459|DRUG|levetiracetam|1000-3000mg/day for 12 months
40861103|NCT05348200|DRUG|Monad 1|Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.
40861104|NCT05348200|DRUG|Monad 2|Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.
41167858|NCT02151578|OTHER|home/community case management|
41391883|NCT03987022|DRUG|Motrin|Use of non-steroidal anti-inflammatory drug for pain control post operatively
41391884|NCT03987022|DRUG|dilaudid|Use of narcotic for pain control post operatively
41391885|NCT04289584|OTHER|Strength and proprioception exercises|Strength and proprioception exercises will be performed with the athlete in different positions depending on the exercise. There will be 3 series with 30 repetitions and 10-second breaks between sets. Each exercise session will be held for 15 minutes. Theraband® exercises are: unipodal balancing on hard surface with open and closed eyes, unipodal balancing on soft surface, squats, lateral walk, isometric contractions with garter and dynamic leg opening, tiptoe, and eccentric hamstring curl with garter.
41391886|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + dual attention|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with double attention.
41391887|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + fixed point|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with fixed point.
41391888|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + exposition|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with exposition.
40861105|NCT05348200|DRUG|Monad 3|Single therapy cream containing Halobetasol Propionate (high strength).
40861106|NCT05348200|DRUG|Combination - CITI-002 (low dose)|Combination cream containing Lidocaine and HBP (low)
41167859|NCT04254562|BEHAVIORAL|Weekly Meetings with a Supported Employment/Supported Education Specialist|Participants will receive intervention for 12 months which includes weekly meetings with a Supported Employment/Supported Education Specialist (HYPE Specialist). During the weekly meetings, the HYPE Specialist will review each participant's education and employment goals, and deliver individualized support relevant to those goals which include use of structured HYPE tools and worksheets as needed.
41391889|NCT00897429|PROCEDURE|laboratory biomarker analysis|Correlative studies
40861107|NCT05348200|DRUG|Combination - CITI-002 (high dose)|Combination cream containing Lidocaine and HBP (high)
40861108|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 1|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 22
40861109|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 2|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 22
40861110|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 3|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 15
40861111|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 4|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 15
40861112|NCT00649506|DRUG|Nitrofurantoin Macrocrystals 100 mg Capsules|100mg, single dose fed
40861113|NCT00649506|DRUG|Macrodantin® 100 mg Capsules|100mg, single dose fed
40861114|NCT02493036|DRUG|SYN-010|
40861115|NCT05668286|DRUG|A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%)|patients in group 1 received an anterior extra-articular steroid injection under USG guidance, patients in group 2 received posterior intra-articular steroid injection under USG guidance. A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%) were injected to all patients.
40861116|NCT04755036|OTHER|Survey and case vignette|We sent a survey and case vignette cases to every responsible in each center
40861117|NCT05381363|DRUG|Inhaled Interferon α2b|Drug: Inhaled Interferon α2b; 1-2 years old: 1 dose, three times per day; 3-7 years old: 1 dose, four times per day; 7-18 years old: 2 doses, four times per day
41512825|NCT03536884|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
41512826|NCT03536884|DRUG|Secukinumab|Subjects will receive secukinumab at pre-specified time-points.
40861118|NCT05381363|OTHER|Standard of Care|Standard of care treatment will be provided based on the New Coronavirus Pneumonia Prevention and Control guideline (9th edition), published by National Health Commission of China
40861119|NCT06500637|DRUG|TB006|TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).
40861120|NCT04107532|OTHER|Virtual Reality Therapy and Imagination Exposure Therapy|Virtual Reality Therapy and Imagination Exposure Therapy
40861121|NCT06332092|DRUG|FID007|Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
40861122|NCT01400568|DRUG|LPS challenge with nebulized LPS|20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
40861123|NCT01400568|DRUG|fluticasone propionate (FP)|The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
40861124|NCT06493058|OTHER|Prone positioning|The babies in the study group were given the supine, right lateral and left lateral positions (12×1), which are used in nursing care practices in the clinic after extubation, in addition to the supine, right lateral and left lateral positions (12×1), the prone position was given twice a day for 2×2 hours twice a day within 48 hours after extubation, with the head on the midline of the neck and the head facing to the right or left side.
40861125|NCT04004325|DRUG|FT-4101|FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
41512827|NCT03536884|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
40861126|NCT04004325|DRUG|FT-4101 placebo|FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
40861127|NCT04004325|OTHER|Deuterated Water|Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
40861128|NCT04751318|DRUG|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
40861129|NCT04751318|DRUG|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
40861130|NCT04728607|DEVICE|Compression device.|A compression device is a device that uses circumferential compression to reduce swelling around a stuck ring. The device is used by placing it near, but not overtop, the offending ring, and then is inflated compressing the finger. The device is applied, and the hand elevated, for approximately five minutes. The device is then removed, and with a small amount of lubricant, the ring is removed.
41040042|NCT03278418|PROCEDURE|Tricuspid Valve Repair|It will be performed according to the surgeon preference
41167860|NCT04254562|BEHAVIORAL|Focused Skill and Strategy Training (FSST)|Participants receive a 12 week Focused Skill and Strategy Training (FSST), a structured cognitive remediation intervention.
41167861|NCT04254562|BEHAVIORAL|Enhanced Services as Usual|One hour meetings every semester to review individual academic needs and review list of available on campus resources to best meet the student's needs.
41167862|NCT04342988|DRUG|Cequa|The effect of Cequa treatment on the accuracy of pre-operative biometry and on corneal higher-order aberrations (HOAs) in cataract patients who have signs of dry eye disease.
41167863|NCT06108453|DRUG|Methotrexate Sodium|Methotrexate oral administration alone
41512828|NCT01867528|PROCEDURE|Laparoscopic adhesiolysis|
41167864|NCT06108453|DRUG|Rifampicin|Co-administration of methotrexate and rifampicin
40861131|NCT03637660|DRUG|Benzathine Penicillin|BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
40861132|NCT03565380|OTHER|12-week community-based multi-model Tai Chi rehabilitation program|Participants will receive 12 x 90 minute sessions of supervised exercises over 12 weeks. In addition to usual care, supervised exercise will be held at the Center of Sports Training and Rehabilitation inside the University and each class will be restricted to no more than 8 participants to ensure sufficient personalized attention. Each training session involves warm-up together with stretching of lower extremity muscles, strengthening exercises of the major lower extremity muscle groups by Theraband, balancing exercise, Tai Chi training, and rest/ cool-down. All lower-extremity exercises will be performed bilaterally.
40861133|NCT03565380|OTHER|Usual post-operative care|No intervention will be provided
40861134|NCT03565380|OTHER|Untreated asymptomatic controls|No intervention will be provided
41040043|NCT03278418|PROCEDURE|Left-sided valve surgery|It will be performed according to the surgeon preference
41040044|NCT00036569|PROCEDURE|adjuvant therapy|
41040045|NCT00036569|BIOLOGICAL|pegylated interferon alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
41167865|NCT05784077|DIAGNOSTIC_TEST|Polysomnography|Study of the sleep pattern
41167866|NCT05784077|BEHAVIORAL|Lifestyle counselling|Weight loss counselling
41167867|NCT02509988|DIETARY_SUPPLEMENT|Study nutritional drink|Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.
41167868|NCT02509988|DIETARY_SUPPLEMENT|Standard nutritional drink|Standard nutritional drink containing a mix of micronutrients.
41512829|NCT01867528|PROCEDURE|Open adhesiolysis|
41512830|NCT05215132|RADIATION|MRI|1.5T or 3T MRI scanner (Siemens Medical Systems)
41040046|NCT00443976|DRUG|Aurora kinase inhibitor AT9283|The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
41167869|NCT01681199|DRUG|Fluvastatin extended release tablet|
41167870|NCT05070234|GENETIC|Blood collection for genetic analysis|Genetic tests in this study are sequential testing, including MS-MLPA, whole exome sequencing, whole genome sequencing, as well as RNA-seq.
41512831|NCT05215132|DRUG|Gadavist 2Ml Solution for Injection|Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)
41040047|NCT02625896|BEHAVIORAL|Intervention|Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
40861135|NCT03884790|DEVICE|surgical repair of long bone defects|"Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect, favoring the migration of cells from the neighboring tissues to fill the gap. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. Different types of synthetic materials have been tested for repair of long bone gaps.~However, at the moment, there is not any bone substitute with the ideal/desirable osteoinductive, osteoconductive and mechanical properties. GreenBone Implant is a synthetic, acellular, reabsorbable, new generation bone graft, being suitable for surgical reconstruction of bone defects."
41040048|NCT05403541|DRUG|Batoclimab 680 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
41040049|NCT05403541|DRUG|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
41040050|NCT05403541|DRUG|Matching Placebo SC|Placebo
41391890|NCT04562298|BIOLOGICAL|LCAR-M23 cells|Prior to infusion of LCAR-M23, subjects will receive a premedication regimen (intravenous infusion of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 once daily for 3 days; fludarabine dose reduction to 25 mg/m2 and cyclophosphamide to 250 mg/m2 are allowed if the subject' s creatinine clearance is 50-70 mL/min/1.73 m2). A single dose, single Infusion of LCAR-M23 is scheduled 5 to 7 days after the initiation of the premedication regimen.
41040051|NCT05403541|DRUG|Batoclimab 340 mg SC bi-weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
41040052|NCT05926401|OTHER|ECG monitoring prior and after cardioversion|Continuous ECG monitoring at home 3-5 days prior to and 5-7 days after planned cardioversion
41040053|NCT04517266|RADIATION|omit of IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
41040054|NCT04517266|RADIATION|IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
41040055|NCT00951483|DRUG|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
41040056|NCT02535910|DIETARY_SUPPLEMENT|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
41512832|NCT06301074|DRUG|HS-10509|"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."
41512833|NCT06301074|DRUG|Placebo|"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."
41512834|NCT00422825|DRUG|imatinib|
40861136|NCT00536471|DRUG|Duloxetine hydrochloride|
40861137|NCT00536471|DRUG|Placebo|
40861138|NCT04909489|OTHER|cross-sectional study without intervention|cross-sectional study without intervention
40861139|NCT03124576|DEVICE|Implantable loop recorder|Continuous rhythm monitoring Medtronic
40861140|NCT02735343|DRUG|Compazine|Compazine 10mg with diphenhydramine 25 mg IV
41040057|NCT02535910|DIETARY_SUPPLEMENT|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
41040058|NCT02535910|DIETARY_SUPPLEMENT|Control|Subjects are asked to consume a breakfast without vitamin D
41391891|NCT05802342|DRUG|Monosialotetrahexose ganglioside sodium injection|The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
41512835|NCT06550414|DRUG|Dexmedetomidine|Active comparator: dexmedetomidine group
40861141|NCT02735343|DRUG|Ketamine|Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
41040059|NCT01088139|DIETARY_SUPPLEMENT|Protein supplementation|Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
41040060|NCT04644250|DRUG|Toripalimab|Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.
41040061|NCT04644250|DRUG|Paclitaxel liposome/Carboplatin|Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.
41391892|NCT06539286|DEVICE|Laser Irradiation|three different laser wavelengths will be used
41391893|NCT01935882|DRUG|Artemether-lumefantrine combination|
41391894|NCT01935882|DRUG|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine|
41391895|NCT01935882|DRUG|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine|
41391896|NCT00866528|DRUG|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
41040062|NCT04644250|RADIATION|Intensity-modulated radiotherapy|A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.
41040063|NCT02999165|OTHER|Breast feeding|Infants on respiratory support will be allowed to attempt to breast feed (with a top up nasogastric tube feed if required).
41040064|NCT02999165|OTHER|Nasogastric feeding|The control intervention is feeding via nasogastric tube
41040065|NCT04259268|OTHER|Quality of preoperative information register|Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)
41040066|NCT04259268|OTHER|Suitability of information contained in the informed consent|Register of information regarding specific individual risks and personal data (patient and doctor identification and signature)
41040067|NCT02580565|OTHER|telephone interview|Clinical assessment for screening and a phone call for questionnaire administration
41040068|NCT01461876|DRUG|antiretroviral therapy|Standard of care antiretroviral therapy
41040069|NCT02137369|DRUG|Selective serotonin re-uptake inhibitor|Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks
41391897|NCT00866528|DRUG|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
41391898|NCT01695837|BEHAVIORAL|Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6|
41512836|NCT06550414|DRUG|Bupivacain|Placebo comparator: bupivacaine group
41512837|NCT05154838|PROCEDURE|Drainage and packing of pilonidal abscess|Patients will be treated as per standard care, their wound drained, cleaned and packed. Microbiology swab samples will be obtained.
41040070|NCT02137369|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
41040071|NCT02137369|OTHER|Combination treatment (SSRI + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
41512838|NCT04584411|DIAGNOSTIC_TEST|Cardiac Magnetic resonance imaging|"The following basic sequences will be conducted:~* Cine imaging using SSFP sequence for cardiac structure and function.~* Tissue characterization imaging, T1 and T2.~* Myocardial perfusion imaging.~* Late gadolinium enhancement.~Diagnosis of myocarditis will be based on the modified Lake Louise criteria:~T2-weighted: any of the following standard T2 sequences: regional high signal standard T2 sequences: global signal intensity ratio (myocardium/skeletal muscle) ≥2 T2 mapping: increased T2 relaxation times T1-weighted: any of the following late enhancement imaging: non-ischemic (subepicardial or mid myocardial) late enhancement native T1 mapping: increased T1 relaxation times or extracellular volume supportive criteria: signs of pericarditis: effusion or pericardial late enhancement regional or global wall motion abnormalities\[5\]"
41512839|NCT06575543|RADIATION|CT|3D CT scan have been used to evaluate the tunnels location after ACL reconstruction, as they can provide excellent perspective of the tunnel aperture, good visualization of bony structure and shape of the intercondylar notch, that preclude the use of a conventional 2-dimensional CT scan for measurement of the ACL tunnels location
41391899|NCT00386854|BEHAVIORAL|physical training|
41391900|NCT02407028|DRUG|Hyperbaric oxygen (1.5 ATA, no NBH)|HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
41391901|NCT02407028|DRUG|Hyperbaric oxygen (2.0 ATA, no NBH)|HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
41512840|NCT00008307|BIOLOGICAL|anti-thymocyte globulin|
41512841|NCT00008307|DRUG|cyclosporine|
41512842|NCT00008307|DRUG|fludarabine phosphate|
41512843|NCT00008307|DRUG|melphalan|
40861142|NCT04590573|BEHAVIORAL|Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)|5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.
40861143|NCT05054426|DRUG|Methotrexate|intravenous versus intrathecal methotrexate
41040072|NCT00837863|DRUG|Somatropin|ALTU-238 0.3 mg/kg daily
41512844|NCT00008307|DRUG|methylprednisolone|
41512845|NCT00008307|DRUG|mycophenolate mofetil|
41512846|NCT00008307|PROCEDURE|allogeneic bone marrow transplantation|
41512847|NCT00008307|PROCEDURE|peripheral blood stem cell transplantation|
41512848|NCT00008307|PROCEDURE|syngeneic bone marrow transplantation|
41391902|NCT02407028|DRUG|Hyperbaric oxygen (2.5 ATA, no NBH)|HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
41391903|NCT02407028|DRUG|Hyperbaric oxygen (1.5 ATA + NBH)|HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
41391904|NCT02407028|DRUG|Hyperbaric oxygen (2.0 ATA + NBH)|HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
41391905|NCT02407028|DRUG|Hyperbaric oxygen (2.5 ATA + NBH)|HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
40861144|NCT03130920|PROCEDURE|Preconditioning|"Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.~Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ."
40861145|NCT04958889|OTHER|No intervention|(observational study)
40861146|NCT06403917|OTHER|Evaluation of breast screening|Evaluation of breast screening program at egyptian women health intiaive
40861147|NCT05703581|PROCEDURE|TRIANGLE operation|dissection the region composed of common hepatic artery (CHA), superior mesenteric artery (SMA) and superior mesenteric vein (SMV)
41040073|NCT00837863|DRUG|Somatropin|ALTU-238 0.6 mg/kg daily
41040074|NCT00837863|DRUG|Somatropin|ALTU-238 0.9 mg/kg daily
41040075|NCT00837863|DRUG|Somatropin|Nutropin AQ 0.043 mg/kg daily
41040076|NCT00636870|DRUG|Fexofenadine|
41040077|NCT01311674|BIOLOGICAL|hepatitis B vaccine|Primary vaccination series 20 µg/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 µg/1.0 mL
41040078|NCT01311674|BIOLOGICAL|hepatitis B vaccine|Primary vaccination series 40 µg/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 µg/1.0 mL
41040079|NCT00357864|DRUG|carbachol|
41040080|NCT03031691|DRUG|brontictuzumab|starting dose of 1.5mg/kg administered intravenously (IV)
41040081|NCT03031691|DRUG|trifluridine/tipiracil|
41040082|NCT00596440|DRUG|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
41040083|NCT05568433|DIAGNOSTIC_TEST|Endoscopic ultrasound fine needle aspiration (EUS-FNA)|Patients with pancreatic cysts who underwent endoscopic ultrasound and endoscopic fine needle aspiration for diagnostic and therapeutic purpose. A sample of the cyst fluid and frozen serum was collected from the patients and stored at minus 80 degrees.
41040084|NCT03095040|DRUG|CM082 combined with everolimus|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles
41040085|NCT03095040|DRUG|CM082|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles
41040086|NCT03095040|DRUG|Everolimus|Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles
41040087|NCT04475913|OTHER|DIG Axial|patients received 4 axial implants and digital impression
41040088|NCT04475913|OTHER|DIG Tilted|received two anterior axial implants and two distal tilted implants, and digital impression
41040089|NCT04475913|OTHER|CIG Axial|patients received 4 axial implants and conventional impression
41040090|NCT04475913|OTHER|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
41040091|NCT04769427|DEVICE|PDO max threads|To determine the effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on quality of life (FACE-Q scale)
40861148|NCT05478083|DRUG|Leuprorelin|Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.
41391906|NCT02407028|DRUG|Normobaric Hyperoxia (NBH)|100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
40861149|NCT04459520|BEHAVIORAL|Positive COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested positive (PCR) for an active COVID-19 infection and that their physician has clinically diagnosed them with COVID-19.
40861150|NCT04459520|BEHAVIORAL|Negative COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested negative (PCR) for an active COVID-19 infection.
40861151|NCT04459520|BEHAVIORAL|Unavailable COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that testing is not available for active COVID-19 infections but that their physician has clinically diagnosed them with COVID-19.
40861152|NCT04496856|DIETARY_SUPPLEMENT|Whey protein and Collagen supplementation|Participants of each arm will consume 30 g daily of the assigned protein supplementation for 30 days. The protein supplementation will be given as protein powder which the participants will have to dissolve in cold drinks. During the intervention fat free mass, muscle strength, functional ability, wound healing and life quality of the participants will be monitored.
40861153|NCT03360643|DIAGNOSTIC_TEST|Point-of-care ultrasound prior to radiology ultrasound|Point-of-care ultrasound performed by pediatric emergency medicine physicians prior to radiology-performed ultrasound
41512849|NCT01323361|PROCEDURE|Laparoscopic ventral hernia repair|Patients operated with laparoscopic repair of ventral or incisional hernia
40861154|NCT03360643|DIAGNOSTIC_TEST|Radiology-performed ultrasound|Ultrasound performed an ultrasound technician and/or radiologist, and interpreted by a radiologist
40861155|NCT01694056|OTHER|Soy protein diet|4 weeks high protein diet (20 en%) with 25gr of soy protein per day
40861156|NCT01694056|OTHER|Control diet|4 weeks high mixed protein diet (20 en%)
41040092|NCT01696422|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
41040093|NCT01696422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
41040094|NCT01696422|OTHER|Placebo|Route:subcutaneous
41512850|NCT01979991|PROCEDURE|CT Imaging and Reconstruction|"Patients will be consented for their permission to save and use the sinogram from their CT chest/lung scan. The sinogram will be de-identified and sent to an archive system for storage.~Later it will be exported to a computer for processing using MBIR (model based image reconstruction). The newly processed images will then be read by blinded readers. The quality of the images will be reviewed to determine if they are as readable and accurate as CT images created with the software that is currently being used."
41040095|NCT01507220|DRUG|morphine sulfate|Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.
41040096|NCT01507220|DRUG|bupivacaine liposome extended-release injectable suspension|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
41040097|NCT04987515|PROCEDURE|fenestration decompression combined with secondary curettage|First，fenestration decompression was performed. then, patients return every 3 months for follow up. If the cystic cavity area was gradually reduced after one year of follow-up, patients should be considered for secondary curettage surgery.
41391907|NCT02407028|OTHER|Usual Care|Will be treated with usual and customary care for severe traumatic brain injury
41512851|NCT03900455|DEVICE|Hydrocellular polyurethane foam multilayer dressing|Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care
40861157|NCT06106802|DRUG|Lazertinib|Lazertinib 240mg/day
40861158|NCT06106802|DRUG|Tepotinib|Tepotinib 500mg/day
40861159|NCT04577469|DRUG|Maldox tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
40861160|NCT04577469|DRUG|G-COSPE® tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
40861161|NCT00000355|DRUG|Buprenorphine|
40861162|NCT04116125|PROCEDURE|Radiotherapy|Adjuvant radiotherapy on axillary region
40861163|NCT05041270|DRUG|normal saline|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline)."
41040098|NCT03330665|BEHAVIORAL|Meditation|Meditate 3 times a week using headspace app
41040099|NCT02107118|BIOLOGICAL|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
41391908|NCT03254537|DIETARY_SUPPLEMENT|Mediterranean Organic|Traditional Mediterranean diet comprised of organic ingredients
40861164|NCT05041270|DRUG|Dexmedetomidine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)."
40861165|NCT05041270|DRUG|Nalbuphine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)."
40861166|NCT05498519|DRUG|SY-4798|FGFR4 selective inhibitor
40861167|NCT05206812|DRUG|durvalumab|"* durvalumab 1500 mg QD\*~* Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)"
40861168|NCT02116452|DIETARY_SUPPLEMENT|Supplemented Formula|50:50 mixture of GOS/PDX formula will be administered
40861169|NCT05813964|DRUG|TDF/FTC 300mg/200mg fixed-dose combination tablets|Event-driven dosing regimen
41040100|NCT02107118|OTHER|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
41040101|NCT02369094|OTHER|acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
41391909|NCT03254537|DIETARY_SUPPLEMENT|Mediterranean conventional|Traditional Mediterranean diet comprised of conventional ingredients
41391910|NCT02913261|DRUG|Ruxolitinib (RUX)|Ruxolitinib was provided as 5 mg tablets for oral use.
41391911|NCT02913261|DRUG|Best Available Therapy (BAT)|BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
41391912|NCT00783562|OTHER|Extension-oriented exercise program|The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
41391913|NCT00783562|OTHER|Informative Brochure|The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
41391914|NCT05359380|OTHER|ADL performance|"ADL performance~All study groups address the following 10 ADL tasks in 9 different combinations of light temperature and light intensity in order possible differences to be revealed among the study groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc / 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc / 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
41391915|NCT04596462|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
41391916|NCT05430568|PROCEDURE|robot-assisted surgery|"1. traditional sternotomy for coronary bypass graft or valvular replacement~2. robot-assisted surgery for coronary bypass graft or valvular replacement"
41391917|NCT01890694|DRUG|Tolvaptan|15 mg once daily
41391918|NCT01890694|DRUG|Placebo|15 mg once daily
41040102|NCT05710601|PROCEDURE|Laparoscopy|Operative laparoscopies carried out according to the most recent national guidelines and following the good clinical practice of our operative unit.
41040103|NCT01733056|BIOLOGICAL|Flu Vaccine|Administration of Fluzone (Influenza Vaccine)
41391919|NCT01890694|BEHAVIORAL|Hepatic Encephalopathy Assessment|The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
41391920|NCT01890694|BEHAVIORAL|Quality of Life Assessment|The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
41391921|NCT01890694|BIOLOGICAL|Vital signs|Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
41391922|NCT01890694|BIOLOGICAL|Blood laboratory tests|Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
41391923|NCT01890694|PROCEDURE|Ascites Evaluation|Ascites will be assessed at every visit.
41391924|NCT01890694|PROCEDURE|Edema|Edema will be assessed at every visit.
41391925|NCT04399902|DEVICE|Thermal Blanket|Ready-Heat 6-Panel Blanket (Military style, manufactured by Techtrade LLC). The 6-panel military-style blanket (86cm x 152 cm, 1.13kg) warms to 40˚C in approximately 15-20 minutes and maintains this temperature for 10 hours.
41391926|NCT01563029|DRUG|Fluticasone Furoate|current asthma medicine
41167871|NCT04651309|OTHER|Transperineal Ultrasound|The ultrasound examination will be conducted using the technique described by Hassan et al (2013). Briefly, transperineal ultrasound images are obtained by placing a covered transducer between the labia below the symphysis pubis. Small lateral movements of the probe are then made to align the ultrasound beam in a midsagittal orientation to include the whole cervical length after which the probe is rotated 90 degrees in order to measure the cervical dilatation. The probe is rotated up and down until the echogenic circle of the cervix is seen. Please note that this technique is widely used within the delivery room and that the ultrasound machine that will be used is frequently used within the delivery room.
41167872|NCT01005368|GENETIC|fluorescence in situ hybridization|
41167873|NCT01005368|GENETIC|mutation analysis|
41167874|NCT01005368|GENETIC|nucleic acid sequencing|
41391927|NCT01563029|DRUG|Fluticasone Propionate|Fluticasone propionate
41512852|NCT03900455|PROCEDURE|Standard preventive care|Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
41512853|NCT04660279|DIAGNOSTIC_TEST|Dynamic Whole-Body parametric PET/CT|Dynamic whole-body PET/CT imaging protocol
41512854|NCT00699426|DRUG|nexium|40 mg once daily is tested together with Yoghurt
41512855|NCT00699426|DRUG|nexium|nexium and placebo are tested
41512856|NCT00699426|DIETARY_SUPPLEMENT|Yoghurt|Yoghurt
41512857|NCT00699426|DRUG|placebo+placebo|placebo and placebo are tested.
41512858|NCT01958138|DRUG|comparison of group-I (low dose propofol with isoflurane)|Prior to LMA removal in group-I, isoflurane MAC awake (MAC less than 0.5) will be achieved in expiratory gases with 60% nitrous oxide and 40% oxygen. Propofol 1 mg/Kg will be combined with Isoflurane MAC awake and LMA will be removed after 20 seconds of propofol administration in group-I. The group-II LMA will be removed at end expiratory isoflurane MAC of 1.2% with 60% nitrous oxide and 40% oxygen
41512859|NCT04578405|PROCEDURE|Intracorporeal anastomosis|Anastomosis performed totally laparoscopically
41512860|NCT04578405|PROCEDURE|Extracorporeal anastomosis|Anastomosis performed through a minilaparotomy
41512861|NCT05159024|DIAGNOSTIC_TEST|CRP, PCT, and WBCs trajectories|the levels of CRP, PCT, and WBCs were assessed before surgery and after the onset of leak
41512862|NCT00277693|DRUG|Spironolactone (drug)|
41512863|NCT05279911|RADIATION|low-level laser therapy (LLLT)|low-level laser therapy (LLLT) with dental implants has been suggested to improve bone quality during osseointegration. Low-level laser (Gallium Aluminum Arsenide Diode \[Ga-Al-As\]) (wavelength: 808 nm, average power density: 50 mW, circular spot diameter:0.71 cm, spot area: 0.4cm2) in continuous mode was applied in six points in contact with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before and immediately after suturing. The application points were divided into two points in the labial region where the implant would be placed (apical and cervical); two points in the lingual region (apical and cervical); and two points in the occlusal direction. After suturing the laser protocol was repeated in the same points following the same protocol, resulting in a total dose of 66 J for each application moment (before and after implant placement).
41512864|NCT04230902|BIOLOGICAL|Microfragmented Adipose Tissue Transplant|Autologous Microfragmented Adipose Tissue derived using Lipogems® Kit
40861170|NCT05813964|DRUG|TAF/FTC 25mg/200mg fixed-dose combination tablets|Event-driven dosing regimen.
41040104|NCT01608074|PROCEDURE|Radical fimbriectomy|"Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)"
41167875|NCT01005368|GENETIC|polymerase chain reaction|
41167876|NCT01005368|GENETIC|western blotting|
40861171|NCT02214290|DRUG|Caffeine|A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
41040105|NCT01608074|OTHER|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
41040106|NCT06059495|DRUG|Dostarlimab|"After inclusion: dostarlimab 500mg IV 30min q3w (± 2-3 days) for 4 cycles (C1-C4)~Then:~At wk12 • If cCR: dostarlimab 1000mg q6w for 2 cycles (C5-C6)~• If downstaging at UGI endoscopy, and no disease progression (PD)/or mets on TAP-CT, \<3 biopsies with tumor cells: dostarlimab 500mg q3w for 4 cycles (C5-C8)~• If loco/loco-regional PD on TAP-CT, macroscopic tumor on UGI endoscopy, no distant mets, and \>2 positive biopsies at wk12 followed by surgery and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 6 cycles (C5-C10)~At 24wk~• If cCR at 12 and 24 wks: dostarlimab 1000mg q6w for 4 cycles (C7-C10)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with \<3 biopsies with tumor cells at wk12 and cCR: dostarlimab 1000mg q6w for 4 cycles (C9-C12)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with and no cCR, surgery will be proposed and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 4 cycles (C9-C12)"
41167877|NCT01005368|OTHER|flow cytometry|
41167878|NCT01005368|OTHER|laboratory biomarker analysis|
41167879|NCT02716077|RADIATION|FDG PET/CT imaging|
41391928|NCT01563029|DRUG|Placebo|placebo
41391929|NCT01299272|DRUG|LY2216684|
41391930|NCT01299272|DRUG|Placebo|
41391931|NCT01299272|DRUG|SSRI|Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.
41391932|NCT02043561|OTHER|induction of urge by rectal distension|
41391933|NCT04011111|PROCEDURE|Intubation tube and voice analysis|After the ıntubation tube application, done voice analysis early postoperative period
40861172|NCT02214290|DRUG|Placebo|A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
40861173|NCT02214290|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline was used to examine the effect of the supplement on arterial function.
41167880|NCT04963946|DRUG|Stop ACA|discontinuation of acalabrutinib after 18 months in treatment-naïve CLL patients
41391934|NCT02952937|DRUG|GLA5PR GLARS-NF3 tablet 300mg|A new formulation(3rd.) of Pregabalin CR tablet
41391935|NCT02952937|DRUG|GLA5PR GLARS-NF1 tablet 300mg|A new formulation(1st.) of Pregabalin CR tablet
41391936|NCT05225116|DRUG|Sintilimab|Sintilimab will be at a dose of 200mg,Q3W
41391937|NCT05225116|DRUG|Lenvatinib|On the first day of the trial, Lenvatinib will be taken orally once daily （8mg/day ≤ 60kg or 12mg/day ≥60kg).
41391938|NCT05225116|RADIATION|radiotherapy|Radiotherapy will be completed within two weeks at a dose of 300cGy× 10 fraction
40861174|NCT03485235|PROCEDURE|D&C|Dilatation and curettage
40861175|NCT03485235|PROCEDURE|ICSI|Intra Cytoplasmic Sperm Injection
40861176|NCT01870115|DIETARY_SUPPLEMENT|Fiber Pill|This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
40861177|NCT01870115|DIETARY_SUPPLEMENT|Melatonin, Strontium citrate, Vitamins D3 and K2|Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
40861178|NCT03554928|DIAGNOSTIC_TEST|magnetic resonance imaging|Participants will receive a 60 minute magnetic resonance imaging assessment
40861179|NCT01926834|DRUG|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
40861180|NCT01926834|DRUG|placebo|normal saline, 500ml,i.v.,qd, for 7 days
40861181|NCT04138446|OTHER|Altitude exposure in climate chamber|Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.
41040107|NCT02468765|OTHER|Neuropsychological and emotional evaluation with monitoring|Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
41040108|NCT02992262|DEVICE|Point of care ocular ultrasound|
41040109|NCT05480475|DRUG|Dabigatran etexilate|On Day 1 (Treatment A1) and on Day 9 (Treatment C1) a single oral dose of 75 mg dabigatran etexilate will be administered under fasted conditions.
40861182|NCT01633164|BEHAVIORAL|SCI Reinvention Protocol Participants|The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
40861183|NCT01633164|OTHER|Waitlist Group|Wait list arm will begin study intervention after 4 1/2 months.
40861184|NCT01960582|BEHAVIORAL|New Practice Strategy|Application of a structured case management strategy on housing adaptation cases
41040110|NCT05480475|DRUG|Rosuvastatin|On Day 3 (Treatment A2) and on Day 11 (Treatment C2) a single oral dose of 10 mg rosuvastatin will be administered under fasted conditions.
41040111|NCT05480475|DRUG|Daridorexant|On Day 7 and Day 8 (Treatment B), on Day 9 and Day 10 (Treatment C1), and on Day 11 through 14 (Treatment C2) subjects will receive 50 mg daridorexant o.d. under fasted conditions.
41040112|NCT03769142|PROCEDURE|All monitoring|All monitoring (TCD, BIS, NIRS) are collected from the healthy side, contralateral to the interventional side
41040113|NCT06143748|DRUG|Cadonilimab|Patients received cadonilimab 10 mg/kg every 3 weeks for up to 16 cycles.
40861185|NCT00007358|DRUG|Dexamethasone or other corticosteroid|Administered during the third trimester of pregnancy
40861186|NCT00271102|PROCEDURE|anterior vaginal repair (colporrhaphy)|vaginal repair
40861187|NCT00271102|PROCEDURE|abdominal paravaginal defect repair|abdominal repair
40861188|NCT01110356|DRUG|Ferinject|Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
41040114|NCT06143748|DRUG|Paclitaxel and cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135 mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will not receive chemotherapy during radiotherapy.
41040115|NCT06143748|RADIATION|intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
41040116|NCT01047839|BIOLOGICAL|IC51|0.25 ml, 2 i.m. vaccinations at Day 0 and 28
41040117|NCT01047839|BIOLOGICAL|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
41040118|NCT01047839|BIOLOGICAL|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
41391939|NCT04247594|DRUG|Voxelotor|synthetic small molecule supplied as 500 mg tablets
41391940|NCT04774809|DRUG|Low Dose SHR0302 Ointment BID|Low Dose SHR0302 Ointment BID
41391941|NCT04774809|DRUG|High Dose SHR0302 Ointment BID|High Dose SHR0302 Ointment BID
41391942|NCT04774809|OTHER|Placebo Comparator: Vehicle|Placebo
41512865|NCT04230902|DRUG|Corticosteroid injection|intra-articular knee injection of corticosteroid
41512866|NCT00108004|DRUG|pramlintide acetate|Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
41512867|NCT01321827|DRUG|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
41167881|NCT04963946|DRUG|ACA Continuation|continuation of acalabrutinib at the same dose
41391943|NCT06330428|BEHAVIORAL|Sexuality-Based Family Planning Education via Podcast|The training program is planned to consist of 5 modules. These trainings will be shared module by module on a daily basis through an application (Spotify) where podcasts are shared. These modules are as follows: 1. Sexual and Reproductive Health / Sexual Rights / Female-Male / Physiology of Sexual Functions, 2. Sexual Myths, 3. Contraceptive Methods-1, 4. Contraceptive Methods-2, 5. Sexually Transmitted Diseases / Safe Sexual Intercourse As a result of randomization, the links of the podcasts will be shared with the women in the experimental group one by one on a daily basis. Podcasts are planned to last an average of 10 minutes. This training content is planned for 5 days and the second tests will be applied by the researcher to the women who finish the podcasts. The 3rd tests will be applied 4 weeks after the second tests.
41391944|NCT00569335|DRUG|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1."
41512868|NCT01321827|DRUG|Itraconazole|Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
41512869|NCT00398424|DRUG|S-1/Cisplatin|"PK Phase (Part 1), Beginning on Day 1 of the Pharmacokinetic Phase, 30 mg/m2 S-1 will be administered orally BID for 14 days (Days 1 through 14), followed by a 1-week recovery period.~On Day -2 and Day 14 of the Pharmacokinetic Phase, all patients will receive a single dose of 30 mg/m2 S-1 administered orally.~Extension Phase, Patients will receive S-1 at the dose that they tolerated in the PK Phase. S-1 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
41512870|NCT05050084|DRUG|Bicalutamide|Anti-androgen
41512871|NCT05050084|DRUG|Buserelin|GnRH agonist
41512872|NCT05050084|DRUG|Darolutamide|Anti-androgen
41512873|NCT05050084|DRUG|Degarelix|GnRH antagonist
40861189|NCT01110356|OTHER|Saline|Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.
41040119|NCT02910648|BEHAVIORAL|Modified Go/No-Go Task|Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
41040120|NCT01239082|PROCEDURE|Colonoscopy|One time screening Colonoscopy to screen for colorectal cancer
40861190|NCT01259180|PROCEDURE|acupuncture treatment|twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with
40861191|NCT01259180|PROCEDURE|Sham acupunture|twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1\~2inches away from real acupuncture point
41040121|NCT01239082|PROCEDURE|FIT|Annual FIT testing
41040122|NCT06276868|DRUG|Dalcilib+letrozole+HP treatment group|"All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.~Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, with all patients receiving 6 cycles of treatment."
41040123|NCT01566045|PROCEDURE|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
41040124|NCT01566045|PROCEDURE|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
41040125|NCT02970500|DRUG|Methylphenidate HCl 10Mg SR|Methylphenidate HCl 10Mg SR (Phase 1) and Methylphenidate HCl 20Mg SR (Phase 2)
41040126|NCT02970500|DRUG|Placebo Group|Placebo
41040127|NCT04832503|BEHAVIORAL|PROMPT- treatment|PROMPTs for Restructuring Oral Muscolar Phonetic Targets
41040128|NCT04832503|BEHAVIORAL|LNSOM-treatment|Language Non-Speech Oral Motor Treatment
41040129|NCT01925079|BEHAVIORAL|Intensive Education|"Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.~Patient education:~1. Routine education at discharge.~2. 4 education brochures will be delivered to patients.~3. Calendar with healthy tips will be delivered to patients before discharge.~4. A follow-up brochure with medical expert letter.~5. A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).~6. Telephone follow ups will be performed according to a standard communication document.~At discharge, patients will be given a brochure for future follow up."
41040130|NCT01925079|OTHER|Control|"Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.~Patient education:~1. Routine education at discharge.~2. A follow-up brochure without medical expert letter.~At discharge, patients will be given a brochure for future follow up."
41040131|NCT05615415|DRUG|PET Tracer|Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.
41040132|NCT05615415|DRUG|MRI Tracer|Injected via intravenous catheter during PET-MR scanning.
41167882|NCT04427878|PROCEDURE|biopsies of subcutaneous adipose tissue|Two 4mm punch biopsies of subcutaneous abdominal or thight adipose tissue
41167883|NCT05082207|OTHER|Remote Ischemic Preconditioning|Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.
41167884|NCT05082207|OTHER|sham group|a deflated cuff placed on the upper arm for 30 min
41391945|NCT02043093|BEHAVIORAL|Sources of Strength|"Sources of Strength (http://www.sourcesofstrength.com/) has three phases:~1. Introduction to school and community partners. Staff advisors for the program are identified and trained.~2. A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.~3. Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos."
41391946|NCT01375569|DRUG|TRC105|
41391947|NCT05348707|OTHER|epidemiology|To review medical records to describe diagnosis and severity of the disease.
41391948|NCT05348707|OTHER|epidemiology|To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
41391949|NCT05699577|DIAGNOSTIC_TEST|serum sample for ELIZA|ELIZA for Ca15-3 and interferon gamma
41391950|NCT05292469|BEHAVIORAL|Comprehensive approach to hypertension management|Trained health workers will review blood pressure (BP) logs and provide treatment. The patients will receive a BP lowering informational package, BP monitoring device and log book and pill-box and medication table. The participants will receive monthly home visits (6 visits) to discuss hypertension and ways to manage it. They will be encouraged to identify problems and developing an action plan to solve them. The participants will be encouraged to set behavioral goals. The follow up visits will review the progress made in implementing action plan and goals set and updating them. Review BP logs and facilitate tailored discussion on topics based on problems faced by participants on barriers to medication adherence, physical activity, weight management or diet. The family members will be involved and be accountable in supporting the patients in achieving the action plans.
41391951|NCT00195585|DRUG|Isovorin|
41391952|NCT00195585|DRUG|UFT|
41040133|NCT05615415|DEVICE|3T PET/MRI|Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.
41040134|NCT03254680|DIETARY_SUPPLEMENT|Turmeric|Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
41040135|NCT03589898|DRUG|Gabapentin|Single dose of gabapentin 900 mg
41040136|NCT02199262|OTHER|music intervention|reminder+ 20 minutes in the morning and 20 minutes in the afternoon of music listening(classical or soft background music), delivered by compact disc players with headphones with disposable ear pads.
41040137|NCT02199262|OTHER|reflexology|reminder + 20 minutes per day feet reflexology massage provided by certified specialist in reflexology massages
41040138|NCT02199262|OTHER|reminder|Implementation of a reminder of guidelines of agitation diagnosis and management
41040139|NCT00726752|DRUG|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
41040140|NCT04340206|BEHAVIORAL|face-to-face support and Chatbot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to support adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program. In addition, they meet and get support from their human coach (i.e., psychology student) twice in the face-to-face meetings.
41167885|NCT00161408|BEHAVIORAL|cognitive behavioural therapy|
41167886|NCT00161408|BEHAVIORAL|psychoeducation|
41167887|NCT05984706|OTHER|Focus groups and Delphi Questionnaire|1. Focus groups to identify relevant domains of PTSD-related functional impairment in trauma-exposed children and adolescents to ensure content validity. 2. Delphi Questionnaire evaluation of a list of domains of PTSD-related functional impairment in trauma-exposed children and adolescents (previously selected from based on a literature review and focus groups) on a Likert scale of 1 to 5 for their relevance
41167888|NCT06350708|OTHER|Virtual reality (VR) tracheostomy educational tool|This is an unsupervised VR training packaged designed to train healthcare professionals and their students the management of the paediatric tracheostomy emergency.
41167889|NCT03895502|DRUG|12-month Edoxaban|Prescription of Edoxaban for 12 months
41167890|NCT03895502|DRUG|3-month Edoxaban|Prescription of Edoxaban for 3 months
41167891|NCT06277518|PROCEDURE|Surgery for malignant tumors of the digestive system|Related treatment or palliative surgery under general anesthesia for digestive system malignancies
41391953|NCT01738490|DEVICE|Bone anchored hearing implant|
41391954|NCT05147285|OTHER|stabilization exercises|Patients will be applied only online supervised stabilization exercises three times a week for 8 weeks.
41391955|NCT05147285|OTHER|combined exercises|Patients will be applied online supervised aerobic exercise training and stabilization exercises.Aerobic exercises will be performed for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week, on the days when stabilization exercises are not performed.
41391956|NCT05147285|OTHER|Physical activity recommendations|The importance of physical activity will be explained to the patients and appropriate physical activity recommendations will be made.
41512874|NCT05050084|DRUG|Flutamide|Anti-androgen
41512875|NCT05050084|DRUG|Goserelin|GnRH agonist
41391957|NCT02331069|DRUG|Dextrose 5% (D5W)|0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
41391958|NCT02331069|OTHER|Physical therapy|Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
41391959|NCT03438331|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
41512876|NCT05050084|DRUG|Histrelin|GnRH agonist
40861192|NCT06323382|PROCEDURE|Locoregional therapy|"TACE procedure The decision to utilize transarterial artery chemoembolization (TACE) was performed through the tumor-feeding artery. The embolization emulsion was a mixture of Epirubicin 30-60 mg, Lobaplatin 30-50 mg, and Lipiodol 10-30 ml, and it was infused into tumor-feeding arteries via a 2.7/2.8 Fr micro-catheter.~HAIC procedure Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2."
40861193|NCT06323382|DRUG|Bevacizumab|15mg/kg or 7.5mg/kg intravenously every 3 weeks
40861194|NCT06323382|DRUG|Atezolizumab|1200mg intravenously every 3 weeks
40861195|NCT06323382|DRUG|Tislelizumab|200mg intravenously every 3 weeks
40861196|NCT06323382|DRUG|Toripalimab|220mg intravenously every 3 weeks
41040141|NCT04340206|BEHAVIORAL|only chat-robot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program.
41391960|NCT03438331|BEHAVIORAL|Cognitive Behavioural Therapy for Depression (CBT-D)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-D delivered within a 10-week window. The main treatment elements of CBT-D include: psycho-education about depression, self-monitoring, behavioural activation, improving social skills, communication skills and problem solving skills, cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
41391961|NCT06538545|BEHAVIORAL|Sitting position is used in Experimental Arms 1-2|sitting position Comparison of sitting position and lithotomy position in labor
41391962|NCT01635686|DRUG|DWP422 25mg|
41040142|NCT04340206|BEHAVIORAL|Control group, no intervention|Behavioral: No intervention
41040143|NCT02148250|DRUG|U-500 insulin, 100 syringe units|Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
41040144|NCT02148250|DRUG|U-500 insulin, 200 syringe units|Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
41391963|NCT01635686|DRUG|ENBREL 25MG PFS INJ.|
41391964|NCT00388115|PROCEDURE|conventional surgery|Standard of care lumpectomy or mastectomy following RFA
41391965|NCT00388115|PROCEDURE|neoadjuvant therapy|Standard of care lumpectomy or mastectomy following RFA
41512877|NCT05050084|DRUG|Leuprolide|GnRH agonist
41512878|NCT05050084|RADIATION|Radiation Therapy|Undergo RT
41512879|NCT05050084|DRUG|Relugolix|GnRH antagonist
41512880|NCT05050084|DRUG|Triptorelin|GnRH agonist
41512881|NCT02254980|DEVICE|Vitamin-E diffused polyethylene acetabular component|Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
40861197|NCT06323382|DRUG|Sintilimab|200mg intravenously every 3 weeks
40861198|NCT06323382|DRUG|Camrelizumab|200mg intravenously every 3 weeks
41512882|NCT02254980|DEVICE|Standard polyethylene acetabular component|Patients will undergo total hip arthroplasty using a standard cemented acetabular component
41512883|NCT05924412|DRUG|Intravenous study drug|40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión
41512884|NCT05924412|OTHER|Intravenous saline solution|Saline solution (same volume as the study drug) will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incision
41512885|NCT05309018|OTHER|Interviews|Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.
41512886|NCT03151174|DRUG|Vitamin D 10000 UNT|10000 IU Vitamin D per day
41512887|NCT03151174|DRUG|Vitamin D 5000 UNT|5000 IU Vitamin D per day
41512888|NCT02423421|OTHER|Faecal microbiota transplantation|Human Stool.
41512889|NCT00978874|RADIATION|fludeoxyglucose F 18|
41391966|NCT00388115|PROCEDURE|radiofrequency ablation|A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
41391967|NCT02156466|DRUG|MSB0010841|MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
41167892|NCT05530330|DIAGNOSTIC_TEST|Platelet/Endothelial proteomics|Samples taken will undergo a targeted proteomic investigation examining platelet/endothelial markers and associated extracellular vesicles
41512890|NCT00978874|RADIATION|fluorine F 18 EF5|
41512891|NCT00367978|DRUG|Amlodipine/benazepril|
41512892|NCT04851392|DRUG|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
41512893|NCT04851392|DRUG|Cannabis with THC without CBD|Cannabis with THC without CBD - inhaled and vaporised cannabis flower
41512894|NCT04851392|DRUG|Placebo cannabis|Placebo cannabis, without THC and without CBD - inhaled and vaporised
40861199|NCT02227667|DRUG|MEDI4736|Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
41391968|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
40861200|NCT06165042|OTHER|glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply glass hybrid restorative system (Equia Forte, GC Europe, Leuven, Belgium)
40861201|NCT06165042|OTHER|Fluoride varnish + Glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
41167893|NCT00040820|DRUG|oxaliplatin|
41167894|NCT00112710|DRUG|carboplatin|
41167895|NCT00112710|DRUG|cisplatin|
41167896|NCT00112710|DRUG|gemcitabine hydrochloride|
41167897|NCT00511771|DRUG|Tegaserod|Tegaserod maleate
41167898|NCT04647305|OTHER|Closed face shield with Surgical face mask use|Use of a closed face shield with a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and proper use of the closed face shield and the surgical face masks.
41512895|NCT03099109|DRUG|LY3321367|Administered IV
41512896|NCT03099109|DRUG|LY3300054|Administered IV
41512897|NCT04758611|DEVICE|eShunt™ Implant|The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.
41512898|NCT04580407|BIOLOGICAL|TAK-672|B-Domain Deleted Recombinant Porcine Factor VIII
41512899|NCT03928301|BEHAVIORAL|Wholetones Music|Participants listened to the Wholetones music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
41512900|NCT03928301|BEHAVIORAL|Classical Music|Participants listened to the classical music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
41512901|NCT01748201|PROCEDURE|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
41512902|NCT02443740|DRUG|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo
41512903|NCT02443740|DRUG|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
41512904|NCT02443740|DRUG|BIIB118|Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension
41512905|NCT03112473|BEHAVIORAL|Task-orientated training|Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.
41512906|NCT03112473|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|The stimulator was 120z Dual-Channel TENS Unit (ITO PHYSITHERAPY\&REHABILITION CO., LTD, Tokyo, Japan). The parameter (100 Hz, 0.2 ms square pulses, intensity barely below the motor threshold) of TENS followed our previous study
41512907|NCT03112473|DEVICE|Sham electrical nerve stimulation|A identical-looking TENS devices that electrical circuit has been disconnected.
41512908|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
41512909|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
41512910|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
41512911|NCT01111955|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
41512912|NCT01111955|DRUG|Metformin|Capsules, Oral, ≥ 1500 mg, once daily, 28 days
41512913|NCT02934191|DRUG|Celecoxib|Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
41512914|NCT02934191|OTHER|Placebo|Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.
41512915|NCT02934191|DRUG|Acetaminophen|Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
40861202|NCT02273661|DRUG|Liposomal amphotericin B (Ambisome®)|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
40861203|NCT02273661|DRUG|placebo|An aerosol of isotonic saline x 1/ week will be administered during 6 months
40861204|NCT02540070|PROCEDURE|Periarticular|
41167899|NCT04647305|OTHER|Surgical face mask use only|Use of a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and the proper use of surgical face masks.
41167900|NCT02148653|OTHER|Multifunctional diet (MFD)|A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.
41391969|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
41391970|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
41167901|NCT02148653|OTHER|Control diet|A nutritionally well formulated diet that excludes the functional food items present in the MFD.
41391971|NCT02156466|DRUG|Placebo|Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
41391972|NCT01771419|DEVICE|Loop-tip wire (Cook Medical) for the cannulation of the CBD|
41391973|NCT01771419|DEVICE|Cannulotome CT-25mm Cook Medical|
41391974|NCT00881452|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
41391975|NCT00881452|DRUG|Placebo|Single unit dose powder of non-active substance administered 3 times per day for 90 days
41391976|NCT05205668|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
41391977|NCT05205668|BIOLOGICAL|Placebo|Placebo administered intravenously
41512916|NCT02934191|DRUG|Oxycodone|Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.
40861205|NCT02540070|PROCEDURE|Motor free|
40861206|NCT02540070|PROCEDURE|Motor free with dex|
41391978|NCT00850837|DRUG|Acidform Lubricant|5 g application of acid buffered gel (pH = 3.5)
41391979|NCT00850837|DRUG|HEC gel|5 g application of hydroxyethylcellulose gel
41391980|NCT01852773|PROCEDURE|Open repair of thoracic aorta injury|open surgical management of aortic injury
41391981|NCT01852773|PROCEDURE|TEVAR|Use of endovascular (minimally invasive) techniques for repair of aortic injury
41391982|NCT06242873|OTHER|Gait training with/without TSCS|To assess the safety and impact of paired stimulation and training on gait in children with iSCI, participants will participate in 24 total sessions. Two sessions will involve assessment only and 22 sessions will include two hours of therapy. Sessions will occur at least three times per week, but may be scheduled as many as five times per week. In each session, participants will receive 60 minutes of treadmill training followed by strengthening, segmental task practice, and gait-based interventions. Participants will receive stimulation based on their group assignment (TSCS or sham).
41391983|NCT01959230|DRUG|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
41391984|NCT01959230|DRUG|Vehicle|Ophthalmic solution to be applied as directed.
40861207|NCT02540070|DRUG|Ropivacaine|
40861208|NCT02540070|DRUG|epinephrine|
40861209|NCT02540070|DRUG|morphine|
40861210|NCT02540070|DRUG|Ketorolac|
40861211|NCT02540070|DRUG|Dexmedetomidine|
40861212|NCT02540070|DRUG|saline|
40861213|NCT01295593|DRUG|valproic acid and 2-chlorodeoxyadenosine|VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
41391985|NCT01959230|DRUG|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
41391986|NCT01959230|DRUG|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
40861214|NCT02655549|BIOLOGICAL|Px563L, RPA563, or placebo|Two intramuscular injections
40861215|NCT02045095|DRUG|MLN7243|"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."
40861216|NCT01156714|BEHAVIORAL|Treadmill training with aerobic exercise|walk on treadmill for aerobic exercise
40861217|NCT01156714|BEHAVIORAL|Memory training with computerized memory program|memory testing and training on computer program
40861218|NCT01156714|BEHAVIORAL|Combination of treadmill training and computerized memory|both exercise and cognitive computer training
41167902|NCT01562587|DRUG|activated recombinant human factor VII|A single bolus dose is administered. Injected intravenously
41167903|NCT01562587|DRUG|activated recombinant human factor VII|A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
41391987|NCT04957914|DRUG|Insulin Glargine|Administered SC
41391988|NCT04957914|DRUG|LY3209590|Administered SC
41391989|NCT02615197|BEHAVIORAL|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
41391990|NCT02615197|BEHAVIORAL|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
41512917|NCT03505970|DIETARY_SUPPLEMENT|Sodium bicarbonate|Sodium bicarbonate in powder form ingested in gelatine capsules. This leads to an increase bicarbonate concentration in blood, increasing buffering capacity which may lead to improvements in exercise
41512918|NCT03505970|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be used as a placebo as it will not lead to any increases in circulating bicarbonate and, at this dose, will not likely have any physiological effect.
41512919|NCT04138498|DRUG|Dexmethylphenidate 5 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
41512920|NCT04138498|DRUG|Dexmethylphenidate 6.25 mg Tablet|Experimental drug for comparative BA evaluation
40861219|NCT05986279|OTHER|Rehab|6 weeks of vestibular rehabilitation guided by the MINDGAPS decision support system
41391991|NCT01518985|DRUG|Bendavia|Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
41391992|NCT01518985|DRUG|Sterile saline (0.9%)|Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
41391993|NCT01518985|OTHER|Cigarette smoking|One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
41391994|NCT00468312|DRUG|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
41512921|NCT04138498|DRUG|Dexmethylphenidate 40 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
41512922|NCT04138498|DRUG|Dexmethylphenidate 50 mg Tablet|Experimental drug for comparative BA evaluation
41391995|NCT00468312|DRUG|Placebo|Two sprays in each nostril in the morning
41391996|NCT06120179|DEVICE|The Bashir™ Endovascular Catheter (BEC|To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse spray of r-tPA for the treatment of acute submassive pulmonary embolism.
41167904|NCT05727488|OTHER|Exercise|Participants will be asked to practice home exercises every day of the week for 12 weeks. The SARAH exercise program consists of 7 mobility and 4 strengthening exercises. Progress will be made by increasing the repetitions and duration of the exercises every week.
41167905|NCT06475183|DIETARY_SUPPLEMENT|Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum|Bouchard Belgian Dark Chocolate Probiotic Napolitains containing 10 billion CFUs of bifidobacterium longum daily for 6 weeks
41167906|NCT00187343|DEVICE|Breast IMRT|
41391997|NCT00103415|BEHAVIORAL|Endurance training|
41391998|NCT00103415|BEHAVIORAL|Weight-lifting training|
41391999|NCT02551302|DEVICE|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
41392000|NCT02551302|DEVICE|CD HORIZON BalanC™ Medtronic|"The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:~CD HORIZON BalanC™ Medtronic"
41392001|NCT06355583|DRUG|EBX-102|EBX-102 is a white size 0 gastro-resistant hydroxypropyl methylcellulose (HPMC) capsule containing communities of dried, intestinal microorganisms extracted from rigorously screened pooled human stool samples obtained from volunteer accredited donors.
40861220|NCT01646281|DRUG|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
40861221|NCT01646281|DRUG|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
41392002|NCT06355583|DRUG|Placebo|The capsules contain inactive ingredients microcrystalline cellulose and magnesium stearate.
41392003|NCT04384926|PROCEDURE|Elective Cancer Surgery|Planned, curative cancer surgery
41392004|NCT01293318|OTHER|No intervention|No intervention
41392005|NCT03648398|OTHER|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
41392006|NCT05797857|OTHER|Exercise Training|A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.
41392007|NCT05050357|DEVICE|Hormonal intrauterine device|insertion of hormonal IUD during menstrual period
40861222|NCT01458483|DEVICE|Baroreceptor Stimulation|The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
40861223|NCT03088488|DIAGNOSTIC_TEST|fasting venous blood samples|
40861224|NCT03470207|PROCEDURE|Post-pulmonary embolism follow up protocol|Structured post-pulmonary embolism follow up protocol (outlined in Aim 1)
41392008|NCT05050357|DRUG|Progestins Norethindrone|oral ethisteron twice daily for three months
41392009|NCT02688309|DRUG|Ozurdex|Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis. Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an AC tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection.
41512923|NCT04663971|PROCEDURE|Any surgery|Any surgical procedures performed for inflammatory bowel diseases
41512924|NCT04663971|PROCEDURE|Any medical treatment|Any treatment (including non-surgical) performed for inflammatory bowel diseases
41512925|NCT00685217|PROCEDURE|TVT Secur (Gynecare)|Sling device for stress urinary incontinence
41512926|NCT00685217|PROCEDURE|TVT (Gynecare)|Sling procedure for stress urinary incontinence
41512927|NCT00549432|DEVICE|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
41512928|NCT03327948|DEVICE|Axonics Sacral Neuromodulation System (SNM) System|Axonics Sacral Neuromodulation System (SNM) System
40861225|NCT02770989|PROCEDURE|Vimecon Laser CAI percutaneous cardiac ablation|The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
40861226|NCT00213265|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|For transplant patients, vaccination will be started at 4 months or greater after transplantation. The second dose will be given 8 weks following the frist, the third dose 8 weeks after the second, and the fourth will be given 8 weeks after the third.
40861227|NCT00213265|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine|"Healthy infants: The Prevnar schedule for healthy infants consists of 3 doses of 0.5 ml each, at approximately 2 month intervals, followed by a fourth dose of 0.5 ml at 12-15 months of age (i.e., 2, 4, 6, and 12-15 months)~Previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, should receive the follwong schedule:~7-11 months of age: 3 doses (2 doses at least 4 weeks apart with the third dose after the first birthday and separated from the second dose by at least two months)~12-23 months of age: 2 doses (at least 2 months apart)~≥24 months through 9 years of age: 1 dose"
40861228|NCT04131062|BEHAVIORAL|Electronic Consent (iPad)|Participants who receive the intervention will be consented using an electronic app presented via iPad and developed according to the Sage eConsent framework.
40861229|NCT04266132|PROCEDURE|General anaesthesia|General anaesthesia will be induced with 8% sevoflurane in oxygen and maintained with 1 MAC sevoflurane via a laryngeal mask.
40861230|NCT04266132|PROCEDURE|Ultrasound-guided RLB|The suggested ultrasound transducer orientation is sagittal paramedian (cephalacaudad direction). We begin our ultrasound scanning in a paramedian sagittal plane by finding desired level (T12- L1).The transverse process view, the costotransverse ligament can be visualized above the paravertebral space. Continuing to scan from lateral to medial, the vertebral laminae come into view.
41167907|NCT02869815|PROCEDURE|ICG+Methylene Blue|"ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out."
41167908|NCT00610805|OTHER|Preventive Cardiology|Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.
41167909|NCT00610805|OTHER|Usual Care|Participants will receive usual care per their primary care physician.
41167910|NCT02882841|OTHER|Biopsies, stool and blood collection|
41167911|NCT02949856|DEVICE|Mallinckrodt, COVIDIEN|
41167912|NCT02949856|DEVICE|Endotracheal tube, Unomedica|
41392010|NCT02688309|PROCEDURE|Surgery|The 60 patients from the operating room will be patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macula hole. All patients will be administered an AC (Anterior Chamber) tap just prior to the surgical procedure while in the OR.
41392011|NCT02688309|PROCEDURE|Anterior Chamber (AC) Tap|A paracentesis removing about 0.1 ml of fluid from the front part of the eye (the aqueous chamber) will be performed in the operating room just prior to surgery or in the clinic. In the operating room, the AC tap is done after the eye is anesthetized and cleaned with 5% povidone iodine for the surgery. A 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is removed. The wound is self-sealing and has no effect on the surgery. In the clinic, the AC tap is done after drops of proparacaine and 5% povidone iodine is placed in the eye and a lid speculum is inserted. The patient is seated at a slit lamp and a 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is aspirated and then the needle is removed.
41392012|NCT01812291|BEHAVIORAL|Step 1: Diabetes-Specific CBT (5 group sessions)|"Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').~Includes:~* Diabetes problem analysis/ definition~* Diabetes problem solving intervention~* Cognitive restructuring of diabetes problems~* Activation of personal and social resources~* Goal definition and agreement"
41392013|NCT01812291|BEHAVIORAL|Step 2: Depression-Specific CBT (6 single sessions)|"Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).~Includes:~* Functional explanatory model of depression~* Cognitive restructuring of negative thoughts~* Practice of alternative beneficial thoughts~* Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity."
41392014|NCT01812291|BEHAVIORAL|Step 3: Referral to Psychotherapist and/or Psychiatrist|Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
41392015|NCT01812291|BEHAVIORAL|Standard Diabetes Education|"Standard diabetes education and professional care.~Includes:~* Health care and specific topics (e. g. blood pressure)~* Diabetes complications~* Healthy and unhealthy foods, cooking recommendations and recipes~* Foot care: exercises, care and control, injuries, and diabetic neuropathy~* Sports, activities and exercise~* Social aspects of living with diabetes"
41392016|NCT05614479|OTHER|GATEKEEPER intervention|"Agents will identify candidates in their areas of work (e.g., associations of elderly people).~Training sessions will be held for healthcare professionals and community agents.~Dissemination of materials, resources, and channels to contact and inform candidates to invite them to participate in the study. Recruitment procedures posters, leaflets, videos, newsletters, or appointments will be used.~Candidates interested and accepted will download the application on their mobile devices and will surf on the app which pretends to promote healthy aging. Users will provide some data and complete questionnaires (available in the application) for the baseline and final assessment.~Professionals will visualize how and how much participants are interacting by using the MAHA dashboard."
41392017|NCT03816956|DRUG|AR-301|AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
41392018|NCT03816956|OTHER|Placebo|Placebo comparator
41392019|NCT03576430|DEVICE|active stress handling|biofeed back stress handling
41392020|NCT02096029|OTHER|Nicotine Replacement Therapy (NRT) Sampling|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
40861231|NCT04266132|PROCEDURE|Ultrasound-guided INB|A high-frequency probe is placed medial to the anterior superior iliac spine with the axis facing the umbilicus. A needle is inserted toward the ilioinguinal nerve as it runs between the transversus abdominis and internal oblique.
41392021|NCT02096029|BEHAVIORAL|Ask, Advise, Refer (physician brief advice)|
41392022|NCT01677442|PROCEDURE|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
41392023|NCT01677442|PROCEDURE|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
41392024|NCT03355807|DRUG|Magnesium|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4
41392025|NCT00246441|DRUG|Paroxetine|16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
41392026|NCT00246441|DRUG|Placebo|treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
41392027|NCT03679845|DRUG|Sarilumab|Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
41392028|NCT01979302|OTHER|Depression CAREPATH|Nurses receive training and agency support in depression assessment and depression care management
40861232|NCT04266132|DRUG|Bupivacaine|0.3 ml.kg of 0.25% bupivacaine will be injected under visualization.
41392029|NCT01979302|OTHER|Usual Care|Nurses receive training in depression assessment and review of usual care procedures.
41392030|NCT03374137|BIOLOGICAL|obinutuzumab|Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
41392031|NCT02421380|DRUG|Hyperpolarized Pyruvate|
41392032|NCT04754919|OTHER|Transition intervention group|Support and on-going treatment intervention; monitoring the uptake of routine annual diabetes tests and encouraging to access where default observed General specialist diabetes support and provision of education and referral to other specialist healthcare agencies as individual requires
41392033|NCT04754919|OTHER|Post transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
41392034|NCT00297206|DRUG|Valaciclovir|Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
41392035|NCT06016413|DRUG|Nab paclitaxel|All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.
41392036|NCT06016413|DRUG|Carboplatin|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
40861233|NCT05192460|BIOLOGICAL|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1/L1.
40861234|NCT05379985|DRUG|RMC-6236|Oral Tablets
41167913|NCT03153098|BEHAVIORAL|Active Herts|Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
41167914|NCT00520871|DRUG|Blueberry juice|
41167915|NCT04517500|BEHAVIORAL|Home-based pulmonary rehabilitation program|Subjects will wear an activity monitor while doing at home exercises using a computer tablet
41167916|NCT04517500|BEHAVIORAL|Mindful breathing module|Additional module on the computer tablet that involves inhaling and exhaling while following an animated ball on the computer screen.
41392037|NCT06016413|DRUG|adelbelimumab|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
41392038|NCT00486577|PROCEDURE|significant chronic primary auditory cortex stimulation during the first two weeks|significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation
41392039|NCT00486577|PROCEDURE|non significant chronic primary auditory cortex stimulation during the first two weeks|non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
41392040|NCT03821831|DEVICE|Continuous Positive Airway Pressure|CPAP machine
41392041|NCT03821831|DEVICE|Orthodontic intervention|Mandibular advancement or Rapid maxillary expansion devices
41392042|NCT00068406|RADIATION|3-Dimensional Conformal Radiation Therapy|
41392043|NCT00068406|DRUG|Cisplatin|Given IV
41392044|NCT00068406|PROCEDURE|Conventional Surgery|
40861235|NCT02837185|PROCEDURE|Botulinum Toxin injection|Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
40861236|NCT02837185|OTHER|Physiological measures|These include TMS and EMG measurements
40861237|NCT03919474|DIAGNOSTIC_TEST|microvascular markers|follow up of microvascular biomarkers during patient follow up
41167917|NCT04517500|BEHAVIORAL|Health coaching|Weekly coaching calls to discuss rehabilitation and health process using motivational interviewing
41167918|NCT02751801|OTHER|no intervention|
41392045|NCT01277406|DRUG|4SC-201(Resminostat)|oral administration
41392046|NCT01277406|DRUG|FOLFIRI|i.v. administration
41392047|NCT06127004|OTHER|Metacognitive Training for Negative Symptoms (MCT)|See arm/group descriptions
41392048|NCT06127004|OTHER|Supportive Counselling|Se arm/group descriptions
41392049|NCT06156579|DRUG|Decitabine|Decitabine 20 mg/m\^2, i.v., once daily, 10 days
41392050|NCT06156579|DRUG|Venetoclax|Venetoclax, 400 mg, p.o., once daily, 28 days
40861238|NCT05796895|BEHAVIORAL|Videogame|Children will be provided with the videogame for eight weeks, through which they will be taught symptom management strategies. Children and their parents will be telephoned every week by a nurse to inquire whether children performed the strategies taught to them and if they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
40861239|NCT05796895|BEHAVIORAL|WhatsApp|Children will be provided with weekly WhatsApp messages on healthy behaviors. Children and their parents will be telephoned every week by a nurse to inquire whether they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
40861240|NCT02534363|DRUG|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
40861241|NCT02534363|DRUG|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
41512929|NCT05807204|DIETARY_SUPPLEMENT|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
41392051|NCT05371483|DIAGNOSTIC_TEST|24-hour Ambulatory Blood Pressure Monitoring|Arm blood pressure cuff that will automatically inflate every 15-30 minutes to check blood pressure while awake and asleep over 24 hours. Patient will also complete a sleep diary and wear an actigraphy watch during this test.
41040145|NCT05339412|BEHAVIORAL|Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
41040146|NCT01467180|DEVICE|septeX|continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
41040147|NCT01467180|DEVICE|HF CVVH|continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
41392052|NCT05371483|DIAGNOSTIC_TEST|Oculo-Cognitive Addition Test (OCAT)|Tracks users' eye movements as they complete a simple mental addition test.
41392053|NCT03077594|DEVICE|Mucosal Impedance|Aim 1: Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Mucosal impedance will be measured 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
40861242|NCT02534363|DRUG|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
40861243|NCT02534363|BEHAVIORAL|Cognitive battery|Completed in the following standardized sequence: 1-the Rey Auditory Verbal Learning Test (RAVLT); 2-WAIS-III digit symbol subtest; 3-Grooved Pegboard Test; 4-The Zoo Map Test; 5-Tower of London Test (ToL); 6-Rey Complex Figure (RCF); 7-Trail Making Test (TMT); 8-WAIS-III digits forward and backward subtests; 9-WAIS-III letter-number sequencing subtest; 10-WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11-Stroop Test; 12-letter (FAS) and semantic (animal) fluency tests; 14-Eyes Task; 15-Continuous Performance Test (CPT).
41512930|NCT05807204|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
41040148|NCT03939468|DEVICE|DES+DCB|A hybrid strategy is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES implantation for a de novo lesion (located in the larger, more proximal part of the vessel) and DCB inflation for a concomitant de novo small vessel disease
41040149|NCT00449176|DRUG|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
41040150|NCT00449176|DRUG|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
40861244|NCT03450954|PROCEDURE|Amniotic membrane transplant|Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
40861245|NCT04647968|PROCEDURE|Primary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of a sutured closure of the tracheotomy following local anesthesia, done at bedside.
41040151|NCT00449176|DRUG|placebo|matching placebo twice daily for 15 weeks
41040152|NCT02336334|DEVICE|Positioning measurement|Logging of posturing informations
41040153|NCT02336334|DEVICE|Patient feedback|Evaluation of patients questionary
41512931|NCT00015886|DRUG|docetaxel|75 milligrams per meter squared intraveneously
41512932|NCT00015886|DRUG|fluorouracil|350 milligrams intraveneously
41512933|NCT05256186|OTHER|Basketball Pre-injury Attack program|The intervention had a total duration of 24 weeks, with 3 sessions per week (before starting training) with a total duration of 12 to 15 minutes per session. Each session consisted of 8 exercises with a load of 2 to 3 series between 6 and 12 repetitions; and with a rest at the end of each series of \<60 seconds.
41392054|NCT03077594|OTHER|Research Biopsies|Aim 1: Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Aim 2: Research biopsies will be taken 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
41392055|NCT03077594|DEVICE|Volumetric Laser Endomicroscopy|Aim 2: Volumetric laser endomicroscopy will be done and marked at 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
41392056|NCT06538636|OTHER|PCP-Facing Tools|PCP-facing tools will be turned on as a package: a) enhanced LCS clinical reminder including DP+ generated smart message; b) Integrated one-click DP+ full decision tool for automating personalized information about the net benefit of LCS based on patient characteristics; c) the TurboHM tool: automated Health maintenance app for tracking all preventive care, including a dedicated LCS section with personalized information
41392057|NCT06538636|OTHER|LCS team population management tools|site-specific dashboard and proactive outreach toolkit
41392058|NCT02377284|OTHER|Photograph|Add a photograph to a chef card.
41392059|NCT03386669|DRUG|F-18|Totally 60 subjects age 20-80 including 20 subjects with a diagnosis of PD,PSP,and CBS. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
41392060|NCT02585973|DRUG|AZD1775|AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
41392061|NCT02585973|DRUG|Cisplatin|40 mg/m2 IV infused over 1 hour D1 of each week of radiation
41392062|NCT02585973|RADIATION|Intensity Modulated Radiotherapy Treatments|Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
41392063|NCT01997099|DEVICE|CADD®-Solis VIP Pump|
41392064|NCT01997099|DEVICE|CADD™ Solis Medication Safety Software Administrator|
41392065|NCT06190899|DRUG|Gedatolisib|Gedatolisib is a potent reversible inhibitor that selectively targets all Class I PI3K isoforms and mTOR.
41392066|NCT06190899|DRUG|Darolutamide|Darolutamide is a novel androgen receptor inhibitor that has been studied and received approval for treatment of patients with nonmetastatic CRPC and in metastatic hormone-sensitive prostate cancer.
41392067|NCT04175873|OTHER|music|Patients will listen to music with MP3 headphones for 1 hour preoperatively and throughout the operation.
41392068|NCT05796531|BEHAVIORAL|Therapeutic Evaluative Conditioning|"Participants are told which pictures are matched pairs. They find the matched pairs among 4 or 8 pictures. By associating pictures and words associated with SITB (e.g., pictures of cut skin, pictures of people engaging in potentially suicidal behaviors, and the word death) with naturally aversive images (e.g., snakes and spiders), it increases the aversion to SITB. The second goal is to increase liking toward the self by pairing self-relevant stimuli (e.g., the participant's name or other self-relevant details, as well as words like I and me)."
41392069|NCT05796531|BEHAVIORAL|Neutral comparison condition|Match neutral pictures to account for doing an intervention.
41392070|NCT01345890|PROCEDURE|electrical stimulation|sub motor threshold stimulation of mylohyoid muscles
41392071|NCT01400672|BIOLOGICAL|Tumor Lysate Vaccine|Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
41392072|NCT01400672|DRUG|Imiquimod|Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
41040154|NCT02336334|PROCEDURE|Usefulness of a sketch|Helping the patients to understand posturing positions by randomized allocation of sketches
41040155|NCT02336334|DEVICE|Closure rate of macular holes|closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
41040156|NCT06326515|BEHAVIORAL|psychoeducation|"To identify and recognize the cognitive distortions To explore the automatic thoughts and emotions about illness Evaluate and respond to thoughts, emotions, and beliefs Automatic thought records were used by patients with some help from therapist (Chattopadhyay et al., 2017).~The cognitive errors were corrected using individual cognitive strategies (Chattopadhyay et al., 2017)."
41040157|NCT06326515|BEHAVIORAL|Stigma Reduction and Relapse Management|"To improve ability to effectively cope with lapse and relapse (Brown \& Vanable, 2008).~To improve relapse management skills (Brown \& Vanable, 2008). Emphasized skill development to cope with OUD-related stressors (Zhang, 2021). To change their conception of OUD (Tshabalala \& Visser, 2011). To change their sense of self-worth and to empower them with more adaptive ways of thinking (Tshabalala \& Visser, 2011).~To deal with their experience of stigma (Tshabalala \& Visser, 2011)."
41040158|NCT01643590|BIOLOGICAL|JVS-100 15 mg dose Injection|Intramyocardial Injection
41392073|NCT01400672|RADIATION|Radiation therapy|"Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby sensitizing residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy."
41392074|NCT04293640|DIAGNOSTIC_TEST|Parasternal electromyogram measurement|Three electrodes are applied to the chest (two to parasternal muscles, one reference electrode to clavicle). Measurements of EMG signals are recorded on appropriate software.
41512934|NCT03782051|PROCEDURE|combined phacoemulsification and viscocanalostomy|phacoemulsification with viscocanalostomy
41512935|NCT03782051|PROCEDURE|combined phacoemulsification and viscocanalostomy and ologen|phacoemulsification with viscocanalostomy with ologen
41040159|NCT01643590|BIOLOGICAL|Placebo Injection|Intramyocardial Injection
41040160|NCT01643590|BIOLOGICAL|JVS-100 30 mg dose injection|Intramyocardial Injection
41040161|NCT02716974|DRUG|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
41040162|NCT02716974|DRUG|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
41040163|NCT02716974|DRUG|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
41040164|NCT02716974|PROCEDURE|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
41392075|NCT06568185|DRUG|Alpha-Lipoic Acid/Vitamin/Mineral Supplement PolyMVA|BIONERV® s the first combination of alpha lipoic acid 300mg and vitamin B complex. Bionerv® is in oral film-coated, orange colour, oblong shape and no marking and embossing on the tablet. Each tablet contains 4 active ingredients as follows: Alpha lipoic acid 300mg, Vitamin B12 (methylcobalamin) 500mcg, Vitamin B6 (pyridoxine) 8mg, Vitamin B1 (thiamine) 39mg. To be taken after meal 1 tablet once daily.
41392076|NCT02719015|DRUG|rAd.CD40L|"Dose Escalation Phase Starting Dose: 5x10\^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10\^11 vp. Subsequently enrolled patients injected at the same dose of 1x10\^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have \>/=2 injectable lesions, at the same injection dose of 1x10\^10 up to three separate sites/lesions if patients have \> 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase."
40861246|NCT04647968|PROCEDURE|Secondary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of removing the tracheotomy canula and applying ointment and an Elastoplast on the site, which will be changed regularly until full healing of the wound.
40861247|NCT00745537|OTHER|repeated mood measures and phone depression care management|The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
41040165|NCT02716974|RADIATION|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
41040166|NCT03282227|DRUG|M207 Microneedle System|M207 Microneedle System 3.8 mg
41040167|NCT03552874|OTHER|The Performance of Upper Limb Questionnaire (PUL)|
41040168|NCT01581281|DRUG|Amitriptyline|Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
41167919|NCT04300153|PROCEDURE|ESP Block|At the end of the skin closure, patients will be positioned in lateral decubitis with the involved site lying superiorly. A convex ultrasound probe will be placed over the transverse process of T12 vertebra in longitudinal axis and an 80- mm 21-gauge needle will be inserted in the plane view under aseptic conditions. A unilateral ESP block will be performed with 30 ml 0.25% bupivacaine into the interfascial plane between erector spinae muscle and T12 transverse process
41392077|NCT02719015|DRUG|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
40861248|NCT01103583|DRUG|Hydroxyurea|500 mg/die per os for two years
40861249|NCT01103583|OTHER|placebo|500 mg/die per os for two years
40861250|NCT02698514|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
41392078|NCT04663711|BEHAVIORAL|degree of adherence of pre-anesthetic tests at kasr Alaini hospital to the NICE-Uk guidelines|"The anesthesiologist, whom is in charge of preoperative assessment at each unit, will assess patients who are scheduled for elective surgery, and will inform senior anesthesiologists with a minimum 3 years of experience.~preoperative investigations will be divided into: First part will be on patient's gender, ASA classification, medical history and examination.~Second part will be on Grade of surgery - Minor/ Intermediate/ Major or complex.~Third part is requested investigation(s), its rationale, the hierarchy of anesthesiologist requested, and the planned date for surgery.~Fourth part is about whether that investigation(s) is adherent with NICE-UK guidelines or not."
40861251|NCT02698514|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
41040169|NCT01581281|DRUG|Topiramate|Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. Dosing of topiramate will be weight-based.
41392079|NCT04902261|DRUG|Tislelizumab|Tislelizumab 200 mg every three weeks
41392080|NCT04902261|DRUG|Nab paclitaxel|Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks
41392081|NCT04902261|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on d1 and d8 every three weeks
41392082|NCT06344988|OTHER|The exercise program|The exercise program developed by Chan et al., consists of a 30-minute exercise period with 5 minute warm-up (diaphragmatic breathing, general body movements) and 5-10 minute cool-down (stretching exercises in addition to the exercises in the warm-up period) periods. Exercises include 6 steps and 5 series (neck, shoulder, spine, abdominals, hip) according to difficulty level. The total exercise program takes 40-45 minutes.
41392083|NCT06344988|OTHER|Online education presentation|This online education presentation includes the role of postural and dynamic muscles, the importance of physical activity, gradual adaptation of the body to workload and physical stressors, rest, and injury management. The education takes 40 minutes and will be done once.
41040170|NCT01581281|DRUG|Placebo|Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
41040171|NCT00205569|BEHAVIORAL|First Steps Educational Curriculum|10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
41040172|NCT05780203|BEHAVIORAL|One session exposure treatment|One session exposure treatment during which patients will be confronted with a height-related situation.
41167920|NCT04300153|OTHER|Global Quality of Recovery-15 score|Global Quality of Recovery-15 score (QoR-15) will be recorded prior to the surgery and at the postoperative 24th hour.
41167921|NCT04300153|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale score will be recorded at the 1.-2.-4.-6.-8.-12.-24.hours. If Numerical Rating Scale score will be equal to or over 4, iv dexketoprofen 50 mg will be applied as rescue analgesic. Numerical Rating Scale scores, the rescue analgesic need and the time for first mobilization of the patient will be recorded and kept in a statistical evaluation.
40861252|NCT05575193|OTHER|Acupressure|The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes.
40861253|NCT01199809|DRUG|Placebo|multiple doses
40861254|NCT01199809|DRUG|RO5310074|multiple ascending doses
41392084|NCT06344988|DEVICE|Smart band|Participants will be given a Xiaomi Mi Smart Band 5 and will be asked not to remove the smart band except for bathing for 8 weeks, and to download the smart phone application (Zepp Life) compatible with the smart band to their phones, which will allow their steps to be recorded on a weekly basis.
40861255|NCT00288678|PROCEDURE|Health Education|
40861256|NCT00380731|BEHAVIORAL|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
40861257|NCT01493973|DRUG|Epoetin alfa|Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
40861258|NCT01493973|DRUG|Placebo|Placebo
40861259|NCT03325959|DEVICE|Hyperbaric oxygen therapy (HBOT) treatment|60 HBOT sessions at 2 ATA 100% oxygen
40861260|NCT03325959|DRUG|Cymbalta / Lyrica treatment|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
40861261|NCT03325959|DEVICE|Crossover Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen after crossover
40861262|NCT05189470|PROCEDURE|Inforatio technique|Inforatio technique is a novel minimal invasive procedure where small cuts are made on wound beds with punch biopsy tools near the wound edges but without involving wound edge epithelia. Inforatio technique is applied after the wound has been surgically debrided for slough and devitalized tissue.
40861263|NCT05189470|OTHER|Usual care of the respective outpatient clinics|Usual care of the DFUs includes local wound care and offloading treatment.
40861264|NCT01006759|OTHER|exercise and orientation|guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
41167922|NCT06471608|OTHER|Ambulatory management|"* Chest tube drainage in emergency department (Furhmann drain connected to Heimlich valve), connected to suction system at -5 to -10 cm H2O until bubbling stops~* Follow-up imaging at 4 hours (chest X-ray or low-dose CT scan, depending on management practices in the centers)~  * if the pneumothorax is still very large, or if clinical tolerance is unsatisfactory (dyspnea, unrelieved pain, abnormal vital parameters), the patient should be admitted to hospital~ * if the lung is in the process of reattachment and a minimal detachment persists, and clinical tolerance is good (assessed on vital parameters, with oxygen saturation above 98%, good hemodynamic stability and pain relieved by analgesics), the patient may be discharged home."
41392085|NCT02733601|OTHER|NIS (Non Interventional Study) observational study|NIS observational study : Epidemiologic registry
41392086|NCT04276285|PROCEDURE|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
41392087|NCT04276285|PROCEDURE|US TAP|Subcostal TAP block will be performed after surgery under US guidance
41392088|NCT03336645|DRUG|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
41392089|NCT02323139|DRUG|Azacitidine and LDE255|Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
40861265|NCT02253953|DRUG|BILR 355 BS, D1|
40861266|NCT02253953|DRUG|BILR 355 BS, D2|
40861267|NCT02253953|DRUG|BILR 355 BS, D3|
41512936|NCT02392949|BEHAVIORAL|Passive mobilization|An anterior-posterior manual pressure act on the cervical spine of the subject
40861268|NCT02253953|DRUG|BILR 355 BS, D4|
40861269|NCT02253953|DRUG|BILR 355 BS, D5|
40861270|NCT02253953|DRUG|BILR 355 BS, D6|
40861271|NCT02253953|DRUG|BILR 355 BS, D7|
40861272|NCT02253953|DRUG|BILR 355 BS, D8|
40861273|NCT02253953|DRUG|BILR 355 BS, D10|
40861274|NCT02253953|DRUG|Placebo|
40861275|NCT02253953|OTHER|high-fat breakfast|
40861276|NCT02253953|DRUG|Ritonavir|
40861277|NCT03780335|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
40861278|NCT01768364|DRUG|Trimetoprim-Sulfa (Bactrim)|
40861279|NCT01768364|OTHER|No antibiotics|
40861280|NCT02089074|BEHAVIORAL|Drug use counselling|
40861281|NCT05244746|PROCEDURE|rectus sheath block|blocking the nerve underneath the rectus muscle by bupivicaine
40861282|NCT00910780|DRUG|Aripiprazole|via oral tablets, everyday
40861283|NCT00910780|DRUG|Zyprexa|via oral tablets, taken once daily
40861284|NCT00910780|DRUG|Risperdal|via oral tablets, taken once daily
40861285|NCT00445185|BIOLOGICAL|Henogen HB vaccine|Month 12, 24 and 36
40861286|NCT00445185|BIOLOGICAL|Fendrix vaccine|Month 12, 24 and 36
40861287|NCT01034930|PROCEDURE|Insertion of dental implants|Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
40861288|NCT01423292|PROCEDURE|Ultrasound Guided Transversus Abdominis Plane (TAP) Block|Ultrasound Guided Transversus Abdominis Plane (TAP) Block
40861289|NCT01423292|DRUG|bupivacaine|0.25 bupivacaine 30ml (15ml on each side)
40861290|NCT01423292|DRUG|Placebo|placebo
40861291|NCT02781480|BIOLOGICAL|AAV RPE65|Comparison of different dosages of AAV RPE65
40861292|NCT04847934|BEHAVIORAL|distraction methods|distraction methods
40861293|NCT04804163|DEVICE|telesurgery by domestic robot|telesurgery of the upper urinary disease by domestic robot
40861294|NCT04862247|BEHAVIORAL|Imaginal Exposure Condition|Participants will be asked to think and write about an eating related fear or anxiety. Specifically, they will be asked to spend 20-30 minutes writing about a specific fear or anxiety they have, then another 20-35 minutes re-reading and imagining that what they have written is happening.
40861295|NCT04862247|BEHAVIORAL|Writing and Thinking Condition|Participants will be asked to think and write about their eating disorder using specific prompts designed to help them process their eating disorder. Specifically, they will be asked to spend 20-30 minutes writing their eating disorder, then another 20-35 minutes re-reading what they wrote.
40861296|NCT01107314|OTHER|Phlebotomy|Blood draws (total 48 cc blood)
40861297|NCT05441631|DRUG|Insulin|"* Preparation: 50 IU of rapidly acting insulin in 50 ml of 0.9% saline solution was delivered through a 50-ml syringe-driven pump.~* Monitoring: The insulin dose was adjusted to whole-blood glucose levels using glucometer every hour and insulin infusion was continued till BG level (Targeted level) was 80-110 mg, and then BG levels were estimated four-hourly~* Insulin dose was titrated according to the Leuven titration protocol (15)"
40861298|NCT05441631|DRUG|Subcutaneous Insulin|"* Insulin dose was titrated according to the Blood glucose level~* monitoring according to glucose in urine"
40861299|NCT03734003|DEVICE|liquid nitrogen|As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied
40861300|NCT03734003|DEVICE|controllable infrared bioeffect system|As an experimental arm, for patients with cutaneous warts
40861301|NCT02936024|PROCEDURE|Two-Stage GSLO Technique|The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.
40861302|NCT02936024|PROCEDURE|One-Stage GSLO Technique|The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
41040173|NCT05780203|BEHAVIORAL|Sham Cognitive Bias Modification training|Sham Cognitive Bias Modification training procedure matched in format to active training but adapted to not target height-related, interpretational processing biases.
41040174|NCT05780203|BEHAVIORAL|Active Cognitive Bias Modification training|Active Cognitive Bias Modification training targeting height-related, interpretational processing biases.
41040175|NCT04660539|DRUG|satralizumab|Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years
41040176|NCT04660539|DRUG|azathioprine (AZA)|Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
40861303|NCT03762031|DRUG|GC4711 30mg|single dose given via a 15 minute intravenous infusion
41167923|NCT06471608|OTHER|Standard Care|"Hospitalisation in a hospital department (pulmonology, thoracic surgery, short-stay emergency unit, critical care, according to the usual pathway of the center in which the patient is included).~In-hospital monitoring until complete resolution of pneumothorax and drain removal (average 4-6 days)."
41167924|NCT00639977|OTHER|Acupuncture|20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
41167925|NCT00639977|OTHER|Sham|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
41167926|NCT01665599|DRUG|Testosterone gel (FE 999303)|
41167927|NCT04522778|DEVICE|Wearable Central Line Securement Device (Vest)|The wearable central line securement device is a vest that has attachments for the central line to safely be secured to the body whether it is being used for infusion or unhooked. It also has a front flap, which protects the line from snagging on external objects.
41167928|NCT04522778|OTHER|Traditional Securement Dressing|All subjects will use sterile dressings throughout the trial as this is the standard of care for central line securement. Subjects randomized to the dressing arm will continue to use standard of care sterile dressing as the only form of central line securement.
40861304|NCT03762031|DRUG|GC4711 60mg|single dose given via a 15 minute intravenous infusion
40861305|NCT03762031|DRUG|GC4711 90mg|single dose given via a 15 minute intravenous infusion
40861306|NCT03762031|DRUG|GC4711 120mg|single dose given via a 15 minute intravenous infusion
40861307|NCT03762031|DRUG|Placebo|single dose of normal saline given via a 15 minute intravenous infusion
41040177|NCT04660539|DRUG|mycophenolate mofetil (MMF)|Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day
41040178|NCT04660539|DRUG|oral corticosteroids|Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
41040179|NCT04183764|DRUG|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
41040180|NCT03295188|DIETARY_SUPPLEMENT|Plasmalogen|Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.
41040181|NCT03295188|DIETARY_SUPPLEMENT|Placebo|Placebo Group takes two placebo capsules per day for 12 weeks.
41167929|NCT01649037|DRUG|nor adrenaline and terlipressin|"IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.\[ No response defined as MAP \< 10, or 4 hr Urine output \< 200 ml\] with maximum dose upto 3 mg/h."
40861308|NCT03762031|DRUG|GC4711 75mg|single dose given via a 15 minute intravenous infusion
40861309|NCT03762031|DRUG|GC4711 105mg|single dose given via a 15 minute intravenous infusion
41040182|NCT03155607|BEHAVIORAL|Virtual Reality Distraction|Patient will utilize a virtual reality device during wound care.
41392090|NCT00593099|DRUG|Bupropion|BUP \[as the intermediate-release (IR) formulation\] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg \[as BUP SR formulation\] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
41392091|NCT00593099|DRUG|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
41392092|NCT02761265|PROCEDURE|Surgical intervention|Surgery to correct spinal deformity
41392093|NCT02761265|OTHER|None (Asymptomatic group)|Gait and balance testing performed, no treatment in this asymptomatic group
41167930|NCT01649037|DRUG|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response \[\< 25% decrease in s.creatinine\] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
41167931|NCT05229770|DIETARY_SUPPLEMENT|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
41167932|NCT04875598|PROCEDURE|Ultrasound assisted - Laparoscopy assisted Transversus Abdominis Plane Block|Ultrasound assisted TAPB application will be applied by an anesthesiology and reanimation specialist and Laparoscopy assisted TAPB application will be applied by the surgeon performing the operation.
41167933|NCT05495919|OTHER|Control|No intervention was perfomed to reduce anxiety in control group
41167934|NCT05495919|OTHER|video interaction|Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.
41392094|NCT04911660|DRUG|Empagliflozin 25 MG|1 empagliflozin 25 mg capsule per day for 14 days
41392095|NCT04911660|OTHER|Placebo|1 placebo capsule per day for 14 days
41392096|NCT00003276|DRUG|irinotecan hydrochloride|
41392097|NCT00004161|DRUG|fenretinide|
41392098|NCT00004161|DRUG|Placebo|
41392099|NCT03765944|DRUG|sirolimus|SIngle administration under fasted condition
40861310|NCT03477045|DIETARY_SUPPLEMENT|Single dose fish oil|Fish oil consumed within a single high fat test meal
41167935|NCT05495919|OTHER|flipped training|Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
41392100|NCT01933139|OTHER|Audio-visual presentation|
41392101|NCT01115699|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
40861311|NCT03477045|DIETARY_SUPPLEMENT|Repeated dose fish oil|Fish oil consumed daily for 8 weeks
40861312|NCT03477045|DIETARY_SUPPLEMENT|single dose Camelina seed oil|camelina seed oil consumed within a single high fat test meal
41392102|NCT06539715|DIAGNOSTIC_TEST|Visual field assessment|Automated perimetry
40861313|NCT03477045|DIETARY_SUPPLEMENT|repeated dose camelina seed oil|camelina seed oil consumed daily for 8 weeks
40861314|NCT00612755|DRUG|Peginterferon alfa-2a + ribavirin|Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
40861315|NCT00640497|BIOLOGICAL|IT-Combination|The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
41040183|NCT00887497|PROCEDURE|Angioembolization|Angioembolization
41040184|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
41040185|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
41392103|NCT05329129|DEVICE|OssDsign® Catalyst|An osteoconductive, resorbable, porous, 100 % nano synthetic calcium phosphate bone void filler
41392104|NCT03793595|DEVICE|Seated Battle Ropes Protocol|Participants will begin swinging the rope as previously described in the seated position using the double arm swing technique for 15 seconds at a cadence of 100 beats/ minutes with a 45 second rest break repeated 10 times.
41392105|NCT03793595|DEVICE|Seated Upper Extremity Arm Bike|A modified Young Men's Christian Association (YMCA) cycle test will be performed.
41392106|NCT06518941|DRUG|Donepezil|Study medication will be initiated at 1mg, to be taken before bed. Dosing will follow a flexible titration. The expected titration will be 1 mg for 2 weeks, 2.5 mg for 2 weeks, then 5 mg for 4 weeks. Doses may be lowered from those recommended by the protocol if side effects are significant.
41392107|NCT01918709|DRUG|Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
41392108|NCT01918709|DRUG|Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
41512937|NCT02392949|OTHER|Placebo|The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
41392109|NCT01918709|DRUG|Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
41392110|NCT01918709|DRUG|Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
41392111|NCT01918709|DRUG|Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
41392112|NCT01918709|DRUG|Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
40861316|NCT03200834|PROCEDURE|Right Hemicolectomy with D2 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
40861317|NCT03200834|PROCEDURE|Right Hemicolectomy with D3 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
40861318|NCT01403155|BIOLOGICAL|INO-3401 + EP|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
40861319|NCT04043442|DEVICE|Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P|rTMS device
40861320|NCT00456287|DEVICE|CPAP (Continuous Positive Airway Pressure)|
40861321|NCT04703426|DRUG|Sargramostim (GM-CSF)|Drug that binds to the protein PD-1 to help immune cells kill cancer cells better, it is given as an intravenous injection through a vein.
40861322|NCT04703426|DRUG|Pembrolizumab (anti-PD-1)|Drug that stimulates blood cells that may help support the immune system during cancer treatment, given as intravenous infusion
40861323|NCT03205683|OTHER|Intraneural facilitation (INF)|INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.
40861324|NCT03205683|OTHER|Sham INF|Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.
40861325|NCT05721521|OTHER|Spin Bike Exercise|30 minute spin bike class led by a qualified instructor.
40861326|NCT05721521|OTHER|Control|30 minute completing seated activities (e.g., wordsearches)
40861327|NCT04339673|PROCEDURE|masseteric nerve block|regional bloc of masseter
40861328|NCT04339673|PROCEDURE|trigger point injection|trigger point injection with local anesthetic
40861329|NCT04339673|PROCEDURE|dry needling|needling with acupuncture needles of trigger points in masseter
40861330|NCT02426736|DRUG|Dexamethasone|
40861331|NCT02426736|DRUG|Bupivacaine|
40861332|NCT02426736|PROCEDURE|Interscalene brachial plexus block|Performed with real time ultrasound guidance.
40861333|NCT02569684|DIETARY_SUPPLEMENT|Prebiotic fibers: oligofructose and inulin|
40861334|NCT02569684|DIETARY_SUPPLEMENT|Maltodextrin|
40861335|NCT03237793|PROCEDURE|Fluorosed Group|A single episode of laser therapy with without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, A group only with desensitising paste and A group with desensitising paste and laser treatment depending on the study group they were assigned
40861336|NCT03237793|PROCEDURE|Non Flourosed Group|A single episode of laser† therapy with or without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, depending on the study group they were assignedGROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment$. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal\*\*) treatment.
41392113|NCT06155669|DEVICE|Virtual Reality|Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. Selected participants, in addition to being administered 25 mg of dexketoprofen, will also use virtual reality goggles.
41392114|NCT04789811|OTHER|Stretching exercise|Stretching exercise: Stretching exercises were planned for 30 seconds, ten repetitions for each stretching, 10 minutes in total, four days a week, for two weeks.
41392115|NCT04789811|OTHER|Dry needling|Dry needling: A total of 3 sessions of dry needling, once a week, were applied to the gastrocnemius muscle.
40861337|NCT05355662|OTHER|Age|The study was retrospective and did not involve the application of interventions.
40861338|NCT03016065|DIETARY_SUPPLEMENT|Pea Fiber|Baked goods (2 snacks) with fiber-fortified with 5 g/snack of ground pea hulls
40861339|NCT03016065|DIETARY_SUPPLEMENT|Control|Baked goods (2 snacks) without added fiber
40861340|NCT00180765|PROCEDURE|Up to 100ml blood will be taken by venupuncture.|
41392116|NCT02148731|OTHER|Frailty markers|Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
41392117|NCT04228289|DRUG|Oxytocin|40 IU intranasal spray
41392118|NCT04228289|OTHER|Placebo|matching intranasal spray
41392119|NCT02421770|OTHER|Chamaemelum nobile 2%|"Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are"
40861341|NCT04014283|DIETARY_SUPPLEMENT|Selenium supplementation or placebo treatment|Patients from this group will receive selenium supplement to achieve optimal selenium level
40861342|NCT04014283|OTHER|Diet modification|Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.
40861343|NCT04014283|OTHER|Selenium supplementation or placebo treatment and diet modification|In this group patients will receive supplement, placebo or diet modification. The goal is to raise selenium concentration in blood
40861344|NCT01008943|BIOLOGICAL|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
41392120|NCT02421770|OTHER|placebo|
41392121|NCT04857684|DRUG|Atezolizumab|Intravenous Infusion
41392122|NCT04857684|DRUG|Bevacizumab|Intravenous Infusion
41392123|NCT04857684|RADIATION|Stereotactic Beam Radiation Therapy (SBRT)|External beam radiation
41392124|NCT05199545|DIETARY_SUPPLEMENT|Dietary supplement|Dietary supplement under study is based on Rhodiola rosea L. and Crocus sativus L. extracts
41392125|NCT05199545|OTHER|Placebo|Placebo of the dietary supplement
41392126|NCT01130701|OTHER|Neoadjuvant capecitabine, panitumumab and radiation|"Patients will receive six weekly doses of panitumumab (2.5mg/kg) in conjunction oral capecitabine 825 mg/m2 PO bid Mon-Friday and external beam radiation therapy. Panitumumab and oral capecitabine will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy.~Patients will be reevaluated for surgical resection 4-6 weeks after completion of neoadjuvant therapy.~After surgical resection, adjuvant systemic chemotherapy with gemcitabine for six months is strongly recommended for all patients."
41392127|NCT05818332|OTHER|Observational study|No intervention, observational only
41392128|NCT05554874|OTHER|Pulsed electromagnetic fields|receiving Pulsed electromagnetic fields 3 times, immediately after the onset of delayed muscle soreness, 24 and 48 hours later.
41392129|NCT05554874|OTHER|Sham Pulsed electromagnetic fields|Sham application will be applied with the same device without applying magnetic current.
41392130|NCT04405674|DRUG|Tislelizumab|Tislelizumab 200mg administered intravenously (IV) on Day 1 of each 21-day cycle
41392131|NCT04405674|DRUG|Carboplatin|Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
41392132|NCT04405674|DRUG|Pemetrexed|Pemetrexed 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
41392133|NCT04405674|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg administered intravenously (IV) on Day 1 of each 21-day cycle
40861345|NCT04975776|BEHAVIORAL|Sleep restriction therapy|The intervention includes psychoeducation and sleep restriction therapy, sleep restriction instructions, problem-solving, and support for participants in adjusting sleep restriction instructions to their individual needs and life circumstances. At the final session, participants create an individual plan for maintaining new sleep habits and coping with insomnia relapse. During the intervention, participants are free to seek and receive standard care for insomnia.
40861346|NCT04975776|BEHAVIORAL|Sleep hygiene|The control condition will include written, general information about sleep and lifestyle and environmental factors that could improve or disturb sleep. The participants will be free to seek and receive standard care for insomnia.
40861347|NCT04862065|DEVICE|Alinity s Anti-HCV II|For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
40861348|NCT04584593|BIOLOGICAL|Sample|Men will give semen, saliva, nasopharyngeal, urine and blood specimens
41040186|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
41040187|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
41040188|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
41040189|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
41040190|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
41040191|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
41040192|NCT01229098|DRUG|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
41040193|NCT02019160|DRUG|25% AgNO3 solution followed by 5% NaF varnish|Dosage of 4.4μg±1.4μg fluoride per use
41040194|NCT02019160|DRUG|38% SDF solution followed by placebo varnish|Dosage of 8.8μg±2.8μg fluoride per use
41040195|NCT03671096|OTHER|Intrastromal TCA Inlay|An intrastromal inlay that will be provided to correct the required hyperopic correction
41040196|NCT03133975|DRUG|Vitamin D3 (Treatment)|Single high dose vitamin D3 in treatment of dyslipedemia
41040197|NCT03133975|OTHER|Mixed diet of carbohydrate and protein (Control)|Mixed diet of carbohydrate and protein
41040198|NCT04230408|DRUG|Durvalumab|Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation
41040199|NCT02868060|DRUG|Romiplostim|
41040200|NCT03359265|DEVICE|underpants|
41040201|NCT02234869|DRUG|Interferon Beta|Subcutaneous injection
41040202|NCT02234869|DRUG|BIIB017 (Peginterferon beta-1a)|Single-use, disposable, prefilled pen for subcutaneous injection
41040203|NCT01595295|OTHER|non interventional|
41040204|NCT02735252|OTHER|Systemic therapy|Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.
41040205|NCT02735252|DEVICE|StrataNGS|CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added
41040206|NCT04137380|DRUG|Mirikizumab - IV|Administered IV
41040207|NCT04137380|DRUG|Mirikizumab - SC|Administered SC
41040208|NCT04137380|DRUG|Placebo - IV|Administered IV
41040209|NCT04137380|DRUG|Placebo - SC|Administered SC
41167936|NCT06183905|DIAGNOSTIC_TEST|Prostate imaging|"Multiparametric ultrasound (mpUS) The mpUS examinations are performed in the order of greyscale imaging, elastography and contrast-enhanced ultrasound (CEUS), with the patients in the left lateral decubitus position.Greyscale imaging and elastography are evaluated by one radiologist. After standard step-sectional greyscale imaging, transverse elastic images are obtained from the base to the apex by manual compression. The amplitude and frequency of compression are adjusted according to the visual compression indicator on the screen to minimize interoperator variability. CEUS is performed using a bolus of 2.4 mL contrast agents (SonoVue, Bracco) using Contrast mode.~Multiparametric MRI (mpMRI) Prostate mpMRI images were acquired using a 3-T scanner with an external phased-array coil."
41167937|NCT06183905|PROCEDURE|Prostate biopsy|All patients will undergo standard 12-core systematic biopsy (SB) within 1 week following the imaging protocol in conjunction with targeted biopsy (TB) for suspicious lesions on mpUS and/or mpMRI. First, 12-core SB is performed, followed by cognitive mpUS-TB with 2-3 cores for each suspicious lesion. The suspicious lesions on mpUS include hypoechoic lesion(s) on greyscale imaging, reproducible stiff lesion(s) on elastography, and hypoperfused area(s) with ill-defined boundaries or increased focal/asymmetric contrast enhancement on CEUS. Thereafter, MRI/US fusion TB is performed sampling 2-3 cores for each lesion with a Prostate Imaging Reporting and Data System (PI-RADS) version 2 score of 3 or above.Each biopsy sample is placed in the micro-cassette and labelled to identify the biopsy technique and location.
41167938|NCT04389346|PROCEDURE|Periapical surgery using autologous platelet aggregate|PRF will be placed over the denuded root surface, following apicoectomy and before flap repositioning
41167939|NCT04389346|PROCEDURE|Periapical surgery without autologous platelet aggregate|Flap will be repositioned following apicoectomy directly without placing any platelet aggregate
41167940|NCT04107181|DEVICE|"Introducer calla device"|The research introducer will be used after the patient consents prior to the annual pap smear.
41167941|NCT04107181|BEHAVIORAL|Interviews only|Healthy volunteer interviews
41167942|NCT03534011|PROCEDURE|Resuscitative Balloon Occlusion of the Aorta|If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.
41040210|NCT05683548|DRUG|REP 2139-Mg|REP 2139-Mg is the magnesium chelate complex of REP 2139
41167943|NCT03534011|DEVICE|REBOA catheter|Catheter with a Resuscitative Balloon for Occlusion of the Aorta
41167944|NCT03827850|DRUG|ERDAFITINIB|Daily in a range from 3 mg to 9 mg
41167945|NCT02316288|BEHAVIORAL|Mindfulness and Acceptance Therapy|Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
41040211|NCT05683548|DRUG|Tenofovir Disoproxil Fumarate|
41167946|NCT02316288|BEHAVIORAL|Health Education|Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
41167947|NCT02450097|OTHER|Caloric restriction|
41167948|NCT02836262|DEVICE|HIT Hip Replacement System|HIT Hip Replacement System
41167949|NCT00725036|DRUG|inhaled human insulin|
41167950|NCT00725036|DRUG|insulin aspart|
41167951|NCT00725036|DRUG|insulin NPH|
41167952|NCT01539408|DRUG|Misoprostol|single dose of 400 mcg misoprostol administered sublingually
41392134|NCT04405674|DRUG|Nab paclitaxel|Nab-paclitaxel 260mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
41040212|NCT05683548|DRUG|Pegylated interferon alpha2a|
41040213|NCT02046980|PROCEDURE|Gufoni|
41040214|NCT02046980|PROCEDURE|Vibration|
41040215|NCT02046980|PROCEDURE|Sham|
41040216|NCT05499429|DEVICE|Transcranial low intensity focused ultrasound stimulation|Low intensity focused transcranial ultrasound stimulation can safely and effectively regulate neuron excitability through mechanical force.
41040217|NCT05624177|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 5 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
41167953|NCT01539408|PROCEDURE|surgery Manual vacuum aspiration (MVA)|standard surgical treatment
41392135|NCT01563393|OTHER|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
41392136|NCT01563393|OTHER|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
41392137|NCT00602979|DEVICE|Macintosh laryngoscope|Used during laryngoscopy to facilitate intubation.
41392138|NCT00602979|DEVICE|Airtraq® Optical Laryngoscope|Used during laryngoscopy to facilitate intubation.
41392139|NCT00602979|DEVICE|Storz DCI Video Laryngoscope®|Used during laryngoscopy to facilitate intubation
41392140|NCT00602979|DEVICE|GlideScope® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
41392141|NCT00602979|DEVICE|McGRATH® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
41392142|NCT05812222|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
41167954|NCT06547671|OTHER|Employment of a confort room to help in anxiety and agitation moments.|Use of the sensory comfort room located in the unit itself, decorated in soft and relaxing tones with motifs inspired by nature. It has relaxation sofas, rocking chair, aromatherapy, chromotherapy, projector, music of the user's choice, weighted blanket mats, balls of various sizes......... to teach people admitted to the area alternatives to cope and control anxiety and prevent the escalation of agitation, as well as to guide them in strategies to help them relax.
41392143|NCT05177237|DRUG|Endostar|Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.
41392144|NCT04256057|DRUG|Magnesium Sulfate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes(23) followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
41040218|NCT05624177|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 10 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
41040219|NCT01956526|DEVICE|CORolla™ TAA device|
41040220|NCT03905655|DRUG|Placebo Oral Tablet|Number of placebo tablets administered orally depends on the arm
41040221|NCT03905655|DRUG|Nitazoxanide|Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm
41040222|NCT03640650|COMBINATION_PRODUCT|Dropless Therapy|The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.
41040223|NCT03640650|DRUG|Usual Care|In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
41040224|NCT04659980|DEVICE|hilotherapy|continuous cooling of hands and feet at a constant temperature
41040225|NCT04659980|DEVICE|frozen gloves|cooling of hands and feet using frozen gloves
41167955|NCT04383847|BEHAVIORAL|Sumadhur Aarambha|Group intervention for newly married women, their husbands, and mothers-in-law with information mainly about nutrition, but also pre-pregnancy health, reproductive/pregnancy health and gender equality.
41392145|NCT00601276|DRUG|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
41040226|NCT03843229|DRUG|Cinobufacini injection|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
41040227|NCT03843229|PROCEDURE|Transarterial Chemoembolization(TACE)|TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.
41392146|NCT00601276|DRUG|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
41392147|NCT04288115|DRUG|Levothyroxine|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
41392148|NCT04288115|OTHER|Placebo|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
41512938|NCT06403254|PROCEDURE|There isn't an intervention name because the study is observational and has only one group.|Follow-up after surgey
41512939|NCT00180999|DRUG|Erythropoiétine|
41392149|NCT03849794|OTHER|Experimental Group|"Chiropractic Care A chiropractor will see participants in the experimental group about 3 times per week using a pragmatic approach for 4 weeks, and each session will be approximately 15-20 minutes in duration. The spinal adjustments performed in this study will be high-velocity, low-amplitude thrusts to the spine, pelvic joints, extremities or instrument-assisted adjustments~Physiotherapy:~Physiotherapists will see participants in each group 3 times per week for four weeks. Each session will be approximately 40 minutes in duration. Physiotherapy interventions are likely to include stretches and exercises, massage and mobilization as required."
41392150|NCT03849794|OTHER|Control group|The control group will receive the same physiotherapy intervention as the experimental group at the same frequency of care. The control group will also attend three passive movement sessions with the chiropractor each week, primarily to minimise the psychological effect of the interaction with the chiropractor, but also to act as a physiological control. These passive movement sessions will be 15 minutes in duration.
41392151|NCT06516302|DRUG|GR1802|GR1802 will be administered SC.
40861349|NCT05194800|OTHER|Virtual Mirror Therapy|Subjects will be offered the use of a Virtual Reality headset therapy game. Fiducial markers will be placed on the residual limb for tracking via front facing cameras on the Oculus Quest 2 and the sound limb movements will be duplicated (flipped for chirality) and mapped onto the residual limb to provide the appearance of their residual limb. The software will direct the subjects through a series of guided movements, stretches, and visualization exercises which last a total of 15 minutes. Afterwards the subjects will be given 5 minutes of unstructured time in the program to perform any of exercises or movements they desire in order to attempt to relieve their phantom limb pain.
40861350|NCT05270837|DRUG|Pegvaliase|Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
40861351|NCT05270837|OTHER|Diet Only|Diet Control
40861352|NCT02292719|DRUG|OBV/PTV/r|Tablet
40861353|NCT02292719|DRUG|Sofosbuvir|Tablet
40861354|NCT02292719|DRUG|Ribavirin (RBV)|Tablet
40861355|NCT03312842|DRUG|CS1001|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type."
40861356|NCT00306085|GENETIC|Autologous bone marrow cells|
40861357|NCT04553900|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Placement of a transesophageal probe and performance of a diagnostic Transesophageal echocardiography examination.
41167956|NCT05428241|BEHAVIORAL|Assigned Interventions|Behavioral: 6 sessions of Motivational Interviewing and 3-month follow-up. 6 sessions of Motivational Interview will be applied to the working group. All sessions will be in the form of face-to-face meetings. Each interview will take an average of 45-60 minutes. With this intervention, it was aimed to increase the levels of coping with motivational interviewing, functionality, adherence to treatment and quality of life in bipolar disorder patients. Study data consists of personal information form, Morisky Treatment Adherence Scale (MMAS), World Health Organization Quality of Life Scale, Short Form (WHOQOL-BREF), Assessment of Coping Attitudes Inventory (COPE), Bipolar Disorder Functioning Questionnaire (BDFQ). Data will be analyzed pre-intervention, post-intervention and 3 months post-intervention. A drug and device will not be administered to participants.
41392152|NCT06516302|DRUG|Placebo|The placebo will be administered SC.
41392153|NCT05027373|DRUG|SSGJ-613|SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.
41392154|NCT05027373|DRUG|Placebo|Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.
40861358|NCT00252603|DRUG|Galantamine|
40861359|NCT04237012|DRUG|Dextenza 0.4Mg Intracanalicular Insert|all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
40861360|NCT04237012|OTHER|Over the counter Artificial tears|over the counter artificial tears PRN at patient discretion
40861361|NCT05842148|OTHER|Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of pathological parameters (oncological radicality resection volume, locoregional extension / TNM / multifocality and tumor biological profile).
40861362|NCT05842148|OTHER|Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of post-surgical complications (dehiscence, liponecrosis, infection, seroma, hematoma, fibrosis, scar hypertrophy).
40861363|NCT05842148|OTHER|Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient.|Control and review of technical analysis by the surgeon, and of psychosocial well-being, physical discomfort, adverse effects of radiotherapy by the patient collected through the administration of a questionnaire.
41167957|NCT00429078|GENETIC|2nd Generation Designer T Cells|
41167958|NCT01095913|DRUG|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
41392155|NCT00449930|DRUG|sitagliptin phosphate|(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
41392156|NCT00449930|DRUG|Comparator: metformin hydrochloride|(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
41392157|NCT03175445|OTHER|CBCT scan by planmeca promax|software measurement tool of CBCT
41392158|NCT00109135|DRUG|taranabant|
41392159|NCT02454309|DIETARY_SUPPLEMENT|Cranberry concentrate|
41392160|NCT02454309|DIETARY_SUPPLEMENT|Placebo|
41392161|NCT06191185|BEHAVIORAL|BPB, No PIN|"Patient-level: standard communication from care team.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion."
40861364|NCT02761343|OTHER|MRI scan|Following the clinically indicated cardiac ablation procedure, a post ablation MRI scan will be performed.
40861365|NCT03642652|BEHAVIORAL|SMS|Text reminders to mobile telephone
40861366|NCT00464503|DRUG|Rosuvastatin-Crestor|
40861367|NCT00464503|DRUG|Pravastatin-Pravasine|
41512940|NCT05547997|OTHER|Stretching exercises|Exercises will be performed in the following order: 1) stretching towards lateral flexion for the upper part of the trapezius; 2) ipsilateral flexion and rotation for the scalene; 3) and flexion for the extensor muscles. Each maneuver will be held for 30 seconds as this is an optimum time to not create alteration in the evoked protentional. Each stretch will be repeated 3 times
41512941|NCT05547997|OTHER|Two way traction|During the traction, the head halter will be fixed posteriorly to cause slight distraction, retraction, and slight extension and at the same time a front anterior strap had weight will be applied over a pulley that allows transverse traction load to be applied to the apex of the participants cervical curve alteration. Weights will start at 15 lbs. (6.8 Kg) on the anterior strap and will increase over consecutive visits to patient tolerance or a maximum of 35 lbs. (15.9 Kg).
41512942|NCT05532033|DEVICE|High flow nasal cannula|A device able to delivery high flow oxygen therapy
41167959|NCT00570557|OTHER|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
41040228|NCT03843229|DRUG|cinobufacini tablet|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
41167960|NCT02673307|BEHAVIORAL|1 chewing gum over 45 minutes|
41040229|NCT06497465|DRUG|Dolutegravir 50mg Tab|Participants will receive Dolutegravir 50mg
41040230|NCT06497465|DRUG|Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet \[DOVATO\]
41040231|NCT06497465|DRUG|Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)|Participants will receive Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
41167961|NCT00694798|BIOLOGICAL|Mycobacterium w|Immunomodulator
41167962|NCT04438122|OTHER|Cabernet Sauvignon|Cabernet Sauvignon is a red wine from a greek company which contains 13.5% alcohol vol.
41392162|NCT06191185|BEHAVIORAL|BPB, PIN|"Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the short messaging service (SMS) text messaging platform, HealthySMS.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion."
41392163|NCT06191185|BEHAVIORAL|No BPB, PIN|Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the SMS text messaging platform, HealthySMS.
41392164|NCT06191185|BEHAVIORAL|No BPB, No PIN|Patient-level: standard communication from their care team.
41167963|NCT04438122|OTHER|Tsipouro|Tsipouro is a greek spirit which contains 38% alcohol vol
41512943|NCT05532033|DEVICE|Facial mask|standard oxygen therapy
41040232|NCT00423176|DRUG|MFNS and antibiotic|MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
41167964|NCT03511573|PROCEDURE|bariatric and other laparoscopic surgery|We have obtained liver samples during laparoscopic surgical procedures in the majority of cases. The majority of laparoscopic procedures were sleeve gastrectomies performed for morbid obesity as a primary restrictive procedure; in 5 cases the liver biopsies were performed during laparoscopic cholecystectomies.
41167965|NCT01677949|DRUG|Clofarabine|Days 1-5: Clofarabine 30 mg/m\^2 for 0-30 years of age or 20 mg/m\^2 for \> 30 years of age intravenously (IV) over 2 hours
41040233|NCT00423176|DRUG|Matching Placebo nasal spray plus antibiotic|Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
41040234|NCT05725317|DEVICE|LID220365 contact lens|Investigational delefilcon A spherical contact lens made with a modified manufacturing process
41040235|NCT05725317|DEVICE|LID006961 contact lens|Commercially available delefilcon A spherical contact lens
41167966|NCT01677949|DRUG|Etoposide|Days 1-5: Etoposide 100mg/m\^2 IV over 2 hours
41040236|NCT05402280|BEHAVIORAL|Sleep protocol|To investigate the effect of a multicomponent sleep protocol on the quality of sleep hospitalized patients assessed both subjectively and objectively.
41167967|NCT01677949|DRUG|Cyclophosphamide|Days 1-5: Cyclophosphamide 300 mg/m\^2 as a 30-60 minute infusion
41167968|NCT01677949|BIOLOGICAL|allogeneic hematopoietic cell transplantation|Between Days 28 and 42: infused independent of this study
41167969|NCT05470881|DRUG|Atropine Sulfate|Administration of one drop QD on both eyes for 14 days.
41167970|NCT05280743|DRUG|Oxycodone|exposure to opioids after Cesarean Section
41167971|NCT03347266|DRUG|VVZ-149 injections|•VVZ-149 injection
41392165|NCT00935415|DRUG|Montelukast|Montelukast 5 mg
41392166|NCT00935415|DRUG|Placebo|capsules of matching placebo
41392167|NCT04403373|BEHAVIORAL|Waitlist control|waitlist control
41512944|NCT01442597|BEHAVIORAL|Standard Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions one time per week last one hour each time.
41512945|NCT01442597|BEHAVIORAL|Individual clinician-provided CBT|Individual drug counseling sessions with trained clinicians using CBT one time per week last one hour per session.
41512946|NCT01442597|BEHAVIORAL|CBT4CBT|Subjects work with a computerized program that teaches skills for stopping drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session.
41512947|NCT05810233|DIETARY_SUPPLEMENT|Ascorbic acid 1000mg|Health supplement
41512948|NCT05810233|OTHER|Placebo|Glucose chewable tablet without any ascorbic acid
41040237|NCT06134544|DIETARY_SUPPLEMENT|Isomaltooligosaccharides (IMO)|Patients will still receive standard treatment, including medicine and other invasive treatment.
41040238|NCT04984148|DIAGNOSTIC_TEST|CT|Contrast-enhanced thoracic computed tomography
41040239|NCT04901429|PROCEDURE|Truncal vagotomy|Truncal vagotomy will be performed in 50% of patients during other routine procedure.
41040240|NCT00802568|BIOLOGICAL|anti-thymocyte globulin|
41040241|NCT00802568|DRUG|busulfan|
41040242|NCT00802568|DRUG|fludarabine phosphate|
41040243|NCT00802568|PROCEDURE|allogeneic bone marrow transplantation|
41040244|NCT00802568|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
41167972|NCT03347266|DRUG|Placebo|water for injection
41512949|NCT00221455|BEHAVIORAL|Patient diabetic self-management using the diabetic patient portal tools|
41392168|NCT04403373|BEHAVIORAL|Moderate-intensity walking exercise|walking exercise
41392169|NCT04403373|BEHAVIORAL|Vigorous-intensity walking exercise|walking exercise
40861368|NCT05024734|DRUG|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin is also the default drug, in case of failure of drug prediction in the in-vitro drug screen in PDO.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
40861369|NCT05024734|DRUG|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
41392170|NCT04227665|OTHER|Sea level|Sea level exposure / sea level exposure combined with microdoses of rHuEPO
40861370|NCT05024734|DRUG|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
40861371|NCT05024734|DRUG|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
40861372|NCT04763941|DIAGNOSTIC_TEST|CDR assessment face-to-face|The assessment of the CDR is administered once by a psychologist with the patient and his caregiver.
40861373|NCT03097965|DIETARY_SUPPLEMENT|PROGRAM|
40861374|NCT03097965|OTHER|DIET|
40861375|NCT02489383|OTHER|Continuous Exercise Training|The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).
40861376|NCT02489383|OTHER|Interval Exercise Training|The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
40861377|NCT02489383|BEHAVIORAL|Education Program|The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
40861378|NCT05974930|DEVICE|IVUS imaging for primary PCI guidance|Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.
40861379|NCT04440748|DEVICE|T-Chair 2.0 Prototype|Participants in the experimental group will perform additional therapy with the T-Chair 2.0. Participants can train in two modes. Participants will either train in the active modus, whereby the participant has to move the seat in a certain direction, or in the passive modus, whereby the participant has to stay in a stable position while the seat is moving underneath the participant. The seat is able to move in mediolateral, anteroposterior, and diagonal and combined directions such as circles or eight-figures. The modus, the type of movement, the range of motion and speed of movement are chosen by the therapist according to the patients' abilities.Training will be coupled with a computer based exercise. During the session preparation time, and time for the questionnaires is needed, thus we expect the actual training time to be on average 30 minutes per training.
41040245|NCT01235468|BIOLOGICAL|ex vivo expansion|ex-vivo expansion of cord blood for transplantation
41040246|NCT03182868|DEVICE|PAS Goggle|PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.
41392171|NCT04227665|OTHER|Altitude|Altitude exposure / altitude exposure Iron metabolism
41392172|NCT00826722|DRUG|Levetiracetam|1000 mg tablet
41392173|NCT02742818|DEVICE|Upper body blanket, Bair Hugger|Upper body warming blanket will be used in patients undergoing LEA and EVAR.
41392174|NCT02742818|DEVICE|Underbody blanket, Bair Hugger|Underbody warming blanket will be used in patients undergoing LEA and EVAR.
41392175|NCT03092089|DRUG|Definity, (Lipid Microspheres) Intravenous Suspension|Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
41392176|NCT03092089|DEVICE|Myocardial Contrast Echocardiography|Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
41392177|NCT03092089|PROCEDURE|Repurfusion therapy with PPCI|Patients will receive reperfusion therapy with PPCI as standard of care
41392178|NCT01393717|DRUG|brentuximab vedotin|Given IV
41392179|NCT01589029|DRUG|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
41512950|NCT00221455|BEHAVIORAL|A variety of educational interventions for non-adopters of the technology, and for non-compliant patients.|
40861380|NCT04440748|OTHER|General Rehabilitation Programme|"The general rehabilitation program that is offered to all patients of Clinic Valens fits the current standards for treatment post-stroke. This program is tailored to the patients needs and consists of a 90 minute so called focus training per day, which includes physical therapy, occupational therapy, resistance training and gait training. According to the patient needs, extra therapy will be given such as robotic therapy, speech therapy and aquatic therapy. The general rehabilitation program in both groups is comparable in content, time and intensity."
40861381|NCT04280627|OTHER|Sample Collection|This study will involve the collection of oral swabs, saliva, urine and faeces samples, blood and skin scrapings from patients before and after kidney and pancreas transplantation at day 0, day 1, week 1 and at 3, 6 and 12 months post-transplant.
40861382|NCT04339816|DRUG|Azithromycin|orally or into nasogastric tube for 5 days
40861383|NCT04339816|DRUG|Hydroxychloroquine|orally or into nasogastric tube for 5 days
40861384|NCT04339816|DRUG|Placebo|orally or into nasogastric tube for 5 days
40861385|NCT05374460|BEHAVIORAL|Explanatory diagram|Participant is told there will be a mismatch between their target finger and the visual indicator of target finger position. They will be shown a diagram explaining this.
40861386|NCT05374460|BEHAVIORAL|Direct vision|Foamboard under mirror removed, making the mirror see-through and the hand directly visible. Mismatch between target hand and visual indicator will be directly visible.
40861387|NCT05374460|BEHAVIORAL|Movement feedback, target hand|After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will be displaced.
40861388|NCT05374460|BEHAVIORAL|Movement feedback, pointing hand|After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will not change, but the cursor indicating pointing hand position will change.
40861389|NCT05374460|BEHAVIORAL|No movement feedback|The visual indicator of the target hand will be displaced, but there will be no cursor to indicate the pointing hand's position.
40861390|NCT05374460|BEHAVIORAL|Attend to the targets|Participants will not be told anything about the visuo-proprioceptive mismatch. Instead, they will be asked simply to attend to the target positions.
40861391|NCT04881617|BEHAVIORAL|Lexical Retrieval Training (LRT)|In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.
40861392|NCT04881617|BEHAVIORAL|Video-Implemented Script Training for Aphasia (VISTA)|In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accur